Cancer_type	QTL_type	tag_SNP	LD	SNP	SNP_position	Alleles	Methylation_probe	Methylation_position	Probe_related_gene	Beta	t-stat	Correlation_coefficient (r)	p-value	Traits
THYM	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg00278517	chr6:167070616	RPS6KA2	0.35	4.58	0.42	1.44e-5	Crohn's disease;
THYM	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.78	-6.29	-0.54	9.87e-9	Lymphocyte percentage of white cells;
THYM	cis	rs4481887	0.741	rs11488133	chr1:248548380	T/C	cg00666640	chr1:248458726	OR2T12	0.54	4.63	0.43	1.17e-5	Common traits (Other);
THYM	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg10523679	chr1:76189770	ACADM	-0.57	-4.83	-0.44	5.17e-6	Daytime sleep phenotypes;
THYM	cis	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-6.16	-0.53	1.75e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs834811	0.863	rs834821	chr7:135895713	A/T	cg01726295	chr7:135938950	NA	0.53	4.72	0.44	8.1e-6	Post-traumatic stress disorder;
THYM	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg06481639	chr22:41940642	POLR3H	0.75	5.04	0.46	2.19e-6	Vitiligo;
THYM	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg23428387	chr22:49814324	NA	-0.55	-5.64	-0.5	1.78e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.63	-5.51	-0.49	3.04e-7	Total body bone mineral density;
THYM	cis	rs1843834	0.823	rs2129610	chr2:225505345	G/A	cg10193763	chr2:225306901	NA	-0.51	-4.94	-0.45	3.38e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs6060717	0.610	rs2244883	chr20:34620896	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-5.47	-0.49	3.58e-7	Hip circumference adjusted for BMI;
THYM	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg13010199	chr12:38710504	ALG10B	0.6	4.51	0.42	1.82e-5	Morning vs. evening chronotype;
THYM	cis	rs75920871	0.528	rs2513094	chr11:116806412	T/C	cg20608306	chr11:116969690	SIK3	-0.52	-5.62	-0.5	1.89e-7	Subjective well-being;
THYM	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8028313	0.731	rs7172055	chr15:67938334	G/C	cg24579218	chr15:68104479	NA	-0.68	-6.49	-0.55	3.86e-9	Obesity;
THYM	cis	rs4499344	0.556	rs259227	chr19:33134791	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.95	6.69	0.57	1.53e-9	Mean platelet volume;
THYM	cis	rs2806561	0.823	rs658508	chr1:23480362	T/C	cg12483005	chr1:23474871	LUZP1	0.6	6.05	0.53	2.81e-8	Height;
THYM	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.19	0.75	4.86e-19	Homoarginine levels;
THYM	cis	rs4072705	0.646	rs915034	chr9:127244955	G/A	cg13476313	chr9:127244764	NR5A1	0.36	5.27	0.48	8.38e-7	Menarche (age at onset);
THYM	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg06238570	chr21:40685208	BRWD1	-0.67	-5.57	-0.5	2.34e-7	Menarche (age at onset);
THYM	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg04063615	chr12:132293388	NA	-0.51	-4.68	-0.43	9.52e-6	Migraine;
THYM	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-5.45	-0.49	3.97e-7	Total body bone mineral density;
THYM	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs236907	0.859	rs12091786	chr1:171768793	A/C	cg20598894	chr1:171756153	METTL13	-0.74	-5.48	-0.49	3.46e-7	Mean platelet volume;
THYM	cis	rs6720763	1.000	rs6720763	chr2:167992286	T/C	cg10633051	chr2:168042982	XIRP2	-0.71	-4.72	-0.44	7.99e-6	Atopic dermatitis;
THYM	trans	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	Neuroticism;
THYM	cis	rs2067615	0.579	rs7975576	chr12:107132501	A/G	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs3017493	0.786	rs112552548	chr11:70675096	G/A	cg14537332	chr11:70508113	SHANK2	1.14	7.77	0.62	9.22e-12	Renal transplant outcome;
THYM	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg06453172	chr10:134556979	INPP5A	-0.63	-4.55	-0.42	1.56e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs9399401	0.626	rs12664563	chr6:142785201	A/G	cg04461802	chr6:142623433	GPR126	0.76	7.04	0.59	2.95e-10	Chronic obstructive pulmonary disease;
THYM	cis	rs12530845	0.887	rs61360007	chr7:135316879	G/A	cg23117316	chr7:135346802	PL-5283	-0.68	-6.01	-0.53	3.37e-8	Red blood cell traits;
THYM	cis	rs5771069	0.931	rs137857	chr22:50444577	A/G	cg27467552	chr22:50353597	PIM3	-0.45	-4.56	-0.42	1.55e-5	Ulcerative colitis;
THYM	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6032067	0.714	rs6104055	chr20:43822962	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.44	-5.26	-0.47	8.92e-7	Blood protein levels;
THYM	cis	rs4631830	0.900	rs9787697	chr10:51533376	C/T	cg16070123	chr10:51489643	NA	-0.53	-4.79	-0.44	6.07e-6	Prostate-specific antigen levels;
THYM	cis	rs2806561	0.729	rs649664	chr1:23324263	C/T	cg08872493	chr1:23521417	HTR1D	-0.39	-4.62	-0.43	1.23e-5	Height;
THYM	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg00631329	chr6:26305371	NA	-0.61	-7.27	-0.6	1.02e-10	Educational attainment;
THYM	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06481639	chr22:41940642	POLR3H	-0.78	-5.22	-0.47	1.05e-6	Vitiligo;
THYM	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.1	-7.57	-0.61	2.45e-11	Schizophrenia;
THYM	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg11905131	chr22:24372483	LOC391322	0.73	5.85	0.51	7.06e-8	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg20283391	chr11:68216788	NA	-0.63	-5.08	-0.46	1.88e-6	Total body bone mineral density;
THYM	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg08885076	chr2:99613938	TSGA10	-0.45	-4.53	-0.42	1.7e-5	Bipolar disorder;
THYM	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-5.2	-0.47	1.16e-6	Hemoglobin concentration;
THYM	cis	rs6032067	0.929	rs17334064	chr20:43839197	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.81	-0.57	8.91e-10	Blood protein levels;
THYM	trans	rs4866334	1.000	rs79543647	chr5:18488484	G/A	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs6876348	0.543	rs257899	chr5:128314616	G/A	cg25555059	chr5:128301488	SLC27A6	-0.45	-4.73	-0.44	7.81e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg13607699	chr17:42295918	UBTF	0.64	5.2	0.47	1.13e-6	Total body bone mineral density;
THYM	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs763014	0.931	rs11648728	chr16:635525	C/T	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs1642645	0.831	rs6689536	chr1:42487523	T/C	cg22816091	chr1:42611670	NA	0.62	5.52	0.49	2.99e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs4654899	0.785	rs7531381	chr1:21403348	A/G	cg01072550	chr1:21505969	NA	-0.77	-7.49	-0.61	3.45e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg00576331	chr11:65640516	EFEMP2	0.68	4.58	0.43	1.42e-5	Crohn's disease;
THYM	cis	rs13006833	0.635	rs291460	chr2:191181585	G/A	cg11845111	chr2:191398756	TMEM194B	0.65	4.51	0.42	1.88e-5	Urinary metabolites;
THYM	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs6988636	1.000	rs10505430	chr8:124191933	A/G	cg22384356	chr8:124195192	FAM83A	0.82	5.02	0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg14517863	chr17:44321492	NA	0.47	5.22	0.47	1.04e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2404602	0.647	rs12439141	chr15:77095423	T/C	cg23625390	chr15:77176239	SCAPER	-0.87	-6.12	-0.53	2.05e-8	Blood metabolite levels;
THYM	cis	rs950027	1.000	rs950027	chr15:45801035	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.58	-4.74	-0.44	7.48e-6	Response to fenofibrate (adiponectin levels);
THYM	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg13319975	chr6:146136371	FBXO30	0.73	6.11	0.53	2.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12310956	0.532	rs1352211	chr12:33983132	G/A	cg06521331	chr12:34319734	NA	-0.92	-8.57	-0.66	1.89e-13	Morning vs. evening chronotype;
THYM	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg22974920	chr21:40686053	BRWD1	-0.63	-4.97	-0.45	2.98e-6	Cognitive function;
THYM	trans	rs2204008	0.807	rs10880234	chr12:38318353	C/T	cg10856724	chr12:34555212	NA	-0.88	-7.44	-0.61	4.48e-11	Bladder cancer;
THYM	cis	rs9611565	1.000	rs5758314	chr22:41762523	T/G	cg06634786	chr22:41940651	POLR3H	-0.58	-4.91	-0.45	3.82e-6	Vitiligo;
THYM	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	trans	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs7746082	0.627	rs7454374	chr6:106499948	A/T	cg02270332	chr6:106475062	NA	-0.65	-5.95	-0.52	4.38e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.17	-0.47	1.28e-6	Joint mobility (Beighton score);
THYM	cis	rs7107174	1.000	rs10793304	chr11:78064907	A/G	cg19901956	chr11:77921274	USP35	-0.65	-5.4	-0.48	5.01e-7	Testicular germ cell tumor;
THYM	cis	rs8114671	0.869	rs66535333	chr20:33656666	G/A	cg08999081	chr20:33150536	PIGU	-0.56	-4.83	-0.44	5.18e-6	Height;
THYM	cis	rs17641971	0.684	rs1876717	chr8:49994968	T/G	cg00325661	chr8:49890786	NA	0.6	4.79	0.44	6.24e-6	Blood metabolite levels;
THYM	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg16926213	chr1:1841314	NA	0.56	5.87	0.52	6.47e-8	Body mass index;
THYM	cis	rs9303280	0.936	rs907091	chr17:37921742	A/G	cg24910161	chr17:38119198	GSDMA	0.44	4.6	0.43	1.31e-5	Self-reported allergy;
THYM	cis	rs7771547	0.642	rs12214285	chr6:36434679	C/T	cg07856975	chr6:36356162	ETV7	-0.59	-5.73	-0.51	1.2e-7	Platelet distribution width;
THYM	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg04398451	chr17:18023971	MYO15A	-0.76	-6.93	-0.58	4.99e-10	Total body bone mineral density;
THYM	cis	rs5769765	0.646	rs9616205	chr22:50309915	A/T	cg26441486	chr22:50317300	CRELD2	0.44	6.87	0.58	6.61e-10	Schizophrenia;
THYM	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs1949733	0.958	rs2631731	chr4:8429817	A/G	cg11789530	chr4:8429930	ACOX3	0.73	5.51	0.49	3.01e-7	Response to antineoplastic agents;
THYM	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg17173187	chr15:85201210	NMB	0.56	5.66	0.5	1.6e-7	Schizophrenia;
THYM	cis	rs9826463	0.715	rs7622662	chr3:142528783	G/A	cg20824294	chr3:142316082	PLS1	0.61	4.75	0.44	7.31e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg07424592	chr7:64974309	NA	-0.99	-5.15	-0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg13695892	chr22:41940480	POLR3H	0.99	7.46	0.61	4.15e-11	Vitiligo;
THYM	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg06917634	chr15:78832804	PSMA4	0.83	7.39	0.6	5.74e-11	Sudden cardiac arrest;
THYM	cis	rs7586879	0.681	rs6545790	chr2:25109302	A/G	cg15423357	chr2:25149977	NA	0.66	7.3	0.6	8.79e-11	Body mass index;
THYM	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg09260853	chr1:2094483	PRKCZ	0.49	4.52	0.42	1.77e-5	Height;
THYM	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg02527881	chr3:46936655	PTH1R	-0.65	-6.44	-0.55	4.94e-9	Colorectal cancer;
THYM	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg27286337	chr10:134555280	INPP5A	0.86	6.45	0.55	4.69e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs13315871	1.000	rs71311873	chr3:58447106	C/A	cg12435725	chr3:58293450	RPP14	-0.46	-4.93	-0.45	3.54e-6	Cholesterol, total;
THYM	cis	rs17102423	0.594	rs10151162	chr14:65566695	T/C	cg11161011	chr14:65562177	MAX	-0.69	-5.58	-0.5	2.31e-7	Obesity-related traits;
THYM	cis	rs76878669	0.793	rs10791867	chr11:66081211	C/G	cg18002602	chr11:66138449	SLC29A2	-0.63	-5.31	-0.48	7.16e-7	Educational attainment (years of education);
THYM	cis	rs1045902	0.583	rs36106493	chr2:73442339	C/T	cg24220031	chr2:73402428	NA	-0.7	-6.58	-0.56	2.53e-9	Intelligence (multi-trait analysis);
THYM	cis	rs12681287	0.640	rs12549332	chr8:87353392	G/A	cg27223183	chr8:87520930	FAM82B	-0.68	-5.06	-0.46	2.07e-6	Caudate activity during reward;
THYM	cis	rs67385638	0.855	rs3759074	chr11:5257778	C/T	cg12559170	chr11:5275217	HBG2	0.88	8.55	0.66	2.03e-13	Hemoglobin levels;
THYM	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22455342	chr2:225449267	CUL3	0.97	9.01	0.68	2.14e-14	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg00129232	chr17:37814104	STARD3	0.69	4.51	0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs76878669	0.561	rs4930362	chr11:66154360	T/C	cg18002602	chr11:66138449	SLC29A2	0.47	4.84	0.44	5.1e-6	Educational attainment (years of education);
THYM	cis	rs3126085	0.560	rs1858485	chr1:152334530	A/G	cg10321714	chr1:152280068	FLG	-0.72	-5.47	-0.49	3.69e-7	Atopic dermatitis;
THYM	cis	rs902774	0.530	rs12819597	chr12:53353956	T/C	cg14581129	chr12:53358946	NA	-0.99	-4.56	-0.42	1.5e-5	Prostate cancer;
THYM	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg03929089	chr4:120376271	NA	-1.03	-12.27	-0.78	2.65e-21	Height;
THYM	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg06238570	chr21:40685208	BRWD1	-0.95	-8.64	-0.66	1.3e-13	Cognitive function;
THYM	cis	rs4363385	0.647	rs1995308	chr1:153014082	A/T	cg13444842	chr1:152974279	SPRR3	-0.56	-4.46	-0.42	2.25e-5	Inflammatory skin disease;
THYM	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.79	-6.94	-0.58	4.8e-10	Tonsillectomy;
THYM	cis	rs765787	0.530	rs12440321	chr15:45529385	G/A	cg24006582	chr15:45444508	DUOX1	0.81	6.55	0.56	2.99e-9	Uric acid levels;
THYM	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg26384229	chr12:38710491	ALG10B	0.73	5.59	0.5	2.2e-7	Morning vs. evening chronotype;
THYM	cis	rs1267303	0.636	rs1267310	chr1:46987307	A/T	cg16387850	chr1:46982889	NA	0.45	5.73	0.51	1.19e-7	Monobrow;
THYM	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.13	7.78	0.62	8.66e-12	Smoking behavior;
THYM	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg26038318	chr20:34205095	SPAG4	0.65	5.25	0.47	9.22e-7	Total cholesterol levels;
THYM	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg12560992	chr17:57184187	TRIM37	0.94	8.84	0.67	5.01e-14	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg13683864	chr3:40499215	RPL14	-0.69	-5.89	-0.52	5.93e-8	Renal cell carcinoma;
THYM	cis	rs17407555	0.609	rs10032742	chr4:10278893	A/G	cg00071950	chr4:10020882	SLC2A9	0.58	5.33	0.48	6.74e-7	Schizophrenia (age at onset);
THYM	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg24846343	chr22:24311635	DDTL	0.37	4.5	0.42	1.95e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg26384229	chr12:38710491	ALG10B	-0.93	-7.55	-0.61	2.63e-11	Bladder cancer;
THYM	cis	rs3862030	0.720	rs11593971	chr10:104234090	C/G	cg00122347	chr10:104236741	TMEM180	0.47	7.02	0.58	3.22e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg15212455	chr7:39170539	POU6F2	0.65	5.88	0.52	6.05e-8	IgG glycosylation;
THYM	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9900062	1.000	rs9900062	chr17:62739574	G/A	cg11885555	chr17:61910219	SMARCD2	0.9	4.7	0.43	8.85e-6	QT interval;
THYM	cis	rs7828089	0.582	rs3817445	chr8:22266054	G/T	cg12081754	chr8:22256438	SLC39A14	0.89	9.11	0.68	1.34e-14	Verbal declarative memory;
THYM	cis	rs6669072	0.565	rs992544	chr1:91278411	A/T	cg08895590	chr1:91227319	NA	-0.39	-4.45	-0.42	2.32e-5	Cognitive function;
THYM	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs2108225	0.714	rs10953548	chr7:107436232	G/A	cg18560240	chr7:107437656	SLC26A3	-1.02	-7.87	-0.63	5.55e-12	Ulcerative colitis;
THYM	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg20476274	chr7:133979776	SLC35B4	0.71	4.6	0.43	1.32e-5	Mean platelet volume;
THYM	cis	rs11690935	0.959	rs6705200	chr2:172637600	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.83	-5.99	-0.52	3.66e-8	Schizophrenia;
THYM	cis	rs11628318	0.515	rs9324049	chr14:103096352	T/C	cg27124170	chr14:102829869	TECPR2;CINP	-0.67	-4.62	-0.43	1.19e-5	Platelet count;
THYM	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg26384229	chr12:38710491	ALG10B	1.03	9.92	0.71	2.51e-16	Heart rate;
THYM	cis	rs630041	0.794	rs604447	chr1:20387306	T/G	cg15555335	chr1:20208763	OTUD3	0.83	4.63	0.43	1.15e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
THYM	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs4851266	1.000	rs4851264	chr2:100810188	T/C	cg14675211	chr2:100938903	LONRF2	0.57	4.51	0.42	1.84e-5	Educational attainment;
THYM	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	9.91	0.71	2.52e-16	Platelet count;
THYM	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.37	-4.55	-0.42	1.56e-5	Longevity;Endometriosis;
THYM	cis	rs7833986	0.534	rs17759244	chr8:57033768	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	6.9	0.58	5.65e-10	Height;
THYM	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg04944784	chr2:26401820	FAM59B	0.78	6.06	0.53	2.71e-8	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg10515332	chr4:99064459	C4orf37	0.61	5.01	0.46	2.54e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9512730	0.527	rs11619784	chr13:27999643	A/G	cg04070771	chr13:27998621	GTF3A	0.8	5.55	0.5	2.52e-7	Schizophrenia;
THYM	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg02353165	chr6:42928485	GNMT	0.74	5.33	0.48	6.74e-7	Blood protein levels;
THYM	cis	rs4718428	0.705	rs2901311	chr7:66415069	T/C	cg26963428	chr7:66367121	NA	-0.63	-4.9	-0.45	3.99e-6	Corneal structure;
THYM	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.85	-6.22	-0.54	1.32e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.37	0.6	6.4e-11	Melanoma;
THYM	cis	rs58950470	0.887	rs1787034	chr11:65382564	A/G	cg27068330	chr11:65405492	SIPA1	0.59	4.46	0.42	2.22e-5	Schizophrenia;
THYM	cis	rs595982	0.546	rs12461075	chr19:49399821	G/A	cg03707168	chr19:49379127	PPP1R15A	0.3	4.45	0.42	2.34e-5	Red cell distribution width;
THYM	cis	rs4851266	0.865	rs11123818	chr2:100867308	G/A	cg14675211	chr2:100938903	LONRF2	0.67	5.59	0.5	2.15e-7	Educational attainment;
THYM	cis	rs6430585	0.527	rs12465544	chr2:136451676	C/T	cg07169764	chr2:136633963	MCM6	1.03	9.12	0.68	1.26e-14	Corneal structure;
THYM	cis	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg05084668	chr3:125655381	ALG1L	-0.72	-4.78	-0.44	6.44e-6	Blood pressure (smoking interaction);
THYM	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg16405210	chr4:1374714	KIAA1530	-1.11	-10.78	-0.74	3.66e-18	Longevity;
THYM	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg20007245	chr22:24372913	LOC391322	-0.7	-6.22	-0.54	1.33e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg12963246	chr6:28129442	ZNF389	-0.88	-7.19	-0.59	1.46e-10	Depression;
THYM	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg02196655	chr2:10830764	NOL10	-0.42	-4.53	-0.42	1.73e-5	Prostate cancer;
THYM	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg25817165	chr18:72167213	CNDP2	-0.99	-7.58	-0.61	2.27e-11	Refractive error;
THYM	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg02915803	chr1:1606292	LOC728661;CDK11B	0.62	5.25	0.47	9.11e-7	Body mass index;
THYM	cis	rs4481887	0.962	rs4244177	chr1:248468279	C/T	cg13385794	chr1:248469461	NA	0.65	4.66	0.43	1.04e-5	Common traits (Other);
THYM	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg06112835	chr11:68658793	MRPL21	0.45	6.39	0.55	6.21e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs288326	0.704	rs79576701	chr2:183704659	T/C	cg09997497	chr2:183902928	NCKAP1	1.01	4.47	0.42	2.18e-5	Blood protein levels;
THYM	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg13114125	chr14:105738426	BRF1	-0.73	-5.69	-0.5	1.43e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	13.34	0.81	1.71e-23	Height;
THYM	cis	rs7078219	0.505	rs6584282	chr10:101286495	A/G	cg23904955	chr10:101282759	NA	-0.36	-4.53	-0.42	1.73e-5	Dental caries;
THYM	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.85	-7.01	-0.58	3.42e-10	Systemic lupus erythematosus;
THYM	cis	rs34638657	0.646	rs72628279	chr16:82199664	A/C	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.03	-0.46	2.29e-6	Lung adenocarcinoma;
THYM	cis	rs4523957	0.890	rs11655813	chr17:2119101	C/T	cg16513277	chr17:2031491	SMG6	-0.79	-7.6	-0.61	2.08e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs73219805	0.793	rs1564576	chr8:26190836	C/G	cg22461835	chr8:26723365	ADRA1A	-0.57	-4.94	-0.45	3.31e-6	Schizophrenia;
THYM	cis	rs3862030	0.836	rs12771867	chr10:104246691	G/A	cg00122347	chr10:104236741	TMEM180	0.49	7.62	0.62	1.85e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg26038318	chr20:34205095	SPAG4	0.59	4.65	0.43	1.08e-5	Total cholesterol levels;
THYM	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg21280719	chr6:42927975	GNMT	-0.52	-7.09	-0.59	2.35e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg12165864	chr7:66369176	NA	-0.81	-6.09	-0.53	2.36e-8	Corneal structure;
THYM	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg07532245	chr17:28927093	LRRC37B2	0.71	4.48	0.42	2.04e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10832963	0.594	rs1550869	chr11:18613498	G/T	cg20219074	chr11:18656078	SPTY2D1	0.63	4.52	0.42	1.81e-5	Breast cancer;
THYM	cis	rs12216545	0.765	rs2204129	chr7:150251439	A/G	cg08960815	chr7:150264767	GIMAP4	-0.89	-8.27	-0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg27494647	chr7:150038898	RARRES2	0.42	5.07	0.46	1.93e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs17401966	0.838	rs12127604	chr1:10352800	T/G	cg19773385	chr1:10388646	KIF1B	-0.57	-4.49	-0.42	2.04e-5	Hepatocellular carcinoma;
THYM	cis	rs11608355	1.000	rs10850135	chr12:109866528	C/A	cg10504392	chr12:110044639	NA	0.67	6.21	0.54	1.41e-8	Neuroticism;
THYM	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg11812906	chr14:75593930	NEK9	-0.78	-7.02	-0.58	3.28e-10	Height;
THYM	cis	rs1018836	0.886	rs12545351	chr8:91636668	C/T	cg16814680	chr8:91681699	NA	-0.99	-9.24	-0.69	7.07e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg10803722	chr21:46713166	LOC642852	-0.42	-5.55	-0.5	2.52e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg12573674	chr2:1569213	NA	-1.22	-4.82	-0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg05283184	chr6:79620031	NA	-0.88	-8.41	-0.65	4.14e-13	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg19418458	chr7:158789849	NA	-0.62	-5.57	-0.5	2.38e-7	Facial morphology (factor 20);
THYM	cis	rs12444156	1	rs12444156	chr16:71841257	C/T	cg08717414	chr16:71523259	ZNF19	-0.97	-4.83	-0.44	5.27e-6	Post bronchodilator FEV1;
THYM	cis	rs40363	1.000	rs37771	chr16:3512866	G/T	cg21433313	chr16:3507492	NAT15	0.8	6.59	0.56	2.41e-9	Tuberculosis;
THYM	cis	rs9959145	1.000	rs1940973	chr18:12550747	T/C	cg14160804	chr18:12703040	PSMG2;CEP76	-0.92	-4.53	-0.42	1.74e-5	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs3096299	0.702	rs2086825	chr16:89471542	C/T	cg02627286	chr16:89590583	SPG7	0.53	4.77	0.44	6.64e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs4866334	1.000	rs79459190	chr5:18504469	T/G	cg04591469	chr5:17810299	NA	-1.14	-4.6	-0.43	1.28e-5	IgG glycosylation;
THYM	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg04731861	chr2:219085781	ARPC2	-0.46	-4.5	-0.42	1.95e-5	Colorectal cancer;
THYM	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg15592062	chr6:167189543	RPS6KA2	0.59	6.0	0.52	3.56e-8	Crohn's disease;
THYM	cis	rs34779708	0.966	rs1478463	chr10:35473035	G/A	cg03585969	chr10:35415529	CREM	0.66	4.76	0.44	6.85e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg13683864	chr3:40499215	RPL14	-0.88	-8.56	-0.66	1.96e-13	Renal cell carcinoma;
THYM	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06634786	chr22:41940651	POLR3H	0.76	5.54	0.49	2.73e-7	Vitiligo;
THYM	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg24692254	chr21:30365293	RNF160	-0.99	-8.66	-0.66	1.23e-13	Dental caries;
THYM	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg13010199	chr12:38710504	ALG10B	-0.66	-4.91	-0.45	3.7e-6	Morning vs. evening chronotype;
THYM	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg08999081	chr20:33150536	PIGU	0.78	7.16	0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg08000102	chr2:233561755	GIGYF2	-0.81	-7.27	-0.6	9.94e-11	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11605275	1.000	rs11604212	chr11:20024894	G/T	cg14835545	chr11:20032148	NAV2	-1.38	-6.36	-0.55	6.98e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs2797160	0.967	rs8180614	chr6:126000599	G/C	cg16306078	chr6:126000798	NA	-0.54	-5.54	-0.49	2.66e-7	Endometrial cancer;
THYM	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg08742575	chr21:47604166	C21orf56	0.7	5.25	0.47	9.17e-7	Testicular germ cell tumor;
THYM	cis	rs11657217	0.677	rs8064811	chr17:77701450	G/A	cg06901238	chr17:77706717	ENPP7	0.79	7.63	0.62	1.78e-11	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
THYM	cis	rs4845459	0.967	rs4845452	chr1:152591647	A/G	cg26135325	chr1:152595322	LCE3A	-0.44	-5.01	-0.46	2.47e-6	Psoriasis;
THYM	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.71	-5.59	-0.5	2.2e-7	Tonsillectomy;
THYM	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg24209194	chr3:40518798	ZNF619	0.67	5.53	0.49	2.85e-7	Renal cell carcinoma;
THYM	cis	rs12984174	0.667	rs374614	chr19:18142682	T/C	cg21649277	chr19:18117794	ARRDC2	0.81	4.61	0.43	1.27e-5	Pulmonary function in asthmatics;
THYM	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	4.65	0.43	1.06e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg13010199	chr12:38710504	ALG10B	-0.62	-5.38	-0.48	5.28e-7	Heart rate;
THYM	cis	rs4072705	0.967	rs4838210	chr9:127546183	A/G	cg13476313	chr9:127244764	NR5A1	-0.32	-4.87	-0.45	4.41e-6	Menarche (age at onset);
THYM	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg02953382	chr22:24373134	LOC391322	0.92	10.35	0.73	2.91e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg00129232	chr17:37814104	STARD3	0.76	5.25	0.47	9.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs995000	0.868	rs10889357	chr1:63160282	C/T	cg06896770	chr1:63153194	DOCK7	0.85	5.54	0.49	2.72e-7	Triglyceride levels;
THYM	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg07936489	chr17:37558343	FBXL20	-0.84	-5.76	-0.51	1.03e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs62103177	0.608	rs8088089	chr18:77832154	A/G	cg07235805	chr18:78004237	PARD6G	-0.48	-5.45	-0.49	4.01e-7	Opioid sensitivity;
THYM	cis	rs1322639	0.614	rs6903921	chr6:169563957	C/T	cg04662567	chr6:169592167	NA	-0.79	-6.17	-0.53	1.69e-8	Pulse pressure;
THYM	cis	rs6840360	0.615	rs7695412	chr4:152488075	A/G	cg17479576	chr4:152424074	FAM160A1	-0.83	-6.46	-0.55	4.43e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg13319975	chr6:146136371	FBXO30	-0.63	-5.16	-0.47	1.36e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg02527881	chr3:46936655	PTH1R	-0.83	-8.25	-0.65	8.99e-13	Birth weight;
THYM	cis	rs9796	0.689	rs8032195	chr15:41448790	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.59	-4.67	-0.43	9.71e-6	Menopause (age at onset);
THYM	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg11494091	chr17:61959527	GH2	0.69	6.16	0.53	1.73e-8	Height;
THYM	cis	rs367615	0.879	rs56689485	chr5:108879828	A/T	cg17395555	chr5:108820864	NA	0.53	4.8	0.44	5.95e-6	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs4595586	0.545	rs4623945	chr12:39364572	A/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02475777	chr4:1388615	CRIPAK	0.66	4.81	0.44	5.68e-6	Longevity;
THYM	cis	rs1003719	0.715	rs2835646	chr21:38546574	G/A	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.7	-5.26	-0.48	8.76e-7	Longevity;Endometriosis;
THYM	cis	rs12122100	0.507	rs1925343	chr1:146505535	A/T	cg02487331	chr1:146550467	NA	-0.6	-4.85	-0.45	4.8e-6	HIV-1 control;
THYM	cis	rs12216545	0.695	rs10276888	chr7:150230326	T/C	cg08960815	chr7:150264767	GIMAP4	-0.89	-8.27	-0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.62	7.93	0.63	4.13e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg26967526	chr14:35346199	BAZ1A	-0.74	-5.4	-0.48	4.9e-7	Psoriasis;
THYM	cis	rs1461503	0.932	rs6589962	chr11:122843535	G/A	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg26314531	chr2:26401878	FAM59B	-0.72	-4.45	-0.42	2.31e-5	Gut microbiome composition (summer);
THYM	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg26752003	chr8:145688521	CYHR1	0.93	8.02	0.64	2.77e-12	Age at first birth;
THYM	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg22764044	chr5:178986830	RUFY1	-0.52	-5.42	-0.49	4.54e-7	Lung cancer;
THYM	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.26	-5.22	-0.47	1.07e-6	Obesity-related traits;
THYM	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19346786	chr7:2764209	NA	-0.75	-6.49	-0.55	3.94e-9	Height;
THYM	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg13010199	chr12:38710504	ALG10B	-0.6	-5.3	-0.48	7.56e-7	Heart rate;
THYM	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06873352	chr17:61820015	STRADA	0.56	5.6	0.5	2.12e-7	Height;
THYM	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg00278517	chr6:167070616	RPS6KA2	-0.35	-4.58	-0.42	1.44e-5	Crohn's disease;
THYM	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg09549813	chr16:4587862	C16orf5	-0.5	-5.4	-0.48	4.94e-7	Schizophrenia;
THYM	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg05872129	chr22:39784769	NA	-0.99	-10.09	-0.72	1.08e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	7.96	0.63	3.74e-12	Monocyte percentage of white cells;
THYM	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs6732160	0.809	rs13406142	chr2:73384098	A/G	cg24220031	chr2:73402428	NA	-0.76	-8.1	-0.64	1.89e-12	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.777	rs55767422	chr20:43802497	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.52	-5.89	-0.52	5.76e-8	Blood protein levels;
THYM	cis	rs669446	0.591	rs636547	chr1:44106516	C/A	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7523273	0.565	rs2796251	chr1:207903688	C/G	cg22525895	chr1:207977042	MIR29B2	-0.53	-5.08	-0.46	1.91e-6	Schizophrenia;
THYM	cis	rs1559088	0.600	rs6510344	chr19:33583942	C/A	cg03563238	chr19:33554763	RHPN2	-0.54	-4.67	-0.43	9.87e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4660306	0.614	rs12032658	chr1:45923851	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.66	4.72	0.44	8.24e-6	Homocysteine levels;
THYM	cis	rs6665290	0.904	rs6677602	chr1:227187838	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.03	-11.22	-0.75	4.16e-19	Myeloid white cell count;
THYM	cis	rs7584330	0.554	rs79020383	chr2:238425834	G/A	cg14458575	chr2:238380390	NA	0.79	4.65	0.43	1.06e-5	Prostate cancer;
THYM	trans	rs8073060	0.586	rs72828038	chr17:33893908	C/A	cg19694781	chr19:47549865	TMEM160	0.98	8.54	0.66	2.12e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs3126085	0.935	rs11586114	chr1:152299767	G/A	cg10321714	chr1:152280068	FLG	-0.71	-4.96	-0.45	3.07e-6	Atopic dermatitis;
THYM	cis	rs1568889	1.000	rs7937117	chr11:28370038	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	4.87	0.45	4.44e-6	Bipolar disorder;
THYM	cis	rs4242434	0.927	rs13271626	chr8:22467760	C/G	cg01710189	chr8:22454888	PDLIM2	-0.55	-5.72	-0.51	1.21e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg08885076	chr2:99613938	TSGA10	0.57	5.28	0.48	8.05e-7	Chronic sinus infection;
THYM	cis	rs965469	0.843	rs6037597	chr20:3408374	A/G	cg25506879	chr20:3388711	C20orf194	-0.82	-5.23	-0.47	9.91e-7	IFN-related cytopenia;
THYM	cis	rs12714314	0.957	rs6723932	chr2:1954897	T/C	cg05313794	chr2:1845466	MYT1L	-0.51	-4.55	-0.42	1.58e-5	Type 2 diabetes (age of onset);
THYM	cis	rs2066819	0.892	rs117305040	chr12:56657888	A/G	cg26714650	chr12:56694279	CS	-1.29	-6.45	-0.55	4.57e-9	Psoriasis vulgaris;
THYM	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg07936489	chr17:37558343	FBXL20	0.85	5.64	0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18402987	chr7:1209562	NA	0.75	5.49	0.49	3.29e-7	Longevity;Endometriosis;
THYM	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7173743	0.756	rs6495339	chr15:79128272	T/C	cg15571903	chr15:79123663	NA	0.54	6.2	0.54	1.48e-8	Coronary artery disease;
THYM	cis	rs7830933	0.822	rs13249197	chr8:23578404	G/T	cg04349084	chr8:23602677	NA	0.67	6.7	0.57	1.47e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs4780355	0.619	rs918737	chr16:11439639	T/C	cg00044050	chr16:11439710	C16orf75	-0.83	-5.74	-0.51	1.15e-7	Crohn's disease and psoriasis;
THYM	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11890956	chr21:40555474	PSMG1	-0.97	-10.97	-0.75	1.45e-18	Cognitive function;
THYM	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg26441486	chr22:50317300	CRELD2	0.44	7.57	0.61	2.37e-11	Schizophrenia;
THYM	cis	rs883565	0.655	rs7649923	chr3:39102137	G/A	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	5.0	0.46	2.59e-6	Handedness;
THYM	cis	rs3809566	0.963	rs4775608	chr15:63331940	A/G	cg00520135	chr15:63333846	TPM1	-0.6	-5.18	-0.47	1.24e-6	Platelet count;
THYM	cis	rs750134	0.901	rs118023614	chr12:109189062	C/G	cg07887608	chr12:109221600	SSH1	0.82	4.55	0.42	1.61e-5	Low high density lipoprotein cholesterol levels;
THYM	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg24812749	chr6:127587940	RNF146	-0.97	-7.88	-0.63	5.36e-12	Breast cancer;
THYM	cis	rs1878931	0.582	rs9635562	chr16:3416689	G/A	cg22508957	chr16:3507546	NAT15	-0.48	-5.12	-0.46	1.63e-6	Body mass index (adult);
THYM	cis	rs2295499	0.610	rs17164090	chr4:2676016	G/C	cg17924901	chr4:3475233	DOK7	0.22	4.84	0.44	5.11e-6	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.81	5.33	0.48	6.74e-7	Platelet count;
THYM	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg03684893	chr10:554711	DIP2C	-0.75	-6.34	-0.55	7.67e-9	Psychosis in Alzheimer's disease;
THYM	cis	rs7937682	0.632	rs4936800	chr11:111734097	T/A	cg09085632	chr11:111637200	PPP2R1B	1.19	12.58	0.79	6.05e-22	Primary sclerosing cholangitis;
THYM	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg08885076	chr2:99613938	TSGA10	-0.46	-4.63	-0.43	1.16e-5	Bipolar disorder;
THYM	cis	rs870825	0.616	rs72705689	chr4:185639894	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg00647820	chr17:40259828	DHX58	-0.62	-4.65	-0.43	1.06e-5	Fibrinogen levels;
THYM	cis	rs1062746	0.527	rs35143469	chr16:87335483	T/C	cg02258303	chr16:87377426	FBXO31	-0.62	-5.01	-0.46	2.51e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg00277334	chr10:82204260	NA	-0.52	-5.37	-0.48	5.53e-7	Post bronchodilator FEV1;
THYM	cis	rs477692	0.583	rs12415589	chr10:131428336	C/G	cg05714579	chr10:131428358	MGMT	-0.96	-10.65	-0.74	6.89e-18	Response to temozolomide;
THYM	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg16405210	chr4:1374714	KIAA1530	-1.03	-9.43	-0.7	2.73e-15	Longevity;
THYM	cis	rs10832963	1.000	rs4757676	chr11:18640477	C/T	cg20219074	chr11:18656078	SPTY2D1	0.81	6.58	0.56	2.52e-9	Breast cancer;
THYM	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg04731861	chr2:219085781	ARPC2	0.54	5.14	0.47	1.46e-6	Colorectal cancer;
THYM	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg23711669	chr6:146136114	FBXO30	-0.91	-8.87	-0.67	4.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10504073	0.584	rs56068225	chr8:49923988	A/G	cg00325661	chr8:49890786	NA	1.04	10.53	0.73	1.2e-17	Blood metabolite ratios;
THYM	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg02527881	chr3:46936655	PTH1R	-0.72	-7.54	-0.61	2.8e-11	Colorectal cancer;
THYM	cis	rs7586879	0.616	rs6726199	chr2:25126328	G/C	cg01884057	chr2:25150051	NA	0.73	7.9	0.63	4.81e-12	Body mass index;
THYM	cis	rs41311933	1.000	rs41311863	chr9:123757620	G/C	cg13567360	chr9:123745713	C5	-1.0	-5.28	-0.48	8.32e-7	Coronary artery disease;
THYM	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03517284	chr6:25882590	NA	-1.22	-11.7	-0.77	4.04e-20	Intelligence (multi-trait analysis);
THYM	cis	rs9902453	0.845	rs7221516	chr17:28232506	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	5.39	0.48	5.11e-7	Coffee consumption (cups per day);
THYM	cis	rs778371	0.676	rs17164	chr2:233593499	C/T	cg08000102	chr2:233561755	GIGYF2	0.79	7.17	0.59	1.64e-10	Schizophrenia;
THYM	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.74	6.19	0.54	1.49e-8	Glycated hemoglobin levels;
THYM	cis	rs673253	0.686	rs72673082	chr1:44059242	G/A	cg24466421	chr1:44070974	PTPRF	-0.61	-5.36	-0.48	5.83e-7	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg02527881	chr3:46936655	PTH1R	0.57	5.06	0.46	2.04e-6	Colorectal cancer;
THYM	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.65	-4.7	-0.43	8.92e-6	Colorectal cancer;
THYM	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg21361702	chr7:150065534	REPIN1	0.67	4.83	0.44	5.28e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	5.31	0.48	7.2e-7	Schizophrenia;
THYM	trans	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg07211511	chr3:129823064	LOC729375	-1.3	-9.82	-0.71	4.04e-16	Blood pressure (smoking interaction);
THYM	cis	rs6942756	1.000	rs2012919	chr7:128890812	C/T	cg02491457	chr7:128862824	NA	-0.44	-4.53	-0.42	1.69e-5	White matter hyperintensity burden;
THYM	cis	rs611744	0.967	rs630492	chr8:109215368	C/T	cg21045802	chr8:109455806	TTC35	-0.59	-5.31	-0.48	7.16e-7	Dupuytren's disease;
THYM	cis	rs13221852	0.722	rs2177167	chr7:3423727	G/A	cg21248987	chr7:3385318	SDK1	0.4	4.98	0.45	2.89e-6	Acute graft versus host disease in bone marrow transplantation (donor effect);
THYM	cis	rs11614062	0.680	rs10859533	chr12:93971310	T/C	cg18151635	chr12:93972918	NA	-0.82	-5.47	-0.49	3.61e-7	Height;
THYM	trans	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg25214090	chr10:38739885	LOC399744	0.94	8.15	0.64	1.49e-12	Corneal astigmatism;
THYM	cis	rs6032067	0.516	rs2743334	chr20:43919745	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.49	-5.24	-0.47	9.82e-7	Blood protein levels;
THYM	cis	rs889398	0.738	rs7196842	chr16:69923333	T/C	cg09409435	chr16:70099608	PDXDC2	0.65	4.99	0.46	2.72e-6	Body mass index;
THYM	cis	rs58804349	0.685	rs9422671	chr10:43288626	T/G	cg08461752	chr10:43522343	NA	-0.9	-4.62	-0.43	1.18e-5	Pediatric bone mineral content (radius);
THYM	cis	rs11249608	0.548	rs10479519	chr5:178450693	T/C	cg01312482	chr5:178451176	ZNF879	-0.75	-6.21	-0.54	1.37e-8	Pubertal anthropometrics;
THYM	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg09184832	chr6:79620586	NA	-0.58	-4.83	-0.44	5.2e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg18806716	chr10:30721971	MAP3K8	-0.57	-5.56	-0.5	2.51e-7	Inflammatory bowel disease;
THYM	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg26149184	chr10:133730230	NA	0.78	4.76	0.44	6.86e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg12165864	chr7:66369176	NA	-0.72	-5.56	-0.5	2.42e-7	Corneal structure;
THYM	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	14.47	0.83	9.53e-26	Chronic sinus infection;
THYM	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg08017756	chr2:100939284	LONRF2	-0.75	-7.79	-0.62	8.17e-12	Intelligence (multi-trait analysis);
THYM	cis	rs1971762	0.545	rs10876466	chr12:53981426	G/C	cg16917193	chr12:54089295	NA	0.69	6.31	0.54	8.67e-9	Height;
THYM	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg17775962	chr7:1200435	ZFAND2A	0.42	5.09	0.46	1.77e-6	Longevity;Endometriosis;
THYM	cis	rs9527	0.590	rs10786738	chr10:104869451	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-5.98	-0.52	3.86e-8	Prostate cancer;
THYM	cis	rs9611519	0.929	rs9611465	chr22:41426139	G/A	cg06481639	chr22:41940642	POLR3H	-0.6	-4.47	-0.42	2.16e-5	Neuroticism;
THYM	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg10803722	chr21:46713166	LOC642852	-0.49	-6.07	-0.53	2.66e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg13736514	chr6:26305472	NA	-0.65	-6.51	-0.56	3.48e-9	Educational attainment;
THYM	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg10661904	chr17:79619235	PDE6G	-0.66	-6.41	-0.55	5.55e-9	Eye color traits;
THYM	cis	rs17125944	0.773	rs1952089	chr14:53339777	C/T	cg00686598	chr14:53173677	PSMC6	-1.09	-4.84	-0.45	4.92e-6	Alzheimer's disease (late onset);
THYM	cis	rs12817549	0.791	rs10161389	chr12:94141259	T/C	cg19571390	chr12:94157676	CRADD	0.58	4.88	0.45	4.31e-6	Hip circumference adjusted for BMI;
THYM	cis	rs7084402	0.967	rs2577392	chr10:60329183	A/G	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs910187	0.678	rs3818012	chr20:45816594	G/A	cg27589058	chr20:45804311	EYA2	-0.56	-4.87	-0.45	4.44e-6	Migraine;
THYM	cis	rs61931739	0.534	rs11052986	chr12:34052578	T/C	cg10856724	chr12:34555212	NA	-0.76	-7.14	-0.59	1.87e-10	Morning vs. evening chronotype;
THYM	cis	rs367615	0.704	rs4286723	chr5:108835959	G/A	cg17395555	chr5:108820864	NA	0.73	8.47	0.66	3e-13	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg06028605	chr16:24865363	SLC5A11	0.5	4.56	0.42	1.53e-5	Intelligence (multi-trait analysis);
THYM	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg12863693	chr15:85201151	NMB	0.57	4.93	0.45	3.54e-6	Schizophrenia;
THYM	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg17063962	chr7:91808500	NA	-1.15	-12.48	-0.79	9.72e-22	Breast cancer;
THYM	cis	rs1011018	1.000	rs1011018	chr7:139463264	G/A	cg06079564	chr7:139468310	HIPK2	-0.73	-5.73	-0.51	1.2e-7	Systolic blood pressure;
THYM	cis	rs6987853	0.736	rs6991995	chr8:42436219	A/C	cg09913449	chr8:42400586	C8orf40	1.07	12.64	0.79	4.53e-22	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg03676636	chr4:99064102	C4orf37	0.42	6.16	0.53	1.78e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg21433313	chr16:3507492	NAT15	0.7	5.09	0.46	1.82e-6	Tuberculosis;
THYM	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg10360139	chr7:1886902	MAD1L1	-0.59	-4.8	-0.44	5.98e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9902453	0.612	rs2617868	chr17:28073247	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs7089973	0.646	rs35453961	chr10:116638166	T/C	cg23260525	chr10:116636907	FAM160B1	0.59	6.06	0.53	2.74e-8	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs861020	1.000	rs630984	chr1:209982293	C/T	cg05527609	chr1:210001259	C1orf107	1.01	7.59	0.61	2.19e-11	Orofacial clefts;
THYM	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg06558623	chr16:89946397	TCF25	1.52	8.37	0.65	4.95e-13	Skin colour saturation;
THYM	cis	rs10887741	0.532	rs791889	chr10:89413057	A/G	cg13926569	chr10:89418898	PAPSS2	0.56	4.93	0.45	3.52e-6	Exercise (leisure time);
THYM	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.01	8.17	0.64	1.3e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs11039798	0.614	rs8188910	chr11:48825740	C/T	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7940866	0.834	rs10894298	chr11:130840571	C/A	cg05962950	chr11:130786565	SNX19	0.71	5.6	0.5	2.11e-7	Schizophrenia;
THYM	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg16778714	chr17:28903809	LRRC37B2	-0.76	-4.49	-0.42	2.03e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg06481639	chr22:41940642	POLR3H	0.84	5.85	0.51	6.94e-8	Vitiligo;
THYM	cis	rs941408	1.000	rs941406	chr19:2803623	A/G	cg19693284	chr19:2783607	SGTA	0.63	4.97	0.45	2.98e-6	Total cholesterol levels;
THYM	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg12419862	chr22:24373484	LOC391322	-0.85	-9.8	-0.71	4.41e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7173743	0.756	rs4539564	chr15:79128499	G/A	cg15571903	chr15:79123663	NA	0.54	6.2	0.54	1.48e-8	Coronary artery disease;
THYM	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg01073479	chr16:3509474	NAT15	-0.68	-5.45	-0.49	4.02e-7	Tuberculosis;
THYM	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.27	10.84	0.74	2.66e-18	Platelet count;
THYM	cis	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg07460842	chr6:66804631	NA	-1.24	-15.46	-0.85	1.1e-27	Exhaled nitric oxide output;
THYM	trans	rs629535	0.814	rs72654071	chr8:70079484	A/G	cg21567404	chr3:27674614	NA	-1.09	-10.28	-0.73	4.24e-17	Dupuytren's disease;
THYM	cis	rs7626444	0.625	rs7638090	chr3:196476836	A/G	cg12930392	chr3:196481615	PAK2	0.4	4.92	0.45	3.58e-6	Monocyte count;
THYM	cis	rs870825	0.616	rs28579226	chr4:185650458	A/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs12681287	0.547	rs6985066	chr8:87526439	A/C	cg27223183	chr8:87520930	FAM82B	-0.74	-5.72	-0.51	1.21e-7	Caudate activity during reward;
THYM	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg07570687	chr10:102243282	WNT8B	0.77	6.86	0.58	7.1e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg03388043	chr17:80084554	CCDC57	0.65	5.41	0.49	4.76e-7	Life satisfaction;
THYM	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs4363385	0.818	rs10888525	chr1:153000215	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg19196401	chr6:110721138	DDO	-0.62	-7.23	-0.6	1.21e-10	Platelet distribution width;
THYM	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.59	7.83	0.63	6.98e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg15744005	chr10:104629667	AS3MT	-0.83	-7.45	-0.61	4.22e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1348850	0.789	rs13027959	chr2:178275887	G/A	cg27490568	chr2:178487706	NA	0.61	5.6	0.5	2.12e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs11622475	0.859	rs12050167	chr14:104527198	C/T	cg12183467	chr14:104352244	NA	-0.55	-4.47	-0.42	2.15e-5	Bipolar disorder;
THYM	cis	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg11663144	chr21:46675770	NA	0.47	5.57	0.5	2.33e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg10950924	chr17:47092072	IGF2BP1	-0.5	-4.64	-0.43	1.13e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs12216545	0.737	rs2103034	chr7:150237917	T/C	cg00323915	chr7:150264987	GIMAP4	-0.49	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs6992848	0.719	rs11778452	chr8:141166097	A/G	cg22504031	chr8:141147661	TRAPPC9	0.62	4.67	0.43	1e-5	Response to amphetamines;
THYM	cis	rs4589258	0.933	rs6483068	chr11:90399758	C/G	cg26138821	chr11:89956704	CHORDC1	0.71	5.96	0.52	4.22e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.86	-4.46	-0.42	2.27e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9397585	0.667	rs9479509	chr6:153427265	G/A	cg12989544	chr6:153429875	RGS17	0.43	4.49	0.42	2.02e-5	Body mass index;
THYM	cis	rs11247915	0.540	rs11582416	chr1:26677721	A/G	cg00852783	chr1:26633632	UBXN11	-0.75	-5.04	-0.46	2.2e-6	Obesity-related traits;
THYM	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2688608	0.592	rs10762559	chr10:75486453	G/C	cg15838173	chr10:75533400	FUT11	-0.54	-5.36	-0.48	5.84e-7	Inflammatory bowel disease;
THYM	cis	rs4237845	0.537	rs10747787	chr12:58260657	A/G	cg00677455	chr12:58241039	CTDSP2	0.8	6.91	0.58	5.45e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg17366294	chr4:99064904	C4orf37	0.57	6.83	0.57	8.15e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg00640147	chr17:61958756	GH2	-0.43	-4.54	-0.42	1.64e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg08999081	chr20:33150536	PIGU	-0.75	-6.73	-0.57	1.29e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs9361491	0.579	rs9352615	chr6:79441493	C/G	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9807989	0.765	rs9807962	chr2:102971664	A/G	cg03938978	chr2:103052716	IL18RAP	0.63	6.46	0.55	4.36e-9	Asthma;
THYM	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg19346786	chr7:2764209	NA	-0.72	-6.08	-0.53	2.46e-8	Height;
THYM	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg10360139	chr7:1886902	MAD1L1	-0.59	-4.96	-0.45	3.09e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7833790	0.724	rs6473299	chr8:82676936	A/G	cg27398817	chr8:82754497	SNX16	-0.76	-5.75	-0.51	1.09e-7	Diastolic blood pressure;
THYM	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg08470875	chr2:26401718	FAM59B	0.74	4.59	0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs3892630	0.588	rs7260037	chr19:33242701	G/A	cg22980127	chr19:33182716	NUDT19	1.14	10.49	0.73	1.46e-17	Red blood cell traits;
THYM	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg13319975	chr6:146136371	FBXO30	-0.72	-6.03	-0.53	3.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11165623	0.792	rs6593599	chr1:96911468	C/T	cg10631902	chr5:14652156	NA	-0.65	-7.36	-0.6	6.59e-11	Hip circumference;Waist circumference;
THYM	cis	rs4642101	0.560	rs4535210	chr3:12839617	T/G	cg05775895	chr3:12838266	CAND2	0.9	7.77	0.62	9.16e-12	QRS complex (12-leadsum);
THYM	cis	rs6840360	1.000	rs751014	chr4:152601902	G/A	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.47	-0.49	3.59e-7	Mean corpuscular volume;
THYM	cis	rs12216545	0.765	rs1879865	chr7:150258423	A/C	cg08960815	chr7:150264767	GIMAP4	-0.87	-7.97	-0.63	3.41e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs6121246	0.609	rs6089075	chr20:30392884	A/G	cg13852791	chr20:30311386	BCL2L1	0.87	8.17	0.64	1.31e-12	Mean corpuscular hemoglobin;
THYM	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg04156016	chr5:1868137	NA	0.49	4.6	0.43	1.31e-5	Cardiovascular disease risk factors;
THYM	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6429082	0.608	rs4659836	chr1:235564412	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.62	-4.62	-0.43	1.19e-5	Adiposity;
THYM	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.38	0.55	6.27e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6430585	0.591	rs3098103	chr2:136656094	T/C	cg07169764	chr2:136633963	MCM6	1.14	10.88	0.74	2.17e-18	Corneal structure;
THYM	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg18252515	chr7:66147081	NA	-0.66	-5.03	-0.46	2.34e-6	Aortic root size;
THYM	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg16342193	chr10:102329863	NA	-0.53	-5.45	-0.49	4.01e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs7786808	0.527	rs62478405	chr7:158188528	G/A	cg01191920	chr7:158217561	PTPRN2	-0.93	-9.5	-0.7	1.93e-15	Obesity-related traits;
THYM	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg21280719	chr6:42927975	GNMT	-0.45	-4.81	-0.44	5.55e-6	Blood protein levels;
THYM	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg11530693	chr1:120165357	ZNF697	1.08	12.42	0.79	1.33e-21	Systemic lupus erythematosus;
THYM	cis	rs7172677	1.000	rs7172205	chr15:75424335	A/G	cg09165964	chr15:75287851	SCAMP5	-0.61	-4.69	-0.43	9.1e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg23711669	chr6:146136114	FBXO30	-0.97	-10.49	-0.73	1.45e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3771570	0.901	rs56129392	chr2:242242439	C/T	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs2507	0.578	rs3816198	chr15:74284209	C/G	cg17221444	chr15:74284820	STOML1	-0.58	-4.74	-0.44	7.48e-6	Coronary artery disease;
THYM	cis	rs2070677	0.866	rs2492664	chr10:135387240	G/T	cg20169779	chr10:135381914	SYCE1	-0.8	-6.17	-0.54	1.63e-8	Gout;
THYM	cis	rs7191700	0.712	rs7187741	chr16:11433103	C/G	cg00044050	chr16:11439710	C16orf75	-0.8	-6.49	-0.55	3.83e-9	Multiple sclerosis;
THYM	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg03806693	chr22:41940476	POLR3H	-1.19	-10.43	-0.73	2.03e-17	Vitiligo;
THYM	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg11266682	chr4:10021025	SLC2A9	-0.52	-7.0	-0.58	3.57e-10	Bone mineral density;
THYM	cis	rs72781680	0.898	rs72786298	chr2:24083011	C/T	cg08917208	chr2:24149416	ATAD2B	1.11	4.97	0.45	2.9e-6	Lymphocyte counts;
THYM	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-1.01	-9.02	-0.68	2.05e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs346785	0.692	rs6501881	chr17:74289839	G/A	cg09812376	chr17:74270190	QRICH2	-0.49	-4.9	-0.45	3.92e-6	White matter hyperintensities in ischemic stroke;
THYM	cis	rs61990749	0.597	rs3783980	chr14:78219807	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.04	0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs17174870	0.911	rs4528767	chr2:112759864	G/C	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.58	-0.61	2.28e-11	Personality dimensions;
THYM	cis	rs9611565	0.506	rs2024567	chr22:41699206	G/C	cg13695892	chr22:41940480	POLR3H	-0.6	-4.69	-0.43	9.11e-6	Vitiligo;
THYM	cis	rs35883536	0.609	rs1577513	chr1:101044402	C/A	cg09408571	chr1:101003634	GPR88	0.48	5.21	0.47	1.07e-6	Monocyte count;
THYM	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.3	8.44	0.65	3.47e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg06728252	chr6:26598149	ABT1	-0.43	-5.11	-0.46	1.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs56079296	0.925	rs10053942	chr5:121402597	C/T	cg05256605	chr5:121412184	LOX	0.58	4.51	0.42	1.88e-5	Coronary artery disease;
THYM	cis	rs3820068	0.603	rs7516453	chr1:15972558	C/G	cg27534772	chr1:16042836	PLEKHM2	0.54	5.48	0.49	3.55e-7	Systolic blood pressure;
THYM	cis	rs9534288	0.762	rs4941539	chr13:46597067	A/T	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg22105103	chr4:187893119	NA	0.89	9.51	0.7	1.86e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs87938	0.863	rs1156916	chr3:41158322	A/T	cg02247160	chr3:41243829	CTNNB1	-0.35	-4.71	-0.43	8.55e-6	Bone mineral density (hip);
THYM	cis	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg18876405	chr7:65276391	NA	-0.56	-4.75	-0.44	7.33e-6	Aortic root size;
THYM	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg13695892	chr22:41940480	POLR3H	-1.04	-8.51	-0.66	2.47e-13	Vitiligo;
THYM	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg03929089	chr4:120376271	NA	-1.03	-12.43	-0.79	1.26e-21	Height;
THYM	cis	rs236907	0.859	rs12742601	chr1:171762125	T/C	cg20598894	chr1:171756153	METTL13	-0.72	-5.2	-0.47	1.13e-6	Mean platelet volume;
THYM	cis	rs10411161	0.702	rs10420224	chr19:52398955	A/G	cg25361850	chr19:52391789	ZNF577	0.74	4.96	0.45	3.14e-6	Breast cancer;
THYM	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7426056	0.671	rs3116491	chr2:204586676	C/T	cg07930752	chr2:204569955	CD28	-0.67	-4.74	-0.44	7.48e-6	Primary sclerosing cholangitis;
THYM	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg26924012	chr15:45694286	SPATA5L1	1.12	10.61	0.74	8.32e-18	Homoarginine levels;
THYM	cis	rs7681440	0.517	rs2619352	chr4:90747709	C/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2108225	0.900	rs2051956	chr7:107441358	G/C	cg18560240	chr7:107437656	SLC26A3	-0.72	-4.85	-0.45	4.84e-6	Ulcerative colitis;
THYM	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg20387954	chr3:183756860	HTR3D	0.56	4.64	0.43	1.11e-5	Anterior chamber depth;
THYM	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.43	0.7	2.73e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs561341	1.000	rs521919	chr17:30298039	G/T	cg20587970	chr11:113659929	NA	-1.27	-9.15	-0.68	1.08e-14	Hip circumference adjusted for BMI;
THYM	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	6.98	0.58	3.97e-10	Lung cancer in ever smokers;
THYM	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.93	-0.45	3.52e-6	Monocyte count;
THYM	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.97	6.8	0.57	9.3e-10	Schizophrenia;
THYM	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.24	4.89	0.45	4.11e-6	Obesity-related traits;
THYM	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-1.07	-9.94	-0.71	2.23e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4638749	0.501	rs1486194	chr2:108755891	C/T	cg25838818	chr2:108905173	SULT1C2	-0.52	-4.89	-0.45	4.13e-6	Blood pressure;
THYM	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs7247513	0.930	rs34321000	chr19:12713088	C/T	cg01871581	chr19:12707946	ZNF490	-0.95	-11.49	-0.76	1.16e-19	Bipolar disorder;
THYM	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg13695892	chr22:41940480	POLR3H	0.89	6.74	0.57	1.2e-9	Vitiligo;
THYM	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg20887711	chr4:1340912	KIAA1530	0.69	6.05	0.53	2.81e-8	Longevity;
THYM	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg25072359	chr17:41440525	NA	0.7	4.92	0.45	3.6e-6	Menopause (age at onset);
THYM	cis	rs72627123	0.867	rs34579846	chr14:74372164	C/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.36	5.5	0.49	3.17e-7	Obesity-related traits;
THYM	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg22841779	chr14:105766346	BRF1	-0.47	-5.81	-0.51	8.18e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.57	4.65	0.43	1.06e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs4975616	1.000	rs4975616	chr5:1315660	G/A	cg06550200	chr5:1325588	CLPTM1L	0.62	4.81	0.44	5.69e-6	Lung cancer;
THYM	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg00277334	chr10:82204260	NA	-0.83	-10.18	-0.72	6.99e-17	Post bronchodilator FEV1;
THYM	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs2236918	0.710	rs2526698	chr1:242029101	T/C	cg21919602	chr1:242011447	EXO1	-0.6	-4.45	-0.42	2.35e-5	Menopause (age at onset);
THYM	cis	rs11645898	0.748	rs3852785	chr16:72198642	G/A	cg14768367	chr16:72042858	DHODH	-0.75	-5.42	-0.49	4.51e-7	Blood protein levels;
THYM	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs11779988	0.545	rs375203	chr8:17769054	T/A	cg01800426	chr8:17659068	MTUS1	-0.68	-4.89	-0.45	4.07e-6	Breast cancer;
THYM	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg11663144	chr21:46675770	NA	-0.76	-10.98	-0.75	1.34e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2219968	0.525	rs6981844	chr8:78874876	T/C	cg00738934	chr8:78996279	NA	0.61	4.93	0.45	3.5e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11048434	0.673	rs1124402	chr12:9062606	C/T	cg13575925	chr12:9217583	LOC144571	0.53	4.82	0.44	5.35e-6	Sjögren's syndrome;
THYM	cis	rs28595532	0.920	rs115085630	chr4:119741765	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs7551222	0.691	rs4951077	chr1:204482262	G/A	cg20240347	chr1:204465584	NA	-0.51	-4.54	-0.42	1.64e-5	Schizophrenia;
THYM	cis	rs6011002	1.000	rs56010802	chr20:62304114	G/C	cg08432509	chr20:62317768	RTEL1	0.7	4.56	0.42	1.52e-5	Dental caries;
THYM	cis	rs3947	1.000	rs709821	chr8:11702594	G/C	cg26752888	chr8:11627280	NEIL2	-0.69	-4.55	-0.42	1.61e-5	Blood protein levels;
THYM	cis	rs28595532	0.841	rs115924581	chr4:119786333	T/C	cg11846333	chr4:119757529	SEC24D	1.33	4.51	0.42	1.84e-5	Cannabis dependence symptom count;
THYM	cis	rs9876781	1.000	rs6770470	chr3:48435123	G/C	cg06066452	chr3:48470258	PLXNB1	0.25	4.74	0.44	7.42e-6	Longevity;
THYM	cis	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg12826209	chr6:26865740	GUSBL1	-0.85	-4.67	-0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9810089	0.843	rs1279086	chr3:136038574	G/A	cg12473912	chr3:136751656	NA	0.6	4.87	0.45	4.42e-6	Gestational age at birth (child effect);
THYM	cis	rs4430311	0.688	rs12746623	chr1:243963175	G/A	cg25706552	chr1:244017396	NA	-0.6	-5.18	-0.47	1.25e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs2288884	0.779	rs10411428	chr19:52607765	C/T	cg05974498	chr19:52599256	ZNF841	0.42	6.14	0.53	1.93e-8	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg12863693	chr15:85201151	NMB	-0.54	-4.64	-0.43	1.12e-5	Schizophrenia;
THYM	cis	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg12981288	chr8:11183844	MTMR9	-0.47	-4.57	-0.42	1.48e-5	Retinal vascular caliber;
THYM	cis	rs8133932	0.690	rs432338	chr21:47347757	C/T	cg20357416	chr21:47294739	PCBP3	0.8	4.88	0.45	4.26e-6	Schizophrenia;
THYM	cis	rs2811415	0.597	rs9819960	chr3:127784513	T/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg07061783	chr6:25882402	NA	0.58	4.58	0.43	1.39e-5	Schizophrenia;
THYM	cis	rs747334	0.846	rs10736059	chr10:92706105	C/A	cg07620928	chr10:92689909	NA	0.58	5.22	0.47	1.04e-6	Fibroblast growth factor basic levels;
THYM	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg03690763	chr11:133734501	NA	0.63	5.44	0.49	4.22e-7	Childhood ear infection;
THYM	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg12165864	chr7:66369176	NA	-0.64	-4.92	-0.45	3.65e-6	Aortic root size;
THYM	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg06027949	chr8:82754900	SNX16	-0.64	-5.35	-0.48	6.18e-7	Diastolic blood pressure;
THYM	cis	rs919433	0.783	rs2565155	chr2:198236425	A/G	cg05783139	chr2:198650985	BOLL	0.56	4.5	0.42	1.96e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7666738	0.606	rs3846447	chr4:99099907	G/A	cg10515332	chr4:99064459	C4orf37	0.57	4.54	0.42	1.62e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg01121180	chr19:51302454	C19orf48;SNORD88B	-0.78	-6.86	-0.58	6.85e-10	Bone mineral density;
THYM	cis	rs7246967	0.611	rs34806882	chr19:22880104	T/C	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg14416269	chr4:6271139	WFS1	0.55	5.69	0.5	1.41e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg06108461	chr20:60628389	TAF4	-0.82	-6.79	-0.57	9.7e-10	Body mass index;
THYM	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg18477163	chr1:228402036	OBSCN	-0.57	-6.22	-0.54	1.31e-8	Diastolic blood pressure;
THYM	cis	rs7078219	0.523	rs4129134	chr10:101284345	C/G	cg07044859	chr10:101282883	NA	-0.39	-4.52	-0.42	1.8e-5	Dental caries;
THYM	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg06981504	chr1:1234844	ACAP3	0.53	4.85	0.45	4.73e-6	Body mass index;
THYM	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg09060608	chr5:178986726	RUFY1	-0.54	-5.66	-0.5	1.59e-7	Lung cancer;
THYM	cis	rs7209460	0.556	rs4790312	chr17:1981480	T/C	cg15816464	chr17:2026533	SMG6	0.37	4.56	0.42	1.55e-5	Coronary artery disease;Total body bone mineral density;
THYM	cis	rs4930776	0.722	rs2361589	chr12:5775247	C/T	cg02086166	chr12:5775618	ANO2	-0.55	-4.86	-0.45	4.66e-6	Plasma clusterin levels;
THYM	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-5.62	-0.5	1.92e-7	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg08132940	chr7:1081526	C7orf50	-1.15	-6.58	-0.56	2.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6939532	0.597	rs2273558	chr6:26466035	A/C	cg12826209	chr6:26865740	GUSBL1	0.66	5.02	0.46	2.43e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9515201	0.627	rs11838637	chr13:111029923	G/A	cg05272587	chr13:111038400	COL4A2	-0.54	-4.73	-0.44	7.75e-6	White matter hyperintensity burden;
THYM	cis	rs7071206	0.947	rs1877998	chr10:79411740	C/T	cg07817648	chr10:79422355	NA	-0.97	-7.5	-0.61	3.32e-11	Bone mineral density;
THYM	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg07169764	chr2:136633963	MCM6	-0.64	-5.91	-0.52	5.45e-8	Mosquito bite size;
THYM	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.91	0.58	5.57e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9649213	0.593	rs12704983	chr7:97927045	G/A	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.6e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg06009448	chr7:1102226	C7orf50	0.44	4.46	0.42	2.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg08645402	chr16:4508243	NA	0.72	6.45	0.55	4.6e-9	Schizophrenia;
THYM	cis	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg13609457	chr4:120235615	NA	0.59	5.39	0.48	5.05e-7	Corneal astigmatism;
THYM	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg06636001	chr8:8085503	FLJ10661	0.66	5.56	0.5	2.45e-7	Neuroticism;
THYM	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg26769984	chr7:1090371	C7orf50	0.84	5.73	0.51	1.2e-7	Bronchopulmonary dysplasia;
THYM	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg16524936	chr4:1340807	KIAA1530	-0.67	-5.07	-0.46	1.99e-6	Longevity;
THYM	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg12031863	chr16:4587854	C16orf5	0.42	4.58	0.42	1.43e-5	Schizophrenia;
THYM	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.35	-0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs611744	0.647	rs2848620	chr8:109249551	G/T	cg21045802	chr8:109455806	TTC35	0.65	5.91	0.52	5.3e-8	Dupuytren's disease;
THYM	cis	rs7582180	0.790	rs4851288	chr2:100920451	T/C	cg14675211	chr2:100938903	LONRF2	0.67	6.48	0.55	4.1e-9	Intelligence (multi-trait analysis);
THYM	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg03929089	chr4:120376271	NA	-1.01	-8.34	-0.65	5.67e-13	Coronary artery disease;
THYM	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.72	-0.44	8.14e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	5.21	0.47	1.08e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13065560	0.594	rs7620018	chr3:38886649	C/T	cg15678707	chr3:39149194	GORASP1;TTC21A	0.57	4.55	0.42	1.58e-5	Interleukin-18 levels;
THYM	cis	rs3750965	1.000	rs7937006	chr11:68843932	C/T	cg06818126	chr11:68850279	TPCN2	-0.69	-4.77	-0.44	6.76e-6	Hair color;
THYM	cis	rs34912216	0.551	rs35720320	chr7:4118602	G/T	cg03141780	chr7:4150753	SDK1	0.62	4.61	0.43	1.25e-5	Motion sickness;
THYM	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg02931644	chr1:25747376	RHCE	0.64	5.01	0.46	2.55e-6	Erythrocyte sedimentation rate;
THYM	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg24675056	chr1:15929824	NA	0.73	5.79	0.51	9.09e-8	Systolic blood pressure;
THYM	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21582582	chr3:182698605	DCUN1D1	0.8	7.0	0.58	3.67e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg27034606	chr17:28928453	LRRC37B2	0.77	5.38	0.48	5.41e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7172809	0.573	rs17383078	chr15:77484746	C/T	cg22256960	chr15:77711686	NA	-0.65	-4.83	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs9517302	0.578	rs2274054	chr13:99098470	C/T	cg22223119	chr13:99095684	FARP1	-0.99	-7.06	-0.59	2.66e-10	Obesity-related traits;
THYM	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg17105886	chr17:28927953	LRRC37B2	1.21	6.45	0.55	4.58e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs611744	0.870	rs2212703	chr8:109198401	G/C	cg21045802	chr8:109455806	TTC35	0.7	6.69	0.57	1.56e-9	Dupuytren's disease;
THYM	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg00129232	chr17:37814104	STARD3	0.76	5.25	0.47	9.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg05775895	chr3:12838266	CAND2	1.02	10.26	0.72	4.71e-17	QRS complex (12-leadsum);
THYM	cis	rs12580035	1.000	rs12580035	chr12:1911860	A/G	cg04012082	chr12:1905096	CACNA2D4	0.5	4.68	0.43	9.41e-6	Urate levels in lean individuals;
THYM	cis	rs6087990	0.735	rs6058892	chr20:31388461	C/T	cg13636640	chr20:31349939	DNMT3B	0.93	9.73	0.71	6.1e-16	Ulcerative colitis;
THYM	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11644478	chr21:40555479	PSMG1	1.08	9.42	0.69	2.93e-15	Cognitive function;
THYM	cis	rs4589258	0.966	rs7116531	chr11:90474658	T/C	cg26138821	chr11:89956704	CHORDC1	-0.69	-5.52	-0.49	3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1784581	0.651	rs1784589	chr6:162389571	A/G	cg17173639	chr6:162384350	PARK2	-0.82	-7.32	-0.6	8.07e-11	Itch intensity from mosquito bite;
THYM	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11644478	chr21:40555479	PSMG1	-0.82	-7.29	-0.6	9.29e-11	Cognitive function;
THYM	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg03929089	chr4:120376271	NA	-0.97	-7.74	-0.62	1.06e-11	Coronary artery disease;
THYM	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg06784218	chr1:46089804	CCDC17	0.31	4.57	0.42	1.46e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg08039701	chr5:74063125	NSA2;GFM2	-0.94	-6.96	-0.58	4.32e-10	Depressive symptoms;
THYM	cis	rs736801	0.704	rs56399423	chr5:131672657	T/C	cg18758796	chr5:131593413	PDLIM4	0.5	4.58	0.42	1.44e-5	Breast cancer;Mosquito bite size;
THYM	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg17863274	chr19:49399704	TULP2	-1.02	-6.56	-0.56	2.8e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg21644426	chr2:191273491	MFSD6	0.74	6.15	0.53	1.84e-8	Pulse pressure;
THYM	cis	rs9916302	0.706	rs1877030	chr17:37740161	T/C	cg07936489	chr17:37558343	FBXL20	-0.78	-4.85	-0.45	4.78e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg19077165	chr18:44547161	KATNAL2	-0.62	-7.95	-0.63	3.75e-12	Personality dimensions;
THYM	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	6.54	0.56	3.02e-9	Schizophrenia;
THYM	cis	rs3087591	1.000	rs12948444	chr17:29443614	A/G	cg24425628	chr17:29625626	OMG;NF1	0.65	5.61	0.5	2e-7	Hip circumference;
THYM	cis	rs4474465	1.000	rs4945277	chr11:78166967	C/T	cg02023728	chr11:77925099	USP35	0.52	4.54	0.42	1.67e-5	Alzheimer's disease (survival time);
THYM	cis	rs921968	0.565	rs35189512	chr2:219628759	T/C	cg02176678	chr2:219576539	TTLL4	-0.47	-4.56	-0.42	1.55e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11563648	0.517	rs10263603	chr7:127035245	G/A	cg23081781	chr7:127225937	GCC1	-0.35	-4.65	-0.43	1.09e-5	Resting heart rate;
THYM	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg08132940	chr7:1081526	C7orf50	-1.25	-7.04	-0.59	3e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs595982	0.527	rs55706579	chr19:49382969	G/A	cg17863274	chr19:49399704	TULP2	-0.91	-5.35	-0.48	6.11e-7	Red cell distribution width;
THYM	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg21237687	chr17:6899380	ALOX12	0.72	9.0	0.68	2.26e-14	Tonsillectomy;
THYM	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg11757124	chr7:157526947	PTPRN2	-0.65	-5.54	-0.49	2.74e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg23791538	chr6:167370224	RNASET2	-0.72	-5.66	-0.5	1.58e-7	Crohn's disease;
THYM	cis	rs9790314	0.669	rs7630768	chr3:160864879	T/A	cg03342759	chr3:160939853	NMD3	-0.61	-4.61	-0.43	1.25e-5	Morning vs. evening chronotype;
THYM	cis	rs2692947	0.770	rs2579552	chr2:96737083	A/G	cg22654517	chr2:96458247	NA	0.67	4.6	0.43	1.31e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs757081	0.608	rs214938	chr11:17188516	C/T	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.6	-0.43	1.29e-5	Systolic blood pressure;
THYM	cis	rs2302063	0.603	rs451690	chr19:3156465	G/T	cg08486065	chr19:3464875	NA	0.56	4.59	0.43	1.37e-5	Glucose homeostasis traits;
THYM	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs3847687	1.000	rs34853396	chr12:131519265	G/T	cg25772418	chr12:131519998	GPR133	-0.48	-7.06	-0.59	2.73e-10	Longevity;
THYM	trans	rs10802346	0.514	rs4443861	chr1:246372574	G/T	cg13514129	chr1:39547527	MACF1	1.03	10.83	0.74	2.8e-18	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg13395646	chr4:1353034	KIAA1530	-0.6	-5.72	-0.51	1.21e-7	Obesity-related traits;
THYM	cis	rs793108	0.712	rs2797897	chr10:31383828	T/C	cg07137701	chr10:31611868	ZEB1	-0.54	-4.8	-0.44	5.99e-6	Multiple sclerosis;Rheumatoid arthritis;
THYM	cis	rs500891	0.525	rs3778205	chr6:84060477	G/T	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg12165864	chr7:66369176	NA	0.67	5.26	0.47	8.99e-7	Aortic root size;
THYM	cis	rs8050907	0.744	rs8055559	chr16:4540227	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.45	5.39	0.48	5.08e-7	Obesity-related traits;
THYM	cis	rs1011018	0.628	rs73158613	chr7:139435454	G/A	cg06079564	chr7:139468310	HIPK2	-0.72	-4.77	-0.44	6.71e-6	Systolic blood pressure;
THYM	cis	rs4242434	0.672	rs6993302	chr8:22527457	T/C	cg11461670	chr8:22454935	PDLIM2	0.31	5.58	0.5	2.23e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs612683	0.517	rs3767832	chr1:100943100	A/G	cg06223162	chr1:101003688	GPR88	-0.79	-7.77	-0.62	9.36e-12	Breast cancer;
THYM	cis	rs889398	0.741	rs10852461	chr16:69928846	T/C	cg09409435	chr16:70099608	PDXDC2	0.65	5.25	0.47	9.28e-7	Body mass index;
THYM	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg19862616	chr7:65841803	NCRNA00174	1.06	11.85	0.77	2e-20	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9868809	0.772	rs9811318	chr3:48702606	A/G	cg00383909	chr3:49044727	WDR6	0.92	4.79	0.44	6.18e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs62435770	1.000	rs62435771	chr6:169470668	G/T	cg07652237	chr6:170125491	PHF10	0.56	4.89	0.45	4.07e-6	Loneliness;
THYM	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg12560992	chr17:57184187	TRIM37	0.94	8.84	0.67	5.01e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg18538332	chr22:24372958	LOC391322	-1.04	-11.65	-0.77	5.14e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7582180	0.627	rs2099611	chr2:101021090	A/G	cg21926883	chr2:100939477	LONRF2	-0.66	-6.26	-0.54	1.13e-8	Intelligence (multi-trait analysis);
THYM	cis	rs8067545	1.000	rs56142708	chr17:19934963	A/C	cg20830565	chr17:20408647	MGC102966	-0.5	-4.47	-0.42	2.15e-5	Schizophrenia;
THYM	cis	rs2273669	0.667	rs12154092	chr6:109313303	C/T	cg17117243	chr6:109341365	SESN1	-0.9	-5.38	-0.48	5.45e-7	Prostate cancer;
THYM	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg16405210	chr4:1374714	KIAA1530	-0.61	-4.65	-0.43	1.08e-5	Obesity-related traits;
THYM	cis	rs2836633	0.894	rs55955614	chr21:40037330	T/G	cg12884169	chr21:40033163	ERG	0.71	9.05	0.68	1.8e-14	Coronary artery disease;
THYM	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg09307838	chr4:120376055	NA	0.6	4.69	0.43	9.26e-6	Corneal astigmatism;
THYM	cis	rs17641971	0.684	rs4873093	chr8:49974740	G/T	cg00325661	chr8:49890786	NA	0.65	4.97	0.45	2.96e-6	Blood metabolite levels;
THYM	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg11494091	chr17:61959527	GH2	1.07	17.09	0.87	9.87e-31	Prudent dietary pattern;
THYM	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg25072359	chr17:41440525	NA	0.69	4.84	0.44	5.11e-6	Menopause (age at onset);
THYM	cis	rs7084402	0.967	rs1649057	chr10:60318114	C/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg13010199	chr12:38710504	ALG10B	0.69	5.43	0.49	4.35e-7	Heart rate;
THYM	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg05738196	chr6:26577821	NA	0.66	5.09	0.46	1.79e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs28595532	0.920	rs114575045	chr4:119739794	A/G	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs11645898	0.935	rs35370634	chr16:72184566	C/T	cg03805757	chr16:71968109	PKD1L3	-0.73	-5.37	-0.48	5.49e-7	Blood protein levels;
THYM	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg14004847	chr7:1930337	MAD1L1	-0.63	-4.93	-0.45	3.49e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg00074818	chr8:8560427	CLDN23	0.54	5.2	0.47	1.16e-6	Obesity-related traits;
THYM	cis	rs9581857	0.615	rs79553479	chr13:28007862	G/A	cg22138327	chr13:27999177	GTF3A	0.91	5.17	0.47	1.29e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs9522267	0.535	rs9515454	chr13:112236885	A/G	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg18252515	chr7:66147081	NA	-0.66	-5.01	-0.46	2.55e-6	Aortic root size;
THYM	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg04111992	chr7:158790115	NA	-0.57	-4.88	-0.45	4.23e-6	Facial morphology (factor 20);
THYM	cis	rs4343996	1.000	rs4343996	chr7:3362642	G/A	cg21248987	chr7:3385318	SDK1	-0.4	-4.77	-0.44	6.69e-6	Motion sickness;
THYM	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg17480646	chr11:65405466	SIPA1	-0.94	-8.85	-0.67	4.72e-14	Acne (severe);
THYM	cis	rs1129187	0.755	rs2296804	chr6:42931261	C/G	cg27588902	chr6:42928151	GNMT	-0.6	-6.32	-0.54	8.6e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.25	-0.47	9.43e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg21252483	chr19:49399788	TULP2	-0.95	-7.2	-0.59	1.41e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs4363385	0.747	rs1415961	chr1:152973464	G/A	cg13444842	chr1:152974279	SPRR3	-0.6	-4.79	-0.44	6.25e-6	Inflammatory skin disease;
THYM	cis	rs4242434	0.819	rs2306518	chr8:22470308	A/G	cg11461670	chr8:22454935	PDLIM2	-0.32	-6.15	-0.53	1.79e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg17366294	chr4:99064904	C4orf37	0.52	6.0	0.52	3.6e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12594515	1.000	rs11070464	chr15:45984776	C/A	cg01629716	chr15:45996671	NA	0.48	4.93	0.45	3.49e-6	Waist circumference;Weight;
THYM	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg05872129	chr22:39784769	NA	-1.04	-11.44	-0.76	1.48e-19	Intelligence (multi-trait analysis);
THYM	cis	rs7940866	0.903	rs7942900	chr11:130839244	G/A	cg23692386	chr11:131799662	NTM	0.43	4.65	0.43	1.06e-5	Schizophrenia;
THYM	cis	rs79149102	0.579	rs3812946	chr15:75288610	G/C	cg09165964	chr15:75287851	SCAMP5	-1.04	-4.98	-0.46	2.84e-6	Lung cancer;
THYM	cis	rs12579753	0.917	rs7132732	chr12:82206053	C/G	cg21231944	chr12:82153410	PPFIA2	-0.66	-5.01	-0.46	2.51e-6	Resting heart rate;
THYM	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg15744005	chr10:104629667	AS3MT	-0.81	-7.41	-0.6	5.28e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg11266682	chr4:10021025	SLC2A9	-0.52	-6.28	-0.54	1.03e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs116095464	1.000	rs7721278	chr5:310530	G/A	cg22857025	chr5:266934	NA	-1.41	-5.27	-0.48	8.69e-7	Breast cancer;
THYM	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg15704280	chr7:45808275	SEPT13	-1.07	-15.26	-0.84	2.74e-27	Height;
THYM	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs12530845	0.623	rs73721664	chr7:135343575	A/C	cg23117316	chr7:135346802	PL-5283	-0.79	-6.0	-0.52	3.57e-8	Red blood cell traits;
THYM	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg12310025	chr6:25882481	NA	0.68	5.49	0.49	3.3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg00757033	chr12:89920650	WDR51B	-0.73	-11.3	-0.76	2.83e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg09549813	chr16:4587862	C16orf5	-0.58	-6.54	-0.56	3.03e-9	Schizophrenia;
THYM	cis	rs66887589	0.807	rs13134517	chr4:120405262	G/A	cg13609457	chr4:120235615	NA	0.47	4.88	0.45	4.3e-6	Diastolic blood pressure;
THYM	cis	rs2637266	0.967	rs2395407	chr10:78380573	T/A	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs12509991	0.582	rs1996601	chr4:127047679	G/A	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg03676636	chr4:99064102	C4orf37	0.43	6.32	0.54	8.55e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8041943	0.643	rs10519270	chr15:79918156	C/T	cg20511832	chr15:78934280	CHRNB4	0.44	4.87	0.45	4.49e-6	Bone mineral density (spine) and age at menarche;
THYM	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg22467129	chr15:76604101	ETFA	-0.56	-5.27	-0.48	8.62e-7	Blood metabolite levels;
THYM	cis	rs12188164	0.931	rs72717407	chr5:424653	G/A	cg26850624	chr5:429559	AHRR	-0.69	-5.39	-0.48	5.09e-7	Cystic fibrosis severity;
THYM	cis	rs4951011	0.938	rs55691630	chr1:203760434	C/T	cg24343524	chr1:203763352	ZC3H11A	-0.67	-5.56	-0.5	2.43e-7	Breast cancer;
THYM	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg25072359	chr17:41440525	NA	0.72	5.26	0.47	8.95e-7	Menopause (age at onset);
THYM	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg09044154	chr16:88155775	NA	-0.74	-4.75	-0.44	7.3e-6	Menopause (age at onset);
THYM	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.22	-0.47	1.04e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6686842	1.000	rs2363803	chr1:41637529	G/A	cg03387723	chr1:41708464	SCMH1	-0.42	-4.96	-0.45	3.1e-6	Height;
THYM	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Body mass index;
THYM	cis	rs7172809	0.573	rs3784787	chr15:77681010	T/C	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg27286337	chr10:134555280	INPP5A	0.88	6.9	0.58	5.88e-10	Migraine;
THYM	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg19761014	chr17:28927070	LRRC37B2	0.76	4.73	0.44	7.7e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.22e-7	Corneal astigmatism;
THYM	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.86	9.19	0.69	8.9e-15	Menarche (age at onset);
THYM	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-6.5	-0.56	3.64e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs3540	0.512	rs3862437	chr15:91084632	A/G	cg22089800	chr15:90895588	ZNF774	-0.64	-4.8	-0.44	5.96e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg15242686	chr22:24348715	GSTTP1	-0.67	-5.79	-0.51	9.22e-8	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs6032067	0.714	rs2206887	chr20:43856024	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.66	-7.59	-0.61	2.22e-11	Blood protein levels;
THYM	cis	rs1065852	0.526	rs9611700	chr22:42401514	C/T	cg01059385	chr22:42394853	WBP2NL	0.57	4.66	0.43	1.04e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs10936602	0.527	rs1920119	chr3:169540397	T/C	cg17737146	chr3:169530037	LRRC34	0.49	4.61	0.43	1.27e-5	Renal cell carcinoma;
THYM	cis	rs10743315	0.547	rs7310796	chr12:19362390	C/T	cg02471346	chr12:19282374	PLEKHA5	-0.78	-5.1	-0.46	1.76e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg27534772	chr1:16042836	PLEKHM2	0.56	6.31	0.54	8.77e-9	Systolic blood pressure;
THYM	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg17554472	chr22:41940697	POLR3H	-0.64	-4.63	-0.43	1.16e-5	Vitiligo;
THYM	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg18681998	chr4:17616180	MED28	0.96	8.93	0.68	3.19e-14	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg22974920	chr21:40686053	BRWD1	0.68	4.65	0.43	1.08e-5	Cognitive function;
THYM	cis	rs36051895	0.632	rs1571438	chr9:5140313	A/C	cg02405213	chr9:5042618	JAK2	-1.03	-10.8	-0.74	3.29e-18	Pediatric autoimmune diseases;
THYM	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg06108461	chr20:60628389	TAF4	1.01	7.26	0.6	1.05e-10	Body mass index;
THYM	cis	rs35883536	1.000	rs2282253	chr1:101094383	C/G	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs7917772	0.715	rs7077678	chr10:104438565	C/T	cg00122347	chr10:104236741	TMEM180	-0.43	-5.59	-0.5	2.14e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg00908189	chr16:619842	PIGQ	1.16	11.18	0.75	5.05e-19	Height;
THYM	cis	rs7247513	0.927	rs34956595	chr19:12702797	A/C	cg01871581	chr19:12707946	ZNF490	-0.95	-11.42	-0.76	1.61e-19	Bipolar disorder;
THYM	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg13319975	chr6:146136371	FBXO30	-0.64	-5.33	-0.48	6.48e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06481639	chr22:41940642	POLR3H	-0.8	-5.55	-0.49	2.63e-7	Vitiligo;
THYM	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs12200560	0.505	rs211182	chr6:97074513	G/A	cg06623918	chr6:96969491	KIAA0776	0.76	5.87	0.52	6.31e-8	Coronary heart disease;
THYM	cis	rs10736390	1.000	rs10736390	chr1:55103945	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.81	-7.55	-0.61	2.66e-11	Survival in pancreatic cancer;
THYM	cis	rs17407555	0.657	rs12508233	chr4:10271037	C/T	cg00071950	chr4:10020882	SLC2A9	0.59	5.53	0.49	2.81e-7	Schizophrenia (age at onset);
THYM	cis	rs7226229	0.948	rs899338	chr17:20899241	T/C	cg21263980	chr17:20946333	USP22	0.72	4.97	0.45	2.94e-6	Blood trace element (Se levels);
THYM	cis	rs11167764	0.945	rs7720832	chr5:141473097	T/G	cg23435118	chr5:141488016	NDFIP1	-0.53	-4.51	-0.42	1.85e-5	Crohn's disease;
THYM	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	6.84	0.57	7.73e-10	Lung cancer in ever smokers;
THYM	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21582582	chr3:182698605	DCUN1D1	0.81	7.19	0.59	1.49e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6700896	0.931	rs10789193	chr1:66129646	A/T	cg04111102	chr1:66153794	NA	0.56	5.27	0.48	8.45e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.71	6.25	0.54	1.16e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3126085	0.935	rs4326625	chr1:152223996	C/T	cg10321714	chr1:152280068	FLG	0.69	4.92	0.45	3.67e-6	Atopic dermatitis;
THYM	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg08736216	chr1:53307985	ZYG11A	0.54	5.01	0.46	2.46e-6	Monocyte count;
THYM	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg18252515	chr7:66147081	NA	-1.57	-8.55	-0.66	2.07e-13	Diabetic kidney disease;
THYM	cis	rs1978968	1.000	rs2099944	chr22:18438578	G/A	cg01550578	chr22:18484421	MICAL3	0.69	5.15	0.47	1.41e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg18402987	chr7:1209562	NA	1.23	7.55	0.61	2.62e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg14019146	chr3:50243930	SLC38A3	-0.82	-7.24	-0.6	1.18e-10	Intelligence (multi-trait analysis);
THYM	cis	rs1018836	0.923	rs10956749	chr8:91621573	G/A	cg16814680	chr8:91681699	NA	-0.85	-7.17	-0.59	1.59e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06481639	chr22:41940642	POLR3H	0.8	5.63	0.5	1.81e-7	Vitiligo;
THYM	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg13736514	chr6:26305472	NA	-0.6	-7.56	-0.61	2.48e-11	Educational attainment;
THYM	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg21854759	chr1:92012499	NA	-0.72	-6.15	-0.53	1.81e-8	Breast cancer;
THYM	cis	rs9810089	1.000	rs1279831	chr3:135933264	A/G	cg12473912	chr3:136751656	NA	0.6	5.19	0.47	1.22e-6	Gestational age at birth (child effect);
THYM	cis	rs6866344	0.697	rs72812613	chr5:178135257	G/A	cg10224037	chr5:178157518	ZNF354A	0.99	7.84	0.63	6.55e-12	Neutrophil percentage of white cells;
THYM	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg08772003	chr10:104629869	AS3MT	-0.59	-5.36	-0.48	5.83e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg26597838	chr10:835615	NA	1.52	11.37	0.76	2.05e-19	Eosinophil percentage of granulocytes;
THYM	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg10589385	chr1:150898437	SETDB1	-0.57	-4.55	-0.42	1.56e-5	Melanoma;
THYM	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg04362960	chr10:104952993	NT5C2	0.58	4.93	0.45	3.52e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg25131247	chr11:118660965	DDX6	0.99	7.14	0.59	1.87e-10	Depressive symptoms;
THYM	cis	rs11696501	0.637	rs3746596	chr20:44312028	C/T	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.57	-0.42	1.46e-5	Brain structure;
THYM	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg06521331	chr12:34319734	NA	-0.98	-8.5	-0.66	2.65e-13	Morning vs. evening chronotype;
THYM	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-4.48	-0.42	2.07e-5	Monocyte percentage of white cells;
THYM	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg08847533	chr14:75593920	NEK9	-1.0	-11.26	-0.76	3.48e-19	Height;
THYM	cis	rs2742234	0.541	rs1254958	chr10:43702143	C/T	cg06632098	chr10:43605906	RET	0.79	5.1	0.46	1.73e-6	Hirschsprung disease;
THYM	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg00278517	chr6:167070616	RPS6KA2	-0.34	-4.64	-0.43	1.13e-5	Crohn's disease;
THYM	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg11764359	chr7:65958608	NA	-0.8	-6.38	-0.55	6.55e-9	Aortic root size;
THYM	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg18681998	chr4:17616180	MED28	0.95	9.44	0.7	2.65e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg16031515	chr1:205743344	RAB7L1	-0.58	-6.08	-0.53	2.53e-8	Menarche (age at onset);
THYM	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs61990749	0.597	rs6574402	chr14:78267950	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	1.18	8.09	0.64	1.98e-12	Fibroblast growth factor basic levels;
THYM	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg18758796	chr5:131593413	PDLIM4	0.5	4.74	0.44	7.49e-6	Blood metabolite levels;
THYM	cis	rs11031096	0.679	rs12292515	chr11:4206385	T/G	cg08557956	chr11:4115526	RRM1	-0.55	-4.99	-0.46	2.76e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7757969	1.000	rs7752077	chr6:112147107	A/G	cg20596647	chr6:112163498	FYN	-0.43	-4.53	-0.42	1.7e-5	Schizophrenia;
THYM	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg05182265	chr7:156933206	UBE3C	-0.69	-9.34	-0.69	4.32e-15	Body mass index;
THYM	cis	rs986417	1.000	rs10148202	chr14:61055940	C/T	cg27398547	chr14:60952738	C14orf39	-1.06	-5.29	-0.48	7.87e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg15445000	chr17:37608096	MED1	-0.44	-5.07	-0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.89	0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg02478829	chr6:26598070	ABT1	-0.33	-4.46	-0.42	2.27e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7599312	0.534	rs10180824	chr2:213407975	G/A	cg16329650	chr2:213403929	ERBB4	0.99	11.32	0.76	2.57e-19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg22431228	chr1:16359049	CLCNKA	-0.42	-4.51	-0.42	1.85e-5	Systolic blood pressure;
THYM	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg07636037	chr3:49044803	WDR6	-0.91	-7.97	-0.63	3.56e-12	Menarche (age at onset);
THYM	cis	rs7219021	0.705	rs9904288	chr17:47031973	T/C	cg09029085	chr17:47094198	IGF2BP1	0.33	4.48	0.42	2.04e-5	Schizophrenia or bipolar disorder;
THYM	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg13395646	chr4:1353034	KIAA1530	-0.55	-5.1	-0.46	1.72e-6	Longevity;
THYM	cis	rs678347	1.000	rs671484	chr8:102458515	A/G	cg27484483	chr8:103249853	RRM2B	0.56	5.1	0.46	1.76e-6	Rheumatoid arthritis;
THYM	cis	rs986417	0.901	rs1955688	chr14:60989237	G/A	cg27398547	chr14:60952738	C14orf39	1.14	5.33	0.48	6.64e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg12262378	chr17:6899522	ALOX12	-0.67	-8.15	-0.64	1.43e-12	Tonsillectomy;
THYM	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg21658235	chr8:22456391	C8orf58	0.5	5.06	0.46	2.04e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2637266	1.000	rs2130798	chr10:78329563	C/T	cg18941641	chr10:78392320	NA	0.83	7.32	0.6	7.86e-11	Pulmonary function;
THYM	cis	rs9807841	0.544	rs10417412	chr19:10766798	A/C	cg16900796	chr19:10755136	SLC44A2	0.32	4.87	0.45	4.5e-6	Inflammatory skin disease;
THYM	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg15592062	chr6:167189543	RPS6KA2	0.59	6.1	0.53	2.29e-8	Crohn's disease;
THYM	cis	rs28595532	0.920	rs114333298	chr4:119765305	C/A	cg21605333	chr4:119757512	SEC24D	1.67	6.15	0.53	1.85e-8	Cannabis dependence symptom count;
THYM	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg12288994	chr5:1860383	NA	0.86	7.08	0.59	2.44e-10	Cardiovascular disease risk factors;
THYM	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg27446573	chr6:127587934	RNF146	0.74	6.53	0.56	3.27e-9	Breast cancer;
THYM	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg20891283	chr12:69753455	YEATS4	0.75	6.43	0.55	5e-9	Blood protein levels;
THYM	cis	rs919433	0.679	rs6757632	chr2:198530266	C/T	cg00792783	chr2:198669748	PLCL1	0.82	5.44	0.49	4.16e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg04267008	chr7:1944627	MAD1L1	-0.67	-5.76	-0.51	1.05e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg00981070	chr1:2046702	PRKCZ	-0.41	-5.17	-0.47	1.27e-6	Height;
THYM	cis	rs11252926	0.574	rs10904065	chr10:423226	G/T	cg14018140	chr10:458528	DIP2C	0.59	5.59	0.5	2.13e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.88	8.14	0.64	1.56e-12	Menarche (age at onset);
THYM	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg13319975	chr6:146136371	FBXO30	0.67	5.64	0.5	1.78e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg10518543	chr12:38710700	ALG10B	-0.58	-4.52	-0.42	1.81e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7106204	0.858	rs2403889	chr11:24210226	T/C	ch.11.24196551F	chr11:24239977	NA	0.99	7.0	0.58	3.64e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg06656553	chr16:89960601	TCF25	-0.84	-4.82	-0.44	5.5e-6	Skin colour saturation;
THYM	cis	rs1747683	0.932	rs10752297	chr10:13375906	T/C	cg25835351	chr10:13388524	SEPHS1	-0.35	-5.73	-0.51	1.17e-7	IgG glycosylation;
THYM	cis	rs7940866	0.874	rs7111478	chr11:130819628	A/G	cg05962950	chr11:130786565	SNX19	0.62	4.82	0.44	5.39e-6	Schizophrenia;
THYM	cis	rs79349575	0.783	rs2112617	chr17:46977125	G/A	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs9970807	0.748	rs6588634	chr1:56938218	C/T	cg11959316	chr1:57001742	PPAP2B	-0.63	-4.88	-0.45	4.29e-6	Myocardial infarction;Coronary artery disease;
THYM	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg12963246	chr6:28129442	ZNF389	0.57	5.45	0.49	3.99e-7	Parkinson's disease;
THYM	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg20887711	chr4:1340912	KIAA1530	-0.58	-4.64	-0.43	1.13e-5	Obesity-related traits;
THYM	cis	rs12935418	0.616	rs13332902	chr16:81005800	T/C	cg16651780	chr16:81037892	C16orf61	0.76	5.4	0.48	4.86e-7	Mean corpuscular volume;
THYM	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg25801113	chr15:45476975	SHF	-0.39	-4.5	-0.42	1.91e-5	Uric acid levels;
THYM	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs3126085	0.935	rs12738889	chr1:152257688	G/A	cg10321714	chr1:152280068	FLG	-0.64	-4.81	-0.44	5.57e-6	Atopic dermatitis;
THYM	cis	rs2404602	0.735	rs11632222	chr15:76712927	C/G	cg23482746	chr15:76478102	C15orf27	0.47	4.61	0.43	1.25e-5	Blood metabolite levels;
THYM	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.44	-0.49	4.16e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg27121462	chr16:89883253	FANCA	0.57	4.54	0.42	1.65e-5	Vitiligo;
THYM	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.66	-0.43	1.05e-5	Eye color traits;
THYM	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg23840854	chr1:161414152	NA	1.03	5.72	0.51	1.23e-7	Rheumatoid arthritis;
THYM	cis	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-5.57	-0.5	2.4e-7	Morning vs. evening chronotype;
THYM	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg08807101	chr21:30365312	RNF160	0.93	7.99	0.63	3.1e-12	Dental caries;
THYM	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg20503657	chr10:835505	NA	0.96	5.68	0.5	1.47e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs490234	0.702	rs4838277	chr9:128367886	C/T	cg14078157	chr9:128172775	NA	-0.77	-6.1	-0.53	2.27e-8	Mean arterial pressure;
THYM	cis	rs6840360	0.615	rs4696094	chr4:152465501	C/T	cg22705602	chr4:152727874	NA	-0.74	-7.91	-0.63	4.55e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7827545	0.644	rs4909452	chr8:135521053	C/G	cg17885191	chr8:135476712	NA	-0.79	-5.98	-0.52	3.89e-8	Hypertension (SNP x SNP interaction);
THYM	cis	rs8192282	0.739	rs4474240	chr1:154457855	A/C	cg16683920	chr1:154474344	TDRD10;SHE	-0.68	-6.22	-0.54	1.35e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg03929089	chr4:120376271	NA	-0.98	-10.67	-0.74	6.29e-18	Coronary artery disease;
THYM	cis	rs1357245	0.631	rs7615277	chr3:27097159	A/G	cg03895047	chr3:27114861	NA	0.49	4.58	0.43	1.42e-5	Breast cancer;
THYM	cis	rs9649213	0.593	rs7795176	chr7:97978287	A/C	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4919669	0.546	rs2145307	chr10:104280664	G/A	cg00122347	chr10:104236741	TMEM180	-0.59	-4.8	-0.44	5.93e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
THYM	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.64	-0.5	1.73e-7	Menopause (age at onset);
THYM	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg26384229	chr12:38710491	ALG10B	-0.89	-9.05	-0.68	1.77e-14	Heart rate;
THYM	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg26384229	chr12:38710491	ALG10B	0.94	8.07	0.64	2.1e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6541297	0.699	rs1555290	chr1:230294989	A/C	cg20703242	chr1:230279135	GALNT2	-0.88	-4.57	-0.42	1.47e-5	Coronary artery disease;
THYM	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.22e-7	Corneal astigmatism;
THYM	cis	rs13082711	0.911	rs17019721	chr3:27424799	A/G	cg02860705	chr3:27208620	NA	0.67	4.7	0.43	8.87e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs2858942	0.602	rs1211375	chr16:240280	G/T	cg17291625	chr16:236080	NA	0.59	4.48	0.42	2.05e-5	Mean corpuscular hemoglobin;
THYM	cis	rs1003719	0.715	rs8126941	chr21:38551542	T/A	cg01329690	chr21:38580129	DSCR9	-0.34	-4.68	-0.43	9.67e-6	Eye color traits;
THYM	cis	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg23417131	chr11:92866768	NA	-0.8	-5.67	-0.5	1.53e-7	Subcortical brain region volumes;
THYM	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs8112211	1.000	rs12611255	chr19:38815483	T/C	cg25820703	chr19:38877220	GGN	-0.48	-4.55	-0.42	1.58e-5	Blood protein levels;
THYM	cis	rs9486719	1.000	rs13210597	chr6:96969694	C/A	cg18709589	chr6:96969512	KIAA0776	-0.68	-4.71	-0.44	8.44e-6	Migraine;Coronary artery disease;
THYM	cis	rs7131987	0.650	rs11050188	chr12:29473108	A/C	cg09582351	chr12:29534625	ERGIC2	-0.59	-5.13	-0.47	1.53e-6	QT interval;
THYM	cis	rs981844	1.000	rs72731674	chr4:154667447	C/A	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg27068330	chr11:65405492	SIPA1	1.03	11.9	0.77	1.56e-20	Systemic lupus erythematosus;
THYM	cis	rs8112449	0.822	rs2043330	chr19:10553618	C/T	cg01466491	chr19:10523363	NA	-0.62	-5.87	-0.52	6.45e-8	Multiple sclerosis;Gastritis;
THYM	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.67	5.9	0.52	5.62e-8	Lung disease severity in cystic fibrosis;
THYM	cis	rs7638995	0.617	rs9842761	chr3:69194345	C/A	cg26574240	chr3:69171822	LMOD3	0.7	5.47	0.49	3.68e-7	Alzheimer's disease (late onset);
THYM	cis	rs1298062	0.763	rs921938	chr19:50982086	C/A	cg11430371	chr19:50961752	MYBPC2	0.46	4.52	0.42	1.77e-5	Age of smoking initiation;
THYM	cis	rs80180425	0.638	rs1561813	chr15:101230050	C/T	cg19187121	chr15:101628653	NA	0.34	4.84	0.44	4.95e-6	Pediatric bone mineral content (spine);
THYM	cis	rs1669338	0.588	rs73009149	chr3:3220473	G/C	cg16797762	chr3:3221439	CRBN	-0.99	-5.37	-0.48	5.48e-7	White matter integrity;
THYM	cis	rs3796352	0.568	rs11713376	chr3:52958927	A/G	cg24530246	chr3:53118167	NA	-0.65	-4.49	-0.42	1.99e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs68170813	0.559	rs7804979	chr7:106999453	C/G	cg00661777	chr7:106511741	PIK3CG	-0.66	-4.61	-0.43	1.25e-5	Coronary artery disease;
THYM	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg24069376	chr3:38537580	EXOG	0.69	6.79	0.57	9.87e-10	Electrocardiographic conduction measures;
THYM	cis	rs7523273	0.597	rs66532523	chr1:207983745	A/C	cg22525895	chr1:207977042	MIR29B2	-0.77	-5.13	-0.47	1.55e-6	Schizophrenia;
THYM	cis	rs72843506	0.656	rs58313980	chr17:19940050	A/G	cg12065943	chr17:19881925	AKAP10	-0.76	-4.58	-0.43	1.41e-5	Schizophrenia;
THYM	cis	rs9796	0.870	rs7181816	chr15:41358720	T/A	cg21153102	chr15:41252147	NA	0.68	6.31	0.54	8.68e-9	Menopause (age at onset);
THYM	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02018176	chr4:1364513	KIAA1530	0.99	10.1	0.72	1.02e-16	Longevity;
THYM	cis	rs7917772	0.604	rs11191358	chr10:104399250	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.61	-4.63	-0.43	1.15e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24549020	chr5:56110836	MAP3K1	0.7	4.58	0.42	1.43e-5	Initial pursuit acceleration;
THYM	cis	rs7216064	0.953	rs8073510	chr17:65839210	A/G	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs448720	0.811	rs1996121	chr15:68181578	G/T	cg24579218	chr15:68104479	NA	-0.52	-4.62	-0.43	1.22e-5	Cognitive performance;
THYM	cis	rs7267979	1.000	rs4815417	chr20:25379526	C/T	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs42648	0.642	rs11771963	chr7:89887587	G/T	cg25739043	chr7:89950458	NA	-0.53	-4.5	-0.42	1.9e-5	Homocysteine levels;
THYM	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg23791538	chr6:167370224	RNASET2	-0.61	-4.81	-0.44	5.66e-6	Crohn's disease;
THYM	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg08975724	chr8:8085496	FLJ10661	-0.63	-4.86	-0.45	4.62e-6	Mood instability;
THYM	cis	rs62103177	0.564	rs55867755	chr18:77723434	C/T	cg02751453	chr18:77725136	HSBP1L1	-0.61	-4.96	-0.45	3.05e-6	Opioid sensitivity;
THYM	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg11812906	chr14:75593930	NEK9	-0.82	-7.38	-0.6	5.94e-11	Height;
THYM	cis	rs7762018	0.607	rs79728466	chr6:170046405	T/C	cg19338460	chr6:170058176	WDR27	-1.06	-6.21	-0.54	1.39e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs7107174	1.000	rs11602622	chr11:78010830	A/G	cg02023728	chr11:77925099	USP35	0.65	5.98	0.52	3.83e-8	Testicular germ cell tumor;
THYM	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg17105886	chr17:28927953	LRRC37B2	-1.35	-7.53	-0.61	2.86e-11	Body mass index;
THYM	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg04362960	chr10:104952993	NT5C2	0.61	4.99	0.46	2.68e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg19770292	chr5:1868693	NA	0.54	4.97	0.45	2.95e-6	Cardiovascular disease risk factors;
THYM	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg18252515	chr7:66147081	NA	0.67	5.25	0.47	9.45e-7	Aortic root size;
THYM	cis	rs861020	0.563	rs61820640	chr1:210041297	G/T	cg05527609	chr1:210001259	C1orf107	-0.84	-5.93	-0.52	4.84e-8	Orofacial clefts;
THYM	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.77	-6.39	-0.55	6.1e-9	Type 2 diabetes;
THYM	cis	rs6500395	0.926	rs9929569	chr16:48677584	C/T	cg04672837	chr16:48644449	N4BP1	0.49	4.76	0.44	7.03e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs910187	0.678	rs3818008	chr20:45816488	C/T	cg27589058	chr20:45804311	EYA2	-0.56	-4.87	-0.45	4.44e-6	Migraine;
THYM	cis	rs2811415	0.569	rs9829877	chr3:127787969	A/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs7940866	0.838	rs10736592	chr11:130800572	C/T	cg12179176	chr11:130786555	SNX19	0.73	5.95	0.52	4.41e-8	Schizophrenia;
THYM	cis	rs10191773	0.589	rs72831634	chr2:112946796	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.78	-4.65	-0.43	1.07e-5	Yeast infection;
THYM	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	4.93	0.45	3.51e-6	Motion sickness;
THYM	cis	rs11662586	0.517	rs7228070	chr18:77698967	C/T	cg20368463	chr18:77673604	PQLC1	0.65	4.8	0.44	5.86e-6	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
THYM	cis	rs8133932	0.654	rs7410101	chr21:47328383	G/A	cg20357416	chr21:47294739	PCBP3	-0.81	-4.93	-0.45	3.54e-6	Schizophrenia;
THYM	cis	rs2109514	1.000	rs7795510	chr7:116156961	T/C	cg12739419	chr7:116140593	CAV2	-0.48	-4.64	-0.43	1.11e-5	Prevalent atrial fibrillation;
THYM	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg00024416	chr22:24240387	NA	-0.63	-7.01	-0.58	3.51e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1346	0.552	rs4326800	chr11:65367253	C/T	cg27068330	chr11:65405492	SIPA1	0.7	4.57	0.42	1.45e-5	Vertical cup-disc ratio;Optic cup area;
THYM	cis	rs9560113	0.622	rs4773388	chr13:112195250	A/C	cg10483660	chr13:112241077	NA	0.67	7.48	0.61	3.65e-11	Menarche (age at onset);
THYM	cis	rs6467136	0.765	rs11764631	chr7:127179493	G/A	cg23081781	chr7:127225937	GCC1	-0.31	-4.52	-0.42	1.75e-5	Type 2 diabetes;
THYM	cis	rs636291	0.517	rs672606	chr1:10526144	G/A	cg05038881	chr1:10490043	APITD1	0.24	4.68	0.43	9.44e-6	Prostate cancer;
THYM	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg02887458	chr19:19495540	GATAD2A	-0.42	-5.08	-0.46	1.87e-6	Bipolar disorder;
THYM	cis	rs9914988	0.943	rs11652272	chr17:27167973	C/G	cg20469991	chr17:27169893	C17orf63	-0.75	-4.47	-0.42	2.13e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs7187994	0.895	rs7184644	chr16:84786460	C/A	cg07647771	chr16:84786436	USP10	-0.55	-5.05	-0.46	2.15e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg13695892	chr22:41940480	POLR3H	-0.94	-7.28	-0.6	9.75e-11	Vitiligo;
THYM	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg20587970	chr11:113659929	NA	-1.37	-8.96	-0.68	2.79e-14	Hip circumference adjusted for BMI;
THYM	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg10523679	chr1:76189770	ACADM	0.92	10.33	0.73	3.22e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	trans	rs877282	0.945	rs17293517	chr10:778770	C/T	cg22713356	chr15:30763199	NA	1.4	11.57	0.76	7.82e-20	Uric acid levels;
THYM	cis	rs2888875	0.547	rs12052942	chr2:43815829	C/T	cg22033476	chr2:43532275	THADA	-0.4	-4.61	-0.43	1.26e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs9287719	0.746	rs6742448	chr2:10759126	G/A	cg02196655	chr2:10830764	NOL10	-0.45	-4.77	-0.44	6.77e-6	Prostate cancer;
THYM	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg07936489	chr17:37558343	FBXL20	-0.67	-4.9	-0.45	3.86e-6	Asthma;
THYM	cis	rs57244997	0.582	rs73030429	chr6:162438902	A/G	cg17173639	chr6:162384350	PARK2	-0.74	-4.93	-0.45	3.43e-6	Mosquito bite size;
THYM	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.28	-5.88	-0.52	6.2e-8	Obesity-related traits;
THYM	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg24531977	chr5:56204891	C5orf35	-0.72	-5.83	-0.51	7.64e-8	Initial pursuit acceleration;
THYM	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg24308560	chr3:49941425	MST1R	0.79	6.8	0.57	9.31e-10	Intelligence (multi-trait analysis);
THYM	cis	rs3772130	0.583	rs28497949	chr3:121448675	T/A	cg20356878	chr3:121714668	ILDR1	0.63	4.89	0.45	4.07e-6	Cognitive performance;
THYM	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg12419862	chr22:24373484	LOC391322	0.97	12.03	0.78	8.51e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6032067	0.714	rs6104055	chr20:43822962	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.6	-5.78	-0.51	9.42e-8	Blood protein levels;
THYM	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg03676636	chr4:99064102	C4orf37	0.38	5.41	0.49	4.62e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs950880	0.710	rs12905	chr2:102960007	G/A	cg03938978	chr2:103052716	IL18RAP	-0.54	-4.75	-0.44	7.28e-6	Serum protein levels (sST2);
THYM	cis	rs2898681	0.874	rs4864688	chr4:53742636	A/G	cg00338735	chr4:53728038	RASL11B	0.53	4.52	0.42	1.82e-5	Optic nerve measurement (cup area);
THYM	cis	rs6430585	0.528	rs6711493	chr2:136692553	A/G	cg23851026	chr2:136556271	LCT	0.7	7.3	0.6	8.77e-11	Corneal structure;
THYM	cis	rs9814567	1.000	rs11706117	chr3:134212526	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-8.1	-0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2554380	0.891	rs2562781	chr15:84312568	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.62	-4.76	-0.44	6.81e-6	Height;
THYM	cis	rs791590	0.752	rs62626325	chr10:6121285	G/A	cg17191567	chr10:6178319	NA	0.7	4.91	0.45	3.83e-6	Soluble interleukin-2 receptor subunit alpha;
THYM	cis	rs1692580	0.870	rs590367	chr1:2162944	C/T	cg24578937	chr1:2090814	PRKCZ	0.52	5.2	0.47	1.14e-6	Coronary artery disease;
THYM	cis	rs11105298	0.891	rs10858854	chr12:89835728	C/A	cg00757033	chr12:89920650	WDR51B	0.73	9.65	0.7	9.03e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs17030434	0.954	rs11724154	chr4:154753108	G/T	cg14289246	chr4:154710475	SFRP2	-0.79	-5.33	-0.48	6.69e-7	Electrocardiographic conduction measures;
THYM	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg27490568	chr2:178487706	NA	0.89	7.42	0.61	4.89e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg21252483	chr19:49399788	TULP2	-0.95	-7.17	-0.59	1.59e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7582180	0.652	rs4443016	chr2:100876628	C/G	cg21926883	chr2:100939477	LONRF2	-0.52	-4.49	-0.42	1.97e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1065852	0.526	rs8138080	chr22:42396371	A/G	cg22189786	chr22:42395067	WBP2NL	-0.56	-5.62	-0.5	1.94e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs6430585	0.591	rs75223002	chr2:136525309	G/T	cg07169764	chr2:136633963	MCM6	1.22	13.28	0.81	2.23e-23	Corneal structure;
THYM	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.7	5.33	0.48	6.5e-7	Tonsillectomy;
THYM	cis	rs9549367	0.804	rs9549704	chr13:113885187	T/C	cg18105134	chr13:113819100	PROZ	-1.05	-9.12	-0.68	1.25e-14	Platelet distribution width;
THYM	cis	rs17604090	0.775	rs73090343	chr7:29688768	T/C	cg19413766	chr7:29689036	LOC646762	-0.92	-5.03	-0.46	2.28e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg18230493	chr5:56204884	C5orf35	-0.86	-6.17	-0.54	1.63e-8	Initial pursuit acceleration;
THYM	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg19746536	chr19:49375674	PPP1R15A	0.79	4.46	0.42	2.28e-5	Red cell distribution width;
THYM	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg15704280	chr7:45808275	SEPT13	1.0	11.16	0.75	5.73e-19	Coronary artery disease;
THYM	cis	rs240764	0.717	rs10872622	chr6:101165017	C/T	cg21058520	chr6:100914733	NA	0.57	4.92	0.45	3.69e-6	Neuroticism;
THYM	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg27034606	chr17:28928453	LRRC37B2	0.66	4.47	0.42	2.19e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.83	0.57	8.15e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs886126	0.901	rs4766557	chr12:111664044	G/C	cg10833066	chr12:111807467	FAM109A	0.43	5.33	0.48	6.48e-7	Coronary heart disease;
THYM	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg06238570	chr21:40685208	BRWD1	0.91	4.93	0.45	3.53e-6	Cognitive function;
THYM	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-9.21	-0.69	7.91e-15	Chronic sinus infection;
THYM	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg10803722	chr21:46713166	LOC642852	0.42	5.4	0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.51	-4.79	-0.44	6.24e-6	Lymphocyte counts;
THYM	cis	rs11048434	0.736	rs2377672	chr12:9112414	A/G	cg13575925	chr12:9217583	LOC144571	0.53	4.97	0.45	2.96e-6	Sjögren's syndrome;
THYM	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg08859206	chr1:53392774	SCP2	-0.53	-5.75	-0.51	1.07e-7	Monocyte count;
THYM	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg05294307	chr14:35346193	BAZ1A	-0.93	-6.68	-0.57	1.64e-9	Psoriasis;
THYM	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg06784218	chr1:46089804	CCDC17	0.29	4.62	0.43	1.18e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.65	-4.75	-0.44	7.21e-6	Response to fenofibrate (adiponectin levels);
THYM	trans	rs9929218	0.906	rs9932679	chr16:68751904	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-7.48	-0.61	3.7e-11	Colorectal cancer;
THYM	cis	rs9296092	0.538	rs9469486	chr6:33516849	G/A	cg13560919	chr6:33536144	NA	-0.94	-9.16	-0.68	1.03e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg00012203	chr2:219082015	ARPC2	-0.81	-7.84	-0.63	6.51e-12	Colorectal cancer;
THYM	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg14004847	chr7:1930337	MAD1L1	0.65	5.14	0.47	1.46e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg04944784	chr2:26401820	FAM59B	1.09	8.74	0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs36051895	0.589	rs17492549	chr9:5202830	A/C	cg02405213	chr9:5042618	JAK2	-0.96	-7.35	-0.6	6.79e-11	Pediatric autoimmune diseases;
THYM	cis	rs7246657	0.943	rs2045908	chr19:37979768	C/G	cg22634378	chr19:37742834	NA	0.61	5.01	0.46	2.52e-6	Coronary artery calcification;
THYM	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs10463554	0.824	rs34818	chr5:102436111	T/A	cg23492399	chr5:102201601	PAM	-0.69	-5.04	-0.46	2.26e-6	Parkinson's disease;
THYM	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg23711669	chr6:146136114	FBXO30	-0.98	-10.65	-0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6032067	0.929	rs1997892	chr20:43810961	A/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs4072705	0.967	rs4144630	chr9:127439200	A/G	cg13476313	chr9:127244764	NR5A1	0.32	4.75	0.44	7.27e-6	Menarche (age at onset);
THYM	cis	rs4731207	0.535	rs7806126	chr7:124601875	T/C	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.82	-4.55	-0.42	1.56e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg21427119	chr20:30132790	HM13	-0.7	-4.7	-0.43	8.88e-6	Mean corpuscular hemoglobin;
THYM	cis	rs778371	0.834	rs778363	chr2:233778896	A/G	cg08000102	chr2:233561755	GIGYF2	-0.63	-4.6	-0.43	1.29e-5	Schizophrenia;
THYM	cis	rs6956675	0.957	rs28541324	chr7:62608767	G/A	cg08930214	chr7:62859557	LOC100287834	0.63	4.65	0.43	1.06e-5	Obesity-related traits;
THYM	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.72	4.77	0.44	6.74e-6	Lung cancer in ever smokers;
THYM	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg19761014	chr17:28927070	LRRC37B2	0.76	4.79	0.44	6.19e-6	Body mass index;
THYM	cis	rs9807841	0.670	rs10948	chr19:10754905	G/T	cg16900796	chr19:10755136	SLC44A2	0.33	5.09	0.46	1.84e-6	Inflammatory skin disease;
THYM	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg08807101	chr21:30365312	RNF160	-0.67	-5.22	-0.47	1.05e-6	Dental caries;
THYM	cis	rs2625529	0.689	rs12050794	chr15:72169466	G/A	cg16672083	chr15:72433130	SENP8	0.53	4.66	0.43	1.04e-5	Red blood cell count;
THYM	cis	rs600806	0.821	rs417270	chr1:109849144	T/C	cg02175308	chr1:109941060	SORT1	-0.56	-4.87	-0.45	4.5e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg18105134	chr13:113819100	PROZ	-0.94	-8.7	-0.67	1e-13	Platelet distribution width;
THYM	cis	rs12478296	0.681	rs73007114	chr2:242984903	T/C	cg06360820	chr2:242988706	NA	-1.34	-7.96	-0.63	3.66e-12	Obesity-related traits;
THYM	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg04731861	chr2:219085781	ARPC2	0.56	5.39	0.48	5.21e-7	Colorectal cancer;
THYM	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg08968635	chr6:28129556	ZNF389	0.61	5.96	0.52	4.34e-8	Parkinson's disease;
THYM	cis	rs13326165	0.760	rs17052058	chr3:52344680	A/G	cg08438690	chr3:52279403	PPM1M	-0.66	-4.73	-0.44	7.82e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs16912285	0.688	rs7929701	chr11:24357964	A/C	ch.11.24196551F	chr11:24239977	NA	0.83	5.72	0.51	1.21e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs8048589	1.000	rs8048589	chr16:12185810	A/G	cg01990910	chr16:12207648	SNX29	-0.44	-4.95	-0.45	3.24e-6	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs17401966	0.867	rs10492973	chr1:10398985	T/C	cg19773385	chr1:10388646	KIF1B	-0.59	-4.82	-0.44	5.39e-6	Hepatocellular carcinoma;
THYM	cis	rs7131987	0.801	rs962866	chr12:29434147	A/G	cg09582351	chr12:29534625	ERGIC2	-0.47	-4.54	-0.42	1.63e-5	QT interval;
THYM	cis	rs12579753	1.000	rs12579753	chr12:82219376	C/T	cg21231944	chr12:82153410	PPFIA2	-0.66	-5.11	-0.46	1.67e-6	Resting heart rate;
THYM	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg22166914	chr1:53195759	ZYG11B	-0.69	-5.33	-0.48	6.5e-7	Monocyte count;
THYM	cis	rs9329289	0.610	rs10903783	chr10:2540623	C/T	cg15501526	chr10:2543763	NA	0.53	4.72	0.44	8.15e-6	Age-related hearing impairment;
THYM	cis	rs10489202	0.608	rs35059151	chr1:168079393	C/A	cg24449463	chr1:168025552	DCAF6	-0.79	-7.54	-0.61	2.77e-11	Schizophrenia;
THYM	cis	rs10982256	0.817	rs10817628	chr9:117259538	A/C	cg15903421	chr9:117267460	DFNB31	-0.53	-4.86	-0.45	4.6e-6	Bipolar disorder;
THYM	cis	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg10856724	chr12:34555212	NA	-0.87	-7.72	-0.62	1.16e-11	Morning vs. evening chronotype;
THYM	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg05368731	chr17:41323189	NBR1	1.2	10.98	0.75	1.36e-18	Menopause (age at onset);
THYM	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.32	-9.88	-0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg15744005	chr10:104629667	AS3MT	-0.84	-8.32	-0.65	6.21e-13	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs10504073	0.647	rs10435574	chr8:49996028	G/A	cg00325661	chr8:49890786	NA	0.93	8.79	0.67	6.32e-14	Blood metabolite ratios;
THYM	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg23711669	chr6:146136114	FBXO30	0.96	10.29	0.73	3.99e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11563648	0.573	rs1419394	chr7:126962068	C/T	cg23081781	chr7:127225937	GCC1	0.37	5.19	0.47	1.17e-6	Resting heart rate;
THYM	cis	rs4919044	0.599	rs11187215	chr10:94670849	A/G	cg05127821	chr10:94822908	CYP26C1	-1.13	-6.78	-0.57	1.03e-9	Coronary artery disease;
THYM	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg17143192	chr8:8559678	CLDN23	0.61	4.55	0.42	1.57e-5	Mood instability;
THYM	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs11039798	1.000	rs12225599	chr11:48755868	T/C	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg13319975	chr6:146136371	FBXO30	-0.71	-5.81	-0.51	8.44e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10484885	0.887	rs17764308	chr6:90602268	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.8	-6.83	-0.57	8.08e-10	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs9563576	0.778	rs9563575	chr13:58656850	T/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.6	4.5	0.42	1.9e-5	Body mass index;
THYM	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg16482183	chr6:26056742	HIST1H1C	-0.69	-4.63	-0.43	1.14e-5	Iron status biomarkers;
THYM	cis	rs12681288	0.550	rs6989880	chr8:957209	A/G	cg08648136	chr8:956695	NA	0.58	5.0	0.46	2.57e-6	Schizophrenia;
THYM	cis	rs2294693	0.947	rs9349176	chr6:40989525	C/T	cg14769373	chr6:40998127	UNC5CL	-0.62	-4.93	-0.45	3.47e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg08859206	chr1:53392774	SCP2	0.51	5.7	0.51	1.32e-7	Monocyte count;
THYM	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.13	9.25	0.69	6.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg00271210	chr6:167070053	RPS6KA2	-0.5	-4.96	-0.45	3.07e-6	Crohn's disease;
THYM	cis	rs3092073	0.617	rs8123864	chr20:44598670	T/C	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.49	-5.07	-0.46	1.98e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg15962314	chr1:44399869	ARTN	0.53	5.39	0.48	5.01e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg11663144	chr21:46675770	NA	-0.7	-9.8	-0.71	4.38e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3760982	0.585	rs10422108	chr19:44294868	C/T	cg11993925	chr19:44307056	LYPD5	0.64	5.0	0.46	2.58e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs2811415	0.597	rs9863134	chr3:127748216	G/T	cg05377949	chr3:127951287	EEFSEC	-0.38	-4.74	-0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs67981189	0.896	rs2526878	chr14:71377295	A/G	cg15910301	chr14:71632612	NA	-0.52	-4.79	-0.44	6.15e-6	Schizophrenia;
THYM	cis	rs74338693	1.000	rs6722431	chr2:166821676	G/A	cg23808213	chr2:166948291	NA	-0.44	-4.45	-0.42	2.33e-5	Schizophrenia;
THYM	cis	rs1403694	1.000	rs1624230	chr3:186438935	A/C	cg12454167	chr3:186435060	KNG1	-0.43	-5.82	-0.51	8.09e-8	Blood protein levels;
THYM	cis	rs2811415	0.597	rs12695503	chr3:127769174	C/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs17321999	0.904	rs906865	chr2:30478173	C/T	cg05247661	chr2:30472410	LBH	0.71	5.22	0.47	1.03e-6	Systemic lupus erythematosus;
THYM	cis	rs262147	0.610	rs2657363	chr7:158684273	C/T	cg23730037	chr7:158596552	ESYT2	-0.8	-4.9	-0.45	4.01e-6	Hippocampal volume;
THYM	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg20887711	chr4:1340912	KIAA1530	0.66	5.61	0.5	2.02e-7	Longevity;
THYM	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg09549813	chr16:4587862	C16orf5	0.59	6.65	0.56	1.84e-9	Schizophrenia;
THYM	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg01448562	chr3:133502909	NA	-0.84	-7.13	-0.59	1.92e-10	Iron status biomarkers;
THYM	trans	rs4596713	0.508	rs12056979	chr9:71778946	A/G	cg16512924	chr15:28394682	HERC2	0.83	6.92	0.58	5.28e-10	Headache;
THYM	cis	rs11252926	0.545	rs1551508	chr10:555469	A/G	cg03684893	chr10:554711	DIP2C	-0.64	-5.2	-0.47	1.14e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs12310956	0.532	rs11052922	chr12:33957476	A/G	cg06521331	chr12:34319734	NA	-0.88	-8.26	-0.65	8.51e-13	Morning vs. evening chronotype;
THYM	cis	rs6596100	0.538	rs66542366	chr5:132159520	T/A	cg02081065	chr5:132209139	LEAP2	-0.67	-4.64	-0.43	1.14e-5	Breast cancer;
THYM	cis	rs9311676	0.656	rs62258128	chr3:58397142	C/G	cg26110898	chr3:58419937	PDHB	0.44	4.68	0.43	9.4e-6	Systemic lupus erythematosus;
THYM	cis	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg05335186	chr13:53173507	NA	-0.4	-5.03	-0.46	2.29e-6	Lewy body disease;
THYM	cis	rs2350702	0.660	rs7562595	chr2:49967393	A/G	cg22592722	chr2:49566210	NA	-0.63	-4.65	-0.43	1.08e-5	Morning vs. evening chronotype;
THYM	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg00129232	chr17:37814104	STARD3	-0.73	-4.98	-0.45	2.87e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7681440	0.606	rs2619354	chr4:90748284	C/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs7828089	0.646	rs7000551	chr8:22276251	A/G	cg12081754	chr8:22256438	SLC39A14	0.92	8.73	0.67	8.64e-14	Verbal declarative memory;
THYM	cis	rs1797081	0.901	rs703059	chr10:16876402	G/A	cg23933602	chr10:16859644	RSU1	0.87	9.11	0.68	1.32e-14	Platelet distribution width;
THYM	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg02527881	chr3:46936655	PTH1R	-0.6	-6.01	-0.52	3.48e-8	Colorectal cancer;
THYM	cis	rs7631605	0.837	rs6796640	chr3:37213274	C/A	cg21328643	chr3:37258149	NA	-0.48	-4.51	-0.42	1.82e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg02734326	chr4:10020555	SLC2A9	-0.56	-4.63	-0.43	1.17e-5	Bone mineral density;
THYM	cis	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg06521331	chr12:34319734	NA	-0.84	-6.44	-0.55	4.78e-9	Morning vs. evening chronotype;
THYM	cis	rs8106542	0.826	rs1560709	chr19:10742463	G/T	cg17848348	chr19:10766748	ILF3	-0.8	-6.65	-0.56	1.88e-9	Platelet distribution width;
THYM	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.78	-6.17	-0.54	1.63e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg22709100	chr7:91322751	NA	-0.63	-5.04	-0.46	2.26e-6	Breast cancer;
THYM	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.35	0.48	6.04e-7	Tonsillectomy;
THYM	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg20203395	chr5:56204925	C5orf35	0.65	4.47	0.42	2.15e-5	Initial pursuit acceleration;
THYM	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg13319975	chr6:146136371	FBXO30	0.64	5.24	0.47	9.69e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg27141850	chr2:20869434	GDF7	-0.6	-5.46	-0.49	3.83e-7	Abdominal aortic aneurysm;
THYM	cis	rs2625529	0.586	rs7175197	chr15:72461648	G/A	cg16672083	chr15:72433130	SENP8	0.49	4.52	0.42	1.76e-5	Red blood cell count;
THYM	cis	rs7524258	0.868	rs10779678	chr1:7300573	A/G	cg07173049	chr1:7289937	CAMTA1	0.81	6.33	0.54	8.04e-9	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs7731657	0.537	rs6889977	chr5:130328628	G/A	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg25767906	chr1:53392781	SCP2	-0.55	-5.53	-0.49	2.84e-7	Monocyte count;
THYM	cis	rs7614311	0.555	rs3774715	chr3:63919876	T/C	cg22134162	chr3:63841271	THOC7	-0.55	-6.19	-0.54	1.52e-8	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs4919087	1.000	rs10786329	chr10:99074621	G/A	cg19453742	chr10:98862320	SLIT1	-0.62	-4.86	-0.45	4.69e-6	Monocyte count;
THYM	cis	rs9595908	0.965	rs12323094	chr13:33143364	C/T	cg12383807	chr13:33924137	NA	-0.53	-4.59	-0.43	1.36e-5	Body mass index;
THYM	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg06221963	chr1:154839813	KCNN3	-0.86	-11.16	-0.75	5.75e-19	Prostate cancer;
THYM	cis	rs7638995	0.941	rs1995664	chr3:69183004	T/C	cg26574240	chr3:69171822	LMOD3	-0.6	-4.82	-0.44	5.4e-6	Alzheimer's disease (late onset);
THYM	cis	rs346785	0.692	rs6501882	chr17:74289875	C/T	cg09812376	chr17:74270190	QRICH2	-0.49	-4.9	-0.45	3.92e-6	White matter hyperintensities in ischemic stroke;
THYM	cis	rs747782	0.527	rs2279822	chr11:48146114	C/T	cg24672777	chr11:48374446	OR4C45	-1.01	-5.56	-0.5	2.46e-7	Intraocular pressure;
THYM	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg13695892	chr22:41940480	POLR3H	0.89	7.27	0.6	1.02e-10	Cannabis dependence symptom count;
THYM	cis	rs921968	0.565	rs1529382	chr2:219626489	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4294134	0.608	rs13233394	chr7:135243240	T/C	cg08396481	chr7:135194601	CNOT4	-0.86	-5.03	-0.46	2.27e-6	Paget's disease;
THYM	cis	rs77320796	0.953	rs6680258	chr1:40399488	G/T	cg05657805	chr1:40942785	ZNF642	0.78	4.55	0.42	1.58e-5	Platelet count;
THYM	cis	rs7226229	1.000	rs4985955	chr17:20898014	C/T	cg21263980	chr17:20946333	USP22	-0.73	-5.07	-0.46	1.93e-6	Blood trace element (Se levels);
THYM	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11644478	chr21:40555479	PSMG1	-0.54	-4.53	-0.42	1.72e-5	Menarche (age at onset);
THYM	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg11752832	chr7:134001865	SLC35B4	0.73	5.5	0.49	3.21e-7	Mean platelet volume;
THYM	cis	rs611744	0.752	rs609197	chr8:109234035	G/A	cg21045802	chr8:109455806	TTC35	0.59	5.25	0.47	9.08e-7	Dupuytren's disease;
THYM	cis	rs9420907	0.748	rs9419958	chr10:105675946	T/C	cg11005552	chr10:105648138	OBFC1	0.59	4.61	0.43	1.23e-5	Telomere length;
THYM	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg16506815	chr2:162101123	NA	0.72	5.84	0.51	7.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	5.54	0.49	2.69e-7	Menarche (age at onset);
THYM	cis	rs1160297	0.576	rs13003962	chr2:53110176	C/T	cg07782112	chr2:53107842	NA	0.75	6.09	0.53	2.4e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs2885056	0.830	rs2018810	chr19:10669172	A/G	cg08312369	chr19:10679775	CDKN2D	-0.64	-4.48	-0.42	2.08e-5	Red cell distribution width;
THYM	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs7248779	0.532	rs10153475	chr19:2413961	G/C	cg22729335	chr19:2427816	TIMM13	1.26	13.38	0.81	1.39e-23	Cortisol levels (saliva);
THYM	cis	rs67311347	0.577	rs1317217	chr3:40271697	T/G	cg13683864	chr3:40499215	RPL14	-0.69	-6.02	-0.53	3.23e-8	Renal cell carcinoma;
THYM	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.48	-4.86	-0.45	4.64e-6	Crohn's disease;
THYM	cis	rs7487075	0.930	rs4076248	chr12:46833605	C/T	cg21428710	chr12:47219797	SLC38A4	0.46	4.54	0.42	1.63e-5	Itch intensity from mosquito bite;
THYM	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1267303	0.675	rs1267312	chr1:46986748	C/G	cg25110126	chr1:46999211	NA	-0.64	-5.01	-0.46	2.51e-6	Monobrow;
THYM	cis	rs986417	0.901	rs1955687	chr14:60988606	A/G	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs4072705	0.967	rs4838195	chr9:127351217	G/A	cg13476313	chr9:127244764	NR5A1	0.31	4.52	0.42	1.8e-5	Menarche (age at onset);
THYM	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg04362960	chr10:104952993	NT5C2	-0.63	-4.47	-0.42	2.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	trans	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg07211511	chr3:129823064	LOC729375	-1.28	-10.3	-0.73	3.76e-17	Blood pressure (smoking interaction);
THYM	cis	rs1747683	0.932	rs6602648	chr10:13383212	C/T	cg25835351	chr10:13388524	SEPHS1	-0.35	-5.9	-0.52	5.49e-8	IgG glycosylation;
THYM	cis	rs6430585	0.583	rs9636213	chr2:136589278	G/A	cg04750100	chr2:136595281	LCT	-0.58	-6.19	-0.54	1.53e-8	Corneal structure;
THYM	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.11e-8	Systolic blood pressure;
THYM	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg00074818	chr8:8560427	CLDN23	0.53	4.76	0.44	6.82e-6	Obesity-related traits;
THYM	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.96	0.68	2.8e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg02725872	chr8:58115012	NA	-0.73	-5.26	-0.47	8.86e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs61931739	0.612	rs2004961	chr12:33994599	A/G	cg06521331	chr12:34319734	NA	-0.59	-4.94	-0.45	3.29e-6	Morning vs. evening chronotype;
THYM	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg00071950	chr4:10020882	SLC2A9	0.75	7.63	0.62	1.81e-11	Bone mineral density;
THYM	cis	rs3126085	0.935	rs3126062	chr1:152272352	G/A	cg10321714	chr1:152280068	FLG	-0.64	-4.81	-0.44	5.57e-6	Atopic dermatitis;
THYM	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs7833986	1.000	rs35883156	chr8:57078933	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	5.05	0.46	2.12e-6	Height;
THYM	cis	rs2456568	0.900	rs2511399	chr11:93682156	C/T	cg17595323	chr11:93583763	C11orf90	0.54	5.22	0.47	1.04e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs10779751	0.770	rs1148480	chr1:11172006	A/G	cg08854313	chr1:11322531	MTOR	0.88	7.82	0.63	7.34e-12	Body mass index;
THYM	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.16	-8.93	-0.68	3.25e-14	Platelet count;
THYM	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	6.96	0.58	4.33e-10	Smoking behavior;
THYM	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg03433033	chr1:76189801	ACADM	0.83	14.1	0.82	5.02e-25	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg05707623	chr12:122985044	ZCCHC8	-0.72	-4.74	-0.44	7.36e-6	Body mass index;
THYM	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11890956	chr21:40555474	PSMG1	-0.9	-9.57	-0.7	1.4e-15	Cognitive function;
THYM	cis	rs2898681	0.614	rs58260946	chr4:53675420	A/G	cg21521518	chr4:53727714	RASL11B	0.47	5.1	0.46	1.7e-6	Optic nerve measurement (cup area);
THYM	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs56161922	0.818	rs111340461	chr1:207870682	A/C	cg09557387	chr1:207818395	CR1L	1.26	5.57	0.5	2.32e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs1113500	0.933	rs10785833	chr1:108639082	A/G	cg06207961	chr1:108661230	NA	0.64	5.09	0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg04315214	chr1:2043799	PRKCZ	0.65	5.29	0.48	7.9e-7	Height;
THYM	cis	rs919433	0.648	rs787975	chr2:198248128	C/T	cg00792783	chr2:198669748	PLCL1	0.81	5.47	0.49	3.63e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg12935359	chr14:103987150	CKB	0.53	6.3	0.54	9.43e-9	Intelligence (multi-trait analysis);
THYM	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg16486109	chr11:613632	IRF7	0.46	5.38	0.48	5.31e-7	Systemic lupus erythematosus;
THYM	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg08048268	chr3:133502702	NA	0.68	5.84	0.51	7.16e-8	Iron status biomarkers;
THYM	cis	rs2769264	0.505	rs4246526	chr1:151403916	G/T	cg18801370	chr1:151430492	POGZ	0.63	4.52	0.42	1.77e-5	Blood trace element (Cu levels);
THYM	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg14137381	chr5:502291	SLC9A3	-0.65	-4.52	-0.42	1.77e-5	Cystic fibrosis severity;
THYM	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg02018176	chr4:1364513	KIAA1530	0.5	4.57	0.42	1.44e-5	Obesity-related traits;
THYM	cis	rs13185784	0.667	rs35551113	chr5:179654221	T/C	cg13944838	chr5:179740914	GFPT2	0.75	4.98	0.46	2.79e-6	TRAIL levels;
THYM	cis	rs2625529	0.689	rs4526973	chr15:72138719	A/G	cg16672083	chr15:72433130	SENP8	-0.49	-4.47	-0.42	2.2e-5	Red blood cell count;
THYM	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg00958927	chr1:175162553	KIAA0040	-0.33	-4.48	-0.42	2.06e-5	Alcohol dependence;
THYM	cis	rs13082711	0.911	rs923941	chr3:27458914	A/G	cg02860705	chr3:27208620	NA	0.72	5.14	0.47	1.46e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs478304	0.817	rs524475	chr11:65518065	T/A	cg27068330	chr11:65405492	SIPA1	0.82	7.91	0.63	4.72e-12	Acne (severe);
THYM	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	4.66	0.43	1.04e-5	Diabetic retinopathy;
THYM	cis	rs7586879	0.681	rs6545800	chr2:25118885	A/G	cg01884057	chr2:25150051	NA	-0.71	-7.7	-0.62	1.31e-11	Body mass index;
THYM	cis	rs763014	0.898	rs8060585	chr16:635794	C/G	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg10505658	chr17:80084571	CCDC57	0.68	7.45	0.61	4.18e-11	Life satisfaction;
THYM	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.47	-0.49	3.59e-7	Mean corpuscular volume;
THYM	cis	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg07460842	chr6:66804631	NA	-0.87	-5.95	-0.52	4.56e-8	Exhaled nitric oxide output;
THYM	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs11048434	0.673	rs11611106	chr12:9060204	A/C	cg13575925	chr12:9217583	LOC144571	-0.52	-4.79	-0.44	6.06e-6	Sjögren's syndrome;
THYM	cis	rs6496667	1.000	rs1839972	chr15:90891354	A/G	cg22089800	chr15:90895588	ZNF774	0.74	5.0	0.46	2.65e-6	Rheumatoid arthritis;
THYM	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg15744005	chr10:104629667	AS3MT	-0.8	-7.4	-0.6	5.47e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7226229	1.000	rs12103803	chr17:20944604	C/T	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg05368731	chr17:41323189	NBR1	1.25	11.13	0.75	6.44e-19	Menopause (age at onset);
THYM	trans	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg05926928	chr17:57297772	GDPD1	1.2	9.3	0.69	5.26e-15	Opioid sensitivity;
THYM	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg10518543	chr12:38710700	ALG10B	-0.57	-4.49	-0.42	2.04e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7178572	0.568	rs1602925	chr15:77685857	T/C	cg22256960	chr15:77711686	NA	-1.05	-8.4	-0.65	4.29e-13	Type 2 diabetes;
THYM	cis	rs2273669	0.667	rs12198182	chr6:109318704	T/G	cg17117243	chr6:109341365	SESN1	-0.9	-5.38	-0.48	5.45e-7	Prostate cancer;
THYM	cis	rs2835345	0.563	rs12482257	chr21:37823958	T/C	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg09354556	chr3:47051341	NA	0.46	4.71	0.44	8.28e-6	Colorectal cancer;
THYM	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	13.4	0.81	1.29e-23	Chronic sinus infection;
THYM	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg13395646	chr4:1353034	KIAA1530	-0.55	-4.6	-0.43	1.31e-5	Longevity;
THYM	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg07636037	chr3:49044803	WDR6	0.96	9.68	0.7	8e-16	Parkinson's disease;
THYM	cis	rs11186	0.556	rs7425292	chr2:189968352	C/G	cg11041835	chr2:189156425	GULP1	0.8	4.58	0.43	1.41e-5	Parkinson's disease;
THYM	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg11764359	chr7:65958608	NA	0.81	6.42	0.55	5.31e-9	Aortic root size;
THYM	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.03	10.73	0.74	4.6e-18	Cognitive ability;
THYM	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4845875	0.529	rs6680385	chr1:11831756	A/G	cg14194983	chr1:11908298	NPPA	0.51	4.64	0.43	1.1e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg00684032	chr4:1343700	KIAA1530	0.75	6.54	0.56	3.03e-9	Obesity-related traits;
THYM	trans	rs9951602	0.512	rs9946123	chr18:76654557	A/G	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg10802521	chr3:52805072	NEK4	-0.6	-5.03	-0.46	2.34e-6	Electroencephalogram traits;
THYM	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg27129171	chr3:47204927	SETD2	-0.8	-7.64	-0.62	1.69e-11	Colorectal cancer;
THYM	cis	rs10028773	0.546	rs13117947	chr4:120257060	A/G	cg13609457	chr4:120235615	NA	0.47	4.84	0.44	5.02e-6	Educational attainment;
THYM	cis	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg18512352	chr11:47633146	NA	-0.38	-4.52	-0.42	1.75e-5	HDL cholesterol;
THYM	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg09035930	chr12:129282057	SLC15A4	0.84	10.37	0.73	2.66e-17	Systemic lupus erythematosus;
THYM	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg10802521	chr3:52805072	NEK4	-0.67	-5.56	-0.5	2.52e-7	Bipolar disorder;
THYM	cis	rs995000	0.931	rs11207990	chr1:63041086	T/C	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs4363385	0.643	rs11576457	chr1:152918556	C/T	cg07796016	chr1:152779584	LCE1C	0.61	4.91	0.45	3.71e-6	Inflammatory skin disease;
THYM	cis	rs7177026	0.500	rs10519265	chr15:79928223	C/T	cg20511832	chr15:78934280	CHRNB4	0.44	5.03	0.46	2.27e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs3087591	0.960	rs2953000	chr17:29509791	C/T	cg24425628	chr17:29625626	OMG;NF1	0.61	5.23	0.47	1.02e-6	Hip circumference;
THYM	cis	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg07460842	chr6:66804631	NA	0.97	6.01	0.52	3.49e-8	Exhaled nitric oxide levels;
THYM	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg22907277	chr7:1156413	C7orf50	0.87	8.71	0.67	9.19e-14	Longevity;Endometriosis;
THYM	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg02527881	chr3:46936655	PTH1R	0.66	6.44	0.55	4.78e-9	Colorectal cancer;
THYM	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs293526	0.959	rs293527	chr6:83647854	C/T	cg23278060	chr6:83777448	DOPEY1	0.62	4.49	0.42	1.98e-5	Crohn's disease;
THYM	trans	rs9951602	0.512	rs9946138	chr18:76654608	A/G	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs1113500	0.933	rs61797344	chr1:108622580	C/T	cg06207961	chr1:108661230	NA	0.66	5.18	0.47	1.24e-6	Growth-regulated protein alpha levels;
THYM	cis	rs7084402	0.967	rs1649048	chr10:60324282	C/T	cg09696939	chr10:60272079	BICC1	-0.45	-5.12	-0.46	1.62e-6	Refractive error;
THYM	cis	rs6840360	0.571	rs4696102	chr4:152529658	C/T	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.98	4.89	0.45	4.07e-6	Initial pursuit acceleration;
THYM	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg08085267	chr17:45401833	C17orf57	-0.61	-4.79	-0.44	6.12e-6	Glaucoma (primary open-angle);
THYM	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg08132940	chr7:1081526	C7orf50	-1.16	-6.65	-0.56	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11039798	0.687	rs11499938	chr11:48957297	G/A	cg24672777	chr11:48374446	OR4C45	-1.09	-6.34	-0.55	7.56e-9	Axial length;
THYM	trans	rs1349882	0.580	rs716414	chr2:52953099	A/C	cg09203490	chr14:60098107	RTN1	0.7	7.13	0.59	1.92e-10	Asymmetrical dimethylarginine levels;
THYM	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	4.68	0.43	9.45e-6	Aortic root size;
THYM	cis	rs7264396	0.563	rs2425117	chr20:34323776	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Total cholesterol levels;
THYM	cis	rs201673768	1	rs201673768	chr12:48699606	TGTTTTGTTTTG/T	cg21466736	chr12:48725269	NA	-0.46	-5.11	-0.46	1.63e-6	Platelet count;
THYM	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.61	-5.95	-0.52	4.41e-8	Prudent dietary pattern;
THYM	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs9361491	0.608	rs9352626	chr6:79455091	C/T	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs11840576	0.588	rs332311	chr13:110319646	C/T	cg16896868	chr13:110319562	NA	-0.8	-6.96	-0.58	4.43e-10	Paclitaxel disposition in epithelial ovarian cancer;
THYM	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg08968635	chr6:28129556	ZNF389	-0.69	-5.76	-0.51	1.04e-7	Depression;
THYM	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg15133208	chr4:90757351	SNCA	-0.52	-4.47	-0.42	2.16e-5	Neuroticism;
THYM	cis	rs2820651	1.000	rs2820656	chr10:1466607	G/A	cg27404824	chr10:1454848	ADARB2	0.92	4.81	0.44	5.74e-6	Migraine with aura;
THYM	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg03806693	chr22:41940476	POLR3H	1.1	8.83	0.67	5.2e-14	Vitiligo;
THYM	cis	rs4242434	0.672	rs900266	chr8:22485295	A/T	cg03733263	chr8:22462867	KIAA1967	1.0	11.13	0.75	6.58e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg07061783	chr6:25882402	NA	-0.57	-4.45	-0.42	2.3e-5	Height;
THYM	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg24503407	chr1:205819492	PM20D1	-0.78	-7.23	-0.6	1.2e-10	Monocyte percentage of white cells;
THYM	cis	rs11048434	0.736	rs34798934	chr12:9108444	C/T	cg13575925	chr12:9217583	LOC144571	0.53	4.94	0.45	3.31e-6	Sjögren's syndrome;
THYM	cis	rs8013055	0.796	rs28662250	chr14:105996341	C/G	cg04429589	chr14:105992532	TMEM121	-0.5	-5.32	-0.48	7e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06850241	chr22:41845214	NA	0.49	4.62	0.43	1.21e-5	Vitiligo;
THYM	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg01364799	chr7:75623366	TMEM120A	-0.62	-4.46	-0.42	2.22e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs174601	0.861	rs174584	chr11:61610750	G/A	cg19610905	chr11:61596333	FADS2	-0.57	-4.81	-0.44	5.59e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
THYM	cis	rs75064307	0.834	rs7636575	chr3:108115862	C/T	cg03329597	chr3:108125523	MYH15	-0.62	-4.63	-0.43	1.16e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg22907277	chr7:1156413	C7orf50	0.83	5.1	0.46	1.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6138458	1.000	rs7269416	chr20:24976196	T/G	cg06937882	chr20:24974362	C20orf3	-0.46	-4.64	-0.43	1.11e-5	Blood protein levels;
THYM	cis	rs6032067	0.777	rs13038275	chr20:43780988	A/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.93	-0.58	5.03e-10	Blood protein levels;
THYM	cis	rs9361491	0.608	rs9448540	chr6:79441675	G/T	cg04547799	chr6:79944526	HMGN3	-0.65	-4.5	-0.42	1.94e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10276303	0.519	rs6971307	chr7:3396217	T/C	cg21248987	chr7:3385318	SDK1	-0.4	-4.97	-0.45	3e-6	Dupuytren's disease;
THYM	cis	rs8017423	0.967	rs11159956	chr14:90715890	C/T	cg04239629	chr14:90701769	NA	0.62	4.52	0.42	1.81e-5	Mortality in heart failure;
THYM	cis	rs7646881	0.504	rs7617304	chr3:158463101	C/T	cg18349298	chr3:158450550	RARRES1	0.55	4.87	0.45	4.49e-6	Tetralogy of Fallot;
THYM	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.61e-20	Menopause (age at onset);
THYM	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg11752832	chr7:134001865	SLC35B4	0.76	5.57	0.5	2.34e-7	Mean platelet volume;
THYM	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg02887458	chr19:19495540	GATAD2A	-0.49	-5.38	-0.48	5.37e-7	Bipolar disorder;
THYM	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	8.39	0.65	4.46e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs3820068	0.603	rs17448778	chr1:15985306	A/G	cg13390004	chr1:15929781	NA	0.66	5.04	0.46	2.17e-6	Systolic blood pressure;
THYM	cis	rs9810089	0.527	rs661739	chr3:135953476	C/T	cg21827317	chr3:136751795	NA	0.64	5.99	0.52	3.69e-8	Gestational age at birth (child effect);
THYM	cis	rs10463554	0.927	rs154369	chr5:102406844	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs12282928	1.000	rs7952009	chr11:48286845	A/G	cg22827986	chr11:48284249	OR4X1	-0.53	-5.5	-0.49	3.18e-7	Migraine - clinic-based;
THYM	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg15448220	chr1:150897856	SETDB1	0.88	7.49	0.61	3.44e-11	Melanoma;
THYM	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg06028605	chr16:24865363	SLC5A11	0.56	5.26	0.47	8.84e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4383453	0.539	rs55762427	chr3:123098421	A/G	cg04890266	chr3:123102914	ADCY5	-0.83	-8.71	-0.67	9.24e-14	Gestational age at birth (maternal effect);
THYM	cis	rs9572053	0.550	rs9564513	chr13:69557671	A/G	cg16757992	chr13:69559194	NA	-0.63	-5.07	-0.46	1.98e-6	Subjective well-being;
THYM	cis	rs7106204	0.562	rs7109606	chr11:24251314	G/T	ch.11.24196551F	chr11:24239977	NA	1.02	7.15	0.59	1.8e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs427394	0.659	rs274695	chr5:6732252	G/C	cg10857441	chr5:6722123	POLS	-0.7	-7.53	-0.61	2.93e-11	Menopause (age at onset);
THYM	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg13319975	chr6:146136371	FBXO30	-0.69	-5.65	-0.5	1.7e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg02753203	chr1:228287806	NA	-0.61	-5.15	-0.47	1.4e-6	Diastolic blood pressure;
THYM	cis	rs79387448	0.638	rs11465670	chr2:103034440	A/G	cg09003973	chr2:102972529	NA	1.08	6.39	0.55	6.26e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg23583168	chr7:148888333	NA	-1.02	-14.09	-0.82	5.29e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg01416388	chr22:39784598	NA	-0.85	-6.5	-0.55	3.78e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs2241584	0.967	rs11740771	chr5:175946944	T/G	cg27658698	chr5:175955578	RNF44	-0.47	-5.6	-0.5	2.1e-7	Menopause (age at onset);
THYM	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg18252515	chr7:66147081	NA	-1.38	-8.11	-0.64	1.75e-12	Diabetic kidney disease;
THYM	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.99	12.51	0.79	8.52e-22	Chronic sinus infection;
THYM	cis	rs13031619	0.607	rs13001751	chr2:3695870	A/G	cg10645314	chr2:3704589	ALLC	-0.58	-4.6	-0.43	1.31e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs870825	0.550	rs59051283	chr4:185646476	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs12476592	0.602	rs1356390	chr2:63669625	C/T	cg17519650	chr2:63277830	OTX1	0.68	4.51	0.42	1.83e-5	Childhood ear infection;
THYM	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg23758822	chr17:41437982	NA	1.21	12.96	0.8	1.02e-22	Menopause (age at onset);
THYM	cis	rs3126085	0.935	rs11204967	chr1:152249720	A/G	cg10321714	chr1:152280068	FLG	-0.6	-4.56	-0.42	1.53e-5	Atopic dermatitis;
THYM	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg25358565	chr5:93447407	FAM172A	1.36	10.94	0.75	1.62e-18	Diabetic retinopathy;
THYM	cis	rs28595532	0.920	rs56124677	chr4:119772213	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs17598306	0.873	rs73402679	chr7:96591973	A/G	cg23184042	chr7:96615519	DLX6AS	0.61	4.76	0.44	6.82e-6	Radiation response;
THYM	cis	rs10927875	0.501	rs61782229	chr1:16220118	G/A	cg21385522	chr1:16154831	NA	-1.04	-7.41	-0.61	5.23e-11	Dilated cardiomyopathy;
THYM	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg14019146	chr3:50243930	SLC38A3	-0.61	-5.3	-0.48	7.4e-7	Intelligence (multi-trait analysis);
THYM	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg13119609	chr19:45449297	APOC2	0.59	5.71	0.51	1.29e-7	Blood protein levels;
THYM	cis	rs3773445	0.740	rs3773439	chr3:25617775	T/C	cg02315353	chr3:25825455	NGLY1	0.53	4.59	0.43	1.36e-5	Airway responsiveness in chronic obstructive pulmonary disease;
THYM	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg19645103	chr12:69753606	YEATS4	-0.56	-4.47	-0.42	2.16e-5	Response to diuretic therapy;
THYM	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg07212818	chr11:638076	DRD4	-0.73	-5.06	-0.46	2.08e-6	Systemic lupus erythematosus;
THYM	cis	rs7226229	1.000	rs1044414	chr17:20904451	A/G	cg21263980	chr17:20946333	USP22	0.65	4.88	0.45	4.33e-6	Blood trace element (Se levels);
THYM	cis	rs8067545	0.586	rs11657161	chr17:20180715	A/G	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs2046867	0.862	rs28632160	chr3:72800690	T/C	cg25664220	chr3:72788482	NA	-0.75	-5.59	-0.5	2.18e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs7843479	1.000	rs66824050	chr8:21815425	T/G	cg17168535	chr8:21777572	XPO7	0.66	4.9	0.45	3.89e-6	Mean corpuscular volume;
THYM	cis	rs901683	1.000	rs17157884	chr10:46015942	C/T	cg18240400	chr10:46168597	ANUBL1	0.74	4.94	0.45	3.29e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17376456	0.569	rs11135397	chr5:93214975	G/T	cg25358565	chr5:93447407	FAM172A	0.93	6.73	0.57	1.27e-9	Diabetic retinopathy;
THYM	trans	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg25214090	chr10:38739885	LOC399744	0.83	7.11	0.59	2.14e-10	Corneal astigmatism;
THYM	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-5.21	-0.47	1.09e-6	Schizophrenia;
THYM	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg13175981	chr1:150552382	MCL1	0.74	5.52	0.49	2.95e-7	Tonsillectomy;
THYM	cis	rs8033133	0.881	rs4344720	chr15:25324141	C/T	cg14481604	chr15:25334117	SNORD116-22	-0.73	-4.74	-0.44	7.64e-6	Blood osmolality (transformed sodium);
THYM	cis	rs6876348	0.928	rs13182341	chr5:128107907	A/G	cg25555059	chr5:128301488	SLC27A6	0.46	4.81	0.44	5.76e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7809950	0.954	rs3779494	chr7:107250355	G/A	cg23024343	chr7:107201750	COG5	0.92	7.65	0.62	1.63e-11	Coronary artery disease;
THYM	cis	rs9581943	0.967	rs9581931	chr13:28468222	A/G	cg16302790	chr13:28498334	PDX1	0.53	4.58	0.43	1.43e-5	Pancreatic cancer;
THYM	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg12011299	chr4:100065546	ADH4	0.85	8.12	0.64	1.67e-12	Alcohol dependence;
THYM	cis	rs61931739	0.963	rs3912355	chr12:34079616	A/G	cg10856724	chr12:34555212	NA	-0.57	-4.76	-0.44	7.03e-6	Morning vs. evening chronotype;
THYM	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg03388043	chr17:80084554	CCDC57	-0.73	-6.17	-0.53	1.69e-8	Life satisfaction;
THYM	cis	rs13126513	0.581	rs2584448	chr4:100392015	A/C	cg05468953	chr4:100565104	NA	-0.65	-5.64	-0.5	1.74e-7	Metabolite levels (MHPG);
THYM	cis	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg12165864	chr7:66369176	NA	0.73	5.56	0.5	2.46e-7	Aortic root size;
THYM	cis	rs12422267	0.793	rs115814769	chr12:132487719	C/T	cg19981660	chr12:132434166	EP400	-1.24	-4.61	-0.43	1.23e-5	Plasma amyloid beta peptide concentrations (ABx-40);
THYM	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg00640147	chr17:61958756	GH2	-0.44	-4.82	-0.44	5.49e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg07570687	chr10:102243282	WNT8B	0.77	7.16	0.59	1.72e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg21028142	chr17:79581711	NPLOC4	0.64	6.74	0.57	1.23e-9	Eye color traits;
THYM	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg26597838	chr10:835615	NA	1.2	8.64	0.66	1.3e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06481639	chr22:41940642	POLR3H	-0.79	-5.42	-0.49	4.54e-7	Vitiligo;
THYM	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg13319975	chr6:146136371	FBXO30	0.73	6.11	0.53	2.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg17757837	chr7:157058334	UBE3C	-0.66	-5.32	-0.48	6.85e-7	Body mass index;
THYM	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg10560079	chr2:191398806	TMEM194B	0.93	7.28	0.6	9.81e-11	Diastolic blood pressure;
THYM	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11890956	chr21:40555474	PSMG1	0.64	5.07	0.46	1.96e-6	Cognitive function;
THYM	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg08859206	chr1:53392774	SCP2	-0.85	-10.09	-0.72	1.05e-16	Monocyte count;
THYM	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg12311346	chr5:56204834	C5orf35	-0.84	-6.23	-0.54	1.28e-8	Initial pursuit acceleration;
THYM	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg00012203	chr2:219082015	ARPC2	0.81	7.56	0.61	2.52e-11	Colorectal cancer;
THYM	trans	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg19862616	chr7:65841803	NCRNA00174	-1.05	-11.42	-0.76	1.59e-19	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs752010	0.714	rs6600384	chr1:42085141	A/G	cg06885757	chr1:42089581	HIVEP3	-0.52	-6.38	-0.55	6.48e-9	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs2296887	0.841	rs10883720	chr10:104010971	G/C	cg26089160	chr10:104170217	PSD	-0.62	-4.66	-0.43	1.01e-5	Parkinson's disease;
THYM	cis	rs34375054	0.525	rs7133864	chr12:125606180	C/T	cg25124228	chr12:125621409	AACS	-0.8	-6.86	-0.58	6.94e-10	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg12981288	chr8:11183844	MTMR9	0.45	4.7	0.43	8.68e-6	Retinal vascular caliber;
THYM	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg18357526	chr6:26021779	HIST1H4A	-0.63	-4.8	-0.44	5.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2276314	1.000	rs62101367	chr18:33550884	C/T	cg05985134	chr18:33552581	C18orf21	0.68	4.77	0.44	6.59e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26314531	chr2:26401878	FAM59B	-0.77	-5.03	-0.46	2.27e-6	Gut microbiome composition (summer);
THYM	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg07424592	chr7:64974309	NA	1.12	5.24	0.47	9.64e-7	Diabetic kidney disease;
THYM	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg10295955	chr4:187884368	NA	-1.22	-17.54	-0.87	1.51e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.73	0.67	8.5e-14	Colorectal cancer;
THYM	cis	rs2455799	0.552	rs2470540	chr3:15718652	T/A	cg16303742	chr3:15540471	COLQ	-0.53	-5.65	-0.5	1.64e-7	Mean platelet volume;
THYM	cis	rs861020	0.563	rs35898529	chr1:210053096	G/A	cg05527609	chr1:210001259	C1orf107	-0.86	-5.74	-0.51	1.14e-7	Orofacial clefts;
THYM	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg25208724	chr1:156163844	SLC25A44	1.11	8.66	0.66	1.22e-13	Testicular germ cell tumor;
THYM	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg00814883	chr7:100076585	TSC22D4	-0.93	-6.43	-0.55	5.13e-9	Platelet count;
THYM	cis	rs3540	0.512	rs8033595	chr15:91083353	G/A	cg22089800	chr15:90895588	ZNF774	-0.67	-5.18	-0.47	1.23e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs4930776	0.722	rs385762	chr12:5767202	A/T	cg02086166	chr12:5775618	ANO2	0.58	5.24	0.47	9.69e-7	Plasma clusterin levels;
THYM	cis	rs13326165	0.585	rs3733063	chr3:52328533	G/A	cg08438690	chr3:52279403	PPM1M	-0.74	-4.64	-0.43	1.12e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.16	-8.66	-0.66	1.18e-13	Platelet count;
THYM	cis	rs6686842	0.965	rs1121866	chr1:41708099	T/C	cg03387723	chr1:41708464	SCMH1	-0.44	-5.1	-0.46	1.73e-6	Height;
THYM	cis	rs870825	1.000	rs870821	chr4:185587377	T/C	cg04058563	chr4:185651563	MLF1IP	0.96	6.74	0.57	1.21e-9	Blood protein levels;
THYM	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg15744005	chr10:104629667	AS3MT	-0.78	-7.33	-0.6	7.48e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs240764	0.578	rs6925065	chr6:101178856	C/T	cg21058520	chr6:100914733	NA	-0.58	-5.05	-0.46	2.11e-6	Neuroticism;
THYM	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs6424115	0.830	rs2503000	chr1:24197898	C/G	cg15997130	chr1:24165203	NA	0.74	6.35	0.55	7.22e-9	Immature fraction of reticulocytes;
THYM	cis	rs4595586	0.545	rs7136002	chr12:39369168	G/A	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg11317459	chr13:21872234	NA	-1.21	-9.22	-0.69	7.83e-15	White matter hyperintensity burden;
THYM	cis	rs7226229	1.000	rs4985954	chr17:20897952	A/G	cg21263980	chr17:20946333	USP22	0.72	4.96	0.45	3.12e-6	Blood trace element (Se levels);
THYM	cis	rs4430311	0.723	rs1809247	chr1:243882064	C/T	cg25706552	chr1:244017396	NA	-0.56	-4.78	-0.44	6.28e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs9467711	0.651	rs1045537	chr6:26096748	G/C	cg01386294	chr6:25732093	NA	0.9	4.88	0.45	4.34e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6840360	0.615	rs10001603	chr4:152647577	T/A	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs859767	0.672	rs10203582	chr2:135362839	C/A	cg12500956	chr2:135428796	TMEM163	-0.49	-4.95	-0.45	3.22e-6	Neuroticism;
THYM	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg07537917	chr2:241836409	C2orf54	-0.27	-6.41	-0.55	5.61e-9	Urinary metabolites;
THYM	cis	rs346785	0.580	rs347676	chr17:74274998	G/A	cg10318678	chr17:74308979	PRPSAP1	-0.5	-4.59	-0.43	1.34e-5	White matter hyperintensities in ischemic stroke;
THYM	cis	rs7084402	1.000	rs11006169	chr10:60269326	T/A	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	trans	rs10118776	0.826	rs13283694	chr9:6209755	A/G	cg02532923	chr16:89110004	NA	1.01	7.85	0.63	6.11e-12	Small cell lung carcinoma;
THYM	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg04944784	chr2:26401820	FAM59B	-0.79	-6.18	-0.54	1.61e-8	Gut microbiome composition (summer);
THYM	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg11366901	chr6:160182831	ACAT2	1.07	9.53	0.7	1.68e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9796	0.840	rs1009913	chr15:41331050	C/T	cg21153102	chr15:41252147	NA	-0.65	-5.83	-0.51	7.6e-8	Menopause (age at onset);
THYM	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.07	11.72	0.77	3.66e-20	Intelligence (multi-trait analysis);
THYM	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg21970626	chr13:21893289	NA	-0.67	-5.95	-0.52	4.5e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1629083	0.934	rs1573559	chr11:118104627	G/A	cg25155064	chr11:118100782	MPZL3	-0.57	-5.04	-0.46	2.25e-6	Lung cancer;
THYM	cis	rs59698941	0.943	rs79586717	chr5:132251790	T/C	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs12410462	0.681	rs113984727	chr1:227553917	C/A	cg23173402	chr1:227635558	NA	0.62	4.94	0.45	3.3e-6	Major depressive disorder;
THYM	cis	rs13082711	0.522	rs533175	chr3:27361432	A/G	cg02860705	chr3:27208620	NA	-0.57	-4.49	-0.42	2.04e-5	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg15704280	chr7:45808275	SEPT13	-0.77	-6.86	-0.58	6.85e-10	Height;
THYM	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg26441486	chr22:50317300	CRELD2	0.44	6.39	0.55	6.13e-9	Schizophrenia;
THYM	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg10560079	chr2:191398806	TMEM194B	-0.85	-6.33	-0.54	8.22e-9	Diastolic blood pressure;
THYM	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg17372223	chr3:52568218	NT5DC2	0.33	5.06	0.46	2.09e-6	Bipolar disorder;
THYM	cis	rs7084921	0.579	rs2862951	chr10:101844948	A/C	cg11344164	chr10:101878520	NA	-0.54	-4.67	-0.43	9.9e-6	Bone mineral density;
THYM	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg02454025	chr1:11042201	C1orf127	0.81	9.49	0.7	2.05e-15	Ewing sarcoma;
THYM	cis	rs4780401	0.609	rs35649585	chr16:11813899	G/A	cg01061890	chr16:11836724	TXNDC11	-0.69	-5.7	-0.5	1.34e-7	Rheumatoid arthritis;
THYM	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.8	-4.79	-0.44	6.23e-6	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg25427524	chr10:38739819	LOC399744	0.65	6.16	0.53	1.75e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs9534288	0.830	rs1126363	chr13:46633459	C/T	cg15192986	chr13:46630673	CPB2	-0.66	-4.66	-0.43	1.03e-5	Blood protein levels;
THYM	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs9361491	0.608	rs4706066	chr6:79459777	T/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg13695892	chr22:41940480	POLR3H	-0.83	-5.98	-0.52	3.93e-8	Vitiligo;
THYM	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg07936489	chr17:37558343	FBXL20	0.92	5.83	0.51	7.7e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs250585	0.850	rs6497673	chr16:23545711	G/A	cg00143387	chr16:23521605	GGA2	-0.72	-4.58	-0.42	1.43e-5	Egg allergy;
THYM	cis	rs1018836	0.923	rs6986689	chr8:91626709	A/C	cg16814680	chr8:91681699	NA	-0.85	-7.17	-0.59	1.59e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg07959070	chr22:50026188	C22orf34	-0.28	-4.88	-0.45	4.25e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg03396347	chr1:1875803	NA	0.5	4.89	0.45	4.03e-6	Body mass index;
THYM	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs3126085	0.736	rs11581433	chr1:152283236	T/C	cg10321714	chr1:152280068	FLG	-0.68	-4.95	-0.45	3.18e-6	Atopic dermatitis;
THYM	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	4.96	0.45	3.05e-6	Motion sickness;
THYM	cis	rs11209185	0.545	rs12030775	chr1:68421189	A/T	cg22082780	chr1:68452167	NA	0.48	5.19	0.47	1.17e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg07460842	chr6:66804631	NA	0.92	5.5	0.49	3.15e-7	Exhaled nitric oxide levels;
THYM	cis	rs7746082	0.627	rs7770156	chr6:106471509	T/A	cg02270332	chr6:106475062	NA	-0.65	-6.21	-0.54	1.38e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs3096299	0.967	rs2911253	chr16:89488587	T/G	cg02187348	chr16:89574699	SPG7	0.78	6.16	0.53	1.72e-8	Multiple myeloma (IgH translocation);
THYM	cis	rs7107174	1.000	rs2510036	chr11:77966788	G/T	cg02023728	chr11:77925099	USP35	0.69	6.19	0.54	1.55e-8	Testicular germ cell tumor;
THYM	cis	rs679087	1.000	rs439639	chr12:29917641	A/C	cg14258853	chr12:29935411	TMTC1	-0.67	-6.12	-0.53	2.12e-8	Schizophrenia;
THYM	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg26384229	chr12:38710491	ALG10B	0.97	7.31	0.6	8.24e-11	Bladder cancer;
THYM	cis	rs12765878	0.967	rs10883948	chr10:105667552	G/T	cg11005552	chr10:105648138	OBFC1	0.87	11.39	0.76	1.84e-19	Coronary artery disease;
THYM	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg08847533	chr14:75593920	NEK9	-0.95	-9.92	-0.71	2.4e-16	Height;
THYM	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg18105134	chr13:113819100	PROZ	-0.96	-8.77	-0.67	6.94e-14	Platelet distribution width;
THYM	trans	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs921968	0.541	rs3755041	chr2:219442499	A/T	cg02176678	chr2:219576539	TTLL4	-0.73	-7.24	-0.6	1.18e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6430585	0.583	rs2304370	chr2:136561735	G/A	cg23851026	chr2:136556271	LCT	0.7	7.49	0.61	3.45e-11	Corneal structure;
THYM	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg14433983	chr11:636460	DRD4	-0.63	-4.55	-0.42	1.6e-5	Systemic lupus erythematosus;
THYM	cis	rs35883536	0.611	rs72977390	chr1:101107147	C/T	cg06223162	chr1:101003688	GPR88	0.58	5.16	0.47	1.34e-6	Monocyte count;
THYM	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.64	4.94	0.45	3.31e-6	Renal function-related traits (BUN);
THYM	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg00383909	chr3:49044727	WDR6	1.33	6.25	0.54	1.18e-8	Cognitive function;
THYM	cis	rs4601821	1.000	rs6589375	chr11:113255111	C/A	cg14159747	chr11:113255604	NA	0.26	5.03	0.46	2.29e-6	Alcoholic chronic pancreatitis;
THYM	cis	rs3816788	0.837	rs6557640	chr8:21771731	A/T	cg17168535	chr8:21777572	XPO7	0.79	6.73	0.57	1.3e-9	Lung cancer in ever smokers;
THYM	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg27129171	chr3:47204927	SETD2	0.69	6.55	0.56	2.93e-9	Colorectal cancer;
THYM	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg22841779	chr14:105766346	BRF1	-0.47	-5.88	-0.52	5.96e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9486715	0.867	rs9373829	chr6:96897201	A/C	cg06623918	chr6:96969491	KIAA0776	-1.1	-9.11	-0.68	1.35e-14	Headache;
THYM	cis	rs28595532	0.920	rs115675321	chr4:119742153	A/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg04025307	chr7:1156635	C7orf50	0.87	8.91	0.67	3.55e-14	Longevity;Endometriosis;
THYM	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg14983838	chr19:29218262	NA	1.09	8.97	0.68	2.58e-14	Methadone dose in opioid dependence;
THYM	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg06623918	chr6:96969491	KIAA0776	1.12	10.77	0.74	3.8e-18	Headache;
THYM	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.27	-6.09	-0.53	2.43e-8	Obesity-related traits;
THYM	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg04518342	chr5:131593106	PDLIM4	0.48	5.37	0.48	5.55e-7	Breast cancer;
THYM	cis	rs6840360	0.532	rs4235221	chr4:152511193	C/T	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11096990	0.964	rs11096986	chr4:39258742	C/T	cg24403649	chr4:39172243	NA	-0.68	-5.77	-0.51	9.87e-8	Cognitive function;
THYM	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.46	-4.85	-0.45	4.84e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs4654899	0.733	rs6698440	chr1:21258712	C/T	cg01072550	chr1:21505969	NA	-0.75	-7.07	-0.59	2.56e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg13695892	chr22:41940480	POLR3H	-0.89	-6.98	-0.58	4.02e-10	Vitiligo;
THYM	cis	rs9807989	0.839	rs1362348	chr2:102984624	C/G	cg03938978	chr2:103052716	IL18RAP	0.66	6.83	0.57	8.06e-10	Asthma;
THYM	cis	rs7084402	0.935	rs10763553	chr10:60274049	C/A	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg02018176	chr4:1364513	KIAA1530	0.55	4.7	0.43	8.82e-6	Obesity-related traits;
THYM	cis	rs236352	0.535	rs1632649	chr6:36894677	T/C	cg03410223	chr6:36853544	C6orf89	0.66	5.25	0.47	9.16e-7	Heart rate;
THYM	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9443645	0.527	rs949846	chr6:79817596	C/T	cg05283184	chr6:79620031	NA	-0.6	-4.68	-0.43	9.44e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.92	7.72	0.62	1.18e-11	Lymphocyte percentage of white cells;
THYM	cis	rs3768617	0.510	rs4491025	chr1:183065183	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.76	0.44	6.83e-6	Fuchs's corneal dystrophy;
THYM	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg00810483	chr4:3375144	RGS12	0.33	4.99	0.46	2.67e-6	Serum sulfate level;
THYM	cis	rs7216064	0.636	rs62084696	chr17:66038181	C/G	cg12091567	chr17:66097778	LOC651250	0.98	8.02	0.64	2.7e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs4888262	0.545	rs4588013	chr16:74703388	C/T	cg01733217	chr16:74700730	RFWD3	0.88	9.63	0.7	1.03e-15	Testicular germ cell tumor;
THYM	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14442939	chr10:27389572	ANKRD26	0.89	7.59	0.61	2.22e-11	Breast cancer;
THYM	cis	rs6840360	0.615	rs12641441	chr4:152607623	A/G	cg22705602	chr4:152727874	NA	-0.79	-10.67	-0.74	6.15e-18	Intelligence (multi-trait analysis);
THYM	cis	rs7769051	0.522	rs6934155	chr6:133124021	C/T	cg07930552	chr6:133119739	C6orf192	1.14	4.51	0.42	1.82e-5	Type 2 diabetes nephropathy;
THYM	cis	rs7507204	0.906	rs1860323	chr19:3424799	G/C	cg08380311	chr19:3435252	NFIC	0.87	7.1	0.59	2.26e-10	Height;
THYM	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg18305652	chr10:134549665	INPP5A	0.78	6.35	0.55	7.31e-9	Migraine;
THYM	cis	rs360798	0.512	rs6739804	chr2:63269604	T/C	cg17519650	chr2:63277830	OTX1	0.76	5.77	0.51	9.7e-8	Coronary artery disease;
THYM	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11039798	0.925	rs10769373	chr11:48531980	T/A	cg24672777	chr11:48374446	OR4C45	-1.16	-7.17	-0.59	1.64e-10	Axial length;
THYM	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg04025307	chr7:1156635	C7orf50	0.52	4.55	0.42	1.57e-5	Longevity;Endometriosis;
THYM	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs12413816	0.818	rs35567671	chr10:13769722	C/A	cg16485048	chr10:13749193	FRMD4A	0.5	4.86	0.45	4.62e-6	Red cell distribution width;
THYM	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg12501888	chr15:85177176	SCAND2	-0.58	-4.59	-0.43	1.35e-5	Schizophrenia;
THYM	cis	rs951188	0.688	rs77731474	chr2:150430640	A/G	cg17961725	chr2:150454027	NA	-1.03	-5.39	-0.48	5.11e-7	Daytime sleep phenotypes;
THYM	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg26597838	chr10:835615	NA	1.1	6.33	0.54	8e-9	Eosinophil percentage of granulocytes;
THYM	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg17279839	chr7:150038598	RARRES2	0.56	5.41	0.49	4.78e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg14004847	chr7:1930337	MAD1L1	-0.63	-4.93	-0.45	3.49e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg22974920	chr21:40686053	BRWD1	0.74	5.02	0.46	2.45e-6	Cognitive function;
THYM	cis	rs10197940	0.578	rs2045025	chr2:152317531	T/C	cg19508488	chr2:152266495	RIF1	0.72	5.66	0.5	1.57e-7	Lung cancer;
THYM	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.61	-4.71	-0.44	8.43e-6	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg16325326	chr1:53192061	ZYG11B	0.69	5.73	0.51	1.18e-7	Monocyte count;
THYM	cis	rs7731657	0.509	rs11960725	chr5:130251428	C/T	cg08523029	chr5:130500466	HINT1	0.91	6.09	0.53	2.39e-8	Fasting plasma glucose;
THYM	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg09367891	chr1:107599246	PRMT6	0.68	4.47	0.42	2.19e-5	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg25817165	chr18:72167213	CNDP2	-0.95	-7.9	-0.63	4.91e-12	Refractive error;
THYM	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.63	5.32	0.48	6.81e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg22709100	chr7:91322751	NA	0.64	4.91	0.45	3.73e-6	Breast cancer;
THYM	cis	rs7107174	1.000	rs7116698	chr11:77995191	T/C	cg02023728	chr11:77925099	USP35	0.66	5.84	0.51	7.32e-8	Testicular germ cell tumor;
THYM	cis	rs8135828	0.739	rs469230	chr22:29954593	G/A	cg16189954	chr22:29138267	HSCB;CHEK2	-0.73	-4.74	-0.44	7.4e-6	Lipid traits;
THYM	cis	rs12478296	1.000	rs56323081	chr2:243040807	A/G	cg06360820	chr2:242988706	NA	-1.05	-6.52	-0.56	3.31e-9	Obesity-related traits;
THYM	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg24250549	chr1:154909240	PMVK	0.79	6.71	0.57	1.41e-9	Prostate cancer;
THYM	cis	rs2608053	0.551	rs2648879	chr8:129073712	C/T	cg21803052	chr8:128748088	MYC	-0.63	-4.57	-0.42	1.49e-5	Hodgkin's lymphoma;
THYM	cis	rs12611088	0.541	rs2682579	chr19:44012609	T/C	cg18042043	chr19:44147545	NA	-0.43	-5.05	-0.46	2.14e-6	Plasma amyloid beta peptide concentrations (ABx-42);
THYM	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg02725872	chr8:58115012	NA	-0.74	-5.43	-0.49	4.35e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs4866334	1.000	rs78003303	chr5:18479948	A/G	cg04591469	chr5:17810299	NA	-1.14	-4.47	-0.42	2.2e-5	IgG glycosylation;
THYM	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg26967526	chr14:35346199	BAZ1A	-0.72	-5.33	-0.48	6.65e-7	Psoriasis;
THYM	cis	rs9420	0.961	rs79260745	chr11:57612960	T/C	cg19752551	chr11:57585705	CTNND1	-0.73	-7.98	-0.63	3.28e-12	Schizophrenia;
THYM	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg12310025	chr6:25882481	NA	-0.87	-7.33	-0.6	7.58e-11	Intelligence (multi-trait analysis);
THYM	cis	rs12049351	0.665	rs10799532	chr1:229584620	T/G	cg11742688	chr1:229674241	ABCB10	-0.55	-4.66	-0.43	1.03e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs7589342	0.669	rs11895604	chr2:106536134	G/A	cg14210321	chr2:106509881	NCK2	-0.71	-5.0	-0.46	2.6e-6	Addiction;
THYM	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg13695892	chr22:41940480	POLR3H	-0.72	-6.73	-0.57	1.3e-9	Vitiligo;
THYM	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg25767906	chr1:53392781	SCP2	-0.58	-5.84	-0.51	7.3e-8	Monocyte count;
THYM	cis	rs1883415	0.534	rs2760143	chr6:24479472	C/T	cg20631270	chr6:24437470	GPLD1	0.53	4.46	0.42	2.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-7.24	-0.6	1.15e-10	Schizophrenia;
THYM	cis	rs7187994	0.848	rs8046664	chr16:84749859	T/C	cg07647771	chr16:84786436	USP10	-0.53	-4.88	-0.45	4.22e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg03060546	chr3:49711283	APEH	-0.67	-5.08	-0.46	1.85e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs1065852	0.526	rs12166549	chr22:42410419	T/C	cg09667013	chr22:42394590	WBP2NL	0.54	4.8	0.44	5.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs1062746	0.527	rs12934628	chr16:87335161	A/G	cg02258303	chr16:87377426	FBXO31	-0.62	-5.01	-0.46	2.51e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs4662945	0.688	rs34713181	chr2:130212385	G/A	cg05903289	chr2:130345205	NA	-0.59	-5.67	-0.5	1.53e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	5.75	0.51	1.1e-7	Height;
THYM	cis	rs10174077	0.874	rs6750342	chr2:152485754	A/G	cg06191203	chr2:152266755	RIF1	-0.71	-4.83	-0.44	5.14e-6	Squamous cell lung carcinoma;
THYM	cis	rs9361491	0.578	rs10943583	chr6:79478464	C/G	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.88e-5	Intelligence (multi-trait analysis);
THYM	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg00999904	chr2:3704751	ALLC	-1.12	-8.35	-0.65	5.4e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs6500395	1.000	rs1420701	chr16:48730873	C/T	cg04672837	chr16:48644449	N4BP1	-0.49	-4.83	-0.44	5.19e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg07936489	chr17:37558343	FBXL20	-0.83	-5.77	-0.51	1e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs12681287	0.640	rs34794500	chr8:87449995	G/A	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs2592394	0.675	rs711827	chr2:176999120	G/A	cg03401519	chr2:177042493	NA	-0.57	-4.51	-0.42	1.88e-5	Magnesium levels;Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs2282300	0.739	rs1616223	chr11:30338783	A/C	cg09906309	chr11:30344399	C11orf46	-0.73	-5.37	-0.48	5.47e-7	Morning vs. evening chronotype;
THYM	cis	rs1003719	0.762	rs2835590	chr21:38463406	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.83	0.67	5.15e-14	Colorectal cancer;
THYM	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg03676636	chr4:99064102	C4orf37	0.46	7.21	0.59	1.36e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg06558623	chr16:89946397	TCF25	1.33	5.62	0.5	1.94e-7	Skin colour saturation;
THYM	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg16405210	chr4:1374714	KIAA1530	0.87	7.71	0.62	1.25e-11	Obesity-related traits;
THYM	cis	rs11096990	0.656	rs2123028	chr4:39303479	C/T	cg24403649	chr4:39172243	NA	-0.6	-5.16	-0.47	1.37e-6	Cognitive function;
THYM	cis	rs293526	0.959	rs293505	chr6:83636237	G/C	cg23278060	chr6:83777448	DOPEY1	0.61	4.49	0.42	2.02e-5	Crohn's disease;
THYM	cis	rs4780401	0.729	rs8045300	chr16:11769266	C/G	cg01061890	chr16:11836724	TXNDC11	-0.61	-4.71	-0.43	8.55e-6	Rheumatoid arthritis;
THYM	cis	rs10089	0.953	rs2016015	chr5:127527253	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.96	6.3	0.54	9.24e-9	Ileal carcinoids;
THYM	cis	rs6032067	0.673	rs4522674	chr20:43893276	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.43	-4.59	-0.43	1.35e-5	Blood protein levels;
THYM	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg11657440	chr19:46296263	DMWD	0.68	6.09	0.53	2.44e-8	Coronary artery disease;
THYM	cis	rs2290159	0.800	rs55762590	chr3:12689451	C/T	cg23032965	chr3:12705835	RAF1	0.85	5.42	0.49	4.55e-7	Cholesterol, total;
THYM	cis	rs9807989	0.801	rs6752482	chr2:102967858	T/C	cg03938978	chr2:103052716	IL18RAP	0.63	6.56	0.56	2.81e-9	Asthma;
THYM	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg15448220	chr1:150897856	SETDB1	0.88	7.49	0.61	3.44e-11	Melanoma;
THYM	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg03929089	chr4:120376271	NA	0.88	8.73	0.67	8.69e-14	Coronary artery disease;
THYM	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.6	-4.63	-0.43	1.17e-5	Longevity;Endometriosis;
THYM	cis	rs7809950	0.911	rs7778250	chr7:107224565	C/A	cg23024343	chr7:107201750	COG5	0.93	8.32	0.65	6.49e-13	Coronary artery disease;
THYM	cis	rs1728785	1.000	rs1749792	chr16:68569440	T/G	cg02972257	chr16:68554789	NA	-0.74	-4.54	-0.42	1.63e-5	Ulcerative colitis;
THYM	cis	rs7191700	0.511	rs243330	chr16:11350991	C/T	cg00044050	chr16:11439710	C16orf75	0.69	5.07	0.46	1.99e-6	Multiple sclerosis;
THYM	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg05340658	chr4:99064831	C4orf37	0.56	4.64	0.43	1.13e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7705042	0.865	rs249643	chr5:141524746	C/G	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg24112000	chr20:60950667	NA	0.77	6.92	0.58	5.29e-10	Colorectal cancer;
THYM	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg18252515	chr7:66147081	NA	-0.66	-4.98	-0.45	2.87e-6	Aortic root size;
THYM	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg11266682	chr4:10021025	SLC2A9	0.73	11.88	0.77	1.74e-20	Bone mineral density;
THYM	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg06108461	chr20:60628389	TAF4	-0.81	-6.74	-0.57	1.22e-9	Body mass index;
THYM	cis	rs990171	1.000	rs917996	chr2:103082273	C/A	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.1	-0.46	1.74e-6	Lymphocyte counts;
THYM	cis	rs9902453	0.874	rs62070271	chr17:28268358	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.11	0.53	2.19e-8	Coffee consumption (cups per day);
THYM	cis	rs12216545	0.765	rs4725915	chr7:150251752	C/T	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs924712	0.677	rs239806	chr6:54808029	T/C	cg04690482	chr6:54711388	FAM83B	0.45	5.39	0.48	5.07e-7	Breast cancer;
THYM	cis	rs2811415	0.597	rs9845369	chr3:127743443	G/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs4383453	0.539	rs4678016	chr3:123101981	C/T	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs9443189	0.763	rs2748952	chr6:76444360	G/A	cg01950844	chr6:76311363	SENP6	-0.77	-4.53	-0.42	1.73e-5	Prostate cancer;
THYM	cis	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.47	-0.42	2.16e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs909002	0.800	rs10914459	chr1:32096918	T/C	cg13919466	chr1:32135498	COL16A1	-0.49	-4.95	-0.45	3.23e-6	Intelligence (multi-trait analysis);
THYM	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg19645103	chr12:69753606	YEATS4	-0.56	-4.47	-0.42	2.16e-5	Response to diuretic therapy;
THYM	cis	rs2109514	0.765	rs28494601	chr7:116101261	A/C	cg12739419	chr7:116140593	CAV2	-0.48	-4.91	-0.45	3.82e-6	Prevalent atrial fibrillation;
THYM	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg23711669	chr6:146136114	FBXO30	-0.98	-10.65	-0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg00383909	chr3:49044727	WDR6	1.2	5.99	0.52	3.76e-8	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06481639	chr22:41940642	POLR3H	0.65	4.77	0.44	6.53e-6	Vitiligo;
THYM	cis	rs2290159	0.800	rs6792773	chr3:12668726	C/T	cg23032965	chr3:12705835	RAF1	0.88	5.63	0.5	1.86e-7	Cholesterol, total;
THYM	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg02527881	chr3:46936655	PTH1R	0.85	9.82	0.71	4.04e-16	Birth weight;
THYM	cis	rs995000	0.965	rs10789112	chr1:62957758	T/C	cg06896770	chr1:63153194	DOCK7	0.96	7.88	0.63	5.37e-12	Triglyceride levels;
THYM	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg00684032	chr4:1343700	KIAA1530	0.79	6.86	0.58	7.09e-10	Obesity-related traits;
THYM	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg26384229	chr12:38710491	ALG10B	0.74	5.45	0.49	3.99e-7	Morning vs. evening chronotype;
THYM	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg24209194	chr3:40518798	ZNF619	-0.63	-5.33	-0.48	6.67e-7	Renal cell carcinoma;
THYM	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg22535103	chr8:58192502	C8orf71	-0.94	-6.12	-0.53	2.12e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03264133	chr6:25882463	NA	-0.83	-6.92	-0.58	5.34e-10	Intelligence (multi-trait analysis);
THYM	cis	rs752010	0.806	rs943375	chr1:42092152	A/G	cg06885757	chr1:42089581	HIVEP3	0.55	6.52	0.56	3.4e-9	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs4839827	1	rs4839827	chr6:96853967	C/T	cg06623918	chr6:96969491	KIAA0776	0.84	6.79	0.57	9.74e-10	Migraine;
THYM	cis	rs950880	0.710	rs56117144	chr2:103074651	T/C	cg03938978	chr2:103052716	IL18RAP	-0.56	-4.77	-0.44	6.57e-6	Serum protein levels (sST2);
THYM	cis	rs611744	0.781	rs75534351	chr8:109118714	A/T	cg21045802	chr8:109455806	TTC35	0.63	5.67	0.5	1.5e-7	Dupuytren's disease;
THYM	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg07599136	chr5:415885	AHRR	1.0	5.62	0.5	1.91e-7	Fat distribution (HIV);
THYM	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg11266682	chr4:10021025	SLC2A9	0.74	10.8	0.74	3.21e-18	Bone mineral density;
THYM	cis	rs6541297	1.000	rs6541296	chr1:230281953	A/G	cg20703242	chr1:230279135	GALNT2	0.92	5.97	0.52	4e-8	Coronary artery disease;
THYM	cis	rs4343996	0.902	rs7798672	chr7:3342334	A/T	cg21248987	chr7:3385318	SDK1	0.39	4.72	0.44	8.15e-6	Motion sickness;
THYM	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	4.8	0.44	5.88e-6	Hip circumference adjusted for BMI;
THYM	cis	rs61990749	0.597	rs176955	chr14:78181220	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.02	0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.91	10.43	0.73	2.04e-17	Prudent dietary pattern;
THYM	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg21280719	chr6:42927975	GNMT	-0.5	-7.01	-0.58	3.44e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1395	0.778	rs1439767	chr2:27389634	A/G	cg22903471	chr2:27725779	GCKR	-0.63	-4.63	-0.43	1.17e-5	Blood metabolite levels;
THYM	cis	rs4595586	0.545	rs1303887	chr12:39366523	C/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs1345301	0.587	rs10186746	chr2:102866377	G/A	cg03938978	chr2:103052716	IL18RAP	-0.51	-4.97	-0.45	2.93e-6	Waist circumference;
THYM	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg16586182	chr3:47516702	SCAP	0.63	5.57	0.5	2.36e-7	Colorectal cancer;
THYM	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg10803722	chr21:46713166	LOC642852	-0.5	-6.28	-0.54	1.02e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9788721	0.902	rs17486195	chr15:78865197	A/G	cg04882995	chr15:78912658	CHRNA3	0.54	4.54	0.42	1.62e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs6840360	0.615	rs1962910	chr4:152479392	T/A	cg17479576	chr4:152424074	FAM160A1	-0.83	-6.46	-0.55	4.43e-9	Intelligence (multi-trait analysis);
THYM	cis	rs4722166	0.630	rs12700390	chr7:22777129	G/T	cg05472934	chr7:22766657	IL6	0.73	5.55	0.49	2.62e-7	Lung cancer;
THYM	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg05552183	chr6:42928497	GNMT	0.72	5.99	0.52	3.66e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2898681	0.581	rs11938140	chr4:53678057	T/A	cg00791764	chr4:53727839	RASL11B	0.44	5.46	0.49	3.81e-7	Optic nerve measurement (cup area);
THYM	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg14582100	chr15:45693742	SPATA5L1	0.62	4.99	0.46	2.71e-6	Homoarginine levels;
THYM	cis	rs13631	0.728	rs7466635	chr9:139980417	T/C	cg03717367	chr9:139980219	LOC100289341;MAN1B1	-0.7	-6.1	-0.53	2.28e-8	Cerebrospinal fluid biomarker levels;
THYM	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg25703541	chr22:24373054	LOC391322	0.84	7.77	0.62	9.1e-12	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs2458413	0.563	rs2458419	chr8:105337141	G/C	cg13045555	chr8:105342365	NA	-0.33	-6.42	-0.55	5.44e-9	Paget's disease;
THYM	cis	rs722208	0.565	rs3020371	chr6:152383820	C/T	cg03627880	chr6:151815985	C6orf97	-0.42	-4.6	-0.43	1.28e-5	Developmental language disorder;
THYM	cis	rs9527	0.615	rs2152915	chr10:104691732	A/T	cg04362960	chr10:104952993	NT5C2	0.6	4.62	0.43	1.2e-5	Arsenic metabolism;
THYM	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg21644426	chr2:191273491	MFSD6	-0.66	-4.57	-0.42	1.49e-5	Diastolic blood pressure;
THYM	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg13319975	chr6:146136371	FBXO30	0.65	5.35	0.48	6.03e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs57994353	0.802	rs12002854	chr9:139377499	G/A	cg14115884	chr9:139300582	SDCCAG3	0.73	5.4	0.48	4.9e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg13609457	chr4:120235615	NA	0.59	5.22	0.47	1.04e-6	Corneal astigmatism;
THYM	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg02221750	chr19:17393354	ANKLE1	-0.99	-9.18	-0.69	9.13e-15	Systemic lupus erythematosus;
THYM	cis	rs34638657	0.872	rs6420435	chr16:82184201	A/C	cg19807685	chr16:82068980	HSD17B2	-0.68	-5.25	-0.47	9.27e-7	Lung adenocarcinoma;
THYM	cis	rs28595532	0.920	rs113034745	chr4:119750044	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg00757033	chr12:89920650	WDR51B	0.74	11.81	0.77	2.43e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs2811415	0.597	rs3774797	chr3:127772793	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs9326248	0.569	rs11216161	chr11:116721201	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.75	4.85	0.45	4.88e-6	Blood protein levels;
THYM	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg13695892	chr22:41940480	POLR3H	0.86	6.33	0.54	8.08e-9	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs8077889	0.956	rs61608877	chr17:41848713	A/C	cg26893861	chr17:41843967	DUSP3	1.04	9.15	0.68	1.09e-14	Triglycerides;
THYM	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg09549813	chr16:4587862	C16orf5	-0.59	-6.65	-0.56	1.84e-9	Schizophrenia;
THYM	cis	rs11756438	0.683	rs17349329	chr6:119002644	T/G	cg21191810	chr6:118973309	C6orf204	0.48	4.53	0.42	1.68e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.74	5.89	0.52	5.86e-8	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs17253792	0.822	rs77990307	chr14:56070049	T/C	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs9560113	0.959	rs9560108	chr13:112180303	A/C	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg11871910	chr12:69753446	YEATS4	1.01	9.81	0.71	4.2e-16	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg10589385	chr1:150898437	SETDB1	-0.57	-4.55	-0.42	1.56e-5	Melanoma;
THYM	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg27284194	chr4:1044797	NA	0.62	4.73	0.44	7.81e-6	Recombination rate (females);
THYM	cis	rs3126085	0.935	rs12407553	chr1:152297517	A/G	cg10321714	chr1:152280068	FLG	-0.65	-4.49	-0.42	2.04e-5	Atopic dermatitis;
THYM	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg26597838	chr10:835615	NA	1.24	8.96	0.68	2.76e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs5758511	0.637	rs5751244	chr22:42617411	T/C	cg22189786	chr22:42395067	WBP2NL	0.48	4.46	0.42	2.28e-5	Birth weight;
THYM	cis	rs7084402	0.935	rs893370	chr10:60360834	A/T	cg09696939	chr10:60272079	BICC1	-0.48	-5.83	-0.51	7.57e-8	Refractive error;
THYM	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg26384229	chr12:38710491	ALG10B	1.0	7.51	0.61	3.15e-11	Bladder cancer;
THYM	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg24060327	chr5:131705240	SLC22A5	-0.68	-5.21	-0.47	1.07e-6	Breast cancer;
THYM	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg00631329	chr6:26305371	NA	-0.6	-7.3	-0.6	8.68e-11	Educational attainment;
THYM	cis	rs17209837	0.607	rs4148821	chr7:87079602	G/C	cg04996195	chr7:87105398	ABCB4	0.63	4.79	0.44	6.03e-6	Gallbladder cancer;
THYM	cis	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg09085632	chr11:111637200	PPP2R1B	1.16	11.93	0.77	1.35e-20	Primary sclerosing cholangitis;
THYM	cis	rs12478296	0.786	rs55876934	chr2:243033816	C/T	cg06360820	chr2:242988706	NA	-0.89	-5.44	-0.49	4.21e-7	Obesity-related traits;
THYM	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg00129232	chr17:37814104	STARD3	-0.73	-4.85	-0.45	4.86e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs59107033	0.559	rs62262395	chr3:123105437	C/A	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Lymphocyte counts;
THYM	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs514406	0.893	rs6588446	chr1:53425260	G/A	cg24675658	chr1:53192096	ZYG11B	0.57	4.54	0.42	1.63e-5	Monocyte count;
THYM	cis	rs7172809	0.607	rs78928643	chr15:77842297	A/G	cg10437265	chr15:77819839	NA	-0.51	-4.68	-0.43	9.7e-6	Glucose homeostasis traits;
THYM	cis	rs4731207	0.698	rs10270784	chr7:124446208	A/T	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg15704280	chr7:45808275	SEPT13	1.02	8.31	0.65	6.7e-13	Coronary artery disease;
THYM	cis	rs6876348	0.928	rs1422446	chr5:128110085	C/T	cg25555059	chr5:128301488	SLC27A6	-0.45	-4.64	-0.43	1.12e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7107770	1.000	rs35969480	chr11:125105927	G/A	cg07747661	chr11:125106135	PKNOX2	-0.92	-5.19	-0.47	1.17e-6	Photic sneeze reflex;
THYM	cis	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg18904891	chr8:8559673	CLDN23	0.6	5.02	0.46	2.37e-6	Neuroticism;
THYM	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg07061783	chr6:25882402	NA	-0.86	-7.57	-0.61	2.35e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs977987	0.800	rs3784935	chr16:75336430	T/G	cg03315344	chr16:75512273	CHST6	0.83	6.67	0.56	1.66e-9	Dupuytren's disease;
THYM	cis	rs735539	0.555	rs8001310	chr13:21339700	G/C	cg27499820	chr13:21296301	IL17D	0.61	4.48	0.42	2.05e-5	Dental caries;
THYM	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg12560992	chr17:57184187	TRIM37	-0.92	-8.68	-0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.65e-6	Aortic root size;
THYM	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs6987853	0.933	rs6474401	chr8:42367068	T/C	cg09913449	chr8:42400586	C8orf40	-0.88	-8.12	-0.64	1.7e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7590720	0.759	rs6737781	chr2:216914920	A/G	cg12620499	chr2:216877984	MREG	0.8	5.27	0.48	8.4e-7	Alcohol dependence;
THYM	cis	rs1003719	0.715	rs9974494	chr21:38566566	C/T	cg01329690	chr21:38580129	DSCR9	-0.36	-4.99	-0.46	2.77e-6	Eye color traits;
THYM	cis	rs11645898	0.745	rs72787062	chr16:72105844	G/A	cg14768367	chr16:72042858	DHODH	-0.74	-5.67	-0.5	1.51e-7	Blood protein levels;
THYM	cis	rs6531656	0.796	rs337602	chr4:38655733	T/C	cg24279243	chr4:38676559	KLF3	0.81	5.49	0.49	3.3e-7	Lymphocyte counts;
THYM	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg07648498	chr16:89883185	FANCA	0.61	4.58	0.43	1.41e-5	Vitiligo;
THYM	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg04267008	chr7:1944627	MAD1L1	-0.68	-6.29	-0.54	9.85e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs42648	0.869	rs42611	chr7:89950060	C/A	cg25739043	chr7:89950458	NA	-0.53	-4.53	-0.42	1.72e-5	Homocysteine levels;
THYM	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg10802521	chr3:52805072	NEK4	-0.75	-7.03	-0.58	3.15e-10	Electroencephalogram traits;
THYM	cis	rs4072705	0.967	rs4240486	chr9:127341110	C/T	cg13476313	chr9:127244764	NR5A1	0.3	4.49	0.42	1.98e-5	Menarche (age at onset);
THYM	cis	rs9527	0.830	rs3740392	chr10:104636855	T/C	cg04362960	chr10:104952993	NT5C2	0.65	4.8	0.44	5.99e-6	Arsenic metabolism;
THYM	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	trans	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Bladder cancer;
THYM	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg05552183	chr6:42928497	GNMT	0.59	4.69	0.43	9.17e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs747334	0.846	rs7897403	chr10:92708780	C/T	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs8067545	0.611	rs12938355	chr17:20195217	A/G	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs479844	1.000	rs479844	chr11:65551957	A/G	cg17480646	chr11:65405466	SIPA1	-0.68	-5.08	-0.46	1.91e-6	Allergic disease (asthma, hay fever or eczema);Atopic march;Atopic dermatitis;
THYM	cis	rs6430585	0.583	rs79633114	chr2:136586825	C/T	cg20242066	chr2:136595261	LCT	0.5	4.68	0.43	9.41e-6	Corneal structure;
THYM	cis	rs981844	0.712	rs1012029	chr4:154749233	C/T	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs7107174	0.892	rs7115850	chr11:78045071	C/G	cg19901956	chr11:77921274	USP35	-0.64	-5.3	-0.48	7.43e-7	Testicular germ cell tumor;
THYM	cis	rs3540	0.533	rs2256097	chr15:90971331	A/T	cg22089800	chr15:90895588	ZNF774	0.69	5.45	0.49	3.89e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs3741151	1.000	rs79794992	chr11:73049352	A/G	cg17517138	chr11:73019481	ARHGEF17	0.99	5.88	0.52	5.97e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs61931739	0.929	rs10844748	chr12:34092930	G/T	cg06521331	chr12:34319734	NA	0.6	4.85	0.45	4.82e-6	Morning vs. evening chronotype;
THYM	cis	rs2730245	0.527	rs2527197	chr7:158735260	G/A	cg24397884	chr7:158709396	WDR60	-0.59	-5.55	-0.49	2.58e-7	Height;
THYM	cis	rs6430585	0.528	rs309113	chr2:136737460	C/A	cg20242066	chr2:136595261	LCT	0.53	5.59	0.5	2.18e-7	Corneal structure;
THYM	cis	rs985746	0.614	rs10433866	chr4:36817743	C/A	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg27394845	chr17:28928406	LRRC37B2	0.97	4.55	0.42	1.57e-5	Body mass index;
THYM	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs6897795	1.000	rs72648830	chr5:177608542	C/T	cg25087499	chr5:177592761	NA	0.56	4.88	0.45	4.27e-6	Plateletcrit;
THYM	cis	rs8017423	0.967	rs11159958	chr14:90716051	T/C	cg04239629	chr14:90701769	NA	-0.62	-4.52	-0.42	1.81e-5	Mortality in heart failure;
THYM	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg02953382	chr22:24373134	LOC391322	0.86	7.1	0.59	2.28e-10	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg17264618	chr3:40429014	ENTPD3	0.51	5.06	0.46	2.03e-6	Renal cell carcinoma;
THYM	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg06238570	chr21:40685208	BRWD1	-0.9	-6.33	-0.54	7.95e-9	Cognitive function;
THYM	trans	rs6089829	0.851	rs10854168	chr20:61669550	A/G	cg13615516	chr5:77269221	NA	0.81	6.9	0.58	5.71e-10	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11031096	0.711	rs10835723	chr11:4207566	G/C	cg18678763	chr11:4115507	RRM1	-0.4	-4.64	-0.43	1.13e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4363385	0.747	rs1015995	chr1:152976114	G/C	cg13444842	chr1:152974279	SPRR3	-0.57	-4.53	-0.42	1.74e-5	Inflammatory skin disease;
THYM	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.73	-5.75	-0.51	1.09e-7	Tonsillectomy;
THYM	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg23187316	chr7:1099788	C7orf50	0.57	4.61	0.43	1.27e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg09307838	chr4:120376055	NA	0.68	4.93	0.45	3.47e-6	Corneal astigmatism;
THYM	cis	rs7590720	0.819	rs6435931	chr2:216892754	C/G	cg12620499	chr2:216877984	MREG	1.03	8.17	0.64	1.29e-12	Alcohol dependence;
THYM	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg11764359	chr7:65958608	NA	0.66	4.69	0.43	8.98e-6	Aortic root size;
THYM	cis	rs2835345	0.561	rs5026478	chr21:37825829	A/G	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs4523957	0.533	rs170043	chr17:2200434	G/T	cg16513277	chr17:2031491	SMG6	-0.63	-4.74	-0.44	7.51e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11039798	0.844	rs6485820	chr11:48264711	A/G	cg24672777	chr11:48374446	OR4C45	-1.17	-7.15	-0.59	1.78e-10	Axial length;
THYM	cis	rs9311676	0.632	rs56288363	chr3:58374533	A/T	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs977987	0.735	rs11149831	chr16:75451461	G/A	cg03315344	chr16:75512273	CHST6	0.72	5.6	0.5	2.1e-7	Dupuytren's disease;
THYM	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg07636037	chr3:49044803	WDR6	0.99	10.2	0.72	6.21e-17	Parkinson's disease;
THYM	cis	rs595982	0.661	rs657008	chr19:49373632	A/G	cg19746536	chr19:49375674	PPP1R15A	1.28	18.33	0.88	5.92e-33	Red cell distribution width;
THYM	cis	rs2075230	0.705	rs1641519	chr17:7550166	C/A	cg27413385	chr17:7515425	FXR2	-0.37	-5.39	-0.48	5.16e-7	Hormone measurements;
THYM	cis	rs2730245	0.527	rs2527194	chr7:158732959	G/A	cg11984989	chr7:158649758	WDR60	-1.03	-8.12	-0.64	1.7e-12	Height;
THYM	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg16405210	chr4:1374714	KIAA1530	-0.77	-6.65	-0.56	1.88e-9	Longevity;
THYM	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg24250549	chr1:154909240	PMVK	0.79	6.82	0.57	8.33e-10	Prostate cancer;
THYM	cis	rs11031096	0.568	rs10767891	chr11:4234524	A/G	cg08557956	chr11:4115526	RRM1	-0.62	-5.0	-0.46	2.63e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs17401966	1.000	rs11578788	chr1:10422958	A/G	cg19773385	chr1:10388646	KIF1B	-0.65	-4.72	-0.44	8.03e-6	Hepatocellular carcinoma;
THYM	cis	rs9796	0.866	rs66818965	chr15:41402279	G/A	cg21153102	chr15:41252147	NA	0.69	6.24	0.54	1.19e-8	Menopause (age at onset);
THYM	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg22509189	chr2:225307070	NA	-0.65	-5.15	-0.47	1.4e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs72627123	0.867	rs17093546	chr14:74353020	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.64	-0.74	7.23e-18	Extrinsic epigenetic age acceleration;
THYM	trans	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	8.11	0.64	1.73e-12	Exhaled nitric oxide output;
THYM	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg04944784	chr2:26401820	FAM59B	1.02	7.8	0.62	8.05e-12	Gut microbiome composition (summer);
THYM	trans	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg25517755	chr10:38738941	LOC399744	-0.77	-7.48	-0.61	3.65e-11	Corneal astigmatism;
THYM	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg25427524	chr10:38739819	LOC399744	-0.64	-5.9	-0.52	5.56e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs72627123	0.867	rs8018226	chr14:74471377	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg09307838	chr4:120376055	NA	0.73	5.19	0.47	1.19e-6	Corneal astigmatism;
THYM	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg18230493	chr5:56204884	C5orf35	0.91	6.65	0.56	1.85e-9	Initial pursuit acceleration;
THYM	cis	rs6815814	0.950	rs11722889	chr4:38810975	C/T	cg02016764	chr4:38805732	TLR1	-0.5	-4.55	-0.42	1.56e-5	Breast cancer;
THYM	cis	rs6980334	0.817	rs10228366	chr7:137794905	T/A	cg06915773	chr7:137028165	PTN	0.58	4.74	0.44	7.59e-6	Blood metabolite ratios;
THYM	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg00271210	chr6:167070053	RPS6KA2	0.72	7.96	0.63	3.73e-12	Crohn's disease;
THYM	cis	rs7119	0.651	rs8025968	chr15:77839616	C/T	cg27398640	chr15:77910606	LINGO1	-0.62	-6.46	-0.55	4.52e-9	Type 2 diabetes;
THYM	trans	rs4940575	0.679	rs7230053	chr18:60836185	T/A	cg08454546	chr15:59731340	FAM81A	1.03	6.96	0.58	4.42e-10	Breast cancer;
THYM	cis	rs7027203	0.964	rs7854075	chr9:96571211	G/A	cg14598338	chr9:96623480	NA	0.48	5.06	0.46	2.06e-6	DNA methylation (variation);
THYM	cis	rs7584330	0.554	rs74449293	chr2:238426458	G/A	cg14458575	chr2:238380390	NA	0.79	4.65	0.43	1.06e-5	Prostate cancer;
THYM	cis	rs6456042	1.000	rs3127417	chr6:166537734	A/G	cg11088901	chr6:166572345	T	-0.52	-4.89	-0.45	4.16e-6	Asthma;
THYM	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg03676636	chr4:99064102	C4orf37	0.47	6.85	0.58	7.22e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg06634786	chr22:41940651	POLR3H	-0.71	-5.84	-0.51	7.37e-8	Vitiligo;
THYM	cis	rs3136739	0.764	rs2020920	chr8:42064994	T/C	cg16230352	chr8:42123158	NA	0.74	5.04	0.46	2.17e-6	Plasma plasminogen activator levels;
THYM	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg10802521	chr3:52805072	NEK4	-0.71	-5.96	-0.52	4.22e-8	Bipolar disorder;
THYM	cis	rs7247513	1.000	rs7247513	chr19:12691185	C/T	cg01871581	chr19:12707946	ZNF490	-0.85	-8.74	-0.67	8.27e-14	Bipolar disorder;
THYM	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg17143192	chr8:8559678	CLDN23	0.82	6.14	0.53	1.88e-8	Obesity-related traits;
THYM	cis	rs2455826	0.500	rs2455852	chr3:15688688	C/T	cg16303742	chr3:15540471	COLQ	-0.55	-5.23	-0.47	9.93e-7	Inflammatory skin disease;
THYM	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg05738196	chr6:26577821	NA	0.63	5.11	0.46	1.68e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg10661904	chr17:79619235	PDE6G	-0.65	-6.34	-0.54	7.88e-9	Eye color traits;
THYM	trans	rs7918405	0.724	rs35059317	chr10:114458434	G/A	cg24847366	chr12:125034283	NA	0.82	7.49	0.61	3.58e-11	QRS duration;
THYM	cis	rs877282	0.945	rs11253397	chr10:789774	A/G	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg15693483	chr7:1102177	C7orf50	0.41	5.82	0.51	7.95e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6596100	0.538	rs34626261	chr5:132174880	A/C	cg02081065	chr5:132209139	LEAP2	-0.94	-5.94	-0.52	4.7e-8	Breast cancer;
THYM	cis	rs1499972	0.941	rs62263082	chr3:117605611	C/T	cg07612923	chr3:117604196	NA	1.3	5.57	0.5	2.35e-7	Schizophrenia;
THYM	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg12292205	chr6:26970375	C6orf41	-0.69	-4.53	-0.42	1.69e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg00990874	chr7:1149470	C7orf50	-0.62	-4.77	-0.44	6.72e-6	Bronchopulmonary dysplasia;
THYM	cis	rs4851266	0.898	rs12615145	chr2:100853116	C/T	cg14675211	chr2:100938903	LONRF2	0.67	5.59	0.5	2.15e-7	Educational attainment;
THYM	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg08132940	chr7:1081526	C7orf50	-0.77	-5.26	-0.47	8.87e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg18512352	chr11:47633146	NA	-0.51	-6.23	-0.54	1.24e-8	Subjective well-being;
THYM	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg10802521	chr3:52805072	NEK4	-0.66	-6.1	-0.53	2.32e-8	Bipolar disorder;
THYM	cis	rs11648796	0.765	rs2003832	chr16:769538	G/A	cg03287339	chr16:711135	WDR90	-0.56	-4.74	-0.44	7.42e-6	Height;
THYM	cis	rs17030434	0.906	rs12643219	chr4:154670798	T/C	cg14289246	chr4:154710475	SFRP2	-0.89	-5.73	-0.51	1.18e-7	Electrocardiographic conduction measures;
THYM	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-6.89	-0.58	6.1e-10	Monocyte percentage of white cells;
THYM	cis	rs2835345	0.563	rs58602880	chr21:37826908	C/G	cg12426652	chr21:37915056	CLDN14	0.54	4.55	0.42	1.58e-5	Pulmonary function;
THYM	cis	rs11225247	0.772	rs12270109	chr11:102229310	G/C	cg11690896	chr11:102217788	BIRC2	1.0	4.57	0.42	1.49e-5	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs11711311	1.000	rs2712348	chr3:113460614	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.59	-5.19	-0.47	1.2e-6	IgG glycosylation;
THYM	cis	rs804280	0.564	rs4639	chr8:11644751	A/G	cg12395012	chr8:11607386	GATA4	-0.54	-5.07	-0.46	1.93e-6	Myopia (pathological);
THYM	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.97	7.98	0.63	3.37e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.75	-0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg17366294	chr4:99064904	C4orf37	0.48	5.43	0.49	4.3e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2985684	1.000	rs2985687	chr14:50100386	T/C	cg02151108	chr14:50098012	C14orf104	-0.67	-5.33	-0.48	6.48e-7	Carotid intima media thickness;
THYM	cis	rs11186	0.591	rs7420319	chr2:189960257	A/G	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.21	9.47	0.7	2.27e-15	Platelet count;
THYM	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg09877947	chr5:131593287	PDLIM4	0.66	5.37	0.48	5.56e-7	Acylcarnitine levels;
THYM	cis	rs981844	1.000	rs2579916	chr4:154659972	G/T	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	trans	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg06636001	chr8:8085503	FLJ10661	-0.76	-7.12	-0.59	2.06e-10	Triglycerides;
THYM	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg08847533	chr14:75593920	NEK9	1.03	11.46	0.76	1.31e-19	Height;
THYM	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg27129171	chr3:47204927	SETD2	0.8	7.91	0.63	4.58e-12	Colorectal cancer;
THYM	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg09555818	chr19:45449301	APOC2	0.7	7.68	0.62	1.43e-11	Blood protein levels;
THYM	cis	rs11864453	0.793	rs7197453	chr16:72079127	G/C	cg23815491	chr16:72088622	HP	0.97	9.39	0.69	3.3e-15	Fibrinogen levels;
THYM	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg06784218	chr1:46089804	CCDC17	-0.3	-4.75	-0.44	7.09e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg25072359	chr17:41440525	NA	0.67	4.71	0.44	8.34e-6	Menopause (age at onset);
THYM	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg23711669	chr6:146136114	FBXO30	-0.93	-9.39	-0.69	3.39e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9527	0.830	rs11191442	chr10:104643596	T/A	cg15744005	chr10:104629667	AS3MT	-0.66	-4.82	-0.44	5.36e-6	Arsenic metabolism;
THYM	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg08000102	chr2:233561755	GIGYF2	-0.68	-6.11	-0.53	2.16e-8	Coronary artery disease;
THYM	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg26752003	chr8:145688521	CYHR1	0.58	4.93	0.45	3.47e-6	Age at first birth;
THYM	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg24060327	chr5:131705240	SLC22A5	0.8	6.52	0.56	3.35e-9	Breast cancer;
THYM	cis	rs7616559	0.962	rs1552194	chr3:156720166	A/C	cg15697575	chr3:156784781	NA	-0.4	-5.03	-0.46	2.35e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg20295408	chr7:1910781	MAD1L1	-0.61	-4.71	-0.44	8.46e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg24060327	chr5:131705240	SLC22A5	-0.64	-4.8	-0.44	6e-6	Breast cancer;
THYM	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg06221963	chr1:154839813	KCNN3	-0.81	-10.03	-0.72	1.42e-16	Prostate cancer;
THYM	cis	rs28374715	0.528	rs28492932	chr15:41624397	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.78	-0.83	2.3e-26	Ulcerative colitis;
THYM	cis	rs4363385	0.693	rs582345	chr1:153033406	G/A	cg13444842	chr1:152974279	SPRR3	-0.61	-5.1	-0.46	1.71e-6	Inflammatory skin disease;
THYM	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg18105134	chr13:113819100	PROZ	-0.95	-8.7	-0.67	1e-13	Platelet distribution width;
THYM	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg10802521	chr3:52805072	NEK4	-0.73	-6.21	-0.54	1.42e-8	Bipolar disorder;
THYM	cis	rs4940575	0.679	rs17070777	chr18:60833814	A/C	cg24349668	chr18:61441546	SERPINB7	0.74	4.58	0.42	1.44e-5	Breast cancer;
THYM	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18404041	chr3:52824283	ITIH1	-0.51	-5.01	-0.46	2.52e-6	Bipolar disorder;
THYM	cis	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg24672777	chr11:48374446	OR4C45	-0.93	-5.95	-0.52	4.55e-8	Axial length;
THYM	cis	rs477692	0.569	rs1762418	chr10:131303353	G/A	cg05714579	chr10:131428358	MGMT	0.59	4.87	0.45	4.4e-6	Response to temozolomide;
THYM	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg23281280	chr6:28129359	ZNF389	0.61	4.74	0.44	7.58e-6	Parkinson's disease;
THYM	cis	rs10995240	1	rs10995240	chr10:64388631	G/C	cg03961010	chr10:64397487	ZNF365	-0.82	-6.88	-0.58	6.48e-10	Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Eosinophil percentage of white cells;Eosinophil counts;
THYM	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg04731861	chr2:219085781	ARPC2	-0.51	-4.81	-0.44	5.65e-6	Colorectal cancer;
THYM	cis	rs2333194	0.869	rs177368	chr14:73761247	T/C	cg09844916	chr14:74004424	HEATR4;ACOT1	0.56	4.46	0.42	2.2e-5	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs4891159	0.756	rs8084155	chr18:74134952	A/G	cg24786174	chr18:74118243	ZNF516	-0.94	-12.92	-0.8	1.19e-22	Longevity;
THYM	cis	rs13315871	1.000	rs13066269	chr3:58449244	T/C	cg00563845	chr3:58318305	PXK	0.53	4.67	0.43	9.78e-6	Cholesterol, total;
THYM	cis	rs6424115	0.800	rs4649123	chr1:24197696	A/G	cg15997130	chr1:24165203	NA	0.74	6.35	0.55	7.22e-9	Immature fraction of reticulocytes;
THYM	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg12011299	chr4:100065546	ADH4	0.86	8.22	0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs6840360	0.642	rs2724567	chr4:152351160	C/T	cg17479576	chr4:152424074	FAM160A1	0.66	4.94	0.45	3.4e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg22974920	chr21:40686053	BRWD1	0.6	4.63	0.43	1.15e-5	Cognitive function;
THYM	cis	rs72781680	0.898	rs72788302	chr2:24107246	C/T	cg08917208	chr2:24149416	ATAD2B	1.11	4.97	0.45	2.9e-6	Lymphocyte counts;
THYM	cis	rs9403317	1.000	rs9399372	chr6:141825133	C/A	cg15052665	chr6:141804349	NA	0.84	7.18	0.59	1.58e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs6840360	0.642	rs6855845	chr4:152417380	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-5.65	-0.5	1.7e-7	Intelligence (multi-trait analysis);
THYM	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.74	8.22	0.64	1.02e-12	Eosinophil percentage of white cells;
THYM	cis	rs2219968	0.717	rs4610733	chr8:78914112	T/G	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7264396	0.887	rs6060438	chr20:34077403	T/C	cg26038318	chr20:34205095	SPAG4	0.53	4.45	0.42	2.33e-5	Total cholesterol levels;
THYM	cis	rs17125944	1.000	rs17125944	chr14:53400629	C/T	cg00686598	chr14:53173677	PSMC6	-0.94	-4.48	-0.42	2.06e-5	Alzheimer's disease (late onset);
THYM	cis	rs4363385	0.818	rs653332	chr1:153010481	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.16	-8.93	-0.68	3.25e-14	Platelet count;
THYM	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg13147721	chr7:65941812	NA	-1.1	-7.08	-0.59	2.51e-10	Diabetic kidney disease;
THYM	cis	rs2742417	0.603	rs2742398	chr3:45759036	A/G	cg04837898	chr3:45731254	SACM1L	-0.71	-5.11	-0.46	1.67e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.47	-0.73	1.61e-17	Primary sclerosing cholangitis;
THYM	cis	rs13315871	1.000	rs11717423	chr3:58330177	C/G	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.95	0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg22875332	chr1:76189707	ACADM	-0.76	-6.66	-0.56	1.77e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg22968622	chr17:43663579	NA	1.16	10.21	0.72	5.86e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg02038168	chr22:39784481	NA	-0.65	-5.27	-0.48	8.54e-7	Intelligence (multi-trait analysis);
THYM	cis	rs865483	0.895	rs2522965	chr17:35816318	C/G	cg06716730	chr17:35851459	DUSP14	0.43	7.3	0.6	8.71e-11	Monocyte count;
THYM	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs11031096	0.782	rs2284450	chr11:4149214	A/T	cg22027985	chr11:4115532	RRM1	-0.53	-5.45	-0.49	4.02e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg16624210	chr5:671434	TPPP	0.82	6.36	0.55	7.05e-9	Obesity-related traits;
THYM	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg00383909	chr3:49044727	WDR6	1.07	6.29	0.54	9.72e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs4466137	0.830	rs6886442	chr5:82973210	A/C	cg16102102	chr5:83017553	HAPLN1	0.75	5.69	0.5	1.43e-7	Prostate cancer;
THYM	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg10281704	chr16:966864	LMF1	-0.26	-4.46	-0.42	2.24e-5	Height;
THYM	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg09537434	chr19:41945824	ATP5SL	-0.69	-5.17	-0.47	1.28e-6	Migraine;Coronary artery disease;
THYM	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg06728252	chr6:26598149	ABT1	-0.44	-5.24	-0.47	9.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs26232	0.583	rs154258	chr5:102363623	G/A	cg23492399	chr5:102201601	PAM	0.65	4.69	0.43	8.99e-6	Rheumatoid arthritis;
THYM	cis	rs2108622	0.727	rs77780918	chr19:15982707	T/C	cg13772218	chr19:15982569	NA	0.5	4.48	0.42	2.06e-5	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14442939	chr10:27389572	ANKRD26	0.86	4.61	0.43	1.25e-5	Breast cancer;
THYM	cis	rs11648796	0.765	rs3829492	chr16:781633	G/A	cg02852791	chr16:710674	WDR90	-0.62	-5.38	-0.48	5.39e-7	Height;
THYM	cis	rs2692947	0.770	rs6719831	chr2:96502590	A/C	cg22654517	chr2:96458247	NA	0.61	4.66	0.43	1.05e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg13026072	chr11:65380126	MAP3K11	0.68	5.45	0.49	3.95e-7	Blood pressure (age interaction);
THYM	cis	rs72627123	0.867	rs72627135	chr14:74396283	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg11494091	chr17:61959527	GH2	1.07	15.94	0.85	1.33e-28	Prudent dietary pattern;
THYM	cis	rs17006441	0.932	rs34255600	chr3:69900520	A/C	cg18496212	chr3:69797108	MITF	0.68	6.85	0.57	7.35e-10	Hemoglobin concentration;
THYM	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg07414643	chr4:187882934	NA	0.64	5.75	0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11157436	0.830	rs61972214	chr14:22620372	T/C	cg26433554	chr14:23315189	MMP14	0.44	4.61	0.43	1.24e-5	Neurocognitive impairment in HIV-1 infection (continuous);
THYM	cis	rs789852	0.867	rs1773176	chr3:194316238	C/G	cg18000598	chr3:194342907	TMEM44	1.26	7.57	0.61	2.35e-11	QT interval;
THYM	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg08508325	chr11:3079039	CARS	0.52	6.39	0.55	6.11e-9	Longevity;
THYM	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg13531842	chr10:38383804	ZNF37A	0.56	4.63	0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg21028142	chr17:79581711	NPLOC4	0.51	5.01	0.46	2.47e-6	Eye color traits;
THYM	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg11266682	chr4:10021025	SLC2A9	0.74	12.07	0.78	6.92e-21	Bone mineral density;
THYM	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg24803719	chr17:45855879	NA	-0.62	-6.57	-0.56	2.65e-9	IgG glycosylation;
THYM	cis	rs1451375	0.617	rs2060763	chr7:50542359	G/A	cg18232548	chr7:50535776	DDC	-0.7	-5.49	-0.49	3.29e-7	Malaria;
THYM	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg10802521	chr3:52805072	NEK4	-0.8	-7.53	-0.61	2.92e-11	Bipolar disorder;
THYM	cis	rs887829	0.570	rs7608175	chr2:234599089	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.79	6.88	0.58	6.26e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg10193763	chr2:225306901	NA	-0.51	-5.36	-0.48	5.86e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg10518543	chr12:38710700	ALG10B	-0.62	-5.05	-0.46	2.12e-6	Morning vs. evening chronotype;
THYM	cis	rs17443541	0.507	rs7594660	chr2:200468594	A/G	cg01795955	chr2:200468626	NA	-0.72	-5.0	-0.46	2.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6686842	1.000	rs213748	chr1:41628730	C/G	cg03387723	chr1:41708464	SCMH1	0.42	4.96	0.45	3.1e-6	Height;
THYM	cis	rs7617773	0.780	rs36075665	chr3:48343087	C/T	cg02219026	chr3:48282209	ZNF589	-0.64	-4.58	-0.43	1.39e-5	Coronary artery disease;
THYM	cis	rs288326	0.561	rs77426227	chr2:183890678	A/T	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs72827839	0.846	rs72825517	chr17:46171824	G/T	cg23391107	chr17:45924227	SP6	0.83	5.6	0.5	2.08e-7	Ease of getting up in the morning;
THYM	cis	rs9457247	0.515	rs1951459	chr6:167402536	G/A	cg15592062	chr6:167189543	RPS6KA2	0.52	5.32	0.48	6.84e-7	Crohn's disease;
THYM	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg21028142	chr17:79581711	NPLOC4	0.61	6.22	0.54	1.32e-8	Eye color traits;
THYM	cis	rs4819143	0.517	rs451920	chr21:47374699	A/C	cg20357416	chr21:47294739	PCBP3	0.77	4.85	0.45	4.73e-6	Insulin resistance/response;
THYM	cis	rs939574	0.858	rs2891733	chr2:220135208	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	0.98	4.68	0.43	9.68e-6	Platelet distribution width;
THYM	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg03388043	chr17:80084554	CCDC57	-0.66	-5.66	-0.5	1.61e-7	Life satisfaction;
THYM	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg17063962	chr7:91808500	NA	0.99	7.94	0.63	3.99e-12	Breast cancer;
THYM	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg24209194	chr3:40518798	ZNF619	0.58	4.78	0.44	6.34e-6	Renal cell carcinoma;
THYM	cis	rs7429990	0.870	rs13089844	chr3:48140231	G/A	cg02219026	chr3:48282209	ZNF589	0.59	4.46	0.42	2.23e-5	Educational attainment (years of education);
THYM	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.8	-5.44	-0.49	4.14e-7	Body mass index;
THYM	cis	rs754466	0.651	rs55738779	chr10:79652395	C/T	cg17075019	chr10:79541650	NA	-0.65	-5.3	-0.48	7.61e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9790314	0.586	rs73021449	chr3:161128941	G/A	cg03342759	chr3:160939853	NMD3	-0.84	-7.31	-0.6	8.38e-11	Morning vs. evening chronotype;
THYM	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg14458575	chr2:238380390	NA	0.92	7.78	0.62	8.76e-12	Prostate cancer;
THYM	cis	rs72712511	0.571	rs6840907	chr4:140762420	C/T	cg15010390	chr4:140216957	NDUFC1	0.66	4.84	0.45	4.94e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.06	0.46	2.02e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1986734	0.576	rs4493564	chr4:77420407	A/G	cg20311846	chr4:77356250	SHROOM3	-0.43	-4.66	-0.43	1.01e-5	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
THYM	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg26408565	chr15:76604113	ETFA	-0.54	-4.64	-0.43	1.13e-5	Blood metabolite levels;
THYM	cis	rs9355610	0.609	rs3756838	chr6:167371251	G/A	cg23791538	chr6:167370224	RNASET2	0.75	4.96	0.45	3.07e-6	Graves' disease;
THYM	trans	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	trans	rs5417	0.761	rs6503010	chr17:7180435	C/T	cg15655154	chr3:113604241	GRAMD1C	-1.0	-8.51	-0.66	2.51e-13	Diastolic blood pressure;
THYM	cis	rs6665290	0.935	rs17600627	chr1:227201449	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.15	-16.89	-0.87	2.27e-30	Myeloid white cell count;
THYM	cis	rs823143	0.549	rs1094647	chr1:205655378	G/A	cg07167872	chr1:205819463	PM20D1	0.91	8.35	0.65	5.47e-13	Monocyte percentage of white cells;
THYM	cis	rs9611519	1.000	rs5758264	chr22:41616284	T/G	cg06481639	chr22:41940642	POLR3H	-0.63	-4.68	-0.43	9.34e-6	Neuroticism;
THYM	cis	rs11225247	0.892	rs61123589	chr11:102265467	T/C	cg06323957	chr11:102217781	BIRC2	1.04	4.84	0.45	4.92e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg26038318	chr20:34205095	SPAG4	0.65	5.25	0.47	9.22e-7	Total cholesterol levels;
THYM	cis	rs6496667	0.865	rs7183944	chr15:90889111	C/T	cg22089800	chr15:90895588	ZNF774	0.76	4.56	0.42	1.52e-5	Rheumatoid arthritis;
THYM	cis	rs1620921	0.901	rs783165	chr6:161177842	A/C	cg17993073	chr6:160527228	IGF2R	0.56	4.45	0.42	2.32e-5	Lipoprotein (a) - cholesterol levels;
THYM	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg00958927	chr1:175162553	KIAA0040	0.36	5.0	0.46	2.56e-6	Alcohol dependence;
THYM	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg06238570	chr21:40685208	BRWD1	-0.96	-9.14	-0.68	1.13e-14	Cognitive function;
THYM	cis	rs1784581	0.569	rs9364629	chr6:162416831	T/G	cg17173639	chr6:162384350	PARK2	0.81	7.47	0.61	3.78e-11	Itch intensity from mosquito bite;
THYM	cis	rs600806	0.888	rs2228604	chr1:109884775	A/C	cg23032129	chr1:109941072	SORT1	-0.57	-4.88	-0.45	4.19e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2334880	0.678	rs16973190	chr16:71508501	T/C	cg06353428	chr16:71660113	MARVELD3	-1.03	-5.14	-0.47	1.44e-6	Malaria;
THYM	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg13736514	chr6:26305472	NA	-0.63	-7.46	-0.61	4.03e-11	Educational attainment;
THYM	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg02018176	chr4:1364513	KIAA1530	0.55	4.7	0.43	8.82e-6	Obesity-related traits;
THYM	cis	rs28595532	0.920	rs17258050	chr4:119672019	G/A	cg21605333	chr4:119757512	SEC24D	1.42	4.79	0.44	6.16e-6	Cannabis dependence symptom count;
THYM	cis	rs1691799	0.899	rs1168314	chr12:66746937	A/G	cg16791601	chr12:66731901	HELB	-0.75	-7.25	-0.6	1.08e-10	White blood cell count (basophil);
THYM	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg17143192	chr8:8559678	CLDN23	0.85	6.58	0.56	2.55e-9	Obesity-related traits;
THYM	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg05738196	chr6:26577821	NA	0.83	8.34	0.65	5.8e-13	Intelligence (multi-trait analysis);
THYM	cis	rs931812	0.825	rs35472498	chr8:101894167	G/A	cg07239293	chr8:101170671	SPAG1	0.68	4.63	0.43	1.17e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08704250	chr15:31115839	NA	0.69	7.77	0.62	9.15e-12	Huntington's disease progression;
THYM	cis	rs6063399	0.546	rs237480	chr20:47993898	A/C	cg06950567	chr20:48807318	CEBPB	0.6	4.51	0.42	1.83e-5	Obesity-related traits;
THYM	cis	rs1003719	0.788	rs1543749	chr21:38446621	A/G	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs5769707	0.632	rs135876	chr22:50013573	A/G	cg05373962	chr22:49881684	NA	-0.7	-6.43	-0.55	5.05e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg25554036	chr4:6271136	WFS1	0.51	4.71	0.44	8.35e-6	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg00376283	chr12:123451042	ABCB9	0.71	4.76	0.44	6.85e-6	Neutrophil percentage of white cells;
THYM	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg05973401	chr12:123451056	ABCB9	0.68	4.55	0.42	1.58e-5	Neutrophil percentage of white cells;
THYM	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg13147721	chr7:65941812	NA	-1.1	-7.08	-0.59	2.51e-10	Diabetic kidney disease;
THYM	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg15605315	chr1:45957053	TESK2	0.78	6.48	0.55	4.03e-9	High light scatter reticulocyte count;
THYM	trans	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg10856724	chr12:34555212	NA	-1.0	-8.75	-0.67	7.77e-14	Bladder cancer;
THYM	cis	rs6032067	0.636	rs17335251	chr20:43902946	T/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.62	-5.39	-0.48	5.03e-7	Blood protein levels;
THYM	cis	rs939658	0.935	rs2204069	chr15:79449335	A/G	cg17916960	chr15:79447300	NA	0.76	9.06	0.68	1.71e-14	Refractive error;
THYM	cis	rs28719689	0.541	rs28376074	chr8:1274394	A/T	cg11592242	chr8:1263433	NA	0.8	5.25	0.47	9.13e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9810089	0.843	rs556788	chr3:136027549	A/G	cg12473912	chr3:136751656	NA	0.61	4.97	0.45	3e-6	Gestational age at birth (child effect);
THYM	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs4951011	0.938	rs12569219	chr1:203762990	A/C	cg24343524	chr1:203763352	ZC3H11A	0.7	5.83	0.51	7.45e-8	Breast cancer;
THYM	cis	rs2213920	0.516	rs6415818	chr9:118210588	A/G	cg13918206	chr9:118159781	DEC1	0.81	4.67	0.43	9.95e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs3905510	0.568	rs958883	chr5:122998955	C/T	cg18093572	chr5:122598329	NA	-0.46	-4.55	-0.42	1.61e-5	Total body bone mineral density;
THYM	cis	rs6906287	0.647	rs11153748	chr6:118773609	A/G	cg21191810	chr6:118973309	C6orf204	0.58	5.78	0.51	9.61e-8	Electrocardiographic conduction measures;
THYM	cis	rs35995292	1.000	rs3779119	chr7:38942248	C/G	cg19166347	chr7:37955598	SFRP4	0.61	4.84	0.44	4.99e-6	Subjective well-being (multi-trait analysis);
THYM	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	5.16	0.47	1.36e-6	Chronic sinus infection;
THYM	cis	rs8114671	0.805	rs6060168	chr20:33621017	C/T	cg08999081	chr20:33150536	PIGU	0.57	4.93	0.45	3.5e-6	Height;
THYM	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg08017756	chr2:100939284	LONRF2	-0.71	-7.37	-0.6	6.18e-11	Intelligence (multi-trait analysis);
THYM	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg06028605	chr16:24865363	SLC5A11	0.55	5.15	0.47	1.41e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13102973	0.720	rs13137300	chr4:135889460	G/A	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg19774624	chr17:42201019	HDAC5	-0.86	-7.56	-0.61	2.53e-11	Total body bone mineral density;
THYM	cis	rs10911232	0.507	rs28477876	chr1:183019882	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs761746	0.921	rs7291918	chr22:32008039	A/G	cg10537193	chr22:32026975	PISD	-0.34	-4.68	-0.43	9.53e-6	Intelligence;
THYM	cis	rs7264396	0.790	rs6121026	chr20:34266883	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-5.74	-0.51	1.15e-7	Total cholesterol levels;
THYM	cis	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg07460842	chr6:66804631	NA	0.92	5.5	0.49	3.15e-7	Exhaled nitric oxide levels;
THYM	cis	rs9443189	0.570	rs569731	chr6:76357593	G/A	cg01950844	chr6:76311363	SENP6	1.05	6.66	0.56	1.73e-9	Prostate cancer;
THYM	cis	rs714031	0.872	rs3788576	chr22:40071894	G/A	cg21377881	chr22:40064566	CACNA1I	-0.62	-5.3	-0.48	7.65e-7	Schizophrenia;
THYM	cis	rs7106204	0.514	rs1443043	chr11:24251991	A/G	ch.11.24196551F	chr11:24239977	NA	1.02	7.07	0.59	2.58e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg13902645	chr11:5959945	NA	-0.57	-4.92	-0.45	3.6e-6	DNA methylation (variation);
THYM	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.13	-0.64	1.6e-12	Mean corpuscular volume;
THYM	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	cis	rs7719624	0.870	rs6894815	chr5:135395864	C/G	cg12897067	chr5:135418308	NA	-0.55	-4.61	-0.43	1.27e-5	Response to cytidine analogues (gemcitabine);
THYM	cis	rs921968	0.643	rs492400	chr2:219349752	C/T	cg02176678	chr2:219576539	TTLL4	0.64	6.22	0.54	1.35e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11645898	0.935	rs11640722	chr16:72172300	C/T	cg03805757	chr16:71968109	PKD1L3	-0.73	-5.37	-0.48	5.49e-7	Blood protein levels;
THYM	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg18105134	chr13:113819100	PROZ	1.02	9.29	0.69	5.36e-15	Platelet distribution width;
THYM	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg16230307	chr14:35515116	FAM177A1	0.85	5.46	0.49	3.73e-7	Psoriasis;
THYM	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg23989207	chr17:80870107	TBCD	0.66	5.58	0.5	2.3e-7	Glycated hemoglobin levels;
THYM	cis	rs2688608	0.592	rs12253482	chr10:75496130	G/A	cg19442545	chr10:75533431	FUT11	-0.62	-6.56	-0.56	2.84e-9	Inflammatory bowel disease;
THYM	cis	rs4285028	1.000	rs4285028	chr3:121660664	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-5.08	-0.46	1.87e-6	Multiple sclerosis;
THYM	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg21252483	chr19:49399788	TULP2	-0.96	-7.25	-0.6	1.09e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs10089	1.000	rs6595800	chr5:127411647	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.96	6.71	0.57	1.42e-9	Ileal carcinoids;
THYM	cis	rs36051895	0.632	rs10115335	chr9:5140963	A/T	cg02405213	chr9:5042618	JAK2	-1.01	-10.2	-0.72	6.29e-17	Pediatric autoimmune diseases;
THYM	cis	rs208520	0.874	rs208469	chr6:66915891	T/C	cg07460842	chr6:66804631	NA	-0.79	-4.96	-0.45	3.05e-6	Exhaled nitric oxide output;
THYM	cis	rs35164067	0.853	rs12983921	chr19:10547226	C/T	cg01466491	chr19:10523363	NA	-0.61	-4.63	-0.43	1.17e-5	Inflammatory bowel disease;
THYM	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg22875332	chr1:76189707	ACADM	-0.54	-5.15	-0.47	1.39e-6	Daytime sleep phenotypes;
THYM	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.24	-5.18	-0.47	1.26e-6	Obesity-related traits;
THYM	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg03806693	chr22:41940476	POLR3H	0.97	8.04	0.64	2.5e-12	Vitiligo;
THYM	cis	rs4474465	0.915	rs10899503	chr11:78149961	C/T	cg02023728	chr11:77925099	USP35	0.53	4.65	0.43	1.08e-5	Alzheimer's disease (survival time);
THYM	cis	rs7582180	0.614	rs4850931	chr2:101005145	C/T	cg21926883	chr2:100939477	LONRF2	-0.67	-6.13	-0.53	2.02e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2282300	0.956	rs654710	chr11:30394303	A/G	cg09906309	chr11:30344399	C11orf46	0.66	4.53	0.42	1.7e-5	Morning vs. evening chronotype;
THYM	cis	rs57244997	0.556	rs73030428	chr6:162437606	T/C	cg17173639	chr6:162384350	PARK2	-0.76	-4.88	-0.45	4.18e-6	Mosquito bite size;
THYM	trans	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg10856724	chr12:34555212	NA	-0.94	-8.13	-0.64	1.61e-12	Drug-induced liver injury (flucloxacillin);
THYM	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg05457628	chr5:178986728	RUFY1	0.57	5.75	0.51	1.07e-7	Lung cancer;
THYM	cis	rs9814567	0.806	rs4955525	chr3:134317008	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.09e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7119	0.604	rs2682921	chr15:77865459	C/T	cg10437265	chr15:77819839	NA	-0.7	-7.1	-0.59	2.28e-10	Type 2 diabetes;
THYM	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg00012203	chr2:219082015	ARPC2	0.69	5.87	0.52	6.36e-8	Colorectal cancer;
THYM	cis	rs62070183	0.882	rs62070164	chr17:31086433	T/C	cg23177095	chr17:30873196	MYO1D	0.64	5.02	0.46	2.41e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.71	6.93	0.58	5.11e-10	Lymphocyte counts;
THYM	cis	rs73086581	1.000	rs6052218	chr20:3970212	A/G	cg02187196	chr20:3869020	PANK2	0.5	5.62	0.5	1.92e-7	Response to antidepressants in depression;
THYM	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs4474465	1.000	rs966456	chr11:78168603	T/A	cg19901956	chr11:77921274	USP35	-0.65	-4.82	-0.44	5.34e-6	Alzheimer's disease (survival time);
THYM	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg21475434	chr5:93447410	FAM172A	0.83	5.31	0.48	7.13e-7	Diabetic retinopathy;
THYM	cis	rs921968	0.643	rs2556384	chr2:219532903	C/T	cg02176678	chr2:219576539	TTLL4	-0.6	-5.84	-0.51	7.3e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg00852783	chr1:26633632	UBXN11	0.7	5.79	0.51	9e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs4481887	1.000	rs10888358	chr1:248471467	C/A	cg13385794	chr1:248469461	NA	0.65	4.66	0.43	1.04e-5	Common traits (Other);
THYM	cis	rs800586	0.500	rs2737234	chr8:116651779	A/G	cg04656070	chr8:116661063	TRPS1	-0.54	-6.14	-0.53	1.86e-8	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs3741151	0.686	rs7114009	chr11:73115314	C/T	cg17517138	chr11:73019481	ARHGEF17	-0.74	-4.68	-0.43	9.57e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg05738196	chr6:26577821	NA	0.94	8.71	0.67	9.53e-14	Intelligence (multi-trait analysis);
THYM	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg09517075	chr8:22133004	PIWIL2	0.64	5.77	0.51	1e-7	Hypertriglyceridemia;
THYM	cis	rs1298062	0.790	rs2445841	chr19:50966531	T/A	cg11430371	chr19:50961752	MYBPC2	0.46	4.57	0.42	1.48e-5	Age of smoking initiation;
THYM	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08704250	chr15:31115839	NA	-0.54	-6.18	-0.54	1.59e-8	Huntington's disease progression;
THYM	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg13397359	chr6:42928475	GNMT	0.69	6.42	0.55	5.32e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs137603	0.603	rs137581	chr22:39677838	C/T	cg24268161	chr22:39747459	SYNGR1	0.62	4.94	0.45	3.39e-6	Primary biliary cholangitis;
THYM	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg11247378	chr22:39784982	NA	-1.06	-14.21	-0.82	3.11e-25	Intelligence (multi-trait analysis);
THYM	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg14349672	chr11:133703707	NA	-0.54	-4.77	-0.44	6.61e-6	Childhood ear infection;
THYM	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg03396347	chr1:1875803	NA	-0.67	-6.81	-0.57	8.66e-10	Body mass index;
THYM	cis	rs7584330	0.657	rs10202292	chr2:238352185	A/T	cg14458575	chr2:238380390	NA	0.89	6.93	0.58	4.97e-10	Prostate cancer;
THYM	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg27446573	chr6:127587934	RNF146	0.7	6.13	0.53	1.99e-8	Breast cancer;
THYM	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg14784868	chr12:69753453	YEATS4	0.74	6.0	0.52	3.51e-8	Blood protein levels;
THYM	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg24692254	chr21:30365293	RNF160	1.03	9.96	0.71	2.03e-16	Dental caries;
THYM	cis	rs4733781	0.527	rs11774633	chr8:131190243	C/T	cg16277922	chr8:131349729	ASAP1	0.57	4.81	0.44	5.72e-6	Tuberculosis;
THYM	cis	rs7267979	1.000	rs4813562	chr20:25352588	G/A	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg18128536	chr17:47092178	IGF2BP1	0.6	9.23	0.69	7.45e-15	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg21773646	chr17:80085082	CCDC57	0.32	4.5	0.42	1.93e-5	Life satisfaction;
THYM	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg25767906	chr1:53392781	SCP2	-0.58	-5.85	-0.51	6.92e-8	Monocyte count;
THYM	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4853012	0.887	rs2122290	chr2:74358901	C/T	cg19729930	chr2:74357872	NA	1.33	12.53	0.79	7.83e-22	Gestational age at birth (maternal effect);
THYM	cis	rs295140	0.565	rs295139	chr2:201159988	T/A	cg23649088	chr2:200775458	C2orf69	0.58	5.05	0.46	2.13e-6	QT interval;
THYM	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg10911889	chr6:126070802	HEY2	0.6	4.82	0.44	5.5e-6	Brugada syndrome;
THYM	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg21361702	chr7:150065534	REPIN1	0.68	4.98	0.46	2.8e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.0	0.63	2.98e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11603020	0.950	rs78364821	chr11:57370742	C/T	cg19752551	chr11:57585705	CTNND1	-0.6	-4.97	-0.45	3e-6	Blood protein levels;
THYM	cis	rs1448094	0.621	rs7315084	chr12:86283817	A/G	cg02569458	chr12:86230093	RASSF9	0.52	4.71	0.44	8.37e-6	Major depressive disorder;
THYM	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg06728252	chr6:26598149	ABT1	-0.43	-5.21	-0.47	1.11e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12681287	0.547	rs6998303	chr8:87510185	T/C	cg27223183	chr8:87520930	FAM82B	-0.71	-5.46	-0.49	3.8e-7	Caudate activity during reward;
THYM	cis	rs807669	0.565	rs5746682	chr22:19185526	C/T	cg02655711	chr22:19163373	SLC25A1	0.76	8.54	0.66	2.16e-13	Metabolite levels;
THYM	cis	rs7322722	0.730	rs2328999	chr13:77686508	T/C	cg04565255	chr13:77565759	CLN5	-0.44	-4.46	-0.42	2.24e-5	Preeclampsia;
THYM	cis	rs17016200	0.513	rs111667843	chr3:78370899	T/G	cg24512093	chr3:78698151	ROBO1	0.95	5.24	0.47	9.53e-7	Facial emotion recognition;
THYM	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg10803722	chr21:46713166	LOC642852	-0.35	-4.65	-0.43	1.09e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg07460842	chr6:66804631	NA	0.89	5.69	0.5	1.42e-7	Exhaled nitric oxide output;
THYM	cis	rs34779708	0.966	rs11010102	chr10:35411066	T/A	cg03585969	chr10:35415529	CREM	0.67	4.76	0.44	6.91e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg13609457	chr4:120235615	NA	0.54	5.0	0.46	2.63e-6	Corneal astigmatism;
THYM	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.65	-11.76	-0.77	3.01e-20	Hemostatic factors and hematological phenotypes;
THYM	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.67	0.66	1.16e-13	Lung cancer in ever smokers;
THYM	cis	rs7089973	0.872	rs11818114	chr10:116634878	G/C	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.05	-0.46	2.15e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11644478	chr21:40555479	PSMG1	1.07	9.23	0.69	7.24e-15	Cognitive function;
THYM	cis	rs684232	0.666	rs423887	chr17:593600	A/G	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.41	-4.81	-0.44	5.75e-6	Prostate cancer;
THYM	cis	rs13315871	1.000	rs71311857	chr3:58323377	A/G	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs13358904	1.000	rs12719140	chr5:111602603	C/T	cg14511739	chr5:112073373	APC	0.67	4.45	0.42	2.33e-5	Suicide ideation score in major depressive disorder;
THYM	cis	rs6427356	0.513	rs80141532	chr1:157147654	G/A	cg27547283	chr1:156698502	C1orf66;ISG20L2	-0.58	-4.49	-0.42	2.02e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs910187	0.678	rs6124964	chr20:45812536	T/G	cg27589058	chr20:45804311	EYA2	-0.62	-5.44	-0.49	4.1e-7	Migraine;
THYM	cis	rs1005224	0.963	rs11623813	chr14:76138194	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.73	-6.06	-0.53	2.69e-8	Large artery stroke;
THYM	cis	rs951188	0.637	rs111446262	chr2:150408504	A/T	cg17961725	chr2:150454027	NA	-1.02	-5.39	-0.48	5.12e-7	Daytime sleep phenotypes;
THYM	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg00898013	chr13:113819073	PROZ	0.9	8.93	0.68	3.24e-14	Platelet distribution width;
THYM	cis	rs10411161	0.702	rs11878580	chr19:52388485	C/T	cg25361850	chr19:52391789	ZNF577	0.74	5.18	0.47	1.22e-6	Breast cancer;
THYM	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg05738196	chr6:26577821	NA	0.84	8.48	0.66	2.87e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2219968	0.962	rs1471585	chr8:78945590	C/T	cg00738934	chr8:78996279	NA	-0.79	-8.42	-0.65	3.88e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8013055	0.796	rs4075104	chr14:106000214	C/A	cg11597832	chr14:105993747	TMEM121	-0.53	-4.59	-0.43	1.36e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs7943358	0.955	rs900869	chr11:15710941	G/T	cg11966998	chr11:15692519	NA	-0.48	-4.65	-0.43	1.08e-5	Gut microbiome composition (summer);
THYM	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg15605315	chr1:45957053	TESK2	-0.78	-6.58	-0.56	2.6e-9	High light scatter reticulocyte count;
THYM	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg23161317	chr6:28129485	ZNF389	0.85	6.33	0.54	8.19e-9	Depression;
THYM	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.22	4.94	0.45	3.32e-6	Obesity-related traits;
THYM	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs2354432	0.607	rs1530336	chr1:146685121	G/A	cg25205988	chr1:146714368	CHD1L	1.1	4.92	0.45	3.66e-6	Mitochondrial DNA levels;
THYM	cis	rs13315871	1.000	rs11713214	chr3:58445991	C/T	cg12435725	chr3:58293450	RPP14	-0.46	-4.93	-0.45	3.54e-6	Cholesterol, total;
THYM	cis	rs554111	0.656	rs10916930	chr1:21395357	C/T	cg01072550	chr1:21505969	NA	-0.56	-4.79	-0.44	6.02e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg03709012	chr19:19516395	GATAD2A	-0.74	-5.8	-0.51	8.48e-8	Tonsillectomy;
THYM	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.68	-5.06	-0.46	2.08e-6	Colorectal cancer;
THYM	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs344364	0.602	rs2983907	chr16:1913336	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.49	5.78	0.51	9.33e-8	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg11764359	chr7:65958608	NA	-0.75	-6.05	-0.53	2.82e-8	Aortic root size;
THYM	cis	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg26378065	chr17:18585709	ZNF286B	0.61	5.05	0.46	2.12e-6	Educational attainment (years of education);
THYM	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg11812906	chr14:75593930	NEK9	0.82	7.45	0.61	4.18e-11	Height;
THYM	cis	rs7809950	1.000	rs4730245	chr7:107087294	C/T	cg23024343	chr7:107201750	COG5	-0.92	-8.11	-0.64	1.73e-12	Coronary artery disease;
THYM	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg16031515	chr1:205743344	RAB7L1	-0.71	-7.44	-0.61	4.5e-11	Menarche (age at onset);
THYM	cis	rs1568889	1.000	rs7934085	chr11:28369660	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	4.87	0.45	4.44e-6	Bipolar disorder;
THYM	cis	rs1650123	0.645	rs703614	chr12:104017614	A/C	cg23227824	chr12:103980017	STAB2	-0.49	-5.19	-0.47	1.21e-6	IgG glycosylation;
THYM	cis	rs4900538	0.821	rs7012	chr14:102814945	C/T	cg18135206	chr14:102964638	TECPR2	-0.82	-6.26	-0.54	1.11e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs73193808	0.627	rs2832218	chr21:30524185	T/G	cg24692254	chr21:30365293	RNF160	0.88	4.45	0.42	2.35e-5	Coronary artery disease;
THYM	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg13319975	chr6:146136371	FBXO30	-0.69	-5.68	-0.5	1.5e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7631605	0.875	rs7638620	chr3:37200085	A/G	cg21328643	chr3:37258149	NA	-0.49	-4.69	-0.43	9.05e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs3087591	0.960	rs11080146	chr17:29578724	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.65	-5.7	-0.5	1.36e-7	Hip circumference;
THYM	cis	rs6987853	0.787	rs2974335	chr8:42417272	C/T	cg09913449	chr8:42400586	C8orf40	1.09	12.37	0.79	1.63e-21	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg16586182	chr3:47516702	SCAP	0.63	5.6	0.5	2.12e-7	Colorectal cancer;
THYM	cis	rs3806843	1.000	rs10037757	chr5:140197222	G/T	cg19875535	chr5:140030758	IK	0.6	4.69	0.43	9.21e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg08999081	chr20:33150536	PIGU	0.78	7.16	0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg14784868	chr12:69753453	YEATS4	1.12	10.83	0.74	2.79e-18	Blood protein levels;
THYM	cis	rs752010	0.523	rs10890158	chr1:42117985	C/T	cg06885757	chr1:42089581	HIVEP3	0.65	8.68	0.67	1.08e-13	Lupus nephritis in systemic lupus erythematosus;
THYM	trans	rs75518195	0.543	rs62302802	chr4:64718563	G/C	cg14706739	chr8:21916355	EPB49	0.76	7.25	0.6	1.09e-10	Triptolide cytotoxicity;
THYM	cis	rs921968	0.565	rs62191658	chr2:219630294	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg16325326	chr1:53192061	ZYG11B	0.71	5.87	0.52	6.4e-8	Monocyte count;
THYM	cis	rs7572733	0.514	rs700686	chr2:198721054	G/A	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg10047753	chr17:41438598	NA	0.97	7.99	0.63	3.21e-12	Menopause (age at onset);
THYM	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg12373951	chr3:133503437	NA	-0.57	-6.12	-0.53	2.07e-8	Iron status biomarkers;
THYM	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg04398451	chr17:18023971	MYO15A	-0.95	-9.66	-0.7	8.99e-16	Total body bone mineral density;
THYM	cis	rs7267979	0.903	rs6050481	chr20:25224580	C/T	cg08601574	chr20:25228251	PYGB	0.59	4.79	0.44	6.25e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg06917634	chr15:78832804	PSMA4	-0.83	-6.85	-0.58	7.29e-10	Sudden cardiac arrest;
THYM	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg13609457	chr4:120235615	NA	0.5	4.9	0.45	3.91e-6	Corneal astigmatism;
THYM	cis	rs11089937	0.651	rs6001217	chr22:22538194	A/G	cg06866756	chr22:22471216	NA	-0.47	-5.34	-0.48	6.43e-7	Periodontitis (PAL4Q3);
THYM	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg15704280	chr7:45808275	SEPT13	-0.84	-8.4	-0.65	4.28e-13	Height;
THYM	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg08132940	chr7:1081526	C7orf50	-1.17	-6.67	-0.56	1.7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17253792	0.500	rs17745274	chr14:55997881	T/C	cg01858014	chr14:56050164	KTN1	-1.19	-4.87	-0.45	4.41e-6	Putamen volume;
THYM	cis	rs11850957	0.502	rs7155485	chr14:25437183	G/A	cg26846476	chr14:24838993	NFATC4	0.93	4.77	0.44	6.66e-6	Subcutaneous adipose tissue;
THYM	cis	rs7178572	0.688	rs12591335	chr15:77774894	A/G	cg22256960	chr15:77711686	NA	0.84	5.99	0.52	3.75e-8	Type 2 diabetes;
THYM	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.07	7.91	0.63	4.56e-12	Smoking behavior;
THYM	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg16049864	chr8:95962084	TP53INP1	-0.74	-6.67	-0.56	1.68e-9	Type 2 diabetes;
THYM	cis	rs6988636	1.000	rs57322232	chr8:124193532	A/G	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg02018176	chr4:1364513	KIAA1530	0.74	7.2	0.59	1.4e-10	Longevity;
THYM	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.14	0.47	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs629535	1.000	rs644951	chr8:70009082	C/T	cg21567404	chr3:27674614	NA	-1.08	-9.75	-0.71	5.63e-16	Dupuytren's disease;
THYM	cis	rs28595532	0.920	rs56162974	chr4:119742333	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs713587	0.691	rs754537	chr2:25176277	A/T	cg01884057	chr2:25150051	NA	-0.58	-5.82	-0.51	7.97e-8	Body mass index in non-asthmatics;
THYM	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg04944784	chr2:26401820	FAM59B	0.71	5.48	0.49	3.46e-7	Gut microbiome composition (summer);
THYM	cis	rs3892630	0.824	rs34425841	chr19:33231619	C/T	cg02283691	chr19:33182526	NUDT19	-0.41	-4.59	-0.43	1.34e-5	Red blood cell traits;
THYM	cis	rs4372836	0.729	rs4132617	chr2:29031312	C/A	cg09522027	chr2:28974177	PPP1CB	-0.62	-4.78	-0.44	6.45e-6	Body mass index;
THYM	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11644478	chr21:40555479	PSMG1	-0.58	-4.76	-0.44	6.94e-6	Menarche (age at onset);
THYM	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg22920501	chr2:26401640	FAM59B	1.04	9.12	0.68	1.26e-14	Gut microbiome composition (summer);
THYM	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12756686	chr19:29218302	NA	1.0	8.27	0.65	8.26e-13	Methadone dose in opioid dependence;
THYM	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-4.98	-0.46	2.84e-6	Chronic sinus infection;
THYM	cis	rs2219968	0.638	rs10504672	chr8:78995199	G/C	cg00738934	chr8:78996279	NA	0.85	8.37	0.65	4.89e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg08885076	chr2:99613938	TSGA10	-0.68	-6.02	-0.53	3.32e-8	Chronic sinus infection;
THYM	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg00677455	chr12:58241039	CTDSP2	0.79	6.22	0.54	1.35e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4474465	0.790	rs10751295	chr11:78266047	T/A	cg19901956	chr11:77921274	USP35	0.62	4.54	0.42	1.65e-5	Alzheimer's disease (survival time);
THYM	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg24812749	chr6:127587940	RNF146	0.7	5.31	0.48	7.18e-7	Breast cancer;
THYM	cis	rs57994353	0.659	rs76259794	chr9:139377405	C/A	cg14115884	chr9:139300582	SDCCAG3	0.73	5.4	0.48	4.9e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs2412459	0.635	rs8036381	chr15:40263362	T/G	cg16127683	chr15:40268777	EIF2AK4	0.54	4.62	0.43	1.2e-5	Response to haloperidol in psychosis;
THYM	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs1950626	0.671	rs34675695	chr14:101447913	C/T	cg11887864	chr14:101510502	MIR1185-2	0.54	4.52	0.42	1.75e-5	Pelvic organ prolapse (moderate/severe);
THYM	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg10150615	chr22:24372951	LOC391322	0.75	6.95	0.58	4.64e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4849845	0.853	rs13386533	chr2:121029586	G/A	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg00256281	chr22:41985642	PMM1	0.64	5.02	0.46	2.42e-6	Vitiligo;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg04901623	chr4:39122942	KLHL5	-0.88	-7.02	-0.58	3.26e-10	Depressive symptoms;
THYM	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6754311	0.551	rs313519	chr2:136439517	A/C	cg23851026	chr2:136556271	LCT	0.59	5.65	0.5	1.65e-7	Mosquito bite size;
THYM	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg23161317	chr6:28129485	ZNF389	0.95	6.98	0.58	3.88e-10	Parkinson's disease;
THYM	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg13147721	chr7:65941812	NA	-1.1	-7.08	-0.59	2.51e-10	Diabetic kidney disease;
THYM	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs12348691	0.503	rs7849834	chr9:100606188	T/C	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Alopecia areata;
THYM	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08280861	chr8:58055591	NA	0.88	6.6	0.56	2.33e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs9534288	0.742	rs1022952	chr13:46649348	C/T	cg15192986	chr13:46630673	CPB2	0.65	4.59	0.43	1.36e-5	Blood protein levels;
THYM	cis	rs1915146	0.935	rs1057234	chr10:126850793	C/G	cg05090351	chr10:126851162	NA	0.75	8.86	0.67	4.61e-14	Menarche (age at onset);
THYM	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg06784218	chr1:46089804	CCDC17	0.3	4.79	0.44	6.18e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6723226	0.721	rs3769600	chr2:32616879	G/A	cg02381751	chr2:32503542	YIPF4	-0.6	-5.12	-0.46	1.61e-6	Intelligence (multi-trait analysis);
THYM	cis	rs240764	0.578	rs11155613	chr6:101176642	T/C	cg21058520	chr6:100914733	NA	-0.61	-5.33	-0.48	6.71e-7	Neuroticism;
THYM	cis	rs7084402	0.967	rs2577393	chr10:60286159	C/T	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.81	0.71	4.11e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs34638657	0.626	rs2911405	chr16:82215972	C/G	cg07307142	chr16:82071433	HSD17B2	-0.57	-4.58	-0.43	1.4e-5	Lung adenocarcinoma;
THYM	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg06623918	chr6:96969491	KIAA0776	-1.1	-10.41	-0.73	2.22e-17	Headache;
THYM	cis	rs7677751	0.747	rs1800809	chr4:55093914	A/G	cg17187183	chr4:55093834	PDGFRA	0.73	5.43	0.49	4.25e-7	Corneal astigmatism;
THYM	cis	rs1466662	0.814	rs10517591	chr4:155313308	A/C	cg05574313	chr4:155338166	DCHS2	-0.68	-4.83	-0.44	5.24e-6	Alzheimer's disease (age of onset);
THYM	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg08859206	chr1:53392774	SCP2	-0.65	-7.35	-0.6	6.82e-11	Monocyte count;
THYM	cis	rs79387448	0.745	rs1403549	chr2:103110745	G/C	cg09003973	chr2:102972529	NA	0.78	4.85	0.45	4.84e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs7122937	0.648	rs12576239	chr11:2502319	C/T	cg27115973	chr11:2481206	KCNQ1	0.59	4.61	0.43	1.25e-5	QT interval;
THYM	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3760982	0.546	rs73048681	chr19:44289945	T/C	cg11993925	chr19:44307056	LYPD5	0.68	5.1	0.46	1.7e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs600806	0.815	rs3768495	chr1:109935325	C/T	cg23616212	chr1:109941201	SORT1	-0.5	-4.65	-0.43	1.06e-5	Intelligence (multi-trait analysis);
THYM	cis	rs713587	0.776	rs3731623	chr2:25163783	T/C	cg01884057	chr2:25150051	NA	0.58	5.81	0.51	8.21e-8	Body mass index in non-asthmatics;
THYM	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg03929089	chr4:120376271	NA	-1.01	-13.5	-0.81	8.23e-24	Height;
THYM	cis	rs1971762	0.527	rs7976398	chr12:54028862	T/C	cg16917193	chr12:54089295	NA	0.76	7.41	0.61	5.15e-11	Height;
THYM	cis	rs9649213	0.593	rs6947208	chr7:97912204	C/T	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg24069376	chr3:38537580	EXOG	0.66	6.64	0.56	1.96e-9	Electrocardiographic conduction measures;
THYM	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.21	8.5	0.66	2.67e-13	Cognitive test performance;
THYM	cis	rs11190604	1.000	rs4604805	chr10:102261409	C/G	cg07570687	chr10:102243282	WNT8B	0.75	6.81	0.57	8.73e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs922692	0.967	rs11633351	chr15:79056815	C/T	cg15571903	chr15:79123663	NA	-0.65	-5.16	-0.47	1.34e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg02734326	chr4:10020555	SLC2A9	0.63	4.92	0.45	3.57e-6	Bone mineral density;
THYM	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs11577318	0.579	rs11247934	chr1:26695758	A/T	cg00852783	chr1:26633632	UBXN11	-0.66	-4.53	-0.42	1.7e-5	Granulocyte percentage of myeloid white cells;
THYM	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg13390004	chr1:15929781	NA	0.63	4.79	0.44	6.2e-6	Systolic blood pressure;
THYM	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg10661904	chr17:79619235	PDE6G	0.66	6.41	0.55	5.55e-9	Eye color traits;
THYM	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg11845111	chr2:191398756	TMEM194B	-1.0	-8.08	-0.64	2.04e-12	Diastolic blood pressure;
THYM	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg23708337	chr7:1209742	NA	0.64	4.67	0.43	9.74e-6	Longevity;Endometriosis;
THYM	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg24642844	chr7:1081250	C7orf50	-1.19	-8.51	-0.66	2.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10203711	0.933	rs4994752	chr2:239567309	C/A	cg14580085	chr2:239553406	NA	0.68	6.18	0.54	1.6e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg13266496	chr6:110720918	DDO	-0.48	-5.23	-0.47	1.02e-6	Platelet distribution width;
THYM	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg03159660	chr11:2078197	NA	0.61	4.67	0.43	9.89e-6	Longevity;
THYM	cis	rs4889855	0.530	rs9901467	chr17:78574008	G/A	cg16591659	chr17:78472290	NA	-0.4	-5.09	-0.46	1.83e-6	Fractional excretion of uric acid;
THYM	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	7.41	0.61	5.09e-11	Prudent dietary pattern;
THYM	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg11266682	chr4:10021025	SLC2A9	0.73	11.88	0.77	1.74e-20	Bone mineral density;
THYM	cis	rs789852	0.867	rs9288751	chr3:194316294	C/G	cg18000598	chr3:194342907	TMEM44	1.11	6.93	0.58	4.95e-10	QT interval;
THYM	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg03605463	chr16:89740564	NA	0.86	6.82	0.57	8.41e-10	Vitiligo;
THYM	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg11871910	chr12:69753446	YEATS4	1.01	9.85	0.71	3.52e-16	Cerebrospinal fluid biomarker levels;
THYM	cis	rs889398	0.967	rs12599391	chr16:69605349	C/T	cg09409435	chr16:70099608	PDXDC2	0.63	4.92	0.45	3.64e-6	Body mass index;
THYM	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg14784868	chr12:69753453	YEATS4	0.77	6.32	0.54	8.57e-9	Blood protein levels;
THYM	cis	rs11089937	0.584	rs6001213	chr22:22536498	A/G	cg21401457	chr22:22472743	NA	0.57	4.85	0.45	4.86e-6	Periodontitis (PAL4Q3);
THYM	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg12516959	chr21:47718080	NA	-0.43	-5.1	-0.46	1.7e-6	Testicular germ cell tumor;
THYM	cis	rs2932538	0.885	rs3762335	chr1:113100548	C/T	cg22162597	chr1:113214053	CAPZA1	0.66	5.21	0.47	1.09e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs9790314	0.967	rs460165	chr3:161087710	G/A	cg04691961	chr3:161091175	C3orf57	-0.68	-6.07	-0.53	2.56e-8	Morning vs. evening chronotype;
THYM	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg08564027	chr20:61660810	NA	0.92	9.77	0.71	5.02e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2282300	0.739	rs1222219	chr11:30344345	G/C	cg09906309	chr11:30344399	C11orf46	-0.73	-5.37	-0.48	5.47e-7	Morning vs. evening chronotype;
THYM	trans	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg13615516	chr5:77269221	NA	0.86	8.01	0.63	2.88e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs7084402	0.967	rs1649032	chr10:60279701	T/C	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg16579431	chr16:433439	TMEM8A;LOC100134368	0.66	5.4	0.48	4.9e-7	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs3126085	0.935	rs12746239	chr1:152246726	G/A	cg10321714	chr1:152280068	FLG	-0.7	-5.11	-0.46	1.67e-6	Atopic dermatitis;
THYM	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg08999081	chr20:33150536	PIGU	0.78	7.16	0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs4077515	0.527	rs10870146	chr9:139308054	G/A	cg14115884	chr9:139300582	SDCCAG3	0.7	6.53	0.56	3.19e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg14416269	chr4:6271139	WFS1	0.55	5.69	0.5	1.41e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg02696790	chr15:75250997	RPP25	0.49	4.71	0.44	8.48e-6	Breast cancer;
THYM	cis	rs7901056	0.934	rs1335552	chr10:26725355	A/G	cg23318538	chr10:26883079	C10orf50	-0.35	-4.48	-0.42	2.1e-5	Lymphocyte counts;
THYM	cis	rs6964587	0.610	rs2888850	chr7:91430027	T/C	cg22709100	chr7:91322751	NA	0.64	4.74	0.44	7.54e-6	Breast cancer;
THYM	cis	rs490234	0.702	rs13287071	chr9:128268224	T/C	cg14078157	chr9:128172775	NA	-0.76	-6.24	-0.54	1.21e-8	Mean arterial pressure;
THYM	cis	rs7267979	1.000	rs6107047	chr20:25442097	G/A	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs11696845	0.649	rs6031782	chr20:43383832	A/G	cg25301532	chr20:43378953	KCNK15	-0.62	-4.9	-0.45	3.88e-6	Obesity-related traits;
THYM	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06873352	chr17:61820015	STRADA	0.78	9.87	0.71	3.13e-16	Prudent dietary pattern;
THYM	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg14129053	chr2:1895732	MYT1L	1.16	4.47	0.42	2.2e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs8067545	0.611	rs2526486	chr17:20101626	T/G	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg01579765	chr21:45077557	HSF2BP	-0.47	-7.43	-0.61	4.78e-11	Mean corpuscular volume;
THYM	cis	rs2120243	0.508	rs4435581	chr3:157096217	G/A	cg24825693	chr3:157122686	VEPH1	-0.48	-4.48	-0.42	2.09e-5	Hepatocellular carcinoma in hepatitis B infection;
THYM	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg09455208	chr3:40491958	NA	0.43	4.47	0.42	2.14e-5	Renal cell carcinoma;
THYM	cis	rs6906287	0.647	rs2213856	chr6:118806793	C/T	cg21191810	chr6:118973309	C6orf204	0.58	5.75	0.51	1.06e-7	Electrocardiographic conduction measures;
THYM	cis	rs61774743	0.636	rs1892423	chr1:41849340	A/C	cg08462924	chr1:41848221	NA	0.82	10.14	0.72	8.5e-17	Intelligence (multi-trait analysis);
THYM	cis	rs4631830	0.900	rs10763588	chr10:51539762	G/T	cg10326726	chr10:51549505	MSMB	-0.62	-6.27	-0.54	1.07e-8	Prostate-specific antigen levels;
THYM	cis	rs6450176	1.000	rs7735253	chr5:53297611	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.81	-6.03	-0.53	3.17e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03576123	chr11:487126	PTDSS2	-1.06	-5.27	-0.48	8.49e-7	Body mass index;
THYM	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg17691542	chr6:26056736	HIST1H1C	0.91	5.54	0.49	2.68e-7	Iron status biomarkers;
THYM	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg26384229	chr12:38710491	ALG10B	0.95	7.55	0.61	2.7e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2070488	1.000	rs13074160	chr3:38455650	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	6.83	0.57	7.89e-10	Electrocardiographic conduction measures;
THYM	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	7.68	0.62	1.38e-11	Platelet count;
THYM	cis	rs1524976	1.000	rs62255282	chr3:65485422	C/T	cg16238336	chr3:65465873	MAGI1	-1.04	-5.74	-0.51	1.11e-7	PR interval;
THYM	cis	rs988913	0.706	rs9396036	chr6:54932506	C/A	cg18532076	chr6:54711417	FAM83B	0.49	4.62	0.43	1.18e-5	Menarche (age at onset);
THYM	cis	rs310642	0.831	rs310652	chr20:62171421	G/C	cg08767838	chr20:62209642	NA	-1.07	-4.52	-0.42	1.79e-5	Hair shape;
THYM	cis	rs4940575	0.786	rs66836460	chr18:60837508	C/A	cg24349668	chr18:61441546	SERPINB7	0.76	4.66	0.43	1.01e-5	Breast cancer;
THYM	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs7078219	0.505	rs11190140	chr10:101291593	T/C	cg04972745	chr10:101287846	NA	-0.51	-4.85	-0.45	4.73e-6	Dental caries;
THYM	cis	rs476633	0.708	rs28770904	chr15:41438881	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.7	-5.46	-0.49	3.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs4294134	0.608	rs11535258	chr7:135247547	A/G	cg08396481	chr7:135194601	CNOT4	-0.74	-4.48	-0.42	2.11e-5	Paget's disease;
THYM	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg22709100	chr7:91322751	NA	0.68	5.42	0.49	4.59e-7	Breast cancer;
THYM	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg14186256	chr22:23484241	RTDR1	0.97	9.38	0.69	3.53e-15	Bone mineral density;
THYM	cis	rs7584330	0.868	rs7569197	chr2:238383073	A/G	cg16989719	chr2:238392110	NA	-0.63	-5.88	-0.52	6.05e-8	Prostate cancer;
THYM	cis	rs55871839	0.708	rs2326213	chr8:59812459	A/G	cg07426533	chr8:59803705	TOX	-0.67	-6.88	-0.58	6.33e-10	Pneumonia;
THYM	cis	rs728616	0.867	rs726289	chr10:81706951	C/T	cg05935833	chr10:81318306	SFTPA2	-0.75	-4.98	-0.45	2.85e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg04865290	chr3:52927548	TMEM110	-0.88	-4.75	-0.44	7.08e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs6840360	0.615	rs7669465	chr4:152609289	C/T	cg22705602	chr4:152727874	NA	-0.79	-10.66	-0.74	6.62e-18	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg10505658	chr17:80084571	CCDC57	0.7	8.07	0.64	2.18e-12	Life satisfaction;
THYM	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg03676636	chr4:99064102	C4orf37	0.5	7.65	0.62	1.6e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1461503	0.512	rs3816621	chr11:122818311	A/G	cg27398637	chr11:122830231	C11orf63	-0.61	-5.41	-0.49	4.79e-7	Menarche (age at onset);
THYM	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg23187316	chr7:1099788	C7orf50	0.59	4.49	0.42	2.01e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs995000	0.931	rs1748199	chr1:63057136	T/C	cg06896770	chr1:63153194	DOCK7	0.92	7.57	0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs863345	0.604	rs1112915	chr1:158444447	T/C	cg12129480	chr1:158549410	OR10X1	-0.49	-4.77	-0.44	6.59e-6	Pneumococcal bacteremia;
THYM	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg04944784	chr2:26401820	FAM59B	-1.05	-8.18	-0.64	1.23e-12	Gut microbiome composition (summer);
THYM	cis	rs1580019	0.921	rs1580023	chr7:32497881	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.59	0.56	2.42e-9	Cognitive ability;
THYM	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.85	0.74	2.52e-18	Chronic sinus infection;
THYM	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg06238570	chr21:40685208	BRWD1	0.96	9.07	0.68	1.61e-14	Cognitive function;
THYM	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg26446133	chr18:72167187	CNDP2	-1.02	-10.4	-0.73	2.35e-17	Refractive error;
THYM	cis	rs4962416	0.509	rs750599	chr10:126692193	C/T	cg04494136	chr10:126703576	CTBP2	-0.37	-5.12	-0.47	1.59e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg10281704	chr16:966864	LMF1	-0.27	-4.56	-0.42	1.5e-5	Height;
THYM	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg24846680	chr1:228362309	C1orf69	0.53	4.71	0.43	8.6e-6	Diastolic blood pressure;
THYM	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg04455712	chr21:45112962	RRP1B	0.51	4.72	0.44	8.23e-6	Mean corpuscular volume;
THYM	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg11752832	chr7:134001865	SLC35B4	0.68	4.92	0.45	3.63e-6	Mean platelet volume;
THYM	cis	rs13102973	0.867	rs4429776	chr4:135883394	G/T	cg14419869	chr4:135874104	NA	0.9	7.67	0.62	1.5e-11	Subjective well-being;
THYM	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg26384229	chr12:38710491	ALG10B	0.97	7.44	0.61	4.48e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2806561	0.780	rs12117752	chr1:23360223	T/C	cg12483005	chr1:23474871	LUZP1	-0.51	-4.69	-0.43	9.25e-6	Height;
THYM	cis	rs11048434	0.736	rs1805732	chr12:9090892	A/G	cg13575925	chr12:9217583	LOC144571	-0.53	-4.94	-0.45	3.31e-6	Sjögren's syndrome;
THYM	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg21427119	chr20:30132790	HM13	-0.86	-5.96	-0.52	4.2e-8	Mean corpuscular hemoglobin;
THYM	trans	rs4596713	0.538	rs7030146	chr9:71756390	T/G	cg16512924	chr15:28394682	HERC2	0.82	6.96	0.58	4.33e-10	Headache;
THYM	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg00944433	chr1:107599041	PRMT6	-0.42	-5.0	-0.46	2.58e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg06009448	chr7:1102226	C7orf50	0.53	5.55	0.49	2.6e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7953508	0.711	rs11611927	chr12:93977591	A/G	cg18151635	chr12:93972918	NA	-0.71	-5.07	-0.46	1.99e-6	Pubertal anthropometrics;
THYM	cis	rs9682041	0.932	rs1525362	chr3:170070702	C/T	cg11886554	chr3:170076028	SKIL	1.17	4.52	0.42	1.79e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs1113500	0.565	rs1781071	chr1:108571034	C/G	cg06207961	chr1:108661230	NA	0.6	4.86	0.45	4.6e-6	Growth-regulated protein alpha levels;
THYM	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg00376283	chr12:123451042	ABCB9	0.7	4.72	0.44	8.27e-6	Neutrophil percentage of white cells;
THYM	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9796	0.505	rs28665387	chr15:41532869	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.58	-4.74	-0.44	7.59e-6	Menopause (age at onset);
THYM	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg23281280	chr6:28129359	ZNF389	0.61	4.74	0.44	7.58e-6	Parkinson's disease;
THYM	cis	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg26384229	chr12:38710491	ALG10B	-0.69	-5.37	-0.48	5.5e-7	Morning vs. evening chronotype;
THYM	cis	rs6912958	0.500	rs3828759	chr6:87806640	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.28	-0.48	8.14e-7	Monocyte percentage of white cells;
THYM	cis	rs10819861	0.645	rs12686105	chr9:98852303	A/G	cg14508093	chr9:98862825	NA	-0.24	-4.65	-0.43	1.08e-5	Electrocardiographic traits;
THYM	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.73	0.44	7.82e-6	Alzheimer's disease (late onset);
THYM	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg16031515	chr1:205743344	RAB7L1	-0.74	-7.3	-0.6	8.61e-11	Menarche (age at onset);
THYM	cis	rs865483	0.826	rs853198	chr17:35849342	A/C	cg06716730	chr17:35851459	DUSP14	0.43	7.12	0.59	2.08e-10	Monocyte count;
THYM	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg02825527	chr7:2087843	MAD1L1	-0.72	-4.7	-0.43	8.82e-6	Bipolar disorder;
THYM	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg09263875	chr16:632152	PIGQ	0.73	6.29	0.54	9.69e-9	Height;
THYM	cis	rs1448094	0.512	rs6539932	chr12:86247497	T/C	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs10899021	0.790	rs12296094	chr11:74321700	C/T	cg25880958	chr11:74394337	NA	-0.72	-4.72	-0.44	7.99e-6	Response to metformin (IC50);
THYM	cis	rs7078219	0.743	rs7095953	chr10:101274425	C/T	cg17888390	chr10:101282816	NA	0.5	4.87	0.45	4.38e-6	Dental caries;
THYM	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg21385522	chr1:16154831	NA	0.67	5.64	0.5	1.74e-7	Systolic blood pressure;
THYM	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg12893697	chr11:970389	AP2A2	-0.33	-5.52	-0.49	2.96e-7	Alzheimer's disease (late onset);
THYM	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg26038318	chr20:34205095	SPAG4	0.6	4.7	0.43	8.69e-6	Total cholesterol levels;
THYM	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg02038168	chr22:39784481	NA	-0.63	-5.19	-0.47	1.17e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs1050631	0.564	rs10153377	chr18:33727984	G/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.28	0.48	8.32e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg20203395	chr5:56204925	C5orf35	-0.65	-4.53	-0.42	1.68e-5	Initial pursuit acceleration;
THYM	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg02782426	chr3:40428986	ENTPD3	-0.51	-4.54	-0.42	1.67e-5	Renal cell carcinoma;
THYM	cis	rs7769051	0.522	rs34688576	chr6:133118214	C/T	cg07930552	chr6:133119739	C6orf192	1.14	4.51	0.42	1.82e-5	Type 2 diabetes nephropathy;
THYM	cis	rs11078597	0.731	rs62090051	chr17:1640640	C/G	cg18436246	chr17:1640651	WDR81	0.64	4.63	0.43	1.14e-5	Serum albumin level;
THYM	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg27129171	chr3:47204927	SETD2	0.68	6.47	0.55	4.19e-9	Colorectal cancer;
THYM	cis	rs7267979	1.000	rs6083856	chr20:25407585	C/T	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2074585	0.583	rs28406958	chr15:91069364	C/A	cg22089800	chr15:90895588	ZNF774	-0.61	-4.45	-0.42	2.29e-5	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
THYM	cis	rs11085466	0.948	rs76881507	chr19:21762189	A/T	cg23026602	chr19:21646605	NA	-0.66	-4.84	-0.45	4.94e-6	Colorectal or endometrial cancer;
THYM	cis	rs35264875	0.950	rs72928659	chr11:68852358	C/T	cg23845249	chr11:68861649	NA	0.55	6.53	0.56	3.22e-9	Blond vs. brown hair color;
THYM	cis	rs11679640	1.000	rs7566761	chr2:43118872	G/A	cg27193366	chr2:43037868	NA	0.76	4.49	0.42	1.99e-5	White matter hyperintensity burden;
THYM	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg13319975	chr6:146136371	FBXO30	0.73	6.11	0.53	2.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg15733309	chr7:157513707	PTPRN2	0.56	5.98	0.52	3.95e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs10751667	0.961	rs7482484	chr11:927020	C/T	cg01483505	chr11:975446	AP2A2	0.63	4.73	0.44	7.87e-6	Alzheimer's disease (late onset);
THYM	cis	rs12681288	0.792	rs4735972	chr8:998618	A/C	cg04918696	chr8:1004106	NA	-0.44	-4.89	-0.45	4.15e-6	Schizophrenia;
THYM	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs78456975	0.739	rs13405352	chr2:1518726	C/T	cg12573674	chr2:1569213	NA	-1.26	-6.07	-0.53	2.61e-8	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs909002	0.742	rs12032291	chr1:32129041	A/G	cg13919466	chr1:32135498	COL16A1	0.54	5.19	0.47	1.17e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3741151	0.773	rs73542976	chr11:73127471	A/G	cg12959048	chr11:73096162	RELT	-0.53	-5.08	-0.46	1.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7666738	0.687	rs6830176	chr4:99093955	G/C	cg10515332	chr4:99064459	C4orf37	0.57	4.54	0.42	1.68e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3812049	0.737	rs790154	chr5:127501235	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.41	0.48	4.8e-7	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs7104764	1.000	rs7104764	chr11:229977	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.1	9.77	0.71	5.16e-16	Menarche (age at onset);
THYM	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg05347473	chr6:146136440	FBXO30	0.56	4.45	0.42	2.34e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7107174	1.000	rs10501426	chr11:78057122	C/T	cg02023728	chr11:77925099	USP35	0.62	6.0	0.52	3.51e-8	Testicular germ cell tumor;
THYM	cis	rs1371867	0.875	rs1612773	chr8:101337818	G/C	cg00191853	chr8:101177733	SPAG1	-0.51	-5.08	-0.46	1.85e-6	Atrioventricular conduction;
THYM	cis	rs7551222	0.752	rs12039454	chr1:204542580	C/T	cg20240347	chr1:204465584	NA	0.54	4.94	0.45	3.36e-6	Schizophrenia;
THYM	cis	rs17739794	0.517	rs35856917	chr8:774395	C/G	cg01971667	chr8:817044	NA	-0.82	-6.39	-0.55	6.01e-9	Clozapine-induced cytotoxicity;
THYM	cis	rs17685	0.753	rs8200	chr7:75696606	C/G	cg16489192	chr7:75678113	MDH2;STYXL1	0.59	6.0	0.52	3.59e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6815814	0.904	rs73236628	chr4:38825443	C/T	cg06935464	chr4:38784597	TLR10	0.71	4.88	0.45	4.31e-6	Breast cancer;
THYM	trans	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs3780378	0.633	rs10758677	chr9:5188078	A/G	cg02405213	chr9:5042618	JAK2	-0.76	-7.62	-0.62	1.88e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs6089584	0.821	rs4925332	chr20:60604639	C/T	cg06108461	chr20:60628389	TAF4	-1.13	-9.54	-0.7	1.6e-15	Body mass index;
THYM	cis	rs6032067	0.636	rs6032094	chr20:43912637	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.66	-7.12	-0.59	2.02e-10	Blood protein levels;
THYM	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg11663144	chr21:46675770	NA	-0.74	-9.5	-0.7	1.97e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg12288994	chr5:1860383	NA	0.86	7.08	0.59	2.44e-10	Cardiovascular disease risk factors;
THYM	cis	rs4242434	0.672	rs900266	chr8:22485295	A/T	cg21658235	chr8:22456391	C8orf58	0.45	4.57	0.42	1.48e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7119	0.604	rs2271397	chr15:77907775	T/C	cg27398640	chr15:77910606	LINGO1	0.63	8.22	0.64	1.03e-12	Type 2 diabetes;
THYM	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg02734326	chr4:10020555	SLC2A9	0.72	6.51	0.56	3.5e-9	Bone mineral density;
THYM	cis	rs6424115	1.000	rs12116511	chr1:24162662	A/G	cg15997130	chr1:24165203	NA	-0.77	-6.63	-0.56	2.01e-9	Immature fraction of reticulocytes;
THYM	cis	rs6496667	0.865	rs7178103	chr15:90926799	C/T	cg22089800	chr15:90895588	ZNF774	0.79	4.75	0.44	7.21e-6	Rheumatoid arthritis;
THYM	cis	rs4919087	0.962	rs10882883	chr10:99013312	A/G	cg19453742	chr10:98862320	SLIT1	-0.64	-4.8	-0.44	5.79e-6	Monocyte count;
THYM	cis	rs4389656	0.625	rs274681	chr5:6748659	T/C	cg10857441	chr5:6722123	POLS	-0.47	-4.52	-0.42	1.76e-5	Coronary artery disease;
THYM	cis	rs259282	0.504	rs259277	chr19:33161103	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.95	6.55	0.56	3e-9	Schizophrenia;
THYM	cis	rs9796	0.611	rs691672	chr15:41444438	A/C	cg21153102	chr15:41252147	NA	0.6	4.98	0.45	2.84e-6	Menopause (age at onset);
THYM	cis	rs9875589	0.509	rs4685062	chr3:14066409	T/C	cg03204825	chr3:13978759	TPRXL	-0.51	-4.46	-0.42	2.26e-5	Ovarian reserve;
THYM	trans	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg10856724	chr12:34555212	NA	-0.9	-8.08	-0.64	2.05e-12	Bladder cancer;
THYM	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg16586182	chr3:47516702	SCAP	0.64	5.62	0.5	1.93e-7	Colorectal cancer;
THYM	cis	rs8050907	0.744	rs13330957	chr16:4525330	G/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.58	0.43	1.38e-5	Obesity-related traits;
THYM	cis	rs775227	0.574	rs66866534	chr3:113147315	T/C	cg18753928	chr3:113234510	CCDC52	-0.82	-5.81	-0.51	8.47e-8	Dental caries;
THYM	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg13395646	chr4:1353034	KIAA1530	0.63	5.44	0.49	4.08e-7	Obesity-related traits;
THYM	cis	rs9399401	0.626	rs7776356	chr6:142777029	A/G	cg04461802	chr6:142623433	GPR126	0.74	7.29	0.6	9.24e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg02487422	chr3:49467188	NICN1	0.63	4.82	0.44	5.48e-6	Resting heart rate;
THYM	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg09455208	chr3:40491958	NA	0.5	5.18	0.47	1.24e-6	Renal cell carcinoma;
THYM	cis	rs11910985	0.557	rs79228900	chr21:48091888	G/A	cg23283320	chr21:48055893	PRMT2	1.46	7.42	0.61	5.03e-11	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg11764359	chr7:65958608	NA	0.8	6.58	0.56	2.51e-9	Aortic root size;
THYM	cis	rs7107770	1.000	rs4936997	chr11:125090227	C/T	cg07747661	chr11:125106135	PKNOX2	-0.85	-4.95	-0.45	3.25e-6	Photic sneeze reflex;
THYM	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.22	9.36	0.69	3.93e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg27034606	chr17:28928453	LRRC37B2	0.79	4.89	0.45	4.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	5.75	0.51	1.06e-7	Platelet count;
THYM	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs7481584	0.624	rs428726	chr11:3046201	G/A	cg03159660	chr11:2078197	NA	0.63	4.76	0.44	7e-6	Calcium levels;
THYM	cis	rs11642862	0.685	rs79974799	chr16:30996795	C/T	cg01070095	chr16:30968205	SETD1A	0.73	4.79	0.44	6.24e-6	Tonsillectomy;
THYM	cis	rs6840360	0.608	rs2724556	chr4:152341717	G/A	cg17479576	chr4:152424074	FAM160A1	-0.65	-4.85	-0.45	4.73e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3892630	0.757	rs8109823	chr19:33183316	A/G	cg22980127	chr19:33182716	NUDT19	1.12	8.96	0.68	2.71e-14	Red blood cell traits;
THYM	cis	rs3008870	1.000	rs4655663	chr1:67430103	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.96	8.0	0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg14004847	chr7:1930337	MAD1L1	-0.63	-4.93	-0.45	3.49e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7264396	0.790	rs6579255	chr20:34219496	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-5.71	-0.51	1.28e-7	Total cholesterol levels;
THYM	cis	rs78761021	0.755	rs17681788	chr17:9794415	C/T	cg26853458	chr17:9805074	RCVRN	0.53	4.49	0.42	2.01e-5	Type 2 diabetes;
THYM	cis	rs78761021	0.720	rs55740146	chr17:9796599	G/A	cg26853458	chr17:9805074	RCVRN	0.53	4.46	0.42	2.24e-5	Type 2 diabetes;
THYM	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg25427524	chr10:38739819	LOC399744	-0.64	-5.87	-0.52	6.38e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs2637266	0.967	rs7477607	chr10:78358768	G/T	cg18941641	chr10:78392320	NA	0.8	6.94	0.58	4.82e-10	Pulmonary function;
THYM	cis	rs7103648	0.567	rs12287076	chr11:47606865	G/C	cg20307385	chr11:47447363	PSMC3	-0.69	-5.27	-0.48	8.55e-7	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs892961	0.932	rs8066646	chr17:75414192	C/T	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs2742417	0.603	rs2742457	chr3:45767487	G/A	cg04837898	chr3:45731254	SACM1L	-0.75	-5.34	-0.48	6.45e-7	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4808199	0.843	rs10402308	chr19:19657500	G/A	cg03709012	chr19:19516395	GATAD2A	0.88	4.75	0.44	7.17e-6	Nonalcoholic fatty liver disease;
THYM	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg03690763	chr11:133734501	NA	-0.62	-4.97	-0.45	3.01e-6	Childhood ear infection;
THYM	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg23711669	chr6:146136114	FBXO30	0.97	10.56	0.73	1.05e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2273669	0.667	rs76732622	chr6:109318280	A/T	cg17117243	chr6:109341365	SESN1	-0.92	-5.21	-0.47	1.09e-6	Prostate cancer;
THYM	cis	rs5417	0.689	rs55868524	chr17:7170665	G/A	cg25256661	chr17:7137939	DVL2	-0.9	-6.6	-0.56	2.31e-9	Diastolic blood pressure;
THYM	cis	rs7178572	0.568	rs4886862	chr15:77652368	T/C	cg22256960	chr15:77711686	NA	-1.05	-8.4	-0.65	4.29e-13	Type 2 diabetes;
THYM	cis	rs6546324	0.625	rs4533457	chr2:67787348	T/G	cg18237512	chr2:67827392	NA	-0.78	-4.57	-0.42	1.47e-5	Endometriosis;
THYM	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg07959070	chr22:50026188	C22orf34	-0.29	-4.99	-0.46	2.68e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg12963246	chr6:28129442	ZNF389	-0.9	-7.64	-0.62	1.73e-11	Depression;
THYM	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18876405	chr7:65276391	NA	0.57	4.67	0.43	9.86e-6	Aortic root size;
THYM	cis	rs8033133	0.602	rs12438531	chr15:25323876	A/C	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.63	-4.7	-0.43	8.66e-6	Blood osmolality (transformed sodium);
THYM	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg12310025	chr6:25882481	NA	-0.71	-5.97	-0.52	4.14e-8	Blood metabolite levels;
THYM	cis	rs1747683	0.809	rs1547772	chr10:13383449	T/C	cg25835351	chr10:13388524	SEPHS1	-0.35	-5.9	-0.52	5.49e-8	IgG glycosylation;
THYM	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg18230493	chr5:56204884	C5orf35	-0.89	-6.53	-0.56	3.25e-9	Initial pursuit acceleration;
THYM	cis	rs55788414	1.000	rs35769936	chr16:81180101	A/G	cg06400318	chr16:81190750	PKD1L2	-1.0	-4.87	-0.45	4.51e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs4285028	0.699	rs1920297	chr3:121598000	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.81	-5.78	-0.51	9.34e-8	Multiple sclerosis;
THYM	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	13.34	0.81	1.71e-23	Height;
THYM	cis	rs912057	0.601	rs1294405	chr6:6737591	A/G	cg13809441	chr6:6737631	NA	0.54	6.82	0.57	8.29e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs897984	0.520	rs4889622	chr16:30870957	A/G	cg03418659	chr16:31128414	MYST1	0.64	4.68	0.43	9.46e-6	Dementia with Lewy bodies;
THYM	cis	rs6547741	0.752	rs7562863	chr2:27892694	T/A	cg27432699	chr2:27873401	GPN1	-0.86	-7.63	-0.62	1.82e-11	Oral cavity cancer;
THYM	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg03929089	chr4:120376271	NA	-0.8	-8.14	-0.64	1.5e-12	Height;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg25499769	chr12:128245397	NA	-1.01	-7.06	-0.59	2.67e-10	Depressive symptoms;
THYM	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg05347473	chr6:146136440	FBXO30	0.77	6.53	0.56	3.19e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8050260	0.500	rs4783650	chr16:68558528	T/C	cg02972257	chr16:68554789	NA	0.8	4.94	0.45	3.39e-6	Plateletcrit;
THYM	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02475777	chr4:1388615	CRIPAK	0.67	4.84	0.44	5.11e-6	Longevity;
THYM	cis	rs919433	0.679	rs67492914	chr2:198523402	T/G	cg00792783	chr2:198669748	PLCL1	0.82	5.44	0.49	4.16e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg00129232	chr17:37814104	STARD3	-0.7	-4.93	-0.45	3.42e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03576123	chr11:487126	PTDSS2	-1.24	-5.21	-0.47	1.1e-6	Body mass index;
THYM	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg22875332	chr1:76189707	ACADM	-0.54	-5.07	-0.46	1.96e-6	Daytime sleep phenotypes;
THYM	cis	rs7923452	0.507	rs215494	chr10:30776589	T/G	cg13289132	chr10:30722225	MAP3K8	-0.59	-4.78	-0.44	6.43e-6	Itch intensity from mosquito bite;
THYM	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg24250549	chr1:154909240	PMVK	0.76	5.98	0.52	3.9e-8	Prostate cancer;
THYM	cis	rs7649443	0.959	rs1073726	chr3:197001008	G/A	cg20744464	chr3:196756875	MFI2	0.62	4.56	0.42	1.53e-5	Nonsyndromic cleft lip with cleft palate;
THYM	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg22433210	chr17:43662623	NA	1.09	8.4	0.65	4.4e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9677476	0.908	rs7598478	chr2:232115887	C/T	cg07929768	chr2:232055508	NA	0.52	5.36	0.48	5.93e-7	Food antigen IgG levels;
THYM	cis	rs10905065	0.965	rs10737019	chr10:5783733	G/A	cg11519256	chr10:5708881	ASB13	0.49	4.85	0.45	4.79e-6	Menopause (age at onset);
THYM	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs950880	0.645	rs56044378	chr2:103065367	G/A	cg03938978	chr2:103052716	IL18RAP	-0.56	-4.78	-0.44	6.51e-6	Serum protein levels (sST2);
THYM	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg03433033	chr1:76189801	ACADM	0.77	10.09	0.72	1.07e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg20387954	chr3:183756860	HTR3D	0.56	4.64	0.43	1.11e-5	Anterior chamber depth;
THYM	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg08257088	chr16:3726052	TRAP1	-0.66	-4.94	-0.45	3.32e-6	Tuberculosis;
THYM	cis	rs4499344	0.730	rs12460624	chr19:33098042	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.48	0.61	3.64e-11	Mean platelet volume;
THYM	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.2	-0.47	1.12e-6	Chronic sinus infection;
THYM	cis	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg09307838	chr4:120376055	NA	0.73	5.32	0.48	6.84e-7	Corneal astigmatism;
THYM	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.65	5.14	0.47	1.47e-6	Lung cancer in ever smokers;
THYM	cis	rs9581857	0.579	rs1759861	chr13:27996406	A/C	cg22138327	chr13:27999177	GTF3A	-1.04	-6.13	-0.53	1.97e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs289828	0.579	rs66521733	chr2:152143578	C/T	cg05960677	chr2:152117363	RBM43	0.75	7.25	0.6	1.1e-10	Blood protein levels;
THYM	cis	rs2777491	0.915	rs7180418	chr15:41629502	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.14	-12.89	-0.8	1.38e-22	Ulcerative colitis;
THYM	cis	rs3126085	0.935	rs7534716	chr1:152198654	A/G	cg26020982	chr1:152196106	HRNR	0.34	4.52	0.42	1.76e-5	Atopic dermatitis;
THYM	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg03188948	chr7:1209495	NA	0.89	4.93	0.45	3.45e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9796	0.621	rs2918462	chr15:41481254	A/G	cg18705301	chr15:41695430	NDUFAF1	0.59	4.83	0.44	5.13e-6	Menopause (age at onset);
THYM	cis	rs4731207	0.698	rs7778544	chr7:124527481	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs2242116	0.833	rs6442038	chr3:46960742	A/G	cg27129171	chr3:47204927	SETD2	0.72	5.93	0.52	4.94e-8	Birth weight;
THYM	cis	rs7043114	0.525	rs10739927	chr9:95052081	G/T	cg14631576	chr9:95140430	CENPP	-0.85	-9.03	-0.68	1.99e-14	Height;
THYM	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg24812749	chr6:127587940	RNF146	0.98	7.86	0.63	5.91e-12	Breast cancer;
THYM	cis	rs28595532	0.920	rs116146507	chr4:119749556	A/G	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg00012203	chr2:219082015	ARPC2	-0.69	-5.87	-0.52	6.36e-8	Colorectal cancer;
THYM	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	6.05	0.53	2.89e-8	Obesity-related traits;
THYM	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs11214589	0.905	rs2186799	chr11:113242533	G/T	cg14159747	chr11:113255604	NA	0.37	7.87	0.63	5.6e-12	Neuroticism;
THYM	cis	rs11157436	0.918	rs11157427	chr14:22622247	T/G	cg26433554	chr14:23315189	MMP14	0.44	4.61	0.43	1.24e-5	Neurocognitive impairment in HIV-1 infection (continuous);
THYM	cis	rs919433	0.680	rs2564383	chr2:198310862	A/G	cg00792783	chr2:198669748	PLCL1	0.82	5.67	0.5	1.54e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs17030434	1.000	rs75418383	chr4:154719084	A/G	cg14289246	chr4:154710475	SFRP2	-0.76	-5.24	-0.47	9.79e-7	Electrocardiographic conduction measures;
THYM	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg27129171	chr3:47204927	SETD2	-0.7	-6.73	-0.57	1.3e-9	Colorectal cancer;
THYM	cis	rs9457247	0.508	rs2285147	chr6:167505548	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.49	-4.49	-0.42	2.01e-5	Crohn's disease;
THYM	cis	rs3087591	0.919	rs11080148	chr17:29609922	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.69	-5.47	-0.49	3.68e-7	Hip circumference;
THYM	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg08807101	chr21:30365312	RNF160	0.94	7.64	0.62	1.69e-11	Dental caries;
THYM	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg05368731	chr17:41323189	NBR1	1.22	10.68	0.74	5.74e-18	Menopause (age at onset);
THYM	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg24578937	chr1:2090814	PRKCZ	-0.6	-6.38	-0.55	6.42e-9	Height;
THYM	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.14	0.47	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg18758796	chr5:131593413	PDLIM4	0.6	5.9	0.52	5.68e-8	Acylcarnitine levels;
THYM	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg06532163	chr17:45867833	NA	0.65	6.55	0.56	2.91e-9	IgG glycosylation;
THYM	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg07648498	chr16:89883185	FANCA	0.61	4.49	0.42	2.02e-5	Vitiligo;
THYM	cis	rs11690935	0.569	rs62183770	chr2:172838117	C/G	cg13550731	chr2:172543902	DYNC1I2	0.62	4.87	0.45	4.51e-6	Schizophrenia;
THYM	cis	rs10992471	0.603	rs10116813	chr9:95090360	C/T	cg14631576	chr9:95140430	CENPP	-1.02	-10.52	-0.73	1.29e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7255045	0.711	rs2077544	chr19:12963285	C/T	cg26870725	chr19:12978805	MAST1	-0.69	-5.31	-0.48	7.23e-7	Mean corpuscular volume;
THYM	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.37	0.55	6.72e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg18512352	chr11:47633146	NA	-0.53	-6.56	-0.56	2.75e-9	Subjective well-being;
THYM	cis	rs7833790	0.777	rs10958042	chr8:82678393	G/T	cg17211192	chr8:82754475	SNX16	-0.85	-6.85	-0.57	7.41e-10	Diastolic blood pressure;
THYM	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.43	1.27e-5	Breast cancer;
THYM	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.14	-0.64	1.54e-12	Mean corpuscular volume;
THYM	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg18681998	chr4:17616180	MED28	0.95	9.51	0.7	1.88e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs988913	1.000	rs7753255	chr6:54832973	C/T	cg18532076	chr6:54711417	FAM83B	0.5	4.91	0.45	3.78e-6	Menarche (age at onset);
THYM	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9644630	0.696	rs7828025	chr8:19314693	A/G	cg01280390	chr8:19363452	CSGALNACT1	0.65	6.96	0.58	4.31e-10	Oropharynx cancer;
THYM	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg12310025	chr6:25882481	NA	0.71	5.78	0.51	9.37e-8	Blood metabolite levels;
THYM	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs4866334	1.000	rs79036917	chr5:18441030	A/C	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg08132940	chr7:1081526	C7orf50	-1.29	-7.4	-0.6	5.36e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7173743	0.756	rs6495337	chr15:79125689	C/G	cg15571903	chr15:79123663	NA	-0.56	-6.26	-0.54	1.12e-8	Coronary artery disease;
THYM	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg22166914	chr1:53195759	ZYG11B	0.91	10.77	0.74	3.71e-18	Monocyte count;
THYM	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06850241	chr22:41845214	NA	-0.6	-5.39	-0.48	5.12e-7	Vitiligo;
THYM	cis	rs2073300	0.609	rs3746733	chr20:23349749	C/T	cg12062639	chr20:23401060	NAPB	1.1	5.73	0.51	1.16e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6598955	0.671	rs41285347	chr1:26644399	C/T	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.7	0.43	8.83e-6	Obesity-related traits;
THYM	cis	rs7264396	0.790	rs6060516	chr20:34214368	T/C	cg26038318	chr20:34205095	SPAG4	0.64	5.28	0.48	8.13e-7	Total cholesterol levels;
THYM	cis	rs2354432	0.714	rs7531962	chr1:146746023	G/A	cg25205988	chr1:146714368	CHD1L	-1.16	-6.7	-0.57	1.46e-9	Mitochondrial DNA levels;
THYM	cis	rs2732480	0.557	rs2732484	chr12:48737245	A/C	cg21466736	chr12:48725269	NA	-0.6	-5.36	-0.48	5.86e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg25251562	chr2:3704773	ALLC	-0.83	-5.59	-0.5	2.16e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs17818399	0.510	rs12105801	chr2:46799343	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.57	4.49	0.42	1.97e-5	Height;
THYM	cis	rs7681440	0.606	rs356163	chr4:90696827	A/C	cg06632027	chr4:90757378	SNCA	0.59	4.61	0.43	1.27e-5	Dementia with Lewy bodies;
THYM	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs9972944	0.756	rs7215462	chr17:63770498	T/C	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs728616	0.764	rs12413678	chr10:81687099	G/A	cg05935833	chr10:81318306	SFTPA2	-0.74	-4.63	-0.43	1.17e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs172166	0.610	rs156737	chr6:27895213	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.64	-5.05	-0.46	2.13e-6	Cardiac Troponin-T levels;
THYM	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg01191920	chr7:158217561	PTPRN2	-0.92	-9.55	-0.7	1.51e-15	Obesity-related traits;
THYM	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	cis	rs9840225	0.769	rs1499643	chr3:25235531	T/C	cg03152121	chr3:26146913	NA	-0.71	-4.46	-0.42	2.28e-5	PR interval in Tripanosoma cruzi seropositivity;
THYM	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg03388025	chr16:89894329	SPIRE2	-0.52	-4.57	-0.42	1.48e-5	Vitiligo;
THYM	cis	rs17401966	1.000	rs11576866	chr1:10414432	A/G	cg19773385	chr1:10388646	KIF1B	-0.64	-4.77	-0.44	6.6e-6	Hepatocellular carcinoma;
THYM	cis	rs16866061	1.000	rs2047134	chr2:225347713	A/C	cg22455342	chr2:225449267	CUL3	0.68	4.88	0.45	4.23e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs10489202	0.683	rs202260	chr1:167956167	G/T	cg24449463	chr1:168025552	DCAF6	-0.9	-9.11	-0.68	1.3e-14	Schizophrenia;
THYM	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg13395646	chr4:1353034	KIAA1530	0.63	5.48	0.49	3.51e-7	Obesity-related traits;
THYM	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.3	-4.73	-0.44	7.88e-6	Obesity-related traits;
THYM	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs9616064	0.853	rs7284865	chr22:46996529	C/T	cg25730555	chr22:47059586	GRAMD4	0.61	4.54	0.42	1.67e-5	Urate levels in obese individuals;
THYM	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg05340658	chr4:99064831	C4orf37	0.58	4.72	0.44	8.07e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7011507	0.700	rs72639011	chr8:49332315	G/A	cg08774009	chr8:49309094	NA	-0.62	-4.83	-0.44	5.19e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs10426930	0.700	rs7246791	chr19:5013776	T/C	cg25246084	chr19:4971487	KDM4B	-0.51	-5.3	-0.48	7.37e-7	Monocyte percentage of white cells;
THYM	cis	rs2282300	0.739	rs3858428	chr11:30296550	T/C	cg09906309	chr11:30344399	C11orf46	0.73	5.38	0.48	5.3e-7	Morning vs. evening chronotype;
THYM	cis	rs2933343	0.729	rs6790091	chr3:128608751	G/C	cg11901034	chr3:128598214	ACAD9	-0.71	-5.55	-0.49	2.56e-7	IgG glycosylation;
THYM	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg05552183	chr6:42928497	GNMT	0.58	4.52	0.42	1.79e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs36051895	0.622	rs10815143	chr9:5009541	G/A	cg02405213	chr9:5042618	JAK2	-1.03	-11.53	-0.76	9.19e-20	Pediatric autoimmune diseases;
THYM	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs637571	0.780	rs653914	chr11:65676516	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	4.98	0.46	2.8e-6	Eosinophil percentage of white cells;
THYM	trans	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs2075230	0.588	rs1642802	chr17:7544271	T/C	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.73	-0.44	7.7e-6	Hormone measurements;
THYM	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg17426766	chr1:2046864	PRKCZ	-0.38	-4.64	-0.43	1.13e-5	Height;
THYM	cis	rs7152530	0.571	rs17096602	chr14:98638936	A/G	cg05180522	chr14:98101740	NA	-0.6	-4.81	-0.44	5.61e-6	Staphylococcus aureus infection;
THYM	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg22974920	chr21:40686053	BRWD1	-0.74	-5.02	-0.46	2.45e-6	Cognitive function;
THYM	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs17253792	0.822	rs76612185	chr14:56037706	T/C	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg06850241	chr22:41845214	NA	0.62	5.06	0.46	2.04e-6	Vitiligo;
THYM	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg07936489	chr17:37558343	FBXL20	0.87	5.78	0.51	9.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.14	0.47	1.49e-6	Height;
THYM	cis	rs453193	0.966	rs658243	chr2:8446695	G/T	cg12167548	chr2:8464763	NA	0.52	5.57	0.5	2.41e-7	Granulocyte percentage of myeloid white cells;
THYM	cis	rs9361491	0.608	rs7768125	chr6:79446389	G/A	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2273669	0.915	rs4470881	chr6:109309287	A/G	cg17117243	chr6:109341365	SESN1	-0.73	-4.56	-0.42	1.52e-5	Prostate cancer;
THYM	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg03388043	chr17:80084554	CCDC57	-0.73	-6.06	-0.53	2.74e-8	Life satisfaction;
THYM	cis	rs11096990	0.634	rs17431358	chr4:39277296	T/C	cg24403649	chr4:39172243	NA	-0.67	-5.84	-0.51	7.33e-8	Cognitive function;
THYM	cis	rs13315871	1.000	rs4362735	chr3:58429893	C/G	cg12435725	chr3:58293450	RPP14	-0.44	-4.73	-0.44	7.65e-6	Cholesterol, total;
THYM	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg00071950	chr4:10020882	SLC2A9	0.88	9.15	0.68	1.09e-14	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg27129171	chr3:47204927	SETD2	0.8	7.67	0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs7586879	0.520	rs6718511	chr2:25122324	A/G	cg27107076	chr2:25050844	ADCY3	-0.29	-4.73	-0.44	7.81e-6	Body mass index;
THYM	cis	rs870825	0.616	rs7678949	chr4:185635018	G/C	cg04058563	chr4:185651563	MLF1IP	1.0	9.28	0.69	5.7e-15	Blood protein levels;
THYM	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg03929089	chr4:120376271	NA	-0.94	-10.74	-0.74	4.27e-18	Coronary artery disease;
THYM	cis	rs5417	0.689	rs55868524	chr17:7170665	G/A	cg03186999	chr17:7165420	CLDN7	-0.51	-5.34	-0.48	6.43e-7	Diastolic blood pressure;
THYM	cis	rs9790314	0.846	rs4560315	chr3:160982132	G/T	cg03342759	chr3:160939853	NMD3	-0.95	-9.47	-0.7	2.2e-15	Morning vs. evening chronotype;
THYM	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg17054759	chr22:49844102	NA	-0.52	-4.72	-0.44	8.24e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs12530845	0.623	rs73721669	chr7:135347107	C/G	cg19897172	chr7:135347071	PL-5283	-0.66	-5.51	-0.49	3.11e-7	Red blood cell traits;
THYM	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	6.25	0.54	1.16e-8	Smoking behavior;
THYM	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg08772003	chr10:104629869	AS3MT	-0.59	-5.35	-0.48	5.97e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg16586182	chr3:47516702	SCAP	-0.65	-5.62	-0.5	1.94e-7	Colorectal cancer;
THYM	cis	rs7000551	0.689	rs2449339	chr8:22387981	G/A	cg12081754	chr8:22256438	SLC39A14	0.65	5.66	0.5	1.59e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg01483505	chr11:975446	AP2A2	0.58	4.75	0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs12681288	0.754	rs4735975	chr8:1000470	T/C	cg04918696	chr8:1004106	NA	-0.46	-4.96	-0.45	3.03e-6	Schizophrenia;
THYM	cis	rs4930776	0.722	rs2361588	chr12:5775065	A/T	cg02086166	chr12:5775618	ANO2	-0.55	-4.86	-0.45	4.66e-6	Plasma clusterin levels;
THYM	cis	rs13315871	0.929	rs11706920	chr3:58279672	C/T	cg12435725	chr3:58293450	RPP14	-0.54	-5.7	-0.5	1.36e-7	Cholesterol, total;
THYM	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg06138931	chr13:21896616	NA	0.58	4.96	0.45	3.12e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs62435770	1.000	rs10485332	chr6:169474687	C/T	cg07652237	chr6:170125491	PHF10	0.57	4.97	0.45	2.98e-6	Loneliness;
THYM	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg23711669	chr6:146136114	FBXO30	0.91	9.21	0.69	8.1e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs12488721	1	rs12488721	chr3:135992645	T/C	cg21827317	chr3:136751795	NA	0.54	4.46	0.42	2.24e-5	Neuroticism;
THYM	cis	rs2502731	0.539	rs3003610	chr9:130985525	G/A	cg09976142	chr9:130955436	CIZ1	0.53	5.1	0.46	1.72e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs6598955	0.640	rs1577507	chr1:26547179	C/T	cg00852783	chr1:26633632	UBXN11	0.84	8.54	0.66	2.17e-13	Obesity-related traits;
THYM	cis	rs9906944	0.707	rs729003	chr17:47117775	C/T	cg09029085	chr17:47094198	IGF2BP1	0.47	6.53	0.56	3.17e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs6429082	0.715	rs2291687	chr1:235594182	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.63	-4.79	-0.44	6.23e-6	Adiposity;
THYM	cis	rs2235649	0.798	rs9932875	chr16:1848012	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.57	-4.91	-0.45	3.81e-6	Blood metabolite levels;
THYM	cis	rs2806561	0.765	rs1757046	chr1:23511821	T/C	cg12483005	chr1:23474871	LUZP1	0.57	5.85	0.51	6.85e-8	Height;
THYM	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	4.83	0.44	5.26e-6	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg18230493	chr5:56204884	C5orf35	-0.89	-6.53	-0.56	3.25e-9	Initial pursuit acceleration;
THYM	cis	rs6032067	0.704	rs62208374	chr20:43765628	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.7	-7.59	-0.61	2.14e-11	Blood protein levels;
THYM	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11890956	chr21:40555474	PSMG1	-0.66	-6.05	-0.53	2.81e-8	Menarche (age at onset);
THYM	cis	rs11739663	0.574	rs67276442	chr5:583918	T/C	cg09021430	chr5:549028	NA	-0.79	-7.64	-0.62	1.71e-11	Ulcerative colitis;
THYM	cis	rs67460515	0.892	rs16832082	chr3:161043571	A/G	cg03342759	chr3:160939853	NMD3	-0.92	-8.1	-0.64	1.85e-12	Parkinson's disease;
THYM	cis	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs4986172	0.726	rs12051846	chr17:43226887	A/G	cg00677574	chr17:43221327	ACBD4	0.7	5.99	0.52	3.67e-8	Height;
THYM	cis	rs7614311	0.636	rs73130576	chr3:63890875	T/C	cg22134162	chr3:63841271	THOC7	-0.58	-7.03	-0.59	3.13e-10	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs7980799	0.716	rs1601008	chr12:33611352	A/G	cg10856724	chr12:34555212	NA	0.6	4.5	0.42	1.93e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs12049351	0.774	rs754023	chr1:229637503	A/T	cg11742688	chr1:229674241	ABCB10	-0.54	-4.47	-0.42	2.14e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs13006833	0.668	rs2136569	chr2:191167414	C/T	cg11845111	chr2:191398756	TMEM194B	-0.66	-4.7	-0.43	8.8e-6	Urinary metabolites;
THYM	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.77	4.99	0.46	2.67e-6	Diabetic retinopathy;
THYM	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06481639	chr22:41940642	POLR3H	-0.74	-5.03	-0.46	2.34e-6	Vitiligo;
THYM	cis	rs2688608	0.592	rs10762560	chr10:75495405	T/G	cg15838173	chr10:75533400	FUT11	-0.5	-5.09	-0.46	1.82e-6	Inflammatory bowel disease;
THYM	cis	rs3741151	0.773	rs79915238	chr11:73272947	C/T	cg17517138	chr11:73019481	ARHGEF17	0.9	4.68	0.43	9.36e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	trans	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg25214090	chr10:38739885	LOC399744	0.97	8.33	0.65	5.98e-13	Corneal astigmatism;
THYM	cis	rs7404928	0.535	rs1858869	chr16:23923186	C/A	cg26685404	chr16:23957272	PRKCB	-0.63	-7.33	-0.6	7.57e-11	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs7582180	0.764	rs12999779	chr2:100924321	T/G	cg08017756	chr2:100939284	LONRF2	-0.73	-7.51	-0.61	3.21e-11	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.81	-4.97	-0.45	2.91e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7631605	0.905	rs12629462	chr3:37226969	A/C	cg21328643	chr3:37258149	NA	-0.48	-4.54	-0.42	1.67e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs7264396	0.580	rs6060648	chr20:34456704	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-4.82	-0.44	5.46e-6	Total cholesterol levels;
THYM	cis	rs2976388	0.692	rs1435453	chr8:143780775	C/T	cg13446199	chr8:143762866	PSCA	-0.41	-4.61	-0.43	1.25e-5	Urinary tract infection frequency;
THYM	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06850241	chr22:41845214	NA	0.59	5.41	0.49	4.76e-7	Vitiligo;
THYM	cis	rs9595908	0.965	rs12323101	chr13:33143406	G/A	cg12383807	chr13:33924137	NA	-0.53	-4.59	-0.43	1.36e-5	Body mass index;
THYM	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.68	-5.03	-0.46	2.27e-6	Menarche (age at onset);
THYM	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg18681998	chr4:17616180	MED28	1.01	10.39	0.73	2.42e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	7.1	0.59	2.3e-10	Platelet count;
THYM	cis	rs600231	0.708	rs2957268	chr11:65245816	A/G	cg17120908	chr11:65337727	SSSCA1	-0.61	-4.76	-0.44	6.93e-6	Bone mineral density;
THYM	cis	rs2658782	0.615	rs2605615	chr11:93233068	G/A	cg15737290	chr11:93063684	CCDC67	0.98	7.13	0.59	1.93e-10	Pulmonary function decline;
THYM	cis	rs12142240	0.698	rs1057534	chr1:46815880	A/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.55	-0.73	1.12e-17	Primary sclerosing cholangitis;
THYM	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg07424592	chr7:64974309	NA	1.15	5.47	0.49	3.58e-7	Diabetic kidney disease;
THYM	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg14784868	chr12:69753453	YEATS4	1.12	10.87	0.74	2.32e-18	Blood protein levels;
THYM	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4072705	0.615	rs6478666	chr9:127249343	C/G	cg13476313	chr9:127244764	NR5A1	-0.39	-6.04	-0.53	2.99e-8	Menarche (age at onset);
THYM	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2898681	1.000	rs2898681	chr4:53757000	C/T	cg00791764	chr4:53727839	RASL11B	0.48	5.77	0.51	1e-7	Optic nerve measurement (cup area);
THYM	cis	rs1568889	1.000	rs61889027	chr11:28281908	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	4.58	0.43	1.4e-5	Bipolar disorder;
THYM	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg12893428	chr3:195717962	SDHAP1	0.53	4.72	0.44	8.11e-6	Pancreatic cancer;
THYM	cis	rs28476539	0.610	rs77589586	chr4:83554334	G/A	cg10249074	chr4:83542146	C4orf11	-0.64	-5.06	-0.46	2.03e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg04267008	chr7:1944627	MAD1L1	-0.68	-6.17	-0.54	1.64e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg06917634	chr15:78832804	PSMA4	-0.9	-7.65	-0.62	1.63e-11	Sudden cardiac arrest;
THYM	cis	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg10911889	chr6:126070802	HEY2	0.56	4.66	0.43	1.03e-5	Brugada syndrome;
THYM	cis	rs10871290	1.000	rs11149710	chr16:74472546	G/T	cg01733217	chr16:74700730	RFWD3	-0.6	-5.17	-0.47	1.31e-6	Breast cancer;
THYM	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg11301795	chr4:187892539	NA	-1.12	-16.92	-0.87	2.01e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9467160	0.520	rs9356934	chr6:24442171	C/T	cg20631270	chr6:24437470	GPLD1	0.57	4.84	0.44	5.04e-6	Liver enzyme levels;
THYM	cis	rs6840360	0.571	rs4696272	chr4:152528229	A/G	cg22705602	chr4:152727874	NA	-0.78	-8.73	-0.67	8.56e-14	Intelligence (multi-trait analysis);
THYM	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg06481639	chr22:41940642	POLR3H	-0.7	-5.64	-0.5	1.74e-7	Neuroticism;
THYM	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs6539288	0.803	rs7305715	chr12:107326552	G/A	cg26297688	chr12:107349093	C12orf23	-0.52	-6.11	-0.53	2.16e-8	Total body bone mineral density;
THYM	cis	rs11948739	0.610	rs6595967	chr5:130252362	A/G	cg08523029	chr5:130500466	HINT1	0.88	5.86	0.52	6.61e-8	Pediatric bone mineral content (hip);
THYM	cis	rs6009824	1.000	rs6009823	chr22:50086334	C/T	cg27029450	chr22:50098074	NA	0.84	5.48	0.49	3.55e-7	Natriuretic peptide levels;
THYM	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg08847533	chr14:75593920	NEK9	-0.96	-10.3	-0.73	3.86e-17	Height;
THYM	cis	rs8044995	0.563	rs73613962	chr16:68361974	T/G	cg09835421	chr16:68378352	PRMT7	-0.72	-4.53	-0.42	1.7e-5	Schizophrenia;
THYM	cis	rs1957429	0.614	rs17883073	chr14:65404059	G/A	cg23373153	chr14:65346875	NA	-1.25	-4.99	-0.46	2.73e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs11025559	0.812	rs16906280	chr11:20472242	T/C	cg19653624	chr11:20408972	PRMT3	-0.75	-5.13	-0.47	1.5e-6	Pursuit maintenance gain;
THYM	cis	rs1048238	0.506	rs848209	chr1:16256007	T/C	cg21385522	chr1:16154831	NA	-0.7	-5.79	-0.51	8.9e-8	Systolic blood pressure;
THYM	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg08355456	chr11:67383691	NA	-0.65	-4.47	-0.42	2.17e-5	Mean corpuscular volume;
THYM	cis	rs6876348	0.516	rs257908	chr5:128327149	A/G	cg25555059	chr5:128301488	SLC27A6	-0.44	-4.6	-0.43	1.29e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11089937	0.584	rs5757245	chr22:22531060	C/T	cg06866756	chr22:22471216	NA	-0.46	-5.0	-0.46	2.59e-6	Periodontitis (PAL4Q3);
THYM	trans	rs629535	0.767	rs72654070	chr8:70079369	G/A	cg21567404	chr3:27674614	NA	-1.09	-10.28	-0.73	4.24e-17	Dupuytren's disease;
THYM	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg24812749	chr6:127587940	RNF146	-0.92	-6.31	-0.54	8.72e-9	Breast cancer;
THYM	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7586879	0.616	rs12713422	chr2:25134497	A/C	cg27107076	chr2:25050844	ADCY3	-0.29	-4.73	-0.44	7.91e-6	Body mass index;
THYM	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg06221963	chr1:154839813	KCNN3	-0.87	-10.89	-0.75	2.07e-18	Prostate cancer;
THYM	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg13114125	chr14:105738426	BRF1	-0.75	-5.87	-0.52	6.23e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	4.5	0.42	1.91e-5	Calcium levels;
THYM	cis	rs9649465	1.000	rs2896334	chr7:123367705	A/C	cg15443791	chr7:124364398	NA	0.58	4.81	0.44	5.62e-6	Migraine;
THYM	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg25566285	chr7:158114605	PTPRN2	0.92	11.54	0.76	9.07e-20	Calcium levels;
THYM	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg11502198	chr6:26597334	ABT1	-0.6	-5.04	-0.46	2.18e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg20283391	chr11:68216788	NA	-0.64	-4.58	-0.43	1.41e-5	Total body bone mineral density;
THYM	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs367615	0.506	rs2914680	chr5:108787146	A/G	cg17395555	chr5:108820864	NA	-0.67	-8.33	-0.65	5.9e-13	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs2070433	0.706	rs55696586	chr21:47733918	T/C	cg12379764	chr21:47803548	PCNT	0.98	5.66	0.5	1.57e-7	Lymphocyte counts;
THYM	cis	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg01364799	chr7:75623366	TMEM120A	0.61	4.46	0.42	2.27e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1670533	1.000	rs629261	chr4:1086763	A/C	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs4363385	0.703	rs4845517	chr1:153003893	T/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Body mass index;
THYM	cis	rs3916	1.000	rs3916	chr12:121177272	G/C	cg21892295	chr12:121157589	UNC119B	-0.51	-4.88	-0.45	4.32e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs67981189	0.896	rs7145484	chr14:71473537	G/A	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg15605315	chr1:45957053	TESK2	0.78	6.78	0.57	9.97e-10	High light scatter reticulocyte count;
THYM	trans	rs4650994	0.544	rs2476560	chr1:178594919	A/G	cg05059571	chr16:84539110	KIAA1609	0.92	10.3	0.73	3.82e-17	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs7100689	0.524	rs7902460	chr10:82199263	T/A	cg01528321	chr10:82214614	TSPAN14	0.6	4.95	0.45	3.18e-6	Post bronchodilator FEV1;
THYM	cis	rs3126085	0.935	rs11204939	chr1:152200942	G/C	cg26020982	chr1:152196106	HRNR	0.37	5.06	0.46	2.05e-6	Atopic dermatitis;
THYM	cis	rs7727544	0.581	rs10075801	chr5:131677642	A/G	cg24060327	chr5:131705240	SLC22A5	-0.64	-4.7	-0.43	8.71e-6	Blood metabolite levels;
THYM	cis	rs4363385	0.626	rs12062770	chr1:153062837	A/C	cg07796016	chr1:152779584	LCE1C	-0.52	-4.52	-0.42	1.78e-5	Inflammatory skin disease;
THYM	cis	rs6121246	0.559	rs1062794	chr20:30381758	G/C	cg13852791	chr20:30311386	BCL2L1	1.01	10.2	0.72	6.3e-17	Mean corpuscular hemoglobin;
THYM	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs13031619	0.517	rs10864995	chr2:3683557	C/T	cg01268866	chr2:3683757	COLEC11	0.74	5.0	0.46	2.59e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.68	9.11	0.68	1.34e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg23982607	chr1:1823379	GNB1	-0.94	-10.22	-0.72	5.49e-17	Body mass index;
THYM	cis	rs7677751	0.806	rs7673984	chr4:55088761	C/T	cg17187183	chr4:55093834	PDGFRA	0.68	5.35	0.48	6.08e-7	Corneal astigmatism;
THYM	cis	rs9970807	0.818	rs72664332	chr1:56980222	A/C	cg11959316	chr1:57001742	PPAP2B	0.8	5.84	0.51	7.12e-8	Myocardial infarction;Coronary artery disease;
THYM	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg00686598	chr14:53173677	PSMC6	1.39	7.01	0.58	3.52e-10	Alzheimer's disease (late onset);
THYM	cis	rs4919087	0.923	rs11189037	chr10:98974707	C/G	cg25902810	chr10:99078978	FRAT1	0.72	4.72	0.44	8.08e-6	Monocyte count;
THYM	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7071206	0.947	rs10824560	chr10:79416901	C/T	cg07817648	chr10:79422355	NA	-0.96	-7.36	-0.6	6.44e-11	Bone mineral density;
THYM	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg13683864	chr3:40499215	RPL14	-0.88	-8.67	-0.66	1.14e-13	Renal cell carcinoma;
THYM	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg17911788	chr17:44343683	NA	-0.79	-7.48	-0.61	3.65e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs76878669	0.561	rs56321771	chr11:66161072	C/T	cg14263139	chr11:66104018	RIN1	-0.36	-4.46	-0.42	2.29e-5	Educational attainment (years of education);
THYM	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	4.78	0.44	6.35e-6	Menarche (age at onset);
THYM	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg15242686	chr22:24348715	GSTTP1	0.56	5.13	0.47	1.55e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11644478	chr21:40555479	PSMG1	-0.58	-4.75	-0.44	7.3e-6	Menarche (age at onset);
THYM	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg04267008	chr7:1944627	MAD1L1	-0.69	-6.41	-0.55	5.59e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg10856724	chr12:34555212	NA	-1.05	-10.54	-0.73	1.17e-17	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg22841779	chr14:105766346	BRF1	-0.49	-6.22	-0.54	1.35e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg24733560	chr20:60626293	TAF4	0.51	4.5	0.42	1.94e-5	Body mass index;
THYM	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg26038318	chr20:34205095	SPAG4	0.59	4.65	0.43	1.08e-5	Total cholesterol levels;
THYM	cis	rs662064	0.962	rs585870	chr1:10549628	G/T	cg20482658	chr1:10539492	PEX14	-0.48	-5.97	-0.52	4.14e-8	Asthma;
THYM	cis	rs17407555	0.738	rs73212898	chr4:10121994	C/T	cg00071950	chr4:10020882	SLC2A9	-0.74	-5.16	-0.47	1.37e-6	Schizophrenia (age at onset);
THYM	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	5.02	0.46	2.39e-6	Menarche (age at onset);
THYM	cis	rs2806561	0.765	rs1997866	chr1:23512524	A/G	cg19743168	chr1:23544995	NA	0.55	5.59	0.5	2.18e-7	Height;
THYM	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg11764359	chr7:65958608	NA	0.75	5.99	0.52	3.7e-8	Aortic root size;
THYM	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg03806693	chr22:41940476	POLR3H	1.16	10.2	0.72	6.06e-17	Vitiligo;
THYM	trans	rs1974653	0.672	rs9606258	chr22:20119712	A/G	cg08822737	chr17:71088851	SLC39A11	-1.02	-7.07	-0.59	2.56e-10	Schizophrenia;
THYM	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.51	5.32	0.48	6.93e-7	Schizophrenia;
THYM	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2241584	0.748	rs13171278	chr5:175944210	C/T	cg27658698	chr5:175955578	RNF44	-0.51	-5.78	-0.51	9.62e-8	Menopause (age at onset);
THYM	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22496380	chr5:211416	CCDC127	-1.3	-8.28	-0.65	7.84e-13	Breast cancer;
THYM	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg03295274	chr13:50190584	NA	0.69	5.19	0.47	1.18e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs10832963	0.961	rs10832954	chr11:18643559	G/A	cg20219074	chr11:18656078	SPTY2D1	0.81	6.58	0.56	2.52e-9	Breast cancer;
THYM	cis	rs8067545	1.000	rs4925065	chr17:19914546	C/T	cg20830565	chr17:20408647	MGC102966	-0.5	-4.66	-0.43	1.02e-5	Schizophrenia;
THYM	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg24692254	chr21:30365293	RNF160	-0.99	-8.66	-0.66	1.23e-13	Dental caries;
THYM	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg24209194	chr3:40518798	ZNF619	0.63	5.11	0.46	1.65e-6	Renal cell carcinoma;
THYM	cis	rs7610301	1.000	rs4683249	chr3:46643141	A/G	cg01693650	chr3:45883855	LZTFL1	-0.61	-4.47	-0.42	2.17e-5	Blood protein levels;
THYM	cis	rs11587400	0.572	rs2268699	chr1:115227896	G/T	cg12756093	chr1:115239321	AMPD1	0.69	5.25	0.47	9.1e-7	Autism;
THYM	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg04455712	chr21:45112962	RRP1B	0.48	4.58	0.43	1.41e-5	Mean corpuscular volume;
THYM	cis	rs4853012	1.000	rs4853012	chr2:74361290	G/A	cg20891558	chr2:74357851	NA	1.27	11.14	0.75	6.13e-19	Gestational age at birth (maternal effect);
THYM	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg09184832	chr6:79620586	NA	-0.58	-4.6	-0.43	1.28e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7312774	0.748	rs1861746	chr12:107301518	G/A	cg16260113	chr12:107380972	MTERFD3	1.05	5.57	0.5	2.4e-7	Severe influenza A (H1N1) infection;
THYM	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg03522245	chr20:25566470	NINL	0.64	4.56	0.42	1.51e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.27	5.56	0.5	2.45e-7	Obesity-related traits;
THYM	cis	rs8016982	0.674	rs3815953	chr14:81685482	G/A	cg01989461	chr14:81687754	GTF2A1	0.81	7.0	0.58	3.63e-10	Schizophrenia;
THYM	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06481639	chr22:41940642	POLR3H	-0.78	-5.56	-0.5	2.42e-7	Vitiligo;
THYM	cis	rs2932538	0.922	rs6671645	chr1:113129128	A/G	cg22162597	chr1:113214053	CAPZA1	0.63	5.21	0.47	1.08e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg17757837	chr7:157058334	UBE3C	0.66	5.32	0.48	6.85e-7	Body mass index;
THYM	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg00147160	chr1:26503991	CNKSR1	0.53	7.17	0.59	1.65e-10	Height;
THYM	cis	rs300703	0.639	rs397719	chr2:204870	T/G	cg21211680	chr2:198530	NA	1.26	8.21	0.64	1.09e-12	Blood protein levels;
THYM	cis	rs3857067	0.776	rs6858265	chr4:95112565	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17689437	0.813	rs72785118	chr16:68638209	C/T	cg26468152	chr16:69355012	VPS4A	-0.66	-4.63	-0.43	1.14e-5	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
THYM	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg23711669	chr6:146136114	FBXO30	0.88	8.49	0.66	2.8e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8067545	0.750	rs9915758	chr17:19964775	A/G	cg08626831	chr17:20841558	NA	-0.47	-4.46	-0.42	2.25e-5	Schizophrenia;
THYM	cis	rs735539	0.528	rs4770068	chr13:21296214	G/C	cg27499820	chr13:21296301	IL17D	0.67	5.12	0.47	1.58e-6	Dental caries;
THYM	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg16989719	chr2:238392110	NA	0.55	4.75	0.44	7.23e-6	Prostate cancer;
THYM	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg02176678	chr2:219576539	TTLL4	0.72	7.17	0.59	1.63e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4242434	0.819	rs55776566	chr8:22469492	T/C	cg01710189	chr8:22454888	PDLIM2	-0.5	-5.49	-0.49	3.3e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs9611519	1.000	rs4820433	chr22:41607065	C/G	cg06481639	chr22:41940642	POLR3H	-0.64	-4.78	-0.44	6.3e-6	Neuroticism;
THYM	cis	rs7618501	0.521	rs3733134	chr3:49939503	C/T	cg14019146	chr3:50243930	SLC38A3	-0.59	-4.91	-0.45	3.72e-6	Intelligence (multi-trait analysis);
THYM	cis	rs910187	0.572	rs6018325	chr20:45810335	A/G	cg27589058	chr20:45804311	EYA2	-0.59	-5.04	-0.46	2.2e-6	Migraine;
THYM	cis	rs7107174	1.000	rs7941617	chr11:78021146	C/T	cg19901956	chr11:77921274	USP35	-0.66	-5.05	-0.46	2.13e-6	Testicular germ cell tumor;
THYM	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg25358565	chr5:93447407	FAM172A	0.98	7.16	0.59	1.71e-10	Diabetic retinopathy;
THYM	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg22974920	chr21:40686053	BRWD1	0.6	4.63	0.43	1.15e-5	Cognitive function;
THYM	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg24642844	chr7:1081250	C7orf50	-1.24	-7.83	-0.63	7e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11645898	0.872	rs72791121	chr16:72225294	C/T	cg03805757	chr16:71968109	PKD1L3	-0.72	-5.53	-0.49	2.8e-7	Blood protein levels;
THYM	cis	rs58749629	1.000	rs3827066	chr20:44586023	C/T	cg04940435	chr20:44420291	WFDC3;DNTTIP1	-0.58	-5.58	-0.5	2.28e-7	Abdominal aortic aneurysm;
THYM	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg13695892	chr22:41940480	POLR3H	-0.93	-7.08	-0.59	2.5e-10	Vitiligo;
THYM	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg24209194	chr3:40518798	ZNF619	0.62	4.9	0.45	3.88e-6	Renal cell carcinoma;
THYM	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg15693483	chr7:1102177	C7orf50	0.41	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg05368731	chr17:41323189	NBR1	1.2	10.93	0.75	1.72e-18	Menopause (age at onset);
THYM	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg07636037	chr3:49044803	WDR6	0.73	5.06	0.46	2.02e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg13393036	chr8:95962371	TP53INP1	-0.47	-4.9	-0.45	3.95e-6	Type 2 diabetes;
THYM	cis	rs921968	0.643	rs532475	chr2:219434208	C/T	cg02176678	chr2:219576539	TTLL4	0.68	6.71	0.57	1.42e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2456568	0.867	rs2462750	chr11:93668590	C/T	cg26875233	chr11:93583750	C11orf90	-0.5	-4.88	-0.45	4.2e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs4285028	0.948	rs71329246	chr3:121680170	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs9329289	0.510	rs12356215	chr10:2545390	C/G	cg07014206	chr10:2547000	NA	-0.59	-5.15	-0.47	1.44e-6	Age-related hearing impairment;
THYM	cis	rs1451375	0.617	rs1376524	chr7:50563582	G/A	cg18232548	chr7:50535776	DDC	-0.68	-5.19	-0.47	1.21e-6	Malaria;
THYM	cis	rs11997175	0.610	rs7842982	chr8:33731186	T/G	ch.8.33884649F	chr8:33765107	NA	0.69	5.1	0.46	1.7e-6	Body mass index;
THYM	cis	rs977987	0.843	rs10459859	chr16:75381950	T/C	cg03315344	chr16:75512273	CHST6	0.8	6.6	0.56	2.34e-9	Dupuytren's disease;
THYM	cis	rs990171	0.955	rs4070554	chr2:103074493	A/G	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.13	-0.47	1.5e-6	Lymphocyte counts;
THYM	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg11764359	chr7:65958608	NA	0.69	4.78	0.44	6.35e-6	Aortic root size;
THYM	cis	rs11563648	0.517	rs10255062	chr7:127024057	T/C	cg23081781	chr7:127225937	GCC1	-0.34	-4.64	-0.43	1.14e-5	Resting heart rate;
THYM	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg17294928	chr15:75287854	SCAMP5	-0.67	-4.59	-0.43	1.37e-5	Blood trace element (Zn levels);
THYM	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.32	0.54	8.42e-9	Platelet count;
THYM	cis	rs11186	0.556	rs72906313	chr2:189956510	T/C	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg26597838	chr10:835615	NA	1.1	6.33	0.54	8e-9	Eosinophil percentage of granulocytes;
THYM	cis	rs2637266	0.783	rs846634	chr10:78535323	C/A	cg18941641	chr10:78392320	NA	0.69	5.52	0.49	2.99e-7	Pulmonary function;
THYM	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg11764359	chr7:65958608	NA	-0.67	-4.77	-0.44	6.52e-6	Aortic root size;
THYM	cis	rs1372520	0.684	rs2583979	chr4:90750588	A/T	cg01966878	chr4:90757139	SNCA	-0.6	-4.62	-0.43	1.19e-5	Neuroticism;
THYM	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg06634786	chr22:41940651	POLR3H	0.68	4.97	0.45	3.01e-6	Vitiligo;
THYM	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs6665290	0.901	rs3795453	chr1:227205331	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.13	-15.03	-0.84	7.6e-27	Myeloid white cell count;
THYM	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg08916839	chr5:415575	AHRR	0.83	5.37	0.48	5.61e-7	Fat distribution (HIV);
THYM	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.55	-0.42	1.61e-5	Type 2 diabetes;
THYM	cis	rs9399401	0.890	rs3748069	chr6:142767633	A/G	cg04461802	chr6:142623433	GPR126	0.47	4.73	0.44	7.86e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs586688	0.625	rs510576	chr1:201654962	G/T	cg14168733	chr1:201708718	NAV1	-0.6	-5.55	-0.49	2.61e-7	Obesity-related traits;
THYM	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg21433313	chr16:3507492	NAT15	-0.51	-4.61	-0.43	1.24e-5	Body mass index (adult);
THYM	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-5.24	-0.47	9.51e-7	Morning vs. evening chronotype;
THYM	cis	rs9790314	0.875	rs336582	chr3:161082659	C/T	cg04691961	chr3:161091175	C3orf57	-0.65	-5.72	-0.51	1.24e-7	Morning vs. evening chronotype;
THYM	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg09549813	chr16:4587862	C16orf5	0.61	5.92	0.52	5.08e-8	Schizophrenia;
THYM	cis	rs2625529	0.761	rs972029	chr15:72172986	C/T	cg16672083	chr15:72433130	SENP8	-0.65	-4.7	-0.43	8.63e-6	Red blood cell count;
THYM	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg10523679	chr1:76189770	ACADM	0.83	7.78	0.62	8.78e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs4243830	0.522	rs10864614	chr1:6596008	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.11	-7.56	-0.61	2.57e-11	Body mass index;
THYM	cis	rs986417	0.748	rs9989223	chr14:60942525	C/A	cg27398547	chr14:60952738	C14orf39	1.13	6.34	0.55	7.63e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg13393036	chr8:95962371	TP53INP1	-0.48	-4.72	-0.44	8.23e-6	Type 2 diabetes;
THYM	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-5.4	-0.48	4.89e-7	Chronic sinus infection;
THYM	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg06238570	chr21:40685208	BRWD1	-0.69	-5.71	-0.51	1.31e-7	Menarche (age at onset);
THYM	cis	rs7119	0.717	rs7181283	chr15:77814544	G/A	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs10861661	0.569	rs10778514	chr12:107303577	G/A	cg26297688	chr12:107349093	C12orf23	-0.47	-4.52	-0.42	1.77e-5	Triglyceride levels;
THYM	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg24818145	chr4:99064322	C4orf37	0.91	5.46	0.49	3.74e-7	Colonoscopy-negative controls vs population controls;
THYM	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.74	5.66	0.5	1.61e-7	Eosinophil percentage of white cells;
THYM	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg14972814	chr11:95582409	MTMR2	-0.71	-6.61	-0.56	2.19e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs17253792	0.732	rs28380739	chr14:56088402	G/A	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs912057	0.671	rs1294427	chr6:6744546	T/G	cg13809441	chr6:6737631	NA	0.45	5.4	0.48	4.99e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs6728642	0.908	rs10203833	chr2:98017363	G/A	cg26665480	chr2:98280029	ACTR1B	-0.77	-4.96	-0.45	3.14e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.01	-0.52	3.46e-8	Life satisfaction;
THYM	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg20295408	chr7:1910781	MAD1L1	-0.58	-4.46	-0.42	2.21e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs9560113	0.550	rs1163633	chr13:112231561	G/T	cg15979348	chr13:112237479	NA	-0.58	-5.49	-0.49	3.3e-7	Menarche (age at onset);
THYM	cis	rs17125944	0.615	rs1886785	chr14:53312106	A/C	cg00686598	chr14:53173677	PSMC6	-1.06	-5.03	-0.46	2.36e-6	Alzheimer's disease (late onset);
THYM	cis	rs9810089	0.835	rs654237	chr3:136068699	T/C	cg12473912	chr3:136751656	NA	0.58	4.69	0.43	9.32e-6	Gestational age at birth (child effect);
THYM	cis	rs7688540	0.771	rs77078697	chr4:252048	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.67	4.9	0.45	3.93e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs1395	0.744	rs11126932	chr2:27476282	G/A	cg23587288	chr2:27483067	SLC30A3	-0.69	-6.19	-0.54	1.53e-8	Blood metabolite levels;
THYM	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg27534772	chr1:16042836	PLEKHM2	0.56	6.24	0.54	1.23e-8	Systolic blood pressure;
THYM	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg25767906	chr1:53392781	SCP2	-0.64	-6.4	-0.55	5.85e-9	Monocyte count;
THYM	cis	rs10499694	0.868	rs1470749	chr7:50578023	G/T	cg00647317	chr7:50633725	DDC	0.3	4.56	0.42	1.51e-5	Body mass index;
THYM	trans	rs11774066	1.000	rs11774066	chr8:99455311	C/T	cg09678939	chr6:149806081	ZC3H12D	-0.54	-7.13	-0.59	1.97e-10	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs514406	0.893	rs6682024	chr1:53439525	T/C	cg22166914	chr1:53195759	ZYG11B	-0.78	-7.68	-0.62	1.39e-11	Monocyte count;
THYM	cis	rs988913	1.000	rs9382407	chr6:54836638	T/C	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.75e-6	Menarche (age at onset);
THYM	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg17264618	chr3:40429014	ENTPD3	0.52	4.97	0.45	2.94e-6	Renal cell carcinoma;
THYM	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg03806693	chr22:41940476	POLR3H	-0.8	-7.05	-0.59	2.86e-10	Neuroticism;
THYM	cis	rs6840360	0.571	rs62329101	chr4:152512239	G/T	cg17479576	chr4:152424074	FAM160A1	-0.8	-5.65	-0.5	1.68e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg05283184	chr6:79620031	NA	-0.88	-8.41	-0.65	4.12e-13	Intelligence (multi-trait analysis);
THYM	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg02569458	chr12:86230093	RASSF9	0.59	5.05	0.46	2.14e-6	Major depressive disorder;
THYM	cis	rs2456568	0.835	rs7936182	chr11:93665532	T/A	cg26875233	chr11:93583750	C11orf90	-0.5	-4.95	-0.45	3.22e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg11366901	chr6:160182831	ACAT2	1.08	9.62	0.7	1.05e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs686320	1.000	rs679643	chr11:65250590	C/A	cg23743554	chr11:65321226	LTBP3	0.73	4.46	0.42	2.21e-5	Hip circumference adjusted for BMI;
THYM	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg19747945	chr6:42946146	PEX6	-0.35	-5.05	-0.46	2.15e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg18252515	chr7:66147081	NA	0.67	5.24	0.47	9.7e-7	Aortic root size;
THYM	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg10505658	chr17:80084571	CCDC57	0.7	8.07	0.64	2.18e-12	Life satisfaction;
THYM	cis	rs986417	0.901	rs2351172	chr14:61008687	A/G	cg27398547	chr14:60952738	C14orf39	1.0	5.05	0.46	2.14e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg08048268	chr3:133502702	NA	-0.67	-5.76	-0.51	1.05e-7	Iron status biomarkers;
THYM	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs4731207	0.596	rs6466966	chr7:124580327	A/G	cg05285228	chr7:124571219	POT1	0.72	5.51	0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs7572733	0.534	rs700678	chr2:198705820	T/C	cg05783139	chr2:198650985	BOLL	0.62	4.8	0.44	5.79e-6	Dermatomyositis;
THYM	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg14456004	chr13:21872349	NA	-1.25	-10.05	-0.72	1.28e-16	White matter hyperintensity burden;
THYM	cis	rs8067545	0.611	rs2013443	chr17:20023109	G/C	cg13482628	chr17:19912719	NA	0.54	4.49	0.42	2e-5	Schizophrenia;
THYM	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg00852783	chr1:26633632	UBXN11	0.7	5.79	0.51	9e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg18876405	chr7:65276391	NA	0.57	4.73	0.44	7.67e-6	Aortic root size;
THYM	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg06636551	chr8:101224915	SPAG1	-0.67	-6.43	-0.55	5.07e-9	Atrioventricular conduction;
THYM	cis	rs8067545	0.750	rs35003563	chr17:19989218	G/A	cg08626831	chr17:20841558	NA	-0.48	-4.53	-0.42	1.7e-5	Schizophrenia;
THYM	cis	rs11690935	0.921	rs908670	chr2:172690180	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.81	-5.84	-0.51	7.21e-8	Schizophrenia;
THYM	cis	rs7575217	0.682	rs4851401	chr2:101700518	T/C	cg23907051	chr2:101730305	TBC1D8	0.41	5.62	0.5	1.91e-7	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg06092702	chr1:163392909	NA	-0.62	-5.65	-0.5	1.69e-7	Motion sickness;
THYM	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	6.0	0.52	3.62e-8	Obesity-related traits;
THYM	cis	rs35883536	0.626	rs80052576	chr1:101039229	A/G	cg09408571	chr1:101003634	GPR88	-0.51	-5.53	-0.49	2.85e-7	Monocyte count;
THYM	cis	rs9595908	1.000	rs7992980	chr13:33181142	T/C	cg12383807	chr13:33924137	NA	-0.53	-4.68	-0.43	9.69e-6	Body mass index;
THYM	cis	rs7584330	0.554	rs7559057	chr2:238435306	A/T	cg08992911	chr2:238395768	MLPH	0.89	5.81	0.51	8.24e-8	Prostate cancer;
THYM	trans	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg07393940	chr7:158741817	NA	-1.17	-9.2	-0.69	8.31e-15	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg12573674	chr2:1569213	NA	-1.16	-8.07	-0.64	2.18e-12	IgG glycosylation;
THYM	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg11845111	chr2:191398756	TMEM194B	-0.96	-7.18	-0.59	1.53e-10	Diastolic blood pressure;
THYM	cis	rs7131987	0.650	rs6487808	chr12:29463359	C/T	cg09582351	chr12:29534625	ERGIC2	0.6	4.73	0.44	7.89e-6	QT interval;
THYM	cis	rs7100689	0.646	rs9420370	chr10:82073248	C/T	cg01528321	chr10:82214614	TSPAN14	0.82	6.28	0.54	9.91e-9	Post bronchodilator FEV1;
THYM	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg04267008	chr7:1944627	MAD1L1	0.58	5.14	0.47	1.47e-6	Bipolar disorder and schizophrenia;
THYM	trans	rs8002861	0.967	rs9533690	chr13:44480598	T/C	cg17145862	chr1:211918768	LPGAT1	0.99	11.5	0.76	1.07e-19	Leprosy;
THYM	cis	rs11574514	1.000	rs117875362	chr16:67909448	C/T	cg09738193	chr16:67926317	PSKH1	-0.91	-4.66	-0.43	1.01e-5	Crohn's disease;
THYM	cis	rs2154427	1.000	rs2833962	chr21:34174289	A/G	cg21871883	chr21:34145043	C21orf49;C21orf66	1.03	5.09	0.46	1.78e-6	Bilirubin levels;
THYM	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg12310025	chr6:25882481	NA	-0.69	-5.47	-0.49	3.69e-7	Blood metabolite levels;
THYM	cis	rs600806	0.854	rs11142	chr1:109897103	A/G	cg23616212	chr1:109941201	SORT1	-0.51	-4.81	-0.44	5.61e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4746818	1.000	rs7909631	chr10:70918676	C/T	cg11621586	chr10:70884670	VPS26A	1.28	11.12	0.75	6.73e-19	Left atrial antero-posterior diameter;
THYM	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg06784218	chr1:46089804	CCDC17	0.31	4.57	0.42	1.46e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7927771	0.524	rs7933184	chr11:47682402	C/T	cg20307385	chr11:47447363	PSMC3	0.61	4.68	0.43	9.62e-6	Subjective well-being;
THYM	cis	rs4986811	1.000	rs4986811	chr11:32451093	T/G	cg04096767	chr11:32449450	WT1	0.6	4.57	0.42	1.45e-5	Rubella-specific interleukin-6 secretion;
THYM	cis	rs62070183	0.938	rs75782470	chr17:31073641	T/A	cg23177095	chr17:30873196	MYO1D	0.66	5.09	0.46	1.78e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs1003719	0.762	rs3787786	chr21:38463436	T/C	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	4.92	0.45	3.56e-6	Total body bone mineral density;
THYM	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg25237894	chr2:233734115	C2orf82	0.35	5.04	0.46	2.25e-6	Coronary artery disease;
THYM	cis	rs2235649	0.828	rs9936486	chr16:1849888	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.46	-4.95	-0.45	3.2e-6	Blood metabolite levels;
THYM	cis	rs9915657	1.000	rs9910864	chr17:70123028	T/A	cg06234051	chr17:70120541	SOX9	-0.64	-5.57	-0.5	2.4e-7	Thyroid hormone levels;
THYM	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg15448220	chr1:150897856	SETDB1	0.9	7.41	0.61	5.25e-11	Melanoma;
THYM	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg03929089	chr4:120376271	NA	-1.01	-13.68	-0.81	3.47e-24	Height;
THYM	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs889398	0.616	rs35808754	chr16:69771710	G/T	cg09409435	chr16:70099608	PDXDC2	-0.6	-4.52	-0.42	1.77e-5	Body mass index;
THYM	cis	rs4389656	0.625	rs274682	chr5:6748518	A/G	cg10857441	chr5:6722123	POLS	-0.44	-4.5	-0.42	1.95e-5	Coronary artery disease;
THYM	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.68	4.53	0.42	1.7e-5	Lung cancer in ever smokers;
THYM	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs514406	0.858	rs564640	chr1:53285187	T/C	cg25767906	chr1:53392781	SCP2	0.5	4.75	0.44	7.09e-6	Monocyte count;
THYM	cis	rs7617773	0.817	rs34225441	chr3:48308891	T/A	cg02219026	chr3:48282209	ZNF589	-0.65	-4.45	-0.42	2.36e-5	Coronary artery disease;
THYM	cis	rs6575793	0.904	rs7493050	chr14:101037599	A/G	cg13673514	chr14:101035818	BEGAIN	-0.47	-4.51	-0.42	1.86e-5	Menarche (age at onset);
THYM	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs11711311	0.868	rs13091621	chr3:113481977	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.61	-5.45	-0.49	4.02e-7	IgG glycosylation;
THYM	cis	rs4595586	0.545	rs1839402	chr12:39371615	C/T	cg26384229	chr12:38710491	ALG10B	0.71	5.56	0.5	2.42e-7	Morning vs. evening chronotype;
THYM	cis	rs7567389	0.677	rs6757492	chr2:127995332	G/A	cg09760422	chr2:128146352	NA	-0.52	-6.0	-0.52	3.51e-8	Self-rated health;
THYM	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg13390004	chr1:15929781	NA	0.63	4.69	0.43	9.18e-6	Systolic blood pressure;
THYM	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg03213289	chr20:61660250	NA	0.94	9.72	0.71	6.59e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2637266	1.000	rs2395394	chr10:78360679	G/C	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg04398451	chr17:18023971	MYO15A	0.89	7.89	0.63	5.03e-12	Total body bone mineral density;
THYM	cis	rs6430585	0.528	rs3099429	chr2:136655582	T/A	cg23851026	chr2:136556271	LCT	0.7	6.76	0.57	1.13e-9	Corneal structure;
THYM	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg08773314	chr2:239334832	ASB1	0.64	9.75	0.71	5.79e-16	Multiple system atrophy;
THYM	cis	rs28595532	0.920	rs114243409	chr4:119756585	C/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs4886920	0.894	rs11637937	chr15:78119830	G/C	cg10461261	chr15:78109450	NA	-0.5	-4.87	-0.45	4.46e-6	Neuroticism;
THYM	cis	rs7646881	0.951	rs6441222	chr3:158449767	A/G	cg18349298	chr3:158450550	RARRES1	0.52	5.0	0.46	2.57e-6	Tetralogy of Fallot;
THYM	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg07424592	chr7:64974309	NA	0.99	5.15	0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs422249	0.547	rs174535	chr11:61551356	T/C	cg19610905	chr11:61596333	FADS2	-0.56	-4.8	-0.44	6e-6	Trans fatty acid levels;
THYM	cis	rs4849845	0.925	rs10168224	chr2:121011660	C/G	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs2073300	0.609	rs6137927	chr20:23372513	A/G	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs17539620	0.630	rs62432757	chr6:154854650	T/A	cg20019720	chr6:154832845	CNKSR3	0.56	5.42	0.49	4.56e-7	Lipoprotein (a) levels;
THYM	cis	rs36051895	0.659	rs7046511	chr9:5045695	C/T	cg02405213	chr9:5042618	JAK2	-1.04	-10.74	-0.74	4.45e-18	Pediatric autoimmune diseases;
THYM	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg02627403	chr17:73823769	UNC13D	0.45	4.61	0.43	1.24e-5	White matter hyperintensity burden;
THYM	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg06611532	chr13:114900021	NA	0.64	7.17	0.59	1.61e-10	Schizophrenia;
THYM	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg06115741	chr20:33292138	TP53INP2	0.7	4.67	0.43	9.98e-6	Coronary artery disease;
THYM	cis	rs11118844	0.843	rs11118848	chr1:221926826	A/G	cg04222084	chr1:221915650	DUSP10	0.97	5.06	0.46	2.01e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg26384229	chr12:38710491	ALG10B	0.97	7.89	0.63	5.19e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg22166914	chr1:53195759	ZYG11B	-0.68	-6.74	-0.57	1.21e-9	Monocyte count;
THYM	cis	rs12935418	0.672	rs78895138	chr16:81048425	A/G	cg16651780	chr16:81037892	C16orf61	0.89	6.36	0.55	6.93e-9	Mean corpuscular volume;
THYM	cis	rs9443645	0.527	rs9350792	chr6:79587173	A/G	cg05283184	chr6:79620031	NA	-0.6	-4.66	-0.43	1.03e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.45	0.49	3.92e-7	Electroencephalogram traits;
THYM	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg11266682	chr4:10021025	SLC2A9	0.73	11.88	0.77	1.74e-20	Bone mineral density;
THYM	cis	rs289828	0.519	rs289921	chr2:152090592	A/G	cg05960677	chr2:152117363	RBM43	-0.7	-7.16	-0.59	1.66e-10	Blood protein levels;
THYM	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6987853	0.814	rs1947296	chr8:42452999	T/C	cg09913449	chr8:42400586	C8orf40	0.95	9.53	0.7	1.64e-15	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4478037	0.558	rs7614585	chr3:33078170	A/G	cg19404215	chr3:33155277	CRTAP	-0.97	-5.63	-0.5	1.8e-7	Major depressive disorder;
THYM	cis	rs3771570	0.786	rs62186396	chr2:242221219	A/G	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs12216545	0.765	rs10237569	chr7:150249527	C/T	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.82	-4.55	-0.42	1.56e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs259282	0.605	rs55687317	chr19:33109191	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.72	5.96	0.52	4.22e-8	Schizophrenia;
THYM	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg26384229	chr12:38710491	ALG10B	0.97	7.44	0.61	4.48e-11	Bladder cancer;
THYM	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg13319975	chr6:146136371	FBXO30	0.65	5.22	0.47	1.05e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.94	6.37	0.55	6.72e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg06238570	chr21:40685208	BRWD1	-0.96	-8.96	-0.68	2.76e-14	Cognitive function;
THYM	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs4866334	1.000	rs76258230	chr5:18433807	G/C	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs7917772	0.582	rs10786682	chr10:104318322	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.77	-6.71	-0.57	1.38e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg01049482	chr12:133151360	FBRSL1	0.53	4.72	0.44	8.09e-6	Anti-saccade response;
THYM	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg23791538	chr6:167370224	RNASET2	-0.58	-4.54	-0.42	1.67e-5	Crohn's disease;
THYM	cis	rs67981189	0.593	rs2526883	chr14:71369575	T/G	cg15910301	chr14:71632612	NA	-0.53	-4.63	-0.43	1.14e-5	Schizophrenia;
THYM	cis	rs35934224	0.769	rs76916615	chr22:19857896	G/A	cg11182965	chr22:19864308	TXNRD2	-0.79	-4.93	-0.45	3.51e-6	Glaucoma (primary open-angle);
THYM	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg10295955	chr4:187884368	NA	-1.2	-16.44	-0.86	1.58e-29	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs853679	0.599	rs202906	chr6:28011652	C/T	cg23161317	chr6:28129485	ZNF389	-0.93	-4.68	-0.43	9.51e-6	Depression;
THYM	cis	rs7584330	0.868	rs13408361	chr2:238382899	A/G	cg16989719	chr2:238392110	NA	-0.64	-5.91	-0.52	5.22e-8	Prostate cancer;
THYM	cis	rs1065852	0.526	rs56234624	chr22:42388826	A/G	cg09667013	chr22:42394590	WBP2NL	0.54	4.8	0.44	5.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs7089973	0.966	rs12772800	chr10:116630962	A/G	cg23260525	chr10:116636907	FAM160B1	0.6	5.44	0.49	4.09e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg11247378	chr22:39784982	NA	1.05	13.78	0.82	2.21e-24	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs7705502	0.926	rs112299234	chr5:173339531	T/C	cg18693985	chr5:173351052	CPEB4	-0.75	-5.7	-0.5	1.35e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs9393692	0.620	rs9379842	chr6:26289310	C/T	cg00631329	chr6:26305371	NA	0.47	4.79	0.44	6.14e-6	Educational attainment;
THYM	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg08975724	chr8:8085496	FLJ10661	0.65	5.1	0.46	1.71e-6	Mood instability;
THYM	cis	rs3126085	0.877	rs3120672	chr1:152255575	A/G	cg10321714	chr1:152280068	FLG	0.64	4.81	0.44	5.57e-6	Atopic dermatitis;
THYM	cis	rs7586879	0.639	rs13407913	chr2:25097644	A/G	cg15423357	chr2:25149977	NA	0.66	7.01	0.58	3.49e-10	Body mass index;
THYM	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg08449448	chr8:58056501	NA	1.0	4.93	0.45	3.48e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6032067	0.632	rs62208389	chr20:43794783	A/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs7078219	0.743	rs17094148	chr10:101280279	A/G	cg07044859	chr10:101282883	NA	-0.46	-4.94	-0.45	3.34e-6	Dental caries;
THYM	cis	rs6876348	0.516	rs11953704	chr5:128326950	G/A	cg02841155	chr5:128301328	SLC27A6	0.51	5.09	0.46	1.83e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3087591	1.000	rs7214792	chr17:29460673	G/A	cg24425628	chr17:29625626	OMG;NF1	0.64	5.45	0.49	3.96e-7	Hip circumference;
THYM	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg23281280	chr6:28129359	ZNF389	0.61	4.94	0.45	3.3e-6	Depression;
THYM	cis	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg10856724	chr12:34555212	NA	-0.78	-6.99	-0.58	3.83e-10	Morning vs. evening chronotype;
THYM	cis	rs11190604	0.767	rs4919458	chr10:102177728	G/A	cg16342193	chr10:102329863	NA	0.47	4.76	0.44	6.92e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7113850	0.541	rs7107940	chr11:24233228	G/A	ch.11.24196551F	chr11:24239977	NA	0.87	4.66	0.43	1.04e-5	Bone fracture in osteoporosis;
THYM	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg18252515	chr7:66147081	NA	0.63	4.74	0.44	7.37e-6	Aortic root size;
THYM	cis	rs7586879	0.593	rs11689546	chr2:25130451	A/G	cg27107076	chr2:25050844	ADCY3	-0.29	-4.56	-0.42	1.53e-5	Body mass index;
THYM	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg13147721	chr7:65941812	NA	-0.94	-5.74	-0.51	1.13e-7	Diabetic kidney disease;
THYM	cis	rs921968	0.565	rs2272188	chr2:219612282	C/T	cg02176678	chr2:219576539	TTLL4	0.45	4.55	0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg13319975	chr6:146136371	FBXO30	0.66	5.52	0.49	2.98e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6956675	0.915	rs7790432	chr7:62631824	T/C	cg27518014	chr7:62859535	LOC100287834	0.6	4.84	0.44	5.07e-6	Obesity-related traits;
THYM	cis	rs4654899	0.604	rs12031023	chr1:21148839	A/G	cg01072550	chr1:21505969	NA	0.7	6.63	0.56	2e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs2295359	0.892	rs10789224	chr1:67605134	C/T	cg11235152	chr1:67600687	NA	-0.69	-6.09	-0.53	2.43e-8	Psoriasis;
THYM	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.01	0.64	2.83e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.66	8.96	0.68	2.76e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2637266	0.935	rs2579727	chr10:78395497	A/C	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs9814567	0.963	rs9844537	chr3:134238341	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-8.41	-0.65	4e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg09990169	chr2:241835740	C2orf54	-0.37	-6.44	-0.55	4.84e-9	Urinary metabolites;
THYM	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg12863693	chr15:85201151	NMB	0.62	5.57	0.5	2.41e-7	Schizophrenia;
THYM	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg14196790	chr5:131705035	SLC22A5	-0.55	-5.04	-0.46	2.21e-6	Blood metabolite levels;
THYM	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.56	0.42	1.52e-5	Diabetic retinopathy;
THYM	cis	rs3741151	1.000	rs74795285	chr11:73033387	A/G	cg12959048	chr11:73096162	RELT	-0.5	-4.84	-0.44	5.08e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs853679	0.527	rs853683	chr6:28295039	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.65	-4.67	-0.43	9.81e-6	Depression;
THYM	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg02269571	chr22:50332266	NA	-1.16	-6.15	-0.53	1.81e-8	Mean platelet volume;
THYM	cis	rs9790314	1.000	rs336583	chr3:161081981	A/T	cg04691961	chr3:161091175	C3orf57	0.6	5.23	0.47	1.02e-6	Morning vs. evening chronotype;
THYM	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg02696790	chr15:75250997	RPP25	0.5	4.62	0.43	1.22e-5	Breast cancer;
THYM	cis	rs2235649	0.753	rs7200472	chr16:1849669	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg13114125	chr14:105738426	BRF1	-0.7	-5.35	-0.48	5.99e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs34779708	0.897	rs9665538	chr10:35461038	T/C	cg03585969	chr10:35415529	CREM	0.66	4.76	0.44	6.85e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg23711669	chr6:146136114	FBXO30	0.82	7.84	0.63	6.69e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg05362011	chr13:21860987	NA	-0.57	-4.65	-0.43	1.09e-5	White matter hyperintensity burden;
THYM	cis	rs17471911	0.541	rs2796752	chr10:100925624	C/T	cg20566587	chr10:101492029	COX15;CUTC	0.79	4.86	0.45	4.67e-6	Neuroticism;
THYM	cis	rs7940866	0.801	rs10894300	chr11:130845943	A/G	cg12179176	chr11:130786555	SNX19	0.68	5.14	0.47	1.45e-6	Schizophrenia;
THYM	cis	rs936229	0.511	rs12591513	chr15:75102714	G/A	cg14664628	chr15:75095509	CSK	-0.83	-6.53	-0.56	3.29e-9	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg12756686	chr19:29218302	NA	0.95	7.63	0.62	1.82e-11	Methadone dose in opioid dependence;
THYM	cis	rs740474	0.831	rs3828677	chr5:140993623	C/T	cg24137543	chr5:140893634	NA	-0.51	-5.99	-0.52	3.8e-8	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7408868	1.000	rs10418305	chr19:15278808	C/G	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg00256281	chr22:41985642	PMM1	-0.57	-4.76	-0.44	7.03e-6	Vitiligo;
THYM	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs761746	0.960	rs5753686	chr22:31947948	G/A	cg01338084	chr22:32026380	PISD	0.53	4.54	0.42	1.65e-5	Intelligence;
THYM	cis	rs2290159	0.800	rs57884385	chr3:12673551	G/C	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs6032067	0.641	rs35882692	chr20:43763968	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.41	-0.49	4.61e-7	Blood protein levels;
THYM	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg04455712	chr21:45112962	RRP1B	0.51	4.71	0.44	8.41e-6	Mean corpuscular volume;
THYM	cis	rs7590720	0.959	rs2372684	chr2:216884764	C/A	cg25588852	chr2:216877276	MREG	-0.59	-5.03	-0.46	2.34e-6	Alcohol dependence;
THYM	cis	rs9876781	1.000	rs725309	chr3:48418708	A/G	cg06066452	chr3:48470258	PLXNB1	-0.25	-4.77	-0.44	6.73e-6	Longevity;
THYM	cis	rs2456568	0.803	rs10831140	chr11:93640689	G/A	cg26875233	chr11:93583750	C11orf90	-0.54	-5.78	-0.51	9.51e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs3796352	0.881	rs34238610	chr3:53026480	A/T	cg07884673	chr3:53033167	SFMBT1	1.27	6.43	0.55	5.06e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs4631830	0.600	rs11004246	chr10:51495349	T/C	cg16070123	chr10:51489643	NA	0.56	5.24	0.47	9.86e-7	Prostate-specific antigen levels;
THYM	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs4595586	0.545	rs3914595	chr12:39388530	G/T	cg26384229	chr12:38710491	ALG10B	0.69	5.19	0.47	1.18e-6	Morning vs. evening chronotype;
THYM	cis	rs748404	0.631	rs11070399	chr15:43646347	A/G	cg12861797	chr15:43585817	TGM7	0.45	4.77	0.44	6.59e-6	Lung cancer;
THYM	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.57	-0.42	1.48e-5	Bipolar disorder;
THYM	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg06481639	chr22:41940642	POLR3H	-0.83	-6.19	-0.54	1.55e-8	Vitiligo;
THYM	cis	rs9902453	0.967	rs1906450	chr17:28515744	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	4.6	0.43	1.33e-5	Coffee consumption (cups per day);
THYM	cis	rs2637266	0.568	rs9919400	chr10:78214099	C/T	cg18941641	chr10:78392320	NA	0.6	4.54	0.42	1.64e-5	Pulmonary function;
THYM	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg06618935	chr21:46677482	NA	-0.97	-9.15	-0.68	1.06e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg05738196	chr6:26577821	NA	-0.83	-8.41	-0.65	4.17e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg00129232	chr17:37814104	STARD3	-0.77	-5.27	-0.48	8.58e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs74417235	0.673	rs6873342	chr5:154051835	A/G	cg07371521	chr5:154026371	NA	-0.58	-5.56	-0.5	2.51e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs926938	0.520	rs6671984	chr1:115257521	C/T	cg12756093	chr1:115239321	AMPD1	-0.56	-4.55	-0.42	1.59e-5	Autism;
THYM	cis	rs9467160	0.559	rs2753911	chr6:24442288	C/T	cg20631270	chr6:24437470	GPLD1	0.64	5.82	0.51	7.99e-8	Liver enzyme levels;
THYM	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg15556689	chr8:8085844	FLJ10661	0.71	5.97	0.52	4.05e-8	Mood instability;
THYM	cis	rs10911232	0.507	rs4652767	chr1:183002483	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs524281	0.731	rs11227433	chr11:66004693	G/A	cg00563793	chr11:65837595	PACS1	0.79	4.71	0.43	8.53e-6	Electroencephalogram traits;
THYM	cis	rs7523273	0.564	rs1977268	chr1:207881036	A/C	cg22525895	chr1:207977042	MIR29B2	0.51	4.68	0.43	9.62e-6	Schizophrenia;
THYM	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg01819759	chr13:79234251	RNF219	0.8	5.13	0.47	1.55e-6	Large artery stroke;
THYM	cis	rs2302612	0.528	rs3771182	chr2:102844627	T/C	cg13315345	chr2:102803985	IL1RL2	0.67	5.41	0.49	4.62e-7	Serum protein levels (sST2);
THYM	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg10047753	chr17:41438598	NA	1.18	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	trans	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg07393940	chr7:158741817	NA	1.14	9.25	0.69	6.69e-15	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7192750	0.652	rs152828	chr16:72123886	T/C	cg06353428	chr16:71660113	MARVELD3	1.0	4.89	0.45	4.08e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	trans	rs1974653	0.672	rs9606247	chr22:20087473	T/A	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg16342193	chr10:102329863	NA	-0.53	-5.43	-0.49	4.35e-7	Palmitoleic acid (16:1n-7) levels;
THYM	trans	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Bladder cancer;
THYM	cis	rs9611565	0.525	rs1883827	chr22:41703579	A/G	cg03806693	chr22:41940476	POLR3H	-0.85	-7.29	-0.6	9.15e-11	Vitiligo;
THYM	cis	rs6496667	0.509	rs2657948	chr15:90948617	G/A	cg22089800	chr15:90895588	ZNF774	0.7	5.38	0.48	5.35e-7	Rheumatoid arthritis;
THYM	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06873352	chr17:61820015	STRADA	0.78	9.49	0.7	2.06e-15	Prudent dietary pattern;
THYM	cis	rs2806561	0.964	rs683052	chr1:23514953	T/C	cg08872493	chr1:23521417	HTR1D	0.38	4.87	0.45	4.46e-6	Height;
THYM	cis	rs2354432	0.607	rs7545467	chr1:146746248	A/G	cg25205988	chr1:146714368	CHD1L	-1.04	-5.56	-0.5	2.5e-7	Mitochondrial DNA levels;
THYM	cis	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs13082711	0.911	rs66694067	chr3:27477337	C/T	cg02860705	chr3:27208620	NA	0.73	5.25	0.47	9.27e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg09877947	chr5:131593287	PDLIM4	0.69	5.7	0.5	1.35e-7	Acylcarnitine levels;
THYM	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg04317338	chr11:64019027	PLCB3	-0.85	-5.81	-0.51	8.33e-8	Mean platelet volume;
THYM	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24531977	chr5:56204891	C5orf35	-1.02	-8.59	-0.66	1.73e-13	Initial pursuit acceleration;
THYM	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg04731861	chr2:219085781	ARPC2	-0.56	-5.39	-0.48	5.21e-7	Colorectal cancer;
THYM	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg07917127	chr4:99064746	C4orf37	0.59	4.5	0.42	1.93e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08219700	chr8:58056026	NA	0.86	6.26	0.54	1.13e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs55665837	1.000	rs10832268	chr11:14465068	C/A	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs3820068	0.608	rs12734937	chr1:16047726	T/C	cg27534772	chr1:16042836	PLEKHM2	0.51	5.25	0.47	9.14e-7	Systolic blood pressure;
THYM	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg20486651	chr6:167070296	RPS6KA2	0.48	4.74	0.44	7.48e-6	Crohn's disease;
THYM	cis	rs2487048	0.773	rs2472494	chr9:107695539	T/C	cg14019050	chr9:107690770	ABCA1	-0.61	-6.72	-0.57	1.35e-9	Intraocular pressure;
THYM	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg26924012	chr15:45694286	SPATA5L1	1.04	9.2	0.69	8.56e-15	Homoarginine levels;
THYM	cis	rs67460515	0.892	rs7648279	chr3:160979646	G/A	cg03342759	chr3:160939853	NMD3	-0.9	-7.94	-0.63	3.98e-12	Parkinson's disease;
THYM	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02475777	chr4:1388615	CRIPAK	0.73	5.26	0.47	8.88e-7	Longevity;
THYM	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-6.65	-0.56	1.84e-9	Chronic sinus infection;
THYM	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg15691649	chr6:25882328	NA	-0.63	-4.5	-0.42	1.95e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg22875332	chr1:76189707	ACADM	0.72	5.53	0.49	2.79e-7	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs12149862	1.000	rs3942897	chr16:69480552	T/C	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs10791097	0.967	rs1944142	chr11:130717440	C/T	cg12179176	chr11:130786555	SNX19	0.68	5.56	0.5	2.42e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7580658	0.963	rs10803585	chr2:128130108	G/A	cg10021288	chr2:128175891	PROC	-0.83	-7.08	-0.59	2.5e-10	Protein C levels;
THYM	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg04267008	chr7:1944627	MAD1L1	-0.7	-6.55	-0.56	2.95e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.26	-7.78	-0.62	8.68e-12	Gut microbiome composition (summer);
THYM	cis	rs7980799	0.682	rs1601007	chr12:33609675	C/G	cg06521331	chr12:34319734	NA	-0.69	-4.93	-0.45	3.47e-6	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg08645402	chr16:4508243	NA	0.76	7.19	0.59	1.47e-10	Schizophrenia;
THYM	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg02389323	chr16:88786976	FAM38A	-0.94	-5.91	-0.52	5.4e-8	Plateletcrit;
THYM	cis	rs57590327	0.555	rs2053805	chr3:81738414	T/C	cg07356753	chr3:81810745	GBE1	-0.88	-6.79	-0.57	9.52e-10	Extraversion;
THYM	cis	rs4242434	0.854	rs11782130	chr8:22452357	G/T	cg21658235	chr8:22456391	C8orf58	0.51	4.99	0.46	2.71e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2456568	0.803	rs10765642	chr11:93640355	C/T	cg17347335	chr11:93583973	C11orf90	0.48	4.63	0.43	1.18e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg09537434	chr19:41945824	ATP5SL	-1.09	-10.25	-0.72	4.86e-17	Height;
THYM	cis	rs4072705	0.835	rs7855360	chr9:127556704	C/T	cg13476313	chr9:127244764	NR5A1	0.32	4.68	0.43	9.61e-6	Menarche (age at onset);
THYM	cis	rs9674544	0.556	rs1390154	chr17:47071483	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.48	-5.51	-0.49	3.1e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs4891159	0.790	rs17059325	chr18:74119567	A/C	cg24786174	chr18:74118243	ZNF516	-0.85	-9.67	-0.7	8.35e-16	Longevity;
THYM	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-4.48	-0.42	2.05e-5	Aortic root size;
THYM	cis	rs6988636	0.710	rs73339623	chr8:124140288	A/G	cg23067535	chr8:124195133	FAM83A	-0.99	-4.82	-0.44	5.52e-6	Urinary uromodulin levels;
THYM	cis	rs12530845	0.887	rs79100776	chr7:135315817	G/A	cg23117316	chr7:135346802	PL-5283	-0.68	-6.01	-0.53	3.37e-8	Red blood cell traits;
THYM	trans	rs637571	0.584	rs594689	chr11:65635559	G/A	cg17712092	chr4:129076599	LARP1B	-0.94	-8.08	-0.64	2.08e-12	Eosinophil percentage of white cells;
THYM	cis	rs28595532	0.841	rs114107504	chr4:119771080	T/C	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.55	-4.74	-0.44	7.38e-6	Platelet count;
THYM	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg24060327	chr5:131705240	SLC22A5	-0.79	-5.8	-0.51	8.82e-8	Blood metabolite levels;
THYM	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg18252515	chr7:66147081	NA	1.43	8.54	0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs977987	0.654	rs8054194	chr16:75497160	G/T	cg03315344	chr16:75512273	CHST6	0.65	5.09	0.46	1.79e-6	Dupuytren's disease;
THYM	cis	rs4246076	0.804	rs10080344	chr6:6590347	G/A	cg11302401	chr6:6688847	NA	0.43	4.74	0.44	7.62e-6	Urate levels in overweight individuals;
THYM	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs711830	0.643	rs2551802	chr2:177022158	C/G	cg13092806	chr2:177043255	NA	0.68	5.1	0.46	1.76e-6	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs13177918	0.677	rs13160685	chr5:149822331	A/G	cg14059543	chr5:149831962	NA	-0.97	-7.25	-0.6	1.09e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs1371867	0.875	rs1660320	chr8:101337579	A/C	cg06636551	chr8:101224915	SPAG1	-0.64	-6.42	-0.55	5.25e-9	Atrioventricular conduction;
THYM	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.66	5.8	0.51	8.69e-8	Bipolar disorder;
THYM	cis	rs28595532	0.920	rs73842253	chr4:119721856	G/A	cg14228332	chr4:119757509	SEC24D	1.42	5.19	0.47	1.18e-6	Cannabis dependence symptom count;
THYM	cis	rs9527	0.568	rs12772775	chr10:104702999	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-5.01	-0.46	2.51e-6	Arsenic metabolism;
THYM	cis	rs901683	1.000	rs9422439	chr10:46040473	C/T	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs6956675	1.000	rs10280052	chr7:62600311	C/T	cg08930214	chr7:62859557	LOC100287834	0.64	4.69	0.43	9.07e-6	Obesity-related traits;
THYM	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg17264618	chr3:40429014	ENTPD3	0.49	4.66	0.43	1.01e-5	Renal cell carcinoma;
THYM	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg02887458	chr19:19495540	GATAD2A	0.46	5.15	0.47	1.39e-6	Bipolar disorder;
THYM	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg04025307	chr7:1156635	C7orf50	0.78	6.72	0.57	1.32e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11948739	0.610	rs11242053	chr5:130272340	T/C	cg08523029	chr5:130500466	HINT1	0.82	5.85	0.51	6.93e-8	Pediatric bone mineral content (hip);
THYM	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg24812749	chr6:127587940	RNF146	0.9	6.51	0.56	3.48e-9	Breast cancer;
THYM	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg02018176	chr4:1364513	KIAA1530	0.55	4.65	0.43	1.08e-5	Obesity-related traits;
THYM	cis	rs1568889	1.000	rs11603799	chr11:28196488	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.55e-6	Bipolar disorder;
THYM	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.74	7.39	0.6	5.68e-11	Chronic sinus infection;
THYM	cis	rs3126085	0.935	rs4845736	chr1:152175551	G/A	cg10321714	chr1:152280068	FLG	0.65	4.72	0.44	8.02e-6	Atopic dermatitis;
THYM	cis	rs9790314	1.000	rs336543	chr3:161061080	C/T	cg03342759	chr3:160939853	NMD3	0.76	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg24692254	chr21:30365293	RNF160	0.65	4.63	0.43	1.15e-5	Selective IgA deficiency;
THYM	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.39	0.6	5.63e-11	Obesity-related traits;
THYM	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14159672	chr1:205819179	PM20D1	0.95	9.55	0.7	1.52e-15	Menarche (age at onset);
THYM	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs7106204	0.748	rs2403891	chr11:24213130	C/T	ch.11.24196551F	chr11:24239977	NA	0.99	7.0	0.58	3.64e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs2050392	0.858	rs306583	chr10:30710057	C/T	cg02070205	chr10:30722105	MAP3K8	0.55	4.82	0.44	5.36e-6	Inflammatory bowel disease;
THYM	trans	rs10900020	0.764	rs10900023	chr10:44829089	G/T	cg13636096	chr10:2815015	NA	0.78	7.35	0.6	6.92e-11	Schizophrenia;
THYM	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4845570	1.000	rs6683364	chr1:151746202	T/A	cg07092448	chr1:151763213	TDRKH	-1.05	-6.74	-0.57	1.24e-9	Coronary artery disease;
THYM	cis	rs7590720	1.000	rs7592663	chr2:216894978	T/C	cg12620499	chr2:216877984	MREG	0.85	5.82	0.51	7.93e-8	Alcohol dependence;
THYM	cis	rs3126085	0.935	rs3126056	chr1:152266503	G/A	cg10321714	chr1:152280068	FLG	-0.67	-5.14	-0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.76	-0.44	7.03e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs1451375	0.959	rs6962356	chr7:50621941	T/C	cg18232548	chr7:50535776	DDC	0.68	5.16	0.47	1.37e-6	Malaria;
THYM	cis	rs4523957	0.928	rs1122645	chr17:2170858	A/G	cg16513277	chr17:2031491	SMG6	-0.79	-7.45	-0.61	4.21e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2371030	0.900	rs2371031	chr2:211570074	A/C	cg18417063	chr2:211583084	NA	-0.56	-4.9	-0.45	3.97e-6	Non-small cell lung cancer;
THYM	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg17366294	chr4:99064904	C4orf37	-0.52	-5.94	-0.52	4.58e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08704250	chr15:31115839	NA	-0.69	-7.64	-0.62	1.7e-11	Huntington's disease progression;
THYM	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg06917634	chr15:78832804	PSMA4	-0.83	-6.84	-0.57	7.67e-10	Sudden cardiac arrest;
THYM	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg25251562	chr2:3704773	ALLC	-0.81	-5.41	-0.49	4.62e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg12311346	chr5:56204834	C5orf35	-0.77	-5.59	-0.5	2.18e-7	Initial pursuit acceleration;
THYM	cis	rs12410462	1.000	rs75637482	chr1:227622944	A/T	cg04117972	chr1:227635322	NA	0.71	4.8	0.44	5.85e-6	Major depressive disorder;
THYM	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07167872	chr1:205819463	PM20D1	1.08	11.32	0.76	2.57e-19	Menarche (age at onset);
THYM	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg18876405	chr7:65276391	NA	-0.53	-4.54	-0.42	1.68e-5	Aortic root size;
THYM	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11890956	chr21:40555474	PSMG1	1.17	13.11	0.8	4.95e-23	Cognitive function;
THYM	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7264396	0.563	rs6060570	chr20:34291166	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.76	-0.44	6.84e-6	Total cholesterol levels;
THYM	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg16325326	chr1:53192061	ZYG11B	-0.78	-6.01	-0.52	3.4e-8	Monocyte count;
THYM	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg02696790	chr15:75250997	RPP25	0.5	4.47	0.42	2.16e-5	Breast cancer;
THYM	cis	rs2282300	0.739	rs10742237	chr11:30310659	C/T	cg25418670	chr11:30344373	C11orf46	0.82	6.97	0.58	4.25e-10	Morning vs. evening chronotype;
THYM	cis	rs6032067	0.641	rs13038485	chr20:43767759	T/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.73	-7.71	-0.62	1.23e-11	Blood protein levels;
THYM	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg27572855	chr1:25598939	RHD	0.66	5.06	0.46	2.01e-6	Erythrocyte sedimentation rate;
THYM	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22455342	chr2:225449267	CUL3	0.96	8.91	0.67	3.56e-14	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg00898013	chr13:113819073	PROZ	-0.88	-9.0	-0.68	2.24e-14	Platelet distribution width;
THYM	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg08968635	chr6:28129556	ZNF389	0.59	4.57	0.42	1.46e-5	Parkinson's disease;
THYM	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11890956	chr21:40555474	PSMG1	1.1	10.87	0.74	2.33e-18	Cognitive function;
THYM	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg24642844	chr7:1081250	C7orf50	-0.73	-5.07	-0.46	2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs477692	0.692	rs7905095	chr10:131448143	C/T	cg05714579	chr10:131428358	MGMT	-0.83	-6.9	-0.58	5.82e-10	Response to temozolomide;
THYM	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg18681998	chr4:17616180	MED28	0.94	8.64	0.66	1.36e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg03859395	chr2:55845619	SMEK2	0.58	5.06	0.46	2.02e-6	Metabolic syndrome;
THYM	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg23281280	chr6:28129359	ZNF389	0.61	4.88	0.45	4.21e-6	Parkinson's disease;
THYM	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg13866156	chr1:1669148	SLC35E2	-0.72	-7.33	-0.6	7.71e-11	Body mass index;
THYM	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg03060546	chr3:49711283	APEH	-0.67	-5.08	-0.46	1.85e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22496380	chr5:211416	CCDC127	-1.28	-7.77	-0.62	9.06e-12	Breast cancer;
THYM	cis	rs35306767	0.855	rs72778229	chr10:951991	C/A	cg26597838	chr10:835615	NA	1.47	9.73	0.71	6.37e-16	Eosinophil percentage of granulocytes;
THYM	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg19507638	chr5:93509721	C5orf36	-0.67	-4.48	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs4919044	0.740	rs73319304	chr10:94777045	A/G	cg05127821	chr10:94822908	CYP26C1	-1.31	-6.9	-0.58	5.75e-10	Coronary artery disease;
THYM	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg02527881	chr3:46936655	PTH1R	-0.61	-5.7	-0.51	1.33e-7	Colorectal cancer;
THYM	cis	rs921968	0.643	rs3931102	chr2:219520405	C/T	cg02176678	chr2:219576539	TTLL4	0.6	5.84	0.51	7.3e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs28595532	0.920	rs114462478	chr4:119752656	T/C	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg06481639	chr22:41940642	POLR3H	-0.66	-4.76	-0.44	6.94e-6	Vitiligo;
THYM	cis	rs80319144	1.000	rs79260998	chr2:159250501	G/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.58	4.53	0.42	1.72e-5	Restless legs syndrome;
THYM	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	5.19	0.47	1.2e-6	Schizophrenia;
THYM	cis	rs12666612	0.748	rs11769889	chr7:18288690	T/C	cg14499053	chr7:19158954	NA	-0.75	-4.67	-0.43	9.94e-6	Obesity-related traits;
THYM	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg13319975	chr6:146136371	FBXO30	-0.64	-5.22	-0.47	1.03e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4595586	0.545	rs1156707	chr12:39372451	G/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs4731207	0.672	rs7792883	chr7:124448021	A/G	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs13202913	0.639	rs9383892	chr6:151747152	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.86	-4.76	-0.44	7.02e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg25767906	chr1:53392781	SCP2	-0.56	-5.4	-0.48	5.01e-7	Monocyte count;
THYM	cis	rs17127169	1.000	rs61784755	chr1:65412091	A/G	cg12075498	chr1:65428216	JAK1	-0.42	-5.21	-0.47	1.09e-6	Sitting height ratio;
THYM	cis	rs2227564	0.620	rs12783161	chr10:75572201	G/C	cg23231163	chr10:75533350	FUT11	-0.35	-4.58	-0.43	1.4e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg17644776	chr2:200775616	C2orf69	0.77	5.4	0.48	5.01e-7	Schizophrenia;
THYM	cis	rs6918586	0.658	rs198814	chr6:26127759	A/G	cg07061783	chr6:25882402	NA	0.57	4.48	0.42	2.07e-5	Schizophrenia;
THYM	cis	rs2016266	0.684	rs4759021	chr12:53714868	G/A	cg16917193	chr12:54089295	NA	-0.59	-4.53	-0.42	1.69e-5	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg20891283	chr12:69753455	YEATS4	-0.86	-7.53	-0.61	2.97e-11	Blood protein levels;
THYM	cis	rs2075230	0.705	rs1641521	chr17:7550143	T/C	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.63	-0.43	1.16e-5	Hormone measurements;
THYM	cis	rs12579753	0.917	rs12822036	chr12:82183009	C/T	cg21231944	chr12:82153410	PPFIA2	-0.68	-5.12	-0.46	1.6e-6	Resting heart rate;
THYM	cis	rs67460515	0.563	rs11922957	chr3:160828865	A/C	cg03342759	chr3:160939853	NMD3	-0.63	-4.7	-0.43	8.93e-6	Parkinson's disease;
THYM	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg24642844	chr7:1081250	C7orf50	-1.41	-6.33	-0.54	7.93e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg10792982	chr14:105748885	BRF1	0.74	7.65	0.62	1.66e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs427394	0.802	rs274712	chr5:6723950	G/A	cg10857441	chr5:6722123	POLS	-0.72	-8.87	-0.67	4.28e-14	Menopause (age at onset);
THYM	cis	rs804280	0.504	rs2645457	chr8:11614112	T/G	cg23916205	chr8:11614368	GATA4	0.5	4.55	0.42	1.56e-5	Myopia (pathological);
THYM	trans	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg07211511	chr3:129823064	LOC729375	-1.28	-10.3	-0.73	3.76e-17	Blood pressure (smoking interaction);
THYM	cis	rs9361491	0.608	rs9352618	chr6:79442428	C/T	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg20891283	chr12:69753455	YEATS4	0.62	4.51	0.42	1.85e-5	Response to diuretic therapy;
THYM	cis	rs11696845	0.626	rs4810439	chr20:43377870	C/G	cg09357268	chr20:43379437	KCNK15	-0.49	-4.94	-0.45	3.41e-6	Obesity-related traits;
THYM	cis	rs919433	0.680	rs788017	chr2:198265173	T/A	cg00792783	chr2:198669748	PLCL1	0.82	5.67	0.5	1.54e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs10823500	0.777	rs10509321	chr10:71985733	A/G	cg02100629	chr10:71892760	AIFM2	0.37	4.46	0.42	2.27e-5	Blood protein levels;
THYM	cis	rs2219968	1.000	rs2128014	chr8:78963292	T/C	cg00738934	chr8:78996279	NA	0.91	9.75	0.71	5.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg05347473	chr6:146136440	FBXO30	0.57	4.48	0.42	2.04e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2273669	0.510	rs11757590	chr6:109370003	T/C	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg26513180	chr16:89883248	FANCA	0.71	7.25	0.6	1.1e-10	Vitiligo;
THYM	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg09021430	chr5:549028	NA	-0.72	-5.39	-0.48	5.07e-7	Obesity-related traits;
THYM	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg23574427	chr4:122746245	BBS7;CCNA2	-0.57	-5.18	-0.47	1.23e-6	Type 2 diabetes;
THYM	cis	rs10788264	0.569	rs10749454	chr10:124029654	C/T	cg09507567	chr10:124027408	NA	0.48	4.94	0.45	3.37e-6	Total body bone mineral density;
THYM	cis	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg24692254	chr21:30365293	RNF160	-0.79	-4.48	-0.42	2.07e-5	Cognitive test performance;
THYM	cis	rs285406	0.892	rs285404	chr8:87025937	T/C	cg06689659	chr8:87110279	ATP6V0D2	0.64	4.6	0.43	1.31e-5	Adverse response to lamotrigine and phenytoin;
THYM	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.57	-4.8	-0.44	5.9e-6	Blood metabolite levels;
THYM	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs7512552	0.839	rs698919	chr1:150387000	A/G	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg03161606	chr19:29218774	NA	0.87	7.71	0.62	1.23e-11	Methadone dose in opioid dependence;
THYM	cis	rs28595532	0.920	rs114462478	chr4:119752656	T/C	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg17264618	chr3:40429014	ENTPD3	0.54	5.28	0.48	8.24e-7	Renal cell carcinoma;
THYM	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg09703963	chr11:616879	IRF7;MUPCDH	-0.76	-6.46	-0.55	4.36e-9	Systemic lupus erythematosus;
THYM	cis	rs12282928	0.959	rs12790767	chr11:48332171	G/A	cg22827986	chr11:48284249	OR4X1	0.55	5.7	0.5	1.34e-7	Migraine - clinic-based;
THYM	cis	rs7107174	1.000	rs4944195	chr11:78003499	T/C	cg02023728	chr11:77925099	USP35	0.65	5.83	0.51	7.52e-8	Testicular germ cell tumor;
THYM	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs17767294	0.708	rs72851156	chr6:28060086	T/C	cg08851530	chr6:28072375	NA	1.15	4.46	0.42	2.28e-5	Parkinson's disease;
THYM	cis	rs28374715	0.562	rs8036686	chr15:41550333	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.91	-8.05	-0.64	2.37e-12	Ulcerative colitis;
THYM	trans	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg25517755	chr10:38738941	LOC399744	-0.76	-6.92	-0.58	5.26e-10	Corneal astigmatism;
THYM	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg06618935	chr21:46677482	NA	-0.98	-9.58	-0.7	1.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1499972	0.941	rs7631320	chr3:117650116	T/C	cg07612923	chr3:117604196	NA	1.3	5.07	0.46	1.94e-6	Schizophrenia;
THYM	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg15744005	chr10:104629667	AS3MT	-0.83	-7.67	-0.62	1.47e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg03433033	chr1:76189801	ACADM	0.79	11.21	0.75	4.52e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4917300	0.626	rs902821	chr8:143100074	G/A	cg25363559	chr8:143086065	NA	-0.56	-5.12	-0.47	1.59e-6	Amyotrophic lateral sclerosis;
THYM	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg08048268	chr3:133502702	NA	-0.66	-5.59	-0.5	2.15e-7	Iron status biomarkers;
THYM	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.45e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg24910161	chr17:38119198	GSDMA	0.45	4.56	0.42	1.54e-5	Self-reported allergy;
THYM	cis	rs7523273	0.565	rs11118453	chr1:207887996	A/C	cg22525895	chr1:207977042	MIR29B2	0.53	5.05	0.46	2.17e-6	Schizophrenia;
THYM	cis	rs12596162	0.623	rs6540005	chr16:87138889	T/C	cg01691827	chr16:86599189	NA	0.51	4.58	0.43	1.4e-5	Possible neuropathic pain in post total joint replacement surgery for osteoarthritis;
THYM	cis	rs990171	1.000	rs7603250	chr2:103068834	T/A	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.13	-0.47	1.5e-6	Lymphocyte counts;
THYM	cis	rs42648	0.869	rs42614	chr7:89950363	C/G	cg25739043	chr7:89950458	NA	-0.52	-4.46	-0.42	2.23e-5	Homocysteine levels;
THYM	cis	rs4792901	0.918	rs2343133	chr17:41639557	T/A	cg21940313	chr17:41620911	ETV4	-0.48	-5.27	-0.48	8.38e-7	Dupuytren's disease;
THYM	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs6450176	1.000	rs59061738	chr5:53296557	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.81	-6.03	-0.53	3.17e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg16624210	chr5:671434	TPPP	0.74	6.34	0.54	7.87e-9	Obesity-related traits;
THYM	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg02734326	chr4:10020555	SLC2A9	-0.62	-5.04	-0.46	2.21e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1568889	0.838	rs11030229	chr11:28173634	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.37	0.6	6.24e-11	Bipolar disorder;
THYM	cis	rs752010	0.841	rs17363834	chr1:42076607	C/T	cg22486000	chr1:42919398	ZMYND12	-0.45	-5.3	-0.48	7.46e-7	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg21028142	chr17:79581711	NPLOC4	0.51	5.01	0.46	2.47e-6	Eye color traits;
THYM	cis	rs11690935	0.851	rs6731562	chr2:172798262	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.65	-4.93	-0.45	3.43e-6	Schizophrenia;
THYM	cis	rs6032067	0.777	rs17423897	chr20:43780307	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.52	-5.89	-0.52	5.76e-8	Blood protein levels;
THYM	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11890956	chr21:40555474	PSMG1	-0.61	-4.66	-0.43	1.05e-5	Menarche (age at onset);
THYM	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.7	6.96	0.58	4.31e-10	Lymphocyte counts;
THYM	cis	rs860818	1.000	rs858286	chr7:23249463	G/A	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg18131467	chr2:239335373	ASB1	0.84	7.06	0.59	2.71e-10	Multiple system atrophy;
THYM	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg06917634	chr15:78832804	PSMA4	0.94	8.55	0.66	2.02e-13	Sudden cardiac arrest;
THYM	cis	rs6952809	0.532	rs2023969	chr7:2449980	T/C	cg13581527	chr7:1708566	NA	-0.73	-5.14	-0.47	1.46e-6	Multiple sclerosis;
THYM	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg17173187	chr15:85201210	NMB	0.56	5.48	0.49	3.49e-7	Schizophrenia;
THYM	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg13385794	chr1:248469461	NA	0.67	4.61	0.43	1.24e-5	Common traits (Other);
THYM	cis	rs4642101	0.765	rs9870269	chr3:12853450	T/G	cg05775895	chr3:12838266	CAND2	0.82	6.65	0.56	1.88e-9	QRS complex (12-leadsum);
THYM	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	7.64	0.62	1.71e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg07507251	chr3:52567010	NT5DC2	0.42	4.88	0.45	4.27e-6	Electroencephalogram traits;
THYM	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg01831904	chr17:28903510	LRRC37B2	-1.0	-5.11	-0.46	1.65e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6840360	0.550	rs7689266	chr4:152561048	T/C	cg22705602	chr4:152727874	NA	-0.8	-8.47	-0.66	3e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7119	0.651	rs12904533	chr15:77845928	G/A	cg10437265	chr15:77819839	NA	0.71	6.36	0.55	6.91e-9	Type 2 diabetes;
THYM	cis	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs3771570	1.000	rs60604866	chr2:242352257	A/G	cg21155796	chr2:242212141	HDLBP	1.25	6.07	0.53	2.57e-8	Prostate cancer;
THYM	cis	rs11711311	1.000	rs2566968	chr3:113474154	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.61	-5.44	-0.49	4.15e-7	IgG glycosylation;
THYM	cis	rs17407555	0.821	rs4533775	chr4:10141404	G/C	cg11266682	chr4:10021025	SLC2A9	-0.6	-5.79	-0.51	8.88e-8	Schizophrenia (age at onset);
THYM	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg14507445	chr22:49886340	NA	-0.51	-4.56	-0.42	1.52e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22455342	chr2:225449267	CUL3	0.97	9.01	0.68	2.14e-14	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg01448562	chr3:133502909	NA	-0.82	-6.85	-0.58	7.13e-10	Iron status biomarkers;
THYM	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg09359103	chr1:154839909	KCNN3	-0.84	-12.13	-0.78	5.18e-21	Prostate cancer;
THYM	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg11752832	chr7:134001865	SLC35B4	0.72	4.92	0.45	3.57e-6	Mean platelet volume;
THYM	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg17372223	chr3:52568218	NT5DC2	0.37	5.66	0.5	1.62e-7	Electroencephalogram traits;
THYM	cis	rs11608355	0.960	rs3742021	chr12:109883117	T/C	cg10504392	chr12:110044639	NA	0.64	5.99	0.52	3.78e-8	Neuroticism;
THYM	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg17105886	chr17:28927953	LRRC37B2	1.29	6.49	0.55	3.84e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg12386194	chr3:101231763	SENP7	0.66	5.0	0.46	2.59e-6	Colorectal cancer;
THYM	cis	rs4430311	0.723	rs897959	chr1:243897774	C/T	cg25706552	chr1:244017396	NA	-0.59	-5.09	-0.46	1.84e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs8017423	0.967	rs55667096	chr14:90714798	C/T	cg04239629	chr14:90701769	NA	-0.63	-4.59	-0.43	1.36e-5	Mortality in heart failure;
THYM	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg19770292	chr5:1868693	NA	0.54	5.0	0.46	2.6e-6	Cardiovascular disease risk factors;
THYM	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg07167872	chr1:205819463	PM20D1	-0.6	-4.69	-0.43	9.12e-6	Prostate-specific antigen levels;
THYM	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg12016809	chr21:47604291	C21orf56	-0.67	-4.98	-0.46	2.78e-6	Testicular germ cell tumor;
THYM	trans	rs9929218	0.581	rs7203337	chr16:68774800	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.95	10.41	0.73	2.25e-17	Colorectal cancer;
THYM	cis	rs9658691	0.920	rs55803311	chr10:90753135	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.94	-5.13	-0.47	1.53e-6	Mosquito bite size;
THYM	cis	rs67311347	0.635	rs62261855	chr3:40294938	C/T	cg17264618	chr3:40429014	ENTPD3	0.48	4.73	0.44	7.65e-6	Renal cell carcinoma;
THYM	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21659725	chr3:3221576	CRBN	0.89	9.76	0.71	5.32e-16	Intelligence (multi-trait analysis);
THYM	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg12560992	chr17:57184187	TRIM37	0.93	8.61	0.66	1.5700000000000001e-13	Intelligence (multi-trait analysis);
THYM	cis	rs16917546	1.000	rs10995251	chr10:64398466	C/T	cg03961010	chr10:64397487	ZNF365	-0.84	-6.72	-0.57	1.34e-9	Basal cell carcinoma;
THYM	cis	rs1401999	0.899	rs2313211	chr3:183738626	T/A	cg20387954	chr3:183756860	HTR3D	0.56	4.63	0.43	1.14e-5	Anterior chamber depth;
THYM	trans	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg10856724	chr12:34555212	NA	-0.94	-8.13	-0.64	1.61e-12	Bladder cancer;
THYM	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg06558623	chr16:89946397	TCF25	1.48	7.81	0.63	7.43e-12	Skin colour saturation;
THYM	trans	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg26384229	chr12:38710491	ALG10B	-0.9	-6.86	-0.58	6.88e-10	Morning vs. evening chronotype;
THYM	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg04944784	chr2:26401820	FAM59B	1.09	8.65	0.66	1.25e-13	Gut microbiome composition (summer);
THYM	cis	rs7107174	0.892	rs2510031	chr11:77969956	T/C	cg02023728	chr11:77925099	USP35	0.7	6.44	0.55	4.94e-9	Testicular germ cell tumor;
THYM	cis	rs7843479	0.965	rs11135742	chr8:21802910	A/T	cg17168535	chr8:21777572	XPO7	0.72	5.25	0.47	9.39e-7	Mean corpuscular volume;
THYM	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.06	-5.25	-0.47	9.31e-7	Body mass index;
THYM	cis	rs367615	0.918	rs17161889	chr5:108855251	A/G	cg17395555	chr5:108820864	NA	-0.53	-4.8	-0.44	5.95e-6	Colorectal cancer (SNP x SNP interaction);
THYM	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg25566285	chr7:158114605	PTPRN2	0.89	11.52	0.76	9.93e-20	Calcium levels;
THYM	cis	rs11671005	0.735	rs3764529	chr19:58945089	A/G	cg18639983	chr19:58920768	ZNF584	0.59	4.82	0.44	5.48e-6	Mean platelet volume;
THYM	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg26384229	chr12:38710491	ALG10B	0.97	7.47	0.61	3.8e-11	Bladder cancer;
THYM	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg00012203	chr2:219082015	ARPC2	-0.65	-5.32	-0.48	6.78e-7	Colorectal cancer;
THYM	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11644478	chr21:40555479	PSMG1	-0.83	-7.37	-0.6	6.12e-11	Cognitive function;
THYM	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg19016782	chr12:123741754	C12orf65	-0.7	-4.59	-0.43	1.35e-5	Neutrophil percentage of white cells;
THYM	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg14349672	chr11:133703707	NA	-0.54	-4.83	-0.44	5.3e-6	Childhood ear infection;
THYM	cis	rs4242434	0.927	rs2272718	chr8:22457388	G/A	cg14690197	chr8:22456421	C8orf58	0.58	5.23	0.47	9.94e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs36051895	0.589	rs16922786	chr9:5200714	A/G	cg02405213	chr9:5042618	JAK2	-0.91	-8.86	-0.67	4.41e-14	Pediatric autoimmune diseases;
THYM	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg13395646	chr4:1353034	KIAA1530	-0.59	-5.8	-0.51	8.57e-8	Obesity-related traits;
THYM	cis	rs7649443	0.959	rs34121928	chr3:197002869	T/C	cg20744464	chr3:196756875	MFI2	0.62	4.56	0.42	1.53e-5	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	8.7	0.67	9.84e-14	Chronic sinus infection;
THYM	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg15962314	chr1:44399869	ARTN	0.54	5.78	0.51	9.62e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2276314	0.857	rs62101393	chr18:33592168	T/C	cg05985134	chr18:33552581	C18orf21	0.66	4.84	0.44	5.02e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs897984	0.520	rs4889536	chr16:30871755	G/T	cg05768032	chr16:30646687	NA	-0.47	-4.61	-0.43	1.28e-5	Dementia with Lewy bodies;
THYM	cis	rs7177699	0.557	rs4073322	chr15:79122541	G/C	cg15571903	chr15:79123663	NA	0.59	6.85	0.58	7.22e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.66	-0.5	1.62e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7192750	0.586	rs28697038	chr16:71952354	G/C	cg06353428	chr16:71660113	MARVELD3	0.76	5.6	0.5	2.04e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs7119	0.717	rs12916682	chr15:77807937	A/T	cg10437265	chr15:77819839	NA	0.76	7.61	0.62	1.98e-11	Type 2 diabetes;
THYM	cis	rs7106204	0.534	rs76474760	chr11:24292598	T/A	ch.11.24196551F	chr11:24239977	NA	0.92	4.82	0.44	5.4e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7213347	1.000	rs7213347	chr17:2153257	G/C	cg16513277	chr17:2031491	SMG6	-0.6	-4.49	-0.42	1.99e-5	Total body bone mineral density;
THYM	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg00376283	chr12:123451042	ABCB9	0.69	4.65	0.43	1.09e-5	Neutrophil percentage of white cells;
THYM	cis	rs7177699	0.581	rs7181432	chr15:79123779	C/T	cg15571903	chr15:79123663	NA	0.58	6.56	0.56	2.77e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg04455712	chr21:45112962	RRP1B	0.54	5.04	0.46	2.22e-6	Mean corpuscular volume;
THYM	cis	rs10992471	0.603	rs10761155	chr9:95153729	C/G	cg14631576	chr9:95140430	CENPP	-1.02	-10.76	-0.74	4.07e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7809950	1.000	rs3801944	chr7:107255548	T/C	cg23024343	chr7:107201750	COG5	0.89	7.51	0.61	3.13e-11	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-5.56	-0.5	2.43e-7	Insulin-like growth factors;
THYM	cis	rs6586111	0.765	rs11186273	chr10:82371312	C/T	cg03086067	chr10:82368399	SH2D4B	-0.59	-7.85	-0.63	6.21e-12	Capecitabine sensitivity;
THYM	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg13395646	chr4:1353034	KIAA1530	-0.67	-6.14	-0.53	1.92e-8	Obesity-related traits;
THYM	cis	rs17741873	0.779	rs12572101	chr10:75600651	A/G	cg18802414	chr10:75757814	VCL	0.88	4.5	0.42	1.93e-5	Paclitaxel disposition in epithelial ovarian cancer;
THYM	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg04772025	chr11:68637568	NA	0.61	6.23	0.54	1.26e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs870825	0.616	rs28618216	chr4:185648998	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs7246967	0.673	rs34342502	chr19:22881428	C/A	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg06481639	chr22:41940642	POLR3H	-0.83	-6.13	-0.53	2e-8	Vitiligo;
THYM	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-5.83	-0.51	7.7e-8	Total cholesterol levels;
THYM	cis	rs17401966	0.931	rs12753426	chr1:10372110	T/C	cg19773385	chr1:10388646	KIF1B	-0.57	-4.49	-0.42	2.04e-5	Hepatocellular carcinoma;
THYM	cis	rs2279817	1.000	rs10888048	chr1:18019742	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.77	4.85	0.45	4.86e-6	Neuroticism;
THYM	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs861020	0.606	rs4844903	chr1:210006267	C/T	cg05527609	chr1:210001259	C1orf107	0.85	6.82	0.57	8.53e-10	Orofacial clefts;
THYM	cis	rs61931739	0.817	rs10772143	chr12:34230651	T/G	cg10856724	chr12:34555212	NA	-0.62	-5.55	-0.49	2.62e-7	Morning vs. evening chronotype;
THYM	cis	rs66887589	0.720	rs2036858	chr4:120249237	A/C	cg13609457	chr4:120235615	NA	0.52	5.23	0.47	1.02e-6	Diastolic blood pressure;
THYM	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg08999081	chr20:33150536	PIGU	-0.56	-4.92	-0.45	3.59e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs36051895	0.559	rs7874495	chr9:5209804	A/G	cg02405213	chr9:5042618	JAK2	-0.91	-9.49	-0.7	2.02e-15	Pediatric autoimmune diseases;
THYM	cis	rs1981331	1.000	rs79694455	chr21:47983979	C/T	cg17243659	chr21:48055224	PRMT2	1.0	4.66	0.43	1.01e-5	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	5.93	0.52	4.96e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6032067	0.516	rs1883829	chr20:43891253	G/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.39	-4.67	-0.43	1e-5	Blood protein levels;
THYM	cis	rs2495707	0.532	rs2495709	chr10:102416833	C/T	cg03943218	chr10:102419600	NA	-0.6	-6.03	-0.53	3.11e-8	Body mass index;
THYM	cis	rs28595532	0.920	rs116105567	chr4:119746204	C/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg07235805	chr18:78004237	PARD6G	-0.44	-5.01	-0.46	2.53e-6	Opioid sensitivity;
THYM	cis	rs6047844	0.569	rs6113543	chr20:22129323	A/G	cg16502866	chr20:23015624	SSTR4	-0.59	-4.78	-0.44	6.44e-6	Male-pattern baldness;
THYM	cis	rs3741151	0.686	rs7118982	chr11:73110668	T/C	cg17517138	chr11:73019481	ARHGEF17	0.79	4.86	0.45	4.54e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg26384229	chr12:38710491	ALG10B	0.73	5.4	0.48	5.01e-7	Morning vs. evening chronotype;
THYM	cis	rs7584330	0.740	rs11896232	chr2:238438124	T/C	cg14458575	chr2:238380390	NA	0.65	5.13	0.47	1.51e-6	Prostate cancer;
THYM	cis	rs6089829	0.888	rs4809467	chr20:61671688	A/G	cg08045932	chr20:61659980	NA	0.94	10.38	0.73	2.54e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6918586	0.658	rs198837	chr6:26113398	A/T	cg03517284	chr6:25882590	NA	-0.66	-5.1	-0.46	1.72e-6	Schizophrenia;
THYM	cis	rs6087990	0.806	rs910085	chr20:31383353	T/G	cg13636640	chr20:31349939	DNMT3B	0.94	10.59	0.74	8.98e-18	Ulcerative colitis;
THYM	cis	rs6500395	0.963	rs2883642	chr16:48685146	C/T	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs10791097	0.967	rs6590512	chr11:130717916	A/G	cg22079354	chr11:130786696	SNX19	-0.52	-4.74	-0.44	7.45e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs78366141	0.536	rs76432068	chr4:89624219	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	1.39	5.71	0.51	1.3e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs8114671	0.967	rs6088753	chr20:33768252	C/T	cg08999081	chr20:33150536	PIGU	0.52	4.67	0.43	9.71e-6	Height;
THYM	cis	rs7264396	0.790	rs10211771	chr20:34219994	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-5.8	-0.51	8.72e-8	Total cholesterol levels;
THYM	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.71	-4.7	-0.43	8.64e-6	Body mass index;
THYM	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg17105886	chr17:28927953	LRRC37B2	1.26	6.27	0.54	1.05e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6812193	0.518	rs10025494	chr4:77189380	C/T	cg20311846	chr4:77356250	SHROOM3	-0.53	-4.66	-0.43	1.02e-5	Parkinson's disease;
THYM	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg10852096	chr15:79043040	NA	-0.63	-4.84	-0.44	4.99e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg08885076	chr2:99613938	TSGA10	0.58	5.76	0.51	1.02e-7	Chronic sinus infection;
THYM	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg26418147	chr1:205743515	RAB7L1	-0.52	-4.51	-0.42	1.88e-5	Menarche (age at onset);
THYM	cis	rs6466832	0.506	rs73220288	chr7:122344407	T/G	cg22586324	chr7:123296098	LMOD2	-0.93	-5.05	-0.46	2.12e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs8067545	0.750	rs9915758	chr17:19964775	A/G	cg13482628	chr17:19912719	NA	0.58	4.9	0.45	3.87e-6	Schizophrenia;
THYM	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg00129232	chr17:37814104	STARD3	0.7	4.93	0.45	3.42e-6	Glomerular filtration rate (creatinine);
THYM	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg04282206	chr17:62833786	PLEKHM1P	-0.83	-8.06	-0.64	2.23e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs7107174	1.000	rs729354	chr11:77962453	T/A	cg19901956	chr11:77921274	USP35	-0.74	-5.74	-0.51	1.14e-7	Testicular germ cell tumor;
THYM	cis	rs924712	0.844	rs10456176	chr6:54730180	T/C	cg19716238	chr6:54711378	FAM83B	-0.46	-4.66	-0.43	1.05e-5	Breast cancer;
THYM	cis	rs17608059	0.545	rs736261	chr17:13936404	A/G	cg11395062	chr17:14139857	CDRT15	0.67	5.34	0.48	6.34e-7	Temperament;
THYM	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg06221963	chr1:154839813	KCNN3	0.73	8.91	0.67	3.56e-14	Prostate cancer;
THYM	cis	rs735539	0.521	rs2818996	chr13:21428271	A/T	cg02792322	chr13:21280448	IL17D	-0.65	-4.68	-0.43	9.45e-6	Dental caries;
THYM	cis	rs10089	1.000	rs10057122	chr5:127512063	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	5.51	0.49	3.01e-7	Ileal carcinoids;
THYM	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg04842962	chr6:43655489	MRPS18A	1.41	15.7	0.85	3.85e-28	IgG glycosylation;
THYM	cis	rs12142240	0.698	rs41293273	chr1:46806393	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs288326	0.561	rs79908577	chr2:183712172	T/G	cg09997497	chr2:183902928	NCKAP1	1.09	5.06	0.46	2.03e-6	Blood protein levels;
THYM	cis	rs17407555	0.738	rs3806817	chr4:10118914	C/T	cg14348967	chr4:10160060	NA	0.56	4.48	0.42	2.09e-5	Schizophrenia (age at onset);
THYM	cis	rs750460	1.000	rs11631579	chr15:74235704	A/G	cg01349856	chr15:74220517	LOXL1	-0.62	-4.56	-0.42	1.51e-5	Height;
THYM	cis	rs4654899	0.931	rs10799669	chr1:21172501	T/C	cg01072550	chr1:21505969	NA	0.69	6.31	0.54	8.96e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs4642101	0.737	rs9877165	chr3:12828497	C/T	cg05775895	chr3:12838266	CAND2	0.74	6.46	0.55	4.42e-9	QRS complex (12-leadsum);
THYM	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.45	0.73	1.84e-17	Prudent dietary pattern;
THYM	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg17689763	chr4:710664	PCGF3	-1.08	-9.75	-0.71	5.54e-16	White blood cell count;
THYM	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg20503657	chr10:835505	NA	1.11	7.14	0.59	1.88e-10	Eosinophil percentage of granulocytes;
THYM	cis	rs4792901	0.808	rs10853083	chr17:41636340	C/T	cg21940313	chr17:41620911	ETV4	-0.49	-5.25	-0.47	9.38e-7	Dupuytren's disease;
THYM	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	6.97	0.58	4.15e-10	Smoking behavior;
THYM	cis	rs877282	0.898	rs12358966	chr10:758703	A/G	cg10556349	chr10:835070	NA	-0.79	-5.32	-0.48	6.88e-7	Uric acid levels;
THYM	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg18681998	chr4:17616180	MED28	0.79	6.79	0.57	9.51e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg24818145	chr4:99064322	C4orf37	0.69	5.41	0.49	4.61e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg05973401	chr12:123451056	ABCB9	0.69	4.59	0.43	1.36e-5	Neutrophil percentage of white cells;
THYM	cis	rs2033711	0.503	rs6510141	chr19:58885786	C/G	cg08504662	chr19:58868256	ZNF497	0.52	4.9	0.45	3.93e-6	Uric acid clearance;
THYM	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs7084402	0.967	rs1626532	chr10:60294685	A/T	cg09696939	chr10:60272079	BICC1	-0.49	-5.78	-0.51	9.6e-8	Refractive error;
THYM	cis	rs2412459	0.635	rs8036388	chr15:40263373	T/C	cg16127683	chr15:40268777	EIF2AK4	0.59	5.16	0.47	1.37e-6	Response to haloperidol in psychosis;
THYM	cis	rs3741151	0.773	rs79994237	chr11:73147974	T/C	cg12959048	chr11:73096162	RELT	-0.53	-5.08	-0.46	1.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg09826364	chr7:158789723	NA	-0.52	-4.59	-0.43	1.36e-5	Facial morphology (factor 20);
THYM	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg13010199	chr12:38710504	ALG10B	0.6	4.52	0.42	1.8e-5	Bladder cancer;
THYM	cis	rs7731657	0.537	rs2189508	chr5:130304209	A/C	cg08523029	chr5:130500466	HINT1	-0.81	-5.69	-0.5	1.42e-7	Fasting plasma glucose;
THYM	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	4.53	0.42	1.68e-5	Mood instability;
THYM	cis	rs7043114	0.525	rs1053446	chr9:95146761	T/A	cg14631576	chr9:95140430	CENPP	-0.86	-9.03	-0.68	1.97e-14	Height;
THYM	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg10523679	chr1:76189770	ACADM	-0.84	-6.64	-0.56	1.96e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg11301795	chr4:187892539	NA	1.12	18.03	0.88	2e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11645898	0.630	rs72791135	chr16:72259718	G/C	cg03805757	chr16:71968109	PKD1L3	-0.67	-4.56	-0.42	1.54e-5	Blood protein levels;
THYM	cis	rs7246657	0.943	rs8109038	chr19:38015709	A/G	cg22634378	chr19:37742834	NA	-0.66	-5.5	-0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.27	9.78	0.71	4.84e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg02187348	chr16:89574699	SPG7	0.75	5.18	0.47	1.25e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg11663144	chr21:46675770	NA	0.72	10.04	0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs259964	0.904	rs259960	chr20:57826162	A/G	cg09005679	chr20:57875326	EDN3	-0.42	-5.08	-0.46	1.9e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg16926213	chr1:1841314	NA	0.54	5.64	0.5	1.71e-7	Body mass index;
THYM	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.78	4.59	0.43	1.36e-5	Lung function (FEV1/FVC);
THYM	cis	rs4285028	0.731	rs2332035	chr3:121715432	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.63	-4.56	-0.42	1.55e-5	Multiple sclerosis;
THYM	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg23711669	chr6:146136114	FBXO30	0.93	9.51	0.7	1.83e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs951366	0.531	rs12030754	chr1:205678043	G/C	cg07157834	chr1:205819609	PM20D1	-0.6	-4.54	-0.42	1.67e-5	Menarche (age at onset);
THYM	cis	rs7610301	1.000	rs6787465	chr3:46645609	C/T	cg22951056	chr3:46887651	NA	-0.79	-5.11	-0.46	1.65e-6	Blood protein levels;
THYM	cis	rs828999	0.715	rs1020174	chr1:108696760	A/T	cg24323958	chr1:108741884	SLC25A24	0.54	5.32	0.48	6.79e-7	Monocyte percentage of white cells;
THYM	trans	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg07393940	chr7:158741817	NA	-1.13	-9.17	-0.69	9.99e-15	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs3849570	0.925	rs6798680	chr3:81905441	C/A	cg07356753	chr3:81810745	GBE1	-0.8	-5.94	-0.52	4.58e-8	Waist circumference;Body mass index;
THYM	cis	rs9653442	0.547	rs1062143	chr2:100659796	A/G	cg22139774	chr2:100720529	AFF3	-0.35	-5.17	-0.47	1.31e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs4974559	0.585	rs1680025	chr4:1265477	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.4	4.58	0.42	1.43e-5	Systolic blood pressure;
THYM	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg21775007	chr8:11205619	TDH	-0.73	-5.66	-0.5	1.63e-7	Retinal vascular caliber;
THYM	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.6	-0.5	2.08e-7	Type 2 diabetes;
THYM	cis	rs4790333	0.692	rs2003969	chr17:2266709	T/C	cg02569219	chr17:2266849	SGSM2	0.72	6.07	0.53	2.57e-8	Proinsulin levels;
THYM	cis	rs10779751	0.770	rs6674994	chr1:11239515	T/C	cg08854313	chr1:11322531	MTOR	0.83	7.47	0.61	3.81e-11	Body mass index;
THYM	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg23711669	chr6:146136114	FBXO30	0.93	9.12	0.68	1.26e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4363385	0.747	rs1413849	chr1:152970233	C/A	cg13444842	chr1:152974279	SPRR3	-0.64	-5.0	-0.46	2.65e-6	Inflammatory skin disease;
THYM	cis	rs10929159	0.928	rs34769167	chr2:236920442	A/G	cg20128773	chr2:236923534	AGAP1	0.35	4.62	0.43	1.23e-5	Parkinson's disease;
THYM	cis	rs34779708	0.966	rs4934736	chr10:35496868	G/A	cg03585969	chr10:35415529	CREM	0.63	4.48	0.42	2.09e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs600806	0.854	rs10745353	chr1:109877506	A/G	cg02175308	chr1:109941060	SORT1	-0.59	-5.22	-0.47	1.04e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9902453	0.904	rs12939344	chr17:28328819	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.57	-0.56	2.63e-9	Coffee consumption (cups per day);
THYM	cis	rs12579753	0.827	rs7311917	chr12:82187551	G/T	cg21231944	chr12:82153410	PPFIA2	-0.68	-5.12	-0.46	1.6e-6	Resting heart rate;
THYM	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg09877947	chr5:131593287	PDLIM4	0.6	5.1	0.46	1.71e-6	Breast cancer;
THYM	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg08296037	chr16:1584118	IFT140;TMEM204	-0.61	-5.18	-0.47	1.24e-6	Coronary artery disease;
THYM	cis	rs1933112	1.000	rs1024176	chr1:168526103	C/T	cg17186328	chr1:168545835	XCL1	-0.54	-4.55	-0.42	1.58e-5	Blood protein levels;
THYM	cis	rs9394152	0.845	rs9366823	chr6:33471059	C/T	cg13560919	chr6:33536144	NA	0.73	6.26	0.54	1.09e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs4950928	0.774	rs4950931	chr1:203164075	G/A	cg17014757	chr1:203156097	CHI3L1	-1.11	-6.68	-0.57	1.6e-9	YKL-40 levels;
THYM	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg00852783	chr1:26633632	UBXN11	0.86	8.94	0.68	3.08e-14	Obesity-related traits;
THYM	cis	rs11585357	0.895	rs72633806	chr1:17617943	A/G	cg08277548	chr1:17600880	PADI3	-0.9	-5.43	-0.49	4.38e-7	Hair shape;
THYM	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg00825309	chr19:58991885	ZNF446	-0.58	-4.55	-0.42	1.58e-5	Uric acid clearance;
THYM	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	13.59	0.81	5.3e-24	Chronic sinus infection;
THYM	cis	rs6500602	0.964	rs62039173	chr16:4463846	G/A	cg08645402	chr16:4508243	NA	0.63	5.37	0.48	5.65e-7	Schizophrenia;
THYM	cis	rs34368983	0.681	rs11013251	chr10:23308256	G/A	cg17782713	chr10:22613360	BMI1	0.96	4.71	0.44	8.42e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg04990556	chr1:26633338	UBXN11	-0.89	-8.53	-0.66	2.26e-13	Obesity-related traits;
THYM	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg06009448	chr7:1102226	C7orf50	0.51	5.35	0.48	5.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg03281154	chr5:1086625	SLC12A7	-0.64	-5.27	-0.48	8.43e-7	Cystic fibrosis severity;
THYM	cis	rs10484885	0.775	rs72919985	chr6:90534641	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.87	-7.73	-0.62	1.13e-11	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs3126085	0.935	rs11204937	chr1:152193851	C/T	cg10321714	chr1:152280068	FLG	0.69	5.04	0.46	2.22e-6	Atopic dermatitis;
THYM	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.19	-0.64	1.21e-12	Mean corpuscular volume;
THYM	trans	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.96	-8.77	-0.67	6.99e-14	Brugada syndrome;
THYM	cis	rs17401966	1.000	rs12136376	chr1:10296452	C/T	cg20482658	chr1:10539492	PEX14	0.37	4.5	0.42	1.91e-5	Hepatocellular carcinoma;
THYM	cis	rs3126085	0.935	rs10888473	chr1:152220235	G/A	cg10321714	chr1:152280068	FLG	0.65	4.72	0.44	8.02e-6	Atopic dermatitis;
THYM	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.42	-0.49	4.57e-7	Bipolar disorder;
THYM	cis	rs17006441	1.000	rs13097379	chr3:69842428	A/G	cg18496212	chr3:69797108	MITF	0.67	6.78	0.57	9.94e-10	Hemoglobin concentration;
THYM	cis	rs7084402	0.967	rs1658457	chr10:60302716	T/C	cg07615347	chr10:60278583	BICC1	0.57	5.36	0.48	5.86e-7	Refractive error;
THYM	trans	rs4970966	1.000	rs4970966	chr1:150584103	A/C	cg24465943	chr1:161185061	FCER1G	0.46	6.98	0.58	3.9e-10	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg12000587	chr17:30186630	C17orf79	0.43	4.67	0.43	1.01e-5	Hip circumference adjusted for BMI;
THYM	trans	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg10856724	chr12:34555212	NA	-0.87	-7.47	-0.61	3.88e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4919694	0.572	rs12243903	chr10:104906992	T/C	cg04362960	chr10:104952993	NT5C2	0.97	6.41	0.55	5.51e-9	Arsenic metabolism;
THYM	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg04362960	chr10:104952993	NT5C2	0.58	4.68	0.43	9.68e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs929596	0.728	rs6744284	chr2:234625297	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.87	-7.07	-0.59	2.6e-10	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs6815814	0.950	rs5743794	chr4:38832727	C/T	cg06935464	chr4:38784597	TLR10	0.72	4.97	0.45	2.94e-6	Breast cancer;
THYM	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg07424592	chr7:64974309	NA	1.06	5.48	0.49	3.47e-7	Diabetic kidney disease;
THYM	cis	rs7582180	0.627	rs2241811	chr2:101011724	C/T	cg08017756	chr2:100939284	LONRF2	-0.71	-7.26	-0.6	1.07e-10	Intelligence (multi-trait analysis);
THYM	cis	rs4975709	0.531	rs6884044	chr5:1871599	C/T	cg12288994	chr5:1860383	NA	0.75	6.19	0.54	1.5e-8	Cardiovascular disease risk factors;
THYM	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg03433033	chr1:76189801	ACADM	0.77	10.09	0.72	1.07e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6456042	1.000	rs3127413	chr6:166535728	G/T	cg11088901	chr6:166572345	T	-0.51	-4.82	-0.44	5.5e-6	Asthma;
THYM	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg12599982	chr1:44399894	ARTN	0.56	4.8	0.44	5.79e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg22968622	chr17:43663579	NA	-1.16	-10.25	-0.72	4.79e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs17376456	0.569	rs13186432	chr5:93336940	G/A	cg21475434	chr5:93447410	FAM172A	-0.67	-4.52	-0.42	1.78e-5	Diabetic retinopathy;
THYM	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg26850624	chr5:429559	AHRR	-0.72	-5.55	-0.49	2.55e-7	Cystic fibrosis severity;
THYM	cis	rs986417	0.901	rs7157458	chr14:60999852	C/T	cg27398547	chr14:60952738	C14orf39	1.02	5.81	0.51	8.44e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs946836	0.562	rs1361443	chr1:48391668	C/T	cg18376692	chr1:48452465	NA	-0.53	-5.2	-0.47	1.12e-6	White matter integrity;
THYM	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg10856724	chr12:34555212	NA	-0.78	-6.99	-0.58	3.83e-10	Morning vs. evening chronotype;
THYM	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg26038318	chr20:34205095	SPAG4	0.59	4.65	0.43	1.08e-5	Total cholesterol levels;
THYM	cis	rs7829975	0.501	rs74345345	chr8:8578435	C/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-4.62	-0.43	1.2e-5	Mood instability;
THYM	cis	rs12596162	0.623	rs6540005	chr16:87138889	T/C	cg02258303	chr16:87377426	FBXO31	0.53	4.51	0.42	1.83e-5	Possible neuropathic pain in post total joint replacement surgery for osteoarthritis;
THYM	cis	rs11603160	0.552	rs10898889	chr11:72605382	G/C	cg13912027	chr11:72759293	FCHSD2	-0.25	-4.46	-0.42	2.23e-5	Body mass index in asthmatics;
THYM	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	cg01483505	chr11:975446	AP2A2	0.69	5.57	0.5	2.41e-7	Alzheimer's disease (late onset);
THYM	cis	rs490234	0.702	rs5016056	chr9:128310807	C/T	cg14078157	chr9:128172775	NA	-0.77	-6.1	-0.53	2.27e-8	Mean arterial pressure;
THYM	cis	rs7568458	0.811	rs3755014	chr2:85764006	C/T	cg17127132	chr2:85788382	GGCX	0.7	6.21	0.54	1.36e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	trans	rs9951602	0.512	rs4799249	chr18:76654370	A/G	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg13609457	chr4:120235615	NA	0.59	5.27	0.48	8.67e-7	Corneal astigmatism;
THYM	cis	rs8008758	0.500	rs1763212	chr14:101693911	G/A	cg26393534	chr14:101700091	NA	-0.47	-5.73	-0.51	1.16e-7	Body mass index (alcohol intake interaction);
THYM	cis	rs12519773	0.562	rs6557066	chr5:92499467	T/A	cg18783429	chr5:92414398	NA	0.53	5.37	0.48	5.63e-7	Migraine;
THYM	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10819861	0.620	rs10989244	chr9:98856772	C/G	cg14508093	chr9:98862825	NA	-0.24	-4.67	-0.43	9.83e-6	Electrocardiographic traits;
THYM	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg15691649	chr6:25882328	NA	-0.78	-6.58	-0.56	2.55e-9	Intelligence (multi-trait analysis);
THYM	cis	rs17818399	0.547	rs7607633	chr2:46759427	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.66	4.58	0.43	1.38e-5	Height;
THYM	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14893161	chr1:205819251	PM20D1	0.89	8.85	0.67	4.74e-14	Menarche (age at onset);
THYM	cis	rs7474896	0.616	rs1985260	chr10:38434090	C/T	cg13531842	chr10:38383804	ZNF37A	-0.76	-4.61	-0.43	1.24e-5	Obesity (extreme);
THYM	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg09307838	chr4:120376055	NA	-0.7	-5.1	-0.46	1.75e-6	Corneal astigmatism;
THYM	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg10150615	chr22:24372951	LOC391322	-0.84	-9.06	-0.68	1.65e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg22875332	chr1:76189707	ACADM	-0.52	-4.82	-0.44	5.5e-6	Daytime sleep phenotypes;
THYM	cis	rs713587	0.967	rs10865320	chr2:25159780	A/G	cg01884057	chr2:25150051	NA	0.67	7.0	0.58	3.58e-10	Body mass index in non-asthmatics;
THYM	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	6.24	0.54	1.21e-8	Urate levels;
THYM	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg00786635	chr1:25594202	NA	0.99	8.16	0.64	1.4e-12	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs2836633	0.929	rs8130434	chr21:40036243	C/T	cg05519781	chr21:40033154	ERG	-0.75	-7.41	-0.6	5.26e-11	Coronary artery disease;
THYM	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg18252515	chr7:66147081	NA	-1.46	-7.9	-0.63	4.85e-12	Diabetic kidney disease;
THYM	cis	rs2637266	0.783	rs12258504	chr10:78477055	C/T	cg18941641	chr10:78392320	NA	0.71	5.95	0.52	4.42e-8	Pulmonary function;
THYM	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg15704280	chr7:45808275	SEPT13	-0.82	-8.73	-0.67	8.61e-14	Height;
THYM	cis	rs12357919	0.542	rs3740471	chr10:105363289	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.52	4.77	0.44	6.71e-6	White matter hyperintensity burden;
THYM	cis	rs4460079	0.531	rs11098209	chr4:114838365	A/G	cg02060584	chr4:113970739	ANK2	0.57	4.7	0.43	8.79e-6	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs4383453	0.539	rs55689356	chr3:123098203	T/C	cg04890266	chr3:123102914	ADCY5	-0.86	-8.67	-0.66	1.12e-13	Gestational age at birth (maternal effect);
THYM	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg00129232	chr17:37814104	STARD3	-0.69	-4.51	-0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs2463822	0.669	rs72919493	chr11:62049651	C/A	cg06239285	chr11:62104954	ASRGL1	-1.27	-5.97	-0.52	4.09e-8	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg26384229	chr12:38710491	ALG10B	0.94	7.9	0.63	4.92e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs12200560	0.505	rs1334318	chr6:97079610	A/G	cg06623918	chr6:96969491	KIAA0776	-0.74	-5.48	-0.49	3.51e-7	Coronary heart disease;
THYM	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs965604	1.000	rs4887057	chr15:78760918	G/A	cg18825076	chr15:78729989	IREB2	0.5	4.49	0.42	1.98e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg05283184	chr6:79620031	NA	-0.88	-8.41	-0.65	4.12e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	-0.64	-4.68	-0.43	9.49e-6	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg08017756	chr2:100939284	LONRF2	-0.73	-7.58	-0.61	2.26e-11	Intelligence (multi-trait analysis);
THYM	cis	rs11577318	0.626	rs11806568	chr1:26686837	C/A	cg19677267	chr1:26645161	CD52;UBXN11	0.53	5.95	0.52	4.51e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg02574844	chr11:5959923	NA	-0.51	-4.51	-0.42	1.85e-5	DNA methylation (variation);
THYM	cis	rs3733631	0.895	rs28592258	chr4:104621036	C/A	cg24090629	chr4:104641072	TACR3	-0.87	-5.51	-0.49	3.08e-7	Menarche (age at onset);
THYM	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg03690763	chr11:133734501	NA	-0.65	-5.4	-0.48	5e-7	Childhood ear infection;
THYM	cis	rs6430585	0.583	rs1435577	chr2:136624947	C/G	cg20242066	chr2:136595261	LCT	0.51	4.87	0.45	4.44e-6	Corneal structure;
THYM	cis	rs34779708	0.931	rs11010132	chr10:35517265	C/G	cg03585969	chr10:35415529	CREM	0.64	4.47	0.42	2.16e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs1524976	1.000	rs4688570	chr3:65466168	G/C	cg16238336	chr3:65465873	MAGI1	1.0	6.76	0.57	1.12e-9	PR interval;
THYM	cis	rs11087114	0.666	rs2208083	chr20:14771194	G/A	cg04470754	chr20:14904432	MACROD2	-0.71	-4.55	-0.42	1.6e-5	Common carotid intima-media thickness in HIV infection;
THYM	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg18876405	chr7:65276391	NA	0.67	5.93	0.52	4.98e-8	Aortic root size;
THYM	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500395	0.963	rs12919278	chr16:48692537	A/G	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs35883536	0.565	rs2809813	chr1:101032003	A/C	cg09408571	chr1:101003634	GPR88	0.52	5.68	0.5	1.44e-7	Monocyte count;
THYM	cis	rs4237845	0.967	rs4553410	chr12:58301211	G/A	cg22764591	chr12:58329936	NA	0.93	7.96	0.63	3.73e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg15445000	chr17:37608096	MED1	-0.44	-5.19	-0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.65	6.74	0.57	1.22e-9	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs12110303	1	rs12110303	chr5:90662839	G/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	5.93	0.52	4.9e-8	Breast cancer;
THYM	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs912057	0.671	rs1294420	chr6:6742752	C/T	cg13809441	chr6:6737631	NA	0.44	5.32	0.48	6.97e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs654128	0.545	rs339325	chr6:117205393	T/C	cg12892004	chr6:117198278	RFX6	-0.66	-4.9	-0.45	3.98e-6	Telomere length;
THYM	cis	rs10865397	0.539	rs13414338	chr2:73383375	C/T	cg24220031	chr2:73402428	NA	-0.75	-6.87	-0.58	6.79e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg20295408	chr7:1910781	MAD1L1	-0.63	-4.87	-0.45	4.45e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg17279839	chr7:150038598	RARRES2	0.56	5.3	0.48	7.64e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11048434	0.736	rs11048337	chr12:9121330	C/A	cg13575925	chr12:9217583	LOC144571	0.51	4.87	0.45	4.42e-6	Sjögren's syndrome;
THYM	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg18451016	chr1:38461880	NA	-0.38	-4.72	-0.44	8.26e-6	Coronary artery disease;
THYM	cis	rs4509693	0.943	rs6584395	chr10:102498008	G/C	cg24127310	chr10:102502104	NA	1.3	10.12	0.72	9.09e-17	Alzheimer's disease;
THYM	cis	rs28647808	1.000	rs7031883	chr9:136276519	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg23161317	chr6:28129485	ZNF389	0.94	7.03	0.58	3.18e-10	Parkinson's disease;
THYM	cis	rs804292	0.800	rs8191542	chr8:11629809	C/G	cg26752888	chr8:11627280	NEIL2	1.15	8.05	0.64	2.38e-12	Alcohol dependence;Nicotine use;
THYM	cis	rs728616	0.867	rs28365998	chr10:81965436	C/A	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.63	4.46	0.42	2.28e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7580658	0.637	rs4580338	chr2:127974937	T/C	cg09152259	chr2:128156114	NA	-0.35	-4.49	-0.42	2e-5	Protein C levels;
THYM	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.99	12.51	0.79	8.52e-22	Chronic sinus infection;
THYM	cis	rs6930083	0.527	rs9368950	chr6:36627872	T/C	cg08179530	chr6:36648295	CDKN1A	-0.83	-5.75	-0.51	1.07e-7	Coronary artery disease;
THYM	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg19761014	chr17:28927070	LRRC37B2	0.71	4.52	0.42	1.77e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg20608306	chr11:116969690	SIK3	0.51	5.51	0.49	3.04e-7	Blood protein levels;
THYM	trans	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg25214090	chr10:38739885	LOC399744	0.97	8.33	0.65	5.98e-13	Corneal astigmatism;
THYM	cis	rs7336332	0.598	rs9581852	chr13:28013748	A/G	cg22138327	chr13:27999177	GTF3A	0.6	4.46	0.42	2.25e-5	Weight;
THYM	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg12560992	chr17:57184187	TRIM37	0.93	8.61	0.66	1.5700000000000001e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6754311	0.593	rs10928542	chr2:136410299	G/A	cg23851026	chr2:136556271	LCT	0.59	5.62	0.5	1.91e-7	Mosquito bite size;
THYM	cis	rs333947	0.641	rs333948	chr1:110470592	C/T	cg05133756	chr1:110256160	GSTM5	0.54	4.52	0.42	1.78e-5	White blood cell count;Monocyte count;
THYM	cis	rs2276314	0.857	rs28651028	chr18:33638910	G/A	cg05985134	chr18:33552581	C18orf21	0.66	4.84	0.44	5.02e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg07636037	chr3:49044803	WDR6	0.98	10.23	0.72	5.46e-17	Parkinson's disease;
THYM	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg17063962	chr7:91808500	NA	0.97	7.4	0.6	5.52e-11	Breast cancer;
THYM	cis	rs274567	0.711	rs404771	chr5:131635092	A/T	cg14196790	chr5:131705035	SLC22A5	0.49	4.52	0.42	1.78e-5	Blood metabolite levels;
THYM	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg03188948	chr7:1209495	NA	0.66	4.85	0.45	4.85e-6	Longevity;Endometriosis;
THYM	cis	rs16858210	0.520	rs35586421	chr3:183544607	G/A	cg03417191	chr3:183542750	MAP6D1	-0.77	-4.56	-0.42	1.53e-5	Menopause (age at onset);
THYM	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.29	5.97	0.52	4.06e-8	Obesity-related traits;
THYM	cis	rs7000551	0.715	rs1879792	chr8:22314029	C/A	cg12081754	chr8:22256438	SLC39A14	0.6	5.25	0.47	9.31e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7078219	0.965	rs7081858	chr10:101274565	G/A	cg17888390	chr10:101282816	NA	-0.5	-4.78	-0.44	6.28e-6	Dental caries;
THYM	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg20608306	chr11:116969690	SIK3	0.55	6.49	0.55	3.9e-9	Blood protein levels;
THYM	cis	rs789852	0.867	rs708632	chr3:194325325	C/T	cg18000598	chr3:194342907	TMEM44	-1.19	-6.77	-0.57	1.05e-9	QT interval;
THYM	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg08923669	chr16:420230	MRPL28	-0.47	-5.26	-0.47	8.93e-7	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs3857067	0.806	rs7654565	chr4:95112939	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.5	-4.58	-0.43	1.4e-5	QT interval;
THYM	cis	rs7688540	0.771	rs4549329	chr4:239785	T/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.67	4.9	0.45	3.93e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs17597773	0.754	rs1826647	chr1:221030954	G/A	cg16008148	chr1:221062819	NA	0.46	4.66	0.43	1.04e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6430585	0.528	rs6743537	chr2:136702601	C/T	cg23851026	chr2:136556271	LCT	0.72	6.6	0.56	2.31e-9	Corneal structure;
THYM	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg22431228	chr1:16359049	CLCNKA	-0.57	-5.35	-0.48	5.97e-7	Systolic blood pressure;
THYM	cis	rs12802200	0.535	rs35391985	chr11:570280	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.58	-4.5	-0.42	1.89e-5	Systemic lupus erythematosus;
THYM	cis	rs10744422	1.000	rs2292134	chr12:123334033	C/G	cg25930673	chr12:123319894	HIP1R	-0.86	-4.84	-0.44	5.09e-6	Schizophrenia;
THYM	cis	rs2073300	0.609	rs17757228	chr20:23351288	A/T	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7769051	0.708	rs62426668	chr6:133225021	C/T	cg22852734	chr6:133119734	C6orf192	0.94	4.46	0.42	2.29e-5	Type 2 diabetes nephropathy;
THYM	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg02696790	chr15:75250997	RPP25	-0.46	-4.72	-0.44	7.98e-6	Caffeine consumption;
THYM	cis	rs1729951	0.546	rs361246	chr3:136695667	G/A	cg12473912	chr3:136751656	NA	0.63	5.13	0.47	1.55e-6	Neuroticism;
THYM	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.83	0.44	5.29e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs36051895	0.564	rs7874624	chr9:5179865	A/G	cg02405213	chr9:5042618	JAK2	-1.01	-11.19	-0.75	4.95e-19	Pediatric autoimmune diseases;
THYM	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-4.96	-0.45	3.03e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg01528321	chr10:82214614	TSPAN14	0.82	6.22	0.54	1.34e-8	Post bronchodilator FEV1;
THYM	cis	rs11585357	0.947	rs2977303	chr1:17611548	A/T	cg08277548	chr1:17600880	PADI3	-0.86	-5.8	-0.51	8.76e-8	Hair shape;
THYM	cis	rs9359856	0.636	rs1179896	chr6:90318610	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.77	-7.08	-0.59	2.53e-10	Bipolar disorder;
THYM	cis	rs4638749	0.677	rs4396668	chr2:108840364	C/T	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg03929089	chr4:120376271	NA	-0.95	-10.79	-0.74	3.5e-18	Height;
THYM	cis	rs6519955	0.860	rs8136098	chr22:46425646	A/G	cg05468064	chr22:46423449	NA	0.48	6.87	0.58	6.61e-10	Dupuytren's disease;
THYM	cis	rs7119	0.931	rs7176875	chr15:77832675	A/G	cg10437265	chr15:77819839	NA	-0.74	-7.27	-0.6	9.86e-11	Type 2 diabetes;
THYM	cis	rs11096990	0.855	rs2167494	chr4:39216221	C/T	cg24403649	chr4:39172243	NA	-0.63	-5.24	-0.47	9.63e-7	Cognitive function;
THYM	trans	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg10856724	chr12:34555212	NA	-1.01	-9.23	-0.69	7.34e-15	Morning vs. evening chronotype;
THYM	cis	rs6700896	0.864	rs11208691	chr1:66092570	A/G	cg04111102	chr1:66153794	NA	0.55	5.18	0.47	1.25e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg05738196	chr6:26577821	NA	0.91	8.18	0.64	1.27e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg15556689	chr8:8085844	FLJ10661	0.68	5.55	0.49	2.62e-7	Mood instability;
THYM	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg08564027	chr20:61660810	NA	0.92	9.77	0.71	5.02e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs28595532	0.920	rs116791817	chr4:119763303	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg15744005	chr10:104629667	AS3MT	-0.78	-7.33	-0.6	7.48e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6543140	0.693	rs7579737	chr2:102987361	A/G	cg03938978	chr2:103052716	IL18RAP	0.59	5.73	0.51	1.17e-7	Blood protein levels;
THYM	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg03806693	chr22:41940476	POLR3H	1.1	8.83	0.67	5.2e-14	Vitiligo;
THYM	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg26354017	chr1:205819088	PM20D1	1.09	11.85	0.77	2.01e-20	Menarche (age at onset);
THYM	cis	rs9796	0.835	rs11856848	chr15:41370961	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.58	-4.72	-0.44	8.26e-6	Menopause (age at onset);
THYM	cis	rs4604732	0.642	rs7515859	chr1:247640057	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	4.8	0.44	5.87e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.68	-4.57	-0.42	1.44e-5	Menarche (age at onset);
THYM	cis	rs2495707	0.624	rs2489006	chr10:102419893	G/A	cg00272971	chr10:102419564	NA	-0.53	-5.84	-0.51	7.37e-8	Body mass index;
THYM	cis	rs2130392	1.000	rs4862406	chr4:185629339	G/A	cg04058563	chr4:185651563	MLF1IP	-0.59	-5.66	-0.5	1.61e-7	Kawasaki disease;
THYM	cis	rs3820068	0.655	rs72645823	chr1:15887442	C/T	cg05660106	chr1:15850417	CASP9	1.16	10.06	0.72	1.25e-16	Systolic blood pressure;
THYM	cis	rs4986172	0.655	rs1044977	chr17:43227214	T/C	cg00677574	chr17:43221327	ACBD4	0.7	5.99	0.52	3.67e-8	Height;
THYM	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg11764359	chr7:65958608	NA	0.63	4.92	0.45	3.66e-6	Aortic root size;
THYM	cis	rs10227331	0.585	rs10240671	chr7:157298637	G/T	cg04156418	chr7:157293606	NA	-0.8	-7.16	-0.59	1.7e-10	Inattentive symptoms;
THYM	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg13147721	chr7:65941812	NA	-0.73	-4.58	-0.43	1.42e-5	Diabetic kidney disease;
THYM	cis	rs5753037	0.745	rs9306465	chr22:30221826	T/A	cg27665648	chr22:30112403	NA	0.5	4.45	0.42	2.35e-5	Type 1 diabetes;
THYM	cis	rs995000	0.895	rs783291	chr1:62914978	G/A	cg06896770	chr1:63153194	DOCK7	0.9	7.4	0.6	5.39e-11	Triglyceride levels;
THYM	cis	rs1451375	0.617	rs12671474	chr7:50591395	C/A	cg18232548	chr7:50535776	DDC	0.67	5.03	0.46	2.31e-6	Malaria;
THYM	cis	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg07870213	chr5:140052090	DND1	-0.69	-8.1	-0.64	1.86e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs10992471	0.553	rs1923599	chr9:95092568	G/C	cg14631576	chr9:95140430	CENPP	-0.67	-5.6	-0.5	2.11e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2233152	0.520	rs56101381	chr19:41272902	T/C	cg26767443	chr19:41316244	NA	0.76	4.87	0.45	4.47e-6	Kawasaki disease;
THYM	cis	rs4919087	0.962	rs10786324	chr10:99054387	A/G	cg19453742	chr10:98862320	SLIT1	-0.67	-5.21	-0.47	1.09e-6	Monocyte count;
THYM	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg00071950	chr4:10020882	SLC2A9	-0.65	-6.0	-0.52	3.54e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg04315214	chr1:2043799	PRKCZ	0.59	4.56	0.42	1.55e-5	Height;
THYM	cis	rs17006441	0.932	rs12330279	chr3:69886775	A/G	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs7267979	1.000	rs6515651	chr20:25414539	T/G	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs75064307	0.834	rs4855560	chr3:108116129	G/C	cg03329597	chr3:108125523	MYH15	0.62	4.63	0.43	1.16e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06634786	chr22:41940651	POLR3H	0.67	5.09	0.46	1.84e-6	Vitiligo;
THYM	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg00814883	chr7:100076585	TSC22D4	-0.98	-6.62	-0.56	2.15e-9	Platelet count;
THYM	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg10334053	chr1:2078117	PRKCZ	-0.48	-4.73	-0.44	7.65e-6	Height;
THYM	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg18252515	chr7:66147081	NA	-0.66	-5.03	-0.46	2.34e-6	Aortic root size;
THYM	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg17644776	chr2:200775616	C2orf69	-0.74	-4.77	-0.44	6.57e-6	Schizophrenia;
THYM	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg18357526	chr6:26021779	HIST1H4A	0.86	7.39	0.6	5.61e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7084402	0.967	rs1593672	chr10:60294379	T/C	cg07615347	chr10:60278583	BICC1	0.56	5.15	0.47	1.43e-6	Refractive error;
THYM	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.09	-7.74	-0.62	1.06e-11	Platelet count;
THYM	cis	rs6032067	0.929	rs6032044	chr20:43819416	C/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.57	-0.42	1.48e-5	Fear of minor pain;
THYM	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg07636037	chr3:49044803	WDR6	0.93	9.44	0.7	2.54e-15	Parkinson's disease;
THYM	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg14675211	chr2:100938903	LONRF2	0.77	8.32	0.65	6.49e-13	Intelligence (multi-trait analysis);
THYM	cis	rs346785	0.692	rs2279057	chr17:74309425	A/G	cg10318678	chr17:74308979	PRPSAP1	-0.48	-4.46	-0.42	2.24e-5	White matter hyperintensities in ischemic stroke;
THYM	cis	rs7090512	0.570	rs4747880	chr10:6152967	A/G	cg17191567	chr10:6178319	NA	0.51	5.07	0.46	1.97e-6	Multiple sclerosis;
THYM	cis	rs7172809	0.573	rs11853696	chr15:77688417	C/T	cg22256960	chr15:77711686	NA	-0.65	-4.82	-0.44	5.54e-6	Glucose homeostasis traits;
THYM	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg03433033	chr1:76189801	ACADM	-0.78	-9.14	-0.68	1.13e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7172809	0.607	rs77744673	chr15:77842311	T/C	cg10437265	chr15:77819839	NA	-0.51	-4.68	-0.43	9.7e-6	Glucose homeostasis traits;
THYM	cis	rs4654899	0.680	rs10916885	chr1:21188703	A/T	cg01072550	chr1:21505969	NA	0.72	6.91	0.58	5.4e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs752010	0.668	rs10890147	chr1:42089725	A/T	cg06885757	chr1:42089581	HIVEP3	0.78	11.79	0.77	2.63e-20	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg13010199	chr12:38710504	ALG10B	-0.59	-4.72	-0.44	8.2e-6	Morning vs. evening chronotype;
THYM	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7705502	1.000	rs56163845	chr5:173373948	A/G	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg05552183	chr6:42928497	GNMT	0.7	5.55	0.49	2.59e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	6.88	0.58	6.35e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs9361491	0.608	rs4706728	chr6:79466811	G/T	cg04547799	chr6:79944526	HMGN3	-0.64	-4.47	-0.42	2.13e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10216189	0.967	rs10215480	chr7:5524682	C/T	cg08928675	chr7:5528044	FBXL18	0.46	4.61	0.43	1.25e-5	Relative hand skill in reading disability;
THYM	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg27532560	chr4:187881888	NA	-0.95	-11.83	-0.77	2.15e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11077998	0.967	rs60488670	chr17:80522667	T/C	cg11779900	chr17:80519722	FOXK2	-0.53	-4.53	-0.42	1.71e-5	Reticulocyte fraction of red cells;
THYM	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg11366901	chr6:160182831	ACAT2	1.07	9.53	0.7	1.68e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg03929089	chr4:120376271	NA	-0.99	-12.81	-0.8	2.07e-22	Height;
THYM	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg18032289	chr17:61959525	GH2	-0.5	-4.55	-0.42	1.58e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs3087591	1.000	rs2854332	chr17:29712378	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.62	-5.13	-0.47	1.54e-6	Hip circumference;
THYM	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg13147721	chr7:65941812	NA	-0.74	-4.83	-0.44	5.22e-6	Diabetic kidney disease;
THYM	cis	rs10203711	0.966	rs10187949	chr2:239558408	T/C	cg14580085	chr2:239553406	NA	0.71	6.64	0.56	1.97e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg10523679	chr1:76189770	ACADM	0.9	9.47	0.7	2.2e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs3135718	0.935	rs4752570	chr10:123337066	T/C	cg15049101	chr10:123353889	FGFR2	0.56	4.85	0.45	4.9100000000000004e-06	Estrogen receptor status in breast cancer;
THYM	cis	rs2361710	0.611	rs3816257	chr17:78074446	G/T	cg04028464	chr17:78073854	GAA;CCDC40	-0.74	-5.78	-0.51	9.32e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
THYM	cis	rs6450176	0.564	rs406621	chr5:53326232	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.94	-8.32	-0.65	6.26e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs1950626	0.750	rs34228453	chr14:101440321	A/C	cg11887864	chr14:101510502	MIR1185-2	0.55	4.63	0.43	1.17e-5	Pelvic organ prolapse (moderate/severe);
THYM	cis	rs4242434	0.672	rs11785031	chr8:22486612	A/G	cg11461670	chr8:22454935	PDLIM2	-0.33	-6.26	-0.54	1.09e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7589342	0.839	rs10192144	chr2:106439854	A/G	cg14210321	chr2:106509881	NCK2	-0.69	-4.9	-0.45	4.01e-6	Addiction;
THYM	cis	rs800586	0.868	rs10505262	chr8:116697852	T/A	cg04656070	chr8:116661063	TRPS1	0.5	4.69	0.43	9.14e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg05313129	chr8:58192883	C8orf71	-0.84	-4.81	-0.44	5.77e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4845570	0.920	rs3811414	chr1:151763246	A/G	cg07092448	chr1:151763213	TDRKH	-1.21	-8.61	-0.66	1.56e-13	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg03676636	chr4:99064102	C4orf37	-0.44	-6.64	-0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6840360	0.571	rs7678080	chr4:152557350	A/G	cg22705602	chr4:152727874	NA	-0.77	-8.58	-0.66	1.81e-13	Intelligence (multi-trait analysis);
THYM	cis	rs11225247	0.881	rs12291114	chr11:102261549	G/A	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg13114125	chr14:105738426	BRF1	-0.75	-5.91	-0.52	5.39e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg07061783	chr6:25882402	NA	0.72	5.75	0.51	1.06e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg13854012	chr2:162103682	NA	-0.65	-5.39	-0.48	5.19e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs600231	0.708	rs3132767	chr11:65234860	C/T	cg17120908	chr11:65337727	SSSCA1	-0.61	-4.75	-0.44	7.33e-6	Bone mineral density;
THYM	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg13447684	chr7:1895903	MAD1L1	0.49	4.45	0.42	2.33e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg10802521	chr3:52805072	NEK4	-0.71	-6.18	-0.54	1.57e-8	Bipolar disorder;
THYM	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg10193763	chr2:225306901	NA	-0.52	-5.48	-0.49	3.41e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9527	0.545	rs12784384	chr10:104957594	G/C	cg04362960	chr10:104952993	NT5C2	0.62	4.74	0.44	7.52e-6	Arsenic metabolism;
THYM	cis	rs3892630	0.878	rs1061686	chr19:33204544	C/T	cg22928329	chr19:33183273	NUDT19	0.78	5.9	0.52	5.55e-8	Red blood cell traits;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg10805004	chr17:9327969	STX8	-0.9	-7.26	-0.6	1.06e-10	Depressive symptoms;
THYM	cis	rs1055129	0.584	rs9895947	chr17:73908566	A/C	cg12407791	chr17:73824354	UNC13D	-0.41	-4.52	-0.42	1.81e-5	White matter hyperintensity burden;
THYM	cis	rs7578361	0.918	rs6708520	chr2:150378544	C/T	cg17961725	chr2:150454027	NA	-0.77	-5.72	-0.51	1.25e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs600550	0.520	rs11560911	chr11:60090369	G/A	cg05040360	chr11:60102449	MS4A6E	-0.5	-4.64	-0.43	1.1e-5	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.6	8.4	0.65	4.21e-13	Monocyte percentage of white cells;
THYM	cis	rs1065852	0.526	rs4822079	chr22:42394612	G/C	cg09667013	chr22:42394590	WBP2NL	0.52	4.58	0.43	1.41e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs636291	0.517	rs670666	chr1:10549380	C/T	cg20482658	chr1:10539492	PEX14	0.33	4.92	0.45	3.7e-6	Prostate cancer;
THYM	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg08885076	chr2:99613938	TSGA10	0.63	5.66	0.5	1.57e-7	Chronic sinus infection;
THYM	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11890956	chr21:40555474	PSMG1	-0.9	-9.57	-0.7	1.4e-15	Cognitive function;
THYM	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.63	4.83	0.44	5.28e-6	Tonsillectomy;
THYM	cis	rs7809615	0.901	rs28862110	chr7:99183531	T/C	cg12290671	chr7:99195819	NA	-0.99	-4.83	-0.44	5.27e-6	Blood metabolite ratios;
THYM	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg24846680	chr1:228362309	C1orf69	0.57	4.72	0.44	8.09e-6	Diastolic blood pressure;
THYM	cis	rs17407555	0.710	rs10939814	chr4:10273329	T/C	cg00071950	chr4:10020882	SLC2A9	0.52	4.89	0.45	4.05e-6	Schizophrenia (age at onset);
THYM	cis	rs6723226	0.698	rs13409142	chr2:32666137	C/T	cg02381751	chr2:32503542	YIPF4	0.63	5.65	0.5	1.68e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg15556689	chr8:8085844	FLJ10661	0.62	5.08	0.46	1.86e-6	Mood instability;
THYM	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg07211511	chr3:129823064	LOC729375	-1.28	-10.3	-0.73	3.76e-17	Blood pressure (smoking interaction);
THYM	cis	rs9443189	0.615	rs602873	chr6:76323818	T/A	cg01950844	chr6:76311363	SENP6	1.05	6.55	0.56	2.95e-9	Prostate cancer;
THYM	cis	rs72827839	1.000	rs72827834	chr17:46413819	G/A	cg23391107	chr17:45924227	SP6	0.76	4.58	0.43	1.39e-5	Ease of getting up in the morning;
THYM	cis	rs2262909	0.566	rs10419058	chr19:22309972	A/C	cg07498013	chr19:22123504	NA	-0.47	-4.49	-0.42	1.99e-5	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
THYM	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg08968635	chr6:28129556	ZNF389	-0.67	-5.27	-0.48	8.37e-7	Depression;
THYM	cis	rs977987	0.778	rs12929908	chr16:75462071	C/T	cg03315344	chr16:75512273	CHST6	0.76	6.17	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06873352	chr17:61820015	STRADA	0.56	5.58	0.5	2.22e-7	Height;
THYM	cis	rs6047844	0.593	rs6137547	chr20:22109895	A/G	cg16502866	chr20:23015624	SSTR4	-0.59	-4.82	-0.44	5.47e-6	Male-pattern baldness;
THYM	cis	rs11031096	0.678	rs2044135	chr11:4187233	G/A	cg18678763	chr11:4115507	RRM1	-0.41	-4.84	-0.44	5.12e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2502731	0.583	rs3003579	chr9:130995751	C/G	cg09976142	chr9:130955436	CIZ1	0.52	4.91	0.45	3.7e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg23711669	chr6:146136114	FBXO30	0.93	9.7	0.71	7.07e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7078219	0.965	rs10883358	chr10:101273857	C/T	cg17888390	chr10:101282816	NA	-0.5	-4.78	-0.44	6.28e-6	Dental caries;
THYM	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6456042	0.756	rs3099266	chr6:166581147	T/C	cg11088901	chr6:166572345	T	-0.56	-5.37	-0.48	5.64e-7	Asthma;
THYM	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg02753203	chr1:228287806	NA	-0.79	-7.07	-0.59	2.6e-10	Diastolic blood pressure;
THYM	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg02725872	chr8:58115012	NA	1.11	7.58	0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs6748734	0.553	rs7340215	chr2:241805851	A/G	cg09990169	chr2:241835740	C2orf54	-0.28	-4.84	-0.44	5.09e-6	Urinary metabolites;
THYM	cis	rs9876781	1.000	rs73074358	chr3:48427247	T/A	cg06066452	chr3:48470258	PLXNB1	0.26	4.88	0.45	4.26e-6	Longevity;
THYM	cis	rs11048434	0.761	rs12827988	chr12:9130287	A/G	cg04155231	chr12:9217510	LOC144571	0.48	4.59	0.43	1.34e-5	Sjögren's syndrome;
THYM	cis	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg23989207	chr17:80870107	TBCD	0.62	5.15	0.47	1.42e-6	Glycated hemoglobin levels;
THYM	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.16	7.96	0.63	3.69e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9296092	0.500	rs9461885	chr6:33521069	G/T	cg13560919	chr6:33536144	NA	-0.94	-9.31	-0.69	4.9e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs17401966	1.000	rs1536263	chr1:10378914	T/C	cg19773385	chr1:10388646	KIF1B	-0.64	-4.77	-0.44	6.6e-6	Hepatocellular carcinoma;
THYM	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs686320	0.667	rs2904976	chr11:65185387	G/A	cg19332572	chr11:65321591	LTBP3	-0.88	-5.13	-0.47	1.52e-6	Hip circumference adjusted for BMI;
THYM	cis	rs12802200	0.561	rs12792868	chr11:566647	T/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.6	-4.64	-0.43	1.1e-5	Systemic lupus erythematosus;
THYM	cis	rs7187994	0.895	rs12598223	chr16:84783873	A/G	cg07647771	chr16:84786436	USP10	-0.53	-4.93	-0.45	3.43e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg18904891	chr8:8559673	CLDN23	0.58	4.59	0.43	1.34e-5	Mood instability;
THYM	cis	rs9902453	0.765	rs3102562	chr17:28040403	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	6.53	0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs6968419	0.609	rs73716708	chr7:115905743	T/C	cg02561103	chr7:115862891	TES	-0.63	-4.5	-0.42	1.91e-5	Intraocular pressure;
THYM	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg02187348	chr16:89574699	SPG7	0.75	5.94	0.52	4.75e-8	Multiple myeloma (IgH translocation);
THYM	cis	rs11676855	0.924	rs11680626	chr2:235927511	A/T	cg14917874	chr2:235941519	SH3BP4	-0.63	-5.67	-0.5	1.55e-7	Dialysis-related mortality;
THYM	trans	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg25214090	chr10:38739885	LOC399744	0.97	8.33	0.65	5.98e-13	Corneal astigmatism;
THYM	cis	rs752010	0.714	rs2182606	chr1:42082375	T/C	cg06885757	chr1:42089581	HIVEP3	0.61	7.92	0.63	4.42e-12	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs13102973	0.932	rs7656273	chr4:135852678	G/A	cg14419869	chr4:135874104	NA	0.9	8.82	0.67	5.49e-14	Subjective well-being;
THYM	cis	rs4866334	1.000	rs114400023	chr5:18432893	T/C	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg18305652	chr10:134549665	INPP5A	0.79	6.5	0.55	3.69e-9	Migraine;
THYM	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg27490568	chr2:178487706	NA	0.66	5.57	0.5	2.31e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs12200560	0.505	rs60879781	chr6:97075466	A/T	cg06623918	chr6:96969491	KIAA0776	0.78	6.03	0.53	3.13e-8	Coronary heart disease;
THYM	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg15693483	chr7:1102177	C7orf50	0.54	6.26	0.54	1.1e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg12826209	chr6:26865740	GUSBL1	1.03	6.64	0.56	1.94e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9527	0.590	rs12775302	chr10:104911356	A/G	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs7523273	0.548	rs3109808	chr1:207948477	C/A	cg22525895	chr1:207977042	MIR29B2	0.94	9.98	0.72	1.81e-16	Schizophrenia;
THYM	cis	rs10911251	0.528	rs10911248	chr1:183080564	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Colorectal cancer;
THYM	cis	rs11825685	0.887	rs35430067	chr11:134561893	G/A	cg02395454	chr11:134605862	NA	-0.99	-4.98	-0.45	2.87e-6	IgG glycosylation;
THYM	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg24530246	chr3:53118167	NA	-0.85	-4.82	-0.44	5.52e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg05425664	chr17:57184151	TRIM37	0.59	4.84	0.44	4.98e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7312774	0.618	rs7953093	chr12:107334540	G/A	cg16260113	chr12:107380972	MTERFD3	1.34	6.39	0.55	6.14e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs4343996	0.754	rs4327753	chr7:3372249	C/G	cg21248987	chr7:3385318	SDK1	-0.37	-4.46	-0.42	2.21e-5	Motion sickness;
THYM	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg09549813	chr16:4587862	C16orf5	-0.56	-6.24	-0.54	1.24e-8	Schizophrenia;
THYM	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg25072359	chr17:41440525	NA	0.65	4.54	0.42	1.64e-5	Menopause (age at onset);
THYM	cis	rs4730276	0.674	rs7779923	chr7:107540244	T/C	cg23293999	chr7:106826042	HBP1	-0.6	-4.86	-0.45	4.65e-6	Ulcerative colitis;
THYM	cis	rs9810089	0.900	rs11915629	chr3:136139730	C/G	cg12473912	chr3:136751656	NA	0.58	4.69	0.43	9.06e-6	Gestational age at birth (child effect);
THYM	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg26038318	chr20:34205095	SPAG4	0.59	4.68	0.43	9.62e-6	Total cholesterol levels;
THYM	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg22105103	chr4:187893119	NA	0.95	10.29	0.73	3.97e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg10862848	chr6:42927986	GNMT	-0.51	-6.85	-0.57	7.42e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6430585	0.528	rs309167	chr2:136669264	C/T	cg23851026	chr2:136556271	LCT	0.77	7.03	0.58	3.16e-10	Corneal structure;
THYM	cis	rs1729407	0.814	rs2071521	chr11:116697848	A/G	cg08985259	chr11:116699649	APOC3	0.58	4.78	0.44	6.39e-6	Apolipoprotein A-IV levels;
THYM	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs12318506	0.826	rs11180452	chr12:75693881	G/T	cg04728562	chr12:75699417	CAPS2	-1.36	-5.71	-0.51	1.27e-7	Coronary artery calcification;
THYM	cis	rs514406	0.893	rs10888759	chr1:53433274	A/G	cg06600287	chr1:53387719	ECHDC2	0.31	5.11	0.46	1.68e-6	Monocyte count;
THYM	cis	rs11785693	0.862	rs73183633	chr8:4994543	G/A	cg26367366	chr8:4980734	NA	1.21	5.9	0.52	5.46e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs7103648	1.000	rs7103648	chr11:47461783	A/G	cg20307385	chr11:47447363	PSMC3	0.94	8.67	0.66	1.15e-13	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs9534288	0.762	rs1571052	chr13:46554849	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-4.52	-0.42	1.8e-5	Blood protein levels;
THYM	cis	rs68170813	0.559	rs76646886	chr7:107034328	T/C	cg00661777	chr7:106511741	PIK3CG	-0.67	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg06112835	chr11:68658793	MRPL21	0.44	6.24	0.54	1.23e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg03929089	chr4:120376271	NA	0.96	10.53	0.73	1.2e-17	Coronary artery disease;
THYM	cis	rs1981331	0.609	rs76937225	chr21:48069682	C/T	cg23283320	chr21:48055893	PRMT2	1.57	7.92	0.63	4.41e-12	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs4900538	0.928	rs1190551	chr14:102911508	A/G	cg18135206	chr14:102964638	TECPR2	-0.92	-7.62	-0.62	1.88e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9420	0.961	rs499188	chr11:57434122	C/A	cg19752551	chr11:57585705	CTNND1	-0.68	-7.93	-0.63	4.15e-12	Schizophrenia;
THYM	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg09021430	chr5:549028	NA	-0.64	-4.84	-0.44	4.98e-6	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg24818145	chr4:99064322	C4orf37	0.74	5.85	0.51	6.85e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg00684032	chr4:1343700	KIAA1530	-0.68	-5.77	-0.51	9.9e-8	Obesity-related traits;
THYM	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg02569458	chr12:86230093	RASSF9	0.62	5.34	0.48	6.31e-7	Major depressive disorder;
THYM	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg23711669	chr6:146136114	FBXO30	-0.76	-6.9	-0.58	5.86e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	6.35	0.55	7.5e-9	Smoking behavior;
THYM	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs448720	0.806	rs11071966	chr15:68163774	G/A	cg23793686	chr15:68133972	NA	0.54	4.49	0.42	1.97e-5	Cognitive performance;
THYM	cis	rs6424115	0.830	rs2502993	chr1:24201262	A/G	cg15997130	chr1:24165203	NA	0.76	6.39	0.55	6.14e-9	Immature fraction of reticulocytes;
THYM	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07157834	chr1:205819609	PM20D1	0.88	8.94	0.68	3.09e-14	Menarche (age at onset);
THYM	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-7.23	-0.6	1.2e-10	Schizophrenia;
THYM	cis	rs1691799	0.867	rs1168311	chr12:66725912	A/C	cg16791601	chr12:66731901	HELB	0.76	7.49	0.61	3.45e-11	White blood cell count (basophil);
THYM	cis	rs2319125	0.683	rs9907729	chr17:64047196	C/G	cg04446870	chr17:64440273	PRKCA	0.5	4.48	0.42	2.12e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg09260853	chr1:2094483	PRKCZ	0.51	4.81	0.44	5.76e-6	Height;
THYM	cis	rs9522267	0.535	rs11069899	chr13:112231553	T/C	cg10483660	chr13:112241077	NA	-0.59	-6.66	-0.56	1.77e-9	Hepatitis;
THYM	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.11e-8	Systolic blood pressure;
THYM	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9649213	0.593	rs3801256	chr7:97992095	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8067545	0.750	rs9944451	chr17:20001316	T/C	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.61e-6	Schizophrenia;
THYM	cis	rs6087990	0.735	rs2424928	chr20:31388636	T/C	cg13636640	chr20:31349939	DNMT3B	0.92	9.89	0.71	2.9e-16	Ulcerative colitis;
THYM	cis	rs4073054	0.510	rs3003596	chr1:161204217	A/G	cg06974388	chr1:161065862	NA	0.55	4.76	0.44	7.01e-6	Blood metabolite levels;
THYM	cis	rs17253792	0.822	rs75763956	chr14:56071176	A/G	cg01858014	chr14:56050164	KTN1	-1.22	-5.13	-0.47	1.52e-6	Putamen volume;
THYM	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.99	8.16	0.64	1.36e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg27534772	chr1:16042836	PLEKHM2	0.53	5.9	0.52	5.65e-8	Systolic blood pressure;
THYM	cis	rs9296092	0.538	rs34222093	chr6:33519584	G/C	cg13560919	chr6:33536144	NA	-0.94	-9.31	-0.69	4.9e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	4.8	0.44	5.88e-6	Hip circumference adjusted for BMI;
THYM	cis	rs7264396	0.790	rs4519606	chr20:34324648	T/C	cg26038318	chr20:34205095	SPAG4	0.64	5.18	0.47	1.22e-6	Total cholesterol levels;
THYM	cis	rs8044868	0.586	rs7201643	chr16:72100780	C/A	cg06353428	chr16:71660113	MARVELD3	0.61	4.56	0.42	1.55e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs10929159	0.928	rs3738993	chr2:236918671	C/T	cg20128773	chr2:236923534	AGAP1	0.36	4.75	0.44	7.23e-6	Parkinson's disease;
THYM	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg15782153	chr7:917662	C7orf20	0.47	4.94	0.45	3.4e-6	Perceived unattractiveness to mosquitoes;
THYM	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg25838465	chr1:92012736	NA	-0.91	-9.25	-0.69	6.55e-15	Breast cancer;
THYM	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg03264133	chr6:25882463	NA	-0.64	-4.87	-0.45	4.53e-6	Height;
THYM	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg00686598	chr14:53173677	PSMC6	1.39	7.01	0.58	3.52e-10	Alzheimer's disease (late onset);
THYM	cis	rs2742234	0.541	rs10899782	chr10:43736361	A/T	cg06632098	chr10:43605906	RET	0.74	4.97	0.45	2.95e-6	Hirschsprung disease;
THYM	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg07424592	chr7:64974309	NA	1.16	5.55	0.5	2.55e-7	Diabetic kidney disease;
THYM	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg00310523	chr12:86230176	RASSF9	0.56	5.03	0.46	2.28e-6	Major depressive disorder;
THYM	cis	rs904251	0.523	rs2776874	chr6:37483197	C/T	cg25019722	chr6:37503610	NA	-0.5	-4.48	-0.42	2.09e-5	Cognitive performance;
THYM	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg12935359	chr14:103987150	CKB	-0.66	-6.48	-0.55	3.99e-9	Body mass index;
THYM	cis	rs55692411	0.537	rs35012435	chr3:50031840	C/T	cg14019146	chr3:50243930	SLC38A3	-0.59	-4.56	-0.42	1.55e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7833986	1.000	rs34037954	chr8:57096841	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	4.78	0.44	6.48e-6	Height;
THYM	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg05973401	chr12:123451056	ABCB9	0.69	4.55	0.42	1.56e-5	Neutrophil percentage of white cells;
THYM	cis	rs752010	0.695	rs11210509	chr1:42109311	A/G	cg06885757	chr1:42089581	HIVEP3	0.49	5.95	0.52	4.52e-8	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-4.74	-0.44	7.42e-6	Joint mobility (Beighton score);
THYM	cis	rs1650123	0.617	rs703618	chr12:104021263	G/A	cg23227824	chr12:103980017	STAB2	0.44	4.45	0.42	2.34e-5	IgG glycosylation;
THYM	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg23161317	chr6:28129485	ZNF389	0.57	4.84	0.44	5.02e-6	Depression;
THYM	cis	rs6032067	0.777	rs34916007	chr20:43782952	T/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs611744	0.870	rs638905	chr8:109203406	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	trans	rs4596713	0.538	rs11145460	chr9:71766091	T/G	cg16512924	chr15:28394682	HERC2	0.83	6.91	0.58	5.43e-10	Headache;
THYM	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg27494647	chr7:150038898	RARRES2	0.49	6.09	0.53	2.44e-8	Blood protein levels;Circulating chemerin levels;
THYM	trans	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg13615516	chr5:77269221	NA	0.84	7.65	0.62	1.66e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg13010199	chr12:38710504	ALG10B	-0.59	-4.71	-0.44	8.36e-6	Morning vs. evening chronotype;
THYM	cis	rs4664308	0.935	rs4292050	chr2:160940899	G/T	cg03641300	chr2:160917029	PLA2R1	-0.78	-6.97	-0.58	4.25e-10	Idiopathic membranous nephropathy;
THYM	cis	rs6087990	0.735	rs2424913	chr20:31374259	C/T	cg13636640	chr20:31349939	DNMT3B	0.88	9.07	0.68	1.57e-14	Ulcerative colitis;
THYM	cis	rs6952809	0.532	rs6952152	chr7:2440912	G/A	cg23289794	chr7:2394357	EIF3B	-0.76	-4.72	-0.44	8.17e-6	Multiple sclerosis;
THYM	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg03060546	chr3:49711283	APEH	-0.67	-5.08	-0.46	1.85e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg10505658	chr17:80084571	CCDC57	0.68	7.45	0.61	4.18e-11	Life satisfaction;
THYM	cis	rs10463554	0.963	rs40093	chr5:102439825	A/T	cg23492399	chr5:102201601	PAM	-0.69	-5.09	-0.46	1.83e-6	Parkinson's disease;
THYM	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg13010199	chr12:38710504	ALG10B	-0.71	-4.87	-0.45	4.46e-6	Heart rate;
THYM	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg23711669	chr6:146136114	FBXO30	0.96	9.6	0.7	1.17e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg12564285	chr5:131593104	PDLIM4	0.52	5.67	0.5	1.54e-7	Breast cancer;
THYM	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg22907277	chr7:1156413	C7orf50	0.83	5.1	0.46	1.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg11301795	chr4:187892539	NA	-1.12	-16.92	-0.87	2.01e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs524281	0.773	rs10791861	chr11:66008470	G/A	cg00563793	chr11:65837595	PACS1	0.79	4.71	0.43	8.53e-6	Electroencephalogram traits;
THYM	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg08807101	chr21:30365312	RNF160	-0.8	-6.25	-0.54	1.15e-8	Dental caries;
THYM	cis	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg09307838	chr4:120376055	NA	0.78	5.87	0.52	6.42e-8	Corneal astigmatism;
THYM	cis	rs112591243	0.685	rs4819263	chr21:47950866	G/A	cg26904215	chr21:47823096	PCNT	-0.96	-4.47	-0.42	2.17e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg10856724	chr12:34555212	NA	-0.74	-5.54	-0.49	2.74e-7	Resting heart rate;
THYM	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg00631329	chr6:26305371	NA	-0.61	-7.35	-0.6	6.96e-11	Educational attainment;
THYM	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg23422044	chr7:1970798	MAD1L1	-0.9	-6.49	-0.55	3.95e-9	Bipolar disorder;
THYM	cis	rs10274279	1.000	rs55941863	chr7:157372989	C/G	cg25259479	chr7:157408632	PTPRN2	-0.83	-4.7	-0.43	8.94e-6	Myopia (pathological);
THYM	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg27535305	chr1:53392650	SCP2	-0.4	-4.52	-0.42	1.78e-5	Monocyte count;
THYM	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	4.54	0.42	1.66e-5	Total body bone mineral density;
THYM	cis	rs1728785	1.000	rs4783653	chr16:68562815	C/T	cg02972257	chr16:68554789	NA	-0.75	-4.63	-0.43	1.16e-5	Ulcerative colitis;
THYM	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.86	7.4	0.6	5.39e-11	Monocyte percentage of white cells;
THYM	cis	rs3017493	0.786	rs79792601	chr11:70675171	G/A	cg03578926	chr11:70508032	SHANK2	0.86	5.12	0.46	1.6e-6	Renal transplant outcome;
THYM	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg23711669	chr6:146136114	FBXO30	-0.93	-9.39	-0.69	3.39e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg14895029	chr7:2775587	GNA12	-0.68	-4.99	-0.46	2.75e-6	Height;
THYM	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg07362569	chr17:61921086	SMARCD2	0.69	6.16	0.53	1.78e-8	Prudent dietary pattern;
THYM	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg17143192	chr8:8559678	CLDN23	0.91	6.69	0.57	1.56e-9	Obesity-related traits;
THYM	cis	rs554111	0.636	rs10916935	chr1:21432112	T/C	cg01072550	chr1:21505969	NA	0.58	5.06	0.46	2.06e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs9403317	1.000	rs9403315	chr6:141839659	A/G	cg15052665	chr6:141804349	NA	0.84	7.32	0.6	8.01e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg19747945	chr6:42946146	PEX6	-0.32	-4.54	-0.42	1.64e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.12	7.98	0.63	3.38e-12	Cognitive test performance;
THYM	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	9.83	0.71	3.72e-16	Platelet count;
THYM	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg18352616	chr4:3374830	RGS12	0.74	8.26	0.65	8.57e-13	Serum sulfate level;
THYM	cis	rs6032067	0.714	rs35665166	chr20:43865006	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-6.24	-0.54	1.22e-8	Blood protein levels;
THYM	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.64	-4.68	-0.43	9.45e-6	Aortic root size;
THYM	cis	rs4773144	0.966	rs7986871	chr13:110960789	T/A	cg02050376	chr13:109984684	NA	0.24	4.69	0.43	9.12e-6	Coronary artery disease;Coronary heart disease;
THYM	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg11764359	chr7:65958608	NA	0.63	4.92	0.45	3.66e-6	Aortic root size;
THYM	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.28	-5.76	-0.51	1.02e-7	Obesity-related traits;
THYM	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg25703541	chr22:24373054	LOC391322	-0.85	-8.93	-0.68	3.21e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg08439880	chr3:133502540	NA	-0.73	-6.46	-0.55	4.44e-9	Iron status biomarkers;
THYM	cis	rs34526934	0.608	rs66727747	chr2:177032386	T/C	cg26754761	chr2:177040938	NA	-0.74	-6.37	-0.55	6.7e-9	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs3540	0.597	rs3743409	chr15:91045539	T/A	cg22089800	chr15:90895588	ZNF774	-0.69	-5.31	-0.48	7.26e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg18105134	chr13:113819100	PROZ	-1.19	-7.86	-0.63	6.05e-12	Platelet distribution width;
THYM	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg04455712	chr21:45112962	RRP1B	-0.51	-4.7	-0.43	8.8e-6	Mean corpuscular volume;
THYM	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg06582575	chr6:163149167	PACRG;PARK2	1.1	7.81	0.63	7.68e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6835098	0.608	rs2332668	chr4:174163360	A/G	cg08422745	chr4:174089978	GALNT7	-0.9	-7.6	-0.61	2.1e-11	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9972944	0.756	rs4791133	chr17:63769118	T/C	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs72901758	0.768	rs11657271	chr17:76249682	A/T	cg25512537	chr17:76250053	NA	0.42	6.27	0.54	1.06e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
THYM	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.91	8.79	0.67	6.37e-14	Menarche (age at onset);
THYM	cis	rs4396968	1.000	rs4396968	chr4:47089184	C/T	cg12205729	chr4:46391694	GABRA2	0.75	4.5	0.42	1.95e-5	Cervical cancer;
THYM	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg02478829	chr6:26598070	ABT1	-0.33	-4.46	-0.42	2.27e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg19626725	chr5:178986131	RUFY1	0.32	5.06	0.46	2.05e-6	Lung cancer;
THYM	cis	rs2354432	0.607	rs12404113	chr1:146750343	C/A	cg25205988	chr1:146714368	CHD1L	-1.04	-5.56	-0.5	2.5e-7	Mitochondrial DNA levels;
THYM	cis	rs7178572	1.000	rs8034133	chr15:77763712	C/G	cg22256960	chr15:77711686	NA	-0.94	-7.93	-0.63	4.23e-12	Type 2 diabetes;
THYM	cis	rs1062753	0.961	rs9620007	chr22:42405657	C/G	cg09667013	chr22:42394590	WBP2NL	0.54	4.8	0.44	5.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs6430585	0.528	rs12464050	chr2:136663110	G/T	cg04750100	chr2:136595281	LCT	0.56	4.96	0.45	3.03e-6	Corneal structure;
THYM	cis	rs7089973	0.872	rs10490908	chr10:116616162	T/C	cg23260525	chr10:116636907	FAM160B1	0.51	4.57	0.42	1.49e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs4732038	0.510	rs28589907	chr7:134270567	C/T	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg26384229	chr12:38710491	ALG10B	-0.71	-5.53	-0.49	2.8e-7	Morning vs. evening chronotype;
THYM	cis	rs4731207	0.596	rs12540261	chr7:124586837	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.96	-5.51	-0.49	3e-7	Red cell distribution width;
THYM	cis	rs9906944	0.713	rs9899580	chr17:47106878	T/G	cg11673840	chr17:47092156	IGF2BP1	-0.54	-5.48	-0.49	3.55e-7	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs11696501	0.739	rs6073843	chr20:44293956	G/A	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg17644776	chr2:200775616	C2orf69	0.8	4.82	0.44	5.52e-6	Schizophrenia;
THYM	cis	rs12310956	0.532	rs2171534	chr12:33838998	C/T	cg10856724	chr12:34555212	NA	-0.65	-5.64	-0.5	1.72e-7	Morning vs. evening chronotype;
THYM	cis	rs11785693	0.862	rs11778306	chr8:4988269	A/C	cg26367366	chr8:4980734	NA	0.97	5.07	0.46	1.97e-6	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs1691799	0.867	rs1168341	chr12:66759080	G/C	cg16791601	chr12:66731901	HELB	-0.73	-6.86	-0.58	6.96e-10	White blood cell count (basophil);
THYM	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.6	0.43	1.32e-5	Breast cancer;
THYM	cis	rs4888262	0.526	rs7205992	chr16:74590578	T/A	cg01733217	chr16:74700730	RFWD3	0.8	8.28	0.65	7.82e-13	Testicular germ cell tumor;
THYM	cis	rs2933343	0.649	rs789219	chr3:128592520	G/A	cg11901034	chr3:128598214	ACAD9	-0.7	-5.68	-0.5	1.47e-7	IgG glycosylation;
THYM	cis	rs2237898	0.667	rs34271604	chr11:2879509	C/T	cg12614029	chr11:2160564	INS-IGF2;IGF2AS;IGF2	-1.2	-4.45	-0.42	2.33e-5	Mosquito bite size;
THYM	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg12179176	chr11:130786555	SNX19	0.89	8.25	0.65	8.93e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11077998	0.967	rs60488670	chr17:80522667	T/C	cg10255544	chr17:80519551	FOXK2	0.5	4.45	0.42	2.3e-5	Reticulocyte fraction of red cells;
THYM	cis	rs17443541	0.507	rs7572945	chr2:200470934	T/C	cg03741458	chr2:200468445	NA	-0.75	-5.77	-0.51	9.74e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2219968	0.962	rs4276683	chr8:78939763	T/G	cg00738934	chr8:78996279	NA	0.79	8.42	0.65	3.88e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6964587	0.626	rs68009402	chr7:91516226	G/A	cg17063962	chr7:91808500	NA	-1.0	-8.67	-0.66	1.16e-13	Breast cancer;
THYM	cis	rs192264	0.614	rs7186848	chr16:65987204	A/G	cg02795155	chr16:66785218	DYNC1LI2	-0.6	-5.0	-0.46	2.63e-6	Subjective well-being;
THYM	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg00106254	chr7:1943704	MAD1L1	-0.49	-4.56	-0.42	1.53e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs28595532	1.000	rs28595532	chr4:119716950	A/C	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs16912285	0.688	rs7128427	chr11:24338598	C/T	ch.11.24196551F	chr11:24239977	NA	0.9	6.21	0.54	1.42e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2504916	0.712	rs2481058	chr6:160739236	C/G	cg19643109	chr6:160697625	NA	-0.64	-4.94	-0.45	3.32e-6	Response to hepatitis C treatment;
THYM	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg03388025	chr16:89894329	SPIRE2	0.54	4.54	0.42	1.67e-5	Vitiligo;
THYM	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg26384229	chr12:38710491	ALG10B	0.92	7.55	0.61	2.63e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg14835575	chr10:16859367	RSU1	0.76	6.02	0.53	3.32e-8	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
THYM	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg26028573	chr6:26043587	HIST1H2BB	-0.52	-4.59	-0.43	1.35e-5	Blood metabolite levels;
THYM	cis	rs9534288	0.731	rs2404730	chr13:46617381	G/A	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg11905131	chr22:24372483	LOC391322	-0.92	-9.9	-0.71	2.72e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg16586182	chr3:47516702	SCAP	-0.59	-4.99	-0.46	2.76e-6	Colorectal cancer;
THYM	cis	rs7027203	0.828	rs10761287	chr9:96609150	A/G	cg13679303	chr9:96623674	NA	-0.5	-5.08	-0.46	1.89e-6	DNA methylation (variation);
THYM	cis	rs6918586	0.658	rs198813	chr6:26128226	C/T	cg07061783	chr6:25882402	NA	0.57	4.48	0.42	2.07e-5	Schizophrenia;
THYM	cis	rs6032067	1.000	rs6032042	chr20:43815949	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	trans	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg07211511	chr3:129823064	LOC729375	-1.33	-8.77	-0.67	7.12e-14	Blood pressure (smoking interaction);
THYM	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg13609457	chr4:120235615	NA	0.56	4.88	0.45	4.25e-6	Corneal astigmatism;
THYM	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg23422044	chr7:1970798	MAD1L1	-0.76	-5.24	-0.47	9.64e-7	Bipolar disorder;
THYM	cis	rs924712	0.545	rs9475040	chr6:54712558	G/A	cg19716238	chr6:54711378	FAM83B	-0.47	-4.55	-0.42	1.61e-5	Breast cancer;
THYM	cis	rs7927771	0.524	rs10838740	chr11:47679980	A/G	cg20307385	chr11:47447363	PSMC3	0.62	4.75	0.44	7.08e-6	Subjective well-being;
THYM	cis	rs1971762	0.545	rs10747675	chr12:54000031	A/G	cg16917193	chr12:54089295	NA	-0.71	-6.64	-0.56	1.94e-9	Height;
THYM	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.85	0.74	2.52e-18	Chronic sinus infection;
THYM	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg21784768	chr11:537496	LRRC56	-1.16	-5.78	-0.51	9.66e-8	Body mass index;
THYM	cis	rs3126085	0.935	rs1552995	chr1:152171427	A/G	cg10321714	chr1:152280068	FLG	0.68	5.07	0.46	1.98e-6	Atopic dermatitis;
THYM	cis	rs9378357	0.510	rs4555972	chr6:3281273	C/T	cg08754725	chr6:3293098	SLC22A23	0.66	4.85	0.45	4.87e-6	Obesity-related traits;
THYM	cis	rs728616	0.614	rs3934643	chr10:81736817	G/A	cg27452691	chr10:81370291	SFTPA1	0.59	4.6	0.43	1.33e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg25072359	chr17:41440525	NA	0.69	4.83	0.44	5.17e-6	Menopause (age at onset);
THYM	cis	rs10799590	1.000	rs4653404	chr1:224879582	A/G	cg01808320	chr1:224927238	CNIH3	0.51	4.53	0.42	1.68e-5	Opioid dependence;
THYM	trans	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg15655154	chr3:113604241	GRAMD1C	0.87	7.13	0.59	1.92e-10	Diastolic blood pressure;
THYM	cis	rs1050631	0.592	rs1789527	chr18:33712229	C/G	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.58	4.56	0.42	1.54e-5	Esophageal squamous cell cancer (length of survival);
THYM	trans	rs877282	0.853	rs7079450	chr10:755932	T/A	cg22713356	chr15:30763199	NA	1.27	9.37	0.69	3.62e-15	Uric acid levels;
THYM	cis	rs35883536	0.967	rs9434126	chr1:101106981	A/G	cg06223162	chr1:101003688	GPR88	-0.68	-5.22	-0.47	1.06e-6	Monocyte count;
THYM	cis	rs2985684	0.894	rs6572586	chr14:50021941	A/C	cg02151108	chr14:50098012	C14orf104	-0.76	-6.49	-0.55	3.96e-9	Carotid intima media thickness;
THYM	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg03806693	chr22:41940476	POLR3H	-1.24	-10.83	-0.74	2.84e-18	Vitiligo;
THYM	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg14784868	chr12:69753453	YEATS4	1.13	10.92	0.75	1.82e-18	Blood protein levels;
THYM	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg13319975	chr6:146136371	FBXO30	-0.69	-5.65	-0.5	1.7e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg12935359	chr14:103987150	CKB	-0.63	-5.84	-0.51	7.4e-8	Body mass index;
THYM	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg03929089	chr4:120376271	NA	-0.94	-10.63	-0.74	7.58e-18	Height;
THYM	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.55	-5.38	-0.48	5.38e-7	Longevity;Endometriosis;
THYM	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg13447684	chr7:1895903	MAD1L1	0.54	4.81	0.44	5.71e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg03909863	chr11:638404	DRD4	-0.76	-6.04	-0.53	2.95e-8	Systemic lupus erythematosus;
THYM	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg12893697	chr11:970389	AP2A2	-0.32	-5.35	-0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	5.1	0.46	1.74e-6	Tonsillectomy;
THYM	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06634786	chr22:41940651	POLR3H	0.63	4.92	0.45	3.62e-6	Vitiligo;
THYM	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg08508325	chr11:3079039	CARS	-0.49	-6.31	-0.54	8.74e-9	Type 2 diabetes;
THYM	cis	rs13185784	0.703	rs17627536	chr5:179678603	G/A	cg13944838	chr5:179740914	GFPT2	0.75	5.05	0.46	2.15e-6	TRAIL levels;
THYM	cis	rs9790314	1.000	rs6441373	chr3:161026717	T/G	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg05025164	chr4:1340916	KIAA1530	0.91	7.06	0.59	2.68e-10	Longevity;
THYM	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg13695892	chr22:41940480	POLR3H	-0.67	-5.07	-0.46	1.98e-6	Vitiligo;
THYM	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg18681998	chr4:17616180	MED28	0.98	9.85	0.71	3.43e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg05335186	chr13:53173507	NA	0.49	7.21	0.59	1.36e-10	Lewy body disease;
THYM	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg08008072	chr16:1524255	CLCN7	-0.55	-6.94	-0.58	4.75e-10	Bone mineral density;
THYM	cis	rs7089973	0.872	rs7909657	chr10:116629096	C/G	cg23260525	chr10:116636907	FAM160B1	0.52	4.72	0.44	8.04e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg22709100	chr7:91322751	NA	-0.6	-4.8	-0.44	5.84e-6	Breast cancer;
THYM	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg23205692	chr1:25664452	TMEM50A	0.86	6.69	0.57	1.54e-9	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs72720396	0.789	rs10922910	chr1:91199862	G/T	cg13456504	chr1:91191583	NA	0.78	5.3	0.48	7.56e-7	Morning vs. evening chronotype;Chronotype;
THYM	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg05973401	chr12:123451056	ABCB9	0.69	4.59	0.43	1.36e-5	Neutrophil percentage of white cells;
THYM	cis	rs4788570	0.545	rs8044144	chr16:71783121	T/C	cg06353428	chr16:71660113	MARVELD3	1.39	9.52	0.7	1.78e-15	Intelligence (multi-trait analysis);
THYM	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs1003719	0.762	rs3787780	chr21:38462614	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.67	4.61	0.43	1.25e-5	Eye color traits;
THYM	cis	rs7507204	1.000	rs7507204	chr19:3428834	G/C	cg08380311	chr19:3435252	NFIC	0.88	7.17	0.59	1.62e-10	Height;
THYM	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg00071950	chr4:10020882	SLC2A9	0.86	10.33	0.73	3.3e-17	Bone mineral density;
THYM	trans	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg10856724	chr12:34555212	NA	-1.01	-8.94	-0.68	3.02e-14	Bladder cancer;
THYM	cis	rs6840360	0.539	rs1443087	chr4:152450095	C/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-5.66	-0.5	1.6e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg10117171	chr1:25599238	RHD	0.64	4.47	0.42	2.14e-5	Erythrocyte sedimentation rate;
THYM	cis	rs765787	0.530	rs12909987	chr15:45512207	C/T	cg25801113	chr15:45476975	SHF	0.39	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg24209194	chr3:40518798	ZNF619	0.63	5.06	0.46	2.04e-6	Renal cell carcinoma;
THYM	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg02734326	chr4:10020555	SLC2A9	-0.71	-6.2	-0.54	1.44e-8	Bone mineral density;
THYM	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06850241	chr22:41845214	NA	-0.57	-5.05	-0.46	2.17e-6	Vitiligo;
THYM	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.27	-5.73	-0.51	1.2e-7	Obesity-related traits;
THYM	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg13147721	chr7:65941812	NA	-0.74	-4.72	-0.44	8.2e-6	Diabetic kidney disease;
THYM	cis	rs870825	0.655	rs6845058	chr4:185653696	G/A	cg04058563	chr4:185651563	MLF1IP	-0.99	-7.67	-0.62	1.46e-11	Blood protein levels;
THYM	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg18252515	chr7:66147081	NA	-0.67	-5.08	-0.46	1.86e-6	Aortic root size;
THYM	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg26038318	chr20:34205095	SPAG4	0.64	5.22	0.47	1.04e-6	Total cholesterol levels;
THYM	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg18305652	chr10:134549665	INPP5A	0.82	6.76	0.57	1.11e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs886716	0.692	rs13243495	chr7:26567342	G/A	cg26364809	chr7:27145159	NA	-0.39	-4.66	-0.43	1.02e-5	Smoking behavior;
THYM	cis	rs4664308	1.000	rs925410	chr2:160912652	C/T	cg03641300	chr2:160917029	PLA2R1	0.76	6.89	0.58	6.12e-10	Idiopathic membranous nephropathy;
THYM	cis	rs9902453	0.689	rs7216948	chr17:28203173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	5.91	0.52	5.32e-8	Coffee consumption (cups per day);
THYM	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs16912285	0.591	rs12794505	chr11:24364195	A/G	ch.11.24196551F	chr11:24239977	NA	-0.84	-5.9	-0.52	5.47e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs939658	1.000	rs8031019	chr15:79458512	C/T	cg17916960	chr15:79447300	NA	-0.77	-9.35	-0.69	4e-15	Refractive error;
THYM	cis	rs686320	1.000	rs1194758	chr11:65238085	A/T	cg19332572	chr11:65321591	LTBP3	-0.88	-5.52	-0.49	2.91e-7	Hip circumference adjusted for BMI;
THYM	cis	rs7523273	0.597	rs4844390	chr1:207934849	A/G	cg22525895	chr1:207977042	MIR29B2	-0.74	-4.9	-0.45	3.87e-6	Schizophrenia;
THYM	cis	rs17253792	0.822	rs118027213	chr14:56039076	T/C	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg19875535	chr5:140030758	IK	-0.63	-5.69	-0.5	1.43e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.87e-6	Resting heart rate;
THYM	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.52	4.66	0.43	1.03e-5	Lymphocyte counts;
THYM	cis	rs6032067	0.538	rs13042667	chr20:43739664	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.54	-4.74	-0.44	7.44e-6	Blood protein levels;
THYM	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg13695892	chr22:41940480	POLR3H	0.87	6.35	0.55	7.28e-9	Vitiligo;
THYM	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg04520793	chr17:42248056	ASB16	-0.34	-4.78	-0.44	6.45e-6	Total body bone mineral density;
THYM	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg23711669	chr6:146136114	FBXO30	0.89	8.8	0.67	5.96e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg20295408	chr7:1910781	MAD1L1	-0.61	-4.85	-0.45	4.75e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg15704280	chr7:45808275	SEPT13	-0.98	-11.44	-0.76	1.43e-19	Coronary artery disease;
THYM	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11167764	1.000	rs3761757	chr5:141488219	A/C	cg23435118	chr5:141488016	NDFIP1	-0.52	-4.52	-0.42	1.79e-5	Crohn's disease;
THYM	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg23989207	chr17:80870107	TBCD	0.62	5.15	0.47	1.42e-6	Glycated hemoglobin levels;
THYM	cis	rs4747241	0.591	rs10823913	chr10:74067344	A/G	cg07828833	chr10:74069493	NA	0.59	5.08	0.46	1.9e-6	Heschl's gyrus morphology;
THYM	cis	rs11690935	0.838	rs10432423	chr2:172753295	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.73	-5.6	-0.5	2.06e-7	Schizophrenia;
THYM	cis	rs7712401	0.577	rs4422528	chr5:122374843	A/C	cg19808643	chr5:122110361	SNX2	-0.61	-5.57	-0.5	2.34e-7	Mean platelet volume;
THYM	cis	rs2505998	0.833	rs2565204	chr10:43603173	T/C	cg06632098	chr10:43605906	RET	-1.11	-11.36	-0.76	2.13e-19	Hirschsprung disease;
THYM	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.86	-0.45	4.62e-6	Eye color traits;
THYM	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg27394845	chr17:28928406	LRRC37B2	0.96	4.77	0.44	6.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs11186	0.556	rs61199451	chr2:189952711	C/T	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs453193	0.789	rs2630707	chr2:8447203	A/C	cg12167548	chr2:8464763	NA	-0.44	-4.63	-0.43	1.17e-5	Granulocyte percentage of myeloid white cells;
THYM	cis	rs7705502	1.000	rs7736263	chr5:173339222	G/T	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg26967526	chr14:35346199	BAZ1A	-0.7	-4.65	-0.43	1.09e-5	Psoriasis;
THYM	cis	rs16917546	0.935	rs10995271	chr10:64438486	G/C	cg03961010	chr10:64397487	ZNF365	-0.67	-5.43	-0.49	4.34e-7	Basal cell carcinoma;
THYM	cis	rs939574	0.799	rs1109867	chr2:220083453	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.2	-5.46	-0.49	3.84e-7	Platelet distribution width;
THYM	cis	rs6732160	0.845	rs9989755	chr2:73361948	T/C	cg24220031	chr2:73402428	NA	-0.73	-7.38	-0.6	6.1e-11	Intelligence (multi-trait analysis);
THYM	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.55	-5.42	-0.49	4.55e-7	Crohn's disease;
THYM	cis	rs2268241	0.938	rs2268242	chr21:34781104	C/T	cg14850771	chr21:34775459	IFNGR2	1.04	6.96	0.58	4.26e-10	Obesity-related traits;
THYM	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4851254	0.618	rs7572939	chr2:100654914	A/G	cg22139774	chr2:100720529	AFF3	-0.4	-4.52	-0.42	1.78e-5	Intelligence (multi-trait analysis);
THYM	trans	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg19862616	chr7:65841803	NCRNA00174	1.09	12.64	0.79	4.47e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg16486109	chr11:613632	IRF7	0.47	5.59	0.5	2.19e-7	Systemic lupus erythematosus;
THYM	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.32	0.54	8.42e-9	Platelet count;
THYM	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg26061582	chr7:22766209	IL6	0.64	5.07	0.46	1.96e-6	Lung cancer;
THYM	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg11245990	chr11:68621969	NA	0.57	7.46	0.61	4.06e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg04602696	chr16:88846723	FAM38A	-0.64	-4.91	-0.45	3.71e-6	Plateletcrit;
THYM	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg25072359	chr17:41440525	NA	0.64	4.48	0.42	2.05e-5	Menopause (age at onset);
THYM	cis	rs4925386	1.000	rs4925382	chr20:60918542	G/C	cg06026331	chr20:60912101	LAMA5	-0.62	-4.9	-0.45	3.89e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs9992101	0.588	rs62300830	chr4:77221028	A/T	cg20311846	chr4:77356250	SHROOM3	-0.51	-5.64	-0.5	1.71e-7	Creatinine levels;
THYM	cis	rs1045902	0.583	rs2303904	chr2:73447775	C/T	cg24220031	chr2:73402428	NA	0.68	6.57	0.56	2.64e-9	Intelligence (multi-trait analysis);
THYM	cis	rs13040088	1.000	rs12480870	chr20:61543606	A/C	cg23096297	chr20:61557774	DIDO1	1.06	7.36	0.6	6.63e-11	Menopause (age at onset);
THYM	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg18876405	chr7:65276391	NA	-0.57	-4.86	-0.45	4.62e-6	Aortic root size;
THYM	cis	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg06521331	chr12:34319734	NA	-0.73	-5.66	-0.5	1.59e-7	Morning vs. evening chronotype;
THYM	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg12560992	chr17:57184187	TRIM37	0.92	8.53	0.66	2.29e-13	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.635	rs1825746	chr12:33939984	C/T	cg10856724	chr12:34555212	NA	-0.63	-5.87	-0.52	6.49e-8	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs34375054	0.660	rs12578446	chr12:125605887	A/G	cg25124228	chr12:125621409	AACS	-0.72	-5.71	-0.51	1.3e-7	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs596169	0.764	rs6693640	chr1:219160601	C/A	cg19270308	chr1:218458869	RRP15	-1.24	-4.52	-0.42	1.81e-5	Intraocular pressure;
THYM	cis	rs699	0.520	rs2479130	chr1:230818411	A/G	cg11527913	chr1:230410329	GALNT2	0.28	4.54	0.42	1.63e-5	Coronary artery disease;
THYM	cis	rs1950626	0.750	rs12895798	chr14:101442793	T/C	cg11887864	chr14:101510502	MIR1185-2	0.55	4.63	0.43	1.17e-5	Pelvic organ prolapse (moderate/severe);
THYM	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg16325326	chr1:53192061	ZYG11B	0.97	11.07	0.75	8.85e-19	Monocyte count;
THYM	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg02018176	chr4:1364513	KIAA1530	-0.81	-7.69	-0.62	1.37e-11	Obesity-related traits;
THYM	trans	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg20290983	chr6:43655470	MRPS18A	1.19	7.74	0.62	1.07e-11	IgG glycosylation;
THYM	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06481639	chr22:41940642	POLR3H	-0.79	-5.46	-0.49	3.87e-7	Vitiligo;
THYM	cis	rs1728785	1.000	rs1645981	chr16:68571648	T/C	cg02972257	chr16:68554789	NA	-0.74	-4.54	-0.42	1.63e-5	Ulcerative colitis;
THYM	cis	rs13082711	0.911	rs77037289	chr3:27512971	C/T	cg02860705	chr3:27208620	NA	0.72	5.06	0.46	2.01e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs4731207	0.596	rs10255638	chr7:124576255	C/T	cg05285228	chr7:124571219	POT1	0.72	5.51	0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs747782	0.527	rs75915859	chr11:48232931	C/T	cg24672777	chr11:48374446	OR4C45	-1.15	-6.73	-0.57	1.29e-9	Intraocular pressure;
THYM	cis	rs7216064	1.000	rs60432293	chr17:65860407	T/C	cg12091567	chr17:66097778	LOC651250	-0.71	-4.76	-0.44	6.86e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs4642101	0.628	rs1003080	chr3:12811628	C/T	cg11882607	chr3:12858926	CAND2	0.42	4.88	0.45	4.2e-6	QRS complex (12-leadsum);
THYM	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg11366901	chr6:160182831	ACAT2	1.02	9.15	0.68	1.08e-14	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs1150668	0.796	rs2531825	chr6:28349264	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.55	-4.61	-0.43	1.25e-5	Pubertal anthropometrics;
THYM	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg14895029	chr7:2775587	GNA12	-0.7	-5.09	-0.46	1.83e-6	Height;
THYM	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg08355456	chr11:67383691	NA	0.85	7.13	0.59	2e-10	Mean corpuscular volume;
THYM	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg07371521	chr5:154026371	NA	-0.57	-5.45	-0.49	3.96e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs192264	0.614	rs393892	chr16:65975397	C/G	cg02795155	chr16:66785218	DYNC1LI2	0.58	4.68	0.43	9.41e-6	Subjective well-being;
THYM	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg25427524	chr10:38739819	LOC399744	0.66	6.09	0.53	2.38e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg09455208	chr3:40491958	NA	-0.5	-5.21	-0.47	1.11e-6	Renal cell carcinoma;
THYM	cis	rs12478296	0.591	rs12719765	chr2:242997202	C/G	cg06360820	chr2:242988706	NA	-0.81	-5.29	-0.48	7.84e-7	Obesity-related traits;
THYM	cis	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg06377222	chr21:46677750	NA	-0.48	-4.46	-0.42	2.22e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg13010199	chr12:38710504	ALG10B	0.71	5.77	0.51	9.75e-8	Heart rate;
THYM	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22857025	chr5:266934	NA	-1.5	-9.71	-0.71	6.9e-16	Breast cancer;
THYM	cis	rs9807841	0.858	rs10410775	chr19:10856273	T/C	cg17848348	chr19:10766748	ILF3	-0.62	-5.01	-0.46	2.51e-6	Inflammatory skin disease;
THYM	cis	rs11089937	0.716	rs743517	chr22:22521525	G/T	cg21401457	chr22:22472743	NA	0.55	4.64	0.43	1.12e-5	Periodontitis (PAL4Q3);
THYM	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs12579753	0.913	rs12579018	chr12:82231943	T/C	cg21231944	chr12:82153410	PPFIA2	-0.66	-4.89	-0.45	4.15e-6	Resting heart rate;
THYM	cis	rs752010	0.967	rs6675999	chr1:42099024	T/G	cg22486000	chr1:42919398	ZMYND12	-0.41	-4.64	-0.43	1.12e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs863345	0.604	rs10908656	chr1:158461016	A/G	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs422249	0.547	rs174537	chr11:61552680	G/T	cg19610905	chr11:61596333	FADS2	-0.6	-5.1	-0.46	1.76e-6	Trans fatty acid levels;
THYM	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg13918804	chr1:2043761	PRKCZ	-0.68	-5.94	-0.52	4.68e-8	Height;
THYM	cis	rs3126085	0.935	rs10888475	chr1:152226012	C/T	cg26020982	chr1:152196106	HRNR	0.36	4.91	0.45	3.72e-6	Atopic dermatitis;
THYM	cis	rs2239547	0.522	rs2336669	chr3:52994138	C/T	cg11645453	chr3:52864694	ITIH4	-0.29	-4.48	-0.42	2.06e-5	Schizophrenia;
THYM	cis	rs11969893	0.850	rs9498409	chr6:101299966	G/A	cg12253828	chr6:101329408	ASCC3	1.21	6.92	0.58	5.19e-10	Economic and political preferences (immigration/crime);
THYM	cis	rs4792901	0.959	rs4792998	chr17:41652781	C/T	cg21940313	chr17:41620911	ETV4	0.45	4.76	0.44	6.89e-6	Dupuytren's disease;
THYM	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	8.49	0.66	2.81e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6424115	1.000	rs35385477	chr1:24155924	G/A	cg15997130	chr1:24165203	NA	0.78	7.04	0.59	2.94e-10	Immature fraction of reticulocytes;
THYM	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8133932	0.736	rs4818804	chr21:47282631	T/C	cg08707771	chr21:46690014	POFUT2	-0.79	-4.79	-0.44	6.02e-6	Schizophrenia;
THYM	cis	rs12956009	0.583	rs16952069	chr18:44904220	T/A	cg19077165	chr18:44547161	KATNAL2	-0.5	-4.76	-0.44	6.97e-6	Educational attainment (years of education);
THYM	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg09323728	chr8:95962352	TP53INP1	-0.44	-4.56	-0.42	1.53e-5	Type 2 diabetes;
THYM	cis	rs7851660	0.527	rs7859751	chr9:100575888	C/T	cg13688889	chr9:100608707	NA	-0.89	-7.25	-0.6	1.09e-10	Strep throat;
THYM	cis	rs490234	0.812	rs4838285	chr9:128446888	C/T	cg14078157	chr9:128172775	NA	-0.68	-5.34	-0.48	6.23e-7	Mean arterial pressure;
THYM	cis	rs34779708	0.966	rs12784482	chr10:35446865	A/G	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg10560079	chr2:191398806	TMEM194B	0.88	7.8	0.63	7.77e-12	Pulse pressure;
THYM	cis	rs2033562	1.000	rs2033562	chr8:103547739	G/C	cg20611272	chr8:103548145	NA	0.41	5.09	0.46	1.77e-6	IgA nephropathy;
THYM	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg21385522	chr1:16154831	NA	0.65	4.61	0.43	1.28e-5	Dilated cardiomyopathy;
THYM	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg04398451	chr17:18023971	MYO15A	0.89	7.89	0.63	5.03e-12	Total body bone mineral density;
THYM	cis	rs208520	0.690	rs207112	chr6:66792092	C/T	cg07460842	chr6:66804631	NA	-1.06	-7.89	-0.63	5.14e-12	Exhaled nitric oxide output;
THYM	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg11752832	chr7:134001865	SLC35B4	0.68	4.93	0.45	3.53e-6	Mean platelet volume;
THYM	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.83	0.67	5.15e-14	Colorectal cancer;
THYM	cis	rs11771526	0.901	rs62457502	chr7:32330797	C/T	cg27532318	chr7:32358331	NA	0.69	4.46	0.42	2.22e-5	Body mass index;
THYM	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg24450063	chr1:156163899	SLC25A44	1.21	15.33	0.84	1.98e-27	Testicular germ cell tumor;
THYM	cis	rs4589258	1.000	rs4601725	chr11:90456066	A/G	cg26138821	chr11:89956704	CHORDC1	-0.63	-5.12	-0.47	1.58e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg06238570	chr21:40685208	BRWD1	-0.96	-9.14	-0.68	1.13e-14	Cognitive function;
THYM	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg11301795	chr4:187892539	NA	-1.12	-16.92	-0.87	2.01e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs698833	0.501	rs35347977	chr2:44506921	C/T	cg04920474	chr2:44395004	PPM1B	0.63	6.28	0.54	1.01e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
THYM	cis	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg07460842	chr6:66804631	NA	-0.85	-5.48	-0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs3781426	0.576	rs2028395	chr10:126726558	G/C	cg04494136	chr10:126703576	CTBP2	-0.39	-5.51	-0.49	3.1e-7	Height;
THYM	cis	rs791590	1.000	rs791590	chr10:6090322	A/T	cg17191567	chr10:6178319	NA	0.74	5.09	0.46	1.8e-6	Soluble interleukin-2 receptor subunit alpha;
THYM	cis	rs8067545	0.611	rs2703771	chr17:20130154	C/G	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs9543976	0.920	rs9543992	chr13:76175074	G/A	cg01531495	chr13:76123901	UCHL3	0.75	5.05	0.46	2.1e-6	Diabetic retinopathy;
THYM	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03264133	chr6:25882463	NA	-0.8	-6.16	-0.53	1.7e-8	Intelligence (multi-trait analysis);
THYM	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg10053473	chr17:62856997	LRRC37A3	-0.89	-7.04	-0.59	2.97e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs637571	0.607	rs574586	chr11:65697083	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.7	5.31	0.48	7.04e-7	Eosinophil percentage of white cells;
THYM	cis	rs2075230	0.588	rs1641530	chr17:7548052	T/C	cg27413385	chr17:7515425	FXR2	-0.35	-4.92	-0.45	3.63e-6	Hormone measurements;
THYM	cis	rs9905704	0.647	rs8077332	chr17:57105223	A/G	cg12560992	chr17:57184187	TRIM37	0.68	5.32	0.48	6.95e-7	Testicular germ cell tumor;
THYM	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg12165864	chr7:66369176	NA	0.65	5.05	0.46	2.12e-6	Aortic root size;
THYM	cis	rs9828933	0.752	rs13433909	chr3:63948609	C/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.87	-5.66	-0.5	1.58e-7	Type 2 diabetes;
THYM	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06634786	chr22:41940651	POLR3H	-0.72	-5.25	-0.47	9.37e-7	Vitiligo;
THYM	cis	rs986417	0.901	rs1956558	chr14:60975956	T/C	cg27398547	chr14:60952738	C14orf39	1.14	5.33	0.48	6.64e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs12681287	0.640	rs12550142	chr8:87471861	C/A	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	cg06064525	chr11:970664	AP2A2	-0.35	-6.8	-0.57	9.32e-10	Alzheimer's disease (late onset);
THYM	cis	rs13418717	1.000	rs13393833	chr2:127653076	C/T	cg25501666	chr2:127640322	NA	1.64	6.58	0.56	2.51e-9	Heart failure;
THYM	cis	rs4509693	0.941	rs7914169	chr10:102495725	A/G	cg24127310	chr10:102502104	NA	1.31	11.03	0.75	1.05e-18	Alzheimer's disease;
THYM	cis	rs2976388	1.000	rs2920293	chr8:143765414	C/G	cg13446199	chr8:143762866	PSCA	0.51	6.42	0.55	5.3300000000000004e-09	Urinary tract infection frequency;
THYM	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg23422044	chr7:1970798	MAD1L1	0.85	5.98	0.52	3.82e-8	Bipolar disorder;
THYM	cis	rs4631830	0.900	rs10763534	chr10:51534920	C/T	cg10326726	chr10:51549505	MSMB	-0.58	-5.76	-0.51	1.04e-7	Prostate-specific antigen levels;
THYM	cis	rs2273669	0.667	rs76094073	chr6:109288036	C/G	cg17117243	chr6:109341365	SESN1	-0.86	-4.9	-0.45	3.88e-6	Prostate cancer;
THYM	cis	rs2637266	0.783	rs12268496	chr10:78487192	G/A	cg18941641	chr10:78392320	NA	0.69	5.68	0.5	1.49e-7	Pulmonary function;
THYM	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg06766960	chr11:133703094	NA	-0.52	-4.83	-0.44	5.25e-6	Childhood ear infection;
THYM	cis	rs921968	0.643	rs483172	chr2:219428299	A/G	cg02176678	chr2:219576539	TTLL4	0.64	6.03	0.53	3.08e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11992162	0.591	rs4240678	chr8:11802426	C/T	cg21775007	chr8:11205619	TDH	-0.62	-4.91	-0.45	3.79e-6	Monocyte count;
THYM	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg19016782	chr12:123741754	C12orf65	-0.7	-4.55	-0.42	1.6e-5	Neutrophil percentage of white cells;
THYM	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4821544	1.000	rs4821544	chr22:37258503	C/T	cg09624565	chr22:37256900	NCF4	-0.28	-4.66	-0.43	1.03e-5	Sum eosinophil basophil counts;Atopic dermatitis;Eosinophil counts;Crohn's disease;
THYM	cis	rs478304	0.654	rs1074156	chr11:65458169	G/T	cg17480646	chr11:65405466	SIPA1	-0.93	-8.16	-0.64	1.38e-12	Acne (severe);
THYM	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg05896524	chr21:47604654	C21orf56	-0.69	-4.87	-0.45	4.4e-6	Testicular germ cell tumor;
THYM	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg08470875	chr2:26401718	FAM59B	-0.72	-4.61	-0.43	1.24e-5	Gut microbiome composition (summer);
THYM	cis	rs7695732	0.595	rs2704577	chr4:89894446	T/C	cg17769793	chr4:89976368	FAM13A	-0.5	-5.57	-0.5	2.36e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg27534772	chr1:16042836	PLEKHM2	0.53	6.07	0.53	2.6e-8	Systolic blood pressure;
THYM	cis	rs9826463	0.582	rs11714244	chr3:142138294	C/T	cg20824294	chr3:142316082	PLS1	0.78	5.31	0.48	7.2e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg23758822	chr17:41437982	NA	1.22	13.08	0.8	5.68e-23	Menopause (age at onset);
THYM	cis	rs1348850	0.560	rs13019660	chr2:178498214	C/T	cg27490568	chr2:178487706	NA	0.62	5.69	0.5	1.39e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	trans	rs17286411	0.836	rs7350856	chr16:71951094	G/T	cg00109465	chr12:54121359	CALCOCO1	-0.98	-6.94	-0.58	4.82e-10	Blood protein levels;
THYM	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg00012203	chr2:219082015	ARPC2	0.57	4.99	0.46	2.74e-6	Colorectal cancer;
THYM	cis	rs11651000	0.894	rs66490177	chr17:45817723	T/C	cg24803719	chr17:45855879	NA	-0.64	-5.14	-0.47	1.47e-6	IgG glycosylation;
THYM	cis	rs8050907	0.744	rs17879291	chr16:4526104	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.58	0.43	1.38e-5	Obesity-related traits;
THYM	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg18252515	chr7:66147081	NA	-1.57	-8.55	-0.66	2.07e-13	Diabetic kidney disease;
THYM	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg09197432	chr4:183729176	NA	0.83	5.18	0.47	1.22e-6	Pediatric autoimmune diseases;
THYM	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.67	5.22	0.47	1.06e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11785693	0.862	rs11784262	chr8:4996942	G/A	cg26367366	chr8:4980734	NA	0.98	5.14	0.47	1.48e-6	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs4499344	0.657	rs402862	chr19:33111102	C/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.91	6.34	0.55	7.69e-9	Mean platelet volume;
THYM	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg18105134	chr13:113819100	PROZ	0.96	9.12	0.68	1.24e-14	Platelet distribution width;
THYM	cis	rs4930103	0.935	rs2525881	chr11:2019333	T/C	cg21926276	chr11:2035255	NA	0.27	4.53	0.42	1.7e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg11494091	chr17:61959527	GH2	1.07	17.57	0.87	1.34e-31	Prudent dietary pattern;
THYM	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg23803603	chr1:2058230	PRKCZ	0.59	4.56	0.42	1.52e-5	Height;
THYM	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg03929089	chr4:120376271	NA	-0.94	-10.74	-0.74	4.27e-18	Coronary artery disease;
THYM	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg04944784	chr2:26401820	FAM59B	-0.62	-4.82	-0.44	5.41e-6	Gut microbiome composition (summer);
THYM	cis	rs34912216	0.580	rs7779346	chr7:4133298	C/G	cg26550874	chr7:4183528	SDK1	0.6	4.46	0.42	2.22e-5	Motion sickness;
THYM	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg19346786	chr7:2764209	NA	-0.54	-4.58	-0.43	1.42e-5	Height;
THYM	cis	rs2133450	0.526	rs10510356	chr3:7350877	C/G	cg19930620	chr3:7340148	GRM7	-0.51	-5.43	-0.49	4.23e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs6754311	0.551	rs10928545	chr2:136501840	A/G	cg20242066	chr2:136595261	LCT	-0.57	-6.88	-0.58	6.42e-10	Mosquito bite size;
THYM	cis	rs7177699	0.557	rs10083696	chr15:79124016	G/A	cg15571903	chr15:79123663	NA	-0.57	-6.35	-0.55	7.46e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	0.58	5.84	0.51	7.42e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9790314	0.875	rs163327	chr3:161062724	A/G	cg03342759	chr3:160939853	NMD3	-0.68	-6.02	-0.53	3.28e-8	Morning vs. evening chronotype;
THYM	cis	rs11690935	0.632	rs17581284	chr2:172659376	C/T	cg13550731	chr2:172543902	DYNC1I2	0.64	5.23	0.47	9.97e-7	Schizophrenia;
THYM	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg03709012	chr19:19516395	GATAD2A	-0.74	-5.8	-0.51	8.48e-8	Tonsillectomy;
THYM	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg10856724	chr12:34555212	NA	-1.05	-10.84	-0.74	2.69e-18	Morning vs. evening chronotype;
THYM	cis	rs2732480	0.577	rs2732448	chr12:48730600	T/C	cg21466736	chr12:48725269	NA	-0.6	-5.36	-0.48	5.86e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg19761014	chr17:28927070	LRRC37B2	0.7	4.47	0.42	2.12e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg12963246	chr6:28129442	ZNF389	0.72	6.2	0.54	1.44e-8	Depression;
THYM	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg06763375	chr16:89025547	CBFA2T3	0.64	5.83	0.51	7.76e-8	Social autistic-like traits;
THYM	cis	rs198389	0.568	rs12406667	chr1:11873851	C/T	cg24844545	chr1:11908347	NPPA	0.5	4.82	0.44	5.39e-6	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
THYM	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs250585	0.736	rs6497669	chr16:23534249	G/C	cg00143387	chr16:23521605	GGA2	-0.72	-4.58	-0.42	1.43e-5	Egg allergy;
THYM	cis	rs10929159	0.928	rs2123512	chr2:236920731	C/T	cg14895183	chr2:236924282	AGAP1	0.52	4.59	0.43	1.37e-5	Parkinson's disease;
THYM	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg18681998	chr4:17616180	MED28	0.79	6.77	0.57	1.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs586688	0.556	rs1256473	chr1:201652342	T/G	cg14168733	chr1:201708718	NAV1	-0.62	-5.8	-0.51	8.6e-8	Obesity-related traits;
THYM	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg01416388	chr22:39784598	NA	-0.86	-6.68	-0.57	1.58e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg03388025	chr16:89894329	SPIRE2	0.55	4.76	0.44	7e-6	Vitiligo;
THYM	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg07362569	chr17:61921086	SMARCD2	0.72	6.37	0.55	6.65e-9	Prudent dietary pattern;
THYM	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg22875332	chr1:76189707	ACADM	0.9	10.62	0.74	7.94e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4845570	1.000	rs1054479	chr1:151746079	A/T	cg07092448	chr1:151763213	TDRKH	-1.05	-6.74	-0.57	1.24e-9	Coronary artery disease;
THYM	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg16586182	chr3:47516702	SCAP	0.64	5.62	0.5	1.93e-7	Colorectal cancer;
THYM	cis	rs4866334	1.000	rs77699507	chr5:18481057	A/G	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs2219968	1.000	rs2219968	chr8:78956658	G/A	cg00738934	chr8:78996279	NA	0.9	9.71	0.71	6.77e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg00814883	chr7:100076585	TSC22D4	-1.0	-6.8	-0.57	9.22e-10	Platelet count;
THYM	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.07	-5.85	-0.51	6.87e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7072216	0.763	rs2274244	chr10:100175218	A/G	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs9826463	0.582	rs73238161	chr3:142081981	A/C	cg20824294	chr3:142316082	PLS1	0.76	5.28	0.48	8.31e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs10788264	0.504	rs7090214	chr10:124036494	T/C	cg09507567	chr10:124027408	NA	0.55	5.58	0.5	2.31e-7	Total body bone mineral density;
THYM	cis	rs8033133	0.581	rs8042796	chr15:25327396	A/C	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.67	-5.11	-0.46	1.66e-6	Blood osmolality (transformed sodium);
THYM	cis	rs3820068	0.705	rs6656907	chr1:15896984	A/G	cg05660106	chr1:15850417	CASP9	1.15	9.92	0.71	2.44e-16	Systolic blood pressure;
THYM	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs3845702	0.668	rs3856415	chr2:180807367	G/A	cg01881094	chr2:180872142	CWC22	-0.85	-5.0	-0.46	2.64e-6	Schizophrenia;
THYM	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg06191203	chr2:152266755	RIF1	-0.75	-4.57	-0.42	1.46e-5	Lung cancer;
THYM	cis	rs7224314	0.895	rs11654663	chr17:65389305	A/C	cg01507342	chr17:65387096	PITPNC1	-0.92	-10.66	-0.74	6.34e-18	Diisocyanate-induced asthma;
THYM	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23248424	chr5:179741104	GFPT2	-0.89	-6.93	-0.58	5.07e-10	Height;
THYM	cis	rs2404602	0.647	rs11072631	chr15:77132909	T/C	cg23625390	chr15:77176239	SCAPER	-0.85	-6.09	-0.53	2.4e-8	Blood metabolite levels;
THYM	trans	rs9929218	0.551	rs8051095	chr16:68722049	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.15	16.76	0.86	3.99e-30	Colorectal cancer;
THYM	cis	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg05084668	chr3:125655381	ALG1L	-0.81	-4.65	-0.43	1.09e-5	Blood pressure (smoking interaction);
THYM	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg13609457	chr4:120235615	NA	0.51	4.76	0.44	6.87e-6	Corneal astigmatism;
THYM	cis	rs9361491	0.608	rs9343800	chr6:79461972	A/G	cg04547799	chr6:79944526	HMGN3	-0.64	-4.54	-0.42	1.64e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4819852	0.958	rs9606204	chr22:19976510	C/A	cg07821417	chr22:19972146	ARVCF	0.49	5.82	0.51	7.96e-8	Pulse pressure;
THYM	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg17971929	chr21:40555470	PSMG1	0.74	4.87	0.45	4.39e-6	Cognitive function;
THYM	cis	rs1957429	0.520	rs77606588	chr14:65356268	G/A	cg23373153	chr14:65346875	NA	-1.25	-5.03	-0.46	2.29e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs9915657	0.773	rs9894696	chr17:70099487	C/T	cg09344028	chr17:70110421	NA	0.55	6.0	0.52	3.52e-8	Thyroid hormone levels;
THYM	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.64	-5.53	-0.49	2.78e-7	Systemic lupus erythematosus;
THYM	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg17757837	chr7:157058334	UBE3C	-0.66	-5.29	-0.48	7.81e-7	Body mass index;
THYM	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg14972814	chr11:95582409	MTMR2	-0.78	-6.52	-0.56	3.3e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12476592	0.602	rs262536	chr2:63906926	T/C	cg17519650	chr2:63277830	OTX1	-0.72	-4.68	-0.43	9.38e-6	Childhood ear infection;
THYM	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	-0.66	-5.26	-0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs2811415	0.597	rs11721281	chr3:127790935	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs7127900	1.000	rs11043133	chr11:2232665	G/A	cg25635251	chr11:2234043	NA	0.74	4.71	0.44	8.43e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg07362569	chr17:61921086	SMARCD2	0.73	6.33	0.54	7.88e-9	Prudent dietary pattern;
THYM	cis	rs293526	0.959	rs293484	chr6:83680594	A/C	cg23278060	chr6:83777448	DOPEY1	0.65	4.75	0.44	7.09e-6	Crohn's disease;
THYM	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg15744005	chr10:104629667	AS3MT	-0.8	-7.31	-0.6	8.4e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-5.14	-0.47	1.5e-6	Hemoglobin concentration;
THYM	cis	rs6032067	0.929	rs17333555	chr20:43809761	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.03	10.73	0.74	4.6e-18	Cognitive ability;
THYM	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06634786	chr22:41940651	POLR3H	-0.72	-5.24	-0.47	9.75e-7	Vitiligo;
THYM	cis	rs7394190	0.748	rs12573448	chr10:75504512	T/G	cg07699608	chr10:75541558	CHCHD1	0.87	4.75	0.44	7.17e-6	Incident atrial fibrillation;
THYM	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg23574427	chr4:122746245	BBS7;CCNA2	-0.57	-5.18	-0.47	1.23e-6	Type 2 diabetes;
THYM	cis	rs3087591	0.960	rs4494610	chr17:29429555	A/G	cg24425628	chr17:29625626	OMG;NF1	0.63	5.19	0.47	1.18e-6	Hip circumference;
THYM	cis	rs6840360	0.615	rs66852535	chr4:152472227	C/A	cg17479576	chr4:152424074	FAM160A1	-0.83	-6.46	-0.55	4.43e-9	Intelligence (multi-trait analysis);
THYM	cis	rs4499344	0.921	rs4805776	chr19:33087759	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.77	-5.45	-0.49	3.92e-7	Mean platelet volume;
THYM	cis	rs2625529	0.652	rs2899776	chr15:72268365	A/T	cg16672083	chr15:72433130	SENP8	0.49	4.48	0.42	2.09e-5	Red blood cell count;
THYM	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.37	6.53	0.56	3.25e-9	Obesity-related traits;
THYM	cis	rs9796	0.621	rs11858678	chr15:41467932	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.58	-4.79	-0.44	6.07e-6	Menopause (age at onset);
THYM	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg05738196	chr6:26577821	NA	0.86	8.0	0.63	3.08e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg16926213	chr1:1841314	NA	0.54	5.64	0.5	1.73e-7	Body mass index;
THYM	cis	rs9393692	0.620	rs9366650	chr6:26335997	G/A	cg13736514	chr6:26305472	NA	-0.46	-4.7	-0.43	8.63e-6	Educational attainment;
THYM	cis	rs4535497	0.544	rs4975642	chr5:1107828	G/A	cg13592947	chr5:1111049	SLC12A7	0.55	5.98	0.52	3.82e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs28829049	0.597	rs12566296	chr1:19498443	A/C	cg13387374	chr1:19411106	UBR4	0.67	4.96	0.45	3.08e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs6840360	0.642	rs2709825	chr4:152365563	C/A	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg26384229	chr12:38710491	ALG10B	0.97	7.89	0.63	5.19e-12	Bladder cancer;
THYM	cis	rs1403694	0.515	rs1648699	chr3:186449890	G/C	cg12454167	chr3:186435060	KNG1	0.44	5.89	0.52	5.76e-8	Blood protein levels;
THYM	cis	rs2285947	0.967	rs2285948	chr7:21584229	T/C	cg04471919	chr7:21584483	DNAH11	0.45	4.46	0.42	2.29e-5	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
THYM	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg06219351	chr7:158114137	PTPRN2	-0.8	-7.16	-0.59	1.7e-10	Response to amphetamines;
THYM	cis	rs472402	0.560	rs10065299	chr5:6654489	T/C	cg12648172	chr5:5886274	NA	0.52	4.72	0.44	7.99e-6	Response to amphetamines;
THYM	cis	rs7937890	1.000	rs6486190	chr11:14401216	A/C	cg19336497	chr11:14380999	RRAS2	-0.53	-5.61	-0.5	1.95e-7	Mitochondrial DNA levels;
THYM	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10463554	0.963	rs26816	chr5:102540522	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.13	-0.47	1.51e-6	Parkinson's disease;
THYM	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg13695892	chr22:41940480	POLR3H	0.99	7.48	0.61	3.75e-11	Vitiligo;
THYM	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.88	9.94	0.71	2.24e-16	Prudent dietary pattern;
THYM	cis	rs11605275	1.000	rs11605704	chr11:20032096	A/G	cg14835545	chr11:20032148	NAV2	1.3	6.89	0.58	6.1e-10	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg13940125	chr1:197237119	CRB1	-0.63	-4.81	-0.44	5.63e-6	Depressive symptoms;
THYM	cis	rs7193541	0.691	rs3851728	chr16:74480660	C/T	cg01733217	chr16:74700730	RFWD3	0.85	7.96	0.63	3.69e-12	Multiple myeloma;
THYM	cis	rs314370	0.855	rs76181418	chr7:100494960	G/T	cg10426581	chr7:100472382	SRRT	1.13	8.97	0.68	2.57e-14	Resting heart rate;
THYM	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-10.21	-0.72	5.85e-17	Coronary artery disease;
THYM	cis	rs420259	0.516	rs460477	chr16:23601237	G/A	cg00143387	chr16:23521605	GGA2	0.76	5.6	0.5	2.1e-7	Bipolar disorder;
THYM	cis	rs4523957	0.928	rs11869805	chr17:2176532	A/G	cg16513277	chr17:2031491	SMG6	-0.79	-7.41	-0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs3791556	0.842	rs55840142	chr2:240106884	G/A	cg27074582	chr2:240114406	HDAC4	0.54	4.75	0.44	7.2e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs447921	0.861	rs12949638	chr17:74444758	C/T	cg17201438	chr17:74438067	UBE2O	0.77	5.46	0.49	3.74e-7	Mitochondrial DNA levels;
THYM	cis	rs2708977	0.966	rs2708978	chr2:97202243	A/C	cg01950434	chr2:97203154	ARID5A	-0.58	-5.2	-0.47	1.17e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs9479482	0.624	rs1194969	chr6:150373613	C/A	cg25797454	chr6:150327115	RAET1K	0.47	4.7	0.43	8.88e-6	Alopecia areata;
THYM	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg14458575	chr2:238380390	NA	0.9	7.53	0.61	2.94e-11	Prostate cancer;
THYM	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg22709100	chr7:91322751	NA	0.61	4.83	0.44	5.26e-6	Breast cancer;
THYM	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg10803722	chr21:46713166	LOC642852	-0.41	-5.33	-0.48	6.47e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2658782	1.000	rs2658778	chr11:93148948	C/G	cg15737290	chr11:93063684	CCDC67	1.05	7.97	0.63	3.42e-12	Pulmonary function decline;
THYM	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.41	-4.48	-0.42	2.05e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7917772	0.582	rs11191352	chr10:104372244	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	trans	rs4866334	1.000	rs76883636	chr5:18488763	G/T	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs6500395	0.928	rs723807	chr16:48691443	A/G	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs11112613	0.713	rs60865625	chr12:105940256	A/C	cg03607813	chr12:105948248	NA	1.05	8.88	0.67	4.18e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg09307838	chr4:120376055	NA	0.66	4.93	0.45	3.45e-6	Corneal astigmatism;
THYM	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.64	-5.55	-0.49	2.61e-7	Coronary artery disease;
THYM	cis	rs922692	0.710	rs1994016	chr15:79080234	C/T	cg22753661	chr15:79092743	ADAMTS7	0.67	4.95	0.45	3.21e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg26031613	chr14:104095156	KLC1	0.78	5.2	0.47	1.14e-6	Body mass index;
THYM	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg05373962	chr22:49881684	NA	-0.59	-5.57	-0.5	2.38e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg27211696	chr2:191398769	TMEM194B	-0.65	-5.1	-0.46	1.76e-6	Diastolic blood pressure;
THYM	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg08645402	chr16:4508243	NA	0.77	7.29	0.6	9.14e-11	Schizophrenia;
THYM	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs11779988	0.630	rs17635854	chr8:17895734	A/G	cg01800426	chr8:17659068	MTUS1	-0.64	-4.91	-0.45	3.81e-6	Breast cancer;
THYM	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03264133	chr6:25882463	NA	0.92	8.02	0.64	2.72e-12	Blood metabolite levels;
THYM	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg20295408	chr7:1910781	MAD1L1	-0.62	-4.8	-0.44	5.93e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12188164	0.840	rs957791	chr5:430217	C/T	cg16294152	chr5:418696	AHRR	-0.58	-4.96	-0.45	3.08e-6	Cystic fibrosis severity;
THYM	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg12573674	chr2:1569213	NA	-1.22	-4.82	-0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs10992471	0.564	rs10491804	chr9:95487407	G/A	cg14631576	chr9:95140430	CENPP	-0.94	-7.64	-0.62	1.75e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7830933	0.955	rs10101061	chr8:23593300	T/A	cg04349084	chr8:23602677	NA	0.58	6.09	0.53	2.42e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg17294928	chr15:75287854	SCAMP5	0.65	4.97	0.45	2.99e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs7084402	0.967	rs1649048	chr10:60324282	C/T	cg07615347	chr10:60278583	BICC1	0.58	5.34	0.48	6.34e-7	Refractive error;
THYM	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg27490568	chr2:178487706	NA	0.58	5.36	0.48	5.82e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1050631	0.564	rs1785931	chr18:33722107	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.28	0.48	8.32e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg27631724	chr1:11040367	C1orf127	0.64	5.61	0.5	1.98e-7	Ewing sarcoma;
THYM	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg03806693	chr22:41940476	POLR3H	-1.22	-10.85	-0.74	2.58e-18	Vitiligo;
THYM	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg23711669	chr6:146136114	FBXO30	0.97	10.59	0.74	9.22e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4589258	0.933	rs11824840	chr11:90417938	A/C	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg16778714	chr17:28903809	LRRC37B2	-0.76	-4.49	-0.42	2.03e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg23711669	chr6:146136114	FBXO30	-0.81	-7.34	-0.6	7.14e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2295499	0.639	rs7681728	chr4:2680515	A/G	cg17924901	chr4:3475233	DOK7	0.21	4.53	0.42	1.69e-5	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg06917634	chr15:78832804	PSMA4	0.94	8.55	0.66	2.02e-13	Sudden cardiac arrest;
THYM	cis	rs7560272	0.723	rs1083923	chr2:73703374	A/G	cg19565262	chr2:73869966	NAT8	0.56	4.75	0.44	7.11e-6	Schizophrenia;
THYM	cis	rs7027203	0.797	rs3996254	chr9:96591239	A/G	cg13679303	chr9:96623674	NA	-0.5	-5.08	-0.46	1.89e-6	DNA methylation (variation);
THYM	cis	rs863345	0.604	rs4584390	chr1:158505975	T/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg18105134	chr13:113819100	PROZ	1.05	9.68	0.7	7.89e-16	Platelet distribution width;
THYM	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg14024328	chr4:719362	PCGF3	-0.7	-4.6	-0.43	1.29e-5	White blood cell count;
THYM	cis	rs7646881	0.767	rs73015669	chr3:158456318	C/A	cg19483011	chr3:158453295	NA	-0.72	-4.68	-0.43	9.34e-6	Tetralogy of Fallot;
THYM	cis	rs7584330	0.740	rs13426236	chr2:238447940	A/G	cg14458575	chr2:238380390	NA	0.7	5.07	0.46	1.97e-6	Prostate cancer;
THYM	cis	rs713587	0.935	rs11676272	chr2:25141538	A/G	cg01884057	chr2:25150051	NA	0.73	8.06	0.64	2.27e-12	Body mass index in non-asthmatics;
THYM	cis	rs931127	0.967	rs6591183	chr11:65400888	A/G	cg27068330	chr11:65405492	SIPA1	-0.71	-5.63	-0.5	1.83e-7	Systemic lupus erythematosus;
THYM	cis	rs9814567	0.858	rs4955548	chr3:134341060	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.57	-0.66	1.88e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs12042938	0.507	rs1765777	chr1:231731742	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-5.81	-0.51	8.3e-8	Neuranatomic and neurocognitive phenotypes;
THYM	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg10661904	chr17:79619235	PDE6G	-0.66	-6.41	-0.55	5.55e-9	Eye color traits;
THYM	cis	rs6582630	0.538	rs12305104	chr12:38336353	C/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.47	-0.42	2.16e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2888674	0.933	rs10267707	chr7:150510973	C/G	cg10409299	chr7:150498843	TMEM176B;TMEM176A	0.48	4.63	0.43	1.15e-5	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
THYM	cis	rs1385374	0.858	rs10847697	chr12:129299385	C/T	cg04043695	chr12:129287642	SLC15A4	-0.8	-4.83	-0.44	5.3e-6	Systemic lupus erythematosus;
THYM	cis	rs8016982	0.633	rs7141288	chr14:81710232	C/A	cg01989461	chr14:81687754	GTF2A1	0.82	7.37	0.6	6.34e-11	Schizophrenia;
THYM	trans	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17712092	chr4:129076599	LARP1B	0.9	7.57	0.61	2.39e-11	Eosinophil percentage of white cells;
THYM	cis	rs7172809	0.599	rs1867780	chr15:77407114	C/G	cg22256960	chr15:77711686	NA	-0.64	-4.76	-0.44	6.94e-6	Glucose homeostasis traits;
THYM	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg15744692	chr15:45671195	LOC145663;GATM	0.44	4.46	0.42	2.22e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs1062753	0.922	rs9611712	chr22:42410993	T/C	cg09667013	chr22:42394590	WBP2NL	0.54	4.8	0.44	5.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs986417	0.901	rs10782440	chr14:61031648	G/C	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs7172677	1.000	rs55662404	chr15:75432341	G/A	cg09165964	chr15:75287851	SCAMP5	0.63	4.75	0.44	7.24e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs7078219	0.505	rs4409764	chr10:101284237	T/G	cg07044859	chr10:101282883	NA	-0.39	-4.52	-0.42	1.8e-5	Dental caries;
THYM	cis	rs10256972	0.678	rs6962989	chr7:1017512	G/A	cg02778551	chr7:1045947	C7orf50	-0.99	-5.04	-0.46	2.2e-6	Longevity;Endometriosis;
THYM	cis	rs7246657	0.765	rs10402455	chr19:37728707	G/A	cg23950597	chr19:37808831	NA	-0.72	-4.52	-0.42	1.81e-5	Coronary artery calcification;
THYM	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg26028573	chr6:26043587	HIST1H2BB	0.52	4.59	0.43	1.35e-5	Blood metabolite levels;
THYM	cis	rs10904908	1.000	rs7903402	chr10:17259772	C/T	cg01003015	chr10:17271136	VIM	-0.63	-5.33	-0.48	6.61e-7	Total cholesterol levels;Cholesterol, total;
THYM	cis	rs6686842	1.000	rs656917	chr1:41569708	T/C	cg03387723	chr1:41708464	SCMH1	0.44	5.22	0.47	1.04e-6	Height;
THYM	cis	rs6754311	0.593	rs313518	chr2:136439090	C/T	cg07169764	chr2:136633963	MCM6	0.7	5.67	0.5	1.55e-7	Mosquito bite size;
THYM	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg06028808	chr11:68637592	NA	0.66	7.11	0.59	2.17e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg07606381	chr6:8435919	SLC35B3	0.59	4.45	0.42	2.36e-5	Motion sickness;
THYM	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg22974920	chr21:40686053	BRWD1	-0.76	-5.14	-0.47	1.46e-6	Cognitive function;
THYM	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg17775962	chr7:1200435	ZFAND2A	0.46	5.44	0.49	4.12e-7	Longevity;Endometriosis;
THYM	cis	rs10162002	1.000	rs73449251	chr13:24042272	C/T	cg00158254	chr13:24040743	NA	0.69	4.8	0.44	5.81e-6	Hypothyroidism;
THYM	trans	rs9296092	0.517	rs6911036	chr6:33471652	C/G	cg00929798	chr10:135150139	CALY	0.69	6.91	0.58	5.61e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg08999081	chr20:33150536	PIGU	-0.78	-7.16	-0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg19318889	chr4:1322082	MAEA	0.66	5.77	0.51	1e-7	Longevity;
THYM	cis	rs28595532	0.841	rs56046449	chr4:119769302	T/C	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs8048589	0.558	rs35208076	chr16:12228169	C/T	cg02910054	chr16:12241554	SNX29	0.75	6.44	0.55	4.91e-9	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg19418458	chr7:158789849	NA	0.67	6.53	0.56	3.29e-9	Facial morphology (factor 20);
THYM	cis	rs6754311	0.510	rs1374329	chr2:136421323	A/G	cg04750100	chr2:136595281	LCT	0.56	5.74	0.51	1.14e-7	Mosquito bite size;
THYM	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg20887711	chr4:1340912	KIAA1530	-0.62	-4.9	-0.45	3.9e-6	Obesity-related traits;
THYM	cis	rs6424115	0.729	rs1737362	chr1:24054800	T/C	cg15997130	chr1:24165203	NA	0.65	5.21	0.47	1.07e-6	Immature fraction of reticulocytes;
THYM	cis	rs17209837	0.607	rs2109505	chr7:87079406	T/A	cg04996195	chr7:87105398	ABCB4	0.63	4.79	0.44	6.03e-6	Gallbladder cancer;
THYM	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg27170947	chr2:26402098	FAM59B	0.79	6.27	0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs6906287	0.647	rs7772214	chr6:118793703	A/T	cg21191810	chr6:118973309	C6orf204	0.56	5.63	0.5	1.84e-7	Electrocardiographic conduction measures;
THYM	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg15693483	chr7:1102177	C7orf50	0.53	6.07	0.53	2.59e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg07169764	chr2:136633963	MCM6	0.64	5.9	0.52	5.48e-8	Mosquito bite size;
THYM	cis	rs9393692	0.620	rs9379844	chr6:26291527	A/G	cg13736514	chr6:26305472	NA	0.48	5.13	0.47	1.54e-6	Educational attainment;
THYM	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg00744431	chr10:134226547	PWWP2B	-0.6	-4.75	-0.44	7.12e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs17006441	1.000	rs9825958	chr3:69830674	C/T	cg18496212	chr3:69797108	MITF	0.75	7.33	0.6	7.46e-11	Hemoglobin concentration;
THYM	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg14004847	chr7:1930337	MAD1L1	-0.61	-4.82	-0.44	5.4e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg03188948	chr7:1209495	NA	0.91	5.04	0.46	2.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9810089	0.786	rs10935183	chr3:136149139	C/T	cg12473912	chr3:136751656	NA	0.62	5.27	0.48	8.44e-7	Gestational age at birth (child effect);
THYM	cis	rs7809950	0.678	rs3801966	chr7:106824580	G/A	cg23024343	chr7:107201750	COG5	-0.99	-8.39	-0.65	4.58e-13	Coronary artery disease;
THYM	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg27168131	chr21:44088823	PDE9A	-0.46	-4.53	-0.42	1.74e-5	Mean corpuscular volume;
THYM	cis	rs6448317	0.954	rs12186333	chr4:24919774	T/C	cg22968281	chr4:24586266	DHX15	0.66	4.53	0.42	1.69e-5	Heschl's gyrus morphology;
THYM	cis	rs12142240	0.659	rs72677602	chr1:46837487	G/A	cg00530320	chr1:46809349	NSUN4	0.8	5.5	0.49	3.16e-7	Menopause (age at onset);
THYM	cis	rs17030434	0.906	rs4145339	chr4:154710481	C/T	cg14289246	chr4:154710475	SFRP2	-0.83	-5.58	-0.5	2.24e-7	Electrocardiographic conduction measures;
THYM	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg11502198	chr6:26597334	ABT1	0.61	5.15	0.47	1.39e-6	Intelligence (multi-trait analysis);
THYM	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg11812906	chr14:75593930	NEK9	-0.77	-7.03	-0.58	3.14e-10	Height;
THYM	cis	rs9527	0.615	rs10883810	chr10:104727224	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-4.68	-0.43	9.59e-6	Arsenic metabolism;
THYM	cis	rs12519773	0.526	rs4869415	chr5:92522764	A/G	cg18783429	chr5:92414398	NA	0.5	4.91	0.45	3.72e-6	Migraine;
THYM	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.59	4.47	0.42	2.19e-5	Calcium levels;
THYM	cis	rs4595586	0.545	rs925829	chr12:39364167	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg26597838	chr10:835615	NA	1.25	9.08	0.68	1.54e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs1788820	0.957	rs1652340	chr18:21099831	A/C	cg14672496	chr18:21087552	C18orf8	0.78	6.19	0.54	1.54e-8	Body mass index;
THYM	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg08901578	chr4:187885870	NA	-0.63	-5.79	-0.51	8.9e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10905065	0.965	rs7100576	chr10:5784649	G/A	cg11519256	chr10:5708881	ASB13	0.49	4.85	0.45	4.79e-6	Menopause (age at onset);
THYM	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg20203395	chr5:56204925	C5orf35	-0.65	-4.55	-0.42	1.6e-5	Initial pursuit acceleration;
THYM	cis	rs10788264	0.544	rs9630110	chr10:124017308	C/T	cg09507567	chr10:124027408	NA	-0.5	-4.8	-0.44	5.86e-6	Total body bone mineral density;
THYM	trans	rs17286411	0.806	rs56309616	chr16:71862448	A/G	cg00109465	chr12:54121359	CALCOCO1	-1.04	-6.88	-0.58	6.2e-10	Blood protein levels;
THYM	cis	rs17153755	0.931	rs3203358	chr8:11617505	C/G	cg12395012	chr8:11607386	GATA4	-0.62	-4.77	-0.44	6.69e-6	Testicular germ cell tumor;
THYM	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg16586182	chr3:47516702	SCAP	0.72	6.4	0.55	5.78e-9	Colorectal cancer;
THYM	cis	rs1079204	1.000	rs10178462	chr2:219083353	G/T	cg05728596	chr2:219128475	GPBAR1	1.25	5.39	0.48	5.06e-7	Smooth-surface caries;
THYM	cis	rs61990749	0.511	rs7146020	chr14:78358319	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.82	5.12	0.47	1.57e-6	Fibroblast growth factor basic levels;
THYM	cis	rs3138083	0.645	rs12376747	chr9:35639629	C/G	cg07116010	chr9:35646325	NA	0.88	8.77	0.67	6.9e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
THYM	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg10589385	chr1:150898437	SETDB1	0.65	5.45	0.49	4.01e-7	Melanoma;
THYM	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg18230493	chr5:56204884	C5orf35	0.91	6.8	0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg27490568	chr2:178487706	NA	0.6	5.23	0.47	9.91e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs72827839	0.740	rs72823509	chr17:46044589	G/A	cg23391107	chr17:45924227	SP6	0.76	4.99	0.46	2.76e-6	Ease of getting up in the morning;
THYM	cis	rs8133932	0.555	rs374331	chr21:47338218	A/G	cg20357416	chr21:47294739	PCBP3	0.8	4.88	0.45	4.26e-6	Schizophrenia;
THYM	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg11461670	chr8:22454935	PDLIM2	-0.34	-6.23	-0.54	1.25e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.88	6.99	0.58	3.71e-10	Multiple sclerosis;
THYM	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg24209194	chr3:40518798	ZNF619	-0.73	-6.31	-0.54	8.87e-9	Renal cell carcinoma;
THYM	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg04398451	chr17:18023971	MYO15A	0.79	7.34	0.6	7.12e-11	Total body bone mineral density;
THYM	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg01304814	chr3:48885189	PRKAR2A	0.96	4.86	0.45	4.55e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg03476357	chr21:30257390	N6AMT1	-0.59	-4.6	-0.43	1.31e-5	Dental caries;
THYM	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg26354017	chr1:205819088	PM20D1	1.09	11.94	0.77	1.32e-20	Menarche (age at onset);
THYM	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg19626725	chr5:178986131	RUFY1	-0.31	-4.75	-0.44	7.26e-6	Lung cancer;
THYM	cis	rs926938	0.584	rs2798663	chr1:115363582	G/A	cg12756093	chr1:115239321	AMPD1	0.61	4.93	0.45	3.5e-6	Autism;
THYM	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	ch.11.42038R	chr11:967971	AP2A2	0.56	4.49	0.42	1.98e-5	Alzheimer's disease (late onset);
THYM	cis	rs11048434	0.761	rs10842660	chr12:9138897	G/A	cg04155231	chr12:9217510	LOC144571	0.5	4.86	0.45	4.7e-6	Sjögren's syndrome;
THYM	cis	rs3771570	0.901	rs62190415	chr2:242426692	A/G	cg21155796	chr2:242212141	HDLBP	1.06	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg00271210	chr6:167070053	RPS6KA2	0.72	7.87	0.63	5.63e-12	Crohn's disease;
THYM	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg25918947	chr17:41365094	TMEM106A	-0.63	-5.18	-0.47	1.25e-6	Menopause (age at onset);
THYM	cis	rs2412459	0.732	rs479500	chr15:40255262	C/G	cg16127683	chr15:40268777	EIF2AK4	0.53	4.63	0.43	1.16e-5	Response to haloperidol in psychosis;
THYM	cis	rs1018836	0.923	rs2023626	chr8:91619264	G/T	cg16814680	chr8:91681699	NA	0.86	7.33	0.6	7.46e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	7.17	0.59	1.59e-10	Platelet count;
THYM	cis	rs28476539	0.567	rs17005922	chr4:83555816	C/G	cg10249074	chr4:83542146	C4orf11	0.62	4.96	0.45	3.12e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs4911253	0.527	rs853859	chr20:31402269	A/G	cg13636640	chr20:31349939	DNMT3B	0.67	6.6	0.56	2.36e-9	Lymphocyte counts;
THYM	cis	rs17253792	0.822	rs117050012	chr14:56038729	G/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg02574844	chr11:5959923	NA	-0.54	-4.75	-0.44	7.09e-6	DNA methylation (variation);
THYM	cis	rs986417	0.901	rs12436953	chr14:61001546	C/T	cg27398547	chr14:60952738	C14orf39	1.01	5.8	0.51	8.68e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs611744	0.647	rs2594358	chr8:109256018	A/G	cg21045802	chr8:109455806	TTC35	0.66	5.74	0.51	1.13e-7	Dupuytren's disease;
THYM	cis	rs2495707	0.647	rs1541266	chr10:102421292	C/T	cg07099331	chr10:102419617	NA	-0.47	-5.51	-0.49	3.09e-7	Body mass index;
THYM	cis	rs4430311	1.000	rs3008659	chr1:244023962	G/C	cg25706552	chr1:244017396	NA	-0.57	-5.06	-0.46	2.01e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs17122693	0.551	rs2934685	chr14:51050865	C/G	cg04730355	chr14:51134070	SAV1	1.02	7.05	0.59	2.83e-10	Cognitive performance;
THYM	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg01341218	chr17:43662625	NA	1.12	9.44	0.7	2.6e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg22467129	chr15:76604101	ETFA	-0.5	-4.94	-0.45	3.32e-6	Blood metabolite levels;
THYM	cis	rs11969893	0.737	rs4098482	chr6:101377808	C/T	cg12253828	chr6:101329408	ASCC3	1.1	6.47	0.55	4.17e-9	Economic and political preferences (immigration/crime);
THYM	cis	rs8001018	0.533	rs9541641	chr13:69524675	C/T	cg16757992	chr13:69559194	NA	-0.59	-4.65	-0.43	1.05e-5	Subjective well-being;
THYM	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.15e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg12893697	chr11:970389	AP2A2	-0.31	-5.21	-0.47	1.08e-6	Alzheimer's disease (late onset);
THYM	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	7.45	0.61	4.17e-11	Platelet count;
THYM	cis	rs9527	0.590	rs10509764	chr10:104776475	G/A	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs11118993	0.902	rs6685780	chr1:206716779	C/G	cg19452316	chr1:206680966	RASSF5	0.65	5.34	0.48	6.25e-7	Neurofibrillary tangles;
THYM	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg27631724	chr1:11040367	C1orf127	0.68	6.42	0.55	5.25e-9	Ewing sarcoma;
THYM	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg11327659	chr7:150037044	RARRES2	0.42	5.0	0.46	2.62e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs28595532	0.920	rs115103359	chr4:119739608	A/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg00640147	chr17:61958756	GH2	-0.44	-4.8	-0.44	5.87e-6	Height;
THYM	cis	rs7100689	0.646	rs7092237	chr10:82165640	A/G	cg01528321	chr10:82214614	TSPAN14	0.92	7.68	0.62	1.42e-11	Post bronchodilator FEV1;
THYM	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg02527881	chr3:46936655	PTH1R	-0.63	-6.29	-0.54	9.52e-9	Colorectal cancer;
THYM	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11696501	0.688	rs6065851	chr20:44279034	C/T	cg11783356	chr20:44313418	WFDC10B	-0.71	-4.79	-0.44	6.07e-6	Brain structure;
THYM	cis	rs4808199	0.649	rs17216693	chr19:19666574	T/C	cg03709012	chr19:19516395	GATAD2A	1.05	5.15	0.47	1.41e-6	Nonalcoholic fatty liver disease;
THYM	cis	rs870825	0.616	rs41278579	chr4:185622402	A/G	cg04058563	chr4:185651563	MLF1IP	1.16	9.67	0.7	8.28e-16	Blood protein levels;
THYM	cis	rs870825	0.616	rs56844261	chr4:185632478	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs2282300	0.956	rs1717773	chr11:30383154	T/C	cg25418670	chr11:30344373	C11orf46	-0.76	-5.95	-0.52	4.53e-8	Morning vs. evening chronotype;
THYM	cis	rs1211375	0.607	rs1203978	chr16:257211	A/C	cg17291625	chr16:236080	NA	0.61	5.17	0.47	1.29e-6	Hematology traits;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs17739167	0.550	rs1426890	chr15:42226125	G/A	cg20935245	chr15:42234343	EHD4	0.4	4.75	0.44	7.17e-6	Monocyte count;
THYM	cis	rs4606347	0.789	rs61780866	chr1:66162693	A/G	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg19508488	chr2:152266495	RIF1	-0.81	-6.42	-0.55	5.26e-9	Lung cancer;
THYM	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg18128536	chr17:47092178	IGF2BP1	-0.59	-8.86	-0.67	4.52e-14	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs7106204	0.514	rs7117803	chr11:24253214	A/T	ch.11.24196551F	chr11:24239977	NA	1.02	7.07	0.59	2.58e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs988913	0.957	rs2397177	chr6:54834133	A/G	cg18532076	chr6:54711417	FAM83B	0.5	4.91	0.45	3.78e-6	Menarche (age at onset);
THYM	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.95	0.71	2.08e-16	Colorectal cancer;
THYM	trans	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.12	8.09	0.64	1.9e-12	Exhaled nitric oxide output;
THYM	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg03733263	chr8:22462867	KIAA1967	-1.12	-11.48	-0.76	1.2e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1198430	0.562	rs7522616	chr1:23794914	A/G	cg19827787	chr1:23763612	ASAP3	0.59	4.82	0.44	5.47e-6	Total cholesterol levels;
THYM	cis	rs7177699	0.557	rs6495333	chr15:79113215	G/A	cg00540400	chr15:79124168	NA	0.64	6.93	0.58	4.98e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg10862848	chr6:42927986	GNMT	-0.51	-6.67	-0.56	1.66e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-4.98	-0.45	2.89e-6	Chronic sinus infection;
THYM	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg13607699	chr17:42295918	UBTF	0.59	4.86	0.45	4.58e-6	Total body bone mineral density;
THYM	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg19418458	chr7:158789849	NA	0.54	4.91	0.45	3.8e-6	Facial morphology (factor 20);
THYM	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg09359103	chr1:154839909	KCNN3	-0.68	-8.1	-0.64	1.82e-12	Prostate cancer;
THYM	cis	rs3540	0.553	rs2158406	chr15:90994499	T/C	cg22089800	chr15:90895588	ZNF774	0.75	5.9	0.52	5.66e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg04398451	chr17:18023971	MYO15A	0.9	8.23	0.65	1e-12	Total body bone mineral density;
THYM	cis	rs4654899	0.931	rs10799679	chr1:21341776	A/G	cg01072550	chr1:21505969	NA	-0.74	-6.82	-0.57	8.58e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg16325326	chr1:53192061	ZYG11B	-0.86	-8.54	-0.66	2.14e-13	Monocyte count;
THYM	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	6.38	0.55	6.43e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs10425738	0.830	rs3844444	chr19:41434047	A/G	cg17435250	chr19:41386441	CYP2A7	-0.63	-4.52	-0.42	1.79e-5	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
THYM	cis	rs6450176	1.000	rs3776705	chr5:53304955	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.13	-0.53	2.01e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs11085466	0.948	rs11668453	chr19:21759357	C/A	cg23004160	chr19:21646329	NA	-0.65	-4.7	-0.43	8.62e-6	Colorectal or endometrial cancer;
THYM	cis	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg10856724	chr12:34555212	NA	-1.07	-10.09	-0.72	1.09e-16	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg03806693	chr22:41940476	POLR3H	1.05	8.42	0.65	3.85e-13	Vitiligo;
THYM	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg19077165	chr18:44547161	KATNAL2	0.51	5.99	0.52	3.73e-8	Personality dimensions;
THYM	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg11965913	chr1:205819406	PM20D1	0.79	7.8	0.62	8.07e-12	Monocyte percentage of white cells;
THYM	cis	rs4363385	0.818	rs57311099	chr1:153005597	A/C	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg10505658	chr17:80084571	CCDC57	-0.72	-7.83	-0.63	6.9e-12	Life satisfaction;
THYM	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg27490568	chr2:178487706	NA	0.56	5.1	0.46	1.77e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.75	-0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg16319517	chr3:190287031	IL1RAP	-0.69	-5.1	-0.46	1.75e-6	Lung adenocarcinoma;
THYM	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg02773041	chr1:40204384	PPIE	0.77	5.94	0.52	4.71e-8	Blood protein levels;
THYM	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg13695892	chr22:41940480	POLR3H	-0.99	-7.48	-0.61	3.62e-11	Vitiligo;
THYM	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.92	-10.65	-0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs4606347	0.932	rs61779735	chr1:66140349	T/G	cg04111102	chr1:66153794	NA	0.57	4.53	0.42	1.73e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7927771	0.524	rs7107792	chr11:47669249	A/C	cg18512352	chr11:47633146	NA	0.41	4.59	0.43	1.34e-5	Subjective well-being;
THYM	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg03709012	chr19:19516395	GATAD2A	-0.85	-7.12	-0.59	2.05e-10	Tonsillectomy;
THYM	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg07936489	chr17:37558343	FBXL20	0.81	5.85	0.51	6.81e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24549020	chr5:56110836	MAP3K1	0.7	4.61	0.43	1.28e-5	Initial pursuit acceleration;
THYM	cis	rs7590720	1.000	rs6755934	chr2:216907198	C/A	cg12620499	chr2:216877984	MREG	0.81	5.52	0.49	2.88e-7	Alcohol dependence;
THYM	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg14159672	chr1:205819179	PM20D1	-0.69	-5.78	-0.51	9.58e-8	Prostate-specific antigen levels;
THYM	cis	rs600550	0.588	rs10792268	chr11:60102631	A/G	cg05040360	chr11:60102449	MS4A6E	-0.5	-4.72	-0.44	8.13e-6	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg06074448	chr4:187884817	NA	-1.02	-12.88	-0.8	1.45e-22	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg03467027	chr4:99064603	C4orf37	0.59	4.5	0.42	1.92e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4595586	0.545	rs11615634	chr12:39364704	A/C	cg13010199	chr12:38710504	ALG10B	0.61	4.65	0.43	1.05e-5	Morning vs. evening chronotype;
THYM	cis	rs10799590	1.000	rs1595151	chr1:224843393	T/C	cg01808320	chr1:224927238	CNIH3	-0.53	-4.73	-0.44	7.81e-6	Opioid dependence;
THYM	trans	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs2795502	0.630	rs1271547	chr10:43507665	C/T	cg08461752	chr10:43522343	NA	-0.74	-4.5	-0.42	1.91e-5	Blood protein levels;
THYM	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg24399712	chr22:39784796	NA	-0.94	-11.05	-0.75	9.4e-19	Intelligence (multi-trait analysis);
THYM	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs1829883	1.000	rs1916599	chr5:98774240	C/G	cg08333243	chr5:99726346	NA	-0.6	-5.94	-0.52	4.71e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.95	7.53	0.61	2.9e-11	Lymphocyte percentage of white cells;
THYM	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.85	9.31	0.69	4.86e-15	Prudent dietary pattern;
THYM	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-6.56	-0.56	2.84e-9	Colorectal cancer;
THYM	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg26384229	chr12:38710491	ALG10B	0.99	7.94	0.63	3.99e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7635838	0.617	rs13071193	chr3:11284226	G/T	cg00170343	chr3:11313890	ATG7	-0.64	-4.87	-0.45	4.41e-6	HDL cholesterol;
THYM	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg07414643	chr4:187882934	NA	0.58	5.13	0.47	1.54e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2279817	0.863	rs1416854	chr1:18024675	G/A	cg21791023	chr1:18019539	ARHGEF10L	0.78	5.09	0.46	1.77e-6	Neuroticism;
THYM	cis	rs6964587	0.773	rs12740	chr7:92029302	A/G	cg17063962	chr7:91808500	NA	1.02	7.32	0.6	7.87e-11	Breast cancer;
THYM	cis	rs7617773	0.780	rs71323395	chr3:48374077	G/A	cg02219026	chr3:48282209	ZNF589	-0.71	-4.97	-0.45	3.01e-6	Coronary artery disease;
THYM	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg04317338	chr11:64019027	PLCB3	0.88	5.82	0.51	7.81e-8	Mean platelet volume;
THYM	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg15448220	chr1:150897856	SETDB1	0.86	6.86	0.58	6.9e-10	Melanoma;
THYM	cis	rs728616	0.614	rs10887229	chr10:81713774	A/G	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs8067545	0.717	rs7207625	chr17:20001612	G/A	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.61e-6	Schizophrenia;
THYM	cis	rs6763768	0.634	rs2358740	chr3:53455569	G/T	cg16894138	chr3:53270350	TKT	0.69	5.24	0.47	9.7e-7	Bacterial meningitis;
THYM	cis	rs728616	0.867	rs12414096	chr10:81713629	A/G	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.74	6.99	0.58	3.77e-10	Chronic sinus infection;
THYM	cis	rs12282928	1.000	rs10838872	chr11:48336147	C/G	cg22827986	chr11:48284249	OR4X1	0.53	5.62	0.5	1.9e-7	Migraine - clinic-based;
THYM	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg17173187	chr15:85201210	NMB	0.54	5.39	0.48	5.09e-7	Schizophrenia;
THYM	cis	rs2797160	1.000	rs1777195	chr6:126006861	A/C	cg16306078	chr6:126000798	NA	0.52	5.23	0.47	1.01e-6	Endometrial cancer;
THYM	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs4638749	0.501	rs13421955	chr2:108748076	A/T	cg25838818	chr2:108905173	SULT1C2	-0.52	-4.89	-0.45	4.13e-6	Blood pressure;
THYM	cis	rs4523957	0.818	rs4790887	chr17:2130592	C/A	cg16513277	chr17:2031491	SMG6	0.8	7.85	0.63	6.16e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9611519	0.780	rs1983631	chr22:41644074	C/T	cg13695892	chr22:41940480	POLR3H	-0.65	-5.14	-0.47	1.44e-6	Neuroticism;
THYM	cis	rs4790312	0.935	rs3744274	chr17:1990959	G/T	cg15816464	chr17:2026533	SMG6	0.39	4.75	0.44	7.18e-6	Left atrial antero-posterior diameter;
THYM	cis	rs4642101	0.640	rs3901666	chr3:12824363	G/T	cg05775895	chr3:12838266	CAND2	-0.82	-6.94	-0.58	4.73e-10	QRS complex (12-leadsum);
THYM	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03264133	chr6:25882463	NA	-0.69	-5.32	-0.48	7.03e-7	Blood metabolite levels;
THYM	cis	rs7572263	1.000	rs7572263	chr2:209051586	A/G	cg23998903	chr2:209048830	C2orf80	-0.44	-5.42	-0.49	4.46e-7	Glioma;Non-glioblastoma glioma;
THYM	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg11166453	chr1:247681781	NA	0.63	5.06	0.46	2.03e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs6032067	0.636	rs6104092	chr20:43906730	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	0.42	4.68	0.43	9.56e-6	Blood protein levels;
THYM	cis	rs2732480	0.577	rs2634684	chr12:48730875	C/T	cg21466736	chr12:48725269	NA	0.6	5.41	0.49	4.79e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg03806693	chr22:41940476	POLR3H	-1.04	-7.62	-0.62	1.86e-11	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs12142240	0.698	rs66847432	chr1:46832013	G/A	cg00530320	chr1:46809349	NSUN4	0.78	5.55	0.49	2.62e-7	Menopause (age at onset);
THYM	cis	rs12519773	0.549	rs11738974	chr5:92537336	G/A	cg18783429	chr5:92414398	NA	0.53	5.35	0.48	6.03e-7	Migraine;
THYM	cis	rs7100689	0.646	rs10736348	chr10:82139244	C/A	cg01528321	chr10:82214614	TSPAN14	0.79	6.01	0.52	3.47e-8	Post bronchodilator FEV1;
THYM	cis	rs1451375	0.794	rs11238133	chr7:50542914	A/C	cg18232548	chr7:50535776	DDC	-0.78	-6.97	-0.58	4.11e-10	Malaria;
THYM	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs26232	0.583	rs26434	chr5:102363402	C/T	cg23492399	chr5:102201601	PAM	0.65	4.69	0.43	8.99e-6	Rheumatoid arthritis;
THYM	cis	rs7631605	0.967	rs6550458	chr3:37188318	A/T	cg21328643	chr3:37258149	NA	-0.49	-4.77	-0.44	6.64e-6	Cerebrospinal P-tau181p levels;
THYM	trans	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg10856724	chr12:34555212	NA	-0.97	-8.82	-0.67	5.55e-14	Bladder cancer;
THYM	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg14458575	chr2:238380390	NA	1.12	7.97	0.63	3.42e-12	Prostate cancer;
THYM	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs9560113	1.000	rs11069895	chr13:112178824	C/T	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs7731657	0.510	rs11748136	chr5:130343725	G/C	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	4.76	0.44	6.83e-6	Obesity-related traits;
THYM	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06873352	chr17:61820015	STRADA	-0.73	-8.34	-0.65	5.74e-13	Prudent dietary pattern;
THYM	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg02569458	chr12:86230093	RASSF9	0.63	5.5	0.49	3.13e-7	Major depressive disorder;
THYM	cis	rs9902453	0.967	rs4493117	chr17:28489770	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	6.58	0.56	2.55e-9	Coffee consumption (cups per day);
THYM	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg13114125	chr14:105738426	BRF1	-0.73	-5.64	-0.5	1.73e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9644630	0.870	rs10888165	chr8:19358961	T/C	cg01280390	chr8:19363452	CSGALNACT1	0.73	7.54	0.61	2.76e-11	Oropharynx cancer;
THYM	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs3213545	0.700	rs2260399	chr12:121469653	C/T	cg02403541	chr12:121454288	C12orf43	0.62	5.12	0.46	1.62e-6	Subjective well-being;Cardiovascular disease risk factors;
THYM	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg02574844	chr11:5959923	NA	-0.52	-4.66	-0.43	1.04e-5	DNA methylation (variation);
THYM	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg04111992	chr7:158790115	NA	-0.6	-5.47	-0.49	3.66e-7	Facial morphology (factor 20);
THYM	cis	rs2124969	0.548	rs72982036	chr2:161031590	G/A	cg03641300	chr2:160917029	PLA2R1	-0.67	-4.69	-0.43	8.99e-6	Waist circumference adjusted for body mass index;
THYM	cis	rs7107174	0.892	rs11237477	chr11:78095069	A/T	cg02023728	chr11:77925099	USP35	0.63	6.11	0.53	2.23e-8	Testicular germ cell tumor;
THYM	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg26384229	chr12:38710491	ALG10B	0.95	7.55	0.61	2.7e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg16342193	chr10:102329863	NA	-0.6	-6.24	-0.54	1.22e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.43	-6.6	-0.56	2.34e-9	Obesity-related traits;
THYM	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg02038168	chr22:39784481	NA	-0.63	-4.99	-0.46	2.75e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12935418	0.672	rs11866803	chr16:81051203	T/G	cg16651780	chr16:81037892	C16orf61	0.79	5.6	0.5	2.11e-7	Mean corpuscular volume;
THYM	cis	rs137603	0.644	rs137621	chr22:39710244	G/A	cg24268161	chr22:39747459	SYNGR1	0.65	5.49	0.49	3.4e-7	Primary biliary cholangitis;
THYM	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg17644776	chr2:200775616	C2orf69	-0.77	-4.5	-0.42	1.95e-5	Schizophrenia;
THYM	cis	rs9649213	0.593	rs6968144	chr7:97915697	G/A	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.96	0.45	3.1e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1557614	0.601	rs11248551	chr10:125246197	C/T	cg03974204	chr10:124252811	HTRA1	-0.51	-4.64	-0.43	1.1e-5	Colorectal cancer;
THYM	cis	rs2070677	0.808	rs3020500	chr10:135381276	T/C	cg20169779	chr10:135381914	SYCE1	0.77	5.93	0.52	4.93e-8	Gout;
THYM	cis	rs4474465	0.850	rs10793324	chr11:78251485	C/T	cg19901956	chr11:77921274	USP35	-0.57	-4.49	-0.42	1.97e-5	Alzheimer's disease (survival time);
THYM	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs854765	0.587	rs12936927	chr17:17726965	C/T	cg04398451	chr17:18023971	MYO15A	0.77	6.92	0.58	5.36e-10	Total body bone mineral density;
THYM	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg18876405	chr7:65276391	NA	-0.56	-4.63	-0.43	1.16e-5	Aortic root size;
THYM	cis	rs3015497	0.789	rs3015502	chr14:51108427	T/C	cg04730355	chr14:51134070	SAV1	-0.53	-4.7	-0.43	8.68e-6	Mean platelet volume;
THYM	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg05973401	chr12:123451056	ABCB9	0.71	4.82	0.44	5.46e-6	Neutrophil percentage of white cells;
THYM	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.53	-4.96	-0.45	3.04e-6	Lymphocyte counts;
THYM	cis	rs700651	0.789	rs1976772	chr2:198868201	G/T	cg00792783	chr2:198669748	PLCL1	0.82	5.63	0.5	1.79e-7	Intracranial aneurysm;
THYM	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg09323728	chr8:95962352	TP53INP1	-0.47	-4.66	-0.43	1.01e-5	Type 2 diabetes;
THYM	cis	rs7614311	0.594	rs3774709	chr3:63882476	A/G	cg22134162	chr3:63841271	THOC7	-0.47	-5.78	-0.51	9.58e-8	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs2688608	0.592	rs13013	chr10:75562161	C/A	cg19442545	chr10:75533431	FUT11	-0.58	-6.1	-0.53	2.24e-8	Inflammatory bowel disease;
THYM	cis	rs17125944	0.686	rs12435704	chr14:53346574	T/C	cg00686598	chr14:53173677	PSMC6	-1.08	-4.83	-0.44	5.23e-6	Alzheimer's disease (late onset);
THYM	cis	rs4845570	0.850	rs4618976	chr1:151766588	A/G	cg18019451	chr1:151746047	TDRKH	0.77	4.61	0.43	1.27e-5	Coronary artery disease;
THYM	cis	rs11651000	0.625	rs11079786	chr17:45805916	A/G	cg06532163	chr17:45867833	NA	-0.57	-5.52	-0.49	2.89e-7	IgG glycosylation;
THYM	trans	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	Myopia (pathological);
THYM	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg26384229	chr12:38710491	ALG10B	-0.87	-8.5	-0.66	2.59e-13	Heart rate;
THYM	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg02569458	chr12:86230093	RASSF9	0.68	5.77	0.51	9.71e-8	Major depressive disorder;
THYM	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg19346786	chr7:2764209	NA	-0.73	-6.25	-0.54	1.18e-8	Height;
THYM	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg07424592	chr7:64974309	NA	1.08	5.73	0.51	1.2e-7	Diabetic kidney disease;
THYM	cis	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg05335186	chr13:53173507	NA	-0.4	-5.03	-0.46	2.36e-6	Lewy body disease;
THYM	cis	rs8060598	0.716	rs11647841	chr16:50743331	G/A	cg05261686	chr16:50743296	NOD2	0.4	4.91	0.45	3.81e-6	Leprosy;
THYM	cis	rs2069036	0.951	rs1935123	chr10:16112855	G/T	cg26633223	chr10:15133461	NA	0.68	4.76	0.44	6.94e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg25767906	chr1:53392781	SCP2	-0.53	-5.2	-0.47	1.13e-6	Monocyte count;
THYM	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg12908607	chr1:44402522	ARTN	-0.6	-5.36	-0.48	5.85e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg24209194	chr3:40518798	ZNF619	0.55	4.58	0.43	1.43e-5	Renal cell carcinoma;
THYM	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg17054759	chr22:49844102	NA	-0.51	-4.46	-0.42	2.22e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7512552	0.839	rs3896342	chr1:150411312	T/C	cg15654264	chr1:150340011	RPRD2	0.44	5.12	0.47	1.58e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg26354017	chr1:205819088	PM20D1	-0.7	-6.04	-0.53	3.05e-8	Prostate-specific antigen levels;
THYM	cis	rs9790314	0.718	rs1599383	chr3:160829820	T/C	cg04691961	chr3:161091175	C3orf57	-0.66	-5.23	-0.47	9.96e-7	Morning vs. evening chronotype;
THYM	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg26028573	chr6:26043587	HIST1H2BB	0.57	4.82	0.44	5.49e-6	Blood metabolite levels;
THYM	cis	rs2439831	0.717	rs2470132	chr15:43835481	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	6.75	0.57	1.14e-9	Lung cancer in ever smokers;
THYM	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg26022315	chr17:47021804	SNF8	0.51	4.87	0.45	4.44e-6	Type 2 diabetes;
THYM	cis	rs7000551	0.560	rs4872483	chr8:22255684	C/T	cg12081754	chr8:22256438	SLC39A14	1.05	10.17	0.72	7.28e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg27129171	chr3:47204927	SETD2	-0.81	-7.81	-0.63	7.51e-12	Colorectal cancer;
THYM	cis	rs6032067	0.537	rs6032033	chr20:43795081	G/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.67	-7.93	-0.63	4.13e-12	Blood protein levels;
THYM	cis	rs735396	1.000	rs1169310	chr12:121439433	G/A	cg02403541	chr12:121454288	C12orf43	0.59	4.73	0.44	7.87e-6	N-glycan levels;
THYM	cis	rs7226229	1.000	rs4985813	chr17:20901001	G/A	cg21263980	chr17:20946333	USP22	0.72	4.97	0.45	2.94e-6	Blood trace element (Se levels);
THYM	cis	rs763014	0.865	rs62030874	chr16:632233	T/C	cg05932139	chr16:680872	WFIKKN1	-0.57	-4.79	-0.44	6.04e-6	Height;
THYM	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg19746536	chr19:49375674	PPP1R15A	0.81	4.59	0.43	1.34e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg01364799	chr7:75623366	TMEM120A	0.64	4.75	0.44	7.32e-6	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs17253792	0.822	rs10150498	chr14:56064124	G/T	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg18681998	chr4:17616180	MED28	0.99	10.21	0.72	5.85e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs8067545	0.641	rs203482	chr17:19827210	G/A	cg20830565	chr17:20408647	MGC102966	-0.53	-4.82	-0.44	5.47e-6	Schizophrenia;
THYM	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg12560992	chr17:57184187	TRIM37	0.93	8.88	0.67	4.06e-14	Intelligence (multi-trait analysis);
THYM	cis	rs61990749	0.571	rs4903655	chr14:78306326	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.89	5.5	0.49	3.22e-7	Fibroblast growth factor basic levels;
THYM	cis	rs514406	0.893	rs6661115	chr1:53426148	G/A	cg16325326	chr1:53192061	ZYG11B	-0.84	-7.79	-0.62	8.22e-12	Monocyte count;
THYM	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg14074117	chr16:1909714	C16orf73	-0.7	-4.45	-0.42	2.3e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg07362569	chr17:61921086	SMARCD2	-0.58	-5.21	-0.47	1.07e-6	Prudent dietary pattern;
THYM	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs524281	0.773	rs11227448	chr11:66048491	G/A	cg00563793	chr11:65837595	PACS1	0.77	4.5	0.42	1.91e-5	Electroencephalogram traits;
THYM	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg09359103	chr1:154839909	KCNN3	-0.84	-10.81	-0.74	3.09e-18	Prostate cancer;
THYM	cis	rs7584330	0.518	rs74970394	chr2:238443483	C/T	cg14458575	chr2:238380390	NA	1.17	5.63	0.5	1.8e-7	Prostate cancer;
THYM	cis	rs748404	0.660	rs518288	chr15:43763999	C/T	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08704250	chr15:31115839	NA	-0.67	-7.15	-0.59	1.74e-10	Huntington's disease progression;
THYM	cis	rs10493773	0.609	rs11161656	chr1:86182414	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.59	-9.23	-0.69	7.42e-15	Urate levels in overweight individuals;
THYM	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs1797885	0.510	rs2633442	chr3:12609937	A/G	cg05467012	chr3:12595696	NA	-0.54	-4.7	-0.43	8.77e-6	Immature fraction of reticulocytes;
THYM	cis	rs2688608	0.592	rs10762560	chr10:75495405	T/G	cg19442545	chr10:75533431	FUT11	-0.51	-5.22	-0.47	1.03e-6	Inflammatory bowel disease;
THYM	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs208520	0.779	rs208451	chr6:66906155	G/A	cg07460842	chr6:66804631	NA	-0.81	-4.98	-0.46	2.79e-6	Exhaled nitric oxide output;
THYM	cis	rs4242434	0.597	rs876714	chr8:22482799	A/G	cg11461670	chr8:22454935	PDLIM2	-0.31	-5.23	-0.47	9.88e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs472402	0.580	rs11134173	chr5:6659696	C/A	cg12648172	chr5:5886274	NA	0.52	4.59	0.43	1.34e-5	Response to amphetamines;
THYM	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3126085	0.877	rs1969019	chr1:152211502	A/C	cg10321714	chr1:152280068	FLG	0.63	4.53	0.42	1.71e-5	Atopic dermatitis;
THYM	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs13082711	0.863	rs77135084	chr3:27423549	A/C	cg02860705	chr3:27208620	NA	0.67	4.72	0.44	8.23e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg27068330	chr11:65405492	SIPA1	0.84	8.34	0.65	5.78e-13	Acne (severe);
THYM	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg02782426	chr3:40428986	ENTPD3	0.55	4.92	0.45	3.58e-6	Renal cell carcinoma;
THYM	cis	rs8078723	1.000	rs7214085	chr17:38169095	T/C	cg17467752	chr17:38218738	THRA	0.86	7.09	0.59	2.4e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg05342682	chr7:94953680	PON1	-0.49	-5.36	-0.48	5.9e-7	Paraoxonase activity;
THYM	cis	rs6430585	0.528	rs2278682	chr2:136743143	G/C	cg07169764	chr2:136633963	MCM6	0.95	8.49	0.66	2.72e-13	Corneal structure;
THYM	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs6754311	0.731	rs309134	chr2:136755684	A/G	cg04750100	chr2:136595281	LCT	-0.53	-5.96	-0.52	4.24e-8	Mosquito bite size;
THYM	cis	rs10484885	0.690	rs292236	chr6:90528422	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.84	-8.24	-0.65	9.44e-13	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg00686598	chr14:53173677	PSMC6	1.52	7.73	0.62	1.09e-11	Alzheimer's disease (late onset);
THYM	cis	rs79387448	0.745	rs7593444	chr2:103158561	G/A	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg23422044	chr7:1970798	MAD1L1	-0.79	-5.34	-0.48	6.39e-7	Bipolar disorder;
THYM	trans	rs11722228	0.549	rs2241488	chr4:10101131	T/C	cg26043149	chr18:55253948	FECH	1.16	10.82	0.74	2.98e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs6009824	0.891	rs6009822	chr22:50085731	C/T	cg18178197	chr22:50098317	NA	0.91	7.29	0.6	8.95e-11	Natriuretic peptide levels;
THYM	trans	rs877282	0.898	rs35743076	chr10:758991	C/T	cg22713356	chr15:30763199	NA	1.41	11.54	0.76	9e-20	Uric acid levels;
THYM	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg06634786	chr22:41940651	POLR3H	-0.73	-5.44	-0.49	4.17e-7	Vitiligo;
THYM	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg16797656	chr11:68205561	LRP5	0.44	4.52	0.42	1.8e-5	Total body bone mineral density;
THYM	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg00922110	chr4:57842668	C4orf14	-0.44	-5.13	-0.47	1.56e-6	Response to bleomycin (chromatid breaks);
THYM	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs2919009	0.607	rs12250320	chr10:122719308	A/T	cg26518861	chr10:122708898	NA	-0.63	-4.9	-0.45	3.97e-6	Obesity-related traits;
THYM	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.78	-7.17	-0.59	1.61e-10	Personality dimensions;
THYM	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg26597838	chr10:835615	NA	1.21	8.65	0.66	1.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg07936489	chr17:37558343	FBXL20	0.82	5.69	0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.92	0.45	3.58e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7681440	0.606	rs2737006	chr4:90749686	A/G	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg21028142	chr17:79581711	NPLOC4	0.64	6.75	0.57	1.17e-9	Eye color traits;
THYM	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg12163867	chr12:51592794	POU6F1	-0.89	-5.63	-0.5	1.86e-7	Cisplatin-induced ototoxicity;
THYM	cis	rs8044868	0.586	rs2070937	chr16:72089740	A/G	cg16558253	chr16:72132732	DHX38	-0.54	-4.58	-0.43	1.39e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg16680214	chr1:154839983	KCNN3	-0.47	-5.21	-0.47	1.1e-6	Prostate cancer;
THYM	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg13010199	chr12:38710504	ALG10B	0.71	4.87	0.45	4.46e-6	Morning vs. evening chronotype;
THYM	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg07414643	chr4:187882934	NA	0.67	5.92	0.52	5.16e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7250872	0.647	rs2304613	chr19:1817943	G/C	cg10370574	chr19:1840461	REXO1	-1.03	-9.28	-0.69	5.77e-15	Bipolar disorder;
THYM	cis	rs9807989	0.507	rs2041739	chr2:102994333	A/G	cg03938978	chr2:103052716	IL18RAP	-0.75	-9.77	-0.71	5.14e-16	Asthma;
THYM	cis	rs6700896	0.932	rs6678033	chr1:66077624	G/A	cg04111102	chr1:66153794	NA	0.53	4.64	0.43	1.12e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs6570726	0.526	rs9376928	chr6:145724403	T/G	cg13319975	chr6:146136371	FBXO30	0.6	4.68	0.43	9.54e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg18709589	chr6:96969512	KIAA0776	-0.55	-4.52	-0.42	1.75e-5	Headache;
THYM	cis	rs28647808	0.881	rs28622217	chr9:136267323	A/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs2811415	0.597	rs13094149	chr3:127795569	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs36051895	0.695	rs10974916	chr9:5017350	G/A	cg02405213	chr9:5042618	JAK2	-1.02	-10.52	-0.73	1.27e-17	Pediatric autoimmune diseases;
THYM	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg10661904	chr17:79619235	PDE6G	0.57	5.3	0.48	7.61e-7	Eye color traits;
THYM	cis	rs10484885	0.757	rs72912535	chr6:90159762	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.72	-5.87	-0.52	6.43e-8	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs4072705	0.562	rs7855918	chr9:127239939	T/C	cg13476313	chr9:127244764	NR5A1	0.37	5.13	0.47	1.52e-6	Menarche (age at onset);
THYM	cis	rs11997175	0.646	rs7005018	chr8:33700210	A/G	ch.8.33884649F	chr8:33765107	NA	0.66	4.99	0.46	2.67e-6	Body mass index;
THYM	cis	rs2404602	0.647	rs3812908	chr15:77176158	C/T	cg23625390	chr15:77176239	SCAPER	0.82	5.85	0.51	6.95e-8	Blood metabolite levels;
THYM	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs11264213	0.901	rs631202	chr1:36449099	G/C	cg27506609	chr1:36549197	TEKT2	1.13	4.46	0.42	2.23e-5	Schizophrenia;
THYM	cis	rs28595532	0.764	rs115298416	chr4:119565383	C/T	cg21605333	chr4:119757512	SEC24D	1.41	4.74	0.44	7.63e-6	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7412746	0.611	rs10888395	chr1:150762171	C/T	cg10589385	chr1:150898437	SETDB1	0.62	5.17	0.47	1.27e-6	Melanoma;
THYM	cis	rs4866334	0.681	rs6452356	chr5:18486255	C/T	cg18608440	chr5:17519013	NA	-1.07	-4.95	-0.45	3.24e-6	IgG glycosylation;
THYM	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.66	-4.61	-0.43	1.25e-5	Gut microbiome composition (summer);
THYM	cis	rs2276314	0.857	rs28396546	chr18:33639024	T/C	cg05985134	chr18:33552581	C18orf21	0.69	4.88	0.45	4.22e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.81	6.2	0.54	1.49e-8	IgG glycosylation;
THYM	cis	rs3087591	1.000	rs2940183	chr17:29416499	T/C	cg24425628	chr17:29625626	OMG;NF1	0.61	5.33	0.48	6.72e-7	Hip circumference;
THYM	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg17063962	chr7:91808500	NA	-1.13	-12.74	-0.79	2.8e-22	Breast cancer;
THYM	cis	rs9515201	0.627	rs4773173	chr13:111025118	A/G	cg15455643	chr13:111040242	COL4A2	0.5	6.1	0.53	2.25e-8	White matter hyperintensity burden;
THYM	cis	rs11690462	0.534	rs13432533	chr2:26571411	G/A	cg11525280	chr2:26624667	C2orf39	-0.53	-5.4	-0.48	4.81e-7	Coronary artery disease;
THYM	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg12863693	chr15:85201151	NMB	0.62	5.41	0.49	4.74e-7	Schizophrenia;
THYM	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	10.29	0.73	3.95e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg03351412	chr1:154909251	PMVK	0.68	5.21	0.47	1.11e-6	Prostate cancer;
THYM	cis	rs11645898	0.748	rs11647889	chr16:72052034	C/G	cg14768367	chr16:72042858	DHODH	-0.8	-5.91	-0.52	5.43e-8	Blood protein levels;
THYM	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg24642844	chr7:1081250	C7orf50	-1.29	-8.3	-0.65	7.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2239547	0.522	rs6445550	chr3:52983434	G/A	cg11645453	chr3:52864694	ITIH4	0.29	4.45	0.42	2.31e-5	Schizophrenia;
THYM	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg26677194	chr12:130822605	PIWIL1	0.8	6.23	0.54	1.25e-8	Menopause (age at onset);
THYM	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg18876405	chr7:65276391	NA	0.7	6.14	0.53	1.87e-8	Calcium levels;
THYM	cis	rs7394190	0.748	rs11000777	chr10:75545063	G/C	cg07699608	chr10:75541558	CHCHD1	0.91	4.93	0.45	3.49e-6	Incident atrial fibrillation;
THYM	cis	rs4606347	0.932	rs11809917	chr1:66146837	T/C	cg04111102	chr1:66153794	NA	0.57	4.53	0.42	1.73e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6964587	0.610	rs10953056	chr7:91466700	C/T	cg22709100	chr7:91322751	NA	0.62	4.56	0.42	1.55e-5	Breast cancer;
THYM	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg05025164	chr4:1340916	KIAA1530	0.65	5.02	0.46	2.39e-6	Longevity;
THYM	cis	rs669446	0.533	rs6429638	chr1:44211010	A/G	cg12599982	chr1:44399894	ARTN	0.52	4.74	0.44	7.55e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs55665837	1.000	rs10832256	chr11:14442875	G/A	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg12419862	chr22:24373484	LOC391322	-0.73	-6.83	-0.57	7.9e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg00071950	chr4:10020882	SLC2A9	-0.67	-5.98	-0.52	3.97e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2903698	0.585	rs61334117	chr4:76378944	T/C	cg03209871	chr4:76438412	RCHY1;THAP6	0.45	5.16	0.47	1.35e-6	Prion diseases;
THYM	cis	rs9560113	0.580	rs9560115	chr13:112193619	G/A	cg15979348	chr13:112237479	NA	0.53	4.65	0.43	1.08e-5	Menarche (age at onset);
THYM	cis	rs6032067	0.516	rs761367	chr20:43913317	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.4	-4.77	-0.44	6.69e-6	Blood protein levels;
THYM	cis	rs28595532	0.920	rs114684527	chr4:119749252	G/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs7262634	1.000	rs8125384	chr20:45829515	C/T	cg18599129	chr20:45867857	ZMYND8	0.83	4.87	0.45	4.48e-6	Response to protease inhibitor treatment in hepatitis c (bilirubin toxicity);
THYM	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg22709100	chr7:91322751	NA	-0.59	-4.77	-0.44	6.76e-6	Breast cancer;
THYM	cis	rs3126085	0.935	rs7533529	chr1:152176871	T/C	cg26020982	chr1:152196106	HRNR	0.36	4.7	0.43	8.63e-6	Atopic dermatitis;
THYM	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7172809	0.573	rs13380202	chr15:77659982	G/A	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs4631830	0.869	rs11006207	chr10:51538176	T/C	cg16070123	chr10:51489643	NA	-0.53	-4.78	-0.44	6.27e-6	Prostate-specific antigen levels;
THYM	trans	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg10856724	chr12:34555212	NA	-1.01	-9.17	-0.69	9.95e-15	Bladder cancer;
THYM	cis	rs854765	0.624	rs12952723	chr17:17731651	T/C	cg04398451	chr17:18023971	MYO15A	0.74	6.5	0.56	3.65e-9	Total body bone mineral density;
THYM	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg06238570	chr21:40685208	BRWD1	-0.99	-9.39	-0.69	3.25e-15	Cognitive function;
THYM	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg06481639	chr22:41940642	POLR3H	-0.69	-5.53	-0.49	2.86e-7	Vitiligo;
THYM	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4917300	0.605	rs10108708	chr8:143102886	A/G	cg26003909	chr8:143102224	NA	-0.32	-4.63	-0.43	1.15e-5	Amyotrophic lateral sclerosis;
THYM	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg08859206	chr1:53392774	SCP2	0.5	5.12	0.47	1.57e-6	Monocyte count;
THYM	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.78	-7.06	-0.59	2.78e-10	Calcium levels;
THYM	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg03929089	chr4:120376271	NA	-0.99	-12.83	-0.8	1.9e-22	Height;
THYM	cis	rs2040771	0.745	rs361956	chr22:19265799	C/T	cg02655711	chr22:19163373	SLC25A1	0.61	6.49	0.55	3.82e-9	Metabolite levels (small molecules and protein measures);
THYM	cis	rs9959145	0.929	rs113231666	chr18:12574010	T/C	cg14160804	chr18:12703040	PSMG2;CEP76	-0.9	-4.47	-0.42	2.15e-5	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg17366294	chr4:99064904	C4orf37	0.57	6.68	0.57	1.63e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg18876405	chr7:65276391	NA	-0.65	-5.53	-0.49	2.85e-7	Aortic root size;
THYM	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg22920501	chr2:26401640	FAM59B	0.73	6.23	0.54	1.28e-8	Gut microbiome composition (summer);
THYM	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg11335335	chr11:637885	DRD4	-0.66	-4.9	-0.45	3.93e-6	Systemic lupus erythematosus;
THYM	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	4.97	0.45	3e-6	Height;
THYM	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg21433313	chr16:3507492	NAT15	-0.86	-9.14	-0.68	1.13e-14	Tuberculosis;
THYM	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg11266682	chr4:10021025	SLC2A9	0.74	10.8	0.74	3.21e-18	Bone mineral density;
THYM	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.89	0.52	5.88e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12956009	0.583	rs16951972	chr18:44898600	C/T	cg19077165	chr18:44547161	KATNAL2	-0.49	-4.7	-0.43	8.81e-6	Educational attainment (years of education);
THYM	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg02825527	chr7:2087843	MAD1L1	-0.77	-5.17	-0.47	1.29e-6	Bipolar disorder;
THYM	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg04944784	chr2:26401820	FAM59B	-1.09	-8.88	-0.67	4.05e-14	Gut microbiome composition (summer);
THYM	cis	rs6732160	0.741	rs10203600	chr2:73361398	G/C	cg24220031	chr2:73402428	NA	-0.73	-7.38	-0.6	6.1e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7216064	0.953	rs1599859	chr17:65837193	C/G	cg12091567	chr17:66097778	LOC651250	-0.73	-4.9	-0.45	3.89e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	trans	rs28595532	1.000	rs17323012	chr4:119605671	A/G	cg13773247	chr2:42276988	PKDCC	0.88	6.91	0.58	5.38e-10	Cannabis dependence symptom count;
THYM	cis	rs2108622	0.727	rs12609900	chr19:15982414	G/A	cg13772218	chr19:15982569	NA	0.5	4.48	0.42	2.06e-5	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs790123	1.000	rs790113	chr3:122383276	T/A	cg15604389	chr3:122379662	NA	0.59	5.54	0.49	2.65e-7	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs17401966	0.627	rs35859381	chr1:10466040	G/A	cg19773385	chr1:10388646	KIF1B	-0.6	-4.89	-0.45	4.13e-6	Hepatocellular carcinoma;
THYM	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg05527609	chr1:210001259	C1orf107	-1.0	-8.13	-0.64	1.56e-12	Orofacial clefts;
THYM	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs8014204	0.967	rs4903266	chr14:75344941	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.59	-5.9	-0.52	5.57e-8	Caffeine consumption;
THYM	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg21926883	chr2:100939477	LONRF2	-0.61	-5.23	-0.47	1.02e-6	Intelligence (multi-trait analysis);
THYM	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg12000587	chr17:30186630	C17orf79	-0.43	-4.67	-0.43	1.01e-5	Hip circumference adjusted for BMI;
THYM	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg26597838	chr10:835615	NA	1.2	8.64	0.66	1.3e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs4499344	0.556	rs259243	chr19:33144726	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.97	7.12	0.59	2.04e-10	Mean platelet volume;
THYM	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg06713675	chr4:122721982	EXOSC9	-0.85	-9.54	-0.7	1.57e-15	Type 2 diabetes;
THYM	cis	rs10411161	0.702	rs7251755	chr19:52388948	G/A	cg25361850	chr19:52391789	ZNF577	0.74	5.18	0.47	1.22e-6	Breast cancer;
THYM	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg10589385	chr1:150898437	SETDB1	0.63	5.2	0.47	1.14e-6	Melanoma;
THYM	cis	rs7567389	0.677	rs11680877	chr2:128090450	A/G	cg06038358	chr2:128176007	PROC	0.43	4.53	0.42	1.7e-5	Self-rated health;
THYM	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg21252483	chr19:49399788	TULP2	-0.88	-6.15	-0.53	1.82e-8	Red cell distribution width;
THYM	cis	rs75059851	0.756	rs73036081	chr11:133840156	C/T	cg14047540	chr11:133829660	NA	-1.1	-7.34	-0.6	7.1e-11	Schizophrenia;
THYM	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg11245990	chr11:68621969	NA	0.56	7.12	0.59	2.05e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.76	0.44	6.93e-6	Diabetic retinopathy;
THYM	cis	rs7267979	1.000	rs2259928	chr20:25281834	G/C	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs6840360	0.642	rs11729923	chr4:152392036	G/T	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs72772090	0.539	rs72773942	chr5:96123366	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.71	5.46	0.49	3.74e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs55871839	0.684	rs10095333	chr8:59815629	G/A	cg07426533	chr8:59803705	TOX	-0.69	-7.22	-0.6	1.27e-10	Pneumonia;
THYM	cis	rs9470366	0.637	rs730506	chr6:36645968	G/C	cg11920449	chr6:36645608	CDKN1A	-0.78	-5.53	-0.49	2.81e-7	QRS duration;
THYM	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg02018176	chr4:1364513	KIAA1530	0.55	4.58	0.42	1.44e-5	Obesity-related traits;
THYM	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg04944784	chr2:26401820	FAM59B	-1.06	-8.27	-0.65	8.28e-13	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg15744005	chr10:104629667	AS3MT	-0.8	-7.6	-0.61	2.08e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs12935418	0.616	rs718954	chr16:80987116	C/G	cg16651780	chr16:81037892	C16orf61	0.91	5.33	0.48	6.72e-7	Mean corpuscular volume;
THYM	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg10862848	chr6:42927986	GNMT	-0.5	-6.77	-0.57	1.08e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22857025	chr5:266934	NA	-1.41	-9.08	-0.68	1.5e-14	Breast cancer;
THYM	cis	rs73086581	1.000	rs17215529	chr20:3975402	A/G	cg02187196	chr20:3869020	PANK2	0.5	5.62	0.5	1.92e-7	Response to antidepressants in depression;
THYM	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg06221963	chr1:154839813	KCNN3	0.9	13.31	0.81	1.95e-23	Prostate cancer;
THYM	trans	rs682457	0.524	rs72962904	chr11:87943861	A/G	cg24704476	chr1:956799	AGRN	0.82	7.0	0.58	3.58e-10	Post-traumatic stress disorder;
THYM	cis	rs9311676	0.632	rs11130642	chr3:58420042	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs586688	0.625	rs672696	chr1:201679080	C/G	cg14168733	chr1:201708718	NAV1	0.59	5.33	0.48	6.54e-7	Obesity-related traits;
THYM	cis	rs9311676	0.586	rs73085867	chr3:58434791	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs3772130	0.962	rs28660600	chr3:121482637	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg20007245	chr22:24372913	LOC391322	-0.7	-6.16	-0.53	1.76e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.91	-4.95	-0.45	3.24e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03517284	chr6:25882590	NA	-0.71	-5.52	-0.49	2.95e-7	Blood metabolite levels;
THYM	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg13683864	chr3:40499215	RPL14	-1.05	-11.37	-0.76	2.04e-19	Renal cell carcinoma;
THYM	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg13852791	chr20:30311386	BCL2L1	0.74	5.35	0.48	6.15e-7	Mean corpuscular hemoglobin;
THYM	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg24692254	chr21:30365293	RNF160	0.64	4.61	0.43	1.25e-5	Selective IgA deficiency;
THYM	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg25036284	chr2:26402008	FAM59B	0.72	4.71	0.43	8.59e-6	Gut microbiome composition (summer);
THYM	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-5.75	-0.51	1.06e-7	Chronic sinus infection;
THYM	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg27398817	chr8:82754497	SNX16	-0.71	-6.05	-0.53	2.89e-8	Diastolic blood pressure;
THYM	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.72	0.57	1.37e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg14993813	chr1:46806288	NSUN4	0.69	4.66	0.43	1.02e-5	Menopause (age at onset);
THYM	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.08	7.64	0.62	1.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs61931739	0.507	rs1352393	chr12:33815820	A/G	cg06521331	chr12:34319734	NA	-0.62	-4.58	-0.43	1.39e-5	Morning vs. evening chronotype;
THYM	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg24818145	chr4:99064322	C4orf37	0.9	7.36	0.6	6.5e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4788570	0.566	rs10468265	chr16:71476943	T/C	cg06353428	chr16:71660113	MARVELD3	-1.01	-5.04	-0.46	2.2e-6	Intelligence (multi-trait analysis);
THYM	cis	rs863345	0.604	rs7514968	chr1:158493852	A/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs6496667	0.509	rs57962570	chr15:90985596	C/G	cg00425431	chr15:90792223	TTLL13	0.41	4.85	0.45	4.83e-6	Rheumatoid arthritis;
THYM	trans	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg25517755	chr10:38738941	LOC399744	-0.8	-7.87	-0.63	5.58e-12	Corneal astigmatism;
THYM	cis	rs4631830	0.863	rs2611489	chr10:51524889	C/T	cg10326726	chr10:51549505	MSMB	-0.59	-5.93	-0.52	4.97e-8	Prostate-specific antigen levels;
THYM	cis	rs1061377	1.000	rs4974997	chr4:39110771	G/T	cg24403649	chr4:39172243	NA	0.56	4.56	0.42	1.55e-5	Uric acid levels;
THYM	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg14768367	chr16:72042858	DHODH	0.62	4.75	0.44	7.33e-6	Fibrinogen levels;
THYM	cis	rs7011507	0.700	rs72639020	chr8:49334866	G/T	cg08774009	chr8:49309094	NA	-0.62	-4.83	-0.44	5.19e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs7917772	0.582	rs10883744	chr10:104347247	A/G	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg09904177	chr6:26538194	HMGN4	0.54	4.54	0.42	1.63e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2070488	1.000	rs7433707	chr3:38443180	G/C	cg24069376	chr3:38537580	EXOG	0.64	6.35	0.55	7.32e-9	Electrocardiographic conduction measures;
THYM	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.26	0.47	8.97e-7	Lung cancer in ever smokers;
THYM	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg21475434	chr5:93447410	FAM172A	0.86	5.57	0.5	2.35e-7	Diabetic retinopathy;
THYM	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06850241	chr22:41845214	NA	0.59	5.16	0.47	1.37e-6	Vitiligo;
THYM	cis	rs4642101	0.662	rs3901664	chr3:12824660	T/C	cg05775895	chr3:12838266	CAND2	1.04	10.22	0.72	5.49e-17	QRS complex (12-leadsum);
THYM	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.97	6.73	0.57	1.25e-9	Schizophrenia;
THYM	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg03929089	chr4:120376271	NA	1.01	8.37	0.65	4.88e-13	Coronary artery disease;
THYM	cis	rs6876348	0.516	rs257905	chr5:128317797	A/G	cg25555059	chr5:128301488	SLC27A6	-0.45	-4.62	-0.43	1.21e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7617773	0.780	rs11130164	chr3:48369034	G/A	cg02219026	chr3:48282209	ZNF589	-0.67	-4.69	-0.43	9.05e-6	Coronary artery disease;
THYM	trans	rs66573146	0.808	rs56268690	chr4:6923887	C/T	cg07817883	chr1:32538562	TMEM39B	1.61	7.12	0.59	2.04e-10	Granulocyte percentage of myeloid white cells;
THYM	cis	rs7264396	0.580	rs2425173	chr20:34445142	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-4.85	-0.45	4.83e-6	Total cholesterol levels;
THYM	cis	rs9443189	0.570	rs276687	chr6:76429995	G/T	cg01950844	chr6:76311363	SENP6	-1.05	-6.66	-0.56	1.73e-9	Prostate cancer;
THYM	cis	rs7394190	0.748	rs3781216	chr10:75522404	G/A	cg07699608	chr10:75541558	CHCHD1	0.91	4.93	0.45	3.49e-6	Incident atrial fibrillation;
THYM	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg03929089	chr4:120376271	NA	-1.01	-8.54	-0.66	2.14e-13	Height;
THYM	cis	rs11148252	0.840	rs56304200	chr13:52781763	T/A	cg00495681	chr13:53174319	NA	0.76	6.87	0.58	6.62e-10	Lewy body disease;
THYM	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg24375607	chr4:120327624	NA	0.66	5.26	0.48	8.74e-7	Corneal astigmatism;
THYM	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.56	0.73	1.04e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs116095464	1.000	rs62331562	chr5:349298	G/C	cg00420510	chr5:1089571	SLC12A7	0.78	4.49	0.42	1.98e-5	Breast cancer;
THYM	cis	rs7809950	0.861	rs10264412	chr7:107183877	G/A	cg23024343	chr7:107201750	COG5	-1.05	-9.25	-0.69	6.47e-15	Coronary artery disease;
THYM	cis	rs13315871	0.790	rs115288459	chr3:58324283	A/G	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	trans	rs10838798	0.504	rs11039530	chr11:48145746	C/T	cg00717180	chr2:96193071	NA	-0.64	-7.09	-0.59	2.39e-10	Height;
THYM	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg23791538	chr6:167370224	RNASET2	0.74	5.92	0.52	5.06e-8	Crohn's disease;
THYM	trans	rs10958605	0.761	rs7818390	chr8:40034287	A/T	cg02560310	chr20:60578131	TAF4	0.73	6.89	0.58	6.01e-10	Parkinson's disease (motor and cognition);
THYM	cis	rs4919687	0.550	rs4264100	chr10:104454113	C/G	cg04362960	chr10:104952993	NT5C2	0.61	4.9	0.45	4.01e-6	Colorectal cancer;
THYM	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs12458462	0.812	rs36073957	chr18:77488441	C/T	cg11879182	chr18:77439856	CTDP1	0.82	7.9	0.63	4.96e-12	Monocyte count;
THYM	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg16586182	chr3:47516702	SCAP	-0.63	-5.31	-0.48	7.25e-7	Colorectal cancer;
THYM	cis	rs9868809	0.649	rs3733086	chr3:48699519	C/T	cg00383909	chr3:49044727	WDR6	1.13	5.77	0.51	1e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4732038	0.510	rs10258909	chr7:134269893	C/T	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4589258	0.737	rs7947495	chr11:90406520	T/G	cg26138821	chr11:89956704	CHORDC1	0.57	4.76	0.44	7.05e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11644478	chr21:40555479	PSMG1	1.08	9.36	0.69	3.9e-15	Cognitive function;
THYM	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg13319975	chr6:146136371	FBXO30	-0.65	-5.33	-0.48	6.73e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4595586	0.545	rs6580889	chr12:39369742	T/C	cg13010199	chr12:38710504	ALG10B	0.67	5.17	0.47	1.32e-6	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3741151	0.572	rs12290623	chr11:73121872	C/G	cg12959048	chr11:73096162	RELT	-0.45	-4.78	-0.44	6.46e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg12311346	chr5:56204834	C5orf35	-0.77	-5.59	-0.5	2.18e-7	Initial pursuit acceleration;
THYM	cis	rs6988636	1.000	rs59834873	chr8:124188824	G/T	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs6500395	1.000	rs11649236	chr16:48632478	C/T	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs1883415	0.648	rs2744584	chr6:24505354	G/A	cg00346970	chr6:24499591	ALDH5A1	0.48	6.13	0.53	1.98e-8	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6763768	0.577	rs35536048	chr3:53388950	C/G	cg22900224	chr3:52804907	NEK4	0.72	4.64	0.43	1.13e-5	Bacterial meningitis;
THYM	cis	rs4731207	0.596	rs10276834	chr7:124607549	A/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs61931739	0.857	rs999715	chr12:34143253	G/C	cg10856724	chr12:34555212	NA	-0.66	-5.93	-0.52	4.95e-8	Morning vs. evening chronotype;
THYM	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg01699819	chr7:1052092	C7orf50	-0.82	-6.87	-0.58	6.68e-10	Bronchopulmonary dysplasia;
THYM	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs2916260	0.800	rs61731040	chr6:40400288	C/T	cg08415973	chr6:40346114	TDRG1	0.75	4.71	0.43	8.56e-6	Incident coronary heart disease;
THYM	cis	rs16937	0.640	rs6664706	chr1:205182563	T/C	cg17889831	chr1:205181581	DSTYK	-0.39	-4.78	-0.44	6.51e-6	Schizophrenia;
THYM	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg11764359	chr7:65958608	NA	0.78	6.31	0.54	8.88e-9	Aortic root size;
THYM	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.79	-6.61	-0.56	2.23e-9	Lymphocyte percentage of white cells;
THYM	cis	rs6930083	0.713	rs1321308	chr6:36638691	A/C	cg08179530	chr6:36648295	CDKN1A	-0.8	-5.95	-0.52	4.42e-8	Coronary artery disease;
THYM	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg16049864	chr8:95962084	TP53INP1	-0.84	-7.41	-0.61	5.2e-11	Type 2 diabetes;
THYM	cis	rs4718428	1.000	rs4718421	chr7:66350300	C/T	cg26963428	chr7:66367121	NA	-0.57	-4.75	-0.44	7.17e-6	Corneal structure;
THYM	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg09307838	chr4:120376055	NA	0.77	5.56	0.5	2.5e-7	Corneal astigmatism;
THYM	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg04731861	chr2:219085781	ARPC2	0.56	5.39	0.48	5.21e-7	Colorectal cancer;
THYM	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg26039829	chr8:22132926	PIWIL2	0.7	6.46	0.55	4.44e-9	Hypertriglyceridemia;
THYM	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg07936489	chr17:37558343	FBXL20	-0.82	-5.61	-0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg18512352	chr11:47633146	NA	-0.53	-6.26	-0.54	1.1e-8	Subjective well-being;
THYM	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg08645402	chr16:4508243	NA	0.76	6.87	0.58	6.72e-10	Schizophrenia;
THYM	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg17480646	chr11:65405466	SIPA1	-0.94	-8.68	-0.67	1.07e-13	Acne (severe);
THYM	cis	rs11605275	1.000	rs11605275	chr11:20031865	C/T	cg14835545	chr11:20032148	NAV2	-1.37	-7.11	-0.59	2.16e-10	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs955333	0.565	rs67309443	chr6:154906587	C/T	cg17771515	chr6:154831774	CNKSR3	0.66	4.55	0.42	1.61e-5	Diabetic kidney disease;
THYM	cis	rs9486719	1.000	rs2142652	chr6:96868504	A/C	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs7432375	0.901	rs1681817	chr3:136473728	C/T	cg12473912	chr3:136751656	NA	-0.63	-5.63	-0.5	1.81e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs9682041	1.000	rs15709	chr3:170110529	T/A	cg21474897	chr3:170136489	CLDN11	-1.03	-4.84	-0.44	5.09e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg14675211	chr2:100938903	LONRF2	-0.75	-7.78	-0.62	8.53e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg21138405	chr5:131827807	IRF1	-0.83	-9.49	-0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg03188948	chr7:1209495	NA	0.9	5.02	0.46	2.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7246657	0.941	rs10418729	chr19:37737065	A/C	cg22634378	chr19:37742834	NA	0.56	4.51	0.42	1.89e-5	Coronary artery calcification;
THYM	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs13064411	0.696	rs13066742	chr3:113208423	T/C	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	trans	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg19862616	chr7:65841803	NCRNA00174	1.04	12.62	0.79	5.01e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg07212818	chr11:638076	DRD4	-0.77	-5.61	-0.5	1.95e-7	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg23682913	chr1:2080710	PRKCZ	-0.59	-5.28	-0.48	8.17e-7	Height;
THYM	cis	rs2674946	0.644	rs35814610	chr17:13041714	T/C	cg12799781	chr17:12569110	MYOCD	-0.56	-5.22	-0.47	1.05e-6	Squamous cell lung carcinoma;
THYM	cis	rs877282	0.853	rs7079299	chr10:756455	A/G	cg10556349	chr10:835070	NA	-0.69	-4.49	-0.42	2.03e-5	Uric acid levels;
THYM	cis	rs662064	0.889	rs1188526	chr1:10549848	G/C	cg20482658	chr1:10539492	PEX14	-0.49	-6.13	-0.53	2e-8	Asthma;
THYM	trans	rs4650994	0.525	rs4457535	chr1:178497186	C/T	cg05059571	chr16:84539110	KIAA1609	0.85	9.79	0.71	4.57e-16	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs750460	0.899	rs8023330	chr15:74220599	A/G	cg23484268	chr15:74220776	LOXL1	-0.42	-4.65	-0.43	1.07e-5	Height;
THYM	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg11764359	chr7:65958608	NA	-0.8	-6.38	-0.55	6.55e-9	Aortic root size;
THYM	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.78	-6.97	-0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg12573674	chr2:1569213	NA	-1.33	-8.16	-0.64	1.42e-12	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs172166	0.560	rs203878	chr6:28048996	T/G	cg09682330	chr6:28411287	ZSCAN23	-0.6	-5.32	-0.48	6.93e-7	Cardiac Troponin-T levels;
THYM	cis	rs524023	0.874	rs7105665	chr11:64396568	T/C	cg19131476	chr11:64387923	NRXN2	-0.39	-5.54	-0.49	2.7e-7	Urate levels in obese individuals;
THYM	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs6980507	0.524	rs62510967	chr8:42441374	C/G	cg09913449	chr8:42400586	C8orf40	0.68	5.92	0.52	5.15e-8	Glycated hemoglobin levels;
THYM	cis	rs9325144	0.723	rs1586373	chr12:39181582	G/A	cg26384229	chr12:38710491	ALG10B	-0.6	-4.62	-0.43	1.18e-5	Morning vs. evening chronotype;
THYM	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg02725872	chr8:58115012	NA	-1.11	-8.56	-0.66	1.98e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs4698048	0.506	rs2080072	chr4:10235622	G/C	cg13000635	chr4:9523653	NA	-0.52	-4.75	-0.44	7.18e-6	Skin aging (microtopography measurement);
THYM	cis	rs367615	0.537	rs17161729	chr5:108660528	C/G	cg17395555	chr5:108820864	NA	-0.56	-6.57	-0.56	2.74e-9	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs3126085	0.825	rs11204933	chr1:152172185	C/T	cg26020982	chr1:152196106	HRNR	0.36	4.7	0.43	8.63e-6	Atopic dermatitis;
THYM	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg27129171	chr3:47204927	SETD2	0.69	5.56	0.5	2.51e-7	Birth weight;
THYM	cis	rs11186	0.524	rs56176197	chr2:189970993	C/T	cg11041835	chr2:189156425	GULP1	0.83	4.81	0.44	5.62e-6	Parkinson's disease;
THYM	cis	rs12282928	0.788	rs7127946	chr11:48250675	C/T	cg22827986	chr11:48284249	OR4X1	-0.44	-4.48	-0.42	2.09e-5	Migraine - clinic-based;
THYM	cis	rs861020	0.959	rs641348	chr1:209992043	A/G	cg05527609	chr1:210001259	C1orf107	1.12	8.22	0.64	1.06e-12	Orofacial clefts;
THYM	cis	rs7607369	0.637	rs3888879	chr2:219290676	C/T	cg02176678	chr2:219576539	TTLL4	-0.69	-6.04	-0.53	3.05e-8	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg04287289	chr16:89883240	FANCA	0.66	6.2	0.54	1.43e-8	Vitiligo;
THYM	cis	rs9534288	0.797	rs4942467	chr13:46599817	A/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs6754311	0.773	rs309178	chr2:136611624	C/T	cg04750100	chr2:136595281	LCT	-0.56	-6.14	-0.53	1.92e-8	Mosquito bite size;
THYM	cis	rs7942486	0.893	rs11828583	chr11:13279963	A/C	cg13286116	chr11:13302098	ARNTL	-0.68	-7.34	-0.6	7.12e-11	Neuroticism;
THYM	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg06850241	chr22:41845214	NA	0.54	4.6	0.43	1.33e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4746818	0.818	rs7076011	chr10:70900430	T/C	cg11621586	chr10:70884670	VPS26A	1.28	11.0	0.75	1.26e-18	Left atrial antero-posterior diameter;
THYM	cis	rs4930776	0.897	rs417642	chr12:5763772	C/T	cg02086166	chr12:5775618	ANO2	0.63	6.32	0.54	8.4e-9	Plasma clusterin levels;
THYM	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg24596788	chr1:163392923	NA	-0.78	-7.19	-0.59	1.5e-10	Motion sickness;
THYM	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg03060546	chr3:49711283	APEH	0.75	6.08	0.53	2.55e-8	Resting heart rate;
THYM	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg24910161	chr17:38119198	GSDMA	0.45	4.67	0.43	9.96e-6	Asthma;
THYM	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg07884673	chr3:53033167	SFMBT1	1.17	5.88	0.52	6.13e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.55	-4.72	-0.44	8.2e-6	Coronary artery disease;
THYM	cis	rs7103648	1.000	rs11039225	chr11:47430599	G/A	cg20307385	chr11:47447363	PSMC3	0.93	8.66	0.66	1.23e-13	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg16524936	chr4:1340807	KIAA1530	-0.64	-5.16	-0.47	1.37e-6	Longevity;
THYM	cis	rs2629046	0.967	rs2602674	chr2:225059163	A/G	cg17778556	chr2:224773702	WDFY1	0.46	4.49	0.42	1.97e-5	Height;
THYM	cis	rs7119038	0.818	rs10892293	chr11:118665575	A/T	cg19308663	chr11:118741387	NA	0.67	5.99	0.52	3.71e-8	Sjögren's syndrome;
THYM	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.09	8.17	0.64	1.33e-12	Smoking behavior;
THYM	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg22907277	chr7:1156413	C7orf50	0.87	7.59	0.61	2.16e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9633740	1.000	rs9633740	chr10:82265271	A/G	cg01528321	chr10:82214614	TSPAN14	0.94	4.48	0.42	2.08e-5	Post bronchodilator FEV1;
THYM	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg04546413	chr19:29218101	NA	1.11	9.63	0.7	1.02e-15	Methadone dose in opioid dependence;
THYM	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg11317459	chr13:21872234	NA	-1.22	-9.26	-0.69	6.43e-15	White matter hyperintensity burden;
THYM	cis	rs6964587	0.692	rs10271430	chr7:91710466	G/C	cg22709100	chr7:91322751	NA	0.61	4.62	0.43	1.22e-5	Breast cancer;
THYM	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg20242066	chr2:136595261	LCT	-0.54	-6.83	-0.57	7.89e-10	Mosquito bite size;
THYM	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg04731861	chr2:219085781	ARPC2	0.57	5.29	0.48	7.94e-7	Colorectal cancer;
THYM	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.91	8.98	0.68	2.51e-14	Menarche (age at onset);
THYM	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg18876405	chr7:65276391	NA	0.63	5.56	0.5	2.42e-7	Aortic root size;
THYM	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg12483005	chr1:23474871	LUZP1	0.58	5.84	0.51	7.3900000000000007e-08	Height;
THYM	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.67	5.9	0.52	5.62e-8	Lung disease severity in cystic fibrosis;
THYM	cis	rs7426056	0.530	rs1181389	chr2:204574890	T/C	cg07930752	chr2:204569955	CD28	-0.73	-5.28	-0.48	8.21e-7	Primary sclerosing cholangitis;
THYM	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	5.55	0.49	2.6e-7	Bipolar disorder;
THYM	trans	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2730245	0.527	rs62476462	chr7:158686619	A/G	cg11984989	chr7:158649758	WDR60	1.01	8.5	0.66	2.65e-13	Height;
THYM	cis	rs10484885	0.824	rs11967579	chr6:90540008	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.89	-8.01	-0.64	2.84e-12	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs7586879	1.000	rs7603153	chr2:25116966	T/C	cg01884057	chr2:25150051	NA	0.63	6.3	0.54	9.31e-9	Body mass index;
THYM	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	4.91	0.45	3.76e-6	Height;
THYM	cis	rs10911251	0.546	rs1062044	chr1:183112412	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.66	0.43	1.02e-5	Colorectal cancer;
THYM	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg01097406	chr16:89675127	NA	-0.54	-4.78	-0.44	6.34e-6	Vitiligo;
THYM	cis	rs7731657	0.588	rs7724661	chr5:130352415	A/G	cg08523029	chr5:130500466	HINT1	0.84	6.1	0.53	2.29e-8	Fasting plasma glucose;
THYM	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg13319975	chr6:146136371	FBXO30	-0.72	-6.03	-0.53	3.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2354432	0.556	rs57388899	chr1:146773422	T/C	cg25205988	chr1:146714368	CHD1L	-1.1	-6.24	-0.54	1.19e-8	Mitochondrial DNA levels;
THYM	cis	rs7719624	0.869	rs6893691	chr5:135395433	A/G	cg12897067	chr5:135418308	NA	0.57	4.55	0.42	1.56e-5	Response to cytidine analogues (gemcitabine);
THYM	trans	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg10856724	chr12:34555212	NA	-0.89	-8.35	-0.65	5.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg18512352	chr11:47633146	NA	-0.53	-6.44	-0.55	4.99e-9	Subjective well-being;
THYM	cis	rs600806	0.821	rs10127790	chr1:109891133	C/T	cg16988986	chr1:109941118	SORT1	-0.43	-4.6	-0.43	1.32e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7020830	0.571	rs3780335	chr9:37376587	A/G	cg14294708	chr9:37120828	ZCCHC7	-0.94	-6.97	-0.58	4.1e-10	Schizophrenia;
THYM	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg11764359	chr7:65958608	NA	0.63	4.92	0.45	3.66e-6	Aortic root size;
THYM	cis	rs2340727	0.660	rs9970209	chr1:161942642	A/C	ch.1.159725313R	chr1:161458689	NA	-0.79	-5.47	-0.49	3.61e-7	White blood cell count;Hematology traits;
THYM	cis	rs4455778	0.557	rs4289754	chr7:49116730	C/A	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs6430585	0.941	rs6708957	chr2:136520043	C/T	cg20242066	chr2:136595261	LCT	0.55	5.64	0.5	1.73e-7	Corneal structure;
THYM	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg01579765	chr21:45077557	HSF2BP	0.52	8.65	0.66	1.28e-13	Mean corpuscular volume;
THYM	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg08994789	chr17:28903642	LRRC37B2	-1.03	-4.94	-0.45	3.29e-6	Body mass index;
THYM	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05901451	chr6:126070800	HEY2	-0.96	-9.66	-0.7	8.6e-16	Brugada syndrome;
THYM	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg22496339	chr2:162101262	NA	0.73	5.88	0.52	6.02e-8	Intelligence (multi-trait analysis);
THYM	cis	rs3803170	0.513	rs4572196	chr12:111831993	A/G	cg10833066	chr12:111807467	FAM109A	0.42	4.53	0.42	1.7e-5	Mean corpuscular hemoglobin;
THYM	cis	rs8041943	0.643	rs72732712	chr15:79921845	G/C	cg20511832	chr15:78934280	CHRNB4	0.42	4.8	0.44	5.88e-6	Bone mineral density (spine) and age at menarche;
THYM	cis	rs490234	0.783	rs2416967	chr9:128440014	T/C	cg14078157	chr9:128172775	NA	-0.66	-5.01	-0.46	2.48e-6	Mean arterial pressure;
THYM	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	8.1	0.64	1.86e-12	Monocyte percentage of white cells;
THYM	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.43	-0.65	3.8e-13	Mean corpuscular volume;
THYM	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg04156016	chr5:1868137	NA	0.5	4.8	0.44	5.78e-6	Cardiovascular disease risk factors;
THYM	cis	rs1021993	1.000	rs1354854	chr1:209468681	A/G	cg06155620	chr1:209527581	NA	0.59	4.73	0.44	7.78e-6	Gut microbiome composition (winter);
THYM	cis	rs722599	0.501	rs2286914	chr14:75387012	T/C	cg08847533	chr14:75593920	NEK9	-0.57	-4.83	-0.44	5.14e-6	IgG glycosylation;
THYM	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg22535103	chr8:58192502	C8orf71	-0.86	-4.82	-0.44	5.4e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4243830	0.850	rs12030607	chr1:6601007	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	1.18	7.93	0.63	4.18e-12	Body mass index;
THYM	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg05660106	chr1:15850417	CASP9	0.73	6.14	0.53	1.88e-8	Systolic blood pressure;
THYM	cis	rs13401104	0.587	rs56146026	chr2:237145629	A/G	cg19324714	chr2:237145437	ASB18	0.63	4.68	0.43	9.6e-6	Educational attainment;
THYM	cis	rs10203711	1.000	rs907108	chr2:239566285	T/C	cg14580085	chr2:239553406	NA	0.68	6.17	0.53	1.65e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6032067	0.777	rs979641	chr20:43786336	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg06713675	chr4:122721982	EXOSC9	-0.51	-4.75	-0.44	7.13e-6	Type 2 diabetes;
THYM	cis	rs10208940	0.614	rs13016244	chr2:68761341	T/A	cg09157127	chr2:69201416	GKN1	0.8	4.5	0.42	1.96e-5	Urate levels in lean individuals;
THYM	cis	rs6500395	0.775	rs28481630	chr16:48663664	G/C	cg04672837	chr16:48644449	N4BP1	0.47	4.62	0.43	1.18e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7582403	0.510	rs13001416	chr2:148871642	A/C	cg23727674	chr2:148602993	ACVR2A	0.63	4.61	0.43	1.24e-5	Neuroticism;
THYM	cis	rs10887741	0.532	rs2755432	chr10:89414779	C/T	cg13926569	chr10:89418898	PAPSS2	-0.62	-5.89	-0.52	5.75e-8	Exercise (leisure time);
THYM	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg09034736	chr1:150693464	HORMAD1	0.51	4.49	0.42	1.98e-5	Tonsillectomy;
THYM	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg13319975	chr6:146136371	FBXO30	-0.69	-5.65	-0.5	1.7e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.43	1.27e-5	Breast cancer;
THYM	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.61	-4.65	-0.43	1.07e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs9788682	0.642	rs2568483	chr15:78752343	A/G	cg18825076	chr15:78729989	IREB2	0.69	5.51	0.49	3.05e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg25427524	chr10:38739819	LOC399744	-0.65	-5.91	-0.52	5.41e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs748404	0.587	rs690276	chr15:43704558	C/T	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs1163251	0.837	rs658442	chr1:120244858	T/G	cg19096424	chr1:120255104	PHGDH	0.67	4.94	0.45	3.29e-6	Blood metabolite levels;
THYM	cis	rs2046867	0.818	rs11929144	chr3:72868234	T/C	cg25664220	chr3:72788482	NA	-0.86	-6.77	-0.57	1.04e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs828999	0.688	rs2053433	chr1:108724060	A/G	cg24323958	chr1:108741884	SLC25A24	0.57	5.61	0.5	1.97e-7	Monocyte percentage of white cells;
THYM	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs4523957	0.620	rs9892754	chr17:2084565	G/T	cg16513277	chr17:2031491	SMG6	-0.95	-8.69	-0.67	1.05e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg21475434	chr5:93447410	FAM172A	0.96	6.1	0.53	2.29e-8	Diabetic retinopathy;
THYM	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg06634786	chr22:41940651	POLR3H	-0.67	-5.22	-0.47	1.06e-6	Vitiligo;
THYM	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg24838063	chr12:130822603	PIWIL1	0.91	6.9	0.58	5.85e-10	Menopause (age at onset);
THYM	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg20295408	chr7:1910781	MAD1L1	-0.61	-4.9	-0.45	3.88e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg02640540	chr1:67518911	SLC35D1	-0.64	-4.68	-0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.71	-6.27	-0.54	1.04e-8	Renal function-related traits (BUN);
THYM	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs11190604	0.767	rs7078070	chr10:102166415	A/C	cg07570687	chr10:102243282	WNT8B	0.82	7.71	0.62	1.25e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	4.86	0.45	4.68e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17445774	1.000	rs1509833	chr2:200865225	G/A	cg17644776	chr2:200775616	C2orf69	0.7	5.46	0.49	3.83e-7	LDL cholesterol to HDL cholesterol ratio;
THYM	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs7264396	0.887	rs4281980	chr20:34096581	T/C	cg26038318	chr20:34205095	SPAG4	0.53	4.45	0.42	2.33e-5	Total cholesterol levels;
THYM	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg13695892	chr22:41940480	POLR3H	0.87	6.35	0.55	7.28e-9	Vitiligo;
THYM	cis	rs7584330	0.554	rs1343768	chr2:238444881	G/A	cg14458575	chr2:238380390	NA	0.74	4.59	0.43	1.34e-5	Prostate cancer;
THYM	cis	rs1113500	0.862	rs2336128	chr1:108640739	G/T	cg06207961	chr1:108661230	NA	0.64	5.09	0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg14137381	chr5:502291	SLC9A3	-0.65	-4.52	-0.42	1.77e-5	Cystic fibrosis severity;
THYM	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.76	0.44	7.04e-6	Bipolar disorder;
THYM	cis	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg06521331	chr12:34319734	NA	-0.99	-9.11	-0.68	1.32e-14	Morning vs. evening chronotype;
THYM	cis	rs11997175	0.624	rs12677772	chr8:33772521	T/C	ch.8.33884649F	chr8:33765107	NA	0.73	5.72	0.51	1.24e-7	Body mass index;
THYM	cis	rs2806561	0.704	rs667330	chr1:23515257	A/G	cg12483005	chr1:23474871	LUZP1	0.59	6.27	0.54	1.05e-8	Height;
THYM	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg02734326	chr4:10020555	SLC2A9	0.78	6.67	0.56	1.68e-9	Bone mineral density;
THYM	cis	rs7078219	0.743	rs17094148	chr10:101280279	A/G	cg17888390	chr10:101282816	NA	-0.5	-4.84	-0.44	4.98e-6	Dental caries;
THYM	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg14784868	chr12:69753453	YEATS4	-0.7	-5.24	-0.47	9.47e-7	Response to diuretic therapy;
THYM	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg08807101	chr21:30365312	RNF160	-0.81	-6.03	-0.53	3.09e-8	Dental caries;
THYM	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs8050907	1.000	rs8050324	chr16:4613292	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.34	5.32	0.48	7e-7	Obesity-related traits;
THYM	trans	rs9747201	1.000	rs4597372	chr17:80175444	G/A	cg07393940	chr7:158741817	NA	1.1	8.4	0.65	4.38e-13	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg02551604	chr5:131831745	NA	0.78	6.17	0.53	1.66e-8	Asthma (sex interaction);
THYM	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg18357526	chr6:26021779	HIST1H4A	0.75	5.49	0.49	3.35e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2336384	0.896	rs11121847	chr1:12062507	T/G	cg24492058	chr1:12203751	TNFRSF8	-0.51	-4.48	-0.42	2.07e-5	Platelet count;
THYM	cis	rs11645898	0.872	rs72787093	chr16:72190766	C/T	cg14768367	chr16:72042858	DHODH	-0.75	-5.44	-0.49	4.18e-7	Blood protein levels;
THYM	cis	rs10411161	0.702	rs10424202	chr19:52387297	G/A	cg25361850	chr19:52391789	ZNF577	0.73	5.09	0.46	1.84e-6	Breast cancer;
THYM	cis	rs8031584	1.000	rs8031584	chr15:31287343	A/T	cg08704250	chr15:31115839	NA	-0.54	-6.37	-0.55	6.73e-9	Huntington's disease progression;
THYM	cis	rs4936891	0.520	rs17760637	chr11:123880581	T/C	cg22125253	chr11:123886957	OR10G4	-0.57	-4.93	-0.45	3.51e-6	Male fertility;
THYM	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.09	0.64	1.96e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg17775962	chr7:1200435	ZFAND2A	0.41	5.02	0.46	2.36e-6	Longevity;Endometriosis;
THYM	cis	rs483180	0.512	rs606312	chr1:120222582	G/A	cg19096424	chr1:120255104	PHGDH	0.68	5.33	0.48	6.6e-7	Macular telangiectasia type 2;
THYM	cis	rs42648	0.819	rs2285399	chr7:89969878	A/G	cg25739043	chr7:89950458	NA	-0.51	-4.45	-0.42	2.31e-5	Homocysteine levels;
THYM	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	7.35	0.6	6.91e-11	Platelet count;
THYM	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg18132916	chr6:79620363	NA	-0.61	-5.49	-0.49	3.3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4746818	1.000	rs906218	chr10:70960913	C/T	cg11621586	chr10:70884670	VPS26A	1.28	11.12	0.75	6.73e-19	Left atrial antero-posterior diameter;
THYM	cis	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.55	-5.45	-0.49	3.95e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7177699	0.525	rs56076311	chr15:79115120	A/G	cg15571903	chr15:79123663	NA	-0.56	-6.18	-0.54	1.58e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	trans	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg07211511	chr3:129823064	LOC729375	-1.27	-9.05	-0.68	1.81e-14	Blood pressure (smoking interaction);
THYM	cis	rs921968	0.565	rs1079177	chr2:219605929	G/A	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg24209194	chr3:40518798	ZNF619	0.66	5.43	0.49	4.4e-7	Renal cell carcinoma;
THYM	cis	rs11148252	0.634	rs4941727	chr13:52721067	A/G	cg00495681	chr13:53174319	NA	-0.59	-5.15	-0.47	1.43e-6	Lewy body disease;
THYM	cis	rs7177699	0.557	rs7403593	chr15:79111962	A/G	cg00540400	chr15:79124168	NA	-0.64	-6.88	-0.58	6.27e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs1403694	1.000	rs1648716	chr3:186439529	C/T	cg12454167	chr3:186435060	KNG1	0.43	5.82	0.51	8.09e-8	Blood protein levels;
THYM	cis	rs17739794	0.677	rs17739674	chr8:801584	G/T	cg01971667	chr8:817044	NA	-0.54	-4.72	-0.44	8.01e-6	Clozapine-induced cytotoxicity;
THYM	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg23583168	chr7:148888333	NA	-1.02	-12.83	-0.8	1.88e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	trans	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs4638749	0.680	rs12612935	chr2:108818409	A/G	cg25838818	chr2:108905173	SULT1C2	-0.73	-6.14	-0.53	1.91e-8	Blood pressure;
THYM	cis	rs72781680	0.846	rs55707417	chr2:24029928	G/A	cg08917208	chr2:24149416	ATAD2B	1.11	4.97	0.45	2.9e-6	Lymphocyte counts;
THYM	cis	rs9906944	0.707	rs9899931	chr17:47108282	G/A	cg10950924	chr17:47092072	IGF2BP1	-0.49	-4.47	-0.42	2.15e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs4363385	0.747	rs4240868	chr1:152981599	G/A	cg13444842	chr1:152974279	SPRR3	-0.59	-4.68	-0.43	9.52e-6	Inflammatory skin disease;
THYM	cis	rs4845459	0.967	rs75567512	chr1:152587933	C/A	cg27206522	chr1:152595629	LCE3A	-0.51	-4.54	-0.42	1.66e-5	Psoriasis;
THYM	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.55	-4.7	-0.43	8.95e-6	Platelet count;
THYM	cis	rs6840360	0.967	rs6823423	chr4:152604723	T/C	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs870825	0.616	rs28442259	chr4:185646962	T/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22968622	chr17:43663579	NA	-1.1	-9.99	-0.72	1.7e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.83	-7.74	-0.62	1.07e-11	Intelligence (multi-trait analysis);
THYM	cis	rs34526934	0.566	rs9141	chr2:177037970	T/C	cg26754761	chr2:177040938	NA	-0.76	-6.58	-0.56	2.53e-9	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.83	-4.57	-0.42	1.44e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg10047753	chr17:41438598	NA	1.15	10.53	0.73	1.23e-17	Menopause (age at onset);
THYM	cis	rs7705042	0.828	rs7737631	chr5:141506615	T/G	cg07392085	chr5:141489673	NDFIP1	0.54	4.51	0.42	1.88e-5	Asthma;
THYM	cis	rs8067545	1.000	rs1860302	chr17:19914399	T/A	cg13482628	chr17:19912719	NA	0.59	4.93	0.45	3.42e-6	Schizophrenia;
THYM	cis	rs9361491	0.608	rs1180822	chr6:79431051	G/A	cg04547799	chr6:79944526	HMGN3	-0.65	-4.77	-0.44	6.71e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg15212455	chr7:39170539	POU6F2	0.61	5.59	0.5	2.16e-7	IgG glycosylation;
THYM	cis	rs960902	0.747	rs6724538	chr2:37728018	A/C	cg25341268	chr2:37734390	NA	-0.56	-4.87	-0.45	4.41e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg07414643	chr4:187882934	NA	0.57	4.97	0.45	3.01e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	7.35	0.6	6.91e-11	Platelet count;
THYM	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg16615211	chr3:44902933	MIR564;TMEM42	-0.46	-5.03	-0.46	2.3e-6	Depressive symptoms;
THYM	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg16384552	chr7:74938386	SPDYE8P	0.74	6.03	0.53	3.08e-8	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9296092	0.538	rs62405948	chr6:33522753	A/C	cg13560919	chr6:33536144	NA	-0.96	-9.45	-0.7	2.53e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1061377	0.965	rs11728058	chr4:39129844	T/G	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs7071206	0.947	rs4979905	chr10:79416367	C/T	cg07817648	chr10:79422355	NA	-0.97	-7.5	-0.61	3.32e-11	Bone mineral density;
THYM	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.99	-10.6	-0.74	8.54e-18	Menarche (age at onset);
THYM	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg22875332	chr1:76189707	ACADM	-0.74	-6.47	-0.55	4.26e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	trans	rs4262150	0.883	rs12659715	chr5:152310058	A/G	cg08281791	chr5:76607845	PDE8B	0.93	7.1	0.59	2.24e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg00129232	chr17:37814104	STARD3	0.76	5.23	0.47	1.01e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs12935418	0.672	rs9888895	chr16:81051101	C/T	cg16651780	chr16:81037892	C16orf61	0.8	5.78	0.51	9.64e-8	Mean corpuscular volume;
THYM	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg11663144	chr21:46675770	NA	0.69	9.67	0.7	8.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg26721908	chr21:47610096	LSS	-0.89	-7.35	-0.6	6.71e-11	Testicular germ cell tumor;
THYM	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg00958927	chr1:175162553	KIAA0040	-0.33	-4.48	-0.42	2.06e-5	Alcohol dependence;
THYM	cis	rs10411161	0.702	rs11878586	chr19:52388576	A/G	cg25361850	chr19:52391789	ZNF577	0.74	5.18	0.47	1.22e-6	Breast cancer;
THYM	trans	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.78	-7.87	-0.63	5.71e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7917772	0.582	rs10786691	chr10:104364652	G/A	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs12142240	0.628	rs56126529	chr1:46808860	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7322722	0.891	rs9788300	chr13:77813811	C/T	cg04565255	chr13:77565759	CLN5	-0.44	-4.51	-0.42	1.82e-5	Preeclampsia;
THYM	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg13609457	chr4:120235615	NA	0.6	5.34	0.48	6.23e-7	Corneal astigmatism;
THYM	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg02569458	chr12:86230093	RASSF9	0.58	5.01	0.46	2.47e-6	Major depressive disorder;
THYM	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg03690763	chr11:133734501	NA	-0.6	-4.71	-0.43	8.51e-6	Childhood ear infection;
THYM	cis	rs6840360	0.571	rs28454076	chr4:152520083	G/T	cg17479576	chr4:152424074	FAM160A1	-0.78	-5.74	-0.51	1.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6988636	1.000	rs11993411	chr8:124180537	T/C	cg22384356	chr8:124195192	FAM83A	-0.85	-5.19	-0.47	1.17e-6	Urinary uromodulin levels;
THYM	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg26384229	chr12:38710491	ALG10B	0.91	7.45	0.61	4.34e-11	Bladder cancer;
THYM	cis	rs6960043	1.000	rs12113083	chr7:15051943	G/C	cg19272540	chr7:15055459	NA	-0.48	-5.81	-0.51	8.28e-8	Type 2 diabetes;
THYM	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg02503808	chr4:7069936	GRPEL1	0.99	8.48	0.66	2.89e-13	Monocyte percentage of white cells;
THYM	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg02487422	chr3:49467188	NICN1	0.63	4.84	0.44	5.06e-6	Resting heart rate;
THYM	cis	rs12282928	0.918	rs1018136	chr11:48241821	G/A	cg22827986	chr11:48284249	OR4X1	-0.5	-5.26	-0.48	8.7e-7	Migraine - clinic-based;
THYM	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11644478	chr21:40555479	PSMG1	-0.8	-6.91	-0.58	5.38e-10	Cognitive function;
THYM	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs1050631	0.592	rs1010955	chr18:33710610	T/C	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.6	4.69	0.43	9.09e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs728616	0.867	rs12414521	chr10:81949534	G/C	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	trans	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs4803468	1.000	rs11670668	chr19:41920454	G/C	cg09537434	chr19:41945824	ATP5SL	-1.06	-9.81	-0.71	4.27e-16	Height;
THYM	cis	rs8077889	0.956	rs4793025	chr17:41841621	T/C	cg26893861	chr17:41843967	DUSP3	1.07	9.87	0.71	3.12e-16	Triglycerides;
THYM	cis	rs6032067	0.929	rs62205504	chr20:43867894	C/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.37	-0.48	5.52e-7	Blood protein levels;
THYM	cis	rs262150	0.536	rs4909109	chr7:158787168	C/G	cg12257156	chr7:158823799	VIPR2	0.59	5.19	0.47	1.17e-6	Facial morphology (factor 20);
THYM	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11890956	chr21:40555474	PSMG1	-0.95	-10.91	-0.75	1.91e-18	Cognitive function;
THYM	cis	rs2227564	0.620	rs10740418	chr10:75519322	T/C	cg23231163	chr10:75533350	FUT11	-0.37	-4.66	-0.43	1.03e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs9814567	0.964	rs10935113	chr3:134173091	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-7.34	-0.6	7.17e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-5.83	-0.51	7.7e-8	Total cholesterol levels;
THYM	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg10295955	chr4:187884368	NA	-1.16	-16.22	-0.86	3.97e-29	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg17366294	chr4:99064904	C4orf37	0.56	6.87	0.58	6.78e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg14349672	chr11:133703707	NA	-0.54	-4.74	-0.44	7.5e-6	Childhood ear infection;
THYM	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg08885076	chr2:99613938	TSGA10	0.62	5.67	0.5	1.5e-7	Chronic sinus infection;
THYM	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22133161	chr19:49891603	CCDC155	0.75	4.97	0.45	2.94e-6	Multiple sclerosis;
THYM	cis	rs7589728	0.563	rs4972044	chr2:88466196	T/C	cg04511125	chr2:88470314	THNSL2	0.66	4.62	0.43	1.21e-5	Plasma clusterin levels;
THYM	cis	rs3126085	0.935	rs11204941	chr1:152203343	A/G	cg26020982	chr1:152196106	HRNR	0.37	5.06	0.46	2.05e-6	Atopic dermatitis;
THYM	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg00530320	chr1:46809349	NSUN4	-0.73	-5.06	-0.46	2.02e-6	Menopause (age at onset);
THYM	cis	rs7078219	0.714	rs10883363	chr10:101287580	C/T	cg07044859	chr10:101282883	NA	-0.48	-5.23	-0.47	1.01e-6	Dental caries;
THYM	cis	rs6939532	0.522	rs4712980	chr6:26355758	G/T	cg14345882	chr6:26364793	BTN3A2	-0.4	-5.13	-0.47	1.55e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg00944433	chr1:107599041	PRMT6	-0.4	-4.84	-0.44	5.09e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs12893597	0.541	rs12589755	chr14:76841939	A/C	cg20290672	chr14:76816747	NA	-0.68	-5.51	-0.49	3.06e-7	Maximal oxygen uptake response;
THYM	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg06064525	chr11:970664	AP2A2	-0.36	-6.98	-0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	cis	rs2073300	1.000	rs17830565	chr20:23444805	G/A	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs3126085	0.935	rs1390490	chr1:152161354	T/C	cg26020982	chr1:152196106	HRNR	0.36	4.56	0.42	1.5e-5	Atopic dermatitis;
THYM	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg18230493	chr5:56204884	C5orf35	-0.89	-6.62	-0.56	2.09e-9	Initial pursuit acceleration;
THYM	cis	rs4601821	0.858	rs4938012	chr11:113259654	A/G	cg14159747	chr11:113255604	NA	0.26	4.69	0.43	9.04e-6	Alcoholic chronic pancreatitis;
THYM	cis	rs1322639	0.574	rs9364360	chr6:169580174	G/A	cg04662567	chr6:169592167	NA	-0.75	-6.2	-0.54	1.43e-8	Pulse pressure;
THYM	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg25767906	chr1:53392781	SCP2	-0.53	-5.28	-0.48	8.05e-7	Monocyte count;
THYM	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg04518342	chr5:131593106	PDLIM4	0.48	5.26	0.48	8.77e-7	Breast cancer;
THYM	cis	rs2505675	1.000	rs2505675	chr6:2355675	A/G	cg01959516	chr6:2449276	NA	-0.54	-4.97	-0.45	3.01e-6	Tuberculosis;
THYM	trans	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg07393940	chr7:158741817	NA	1.14	9.25	0.69	6.69e-15	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs2991971	0.776	rs12139364	chr1:45890155	T/C	cg15605315	chr1:45957053	TESK2	0.64	5.05	0.46	2.16e-6	High light scatter reticulocyte count;
THYM	cis	rs2762353	0.526	rs6456693	chr6:25710087	C/G	cg03517284	chr6:25882590	NA	0.66	4.52	0.42	1.79e-5	Blood metabolite levels;
THYM	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	4.63	0.43	1.18e-5	Aortic root size;
THYM	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs4343996	0.967	rs10276933	chr7:3349262	C/A	cg21248987	chr7:3385318	SDK1	0.41	4.95	0.45	3.17e-6	Motion sickness;
THYM	cis	rs9914544	0.564	rs11868520	chr17:18770367	A/G	cg26378065	chr17:18585709	ZNF286B	0.59	4.5	0.42	1.9e-5	Educational attainment (years of education);
THYM	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg08132940	chr7:1081526	C7orf50	-1.17	-6.67	-0.56	1.7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4589258	0.864	rs12575846	chr11:90418822	G/A	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2281845	0.826	rs4915484	chr1:201076917	C/G	cg22815214	chr1:201083145	CACNA1S	0.59	5.26	0.48	8.83e-7	Permanent tooth development;
THYM	cis	rs6840360	0.533	rs13121178	chr4:152729047	T/C	cg22705602	chr4:152727874	NA	0.76	9.94	0.71	2.21e-16	Intelligence (multi-trait analysis);
THYM	cis	rs9790314	0.846	rs7627528	chr3:160990878	A/G	cg03342759	chr3:160939853	NMD3	-0.95	-9.02	-0.68	2.01e-14	Morning vs. evening chronotype;
THYM	cis	rs7524258	0.868	rs6693725	chr1:7307810	G/T	cg07173049	chr1:7289937	CAMTA1	0.75	6.07	0.53	2.63e-8	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs11756438	0.658	rs6937176	chr6:119007308	A/G	cg21191810	chr6:118973309	C6orf204	0.52	4.88	0.45	4.35e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs2235642	0.533	rs17135391	chr16:1605606	C/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.47	-4.67	-0.43	9.99e-6	Coronary artery disease;
THYM	cis	rs2412459	0.635	rs548091	chr15:40253723	C/G	cg16127683	chr15:40268777	EIF2AK4	0.53	4.63	0.43	1.16e-5	Response to haloperidol in psychosis;
THYM	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.78	4.52	0.42	1.81e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs2299587	0.637	rs6586677	chr8:17890687	A/G	cg01800426	chr8:17659068	MTUS1	-0.57	-4.52	-0.42	1.81e-5	Economic and political preferences;
THYM	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg24818145	chr4:99064322	C4orf37	0.73	5.87	0.52	6.3e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2730245	0.527	rs712197	chr7:158660846	C/G	cg11984989	chr7:158649758	WDR60	1.03	8.36	0.65	5.29e-13	Height;
THYM	cis	rs6076065	0.723	rs2424544	chr20:23390314	C/T	cg11657817	chr20:23433608	CST11	0.31	4.57	0.42	1.48e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg22431228	chr1:16359049	CLCNKA	0.53	4.65	0.43	1.05e-5	Dilated cardiomyopathy;
THYM	cis	rs1535500	1.000	rs3734618	chr6:39284184	A/G	cg00012638	chr6:39280541	KCNK17	0.63	8.4	0.65	4.26e-13	Type 2 diabetes;
THYM	cis	rs4731207	0.596	rs12111660	chr7:124584795	A/C	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg13447684	chr7:1895903	MAD1L1	0.71	6.93	0.58	5.05e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs9658691	0.646	rs2862834	chr10:90741374	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.85	4.84	0.44	4.98e-6	Mosquito bite size;
THYM	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg02869364	chr7:1081709	C7orf50	-0.59	-5.31	-0.48	7.12e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4866334	1.000	rs74368495	chr5:18483062	T/C	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-7.5	-0.61	3.41e-11	Platelet count;
THYM	cis	rs17433780	0.808	rs12122780	chr1:89508916	T/C	cg09516651	chr1:89888402	LOC400759	0.97	8.07	0.64	2.12e-12	Carotid intima media thickness;
THYM	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg05738196	chr6:26577821	NA	-0.66	-5.16	-0.47	1.33e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4662945	0.525	rs28819474	chr2:130264623	T/C	cg05903289	chr2:130345205	NA	-0.55	-5.12	-0.46	1.62e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs2898681	0.874	rs6852148	chr4:53750002	T/C	cg21521518	chr4:53727714	RASL11B	0.45	4.88	0.45	4.27e-6	Optic nerve measurement (cup area);
THYM	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg22947322	chr17:47091978	IGF2BP1	-0.55	-4.69	-0.43	9.11e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	trans	rs629535	0.814	rs62513378	chr8:70095788	G/C	cg21567404	chr3:27674614	NA	-1.08	-10.13	-0.72	8.62e-17	Dupuytren's disease;
THYM	cis	rs7107174	1.000	rs7127187	chr11:77995188	G/A	cg02023728	chr11:77925099	USP35	0.66	5.84	0.51	7.32e-8	Testicular germ cell tumor;
THYM	cis	rs761746	0.960	rs4535154	chr22:31896232	T/C	cg10537193	chr22:32026975	PISD	0.4	5.24	0.47	9.77e-7	Intelligence;
THYM	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg26597838	chr10:835615	NA	1.1	6.33	0.54	8e-9	Eosinophil percentage of granulocytes;
THYM	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg07936489	chr17:37558343	FBXL20	0.83	5.77	0.51	1e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs977987	0.806	rs1109342	chr16:75445675	A/G	cg03315344	chr16:75512273	CHST6	-0.76	-6.07	-0.53	2.62e-8	Dupuytren's disease;
THYM	cis	rs9876781	1.000	rs11130171	chr3:48462461	A/G	cg06066452	chr3:48470258	PLXNB1	0.27	4.85	0.45	4.78e-6	Longevity;
THYM	cis	rs2108622	0.727	rs62107770	chr19:15985425	A/G	cg13772218	chr19:15982569	NA	0.5	4.48	0.42	2.06e-5	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg27068330	chr11:65405492	SIPA1	-0.96	-9.31	-0.69	4.93e-15	Acne (severe);
THYM	cis	rs6876348	0.516	rs2526254	chr5:128311451	A/C	cg25555059	chr5:128301488	SLC27A6	0.46	4.84	0.45	4.92e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg26384229	chr12:38710491	ALG10B	0.97	7.35	0.6	7e-11	Bladder cancer;
THYM	cis	rs6732160	0.574	rs1991612	chr2:73480501	G/C	cg24220031	chr2:73402428	NA	-0.8	-9.64	-0.7	9.8e-16	Intelligence (multi-trait analysis);
THYM	cis	rs995000	0.931	rs1748195	chr1:63049593	C/G	cg06896770	chr1:63153194	DOCK7	-0.93	-7.59	-0.61	2.2e-11	Triglyceride levels;
THYM	cis	rs3087591	0.960	rs2905880	chr17:29546175	A/G	cg24425628	chr17:29625626	OMG;NF1	0.66	5.79	0.51	9.11e-8	Hip circumference;
THYM	cis	rs2236521	0.714	rs6062210	chr20:60890375	A/G	cg06026331	chr20:60912101	LAMA5	0.81	6.26	0.54	1.12e-8	Pelvic organ prolapse;
THYM	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg21775007	chr8:11205619	TDH	0.63	4.98	0.46	2.83e-6	Retinal vascular caliber;
THYM	cis	rs7107174	1.000	rs7939352	chr11:78003151	G/A	cg02023728	chr11:77925099	USP35	0.67	6.21	0.54	1.38e-8	Testicular germ cell tumor;
THYM	cis	rs6840360	0.642	rs7677131	chr4:152353015	T/C	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs13070279	0.655	rs11927001	chr3:71795224	A/G	cg19388776	chr3:71835112	PROK2	0.88	5.12	0.46	1.61e-6	Monocyte count;
THYM	cis	rs11169225	0.756	rs3759124	chr12:50343166	G/A	cg04450003	chr12:50355995	AQP5	0.86	6.52	0.56	3.38e-9	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg04025307	chr7:1156635	C7orf50	0.63	5.82	0.51	8.1e-8	Longevity;Endometriosis;
THYM	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3771570	0.901	rs3771585	chr2:242400723	G/A	cg21155796	chr2:242212141	HDLBP	1.02	6.18	0.54	1.6e-8	Prostate cancer;
THYM	cis	rs9403317	0.537	rs4339483	chr6:142019782	C/A	cg15052665	chr6:141804349	NA	-0.75	-5.5	-0.49	3.23e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.33e-5	Retinal vascular caliber;
THYM	cis	rs700651	0.821	rs770661	chr2:198725444	A/G	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Intracranial aneurysm;
THYM	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg11764359	chr7:65958608	NA	0.81	6.42	0.55	5.45e-9	Aortic root size;
THYM	cis	rs1113500	0.897	rs4628530	chr1:108638708	T/G	cg06207961	chr1:108661230	NA	0.64	5.09	0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg04043695	chr12:129287642	SLC15A4	-0.65	-5.15	-0.47	1.41e-6	Systemic lupus erythematosus;
THYM	cis	rs995000	0.965	rs11485618	chr1:63094207	A/G	cg06896770	chr1:63153194	DOCK7	0.99	8.07	0.64	2.19e-12	Triglyceride levels;
THYM	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg15997130	chr1:24165203	NA	-0.74	-6.66	-0.56	1.81e-9	Immature fraction of reticulocytes;
THYM	cis	rs9902453	0.904	rs4567782	chr17:28268800	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.11	0.53	2.19e-8	Coffee consumption (cups per day);
THYM	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg24060327	chr5:131705240	SLC22A5	0.84	7.01	0.58	3.43e-10	Breast cancer;
THYM	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg22166914	chr1:53195759	ZYG11B	0.82	8.9	0.67	3.66e-14	Monocyte count;
THYM	cis	rs7264396	0.563	rs7264869	chr20:34346502	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-4.59	-0.43	1.34e-5	Total cholesterol levels;
THYM	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg06191203	chr2:152266755	RIF1	0.74	4.98	0.45	2.89e-6	Lung cancer;
THYM	cis	rs425535	0.653	rs1025596	chr4:74810082	G/C	cg07868155	chr4:74864709	CXCL5	0.63	4.47	0.42	2.15e-5	Blood protein levels;
THYM	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg16558253	chr16:72132732	DHX38	-0.56	-4.87	-0.45	4.39e-6	Fibrinogen levels;
THYM	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1003719	0.762	rs2835598	chr21:38466669	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg21110456	chr7:2059412	MAD1L1	-0.47	-4.73	-0.44	7.86e-6	Neuroticism;
THYM	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg04362960	chr10:104952993	NT5C2	0.58	4.68	0.43	9.68e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg09034736	chr1:150693464	HORMAD1	0.52	4.68	0.43	9.35e-6	Tonsillectomy;
THYM	cis	rs4944092	0.855	rs608747	chr11:75916477	A/G	cg04588336	chr11:75916460	WNT11	-0.69	-7.07	-0.59	2.6200000000000003e-10	PR interval;
THYM	cis	rs6495122	0.594	rs11072507	chr15:75054866	G/C	cg14664628	chr15:75095509	CSK	-0.71	-5.26	-0.47	8.96e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg09021430	chr5:549028	NA	-0.72	-5.39	-0.48	5.07e-7	Obesity-related traits;
THYM	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs6163	0.588	rs12763284	chr10:104508202	C/T	cg15744005	chr10:104629667	AS3MT	0.76	7.34	0.6	7.09e-11	Waist circumference;Hip circumference;
THYM	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg04546413	chr19:29218101	NA	0.88	5.66	0.5	1.62e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs9788721	0.868	rs17486278	chr15:78867482	A/C	cg18825076	chr15:78729989	IREB2	-0.54	-4.94	-0.45	3.28e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg06981504	chr1:1234844	ACAP3	-0.55	-5.17	-0.47	1.3e-6	Body mass index;
THYM	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg13395646	chr4:1353034	KIAA1530	-0.58	-5.4	-0.48	4.91e-7	Longevity;
THYM	cis	rs13177918	0.677	rs2070844	chr5:149823785	G/A	cg14059543	chr5:149831962	NA	-1.0	-7.6	-0.61	2.11e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	6.38	0.55	6.45e-9	Smoking behavior;
THYM	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg12863693	chr15:85201151	NMB	0.62	5.63	0.5	1.86e-7	Schizophrenia;
THYM	cis	rs6496667	0.865	rs13329288	chr15:90897451	C/T	cg22089800	chr15:90895588	ZNF774	0.74	5.0	0.46	2.65e-6	Rheumatoid arthritis;
THYM	cis	rs42648	0.738	rs13247172	chr7:89889204	A/C	cg25739043	chr7:89950458	NA	-0.54	-4.47	-0.42	2.16e-5	Homocysteine levels;
THYM	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.16e-6	Corneal astigmatism;
THYM	cis	rs9880211	1.000	rs9828976	chr3:136536835	C/G	cg21827317	chr3:136751795	NA	-0.71	-4.84	-0.44	5.12e-6	Body mass index;Height;
THYM	cis	rs6840360	0.571	rs62327274	chr4:152548012	C/T	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg07648498	chr16:89883185	FANCA	0.63	4.78	0.44	6.49e-6	Vitiligo;
THYM	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.54	-6.0	-0.52	3.58e-8	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9677476	0.863	rs16827863	chr2:232077670	C/T	cg07929768	chr2:232055508	NA	-0.59	-6.1	-0.53	2.28e-8	Food antigen IgG levels;
THYM	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg07061783	chr6:25882402	NA	-0.82	-7.15	-0.59	1.81e-10	Blood metabolite levels;
THYM	trans	rs9747201	1.000	rs4280305	chr17:80177069	A/C	cg07393940	chr7:158741817	NA	1.07	8.04	0.64	2.45e-12	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs11563648	0.553	rs6957320	chr7:126998210	C/T	cg23081781	chr7:127225937	GCC1	-0.34	-4.46	-0.42	2.28e-5	Resting heart rate;
THYM	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg06028808	chr11:68637592	NA	0.69	7.22	0.6	1.29e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7582180	0.764	rs12712075	chr2:100924129	T/C	cg08017756	chr2:100939284	LONRF2	-0.73	-7.51	-0.61	3.21e-11	Intelligence (multi-trait analysis);
THYM	cis	rs9611198	0.846	rs5757730	chr22:39967430	A/G	cg19570171	chr22:39239822	NPTXR	0.63	5.11	0.46	1.69e-6	Schizophrenia;
THYM	cis	rs6430585	1.000	rs6732236	chr2:136501509	T/G	cg07169764	chr2:136633963	MCM6	0.95	8.28	0.65	7.78e-13	Corneal structure;
THYM	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg09260853	chr1:2094483	PRKCZ	0.45	4.69	0.43	9.16e-6	Height;
THYM	cis	rs10510102	1.000	rs6585764	chr10:123596823	T/G	cg24202772	chr10:124402857	DMBT1	-0.62	-4.54	-0.42	1.66e-5	Breast cancer;
THYM	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg01059385	chr22:42394853	WBP2NL	0.78	5.06	0.46	2.02e-6	Birth weight;
THYM	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg12310025	chr6:25882481	NA	-0.73	-5.67	-0.5	1.51e-7	Blood metabolite levels;
THYM	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14829155	chr15:31115871	NA	-0.72	-6.12	-0.53	2.1e-8	Huntington's disease progression;
THYM	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg15556689	chr8:8085844	FLJ10661	-0.64	-4.92	-0.45	3.65e-6	Mood instability;
THYM	cis	rs8077889	0.826	rs60085355	chr17:41847415	T/C	cg26893861	chr17:41843967	DUSP3	1.04	9.15	0.68	1.09e-14	Triglycerides;
THYM	cis	rs7172809	0.573	rs74025074	chr15:77439363	T/C	cg22256960	chr15:77711686	NA	-0.64	-4.76	-0.44	7.01e-6	Glucose homeostasis traits;
THYM	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg17366294	chr4:99064904	C4orf37	0.48	5.43	0.49	4.3e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9876781	1.000	rs28824259	chr3:48425675	T/C	cg06066452	chr3:48470258	PLXNB1	0.26	4.88	0.45	4.26e-6	Longevity;
THYM	cis	rs2282300	0.739	rs7942129	chr11:30224692	G/A	cg09906309	chr11:30344399	C11orf46	-0.69	-5.16	-0.47	1.37e-6	Morning vs. evening chronotype;
THYM	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs79149102	0.579	rs9673012	chr15:75293737	C/T	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3820068	0.603	rs6695903	chr1:15985940	C/T	cg27534772	chr1:16042836	PLEKHM2	0.57	6.41	0.55	5.7e-9	Systolic blood pressure;
THYM	cis	rs28785552	0.769	rs28796114	chr19:53234319	T/C	cg10871876	chr19:53194124	ZNF83	0.81	6.93	0.58	5.12e-10	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs7072216	0.691	rs7910973	chr10:100166732	G/A	cg26618903	chr10:100175079	PYROXD2	-0.48	-4.6	-0.43	1.33e-5	Metabolite levels;
THYM	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg06092702	chr1:163392909	NA	-0.61	-5.39	-0.48	5.13e-7	Motion sickness;
THYM	cis	rs17321999	1.000	rs6732241	chr2:30479927	C/T	cg05247661	chr2:30472410	LBH	0.63	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg06028808	chr11:68637592	NA	0.66	7.11	0.59	2.17e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg08772003	chr10:104629869	AS3MT	0.57	4.95	0.45	3.18e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs1371867	0.875	rs962451	chr8:101331010	C/T	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs10779751	1.000	rs2300092	chr1:11266464	T/C	cg08854313	chr1:11322531	MTOR	0.99	9.4	0.69	3.15e-15	Body mass index;
THYM	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg12311346	chr5:56204834	C5orf35	0.97	7.56	0.61	2.49e-11	Initial pursuit acceleration;
THYM	cis	rs950394	1.000	rs4535062	chr2:104976198	G/A	cg20302975	chr2:105468274	NA	-0.72	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	cis	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg07988820	chr12:82153109	PPFIA2	-0.85	-5.59	-0.5	2.16e-7	Resting heart rate;
THYM	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.95	0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.78	-7.01	-0.58	3.49e-10	Prudent dietary pattern;
THYM	cis	rs747334	0.846	rs3885867	chr10:92723320	T/C	cg07620928	chr10:92689909	NA	0.57	5.13	0.47	1.54e-6	Fibroblast growth factor basic levels;
THYM	cis	rs12291225	0.546	rs11023199	chr11:14394258	A/G	cg19336497	chr11:14380999	RRAS2	-0.9	-12.96	-0.8	1.01e-22	Sense of smell;
THYM	cis	rs2976388	0.967	rs2585183	chr8:143766059	C/G	cg13446199	chr8:143762866	PSCA	0.52	6.08	0.53	2.45e-8	Urinary tract infection frequency;
THYM	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg22535103	chr8:58192502	C8orf71	-0.96	-5.47	-0.49	3.7e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs7953249	0.656	rs2243616	chr12:121406370	G/T	cg02403541	chr12:121454288	C12orf43	-0.71	-6.32	-0.54	8.42e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg14779329	chr11:130786720	SNX19	0.5	5.06	0.46	2.03e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg03186999	chr17:7165420	CLDN7	0.54	5.81	0.51	8.22e-8	Diastolic blood pressure;
THYM	cis	rs7172809	0.643	rs907370	chr15:77844272	G/C	cg22256960	chr15:77711686	NA	-0.71	-5.29	-0.48	7.82e-7	Glucose homeostasis traits;
THYM	cis	rs11048434	0.761	rs12824380	chr12:9132017	A/G	cg13575925	chr12:9217583	LOC144571	0.52	5.04	0.46	2.24e-6	Sjögren's syndrome;
THYM	cis	rs71403859	0.730	rs12446333	chr16:71752157	T/C	cg08717414	chr16:71523259	ZNF19	-0.89	-4.98	-0.45	2.88e-6	Post bronchodilator FEV1;
THYM	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg04362960	chr10:104952993	NT5C2	0.58	4.68	0.43	9.68e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs909002	0.830	rs1356803	chr1:32131163	C/G	cg13919466	chr1:32135498	COL16A1	-0.52	-5.13	-0.47	1.52e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.34	-0.48	6.35e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2073300	1.000	rs6048835	chr20:23462343	G/C	cg12062639	chr20:23401060	NAPB	0.96	4.84	0.45	4.95e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7638995	0.774	rs2872690	chr3:69171803	T/C	cg26574240	chr3:69171822	LMOD3	-0.77	-5.16	-0.47	1.34e-6	Alzheimer's disease (late onset);
THYM	cis	rs3136739	0.764	rs58134732	chr8:42076161	T/G	cg16230352	chr8:42123158	NA	0.8	4.76	0.44	6.84e-6	Plasma plasminogen activator levels;
THYM	cis	rs992157	1.000	rs13003334	chr2:219124921	T/A	cg00012203	chr2:219082015	ARPC2	0.85	7.65	0.62	1.64e-11	Colorectal cancer;
THYM	cis	rs9527	0.545	rs35756290	chr10:104585572	G/A	cg08772003	chr10:104629869	AS3MT	-0.59	-4.76	-0.44	6.83e-6	Arsenic metabolism;
THYM	cis	rs941408	1.000	rs1736179	chr19:2795516	T/A	cg17333051	chr19:2783644	SGTA	0.56	5.08	0.46	1.91e-6	Total cholesterol levels;
THYM	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg25036284	chr2:26402008	FAM59B	-0.74	-4.87	-0.45	4.39e-6	Gut microbiome composition (summer);
THYM	cis	rs11715566	0.515	rs4277680	chr3:117605916	A/G	cg07190778	chr3:117604296	NA	-0.41	-5.53	-0.49	2.79e-7	Menarche (age at onset);
THYM	trans	rs2014511	1.000	rs79403652	chr4:154457001	T/A	cg26834479	chr1:41327090	CITED4	-1.93	-6.89	-0.58	6.17e-10	Platelet distribution width;Mean platelet volume;
THYM	cis	rs4242434	0.672	rs4615566	chr8:22520682	T/C	cg03733263	chr8:22462867	KIAA1967	-1.03	-11.07	-0.75	8.57e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs526231	0.543	rs62362521	chr5:102306061	G/A	cg23492399	chr5:102201601	PAM	-0.61	-4.61	-0.43	1.27e-5	Primary biliary cholangitis;
THYM	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg05340658	chr4:99064831	C4orf37	0.54	4.52	0.42	1.78e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg26384229	chr12:38710491	ALG10B	-0.73	-5.61	-0.5	2e-7	Morning vs. evening chronotype;
THYM	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg17063962	chr7:91808500	NA	1.13	10.53	0.73	1.22e-17	Breast cancer;
THYM	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.38	-4.67	-0.43	9.74e-6	Longevity;Endometriosis;
THYM	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg15445000	chr17:37608096	MED1	0.41	4.94	0.45	3.28e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4731207	0.672	rs66823127	chr7:124472329	G/T	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs763014	0.500	rs11865749	chr16:717971	C/G	cg07343612	chr16:622815	PIGQ	-0.71	-5.63	-0.5	1.82e-7	Height;
THYM	cis	rs9790314	0.875	rs336568	chr3:161072763	G/C	cg04691961	chr3:161091175	C3orf57	-0.65	-5.72	-0.51	1.24e-7	Morning vs. evening chronotype;
THYM	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08109568	chr15:31115862	NA	-0.76	-6.77	-0.57	1.05e-9	Huntington's disease progression;
THYM	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg18252515	chr7:66147081	NA	-1.62	-8.8	-0.67	5.99e-14	Diabetic kidney disease;
THYM	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22857025	chr5:266934	NA	-1.5	-9.71	-0.71	6.9e-16	Breast cancer;
THYM	cis	rs9543976	0.623	rs8192756	chr13:76164938	C/T	cg01531495	chr13:76123901	UCHL3	0.66	4.8	0.44	5.85e-6	Diabetic retinopathy;
THYM	cis	rs4660306	1.000	rs7522705	chr1:45992300	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.58	4.59	0.43	1.36e-5	Homocysteine levels;
THYM	cis	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.59	-0.43	1.36e-5	Resting heart rate;
THYM	cis	rs11650494	0.908	rs118099826	chr17:47447836	G/T	cg08112188	chr17:47440006	ZNF652	1.24	5.37	0.48	5.59e-7	Prostate cancer;
THYM	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.54	-5.17	-0.47	1.31e-6	Lymphocyte counts;
THYM	cis	rs4988958	0.565	rs3755265	chr2:103052816	C/A	cg03938978	chr2:103052716	IL18RAP	0.75	9.86	0.71	3.25e-16	Asthma (childhood onset);
THYM	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg26384229	chr12:38710491	ALG10B	1.01	8.01	0.64	2.84e-12	Bladder cancer;
THYM	cis	rs7009516	0.669	rs13270982	chr8:24248552	T/C	cg01759110	chr8:24241694	ADAMDEC1	-0.54	-4.88	-0.45	4.35e-6	Hair greying;
THYM	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg23711669	chr6:146136114	FBXO30	-0.97	-10.07	-0.72	1.15e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg22920501	chr2:26401640	FAM59B	-0.71	-6.33	-0.54	7.92e-9	Gut microbiome composition (summer);
THYM	cis	rs4589258	0.737	rs7116727	chr11:90426777	G/A	cg26138821	chr11:89956704	CHORDC1	0.56	4.68	0.43	9.36e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9549260	0.683	rs4941988	chr13:41196006	T/G	cg21288729	chr13:41239152	FOXO1	0.69	5.26	0.47	8.95e-7	Red blood cell count;
THYM	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6920965	0.507	rs4285341	chr6:126205589	T/G	cg10911889	chr6:126070802	HEY2	0.71	5.01	0.46	2.49e-6	High light scatter reticulocyte count;
THYM	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg02353165	chr6:42928485	GNMT	1.01	10.16	0.72	7.6e-17	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7481584	0.624	rs2106229	chr11:3041195	G/A	cg03159660	chr11:2078197	NA	0.66	4.9	0.45	3.94e-6	Calcium levels;
THYM	cis	rs752010	0.714	rs6600384	chr1:42085141	A/G	cg22486000	chr1:42919398	ZMYND12	0.4	4.67	0.43	9.79e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg21773646	chr17:80085082	CCDC57	0.31	4.49	0.42	2.02e-5	Life satisfaction;
THYM	cis	rs7010267	0.935	rs11573829	chr8:119959623	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.6	4.87	0.45	4.36e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs4654899	1.000	rs10799686	chr1:21486445	A/T	cg01072550	chr1:21505969	NA	0.74	6.76	0.57	1.11e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg04234412	chr22:24373322	LOC391322	-0.91	-10.12	-0.72	9.17e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg22535103	chr8:58192502	C8orf71	-0.98	-5.82	-0.51	8e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs9902453	0.934	rs7213902	chr17:28322935	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.81	0.44	5.74e-6	Coffee consumption (cups per day);
THYM	cis	rs2404618	0.593	rs7829532	chr8:1485190	C/A	cg13402656	chr8:1511478	DLGAP2	-0.78	-7.02	-0.58	3.27e-10	Lung cancer;
THYM	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.73	-0.44	7.7e-6	Crohn's disease;
THYM	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg03929089	chr4:120376271	NA	1.03	8.74	0.67	8.32e-14	Coronary artery disease;
THYM	cis	rs9875589	0.509	rs7651599	chr3:14010974	C/G	cg03204825	chr3:13978759	TPRXL	-0.54	-4.69	-0.43	9.06e-6	Ovarian reserve;
THYM	cis	rs7614311	0.636	rs73117066	chr3:63926236	A/G	cg22134162	chr3:63841271	THOC7	-0.56	-6.48	-0.55	4.02e-9	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg26384229	chr12:38710491	ALG10B	-0.72	-5.68	-0.5	1.5e-7	Morning vs. evening chronotype;
THYM	cis	rs2639990	1.000	rs655156	chr18:72898181	T/C	cg11568697	chr18:72916393	ZADH2	1.2	5.71	0.51	1.29e-7	Vascular endothelial growth factor levels;
THYM	cis	rs7833986	0.501	rs72653953	chr8:56970795	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.27	0.6	9.88e-11	Height;
THYM	cis	rs12142240	0.698	rs56284503	chr1:46847127	C/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs1986734	0.555	rs12500824	chr4:77416627	A/G	cg20311846	chr4:77356250	SHROOM3	-0.43	-4.68	-0.43	9.67e-6	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
THYM	cis	rs7917772	0.582	rs4917975	chr10:104358407	C/G	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg15445000	chr17:37608096	MED1	0.41	4.85	0.45	4.83e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs966423	0.527	rs11680689	chr2:218297700	C/G	cg15335768	chr2:218268053	DIRC3	0.37	5.43	0.49	4.37e-7	Thyroid cancer;
THYM	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg05368731	chr17:41323189	NBR1	1.2	10.98	0.75	1.36e-18	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6546324	0.625	rs980227	chr2:67864258	T/G	cg18237512	chr2:67827392	NA	-0.78	-4.68	-0.43	9.42e-6	Endometriosis;
THYM	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg23851026	chr2:136556271	LCT	-0.56	-5.9	-0.52	5.57e-8	Mosquito bite size;
THYM	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs3126085	0.560	rs11803108	chr1:152344386	G/A	cg10321714	chr1:152280068	FLG	-0.76	-5.43	-0.49	4.27e-7	Atopic dermatitis;
THYM	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg11494091	chr17:61959527	GH2	0.69	6.42	0.55	5.32e-9	Height;
THYM	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg24818145	chr4:99064322	C4orf37	0.7	5.51	0.49	3.09e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs6960043	0.791	rs2191346	chr7:15053878	C/G	cg19272540	chr7:15055459	NA	-0.48	-5.13	-0.47	1.53e-6	Type 2 diabetes;
THYM	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg12893428	chr3:195717962	SDHAP1	0.52	4.65	0.43	1.09e-5	Pancreatic cancer;
THYM	cis	rs12530845	0.623	rs77454235	chr7:135341862	T/C	cg23117316	chr7:135346802	PL-5283	-0.73	-5.88	-0.52	6.18e-8	Red blood cell traits;
THYM	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg22681709	chr2:178499509	PDE11A	0.54	4.79	0.44	6.23e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs35934224	0.783	rs34593728	chr22:19857489	T/C	cg11182965	chr22:19864308	TXNRD2	-0.75	-6.18	-0.54	1.59e-8	Glaucoma (primary open-angle);
THYM	cis	rs10851411	0.789	rs12913324	chr15:42768379	A/G	cg04308337	chr15:42867303	STARD9	-0.62	-4.61	-0.43	1.24e-5	Glucose homeostasis traits;
THYM	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg07747251	chr5:1868357	NA	0.68	5.86	0.52	6.67e-8	Cardiovascular disease risk factors;
THYM	cis	rs7131987	0.903	rs67150462	chr12:29393325	T/C	cg09582351	chr12:29534625	ERGIC2	-0.49	-4.66	-0.43	1.01e-5	QT interval;
THYM	cis	rs10992471	0.756	rs7043152	chr9:95138499	A/G	cg14631576	chr9:95140430	CENPP	-0.95	-10.73	-0.74	4.66e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg18904891	chr8:8559673	CLDN23	-0.69	-5.25	-0.47	9.09e-7	Obesity-related traits;
THYM	cis	rs8067545	0.616	rs203465	chr17:19810720	T/G	cg20830565	chr17:20408647	MGC102966	-0.53	-4.82	-0.44	5.37e-6	Schizophrenia;
THYM	cis	rs2806561	1.000	rs1208932	chr1:23429122	T/G	cg19743168	chr1:23544995	NA	-0.58	-5.94	-0.52	4.76e-8	Height;
THYM	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg24006582	chr15:45444508	DUOX1	-0.82	-7.19	-0.59	1.5e-10	Uric acid levels;
THYM	cis	rs6009824	0.891	rs11090995	chr22:50085210	G/A	cg18178197	chr22:50098317	NA	0.84	6.42	0.55	5.34e-9	Natriuretic peptide levels;
THYM	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.32	-9.88	-0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs354225	0.544	rs3796017	chr2:54807452	T/A	cg23486701	chr2:54789491	SPTBN1	0.36	4.77	0.44	6.58e-6	Schizophrenia;
THYM	cis	rs3126085	0.935	rs2184953	chr1:152280782	A/G	cg10321714	chr1:152280068	FLG	-0.66	-5.07	-0.46	1.97e-6	Atopic dermatitis;
THYM	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	trans	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg07211511	chr3:129823064	LOC729375	-1.23	-9.83	-0.71	3.75e-16	Blood pressure (smoking interaction);
THYM	cis	rs9790314	1.000	rs2218803	chr3:161047973	T/G	cg03342759	chr3:160939853	NMD3	-0.78	-6.87	-0.58	6.79e-10	Morning vs. evening chronotype;
THYM	cis	rs941408	0.928	rs2741991	chr19:2802092	T/C	cg19693284	chr19:2783607	SGTA	0.69	5.48	0.49	3.47e-7	Total cholesterol levels;
THYM	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg16850897	chr7:100343110	ZAN	0.71	5.45	0.49	4e-7	Other erythrocyte phenotypes;
THYM	cis	rs748404	0.690	rs1079309	chr15:43783164	C/A	cg12861797	chr15:43585817	TGM7	0.44	4.53	0.42	1.71e-5	Lung cancer;
THYM	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg02782426	chr3:40428986	ENTPD3	-0.53	-4.52	-0.42	1.79e-5	Renal cell carcinoma;
THYM	trans	rs9929218	0.906	rs4783565	chr16:68750190	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.89	-7.54	-0.61	2.79e-11	Colorectal cancer;
THYM	cis	rs4535497	0.544	rs4975642	chr5:1107828	G/A	cg00278107	chr5:1061253	SLC12A7	0.64	5.17	0.47	1.31e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg15557168	chr22:42548783	NA	-0.62	-4.83	-0.44	5.24e-6	Schizophrenia;
THYM	cis	rs1395	0.778	rs6749393	chr2:27451000	C/T	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.52	-0.49	2.95e-7	Blood metabolite levels;
THYM	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg08885076	chr2:99613938	TSGA10	-0.46	-4.63	-0.43	1.17e-5	Bipolar disorder;
THYM	cis	rs7980799	0.682	rs7138529	chr12:33634855	T/C	cg06521331	chr12:34319734	NA	0.69	4.85	0.45	4.81e-6	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs113835537	0.529	rs2305535	chr11:66272237	A/G	cg24851651	chr11:66362959	CCS	-0.73	-5.16	-0.47	1.35e-6	Airway imaging phenotypes;
THYM	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs4595586	0.545	rs11615638	chr12:39364766	A/C	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs13031619	0.607	rs13011199	chr2:3694994	A/G	cg25251562	chr2:3704773	ALLC	0.63	4.54	0.42	1.66e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs2898681	0.642	rs11538878	chr4:53728524	T/C	cg00338735	chr4:53728038	RASL11B	0.57	5.4	0.48	4.86e-7	Optic nerve measurement (cup area);
THYM	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg08736216	chr1:53307985	ZYG11A	-0.6	-5.56	-0.5	2.5e-7	Monocyte count;
THYM	cis	rs12188164	0.965	rs72717415	chr5:430059	G/A	cg14137381	chr5:502291	SLC9A3	-0.62	-4.57	-0.42	1.45e-5	Cystic fibrosis severity;
THYM	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg11301795	chr4:187892539	NA	-1.1	-17.0	-0.87	1.46e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs16857609	0.564	rs6734808	chr2:218294571	C/T	cg15335768	chr2:218268053	DIRC3	-0.5	-7.17	-0.59	1.59e-10	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	cis	rs7177699	0.557	rs12442476	chr15:79117856	G/A	cg00540400	chr15:79124168	NA	0.63	6.89	0.58	6.04e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs4523957	0.548	rs7225623	chr17:2089548	T/C	cg16513277	chr17:2031491	SMG6	-0.97	-8.83	-0.67	5.35e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg03407747	chr17:6899364	ALOX12	-0.79	-9.22	-0.69	7.77e-15	Tonsillectomy;
THYM	cis	rs9314614	0.872	rs2977794	chr8:6710357	A/G	cg27319216	chr8:6693540	XKR5	-0.59	-6.25	-0.54	1.15e-8	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12756686	chr19:29218302	NA	0.96	8.21	0.64	1.08e-12	Methadone dose in opioid dependence;
THYM	cis	rs1351164	1.000	rs1351164	chr2:218271898	C/T	cg15335768	chr2:218268053	DIRC3	0.4	5.47	0.49	3.61e-7	Height;
THYM	cis	rs985746	0.803	rs10002949	chr4:36836452	C/A	cg04301614	chr4:37585993	C4orf19	0.63	4.57	0.42	1.48e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.35	-0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs9959145	1.000	rs79692970	chr18:12580217	A/G	cg14160804	chr18:12703040	PSMG2;CEP76	-0.9	-4.47	-0.42	2.15e-5	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs1050631	0.810	rs948419	chr18:33707884	T/C	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.63	4.5	0.42	1.93e-5	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs9677476	0.818	rs6749936	chr2:232055684	C/T	cg07929768	chr2:232055508	NA	0.64	6.45	0.55	4.73e-9	Food antigen IgG levels;
THYM	cis	rs28595532	0.920	rs116799007	chr4:119763562	A/G	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs4478037	0.915	rs60206069	chr3:33152508	C/A	cg19404215	chr3:33155277	CRTAP	1.27	8.85	0.67	4.83e-14	Major depressive disorder;
THYM	cis	rs227425	0.505	rs7148145	chr14:70417846	A/C	cg12046056	chr14:71067695	MED6	0.55	5.0	0.46	2.65e-6	Bone mineral density;
THYM	cis	rs58749629	1.000	rs7270354	chr20:44607661	C/T	cg04940435	chr20:44420291	WFDC3;DNTTIP1	-0.62	-6.17	-0.54	1.63e-8	Abdominal aortic aneurysm;
THYM	cis	rs13102973	0.720	rs13137075	chr4:135889366	G/A	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg22875332	chr1:76189707	ACADM	-0.74	-6.47	-0.55	4.26e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2692947	0.832	rs2692954	chr2:96683378	T/G	cg23100626	chr2:96804247	ASTL	0.39	4.95	0.45	3.21e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs2276498	0.751	rs73133436	chr20:52634850	A/G	cg23682609	chr20:52687365	BCAS1	0.7	5.58	0.5	2.26e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.98	4.89	0.45	4.07e-6	Initial pursuit acceleration;
THYM	cis	rs4077515	0.967	rs4266763	chr9:139289825	C/T	cg14115884	chr9:139300582	SDCCAG3	-0.74	-7.5	-0.61	3.36e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7512552	0.839	rs7523428	chr1:150430472	G/A	cg15654264	chr1:150340011	RPRD2	0.44	5.12	0.47	1.58e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs6748734	0.516	rs4605365	chr2:241892009	G/A	cg15164180	chr2:241846931	NA	-0.39	-5.01	-0.46	2.54e-6	Urinary metabolites;
THYM	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs11811982	0.793	rs79892036	chr1:227404012	T/C	cg09853570	chr1:228403422	OBSCN	1.21	4.67	0.43	9.81e-6	Optic disc area;
THYM	trans	rs11186	0.556	rs72906352	chr2:189961592	G/A	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	cis	rs4631830	0.720	rs11004415	chr10:51498181	G/A	cg10326726	chr10:51549505	MSMB	0.53	5.15	0.47	1.38e-6	Prostate-specific antigen levels;
THYM	cis	rs28595532	0.920	rs116062544	chr4:119735548	G/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg21138405	chr5:131827807	IRF1	-0.84	-9.29	-0.69	5.56e-15	Asthma (sex interaction);
THYM	cis	rs6466832	0.568	rs12538550	chr7:122327741	A/G	cg22586324	chr7:123296098	LMOD2	-0.95	-5.15	-0.47	1.39e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg24874828	chr4:187887005	NA	0.74	7.77	0.62	9.38e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg05962950	chr11:130786565	SNX19	0.9	8.8	0.67	6.1e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9876781	1.000	rs2242150	chr3:48505964	A/C	cg06066452	chr3:48470258	PLXNB1	-0.27	-4.85	-0.45	4.87e-6	Longevity;
THYM	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg04043695	chr12:129287642	SLC15A4	0.64	5.26	0.47	9.04e-7	Systemic lupus erythematosus;
THYM	cis	rs6866344	0.697	rs62392831	chr5:178134365	A/G	cg10224037	chr5:178157518	ZNF354A	0.95	7.68	0.62	1.38e-11	Neutrophil percentage of white cells;
THYM	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg06697600	chr4:7070879	GRPEL1	-0.54	-4.78	-0.44	6.39e-6	Monocyte percentage of white cells;
THYM	cis	rs7119	0.651	rs12909292	chr15:77837982	G/T	cg10437265	chr15:77819839	NA	0.79	7.77	0.62	9.18e-12	Type 2 diabetes;
THYM	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	6.4	0.55	5.89e-9	Obesity-related traits;
THYM	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg00012203	chr2:219082015	ARPC2	0.88	8.59	0.66	1.66e-13	Colorectal cancer;
THYM	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg07570687	chr10:102243282	WNT8B	0.75	6.53	0.56	3.17e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs34779708	0.966	rs4934536	chr10:35441169	A/G	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs10744422	0.858	rs10773627	chr12:123311853	A/G	cg25930673	chr12:123319894	HIP1R	-0.88	-5.15	-0.47	1.43e-6	Schizophrenia;
THYM	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg07424592	chr7:64974309	NA	1.03	5.4	0.48	4.94e-7	Diabetic kidney disease;
THYM	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg13607699	chr17:42295918	UBTF	-0.63	-5.29	-0.48	7.69e-7	Total body bone mineral density;
THYM	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg22920501	chr2:26401640	FAM59B	-1.04	-9.12	-0.68	1.26e-14	Gut microbiome composition (summer);
THYM	cis	rs62103177	0.608	rs34383580	chr18:77833263	A/G	cg07235805	chr18:78004237	PARD6G	-0.48	-5.47	-0.49	3.62e-7	Opioid sensitivity;
THYM	cis	rs2072510	0.569	rs61937880	chr12:96390867	C/A	cg18817487	chr12:96390143	HAL	0.47	5.71	0.51	1.31e-7	Metabolite levels (small molecules and protein measures);
THYM	cis	rs2862064	0.685	rs2862066	chr5:156447395	T/G	cg12943317	chr5:156479607	HAVCR1	-0.83	-5.12	-0.46	1.61e-6	Platelet count;
THYM	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6121246	0.559	rs6060944	chr20:30372114	G/A	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg07460842	chr6:66804631	NA	1.21	14.3	0.83	2.03e-25	Exhaled nitric oxide output;
THYM	cis	rs2120019	0.608	rs4886414	chr15:75308650	C/T	cg09165964	chr15:75287851	SCAMP5	1.09	11.38	0.76	1.9e-19	Blood trace element (Zn levels);
THYM	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.52e-10	Prudent dietary pattern;
THYM	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg08430604	chr3:44902960	MIR564;TMEM42	0.52	4.93	0.45	3.46e-6	Depressive symptoms;
THYM	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg16615211	chr3:44902933	MIR564;TMEM42	0.5	5.28	0.48	8.31e-7	Depressive symptoms;
THYM	cis	rs514406	0.893	rs4584343	chr1:53434539	A/C	cg08859206	chr1:53392774	SCP2	0.65	7.33	0.6	7.72e-11	Monocyte count;
THYM	cis	rs7106204	0.514	rs34587986	chr11:24253053	T/C	ch.11.24196551F	chr11:24239977	NA	1.02	7.07	0.59	2.58e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs10540	0.509	rs36002993	chr11:540005	C/T	cg19913688	chr11:428466	ANO9	-1.0	-4.73	-0.44	7.83e-6	Body mass index;
THYM	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg00376283	chr12:123451042	ABCB9	-0.72	-4.88	-0.45	4.24e-6	Neutrophil percentage of white cells;
THYM	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg19052272	chr2:3704530	ALLC	0.64	5.02	0.46	2.39e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs34638657	0.872	rs11859599	chr16:82182832	C/G	cg09439754	chr16:82129088	HSD17B2	-0.54	-4.58	-0.43	1.41e-5	Lung adenocarcinoma;
THYM	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg13319975	chr6:146136371	FBXO30	-0.72	-6.01	-0.52	3.42e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1003719	0.762	rs1015551	chr21:38449510	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg17264618	chr3:40429014	ENTPD3	-0.53	-5.15	-0.47	1.38e-6	Renal cell carcinoma;
THYM	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg13642260	chr9:130955380	CIZ1	-0.81	-6.81	-0.57	8.62e-10	Attention deficit hyperactivity disorder;
THYM	cis	rs9796	0.775	rs57393155	chr15:41426251	A/G	cg21153102	chr15:41252147	NA	0.7	6.26	0.54	1.1e-8	Menopause (age at onset);
THYM	cis	rs6076065	0.723	rs2424537	chr20:23382026	T/C	cg11657817	chr20:23433608	CST11	0.31	4.57	0.42	1.48e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs72949976	0.934	rs13406406	chr2:214034826	C/T	cg08319019	chr2:214017104	IKZF2	-0.6	-4.46	-0.42	2.24e-5	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg18131467	chr2:239335373	ASB1	1.07	10.06	0.72	1.22e-16	Multiple system atrophy;
THYM	cis	rs6840360	0.615	rs1877188	chr4:152607931	T/C	cg22705602	chr4:152727874	NA	-0.79	-10.66	-0.74	6.62e-18	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg02527881	chr3:46936655	PTH1R	-0.6	-5.53	-0.49	2.77e-7	Colorectal cancer;
THYM	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg01570182	chr17:44337453	NA	0.63	6.62	0.56	2.1e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg18240062	chr17:79603768	NPLOC4	-0.73	-6.57	-0.56	2.74e-9	Eye color traits;
THYM	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg09260853	chr1:2094483	PRKCZ	-0.45	-4.76	-0.44	6.9e-6	Height;
THYM	cis	rs669446	0.561	rs628342	chr1:44090736	C/T	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs34172651	0.545	rs9302428	chr16:24717600	C/G	cg06028605	chr16:24865363	SLC5A11	-0.48	-4.54	-0.42	1.66e-5	Intelligence (multi-trait analysis);
THYM	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg12386194	chr3:101231763	SENP7	0.7	5.29	0.48	7.86e-7	Colorectal cancer;
THYM	cis	rs7178572	0.524	rs12904088	chr15:77399397	C/G	cg22256960	chr15:77711686	NA	-0.97	-7.44	-0.61	4.49e-11	Type 2 diabetes;
THYM	cis	rs11645898	0.935	rs35370634	chr16:72184566	C/T	cg14768367	chr16:72042858	DHODH	-0.77	-5.59	-0.5	2.21e-7	Blood protein levels;
THYM	cis	rs2154427	0.511	rs7279487	chr21:34001824	T/C	cg21871883	chr21:34145043	C21orf49;C21orf66	0.99	5.44	0.49	4.22e-7	Bilirubin levels;
THYM	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs4731207	0.565	rs7811203	chr7:124653374	T/C	cg05285228	chr7:124571219	POT1	-0.72	-5.53	-0.49	2.81e-7	Cutaneous malignant melanoma;
THYM	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg16558253	chr16:72132732	DHX38	-0.66	-5.89	-0.52	5.82e-8	Fibrinogen levels;
THYM	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11890956	chr21:40555474	PSMG1	0.97	11.03	0.75	1.05e-18	Cognitive function;
THYM	cis	rs4951011	0.938	rs4542275	chr1:203760414	C/T	cg24343524	chr1:203763352	ZC3H11A	-0.7	-6.27	-0.54	1.07e-8	Breast cancer;
THYM	cis	rs7833986	0.501	rs2976036	chr8:57031721	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	6.88	0.58	6.47e-10	Height;
THYM	cis	rs713587	0.967	rs10182458	chr2:25150641	A/G	cg01884057	chr2:25150051	NA	0.72	7.91	0.63	4.58e-12	Body mass index in non-asthmatics;
THYM	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg13319975	chr6:146136371	FBXO30	0.65	5.35	0.48	6.09e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11671005	0.735	rs34188294	chr19:58919557	G/A	cg18639983	chr19:58920768	ZNF584	0.61	4.9	0.45	3.87e-6	Mean platelet volume;
THYM	cis	rs847577	0.677	rs10242903	chr7:97741795	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.58	-4.47	-0.42	2.13e-5	Breast cancer;
THYM	cis	rs4788570	0.566	rs72791974	chr16:71478574	A/T	cg06353428	chr16:71660113	MARVELD3	-1.0	-4.99	-0.46	2.68e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg08045932	chr20:61659980	NA	0.93	10.51	0.73	1.33e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9992101	0.589	rs7675217	chr4:77413142	G/C	cg20311846	chr4:77356250	SHROOM3	-0.45	-4.72	-0.44	8.12e-6	Creatinine levels;
THYM	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.82	-5.24	-0.47	9.64e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs17174870	0.955	rs7563113	chr2:112768177	T/A	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg26597838	chr10:835615	NA	1.52	11.37	0.76	2.05e-19	Eosinophil percentage of granulocytes;
THYM	cis	rs7122539	0.506	rs10791896	chr11:66689240	G/T	cg04006266	chr11:66300458	BBS1	0.44	4.96	0.45	3.03e-6	HIV-1 susceptibility;
THYM	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.02	0.46	2.4e-6	Prudent dietary pattern;
THYM	cis	rs7814319	1.000	rs2643338	chr8:97247469	A/G	cg20787634	chr8:97240163	UQCRB	-0.75	-8.43	-0.65	3.62e-13	Lung function (FVC);
THYM	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1912528	0.783	rs769663	chr4:140868446	G/A	cg11128457	chr4:140864437	MAML3	0.5	5.36	0.48	5.72e-7	Educational attainment (years of education);
THYM	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg12407791	chr17:73824354	UNC13D	-0.41	-4.5	-0.42	1.92e-5	White matter hyperintensity burden;
THYM	cis	rs9796	0.689	rs561301	chr15:41444723	C/T	cg21153102	chr15:41252147	NA	0.6	4.98	0.45	2.84e-6	Menopause (age at onset);
THYM	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg26818010	chr10:134567672	INPP5A	-0.77	-6.08	-0.53	2.47e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs10489202	0.632	rs12410730	chr1:168069477	T/C	cg24449463	chr1:168025552	DCAF6	-0.79	-7.87	-0.63	5.64e-12	Schizophrenia;
THYM	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	8.18	0.64	1.26e-12	Lung cancer in ever smokers;
THYM	cis	rs2731664	0.792	rs2731662	chr5:176872494	C/T	cg14098951	chr5:176875120	PRR7	-0.58	-5.16	-0.47	1.36e-6	Intelligence (multi-trait analysis);
THYM	cis	rs950880	0.710	rs66919607	chr2:103008969	C/G	cg03938978	chr2:103052716	IL18RAP	-0.5	-4.46	-0.42	2.24e-5	Serum protein levels (sST2);
THYM	trans	rs11186	0.556	rs7425816	chr2:189960559	T/C	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg24584345	chr6:136760679	MAP7	-0.96	-7.19	-0.59	1.45e-10	Depressive symptoms;
THYM	cis	rs2290159	0.752	rs5746182	chr3:12672550	A/G	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs17006441	0.901	rs6761994	chr3:69801131	G/A	cg18496212	chr3:69797108	MITF	0.64	6.54	0.56	3.08e-9	Hemoglobin concentration;
THYM	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg14675211	chr2:100938903	LONRF2	0.77	8.32	0.65	6.49e-13	Intelligence (multi-trait analysis);
THYM	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg24399712	chr22:39784796	NA	-0.95	-10.89	-0.75	2.08e-18	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg23758822	chr17:41437982	NA	1.17	11.04	0.75	1.02e-18	Menopause (age at onset);
THYM	cis	rs7584330	0.554	rs729388	chr2:238425004	G/C	cg08992911	chr2:238395768	MLPH	0.75	5.1	0.46	1.76e-6	Prostate cancer;
THYM	cis	rs28595532	0.920	rs17324821	chr4:119770716	A/G	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	5.4	0.48	4.89e-7	Schizophrenia;
THYM	cis	rs11690935	0.959	rs10194102	chr2:172626143	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.84	-6.16	-0.53	1.77e-8	Schizophrenia;
THYM	cis	rs476633	0.679	rs2955810	chr15:41433697	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.72	-5.7	-0.5	1.34e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg05662444	chr5:154026397	NA	0.55	4.83	0.44	5.29e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs977987	0.806	rs35787595	chr16:75466847	G/C	cg03315344	chr16:75512273	CHST6	0.73	5.88	0.52	6.15e-8	Dupuytren's disease;
THYM	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg25036284	chr2:26402008	FAM59B	0.8	5.36	0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs11153147	0.649	rs10456863	chr6:109299092	A/T	cg17117243	chr6:109341365	SESN1	-0.86	-5.06	-0.46	2.03e-6	Mean corpuscular volume;
THYM	cis	rs7568458	0.837	rs35215812	chr2:85792384	G/A	cg17127132	chr2:85788382	GGCX	0.68	5.47	0.49	3.71e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	trans	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs6732160	0.510	rs57825971	chr2:73384796	C/G	cg24220031	chr2:73402428	NA	-0.75	-6.87	-0.58	6.79e-10	Intelligence (multi-trait analysis);
THYM	cis	rs73086581	0.898	rs11906452	chr20:3981559	A/G	cg02187196	chr20:3869020	PANK2	0.48	5.47	0.49	3.63e-7	Response to antidepressants in depression;
THYM	cis	rs490234	0.756	rs10986849	chr9:128469683	A/G	cg14078157	chr9:128172775	NA	-0.61	-4.54	-0.42	1.65e-5	Mean arterial pressure;
THYM	cis	rs58873874	0.737	rs78565801	chr5:156886334	C/G	cg08916508	chr5:156566250	MED7	-1.29	-4.86	-0.45	4.57e-6	Bipolar disorder (body mass index interaction);
THYM	cis	rs7781557	1.000	rs7790451	chr7:102465988	G/A	cg06322601	chr7:102330635	NA	0.63	4.72	0.44	8e-6	Colorectal adenoma (advanced);
THYM	cis	rs4930776	0.966	rs440899	chr12:5769274	G/C	cg02086166	chr12:5775618	ANO2	0.57	5.51	0.49	3.1e-7	Plasma clusterin levels;
THYM	cis	rs888194	0.544	rs7316486	chr12:109849540	A/G	cg10504392	chr12:110044639	NA	0.66	5.95	0.52	4.49e-8	Neuroticism;
THYM	cis	rs6430585	0.527	rs2278731	chr2:136396300	T/C	cg23851026	chr2:136556271	LCT	0.64	5.84	0.51	7.37e-8	Corneal structure;
THYM	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg15704280	chr7:45808275	SEPT13	1.02	8.31	0.65	6.7e-13	Coronary artery disease;
THYM	cis	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg11548083	chr8:10208156	MSRA	0.45	4.83	0.44	5.2e-6	Neuroticism;
THYM	cis	rs6427356	0.550	rs4661092	chr1:157149365	A/T	cg27547283	chr1:156698502	C1orf66;ISG20L2	-0.57	-4.47	-0.42	2.16e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs8062405	0.755	rs56272201	chr16:28580685	A/G	cg09046979	chr16:28333134	SBK1	-0.53	-4.47	-0.42	2.18e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs12347191	0.500	rs907579	chr9:100622723	G/T	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Orofacial clefts;
THYM	cis	rs6924995	0.501	rs9464871	chr6:16192759	C/G	cg11805552	chr6:16175128	NA	0.53	4.64	0.43	1.14e-5	Response to statins (LDL cholesterol change);
THYM	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg01475377	chr6:109611718	NA	-0.58	-4.91	-0.45	3.76e-6	Reticulocyte fraction of red cells;
THYM	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg03929089	chr4:120376271	NA	-0.99	-12.81	-0.8	2.07e-22	Height;
THYM	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg26441486	chr22:50317300	CRELD2	0.43	6.57	0.56	2.71e-9	Schizophrenia;
THYM	cis	rs11650494	0.831	rs11650886	chr17:47449193	G/A	cg08112188	chr17:47440006	ZNF652	1.24	5.37	0.48	5.59e-7	Prostate cancer;
THYM	cis	rs4642101	0.883	rs6810325	chr3:12840934	T/C	cg05775895	chr3:12838266	CAND2	0.8	5.83	0.51	7.49e-8	QRS complex (12-leadsum);
THYM	cis	rs2195525	0.572	rs3814760	chr11:119217556	G/A	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.44	4.92	0.45	3.56e-6	Urate levels;
THYM	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg08901578	chr4:187885870	NA	0.7	6.51	0.56	3.57e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg26384229	chr12:38710491	ALG10B	-0.89	-7.49	-0.61	3.48e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1003719	0.788	rs2835605	chr21:38490734	T/A	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg24060327	chr5:131705240	SLC22A5	-0.67	-4.85	-0.45	4.89e-6	Breast cancer;
THYM	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg26384229	chr12:38710491	ALG10B	1.02	8.22	0.64	1.05e-12	Bladder cancer;
THYM	cis	rs6918586	0.658	rs198814	chr6:26127759	A/G	cg03264133	chr6:25882463	NA	0.65	5.06	0.46	2e-6	Schizophrenia;
THYM	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg04398451	chr17:18023971	MYO15A	0.92	8.39	0.65	4.49e-13	Total body bone mineral density;
THYM	cis	rs13082711	0.595	rs62255583	chr3:27309704	G/T	cg02860705	chr3:27208620	NA	0.95	7.1	0.59	2.27e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg09184832	chr6:79620586	NA	-0.58	-4.59	-0.43	1.37e-5	Intelligence (multi-trait analysis);
THYM	cis	rs977102	0.556	rs66731212	chr3:67354761	T/C	cg06096184	chr3:66549732	LRIG1	0.66	4.6	0.43	1.32e-5	Response to amphetamines;
THYM	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg06850241	chr22:41845214	NA	0.54	4.61	0.43	1.23e-5	Vitiligo;
THYM	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.63	-6.47	-0.55	4.21e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg18132916	chr6:79620363	NA	-0.55	-4.84	-0.44	4.98e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2072499	0.898	rs2736609	chr1:156202640	C/T	cg25208724	chr1:156163844	SLC25A44	0.98	9.88	0.71	3.05e-16	Testicular germ cell tumor;
THYM	trans	rs28595532	0.557	rs13435618	chr4:119308814	C/T	cg26518628	chr1:97050305	NA	-1.1	-8.54	-0.66	2.15e-13	Cannabis dependence symptom count;
THYM	cis	rs616402	0.564	rs7419116	chr1:10578606	G/A	cg20482658	chr1:10539492	PEX14	-0.35	-5.23	-0.47	1e-6	Breast size;
THYM	cis	rs12291225	0.585	rs4517475	chr11:14386145	A/G	cg05501817	chr11:14380813	RRAS2	-0.8	-6.65	-0.56	1.88e-9	Sense of smell;
THYM	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	4.51	0.42	1.82e-5	Aortic root size;
THYM	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg27170947	chr2:26402098	FAM59B	0.78	6.13	0.53	2.02e-8	Gut microbiome composition (summer);
THYM	cis	rs6500602	1.000	rs11647946	chr16:4462836	G/A	cg08645402	chr16:4508243	NA	0.64	5.31	0.48	7.26e-7	Schizophrenia;
THYM	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs6748734	0.600	rs10202620	chr2:241820912	G/C	cg15164180	chr2:241846931	NA	-0.34	-4.63	-0.43	1.14e-5	Urinary metabolites;
THYM	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg08132940	chr7:1081526	C7orf50	-0.76	-5.1	-0.46	1.74e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12935418	0.583	rs2549839	chr16:81023235	C/T	cg16651780	chr16:81037892	C16orf61	-0.85	-6.53	-0.56	3.16e-9	Mean corpuscular volume;
THYM	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	5.07	0.46	2e-6	Rheumatoid arthritis;
THYM	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg26924012	chr15:45694286	SPATA5L1	1.06	9.54	0.7	1.62e-15	Homoarginine levels;
THYM	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg12379764	chr21:47803548	PCNT	-0.81	-5.07	-0.46	1.98e-6	Testicular germ cell tumor;
THYM	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06873352	chr17:61820015	STRADA	0.54	5.49	0.49	3.33e-7	Height;
THYM	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg10802521	chr3:52805072	NEK4	-0.72	-6.17	-0.53	1.66e-8	Bipolar disorder;
THYM	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg12463550	chr7:65579703	CRCP	-0.57	-4.62	-0.43	1.23e-5	Aortic root size;
THYM	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.49	-5.14	-0.47	1.45e-6	Depressive symptoms;
THYM	cis	rs7100689	0.646	rs10400045	chr10:82077032	A/G	cg01528321	chr10:82214614	TSPAN14	0.84	6.43	0.55	5.15e-9	Post bronchodilator FEV1;
THYM	cis	rs56104184	1.000	rs56104184	chr19:49370310	C/T	cg17863274	chr19:49399704	TULP2	-0.88	-5.53	-0.49	2.77e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs62103177	0.561	rs891489	chr18:77637493	G/A	cg19746982	chr18:77552568	NA	-0.64	-4.45	-0.42	2.31e-5	Opioid sensitivity;
THYM	cis	rs12291225	0.585	rs11023197	chr11:14380998	G/A	cg05501817	chr11:14380813	RRAS2	-0.8	-6.65	-0.56	1.88e-9	Sense of smell;
THYM	cis	rs4363385	0.747	rs1413848	chr1:152970210	C/T	cg13444842	chr1:152974279	SPRR3	-0.62	-4.87	-0.45	4.52e-6	Inflammatory skin disease;
THYM	cis	rs40363	0.645	rs40447	chr16:3514841	G/A	cg05754148	chr16:3507555	NAT15	0.7	6.71	0.57	1.41e-9	Tuberculosis;
THYM	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg04900672	chr7:1987197	MAD1L1	0.7	4.49	0.42	1.98e-5	Multiple sclerosis;
THYM	cis	rs7968440	1.000	rs7305655	chr12:51005289	A/G	cg20014596	chr12:50898483	DIP2B	-0.56	-4.55	-0.42	1.57e-5	Fibrinogen;
THYM	cis	rs240764	0.817	rs239238	chr6:101094880	G/T	cg21058520	chr6:100914733	NA	-0.57	-5.06	-0.46	2.04e-6	Neuroticism;
THYM	cis	rs981844	0.767	rs6857738	chr4:154689140	A/C	cg09973105	chr4:154681532	RNF175	0.54	5.01	0.46	2.52e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs2336384	0.593	rs28718032	chr1:12046880	C/T	cg24492058	chr1:12203751	TNFRSF8	-0.62	-5.89	-0.52	5.88e-8	Platelet count;
THYM	cis	rs2836974	0.800	rs12482857	chr21:40514861	T/C	cg06238570	chr21:40685208	BRWD1	0.87	6.15	0.53	1.84e-8	Cognitive function;
THYM	cis	rs2688608	0.592	rs3933085	chr10:75483331	C/T	cg19442545	chr10:75533431	FUT11	-0.58	-5.96	-0.52	4.22e-8	Inflammatory bowel disease;
THYM	cis	rs988913	1.000	rs9396011	chr6:54836739	C/T	cg18532076	chr6:54711417	FAM83B	0.49	4.87	0.45	4.53e-6	Menarche (age at onset);
THYM	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22968622	chr17:43663579	NA	0.82	7.02	0.58	3.23e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg11266682	chr4:10021025	SLC2A9	0.71	9.91	0.71	2.51e-16	Bone mineral density;
THYM	cis	rs931812	0.825	rs6993937	chr8:101898707	A/G	cg07239293	chr8:101170671	SPAG1	0.69	4.64	0.43	1.1e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.78	0.51	9.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1729951	0.514	rs75977	chr3:136700549	C/A	cg21827317	chr3:136751795	NA	0.74	6.59	0.56	2.41e-9	Neuroticism;
THYM	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg24209194	chr3:40518798	ZNF619	-0.73	-6.19	-0.54	1.54e-8	Renal cell carcinoma;
THYM	trans	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg10856724	chr12:34555212	NA	-0.94	-8.22	-0.64	1.01e-12	Bladder cancer;
THYM	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg20891283	chr12:69753455	YEATS4	0.7	5.98	0.52	3.85e-8	Blood protein levels;
THYM	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg24308560	chr3:49941425	MST1R	-0.76	-6.34	-0.55	7.57e-9	Intelligence (multi-trait analysis);
THYM	cis	rs533581	0.873	rs555191	chr16:88978850	C/T	cg06763375	chr16:89025547	CBFA2T3	-0.65	-5.88	-0.52	6.1e-8	Social autistic-like traits;
THYM	cis	rs7107174	0.901	rs2912	chr11:77926292	G/A	cg19901956	chr11:77921274	USP35	-0.8	-6.2	-0.54	1.48e-8	Testicular germ cell tumor;
THYM	cis	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.72	-0.44	7.99e-6	Resting heart rate;
THYM	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg09537434	chr19:41945824	ATP5SL	1.09	10.7	0.74	5.25e-18	Height;
THYM	cis	rs4072705	0.967	rs10818985	chr9:127450571	C/T	cg01786973	chr9:127249749	NR5A1	0.35	4.69	0.43	9.25e-6	Menarche (age at onset);
THYM	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs752010	0.841	rs58737163	chr1:42079821	G/T	cg22486000	chr1:42919398	ZMYND12	-0.49	-5.64	-0.5	1.75e-7	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg06009448	chr7:1102226	C7orf50	0.35	4.46	0.42	2.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs34779708	0.931	rs7923217	chr10:35309589	A/G	cg03585969	chr10:35415529	CREM	0.63	4.66	0.43	1.01e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg05660106	chr1:15850417	CASP9	0.76	6.27	0.54	1.06e-8	Systolic blood pressure;
THYM	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg10589385	chr1:150898437	SETDB1	0.66	5.58	0.5	2.27e-7	Tonsillectomy;
THYM	cis	rs208520	0.837	rs208509	chr6:66941706	A/G	cg07460842	chr6:66804631	NA	-0.78	-5.05	-0.46	2.16e-6	Exhaled nitric oxide output;
THYM	cis	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg21775007	chr8:11205619	TDH	0.74	6.67	0.57	1.65e-9	Retinal vascular caliber;
THYM	cis	rs7575217	0.670	rs2592392	chr2:101723343	A/G	cg23907051	chr2:101730305	TBC1D8	0.42	5.69	0.5	1.43e-7	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs4589258	0.737	rs1783804	chr11:90431758	G/C	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg21252483	chr19:49399788	TULP2	-0.95	-7.2	-0.59	1.41e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22590775	chr19:49891494	CCDC155	0.86	7.19	0.59	1.45e-10	Multiple sclerosis;
THYM	cis	rs72828912	0.731	rs9393526	chr6:24072458	C/T	cg26336265	chr6:25042955	NA	-0.78	-5.1	-0.46	1.73e-6	Squamous cell lung carcinoma;
THYM	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.89	5.72	0.51	1.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10992471	0.756	rs10115222	chr9:95128149	C/T	cg14631576	chr9:95140430	CENPP	0.95	10.73	0.74	4.66e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	trans	rs4650994	0.505	rs2811291	chr1:178574217	C/T	cg05059571	chr16:84539110	KIAA1609	0.95	11.16	0.75	5.75e-19	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg10636054	chr15:40330586	SRP14	-1.05	-5.44	-0.49	4.14e-7	Corneal curvature;
THYM	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg24578937	chr1:2090814	PRKCZ	-0.57	-5.46	-0.49	3.75e-7	Height;
THYM	cis	rs216026	0.689	rs61907987	chr12:2768017	G/A	cg19945202	chr12:2788847	CACNA1C	-0.72	-4.79	-0.44	6.22e-6	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs12048904	0.541	rs1571046	chr1:101299216	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.86	6.84	0.57	7.57e-10	Multiple sclerosis;
THYM	cis	rs2034088	0.833	rs9748016	chr17:410451	G/T	cg13332499	chr17:408570	NA	0.57	4.57	0.42	1.44e-5	Hip circumference adjusted for BMI;
THYM	cis	rs4631830	0.540	rs2926493	chr10:51492131	G/A	cg16070123	chr10:51489643	NA	-0.62	-6.06	-0.53	2.68e-8	Prostate-specific antigen levels;
THYM	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg17264618	chr3:40429014	ENTPD3	0.51	5.01	0.46	2.56e-6	Renal cell carcinoma;
THYM	cis	rs13403149	0.962	rs13403136	chr2:2843337	G/A	cg12915819	chr2:3453113	TTC15	-0.5	-4.48	-0.42	2.07e-5	Smoking initiation;
THYM	cis	rs9916302	0.652	rs9903269	chr17:37742383	A/T	cg07936489	chr17:37558343	FBXL20	-0.84	-5.35	-0.48	6.16e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs10911251	0.546	rs7473	chr1:183114634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.68	0.43	9.48e-6	Colorectal cancer;
THYM	cis	rs2204008	0.528	rs11503820	chr12:38395379	G/A	cg10518543	chr12:38710700	ALG10B	-0.57	-4.49	-0.42	2.04e-5	Bladder cancer;
THYM	cis	rs7546094	0.935	rs4839254	chr1:113140926	C/T	cg25616829	chr1:112535356	NA	0.57	4.72	0.44	8.11e-6	Platelet distribution width;
THYM	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22857025	chr5:266934	NA	-1.43	-9.3	-0.69	5.28e-15	Breast cancer;
THYM	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg13695892	chr22:41940480	POLR3H	0.99	7.48	0.61	3.75e-11	Vitiligo;
THYM	cis	rs868036	0.681	rs4776976	chr15:68103291	C/T	cg24579218	chr15:68104479	NA	-0.82	-8.85	-0.67	4.77e-14	Restless legs syndrome;
THYM	cis	rs6430585	0.527	rs2278731	chr2:136396300	T/C	cg07169764	chr2:136633963	MCM6	0.97	8.64	0.66	1.32e-13	Corneal structure;
THYM	cis	rs7797990	0.561	rs6974523	chr7:156016820	G/T	cg03831405	chr7:155588795	NA	0.45	4.52	0.42	1.81e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-6.3	-0.54	9.33e-9	Schizophrenia;
THYM	cis	rs2075230	0.588	rs1642802	chr17:7544271	T/C	cg10509001	chr17:7553872	ATP1B2	-0.57	-4.61	-0.43	1.26e-5	Hormone measurements;
THYM	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs4919044	0.562	rs79873247	chr10:94622388	A/C	cg05127821	chr10:94822908	CYP26C1	-1.14	-6.82	-0.57	8.49e-10	Coronary artery disease;
THYM	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg22189786	chr22:42395067	WBP2NL	0.57	5.17	0.47	1.27e-6	Birth weight;
THYM	cis	rs611744	0.967	rs677842	chr8:109212468	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.31	0.48	7.16e-7	Dupuytren's disease;
THYM	cis	rs2898681	0.581	rs10003908	chr4:53681089	T/C	cg00791764	chr4:53727839	RASL11B	0.44	5.46	0.49	3.81e-7	Optic nerve measurement (cup area);
THYM	cis	rs7794273	0.821	rs7810384	chr7:18844771	C/T	cg13420273	chr7:18810212	HDAC9	0.61	5.06	0.46	2.08e-6	Night sleep phenotypes;
THYM	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg17264618	chr3:40429014	ENTPD3	0.54	5.13	0.47	1.5e-6	Renal cell carcinoma;
THYM	cis	rs4750440	0.702	rs7922870	chr10:14030921	C/T	cg27542038	chr10:14027202	FRMD4A	-0.5	-4.45	-0.42	2.36e-5	Adiponectin levels;
THYM	cis	rs9796	0.553	rs2925343	chr15:41306493	T/C	cg18705301	chr15:41695430	NDUFAF1	0.7	6.23	0.54	1.3e-8	Menopause (age at onset);
THYM	cis	rs35264875	0.950	rs72928659	chr11:68852358	C/T	cg01993067	chr11:68851601	TPCN2	1.0	5.3	0.48	7.4e-7	Blond vs. brown hair color;
THYM	cis	rs13279522	0.908	rs6472246	chr8:67007427	A/G	cg20171999	chr8:67343066	NA	0.47	4.48	0.42	2.07e-5	Coronary heart disease event reduction (statin therapy interaction);
THYM	cis	rs4285028	0.747	rs11923248	chr3:121566498	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-6.63	-0.56	2.01e-9	Multiple sclerosis;
THYM	cis	rs7523273	0.565	rs11118451	chr1:207887493	A/G	cg22525895	chr1:207977042	MIR29B2	0.53	5.05	0.46	2.17e-6	Schizophrenia;
THYM	cis	rs13006833	0.739	rs291428	chr2:191197226	G/T	cg11845111	chr2:191398756	TMEM194B	0.66	4.71	0.43	8.54e-6	Urinary metabolites;
THYM	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.44	-0.49	4.11e-7	Mood instability;
THYM	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.58	0.56	2.58e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs526231	0.511	rs55896090	chr5:102362004	G/C	cg23492399	chr5:102201601	PAM	-0.7	-5.21	-0.47	1.08e-6	Primary biliary cholangitis;
THYM	cis	rs72717009	0.825	rs9427397	chr1:161476204	C/T	cg15358701	chr1:161410459	NA	-0.95	-5.06	-0.46	2.08e-6	Rheumatoid arthritis;
THYM	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11890956	chr21:40555474	PSMG1	-0.9	-9.61	-0.7	1.12e-15	Cognitive function;
THYM	cis	rs12216545	0.737	rs7808866	chr7:150223982	A/T	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs35881094	0.933	rs4672254	chr2:58892534	T/C	cg09452692	chr2:58468460	FANCL	0.59	4.53	0.42	1.7e-5	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs72627123	0.531	rs79328555	chr14:74588572	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.29	7.08	0.59	2.46e-10	Morning vs. evening chronotype;
THYM	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.85	-0.51	7.09e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs4595586	0.545	rs4768505	chr12:39380338	C/A	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs4732038	0.510	rs10246041	chr7:134272478	C/T	cg06906464	chr7:134288099	NA	-0.51	-4.93	-0.45	3.54e-6	Longevity;
THYM	cis	rs28374715	0.528	rs7181982	chr15:41623020	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.78	-0.83	2.3e-26	Ulcerative colitis;
THYM	cis	rs6840360	0.615	rs10021407	chr4:152465002	A/G	cg22705602	chr4:152727874	NA	-0.71	-7.94	-0.63	4.03e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg24069376	chr3:38537580	EXOG	0.68	6.73	0.57	1.26e-9	Electrocardiographic conduction measures;
THYM	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.8	-7.28	-0.6	9.51e-11	Intelligence (multi-trait analysis);
THYM	cis	rs6089829	0.589	rs73921629	chr20:61676036	G/C	cg08564027	chr20:61660810	NA	-0.82	-6.41	-0.55	5.59e-9	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs928736	0.599	rs1000005	chr21:34433051	C/G	cg00274965	chr21:34405681	NA	0.48	5.43	0.49	4.35e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs600806	0.888	rs3853498	chr1:109860144	T/C	cg23032129	chr1:109941072	SORT1	-0.57	-4.84	-0.44	5.11e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg13609457	chr4:120235615	NA	0.58	5.34	0.48	6.38e-7	Corneal astigmatism;
THYM	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg23815491	chr16:72088622	HP	-0.76	-6.58	-0.56	2.51e-9	Prostate cancer;
THYM	cis	rs6980334	0.817	rs10228704	chr7:137795206	T/C	cg22979093	chr7:137028410	PTN	0.62	4.95	0.45	3.19e-6	Blood metabolite ratios;
THYM	cis	rs2354432	0.556	rs2353984	chr1:146813358	C/T	cg25205988	chr1:146714368	CHD1L	0.93	4.93	0.45	3.52e-6	Mitochondrial DNA levels;
THYM	cis	rs2108622	1.000	rs55744319	chr19:15981821	G/A	cg13772218	chr19:15982569	NA	0.6	5.2	0.47	1.14e-6	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs9287719	0.674	rs759399	chr2:10796883	T/C	cg03983476	chr2:10830698	NOL10	0.62	5.33	0.48	6.66e-7	Prostate cancer;
THYM	cis	rs1005224	0.654	rs8005753	chr14:76136086	A/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.72	-5.93	-0.52	4.77e-8	Large artery stroke;
THYM	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.8	-0.51	8.64e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg17366294	chr4:99064904	C4orf37	0.55	6.43	0.55	5.06e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs41005	1.000	rs798450	chr2:8107093	C/T	cg03155496	chr2:8117019	LOC339788	0.97	9.21	0.69	8.25e-15	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs8078723	1.000	rs1042658	chr17:38173902	C/T	cg17467752	chr17:38218738	THRA	0.83	6.68	0.57	1.59e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg11663144	chr21:46675770	NA	-0.45	-4.53	-0.42	1.69e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7568458	0.837	rs35565292	chr2:85790316	T/A	cg17127132	chr2:85788382	GGCX	0.67	5.38	0.48	5.3e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg21433313	chr16:3507492	NAT15	0.58	4.82	0.44	5.39e-6	Body mass index (adult);
THYM	cis	rs7771547	0.607	rs632943	chr6:36469121	A/G	cg07856975	chr6:36356162	ETV7	0.52	5.01	0.46	2.48e-6	Platelet distribution width;
THYM	cis	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg06636001	chr8:8085503	FLJ10661	-0.73	-7.25	-0.6	1.11e-10	Mood instability;
THYM	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg03929089	chr4:120376271	NA	1.03	8.74	0.67	8.32e-14	Height;
THYM	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg12165864	chr7:66369176	NA	-0.81	-5.94	-0.52	4.74e-8	Corneal structure;
THYM	cis	rs7178572	0.849	rs12901503	chr15:77819056	A/G	cg22256960	chr15:77711686	NA	-0.94	-7.69	-0.62	1.33e-11	Type 2 diabetes;
THYM	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg17077180	chr1:38461687	NA	-0.42	-4.82	-0.44	5.5e-6	Coronary artery disease;
THYM	cis	rs854765	0.583	rs8078583	chr17:17811465	C/T	cg04398451	chr17:18023971	MYO15A	-0.8	-7.33	-0.6	7.5e-11	Total body bone mineral density;
THYM	cis	rs6968419	0.504	rs2402032	chr7:115759884	T/G	cg02561103	chr7:115862891	TES	-0.6	-4.48	-0.42	2.09e-5	Intraocular pressure;
THYM	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-4.55	-0.42	1.6e-5	Crohn's disease;
THYM	cis	rs2073300	0.609	rs8183135	chr20:23384284	C/T	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg19346786	chr7:2764209	NA	-0.66	-5.66	-0.5	1.58e-7	Height;
THYM	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg07936489	chr17:37558343	FBXL20	-0.81	-5.3	-0.48	7.45e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg06558623	chr16:89946397	TCF25	1.18	5.5	0.49	3.19e-7	Skin colour saturation;
THYM	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg05340658	chr4:99064831	C4orf37	0.54	4.55	0.42	1.58e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg22852734	chr6:133119734	C6orf192	-1.22	-7.45	-0.61	4.31e-11	Type 2 diabetes nephropathy;
THYM	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg05347473	chr6:146136440	FBXO30	-0.57	-4.52	-0.42	1.75e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6121246	0.609	rs6060627	chr20:30262159	C/T	cg13852791	chr20:30311386	BCL2L1	0.89	8.56	0.66	1.98e-13	Mean corpuscular hemoglobin;
THYM	trans	rs9503551	0.710	rs4128536	chr6:3328453	C/T	cg17620335	chr10:51566824	NCOA4	0.92	6.9	0.58	5.82e-10	Nicotine dependence;
THYM	trans	rs34156428	1.000	rs7950287	chr11:16492118	G/T	cg02688867	chr12:133019854	NA	0.54	6.89	0.58	6.12e-10	Coronary artery disease;
THYM	trans	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg25214090	chr10:38739885	LOC399744	0.83	7.11	0.59	2.14e-10	Corneal astigmatism;
THYM	cis	rs986417	1.000	rs1956557	chr14:60972569	G/A	cg27398547	chr14:60952738	C14orf39	1.25	6.45	0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg12923728	chr3:195709715	SDHAP1	-0.78	-6.36	-0.55	7.14e-9	Pancreatic cancer;
THYM	cis	rs752010	0.871	rs10890149	chr1:42092791	T/A	cg22486000	chr1:42919398	ZMYND12	-0.49	-5.62	-0.5	1.94e-7	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs800586	0.833	rs800537	chr8:116721984	A/G	cg04656070	chr8:116661063	TRPS1	-0.43	-4.47	-0.42	2.16e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs8018808	0.935	rs11627016	chr14:77881138	T/C	cg20045696	chr14:77926864	AHSA1	0.53	4.8	0.44	5.9e-6	Myeloid white cell count;
THYM	cis	rs2455799	0.593	rs13078487	chr3:15929590	G/T	cg16303742	chr3:15540471	COLQ	-0.51	-5.17	-0.47	1.29e-6	Mean platelet volume;
THYM	cis	rs12149862	1.000	rs11866682	chr16:69484625	G/C	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs1499972	0.941	rs73168388	chr3:117645824	C/T	cg07612923	chr3:117604196	NA	1.3	5.07	0.46	1.94e-6	Schizophrenia;
THYM	cis	rs807029	0.577	rs11190787	chr10:102758625	G/T	cg14905631	chr10:102746534	C10orf2;MRPL43	0.36	5.08	0.46	1.92e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	trans	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg07211511	chr3:129823064	LOC729375	0.9	7.25	0.6	1.13e-10	Blood pressure (smoking interaction);
THYM	cis	rs6429082	0.755	rs291372	chr1:235694106	G/C	cg26050004	chr1:235667680	B3GALNT2	0.78	7.09	0.59	2.34e-10	Adiposity;
THYM	cis	rs7610301	1.000	rs4683251	chr3:46643387	C/T	cg22951056	chr3:46887651	NA	-0.8	-5.23	-0.47	1.01e-6	Blood protein levels;
THYM	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs7671261	0.638	rs6846010	chr4:90020087	G/T	cg17769793	chr4:89976368	FAM13A	0.43	4.61	0.43	1.25e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs9914988	0.943	rs4795467	chr17:27180784	C/T	cg20469991	chr17:27169893	C17orf63	-0.84	-4.68	-0.43	9.39e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.67	0.74	6.03e-18	Prudent dietary pattern;
THYM	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs9467773	0.626	rs9379860	chr6:26370605	T/C	cg14345882	chr6:26364793	BTN3A2	0.34	4.6	0.43	1.29e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7582180	0.638	rs6734316	chr2:100976210	A/G	cg14675211	chr2:100938903	LONRF2	0.6	5.68	0.5	1.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs883565	0.792	rs784498	chr3:39180099	A/G	cg15678707	chr3:39149194	GORASP1;TTC21A	-0.67	-4.55	-0.42	1.55e-5	Handedness;
THYM	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg04398451	chr17:18023971	MYO15A	-0.95	-9.65	-0.7	9.09e-16	Total body bone mineral density;
THYM	cis	rs5753037	0.774	rs140118	chr22:30135806	G/A	cg27665648	chr22:30112403	NA	0.5	4.45	0.42	2.31e-5	Type 1 diabetes;
THYM	cis	rs7103648	0.669	rs7927445	chr11:47780754	G/T	cg20307385	chr11:47447363	PSMC3	0.82	6.53	0.56	3.26e-9	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg05347473	chr6:146136440	FBXO30	0.59	4.63	0.43	1.14e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg13010199	chr12:38710504	ALG10B	0.71	5.49	0.49	3.34e-7	Heart rate;
THYM	cis	rs1395	0.925	rs1659676	chr2:27399294	C/T	cg23587288	chr2:27483067	SLC30A3	0.57	5.04	0.46	2.2e-6	Blood metabolite levels;
THYM	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.77	-0.44	6.61e-6	Eye color traits;
THYM	cis	rs71403859	0.614	rs12447033	chr16:71583655	G/T	cg08717414	chr16:71523259	ZNF19	-1.18	-6.44	-0.55	4.93e-9	Post bronchodilator FEV1;
THYM	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.57	4.55	0.42	1.58e-5	Homoarginine levels;
THYM	cis	rs7927592	0.513	rs630225	chr11:68194611	A/C	cg16797656	chr11:68205561	LRP5	0.54	6.23	0.54	1.25e-8	Total body bone mineral density;
THYM	cis	rs8013055	0.846	rs10152050	chr14:105984145	C/G	cg11597832	chr14:105993747	TMEM121	-0.53	-4.54	-0.42	1.62e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	13.05	0.8	6.7e-23	Chronic sinus infection;
THYM	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg22709100	chr7:91322751	NA	0.61	4.83	0.44	5.26e-6	Breast cancer;
THYM	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg16325326	chr1:53192061	ZYG11B	0.81	7.53	0.61	2.93e-11	Monocyte count;
THYM	cis	rs12594515	0.967	rs71405295	chr15:45988921	T/C	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs4557020	0.836	rs4599153	chr2:54695937	T/C	cg11007406	chr2:54682859	SPTBN1	-0.35	-4.64	-0.43	1.11e-5	Myopia (pathological);
THYM	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	5.55	0.5	2.53e-7	Blood metabolite levels;
THYM	cis	rs6840360	0.615	rs4696095	chr4:152467243	A/G	cg17479576	chr4:152424074	FAM160A1	-0.85	-6.4	-0.55	5.9e-9	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg24910161	chr17:38119198	GSDMA	-0.47	-4.84	-0.45	4.92e-6	Self-reported allergy;
THYM	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg03060546	chr3:49711283	APEH	0.77	6.37	0.55	6.65e-9	Resting heart rate;
THYM	cis	rs55788414	0.929	rs66463064	chr16:81180995	T/C	cg06400318	chr16:81190750	PKD1L2	-0.99	-4.99	-0.46	2.72e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg09260853	chr1:2094483	PRKCZ	0.47	4.67	0.43	9.79e-6	Height;
THYM	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg00256281	chr22:41985642	PMM1	0.65	5.14	0.47	1.46e-6	Vitiligo;
THYM	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg14798641	chr3:49314920	USP4;C3orf62	-0.69	-4.69	-0.43	9.23e-6	Cognitive function;
THYM	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg06618935	chr21:46677482	NA	-0.97	-8.05	-0.64	2.38e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1003719	0.715	rs9981715	chr21:38499610	C/G	cg01329690	chr21:38580129	DSCR9	-0.38	-5.21	-0.47	1.09e-6	Eye color traits;
THYM	trans	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17712092	chr4:129076599	LARP1B	0.91	7.63	0.62	1.8e-11	Eosinophil percentage of white cells;
THYM	cis	rs9462846	0.881	rs9296402	chr6:42875650	G/A	cg09436375	chr6:42928200	GNMT	-0.37	-4.55	-0.42	1.56e-5	Blood protein levels;
THYM	cis	rs9790314	0.871	rs336551	chr3:161109720	T/C	cg03342759	chr3:160939853	NMD3	-0.82	-7.54	-0.61	2.76e-11	Morning vs. evening chronotype;
THYM	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	9.42	0.69	2.88e-15	Chronic sinus infection;
THYM	cis	rs6500395	1.000	rs7184144	chr16:48606077	C/T	cg04672837	chr16:48644449	N4BP1	0.54	5.5	0.49	3.25e-7	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs981844	0.683	rs1105495	chr4:154756867	T/C	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs250677	0.522	rs4705301	chr5:148354902	C/G	cg18129178	chr5:148520854	ABLIM3	-0.69	-5.17	-0.47	1.32e-6	Breast cancer;
THYM	cis	rs9810089	0.786	rs10935183	chr3:136149139	C/T	cg21827317	chr3:136751795	NA	0.59	5.05	0.46	2.11e-6	Gestational age at birth (child effect);
THYM	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg03476357	chr21:30257390	N6AMT1	0.6	4.52	0.42	1.8e-5	Dental caries;
THYM	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	5.03	0.46	2.34e-6	Rheumatoid arthritis;
THYM	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg13393036	chr8:95962371	TP53INP1	-0.47	-4.9	-0.45	3.95e-6	Type 2 diabetes;
THYM	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.88	9.94	0.71	2.24e-16	Prudent dietary pattern;
THYM	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.61	-0.43	1.24e-5	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg06640241	chr16:89574553	SPG7	0.67	5.14	0.47	1.48e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs3857067	0.806	rs722486	chr4:95092315	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.48	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg26384229	chr12:38710491	ALG10B	0.74	6.1	0.53	2.3e-8	Morning vs. evening chronotype;
THYM	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg00080972	chr5:178986291	RUFY1	0.54	6.18	0.54	1.56e-8	Lung cancer;
THYM	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg06636001	chr8:8085503	FLJ10661	0.7	5.72	0.51	1.22e-7	Neuroticism;
THYM	cis	rs4481887	0.893	rs10736379	chr1:248455876	A/T	cg00666640	chr1:248458726	OR2T12	0.56	4.61	0.43	1.26e-5	Common traits (Other);
THYM	cis	rs939658	0.683	rs1434459	chr15:79465210	T/C	cg17916960	chr15:79447300	NA	-0.67	-7.7	-0.62	1.3e-11	Refractive error;
THYM	cis	rs7394190	0.748	rs60632610	chr10:75415677	C/T	cg02286717	chr10:75415704	SYNPO2L	-0.74	-4.83	-0.44	5.27e-6	Incident atrial fibrillation;
THYM	cis	rs62070183	0.752	rs17781005	chr17:31132529	T/C	cg02981443	chr17:31254875	TMEM98	-0.58	-5.19	-0.47	1.2e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg16586182	chr3:47516702	SCAP	-0.63	-5.52	-0.49	2.96e-7	Colorectal cancer;
THYM	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.91	0.45	3.71e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	4.84	0.44	4.97e-6	Menarche (age at onset);
THYM	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11890956	chr21:40555474	PSMG1	1.06	10.3	0.73	3.8e-17	Cognitive function;
THYM	cis	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg02825527	chr7:2087843	MAD1L1	-0.82	-5.18	-0.47	1.24e-6	Neuroticism;
THYM	trans	rs1974653	0.672	rs9606238	chr22:20070171	T/C	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs7100689	0.622	rs1340383	chr10:82095968	T/G	cg01528321	chr10:82214614	TSPAN14	0.84	6.43	0.55	5.15e-9	Post bronchodilator FEV1;
THYM	cis	rs4014195	0.521	rs12576996	chr11:65580638	G/T	cg27068330	chr11:65405492	SIPA1	0.71	5.13	0.47	1.52e-6	Glomerular filtration rate (creatinine);Chronic kidney disease;
THYM	cis	rs4243830	0.850	rs4908904	chr1:6580250	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	1.08	7.53	0.61	2.9100000000000002e-11	Body mass index;
THYM	cis	rs988913	0.957	rs6908170	chr6:54821152	C/T	cg19716238	chr6:54711378	FAM83B	0.53	5.24	0.47	9.86e-7	Menarche (age at onset);
THYM	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg05872129	chr22:39784769	NA	-1.05	-11.58	-0.77	7.31e-20	Intelligence (multi-trait analysis);
THYM	cis	rs4919044	0.808	rs55856996	chr10:94808618	T/G	cg05127821	chr10:94822908	CYP26C1	-1.23	-6.66	-0.56	1.76e-9	Coronary artery disease;
THYM	cis	rs2974760	0.606	rs6600143	chr16:201389	A/C	cg08400316	chr16:204221	HBZ	-0.76	-6.08	-0.53	2.48e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7104764	0.957	rs6598071	chr11:219800	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.1	9.77	0.71	5.16e-16	Menarche (age at onset);
THYM	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg13683864	chr3:40499215	RPL14	-1.05	-11.46	-0.76	1.29e-19	Renal cell carcinoma;
THYM	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg18252515	chr7:66147081	NA	1.33	7.34	0.6	7.32e-11	Diabetic kidney disease;
THYM	cis	rs10479542	0.766	rs9286047	chr5:178969147	C/A	cg14820908	chr5:178986412	RUFY1	-0.53	-4.99	-0.46	2.71e-6	Lung cancer;
THYM	cis	rs1395	0.885	rs7575245	chr2:27527321	G/A	cg23587288	chr2:27483067	SLC30A3	-0.59	-4.7	-0.43	8.72e-6	Blood metabolite levels;
THYM	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg03684893	chr10:554711	DIP2C	0.76	6.63	0.56	1.99e-9	Psychosis in Alzheimer's disease;
THYM	cis	rs293526	0.959	rs293509	chr6:83642313	T/C	cg23278060	chr6:83777448	DOPEY1	0.61	4.48	0.42	2.1e-5	Crohn's disease;
THYM	cis	rs11190604	0.767	rs10883489	chr10:102194532	T/C	cg16342193	chr10:102329863	NA	-0.5	-5.17	-0.47	1.29e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg27535305	chr1:53392650	SCP2	0.38	4.55	0.42	1.6e-5	Monocyte count;
THYM	cis	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs77204473	0.655	rs11216183	chr11:116781545	C/A	cg20608306	chr11:116969690	SIK3	-0.65	-4.46	-0.42	2.22e-5	Eosinophil counts;Sum eosinophil basophil counts;
THYM	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	5.09	0.46	1.81e-6	Hip circumference adjusted for BMI;
THYM	cis	rs7267979	1.000	rs2482937	chr20:25340786	A/G	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6980334	0.911	rs10280628	chr7:137767310	C/T	cg06915773	chr7:137028165	PTN	0.6	4.8	0.44	5.89e-6	Blood metabolite ratios;
THYM	cis	rs10743315	0.778	rs7397459	chr12:19377578	C/G	cg02471346	chr12:19282374	PLEKHA5	0.8	5.34	0.48	6.2e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg27490568	chr2:178487706	NA	0.64	5.81	0.51	8.33e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9595908	1.000	rs7332115	chr13:33147548	T/G	cg12383807	chr13:33924137	NA	-0.55	-4.87	-0.45	4.38e-6	Body mass index;
THYM	cis	rs612683	0.759	rs12722868	chr1:100956478	A/G	cg06223162	chr1:101003688	GPR88	0.73	6.08	0.53	2.52e-8	Breast cancer;
THYM	cis	rs870825	0.655	rs7675046	chr4:185652201	G/A	cg04058563	chr4:185651563	MLF1IP	-1.06	-9.32	-0.69	4.75e-15	Blood protein levels;
THYM	cis	rs10979	1.000	rs9484769	chr6:143896719	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	trans	rs208520	0.690	rs207119	chr6:66786408	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.66	-0.62	1.53e-11	Exhaled nitric oxide output;
THYM	cis	rs9352866	0.934	rs1538538	chr6:81525961	A/G	cg08356243	chr6:80645827	ELOVL4	-0.45	-4.46	-0.42	2.23e-5	Antibody level in response to infection;
THYM	cis	rs1971256	0.500	rs17081284	chr6:151800796	C/G	cg25855249	chr6:151646817	AKAP12	0.8	4.52	0.42	1.8e-5	Endometriosis;
THYM	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg21784768	chr11:537496	LRRC56	-1.14	-5.72	-0.51	1.21e-7	Body mass index;
THYM	cis	rs4866334	1.000	rs75533364	chr5:18453341	G/A	cg24599790	chr5:18972260	NA	-1.14	-4.67	-0.43	9.77e-6	IgG glycosylation;
THYM	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg13010199	chr12:38710504	ALG10B	0.74	5.91	0.52	5.32e-8	Heart rate;
THYM	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg06766960	chr11:133703094	NA	-0.61	-5.42	-0.49	4.41e-7	Childhood ear infection;
THYM	cis	rs8032315	0.965	rs1894400	chr15:91428955	C/T	cg04510874	chr15:91427884	FES	0.63	4.68	0.43	9.53e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9790314	1.000	rs336585	chr3:161081670	A/G	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.5e-6	Morning vs. evening chronotype;
THYM	cis	rs9880211	0.613	rs12330335	chr3:135853532	A/C	cg21827317	chr3:136751795	NA	-0.71	-5.16	-0.47	1.33e-6	Body mass index;Height;
THYM	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg06609049	chr19:2785107	THOP1	0.69	5.8	0.51	8.54e-8	Total cholesterol levels;
THYM	cis	rs136161	1.000	rs713753	chr22:36658534	C/T	cg15716373	chr22:36655542	APOL1	-0.31	-4.48	-0.42	2.12e-5	Diabetic kidney disease;
THYM	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg18850127	chr7:39170497	POU6F2	0.53	4.82	0.44	5.39e-6	IgG glycosylation;
THYM	trans	rs877282	0.573	rs2256711	chr10:802272	C/T	cg22713356	chr15:30763199	NA	-0.91	-6.98	-0.58	4.05e-10	Uric acid levels;
THYM	cis	rs3741798	1.000	rs118108016	chr12:12482820	C/A	cg08615371	chr12:12503544	MANSC1	0.89	4.96	0.45	3.03e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7107174	1.000	rs10793297	chr11:78009660	T/C	cg02023728	chr11:77925099	USP35	0.65	5.83	0.51	7.52e-8	Testicular germ cell tumor;
THYM	cis	rs6960043	0.818	rs10807778	chr7:15054190	C/G	cg19272540	chr7:15055459	NA	0.55	6.21	0.54	1.37e-8	Type 2 diabetes;
THYM	cis	rs61931739	0.929	rs1825358	chr12:34011895	C/T	cg06521331	chr12:34319734	NA	0.57	4.49	0.42	2.01e-5	Morning vs. evening chronotype;
THYM	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg21644426	chr2:191273491	MFSD6	-0.74	-5.2	-0.47	1.13e-6	Diastolic blood pressure;
THYM	cis	rs6032067	0.929	rs2233895	chr20:43850143	T/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.5	-0.49	3.14e-7	Blood protein levels;
THYM	cis	rs7187994	0.848	rs35210690	chr16:84782857	C/G	cg07647771	chr16:84786436	USP10	-0.53	-4.91	-0.45	3.81e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg07936489	chr17:37558343	FBXL20	0.82	5.69	0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg14349672	chr11:133703707	NA	-0.56	-5.01	-0.46	2.49e-6	Childhood ear infection;
THYM	cis	rs10892173	1.000	rs10892173	chr11:117672561	C/T	cg21640587	chr11:117668038	DSCAML1	0.61	4.99	0.46	2.71e-6	Myopia;
THYM	cis	rs4662945	1.000	rs4662945	chr2:130216043	A/G	cg05903289	chr2:130345205	NA	-0.52	-5.08	-0.46	1.86e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs2404602	0.647	rs11072612	chr15:76960984	A/T	cg23625390	chr15:77176239	SCAPER	-0.86	-5.98	-0.52	3.87e-8	Blood metabolite levels;
THYM	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg23260525	chr10:116636907	FAM160B1	0.52	5.19	0.47	1.19e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg03388043	chr17:80084554	CCDC57	0.71	5.9	0.52	5.47e-8	Life satisfaction;
THYM	cis	rs1003719	0.680	rs2154537	chr21:38502012	G/C	cg01329690	chr21:38580129	DSCR9	-0.42	-5.84	-0.51	7.24e-8	Eye color traits;
THYM	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg11764359	chr7:65958608	NA	-0.82	-6.57	-0.56	2.68e-9	Aortic root size;
THYM	cis	rs7236492	0.748	rs80321964	chr18:77210152	G/C	cg15644404	chr18:77186268	NFATC1	-1.06	-4.97	-0.45	2.96e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs912057	0.601	rs1294413	chr6:6739924	C/A	cg13809441	chr6:6737631	NA	0.53	6.74	0.57	1.19e-9	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs9914544	0.689	rs1634423	chr17:18844736	C/T	cg26378065	chr17:18585709	ZNF286B	0.63	5.27	0.48	8.39e-7	Educational attainment (years of education);
THYM	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg27490568	chr2:178487706	NA	0.58	4.81	0.44	5.71e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs76878669	0.538	rs73489638	chr11:66127639	C/T	cg18002602	chr11:66138449	SLC29A2	-0.48	-4.72	-0.44	8.12e-6	Educational attainment (years of education);
THYM	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6733011	0.518	rs12992214	chr2:99466337	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-4.54	-0.42	1.62e-5	Bipolar disorder;
THYM	cis	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	trans	rs9929218	0.529	rs11640736	chr16:68738324	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.97	11.22	0.75	4.27e-19	Colorectal cancer;
THYM	cis	rs708547	0.575	rs6847086	chr4:57791864	A/G	cg00922110	chr4:57842668	C4orf14	0.4	4.74	0.44	7.59e-6	Response to bleomycin (chromatid breaks);
THYM	cis	rs7246657	0.943	rs10403613	chr19:37844306	C/T	cg22634378	chr19:37742834	NA	0.68	5.67	0.5	1.55e-7	Coronary artery calcification;
THYM	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg11871910	chr12:69753446	YEATS4	1.06	9.8	0.71	4.32e-16	Blood protein levels;
THYM	cis	rs10140922	0.966	rs10132397	chr14:35822447	G/T	cg07166546	chr14:35805898	NA	-0.27	-6.46	-0.55	4.35e-9	Hip circumference adjusted for BMI;
THYM	cis	rs1167827	0.680	rs1167800	chr7:75176196	G/A	cg04681579	chr7:75027559	TRIM73;TRIM74	-0.76	-5.88	-0.52	6.18e-8	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12496230	1.000	rs36016775	chr3:66838437	A/G	cg04995300	chr3:66848608	NA	0.99	6.14	0.53	1.89e-8	Type 2 diabetes;
THYM	cis	rs73086581	1.000	rs17215340	chr20:3970173	C/G	cg02187196	chr20:3869020	PANK2	-0.5	-5.57	-0.5	2.38e-7	Response to antidepressants in depression;
THYM	cis	rs3008870	0.536	rs2208576	chr1:67513401	C/G	cg02640540	chr1:67518911	SLC35D1	-0.69	-5.41	-0.49	4.64e-7	Lymphocyte percentage of white cells;
THYM	cis	rs7568458	0.709	rs1446669	chr2:85762209	T/C	cg02493740	chr2:85810744	VAMP5	-0.64	-4.86	-0.45	4.54e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs3947	0.950	rs2740592	chr8:11701253	A/G	cg26752888	chr8:11627280	NEIL2	-0.7	-4.63	-0.43	1.16e-5	Blood protein levels;
THYM	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg08994789	chr17:28903642	LRRC37B2	1.0	4.97	0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6032067	0.925	rs35751129	chr20:43847658	C/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.68	-6.07	-0.53	2.63e-8	Blood protein levels;
THYM	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg08885076	chr2:99613938	TSGA10	-0.46	-4.63	-0.43	1.16e-5	Fear of minor pain;
THYM	cis	rs12478296	0.534	rs67092377	chr2:243002171	T/G	cg06360820	chr2:242988706	NA	-0.85	-5.5	-0.49	3.15e-7	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg27118825	chr19:46318748	RSPH6A;SYMPK	-0.33	-4.66	-0.43	1.03e-5	Coronary artery disease;
THYM	cis	rs10929159	0.928	rs6761121	chr2:236922541	T/C	cg20128773	chr2:236923534	AGAP1	0.35	4.66	0.43	1.01e-5	Parkinson's disease;
THYM	cis	rs7592578	0.537	rs62180982	chr2:191264485	G/T	cg25963032	chr2:191064776	C2orf88	-0.64	-4.65	-0.43	1.06e-5	Diastolic blood pressure;
THYM	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg22431228	chr1:16359049	CLCNKA	-0.43	-4.48	-0.42	2.05e-5	Systolic blood pressure;
THYM	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.48	-4.8	-0.44	5.86e-6	Crohn's disease;
THYM	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg10589385	chr1:150898437	SETDB1	0.58	4.81	0.44	5.55e-6	Melanoma;
THYM	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg06009448	chr7:1102226	C7orf50	0.44	4.46	0.42	2.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg03209412	chr4:183728196	NA	0.66	5.98	0.52	3.88e-8	Pediatric autoimmune diseases;
THYM	cis	rs763014	0.898	rs8060585	chr16:635794	C/G	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs10857712	0.904	rs36118799	chr10:135222369	T/G	cg19904058	chr10:135279010	LOC619207	-0.51	-4.79	-0.44	6.24e-6	Systemic lupus erythematosus;
THYM	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg11764359	chr7:65958608	NA	-0.84	-7.06	-0.59	2.78e-10	Aortic root size;
THYM	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg07061783	chr6:25882402	NA	-0.81	-6.65	-0.56	1.89e-9	Intelligence (multi-trait analysis);
THYM	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg14895029	chr7:2775587	GNA12	-0.68	-5.03	-0.46	2.27e-6	Height;
THYM	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg10523679	chr1:76189770	ACADM	-0.58	-4.96	-0.45	3.14e-6	Daytime sleep phenotypes;
THYM	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg11764359	chr7:65958608	NA	0.75	6.05	0.53	2.82e-8	Aortic root size;
THYM	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs888194	0.966	rs6606725	chr12:109905368	C/A	cg11367159	chr12:110044531	NA	0.49	4.53	0.42	1.71e-5	Neuroticism;
THYM	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg22166914	chr1:53195759	ZYG11B	0.77	7.61	0.62	1.98e-11	Monocyte count;
THYM	cis	rs7568458	0.783	rs2166529	chr2:85742175	A/C	cg17127132	chr2:85788382	GGCX	-0.77	-5.24	-0.47	9.6e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg02070205	chr10:30722105	MAP3K8	-0.6	-5.03	-0.46	2.3e-6	Inflammatory bowel disease;
THYM	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg07061783	chr6:25882402	NA	-0.88	-8.54	-0.66	2.14e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9915657	0.870	rs1042667	chr17:70120551	A/C	cg06234051	chr17:70120541	SOX9	-0.78	-7.42	-0.61	4.92e-11	Thyroid hormone levels;
THYM	cis	rs9914988	0.943	rs67327562	chr17:27108828	G/A	cg20469991	chr17:27169893	C17orf63	-0.77	-4.59	-0.43	1.33e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg12564285	chr5:131593104	PDLIM4	0.44	4.78	0.44	6.47e-6	Blood metabolite levels;
THYM	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg13175981	chr1:150552382	MCL1	0.78	5.79	0.51	8.88e-8	Tonsillectomy;
THYM	cis	rs9399401	0.626	rs13198644	chr6:142783233	A/G	cg04461802	chr6:142623433	GPR126	0.77	7.26	0.6	1.08e-10	Chronic obstructive pulmonary disease;
THYM	cis	rs758324	0.680	rs156043	chr5:131491850	G/A	cg16205897	chr5:131564050	P4HA2	0.54	4.76	0.44	6.9e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg15741354	chr8:8146129	NA	-0.28	-4.63	-0.43	1.16e-5	Joint mobility (Beighton score);
THYM	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg20486651	chr6:167070296	RPS6KA2	0.5	4.79	0.44	6.18e-6	Crohn's disease;
THYM	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg26116260	chr4:7069785	GRPEL1	1.09	10.63	0.74	7.51e-18	Monocyte percentage of white cells;
THYM	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg07636037	chr3:49044803	WDR6	0.91	8.13	0.64	1.59e-12	Parkinson's disease;
THYM	cis	rs3772130	0.962	rs4413346	chr3:121486310	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs346785	0.666	rs9902690	chr17:74295140	A/G	cg09812376	chr17:74270190	QRICH2	-0.49	-4.99	-0.46	2.77e-6	White matter hyperintensities in ischemic stroke;
THYM	cis	rs12681287	0.927	rs7003059	chr8:87330713	C/T	cg27223183	chr8:87520930	FAM82B	-0.65	-4.76	-0.44	6.8e-6	Caudate activity during reward;
THYM	cis	rs12681287	0.547	rs13267858	chr8:87510871	G/A	cg27223183	chr8:87520930	FAM82B	-0.71	-5.46	-0.49	3.8e-7	Caudate activity during reward;
THYM	cis	rs2945412	0.569	rs62057779	chr17:25819513	G/A	cg07487925	chr17:25620950	WSB1	0.62	4.47	0.42	2.2e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg02569458	chr12:86230093	RASSF9	-0.59	-5.21	-0.47	1.11e-6	Major depressive disorder;
THYM	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.16	-8.93	-0.68	3.28e-14	Schizophrenia;
THYM	cis	rs8033133	0.957	rs7162559	chr15:25352341	C/T	cg14481604	chr15:25334117	SNORD116-22	0.67	4.47	0.42	2.16e-5	Blood osmolality (transformed sodium);
THYM	cis	rs367615	0.659	rs13435970	chr5:108884660	C/T	cg17395555	chr5:108820864	NA	0.53	4.8	0.44	5.95e-6	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs3741151	0.687	rs7933355	chr11:73236817	G/C	cg12959048	chr11:73096162	RELT	-0.51	-4.51	-0.42	1.87e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg09165964	chr15:75287851	SCAMP5	-1.09	-10.42	-0.73	2.09e-17	Blood trace element (Zn levels);
THYM	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg05457628	chr5:178986728	RUFY1	0.63	6.6	0.56	2.32e-9	Lung cancer;
THYM	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg03676636	chr4:99064102	C4orf37	0.5	7.59	0.61	2.14e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.59	-7.59	-0.61	2.16e-11	Longevity;Endometriosis;
THYM	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg24675658	chr1:53192096	ZYG11B	-0.82	-7.54	-0.61	2.75e-11	Monocyte count;
THYM	cis	rs7172809	0.599	rs17471431	chr15:77749068	T/C	cg10437265	chr15:77819839	NA	-0.5	-4.57	-0.42	1.47e-5	Glucose homeostasis traits;
THYM	cis	rs4919044	0.641	rs11187225	chr10:94714427	C/G	cg05127821	chr10:94822908	CYP26C1	-1.2	-7.07	-0.59	2.6e-10	Coronary artery disease;
THYM	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg20887711	chr4:1340912	KIAA1530	-0.82	-7.15	-0.59	1.74e-10	Longevity;
THYM	cis	rs7582180	0.675	rs4851313	chr2:101029002	A/G	cg14675211	chr2:100938903	LONRF2	-0.59	-5.69	-0.5	1.4e-7	Intelligence (multi-trait analysis);
THYM	cis	rs289828	0.579	rs2194492	chr2:152146194	G/C	cg05960677	chr2:152117363	RBM43	0.73	7.23	0.6	1.2e-10	Blood protein levels;
THYM	cis	rs7688540	0.511	rs11731623	chr4:201010	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.91	5.56	0.5	2.45e-7	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs3771570	0.901	rs4075818	chr2:242432142	T/C	cg21155796	chr2:242212141	HDLBP	1.14	5.7	0.5	1.33e-7	Prostate cancer;
THYM	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.68	4.9	0.45	3.9e-6	Height;
THYM	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg11494091	chr17:61959527	GH2	0.69	6.32	0.54	8.45e-9	Height;
THYM	cis	rs1113500	0.933	rs3893034	chr1:108632178	G/A	cg06207961	chr1:108661230	NA	0.66	5.17	0.47	1.28e-6	Growth-regulated protein alpha levels;
THYM	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs533581	0.866	rs871756	chr16:88969076	G/C	cg08484992	chr16:88977278	CBFA2T3	0.45	5.46	0.49	3.78e-7	Social autistic-like traits;
THYM	cis	rs9649213	0.593	rs12704989	chr7:98029438	G/T	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg24812749	chr6:127587940	RNF146	0.99	8.06	0.64	2.3e-12	Breast cancer;
THYM	cis	rs17125944	0.615	rs1886786	chr14:53312189	A/T	cg00686598	chr14:53173677	PSMC6	-1.07	-4.91	-0.45	3.77e-6	Alzheimer's disease (late onset);
THYM	cis	rs4595586	0.545	rs6580888	chr12:39369704	C/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg07061783	chr6:25882402	NA	-0.83	-7.34	-0.6	7.31e-11	Intelligence (multi-trait analysis);
THYM	cis	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg15298719	chr17:7165255	CLDN7	-0.38	-5.59	-0.5	2.21e-7	Diastolic blood pressure;
THYM	cis	rs2073300	1.000	rs6137962	chr20:23443966	T/C	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg17173187	chr15:85201210	NMB	0.57	5.27	0.48	8.52e-7	Schizophrenia;
THYM	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg22535103	chr8:58192502	C8orf71	0.88	5.02	0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7626444	0.647	rs844546	chr3:196475274	T/G	cg12930392	chr3:196481615	PAK2	0.4	4.97	0.45	2.97e-6	Monocyte count;
THYM	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg04117972	chr1:227635322	NA	0.81	4.63	0.43	1.17e-5	Major depressive disorder;
THYM	cis	rs28595532	0.925	rs10000445	chr4:119485311	C/T	cg14228332	chr4:119757509	SEC24D	1.38	4.99	0.46	2.77e-6	Cannabis dependence symptom count;
THYM	cis	rs981844	1.000	rs56232929	chr4:154665700	A/G	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs778371	0.723	rs13001052	chr2:233683984	C/T	cg08000102	chr2:233561755	GIGYF2	-0.8	-6.95	-0.58	4.6e-10	Schizophrenia;
THYM	cis	rs34638657	0.872	rs6420436	chr16:82186719	C/G	cg09894383	chr16:82067445	HSD17B2	-0.52	-5.24	-0.47	9.56e-7	Lung adenocarcinoma;
THYM	cis	rs1018836	0.892	rs2187981	chr8:91549629	T/C	cg16814680	chr8:91681699	NA	-0.83	-7.26	-0.6	1.08e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg15448220	chr1:150897856	SETDB1	0.87	7.37	0.6	6.4e-11	Melanoma;
THYM	cis	rs1692580	0.840	rs696094	chr1:2169215	G/A	cg21194808	chr1:2205498	SKI	0.32	4.52	0.42	1.79e-5	Coronary artery disease;
THYM	cis	rs9880211	1.000	rs6805316	chr3:135952112	A/G	cg21827317	chr3:136751795	NA	-0.71	-4.97	-0.45	3e-6	Body mass index;Height;
THYM	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg21773646	chr17:80085082	CCDC57	0.32	4.5	0.42	1.93e-5	Life satisfaction;
THYM	cis	rs478304	0.903	rs1151502	chr11:65503485	G/C	cg27068330	chr11:65405492	SIPA1	0.82	7.91	0.63	4.72e-12	Acne (severe);
THYM	cis	rs13006833	0.635	rs2664251	chr2:191147667	C/T	cg11845111	chr2:191398756	TMEM194B	0.65	4.55	0.42	1.56e-5	Urinary metabolites;
THYM	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg06634786	chr22:41940651	POLR3H	0.7	4.92	0.45	3.59e-6	Cannabis dependence symptom count;
THYM	cis	rs1003719	0.715	rs2051398	chr21:38550258	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.63	4.52	0.42	1.76e-5	Eye color traits;
THYM	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg05527609	chr1:210001259	C1orf107	1.07	8.77	0.67	7.01e-14	Orofacial clefts;
THYM	cis	rs7712401	0.599	rs7726933	chr5:122373399	T/A	cg19808643	chr5:122110361	SNX2	-0.57	-5.07	-0.46	1.98e-6	Mean platelet volume;
THYM	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg08645402	chr16:4508243	NA	0.76	6.73	0.57	1.27e-9	Schizophrenia;
THYM	cis	rs9462846	0.959	rs9462843	chr6:42856499	T/G	cg10862848	chr6:42927986	GNMT	-0.45	-4.68	-0.43	9.33e-6	Blood protein levels;
THYM	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg15921436	chr17:44337874	NA	-0.91	-6.85	-0.58	7.19e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs600806	0.821	rs10127790	chr1:109891133	C/T	cg23616212	chr1:109941201	SORT1	-0.5	-4.72	-0.44	8.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs6032067	0.683	rs16989763	chr20:43779963	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.64	-6.42	-0.55	5.27e-9	Blood protein levels;
THYM	cis	rs1692580	0.846	rs377599	chr1:2164699	C/T	cg21442419	chr1:2182373	SKI	-0.41	-4.55	-0.42	1.61e-5	Coronary artery disease;
THYM	cis	rs12149862	0.891	rs11859839	chr16:69479132	A/T	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg03806693	chr22:41940476	POLR3H	-1.0	-9.14	-0.68	1.15e-14	Vitiligo;
THYM	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-5.4	-0.48	4.92e-7	Hemoglobin concentration;
THYM	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg23982607	chr1:1823379	GNB1	-0.94	-10.23	-0.72	5.46e-17	Body mass index;
THYM	cis	rs6430585	0.527	rs2289959	chr2:136423904	C/T	cg07169764	chr2:136633963	MCM6	0.92	8.15	0.64	1.47e-12	Corneal structure;
THYM	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00475322	chr7:917719	C7orf20	0.5	6.28	0.54	1.02e-8	Perceived unattractiveness to mosquitoes;
THYM	cis	rs7072216	0.763	rs4475861	chr10:100164989	C/T	cg03852570	chr10:100175106	PYROXD2	0.37	4.8	0.44	5.8e-6	Metabolite levels;
THYM	cis	rs3741489	1.000	rs2062162	chr12:133432744	C/T	cg03157182	chr12:132655797	NA	-0.54	-4.47	-0.42	2.18e-5	Cognitive function;
THYM	cis	rs9868809	0.649	rs17256786	chr3:48604016	C/G	cg00383909	chr3:49044727	WDR6	1.24	4.95	0.45	3.17e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.75	-5.74	-0.51	1.12e-7	Response to bleomycin (chromatid breaks);
THYM	cis	rs8114671	0.935	rs35193912	chr20:33785050	C/T	cg08999081	chr20:33150536	PIGU	-0.53	-4.77	-0.44	6.63e-6	Height;
THYM	cis	rs7247513	0.964	rs35235213	chr19:12713156	C/T	cg01871581	chr19:12707946	ZNF490	-0.87	-9.36	-0.69	3.84e-15	Bipolar disorder;
THYM	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg19623624	chr10:135278901	LOC619207	-0.6	-4.74	-0.44	7.47e-6	Systemic lupus erythematosus;
THYM	cis	rs752010	0.695	rs12134166	chr1:42105867	C/T	cg06885757	chr1:42089581	HIVEP3	0.48	5.84	0.51	7.38e-8	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs7011507	0.700	rs55847910	chr8:49334732	G/C	cg08774009	chr8:49309094	NA	-0.62	-4.83	-0.44	5.19e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs1062177	1.000	rs973529	chr5:151188158	T/C	cg12924095	chr5:151150029	G3BP1	0.5	4.5	0.42	1.92e-5	Preschool internalizing problems;
THYM	cis	rs12367572	0.620	rs1857925	chr12:45344385	T/C	cg03114573	chr12:45410052	DBX2	-0.54	-4.97	-0.45	3e-6	Gut microbiome composition (summer);
THYM	cis	rs28493229	0.522	rs2233152	chr19:41281016	C/T	cg21869046	chr19:41225005	ITPKC	0.51	4.9	0.45	3.96e-6	Kawasaki disease;
THYM	cis	rs4953076	0.573	rs920519	chr2:44452344	T/C	cg04920474	chr2:44395004	PPM1B	0.66	5.49	0.49	3.29e-7	Height;
THYM	cis	rs17006441	0.932	rs56199973	chr3:69877651	T/C	cg18496212	chr3:69797108	MITF	0.64	6.17	0.54	1.64e-8	Hemoglobin concentration;
THYM	cis	rs870825	0.929	rs72689273	chr4:185592750	C/T	cg04058563	chr4:185651563	MLF1IP	1.01	7.12	0.59	2.08e-10	Blood protein levels;
THYM	cis	rs981844	0.775	rs17371545	chr4:154763980	A/G	cg09973105	chr4:154681532	RNF175	0.62	5.1	0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg18252515	chr7:66147081	NA	1.37	8.05	0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg11245990	chr11:68621969	NA	0.57	7.18	0.59	1.54e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9527	0.590	rs2182348	chr10:104872684	A/G	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	trans	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg10856724	chr12:34555212	NA	-0.87	-7.64	-0.62	1.75e-11	Morning vs. evening chronotype;
THYM	cis	rs9906944	0.678	rs56015440	chr17:47136631	C/G	cg11673840	chr17:47092156	IGF2BP1	-0.48	-4.74	-0.44	7.63e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs2041895	0.509	rs7970139	chr12:107312430	T/C	cg26297688	chr12:107349093	C12orf23	-0.49	-4.81	-0.44	5.66e-6	Glaucoma (low intraocular pressure);
THYM	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg22907277	chr7:1156413	C7orf50	0.81	4.97	0.45	2.94e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6032067	0.639	rs62205502	chr20:43864197	G/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.36	-0.48	5.9e-7	Blood protein levels;
THYM	cis	rs2970992	0.728	rs1028045	chr2:101321075	G/A	cg01042948	chr2:101319752	NA	-0.63	-6.28	-0.54	1e-8	Educational attainment;
THYM	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22496380	chr5:211416	CCDC127	1.4	9.16	0.68	1.03e-14	Breast cancer;
THYM	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg01364799	chr7:75623366	TMEM120A	0.63	4.56	0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.57	4.59	0.43	1.34e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs1389724	0.648	rs11102158	chr1:111318682	A/T	cg25283465	chr1:111323341	NA	0.58	4.58	0.43	1.4e-5	Schizophrenia;
THYM	cis	rs1129187	0.702	rs2296805	chr6:42928758	T/G	cg19747945	chr6:42946146	PEX6	-0.34	-5.08	-0.46	1.88e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6835098	1.000	rs28477433	chr4:174085820	T/C	cg08422745	chr4:174089978	GALNT7	-1.0	-8.54	-0.66	2.21e-13	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg00376283	chr12:123451042	ABCB9	0.73	5.6	0.5	2.1e-7	Neutrophil percentage of white cells;
THYM	cis	rs7528419	1.000	rs646776	chr1:109818530	C/T	cg00908766	chr1:109817496	CELSR2	0.85	6.86	0.58	7.11e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
THYM	trans	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg10856724	chr12:34555212	NA	-0.81	-7.07	-0.59	2.57e-10	Bladder cancer;
THYM	trans	rs7952251	0.812	rs7928088	chr11:112418431	T/G	cg14154186	chr1:204970430	NFASC	-0.73	-7.37	-0.6	6.15e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7940866	0.834	rs2324315	chr11:130839772	C/G	cg12179176	chr11:130786555	SNX19	0.63	4.84	0.44	5e-6	Schizophrenia;
THYM	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg16928487	chr17:17741425	SREBF1	0.47	4.56	0.42	1.55e-5	Total body bone mineral density;
THYM	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg06481639	chr22:41940642	POLR3H	0.74	4.78	0.44	6.39e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs6598955	0.670	rs7531518	chr1:26539749	T/C	cg04990556	chr1:26633338	UBXN11	-0.88	-7.99	-0.63	3.1e-12	Obesity-related traits;
THYM	cis	rs990171	1.000	rs3755267	chr2:103038587	G/T	cg13897122	chr2:103039542	IL18RAP	0.4	4.81	0.44	5.58e-6	Lymphocyte counts;
THYM	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg16586182	chr3:47516702	SCAP	0.61	5.29	0.48	7.83e-7	Colorectal cancer;
THYM	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg06481639	chr22:41940642	POLR3H	0.73	5.29	0.48	7.78e-7	Vitiligo;
THYM	cis	rs7616559	0.812	rs2128536	chr3:156767062	C/T	cg15697575	chr3:156784781	NA	0.42	5.37	0.48	5.54e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg02187348	chr16:89574699	SPG7	0.76	6.3	0.54	9.24e-9	Multiple myeloma (IgH translocation);
THYM	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg22907277	chr7:1156413	C7orf50	0.83	7.12	0.59	2.04e-10	Longevity;Endometriosis;
THYM	cis	rs9790314	0.838	rs4414866	chr3:160928709	C/T	cg04691961	chr3:161091175	C3orf57	-0.6	-4.96	-0.45	3.07e-6	Morning vs. evening chronotype;
THYM	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg20887711	chr4:1340912	KIAA1530	-0.58	-4.64	-0.43	1.13e-5	Obesity-related traits;
THYM	cis	rs9902453	0.740	rs2617884	chr17:28120430	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs1499972	0.887	rs7630428	chr3:117528682	A/G	cg07612923	chr3:117604196	NA	1.31	5.35	0.48	6.02e-7	Schizophrenia;
THYM	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg09307838	chr4:120376055	NA	0.62	4.73	0.44	7.88e-6	Corneal astigmatism;
THYM	cis	rs728616	0.867	rs4387301	chr10:81736399	C/T	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg14675211	chr2:100938903	LONRF2	0.76	8.42	0.65	3.99e-13	Intelligence (multi-trait analysis);
THYM	cis	rs950880	0.710	rs7597017	chr2:103062116	A/G	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.71	-0.44	8.33e-6	Serum protein levels (sST2);
THYM	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg11752832	chr7:134001865	SLC35B4	0.72	5.13	0.47	1.53e-6	Mean platelet volume;
THYM	cis	rs921665	0.749	rs4854133	chr2:3199626	C/T	cg16434511	chr2:3151078	NA	-0.81	-5.29	-0.48	7.69e-7	World class endurance athleticism;
THYM	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg00852783	chr1:26633632	UBXN11	0.7	5.79	0.51	9e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4481887	0.927	rs4381224	chr1:248456826	A/T	cg00666640	chr1:248458726	OR2T12	0.56	4.61	0.43	1.26e-5	Common traits (Other);
THYM	cis	rs1003719	0.715	rs2212742	chr21:38578685	A/G	cg01329690	chr21:38580129	DSCR9	-0.36	-5.0	-0.46	2.67e-6	Eye color traits;
THYM	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg16325326	chr1:53192061	ZYG11B	0.94	9.94	0.71	2.22e-16	Monocyte count;
THYM	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.58	-10.88	-0.74	2.23e-18	Hemostatic factors and hematological phenotypes;
THYM	cis	rs4654899	0.865	rs9426730	chr1:21452255	A/T	cg01072550	chr1:21505969	NA	-0.75	-6.82	-0.57	8.48e-10	Superior frontal gyrus grey matter volume;
THYM	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg00129232	chr17:37814104	STARD3	-0.87	-7.23	-0.6	1.23e-10	Asthma;
THYM	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4988958	0.527	rs11465641	chr2:103000868	T/G	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma (childhood onset);
THYM	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	10.22	0.72	5.61e-17	Chronic sinus infection;
THYM	cis	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg21775007	chr8:11205619	TDH	-0.68	-5.06	-0.46	2.06e-6	Retinal vascular caliber;
THYM	cis	rs2085601	0.509	rs2609267	chr4:89887848	T/A	cg17769793	chr4:89976368	FAM13A	-0.4	-4.92	-0.45	3.67e-6	Hair greying;
THYM	cis	rs7089973	0.872	rs35010779	chr10:116631816	A/C	cg23260525	chr10:116636907	FAM160B1	0.52	4.66	0.43	1.02e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg11812906	chr14:75593930	NEK9	-0.87	-8.3	-0.65	7.13e-13	Height;
THYM	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg20891283	chr12:69753455	YEATS4	0.71	6.0	0.52	3.54e-8	Response to diuretic therapy;
THYM	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg23791538	chr6:167370224	RNASET2	-0.72	-5.66	-0.5	1.58e-7	Crohn's disease;
THYM	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg24642844	chr7:1081250	C7orf50	-1.17	-7.15	-0.59	1.75e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg07131210	chr7:1025825	CYP2W1	-0.82	-4.85	-0.45	4.9e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs36051895	0.623	rs10975033	chr9:5262567	C/T	cg02405213	chr9:5042618	JAK2	-0.86	-8.62	-0.66	1.5e-13	Pediatric autoimmune diseases;
THYM	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07167872	chr1:205819463	PM20D1	-0.97	-9.74	-0.71	5.94e-16	Menarche (age at onset);
THYM	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs986417	0.711	rs761556	chr14:61061034	T/G	cg27398547	chr14:60952738	C14orf39	1.3	6.11	0.53	2.15e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs7572733	0.576	rs1368989	chr2:198937082	T/C	cg00792783	chr2:198669748	PLCL1	0.7	4.61	0.43	1.25e-5	Dermatomyositis;
THYM	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg26354017	chr1:205819088	PM20D1	0.58	4.65	0.43	1.09e-5	Parkinson's disease;
THYM	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg15592062	chr6:167189543	RPS6KA2	-0.47	-4.76	-0.44	7.02e-6	Crohn's disease;
THYM	cis	rs6558530	0.897	rs10481354	chr8:1704030	A/G	cg09410841	chr8:1729607	CLN8	-0.68	-5.21	-0.47	1.08e-6	Systolic blood pressure;
THYM	cis	rs7103648	0.695	rs7933019	chr11:47509137	G/C	cg20307385	chr11:47447363	PSMC3	0.9	7.09	0.59	2.41e-10	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs11083475	0.599	rs7250443	chr19:39267345	T/C	cg07403899	chr19:39283540	NA	-0.58	-4.67	-0.43	1e-5	Heart rate;
THYM	cis	rs988913	1.000	rs7765236	chr6:54835567	G/A	cg04690482	chr6:54711388	FAM83B	0.46	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs950880	0.710	rs11123928	chr2:103061286	G/A	cg03938978	chr2:103052716	IL18RAP	-0.54	-4.62	-0.43	1.22e-5	Serum protein levels (sST2);
THYM	cis	rs12190007	0.508	rs6605537	chr6:169730781	G/A	cg16388071	chr6:169726476	NA	0.69	5.99	0.52	3.71e-8	Obesity-related traits;
THYM	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12667521	chr19:29218732	NA	0.88	7.82	0.63	7.26e-12	Methadone dose in opioid dependence;
THYM	cis	rs1448094	0.512	rs7303330	chr12:86255123	G/A	cg00310523	chr12:86230176	RASSF9	0.53	4.82	0.44	5.5e-6	Major depressive disorder;
THYM	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg08859206	chr1:53392774	SCP2	-0.6	-6.87	-0.58	6.76e-10	Monocyte count;
THYM	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg18681998	chr4:17616180	MED28	0.79	6.77	0.57	1.05e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs11209185	0.563	rs10889735	chr1:68435400	T/C	cg22082780	chr1:68452167	NA	-0.51	-6.18	-0.54	1.6e-8	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg10518543	chr12:38710700	ALG10B	-0.59	-4.7	-0.43	8.88e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg10465839	chr16:1584050	IFT140;TMEM204	-0.64	-5.56	-0.5	2.51e-7	Coronary artery disease;
THYM	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.82	-7.92	-0.63	4.45e-12	Intelligence (multi-trait analysis);
THYM	cis	rs354225	0.584	rs6739140	chr2:54823502	C/G	cg23486701	chr2:54789491	SPTBN1	0.35	4.68	0.43	9.65e-6	Schizophrenia;
THYM	cis	rs2637266	1.000	rs2395387	chr10:78357029	T/C	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs12935418	0.616	rs56299740	chr16:80964169	A/T	cg16651780	chr16:81037892	C16orf61	0.83	5.33	0.48	6.62e-7	Mean corpuscular volume;
THYM	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg09455208	chr3:40491958	NA	-0.49	-5.46	-0.49	3.77e-7	Renal cell carcinoma;
THYM	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg16325326	chr1:53192061	ZYG11B	0.79	7.51	0.61	3.2e-11	Monocyte count;
THYM	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg24531977	chr5:56204891	C5orf35	-0.93	-7.44	-0.61	4.48e-11	Initial pursuit acceleration;
THYM	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs7426056	0.627	rs10211209	chr2:204642533	G/A	cg07930752	chr2:204569955	CD28	-0.65	-4.47	-0.42	2.2e-5	Primary sclerosing cholangitis;
THYM	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg06623918	chr6:96969491	KIAA0776	1.09	9.94	0.71	2.21e-16	Headache;
THYM	cis	rs8114671	0.904	rs6060197	chr20:33654315	C/T	cg08999081	chr20:33150536	PIGU	-0.56	-4.83	-0.44	5.18e-6	Height;
THYM	cis	rs3126085	1.000	rs72697000	chr1:152276772	C/A	cg10321714	chr1:152280068	FLG	-0.76	-5.68	-0.5	1.47e-7	Atopic dermatitis;
THYM	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24549020	chr5:56110836	MAP3K1	0.72	4.66	0.43	1.02e-5	Initial pursuit acceleration;
THYM	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.36	0.69	3.89e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.69	0.43	9.17e-6	Bipolar disorder;
THYM	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11608355	1.000	rs930356	chr12:109852372	T/C	cg10504392	chr12:110044639	NA	0.65	6.14	0.53	1.93e-8	Neuroticism;
THYM	cis	rs10463554	0.927	rs34824	chr5:102438931	A/C	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Parkinson's disease;
THYM	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg27572855	chr1:25598939	RHD	0.69	5.3	0.48	7.61e-7	Erythrocyte sedimentation rate;
THYM	cis	rs11118346	1.000	rs11118346	chr1:219743719	C/T	cg07908999	chr1:219785142	NA	-0.38	-4.47	-0.42	2.19e-5	Height;
THYM	cis	rs3126085	0.935	rs12742573	chr1:152260103	A/C	cg10321714	chr1:152280068	FLG	-0.69	-4.99	-0.46	2.71e-6	Atopic dermatitis;
THYM	cis	rs6456042	0.893	rs9295324	chr6:166573712	G/A	cg11088901	chr6:166572345	T	-0.51	-5.03	-0.46	2.35e-6	Asthma;
THYM	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg12310025	chr6:25882481	NA	-0.66	-5.06	-0.46	2.06e-6	Height;
THYM	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg03388025	chr16:89894329	SPIRE2	0.53	4.65	0.43	1.05e-5	Vitiligo;
THYM	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg12011299	chr4:100065546	ADH4	0.86	7.81	0.63	7.59e-12	Alcohol dependence;
THYM	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg20290983	chr6:43655470	MRPS18A	1.44	15.94	0.85	1.35e-28	IgG glycosylation;
THYM	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg19077165	chr18:44547161	KATNAL2	0.57	7.17	0.59	1.59e-10	Personality dimensions;
THYM	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg07075026	chr17:47091521	IGF2BP1	-0.53	-5.64	-0.5	1.71e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg16586182	chr3:47516702	SCAP	0.63	5.6	0.5	2.12e-7	Colorectal cancer;
THYM	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	4.61	0.43	1.24e-5	Prudent dietary pattern;
THYM	cis	rs7084402	0.905	rs1649031	chr10:60279742	G/A	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs3960554	0.808	rs3779419	chr7:75695081	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-4.89	-0.45	4.04e-6	Eotaxin levels;
THYM	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg03806693	chr22:41940476	POLR3H	1.08	8.77	0.67	7.1e-14	Vitiligo;
THYM	cis	rs526231	0.543	rs26258	chr5:102549721	A/C	cg23492399	chr5:102201601	PAM	-0.71	-5.32	-0.48	6.82e-7	Primary biliary cholangitis;
THYM	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03647317	chr4:187891568	NA	-0.83	-9.1	-0.68	1.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg04520793	chr17:42248056	ASB16	-0.33	-4.56	-0.42	1.54e-5	Total body bone mineral density;
THYM	cis	rs9560113	1.000	rs9555806	chr13:112179954	G/A	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg26131816	chr17:42072204	PYY	0.56	4.66	0.43	1.03e-5	Menopause (age at onset);
THYM	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	6.96	0.58	4.43e-10	Lung cancer in ever smokers;
THYM	cis	rs7106204	1.000	rs7931691	chr11:24221123	C/A	ch.11.24196551F	chr11:24239977	NA	0.96	6.08	0.53	2.49e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7264396	0.690	rs2425170	chr20:34442672	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-5.39	-0.48	5.2e-7	Total cholesterol levels;
THYM	cis	rs858239	0.669	rs1618339	chr7:23229774	T/C	cg05407003	chr7:23246146	NA	-0.63	-5.11	-0.46	1.67e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6087990	0.806	rs992472	chr20:31385269	G/T	cg13636640	chr20:31349939	DNMT3B	0.93	10.39	0.73	2.42e-17	Ulcerative colitis;
THYM	cis	rs6980334	1.000	rs7795946	chr7:137785091	A/G	cg22979093	chr7:137028410	PTN	0.61	4.91	0.45	3.77e-6	Blood metabolite ratios;
THYM	cis	rs7828089	0.819	rs4872488	chr8:22257012	G/A	cg12081754	chr8:22256438	SLC39A14	0.68	6.22	0.54	1.36e-8	Verbal declarative memory;
THYM	cis	rs57590327	0.508	rs9820349	chr3:81958587	A/G	cg07356753	chr3:81810745	GBE1	-0.7	-4.72	-0.44	8.04e-6	Extraversion;
THYM	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.45	0.49	4.03e-7	Height;
THYM	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11890956	chr21:40555474	PSMG1	-0.93	-10.04	-0.72	1.34e-16	Cognitive function;
THYM	cis	rs4790333	0.653	rs2447103	chr17:2262997	A/C	cg02569219	chr17:2266849	SGSM2	0.69	5.96	0.52	4.18e-8	Proinsulin levels;
THYM	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg03806693	chr22:41940476	POLR3H	-0.77	-5.95	-0.52	4.56e-8	Neuroticism;
THYM	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg16680214	chr1:154839983	KCNN3	-0.44	-4.87	-0.45	4.51e-6	Prostate cancer;
THYM	cis	rs778371	1.000	rs778370	chr2:233743363	C/T	cg08000102	chr2:233561755	GIGYF2	-0.85	-7.09	-0.59	2.34e-10	Schizophrenia;
THYM	cis	rs6009824	0.579	rs34296882	chr22:50098333	C/T	cg18178197	chr22:50098317	NA	0.92	7.4	0.6	5.3e-11	Natriuretic peptide levels;
THYM	cis	rs13315871	0.929	rs71311852	chr3:58298843	G/A	cg12435725	chr3:58293450	RPP14	-0.53	-5.57	-0.5	2.32e-7	Cholesterol, total;
THYM	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06634786	chr22:41940651	POLR3H	0.84	6.24	0.54	1.21e-8	Vitiligo;
THYM	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg14972814	chr11:95582409	MTMR2	-0.73	-6.9	-0.58	5.75e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.68	6.19	0.54	1.54e-8	Personality dimensions;
THYM	cis	rs10484885	0.759	rs56230212	chr6:90234654	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.8	-6.58	-0.56	2.57e-9	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs6500395	1.000	rs2111243	chr16:48724897	C/T	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg25208724	chr1:156163844	SLC25A44	0.68	4.84	0.44	5.01e-6	Testicular germ cell tumor;
THYM	cis	rs9470366	0.772	rs9918353	chr6:36622677	A/C	cg24425727	chr6:36645648	CDKN1A	-0.58	-4.62	-0.43	1.21e-5	QRS duration;
THYM	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-7.53	-0.61	2.93e-11	Schizophrenia;
THYM	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	10.0	0.72	1.67e-16	Platelet count;
THYM	cis	rs7580658	0.676	rs58475809	chr2:128002650	A/G	cg10021288	chr2:128175891	PROC	-0.62	-5.72	-0.51	1.21e-7	Protein C levels;
THYM	cis	rs9311676	0.656	rs6773193	chr3:58385960	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg26031613	chr14:104095156	KLC1	0.81	5.35	0.48	6.02e-7	Body mass index;
THYM	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg11245990	chr11:68621969	NA	-0.56	-7.23	-0.6	1.2e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	5.07	0.46	1.92e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7909074	0.966	rs4245614	chr10:45397007	C/T	cg05187965	chr10:45406764	TMEM72	-0.5	-4.66	-0.43	1.02e-5	Mean corpuscular volume;
THYM	cis	rs67478160	0.619	rs28698555	chr14:104316486	C/A	cg08213375	chr14:104286397	PPP1R13B	-0.56	-6.89	-0.58	6.11e-10	Schizophrenia;
THYM	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg07936489	chr17:37558343	FBXL20	0.85	5.64	0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs9816226	0.618	rs869399	chr3:185826764	C/T	cg00760338	chr3:185826511	ETV5	0.87	7.53	0.61	2.85e-11	Obesity;Body mass index;
THYM	cis	rs4866334	1.000	rs77695209	chr5:18483369	T/C	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs9902453	0.817	rs2321333	chr17:28140857	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	6.53	0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg17143192	chr8:8559678	CLDN23	0.62	4.84	0.44	5.06e-6	Mood instability;
THYM	cis	rs7980799	0.682	rs1601005	chr12:33634658	A/G	cg06521331	chr12:34319734	NA	0.71	5.02	0.46	2.39e-6	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg00255919	chr5:131827918	IRF1	0.47	5.21	0.47	1.1e-6	Asthma (sex interaction);
THYM	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg26566898	chr11:117069891	TAGLN	-0.41	-5.21	-0.47	1.11e-6	Blood protein levels;
THYM	cis	rs7746082	0.596	rs11152949	chr6:106449085	A/G	cg02270332	chr6:106475062	NA	-0.63	-5.95	-0.52	4.45e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs71403859	0.730	rs12931191	chr16:71621373	A/T	cg08717414	chr16:71523259	ZNF19	1.11	5.96	0.52	4.21e-8	Post bronchodilator FEV1;
THYM	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35883536	0.609	rs10783142	chr1:101043902	C/G	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs1904096	0.506	rs6841121	chr4:95222995	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.51	-4.45	-0.42	2.32e-5	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2282300	0.739	rs7926465	chr11:30333016	C/T	cg06241208	chr11:30344200	C11orf46	0.78	5.65	0.5	1.64e-7	Morning vs. evening chronotype;
THYM	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.58	0.5	2.29e-7	Rheumatoid arthritis;
THYM	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg22431228	chr1:16359049	CLCNKA	-0.53	-5.0	-0.46	2.61e-6	Dilated cardiomyopathy;
THYM	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg05738196	chr6:26577821	NA	0.76	6.45	0.55	4.59e-9	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg11764359	chr7:65958608	NA	0.69	4.78	0.44	6.27e-6	Aortic root size;
THYM	cis	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg13443165	chr9:33130375	B4GALT1	-0.86	-7.96	-0.63	3.71e-12	IgG glycosylation;
THYM	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-4.94	-0.45	3.39e-6	Lymphocyte counts;
THYM	cis	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.54	-5.48	-0.49	3.55e-7	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs9875589	0.533	rs12490233	chr3:13977365	G/A	cg03204825	chr3:13978759	TPRXL	-0.58	-5.03	-0.46	2.29e-6	Ovarian reserve;
THYM	cis	rs986417	0.688	rs6573321	chr14:61101710	A/G	cg27398547	chr14:60952738	C14orf39	1.04	5.74	0.51	1.14e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg00271210	chr6:167070053	RPS6KA2	0.72	7.96	0.63	3.73e-12	Crohn's disease;
THYM	cis	rs2282300	0.956	rs1222212	chr11:30374643	C/T	cg25418670	chr11:30344373	C11orf46	-0.74	-5.84	-0.51	7.14e-8	Morning vs. evening chronotype;
THYM	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg12599982	chr1:44399894	ARTN	0.56	4.66	0.43	1.02e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs6448317	0.906	rs6448313	chr4:24905088	G/A	cg22968281	chr4:24586266	DHX15	-0.7	-5.2	-0.47	1.15e-6	Heschl's gyrus morphology;
THYM	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06634786	chr22:41940651	POLR3H	-0.77	-5.78	-0.51	9.26e-8	Vitiligo;
THYM	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg16558253	chr16:72132732	DHX38	-0.66	-5.88	-0.52	6.13e-8	Fibrinogen levels;
THYM	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.11e-8	Systolic blood pressure;
THYM	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg27129171	chr3:47204927	SETD2	0.69	6.65	0.56	1.82e-9	Colorectal cancer;
THYM	cis	rs28595532	0.920	rs116062544	chr4:119735548	G/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg24308560	chr3:49941425	MST1R	0.79	6.98	0.58	4.02e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg24733560	chr20:60626293	TAF4	0.51	4.53	0.42	1.71e-5	Body mass index;
THYM	cis	rs7572733	0.534	rs700688	chr2:198723833	A/G	cg00792783	chr2:198669748	PLCL1	-0.8	-5.48	-0.49	3.53e-7	Dermatomyositis;
THYM	cis	rs34526934	0.524	rs1124052	chr2:177040084	G/A	cg14324370	chr2:177042789	NA	-0.69	-5.71	-0.51	1.28e-7	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs137603	0.644	rs137635	chr22:39720656	G/C	cg24268161	chr22:39747459	SYNGR1	0.64	5.29	0.48	7.67e-7	Primary biliary cholangitis;
THYM	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.01	0.58	3.39e-10	Prudent dietary pattern;
THYM	cis	rs9807989	0.507	rs3755266	chr2:103042712	G/A	cg03938978	chr2:103052716	IL18RAP	0.75	9.8	0.71	4.43e-16	Asthma;
THYM	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg06481639	chr22:41940642	POLR3H	-0.8	-5.6	-0.5	2.11e-7	Vitiligo;
THYM	cis	rs34638657	0.732	rs62045962	chr16:82200604	T/C	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.25	-0.47	9.14e-7	Lung adenocarcinoma;
THYM	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg02503808	chr4:7069936	GRPEL1	0.97	7.9	0.63	5e-12	Monocyte percentage of white cells;
THYM	cis	rs4654899	0.865	rs10916927	chr1:21385795	T/C	cg01072550	chr1:21505969	NA	-0.71	-6.29	-0.54	9.55e-9	Superior frontal gyrus grey matter volume;
THYM	trans	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Bladder cancer;
THYM	cis	rs4901869	0.966	rs12878614	chr14:59339477	A/C	cg02291164	chr14:59296302	NA	0.8	8.12	0.64	1.64e-12	Panic disorder;
THYM	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg25703541	chr22:24373054	LOC391322	0.88	9.55	0.7	1.49e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg08736216	chr1:53307985	ZYG11A	-0.65	-5.79	-0.51	9.22e-8	Monocyte count;
THYM	cis	rs3772130	0.564	rs28620947	chr3:121585631	G/A	cg20356878	chr3:121714668	ILDR1	0.73	6.46	0.55	4.38e-9	Cognitive performance;
THYM	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg09035930	chr12:129282057	SLC15A4	0.85	10.29	0.73	3.94e-17	Systemic lupus erythematosus;
THYM	cis	rs7843479	0.601	rs11781959	chr8:21841863	C/G	cg17168535	chr8:21777572	XPO7	0.94	8.32	0.65	6.21e-13	Mean corpuscular volume;
THYM	cis	rs752010	0.695	rs12123834	chr1:42105727	T/C	cg06885757	chr1:42089581	HIVEP3	0.48	5.84	0.51	7.38e-8	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs58688157	0.626	rs7941198	chr11:571681	A/G	cg09703963	chr11:616879	IRF7;MUPCDH	-0.58	-4.5	-0.42	1.89e-5	Systemic lupus erythematosus;
THYM	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.65	-5.4	-0.48	4.86e-7	Renal function-related traits (BUN);
THYM	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs477692	0.544	rs7904404	chr10:131447612	G/A	cg05714579	chr10:131428358	MGMT	-0.94	-9.46	-0.7	2.39e-15	Response to temozolomide;
THYM	cis	rs55871839	0.708	rs4738732	chr8:59809943	A/G	cg07426533	chr8:59803705	TOX	0.66	6.56	0.56	2.84e-9	Pneumonia;
THYM	cis	rs7917772	0.582	rs7922780	chr10:104401203	G/A	cg00122347	chr10:104236741	TMEM180	0.41	5.47	0.49	3.66e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9914988	0.943	rs7217547	chr17:27106872	C/G	cg20469991	chr17:27169893	C17orf63	-0.86	-5.22	-0.47	1.07e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.7	5.63	0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs7098100	0.851	rs11012737	chr10:21849769	G/A	cg10900703	chr10:21824407	MLLT10	-0.45	-4.6	-0.43	1.31e-5	Breast cancer;
THYM	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg08000102	chr2:233561755	GIGYF2	0.69	6.09	0.53	2.35e-8	Coronary artery disease;
THYM	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg04398451	chr17:18023971	MYO15A	0.73	6.58	0.56	2.56e-9	Total body bone mineral density;
THYM	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7107174	1.000	rs4627115	chr11:78007873	T/G	cg19901956	chr11:77921274	USP35	-0.69	-5.3	-0.48	7.42e-7	Testicular germ cell tumor;
THYM	cis	rs11039798	0.764	rs11040030	chr11:48800985	C/T	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs2737618	0.551	rs2816992	chr1:200069216	C/T	cg21825944	chr1:200113062	NR5A2	0.6	5.07	0.46	1.95e-6	Uric acid levels;
THYM	cis	rs12928939	0.517	rs8050058	chr16:71981374	T/G	cg03805757	chr16:71968109	PKD1L3	-1.0	-9.82	-0.71	4.03e-16	Post bronchodilator FEV1;
THYM	cis	rs1163251	0.756	rs539799	chr1:120208472	C/T	cg19096424	chr1:120255104	PHGDH	0.6	4.77	0.44	6.63e-6	Blood metabolite levels;
THYM	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21659725	chr3:3221576	CRBN	0.87	9.31	0.69	4.9e-15	Intelligence (multi-trait analysis);
THYM	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg24253500	chr15:84953950	NA	-0.54	-4.48	-0.42	2.04e-5	Schizophrenia;
THYM	cis	rs2370759	0.891	rs76164690	chr10:32590362	T/G	cg01819863	chr10:32635814	EPC1	1.02	5.3	0.48	7.49e-7	Sexual dysfunction (female);
THYM	cis	rs939658	0.805	rs34478496	chr15:79440997	C/A	cg17916960	chr15:79447300	NA	-0.73	-8.58	-0.66	1.81e-13	Refractive error;
THYM	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg24818145	chr4:99064322	C4orf37	0.72	5.66	0.5	1.62e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8033133	0.560	rs11161166	chr15:25324677	A/T	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	0.65	5.06	0.46	2.02e-6	Blood osmolality (transformed sodium);
THYM	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-6.13	-0.53	1.99e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs11118844	0.843	rs12144586	chr1:221919378	A/G	cg04222084	chr1:221915650	DUSP10	-1.02	-5.4	-0.48	4.88e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2268241	0.938	rs7283827	chr21:34769904	A/G	cg14850771	chr21:34775459	IFNGR2	1.0	7.12	0.59	2.09e-10	Obesity-related traits;
THYM	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.79	7.89	0.63	5.15e-12	Blood protein levels;
THYM	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg24920358	chr1:40204285	PPIE	0.59	5.47	0.49	3.58e-7	Blood protein levels;
THYM	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.54	6.01	0.52	3.42e-8	Schizophrenia;
THYM	cis	rs367615	0.704	rs7726991	chr5:108847434	C/T	cg17395555	chr5:108820864	NA	0.74	8.82	0.67	5.59e-14	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs35883536	0.647	rs12026951	chr1:101046273	C/T	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg23791538	chr6:167370224	RNASET2	0.74	5.92	0.52	5.06e-8	Crohn's disease;
THYM	cis	rs11651000	0.817	rs7502875	chr17:45823227	A/C	cg03474202	chr17:45855739	NA	-0.73	-6.36	-0.55	7.05e-9	IgG glycosylation;
THYM	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs79349575	0.783	rs318096	chr17:46975370	G/A	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs892961	0.899	rs35217221	chr17:75412385	G/A	cg05865280	chr17:75406074	SEPT9	0.48	8.22	0.64	1.06e-12	Airflow obstruction;
THYM	cis	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg06521331	chr12:34319734	NA	-1.0	-8.81	-0.67	5.71e-14	Morning vs. evening chronotype;
THYM	cis	rs59107033	0.559	rs58531872	chr3:123105640	C/G	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Lymphocyte counts;
THYM	cis	rs1003719	0.680	rs3737540	chr21:38523266	C/A	cg01329690	chr21:38580129	DSCR9	-0.34	-4.66	-0.43	1.04e-5	Eye color traits;
THYM	cis	rs1545348	0.625	rs114511606	chr5:34734351	T/A	cg01146980	chr5:34930244	DNAJC21	-0.77	-4.64	-0.43	1.13e-5	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs765787	0.530	rs3759892	chr15:45542709	A/G	cg24006582	chr15:45444508	DUOX1	0.82	6.6	0.56	2.38e-9	Uric acid levels;
THYM	cis	rs3087591	1.000	rs1123232	chr17:29423989	A/G	cg24425628	chr17:29625626	OMG;NF1	0.64	5.52	0.49	2.89e-7	Hip circumference;
THYM	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg23428387	chr22:49814324	NA	-0.51	-4.91	-0.45	3.78e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-5.43	-0.49	4.34e-7	Monocyte percentage of white cells;
THYM	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg22907277	chr7:1156413	C7orf50	0.83	5.1	0.46	1.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7582180	0.701	rs4622752	chr2:100892018	A/G	cg14675211	chr2:100938903	LONRF2	-0.74	-7.49	-0.61	3.48e-11	Intelligence (multi-trait analysis);
THYM	cis	rs2639990	1.000	rs609303	chr18:72895242	C/T	cg02750262	chr18:72916776	ZADH2	1.29	6.44	0.55	4.98e-9	Vascular endothelial growth factor levels;
THYM	trans	rs34156428	1.000	rs12796718	chr11:16496382	C/T	cg02688867	chr12:133019854	NA	0.54	6.89	0.58	6.12e-10	Coronary artery disease;
THYM	cis	rs2219968	1.000	rs11783293	chr8:78958925	G/T	cg00738934	chr8:78996279	NA	0.91	9.75	0.71	5.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs2637266	0.745	rs2579733	chr10:78441896	C/T	cg18941641	chr10:78392320	NA	-0.77	-6.5	-0.55	3.77e-9	Pulmonary function;
THYM	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs12200560	0.505	rs211174	chr6:97071120	C/T	cg06623918	chr6:96969491	KIAA0776	0.76	5.87	0.52	6.31e-8	Coronary heart disease;
THYM	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg18252515	chr7:66147081	NA	0.64	4.6	0.43	1.29e-5	Aortic root size;
THYM	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs9972944	0.756	rs2318869	chr17:63767736	C/G	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.67	-5.18	-0.47	1.22e-6	Tonsillectomy;
THYM	cis	rs6840360	0.607	rs2724565	chr4:152350305	A/G	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4732038	0.510	rs58505554	chr7:134275374	C/A	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg17127132	chr2:85788382	GGCX	0.71	6.21	0.54	1.41e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs7267979	1.000	rs6115159	chr20:25350944	T/C	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7567389	0.504	rs1568278	chr2:128190195	G/A	cg06038358	chr2:128176007	PROC	0.42	4.67	0.43	9.71e-6	Self-rated health;
THYM	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg11845111	chr2:191398756	TMEM194B	-0.97	-6.77	-0.57	1.06e-9	Diastolic blood pressure;
THYM	cis	rs10170846	0.861	rs6740452	chr2:223518452	C/T	cg25565276	chr2:223520875	FARSB	0.61	4.9	0.45	3.94e-6	Schizophrenia (inflammation and infection response interaction);
THYM	cis	rs17407555	0.821	rs4292329	chr4:10144459	C/G	cg11266682	chr4:10021025	SLC2A9	-0.6	-5.79	-0.51	8.88e-8	Schizophrenia (age at onset);
THYM	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06850241	chr22:41845214	NA	0.59	5.09	0.46	1.83e-6	Vitiligo;
THYM	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7084402	0.935	rs4948524	chr10:60351224	C/A	cg07615347	chr10:60278583	BICC1	0.54	5.06	0.46	2.04e-6	Refractive error;
THYM	cis	rs7582180	0.627	rs4407265	chr2:101005846	C/G	cg21926883	chr2:100939477	LONRF2	-0.67	-6.36	-0.55	6.89e-9	Intelligence (multi-trait analysis);
THYM	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg23205692	chr1:25664452	TMEM50A	0.86	6.89	0.58	6.04e-10	Erythrocyte sedimentation rate;
THYM	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg22907277	chr7:1156413	C7orf50	0.75	6.24	0.54	1.22e-8	Longevity;Endometriosis;
THYM	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg06618935	chr21:46677482	NA	-0.97	-8.97	-0.68	2.62e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg13647721	chr17:30228624	UTP6	0.73	4.71	0.44	8.48e-6	Hip circumference adjusted for BMI;
THYM	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg06558623	chr16:89946397	TCF25	1.48	7.81	0.63	7.43e-12	Skin colour saturation;
THYM	cis	rs4455778	0.580	rs6952911	chr7:49092794	C/T	cg26309511	chr7:48887640	NA	0.68	5.94	0.52	4.63e-8	Lung cancer in never smokers;
THYM	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg24112000	chr20:60950667	NA	-0.61	-5.05	-0.46	2.11e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg00012203	chr2:219082015	ARPC2	-0.65	-5.32	-0.48	6.78e-7	Colorectal cancer;
THYM	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10463554	0.857	rs34376	chr5:102401113	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs1034435	0.755	rs713923	chr22:48891519	C/T	cg05992904	chr22:48892994	FAM19A5	0.81	8.45	0.66	3.31e-13	Late-onset Alzheimer's disease;
THYM	cis	rs13082711	0.516	rs1492339	chr3:27371526	A/C	cg02860705	chr3:27208620	NA	-0.67	-5.03	-0.46	2.3e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs6835098	0.816	rs13111572	chr4:174159788	G/A	cg08422745	chr4:174089978	GALNT7	1.0	7.84	0.63	6.46e-12	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg09034736	chr1:150693464	HORMAD1	0.52	4.68	0.43	9.35e-6	Tonsillectomy;
THYM	cis	rs7926906	0.664	rs10765389	chr11:90519401	C/A	cg26138821	chr11:89956704	CHORDC1	-0.53	-4.72	-0.44	8.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-6.5	-0.55	3.66e-9	Monocyte percentage of white cells;
THYM	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.66	-6.12	-0.53	2.05e-8	Prudent dietary pattern;
THYM	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs11008222	1.000	rs10826864	chr10:31044209	G/A	cg00941203	chr10:31016591	NA	-0.35	-4.94	-0.45	3.39e-6	Congenital left-sided heart lesions (maternal effect);
THYM	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg07636037	chr3:49044803	WDR6	0.99	10.4	0.73	2.28e-17	Parkinson's disease;
THYM	cis	rs17253792	0.598	rs35830444	chr14:56017350	T/C	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs4845570	0.764	rs12122917	chr1:151716712	C/A	cg18019451	chr1:151746047	TDRKH	-0.9	-5.04	-0.46	2.19e-6	Coronary artery disease;
THYM	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg17127132	chr2:85788382	GGCX	-0.63	-5.37	-0.48	5.56e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs3960554	0.674	rs112742093	chr7:75800597	T/C	cg17398381	chr7:75624190	TMEM120A	-0.47	-4.53	-0.42	1.75e-5	Eotaxin levels;
THYM	cis	rs758324	0.687	rs141249	chr5:131485506	C/G	cg16205897	chr5:131564050	P4HA2	0.61	5.04	0.46	2.2e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.64	-0.5	1.73e-7	Menopause (age at onset);
THYM	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg00757033	chr12:89920650	WDR51B	0.74	10.6	0.74	8.72e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg10589385	chr1:150898437	SETDB1	-0.62	-5.08	-0.46	1.9e-6	Melanoma;
THYM	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg03351412	chr1:154909251	PMVK	0.73	5.58	0.5	2.27e-7	Prostate cancer;
THYM	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.7	5.66	0.5	1.59e-7	Menarche (age at onset);
THYM	cis	rs6918586	0.658	rs198844	chr6:26108282	C/G	cg12310025	chr6:25882481	NA	0.68	5.49	0.49	3.36e-7	Schizophrenia;
THYM	cis	rs941408	1.000	rs759068	chr19:2792566	G/A	cg17333051	chr19:2783644	SGTA	0.58	5.08	0.46	1.89e-6	Total cholesterol levels;
THYM	cis	rs7084402	0.870	rs1896245	chr10:60276083	T/G	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	trans	rs877282	0.786	rs11253392	chr10:788768	G/A	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg01364799	chr7:75623366	TMEM120A	-0.62	-4.46	-0.42	2.22e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2836974	0.544	rs2776312	chr21:40718518	A/G	cg11644478	chr21:40555479	PSMG1	0.65	4.69	0.43	9e-6	Cognitive function;
THYM	cis	rs924712	0.547	rs239794	chr6:54802375	C/T	cg04690482	chr6:54711388	FAM83B	-0.49	-5.87	-0.52	6.37e-8	Breast cancer;
THYM	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.87	0.58	6.52e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs6988636	1.000	rs62521826	chr8:124186668	C/T	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg14983838	chr19:29218262	NA	1.09	9.77	0.71	5e-16	Methadone dose in opioid dependence;
THYM	trans	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg05926928	chr17:57297772	GDPD1	1.26	10.02	0.72	1.5e-16	Opioid sensitivity;
THYM	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg11673840	chr17:47092156	IGF2BP1	-0.59	-7.55	-0.61	2.61e-11	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs13102973	0.600	rs13122485	chr4:135834437	G/A	cg14419869	chr4:135874104	NA	0.7	5.72	0.51	1.26e-7	Subjective well-being;
THYM	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.63	-5.48	-0.49	3.44e-7	Renal function-related traits (BUN);
THYM	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.24	-10.02	-0.72	1.53e-16	Platelet count;
THYM	cis	rs988913	1.000	rs6926997	chr6:54817326	C/G	cg04690482	chr6:54711388	FAM83B	0.47	5.24	0.47	9.74e-7	Menarche (age at onset);
THYM	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg06565975	chr8:143823917	SLURP1	-0.76	-8.91	-0.67	3.46e-14	Urinary tract infection frequency;
THYM	cis	rs3087591	1.000	rs2952982	chr17:29470646	A/C	cg24425628	chr17:29625626	OMG;NF1	0.64	5.54	0.49	2.68e-7	Hip circumference;
THYM	cis	rs7084402	1.000	rs7917717	chr10:60269100	C/A	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs4631830	0.657	rs2611502	chr10:51500301	A/G	cg16070123	chr10:51489643	NA	-0.54	-4.94	-0.45	3.4e-6	Prostate-specific antigen levels;
THYM	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs6430585	0.528	rs309167	chr2:136669264	C/T	cg04750100	chr2:136595281	LCT	0.54	4.87	0.45	4.39e-6	Corneal structure;
THYM	cis	rs2820651	1.000	rs76865516	chr10:1469531	G/A	cg27404824	chr10:1454848	ADARB2	0.92	4.81	0.44	5.74e-6	Migraine with aura;
THYM	cis	rs4638749	0.677	rs10174695	chr2:108842164	G/A	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs113835537	0.529	rs7950790	chr11:66258053	G/A	cg10315249	chr11:66235081	PELI3	0.42	4.52	0.42	1.76e-5	Airway imaging phenotypes;
THYM	cis	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	7.0	0.58	3.6e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs4655537	0.500	rs4278348	chr1:66175395	T/C	cg04111102	chr1:66153794	NA	0.52	4.76	0.44	6.94e-6	Blood protein levels;
THYM	cis	rs12348691	0.503	rs6478423	chr9:100592030	C/T	cg13688889	chr9:100608707	NA	-0.86	-5.87	-0.52	6.45e-8	Alopecia areata;
THYM	cis	rs10873998	0.502	rs1937015	chr1:79285408	G/A	cg17415326	chr1:79350918	NA	-0.45	-5.09	-0.46	1.78e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs665401	0.692	rs339309	chr6:117178329	T/C	cg20376953	chr6:117187980	NA	0.61	4.89	0.45	4.05e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1728785	1.000	rs1728801	chr16:68571457	A/C	cg02972257	chr16:68554789	NA	-0.74	-4.54	-0.42	1.63e-5	Ulcerative colitis;
THYM	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg24060327	chr5:131705240	SLC22A5	-0.68	-5.21	-0.47	1.07e-6	Breast cancer;
THYM	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg13246856	chr1:44399776	ARTN	0.48	4.95	0.45	3.27e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg27490568	chr2:178487706	NA	0.59	5.27	0.48	8.35e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg18252515	chr7:66147081	NA	-1.62	-8.8	-0.67	5.99e-14	Diabetic kidney disease;
THYM	cis	rs863345	0.625	rs7534112	chr1:158532065	G/A	cg12129480	chr1:158549410	OR10X1	-0.52	-5.24	-0.47	9.55e-7	Pneumococcal bacteremia;
THYM	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg24069376	chr3:38537580	EXOG	0.62	6.17	0.54	1.64e-8	Electrocardiographic conduction measures;
THYM	cis	rs863345	0.604	rs12118446	chr1:158496235	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg25358565	chr5:93447407	FAM172A	-0.96	-6.78	-0.57	1.01e-9	Diabetic retinopathy;
THYM	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg24250549	chr1:154909240	PMVK	0.79	6.82	0.57	8.39e-10	Prostate cancer;
THYM	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg21775007	chr8:11205619	TDH	-0.62	-4.5	-0.42	1.93e-5	Neuroticism;
THYM	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg01324343	chr3:183735012	ABCC5	0.89	13.33	0.81	1.82e-23	Anterior chamber depth;
THYM	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg21784768	chr11:537496	LRRC56	-1.16	-5.78	-0.51	9.66e-8	Body mass index;
THYM	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg24399712	chr22:39784796	NA	-0.86	-9.76	-0.71	5.39e-16	Intelligence (multi-trait analysis);
THYM	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	5.18	0.47	1.24e-6	Mean corpuscular hemoglobin;
THYM	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg10360139	chr7:1886902	MAD1L1	-0.61	-5.17	-0.47	1.28e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs919433	0.680	rs788018	chr2:198265526	A/G	cg05783139	chr2:198650985	BOLL	0.63	4.93	0.45	3.48e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs12714314	0.957	rs2060196	chr2:1955972	T/A	cg05313794	chr2:1845466	MYT1L	-0.51	-4.55	-0.42	1.58e-5	Type 2 diabetes (age of onset);
THYM	cis	rs1322639	0.806	rs1322640	chr6:169586887	T/C	cg04662567	chr6:169592167	NA	0.78	7.07	0.59	2.58e-10	Pulse pressure;
THYM	cis	rs988913	0.957	rs4712081	chr6:54756529	A/G	cg04690482	chr6:54711388	FAM83B	-0.49	-5.15	-0.47	1.43e-6	Menarche (age at onset);
THYM	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg15445000	chr17:37608096	MED1	0.41	4.85	0.45	4.83e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4930776	0.722	rs2361590	chr12:5775387	A/G	cg02086166	chr12:5775618	ANO2	-0.55	-4.86	-0.45	4.66e-6	Plasma clusterin levels;
THYM	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg27494647	chr7:150038898	RARRES2	0.4	4.59	0.43	1.35e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs9926296	0.687	rs397891	chr16:89753031	G/C	cg03605463	chr16:89740564	NA	0.82	6.25	0.54	1.15e-8	Vitiligo;
THYM	cis	rs61990749	0.511	rs10130790	chr14:78324192	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.87	5.4	0.48	5.01e-7	Fibroblast growth factor basic levels;
THYM	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg17747265	chr1:1875780	NA	0.55	5.59	0.5	2.19e-7	Body mass index;
THYM	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.15	9.01	0.68	2.18e-14	Cognitive test performance;
THYM	cis	rs9677476	0.821	rs6708809	chr2:232112730	A/C	cg23338755	chr2:231921595	PSMD1	0.67	4.84	0.44	5.1e-6	Food antigen IgG levels;
THYM	cis	rs35934224	0.769	rs76945759	chr22:19860977	G/A	cg11182965	chr22:19864308	TXNRD2	-0.88	-5.2	-0.47	1.14e-6	Glaucoma (primary open-angle);
THYM	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs12142240	0.698	rs72677596	chr1:46833930	C/T	cg00530320	chr1:46809349	NSUN4	0.8	5.5	0.49	3.16e-7	Menopause (age at onset);
THYM	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.73	-4.82	-0.44	5.35e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg07389463	chr12:132296394	NA	-0.57	-5.56	-0.5	2.5e-7	Migraine;
THYM	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg23791538	chr6:167370224	RNASET2	-0.61	-4.81	-0.44	5.66e-6	Crohn's disease;
THYM	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs6956675	1.000	rs1879843	chr7:62586129	A/G	cg27518014	chr7:62859535	LOC100287834	0.66	5.15	0.47	1.43e-6	Obesity-related traits;
THYM	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	5.22	0.47	1.06e-6	Schizophrenia;
THYM	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12282928	0.959	rs2101185	chr11:48319573	G/T	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs654950	0.776	rs2759252	chr1:42021854	G/A	cg06885757	chr1:42089581	HIVEP3	-0.59	-7.93	-0.63	4.17e-12	Airway imaging phenotypes;
THYM	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg08885076	chr2:99613938	TSGA10	0.52	5.04	0.46	2.24e-6	Chronic sinus infection;
THYM	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg03396347	chr1:1875803	NA	-0.71	-7.26	-0.6	1.04e-10	Body mass index;
THYM	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg24069376	chr3:38537580	EXOG	-0.69	-6.79	-0.57	9.87e-10	Electrocardiographic conduction measures;
THYM	cis	rs5760092	0.717	rs5760101	chr22:24248712	T/C	cg12419862	chr22:24373484	LOC391322	-0.61	-4.58	-0.43	1.4e-5	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.66	-4.47	-0.42	2.16e-5	Body mass index;
THYM	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg14784868	chr12:69753453	YEATS4	0.77	6.32	0.54	8.57e-9	Blood protein levels;
THYM	cis	rs13082711	0.595	rs7615321	chr3:27368010	A/G	cg02860705	chr3:27208620	NA	0.91	6.79	0.57	9.84e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs6743226	1.000	rs6743226	chr2:242236972	T/C	cg10021735	chr2:242295487	FARP2	0.63	4.49	0.42	1.98e-5	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs4930776	0.932	rs400848	chr12:5759094	T/C	cg02086166	chr12:5775618	ANO2	0.62	6.17	0.53	1.69e-8	Plasma clusterin levels;
THYM	cis	rs9470366	0.883	rs9462210	chr6:36628953	G/A	cg11920449	chr6:36645608	CDKN1A	-0.71	-5.48	-0.49	3.52e-7	QRS duration;
THYM	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg12031863	chr16:4587854	C16orf5	-0.46	-4.94	-0.45	3.33e-6	Schizophrenia;
THYM	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg19418458	chr7:158789849	NA	-0.66	-6.36	-0.55	6.94e-9	Facial morphology (factor 20);
THYM	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg22166914	chr1:53195759	ZYG11B	-0.92	-10.93	-0.75	1.7e-18	Monocyte count;
THYM	cis	rs909002	0.800	rs968335	chr1:32085776	G/A	cg13919466	chr1:32135498	COL16A1	-0.5	-5.13	-0.47	1.51e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4722166	0.630	rs13311199	chr7:22789793	A/C	cg13104385	chr7:22767384	IL6	0.54	4.57	0.42	1.46e-5	Lung cancer;
THYM	cis	rs6598955	0.670	rs10794525	chr1:26537193	C/A	cg04990556	chr1:26633338	UBXN11	-0.88	-7.99	-0.63	3.1e-12	Obesity-related traits;
THYM	cis	rs6584283	0.766	rs7911680	chr10:101293468	A/C	cg23904955	chr10:101282759	NA	-0.36	-4.54	-0.42	1.66e-5	Ulcerative colitis;
THYM	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg00898013	chr13:113819073	PROZ	0.89	8.66	0.66	1.22e-13	Platelet distribution width;
THYM	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.49	-5.14	-0.47	1.45e-6	Depressive symptoms;
THYM	cis	rs9326248	0.581	rs11216267	chr11:116952392	C/T	cg20608306	chr11:116969690	SIK3	0.64	7.97	0.63	3.42e-12	Blood protein levels;
THYM	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.7	4.71	0.43	8.57e-6	Menarche (age at onset);
THYM	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg04455712	chr21:45112962	RRP1B	0.49	4.48	0.42	2.07e-5	Mean corpuscular volume;
THYM	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg24503407	chr1:205819492	PM20D1	0.99	9.93	0.71	2.28e-16	Menarche (age at onset);
THYM	cis	rs8067545	0.641	rs860335	chr17:19837679	A/G	cg20830565	chr17:20408647	MGC102966	-0.5	-4.57	-0.42	1.46e-5	Schizophrenia;
THYM	cis	rs79149102	0.579	rs3816261	chr15:75336173	T/A	cg17294928	chr15:75287854	SCAMP5	-1.07	-5.23	-0.47	9.89e-7	Lung cancer;
THYM	cis	rs17321999	1.000	rs72787722	chr2:30489941	T/C	cg05247661	chr2:30472410	LBH	0.66	4.54	0.42	1.64e-5	Systemic lupus erythematosus;
THYM	cis	rs34638657	0.656	rs1134847	chr16:82203742	C/T	cg07307142	chr16:82071433	HSD17B2	0.86	7.51	0.61	3.23e-11	Lung adenocarcinoma;
THYM	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs7084402	0.902	rs1649017	chr10:60288531	T/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.7e-7	Refractive error;
THYM	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg07414643	chr4:187882934	NA	0.64	5.75	0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg14895029	chr7:2775587	GNA12	-0.67	-4.95	-0.45	3.21e-6	Height;
THYM	cis	rs6840360	1.000	rs4696109	chr4:152668785	A/C	cg22705602	chr4:152727874	NA	-0.58	-6.26	-0.54	1.1e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.38	4.64	0.43	1.11e-5	Systolic blood pressure;
THYM	cis	rs11078917	1	rs11078917	chr17:37746359	A/C	cg07936489	chr17:37558343	FBXL20	-0.86	-5.89	-0.52	5.87e-8	Mean corpuscular volume;
THYM	cis	rs4889855	0.530	rs62068346	chr17:78608052	A/G	cg16591659	chr17:78472290	NA	-0.4	-5.09	-0.46	1.83e-6	Fractional excretion of uric acid;
THYM	cis	rs6840360	0.615	rs4696095	chr4:152467243	A/G	cg22705602	chr4:152727874	NA	-0.71	-7.43	-0.61	4.71e-11	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-1.04	-9.39	-0.69	3.29e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg27034606	chr17:28928453	LRRC37B2	0.76	5.06	0.46	2.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg22079354	chr11:130786696	SNX19	0.53	4.85	0.45	4.9100000000000004e-06	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs863345	0.584	rs6657638	chr1:158497184	C/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs112998813	0.571	rs11147317	chr13:114939396	A/G	cg09715768	chr13:114202537	TMCO3	0.75	5.0	0.46	2.61e-6	Nodular sclerosis Hodgkin lymphoma;
THYM	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg02869364	chr7:1081709	C7orf50	-0.57	-4.55	-0.42	1.58e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg24324837	chr19:49891574	CCDC155	0.52	4.79	0.44	6.25e-6	Multiple sclerosis;
THYM	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.57	-5.62	-0.5	1.87e-7	Longevity;Endometriosis;
THYM	cis	rs4273100	0.512	rs7502682	chr17:19295450	G/T	cg25447019	chr17:19030144	GRAPL	0.75	5.86	0.52	6.62e-8	Schizophrenia;
THYM	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg07636037	chr3:49044803	WDR6	-0.85	-7.57	-0.61	2.36e-11	Menarche (age at onset);
THYM	cis	rs1061377	1.000	rs10027813	chr4:39121438	T/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs7731657	0.537	rs4705976	chr5:130286160	T/C	cg08523029	chr5:130500466	HINT1	0.83	6.03	0.53	3.16e-8	Fasting plasma glucose;
THYM	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg05347473	chr6:146136440	FBXO30	0.6	4.86	0.45	4.66e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7617773	0.780	rs11716848	chr3:48378500	G/A	cg02219026	chr3:48282209	ZNF589	-0.67	-4.61	-0.43	1.25e-5	Coronary artery disease;
THYM	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg17328964	chr8:145687451	CYHR1	0.65	5.52	0.49	2.94e-7	Age at first birth;
THYM	cis	rs11077998	0.844	rs8064433	chr17:80501046	A/T	cg10255544	chr17:80519551	FOXK2	0.5	4.47	0.42	2.14e-5	Reticulocyte fraction of red cells;
THYM	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg02018176	chr4:1364513	KIAA1530	0.85	8.46	0.66	3.18e-13	Longevity;
THYM	cis	rs919433	0.617	rs700638	chr2:198588950	A/C	cg00792783	chr2:198669748	PLCL1	0.74	5.02	0.46	2.41e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs11186	0.524	rs72906338	chr2:189959268	T/C	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs4845875	0.626	rs2004445	chr1:11841366	C/T	cg25341925	chr1:11908058	NPPA	0.42	4.49	0.42	1.99e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg10802521	chr3:52805072	NEK4	-0.72	-5.95	-0.52	4.49e-8	Bipolar disorder;
THYM	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7247513	0.964	rs4371272	chr19:12711281	A/T	cg01871581	chr19:12707946	ZNF490	-0.87	-9.36	-0.69	3.84e-15	Bipolar disorder;
THYM	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg03060546	chr3:49711283	APEH	0.64	4.78	0.44	6.39e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg10523679	chr1:76189770	ACADM	0.94	8.52	0.66	2.42e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.76	-5.06	-0.46	2.05e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs988913	0.813	rs1566723	chr6:54777833	G/A	cg04690482	chr6:54711388	FAM83B	0.5	5.41	0.49	4.67e-7	Menarche (age at onset);
THYM	cis	rs8180040	0.903	rs12487736	chr3:47459679	C/T	cg27129171	chr3:47204927	SETD2	0.7	6.68	0.57	1.61e-9	Colorectal cancer;
THYM	cis	rs7224737	1.000	rs7225608	chr17:40298326	G/A	cg00647820	chr17:40259828	DHX58	-0.66	-4.94	-0.45	3.37e-6	Fibrinogen levels;
THYM	cis	rs17021463	0.902	rs34465979	chr4:95257554	C/A	cg11021082	chr4:95130006	SMARCAD1	0.52	4.45	0.42	2.36e-5	Testicular germ cell tumor;
THYM	cis	rs2377058	0.961	rs16965913	chr16:89734788	C/T	cg03605463	chr16:89740564	NA	-0.61	-4.5	-0.42	1.92e-5	Hip circumference adjusted for BMI;
THYM	cis	rs863345	0.584	rs10797023	chr1:158497079	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs72772090	0.539	rs2042386	chr5:96156783	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.79	-4.7	-0.43	8.84e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg21433313	chr16:3507492	NAT15	0.78	6.7	0.57	1.43e-9	Tuberculosis;
THYM	cis	rs174601	0.721	rs174530	chr11:61546592	A/G	cg19610905	chr11:61596333	FADS2	-0.58	-4.7	-0.43	8.88e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
THYM	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.26	10.1	0.72	1.01e-16	Platelet count;
THYM	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg06238570	chr21:40685208	BRWD1	0.95	8.64	0.66	1.3e-13	Cognitive function;
THYM	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg10803722	chr21:46713166	LOC642852	-0.43	-5.67	-0.5	1.52e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg03806693	chr22:41940476	POLR3H	-1.19	-10.43	-0.73	2.03e-17	Vitiligo;
THYM	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.69	4.67	0.43	9.8200000000000008e-06	Lung cancer in ever smokers;
THYM	cis	rs7089973	0.604	rs12218498	chr10:116578489	T/C	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.45	-0.42	2.36e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg04756594	chr16:24857601	SLC5A11	0.76	5.49	0.49	3.29e-7	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	10.77	0.74	3.77e-18	Chronic sinus infection;
THYM	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg09165964	chr15:75287851	SCAMP5	-0.67	-4.5	-0.42	1.94e-5	Blood trace element (Zn levels);
THYM	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg06558623	chr16:89946397	TCF25	1.07	4.59	0.43	1.37e-5	Skin colour saturation;
THYM	cis	rs6956675	1.000	rs6968327	chr7:62574489	A/G	cg27518014	chr7:62859535	LOC100287834	0.64	5.0	0.46	2.6e-6	Obesity-related traits;
THYM	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg25554036	chr4:6271136	WFS1	0.59	5.47	0.49	3.68e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs7192750	0.586	rs8062946	chr16:71930807	A/G	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg24578937	chr1:2090814	PRKCZ	0.59	5.88	0.52	6.22e-8	Height;
THYM	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.69	0.43	9.17e-6	Bipolar disorder;
THYM	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg06784218	chr1:46089804	CCDC17	-0.29	-4.54	-0.42	1.65e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg19912559	chr1:40204330	PPIE	0.64	4.92	0.45	3.61e-6	Blood protein levels;
THYM	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg24675658	chr1:53192096	ZYG11B	-0.8	-7.18	-0.59	1.52e-10	Monocyte count;
THYM	cis	rs9880211	0.613	rs28535121	chr3:135892798	T/C	cg21827317	chr3:136751795	NA	-0.71	-5.16	-0.47	1.33e-6	Body mass index;Height;
THYM	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26314531	chr2:26401878	FAM59B	-0.78	-5.13	-0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg09152259	chr2:128156114	NA	0.35	4.53	0.42	1.69e-5	Protein C levels;
THYM	cis	rs1372520	0.532	rs2583972	chr4:90747411	T/G	cg15133208	chr4:90757351	SNCA	-0.56	-4.61	-0.43	1.27e-5	Neuroticism;
THYM	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg09263875	chr16:632152	PIGQ	0.71	6.15	0.53	1.85e-8	Height;
THYM	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg06238570	chr21:40685208	BRWD1	-0.96	-9.24	-0.69	7.07e-15	Cognitive function;
THYM	cis	rs6942756	1.000	rs9640854	chr7:128884057	A/T	cg02491457	chr7:128862824	NA	-0.44	-4.54	-0.42	1.64e-5	White matter hyperintensity burden;
THYM	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg03060546	chr3:49711283	APEH	0.75	6.08	0.53	2.55e-8	Resting heart rate;
THYM	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg10360139	chr7:1886902	MAD1L1	-0.83	-7.4	-0.6	5.4e-11	Bipolar disorder and schizophrenia;
THYM	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg10803722	chr21:46713166	LOC642852	-0.41	-5.28	-0.48	8.15e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg18252515	chr7:66147081	NA	0.64	4.9	0.45	3.89e-6	Aortic root size;
THYM	cis	rs9297145	0.565	rs7794690	chr7:98764768	G/A	cg05967295	chr7:98741636	SMURF1	-0.71	-5.82	-0.51	8.06e-8	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg06219351	chr7:158114137	PTPRN2	0.69	6.87	0.58	6.7e-10	Calcium levels;
THYM	cis	rs6693295	0.618	rs12084862	chr1:246203214	A/G	cg04134399	chr1:246231142	SMYD3	-0.36	-4.54	-0.42	1.68e-5	Migraine - clinic-based;Migraine with aura;
THYM	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg22681709	chr2:178499509	PDE11A	-0.59	-5.62	-0.5	1.91e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2456568	0.900	rs2511376	chr11:93670388	C/T	cg17595323	chr11:93583763	C11orf90	-0.54	-5.22	-0.47	1.05e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs1214752	0.935	rs9357411	chr6:43379841	A/T	cg09674015	chr6:43045187	PTK7	-0.51	-4.79	-0.44	6.02e-6	Coronary artery disease;
THYM	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg15247329	chr7:2764246	NA	-0.69	-5.64	-0.5	1.76e-7	Height;
THYM	cis	rs7107174	1.000	rs10899455	chr11:77999163	T/C	cg02023728	chr11:77925099	USP35	0.67	5.88	0.52	6.07e-8	Testicular germ cell tumor;
THYM	cis	rs10503871	0.604	rs12548308	chr8:30446493	G/A	cg12158488	chr8:31336998	NA	-0.42	-4.73	-0.44	7.77e-6	Metabolite levels  (X-11787);
THYM	cis	rs3017493	0.786	rs74344478	chr11:70681107	G/A	cg14537332	chr11:70508113	SHANK2	1.15	7.22	0.6	1.3e-10	Renal transplant outcome;
THYM	cis	rs7106204	0.748	rs4360697	chr11:24217160	A/G	ch.11.24196551F	chr11:24239977	NA	0.96	6.87	0.58	6.52e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs12911832	0.701	rs452698	chr15:59105571	A/G	cg05156742	chr15:59063176	FAM63B	0.58	4.95	0.45	3.22e-6	Schizophrenia;
THYM	cis	rs6980334	0.679	rs2306847	chr7:137798593	A/T	cg06915773	chr7:137028165	PTN	0.62	4.95	0.45	3.26e-6	Blood metabolite ratios;
THYM	cis	rs804280	0.593	rs2645396	chr8:11608126	C/A	cg12395012	chr8:11607386	GATA4	-0.65	-5.07	-0.46	1.95e-6	Myopia (pathological);
THYM	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg06028808	chr11:68637592	NA	0.71	7.61	0.62	1.99e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg13010199	chr12:38710504	ALG10B	0.71	5.49	0.49	3.34e-7	Heart rate;
THYM	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs79349575	0.783	rs61576918	chr17:46985593	A/C	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs11731175	1.000	rs12647666	chr4:189862164	G/T	cg00431894	chr4:189871012	NA	-0.82	-6.23	-0.54	1.29e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs16866061	1.000	rs16866061	chr2:225439844	A/G	cg22455342	chr2:225449267	CUL3	0.65	4.66	0.43	1.02e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	trans	rs1974653	0.672	rs9606231	chr22:20065276	T/C	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg07777115	chr5:623756	CEP72	0.8	4.78	0.44	6.48e-6	Obesity-related traits;
THYM	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg16989719	chr2:238392110	NA	-0.56	-5.38	-0.48	5.36e-7	Prostate cancer;
THYM	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg23803603	chr1:2058230	PRKCZ	-0.58	-4.93	-0.45	3.53e-6	Height;
THYM	cis	rs757110	0.933	rs7124355	chr11:17412960	C/T	cg15432903	chr11:17409602	KCNJ11	-0.61	-6.79	-0.57	9.67e-10	Type 2 diabetes;
THYM	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg12419862	chr22:24373484	LOC391322	0.8	6.85	0.58	7.19e-10	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs4731207	0.596	rs1600741	chr7:124692292	A/G	cg05285228	chr7:124571219	POT1	-0.65	-5.0	-0.46	2.64e-6	Cutaneous malignant melanoma;
THYM	cis	rs6490294	0.583	rs1005902	chr12:112667675	G/T	cg10833066	chr12:111807467	FAM109A	-0.45	-4.98	-0.46	2.79e-6	Mean platelet volume;
THYM	cis	rs9329289	0.510	rs28579610	chr10:2546080	C/A	cg15501526	chr10:2543763	NA	0.51	4.67	0.43	9.95e-6	Age-related hearing impairment;
THYM	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.86	-5.78	-0.51	9.5e-8	Yeast infection;
THYM	trans	rs4650994	1.000	rs10798617	chr1:178515806	T/C	cg05059571	chr16:84539110	KIAA1609	-0.75	-7.95	-0.63	3.83e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs73195822	0.649	rs56159960	chr12:110994068	T/C	cg24010859	chr12:110868153	NA	0.63	4.51	0.42	1.88e-5	Itch intensity from mosquito bite;
THYM	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg13770153	chr20:60521292	NA	1.23	11.97	0.78	1.15e-20	Obesity-related traits;
THYM	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg14972814	chr11:95582409	MTMR2	-0.71	-6.19	-0.54	1.53e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs60695258	0.512	rs2053770	chr4:87908085	C/T	cg10685359	chr4:87814065	C4orf36	0.45	5.65	0.5	1.66e-7	Hematocrit;
THYM	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	5.08	0.46	1.9e-6	Diabetic retinopathy;
THYM	cis	rs600806	0.850	rs2140924	chr1:109935775	A/C	cg02175308	chr1:109941060	SORT1	-0.56	-4.99	-0.46	2.76e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1161098	0.723	rs1178001	chr12:67825798	G/A	cg20473420	chr12:67782441	NA	0.86	4.46	0.42	2.26e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs919433	0.680	rs787983	chr2:198345797	C/T	cg00792783	chr2:198669748	PLCL1	0.87	6.21	0.54	1.36e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs36051895	0.632	rs10815166	chr9:5149920	T/G	cg02405213	chr9:5042618	JAK2	-1.04	-10.96	-0.75	1.47e-18	Pediatric autoimmune diseases;
THYM	cis	rs9311676	0.656	rs11130635	chr3:58379143	A/G	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs7584330	0.504	rs11890255	chr2:238434605	A/G	cg14458575	chr2:238380390	NA	0.77	4.48	0.42	2.11e-5	Prostate cancer;
THYM	cis	rs240764	0.817	rs239226	chr6:101107969	G/C	cg21058520	chr6:100914733	NA	-0.57	-5.03	-0.46	2.29e-6	Neuroticism;
THYM	cis	rs7104764	0.957	rs1045454	chr11:204228	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	-1.13	-9.93	-0.71	2.28e-16	Menarche (age at onset);
THYM	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg19774624	chr17:42201019	HDAC5	0.73	5.95	0.52	4.46e-8	Total body bone mineral density;
THYM	cis	rs888405	0.541	rs697287	chr3:64211102	G/A	cg23047271	chr3:64210991	PRICKLE2	0.63	4.77	0.44	6.77e-6	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
THYM	cis	rs7580658	0.637	rs9636235	chr2:127981551	C/T	cg10021288	chr2:128175891	PROC	-0.61	-5.45	-0.49	3.89e-7	Protein C levels;
THYM	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg17054759	chr22:49844102	NA	-0.53	-5.17	-0.47	1.32e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs10752881	0.905	rs10797830	chr1:183036274	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Colorectal cancer;
THYM	cis	rs6598955	0.671	rs11247904	chr1:26621804	G/A	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.76	0.44	7.03e-6	Obesity-related traits;
THYM	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg26384229	chr12:38710491	ALG10B	1.0	7.61	0.62	1.97e-11	Bladder cancer;
THYM	cis	rs240764	0.511	rs9377232	chr6:101240430	G/A	cg21058520	chr6:100914733	NA	-0.57	-4.51	-0.42	1.86e-5	Neuroticism;
THYM	cis	rs6980334	1.000	rs7787591	chr7:137778203	C/T	cg26979473	chr7:137028389	PTN	0.61	4.5	0.42	1.92e-5	Blood metabolite ratios;
THYM	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg06481639	chr22:41940642	POLR3H	0.72	5.18	0.47	1.22e-6	Vitiligo;
THYM	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7894051	0.764	rs12242667	chr10:135192346	G/C	cg12428399	chr10:135191333	PAOX	-1.02	-4.68	-0.43	9.52e-6	Lifespan;
THYM	cis	rs686320	0.748	rs580933	chr11:65196884	C/G	cg19332572	chr11:65321591	LTBP3	-1.07	-5.87	-0.52	6.37e-8	Hip circumference adjusted for BMI;
THYM	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg18252515	chr7:66147081	NA	-0.63	-4.7	-0.43	8.9e-6	Aortic root size;
THYM	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg03676636	chr4:99064102	C4orf37	0.43	6.32	0.54	8.55e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg10589385	chr1:150898437	SETDB1	0.65	5.45	0.49	4.01e-7	Melanoma;
THYM	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg12179176	chr11:130786555	SNX19	-0.88	-8.3	-0.65	7.08e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg02475777	chr4:1388615	CRIPAK	0.72	5.2	0.47	1.13e-6	Longevity;
THYM	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg04362960	chr10:104952993	NT5C2	0.63	4.47	0.42	2.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	trans	rs8073060	0.586	rs72829933	chr17:34056406	C/T	cg19694781	chr19:47549865	TMEM160	0.98	8.12	0.64	1.68e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg10334053	chr1:2078117	PRKCZ	-0.46	-4.67	-0.43	9.8e-6	Height;
THYM	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Blood metabolite levels;
THYM	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg04731861	chr2:219085781	ARPC2	0.54	5.05	0.46	2.11e-6	Colorectal cancer;
THYM	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg22920501	chr2:26401640	FAM59B	-0.74	-6.28	-0.54	9.97e-9	Gut microbiome composition (summer);
THYM	cis	rs9549260	0.755	rs2701863	chr13:41170140	C/T	cg21288729	chr13:41239152	FOXO1	0.66	5.41	0.48	4.8e-7	Red blood cell count;
THYM	cis	rs7523273	0.568	rs1318653	chr1:208014922	C/T	cg22525895	chr1:207977042	MIR29B2	0.75	5.53	0.49	2.87e-7	Schizophrenia;
THYM	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg17775962	chr7:1200435	ZFAND2A	0.5	5.54	0.49	2.68e-7	Longevity;Endometriosis;
THYM	cis	rs11039798	0.511	rs717896	chr11:48375335	G/T	cg24672777	chr11:48374446	OR4C45	0.96	6.27	0.54	1.05e-8	Axial length;
THYM	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg09359103	chr1:154839909	KCNN3	0.69	9.28	0.69	5.69e-15	Prostate cancer;
THYM	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.96e-6	Resting heart rate;
THYM	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg13390004	chr1:15929781	NA	0.61	4.63	0.43	1.15e-5	Systolic blood pressure;
THYM	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg03159660	chr11:2078197	NA	0.62	4.56	0.42	1.53e-5	Calcium levels;
THYM	cis	rs10779751	1.000	rs10779751	chr1:11284336	A/G	cg08854313	chr1:11322531	MTOR	0.91	7.73	0.62	1.14e-11	Body mass index;
THYM	cis	rs870825	0.587	rs35377170	chr4:185639728	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs11676855	0.927	rs4341884	chr2:235918504	G/T	cg14917874	chr2:235941519	SH3BP4	0.61	5.12	0.46	1.61e-6	Dialysis-related mortality;
THYM	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11096990	0.613	rs9997015	chr4:39224297	A/G	cg24403649	chr4:39172243	NA	-0.62	-5.42	-0.49	4.43e-7	Cognitive function;
THYM	cis	rs11992162	0.573	rs13264994	chr8:11782759	G/A	cg21775007	chr8:11205619	TDH	-0.59	-4.55	-0.42	1.56e-5	Monocyte count;
THYM	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg08736216	chr1:53307985	ZYG11A	-0.58	-5.29	-0.48	7.85e-7	Monocyte count;
THYM	cis	rs9972944	0.756	rs6504349	chr17:63764140	G/A	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22857025	chr5:266934	NA	-1.41	-9.08	-0.68	1.5e-14	Breast cancer;
THYM	cis	rs295140	1.000	rs1367857	chr2:201160765	T/C	cg04283868	chr2:201171347	SPATS2L	0.75	5.71	0.51	1.31e-7	QT interval;
THYM	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg07424592	chr7:64974309	NA	1.05	4.76	0.44	6.92e-6	Diabetic kidney disease;
THYM	cis	rs3126085	0.935	rs4845750	chr1:152201217	A/G	cg10321714	chr1:152280068	FLG	0.7	5.03	0.46	2.3e-6	Atopic dermatitis;
THYM	cis	rs1520896	0.915	rs7114948	chr11:20265327	G/C	cg21745110	chr11:19798742	NAV2	-0.7	-4.55	-0.42	1.58e-5	Response to platinum-based chemotherapy (cisplatin);
THYM	cis	rs9807841	0.723	rs1965767	chr19:10860215	T/C	cg16900796	chr19:10755136	SLC44A2	0.31	4.78	0.44	6.34e-6	Inflammatory skin disease;
THYM	cis	rs11731175	1.000	rs62342332	chr4:189858747	C/T	cg00431894	chr4:189871012	NA	-0.82	-6.24	-0.54	1.2e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs3857067	0.806	rs17302300	chr4:95109177	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs754466	0.510	rs10824579	chr10:79590685	C/T	cg17075019	chr10:79541650	NA	-0.64	-5.32	-0.48	6.97e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg09904177	chr6:26538194	HMGN4	0.54	4.57	0.42	1.47e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9796	0.804	rs28688742	chr15:41403638	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.61	-4.7	-0.43	8.86e-6	Menopause (age at onset);
THYM	trans	rs7952251	0.812	rs7947242	chr11:112407771	A/G	cg14154186	chr1:204970430	NFASC	-0.73	-7.54	-0.61	2.79e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs3750965	0.734	rs11604251	chr11:68820429	A/G	cg01403660	chr11:68851641	TPCN2	-0.66	-4.98	-0.46	2.84e-6	Hair color;
THYM	cis	rs4568518	0.535	rs7781290	chr7:18062610	G/A	cg00911873	chr7:18067463	PRPS1L1	-0.57	-4.62	-0.43	1.23e-5	Measles;
THYM	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11644478	chr21:40555479	PSMG1	0.83	7.21	0.59	1.32e-10	Cognitive function;
THYM	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs7580658	0.857	rs17015199	chr2:128094053	A/G	cg10021288	chr2:128175891	PROC	-0.73	-6.27	-0.54	1.08e-8	Protein C levels;
THYM	cis	rs9682041	0.867	rs6444925	chr3:170123358	G/T	cg11886554	chr3:170076028	SKIL	1.45	5.45	0.49	4.03e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs208520	0.690	rs851468	chr6:66825875	G/A	cg07460842	chr6:66804631	NA	-0.97	-6.96	-0.58	4.44e-10	Exhaled nitric oxide output;
THYM	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg04436690	chr7:637132	PRKAR1B	-0.57	-4.6	-0.43	1.33e-5	Longevity;Endometriosis;
THYM	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	8.03	0.64	2.6e-12	Chronic sinus infection;
THYM	cis	rs6669072	0.967	rs12130887	chr1:91240696	G/T	cg08895590	chr1:91227319	NA	-0.55	-6.62	-0.56	2.09e-9	Cognitive function;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg05376756	chr1:101493828	NA	-0.97	-7.28	-0.6	9.37e-11	Depressive symptoms;
THYM	cis	rs4851266	0.865	rs11123818	chr2:100867308	G/A	cg08017756	chr2:100939284	LONRF2	-0.56	-4.45	-0.42	2.31e-5	Educational attainment;
THYM	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg24812749	chr6:127587940	RNF146	0.87	6.2	0.54	1.44e-8	Breast cancer;
THYM	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg07777115	chr5:623756	CEP72	-0.8	-4.78	-0.44	6.48e-6	Obesity-related traits;
THYM	cis	rs11997175	0.624	rs4733179	chr8:33692223	T/G	ch.8.33884649F	chr8:33765107	NA	0.66	5.07	0.46	1.92e-6	Body mass index;
THYM	cis	rs807029	0.758	rs807025	chr10:102764821	C/T	cg14905631	chr10:102746534	C10orf2;MRPL43	0.33	4.49	0.42	2.03e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs8073060	0.821	rs11080355	chr17:33872694	T/A	cg07895132	chr17:33825172	SLFN12L	0.62	5.68	0.5	1.48e-7	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg18681998	chr4:17616180	MED28	0.9	8.39	0.65	4.46e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg00071950	chr4:10020882	SLC2A9	-0.75	-7.53	-0.61	2.88e-11	Bone mineral density;
THYM	cis	rs2625529	0.775	rs2723342	chr15:72107699	G/C	cg16672083	chr15:72433130	SENP8	-0.6	-4.86	-0.45	4.71e-6	Red blood cell count;
THYM	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg08645402	chr16:4508243	NA	0.75	6.69	0.57	1.51e-9	Schizophrenia;
THYM	cis	rs4892230	1	rs4892230	chr18:72155572	G/A	cg26446133	chr18:72167187	CNDP2	-0.74	-5.95	-0.52	4.47e-8	Mononucleosis;
THYM	cis	rs2286885	1.000	rs4837093	chr9:129254443	G/A	cg14294646	chr9:129243551	FAM125B	-0.57	-5.32	-0.48	6.84e-7	Intraocular pressure;
THYM	cis	rs595982	0.702	rs626974	chr19:49375900	T/C	cg19746536	chr19:49375674	PPP1R15A	1.26	16.93	0.87	1.97e-30	Red cell distribution width;
THYM	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg05660106	chr1:15850417	CASP9	0.76	6.27	0.54	1.06e-8	Systolic blood pressure;
THYM	cis	rs12711979	0.765	rs6705742	chr2:3820672	C/T	cg17052675	chr2:3827356	NA	-0.48	-5.21	-0.47	1.11e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg18512352	chr11:47633146	NA	-0.5	-6.11	-0.53	2.17e-8	Subjective well-being;
THYM	cis	rs6980334	0.817	rs10954603	chr7:137794021	A/G	cg06915773	chr7:137028165	PTN	0.58	4.74	0.44	7.59e-6	Blood metabolite ratios;
THYM	cis	rs4481887	1.000	rs10888356	chr1:248465044	C/T	cg00666640	chr1:248458726	OR2T12	-0.57	-4.66	-0.43	1.05e-5	Common traits (Other);
THYM	cis	rs7953508	0.711	rs11107116	chr12:93978504	G/T	cg13201927	chr12:93977447	NA	0.75	5.33	0.48	6.69e-7	Pubertal anthropometrics;
THYM	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg21100191	chr22:23484243	RTDR1	-0.73	-6.5	-0.55	3.66e-9	Bone mineral density;
THYM	cis	rs55702914	0.839	rs2059922	chr2:198188903	C/G	cg00792783	chr2:198669748	PLCL1	-0.63	-4.76	-0.44	6.97e-6	Major depression and alcohol dependence;
THYM	cis	rs7586879	0.520	rs6718511	chr2:25122324	A/G	cg15423357	chr2:25149977	NA	0.7	7.75	0.62	1e-11	Body mass index;
THYM	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg24642844	chr7:1081250	C7orf50	-0.74	-5.18	-0.47	1.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13256369	0.590	rs10113115	chr8:8559588	A/G	cg18904891	chr8:8559673	CLDN23	0.63	4.98	0.45	2.85e-6	Obesity-related traits;
THYM	cis	rs10779751	1.000	rs1010447	chr1:11269796	A/G	cg08854313	chr1:11322531	MTOR	0.9	7.66	0.62	1.58e-11	Body mass index;
THYM	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg04865290	chr3:52927548	TMEM110	-0.96	-4.97	-0.45	2.97e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs10911232	0.507	rs10732271	chr1:183025898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs72827839	0.846	rs16953461	chr17:46261736	G/T	cg23391107	chr17:45924227	SP6	-0.88	-6.12	-0.53	2.04e-8	Ease of getting up in the morning;
THYM	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg24154853	chr7:158122151	PTPRN2	0.58	5.18	0.47	1.25e-6	Calcium levels;
THYM	cis	rs6430585	0.591	rs75223002	chr2:136525309	G/T	cg23851026	chr2:136556271	LCT	0.79	7.53	0.61	2.86e-11	Corneal structure;
THYM	cis	rs56235845	0.685	rs35630910	chr5:176757841	A/C	cg17509989	chr5:176798049	RGS14	0.71	6.46	0.55	4.39e-9	Hemoglobin concentration;Hematocrit;
THYM	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg26384229	chr12:38710491	ALG10B	0.98	7.15	0.59	1.8e-10	Bladder cancer;
THYM	cis	rs6032067	0.929	rs876835	chr20:43827241	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs3733631	1.000	rs10010631	chr4:104644543	A/G	cg24090629	chr4:104641072	TACR3	-0.86	-5.52	-0.49	2.9e-7	Menarche (age at onset);
THYM	cis	rs4732038	0.510	rs57460017	chr7:134279055	C/T	cg06906464	chr7:134288099	NA	-0.56	-5.49	-0.49	3.31e-7	Longevity;
THYM	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg07541023	chr7:19748670	TWISTNB	1.12	7.27	0.6	9.9e-11	Night sleep phenotypes;
THYM	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg03929089	chr4:120376271	NA	-0.94	-10.56	-0.73	1.03e-17	Height;
THYM	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.73	-6.69	-0.57	1.52e-9	Lung cancer;
THYM	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg26597838	chr10:835615	NA	1.58	12.04	0.78	8.01e-21	Eosinophil percentage of granulocytes;
THYM	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg18230493	chr5:56204884	C5orf35	-0.86	-4.79	-0.44	6.13e-6	Type 2 diabetes;
THYM	cis	rs11651000	0.654	rs12451801	chr17:45820975	T/C	cg06532163	chr17:45867833	NA	0.56	5.48	0.49	3.51e-7	IgG glycosylation;
THYM	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg08736216	chr1:53307985	ZYG11A	-0.73	-6.38	-0.55	6.46e-9	Monocyte count;
THYM	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg16342193	chr10:102329863	NA	-0.59	-6.2	-0.54	1.48e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1823778	0.609	rs892767	chr18:67699093	C/T	cg12929678	chr18:67624393	CD226	1.28	4.87	0.45	4.4e-6	Mean platelet volume;
THYM	cis	rs4803468	0.967	rs7259900	chr19:41889429	A/T	cg09537434	chr19:41945824	ATP5SL	-1.09	-9.94	-0.71	2.27e-16	Height;
THYM	cis	rs3820068	0.580	rs12760698	chr1:16009814	G/A	cg24675056	chr1:15929824	NA	0.75	5.94	0.52	4.59e-8	Systolic blood pressure;
THYM	cis	rs4074961	0.604	rs4411102	chr1:38063424	C/G	cg17933807	chr1:38061675	GNL2	1.07	13.25	0.81	2.56e-23	Axial length;
THYM	cis	rs7553864	0.667	rs6576866	chr1:87601471	T/C	cg17420885	chr1:87600446	LOC339524	-0.82	-7.13	-0.59	1.93e-10	Smoking behavior;
THYM	cis	rs9633835	0.524	rs1481876	chr11:13272171	A/G	cg13286116	chr11:13302098	ARNTL	-0.72	-8.03	-0.64	2.61e-12	Body mass index;
THYM	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg05717871	chr11:638507	DRD4	-0.69	-6.03	-0.53	3.1e-8	Systemic lupus erythematosus;
THYM	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg06028808	chr11:68637592	NA	0.68	7.24	0.6	1.18e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2227564	0.620	rs3812637	chr10:75568846	C/T	cg23231163	chr10:75533350	FUT11	-0.35	-4.58	-0.43	1.4e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg16624210	chr5:671434	TPPP	0.65	4.53	0.42	1.74e-5	Lung disease severity in cystic fibrosis;
THYM	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06634786	chr22:41940651	POLR3H	-0.79	-6.08	-0.53	2.5e-8	Vitiligo;
THYM	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg17863274	chr19:49399704	TULP2	-1.0	-6.41	-0.55	5.72e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs12579753	0.917	rs12311988	chr12:82177209	C/A	cg21231944	chr12:82153410	PPFIA2	-0.7	-5.26	-0.47	8.99e-7	Resting heart rate;
THYM	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg14196790	chr5:131705035	SLC22A5	0.5	4.47	0.42	2.15e-5	Blood metabolite levels;
THYM	cis	rs12681287	0.640	rs10095498	chr8:87425651	C/T	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs728616	0.717	rs116884206	chr10:81990546	A/G	cg27452691	chr10:81370291	SFTPA1	0.83	4.59	0.43	1.38e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg14196790	chr5:131705035	SLC22A5	0.51	4.62	0.43	1.23e-5	Blood metabolite levels;
THYM	cis	rs1278352	0.767	rs1278356	chr10:127774218	T/C	cg08295661	chr10:127769903	ADAM12	-0.55	-5.64	-0.5	1.71e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg06521331	chr12:34319734	NA	-0.95	-9.13	-0.68	1.19e-14	Morning vs. evening chronotype;
THYM	cis	rs924712	0.545	rs12207559	chr6:54709868	A/C	cg18532076	chr6:54711417	FAM83B	0.49	4.55	0.42	1.57e-5	Breast cancer;
THYM	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg12408189	chr10:30722286	MAP3K8	-0.55	-4.67	-0.43	1.01e-5	Inflammatory bowel disease;
THYM	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg07636037	chr3:49044803	WDR6	0.87	6.17	0.54	1.63e-8	Menarche (age at onset);
THYM	cis	rs6690583	0.697	rs2012369	chr1:85520845	T/C	cg22153463	chr1:85462885	MCOLN2	-0.68	-4.47	-0.42	2.19e-5	Serum sulfate level;
THYM	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	5.04	0.46	2.22e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg08772003	chr10:104629869	AS3MT	-0.61	-5.37	-0.48	5.62e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4888262	0.526	rs8055803	chr16:74615190	A/G	cg01733217	chr16:74700730	RFWD3	0.84	8.52	0.66	2.4e-13	Testicular germ cell tumor;
THYM	cis	rs2075230	0.705	rs1641542	chr17:7544272	T/C	cg10509001	chr17:7553872	ATP1B2	-0.57	-4.61	-0.43	1.26e-5	Hormone measurements;
THYM	cis	rs8050907	1.000	rs28505517	chr16:4608099	G/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.57	0.42	1.47e-5	Obesity-related traits;
THYM	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	8.89	0.67	3.88e-14	Chronic sinus infection;
THYM	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2130392	0.962	rs13132498	chr4:185611454	T/C	cg04058563	chr4:185651563	MLF1IP	-0.58	-5.54	-0.49	2.66e-7	Kawasaki disease;
THYM	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11563648	0.553	rs10253737	chr7:127004565	A/G	cg23081781	chr7:127225937	GCC1	-0.34	-4.57	-0.42	1.45e-5	Resting heart rate;
THYM	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg20290983	chr6:43655470	MRPS18A	1.44	16.02	0.85	9.41e-29	IgG glycosylation;
THYM	cis	rs9253	0.605	rs35275661	chr1:37972258	T/G	cg17933807	chr1:38061675	GNL2	0.73	4.6	0.43	1.33e-5	Hemostatic factors and hematological phenotypes;
THYM	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9534288	0.797	rs9534277	chr13:46578349	T/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg01579765	chr21:45077557	HSF2BP	0.52	8.58	0.66	1.78e-13	Mean corpuscular volume;
THYM	cis	rs7463256	1.000	rs7459962	chr8:23101743	C/G	cg14349055	chr8:23104193	CHMP7	-1.04	-12.95	-0.8	1.07e-22	Attention deficit hyperactivity disorder;
THYM	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg07917127	chr4:99064746	C4orf37	0.59	4.5	0.42	1.93e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg06238570	chr21:40685208	BRWD1	0.96	8.93	0.68	3.27e-14	Cognitive function;
THYM	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg02524346	chr8:600233	NA	1.06	4.77	0.44	6.78e-6	IgG glycosylation;
THYM	cis	rs11048434	0.736	rs12823100	chr12:9108908	C/A	cg04155231	chr12:9217510	LOC144571	0.47	4.47	0.42	2.14e-5	Sjögren's syndrome;
THYM	cis	rs2903698	0.565	rs13134862	chr4:76425896	G/A	cg03209871	chr4:76438412	RCHY1;THAP6	0.4	4.7	0.43	8.84e-6	Prion diseases;
THYM	cis	rs2932538	0.922	rs12137107	chr1:113127437	A/G	cg22162597	chr1:113214053	CAPZA1	0.63	5.17	0.47	1.29e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23248424	chr5:179741104	GFPT2	-0.89	-6.93	-0.58	5.07e-10	Height;
THYM	cis	rs7614311	0.681	rs6776209	chr3:63858633	G/C	cg22134162	chr3:63841271	THOC7	-0.56	-6.85	-0.57	7.34e-10	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs7267979	1.000	rs2257985	chr20:25269743	G/T	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7731657	0.537	rs10520092	chr5:130202197	C/T	cg08523029	chr5:130500466	HINT1	0.69	4.64	0.43	1.1e-5	Fasting plasma glucose;
THYM	cis	rs4363385	0.818	rs1591736	chr1:152987497	A/C	cg13444842	chr1:152974279	SPRR3	-0.61	-5.08	-0.46	1.86e-6	Inflammatory skin disease;
THYM	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg04654363	chr8:8581213	NA	-0.48	-4.61	-0.43	1.25e-5	Obesity-related traits;
THYM	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg09197432	chr4:183729176	NA	0.85	5.3	0.48	7.49e-7	Pediatric autoimmune diseases;
THYM	cis	rs9682041	0.935	rs11923053	chr3:170095281	T/C	cg11886554	chr3:170076028	SKIL	1.3	5.11	0.46	1.63e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs9470366	0.545	rs2395655	chr6:36645696	C/T	cg11920449	chr6:36645608	CDKN1A	0.9	8.91	0.67	3.52e-14	QRS duration;
THYM	cis	rs929596	0.517	rs1875263	chr2:234625622	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.86	-7.09	-0.59	2.32e-10	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg11764359	chr7:65958608	NA	-0.8	-6.38	-0.55	6.55e-9	Aortic root size;
THYM	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs116139393	0.634	rs17789828	chr7:6738637	C/T	cg03005310	chr7:6897353	NA	-0.63	-4.58	-0.43	1.39e-5	Alzheimer's disease (APOE e4 interaction);
THYM	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg23711669	chr6:146136114	FBXO30	0.91	9.57	0.7	1.4e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg15691649	chr6:25882328	NA	-0.76	-6.49	-0.55	3.86e-9	Intelligence (multi-trait analysis);
THYM	cis	rs56104184	0.578	rs7254608	chr19:49395774	G/T	cg19746536	chr19:49375674	PPP1R15A	1.0	9.1	0.68	1.35e-14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7772486	0.558	rs702316	chr6:146004677	C/A	cg23711669	chr6:146136114	FBXO30	-0.84	-6.86	-0.58	6.87e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg13319975	chr6:146136371	FBXO30	-0.63	-4.98	-0.45	2.87e-6	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	cis	rs6840360	1.000	rs6823002	chr4:152604467	T/G	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs941408	1.000	rs941410	chr19:2787329	G/A	cg17333051	chr19:2783644	SGTA	0.64	5.63	0.5	1.81e-7	Total cholesterol levels;
THYM	cis	rs1775715	0.870	rs1755084	chr10:32253709	C/T	cg04359828	chr10:32216031	ARHGAP12	0.4	5.18	0.47	1.24e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-5.48	-0.49	3.43e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs2133450	0.712	rs62237081	chr3:7366057	G/A	cg19930620	chr3:7340148	GRM7	-0.48	-4.58	-0.43	1.4e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs1062746	0.520	rs17698303	chr16:87329543	C/G	cg02258303	chr16:87377426	FBXO31	-0.6	-4.54	-0.42	1.66e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg26818010	chr10:134567672	INPP5A	-0.82	-6.62	-0.56	2.15e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs17767294	0.708	rs17693877	chr6:27707046	G/A	cg08851530	chr6:28072375	NA	1.3	5.23	0.47	9.89e-7	Parkinson's disease;
THYM	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22968622	chr17:43663579	NA	-0.82	-7.08	-0.59	2.44e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg18758796	chr5:131593413	PDLIM4	0.51	4.83	0.44	5.32e-6	Acylcarnitine levels;
THYM	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07167872	chr1:205819463	PM20D1	1.09	12.0	0.78	9.74e-21	Menarche (age at onset);
THYM	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg17775962	chr7:1200435	ZFAND2A	0.52	5.98	0.52	3.94e-8	Longevity;Endometriosis;
THYM	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg13010199	chr12:38710504	ALG10B	-0.62	-4.46	-0.42	2.21e-5	Bladder cancer;
THYM	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08704250	chr15:31115839	NA	0.68	7.54	0.61	2.77e-11	Huntington's disease progression;
THYM	cis	rs977987	0.778	rs4888426	chr16:75476451	G/A	cg03315344	chr16:75512273	CHST6	0.74	5.92	0.52	5.07e-8	Dupuytren's disease;
THYM	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg20891283	chr12:69753455	YEATS4	1.09	12.03	0.78	8.44e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs11048434	0.636	rs7306165	chr12:9059081	T/C	cg13575925	chr12:9217583	LOC144571	0.52	4.72	0.44	8.1e-6	Sjögren's syndrome;
THYM	cis	rs3857067	0.806	rs12513267	chr4:95109545	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg02228675	chr17:40259724	DHX58	-0.66	-5.49	-0.49	3.28e-7	Fibrinogen levels;
THYM	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg05896524	chr21:47604654	C21orf56	-0.73	-5.18	-0.47	1.25e-6	Testicular germ cell tumor;
THYM	cis	rs6815814	0.898	rs115807384	chr4:38851585	A/C	cg02016764	chr4:38805732	TLR1	-0.54	-4.81	-0.44	5.64e-6	Breast cancer;
THYM	cis	rs9486719	0.947	rs9398072	chr6:96911304	T/C	cg18709589	chr6:96969512	KIAA0776	0.76	5.0	0.46	2.57e-6	Migraine;Coronary artery disease;
THYM	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg18850127	chr7:39170497	POU6F2	0.58	5.44	0.49	4.16e-7	IgG glycosylation;
THYM	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs9302065	1.000	rs2389236	chr13:95971477	G/A	cg24476569	chr13:95954382	ABCC4	-0.57	-5.18	-0.47	1.26e-6	Blood metabolite levels;
THYM	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	10.13	0.72	8.76e-17	Platelet count;
THYM	cis	rs10779751	0.762	rs6540965	chr1:11325521	C/G	cg08854313	chr1:11322531	MTOR	-0.86	-8.41	-0.65	4.17e-13	Body mass index;
THYM	cis	rs3768617	0.510	rs4651143	chr1:183097398	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.91	0.45	3.8e-6	Fuchs's corneal dystrophy;
THYM	cis	rs9297145	0.724	rs6954584	chr7:98766930	G/A	cg05967295	chr7:98741636	SMURF1	0.86	6.39	0.55	6.04e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg20608306	chr11:116969690	SIK3	-0.52	-5.59	-0.5	2.18e-7	Blood protein levels;
THYM	cis	rs3126085	0.560	rs3120665	chr1:152316590	A/G	cg10321714	chr1:152280068	FLG	-0.75	-5.29	-0.48	7.81e-7	Atopic dermatitis;
THYM	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg01831904	chr17:28903510	LRRC37B2	-1.13	-5.5	-0.49	3.13e-7	Body mass index;
THYM	cis	rs11112613	0.775	rs12371537	chr12:105971425	T/C	cg03607813	chr12:105948248	NA	0.92	6.66	0.56	1.73e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs11731175	1.000	rs62341079	chr4:189860582	C/T	cg00431894	chr4:189871012	NA	-0.82	-6.24	-0.54	1.2e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg24060327	chr5:131705240	SLC22A5	-0.83	-6.92	-0.58	5.2e-10	Blood metabolite levels;
THYM	cis	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg10856724	chr12:34555212	NA	-1.05	-10.54	-0.73	1.17e-17	Morning vs. evening chronotype;
THYM	cis	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg07460842	chr6:66804631	NA	-0.9	-6.58	-0.56	2.6e-9	Exhaled nitric oxide output;
THYM	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.59	-4.49	-0.42	1.98e-5	Breast cancer;
THYM	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg01097406	chr16:89675127	NA	0.72	6.81	0.57	8.87e-10	Vitiligo;
THYM	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg24531977	chr5:56204891	C5orf35	-1.01	-8.29	-0.65	7.47e-13	Initial pursuit acceleration;
THYM	cis	rs702490	0.735	rs1173589	chr1:54172944	A/G	cg02905900	chr1:55013517	ACOT11	0.46	4.87	0.45	4.48e-6	Monobrow;
THYM	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg10589385	chr1:150898437	SETDB1	0.62	5.21	0.47	1.08e-6	Melanoma;
THYM	cis	rs4227	0.565	rs10438740	chr17:7472884	A/G	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	0.25	4.6	0.43	1.32e-5	IgA nephropathy;
THYM	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg19418458	chr7:158789849	NA	-0.62	-5.88	-0.52	6.09e-8	Facial morphology (factor 20);
THYM	cis	rs8050907	0.744	rs56235717	chr16:4524374	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.58	0.43	1.38e-5	Obesity-related traits;
THYM	cis	rs13064411	0.696	rs7610638	chr3:113139656	A/G	cg10517650	chr3:113235015	CCDC52	-0.6	-5.06	-0.46	2.06e-6	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg22709100	chr7:91322751	NA	0.63	4.86	0.45	4.55e-6	Breast cancer;
THYM	cis	rs4363385	0.588	rs7540609	chr1:153024589	C/A	cg13444842	chr1:152974279	SPRR3	-0.61	-4.92	-0.45	3.64e-6	Inflammatory skin disease;
THYM	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	5.78	0.51	9.49e-8	Height;
THYM	cis	rs7840202	0.524	rs71506353	chr8:103413983	A/G	cg09990700	chr8:103251014	RRM2B	-1.04	-4.96	-0.45	3.14e-6	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);
THYM	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03264133	chr6:25882463	NA	-0.69	-5.32	-0.48	7.03e-7	Blood metabolite levels;
THYM	cis	rs665401	0.965	rs339351	chr6:117200434	C/A	cg20376953	chr6:117187980	NA	0.6	4.7	0.43	8.67e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg08859206	chr1:53392774	SCP2	0.61	6.85	0.58	7.17e-10	Monocyte count;
THYM	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg07884673	chr3:53033167	SFMBT1	1.03	4.98	0.46	2.8e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs1670533	1.000	rs2100411	chr4:1074412	T/C	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg22920501	chr2:26401640	FAM59B	1.07	9.54	0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs6430585	0.528	rs10496738	chr2:136751488	C/T	cg20242066	chr2:136595261	LCT	0.56	5.2	0.47	1.14e-6	Corneal structure;
THYM	cis	rs1403694	0.515	rs1648722	chr3:186448989	C/T	cg12454167	chr3:186435060	KNG1	0.43	5.73	0.51	1.18e-7	Blood protein levels;
THYM	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg21984481	chr17:79567631	NPLOC4	0.46	4.86	0.45	4.62e-6	Eye color traits;
THYM	cis	rs12971120	0.838	rs2241510	chr18:72180739	G/A	cg26446133	chr18:72167187	CNDP2	-1.01	-7.53	-0.61	2.9e-11	Refractive error;
THYM	cis	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg24692254	chr21:30365293	RNF160	-0.79	-4.48	-0.42	2.07e-5	Cognitive test performance;
THYM	cis	rs9807841	0.670	rs2010492	chr19:10803395	A/G	cg16900796	chr19:10755136	SLC44A2	0.32	4.87	0.45	4.5e-6	Inflammatory skin disease;
THYM	cis	rs7084402	1.000	rs1863664	chr10:60266839	A/G	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs8028313	0.630	rs12900208	chr15:67963058	C/G	cg26545918	chr15:68124484	LBXCOR1	0.55	5.0	0.46	2.58e-6	Obesity;
THYM	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg09877947	chr5:131593287	PDLIM4	0.65	5.41	0.49	4.63e-7	Acylcarnitine levels;
THYM	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg04352962	chr1:209979756	IRF6	0.66	5.97	0.52	4.06e-8	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
THYM	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg15536230	chr21:44985092	HSF2BP	-0.41	-5.14	-0.47	1.46e-6	Mean corpuscular volume;
THYM	cis	rs10791097	0.702	rs11222346	chr11:130715343	T/C	cg14779329	chr11:130786720	SNX19	-0.48	-4.79	-0.44	6.22e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg18825531	chr11:62321136	NA	-0.46	-5.32	-0.48	6.94e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs8030485	0.545	rs4778637	chr15:79396520	C/T	cg17916960	chr15:79447300	NA	0.52	5.13	0.47	1.51e-6	Left ventricle wall thickness;
THYM	cis	rs6840360	0.571	rs62327268	chr4:152522326	T/A	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	4.96	0.45	3.07e-6	Hip circumference adjusted for BMI;
THYM	cis	rs737008	0.500	rs7189239	chr16:11402515	T/C	cg00044050	chr16:11439710	C16orf75	0.97	8.38	0.65	4.78e-13	Obesity-related traits;
THYM	cis	rs2742234	0.590	rs741968	chr10:43611708	A/G	cg06632098	chr10:43605906	RET	-0.78	-4.97	-0.45	2.99e-6	Hirschsprung disease;
THYM	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06481639	chr22:41940642	POLR3H	0.83	5.86	0.52	6.65e-8	Vitiligo;
THYM	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs921968	0.565	rs13408427	chr2:219628389	C/T	cg02176678	chr2:219576539	TTLL4	-0.47	-4.56	-0.42	1.55e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1456522	0.513	rs12616381	chr2:199871820	T/C	ch.2.199792288R	chr2:200084043	NA	0.58	4.61	0.43	1.26e-5	Menarche (age at onset);
THYM	cis	rs4595586	0.545	rs6580894	chr12:39371951	A/G	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs12611088	0.602	rs2599455	chr19:44025235	T/A	cg18042043	chr19:44147545	NA	-0.42	-4.78	-0.44	6.49e-6	Plasma amyloid beta peptide concentrations (ABx-42);
THYM	cis	rs9902453	1.000	rs9890886	chr17:28391076	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs7572733	0.534	rs700682	chr2:198712310	C/A	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg06636001	chr8:8085503	FLJ10661	-0.73	-6.11	-0.53	2.15e-8	Joint mobility (Beighton score);
THYM	cis	rs41311933	1.000	rs41311933	chr9:123739560	C/T	cg13567360	chr9:123745713	C5	-0.97	-4.94	-0.45	3.34e-6	Coronary artery disease;
THYM	cis	rs3857067	0.806	rs10212784	chr4:95101638	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs7119	0.717	rs35284122	chr15:77804568	G/T	cg10437265	chr15:77819839	NA	0.76	7.61	0.62	1.98e-11	Type 2 diabetes;
THYM	cis	rs887829	0.570	rs13015720	chr2:234600999	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.79	-6.88	-0.58	6.26e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs2495707	0.624	rs1419177	chr10:102423699	G/C	cg03943218	chr10:102419600	NA	-0.61	-6.81	-0.57	8.75e-10	Body mass index;
THYM	cis	rs3862030	0.720	rs11593583	chr10:104228149	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	5.98	0.52	3.85e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs4282339	0.743	rs76917517	chr5:168267677	C/A	cg18364770	chr5:168310523	SLIT3	0.38	5.08	0.46	1.85e-6	Height;
THYM	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg13010199	chr12:38710504	ALG10B	0.73	6.09	0.53	2.41e-8	Heart rate;
THYM	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg02527881	chr3:46936655	PTH1R	-0.68	-6.87	-0.58	6.62e-10	Colorectal cancer;
THYM	cis	rs56104184	0.830	rs28556985	chr19:49351149	C/T	cg15549821	chr19:49342101	PLEKHA4	-1.24	-7.42	-0.61	4.82e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg23815491	chr16:72088622	HP	0.81	6.46	0.55	4.54e-9	Fibrinogen levels;
THYM	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg04315214	chr1:2043799	PRKCZ	0.54	4.49	0.42	1.97e-5	Height;
THYM	cis	rs4606347	0.932	rs61779734	chr1:66139087	T/C	cg04111102	chr1:66153794	NA	0.57	4.53	0.42	1.73e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs747782	0.528	rs624348	chr11:48400795	G/A	cg24672777	chr11:48374446	OR4C45	1.16	7.24	0.6	1.16e-10	Intraocular pressure;
THYM	cis	rs950881	0.932	rs10189526	chr2:102937883	C/T	cg20060108	chr2:102954350	IL1RL1	0.87	4.77	0.44	6.56e-6	Allergy;
THYM	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg18758796	chr5:131593413	PDLIM4	-0.5	-4.72	-0.44	8.15e-6	Blood metabolite levels;
THYM	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.7	0.71	7.32e-16	Colorectal cancer;
THYM	cis	rs933688	1.000	rs6452951	chr5:90653868	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.8	5.19	0.47	1.19e-6	Smoking behavior;
THYM	cis	rs12530845	0.673	rs73721607	chr7:135335822	C/T	cg23117316	chr7:135346802	PL-5283	-0.73	-5.82	-0.51	7.9e-8	Red blood cell traits;
THYM	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.79	6.32	0.54	8.27e-9	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg12011299	chr4:100065546	ADH4	0.94	9.78	0.71	4.9e-16	Alcohol dependence;
THYM	cis	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg07988820	chr12:82153109	PPFIA2	0.76	4.83	0.44	5.13e-6	Resting heart rate;
THYM	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22133161	chr19:49891603	CCDC155	-0.74	-4.99	-0.46	2.72e-6	Multiple sclerosis;
THYM	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg06112835	chr11:68658793	MRPL21	0.43	6.1	0.53	2.3e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg16928487	chr17:17741425	SREBF1	-0.56	-5.57	-0.5	2.37e-7	Total body bone mineral density;
THYM	cis	rs1065852	0.526	rs7290907	chr22:42390209	G/A	cg01059385	chr22:42394853	WBP2NL	0.57	4.66	0.43	1.04e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs600806	0.888	rs638542	chr1:109845252	G/A	cg02175308	chr1:109941060	SORT1	-0.53	-4.6	-0.43	1.33e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4654899	0.643	rs12123092	chr1:21067001	A/G	cg01072550	chr1:21505969	NA	0.57	4.84	0.44	4.95e-6	Superior frontal gyrus grey matter volume;
THYM	cis	rs1335645	1.000	rs2275122	chr1:111726288	T/G	cg00321911	chr1:111669324	DRAM2	-1.15	-5.67	-0.5	1.51e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg12935359	chr14:103987150	CKB	-0.42	-5.0	-0.46	2.67e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7894051	1.000	rs2185746	chr10:135195332	A/G	cg20534287	chr10:135191450	PAOX	-0.66	-4.81	-0.44	5.64e-6	Lifespan;
THYM	cis	rs36051895	0.632	rs62541958	chr9:5175621	T/C	cg02405213	chr9:5042618	JAK2	-1.02	-10.66	-0.74	6.51e-18	Pediatric autoimmune diseases;
THYM	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11890956	chr21:40555474	PSMG1	0.96	8.19	0.64	1.21e-12	Cognitive function;
THYM	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.79	7.3	0.6	8.54e-11	Hip circumference adjusted for BMI;
THYM	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs9430161	0.644	rs6685766	chr1:11037051	T/C	cg27631724	chr1:11040367	C1orf127	0.68	6.42	0.55	5.25e-9	Ewing sarcoma;
THYM	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg15445000	chr17:37608096	MED1	0.42	4.79	0.44	6.23e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9902453	0.967	rs12150261	chr17:28320473	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-4.81	-0.44	5.64e-6	Coffee consumption (cups per day);
THYM	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg13393036	chr8:95962371	TP53INP1	-0.46	-4.61	-0.43	1.24e-5	Type 2 diabetes;
THYM	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg22105103	chr4:187893119	NA	-0.92	-10.09	-0.72	1.04e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4654899	0.802	rs12127519	chr1:21247365	C/T	cg01072550	chr1:21505969	NA	-0.69	-6.28	-0.54	1.02e-8	Superior frontal gyrus grey matter volume;
THYM	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg03929089	chr4:120376271	NA	-1.03	-12.43	-0.79	1.26e-21	Height;
THYM	cis	rs7119167	0.711	rs55918832	chr11:73077187	C/T	cg17517138	chr11:73019481	ARHGEF17	0.75	4.78	0.44	6.3e-6	Blood protein levels;
THYM	cis	rs8180040	0.768	rs11915074	chr3:47309757	A/T	cg02527881	chr3:46936655	PTH1R	0.59	5.48	0.49	3.44e-7	Colorectal cancer;
THYM	cis	rs711830	1.000	rs1549334	chr2:177039197	G/A	cg13092806	chr2:177043255	NA	0.59	4.75	0.44	7.22e-6	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs10788264	0.538	rs1998344	chr10:124030137	A/G	cg09507567	chr10:124027408	NA	0.56	5.85	0.51	6.8e-8	Total body bone mineral density;
THYM	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg03388043	chr17:80084554	CCDC57	-0.71	-5.85	-0.51	6.98e-8	Life satisfaction;
THYM	cis	rs9611565	1.000	rs9611565	chr22:41767486	T/C	cg13695892	chr22:41940480	POLR3H	-0.78	-6.29	-0.54	9.75e-9	Vitiligo;
THYM	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg24308560	chr3:49941425	MST1R	-0.76	-6.48	-0.55	4.1e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9807841	0.670	rs2360942	chr19:10780802	G/A	cg17848348	chr19:10766748	ILF3	-0.85	-7.48	-0.61	3.69e-11	Inflammatory skin disease;
THYM	cis	rs250677	0.522	rs17109208	chr5:148378475	G/A	cg18129178	chr5:148520854	ABLIM3	-0.69	-4.86	-0.45	4.69e-6	Breast cancer;
THYM	cis	rs4455778	0.580	rs4543492	chr7:49097005	C/T	cg26309511	chr7:48887640	NA	0.68	5.94	0.52	4.63e-8	Lung cancer in never smokers;
THYM	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	7.53	0.61	2.85e-11	Platelet count;
THYM	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg24060327	chr5:131705240	SLC22A5	0.73	5.47	0.49	3.61e-7	Blood metabolite levels;
THYM	cis	rs4733781	0.871	rs12546206	chr8:131167048	A/G	cg16277922	chr8:131349729	ASAP1	-0.58	-4.65	-0.43	1.08e-5	Tuberculosis;
THYM	cis	rs9677476	0.863	rs58067379	chr2:232088295	A/T	cg23338755	chr2:231921595	PSMD1	0.67	5.16	0.47	1.33e-6	Food antigen IgG levels;
THYM	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg07061783	chr6:25882402	NA	0.86	7.64	0.62	1.74e-11	Blood metabolite levels;
THYM	cis	rs11771526	1.000	rs6462350	chr7:32342000	G/A	cg27511599	chr7:32358540	NA	0.74	4.9	0.45	3.95e-6	Body mass index;
THYM	cis	rs9560113	1.000	rs61967684	chr13:112178026	G/C	cg14154082	chr13:112174009	NA	0.85	7.8	0.62	8.1e-12	Menarche (age at onset);
THYM	cis	rs7512552	0.839	rs486275	chr1:150282784	G/A	cg15654264	chr1:150340011	RPRD2	-0.44	-5.19	-0.47	1.21e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg06656553	chr16:89960601	TCF25	-0.78	-4.47	-0.42	2.16e-5	Skin colour saturation;
THYM	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg20503657	chr10:835505	NA	1.17	8.29	0.65	7.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg12560992	chr17:57184187	TRIM37	0.89	7.91	0.63	4.68e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7917772	0.582	rs10883753	chr10:104372441	C/T	cg00122347	chr10:104236741	TMEM180	-0.41	-5.77	-0.51	9.92e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg21475434	chr5:93447410	FAM172A	0.83	5.31	0.48	7.13e-7	Diabetic retinopathy;
THYM	trans	rs877282	0.898	rs11253350	chr10:765968	G/A	cg22713356	chr15:30763199	NA	1.36	9.83	0.71	3.89e-16	Uric acid levels;
THYM	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg05425664	chr17:57184151	TRIM37	0.59	4.71	0.44	8.33e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg24154853	chr7:158122151	PTPRN2	0.55	4.82	0.44	5.35e-6	Calcium levels;
THYM	cis	rs7191439	0.728	rs8043924	chr16:88787704	G/C	cg02389323	chr16:88786976	FAM38A	1.04	6.49	0.55	3.93e-9	Plateletcrit;
THYM	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.47	0.49	3.65e-7	Obesity-related traits;
THYM	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg17366294	chr4:99064904	C4orf37	-0.54	-6.01	-0.53	3.37e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg21427119	chr20:30132790	HM13	-0.86	-5.96	-0.52	4.2e-8	Mean corpuscular hemoglobin;
THYM	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg16928487	chr17:17741425	SREBF1	-0.48	-4.48	-0.42	2.09e-5	Total body bone mineral density;
THYM	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg17105886	chr17:28927953	LRRC37B2	-1.3	-6.95	-0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4631830	0.869	rs4131357	chr10:51537292	C/A	cg16070123	chr10:51489643	NA	-0.53	-4.78	-0.44	6.27e-6	Prostate-specific antigen levels;
THYM	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs4363385	0.720	rs1415968	chr1:152970219	C/G	cg13444842	chr1:152974279	SPRR3	-0.62	-4.87	-0.45	4.52e-6	Inflammatory skin disease;
THYM	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg16325326	chr1:53192061	ZYG11B	0.83	7.91	0.63	4.67e-12	Monocyte count;
THYM	cis	rs13064411	0.735	rs13098166	chr3:113210038	A/G	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7731657	0.537	rs72801791	chr5:130374799	T/C	cg08523029	chr5:130500466	HINT1	-0.84	-5.88	-0.52	6.17e-8	Fasting plasma glucose;
THYM	cis	rs9787249	0.957	rs12074147	chr1:40203722	T/C	cg19912559	chr1:40204330	PPIE	0.63	4.63	0.43	1.18e-5	Blood protein levels;
THYM	cis	rs1403694	0.695	rs1836860	chr3:186436604	C/T	cg12454167	chr3:186435060	KNG1	-0.53	-7.54	-0.61	2.78e-11	Blood protein levels;
THYM	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg07532245	chr17:28927093	LRRC37B2	0.71	4.48	0.42	2.04e-5	Body mass index;
THYM	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg07511668	chr11:68622177	NA	0.44	4.63	0.43	1.16e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg12560992	chr17:57184187	TRIM37	0.93	8.61	0.66	1.5700000000000001e-13	Intelligence (multi-trait analysis);
THYM	cis	rs911119	1.000	rs5030707	chr20:23618656	C/G	cg16589663	chr20:23618590	CST3	0.76	4.69	0.43	9.26e-6	Chronic kidney disease;
THYM	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.55	-5.63	-0.5	1.84e-7	Crohn's disease;
THYM	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.91	-6.52	-0.56	3.31e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg21854759	chr1:92012499	NA	0.7	5.67	0.5	1.5e-7	Breast cancer;
THYM	cis	rs310008	0.609	rs17197603	chr16:81497498	A/G	cg02547035	chr16:81564553	CMIP	0.49	4.54	0.42	1.64e-5	Menarche (age at onset);
THYM	cis	rs3892630	0.878	rs6510277	chr19:33183669	C/A	cg22980127	chr19:33182716	NUDT19	1.13	9.17	0.69	9.73e-15	Red blood cell traits;
THYM	cis	rs57244997	0.932	rs73026582	chr6:162406460	C/T	cg17173639	chr6:162384350	PARK2	-0.91	-5.11	-0.46	1.66e-6	Mosquito bite size;
THYM	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg20608306	chr11:116969690	SIK3	0.52	5.49	0.49	3.32e-7	Blood protein levels;
THYM	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg10334053	chr1:2078117	PRKCZ	-0.51	-5.2	-0.47	1.17e-6	Height;
THYM	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg04267008	chr7:1944627	MAD1L1	-0.66	-5.45	-0.49	3.89e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs1403694	0.695	rs13095338	chr3:186435583	T/C	cg12454167	chr3:186435060	KNG1	0.53	7.54	0.61	2.83e-11	Blood protein levels;
THYM	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg22974920	chr21:40686053	BRWD1	-0.63	-4.97	-0.45	2.98e-6	Cognitive function;
THYM	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg14137381	chr5:502291	SLC9A3	-0.67	-4.68	-0.43	9.62e-6	Cystic fibrosis severity;
THYM	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg06808227	chr14:105710500	BRF1	-1.05	-9.15	-0.68	1.07e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11031096	0.711	rs10767882	chr11:4205841	G/A	cg08557956	chr11:4115526	RRM1	-0.55	-4.99	-0.46	2.76e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg18105134	chr13:113819100	PROZ	0.99	9.19	0.69	8.83e-15	Platelet distribution width;
THYM	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9814567	0.896	rs4245907	chr3:134347876	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-8.47	-0.66	3e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.43e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs611744	0.538	rs59930666	chr8:109262296	T/C	cg21045802	chr8:109455806	TTC35	0.74	7.2	0.59	1.38e-10	Dupuytren's disease;
THYM	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg02753203	chr1:228287806	NA	-0.66	-5.87	-0.52	6.47e-8	Diastolic blood pressure;
THYM	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg23851026	chr2:136556271	LCT	0.56	6.04	0.53	2.93e-8	Mosquito bite size;
THYM	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Body mass index;
THYM	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg17063962	chr7:91808500	NA	1.16	13.12	0.8	4.77e-23	Breast cancer;
THYM	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Body mass index;
THYM	trans	rs4749080	0.573	rs1935483	chr10:26440886	T/G	cg00192819	chr18:76486611	NA	1.0	7.09	0.59	2.41e-10	Obesity-related traits;
THYM	cis	rs2281845	0.929	rs10920121	chr1:201079718	C/T	cg22815214	chr1:201083145	CACNA1S	0.77	7.57	0.61	2.42e-11	Permanent tooth development;
THYM	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.53	-5.0	-0.46	2.57e-6	Lymphocyte counts;
THYM	cis	rs1784581	0.674	rs1789996	chr6:162391895	T/C	cg17173639	chr6:162384350	PARK2	-0.82	-7.22	-0.59	1.3100000000000001e-10	Itch intensity from mosquito bite;
THYM	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg24642844	chr7:1081250	C7orf50	-1.28	-8.22	-0.64	1.06e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6998277	1.000	rs34217554	chr8:103646352	T/C	cg10187029	chr8:103597600	NA	0.57	4.49	0.42	2.04e-5	Migraine;
THYM	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.76	0.44	6.99e-6	Aortic root size;
THYM	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg24675658	chr1:53192096	ZYG11B	-0.77	-6.23	-0.54	1.25e-8	Monocyte count;
THYM	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg06600287	chr1:53387719	ECHDC2	-0.33	-5.12	-0.46	1.6e-6	Monocyte count;
THYM	cis	rs11792861	0.566	rs966466	chr9:111851333	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	5.08	0.46	1.85e-6	Menarche (age at onset);
THYM	cis	rs9326248	0.581	rs11216242	chr11:116901549	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.66	5.27	0.48	8.6e-7	Blood protein levels;
THYM	cis	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.59	-0.43	1.37e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg01528321	chr10:82214614	TSPAN14	0.64	5.63	0.5	1.84e-7	Post bronchodilator FEV1;
THYM	cis	rs8070624	0.543	rs8068175	chr17:17874486	C/T	cg16928487	chr17:17741425	SREBF1	-0.51	-4.63	-0.43	1.18e-5	Total body bone mineral density;
THYM	cis	rs3126085	0.935	rs10788824	chr1:152161694	A/G	cg26020982	chr1:152196106	HRNR	0.39	5.12	0.46	1.61e-6	Atopic dermatitis;
THYM	cis	rs3862030	0.720	rs7341995	chr10:104223831	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.65	-5.42	-0.49	4.42e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg17863274	chr19:49399704	TULP2	-1.01	-6.47	-0.55	4.29e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg02527881	chr3:46936655	PTH1R	-0.86	-8.53	-0.66	2.23e-13	Birth weight;
THYM	cis	rs2625529	0.824	rs1074330	chr15:72250741	C/T	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs6539288	0.630	rs10778519	chr12:107357329	A/G	cg26297688	chr12:107349093	C12orf23	-0.47	-5.11	-0.46	1.7e-6	Total body bone mineral density;
THYM	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg02887458	chr19:19495540	GATAD2A	-0.44	-5.19	-0.47	1.17e-6	Bipolar disorder;
THYM	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg06002616	chr8:101225028	SPAG1	-0.45	-4.65	-0.43	1.08e-5	Atrioventricular conduction;
THYM	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs79387448	0.655	rs11891827	chr2:102951182	A/G	cg09003973	chr2:102972529	NA	1.29	6.82	0.57	8.38e-10	Gut microbiota (bacterial taxa);
THYM	cis	rs665401	0.965	rs339353	chr6:117202475	C/A	cg20376953	chr6:117187980	NA	0.6	4.7	0.43	8.67e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg05985134	chr18:33552581	C18orf21	0.68	4.77	0.44	6.59e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.81	0.57	8.7e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9355610	0.609	rs3756838	chr6:167371251	G/A	cg15592062	chr6:167189543	RPS6KA2	0.55	4.58	0.43	1.4e-5	Graves' disease;
THYM	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2274089	0.737	rs7747371	chr6:25603102	G/A	cg18357526	chr6:26021779	HIST1H4A	1.04	4.52	0.42	1.81e-5	Iron status biomarkers;
THYM	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	5.72	0.51	1.23e-7	Platelet count;
THYM	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.08	7.64	0.62	1.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1403694	1.000	rs1403694	chr3:186439998	T/C	cg12454167	chr3:186435060	KNG1	0.43	5.82	0.51	8.09e-8	Blood protein levels;
THYM	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg07636037	chr3:49044803	WDR6	0.87	7.94	0.63	4.12e-12	Parkinson's disease;
THYM	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg21361702	chr7:150065534	REPIN1	0.67	4.93	0.45	3.53e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs3540	0.533	rs2601197	chr15:90940059	C/A	cg00487526	chr15:90818384	NA	-0.63	-5.06	-0.46	2.03e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs72828912	0.656	rs2139792	chr6:24094347	C/T	cg26336265	chr6:25042955	NA	0.71	5.29	0.48	7.93e-7	Squamous cell lung carcinoma;
THYM	cis	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg06360820	chr2:242988706	NA	-0.97	-6.62	-0.56	2.16e-9	Obesity-related traits;
THYM	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.14	-0.64	1.51e-12	Personality dimensions;
THYM	cis	rs2976388	0.609	rs2572908	chr8:143802636	A/G	cg06565975	chr8:143823917	SLURP1	0.45	4.97	0.45	2.99e-6	Urinary tract infection frequency;
THYM	cis	rs10911251	0.528	rs2333622	chr1:183075456	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Colorectal cancer;
THYM	cis	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg00495681	chr13:53174319	NA	0.73	6.85	0.57	7.36e-10	Lewy body disease;
THYM	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg22920501	chr2:26401640	FAM59B	1.02	6.85	0.57	7.3e-10	Gut microbiome composition (summer);
THYM	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg03609598	chr5:56110824	MAP3K1	-0.69	-5.18	-0.47	1.25e-6	Type 2 diabetes;
THYM	trans	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg10856724	chr12:34555212	NA	-0.9	-8.08	-0.64	2.05e-12	Bladder cancer;
THYM	cis	rs7901056	0.967	rs9284109	chr10:26722663	T/C	cg23318538	chr10:26883079	C10orf50	-0.37	-4.96	-0.45	3.12e-6	Lymphocyte counts;
THYM	cis	rs921968	0.678	rs500422	chr2:219432995	C/A	cg02176678	chr2:219576539	TTLL4	0.66	6.01	0.52	3.4e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg12908607	chr1:44402522	ARTN	-0.59	-4.96	-0.45	3.12e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg11965913	chr1:205819406	PM20D1	0.52	4.57	0.42	1.44e-5	Parkinson's disease;
THYM	cis	rs4654899	0.680	rs6692553	chr1:21221497	C/T	cg01072550	chr1:21505969	NA	0.73	7.11	0.59	2.15e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg10803722	chr21:46713166	LOC642852	-0.41	-5.33	-0.48	6.47e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7851660	0.527	rs7870540	chr9:100573925	T/C	cg13688889	chr9:100608707	NA	-0.97	-8.61	-0.66	1.56e-13	Strep throat;
THYM	cis	rs2806561	0.715	rs10753550	chr1:23322471	C/G	cg19743168	chr1:23544995	NA	-0.61	-5.82	-0.51	7.9e-8	Height;
THYM	cis	rs7909074	0.651	rs10900127	chr10:45390103	C/A	cg04218760	chr10:45406644	TMEM72	-0.58	-5.24	-0.47	9.62e-7	Mean corpuscular volume;
THYM	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg21427119	chr20:30132790	HM13	-0.86	-5.96	-0.52	4.2e-8	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs4455778	0.626	rs6583485	chr7:49014353	A/G	cg26309511	chr7:48887640	NA	-0.5	-4.54	-0.42	1.66e-5	Lung cancer in never smokers;
THYM	cis	rs9560113	1.000	rs9555812	chr13:112181535	A/G	cg14154082	chr13:112174009	NA	0.86	7.89	0.63	5.23e-12	Menarche (age at onset);
THYM	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg10360139	chr7:1886902	MAD1L1	-0.59	-5.14	-0.47	1.44e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg09323728	chr8:95962352	TP53INP1	-0.45	-4.48	-0.42	2.12e-5	Type 2 diabetes;
THYM	cis	rs669446	0.533	rs6429638	chr1:44211010	A/G	cg15962314	chr1:44399869	ARTN	0.47	5.05	0.46	2.16e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg03405983	chr8:143858548	LYNX1	0.54	5.88	0.52	6.01e-8	Urinary tract infection frequency;
THYM	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg26441486	chr22:50317300	CRELD2	0.37	5.55	0.49	2.57e-7	Schizophrenia;
THYM	cis	rs72627123	0.530	rs79371463	chr14:74474856	T/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs17122693	1.000	rs1018039	chr14:51085793	C/T	cg04730355	chr14:51134070	SAV1	0.91	4.95	0.45	3.19e-6	Cognitive performance;
THYM	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg15997130	chr1:24165203	NA	0.76	6.75	0.57	1.19e-9	Immature fraction of reticulocytes;
THYM	cis	rs2730245	0.527	rs2527202	chr7:158738849	T/C	cg01219135	chr7:158766336	NA	-0.63	-4.56	-0.42	1.51e-5	Height;
THYM	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg22117172	chr7:91764530	CYP51A1	0.38	4.92	0.45	3.65e-6	Breast cancer;
THYM	cis	rs2688608	0.592	rs12253482	chr10:75496130	G/A	cg23231163	chr10:75533350	FUT11	-0.47	-6.62	-0.56	2.13e-9	Inflammatory bowel disease;
THYM	cis	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg10856724	chr12:34555212	NA	-0.83	-7.32	-0.6	7.93e-11	Morning vs. evening chronotype;
THYM	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg00981070	chr1:2046702	PRKCZ	-0.4	-4.88	-0.45	4.24e-6	Height;
THYM	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg10560079	chr2:191398806	TMEM194B	-0.93	-7.28	-0.6	9.81e-11	Diastolic blood pressure;
THYM	cis	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg21775007	chr8:11205619	TDH	-0.68	-5.27	-0.48	8.47e-7	Retinal vascular caliber;
THYM	cis	rs3092073	0.617	rs8123864	chr20:44598670	T/C	cg04940435	chr20:44420291	WFDC3;DNTTIP1	-0.47	-4.92	-0.45	3.6e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11644478	chr21:40555479	PSMG1	-0.56	-4.69	-0.43	9.07e-6	Menarche (age at onset);
THYM	trans	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs654950	0.967	rs621727	chr1:41984612	C/T	cg06885757	chr1:42089581	HIVEP3	-0.62	-7.96	-0.63	3.61e-12	Airway imaging phenotypes;
THYM	cis	rs7149242	0.961	rs7142683	chr14:101158882	A/G	cg18089426	chr14:101175970	NA	-0.58	-5.78	-0.51	9.52e-8	Platelet count;
THYM	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg23161317	chr6:28129485	ZNF389	0.84	6.3	0.54	9.31e-9	Depression;
THYM	cis	rs6547741	0.935	rs12615690	chr2:27851120	T/C	cg27432699	chr2:27873401	GPN1	0.72	6.29	0.54	9.46e-9	Oral cavity cancer;
THYM	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg10523679	chr1:76189770	ACADM	-0.87	-8.86	-0.67	4.47e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7100689	0.725	rs2185425	chr10:82139941	T/C	cg01528321	chr10:82214614	TSPAN14	0.96	7.28	0.6	9.52e-11	Post bronchodilator FEV1;
THYM	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg17366294	chr4:99064904	C4orf37	0.54	6.05	0.53	2.81e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2999083	0.524	rs9827325	chr3:127736174	T/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg05373962	chr22:49881684	NA	-0.7	-7.08	-0.59	2.45e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg10802521	chr3:52805072	NEK4	-0.8	-7.53	-0.61	2.92e-11	Bipolar disorder;
THYM	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg19196401	chr6:110721138	DDO	-0.54	-6.03	-0.53	3.16e-8	Platelet distribution width;
THYM	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11644478	chr21:40555479	PSMG1	-0.54	-4.53	-0.42	1.72e-5	Menarche (age at onset);
THYM	cis	rs1483890	0.723	rs6783070	chr3:69411596	A/C	cg22125112	chr3:69402811	FRMD4B	-0.53	-6.59	-0.56	2.47e-9	Resting heart rate;
THYM	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.66	0.5	1.6e-7	Bipolar disorder;
THYM	cis	rs4455778	0.580	rs4292637	chr7:49121114	C/T	cg26309511	chr7:48887640	NA	-0.69	-5.93	-0.52	4.79e-8	Lung cancer in never smokers;
THYM	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg03690763	chr11:133734501	NA	-0.64	-5.07	-0.46	1.94e-6	Childhood ear infection;
THYM	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg18230493	chr5:56204884	C5orf35	0.81	5.4	0.48	4.94e-7	Initial pursuit acceleration;
THYM	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg06618935	chr21:46677482	NA	-0.98	-9.36	-0.69	3.94e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs702490	0.889	rs808860	chr1:54196929	A/G	cg02905900	chr1:55013517	ACOT11	0.44	4.73	0.44	7.7e-6	Monobrow;
THYM	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg09455208	chr3:40491958	NA	0.49	5.1	0.46	1.75e-6	Renal cell carcinoma;
THYM	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg18252515	chr7:66147081	NA	1.49	8.98	0.68	2.47e-14	Diabetic kidney disease;
THYM	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg17509989	chr5:176798049	RGS14	-0.67	-5.95	-0.52	4.45e-8	Urate levels in lean individuals;
THYM	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03452623	chr4:187889614	NA	-1.16	-21.11	-0.91	1.23e-37	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg02753203	chr1:228287806	NA	0.72	6.15	0.53	1.8e-8	Diastolic blood pressure;
THYM	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs8073060	0.963	rs4795082	chr17:33873501	C/T	cg24895173	chr17:33825374	SLFN12L	0.63	4.96	0.45	3.05e-6	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs11031096	0.782	rs11031110	chr11:4162652	G/C	cg22027985	chr11:4115532	RRM1	-0.53	-5.45	-0.49	4.02e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7267979	1.000	rs1047171	chr20:25428786	T/C	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg06981504	chr1:1234844	ACAP3	0.54	5.1	0.46	1.71e-6	Body mass index;
THYM	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.75	-0.67	7.74e-14	Mean corpuscular volume;
THYM	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	4.46	0.42	2.23e-5	Rheumatoid arthritis;
THYM	cis	rs763014	0.931	rs11648728	chr16:635525	C/T	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs10911232	0.507	rs7515822	chr1:183037803	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg23791538	chr6:167370224	RNASET2	-0.78	-6.28	-0.54	1.02e-8	Crohn's disease;
THYM	cis	rs919433	1.000	rs112572902	chr2:198175179	G/C	cg00792783	chr2:198669748	PLCL1	-0.69	-5.03	-0.46	2.28e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	4.94	0.45	3.3e-6	Menarche (age at onset);
THYM	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg13531842	chr10:38383804	ZNF37A	-0.54	-4.53	-0.42	1.73e-5	Extrinsic epigenetic age acceleration;
THYM	trans	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg26714205	chr6:49522045	NA	-0.61	-6.97	-0.58	4.23e-10	Lung adenocarcinoma;
THYM	cis	rs748404	0.631	rs12905772	chr15:43648444	G/A	cg12861797	chr15:43585817	TGM7	0.44	4.67	0.43	9.79e-6	Lung cancer;
THYM	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg15556689	chr8:8085844	FLJ10661	0.67	5.38	0.48	5.29e-7	Mood instability;
THYM	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06850241	chr22:41845214	NA	0.63	4.69	0.43	9.32e-6	Vitiligo;
THYM	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg24209194	chr3:40518798	ZNF619	0.58	4.76	0.44	6.92e-6	Renal cell carcinoma;
THYM	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg17264618	chr3:40429014	ENTPD3	0.47	4.48	0.42	2.1e-5	Renal cell carcinoma;
THYM	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-4.62	-0.43	1.19e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7523273	0.606	rs2796271	chr1:207941927	A/G	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12667521	chr19:29218732	NA	0.89	8.17	0.64	1.34e-12	Methadone dose in opioid dependence;
THYM	cis	rs10501293	0.703	rs7937503	chr11:43008602	G/C	cg03447554	chr11:43094025	NA	0.6	4.46	0.42	2.21e-5	Cognitive performance;
THYM	cis	rs300703	0.542	rs415660	chr2:189972	C/T	cg21211680	chr2:198530	NA	0.94	6.29	0.54	9.74e-9	Blood protein levels;
THYM	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg08017756	chr2:100939284	LONRF2	-0.73	-7.71	-0.62	1.25e-11	Intelligence (multi-trait analysis);
THYM	cis	rs12142240	0.698	rs61519400	chr1:46855298	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg23161317	chr6:28129485	ZNF389	0.84	6.3	0.54	9.31e-9	Depression;
THYM	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg06917634	chr15:78832804	PSMA4	-0.68	-4.63	-0.43	1.14e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg06697600	chr4:7070879	GRPEL1	-0.54	-4.78	-0.44	6.39e-6	Monocyte percentage of white cells;
THYM	trans	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg05926928	chr17:57297772	GDPD1	1.25	9.97	0.72	1.88e-16	Opioid sensitivity;
THYM	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.64	-5.53	-0.49	2.78e-7	Systemic lupus erythematosus;
THYM	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg16586182	chr3:47516702	SCAP	-0.63	-5.58	-0.5	2.26e-7	Colorectal cancer;
THYM	cis	rs4722166	0.695	rs7787893	chr7:22774437	A/G	cg05472934	chr7:22766657	IL6	0.67	5.12	0.47	1.56e-6	Lung cancer;
THYM	cis	rs36051895	0.632	rs61461940	chr9:5157277	T/C	cg02405213	chr9:5042618	JAK2	-1.04	-10.93	-0.75	1.76e-18	Pediatric autoimmune diseases;
THYM	cis	rs7705502	1.000	rs10516107	chr5:173348156	G/A	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg27572855	chr1:25598939	RHD	0.73	5.71	0.51	1.26e-7	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg00277334	chr10:82204260	NA	-0.83	-10.18	-0.72	6.99e-17	Post bronchodilator FEV1;
THYM	cis	rs4866334	1.000	rs77052976	chr5:18453061	A/T	cg04591469	chr5:17810299	NA	-1.12	-4.54	-0.42	1.65e-5	IgG glycosylation;
THYM	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-4.98	-0.46	2.83e-6	Chronic sinus infection;
THYM	cis	rs986417	0.901	rs4640083	chr14:61097779	G/A	cg27398547	chr14:60952738	C14orf39	1.26	6.1	0.53	2.29e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07157834	chr1:205819609	PM20D1	0.97	10.43	0.73	2.04e-17	Menarche (age at onset);
THYM	cis	rs303386	0.501	rs4908303	chr1:99583230	C/T	cg03593336	chr1:99471295	LPPR5	-0.4	-4.49	-0.42	2.01e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
THYM	cis	rs2811415	0.597	rs6770188	chr3:127754676	A/G	cg05377949	chr3:127951287	EEFSEC	0.39	4.76	0.44	6.8e-6	Lung function (FEV1/FVC);
THYM	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg05368731	chr17:41323189	NBR1	1.2	10.93	0.75	1.72e-18	Menopause (age at onset);
THYM	cis	rs6596100	0.538	rs66481372	chr5:132179592	T/A	cg02081065	chr5:132209139	LEAP2	-0.96	-6.11	-0.53	2.22e-8	Breast cancer;
THYM	cis	rs4654899	0.758	rs35913932	chr1:21423025	G/T	cg01072550	chr1:21505969	NA	-0.76	-7.43	-0.61	4.71e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs72627123	0.867	rs74492048	chr14:74439895	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.14	6.41	0.55	5.69e-9	Morning vs. evening chronotype;
THYM	cis	rs13315871	0.929	rs13101057	chr3:58291467	A/G	cg00563845	chr3:58318305	PXK	0.59	5.03	0.46	2.29e-6	Cholesterol, total;
THYM	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg09338302	chr7:1325757	NA	0.47	4.46	0.42	2.27e-5	Bipolar disorder;
THYM	cis	rs4363385	0.626	rs11205192	chr1:153062767	C/T	cg06563695	chr1:153756334	NA	-0.59	-4.89	-0.45	4.17e-6	Inflammatory skin disease;
THYM	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg23187316	chr7:1099788	C7orf50	0.58	4.45	0.42	2.32e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs28595532	0.920	rs116821181	chr4:119734892	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs7589342	0.862	rs10469862	chr2:106509907	C/T	cg14210321	chr2:106509881	NCK2	-0.8	-6.05	-0.53	2.83e-8	Addiction;
THYM	cis	rs6754311	0.552	rs1030765	chr2:136553188	A/T	cg04750100	chr2:136595281	LCT	-0.56	-6.54	-0.56	3.13e-9	Mosquito bite size;
THYM	trans	rs8002861	0.875	rs11616803	chr13:44457109	A/G	cg17145862	chr1:211918768	LPGAT1	-0.97	-9.58	-0.7	1.28e-15	Leprosy;
THYM	cis	rs9534288	0.731	rs7981685	chr13:46605495	G/A	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg16325326	chr1:53192061	ZYG11B	-0.77	-7.04	-0.59	2.94e-10	Monocyte count;
THYM	cis	rs2811415	0.597	rs9824536	chr3:127763956	C/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg16926213	chr1:1841314	NA	-0.54	-5.62	-0.5	1.92e-7	Body mass index;
THYM	cis	rs11039798	0.588	rs10838979	chr11:48626810	T/G	cg24672777	chr11:48374446	OR4C45	-0.93	-6.01	-0.52	3.39e-8	Axial length;
THYM	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg23161317	chr6:28129485	ZNF389	-0.73	-4.87	-0.45	4.5e-6	Parkinson's disease;
THYM	cis	rs11711311	1.000	rs2242109	chr3:113434100	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.27	-0.48	8.41e-7	IgG glycosylation;
THYM	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg00981070	chr1:2046702	PRKCZ	-0.48	-5.34	-0.48	6.34e-7	Height;
THYM	cis	rs7944584	0.563	rs2280231	chr11:47600438	C/T	cg20307385	chr11:47447363	PSMC3	0.78	5.43	0.49	4.25e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
THYM	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg09877947	chr5:131593287	PDLIM4	0.57	4.61	0.43	1.24e-5	Blood metabolite levels;
THYM	cis	rs62244186	0.659	rs4431151	chr3:44510906	G/C	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.46	-4.93	-0.45	3.49e-6	Depressive symptoms;
THYM	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg19077165	chr18:44547161	KATNAL2	-0.58	-7.25	-0.6	1.11e-10	Personality dimensions;
THYM	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs7909074	0.691	rs11239274	chr10:45393219	A/C	cg05187965	chr10:45406764	TMEM72	0.5	4.81	0.44	5.56e-6	Mean corpuscular volume;
THYM	cis	rs9807989	0.729	rs10170583	chr2:102974764	G/A	cg03938978	chr2:103052716	IL18RAP	0.63	6.55	0.56	2.99e-9	Asthma;
THYM	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	9.23	0.69	7.28e-15	Chronic sinus infection;
THYM	cis	rs35883536	0.626	rs12135243	chr1:101092955	G/A	cg09408571	chr1:101003634	GPR88	-0.48	-5.08	-0.46	1.87e-6	Monocyte count;
THYM	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.57	-0.42	1.45e-5	Prostate cancer;
THYM	cis	rs7669967	0.576	rs2880418	chr4:156069879	A/G	cg17641028	chr4:156585641	NA	-0.56	-4.99	-0.46	2.73e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs56309584	0.715	rs3027246	chr17:8131223	C/T	cg08322244	chr17:8066669	VAMP2	-0.56	-5.07	-0.46	1.95e-6	Initial pursuit acceleration;
THYM	cis	rs10463554	0.963	rs1552916	chr5:102337740	A/G	cg23492399	chr5:102201601	PAM	-0.64	-4.98	-0.46	2.83e-6	Parkinson's disease;
THYM	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg08968635	chr6:28129556	ZNF389	0.71	5.58	0.5	2.28e-7	Parkinson's disease;
THYM	cis	rs67311347	0.577	rs1317217	chr3:40271697	T/G	cg09455208	chr3:40491958	NA	0.43	4.54	0.42	1.65e-5	Renal cell carcinoma;
THYM	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg02389323	chr16:88786976	FAM38A	0.99	5.83	0.51	7.59e-8	Plateletcrit;
THYM	cis	rs870825	0.518	rs56034065	chr4:185655402	A/G	cg27112742	chr4:185696749	ACSL1	-0.94	-4.89	-0.45	4.04e-6	Blood protein levels;
THYM	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg00071950	chr4:10020882	SLC2A9	-0.68	-7.07	-0.59	2.61e-10	Bone mineral density;
THYM	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs9674544	0.792	rs8076012	chr17:47101989	G/A	cg11673840	chr17:47092156	IGF2BP1	-0.58	-7.96	-0.63	3.69e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg03676636	chr4:99064102	C4orf37	0.42	6.16	0.53	1.78e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21659725	chr3:3221576	CRBN	0.89	9.76	0.71	5.32e-16	Intelligence (multi-trait analysis);
THYM	cis	rs2663905	0.560	rs1879454	chr15:81377717	C/A	cg27419860	chr15:81426477	C15orf26	-0.75	-5.31	-0.48	7.05e-7	QT interval (drug interaction);
THYM	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg08916839	chr5:415575	AHRR	1.14	6.87	0.58	6.77e-10	Fat distribution (HIV);
THYM	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg11941060	chr3:133502564	NA	-0.73	-6.23	-0.54	1.24e-8	Iron status biomarkers;
THYM	cis	rs4595586	0.545	rs7294600	chr12:39373416	A/G	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg10802521	chr3:52805072	NEK4	-0.7	-5.93	-0.52	4.97e-8	Bipolar disorder;
THYM	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg11764359	chr7:65958608	NA	-0.66	-5.2	-0.47	1.15e-6	Aortic root size;
THYM	cis	rs17608059	0.545	rs9944522	chr17:13918783	C/T	cg11395062	chr17:14139857	CDRT15	0.7	5.59	0.5	2.21e-7	Temperament;
THYM	cis	rs6877440	1.000	rs6877440	chr5:109044067	C/T	cg17395555	chr5:108820864	NA	-0.55	-4.65	-0.43	1.09e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs55883249	0.957	rs10495572	chr2:9734859	C/G	cg23886495	chr2:9695866	ADAM17	-0.8	-5.06	-0.46	2.01e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg13010199	chr12:38710504	ALG10B	0.69	5.19	0.47	1.19e-6	Heart rate;
THYM	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg18252515	chr7:66147081	NA	-1.45	-8.82	-0.67	5.41e-14	Diabetic kidney disease;
THYM	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg17143192	chr8:8559678	CLDN23	0.93	6.95	0.58	4.51e-10	Obesity-related traits;
THYM	cis	rs17443541	0.507	rs7562008	chr2:200454560	A/G	cg01795955	chr2:200468626	NA	-0.71	-4.69	-0.43	9.29e-6	Intelligence (multi-trait analysis);
THYM	cis	rs5769765	0.837	rs7284417	chr22:50314346	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-6.3	-0.54	9.33e-9	Schizophrenia;
THYM	cis	rs10858396	0.602	rs9410019	chr9:138275622	C/T	cg04393196	chr9:139090421	LHX3	0.48	4.89	0.45	4.04e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs3126085	0.935	rs11589587	chr1:152184129	T/C	cg10321714	chr1:152280068	FLG	-0.75	-5.5	-0.49	3.22e-7	Atopic dermatitis;
THYM	cis	rs6700896	0.931	rs11208711	chr1:66147846	G/T	cg04111102	chr1:66153794	NA	0.57	5.42	0.49	4.47e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg14456004	chr13:21872349	NA	1.26	10.86	0.74	2.49e-18	White matter hyperintensity burden;
THYM	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg25703541	chr22:24373054	LOC391322	-0.58	-4.57	-0.42	1.46e-5	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.15	-0.59	1.75e-10	Triglycerides;
THYM	cis	rs7617773	0.743	rs13071960	chr3:48367537	A/G	cg02219026	chr3:48282209	ZNF589	-0.67	-4.69	-0.43	9.05e-6	Coronary artery disease;
THYM	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-5.4	-0.48	4.92e-7	Hemoglobin concentration;
THYM	cis	rs4294134	0.545	rs11534080	chr7:135247528	C/T	cg08396481	chr7:135194601	CNOT4	-0.74	-4.48	-0.42	2.11e-5	Paget's disease;
THYM	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg03929089	chr4:120376271	NA	-0.97	-7.74	-0.62	1.06e-11	Coronary artery disease;
THYM	cis	rs2070677	0.799	rs3020498	chr10:135379710	A/C	cg20169779	chr10:135381914	SYCE1	0.79	5.76	0.51	1.01e-7	Gout;
THYM	cis	rs61931739	0.534	rs2087128	chr12:34000173	T/C	cg06521331	chr12:34319734	NA	-0.91	-8.47	-0.66	3.07e-13	Morning vs. evening chronotype;
THYM	cis	rs72627509	0.680	rs66790703	chr4:57773908	G/A	cg26694713	chr4:57773883	REST	0.75	4.83	0.44	5.13e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg04398451	chr17:18023971	MYO15A	-0.92	-8.71	-0.67	9.4e-14	Total body bone mineral density;
THYM	cis	rs13102973	0.611	rs4298187	chr4:135886186	G/A	cg14419869	chr4:135874104	NA	0.89	8.23	0.65	9.64e-13	Subjective well-being;
THYM	cis	rs7172677	1.000	rs4886422	chr15:75426723	C/T	cg09165964	chr15:75287851	SCAMP5	-0.6	-4.75	-0.44	7.13e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs28719689	0.892	rs28415621	chr8:1270475	C/T	cg11592242	chr8:1263433	NA	0.73	4.6	0.43	1.32e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg22875332	chr1:76189707	ACADM	0.88	11.06	0.75	9.05e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6163	0.508	rs12776506	chr10:104532828	A/G	cg04362960	chr10:104952993	NT5C2	0.68	5.42	0.49	4.51e-7	Waist circumference;Hip circumference;
THYM	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6840360	0.571	rs7674244	chr4:152488302	T/C	cg22705602	chr4:152727874	NA	-0.77	-8.64	-0.66	1.36e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg26028573	chr6:26043587	HIST1H2BB	0.52	4.59	0.43	1.35e-5	Blood metabolite levels;
THYM	cis	rs9905704	0.918	rs11650343	chr17:56919549	G/A	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.89e-6	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg03676636	chr4:99064102	C4orf37	0.46	6.83	0.57	8.08e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7089973	0.564	rs55671354	chr10:116571281	T/C	cg08188268	chr10:116634841	FAM160B1	-0.27	-4.67	-0.43	9.84e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7695732	0.595	rs2609275	chr4:89894626	A/G	cg17769793	chr4:89976368	FAM13A	-0.5	-5.57	-0.5	2.36e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg00376283	chr12:123451042	ABCB9	0.73	4.97	0.45	2.96e-6	Neutrophil percentage of white cells;
THYM	cis	rs6906287	0.647	rs12192682	chr6:118863594	A/G	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg18230493	chr5:56204884	C5orf35	0.63	4.8	0.44	5.9e-6	Initial pursuit acceleration;
THYM	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg04455712	chr21:45112962	RRP1B	0.49	4.46	0.42	2.21e-5	Mean corpuscular volume;
THYM	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.74	5.12	0.47	1.58e-6	Height;
THYM	cis	rs240764	0.658	rs2132169	chr6:101177663	C/A	cg21058520	chr6:100914733	NA	0.6	5.29	0.48	7.79e-7	Neuroticism;
THYM	cis	rs7975161	0.572	rs4614534	chr12:104597917	C/T	cg25273343	chr12:104657179	TXNRD1	0.71	4.85	0.45	4.77e-6	Toenail selenium levels;
THYM	cis	rs1387259	0.758	rs2634670	chr12:48771877	G/A	cg21466736	chr12:48725269	NA	-0.6	-5.43	-0.49	4.29e-7	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg02953382	chr22:24373134	LOC391322	-0.81	-7.97	-0.63	3.51e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11039798	1.000	rs10769383	chr11:48592510	C/G	cg24672777	chr11:48374446	OR4C45	-1.05	-6.02	-0.53	3.31e-8	Axial length;
THYM	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg27170947	chr2:26402098	FAM59B	-0.62	-5.01	-0.46	2.5e-6	Gut microbiome composition (summer);
THYM	trans	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs2237457	0.525	rs2715114	chr7:50704837	G/T	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.48e-6	Schizophrenia (treatment resistant);
THYM	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9913156	0.708	rs9915105	chr17:4568742	G/C	cg19197139	chr17:4613644	ARRB2	-0.78	-5.0	-0.46	2.66e-6	Lymphocyte counts;
THYM	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg13147721	chr7:65941812	NA	0.76	4.93	0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs7264396	0.836	rs41293080	chr20:34187697	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-4.5	-0.42	1.89e-5	Total cholesterol levels;
THYM	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.59	-0.61	2.22e-11	Personality dimensions;
THYM	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg12826209	chr6:26865740	GUSBL1	0.85	4.68	0.43	9.63e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs8114671	0.562	rs8117491	chr20:33510120	T/C	cg08999081	chr20:33150536	PIGU	0.63	5.21	0.47	1.09e-6	Height;
THYM	cis	rs6502050	0.835	rs8064935	chr17:80180178	T/C	cg03388043	chr17:80084554	CCDC57	-0.64	-5.3	-0.48	7.51e-7	Life satisfaction;
THYM	cis	rs9457247	0.534	rs9366078	chr6:167399512	A/G	cg00271210	chr6:167070053	RPS6KA2	0.48	4.72	0.44	8e-6	Crohn's disease;
THYM	trans	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17712092	chr4:129076599	LARP1B	0.88	7.36	0.6	6.44e-11	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg14349672	chr11:133703707	NA	-0.56	-4.97	-0.45	2.97e-6	Childhood ear infection;
THYM	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg11366901	chr6:160182831	ACAT2	1.05	9.61	0.7	1.11e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg07606381	chr6:8435919	SLC35B3	0.61	4.45	0.42	2.31e-5	Motion sickness;
THYM	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg00129232	chr17:37814104	STARD3	-0.75	-5.25	-0.47	9.36e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg05025164	chr4:1340916	KIAA1530	-0.7	-5.4	-0.48	4.85e-7	Obesity-related traits;
THYM	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	5.54	0.49	2.69e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg21775007	chr8:11205619	TDH	0.63	5.05	0.46	2.16e-6	Retinal vascular caliber;
THYM	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg01579765	chr21:45077557	HSF2BP	0.5	8.28	0.65	7.73e-13	Mean corpuscular volume;
THYM	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg11757124	chr7:157526947	PTPRN2	-0.65	-5.29	-0.48	7.92e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs3812049	0.611	rs251393	chr5:127533085	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	5.6	0.5	2.06e-7	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs4606347	0.789	rs61780877	chr1:66165816	C/A	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs1451375	0.698	rs56766899	chr7:50648938	T/C	cg18232548	chr7:50535776	DDC	0.69	5.35	0.48	6.03e-7	Malaria;
THYM	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg23711669	chr6:146136114	FBXO30	0.84	7.79	0.62	8.39e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg06108461	chr20:60628389	TAF4	-1.04	-8.24	-0.65	9.18e-13	Body mass index;
THYM	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-5.81	-0.51	8.27e-8	Total cholesterol levels;
THYM	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg07424592	chr7:64974309	NA	-1.04	-5.27	-0.48	8.52e-7	Diabetic kidney disease;
THYM	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg24253500	chr15:84953950	NA	0.54	4.56	0.42	1.53e-5	Schizophrenia;
THYM	cis	rs6840360	0.554	rs6849111	chr4:152708874	T/C	cg22705602	chr4:152727874	NA	-0.82	-11.15	-0.75	6.01e-19	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg10360139	chr7:1886902	MAD1L1	-0.59	-5.13	-0.47	1.5e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs6980334	0.680	rs10244249	chr7:137790650	A/C	cg18769353	chr7:137028617	PTN	0.64	5.06	0.46	2.01e-6	Blood metabolite ratios;
THYM	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg16926213	chr1:1841314	NA	0.51	5.19	0.47	1.2e-6	Body mass index;
THYM	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg14458575	chr2:238380390	NA	0.9	7.53	0.61	2.94e-11	Prostate cancer;
THYM	cis	rs447921	0.861	rs12950218	chr17:74409547	G/A	cg17201438	chr17:74438067	UBE2O	0.81	5.85	0.51	6.9e-8	Mitochondrial DNA levels;
THYM	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg04824913	chr4:887549	GAK	-0.76	-6.0	-0.52	3.6e-8	Systemic sclerosis;
THYM	cis	rs7586879	0.765	rs10171663	chr2:25086431	T/C	cg01884057	chr2:25150051	NA	0.54	4.86	0.45	4.64e-6	Body mass index;
THYM	cis	rs6456156	0.586	rs2285148	chr6:167490999	G/T	cg00271210	chr6:167070053	RPS6KA2	-0.55	-5.62	-0.5	1.91e-7	Primary biliary cholangitis;
THYM	cis	rs11096990	0.855	rs2711986	chr4:39153878	G/A	cg24403649	chr4:39172243	NA	-0.6	-5.09	-0.46	1.77e-6	Cognitive function;
THYM	cis	rs919433	0.680	rs7568250	chr2:198409611	G/A	cg00792783	chr2:198669748	PLCL1	0.81	5.51	0.49	3.1e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs3125734	0.633	rs4979782	chr10:63998527	C/T	cg09941381	chr10:64027924	RTKN2	-0.55	-4.56	-0.42	1.51e-5	Rheumatoid arthritis;
THYM	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.75e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.63	5.38	0.48	5.35e-7	Lung disease severity in cystic fibrosis;
THYM	cis	rs7020830	0.861	rs2291589	chr9:37079661	T/G	cg14294708	chr9:37120828	ZCCHC7	1.26	16.19	0.86	4.51e-29	Schizophrenia;
THYM	trans	rs561341	0.714	rs547473	chr17:30297560	T/G	cg20587970	chr11:113659929	NA	-1.26	-9.01	-0.68	2.16e-14	Hip circumference adjusted for BMI;
THYM	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg04772025	chr11:68637568	NA	0.62	6.55	0.56	2.96e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg08133631	chr1:26527909	CATSPER4	-0.61	-5.08	-0.46	1.92e-6	Obesity-related traits;
THYM	cis	rs965469	0.895	rs6051843	chr20:3400538	A/G	cg25506879	chr20:3388711	C20orf194	-0.84	-5.13	-0.47	1.51e-6	IFN-related cytopenia;
THYM	cis	rs11166927	0.594	rs4736007	chr8:140817192	A/G	cg16909799	chr8:140841666	TRAPPC9	0.55	4.49	0.42	1.98e-5	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs2439831	0.681	rs28653441	chr15:43677262	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	6.89	0.58	5.93e-10	Lung cancer in ever smokers;
THYM	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.76	8.44	0.65	3.53e-13	Eosinophil percentage of white cells;
THYM	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg05887092	chr17:76393375	PGS1	0.41	4.67	0.43	9.98e-6	HDL cholesterol levels;
THYM	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg14004847	chr7:1930337	MAD1L1	0.64	5.17	0.47	1.3e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg18301423	chr5:131593218	PDLIM4	0.5	4.7	0.43	8.95e-6	Acylcarnitine levels;
THYM	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs9359856	0.529	rs72919916	chr6:90489773	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs4589258	0.750	rs1547882	chr11:90471688	G/A	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.81	-0.44	5.58e-6	Intelligence (multi-trait analysis);
THYM	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg14893161	chr1:205819251	PM20D1	-0.6	-4.6	-0.43	1.32e-5	Menarche (age at onset);
THYM	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg12386194	chr3:101231763	SENP7	0.69	5.16	0.47	1.34e-6	Colorectal cancer;
THYM	cis	rs7705042	0.865	rs6580225	chr5:141489381	G/C	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.85	-0.51	7.09e-8	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg12863693	chr15:85201151	NMB	0.62	5.57	0.5	2.41e-7	Schizophrenia;
THYM	cis	rs758324	0.732	rs45512	chr5:131439336	A/T	cg16205897	chr5:131564050	P4HA2	0.57	4.86	0.45	4.56e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg09904177	chr6:26538194	HMGN4	-0.62	-5.14	-0.47	1.44e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.49	-4.51	-0.42	1.82e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs1065852	0.526	rs4822079	chr22:42394612	G/C	cg08431931	chr22:42394659	WBP2NL	0.69	5.66	0.5	1.6e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs7084402	0.967	rs1427198	chr10:60274970	T/G	cg07615347	chr10:60278583	BICC1	-0.53	-4.65	-0.43	1.08e-5	Refractive error;
THYM	cis	rs2898681	0.581	rs730247	chr4:53680696	T/G	cg00338735	chr4:53728038	RASL11B	0.6	5.56	0.5	2.5e-7	Optic nerve measurement (cup area);
THYM	cis	rs4474465	0.850	rs10899552	chr11:78262262	G/A	cg19901956	chr11:77921274	USP35	0.66	4.86	0.45	4.68e-6	Alzheimer's disease (survival time);
THYM	cis	rs9790314	1.000	rs189270	chr3:161063504	T/C	cg04691961	chr3:161091175	C3orf57	-0.62	-5.37	-0.48	5.6e-7	Morning vs. evening chronotype;
THYM	cis	rs7523273	0.565	rs2796250	chr1:207903654	T/C	cg22525895	chr1:207977042	MIR29B2	-0.53	-5.08	-0.46	1.91e-6	Schizophrenia;
THYM	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs6032067	0.538	rs62206429	chr20:43730333	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.41	-4.48	-0.42	2.07e-5	Blood protein levels;
THYM	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06481639	chr22:41940642	POLR3H	-0.81	-5.55	-0.49	2.58e-7	Vitiligo;
THYM	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.65	5.22	0.47	1.05e-6	Blood protein levels;
THYM	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	trans	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Bladder cancer;
THYM	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.16	-0.75	5.56e-19	Primary sclerosing cholangitis;
THYM	cis	rs2717559	0.522	rs2572922	chr8:143871652	G/A	cg17252645	chr8:143867129	LY6D	0.78	9.27	0.69	6.12e-15	Urinary tract infection frequency;
THYM	cis	rs12137294	0.794	rs1172160	chr1:205207015	G/A	cg17889831	chr1:205181581	DSTYK	-0.41	-5.05	-0.46	2.13e-6	Red cell distribution width;
THYM	cis	rs16949788	1.000	rs74521803	chr15:66832261	T/G	cg08120210	chr15:66682733	MAP2K1	-0.77	-4.56	-0.42	1.54e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7267979	0.903	rs2500423	chr20:25374882	G/A	cg08601574	chr20:25228251	PYGB	-0.58	-4.71	-0.43	8.54e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg05368731	chr17:41323189	NBR1	1.26	11.54	0.76	9.06e-20	Menopause (age at onset);
THYM	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg20891283	chr12:69753455	YEATS4	0.85	7.17	0.59	1.61e-10	Blood protein levels;
THYM	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg00278517	chr6:167070616	RPS6KA2	-0.32	-4.47	-0.42	2.2e-5	Primary biliary cholangitis;
THYM	cis	rs10992471	0.603	rs12341817	chr9:95252152	C/T	cg14631576	chr9:95140430	CENPP	-0.99	-9.94	-0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs1335645	0.570	rs61804560	chr1:111644247	G/A	cg00321911	chr1:111669324	DRAM2	-1.2	-6.73	-0.57	1.3e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs17125944	0.686	rs7141335	chr14:53336934	C/T	cg00686598	chr14:53173677	PSMC6	-1.08	-4.81	-0.44	5.6e-6	Alzheimer's disease (late onset);
THYM	cis	rs1018836	0.851	rs7004287	chr8:91620842	G/C	cg16814680	chr8:91681699	NA	-0.99	-9.24	-0.69	7.07e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs747334	0.777	rs12219023	chr10:92716097	T/G	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.6	7.71	0.62	1.22e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg17211192	chr8:82754475	SNX16	-0.82	-7.41	-0.61	5.09e-11	Diastolic blood pressure;
THYM	cis	rs28647808	1.000	rs28556828	chr9:136273106	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg11965913	chr1:205819406	PM20D1	0.93	10.1	0.72	1.02e-16	Menarche (age at onset);
THYM	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg16342193	chr10:102329863	NA	-0.53	-5.28	-0.48	8.1e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9563576	0.778	rs9563567	chr13:58564813	C/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg08498830	chr11:832797	CD151	-0.62	-4.51	-0.42	1.82e-5	Mean platelet volume;
THYM	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg23422044	chr7:1970798	MAD1L1	-0.94	-6.45	-0.55	4.6e-9	Bipolar disorder;
THYM	cis	rs490234	0.627	rs4838276	chr9:128364901	A/G	cg14078157	chr9:128172775	NA	0.74	5.99	0.52	3.68e-8	Mean arterial pressure;
THYM	cis	rs910187	0.624	rs6018311	chr20:45792634	A/G	cg27589058	chr20:45804311	EYA2	-0.58	-4.83	-0.44	5.21e-6	Migraine;
THYM	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	7.35	0.6	6.91e-11	Platelet count;
THYM	cis	rs259282	0.669	rs731673	chr19:33132295	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.71	5.87	0.52	6.45e-8	Schizophrenia;
THYM	cis	rs1451375	0.550	rs10239830	chr7:50603829	A/G	cg18232548	chr7:50535776	DDC	0.67	5.03	0.46	2.31e-6	Malaria;
THYM	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg07884673	chr3:53033167	SFMBT1	1.13	5.83	0.51	7.45e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg20242066	chr2:136595261	LCT	-0.54	-6.83	-0.57	7.89e-10	Mosquito bite size;
THYM	cis	rs1003719	0.788	rs2835593	chr21:38465873	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg21231944	chr12:82153410	PPFIA2	-0.64	-4.76	-0.44	7.01e-6	Resting heart rate;
THYM	cis	rs420259	0.516	rs120962	chr16:23589986	A/G	cg00143387	chr16:23521605	GGA2	0.76	5.6	0.5	2.1e-7	Bipolar disorder;
THYM	cis	rs10791111	1	rs10791111	chr11:130856099	T/G	cg05962950	chr11:130786565	SNX19	0.74	5.64	0.5	1.75e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs8078723	0.630	rs60137005	chr17:38129996	A/T	cg17467752	chr17:38218738	THRA	0.73	5.48	0.49	3.47e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs6687430	0.532	rs9430149	chr1:10612820	G/C	cg20482658	chr1:10539492	PEX14	0.5	6.32	0.54	8.53e-9	Hand grip strength;
THYM	cis	rs11089937	0.864	rs4820338	chr22:22521058	C/G	cg21401457	chr22:22472743	NA	0.54	4.53	0.42	1.69e-5	Periodontitis (PAL4Q3);
THYM	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs7617773	0.743	rs11716371	chr3:48362750	C/T	cg02219026	chr3:48282209	ZNF589	-0.69	-4.83	-0.44	5.12e-6	Coronary artery disease;
THYM	cis	rs950880	0.710	rs3821203	chr2:102996872	C/T	cg03938978	chr2:103052716	IL18RAP	-0.5	-4.46	-0.42	2.24e-5	Serum protein levels (sST2);
THYM	cis	rs12681287	0.609	rs13281414	chr8:87495254	A/C	cg27223183	chr8:87520930	FAM82B	-0.71	-5.09	-0.46	1.82e-6	Caudate activity during reward;
THYM	cis	rs4808199	0.895	rs4808196	chr19:19476520	G/A	cg03709012	chr19:19516395	GATAD2A	1.23	7.48	0.61	3.68e-11	Nonalcoholic fatty liver disease;
THYM	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg24253500	chr15:84953950	NA	0.54	4.5	0.42	1.89e-5	Schizophrenia;
THYM	cis	rs12458462	0.851	rs60298379	chr18:77488422	C/T	cg11879182	chr18:77439856	CTDP1	0.82	7.9	0.63	4.96e-12	Monocyte count;
THYM	cis	rs12530845	0.830	rs73721678	chr7:135355710	T/G	cg23117316	chr7:135346802	PL-5283	-0.73	-6.24	-0.54	1.19e-8	Red blood cell traits;
THYM	cis	rs7267979	0.966	rs2387885	chr20:25415224	G/A	cg08601574	chr20:25228251	PYGB	-0.58	-4.69	-0.43	8.97e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg24250549	chr1:154909240	PMVK	0.79	6.82	0.57	8.33e-10	Prostate cancer;
THYM	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg00383909	chr3:49044727	WDR6	1.21	7.52	0.61	3.1e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs4731207	0.596	rs10500098	chr7:124658055	C/G	cg05285228	chr7:124571219	POT1	-0.72	-5.53	-0.49	2.81e-7	Cutaneous malignant melanoma;
THYM	cis	rs7590720	1.000	rs1991533	chr2:216908910	T/C	cg12620499	chr2:216877984	MREG	0.81	5.52	0.49	2.88e-7	Alcohol dependence;
THYM	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7107174	1.000	rs2511182	chr11:77982130	G/C	cg19901956	chr11:77921274	USP35	-0.68	-5.25	-0.47	9.31e-7	Testicular germ cell tumor;
THYM	cis	rs89107	0.551	rs2078383	chr6:118706643	C/T	cg21191810	chr6:118973309	C6orf204	0.52	4.99	0.46	2.67e-6	Cardiac structure and function;
THYM	cis	rs2836633	0.931	rs2836635	chr21:40069850	A/G	cg05519781	chr21:40033154	ERG	0.65	5.95	0.52	4.56e-8	Coronary artery disease;
THYM	cis	rs9486719	1.000	rs11152959	chr6:96900272	C/T	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs10752881	1.000	rs10797802	chr1:182973158	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.63	-4.94	-0.45	3.36e-6	Colorectal cancer;
THYM	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg26384229	chr12:38710491	ALG10B	0.99	7.63	0.62	1.81e-11	Bladder cancer;
THYM	cis	rs354225	0.544	rs10170355	chr2:54808322	G/A	cg23486701	chr2:54789491	SPTBN1	0.36	4.96	0.45	3.11e-6	Schizophrenia;
THYM	cis	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs4242434	0.819	rs6558167	chr8:22473850	T/C	cg11461670	chr8:22454935	PDLIM2	-0.32	-6.17	-0.53	1.68e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs12579753	0.956	rs7965168	chr12:82184467	C/A	cg07988820	chr12:82153109	PPFIA2	-0.76	-4.83	-0.44	5.13e-6	Resting heart rate;
THYM	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs55728055	0.661	rs62237833	chr22:32012141	G/A	cg01338084	chr22:32026380	PISD	1.39	6.0	0.52	3.57e-8	Age-related hearing impairment;
THYM	cis	rs9534288	0.762	rs9534264	chr13:46541673	T/A	cg15192986	chr13:46630673	CPB2	-0.6	-4.52	-0.42	1.8e-5	Blood protein levels;
THYM	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg01831904	chr17:28903510	LRRC37B2	-1.0	-4.82	-0.44	5.4e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg09165964	chr15:75287851	SCAMP5	0.6	4.59	0.43	1.38e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg00484396	chr16:3507460	NAT15	-0.62	-5.38	-0.48	5.46e-7	Tuberculosis;
THYM	cis	rs9807989	0.507	rs10200952	chr2:103027651	A/C	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg13852791	chr20:30311386	BCL2L1	0.85	6.24	0.54	1.23e-8	Mean corpuscular hemoglobin;
THYM	cis	rs7172809	0.524	rs74025105	chr15:77572357	G/A	cg22256960	chr15:77711686	NA	-0.65	-4.86	-0.45	4.71e-6	Glucose homeostasis traits;
THYM	cis	rs1021993	1.000	rs2660643	chr1:209472439	T/C	cg06155620	chr1:209527581	NA	0.58	4.67	0.43	9.97e-6	Gut microbiome composition (winter);
THYM	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg00376283	chr12:123451042	ABCB9	0.71	4.75	0.44	7.32e-6	Neutrophil percentage of white cells;
THYM	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg15212455	chr7:39170539	POU6F2	0.63	5.81	0.51	8.33e-8	IgG glycosylation;
THYM	cis	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-5.43	-0.49	4.23e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4242434	0.699	rs878053	chr8:22483849	T/C	cg01710189	chr8:22454888	PDLIM2	-0.5	-5.13	-0.47	1.53e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg27572855	chr1:25598939	RHD	-0.65	-4.93	-0.45	3.43e-6	Erythrocyte sedimentation rate;
THYM	cis	rs6840360	0.571	rs7685697	chr4:152558849	A/G	cg17479576	chr4:152424074	FAM160A1	-0.78	-5.66	-0.5	1.62e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03647317	chr4:187891568	NA	0.83	9.2	0.69	8.27e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10479542	0.766	rs9286047	chr5:178969147	C/A	cg05457628	chr5:178986728	RUFY1	-0.55	-4.97	-0.45	2.92e-6	Lung cancer;
THYM	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg16680214	chr1:154839983	KCNN3	-0.58	-7.24	-0.6	1.17e-10	Prostate cancer;
THYM	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-4.98	-0.45	2.89e-6	Chronic sinus infection;
THYM	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg14784868	chr12:69753453	YEATS4	0.79	6.39	0.55	6.19e-9	Blood protein levels;
THYM	cis	rs888194	0.934	rs3742015	chr12:110017125	T/C	cg10504392	chr12:110044639	NA	0.6	5.82	0.51	8.07e-8	Neuroticism;
THYM	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg24069376	chr3:38537580	EXOG	0.68	6.73	0.57	1.26e-9	Electrocardiographic conduction measures;
THYM	cis	rs11031096	0.711	rs1348309	chr11:4202000	A/T	cg22027985	chr11:4115532	RRM1	-0.55	-5.06	-0.46	2.06e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4148689	1.000	rs2283056	chr7:117132179	A/G	cg17204129	chr7:117119601	CFTR	-0.59	-4.7	-0.43	8.83e-6	Gout;
THYM	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg24209194	chr3:40518798	ZNF619	0.67	5.53	0.49	2.85e-7	Renal cell carcinoma;
THYM	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg17264618	chr3:40429014	ENTPD3	-0.5	-4.79	-0.44	6.03e-6	Renal cell carcinoma;
THYM	cis	rs4907240	0.961	rs66727130	chr2:97324991	G/C	cg18419276	chr2:96971862	SNRNP200	-0.4	-4.64	-0.43	1.13e-5	Event-related brain oscillations;
THYM	cis	rs7909074	0.651	rs10900127	chr10:45390103	C/A	cg05187965	chr10:45406764	TMEM72	-0.48	-4.68	-0.43	9.36e-6	Mean corpuscular volume;
THYM	cis	rs227425	0.544	rs7157289	chr14:70415359	C/T	cg12046056	chr14:71067695	MED6	0.54	5.03	0.46	2.28e-6	Bone mineral density;
THYM	cis	rs367615	0.661	rs9326773	chr5:108833523	C/T	cg17395555	chr5:108820864	NA	0.76	9.83	0.71	3.84e-16	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs17739167	0.550	rs4924589	chr15:42229632	C/T	cg20935245	chr15:42234343	EHD4	0.41	4.96	0.45	3.14e-6	Monocyte count;
THYM	cis	rs1450985	0.966	rs6764606	chr3:64020447	C/T	cg06859735	chr3:64012970	NA	-0.41	-4.5	-0.42	1.95e-5	Breast cancer;
THYM	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22496380	chr5:211416	CCDC127	-1.28	-7.72	-0.62	1.17e-11	Breast cancer;
THYM	cis	rs4722585	0.533	rs757371	chr7:26199207	A/G	cg07876897	chr7:26191696	NFE2L3	0.56	4.47	0.42	2.16e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs2639990	1.000	rs609303	chr18:72895242	C/T	cg11568697	chr18:72916393	ZADH2	1.2	5.71	0.51	1.29e-7	Vascular endothelial growth factor levels;
THYM	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg04944784	chr2:26401820	FAM59B	1.09	8.74	0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs9790314	1.000	rs336591	chr3:161078080	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-6.54	-0.56	3.03e-9	Morning vs. evening chronotype;
THYM	cis	rs34638657	0.872	rs2967326	chr16:82188246	A/G	cg09894383	chr16:82067445	HSD17B2	-0.52	-5.23	-0.47	1.01e-6	Lung adenocarcinoma;
THYM	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg24733560	chr20:60626293	TAF4	0.6	6.2	0.54	1.45e-8	Body mass index;
THYM	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07157834	chr1:205819609	PM20D1	0.87	8.66	0.66	1.19e-13	Menarche (age at onset);
THYM	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg03476357	chr21:30257390	N6AMT1	-0.61	-4.64	-0.43	1.1e-5	Dental caries;
THYM	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.72	4.65	0.43	1.07e-5	Lymphocyte percentage of white cells;
THYM	cis	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-5.83	-0.51	7.47e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg26597838	chr10:835615	NA	1.52	11.37	0.76	2.05e-19	Eosinophil percentage of granulocytes;
THYM	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg09549813	chr16:4587862	C16orf5	-0.59	-6.84	-0.57	7.79e-10	Schizophrenia;
THYM	cis	rs595982	0.546	rs9941490	chr19:49396737	G/A	cg19746536	chr19:49375674	PPP1R15A	0.99	9.48	0.7	2.18e-15	Red cell distribution width;
THYM	cis	rs9880211	0.613	rs67109185	chr3:135827392	G/A	cg21827317	chr3:136751795	NA	-0.72	-5.21	-0.47	1.11e-6	Body mass index;Height;
THYM	cis	rs2229238	0.911	rs6681207	chr1:154517217	T/C	cg21262032	chr1:154437693	IL6R	-0.61	-5.15	-0.47	1.39e-6	Coronary heart disease;
THYM	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg21100191	chr22:23484243	RTDR1	0.73	6.5	0.55	3.66e-9	Bone mineral density;
THYM	cis	rs12681287	0.604	rs34227066	chr8:87449366	C/T	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs9311676	0.656	rs11712139	chr3:58384775	C/T	cg26110898	chr3:58419937	PDHB	0.43	4.61	0.43	1.27e-5	Systemic lupus erythematosus;
THYM	cis	rs17122693	0.710	rs77598393	chr14:51159342	T/G	cg04730355	chr14:51134070	SAV1	1.01	6.03	0.53	3.14e-8	Cognitive performance;
THYM	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg20283391	chr11:68216788	NA	-0.68	-5.11	-0.46	1.69e-6	Total body bone mineral density;
THYM	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs10486003	1.000	rs6948859	chr7:97239206	G/C	cg19056687	chr7:97922028	BAIAP2L1;BRI3	1.04	4.85	0.45	4.78e-6	Response to platinum-based agents;
THYM	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg13390004	chr1:15929781	NA	0.63	4.83	0.44	5.25e-6	Systolic blood pressure;
THYM	cis	rs35934224	0.783	rs5993849	chr22:19866194	G/C	cg11182965	chr22:19864308	TXNRD2	-0.84	-6.41	-0.55	5.53e-9	Glaucoma (primary open-angle);
THYM	cis	rs3767633	0.925	rs4579731	chr1:161766859	G/A	cg27495845	chr1:161693088	FCRLB	-0.51	-4.69	-0.43	9.13e-6	IgG glycosylation;
THYM	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg24375607	chr4:120327624	NA	0.64	5.11	0.46	1.67e-6	Corneal astigmatism;
THYM	cis	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg08133631	chr1:26527909	CATSPER4	-0.57	-4.69	-0.43	9.29e-6	Obesity-related traits;
THYM	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg00129232	chr17:37814104	STARD3	0.71	4.8	0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs1865721	0.771	rs6566092	chr18:73136496	C/T	cg26385618	chr18:73139727	C18orf62	-0.68	-5.12	-0.47	1.57e-6	Intelligence;
THYM	cis	rs13102973	0.640	rs6535053	chr4:135882242	T/C	cg14419869	chr4:135874104	NA	0.85	7.05	0.59	2.84e-10	Subjective well-being;
THYM	cis	rs36051895	0.664	rs7851455	chr9:5100501	G/C	cg02405213	chr9:5042618	JAK2	-1.01	-11.42	-0.76	1.59e-19	Pediatric autoimmune diseases;
THYM	cis	rs6867032	1.000	rs16902321	chr5:2015148	A/G	cg26168224	chr5:2018326	NA	1.29	15.53	0.85	8.25e-28	Gut microbiome composition (winter);
THYM	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg18681998	chr4:17616180	MED28	0.79	6.77	0.57	1.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9905704	0.918	rs2567901	chr17:56783255	C/T	cg12560992	chr17:57184187	TRIM37	0.67	4.68	0.43	9.59e-6	Testicular germ cell tumor;
THYM	cis	rs2235649	0.833	rs9929262	chr16:1851928	T/C	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs7616559	0.849	rs1384542	chr3:156756660	C/T	cg15697575	chr3:156784781	NA	-0.42	-5.37	-0.48	5.54e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs7193541	0.684	rs4887783	chr16:74700743	G/C	cg01733217	chr16:74700730	RFWD3	1.04	13.1	0.8	5.19e-23	Multiple myeloma;
THYM	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg06917634	chr15:78832804	PSMA4	0.94	8.49	0.66	2.82e-13	Sudden cardiac arrest;
THYM	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg17911788	chr17:44343683	NA	-0.79	-7.48	-0.61	3.65e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg23260525	chr10:116636907	FAM160B1	0.51	5.21	0.47	1.09e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg09436375	chr6:42928200	GNMT	-0.43	-5.72	-0.51	1.23e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	1.03	13.66	0.81	3.81e-24	Subjective well-being;
THYM	cis	rs2836950	0.501	rs2070865	chr21:40715519	C/T	cg11890956	chr21:40555474	PSMG1	-0.59	-5.3	-0.48	7.35e-7	Menarche (age at onset);
THYM	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg08999081	chr20:33150536	PIGU	0.79	7.48	0.61	3.72e-11	Coronary artery disease;
THYM	cis	rs4803468	1.000	rs284654	chr19:41928724	G/A	cg09537434	chr19:41945824	ATP5SL	-1.05	-9.25	-0.69	6.47e-15	Height;
THYM	cis	rs2354432	0.607	rs6703847	chr1:146669444	G/A	cg25205988	chr1:146714368	CHD1L	1.1	4.92	0.45	3.66e-6	Mitochondrial DNA levels;
THYM	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg08994789	chr17:28903642	LRRC37B2	-1.05	-5.39	-0.48	5.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9826463	0.702	rs28365824	chr3:142315114	C/A	cg20824294	chr3:142316082	PLS1	0.64	4.62	0.43	1.2e-5	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.54	-0.42	1.64e-5	Fear of minor pain;
THYM	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.88	0.63	5.43e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2625529	0.824	rs4238449	chr15:72421603	G/A	cg16672083	chr15:72433130	SENP8	-0.54	-4.78	-0.44	6.33e-6	Red blood cell count;
THYM	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg08736216	chr1:53307985	ZYG11A	0.59	5.54	0.49	2.74e-7	Monocyte count;
THYM	cis	rs752010	0.746	rs10749837	chr1:42089471	T/C	cg06885757	chr1:42089581	HIVEP3	0.58	7.33	0.6	7.48e-11	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.62	0.66	1.45e-13	Cognitive test performance;
THYM	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg09165964	chr15:75287851	SCAMP5	-1.06	-10.7	-0.74	5.29e-18	Blood trace element (Zn levels);
THYM	cis	rs2991971	1.000	rs622798	chr1:46015271	T/G	cg15605315	chr1:45957053	TESK2	0.65	5.13	0.47	1.52e-6	High light scatter reticulocyte count;
THYM	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg27129171	chr3:47204927	SETD2	0.8	7.93	0.63	4.18e-12	Colorectal cancer;
THYM	cis	rs2074585	0.806	rs2657949	chr15:90950790	G/A	cg22089800	chr15:90895588	ZNF774	0.7	5.4	0.48	4.97e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
THYM	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg16031515	chr1:205743344	RAB7L1	0.51	5.05	0.46	2.12e-6	Monocyte percentage of white cells;
THYM	cis	rs40363	1.000	rs37773	chr16:3512834	G/A	cg21433313	chr16:3507492	NAT15	0.81	7.34	0.6	7.29e-11	Tuberculosis;
THYM	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg13397359	chr6:42928475	GNMT	0.64	5.74	0.51	1.15e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9355610	0.727	rs2247315	chr6:167370211	A/C	cg23791538	chr6:167370224	RNASET2	0.84	7.49	0.61	3.58e-11	Graves' disease;
THYM	cis	rs7584330	0.518	rs74003105	chr2:238446851	T/C	cg08992911	chr2:238395768	MLPH	0.9	5.47	0.49	3.65e-7	Prostate cancer;
THYM	cis	rs11039798	1.000	rs7102865	chr11:48458361	A/C	cg24672777	chr11:48374446	OR4C45	-1.14	-6.89	-0.58	6.15e-10	Axial length;
THYM	cis	rs9311676	0.632	rs11130646	chr3:58447013	C/G	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs1499972	0.941	rs73183041	chr3:117610500	C/A	cg07612923	chr3:117604196	NA	1.29	5.39	0.48	5.06e-7	Schizophrenia;
THYM	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs7119	0.717	rs12904212	chr15:77815833	C/A	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs10899021	0.790	rs7932194	chr11:74327378	C/G	cg25880958	chr11:74394337	NA	-0.72	-4.72	-0.44	7.99e-6	Response to metformin (IC50);
THYM	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg13683864	chr3:40499215	RPL14	0.92	9.25	0.69	6.51e-15	Renal cell carcinoma;
THYM	cis	rs11651000	0.857	rs11658383	chr17:45842354	A/C	cg24803719	chr17:45855879	NA	-0.57	-5.87	-0.52	6.44e-8	IgG glycosylation;
THYM	cis	rs7084402	0.967	rs1658440	chr10:60323933	T/A	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg26384229	chr12:38710491	ALG10B	1.01	9.54	0.7	1.6e-15	Heart rate;
THYM	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg01528321	chr10:82214614	TSPAN14	0.69	5.93	0.52	4.84e-8	Post bronchodilator FEV1;
THYM	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg10057126	chr4:77819792	ANKRD56	0.7	5.93	0.52	4.87e-8	Emphysema distribution in smoking;
THYM	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg15556689	chr8:8085844	FLJ10661	0.71	6.19	0.54	1.55e-8	Mood instability;
THYM	cis	rs9640161	0.830	rs12703061	chr7:150062545	T/C	cg10018233	chr7:150070692	REPIN1	0.51	8.15	0.64	1.48e-12	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4731207	0.698	rs7782327	chr7:124505951	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs9682041	1.000	rs57508070	chr3:170074374	C/A	cg11886554	chr3:170076028	SKIL	1.18	4.76	0.44	6.95e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg17252645	chr8:143867129	LY6D	-0.81	-9.96	-0.71	1.98e-16	Urinary tract infection frequency;
THYM	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23248424	chr5:179741104	GFPT2	-0.89	-6.48	-0.55	4.09e-9	Height;
THYM	cis	rs6840360	0.571	rs1978955	chr4:152509509	G/A	cg22705602	chr4:152727874	NA	-0.78	-8.16	-0.64	1.38e-12	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs114547492	chr4:119773078	G/C	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs6138458	1.000	rs7268095	chr20:24972333	C/T	cg06937882	chr20:24974362	C20orf3	-0.46	-4.58	-0.43	1.43e-5	Blood protein levels;
THYM	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg02734326	chr4:10020555	SLC2A9	0.76	6.89	0.58	6.16e-10	Bone mineral density;
THYM	cis	rs73110464	0.562	rs2363634	chr12:53354683	A/G	cg16329197	chr12:53359506	NA	-0.59	-4.7	-0.43	8.72e-6	Cancer (pleiotropy);
THYM	cis	rs2625529	0.652	rs7497104	chr15:72154000	C/T	cg16672083	chr15:72433130	SENP8	-0.5	-4.61	-0.43	1.24e-5	Red blood cell count;
THYM	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg16797656	chr11:68205561	LRP5	0.45	4.73	0.44	7.75e-6	Total body bone mineral density;
THYM	cis	rs13102973	0.867	rs4543187	chr4:135906850	G/A	cg14419869	chr4:135874104	NA	0.82	6.86	0.58	7.03e-10	Subjective well-being;
THYM	cis	rs10489202	1.000	rs4657727	chr1:167965241	T/C	cg24449463	chr1:168025552	DCAF6	-0.83	-6.51	-0.56	3.58e-9	Schizophrenia;
THYM	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg17063962	chr7:91808500	NA	1.13	9.91	0.71	2.56e-16	Breast cancer;
THYM	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	10.77	0.74	3.77e-18	Chronic sinus infection;
THYM	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg16571642	chr7:158045996	PTPRN2	0.48	5.32	0.48	6.83e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs12142240	0.698	rs72677599	chr1:46834251	G/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg08645402	chr16:4508243	NA	0.69	5.84	0.51	7.19e-8	Schizophrenia;
THYM	cis	rs11048434	0.761	rs2110191	chr12:9136263	G/A	cg26114124	chr12:9217669	LOC144571	0.47	4.73	0.44	7.93e-6	Sjögren's syndrome;
THYM	cis	rs10779751	0.770	rs12041740	chr1:11236524	G/A	cg08854313	chr1:11322531	MTOR	0.83	7.47	0.61	3.81e-11	Body mass index;
THYM	cis	rs818427	0.737	rs464708	chr5:112154303	T/G	cg04614008	chr5:112630677	MCC	-0.63	-4.48	-0.42	2.09e-5	Total body bone mineral density;
THYM	cis	rs611744	0.905	rs677031	chr8:109152068	G/A	cg21045802	chr8:109455806	TTC35	0.57	4.89	0.45	4.12e-6	Dupuytren's disease;
THYM	cis	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg07460842	chr6:66804631	NA	0.88	5.69	0.5	1.42e-7	Exhaled nitric oxide output;
THYM	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg23281280	chr6:28129359	ZNF389	0.61	4.88	0.45	4.21e-6	Depression;
THYM	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg16586182	chr3:47516702	SCAP	0.65	5.53	0.49	2.84e-7	Colorectal cancer;
THYM	cis	rs332507	0.830	rs4678144	chr3:124404399	C/T	cg14688451	chr3:124303035	KALRN	-0.6	-4.65	-0.43	1.07e-5	Plateletcrit;
THYM	cis	rs28647808	0.881	rs7040821	chr9:136263584	C/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs72687362	0.560	rs58635845	chr8:143384780	C/T	cg21926626	chr8:143382226	TSNARE1	0.42	4.52	0.42	1.77e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1215050	0.740	rs783963	chr4:98989070	A/G	cg17366294	chr4:99064904	C4orf37	0.43	4.78	0.44	6.4e-6	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4363385	0.747	rs1055935	chr1:152975941	C/G	cg13444842	chr1:152974279	SPRR3	-0.6	-4.78	-0.44	6.32e-6	Inflammatory skin disease;
THYM	trans	rs9951602	0.512	rs12607561	chr18:76644284	G/A	cg02800362	chr5:177631904	HNRNPAB	1.11	8.66	0.66	1.21e-13	Obesity-related traits;
THYM	cis	rs500891	0.525	rs12524172	chr6:84069668	C/T	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg10523679	chr1:76189770	ACADM	0.9	9.53	0.7	1.67e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg02569458	chr12:86230093	RASSF9	0.59	5.09	0.46	1.78e-6	Major depressive disorder;
THYM	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg24530246	chr3:53118167	NA	-0.83	-4.78	-0.44	6.39e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg06009448	chr7:1102226	C7orf50	0.46	4.79	0.44	6.06e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg06481639	chr22:41940642	POLR3H	-0.74	-4.85	-0.45	4.81e-6	Vitiligo;
THYM	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs7189233	0.955	rs72801821	chr16:53479652	G/A	cg02965178	chr16:53538660	AKTIP	-0.58	-4.61	-0.43	1.26e-5	Intelligence (multi-trait analysis);
THYM	cis	rs748404	0.631	rs6493083	chr15:43637985	A/G	cg12861797	chr15:43585817	TGM7	0.45	4.75	0.44	7.23e-6	Lung cancer;
THYM	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg18240062	chr17:79603768	NPLOC4	0.56	4.75	0.44	7.07e-6	Eye color traits;
THYM	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg21926883	chr2:100939477	LONRF2	-0.67	-6.21	-0.54	1.37e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg09537434	chr19:41945824	ATP5SL	-1.09	-10.25	-0.72	4.86e-17	Height;
THYM	cis	rs986417	0.818	rs8008804	chr14:61082357	A/T	cg27398547	chr14:60952738	C14orf39	1.26	6.1	0.53	2.29e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs9467773	0.526	rs3734536	chr6:26365346	C/G	cg14345882	chr6:26364793	BTN3A2	0.35	4.66	0.43	1.01e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6956675	0.915	rs4717497	chr7:62645096	A/G	cg27518014	chr7:62859535	LOC100287834	0.54	4.46	0.42	2.25e-5	Obesity-related traits;
THYM	cis	rs3087591	0.922	rs2905788	chr17:29480295	C/T	cg24425628	chr17:29625626	OMG;NF1	0.65	5.69	0.5	1.38e-7	Hip circumference;
THYM	cis	rs8028313	0.731	rs4331293	chr15:67987801	A/G	cg24579218	chr15:68104479	NA	-0.67	-4.85	-0.45	4.84e-6	Obesity;
THYM	cis	rs863345	0.604	rs10797012	chr1:158465485	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs8016982	0.657	rs8021125	chr14:81704787	C/T	cg01989461	chr14:81687754	GTF2A1	-0.82	-7.69	-0.62	1.32e-11	Schizophrenia;
THYM	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg24531977	chr5:56204891	C5orf35	-0.66	-5.11	-0.46	1.64e-6	Coronary artery disease;
THYM	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg17105886	chr17:28927953	LRRC37B2	1.29	6.49	0.55	3.84e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9826463	0.527	rs6780665	chr3:142063689	G/A	cg20824294	chr3:142316082	PLS1	0.76	5.28	0.48	8.31e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg15445000	chr17:37608096	MED1	-0.44	-5.19	-0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs12200560	0.505	rs4839849	chr6:97076673	T/C	cg06623918	chr6:96969491	KIAA0776	0.78	6.01	0.52	3.39e-8	Coronary heart disease;
THYM	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23248424	chr5:179741104	GFPT2	-0.84	-6.59	-0.56	2.49e-9	Height;
THYM	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg13447684	chr7:1895903	MAD1L1	0.53	4.77	0.44	6.52e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2862064	0.932	rs6870977	chr5:156446249	T/C	cg12943317	chr5:156479607	HAVCR1	-0.86	-5.28	-0.48	8.3e-7	Platelet count;
THYM	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg06917634	chr15:78832804	PSMA4	0.91	7.9	0.63	4.85e-12	Sudden cardiac arrest;
THYM	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.72	-4.65	-0.43	1.07e-5	Lymphocyte percentage of white cells;
THYM	cis	rs6543140	0.964	rs10193485	chr2:103089573	T/C	cg03938978	chr2:103052716	IL18RAP	0.62	6.01	0.52	3.42e-8	Blood protein levels;
THYM	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg21280719	chr6:42927975	GNMT	-0.5	-6.77	-0.57	1.04e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2288884	0.708	rs11665783	chr19:52517894	G/A	cg05974498	chr19:52599256	ZNF841	0.35	4.51	0.42	1.85e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs72627123	0.867	rs73301500	chr14:74473413	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.1	6.16	0.53	1.76e-8	Morning vs. evening chronotype;
THYM	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg05425664	chr17:57184151	TRIM37	-0.56	-4.48	-0.42	2.06e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	4.78	0.44	6.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4589258	0.788	rs4463819	chr11:90462544	C/T	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.75	-0.44	7.12e-6	Intelligence (multi-trait analysis);
THYM	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg11416102	chr8:651193	ERICH1	1.09	4.45	0.42	2.37e-5	IgG glycosylation;
THYM	cis	rs1345301	0.518	rs56238602	chr2:102863095	G/T	cg03938978	chr2:103052716	IL18RAP	-0.52	-4.92	-0.45	3.59e-6	Waist circumference;
THYM	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg26039829	chr8:22132926	PIWIL2	-0.67	-6.01	-0.52	3.4e-8	Hypertriglyceridemia;
THYM	cis	rs490234	0.812	rs12553699	chr9:128294526	C/G	cg14078157	chr9:128172775	NA	-0.65	-5.28	-0.48	8.05e-7	Mean arterial pressure;
THYM	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	5.75	0.51	1.08e-7	Blood metabolite levels;
THYM	cis	rs6720763	0.945	rs11888230	chr2:168007034	C/T	cg10633051	chr2:168042982	XIRP2	-0.68	-4.69	-0.43	9.2e-6	Atopic dermatitis;
THYM	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08677398	chr8:58056175	NA	0.84	5.79	0.51	8.88e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7695732	0.595	rs7697075	chr4:89908308	A/G	cg17769793	chr4:89976368	FAM13A	-0.47	-4.99	-0.46	2.74e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs977987	0.806	rs8051407	chr16:75448659	A/G	cg03315344	chr16:75512273	CHST6	0.76	6.16	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg00191853	chr8:101177733	SPAG1	0.55	5.09	0.46	1.83e-6	Atrioventricular conduction;
THYM	cis	rs7107174	0.786	rs2450134	chr11:77925778	A/G	cg19901956	chr11:77921274	USP35	-0.7	-5.55	-0.49	2.61e-7	Testicular germ cell tumor;
THYM	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs6840360	1.000	rs3792691	chr4:152635803	C/T	cg22705602	chr4:152727874	NA	0.59	6.44	0.55	4.94e-9	Intelligence (multi-trait analysis);
THYM	cis	rs76662990	0.610	rs6886768	chr5:73927770	C/G	cg13275603	chr5:73927487	ENC1	-0.78	-4.52	-0.42	1.81e-5	Residual cognition;
THYM	cis	rs11209185	0.509	rs9326078	chr1:68452388	A/G	cg22082780	chr1:68452167	NA	0.69	9.4	0.69	3.22e-15	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg18876405	chr7:65276391	NA	0.56	4.73	0.44	7.72e-6	Aortic root size;
THYM	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs3820068	0.608	rs10927831	chr1:16028373	T/G	cg05660106	chr1:15850417	CASP9	0.72	5.59	0.5	2.2e-7	Systolic blood pressure;
THYM	cis	rs8063160	0.622	rs34659644	chr16:89796017	G/A	cg07984980	chr16:89898383	SPIRE2	1.6	6.42	0.55	5.28e-9	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg09517075	chr8:22133004	PIWIL2	-0.6	-5.44	-0.49	4.19e-7	Hypertriglyceridemia;
THYM	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.23	9.82	0.71	4.08e-16	Platelet count;
THYM	cis	rs885814	0.572	rs12741655	chr1:21898205	A/G	cg14781605	chr1:21864896	ALPL	-0.6	-4.66	-0.43	1.02e-5	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg08645402	chr16:4508243	NA	0.76	6.86	0.58	6.97e-10	Schizophrenia;
THYM	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.76	-0.44	6.98e-6	Crohn's disease;
THYM	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg14779329	chr11:130786720	SNX19	0.55	5.83	0.51	7.58e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6906287	0.647	rs3798420	chr6:118786486	T/C	cg21191810	chr6:118973309	C6orf204	0.57	5.72	0.51	1.24e-7	Electrocardiographic conduction measures;
THYM	cis	rs4664308	0.905	rs62175518	chr2:160915149	C/T	cg03641300	chr2:160917029	PLA2R1	-0.76	-6.79	-0.57	9.83e-10	Idiopathic membranous nephropathy;
THYM	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg13695892	chr22:41940480	POLR3H	-1.04	-8.51	-0.66	2.47e-13	Vitiligo;
THYM	cis	rs11696501	0.694	rs2171371	chr20:44273482	T/C	cg11783356	chr20:44313418	WFDC10B	-0.66	-4.54	-0.42	1.66e-5	Brain structure;
THYM	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.75	6.93	0.58	4.96e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs6840360	0.615	rs6831810	chr4:152461995	A/G	cg22705602	chr4:152727874	NA	-0.71	-7.43	-0.61	4.71e-11	Intelligence (multi-trait analysis);
THYM	cis	rs12801636	0.739	rs12790427	chr11:65384727	C/T	cg24147428	chr11:65409760	SIPA1	-0.65	-4.79	-0.44	6.25e-6	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg08807101	chr21:30365312	RNF160	-0.67	-4.87	-0.45	4.5e-6	Dental caries;
THYM	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7246967	0.673	rs34003335	chr19:22925602	T/C	cg05241461	chr19:22816980	ZNF492	0.59	4.61	0.43	1.26e-5	Bronchopulmonary dysplasia;
THYM	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg00852783	chr1:26633632	UBXN11	0.86	8.81	0.67	5.74e-14	Obesity-related traits;
THYM	cis	rs1580019	0.961	rs3801328	chr7:32496930	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.59	0.56	2.42e-9	Cognitive ability;
THYM	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg21028142	chr17:79581711	NPLOC4	0.61	6.22	0.54	1.32e-8	Eye color traits;
THYM	cis	rs7246657	0.943	rs10420430	chr19:37894194	C/G	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs2985684	0.779	rs12160	chr14:50091932	T/A	cg02151108	chr14:50098012	C14orf104	-0.68	-5.42	-0.49	4.54e-7	Carotid intima media thickness;
THYM	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg03576123	chr11:487126	PTDSS2	-1.11	-4.78	-0.44	6.51e-6	Body mass index;
THYM	cis	rs6835098	0.961	rs11737748	chr4:174130503	T/C	cg08422745	chr4:174089978	GALNT7	0.99	7.64	0.62	1.69e-11	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs208520	1.000	rs208523	chr6:66954195	G/C	cg07460842	chr6:66804631	NA	-0.85	-5.48	-0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs34779708	0.966	rs17499247	chr10:35426755	A/G	cg03585969	chr10:35415529	CREM	0.66	4.76	0.44	6.85e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs73198271	0.737	rs565203	chr8:8632957	T/C	cg06636001	chr8:8085503	FLJ10661	-0.67	-4.96	-0.45	3.12e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs28595532	0.541	rs114463740	chr4:119763329	C/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs2625529	0.652	rs2957735	chr15:72265173	T/C	cg16672083	chr15:72433130	SENP8	0.49	4.48	0.42	2.09e-5	Red blood cell count;
THYM	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg06028808	chr11:68637592	NA	0.68	7.24	0.6	1.18e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2273669	0.665	rs66606621	chr6:109405273	T/G	cg17117243	chr6:109341365	SESN1	-0.77	-4.49	-0.42	1.98e-5	Prostate cancer;
THYM	cis	rs9486719	1.000	rs2499804	chr6:96861216	A/G	cg18709589	chr6:96969512	KIAA0776	0.71	4.75	0.44	7.32e-6	Migraine;Coronary artery disease;
THYM	cis	rs4601821	1.000	rs3897584	chr11:113249725	C/G	cg14159747	chr11:113255604	NA	-0.25	-4.86	-0.45	4.66e-6	Alcoholic chronic pancreatitis;
THYM	cis	rs859767	0.741	rs11684785	chr2:135393110	C/T	cg12500956	chr2:135428796	TMEM163	-0.5	-5.15	-0.47	1.43e-6	Neuroticism;
THYM	cis	rs11096990	0.855	rs11737290	chr4:39193938	T/C	cg24403649	chr4:39172243	NA	-0.65	-5.47	-0.49	3.69e-7	Cognitive function;
THYM	cis	rs4363385	0.588	rs11586559	chr1:153025714	G/A	cg13444842	chr1:152974279	SPRR3	-0.63	-4.96	-0.45	3.05e-6	Inflammatory skin disease;
THYM	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg24874828	chr4:187887005	NA	-0.76	-8.24	-0.65	9.29e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12956009	0.559	rs12607072	chr18:44839888	G/A	cg19077165	chr18:44547161	KATNAL2	-0.48	-4.51	-0.42	1.88e-5	Educational attainment (years of education);
THYM	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs611744	0.967	rs2600615	chr8:109201170	G/A	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs3126085	0.515	rs10788837	chr1:152351487	A/G	cg10321714	chr1:152280068	FLG	-0.64	-4.62	-0.43	1.22e-5	Atopic dermatitis;
THYM	cis	rs2718058	0.692	rs2718041	chr7:37783944	A/G	cg15028436	chr7:37888078	TXNDC3	0.6	4.68	0.43	9.42e-6	Alzheimer's disease (late onset);
THYM	cis	rs2046867	0.862	rs35178407	chr3:72799703	C/T	cg25664220	chr3:72788482	NA	-0.83	-6.34	-0.55	7.78e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg12311346	chr5:56204834	C5orf35	0.89	6.29	0.54	9.66e-9	Initial pursuit acceleration;
THYM	trans	rs1997103	0.954	rs9649780	chr7:55411741	A/C	cg20935933	chr6:143382018	AIG1	0.86	6.91	0.58	5.41e-10	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs28595532	0.920	rs17324884	chr4:119771477	C/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs11997175	0.646	rs7464237	chr8:33716596	C/T	ch.8.33884649F	chr8:33765107	NA	0.63	4.76	0.44	6.85e-6	Body mass index;
THYM	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg22907277	chr7:1156413	C7orf50	0.62	5.45	0.49	4.02e-7	Longevity;Endometriosis;
THYM	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg07362569	chr17:61921086	SMARCD2	0.72	6.37	0.55	6.65e-9	Prudent dietary pattern;
THYM	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg07511668	chr11:68622177	NA	0.44	4.47	0.42	2.15e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9807841	0.592	rs6511707	chr19:10767790	C/T	cg16900796	chr19:10755136	SLC44A2	0.4	6.32	0.54	8.4e-9	Inflammatory skin disease;
THYM	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.7	9.28	0.69	5.8e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs11030122	0.702	rs10835311	chr11:3949027	G/T	cg22027985	chr11:4115532	RRM1	-0.47	-4.45	-0.42	2.33e-5	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg18032289	chr17:61959525	GH2	-0.47	-4.47	-0.42	2.17e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs10463554	1.000	rs10463554	chr5:102318974	T/C	cg23492399	chr5:102201601	PAM	-0.64	-4.92	-0.45	3.6e-6	Parkinson's disease;
THYM	cis	rs11948739	0.610	rs10040560	chr5:130300594	C/T	cg08523029	chr5:130500466	HINT1	0.78	5.58	0.5	2.26e-7	Pediatric bone mineral content (hip);
THYM	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	6.49	0.55	3.87e-9	Total body bone mineral density;
THYM	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg23815491	chr16:72088622	HP	0.81	6.46	0.55	4.54e-9	Fibrinogen levels;
THYM	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.51	-5.24	-0.47	9.82e-7	Depressive symptoms;
THYM	cis	rs10191773	0.589	rs72831641	chr2:112955815	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.78	-4.57	-0.42	1.44e-5	Yeast infection;
THYM	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg13609457	chr4:120235615	NA	0.51	4.76	0.44	6.87e-6	Corneal astigmatism;
THYM	cis	rs73151930	0.948	rs7643549	chr3:147413101	A/G	cg24847685	chr3:147087653	NA	0.58	4.91	0.45	3.83e-6	Daytime sleep phenotypes;
THYM	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.97	8.9	0.67	3.72e-14	Chronic sinus infection;
THYM	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12257961	0.579	rs6602844	chr10:15388129	T/G	cg10616319	chr10:15468812	NA	-0.64	-5.43	-0.49	4.39e-7	Selective IgA deficiency;
THYM	cis	rs9914544	1.000	rs1737944	chr17:18840433	G/A	cg26378065	chr17:18585709	ZNF286B	0.56	4.54	0.42	1.68e-5	Educational attainment (years of education);
THYM	cis	rs7917772	0.582	rs7907760	chr10:104345197	C/T	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10927875	0.541	rs1739842	chr1:16342848	T/G	cg21385522	chr1:16154831	NA	0.65	4.54	0.42	1.65e-5	Dilated cardiomyopathy;
THYM	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.89	-5.78	-0.51	9.31e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg27398817	chr8:82754497	SNX16	0.83	6.57	0.56	2.65e-9	Diastolic blood pressure;
THYM	cis	rs40363	0.767	rs1003330	chr16:3541039	A/G	cg05754148	chr16:3507555	NAT15	-0.85	-5.92	-0.52	5.19e-8	Tuberculosis;
THYM	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg27121462	chr16:89883253	FANCA	0.57	4.56	0.42	1.53e-5	Vitiligo;
THYM	cis	rs1878931	0.582	rs27231	chr16:3434966	C/T	cg22508957	chr16:3507546	NAT15	-0.48	-5.1	-0.46	1.73e-6	Body mass index (adult);
THYM	cis	rs2692947	0.770	rs58730124	chr2:96413338	T/C	cg22654517	chr2:96458247	NA	0.71	5.34	0.48	6.39e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs2732480	0.577	rs2634691	chr12:48708259	G/T	cg21466736	chr12:48725269	NA	-0.62	-5.52	-0.49	2.92e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg27034606	chr17:28928453	LRRC37B2	0.83	5.47	0.49	3.6e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2898681	1.000	rs6833096	chr4:53744275	G/C	cg00791764	chr4:53727839	RASL11B	0.48	5.78	0.51	9.28e-8	Optic nerve measurement (cup area);
THYM	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06481639	chr22:41940642	POLR3H	0.67	4.71	0.44	8.42e-6	Vitiligo;
THYM	cis	rs12579753	0.917	rs10778833	chr12:82197983	G/T	cg21231944	chr12:82153410	PPFIA2	-0.66	-5.01	-0.46	2.51e-6	Resting heart rate;
THYM	cis	rs35883536	0.647	rs59667512	chr1:101046712	C/T	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs3741151	1.000	rs75114310	chr11:73042047	C/T	cg17517138	chr11:73019481	ARHGEF17	0.99	5.88	0.52	5.97e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs11048434	0.761	rs2110190	chr12:9128289	A/C	cg26114124	chr12:9217669	LOC144571	0.46	4.51	0.42	1.85e-5	Sjögren's syndrome;
THYM	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8018808	0.935	rs7146595	chr14:77932017	A/C	cg20045696	chr14:77926864	AHSA1	0.5	4.54	0.42	1.63e-5	Myeloid white cell count;
THYM	cis	rs6842047	1.000	rs1511800	chr4:187135556	C/T	cg23442198	chr4:187126114	CYP4V2	0.96	4.48	0.42	2.1e-5	Blood protein levels;
THYM	cis	rs2718058	0.519	rs2598071	chr7:37875347	G/A	cg02531859	chr7:37888154	TXNDC3	-0.86	-5.67	-0.5	1.52e-7	Alzheimer's disease (late onset);
THYM	cis	rs17789174	1.000	rs17789174	chr16:85103885	A/G	cg01715842	chr16:85045600	ZDHHC7	0.48	5.18	0.47	1.22e-6	Dysphagia;
THYM	cis	rs12935418	1.000	rs12935418	chr16:81070008	G/C	cg16651780	chr16:81037892	C16orf61	0.89	4.76	0.44	7.01e-6	Mean corpuscular volume;
THYM	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.58	0.56	2.61e-9	Total body bone mineral density;
THYM	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.7	5.63	0.5	1.85e-7	Menarche (age at onset);
THYM	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg25358565	chr5:93447407	FAM172A	-1.45	-10.45	-0.73	1.84e-17	Diabetic retinopathy;
THYM	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs4731207	0.698	rs34014883	chr7:124480577	C/T	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs9633835	0.524	rs4756762	chr11:13272778	G/A	cg13286116	chr11:13302098	ARNTL	-0.72	-8.03	-0.64	2.61e-12	Body mass index;
THYM	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg16414030	chr3:133502952	NA	-0.92	-9.1	-0.68	1.37e-14	Iron status biomarkers;
THYM	cis	rs11651000	0.857	rs56172120	chr17:45824904	G/A	cg03474202	chr17:45855739	NA	-0.78	-6.79	-0.57	9.74e-10	IgG glycosylation;
THYM	cis	rs17253792	0.571	rs112129578	chr14:56028415	T/C	cg01858014	chr14:56050164	KTN1	-1.16	-4.92	-0.45	3.69e-6	Putamen volume;
THYM	cis	rs4731207	0.698	rs10243736	chr7:124458966	A/G	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.85	-5.11	-0.46	1.69e-6	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs748404	0.578	rs2244746	chr15:43695083	T/A	cg12861797	chr15:43585817	TGM7	0.47	4.98	0.46	2.8e-6	Lung cancer;
THYM	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11583043	0.918	rs11582211	chr1:101416871	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.62	4.59	0.43	1.36e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs12282928	0.959	rs11500496	chr11:48304436	A/G	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg26446133	chr18:72167187	CNDP2	-1.0	-7.99	-0.63	3.12e-12	Refractive error;
THYM	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg08999081	chr20:33150536	PIGU	-0.57	-4.95	-0.45	3.25e-6	Height;
THYM	cis	rs7107174	1.000	rs10899465	chr11:78013588	G/A	cg19901956	chr11:77921274	USP35	-0.74	-5.57	-0.5	2.39e-7	Testicular germ cell tumor;
THYM	cis	rs1357245	0.631	rs7648066	chr3:27097225	C/T	cg03895047	chr3:27114861	NA	0.49	4.58	0.43	1.42e-5	Breast cancer;
THYM	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11890956	chr21:40555474	PSMG1	-0.97	-11.25	-0.76	3.73e-19	Cognitive function;
THYM	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg22920501	chr2:26401640	FAM59B	-1.05	-9.21	-0.69	8.04e-15	Gut microbiome composition (summer);
THYM	cis	rs1232027	0.545	rs1650742	chr5:79990883	T/G	cg24834873	chr5:79865402	ANKRD34B	-0.6	-4.48	-0.42	2.09e-5	Huntington's disease progression;
THYM	cis	rs4417704	0.551	rs4675843	chr2:241875494	C/T	cg15164180	chr2:241846931	NA	-0.36	-4.63	-0.43	1.15e-5	Joint mobility (Beighton score);
THYM	cis	rs877282	0.945	rs34367686	chr10:791868	G/C	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg26384229	chr12:38710491	ALG10B	0.98	7.15	0.59	1.8e-10	Bladder cancer;
THYM	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg22535103	chr8:58192502	C8orf71	-1.06	-6.61	-0.56	2.24e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.72	0.51	1.23e-7	Lung cancer in ever smokers;
THYM	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg06028605	chr16:24865363	SLC5A11	-0.56	-5.18	-0.47	1.25e-6	Intelligence (multi-trait analysis);
THYM	cis	rs897984	0.520	rs4889614	chr16:30862135	G/A	cg05768032	chr16:30646687	NA	-0.47	-4.61	-0.43	1.28e-5	Dementia with Lewy bodies;
THYM	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg00852783	chr1:26633632	UBXN11	0.7	5.79	0.51	9e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs59698941	0.943	rs12513758	chr5:132239939	C/G	cg02081065	chr5:132209139	LEAP2	-0.85	-5.76	-0.51	1.03e-7	Apolipoprotein A-IV levels;
THYM	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg08085267	chr17:45401833	C17orf57	-0.57	-4.99	-0.46	2.71e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
THYM	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.67	0.62	1.48e-11	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg23131131	chr22:24373011	LOC391322	0.67	5.96	0.52	4.35e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02018176	chr4:1364513	KIAA1530	0.95	8.95	0.68	2.83e-14	Longevity;
THYM	cis	rs16854884	0.657	rs35193361	chr3:143716420	A/G	cg05063096	chr3:143689810	C3orf58	0.69	4.51	0.42	1.86e-5	Economic and political preferences (feminism/equality);
THYM	cis	rs889398	0.935	rs244420	chr16:69657996	T/G	cg09409435	chr16:70099608	PDXDC2	-0.63	-4.92	-0.45	3.64e-6	Body mass index;
THYM	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	6.54	0.56	3.03e-9	Cognitive test performance;
THYM	cis	rs72848980	0.706	rs11191732	chr10:105331761	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.6	4.92	0.45	3.59e-6	White matter hyperintensity burden;
THYM	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2898681	1.000	rs2898681	chr4:53757000	C/T	cg21521518	chr4:53727714	RASL11B	0.51	5.64	0.5	1.73e-7	Optic nerve measurement (cup area);
THYM	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg27284194	chr4:1044797	NA	-0.64	-4.87	-0.45	4.42e-6	Recombination rate (females);
THYM	cis	rs8133932	0.576	rs2839039	chr21:47321499	T/G	cg20357416	chr21:47294739	PCBP3	-0.81	-4.92	-0.45	3.56e-6	Schizophrenia;
THYM	cis	rs7084402	0.967	rs1658434	chr10:60328756	G/C	cg07615347	chr10:60278583	BICC1	0.54	5.0	0.46	2.58e-6	Refractive error;
THYM	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg02187348	chr16:89574699	SPG7	-0.74	-6.27	-0.54	1.07e-8	Multiple myeloma (IgH translocation);
THYM	cis	rs35883536	0.525	rs2647321	chr1:101032006	T/G	cg09408571	chr1:101003634	GPR88	0.53	5.86	0.52	6.54e-8	Monocyte count;
THYM	cis	rs11252926	0.501	rs2050971	chr10:525530	T/G	cg03684893	chr10:554711	DIP2C	0.68	5.54	0.49	2.7e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs11563648	0.517	rs2269728	chr7:127032580	A/G	cg23081781	chr7:127225937	GCC1	-0.34	-4.65	-0.43	1.07e-5	Resting heart rate;
THYM	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg02782426	chr3:40428986	ENTPD3	-0.52	-4.68	-0.43	9.49e-6	Renal cell carcinoma;
THYM	cis	rs7705502	0.962	rs17694835	chr5:173328024	G/T	cg18693985	chr5:173351052	CPEB4	-0.78	-5.64	-0.5	1.71e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs8030485	0.545	rs78118096	chr15:79385039	C/T	cg17916960	chr15:79447300	NA	0.5	4.78	0.44	6.49e-6	Left ventricle wall thickness;
THYM	cis	rs6430585	0.591	rs309118	chr2:136746224	G/C	cg04750100	chr2:136595281	LCT	0.55	5.71	0.51	1.26e-7	Corneal structure;
THYM	cis	rs2888875	0.632	rs72613902	chr2:43714728	C/T	cg22033476	chr2:43532275	THADA	-0.41	-4.65	-0.43	1.06e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs9326248	0.581	rs12225187	chr11:116793231	G/A	cg20608306	chr11:116969690	SIK3	0.64	7.67	0.62	1.5e-11	Blood protein levels;
THYM	cis	rs4930776	1.000	rs10849311	chr12:5766698	T/C	cg02086166	chr12:5775618	ANO2	-0.58	-5.71	-0.51	1.3e-7	Plasma clusterin levels;
THYM	cis	rs7824557	0.585	rs2572382	chr8:11211302	T/G	cg21775007	chr8:11205619	TDH	0.67	5.26	0.47	9.04e-7	Retinal vascular caliber;
THYM	cis	rs7107174	1.000	rs10899477	chr11:78052104	A/T	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg06481639	chr22:41940642	POLR3H	-0.79	-5.94	-0.52	4.6e-8	Vitiligo;
THYM	cis	rs7843479	0.544	rs11135735	chr8:21791557	C/T	cg17168535	chr8:21777572	XPO7	0.86	7.59	0.61	2.15e-11	Mean corpuscular volume;
THYM	cis	rs4455778	0.580	rs4268080	chr7:49117682	A/G	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg25554036	chr4:6271136	WFS1	-0.51	-4.6	-0.43	1.3e-5	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg23711669	chr6:146136114	FBXO30	0.99	10.16	0.72	7.58e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg06138931	chr13:21896616	NA	0.63	5.25	0.47	9.11e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg10505658	chr17:80084571	CCDC57	0.68	7.45	0.61	4.18e-11	Life satisfaction;
THYM	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg02734326	chr4:10020555	SLC2A9	-0.7	-6.08	-0.53	2.47e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2147904	0.704	rs809173	chr1:42363381	C/T	cg16685388	chr1:42384056	HIVEP3	0.56	4.76	0.44	7e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
THYM	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg04455712	chr21:45112962	RRP1B	0.49	4.48	0.42	2.07e-5	Mean corpuscular volume;
THYM	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg23262073	chr20:60523788	NA	0.93	6.95	0.58	4.64e-10	Obesity-related traits;
THYM	cis	rs55728055	0.661	rs16989334	chr22:32016092	A/G	cg01338084	chr22:32026380	PISD	1.26	6.51	0.56	3.51e-9	Age-related hearing impairment;
THYM	cis	rs6840360	0.642	rs6845648	chr4:152376050	C/T	cg17479576	chr4:152424074	FAM160A1	-0.68	-5.17	-0.47	1.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4372836	0.658	rs7579321	chr2:28983166	T/C	cg09522027	chr2:28974177	PPP1CB	-0.65	-5.15	-0.47	1.39e-6	Body mass index;
THYM	cis	rs2197308	0.813	rs11504316	chr12:38219320	G/A	cg10518543	chr12:38710700	ALG10B	-0.59	-4.8	-0.44	5.97e-6	Morning vs. evening chronotype;
THYM	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg13390004	chr1:15929781	NA	0.63	4.8	0.44	5.87e-6	Systolic blood pressure;
THYM	cis	rs7216064	1.000	rs62084214	chr17:65843325	C/G	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.77	-0.44	6.53e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg11764359	chr7:65958608	NA	-0.8	-6.38	-0.55	6.55e-9	Aortic root size;
THYM	cis	rs600806	0.888	rs2228604	chr1:109884775	A/C	cg02175308	chr1:109941060	SORT1	-0.57	-4.99	-0.46	2.67e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs7119	0.931	rs12901998	chr15:77833524	G/T	cg27398640	chr15:77910606	LINGO1	-0.57	-5.64	-0.5	1.74e-7	Type 2 diabetes;
THYM	cis	rs12496230	0.953	rs1036970	chr3:66850707	A/G	cg04995300	chr3:66848608	NA	1.05	5.82	0.51	8.08e-8	Type 2 diabetes;
THYM	cis	rs654950	0.840	rs2810551	chr1:41995402	G/A	cg06885757	chr1:42089581	HIVEP3	-0.44	-5.26	-0.47	9e-7	Airway imaging phenotypes;
THYM	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs8018808	0.902	rs8006688	chr14:77926649	G/A	cg20045696	chr14:77926864	AHSA1	0.5	4.46	0.42	2.28e-5	Myeloid white cell count;
THYM	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg06634786	chr22:41940651	POLR3H	-0.71	-5.46	-0.49	3.81e-7	Vitiligo;
THYM	cis	rs2244613	0.882	rs7200877	chr16:55794882	A/T	cg27396498	chr16:55794478	CES4	0.75	5.28	0.48	8.06e-7	Response to dabigatran etexilate treatment;
THYM	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg06028808	chr11:68637592	NA	-0.71	-7.73	-0.62	1.13e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs17006441	0.932	rs6805563	chr3:69879323	G/A	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs7189233	1.000	rs7194519	chr16:53535276	C/G	cg02965178	chr16:53538660	AKTIP	-0.65	-5.23	-0.47	1.01e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg11845111	chr2:191398756	TMEM194B	-1.0	-7.65	-0.62	1.66e-11	Diastolic blood pressure;
THYM	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg23187316	chr7:1099788	C7orf50	0.59	4.52	0.42	1.76e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2717559	0.522	rs2585158	chr8:143875832	C/T	cg17888033	chr8:143858414	LYNX1	0.47	5.34	0.48	6.24e-7	Urinary tract infection frequency;
THYM	cis	rs7255045	0.742	rs6511841	chr19:12955149	G/T	cg26870725	chr19:12978805	MAST1	-0.63	-4.9	-0.45	3.96e-6	Mean corpuscular volume;
THYM	cis	rs728616	0.867	rs1054054	chr10:81682728	C/T	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6700896	0.931	rs4655574	chr1:66135328	T/A	cg04111102	chr1:66153794	NA	0.56	5.27	0.48	8.45e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs1023500	1.000	rs1023497	chr22:42340508	C/G	cg19448990	chr22:41842841	TOB2	-0.77	-5.01	-0.46	2.56e-6	Schizophrenia;
THYM	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg08470875	chr2:26401718	FAM59B	0.74	4.59	0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs10504073	0.584	rs62507177	chr8:49937306	C/A	cg00325661	chr8:49890786	NA	1.08	11.18	0.75	5.05e-19	Blood metabolite ratios;
THYM	cis	rs35883536	0.647	rs2809790	chr1:101040461	C/T	cg09408571	chr1:101003634	GPR88	0.51	5.56	0.5	2.44e-7	Monocyte count;
THYM	cis	rs10208649	0.808	rs6730494	chr2:54219186	C/T	cg04546899	chr2:54196757	PSME4	0.67	4.66	0.43	1.05e-5	Body mass index;
THYM	cis	rs9560113	0.556	rs9560128	chr13:112221924	A/G	cg15979348	chr13:112237479	NA	0.58	5.41	0.49	4.63e-7	Menarche (age at onset);
THYM	cis	rs2219968	0.683	rs59439603	chr8:78906502	G/A	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11644478	chr21:40555479	PSMG1	0.81	7.04	0.59	3.04e-10	Cognitive function;
THYM	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg07959070	chr22:50026188	C22orf34	-0.28	-4.98	-0.46	2.82e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs12928939	0.517	rs8049508	chr16:71978313	C/T	cg03805757	chr16:71968109	PKD1L3	-0.99	-9.88	-0.71	2.99e-16	Post bronchodilator FEV1;
THYM	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg11871910	chr12:69753446	YEATS4	1.06	9.8	0.71	4.32e-16	Blood protein levels;
THYM	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg03188948	chr7:1209495	NA	0.91	7.1	0.59	2.21e-10	Longevity;Endometriosis;
THYM	trans	rs10802346	0.545	rs1770003	chr1:246408356	A/G	cg13514129	chr1:39547527	MACF1	1.03	10.38	0.73	2.58e-17	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg12011299	chr4:100065546	ADH4	0.94	9.78	0.71	4.9e-16	Alcohol dependence;
THYM	trans	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg15782153	chr7:917662	C7orf20	0.68	4.48	0.42	2.09e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs112591243	0.685	rs4819263	chr21:47950866	G/A	cg26697654	chr21:47851941	PCNT	0.81	4.52	0.42	1.76e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs9790314	1.000	rs9790314	chr3:161019558	T/C	cg03342759	chr3:160939853	NMD3	-0.76	-7.0	-0.58	3.68e-10	Morning vs. evening chronotype;
THYM	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg15536230	chr21:44985092	HSF2BP	-0.38	-4.49	-0.42	1.99e-5	Mean corpuscular volume;
THYM	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs2732480	0.577	rs2732457	chr12:48758379	A/G	cg21466736	chr12:48725269	NA	0.59	5.38	0.48	5.25e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg07362569	chr17:61921086	SMARCD2	0.72	6.37	0.55	6.65e-9	Prudent dietary pattern;
THYM	cis	rs12893597	0.580	rs35068962	chr14:76818804	G/A	cg20290672	chr14:76816747	NA	-0.57	-4.59	-0.43	1.37e-5	Maximal oxygen uptake response;
THYM	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg23216685	chr1:86174607	ZNHIT6	-0.45	-5.13	-0.47	1.53e-6	Urate levels in overweight individuals;
THYM	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg03188948	chr7:1209495	NA	0.89	6.89	0.58	6.01e-10	Longevity;Endometriosis;
THYM	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg19774624	chr17:42201019	HDAC5	-0.77	-7.16	-0.59	1.73e-10	Total body bone mineral density;
THYM	cis	rs870825	0.616	rs28375770	chr4:185647395	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs28595532	0.920	rs56342843	chr4:119765070	G/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs17253792	0.822	rs74968702	chr14:56076818	A/T	cg01858014	chr14:56050164	KTN1	-1.22	-5.13	-0.47	1.52e-6	Putamen volume;
THYM	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs6500395	1.000	rs3848319	chr16:48610933	T/C	cg04672837	chr16:48644449	N4BP1	0.54	5.5	0.49	3.25e-7	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg15448220	chr1:150897856	SETDB1	0.86	6.94	0.58	4.73e-10	Tonsillectomy;
THYM	cis	rs34638657	0.732	rs7206093	chr16:82201884	G/A	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.25	-0.47	9.14e-7	Lung adenocarcinoma;
THYM	cis	rs899997	0.953	rs11633519	chr15:78999552	A/G	cg04896959	chr15:78267971	NA	0.83	6.62	0.56	2.15e-9	Coronary artery disease or large artery stroke;
THYM	cis	rs4665630	0.764	rs12617532	chr2:23891695	G/T	cg08081869	chr2:24582653	ITSN2	0.76	4.47	0.42	2.19e-5	Hypertension;
THYM	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg20203395	chr5:56204925	C5orf35	-0.7	-4.81	-0.44	5.59e-6	Initial pursuit acceleration;
THYM	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg24846680	chr1:228362309	C1orf69	0.52	4.71	0.43	8.6e-6	Diastolic blood pressure;
THYM	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1729407	0.632	rs2071523	chr11:116697344	C/T	cg08985259	chr11:116699649	APOC3	-0.59	-4.96	-0.45	3.02e-6	Apolipoprotein A-IV levels;
THYM	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg10047753	chr17:41438598	NA	1.19	11.33	0.76	2.52e-19	Menopause (age at onset);
THYM	cis	rs3733631	0.843	rs10019555	chr4:104615281	G/A	cg24090629	chr4:104641072	TACR3	-0.87	-5.51	-0.49	3.08e-7	Menarche (age at onset);
THYM	cis	rs57994353	0.826	rs34619169	chr9:139327277	G/A	cg01241850	chr9:138798996	CAMSAP1	0.7	4.56	0.42	1.55e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs6500395	1.000	rs9931737	chr16:48623539	C/T	cg04672837	chr16:48644449	N4BP1	0.51	4.98	0.45	2.85e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg18132916	chr6:79620363	NA	-0.54	-4.78	-0.44	6.44e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg07424592	chr7:64974309	NA	1.08	4.97	0.45	2.94e-6	Diabetic kidney disease;
THYM	cis	rs7572733	0.534	rs6760891	chr2:198768166	T/G	cg00792783	chr2:198669748	PLCL1	0.84	5.97	0.52	4.15e-8	Dermatomyositis;
THYM	cis	rs7107174	1.000	rs2512546	chr11:77957276	T/C	cg19901956	chr11:77921274	USP35	-0.76	-5.7	-0.5	1.35e-7	Testicular germ cell tumor;
THYM	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg22841779	chr14:105766346	BRF1	-0.47	-5.81	-0.51	8.18e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.61	-4.69	-0.43	9.22e-6	Intelligence (multi-trait analysis);
THYM	cis	rs919433	0.963	rs10199410	chr2:198155776	A/T	cg00792783	chr2:198669748	PLCL1	-0.69	-4.96	-0.45	3.12e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg13010199	chr12:38710504	ALG10B	-0.62	-5.38	-0.48	5.28e-7	Heart rate;
THYM	cis	rs9796	0.866	rs516156	chr15:41381257	A/G	cg21153102	chr15:41252147	NA	0.69	6.24	0.54	1.19e-8	Menopause (age at onset);
THYM	cis	rs7823896	0.929	rs73311394	chr8:110151107	T/C	cg18044723	chr8:109261011	EIF3E	-0.89	-4.68	-0.43	9.42e-6	Myopia (pathological);
THYM	cis	rs3126085	0.935	rs4845421	chr1:152173259	G/T	cg26020982	chr1:152196106	HRNR	0.36	4.7	0.43	8.63e-6	Atopic dermatitis;
THYM	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2816062	0.813	rs2745318	chr1:18895844	C/T	cg18795169	chr1:18902165	NA	0.99	12.14	0.78	5.02e-21	Urate levels in lean individuals;
THYM	trans	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg10856724	chr12:34555212	NA	-0.87	-7.57	-0.61	2.38e-11	Heart rate;
THYM	cis	rs736408	0.648	rs2268023	chr3:52819327	T/A	cg10802521	chr3:52805072	NEK4	-0.61	-4.81	-0.44	5.56e-6	Bipolar disorder;
THYM	cis	rs4727027	0.704	rs12704071	chr7:148904795	C/T	cg23583168	chr7:148888333	NA	-1.06	-15.94	-0.85	1.35e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	6.97	0.58	4.12e-10	Platelet count;
THYM	cis	rs3771180	0.505	rs2160203	chr2:102960824	A/G	cg03938978	chr2:103052716	IL18RAP	0.6	4.79	0.44	6.04e-6	Asthma;
THYM	cis	rs6901250	0.788	rs571296	chr6:117092558	A/G	cg12892004	chr6:117198278	RFX6	-0.71	-6.89	-0.58	6.07e-10	C-reactive protein levels;
THYM	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.69	-8.91	-0.67	3.51e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.81	-7.04	-0.59	2.97e-10	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.583	rs12452219	chr17:17829423	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.34	0.55	7.83e-9	Total body bone mineral density;
THYM	cis	rs4285028	0.699	rs2689285	chr3:121586486	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.81	5.78	0.51	9.34e-8	Multiple sclerosis;
THYM	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg20295408	chr7:1910781	MAD1L1	-0.65	-5.23	-0.47	1.02e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg10856724	chr12:34555212	NA	-0.92	-9.27	-0.69	6.02e-15	Morning vs. evening chronotype;
THYM	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg22764044	chr5:178986830	RUFY1	0.6	5.94	0.52	4.59e-8	Lung cancer;
THYM	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg14942906	chr11:67384040	NA	0.56	4.49	0.42	2.03e-5	Mean corpuscular volume;
THYM	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg09165964	chr15:75287851	SCAMP5	0.63	4.49	0.42	1.97e-5	Caffeine consumption;
THYM	cis	rs10982256	0.817	rs2297814	chr9:117267172	G/A	cg15903421	chr9:117267460	DFNB31	-0.55	-5.22	-0.47	1.05e-6	Bipolar disorder;
THYM	cis	rs7264396	0.635	rs6060720	chr20:34548336	A/C	cg26038318	chr20:34205095	SPAG4	0.59	4.81	0.44	5.6e-6	Total cholesterol levels;
THYM	cis	rs7572733	0.534	rs1401092	chr2:198792320	C/A	cg00792783	chr2:198669748	PLCL1	-0.84	-6.0	-0.52	3.54e-8	Dermatomyositis;
THYM	cis	rs6032067	0.929	rs13039213	chr20:43805712	A/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs6541297	0.941	rs2180078	chr1:230280513	T/C	cg20703242	chr1:230279135	GALNT2	0.92	5.97	0.52	4e-8	Coronary artery disease;
THYM	cis	rs6754311	0.834	rs12465802	chr2:136381348	A/G	cg04750100	chr2:136595281	LCT	-0.5	-4.52	-0.42	1.81e-5	Mosquito bite size;
THYM	cis	rs34912216	0.580	rs11979859	chr7:4130541	C/G	cg03141780	chr7:4150753	SDK1	0.65	4.89	0.45	4.1e-6	Motion sickness;
THYM	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg24692254	chr21:30365293	RNF160	-0.88	-7.59	-0.61	2.17e-11	Dental caries;
THYM	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg25554036	chr4:6271136	WFS1	0.59	5.47	0.49	3.68e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs4474465	0.915	rs10899503	chr11:78149961	C/T	cg19901956	chr11:77921274	USP35	-0.59	-4.52	-0.42	1.8e-5	Alzheimer's disease (survival time);
THYM	cis	rs9443189	0.762	rs2748943	chr6:76435543	C/T	cg01950844	chr6:76311363	SENP6	-0.82	-4.65	-0.43	1.05e-5	Prostate cancer;
THYM	cis	rs7830933	0.955	rs13261166	chr8:23594733	A/G	cg04349084	chr8:23602677	NA	0.66	7.09	0.59	2.33e-10	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	5.76	0.51	1.05e-7	Height;
THYM	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg18131467	chr2:239335373	ASB1	0.93	6.91	0.58	5.51e-10	Multiple system atrophy;
THYM	cis	rs4919044	0.808	rs11187252	chr10:94796166	A/T	cg05127821	chr10:94822908	CYP26C1	-1.21	-6.28	-0.54	9.93e-9	Coronary artery disease;
THYM	cis	rs2820651	0.614	rs75834807	chr10:1485054	T/C	cg13720710	chr10:1452970	ADARB2	0.77	4.83	0.44	5.17e-6	Migraine with aura;
THYM	cis	rs28595532	0.920	rs115446044	chr4:119754635	T/C	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs28595532	0.920	rs114019902	chr4:119755564	G/A	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs7582180	0.739	rs11123822	chr2:100911582	G/T	cg21926883	chr2:100939477	LONRF2	-0.53	-4.46	-0.42	2.26e-5	Intelligence (multi-trait analysis);
THYM	cis	rs12410462	0.792	rs994666	chr1:227651454	C/T	cg23173402	chr1:227635558	NA	-0.57	-5.36	-0.48	5.86e-7	Major depressive disorder;
THYM	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg10661904	chr17:79619235	PDE6G	-0.65	-6.14	-0.53	1.89e-8	Eye color traits;
THYM	cis	rs12444261	1.000	rs55693174	chr16:11743695	G/A	cg09662852	chr16:11707685	NA	-0.48	-4.51	-0.42	1.87e-5	QT interval;
THYM	cis	rs800586	0.628	rs3808477	chr8:116670347	A/G	cg04656070	chr8:116661063	TRPS1	0.58	5.73	0.51	1.18e-7	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs55788414	0.932	rs35852981	chr16:81180897	G/A	cg06400318	chr16:81190750	PKD1L2	-0.99	-4.99	-0.46	2.72e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs6426558	0.681	rs10495274	chr1:227175253	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.67	-5.81	-0.51	8.29e-8	Neutrophil percentage of white cells;
THYM	cis	rs420259	0.516	rs11643602	chr16:23556909	G/A	cg00143387	chr16:23521605	GGA2	-0.75	-5.37	-0.48	5.57e-7	Bipolar disorder;
THYM	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg00757033	chr12:89920650	WDR51B	0.74	11.81	0.77	2.43e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7274811	0.846	rs57668191	chr20:32289763	A/G	cg08240466	chr20:32847653	ASIP	-0.51	-4.64	-0.43	1.12e-5	Height;
THYM	cis	rs9790314	1.000	rs4370045	chr3:160943865	A/G	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg00495681	chr13:53174319	NA	0.73	7.22	0.6	1.25e-10	Lewy body disease;
THYM	cis	rs4731207	0.698	rs2402755	chr7:124448608	T/C	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.74	4.52	0.42	1.79e-5	Diabetic retinopathy;
THYM	cis	rs6906287	0.559	rs2798322	chr6:118991605	G/T	cg21191810	chr6:118973309	C6orf204	0.68	7.33	0.6	7.66e-11	Electrocardiographic conduction measures;
THYM	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg10224037	chr5:178157518	ZNF354A	0.95	7.83	0.63	6.91e-12	Neutrophil percentage of white cells;
THYM	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg24642844	chr7:1081250	C7orf50	-1.24	-5.83	-0.51	7.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7937	0.693	rs17726276	chr19:41291119	A/G	cg21869046	chr19:41225005	ITPKC	0.3	4.54	0.42	1.62e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Chronic obstructive pulmonary disease;Emphysema imaging phenotypes;
THYM	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg21658235	chr8:22456391	C8orf58	-0.57	-5.5	-0.49	3.19e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg11764359	chr7:65958608	NA	-0.83	-6.6	-0.56	2.37e-9	Aortic root size;
THYM	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs6138458	1.000	rs227618	chr20:24909472	T/C	cg06937882	chr20:24974362	C20orf3	-0.47	-4.48	-0.42	2.08e-5	Blood protein levels;
THYM	cis	rs9486719	1.000	rs2971603	chr6:97035418	C/T	cg06623918	chr6:96969491	KIAA0776	-0.73	-4.84	-0.44	5.06e-6	Migraine;Coronary artery disease;
THYM	cis	rs11630290	0.736	rs6494440	chr15:64145709	C/T	cg12036633	chr15:63758958	NA	0.87	4.72	0.44	8.1e-6	Iris characteristics;
THYM	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg03875235	chr11:625052	MUPCDH	0.54	4.78	0.44	6.49e-6	Systemic lupus erythematosus;
THYM	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg21798802	chr22:38057573	PDXP	0.47	5.37	0.48	5.51e-7	Fat distribution (HIV);
THYM	cis	rs2219968	0.525	rs2054826	chr8:78895005	G/A	cg00738934	chr8:78996279	NA	0.61	4.95	0.45	3.21e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11608355	1.000	rs3742020	chr12:109883254	T/C	cg11367159	chr12:110044531	NA	0.63	5.98	0.52	3.95e-8	Neuroticism;
THYM	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg03517284	chr6:25882590	NA	0.71	5.57	0.5	2.33e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg08901578	chr4:187885870	NA	-0.63	-5.79	-0.51	8.9e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12476592	0.543	rs2592387	chr2:63894834	C/T	cg17519650	chr2:63277830	OTX1	-0.69	-4.69	-0.43	9.3e-6	Childhood ear infection;
THYM	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg27129171	chr3:47204927	SETD2	0.8	7.67	0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg11764359	chr7:65958608	NA	0.87	7.04	0.59	3.02e-10	Aortic root size;
THYM	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg23352942	chr3:46931381	PTH1R	-0.59	-5.25	-0.47	9.32e-7	Birth weight;
THYM	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg02734326	chr4:10020555	SLC2A9	-0.71	-6.07	-0.53	2.58e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs59112743	0.510	rs1040410	chr6:15547476	G/A	cg10111214	chr6:14815676	NA	0.74	4.99	0.46	2.71e-6	Multiple keratinocyte cancers;
THYM	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg00684032	chr4:1343700	KIAA1530	0.58	5.26	0.47	8.87e-7	Obesity-related traits;
THYM	cis	rs36051895	0.664	rs7852755	chr9:5100862	C/T	cg02405213	chr9:5042618	JAK2	-1.0	-11.18	-0.75	5.12e-19	Pediatric autoimmune diseases;
THYM	cis	rs533581	0.873	rs555191	chr16:88978850	C/T	cg07027457	chr16:89025522	CBFA2T3	-0.63	-5.52	-0.49	2.91e-7	Social autistic-like traits;
THYM	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4243830	0.850	rs10864612	chr1:6593830	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.11	-7.56	-0.61	2.57e-11	Body mass index;
THYM	cis	rs941408	1.000	rs1736177	chr19:2791624	C/T	cg17333051	chr19:2783644	SGTA	0.58	5.01	0.46	2.53e-6	Total cholesterol levels;
THYM	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg03806693	chr22:41940476	POLR3H	0.97	8.42	0.65	3.87e-13	Vitiligo;
THYM	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-5.21	-0.47	1.09e-6	Mean platelet volume;
THYM	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg05335186	chr13:53173507	NA	-0.41	-4.85	-0.45	4.74e-6	Lewy body disease;
THYM	cis	rs3892630	0.620	rs10413279	chr19:33182746	A/G	cg22928329	chr19:33183273	NUDT19	-0.63	-5.05	-0.46	2.1e-6	Red blood cell traits;
THYM	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.43	1.27e-5	Breast cancer;
THYM	cis	rs7264396	0.563	rs11906854	chr20:34383634	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-4.57	-0.42	1.45e-5	Total cholesterol levels;
THYM	cis	rs858239	0.730	rs858290	chr7:23248036	A/G	cg05407003	chr7:23246146	NA	-0.73	-6.39	-0.55	6e-9	Cerebrospinal fluid biomarker levels;
THYM	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg10792982	chr14:105748885	BRF1	0.75	7.7	0.62	1.29e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs13202913	0.837	rs9397054	chr6:151789912	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.84	5.13	0.47	1.56e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs2273669	0.915	rs6908714	chr6:109294336	T/C	cg17117243	chr6:109341365	SESN1	-0.76	-4.55	-0.42	1.6e-5	Prostate cancer;
THYM	cis	rs995000	0.965	rs3850634	chr1:63050598	T/G	cg06896770	chr1:63153194	DOCK7	1.0	8.17	0.64	1.31e-12	Triglyceride levels;
THYM	cis	rs4478037	0.749	rs9311003	chr3:33131070	A/G	cg19404215	chr3:33155277	CRTAP	-0.89	-6.22	-0.54	1.34e-8	Major depressive disorder;
THYM	cis	rs240764	0.817	rs239211	chr6:101144965	A/C	cg21058520	chr6:100914733	NA	-0.58	-5.32	-0.48	6.97e-7	Neuroticism;
THYM	cis	rs6565180	0.507	rs4471699	chr16:30320307	G/T	cg17640201	chr16:30407289	ZNF48	-0.63	-4.81	-0.44	5.65e-6	Tonsillectomy;
THYM	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg03526776	chr6:41159608	TREML2	0.51	4.85	0.45	4.77e-6	Alzheimer's disease (late onset);
THYM	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg18230493	chr5:56204884	C5orf35	0.63	4.79	0.44	6.15e-6	Initial pursuit acceleration;
THYM	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg16325326	chr1:53192061	ZYG11B	-0.99	-11.53	-0.76	9.48e-20	Monocyte count;
THYM	cis	rs4808199	0.793	rs12459676	chr19:19425141	A/T	cg03709012	chr19:19516395	GATAD2A	1.19	6.29	0.54	9.56e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg26384229	chr12:38710491	ALG10B	0.99	7.63	0.62	1.81e-11	Bladder cancer;
THYM	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	14.79	0.83	2.2e-26	Chronic sinus infection;
THYM	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22857025	chr5:266934	NA	-1.59	-10.2	-0.72	6.04e-17	Breast cancer;
THYM	cis	rs17152411	1.000	rs12355869	chr10:126645231	G/T	cg07906193	chr10:126599966	NA	0.68	4.69	0.43	8.98e-6	Height;
THYM	cis	rs4866334	1.000	rs114675067	chr5:18448226	G/A	cg18608440	chr5:17519013	NA	1.16	5.19	0.47	1.17e-6	IgG glycosylation;
THYM	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg06713675	chr4:122721982	EXOSC9	-0.85	-9.54	-0.7	1.57e-15	Type 2 diabetes;
THYM	cis	rs240764	0.817	rs239189	chr6:101128787	C/T	cg21058520	chr6:100914733	NA	-0.57	-4.99	-0.46	2.77e-6	Neuroticism;
THYM	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg27534772	chr1:16042836	PLEKHM2	0.56	6.21	0.54	1.4e-8	Systolic blood pressure;
THYM	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.61	-0.43	1.27e-5	Type 2 diabetes;
THYM	cis	rs2066819	0.818	rs703830	chr12:56701872	T/C	cg26714650	chr12:56694279	CS	1.26	7.39	0.6	5.59e-11	Psoriasis vulgaris;
THYM	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.63	4.85	0.45	4.9100000000000004e-06	Eosinophil percentage of white cells;
THYM	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg20891283	chr12:69753455	YEATS4	1.06	10.24	0.72	5.15e-17	Blood protein levels;
THYM	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg23803603	chr1:2058230	PRKCZ	0.64	5.53	0.49	2.81e-7	Height;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg00822591	chr3:16306489	DPH3;OXNAD1	-1.39	-7.49	-0.61	3.58e-11	Pulmonary function decline;
THYM	cis	rs2456568	0.564	rs4608039	chr11:93624799	C/G	cg08514419	chr11:93583937	C11orf90	0.47	4.63	0.43	1.16e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg18252515	chr7:66147081	NA	-0.62	-4.55	-0.42	1.59e-5	Aortic root size;
THYM	cis	rs28595532	0.920	rs56283736	chr4:119747268	A/G	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8028313	0.731	rs4776964	chr15:68016955	T/G	cg24579218	chr15:68104479	NA	-0.72	-6.74	-0.57	1.19e-9	Obesity;
THYM	cis	rs9297145	0.724	rs62473013	chr7:98762418	G/T	cg05967295	chr7:98741636	SMURF1	0.86	6.39	0.55	6.04e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs2806561	0.734	rs11578046	chr1:23425139	G/A	cg12483005	chr1:23474871	LUZP1	0.53	5.34	0.48	6.33e-7	Height;
THYM	cis	rs7688540	0.771	rs61794997	chr4:222103	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.72	4.88	0.45	4.35e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	trans	rs877282	0.891	rs12767043	chr10:797943	C/T	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs12216545	0.765	rs12538773	chr7:150250055	A/G	cg08960815	chr7:150264767	GIMAP4	-0.89	-8.27	-0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs3087591	1.000	rs4239229	chr17:29425170	T/G	cg24425628	chr17:29625626	OMG;NF1	0.6	4.67	0.43	9.81e-6	Hip circumference;
THYM	cis	rs9915657	0.966	rs1042673	chr17:70121339	A/G	cg09344028	chr17:70110421	NA	0.49	4.79	0.44	6.24e-6	Thyroid hormone levels;
THYM	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7084402	0.523	rs10740730	chr10:60334939	T/C	cg09696939	chr10:60272079	BICC1	-0.49	-5.7	-0.5	1.35e-7	Refractive error;
THYM	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg23422044	chr7:1970798	MAD1L1	-0.76	-5.35	-0.48	5.98e-7	Bipolar disorder;
THYM	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	4.84	0.44	4.97e-6	Menarche (age at onset);
THYM	cis	rs6921919	0.609	rs1005127	chr6:28367658	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.5	-0.42	1.89e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs13082711	0.871	rs35572617	chr3:27499247	A/T	cg02860705	chr3:27208620	NA	0.72	5.14	0.47	1.46e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs11696501	0.688	rs4810465	chr20:44311354	A/G	cg11783356	chr20:44313418	WFDC10B	0.68	4.74	0.44	7.46e-6	Brain structure;
THYM	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs11966931	1.000	rs6925509	chr6:108140504	A/T	cg25323841	chr6:108444506	NA	-0.67	-4.65	-0.43	1.07e-5	Neutrophil percentage of white cells;
THYM	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	4.49	0.42	2.04e-5	Aortic root size;
THYM	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs921968	0.643	rs2243911	chr2:219529348	C/T	cg01872077	chr2:219646372	CYP27A1	-0.58	-4.49	-0.42	2e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg24692254	chr21:30365293	RNF160	-0.99	-9.28	-0.69	5.71e-15	Dental caries;
THYM	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs901683	1.000	rs9422650	chr10:46045761	G/T	cg18240400	chr10:46168597	ANUBL1	0.65	4.56	0.42	1.52e-5	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg19747945	chr6:42946146	PEX6	-0.34	-5.02	-0.46	2.4e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs3771570	0.901	rs869943	chr2:242431585	C/G	cg21155796	chr2:242212141	HDLBP	1.14	5.7	0.5	1.33e-7	Prostate cancer;
THYM	cis	rs4499344	0.531	rs259247	chr19:33147657	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.75	5.5	0.49	3.23e-7	Mean platelet volume;
THYM	cis	rs12291225	0.585	rs11023194	chr11:14369769	T/C	cg19336497	chr11:14380999	RRAS2	-0.91	-13.71	-0.82	3.02e-24	Sense of smell;
THYM	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs1003719	0.762	rs9975361	chr21:38450025	T/C	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs6906287	0.647	rs13192574	chr6:118875258	C/T	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.12e-7	Electrocardiographic conduction measures;
THYM	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg18876405	chr7:65276391	NA	0.61	5.2	0.47	1.13e-6	Aortic root size;
THYM	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg17143192	chr8:8559678	CLDN23	0.61	4.55	0.42	1.57e-5	Mood instability;
THYM	cis	rs9311676	0.609	rs62258077	chr3:58363371	T/C	cg26110898	chr3:58419937	PDHB	0.44	4.6	0.43	1.29e-5	Systemic lupus erythematosus;
THYM	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg06108461	chr20:60628389	TAF4	-1.03	-8.14	-0.64	1.49e-12	Body mass index;
THYM	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg25072359	chr17:41440525	NA	0.75	5.75	0.51	1.07e-7	Menopause (age at onset);
THYM	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs500891	0.525	rs1170484	chr6:84038522	A/G	cg21688264	chr6:84418724	SNAP91	0.74	4.51	0.42	1.87e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs6541297	1.000	rs6674744	chr1:230279011	C/T	cg20703242	chr1:230279135	GALNT2	0.92	6.25	0.54	1.14e-8	Coronary artery disease;
THYM	cis	rs9565309	0.579	rs75343734	chr13:77585992	C/A	cg13866767	chr13:78470850	EDNRB	1.06	4.81	0.44	5.76e-6	Morning vs. evening chronotype;
THYM	cis	rs1775715	0.835	rs12266771	chr10:32231380	G/A	cg04359828	chr10:32216031	ARHGAP12	0.41	5.2	0.47	1.14e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs2302612	0.528	rs12467251	chr2:102812194	G/T	cg13315345	chr2:102803985	IL1RL2	0.68	4.71	0.43	8.61e-6	Serum protein levels (sST2);
THYM	cis	rs600806	0.815	rs3768495	chr1:109935325	C/T	cg23032129	chr1:109941072	SORT1	-0.59	-5.03	-0.46	2.31e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4234284	0.556	rs9968173	chr3:126965437	G/A	cg27326032	chr3:127006922	NA	-0.82	-5.37	-0.48	5.46e-7	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
THYM	cis	rs630041	0.895	rs528614	chr1:20395868	G/A	cg15555335	chr1:20208763	OTUD3	0.81	4.58	0.43	1.39e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
THYM	cis	rs11157436	0.918	rs11157426	chr14:22621647	A/C	cg26433554	chr14:23315189	MMP14	0.44	4.61	0.43	1.24e-5	Neurocognitive impairment in HIV-1 infection (continuous);
THYM	cis	rs4891159	0.584	rs690397	chr18:74117767	C/T	cg24786174	chr18:74118243	ZNF516	0.97	14.75	0.83	2.65e-26	Longevity;
THYM	cis	rs10463554	0.824	rs60588319	chr5:102324360	G/A	cg23492399	chr5:102201601	PAM	-0.7	-5.25	-0.47	9.18e-7	Parkinson's disease;
THYM	cis	rs4242434	0.757	rs4872531	chr8:22529695	A/G	cg11461670	chr8:22454935	PDLIM2	0.36	5.72	0.51	1.23e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1003719	0.788	rs1155785	chr21:38447939	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.75	8.37	0.65	4.89e-13	Eosinophil percentage of white cells;
THYM	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg00645579	chr11:617140	IRF7;MUPCDH	-0.53	-6.0	-0.52	3.64e-8	Systemic lupus erythematosus;
THYM	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg00339695	chr16:24857497	SLC5A11	0.68	6.32	0.54	8.53e-9	Intelligence (multi-trait analysis);
THYM	cis	rs2046867	0.908	rs62251649	chr3:72809610	A/C	cg25664220	chr3:72788482	NA	-0.86	-6.54	-0.56	3.05e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs9527	0.569	rs10883801	chr10:104677887	A/C	cg04362960	chr10:104952993	NT5C2	0.6	4.62	0.43	1.2e-5	Arsenic metabolism;
THYM	cis	rs6960043	0.714	rs7784091	chr7:15047637	A/G	cg19272540	chr7:15055459	NA	-0.52	-5.58	-0.5	2.24e-7	Type 2 diabetes;
THYM	cis	rs9443189	0.570	rs7755068	chr6:76405700	A/G	cg01950844	chr6:76311363	SENP6	1.05	6.66	0.56	1.73e-9	Prostate cancer;
THYM	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.17	0.47	1.29e-6	Bipolar disorder;
THYM	cis	rs1160297	0.517	rs1451462	chr2:53123412	C/T	cg07782112	chr2:53107842	NA	-0.63	-5.43	-0.49	4.36e-7	Hemostatic factors and hematological phenotypes;
THYM	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg21385522	chr1:16154831	NA	0.69	4.75	0.44	7.18e-6	Systolic blood pressure;
THYM	cis	rs988913	0.957	rs9367597	chr6:54784652	C/T	cg19716238	chr6:54711378	FAM83B	0.51	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg05855489	chr10:104503620	C10orf26	0.56	4.49	0.42	1.99e-5	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg05025164	chr4:1340916	KIAA1530	0.91	7.11	0.59	2.11e-10	Longevity;
THYM	cis	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.62	0.43	1.23e-5	Obesity-related traits;
THYM	cis	rs6669072	0.565	rs12743498	chr1:91267791	C/A	cg08895590	chr1:91227319	NA	-0.39	-4.45	-0.42	2.32e-5	Cognitive function;
THYM	cis	rs1557488	0.565	rs10790845	chr11:126705844	C/T	cg03950493	chr11:126582183	KIRREL3	-0.37	-4.47	-0.42	2.15e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs2290159	0.948	rs5746255	chr3:12624321	A/G	cg23032965	chr3:12705835	RAF1	0.73	5.11	0.46	1.67e-6	Cholesterol, total;
THYM	cis	rs7941600	1.000	rs7941600	chr11:9280284	G/A	cg21110646	chr11:9336536	TMEM41B	1.2	6.93	0.58	4.91e-10	Coronary artery disease;
THYM	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.59	5.3	0.48	7.4e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9560113	1.000	rs4773386	chr13:112180896	C/G	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg22316451	chr20:60645197	NA	-0.48	-4.58	-0.43	1.4e-5	Body mass index;
THYM	trans	rs8073060	0.544	rs2626626	chr17:34026717	A/G	cg19694781	chr19:47549865	TMEM160	-1.02	-8.69	-0.67	1.01e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs11651000	0.857	rs56172120	chr17:45824904	G/A	cg06532163	chr17:45867833	NA	0.61	5.83	0.51	7.63e-8	IgG glycosylation;
THYM	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.55	-0.56	2.92e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7779057	0.698	rs13242287	chr7:106589960	G/A	cg04243581	chr7:107301842	SLC26A4;LOC286002	0.9	4.5	0.42	1.95e-5	Serum tamsulosin hydrochloride concentration;
THYM	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg11845111	chr2:191398756	TMEM194B	0.96	8.56	0.66	1.99e-13	Pulse pressure;
THYM	cis	rs4731207	0.596	rs922713	chr7:124607059	A/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs270601	0.866	rs460271	chr5:131630062	C/G	cg24060327	chr5:131705240	SLC22A5	-0.81	-6.14	-0.53	1.89e-8	Acylcarnitine levels;
THYM	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg18032289	chr17:61959525	GH2	-0.46	-4.49	-0.42	2.04e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs665401	0.640	rs88520	chr6:117181666	C/A	cg20376953	chr6:117187980	NA	0.61	4.89	0.45	4.05e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg07414643	chr4:187882934	NA	0.64	5.75	0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2933343	0.672	rs1872545	chr3:128645039	G/C	cg11901034	chr3:128598214	ACAD9	-0.69	-5.57	-0.5	2.32e-7	IgG glycosylation;
THYM	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg26038318	chr20:34205095	SPAG4	-0.63	-5.13	-0.47	1.54e-6	Total cholesterol levels;
THYM	cis	rs1729951	0.575	rs361241	chr3:136699561	C/A	cg21827317	chr3:136751795	NA	0.75	6.63	0.56	2.03e-9	Neuroticism;
THYM	cis	rs7705042	0.828	rs1835966	chr5:141501508	C/T	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs7246657	0.943	rs34603719	chr19:37794528	T/G	cg22634378	chr19:37742834	NA	0.66	5.48	0.49	3.53e-7	Coronary artery calcification;
THYM	cis	rs12956009	0.583	rs11082575	chr18:44905068	C/G	cg19077165	chr18:44547161	KATNAL2	0.49	4.69	0.43	9.24e-6	Educational attainment (years of education);
THYM	cis	rs10095849	0.608	rs4734001	chr8:39441186	T/A	cg01911981	chr8:39380341	ADAM3A	-0.58	-4.91	-0.45	3.84e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs1499972	0.941	rs62263116	chr3:117622719	T/G	cg07612923	chr3:117604196	NA	1.19	5.0	0.46	2.66e-6	Schizophrenia;
THYM	cis	rs36051895	0.587	rs7035915	chr9:5238253	C/T	cg02405213	chr9:5042618	JAK2	-0.9	-9.05	-0.68	1.75e-14	Pediatric autoimmune diseases;
THYM	cis	rs28595532	0.920	rs116106661	chr4:119749794	A/G	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg25427524	chr10:38739819	LOC399744	0.63	5.89	0.52	5.88e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Gout;
THYM	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg14784868	chr12:69753453	YEATS4	1.12	10.87	0.74	2.32e-18	Blood protein levels;
THYM	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.79	6.63	0.56	1.99e-9	Lymphocyte percentage of white cells;
THYM	cis	rs28595532	0.920	rs114575045	chr4:119739794	A/G	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs12701220	0.689	rs12533004	chr7:1095410	C/T	cg01699819	chr7:1052092	C7orf50	-0.83	-6.96	-0.58	4.26e-10	Bronchopulmonary dysplasia;
THYM	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg05234568	chr11:5960015	NA	-0.62	-5.51	-0.49	3.06e-7	DNA methylation (variation);
THYM	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9326248	0.581	rs6589590	chr11:116936081	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.66	5.27	0.48	8.49e-7	Blood protein levels;
THYM	cis	rs9527	0.590	rs10786741	chr10:104939182	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.49	-0.42	1.98e-5	Arsenic metabolism;
THYM	cis	rs28595532	0.920	rs17257945	chr4:119666465	T/A	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg06656553	chr16:89960601	TCF25	-0.95	-4.58	-0.43	1.41e-5	Skin colour saturation;
THYM	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg21385522	chr1:16154831	NA	-1.31	-14.68	-0.83	3.56e-26	Dilated cardiomyopathy;
THYM	cis	rs7027203	0.828	rs3996239	chr9:96611290	T/A	cg14598338	chr9:96623480	NA	-0.51	-5.65	-0.5	1.69e-7	DNA methylation (variation);
THYM	cis	rs36051895	0.623	rs11506668	chr9:5252789	C/T	cg02405213	chr9:5042618	JAK2	-0.95	-9.72	-0.71	6.45e-16	Pediatric autoimmune diseases;
THYM	cis	rs6539288	0.677	rs1348565	chr12:107329104	G/T	cg26297688	chr12:107349093	C12orf23	-0.51	-6.04	-0.53	2.94e-8	Total body bone mineral density;
THYM	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg06074448	chr4:187884817	NA	-1.0	-13.3	-0.81	2.08e-23	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs72627509	0.951	rs6554401	chr4:57825336	C/G	cg26694713	chr4:57773883	REST	0.72	4.56	0.42	1.55e-5	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs6430585	0.528	rs660002	chr2:136723504	C/T	cg04750100	chr2:136595281	LCT	0.53	5.67	0.5	1.53e-7	Corneal structure;
THYM	cis	rs9388451	0.531	rs9375414	chr6:126154475	G/A	cg05901451	chr6:126070800	HEY2	-0.6	-4.48	-0.42	2.1e-5	Brugada syndrome;
THYM	cis	rs11030122	0.702	rs66503725	chr11:3980998	G/A	cg22027985	chr11:4115532	RRM1	-0.48	-4.59	-0.43	1.36e-5	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7200543	1.000	rs7200543	chr16:15129970	C/T	cg01933576	chr16:15083564	PDXDC1	0.97	8.22	0.64	1.01e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg08999081	chr20:33150536	PIGU	0.56	4.79	0.44	6.1e-6	Coronary artery disease;
THYM	cis	rs977987	0.806	rs11641587	chr16:75464419	G/T	cg03315344	chr16:75512273	CHST6	0.73	5.83	0.51	7.5e-8	Dupuytren's disease;
THYM	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg03433033	chr1:76189801	ACADM	0.77	10.09	0.72	1.07e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg00129232	chr17:37814104	STARD3	-0.76	-5.52	-0.49	2.94e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg15242686	chr22:24348715	GSTTP1	0.55	5.08	0.46	1.9e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs36051895	0.695	rs7043489	chr9:5023604	A/C	cg02405213	chr9:5042618	JAK2	-1.03	-10.87	-0.74	2.36e-18	Pediatric autoimmune diseases;
THYM	cis	rs8067545	0.750	rs11867585	chr17:19992607	A/G	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.63e-6	Schizophrenia;
THYM	cis	rs4653767	1.000	rs708774	chr1:226921530	C/G	cg05262829	chr1:226921576	ITPKB	-0.54	-5.34	-0.48	6.34e-7	Parkinson's disease;
THYM	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs4654899	0.965	rs10753513	chr1:21492168	T/C	cg01072550	chr1:21505969	NA	0.74	6.76	0.57	1.11e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs11771526	0.901	rs10282699	chr7:32297967	C/T	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs7107770	1.000	rs35183670	chr11:125090912	G/A	cg07747661	chr11:125106135	PKNOX2	-0.85	-4.91	-0.45	3.75e-6	Photic sneeze reflex;
THYM	cis	rs79839061	0.732	rs73207773	chr4:827249	G/A	cg23992470	chr4:843637	GAK	1.15	5.11	0.46	1.68e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6463094	0.713	rs1029619	chr7:42259381	T/C	cg00560277	chr7:42267269	GLI3	-0.57	-4.51	-0.42	1.85e-5	Gut microbiome composition (summer);
THYM	cis	rs7216064	0.953	rs11079705	chr17:65835452	A/T	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs829883	0.664	rs829876	chr12:98842138	A/G	cg25150519	chr12:98850993	NA	0.53	5.22	0.47	1.05e-6	Colorectal adenoma (advanced);
THYM	cis	rs7084402	0.967	rs10763551	chr10:60273898	G/A	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg25566285	chr7:158114605	PTPRN2	0.89	10.22	0.72	5.47e-17	Calcium levels;
THYM	cis	rs2404602	0.735	rs3765115	chr15:76673716	T/C	cg23625390	chr15:77176239	SCAPER	-0.65	-4.7	-0.43	8.68e-6	Blood metabolite levels;
THYM	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs4788570	0.609	rs72795869	chr16:71485515	C/T	cg06353428	chr16:71660113	MARVELD3	-1.04	-5.01	-0.46	2.5e-6	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs9814567	0.793	rs55940445	chr3:134306064	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	8.51	0.66	2.53e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2408955	0.522	rs4760612	chr12:48421856	C/T	cg21466736	chr12:48725269	NA	0.48	4.64	0.43	1.11e-5	Glycated hemoglobin levels;
THYM	cis	rs12681287	0.547	rs56752411	chr8:87515156	C/T	cg27223183	chr8:87520930	FAM82B	-0.71	-5.44	-0.49	4.19e-7	Caudate activity during reward;
THYM	cis	rs8078723	0.510	rs9898547	chr17:38136026	G/T	cg17467752	chr17:38218738	THRA	-0.72	-5.36	-0.48	5.91e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs533581	0.866	rs502258	chr16:88968547	G/A	cg15388900	chr16:88312269	NA	-0.61	-4.65	-0.43	1.06e-5	Social autistic-like traits;
THYM	cis	rs12142240	0.738	rs67545510	chr1:46806242	G/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg02725872	chr8:58115012	NA	-0.74	-5.52	-0.49	2.98e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg10360139	chr7:1886902	MAD1L1	0.53	4.54	0.42	1.65e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs6558530	0.730	rs6991773	chr8:1723177	A/G	cg09410841	chr8:1729607	CLN8	0.79	5.99	0.52	3.77e-8	Systolic blood pressure;
THYM	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg11663144	chr21:46675770	NA	-0.72	-10.48	-0.73	1.54e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg06481639	chr22:41940642	POLR3H	-0.6	-4.77	-0.44	6.6e-6	Neuroticism;
THYM	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg20007245	chr22:24372913	LOC391322	-0.73	-6.6	-0.56	2.32e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9486719	0.947	rs6916232	chr6:96985959	A/T	cg18709589	chr6:96969512	KIAA0776	0.66	4.61	0.43	1.25e-5	Migraine;Coronary artery disease;
THYM	cis	rs6987853	0.814	rs2923415	chr8:42455577	A/G	cg09913449	chr8:42400586	C8orf40	0.84	7.87	0.63	5.79e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg21110456	chr7:2059412	MAD1L1	-0.48	-5.35	-0.48	6.06e-7	Neuroticism;
THYM	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-6.02	-0.53	3.28e-8	Gut microbiome composition (summer);
THYM	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg12463550	chr7:65579703	CRCP	-0.56	-4.67	-0.43	9.84e-6	Aortic root size;
THYM	cis	rs1372520	0.564	rs356186	chr4:90705364	A/G	cg01966878	chr4:90757139	SNCA	-0.61	-4.69	-0.43	9.28e-6	Neuroticism;
THYM	cis	rs67072384	0.818	rs1872128	chr11:72465526	C/T	cg01380194	chr11:72452482	ARAP1	-0.81	-4.57	-0.42	1.49e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	trans	rs877282	0.898	rs11253339	chr10:759640	C/T	cg22713356	chr15:30763199	NA	1.36	10.13	0.72	8.77e-17	Uric acid levels;
THYM	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg27129171	chr3:47204927	SETD2	0.77	7.65	0.62	1.67e-11	Colorectal cancer;
THYM	cis	rs259282	0.589	rs6510271	chr19:33117666	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.6	4.47	0.42	2.14e-5	Schizophrenia;
THYM	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg26031613	chr14:104095156	KLC1	0.79	5.22	0.47	1.06e-6	Body mass index;
THYM	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03762994	chr17:6899332	ALOX12	0.71	9.85	0.71	3.48e-16	Tonsillectomy;
THYM	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg00071950	chr4:10020882	SLC2A9	-0.66	-5.9	-0.52	5.59e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.16	7.95	0.63	3.91e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg08859206	chr1:53392774	SCP2	0.51	5.48	0.49	3.47e-7	Monocyte count;
THYM	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs7119	0.651	rs12902948	chr15:77849254	T/C	cg10437265	chr15:77819839	NA	0.73	6.7	0.57	1.44e-9	Type 2 diabetes;
THYM	cis	rs12137294	0.866	rs1172153	chr1:205220661	T/C	cg17889831	chr1:205181581	DSTYK	-0.41	-5.09	-0.46	1.82e-6	Red cell distribution width;
THYM	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7771547	0.573	rs547026	chr6:36398616	G/A	cg07856975	chr6:36356162	ETV7	0.52	4.72	0.44	8.26e-6	Platelet distribution width;
THYM	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs4262150	0.767	rs4958596	chr5:152327668	A/G	cg13583454	chr5:153038077	GRIA1	-0.91	-6.15	-0.53	1.83e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg13866156	chr1:1669148	SLC35E2	-0.69	-6.76	-0.57	1.1e-9	Body mass index;
THYM	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg24503407	chr1:205819492	PM20D1	0.65	5.04	0.46	2.18e-6	Menarche (age at onset);
THYM	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs548181	0.736	rs543389	chr11:125464841	A/G	cg03464685	chr11:125439445	EI24	1.28	7.71	0.62	1.24e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg19693284	chr19:2783607	SGTA	0.83	6.02	0.53	3.2e-8	Total cholesterol levels;
THYM	cis	rs73787773	0.741	rs17253030	chr5:111465546	C/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.99	-5.26	-0.48	8.83e-7	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.54e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs892961	1.000	rs1110638	chr17:75400690	T/C	cg11351908	chr17:75402473	SEPT9	0.6	6.06	0.53	2.71e-8	Airflow obstruction;
THYM	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.74	5.66	0.5	1.61e-7	Eosinophil percentage of white cells;
THYM	cis	rs2718058	0.601	rs2709104	chr7:37762810	A/G	cg15028436	chr7:37888078	TXNDC3	-0.59	-4.5	-0.42	1.95e-5	Alzheimer's disease (late onset);
THYM	cis	rs8101881	0.510	rs7257884	chr19:33357844	G/C	cg16861209	chr19:33361127	SLC7A9	0.51	4.74	0.44	7.39e-6	Blood metabolite levels;Urinary metabolites;Urinary metabolites (H-NMR features);
THYM	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg21280719	chr6:42927975	GNMT	-0.51	-6.84	-0.57	7.67e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4631830	0.720	rs2125771	chr10:51506957	C/T	cg10326726	chr10:51549505	MSMB	-0.61	-6.17	-0.53	1.67e-8	Prostate-specific antigen levels;
THYM	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg23791538	chr6:167370224	RNASET2	-0.72	-5.66	-0.5	1.59e-7	Crohn's disease;
THYM	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs6575793	1.000	rs8006389	chr14:101033435	A/G	cg13521842	chr14:101036202	BEGAIN	-0.53	-4.82	-0.44	5.33e-6	Menarche (age at onset);
THYM	cis	rs4919687	0.679	rs12762176	chr10:104499232	A/T	cg05855489	chr10:104503620	C10orf26	0.7	5.51	0.49	3.01e-7	Colorectal cancer;
THYM	cis	rs4262150	0.960	rs4285285	chr5:152289810	C/T	cg06854687	chr5:151642065	NA	-0.6	-4.76	-0.44	6.96e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4478037	0.558	rs55980934	chr3:33081696	C/T	cg19404215	chr3:33155277	CRTAP	1.13	6.07	0.53	2.59e-8	Major depressive disorder;
THYM	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4720575	1.000	rs1074575	chr7:47090545	A/C	cg00036614	chr7:47093842	NA	-0.59	-5.24	-0.47	9.71e-7	Angiotensin-converting enzyme inhibitor intolerance;
THYM	cis	rs3126085	0.673	rs3126089	chr1:152306187	T/A	cg26020982	chr1:152196106	HRNR	-0.36	-4.95	-0.45	3.19e-6	Atopic dermatitis;
THYM	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg23815491	chr16:72088622	HP	0.68	5.23	0.47	1.01e-6	Fibrinogen levels;
THYM	cis	rs9311676	0.618	rs62258135	chr3:58403330	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg02782426	chr3:40428986	ENTPD3	0.5	4.62	0.43	1.18e-5	Renal cell carcinoma;
THYM	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg01304814	chr3:48885189	PRKAR2A	0.96	4.86	0.45	4.55e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs13315871	0.929	rs11130627	chr3:58315749	G/A	cg12435725	chr3:58293450	RPP14	-0.53	-5.51	-0.49	3.09e-7	Cholesterol, total;
THYM	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg18252515	chr7:66147081	NA	0.6	4.52	0.42	1.76e-5	Aortic root size;
THYM	cis	rs6700896	0.966	rs7542446	chr1:66091106	G/A	cg04111102	chr1:66153794	NA	0.53	4.7	0.43	8.76e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg22535103	chr8:58192502	C8orf71	-0.89	-5.1	-0.46	1.73e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7098100	0.673	rs10740991	chr10:22058137	G/C	cg04231319	chr10:21824447	MLLT10	0.32	4.45	0.42	2.34e-5	Breast cancer;
THYM	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg05650719	chr12:132293520	NA	-0.53	-5.0	-0.46	2.61e-6	Migraine;
THYM	cis	rs79149102	0.579	rs73438569	chr15:75354486	T/A	cg17294928	chr15:75287854	SCAMP5	-0.94	-5.03	-0.46	2.27e-6	Lung cancer;
THYM	cis	rs995000	0.931	rs2131925	chr1:63025942	G/T	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs55823223	0.648	rs11867560	chr17:73857206	A/G	cg08125733	chr17:73851984	WBP2	1.24	8.44	0.65	3.58e-13	Psoriasis;
THYM	cis	rs7840202	0.524	rs35655607	chr8:103424808	G/A	cg09990700	chr8:103251014	RRM2B	-1.04	-4.96	-0.45	3.14e-6	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);
THYM	cis	rs1055129	0.682	rs7217432	chr17:73834604	A/G	cg02627403	chr17:73823769	UNC13D	-0.45	-4.59	-0.43	1.38e-5	White matter hyperintensity burden;
THYM	cis	rs3540	0.533	rs2601197	chr15:90940059	C/A	cg22089800	chr15:90895588	ZNF774	0.72	5.85	0.51	6.82e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs9549260	0.848	rs966968	chr13:41248037	C/T	cg21288729	chr13:41239152	FOXO1	-0.71	-5.53	-0.49	2.86e-7	Red blood cell count;
THYM	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg17063962	chr7:91808500	NA	-1.11	-12.72	-0.79	3.08e-22	Breast cancer;
THYM	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg08807101	chr21:30365312	RNF160	-0.81	-6.26	-0.54	1.1e-8	Dental caries;
THYM	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22433210	chr17:43662623	NA	0.86	6.95	0.58	4.51e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2710642	0.586	rs62180020	chr2:62819915	C/G	cg17519650	chr2:63277830	OTX1	0.62	4.54	0.42	1.67e-5	LDL cholesterol levels;LDL cholesterol;
THYM	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg23803603	chr1:2058230	PRKCZ	0.63	5.37	0.48	5.58e-7	Height;
THYM	trans	rs2136093	0.600	rs12137490	chr1:90910544	C/T	cg21057494	chr3:45066971	CLEC3B	0.53	7.07	0.59	2.65e-10	Response to antidepressants;
THYM	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg04362960	chr10:104952993	NT5C2	0.58	4.69	0.43	9.04e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs17608059	0.518	rs4792436	chr17:13972307	T/A	cg27005118	chr17:13972210	COX10	0.67	7.95	0.63	3.9e-12	Temperament;
THYM	cis	rs1445130	1.000	rs1445130	chr2:18834651	A/G	cg21927971	chr2:17837235	VSNL1	0.71	4.46	0.42	2.24e-5	Bulimia nervosa;
THYM	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg12527260	chr11:63683744	RCOR2	0.58	6.89	0.58	6.01e-10	Pulse pressure;
THYM	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg01191920	chr7:158217561	PTPRN2	1.06	12.51	0.79	8.38e-22	Obesity-related traits;
THYM	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg23982607	chr1:1823379	GNB1	-0.94	-10.23	-0.72	5.46e-17	Body mass index;
THYM	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg04111992	chr7:158790115	NA	-0.58	-4.93	-0.45	3.46e-6	Facial morphology (factor 20);
THYM	cis	rs9560113	0.960	rs9560101	chr13:112173798	G/A	cg14154082	chr13:112174009	NA	0.86	8.0	0.63	2.95e-12	Menarche (age at onset);
THYM	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg08885076	chr2:99613938	TSGA10	-0.63	-6.01	-0.52	3.46e-8	Chronic sinus infection;
THYM	cis	rs12704876	0.509	rs6966856	chr7:96367627	G/A	cg03808172	chr7:96339361	SHFM1	0.73	5.11	0.46	1.68e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg04398451	chr17:18023971	MYO15A	-0.83	-7.73	-0.62	1.1e-11	Total body bone mineral density;
THYM	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg23851026	chr2:136556271	LCT	-0.5	-4.76	-0.44	6.97e-6	Mosquito bite size;
THYM	cis	rs2712184	0.967	rs2541385	chr2:217669595	C/T	cg05032264	chr2:217675019	NA	-0.56	-4.79	-0.44	6.05e-6	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs6495122	0.532	rs2472304	chr15:75044238	G/A	cg14664628	chr15:75095509	CSK	-0.66	-4.95	-0.45	3.24e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg24503407	chr1:205819492	PM20D1	1.13	11.9	0.77	1.6e-20	Menarche (age at onset);
THYM	cis	rs4731207	0.562	rs6975534	chr7:124686461	G/T	cg05285228	chr7:124571219	POT1	-0.65	-5.0	-0.46	2.64e-6	Cutaneous malignant melanoma;
THYM	cis	rs924712	0.645	rs239779	chr6:54757531	A/G	cg04690482	chr6:54711388	FAM83B	0.45	5.17	0.47	1.32e-6	Breast cancer;
THYM	cis	rs2108622	0.727	rs3093216	chr19:15987737	A/G	cg13772218	chr19:15982569	NA	0.5	4.48	0.42	2.06e-5	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6754311	0.638	rs1011361	chr2:136553639	G/A	cg23851026	chr2:136556271	LCT	-0.58	-6.06	-0.53	2.74e-8	Mosquito bite size;
THYM	cis	rs8067545	0.611	rs11653630	chr17:20189046	C/T	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs17826219	0.789	rs4794873	chr17:28748352	C/T	cg17105886	chr17:28927953	LRRC37B2	1.08	4.98	0.45	2.85e-6	Body mass index;
THYM	cis	rs72627123	0.867	rs78742875	chr14:74457214	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.14	6.41	0.55	5.69e-9	Morning vs. evening chronotype;
THYM	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg00310523	chr12:86230176	RASSF9	0.61	5.31	0.48	7.29e-7	Major depressive disorder;
THYM	cis	rs1692580	0.840	rs263526	chr1:2173504	T/C	cg24578937	chr1:2090814	PRKCZ	0.51	5.18	0.47	1.24e-6	Coronary artery disease;
THYM	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg14983838	chr19:29218262	NA	1.09	9.79	0.71	4.67e-16	Methadone dose in opioid dependence;
THYM	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg25072359	chr17:41440525	NA	0.67	4.64	0.43	1.1e-5	Menopause (age at onset);
THYM	cis	rs877282	0.945	rs71489301	chr10:770191	A/G	cg10556349	chr10:835070	NA	-0.73	-5.09	-0.46	1.79e-6	Uric acid levels;
THYM	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13418717	1.000	rs951816	chr2:127665049	A/G	cg25501666	chr2:127640322	NA	1.4	6.47	0.55	4.32e-9	Heart failure;
THYM	cis	rs295140	0.507	rs13019821	chr2:201106815	C/G	cg23649088	chr2:200775458	C2orf69	-0.64	-5.53	-0.49	2.81e-7	QT interval;
THYM	cis	rs4481887	0.830	rs10888341	chr1:248441995	T/C	cg00666640	chr1:248458726	OR2T12	0.56	4.75	0.44	7.28e-6	Common traits (Other);
THYM	cis	rs6980334	0.798	rs10280394	chr7:137767201	C/A	cg03464514	chr7:137028442	PTN	0.56	4.5	0.42	1.9e-5	Blood metabolite ratios;
THYM	cis	rs7224737	1.000	rs7225608	chr17:40298326	G/A	cg20291162	chr17:40259547	DHX58	-0.73	-6.9	-0.58	5.87e-10	Fibrinogen levels;
THYM	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg01073479	chr16:3509474	NAT15	0.55	5.46	0.49	3.73e-7	Tuberculosis;
THYM	cis	rs901683	0.850	rs36109121	chr10:46039511	G/A	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs17604090	0.938	rs68158127	chr7:29684698	A/G	cg19413766	chr7:29689036	LOC646762	-0.93	-5.09	-0.46	1.77e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs6547741	0.844	rs7586655	chr2:27915659	A/G	cg27432699	chr2:27873401	GPN1	-0.89	-8.13	-0.64	1.63e-12	Oral cavity cancer;
THYM	cis	rs8067545	0.750	rs4925079	chr17:19986861	T/A	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.64e-6	Schizophrenia;
THYM	cis	rs7104764	1.000	rs2293167	chr11:211644	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	-1.12	-9.8	-0.71	4.34e-16	Menarche (age at onset);
THYM	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg11764359	chr7:65958608	NA	-0.81	-6.42	-0.55	5.45e-9	Aortic root size;
THYM	cis	rs10927875	0.518	rs1763604	chr1:16339772	C/G	cg21385522	chr1:16154831	NA	0.66	4.74	0.44	7.53e-6	Dilated cardiomyopathy;
THYM	cis	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs1062746	0.502	rs11649601	chr16:87339220	G/C	cg02258303	chr16:87377426	FBXO31	-0.61	-4.82	-0.44	5.53e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs2276314	0.857	rs28375959	chr18:33601534	T/G	cg19628046	chr18:33552617	C18orf21	0.75	5.33	0.48	6.55e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.33e-5	Retinal vascular caliber;
THYM	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg01017244	chr2:74357527	NA	1.08	9.62	0.7	1.09e-15	Gestational age at birth (maternal effect);
THYM	cis	rs17253792	0.822	rs75509578	chr14:56133493	G/A	cg01858014	chr14:56050164	KTN1	-1.06	-4.54	-0.42	1.66e-5	Putamen volume;
THYM	cis	rs2282300	0.739	rs1717772	chr11:30340133	C/T	cg09906309	chr11:30344399	C11orf46	-0.73	-5.33	-0.48	6.63e-7	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg06565975	chr8:143823917	SLURP1	0.44	4.93	0.45	3.51e-6	Urinary tract infection frequency;
THYM	cis	rs9549260	0.727	rs4603422	chr13:41148353	T/C	cg21288729	chr13:41239152	FOXO1	0.73	5.63	0.5	1.82e-7	Red blood cell count;
THYM	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg03806693	chr22:41940476	POLR3H	-1.06	-10.01	-0.72	1.6e-16	Vitiligo;
THYM	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg09549813	chr16:4587862	C16orf5	-0.6	-6.76	-0.57	1.12e-9	Schizophrenia;
THYM	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs11645898	0.748	rs72791112	chr16:72204069	T/A	cg03805757	chr16:71968109	PKD1L3	-0.71	-5.35	-0.48	5.96e-7	Blood protein levels;
THYM	cis	rs9527	0.615	rs1556960	chr10:104726673	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-4.68	-0.43	9.59e-6	Arsenic metabolism;
THYM	cis	rs11677370	0.533	rs12711971	chr2:3820821	G/C	cg17052675	chr2:3827356	NA	-0.64	-6.3	-0.54	9.25e-9	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4595586	0.545	rs12816546	chr12:39398913	C/T	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg04756594	chr16:24857601	SLC5A11	-0.79	-5.38	-0.48	5.45e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3741151	1.000	rs75004180	chr11:73024739	A/G	cg17517138	chr11:73019481	ARHGEF17	0.99	5.88	0.52	5.97e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg00376283	chr12:123451042	ABCB9	0.71	4.87	0.45	4.45e-6	Neutrophil percentage of white cells;
THYM	cis	rs6728642	0.572	rs13387563	chr2:97600916	C/A	cg26665480	chr2:98280029	ACTR1B	-0.74	-5.01	-0.46	2.56e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs950880	0.710	rs3732123	chr2:103018077	C/G	cg03938978	chr2:103052716	IL18RAP	-0.53	-4.62	-0.43	1.2e-5	Serum protein levels (sST2);
THYM	cis	rs853679	0.515	rs4580862	chr6:28367663	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.5	-0.42	1.89e-5	Depression;
THYM	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg00786635	chr1:25594202	NA	0.99	8.22	0.64	1.04e-12	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs877282	0.682	rs2265092	chr10:780293	C/T	cg10556349	chr10:835070	NA	0.6	4.65	0.43	1.07e-5	Uric acid levels;
THYM	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.64	0.5	1.77e-7	Height;
THYM	cis	rs4455778	0.501	rs10227306	chr7:49048026	A/G	cg26309511	chr7:48887640	NA	0.63	5.47	0.49	3.67e-7	Lung cancer in never smokers;
THYM	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg03388043	chr17:80084554	CCDC57	-0.66	-5.66	-0.5	1.61e-7	Life satisfaction;
THYM	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2299587	0.623	rs7816738	chr8:17768482	A/G	cg01800426	chr8:17659068	MTUS1	-0.55	-4.48	-0.42	2.11e-5	Economic and political preferences;
THYM	cis	rs9790314	0.747	rs7619011	chr3:160855676	A/G	cg04691961	chr3:161091175	C3orf57	-0.66	-5.23	-0.47	9.96e-7	Morning vs. evening chronotype;
THYM	cis	rs8453	0.708	rs10858054	chr1:115338190	G/T	cg00771553	chr1:116184225	VANGL1	0.34	4.48	0.42	2.07e-5	Autism;
THYM	cis	rs10466239	0.892	rs74701654	chr10:43846311	G/A	cg12352960	chr10:43428578	NA	-0.96	-4.63	-0.43	1.17e-5	Telomere length;
THYM	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg25918947	chr17:41365094	TMEM106A	-0.59	-4.92	-0.45	3.66e-6	Menopause (age at onset);
THYM	cis	rs514406	0.893	rs6682024	chr1:53439525	T/C	cg24675658	chr1:53192096	ZYG11B	0.57	4.54	0.42	1.62e-5	Monocyte count;
THYM	cis	rs9972944	0.756	rs7220733	chr17:63764890	A/T	cg07283582	chr17:63770753	CCDC46	-0.65	-5.1	-0.46	1.76e-6	Total body bone mineral density;
THYM	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.88	-7.81	-0.63	7.51e-12	Monocyte percentage of white cells;
THYM	cis	rs8114671	0.967	rs2069952	chr20:33763951	C/T	cg08999081	chr20:33150536	PIGU	0.53	4.77	0.44	6.63e-6	Height;
THYM	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs977987	0.778	rs8057849	chr16:75443816	T/C	cg03315344	chr16:75512273	CHST6	0.77	6.3	0.54	9.16e-9	Dupuytren's disease;
THYM	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg08859206	chr1:53392774	SCP2	-0.81	-9.43	-0.7	2.78e-15	Monocyte count;
THYM	cis	rs55665837	0.961	rs11023226	chr11:14458817	C/T	cg19336497	chr11:14380999	RRAS2	-0.64	-7.04	-0.59	3e-10	Vitamin D levels;
THYM	trans	rs637571	0.607	rs575479	chr11:65690300	T/G	cg17712092	chr4:129076599	LARP1B	1.03	9.82	0.71	3.97e-16	Eosinophil percentage of white cells;
THYM	cis	rs1018836	0.828	rs9297870	chr8:91570691	C/G	cg16814680	chr8:91681699	NA	-0.92	-8.12	-0.64	1.64e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs75045569	1.000	rs75045569	chr7:143109208	T/G	cg05908241	chr7:143109367	NA	-0.61	-5.47	-0.49	3.71e-7	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.05	-0.64	2.37e-12	Life satisfaction;
THYM	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg20999797	chr1:1681921	NA	-0.45	-4.82	-0.44	5.41e-6	Body mass index;
THYM	cis	rs6582630	0.577	rs12312748	chr12:38343326	T/C	cg10518543	chr12:38710700	ALG10B	-0.57	-4.47	-0.42	2.16e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs3791406	1.000	rs3791412	chr2:240031088	A/G	cg14550559	chr2:240039617	HDAC4	-0.6	-5.42	-0.49	4.58e-7	Skin aging (microtopography measurement);
THYM	cis	rs28830936	0.510	rs12440605	chr15:42102285	A/G	cg17847044	chr15:42102381	MAPKBP1	0.36	6.59	0.56	2.41e-9	Diastolic blood pressure;
THYM	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs459482	1.000	rs461981	chr21:42794081	T/C	cg16733866	chr21:42792609	MX1	0.56	4.88	0.45	4.2e-6	IgG glycosylation;
THYM	cis	rs7640424	0.819	rs179046	chr3:107840773	A/C	cg09227934	chr3:107805635	CD47	-0.54	-4.56	-0.42	1.52e-5	Body mass index;
THYM	cis	rs9527	0.590	rs1926037	chr10:104878010	A/C	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs9467160	0.520	rs793671	chr6:24438662	C/T	cg20631270	chr6:24437470	GPLD1	-0.57	-4.84	-0.45	4.94e-6	Liver enzyme levels;
THYM	cis	rs13102973	0.640	rs4608865	chr4:135885434	G/A	cg14419869	chr4:135874104	NA	-0.77	-6.46	-0.55	4.35e-9	Subjective well-being;
THYM	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg06558623	chr16:89946397	TCF25	1.42	6.85	0.58	7.17e-10	Skin colour saturation;
THYM	cis	rs11585357	1.000	rs11203346	chr1:17600822	A/G	cg08277548	chr1:17600880	PADI3	-0.96	-6.55	-0.56	2.97e-9	Hair shape;
THYM	cis	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.59	6.1	0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg01386294	chr6:25732093	NA	-0.89	-4.51	-0.42	1.84e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs4747241	0.774	rs10762507	chr10:74058471	C/G	cg07828833	chr10:74069493	NA	0.59	5.02	0.46	2.43e-6	Heschl's gyrus morphology;
THYM	cis	rs2625529	0.668	rs34487006	chr15:72462350	G/T	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs921968	0.643	rs3770218	chr2:219525335	C/T	cg02176678	chr2:219576539	TTLL4	0.6	5.84	0.51	7.3e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg07570687	chr10:102243282	WNT8B	0.79	7.32	0.6	8.03e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9788721	0.902	rs17486195	chr15:78865197	A/G	cg18825076	chr15:78729989	IREB2	-0.54	-4.77	-0.44	6.53e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs600231	0.708	rs2957269	chr11:65243007	C/G	cg17120908	chr11:65337727	SSSCA1	-0.61	-4.76	-0.44	6.93e-6	Bone mineral density;
THYM	cis	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg24672777	chr11:48374446	OR4C45	-0.65	-4.54	-0.42	1.67e-5	Coronary artery disease;
THYM	cis	rs752010	0.871	rs2038976	chr1:42094498	A/G	cg06885757	chr1:42089581	HIVEP3	0.52	6.5	0.56	3.62e-9	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs34638657	0.827	rs3829548	chr16:82206238	C/A	cg07307142	chr16:82071433	HSD17B2	-0.71	-6.33	-0.54	8.06e-9	Lung adenocarcinoma;
THYM	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg18681998	chr4:17616180	MED28	0.79	6.71	0.57	1.38e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.56	-5.2	-0.47	1.12e-6	Lymphocyte counts;
THYM	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg10360139	chr7:1886902	MAD1L1	-0.82	-7.31	-0.6	8.13e-11	Bipolar disorder and schizophrenia;
THYM	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg10047753	chr17:41438598	NA	1.18	11.26	0.76	3.4e-19	Menopause (age at onset);
THYM	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg06784218	chr1:46089804	CCDC17	-0.29	-4.61	-0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6700896	0.931	rs4655584	chr1:66155515	T/G	cg04111102	chr1:66153794	NA	0.57	5.42	0.49	4.47e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7731657	0.537	rs10079657	chr5:130187843	T/C	cg08523029	chr5:130500466	HINT1	-0.65	-4.65	-0.43	1.09e-5	Fasting plasma glucose;
THYM	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg11663144	chr21:46675770	NA	-0.71	-9.92	-0.71	2.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.65	0.5	1.64e-7	Tonsillectomy;
THYM	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg01181863	chr3:195395398	SDHAP2	-0.63	-4.89	-0.45	4.09e-6	Pancreatic cancer;
THYM	cis	rs8048589	0.604	rs2175020	chr16:12219190	C/T	cg01990910	chr16:12207648	SNX29	-0.53	-5.9	-0.52	5.49e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg07936489	chr17:37558343	FBXL20	-0.64	-4.73	-0.44	7.94e-6	Asthma;
THYM	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg08847533	chr14:75593920	NEK9	-0.93	-10.06	-0.72	1.22e-16	Height;
THYM	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg00129232	chr17:37814104	STARD3	-0.78	-5.15	-0.47	1.39e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs28595532	0.920	rs115084148	chr4:119739290	A/G	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs2282032	0.527	rs8020828	chr14:90768183	C/T	cg14092571	chr14:90743983	NA	0.63	6.26	0.54	1.11e-8	Longevity;
THYM	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	trans	rs9929218	0.551	rs2296409	chr16:68713730	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.1	15.05	0.84	6.84e-27	Colorectal cancer;
THYM	cis	rs9311676	0.632	rs11719192	chr3:58431817	C/G	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs4076764	0.914	rs12123378	chr1:163377846	C/T	cg06092702	chr1:163392909	NA	-0.61	-5.3	-0.48	7.43e-7	Motion sickness;
THYM	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg21100191	chr22:23484243	RTDR1	0.75	6.63	0.56	2.01e-9	Bone mineral density;
THYM	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg09260853	chr1:2094483	PRKCZ	-0.44	-4.56	-0.42	1.55e-5	Height;
THYM	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.87	-4.64	-0.43	1.11e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.0	-5.48	-0.49	3.49e-7	Body mass index;
THYM	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08109568	chr15:31115862	NA	-0.76	-6.77	-0.57	1.05e-9	Huntington's disease progression;
THYM	cis	rs4595586	0.545	rs12819907	chr12:39356906	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs7020830	0.898	rs7038219	chr9:37182892	C/A	cg14294708	chr9:37120828	ZCCHC7	1.21	13.68	0.81	3.45e-24	Schizophrenia;
THYM	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs55882075	0.765	rs34329357	chr5:179130408	G/C	cg14593053	chr5:179126677	CANX	0.66	4.88	0.45	4.25e-6	Monocyte percentage of white cells;
THYM	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Body mass index;
THYM	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3820068	0.608	rs7552400	chr1:16035892	A/G	cg05660106	chr1:15850417	CASP9	0.72	5.59	0.5	2.2e-7	Systolic blood pressure;
THYM	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg17063962	chr7:91808500	NA	1.16	13.12	0.8	4.77e-23	Breast cancer;
THYM	cis	rs10463554	0.963	rs1011454	chr5:102368255	A/G	cg23492399	chr5:102201601	PAM	-0.67	-5.18	-0.47	1.26e-6	Parkinson's disease;
THYM	cis	rs7705042	0.865	rs4912804	chr5:141493614	T/C	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs926938	0.520	rs6660624	chr1:115272163	G/A	cg12756093	chr1:115239321	AMPD1	-0.55	-4.47	-0.42	2.18e-5	Autism;
THYM	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg00376283	chr12:123451042	ABCB9	0.93	7.88	0.63	5.44e-12	Platelet count;
THYM	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.43	-0.65	3.66e-13	Mean corpuscular volume;
THYM	cis	rs1345301	0.518	rs17689452	chr2:102864681	A/G	cg03938978	chr2:103052716	IL18RAP	-0.52	-4.92	-0.45	3.65e-6	Waist circumference;
THYM	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13082711	0.911	rs13100751	chr3:27454964	A/G	cg02860705	chr3:27208620	NA	0.83	5.74	0.51	1.11e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs6815814	0.950	rs67719080	chr4:38787252	A/G	cg02016764	chr4:38805732	TLR1	-0.5	-4.81	-0.44	5.61e-6	Breast cancer;
THYM	cis	rs9563576	0.778	rs9569817	chr13:58673091	C/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.6	4.5	0.42	1.9e-5	Body mass index;
THYM	cis	rs7731657	0.537	rs2419938	chr5:130349567	G/A	cg08523029	chr5:130500466	HINT1	0.85	6.2	0.54	1.42e-8	Fasting plasma glucose;
THYM	trans	rs629535	0.773	rs686683	chr8:70070364	G/A	cg21567404	chr3:27674614	NA	1.08	10.14	0.72	8.19e-17	Dupuytren's disease;
THYM	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg12165864	chr7:66369176	NA	0.67	5.24	0.47	9.64e-7	Aortic root size;
THYM	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg11871910	chr12:69753446	YEATS4	0.76	6.17	0.53	1.69e-8	Blood protein levels;
THYM	trans	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.12	-13.73	-0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs988913	0.957	rs1910350	chr6:54852462	C/A	cg04690482	chr6:54711388	FAM83B	0.5	5.49	0.49	3.28e-7	Menarche (age at onset);
THYM	cis	rs6988636	1.000	rs57165742	chr8:124184559	G/A	cg22384356	chr8:124195192	FAM83A	-0.86	-5.15	-0.47	1.41e-6	Urinary uromodulin levels;
THYM	cis	rs7104764	0.957	rs6598075	chr11:207275	C/G	cg18336825	chr11:236787	PSMD13;SIRT3	-1.11	-9.7	-0.71	7.11e-16	Menarche (age at onset);
THYM	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs4595586	0.545	rs6580910	chr12:39390052	C/A	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg14784868	chr12:69753453	YEATS4	0.79	6.48	0.55	4.06e-9	Blood protein levels;
THYM	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg14186256	chr22:23484241	RTDR1	0.95	9.14	0.68	1.16e-14	Bone mineral density;
THYM	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg00631329	chr6:26305371	NA	-0.57	-5.37	-0.48	5.66e-7	Mosquito bite size;
THYM	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Urate levels;
THYM	cis	rs293526	0.959	rs2813802	chr6:83644702	A/G	cg23278060	chr6:83777448	DOPEY1	0.61	4.49	0.42	2.02e-5	Crohn's disease;
THYM	cis	rs6500395	1.000	rs1477134	chr16:48706973	G/A	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg16414030	chr3:133502952	NA	-0.82	-7.97	-0.63	3.53e-12	Iron status biomarkers;
THYM	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg08779649	chr13:50194554	NA	0.59	5.11	0.46	1.63e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs986417	1.000	rs1956555	chr14:60968804	A/G	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg08847533	chr14:75593920	NEK9	-1.03	-11.3	-0.76	2.92e-19	Height;
THYM	cis	rs13082711	0.522	rs480646	chr3:27327143	C/T	cg02860705	chr3:27208620	NA	0.65	5.09	0.46	1.79e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs7584330	0.554	rs6736468	chr2:238422228	A/G	cg08992911	chr2:238395768	MLPH	0.83	5.52	0.49	2.97e-7	Prostate cancer;
THYM	cis	rs9858542	0.537	rs34514189	chr3:49373045	A/G	cg00383909	chr3:49044727	WDR6	0.77	5.05	0.46	2.16e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs8050907	0.744	rs55810554	chr16:4524392	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.58	0.43	1.38e-5	Obesity-related traits;
THYM	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.55	5.02	0.46	2.36e-6	Lymphocyte counts;
THYM	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg13609457	chr4:120235615	NA	0.58	5.33	0.48	6.48e-7	Corneal astigmatism;
THYM	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg18876405	chr7:65276391	NA	0.67	5.76	0.51	1.04e-7	Aortic root size;
THYM	cis	rs10463554	0.926	rs34778	chr5:102452556	C/T	cg23492399	chr5:102201601	PAM	-0.7	-5.11	-0.46	1.69e-6	Parkinson's disease;
THYM	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg03806693	chr22:41940476	POLR3H	1.11	8.99	0.68	2.33e-14	Vitiligo;
THYM	cis	rs1994135	0.715	rs10844624	chr12:33691010	A/G	cg06521331	chr12:34319734	NA	-0.77	-5.44	-0.49	4.13e-7	Resting heart rate;
THYM	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs34421088	0.702	rs7838131	chr8:11596163	G/A	cg12395012	chr8:11607386	GATA4	0.54	4.64	0.43	1.1e-5	Neuroticism;
THYM	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg20007245	chr22:24372913	LOC391322	-0.81	-7.92	-0.63	4.5e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3138083	0.623	rs3138087	chr9:35645779	C/A	cg07116010	chr9:35646325	NA	0.89	8.89	0.67	3.92e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
THYM	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg26116260	chr4:7069785	GRPEL1	-1.09	-10.57	-0.74	9.93e-18	Monocyte percentage of white cells;
THYM	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	7.84	0.63	6.45e-12	Smoking behavior;
THYM	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg18252515	chr7:66147081	NA	-0.68	-4.95	-0.45	3.25e-6	Aortic root size;
THYM	cis	rs977987	0.806	rs7199132	chr16:75450039	C/T	cg03315344	chr16:75512273	CHST6	0.76	6.16	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg11764359	chr7:65958608	NA	0.84	7.06	0.59	2.69e-10	Aortic root size;
THYM	cis	rs9527	0.545	rs12247514	chr10:104958066	C/A	cg04362960	chr10:104952993	NT5C2	0.62	4.62	0.43	1.22e-5	Arsenic metabolism;
THYM	cis	rs763014	0.931	rs7199839	chr16:636126	T/C	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg23281280	chr6:28129359	ZNF389	0.61	4.94	0.45	3.3e-6	Depression;
THYM	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg19077165	chr18:44547161	KATNAL2	-0.45	-4.56	-0.42	1.53e-5	Educational attainment;
THYM	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg05347473	chr6:146136440	FBXO30	-0.56	-4.45	-0.42	2.34e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2625529	0.668	rs12591338	chr15:72556847	T/A	cg16672083	chr15:72433130	SENP8	-0.54	-4.85	-0.45	4.88e-6	Red blood cell count;
THYM	cis	rs4788570	0.566	rs72795864	chr16:71483497	C/G	cg06353428	chr16:71660113	MARVELD3	-1.04	-5.01	-0.46	2.5e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3772130	0.564	rs4420917	chr3:121567863	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.86	7.17	0.59	1.63e-10	Cognitive performance;
THYM	cis	rs12200560	0.505	rs172425	chr6:97075299	A/T	cg06623918	chr6:96969491	KIAA0776	0.78	6.03	0.53	3.13e-8	Coronary heart disease;
THYM	cis	rs2836950	0.501	rs2070865	chr21:40715519	C/T	cg06238570	chr21:40685208	BRWD1	-0.72	-6.06	-0.53	2.69e-8	Menarche (age at onset);
THYM	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg01236616	chr12:121019343	POP5	1.31	10.38	0.73	2.57e-17	Type 1 diabetes nephropathy;
THYM	cis	rs995000	0.931	rs10159255	chr1:63020816	C/A	cg06896770	chr1:63153194	DOCK7	1.0	8.27	0.65	7.91e-13	Triglyceride levels;
THYM	cis	rs11048434	0.761	rs11494570	chr12:9127147	T/C	cg13575925	chr12:9217583	LOC144571	0.52	5.04	0.46	2.24e-6	Sjögren's syndrome;
THYM	cis	rs748404	0.660	rs2467738	chr15:43739936	T/A	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.78	5.9	0.52	5.53e-8	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs921665	0.831	rs6548167	chr2:3181062	A/G	cg16434511	chr2:3151078	NA	-0.85	-5.29	-0.48	7.76e-7	World class endurance athleticism;
THYM	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg10802521	chr3:52805072	NEK4	-0.73	-6.35	-0.55	7.48e-9	Bipolar disorder;
THYM	cis	rs3017493	0.786	rs59579317	chr11:70684569	A/G	cg14537332	chr11:70508113	SHANK2	1.15	7.22	0.6	1.3e-10	Renal transplant outcome;
THYM	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.68	6.04	0.53	2.94e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg17845761	chr1:175162550	KIAA0040	0.38	4.81	0.44	5.73e-6	Alcohol dependence;
THYM	cis	rs2281636	0.540	rs12249652	chr10:101478721	G/A	cg05149213	chr10:101381631	SLC25A28	-0.44	-4.6	-0.43	1.32e-5	Obesity-related traits;
THYM	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs6754311	0.517	rs1469995	chr2:136542559	G/A	cg23851026	chr2:136556271	LCT	0.64	5.86	0.52	6.55e-8	Mosquito bite size;
THYM	cis	rs12291225	0.585	rs34171876	chr11:14353957	G/C	cg19336497	chr11:14380999	RRAS2	-0.91	-13.6	-0.81	5.02e-24	Sense of smell;
THYM	cis	rs9486719	0.790	rs2499790	chr6:96845078	G/A	cg18709589	chr6:96969512	KIAA0776	0.75	4.49	0.42	2.02e-5	Migraine;Coronary artery disease;
THYM	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg18105134	chr13:113819100	PROZ	-0.98	-9.05	-0.68	1.79e-14	Platelet distribution width;
THYM	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.17	0.64	1.33e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.8e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg00339695	chr16:24857497	SLC5A11	-0.47	-4.66	-0.43	1.03e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10089	0.953	rs1036171	chr5:127402798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.96	6.36	0.55	7.05e-9	Ileal carcinoids;
THYM	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3820068	0.608	rs7516683	chr1:16020502	A/G	cg13390004	chr1:15929781	NA	-0.68	-5.03	-0.46	2.35e-6	Systolic blood pressure;
THYM	cis	rs6121246	0.609	rs6060955	chr20:30385071	A/G	cg13852791	chr20:30311386	BCL2L1	0.87	8.17	0.64	1.31e-12	Mean corpuscular hemoglobin;
THYM	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg26384229	chr12:38710491	ALG10B	-0.72	-5.64	-0.5	1.75e-7	Morning vs. evening chronotype;
THYM	cis	rs12530845	0.673	rs73725437	chr7:135327853	G/A	cg23117316	chr7:135346802	PL-5283	-0.73	-5.82	-0.51	7.9e-8	Red blood cell traits;
THYM	cis	rs17001868	0.568	rs9611310	chr22:40733777	A/G	cg07138101	chr22:40742427	ADSL	0.82	4.85	0.45	4.8e-6	Mammographic density (dense area);
THYM	cis	rs7394190	0.748	rs3088070	chr10:75530013	C/T	cg07699608	chr10:75541558	CHCHD1	0.91	4.93	0.45	3.49e-6	Incident atrial fibrillation;
THYM	cis	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-5.49	-0.49	3.39e-7	Mood instability;
THYM	cis	rs10431058	0.930	rs7948142	chr11:107478703	T/G	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.75	5.79	0.51	9.14e-8	Common traits (Other);
THYM	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg12292205	chr6:26970375	C6orf41	0.59	4.97	0.45	2.99e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.05	-10.16	-0.72	7.64e-17	Primary sclerosing cholangitis;
THYM	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg26384229	chr12:38710491	ALG10B	0.67	6.07	0.53	2.66e-8	Heart rate;
THYM	cis	rs9877502	0.773	rs9838279	chr3:190601893	T/C	cg25724246	chr3:190595776	SNAR-I	-0.55	-4.49	-0.42	2.03e-5	Alzheimer's disease biomarkers;
THYM	cis	rs7843479	0.562	rs6988010	chr8:21859084	G/A	cg17168535	chr8:21777572	XPO7	0.81	7.06	0.59	2.76e-10	Mean corpuscular volume;
THYM	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg12419862	chr22:24373484	LOC391322	-0.84	-9.56	-0.7	1.46e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg03676636	chr4:99064102	C4orf37	0.42	6.05	0.53	2.83e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg10856724	chr12:34555212	NA	-0.99	-8.92	-0.68	3.37e-14	Bladder cancer;
THYM	cis	rs56775891	0.959	rs7238071	chr18:77579812	C/T	cg13263691	chr18:77568018	NA	-0.7	-5.13	-0.47	1.55e-6	Schizophrenia;
THYM	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11642862	0.710	rs17849880	chr16:30999198	C/T	cg01070095	chr16:30968205	SETD1A	0.73	4.79	0.44	6.24e-6	Tonsillectomy;
THYM	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg11526020	chr17:80870163	TBCD	0.46	4.49	0.42	1.98e-5	Glycated hemoglobin levels;
THYM	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg09976142	chr9:130955436	CIZ1	-0.66	-6.91	-0.58	5.52e-10	Attention deficit hyperactivity disorder;
THYM	cis	rs524023	1.000	rs12786214	chr11:64364203	G/A	cg19131476	chr11:64387923	NRXN2	-0.39	-5.64	-0.5	1.75e-7	Urate levels in obese individuals;
THYM	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.17	11.49	0.76	1.16e-19	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs912057	0.932	rs1294406	chr6:6737737	A/G	cg06612196	chr6:6737390	NA	0.69	9.7	0.71	7.34e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg10515332	chr4:99064459	C4orf37	0.6	4.74	0.44	7.59e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.02	10.73	0.74	4.65e-18	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg20295408	chr7:1910781	MAD1L1	-0.63	-4.54	-0.42	1.67e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	6.12	0.53	2.12e-8	Schizophrenia;
THYM	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg17252645	chr8:143867129	LY6D	-0.85	-10.51	-0.73	1.35e-17	Urinary tract infection frequency;
THYM	cis	rs6748734	0.625	rs4295000	chr2:241821237	C/T	cg15164180	chr2:241846931	NA	-0.33	-4.59	-0.43	1.38e-5	Urinary metabolites;
THYM	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg18512352	chr11:47633146	NA	-0.5	-6.09	-0.53	2.41e-8	Subjective well-being;
THYM	cis	rs2456568	0.803	rs10831138	chr11:93640468	T/C	cg26875233	chr11:93583750	C11orf90	-0.54	-5.78	-0.51	9.51e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg09021430	chr5:549028	NA	0.66	6.32	0.54	8.35e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs28595532	0.688	rs116580819	chr4:119767362	T/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs3771570	0.901	rs4675944	chr2:242430170	C/T	cg21155796	chr2:242212141	HDLBP	1.09	6.23	0.54	1.26e-8	Prostate cancer;
THYM	cis	rs9515201	0.787	rs9521734	chr13:111037289	A/T	cg26053697	chr13:111039873	COL4A2	0.58	4.77	0.44	6.6e-6	White matter hyperintensity burden;
THYM	cis	rs6496667	0.865	rs7171422	chr15:90904741	G/A	cg22089800	chr15:90895588	ZNF774	0.84	4.92	0.45	3.68e-6	Rheumatoid arthritis;
THYM	cis	rs12496230	1.000	rs12495879	chr3:66861656	A/G	cg23477460	chr3:66848765	NA	-1.24	-8.15	-0.64	1.47e-12	Type 2 diabetes;
THYM	cis	rs9467711	0.520	rs13211947	chr6:25864818	C/T	cg16898833	chr6:26189333	HIST1H4D	1.33	4.6	0.43	1.32e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7216064	1.000	rs3935969	chr17:65881959	A/G	cg12091567	chr17:66097778	LOC651250	-0.69	-4.65	-0.43	1.05e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs314370	0.951	rs12705092	chr7:100473550	G/A	cg10426581	chr7:100472382	SRRT	1.13	8.97	0.68	2.57e-14	Resting heart rate;
THYM	cis	rs7084402	0.967	rs1649042	chr10:60328663	T/C	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg11861562	chr11:117069780	TAGLN	-0.32	-4.78	-0.44	6.32e-6	Blood protein levels;
THYM	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11644478	chr21:40555479	PSMG1	1.1	9.84	0.71	3.61e-16	Cognitive function;
THYM	trans	rs4262150	0.883	rs72802874	chr5:152240163	C/T	cg08281791	chr5:76607845	PDE8B	0.92	6.91	0.58	5.62e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs4262150	0.883	rs113844564	chr5:152317522	G/A	cg06854687	chr5:151642065	NA	0.71	5.0	0.46	2.63e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2290159	0.800	rs73132351	chr3:12688284	A/G	cg23032965	chr3:12705835	RAF1	0.87	5.54	0.49	2.72e-7	Cholesterol, total;
THYM	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg24308560	chr3:49941425	MST1R	0.63	4.78	0.44	6.37e-6	Body mass index;
THYM	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg24060327	chr5:131705240	SLC22A5	0.8	6.52	0.56	3.35e-9	Blood metabolite levels;
THYM	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03517284	chr6:25882590	NA	-0.76	-5.98	-0.52	3.87e-8	Blood metabolite levels;
THYM	cis	rs8067545	0.967	rs1034904	chr17:19927699	A/G	cg08626831	chr17:20841558	NA	0.47	4.59	0.43	1.38e-5	Schizophrenia;
THYM	cis	rs4595586	0.545	rs11615718	chr12:39395335	A/G	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs11690462	0.591	rs6546910	chr2:26544524	C/G	cg11525280	chr2:26624667	C2orf39	0.43	4.47	0.42	2.17e-5	Coronary artery disease;
THYM	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg19626725	chr5:178986131	RUFY1	0.33	5.15	0.47	1.39e-6	Lung cancer;
THYM	trans	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg05926928	chr17:57297772	GDPD1	1.26	10.02	0.72	1.5e-16	Opioid sensitivity;
THYM	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg06437703	chr8:37914619	EIF4EBP1	-0.81	-8.64	-0.66	1.32e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg24818145	chr4:99064322	C4orf37	0.97	6.03	0.53	3.12e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2742234	0.590	rs2435383	chr10:43675671	T/C	cg06632098	chr10:43605906	RET	-0.79	-5.1	-0.46	1.73e-6	Hirschsprung disease;
THYM	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg26384229	chr12:38710491	ALG10B	1.05	10.43	0.73	1.96e-17	Heart rate;
THYM	cis	rs4788570	0.566	rs3886947	chr16:71483958	G/C	cg06353428	chr16:71660113	MARVELD3	-1.04	-5.01	-0.46	2.5e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg09085632	chr11:111637200	PPP2R1B	1.22	13.43	0.81	1.13e-23	Primary sclerosing cholangitis;
THYM	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg16586182	chr3:47516702	SCAP	-0.62	-5.32	-0.48	6.82e-7	Colorectal cancer;
THYM	cis	rs1499972	0.941	rs55704727	chr3:117616431	C/T	cg07612923	chr3:117604196	NA	1.2	5.04	0.46	2.19e-6	Schizophrenia;
THYM	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9796	0.870	rs4923890	chr15:41258990	T/C	cg21153102	chr15:41252147	NA	-0.69	-6.38	-0.55	6.37e-9	Menopause (age at onset);
THYM	cis	rs2154427	0.752	rs78511491	chr21:34124249	T/C	cg21871883	chr21:34145043	C21orf49;C21orf66	1.03	5.21	0.47	1.12e-6	Bilirubin levels;
THYM	trans	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	Neuroticism;
THYM	cis	rs7508	0.711	rs3810	chr8:17914117	T/G	cg18067069	chr8:17937731	ASAH1	-0.56	-4.71	-0.43	8.54e-6	Atrial fibrillation;
THYM	cis	rs6754311	0.593	rs313524	chr2:136444123	C/T	cg23851026	chr2:136556271	LCT	0.59	5.62	0.5	1.91e-7	Mosquito bite size;
THYM	cis	rs36051895	0.658	rs12345127	chr9:5021191	A/T	cg02405213	chr9:5042618	JAK2	-1.03	-10.48	-0.73	1.6e-17	Pediatric autoimmune diseases;
THYM	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.05	-10.37	-0.73	2.72e-17	Primary sclerosing cholangitis;
THYM	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg27532560	chr4:187881888	NA	0.94	11.45	0.76	1.37e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7726839	0.555	rs7720419	chr5:589343	A/T	cg09021430	chr5:549028	NA	-0.85	-8.88	-0.67	4.08e-14	Obesity-related traits;
THYM	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg10589385	chr1:150898437	SETDB1	0.67	5.55	0.49	2.58e-7	Melanoma;
THYM	cis	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg09085632	chr11:111637200	PPP2R1B	1.2	12.92	0.8	1.24e-22	Primary sclerosing cholangitis;
THYM	cis	rs13326165	0.543	rs7643913	chr3:52303213	G/A	cg08438690	chr3:52279403	PPM1M	-0.88	-5.21	-0.47	1.1e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg13010199	chr12:38710504	ALG10B	0.71	5.48	0.49	3.44e-7	Heart rate;
THYM	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	cis	rs10992471	0.603	rs10820968	chr9:95106443	A/G	cg14631576	chr9:95140430	CENPP	-1.04	-11.32	-0.76	2.57e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg10802521	chr3:52805072	NEK4	-0.73	-6.3	-0.54	9.45e-9	Bipolar disorder;
THYM	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg11764359	chr7:65958608	NA	0.69	4.67	0.43	9.75e-6	Aortic root size;
THYM	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg16329197	chr12:53359506	NA	-0.57	-4.71	-0.44	8.38e-6	Prostate cancer;
THYM	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg01528321	chr10:82214614	TSPAN14	0.63	4.63	0.43	1.14e-5	Post bronchodilator FEV1;
THYM	cis	rs7688540	0.771	rs6599318	chr4:243968	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.72	4.88	0.45	4.35e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg13683864	chr3:40499215	RPL14	0.78	7.15	0.59	1.74e-10	Renal cell carcinoma;
THYM	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg23711669	chr6:146136114	FBXO30	0.96	10.33	0.73	3.3e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs35264875	0.796	rs72928657	chr11:68852336	T/C	cg01993067	chr11:68851601	TPCN2	1.0	5.3	0.48	7.4e-7	Blond vs. brown hair color;
THYM	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg14768367	chr16:72042858	DHODH	0.65	5.08	0.46	1.89e-6	Fibrinogen levels;
THYM	cis	rs539096	0.872	rs674725	chr1:44061795	C/T	cg08936794	chr1:43833873	ELOVL1	0.66	4.58	0.43	1.41e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg18512352	chr11:47633146	NA	-0.38	-4.52	-0.42	1.75e-5	HDL cholesterol;
THYM	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg10515332	chr4:99064459	C4orf37	0.57	4.56	0.42	1.54e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7731657	0.575	rs12513465	chr5:130364503	A/G	cg08523029	chr5:130500466	HINT1	-0.85	-5.98	-0.52	3.88e-8	Fasting plasma glucose;
THYM	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg14004847	chr7:1930337	MAD1L1	-0.65	-5.29	-0.48	7.86e-7	Autism spectrum disorder or schizophrenia;
THYM	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg15704280	chr7:45808275	SEPT13	-0.94	-7.21	-0.59	1.35e-10	Coronary artery disease;
THYM	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg19016782	chr12:123741754	C12orf65	-0.7	-4.61	-0.43	1.25e-5	Neutrophil percentage of white cells;
THYM	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12379764	chr21:47803548	PCNT	0.7	4.94	0.45	3.31e-6	Testicular germ cell tumor;
THYM	cis	rs500891	0.525	rs1535588	chr6:84051050	A/C	cg08257003	chr6:84140564	ME1	0.58	4.66	0.43	1.01e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs10911232	0.507	rs12037623	chr1:183000148	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg18131467	chr2:239335373	ASB1	1.08	10.32	0.73	3.44e-17	Multiple system atrophy;
THYM	cis	rs2970992	0.764	rs4851368	chr2:101324320	G/A	cg01042948	chr2:101319752	NA	0.63	6.38	0.55	6.33e-9	Educational attainment;
THYM	cis	rs7582180	0.627	rs4149523	chr2:101007039	T/C	cg21926883	chr2:100939477	LONRF2	-0.67	-6.27	-0.54	1.04e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6430585	0.583	rs3754689	chr2:136590746	C/T	cg07169764	chr2:136633963	MCM6	1.09	12.78	0.8	2.38e-22	Corneal structure;
THYM	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11890956	chr21:40555474	PSMG1	1.15	12.23	0.78	3.25e-21	Cognitive function;
THYM	cis	rs4845570	0.920	rs11810571	chr1:151762308	C/G	cg07092448	chr1:151763213	TDRKH	1.18	8.68	0.67	1.09e-13	Coronary artery disease;
THYM	cis	rs490234	0.746	rs1266009	chr9:128192316	A/G	cg14078157	chr9:128172775	NA	-0.71	-5.74	-0.51	1.12e-7	Mean arterial pressure;
THYM	cis	rs995000	0.931	rs7548877	chr1:63005950	T/C	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg21784768	chr11:537496	LRRC56	-1.14	-5.72	-0.51	1.21e-7	Body mass index;
THYM	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg01475377	chr6:109611718	NA	-0.57	-4.88	-0.45	4.28e-6	Reticulocyte fraction of red cells;
THYM	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg08779649	chr13:50194554	NA	0.58	5.05	0.46	2.16e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs7849270	0.921	rs7868476	chr9:131918133	A/G	cg14069949	chr9:131965419	NA	0.5	4.52	0.42	1.8e-5	Blood metabolite ratios;
THYM	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.68	-4.57	-0.42	1.44e-5	Menarche (age at onset);
THYM	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs4363385	0.747	rs10494285	chr1:152982285	G/A	cg13444842	chr1:152974279	SPRR3	-0.59	-4.68	-0.43	9.52e-6	Inflammatory skin disease;
THYM	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg09354556	chr3:47051341	NA	0.46	4.72	0.44	8.03e-6	Colorectal cancer;
THYM	cis	rs6495122	0.699	rs4886410	chr15:75065644	G/C	cg14664628	chr15:75095509	CSK	-0.79	-6.11	-0.53	2.18e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs1559088	0.600	rs7259117	chr19:33550113	G/T	cg03563238	chr19:33554763	RHPN2	-0.55	-4.69	-0.43	8.98e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs921968	0.541	rs1863704	chr2:219562675	C/T	cg02176678	chr2:219576539	TTLL4	-0.73	-7.19	-0.59	1.46e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4919687	0.550	rs12784517	chr10:104464970	T/C	cg05855489	chr10:104503620	C10orf26	0.68	5.35	0.48	5.95e-7	Colorectal cancer;
THYM	cis	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg19875535	chr5:140030758	IK	-0.6	-4.75	-0.44	7.26e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg11009520	chr8:12052164	FAM86B1	-0.56	-4.76	-0.44	6.96e-6	Retinal vascular caliber;
THYM	cis	rs7586879	1.000	rs10175064	chr2:25117537	T/C	cg01884057	chr2:25150051	NA	0.63	6.3	0.54	9.31e-9	Body mass index;
THYM	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg00071950	chr4:10020882	SLC2A9	0.81	8.75	0.67	7.56e-14	Bone mineral density;
THYM	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg00012203	chr2:219082015	ARPC2	-0.65	-5.33	-0.48	6.52e-7	Pyoderma gangrenosum in inflammatory bowel disease;
THYM	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs1659258	0.655	rs6547764	chr2:88550275	A/G	cg03704645	chr2:88367503	SMYD1	0.83	4.48	0.42	2.07e-5	Visceral fat;
THYM	cis	rs4722166	0.630	rs13311155	chr7:22789789	A/C	cg05472934	chr7:22766657	IL6	0.9	6.98	0.58	3.9e-10	Lung cancer;
THYM	cis	rs12144309	0.577	rs11102660	chr1:114150717	C/T	cg03325407	chr1:114423726	BCL2L15	-0.61	-4.56	-0.42	1.5e-5	Coronary artery disease;
THYM	cis	rs9467711	1.000	rs1883215	chr6:26314233	G/C	cg16898833	chr6:26189333	HIST1H4D	1.05	5.02	0.46	2.42e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs988913	0.957	rs9382397	chr6:54782893	A/G	cg18532076	chr6:54711417	FAM83B	0.52	4.83	0.44	5.13e-6	Menarche (age at onset);
THYM	cis	rs782590	0.729	rs706548	chr2:55850106	C/G	cg03859395	chr2:55845619	SMEK2	0.57	5.33	0.48	6.57e-7	Metabolic syndrome;
THYM	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.64	-5.77	-0.51	9.99e-8	Total body bone mineral density;
THYM	cis	rs11186	0.556	rs72902398	chr2:189925070	C/G	cg11041835	chr2:189156425	GULP1	0.78	4.69	0.43	9.21e-6	Parkinson's disease;
THYM	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs3781426	0.642	rs11245482	chr10:126733546	T/C	cg04494136	chr10:126703576	CTBP2	-0.42	-6.37	-0.55	6.86e-9	Height;
THYM	cis	rs7917772	0.582	rs12779854	chr10:104358474	G/A	cg00122347	chr10:104236741	TMEM180	0.42	6.22	0.54	1.34e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9914544	0.505	rs59633160	chr17:18761396	C/T	cg26378065	chr17:18585709	ZNF286B	0.58	4.51	0.42	1.88e-5	Educational attainment (years of education);
THYM	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg03877680	chr5:178157825	ZNF354A	0.75	5.0	0.46	2.57e-6	Neutrophil percentage of white cells;
THYM	cis	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg02317251	chr4:10116515	WDR1	-0.56	-4.95	-0.45	3.23e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs2639990	1.000	rs1702831	chr18:72897368	C/A	cg21330207	chr18:72916311	ZADH2	1.21	6.2	0.54	1.45e-8	Vascular endothelial growth factor levels;
THYM	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.02	0.53	3.27e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1975974	0.935	rs41361749	chr17:21732693	A/G	cg18423549	chr17:21743878	NA	0.6	4.76	0.44	6.88e-6	Psoriasis;
THYM	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg22467129	chr15:76604101	ETFA	-0.5	-4.94	-0.45	3.32e-6	Blood metabolite levels;
THYM	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg06766960	chr11:133703094	NA	-0.64	-5.77	-0.51	9.8e-8	Childhood ear infection;
THYM	cis	rs28493229	0.522	rs2287692	chr19:41289756	G/A	cg21869046	chr19:41225005	ITPKC	0.49	4.52	0.42	1.81e-5	Kawasaki disease;
THYM	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg21854759	chr1:92012499	NA	-0.74	-5.17	-0.47	1.3e-6	Eosinophil percentage of white cells;
THYM	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg14004847	chr7:1930337	MAD1L1	-0.66	-4.87	-0.45	4.36e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2282300	0.739	rs1631451	chr11:30349133	G/C	cg09906309	chr11:30344399	C11orf46	-0.73	-5.37	-0.48	5.47e-7	Morning vs. evening chronotype;
THYM	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg22117172	chr7:91764530	CYP51A1	0.36	4.47	0.42	2.14e-5	Breast cancer;
THYM	cis	rs7586879	0.639	rs2033656	chr2:25100902	C/G	cg15423357	chr2:25149977	NA	0.68	7.43	0.61	4.76e-11	Body mass index;
THYM	cis	rs62158800	0.568	rs78879709	chr2:108373597	G/T	cg10013287	chr2:108537568	NA	1.12	5.41	0.49	4.61e-7	Facial morphology (factor 22);
THYM	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg03433033	chr1:76189801	ACADM	-0.65	-6.0	-0.52	3.54e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9814567	1.000	rs6769885	chr3:134286913	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13012494	chr21:47604986	C21orf56	0.87	5.9	0.52	5.57e-8	Testicular germ cell tumor;
THYM	cis	rs73086581	1.000	rs6116130	chr20:3947026	A/T	cg02187196	chr20:3869020	PANK2	0.5	5.62	0.5	1.92e-7	Response to antidepressants in depression;
THYM	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg01069141	chr11:67398826	TBX10;NUDT8	0.53	5.67	0.5	1.5e-7	Mean corpuscular volume;
THYM	cis	rs4790333	1.000	rs4790332	chr17:2262611	G/A	cg02569219	chr17:2266849	SGSM2	0.67	6.19	0.54	1.5e-8	Proinsulin levels;
THYM	cis	rs75920871	0.748	rs7106662	chr11:116951385	T/C	cg20608306	chr11:116969690	SIK3	-0.52	-5.78	-0.51	9.38e-8	Subjective well-being;
THYM	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg12698349	chr2:225449008	CUL3	0.73	5.48	0.49	3.54e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs7572733	0.555	rs7600269	chr2:198923468	C/G	cg00792783	chr2:198669748	PLCL1	0.73	4.79	0.44	6.22e-6	Dermatomyositis;
THYM	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg17294928	chr15:75287854	SCAMP5	-1.02	-9.12	-0.68	1.26e-14	Blood trace element (Zn levels);
THYM	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs7189233	1.000	rs16952251	chr16:53483138	A/G	cg02965178	chr16:53538660	AKTIP	-0.61	-4.9	-0.45	3.9e-6	Intelligence (multi-trait analysis);
THYM	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.84	0.51	7.19e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03576123	chr11:487126	PTDSS2	-1.29	-6.25	-0.54	1.18e-8	Body mass index;
THYM	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1178127	0.729	rs1178148	chr7:18778113	G/T	cg13420273	chr7:18810212	HDAC9	-0.67	-4.48	-0.42	2.11e-5	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7219021	0.926	rs7217983	chr17:46853345	A/G	cg09029085	chr17:47094198	IGF2BP1	0.33	4.5	0.42	1.89e-5	Schizophrenia or bipolar disorder;
THYM	cis	rs8067545	0.611	rs2703800	chr17:20086562	C/T	cg20830565	chr17:20408647	MGC102966	-0.48	-4.46	-0.42	2.28e-5	Schizophrenia;
THYM	cis	rs11997175	0.716	rs7460818	chr8:33816362	A/G	ch.8.33884649F	chr8:33765107	NA	0.74	5.87	0.52	6.33e-8	Body mass index;
THYM	cis	rs977987	0.832	rs37597	chr16:75500275	T/G	cg03315344	chr16:75512273	CHST6	-0.65	-5.13	-0.47	1.54e-6	Dupuytren's disease;
THYM	cis	rs4343996	0.902	rs4336505	chr7:3373740	A/C	cg21248987	chr7:3385318	SDK1	-0.41	-4.84	-0.44	4.95e-6	Motion sickness;
THYM	cis	rs6956675	1.000	rs7801458	chr7:62597651	A/G	cg08930214	chr7:62859557	LOC100287834	0.65	4.79	0.44	6.1e-6	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs295140	0.546	rs295119	chr2:201117944	C/T	cg23649088	chr2:200775458	C2orf69	0.62	5.22	0.47	1.07e-6	QT interval;
THYM	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg05368731	chr17:41323189	NBR1	1.25	11.25	0.76	3.57e-19	Menopause (age at onset);
THYM	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg13289132	chr10:30722225	MAP3K8	-0.57	-4.86	-0.45	4.63e-6	Inflammatory bowel disease;
THYM	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg12419862	chr22:24373484	LOC391322	-0.7	-6.07	-0.53	2.6e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2282032	0.527	rs55664487	chr14:90765880	C/T	cg14092571	chr14:90743983	NA	0.64	6.32	0.54	8.28e-9	Longevity;
THYM	cis	rs988913	1.000	rs1393772	chr6:54838388	C/T	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.75e-6	Menarche (age at onset);
THYM	cis	rs925255	0.817	rs7606480	chr2:28632377	G/A	cg01273330	chr2:28605224	NA	0.72	6.74	0.57	1.22e-9	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg11266682	chr4:10021025	SLC2A9	0.68	9.68	0.7	7.95e-16	Bone mineral density;
THYM	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg21672276	chr3:44754072	ZNF502	-0.48	-4.59	-0.43	1.34e-5	Depressive symptoms;
THYM	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg23649088	chr2:200775458	C2orf69	0.83	6.97	0.58	4.07e-10	Osteoporosis;
THYM	cis	rs12464624	0.766	rs34328670	chr2:71734431	G/T	cg17415947	chr2:71682597	DYSF	0.57	4.46	0.42	2.25e-5	Urate levels in overweight individuals;
THYM	cis	rs76878669	0.754	rs10896113	chr11:66117111	C/T	cg18002602	chr11:66138449	SLC29A2	-0.66	-5.59	-0.5	2.16e-7	Educational attainment (years of education);
THYM	cis	rs28595532	0.920	rs115430947	chr4:119737149	C/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs1728785	1.000	rs1099296	chr16:68588653	G/A	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg08564027	chr20:61660810	NA	0.96	10.55	0.73	1.11e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg27534772	chr1:16042836	PLEKHM2	0.56	6.31	0.54	8.77e-9	Systolic blood pressure;
THYM	cis	rs4660306	0.961	rs2991966	chr1:45999503	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.64	-5.2	-0.47	1.12e-6	Homocysteine levels;
THYM	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg17279839	chr7:150038598	RARRES2	0.51	4.51	0.42	1.89e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2235642	0.533	rs2667679	chr16:1654946	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.47	-5.53	-0.49	2.78e-7	Coronary artery disease;
THYM	cis	rs7578361	0.918	rs12473350	chr2:150369816	G/T	cg17961725	chr2:150454027	NA	0.78	5.97	0.52	4.06e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9814567	0.727	rs7641798	chr3:134345719	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-7.5	-0.61	3.34e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	trans	rs629535	0.911	rs688612	chr8:70011887	C/T	cg21567404	chr3:27674614	NA	-1.11	-10.75	-0.74	4.16e-18	Dupuytren's disease;
THYM	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.95	0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs3820068	0.705	rs41486146	chr1:15900517	A/G	cg05660106	chr1:15850417	CASP9	-1.13	-9.18	-0.69	9.25e-15	Systolic blood pressure;
THYM	cis	rs8008758	1.000	rs915379	chr14:101689392	T/C	cg26224664	chr14:101693935	NA	-0.56	-4.57	-0.42	1.44e-5	Body mass index (alcohol intake interaction);
THYM	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg08772003	chr10:104629869	AS3MT	-0.57	-4.92	-0.45	3.69e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs12908161	1.000	rs35808647	chr15:85377441	G/A	cg12863693	chr15:85201151	NMB	0.61	5.23	0.47	9.93e-7	Schizophrenia;
THYM	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7705502	1.000	rs72812816	chr5:173356638	G/A	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg22841779	chr14:105766346	BRF1	-0.47	-5.87	-0.52	6.26e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg14458575	chr2:238380390	NA	1.09	8.79	0.67	6.36e-14	Prostate cancer;
THYM	cis	rs6584283	0.716	rs10786558	chr10:101287610	G/A	cg00674004	chr10:101280750	NA	0.5	5.15	0.47	1.41e-6	Ulcerative colitis;
THYM	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg00383909	chr3:49044727	WDR6	1.03	5.9	0.52	5.64e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.67	-0.5	1.52e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg07507251	chr3:52567010	NT5DC2	0.39	4.52	0.42	1.81e-5	Bipolar disorder;
THYM	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg03709012	chr19:19516395	GATAD2A	0.76	6.05	0.53	2.87e-8	Tonsillectomy;
THYM	cis	rs6988636	1.000	rs9987357	chr8:124187620	T/G	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg08017756	chr2:100939284	LONRF2	-0.75	-7.8	-0.62	7.89e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg23711669	chr6:146136114	FBXO30	0.85	7.99	0.63	3.12e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12496230	1.000	rs12495879	chr3:66861656	A/G	cg17646820	chr3:66848679	NA	-0.96	-6.09	-0.53	2.4e-8	Type 2 diabetes;
THYM	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg15921436	chr17:44337874	NA	0.78	6.25	0.54	1.17e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9543976	0.623	rs6562913	chr13:76167433	T/A	cg01531495	chr13:76123901	UCHL3	0.66	4.8	0.44	5.85e-6	Diabetic retinopathy;
THYM	cis	rs11186	0.556	rs56667101	chr2:189957471	G/A	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs10857712	0.528	rs2265638	chr10:135217175	A/G	cg19899694	chr10:135237140	SPRN	0.71	6.53	0.56	3.25e-9	Systemic lupus erythematosus;
THYM	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.62	-0.5	1.9e-7	Menopause (age at onset);
THYM	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg04750100	chr2:136595281	LCT	0.57	6.2	0.54	1.44e-8	Mosquito bite size;
THYM	cis	rs7043114	0.544	rs12335553	chr9:95297871	A/C	cg14631576	chr9:95140430	CENPP	-0.76	-7.12	-0.59	2.08e-10	Height;
THYM	cis	rs611744	0.967	rs686630	chr8:109233239	G/C	cg21045802	chr8:109455806	TTC35	0.59	5.25	0.47	9.08e-7	Dupuytren's disease;
THYM	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg04025307	chr7:1156635	C7orf50	0.63	5.83	0.51	7.74e-8	Longevity;Endometriosis;
THYM	cis	rs9807989	0.839	rs4988958	chr2:102968285	T/C	cg03938978	chr2:103052716	IL18RAP	0.63	6.56	0.56	2.81e-9	Asthma;
THYM	cis	rs1728785	1.000	rs7196104	chr16:68579746	C/A	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs7267979	1.000	rs6076336	chr20:25319212	C/T	cg08601574	chr20:25228251	PYGB	-0.57	-4.59	-0.43	1.35e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2046867	0.908	rs11927126	chr3:72806622	A/G	cg25664220	chr3:72788482	NA	-0.79	-6.15	-0.53	1.81e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs3807375	1.000	rs3807375	chr7:150667210	C/T	cg10636020	chr7:150656979	KCNH2	-0.69	-5.57	-0.5	2.34e-7	Electrocardiographic traits;QT interval;
THYM	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg26384229	chr12:38710491	ALG10B	0.98	9.7	0.71	7.22e-16	Heart rate;
THYM	cis	rs4731207	0.596	rs13240512	chr7:124571890	G/A	cg05285228	chr7:124571219	POT1	-0.69	-5.25	-0.47	9.35e-7	Cutaneous malignant melanoma;
THYM	cis	rs6547741	1.000	rs4666009	chr2:27857992	T/A	cg27432699	chr2:27873401	GPN1	0.74	6.52	0.56	3.37e-9	Oral cavity cancer;
THYM	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg21385522	chr1:16154831	NA	0.67	5.62	0.5	1.89e-7	Systolic blood pressure;
THYM	cis	rs293526	0.876	rs2480091	chr6:83706592	A/G	cg23278060	chr6:83777448	DOPEY1	0.63	4.54	0.42	1.67e-5	Crohn's disease;
THYM	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg23161317	chr6:28129485	ZNF389	0.72	4.79	0.44	6.09e-6	Parkinson's disease;
THYM	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg11166453	chr1:247681781	NA	0.59	4.77	0.44	6.54e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs995000	0.868	rs1168107	chr1:63161173	A/T	cg06896770	chr1:63153194	DOCK7	-0.69	-4.89	-0.45	4.13e-6	Triglyceride levels;
THYM	trans	rs4262150	0.883	rs4437425	chr5:152238341	G/A	cg08281791	chr5:76607845	PDE8B	0.92	6.91	0.58	5.62e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs3112255	0.967	rs2137675	chr2:101310912	C/T	cg01042948	chr2:101319752	NA	-0.65	-5.69	-0.5	1.38e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10911232	0.507	rs10737239	chr1:183030170	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs921968	0.541	rs7604319	chr2:219538799	A/C	cg02176678	chr2:219576539	TTLL4	-0.73	-7.22	-0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4845459	0.967	rs1886734	chr1:152591142	A/C	cg26135325	chr1:152595322	LCE3A	-0.45	-5.21	-0.47	1.09e-6	Psoriasis;
THYM	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg13609457	chr4:120235615	NA	-0.59	-5.25	-0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg11663144	chr21:46675770	NA	-0.69	-9.27	-0.69	6.12e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05901451	chr6:126070800	HEY2	-0.96	-9.66	-0.7	8.6e-16	Brugada syndrome;
THYM	cis	rs6087990	0.735	rs2424914	chr20:31374520	A/G	cg13636640	chr20:31349939	DNMT3B	0.9	9.19	0.69	8.89e-15	Ulcerative colitis;
THYM	cis	rs11685299	1	rs11685299	chr2:225391296	C/A	cg12698349	chr2:225449008	CUL3	1.14	10.37	0.73	2.69e-17	Schizophrenia;
THYM	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg03676636	chr4:99064102	C4orf37	0.4	5.77	0.51	9.89e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6430585	0.640	rs58301703	chr2:136532225	G/A	cg20242066	chr2:136595261	LCT	0.5	4.7	0.43	8.63e-6	Corneal structure;
THYM	cis	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-5.83	-0.51	7.47e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.66	0.5	1.63e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg07936489	chr17:37558343	FBXL20	0.85	5.64	0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs966423	0.550	rs4674176	chr2:218301119	C/G	cg15335768	chr2:218268053	DIRC3	0.38	5.51	0.49	3.06e-7	Thyroid cancer;
THYM	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg16928487	chr17:17741425	SREBF1	-0.53	-5.32	-0.48	6.96e-7	Total body bone mineral density;
THYM	cis	rs1569175	0.655	rs166847	chr2:200840612	A/G	cg23649088	chr2:200775458	C2orf69	-0.91	-5.2	-0.47	1.14e-6	Response to treatment for acute lymphoblastic leukemia;
THYM	cis	rs919433	0.680	rs2124317	chr2:198477606	G/A	cg00792783	chr2:198669748	PLCL1	0.82	5.73	0.51	1.17e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2075230	0.705	rs1642809	chr17:7545496	T/C	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.74	-0.44	7.55e-6	Hormone measurements;
THYM	cis	rs6980334	0.817	rs1038626	chr7:137797477	A/T	cg06915773	chr7:137028165	PTN	0.6	4.82	0.44	5.33e-6	Blood metabolite ratios;
THYM	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg18758796	chr5:131593413	PDLIM4	-0.64	-6.37	-0.55	6.83e-9	Breast cancer;
THYM	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02018176	chr4:1364513	KIAA1530	0.94	8.73	0.67	8.68e-14	Longevity;
THYM	cis	rs1957429	0.522	rs76721513	chr14:65403891	C/G	cg23373153	chr14:65346875	NA	-1.25	-5.03	-0.46	2.29e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg11764359	chr7:65958608	NA	0.78	6.31	0.54	8.68e-9	Aortic root size;
THYM	cis	rs9560113	0.960	rs61967677	chr13:112174044	A/G	cg10483660	chr13:112241077	NA	0.53	4.76	0.44	6.81e-6	Menarche (age at onset);
THYM	cis	rs9790314	0.637	rs778643	chr3:160706041	G/A	cg04691961	chr3:161091175	C3orf57	-0.58	-4.63	-0.43	1.15e-5	Morning vs. evening chronotype;
THYM	cis	rs9324022	0.929	rs72698718	chr14:101178555	G/A	cg18089426	chr14:101175970	NA	0.75	5.12	0.46	1.61e-6	Plateletcrit;
THYM	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs12121840	0.790	rs58058936	chr1:165545686	A/G	cg19407955	chr1:165599744	MGST3	-0.65	-4.77	-0.44	6.66e-6	Interleukin-1-receptor antagonist levels;
THYM	cis	rs7851660	0.967	rs1867280	chr9:100616066	G/C	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg23711669	chr6:146136114	FBXO30	0.98	10.77	0.74	3.75e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg24450063	chr1:156163899	SLC25A44	1.16	9.68	0.7	8.04e-16	Testicular germ cell tumor;
THYM	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs4148883	0.504	rs28720150	chr4:100132790	T/G	cg12011299	chr4:100065546	ADH4	-0.57	-5.14	-0.47	1.48e-6	Alcohol dependence;
THYM	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11890956	chr21:40555474	PSMG1	-0.97	-11.03	-0.75	1.05e-18	Cognitive function;
THYM	cis	rs747334	0.846	rs7071167	chr10:92721257	A/T	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs6456042	1.000	rs3127416	chr6:166537412	G/A	cg11088901	chr6:166572345	T	-0.52	-4.89	-0.45	4.16e-6	Asthma;
THYM	cis	rs4919694	0.572	rs4917995	chr10:104845443	A/T	cg04362960	chr10:104952993	NT5C2	-0.97	-6.41	-0.55	5.51e-9	Arsenic metabolism;
THYM	cis	rs6596100	0.500	rs67685368	chr5:132292946	T/G	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Breast cancer;
THYM	cis	rs1021993	0.868	rs6674103	chr1:209530638	A/G	cg06155620	chr1:209527581	NA	-0.65	-5.13	-0.47	1.52e-6	Gut microbiome composition (winter);
THYM	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg06108461	chr20:60628389	TAF4	-0.81	-6.62	-0.56	2.15e-9	Body mass index;
THYM	cis	rs9921222	0.565	rs1805105	chr16:396264	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.42	7.74	0.62	1.05e-11	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg22535103	chr8:58192502	C8orf71	-1.06	-6.61	-0.56	2.24e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs293526	0.959	rs293528	chr6:83647188	C/A	cg23278060	chr6:83777448	DOPEY1	0.62	4.49	0.42	1.98e-5	Crohn's disease;
THYM	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg22683308	chr4:1340831	KIAA1530	0.61	4.5	0.42	1.93e-5	Longevity;
THYM	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg22841779	chr14:105766346	BRF1	-0.49	-6.09	-0.53	2.42e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.7	6.82	0.57	8.42e-10	Lymphocyte counts;
THYM	cis	rs9611198	0.846	rs5757731	chr22:39967785	C/G	cg19570171	chr22:39239822	NPTXR	-0.58	-4.67	-0.43	9.85e-6	Schizophrenia;
THYM	cis	rs7586879	0.551	rs7565460	chr2:25130073	C/T	cg01884057	chr2:25150051	NA	0.73	7.92	0.63	4.47e-12	Body mass index;
THYM	cis	rs6984449	0.508	rs62496184	chr8:19319423	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.62	5.67	0.5	1.54e-7	Educational attainment;
THYM	cis	rs11563648	0.553	rs10249166	chr7:127016155	G/C	cg08586737	chr7:127225949	GCC1	-0.33	-4.56	-0.42	1.5e-5	Resting heart rate;
THYM	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg00278517	chr6:167070616	RPS6KA2	-0.33	-4.52	-0.42	1.79e-5	Crohn's disease;
THYM	trans	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg07393940	chr7:158741817	NA	1.1	8.4	0.65	4.38e-13	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.8	-7.41	-0.61	5.14e-11	Personality dimensions;
THYM	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg05962950	chr11:130786565	SNX19	-0.71	-5.64	-0.5	1.78e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg14784868	chr12:69753453	YEATS4	1.13	10.92	0.75	1.82e-18	Blood protein levels;
THYM	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg05457628	chr5:178986728	RUFY1	0.64	6.53	0.56	3.29e-9	Lung cancer;
THYM	cis	rs7119	0.651	rs12917044	chr15:77850146	A/G	cg10437265	chr15:77819839	NA	-0.74	-7.05	-0.59	2.87e-10	Type 2 diabetes;
THYM	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.47	-4.47	-0.42	2.19e-5	Crohn's disease;
THYM	cis	rs17534004	1.000	rs17599764	chr13:31469580	G/A	cg00367615	chr13:31480979	C13orf33	0.66	4.76	0.44	7.05e-6	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs7731657	0.537	rs2419756	chr5:130259779	T/C	cg08523029	chr5:130500466	HINT1	0.83	5.89	0.52	5.78e-8	Fasting plasma glucose;
THYM	cis	rs7572733	0.555	rs6434954	chr2:198929716	T/C	cg00792783	chr2:198669748	PLCL1	0.71	4.79	0.44	6.11e-6	Dermatomyositis;
THYM	cis	rs6430585	0.583	rs9636213	chr2:136589278	G/A	cg23851026	chr2:136556271	LCT	-0.68	-7.04	-0.59	3.05e-10	Corneal structure;
THYM	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg13397359	chr6:42928475	GNMT	0.61	5.49	0.49	3.39e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7429990	0.965	rs7426976	chr3:48022573	A/C	cg02219026	chr3:48282209	ZNF589	0.6	4.5	0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	4.87	0.45	4.41e-6	Hip circumference adjusted for BMI;
THYM	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg02153584	chr22:29168773	CCDC117	0.58	4.56	0.42	1.52e-5	Lymphocyte counts;
THYM	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.96	6.24	0.54	1.22e-8	Smoking behavior;
THYM	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg14196790	chr5:131705035	SLC22A5	0.5	4.5	0.42	1.96e-5	Blood metabolite levels;
THYM	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	4.46	0.42	2.27e-5	Breast cancer;
THYM	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs67981189	0.896	rs2526874	chr14:71381219	G/A	cg15910301	chr14:71632612	NA	-0.52	-4.79	-0.44	6.15e-6	Schizophrenia;
THYM	cis	rs854765	0.624	rs12952723	chr17:17731651	T/C	cg16928487	chr17:17741425	SREBF1	0.52	4.89	0.45	4.12e-6	Total body bone mineral density;
THYM	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg13319975	chr6:146136371	FBXO30	-0.72	-6.02	-0.53	3.33e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1800871	0.954	rs1518111	chr1:206944645	T/C	cg12587213	chr1:206589868	SRGAP2	0.48	4.48	0.42	2.08e-5	Gut microbiota (functional units);Behcet's disease;
THYM	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.7	-5.63	-0.5	1.83e-7	Prostate cancer;
THYM	cis	rs4789939	0.528	rs2377003	chr17:76878902	T/C	cg26927190	chr17:76875678	TIMP2	-1.47	-7.12	-0.59	2.04e-10	Dupuytren's disease;
THYM	cis	rs2235573	0.625	rs139900	chr22:38405417	C/T	cg19171272	chr22:38449367	NA	-0.51	-5.21	-0.47	1.1e-6	Glioblastoma;Glioma;
THYM	cis	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg07988820	chr12:82153109	PPFIA2	-0.83	-5.27	-0.48	8.34e-7	Resting heart rate;
THYM	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg04234412	chr22:24373322	LOC391322	0.93	8.14	0.64	1.55e-12	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1371867	0.846	rs1788181	chr8:101334068	C/T	cg00191853	chr8:101177733	SPAG1	-0.51	-5.03	-0.46	2.29e-6	Atrioventricular conduction;
THYM	cis	rs7927771	0.524	rs10742817	chr11:47689343	A/G	cg20307385	chr11:47447363	PSMC3	-0.58	-4.75	-0.44	7.3e-6	Subjective well-being;
THYM	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4481887	1.000	rs4360555	chr1:248468591	G/T	cg13385794	chr1:248469461	NA	0.65	4.66	0.43	1.04e-5	Common traits (Other);
THYM	cis	rs12291225	0.535	rs12806025	chr11:14413817	G/A	cg19336497	chr11:14380999	RRAS2	-0.83	-11.23	-0.76	4.06e-19	Sense of smell;
THYM	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03517284	chr6:25882590	NA	-0.99	-8.89	-0.67	3.85e-14	Intelligence (multi-trait analysis);
THYM	cis	rs13102973	0.931	rs13134190	chr4:135854932	T/C	cg14419869	chr4:135874104	NA	0.9	8.82	0.67	5.39e-14	Subjective well-being;
THYM	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg25588787	chr5:154027256	NA	0.9	4.6	0.43	1.32e-5	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs11690935	1.000	rs6721680	chr2:172543913	G/T	cg13550731	chr2:172543902	DYNC1I2	0.89	6.69	0.57	1.56e-9	Schizophrenia;
THYM	cis	rs611744	0.625	rs6469168	chr8:109288399	G/T	cg21045802	chr8:109455806	TTC35	0.71	6.5	0.55	3.66e-9	Dupuytren's disease;
THYM	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg23758822	chr17:41437982	NA	1.17	11.02	0.75	1.14e-18	Menopause (age at onset);
THYM	cis	rs7599312	0.517	rs10192988	chr2:213407782	T/G	cg20637307	chr2:213403960	ERBB4	1.04	11.16	0.75	5.66e-19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg24069376	chr3:38537580	EXOG	-0.66	-6.36	-0.55	7.17e-9	Electrocardiographic conduction measures;
THYM	cis	rs2898681	0.618	rs116241740	chr4:53733523	A/G	cg21521518	chr4:53727714	RASL11B	0.63	5.48	0.49	3.5e-7	Optic nerve measurement (cup area);
THYM	cis	rs6835098	0.692	rs10520252	chr4:174070959	T/C	cg08422745	chr4:174089978	GALNT7	-0.93	-7.38	-0.6	5.97e-11	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg14129053	chr2:1895732	MYT1L	1.13	4.49	0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs6032067	1.000	rs13041304	chr20:43811697	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs13102973	0.965	rs11730310	chr4:135861925	A/G	cg14419869	chr4:135874104	NA	0.9	8.82	0.67	5.39e-14	Subjective well-being;
THYM	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.32	-9.88	-0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg05283184	chr6:79620031	NA	-0.87	-8.15	-0.64	1.43e-12	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg25358565	chr5:93447407	FAM172A	1.36	10.94	0.75	1.67e-18	Diabetic retinopathy;
THYM	cis	rs9807989	0.801	rs7558339	chr2:102970243	T/G	cg03938978	chr2:103052716	IL18RAP	0.63	6.46	0.55	4.36e-9	Asthma;
THYM	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg00310523	chr12:86230176	RASSF9	0.58	5.36	0.48	5.81e-7	Major depressive disorder;
THYM	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11644478	chr21:40555479	PSMG1	1.03	8.53	0.66	2.25e-13	Cognitive function;
THYM	cis	rs2806561	0.780	rs6650086	chr1:23338384	T/C	cg19743168	chr1:23544995	NA	-0.61	-6.06	-0.53	2.74e-8	Height;
THYM	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	5.62	0.5	1.88e-7	Blood metabolite levels;
THYM	cis	rs17253792	0.908	rs9972177	chr14:56073206	G/A	cg01858014	chr14:56050164	KTN1	-1.22	-5.13	-0.47	1.52e-6	Putamen volume;
THYM	cis	rs1003719	0.788	rs4817845	chr21:38447132	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs11574514	1.000	rs79407301	chr16:67717264	G/A	cg09738193	chr16:67926317	PSKH1	-0.91	-4.66	-0.43	1.01e-5	Crohn's disease;
THYM	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1784581	0.588	rs1789986	chr6:162409978	C/T	cg17173639	chr6:162384350	PARK2	-0.8	-7.47	-0.61	3.85e-11	Itch intensity from mosquito bite;
THYM	cis	rs7894051	1.000	rs10776675	chr10:135183094	C/A	cg14353649	chr10:135191496	PAOX	-0.79	-4.9	-0.45	3.96e-6	Lifespan;
THYM	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg18305652	chr10:134549665	INPP5A	-0.74	-5.92	-0.52	5.14e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02788857	chr8:22132959	PIWIL2	0.61	5.62	0.5	1.89e-7	Hypertriglyceridemia;
THYM	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs654128	0.640	rs339348	chr6:117220253	T/C	cg12892004	chr6:117198278	RFX6	-0.72	-5.66	-0.5	1.61e-7	Telomere length;
THYM	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg06112835	chr11:68658793	MRPL21	0.44	6.2	0.54	1.43e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9534288	0.659	rs9534314	chr13:46654844	A/G	cg15192986	chr13:46630673	CPB2	-0.65	-4.57	-0.42	1.44e-5	Blood protein levels;
THYM	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg17372223	chr3:52568218	NT5DC2	0.37	5.78	0.51	9.55e-8	Electroencephalogram traits;
THYM	cis	rs600231	0.719	rs7114809	chr11:65251444	A/G	cg17120908	chr11:65337727	SSSCA1	-0.62	-4.75	-0.44	7.08e-6	Bone mineral density;
THYM	cis	rs7100689	0.646	rs10736345	chr10:82134140	C/T	cg01528321	chr10:82214614	TSPAN14	0.79	6.01	0.52	3.47e-8	Post bronchodilator FEV1;
THYM	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.22	-0.47	1.06e-6	Chronic sinus infection;
THYM	cis	rs3741151	0.687	rs724111	chr11:73238645	G/A	cg17517138	chr11:73019481	ARHGEF17	0.9	4.73	0.44	7.74e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg16325326	chr1:53192061	ZYG11B	0.81	7.53	0.61	2.93e-11	Monocyte count;
THYM	cis	rs7851660	0.874	rs2417576	chr9:100628707	C/T	cg13688889	chr9:100608707	NA	-0.79	-5.92	-0.52	5.07e-8	Strep throat;
THYM	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.91	-6.52	-0.56	3.31e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7688540	0.771	rs4582105	chr4:246342	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.72	4.88	0.45	4.35e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs669446	0.528	rs4660743	chr1:44195404	C/T	cg12599982	chr1:44399894	ARTN	0.51	4.71	0.44	8.48e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs868036	1.000	rs4776377	chr15:68103387	T/C	cg24579218	chr15:68104479	NA	-0.65	-6.51	-0.56	3.59e-9	Restless legs syndrome;
THYM	cis	rs7809950	0.817	rs3779495	chr7:107250260	G/A	cg23024343	chr7:107201750	COG5	1.02	8.56	0.66	2.01e-13	Coronary artery disease;
THYM	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg00074818	chr8:8560427	CLDN23	-0.47	-4.53	-0.42	1.71e-5	Mood instability;
THYM	cis	rs11838776	0.522	rs7318424	chr13:111021623	C/G	cg15455643	chr13:111040242	COL4A2	-0.45	-5.78	-0.51	9.54e-8	Coronary artery disease;
THYM	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs5009270	0.513	rs728461	chr7:112217909	A/G	cg23628563	chr7:112262597	NA	0.63	4.48	0.42	2.12e-5	Osteoarthritis (hip);
THYM	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg11266682	chr4:10021025	SLC2A9	0.67	8.59	0.66	1.69e-13	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg02454025	chr1:11042201	C1orf127	0.85	9.91	0.71	2.54e-16	Ewing sarcoma;
THYM	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg01579765	chr21:45077557	HSF2BP	-0.46	-6.61	-0.56	2.26e-9	Mean corpuscular volume;
THYM	cis	rs10193935	0.901	rs7594010	chr2:42534896	C/T	cg27598129	chr2:42591480	NA	-0.75	-4.61	-0.43	1.25e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8050907	0.744	rs55810554	chr16:4524392	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.3	5.2	0.47	1.16e-6	Obesity-related traits;
THYM	cis	rs6032067	0.609	rs1011536	chr20:43793370	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-6.26	-0.54	1.12e-8	Blood protein levels;
THYM	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg23649088	chr2:200775458	C2orf69	0.73	5.13	0.47	1.53e-6	Schizophrenia;
THYM	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg24209194	chr3:40518798	ZNF619	-0.93	-5.13	-0.47	1.52e-6	Renal cell carcinoma;
THYM	cis	rs6942756	1.000	rs6942756	chr7:128886821	T/G	cg02491457	chr7:128862824	NA	-0.44	-4.53	-0.42	1.69e-5	White matter hyperintensity burden;
THYM	cis	rs4660306	0.677	rs1691216	chr1:45899416	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.66	4.65	0.43	1.06e-5	Homocysteine levels;
THYM	cis	rs887829	0.569	rs7574296	chr2:234638249	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.74	-6.01	-0.52	3.48e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg24375607	chr4:120327624	NA	0.64	4.9	0.45	3.93e-6	Corneal astigmatism;
THYM	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg11764359	chr7:65958608	NA	-0.65	-5.05	-0.46	2.15e-6	Aortic root size;
THYM	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7224314	1.000	rs7226214	chr17:65383323	C/T	cg01507342	chr17:65387096	PITPNC1	-0.95	-10.71	-0.74	5.15e-18	Diisocyanate-induced asthma;
THYM	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg00129232	chr17:37814104	STARD3	-0.96	-7.56	-0.61	2.57e-11	Asthma;
THYM	cis	rs1878931	0.597	rs37814	chr16:3455247	C/T	cg22508957	chr16:3507546	NAT15	0.5	5.22	0.47	1.04e-6	Body mass index (adult);
THYM	cis	rs2038227	1	rs2038227	chr16:539140	C/A	cg06259664	chr16:537672	RAB11FIP3	0.56	5.28	0.48	8.2e-7	Venous thromboembolism (SNP x SNP interaction);
THYM	cis	rs7513165	0.935	rs4951316	chr1:204161490	C/T	cg04791601	chr1:204159016	NA	-0.38	-4.75	-0.44	7.13e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
THYM	cis	rs3204270	0.639	rs7216239	chr17:79660187	C/T	cg13117272	chr17:79681052	SLC25A10	-0.79	-4.98	-0.46	2.79e-6	Dental caries;
THYM	cis	rs17407555	0.955	rs56099802	chr4:10179379	C/G	cg00071950	chr4:10020882	SLC2A9	-0.71	-5.23	-0.47	9.86e-7	Schizophrenia (age at onset);
THYM	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7567389	0.600	rs7590030	chr2:128055967	G/A	cg09760422	chr2:128146352	NA	-0.41	-4.91	-0.45	3.73e-6	Self-rated health;
THYM	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06850241	chr22:41845214	NA	-0.62	-5.37	-0.48	5.66e-7	Vitiligo;
THYM	cis	rs9359856	0.529	rs72919922	chr6:90492997	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs2835345	0.596	rs12482097	chr21:37823890	A/G	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg00383909	chr3:49044727	WDR6	1.12	6.06	0.53	2.75e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4660531	1.000	rs4660532	chr1:41840197	C/T	cg01193554	chr1:41846683	NA	-0.34	-4.49	-0.42	2.01e-5	Bipolar disorder;
THYM	cis	rs1061377	1.000	rs2381284	chr4:39119596	G/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11644478	chr21:40555479	PSMG1	1.02	8.35	0.65	5.48e-13	Cognitive function;
THYM	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.97	-5.14	-0.47	1.49e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6906287	0.647	rs7766375	chr6:118918269	G/A	cg21191810	chr6:118973309	C6orf204	0.57	5.67	0.5	1.54e-7	Electrocardiographic conduction measures;
THYM	cis	rs35883536	0.611	rs61070860	chr1:101097628	G/A	cg06223162	chr1:101003688	GPR88	0.62	5.52	0.49	2.96e-7	Monocyte count;
THYM	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg06623918	chr6:96969491	KIAA0776	-1.05	-10.47	-0.73	1.63e-17	Headache;
THYM	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs59112743	0.510	rs2619530	chr6:15562646	T/A	cg10111214	chr6:14815676	NA	0.77	5.0	0.46	2.66e-6	Multiple keratinocyte cancers;
THYM	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs448720	0.811	rs1996121	chr15:68181578	G/T	cg23793686	chr15:68133972	NA	-0.54	-5.04	-0.46	2.24e-6	Cognitive performance;
THYM	cis	rs2273669	0.667	rs6918331	chr6:109317394	C/G	cg17117243	chr6:109341365	SESN1	-0.91	-5.45	-0.49	4.01e-7	Prostate cancer;
THYM	cis	rs7804356	0.871	rs2189017	chr7:26795073	A/G	cg24979288	chr7:27242424	NA	0.63	4.54	0.42	1.66e-5	Type 1 diabetes;
THYM	cis	rs28595532	0.920	rs114696063	chr4:119760624	T/A	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs2273669	0.915	rs6651002	chr6:109318516	G/C	cg17117243	chr6:109341365	SESN1	-0.71	-4.46	-0.42	2.26e-5	Prostate cancer;
THYM	cis	rs1524976	1.000	rs62255276	chr3:65457776	C/A	cg16238336	chr3:65465873	MAGI1	-1.01	-6.33	-0.54	8.04e-9	PR interval;
THYM	cis	rs28647808	0.867	rs34399743	chr9:136251358	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.11	-4.8	-0.44	5.91e-6	Blood protein levels;
THYM	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg10589385	chr1:150898437	SETDB1	0.64	5.48	0.49	3.48e-7	Melanoma;
THYM	cis	rs1371867	0.875	rs1660319	chr8:101337530	A/G	cg00191853	chr8:101177733	SPAG1	-0.51	-5.08	-0.46	1.85e-6	Atrioventricular conduction;
THYM	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg21226059	chr5:178986404	RUFY1	0.64	7.41	0.61	5.22e-11	Lung cancer;
THYM	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.12e-6	Corneal astigmatism;
THYM	cis	rs11645898	0.622	rs4788463	chr16:72223716	G/T	cg14768367	chr16:72042858	DHODH	-0.68	-4.97	-0.45	2.9e-6	Blood protein levels;
THYM	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg05527609	chr1:210001259	C1orf107	-0.83	-6.03	-0.53	3.14e-8	Orofacial clefts;
THYM	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2730245	0.527	rs62475645	chr7:158656825	G/A	cg01219135	chr7:158766336	NA	0.57	4.54	0.42	1.65e-5	Height;
THYM	cis	rs7940866	0.774	rs7480903	chr11:130832276	A/G	cg05962950	chr11:130786565	SNX19	0.75	5.7	0.5	1.37e-7	Schizophrenia;
THYM	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Parkinson's disease;
THYM	cis	rs9311676	0.656	rs62258093	chr3:58371745	T/C	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg04181038	chr4:183730758	NA	1.02	8.45	0.66	3.35e-13	Pediatric autoimmune diseases;
THYM	cis	rs981844	0.683	rs1563462	chr4:154755051	G/A	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs10892173	0.566	rs111578166	chr11:117666714	G/T	cg07621104	chr11:117668040	DSCAML1	0.77	5.98	0.52	3.82e-8	Myopia;
THYM	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs11264213	0.901	rs716926	chr1:36424476	A/G	cg27506609	chr1:36549197	TEKT2	0.92	4.83	0.44	5.3e-6	Schizophrenia;
THYM	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg08968635	chr6:28129556	ZNF389	0.59	4.57	0.42	1.46e-5	Parkinson's disease;
THYM	cis	rs975722	0.615	rs12534210	chr7:117322403	G/T	cg10524701	chr7:117356490	CTTNBP2	0.56	4.48	0.42	2.05e-5	Coronary artery disease;
THYM	cis	rs8041943	0.583	rs72730841	chr15:79907997	G/A	cg20511832	chr15:78934280	CHRNB4	0.41	4.47	0.42	2.15e-5	Bone mineral density (spine) and age at menarche;
THYM	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg21773646	chr17:80085082	CCDC57	0.31	4.49	0.42	2.02e-5	Life satisfaction;
THYM	cis	rs17019602	0.666	rs6583028	chr1:108150238	G/A	cg02990361	chr1:107599529	PRMT6	0.84	5.0	0.46	2.58e-6	IgA nephropathy;
THYM	cis	rs12496230	0.953	rs13096599	chr3:66848809	T/C	cg17646820	chr3:66848679	NA	0.91	5.2	0.47	1.15e-6	Type 2 diabetes;
THYM	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg15704280	chr7:45808275	SEPT13	-1.07	-15.26	-0.84	2.74e-27	Height;
THYM	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg12863693	chr15:85201151	NMB	0.52	4.67	0.43	9.92e-6	Schizophrenia;
THYM	cis	rs6980334	1.000	rs13243992	chr7:137784790	C/T	cg03464514	chr7:137028442	PTN	0.56	4.67	0.43	9.74e-6	Blood metabolite ratios;
THYM	cis	rs4268898	0.636	rs76172309	chr2:24458911	G/C	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	cis	rs4924935	1.000	rs1737947	chr17:18831432	A/G	cg26378065	chr17:18585709	ZNF286B	-0.71	-5.27	-0.48	8.44e-7	Pancreatic cancer;
THYM	cis	rs4383453	0.539	rs56276445	chr3:123098242	C/A	cg04890266	chr3:123102914	ADCY5	-0.83	-8.55	-0.66	2.11e-13	Gestational age at birth (maternal effect);
THYM	cis	rs4936891	0.599	rs10893128	chr11:123890745	C/T	cg22125253	chr11:123886957	OR10G4	-0.56	-4.94	-0.45	3.29e-6	Male fertility;
THYM	cis	rs7084402	0.935	rs10763564	chr10:60360423	C/A	cg09696939	chr10:60272079	BICC1	-0.48	-5.89	-0.52	5.85e-8	Refractive error;
THYM	cis	rs1568889	1.000	rs12802830	chr11:28321196	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	4.87	0.45	4.44e-6	Bipolar disorder;
THYM	cis	rs3733631	0.557	rs78690143	chr4:104686285	T/C	cg24090629	chr4:104641072	TACR3	-0.86	-4.55	-0.42	1.57e-5	Menarche (age at onset);
THYM	cis	rs8014204	0.836	rs12888998	chr14:75292662	G/T	cg06637938	chr14:75390232	RPS6KL1	0.55	5.34	0.48	6.42e-7	Caffeine consumption;
THYM	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.17	-0.47	1.28e-6	Joint mobility (Beighton score);
THYM	cis	rs711830	0.965	rs2072590	chr2:177042633	A/C	cg13092806	chr2:177043255	NA	0.58	4.6	0.43	1.33e-5	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs4499344	0.521	rs259222	chr19:33136895	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.93	6.54	0.56	3.01e-9	Mean platelet volume;
THYM	cis	rs2235642	1.000	rs2235642	chr16:1584866	T/C	cg10465839	chr16:1584050	IFT140;TMEM204	-0.57	-4.77	-0.44	6.7e-6	Coronary artery disease;
THYM	trans	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg14086364	chr5:150678334	SLC36A3	0.48	4.69	0.43	9.1e-6	Skin aging (microtopography measurement);
THYM	trans	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg10856724	chr12:34555212	NA	-0.88	-7.58	-0.61	2.31e-11	Bladder cancer;
THYM	cis	rs2050392	0.517	rs602097	chr10:30747546	C/T	cg02070205	chr10:30722105	MAP3K8	-0.63	-5.02	-0.46	2.41e-6	Inflammatory bowel disease;
THYM	cis	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg10856724	chr12:34555212	NA	0.85	7.65	0.62	1.61e-11	Morning vs. evening chronotype;
THYM	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	8.85	0.67	4.81e-14	Chronic sinus infection;
THYM	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06873352	chr17:61820015	STRADA	0.79	10.0	0.72	1.62e-16	Prudent dietary pattern;
THYM	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg25036284	chr2:26402008	FAM59B	0.8	5.42	0.49	4.48e-7	Gut microbiome composition (summer);
THYM	cis	rs7432375	0.609	rs835637	chr3:136673157	A/T	cg21827317	chr3:136751795	NA	0.62	5.32	0.48	7.01e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs807029	0.577	rs3740490	chr10:102756743	G/C	cg14905631	chr10:102746534	C10orf2;MRPL43	0.37	4.96	0.45	3.08e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg08885076	chr2:99613938	TSGA10	-0.45	-4.53	-0.42	1.7e-5	Fear of minor pain;
THYM	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs3087591	0.959	rs2051505	chr17:29699859	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.61	-5.11	-0.46	1.63e-6	Hip circumference;
THYM	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg14186256	chr22:23484241	RTDR1	0.97	9.53	0.7	1.67e-15	Bone mineral density;
THYM	cis	rs12188164	1.000	rs72717414	chr5:429818	C/G	cg26850624	chr5:429559	AHRR	-0.69	-5.39	-0.48	5.09e-7	Cystic fibrosis severity;
THYM	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.65	-11.83	-0.77	2.19e-20	Hemostatic factors and hematological phenotypes;
THYM	cis	rs17006441	0.932	rs11921548	chr3:69844703	C/A	cg18496212	chr3:69797108	MITF	0.7	7.17	0.59	1.6e-10	Hemoglobin concentration;
THYM	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg06219351	chr7:158114137	PTPRN2	0.8	7.55	0.61	2.61e-11	Response to amphetamines;
THYM	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6121246	0.559	rs6087782	chr20:30391580	C/T	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs208520	0.874	rs208470	chr6:66916402	G/A	cg07460842	chr6:66804631	NA	-0.78	-4.77	-0.44	6.64e-6	Exhaled nitric oxide output;
THYM	cis	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8067545	0.611	rs9907516	chr17:20070490	G/A	cg13482628	chr17:19912719	NA	0.54	4.49	0.42	2e-5	Schizophrenia;
THYM	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg04455712	chr21:45112962	RRP1B	0.54	5.04	0.46	2.22e-6	Mean corpuscular volume;
THYM	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg13683864	chr3:40499215	RPL14	1.07	12.42	0.79	1.31e-21	Renal cell carcinoma;
THYM	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg03806693	chr22:41940476	POLR3H	-1.06	-9.97	-0.72	1.9e-16	Vitiligo;
THYM	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg04731861	chr2:219085781	ARPC2	0.54	5.05	0.46	2.11e-6	Colorectal cancer;
THYM	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg03806693	chr22:41940476	POLR3H	-1.24	-10.73	-0.74	4.49e-18	Vitiligo;
THYM	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs988913	0.957	rs9382397	chr6:54782893	A/G	cg04690482	chr6:54711388	FAM83B	0.51	5.38	0.48	5.24e-7	Menarche (age at onset);
THYM	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	5.84	0.51	7.18e-8	Schizophrenia;
THYM	cis	rs501916	0.714	rs11854427	chr15:48047421	G/A	cg16110827	chr15:48056943	SEMA6D	-0.63	-4.53	-0.42	1.75e-5	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg11663144	chr21:46675770	NA	-0.71	-9.92	-0.71	2.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg24324837	chr19:49891574	CCDC155	0.52	4.76	0.44	6.89e-6	Multiple sclerosis;
THYM	cis	rs12681287	0.927	rs2976177	chr8:87332332	A/T	cg27223183	chr8:87520930	FAM82B	-0.65	-4.76	-0.44	6.8e-6	Caudate activity during reward;
THYM	cis	rs34779708	0.966	rs6481941	chr10:35440141	G/A	cg03585969	chr10:35415529	CREM	0.67	5.01	0.46	2.51e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg02915803	chr1:1606292	LOC728661;CDK11B	0.63	5.32	0.48	6.98e-7	Body mass index;
THYM	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs1568889	1.000	rs7951681	chr11:28273894	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.69	4.5	0.42	1.95e-5	Bipolar disorder;
THYM	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.49	0.49	3.33e-7	Platelet count;
THYM	cis	rs713587	0.934	rs6738433	chr2:25159501	G/C	cg01884057	chr2:25150051	NA	0.67	7.0	0.58	3.58e-10	Body mass index in non-asthmatics;
THYM	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg22907277	chr7:1156413	C7orf50	0.72	5.79	0.51	9.1e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10248839	0.518	rs34011864	chr7:29698499	G/A	cg19413766	chr7:29689036	LOC646762	-0.94	-6.68	-0.57	1.65e-9	Facial emotion recognition (angry faces);
THYM	cis	rs12950390	0.512	rs72831681	chr17:45847174	C/G	cg24803719	chr17:45855879	NA	-0.63	-5.23	-0.47	1.01e-6	IgG glycosylation;
THYM	cis	rs7635838	0.617	rs347587	chr3:11287155	A/G	cg00170343	chr3:11313890	ATG7	-0.65	-5.08	-0.46	1.92e-6	HDL cholesterol;
THYM	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg23851026	chr2:136556271	LCT	-0.56	-5.9	-0.52	5.57e-8	Mosquito bite size;
THYM	cis	rs7428297	0.778	rs71327796	chr3:127070903	C/T	cg21487550	chr3:127056955	NA	0.73	4.58	0.42	1.43e-5	Clozapine-induced agranulocytosis;
THYM	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg08431931	chr22:42394659	WBP2NL	0.71	5.07	0.46	1.98e-6	Birth weight;
THYM	cis	rs7781557	1.000	rs17474893	chr7:102480757	C/T	cg06322601	chr7:102330635	NA	0.67	5.05	0.46	2.1e-6	Colorectal adenoma (advanced);
THYM	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg23711669	chr6:146136114	FBXO30	-0.95	-9.69	-0.71	7.63e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg21926883	chr2:100939477	LONRF2	-0.68	-6.43	-0.55	5.2e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs13082711	0.911	rs11709954	chr3:27421427	C/T	cg02860705	chr3:27208620	NA	0.81	5.49	0.49	3.28e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	6.89	0.58	5.96e-10	Electrocardiographic conduction measures;
THYM	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg26314531	chr2:26401878	FAM59B	-0.76	-5.02	-0.46	2.37e-6	Gut microbiome composition (summer);
THYM	cis	rs61931739	0.817	rs7963318	chr12:34244929	C/G	cg06521331	chr12:34319734	NA	0.6	5.15	0.47	1.43e-6	Morning vs. evening chronotype;
THYM	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg08017756	chr2:100939284	LONRF2	-0.74	-7.3	-0.6	8.73e-11	Intelligence (multi-trait analysis);
THYM	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg10792982	chr14:105748885	BRF1	0.76	7.95	0.63	3.92e-12	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs1729951	0.546	rs835634	chr3:136676303	C/T	cg12473912	chr3:136751656	NA	0.63	5.12	0.47	1.57e-6	Neuroticism;
THYM	cis	rs7836436	0.686	rs7006901	chr8:120954780	C/G	cg05020510	chr8:120428057	NOV	1.04	5.18	0.47	1.24e-6	HIV-1 viral setpoint;
THYM	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg22433210	chr17:43662623	NA	1.11	8.44	0.65	3.45e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2139634	0.965	rs1520483	chr3:46510209	C/T	cg02332537	chr3:46540019	RTP3	0.48	4.94	0.45	3.39e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg04267008	chr7:1944627	MAD1L1	0.52	4.54	0.42	1.65e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs1021993	0.868	rs906347	chr1:209528407	G/A	cg06155620	chr1:209527581	NA	-0.64	-5.25	-0.47	9.28e-7	Gut microbiome composition (winter);
THYM	cis	rs28595532	0.920	rs17325017	chr4:119774607	A/G	cg14228332	chr4:119757509	SEC24D	1.59	5.76	0.51	1.02e-7	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11039798	0.764	rs11039771	chr11:48513273	C/T	cg24672777	chr11:48374446	OR4C45	-1.14	-6.89	-0.58	6.15e-10	Axial length;
THYM	cis	rs8112449	1.000	rs35951601	chr19:10521548	G/A	cg01466491	chr19:10523363	NA	-0.68	-6.58	-0.56	2.59e-9	Multiple sclerosis;Gastritis;
THYM	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg22166914	chr1:53195759	ZYG11B	0.82	8.68	0.66	1.1e-13	Monocyte count;
THYM	cis	rs6866344	0.697	rs6873150	chr5:178125704	G/A	cg10224037	chr5:178157518	ZNF354A	1.01	7.73	0.62	1.13e-11	Neutrophil percentage of white cells;
THYM	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg11861562	chr11:117069780	TAGLN	0.31	4.45	0.42	2.34e-5	Blood protein levels;
THYM	cis	rs4731207	0.596	rs1994023	chr7:124580670	A/C	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs4836694	0.574	rs3824542	chr9:132936132	C/T	cg05251000	chr9:132935664	FREQ	0.76	5.02	0.46	2.44e-6	Alzheimer's disease (cognitive decline);
THYM	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg05872129	chr22:39784769	NA	-1.07	-11.96	-0.78	1.19e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs35883536	0.647	rs7535762	chr1:101047534	A/G	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs2820651	0.614	rs80334103	chr10:1489460	T/C	cg27404824	chr10:1454848	ADARB2	0.88	4.75	0.44	7.06e-6	Migraine with aura;
THYM	cis	rs763014	0.865	rs8909	chr16:633851	T/C	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.59	4.45	0.42	2.31e-5	Renal function-related traits (BUN);
THYM	cis	rs2458413	0.669	rs1812214	chr8:105344070	A/G	cg04554929	chr8:105342491	NA	-0.42	-6.08	-0.53	2.49e-8	Paget's disease;
THYM	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg02773041	chr1:40204384	PPIE	-0.77	-5.99	-0.52	3.8e-8	Blood protein levels;
THYM	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg11266682	chr4:10021025	SLC2A9	0.69	10.64	0.74	7.14e-18	Bone mineral density;
THYM	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg22764044	chr5:178986830	RUFY1	0.6	5.91	0.52	5.42e-8	Lung cancer;
THYM	cis	rs4845875	0.600	rs4846040	chr1:11837048	C/G	cg14194983	chr1:11908298	NPPA	0.54	4.97	0.45	2.93e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg27068330	chr11:65405492	SIPA1	0.84	8.34	0.65	5.78e-13	Acne (severe);
THYM	cis	rs13006833	0.739	rs291428	chr2:191197226	G/T	cg21644426	chr2:191273491	MFSD6	0.62	4.49	0.42	1.99e-5	Urinary metabolites;
THYM	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg17757837	chr7:157058334	UBE3C	0.66	5.29	0.48	7.81e-7	Body mass index;
THYM	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg11764359	chr7:65958608	NA	-0.82	-6.57	-0.56	2.65e-9	Aortic root size;
THYM	cis	rs76935404	0.811	rs4609955	chr19:41433613	T/C	cg19493303	chr19:41414353	NA	0.56	5.1	0.46	1.75e-6	nicotine metabolite ratio in current smokers;
THYM	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg14228332	chr4:119757509	SEC24D	-1.26	-4.88	-0.45	4.25e-6	Cannabis dependence symptom count;
THYM	cis	rs2276314	0.857	rs3737474	chr18:33613595	T/C	cg19628046	chr18:33552617	C18orf21	0.75	5.33	0.48	6.55e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg24642439	chr20:33292090	TP53INP2	0.68	5.12	0.46	1.62e-6	Coronary artery disease;
THYM	trans	rs75518195	0.543	rs62301928	chr4:64674543	A/G	cg14706739	chr8:21916355	EPB49	0.75	7.37	0.6	6.34e-11	Triptolide cytotoxicity;
THYM	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11031096	0.678	rs11031220	chr11:4197638	G/A	cg22027985	chr11:4115532	RRM1	-0.56	-5.25	-0.47	9.12e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9992101	0.547	rs2137153	chr4:77411660	G/A	cg20311846	chr4:77356250	SHROOM3	-0.45	-4.72	-0.44	8.12e-6	Creatinine levels;
THYM	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg27129171	chr3:47204927	SETD2	0.8	7.67	0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg25072359	chr17:41440525	NA	0.77	5.74	0.51	1.15e-7	Menopause (age at onset);
THYM	cis	rs1050631	0.592	rs1789508	chr18:33736845	G/A	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.58	4.56	0.42	1.54e-5	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg13695892	chr22:41940480	POLR3H	0.85	6.98	0.58	3.94e-10	Vitiligo;
THYM	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg01299579	chr2:10830716	NOL10	0.49	4.65	0.43	1.06e-5	Prostate cancer;
THYM	cis	rs13223928	0.536	rs12700594	chr7:3156701	G/A	cg19214707	chr7:3157722	NA	0.85	7.33	0.6	7.65e-11	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs10484885	0.887	rs2273246	chr6:90453263	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.84	-7.98	-0.63	3.27e-12	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs9302635	0.513	rs3812987	chr16:72158920	C/A	cg23815491	chr16:72088622	HP	0.79	6.16	0.53	1.71e-8	Blood protein levels;
THYM	cis	rs28735056	0.563	rs12968139	chr18:77685520	A/G	cg20368463	chr18:77673604	PQLC1	-0.67	-5.05	-0.46	2.16e-6	Schizophrenia;
THYM	trans	rs629535	0.862	rs638412	chr8:70047690	C/T	cg21567404	chr3:27674614	NA	1.12	10.86	0.74	2.44e-18	Dupuytren's disease;
THYM	cis	rs9902453	0.740	rs2617867	chr17:28049399	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg06634786	chr22:41940651	POLR3H	0.62	4.81	0.44	5.64e-6	Vitiligo;
THYM	cis	rs12803635	0.557	rs35121740	chr11:67175349	G/A	cg13973090	chr11:66206505	MRPL11	1.24	4.83	0.44	5.19e-6	Mean corpuscular volume;
THYM	cis	rs208520	1.000	rs208536	chr6:66963440	T/C	cg07460842	chr6:66804631	NA	-0.85	-5.48	-0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs4723738	0.729	rs10226230	chr7:38269292	C/T	cg02695349	chr7:38269241	STARD3NL	0.35	4.48	0.42	2.11e-5	Treatment response for severe sepsis;
THYM	cis	rs17407555	0.909	rs2868939	chr4:10314921	G/A	cg11266682	chr4:10021025	SLC2A9	-0.51	-4.65	-0.43	1.09e-5	Schizophrenia (age at onset);
THYM	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg08999081	chr20:33150536	PIGU	-0.73	-6.56	-0.56	2.86e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg03264133	chr6:25882463	NA	-0.66	-4.49	-0.42	2.02e-5	Height;
THYM	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg02353165	chr6:42928485	GNMT	0.76	5.5	0.49	3.14e-7	Blood protein levels;
THYM	cis	rs6456156	0.774	rs1012656	chr6:167525303	G/C	cg09487078	chr6:167525398	CCR6	-0.45	-5.09	-0.46	1.82e-6	Primary biliary cholangitis;
THYM	cis	rs4242434	0.672	rs2404654	chr8:22484949	T/C	cg21658235	chr8:22456391	C8orf58	0.45	4.57	0.42	1.48e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg02725872	chr8:58115012	NA	-0.91	-6.92	-0.58	5.22e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg02734326	chr4:10020555	SLC2A9	0.76	7.25	0.6	1.13e-10	Bone mineral density;
THYM	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg04287289	chr16:89883240	FANCA	0.65	5.87	0.52	6.49e-8	Vitiligo;
THYM	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg11494091	chr17:61959527	GH2	0.7	6.38	0.55	6.38e-9	Height;
THYM	cis	rs3780378	0.935	rs6476939	chr9:5084837	T/A	cg02405213	chr9:5042618	JAK2	-0.71	-6.48	-0.55	4.05e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs9915657	0.660	rs12602039	chr17:70089384	A/G	cg06234051	chr17:70120541	SOX9	-0.64	-5.84	-0.51	7.43e-8	Thyroid hormone levels;
THYM	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg11752832	chr7:134001865	SLC35B4	0.76	5.72	0.51	1.24e-7	Mean platelet volume;
THYM	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg00419117	chr1:228361641	C1orf69	0.47	4.54	0.42	1.67e-5	Diastolic blood pressure;
THYM	cis	rs7113850	0.541	rs7118538	chr11:24223615	C/T	ch.11.24196551F	chr11:24239977	NA	0.92	4.89	0.45	4.04e-6	Bone fracture in osteoporosis;
THYM	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg24675056	chr1:15929824	NA	0.71	5.65	0.5	1.68e-7	Systolic blood pressure;
THYM	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.47	0.49	3.63e-7	Bipolar disorder;
THYM	cis	rs28647808	0.786	rs4962136	chr9:136256794	A/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg21385522	chr1:16154831	NA	0.69	4.75	0.44	7.18e-6	Systolic blood pressure;
THYM	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg25703541	chr22:24373054	LOC391322	-0.84	-9.08	-0.68	1.5e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	4.68	0.43	9.45e-6	Aortic root size;
THYM	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg16325326	chr1:53192061	ZYG11B	0.8	7.54	0.61	2.79e-11	Monocyte count;
THYM	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg12463550	chr7:65579703	CRCP	-0.57	-4.76	-0.44	7.01e-6	Aortic root size;
THYM	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg16926213	chr1:1841314	NA	0.56	5.87	0.52	6.45e-8	Body mass index;
THYM	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg09455208	chr3:40491958	NA	0.46	4.67	0.43	9.9e-6	Renal cell carcinoma;
THYM	cis	rs6840360	0.571	rs7685697	chr4:152558849	A/G	cg22705602	chr4:152727874	NA	-0.77	-8.58	-0.66	1.81e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4919694	1.000	rs112809537	chr10:104670346	C/T	cg04362960	chr10:104952993	NT5C2	1.14	6.92	0.58	5.36e-10	Arsenic metabolism;
THYM	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg17063962	chr7:91808500	NA	1.14	12.22	0.78	3.42e-21	Breast cancer;
THYM	cis	rs10927875	0.619	rs28537253	chr1:16148600	A/C	cg21385522	chr1:16154831	NA	-0.79	-6.86	-0.58	6.83e-10	Dilated cardiomyopathy;
THYM	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17407555	0.865	rs78272916	chr4:10286838	A/G	cg00071950	chr4:10020882	SLC2A9	-0.65	-4.45	-0.42	2.3e-5	Schizophrenia (age at onset);
THYM	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg12560992	chr17:57184187	TRIM37	0.84	7.84	0.63	6.52e-12	Intelligence (multi-trait analysis);
THYM	cis	rs8048589	0.577	rs8055516	chr16:12180198	A/T	cg02910054	chr16:12241554	SNX29	0.63	5.6	0.5	2.06e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs10140922	0.931	rs4982258	chr14:35821891	G/A	cg07166546	chr14:35805898	NA	-0.27	-6.66	-0.56	1.77e-9	Hip circumference adjusted for BMI;
THYM	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg07570687	chr10:102243282	WNT8B	-0.82	-7.87	-0.63	5.73e-12	Palmitoleic acid (16:1n-7) levels;
THYM	trans	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg10856724	chr12:34555212	NA	-0.9	-8.08	-0.64	2.05e-12	Bladder cancer;
THYM	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	cis	rs7084402	0.875	rs1593671	chr10:60295969	A/T	cg07615347	chr10:60278583	BICC1	0.56	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg14784868	chr12:69753453	YEATS4	1.13	12.31	0.78	2.2e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg23711669	chr6:146136114	FBXO30	-0.93	-9.39	-0.69	3.39e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg14675211	chr2:100938903	LONRF2	0.77	8.11	0.64	1.75e-12	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg06521331	chr12:34319734	NA	-1.02	-10.3	-0.73	3.78e-17	Morning vs. evening chronotype;
THYM	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg27170947	chr2:26402098	FAM59B	-0.78	-6.09	-0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg06565975	chr8:143823917	SLURP1	-0.76	-8.91	-0.67	3.46e-14	Urinary tract infection frequency;
THYM	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg09021430	chr5:549028	NA	-0.72	-5.32	-0.48	6.89e-7	Ulcerative colitis;
THYM	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.39	-4.53	-0.42	1.72e-5	Schizophrenia;
THYM	cis	rs859767	0.741	rs6713239	chr2:135434849	C/T	cg12500956	chr2:135428796	TMEM163	-0.51	-5.12	-0.46	1.6e-6	Neuroticism;
THYM	cis	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg06609049	chr19:2785107	THOP1	0.62	5.01	0.46	2.53e-6	Total cholesterol levels;
THYM	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg27490568	chr2:178487706	NA	0.6	5.22	0.47	1.05e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg21394778	chr1:3037102	PRDM16	0.47	4.57	0.42	1.46e-5	Height;
THYM	cis	rs4866334	1.000	rs116612534	chr5:18506467	C/A	cg02002538	chr5:17811409	NA	-1.1	-4.55	-0.42	1.61e-5	IgG glycosylation;
THYM	cis	rs11190604	1.000	rs2489053	chr10:102353341	A/G	cg07570687	chr10:102243282	WNT8B	0.71	5.64	0.5	1.75e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg09359103	chr1:154839909	KCNN3	-0.7	-7.82	-0.63	7.17e-12	Prostate cancer;
THYM	cis	rs9549260	0.564	rs12184871	chr13:41291928	C/A	cg21288729	chr13:41239152	FOXO1	0.68	5.14	0.47	1.49e-6	Red blood cell count;
THYM	cis	rs72627123	0.609	rs72627131	chr14:74377608	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.09	6.53	0.56	3.16e-9	Morning vs. evening chronotype;
THYM	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg04398451	chr17:18023971	MYO15A	-0.78	-7.23	-0.6	1.22e-10	Total body bone mineral density;
THYM	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg25703541	chr22:24373054	LOC391322	-0.85	-8.93	-0.68	3.21e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.6	5.48	0.49	3.44e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs36051895	0.664	rs3780377	chr9:5110899	T/C	cg02405213	chr9:5042618	JAK2	-1.04	-11.53	-0.76	9.46e-20	Pediatric autoimmune diseases;
THYM	cis	rs2033562	1.000	rs1347319	chr8:103548424	G/C	cg20611272	chr8:103548145	NA	0.42	5.11	0.46	1.65e-6	IgA nephropathy;
THYM	cis	rs7172809	0.863	rs74026932	chr15:77825729	T/C	cg22256960	chr15:77711686	NA	-0.67	-4.61	-0.43	1.27e-5	Glucose homeostasis traits;
THYM	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.11	-10.66	-0.74	6.57e-18	Primary sclerosing cholangitis;
THYM	cis	rs34375054	0.525	rs7136220	chr12:125602684	T/C	cg25124228	chr12:125621409	AACS	-0.82	-7.05	-0.59	2.9e-10	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	0.65	4.92	0.45	3.67e-6	Diastolic blood pressure;
THYM	cis	rs9560113	1.000	rs4773383	chr13:112177764	C/T	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs7607369	0.580	rs17573724	chr2:219652141	T/A	cg02176678	chr2:219576539	TTLL4	-0.59	-5.48	-0.49	3.54e-7	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-6.0	-0.52	3.63e-8	Prostate cancer;
THYM	cis	rs679087	0.686	rs10843500	chr12:29918582	C/G	cg14258853	chr12:29935411	TMTC1	0.52	4.63	0.43	1.18e-5	Schizophrenia;
THYM	cis	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg06521331	chr12:34319734	NA	-0.74	-5.69	-0.5	1.4e-7	Morning vs. evening chronotype;
THYM	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg09469691	chr10:81107165	PPIF	0.66	4.79	0.44	6.2e-6	Height;
THYM	cis	rs2806561	0.929	rs628096	chr1:23537676	C/G	cg19743168	chr1:23544995	NA	0.68	7.55	0.61	2.67e-11	Height;
THYM	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.5	-0.49	3.18e-7	Obesity-related traits;
THYM	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg16989719	chr2:238392110	NA	-0.62	-5.34	-0.48	6.27e-7	Prostate cancer;
THYM	cis	rs7119038	0.774	rs11217038	chr11:118677355	G/A	cg19308663	chr11:118741387	NA	0.57	5.87	0.52	6.34e-8	Sjögren's syndrome;
THYM	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg10018233	chr7:150070692	REPIN1	-0.39	-5.52	-0.49	2.95e-7	Blood protein levels;Circulating chemerin levels;
THYM	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg15704280	chr7:45808275	SEPT13	-0.98	-11.35	-0.76	2.22e-19	Coronary artery disease;
THYM	cis	rs6531656	0.633	rs337644	chr4:38613306	T/A	cg24279243	chr4:38676559	KLF3	0.81	6.99	0.58	3.82e-10	Lymphocyte counts;
THYM	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg20007245	chr22:24372913	LOC391322	-0.65	-4.55	-0.42	1.56e-5	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg06850241	chr22:41845214	NA	0.53	4.45	0.42	2.34e-5	Vitiligo;
THYM	cis	rs28374715	0.662	rs28382348	chr15:41487934	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.02	-8.4	-0.65	4.27e-13	Ulcerative colitis;
THYM	cis	rs7580658	0.895	rs9636237	chr2:128076022	T/C	cg10021288	chr2:128175891	PROC	-0.72	-6.36	-0.55	7.09e-9	Protein C levels;
THYM	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.79e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg20486651	chr6:167070296	RPS6KA2	0.5	4.79	0.44	6.18e-6	Crohn's disease;
THYM	cis	rs10979	1.000	rs9386032	chr6:143887492	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs6754311	0.509	rs10188066	chr2:136539513	G/A	cg04750100	chr2:136595281	LCT	-0.51	-5.24	-0.47	9.53e-7	Mosquito bite size;
THYM	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13006833	0.668	rs2136566	chr2:191141283	C/T	cg11845111	chr2:191398756	TMEM194B	0.65	4.5	0.42	1.89e-5	Urinary metabolites;
THYM	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.78	-6.87	-0.58	6.69e-10	Intelligence (multi-trait analysis);
THYM	cis	rs11651000	0.817	rs11657479	chr17:45822901	T/C	cg03474202	chr17:45855739	NA	-0.72	-6.05	-0.53	2.84e-8	IgG glycosylation;
THYM	cis	rs1371867	0.846	rs1788196	chr8:101290088	C/T	cg00191853	chr8:101177733	SPAG1	-0.5	-5.01	-0.46	2.54e-6	Atrioventricular conduction;
THYM	cis	rs11910985	0.557	rs79228900	chr21:48091888	G/A	cg17243659	chr21:48055224	PRMT2	1.23	5.72	0.51	1.23e-7	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	trans	rs9951602	0.512	rs12455566	chr18:76655926	A/G	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg25214090	chr10:38739885	LOC399744	0.92	7.7	0.62	1.26e-11	Corneal astigmatism;
THYM	cis	rs28595532	0.841	rs114966236	chr4:119733437	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg06112835	chr11:68658793	MRPL21	0.44	6.33	0.54	8.1e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs3126085	0.825	rs11204933	chr1:152172185	C/T	cg10321714	chr1:152280068	FLG	0.69	5.08	0.46	1.88e-6	Atopic dermatitis;
THYM	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12667521	chr19:29218732	NA	0.96	8.39	0.65	4.58e-13	Methadone dose in opioid dependence;
THYM	cis	rs1557488	0.599	rs4494313	chr11:126723893	G/C	cg03950493	chr11:126582183	KIRREL3	-0.39	-4.56	-0.42	1.52e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg14664628	chr15:75095509	CSK	0.86	7.11	0.59	2.2e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs7084402	0.967	rs1427196	chr10:60278573	C/T	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.61e-20	Menopause (age at onset);
THYM	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg06713675	chr4:122721982	EXOSC9	-0.51	-4.75	-0.44	7.13e-6	Type 2 diabetes;
THYM	cis	rs1331623	0.570	rs10739537	chr9:122188604	G/T	cg25935911	chr9:122132261	DBC1	-0.5	-4.48	-0.42	2.06e-5	Height;
THYM	cis	rs7975161	0.580	rs4246270	chr12:104728530	G/A	cg25273343	chr12:104657179	TXNRD1	-0.74	-4.51	-0.42	1.83e-5	Toenail selenium levels;
THYM	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg08847533	chr14:75593920	NEK9	-0.95	-9.92	-0.71	2.4e-16	Height;
THYM	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.83	-7.95	-0.63	3.76e-12	Lung cancer;
THYM	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg15704280	chr7:45808275	SEPT13	-1.02	-13.33	-0.81	1.74e-23	Coronary artery disease;
THYM	cis	rs72781680	0.898	rs72798041	chr2:23953076	T/C	cg08917208	chr2:24149416	ATAD2B	1.1	4.81	0.44	5.71e-6	Lymphocyte counts;
THYM	cis	rs800586	0.871	rs1040333	chr8:116825349	T/C	cg04656070	chr8:116661063	TRPS1	0.46	4.48	0.42	2.06e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg10862848	chr6:42927986	GNMT	-0.5	-6.75	-0.57	1.15e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg01699819	chr7:1052092	C7orf50	-0.77	-6.84	-0.57	7.5e-10	Bronchopulmonary dysplasia;
THYM	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg25817165	chr18:72167213	CNDP2	-0.98	-10.2	-0.72	6.18e-17	Refractive error;
THYM	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs800586	0.748	rs800508	chr8:116796912	C/A	cg04656070	chr8:116661063	TRPS1	0.49	4.7	0.43	8.9e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs3812049	0.784	rs6889311	chr5:127431285	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.42	0.49	4.45e-7	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.61	4.95	0.45	3.16e-6	Chronic sinus infection;
THYM	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg11789530	chr4:8429930	ACOX3	-0.74	-6.0	-0.52	3.55e-8	Response to antineoplastic agents;
THYM	cis	rs6499129	0.571	rs3729639	chr16:67225501	C/T	cg26912222	chr16:68000829	SLC12A4	0.69	4.58	0.42	1.44e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7572733	0.534	rs700692	chr2:198728500	T/C	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs11811982	0.793	rs116647640	chr1:227408696	A/G	cg09853570	chr1:228403422	OBSCN	1.21	4.67	0.43	9.81e-6	Optic disc area;
THYM	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg22709100	chr7:91322751	NA	0.63	4.86	0.45	4.55e-6	Breast cancer;
THYM	cis	rs4654899	0.796	rs59950774	chr1:21534844	C/A	cg01072550	chr1:21505969	NA	-0.73	-6.6	-0.56	2.36e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg23205692	chr1:25664452	TMEM50A	0.8	6.14	0.53	1.88e-8	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs72772090	0.539	rs72773932	chr5:96118148	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg13695892	chr22:41940480	POLR3H	0.87	6.19	0.54	1.5e-8	Vitiligo;
THYM	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg14784868	chr12:69753453	YEATS4	1.13	12.35	0.79	1.8e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	8.11	0.64	1.75e-12	Lung cancer in ever smokers;
THYM	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs12950390	1.000	rs8068453	chr17:45852354	A/G	cg24803719	chr17:45855879	NA	0.6	5.47	0.49	3.59e-7	IgG glycosylation;
THYM	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg26384229	chr12:38710491	ALG10B	-0.71	-5.52	-0.49	2.92e-7	Morning vs. evening chronotype;
THYM	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.26	0.47	8.97e-7	Lung cancer in ever smokers;
THYM	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg03929089	chr4:120376271	NA	-0.8	-8.56	-0.66	1.95e-13	Height;
THYM	cis	rs28647808	0.786	rs4962135	chr9:136256630	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg19507638	chr5:93509721	C5orf36	-0.65	-4.54	-0.42	1.63e-5	Diabetic retinopathy;
THYM	cis	rs7264396	0.747	rs2425158	chr20:34419664	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-5.77	-0.51	9.89e-8	Total cholesterol levels;
THYM	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs2658782	1.000	rs2019814	chr11:93168885	A/G	cg15737290	chr11:93063684	CCDC67	1.05	7.97	0.63	3.42e-12	Pulmonary function decline;
THYM	cis	rs240764	0.658	rs4840148	chr6:101182500	G/A	cg21058520	chr6:100914733	NA	0.56	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs9902453	0.765	rs2264302	chr17:28057095	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs28647808	0.881	rs71483208	chr9:136258824	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg17554472	chr22:41940697	POLR3H	0.64	4.51	0.42	1.88e-5	Vitiligo;
THYM	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8133932	0.554	rs11089028	chr21:47298312	T/C	cg20357416	chr21:47294739	PCBP3	-0.83	-5.27	-0.48	8.56e-7	Schizophrenia;
THYM	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	4.77	0.44	6.7e-6	Obesity-related traits;
THYM	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg03476357	chr21:30257390	N6AMT1	-0.61	-4.59	-0.43	1.38e-5	Dental caries;
THYM	cis	rs1829883	0.862	rs2460655	chr5:98797742	C/T	cg08333243	chr5:99726346	NA	-0.54	-4.95	-0.45	3.26e-6	Hemostatic factors and hematological phenotypes;
THYM	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg08645402	chr16:4508243	NA	0.8	7.9	0.63	4.95e-12	Schizophrenia;
THYM	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg23428387	chr22:49814324	NA	-0.57	-6.05	-0.53	2.91e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg03474202	chr17:45855739	NA	-0.74	-6.48	-0.55	4.1e-9	IgG glycosylation;
THYM	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg00310523	chr12:86230176	RASSF9	-0.53	-4.86	-0.45	4.64e-6	Major depressive disorder;
THYM	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg23356831	chr14:105996513	TMEM121	0.58	6.17	0.54	1.64e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs2637266	0.783	rs2588334	chr10:78518504	C/T	cg18941641	chr10:78392320	NA	0.68	5.51	0.49	3e-7	Pulmonary function;
THYM	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg26354017	chr1:205819088	PM20D1	-0.74	-7.04	-0.59	3.01e-10	Monocyte percentage of white cells;
THYM	cis	rs7107174	1.000	rs11237471	chr11:78082604	C/T	cg02023728	chr11:77925099	USP35	0.63	6.11	0.53	2.23e-8	Testicular germ cell tumor;
THYM	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27286337	chr10:134555280	INPP5A	0.8	5.52	0.49	2.9e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs988913	0.634	rs9464182	chr6:54921938	A/G	cg19716238	chr6:54711378	FAM83B	0.47	4.47	0.42	2.13e-5	Menarche (age at onset);
THYM	cis	rs9790314	0.747	rs1599386	chr3:160856314	C/T	cg04691961	chr3:161091175	C3orf57	0.61	4.71	0.44	8.33e-6	Morning vs. evening chronotype;
THYM	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs4455778	0.538	rs34820160	chr7:49115948	C/A	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg16325326	chr1:53192061	ZYG11B	-0.98	-11.09	-0.75	7.79e-19	Monocyte count;
THYM	cis	rs11628318	0.572	rs7142319	chr14:103119425	C/T	cg27124170	chr14:102829869	TECPR2;CINP	0.63	4.53	0.42	1.74e-5	Platelet count;
THYM	cis	rs9905704	0.918	rs385793	chr17:56730593	G/A	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.7e-6	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg20587970	chr11:113659929	NA	-1.13	-7.36	-0.6	6.5500000000000006e-11	Hip circumference adjusted for BMI;
THYM	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg01304814	chr3:48885189	PRKAR2A	0.89	4.66	0.43	1.03e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg15448220	chr1:150897856	SETDB1	-0.82	-6.52	-0.56	3.43e-9	Urate levels;
THYM	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg11984989	chr7:158649758	WDR60	1.11	15.39	0.84	1.5e-27	Height;
THYM	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg12310025	chr6:25882481	NA	0.92	8.1	0.64	1.86e-12	Intelligence (multi-trait analysis);
THYM	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg05043794	chr9:111880884	C9orf5	-0.43	-6.35	-0.55	7.29e-9	Menarche (age at onset);
THYM	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg09307838	chr4:120376055	NA	0.64	4.69	0.43	9.31e-6	Corneal astigmatism;
THYM	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs72772090	0.539	rs11738115	chr5:96113072	A/T	cg17330273	chr5:96107758	CAST;ERAP1	0.77	4.63	0.43	1.17e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs12142240	0.659	rs67547686	chr1:46832229	G/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs6748734	0.600	rs10202620	chr2:241820912	G/C	cg09990169	chr2:241835740	C2orf54	-0.32	-5.16	-0.47	1.33e-6	Urinary metabolites;
THYM	cis	rs4363385	0.658	rs426147	chr1:153045011	G/C	cg13444842	chr1:152974279	SPRR3	-0.61	-5.01	-0.46	2.46e-6	Inflammatory skin disease;
THYM	cis	rs10743315	0.599	rs11044451	chr12:19365798	C/T	cg02471346	chr12:19282374	PLEKHA5	-1.14	-6.82	-0.57	8.49e-10	Gut microbiota (bacterial taxa);
THYM	cis	rs6032067	0.929	rs17425504	chr20:43880089	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.37	-0.48	5.52e-7	Blood protein levels;
THYM	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6840360	0.615	rs4696266	chr4:152463421	A/G	cg22705602	chr4:152727874	NA	-0.71	-7.43	-0.61	4.71e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg02493740	chr2:85810744	VAMP5	-0.64	-5.05	-0.46	2.12e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg06221963	chr1:154839813	KCNN3	-0.87	-10.88	-0.74	2.16e-18	Prostate cancer;
THYM	trans	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg13615516	chr5:77269221	NA	0.88	7.4	0.6	5.34e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11122895	0.839	rs12999970	chr2:112446831	C/A	cg23262488	chr2:112468472	NA	0.6	7.79	0.62	8.41e-12	Allergic sensitization;
THYM	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs240764	0.853	rs12191199	chr6:101008093	C/T	cg21058520	chr6:100914733	NA	0.57	5.14	0.47	1.49e-6	Neuroticism;
THYM	cis	rs4242434	0.536	rs1871900	chr8:22481449	A/G	cg01710189	chr8:22454888	PDLIM2	-0.47	-4.51	-0.42	1.85e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs8048589	0.515	rs4780412	chr16:12232409	A/G	cg02910054	chr16:12241554	SNX29	0.71	6.57	0.56	2.66e-9	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg04518342	chr5:131593106	PDLIM4	0.47	4.94	0.45	3.37e-6	Blood metabolite levels;
THYM	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs713587	1.000	rs2384054	chr2:25156773	T/C	cg15423357	chr2:25149977	NA	0.68	7.69	0.62	1.32e-11	Body mass index in non-asthmatics;
THYM	cis	rs11671005	0.695	rs11673069	chr19:58934918	C/G	cg18639983	chr19:58920768	ZNF584	0.61	5.02	0.46	2.37e-6	Mean platelet volume;
THYM	cis	rs6500395	0.962	rs9924483	chr16:48646258	C/T	cg04672837	chr16:48644449	N4BP1	0.48	4.59	0.43	1.35e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2463822	0.669	rs72919480	chr11:62043133	G/A	cg06239285	chr11:62104954	ASRGL1	-1.24	-5.95	-0.52	4.51e-8	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg27170947	chr2:26402098	FAM59B	-0.82	-6.96	-0.58	4.28e-10	Gut microbiome composition (summer);
THYM	cis	rs2777491	1.000	rs1757455	chr15:41761332	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.09	-12.45	-0.79	1.11e-21	Ulcerative colitis;
THYM	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs977987	0.778	rs11862719	chr16:75431708	T/A	cg03315344	chr16:75512273	CHST6	0.73	6.16	0.53	1.73e-8	Dupuytren's disease;
THYM	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	7.49	0.61	3.6e-11	Platelet count;
THYM	cis	rs9303401	0.555	rs8071831	chr17:57292950	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.66	5.01	0.46	2.52e-6	Cognitive test performance;
THYM	cis	rs7264396	0.635	rs6058346	chr20:34481043	G/T	cg26038318	chr20:34205095	SPAG4	0.6	4.72	0.44	8.09e-6	Total cholesterol levels;
THYM	cis	rs2072499	0.900	rs2248080	chr1:156195971	T/A	cg25208724	chr1:156163844	SLC25A44	1.12	11.98	0.78	1.06e-20	Testicular germ cell tumor;
THYM	cis	rs2282300	0.739	rs10835648	chr11:30320506	A/G	cg22891988	chr11:30607959	MPPED2	0.69	4.58	0.43	1.41e-5	Morning vs. evening chronotype;
THYM	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg00640147	chr17:61958756	GH2	-0.42	-4.48	-0.42	2.09e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg13918804	chr1:2043761	PRKCZ	-0.82	-7.43	-0.61	4.76e-11	Height;
THYM	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg24955955	chr5:415729	AHRR	1.02	5.72	0.51	1.21e-7	Fat distribution (HIV);
THYM	cis	rs9796	0.553	rs2925343	chr15:41306493	T/C	cg21153102	chr15:41252147	NA	-0.55	-4.78	-0.44	6.32e-6	Menopause (age at onset);
THYM	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-4.62	-0.43	1.19e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7100689	0.577	rs9420349	chr10:82031160	T/C	cg01528321	chr10:82214614	TSPAN14	0.95	7.81	0.63	7.54e-12	Post bronchodilator FEV1;
THYM	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.79	-5.64	-0.5	1.71e-7	Chronic sinus infection;
THYM	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg03676636	chr4:99064102	C4orf37	0.5	7.65	0.62	1.6e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg09549813	chr16:4587862	C16orf5	-0.57	-6.28	-0.54	1.02e-8	Schizophrenia;
THYM	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.57	5.82	0.51	8.07e-8	Eosinophil percentage of white cells;
THYM	cis	rs6060960	0.537	rs6089103	chr20:30464919	G/T	cg09796376	chr20:30640595	HCK	0.71	4.62	0.43	1.2e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg23583168	chr7:148888333	NA	-0.99	-13.63	-0.81	4.33e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg14582100	chr15:45693742	SPATA5L1	0.6	4.8	0.44	5.91e-6	Homoarginine levels;
THYM	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg15704280	chr7:45808275	SEPT13	-0.98	-11.44	-0.76	1.43e-19	Coronary artery disease;
THYM	cis	rs4919044	0.534	rs7918909	chr10:94660689	G/A	cg05127821	chr10:94822908	CYP26C1	-1.13	-6.96	-0.58	4.37e-10	Coronary artery disease;
THYM	cis	rs7084402	0.967	rs1649041	chr10:60328782	T/C	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs10191773	0.589	rs72831636	chr2:112948248	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.78	-4.65	-0.43	1.07e-5	Yeast infection;
THYM	cis	rs2050392	0.792	rs303434	chr10:30714440	G/A	cg02070205	chr10:30722105	MAP3K8	-0.53	-4.54	-0.42	1.67e-5	Inflammatory bowel disease;
THYM	cis	rs3820068	0.603	rs17448778	chr1:15985306	A/G	cg27534772	chr1:16042836	PLEKHM2	0.54	5.85	0.51	6.84e-8	Systolic blood pressure;
THYM	cis	rs11190604	0.767	rs35508946	chr10:102191156	A/G	cg16342193	chr10:102329863	NA	-0.5	-5.17	-0.47	1.29e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg01380346	chr19:18557039	ELL	-0.47	-4.69	-0.43	8.97e-6	Breast cancer;
THYM	cis	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg08133631	chr1:26527909	CATSPER4	-0.57	-4.69	-0.43	9.29e-6	Obesity-related traits;
THYM	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg06634786	chr22:41940651	POLR3H	0.73	5.33	0.48	6.69e-7	Vitiligo;
THYM	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03452623	chr4:187889614	NA	-1.16	-21.11	-0.91	1.23e-37	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7677751	0.806	rs6850748	chr4:55099164	T/G	cg17187183	chr4:55093834	PDGFRA	0.74	5.58	0.5	2.27e-7	Corneal astigmatism;
THYM	cis	rs12983728	0.505	rs12460050	chr19:58666109	G/A	cg07378217	chr19:58662286	ZNF329	-0.75	-4.85	-0.45	4.79e-6	Cholesterol, total;
THYM	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22857025	chr5:266934	NA	-1.37	-8.88	-0.67	4.08e-14	Breast cancer;
THYM	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.81	-7.13	-0.59	1.96e-10	Monocyte percentage of white cells;
THYM	cis	rs11599315	0.507	rs12220554	chr10:1341852	C/T	cg09624528	chr10:1369823	ADARB2	0.77	6.14	0.53	1.87e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs11264213	0.901	rs794222	chr1:36369024	T/C	cg27506609	chr1:36549197	TEKT2	0.93	4.87	0.45	4.47e-6	Schizophrenia;
THYM	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs11599315	0.507	rs12220554	chr10:1341852	C/T	cg01270228	chr10:1369114	ADARB2	0.72	5.82	0.51	7.86e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Gout;
THYM	cis	rs1371867	0.875	rs1660311	chr8:101330579	C/T	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg08847533	chr14:75593920	NEK9	-0.87	-8.74	-0.67	7.97e-14	Coronary artery disease;
THYM	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg26752003	chr8:145688521	CYHR1	-0.78	-6.28	-0.54	9.96e-9	Age at first birth;
THYM	cis	rs55728055	0.661	rs12168645	chr22:32061014	G/A	cg10537193	chr22:32026975	PISD	-0.93	-6.25	-0.54	1.16e-8	Age-related hearing impairment;
THYM	cis	rs2133450	0.712	rs13090234	chr3:7365244	T/A	cg19930620	chr3:7340148	GRM7	-0.48	-4.57	-0.42	1.44e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg17480646	chr11:65405466	SIPA1	-0.97	-9.19	-0.69	9.05e-15	Acne (severe);
THYM	trans	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg10856724	chr12:34555212	NA	-0.87	-7.55	-0.61	2.64e-11	Bladder cancer;
THYM	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9399401	0.667	rs17071756	chr6:142715195	C/T	cg04461802	chr6:142623433	GPR126	-0.74	-7.32	-0.6	8.1e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg07131210	chr7:1025825	CYP2W1	-0.84	-4.62	-0.43	1.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs554111	0.634	rs10799673	chr1:21274671	T/G	cg00373020	chr1:21041521	KIF17	-0.54	-4.6	-0.43	1.32e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs10425738	0.536	rs10426903	chr19:41417719	T/C	cg17435250	chr19:41386441	CYP2A7	-0.66	-5.56	-0.5	2.46e-7	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
THYM	cis	rs1551570	0.755	rs2290687	chr19:10229521	C/T	cg16327482	chr19:10226339	EIF3G	0.42	6.16	0.53	1.72e-8	Narcolepsy;
THYM	cis	rs13315871	0.929	rs11715290	chr3:58298413	C/T	cg12435725	chr3:58293450	RPP14	-0.53	-5.57	-0.5	2.32e-7	Cholesterol, total;
THYM	cis	rs2154427	0.872	rs76549663	chr21:34099768	G/A	cg21871883	chr21:34145043	C21orf49;C21orf66	1.01	5.23	0.47	9.88e-7	Bilirubin levels;
THYM	cis	rs2898681	0.739	rs8287	chr4:53732586	T/C	cg00812761	chr4:53799391	SCFD2	-0.5	-4.47	-0.42	2.19e-5	Optic nerve measurement (cup area);
THYM	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg18681998	chr4:17616180	MED28	0.82	6.97	0.58	4.24e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6542838	0.611	rs6742047	chr2:99531460	C/A	cg08885076	chr2:99613938	TSGA10	-0.47	-4.63	-0.43	1.17e-5	Fear of minor pain;
THYM	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs7616559	0.606	rs2220051	chr3:156764263	T/C	cg15697575	chr3:156784781	NA	0.46	6.65	0.56	1.82e-9	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg04398451	chr17:18023971	MYO15A	-0.9	-8.29	-0.65	7.43e-13	Total body bone mineral density;
THYM	cis	rs3820068	0.734	rs72645830	chr1:15889910	A/G	cg05660106	chr1:15850417	CASP9	1.15	9.97	0.72	1.88e-16	Systolic blood pressure;
THYM	cis	rs714027	0.967	rs193477	chr22:30451486	C/T	cg11564601	chr22:30592435	NA	-0.29	-5.07	-0.46	1.99e-6	Lymphocyte counts;
THYM	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg11752832	chr7:134001865	SLC35B4	0.68	4.93	0.45	3.53e-6	Mean platelet volume;
THYM	cis	rs1335645	1.000	rs61805898	chr1:111684719	A/G	cg00321911	chr1:111669324	DRAM2	-1.24	-6.5	-0.55	3.78e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10845606	0.581	rs10772592	chr12:12835874	A/G	cg04118741	chr12:12551013	LOH12CR1	0.5	4.59	0.43	1.34e-5	Systemic lupus erythematosus;
THYM	cis	rs4072705	0.615	rs6478666	chr9:127249343	C/G	cg14219918	chr9:127249562	NR5A1	-0.3	-4.61	-0.43	1.27e-5	Menarche (age at onset);
THYM	cis	rs2295499	0.650	rs916206	chr4:2571696	G/T	cg17924901	chr4:3475233	DOK7	0.21	4.51	0.42	1.84e-5	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg13010199	chr12:38710504	ALG10B	0.76	6.07	0.53	2.59e-8	Heart rate;
THYM	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.71	6.93	0.58	5.11e-10	Lymphocyte counts;
THYM	cis	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg10505658	chr17:80084571	CCDC57	0.7	7.91	0.63	4.66e-12	Life satisfaction;
THYM	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.14	-0.64	1.51e-12	Personality dimensions;
THYM	cis	rs11771526	0.792	rs17161105	chr7:32299187	T/C	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs7119	0.634	rs2682922	chr15:77865006	A/C	cg10437265	chr15:77819839	NA	-0.66	-6.82	-0.57	8.23e-10	Type 2 diabetes;
THYM	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg08508325	chr11:3079039	CARS	-0.52	-6.75	-0.57	1.15e-9	Longevity;
THYM	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg23187316	chr7:1099788	C7orf50	0.59	4.49	0.42	2.01e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3804749	0.966	rs3792366	chr3:122839876	G/A	cg10259872	chr3:122802215	PDIA5	0.49	5.46	0.49	3.85e-7	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs72827839	0.761	rs79541578	chr17:46102728	G/A	cg23391107	chr17:45924227	SP6	0.86	5.87	0.52	6.5e-8	Ease of getting up in the morning;
THYM	cis	rs10463554	0.892	rs10434791	chr5:102389472	C/G	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs112184198	1.000	rs112184198	chr10:102604514	G/A	cg03679755	chr10:101875035	NA	-0.83	-4.94	-0.45	3.37e-6	Systolic blood pressure;
THYM	cis	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.86	0.45	4.66e-6	Obesity-related traits;
THYM	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg00958927	chr1:175162553	KIAA0040	0.35	4.88	0.45	4.32e-6	Alcohol dependence;
THYM	cis	rs1957429	1.000	rs1998333	chr14:65353632	A/G	cg23373153	chr14:65346875	NA	1.11	6.67	0.56	1.7e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs11992162	0.636	rs4841642	chr8:11798334	C/T	cg21775007	chr8:11205619	TDH	0.61	4.82	0.44	5.41e-6	Monocyte count;
THYM	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg17063962	chr7:91808500	NA	1.1	12.05	0.78	7.69e-21	Breast cancer;
THYM	cis	rs6430585	0.583	rs2839740	chr2:136648883	G/T	cg07169764	chr2:136633963	MCM6	1.19	11.2	0.75	4.62e-19	Corneal structure;
THYM	cis	rs9644630	0.841	rs3185	chr8:19328959	A/C	cg01280390	chr8:19363452	CSGALNACT1	-0.72	-7.6	-0.62	2.04e-11	Oropharynx cancer;
THYM	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg13147721	chr7:65941812	NA	-1.0	-6.2	-0.54	1.47e-8	Diabetic kidney disease;
THYM	cis	rs17718580	0.536	rs56208926	chr14:51045042	C/T	cg04730355	chr14:51134070	SAV1	0.97	4.72	0.44	8.06e-6	Cognitive performance;
THYM	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg03517284	chr6:25882590	NA	-0.69	-4.65	-0.43	1.06e-5	Height;
THYM	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.74	-7.42	-0.61	4.94e-11	Lymphocyte counts;
THYM	cis	rs12257961	0.549	rs7900826	chr10:15382981	C/A	cg10616319	chr10:15468812	NA	0.61	5.24	0.47	9.58e-7	Selective IgA deficiency;
THYM	trans	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg02527881	chr3:46936655	PTH1R	-0.68	-6.87	-0.58	6.62e-10	Colorectal cancer;
THYM	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.74	-4.66	-0.43	1.04e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg26384229	chr12:38710491	ALG10B	0.99	7.46	0.61	4.12e-11	Bladder cancer;
THYM	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg10802521	chr3:52805072	NEK4	-0.8	-7.53	-0.61	2.92e-11	Bipolar disorder;
THYM	cis	rs7267979	0.966	rs2424714	chr20:25418681	T/G	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg06618935	chr21:46677482	NA	-0.98	-9.58	-0.7	1.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06481639	chr22:41940642	POLR3H	-0.81	-5.61	-0.5	2.03e-7	Vitiligo;
THYM	cis	rs4845875	0.563	rs11121829	chr1:11834765	A/G	cg14194983	chr1:11908298	NPPA	0.53	4.83	0.44	5.13e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg12407791	chr17:73824354	UNC13D	-0.41	-4.52	-0.42	1.81e-5	White matter hyperintensity burden;
THYM	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg20744362	chr22:50050164	C22orf34	0.76	7.31	0.6	8.29e-11	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1499972	0.887	rs55718530	chr3:117534125	T/C	cg07612923	chr3:117604196	NA	1.31	5.35	0.48	6.02e-7	Schizophrenia;
THYM	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg21970626	chr13:21893289	NA	-0.64	-5.9	-0.52	5.53e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg17063962	chr7:91808500	NA	1.13	12.56	0.79	6.81e-22	Breast cancer;
THYM	cis	rs9563576	0.778	rs9569790	chr13:58551841	A/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg08885076	chr2:99613938	TSGA10	0.52	5.04	0.46	2.24e-6	Chronic sinus infection;
THYM	cis	rs58106596	0.747	rs10166046	chr2:232560984	C/T	cg18146074	chr2:232242955	NA	-0.35	-5.01	-0.46	2.5e-6	White blood cell count;Lymphocyte counts;
THYM	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg22875332	chr1:76189707	ACADM	0.9	12.07	0.78	7.08e-21	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9913711	0.868	rs7216619	chr17:70079708	C/A	cg06234051	chr17:70120541	SOX9	-0.63	-5.4	-0.48	4.99e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs939658	0.935	rs4778651	chr15:79447810	G/A	cg17916960	chr15:79447300	NA	-0.76	-8.84	-0.67	4.96e-14	Refractive error;
THYM	cis	rs2888875	0.574	rs6705356	chr2:43788877	A/T	cg22033476	chr2:43532275	THADA	-0.39	-4.49	-0.42	1.99e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg08807101	chr21:30365312	RNF160	0.73	5.56	0.5	2.46e-7	Dental caries;
THYM	cis	rs981844	0.775	rs62323977	chr4:154746141	G/A	cg09973105	chr4:154681532	RNF175	-0.62	-5.1	-0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg11502198	chr6:26597334	ABT1	-0.64	-5.68	-0.5	1.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs12216545	0.711	rs939957	chr7:150257605	G/A	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	trans	rs75518195	0.500	rs62301955	chr4:64681601	C/T	cg14706739	chr8:21916355	EPB49	0.75	7.37	0.6	6.34e-11	Triptolide cytotoxicity;
THYM	cis	rs921968	0.541	rs17572485	chr2:219296545	C/T	cg02176678	chr2:219576539	TTLL4	-0.75	-7.66	-0.62	1.55e-11	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7681440	0.583	rs2737034	chr4:90777464	C/G	cg06632027	chr4:90757378	SNCA	-0.66	-5.29	-0.48	7.91e-7	Dementia with Lewy bodies;
THYM	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Alcohol dependence;
THYM	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs9906944	0.678	rs56015440	chr17:47136631	C/G	cg14634687	chr17:47094252	IGF2BP1	0.31	4.73	0.44	7.86e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg23711669	chr6:146136114	FBXO30	0.91	9.55	0.7	1.49e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7246657	0.551	rs12972146	chr19:37626095	G/T	cg22634378	chr19:37742834	NA	0.63	4.53	0.42	1.72e-5	Coronary artery calcification;
THYM	cis	rs7100689	0.784	rs10887838	chr10:82161380	G/A	cg01528321	chr10:82214614	TSPAN14	1.08	8.58	0.66	1.76e-13	Post bronchodilator FEV1;
THYM	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg01616529	chr11:638424	DRD4	-0.78	-6.62	-0.56	2.16e-9	Systemic lupus erythematosus;
THYM	cis	rs2456568	0.548	rs7117597	chr11:93655091	A/G	cg17595323	chr11:93583763	C11orf90	-0.52	-5.59	-0.5	2.21e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7107174	1.000	rs10899491	chr11:78106305	T/C	cg02023728	chr11:77925099	USP35	0.63	6.01	0.53	3.35e-8	Testicular germ cell tumor;
THYM	cis	rs4820539	1.000	rs885965	chr22:23461425	A/G	cg14186256	chr22:23484241	RTDR1	0.96	9.07	0.68	1.6e-14	Bone mineral density;
THYM	cis	rs7731657	0.588	rs11242054	chr5:130330693	A/C	cg08523029	chr5:130500466	HINT1	0.84	6.14	0.53	1.87e-8	Fasting plasma glucose;
THYM	cis	rs7705502	1.000	rs17695092	chr5:173337853	G/T	cg18693985	chr5:173351052	CPEB4	0.76	5.62	0.5	1.93e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg14829155	chr15:31115871	NA	0.7	6.15	0.53	1.81e-8	Huntington's disease progression;
THYM	cis	rs919433	0.854	rs13013049	chr2:198208664	C/T	cg00792783	chr2:198669748	PLCL1	-0.7	-4.78	-0.44	6.3e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06481639	chr22:41940642	POLR3H	0.65	4.77	0.44	6.53e-6	Vitiligo;
THYM	cis	rs11690935	0.959	rs12692970	chr2:172594197	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.85	-6.26	-0.54	1.09e-8	Schizophrenia;
THYM	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg23281280	chr6:28129359	ZNF389	0.61	4.88	0.45	4.21e-6	Depression;
THYM	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg07061783	chr6:25882402	NA	-0.86	-7.88	-0.63	5.43e-12	Intelligence (multi-trait analysis);
THYM	cis	rs10489202	0.632	rs202259	chr1:167962072	G/A	cg24449463	chr1:168025552	DCAF6	-0.9	-9.11	-0.68	1.3e-14	Schizophrenia;
THYM	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg27211696	chr2:191398769	TMEM194B	-0.64	-4.61	-0.43	1.26e-5	Diastolic blood pressure;
THYM	cis	rs12946454	0.696	rs4792819	chr17:43247957	A/C	cg00677574	chr17:43221327	ACBD4	0.56	4.73	0.44	7.91e-6	Systolic blood pressure;
THYM	cis	rs921665	0.831	rs2305491	chr2:3198175	C/T	cg16434511	chr2:3151078	NA	-0.87	-5.44	-0.49	4.16e-7	World class endurance athleticism;
THYM	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg02038168	chr22:39784481	NA	-0.67	-5.2	-0.47	1.16e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9303280	0.901	rs921650	chr17:38069076	G/A	cg24910161	chr17:38119198	GSDMA	-0.51	-5.22	-0.47	1.04e-6	Self-reported allergy;
THYM	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg19077165	chr18:44547161	KATNAL2	0.5	5.98	0.52	3.95e-8	Personality dimensions;
THYM	cis	rs7107174	0.892	rs11237450	chr11:78023356	C/A	cg02023728	chr11:77925099	USP35	0.62	5.46	0.49	3.85e-7	Testicular germ cell tumor;
THYM	cis	rs7528684	1.000	rs3761959	chr1:157669278	C/T	cg17134153	chr1:157670328	FCRL3	-0.54	-4.87	-0.45	4.51e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
THYM	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.14	8.21	0.64	1.1e-12	Cognitive test performance;
THYM	cis	rs3796352	0.667	rs9831977	chr3:52854140	T/G	cg07884673	chr3:53033167	SFMBT1	0.79	4.47	0.42	2.19e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg06064525	chr11:970664	AP2A2	-0.36	-6.98	-0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	cis	rs7586879	0.789	rs13404163	chr2:25126616	A/G	cg01884057	chr2:25150051	NA	0.52	4.6	0.43	1.29e-5	Body mass index;
THYM	cis	rs3741798	0.614	rs61922044	chr12:12490914	G/A	cg08615371	chr12:12503544	MANSC1	0.91	5.07	0.46	1.93e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg23711669	chr6:146136114	FBXO30	0.88	8.52	0.66	2.41e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11677370	0.561	rs13003140	chr2:3816759	G/T	cg17052675	chr2:3827356	NA	-0.64	-5.94	-0.52	4.69e-8	Type 2 diabetes;
THYM	cis	rs34375054	0.553	rs12581512	chr12:125622262	G/A	cg25124228	chr12:125621409	AACS	-0.76	-6.08	-0.53	2.49e-8	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg18230493	chr5:56204884	C5orf35	-0.82	-5.98	-0.52	3.83e-8	Initial pursuit acceleration;
THYM	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg04398451	chr17:18023971	MYO15A	0.83	7.73	0.62	1.1e-11	Total body bone mineral density;
THYM	cis	rs834811	0.797	rs2633365	chr7:135879797	A/G	cg01726295	chr7:135938950	NA	0.63	5.34	0.48	6.28e-7	Post-traumatic stress disorder;
THYM	cis	rs870825	0.587	rs35845099	chr4:185639762	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg22920501	chr2:26401640	FAM59B	1.03	7.1	0.59	2.3e-10	Gut microbiome composition (summer);
THYM	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs1372520	0.623	rs2583975	chr4:90748488	T/C	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2637266	0.729	rs860166	chr10:78549111	C/T	cg18941641	chr10:78392320	NA	0.7	5.56	0.5	2.45e-7	Pulmonary function;
THYM	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs6430585	1.000	rs6430585	chr2:136506927	A/C	cg20242066	chr2:136595261	LCT	-0.49	-4.9	-0.45	3.91e-6	Corneal structure;
THYM	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs7512552	0.809	rs2794679	chr1:150324857	G/A	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2237457	0.929	rs11238265	chr7:50706771	T/C	cg08586669	chr7:50727761	GRB10	0.31	4.77	0.44	6.66e-6	Schizophrenia (treatment resistant);
THYM	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg26039829	chr8:22132926	PIWIL2	0.7	6.08	0.53	2.44e-8	Hypertriglyceridemia;
THYM	cis	rs2932538	0.922	rs6691917	chr1:113137043	G/C	cg22162597	chr1:113214053	CAPZA1	0.63	5.21	0.47	1.08e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs13064411	0.627	rs28536176	chr3:113143625	T/C	cg18753928	chr3:113234510	CCDC52	-0.91	-8.22	-0.64	1.04e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs354225	0.544	rs12713264	chr2:54805218	A/C	cg23486701	chr2:54789491	SPTBN1	-0.34	-4.49	-0.42	2e-5	Schizophrenia;
THYM	cis	rs938554	0.513	rs3733588	chr4:9997303	A/G	cg26689780	chr4:10079554	WDR1	0.39	4.55	0.42	1.59e-5	Blood metabolite levels;
THYM	cis	rs89107	0.651	rs447193	chr6:118607662	G/A	cg21191810	chr6:118973309	C6orf204	0.5	4.5	0.42	1.93e-5	Cardiac structure and function;
THYM	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg06221963	chr1:154839813	KCNN3	-0.73	-8.77	-0.67	7.12e-14	Prostate cancer;
THYM	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg05552183	chr6:42928497	GNMT	-0.59	-4.69	-0.43	9.17e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7107174	0.892	rs1007837	chr11:77941076	A/G	cg02023728	chr11:77925099	USP35	0.68	6.5	0.55	3.68e-9	Testicular germ cell tumor;
THYM	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg20486651	chr6:167070296	RPS6KA2	0.5	4.68	0.43	9.47e-6	Crohn's disease;
THYM	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg14798641	chr3:49314920	USP4;C3orf62	-0.69	-4.69	-0.43	9.23e-6	Cognitive function;
THYM	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg03806693	chr22:41940476	POLR3H	-0.86	-8.43	-0.65	3.65e-13	Vitiligo;
THYM	cis	rs1160297	0.643	rs13031599	chr2:53075902	T/C	cg07782112	chr2:53107842	NA	0.74	6.06	0.53	2.74e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg14298792	chr15:30685198	CHRFAM7A	-0.8	-5.59	-0.5	2.21e-7	Huntington's disease progression;
THYM	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg09035930	chr12:129282057	SLC15A4	-0.86	-11.57	-0.76	7.67e-20	Systemic lupus erythematosus;
THYM	cis	rs7107174	1.000	rs10899465	chr11:78013588	G/A	cg02023728	chr11:77925099	USP35	0.67	5.86	0.52	6.61e-8	Testicular germ cell tumor;
THYM	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.98	-10.72	-0.74	4.83e-18	Menarche (age at onset);
THYM	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg25072359	chr17:41440525	NA	0.66	4.67	0.43	9.85e-6	Menopause (age at onset);
THYM	cis	rs56341938	0.935	rs62273760	chr3:168741162	G/A	cg09107232	chr3:169491072	MYNN	0.54	4.58	0.43	1.42e-5	Lung function (FEV1/FVC);
THYM	cis	rs6754311	0.517	rs1469995	chr2:136542559	G/A	cg07169764	chr2:136633963	MCM6	0.94	8.28	0.65	7.82e-13	Mosquito bite size;
THYM	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg23711669	chr6:146136114	FBXO30	1.0	11.18	0.75	5.12e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10851411	0.606	rs8036544	chr15:42755490	G/C	cg04857231	chr15:42782520	NA	-0.47	-4.67	-0.43	9.91e-6	Glucose homeostasis traits;
THYM	cis	rs941408	1.000	rs1736184	chr19:2810248	G/A	cg17333051	chr19:2783644	SGTA	0.57	5.27	0.48	8.41e-7	Total cholesterol levels;
THYM	cis	rs9549260	0.564	rs4941989	chr13:41299687	T/C	cg21288729	chr13:41239152	FOXO1	0.68	5.14	0.47	1.49e-6	Red blood cell count;
THYM	cis	rs6032067	0.925	rs6032061	chr20:43853276	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.5	-0.49	3.14e-7	Blood protein levels;
THYM	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg05738196	chr6:26577821	NA	-0.94	-9.52	-0.7	1.74e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7586879	0.681	rs6705446	chr2:25118608	T/C	cg15423357	chr2:25149977	NA	0.68	7.53	0.61	2.9e-11	Body mass index;
THYM	cis	rs72627123	0.867	rs57685514	chr14:74487592	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg24250549	chr1:154909240	PMVK	0.77	6.51	0.56	3.49e-9	Prostate cancer;
THYM	cis	rs4889855	0.505	rs8077626	chr17:78600552	G/C	cg16591659	chr17:78472290	NA	-0.4	-5.08	-0.46	1.9e-6	Fractional excretion of uric acid;
THYM	cis	rs61931739	0.963	rs59195137	chr12:34091838	G/A	cg10856724	chr12:34555212	NA	0.59	4.89	0.45	4.13e-6	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.75	-0.67	7.74e-14	Mean corpuscular volume;
THYM	cis	rs4664308	0.618	rs3792192	chr2:160886875	G/A	cg03641300	chr2:160917029	PLA2R1	-0.63	-5.3	-0.48	7.6e-7	Idiopathic membranous nephropathy;
THYM	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs55871839	0.559	rs66954327	chr8:59825133	A/G	cg07426533	chr8:59803705	TOX	0.62	5.11	0.46	1.63e-6	Pneumonia;
THYM	cis	rs2806561	0.664	rs55764475	chr1:23318983	C/T	cg19743168	chr1:23544995	NA	0.5	4.84	0.44	5.12e-6	Height;
THYM	cis	rs9790314	1.000	rs336593	chr3:161076431	T/C	cg03342759	chr3:160939853	NMD3	-0.73	-6.54	-0.56	3.03e-9	Morning vs. evening chronotype;
THYM	cis	rs4455778	0.580	rs6976152	chr7:49087711	A/G	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg05425664	chr17:57184151	TRIM37	-0.58	-4.61	-0.43	1.27e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1669338	0.507	rs4685607	chr3:3179400	C/T	cg16797762	chr3:3221439	CRBN	0.9	5.17	0.47	1.27e-6	White matter integrity;
THYM	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg22709100	chr7:91322751	NA	0.63	4.86	0.45	4.55e-6	Breast cancer;
THYM	cis	rs7119	0.679	rs12909808	chr15:77816944	A/G	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs17597773	0.674	rs12089958	chr1:221001363	G/A	cg16008148	chr1:221062819	NA	0.43	4.47	0.42	2.2e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg24250549	chr1:154909240	PMVK	0.79	6.71	0.57	1.41e-9	Prostate cancer;
THYM	cis	rs10896135	0.526	rs624561	chr11:66414915	C/T	cg15964523	chr11:66469143	SPTBN2	0.84	6.67	0.56	1.67e-9	Bipolar disorder;
THYM	cis	rs6733011	0.560	rs7579189	chr2:99464718	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.56	-0.42	1.54e-5	Bipolar disorder;
THYM	cis	rs7809950	0.817	rs34325395	chr7:107113808	C/G	cg23024343	chr7:107201750	COG5	-1.04	-8.85	-0.67	4.69e-14	Coronary artery disease;
THYM	cis	rs1448094	0.545	rs11117077	chr12:86277317	A/G	cg02569458	chr12:86230093	RASSF9	0.52	4.73	0.44	7.8e-6	Major depressive disorder;
THYM	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg20203395	chr5:56204925	C5orf35	-0.67	-4.58	-0.42	1.44e-5	Initial pursuit acceleration;
THYM	cis	rs3126085	0.935	rs4326625	chr1:152223996	C/T	cg26020982	chr1:152196106	HRNR	0.35	4.53	0.42	1.69e-5	Atopic dermatitis;
THYM	cis	rs1883415	0.553	rs760907	chr6:24479873	T/C	cg20631270	chr6:24437470	GPLD1	0.53	4.46	0.42	2.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4654899	0.802	rs17416732	chr1:21256368	T/C	cg01072550	chr1:21505969	NA	-0.69	-6.28	-0.54	1.02e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs28647808	1.000	rs13940	chr9:136271546	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs1198430	0.925	rs2811975	chr1:23801081	A/T	cg19827787	chr1:23763612	ASAP3	0.75	4.7	0.43	8.89e-6	Total cholesterol levels;
THYM	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg23711669	chr6:146136114	FBXO30	0.87	8.52	0.66	2.36e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg11752832	chr7:134001865	SLC35B4	0.76	5.72	0.51	1.24e-7	Mean platelet volume;
THYM	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg25358565	chr5:93447407	FAM172A	-0.94	-7.34	-0.6	7.07e-11	Diabetic retinopathy;
THYM	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg17143192	chr8:8559678	CLDN23	0.95	6.99	0.58	3.84e-10	Obesity-related traits;
THYM	cis	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.29	-0.54	9.48e-9	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg13854012	chr2:162103682	NA	-0.64	-5.16	-0.47	1.34e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11031096	0.711	rs4910890	chr11:4153407	C/T	cg22027985	chr11:4115532	RRM1	-0.53	-5.45	-0.49	4.02e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs11096990	0.855	rs75746161	chr4:39169101	G/C	cg24403649	chr4:39172243	NA	-0.65	-5.56	-0.5	2.52e-7	Cognitive function;
THYM	cis	rs12122100	0.507	rs1925343	chr1:146505535	A/T	cg03526459	chr1:146549940	NA	-0.57	-5.15	-0.47	1.43e-6	HIV-1 control;
THYM	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg00640147	chr17:61958756	GH2	-0.43	-4.54	-0.42	1.64e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs79387448	0.745	rs72995626	chr2:103162580	T/C	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg04414720	chr1:150670196	GOLPH3L	0.59	4.46	0.42	2.24e-5	Tonsillectomy;
THYM	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.58	0.43	1.41e-5	Bipolar disorder;
THYM	cis	rs4889855	0.530	rs4477776	chr17:78581765	G/A	cg16591659	chr17:78472290	NA	-0.41	-5.19	-0.47	1.22e-6	Fractional excretion of uric acid;
THYM	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg24675056	chr1:15929824	NA	0.73	5.89	0.52	5.95e-8	Systolic blood pressure;
THYM	cis	rs8064299	0.967	rs7420	chr17:72765215	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.62	-5.23	-0.47	1.02e-6	Monocyte count;
THYM	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg22947322	chr17:47091978	IGF2BP1	-0.76	-7.79	-0.62	8.22e-12	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs3781426	0.920	rs11245479	chr10:126728195	C/T	cg04494136	chr10:126703576	CTBP2	-0.39	-5.28	-0.48	8.1e-7	Height;
THYM	cis	rs36051895	0.625	rs12340344	chr9:5176281	C/A	cg02405213	chr9:5042618	JAK2	-0.99	-10.61	-0.74	8.16e-18	Pediatric autoimmune diseases;
THYM	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg00757033	chr12:89920650	WDR51B	0.75	12.04	0.78	7.96e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2702888	0.622	rs2702933	chr8:6760142	A/G	cg26795848	chr8:6756730	NA	-0.63	-5.3	-0.48	7.36e-7	Blood pressure;
THYM	cis	rs89107	0.575	rs11153768	chr6:118988152	A/G	cg21191810	chr6:118973309	C6orf204	-0.52	-5.34	-0.48	6.26e-7	Cardiac structure and function;
THYM	cis	rs10927875	0.541	rs1763599	chr1:16342602	C/T	cg22431228	chr1:16359049	CLCNKA	-0.49	-4.61	-0.43	1.27e-5	Dilated cardiomyopathy;
THYM	cis	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg06521331	chr12:34319734	NA	-0.85	-6.2	-0.54	1.45e-8	Morning vs. evening chronotype;
THYM	cis	rs919433	0.927	rs3843857	chr2:198195965	T/C	cg00792783	chr2:198669748	PLCL1	-0.69	-5.08	-0.46	1.85e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2412459	0.803	rs510949	chr15:40254155	A/G	cg16127683	chr15:40268777	EIF2AK4	0.53	4.63	0.43	1.16e-5	Response to haloperidol in psychosis;
THYM	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg08772003	chr10:104629869	AS3MT	-0.57	-4.92	-0.45	3.69e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4242434	0.819	rs720745	chr8:22471147	G/T	cg11461670	chr8:22454935	PDLIM2	-0.32	-6.17	-0.53	1.67e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2354432	0.607	rs6683243	chr1:146733422	A/T	cg25205988	chr1:146714368	CHD1L	-1.08	-5.63	-0.5	1.86e-7	Mitochondrial DNA levels;
THYM	cis	rs8112211	0.863	rs73043037	chr19:38856372	T/A	cg09474229	chr19:39360330	RINL	-0.52	-4.78	-0.44	6.5e-6	Blood protein levels;
THYM	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg20503657	chr10:835505	NA	0.86	5.34	0.48	6.25e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19346786	chr7:2764209	NA	-0.83	-7.73	-0.62	1.09e-11	Height;
THYM	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg10802521	chr3:52805072	NEK4	-0.73	-6.43	-0.55	5.15e-9	Bipolar disorder;
THYM	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg17264618	chr3:40429014	ENTPD3	0.56	5.35	0.48	5.95e-7	Renal cell carcinoma;
THYM	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg10515332	chr4:99064459	C4orf37	0.57	4.54	0.42	1.68e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6842047	0.706	rs4862666	chr4:187136307	A/G	cg02012338	chr4:187126139	CYP4V2	1.01	4.77	0.44	6.71e-6	Blood protein levels;
THYM	cis	rs12496230	0.953	rs1036972	chr3:66846010	C/T	cg23477460	chr3:66848765	NA	1.25	7.64	0.62	1.69e-11	Type 2 diabetes;
THYM	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg14784868	chr12:69753453	YEATS4	1.13	10.88	0.74	2.25e-18	Blood protein levels;
THYM	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg00376283	chr12:123451042	ABCB9	0.72	4.94	0.45	3.36e-6	Neutrophil percentage of white cells;
THYM	cis	rs12446552	0.661	rs72781039	chr16:11701021	G/A	cg09662852	chr16:11707685	NA	-0.64	-6.06	-0.53	2.68e-8	Colorectal or endometrial cancer;
THYM	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs865483	0.965	rs853199	chr17:35850225	T/C	cg06716730	chr17:35851459	DUSP14	0.45	7.67	0.62	1.52e-11	Monocyte count;
THYM	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Body mass index;
THYM	cis	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.55	-5.53	-0.49	2.86e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg16325326	chr1:53192061	ZYG11B	0.74	6.2	0.54	1.44e-8	Monocyte count;
THYM	cis	rs3768617	0.510	rs10797846	chr1:183087485	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg04111992	chr7:158790115	NA	-0.6	-5.47	-0.49	3.66e-7	Facial morphology (factor 20);
THYM	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg14784868	chr12:69753453	YEATS4	0.8	6.2	0.54	1.44e-8	Response to diuretic therapy;
THYM	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg23482746	chr15:76478102	C15orf27	-0.38	-4.55	-0.42	1.61e-5	Blood metabolite levels;
THYM	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.88	0.63	5.43e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1003719	0.715	rs6579	chr21:38568308	C/T	cg01329690	chr21:38580129	DSCR9	-0.36	-5.0	-0.46	2.67e-6	Eye color traits;
THYM	cis	rs644799	0.896	rs12146644	chr11:95492878	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	9.91	0.71	2.57e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg10589385	chr1:150898437	SETDB1	0.67	5.55	0.49	2.58e-7	Melanoma;
THYM	cis	rs4919694	0.572	rs12261294	chr10:104934952	C/T	cg04362960	chr10:104952993	NT5C2	0.98	6.42	0.55	5.4e-9	Arsenic metabolism;
THYM	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg22920501	chr2:26401640	FAM59B	-0.73	-6.42	-0.55	5.34e-9	Gut microbiome composition (summer);
THYM	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg20290983	chr6:43655470	MRPS18A	1.27	12.52	0.79	8.24e-22	IgG glycosylation;
THYM	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs6495367	1.000	rs1961579	chr15:79380516	G/A	cg17916960	chr15:79447300	NA	0.56	6.08	0.53	2.5e-8	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7364180	0.515	rs6002503	chr22:42208672	A/G	cg06481639	chr22:41940642	POLR3H	-0.62	-4.87	-0.45	4.41e-6	Alzheimer's disease biomarkers;
THYM	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg01579765	chr21:45077557	HSF2BP	-0.48	-7.45	-0.61	4.28e-11	Mean corpuscular volume;
THYM	cis	rs73198271	0.740	rs67766414	chr8:8649533	C/T	cg15556689	chr8:8085844	FLJ10661	-0.78	-5.15	-0.47	1.42e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg24450063	chr1:156163899	SLC25A44	1.17	9.81	0.71	4.12e-16	Testicular germ cell tumor;
THYM	cis	rs11997175	0.587	rs72612118	chr8:33695225	T/C	ch.8.33884649F	chr8:33765107	NA	0.66	4.99	0.46	2.67e-6	Body mass index;
THYM	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg17063962	chr7:91808500	NA	1.16	13.12	0.8	4.77e-23	Breast cancer;
THYM	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg17252645	chr8:143867129	LY6D	-0.85	-10.81	-0.74	3.04e-18	Urinary tract infection frequency;
THYM	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg11984989	chr7:158649758	WDR60	1.15	14.92	0.84	1.24e-26	Height;
THYM	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg06481639	chr22:41940642	POLR3H	-0.74	-5.42	-0.49	4.5e-7	Neuroticism;
THYM	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs66887589	0.967	rs7678973	chr4:120511817	T/C	cg13609457	chr4:120235615	NA	-0.47	-4.93	-0.45	3.55e-6	Diastolic blood pressure;
THYM	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs6087771	0.890	rs6089056	chr20:30325773	A/G	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Subcortical brain region volumes;Putamen volume;
THYM	cis	rs4866334	1.000	rs75904205	chr5:18402670	C/T	cg18608440	chr5:17519013	NA	1.19	4.97	0.45	2.93e-6	IgG glycosylation;
THYM	cis	rs73198271	0.960	rs10503392	chr8:8609555	G/C	cg06636001	chr8:8085503	FLJ10661	-0.72	-4.6	-0.43	1.32e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs11771526	0.901	rs34376799	chr7:32316932	T/C	cg13207630	chr7:32358064	NA	0.84	5.28	0.48	8.15e-7	Body mass index;
THYM	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg07870213	chr5:140052090	DND1	0.73	8.28	0.65	7.61e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg27490568	chr2:178487706	NA	0.54	4.68	0.43	9.42e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg20469991	chr17:27169893	C17orf63	-0.74	-4.61	-0.43	1.23e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs61990749	0.597	rs12896026	chr14:78244436	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	1.16	7.96	0.63	3.68e-12	Fibroblast growth factor basic levels;
THYM	cis	rs6087990	0.806	rs6088008	chr20:31382860	A/G	cg13636640	chr20:31349939	DNMT3B	0.94	10.1	0.72	1.02e-16	Ulcerative colitis;
THYM	cis	rs10090774	0.965	rs306952	chr8:142014969	T/C	cg10548399	chr8:143009151	NA	0.41	4.56	0.42	1.51e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg14893161	chr1:205819251	PM20D1	0.67	5.75	0.51	1.09e-7	Menarche (age at onset);
THYM	cis	rs2797160	0.967	rs984041	chr6:126021328	A/T	cg16306078	chr6:126000798	NA	0.52	5.31	0.48	7.3e-7	Endometrial cancer;
THYM	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg07061783	chr6:25882402	NA	0.57	4.48	0.42	2.08e-5	Schizophrenia;
THYM	cis	rs904251	0.861	rs1757171	chr6:37487044	T/C	cg01843034	chr6:37503916	NA	-0.72	-5.6	-0.5	2.09e-7	Cognitive performance;
THYM	cis	rs11608355	0.618	rs2075435	chr12:109796832	C/T	cg11367159	chr12:110044531	NA	0.52	4.86	0.45	4.69e-6	Neuroticism;
THYM	cis	rs1788820	0.843	rs1788821	chr18:21120869	A/G	cg14672496	chr18:21087552	C18orf8	0.76	5.98	0.52	3.97e-8	Body mass index;
THYM	cis	rs2742417	0.603	rs1019129	chr3:45780780	T/C	cg04837898	chr3:45731254	SACM1L	-0.72	-5.01	-0.46	2.55e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg25918947	chr17:41365094	TMEM106A	-0.68	-5.74	-0.51	1.15e-7	Menopause (age at onset);
THYM	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg15592062	chr6:167189543	RPS6KA2	-0.5	-4.82	-0.44	5.43e-6	Crohn's disease;
THYM	cis	rs2109514	0.792	rs4727831	chr7:116093983	A/G	cg12739419	chr7:116140593	CAV2	-0.47	-4.69	-0.43	9.13e-6	Prevalent atrial fibrillation;
THYM	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg08885076	chr2:99613938	TSGA10	-0.69	-6.56	-0.56	2.82e-9	Chronic sinus infection;
THYM	cis	rs4589258	0.788	rs10830571	chr11:90498522	G/C	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.96	-0.45	3.02e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6754311	0.593	rs1438305	chr2:136502792	C/G	cg04750100	chr2:136595281	LCT	-0.55	-6.28	-0.54	1.01e-8	Mosquito bite size;
THYM	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.73	5.72	0.51	1.24e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg27170947	chr2:26402098	FAM59B	0.57	4.87	0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs682331	0.588	rs861575	chr1:184725099	T/C	cg16716196	chr1:184195068	NA	-0.6	-4.67	-0.43	9.77e-6	Obesity-related traits;
THYM	cis	rs72828912	0.731	rs9379636	chr6:24069649	G/T	cg19882886	chr6:25043046	NA	-0.86	-4.47	-0.42	2.14e-5	Squamous cell lung carcinoma;
THYM	cis	rs7633857	0.532	rs1580254	chr3:160767278	C/T	cg03342759	chr3:160939853	NMD3	-0.63	-4.82	-0.44	5.46e-6	Educational attainment (years of education);
THYM	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg24154853	chr7:158122151	PTPRN2	0.54	4.76	0.44	6.93e-6	Calcium levels;
THYM	cis	rs9393777	0.920	rs34953377	chr6:27381660	T/C	cg23161317	chr6:28129485	ZNF389	1.11	4.54	0.42	1.65e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3849570	0.961	rs7620240	chr3:81762787	G/T	cg07356753	chr3:81810745	GBE1	-0.93	-7.68	-0.62	1.43e-11	Waist circumference;Body mass index;
THYM	cis	rs4747241	0.962	rs6480614	chr10:74047616	T/A	cg07828833	chr10:74069493	NA	0.54	4.47	0.42	2.18e-5	Heschl's gyrus morphology;
THYM	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.16	-0.75	5.56e-19	Primary sclerosing cholangitis;
THYM	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg11764359	chr7:65958608	NA	-0.87	-7.46	-0.61	4.15e-11	Aortic root size;
THYM	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg26513180	chr16:89883248	FANCA	0.49	4.5	0.42	1.95e-5	Vitiligo;
THYM	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg03396347	chr1:1875803	NA	-0.67	-6.81	-0.57	8.73e-10	Body mass index;
THYM	cis	rs9287719	0.674	rs11684157	chr2:10827157	C/A	cg02196655	chr2:10830764	NOL10	0.49	4.99	0.46	2.77e-6	Prostate cancer;
THYM	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg06636001	chr8:8085503	FLJ10661	-0.72	-6.12	-0.53	2.05e-8	Joint mobility (Beighton score);
THYM	cis	rs2898681	0.581	rs11938140	chr4:53678057	T/A	cg00338735	chr4:53728038	RASL11B	0.6	5.56	0.5	2.5e-7	Optic nerve measurement (cup area);
THYM	cis	rs4242434	0.689	rs4872006	chr8:22536502	T/C	cg01710189	chr8:22454888	PDLIM2	0.5	4.99	0.46	2.76e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6684428	1.000	rs6684334	chr1:56359726	T/C	cg11651538	chr1:56320950	NA	-0.6	-4.54	-0.42	1.63e-5	Airflow obstruction;
THYM	cis	rs791888	0.698	rs7893652	chr10:89431060	A/G	cg10377144	chr10:89419177	PAPSS2	-0.41	-7.02	-0.58	3.26e-10	Magnesium levels;
THYM	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg01570182	chr17:44337453	NA	0.9	9.73	0.71	6.22e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs89107	0.576	rs17825393	chr6:118772583	A/G	cg21191810	chr6:118973309	C6orf204	0.49	4.94	0.45	3.36e-6	Cardiac structure and function;
THYM	cis	rs3796619	0.961	rs62294748	chr4:1082999	G/A	cg27284194	chr4:1044797	NA	0.53	4.95	0.45	3.22e-6	Recombination rate (males);
THYM	cis	rs6732160	1.000	rs6732160	chr2:73387228	A/G	cg24220031	chr2:73402428	NA	-0.68	-6.63	-0.56	2.07e-9	Intelligence (multi-trait analysis);
THYM	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-5.2	-0.47	1.16e-6	Hemoglobin concentration;
THYM	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg00786635	chr1:25594202	NA	0.91	7.17	0.59	1.59e-10	Erythrocyte sedimentation rate;
THYM	cis	rs2039659	0.719	rs1764964	chr13:86258790	A/G	cg25308322	chr13:86268291	NA	0.68	5.83	0.51	7.46e-8	Blood osmolality (transformed sodium);
THYM	cis	rs7927592	0.546	rs497261	chr11:68192244	T/C	cg16797656	chr11:68205561	LRP5	0.54	6.19	0.54	1.52e-8	Total body bone mineral density;
THYM	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg12826209	chr6:26865740	GUSBL1	0.94	5.02	0.46	2.37e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6992820	0.899	rs7013301	chr8:56688226	G/T	cg06880721	chr8:56792545	LYN	-0.68	-5.57	-0.5	2.34e-7	Mean platelet volume;
THYM	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg14779329	chr11:130786720	SNX19	0.52	5.7	0.51	1.32e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs367615	0.552	rs3828603	chr5:108712068	G/C	cg17395555	chr5:108820864	NA	-0.51	-5.97	-0.52	4.11e-8	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs7107174	0.901	rs901105	chr11:77924607	A/C	cg19901956	chr11:77921274	USP35	-0.8	-6.2	-0.54	1.48e-8	Testicular germ cell tumor;
THYM	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg17211192	chr8:82754475	SNX16	-0.88	-6.96	-0.58	4.3e-10	Diastolic blood pressure;
THYM	cis	rs4481887	1.000	rs4430369	chr1:248464330	A/G	cg13385794	chr1:248469461	NA	0.67	4.58	0.43	1.4e-5	Common traits (Other);
THYM	cis	rs1018836	0.828	rs10091275	chr8:91559751	A/G	cg16814680	chr8:91681699	NA	-0.9	-7.85	-0.63	6.31e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4803468	1.000	rs284649	chr19:41926838	C/T	cg09537434	chr19:41945824	ATP5SL	-1.05	-9.33	-0.69	4.53e-15	Height;
THYM	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg04362960	chr10:104952993	NT5C2	0.58	4.8	0.44	5.78e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs61774743	0.754	rs11581271	chr1:41835061	C/G	cg19619003	chr1:41846758	NA	-0.27	-5.7	-0.51	1.33e-7	Intelligence (multi-trait analysis);
THYM	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg06636001	chr8:8085503	FLJ10661	0.68	5.85	0.51	6.85e-8	Joint mobility (Beighton score);
THYM	cis	rs4642101	0.686	rs13085726	chr3:12832672	A/C	cg05775895	chr3:12838266	CAND2	1.06	10.49	0.73	1.47e-17	QRS complex (12-leadsum);
THYM	cis	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.1	-0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg00981070	chr1:2046702	PRKCZ	0.47	5.21	0.47	1.1e-6	Height;
THYM	trans	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg25214090	chr10:38739885	LOC399744	0.92	7.7	0.62	1.26e-11	Corneal astigmatism;
THYM	cis	rs78456975	0.506	rs6756310	chr2:1549809	A/G	cg12573674	chr2:1569213	NA	-1.35	-8.52	-0.66	2.42e-13	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs35883536	0.647	rs10875314	chr1:101043207	G/C	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs600806	0.850	rs3879452	chr1:109929237	G/A	cg02175308	chr1:109941060	SORT1	-0.6	-5.3	-0.48	7.58e-7	Intelligence (multi-trait analysis);
THYM	cis	rs672413	0.620	rs663646	chr5:78285778	G/A	cg11541897	chr5:78281793	ARSB	-0.53	-4.81	-0.44	5.7e-6	Blood and toenail selenium levels;Blood protein levels;
THYM	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.96	-5.51	-0.49	3e-7	Red cell distribution width;
THYM	cis	rs9527	0.590	rs7087040	chr10:104799668	G/A	cg04362960	chr10:104952993	NT5C2	0.6	4.55	0.42	1.56e-5	Arsenic metabolism;
THYM	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.27	-0.48	8.61e-7	Hemoglobin concentration;
THYM	cis	rs6456042	1.000	rs6456041	chr6:166534679	G/A	cg11088901	chr6:166572345	T	-0.52	-4.82	-0.44	5.34e-6	Asthma;
THYM	cis	rs7107174	1.000	rs11237471	chr11:78082604	C/T	cg19901956	chr11:77921274	USP35	-0.65	-5.34	-0.48	6.41e-7	Testicular germ cell tumor;
THYM	cis	rs4455778	0.519	rs6583488	chr7:49039939	A/G	cg26309511	chr7:48887640	NA	0.63	5.47	0.49	3.67e-7	Lung cancer in never smokers;
THYM	cis	rs4820539	0.966	rs5751590	chr22:23486830	A/C	cg14186256	chr22:23484241	RTDR1	0.96	8.8	0.67	6.01e-14	Bone mineral density;
THYM	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7582180	0.739	rs11123824	chr2:100924029	G/A	cg14675211	chr2:100938903	LONRF2	0.76	8.22	0.64	1.01e-12	Intelligence (multi-trait analysis);
THYM	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg01238044	chr22:24384105	GSTT1	-0.54	-4.9	-0.45	3.99e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	8.42	0.65	3.98e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg02353165	chr6:42928485	GNMT	0.98	10.22	0.72	5.53e-17	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg02734326	chr4:10020555	SLC2A9	0.67	5.9	0.52	5.48e-8	Bone mineral density;
THYM	cis	rs3820068	0.608	rs10927836	chr1:16034368	G/C	cg27534772	chr1:16042836	PLEKHM2	0.51	5.25	0.47	9.14e-7	Systolic blood pressure;
THYM	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg17757837	chr7:157058334	UBE3C	0.65	5.24	0.47	9.83e-7	Body mass index;
THYM	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg14784868	chr12:69753453	YEATS4	1.12	10.87	0.74	2.32e-18	Blood protein levels;
THYM	trans	rs9951602	0.512	rs9952372	chr18:76656295	A/G	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs11608355	0.960	rs11066526	chr12:109854476	G/C	cg11367159	chr12:110044531	NA	0.67	6.4	0.55	5.97e-9	Neuroticism;
THYM	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg10802521	chr3:52805072	NEK4	-0.8	-7.53	-0.61	2.92e-11	Bipolar disorder;
THYM	cis	rs7725337	0.929	rs1159665	chr5:88334952	C/T	cg11280525	chr5:87955695	LOC645323	-0.42	-4.67	-0.43	1e-5	Total body bone mineral density;
THYM	cis	rs11822910	0.911	rs2250887	chr11:57202184	G/A	cg00522883	chr11:57194120	SLC43A3	0.7	4.94	0.45	3.39e-6	Platelet distribution width;
THYM	cis	rs9486719	1.000	rs11752584	chr6:96884952	C/A	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs8067545	0.641	rs203466	chr17:19809953	C/G	cg20830565	chr17:20408647	MGC102966	0.54	5.02	0.46	2.45e-6	Schizophrenia;
THYM	cis	rs3087591	1.000	rs8082020	chr17:29694795	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.61	-5.1	-0.46	1.73e-6	Hip circumference;
THYM	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg19913688	chr11:428466	ANO9	-0.88	-4.6	-0.43	1.3e-5	Body mass index;
THYM	cis	rs7107174	1.000	rs11603112	chr11:78073491	G/A	cg02023728	chr11:77925099	USP35	0.62	6.0	0.52	3.51e-8	Testicular germ cell tumor;
THYM	cis	rs10519937	1.000	rs6595767	chr5:126734267	A/G	cg19552640	chr5:126627061	MEGF10	-0.6	-4.48	-0.42	2.08e-5	IgG glycosylation;
THYM	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.69	5.56	0.5	2.44e-7	Tonsillectomy;
THYM	cis	rs3807375	0.755	rs11762978	chr7:150610100	C/T	cg10636020	chr7:150656979	KCNH2	0.58	4.64	0.43	1.1e-5	Electrocardiographic traits;QT interval;
THYM	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.53	-4.96	-0.45	3.04e-6	Lymphocyte counts;
THYM	cis	rs6952808	0.572	rs1860826	chr7:2112506	G/A	cg06667968	chr7:2107380	MAD1L1	0.54	4.53	0.42	1.69e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs11563648	0.553	rs10249162	chr7:127016146	G/T	cg08586737	chr7:127225949	GCC1	-0.33	-4.56	-0.42	1.5e-5	Resting heart rate;
THYM	cis	rs300703	0.872	rs7568288	chr2:276908	C/G	cg21211680	chr2:198530	NA	1.33	5.61	0.5	1.97e-7	Blood protein levels;
THYM	cis	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg25918947	chr17:41365094	TMEM106A	-0.69	-5.84	-0.51	7.34e-8	Menopause (age at onset);
THYM	cis	rs34779708	0.931	rs11010101	chr10:35411045	T/A	cg03585969	chr10:35415529	CREM	0.67	4.76	0.44	6.91e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs1371867	0.875	rs962451	chr8:101331010	C/T	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.94	-6.98	-0.58	4.05e-10	Schizophrenia;
THYM	cis	rs7926906	1.000	rs7926906	chr11:90524290	C/A	cg26138821	chr11:89956704	CHORDC1	-0.52	-4.71	-0.44	8.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg22764044	chr5:178986830	RUFY1	0.47	4.81	0.44	5.63e-6	Lung cancer;
THYM	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg22166914	chr1:53195759	ZYG11B	0.94	11.08	0.75	8.2e-19	Monocyte count;
THYM	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg03806693	chr22:41940476	POLR3H	-1.21	-10.85	-0.74	2.54e-18	Vitiligo;
THYM	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg09467607	chr2:36825704	FEZ2	-0.4	-4.87	-0.45	4.48e-6	Height;
THYM	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg26441486	chr22:50317300	CRELD2	0.44	7.57	0.61	2.37e-11	Schizophrenia;
THYM	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	trans	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg13615516	chr5:77269221	NA	0.83	7.44	0.61	4.57e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg23428387	chr22:49814324	NA	-0.59	-6.13	-0.53	2.01e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg03806693	chr22:41940476	POLR3H	-1.21	-10.2	-0.72	6.07e-17	Vitiligo;
THYM	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg16586182	chr3:47516702	SCAP	-0.65	-5.49	-0.49	3.29e-7	Colorectal cancer;
THYM	cis	rs921968	0.509	rs10932782	chr2:219353195	C/T	cg02176678	chr2:219576539	TTLL4	0.73	7.09	0.59	2.4e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06850241	chr22:41845214	NA	-0.59	-5.16	-0.47	1.37e-6	Vitiligo;
THYM	cis	rs868036	0.718	rs4776984	chr15:68118194	A/C	cg24579218	chr15:68104479	NA	-0.79	-8.4	-0.65	4.38e-13	Restless legs syndrome;
THYM	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.09	-0.46	1.83e-6	Life satisfaction;
THYM	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.78	-6.18	-0.54	1.63e-8	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg16926213	chr1:1841314	NA	-0.58	-6.27	-0.54	1.08e-8	Body mass index;
THYM	cis	rs2295499	0.553	rs17164088	chr4:2675893	A/G	cg17924901	chr4:3475233	DOK7	0.22	4.84	0.44	5.11e-6	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg04043695	chr12:129287642	SLC15A4	0.6	4.83	0.44	5.27e-6	Systemic lupus erythematosus;
THYM	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.78	4.59	0.43	1.36e-5	Lung function (FEV1/FVC);
THYM	cis	rs4589258	0.933	rs1783785	chr11:90435705	C/T	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg16325326	chr1:53192061	ZYG11B	0.74	6.37	0.55	6.84e-9	Monocyte count;
THYM	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg11764359	chr7:65958608	NA	0.64	5.0	0.46	2.62e-6	Aortic root size;
THYM	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-6.11	-0.53	2.19e-8	Schizophrenia;
THYM	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg11764359	chr7:65958608	NA	-0.81	-6.42	-0.55	5.45e-9	Aortic root size;
THYM	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg17830980	chr10:43048298	ZNF37B	-1.01	-10.06	-0.72	1.21e-16	Extrinsic epigenetic age acceleration;
THYM	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg06238570	chr21:40685208	BRWD1	-0.68	-5.75	-0.51	1.06e-7	Menarche (age at onset);
THYM	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg27170947	chr2:26402098	FAM59B	0.79	6.27	0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg18252515	chr7:66147081	NA	-1.62	-8.8	-0.67	5.99e-14	Diabetic kidney disease;
THYM	cis	rs854765	0.583	rs12452219	chr17:17829423	C/T	cg04398451	chr17:18023971	MYO15A	-0.83	-7.74	-0.62	1.04e-11	Total body bone mineral density;
THYM	cis	rs77320796	1.000	rs61781291	chr1:40401838	T/A	cg05657805	chr1:40942785	ZNF642	0.78	4.55	0.42	1.58e-5	Platelet count;
THYM	cis	rs6496667	0.533	rs2601206	chr15:90962699	C/T	cg00425431	chr15:90792223	TTLL13	0.42	4.79	0.44	6.18e-6	Rheumatoid arthritis;
THYM	cis	rs7226229	1.000	rs7216978	chr17:20926294	G/A	cg21263980	chr17:20946333	USP22	0.67	4.92	0.45	3.6e-6	Blood trace element (Se levels);
THYM	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg04234412	chr22:24373322	LOC391322	-0.91	-9.33	-0.69	4.39e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg18876405	chr7:65276391	NA	-0.6	-5.16	-0.47	1.32e-6	Aortic root size;
THYM	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs854765	0.583	rs8080823	chr17:17864048	T/C	cg04398451	chr17:18023971	MYO15A	-0.86	-8.06	-0.64	2.28e-12	Total body bone mineral density;
THYM	cis	rs9560113	1.000	rs9560113	chr13:112183348	A/G	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs9486715	0.825	rs211158	chr6:97022938	C/G	cg06623918	chr6:96969491	KIAA0776	-1.05	-8.69	-0.67	1.05e-13	Headache;
THYM	cis	rs7851660	0.967	rs1443434	chr9:100617479	G/T	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs7192750	0.517	rs9932922	chr16:71918178	T/C	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs6565180	0.926	rs4788409	chr16:30393771	G/A	cg17640201	chr16:30407289	ZNF48	0.87	7.45	0.61	4.17e-11	Tonsillectomy;
THYM	cis	rs10799590	1.000	rs12121558	chr1:224832749	T/C	cg01808320	chr1:224927238	CNIH3	-0.55	-4.87	-0.45	4.52e-6	Opioid dependence;
THYM	cis	rs17102423	0.594	rs7159443	chr14:65550816	T/A	cg11161011	chr14:65562177	MAX	-0.69	-5.58	-0.5	2.31e-7	Obesity-related traits;
THYM	cis	rs13102973	0.640	rs12499343	chr4:135880463	A/G	cg14419869	chr4:135874104	NA	0.85	7.05	0.59	2.84e-10	Subjective well-being;
THYM	cis	rs4737010	0.570	rs6474364	chr8:41646997	T/G	cg08923054	chr8:41654455	ANK1	0.77	4.79	0.44	6.07e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
THYM	cis	rs8114671	0.836	rs1885114	chr20:33577361	A/G	cg08999081	chr20:33150536	PIGU	-0.55	-4.76	-0.44	6.8e-6	Height;
THYM	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg03806693	chr22:41940476	POLR3H	1.25	10.78	0.74	3.56e-18	Vitiligo;
THYM	cis	rs4866334	1.000	rs74805322	chr5:18487623	C/A	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10489202	0.633	rs4657734	chr1:168086743	C/T	cg24449463	chr1:168025552	DCAF6	-0.75	-7.13	-0.59	1.92e-10	Schizophrenia;
THYM	cis	rs4280164	0.551	rs3212242	chr14:24810401	C/T	cg18846074	chr14:24801073	ADCY4	-0.56	-4.53	-0.42	1.71e-5	Parent of origin effect on language impairment (paternal);
THYM	cis	rs9649213	0.593	rs62478177	chr7:97964611	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6964587	0.620	rs7808587	chr7:91620096	G/A	cg17063962	chr7:91808500	NA	1.0	9.03	0.68	2e-14	Breast cancer;
THYM	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg02524346	chr8:600233	NA	1.0	4.54	0.42	1.65e-5	IgG glycosylation;
THYM	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.64	11.72	0.77	3.65e-20	Hemostatic factors and hematological phenotypes;
THYM	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg18825531	chr11:62321136	NA	0.42	4.71	0.44	8.41e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs859767	0.887	rs842348	chr2:135342391	T/G	cg12500956	chr2:135428796	TMEM163	0.54	5.34	0.48	6.36e-7	Neuroticism;
THYM	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs6763768	0.606	rs9942027	chr3:53392663	C/T	cg22900224	chr3:52804907	NEK4	0.72	4.67	0.43	9.9e-6	Bacterial meningitis;
THYM	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg13390004	chr1:15929781	NA	0.61	4.63	0.43	1.15e-5	Systolic blood pressure;
THYM	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.9	7.28	0.6	9.61e-11	Lymphocyte percentage of white cells;
THYM	cis	rs60871478	0.588	rs4721358	chr7:844372	G/A	cg10248100	chr7:872053	UNC84A	0.74	4.85	0.45	4.86e-6	Cerebrospinal P-tau181p levels;
THYM	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	cis	rs6541297	0.941	rs2144299	chr1:230280366	A/G	cg20703242	chr1:230279135	GALNT2	0.9	5.2	0.47	1.14e-6	Coronary artery disease;
THYM	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs3760982	0.585	rs11673534	chr19:44298884	G/A	cg11993925	chr19:44307056	LYPD5	0.64	5.02	0.46	2.4e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs1018836	0.798	rs4735295	chr8:91671608	C/A	cg16814680	chr8:91681699	NA	-0.97	-9.13	-0.68	1.22e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs600550	0.557	rs1899572	chr11:60086024	C/A	cg05040360	chr11:60102449	MS4A6E	-0.51	-4.75	-0.44	7.08e-6	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg17845761	chr1:175162550	KIAA0040	0.38	4.86	0.45	4.62e-6	Alcohol dependence;
THYM	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg02493740	chr2:85810744	VAMP5	-0.6	-4.57	-0.42	1.48e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg03676636	chr4:99064102	C4orf37	0.5	7.65	0.62	1.6e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg06481639	chr22:41940642	POLR3H	-0.72	-5.25	-0.47	9.4e-7	Neuroticism;
THYM	cis	rs10911232	0.507	rs3935384	chr1:183028970	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs17443541	0.507	rs4675708	chr2:200457388	C/A	cg01795955	chr2:200468626	NA	-0.66	-4.59	-0.43	1.38e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4845875	0.600	rs6699881	chr1:11836628	T/C	cg14194983	chr1:11908298	NPPA	0.54	4.97	0.45	2.93e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg02725872	chr8:58115012	NA	-1.1	-6.73	-0.57	1.29e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs988913	0.706	rs7453866	chr6:54753626	A/C	cg19716238	chr6:54711378	FAM83B	0.48	5.29	0.48	7.86e-7	Menarche (age at onset);
THYM	cis	rs6575793	0.904	rs7493050	chr14:101037599	A/G	cg13521842	chr14:101036202	BEGAIN	-0.51	-4.68	-0.43	9.7e-6	Menarche (age at onset);
THYM	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg11494091	chr17:61959527	GH2	1.07	16.26	0.86	3.42e-29	Prudent dietary pattern;
THYM	cis	rs9914988	0.619	rs35477460	chr17:27320276	C/T	cg26182037	chr17:27055700	NEK8	0.84	4.53	0.42	1.72e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs1113500	0.799	rs1777459	chr1:108584999	G/C	cg06207961	chr1:108661230	NA	-0.71	-5.52	-0.49	2.94e-7	Growth-regulated protein alpha levels;
THYM	cis	rs2505998	0.957	rs1864408	chr10:43575883	T/C	cg06632098	chr10:43605906	RET	-1.06	-9.44	-0.7	2.63e-15	Hirschsprung disease;
THYM	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg03709012	chr19:19516395	GATAD2A	0.8	6.46	0.55	4.51e-9	Tonsillectomy;
THYM	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg01819863	chr10:32635814	EPC1	1.04	6.58	0.56	2.51e-9	Sexual dysfunction (female);
THYM	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg08901578	chr4:187885870	NA	-0.69	-6.92	-0.58	5.19e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg23711669	chr6:146136114	FBXO30	0.96	9.81	0.71	4.28e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg04034577	chr2:241836375	C2orf54	-0.47	-8.21	-0.64	1.11e-12	Urinary metabolites;
THYM	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg12698349	chr2:225449008	CUL3	1.13	13.32	0.81	1.86e-23	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs868036	0.645	rs4776987	chr15:68123915	A/T	cg26545918	chr15:68124484	LBXCOR1	-0.51	-4.54	-0.42	1.66e-5	Restless legs syndrome;
THYM	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg04546413	chr19:29218101	NA	1.08	9.01	0.68	2.2e-14	Methadone dose in opioid dependence;
THYM	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs13065560	0.593	rs9818630	chr3:38930307	T/G	cg15678707	chr3:39149194	GORASP1;TTC21A	0.59	4.64	0.43	1.12e-5	Interleukin-18 levels;
THYM	cis	rs539096	0.915	rs2842194	chr1:44028962	G/A	cg00143623	chr1:44495758	SLC6A9	-0.72	-5.59	-0.5	2.19e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9913156	0.802	rs4538065	chr17:4566015	G/A	cg19197139	chr17:4613644	ARRB2	-0.84	-5.2	-0.47	1.16e-6	Lymphocyte counts;
THYM	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg09455208	chr3:40491958	NA	0.47	4.86	0.45	4.64e-6	Renal cell carcinoma;
THYM	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8017423	0.669	rs7153190	chr14:90703904	T/G	cg04239629	chr14:90701769	NA	-0.64	-4.69	-0.43	9.24e-6	Mortality in heart failure;
THYM	cis	rs11170631	0.504	rs12817180	chr12:54035448	A/G	cg16917193	chr12:54089295	NA	0.76	7.41	0.6	5.28e-11	Height;
THYM	cis	rs3204270	0.639	rs7215738	chr17:79659847	C/T	cg18367735	chr17:79674897	NA	0.75	4.49	0.42	1.99e-5	Dental caries;
THYM	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg10515332	chr4:99064459	C4orf37	0.71	5.67	0.5	1.51e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs55728055	0.661	rs7293143	chr22:32013365	A/G	cg10537193	chr22:32026975	PISD	0.66	4.61	0.43	1.26e-5	Age-related hearing impairment;
THYM	cis	rs9868809	0.772	rs12107252	chr3:48691316	T/C	cg00383909	chr3:49044727	WDR6	0.87	4.78	0.44	6.44e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg12292205	chr6:26970375	C6orf41	-0.64	-5.19	-0.47	1.19e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg06618935	chr21:46677482	NA	-0.92	-8.6	-0.66	1.62e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2072510	0.683	rs2540487	chr12:96429783	C/T	cg18817487	chr12:96390143	HAL	0.42	5.11	0.46	1.65e-6	Metabolite levels (small molecules and protein measures);
THYM	cis	rs9837602	1.000	rs17379739	chr3:99724792	G/A	cg00175735	chr3:99903386	TMEM30C	-0.76	-4.55	-0.42	1.6e-5	Breast cancer;
THYM	cis	rs7695732	0.595	rs6815703	chr4:89909917	G/T	cg17769793	chr4:89976368	FAM13A	-0.49	-5.2	-0.47	1.17e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7590720	0.819	rs1344694	chr2:216893637	T/G	cg25588852	chr2:216877276	MREG	-0.57	-4.94	-0.45	3.32e-6	Alcohol dependence;
THYM	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg27446573	chr6:127587934	RNF146	0.74	6.53	0.56	3.27e-9	Breast cancer;
THYM	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11644478	chr21:40555479	PSMG1	1.11	9.99	0.72	1.76e-16	Cognitive function;
THYM	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg10792982	chr14:105748885	BRF1	0.72	7.37	0.6	6.13e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg17366294	chr4:99064904	C4orf37	0.54	6.05	0.53	2.81e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7731657	0.537	rs10060101	chr5:130319652	A/T	cg08523029	chr5:130500466	HINT1	-0.84	-6.14	-0.53	1.87e-8	Fasting plasma glucose;
THYM	cis	rs793571	0.502	rs421829	chr15:59079902	G/C	cg05156742	chr15:59063176	FAM63B	0.58	4.94	0.45	3.32e-6	Schizophrenia;
THYM	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg12573674	chr2:1569213	NA	-1.36	-9.13	-0.68	1.18e-14	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg26408565	chr15:76604113	ETFA	-0.53	-4.64	-0.43	1.13e-5	Blood metabolite levels;
THYM	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg26384229	chr12:38710491	ALG10B	1.05	10.44	0.73	1.86e-17	Heart rate;
THYM	cis	rs941408	1.000	rs1736184	chr19:2810248	G/A	cg06609049	chr19:2785107	THOP1	0.69	5.77	0.51	9.77e-8	Total cholesterol levels;
THYM	cis	rs67460515	0.563	rs13071892	chr3:160817877	A/C	cg03342759	chr3:160939853	NMD3	-0.63	-4.7	-0.43	8.8e-6	Parkinson's disease;
THYM	cis	rs793571	0.502	rs688756	chr15:59076272	A/C	cg05156742	chr15:59063176	FAM63B	0.56	4.74	0.44	7.53e-6	Schizophrenia;
THYM	cis	rs17818399	0.645	rs35870739	chr2:46784231	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.73	4.88	0.45	4.29e-6	Height;
THYM	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.97	-5.16	-0.47	1.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg13319975	chr6:146136371	FBXO30	-0.69	-5.71	-0.51	1.27e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs490234	0.756	rs1398142	chr9:128226712	C/A	cg14078157	chr9:128172775	NA	-0.7	-5.37	-0.48	5.48e-7	Mean arterial pressure;
THYM	cis	rs17407555	0.738	rs55731306	chr4:10067885	G/T	cg11266682	chr4:10021025	SLC2A9	-0.59	-5.81	-0.51	8.36e-8	Schizophrenia (age at onset);
THYM	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg13695892	chr22:41940480	POLR3H	-0.93	-7.13	-0.59	1.99e-10	Vitiligo;
THYM	cis	rs7177699	0.557	rs10083697	chr15:79124039	G/A	cg15571903	chr15:79123663	NA	-0.57	-6.35	-0.55	7.46e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs61990749	0.597	rs12887606	chr14:78200620	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.02	0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs728616	0.867	rs116994688	chr10:81738137	G/C	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7631605	0.875	rs56304874	chr3:37245983	G/T	cg21328643	chr3:37258149	NA	-0.52	-4.95	-0.45	3.25e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs7107174	1.000	rs2511157	chr11:77972632	G/A	cg02023728	chr11:77925099	USP35	0.69	6.19	0.54	1.55e-8	Testicular germ cell tumor;
THYM	cis	rs8112449	1.000	rs12978984	chr19:10520891	A/T	cg01466491	chr19:10523363	NA	-0.68	-6.58	-0.56	2.59e-9	Multiple sclerosis;Gastritis;
THYM	cis	rs138249	0.966	rs138238	chr22:50563140	T/C	cg00395632	chr22:50709221	MAPK11	0.48	4.45	0.42	2.34e-5	Gestational age at birth in labor-initiated deliveries (child effect);
THYM	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg27535305	chr1:53392650	SCP2	-0.4	-4.65	-0.43	1.05e-5	Monocyte count;
THYM	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg04842962	chr6:43655489	MRPS18A	1.4	15.42	0.85	1.3e-27	IgG glycosylation;
THYM	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg23131131	chr22:24373011	LOC391322	0.84	8.04	0.64	2.47e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg13944838	chr5:179740914	GFPT2	-0.86	-6.3	-0.54	9.2e-9	Height;
THYM	cis	rs28595532	0.920	rs115673173	chr4:119755321	C/T	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs7180079	0.502	rs6494466	chr15:64508763	A/G	cg02848875	chr15:64387786	SNX1	0.69	6.0	0.52	3.64e-8	Monocyte count;
THYM	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg11266682	chr4:10021025	SLC2A9	0.74	10.8	0.74	3.21e-18	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg08999081	chr20:33150536	PIGU	0.54	4.52	0.42	1.75e-5	Coronary artery disease;
THYM	cis	rs9467711	0.790	rs55706012	chr6:26266311	A/C	cg16898833	chr6:26189333	HIST1H4D	1.36	5.3	0.48	7.48e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg23982607	chr1:1823379	GNB1	-0.92	-9.46	-0.7	2.39e-15	Body mass index;
THYM	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.93	7.76	0.62	9.52e-12	Lymphocyte percentage of white cells;
THYM	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg19761014	chr17:28927070	LRRC37B2	0.76	4.76	0.44	6.88e-6	Body mass index;
THYM	trans	rs11186	0.556	rs72906325	chr2:189957810	C/T	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg22681709	chr2:178499509	PDE11A	-0.59	-5.62	-0.5	1.91e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7635838	0.684	rs2606762	chr3:11343889	G/C	cg00170343	chr3:11313890	ATG7	0.57	4.56	0.42	1.51e-5	HDL cholesterol;
THYM	cis	rs886774	0.526	rs73193722	chr7:107508246	A/C	cg23293999	chr7:106826042	HBP1	-0.58	-4.59	-0.43	1.35e-5	Ulcerative colitis;
THYM	cis	rs1550582	0.548	rs11538239	chr8:135490539	A/G	cg17885191	chr8:135476712	NA	-1.15	-9.12	-0.68	1.28e-14	Educational attainment;
THYM	cis	rs7771547	0.519	rs9654588	chr6:36363923	A/C	cg07856975	chr6:36356162	ETV7	0.69	5.92	0.52	5.13e-8	Platelet distribution width;
THYM	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.64	-5.29	-0.48	7.97e-7	Renal function-related traits (BUN);
THYM	cis	rs12478296	0.901	rs67951957	chr2:243004901	A/G	cg18898632	chr2:242989856	NA	-0.66	-4.46	-0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03576123	chr11:487126	PTDSS2	-1.29	-6.68	-0.57	1.6e-9	Body mass index;
THYM	trans	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.12	8.09	0.64	1.9e-12	Exhaled nitric oxide output;
THYM	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg10053473	chr17:62856997	LRRC37A3	-0.97	-7.62	-0.62	1.88e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6032067	0.852	rs17333103	chr20:43803613	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.52	-5.89	-0.52	5.76e-8	Blood protein levels;
THYM	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.31	7.64	0.62	1.72e-11	Gut microbiome composition (summer);
THYM	cis	rs6754311	0.517	rs1469996	chr2:136542560	A/G	cg07169764	chr2:136633963	MCM6	0.96	8.13	0.64	1.62e-12	Mosquito bite size;
THYM	cis	rs36051895	0.623	rs12351715	chr9:5262349	A/G	cg02405213	chr9:5042618	JAK2	-0.93	-9.22	-0.69	7.63e-15	Pediatric autoimmune diseases;
THYM	cis	rs9443189	0.570	rs7770824	chr6:76408189	G/A	cg01950844	chr6:76311363	SENP6	1.05	6.66	0.56	1.73e-9	Prostate cancer;
THYM	cis	rs3096299	0.866	rs4238829	chr16:89462262	G/A	cg02187348	chr16:89574699	SPG7	0.63	4.71	0.44	8.29e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs4924935	0.851	rs12936834	chr17:18807078	A/G	cg26378065	chr17:18585709	ZNF286B	0.7	4.85	0.45	4.75e-6	Pancreatic cancer;
THYM	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg03806693	chr22:41940476	POLR3H	-0.84	-6.96	-0.58	4.38e-10	Neuroticism;
THYM	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg06521331	chr12:34319734	NA	0.76	5.88	0.52	6.13e-8	Morning vs. evening chronotype;
THYM	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg15962314	chr1:44399869	ARTN	0.53	5.32	0.48	6.88e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg22756211	chr11:134118834	THYN1	-0.93	-6.97	-0.58	4.12e-10	Depressive symptoms;
THYM	cis	rs11711311	1.000	rs3806641	chr3:113465761	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.26	-0.47	9.01e-7	IgG glycosylation;
THYM	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7704138	0.553	rs11738760	chr5:55015306	A/C	cg18456523	chr5:54516805	NA	0.6	4.68	0.43	9.52e-6	Height;
THYM	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs28595532	0.920	rs116612909	chr4:119749823	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs7546094	1.000	rs902289	chr1:113236087	C/T	cg22162597	chr1:113214053	CAPZA1	-0.47	-4.75	-0.44	7.09e-6	Platelet distribution width;
THYM	cis	rs72901758	0.661	rs56683270	chr17:76247827	T/C	cg25512537	chr17:76250053	NA	0.44	6.47	0.55	4.24e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
THYM	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.82	8.35	0.65	5.6e-13	Lymphocyte counts;
THYM	cis	rs7084402	0.967	rs1649092	chr10:60289389	A/T	cg09696939	chr10:60272079	BICC1	-0.45	-5.07	-0.46	1.98e-6	Refractive error;
THYM	cis	rs3741151	0.686	rs7112924	chr11:73106408	C/T	cg12959048	chr11:73096162	RELT	-0.44	-4.77	-0.44	6.68e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs61612642	0.590	rs6931028	chr6:42193064	A/T	cg01092361	chr6:42185687	MRPS10	0.98	5.87	0.52	6.38e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg10589385	chr1:150898437	SETDB1	0.62	5.26	0.47	8.86e-7	Tonsillectomy;
THYM	cis	rs11608355	1.000	rs11066523	chr12:109851899	A/G	cg11367159	chr12:110044531	NA	-0.64	-6.09	-0.53	2.34e-8	Neuroticism;
THYM	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.49	0.42	1.97e-5	Diabetic retinopathy;
THYM	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg15744692	chr15:45671195	LOC145663;GATM	0.45	4.48	0.42	2.08e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4731207	0.596	rs6952915	chr7:124685952	T/G	cg05285228	chr7:124571219	POT1	-0.63	-4.76	-0.44	6.82e-6	Cutaneous malignant melanoma;
THYM	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.68	-5.59	-0.5	2.19e-7	Blood metabolite levels;
THYM	cis	rs2797160	1.000	rs1418642	chr6:125999768	G/A	cg16306078	chr6:126000798	NA	-0.52	-5.25	-0.47	9.19e-7	Endometrial cancer;
THYM	cis	rs2302612	0.528	rs7599472	chr2:102809534	A/G	cg13315345	chr2:102803985	IL1RL2	0.69	4.76	0.44	6.86e-6	Serum protein levels (sST2);
THYM	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg06481639	chr22:41940642	POLR3H	0.84	5.85	0.51	6.94e-8	Vitiligo;
THYM	cis	rs7607369	0.637	rs3731866	chr2:219288899	C/T	cg02176678	chr2:219576539	TTLL4	-0.69	-6.02	-0.53	3.21e-8	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs986417	1.000	rs2144114	chr14:61064210	T/C	cg27398547	chr14:60952738	C14orf39	1.3	6.11	0.53	2.15e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs1160297	0.576	rs724859	chr2:53099305	C/T	cg07782112	chr2:53107842	NA	0.79	6.58	0.56	2.52e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs800586	0.500	rs2178950	chr8:116653018	C/G	cg04656070	chr8:116661063	TRPS1	0.55	6.37	0.55	6.77e-9	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg13695892	chr22:41940480	POLR3H	-0.75	-6.61	-0.56	2.27e-9	Vitiligo;
THYM	cis	rs977987	0.843	rs60730309	chr16:75431769	C/G	cg03315344	chr16:75512273	CHST6	0.73	6.28	0.54	1.02e-8	Dupuytren's disease;
THYM	cis	rs6434928	1	rs6434928	chr2:198304577	G/A	cg05783139	chr2:198650985	BOLL	0.63	4.93	0.45	3.48e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.72	0.57	1.34e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4595586	0.545	rs61939643	chr12:39378460	G/A	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs828999	1.000	rs828999	chr1:108744934	A/G	cg24323958	chr1:108741884	SLC25A24	0.47	4.51	0.42	1.89e-5	Monocyte percentage of white cells;
THYM	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg15744005	chr10:104629667	AS3MT	-0.78	-7.16	-0.59	1.73e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs761746	0.960	rs5998042	chr22:31953962	T/C	cg01338084	chr22:32026380	PISD	0.52	4.49	0.42	2.02e-5	Intelligence;
THYM	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg02574844	chr11:5959923	NA	0.53	4.72	0.44	8.02e-6	DNA methylation (variation);
THYM	cis	rs9527	0.615	rs10883800	chr10:104671212	A/C	cg15744005	chr10:104629667	AS3MT	-0.6	-4.58	-0.42	1.43e-5	Arsenic metabolism;
THYM	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg02734326	chr4:10020555	SLC2A9	-0.64	-5.9	-0.52	5.59e-8	Bone mineral density;
THYM	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg02018176	chr4:1364513	KIAA1530	0.72	6.69	0.57	1.52e-9	Longevity;
THYM	cis	rs11626933	1.000	rs7146724	chr14:90766092	C/T	cg14092571	chr14:90743983	NA	-0.86	-9.36	-0.69	3.84e-15	Gut microbiota (bacterial taxa);
THYM	cis	rs637571	0.607	rs575479	chr11:65690300	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	6.36	0.55	6.91e-9	Eosinophil percentage of white cells;
THYM	cis	rs10744422	0.925	rs897391	chr12:123326374	G/A	cg25930673	chr12:123319894	HIP1R	-0.88	-5.15	-0.47	1.43e-6	Schizophrenia;
THYM	cis	rs28595532	0.920	rs115090643	chr4:119729825	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs7020830	0.898	rs7846747	chr9:37167539	A/C	cg14294708	chr9:37120828	ZCCHC7	1.28	16.47	0.86	1.37e-29	Schizophrenia;
THYM	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg00898013	chr13:113819073	PROZ	-0.88	-8.96	-0.68	2.83e-14	Platelet distribution width;
THYM	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg27170947	chr2:26402098	FAM59B	-0.85	-5.75	-0.51	1.08e-7	Gut microbiome composition (summer);
THYM	cis	rs988913	1.000	rs9475081	chr6:54813738	G/T	cg04690482	chr6:54711388	FAM83B	0.5	5.32	0.48	6.99e-7	Menarche (age at onset);
THYM	cis	rs901683	1.000	rs35670420	chr10:46088052	T/G	cg18240400	chr10:46168597	ANUBL1	0.73	4.73	0.44	7.89e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg06917634	chr15:78832804	PSMA4	0.92	8.46	0.66	3.27e-13	Sudden cardiac arrest;
THYM	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg10523679	chr1:76189770	ACADM	0.9	7.37	0.6	6.26e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.03	-11.97	-0.78	1.13e-20	Chronic sinus infection;
THYM	cis	rs8013055	0.846	rs12717698	chr14:105979015	G/A	cg04429589	chr14:105992532	TMEM121	-0.5	-5.49	-0.49	3.39e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg18758796	chr5:131593413	PDLIM4	0.63	6.13	0.53	1.98e-8	Breast cancer;
THYM	cis	rs7640424	0.819	rs34937412	chr3:107829484	G/C	cg09227934	chr3:107805635	CD47	-0.54	-4.56	-0.42	1.52e-5	Body mass index;
THYM	cis	rs2073300	0.609	rs6132610	chr20:23403987	C/T	cg12062639	chr20:23401060	NAPB	1.1	5.73	0.51	1.16e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7084402	0.967	rs7098326	chr10:60276906	C/T	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.57e-7	Refractive error;
THYM	cis	rs7084402	0.934	rs1158212	chr10:60318276	G/A	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs9534288	0.830	rs7987953	chr13:46634395	C/T	cg15192986	chr13:46630673	CPB2	-0.66	-4.66	-0.43	1.03e-5	Blood protein levels;
THYM	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	4.66	0.43	1.05e-5	Bipolar disorder;
THYM	cis	rs595982	0.510	rs3826817	chr19:49401444	C/T	cg19746536	chr19:49375674	PPP1R15A	0.99	9.63	0.7	1.03e-15	Red cell distribution width;
THYM	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg14675211	chr2:100938903	LONRF2	0.77	8.14	0.64	1.52e-12	Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg23682913	chr1:2080710	PRKCZ	-0.57	-5.23	-0.47	1e-6	Height;
THYM	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs865483	0.895	rs2107105	chr17:35835080	C/T	cg06716730	chr17:35851459	DUSP14	0.43	7.3	0.6	8.71e-11	Monocyte count;
THYM	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg07157834	chr1:205819609	PM20D1	-0.63	-4.95	-0.45	3.18e-6	Menarche (age at onset);
THYM	cis	rs6542838	0.611	rs17758170	chr2:99531842	G/A	cg08885076	chr2:99613938	TSGA10	-0.54	-5.1	-0.46	1.75e-6	Fear of minor pain;
THYM	cis	rs80319144	1.000	rs116466468	chr2:159137557	T/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.58	4.66	0.43	1.02e-5	Restless legs syndrome;
THYM	cis	rs2898681	0.581	rs936690	chr4:53691035	A/G	cg21521518	chr4:53727714	RASL11B	0.46	5.2	0.47	1.14e-6	Optic nerve measurement (cup area);
THYM	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs289828	0.560	rs67693192	chr2:152156762	A/G	cg05960677	chr2:152117363	RBM43	0.71	6.64	0.56	1.94e-9	Blood protein levels;
THYM	cis	rs12549902	0.800	rs7825494	chr8:41507350	C/T	cg21772509	chr8:41503840	NKX6-3	0.64	5.47	0.49	3.6e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
THYM	cis	rs2816062	0.735	rs2816054	chr1:18896431	C/T	cg18795169	chr1:18902165	NA	-0.99	-12.14	-0.78	5.02e-21	Urate levels in lean individuals;
THYM	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg03433033	chr1:76189801	ACADM	0.76	8.16	0.64	1.4e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg07460842	chr6:66804631	NA	0.92	5.5	0.49	3.15e-7	Exhaled nitric oxide levels;
THYM	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg03476357	chr21:30257390	N6AMT1	0.6	4.57	0.42	1.44e-5	Dental caries;
THYM	cis	rs13064411	0.696	rs7624994	chr3:113228009	T/C	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg02187348	chr16:89574699	SPG7	0.8	6.88	0.58	6.26e-10	Multiple myeloma (IgH translocation);
THYM	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg26441486	chr22:50317300	CRELD2	0.44	6.39	0.55	6.13e-9	Schizophrenia;
THYM	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg00024416	chr22:24240387	NA	0.76	7.49	0.61	3.57e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs56104184	0.887	rs67286688	chr19:49343329	T/C	cg15549821	chr19:49342101	PLEKHA4	-1.25	-8.53	-0.66	2.24e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs4148689	1.000	rs35608825	chr7:117164863	T/C	cg17204129	chr7:117119601	CFTR	-0.62	-4.79	-0.44	6.23e-6	Gout;
THYM	cis	rs1551570	0.563	rs4804122	chr19:10241944	C/T	cg07543883	chr19:10213271	ANGPTL6	-0.48	-4.65	-0.43	1.07e-5	Narcolepsy;
THYM	cis	rs3820068	0.577	rs9728986	chr1:16040603	G/A	cg13390004	chr1:15929781	NA	0.65	4.81	0.44	5.56e-6	Systolic blood pressure;
THYM	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg24733560	chr20:60626293	TAF4	-0.59	-4.76	-0.44	6.8e-6	Body mass index;
THYM	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg24874828	chr4:187887005	NA	-0.72	-7.22	-0.6	1.26e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg22105103	chr4:187893119	NA	0.95	10.29	0.73	3.97e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3752962	0.569	rs3803806	chr17:1940713	T/C	cg24156229	chr17:1948635	NA	-0.61	-5.14	-0.47	1.48e-6	Itch intensity from mosquito bite;
THYM	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1499972	0.887	rs817504	chr3:117678862	A/C	cg07612923	chr3:117604196	NA	-1.42	-5.49	-0.49	3.4e-7	Schizophrenia;
THYM	cis	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	10.09	0.72	1.05e-16	Platelet count;
THYM	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg11247378	chr22:39784982	NA	-0.92	-8.43	-0.65	3.75e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	trans	rs11109072	0.826	rs11109073	chr12:97902788	G/C	cg24015747	chr19:4323081	FSD1	0.73	7.22	0.6	1.25e-10	Obesity (early onset extreme);
THYM	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg23205692	chr1:25664452	TMEM50A	0.89	7.13	0.59	1.92e-10	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg21773646	chr17:80085082	CCDC57	0.31	4.49	0.42	2.02e-5	Life satisfaction;
THYM	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg23711669	chr6:146136114	FBXO30	0.95	9.55	0.7	1.52e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg08772003	chr10:104629869	AS3MT	-0.56	-4.81	-0.44	5.62e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg21984481	chr17:79567631	NPLOC4	-0.47	-4.95	-0.45	3.22e-6	Eye color traits;
THYM	trans	rs4940575	0.679	rs7228914	chr18:60833226	A/G	cg01781374	chr5:110777659	CAMK4	0.93	7.11	0.59	2.14e-10	Breast cancer;
THYM	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg10518543	chr12:38710700	ALG10B	-0.56	-4.56	-0.42	1.5e-5	Morning vs. evening chronotype;
THYM	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg00981070	chr1:2046702	PRKCZ	0.47	5.63	0.5	1.85e-7	Height;
THYM	cis	rs112591243	0.685	rs115448966	chr21:47988420	G/A	cg26904215	chr21:47823096	PCNT	-0.91	-4.46	-0.42	2.24e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs54211	0.831	rs137649	chr22:39730700	T/C	cg04982781	chr22:39714193	RPL3;RNU86	-0.35	-4.48	-0.42	2.06e-5	Sudden cardiac arrest;
THYM	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg18904891	chr8:8559673	CLDN23	0.72	5.39	0.48	5.14e-7	Obesity-related traits;
THYM	cis	rs9326248	0.530	rs10750101	chr11:116979689	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.87	4.82	0.44	5.36e-6	Blood protein levels;
THYM	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg14196790	chr5:131705035	SLC22A5	0.5	4.47	0.42	2.15e-5	Blood metabolite levels;
THYM	cis	rs941408	0.515	rs759066	chr19:2775337	G/T	cg17333051	chr19:2783644	SGTA	0.69	5.55	0.49	2.57e-7	Total cholesterol levels;
THYM	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg18681998	chr4:17616180	MED28	0.99	10.19	0.72	6.42e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs3799379	0.550	rs9467736	chr6:26380032	A/G	cg12826209	chr6:26865740	GUSBL1	0.78	6.0	0.52	3.56e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4919669	0.777	rs5011218	chr10:104401218	A/C	cg24934431	chr10:104597864	CYP17A1	0.57	4.87	0.45	4.38e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
THYM	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs968451	0.547	rs738331	chr22:39714216	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.6	4.59	0.43	1.33e-5	Primary biliary cholangitis;
THYM	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg15009913	chr1:2287741	MORN1	0.48	4.48	0.42	2.08e-5	Body mass index;
THYM	cis	rs6992848	1.000	rs6992848	chr8:141150169	T/C	cg22504031	chr8:141147661	TRAPPC9	0.62	5.0	0.46	2.65e-6	Response to amphetamines;
THYM	cis	rs7107174	0.901	rs2512525	chr11:77923019	T/C	cg02023728	chr11:77925099	USP35	0.7	6.19	0.54	1.5e-8	Testicular germ cell tumor;
THYM	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06850241	chr22:41845214	NA	-0.6	-5.24	-0.47	9.66e-7	Vitiligo;
THYM	cis	rs7119	0.717	rs12909645	chr15:77816819	A/T	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg16342193	chr10:102329863	NA	-0.53	-5.28	-0.48	8.1e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg13683864	chr3:40499215	RPL14	1.05	10.98	0.75	1.35e-18	Renal cell carcinoma;
THYM	cis	rs61931739	1.000	rs1852223	chr12:34013251	C/T	cg06521331	chr12:34319734	NA	0.58	4.57	0.42	1.49e-5	Morning vs. evening chronotype;
THYM	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.78	-6.45	-0.55	4.76e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg27284194	chr4:1044797	NA	0.61	4.6	0.43	1.29e-5	Recombination rate (females);
THYM	cis	rs7731657	0.537	rs10053245	chr5:130353033	G/A	cg08523029	chr5:130500466	HINT1	-0.81	-5.6	-0.5	2.04e-7	Fasting plasma glucose;
THYM	cis	rs1062753	0.771	rs5751245	chr22:42620940	T/C	cg08431931	chr22:42394659	WBP2NL	0.58	4.78	0.44	6.27e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg19677267	chr1:26645161	CD52;UBXN11	0.5	4.55	0.42	1.59e-5	Granulocyte percentage of myeloid white cells;
THYM	cis	rs754466	0.651	rs11002316	chr10:79617511	C/G	cg17075019	chr10:79541650	NA	-0.69	-5.92	-0.52	5.14e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs8067545	0.611	rs12938355	chr17:20195217	A/G	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs9543976	0.623	rs9543990	chr13:76172434	G/T	cg01531495	chr13:76123901	UCHL3	0.69	5.0	0.46	2.59e-6	Diabetic retinopathy;
THYM	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg25358565	chr5:93447407	FAM172A	0.96	6.78	0.57	1.01e-9	Diabetic retinopathy;
THYM	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.6	0.56	2.3e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg02869364	chr7:1081709	C7orf50	-0.45	-5.13	-0.47	1.53e-6	Longevity;Endometriosis;
THYM	cis	rs9549260	0.564	rs9315785	chr13:41322732	T/C	cg21288729	chr13:41239152	FOXO1	0.7	5.23	0.47	9.9e-7	Red blood cell count;
THYM	cis	rs921968	0.565	rs2037622	chr2:219609440	T/C	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4604732	0.536	rs12037221	chr1:247631212	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.7	4.88	0.45	4.32e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs4930776	1.000	rs4399394	chr12:5765928	A/C	cg02086166	chr12:5775618	ANO2	-0.58	-5.71	-0.51	1.3e-7	Plasma clusterin levels;
THYM	cis	rs742614	0.533	rs6087526	chr20:32398295	A/C	cg06304546	chr20:32448765	NA	-0.99	-10.45	-0.73	1.85e-17	Stearic acid (18:0) levels;
THYM	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg04362960	chr10:104952993	NT5C2	-0.6	-5.12	-0.46	1.61e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg12963246	chr6:28129442	ZNF389	0.53	4.71	0.44	8.3e-6	Parkinson's disease;
THYM	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs4654899	1.000	rs2271115	chr1:21295864	C/T	cg01072550	chr1:21505969	NA	-0.73	-6.55	-0.56	2.95e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs4499344	0.556	rs259225	chr19:33135458	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.98	7.07	0.59	2.55e-10	Mean platelet volume;
THYM	cis	rs7220711	0.902	rs12603100	chr17:41781344	T/G	cg26893861	chr17:41843967	DUSP3	0.62	5.21	0.47	1.11e-6	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg03476357	chr21:30257390	N6AMT1	-0.67	-5.02	-0.46	2.4e-6	Cognitive test performance;
THYM	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-4.46	-0.42	2.26e-5	Monocyte percentage of white cells;
THYM	cis	rs35264875	0.851	rs72930621	chr11:68866745	C/T	cg23845249	chr11:68861649	NA	0.53	6.15	0.53	1.86e-8	Blond vs. brown hair color;
THYM	cis	rs2219968	0.828	rs28764193	chr8:78942561	T/G	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs950880	0.710	rs10490203	chr2:103059237	T/G	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.71	-0.44	8.33e-6	Serum protein levels (sST2);
THYM	cis	rs17401966	1.000	rs11121532	chr1:10277898	G/T	cg20482658	chr1:10539492	PEX14	0.4	4.79	0.44	6.2e-6	Hepatocellular carcinoma;
THYM	cis	rs7616559	0.962	rs9880927	chr3:156739911	A/C	cg15697575	chr3:156784781	NA	0.4	4.99	0.46	2.78e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.54	-6.0	-0.52	3.58e-8	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1499972	0.941	rs56204450	chr3:117604215	G/A	cg07612923	chr3:117604196	NA	1.29	5.39	0.48	5.06e-7	Schizophrenia;
THYM	cis	rs983545	0.586	rs9880307	chr3:16974610	C/A	cg24159436	chr3:16974681	PLCL2	0.35	5.9	0.52	5.62e-8	Blood protein levels;
THYM	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg08847533	chr14:75593920	NEK9	-0.96	-10.3	-0.73	3.86e-17	Height;
THYM	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg05234568	chr11:5960015	NA	-0.59	-4.75	-0.44	7.28e-6	DNA methylation (variation);
THYM	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg00310523	chr12:86230176	RASSF9	-0.58	-5.19	-0.47	1.2e-6	Major depressive disorder;
THYM	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg26597838	chr10:835615	NA	1.26	8.09	0.64	1.95e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg04398451	chr17:18023971	MYO15A	-0.8	-7.37	-0.6	6.13e-11	Total body bone mineral density;
THYM	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg13615516	chr5:77269221	NA	0.86	8.01	0.63	2.88e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg14895029	chr7:2775587	GNA12	-0.67	-4.79	-0.44	6.16e-6	Height;
THYM	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg24675056	chr1:15929824	NA	0.71	5.65	0.5	1.68e-7	Systolic blood pressure;
THYM	cis	rs1642645	0.831	rs10736422	chr1:42480320	C/T	cg22816091	chr1:42611670	NA	0.62	5.52	0.49	2.99e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg24308560	chr3:49941425	MST1R	0.8	6.84	0.57	7.6e-10	Intelligence (multi-trait analysis);
THYM	cis	rs12496230	0.700	rs13078081	chr3:66852901	T/C	cg23477460	chr3:66848765	NA	0.88	5.83	0.51	7.5e-8	Type 2 diabetes;
THYM	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg03929089	chr4:120376271	NA	-0.94	-10.56	-0.73	1.03e-17	Height;
THYM	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.94	7.1	0.59	2.21e-10	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs12935418	0.583	rs2970086	chr16:81028440	T/A	cg16651780	chr16:81037892	C16orf61	-0.8	-6.24	-0.54	1.2e-8	Mean corpuscular volume;
THYM	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.47	0.49	3.63e-7	Bipolar disorder;
THYM	cis	rs9296092	0.538	rs75652975	chr6:33516251	C/T	cg13560919	chr6:33536144	NA	-0.94	-9.16	-0.68	1.03e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg27490568	chr2:178487706	NA	-0.59	-5.26	-0.47	8.97e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg02734326	chr4:10020555	SLC2A9	0.8	7.56	0.61	2.47e-11	Bone mineral density;
THYM	cis	rs394563	0.775	rs399673	chr6:149783221	T/C	cg26849637	chr6:150530249	PPP1R14C	-0.43	-4.79	-0.44	6.23e-6	Dupuytren's disease;
THYM	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9896052	0.591	rs11077790	chr17:73464718	G/A	cg00900735	chr17:73316505	GRB2	0.6	4.85	0.45	4.75e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
THYM	cis	rs9814567	1.000	rs4974483	chr3:134219001	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-8.41	-0.65	4e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs11628318	0.564	rs8006489	chr14:103121232	G/A	cg27124170	chr14:102829869	TECPR2;CINP	0.63	4.53	0.42	1.74e-5	Platelet count;
THYM	cis	rs8067545	0.611	rs2703786	chr17:20156369	T/C	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs34779708	0.966	rs2126984	chr10:35410291	A/G	cg03585969	chr10:35415529	CREM	0.67	5.01	0.46	2.51e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs2073300	0.609	rs6137910	chr20:23346515	C/G	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs28374715	0.662	rs28554139	chr15:41531084	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.08	-8.7	-0.67	9.69e-14	Ulcerative colitis;
THYM	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg05025164	chr4:1340916	KIAA1530	-0.7	-5.42	-0.49	4.53e-7	Obesity-related traits;
THYM	cis	rs61931739	1.000	rs11052967	chr12:34020030	T/G	cg10856724	chr12:34555212	NA	0.58	4.99	0.46	2.75e-6	Morning vs. evening chronotype;
THYM	cis	rs9807989	0.507	rs7581119	chr2:103049865	G/A	cg03938978	chr2:103052716	IL18RAP	0.75	9.8	0.71	4.43e-16	Asthma;
THYM	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-7.18	-0.59	1.55e-10	Gut microbiome composition (summer);
THYM	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg24675658	chr1:53192096	ZYG11B	0.71	6.38	0.55	6.49e-9	Monocyte count;
THYM	cis	rs9905704	0.846	rs302863	chr17:56698827	A/G	cg12560992	chr17:57184187	TRIM37	-0.65	-4.51	-0.42	1.89e-5	Testicular germ cell tumor;
THYM	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg26354017	chr1:205819088	PM20D1	0.96	10.23	0.72	5.38e-17	Menarche (age at onset);
THYM	cis	rs7177699	0.557	rs7164479	chr15:79123054	C/T	cg00540400	chr15:79124168	NA	0.65	7.03	0.58	3.16e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6429082	0.715	rs2131924	chr1:235580928	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.62	-4.69	-0.43	9.14e-6	Adiposity;
THYM	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	5.41	0.49	4.67e-7	Platelet count;
THYM	cis	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg06521331	chr12:34319734	NA	-0.86	-6.28	-0.54	1.01e-8	Morning vs. evening chronotype;
THYM	trans	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg19862616	chr7:65841803	NCRNA00174	1.12	13.73	0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg25072359	chr17:41440525	NA	0.64	4.48	0.42	2.05e-5	Menopause (age at onset);
THYM	cis	rs10140922	0.966	rs4982259	chr14:35821950	T/C	cg07166546	chr14:35805898	NA	-0.27	-6.66	-0.56	1.77e-9	Hip circumference adjusted for BMI;
THYM	cis	rs1335645	0.570	rs56273356	chr1:111664041	C/T	cg00321911	chr1:111669324	DRAM2	-1.25	-6.96	-0.58	4.29e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2737618	0.574	rs2252801	chr1:200076652	C/T	cg21825944	chr1:200113062	NR5A2	-0.64	-5.3	-0.48	7.52e-7	Uric acid levels;
THYM	cis	rs12983728	1.000	rs12983728	chr19:58671267	G/A	cg07378217	chr19:58662286	ZNF329	-0.91	-5.68	-0.5	1.46e-7	Cholesterol, total;
THYM	cis	rs9915657	0.773	rs9912974	chr17:70095963	C/T	cg09344028	chr17:70110421	NA	0.52	5.36	0.48	5.71e-7	Thyroid hormone levels;
THYM	cis	rs1021993	0.868	rs906351	chr1:209527925	C/T	cg17822955	chr1:209527491	NA	-0.47	-4.48	-0.42	2.08e-5	Gut microbiome composition (winter);
THYM	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg24675658	chr1:53192096	ZYG11B	-0.67	-5.23	-0.47	1e-6	Monocyte count;
THYM	cis	rs1003719	0.715	rs8128387	chr21:38556787	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs9534288	0.699	rs9534321	chr13:46669032	A/G	cg15192986	chr13:46630673	CPB2	-0.64	-4.49	-0.42	2.01e-5	Blood protein levels;
THYM	cis	rs9807989	0.839	rs9308857	chr2:102979624	G/A	cg03938978	chr2:103052716	IL18RAP	0.63	6.55	0.56	2.99e-9	Asthma;
THYM	cis	rs12310956	0.510	rs11612987	chr12:33879130	T/C	cg10856724	chr12:34555212	NA	-0.65	-5.89	-0.52	5.95e-8	Morning vs. evening chronotype;
THYM	cis	rs611744	0.967	rs639059	chr8:109236119	G/A	cg21045802	chr8:109455806	TTC35	0.59	5.32	0.48	6.89e-7	Dupuytren's disease;
THYM	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg00071950	chr4:10020882	SLC2A9	0.86	10.33	0.73	3.3e-17	Bone mineral density;
THYM	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.47	-0.49	3.59e-7	Mean corpuscular volume;
THYM	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg06850241	chr22:41845214	NA	0.48	4.52	0.42	1.78e-5	Vitiligo;
THYM	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg22683308	chr4:1340831	KIAA1530	-0.59	-4.62	-0.43	1.2e-5	Longevity;
THYM	cis	rs4845459	0.967	rs6693105	chr1:152590663	C/T	cg26135325	chr1:152595322	LCE3A	0.42	4.76	0.44	6.78e-6	Psoriasis;
THYM	cis	rs9876781	1.000	rs9883927	chr3:48463711	T/C	cg06066452	chr3:48470258	PLXNB1	0.27	4.85	0.45	4.78e-6	Longevity;
THYM	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg07936489	chr17:37558343	FBXL20	0.79	5.7	0.5	1.37e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs208520	0.837	rs208486	chr6:66926255	A/T	cg07460842	chr6:66804631	NA	-0.79	-4.96	-0.45	3.05e-6	Exhaled nitric oxide output;
THYM	cis	rs35934224	0.831	rs8141610	chr22:19870147	A/G	cg11182965	chr22:19864308	TXNRD2	0.96	7.65	0.62	1.61e-11	Glaucoma (primary open-angle);
THYM	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg26384229	chr12:38710491	ALG10B	-0.89	-9.05	-0.68	1.77e-14	Heart rate;
THYM	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg06009448	chr7:1102226	C7orf50	0.44	4.66	0.43	1.05e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs61931739	0.817	rs11833948	chr12:34276942	G/T	cg06521331	chr12:34319734	NA	-0.66	-5.46	-0.49	3.75e-7	Morning vs. evening chronotype;
THYM	cis	rs5769707	0.521	rs74351010	chr22:50036820	G/A	cg05373962	chr22:49881684	NA	0.73	5.37	0.48	5.68e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg23422044	chr7:1970798	MAD1L1	-0.95	-6.58	-0.56	2.51e-9	Bipolar disorder;
THYM	cis	rs11671005	0.735	rs11666716	chr19:58920952	A/G	cg18639983	chr19:58920768	ZNF584	0.59	5.0	0.46	2.63e-6	Mean platelet volume;
THYM	cis	rs673253	0.593	rs3791151	chr1:44078602	C/A	cg24466421	chr1:44070974	PTPRF	-0.59	-5.12	-0.46	1.62e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6087990	0.965	rs2424903	chr20:31349315	C/T	cg13636640	chr20:31349939	DNMT3B	0.93	9.87	0.71	3.11e-16	Ulcerative colitis;
THYM	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg25358565	chr5:93447407	FAM172A	1.34	10.59	0.74	9.3e-18	Diabetic retinopathy;
THYM	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg18240062	chr17:79603768	NPLOC4	0.73	6.2	0.54	1.42e-8	Eye color traits;
THYM	cis	rs5769707	0.632	rs6009782	chr22:50010812	C/G	cg05373962	chr22:49881684	NA	-0.7	-6.48	-0.55	4.07e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg24375607	chr4:120327624	NA	0.58	4.8	0.44	5.82e-6	Corneal astigmatism;
THYM	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg10515332	chr4:99064459	C4orf37	0.67	5.33	0.48	6.48e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7264396	0.790	rs8125090	chr20:34360015	C/G	cg26038318	chr20:34205095	SPAG4	0.59	4.68	0.43	9.34e-6	Total cholesterol levels;
THYM	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.63	0.62	1.78e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7617773	0.780	rs13082158	chr3:48372470	T/C	cg02219026	chr3:48282209	ZNF589	-0.67	-4.69	-0.43	9.05e-6	Coronary artery disease;
THYM	cis	rs2257205	0.600	rs8071081	chr17:56709055	T/G	cg22900075	chr17:55952563	CUEDC1	0.81	4.45	0.42	2.31e-5	Pancreatic cancer;
THYM	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg18132916	chr6:79620363	NA	-0.6	-5.66	-0.5	1.6e-7	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4148883	0.675	rs10000357	chr4:100099942	G/C	cg12011299	chr4:100065546	ADH4	0.66	5.65	0.5	1.65e-7	Alcohol dependence;
THYM	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg22920501	chr2:26401640	FAM59B	-0.8	-7.19	-0.59	1.44e-10	Gut microbiome composition (summer);
THYM	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg13010199	chr12:38710504	ALG10B	0.69	5.5	0.49	3.16e-7	Heart rate;
THYM	cis	rs7551222	0.752	rs11240755	chr1:204478649	C/T	cg20240347	chr1:204465584	NA	-0.51	-4.54	-0.42	1.64e-5	Schizophrenia;
THYM	cis	rs9831754	0.906	rs2102601	chr3:78410536	G/A	cg06138941	chr3:78371609	NA	-0.64	-4.59	-0.43	1.36e-5	Calcium levels;
THYM	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg06238570	chr21:40685208	BRWD1	0.87	6.38	0.55	6.56e-9	Cognitive function;
THYM	cis	rs2797685	1.000	rs707466	chr1:7861600	C/A	cg06712362	chr1:7811235	CAMTA1	0.65	4.68	0.43	9.42e-6	Crohn's disease;
THYM	cis	rs2439831	0.681	rs28594657	chr15:43588888	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	8.0	0.63	3.04e-12	Lung cancer in ever smokers;
THYM	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg07541023	chr7:19748670	TWISTNB	-1.14	-6.3	-0.54	9.2e-9	Thyroid stimulating hormone;
THYM	cis	rs6738485	0.507	rs72819611	chr2:106845912	G/A	cg16099169	chr2:106886729	NA	-0.85	-5.64	-0.5	1.73e-7	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
THYM	cis	rs67460515	0.892	rs1478566	chr3:161030335	A/T	cg03342759	chr3:160939853	NMD3	-0.94	-8.14	-0.64	1.55e-12	Parkinson's disease;
THYM	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07167872	chr1:205819463	PM20D1	1.0	10.16	0.72	7.66e-17	Menarche (age at onset);
THYM	cis	rs12410462	0.681	rs58496521	chr1:227582375	T/C	cg04117972	chr1:227635322	NA	0.81	5.08	0.46	1.88e-6	Major depressive disorder;
THYM	cis	rs4936891	0.520	rs61908589	chr11:123869583	C/T	cg22125253	chr11:123886957	OR10G4	-0.57	-4.94	-0.45	3.35e-6	Male fertility;
THYM	cis	rs4523957	0.579	rs2307143	chr17:2089754	G/A	cg16513277	chr17:2031491	SMG6	-0.97	-8.83	-0.67	5.35e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	7.89	0.63	5.06e-12	Monocyte percentage of white cells;
THYM	cis	rs72627123	0.867	rs17093882	chr14:74368741	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg18758796	chr5:131593413	PDLIM4	0.48	4.47	0.42	2.13e-5	Breast cancer;Mosquito bite size;
THYM	cis	rs9790314	0.846	rs4856714	chr3:160961824	T/C	cg03342759	chr3:160939853	NMD3	-0.95	-9.47	-0.7	2.2e-15	Morning vs. evening chronotype;
THYM	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.63	4.51	0.42	1.82e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7731657	0.518	rs12522464	chr5:130380123	C/T	cg08523029	chr5:130500466	HINT1	-0.8	-4.91	-0.45	3.8e-6	Fasting plasma glucose;
THYM	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg00981070	chr1:2046702	PRKCZ	-0.4	-4.96	-0.45	3.1e-6	Height;
THYM	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg13246856	chr1:44399776	ARTN	-0.5	-5.46	-0.49	3.82e-7	Intelligence (multi-trait analysis);
THYM	trans	rs8002861	0.619	rs9567289	chr13:44437104	C/T	cg17145862	chr1:211918768	LPGAT1	0.85	7.64	0.62	1.69e-11	Leprosy;
THYM	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg09184832	chr6:79620586	NA	-0.57	-4.62	-0.43	1.19e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg01200585	chr1:228362443	C1orf69	0.42	4.51	0.42	1.85e-5	Diastolic blood pressure;
THYM	cis	rs9807841	0.592	rs7250071	chr19:10765819	A/G	cg16900796	chr19:10755136	SLC44A2	-0.42	-6.86	-0.58	7.01e-10	Inflammatory skin disease;
THYM	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg13010199	chr12:38710504	ALG10B	0.72	5.86	0.52	6.65e-8	Heart rate;
THYM	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg06112835	chr11:68658793	MRPL21	0.45	6.44	0.55	4.77e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4654899	0.931	rs4654730	chr1:21229286	A/T	cg01072550	chr1:21505969	NA	-0.7	-6.27	-0.54	1.06e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs11711311	1.000	rs7649590	chr3:113447267	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.59	-5.19	-0.47	1.2e-6	IgG glycosylation;
THYM	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg22535103	chr8:58192502	C8orf71	-1.06	-6.61	-0.56	2.24e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs11030122	0.702	rs12281293	chr11:3963814	C/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.73	-0.51	1.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg08305652	chr11:111469057	NA	0.53	4.51	0.42	1.88e-5	Primary sclerosing cholangitis;
THYM	cis	rs4974559	0.594	rs59544360	chr4:1313575	G/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.4	-4.62	-0.43	1.2e-5	Systolic blood pressure;
THYM	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg06108461	chr20:60628389	TAF4	-0.99	-7.54	-0.61	2.73e-11	Body mass index;
THYM	cis	rs6840360	0.870	rs6814554	chr4:152454334	G/A	cg17479576	chr4:152424074	FAM160A1	-0.63	-4.74	-0.44	7.37e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10744422	1.000	rs7309225	chr12:123288439	A/G	cg25930673	chr12:123319894	HIP1R	-0.83	-4.99	-0.46	2.7e-6	Schizophrenia;
THYM	cis	rs7119	0.717	rs12917175	chr15:77818193	A/G	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs11711311	1.000	rs12736	chr3:113530211	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.63	-5.51	-0.49	3.06e-7	IgG glycosylation;
THYM	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.78	6.29	0.54	9.87e-9	Lymphocyte percentage of white cells;
THYM	cis	rs987493	1.000	rs4296979	chr7:77745281	A/G	cg24523301	chr7:77325698	RSBN1L	0.88	5.07	0.46	1.94e-6	Pursuit maintenance gain;
THYM	trans	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg10856724	chr12:34555212	NA	-0.8	-7.08	-0.59	2.49e-10	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs3768617	0.510	rs1413390	chr1:183096634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs4253772	0.626	rs12169526	chr22:46763846	C/T	cg15879316	chr22:46934089	CELSR1	0.72	4.55	0.42	1.59e-5	LDL cholesterol;Cholesterol, total;
THYM	cis	rs889398	0.771	rs1566453	chr16:69899787	C/T	cg09409435	chr16:70099608	PDXDC2	0.59	4.75	0.44	7.23e-6	Body mass index;
THYM	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg08736216	chr1:53307985	ZYG11A	-0.58	-5.29	-0.48	7.85e-7	Monocyte count;
THYM	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg13939156	chr17:80058883	NA	0.38	4.81	0.44	5.77e-6	Life satisfaction;
THYM	cis	rs7404928	0.651	rs56350292	chr16:23947611	C/A	cg26685404	chr16:23957272	PRKCB	0.68	7.99	0.63	3.22e-12	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs8133932	0.736	rs4819159	chr21:47285605	A/G	cg20357416	chr21:47294739	PCBP3	-0.84	-5.2	-0.47	1.12e-6	Schizophrenia;
THYM	cis	rs4654899	0.865	rs72973154	chr1:21459125	G/T	cg01072550	chr1:21505969	NA	-0.75	-6.56	-0.56	2.79e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg16384552	chr7:74938386	SPDYE8P	-0.77	-6.64	-0.56	1.94e-9	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg19912559	chr1:40204330	PPIE	0.64	4.92	0.45	3.61e-6	Blood protein levels;
THYM	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg19336497	chr11:14380999	RRAS2	0.54	5.8	0.51	8.71e-8	Mitochondrial DNA levels;
THYM	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.5	-4.66	-0.43	1.04e-5	Lymphocyte counts;
THYM	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg23711669	chr6:146136114	FBXO30	0.85	8.17	0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs860818	1.000	rs858245	chr7:23222727	A/C	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs7119038	0.865	rs7951740	chr11:118740418	G/C	cg19308663	chr11:118741387	NA	-0.59	-5.67	-0.5	1.5e-7	Sjögren's syndrome;
THYM	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg20503657	chr10:835505	NA	1.15	8.11	0.64	1.78e-12	Eosinophil percentage of granulocytes;
THYM	trans	rs11722228	0.522	rs73212880	chr4:10115692	T/A	cg26043149	chr18:55253948	FECH	1.18	11.04	0.75	1.03e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs4638749	0.677	rs7370742	chr2:108815385	T/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg06917634	chr15:78832804	PSMA4	0.94	8.55	0.66	2.02e-13	Sudden cardiac arrest;
THYM	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg10515332	chr4:99064459	C4orf37	0.65	5.25	0.47	9.16e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg14349672	chr11:133703707	NA	-0.53	-5.14	-0.47	1.49e-6	Childhood ear infection;
THYM	cis	rs7119038	0.818	rs6589685	chr11:118612197	T/C	cg19308663	chr11:118741387	NA	0.46	4.71	0.44	8.41e-6	Sjögren's syndrome;
THYM	cis	rs714027	0.585	rs41170	chr22:30421066	C/T	cg27665648	chr22:30112403	NA	0.5	4.49	0.42	1.97e-5	Lymphocyte counts;
THYM	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg03859395	chr2:55845619	SMEK2	-0.6	-5.52	-0.49	2.95e-7	Metabolic syndrome;
THYM	cis	rs977987	0.843	rs12928036	chr16:75483132	G/A	cg03315344	chr16:75512273	CHST6	0.73	5.95	0.52	4.4e-8	Dupuytren's disease;
THYM	cis	rs7851660	0.933	rs12341377	chr9:100610382	C/G	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg23758822	chr17:41437982	NA	1.16	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.41	-6.4	-0.55	5.78e-9	Obesity-related traits;
THYM	cis	rs293526	0.959	rs2770679	chr6:83639376	T/C	cg23278060	chr6:83777448	DOPEY1	0.61	4.48	0.42	2.1e-5	Crohn's disease;
THYM	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg06850241	chr22:41845214	NA	0.54	4.77	0.44	6.68e-6	Vitiligo;
THYM	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22496380	chr5:211416	CCDC127	-1.35	-7.5	-0.61	3.41e-11	Breast cancer;
THYM	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg24675658	chr1:53192096	ZYG11B	-0.77	-6.93	-0.58	5.04e-10	Monocyte count;
THYM	cis	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs61931739	0.635	rs10772122	chr12:33964674	A/C	cg06521331	chr12:34319734	NA	-0.56	-4.69	-0.43	8.97e-6	Morning vs. evening chronotype;
THYM	cis	rs55665837	1.000	rs11023229	chr11:14461001	G/C	cg19336497	chr11:14380999	RRAS2	-0.64	-7.04	-0.59	3e-10	Vitamin D levels;
THYM	cis	rs17604090	0.938	rs850027	chr7:29675792	G/T	cg19413766	chr7:29689036	LOC646762	-0.96	-5.36	-0.48	5.91e-7	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs4638749	0.677	rs1563111	chr2:108845717	A/G	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs2456568	0.867	rs7935801	chr11:93658000	G/A	cg26875233	chr11:93583750	C11orf90	-0.52	-5.13	-0.47	1.53e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs17443541	0.507	rs12622777	chr2:200465331	G/A	cg01795955	chr2:200468626	NA	-0.72	-5.0	-0.46	2.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11771526	0.818	rs17161140	chr7:32324199	T/C	cg13207630	chr7:32358064	NA	0.84	5.28	0.48	8.15e-7	Body mass index;
THYM	cis	rs6882076	1.000	rs6878680	chr5:156387137	G/C	cg12943317	chr5:156479607	HAVCR1	-0.7	-5.86	-0.52	6.59e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs6435161	0.959	rs1544913	chr2:203484781	T/C	cg18429434	chr2:203499731	FAM117B	-0.68	-4.47	-0.42	2.14e-5	Total cholesterol levels;
THYM	cis	rs7000551	0.715	rs34649162	chr8:22314730	T/C	cg12081754	chr8:22256438	SLC39A14	0.6	5.25	0.47	9.31e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg10802521	chr3:52805072	NEK4	0.79	7.58	0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs12282928	0.959	rs1503181	chr11:48265379	G/C	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs6032067	0.929	rs45461302	chr20:43805274	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.13	-0.64	1.63e-12	Blood protein levels;
THYM	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg24060327	chr5:131705240	SLC22A5	-0.79	-5.8	-0.51	8.82e-8	Blood metabolite levels;
THYM	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.89	0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7582180	0.874	rs7601442	chr2:100897351	T/A	cg14675211	chr2:100938903	LONRF2	0.64	5.43	0.49	4.28e-7	Intelligence (multi-trait analysis);
THYM	cis	rs8050907	0.744	rs8044698	chr16:4577069	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	-1.13	-4.48	-0.42	2.08e-5	Obesity-related traits;
THYM	cis	rs863345	0.647	rs923663	chr1:158507732	A/T	cg12129480	chr1:158549410	OR10X1	0.49	4.78	0.44	6.5e-6	Pneumococcal bacteremia;
THYM	cis	rs7177699	0.557	rs10083697	chr15:79124039	G/A	cg00540400	chr15:79124168	NA	-0.64	-6.85	-0.58	7.18e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	trans	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg17712092	chr4:129076599	LARP1B	0.94	8.43	0.65	3.68e-13	Eosinophil percentage of white cells;
THYM	cis	rs2562456	0.917	rs2562471	chr19:21715819	C/T	cg21751540	chr19:21541537	ZNF738	0.67	4.66	0.43	1.04e-5	Pain;
THYM	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg19875535	chr5:140030758	IK	0.65	5.12	0.47	1.56e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg23188684	chr11:67383651	NA	0.59	4.56	0.42	1.54e-5	Mean corpuscular volume;
THYM	cis	rs988913	1.000	rs9370342	chr6:54820670	C/A	cg04690482	chr6:54711388	FAM83B	0.47	5.23	0.47	1.03e-6	Menarche (age at onset);
THYM	cis	rs901683	1.000	rs34618850	chr10:46087863	C/T	cg18240400	chr10:46168597	ANUBL1	0.73	4.73	0.44	7.89e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs13315871	0.929	rs13082278	chr3:58318224	A/G	cg12435725	chr3:58293450	RPP14	-0.52	-5.47	-0.49	3.67e-7	Cholesterol, total;
THYM	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg03161606	chr19:29218774	NA	0.67	4.64	0.43	1.13e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg21605333	chr4:119757512	SEC24D	1.4	4.99	0.46	2.74e-6	Cannabis dependence symptom count;
THYM	cis	rs13064411	0.696	rs9808893	chr3:113228444	G/A	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg26384229	chr12:38710491	ALG10B	0.71	5.52	0.49	2.92e-7	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg06634786	chr22:41940651	POLR3H	0.67	5.11	0.46	1.66e-6	Vitiligo;
THYM	cis	rs10779751	0.959	rs2300091	chr1:11266711	C/T	cg08854313	chr1:11322531	MTOR	1.01	9.78	0.71	4.97e-16	Body mass index;
THYM	cis	rs863345	0.604	rs879637	chr1:158462697	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs10499694	0.933	rs11575356	chr7:50594821	T/C	cg00647317	chr7:50633725	DDC	0.3	4.56	0.42	1.52e-5	Body mass index;
THYM	cis	rs13315871	1.000	rs71311855	chr3:58320507	A/G	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs28595532	0.920	rs114659035	chr4:119740028	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs1003719	0.553	rs1063948	chr21:38574674	C/G	cg01329690	chr21:38580129	DSCR9	-0.36	-5.0	-0.46	2.67e-6	Eye color traits;
THYM	cis	rs3741151	0.773	rs7945825	chr11:73287140	G/C	cg12959048	chr11:73096162	RELT	-0.52	-4.58	-0.43	1.43e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg08048268	chr3:133502702	NA	0.68	5.84	0.51	7.16e-8	Iron status biomarkers;
THYM	cis	rs7582180	0.663	rs6542944	chr2:100988038	T/C	cg08017756	chr2:100939284	LONRF2	-0.72	-7.39	-0.6	5.75e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7719624	0.967	rs10463536	chr5:135362682	T/C	cg15329133	chr5:135467951	SMAD5;SMAD5OS	0.54	4.54	0.42	1.64e-5	Response to cytidine analogues (gemcitabine);
THYM	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg06634786	chr22:41940651	POLR3H	-0.73	-5.36	-0.48	5.89e-7	Vitiligo;
THYM	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg26516362	chr5:178986906	RUFY1	-0.37	-4.69	-0.43	9.02e-6	Lung cancer;
THYM	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.36e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg15448220	chr1:150897856	SETDB1	0.85	7.2	0.59	1.39e-10	Melanoma;
THYM	cis	rs13315871	0.858	rs13090428	chr3:58314412	A/G	cg12435725	chr3:58293450	RPP14	-0.52	-5.47	-0.49	3.67e-7	Cholesterol, total;
THYM	cis	rs4589258	0.788	rs7931598	chr11:90497784	T/C	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.94	-0.45	3.36e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg24257776	chr3:47051546	LOC100129354	0.39	4.52	0.42	1.78e-5	Colorectal cancer;
THYM	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg13447684	chr7:1895903	MAD1L1	0.54	4.81	0.44	5.71e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.62	5.43	0.49	4.32e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1878931	0.597	rs37814	chr16:3455247	C/T	cg05754148	chr16:3507555	NAT15	0.57	4.62	0.43	1.23e-5	Body mass index (adult);
THYM	cis	rs17407555	0.601	rs73229828	chr4:10026833	A/G	cg11266682	chr4:10021025	SLC2A9	-0.56	-5.73	-0.51	1.2e-7	Schizophrenia (age at onset);
THYM	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	7.61	0.62	1.99e-11	Smoking behavior;
THYM	cis	rs4606347	0.872	rs34749903	chr1:66128057	T/G	cg04111102	chr1:66153794	NA	0.69	5.21	0.47	1.07e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs912057	0.671	rs1024246	chr6:6743505	A/T	cg13809441	chr6:6737631	NA	0.44	5.32	0.48	6.97e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg18357526	chr6:26021779	HIST1H4A	0.63	4.78	0.44	6.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6435161	0.919	rs72928971	chr2:203591967	A/G	cg18429434	chr2:203499731	FAM117B	-0.74	-4.95	-0.45	3.18e-6	Total cholesterol levels;
THYM	cis	rs2658782	0.547	rs3020052	chr11:93055184	C/G	cg15737290	chr11:93063684	CCDC67	1.16	11.34	0.76	2.38e-19	Pulmonary function decline;
THYM	cis	rs1808579	0.935	rs6507720	chr18:21119291	A/G	cg14672496	chr18:21087552	C18orf8	0.49	4.53	0.42	1.75e-5	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
THYM	cis	rs2213920	0.679	rs6478168	chr9:118225951	A/T	cg13918206	chr9:118159781	DEC1	0.8	4.54	0.42	1.67e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9314614	0.789	rs4841776	chr8:6712219	T/G	cg27319216	chr8:6693540	XKR5	-0.63	-6.6	-0.56	2.3e-9	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg12893697	chr11:970389	AP2A2	0.32	5.41	0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs7267979	0.934	rs6037085	chr20:25305202	C/T	cg08601574	chr20:25228251	PYGB	-0.57	-4.59	-0.43	1.35e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs11574514	0.661	rs117713176	chr16:67503354	C/A	cg09738193	chr16:67926317	PSKH1	-0.92	-4.49	-0.42	2e-5	Crohn's disease;
THYM	cis	rs6032067	0.641	rs34313230	chr20:43755858	C/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.72	-7.65	-0.62	1.63e-11	Blood protein levels;
THYM	trans	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	Myopia (pathological);
THYM	cis	rs4824093	0.610	rs4824113	chr22:50284974	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.04	-4.76	-0.44	6.85e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg03929089	chr4:120376271	NA	-0.99	-12.81	-0.8	2.07e-22	Height;
THYM	cis	rs9796	0.621	rs690733	chr15:41476465	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.58	-4.79	-0.44	6.07e-6	Menopause (age at onset);
THYM	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg10760299	chr15:45669010	GATM	0.93	7.63	0.62	1.79e-11	Homoarginine levels;
THYM	cis	rs11089937	0.864	rs5757041	chr22:22494931	G/T	cg21401457	chr22:22472743	NA	0.61	5.14	0.47	1.47e-6	Periodontitis (PAL4Q3);
THYM	cis	rs4845459	1.000	rs4845459	chr1:152603842	C/A	cg26135325	chr1:152595322	LCE3A	-0.45	-5.02	-0.46	2.45e-6	Psoriasis;
THYM	cis	rs28374715	0.532	rs28703570	chr15:41679492	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.78	-0.83	2.3e-26	Ulcerative colitis;
THYM	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg10518543	chr12:38710700	ALG10B	-0.57	-4.49	-0.42	2.04e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7757969	1.000	rs6939727	chr6:112116451	C/T	cg08601457	chr6:112115117	FYN	0.42	4.79	0.44	6.23e-6	Schizophrenia;
THYM	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.39	-4.6	-0.43	1.3e-5	Monocyte percentage of white cells;
THYM	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg08017756	chr2:100939284	LONRF2	-0.73	-7.71	-0.62	1.25e-11	Intelligence (multi-trait analysis);
THYM	cis	rs4666002	0.709	rs6719175	chr2:27859351	T/A	cg27432699	chr2:27873401	GPN1	0.63	4.81	0.44	5.57e-6	Phospholipid levels (plasma);
THYM	cis	rs11731175	1.000	rs4012750	chr4:189852738	A/G	cg00431894	chr4:189871012	NA	-0.88	-6.75	-0.57	1.15e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2440012	0.779	rs57068715	chr13:19402394	G/A	cg05791018	chr13:19965014	NA	-0.65	-4.54	-0.42	1.62e-5	Longevity;
THYM	cis	rs7582180	0.652	rs4443016	chr2:100876628	C/G	cg14675211	chr2:100938903	LONRF2	0.53	4.81	0.44	5.63e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7586879	0.575	rs6712981	chr2:25126230	A/G	cg01884057	chr2:25150051	NA	0.73	7.9	0.63	4.81e-12	Body mass index;
THYM	cis	rs2046867	0.628	rs62249880	chr3:72918940	C/T	cg25664220	chr3:72788482	NA	-0.77	-6.93	-0.58	5.07e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg14413466	chr17:79170920	AZI1	-0.7	-5.95	-0.52	4.48e-8	Frontotemporal dementia;
THYM	cis	rs34602589	0.778	rs62206432	chr20:43748038	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.44	-4.7	-0.43	8.66e-6	Parental longevity (mother's age at death);
THYM	cis	rs2033562	0.893	rs1347320	chr8:103548510	A/G	cg20611272	chr8:103548145	NA	0.42	5.11	0.46	1.65e-6	IgA nephropathy;
THYM	cis	rs4907240	0.770	rs4907236	chr2:97187605	C/T	cg18419276	chr2:96971862	SNRNP200	-0.42	-5.09	-0.46	1.83e-6	Event-related brain oscillations;
THYM	cis	rs4595586	0.545	rs12819061	chr12:39386976	C/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs17174870	0.955	rs11893308	chr2:112778509	A/G	cg17354880	chr2:112658759	MERTK	-0.59	-4.47	-0.42	2.13e-5	Multiple sclerosis;
THYM	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg10360139	chr7:1886902	MAD1L1	-0.6	-5.09	-0.46	1.78e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg13609457	chr4:120235615	NA	0.59	5.27	0.48	8.67e-7	Corneal astigmatism;
THYM	trans	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg23505145	chr19:12996616	KLF1	1.05	10.29	0.73	4.07e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg01966878	chr4:90757139	SNCA	-0.54	-4.48	-0.42	2.07e-5	Neuroticism;
THYM	cis	rs10779751	0.922	rs4845985	chr1:11288618	G/A	cg08854313	chr1:11322531	MTOR	0.96	8.41	0.65	4.17e-13	Body mass index;
THYM	cis	rs1061377	0.965	rs1138494	chr4:39124935	C/T	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs1278352	0.728	rs1298111	chr10:127774525	T/C	cg08295661	chr10:127769903	ADAM12	-0.55	-5.64	-0.5	1.71e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg06636001	chr8:8085503	FLJ10661	-0.65	-5.89	-0.52	5.95e-8	Joint mobility (Beighton score);
THYM	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg24308560	chr3:49941425	MST1R	-0.76	-6.37	-0.55	6.71e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1003719	0.715	rs2835649	chr21:38552230	C/T	cg01329690	chr21:38580129	DSCR9	0.38	5.23	0.47	1e-6	Eye color traits;
THYM	cis	rs354225	0.553	rs7564719	chr2:54829731	A/C	cg23486701	chr2:54789491	SPTBN1	0.37	4.9	0.45	3.94e-6	Schizophrenia;
THYM	cis	rs5769765	0.542	rs1535189	chr22:50249131	T/C	cg08270630	chr22:50330655	NA	0.73	4.64	0.43	1.11e-5	Schizophrenia;
THYM	cis	rs2562456	0.652	rs4809145	chr19:21780709	A/C	cg21751540	chr19:21541537	ZNF738	-0.77	-5.05	-0.46	2.12e-6	Pain;
THYM	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg11189052	chr15:85197271	WDR73	-0.61	-4.65	-0.43	1.08e-5	P wave terminal force;
THYM	cis	rs10744422	0.920	rs10773657	chr12:123327900	C/A	cg25930673	chr12:123319894	HIP1R	-0.88	-5.15	-0.47	1.43e-6	Schizophrenia;
THYM	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	5.47	0.49	3.69e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg00376283	chr12:123451042	ABCB9	0.71	4.75	0.44	7.32e-6	Neutrophil percentage of white cells;
THYM	cis	rs12935418	0.523	rs2549845	chr16:81024125	C/A	cg16651780	chr16:81037892	C16orf61	-0.84	-6.56	-0.56	2.82e-9	Mean corpuscular volume;
THYM	cis	rs1160297	0.609	rs2356680	chr2:53095313	T/C	cg07782112	chr2:53107842	NA	0.78	6.07	0.53	2.65e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.44	0.61	4.38e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4474465	0.688	rs10899553	chr11:78265210	A/G	cg19901956	chr11:77921274	USP35	0.61	4.64	0.43	1.12e-5	Alzheimer's disease (survival time);
THYM	trans	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg05926928	chr17:57297772	GDPD1	1.26	10.02	0.72	1.5e-16	Opioid sensitivity;
THYM	cis	rs7084402	0.967	rs1620186	chr10:60314275	G/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.47	-0.49	3.63e-7	Refractive error;
THYM	cis	rs2901656	0.677	rs1063412	chr1:172410967	G/A	cg03748243	chr1:172413542	C1orf105;PIGC	0.59	6.57	0.56	2.73e-9	Red cell distribution width;Platelet distribution width;
THYM	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg08901578	chr4:187885870	NA	0.66	6.26	0.54	1.12e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7226229	1.000	rs3612	chr17:20905084	G/T	cg21263980	chr17:20946333	USP22	0.68	4.92	0.45	3.65e-6	Blood trace element (Se levels);
THYM	cis	rs2599510	0.840	rs466146	chr2:32539236	A/C	cg02381751	chr2:32503542	YIPF4	0.58	4.71	0.44	8.35e-6	Interleukin-18 levels;
THYM	cis	rs7078219	0.714	rs11190139	chr10:101288099	C/G	cg23904955	chr10:101282759	NA	-0.4	-4.61	-0.43	1.26e-5	Dental caries;
THYM	trans	rs7794364	0.658	rs2193255	chr7:117520009	A/C	cg21837391	chr1:1159412	SDF4	0.92	7.57	0.61	2.39e-11	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg02915803	chr1:1606292	LOC728661;CDK11B	-0.69	-6.42	-0.55	5.28e-9	Body mass index;
THYM	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg20608306	chr11:116969690	SIK3	0.51	5.5	0.49	3.2e-7	Blood protein levels;
THYM	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17443541	0.507	rs2122534	chr2:200459294	C/G	cg03741458	chr2:200468445	NA	-0.8	-6.04	-0.53	3.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7326068	0.610	rs2596150	chr13:21317048	C/T	cg02792322	chr13:21280448	IL17D	-0.65	-4.56	-0.42	1.55e-5	Schizophrenia, bipolar disorder and depression (combined);
THYM	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg05182265	chr7:156933206	UBE3C	0.7	9.62	0.7	1.06e-15	Body mass index;
THYM	cis	rs4383453	0.539	rs4677886	chr3:123100196	A/G	cg04890266	chr3:123102914	ADCY5	-0.83	-8.64	-0.66	1.32e-13	Gestational age at birth (maternal effect);
THYM	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg13918804	chr1:2043761	PRKCZ	0.64	4.78	0.44	6.29e-6	Height;
THYM	cis	rs4285028	0.948	rs6790281	chr3:121665543	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.77	-5.02	-0.46	2.45e-6	Mean platelet volume;
THYM	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg07570687	chr10:102243282	WNT8B	0.76	6.76	0.57	1.13e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg24253500	chr15:84953950	NA	0.57	4.51	0.42	1.85e-5	Schizophrenia;
THYM	cis	rs3781426	0.793	rs3781423	chr10:126704704	G/C	cg04494136	chr10:126703576	CTBP2	-0.43	-6.35	-0.55	7.2e-9	Height;
THYM	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg09354556	chr3:47051341	NA	0.43	4.53	0.42	1.74e-5	Colorectal cancer;
THYM	cis	rs7523273	0.597	rs11118580	chr1:207959070	T/C	cg22525895	chr1:207977042	MIR29B2	-0.74	-4.9	-0.45	3.98e-6	Schizophrenia;
THYM	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg03388025	chr16:89894329	SPIRE2	0.54	4.54	0.42	1.67e-5	Vitiligo;
THYM	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg24675658	chr1:53192096	ZYG11B	-0.6	-4.93	-0.45	3.43e-6	Monocyte count;
THYM	cis	rs6430585	0.793	rs11684545	chr2:136539122	G/T	cg20242066	chr2:136595261	LCT	-0.57	-6.92	-0.58	5.18e-10	Corneal structure;
THYM	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg02503808	chr4:7069936	GRPEL1	0.99	8.48	0.66	2.89e-13	Monocyte percentage of white cells;
THYM	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg25566285	chr7:158114605	PTPRN2	-0.86	-9.9	-0.71	2.74e-16	Calcium levels;
THYM	cis	rs7568458	0.837	rs3770098	chr2:85805367	C/A	cg17127132	chr2:85788382	GGCX	0.65	5.14	0.47	1.47e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs17407555	0.606	rs3775945	chr4:10011996	A/T	cg00071950	chr4:10020882	SLC2A9	-0.78	-6.15	-0.53	1.84e-8	Schizophrenia (age at onset);
THYM	cis	rs662064	0.852	rs2056417	chr1:10581658	G/A	cg20482658	chr1:10539492	PEX14	0.49	6.04	0.53	2.95e-8	Asthma;
THYM	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11890956	chr21:40555474	PSMG1	-0.65	-6.06	-0.53	2.76e-8	Menarche (age at onset);
THYM	cis	rs6918586	0.636	rs198816	chr6:26127184	C/T	cg03264133	chr6:25882463	NA	0.65	5.06	0.46	2e-6	Schizophrenia;
THYM	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.02	-9.68	-0.7	8.14e-16	Primary sclerosing cholangitis;
THYM	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg09549813	chr16:4587862	C16orf5	-0.58	-6.74	-0.57	1.2e-9	Schizophrenia;
THYM	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28595532	1.000	rs114682099	chr4:119702004	C/T	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg02640540	chr1:67518911	SLC35D1	0.62	4.53	0.42	1.72e-5	Lymphocyte percentage of white cells;
THYM	cis	rs476633	0.595	rs11857726	chr15:41530359	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.7	-5.81	-0.51	8.44e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs1270639	0.778	rs1796271	chr7:157438129	T/G	cg13357408	chr7:157437802	PTPRN2	0.46	4.92	0.45	3.65e-6	Colorectal cancer;
THYM	cis	rs714031	0.934	rs2235341	chr22:40068679	T/G	cg21377881	chr22:40064566	CACNA1I	-0.59	-5.3	-0.48	7.51e-7	Schizophrenia;
THYM	cis	rs3741151	0.686	rs7114009	chr11:73115314	C/T	cg12959048	chr11:73096162	RELT	0.45	4.84	0.44	5.1e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg19508488	chr2:152266495	RIF1	0.79	6.2	0.54	1.45e-8	Lung cancer;
THYM	cis	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg21110456	chr7:2059412	MAD1L1	-0.43	-4.51	-0.42	1.89e-5	Neuroticism;
THYM	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg27490568	chr2:178487706	NA	-0.63	-4.99	-0.46	2.72e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.68	-0.67	1.07e-13	Mean corpuscular volume;
THYM	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs12282928	0.885	rs10838874	chr11:48347140	T/C	cg22827986	chr11:48284249	OR4X1	0.53	5.59	0.5	2.21e-7	Migraine - clinic-based;
THYM	cis	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.64	-0.43	1.14e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9393777	0.588	rs6456727	chr6:26471155	T/C	cg12826209	chr6:26865740	GUSBL1	0.96	6.45	0.55	4.59e-9	Intelligence (multi-trait analysis);
THYM	cis	rs17125944	0.686	rs3818453	chr14:53326454	C/A	cg00686598	chr14:53173677	PSMC6	-1.07	-5.06	-0.46	2.07e-6	Alzheimer's disease (late onset);
THYM	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg15556689	chr8:8085844	FLJ10661	0.75	6.45	0.55	4.62e-9	Mood instability;
THYM	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7909791	0.743	rs11191821	chr10:105597446	G/A	cg24587175	chr10:105670608	OBFC1	0.63	5.68	0.5	1.45e-7	White matter hyperintensity burden;
THYM	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg03605463	chr16:89740564	NA	0.88	6.97	0.58	4.12e-10	Vitiligo;
THYM	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg18758796	chr5:131593413	PDLIM4	0.49	4.47	0.42	2.17e-5	Breast cancer;Mosquito bite size;
THYM	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.72	-4.65	-0.43	1.06e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	5.08	0.46	1.9e-6	Diabetic retinopathy;
THYM	cis	rs208520	0.837	rs208488	chr6:66926902	C/T	cg07460842	chr6:66804631	NA	-0.86	-5.5	-0.49	3.15e-7	Exhaled nitric oxide output;
THYM	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg04518342	chr5:131593106	PDLIM4	0.52	6.04	0.53	2.96e-8	Acylcarnitine levels;
THYM	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg07424592	chr7:64974309	NA	1.12	5.24	0.47	9.64e-7	Diabetic kidney disease;
THYM	cis	rs7246657	0.943	rs2126977	chr19:37995747	C/G	cg22634378	chr19:37742834	NA	-0.56	-4.61	-0.43	1.26e-5	Coronary artery calcification;
THYM	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg12408189	chr10:30722286	MAP3K8	0.61	5.54	0.49	2.69e-7	Inflammatory bowel disease;
THYM	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg12419862	chr22:24373484	LOC391322	-0.74	-7.06	-0.59	2.68e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7757969	1.000	rs9487722	chr6:112121766	C/T	cg08601457	chr6:112115117	FYN	0.42	4.88	0.45	4.22e-6	Schizophrenia;
THYM	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.58	4.95	0.45	3.25e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7100689	0.753	rs1572816	chr10:82137600	A/G	cg01528321	chr10:82214614	TSPAN14	0.97	7.37	0.6	6.38e-11	Post bronchodilator FEV1;
THYM	cis	rs1915146	0.967	rs57592469	chr10:126850489	A/G	cg05090351	chr10:126851162	NA	0.75	8.83	0.67	5.13e-14	Menarche (age at onset);
THYM	cis	rs7107174	1.000	rs4944198	chr11:78032605	T/A	cg19901956	chr11:77921274	USP35	-0.68	-5.58	-0.5	2.26e-7	Testicular germ cell tumor;
THYM	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg03806693	chr22:41940476	POLR3H	-0.9	-8.21	-0.64	1.08e-12	Vitiligo;
THYM	cis	rs42648	0.869	rs1015403	chr7:89913702	A/G	cg25739043	chr7:89950458	NA	-0.53	-4.53	-0.42	1.72e-5	Homocysteine levels;
THYM	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg24450063	chr1:156163899	SLC25A44	0.77	5.94	0.52	4.63e-8	Testicular germ cell tumor;
THYM	cis	rs4654899	0.865	rs12119348	chr1:21484633	C/T	cg01072550	chr1:21505969	NA	-0.74	-6.68	-0.57	1.63e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03517284	chr6:25882590	NA	0.89	7.36	0.6	6.58e-11	Intelligence (multi-trait analysis);
THYM	cis	rs55728055	0.661	rs16989635	chr22:31847912	A/C	cg01338084	chr22:32026380	PISD	1.18	4.49	0.42	2e-5	Age-related hearing impairment;
THYM	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19346786	chr7:2764209	NA	-0.75	-6.49	-0.55	3.94e-9	Height;
THYM	cis	rs7845219	0.539	rs10441538	chr8:95868608	G/A	cg16049864	chr8:95962084	TP53INP1	-0.64	-5.44	-0.49	4.13e-7	Type 2 diabetes;
THYM	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg14517863	chr17:44321492	NA	-0.44	-5.0	-0.46	2.59e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg18758796	chr5:131593413	PDLIM4	0.61	6.16	0.53	1.77e-8	Breast cancer;
THYM	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg06636001	chr8:8085503	FLJ10661	0.7	5.85	0.51	6.81e-8	Neuroticism;
THYM	cis	rs3096299	0.702	rs2086824	chr16:89471246	G/T	cg02627286	chr16:89590583	SPG7	-0.51	-4.74	-0.44	7.41e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg17063962	chr7:91808500	NA	1.15	12.7	0.79	3.49e-22	Breast cancer;
THYM	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg17063962	chr7:91808500	NA	-1.12	-12.68	-0.79	3.85e-22	Breast cancer;
THYM	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11890956	chr21:40555474	PSMG1	-1.15	-12.55	-0.79	6.97e-22	Cognitive function;
THYM	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.25	-5.11	-0.46	1.64e-6	Obesity-related traits;
THYM	cis	rs7582403	0.737	rs6430287	chr2:148849418	G/A	cg23727674	chr2:148602993	ACVR2A	-0.58	-4.79	-0.44	6.24e-6	Neuroticism;
THYM	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg27631724	chr1:11040367	C1orf127	0.68	6.42	0.55	5.25e-9	Ewing sarcoma;
THYM	cis	rs6684428	0.706	rs12058087	chr1:56319257	C/G	cg11651538	chr1:56320950	NA	-0.65	-5.23	-0.47	9.97e-7	Airflow obstruction;
THYM	cis	rs4242434	0.819	rs55776566	chr8:22469492	T/C	cg21658235	chr8:22456391	C8orf58	0.44	4.56	0.42	1.54e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9790314	1.000	rs7638668	chr3:161047283	G/A	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs7149242	1.000	rs11620937	chr14:101151012	C/G	cg18089426	chr14:101175970	NA	0.64	6.35	0.55	7.34e-9	Platelet count;
THYM	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.03	0.46	2.34e-6	Prudent dietary pattern;
THYM	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg12292205	chr6:26970375	C6orf41	0.53	4.49	0.42	1.99e-5	Schizophrenia;
THYM	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg22852734	chr6:133119734	C6orf192	1.27	8.53	0.66	2.32e-13	Type 2 diabetes nephropathy;
THYM	cis	rs7719624	0.756	rs6880837	chr5:135396669	A/G	cg15329133	chr5:135467951	SMAD5;SMAD5OS	0.54	4.82	0.44	5.49e-6	Response to cytidine analogues (gemcitabine);
THYM	trans	rs629535	0.862	rs655028	chr8:70049047	T/C	cg21567404	chr3:27674614	NA	1.12	10.86	0.74	2.44e-18	Dupuytren's disease;
THYM	cis	rs800586	0.871	rs800550	chr8:116819629	T/A	cg04656070	chr8:116661063	TRPS1	0.48	4.98	0.45	2.88e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7107174	0.892	rs2512529	chr11:77977351	C/T	cg19901956	chr11:77921274	USP35	-0.68	-4.93	-0.45	3.5e-6	Testicular germ cell tumor;
THYM	cis	rs9399401	0.626	rs4304190	chr6:142778912	A/G	cg04461802	chr6:142623433	GPR126	0.77	7.26	0.6	1.08e-10	Chronic obstructive pulmonary disease;
THYM	trans	rs877282	0.731	rs67369760	chr10:791583	C/T	cg22713356	chr15:30763199	NA	1.2	9.31	0.69	4.88e-15	Uric acid levels;
THYM	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg11062466	chr8:58055876	NA	0.92	4.62	0.43	1.19e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	4.79	0.44	6.04e-6	Menarche (age at onset);
THYM	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg10802521	chr3:52805072	NEK4	-0.72	-6.07	-0.53	2.55e-8	Bipolar disorder;
THYM	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg06112835	chr11:68658793	MRPL21	-0.44	-6.28	-0.54	1.03e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2229238	0.911	rs59838898	chr1:154466301	C/T	cg21262032	chr1:154437693	IL6R	-0.55	-4.81	-0.44	5.6e-6	Coronary heart disease;
THYM	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg15445000	chr17:37608096	MED1	0.44	5.07	0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg12963246	chr6:28129442	ZNF389	0.53	4.71	0.44	8.3e-6	Parkinson's disease;
THYM	cis	rs7247513	0.964	rs4804202	chr19:12718619	T/C	cg01871581	chr19:12707946	ZNF490	-0.85	-9.22	-0.69	7.86e-15	Bipolar disorder;
THYM	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22509189	chr2:225307070	NA	0.85	7.11	0.59	2.13e-10	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg22920501	chr2:26401640	FAM59B	-1.04	-9.12	-0.68	1.26e-14	Gut microbiome composition (summer);
THYM	cis	rs7704138	0.553	rs3857289	chr5:55017909	G/A	cg18456523	chr5:54516805	NA	-0.58	-4.59	-0.43	1.34e-5	Height;
THYM	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg15247329	chr7:2764246	NA	-0.68	-5.73	-0.51	1.2e-7	Height;
THYM	cis	rs4792901	0.959	rs28659819	chr17:41627530	G/A	cg21940313	chr17:41620911	ETV4	-0.52	-5.51	-0.49	3.08e-7	Dupuytren's disease;
THYM	cis	rs7616559	0.530	rs12638952	chr3:156722071	C/T	cg15697575	chr3:156784781	NA	0.35	5.19	0.47	1.21e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs8067545	0.611	rs2703775	chr17:20134466	A/G	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	cis	rs4863692	0.524	rs795994	chr4:140737649	A/T	cg15010390	chr4:140216957	NDUFC1	-0.73	-6.23	-0.54	1.27e-8	Educational attainment (years of education);
THYM	cis	rs7226229	1.000	rs1038108	chr17:20921548	C/A	cg21263980	chr17:20946333	USP22	0.65	4.88	0.45	4.33e-6	Blood trace element (Se levels);
THYM	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg02725872	chr8:58115012	NA	-0.89	-5.38	-0.48	5.33e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg23682913	chr1:2080710	PRKCZ	0.57	4.91	0.45	3.79e-6	Height;
THYM	cis	rs6060717	0.553	rs2590958	chr20:34616590	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-5.41	-0.49	4.66e-7	Hip circumference adjusted for BMI;
THYM	cis	rs977987	0.843	rs7499872	chr16:75426529	G/A	cg03315344	chr16:75512273	CHST6	0.73	6.28	0.54	1.02e-8	Dupuytren's disease;
THYM	cis	rs36051895	0.632	rs12115301	chr9:5180548	A/G	cg02405213	chr9:5042618	JAK2	1.0	10.56	0.73	1.05e-17	Pediatric autoimmune diseases;
THYM	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg00645579	chr11:617140	IRF7;MUPCDH	-0.44	-4.89	-0.45	4.07e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg18402987	chr7:1209562	NA	0.64	4.87	0.45	4.51e-6	Longevity;Endometriosis;
THYM	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg17644776	chr2:200775616	C2orf69	-0.8	-4.82	-0.44	5.52e-6	Schizophrenia;
THYM	cis	rs16917546	0.967	rs10995239	chr10:64388365	A/G	cg03961010	chr10:64397487	ZNF365	-0.8	-6.76	-0.57	1.13e-9	Basal cell carcinoma;
THYM	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08109568	chr15:31115862	NA	-0.59	-5.74	-0.51	1.15e-7	Huntington's disease progression;
THYM	cis	rs6500395	1.000	rs1872654	chr16:48671050	C/T	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg22907277	chr7:1156413	C7orf50	0.86	8.71	0.67	9.19e-14	Longevity;Endometriosis;
THYM	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg20283391	chr11:68216788	NA	0.59	4.47	0.42	2.17e-5	Total body bone mineral density;
THYM	cis	rs9825379	0.786	rs59075313	chr3:141152220	C/G	cg13411656	chr3:141121016	ZBTB38	-0.49	-4.61	-0.43	1.24e-5	Height;
THYM	cis	rs7255436	0.965	rs7249624	chr19:8446135	G/A	cg10174797	chr19:8464628	RAB11B	0.42	4.97	0.45	2.99e-6	HDL cholesterol;
THYM	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11096990	0.634	rs6854358	chr4:39283112	C/G	cg24403649	chr4:39172243	NA	-0.64	-5.54	-0.49	2.67e-7	Cognitive function;
THYM	cis	rs17818399	0.547	rs13020299	chr2:46758717	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.69	4.76	0.44	6.92e-6	Height;
THYM	cis	rs2404602	0.647	rs12440511	chr15:76993135	A/G	cg23625390	chr15:77176239	SCAPER	-0.83	-5.7	-0.5	1.36e-7	Blood metabolite levels;
THYM	cis	rs2115630	0.936	rs6496318	chr15:85215229	C/T	cg11189052	chr15:85197271	WDR73	-0.62	-4.65	-0.43	1.06e-5	P wave terminal force;
THYM	cis	rs11711311	0.955	rs9830102	chr3:113408302	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.57	-4.78	-0.44	6.38e-6	IgG glycosylation;
THYM	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg00898013	chr13:113819073	PROZ	0.9	8.81	0.67	5.86e-14	Platelet distribution width;
THYM	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg14018140	chr10:458528	DIP2C	-0.61	-7.21	-0.59	1.34e-10	Psychosis in Alzheimer's disease;
THYM	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg01386294	chr6:25732093	NA	0.88	4.7	0.43	8.83e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6138458	0.626	rs6132789	chr20:25012809	C/T	cg26195577	chr20:24973756	C20orf3	-0.75	-6.25	-0.54	1.17e-8	Blood protein levels;
THYM	cis	rs7172809	0.587	rs28375490	chr15:77849019	C/G	cg22256960	chr15:77711686	NA	-0.78	-5.65	-0.5	1.69e-7	Glucose homeostasis traits;
THYM	cis	rs7834588	0.544	rs979843	chr8:63807649	T/G	cg25248160	chr8:63776642	NKAIN3	-0.62	-5.18	-0.47	1.24e-6	Response to Vitamin E supplementation;
THYM	cis	rs2072499	0.865	rs2758608	chr1:156202860	A/T	cg24450063	chr1:156163899	SLC25A44	1.02	11.45	0.76	1.41e-19	Testicular germ cell tumor;
THYM	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg01577475	chr2:114033581	PAX8;LOC440839	-0.49	-4.59	-0.43	1.34e-5	Lymphocyte counts;
THYM	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg17063962	chr7:91808500	NA	1.13	11.75	0.77	3.19e-20	Breast cancer;
THYM	cis	rs4481887	1.000	rs4244178	chr1:248468441	A/G	cg13385794	chr1:248469461	NA	0.65	4.66	0.43	1.04e-5	Common traits (Other);
THYM	cis	rs16863765	0.534	rs75229528	chr3:151615489	C/T	cg05086811	chr3:152552603	P2RY1	0.92	4.77	0.44	6.66e-6	Male-pattern baldness;
THYM	cis	rs9314614	0.902	rs2738062	chr8:6708249	G/T	cg27319216	chr8:6693540	XKR5	0.61	6.29	0.54	9.54e-9	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs1368882	1.000	rs1368882	chr1:55107019	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.63	-4.9	-0.45	4e-6	Non-substance related behavioral disinhibition;
THYM	cis	rs524023	1.000	rs524023	chr11:64358265	C/T	cg19131476	chr11:64387923	NRXN2	0.35	4.84	0.44	4.98e-6	Urate levels in obese individuals;
THYM	cis	rs8078723	0.714	rs9915252	chr17:38145088	C/G	cg17467752	chr17:38218738	THRA	-0.8	-6.7	-0.57	1.46e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs12478296	0.786	rs13409307	chr2:242995499	G/C	cg06360820	chr2:242988706	NA	-1.01	-7.18	-0.59	1.55e-10	Obesity-related traits;
THYM	cis	rs7731657	0.567	rs10074477	chr5:130315505	T/C	cg08523029	chr5:130500466	HINT1	-0.82	-6.07	-0.53	2.66e-8	Fasting plasma glucose;
THYM	cis	rs7561149	0.966	rs12471428	chr2:179687519	A/G	cg12089249	chr2:179345200	MIR548N;PLEKHA3	-0.63	-4.63	-0.43	1.17e-5	QT interval;
THYM	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.3	-0.65	6.86e-13	Mean corpuscular volume;
THYM	cis	rs1335645	0.570	rs12406191	chr1:111639491	C/G	cg00321911	chr1:111669324	DRAM2	-1.2	-6.73	-0.57	1.3e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1971762	0.563	rs11170645	chr12:54079080	G/T	cg16917193	chr12:54089295	NA	0.9	9.22	0.69	7.82e-15	Height;
THYM	cis	rs17598306	0.873	rs2016644	chr7:96596049	C/T	cg13449377	chr7:96631089	DLX6AS	0.76	4.78	0.44	6.38e-6	Radiation response;
THYM	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-4.49	-0.42	2.02e-5	Recombination measurement;
THYM	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs58530613	1.000	rs79356205	chr4:124730487	A/T	cg11268546	chr4:124983615	NA	0.7	4.45	0.42	2.36e-5	Platelet count;
THYM	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg00071950	chr4:10020882	SLC2A9	0.88	9.22	0.69	7.56e-15	Bone mineral density;
THYM	cis	rs796364	0.625	rs13035260	chr2:201132377	A/G	cg17644776	chr2:200775616	C2orf69	-0.75	-4.56	-0.42	1.52e-5	Schizophrenia;
THYM	cis	rs1642645	0.831	rs12042133	chr1:42499365	A/C	cg06092502	chr1:42611687	NA	-0.61	-4.81	-0.44	5.61e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs1568889	0.838	rs10767708	chr11:28294847	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.64	-4.68	-0.43	9.69e-6	Colorectal cancer;
THYM	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg02018176	chr4:1364513	KIAA1530	0.55	4.69	0.43	9.28e-6	Obesity-related traits;
THYM	cis	rs2997447	0.669	rs61776624	chr1:26474580	A/C	cg03844060	chr1:26490628	NA	0.68	4.96	0.45	3.12e-6	QRS complex (12-leadsum);
THYM	cis	rs3804749	0.966	rs4677875	chr3:122841062	G/A	cg10259872	chr3:122802215	PDIA5	0.49	5.45	0.49	3.99e-7	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg20283391	chr11:68216788	NA	-0.59	-4.67	-0.43	9.91e-6	Total body bone mineral density;
THYM	trans	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg25214090	chr10:38739885	LOC399744	0.93	7.92	0.63	4.43e-12	Corneal astigmatism;
THYM	cis	rs17708984	0.585	rs7247875	chr19:16192625	A/G	cg13618979	chr19:16186840	TPM4	-0.36	-4.78	-0.44	6.3e-6	Platelet count;Platelet distribution width;
THYM	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg02228675	chr17:40259724	DHX58	-0.66	-5.49	-0.49	3.28e-7	Fibrinogen levels;
THYM	cis	rs34375054	0.624	rs7295689	chr12:125680922	T/G	cg25124228	chr12:125621409	AACS	-0.65	-4.69	-0.43	9.18e-6	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs28595532	0.841	rs114465037	chr4:119778165	A/G	cg11846333	chr4:119757529	SEC24D	1.45	5.08	0.46	1.92e-6	Cannabis dependence symptom count;
THYM	cis	rs11031096	0.678	rs17284356	chr11:4189232	G/C	cg22027985	chr11:4115532	RRM1	-0.56	-5.25	-0.47	9.12e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs268134	0.530	rs35315862	chr2:65579047	T/C	cg03233656	chr2:65214625	SLC1A4	0.63	4.55	0.42	1.61e-5	Educational attainment (years of education);Systemic lupus erythematosus;
THYM	cis	rs2229238	0.911	rs4633282	chr1:154507899	T/C	cg21262032	chr1:154437693	IL6R	-0.63	-5.65	-0.5	1.68e-7	Coronary heart disease;
THYM	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg10295955	chr4:187884368	NA	1.19	17.25	0.87	5.06e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2219968	0.962	rs9643733	chr8:78950551	G/T	cg00738934	chr8:78996279	NA	0.8	8.43	0.65	3.79e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg06784218	chr1:46089804	CCDC17	0.31	4.57	0.42	1.46e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs2811415	0.597	rs13063604	chr3:127804730	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs7078219	0.505	rs6584281	chr10:101286480	A/G	cg17888390	chr10:101282816	NA	-0.44	-4.51	-0.42	1.83e-5	Dental caries;
THYM	cis	rs6500395	0.890	rs9936271	chr16:48601291	A/G	cg04672837	chr16:48644449	N4BP1	0.47	4.56	0.42	1.54e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg00645579	chr11:617140	IRF7;MUPCDH	-0.52	-6.46	-0.55	4.44e-9	Systemic lupus erythematosus;
THYM	cis	rs7119	0.717	rs12901471	chr15:77818992	A/G	cg10437265	chr15:77819839	NA	0.77	7.68	0.62	1.42e-11	Type 2 diabetes;
THYM	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg02493740	chr2:85810744	VAMP5	0.61	4.69	0.43	9.22e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs4654899	0.758	rs2874367	chr1:21324491	A/C	cg01072550	chr1:21505969	NA	0.8	7.91	0.63	4.63e-12	Superior frontal gyrus grey matter volume;
THYM	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg21854759	chr1:92012499	NA	-0.7	-5.67	-0.5	1.5e-7	Breast cancer;
THYM	cis	rs4523957	0.620	rs8064309	chr17:2059961	T/C	cg16513277	chr17:2031491	SMG6	-0.94	-8.42	-0.65	3.95e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs924712	0.816	rs6918402	chr6:54732919	G/A	cg19716238	chr6:54711378	FAM83B	-0.46	-4.63	-0.43	1.15e-5	Breast cancer;
THYM	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg15448220	chr1:150897856	SETDB1	0.9	7.66	0.62	1.56e-11	Melanoma;
THYM	cis	rs8044995	0.563	rs57434514	chr16:68402649	G/A	cg09835421	chr16:68378352	PRMT7	-0.72	-4.56	-0.42	1.5e-5	Schizophrenia;
THYM	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg00814883	chr7:100076585	TSC22D4	-1.03	-7.03	-0.58	3.21e-10	Platelet count;
THYM	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg24874828	chr4:187887005	NA	-0.76	-8.24	-0.65	9.29e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg20295408	chr7:1910781	MAD1L1	-0.58	-4.63	-0.43	1.14e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	4.66	0.43	1.02e-5	Schizophrenia;
THYM	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs9814567	0.806	rs12637301	chr3:134317966	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.09e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg17845761	chr1:175162550	KIAA0040	-0.36	-4.57	-0.42	1.45e-5	Alcohol dependence;
THYM	cis	rs9287719	0.674	rs11691060	chr2:10827061	T/C	cg02196655	chr2:10830764	NOL10	0.49	4.99	0.46	2.77e-6	Prostate cancer;
THYM	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg17889831	chr1:205181581	DSTYK	-0.4	-4.49	-0.42	2.01e-5	Mean corpuscular volume;Mean platelet volume;
THYM	cis	rs10089	0.953	rs10045113	chr5:127386631	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.95	6.46	0.55	4.39e-9	Ileal carcinoids;
THYM	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg08017756	chr2:100939284	LONRF2	-0.74	-7.3	-0.6	8.73e-11	Intelligence (multi-trait analysis);
THYM	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg24324837	chr19:49891574	CCDC155	0.52	4.75	0.44	7.07e-6	Multiple sclerosis;
THYM	cis	rs7872515	0.536	rs7869851	chr9:94759072	T/C	cg13922115	chr9:95397568	IPPK	0.88	4.51	0.42	1.85e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.1	-0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg18681998	chr4:17616180	MED28	0.99	10.09	0.72	1.08e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	5.52	0.49	2.88e-7	Hip circumference adjusted for BMI;
THYM	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs9875589	0.509	rs9824910	chr3:14040136	C/T	cg03204825	chr3:13978759	TPRXL	-0.51	-4.46	-0.42	2.26e-5	Ovarian reserve;
THYM	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg00786635	chr1:25594202	NA	-0.92	-7.2	-0.59	1.38e-10	Erythrocyte sedimentation rate;
THYM	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs6700896	0.897	rs1938494	chr1:66117691	G/T	cg04111102	chr1:66153794	NA	0.55	5.22	0.47	1.06e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg25918947	chr17:41365094	TMEM106A	-0.59	-4.92	-0.45	3.66e-6	Menopause (age at onset);
THYM	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg02734326	chr4:10020555	SLC2A9	-0.64	-5.9	-0.52	5.59e-8	Bone mineral density;
THYM	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg08048268	chr3:133502702	NA	0.63	5.55	0.5	2.53e-7	Iron status biomarkers;
THYM	cis	rs7084402	1.000	rs1427201	chr10:60269755	G/T	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg09555818	chr19:45449301	APOC2	0.67	7.41	0.61	5.05e-11	Blood protein levels;
THYM	cis	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg21775007	chr8:11205619	TDH	0.74	6.67	0.57	1.65e-9	Retinal vascular caliber;
THYM	cis	rs2692947	0.526	rs58719199	chr2:96578247	G/A	cg22654517	chr2:96458247	NA	0.74	5.38	0.48	5.33e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs1729951	0.575	rs361243	chr3:136697786	C/T	cg12473912	chr3:136751656	NA	0.63	5.12	0.47	1.57e-6	Neuroticism;
THYM	cis	rs11792861	0.566	rs1003346	chr9:111815340	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	5.42	0.49	4.57e-7	Menarche (age at onset);
THYM	cis	rs4730276	0.674	rs34822274	chr7:107534132	T/C	cg23293999	chr7:106826042	HBP1	-0.58	-4.58	-0.43	1.42e-5	Ulcerative colitis;
THYM	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg18876405	chr7:65276391	NA	0.54	4.76	0.44	6.86e-6	Calcium levels;
THYM	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg21775007	chr8:11205619	TDH	-0.7	-5.38	-0.48	5.38e-7	Retinal vascular caliber;
THYM	cis	rs4638749	1.000	rs1466212	chr2:108856532	G/A	cg25838818	chr2:108905173	SULT1C2	-0.6	-6.13	-0.53	1.97e-8	Blood pressure;
THYM	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.89	5.66	0.5	1.63e-7	Yeast infection;
THYM	cis	rs13064411	0.696	rs7624994	chr3:113228009	T/C	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs62066768	0.706	rs16964368	chr17:26825506	G/T	cg13568106	chr17:26835115	NA	-0.36	-4.82	-0.44	5.42e-6	Tonsillectomy;
THYM	cis	rs10979	1.000	rs9376762	chr6:143887248	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg16006841	chr5:176797999	RGS14	-0.47	-5.67	-0.5	1.51e-7	Hemoglobin concentration;Hematocrit;
THYM	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.44	-0.49	4.16e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs931127	0.502	rs1466462	chr11:65419364	C/G	cg17480646	chr11:65405466	SIPA1	0.81	7.36	0.6	6.65e-11	Systemic lupus erythematosus;
THYM	cis	rs763014	0.898	rs4984892	chr16:622325	A/G	cg00908189	chr16:619842	PIGQ	1.03	9.46	0.7	2.34e-15	Height;
THYM	cis	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.61	-6.51	-0.56	3.61e-9	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg06238570	chr21:40685208	BRWD1	0.68	5.75	0.51	1.06e-7	Menarche (age at onset);
THYM	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2898681	0.581	rs10003908	chr4:53681089	T/C	cg00338735	chr4:53728038	RASL11B	0.6	5.56	0.5	2.5e-7	Optic nerve measurement (cup area);
THYM	cis	rs7084402	0.967	rs1621811	chr10:60320664	T/C	cg07615347	chr10:60278583	BICC1	0.56	5.15	0.47	1.4e-6	Refractive error;
THYM	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg03467027	chr4:99064603	C4orf37	-0.59	-4.49	-0.42	1.97e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs995000	0.965	rs1168046	chr1:62983693	A/C	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs1401999	0.864	rs4148563	chr3:183725999	T/C	cg20387954	chr3:183756860	HTR3D	0.56	4.63	0.43	1.15e-5	Anterior chamber depth;
THYM	cis	rs2354432	0.607	rs7516430	chr1:146767062	A/G	cg25205988	chr1:146714368	CHD1L	-1.1	-6.28	-0.54	1e-8	Mitochondrial DNA levels;
THYM	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg26022315	chr17:47021804	SNF8	0.51	4.87	0.45	4.44e-6	Type 2 diabetes;
THYM	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs2933343	0.621	rs789241	chr3:128585752	G/A	cg11901034	chr3:128598214	ACAD9	-0.7	-5.68	-0.5	1.47e-7	IgG glycosylation;
THYM	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg18402987	chr7:1209562	NA	0.72	5.38	0.48	5.23e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.18	8.91	0.67	3.51e-14	Cognitive test performance;
THYM	cis	rs72949976	0.864	rs13389834	chr2:214025112	G/A	cg08319019	chr2:214017104	IKZF2	-0.71	-5.54	-0.49	2.66e-7	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs4148689	0.951	rs1820871	chr7:117189272	G/A	cg17204129	chr7:117119601	CFTR	-0.59	-4.6	-0.43	1.32e-5	Gout;
THYM	cis	rs3862030	0.694	rs41306870	chr10:104229785	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.71	-5.96	-0.52	4.3e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs1018697	0.518	rs2790914	chr10:104568018	C/T	cg04362960	chr10:104952993	NT5C2	-0.74	-5.13	-0.47	1.52e-6	Colorectal adenoma (advanced);
THYM	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15378786	chr11:17036137	PLEKHA7	1.04	10.1	0.72	1.02e-16	Coronary artery disease;
THYM	cis	rs1329573	1.000	rs7047835	chr9:36999901	T/C	cg14294708	chr9:37120828	ZCCHC7	-1.09	-4.72	-0.44	8.22e-6	Intelligence;
THYM	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg09877947	chr5:131593287	PDLIM4	0.54	4.59	0.43	1.36e-5	Breast cancer;Mosquito bite size;
THYM	cis	rs854765	0.718	rs12943500	chr17:17790588	C/T	cg16928487	chr17:17741425	SREBF1	0.62	5.76	0.51	1.04e-7	Total body bone mineral density;
THYM	trans	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg06636001	chr8:8085503	FLJ10661	-0.77	-6.85	-0.57	7.3e-10	Neuroticism;
THYM	cis	rs7107174	1.000	rs2510054	chr11:77959659	A/G	cg19901956	chr11:77921274	USP35	0.77	5.86	0.52	6.59e-8	Testicular germ cell tumor;
THYM	cis	rs3892630	0.818	rs80137870	chr19:33182750	C/T	cg22980127	chr19:33182716	NUDT19	1.12	8.95	0.68	2.85e-14	Red blood cell traits;
THYM	cis	rs2130392	1.000	rs11132254	chr4:185611592	G/T	cg04058563	chr4:185651563	MLF1IP	0.59	5.73	0.51	1.16e-7	Kawasaki disease;
THYM	cis	rs9560113	1.000	rs60374273	chr13:112179206	A/T	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs807029	0.577	rs3740489	chr10:102754238	A/G	cg14905631	chr10:102746534	C10orf2;MRPL43	0.36	4.93	0.45	3.44e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9633835	0.610	rs11826177	chr11:13349477	T/C	cg13286116	chr11:13302098	ARNTL	-0.62	-6.47	-0.55	4.21e-9	Body mass index;
THYM	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg21773646	chr17:80085082	CCDC57	0.36	4.98	0.45	2.87e-6	Life satisfaction;
THYM	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4455778	0.692	rs2191297	chr7:49010701	A/G	cg26309511	chr7:48887640	NA	-0.52	-4.71	-0.43	8.57e-6	Lung cancer in never smokers;
THYM	cis	rs6032067	0.714	rs35770435	chr20:43788804	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.76	-8.38	-0.65	4.67e-13	Blood protein levels;
THYM	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg07936489	chr17:37558343	FBXL20	-0.64	-4.52	-0.42	1.79e-5	Asthma;
THYM	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	4.86	0.45	4.63e-6	Hip circumference adjusted for BMI;
THYM	cis	rs2976388	1.000	rs1045574	chr8:143763958	C/T	cg06565975	chr8:143823917	SLURP1	-0.45	-5.23	-0.47	9.95e-7	Urinary tract infection frequency;
THYM	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg21361702	chr7:150065534	REPIN1	0.69	5.83	0.51	7.62e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs11118844	0.843	rs4589119	chr1:221915967	G/A	cg04222084	chr1:221915650	DUSP10	-1.03	-5.43	-0.49	4.35e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs9470366	0.545	rs2395655	chr6:36645696	C/T	cg24425727	chr6:36645648	CDKN1A	0.87	9.59	0.7	1.24e-15	QRS duration;
THYM	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg11812906	chr14:75593930	NEK9	-0.8	-7.19	-0.59	1.48e-10	Height;
THYM	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg15110403	chr19:17392923	ANKLE1	-0.56	-4.67	-0.43	9.97e-6	Systemic lupus erythematosus;
THYM	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs61931739	0.513	rs7956626	chr12:33901640	C/T	cg10856724	chr12:34555212	NA	-0.64	-5.83	-0.51	7.46e-8	Morning vs. evening chronotype;
THYM	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.57	-5.57	-0.5	2.41e-7	Lymphocyte counts;
THYM	cis	rs6840360	1.000	rs28710456	chr4:152667171	T/C	cg22705602	chr4:152727874	NA	-0.58	-6.26	-0.54	1.1e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg07169764	chr2:136633963	MCM6	-0.71	-6.29	-0.54	9.76e-9	Mosquito bite size;
THYM	cis	rs2455799	0.613	rs12491914	chr3:15808672	A/C	cg16303742	chr3:15540471	COLQ	-0.54	-5.78	-0.51	9.67e-8	Mean platelet volume;
THYM	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg13902645	chr11:5959945	NA	-0.53	-4.66	-0.43	1.03e-5	DNA methylation (variation);
THYM	cis	rs7578361	0.879	rs12463472	chr2:150445645	T/G	cg17961725	chr2:150454027	NA	0.75	6.45	0.55	4.58e-9	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs7119	0.717	rs8033654	chr15:77825250	T/C	cg27398640	chr15:77910606	LINGO1	-0.55	-5.53	-0.49	2.82e-7	Type 2 diabetes;
THYM	cis	rs7607369	0.714	rs1344643	chr2:219584975	G/C	cg02176678	chr2:219576539	TTLL4	-0.63	-6.02	-0.53	3.22e-8	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg22117172	chr7:91764530	CYP51A1	-0.39	-4.82	-0.44	5.42e-6	Breast cancer;
THYM	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2455799	0.613	rs1976479	chr3:15729714	C/G	cg16303742	chr3:15540471	COLQ	-0.54	-5.62	-0.5	1.92e-7	Mean platelet volume;
THYM	cis	rs9814567	1.000	rs7619451	chr3:134233238	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-5.19	-0.47	1.19e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22133161	chr19:49891603	CCDC155	0.82	5.5	0.49	3.2e-7	Multiple sclerosis;
THYM	cis	rs11608355	1.000	rs10774690	chr12:109859682	G/A	cg11367159	chr12:110044531	NA	0.66	6.29	0.54	9.83e-9	Neuroticism;
THYM	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	5.88	0.52	6.2e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg02187348	chr16:89574699	SPG7	0.65	4.72	0.44	7.97e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg02317251	chr4:10116515	WDR1	-0.56	-4.95	-0.45	3.23e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg04267008	chr7:1944627	MAD1L1	-0.69	-5.64	-0.5	1.75e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9649213	0.593	rs6465673	chr7:97968887	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.51	4.58	0.43	1.42e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg17863274	chr19:49399704	TULP2	-0.99	-6.13	-0.53	1.98e-8	Red cell distribution width;
THYM	cis	rs7769051	0.522	rs7759524	chr6:133109574	A/G	cg07930552	chr6:133119739	C6orf192	1.21	5.29	0.48	7.84e-7	Type 2 diabetes nephropathy;
THYM	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg05373962	chr22:49881684	NA	-0.6	-5.74	-0.51	1.12e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4766646	0.619	rs7966820	chr12:110302270	A/G	cg10794374	chr12:110278745	NA	0.22	4.69	0.43	9.06e-6	Metabolite levels (MHPG);
THYM	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs919433	0.647	rs1979239	chr2:198498316	T/G	cg00792783	chr2:198669748	PLCL1	0.79	5.13	0.47	1.53e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4746818	0.688	rs951718	chr10:70928044	A/G	cg11621586	chr10:70884670	VPS26A	1.28	11.12	0.75	6.73e-19	Left atrial antero-posterior diameter;
THYM	cis	rs9467160	0.734	rs10946702	chr6:24462672	A/G	cg20631270	chr6:24437470	GPLD1	-0.62	-4.55	-0.42	1.6e-5	Liver enzyme levels;
THYM	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg18681998	chr4:17616180	MED28	-0.81	-7.32	-0.6	8.09e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs747334	0.811	rs7095281	chr10:92711682	G/A	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs36051895	0.632	rs62541959	chr9:5175687	G/C	cg02405213	chr9:5042618	JAK2	-1.02	-10.66	-0.74	6.51e-18	Pediatric autoimmune diseases;
THYM	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg18252515	chr7:66147081	NA	0.72	5.57	0.5	2.31e-7	Aortic root size;
THYM	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg00310523	chr12:86230176	RASSF9	0.53	4.6	0.43	1.32e-5	Major depressive disorder;
THYM	cis	rs4903604	0.513	rs12880891	chr14:78035233	T/C	cg18872420	chr14:78023429	SPTLC2	0.53	4.53	0.42	1.69e-5	Gut microbiome composition (winter);
THYM	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg06481639	chr22:41940642	POLR3H	0.79	5.52	0.49	2.89e-7	Vitiligo;
THYM	cis	rs2282930	0.512	rs2237460	chr7:50729511	A/G	cg08586669	chr7:50727761	GRB10	-0.32	-4.77	-0.44	6.53e-6	Bone mineral density;
THYM	cis	rs2439831	0.867	rs2245715	chr15:43818052	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	6.55	0.56	2.93e-9	Lung cancer in ever smokers;
THYM	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.92	-7.96	-0.63	3.73e-12	Menarche (age at onset);
THYM	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs6586111	1.000	rs4934371	chr10:82372795	A/G	cg03086067	chr10:82368399	SH2D4B	0.51	6.5	0.56	3.64e-9	Capecitabine sensitivity;
THYM	cis	rs10158481	0.727	rs4649071	chr1:25488864	A/G	cg09264742	chr1:25757510	TMEM57	-0.64	-4.58	-0.43	1.41e-5	Urate levels in obese individuals;
THYM	cis	rs17125944	0.615	rs12586707	chr14:53298277	A/G	cg00686598	chr14:53173677	PSMC6	-1.1	-5.35	-0.48	6.08e-7	Alzheimer's disease (late onset);
THYM	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg14829155	chr15:31115871	NA	-0.75	-6.3	-0.54	9.11e-9	Huntington's disease progression;
THYM	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg18538332	chr22:24372958	LOC391322	-1.06	-14.25	-0.83	2.49e-25	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg23649088	chr2:200775458	C2orf69	0.81	6.14	0.53	1.88e-8	Schizophrenia;
THYM	cis	rs7731657	0.510	rs986496	chr5:130282172	C/T	cg08523029	chr5:130500466	HINT1	0.76	5.21	0.47	1.11e-6	Fasting plasma glucose;
THYM	cis	rs12765878	1.000	rs11191846	chr10:105649813	A/G	cg11005552	chr10:105648138	OBFC1	0.87	11.39	0.76	1.84e-19	Coronary artery disease;
THYM	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg18681998	chr4:17616180	MED28	0.81	6.87	0.58	6.5e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg07343612	chr16:622815	PIGQ	-1.08	-11.34	-0.76	2.36e-19	Height;
THYM	cis	rs2070488	1.000	rs17733640	chr3:38446742	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	6.69	0.57	1.55e-9	Electrocardiographic conduction measures;
THYM	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs483180	0.855	rs562038	chr1:120254545	G/C	cg19096424	chr1:120255104	PHGDH	0.89	7.49	0.61	3.55e-11	Macular telangiectasia type 2;
THYM	cis	rs526231	0.543	rs6881225	chr5:102307592	T/C	cg23492399	chr5:102201601	PAM	-0.61	-4.6	-0.43	1.31e-5	Primary biliary cholangitis;
THYM	cis	rs35883536	0.551	rs6666607	chr1:101032368	A/G	cg06223162	chr1:101003688	GPR88	-0.88	-7.55	-0.61	2.59e-11	Monocyte count;
THYM	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg18105134	chr13:113819100	PROZ	-1.07	-8.48	-0.66	2.92e-13	Platelet distribution width;
THYM	cis	rs17321999	1.000	rs13389106	chr2:30480750	T/G	cg05247661	chr2:30472410	LBH	0.62	4.47	0.42	2.16e-5	Systemic lupus erythematosus;
THYM	cis	rs293526	0.917	rs293496	chr6:83628818	A/C	cg23278060	chr6:83777448	DOPEY1	0.61	4.49	0.42	2.02e-5	Crohn's disease;
THYM	cis	rs9563576	0.778	rs2166317	chr13:58668745	G/C	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.6	4.5	0.42	1.9e-5	Body mass index;
THYM	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg22681709	chr2:178499509	PDE11A	-0.59	-5.11	-0.46	1.65e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs67311347	0.544	rs9877105	chr3:40333366	T/C	cg13683864	chr3:40499215	RPL14	-0.76	-7.1	-0.59	2.3e-10	Renal cell carcinoma;
THYM	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	5.75	0.51	1.07e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs2295359	1.000	rs12043240	chr1:67624304	C/T	cg11235152	chr1:67600687	NA	0.56	4.5	0.42	1.94e-5	Psoriasis;
THYM	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg20607798	chr8:58055168	NA	0.88	4.59	0.43	1.33e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg13010199	chr12:38710504	ALG10B	0.64	4.61	0.43	1.25e-5	Morning vs. evening chronotype;
THYM	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg07511668	chr11:68622177	NA	0.45	4.8	0.44	5.87e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg11764359	chr7:65958608	NA	0.67	4.85	0.45	4.84e-6	Aortic root size;
THYM	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.64	-5.64	-0.5	1.71e-7	Chronic sinus infection;
THYM	cis	rs6831352	0.840	rs34634551	chr4:100067362	C/A	cg12011299	chr4:100065546	ADH4	-0.82	-7.62	-0.62	1.91e-11	Alcohol dependence;
THYM	cis	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg11879182	chr18:77439856	CTDP1	0.79	7.8	0.62	7.95e-12	Monocyte count;
THYM	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs2072499	0.898	rs2758609	chr1:156202868	G/A	cg25208724	chr1:156163844	SLC25A44	0.98	9.88	0.71	3.05e-16	Testicular germ cell tumor;
THYM	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg11335335	chr11:637885	DRD4	-0.56	-4.45	-0.42	2.33e-5	Systemic lupus erythematosus;
THYM	cis	rs11850957	0.502	rs17109462	chr14:25466465	A/C	cg26846476	chr14:24838993	NFATC4	-0.88	-4.55	-0.42	1.61e-5	Subcutaneous adipose tissue;
THYM	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg02725872	chr8:58115012	NA	-1.11	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6988636	0.710	rs62521799	chr8:124134987	G/A	cg23067535	chr8:124195133	FAM83A	-1.05	-4.77	-0.44	6.56e-6	Urinary uromodulin levels;
THYM	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg18252515	chr7:66147081	NA	0.66	5.05	0.46	2.16e-6	Aortic root size;
THYM	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg13736514	chr6:26305472	NA	-0.55	-6.74	-0.57	1.2e-9	Educational attainment;
THYM	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg14004847	chr7:1930337	MAD1L1	-0.65	-4.86	-0.45	4.7e-6	Schizophrenia;
THYM	cis	rs6912958	0.500	rs4706287	chr6:87806496	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.65	-5.42	-0.49	4.59e-7	Monocyte percentage of white cells;
THYM	cis	rs6763768	0.606	rs6798771	chr3:53312915	C/T	cg16894138	chr3:53270350	TKT	0.69	5.12	0.47	1.57e-6	Bacterial meningitis;
THYM	cis	rs11677370	0.603	rs1454242	chr2:3848532	G/A	cg17052675	chr2:3827356	NA	-0.71	-6.57	-0.56	2.7e-9	Type 2 diabetes;
THYM	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	cis	rs4638749	0.501	rs9917181	chr2:108747865	C/T	cg25838818	chr2:108905173	SULT1C2	-0.49	-4.88	-0.45	4.3e-6	Blood pressure;
THYM	cis	rs9611519	0.929	rs73174657	chr22:41434158	G/A	cg03806693	chr22:41940476	POLR3H	-0.77	-5.95	-0.52	4.56e-8	Neuroticism;
THYM	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg20387954	chr3:183756860	HTR3D	0.78	7.12	0.59	2.1e-10	Anterior chamber depth;
THYM	cis	rs2072499	0.898	rs2736609	chr1:156202640	C/T	cg24450063	chr1:156163899	SLC25A44	1.02	11.45	0.76	1.41e-19	Testicular germ cell tumor;
THYM	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg14004847	chr7:1930337	MAD1L1	-0.61	-4.78	-0.44	6.39e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg12386194	chr3:101231763	SENP7	0.71	5.39	0.48	5.17e-7	Colorectal cancer;
THYM	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg06808227	chr14:105710500	BRF1	-1.04	-9.01	-0.68	2.19e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs3892630	0.588	rs7245709	chr19:33242755	C/T	cg22928329	chr19:33183273	NUDT19	-0.66	-5.14	-0.47	1.44e-6	Red blood cell traits;
THYM	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg24375607	chr4:120327624	NA	-0.64	-5.08	-0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg12000587	chr17:30186630	C17orf79	-0.4	-4.56	-0.42	1.53e-5	Hip circumference adjusted for BMI;
THYM	cis	rs12049351	0.665	rs7545592	chr1:229592660	A/G	cg11742688	chr1:229674241	ABCB10	-0.55	-4.66	-0.43	1.03e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs4242434	0.854	rs4872007	chr8:22538879	G/A	cg14690197	chr8:22456421	C8orf58	-0.52	-4.59	-0.43	1.34e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6748734	0.625	rs4675871	chr2:241823849	G/A	cg15164180	chr2:241846931	NA	-0.33	-4.54	-0.42	1.65e-5	Urinary metabolites;
THYM	cis	rs3540	0.533	rs4932342	chr15:90982923	C/T	cg22089800	chr15:90895588	ZNF774	0.74	5.72	0.51	1.23e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs8067545	0.611	rs2703775	chr17:20134466	A/G	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg02782426	chr3:40428986	ENTPD3	0.53	4.66	0.43	1.04e-5	Renal cell carcinoma;
THYM	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg07061783	chr6:25882402	NA	-0.84	-7.29	-0.6	9.23e-11	Intelligence (multi-trait analysis);
THYM	cis	rs4266144	0.581	rs1806867	chr3:156828302	C/T	cg16248515	chr3:156840234	NA	-0.53	-4.9	-0.45	3.95e-6	Coronary artery disease;
THYM	cis	rs62344088	0.590	rs62346174	chr5:296308	C/A	cg22857025	chr5:266934	NA	-1.59	-5.22	-0.47	1.06e-6	Asthma (childhood onset);
THYM	cis	rs10992471	0.603	rs755209	chr9:95489671	G/A	cg14631576	chr9:95140430	CENPP	-0.94	-7.64	-0.62	1.75e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.05	6.74	0.57	1.23e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg09462578	chr12:12878428	APOLD1	-0.9	-5.44	-0.49	4.07e-7	Systemic lupus erythematosus;
THYM	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.18	8.91	0.67	3.51e-14	Cognitive test performance;
THYM	cis	rs922692	0.744	rs4886592	chr15:79082547	T/C	cg15571903	chr15:79123663	NA	-0.49	-4.59	-0.43	1.37e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs714031	0.934	rs5750870	chr22:40067640	G/A	cg21377881	chr22:40064566	CACNA1I	-0.6	-5.32	-0.48	6.81e-7	Schizophrenia;
THYM	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg23758822	chr17:41437982	NA	1.16	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg17644776	chr2:200775616	C2orf69	-0.79	-4.49	-0.42	2.01e-5	Schizophrenia;
THYM	cis	rs12594515	1.000	rs6493175	chr15:45989898	T/C	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs3771317	1.000	rs4853515	chr2:191552575	A/C	cg17118478	chr2:191543902	NAB1	-0.62	-4.58	-0.43	1.41e-5	Primary biliary cholangitis;
THYM	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2229238	0.824	rs6669229	chr1:154444591	A/G	cg21262032	chr1:154437693	IL6R	0.59	5.16	0.47	1.37e-6	Coronary heart disease;
THYM	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.22	-0.47	1.07e-6	Mean corpuscular volume;
THYM	cis	rs11671005	0.735	rs11671591	chr19:58918337	A/G	cg18639983	chr19:58920768	ZNF584	-0.59	-5.0	-0.46	2.63e-6	Mean platelet volume;
THYM	cis	rs1018836	0.786	rs10086401	chr8:91572818	C/T	cg16814680	chr8:91681699	NA	-0.9	-7.83	-0.63	6.74e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg26769984	chr7:1090371	C7orf50	0.81	5.42	0.49	4.45e-7	Bronchopulmonary dysplasia;
THYM	cis	rs3845702	0.736	rs6727890	chr2:180832675	T/C	cg01881094	chr2:180872142	CWC22	-0.89	-5.34	-0.48	6.22e-7	Schizophrenia;
THYM	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg09323728	chr8:95962352	TP53INP1	-0.48	-4.93	-0.45	3.53e-6	Type 2 diabetes;
THYM	cis	rs11782517	1.000	rs11782541	chr8:10113556	T/C	cg19847130	chr8:10466454	RP1L1	-0.55	-4.6	-0.43	1.32e-5	Nose size;
THYM	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.2	8.02	0.64	2.74e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs5771225	0.544	rs909688	chr22:50689030	A/G	cg16473166	chr22:50639996	SELO	0.64	4.57	0.42	1.47e-5	Late-onset Alzheimer's disease;
THYM	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg06558623	chr16:89946397	TCF25	1.36	6.6	0.56	2.33e-9	Skin colour saturation;
THYM	cis	rs4474465	0.920	rs7125628	chr11:78223028	C/G	cg19901956	chr11:77921274	USP35	0.65	4.85	0.45	4.85e-6	Alzheimer's disease (survival time);
THYM	cis	rs7909791	0.743	rs11191832	chr10:105619362	T/C	cg24587175	chr10:105670608	OBFC1	0.69	6.5	0.55	3.77e-9	White matter hyperintensity burden;
THYM	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14893161	chr1:205819251	PM20D1	1.11	13.21	0.8	3.05e-23	Menarche (age at onset);
THYM	cis	rs7127900	0.679	rs72853960	chr11:2223264	G/T	cg25635251	chr11:2234043	NA	-0.75	-4.73	-0.44	7.73e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg05335186	chr13:53173507	NA	-0.4	-5.03	-0.46	2.36e-6	Lewy body disease;
THYM	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg02527881	chr3:46936655	PTH1R	0.51	4.63	0.43	1.18e-5	Colorectal cancer;
THYM	cis	rs58688157	0.626	rs7941198	chr11:571681	A/G	cg03909863	chr11:638404	DRD4	-0.67	-4.79	-0.44	6.2e-6	Systemic lupus erythematosus;
THYM	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.46	-4.53	-0.42	1.73e-5	Crohn's disease;
THYM	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg24642439	chr20:33292090	TP53INP2	0.68	5.14	0.47	1.47e-6	Coronary artery disease;
THYM	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg08968635	chr6:28129556	ZNF389	0.59	5.29	0.48	7.81e-7	Depression;
THYM	cis	rs1215050	0.716	rs11940331	chr4:99054041	G/C	cg17366294	chr4:99064904	C4orf37	0.43	4.78	0.44	6.39e-6	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4523957	0.690	rs7213715	chr17:2093511	A/T	cg16513277	chr17:2031491	SMG6	-0.97	-9.1	-0.68	1.39e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs896854	0.517	rs10112447	chr8:95955701	C/T	cg16049864	chr8:95962084	TP53INP1	-0.78	-5.75	-0.51	1.1e-7	Type 2 diabetes;
THYM	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg21100191	chr22:23484243	RTDR1	0.73	6.5	0.55	3.66e-9	Bone mineral density;
THYM	cis	rs2717559	0.522	rs2585160	chr8:143875204	G/A	cg03405983	chr8:143858548	LYNX1	0.56	6.1	0.53	2.25e-8	Urinary tract infection frequency;
THYM	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg07212818	chr11:638076	DRD4	-0.79	-6.69	-0.57	1.57e-9	Systemic lupus erythematosus;
THYM	cis	rs911119	1.000	rs67567111	chr20:23619075	G/T	cg16589663	chr20:23618590	CST3	0.76	4.69	0.43	9.26e-6	Chronic kidney disease;
THYM	cis	rs7408868	1.000	rs7245814	chr19:15274503	A/G	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs72781680	1.000	rs963725	chr2:24148231	T/C	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg19016782	chr12:123741754	C12orf65	-0.71	-4.66	-0.43	1.05e-5	Neutrophil percentage of white cells;
THYM	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg02887458	chr19:19495540	GATAD2A	-0.42	-4.86	-0.45	4.6e-6	Bipolar disorder;
THYM	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg26384229	chr12:38710491	ALG10B	-0.72	-6.0	-0.52	3.63e-8	Morning vs. evening chronotype;
THYM	cis	rs2898681	0.567	rs77657787	chr4:53729981	G/A	cg03786743	chr4:53727781	RASL11B	0.63	5.65	0.5	1.66e-7	Optic nerve measurement (cup area);
THYM	cis	rs9790314	1.000	rs163328	chr3:161073599	A/G	cg04691961	chr3:161091175	C3orf57	-0.6	-5.26	-0.47	8.85e-7	Morning vs. evening chronotype;
THYM	cis	rs10744422	0.800	rs2343110	chr12:123343571	T/G	cg25930673	chr12:123319894	HIP1R	-0.84	-4.74	-0.44	7.56e-6	Schizophrenia;
THYM	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.5	-4.93	-0.45	3.5e-6	Crohn's disease;
THYM	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg06112835	chr11:68658793	MRPL21	0.37	4.7	0.43	8.7e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg23260525	chr10:116636907	FAM160B1	0.5	5.31	0.48	7.06e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs349045	0.560	rs11083725	chr19:44300576	C/T	cg11993925	chr19:44307056	LYPD5	-0.58	-4.64	-0.43	1.12e-5	Reading or mathematical ability;
THYM	cis	rs10489202	0.632	rs6659713	chr1:168072249	G/T	cg24449463	chr1:168025552	DCAF6	0.76	7.59	0.61	2.16e-11	Schizophrenia;
THYM	cis	rs12643440	0.538	rs4435747	chr4:17139645	C/T	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs988913	1.000	rs960834	chr6:54823431	C/T	cg19716238	chr6:54711378	FAM83B	0.5	5.02	0.46	2.43e-6	Menarche (age at onset);
THYM	trans	rs9951602	0.512	rs1599633	chr18:76643526	T/C	cg02800362	chr5:177631904	HNRNPAB	1.11	8.66	0.66	1.21e-13	Obesity-related traits;
THYM	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg24209194	chr3:40518798	ZNF619	0.68	5.54	0.49	2.73e-7	Renal cell carcinoma;
THYM	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg10047753	chr17:41438598	NA	1.2	11.36	0.76	2.13e-19	Menopause (age at onset);
THYM	cis	rs8077889	0.917	rs1859048	chr17:41892039	A/C	cg26893861	chr17:41843967	DUSP3	-0.98	-8.53	-0.66	2.26e-13	Triglycerides;
THYM	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-5.91	-0.52	5.44e-8	Bone mineral density;
THYM	cis	rs71403859	0.803	rs34381861	chr16:71640230	T/C	cg08717414	chr16:71523259	ZNF19	-1.11	-5.78	-0.51	9.62e-8	Post bronchodilator FEV1;
THYM	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg00129232	chr17:37814104	STARD3	-0.87	-7.03	-0.59	3.07e-10	Asthma;
THYM	cis	rs12142240	0.698	rs57267378	chr1:46816644	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs4654899	0.643	rs651538	chr1:21097866	A/G	cg01072550	chr1:21505969	NA	-0.62	-5.66	-0.5	1.62e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs2067615	0.560	rs12298717	chr12:107099883	C/T	cg15890332	chr12:107067104	RFX4	-0.49	-5.75	-0.51	1.1e-7	Heart rate;
THYM	cis	rs78579285	0.583	rs1061238	chr16:88781850	A/G	cg04002220	chr16:89598305	SPG7	-0.64	-4.72	-0.44	7.96e-6	Joint mobility (Beighton score);
THYM	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.09e-8	Systolic blood pressure;
THYM	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs470093	0.935	rs129655	chr22:44274202	T/C	cg09142166	chr22:44276013	PNPLA5	-0.61	-5.83	-0.51	7.72e-8	Staphylococcus aureus infection;
THYM	cis	rs3862030	0.720	rs11595149	chr10:104235978	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.65	-5.42	-0.49	4.43e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg23758822	chr17:41437982	NA	1.18	11.2	0.75	4.58e-19	Menopause (age at onset);
THYM	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg03609598	chr5:56110824	MAP3K1	0.89	6.07	0.53	2.63e-8	Initial pursuit acceleration;
THYM	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-5.89	-0.52	5.93e-8	Total cholesterol levels;
THYM	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.11	7.46	0.61	3.98e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17253792	0.545	rs12893061	chr14:56016097	A/T	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs25645	0.502	rs9895948	chr17:38108363	T/C	cg26162295	chr17:38119207	GSDMA	-0.42	-5.05	-0.46	2.09e-6	Myeloid white cell count;
THYM	cis	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg19442545	chr10:75533431	FUT11	-0.63	-6.41	-0.55	5.66e-9	Inflammatory bowel disease;
THYM	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	10.36	0.73	2.81e-17	Chronic sinus infection;
THYM	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-5.37	-0.48	5.52e-7	Neuroticism;
THYM	cis	rs61774743	0.636	rs1892423	chr1:41849340	A/C	cg19619003	chr1:41846758	NA	-0.28	-6.03	-0.53	3.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs3126085	0.560	rs1923505	chr1:152359837	T/C	cg10321714	chr1:152280068	FLG	-0.69	-4.84	-0.44	5.1e-6	Atopic dermatitis;
THYM	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3796352	1.000	rs2564926	chr3:53094730	G/A	cg07884673	chr3:53033167	SFMBT1	-1.1	-5.88	-0.52	5.96e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7833986	0.534	rs2976022	chr8:57007843	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	6.82	0.57	8.29e-10	Height;
THYM	cis	rs2637266	0.783	rs846645	chr10:78516000	A/G	cg18941641	chr10:78392320	NA	0.71	5.69	0.5	1.38e-7	Pulmonary function;
THYM	cis	rs11089937	0.616	rs4991798	chr22:22533305	G/T	cg06866756	chr22:22471216	NA	-0.46	-4.86	-0.45	4.66e-6	Periodontitis (PAL4Q3);
THYM	cis	rs4662945	0.603	rs10496678	chr2:130262209	C/T	cg05903289	chr2:130345205	NA	-0.57	-5.43	-0.49	4.34e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs1878931	0.507	rs11648783	chr16:3406626	A/G	cg00484396	chr16:3507460	NAT15	-0.45	-4.52	-0.42	1.81e-5	Body mass index (adult);
THYM	cis	rs7917772	0.560	rs3862030	chr10:104327584	A/G	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9378357	0.510	rs4613858	chr6:3287681	C/T	cg08754725	chr6:3293098	SLC22A23	0.79	4.92	0.45	3.7e-6	Obesity-related traits;
THYM	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs6894249	0.874	rs11745587	chr5:131796922	A/G	cg21138405	chr5:131827807	IRF1	-0.51	-4.81	-0.44	5.63e-6	Asthma;
THYM	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg07424592	chr7:64974309	NA	1.05	5.47	0.49	3.61e-7	Diabetic kidney disease;
THYM	cis	rs6732160	0.932	rs768851	chr2:73378241	G/A	cg24220031	chr2:73402428	NA	-0.65	-6.38	-0.55	6.44e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9858542	0.537	rs9874474	chr3:49326178	A/G	cg00383909	chr3:49044727	WDR6	0.7	4.7	0.43	8.68e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs12496230	0.909	rs13075691	chr3:66857626	T/A	cg04995300	chr3:66848608	NA	0.95	6.53	0.56	3.27e-9	Type 2 diabetes;
THYM	cis	rs1061377	1.000	rs7685468	chr4:39118269	C/T	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs7084402	0.902	rs1658417	chr10:60333039	T/C	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg14675211	chr2:100938903	LONRF2	0.77	8.32	0.65	6.49e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg06636001	chr8:8085503	FLJ10661	0.76	6.85	0.57	7.3e-10	Mood instability;
THYM	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg18252515	chr7:66147081	NA	-1.61	-8.54	-0.66	2.21e-13	Diabetic kidney disease;
THYM	cis	rs7084402	0.935	rs10740731	chr10:60348886	G/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.72	-0.51	1.25e-7	Refractive error;
THYM	cis	rs261532	0.817	rs261534	chr5:138943690	T/C	cg08720517	chr5:138729919	LOC389333	0.58	4.86	0.45	4.6e-6	Immune reponse to smallpox (secreted IFN-alpha);
THYM	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg22535103	chr8:58192502	C8orf71	-0.93	-4.56	-0.42	1.52e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs710865	0.519	rs10753518	chr1:19483593	T/C	cg13387374	chr1:19411106	UBR4	0.66	5.44	0.49	4.14e-7	Brain structure;
THYM	cis	rs11030122	0.702	rs11030276	chr11:3946134	A/G	cg22027985	chr11:4115532	RRM1	-0.48	-4.59	-0.43	1.36e-5	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7107174	0.901	rs10899493	chr11:78117534	T/C	cg19901956	chr11:77921274	USP35	-0.63	-5.03	-0.46	2.34e-6	Testicular germ cell tumor;
THYM	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs944002	1.000	rs17101241	chr14:103564820	A/T	cg16996574	chr14:103691482	NA	0.53	4.76	0.44	6.9e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;
THYM	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg19913688	chr11:428466	ANO9	-0.86	-4.53	-0.42	1.69e-5	Body mass index;
THYM	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs995000	0.931	rs10889344	chr1:63033941	T/C	cg06896770	chr1:63153194	DOCK7	-0.89	-7.31	-0.6	8.2e-11	Triglyceride levels;
THYM	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs599083	0.530	rs2508834	chr11:68175354	C/T	cg16797656	chr11:68205561	LRP5	-0.46	-4.98	-0.46	2.81e-6	Bone mineral density (spine);
THYM	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg17366294	chr4:99064904	C4orf37	0.59	6.78	0.57	1e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17598306	1.000	rs17656761	chr7:96581553	G/A	cg13449377	chr7:96631089	DLX6AS	0.76	4.78	0.44	6.38e-6	Radiation response;
THYM	cis	rs4455778	0.536	rs38769	chr7:48940934	C/T	cg26309511	chr7:48887640	NA	0.62	6.31	0.54	8.85e-9	Lung cancer in never smokers;
THYM	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg00645579	chr11:617140	IRF7;MUPCDH	-0.47	-6.04	-0.53	3.05e-8	Systemic lupus erythematosus;
THYM	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-9.24	-0.69	7.05e-15	Chronic sinus infection;
THYM	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs295140	1.000	rs67190025	chr2:201172086	C/T	cg04283868	chr2:201171347	SPATS2L	0.74	5.53	0.49	2.81e-7	QT interval;
THYM	cis	rs9309711	0.961	rs11890651	chr2:3482796	T/G	cg10845886	chr2:3471009	TTC15	-0.62	-5.24	-0.47	9.68e-7	Neurofibrillary tangles;
THYM	cis	rs7575217	0.552	rs13032971	chr2:101689726	T/G	cg12594615	chr2:101643137	TBC1D8	0.58	4.75	0.44	7.16e-6	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs1371867	0.846	rs1660312	chr8:101330634	C/G	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	trans	rs11109072	1.000	rs11109077	chr12:97903945	A/G	cg17633015	chr7:2020501	MAD1L1	1.0	7.4	0.6	5.45e-11	Obesity (early onset extreme);
THYM	cis	rs3015497	0.752	rs6572682	chr14:51144800	A/T	cg04730355	chr14:51134070	SAV1	-0.53	-4.68	-0.43	9.39e-6	Mean platelet volume;
THYM	cis	rs988913	1.000	rs9349740	chr6:54825708	A/C	cg18532076	chr6:54711417	FAM83B	0.49	4.87	0.45	4.53e-6	Menarche (age at onset);
THYM	cis	rs17604090	0.761	rs115923387	chr7:29720702	A/G	cg19413766	chr7:29689036	LOC646762	-0.97	-5.46	-0.49	3.8e-7	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs1278352	0.964	rs1278351	chr10:127773238	T/C	cg08295661	chr10:127769903	ADAM12	-0.47	-5.16	-0.47	1.35e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg25358565	chr5:93447407	FAM172A	-1.21	-8.24	-0.65	9.53e-13	Diabetic retinopathy;
THYM	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg06453172	chr10:134556979	INPP5A	0.69	5.08	0.46	1.86e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg11245990	chr11:68621969	NA	0.51	6.45	0.55	4.76e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4474465	1.000	rs10899521	chr11:78184560	T/A	cg19901956	chr11:77921274	USP35	-0.59	-4.51	-0.42	1.85e-5	Alzheimer's disease (survival time);
THYM	cis	rs17006441	0.932	rs62251038	chr3:69868660	A/G	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs12620999	1.000	rs4377286	chr2:238069686	C/T	cg15976283	chr2:238042351	NA	0.63	4.94	0.45	3.33e-6	Systemic lupus erythematosus;
THYM	cis	rs4654899	0.931	rs7520481	chr1:21140385	T/G	cg01072550	chr1:21505969	NA	0.7	6.41	0.55	5.56e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs4733781	0.965	rs1469288	chr8:131226652	G/A	cg16277922	chr8:131349729	ASAP1	0.71	5.12	0.47	1.57e-6	Tuberculosis;
THYM	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg07212818	chr11:638076	DRD4	-0.76	-5.49	-0.49	3.28e-7	Systemic lupus erythematosus;
THYM	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10203711	0.789	rs6431616	chr2:239540279	A/G	cg14580085	chr2:239553406	NA	0.68	6.26	0.54	1.1e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8048589	0.558	rs34565142	chr16:12231347	C/T	cg01990910	chr16:12207648	SNX29	-0.43	-5.16	-0.47	1.32e-6	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.12	7.95	0.63	3.93e-12	Platelet count;
THYM	cis	rs919433	0.617	rs10460394	chr2:198548741	G/A	cg05783139	chr2:198650985	BOLL	-0.67	-5.27	-0.48	8.58e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg11764359	chr7:65958608	NA	-0.76	-6.23	-0.54	1.27e-8	Aortic root size;
THYM	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs6032067	0.866	rs6104054	chr20:43822771	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.64	-7.35	-0.6	6.75e-11	Blood protein levels;
THYM	cis	rs2836633	0.894	rs55955614	chr21:40037330	T/G	cg05519781	chr21:40033154	ERG	0.79	7.8	0.62	7.93e-12	Coronary artery disease;
THYM	cis	rs7917772	0.582	rs10786682	chr10:104318322	A/C	cg00122347	chr10:104236741	TMEM180	0.41	5.75	0.51	1.06e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	5.19	0.47	1.18e-6	Hip circumference adjusted for BMI;
THYM	cis	rs2237457	0.508	rs2108353	chr7:50704247	A/C	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.48e-6	Schizophrenia (treatment resistant);
THYM	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg22920501	chr2:26401640	FAM59B	-1.05	-9.27	-0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11890956	chr21:40555474	PSMG1	1.15	12.23	0.78	3.25e-21	Cognitive function;
THYM	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg13683864	chr3:40499215	RPL14	1.05	11.64	0.77	5.54e-20	Renal cell carcinoma;
THYM	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg00012203	chr2:219082015	ARPC2	-0.67	-5.68	-0.5	1.44e-7	Colorectal cancer;
THYM	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs6840360	0.837	rs13137669	chr4:152710943	A/G	cg22705602	chr4:152727874	NA	-0.57	-6.19	-0.54	1.54e-8	Intelligence (multi-trait analysis);
THYM	cis	rs10924970	0.967	rs3765793	chr1:235368277	T/A	cg26050004	chr1:235667680	B3GALNT2	0.6	4.61	0.43	1.26e-5	Asthma;
THYM	cis	rs4363385	0.818	rs529077	chr1:153012149	T/C	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs4654899	0.680	rs10916900	chr1:21239059	C/G	cg01072550	chr1:21505969	NA	-0.72	-7.05	-0.59	2.81e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs4343996	0.580	rs10262464	chr7:3406961	A/C	cg21248987	chr7:3385318	SDK1	0.41	5.17	0.47	1.32e-6	Motion sickness;
THYM	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg27129171	chr3:47204927	SETD2	-0.8	-7.67	-0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.26	-5.22	-0.47	1.07e-6	Obesity-related traits;
THYM	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg08859206	chr1:53392774	SCP2	-0.49	-5.15	-0.47	1.4e-6	Monocyte count;
THYM	cis	rs7192380	0.571	rs10852456	chr16:69605613	G/T	cg09409435	chr16:70099608	PDXDC2	0.61	4.74	0.44	7.48e-6	Sjögren's syndrome;
THYM	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg00684032	chr4:1343700	KIAA1530	0.53	4.62	0.43	1.2e-5	Longevity;
THYM	cis	rs986417	1.000	rs1254324	chr14:60908551	C/T	cg27398547	chr14:60952738	C14orf39	-1.06	-5.59	-0.5	2.16e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs1062746	0.528	rs11646030	chr16:87339278	T/C	cg02258303	chr16:87377426	FBXO31	-0.61	-4.82	-0.44	5.53e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg24060327	chr5:131705240	SLC22A5	0.73	5.47	0.49	3.61e-7	Blood metabolite levels;
THYM	cis	rs4803455	0.565	rs11670143	chr19:41864971	A/G	cg09537434	chr19:41945824	ATP5SL	-0.75	-5.87	-0.52	6.26e-8	Migraine;Coronary artery disease;
THYM	cis	rs1942	0.742	rs1655558	chr15:41787585	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.66	-5.28	-0.48	8.12e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs1046896	0.607	rs12449739	chr17:80683420	G/A	cg16060761	chr17:80687452	NA	-0.58	-4.5	-0.42	1.94e-5	Glycated hemoglobin levels;
THYM	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg11494091	chr17:61959527	GH2	-0.68	-6.04	-0.53	2.98e-8	Height;
THYM	cis	rs4660306	0.677	rs781060	chr1:45934166	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.66	4.74	0.44	7.56e-6	Homocysteine levels;
THYM	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg19318889	chr4:1322082	MAEA	-0.52	-4.53	-0.42	1.7e-5	Obesity-related traits;
THYM	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg17063962	chr7:91808500	NA	-1.12	-12.68	-0.79	3.85e-22	Breast cancer;
THYM	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg05973401	chr12:123451056	ABCB9	0.65	4.72	0.44	8.08e-6	Platelet count;
THYM	cis	rs12149862	1.000	rs78784055	chr16:69468869	G/A	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg07636037	chr3:49044803	WDR6	1.02	9.66	0.7	8.74e-16	Parkinson's disease;
THYM	cis	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg26384229	chr12:38710491	ALG10B	-0.74	-6.26	-0.54	1.13e-8	Morning vs. evening chronotype;
THYM	cis	rs941408	1.000	rs1736183	chr19:2809672	A/G	cg06609049	chr19:2785107	THOP1	0.69	5.66	0.5	1.63e-7	Total cholesterol levels;
THYM	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg05294307	chr14:35346193	BAZ1A	-0.85	-5.67	-0.5	1.52e-7	Psoriasis;
THYM	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.51	0.81	7.55e-24	Height;
THYM	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg17366294	chr4:99064904	C4orf37	0.52	6.0	0.52	3.6e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9534288	0.763	rs7989605	chr13:46534036	G/A	cg15192986	chr13:46630673	CPB2	-0.6	-4.52	-0.42	1.8e-5	Blood protein levels;
THYM	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24549020	chr5:56110836	MAP3K1	0.7	4.5	0.42	1.94e-5	Initial pursuit acceleration;
THYM	cis	rs1942	0.813	rs8032846	chr15:41605653	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.67	-5.38	-0.48	5.24e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs684232	0.644	rs2543781	chr17:602469	C/G	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.39	-4.72	-0.44	8.25e-6	Prostate cancer;
THYM	cis	rs7584330	0.554	rs75559690	chr2:238428454	T/C	cg08992911	chr2:238395768	MLPH	1.01	5.85	0.51	6.94e-8	Prostate cancer;
THYM	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg11984989	chr7:158649758	WDR60	1.11	12.84	0.8	1.76e-22	Height;
THYM	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.54	-6.0	-0.52	3.58e-8	Autism spectrum disorder or schizophrenia;
THYM	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg11764359	chr7:65958608	NA	0.84	7.06	0.59	2.78e-10	Aortic root size;
THYM	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg00277334	chr10:82204260	NA	-0.83	-10.18	-0.72	6.99e-17	Post bronchodilator FEV1;
THYM	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg12386194	chr3:101231763	SENP7	-0.69	-5.16	-0.47	1.34e-6	Colorectal cancer;
THYM	cis	rs10779751	0.734	rs2261317	chr1:11124979	A/G	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg24308560	chr3:49941425	MST1R	0.79	6.8	0.57	9.31e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7267979	0.966	rs2227892	chr20:25264814	T/C	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs17209837	0.607	rs4148811	chr7:87101486	T/G	cg04996195	chr7:87105398	ABCB4	0.63	4.84	0.44	5.09e-6	Gallbladder cancer;
THYM	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg09436375	chr6:42928200	GNMT	-0.44	-5.86	-0.52	6.75e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4595586	0.545	rs11615700	chr12:39365104	A/G	cg26384229	chr12:38710491	ALG10B	0.69	5.35	0.48	6.11e-7	Morning vs. evening chronotype;
THYM	cis	rs9527	0.615	rs11191401	chr10:104573403	A/G	cg05855489	chr10:104503620	C10orf26	0.64	4.82	0.44	5.42e-6	Arsenic metabolism;
THYM	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg12031863	chr16:4587854	C16orf5	-0.46	-4.96	-0.45	3.09e-6	Schizophrenia;
THYM	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.47	0.61	3.8e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2286885	1.000	rs1537987	chr9:129242112	T/C	cg14294646	chr9:129243551	FAM125B	-0.67	-6.41	-0.55	5.49e-9	Intraocular pressure;
THYM	cis	rs7849270	1.000	rs34055941	chr9:131895076	T/C	cg14069949	chr9:131965419	NA	0.5	4.52	0.42	1.8e-5	Blood metabolite ratios;
THYM	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg03732007	chr1:2071316	PRKCZ	0.51	4.93	0.45	3.44e-6	Height;
THYM	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg12165864	chr7:66369176	NA	0.67	5.19	0.47	1.18e-6	Aortic root size;
THYM	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg08305652	chr11:111469057	NA	0.53	4.58	0.43	1.41e-5	Primary sclerosing cholangitis;
THYM	cis	rs7546094	0.875	rs7522288	chr1:113151205	T/C	cg25616829	chr1:112535356	NA	0.58	4.71	0.44	8.34e-6	Platelet distribution width;
THYM	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg00191853	chr8:101177733	SPAG1	-0.56	-5.59	-0.5	2.15e-7	Atrioventricular conduction;
THYM	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	9.71	0.71	6.96e-16	Platelet count;
THYM	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07167872	chr1:205819463	PM20D1	0.95	9.06	0.68	1.69e-14	Menarche (age at onset);
THYM	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2034650	0.544	rs661488	chr15:40721420	G/C	cg12699599	chr15:40643142	PHGR1	-0.6	-5.25	-0.47	9.09e-7	Interstitial lung disease;
THYM	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg09165964	chr15:75287851	SCAMP5	-0.97	-8.7	-0.67	1e-13	Blood trace element (Zn levels);
THYM	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	5.64	0.5	1.76e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs10186029	0.680	rs1530238	chr2:213957928	G/C	cg08319019	chr2:214017104	IKZF2	0.8	6.46	0.55	4.39e-9	Systemic sclerosis;
THYM	trans	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs778371	0.915	rs748002	chr2:233757679	G/A	cg08000102	chr2:233561755	GIGYF2	-0.82	-6.78	-0.57	1.01e-9	Schizophrenia;
THYM	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg00631329	chr6:26305371	NA	-0.63	-7.46	-0.61	3.99e-11	Educational attainment;
THYM	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg02527881	chr3:46936655	PTH1R	-0.65	-6.25	-0.54	1.15e-8	Colorectal cancer;
THYM	cis	rs6906287	0.669	rs6913012	chr6:118973137	G/A	cg21191810	chr6:118973309	C6orf204	0.63	6.43	0.55	5e-9	Electrocardiographic conduction measures;
THYM	cis	rs28829049	0.570	rs12060125	chr1:19391108	A/G	cg13387374	chr1:19411106	UBR4	-0.67	-5.35	-0.48	6.04e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.03	10.29	0.73	4.07e-17	Intelligence (multi-trait analysis);
THYM	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg06565975	chr8:143823917	SLURP1	-0.76	-8.91	-0.67	3.46e-14	Urinary tract infection frequency;
THYM	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg08859206	chr1:53392774	SCP2	0.6	6.72	0.57	1.34e-9	Monocyte count;
THYM	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg02527881	chr3:46936655	PTH1R	0.61	5.71	0.51	1.28e-7	Colorectal cancer;
THYM	cis	rs10208649	0.908	rs7556936	chr2:54255731	A/G	cg04546899	chr2:54196757	PSME4	0.68	4.7	0.43	8.91e-6	Body mass index;
THYM	cis	rs1003719	0.715	rs7282195	chr21:38508619	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-4.75	-0.44	7.3e-6	Eye color traits;
THYM	cis	rs28374715	0.787	rs11856169	chr15:41547938	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.06	-9.2	-0.69	8.64e-15	Ulcerative colitis;
THYM	cis	rs900145	0.773	rs7934154	chr11:13314148	G/T	cg13286116	chr11:13302098	ARNTL	0.59	4.56	0.42	1.54e-5	Menarche (age at onset);
THYM	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg23958373	chr8:599963	NA	-1.02	-4.95	-0.45	3.25e-6	IgG glycosylation;
THYM	cis	rs7078219	0.743	rs7095953	chr10:101274425	C/T	cg23904955	chr10:101282759	NA	0.42	4.99	0.46	2.72e-6	Dental caries;
THYM	cis	rs11779988	0.545	rs431961	chr8:17786204	T/G	cg01800426	chr8:17659068	MTUS1	-0.76	-5.32	-0.48	6.94e-7	Breast cancer;
THYM	cis	rs262150	0.545	rs73167302	chr7:158789762	G/A	cg19418458	chr7:158789849	NA	0.64	4.61	0.43	1.27e-5	Facial morphology (factor 20);
THYM	cis	rs4638749	0.677	rs10185601	chr2:108828278	A/G	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs9868809	0.772	rs13070798	chr3:48705934	C/T	cg00383909	chr3:49044727	WDR6	-0.91	-5.09	-0.46	1.81e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs6032067	0.777	rs35476703	chr20:43802875	C/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.41	-0.65	4.05e-13	Blood protein levels;
THYM	cis	rs6084875	0.840	rs2422936	chr20:4720830	C/T	cg19614321	chr20:4804581	RASSF2	0.44	4.47	0.42	2.19e-5	Systemic lupus erythematosus;
THYM	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs907683	0.583	rs10932803	chr2:220292739	A/T	cg15015639	chr2:220282977	DES	0.39	5.13	0.47	1.53e-6	Resting heart rate;
THYM	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg14004847	chr7:1930337	MAD1L1	-0.71	-5.61	-0.5	1.98e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs75059851	0.756	rs2000853	chr11:133838417	A/G	cg14047540	chr11:133829660	NA	-1.06	-7.03	-0.58	3.14e-10	Schizophrenia;
THYM	cis	rs16917546	1.000	rs10995255	chr10:64402433	G/A	cg03961010	chr10:64397487	ZNF365	-0.79	-6.52	-0.56	3.41e-9	Basal cell carcinoma;
THYM	cis	rs3796352	1.000	rs34340609	chr3:53077276	A/G	cg07884673	chr3:53033167	SFMBT1	1.11	6.28	0.54	1.01e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg12908607	chr1:44402522	ARTN	0.5	4.64	0.43	1.1e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9527	0.662	rs4919686	chr10:104592249	A/C	cg04362960	chr10:104952993	NT5C2	0.66	5.12	0.46	1.6e-6	Arsenic metabolism;
THYM	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg26924012	chr15:45694286	SPATA5L1	0.98	9.12	0.68	1.23e-14	Homoarginine levels;
THYM	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg23205692	chr1:25664452	TMEM50A	0.83	6.37	0.55	6.66e-9	Erythrocyte sedimentation rate;
THYM	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.59	-4.66	-0.43	1.02e-5	Chronic sinus infection;
THYM	cis	rs9658691	0.607	rs34891735	chr10:90779212	A/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.88	-5.86	-0.52	6.56e-8	Mosquito bite size;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg06838940	chr17:11901614	ZNF18	-0.89	-7.07	-0.59	2.64e-10	Depressive symptoms;
THYM	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03452623	chr4:187889614	NA	-1.19	-19.05	-0.89	3.26e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs6500395	1.000	rs3826174	chr16:48591012	T/C	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7646881	0.904	rs112493023	chr3:158448276	A/G	cg18349298	chr3:158450550	RARRES1	0.52	5.02	0.46	2.38e-6	Tetralogy of Fallot;
THYM	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7940866	0.803	rs1865296	chr11:130882944	C/T	cg12179176	chr11:130786555	SNX19	-0.66	-5.05	-0.46	2.15e-6	Schizophrenia;
THYM	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg13395646	chr4:1353034	KIAA1530	0.6	5.41	0.49	4.79e-7	Obesity-related traits;
THYM	cis	rs8067545	0.750	rs918228	chr17:20002012	C/T	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.61e-6	Schizophrenia;
THYM	cis	rs28374715	0.662	rs8038983	chr15:41473316	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.02	-8.4	-0.65	4.27e-13	Ulcerative colitis;
THYM	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg11764359	chr7:65958608	NA	-0.62	-4.73	-0.44	7.94e-6	Aortic root size;
THYM	cis	rs10845606	1.000	rs10845609	chr12:12838920	T/A	cg04607235	chr12:12878440	APOLD1	-0.77	-4.71	-0.44	8.45e-6	Systemic lupus erythematosus;
THYM	cis	rs8016982	0.633	rs8019108	chr14:81716781	A/T	cg01989461	chr14:81687754	GTF2A1	0.79	7.13	0.59	1.98e-10	Schizophrenia;
THYM	cis	rs34638657	0.789	rs2303264	chr16:82203711	G/T	cg09439754	chr16:82129088	HSD17B2	-0.61	-6.03	-0.53	3.19e-8	Lung adenocarcinoma;
THYM	cis	rs11048434	0.736	rs2377674	chr12:9112761	A/G	cg13575925	chr12:9217583	LOC144571	0.51	4.87	0.45	4.42e-6	Sjögren's syndrome;
THYM	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg00255919	chr5:131827918	IRF1	0.44	5.03	0.46	2.3e-6	Asthma (sex interaction);
THYM	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg18755752	chr8:142205143	DENND3	-0.81	-8.04	-0.64	2.43e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs9992101	0.645	rs4272041	chr4:77330682	A/G	cg20311846	chr4:77356250	SHROOM3	-0.53	-5.83	-0.51	7.6e-8	Creatinine levels;
THYM	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg10515332	chr4:99064459	C4orf37	-0.61	-4.8	-0.44	5.99e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg23758822	chr17:41437982	NA	1.18	11.13	0.75	6.64e-19	Menopause (age at onset);
THYM	cis	rs10992471	0.835	rs12686606	chr9:95563128	A/G	cg14631576	chr9:95140430	CENPP	0.58	4.76	0.44	7.05e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg11879182	chr18:77439856	CTDP1	0.81	7.86	0.63	5.87e-12	Monocyte count;
THYM	cis	rs6840360	0.642	rs7676059	chr4:152393267	T/C	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg08999081	chr20:33150536	PIGU	0.55	4.46	0.42	2.27e-5	Coronary artery disease;
THYM	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.27	-5.73	-0.51	1.2e-7	Obesity-related traits;
THYM	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg12863693	chr15:85201151	NMB	0.62	5.39	0.48	5.18e-7	Schizophrenia;
THYM	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-5.4	-0.48	4.89e-7	Chronic sinus infection;
THYM	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg26384229	chr12:38710491	ALG10B	0.95	7.98	0.63	3.38e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs36051895	0.623	rs7859361	chr9:5237479	C/T	cg02405213	chr9:5042618	JAK2	-0.93	-9.39	-0.69	3.26e-15	Pediatric autoimmune diseases;
THYM	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg04944784	chr2:26401820	FAM59B	-1.06	-7.74	-0.62	1.08e-11	Gut microbiome composition (summer);
THYM	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg05738196	chr6:26577821	NA	0.95	9.38	0.69	3.53e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7582180	0.663	rs10199518	chr2:100946041	G/A	cg14675211	chr2:100938903	LONRF2	0.62	5.99	0.52	3.73e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1129187	0.702	rs2296805	chr6:42928758	T/G	cg09436375	chr6:42928200	GNMT	-0.47	-6.42	-0.55	5.27e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs240764	0.817	rs239246	chr6:101089134	G/A	cg21058520	chr6:100914733	NA	-0.57	-5.06	-0.46	2.04e-6	Neuroticism;
THYM	cis	rs75884327	0.584	rs2836901	chr21:40499194	A/G	cg24979093	chr21:39577464	DSCR10	-0.73	-4.53	-0.42	1.72e-5	Daytime sleep phenotypes;
THYM	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg26418147	chr1:205743515	RAB7L1	-0.6	-4.99	-0.46	2.77e-6	Menarche (age at onset);
THYM	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg18681998	chr4:17616180	MED28	0.81	7.08	0.59	2.43e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6430585	0.583	rs12373779	chr2:136586840	A/C	cg07169764	chr2:136633963	MCM6	1.2	14.22	0.82	2.98e-25	Corneal structure;
THYM	cis	rs728616	0.614	rs10788319	chr10:81713510	T/A	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	4.93	0.45	3.51e-6	Motion sickness;
THYM	cis	rs7246967	0.551	rs7257333	chr19:22881149	C/T	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs4732038	0.565	rs782542	chr7:134269242	A/G	cg06906464	chr7:134288099	NA	-0.48	-4.76	-0.44	7e-6	Longevity;
THYM	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs7106204	0.800	rs6484026	chr11:24214633	G/A	ch.11.24196551F	chr11:24239977	NA	1.0	7.01	0.58	3.4e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7757969	1.000	rs1409839	chr6:112115355	T/C	cg08601457	chr6:112115117	FYN	0.42	4.77	0.44	6.65e-6	Schizophrenia;
THYM	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.59	-4.87	-0.45	4.53e-6	Bipolar disorder;
THYM	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Bladder cancer;
THYM	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg07424592	chr7:64974309	NA	1.04	5.31	0.48	7.18e-7	Diabetic kidney disease;
THYM	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg14675211	chr2:100938903	LONRF2	0.76	7.93	0.63	4.17e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4986172	0.690	rs11657325	chr17:43242694	C/T	cg06100756	chr17:43221575	NA	0.78	8.33	0.65	5.94e-13	Height;
THYM	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg08885076	chr2:99613938	TSGA10	-0.63	-6.05	-0.53	2.86e-8	Chronic sinus infection;
THYM	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg01264106	chr22:38071602	LGALS1	0.39	4.65	0.43	1.07e-5	Fat distribution (HIV);
THYM	cis	rs8180040	0.676	rs1108301	chr3:47029426	G/A	cg27129171	chr3:47204927	SETD2	-0.71	-6.82	-0.57	8.39e-10	Colorectal cancer;
THYM	cis	rs1011018	0.955	rs4725579	chr7:139468213	A/C	cg06079564	chr7:139468310	HIPK2	-0.75	-5.88	-0.52	6.14e-8	Systolic blood pressure;
THYM	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg24209194	chr3:40518798	ZNF619	0.66	5.57	0.5	2.41e-7	Renal cell carcinoma;
THYM	cis	rs11574514	1.000	rs117648818	chr16:67791428	A/C	cg09738193	chr16:67926317	PSKH1	-0.91	-4.66	-0.43	1.01e-5	Crohn's disease;
THYM	cis	rs3892630	0.878	rs8112955	chr19:33191192	C/T	cg22980127	chr19:33182716	NUDT19	1.14	9.17	0.69	9.93e-15	Red blood cell traits;
THYM	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	4.51	0.42	1.85e-5	Axial length;
THYM	cis	rs8048589	0.898	rs8063329	chr16:12186047	G/A	cg01990910	chr16:12207648	SNX29	-0.44	-4.95	-0.45	3.24e-6	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs10847980	0.590	rs12299742	chr12:123323357	T/G	cg25930673	chr12:123319894	HIP1R	1.08	5.36	0.48	5.72e-7	Adiponectin levels;
THYM	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	10.01	0.72	1.59e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4820539	0.966	rs2283803	chr22:23454881	G/A	cg14186256	chr22:23484241	RTDR1	0.93	9.04	0.68	1.9e-14	Bone mineral density;
THYM	cis	rs1018836	0.786	rs10956736	chr8:91602067	C/T	cg16814680	chr8:91681699	NA	-0.93	-7.89	-0.63	5.06e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs11087123	0.500	rs11908639	chr20:15118513	A/G	cg09937190	chr20:15177509	MACROD2	0.48	5.31	0.48	7.24e-7	Eating disorders;
THYM	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg18230493	chr5:56204884	C5orf35	0.91	6.65	0.56	1.85e-9	Initial pursuit acceleration;
THYM	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.93	-6.1	-0.53	2.31e-8	Schizophrenia;
THYM	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg13319975	chr6:146136371	FBXO30	-0.71	-5.99	-0.52	3.78e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1965732	0.504	rs10170315	chr2:3715832	G/A	cg25251562	chr2:3704773	ALLC	-0.58	-4.57	-0.42	1.48e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.94	6.12	0.53	2.08e-8	Smoking behavior;
THYM	cis	rs9583531	0.600	rs4773240	chr13:111360585	G/A	cg24331049	chr13:111365604	ING1	0.72	6.04	0.53	2.96e-8	Coronary artery disease;
THYM	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg08772003	chr10:104629869	AS3MT	-0.61	-5.41	-0.49	4.63e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4654899	0.897	rs611658	chr1:21089133	T/G	cg01072550	chr1:21505969	NA	-0.58	-5.05	-0.46	2.14e-6	Superior frontal gyrus grey matter volume;
THYM	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-5.77	-0.51	9.69e-8	Gut microbiome composition (summer);
THYM	cis	rs858239	0.698	rs858295	chr7:23245569	A/G	cg18081818	chr7:23246105	NA	-0.6	-5.43	-0.49	4.39e-7	Cerebrospinal fluid biomarker levels;
THYM	trans	rs9929218	1.000	rs17772363	chr16:68788909	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.85	-6.84	-0.57	7.56e-10	Colorectal cancer;
THYM	cis	rs72827839	1.000	rs72827887	chr17:46537636	A/G	cg03177231	chr17:45772386	TBKBP1	0.89	4.58	0.43	1.4e-5	Ease of getting up in the morning;
THYM	cis	rs775227	0.528	rs775231	chr3:113027214	A/C	cg18753928	chr3:113234510	CCDC52	0.78	5.86	0.52	6.73e-8	Dental caries;
THYM	cis	rs11886999	0.812	rs62153022	chr2:96888164	T/C	cg18419276	chr2:96971862	SNRNP200	-0.5	-4.77	-0.44	6.69e-6	Cardiac Troponin-T levels;
THYM	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg18538332	chr22:24372958	LOC391322	-1.06	-14.14	-0.82	4.22e-25	Liver enzyme levels (gamma-glutamyl transferase);
THYM	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg06636001	chr8:8085503	FLJ10661	0.76	6.85	0.57	7.39e-10	Myopia (pathological);
THYM	cis	rs4919694	1.000	rs75219158	chr10:104747594	C/T	cg15744005	chr10:104629667	AS3MT	-0.84	-4.62	-0.43	1.21e-5	Arsenic metabolism;
THYM	cis	rs611744	0.781	rs656406	chr8:109173843	G/A	cg21045802	chr8:109455806	TTC35	0.7	6.79	0.57	9.74e-10	Dupuytren's disease;
THYM	cis	rs7216064	1.000	rs62084240	chr17:65859233	C/A	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs7851660	0.844	rs907581	chr9:100622189	A/G	cg13688889	chr9:100608707	NA	-0.77	-5.31	-0.48	7.25e-7	Strep throat;
THYM	cis	rs10752881	0.967	rs8179361	chr1:182974572	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg00129232	chr17:37814104	STARD3	0.69	4.45	0.42	2.32e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs89107	0.583	rs11752626	chr6:118788652	G/T	cg21191810	chr6:118973309	C6orf204	0.5	5.04	0.46	2.25e-6	Cardiac structure and function;
THYM	cis	rs6840360	0.615	rs4696266	chr4:152463421	A/G	cg17479576	chr4:152424074	FAM160A1	-0.85	-6.4	-0.55	5.9e-9	Intelligence (multi-trait analysis);
THYM	cis	rs931812	0.516	rs1901362	chr8:101959609	G/A	cg04962480	chr8:101962118	YWHAZ	-0.37	-5.65	-0.5	1.7e-7	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs6032067	0.714	rs2206887	chr20:43856024	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.36	-0.48	5.9e-7	Blood protein levels;
THYM	cis	rs11096990	0.634	rs11947159	chr4:39288520	T/C	cg24403649	chr4:39172243	NA	-0.64	-5.38	-0.48	5.25e-7	Cognitive function;
THYM	cis	rs2860975	0.501	rs602941	chr10:96961184	G/A	cg09036531	chr10:96991505	NA	-0.67	-5.89	-0.52	5.91e-8	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.69	-5.16	-0.47	1.36e-6	Tonsillectomy;
THYM	cis	rs2806561	0.514	rs7414010	chr1:23543929	T/C	cg19743168	chr1:23544995	NA	0.92	8.02	0.64	2.67e-12	Height;
THYM	cis	rs4631830	0.863	rs3123078	chr10:51524971	A/G	cg16070123	chr10:51489643	NA	0.5	4.53	0.42	1.71e-5	Prostate-specific antigen levels;
THYM	cis	rs7617773	0.743	rs6804986	chr3:48363595	A/G	cg02219026	chr3:48282209	ZNF589	-0.66	-4.64	-0.43	1.11e-5	Coronary artery disease;
THYM	cis	rs4372836	0.754	rs6709674	chr2:28989667	A/G	cg09522027	chr2:28974177	PPP1CB	-0.65	-5.07	-0.46	1.98e-6	Body mass index;
THYM	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg24020549	chr11:64937741	SPDYC	-0.46	-4.46	-0.42	2.23e-5	Eosinophil percentage of white cells;
THYM	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg08859206	chr1:53392774	SCP2	0.6	6.92	0.58	5.22e-10	Monocyte count;
THYM	cis	rs6426551	1.000	rs7517174	chr1:226540327	A/C	ch.1.224314189F	chr1:226247566	NA	0.55	4.49	0.42	2e-5	Coronary artery disease;
THYM	cis	rs2820651	0.614	rs56003778	chr10:1490006	C/T	cg27404824	chr10:1454848	ADARB2	0.88	4.75	0.44	7.06e-6	Migraine with aura;
THYM	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg09904177	chr6:26538194	HMGN4	0.53	4.47	0.42	2.16e-5	Intelligence (multi-trait analysis);
THYM	cis	rs611744	0.934	rs2848619	chr8:109198185	T/C	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs2832077	0.505	rs9305386	chr21:30386751	A/G	cg20220242	chr21:30392188	RWDD2B	0.78	4.64	0.43	1.13e-5	Cognitive test performance;
THYM	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg23583168	chr7:148888333	NA	-1.0	-13.49	-0.81	8.5e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs58688157	0.705	rs936468	chr11:607175	G/A	cg07212818	chr11:638076	DRD4	-0.72	-5.26	-0.47	8.99e-7	Systemic lupus erythematosus;
THYM	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs4731207	0.596	rs1471572	chr7:124650942	C/A	cg05285228	chr7:124571219	POT1	-0.71	-5.47	-0.49	3.59e-7	Cutaneous malignant melanoma;
THYM	cis	rs4780401	0.573	rs8045673	chr16:11804385	C/A	cg01061890	chr16:11836724	TXNDC11	-0.69	-5.71	-0.51	1.27e-7	Rheumatoid arthritis;
THYM	cis	rs61931739	0.824	rs406753	chr12:34117408	A/G	cg10856724	chr12:34555212	NA	-0.6	-5.27	-0.48	8.62e-7	Morning vs. evening chronotype;
THYM	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	5.42	0.49	4.43e-7	Rheumatoid arthritis;
THYM	cis	rs8067545	0.967	rs4924801	chr17:19921070	T/C	cg13482628	chr17:19912719	NA	0.58	4.91	0.45	3.73e-6	Schizophrenia;
THYM	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg06028808	chr11:68637592	NA	0.65	6.79	0.57	9.52e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7264396	0.528	rs6058370	chr20:34518592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-4.69	-0.43	9.01e-6	Total cholesterol levels;
THYM	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg00071950	chr4:10020882	SLC2A9	0.88	9.22	0.69	7.56e-15	Bone mineral density;
THYM	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg12179176	chr11:130786555	SNX19	0.69	5.56	0.5	2.51e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg02018176	chr4:1364513	KIAA1530	0.58	4.57	0.42	1.46e-5	Obesity-related traits;
THYM	cis	rs11225247	0.772	rs35623064	chr11:102237391	T/C	cg06323957	chr11:102217781	BIRC2	1.02	4.74	0.44	7.52e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg07061783	chr6:25882402	NA	-0.91	-8.75	-0.67	7.75e-14	Intelligence (multi-trait analysis);
THYM	cis	rs62064224	0.589	rs2285428	chr17:30820176	C/T	cg18200150	chr17:30822561	MYO1D	-0.56	-4.68	-0.43	9.66e-6	Schizophrenia;
THYM	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs892961	0.932	rs8065422	chr17:75420165	T/C	cg11351908	chr17:75402473	SEPT9	0.65	6.55	0.56	3e-9	Airflow obstruction;
THYM	cis	rs888194	0.966	rs1558804	chr12:109898732	A/G	cg11367159	chr12:110044531	NA	0.49	4.53	0.42	1.71e-5	Neuroticism;
THYM	cis	rs9788721	0.640	rs1394371	chr15:78724469	C/T	cg18825076	chr15:78729989	IREB2	-0.6	-5.37	-0.48	5.64e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs4746818	1.000	rs7899844	chr10:70949694	A/G	cg04149295	chr10:70884716	VPS26A	0.78	5.31	0.48	7.18e-7	Left atrial antero-posterior diameter;
THYM	cis	rs17001868	0.568	rs6001894	chr22:40779197	T/C	cg07138101	chr22:40742427	ADSL	0.85	5.03	0.46	2.29e-6	Mammographic density (dense area);
THYM	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Bladder cancer;
THYM	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg02569458	chr12:86230093	RASSF9	0.63	5.56	0.5	2.51e-7	Major depressive disorder;
THYM	cis	rs8180040	0.903	rs11130124	chr3:47292183	T/C	cg27129171	chr3:47204927	SETD2	0.75	7.27	0.6	9.95e-11	Colorectal cancer;
THYM	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg08132940	chr7:1081526	C7orf50	-1.17	-6.69	-0.57	1.51e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17443541	0.507	rs6755597	chr2:200451440	A/G	cg03741458	chr2:200468445	NA	-0.8	-5.86	-0.52	6.75e-8	Intelligence (multi-trait analysis);
THYM	cis	rs3820068	0.608	rs9660255	chr1:16031891	T/G	cg27534772	chr1:16042836	PLEKHM2	0.51	5.25	0.47	9.14e-7	Systolic blood pressure;
THYM	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs67478160	0.625	rs7141473	chr14:104316055	A/C	cg08213375	chr14:104286397	PPP1R13B	-0.56	-6.73	-0.57	1.26e-9	Schizophrenia;
THYM	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.61	4.6	0.43	1.29e-5	Renal function-related traits (BUN);
THYM	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs9790314	0.696	rs9290069	chr3:160890946	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-4.73	-0.44	7.66e-6	Morning vs. evening chronotype;
THYM	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs11252926	0.545	rs10466270	chr10:556129	A/G	cg03684893	chr10:554711	DIP2C	-0.65	-5.24	-0.47	9.72e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg16342193	chr10:102329863	NA	-0.54	-5.35	-0.48	6.03e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11776767	0.793	rs1469556	chr8:10705896	T/C	cg13457217	chr8:10683266	MIR1322;PINX1	-0.63	-4.58	-0.43	1.4e-5	Triglycerides;
THYM	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg15704280	chr7:45808275	SEPT13	0.99	10.18	0.72	6.74e-17	Coronary artery disease;
THYM	cis	rs17125944	0.556	rs12588482	chr14:53311552	G/A	cg00686598	chr14:53173677	PSMC6	-1.06	-4.78	-0.44	6.42e-6	Alzheimer's disease (late onset);
THYM	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg18876405	chr7:65276391	NA	-0.63	-5.27	-0.48	8.53e-7	Aortic root size;
THYM	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.23	-10.06	-0.72	1.25e-16	Platelet count;
THYM	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg00631329	chr6:26305371	NA	0.59	7.16	0.59	1.69e-10	Educational attainment;
THYM	cis	rs2070677	0.736	rs4529856	chr10:135414020	C/G	cg20169779	chr10:135381914	SYCE1	-0.76	-4.97	-0.45	2.99e-6	Gout;
THYM	cis	rs2625529	0.652	rs28650442	chr15:72155445	A/T	cg16672083	chr15:72433130	SENP8	-0.49	-4.57	-0.42	1.48e-5	Red blood cell count;
THYM	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9831754	0.906	rs9869812	chr3:78385679	G/A	cg06138941	chr3:78371609	NA	-0.63	-4.49	-0.42	2e-5	Calcium levels;
THYM	cis	rs887829	0.570	rs6724485	chr2:234592816	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.79	-6.64	-0.56	1.94e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs11690935	0.571	rs1008151	chr2:172912098	G/A	cg13550731	chr2:172543902	DYNC1I2	0.69	5.51	0.49	3.09e-7	Schizophrenia;
THYM	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.68	-7.75	-0.62	9.97e-12	Crohn's disease;
THYM	cis	rs7586879	0.639	rs2033656	chr2:25100902	C/G	cg01884057	chr2:25150051	NA	0.71	7.55	0.61	2.68e-11	Body mass index;
THYM	cis	rs1971762	1.000	rs10876480	chr12:54066271	C/G	cg22997177	chr12:54070527	ATP5G2	-0.48	-5.15	-0.47	1.38e-6	Height;
THYM	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg07606381	chr6:8435919	SLC35B3	0.66	4.93	0.45	3.51e-6	Motion sickness;
THYM	cis	rs1784581	0.674	rs1784592	chr6:162387365	T/A	cg17173639	chr6:162384350	PARK2	-0.84	-7.88	-0.63	5.43e-12	Itch intensity from mosquito bite;
THYM	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg06108461	chr20:60628389	TAF4	-1.07	-9.25	-0.69	6.67e-15	Body mass index;
THYM	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg09338302	chr7:1325757	NA	0.48	4.55	0.42	1.6e-5	Bipolar disorder;
THYM	cis	rs7942486	0.893	rs11823901	chr11:13279949	C/T	cg13286116	chr11:13302098	ARNTL	-0.72	-8.02	-0.64	2.71e-12	Neuroticism;
THYM	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.88	5.64	0.5	1.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7656342	0.619	rs7688167	chr4:9893506	G/A	cg11266682	chr4:10021025	SLC2A9	-0.44	-4.45	-0.42	2.33e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs7590720	0.704	rs7603645	chr2:216876949	C/G	cg25588852	chr2:216877276	MREG	-0.7	-6.83	-0.57	8e-10	Alcohol dependence;
THYM	cis	rs4975709	0.758	rs4975756	chr5:1882443	T/C	cg19770292	chr5:1868693	NA	0.51	4.67	0.43	9.87e-6	Cardiovascular disease risk factors;
THYM	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg20290983	chr6:43655470	MRPS18A	1.44	15.94	0.85	1.35e-28	IgG glycosylation;
THYM	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg26384229	chr12:38710491	ALG10B	0.69	5.26	0.48	8.82e-7	Morning vs. evening chronotype;
THYM	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.18	7.92	0.63	4.46e-12	Body mass index;
THYM	cis	rs36051895	0.659	rs4495487	chr9:5072798	T/C	cg02405213	chr9:5042618	JAK2	-1.03	-11.11	-0.75	7.02e-19	Pediatric autoimmune diseases;
THYM	cis	rs11577318	0.853	rs7541333	chr1:26622889	C/T	cg00852783	chr1:26633632	UBXN11	0.68	5.73	0.51	1.16e-7	Granulocyte percentage of myeloid white cells;
THYM	cis	rs6921919	0.583	rs4357130	chr6:28367683	T/G	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.5	-0.42	1.89e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1642645	0.872	rs238675	chr1:42470274	C/T	cg10197057	chr1:42612518	NA	0.45	4.96	0.45	3.14e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs8067545	0.611	rs4925090	chr17:20066631	C/T	cg13482628	chr17:19912719	NA	0.54	4.49	0.42	2e-5	Schizophrenia;
THYM	cis	rs6547741	0.935	rs4260197	chr2:27794150	C/G	cg27432699	chr2:27873401	GPN1	-0.63	-5.49	-0.49	3.38e-7	Oral cavity cancer;
THYM	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11644478	chr21:40555479	PSMG1	-0.58	-4.76	-0.44	6.94e-6	Menarche (age at onset);
THYM	cis	rs9358749	0.661	rs1915462	chr6:24067026	A/C	cg00729264	chr6:24476663	GPLD1	1.0	4.46	0.42	2.22e-5	Response to abacavir-containing treatment in HIV-1 infection (virologic failure);Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
THYM	cis	rs7113850	0.541	rs77868378	chr11:24233684	C/T	ch.11.24196551F	chr11:24239977	NA	0.98	5.14	0.47	1.49e-6	Bone fracture in osteoporosis;
THYM	cis	rs7078219	0.714	rs12414770	chr10:101288238	G/T	cg07044859	chr10:101282883	NA	-0.48	-5.23	-0.47	1.01e-6	Dental caries;
THYM	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg00757033	chr12:89920650	WDR51B	0.75	12.04	0.78	7.96e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs7617773	0.780	rs11714944	chr3:48366971	C/A	cg02219026	chr3:48282209	ZNF589	-0.69	-4.83	-0.44	5.12e-6	Coronary artery disease;
THYM	cis	rs6700896	0.931	rs12043644	chr1:66147348	A/G	cg04111102	chr1:66153794	NA	0.57	5.42	0.49	4.47e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4907240	0.883	rs11678174	chr2:97249103	T/C	cg01950434	chr2:97203154	ARID5A	-0.58	-4.9	-0.45	3.86e-6	Event-related brain oscillations;
THYM	cis	rs9581943	0.967	rs7993114	chr13:28476277	A/G	cg16302790	chr13:28498334	PDX1	0.52	4.71	0.44	8.36e-6	Pancreatic cancer;
THYM	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11890956	chr21:40555474	PSMG1	1.05	9.92	0.71	2.44e-16	Cognitive function;
THYM	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg13319975	chr6:146136371	FBXO30	-0.65	-5.18	-0.47	1.24e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg22920501	chr2:26401640	FAM59B	-0.74	-6.28	-0.54	9.97e-9	Gut microbiome composition (summer);
THYM	cis	rs11585357	0.947	rs3003441	chr1:17611869	C/T	cg08277548	chr1:17600880	PADI3	0.87	5.92	0.52	5.07e-8	Hair shape;
THYM	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs1729951	0.575	rs361245	chr3:136695706	A/G	cg12473912	chr3:136751656	NA	0.63	5.0	0.46	2.66e-6	Neuroticism;
THYM	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.82	8.35	0.65	5.6e-13	Lymphocyte counts;
THYM	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg00071950	chr4:10020882	SLC2A9	0.86	9.24	0.69	7.11e-15	Bone mineral density;
THYM	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg10117171	chr1:25599238	RHD	-0.65	-4.82	-0.44	5.49e-6	Erythrocyte sedimentation rate;
THYM	cis	rs11645898	0.935	rs8047881	chr16:72193906	A/G	cg14768367	chr16:72042858	DHODH	-0.68	-5.07	-0.46	1.92e-6	Blood protein levels;
THYM	cis	rs78456975	0.546	rs72776254	chr2:1527881	C/T	cg12573674	chr2:1569213	NA	-1.24	-4.55	-0.42	1.59e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs317689	0.690	rs10878946	chr12:69642315	C/T	cg20891283	chr12:69753455	YEATS4	0.62	4.57	0.42	1.48e-5	Response to diuretic therapy;
THYM	cis	rs2859741	0.528	rs3753776	chr1:37480144	C/T	cg09363841	chr1:37513479	NA	-0.66	-5.15	-0.47	1.4e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs2898681	0.874	rs59649036	chr4:53741175	T/C	cg00791764	chr4:53727839	RASL11B	0.49	6.31	0.54	8.93e-9	Optic nerve measurement (cup area);
THYM	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg09537434	chr19:41945824	ATP5SL	0.66	5.02	0.46	2.36e-6	Migraine;Coronary artery disease;
THYM	cis	rs8114671	0.933	rs2103971	chr20:33786256	T/C	cg08999081	chr20:33150536	PIGU	-0.53	-4.77	-0.44	6.63e-6	Height;
THYM	cis	rs2456568	0.803	rs10831141	chr11:93640728	C/T	cg17595323	chr11:93583763	C11orf90	-0.6	-6.33	-0.54	8.23e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg12419862	chr22:24373484	LOC391322	-0.67	-5.94	-0.52	4.6e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2635047	0.967	rs12960378	chr18:44614090	A/C	cg19077165	chr18:44547161	KATNAL2	-0.52	-5.29	-0.48	7.88e-7	Educational attainment;
THYM	cis	rs9515201	0.859	rs9515199	chr13:111033704	C/T	cg15455643	chr13:111040242	COL4A2	-0.49	-5.27	-0.48	8.5e-7	White matter hyperintensity burden;
THYM	cis	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg17366294	chr4:99064904	C4orf37	-0.56	-6.73	-0.57	1.25e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6032067	0.641	rs35227660	chr20:43756697	C/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.64	-5.8	-0.51	8.81e-8	Blood protein levels;
THYM	cis	rs1403694	0.695	rs1851665	chr3:186436398	A/G	cg12454167	chr3:186435060	KNG1	0.53	7.54	0.61	2.83e-11	Blood protein levels;
THYM	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg11764359	chr7:65958608	NA	-0.88	-7.56	-0.61	2.55e-11	Aortic root size;
THYM	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg02574844	chr11:5959923	NA	-0.55	-4.77	-0.44	6.58e-6	DNA methylation (variation);
THYM	cis	rs36051895	0.589	rs7038763	chr9:5076399	T/C	cg02405213	chr9:5042618	JAK2	-1.03	-11.16	-0.75	5.69e-19	Pediatric autoimmune diseases;
THYM	cis	rs8006682	0.503	rs8010235	chr14:69085123	C/G	cg21123519	chr14:69095679	NA	-0.61	-4.56	-0.42	1.55e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs860818	1.000	rs10634	chr7:23240596	C/T	cg05407003	chr7:23246146	NA	1.27	4.72	0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg00012203	chr2:219082015	ARPC2	0.85	7.66	0.62	1.52e-11	Colorectal cancer;
THYM	cis	rs1933112	0.900	rs7519937	chr1:168504641	A/C	cg00154920	chr1:168513310	XCL2	-0.49	-4.88	-0.45	4.25e-6	Blood protein levels;
THYM	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg08773314	chr2:239334832	ASB1	0.64	9.78	0.71	4.82e-16	Multiple system atrophy;
THYM	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg25251562	chr2:3704773	ALLC	-0.81	-5.41	-0.49	4.62e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03517284	chr6:25882590	NA	-0.94	-7.9	-0.63	5e-12	Intelligence (multi-trait analysis);
THYM	cis	rs637571	0.607	rs574586	chr11:65697083	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	6.34	0.55	7.83e-9	Eosinophil percentage of white cells;
THYM	cis	rs6828523	0.764	rs73869045	chr4:175854469	C/T	cg14561282	chr4:175839468	ADAM29	0.61	4.51	0.42	1.83e-5	Breast cancer;
THYM	cis	rs3925075	1.000	rs9673404	chr16:31347592	A/T	cg02846316	chr16:31340340	ITGAM	0.57	5.99	0.52	3.79e-8	IgA nephropathy;
THYM	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg19761014	chr17:28927070	LRRC37B2	0.71	4.52	0.42	1.77e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg01579765	chr21:45077557	HSF2BP	-0.51	-7.89	-0.63	5.21e-12	Mean corpuscular volume;
THYM	cis	rs889398	0.802	rs12925700	chr16:69793463	C/A	cg09409435	chr16:70099608	PDXDC2	-0.6	-4.52	-0.42	1.77e-5	Body mass index;
THYM	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg17105886	chr17:28927953	LRRC37B2	1.26	6.35	0.55	7.32e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2456568	0.803	rs10765641	chr11:93640312	T/C	cg17595323	chr11:93583763	C11orf90	-0.6	-6.33	-0.54	8.23e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.37	0.55	6.78e-9	Prudent dietary pattern;
THYM	cis	rs75059851	0.756	rs11223656	chr11:133842973	T/A	cg14047540	chr11:133829660	NA	-1.1	-7.34	-0.6	7.1e-11	Schizophrenia;
THYM	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.96	8.0	0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs7020830	0.858	rs67036212	chr9:37133538	A/G	cg14294708	chr9:37120828	ZCCHC7	1.3	15.54	0.85	7.71e-28	Schizophrenia;
THYM	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg09549813	chr16:4587862	C16orf5	-0.55	-6.18	-0.54	1.61e-8	Schizophrenia;
THYM	cis	rs3820068	0.603	rs7536654	chr1:15989141	C/G	cg24675056	chr1:15929824	NA	0.76	6.26	0.54	1.13e-8	Systolic blood pressure;
THYM	trans	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg10856724	chr12:34555212	NA	-0.94	-8.13	-0.64	1.61e-12	Bladder cancer;
THYM	cis	rs3136739	0.764	rs7014476	chr8:42076046	G/T	cg12091331	chr8:42065314	PLAT	-0.72	-5.4	-0.48	4.95e-7	Plasma plasminogen activator levels;
THYM	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2637266	0.935	rs1866891	chr10:78396941	C/A	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs9831754	0.906	rs9840031	chr3:78396140	C/T	cg06138941	chr3:78371609	NA	0.64	4.55	0.42	1.6e-5	Calcium levels;
THYM	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg05043794	chr9:111880884	C9orf5	-0.36	-5.15	-0.47	1.43e-6	Menarche (age at onset);
THYM	cis	rs12586317	0.576	rs12586302	chr14:35691074	G/C	cg07166546	chr14:35805898	NA	-0.21	-5.0	-0.46	2.57e-6	Psoriasis;
THYM	cis	rs11157436	0.918	rs1076546	chr14:22626948	A/T	cg26433554	chr14:23315189	MMP14	0.43	4.5	0.42	1.89e-5	Neurocognitive impairment in HIV-1 infection (continuous);
THYM	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg16405210	chr4:1374714	KIAA1530	-1.03	-9.59	-0.7	1.24e-15	Longevity;
THYM	cis	rs9970807	1.000	rs17114046	chr1:56966350	A/G	cg11959316	chr1:57001742	PPAP2B	0.69	5.32	0.48	7e-7	Myocardial infarction;Coronary artery disease;
THYM	trans	rs4866334	1.000	rs114114986	chr5:18428605	C/A	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs2346160	0.831	rs1467391	chr6:167690062	A/G	cg21686812	chr6:168078911	NA	-0.52	-4.76	-0.44	6.96e-6	Parental extreme longevity (95 years and older);
THYM	cis	rs7731657	0.537	rs973901	chr5:130362623	G/T	cg08523029	chr5:130500466	HINT1	-0.85	-5.98	-0.52	3.88e-8	Fasting plasma glucose;
THYM	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg12564285	chr5:131593104	PDLIM4	0.5	5.63	0.5	1.84e-7	Breast cancer;
THYM	cis	rs9807989	0.839	rs10192036	chr2:102968211	C/A	cg03938978	chr2:103052716	IL18RAP	0.63	6.56	0.56	2.81e-9	Asthma;
THYM	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg13695892	chr22:41940480	POLR3H	0.94	8.24	0.65	9.49e-13	Vitiligo;
THYM	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg13736514	chr6:26305472	NA	-0.58	-7.15	-0.59	1.74e-10	Educational attainment;
THYM	cis	rs2294693	0.531	rs12210310	chr6:40950807	T/C	cg21128951	chr6:40996213	UNC5CL	0.64	4.59	0.43	1.37e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs2273669	0.588	rs79465564	chr6:109350290	C/T	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	cis	rs4866334	1.000	rs116499870	chr5:18479009	G/A	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs72792324	1.000	rs17097238	chr5:140742483	A/G	cg21929183	chr5:140807225	PCDHGA4;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB8P;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	-0.89	-4.6	-0.43	1.31e-5	Mean platelet volume;
THYM	cis	rs71403859	0.502	rs75986475	chr16:71464058	C/G	cg08717414	chr16:71523259	ZNF19	-1.23	-5.38	-0.48	5.26e-7	Post bronchodilator FEV1;
THYM	cis	rs367615	0.552	rs2963010	chr5:108737043	T/C	cg17395555	chr5:108820864	NA	-0.56	-7.04	-0.59	3.02e-10	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg15921436	chr17:44337874	NA	-0.91	-6.85	-0.58	7.19e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2811415	0.597	rs1042912	chr3:127789695	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs600806	0.815	rs10858089	chr1:109926828	T/C	cg02175308	chr1:109941060	SORT1	-0.6	-5.3	-0.48	7.58e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg10360139	chr7:1886902	MAD1L1	0.61	5.4	0.48	4.94e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs9522267	0.535	rs2039915	chr13:112238794	C/T	cg10483660	chr13:112241077	NA	-0.59	-6.84	-0.57	7.61e-10	Hepatitis;
THYM	cis	rs9311676	0.632	rs56281646	chr3:58424917	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs28595532	0.841	rs114385163	chr4:119737058	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs9902453	0.780	rs7210991	chr17:28190961	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.65	0.43	1.08e-5	Coffee consumption (cups per day);
THYM	cis	rs13064411	0.696	rs6773497	chr3:113186514	T/C	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs11838776	0.522	rs7318424	chr13:111021623	C/G	cg06243866	chr13:111019493	COL4A2	0.92	11.71	0.77	3.99e-20	Coronary artery disease;
THYM	cis	rs7833986	0.501	rs72653967	chr8:56999432	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	6.82	0.57	8.29e-10	Height;
THYM	cis	rs2404602	0.684	rs4886816	chr15:76874707	A/C	cg23625390	chr15:77176239	SCAPER	-0.9	-6.41	-0.55	5.72e-9	Blood metabolite levels;
THYM	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg11663144	chr21:46675770	NA	-0.7	-9.8	-0.71	4.38e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs36051895	0.623	rs62541541	chr9:5040817	G/C	cg02405213	chr9:5042618	JAK2	-1.03	-10.88	-0.74	2.16e-18	Pediatric autoimmune diseases;
THYM	cis	rs6546324	0.625	rs2861695	chr2:67846727	A/G	cg18237512	chr2:67827392	NA	-0.8	-4.77	-0.44	6.69e-6	Endometriosis;
THYM	cis	rs7000551	0.681	rs2461488	chr8:22371858	G/A	cg12081754	chr8:22256438	SLC39A14	0.63	5.44	0.49	4.08e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.34	0.48	6.29e-7	Iron status biomarkers;
THYM	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg24505687	chr6:33548425	BAK1	0.52	4.75	0.44	7.31e-6	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
THYM	cis	rs969413	0.624	rs9914093	chr17:79260653	C/G	cg14413466	chr17:79170920	AZI1	-0.66	-5.96	-0.52	4.2e-8	Frontotemporal dementia;
THYM	cis	rs9486719	0.948	rs11153059	chr6:97014537	T/A	cg18709589	chr6:96969512	KIAA0776	-0.68	-4.7	-0.43	8.62e-6	Migraine;Coronary artery disease;
THYM	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.86	7.55	0.61	2.63e-11	Monocyte percentage of white cells;
THYM	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg22166914	chr1:53195759	ZYG11B	0.78	7.69	0.62	1.37e-11	Monocyte count;
THYM	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg17063962	chr7:91808500	NA	-1.12	-12.68	-0.79	3.85e-22	Breast cancer;
THYM	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg12031863	chr16:4587854	C16orf5	-0.46	-4.99	-0.46	2.75e-6	Schizophrenia;
THYM	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg27129171	chr3:47204927	SETD2	0.8	7.67	0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.03	0.58	3.15e-10	Prudent dietary pattern;
THYM	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg13609457	chr4:120235615	NA	0.51	4.76	0.44	6.87e-6	Educational attainment;
THYM	trans	rs4650994	1.000	rs17361251	chr1:178520577	C/A	cg05059571	chr16:84539110	KIAA1609	-0.73	-7.57	-0.61	2.44e-11	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg02187348	chr16:89574699	SPG7	0.79	6.6	0.56	2.32e-9	Multiple myeloma (IgH translocation);
THYM	cis	rs36051895	0.632	rs1328919	chr9:5166548	C/T	cg02405213	chr9:5042618	JAK2	-0.98	-9.46	-0.7	2.37e-15	Pediatric autoimmune diseases;
THYM	cis	rs6500602	1.000	rs12447826	chr16:4464617	T/C	cg09549813	chr16:4587862	C16orf5	-0.5	-5.09	-0.46	1.78e-6	Schizophrenia;
THYM	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.37	0.73	2.66e-17	Prudent dietary pattern;
THYM	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg27129171	chr3:47204927	SETD2	-0.79	-7.59	-0.61	2.15e-11	QT interval;
THYM	cis	rs9527	0.590	rs3740386	chr10:104931051	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.49	-0.42	1.98e-5	Arsenic metabolism;
THYM	cis	rs476633	0.708	rs28547298	chr15:41446951	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.66	-4.95	-0.45	3.23e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg02527881	chr3:46936655	PTH1R	0.84	8.34	0.65	5.7e-13	Birth weight;
THYM	cis	rs9486719	0.552	rs9399923	chr6:96850379	G/A	cg18709589	chr6:96969512	KIAA0776	0.71	4.86	0.45	4.54e-6	Migraine;Coronary artery disease;
THYM	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg13319975	chr6:146136371	FBXO30	0.67	5.41	0.48	4.79e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg21775007	chr8:11205619	TDH	-0.73	-5.68	-0.5	1.49e-7	Retinal vascular caliber;
THYM	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg25358565	chr5:93447407	FAM172A	-1.0	-7.31	-0.6	8.27e-11	Diabetic retinopathy;
THYM	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg06558623	chr16:89946397	TCF25	1.14	6.15	0.53	1.82e-8	Skin colour saturation;
THYM	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg13609457	chr4:120235615	NA	0.51	4.8	0.44	5.83e-6	Corneal astigmatism;
THYM	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg03474202	chr17:45855739	NA	-0.77	-6.77	-0.57	1.08e-9	IgG glycosylation;
THYM	cis	rs1005224	0.963	rs2303345	chr14:76156609	A/G	cg04684003	chr14:76127793	TTLL5;C14orf1	0.72	5.8	0.51	8.78e-8	Large artery stroke;
THYM	cis	rs10089	0.857	rs7718286	chr5:127459414	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs6546324	0.625	rs4671812	chr2:67832486	C/T	cg18237512	chr2:67827392	NA	-0.78	-4.63	-0.43	1.16e-5	Endometriosis;
THYM	cis	rs4654899	0.865	rs12406144	chr1:21347228	A/C	cg01072550	chr1:21505969	NA	-0.75	-6.6	-0.56	2.29e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg27423445	chr12:12879764	APOLD1	0.53	4.52	0.42	1.78e-5	Systemic lupus erythematosus;
THYM	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg17211192	chr8:82754475	SNX16	-0.86	-6.98	-0.58	3.98e-10	Diastolic blood pressure;
THYM	cis	rs868036	0.681	rs9920643	chr15:68104314	C/T	cg24579218	chr15:68104479	NA	-0.82	-8.85	-0.67	4.77e-14	Restless legs syndrome;
THYM	cis	rs36051895	0.664	rs9695933	chr9:5153104	C/T	cg02405213	chr9:5042618	JAK2	-1.04	-11.68	-0.77	4.5e-20	Pediatric autoimmune diseases;
THYM	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg07167872	chr1:205819463	PM20D1	-0.67	-5.0	-0.46	2.62e-6	Menarche (age at onset);
THYM	cis	rs600806	0.850	rs10776806	chr1:109952127	G/A	cg02175308	chr1:109941060	SORT1	-0.56	-4.99	-0.46	2.76e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg15693483	chr7:1102177	C7orf50	0.53	6.21	0.54	1.41e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg11871910	chr12:69753446	YEATS4	0.65	4.73	0.44	7.91e-6	Response to diuretic therapy;
THYM	cis	rs6424115	0.830	rs2501424	chr1:24199182	T/C	cg15997130	chr1:24165203	NA	0.75	6.53	0.56	3.18e-9	Immature fraction of reticulocytes;
THYM	cis	rs977987	0.735	rs166013	chr16:75434146	C/T	cg07303275	chr16:75499416	TMEM170A	-0.58	-4.75	-0.44	7.16e-6	Dupuytren's disease;
THYM	cis	rs7599312	0.534	rs6435711	chr2:213410065	G/A	cg20637307	chr2:213403960	ERBB4	1.04	11.31	0.76	2.72e-19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.65	-11.83	-0.77	2.19e-20	Hemostatic factors and hematological phenotypes;
THYM	cis	rs10743315	0.557	rs77782809	chr12:19364138	T/C	cg02471346	chr12:19282374	PLEKHA5	1.09	4.55	0.42	1.58e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs6956675	1.000	rs1879843	chr7:62586129	A/G	cg08930214	chr7:62859557	LOC100287834	0.64	4.69	0.43	9.07e-6	Obesity-related traits;
THYM	cis	rs7584330	0.554	rs114331205	chr2:238432559	A/C	cg14458575	chr2:238380390	NA	0.8	4.67	0.43	9.97e-6	Prostate cancer;
THYM	cis	rs8067545	0.611	rs77449863	chr17:20191860	C/G	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg04750100	chr2:136595281	LCT	-0.55	-6.19	-0.54	1.51e-8	Mosquito bite size;
THYM	cis	rs7178572	0.568	rs12907847	chr15:77493174	C/T	cg22256960	chr15:77711686	NA	-1.04	-8.57	-0.66	1.83e-13	Type 2 diabetes;
THYM	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg17143192	chr8:8559678	CLDN23	0.62	4.72	0.44	7.96e-6	Mood instability;
THYM	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg24209194	chr3:40518798	ZNF619	-0.54	-4.48	-0.42	2.06e-5	Renal cell carcinoma;
THYM	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg06219351	chr7:158114137	PTPRN2	-0.74	-7.25	-0.6	1.13e-10	Calcium levels;
THYM	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg24257776	chr3:47051546	LOC100129354	0.41	4.78	0.44	6.38e-6	Colorectal cancer;
THYM	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg08439880	chr3:133502540	NA	-0.73	-6.29	-0.54	9.52e-9	Iron status biomarkers;
THYM	cis	rs34779708	0.966	rs12773647	chr10:35440327	A/G	cg03585969	chr10:35415529	CREM	0.65	4.51	0.42	1.87e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs11078597	0.671	rs34599286	chr17:1645747	C/A	cg18436246	chr17:1640651	WDR81	0.65	4.6	0.43	1.29e-5	Serum albumin level;
THYM	cis	rs17655565	0.533	rs12825729	chr12:52706854	G/A	cg20997463	chr12:53689079	PFDN5	0.68	4.48	0.42	2.12e-5	Plasma amyloid beta peptide concentrations (ABx-42);
THYM	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg03517284	chr6:25882590	NA	0.71	5.59	0.5	2.14e-7	Schizophrenia;
THYM	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg04154034	chr17:28927549	LRRC37B2	0.88	4.53	0.42	1.73e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9653442	0.835	rs11694875	chr2:100732845	A/G	cg07810366	chr2:100720526	AFF3	0.4	5.85	0.51	7.02e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs6754311	0.731	rs309168	chr2:136670298	C/T	cg07169764	chr2:136633963	MCM6	0.69	5.68	0.5	1.44e-7	Mosquito bite size;
THYM	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg23711669	chr6:146136114	FBXO30	0.93	9.15	0.68	1.08e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg14784868	chr12:69753453	YEATS4	0.75	5.63	0.5	1.83e-7	Response to diuretic therapy;
THYM	cis	rs6988636	0.818	rs10111810	chr8:124169565	G/A	cg22384356	chr8:124195192	FAM83A	-0.8	-4.56	-0.42	1.5e-5	Urinary uromodulin levels;
THYM	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12756686	chr19:29218302	NA	0.86	6.94	0.58	4.77e-10	Methadone dose in opioid dependence;
THYM	cis	rs1950626	0.705	rs34991312	chr14:101435167	A/C	cg11887864	chr14:101510502	MIR1185-2	0.55	4.63	0.43	1.17e-5	Pelvic organ prolapse (moderate/severe);
THYM	cis	rs7567389	0.719	rs4150499	chr2:128028792	T/C	cg09760422	chr2:128146352	NA	-0.4	-4.52	-0.42	1.8e-5	Self-rated health;
THYM	cis	rs11722228	0.549	rs73212853	chr4:10096230	C/T	cg02317251	chr4:10116515	WDR1	-0.56	-4.95	-0.45	3.23e-6	Gout;Urate levels;Serum uric acid levels;
THYM	trans	rs58106596	0.800	rs67402940	chr2:232566499	T/C	cg01370599	chr3:116745421	NA	0.94	7.06	0.59	2.75e-10	White blood cell count;Lymphocyte counts;
THYM	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg05707623	chr12:122985044	ZCCHC8	0.72	4.77	0.44	6.6e-6	Body mass index;
THYM	cis	rs11625487	0.515	rs12434419	chr14:77855617	G/A	cg20045696	chr14:77926864	AHSA1	-0.91	-8.22	-0.64	1.02e-12	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
THYM	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg22709100	chr7:91322751	NA	-0.62	-4.77	-0.44	6.6e-6	Breast cancer;
THYM	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg25554036	chr4:6271136	WFS1	0.57	5.18	0.47	1.23e-6	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.56	-4.5	-0.42	1.93e-5	Platelet count;
THYM	cis	rs78366141	0.649	rs10428273	chr4:89672738	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	1.14	4.83	0.44	5.28e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg11905131	chr22:24372483	LOC391322	-0.68	-4.82	-0.44	5.48e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs2948294	0.566	rs13274039	chr8:8111659	A/G	cg06636001	chr8:8085503	FLJ10661	0.71	6.18	0.54	1.6e-8	Red cell distribution width;
THYM	cis	rs8050907	0.744	rs11866840	chr16:4536354	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.28	5.13	0.47	1.5e-6	Obesity-related traits;
THYM	cis	rs8016982	0.611	rs8008870	chr14:81709374	C/T	cg21807262	chr14:81713016	NA	-0.58	-5.3	-0.48	7.62e-7	Schizophrenia;
THYM	cis	rs7426056	0.671	rs56209416	chr2:204627500	T/C	cg07930752	chr2:204569955	CD28	-0.66	-4.46	-0.42	2.26e-5	Primary sclerosing cholangitis;
THYM	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg00684032	chr4:1343700	KIAA1530	-0.66	-5.62	-0.5	1.9e-7	Obesity-related traits;
THYM	cis	rs250585	0.688	rs30017	chr16:23412310	G/A	cg00143387	chr16:23521605	GGA2	0.74	5.21	0.47	1.11e-6	Egg allergy;
THYM	trans	rs8073060	0.586	rs2523116	chr17:34025460	T/C	cg19694781	chr19:47549865	TMEM160	-1.02	-8.69	-0.67	1.01e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs6435161	0.959	rs72926952	chr2:203485086	G/T	cg18429434	chr2:203499731	FAM117B	-0.68	-4.47	-0.42	2.14e-5	Total cholesterol levels;
THYM	cis	rs9649465	0.967	rs598115	chr7:123402603	C/G	cg15443791	chr7:124364398	NA	-0.57	-4.87	-0.45	4.48e-6	Migraine;
THYM	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg02788857	chr8:22132959	PIWIL2	0.57	5.15	0.47	1.4e-6	Hypertriglyceridemia;
THYM	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg04287289	chr16:89883240	FANCA	0.58	5.31	0.48	7.31e-7	Vitiligo;
THYM	cis	rs7119	0.678	rs12914098	chr15:77823013	C/T	cg10437265	chr15:77819839	NA	0.76	7.54	0.61	2.76e-11	Type 2 diabetes;
THYM	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg24874828	chr4:187887005	NA	-0.72	-7.43	-0.61	4.68e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7705502	0.580	rs72810955	chr5:173297302	C/T	cg18693985	chr5:173351052	CPEB4	-0.79	-5.72	-0.51	1.24e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg01191920	chr7:158217561	PTPRN2	-1.06	-12.51	-0.79	8.38e-22	Obesity-related traits;
THYM	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg04248312	chr19:17393744	ANKLE1	-0.96	-12.68	-0.79	3.82e-22	Systemic lupus erythematosus;
THYM	cis	rs2742234	0.541	rs61268333	chr10:43721370	G/A	cg06632098	chr10:43605906	RET	0.8	5.26	0.47	8.98e-7	Hirschsprung disease;
THYM	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg10589385	chr1:150898437	SETDB1	0.6	4.82	0.44	5.42e-6	Melanoma;
THYM	cis	rs2282300	0.739	rs1616223	chr11:30338783	A/C	cg25418670	chr11:30344373	C11orf46	-0.82	-6.98	-0.58	3.93e-10	Morning vs. evening chronotype;
THYM	cis	rs7078219	0.505	rs6584281	chr10:101286480	A/G	cg07044859	chr10:101282883	NA	-0.4	-4.62	-0.43	1.19e-5	Dental caries;
THYM	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg08885076	chr2:99613938	TSGA10	0.52	5.02	0.46	2.4e-6	Chronic sinus infection;
THYM	cis	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg19693284	chr19:2783607	SGTA	0.65	5.31	0.48	7.33e-7	Total cholesterol levels;
THYM	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg06808227	chr14:105710500	BRF1	-1.02	-8.64	-0.66	1.33e-13	Mean platelet volume;Platelet distribution width;
THYM	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg14829155	chr15:31115871	NA	-0.58	-5.13	-0.47	1.51e-6	Huntington's disease progression;
THYM	cis	rs4460079	0.531	rs4444906	chr4:114838743	A/G	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs4722166	0.630	rs2091115	chr7:22810166	G/T	cg05472934	chr7:22766657	IL6	0.75	6.93	0.58	4.98e-10	Lung cancer;
THYM	cis	rs73086581	0.945	rs6052219	chr20:3970307	A/G	cg02187196	chr20:3869020	PANK2	0.5	5.62	0.5	1.92e-7	Response to antidepressants in depression;
THYM	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg26384229	chr12:38710491	ALG10B	0.97	7.47	0.61	3.87e-11	Bladder cancer;
THYM	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs12579753	0.913	rs7965664	chr12:82237340	G/T	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.67	-0.43	1.01e-5	Resting heart rate;
THYM	cis	rs2235649	0.623	rs8048162	chr16:1848918	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.61	-5.31	-0.48	7.12e-7	Blood metabolite levels;
THYM	cis	rs870825	0.556	rs6552811	chr4:185653351	T/A	cg04058563	chr4:185651563	MLF1IP	-1.08	-9.22	-0.69	7.72e-15	Blood protein levels;
THYM	cis	rs13102973	0.932	rs4130840	chr4:135869598	T/G	cg14419869	chr4:135874104	NA	-0.82	-7.94	-0.63	4.06e-12	Subjective well-being;
THYM	trans	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11039798	1.000	rs6485848	chr11:48541517	G/T	cg24672777	chr11:48374446	OR4C45	-1.14	-6.95	-0.58	4.55e-10	Axial length;
THYM	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg04455712	chr21:45112962	RRP1B	0.51	4.72	0.44	8.23e-6	Mean corpuscular volume;
THYM	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.09e-8	Systolic blood pressure;
THYM	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg22189786	chr22:42395067	WBP2NL	0.57	5.17	0.47	1.27e-6	Birth weight;
THYM	cis	rs6430585	0.583	rs61253125	chr2:136618178	T/C	cg04750100	chr2:136595281	LCT	0.57	5.29	0.48	7.86e-7	Corneal structure;
THYM	cis	rs1691799	0.899	rs1168317	chr12:66746225	C/T	cg16791601	chr12:66731901	HELB	-0.75	-7.21	-0.59	1.32e-10	White blood cell count (basophil);
THYM	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.78	-7.17	-0.59	1.61e-10	Personality dimensions;
THYM	cis	rs9914988	0.887	rs62066838	chr17:27184533	C/T	cg20469991	chr17:27169893	C17orf63	0.79	4.83	0.44	5.2e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg15744005	chr10:104629667	AS3MT	-0.78	-7.33	-0.6	7.48e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2046867	0.818	rs34582798	chr3:72882778	A/C	cg25664220	chr3:72788482	NA	-0.96	-7.85	-0.63	6.21e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg10224037	chr5:178157518	ZNF354A	0.99	8.05	0.64	2.38e-12	Neutrophil percentage of white cells;
THYM	cis	rs11249608	0.548	rs17078988	chr5:178459283	A/G	cg01312482	chr5:178451176	ZNF879	-0.76	-6.3	-0.54	9.29e-9	Pubertal anthropometrics;
THYM	cis	rs2235642	0.701	rs2281230	chr16:1601767	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.54	-5.93	-0.52	4.97e-8	Coronary artery disease;
THYM	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs62435770	1.000	rs62433641	chr6:169539442	C/G	cg07652237	chr6:170125491	PHF10	0.51	4.5	0.42	1.96e-5	Loneliness;
THYM	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg18252515	chr7:66147081	NA	-0.67	-5.13	-0.47	1.5e-6	Aortic root size;
THYM	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg11629889	chr17:40839022	CNTNAP1	0.62	4.83	0.44	5.3e-6	Colorectal or endometrial cancer;
THYM	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg24642844	chr7:1081250	C7orf50	-1.14	-7.81	-0.63	7.41e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg26131816	chr17:42072204	PYY	0.54	4.65	0.43	1.07e-5	Menopause (age at onset);
THYM	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg19748678	chr4:122722346	EXOSC9	0.73	5.15	0.47	1.42e-6	Type 2 diabetes;
THYM	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg08968635	chr6:28129556	ZNF389	0.57	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs77140172	0.655	rs79387006	chr4:89672775	A/T	cg01026744	chr4:89619053	NAP1L5;HERC3	1.14	4.83	0.44	5.28e-6	Post bronchodilator FEV1;
THYM	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg06640241	chr16:89574553	SPG7	0.91	8.52	0.66	2.4e-13	Multiple myeloma (IgH translocation);
THYM	cis	rs11645898	0.810	rs11646364	chr16:72108687	A/T	cg14768367	chr16:72042858	DHODH	-0.79	-5.73	-0.51	1.18e-7	Blood protein levels;
THYM	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06634786	chr22:41940651	POLR3H	-0.77	-5.81	-0.51	8.35e-8	Vitiligo;
THYM	cis	rs5769707	0.632	rs135876	chr22:50013573	A/G	cg20744362	chr22:50050164	C22orf34	0.8	6.92	0.58	5.17e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg05564831	chr3:52568323	NT5DC2	0.48	5.07	0.46	1.99e-6	Electroencephalogram traits;
THYM	cis	rs1003719	0.751	rs55992706	chr21:38542749	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.75e-5	Eye color traits;
THYM	cis	rs9921222	0.565	rs1805105	chr16:396264	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.51	-5.18	-0.47	1.22e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg10360139	chr7:1886902	MAD1L1	-0.61	-4.94	-0.45	3.36e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs892961	0.932	rs6501954	chr17:75414398	G/C	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs11690935	0.959	rs7355594	chr2:172639448	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.79	-5.64	-0.5	1.75e-7	Schizophrenia;
THYM	cis	rs6995541	0.505	rs7013032	chr8:10706359	C/G	cg13457217	chr8:10683266	MIR1322;PINX1	-0.62	-4.52	-0.42	1.78e-5	Triglyceride levels;
THYM	cis	rs61931739	1.000	rs12424741	chr12:34022771	C/T	cg10856724	chr12:34555212	NA	0.58	4.99	0.46	2.75e-6	Morning vs. evening chronotype;
THYM	cis	rs9796	0.870	rs8023345	chr15:41338348	T/G	cg21153102	chr15:41252147	NA	0.71	6.51	0.56	3.61e-9	Menopause (age at onset);
THYM	cis	rs1697139	1.000	rs1697139	chr5:66511535	A/G	cg11553311	chr5:66541588	NA	0.49	5.28	0.48	8.09e-7	Breast cancer;
THYM	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs7089973	0.872	rs35628210	chr10:116630031	G/A	cg23260525	chr10:116636907	FAM160B1	0.51	4.61	0.43	1.24e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs6728642	0.908	rs7588921	chr2:98021001	C/T	cg26665480	chr2:98280029	ACTR1B	-0.83	-5.09	-0.46	1.79e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg08999081	chr20:33150536	PIGU	0.71	6.16	0.53	1.73e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.94	-0.63	4.09e-12	Personality dimensions;
THYM	cis	rs3008870	0.727	rs11208971	chr1:67383901	G/A	cg02640540	chr1:67518911	SLC35D1	0.6	4.77	0.44	6.68e-6	Lymphocyte percentage of white cells;
THYM	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg05738196	chr6:26577821	NA	0.83	8.34	0.65	5.62e-13	Intelligence (multi-trait analysis);
THYM	cis	rs72627123	0.656	rs77660260	chr14:74569573	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.29	7.08	0.59	2.46e-10	Morning vs. evening chronotype;
THYM	cis	rs4866334	1.000	rs79246642	chr5:18442878	C/T	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg00129232	chr17:37814104	STARD3	-0.84	-6.63	-0.56	2.03e-9	Asthma;
THYM	cis	rs10193935	0.901	rs2286701	chr2:42555636	T/C	cg27598129	chr2:42591480	NA	-0.75	-4.61	-0.43	1.25e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg17063962	chr7:91808500	NA	1.15	11.08	0.75	8.21e-19	Breast cancer;
THYM	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg22681709	chr2:178499509	PDE11A	-0.6	-5.78	-0.51	9.6e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs59698941	0.943	rs67952459	chr5:132297902	C/T	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs941408	0.890	rs1640269	chr19:2793194	A/C	cg19693284	chr19:2783607	SGTA	0.65	5.09	0.46	1.81e-6	Total cholesterol levels;
THYM	cis	rs7727544	0.582	rs6896703	chr5:131521295	C/G	cg16205897	chr5:131564050	P4HA2	0.46	4.73	0.44	7.86e-6	Blood metabolite levels;
THYM	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs1003719	0.737	rs2835587	chr21:38461795	A/T	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs490234	0.841	rs7044663	chr9:128268263	C/T	cg14078157	chr9:128172775	NA	-0.7	-5.59	-0.5	2.17e-7	Mean arterial pressure;
THYM	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg11764359	chr7:65958608	NA	-0.78	-6.31	-0.54	8.88e-9	Aortic root size;
THYM	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg05147244	chr20:61493195	TCFL5	1.03	6.29	0.54	9.88e-9	Obesity-related traits;
THYM	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg11764359	chr7:65958608	NA	0.87	7.45	0.61	4.16e-11	Aortic root size;
THYM	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg00300879	chr1:26503847	CNKSR1	0.43	5.74	0.51	1.15e-7	Height;
THYM	cis	rs9287719	0.781	rs6714795	chr2:10759134	C/T	cg03983476	chr2:10830698	NOL10	-0.58	-5.35	-0.48	6.15e-7	Prostate cancer;
THYM	cis	rs12348691	0.503	rs10739513	chr9:100592705	C/T	cg13688889	chr9:100608707	NA	-0.88	-5.98	-0.52	3.87e-8	Alopecia areata;
THYM	cis	rs4638749	0.677	rs13023102	chr2:108837663	C/T	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg22907277	chr7:1156413	C7orf50	0.86	5.37	0.48	5.5e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10463554	0.927	rs469094	chr5:102423579	A/C	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs1728785	1.000	rs698719	chr16:68560125	C/T	cg02972257	chr16:68554789	NA	-0.74	-4.6	-0.43	1.31e-5	Ulcerative colitis;
THYM	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg03929089	chr4:120376271	NA	0.86	8.5	0.66	2.63e-13	Height;
THYM	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg14074117	chr16:1909714	C16orf73	-0.7	-4.45	-0.42	2.3e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg11189052	chr15:85197271	WDR73	-0.67	-5.52	-0.49	2.94e-7	P wave terminal force;
THYM	cis	rs6835098	0.962	rs10027704	chr4:174083107	T/C	cg08422745	chr4:174089978	GALNT7	-0.97	-8.28	-0.65	7.55e-13	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg12165864	chr7:66369176	NA	-0.63	-5.01	-0.46	2.51e-6	Aortic root size;
THYM	cis	rs9914578	1.000	rs9915112	chr17:2007826	A/G	cg16513277	chr17:2031491	SMG6	-0.7	-4.59	-0.43	1.38e-5	Body mass index;
THYM	cis	rs9814567	0.806	rs9857995	chr3:134316706	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.8	8.17	0.64	1.3e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6490294	0.659	rs737280	chr12:112194976	T/C	cg10833066	chr12:111807467	FAM109A	0.5	5.4	0.48	4.84e-7	Mean platelet volume;
THYM	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg26384229	chr12:38710491	ALG10B	1.04	9.99	0.72	1.71e-16	Heart rate;
THYM	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg24531977	chr5:56204891	C5orf35	-0.63	-4.82	-0.44	5.45e-6	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17174870	0.955	rs4349353	chr2:112764508	G/A	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs3796352	1.000	rs1346719	chr3:53077372	A/G	cg07884673	chr3:53033167	SFMBT1	0.89	4.82	0.44	5.43e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs912057	0.671	rs1294425	chr6:6744292	G/A	cg06612196	chr6:6737390	NA	0.71	11.9	0.77	1.57e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs62070183	0.882	rs17183295	chr17:31078272	C/T	cg23177095	chr17:30873196	MYO1D	0.64	5.02	0.46	2.41e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs6430585	0.528	rs309158	chr2:136680534	A/G	cg07169764	chr2:136633963	MCM6	1.04	11.13	0.75	6.52e-19	Corneal structure;
THYM	cis	rs679087	0.659	rs302318	chr12:29921667	T/C	cg14258853	chr12:29935411	TMTC1	-0.54	-4.96	-0.45	3.02e-6	Schizophrenia;
THYM	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg15556689	chr8:8085844	FLJ10661	0.71	6.09	0.53	2.42e-8	Neuroticism;
THYM	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs300703	0.542	rs67993758	chr2:179594	C/T	cg21211680	chr2:198530	NA	-0.86	-5.61	-0.5	1.95e-7	Blood protein levels;
THYM	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.09	0.64	1.91e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs804280	1.000	rs804281	chr8:11611865	A/G	cg12395012	chr8:11607386	GATA4	-0.59	-5.53	-0.49	2.84e-7	Myopia (pathological);
THYM	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-14.05	-0.82	6.23e-25	Height;
THYM	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg26566898	chr11:117069891	TAGLN	-0.4	-5.14	-0.47	1.45e-6	Blood protein levels;
THYM	cis	rs9393777	0.623	rs1884943	chr6:26485725	G/A	cg12826209	chr6:26865740	GUSBL1	0.87	5.84	0.51	7.22e-8	Intelligence (multi-trait analysis);
THYM	cis	rs240764	0.764	rs6903206	chr6:100929516	A/G	cg21058520	chr6:100914733	NA	-0.57	-5.26	-0.47	9.03e-7	Neuroticism;
THYM	cis	rs6032067	0.777	rs62208386	chr20:43790872	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs995000	0.899	rs9436223	chr1:62903547	C/T	cg06896770	chr1:63153194	DOCK7	0.92	7.12	0.59	2.07e-10	Triglyceride levels;
THYM	cis	rs11711311	1.000	rs9830975	chr3:113486019	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.58	-5.13	-0.47	1.55e-6	IgG glycosylation;
THYM	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg01416388	chr22:39784598	NA	-0.79	-6.31	-0.54	8.71e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg09455208	chr3:40491958	NA	0.51	5.39	0.48	5.03e-7	Renal cell carcinoma;
THYM	cis	rs6960043	0.738	rs2358159	chr7:15054908	T/C	cg19272540	chr7:15055459	NA	0.53	5.98	0.52	3.98e-8	Type 2 diabetes;
THYM	cis	rs227932	0.764	rs4722246	chr7:23721978	T/C	cg20265043	chr7:23510089	IGF2BP3	-0.67	-4.64	-0.43	1.13e-5	Schizophrenia;
THYM	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg05802129	chr4:122689817	NA	-0.63	-5.15	-0.47	1.41e-6	Type 2 diabetes;
THYM	cis	rs9443189	0.570	rs7765254	chr6:76398143	T/C	cg01950844	chr6:76311363	SENP6	1.11	6.09	0.53	2.37e-8	Prostate cancer;
THYM	cis	rs7107770	1.000	rs12791760	chr11:125091568	C/T	cg07747661	chr11:125106135	PKNOX2	0.79	4.62	0.43	1.22e-5	Photic sneeze reflex;
THYM	cis	rs7193541	0.662	rs8058133	chr16:74657485	A/T	cg01733217	chr16:74700730	RFWD3	1.04	12.89	0.8	1.41e-22	Multiple myeloma;
THYM	cis	rs9915657	0.803	rs12449851	chr17:70099002	C/T	cg09344028	chr17:70110421	NA	-0.47	-4.93	-0.45	3.43e-6	Thyroid hormone levels;
THYM	cis	rs7551222	0.662	rs4951399	chr1:204533255	G/A	cg20240347	chr1:204465584	NA	-0.53	-4.68	-0.43	9.35e-6	Schizophrenia;
THYM	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg04944784	chr2:26401820	FAM59B	-1.07	-8.38	-0.65	4.66e-13	Gut microbiome composition (summer);
THYM	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg15448220	chr1:150897856	SETDB1	0.88	7.31	0.6	8.31e-11	Melanoma;
THYM	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg04181038	chr4:183730758	NA	1.01	8.37	0.65	4.88e-13	Pediatric autoimmune diseases;
THYM	cis	rs10883723	0.962	rs1056740	chr10:104236552	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.48	0.61	3.66e-11	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.38	5.88	0.52	6.06e-8	Obesity-related traits;
THYM	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg13695892	chr22:41940480	POLR3H	-0.86	-5.96	-0.52	4.19e-8	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs1061377	0.585	rs2163271	chr4:39078145	C/G	cg24403649	chr4:39172243	NA	0.57	4.59	0.43	1.35e-5	Uric acid levels;
THYM	cis	rs3768617	0.510	rs10911239	chr1:183062450	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.76	0.44	6.83e-6	Fuchs's corneal dystrophy;
THYM	cis	rs899997	1.000	rs2017091	chr15:79032744	G/A	cg22753661	chr15:79092743	ADAMTS7	0.72	4.59	0.43	1.36e-5	Coronary artery disease or large artery stroke;
THYM	cis	rs4243830	0.850	rs11122043	chr1:6580429	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.78	-4.47	-0.42	2.15e-5	Body mass index;
THYM	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg02953382	chr22:24373134	LOC391322	-0.62	-4.77	-0.44	6.71e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7084402	0.967	rs1658438	chr10:60326583	A/G	cg07615347	chr10:60278583	BICC1	-0.57	-5.36	-0.48	5.86e-7	Refractive error;
THYM	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3924048	0.574	rs34494202	chr1:12612868	G/A	cg00291366	chr1:12616550	NA	0.41	6.37	0.55	6.58e-9	Optic cup area;
THYM	cis	rs1198430	0.683	rs534417	chr1:23784965	A/G	cg19827787	chr1:23763612	ASAP3	0.67	5.24	0.47	9.56e-7	Total cholesterol levels;
THYM	cis	rs6430585	0.528	rs309172	chr2:136674028	A/G	cg04750100	chr2:136595281	LCT	0.59	6.16	0.53	1.74e-8	Corneal structure;
THYM	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg06766960	chr11:133703094	NA	-0.6	-5.63	-0.5	1.82e-7	Childhood ear infection;
THYM	cis	rs739496	0.542	rs7306529	chr12:111780644	A/G	cg10833066	chr12:111807467	FAM109A	0.52	6.08	0.53	2.48e-8	Platelet count;
THYM	cis	rs1351696	1	rs1351696	chr11:48382471	A/G	cg24672777	chr11:48374446	OR4C45	1.16	7.24	0.6	1.16e-10	D-dimer levels;
THYM	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg12863693	chr15:85201151	NMB	-0.58	-5.0	-0.46	2.58e-6	Schizophrenia;
THYM	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg05347473	chr6:146136440	FBXO30	0.78	6.94	0.58	4.68e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs35264875	1.000	rs72919428	chr11:68828949	C/T	cg23845249	chr11:68861649	NA	0.54	5.48	0.49	3.53e-7	Blond vs. brown hair color;
THYM	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg12311346	chr5:56204834	C5orf35	-0.96	-7.47	-0.61	3.78e-11	Type 2 diabetes;
THYM	cis	rs6733011	0.581	rs4851162	chr2:99466659	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.56	-0.42	1.54e-5	Bipolar disorder;
THYM	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.29	-9.45	-0.7	2.43e-15	Gut microbiome composition (summer);
THYM	cis	rs2241584	0.967	rs11748814	chr5:175939898	G/C	cg02270010	chr5:175958651	RNF44	-0.3	-4.72	-0.44	8.01e-6	Menopause (age at onset);
THYM	cis	rs12149862	1.000	rs13337337	chr16:69461367	A/G	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs2282930	0.512	rs2237462	chr7:50729944	C/T	cg08586669	chr7:50727761	GRB10	0.32	4.77	0.44	6.53e-6	Bone mineral density;
THYM	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg04362960	chr10:104952993	NT5C2	0.57	4.67	0.43	9.99e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs3126085	0.935	rs34188926	chr1:152293481	A/C	cg10321714	chr1:152280068	FLG	-0.68	-4.95	-0.45	3.18e-6	Atopic dermatitis;
THYM	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	6.03	0.53	3.12e-8	Obesity-related traits;
THYM	cis	rs870825	0.616	rs6834156	chr4:185639903	G/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs17473412	0.963	rs11740716	chr5:122701234	A/G	cg18093572	chr5:122598329	NA	0.55	4.68	0.43	9.42e-6	Total body bone mineral density;
THYM	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-6.02	-0.53	3.27e-8	Prostate cancer;
THYM	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg19729930	chr2:74357872	NA	-1.25	-10.62	-0.74	7.79e-18	Gestational age at birth (maternal effect);
THYM	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Schizophrenia;
THYM	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg06917634	chr15:78832804	PSMA4	0.96	8.89	0.67	3.96e-14	Sudden cardiac arrest;
THYM	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg27535305	chr1:53392650	SCP2	-0.42	-4.82	-0.44	5.5e-6	Monocyte count;
THYM	cis	rs7568458	0.870	rs6733913	chr2:85757379	T/C	cg17127132	chr2:85788382	GGCX	0.65	5.25	0.47	9.44e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs4242434	0.672	rs3758042	chr8:22486951	T/C	cg11461670	chr8:22454935	PDLIM2	-0.33	-6.26	-0.54	1.09e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg02228675	chr17:40259724	DHX58	-0.66	-5.49	-0.49	3.28e-7	Fibrinogen levels;
THYM	cis	rs6032067	0.777	rs13037651	chr20:43782230	C/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs986417	0.901	rs1015119	chr14:61027510	G/T	cg27398547	chr14:60952738	C14orf39	1.21	6.17	0.53	1.69e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs13424612	0.965	rs4149541	chr2:240957734	G/A	cg01812947	chr2:240904978	NDUFA10	0.59	4.5	0.42	1.92e-5	Odorant perception (isobutyraldehyde);
THYM	cis	rs7107174	1.000	rs2511180	chr11:77937255	A/G	cg19901956	chr11:77921274	USP35	-0.72	-5.72	-0.51	1.22e-7	Testicular germ cell tumor;
THYM	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg22841779	chr14:105766346	BRF1	-0.47	-5.84	-0.51	7.22e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg13114125	chr14:105738426	BRF1	-0.74	-5.72	-0.51	1.22e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs12519773	0.526	rs6897863	chr5:92512481	A/C	cg18783429	chr5:92414398	NA	0.48	4.62	0.43	1.2e-5	Migraine;
THYM	cis	rs11009175	0.615	rs6481818	chr10:33299356	C/A	cg00146027	chr10:33299147	NA	-0.68	-5.13	-0.47	1.55e-6	Depression (quantitative trait);
THYM	cis	rs240764	0.658	rs10457077	chr6:101196767	C/T	cg21058520	chr6:100914733	NA	0.56	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg03806693	chr22:41940476	POLR3H	-0.96	-8.9	-0.67	3.74e-14	Vitiligo;
THYM	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg04025307	chr7:1156635	C7orf50	0.79	7.15	0.59	1.78e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2115630	1.000	rs6496452	chr15:85372645	A/T	cg11189052	chr15:85197271	WDR73	-0.69	-5.13	-0.47	1.52e-6	P wave terminal force;
THYM	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg08859206	chr1:53392774	SCP2	-0.73	-8.49	-0.66	2.75e-13	Monocyte count;
THYM	cis	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg24308560	chr3:49941425	MST1R	-0.73	-6.11	-0.53	2.19e-8	Intelligence (multi-trait analysis);
THYM	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.65	-6.73	-0.57	1.26e-9	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs193541	0.509	rs10044462	chr5:122231523	A/G	cg19808643	chr5:122110361	SNX2	-0.64	-5.37	-0.48	5.46e-7	Glucose homeostasis traits;
THYM	cis	rs12711979	0.729	rs6714956	chr2:3820454	T/C	cg17052675	chr2:3827356	NA	-0.48	-5.16	-0.47	1.35e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs9653442	0.675	rs2871326	chr2:100662010	T/C	cg22139774	chr2:100720529	AFF3	-0.35	-5.2	-0.47	1.13e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs72949976	1.000	rs6747328	chr2:214032156	C/G	cg08319019	chr2:214017104	IKZF2	-0.63	-4.7	-0.43	8.82e-6	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs600806	0.888	rs10745352	chr1:109871787	T/C	cg02175308	chr1:109941060	SORT1	-0.57	-4.96	-0.45	3.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg22709100	chr7:91322751	NA	-0.65	-4.94	-0.45	3.35e-6	Breast cancer;
THYM	cis	rs9403317	0.620	rs62433126	chr6:141984357	G/A	cg15052665	chr6:141804349	NA	0.74	5.59	0.5	2.2e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12935418	0.524	rs9933697	chr16:80973534	A/G	cg16651780	chr16:81037892	C16orf61	0.75	5.66	0.5	1.57e-7	Mean corpuscular volume;
THYM	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg14018140	chr10:458528	DIP2C	-0.61	-7.25	-0.6	1.13e-10	Psychosis in Alzheimer's disease;
THYM	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	4.95	0.45	3.23e-6	Height;
THYM	cis	rs3096299	0.934	rs9927904	chr16:89462847	G/A	cg10164272	chr16:89456328	ANKRD11	0.63	4.63	0.43	1.14e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg04750100	chr2:136595281	LCT	-0.56	-6.49	-0.55	3.8e-9	Mosquito bite size;
THYM	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg01416388	chr22:39784598	NA	-0.92	-9.0	-0.68	2.32e-14	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs6840360	0.615	rs72728173	chr4:152469373	C/T	cg22705602	chr4:152727874	NA	-0.71	-7.43	-0.61	4.71e-11	Intelligence (multi-trait analysis);
THYM	cis	rs2361701	0.500	rs12601244	chr17:78069367	G/A	cg04028464	chr17:78073854	GAA;CCDC40	0.9	5.41	0.49	4.67e-7	IgG glycosylation;
THYM	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg03188948	chr7:1209495	NA	0.9	5.01	0.46	2.49e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg26116260	chr4:7069785	GRPEL1	1.1	9.66	0.7	8.89e-16	Monocyte percentage of white cells;
THYM	cis	rs2976388	0.632	rs2585139	chr8:143808175	C/G	cg06565975	chr8:143823917	SLURP1	0.47	5.16	0.47	1.33e-6	Urinary tract infection frequency;
THYM	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg18512352	chr11:47633146	NA	-0.48	-5.84	-0.51	7.24e-8	Subjective well-being;
THYM	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg04025307	chr7:1156635	C7orf50	0.63	5.15	0.47	1.42e-6	Longevity;Endometriosis;
THYM	cis	rs6840360	0.667	rs9994482	chr4:152391230	T/C	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11785693	0.862	rs62491171	chr8:4987177	G/A	cg26367366	chr8:4980734	NA	0.98	5.32	0.48	6.92e-7	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03452623	chr4:187889614	NA	-1.17	-20.2	-0.9	3.72e-36	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg23711669	chr6:146136114	FBXO30	-0.97	-10.14	-0.72	8.1e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg02734326	chr4:10020555	SLC2A9	0.62	4.84	0.45	4.95e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs800586	0.500	rs2737244	chr8:116658231	A/T	cg04656070	chr8:116661063	TRPS1	-0.57	-6.9	-0.58	5.72e-10	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg17105886	chr17:28927953	LRRC37B2	1.33	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg16342193	chr10:102329863	NA	-0.52	-5.29	-0.48	7.74e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1018836	0.923	rs12680211	chr8:91633434	C/T	cg16814680	chr8:91681699	NA	-0.86	-7.34	-0.6	7.31e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.79	-4.65	-0.43	1.08e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs675209	0.576	rs13213992	chr6:7083218	C/T	cg24899545	chr6:7112846	RREB1	-0.53	-5.01	-0.46	2.49e-6	Urate levels;
THYM	trans	rs9929218	0.507	rs62057805	chr16:68742390	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.07	13.2	0.8	3.3e-23	Colorectal cancer;
THYM	cis	rs7119	0.717	rs8033654	chr15:77825250	T/C	cg10437265	chr15:77819839	NA	0.75	7.41	0.6	5.28e-11	Type 2 diabetes;
THYM	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.7	5.56	0.5	2.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg08885076	chr2:99613938	TSGA10	-0.65	-5.96	-0.52	4.31e-8	Chronic sinus infection;
THYM	trans	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg10856724	chr12:34555212	NA	-1.0	-8.86	-0.67	4.42e-14	Bladder cancer;
THYM	cis	rs858239	0.669	rs1006709	chr7:23140099	C/T	cg05407003	chr7:23246146	NA	-0.55	-4.54	-0.42	1.66e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg09549813	chr16:4587862	C16orf5	-0.5	-5.47	-0.49	3.66e-7	Schizophrenia;
THYM	cis	rs240764	0.817	rs239229	chr6:101105975	T/C	cg21058520	chr6:100914733	NA	-0.57	-5.07	-0.46	1.96e-6	Neuroticism;
THYM	cis	rs12121840	0.790	rs16847148	chr1:165539804	C/G	cg19407955	chr1:165599744	MGST3	-0.65	-4.64	-0.43	1.12e-5	Interleukin-1-receptor antagonist levels;
THYM	cis	rs7679	1.000	rs6073957	chr20:44549476	T/C	cg09053081	chr20:44746392	CD40	0.82	4.55	0.42	1.6e-5	Triglycerides;HDL cholesterol;Gut microbiota (functional units);
THYM	cis	rs921968	0.565	rs6745700	chr2:219639862	T/C	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11039571	0.588	rs10734564	chr11:48160429	A/G	cg24672777	chr11:48374446	OR4C45	0.78	4.52	0.42	1.78e-5	D-dimer levels;
THYM	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.88	-8.7	-0.67	1e-13	Lung cancer in ever smokers;
THYM	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2663905	1.000	rs2663905	chr15:81359137	G/A	cg09888468	chr15:81410853	NA	-0.76	-6.6	-0.56	2.32e-9	QT interval (drug interaction);
THYM	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg00898013	chr13:113819073	PROZ	-0.82	-8.1	-0.64	1.81e-12	Platelet distribution width;
THYM	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg22875332	chr1:76189707	ACADM	0.88	9.09	0.68	1.44e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs921665	0.831	rs2167962	chr2:3192427	G/A	cg16434511	chr2:3151078	NA	-0.79	-5.31	-0.48	7.18e-7	World class endurance athleticism;
THYM	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg19318889	chr4:1322082	MAEA	-0.51	-4.48	-0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs490234	0.934	rs4837018	chr9:128275991	A/G	cg14078157	chr9:128172775	NA	-0.62	-4.83	-0.44	5.31e-6	Mean arterial pressure;
THYM	cis	rs7078219	0.505	rs7085798	chr10:101288347	C/A	cg04972745	chr10:101287846	NA	-0.51	-4.84	-0.44	5.09e-6	Dental caries;
THYM	cis	rs7626444	0.625	rs843539	chr3:196474856	T/C	cg12930392	chr3:196481615	PAK2	0.43	5.3	0.48	7.4e-7	Monocyte count;
THYM	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg18876405	chr7:65276391	NA	0.76	7.24	0.6	1.15e-10	Aortic root size;
THYM	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg02221750	chr19:17393354	ANKLE1	-0.97	-8.6	-0.66	1.61e-13	Systemic lupus erythematosus;
THYM	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg06027949	chr8:82754900	SNX16	-0.62	-5.06	-0.46	2.01e-6	Diastolic blood pressure;
THYM	cis	rs686320	1.000	rs2957267	chr11:65235792	C/T	cg19332572	chr11:65321591	LTBP3	0.9	5.18	0.47	1.26e-6	Hip circumference adjusted for BMI;
THYM	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg05373962	chr22:49881684	NA	-0.62	-6.02	-0.53	3.27e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs13064411	0.696	rs6438156	chr3:113206929	C/A	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7072216	0.763	rs7910247	chr10:100172252	C/T	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs747334	0.633	rs7896199	chr10:92691072	G/T	cg07620928	chr10:92689909	NA	-0.54	-5.04	-0.46	2.17e-6	Fibroblast growth factor basic levels;
THYM	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg14784868	chr12:69753453	YEATS4	1.13	12.31	0.78	2.2e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg18252515	chr7:66147081	NA	-0.67	-5.3	-0.48	7.62e-7	Aortic root size;
THYM	cis	rs889398	0.900	rs4783722	chr16:69581912	A/G	cg09409435	chr16:70099608	PDXDC2	-0.61	-4.9	-0.45	3.91e-6	Body mass index;
THYM	cis	rs2688608	0.869	rs2633308	chr10:75653904	A/T	cg08958656	chr10:75277450	USP54	0.51	4.58	0.43	1.4e-5	Inflammatory bowel disease;
THYM	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg20007245	chr22:24372913	LOC391322	-0.67	-4.75	-0.44	7.28e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg23815491	chr16:72088622	HP	-0.82	-6.68	-0.57	1.58e-9	Fibrinogen levels;
THYM	cis	rs4363385	0.647	rs7548977	chr1:152987365	T/G	cg13444842	chr1:152974279	SPRR3	-0.6	-4.9	-0.45	3.98e-6	Inflammatory skin disease;
THYM	cis	rs977987	0.806	rs4888388	chr16:75394148	G/A	cg03315344	chr16:75512273	CHST6	0.74	6.14	0.53	1.92e-8	Dupuytren's disease;
THYM	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg00786635	chr1:25594202	NA	0.99	8.22	0.64	1.04e-12	Erythrocyte sedimentation rate;
THYM	cis	rs2637266	0.935	rs1907300	chr10:78325091	A/G	cg18941641	chr10:78392320	NA	0.69	5.5	0.49	3.16e-7	Pulmonary function;
THYM	cis	rs1113500	0.933	rs11185259	chr1:108635062	A/G	cg06207961	chr1:108661230	NA	-0.64	-5.09	-0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs17443541	0.507	rs1823490	chr2:200463516	C/T	cg01795955	chr2:200468626	NA	-0.66	-4.59	-0.43	1.38e-5	Intelligence (multi-trait analysis);
THYM	cis	rs919433	0.817	rs10931780	chr2:198175297	G/C	cg00792783	chr2:198669748	PLCL1	-0.7	-5.18	-0.47	1.25e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs66887589	1.000	rs66887589	chr4:120509279	T/C	cg13609457	chr4:120235615	NA	-0.44	-4.65	-0.43	1.07e-5	Diastolic blood pressure;
THYM	cis	rs56079296	0.929	rs79742050	chr5:121379775	C/T	cg05256605	chr5:121412184	LOX	0.64	5.05	0.46	2.11e-6	Coronary artery disease;
THYM	cis	rs983545	0.927	rs2014490	chr3:16972211	A/G	cg24159436	chr3:16974681	PLCL2	-0.36	-5.22	-0.47	1.04e-6	Blood protein levels;
THYM	trans	rs4866334	1.000	rs78178098	chr5:18487497	T/C	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs34779708	0.966	rs1057108	chr10:35484949	T/G	cg03585969	chr10:35415529	CREM	0.64	4.53	0.42	1.7e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg08773314	chr2:239334832	ASB1	0.6	8.82	0.67	5.61e-14	Multiple system atrophy;
THYM	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg09307838	chr4:120376055	NA	0.77	5.56	0.5	2.5e-7	Corneal astigmatism;
THYM	cis	rs11252926	0.545	rs10466270	chr10:556129	A/G	cg14018140	chr10:458528	DIP2C	-0.5	-5.1	-0.46	1.72e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg26963428	chr7:66367121	NA	-0.59	-4.69	-0.43	9.05e-6	Corneal structure;
THYM	cis	rs3820068	0.705	rs59502343	chr1:15872617	T/C	cg05660106	chr1:15850417	CASP9	1.14	9.89	0.71	2.91e-16	Systolic blood pressure;
THYM	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.88	7.81	0.63	7.51e-12	Monocyte percentage of white cells;
THYM	cis	rs9807989	0.811	rs11688559	chr2:102969913	C/T	cg03938978	chr2:103052716	IL18RAP	0.63	6.46	0.55	4.36e-9	Asthma;
THYM	cis	rs7762018	0.660	rs78181018	chr6:170096652	A/C	cg19338460	chr6:170058176	WDR27	-1.06	-6.21	-0.54	1.39e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs9419702	0.639	rs9419624	chr10:133534822	G/A	cg20568497	chr10:133558893	NA	0.47	4.65	0.43	1.08e-5	Survival in rectal cancer;
THYM	cis	rs807669	0.770	rs807458	chr22:19220648	G/T	cg02655711	chr22:19163373	SLC25A1	0.52	5.52	0.49	3e-7	Metabolite levels;
THYM	cis	rs7246967	0.673	rs36029703	chr19:22906188	C/A	cg05241461	chr19:22816980	ZNF492	0.61	4.75	0.44	7.2e-6	Bronchopulmonary dysplasia;
THYM	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg00071950	chr4:10020882	SLC2A9	-0.66	-5.9	-0.52	5.59e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2456568	0.802	rs7101791	chr11:93638998	A/G	cg17595323	chr11:93583763	C11orf90	-0.58	-6.09	-0.53	2.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7616559	0.629	rs13082176	chr3:156755228	A/T	cg15697575	chr3:156784781	NA	0.46	6.65	0.56	1.82e-9	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs2692947	0.763	rs7570074	chr2:96407037	T/C	cg22654517	chr2:96458247	NA	0.58	4.59	0.43	1.36e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs1421898	0.625	rs10476258	chr5:157944049	C/T	cg06698293	chr5:158690540	UBLCP1	-0.97	-4.6	-0.43	1.28e-5	Inflammatory skin disease;
THYM	cis	rs9905704	0.846	rs304298	chr17:56839689	G/A	cg12560992	chr17:57184187	TRIM37	0.64	4.5	0.42	1.93e-5	Testicular germ cell tumor;
THYM	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg04455712	chr21:45112962	RRP1B	0.54	5.04	0.46	2.22e-6	Mean corpuscular volume;
THYM	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14893161	chr1:205819251	PM20D1	0.73	7.17	0.59	1.61e-10	Menarche (age at onset);
THYM	cis	rs600806	0.854	rs11142	chr1:109897103	A/G	cg23032129	chr1:109941072	SORT1	-0.56	-4.82	-0.44	5.41e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7113850	0.541	rs7928230	chr11:24220604	A/G	ch.11.24196551F	chr11:24239977	NA	0.92	4.89	0.45	4.04e-6	Bone fracture in osteoporosis;
THYM	cis	rs4638749	0.734	rs6722745	chr2:108875244	C/T	cg06795125	chr2:108905320	SULT1C2	0.34	4.58	0.43	1.38e-5	Blood pressure;
THYM	cis	rs920590	0.510	rs4922101	chr8:19648895	A/G	cg03894339	chr8:19674705	INTS10	0.9	7.3	0.6	8.7e-11	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9479482	0.935	rs9479507	chr6:150366514	T/G	cg25797454	chr6:150327115	RAET1K	0.44	4.69	0.43	9.06e-6	Alopecia areata;
THYM	cis	rs7512552	0.809	rs9436108	chr1:150360930	A/G	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2219968	0.525	rs2171314	chr8:78883326	T/G	cg00738934	chr8:78996279	NA	0.61	4.95	0.45	3.21e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7553864	1.000	rs975038	chr1:87613583	C/G	cg17420885	chr1:87600446	LOC339524	-0.75	-6.12	-0.53	2.05e-8	Smoking behavior;
THYM	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg10802521	chr3:52805072	NEK4	-0.68	-5.79	-0.51	9.01e-8	Bipolar disorder;
THYM	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg11502198	chr6:26597334	ABT1	0.63	5.61	0.5	2.02e-7	Intelligence (multi-trait analysis);
THYM	cis	rs12765878	0.603	rs10883944	chr10:105651657	G/T	cg04688330	chr10:105451802	SH3PXD2A	0.35	4.45	0.42	2.33e-5	Coronary artery disease;
THYM	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg18230493	chr5:56204884	C5orf35	-0.89	-6.53	-0.56	3.25e-9	Initial pursuit acceleration;
THYM	cis	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg06521331	chr12:34319734	NA	-0.96	-9.28	-0.69	5.69e-15	Morning vs. evening chronotype;
THYM	cis	rs9443645	0.527	rs9352691	chr6:79785607	C/T	cg05283184	chr6:79620031	NA	-0.6	-4.67	-0.43	9.91e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4886920	0.894	rs7182697	chr15:78118624	G/T	cg10461261	chr15:78109450	NA	-0.48	-4.6	-0.43	1.29e-5	Neuroticism;
THYM	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg09682330	chr6:28411287	ZSCAN23	0.61	5.54	0.49	2.68e-7	Cardiac Troponin-T levels;
THYM	cis	rs7943203	0.886	rs11212676	chr11:108361578	A/G	cg04873221	chr11:107992290	ACAT1	0.62	4.51	0.42	1.88e-5	Red blood cell count;Mean corpuscular volume;
THYM	cis	rs261532	0.906	rs355162	chr5:138956241	T/C	cg08720517	chr5:138729919	LOC389333	0.57	4.71	0.44	8.34e-6	Immune reponse to smallpox (secreted IFN-alpha);
THYM	cis	rs7605378	1.000	rs7577763	chr2:200681753	C/T	cg17644776	chr2:200775616	C2orf69	0.64	4.97	0.45	2.96e-6	Osteoporosis;
THYM	cis	rs4654899	1.000	rs12126133	chr1:21456537	T/C	cg01072550	chr1:21505969	NA	-0.74	-6.69	-0.57	1.54e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.57	4.81	0.44	5.69e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.24	-0.47	9.63e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg11764359	chr7:65958608	NA	-0.87	-7.52	-0.61	2.98e-11	Aortic root size;
THYM	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg06713675	chr4:122721982	EXOSC9	-0.88	-10.36	-0.73	2.77e-17	Type 2 diabetes;
THYM	cis	rs2130392	0.892	rs11728389	chr4:185622046	C/T	cg04058563	chr4:185651563	MLF1IP	-0.58	-5.54	-0.49	2.66e-7	Kawasaki disease;
THYM	trans	rs8002861	0.641	rs4942252	chr13:44443039	C/T	cg17145862	chr1:211918768	LPGAT1	0.88	8.09	0.64	1.97e-12	Leprosy;
THYM	trans	rs1974653	0.672	rs112629076	chr22:20079688	T/C	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg08736216	chr1:53307985	ZYG11A	-0.57	-5.21	-0.47	1.11e-6	Monocyte count;
THYM	cis	rs2235649	0.798	rs9922462	chr16:1848011	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-4.78	-0.44	6.27e-6	Blood metabolite levels;
THYM	cis	rs476633	0.708	rs13329237	chr15:41450808	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.72	-5.63	-0.5	1.83e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs34779708	0.931	rs7079498	chr10:35375344	C/T	cg03585969	chr10:35415529	CREM	0.66	4.65	0.43	1.06e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7580658	0.637	rs9636236	chr2:127982941	G/A	cg09152259	chr2:128156114	NA	-0.37	-4.85	-0.45	4.82e-6	Protein C levels;
THYM	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg25767906	chr1:53392781	SCP2	0.55	5.46	0.49	3.83e-7	Monocyte count;
THYM	cis	rs924712	0.545	rs12207559	chr6:54709868	A/C	cg19716238	chr6:54711378	FAM83B	0.47	4.61	0.43	1.27e-5	Breast cancer;
THYM	cis	rs789852	0.764	rs1773184	chr3:194313832	T/C	cg18000598	chr3:194342907	TMEM44	-1.15	-6.99	-0.58	3.76e-10	QT interval;
THYM	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg02725872	chr8:58115012	NA	-1.15	-7.6	-0.61	2.13e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs28595532	0.841	rs114735834	chr4:119772722	G/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs7586879	0.681	rs6705446	chr2:25118608	T/C	cg01884057	chr2:25150051	NA	0.71	7.7	0.62	1.31e-11	Body mass index;
THYM	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	trans	rs8002861	0.840	rs1819596	chr13:44429554	A/G	cg17145862	chr1:211918768	LPGAT1	0.87	9.02	0.68	2.02e-14	Leprosy;
THYM	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1728785	0.818	rs12926059	chr16:68569459	T/C	cg02972257	chr16:68554789	NA	-0.74	-4.54	-0.42	1.63e-5	Ulcerative colitis;
THYM	cis	rs977987	0.736	rs11865296	chr16:75473693	C/T	cg03315344	chr16:75512273	CHST6	0.71	5.66	0.5	1.59e-7	Dupuytren's disease;
THYM	cis	rs7428	0.545	rs17026212	chr2:85551696	T/G	cg24342717	chr2:85555507	TGOLN2	-0.77	-6.63	-0.56	2.06e-9	Ear protrusion;
THYM	cis	rs11627756	0.958	rs2146429	chr14:103071816	A/T	cg27124170	chr14:102829869	TECPR2;CINP	-0.66	-4.53	-0.42	1.69e-5	Mean platelet volume;
THYM	cis	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	6.05	0.53	2.89e-8	Obesity-related traits;
THYM	cis	rs2072732	0.821	rs10909868	chr1:2962207	A/C	cg08733933	chr1:2954429	NA	-0.56	-4.46	-0.42	2.28e-5	Plateletcrit;
THYM	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg07570687	chr10:102243282	WNT8B	0.75	6.62	0.56	2.11e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs2836633	1.000	rs2836634	chr21:40068230	T/A	cg05519781	chr21:40033154	ERG	0.66	6.29	0.54	9.64e-9	Coronary artery disease;
THYM	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs11039798	0.920	rs11500574	chr11:48713986	A/T	cg24672777	chr11:48374446	OR4C45	-1.12	-6.73	-0.57	1.28e-9	Axial length;
THYM	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg14895029	chr7:2775587	GNA12	-0.68	-4.91	-0.45	3.78e-6	Height;
THYM	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg22907277	chr7:1156413	C7orf50	0.88	7.59	0.61	2.18e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs420259	0.516	rs801754	chr16:23597878	T/A	cg00143387	chr16:23521605	GGA2	0.76	5.6	0.5	2.1e-7	Bipolar disorder;
THYM	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6674176	1.000	rs11210937	chr1:44405563	T/C	cg12908607	chr1:44402522	ARTN	-0.62	-4.91	-0.45	3.74e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg11494091	chr17:61959527	GH2	-1.03	-19.4	-0.89	8.16e-35	Prudent dietary pattern;
THYM	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg00981070	chr1:2046702	PRKCZ	0.42	5.19	0.47	1.2e-6	Height;
THYM	cis	rs2213920	0.679	rs6415820	chr9:118231832	A/C	cg13918206	chr9:118159781	DEC1	0.8	4.53	0.42	1.74e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg27034606	chr17:28928453	LRRC37B2	0.79	4.89	0.45	4.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9896850	0.513	rs10445407	chr17:79261809	A/C	cg15215033	chr17:79258732	SLC38A10	-0.39	-4.66	-0.43	1.03e-5	Frontotemporal dementia;
THYM	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg16586182	chr3:47516702	SCAP	-0.65	-5.62	-0.5	1.94e-7	Colorectal cancer;
THYM	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg04772025	chr11:68637568	NA	0.64	6.64	0.56	1.9e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg08999081	chr20:33150536	PIGU	0.55	4.85	0.45	4.82e-6	Height;
THYM	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs12282928	0.918	rs6485815	chr11:48243186	A/C	cg22827986	chr11:48284249	OR4X1	-0.51	-5.43	-0.49	4.28e-7	Migraine - clinic-based;
THYM	cis	rs7953249	0.618	rs7954331	chr12:121398657	G/T	cg02403541	chr12:121454288	C12orf43	-0.73	-6.78	-0.57	1.03e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs12579753	1.000	rs12367791	chr12:82237278	C/T	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.67	-0.43	1.01e-5	Resting heart rate;
THYM	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg03188948	chr7:1209495	NA	0.92	5.16	0.47	1.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	7.8	0.62	7.81e-12	Platelet count;
THYM	cis	rs2050392	0.928	rs2250077	chr10:30702929	A/G	cg02070205	chr10:30722105	MAP3K8	-0.54	-4.84	-0.44	5.11e-6	Inflammatory bowel disease;
THYM	cis	rs220324	0.688	rs9975464	chr21:43560055	T/C	cg09727148	chr21:43560719	UMODL1	0.84	10.06	0.72	1.26e-16	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs6763768	0.606	rs4687576	chr3:53385418	T/C	cg16894138	chr3:53270350	TKT	0.72	5.47	0.49	3.68e-7	Bacterial meningitis;
THYM	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.87	-0.82	1.48e-24	Height;
THYM	cis	rs9633740	1.000	rs7910643	chr10:82251769	G/A	cg01528321	chr10:82214614	TSPAN14	0.94	4.5	0.42	1.9e-5	Post bronchodilator FEV1;
THYM	cis	rs3857067	0.772	rs10516947	chr4:95110897	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg17366294	chr4:99064904	C4orf37	0.55	6.73	0.57	1.26e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2237898	0.585	rs35723063	chr11:2875965	G/A	cg12614029	chr11:2160564	INS-IGF2;IGF2AS;IGF2	-1.21	-4.47	-0.42	2.19e-5	Mosquito bite size;
THYM	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg02953382	chr22:24373134	LOC391322	0.87	9.59	0.7	1.27e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4731207	0.596	rs719972	chr7:124631797	G/A	cg05285228	chr7:124571219	POT1	-0.71	-5.45	-0.49	3.91e-7	Cutaneous malignant melanoma;
THYM	cis	rs9810089	0.676	rs526574	chr3:136103349	A/G	cg21827317	chr3:136751795	NA	0.6	5.42	0.49	4.57e-7	Gestational age at birth (child effect);
THYM	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg27170947	chr2:26402098	FAM59B	-0.58	-4.89	-0.45	4.18e-6	Gut microbiome composition (summer);
THYM	cis	rs7078219	1.000	rs6584278	chr10:101278099	C/T	cg07044859	chr10:101282883	NA	-0.47	-5.14	-0.47	1.45e-6	Dental caries;
THYM	cis	rs13256369	0.762	rs13278972	chr8:8597180	T/C	cg00074818	chr8:8560427	CLDN23	0.54	5.04	0.46	2.18e-6	Obesity-related traits;
THYM	cis	rs2811415	0.597	rs9812487	chr3:127807835	G/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs7084402	0.934	rs1658453	chr10:60309602	T/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.65e-7	Refractive error;
THYM	cis	rs6121246	0.559	rs6119652	chr20:30259445	C/G	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg23281280	chr6:28129359	ZNF389	0.55	4.83	0.44	5.12e-6	Depression;
THYM	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg26354017	chr1:205819088	PM20D1	-0.78	-7.47	-0.61	3.89e-11	Menarche (age at onset);
THYM	cis	rs4638749	0.773	rs4676190	chr2:108858619	A/G	cg25838818	chr2:108905173	SULT1C2	-0.72	-6.36	-0.55	7.15e-9	Blood pressure;
THYM	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg13609457	chr4:120235615	NA	0.6	5.34	0.48	6.23e-7	Corneal astigmatism;
THYM	cis	rs950880	0.710	rs56331791	chr2:103048157	G/A	cg03938978	chr2:103052716	IL18RAP	-0.54	-4.6	-0.43	1.32e-5	Serum protein levels (sST2);
THYM	cis	rs9640161	0.789	rs10248490	chr7:150051418	C/G	cg21361702	chr7:150065534	REPIN1	0.66	4.67	0.43	9.84e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg17757837	chr7:157058334	UBE3C	0.66	5.29	0.48	7.82e-7	Body mass index;
THYM	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg09307838	chr4:120376055	NA	0.71	5.41	0.49	4.61e-7	Corneal astigmatism;
THYM	cis	rs11671005	0.610	rs2305122	chr19:59056752	G/C	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.62	-5.03	-0.46	2.29e-6	Mean platelet volume;
THYM	cis	rs12681288	0.576	rs6990403	chr8:963471	C/A	cg08648136	chr8:956695	NA	0.56	4.67	0.43	9.71e-6	Schizophrenia;
THYM	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg09549813	chr16:4587862	C16orf5	-0.56	-6.24	-0.54	1.24e-8	Schizophrenia;
THYM	cis	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg19693284	chr19:2783607	SGTA	0.67	5.3	0.48	7.41e-7	Total cholesterol levels;
THYM	cis	rs4589258	0.762	rs4448654	chr11:90459281	C/A	cg26138821	chr11:89956704	CHORDC1	-0.55	-4.46	-0.42	2.22e-5	Intelligence (multi-trait analysis);
THYM	cis	rs889398	0.741	rs7192213	chr16:69926280	G/A	cg09409435	chr16:70099608	PDXDC2	0.63	4.89	0.45	4.04e-6	Body mass index;
THYM	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.7	5.42	0.49	4.49e-7	Tonsillectomy;
THYM	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg12179176	chr11:130786555	SNX19	0.83	6.89	0.58	6.06e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4886920	0.862	rs34549121	chr15:78123986	T/C	cg10461261	chr15:78109450	NA	-0.45	-4.5	-0.42	1.89e-5	Neuroticism;
THYM	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg03806693	chr22:41940476	POLR3H	1.1	8.83	0.67	5.2e-14	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs10411161	0.702	rs1433081	chr19:52390710	A/C	cg25361850	chr19:52391789	ZNF577	0.76	5.29	0.48	7.84e-7	Breast cancer;
THYM	cis	rs7776786	0.745	rs12540872	chr7:18836667	G/A	cg13420273	chr7:18810212	HDAC9	-0.66	-7.29	-0.6	9.05e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8106542	0.865	rs12972963	chr19:10741907	A/G	cg17848348	chr19:10766748	ILF3	-0.8	-6.62	-0.56	2.13e-9	Platelet distribution width;
THYM	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg09936400	chr10:82049201	MAT1A	0.43	4.54	0.42	1.64e-5	Post bronchodilator FEV1;
THYM	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.6	0.7	1.21e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2213920	0.620	rs7852799	chr9:118188696	T/C	cg13918206	chr9:118159781	DEC1	0.86	4.9	0.45	3.86e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg10856724	chr12:34555212	NA	-0.75	-6.61	-0.56	2.21e-9	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg06238570	chr21:40685208	BRWD1	-0.69	-6.08	-0.53	2.47e-8	Menarche (age at onset);
THYM	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg20744362	chr22:50050164	C22orf34	0.71	7.23	0.6	1.23e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4499344	0.555	rs7250741	chr19:33033231	T/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.71	-4.79	-0.44	6.07e-6	Mean platelet volume;
THYM	cis	rs1729951	0.575	rs835641	chr3:136703474	G/T	cg12473912	chr3:136751656	NA	0.62	5.03	0.46	2.34e-6	Neuroticism;
THYM	cis	rs13223928	0.516	rs11763949	chr7:3150279	A/C	cg19214707	chr7:3157722	NA	-0.84	-7.28	-0.6	9.42e-11	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs1568889	1.000	rs2354427	chr11:28049623	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	4.49	0.42	2.03e-5	Bipolar disorder;
THYM	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs6547741	0.844	rs9678851	chr2:27887034	C/A	cg27432699	chr2:27873401	GPN1	-0.89	-8.11	-0.64	1.78e-12	Oral cavity cancer;
THYM	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg17173187	chr15:85201210	NMB	0.56	5.51	0.49	3.07e-7	Schizophrenia;
THYM	cis	rs7681440	0.583	rs2583966	chr4:90741519	G/A	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg23791538	chr6:167370224	RNASET2	-0.59	-4.53	-0.42	1.71e-5	Crohn's disease;
THYM	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg15556689	chr8:8085844	FLJ10661	0.72	5.79	0.51	8.98e-8	Mood instability;
THYM	cis	rs7107174	1.000	rs2511190	chr11:77988310	T/C	cg19901956	chr11:77921274	USP35	-0.68	-5.25	-0.47	9.31e-7	Testicular germ cell tumor;
THYM	cis	rs13040088	1.000	rs2273412	chr20:61553802	G/A	cg23096297	chr20:61557774	DIDO1	1.06	7.24	0.6	1.13e-10	Menopause (age at onset);
THYM	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-11.44	-0.76	1.44e-19	Height;
THYM	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg12863693	chr15:85201151	NMB	0.62	5.57	0.5	2.41e-7	Schizophrenia;
THYM	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.97	8.9	0.67	3.72e-14	Chronic sinus infection;
THYM	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg04398451	chr17:18023971	MYO15A	-0.78	-7.23	-0.6	1.22e-10	Total body bone mineral density;
THYM	cis	rs7586879	0.639	rs2384058	chr2:25100328	A/G	cg15423357	chr2:25149977	NA	0.69	7.43	0.61	4.72e-11	Body mass index;
THYM	cis	rs8078723	0.933	rs55846942	chr17:38164470	G/A	cg17467752	chr17:38218738	THRA	0.86	7.09	0.59	2.4e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	trans	rs11109072	1.000	rs11109085	chr12:97909600	T/C	cg17633015	chr7:2020501	MAD1L1	1.0	7.4	0.6	5.45e-11	Obesity (early onset extreme);
THYM	cis	rs800586	0.500	rs2737243	chr8:116657881	G/C	cg04656070	chr8:116661063	TRPS1	-0.56	-6.66	-0.56	1.75e-9	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg02953382	chr22:24373134	LOC391322	0.81	7.72	0.62	1.15e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03517284	chr6:25882590	NA	0.77	6.11	0.53	2.18e-8	Blood metabolite levels;
THYM	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.77	0.51	1.01e-7	Rheumatoid arthritis;
THYM	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg01483505	chr11:975446	AP2A2	0.58	4.73	0.44	7.82e-6	Alzheimer's disease (late onset);
THYM	cis	rs9876781	1.000	rs6804774	chr3:48430617	G/C	cg06066452	chr3:48470258	PLXNB1	0.28	5.14	0.47	1.49e-6	Longevity;
THYM	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg22105103	chr4:187893119	NA	0.95	10.29	0.73	3.97e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs78062588	1.000	rs72999485	chr1:154559360	G/C	cg13098855	chr1:153588927	S100A14	0.6	4.78	0.44	6.29e-6	Lung cancer;
THYM	cis	rs1978968	1.000	rs7286607	chr22:18444657	T/C	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7191700	0.578	rs243327	chr16:11353304	C/T	cg00044050	chr16:11439710	C16orf75	-0.66	-4.89	-0.45	4.03e-6	Multiple sclerosis;
THYM	trans	rs2562456	0.920	rs2650784	chr19:21666597	T/C	cg22241504	chr17:3539680	CTNS;SHPK	0.86	6.97	0.58	4.12e-10	Pain;
THYM	cis	rs8114671	0.836	rs734308	chr20:33572096	A/G	cg08999081	chr20:33150536	PIGU	-0.55	-4.85	-0.45	4.82e-6	Height;
THYM	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg21252483	chr19:49399788	TULP2	-0.95	-7.2	-0.59	1.41e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	trans	rs8002861	0.846	rs56408817	chr13:44471983	A/G	cg17145862	chr1:211918768	LPGAT1	-0.97	-9.72	-0.71	6.62e-16	Leprosy;
THYM	cis	rs7027203	0.828	rs3957506	chr9:96588133	C/T	cg13679303	chr9:96623674	NA	-0.5	-5.1	-0.46	1.75e-6	DNA methylation (variation);
THYM	cis	rs2806561	0.780	rs12135629	chr1:23338899	A/G	cg08872493	chr1:23521417	HTR1D	-0.37	-4.53	-0.42	1.74e-5	Height;
THYM	cis	rs4767234	1.000	rs978498	chr12:114645356	G/T	cg13131185	chr12:113914611	NA	-0.47	-4.54	-0.42	1.64e-5	Airflow obstruction;
THYM	cis	rs11148252	0.514	rs9526843	chr13:52730056	C/T	cg05335186	chr13:53173507	NA	-0.41	-4.75	-0.44	7.09e-6	Lewy body disease;
THYM	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03647317	chr4:187891568	NA	-0.83	-9.2	-0.69	8.27e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7917772	0.582	rs7907417	chr10:104370662	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.77	-6.73	-0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg14345882	chr6:26364793	BTN3A2	-0.56	-5.52	-0.49	2.91e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7610301	1.000	rs7610301	chr3:46646028	G/A	cg10242476	chr3:46619364	LRRC2;TDGF1	0.45	4.48	0.42	2.07e-5	Blood protein levels;
THYM	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg12564285	chr5:131593104	PDLIM4	0.5	5.63	0.5	1.82e-7	Breast cancer;
THYM	cis	rs524281	0.773	rs7925123	chr11:65993213	G/C	cg00563793	chr11:65837595	PACS1	0.79	4.71	0.43	8.57e-6	Electroencephalogram traits;
THYM	cis	rs883565	0.655	rs4676649	chr3:39064948	T/C	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	5.0	0.46	2.59e-6	Handedness;
THYM	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg25703541	chr22:24373054	LOC391322	-0.85	-9.25	-0.69	6.76e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs28595532	0.920	rs56227053	chr4:119772460	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg16414030	chr3:133502952	NA	-0.95	-9.48	-0.7	2.17e-15	Iron status biomarkers;
THYM	cis	rs7216064	1.000	rs7209675	chr17:65831258	A/T	cg12091567	chr17:66097778	LOC651250	-0.7	-4.67	-0.43	9.96e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg03388025	chr16:89894329	SPIRE2	0.53	4.49	0.42	1.99e-5	Vitiligo;
THYM	trans	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	Neuroticism;
THYM	cis	rs17253792	0.822	rs12100753	chr14:56042870	G/A	cg01858014	chr14:56050164	KTN1	-1.17	-4.89	-0.45	4.1e-6	Putamen volume;
THYM	cis	rs9880211	0.846	rs73230043	chr3:136407159	G/T	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Bladder cancer;
THYM	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg25554036	chr4:6271136	WFS1	0.59	5.5	0.49	3.17e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs8067545	0.641	rs203450	chr17:19823070	C/T	cg20830565	chr17:20408647	MGC102966	-0.5	-4.57	-0.42	1.46e-5	Schizophrenia;
THYM	cis	rs9677476	0.818	rs62197333	chr2:232085049	G/C	cg23338755	chr2:231921595	PSMD1	0.72	5.44	0.49	4.18e-7	Food antigen IgG levels;
THYM	cis	rs8114671	0.967	rs6142323	chr20:33788983	A/G	cg08999081	chr20:33150536	PIGU	-0.53	-4.77	-0.44	6.63e-6	Height;
THYM	cis	rs79149102	0.579	rs12594117	chr15:75323648	C/G	cg17294928	chr15:75287854	SCAMP5	-1.03	-5.57	-0.5	2.32e-7	Lung cancer;
THYM	cis	rs67981189	0.821	rs2286310	chr14:71523605	C/T	cg15910301	chr14:71632612	NA	0.51	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg26818010	chr10:134567672	INPP5A	0.93	7.57	0.61	2.41e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg08133631	chr1:26527909	CATSPER4	-0.61	-5.08	-0.46	1.92e-6	Obesity-related traits;
THYM	cis	rs28595532	0.841	rs114123875	chr4:119733408	A/G	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs2862064	0.929	rs4704837	chr5:156464212	T/G	cg12943317	chr5:156479607	HAVCR1	-0.86	-5.28	-0.48	8e-7	Platelet count;
THYM	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg12419862	chr22:24373484	LOC391322	-0.66	-4.73	-0.44	7.83e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs2898681	0.739	rs8287	chr4:53732586	T/C	cg03786743	chr4:53727781	RASL11B	0.39	4.55	0.42	1.57e-5	Optic nerve measurement (cup area);
THYM	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg24250549	chr1:154909240	PMVK	0.75	6.45	0.55	4.66e-9	Prostate cancer;
THYM	cis	rs3772130	0.962	rs7629369	chr3:121566282	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.75	4.64	0.43	1.1e-5	Cognitive performance;
THYM	cis	rs28595532	0.764	rs115877991	chr4:119728298	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs42648	0.837	rs12375075	chr7:89940331	G/A	cg25739043	chr7:89950458	NA	-0.52	-4.46	-0.42	2.27e-5	Homocysteine levels;
THYM	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg00814883	chr7:100076585	TSC22D4	-0.95	-6.36	-0.55	6.93e-9	Platelet count;
THYM	cis	rs929596	0.958	rs17862873	chr2:234646722	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.91	-6.74	-0.57	1.25e-9	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs11690935	0.959	rs12692973	chr2:172642057	A/G	cg13550731	chr2:172543902	DYNC1I2	0.82	6.02	0.53	3.29e-8	Schizophrenia;
THYM	cis	rs67981189	0.896	rs34763296	chr14:71550175	C/G	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	trans	rs4262150	0.883	rs72804781	chr5:152314450	T/C	cg08281791	chr5:76607845	PDE8B	0.94	7.09	0.59	2.41e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg11245990	chr11:68621969	NA	0.57	7.46	0.61	4.06e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg26384229	chr12:38710491	ALG10B	-0.72	-5.64	-0.5	1.75e-7	Morning vs. evening chronotype;
THYM	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg26818010	chr10:134567672	INPP5A	-0.76	-6.12	-0.53	2.04e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs1160297	0.576	rs10206560	chr2:53089060	G/C	cg07782112	chr2:53107842	NA	0.77	6.31	0.54	8.76e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.89	0.52	5.88e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.59	-5.24	-0.47	9.86e-7	Total body bone mineral density;
THYM	trans	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg09537434	chr19:41945824	ATP5SL	-1.11	-10.88	-0.74	2.18e-18	Height;
THYM	cis	rs981844	0.712	rs897610	chr4:154755439	C/A	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs9388451	0.505	rs9372828	chr6:126175185	A/T	cg05901451	chr6:126070800	HEY2	-0.67	-4.82	-0.44	5.39e-6	Brugada syndrome;
THYM	cis	rs6918586	0.658	rs198813	chr6:26128226	C/T	cg03517284	chr6:25882590	NA	0.71	5.64	0.5	1.75e-7	Schizophrenia;
THYM	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg09549813	chr16:4587862	C16orf5	-0.58	-6.43	-0.55	5.02e-9	Schizophrenia;
THYM	cis	rs4731207	0.672	rs2896360	chr7:124448516	T/C	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg27494647	chr7:150038898	RARRES2	0.39	4.51	0.42	1.84e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7614311	0.636	rs77639204	chr3:64005452	C/T	cg22134162	chr3:63841271	THOC7	-0.5	-6.15	-0.53	1.84e-8	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg22920501	chr2:26401640	FAM59B	-1.06	-9.44	-0.7	2.57e-15	Gut microbiome composition (summer);
THYM	cis	rs4718428	0.924	rs6971897	chr7:66412774	T/A	cg12165864	chr7:66369176	NA	-0.71	-5.36	-0.48	5.77e-7	Corneal structure;
THYM	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.9	7.83	0.63	6.8e-12	Multiple sclerosis;
THYM	cis	rs10887741	0.646	rs4244979	chr10:89425507	A/C	cg13926569	chr10:89418898	PAPSS2	0.63	7.39	0.6	5.63e-11	Exercise (leisure time);
THYM	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg19418458	chr7:158789849	NA	-0.62	-5.83	-0.51	7.71e-8	Facial morphology (factor 20);
THYM	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.3	-0.48	7.47e-7	Bipolar disorder;
THYM	cis	rs919433	0.927	rs1429412	chr2:198190894	A/G	cg00792783	chr2:198669748	PLCL1	-0.69	-5.08	-0.46	1.85e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24549020	chr5:56110836	MAP3K1	0.7	4.61	0.43	1.28e-5	Initial pursuit acceleration;
THYM	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg22875332	chr1:76189707	ACADM	0.86	9.79	0.71	4.57e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7098100	0.924	rs12779865	chr10:21829162	T/C	cg04231319	chr10:21824447	MLLT10	-0.34	-4.79	-0.44	6.07e-6	Breast cancer;
THYM	cis	rs7940866	0.903	rs7942900	chr11:130839244	G/A	cg05962950	chr11:130786565	SNX19	0.6	4.67	0.43	9.81e-6	Schizophrenia;
THYM	cis	rs55637147	0.671	rs60931171	chr11:57134381	C/G	cg15971518	chr11:57159174	PRG2	-0.67	-5.37	-0.48	5.46e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg23583168	chr7:148888333	NA	-0.97	-12.0	-0.78	9.64e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.81	5.34	0.48	6.27e-7	Platelet count;
THYM	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg19746536	chr19:49375674	PPP1R15A	0.81	4.6	0.43	1.33e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg23161317	chr6:28129485	ZNF389	0.78	6.42	0.55	5.24e-9	Depression;
THYM	cis	rs55823223	0.648	rs11869977	chr17:73857382	C/G	cg09253696	chr17:73873529	TRIM47	-0.69	-4.74	-0.44	7.59e-6	Psoriasis;
THYM	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg08132940	chr7:1081526	C7orf50	-1.17	-6.67	-0.56	1.7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1003719	0.788	rs2835578	chr21:38457671	T/C	cg01329690	chr21:38580129	DSCR9	0.39	5.25	0.47	9.23e-7	Eye color traits;
THYM	cis	rs36051895	0.586	rs12342421	chr9:5065750	G/C	cg02405213	chr9:5042618	JAK2	-1.02	-11.39	-0.76	1.87e-19	Pediatric autoimmune diseases;
THYM	cis	rs8013055	0.846	rs35590487	chr14:105989599	C/T	cg23356831	chr14:105996513	TMEM121	0.59	5.78	0.51	9.65e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs2898681	0.739	rs8287	chr4:53732586	T/C	cg00791764	chr4:53727839	RASL11B	0.46	6.1	0.53	2.28e-8	Optic nerve measurement (cup area);
THYM	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.33	9.84	0.71	3.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4866334	1.000	rs75533364	chr5:18453341	G/A	cg18608440	chr5:17519013	NA	1.16	5.19	0.47	1.17e-6	IgG glycosylation;
THYM	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs5417	0.780	rs222849	chr17:7185861	T/C	cg25256661	chr17:7137939	DVL2	-1.09	-8.48	-0.66	2.92e-13	Diastolic blood pressure;
THYM	cis	rs11969893	0.850	rs9485417	chr6:101300038	C/T	cg12253828	chr6:101329408	ASCC3	-1.17	-6.59	-0.56	2.45e-9	Economic and political preferences (immigration/crime);
THYM	trans	rs9513868	0.898	rs7982539	chr13:101901838	C/T	cg04067066	chr2:219756890	WNT10A	-0.68	-6.91	-0.58	5.56e-10	Prudent dietary pattern;
THYM	cis	rs1885364	1.000	rs5752612	chr22:28095488	A/G	cg17187762	chr22:28070120	NA	0.4	4.81	0.44	5.7e-6	Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion);
THYM	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg26384229	chr12:38710491	ALG10B	0.95	7.55	0.61	2.7e-11	Bladder cancer;
THYM	cis	rs3087591	0.960	rs2066736	chr17:29559932	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.68	-5.9	-0.52	5.49e-8	Hip circumference;
THYM	cis	rs7078219	1.000	rs6584278	chr10:101278099	C/T	cg17888390	chr10:101282816	NA	-0.5	-4.78	-0.44	6.28e-6	Dental caries;
THYM	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg05457628	chr5:178986728	RUFY1	0.64	6.11	0.53	2.15e-8	Lung cancer;
THYM	cis	rs7180079	0.502	rs8033972	chr15:64524980	G/A	cg02848875	chr15:64387786	SNX1	-0.7	-5.89	-0.52	5.77e-8	Monocyte count;
THYM	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	trans	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg10856724	chr12:34555212	NA	-0.89	-7.85	-0.63	6.11e-12	Bladder cancer;
THYM	cis	rs8180040	0.767	rs11920853	chr3:47308183	G/A	cg27129171	chr3:47204927	SETD2	-0.75	-7.08	-0.59	2.48e-10	Colorectal cancer;
THYM	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg26384229	chr12:38710491	ALG10B	1.02	9.76	0.71	5.3e-16	Heart rate;
THYM	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-5.49	-0.49	3.29e-7	Morning vs. evening chronotype;
THYM	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg13397359	chr6:42928475	GNMT	0.61	5.49	0.49	3.39e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs11924390	0.789	rs822366	chr3:186452490	A/G	cg12454167	chr3:186435060	KNG1	0.46	6.08	0.53	2.55e-8	Adiponectin levels;
THYM	cis	rs921968	0.643	rs659185	chr2:219335935	C/T	cg02176678	chr2:219576539	TTLL4	0.65	6.27	0.54	1.05e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9902453	1.000	rs9902453	chr17:28349095	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-4.81	-0.44	5.64e-6	Coffee consumption (cups per day);
THYM	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs36051895	0.623	rs6476956	chr9:5261238	A/G	cg02405213	chr9:5042618	JAK2	-0.96	-9.77	-0.71	5.02e-16	Pediatric autoimmune diseases;
THYM	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg24250549	chr1:154909240	PMVK	0.8	6.36	0.55	7.09e-9	Prostate cancer;
THYM	cis	rs7177699	0.557	rs34372090	chr15:79110735	C/T	cg15571903	chr15:79123663	NA	-0.59	-6.55	-0.56	2.92e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs8067545	0.611	rs2703800	chr17:20086562	C/T	cg13482628	chr17:19912719	NA	0.53	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs427394	0.802	rs274718	chr5:6720988	G/T	cg10857441	chr5:6722123	POLS	-0.73	-8.72	-0.67	8.9e-14	Menopause (age at onset);
THYM	cis	rs6835098	1.000	rs6835098	chr4:174089238	T/C	cg08422745	chr4:174089978	GALNT7	-1.02	-8.74	-0.67	8.01e-14	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs6032067	0.673	rs36019441	chr20:43892401	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.64	-6.49	-0.55	3.95e-9	Blood protein levels;
THYM	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03517284	chr6:25882590	NA	1.02	9.37	0.69	3.66e-15	Blood metabolite levels;
THYM	cis	rs240764	0.853	rs1875401	chr6:101023588	G/A	cg21058520	chr6:100914733	NA	0.57	5.02	0.46	2.37e-6	Neuroticism;
THYM	cis	rs6669072	0.967	rs4101233	chr1:91238773	C/T	cg08895590	chr1:91227319	NA	-0.55	-6.68	-0.57	1.64e-9	Cognitive function;
THYM	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg01448562	chr3:133502909	NA	-0.83	-7.08	-0.59	2.48e-10	Iron status biomarkers;
THYM	cis	rs929596	0.574	rs75444879	chr2:234587848	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-6.38	-0.55	6.3e-9	Total bilirubin levels in HIV-1 infection;
THYM	trans	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg19862616	chr7:65841803	NCRNA00174	1.13	13.2	0.8	3.22e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg03188948	chr7:1209495	NA	0.9	5.0	0.46	2.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg21775007	chr8:11205619	TDH	-0.73	-5.68	-0.5	1.49e-7	Retinal vascular caliber;
THYM	cis	rs3110496	0.650	rs614334	chr17:27904985	A/G	cg04498198	chr17:27899966	TP53I13	-0.56	-6.11	-0.53	2.15e-8	Height;
THYM	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg06112835	chr11:68658793	MRPL21	0.44	6.41	0.55	5.69e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg00495681	chr13:53174319	NA	-0.73	-6.69	-0.57	1.57e-9	Lewy body disease;
THYM	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg14458575	chr2:238380390	NA	0.9	7.53	0.61	2.94e-11	Prostate cancer;
THYM	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg23187316	chr7:1099788	C7orf50	0.59	4.52	0.42	1.76e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4790333	0.677	rs2447099	chr17:2268139	G/C	cg02569219	chr17:2266849	SGSM2	0.72	6.06	0.53	2.72e-8	Proinsulin levels;
THYM	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	cis	rs7426056	0.525	rs4673263	chr2:204622019	C/T	cg07930752	chr2:204569955	CD28	-0.63	-4.99	-0.46	2.76e-6	Primary sclerosing cholangitis;
THYM	cis	rs7474896	0.561	rs2474603	chr10:38445682	C/T	cg25427524	chr10:38739819	LOC399744	-0.74	-4.74	-0.44	7.42e-6	Obesity (extreme);
THYM	cis	rs13006833	0.694	rs291448	chr2:191177216	T/C	cg11845111	chr2:191398756	TMEM194B	0.65	4.65	0.43	1.09e-5	Urinary metabolites;
THYM	cis	rs137603	1.000	rs137603	chr22:39694225	A/C	cg24268161	chr22:39747459	SYNGR1	0.57	5.08	0.46	1.87e-6	Primary biliary cholangitis;
THYM	cis	rs868036	0.681	rs2241423	chr15:68086838	G/A	cg24579218	chr15:68104479	NA	-0.82	-8.85	-0.67	4.77e-14	Restless legs syndrome;
THYM	cis	rs1691799	0.867	rs1039056	chr12:66760391	C/T	cg16791601	chr12:66731901	HELB	-0.68	-5.88	-0.52	6.09e-8	White blood cell count (basophil);
THYM	cis	rs8133932	0.654	rs375971	chr21:47338854	C/G	cg20357416	chr21:47294739	PCBP3	0.8	4.88	0.45	4.26e-6	Schizophrenia;
THYM	cis	rs4654899	0.802	rs61781104	chr1:21257235	T/A	cg01072550	chr1:21505969	NA	-0.7	-6.16	-0.53	1.75e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg10589385	chr1:150898437	SETDB1	0.67	5.55	0.49	2.58e-7	Melanoma;
THYM	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs858239	0.669	rs1618339	chr7:23229774	T/C	cg18081818	chr7:23246105	NA	-0.54	-4.72	-0.44	8.2e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg03676636	chr4:99064102	C4orf37	0.42	6.16	0.53	1.78e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4666002	0.789	rs12998770	chr2:27913188	T/C	cg27432699	chr2:27873401	GPN1	0.61	4.77	0.44	6.75e-6	Phospholipid levels (plasma);
THYM	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg02869364	chr7:1081709	C7orf50	-0.58	-4.71	-0.44	8.46e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10911232	0.507	rs6664995	chr1:183017345	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg11879480	chr11:92930739	SLC36A4	0.7	4.51	0.42	1.87e-5	Subcortical brain region volumes;
THYM	cis	rs912057	0.833	rs1294426	chr6:6744477	T/C	cg06612196	chr6:6737390	NA	0.69	9.83	0.71	3.75e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg02725872	chr8:58115012	NA	-1.15	-7.6	-0.61	2.13e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs12681287	0.547	rs66808088	chr8:87521212	C/T	cg27223183	chr8:87520930	FAM82B	-0.71	-5.47	-0.49	3.66e-7	Caudate activity during reward;
THYM	cis	rs9902453	0.715	rs2628176	chr17:28139292	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-5.6	-0.5	2.1e-7	Coffee consumption (cups per day);
THYM	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg18352616	chr4:3374830	RGS12	0.74	8.4	0.65	4.35e-13	Serum sulfate level;
THYM	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.85	7.62	0.62	1.88e-11	Cognitive ability;
THYM	cis	rs7572733	0.534	rs770657	chr2:198674184	C/A	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg13609457	chr4:120235615	NA	0.58	5.33	0.48	6.55e-7	Corneal astigmatism;
THYM	cis	rs472402	0.560	rs4702382	chr5:6665681	T/G	cg12648172	chr5:5886274	NA	0.52	4.57	0.42	1.47e-5	Response to amphetamines;
THYM	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg10802521	chr3:52805072	NEK4	-0.8	-7.53	-0.61	2.92e-11	Bipolar disorder;
THYM	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg23649088	chr2:200775458	C2orf69	0.83	6.97	0.58	4.07e-10	Osteoporosis;
THYM	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg06611532	chr13:114900021	NA	-0.6	-6.6	-0.56	2.29e-9	Schizophrenia;
THYM	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.81	-6.04	-0.53	3e-8	Cognitive test performance;
THYM	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg18105134	chr13:113819100	PROZ	-0.99	-9.17	-0.69	9.97e-15	Platelet distribution width;
THYM	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg01819759	chr13:79234251	RNF219	-0.7	-4.63	-0.43	1.14e-5	Large artery stroke;
THYM	cis	rs600550	0.588	rs11230251	chr11:60088755	G/A	cg05040360	chr11:60102449	MS4A6E	-0.5	-4.66	-0.43	1.05e-5	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs870825	0.616	rs57316663	chr4:185630011	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs2371030	0.965	rs4673548	chr2:211571627	T/C	cg18417063	chr2:211583084	NA	-0.56	-4.9	-0.45	3.97e-6	Non-small cell lung cancer;
THYM	cis	rs4568518	0.535	rs4555994	chr7:18062657	G/A	cg00911873	chr7:18067463	PRPS1L1	-0.57	-4.62	-0.43	1.23e-5	Measles;
THYM	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg07870213	chr5:140052090	DND1	0.73	8.28	0.65	7.61e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs3008870	1.000	rs2755246	chr1:67488984	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.91	7.46	0.61	4e-11	Lymphocyte percentage of white cells;
THYM	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg02725872	chr8:58115012	NA	-0.86	-6.04	-0.53	2.97e-8	Developmental language disorder (linguistic errors);
THYM	trans	rs8002861	0.840	rs1819597	chr13:44429553	G/A	cg17145862	chr1:211918768	LPGAT1	0.87	9.02	0.68	2.02e-14	Leprosy;
THYM	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg11764359	chr7:65958608	NA	0.67	4.48	0.42	2.08e-5	Aortic root size;
THYM	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg16926213	chr1:1841314	NA	0.54	5.64	0.5	1.73e-7	Body mass index;
THYM	cis	rs870825	0.616	rs6852082	chr4:185645783	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs4919044	0.808	rs10748590	chr10:94812426	A/T	cg05127821	chr10:94822908	CYP26C1	1.23	6.66	0.56	1.76e-9	Coronary artery disease;
THYM	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg03676636	chr4:99064102	C4orf37	0.5	7.59	0.61	2.14e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg08704250	chr15:31115839	NA	0.47	5.54	0.49	2.68e-7	Huntington's disease progression;
THYM	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg15448220	chr1:150897856	SETDB1	-0.88	-7.18	-0.59	1.51e-10	Melanoma;
THYM	cis	rs11809207	1.000	rs11809207	chr1:26521140	G/A	cg03844060	chr1:26490628	NA	0.68	4.87	0.45	4.36e-6	Height;
THYM	cis	rs28595532	0.920	rs115090643	chr4:119729825	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs887829	0.570	rs10203266	chr2:234596368	G/C	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.57	-0.42	1.45e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg23711669	chr6:146136114	FBXO30	0.9	9.23	0.69	7.15e-15	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg19862616	chr7:65841803	NCRNA00174	1.1	13.67	0.81	3.71e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg10224037	chr5:178157518	ZNF354A	0.98	7.97	0.63	3.43e-12	Neutrophil percentage of white cells;
THYM	cis	rs7119	0.667	rs1058129	chr15:77905661	A/G	cg10437265	chr15:77819839	NA	-0.54	-5.33	-0.48	6.52e-7	Type 2 diabetes;
THYM	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg19875535	chr5:140030758	IK	-0.63	-5.69	-0.5	1.43e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7177699	0.581	rs7165081	chr15:79123396	C/G	cg15571903	chr15:79123663	NA	0.58	6.56	0.56	2.77e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg03929089	chr4:120376271	NA	-0.95	-10.32	-0.73	3.39e-17	Height;
THYM	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	5.64	0.5	1.73e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.8	-8.17	-0.64	1.33e-12	Lymphocyte counts;
THYM	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg07936489	chr17:37558343	FBXL20	-0.77	-5.03	-0.46	2.28e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs10929159	0.928	rs1349731	chr2:236924047	C/T	cg20128773	chr2:236923534	AGAP1	-0.35	-4.53	-0.42	1.69e-5	Parkinson's disease;
THYM	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg14820908	chr5:178986412	RUFY1	-0.64	-7.07	-0.59	2.57e-10	Lung cancer;
THYM	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg16006841	chr5:176797999	RGS14	-0.53	-6.19	-0.54	1.55e-8	Urate levels in lean individuals;
THYM	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg12863693	chr15:85201151	NMB	0.62	5.39	0.48	5.09e-7	Schizophrenia;
THYM	cis	rs6138458	1.000	rs6138458	chr20:24973769	C/T	cg06937882	chr20:24974362	C20orf3	-0.46	-4.64	-0.43	1.11e-5	Blood protein levels;
THYM	cis	rs1003719	0.788	rs4817849	chr21:38469796	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.71	5.79	0.51	8.91e-8	Menarche (age at onset);
THYM	cis	rs35881094	0.933	rs6759145	chr2:58896674	A/G	cg09452692	chr2:58468460	FANCL	0.59	4.53	0.42	1.7e-5	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg03433033	chr1:76189801	ACADM	0.77	9.42	0.69	2.92e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs240764	0.658	rs12212435	chr6:101196080	T/C	cg21058520	chr6:100914733	NA	0.56	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg17264618	chr3:40429014	ENTPD3	0.53	4.94	0.45	3.41e-6	Renal cell carcinoma;
THYM	cis	rs2898681	0.618	rs79471207	chr4:53738524	C/T	cg00791764	chr4:53727839	RASL11B	0.64	6.51	0.56	3.52e-9	Optic nerve measurement (cup area);
THYM	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg06623918	chr6:96969491	KIAA0776	1.09	10.37	0.73	2.65e-17	Headache;
THYM	cis	rs35883536	0.631	rs2783704	chr1:101040652	T/A	cg09408571	chr1:101003634	GPR88	0.51	5.56	0.5	2.44e-7	Monocyte count;
THYM	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg01097406	chr16:89675127	NA	0.81	7.34	0.6	7.22e-11	Vitiligo;
THYM	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg10755058	chr3:40428713	ENTPD3	-0.52	-4.45	-0.42	2.29e-5	Renal cell carcinoma;
THYM	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg24675658	chr1:53192096	ZYG11B	0.71	6.38	0.55	6.56e-9	Monocyte count;
THYM	cis	rs753778	0.962	rs4961341	chr8:142235154	G/T	cg18755752	chr8:142205143	DENND3	-0.63	-4.71	-0.44	8.36e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13012494	chr21:47604986	C21orf56	0.74	4.86	0.45	4.6e-6	Testicular germ cell tumor;
THYM	cis	rs1524976	0.708	rs34835630	chr3:65524650	T/C	cg16238336	chr3:65465873	MAGI1	-0.84	-4.46	-0.42	2.23e-5	PR interval;
THYM	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7695732	0.595	rs6844655	chr4:89915359	T/C	cg17769793	chr4:89976368	FAM13A	-0.5	-5.27	-0.48	8.39e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg21644426	chr2:191273491	MFSD6	0.76	6.32	0.54	8.54e-9	Pulse pressure;
THYM	cis	rs11563648	0.553	rs10249162	chr7:127016146	G/T	cg23081781	chr7:127225937	GCC1	-0.37	-5.12	-0.46	1.61e-6	Resting heart rate;
THYM	cis	rs870825	0.860	rs28799091	chr4:185598594	G/A	cg04058563	chr4:185651563	MLF1IP	0.91	6.95	0.58	4.63e-10	Blood protein levels;
THYM	cis	rs17818399	1.000	rs62136864	chr2:46829124	G/A	cg09399716	chr2:46890238	NA	-0.53	-4.85	-0.45	4.76e-6	Height;
THYM	trans	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs12216545	0.765	rs2140141	chr7:150249079	A/G	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg05313129	chr8:58192883	C8orf71	-0.8	-4.52	-0.42	1.76e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs4662945	0.737	rs896793	chr2:130216695	G/T	cg05903289	chr2:130345205	NA	-0.52	-4.96	-0.45	3.05e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs986417	0.901	rs4901987	chr14:60987529	C/T	cg27398547	chr14:60952738	C14orf39	1.14	5.33	0.48	6.64e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs62084913	0.511	rs895690	chr17:72784649	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.63	5.25	0.47	9.17e-7	Breast cancer;
THYM	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg03684893	chr10:554711	DIP2C	-0.74	-5.81	-0.51	8.27e-8	Psychosis in Alzheimer's disease;
THYM	trans	rs11186	0.556	rs56080628	chr2:189958076	G/T	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs7614311	0.954	rs6762506	chr3:63794548	C/G	cg22134162	chr3:63841271	THOC7	-0.5	-6.34	-0.55	7.53e-9	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg19774624	chr17:42201019	HDAC5	0.71	6.24	0.54	1.23e-8	Total body bone mineral density;
THYM	cis	rs9361491	0.608	rs11752686	chr6:79473779	C/T	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.88e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7894051	0.614	rs11101707	chr10:135175844	T/C	cg20534287	chr10:135191450	PAOX	-0.67	-4.81	-0.44	5.65e-6	Lifespan;
THYM	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.9	0.58	5.8e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7107174	1.000	rs114142124	chr11:78047537	T/C	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs472402	0.580	rs7720479	chr5:6640049	A/G	cg12648172	chr5:5886274	NA	0.5	4.58	0.43	1.4e-5	Response to amphetamines;
THYM	cis	rs6047844	0.569	rs56146537	chr20:22125501	T/C	cg16502866	chr20:23015624	SSTR4	-0.59	-4.86	-0.45	4.64e-6	Male-pattern baldness;
THYM	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.64	8.83	0.67	5.25e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg22875332	chr1:76189707	ACADM	-0.88	-10.14	-0.72	8.31e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4242434	0.672	rs3758041	chr8:22486987	A/G	cg11461670	chr8:22454935	PDLIM2	-0.33	-6.26	-0.54	1.09e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg00383909	chr3:49044727	WDR6	1.03	5.9	0.52	5.64e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs9534288	0.740	rs7989892	chr13:46630641	C/T	cg15192986	chr13:46630673	CPB2	-0.66	-4.58	-0.43	1.39e-5	Blood protein levels;
THYM	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg02353165	chr6:42928485	GNMT	0.82	7.82	0.63	7.03e-12	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9543976	1.000	rs2296146	chr13:76143572	T/C	cg01531495	chr13:76123901	UCHL3	-0.75	-4.68	-0.43	9.4e-6	Diabetic retinopathy;
THYM	cis	rs4523957	0.893	rs12950555	chr17:2156910	C/G	cg16513277	chr17:2031491	SMG6	0.79	7.41	0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6988636	1.000	rs13260318	chr8:124190165	C/G	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs4474465	1.000	rs10899533	chr11:78208480	T/C	cg19901956	chr11:77921274	USP35	0.67	4.94	0.45	3.29e-6	Alzheimer's disease (survival time);
THYM	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg13695892	chr22:41940480	POLR3H	0.88	6.15	0.53	1.81e-8	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg04731861	chr2:219085781	ARPC2	0.5	4.83	0.44	5.17e-6	Colorectal cancer;
THYM	cis	rs8192282	0.739	rs4518898	chr1:154492432	T/C	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs11651000	0.857	rs56172120	chr17:45824904	G/A	cg25856473	chr17:45174155	NA	0.59	4.54	0.42	1.62e-5	IgG glycosylation;
THYM	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg22968622	chr17:43663579	NA	1.18	10.66	0.74	6.45e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4690686	0.500	rs35703625	chr4:177263286	G/A	cg17059388	chr4:177262070	NA	0.48	6.73	0.57	1.29e-9	Essential tremor;
THYM	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-4.96	-0.45	3.03e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg04398451	chr17:18023971	MYO15A	-0.76	-6.96	-0.58	4.39e-10	Total body bone mineral density;
THYM	cis	rs4589258	0.737	rs7110548	chr11:90397761	A/G	cg26138821	chr11:89956704	CHORDC1	0.56	4.74	0.44	7.42e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.596	rs7788066	chr7:124630145	A/G	cg05285228	chr7:124571219	POT1	-0.69	-5.08	-0.46	1.9e-6	Cutaneous malignant melanoma;
THYM	cis	rs2742234	0.590	rs2435377	chr10:43683600	A/G	cg06632098	chr10:43605906	RET	0.79	5.1	0.46	1.73e-6	Hirschsprung disease;
THYM	cis	rs16866061	1.000	rs1568750	chr2:225342597	A/T	cg22455342	chr2:225449267	CUL3	0.68	4.88	0.45	4.23e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs7178572	0.568	rs7175674	chr15:77670910	C/T	cg22256960	chr15:77711686	NA	-1.05	-8.4	-0.65	4.29e-13	Type 2 diabetes;
THYM	cis	rs12496230	1.000	rs17782285	chr3:66833592	A/G	cg04995300	chr3:66848608	NA	1.01	6.12	0.53	2.09e-8	Type 2 diabetes;
THYM	cis	rs3825199	0.515	rs2072593	chr12:93970026	T/C	cg18151635	chr12:93972918	NA	-0.85	-5.92	-0.52	5.14e-8	Height;
THYM	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg06238570	chr21:40685208	BRWD1	-0.71	-6.0	-0.52	3.63e-8	Menarche (age at onset);
THYM	cis	rs526231	0.543	rs34808	chr5:102429188	T/A	cg23492399	chr5:102201601	PAM	-0.7	-5.18	-0.47	1.23e-6	Primary biliary cholangitis;
THYM	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg26597838	chr10:835615	NA	1.52	11.37	0.76	2.05e-19	Eosinophil percentage of granulocytes;
THYM	cis	rs2115630	0.818	rs7176522	chr15:85215383	C/G	cg11189052	chr15:85197271	WDR73	-0.66	-5.17	-0.47	1.31e-6	P wave terminal force;
THYM	cis	rs1580019	0.922	rs1376289	chr7:32486980	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.87	-6.32	-0.54	8.29e-9	Cognitive ability;
THYM	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4474465	1.000	rs7950813	chr11:78215082	A/T	cg19901956	chr11:77921274	USP35	0.65	4.83	0.44	5.24e-6	Alzheimer's disease (survival time);
THYM	cis	rs669446	0.562	rs3791036	chr1:44155383	A/G	cg12599982	chr1:44399894	ARTN	0.53	4.81	0.44	5.77e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs2219968	0.525	rs11774685	chr8:78884914	T/C	cg00738934	chr8:78996279	NA	0.61	4.95	0.45	3.21e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.68	5.21	0.47	1.09e-6	Tonsillectomy;
THYM	cis	rs6946131	0.967	rs2061050	chr7:54778871	T/G	cg16668896	chr7:54900801	NA	0.36	4.48	0.42	2.08e-5	Systemic lupus erythematosus;
THYM	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg11494091	chr17:61959527	GH2	-1.09	-17.19	-0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs3812049	0.693	rs9327468	chr5:127441861	C/A	cg05443326	chr5:126853169	PRRC1	-0.65	-4.49	-0.42	2.02e-5	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs7100689	0.646	rs1934694	chr10:82125325	G/A	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs7107174	1.000	rs2511166	chr11:77964331	T/C	cg02023728	chr11:77925099	USP35	0.7	6.44	0.55	4.94e-9	Testicular germ cell tumor;
THYM	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06850241	chr22:41845214	NA	0.59	5.36	0.48	5.81e-7	Vitiligo;
THYM	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg26924012	chr15:45694286	SPATA5L1	-0.98	-7.76	-0.62	9.74e-12	Homoarginine levels;
THYM	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-5.83	-0.51	7.7e-8	Total cholesterol levels;
THYM	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg26131816	chr17:42072204	PYY	0.53	4.6	0.43	1.28e-5	Menopause (age at onset);
THYM	cis	rs4072705	1.000	rs10760370	chr9:127418003	G/C	cg13476313	chr9:127244764	NR5A1	0.33	5.13	0.47	1.53e-6	Menarche (age at onset);
THYM	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs13082711	0.522	rs6551192	chr3:27343376	C/T	cg02860705	chr3:27208620	NA	0.65	5.09	0.46	1.83e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs7172809	0.573	rs13380152	chr15:77436386	A/T	cg22256960	chr15:77711686	NA	-0.64	-4.76	-0.44	6.83e-6	Glucose homeostasis traits;
THYM	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg24675658	chr1:53192096	ZYG11B	-0.81	-7.29	-0.6	8.99e-11	Monocyte count;
THYM	trans	rs9296092	0.517	rs7743064	chr6:33470529	C/T	cg00929798	chr10:135150139	CALY	0.69	6.91	0.58	5.61e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs6500602	0.819	rs3747580	chr16:4455675	G/A	cg09549813	chr16:4587862	C16orf5	-0.57	-5.84	-0.51	7.42e-8	Schizophrenia;
THYM	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg08645402	chr16:4508243	NA	0.76	6.87	0.58	6.72e-10	Schizophrenia;
THYM	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.65	-0.43	1.09e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7084402	1.000	rs717452	chr10:60268270	A/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.48	-0.49	3.52e-7	Refractive error;
THYM	trans	rs877282	0.853	rs12777155	chr10:754731	G/C	cg22713356	chr15:30763199	NA	1.27	9.37	0.69	3.62e-15	Uric acid levels;
THYM	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.53	0.42	1.74e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg12826209	chr6:26865740	GUSBL1	0.87	4.6	0.43	1.28e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs595982	0.726	rs607356	chr19:49371241	T/C	cg19746536	chr19:49375674	PPP1R15A	1.24	14.08	0.82	5.66e-25	Red cell distribution width;
THYM	cis	rs1011018	0.955	rs4132078	chr7:139419930	T/C	cg06079564	chr7:139468310	HIPK2	-0.73	-5.52	-0.49	2.93e-7	Systolic blood pressure;
THYM	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg21433313	chr16:3507492	NAT15	0.59	4.99	0.46	2.75e-6	Body mass index (adult);
THYM	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	4.86	0.45	4.63e-6	Obesity-related traits;
THYM	cis	rs921968	0.613	rs1344642	chr2:219555262	G/A	cg02176678	chr2:219576539	TTLL4	-0.52	-5.32	-0.48	6.77e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.68	6.71	0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs2237457	0.543	rs2190495	chr7:50699352	T/G	cg08586669	chr7:50727761	GRB10	-0.29	-4.62	-0.43	1.21e-5	Schizophrenia (treatment resistant);
THYM	cis	rs4654899	0.931	rs4654880	chr1:21186608	C/A	cg01072550	chr1:21505969	NA	0.71	6.58	0.56	2.61e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs4237845	0.837	rs7954957	chr12:58299250	C/T	cg22764591	chr12:58329936	NA	0.98	7.83	0.63	7.02e-12	Intelligence (multi-trait analysis);
THYM	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg12310025	chr6:25882481	NA	-0.79	-6.36	-0.55	7.02e-9	Intelligence (multi-trait analysis);
THYM	trans	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg19862616	chr7:65841803	NCRNA00174	1.13	13.2	0.8	3.22e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7567389	0.637	rs4150421	chr2:128044930	A/G	cg06038358	chr2:128176007	PROC	-0.43	-4.53	-0.42	1.7e-5	Self-rated health;
THYM	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg02524346	chr8:600233	NA	-0.9	-4.46	-0.42	2.29e-5	IgG glycosylation;
THYM	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.83	-6.4	-0.55	5.87e-9	IgG glycosylation;
THYM	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg09549813	chr16:4587862	C16orf5	-0.56	-6.45	-0.55	4.67e-9	Schizophrenia;
THYM	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg13135455	chr2:241860318	NA	-0.41	-4.88	-0.45	4.24e-6	Urinary metabolites;
THYM	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg07157834	chr1:205819609	PM20D1	0.6	4.65	0.43	1.09e-5	Menarche (age at onset);
THYM	cis	rs7809950	0.678	rs62482499	chr7:106975059	C/G	cg23024343	chr7:107201750	COG5	-0.97	-8.28	-0.65	7.7e-13	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg05283184	chr6:79620031	NA	-0.88	-8.42	-0.65	3.86e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs7580658	0.864	rs3088374	chr2:128062048	T/C	cg22856114	chr2:128175905	PROC	-0.63	-5.18	-0.47	1.23e-6	Protein C levels;
THYM	cis	rs2290159	0.948	rs7956	chr3:12624763	C/T	cg23032965	chr3:12705835	RAF1	-0.71	-4.93	-0.45	3.46e-6	Cholesterol, total;
THYM	cis	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg10856724	chr12:34555212	NA	1.05	10.54	0.73	1.17e-17	Morning vs. evening chronotype;
THYM	cis	rs12257961	0.549	rs11259613	chr10:15382515	A/C	cg10616319	chr10:15468812	NA	0.59	4.88	0.45	4.23e-6	Selective IgA deficiency;
THYM	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-5.07	-0.46	1.95e-6	Neuroticism;
THYM	cis	rs6430585	0.591	rs72970243	chr2:136484232	G/A	cg07169764	chr2:136633963	MCM6	0.94	9.32	0.69	4.67e-15	Corneal structure;
THYM	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg11247378	chr22:39784982	NA	-1.01	-9.5	-0.7	1.97e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg00080972	chr5:178986291	RUFY1	0.57	7.35	0.6	6.84e-11	Lung cancer;
THYM	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-5.34	-0.48	6.41e-7	Lymphocyte counts;
THYM	cis	rs1559088	0.649	rs4528686	chr19:33556074	A/G	cg03563238	chr19:33554763	RHPN2	-0.51	-4.53	-0.42	1.69e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs35883536	0.647	rs2783696	chr1:101044089	G/A	cg09408571	chr1:101003634	GPR88	0.48	5.22	0.47	1.05e-6	Monocyte count;
THYM	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg07212818	chr11:638076	DRD4	-0.79	-6.7	-0.57	1.48e-9	Systemic lupus erythematosus;
THYM	cis	rs2180341	0.532	rs6933893	chr6:127707250	A/G	cg27446573	chr6:127587934	RNF146	0.74	6.05	0.53	2.85e-8	Breast cancer;
THYM	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs137603	0.602	rs9611146	chr22:39718120	G/T	cg24268161	chr22:39747459	SYNGR1	0.65	5.49	0.49	3.4e-7	Primary biliary cholangitis;
THYM	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg24818145	chr4:99064322	C4orf37	0.87	7.23	0.6	1.19e-10	Colonoscopy-negative controls vs population controls;
THYM	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg15704280	chr7:45808275	SEPT13	-1.03	-11.39	-0.76	1.85e-19	Coronary artery disease;
THYM	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg01448562	chr3:133502909	NA	-0.97	-8.3	-0.65	6.86e-13	Iron status biomarkers;
THYM	cis	rs9329289	0.610	rs10903783	chr10:2540623	C/T	cg07014206	chr10:2547000	NA	-0.53	-4.61	-0.43	1.24e-5	Age-related hearing impairment;
THYM	cis	rs7582180	0.663	rs4850929	chr2:100990707	A/C	cg14675211	chr2:100938903	LONRF2	0.59	5.65	0.5	1.67e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg12310025	chr6:25882481	NA	-0.67	-4.64	-0.43	1.1e-5	Height;
THYM	cis	rs1499972	0.838	rs7644473	chr3:117520833	G/T	cg07612923	chr3:117604196	NA	-1.31	-5.35	-0.48	6.02e-7	Schizophrenia;
THYM	cis	rs9549367	0.789	rs9549698	chr13:113877701	A/G	cg00898013	chr13:113819073	PROZ	-0.9	-9.1	-0.68	1.4e-14	Platelet distribution width;
THYM	cis	rs526821	0.553	rs295597	chr11:55470003	T/C	cg26866625	chr11:55406191	OR4P4	-0.59	-5.2	-0.47	1.15e-6	Pediatric bone mineral density (spine);
THYM	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg18252515	chr7:66147081	NA	0.72	5.6	0.5	2.03e-7	Aortic root size;
THYM	cis	rs899997	0.731	rs58717592	chr15:79030417	T/C	cg10852096	chr15:79043040	NA	0.74	4.76	0.44	6.87e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg23281280	chr6:28129359	ZNF389	0.61	4.74	0.44	7.58e-6	Parkinson's disease;
THYM	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.63	-4.56	-0.42	1.53e-5	Aortic root size;
THYM	cis	rs3008870	1.000	rs2815357	chr1:67491854	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.92	7.55	0.61	2.6e-11	Lymphocyte percentage of white cells;
THYM	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg24733560	chr20:60626293	TAF4	0.62	6.35	0.55	7.47e-9	Body mass index;
THYM	cis	rs11048434	0.723	rs12820395	chr12:9137096	T/G	cg14913610	chr12:9142341	KLRG1	-0.29	-4.45	-0.42	2.33e-5	Sjögren's syndrome;
THYM	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg13319975	chr6:146136371	FBXO30	0.66	5.33	0.48	6.56e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.73	-6.21	-0.54	1.4e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6430585	0.583	rs58509842	chr2:136586027	G/A	cg20242066	chr2:136595261	LCT	0.47	4.64	0.43	1.1e-5	Corneal structure;
THYM	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg25918947	chr17:41365094	TMEM106A	-0.57	-4.8	-0.44	5.92e-6	Menopause (age at onset);
THYM	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg15212455	chr7:39170539	POU6F2	0.58	5.32	0.48	6.95e-7	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg27398817	chr8:82754497	SNX16	-0.69	-5.81	-0.51	8.17e-8	Diastolic blood pressure;
THYM	cis	rs295140	0.585	rs4233996	chr2:201131228	A/T	cg23649088	chr2:200775458	C2orf69	-0.61	-5.1	-0.46	1.74e-6	QT interval;
THYM	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg10295955	chr4:187884368	NA	-0.96	-10.18	-0.72	6.79e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13012494	chr21:47604986	C21orf56	0.75	5.19	0.47	1.18e-6	Testicular germ cell tumor;
THYM	cis	rs1729951	0.575	rs16844325	chr3:136678161	C/G	cg12473912	chr3:136751656	NA	0.63	5.13	0.47	1.55e-6	Neuroticism;
THYM	cis	rs6500602	1.000	rs6500602	chr16:4497451	T/C	cg09549813	chr16:4587862	C16orf5	-0.5	-5.4	-0.48	4.94e-7	Schizophrenia;
THYM	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg16615211	chr3:44902933	MIR564;TMEM42	0.51	5.45	0.49	4e-7	Depressive symptoms;
THYM	cis	rs12476592	0.602	rs6736411	chr2:63674060	G/A	cg17519650	chr2:63277830	OTX1	-0.68	-4.51	-0.42	1.83e-5	Childhood ear infection;
THYM	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg00825309	chr19:58991885	ZNF446	-0.6	-4.69	-0.43	9.02e-6	Uric acid clearance;
THYM	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg14074117	chr16:1909714	C16orf73	-0.78	-4.97	-0.45	3.01e-6	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg08508325	chr11:3079039	CARS	-0.52	-6.46	-0.55	4.45e-9	Longevity;
THYM	cis	rs968451	0.526	rs5757617	chr22:39722714	G/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.57	4.47	0.42	2.2e-5	Primary biliary cholangitis;
THYM	cis	rs35883536	0.647	rs12046413	chr1:101047430	T/C	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg06138931	chr13:21896616	NA	0.62	5.08	0.46	1.87e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs9311676	0.656	rs55727087	chr3:58404547	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs6815814	0.861	rs10034903	chr4:38784678	C/G	cg06935464	chr4:38784597	TLR10	0.72	5.23	0.47	9.87e-7	Breast cancer;
THYM	cis	rs2237457	0.543	rs4513921	chr7:50702480	G/A	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.48e-6	Schizophrenia (treatment resistant);
THYM	cis	rs6541297	0.938	rs1555289	chr1:230292499	C/T	cg20703242	chr1:230279135	GALNT2	-1.02	-6.08	-0.53	2.55e-8	Coronary artery disease;
THYM	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg04476341	chr5:669733	TPPP	0.48	4.83	0.44	5.22e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg05335186	chr13:53173507	NA	-0.49	-5.89	-0.52	5.94e-8	Lewy body disease;
THYM	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.72	6.3	0.54	9.21e-9	Calcium levels;
THYM	cis	rs12681287	0.640	rs13256765	chr8:87457833	C/T	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs28595532	0.920	rs114564223	chr4:119729953	A/G	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs7107174	1.000	rs2512535	chr11:77971468	C/T	cg02023728	chr11:77925099	USP35	0.7	6.44	0.55	4.94e-9	Testicular germ cell tumor;
THYM	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg24642844	chr7:1081250	C7orf50	-0.83	-5.14	-0.47	1.45e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs9929218	0.551	rs2274239	chr16:68725783	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.1	14.76	0.83	2.57e-26	Colorectal cancer;
THYM	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs10089	0.903	rs6862701	chr5:127391249	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.97	6.65	0.56	1.82e-9	Ileal carcinoids;
THYM	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg11764359	chr7:65958608	NA	0.81	6.61	0.56	2.21e-9	Aortic root size;
THYM	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg22431228	chr1:16359049	CLCNKA	0.52	4.75	0.44	7.3e-6	Dilated cardiomyopathy;
THYM	cis	rs7943358	0.955	rs10766276	chr11:15704877	T/C	cg11966998	chr11:15692519	NA	-0.48	-4.66	-0.43	1.03e-5	Gut microbiome composition (summer);
THYM	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg01073479	chr16:3509474	NAT15	0.58	4.89	0.45	4.18e-6	Tuberculosis;
THYM	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg04362960	chr10:104952993	NT5C2	0.58	4.77	0.44	6.73e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg10792982	chr14:105748885	BRF1	-0.73	-7.54	-0.61	2.8e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg24531977	chr5:56204891	C5orf35	0.67	5.44	0.49	4.15e-7	Initial pursuit acceleration;
THYM	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg06481639	chr22:41940642	POLR3H	0.69	5.03	0.46	2.32e-6	Vitiligo;
THYM	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg14456004	chr13:21872349	NA	1.26	11.44	0.76	1.44e-19	White matter hyperintensity burden;
THYM	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs4285028	0.848	rs4118376	chr3:121636450	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.81	-5.59	-0.5	2.15e-7	Multiple sclerosis;
THYM	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2282300	0.739	rs67670125	chr11:30214914	C/T	cg09906309	chr11:30344399	C11orf46	-0.69	-5.16	-0.47	1.37e-6	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg06481639	chr22:41940642	POLR3H	0.82	5.68	0.5	1.49e-7	Vitiligo;
THYM	cis	rs9796	0.689	rs8032195	chr15:41448790	G/A	cg21153102	chr15:41252147	NA	0.6	5.05	0.46	2.09e-6	Menopause (age at onset);
THYM	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg09085632	chr11:111637200	PPP2R1B	1.06	9.94	0.71	2.22e-16	Primary sclerosing cholangitis;
THYM	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07157834	chr1:205819609	PM20D1	1.01	10.2	0.72	6.07e-17	Menarche (age at onset);
THYM	cis	rs3008870	0.959	rs3008852	chr1:67383416	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.95	7.79	0.62	8.27e-12	Lymphocyte percentage of white cells;
THYM	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg14675211	chr2:100938903	LONRF2	0.78	8.49	0.66	2.78e-13	Intelligence (multi-trait analysis);
THYM	cis	rs174601	0.615	rs174534	chr11:61549458	C/T	cg19610905	chr11:61596333	FADS2	0.59	4.76	0.44	7.01e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
THYM	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs1150668	0.699	rs1736895	chr6:28219826	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.67	-5.52	-0.49	2.99e-7	Pubertal anthropometrics;
THYM	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg15693483	chr7:1102177	C7orf50	0.53	6.19	0.54	1.52e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2717559	0.542	rs2717560	chr8:143881670	G/A	cg17252645	chr8:143867129	LY6D	-0.84	-10.17	-0.72	7.06e-17	Urinary tract infection frequency;
THYM	cis	rs4242434	0.672	rs7830206	chr8:22485375	C/T	cg11461670	chr8:22454935	PDLIM2	-0.37	-6.59	-0.56	2.48e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7100689	0.784	rs10887838	chr10:82161380	G/A	cg09936400	chr10:82049201	MAT1A	0.45	4.6	0.43	1.29e-5	Post bronchodilator FEV1;
THYM	cis	rs9915657	0.870	rs11077595	chr17:70130030	C/T	cg06234051	chr17:70120541	SOX9	-0.72	-6.82	-0.57	8.53e-10	Thyroid hormone levels;
THYM	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg16586182	chr3:47516702	SCAP	0.71	5.69	0.5	1.37e-7	Colorectal cancer;
THYM	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	4.63	0.43	1.18e-5	Aortic root size;
THYM	cis	rs7078219	0.743	rs7095953	chr10:101274425	C/T	cg07044859	chr10:101282883	NA	0.46	4.98	0.45	2.86e-6	Dental caries;
THYM	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg26031613	chr14:104095156	KLC1	0.79	5.22	0.47	1.06e-6	Body mass index;
THYM	cis	rs921968	0.643	rs4674324	chr2:219523433	T/G	cg02176678	chr2:219576539	TTLL4	0.6	5.84	0.51	7.3e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6500602	0.584	rs11646063	chr16:4439209	A/G	cg08645402	chr16:4508243	NA	-0.56	-4.63	-0.43	1.17e-5	Schizophrenia;
THYM	cis	rs59698941	0.943	rs57045911	chr5:132272311	T/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs17253792	0.822	rs10148983	chr14:56051879	A/G	cg01858014	chr14:56050164	KTN1	-1.18	-4.68	-0.43	9.63e-6	Putamen volume;
THYM	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg05368731	chr17:41323189	NBR1	1.2	10.93	0.75	1.72e-18	Menopause (age at onset);
THYM	cis	rs3796619	1.000	rs13146371	chr4:1082887	C/T	cg27284194	chr4:1044797	NA	0.54	4.92	0.45	3.69e-6	Recombination rate (males);
THYM	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg15962314	chr1:44399869	ARTN	0.51	4.67	0.43	9.88e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs7107770	1.000	rs61912983	chr11:125107107	A/G	cg07747661	chr11:125106135	PKNOX2	-0.92	-5.19	-0.47	1.17e-6	Photic sneeze reflex;
THYM	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg20283391	chr11:68216788	NA	-0.65	-5.16	-0.47	1.34e-6	Total body bone mineral density;
THYM	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg09307838	chr4:120376055	NA	0.74	5.08	0.46	1.91e-6	Corneal astigmatism;
THYM	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.64	8.83	0.67	5.25e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg02788857	chr8:22132959	PIWIL2	0.55	4.89	0.45	4.09e-6	Hypertriglyceridemia;
THYM	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg12386194	chr3:101231763	SENP7	0.96	7.53	0.61	2.97e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg19746536	chr19:49375674	PPP1R15A	0.81	4.59	0.43	1.34e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs11169225	0.906	rs399023	chr12:50338952	A/C	cg23855989	chr12:50355821	AQP5	0.71	6.59	0.56	2.45e-9	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg25566285	chr7:158114605	PTPRN2	0.89	9.54	0.7	1.58e-15	Calcium levels;
THYM	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs1466662	0.677	rs17301342	chr4:155305233	A/G	cg05574313	chr4:155338166	DCHS2	0.66	4.79	0.44	6.2e-6	Alzheimer's disease (age of onset);
THYM	cis	rs9914266	1	rs9914266	chr17:2133250	T/C	cg16513277	chr17:2031491	SMG6	-0.8	-8.0	-0.63	2.95e-12	Myocardial infarction;
THYM	cis	rs4866334	1.000	rs75023127	chr5:18487706	A/G	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11890956	chr21:40555474	PSMG1	0.97	10.86	0.74	2.49e-18	Cognitive function;
THYM	cis	rs9906944	0.742	rs4073893	chr17:47118523	A/G	cg09029085	chr17:47094198	IGF2BP1	0.47	6.53	0.56	3.17e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs2069036	0.951	rs4748242	chr10:16101247	A/G	cg26633223	chr10:15133461	NA	0.66	4.65	0.43	1.08e-5	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs2888875	0.505	rs12185704	chr2:43542507	C/T	cg22033476	chr2:43532275	THADA	-0.39	-4.45	-0.42	2.32e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs4509693	0.782	rs12268880	chr10:102495285	G/C	cg24127310	chr10:102502104	NA	1.24	9.04	0.68	1.9e-14	Alzheimer's disease;
THYM	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.54	-4.51	-0.42	1.86e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22133161	chr19:49891603	CCDC155	0.84	5.78	0.51	9.5e-8	Multiple sclerosis;
THYM	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7940866	0.646	rs10894293	chr11:130824213	C/T	cg12179176	chr11:130786555	SNX19	-0.66	-5.34	-0.48	6.43e-7	Schizophrenia;
THYM	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg13319975	chr6:146136371	FBXO30	-0.64	-5.05	-0.46	2.14e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs5995756	0.554	rs4522708	chr22:39985283	G/A	cg21377881	chr22:40064566	CACNA1I	-0.56	-4.83	-0.44	5.31e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg00256281	chr22:41985642	PMM1	0.61	4.65	0.43	1.08e-5	Vitiligo;
THYM	cis	rs17122693	1.000	rs72679592	chr14:51094047	T/C	cg04730355	chr14:51134070	SAV1	0.91	4.95	0.45	3.19e-6	Cognitive performance;
THYM	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg22189786	chr22:42395067	WBP2NL	0.67	5.35	0.48	6.07e-7	Birth weight;
THYM	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg00376283	chr12:123451042	ABCB9	0.72	4.94	0.45	3.36e-6	Neutrophil percentage of white cells;
THYM	cis	rs13082711	0.911	rs6776318	chr3:27523457	T/C	cg02860705	chr3:27208620	NA	0.72	5.06	0.46	2.01e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9914544	0.545	rs9903574	chr17:18768582	C/T	cg26378065	chr17:18585709	ZNF286B	0.6	4.71	0.44	8.44e-6	Educational attainment (years of education);
THYM	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg18681998	chr4:17616180	MED28	0.88	8.09	0.64	1.94e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg07606381	chr6:8435919	SLC35B3	0.62	4.62	0.43	1.21e-5	Motion sickness;
THYM	cis	rs9527	0.662	rs4919687	chr10:104595248	G/A	cg04362960	chr10:104952993	NT5C2	0.64	4.98	0.45	2.85e-6	Arsenic metabolism;
THYM	cis	rs17598306	0.935	rs2894086	chr7:96584416	A/G	cg13449377	chr7:96631089	DLX6AS	0.76	4.78	0.44	6.38e-6	Radiation response;
THYM	cis	rs733175	0.855	rs6853437	chr4:10005435	A/G	cg11266682	chr4:10021025	SLC2A9	-0.52	-4.6	-0.43	1.31e-5	Psychosis and Alzheimer's disease;
THYM	cis	rs3126085	0.560	rs11204982	chr1:152322042	A/G	cg10321714	chr1:152280068	FLG	-0.67	-4.93	-0.45	3.54e-6	Atopic dermatitis;
THYM	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg03806693	chr22:41940476	POLR3H	1.25	10.88	0.74	2.22e-18	Vitiligo;
THYM	cis	rs11112613	0.595	rs871219	chr12:105938519	C/A	cg03607813	chr12:105948248	NA	1.06	9.06	0.68	1.69e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs240764	0.736	rs2007134	chr6:100926370	T/G	cg21058520	chr6:100914733	NA	0.57	4.7	0.43	8.76e-6	Neuroticism;
THYM	cis	rs6768930	0.509	rs28495214	chr3:57746474	G/C	cg07735586	chr3:57945651	NA	-0.33	-4.9	-0.45	3.9e-6	Obesity-related traits;
THYM	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg18825531	chr11:62321136	NA	-0.42	-4.78	-0.44	6.48e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs865483	0.895	rs2522972	chr17:35839021	C/T	cg06716730	chr17:35851459	DUSP14	0.43	7.3	0.6	8.71e-11	Monocyte count;
THYM	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg00898013	chr13:113819073	PROZ	-1.04	-7.32	-0.6	7.98e-11	Platelet distribution width;
THYM	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs4363385	0.818	rs382653	chr1:153006761	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs1904096	0.506	rs10028613	chr4:95223698	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.55	-4.55	-0.42	1.57e-5	Type 2 diabetes;
THYM	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg27284194	chr4:1044797	NA	0.62	4.72	0.44	8.27e-6	Recombination rate (females);
THYM	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg02527881	chr3:46936655	PTH1R	0.57	5.5	0.49	3.16e-7	Colorectal cancer;
THYM	cis	rs6669072	0.527	rs11578758	chr1:91284351	T/G	cg08895590	chr1:91227319	NA	-0.39	-4.45	-0.42	2.32e-5	Cognitive function;
THYM	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs11690935	0.632	rs6737308	chr2:172872042	G/A	cg13550731	chr2:172543902	DYNC1I2	0.64	5.1	0.46	1.77e-6	Schizophrenia;
THYM	cis	rs8050907	1.000	rs13335998	chr16:4651921	G/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.34	5.32	0.48	7e-7	Obesity-related traits;
THYM	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg03929089	chr4:120376271	NA	-0.95	-10.82	-0.74	2.97e-18	Height;
THYM	cis	rs7843479	1.000	rs13276082	chr8:21823184	A/G	cg17168535	chr8:21777572	XPO7	0.65	4.82	0.44	5.41e-6	Mean corpuscular volume;
THYM	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg18904891	chr8:8559673	CLDN23	0.64	4.96	0.45	3.07e-6	Obesity-related traits;
THYM	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg10589385	chr1:150898437	SETDB1	0.66	5.21	0.47	1.09e-6	Urate levels;
THYM	cis	rs17152411	1.000	rs733402	chr10:126594152	T/C	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs7746082	0.627	rs12216416	chr6:106473270	C/T	cg02270332	chr6:106475062	NA	0.65	6.21	0.54	1.38e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs36051895	0.626	rs10283564	chr9:5075628	C/G	cg02405213	chr9:5042618	JAK2	-1.03	-11.11	-0.75	7.02e-19	Pediatric autoimmune diseases;
THYM	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg20503657	chr10:835505	NA	1.17	8.3	0.65	7.12e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs611744	0.934	rs672408	chr8:109224390	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.25	0.47	9.08e-7	Dupuytren's disease;
THYM	cis	rs2625529	0.938	rs2742323	chr15:72116778	A/T	cg16672083	chr15:72433130	SENP8	0.54	4.93	0.45	3.48e-6	Red blood cell count;
THYM	cis	rs34779708	0.742	rs35912711	chr10:35312996	T/C	cg03585969	chr10:35415529	CREM	0.64	4.5	0.42	1.93e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg03609598	chr5:56110824	MAP3K1	-0.85	-5.85	-0.51	6.86e-8	Initial pursuit acceleration;
THYM	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11890956	chr21:40555474	PSMG1	-0.63	-5.03	-0.46	2.34e-6	Menarche (age at onset);
THYM	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg08736216	chr1:53307985	ZYG11A	-0.58	-5.29	-0.48	7.85e-7	Monocyte count;
THYM	trans	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg10856724	chr12:34555212	NA	-1.02	-9.32	-0.69	4.7e-15	Morning vs. evening chronotype;
THYM	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	cis	rs4919087	1.000	rs10786326	chr10:99070377	G/A	cg19453742	chr10:98862320	SLIT1	-0.63	-5.17	-0.47	1.31e-6	Monocyte count;
THYM	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg12981288	chr8:11183844	MTMR9	0.45	4.48	0.42	2.09e-5	Retinal vascular caliber;
THYM	cis	rs7681440	0.583	rs2583959	chr4:90721637	C/G	cg06632027	chr4:90757378	SNCA	-0.66	-5.19	-0.47	1.18e-6	Dementia with Lewy bodies;
THYM	trans	rs1974653	0.672	rs7288396	chr22:20086571	G/T	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg02527881	chr3:46936655	PTH1R	0.52	4.99	0.46	2.77e-6	Colorectal cancer;
THYM	cis	rs1747683	0.966	rs7475361	chr10:13373716	C/T	cg00142036	chr10:13388442	SEPHS1	0.29	5.17	0.47	1.32e-6	IgG glycosylation;
THYM	trans	rs7224737	0.750	rs2230326	chr17:40280291	G/A	cg01049205	chr10:85997177	LRIT1	-1.08	-7.48	-0.61	3.67e-11	Fibrinogen levels;
THYM	cis	rs12594515	1.000	rs12592190	chr15:45994028	G/A	cg01629716	chr15:45996671	NA	0.53	5.27	0.48	8.66e-7	Waist circumference;Weight;
THYM	cis	rs7546094	1.000	rs1994604	chr1:113156426	C/T	cg22162597	chr1:113214053	CAPZA1	0.48	4.91	0.45	3.81e-6	Platelet distribution width;
THYM	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	trans	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg01831904	chr17:28903510	LRRC37B2	0.84	4.72	0.44	8.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2290159	0.948	rs73130305	chr3:12621075	C/T	cg23032965	chr3:12705835	RAF1	0.76	5.1	0.46	1.72e-6	Cholesterol, total;
THYM	cis	rs16866061	1.000	rs72974205	chr2:225408468	C/T	cg12698349	chr2:225449008	CUL3	1.14	10.37	0.73	2.69e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg00071950	chr4:10020882	SLC2A9	-0.66	-5.92	-0.52	5.11e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-6.32	-0.54	8.52e-9	Total body bone mineral density;
THYM	cis	rs2625529	0.529	rs1552133	chr15:72232897	T/A	cg16672083	chr15:72433130	SENP8	0.49	4.45	0.42	2.31e-5	Red blood cell count;
THYM	cis	rs7809950	0.678	rs62482507	chr7:107024488	T/G	cg23024343	chr7:107201750	COG5	-0.92	-7.48	-0.61	3.77e-11	Coronary artery disease;
THYM	cis	rs6424115	0.830	rs2502999	chr1:24198321	A/G	cg15997130	chr1:24165203	NA	0.74	6.35	0.55	7.22e-9	Immature fraction of reticulocytes;
THYM	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15541040	chr2:3486749	NA	-0.57	-4.58	-0.43	1.43e-5	Neurofibrillary tangles;
THYM	cis	rs236907	0.859	rs35631282	chr1:171760682	C/T	cg20598894	chr1:171756153	METTL13	-0.72	-5.11	-0.46	1.68e-6	Mean platelet volume;
THYM	cis	rs2439831	1.000	rs565007	chr15:43716641	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.56	-0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.88	7.81	0.63	7.51e-12	Monocyte percentage of white cells;
THYM	cis	rs4803468	1.000	rs4674	chr19:41930396	A/G	cg09537434	chr19:41945824	ATP5SL	-1.05	-9.33	-0.69	4.53e-15	Height;
THYM	cis	rs4589258	0.504	rs4753021	chr11:90388399	C/T	cg26138821	chr11:89956704	CHORDC1	0.62	4.45	0.42	2.36e-5	Intelligence (multi-trait analysis);
THYM	cis	rs11771526	0.818	rs17161140	chr7:32324199	T/C	cg27532318	chr7:32358331	NA	0.77	5.06	0.46	2.03e-6	Body mass index;
THYM	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg06784218	chr1:46089804	CCDC17	-0.29	-4.6	-0.43	1.33e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg27490568	chr2:178487706	NA	0.6	5.49	0.49	3.3e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs11096990	0.593	rs6531700	chr4:39270885	T/G	cg24403649	chr4:39172243	NA	-0.67	-5.84	-0.51	7.33e-8	Cognitive function;
THYM	cis	rs9318086	0.687	rs9507182	chr13:24442365	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.54	4.66	0.43	1.02e-5	Myopia (pathological);
THYM	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg05182265	chr7:156933206	UBE3C	-0.63	-8.19	-0.64	1.22e-12	Body mass index;
THYM	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg07884673	chr3:53033167	SFMBT1	1.11	5.86	0.52	6.73e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg13319975	chr6:146136371	FBXO30	-0.68	-5.66	-0.5	1.62e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg13334819	chr7:99746414	C7orf59	-0.72	-4.82	-0.44	5.4e-6	Coronary artery disease;
THYM	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22133161	chr19:49891603	CCDC155	0.74	4.99	0.46	2.71e-6	Multiple sclerosis;
THYM	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs778371	0.958	rs2675968	chr2:233736244	A/G	cg08000102	chr2:233561755	GIGYF2	0.83	6.84	0.57	7.56e-10	Schizophrenia;
THYM	cis	rs9902453	0.933	rs1532042	chr17:28504389	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.83	0.44	5.26e-6	Coffee consumption (cups per day);
THYM	cis	rs8180040	0.871	rs11716661	chr3:47517773	G/T	cg16586182	chr3:47516702	SCAP	0.63	5.57	0.5	2.35e-7	Colorectal cancer;
THYM	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.75	-0.67	7.74e-14	Mean corpuscular volume;
THYM	cis	rs11677370	0.603	rs10171309	chr2:3851690	C/T	cg17052675	chr2:3827356	NA	-0.71	-6.57	-0.56	2.7e-9	Type 2 diabetes;
THYM	cis	rs3087591	1.000	rs2952989	chr17:29516113	G/A	cg24425628	chr17:29625626	OMG;NF1	0.65	5.69	0.5	1.38e-7	Hip circumference;
THYM	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs1729951	0.575	rs361245	chr3:136695706	A/G	cg21827317	chr3:136751795	NA	0.76	6.7	0.57	1.5e-9	Neuroticism;
THYM	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.0	-0.63	2.97e-12	Mean corpuscular volume;
THYM	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.33	9.84	0.71	3.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9296092	0.517	rs9461876	chr6:33516657	C/T	cg13560919	chr6:33536144	NA	-0.93	-9.07	-0.68	1.58e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs11157436	0.792	rs12433875	chr14:22622423	A/G	cg26433554	chr14:23315189	MMP14	0.44	4.61	0.43	1.24e-5	Neurocognitive impairment in HIV-1 infection (continuous);
THYM	cis	rs7578361	0.959	rs7587837	chr2:150455395	A/G	cg17961725	chr2:150454027	NA	0.75	6.2	0.54	1.47e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg23281280	chr6:28129359	ZNF389	-0.65	-5.02	-0.46	2.45e-6	Parkinson's disease;
THYM	cis	rs6450176	0.951	rs255757	chr5:53309371	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.13	-0.53	2.01e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs11631955	1	rs11631955	chr15:79085915	A/G	cg15571903	chr15:79123663	NA	-0.54	-5.12	-0.47	1.57e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.05	6.74	0.57	1.23e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7681423	1.000	rs7659024	chr4:155520930	G/A	cg20735720	chr4:155535218	FGG	-0.71	-5.57	-0.5	2.39e-7	Fibrinogen;
THYM	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg01751800	chr4:77820391	ANKRD56	0.55	4.59	0.43	1.36e-5	Emphysema distribution in smoking;
THYM	cis	rs9324022	0.580	rs10151519	chr14:101175798	G/A	cg18089426	chr14:101175970	NA	0.77	5.36	0.48	5.85e-7	Plateletcrit;
THYM	cis	rs7635838	0.684	rs2606758	chr3:11353064	G/A	cg00170343	chr3:11313890	ATG7	0.57	4.56	0.42	1.51e-5	HDL cholesterol;
THYM	cis	rs11118346	0.501	rs10735496	chr1:219723406	C/T	cg07908999	chr1:219785142	NA	-0.44	-5.0	-0.46	2.59e-6	Height;
THYM	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg23711669	chr6:146136114	FBXO30	0.93	9.69	0.7	7.64e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs62236223	1	rs62236223	chr22:31863554	T/C	cg01338084	chr22:32026380	PISD	1.35	4.92	0.45	3.69e-6	Age-related hearing impairment;
THYM	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg03161606	chr19:29218774	NA	0.77	6.42	0.55	5.32e-9	Methadone dose in opioid dependence;
THYM	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg12826209	chr6:26865740	GUSBL1	-0.82	-4.6	-0.43	1.29e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg15358701	chr1:161410459	NA	0.97	5.37	0.48	5.56e-7	Rheumatoid arthritis;
THYM	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4731207	0.698	rs10223980	chr7:124536558	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs476633	0.708	rs111717706	chr15:41441162	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.7	-5.46	-0.49	3.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.57	-5.62	-0.5	1.87e-7	Longevity;Endometriosis;
THYM	cis	rs611744	0.967	rs689256	chr8:109186398	T/A	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs28595532	0.844	rs116721336	chr4:119536538	A/G	cg21605333	chr4:119757512	SEC24D	1.44	5.22	0.47	1.03e-6	Cannabis dependence symptom count;
THYM	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg08807101	chr21:30365312	RNF160	-0.94	-8.11	-0.64	1.8e-12	Dental caries;
THYM	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg23281280	chr6:28129359	ZNF389	0.66	5.09	0.46	1.78e-6	Depression;
THYM	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg04447362	chr2:237654635	NA	0.48	4.49	0.42	2.03e-5	Prostate cancer;
THYM	cis	rs924712	0.677	rs3105250	chr6:54843858	A/G	cg04690482	chr6:54711388	FAM83B	0.43	5.16	0.47	1.33e-6	Breast cancer;
THYM	cis	rs7017697	1.000	rs7017697	chr8:19685909	G/T	cg01411142	chr8:19674711	INTS10	-0.53	-4.52	-0.42	1.77e-5	Breast cancer;
THYM	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.75	4.71	0.43	8.59e-6	Smoking behavior;
THYM	cis	rs7818345	0.967	rs12679712	chr8:19271032	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.65	0.43	1.06e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs6429082	0.668	rs291395	chr1:235652049	A/C	cg26050004	chr1:235667680	B3GALNT2	-0.76	-5.9	-0.52	5.55e-8	Adiposity;
THYM	cis	rs3126085	0.825	rs12045492	chr1:152253866	A/T	cg10321714	chr1:152280068	FLG	0.61	4.63	0.43	1.17e-5	Atopic dermatitis;
THYM	cis	rs17253792	0.749	rs17747301	chr14:56125030	C/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.92	5.77	0.51	1.01e-7	Platelet count;
THYM	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg00376283	chr12:123451042	ABCB9	0.72	4.94	0.45	3.36e-6	Neutrophil percentage of white cells;
THYM	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg20503657	chr10:835505	NA	0.92	5.02	0.46	2.4e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg05368731	chr17:41323189	NBR1	1.28	11.2	0.75	4.68e-19	Menopause (age at onset);
THYM	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg23711669	chr6:146136114	FBXO30	-0.99	-10.66	-0.74	6.63e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg11494091	chr17:61959527	GH2	-0.97	-11.75	-0.77	3.27e-20	Prudent dietary pattern;
THYM	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.61	-5.17	-0.47	1.32e-6	Coronary artery disease;
THYM	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg06917634	chr15:78832804	PSMA4	0.96	8.76	0.67	7.4e-14	Sudden cardiac arrest;
THYM	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg09060608	chr5:178986726	RUFY1	-0.58	-6.5	-0.55	3.74e-9	Lung cancer;
THYM	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg26408565	chr15:76604113	ETFA	-0.53	-4.64	-0.43	1.13e-5	Blood metabolite levels;
THYM	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg21854759	chr1:92012499	NA	-0.72	-6.15	-0.53	1.81e-8	Breast cancer;
THYM	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg25703541	chr22:24373054	LOC391322	-0.88	-10.89	-0.75	2.08e-18	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11767557	1.000	rs11767557	chr7:143109139	A/G	cg05908241	chr7:143109367	NA	-0.63	-6.18	-0.54	1.56e-8	Alzheimer's disease (late onset);
THYM	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg21658235	chr8:22456391	C8orf58	-0.5	-4.85	-0.45	4.79e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2455799	0.613	rs12485852	chr3:15914511	G/C	cg16303742	chr3:15540471	COLQ	-0.57	-5.76	-0.51	1.04e-7	Mean platelet volume;
THYM	cis	rs13102973	0.682	rs7691622	chr4:135889689	T/C	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg13010199	chr12:38710504	ALG10B	-0.62	-5.38	-0.48	5.28e-7	Heart rate;
THYM	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg15744005	chr10:104629667	AS3MT	-0.85	-8.32	-0.65	6.25e-13	Arsenic metabolism;
THYM	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg14416269	chr4:6271139	WFS1	-0.57	-4.96	-0.45	3.07e-6	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg00801512	chr17:28996047	NA	-0.76	-4.9	-0.45	3.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg23187316	chr7:1099788	C7orf50	0.47	5.3	0.48	7.61e-7	Longevity;Endometriosis;
THYM	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg22431228	chr1:16359049	CLCNKA	-0.43	-4.66	-0.43	1.03e-5	Systolic blood pressure;
THYM	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.07	-0.82	5.85e-25	Height;
THYM	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg02753203	chr1:228287806	NA	-0.61	-5.28	-0.48	8.19e-7	Diastolic blood pressure;
THYM	cis	rs6032067	0.683	rs13042431	chr20:43781253	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-6.26	-0.54	1.12e-8	Blood protein levels;
THYM	cis	rs7584330	0.554	rs74832280	chr2:238426625	G/A	cg14458575	chr2:238380390	NA	0.79	4.65	0.43	1.06e-5	Prostate cancer;
THYM	cis	rs2235649	0.833	rs9926962	chr16:1851826	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-4.98	-0.45	2.86e-6	Blood metabolite levels;
THYM	cis	rs2050392	1.000	rs2253585	chr10:30696503	C/T	cg02070205	chr10:30722105	MAP3K8	-0.5	-4.45	-0.42	2.31e-5	Inflammatory bowel disease;
THYM	cis	rs2898681	0.614	rs6839900	chr4:53675334	A/G	cg21521518	chr4:53727714	RASL11B	0.47	5.18	0.47	1.26e-6	Optic nerve measurement (cup area);
THYM	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs59698941	0.709	rs12163973	chr5:132226664	G/A	cg02081065	chr5:132209139	LEAP2	-0.85	-5.74	-0.51	1.14e-7	Apolipoprotein A-IV levels;
THYM	cis	rs6882716	0.534	rs7719906	chr5:10809586	G/A	cg14521931	chr5:10832172	NA	-0.73	-6.3	-0.54	9.37e-9	Alcohol consumption (maxi-drinks);
THYM	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg17971929	chr21:40555470	PSMG1	0.72	4.65	0.43	1.07e-5	Cognitive function;
THYM	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg11645453	chr3:52864694	ITIH4	0.3	4.69	0.43	8.99e-6	Schizophrenia;
THYM	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg16031515	chr1:205743344	RAB7L1	-0.72	-7.65	-0.62	1.59e-11	Menarche (age at onset);
THYM	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.74	5.89	0.52	5.86e-8	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg10360139	chr7:1886902	MAD1L1	0.57	4.93	0.45	3.48e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs9790314	0.718	rs6774635	chr3:160847908	A/G	cg04691961	chr3:161091175	C3orf57	-0.61	-4.71	-0.44	8.33e-6	Morning vs. evening chronotype;
THYM	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.61	-5.18	-0.47	1.24e-6	Coronary artery disease;
THYM	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg18252515	chr7:66147081	NA	-1.48	-8.83	-0.67	5.15e-14	Diabetic kidney disease;
THYM	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg22709100	chr7:91322751	NA	-0.6	-4.8	-0.44	5.84e-6	Breast cancer;
THYM	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-5.21	-0.47	1.09e-6	Mean platelet volume;
THYM	cis	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg16898833	chr6:26189333	HIST1H4D	1.33	4.95	0.45	3.27e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1505368	0.532	rs2888093	chr2:213328348	G/A	cg16329650	chr2:213403929	ERBB4	0.65	5.47	0.49	3.65e-7	Symmetrical dimethylarginine levels;
THYM	trans	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg25214090	chr10:38739885	LOC399744	0.81	6.93	0.58	4.99e-10	Corneal astigmatism;
THYM	cis	rs2108225	1.000	rs6466190	chr7:107451045	G/T	cg18560240	chr7:107437656	SLC26A3	0.79	5.57	0.5	2.39e-7	Ulcerative colitis;
THYM	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg09455208	chr3:40491958	NA	0.44	4.61	0.43	1.27e-5	Renal cell carcinoma;
THYM	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg11752832	chr7:134001865	SLC35B4	0.68	4.92	0.45	3.63e-6	Mean platelet volume;
THYM	trans	rs4959799	0.655	rs61422318	chr6:3287916	T/G	cg13094752	chr14:23305548	MMP14	1.11	6.98	0.58	3.92e-10	Survival in rectal cancer;
THYM	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg12698349	chr2:225449008	CUL3	0.73	5.47	0.49	3.64e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg10523679	chr1:76189770	ACADM	0.92	10.12	0.72	9.07e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs11948739	0.648	rs10063639	chr5:130180928	A/G	cg08523029	chr5:130500466	HINT1	-0.63	-4.51	-0.42	1.88e-5	Pediatric bone mineral content (hip);
THYM	cis	rs11731175	1.000	rs3849629	chr4:189855923	C/T	cg00431894	chr4:189871012	NA	-0.81	-6.19	-0.54	1.52e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg00898013	chr13:113819073	PROZ	0.88	8.78	0.67	6.63e-14	Platelet distribution width;
THYM	cis	rs9467160	0.581	rs2760131	chr6:24487894	C/T	cg00346970	chr6:24499591	ALDH5A1	0.37	4.56	0.42	1.52e-5	Liver enzyme levels;
THYM	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg21984481	chr17:79567631	NPLOC4	-0.49	-5.34	-0.48	6.4e-7	Eye color traits;
THYM	cis	rs11048434	0.736	rs12423746	chr12:9113002	G/T	cg04155231	chr12:9217510	LOC144571	0.47	4.47	0.42	2.14e-5	Sjögren's syndrome;
THYM	cis	rs8033133	0.958	rs6420956	chr15:25309559	T/C	cg14481604	chr15:25334117	SNORD116-22	-0.71	-4.58	-0.43	1.39e-5	Blood osmolality (transformed sodium);
THYM	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.12	7.95	0.63	3.93e-12	Platelet count;
THYM	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg18252515	chr7:66147081	NA	-0.71	-5.67	-0.5	1.56e-7	Aortic root size;
THYM	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg02725872	chr8:58115012	NA	-0.85	-6.02	-0.53	3.21e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg07212818	chr11:638076	DRD4	-0.77	-5.92	-0.52	5.09e-8	Systemic lupus erythematosus;
THYM	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg04842962	chr6:43655489	MRPS18A	1.4	15.42	0.85	1.3e-27	IgG glycosylation;
THYM	cis	rs4148689	1.000	rs3757802	chr7:117127739	A/C	cg17204129	chr7:117119601	CFTR	-0.6	-4.6	-0.43	1.32e-5	Gout;
THYM	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs11587400	0.572	rs2268697	chr1:115227493	A/G	cg12756093	chr1:115239321	AMPD1	0.69	5.25	0.47	9.1e-7	Autism;
THYM	cis	rs477692	0.563	rs7079165	chr10:131430240	G/A	cg05714579	chr10:131428358	MGMT	-0.81	-7.88	-0.63	5.42e-12	Response to temozolomide;
THYM	cis	rs9296092	0.517	rs11751684	chr6:33528739	G/T	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	trans	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg07211511	chr3:129823064	LOC729375	-1.22	-9.75	-0.71	5.63e-16	Blood pressure (smoking interaction);
THYM	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg09455208	chr3:40491958	NA	0.49	5.1	0.46	1.75e-6	Renal cell carcinoma;
THYM	cis	rs675209	0.576	rs13193887	chr6:7128198	G/T	cg24899545	chr6:7112846	RREB1	-0.47	-4.87	-0.45	4.44e-6	Urate levels;
THYM	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1178127	0.765	rs1178128	chr7:18767714	C/T	cg13420273	chr7:18810212	HDAC9	-0.61	-4.86	-0.45	4.59e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs4845875	0.600	rs10779765	chr1:11838011	T/C	cg06193043	chr1:11908199	NPPA	0.58	4.95	0.45	3.18e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg11764359	chr7:65958608	NA	-0.74	-6.15	-0.53	1.85e-8	Aortic root size;
THYM	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg15110403	chr19:17392923	ANKLE1	0.58	5.01	0.46	2.46e-6	Systemic lupus erythematosus;
THYM	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg00071950	chr4:10020882	SLC2A9	0.89	9.63	0.7	1.04e-15	Bone mineral density;
THYM	cis	rs4789939	0.528	rs2377003	chr17:76878902	T/C	cg00863893	chr17:76876239	TIMP2	-1.22	-8.75	-0.67	7.89e-14	Dupuytren's disease;
THYM	cis	rs2018683	0.649	rs12536605	chr7:28970500	C/T	cg27487796	chr7:28973253	NA	-0.27	-4.67	-0.43	9.84e-6	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
THYM	cis	rs11122895	0.527	rs10186692	chr2:112444296	G/T	cg23262488	chr2:112468472	NA	0.49	6.62	0.56	2.09e-9	Allergic sensitization;
THYM	cis	rs57920188	0.568	rs10915665	chr1:4093717	G/T	cg20703997	chr1:4087676	NA	0.91	5.96	0.52	4.2e-8	Interleukin-17 levels;
THYM	cis	rs3820068	0.608	rs9660255	chr1:16031891	T/G	cg24675056	chr1:15929824	NA	0.78	6.16	0.53	1.73e-8	Systolic blood pressure;
THYM	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg13939156	chr17:80058883	NA	0.4	5.29	0.48	7.68e-7	Life satisfaction;
THYM	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.64	4.6	0.43	1.32e-5	Body mass index (adult);
THYM	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs1335645	1.000	rs56273250	chr1:111675762	G/A	cg00321911	chr1:111669324	DRAM2	-1.13	-5.54	-0.49	2.73e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg13918804	chr1:2043761	PRKCZ	-0.82	-7.43	-0.61	4.76e-11	Height;
THYM	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg05973401	chr12:123451056	ABCB9	0.69	4.59	0.43	1.36e-5	Neutrophil percentage of white cells;
THYM	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg08470875	chr2:26401718	FAM59B	-0.72	-4.46	-0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs13315871	1.000	rs28626602	chr3:58409786	G/C	cg12435725	chr3:58293450	RPP14	-0.46	-4.93	-0.45	3.54e-6	Cholesterol, total;
THYM	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg07570687	chr10:102243282	WNT8B	0.75	6.59	0.56	2.4e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs7584330	0.554	rs10208231	chr2:238433225	C/T	cg08992911	chr2:238395768	MLPH	0.88	5.73	0.51	1.17e-7	Prostate cancer;
THYM	cis	rs3826795	0.569	rs11671319	chr19:46795067	T/C	cg15229275	chr19:46800054	HIF3A	0.93	5.64	0.5	1.77e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs6435161	1.000	rs6435161	chr2:203519783	T/G	cg18429434	chr2:203499731	FAM117B	-0.76	-5.01	-0.46	2.49e-6	Total cholesterol levels;
THYM	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg25918947	chr17:41365094	TMEM106A	-0.68	-5.74	-0.51	1.15e-7	Menopause (age at onset);
THYM	cis	rs526231	0.543	rs34832	chr5:102444595	T/C	cg23492399	chr5:102201601	PAM	-0.7	-5.23	-0.47	9.9e-7	Primary biliary cholangitis;
THYM	cis	rs7631605	0.905	rs11717564	chr3:37220888	T/A	cg21328643	chr3:37258149	NA	-0.53	-5.0	-0.46	2.61e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	5.51	0.49	3.1e-7	Schizophrenia;
THYM	cis	rs1728785	0.901	rs3087783	chr16:68599668	C/T	cg02972257	chr16:68554789	NA	-0.77	-4.9	-0.45	3.98e-6	Ulcerative colitis;
THYM	cis	rs57561814	0.510	rs1800796	chr7:22766246	G/C	cg01770232	chr7:22766155	IL6	0.95	4.53	0.42	1.7e-5	Tonsillectomy;
THYM	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.81	-0.63	7.44e-12	Chronic sinus infection;
THYM	cis	rs4889855	0.530	rs4890048	chr17:78549602	G/A	cg16591659	chr17:78472290	NA	0.45	5.2	0.47	1.13e-6	Fractional excretion of uric acid;
THYM	cis	rs7072216	0.727	rs7901577	chr10:100164442	A/G	cg03852570	chr10:100175106	PYROXD2	0.37	4.97	0.45	2.91e-6	Metabolite levels;
THYM	cis	rs11997175	0.503	rs7013967	chr8:33826107	T/G	ch.8.33884649F	chr8:33765107	NA	0.7	5.4	0.48	5e-7	Body mass index;
THYM	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6089584	0.566	rs12373885	chr20:60556393	A/C	cg22316451	chr20:60645197	NA	-0.46	-4.45	-0.42	2.29e-5	Body mass index;
THYM	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg23711669	chr6:146136114	FBXO30	0.9	9.23	0.69	7.15e-15	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs9807841	0.545	rs4804514	chr19:10764203	G/T	cg16900796	chr19:10755136	SLC44A2	0.4	6.3	0.54	9.34e-9	Inflammatory skin disease;
THYM	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg17757837	chr7:157058334	UBE3C	0.65	5.24	0.47	9.83e-7	Body mass index;
THYM	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg07936489	chr17:37558343	FBXL20	0.83	5.84	0.51	7.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs7584330	0.554	rs10178682	chr2:238433818	T/G	cg08992911	chr2:238395768	MLPH	0.88	5.73	0.51	1.17e-7	Prostate cancer;
THYM	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg18230493	chr5:56204884	C5orf35	-0.89	-6.53	-0.56	3.25e-9	Initial pursuit acceleration;
THYM	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg24733560	chr20:60626293	TAF4	-0.57	-4.73	-0.44	7.64e-6	Body mass index;
THYM	cis	rs4589258	0.966	rs4463818	chr11:90507372	C/T	cg26138821	chr11:89956704	CHORDC1	-0.58	-4.78	-0.44	6.31e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg13390004	chr1:15929781	NA	0.61	4.63	0.43	1.15e-5	Systolic blood pressure;
THYM	cis	rs2976388	0.669	rs1836633	chr8:143774592	G/A	cg13446199	chr8:143762866	PSCA	-0.41	-4.51	-0.42	1.88e-5	Urinary tract infection frequency;
THYM	cis	rs6918586	0.594	rs198842	chr6:26111448	C/T	cg07061783	chr6:25882402	NA	0.58	4.57	0.42	1.46e-5	Schizophrenia;
THYM	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.28	-4.69	-0.43	9.05e-6	Obesity-related traits;
THYM	cis	rs3771570	0.901	rs4675963	chr2:242324763	G/A	cg21155796	chr2:242212141	HDLBP	1.09	6.4	0.55	5.95e-9	Prostate cancer;
THYM	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg04398451	chr17:18023971	MYO15A	0.83	8.06	0.64	2.26e-12	Total body bone mineral density;
THYM	cis	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg10856724	chr12:34555212	NA	-0.91	-8.9	-0.67	3.68e-14	Morning vs. evening chronotype;
THYM	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg01264106	chr22:38071602	LGALS1	0.39	4.64	0.43	1.1e-5	Fat distribution (HIV);
THYM	cis	rs9420	0.961	rs527528	chr11:57433327	C/T	cg19752551	chr11:57585705	CTNND1	-0.65	-7.59	-0.61	2.17e-11	Schizophrenia;
THYM	cis	rs13006833	0.668	rs291453	chr2:191160196	G/A	cg11845111	chr2:191398756	TMEM194B	0.66	4.7	0.43	8.83e-6	Urinary metabolites;
THYM	cis	rs7849270	1.000	rs9697030	chr9:131920181	T/C	cg14069949	chr9:131965419	NA	0.5	4.52	0.42	1.8e-5	Blood metabolite ratios;
THYM	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.45	0.81	1.03e-23	Height;
THYM	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg04429589	chr14:105992532	TMEM121	-0.48	-5.33	-0.48	6.64e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs6754311	0.638	rs2322659	chr2:136555659	A/G	cg23851026	chr2:136556271	LCT	-0.55	-5.72	-0.51	1.21e-7	Mosquito bite size;
THYM	cis	rs829883	0.738	rs249854	chr12:98862772	G/A	cg25150519	chr12:98850993	NA	0.55	5.49	0.49	3.29e-7	Colorectal adenoma (advanced);
THYM	cis	rs2404602	0.647	rs12898416	chr15:77042292	C/G	cg23625390	chr15:77176239	SCAPER	-0.86	-5.88	-0.52	6.21e-8	Blood metabolite levels;
THYM	cis	rs9807989	0.839	rs10182710	chr2:102981306	A/G	cg03938978	chr2:103052716	IL18RAP	0.63	6.55	0.56	2.99e-9	Asthma;
THYM	cis	rs13315871	1.000	rs9821570	chr3:58335919	C/G	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06873352	chr17:61820015	STRADA	-0.79	-9.97	-0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs8044868	0.586	rs7188962	chr16:72098962	A/G	cg06353428	chr16:71660113	MARVELD3	0.61	4.55	0.42	1.57e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs6732160	0.845	rs6546805	chr2:73386115	G/T	cg24220031	chr2:73402428	NA	-0.79	-8.39	-0.65	4.59e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg13147721	chr7:65941812	NA	-1.16	-7.64	-0.62	1.7e-11	Diabetic kidney disease;
THYM	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg23711669	chr6:146136114	FBXO30	0.96	10.33	0.73	3.3e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11039798	0.588	rs10437592	chr11:48598859	G/T	cg24672777	chr11:48374446	OR4C45	-0.93	-6.01	-0.52	3.39e-8	Axial length;
THYM	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg16624210	chr5:671434	TPPP	0.83	6.18	0.54	1.56e-8	Lung disease severity in cystic fibrosis;
THYM	cis	rs1775715	0.835	rs113450267	chr10:32223728	G/A	cg04359828	chr10:32216031	ARHGAP12	0.39	4.87	0.45	4.49e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs2637266	1.000	rs10219023	chr10:78364537	G/A	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs259964	1.000	rs259962	chr20:57824960	A/G	cg20910807	chr20:57875384	EDN3	-0.43	-4.67	-0.43	9.83e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7582180	0.627	rs2099611	chr2:101021090	A/G	cg14675211	chr2:100938903	LONRF2	0.6	5.71	0.51	1.28e-7	Intelligence (multi-trait analysis);
THYM	cis	rs422249	0.511	rs102274	chr11:61557826	T/C	cg19610905	chr11:61596333	FADS2	-0.61	-5.16	-0.47	1.36e-6	Trans fatty acid levels;
THYM	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7220401	0.542	rs55644350	chr17:27913368	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.58	4.57	0.42	1.46e-5	Coronary artery disease;
THYM	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg03433033	chr1:76189801	ACADM	-0.66	-6.37	-0.55	6.72e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	6.03	0.53	3.12e-8	Obesity-related traits;
THYM	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs79387448	0.638	rs76255660	chr2:103091028	T/C	cg09003973	chr2:102972529	NA	1.18	6.5	0.55	3.69e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs7084402	0.967	rs1658436	chr10:60326910	G/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs10995271	0.525	rs10761659	chr10:64445564	C/T	cg03961010	chr10:64397487	ZNF365	0.54	4.55	0.42	1.58e-5	Crohn's disease;
THYM	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg13699009	chr12:122356056	WDR66	-0.46	-4.54	-0.42	1.63e-5	Mean corpuscular volume;
THYM	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.74	-5.95	-0.52	4.55e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg26384229	chr12:38710491	ALG10B	0.93	7.9	0.63	4.86e-12	Bladder cancer;
THYM	cis	rs72627123	1.000	rs72627125	chr14:74369623	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs4454254	0.518	rs7843613	chr8:141059415	G/T	cg05910124	chr8:141057427	TRAPPC9	0.6	4.61	0.43	1.26e-5	Pulse pressure;
THYM	cis	rs7961581	0.748	rs1798078	chr12:71595123	A/T	cg22457860	chr12:71149597	PTPRR	0.76	4.63	0.43	1.14e-5	Type 2 diabetes;
THYM	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg20283391	chr11:68216788	NA	-0.65	-5.15	-0.47	1.4e-6	Total body bone mineral density;
THYM	cis	rs13326165	0.543	rs60382084	chr3:52298161	C/A	cg08438690	chr3:52279403	PPM1M	-0.74	-4.64	-0.43	1.12e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs919433	0.647	rs13404366	chr2:198522632	A/G	cg00792783	chr2:198669748	PLCL1	0.86	5.86	0.52	6.77e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg00376283	chr12:123451042	ABCB9	0.7	4.72	0.44	8.27e-6	Neutrophil percentage of white cells;
THYM	cis	rs9876781	1.000	rs6442123	chr3:48500286	G/A	cg06066452	chr3:48470258	PLXNB1	0.27	4.85	0.45	4.87e-6	Longevity;
THYM	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.79	6.94	0.58	4.8e-10	Tonsillectomy;
THYM	cis	rs6906287	0.631	rs9320663	chr6:118986172	A/G	cg21191810	chr6:118973309	C6orf204	0.63	6.6	0.56	2.38e-9	Electrocardiographic conduction measures;
THYM	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg07022442	chr13:21864356	NA	0.73	4.93	0.45	3.5e-6	White matter hyperintensity burden;
THYM	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg13246856	chr1:44399776	ARTN	0.48	4.95	0.45	3.27e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg21252483	chr19:49399788	TULP2	-0.96	-7.25	-0.6	1.09e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg07648498	chr16:89883185	FANCA	0.63	4.7	0.43	8.95e-6	Vitiligo;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg19556901	chr15:25414769	SNORD115-1	1.22	6.85	0.57	7.22e-10	Pulmonary function decline;
THYM	cis	rs8049634	0.528	rs76669578	chr16:84096577	A/G	cg04832210	chr16:84151246	MBTPS1	-0.47	-4.96	-0.45	3.05e-6	Small cell lung carcinoma;
THYM	cis	rs28595532	0.920	rs115464801	chr4:119730673	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs1878931	0.535	rs7188903	chr16:3412861	A/G	cg21433313	chr16:3507492	NAT15	-0.58	-4.91	-0.45	3.71e-6	Body mass index (adult);
THYM	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg00129232	chr17:37814104	STARD3	0.72	5.14	0.47	1.46e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs10799590	1.000	rs298734	chr1:224842603	C/T	cg01808320	chr1:224927238	CNIH3	-0.53	-4.71	-0.44	8.41e-6	Opioid dependence;
THYM	cis	rs9788682	0.747	rs7183604	chr15:78899213	T/C	cg18825076	chr15:78729989	IREB2	-0.57	-4.72	-0.44	7.97e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg06481639	chr22:41940642	POLR3H	-0.72	-5.25	-0.47	9.4e-7	Neuroticism;
THYM	cis	rs6686842	0.965	rs2802551	chr1:41497443	C/T	cg03387723	chr1:41708464	SCMH1	-0.44	-5.22	-0.47	1.04e-6	Height;
THYM	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg04063615	chr12:132293388	NA	0.49	4.63	0.43	1.16e-5	Migraine;
THYM	cis	rs4930776	1.000	rs436383	chr12:5768151	T/G	cg02086166	chr12:5775618	ANO2	0.58	5.71	0.51	1.3e-7	Plasma clusterin levels;
THYM	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg24450063	chr1:156163899	SLC25A44	1.09	9.58	0.7	1.32e-15	Testicular germ cell tumor;
THYM	cis	rs2180341	0.842	rs6569476	chr6:127553539	G/A	cg24812749	chr6:127587940	RNF146	0.92	6.28	0.54	1.02e-8	Breast cancer;
THYM	cis	rs7247513	0.790	rs17476839	chr19:12762783	C/T	cg01871581	chr19:12707946	ZNF490	0.66	6.09	0.53	2.41e-8	Bipolar disorder;
THYM	cis	rs6665290	0.904	rs11578103	chr1:227189642	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.14	-15.82	-0.85	2.32e-28	Myeloid white cell count;
THYM	cis	rs13232179	1.000	rs13232179	chr7:151120948	T/A	cg01177956	chr7:150756509	SLC4A2;CDK5	-0.79	-4.7	-0.43	8.74e-6	Coronary heart disease;
THYM	cis	rs11030122	0.632	rs10835556	chr11:4083013	A/G	cg18678763	chr11:4115507	RRM1	-0.43	-5.6	-0.5	2.12e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11118844	0.744	rs6655994	chr1:221933888	A/G	cg04222084	chr1:221915650	DUSP10	-1.07	-5.44	-0.49	4.18e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg04398451	chr17:18023971	MYO15A	-0.95	-9.84	-0.71	3.63e-16	Total body bone mineral density;
THYM	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.52	-5.14	-0.47	1.44e-6	Eosinophil percentage of white cells;
THYM	cis	rs75920871	0.588	rs3181	chr11:116907043	C/T	cg20608306	chr11:116969690	SIK3	-0.49	-5.34	-0.48	6.24e-7	Subjective well-being;
THYM	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9527	0.615	rs12248123	chr10:104735366	A/G	cg04362960	chr10:104952993	NT5C2	0.61	4.67	0.43	9.72e-6	Arsenic metabolism;
THYM	cis	rs4595586	0.525	rs12812749	chr12:39363254	C/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs1385374	0.502	rs923077	chr12:129276708	C/A	cg04043695	chr12:129287642	SLC15A4	0.77	4.93	0.45	3.52e-6	Systemic lupus erythematosus;
THYM	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.79	6.34	0.55	7.85e-9	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs1629083	0.790	rs647099	chr11:118067009	A/G	cg18857871	chr11:118064634	AMICA1	0.43	4.6	0.43	1.31e-5	Lung cancer;
THYM	cis	rs7843479	0.965	rs17581910	chr8:21799626	A/G	cg17168535	chr8:21777572	XPO7	0.72	5.12	0.47	1.57e-6	Mean corpuscular volume;
THYM	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs863345	0.584	rs1117125	chr1:158509396	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.82	-0.44	5.46e-6	Pneumococcal bacteremia;
THYM	cis	rs12681287	0.577	rs10481197	chr8:87546551	A/T	cg27223183	chr8:87520930	FAM82B	0.71	5.56	0.5	2.44e-7	Caudate activity during reward;
THYM	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg17366294	chr4:99064904	C4orf37	0.54	6.05	0.53	2.81e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1568889	0.938	rs1464898	chr11:28034748	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	4.51	0.42	1.82e-5	Bipolar disorder;
THYM	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7119	0.651	rs34829483	chr15:77835986	C/T	cg27398640	chr15:77910606	LINGO1	-0.61	-6.36	-0.55	7.18e-9	Type 2 diabetes;
THYM	cis	rs17401966	0.931	rs4846213	chr1:10399178	A/G	cg19773385	chr1:10388646	KIF1B	-0.6	-4.7	-0.43	8.88e-6	Hepatocellular carcinoma;
THYM	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg13683864	chr3:40499215	RPL14	-0.92	-9.22	-0.69	7.64e-15	Renal cell carcinoma;
THYM	cis	rs2273669	0.504	rs78242270	chr6:109468570	G/T	cg17117243	chr6:109341365	SESN1	-0.82	-4.8	-0.44	5.98e-6	Prostate cancer;
THYM	cis	rs13401104	0.587	rs62190973	chr2:237145231	T/A	cg19324714	chr2:237145437	ASB18	0.63	4.68	0.43	9.6e-6	Educational attainment;
THYM	cis	rs9443645	0.527	rs10943588	chr6:79510994	A/C	cg05283184	chr6:79620031	NA	-0.61	-4.73	-0.44	7.75e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg24692254	chr21:30365293	RNF160	-0.71	-5.14	-0.47	1.48e-6	Cognitive test performance;
THYM	cis	rs791590	0.752	rs41295105	chr10:6122674	T/G	cg17191567	chr10:6178319	NA	0.7	4.82	0.44	5.34e-6	Soluble interleukin-2 receptor subunit alpha;
THYM	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg18758796	chr5:131593413	PDLIM4	0.5	4.77	0.44	6.69e-6	Breast cancer;
THYM	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg18850127	chr7:39170497	POU6F2	0.53	4.82	0.44	5.39e-6	IgG glycosylation;
THYM	cis	rs910187	0.605	rs3787235	chr20:45803522	C/T	cg27589058	chr20:45804311	EYA2	-0.7	-6.42	-0.55	5.42e-9	Migraine;
THYM	cis	rs17433780	0.666	rs2624	chr1:89518623	C/T	cg09516651	chr1:89888402	LOC400759	-0.78	-6.7	-0.57	1.45e-9	Carotid intima media thickness;
THYM	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg13319975	chr6:146136371	FBXO30	-0.74	-6.33	-0.54	7.91e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4845875	0.626	rs11121828	chr1:11834454	C/T	cg24844545	chr1:11908347	NPPA	0.46	4.67	0.43	9.98e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg24060327	chr5:131705240	SLC22A5	-0.82	-6.73	-0.57	1.29e-9	Blood metabolite levels;
THYM	cis	rs2455799	0.573	rs2455834	chr3:15753641	A/G	cg16303742	chr3:15540471	COLQ	-0.56	-5.73	-0.51	1.18e-7	Mean platelet volume;
THYM	cis	rs7584330	0.554	rs76408976	chr2:238384784	C/T	cg14458575	chr2:238380390	NA	0.94	4.76	0.44	6.96e-6	Prostate cancer;
THYM	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg24733560	chr20:60626293	TAF4	0.6	6.21	0.54	1.37e-8	Body mass index;
THYM	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg13319975	chr6:146136371	FBXO30	-0.67	-5.89	-0.52	5.9e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg00310523	chr12:86230176	RASSF9	-0.57	-4.83	-0.44	5.15e-6	Major depressive disorder;
THYM	cis	rs6946131	0.509	rs35297086	chr7:54777348	A/G	cg16668896	chr7:54900801	NA	0.44	4.52	0.42	1.76e-5	Systemic lupus erythematosus;
THYM	cis	rs11190604	0.767	rs35508946	chr10:102191156	A/G	cg07570687	chr10:102243282	WNT8B	0.85	8.46	0.66	3.16e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2811415	0.597	rs13100212	chr3:127803657	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg13683864	chr3:40499215	RPL14	-0.84	-7.8	-0.62	8.04e-12	Renal cell carcinoma;
THYM	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg11526020	chr17:80870163	TBCD	-0.43	-4.67	-0.43	9.74e-6	Breast cancer;
THYM	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.81	4.85	0.45	4.89e-6	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs7267979	0.966	rs454723	chr20:25438928	G/C	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs12760731	0.623	rs12045201	chr1:178399218	A/G	cg04506114	chr1:179322762	SOAT1	0.48	4.67	0.43	9.89e-6	Obesity-related traits;
THYM	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.34	-0.65	5.7e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg14829155	chr15:31115871	NA	-0.71	-6.08	-0.53	2.47e-8	Huntington's disease progression;
THYM	cis	rs986417	1.000	rs1268621	chr14:60921571	G/A	cg27398547	chr14:60952738	C14orf39	-1.15	-5.91	-0.52	5.37e-8	Gut microbiota (bacterial taxa);
THYM	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg03929089	chr4:120376271	NA	-0.98	-12.21	-0.78	3.51e-21	Coronary artery disease;
THYM	cis	rs2933343	0.700	rs789240	chr3:128630635	T/C	cg11901034	chr3:128598214	ACAD9	-0.68	-5.57	-0.5	2.4e-7	IgG glycosylation;
THYM	cis	rs9790314	0.632	rs778645	chr3:160707459	A/T	cg04691961	chr3:161091175	C3orf57	-0.56	-4.49	-0.42	2.01e-5	Morning vs. evening chronotype;
THYM	cis	rs72712511	0.527	rs60885103	chr4:140771815	C/G	cg15010390	chr4:140216957	NDUFC1	0.63	4.55	0.42	1.59e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1150668	0.796	rs1052215	chr6:28348158	T/G	cg13525197	chr6:28411240	ZSCAN23	0.56	4.61	0.43	1.28e-5	Pubertal anthropometrics;
THYM	cis	rs2294693	0.947	rs10456496	chr6:40988840	A/G	cg14418226	chr6:40996092	UNC5CL	-0.65	-5.74	-0.51	1.11e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs7567389	0.710	rs72848618	chr2:128135325	A/C	cg09760422	chr2:128146352	NA	0.4	4.53	0.42	1.7e-5	Self-rated health;
THYM	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg10802521	chr3:52805072	NEK4	0.68	6.23	0.54	1.25e-8	Electroencephalogram traits;
THYM	cis	rs7731657	0.537	rs12719432	chr5:130354295	C/T	cg08523029	chr5:130500466	HINT1	-0.85	-6.19	-0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg21226059	chr5:178986404	RUFY1	0.61	7.12	0.59	2.06e-10	Lung cancer;
THYM	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg15693483	chr7:1102177	C7orf50	0.5	5.65	0.5	1.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg19862616	chr7:65841803	NCRNA00174	1.12	13.73	0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4242434	0.854	rs13258100	chr8:22451116	A/T	cg01710189	chr8:22454888	PDLIM2	-0.54	-5.03	-0.46	2.34e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg17554472	chr22:41940697	POLR3H	0.72	5.06	0.46	2.07e-6	Vitiligo;
THYM	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg27286337	chr10:134555280	INPP5A	0.97	8.2	0.64	1.16e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7572733	0.534	rs700687	chr2:198721560	A/T	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs889398	0.741	rs6499270	chr16:69917740	A/G	cg09409435	chr16:70099608	PDXDC2	-0.63	-4.89	-0.45	4.05e-6	Body mass index;
THYM	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.37	-0.65	5.05e-13	Chronic sinus infection;
THYM	cis	rs11249608	0.548	rs34054398	chr5:178458371	A/G	cg01312482	chr5:178451176	ZNF879	-0.76	-6.3	-0.54	9.29e-9	Pubertal anthropometrics;
THYM	cis	rs9972944	0.639	rs2052153	chr17:63800382	G/T	cg07283582	chr17:63770753	CCDC46	-0.63	-4.9	-0.45	3.94e-6	Total body bone mineral density;
THYM	cis	rs9880211	1.000	rs6774964	chr3:136275582	G/A	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg18681998	chr4:17616180	MED28	0.79	6.77	0.57	1.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg11764359	chr7:65958608	NA	0.78	6.31	0.54	8.88e-9	Aortic root size;
THYM	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg13695892	chr22:41940480	POLR3H	0.83	6.88	0.58	6.29e-10	Vitiligo;
THYM	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg22907277	chr7:1156413	C7orf50	0.77	4.48	0.42	2.09e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12681287	0.640	rs7007855	chr8:87429491	T/G	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs4372836	0.553	rs6706858	chr2:28992607	C/G	cg09522027	chr2:28974177	PPP1CB	-0.62	-4.79	-0.44	6.18e-6	Body mass index;
THYM	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg06873352	chr17:61820015	STRADA	0.59	6.76	0.57	1.13e-9	Prudent dietary pattern;
THYM	cis	rs2933343	0.729	rs1683780	chr3:128640239	C/T	cg11901034	chr3:128598214	ACAD9	-0.7	-5.45	-0.49	4e-7	IgG glycosylation;
THYM	cis	rs1461503	0.900	rs10892935	chr11:122838590	C/T	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs6430585	0.528	rs309123	chr2:136761175	C/G	cg23851026	chr2:136556271	LCT	0.7	7.37	0.6	6.34e-11	Corneal structure;
THYM	cis	rs4638749	0.734	rs35184015	chr2:108870540	C/T	cg25838818	chr2:108905173	SULT1C2	-0.54	-5.68	-0.5	1.45e-7	Blood pressure;
THYM	cis	rs6430585	0.528	rs586964	chr2:136652491	G/A	cg04750100	chr2:136595281	LCT	0.56	4.93	0.45	3.46e-6	Corneal structure;
THYM	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs1866758	1.000	rs582123	chr1:42327814	C/T	cg19619028	chr1:42327967	HIVEP3	0.51	4.61	0.43	1.23e-5	Intraocular pressure;
THYM	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4557020	0.904	rs4671219	chr2:54723688	C/T	cg11007406	chr2:54682859	SPTBN1	-0.34	-4.47	-0.42	2.16e-5	Myopia (pathological);
THYM	cis	rs2115536	0.967	rs934137	chr15:80211768	T/C	cg00225070	chr15:80189496	MTHFS	0.59	5.06	0.46	2.06e-6	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg10523679	chr1:76189770	ACADM	-0.57	-4.83	-0.44	5.17e-6	Daytime sleep phenotypes;
THYM	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.74	4.52	0.42	1.79e-5	Diabetic retinopathy;
THYM	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg19318889	chr4:1322082	MAEA	0.69	6.05	0.53	2.86e-8	Longevity;
THYM	cis	rs288326	0.561	rs79074459	chr2:183767098	T/C	cg09997497	chr2:183902928	NCKAP1	1.25	5.46	0.49	3.83e-7	Blood protein levels;
THYM	cis	rs12928939	0.723	rs28501298	chr16:71855133	C/G	cg03805757	chr16:71968109	PKD1L3	-0.82	-5.88	-0.52	6.1e-8	Post bronchodilator FEV1;
THYM	cis	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg06521331	chr12:34319734	NA	-0.96	-9.28	-0.69	5.69e-15	Morning vs. evening chronotype;
THYM	cis	rs16917546	1.000	rs10995249	chr10:64396916	C/T	cg03961010	chr10:64397487	ZNF365	-0.8	-6.74	-0.57	1.19e-9	Basal cell carcinoma;
THYM	cis	rs7107174	1.000	rs2512538	chr11:77972461	T/G	cg02023728	chr11:77925099	USP35	0.69	6.19	0.54	1.55e-8	Testicular germ cell tumor;
THYM	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs778371	0.723	rs6739794	chr2:233576165	G/A	cg08000102	chr2:233561755	GIGYF2	0.84	7.76	0.62	9.6e-12	Schizophrenia;
THYM	cis	rs59698941	0.709	rs58237345	chr5:132266351	T/A	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg06481639	chr22:41940642	POLR3H	0.75	5.04	0.46	2.19e-6	Vitiligo;
THYM	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs12142240	0.698	rs72677589	chr1:46817770	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg27490568	chr2:178487706	NA	-0.57	-5.26	-0.48	8.8e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg10515332	chr4:99064459	C4orf37	0.6	4.75	0.44	7.27e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4455778	0.580	rs4467894	chr7:49116541	G/T	cg26309511	chr7:48887640	NA	-0.67	-5.91	-0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs7429990	0.932	rs12493348	chr3:48143538	A/T	cg02219026	chr3:48282209	ZNF589	0.59	4.46	0.42	2.23e-5	Educational attainment (years of education);
THYM	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg19442545	chr10:75533431	FUT11	-0.62	-6.68	-0.57	1.58e-9	Inflammatory bowel disease;
THYM	trans	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	5.35	0.48	5.95e-7	Schizophrenia;
THYM	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2069036	0.903	rs1891137	chr10:16078945	G/A	cg26633223	chr10:15133461	NA	0.64	4.5	0.42	1.93e-5	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg08645402	chr16:4508243	NA	0.76	6.54	0.56	3.07e-9	Schizophrenia;
THYM	cis	rs654950	0.806	rs2759251	chr1:42041749	C/G	cg06885757	chr1:42089581	HIVEP3	-0.58	-7.82	-0.63	7.37e-12	Airway imaging phenotypes;
THYM	cis	rs4980785	1.000	rs4980785	chr11:69234494	A/G	cg23978357	chr11:69490378	ORAOV1	-0.49	-4.62	-0.43	1.19e-5	Renal cell carcinoma;
THYM	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg06618935	chr21:46677482	NA	-0.96	-9.38	-0.69	3.52e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1993976	0.705	rs899673	chr15:98627699	G/A	cg22042896	chr15:99057957	FAM169B	-0.67	-4.87	-0.45	4.5e-6	Fat distribution (HIV);
THYM	cis	rs6838801	0.930	rs6532535	chr4:77562538	T/A	cg01477861	chr4:77609841	SHROOM3	-0.45	-4.52	-0.42	1.79e-5	Cleft lip with or without cleft palate;
THYM	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs56104184	1.000	rs56104184	chr19:49370310	C/T	cg21252483	chr19:49399788	TULP2	-0.76	-5.34	-0.48	6.46e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs6840360	0.571	rs10007653	chr4:152524055	A/G	cg17479576	chr4:152424074	FAM160A1	-0.78	-5.74	-0.51	1.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs66887589	0.807	rs9799664	chr4:120326678	C/T	cg13609457	chr4:120235615	NA	0.47	4.88	0.45	4.28e-6	Diastolic blood pressure;
THYM	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs259282	0.652	rs2161458	chr19:33129038	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.72	6.45	0.55	4.73e-9	Schizophrenia;
THYM	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10486003	1.000	rs17147602	chr7:97255488	C/T	cg19056687	chr7:97922028	BAIAP2L1;BRI3	1.09	5.16	0.47	1.36e-6	Response to platinum-based agents;
THYM	cis	rs1978968	0.956	rs5992925	chr22:18447697	G/A	cg01550578	chr22:18484421	MICAL3	0.68	5.16	0.47	1.37e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs10463554	0.963	rs3776860	chr5:102349970	G/C	cg23492399	chr5:102201601	PAM	-0.69	-5.24	-0.47	9.68e-7	Parkinson's disease;
THYM	cis	rs4363385	0.818	rs407103	chr1:153007106	C/T	cg13444842	chr1:152974279	SPRR3	0.58	4.65	0.43	1.06e-5	Inflammatory skin disease;
THYM	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs7731657	0.537	rs33962216	chr5:130290180	T/C	cg08523029	chr5:130500466	HINT1	-0.83	-6.03	-0.53	3.16e-8	Fasting plasma glucose;
THYM	cis	rs7246967	0.542	rs56355379	chr19:22900455	C/T	cg05241461	chr19:22816980	ZNF492	0.61	4.75	0.44	7.2e-6	Bronchopulmonary dysplasia;
THYM	cis	rs5769707	0.706	rs763128	chr22:50018045	G/A	cg17054759	chr22:49844102	NA	-0.53	-4.64	-0.43	1.13e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg01579765	chr21:45077557	HSF2BP	-0.48	-7.55	-0.61	2.61e-11	Mean corpuscular volume;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg17655527	chr19:56128027	NA	1.24	6.86	0.58	7.12e-10	Pulmonary function decline;
THYM	cis	rs2294693	0.947	rs6924722	chr6:41002195	C/T	cg14769373	chr6:40998127	UNC5CL	0.57	4.62	0.43	1.22e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-4.75	-0.44	7.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg00898013	chr13:113819073	PROZ	-0.82	-8.1	-0.64	1.81e-12	Platelet distribution width;
THYM	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg17372223	chr3:52568218	NT5DC2	0.31	4.78	0.44	6.34e-6	Bipolar disorder;
THYM	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.57	4.65	0.43	1.06e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7246657	0.943	rs1035479	chr19:37893300	G/T	cg22634378	chr19:37742834	NA	-0.62	-5.18	-0.47	1.22e-6	Coronary artery calcification;
THYM	cis	rs55665837	1.000	rs11023215	chr11:14436970	C/T	cg19336497	chr11:14380999	RRAS2	-0.59	-6.42	-0.55	5.44e-9	Vitamin D levels;
THYM	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg10802521	chr3:52805072	NEK4	-0.67	-5.49	-0.49	3.34e-7	Bipolar disorder;
THYM	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg08999081	chr20:33150536	PIGU	0.57	4.79	0.44	6.02e-6	Coronary artery disease;
THYM	cis	rs2219968	0.683	rs35533540	chr8:78899422	T/C	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12148329	0.604	rs78657552	chr15:81009080	A/G	cg01654770	chr15:80543586	NA	-0.87	-4.49	-0.42	2.01e-5	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	5.18	0.47	1.24e-6	Bipolar disorder;
THYM	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg11871910	chr12:69753446	YEATS4	0.73	5.85	0.51	6.88e-8	Response to diuretic therapy;
THYM	cis	rs7246657	0.943	rs9917081	chr19:37876616	T/C	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs12142240	0.920	rs6697623	chr1:46757542	G/A	cg00530320	chr1:46809349	NSUN4	0.86	5.58	0.5	2.26e-7	Menopause (age at onset);
THYM	cis	rs3008870	0.755	rs2815349	chr1:67472280	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.79	6.84	0.57	7.8e-10	Lymphocyte percentage of white cells;
THYM	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03452623	chr4:187889614	NA	1.17	20.2	0.9	3.72e-36	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs612683	0.735	rs3754131	chr1:100931073	A/C	cg06223162	chr1:101003688	GPR88	0.72	6.25	0.54	1.17e-8	Breast cancer;
THYM	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg08000102	chr2:233561755	GIGYF2	0.68	6.11	0.53	2.16e-8	Coronary artery disease;
THYM	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg11266682	chr4:10021025	SLC2A9	-0.52	-7.0	-0.58	3.57e-10	Bone mineral density;
THYM	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9902453	1.000	rs59274738	chr17:28437635	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.76	0.44	6.86e-6	Coffee consumption (cups per day);
THYM	cis	rs12509991	0.582	rs57231003	chr4:127039389	C/A	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs56341938	0.935	rs62275516	chr3:168726275	T/C	cg09107232	chr3:169491072	MYNN	0.56	4.81	0.44	5.75e-6	Lung function (FEV1/FVC);
THYM	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg26267310	chr19:49340593	PLEKHA4;HSD17B14	0.94	4.94	0.45	3.28e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs67385638	0.792	rs16912979	chr11:5309695	T/C	cg12559170	chr11:5275217	HBG2	0.72	6.37	0.55	6.68e-9	Hemoglobin levels;
THYM	cis	rs9583531	0.600	rs7986286	chr13:111357207	A/G	cg24331049	chr13:111365604	ING1	0.72	6.04	0.53	2.96e-8	Coronary artery disease;
THYM	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg09549813	chr16:4587862	C16orf5	-0.56	-6.18	-0.54	1.58e-8	Schizophrenia;
THYM	cis	rs4919694	0.615	rs78384860	chr10:105003019	G/T	cg04362960	chr10:104952993	NT5C2	0.99	5.86	0.52	6.71e-8	Arsenic metabolism;
THYM	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg24803719	chr17:45855879	NA	-0.6	-6.26	-0.54	1.08e-8	IgG glycosylation;
THYM	cis	rs11711311	1.000	rs62268168	chr3:113489447	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.62	-5.52	-0.49	2.89e-7	IgG glycosylation;
THYM	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg10560079	chr2:191398806	TMEM194B	0.87	7.94	0.63	4.04e-12	Pulse pressure;
THYM	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03517284	chr6:25882590	NA	-1.3	-14.93	-0.84	1.2e-26	Urate levels;
THYM	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg24450063	chr1:156163899	SLC25A44	1.1	9.41	0.69	3.04e-15	Testicular germ cell tumor;
THYM	cis	rs55665837	1.000	rs12295888	chr11:14450531	T/C	cg19336497	chr11:14380999	RRAS2	-0.65	-7.16	-0.59	1.71e-10	Vitamin D levels;
THYM	cis	rs57920188	0.535	rs77116992	chr1:4095498	T/A	cg08764037	chr1:3634867	TP73	-0.45	-4.68	-0.43	9.66e-6	Interleukin-17 levels;
THYM	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg05962950	chr11:130786565	SNX19	0.84	7.29	0.6	9.11e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.87	0.45	4.53e-6	Bipolar disorder;
THYM	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg10018233	chr7:150070692	REPIN1	0.37	5.32	0.48	6.97e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg22875332	chr1:76189707	ACADM	-0.75	-6.46	-0.55	4.51e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs17102423	0.755	rs7154852	chr14:65553822	C/A	cg11161011	chr14:65562177	MAX	-0.83	-6.62	-0.56	2.13e-9	Obesity-related traits;
THYM	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg26531700	chr6:26746687	NA	0.67	5.85	0.51	6.96e-8	Intelligence (multi-trait analysis);
THYM	cis	rs35883536	1.000	rs2297712	chr1:101092813	C/T	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs7481584	0.669	rs12793371	chr11:3034709	A/G	cg03159660	chr11:2078197	NA	0.64	4.75	0.44	7.1e-6	Calcium levels;
THYM	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Body mass index;
THYM	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg03909863	chr11:638404	DRD4	-0.82	-5.87	-0.52	6.28e-8	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg26038318	chr20:34205095	SPAG4	0.65	5.25	0.47	9.22e-7	Total cholesterol levels;
THYM	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg19592336	chr6:28129416	ZNF389	-0.67	-4.48	-0.42	2.12e-5	Depression;
THYM	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.72	5.72	0.51	1.24e-7	Blood protein levels;
THYM	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13012494	chr21:47604986	C21orf56	0.69	4.8	0.44	5.95e-6	Testicular germ cell tumor;
THYM	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg26038318	chr20:34205095	SPAG4	-0.58	-4.6	-0.43	1.3e-5	Total cholesterol levels;
THYM	cis	rs4285028	0.948	rs12637351	chr3:121694412	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.72	4.94	0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg22920501	chr2:26401640	FAM59B	0.77	5.88	0.52	6.04e-8	Gut microbiome composition (summer);
THYM	cis	rs7131987	0.650	rs7311912	chr12:29475703	G/C	cg09582351	chr12:29534625	ERGIC2	-0.59	-5.13	-0.47	1.53e-6	QT interval;
THYM	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg24642439	chr20:33292090	TP53INP2	0.61	4.68	0.43	9.34e-6	Coronary artery disease;
THYM	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.7	0.71	7.32e-16	Colorectal cancer;
THYM	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg07884673	chr3:53033167	SFMBT1	1.13	5.83	0.51	7.45e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs55871839	0.559	rs4737526	chr8:59823372	A/G	cg07426533	chr8:59803705	TOX	0.62	5.11	0.46	1.63e-6	Pneumonia;
THYM	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg08470875	chr2:26401718	FAM59B	-0.73	-4.51	-0.42	1.88e-5	Gut microbiome composition (summer);
THYM	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg22105103	chr4:187893119	NA	0.95	10.29	0.73	3.97e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2730245	0.527	rs62476464	chr7:158698063	C/T	cg24397884	chr7:158709396	WDR60	0.55	5.36	0.48	5.79e-7	Height;
THYM	cis	rs877282	0.853	rs11593836	chr10:756715	G/A	cg10556349	chr10:835070	NA	-0.69	-4.49	-0.42	2.03e-5	Uric acid levels;
THYM	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.24	0.6	1.18e-10	Obesity-related traits;
THYM	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg09260853	chr1:2094483	PRKCZ	-0.43	-4.55	-0.42	1.61e-5	Height;
THYM	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg06634786	chr22:41940651	POLR3H	0.73	5.33	0.48	6.69e-7	Vitiligo;
THYM	cis	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg24308560	chr3:49941425	MST1R	-0.73	-6.11	-0.53	2.19e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8067545	0.717	rs34401389	chr17:19989436	A/T	cg13482628	chr17:19912719	NA	0.58	4.77	0.44	6.57e-6	Schizophrenia;
THYM	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg15501526	chr10:2543763	NA	0.73	6.89	0.58	6.14e-10	Age-related hearing impairment;
THYM	cis	rs67981189	0.529	rs61990379	chr14:71467070	A/G	cg15910301	chr14:71632612	NA	0.56	4.88	0.45	4.23e-6	Schizophrenia;
THYM	cis	rs6840360	0.571	rs2407069	chr4:152533201	G/A	cg22705602	chr4:152727874	NA	-0.78	-8.73	-0.67	8.56e-14	Intelligence (multi-trait analysis);
THYM	cis	rs6427356	0.513	rs10908534	chr1:157147586	C/T	cg27547283	chr1:156698502	C1orf66;ISG20L2	-0.58	-4.49	-0.42	2.02e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	trans	rs208520	0.674	rs207103	chr6:66795568	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.66	-0.62	1.53e-11	Exhaled nitric oxide output;
THYM	cis	rs10911232	0.507	rs4652769	chr1:183009196	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg08901578	chr4:187885870	NA	-0.68	-6.86	-0.58	6.97e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Alcohol dependence;
THYM	cis	rs9326248	0.773	rs1060211	chr11:117039797	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.7	4.77	0.44	6.69e-6	Blood protein levels;
THYM	cis	rs7222240	0.680	rs58219619	chr17:43207624	G/A	cg24806326	chr17:43207588	PLCD3	0.53	4.82	0.44	5.43e-6	Craniofacial microsomia;
THYM	cis	rs4888262	0.508	rs4544266	chr16:74660993	C/A	cg01733217	chr16:74700730	RFWD3	0.82	8.22	0.64	1.03e-12	Testicular germ cell tumor;
THYM	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg08885076	chr2:99613938	TSGA10	0.57	5.3	0.48	7.37e-7	Chronic sinus infection;
THYM	cis	rs1728785	0.901	rs933713	chr16:68581378	C/A	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg04362960	chr10:104952993	NT5C2	0.57	4.64	0.43	1.11e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs17030434	0.953	rs10010787	chr4:154692059	G/A	cg14289246	chr4:154710475	SFRP2	-0.76	-5.24	-0.47	9.79e-7	Electrocardiographic conduction measures;
THYM	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.62	-4.5	-0.42	1.93e-5	Colorectal cancer;
THYM	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg27535305	chr1:53392650	SCP2	-0.42	-4.74	-0.44	7.45e-6	Monocyte count;
THYM	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg12165864	chr7:66369176	NA	-0.64	-4.98	-0.46	2.82e-6	Aortic root size;
THYM	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg10505658	chr17:80084571	CCDC57	-0.69	-7.95	-0.63	3.85e-12	Life satisfaction;
THYM	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg06219351	chr7:158114137	PTPRN2	-0.74	-7.14	-0.59	1.86e-10	Calcium levels;
THYM	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg14349672	chr11:133703707	NA	-0.56	-5.0	-0.46	2.57e-6	Childhood ear infection;
THYM	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg11245990	chr11:68621969	NA	0.53	6.78	0.57	1.03e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg02503808	chr4:7069936	GRPEL1	1.0	7.76	0.62	9.71e-12	Monocyte percentage of white cells;
THYM	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg24060327	chr5:131705240	SLC22A5	0.77	6.31	0.54	8.66e-9	Breast cancer;
THYM	cis	rs34375054	0.526	rs7302475	chr12:125677886	T/C	cg25124228	chr12:125621409	AACS	-0.76	-5.75	-0.51	1.1e-7	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs6995541	0.505	rs11250081	chr8:10694571	C/A	cg13457217	chr8:10683266	MIR1322;PINX1	-0.67	-5.02	-0.46	2.39e-6	Triglyceride levels;
THYM	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg00256281	chr22:41985642	PMM1	0.58	5.06	0.46	2.09e-6	Vitiligo;
THYM	cis	rs4731207	0.596	rs6466988	chr7:124678116	G/A	cg05285228	chr7:124571219	POT1	-0.65	-4.98	-0.45	2.9e-6	Cutaneous malignant melanoma;
THYM	cis	rs911119	1.000	rs3827143	chr20:23619617	A/G	cg16589663	chr20:23618590	CST3	0.76	4.69	0.43	9.26e-6	Chronic kidney disease;
THYM	cis	rs2985684	0.895	rs3007033	chr14:50103816	T/C	cg02151108	chr14:50098012	C14orf104	-0.67	-5.33	-0.48	6.48e-7	Carotid intima media thickness;
THYM	cis	rs1003719	0.751	rs56268364	chr21:38542765	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.75e-5	Eye color traits;
THYM	cis	rs3126085	0.935	rs12407156	chr1:152295942	A/G	cg10321714	chr1:152280068	FLG	-0.73	-5.2	-0.47	1.12e-6	Atopic dermatitis;
THYM	cis	rs828999	0.653	rs6677101	chr1:108699730	T/G	cg24323958	chr1:108741884	SLC25A24	0.55	5.4	0.48	4.98e-7	Monocyte percentage of white cells;
THYM	cis	rs7797990	0.585	rs1922085	chr7:156016068	A/C	cg03831405	chr7:155588795	NA	0.45	4.52	0.42	1.81e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2066819	1.000	rs2066808	chr12:56737973	A/G	cg26714650	chr12:56694279	CS	-1.25	-7.11	-0.59	2.17e-10	Psoriasis vulgaris;
THYM	cis	rs6063312	0.551	rs4809720	chr20:47341312	A/G	cg02903601	chr20:47895381	SNORD12B;C20orf199;SNORD12C;MIR1259;ZNFX1	-0.95	-4.45	-0.42	2.35e-5	Tonometry;
THYM	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-4.92	-0.45	3.68e-6	Hemoglobin concentration;
THYM	cis	rs791590	0.941	rs12722527	chr10:6077328	C/T	cg17191567	chr10:6178319	NA	0.68	4.6	0.43	1.29e-5	Soluble interleukin-2 receptor subunit alpha;
THYM	cis	rs198426	0.506	rs11230767	chr11:61426932	G/A	cg19838087	chr11:61442541	NA	0.59	6.79	0.57	9.45e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
THYM	cis	rs7917772	0.555	rs2244524	chr10:104486974	C/T	cg00122347	chr10:104236741	TMEM180	-0.36	-4.48	-0.42	2.1e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs57590327	0.555	rs13072957	chr3:81776242	A/G	cg07356753	chr3:81810745	GBE1	0.89	6.63	0.56	2.05e-9	Extraversion;
THYM	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.89	0.52	5.88e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.49	4.62	0.43	1.22e-5	Birth weight;
THYM	cis	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg18512352	chr11:47633146	NA	-0.38	-4.52	-0.42	1.75e-5	HDL cholesterol;
THYM	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg11663144	chr21:46675770	NA	-0.69	-8.07	-0.64	2.19e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg18105134	chr13:113819100	PROZ	-1.15	-10.31	-0.73	3.57e-17	Platelet distribution width;
THYM	cis	rs2806561	0.808	rs1413974	chr1:23347125	C/T	cg19743168	chr1:23544995	NA	-0.59	-5.55	-0.49	2.55e-7	Height;
THYM	cis	rs877282	0.838	rs11253373	chr10:774857	A/G	cg10556349	chr10:835070	NA	-0.8	-5.5	-0.49	3.23e-7	Uric acid levels;
THYM	cis	rs67311347	0.544	rs12054197	chr3:40337562	C/T	cg13683864	chr3:40499215	RPL14	-0.79	-7.44	-0.61	4.43e-11	Renal cell carcinoma;
THYM	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg24812749	chr6:127587940	RNF146	0.95	7.54	0.61	2.83e-11	Breast cancer;
THYM	cis	rs6032067	0.777	rs35476703	chr20:43802875	C/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.93	-0.58	5.03e-10	Blood protein levels;
THYM	cis	rs7312774	0.618	rs7968263	chr12:107330844	C/A	cg16260113	chr12:107380972	MTERFD3	1.34	6.39	0.55	6.14e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs988913	1.000	rs2221334	chr6:54834541	A/C	cg18532076	chr6:54711417	FAM83B	0.5	4.91	0.45	3.78e-6	Menarche (age at onset);
THYM	cis	rs9790314	0.631	rs2061804	chr3:161102474	C/A	cg03342759	chr3:160939853	NMD3	-0.74	-6.45	-0.55	4.66e-9	Morning vs. evening chronotype;
THYM	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg00024416	chr22:24240387	NA	-0.73	-6.65	-0.56	1.84e-9	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.43	0.7	2.73e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9348739	1	rs9348739	chr6:26923099	G/C	cg12826209	chr6:26865740	GUSBL1	0.99	5.65	0.5	1.69e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7575217	0.740	rs13392166	chr2:101768104	T/C	cg23907051	chr2:101730305	TBC1D8	-0.33	-4.49	-0.42	2.02e-5	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs977987	0.671	rs9922008	chr16:75335406	T/C	cg07303275	chr16:75499416	TMEM170A	0.63	5.13	0.47	1.54e-6	Dupuytren's disease;
THYM	cis	rs3008870	0.959	rs2985808	chr1:67367741	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.91	7.04	0.59	2.95e-10	Lymphocyte percentage of white cells;
THYM	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs4273100	0.688	rs12938803	chr17:19204432	A/C	cg25447019	chr17:19030144	GRAPL	0.74	5.8	0.51	8.71e-8	Schizophrenia;
THYM	cis	rs3136739	0.558	rs28450020	chr8:42112206	T/C	cg12091331	chr8:42065314	PLAT	-0.56	-4.48	-0.42	2.05e-5	Plasma plasminogen activator levels;
THYM	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg22166914	chr1:53195759	ZYG11B	0.77	7.61	0.62	1.98e-11	Monocyte count;
THYM	cis	rs2139634	1.000	rs2139634	chr3:46521392	G/T	cg02332537	chr3:46540019	RTP3	0.47	4.68	0.43	9.46e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg11502198	chr6:26597334	ABT1	0.64	5.68	0.5	1.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg17888033	chr8:143858414	LYNX1	0.46	5.18	0.47	1.24e-6	Urinary tract infection frequency;
THYM	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg18252515	chr7:66147081	NA	0.87	6.54	0.56	3.1e-9	Corneal structure;
THYM	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg23649088	chr2:200775458	C2orf69	0.85	7.29	0.6	8.99e-11	Osteoporosis;
THYM	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg06074448	chr4:187884817	NA	-1.0	-13.48	-0.81	8.89e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6060717	0.610	rs2590965	chr20:34613120	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.73	5.28	0.48	8.08e-7	Hip circumference adjusted for BMI;
THYM	cis	rs7172809	0.796	rs4886870	chr15:77827471	A/C	cg10437265	chr15:77819839	NA	-0.53	-4.54	-0.42	1.66e-5	Glucose homeostasis traits;
THYM	cis	rs2456568	0.867	rs7114457	chr11:93657817	C/T	cg26875233	chr11:93583750	C11orf90	-0.52	-5.12	-0.47	1.57e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs6988636	1.000	rs17323510	chr8:124186089	A/G	cg22384356	chr8:124195192	FAM83A	0.86	5.42	0.49	4.58e-7	Urinary uromodulin levels;
THYM	cis	rs34375054	0.525	rs12316499	chr12:125593318	G/A	cg25124228	chr12:125621409	AACS	-0.83	-6.85	-0.57	7.41e-10	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs6496667	0.558	rs10459677	chr15:91042399	A/C	cg22089800	chr15:90895588	ZNF774	-0.67	-4.85	-0.45	4.76e-6	Rheumatoid arthritis;
THYM	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg17279839	chr7:150038598	RARRES2	0.55	4.9	0.45	3.88e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.02	-9.52	-0.7	1.73e-15	Primary sclerosing cholangitis;
THYM	cis	rs9527	0.615	rs1556960	chr10:104726673	A/G	cg15744005	chr10:104629667	AS3MT	-0.61	-4.55	-0.42	1.61e-5	Arsenic metabolism;
THYM	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg08859206	chr1:53392774	SCP2	-0.73	-8.24	-0.65	9.39e-13	Monocyte count;
THYM	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg26384229	chr12:38710491	ALG10B	1.05	10.43	0.73	1.96e-17	Heart rate;
THYM	cis	rs57994353	0.897	rs12551527	chr9:139358425	C/G	cg14115884	chr9:139300582	SDCCAG3	0.68	4.68	0.43	9.68e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs4788570	0.697	rs4788443	chr16:71805160	G/A	cg06353428	chr16:71660113	MARVELD3	1.38	8.22	0.64	1.05e-12	Intelligence (multi-trait analysis);
THYM	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14240646	chr10:27532245	ACBD5	-0.78	-4.74	-0.44	7.52e-6	Breast cancer;
THYM	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.67	-4.56	-0.42	1.5e-5	Lung cancer in ever smokers;
THYM	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.25	-10.14	-0.72	8.26e-17	Platelet count;
THYM	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg12310025	chr6:25882481	NA	0.69	5.64	0.5	1.74e-7	Schizophrenia;
THYM	trans	rs2136093	0.600	rs12128841	chr1:90909557	G/T	cg21057494	chr3:45066971	CLEC3B	0.53	7.07	0.59	2.65e-10	Response to antidepressants;
THYM	cis	rs7173743	0.525	rs7166723	chr15:79133848	C/T	cg00540400	chr15:79124168	NA	0.56	5.38	0.48	5.35e-7	Coronary artery disease;
THYM	cis	rs12148477	0.623	rs4775942	chr15:51663597	A/G	cg25905881	chr15:51634250	GLDN	-0.55	-4.47	-0.42	2.12e-5	Follicule stimulating hormone;
THYM	cis	rs9796	0.689	rs9888710	chr15:41446153	G/C	cg21153102	chr15:41252147	NA	0.6	5.05	0.46	2.09e-6	Menopause (age at onset);
THYM	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.47	-4.7	-0.43	8.85e-6	Crohn's disease;
THYM	cis	rs8100891	0.734	rs741445	chr19:32836592	G/T	cg16662424	chr19:32837316	ZNF507	-0.43	-4.75	-0.44	7.3e-6	Neuroticism;
THYM	cis	rs7103648	0.966	rs10838702	chr11:47410888	G/T	cg20307385	chr11:47447363	PSMC3	0.91	7.88	0.63	5.39e-12	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs2130392	0.926	rs7679215	chr4:185635311	C/T	cg04058563	chr4:185651563	MLF1IP	-0.57	-5.44	-0.49	4.12e-7	Kawasaki disease;
THYM	cis	rs9914988	0.576	rs67777803	chr17:27323322	G/T	cg26182037	chr17:27055700	NEK8	0.88	4.83	0.44	5.15e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs7408868	1.000	rs7247835	chr19:15262844	A/G	cg14696996	chr19:15285081	NOTCH3	0.97	5.57	0.5	2.37e-7	Pulse pressure;
THYM	cis	rs9467160	0.765	rs793712	chr6:24446882	T/C	cg20631270	chr6:24437470	GPLD1	-0.67	-4.64	-0.43	1.13e-5	Liver enzyme levels;
THYM	trans	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg10856724	chr12:34555212	NA	-0.95	-8.21	-0.64	1.07e-12	Bladder cancer;
THYM	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg11965913	chr1:205819406	PM20D1	0.56	4.59	0.43	1.37e-5	Parkinson's disease;
THYM	cis	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg21775007	chr8:11205619	TDH	-0.65	-5.08	-0.46	1.9e-6	Retinal vascular caliber;
THYM	cis	rs911263	0.961	rs1885013	chr14:68754695	G/A	cg18825221	chr14:68749962	RAD51L1	0.58	6.44	0.55	4.93e-9	Primary biliary cholangitis;
THYM	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs8002861	0.713	rs7339417	chr13:44413496	A/T	cg17145862	chr1:211918768	LPGAT1	0.85	7.64	0.62	1.69e-11	Leprosy;
THYM	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg05660106	chr1:15850417	CASP9	0.75	6.05	0.53	2.87e-8	Systolic blood pressure;
THYM	cis	rs791888	0.965	rs791875	chr10:89406088	C/T	cg10377144	chr10:89419177	PAPSS2	-0.38	-5.97	-0.52	4.1e-8	Magnesium levels;
THYM	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03452623	chr4:187889614	NA	-1.16	-21.11	-0.91	1.23e-37	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg12826209	chr6:26865740	GUSBL1	0.84	5.92	0.52	5.09e-8	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs61774743	0.754	rs11578963	chr1:41834183	A/G	cg08462924	chr1:41848221	NA	-0.78	-9.16	-0.68	1.05e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2334880	0.678	rs12919092	chr16:71446490	T/C	cg06353428	chr16:71660113	MARVELD3	-1.0	-5.07	-0.46	1.93e-6	Malaria;
THYM	cis	rs7084402	0.967	rs1658469	chr10:60292402	C/T	cg07615347	chr10:60278583	BICC1	-0.56	-5.2	-0.47	1.12e-6	Refractive error;
THYM	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg13695892	chr22:41940480	POLR3H	-0.86	-6.16	-0.53	1.72e-8	Vitiligo;
THYM	cis	rs17407555	0.789	rs4348091	chr4:10115363	T/C	cg00071950	chr4:10020882	SLC2A9	-0.53	-4.64	-0.43	1.11e-5	Schizophrenia (age at onset);
THYM	cis	rs7582180	0.663	rs930374	chr2:100962700	A/G	cg21926883	chr2:100939477	LONRF2	-0.67	-6.14	-0.53	1.92e-8	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.800	rs6768221	chr3:47296899	C/G	cg02527881	chr3:46936655	PTH1R	0.59	5.48	0.49	3.44e-7	Colorectal cancer;
THYM	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg01236616	chr12:121019343	POP5	1.31	10.47	0.73	1.61e-17	Type 1 diabetes nephropathy;
THYM	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg21028142	chr17:79581711	NPLOC4	-0.61	-6.22	-0.54	1.33e-8	Eye color traits;
THYM	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22307029	chr19:49891270	CCDC155	0.81	7.2	0.59	1.42e-10	Multiple sclerosis;
THYM	cis	rs6032067	0.641	rs34919068	chr20:43755830	C/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.72	-7.65	-0.62	1.63e-11	Blood protein levels;
THYM	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg12826209	chr6:26865740	GUSBL1	0.85	4.68	0.43	9.63e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg01304814	chr3:48885189	PRKAR2A	1.01	4.61	0.43	1.27e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs4889855	0.530	rs4303599	chr17:78566700	C/T	cg16591659	chr17:78472290	NA	0.45	5.14	0.47	1.46e-6	Fractional excretion of uric acid;
THYM	cis	rs3087591	0.920	rs7225014	chr17:29572973	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.63	-5.38	-0.48	5.3e-7	Hip circumference;
THYM	cis	rs17407555	0.741	rs12509713	chr4:10107069	C/T	cg11266682	chr4:10021025	SLC2A9	-0.39	-4.51	-0.42	1.85e-5	Schizophrenia (age at onset);
THYM	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.99	-0.75	1.26e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.74	-6.7	-0.57	1.47e-9	Personality dimensions;
THYM	cis	rs12476592	0.571	rs10171223	chr2:63687700	A/G	cg17519650	chr2:63277830	OTX1	-0.68	-4.51	-0.42	1.83e-5	Childhood ear infection;
THYM	cis	rs870825	0.616	rs28445002	chr4:185648977	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	trans	rs868153	0.625	rs6907053	chr6:122476695	C/T	cg25287149	chr4:125353337	NA	-0.64	-6.89	-0.58	6.19e-10	Vertical cup-disc ratio;
THYM	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg03433033	chr1:76189801	ACADM	-0.51	-5.37	-0.48	5.57e-7	Daytime sleep phenotypes;
THYM	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg14019146	chr3:50243930	SLC38A3	0.54	4.56	0.42	1.53e-5	Body mass index;
THYM	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg11871910	chr12:69753446	YEATS4	0.63	4.58	0.43	1.38e-5	Response to diuretic therapy;
THYM	cis	rs12611088	0.600	rs2682578	chr19:44012880	A/G	cg18042043	chr19:44147545	NA	-0.41	-4.79	-0.44	6.19e-6	Plasma amyloid beta peptide concentrations (ABx-42);
THYM	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.93	5.98	0.52	3.95e-8	Smoking behavior;
THYM	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg06238570	chr21:40685208	BRWD1	-0.96	-9.18	-0.69	9.29e-15	Cognitive function;
THYM	cis	rs7542375	0.655	rs4846670	chr1:221069017	G/T	cg16008148	chr1:221062819	NA	0.49	5.74	0.51	1.12e-7	Obesity-related traits;
THYM	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg10505658	chr17:80084571	CCDC57	-0.69	-7.95	-0.63	3.85e-12	Life satisfaction;
THYM	cis	rs11696501	0.688	rs6073848	chr20:44298550	G/A	cg11783356	chr20:44313418	WFDC10B	-0.69	-4.73	-0.44	7.72e-6	Brain structure;
THYM	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg08000102	chr2:233561755	GIGYF2	-0.68	-6.11	-0.53	2.16e-8	Coronary artery disease;
THYM	cis	rs7264396	0.563	rs2425081	chr20:34299733	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.76	-0.44	6.84e-6	Total cholesterol levels;
THYM	cis	rs6840360	0.571	rs11736116	chr4:152531816	A/G	cg17479576	chr4:152424074	FAM160A1	-0.78	-5.74	-0.51	1.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03517284	chr6:25882590	NA	-0.93	-8.11	-0.64	1.8e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-4.75	-0.44	7.16e-6	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4746818	0.793	rs2008553	chr10:70860475	C/G	cg11621586	chr10:70884670	VPS26A	1.06	7.75	0.62	1.01e-11	Left atrial antero-posterior diameter;
THYM	cis	rs7980799	0.682	rs1601007	chr12:33609675	C/G	cg10856724	chr12:34555212	NA	-0.6	-4.5	-0.42	1.93e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs4233567	0.559	rs10189912	chr2:144162609	A/G	cg17056048	chr2:144271431	ARHGAP15	-0.55	-4.6	-0.43	1.32e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg25036284	chr2:26402008	FAM59B	0.74	4.87	0.45	4.39e-6	Gut microbiome composition (summer);
THYM	cis	rs4792901	0.802	rs28636996	chr17:41572786	T/C	cg21940313	chr17:41620911	ETV4	-0.53	-5.03	-0.46	2.28e-6	Dupuytren's disease;
THYM	cis	rs1003719	0.680	rs767998	chr21:38525652	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-4.72	-0.44	8.18e-6	Eye color traits;
THYM	cis	rs11031096	0.678	rs11031220	chr11:4197638	G/A	cg18678763	chr11:4115507	RRM1	-0.42	-4.95	-0.45	3.17e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2637266	0.745	rs2583039	chr10:78440187	A/G	cg18941641	chr10:78392320	NA	0.76	6.39	0.55	6.21e-9	Pulmonary function;
THYM	cis	rs911119	1.000	rs6036478	chr20:23611359	C/A	cg16589663	chr20:23618590	CST3	0.77	4.71	0.44	8.31e-6	Chronic kidney disease;
THYM	cis	rs73086581	1.000	rs73086535	chr20:3944150	T/C	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg22920501	chr2:26401640	FAM59B	1.07	9.54	0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg05855489	chr10:104503620	C10orf26	-0.59	-4.62	-0.43	1.23e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9560113	1.000	rs4773379	chr13:112176088	G/C	cg10483660	chr13:112241077	NA	0.53	4.76	0.44	6.81e-6	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg24675658	chr1:53192096	ZYG11B	0.57	4.7	0.43	8.7e-6	Monocyte count;
THYM	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7100689	0.542	rs10887869	chr10:82194689	A/G	cg01528321	chr10:82214614	TSPAN14	0.59	4.79	0.44	6.18e-6	Post bronchodilator FEV1;
THYM	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11890956	chr21:40555474	PSMG1	-0.66	-6.38	-0.55	6.51e-9	Menarche (age at onset);
THYM	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg02734326	chr4:10020555	SLC2A9	-0.61	-5.0	-0.46	2.66e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs332507	0.830	rs2289428	chr3:124412524	T/G	cg14688451	chr3:124303035	KALRN	0.61	4.55	0.42	1.56e-5	Plateletcrit;
THYM	cis	rs113835537	0.529	rs10501397	chr11:66272976	G/T	cg24851651	chr11:66362959	CCS	0.7	4.89	0.45	4.04e-6	Airway imaging phenotypes;
THYM	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01570182	chr17:44337453	NA	-0.63	-6.77	-0.57	1.05e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg23791538	chr6:167370224	RNASET2	-0.64	-4.93	-0.45	3.53e-6	Crohn's disease;
THYM	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	9.55	0.7	1.49e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1865721	0.839	rs59718187	chr18:73144032	C/T	cg26385618	chr18:73139727	C18orf62	-0.63	-4.56	-0.42	1.5e-5	Intelligence;
THYM	trans	rs629535	0.814	rs62513376	chr8:70086881	C/T	cg21567404	chr3:27674614	NA	-1.09	-10.28	-0.73	4.24e-17	Dupuytren's disease;
THYM	cis	rs728616	0.867	rs4633405	chr10:81927446	G/T	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg00129232	chr17:37814104	STARD3	-0.77	-5.27	-0.48	8.58e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7731657	0.537	rs6595976	chr5:130328123	T/A	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	4.51	0.42	1.82e-5	Aortic root size;
THYM	cis	rs4919669	0.546	rs3740416	chr10:104230437	C/G	cg00122347	chr10:104236741	TMEM180	-0.58	-4.8	-0.44	5.83e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
THYM	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11190604	1.000	rs4919472	chr10:102315864	T/A	cg16342193	chr10:102329863	NA	-0.6	-6.24	-0.54	1.22e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6992820	0.592	rs3808391	chr8:56790649	A/G	cg06880721	chr8:56792545	LYN	-0.63	-5.48	-0.49	3.56e-7	Mean platelet volume;
THYM	cis	rs7843479	1.000	rs1032094	chr8:21820479	A/T	cg17168535	chr8:21777572	XPO7	0.73	5.25	0.47	9.34e-7	Mean corpuscular volume;
THYM	cis	rs4849845	0.889	rs4849847	chr2:121034530	A/G	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg10518543	chr12:38710700	ALG10B	-0.54	-4.54	-0.42	1.64e-5	Morning vs. evening chronotype;
THYM	cis	rs6906287	0.647	rs11153753	chr6:118836153	T/C	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.12e-7	Electrocardiographic conduction measures;
THYM	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.58	-5.88	-0.52	6.01e-8	Crohn's disease;
THYM	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg25703541	chr22:24373054	LOC391322	-0.89	-11.25	-0.76	3.61e-19	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7078219	0.543	rs7096296	chr10:101277816	A/G	cg04972745	chr10:101287846	NA	0.52	4.94	0.45	3.35e-6	Dental caries;
THYM	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg04756594	chr16:24857601	SLC5A11	-0.77	-5.35	-0.48	6.1e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4072705	0.967	rs4076333	chr9:127385609	A/G	cg13476313	chr9:127244764	NR5A1	0.32	4.75	0.44	7.27e-6	Menarche (age at onset);
THYM	cis	rs4638749	1.000	rs2219078	chr2:108875198	C/T	cg25838818	chr2:108905173	SULT1C2	-0.6	-6.21	-0.54	1.41e-8	Blood pressure;
THYM	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg12560992	chr17:57184187	TRIM37	-0.92	-8.68	-0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	trans	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Bladder cancer;
THYM	cis	rs4430311	0.723	rs10927075	chr1:243956120	A/T	cg25706552	chr1:244017396	NA	-0.58	-5.02	-0.46	2.39e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs11628318	0.515	rs11850580	chr14:103156586	C/T	cg27124170	chr14:102829869	TECPR2;CINP	0.67	4.55	0.42	1.61e-5	Platelet count;
THYM	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg02869364	chr7:1081709	C7orf50	-0.61	-4.91	-0.45	3.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2562456	0.755	rs1879234	chr19:21704479	T/G	cg21751540	chr19:21541537	ZNF738	0.66	4.6	0.43	1.3e-5	Pain;
THYM	cis	rs6032067	0.516	rs991049	chr20:43898139	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	0.61	6.93	0.58	5.05e-10	Blood protein levels;
THYM	cis	rs7824557	0.591	rs2293859	chr8:11216761	T/G	cg21775007	chr8:11205619	TDH	0.8	7.14	0.59	1.88e-10	Retinal vascular caliber;
THYM	cis	rs9832461	0.790	rs867607	chr3:39798648	C/T	cg21490179	chr3:40494492	NA	-0.89	-4.6	-0.43	1.32e-5	Brain structure (temporal lobe volume);
THYM	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.79	-0.44	6.18e-6	Mean corpuscular volume;
THYM	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg03476357	chr21:30257390	N6AMT1	-0.58	-4.56	-0.42	1.5e-5	Dental caries;
THYM	cis	rs7671261	0.514	rs13138927	chr4:90041366	C/T	cg17769793	chr4:89976368	FAM13A	0.42	4.56	0.42	1.54e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg14018140	chr10:458528	DIP2C	0.6	6.33	0.54	7.96e-9	Psychosis in Alzheimer's disease;
THYM	cis	rs611744	0.967	rs685690	chr8:109192145	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	trans	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg16405210	chr4:1374714	KIAA1530	-1.02	-9.27	-0.69	5.89e-15	Longevity;
THYM	cis	rs11031096	0.683	rs55898672	chr11:4189284	G/C	cg22027985	chr11:4115532	RRM1	-0.56	-5.25	-0.47	9.12e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg07362569	chr17:61921086	SMARCD2	0.73	6.42	0.55	5.26e-9	Prudent dietary pattern;
THYM	cis	rs2562456	0.917	rs2650804	chr19:21680184	A/G	cg21751540	chr19:21541537	ZNF738	-0.68	-4.79	-0.44	6.17e-6	Pain;
THYM	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs55883249	0.957	rs62119431	chr2:9750461	G/A	cg23886495	chr2:9695866	ADAM17	0.81	5.04	0.46	2.24e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs9790314	0.670	rs9864752	chr3:160937591	A/C	cg03342759	chr3:160939853	NMD3	-0.74	-6.28	-0.54	9.97e-9	Morning vs. evening chronotype;
THYM	cis	rs6669072	0.679	rs1766163	chr1:91314510	C/T	cg08895590	chr1:91227319	NA	-0.51	-5.8	-0.51	8.6e-8	Cognitive function;
THYM	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg01069141	chr11:67398826	TBX10;NUDT8	0.53	5.82	0.51	7.79e-8	Mean corpuscular volume;
THYM	cis	rs17818399	0.547	rs7607633	chr2:46759427	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.66	-4.7	-0.43	8.94e-6	Height;
THYM	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg00271210	chr6:167070053	RPS6KA2	0.69	7.42	0.61	4.85e-11	Lung cancer;
THYM	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg02869364	chr7:1081709	C7orf50	-0.45	-5.13	-0.47	1.53e-6	Longevity;Endometriosis;
THYM	cis	rs3925075	1.000	rs3925074	chr16:31347807	G/A	cg02846316	chr16:31340340	ITGAM	0.58	6.08	0.53	2.44e-8	IgA nephropathy;
THYM	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg14582100	chr15:45693742	SPATA5L1	0.62	5.17	0.47	1.29e-6	Homoarginine levels;
THYM	cis	rs901683	1.000	rs71496610	chr10:46021646	C/G	cg18240400	chr10:46168597	ANUBL1	0.8	5.19	0.47	1.19e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs55883249	0.957	rs17362839	chr2:9754439	T/C	cg23886495	chr2:9695866	ADAM17	0.72	4.5	0.42	1.89e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg06009448	chr7:1102226	C7orf50	0.52	5.44	0.49	4.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg15448220	chr1:150897856	SETDB1	0.83	6.83	0.57	8.08e-10	Tonsillectomy;
THYM	cis	rs2066819	0.901	rs1274490	chr12:56649601	A/G	cg26714650	chr12:56694279	CS	1.25	6.95	0.58	4.46e-10	Psoriasis vulgaris;
THYM	cis	rs1971762	0.527	rs7952858	chr12:54039692	C/G	cg16917193	chr12:54089295	NA	0.76	7.41	0.6	5.28e-11	Height;
THYM	cis	rs4780401	0.609	rs4780399	chr16:11828701	A/T	cg01061890	chr16:11836724	TXNDC11	-0.69	-5.43	-0.49	4.24e-7	Rheumatoid arthritis;
THYM	cis	rs782590	0.967	rs17278044	chr2:55748217	G/C	cg03859395	chr2:55845619	SMEK2	0.66	6.08	0.53	2.51e-8	Metabolic syndrome;
THYM	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg27572855	chr1:25598939	RHD	-0.61	-4.67	-0.43	9.87e-6	Erythrocyte sedimentation rate;
THYM	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg26850624	chr5:429559	AHRR	-0.72	-5.68	-0.5	1.45e-7	Cystic fibrosis severity;
THYM	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg27144592	chr16:783916	NARFL	-0.47	-5.09	-0.46	1.78e-6	Height;
THYM	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg09021430	chr5:549028	NA	-0.6	-5.63	-0.5	1.82e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg06634786	chr22:41940651	POLR3H	0.62	4.81	0.44	5.64e-6	Vitiligo;
THYM	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.61	5.22	0.47	1.03e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11690935	0.632	rs6433323	chr2:172873060	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.64	-5.42	-0.49	4.57e-7	Schizophrenia;
THYM	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg06636001	chr8:8085503	FLJ10661	-0.73	-6.27	-0.54	1.07e-8	Joint mobility (Beighton score);
THYM	cis	rs259282	0.605	rs8100423	chr19:33109003	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.57	4.73	0.44	7.9e-6	Schizophrenia;
THYM	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg24250549	chr1:154909240	PMVK	0.79	6.82	0.57	8.33e-10	Prostate cancer;
THYM	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg19508488	chr2:152266495	RIF1	0.76	6.04	0.53	2.99e-8	Lung cancer;
THYM	cis	rs13064411	0.660	rs1872747	chr3:113175785	T/A	cg18753928	chr3:113234510	CCDC52	-0.9	-7.98	-0.63	3.34e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.26	0.47	8.97e-7	Lung cancer in ever smokers;
THYM	cis	rs10089	0.953	rs7713860	chr5:127428789	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs728616	0.867	rs12414877	chr10:81780708	A/G	cg27452691	chr10:81370291	SFTPA1	0.84	4.53	0.42	1.71e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg02527881	chr3:46936655	PTH1R	0.52	4.99	0.46	2.77e-6	Colorectal cancer;
THYM	cis	rs2456568	0.548	rs4753113	chr11:93660974	G/A	cg17595323	chr11:93583763	C11orf90	-0.55	-5.83	-0.51	7.52e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg07424592	chr7:64974309	NA	1.04	5.48	0.49	3.42e-7	Diabetic kidney disease;
THYM	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12667521	chr19:29218732	NA	0.89	8.17	0.64	1.34e-12	Methadone dose in opioid dependence;
THYM	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg08847533	chr14:75593920	NEK9	0.95	9.75	0.71	5.61e-16	Height;
THYM	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg25427524	chr10:38739819	LOC399744	-0.58	-5.01	-0.46	2.52e-6	Extrinsic epigenetic age acceleration;
THYM	cis	rs7428297	0.943	rs13078084	chr3:127074386	A/G	cg26312807	chr3:127057048	NA	-0.7	-4.89	-0.45	4.03e-6	Clozapine-induced agranulocytosis;
THYM	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg02269571	chr22:50332266	NA	-0.71	-4.91	-0.45	3.78e-6	Schizophrenia;
THYM	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg16850897	chr7:100343110	ZAN	-0.7	-5.32	-0.48	6.82e-7	Other erythrocyte phenotypes;
THYM	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.05	-0.53	2.84e-8	Life satisfaction;
THYM	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg16989719	chr2:238392110	NA	-0.61	-5.0	-0.46	2.64e-6	Prostate cancer;
THYM	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg08999081	chr20:33150536	PIGU	0.76	6.73	0.57	1.27e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs365132	1.000	rs2292255	chr5:176334195	C/T	cg17809377	chr5:176326619	HK3	-0.31	-4.64	-0.43	1.13e-5	Menarche and menopause (age at onset);Menopause (age at onset);
THYM	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg00277334	chr10:82204260	NA	-0.53	-5.41	-0.49	4.72e-7	Post bronchodilator FEV1;
THYM	cis	rs3772130	0.583	rs11710169	chr3:121426655	A/G	cg20356878	chr3:121714668	ILDR1	0.63	4.89	0.45	4.07e-6	Cognitive performance;
THYM	cis	rs138918	1.000	rs138914	chr22:43555921	G/A	cg02233750	chr22:43539658	MCAT	0.56	4.85	0.45	4.8e-6	Monocyte count;
THYM	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg21475434	chr5:93447410	FAM172A	0.96	6.1	0.53	2.29e-8	Diabetic retinopathy;
THYM	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg26384229	chr12:38710491	ALG10B	0.73	5.4	0.48	5.01e-7	Morning vs. evening chronotype;
THYM	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg02569458	chr12:86230093	RASSF9	0.59	5.09	0.46	1.78e-6	Major depressive disorder;
THYM	cis	rs1021993	0.868	rs906348	chr1:209528346	A/T	cg06155620	chr1:209527581	NA	-0.6	-4.84	-0.44	5.05e-6	Gut microbiome composition (winter);
THYM	cis	rs9915657	0.840	rs10512582	chr17:70139393	A/C	cg09344028	chr17:70110421	NA	0.51	5.09	0.46	1.82e-6	Thyroid hormone levels;
THYM	cis	rs3892630	0.878	rs2903759	chr19:33195947	A/G	cg02283691	chr19:33182526	NUDT19	-0.42	-5.0	-0.46	2.64e-6	Red blood cell traits;
THYM	cis	rs6840360	0.571	rs62327269	chr4:152527973	G/C	cg22705602	chr4:152727874	NA	-0.78	-8.16	-0.64	1.38e-12	Intelligence (multi-trait analysis);
THYM	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg05294307	chr14:35346193	BAZ1A	-0.82	-5.51	-0.49	3.06e-7	Psoriasis;
THYM	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg08132940	chr7:1081526	C7orf50	-1.15	-6.65	-0.56	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.67	5.9	0.52	5.62e-8	Lung disease severity in cystic fibrosis;
THYM	cis	rs12754538	0.648	rs7524437	chr1:8856603	A/G	cg06159269	chr1:8767347	RERE	0.22	4.63	0.43	1.14e-5	Subjective well-being;
THYM	cis	rs13315871	1.000	rs9824965	chr3:58433505	T/A	cg00563845	chr3:58318305	PXK	0.53	4.67	0.43	9.78e-6	Cholesterol, total;
THYM	cis	rs7818345	0.712	rs13261442	chr8:19352333	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.6	5.08	0.46	1.9e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs67311347	0.544	rs9864601	chr3:40345318	C/T	cg13683864	chr3:40499215	RPL14	-0.79	-7.48	-0.61	3.69e-11	Renal cell carcinoma;
THYM	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg23649088	chr2:200775458	C2orf69	-0.74	-4.49	-0.42	2.02e-5	Schizophrenia;
THYM	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Body mass index;
THYM	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg00631329	chr6:26305371	NA	-0.44	-4.9	-0.45	3.94e-6	Educational attainment;
THYM	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs55665837	1.000	rs11023246	chr11:14536956	T/C	cg19336497	chr11:14380999	RRAS2	-0.64	-7.04	-0.59	3e-10	Vitamin D levels;
THYM	cis	rs55702914	1.000	rs55702914	chr2:198214396	C/G	cg00792783	chr2:198669748	PLCL1	0.6	4.48	0.42	2.04e-5	Major depression and alcohol dependence;
THYM	cis	rs12188164	0.812	rs10072668	chr5:422752	T/C	cg00049323	chr5:472564	LOC25845	-0.41	-4.73	-0.44	7.83e-6	Cystic fibrosis severity;
THYM	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg00801512	chr17:28996047	NA	-0.8	-5.41	-0.49	4.74e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-4.95	-0.45	3.21e-6	Neuroticism;
THYM	cis	rs1971762	0.545	rs6580949	chr12:53924293	T/C	cg16917193	chr12:54089295	NA	0.74	6.35	0.55	7.5e-9	Height;
THYM	cis	rs892961	0.932	rs67719929	chr17:75412605	G/A	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg23281280	chr6:28129359	ZNF389	0.62	4.55	0.42	1.56e-5	Parkinson's disease;
THYM	cis	rs9443189	0.526	rs9359132	chr6:76289553	G/A	cg01950844	chr6:76311363	SENP6	1.1	6.88	0.58	6.48e-10	Prostate cancer;
THYM	cis	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.62	0.43	1.23e-5	Obesity-related traits;
THYM	cis	rs17401966	1.000	rs12402052	chr1:10318652	C/G	cg20482658	chr1:10539492	PEX14	0.39	4.66	0.43	1.04e-5	Hepatocellular carcinoma;
THYM	cis	rs35934224	0.542	rs8139091	chr22:19845283	G/C	cg11182965	chr22:19864308	TXNRD2	-0.55	-4.77	-0.44	6.72e-6	Glaucoma (primary open-angle);
THYM	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg02527881	chr3:46936655	PTH1R	0.64	6.07	0.53	2.63e-8	Colorectal cancer;
THYM	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22133161	chr19:49891603	CCDC155	0.74	4.99	0.46	2.71e-6	Multiple sclerosis;
THYM	cis	rs7582180	1.000	rs2033749	chr2:100916051	T/C	cg14675211	chr2:100938903	LONRF2	0.6	4.59	0.43	1.36e-5	Intelligence (multi-trait analysis);
THYM	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg19346786	chr7:2764209	NA	-0.7	-5.81	-0.51	8.28e-8	Height;
THYM	cis	rs6032067	0.929	rs17424868	chr20:43818519	T/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.39	0.48	5.09e-7	Tonsillectomy;
THYM	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg09307838	chr4:120376055	NA	-0.62	-4.73	-0.44	7.88e-6	Corneal astigmatism;
THYM	cis	rs6921919	0.515	rs1558205	chr6:28382262	A/C	cg18815343	chr6:28367644	ZSCAN12	0.57	4.52	0.42	1.75e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs600806	0.850	rs3879452	chr1:109929237	G/A	cg16988986	chr1:109941118	SORT1	-0.43	-4.56	-0.42	1.5e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2276314	1.000	rs8086395	chr18:33564592	C/G	cg05985134	chr18:33552581	C18orf21	0.68	4.77	0.44	6.59e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs4389656	0.857	rs453536	chr5:6736458	T/G	cg10857441	chr5:6722123	POLS	-0.44	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg05340658	chr4:99064831	C4orf37	0.56	4.75	0.44	7.21e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.57	4.8	0.44	5.82e-6	Blood metabolite levels;
THYM	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg26924012	chr15:45694286	SPATA5L1	0.99	8.43	0.65	3.77e-13	Homoarginine levels;
THYM	cis	rs7704138	0.639	rs4865981	chr5:55020188	C/T	cg18456523	chr5:54516805	NA	0.58	4.59	0.43	1.34e-5	Height;
THYM	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg02038168	chr22:39784481	NA	-0.68	-5.69	-0.5	1.43e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg13877915	chr19:58951672	ZNF132	0.91	8.38	0.65	4.65e-13	Uric acid clearance;
THYM	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg04025307	chr7:1156635	C7orf50	0.77	6.54	0.56	3.05e-9	Longevity;Endometriosis;
THYM	cis	rs4606347	0.789	rs61780861	chr1:66162303	G/A	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg11764359	chr7:65958608	NA	-0.67	-4.77	-0.44	6.52e-6	Aortic root size;
THYM	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg09307838	chr4:120376055	NA	0.72	5.06	0.46	2.02e-6	Corneal astigmatism;
THYM	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg27588902	chr6:42928151	GNMT	-0.51	-4.93	-0.45	3.48e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg05368731	chr17:41323189	NBR1	1.19	10.93	0.75	1.74e-18	Menopause (age at onset);
THYM	cis	rs8050907	0.744	rs13335503	chr16:4529028	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.45	5.44	0.49	4.2e-7	Obesity-related traits;
THYM	cis	rs1401999	0.565	rs4912515	chr3:183653718	A/G	cg01324343	chr3:183735012	ABCC5	0.6	6.51	0.56	3.61e-9	Anterior chamber depth;
THYM	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06481639	chr22:41940642	POLR3H	-0.62	-4.63	-0.43	1.14e-5	Vitiligo;
THYM	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	9.51	0.7	1.8e-15	Platelet count;
THYM	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg12179176	chr11:130786555	SNX19	0.94	9.72	0.71	6.45e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg11494091	chr17:61959527	GH2	-0.8	-7.93	-0.63	4.29e-12	Height;
THYM	cis	rs7072216	0.763	rs3814140	chr10:100170762	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs3781426	0.824	rs3781396	chr10:126725553	C/G	cg04494136	chr10:126703576	CTBP2	-0.33	-4.46	-0.42	2.25e-5	Height;
THYM	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg03929089	chr4:120376271	NA	-0.98	-12.21	-0.78	3.51e-21	Coronary artery disease;
THYM	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs453301	0.653	rs2953806	chr8:8914124	C/T	cg06636001	chr8:8085503	FLJ10661	0.79	6.72	0.57	1.35e-9	Joint mobility (Beighton score);
THYM	cis	rs7236492	0.748	rs11664153	chr18:77195813	G/A	cg15644404	chr18:77186268	NFATC1	-1.05	-4.96	-0.45	3.04e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs9329289	0.510	rs12359941	chr10:2547015	G/A	cg15501526	chr10:2543763	NA	0.51	4.67	0.43	1e-5	Age-related hearing impairment;
THYM	cis	rs17401966	1.000	rs3748578	chr1:10420918	A/G	cg19773385	chr1:10388646	KIF1B	0.66	4.89	0.45	4.03e-6	Hepatocellular carcinoma;
THYM	cis	rs6543140	0.964	rs1035126	chr2:103019981	C/T	cg03938978	chr2:103052716	IL18RAP	0.61	6.13	0.53	1.96e-8	Blood protein levels;
THYM	cis	rs2072510	0.569	rs61937881	chr12:96393587	C/T	cg18817487	chr12:96390143	HAL	0.47	5.71	0.51	1.31e-7	Metabolite levels (small molecules and protein measures);
THYM	cis	rs6429082	0.689	rs10925965	chr1:235708443	C/A	cg26050004	chr1:235667680	B3GALNT2	-0.64	-4.72	-0.44	8.15e-6	Adiposity;
THYM	cis	rs1784581	0.588	rs7758559	chr6:162438635	G/T	cg17173639	chr6:162384350	PARK2	0.84	7.87	0.63	5.59e-12	Itch intensity from mosquito bite;
THYM	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg23205692	chr1:25664452	TMEM50A	0.81	6.41	0.55	5.68e-9	Erythrocyte sedimentation rate;
THYM	cis	rs7107174	1.000	rs10501426	chr11:78057122	C/T	cg19901956	chr11:77921274	USP35	-0.65	-5.37	-0.48	5.66e-7	Testicular germ cell tumor;
THYM	cis	rs4595586	0.679	rs7955725	chr12:39322903	C/T	cg26384229	chr12:38710491	ALG10B	0.56	4.46	0.42	2.24e-5	Morning vs. evening chronotype;
THYM	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg15693483	chr7:1102177	C7orf50	0.46	4.89	0.45	4.05e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg10803722	chr21:46713166	LOC642852	0.42	5.4	0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11264213	0.901	rs12031138	chr1:36407806	C/T	cg27506609	chr1:36549197	TEKT2	-0.92	-4.83	-0.44	5.3e-6	Schizophrenia;
THYM	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg13607699	chr17:42295918	UBTF	0.9	9.27	0.69	5.91e-15	Total body bone mineral density;
THYM	cis	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg02317251	chr4:10116515	WDR1	-0.56	-4.95	-0.45	3.23e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs10789491	1.000	rs35861275	chr1:47171909	A/C	cg15501359	chr1:47185051	KIAA0494	-1.14	-8.24	-0.65	9.45e-13	Response to hepatitis C treatment;
THYM	cis	rs7553864	1.000	rs4551570	chr1:87614019	C/A	cg17420885	chr1:87600446	LOC339524	-0.77	-6.37	-0.55	6.71e-9	Smoking behavior;
THYM	cis	rs17685	0.753	rs869806	chr7:75688623	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.1	-0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg00339695	chr16:24857497	SLC5A11	0.69	6.38	0.55	6.46e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg15744005	chr10:104629667	AS3MT	-0.86	-8.65	-0.66	1.29e-13	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg10523679	chr1:76189770	ACADM	-0.55	-4.67	-0.43	9.97e-6	Daytime sleep phenotypes;
THYM	cis	rs13102973	0.899	rs13127569	chr4:135900762	C/A	cg14419869	chr4:135874104	NA	0.82	6.86	0.58	7.03e-10	Subjective well-being;
THYM	cis	rs4808199	0.901	rs12973258	chr19:19488718	T/C	cg03709012	chr19:19516395	GATAD2A	1.16	7.63	0.62	1.76e-11	Nonalcoholic fatty liver disease;
THYM	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-8.42	-0.65	3.8e-13	Schizophrenia;
THYM	cis	rs6754311	0.593	rs12619365	chr2:136398174	C/T	cg07169764	chr2:136633963	MCM6	0.7	5.67	0.5	1.55e-7	Mosquito bite size;
THYM	cis	rs9992101	0.547	rs7656186	chr4:77409818	C/T	cg27417997	chr4:77356416	SHROOM3	-0.37	-4.46	-0.42	2.22e-5	Creatinine levels;
THYM	cis	rs6541297	1.000	rs4846838	chr1:230281618	G/A	cg05784532	chr1:230284198	GALNT2	0.81	4.88	0.45	4.3e-6	Coronary artery disease;
THYM	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg15556689	chr8:8085844	FLJ10661	-0.69	-5.67	-0.5	1.57e-7	Mood instability;
THYM	cis	rs9527	0.569	rs78193706	chr10:104780564	T/C	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs4481887	1.000	rs4244179	chr1:248470984	T/A	cg13385794	chr1:248469461	NA	0.65	4.66	0.43	1.04e-5	Common traits (Other);
THYM	cis	rs8067354	0.681	rs9907923	chr17:57824927	C/T	cg20151207	chr17:57696971	CLTC	-0.7	-4.67	-0.43	9.76e-6	Hemoglobin concentration;
THYM	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg11266682	chr4:10021025	SLC2A9	-0.52	-6.42	-0.55	5.41e-9	Bone mineral density;
THYM	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg08048268	chr3:133502702	NA	-0.66	-5.71	-0.51	1.27e-7	Iron status biomarkers;
THYM	cis	rs76878669	0.561	rs7117630	chr11:66154777	C/T	cg18002602	chr11:66138449	SLC29A2	-0.45	-4.48	-0.42	2.12e-5	Educational attainment (years of education);
THYM	cis	rs7567389	0.677	rs11680949	chr2:128123562	C/G	cg06038358	chr2:128176007	PROC	0.43	4.52	0.42	1.79e-5	Self-rated health;
THYM	cis	rs288326	0.561	rs79221349	chr2:183751591	T/A	cg09997497	chr2:183902928	NCKAP1	1.11	5.07	0.46	1.94e-6	Blood protein levels;
THYM	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg08645402	chr16:4508243	NA	-0.76	-7.06	-0.59	2.68e-10	Schizophrenia;
THYM	cis	rs12935418	0.672	rs9934957	chr16:81049683	C/T	cg16651780	chr16:81037892	C16orf61	-0.83	-6.11	-0.53	2.15e-8	Mean corpuscular volume;
THYM	cis	rs6748734	0.625	rs7355583	chr2:241821707	T/C	cg02820040	chr2:241836501	C2orf54	-0.24	-4.61	-0.43	1.25e-5	Urinary metabolites;
THYM	cis	rs892961	0.867	rs312909	chr17:75413954	T/C	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs1797885	0.510	rs2442802	chr3:12608045	A/C	cg05467012	chr3:12595696	NA	0.57	5.01	0.46	2.48e-6	Immature fraction of reticulocytes;
THYM	cis	rs877282	0.945	rs11253398	chr10:790012	T/C	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs55728055	0.661	rs16989635	chr22:31847912	A/C	cg10537193	chr22:32026975	PISD	-0.83	-5.05	-0.46	2.12e-6	Age-related hearing impairment;
THYM	cis	rs3741151	0.686	rs11823913	chr11:73141627	C/G	cg12959048	chr11:73096162	RELT	-0.46	-4.94	-0.45	3.32e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs4660306	0.961	rs4660860	chr1:45946233	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.43	-0.49	4.37e-7	Homocysteine levels;
THYM	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg22907277	chr7:1156413	C7orf50	0.89	7.95	0.63	3.87e-12	Longevity;Endometriosis;
THYM	cis	rs11997175	0.558	rs6468207	chr8:33798095	G/A	ch.8.33884649F	chr8:33765107	NA	-0.59	-4.46	-0.42	2.26e-5	Body mass index;
THYM	cis	rs4788815	0.513	rs12929547	chr16:71794734	A/G	cg06353428	chr16:71660113	MARVELD3	1.42	8.29	0.65	7.34e-13	Metabolite levels;
THYM	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg23205692	chr1:25664452	TMEM50A	0.84	6.43	0.55	5.09e-9	Erythrocyte sedimentation rate;
THYM	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg11764359	chr7:65958608	NA	-0.63	-4.76	-0.44	6.87e-6	Aortic root size;
THYM	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12496230	0.855	rs1036971	chr3:66850677	T/A	cg23477460	chr3:66848765	NA	1.25	7.79	0.62	8.46e-12	Type 2 diabetes;
THYM	cis	rs56161922	0.908	rs113826410	chr1:207849815	C/T	cg09557387	chr1:207818395	CR1L	1.13	5.05	0.46	2.11e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6598955	0.671	rs10159433	chr1:26618370	A/G	cg08133631	chr1:26527909	CATSPER4	-0.55	-4.59	-0.43	1.34e-5	Obesity-related traits;
THYM	cis	rs11118346	1.000	rs17544942	chr1:219739664	C/T	cg07908999	chr1:219785142	NA	-0.39	-4.47	-0.42	2.16e-5	Height;
THYM	cis	rs149313	0.577	rs26506	chr5:96079402	C/T	cg11214001	chr5:96078430	CAST	-0.59	-4.96	-0.45	3.11e-6	Blood protein levels;
THYM	cis	rs7465272	1.000	rs13258638	chr8:143683582	C/T	cg10104451	chr8:143696006	ARC	-0.78	-5.42	-0.49	4.45e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.67	9.16	0.68	1.04e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs240764	0.853	rs17303769	chr6:100967531	G/A	cg21058520	chr6:100914733	NA	0.57	5.03	0.46	2.35e-6	Neuroticism;
THYM	cis	rs4642101	0.534	rs13316229	chr3:12807371	C/T	cg11882607	chr3:12858926	CAND2	-0.46	-5.24	-0.47	9.7e-7	QRS complex (12-leadsum);
THYM	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg23711669	chr6:146136114	FBXO30	0.83	7.91	0.63	4.62e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.66	-0.43	1.03e-5	Prostate cancer;
THYM	cis	rs2302729	0.578	rs11062298	chr12:2771709	A/C	cg19945202	chr12:2788847	CACNA1C	-0.72	-5.72	-0.51	1.26e-7	Sleep quality;
THYM	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg25554036	chr4:6271136	WFS1	0.59	5.47	0.49	3.68e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs902774	0.597	rs7299694	chr12:53352572	A/C	cg16329197	chr12:53359506	NA	-0.53	-4.6	-0.43	1.31e-5	Prostate cancer;
THYM	cis	rs28595532	0.920	rs115320476	chr4:119759680	G/A	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg15247329	chr7:2764246	NA	-0.7	-5.9	-0.52	5.62e-8	Height;
THYM	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4417704	0.502	rs6714289	chr2:241880461	G/A	cg15164180	chr2:241846931	NA	-0.36	-4.62	-0.43	1.22e-5	Joint mobility (Beighton score);
THYM	cis	rs4747241	0.962	rs11000248	chr10:74042601	G/A	cg07828833	chr10:74069493	NA	0.56	4.76	0.44	6.84e-6	Heschl's gyrus morphology;
THYM	cis	rs6032067	0.714	rs6094110	chr20:43864889	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.36	-0.48	5.9e-7	Blood protein levels;
THYM	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg07424592	chr7:64974309	NA	1.12	5.24	0.47	9.64e-7	Diabetic kidney disease;
THYM	cis	rs59698941	0.943	rs72799496	chr5:132290911	T/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs6076065	0.630	rs2424558	chr20:23429344	A/G	cg11657817	chr20:23433608	CST11	0.39	5.97	0.52	4.1e-8	Facial morphology (factor 15, philtrum width);
THYM	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08109568	chr15:31115862	NA	-0.63	-5.88	-0.52	5.99e-8	Huntington's disease progression;
THYM	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22496380	chr5:211416	CCDC127	-1.38	-8.23	-0.65	9.68e-13	Breast cancer;
THYM	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg17143192	chr8:8559678	CLDN23	1.01	7.79	0.62	8.28e-12	Obesity-related traits;
THYM	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs2274459	0.841	rs34778247	chr6:33658552	C/A	cg06253072	chr6:33679850	C6orf125	0.46	4.45	0.42	2.32e-5	Obesity (extreme);
THYM	cis	rs7220711	1.000	rs9902329	chr17:41787573	A/G	cg26893861	chr17:41843967	DUSP3	0.65	5.63	0.5	1.83e-7	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs7681440	0.606	rs2619359	chr4:90754828	A/C	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs300774	0.764	rs300756	chr2:233416	G/A	cg04617936	chr2:214353	NA	0.71	4.48	0.42	2.11e-5	Suicide attempts in bipolar disorder;
THYM	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg07343612	chr16:622815	PIGQ	-1.08	-10.53	-0.73	1.25e-17	Height;
THYM	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg06238570	chr21:40685208	BRWD1	-0.71	-6.0	-0.52	3.63e-8	Menarche (age at onset);
THYM	cis	rs9403317	0.538	rs9403330	chr6:141999967	G/A	cg15052665	chr6:141804349	NA	0.74	5.41	0.49	4.63e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs58235267	0.656	rs12713469	chr2:63059927	C/T	cg17519650	chr2:63277830	OTX1	-0.66	-5.76	-0.51	1.03e-7	Prostate-specific antigen levels (conditioned on lead SNPs);
THYM	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg08645402	chr16:4508243	NA	-0.69	-6.09	-0.53	2.36e-8	Schizophrenia;
THYM	cis	rs6032067	0.714	rs6104065	chr20:43848079	C/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.61	-5.89	-0.52	5.91e-8	Blood protein levels;
THYM	cis	rs71403859	0.730	rs71386933	chr16:71821800	A/T	cg08717414	chr16:71523259	ZNF19	-0.92	-5.14	-0.47	1.48e-6	Post bronchodilator FEV1;
THYM	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg08017756	chr2:100939284	LONRF2	-0.75	-7.8	-0.62	7.89e-12	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg00684032	chr4:1343700	KIAA1530	0.55	4.8	0.44	5.9e-6	Obesity-related traits;
THYM	cis	rs6828523	0.698	rs73869046	chr4:175854498	C/T	cg14561282	chr4:175839468	ADAM29	0.62	4.53	0.42	1.7e-5	Breast cancer;
THYM	cis	rs684232	0.583	rs4968094	chr17:507120	A/T	cg15660573	chr17:549704	VPS53	-1.02	-10.8	-0.74	3.31e-18	Prostate cancer;
THYM	cis	rs921665	0.831	rs12476669	chr2:3195428	A/T	cg16434511	chr2:3151078	NA	-0.88	-5.51	-0.49	3.11e-7	World class endurance athleticism;
THYM	cis	rs11574514	1.000	rs7200950	chr16:67689752	C/T	cg04582263	chr16:67973788	LCAT	0.97	4.56	0.42	1.54e-5	Crohn's disease;
THYM	cis	rs747334	0.846	rs4397747	chr10:92724176	T/G	cg07620928	chr10:92689909	NA	0.57	5.13	0.47	1.54e-6	Fibroblast growth factor basic levels;
THYM	cis	rs7582403	0.510	rs12691778	chr2:148914894	T/C	cg23727674	chr2:148602993	ACVR2A	0.63	4.64	0.43	1.13e-5	Neuroticism;
THYM	cis	rs7757969	1.000	rs1327201	chr6:112141732	T/C	cg08601457	chr6:112115117	FYN	0.41	4.83	0.44	5.33e-6	Schizophrenia;
THYM	cis	rs11122895	0.846	rs11692656	chr2:112442724	C/T	cg23262488	chr2:112468472	NA	0.62	8.16	0.64	1.37e-12	Allergic sensitization;
THYM	cis	rs9399401	0.667	rs6903424	chr6:142699948	A/C	cg03128060	chr6:142623767	GPR126	0.57	7.42	0.61	4.86e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg00786635	chr1:25594202	NA	0.92	7.28	0.6	9.7e-11	Erythrocyte sedimentation rate;
THYM	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg08975724	chr8:8085496	FLJ10661	-0.68	-5.48	-0.49	3.46e-7	Neuroticism;
THYM	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg26924012	chr15:45694286	SPATA5L1	1.03	9.3	0.69	5.23e-15	Homoarginine levels;
THYM	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg08885076	chr2:99613938	TSGA10	0.69	6.47	0.55	4.31e-9	Chronic sinus infection;
THYM	cis	rs854765	0.663	rs2236513	chr17:17747366	A/C	cg16928487	chr17:17741425	SREBF1	0.54	5.16	0.47	1.34e-6	Total body bone mineral density;
THYM	cis	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg07460842	chr6:66804631	NA	1.23	15.85	0.85	2.01e-28	Exhaled nitric oxide output;
THYM	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg10515332	chr4:99064459	C4orf37	-0.61	-4.94	-0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9486719	1.000	rs11152951	chr6:96894135	C/G	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg15744005	chr10:104629667	AS3MT	-0.84	-8.33	-0.65	6.07e-13	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs2898681	0.561	rs2200225	chr4:53738411	A/G	cg00791764	chr4:53727839	RASL11B	0.63	7.42	0.61	4.83e-11	Optic nerve measurement (cup area);
THYM	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.68	-5.92	-0.52	5.15e-8	Total body bone mineral density;
THYM	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg25918947	chr17:41365094	TMEM106A	-0.58	-4.95	-0.45	3.22e-6	Menopause (age at onset);
THYM	cis	rs3020340	0.817	rs7749650	chr6:152044872	A/T	cg22157087	chr6:152012887	ESR1	0.45	4.55	0.42	1.61e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs245880	0.740	rs245902	chr7:29194919	T/A	cg17163760	chr7:29186267	CPVL	-0.61	-4.93	-0.45	3.54e-6	Warfarin maintenance dose;
THYM	cis	rs1161098	0.767	rs1152883	chr12:67829814	T/G	cg20473420	chr12:67782441	NA	0.93	4.77	0.44	6.59e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs924712	0.514	rs421957	chr6:54795735	C/G	cg04690482	chr6:54711388	FAM83B	0.47	5.61	0.5	1.99e-7	Breast cancer;
THYM	cis	rs35883536	0.647	rs1995142	chr1:101041174	G/A	cg06223162	chr1:101003688	GPR88	0.83	7.06	0.59	2.67e-10	Monocyte count;
THYM	trans	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg08305652	chr11:111469057	NA	0.53	4.58	0.43	1.41e-5	Primary sclerosing cholangitis;
THYM	cis	rs9790314	0.521	rs13084746	chr3:161086038	G/A	cg03342759	chr3:160939853	NMD3	-0.71	-5.99	-0.52	3.81e-8	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg17366294	chr4:99064904	C4orf37	0.59	6.89	0.58	6.16e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.69	6.15	0.53	1.82e-8	Personality dimensions;
THYM	cis	rs4733781	0.871	rs7839155	chr8:131318869	G/A	cg16277922	chr8:131349729	ASAP1	0.7	5.03	0.46	2.28e-6	Tuberculosis;
THYM	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg13289132	chr10:30722225	MAP3K8	0.56	4.88	0.45	4.24e-6	Inflammatory bowel disease;
THYM	cis	rs1883415	0.853	rs2760141	chr6:24480897	C/T	cg00346970	chr6:24499591	ALDH5A1	0.34	4.62	0.43	1.21e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9972944	0.756	rs12600343	chr17:63764721	G/A	cg07283582	chr17:63770753	CCDC46	-0.69	-5.34	-0.48	6.25e-7	Total body bone mineral density;
THYM	cis	rs9543976	0.688	rs56084319	chr13:76110679	A/G	cg01531495	chr13:76123901	UCHL3	-0.98	-5.78	-0.51	9.41e-8	Diabetic retinopathy;
THYM	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg13852791	chr20:30311386	BCL2L1	0.68	4.95	0.45	3.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs1949733	1.000	rs3103067	chr4:8511223	A/G	cg11789530	chr4:8429930	ACOX3	0.74	6.02	0.53	3.26e-8	Response to antineoplastic agents;
THYM	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.62	-4.99	-0.46	2.7e-6	Height;
THYM	cis	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg06521331	chr12:34319734	NA	-0.72	-4.99	-0.46	2.68e-6	Resting heart rate;
THYM	cis	rs4523957	0.928	rs403553	chr17:2191260	C/T	cg16513277	chr17:2031491	SMG6	0.8	7.52	0.61	3e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg05962950	chr11:130786565	SNX19	0.84	7.29	0.6	9.11e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs66887589	0.748	rs28439855	chr4:120262256	G/A	cg13609457	chr4:120235615	NA	0.49	4.96	0.45	3.09e-6	Diastolic blood pressure;
THYM	cis	rs3126085	0.935	rs12405678	chr1:152195308	C/G	cg10321714	chr1:152280068	FLG	-0.74	-5.53	-0.49	2.82e-7	Atopic dermatitis;
THYM	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg10661904	chr17:79619235	PDE6G	-0.54	-4.79	-0.44	6.25e-6	Eye color traits;
THYM	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.58	-5.58	-0.5	2.3e-7	Longevity;Endometriosis;
THYM	cis	rs12765878	1.000	rs4918068	chr10:105644736	T/G	cg11005552	chr10:105648138	OBFC1	0.85	11.02	0.75	1.12e-18	Coronary artery disease;
THYM	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg11941060	chr3:133502564	NA	-0.82	-6.99	-0.58	3.8e-10	Iron status biomarkers;
THYM	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11644478	chr21:40555479	PSMG1	0.64	4.66	0.43	1.04e-5	Cognitive function;
THYM	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.58	5.03	0.46	2.3e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2340727	0.668	rs1503815	chr1:161838128	C/T	cg06514368	chr1:161719587	DUSP12	-0.78	-4.49	-0.42	2.04e-5	White blood cell count;Hematology traits;
THYM	cis	rs35264875	0.796	rs72930637	chr11:68869967	C/T	cg23845249	chr11:68861649	NA	0.49	5.21	0.47	1.09e-6	Blond vs. brown hair color;
THYM	cis	rs7100689	0.646	rs1538815	chr10:82137670	A/G	cg01528321	chr10:82214614	TSPAN14	0.79	6.01	0.52	3.47e-8	Post bronchodilator FEV1;
THYM	cis	rs9560113	0.573	rs9560133	chr13:112240013	C/A	cg15979348	chr13:112237479	NA	0.55	5.24	0.47	9.85e-7	Menarche (age at onset);
THYM	cis	rs7909074	0.714	rs10900129	chr10:45398609	G/C	cg05187965	chr10:45406764	TMEM72	-0.5	-4.77	-0.44	6.72e-6	Mean corpuscular volume;
THYM	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg11965913	chr1:205819406	PM20D1	0.91	9.68	0.7	8.07e-16	Menarche (age at onset);
THYM	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg18252515	chr7:66147081	NA	1.37	8.05	0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06873352	chr17:61820015	STRADA	0.56	5.6	0.5	2.12e-7	Height;
THYM	cis	rs3925075	0.966	rs7195915	chr16:31344455	A/G	cg02846316	chr16:31340340	ITGAM	0.58	6.06	0.53	2.7e-8	IgA nephropathy;
THYM	cis	rs1912528	0.783	rs769662	chr4:140868894	G/A	cg11128457	chr4:140864437	MAML3	0.48	5.25	0.47	9.09e-7	Educational attainment (years of education);
THYM	cis	rs7246967	0.604	rs8107322	chr19:22897432	A/C	cg05241461	chr19:22816980	ZNF492	0.6	4.66	0.43	1.05e-5	Bronchopulmonary dysplasia;
THYM	cis	rs988913	0.793	rs995851	chr6:54735594	G/A	cg19716238	chr6:54711378	FAM83B	0.52	5.04	0.46	2.27e-6	Menarche (age at onset);
THYM	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg19901468	chr14:105411992	AHNAK2	-0.81	-6.59	-0.56	2.48e-9	Rheumatoid arthritis;
THYM	cis	rs155076	1.000	rs566364	chr13:21837583	T/C	cg07022442	chr13:21864356	NA	0.71	4.66	0.43	1.03e-5	White matter hyperintensity burden;
THYM	cis	rs10779751	0.734	rs2791648	chr1:11132638	G/T	cg08854313	chr1:11322531	MTOR	0.85	6.82	0.57	8.38e-10	Body mass index;
THYM	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg04553112	chr3:125709451	NA	-0.67	-4.63	-0.43	1.15e-5	Blood pressure (smoking interaction);
THYM	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Gout;
THYM	cis	rs116095464	0.558	rs114607464	chr5:300468	C/T	cg22857025	chr5:266934	NA	-1.41	-8.94	-0.68	3.05e-14	Breast cancer;
THYM	cis	rs57920188	0.584	rs12080516	chr1:4089613	C/T	cg20703997	chr1:4087676	NA	0.85	5.76	0.51	1.04e-7	Interleukin-17 levels;
THYM	cis	rs4523957	0.928	rs4790071	chr17:2173184	A/G	cg16513277	chr17:2031491	SMG6	-0.82	-7.72	-0.62	1.17e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg19507638	chr5:93509721	C5orf36	-0.65	-4.54	-0.42	1.63e-5	Diabetic retinopathy;
THYM	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg22681709	chr2:178499509	PDE11A	-0.54	-5.12	-0.46	1.62e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs5769707	0.592	rs6009783	chr22:50011001	C/G	cg07959070	chr22:50026188	C22orf34	-0.28	-4.85	-0.45	4.85e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg03388043	chr17:80084554	CCDC57	0.73	6.11	0.53	2.19e-8	Life satisfaction;
THYM	cis	rs11756438	0.683	rs11754023	chr6:119005785	A/G	cg01113488	chr6:119027122	NA	0.56	4.5	0.42	1.92e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7572733	0.534	rs1518361	chr2:198812874	A/G	cg00792783	chr2:198669748	PLCL1	0.82	5.75	0.51	1.08e-7	Dermatomyositis;
THYM	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.42	0.49	4.44e-7	Height;
THYM	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg22166914	chr1:53195759	ZYG11B	0.77	7.6	0.62	2.04e-11	Monocyte count;
THYM	cis	rs4853012	0.887	rs2122290	chr2:74358901	C/T	cg05890377	chr2:74357713	NA	1.12	9.52	0.7	1.76e-15	Gestational age at birth (maternal effect);
THYM	cis	rs4589258	0.933	rs7118269	chr11:90427240	C/T	cg26138821	chr11:89956704	CHORDC1	0.68	5.71	0.51	1.29e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6684428	0.706	rs12119904	chr1:56327241	G/T	cg11651538	chr1:56320950	NA	-0.63	-4.97	-0.45	2.91e-6	Airflow obstruction;
THYM	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg05717871	chr11:638507	DRD4	-0.64	-5.11	-0.46	1.69e-6	Systemic lupus erythematosus;
THYM	cis	rs6430585	0.583	rs61253125	chr2:136618178	T/C	cg23851026	chr2:136556271	LCT	0.79	7.51	0.61	3.2e-11	Corneal structure;
THYM	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg10515332	chr4:99064459	C4orf37	0.71	5.67	0.5	1.51e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs748404	0.660	rs548704	chr15:43791706	A/C	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs7100689	0.784	rs2153455	chr10:82139732	T/C	cg01528321	chr10:82214614	TSPAN14	0.96	7.28	0.6	9.52e-11	Post bronchodilator FEV1;
THYM	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg12310025	chr6:25882481	NA	-0.71	-6.26	-0.54	1.11e-8	Intelligence (multi-trait analysis);
THYM	cis	rs13082711	0.689	rs34641383	chr3:27320210	G/A	cg02860705	chr3:27208620	NA	1.13	8.51	0.66	2.55e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs12216545	0.737	rs4339548	chr7:150229315	G/T	cg00323915	chr7:150264987	GIMAP4	-0.49	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.84e-8	Systolic blood pressure;
THYM	cis	rs7511006	0.893	rs760743	chr22:50647375	C/T	cg11077631	chr22:50617003	PANX2	-0.55	-6.16	-0.53	1.78e-8	Obesity-related traits;
THYM	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg13683864	chr3:40499215	RPL14	0.86	8.25	0.65	9.03e-13	Renal cell carcinoma;
THYM	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.54	6.01	0.52	3.39e-8	Autism spectrum disorder or schizophrenia;
THYM	cis	rs57590327	0.555	rs13088603	chr3:81791167	A/G	cg07356753	chr3:81810745	GBE1	-0.88	-6.67	-0.56	1.67e-9	Extraversion;
THYM	cis	rs28735056	0.563	rs55642704	chr18:77688124	C/T	cg20368463	chr18:77673604	PQLC1	-0.64	-4.6	-0.43	1.3e-5	Schizophrenia;
THYM	cis	rs2504916	0.784	rs3004077	chr6:160767443	T/C	cg19643109	chr6:160697625	NA	-0.63	-4.46	-0.42	2.24e-5	Response to hepatitis C treatment;
THYM	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg19774624	chr17:42201019	HDAC5	-0.85	-8.23	-0.65	9.73e-13	Total body bone mineral density;
THYM	cis	rs34638657	0.872	rs6420436	chr16:82186719	C/G	cg07307142	chr16:82071433	HSD17B2	-1.0	-7.81	-0.63	7.4e-12	Lung adenocarcinoma;
THYM	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg20290983	chr6:43655470	MRPS18A	1.18	7.85	0.63	6.13e-12	IgG glycosylation;
THYM	cis	rs9467711	0.790	rs41266839	chr6:26409890	G/C	cg16898833	chr6:26189333	HIST1H4D	1.3	4.47	0.42	2.14e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg00339695	chr16:24857497	SLC5A11	-0.7	-6.31	-0.54	8.96e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg09877947	chr5:131593287	PDLIM4	0.57	4.61	0.43	1.24e-5	Blood metabolite levels;
THYM	cis	rs8063160	0.740	rs35850949	chr16:89720724	C/A	cg07984980	chr16:89898383	SPIRE2	1.49	6.02	0.53	3.3e-8	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs2522056	1.000	rs10900807	chr5:131757480	G/C	cg24060327	chr5:131705240	SLC22A5	0.73	4.5	0.42	1.92e-5	Lymphocyte counts;Fibrinogen;
THYM	cis	rs10799590	1.000	rs12130499	chr1:224836514	A/G	cg01808320	chr1:224927238	CNIH3	0.55	5.01	0.46	2.51e-6	Opioid dependence;
THYM	cis	rs11809207	0.723	rs57653638	chr1:26524401	A/G	cg03844060	chr1:26490628	NA	0.68	4.87	0.45	4.36e-6	Height;
THYM	cis	rs4930776	0.593	rs365224	chr12:5757331	A/G	cg02086166	chr12:5775618	ANO2	0.59	4.94	0.45	3.37e-6	Plasma clusterin levels;
THYM	cis	rs57244997	0.860	rs9458425	chr6:162376946	C/T	cg17173639	chr6:162384350	PARK2	-0.79	-4.69	-0.43	9.1e-6	Mosquito bite size;
THYM	cis	rs10819861	0.645	rs10819835	chr9:98858665	C/T	cg14508093	chr9:98862825	NA	-0.24	-4.64	-0.43	1.12e-5	Electrocardiographic traits;
THYM	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	6.47	0.55	4.18e-9	Platelet count;
THYM	cis	rs4065321	0.609	rs8075668	chr17:38137623	C/T	cg25038082	chr17:37896074	GRB7	-0.59	-4.8	-0.44	5.85e-6	White blood cell count (basophil);White blood cell count;
THYM	cis	rs3540	0.574	rs8035980	chr15:90974390	C/G	cg22089800	chr15:90895588	ZNF774	0.7	5.47	0.49	3.67e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs7084402	0.967	rs1658425	chr10:60331547	G/C	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg23428387	chr22:49814324	NA	-0.62	-6.38	-0.55	6.27e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4363385	0.720	rs1134220	chr1:152976306	T/G	cg13444842	chr1:152974279	SPRR3	-0.59	-4.68	-0.43	9.41e-6	Inflammatory skin disease;
THYM	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg23422044	chr7:1970798	MAD1L1	-0.95	-6.58	-0.56	2.51e-9	Bipolar disorder;
THYM	cis	rs36051895	0.587	rs7036761	chr9:5198781	A/C	cg02405213	chr9:5042618	JAK2	0.89	8.05	0.64	2.32e-12	Pediatric autoimmune diseases;
THYM	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg10523679	chr1:76189770	ACADM	0.9	9.47	0.7	2.2e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg02725872	chr8:58115012	NA	-1.11	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg27490568	chr2:178487706	NA	0.6	5.3	0.48	7.35e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7586879	1.000	rs12713419	chr2:25121853	G/A	cg01884057	chr2:25150051	NA	0.62	5.94	0.52	4.59e-8	Body mass index;
THYM	trans	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg11965913	chr1:205819406	PM20D1	1.04	12.57	0.79	6.3e-22	Menarche (age at onset);
THYM	cis	rs7255045	0.752	rs2242514	chr19:12982798	C/T	cg04657146	chr19:12876947	HOOK2	0.69	4.45	0.42	2.36e-5	Mean corpuscular volume;
THYM	cis	rs9814567	0.806	rs4245903	chr3:134317074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-7.88	-0.63	5.49e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7119	0.717	rs62009070	chr15:77817884	G/C	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.72	0.51	1.23e-7	Lung cancer in ever smokers;
THYM	cis	rs3820068	0.581	rs6429762	chr1:15945595	A/C	cg13390004	chr1:15929781	NA	0.63	4.87	0.45	4.53e-6	Systolic blood pressure;
THYM	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg16615211	chr3:44902933	MIR564;TMEM42	0.55	6.03	0.53	3.12e-8	Depressive symptoms;
THYM	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11644478	chr21:40555479	PSMG1	-0.79	-6.78	-0.57	1e-9	Cognitive function;
THYM	cis	rs9388451	0.505	rs6920965	chr6:126179111	G/A	cg10911889	chr6:126070802	HEY2	0.64	4.53	0.42	1.7e-5	Brugada syndrome;
THYM	trans	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg18335740	chr13:41363409	SLC25A15	0.81	8.22	0.64	1.03e-12	Lewy body disease;
THYM	cis	rs9486719	0.947	rs72932805	chr6:96902933	T/G	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg23482746	chr15:76478102	C15orf27	-0.42	-4.97	-0.45	2.91e-6	Blood metabolite levels;
THYM	cis	rs41005	1.000	rs193931	chr2:8107435	A/G	cg03155496	chr2:8117019	LOC339788	-0.97	-9.52	-0.7	1.76e-15	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg10661904	chr17:79619235	PDE6G	-0.66	-6.41	-0.55	5.55e-9	Eye color traits;
THYM	cis	rs11822910	1.000	rs2439448	chr11:57199211	T/C	cg00522883	chr11:57194120	SLC43A3	0.62	4.78	0.44	6.42e-6	Platelet distribution width;
THYM	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg02788857	chr8:22132959	PIWIL2	0.58	5.36	0.48	5.94e-7	Hypertriglyceridemia;
THYM	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06634786	chr22:41940651	POLR3H	-0.62	-4.83	-0.44	5.24e-6	Vitiligo;
THYM	cis	rs2806561	0.765	rs2776815	chr1:23510584	C/T	cg12483005	chr1:23474871	LUZP1	-0.59	-6.31	-0.54	9.03e-9	Height;
THYM	cis	rs4851266	0.933	rs6709656	chr2:100806719	A/G	cg07810366	chr2:100720526	AFF3	-0.34	-4.46	-0.42	2.26e-5	Educational attainment;
THYM	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg06636001	chr8:8085503	FLJ10661	-0.75	-6.51	-0.56	3.61e-9	Mood instability;
THYM	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg02527881	chr3:46936655	PTH1R	0.68	7.05	0.59	2.82e-10	Colorectal cancer;
THYM	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg22307029	chr19:49891270	CCDC155	0.65	5.95	0.52	4.41e-8	Multiple sclerosis;
THYM	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.78	-6.74	-0.57	1.22e-9	Intelligence (multi-trait analysis);
THYM	cis	rs2108225	0.967	rs6979054	chr7:107447488	A/C	cg18560240	chr7:107437656	SLC26A3	-0.79	-5.67	-0.5	1.52e-7	Ulcerative colitis;
THYM	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg10047753	chr17:41438598	NA	1.18	10.87	0.74	2.37e-18	Menopause (age at onset);
THYM	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg08859206	chr1:53392774	SCP2	-0.51	-5.47	-0.49	3.67e-7	Monocyte count;
THYM	cis	rs17407555	0.738	rs56143194	chr4:10067535	C/T	cg13000635	chr4:9523653	NA	0.66	4.52	0.42	1.78e-5	Schizophrenia (age at onset);
THYM	cis	rs7172809	0.573	rs7496431	chr15:77452054	T/C	cg22256960	chr15:77711686	NA	-0.64	-4.76	-0.44	6.83e-6	Glucose homeostasis traits;
THYM	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2976388	1.000	rs2976388	chr8:143760256	G/A	cg13446199	chr8:143762866	PSCA	0.53	5.86	0.52	6.72e-8	Urinary tract infection frequency;
THYM	cis	rs2273669	0.667	rs17070139	chr6:109358345	C/G	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg01616529	chr11:638424	DRD4	-0.74	-5.68	-0.5	1.45e-7	Systemic lupus erythematosus;
THYM	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg27534772	chr1:16042836	PLEKHM2	0.54	5.92	0.52	5.1e-8	Systolic blood pressure;
THYM	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg04520793	chr17:42248056	ASB16	-0.35	-4.98	-0.45	2.85e-6	Total body bone mineral density;
THYM	cis	rs1883415	0.648	rs61072898	chr6:24505647	C/T	cg00346970	chr6:24499591	ALDH5A1	0.48	6.11	0.53	2.17e-8	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Educational attainment;
THYM	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg00990874	chr7:1149470	C7orf50	-0.65	-4.96	-0.45	3.05e-6	Bronchopulmonary dysplasia;
THYM	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11644478	chr21:40555479	PSMG1	0.95	7.08	0.59	2.45e-10	Cognitive function;
THYM	cis	rs4803468	1.000	rs2231940	chr19:41944237	T/C	cg09537434	chr19:41945824	ATP5SL	1.04	9.33	0.69	4.41e-15	Height;
THYM	cis	rs36051895	0.626	rs10815149	chr9:5063701	T/C	cg02405213	chr9:5042618	JAK2	-1.04	-10.91	-0.75	1.87e-18	Pediatric autoimmune diseases;
THYM	cis	rs17006441	0.932	rs62252223	chr3:69883525	G/T	cg18496212	chr3:69797108	MITF	0.65	6.36	0.55	7.15e-9	Hemoglobin concentration;
THYM	cis	rs854765	0.624	rs4925116	chr17:17731200	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.59	-4.97	-0.45	2.95e-6	Total body bone mineral density;
THYM	cis	rs921968	0.643	rs590771	chr2:219369851	C/T	cg02176678	chr2:219576539	TTLL4	0.68	6.71	0.57	1.42e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9788682	0.747	rs2915695	chr15:78739471	T/C	cg18825076	chr15:78729989	IREB2	-0.7	-5.36	-0.48	5.71e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg27171569	chr16:83987465	OSGIN1	0.65	6.44	0.55	4.83e-9	Pursuit maintenance gain;
THYM	trans	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2039659	0.641	rs1556772	chr13:86286169	C/T	cg25308322	chr13:86268291	NA	0.61	5.14	0.47	1.45e-6	Blood osmolality (transformed sodium);
THYM	cis	rs16857609	0.564	rs13388148	chr2:218281500	T/G	cg15335768	chr2:218268053	DIRC3	-0.49	-7.12	-0.59	2.08e-10	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg23815491	chr16:72088622	HP	0.66	5.05	0.46	2.17e-6	Fibrinogen levels;
THYM	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg06009448	chr7:1102226	C7orf50	0.53	5.59	0.5	2.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg11266682	chr4:10021025	SLC2A9	0.73	11.88	0.77	1.74e-20	Bone mineral density;
THYM	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg24531977	chr5:56204891	C5orf35	-0.69	-5.41	-0.49	4.63e-7	Coronary artery disease;
THYM	cis	rs7580658	0.676	rs58475809	chr2:128002650	A/G	cg09152259	chr2:128156114	NA	-0.34	-4.47	-0.42	2.16e-5	Protein C levels;
THYM	cis	rs10504073	0.584	rs115370638	chr8:49916452	A/G	cg00325661	chr8:49890786	NA	1.02	10.3	0.73	3.73e-17	Blood metabolite ratios;
THYM	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg20387954	chr3:183756860	HTR3D	0.78	7.12	0.59	2.1e-10	Anterior chamber depth;
THYM	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg05738196	chr6:26577821	NA	-0.57	-4.55	-0.42	1.61e-5	Schizophrenia;
THYM	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg22709100	chr7:91322751	NA	0.68	5.41	0.49	4.62e-7	Breast cancer;
THYM	cis	rs4363385	0.510	rs6693927	chr1:153044009	G/A	cg13444842	chr1:152974279	SPRR3	-0.6	-4.74	-0.44	7.54e-6	Inflammatory skin disease;
THYM	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg16586182	chr3:47516702	SCAP	-0.65	-5.62	-0.5	1.94e-7	Colorectal cancer;
THYM	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg07212818	chr11:638076	DRD4	-0.79	-6.69	-0.57	1.57e-9	Systemic lupus erythematosus;
THYM	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg13866156	chr1:1669148	SLC35E2	-0.72	-7.32	-0.6	7.77e-11	Body mass index;
THYM	cis	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg19847130	chr8:10466454	RP1L1	0.53	5.02	0.46	2.43e-6	Neuroticism;
THYM	cis	rs3796619	1.000	rs11247973	chr4:1094314	G/A	cg27284194	chr4:1044797	NA	0.55	4.97	0.45	2.94e-6	Recombination rate (males);
THYM	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg08411435	chr17:37784024	PPP1R1B	-0.32	-4.48	-0.42	2.08e-5	Asthma;
THYM	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg08999081	chr20:33150536	PIGU	0.76	6.73	0.57	1.27e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs59698941	0.943	rs59484796	chr5:132293543	C/T	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg09033563	chr22:24373618	LOC391322	0.6	5.38	0.48	5.35e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg18876405	chr7:65276391	NA	-0.55	-4.63	-0.43	1.18e-5	Aortic root size;
THYM	cis	rs7575217	0.921	rs2871393	chr2:101770430	C/G	cg23907051	chr2:101730305	TBC1D8	-0.36	-4.74	-0.44	7.62e-6	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs6860806	0.507	rs270614	chr5:131640813	G/A	cg24060327	chr5:131705240	SLC22A5	-0.78	-6.15	-0.53	1.84e-8	Breast cancer;
THYM	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg03609598	chr5:56110824	MAP3K1	-0.89	-6.07	-0.53	2.63e-8	Initial pursuit acceleration;
THYM	cis	rs6732160	0.809	rs13416592	chr2:73365056	C/T	cg24220031	chr2:73402428	NA	-0.7	-7.1	-0.59	2.27e-10	Intelligence (multi-trait analysis);
THYM	cis	rs35883536	1.000	rs4243810	chr1:101139914	T/C	cg06223162	chr1:101003688	GPR88	0.67	5.18	0.47	1.25e-6	Monocyte count;
THYM	cis	rs13315871	0.929	rs71311854	chr3:58319159	G/A	cg00563845	chr3:58318305	PXK	0.59	5.02	0.46	2.37e-6	Cholesterol, total;
THYM	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	5.66	0.5	1.63e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg00012203	chr2:219082015	ARPC2	0.55	4.77	0.44	6.67e-6	Colorectal cancer;
THYM	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.94	0.58	4.68e-10	Prudent dietary pattern;
THYM	cis	rs6988636	1.000	rs7002021	chr8:124185250	G/A	cg22384356	chr8:124195192	FAM83A	-0.86	-5.15	-0.47	1.41e-6	Urinary uromodulin levels;
THYM	cis	rs4589258	0.933	rs7117293	chr11:90396387	C/A	cg26138821	chr11:89956704	CHORDC1	0.71	6.0	0.52	3.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg08807101	chr21:30365312	RNF160	-0.67	-4.87	-0.45	4.5e-6	Dental caries;
THYM	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg18758796	chr5:131593413	PDLIM4	-0.5	-4.72	-0.44	8.15e-6	Breast cancer;
THYM	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs4273100	0.688	rs1467028	chr17:19174874	T/C	cg25447019	chr17:19030144	GRAPL	-0.79	-6.19	-0.54	1.49e-8	Schizophrenia;
THYM	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg26384229	chr12:38710491	ALG10B	-0.89	-9.05	-0.68	1.77e-14	Heart rate;
THYM	cis	rs12935418	0.672	rs12448656	chr16:81042481	G/T	cg16651780	chr16:81037892	C16orf61	0.87	6.11	0.53	2.15e-8	Mean corpuscular volume;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg01973725	chr5:80608537	RNU5E;RNU5D;ZCCHC9	0.96	6.86	0.58	7.04e-10	Depressive symptoms;
THYM	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg27490568	chr2:178487706	NA	0.6	5.3	0.48	7.61e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7107174	1.000	rs10899457	chr11:78001163	T/A	cg02023728	chr11:77925099	USP35	0.65	5.83	0.51	7.52e-8	Testicular germ cell tumor;
THYM	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.51	-0.66	2.53e-13	Monocyte count;
THYM	cis	rs7709377	0.544	rs6892663	chr5:115699265	A/G	cg23915769	chr5:115297488	LVRN	-0.76	-4.48	-0.42	2.09e-5	Metabolite levels  (X-11787);
THYM	cis	rs6032067	0.777	rs62208416	chr20:43803226	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.41	-0.65	4.05e-13	Blood protein levels;
THYM	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg18811423	chr2:55921094	PNPT1	-0.69	-6.41	-0.55	5.6e-9	Metabolic syndrome;
THYM	cis	rs17174870	0.955	rs76944504	chr2:112745774	G/A	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg20283391	chr11:68216788	NA	-0.71	-5.27	-0.48	8.44e-7	Total body bone mineral density;
THYM	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg22535103	chr8:58192502	C8orf71	-0.93	-5.25	-0.47	9.15e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	5.27	0.48	8.48e-7	Total body bone mineral density;
THYM	cis	rs4919687	0.550	rs12775883	chr10:104485301	G/A	cg05855489	chr10:104503620	C10orf26	0.71	5.46	0.49	3.85e-7	Colorectal cancer;
THYM	cis	rs7786808	0.579	rs55701656	chr7:158188812	G/A	cg15440763	chr7:158190612	PTPRN2	0.49	4.61	0.43	1.24e-5	Obesity-related traits;
THYM	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg18512352	chr11:47633146	NA	-0.5	-6.15	-0.53	1.83e-8	Subjective well-being;
THYM	cis	rs4474465	1.000	rs12280198	chr11:78161361	C/T	cg19901956	chr11:77921274	USP35	-0.65	-4.48	-0.42	2.05e-5	Alzheimer's disease (survival time);
THYM	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg17178900	chr1:205818956	PM20D1	-0.57	-4.51	-0.42	1.83e-5	Parkinson's disease;
THYM	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.51	4.7	0.43	8.85e-6	Birth weight;
THYM	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Electroencephalogram traits;
THYM	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.1	-0.53	2.29e-8	Crohn's disease;
THYM	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs9467711	0.591	rs7748167	chr6:25904652	A/C	cg12826209	chr6:26865740	GUSBL1	0.97	4.89	0.45	4.07e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg21394778	chr1:3037102	PRDM16	0.46	4.47	0.42	2.12e-5	Height;
THYM	cis	rs9420	0.961	rs11229148	chr11:57621460	A/T	cg19752551	chr11:57585705	CTNND1	-0.73	-7.98	-0.63	3.28e-12	Schizophrenia;
THYM	cis	rs36051895	0.626	rs12349785	chr9:5076613	G/C	cg02405213	chr9:5042618	JAK2	-1.03	-11.11	-0.75	7.02e-19	Pediatric autoimmune diseases;
THYM	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg09904177	chr6:26538194	HMGN4	0.64	5.4	0.48	4.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9534288	0.797	rs9526134	chr13:46618046	G/T	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs7582180	0.838	rs13024601	chr2:100902032	C/T	cg14675211	chr2:100938903	LONRF2	0.65	5.52	0.49	2.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.65	-5.09	-0.46	1.78e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9549260	0.816	rs7324090	chr13:41253958	A/T	cg21288729	chr13:41239152	FOXO1	0.72	5.74	0.51	1.15e-7	Red blood cell count;
THYM	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg27129171	chr3:47204927	SETD2	0.69	6.56	0.56	2.84e-9	Colorectal cancer;
THYM	cis	rs7851660	0.935	rs12347191	chr9:100619719	C/T	cg13688889	chr9:100608707	NA	-0.85	-7.42	-0.61	4.87e-11	Strep throat;
THYM	cis	rs988913	1.000	rs1503135	chr6:54841672	C/T	cg04690482	chr6:54711388	FAM83B	0.46	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	cis	rs7107174	0.901	rs10899473	chr11:78042983	A/C	cg02023728	chr11:77925099	USP35	0.64	6.32	0.54	8.48e-9	Testicular germ cell tumor;
THYM	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg08773314	chr2:239334832	ASB1	-0.64	-9.92	-0.71	2.51e-16	Multiple system atrophy;
THYM	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg17063962	chr7:91808500	NA	-1.1	-11.62	-0.77	5.94e-20	Breast cancer;
THYM	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg17063962	chr7:91808500	NA	1.01	10.41	0.73	2.19e-17	Breast cancer;
THYM	cis	rs7727544	0.788	rs270613	chr5:131640583	A/G	cg24060327	chr5:131705240	SLC22A5	-0.77	-5.59	-0.5	2.18e-7	Blood metabolite levels;
THYM	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg18402987	chr7:1209562	NA	1.26	7.82	0.63	7.22e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.71	-5.27	-0.48	8.64e-7	Prostate cancer;
THYM	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.84e-8	Systolic blood pressure;
THYM	cis	rs782590	0.721	rs782641	chr2:55929294	C/T	cg03859395	chr2:55845619	SMEK2	0.57	4.83	0.44	5.19e-6	Metabolic syndrome;
THYM	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4732038	0.510	rs10275567	chr7:134272598	C/T	cg06906464	chr7:134288099	NA	0.51	5.0	0.46	2.59e-6	Longevity;
THYM	cis	rs9326248	0.539	rs10892058	chr11:116876621	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.62	4.97	0.45	3.01e-6	Blood protein levels;
THYM	cis	rs2712184	0.873	rs1548945	chr2:217665788	T/C	cg05032264	chr2:217675019	NA	-0.56	-4.62	-0.43	1.23e-5	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs6087990	0.899	rs998382	chr20:31384136	C/T	cg13636640	chr20:31349939	DNMT3B	-0.92	-9.97	-0.71	1.94e-16	Ulcerative colitis;
THYM	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs4737010	0.570	rs10112594	chr8:41645565	C/T	cg08923054	chr8:41654455	ANK1	0.8	4.89	0.45	4.05e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
THYM	cis	rs9399401	0.626	rs7756434	chr6:142775295	A/G	cg03128060	chr6:142623767	GPR126	0.65	8.54	0.66	2.17e-13	Chronic obstructive pulmonary disease;
THYM	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg26769984	chr7:1090371	C7orf50	0.83	5.35	0.48	6.11e-7	Bronchopulmonary dysplasia;
THYM	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.68	-4.98	-0.45	2.88e-6	Height;
THYM	cis	rs9653442	0.593	rs7597861	chr2:100853187	G/A	cg08017756	chr2:100939284	LONRF2	-0.68	-5.11	-0.46	1.67e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg23682913	chr1:2080710	PRKCZ	0.64	5.78	0.51	9.66e-8	Height;
THYM	cis	rs778371	0.723	rs1022329	chr2:233591239	T/C	cg08000102	chr2:233561755	GIGYF2	0.83	7.52	0.61	3.07e-11	Schizophrenia;
THYM	cis	rs1007190	0.881	rs75199539	chr17:42930246	A/C	cg15406952	chr17:42872593	NA	0.75	4.68	0.43	9.49e-6	DNA methylation (variation);
THYM	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg18404041	chr3:52824283	ITIH1	-0.52	-5.01	-0.46	2.49e-6	Bipolar disorder;
THYM	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg09307838	chr4:120376055	NA	0.71	5.07	0.46	1.98e-6	Corneal astigmatism;
THYM	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg19507638	chr5:93509721	C5orf36	-0.68	-4.57	-0.42	1.49e-5	Diabetic retinopathy;
THYM	cis	rs1065852	0.526	rs9611711	chr22:42410695	G/A	cg01059385	chr22:42394853	WBP2NL	0.57	4.66	0.43	1.04e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg02018176	chr4:1364513	KIAA1530	0.57	4.46	0.42	2.23e-5	Obesity-related traits;
THYM	cis	rs807669	0.903	rs807666	chr22:19160549	C/T	cg02655711	chr22:19163373	SLC25A1	0.95	11.66	0.77	5.07e-20	Metabolite levels;
THYM	cis	rs9399401	0.626	rs7776356	chr6:142777029	A/G	cg03128060	chr6:142623767	GPR126	0.65	8.44	0.65	3.5e-13	Chronic obstructive pulmonary disease;
THYM	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg11764359	chr7:65958608	NA	0.62	4.73	0.44	7.94e-6	Aortic root size;
THYM	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.85	-7.43	-0.61	4.58e-11	Monocyte percentage of white cells;
THYM	cis	rs1642645	0.915	rs6696291	chr1:42500421	C/T	cg10197057	chr1:42612518	NA	-0.45	-4.84	-0.44	5.05e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg27129171	chr3:47204927	SETD2	0.71	5.89	0.52	5.92e-8	Birth weight;
THYM	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg22117172	chr7:91764530	CYP51A1	0.37	4.72	0.44	8.16e-6	Breast cancer;
THYM	cis	rs11195062	0.766	rs1935465	chr10:112029300	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.46	-4.65	-0.43	1.07e-5	Multiple myeloma;
THYM	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg05283184	chr6:79620031	NA	-0.92	-9.08	-0.68	1.52e-14	Intelligence (multi-trait analysis);
THYM	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.47	-4.64	-0.43	1.13e-5	Crohn's disease;
THYM	cis	rs2798269	0.604	rs6490662	chr13:22153280	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.61	-4.64	-0.43	1.12e-5	PR segment;
THYM	cis	rs13064411	0.696	rs6798938	chr3:113218206	C/T	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03264133	chr6:25882463	NA	0.74	5.74	0.51	1.11e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg07690219	chr3:49449608	TCTA;RHOA	0.69	4.57	0.42	1.47e-5	Menarche (age at onset);
THYM	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg19761014	chr17:28927070	LRRC37B2	0.8	4.73	0.44	7.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg22681709	chr2:178499509	PDE11A	-0.51	-4.83	-0.44	5.16e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg26038318	chr20:34205095	SPAG4	0.63	5.16	0.47	1.36e-6	Total cholesterol levels;
THYM	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs897984	0.646	rs9938088	chr16:30830004	G/A	cg02466173	chr16:30829666	NA	-0.56	-4.84	-0.44	5.09e-6	Dementia with Lewy bodies;
THYM	cis	rs425535	0.757	rs352007	chr4:74847292	G/C	cg07868155	chr4:74864709	CXCL5	0.65	5.47	0.49	3.65e-7	Blood protein levels;
THYM	cis	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg21775007	chr8:11205619	TDH	-0.7	-5.45	-0.49	4.05e-7	Retinal vascular caliber;
THYM	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg03806693	chr22:41940476	POLR3H	-1.19	-10.43	-0.73	2.03e-17	Vitiligo;
THYM	cis	rs236352	0.521	rs2293393	chr6:36884042	A/G	cg03410223	chr6:36853544	C6orf89	0.72	6.0	0.52	3.51e-8	Heart rate;
THYM	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg27129171	chr3:47204927	SETD2	-0.73	-6.68	-0.57	1.61e-9	Colorectal cancer;
THYM	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg21640587	chr11:117668038	DSCAML1	1.1	9.64	0.7	9.84e-16	Myopia;
THYM	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs2229238	0.911	rs73020246	chr1:154485640	A/G	cg21262032	chr1:154437693	IL6R	-0.6	-5.39	-0.48	5.21e-7	Coronary heart disease;
THYM	cis	rs2413151	0.655	rs715572	chr22:33234931	C/T	cg18989477	chr22:32435639	NA	0.53	4.68	0.43	9.4e-6	Blood protein levels;
THYM	cis	rs1975974	0.549	rs4889746	chr17:21745187	T/C	cg18423549	chr17:21743878	NA	-0.68	-5.56	-0.5	2.45e-7	Psoriasis;
THYM	cis	rs946836	0.537	rs10890513	chr1:48380745	T/C	cg18376692	chr1:48452465	NA	-0.5	-4.97	-0.45	2.94e-6	White matter integrity;
THYM	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg11764359	chr7:65958608	NA	0.87	7.45	0.61	4.16e-11	Aortic root size;
THYM	cis	rs854765	0.624	rs8078756	chr17:17744725	T/C	cg04398451	chr17:18023971	MYO15A	0.85	7.72	0.62	1.15e-11	Total body bone mineral density;
THYM	cis	rs7177699	0.550	rs7182716	chr15:79123753	T/C	cg15571903	chr15:79123663	NA	0.58	6.56	0.56	2.77e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs800586	0.548	rs3808478	chr8:116678277	C/T	cg04656070	chr8:116661063	TRPS1	0.51	5.89	0.52	5.91e-8	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg22875332	chr1:76189707	ACADM	0.8	6.69	0.57	1.54e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs10924970	0.781	rs10802590	chr1:235444051	A/G	cg26050004	chr1:235667680	B3GALNT2	0.6	4.58	0.43	1.4e-5	Asthma;
THYM	cis	rs921968	0.565	rs3755045	chr2:219609162	T/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7851660	0.933	rs894673	chr9:100612270	A/T	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg11764359	chr7:65958608	NA	0.78	6.22	0.54	1.33e-8	Aortic root size;
THYM	cis	rs12791968	0.917	rs11038238	chr11:45002010	A/G	cg11846598	chr11:44996168	LOC221122	-0.94	-8.04	-0.64	2.5e-12	Inhibitory control;
THYM	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs490234	0.588	rs34983978	chr9:128169170	G/A	cg14078157	chr9:128172775	NA	-1.01	-8.74	-0.67	7.95e-14	Mean arterial pressure;
THYM	cis	rs10887741	0.966	rs7904314	chr10:89421266	G/A	cg13926569	chr10:89418898	PAPSS2	-0.61	-6.58	-0.56	2.6e-9	Exercise (leisure time);
THYM	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg03877680	chr5:178157825	ZNF354A	0.66	4.61	0.43	1.26e-5	Neutrophil percentage of white cells;
THYM	cis	rs2811415	0.627	rs9289325	chr3:127779693	A/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs4803468	1.000	rs284663	chr19:41932612	C/T	cg09537434	chr19:41945824	ATP5SL	-1.02	-8.91	-0.67	3.55e-14	Height;
THYM	cis	rs6541297	0.645	rs4846918	chr1:230300586	A/G	cg20703242	chr1:230279135	GALNT2	-0.85	-4.69	-0.43	9.22e-6	Coronary artery disease;
THYM	cis	rs9866391	0.607	rs6440003	chr3:141094209	A/G	cg13411656	chr3:141121016	ZBTB38	0.34	5.12	0.47	1.6e-6	Myopia;
THYM	cis	rs7512552	0.839	rs11577600	chr1:150407443	G/A	cg15654264	chr1:150340011	RPRD2	0.45	5.32	0.48	7.01e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs6876348	0.544	rs257897	chr5:128314092	G/A	cg02841155	chr5:128301328	SLC27A6	-0.5	-4.86	-0.45	4.54e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.79	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs7084402	0.967	rs1658478	chr10:60289551	C/T	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg05283184	chr6:79620031	NA	-0.94	-9.26	-0.69	6.41e-15	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.75	-0.44	7.15e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg00074818	chr8:8560427	CLDN23	0.59	5.47	0.49	3.61e-7	Obesity-related traits;
THYM	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg11871910	chr12:69753446	YEATS4	0.76	6.18	0.54	1.6e-8	Blood protein levels;
THYM	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg00339695	chr16:24857497	SLC5A11	-0.68	-5.95	-0.52	4.37e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7336332	0.598	rs9581850	chr13:28012265	A/G	cg22138327	chr13:27999177	GTF3A	0.62	4.62	0.43	1.21e-5	Weight;
THYM	cis	rs6032067	0.586	rs13044116	chr20:43754444	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.67	-5.94	-0.52	4.77e-8	Blood protein levels;
THYM	cis	rs3540	0.533	rs7495080	chr15:91056681	G/A	cg22089800	chr15:90895588	ZNF774	-0.71	-5.41	-0.49	4.74e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg25554036	chr4:6271136	WFS1	0.59	5.47	0.49	3.68e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs6700896	0.864	rs12030956	chr1:66115298	G/T	cg04111102	chr1:66153794	NA	0.55	5.23	0.47	9.89e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.27	10.84	0.74	2.66e-18	Platelet count;
THYM	cis	rs28595532	0.841	rs115209862	chr4:119742225	G/A	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11644478	chr21:40555479	PSMG1	1.1	9.84	0.71	3.61e-16	Cognitive function;
THYM	cis	rs1061377	1.000	rs7694760	chr4:39128101	A/T	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg26446133	chr18:72167187	CNDP2	-0.95	-7.65	-0.62	1.65e-11	Refractive error;
THYM	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg22709100	chr7:91322751	NA	0.66	5.21	0.47	1.1e-6	Breast cancer;
THYM	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs12752838	0.777	rs11590606	chr1:8917669	C/T	cg10211414	chr1:8875053	RERE	-0.66	-6.3	-0.54	9.13e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	trans	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg02527881	chr3:46936655	PTH1R	-0.66	-6.44	-0.55	4.86e-9	Colorectal cancer;
THYM	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg10360139	chr7:1886902	MAD1L1	-0.58	-5.1	-0.46	1.72e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs28595532	0.764	rs56359736	chr4:119769689	G/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg16230307	chr14:35515116	FAM177A1	0.95	5.92	0.52	5.06e-8	Psoriasis;
THYM	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504073	0.584	rs4873092	chr8:49974053	T/C	cg00325661	chr8:49890786	NA	1.06	10.54	0.73	1.17e-17	Blood metabolite ratios;
THYM	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-8.1	-0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg02478829	chr6:26598070	ABT1	-0.34	-4.56	-0.42	1.55e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2730245	0.527	rs2788470	chr7:158649801	G/T	cg11984989	chr7:158649758	WDR60	1.02	8.57	0.66	1.9e-13	Height;
THYM	cis	rs4790312	0.875	rs9901671	chr17:1978484	T/C	cg15816464	chr17:2026533	SMG6	0.38	4.93	0.45	3.45e-6	Left atrial antero-posterior diameter;
THYM	cis	rs995000	0.931	rs1627591	chr1:62989807	C/T	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg01699819	chr7:1052092	C7orf50	-0.52	-4.64	-0.43	1.14e-5	Bronchopulmonary dysplasia;
THYM	cis	rs1878931	0.559	rs11643501	chr16:3392752	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.69	4.98	0.45	2.87e-6	Body mass index (adult);
THYM	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg05347473	chr6:146136440	FBXO30	0.59	4.63	0.43	1.14e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg24874828	chr4:187887005	NA	-0.72	-7.44	-0.61	4.48e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg18252515	chr7:66147081	NA	-0.84	-6.48	-0.55	4.09e-9	Corneal structure;
THYM	cis	rs4790333	0.677	rs2447099	chr17:2268139	G/C	cg27406664	chr17:2294951	MNT	0.53	4.67	0.43	9.8e-6	Proinsulin levels;
THYM	cis	rs6947395	0.696	rs17363468	chr7:69452115	C/T	cg10619644	chr7:69149951	AUTS2	0.83	5.3	0.48	7.58e-7	Body mass index;
THYM	cis	rs10186029	0.509	rs6435755	chr2:213941131	C/T	cg08319019	chr2:214017104	IKZF2	-0.63	-4.73	-0.44	7.94e-6	Systemic sclerosis;
THYM	cis	rs9796	0.870	rs2925345	chr15:41311799	T/C	cg18705301	chr15:41695430	NDUFAF1	0.57	4.62	0.43	1.21e-5	Menopause (age at onset);
THYM	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg08449448	chr8:58056501	NA	0.81	4.65	0.43	1.06e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs9914988	0.943	rs9902953	chr17:27139834	C/A	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs10743315	0.557	rs17270134	chr12:19367047	G/A	cg02471346	chr12:19282374	PLEKHA5	1.09	4.55	0.42	1.58e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg07936489	chr17:37558343	FBXL20	0.85	5.64	0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg05738196	chr6:26577821	NA	0.82	7.81	0.63	7.7e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7809950	1.000	rs2237677	chr7:107202502	A/C	cg23024343	chr7:107201750	COG5	-0.87	-7.99	-0.63	3.13e-12	Coronary artery disease;
THYM	cis	rs2074585	0.839	rs11638780	chr15:91041896	G/T	cg22089800	chr15:90895588	ZNF774	-0.69	-5.32	-0.48	6.82e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
THYM	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg18512352	chr11:47633146	NA	-0.52	-6.14	-0.53	1.92e-8	Subjective well-being;
THYM	cis	rs7927771	0.524	rs6485763	chr11:47627302	C/T	cg18512352	chr11:47633146	NA	0.41	4.62	0.43	1.21e-5	Subjective well-being;
THYM	cis	rs2273669	0.596	rs17070144	chr6:109400279	T/C	cg17117243	chr6:109341365	SESN1	-0.77	-4.73	-0.44	7.79e-6	Prostate cancer;
THYM	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg14798641	chr3:49314920	USP4;C3orf62	-0.66	-4.63	-0.43	1.17e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg03609598	chr5:56110824	MAP3K1	-0.65	-4.58	-0.42	1.44e-5	Coronary artery disease;
THYM	cis	rs2976388	0.590	rs10110970	chr8:143820410	G/C	cg06565975	chr8:143823917	SLURP1	-0.61	-7.51	-0.61	3.22e-11	Urinary tract infection frequency;
THYM	cis	rs6957923	0.609	rs2390791	chr7:23579502	C/T	cg20265043	chr7:23510089	IGF2BP3	0.5	5.47	0.49	3.65e-7	Height;
THYM	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg24874828	chr4:187887005	NA	-0.72	-7.15	-0.59	1.75e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg04287289	chr16:89883240	FANCA	-0.61	-5.54	-0.49	2.75e-7	Vitiligo;
THYM	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg04320152	chr17:18167836	SMCR7	0.62	4.76	0.44	6.78e-6	Total body bone mineral density;
THYM	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg00757033	chr12:89920650	WDR51B	0.75	12.04	0.78	7.96e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg10803722	chr21:46713166	LOC642852	-0.39	-5.36	-0.48	5.86e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9902453	0.619	rs2244585	chr17:28072176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.8	-0.57	9.08e-10	Coffee consumption (cups per day);
THYM	cis	rs17750015	0.733	rs12454362	chr18:54396186	G/A	cg18434998	chr18:54306185	TXNL1	-0.6	-4.92	-0.45	3.7e-6	Depression and alcohol dependence;
THYM	cis	rs4866334	1.000	rs114675067	chr5:18448226	G/A	cg02002538	chr5:17811409	NA	-1.09	-4.54	-0.42	1.67e-5	IgG glycosylation;
THYM	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg03806693	chr22:41940476	POLR3H	1.25	10.88	0.74	2.22e-18	Vitiligo;
THYM	cis	rs892961	0.932	rs9916143	chr17:75409282	C/G	cg11351908	chr17:75402473	SEPT9	-0.56	-5.45	-0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg27129171	chr3:47204927	SETD2	0.79	7.89	0.63	5.02e-12	Colorectal cancer;
THYM	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs3960554	0.808	rs9801125	chr7:75792451	C/T	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.5	-0.42	1.92e-5	Eotaxin levels;
THYM	cis	rs1461503	0.934	rs7121840	chr11:122845360	A/G	cg27398637	chr11:122830231	C11orf63	-0.71	-6.63	-0.56	2.04e-9	Menarche (age at onset);
THYM	cis	rs6546324	0.625	rs2902007	chr2:67795462	A/T	cg18237512	chr2:67827392	NA	-0.8	-4.74	-0.44	7.44e-6	Endometriosis;
THYM	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg14004847	chr7:1930337	MAD1L1	-0.64	-5.11	-0.46	1.67e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg20007245	chr22:24372913	LOC391322	-0.62	-4.54	-0.42	1.62e-5	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg14780466	chr2:20870812	GDF7	-0.8	-6.82	-0.57	8.56e-10	Abdominal aortic aneurysm;
THYM	cis	rs4746818	0.901	rs10740317	chr10:70937566	G/A	cg11621586	chr10:70884670	VPS26A	1.17	7.32	0.6	8.04e-11	Left atrial antero-posterior diameter;
THYM	cis	rs1448094	0.512	rs4488288	chr12:86245450	A/C	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg23803603	chr1:2058230	PRKCZ	0.59	4.56	0.42	1.52e-5	Height;
THYM	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg15704280	chr7:45808275	SEPT13	-0.82	-8.18	-0.64	1.28e-12	Height;
THYM	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg23422044	chr7:1970798	MAD1L1	-0.95	-6.58	-0.56	2.51e-9	Bipolar disorder;
THYM	cis	rs1747683	0.545	rs1414399	chr10:13381835	A/C	cg25835351	chr10:13388524	SEPHS1	-0.28	-4.89	-0.45	4.14e-6	IgG glycosylation;
THYM	cis	rs2888875	0.591	rs17031102	chr2:43822518	C/A	cg22033476	chr2:43532275	THADA	-0.4	-4.61	-0.43	1.26e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs12532960	0.818	rs12535287	chr7:42376527	A/T	cg23473276	chr7:42834405	NA	0.87	4.77	0.44	6.71e-6	Inflammatory biomarkers;
THYM	cis	rs7917772	0.582	rs10786691	chr10:104364652	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4690686	0.808	rs6553945	chr4:177270965	T/C	cg17059388	chr4:177262070	NA	0.39	5.39	0.48	5.1e-7	Essential tremor;
THYM	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg02527881	chr3:46936655	PTH1R	0.61	5.7	0.51	1.33e-7	Colorectal cancer;
THYM	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs1003719	0.788	rs3787782	chr21:38462909	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg19052272	chr2:3704530	ALLC	-0.67	-5.0	-0.46	2.62e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg06582575	chr6:163149167	PACRG;PARK2	1.16	7.96	0.63	3.69e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs6840360	0.615	rs1561916	chr4:152479234	C/T	cg22705602	chr4:152727874	NA	-0.71	-7.43	-0.61	4.71e-11	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg27535305	chr1:53392650	SCP2	-0.4	-4.65	-0.43	1.06e-5	Monocyte count;
THYM	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg18252515	chr7:66147081	NA	-0.63	-4.69	-0.43	8.99e-6	Aortic root size;
THYM	cis	rs2806561	0.765	rs641808	chr1:23514123	T/G	cg12483005	chr1:23474871	LUZP1	0.59	6.28	0.54	1.01e-8	Height;
THYM	cis	rs11008222	0.792	rs10826863	chr10:31043732	C/T	cg00941203	chr10:31016591	NA	-0.35	-4.86	-0.45	4.55e-6	Congenital left-sided heart lesions (maternal effect);
THYM	cis	rs17152411	1.000	rs7082846	chr10:126593310	C/A	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg15445000	chr17:37608096	MED1	-0.41	-5.04	-0.46	2.26e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2637266	0.626	rs846616	chr10:78547311	A/G	cg18941641	chr10:78392320	NA	0.74	5.81	0.51	8.27e-8	Pulmonary function;
THYM	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg06656553	chr16:89960601	TCF25	-0.92	-4.45	-0.42	2.34e-5	Skin colour saturation;
THYM	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg12560992	chr17:57184187	TRIM37	-0.91	-8.18	-0.64	1.23e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7578361	0.959	rs6435511	chr2:150407982	G/A	cg17961725	chr2:150454027	NA	0.74	5.82	0.51	8.04e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg26384229	chr12:38710491	ALG10B	-0.61	-4.6	-0.43	1.29e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg03188948	chr7:1209495	NA	0.9	5.0	0.46	2.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17401966	0.898	rs11587495	chr1:10448999	T/C	cg19773385	chr1:10388646	KIF1B	-0.6	-4.7	-0.43	8.88e-6	Hepatocellular carcinoma;
THYM	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg03806693	chr22:41940476	POLR3H	-0.84	-6.41	-0.55	5.61e-9	Neuroticism;
THYM	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg18681998	chr4:17616180	MED28	0.82	7.26	0.6	1.06e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7568458	0.846	rs10179195	chr2:85762761	A/G	cg17127132	chr2:85788382	GGCX	0.72	6.21	0.54	1.42e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs2219968	1.000	rs6473087	chr8:78974859	A/G	cg00738934	chr8:78996279	NA	0.91	9.74	0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs758324	0.582	rs152054	chr5:131519540	G/A	cg16205897	chr5:131564050	P4HA2	0.61	5.11	0.46	1.64e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs3015497	0.789	rs11621971	chr14:51124527	C/T	cg04730355	chr14:51134070	SAV1	0.55	4.92	0.45	3.58e-6	Mean platelet volume;
THYM	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg07061783	chr6:25882402	NA	-0.89	-8.59	-0.66	1.73e-13	Intelligence (multi-trait analysis);
THYM	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg14972814	chr11:95582409	MTMR2	-0.58	-5.3	-0.48	7.56e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg23583168	chr7:148888333	NA	-0.98	-13.39	-0.81	1.35e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs7124681	0.565	rs2203712	chr11:47534964	T/C	cg20307385	chr11:47447363	PSMC3	0.61	4.67	0.43	9.88e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg26384229	chr12:38710491	ALG10B	-0.69	-5.37	-0.48	5.5e-7	Morning vs. evening chronotype;
THYM	cis	rs2295359	0.892	rs56920441	chr1:67652012	A/G	cg11235152	chr1:67600687	NA	0.66	5.49	0.49	3.37e-7	Psoriasis;
THYM	cis	rs13315871	1.000	rs28489489	chr3:58443755	C/A	cg00563845	chr3:58318305	PXK	0.53	4.67	0.43	9.78e-6	Cholesterol, total;
THYM	cis	rs4808199	0.948	rs2074301	chr19:19381715	G/A	cg03709012	chr19:19516395	GATAD2A	1.16	6.77	0.57	1.04e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs9649213	0.593	rs6955647	chr7:98004562	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6995541	0.529	rs66844016	chr8:10691034	A/G	cg13457217	chr8:10683266	MIR1322;PINX1	-0.67	-5.02	-0.46	2.39e-6	Triglyceride levels;
THYM	cis	rs7626444	0.625	rs843531	chr3:196481771	T/C	cg12930392	chr3:196481615	PAK2	0.4	4.97	0.45	2.97e-6	Monocyte count;
THYM	cis	rs9309473	0.500	rs4286298	chr2:73882108	T/A	cg19565262	chr2:73869966	NAT8	0.56	4.61	0.43	1.24e-5	Metabolite levels;
THYM	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg09455208	chr3:40491958	NA	0.44	4.67	0.43	1e-5	Renal cell carcinoma;
THYM	cis	rs7572733	0.534	rs1607375	chr2:198800387	C/T	cg00792783	chr2:198669748	PLCL1	0.82	5.75	0.51	1.08e-7	Dermatomyositis;
THYM	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg20203395	chr5:56204925	C5orf35	-0.69	-4.75	-0.44	7.14e-6	Initial pursuit acceleration;
THYM	cis	rs7523273	0.565	rs1998538	chr1:207886487	C/T	cg22525895	chr1:207977042	MIR29B2	-0.53	-5.05	-0.46	2.17e-6	Schizophrenia;
THYM	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg10802521	chr3:52805072	NEK4	-0.68	-6.16	-0.53	1.72e-8	Bipolar disorder;
THYM	cis	rs7104764	0.957	rs3782120	chr11:206089	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	-1.12	-9.8	-0.71	4.34e-16	Menarche (age at onset);
THYM	cis	rs977987	0.806	rs72787160	chr16:75445162	G/C	cg03315344	chr16:75512273	CHST6	0.77	6.3	0.54	9.16e-9	Dupuytren's disease;
THYM	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg17366294	chr4:99064904	C4orf37	0.55	6.63	0.56	2.03e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg06238570	chr21:40685208	BRWD1	0.89	6.42	0.55	5.45e-9	Cognitive function;
THYM	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg06623918	chr6:96969491	KIAA0776	1.09	10.37	0.73	2.65e-17	Headache;
THYM	cis	rs7000551	0.725	rs2449349	chr8:22383284	A/G	cg12081754	chr8:22256438	SLC39A14	0.66	6.14	0.53	1.91e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs1347297	0.526	rs6757186	chr2:179259719	G/C	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.61	-4.85	-0.45	4.89e-6	Alzheimer disease and age of onset;
THYM	cis	rs11039216	1	rs11039216	chr11:47406592	C/T	cg18512352	chr11:47633146	NA	0.41	4.75	0.44	7.28e-6	Neuroticism;
THYM	cis	rs2302612	0.528	rs1024791	chr2:102837910	T/C	cg13315345	chr2:102803985	IL1RL2	0.68	4.58	0.43	1.4e-5	Serum protein levels (sST2);
THYM	cis	rs8025790	0.508	rs4776943	chr15:67836069	T/C	cg24579218	chr15:68104479	NA	-0.68	-6.16	-0.53	1.74e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs7481584	0.646	rs434114	chr11:3050210	A/G	cg03159660	chr11:2078197	NA	0.62	4.6	0.43	1.3e-5	Calcium levels;
THYM	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22307029	chr19:49891270	CCDC155	0.78	7.02	0.58	3.36e-10	Multiple sclerosis;
THYM	cis	rs11225247	0.772	rs11225222	chr11:102230129	T/A	cg06323957	chr11:102217781	BIRC2	1.02	4.74	0.44	7.52e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.66e-11	Aortic root size;
THYM	cis	rs4803468	1.000	rs2241706	chr19:41912807	A/G	cg09537434	chr19:41945824	ATP5SL	-1.09	-10.13	-0.72	8.87e-17	Height;
THYM	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg13918804	chr1:2043761	PRKCZ	-0.61	-4.62	-0.43	1.19e-5	Height;
THYM	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg27129171	chr3:47204927	SETD2	0.71	6.66	0.56	1.81e-9	Colorectal cancer;
THYM	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg11764359	chr7:65958608	NA	-0.7	-4.89	-0.45	4.09e-6	Aortic root size;
THYM	cis	rs981844	1.000	rs2606342	chr4:154659980	C/A	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.96	4.84	0.44	4.97e-6	Initial pursuit acceleration;
THYM	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg17173187	chr15:85201210	NMB	0.57	5.85	0.51	6.94e-8	Schizophrenia;
THYM	cis	rs919433	0.680	rs4685	chr2:198257795	C/T	cg05783139	chr2:198650985	BOLL	-0.63	-4.89	-0.45	4.11e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.68	5.13	0.47	1.53e-6	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4722166	0.630	rs7781534	chr7:22778592	A/C	cg05472934	chr7:22766657	IL6	0.73	5.55	0.49	2.62e-7	Lung cancer;
THYM	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg05043794	chr9:111880884	C9orf5	-0.43	-6.35	-0.55	7.29e-9	Menarche (age at onset);
THYM	cis	rs7731657	0.537	rs10051616	chr5:130315631	A/G	cg08523029	chr5:130500466	HINT1	-0.82	-6.07	-0.53	2.66e-8	Fasting plasma glucose;
THYM	cis	rs4595586	0.545	rs1400284	chr12:39400419	G/A	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs6430585	0.591	rs1374330	chr2:136420908	A/C	cg23851026	chr2:136556271	LCT	0.65	5.48	0.49	3.48e-7	Corneal structure;
THYM	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg22968622	chr17:43663579	NA	1.18	10.66	0.74	6.45e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg07414643	chr4:187882934	NA	0.58	5.13	0.47	1.54e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs75059851	1.000	rs75059851	chr11:133822569	A/G	cg14047540	chr11:133829660	NA	-1.21	-8.44	-0.65	3.52e-13	Schizophrenia;
THYM	cis	rs4435363	0.874	rs4803981	chr19:47065147	C/T	cg10017888	chr19:47105860	CALM3	-0.84	-5.29	-0.48	7.98e-7	Immature fraction of reticulocytes;P wave terminal force;
THYM	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs4242434	0.927	rs2272718	chr8:22457388	G/A	cg11461670	chr8:22454935	PDLIM2	-0.41	-6.81	-0.57	8.77e-10	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg12863693	chr15:85201151	NMB	0.64	5.61	0.5	2.02e-7	Schizophrenia;
THYM	cis	rs476633	0.573	rs6492995	chr15:41529712	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.85	-6.67	-0.56	1.71e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs4430311	0.723	rs12125920	chr1:243911397	A/C	cg25706552	chr1:244017396	NA	-0.55	-4.86	-0.45	4.59e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs7107770	1.000	rs4935914	chr11:125106678	C/G	cg07747661	chr11:125106135	PKNOX2	-0.92	-5.19	-0.47	1.17e-6	Photic sneeze reflex;
THYM	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg23131131	chr22:24373011	LOC391322	-0.83	-7.75	-0.62	1e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg19913688	chr11:428466	ANO9	-0.88	-4.6	-0.43	1.3e-5	Body mass index;
THYM	cis	rs7487075	0.780	rs12307969	chr12:46759057	G/C	cg11331445	chr12:47219877	SLC38A4	0.48	4.59	0.43	1.38e-5	Itch intensity from mosquito bite;
THYM	cis	rs87938	0.799	rs17280306	chr3:41168084	A/G	cg02247160	chr3:41243829	CTNNB1	0.33	4.51	0.42	1.83e-5	Bone mineral density (hip);
THYM	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg14993813	chr1:46806288	NSUN4	0.69	4.66	0.43	1.02e-5	Menopause (age at onset);
THYM	cis	rs4523957	0.547	rs11078856	chr17:2092064	G/A	cg16513277	chr17:2031491	SMG6	-0.98	-9.04	-0.68	1.86e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg08994789	chr17:28903642	LRRC37B2	-1.06	-5.25	-0.47	9.31e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg05368731	chr17:41323189	NBR1	1.28	12.01	0.78	9.37e-21	Menopause (age at onset);
THYM	cis	rs822354	1.000	rs822355	chr3:186480123	C/T	cg23249140	chr3:186560453	ADIPOQ	-0.54	-5.27	-0.48	8.46e-7	Adiponectin levels;
THYM	cis	rs73086581	1.000	rs73086597	chr20:3983571	G/A	cg02187196	chr20:3869020	PANK2	0.5	5.52	0.49	2.94e-7	Response to antidepressants in depression;
THYM	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg24130564	chr14:104152367	KLC1	-0.66	-5.88	-0.52	6.14e-8	Intelligence (multi-trait analysis);
THYM	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.93	-6.05	-0.53	2.84e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg25767906	chr1:53392781	SCP2	0.52	5.19	0.47	1.19e-6	Monocyte count;
THYM	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17030434	0.834	rs11734251	chr4:154732218	C/T	cg14289246	chr4:154710475	SFRP2	-0.67	-4.76	-0.44	7.04e-6	Electrocardiographic conduction measures;
THYM	cis	rs7223966	0.881	rs3020608	chr17:61979993	C/A	cg00640147	chr17:61958756	GH2	-0.45	-4.77	-0.44	6.6e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg02915803	chr1:1606292	LOC728661;CDK11B	0.62	5.25	0.47	9.23e-7	Body mass index;
THYM	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg02640540	chr1:67518911	SLC35D1	0.64	4.73	0.44	7.69e-6	Lymphocyte percentage of white cells;
THYM	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg24675658	chr1:53192096	ZYG11B	0.69	6.11	0.53	2.18e-8	Monocyte count;
THYM	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg23260525	chr10:116636907	FAM160B1	0.49	5.02	0.46	2.38e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs8018808	0.875	rs176781	chr14:77887681	C/T	cg20045696	chr14:77926864	AHSA1	0.53	4.8	0.44	5.9e-6	Myeloid white cell count;
THYM	cis	rs500891	0.525	rs12190282	chr6:84056328	A/G	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg00814883	chr7:100076585	TSC22D4	-1.0	-6.85	-0.57	7.35e-10	Platelet count;
THYM	cis	rs2495707	0.602	rs75205635	chr10:102416299	G/T	cg07099331	chr10:102419617	NA	-0.45	-4.92	-0.45	3.65e-6	Body mass index;
THYM	cis	rs2976388	0.590	rs10087426	chr8:143814554	G/A	cg06565975	chr8:143823917	SLURP1	-0.61	-7.37	-0.6	6.26e-11	Urinary tract infection frequency;
THYM	cis	rs13263959	0.615	rs10092668	chr8:142654823	C/T	cg24384331	chr8:142183860	DENND3	0.46	4.47	0.42	2.2e-5	Hair color;
THYM	cis	rs7177699	0.526	rs7182529	chr15:79123631	T/C	cg15571903	chr15:79123663	NA	0.58	6.56	0.56	2.77e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6748734	0.600	rs10933510	chr2:241826754	G/A	cg02820040	chr2:241836501	C2orf54	-0.24	-4.54	-0.42	1.67e-5	Urinary metabolites;
THYM	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg25811766	chr13:21894605	NA	-0.78	-5.04	-0.46	2.21e-6	White matter hyperintensity burden;
THYM	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg06808227	chr14:105710500	BRF1	-1.03	-8.98	-0.68	2.5e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.64	-0.5	1.72e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg05234568	chr11:5960015	NA	-0.64	-5.17	-0.47	1.29e-6	DNA methylation (variation);
THYM	cis	rs78707713	0.560	rs12784882	chr10:71230334	C/G	cg08851181	chr10:71228077	TSPAN15	-0.8	-5.95	-0.52	4.46e-8	Venous thromboembolism;
THYM	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13126279	chr21:47581558	C21orf56	-0.66	-4.53	-0.42	1.74e-5	Testicular germ cell tumor;
THYM	cis	rs6121246	0.609	rs1009453	chr20:30404840	C/G	cg13852791	chr20:30311386	BCL2L1	0.87	8.17	0.64	1.31e-12	Mean corpuscular hemoglobin;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg18115244	chr2:55315271	NA	-0.88	-6.89	-0.58	6.11e-10	Depressive symptoms;
THYM	cis	rs1784581	0.894	rs1784594	chr6:162382734	A/G	cg17173639	chr6:162384350	PARK2	-0.93	-9.03	-0.68	1.94e-14	Itch intensity from mosquito bite;
THYM	cis	rs9467160	0.871	rs13191455	chr6:24448459	T/C	cg20631270	chr6:24437470	GPLD1	0.75	5.95	0.52	4.43e-8	Liver enzyme levels;
THYM	cis	rs13394619	0.744	rs10929759	chr2:11722012	C/G	cg07314298	chr2:11723111	GREB1	0.51	4.87	0.45	4.53e-6	Endometriosis;
THYM	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg11812906	chr14:75593930	NEK9	-0.79	-7.33	-0.6	7.61e-11	Height;
THYM	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg06238570	chr21:40685208	BRWD1	-0.96	-8.95	-0.68	2.83e-14	Cognitive function;
THYM	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg26384229	chr12:38710491	ALG10B	1.02	8.46	0.66	3.1400000000000003e-13	Heart rate;
THYM	cis	rs4474465	1.000	rs2063728	chr11:78185636	G/C	cg19901956	chr11:77921274	USP35	-0.62	-4.63	-0.43	1.15e-5	Alzheimer's disease (survival time);
THYM	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg06634786	chr22:41940651	POLR3H	0.63	4.74	0.44	7.51e-6	Vitiligo;
THYM	cis	rs4604732	0.536	rs12074913	chr1:247631607	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.7	4.88	0.45	4.32e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg23422044	chr7:1970798	MAD1L1	-0.79	-5.34	-0.48	6.39e-7	Bipolar disorder;
THYM	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg06221963	chr1:154839813	KCNN3	-0.78	-9.74	-0.71	5.93e-16	Prostate cancer;
THYM	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25427524	chr10:38739819	LOC399744	-0.73	-6.77	-0.57	1.04e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.69	6.26	0.54	1.11e-8	Blood protein levels;
THYM	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.74	-5.59	-0.5	2.19e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7103648	0.669	rs7131262	chr11:47836302	T/A	cg20307385	chr11:47447363	PSMC3	0.81	6.57	0.56	2.7e-9	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs11597390	0.865	rs12781812	chr10:101891222	G/T	cg11344164	chr10:101878520	NA	-0.59	-5.15	-0.47	1.4e-6	Liver enzyme levels;
THYM	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg13147721	chr7:65941812	NA	0.83	5.43	0.49	4.3e-7	Diabetic kidney disease;
THYM	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg09359103	chr1:154839909	KCNN3	-0.67	-8.06	-0.64	2.2e-12	Prostate cancer;
THYM	cis	rs1062746	0.520	rs17770996	chr16:87330207	G/A	cg02258303	chr16:87377426	FBXO31	-0.62	-4.73	-0.44	7.95e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs6531209	0.748	rs4666368	chr2:20347806	A/G	cg24416238	chr2:20211868	MATN3	-0.59	-4.81	-0.44	5.58e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg10057126	chr4:77819792	ANKRD56	0.74	6.36	0.55	6.96e-9	Emphysema distribution in smoking;
THYM	cis	rs4523957	0.820	rs9908972	chr17:2103810	A/C	cg16513277	chr17:2031491	SMG6	-0.79	-7.76	-0.62	9.62e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs782590	0.721	rs1084525	chr2:55929430	C/T	cg03859395	chr2:55845619	SMEK2	0.57	4.83	0.44	5.19e-6	Metabolic syndrome;
THYM	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg02887458	chr19:19495540	GATAD2A	0.42	4.93	0.45	3.51e-6	Bipolar disorder;
THYM	cis	rs13064411	0.696	rs6786974	chr3:113190149	T/A	cg18753928	chr3:113234510	CCDC52	-0.94	-8.58	-0.66	1.76e-13	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg09085632	chr11:111637200	PPP2R1B	0.95	8.53	0.66	2.33e-13	Primary sclerosing cholangitis;
THYM	cis	rs6840360	0.642	rs4696089	chr4:152395733	A/G	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg08999081	chr20:33150536	PIGU	-0.83	-7.54	-0.61	2.75e-11	Glomerular filtration rate (creatinine);
THYM	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.83	0.44	5.26e-6	Obesity-related traits;
THYM	cis	rs3925075	0.584	rs12600286	chr16:31360679	G/C	cg02846316	chr16:31340340	ITGAM	0.56	5.7	0.5	1.37e-7	IgA nephropathy;
THYM	cis	rs500891	0.525	rs2096223	chr6:84077446	T/G	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs7192750	0.586	rs8050651	chr16:71881444	C/G	cg06353428	chr16:71660113	MARVELD3	0.76	5.59	0.5	2.13e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs11096990	0.634	rs12648082	chr4:39279724	T/C	cg24403649	chr4:39172243	NA	-0.67	-5.84	-0.51	7.33e-8	Cognitive function;
THYM	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs28595532	0.920	rs55671478	chr4:119753811	A/G	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.23	4.9	0.45	3.95e-6	Obesity-related traits;
THYM	cis	rs6665290	0.901	rs12410103	chr1:227197408	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs7267979	1.000	rs6050573	chr20:25366065	C/G	cg08601574	chr20:25228251	PYGB	0.56	4.47	0.42	2.15e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs10496702	0.872	rs7603759	chr2:134015208	C/T	cg05012457	chr2:133672682	NCKAP5	-0.88	-4.91	-0.45	3.81e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9527	0.590	rs12414232	chr10:104914491	A/T	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	trans	rs10958605	0.761	rs2980815	chr8:40044598	A/G	cg02560310	chr20:60578131	TAF4	-0.73	-6.86	-0.58	6.92e-10	Parkinson's disease (motor and cognition);
THYM	cis	rs12049351	0.665	rs10916479	chr1:229583547	C/T	cg11742688	chr1:229674241	ABCB10	-0.55	-4.62	-0.43	1.2e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs2463822	0.592	rs72919486	chr11:62043501	G/C	cg06239285	chr11:62104954	ASRGL1	-1.24	-5.95	-0.52	4.51e-8	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9790314	0.750	rs6765270	chr3:160899974	A/G	cg03342759	chr3:160939853	NMD3	-0.58	-4.49	-0.42	2.02e-5	Morning vs. evening chronotype;
THYM	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg00129232	chr17:37814104	STARD3	-0.76	-5.25	-0.47	9.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs11645898	0.688	rs398580	chr16:72095453	A/G	cg14768367	chr16:72042858	DHODH	-0.78	-5.37	-0.48	5.63e-7	Blood protein levels;
THYM	cis	rs6456156	0.811	rs975822	chr6:167516458	C/T	cg09487078	chr6:167525398	CCR6	-0.46	-5.07	-0.46	1.98e-6	Primary biliary cholangitis;
THYM	cis	rs981844	0.689	rs6835372	chr4:154682056	T/C	cg09973105	chr4:154681532	RNF175	0.52	4.8	0.44	5.91e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs713587	0.935	rs4430895	chr2:25161386	C/T	cg15423357	chr2:25149977	NA	0.61	6.46	0.55	4.43e-9	Body mass index in non-asthmatics;
THYM	cis	rs112591243	0.685	rs2839323	chr21:47978421	G/A	cg26904215	chr21:47823096	PCNT	-0.99	-4.51	-0.42	1.86e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg26418147	chr1:205743515	RAB7L1	-0.52	-4.51	-0.42	1.87e-5	Menarche (age at onset);
THYM	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg10802521	chr3:52805072	NEK4	-0.75	-7.03	-0.58	3.15e-10	Electroencephalogram traits;
THYM	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg05890377	chr2:74357713	NA	1.04	8.51	0.66	2.54e-13	Gestational age at birth (maternal effect);
THYM	cis	rs11969893	0.850	rs9386260	chr6:101329428	G/A	cg12253828	chr6:101329408	ASCC3	1.27	7.31	0.6	8.44e-11	Economic and political preferences (immigration/crime);
THYM	cis	rs995000	0.931	rs10889343	chr1:63026429	T/G	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs4930776	0.932	rs411002	chr12:5759046	G/T	cg02086166	chr12:5775618	ANO2	0.62	6.17	0.53	1.69e-8	Plasma clusterin levels;
THYM	cis	rs9543976	0.623	rs4885323	chr13:76172414	C/T	cg01531495	chr13:76123901	UCHL3	0.66	4.8	0.44	5.85e-6	Diabetic retinopathy;
THYM	cis	rs4383453	0.539	rs4678018	chr3:123102044	G/A	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs1401999	0.546	rs56889301	chr3:183675315	T/C	cg01324343	chr3:183735012	ABCC5	0.75	9.39	0.69	3.36e-15	Anterior chamber depth;
THYM	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg08999081	chr20:33150536	PIGU	0.56	4.77	0.44	6.52e-6	Height;
THYM	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs1568889	0.730	rs6484350	chr11:28113658	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.82	-6.81	-0.57	8.87e-10	Bipolar disorder;
THYM	cis	rs8101881	0.510	rs7257884	chr19:33357844	G/C	cg05467458	chr19:33361032	SLC7A9	0.57	5.21	0.47	1.09e-6	Blood metabolite levels;Urinary metabolites;Urinary metabolites (H-NMR features);
THYM	cis	rs59112743	0.510	rs9476845	chr6:15554095	C/T	cg10111214	chr6:14815676	NA	0.74	4.84	0.44	5.08e-6	Multiple keratinocyte cancers;
THYM	cis	rs11077998	0.935	rs11653926	chr17:80484953	G/A	cg11779900	chr17:80519722	FOXK2	-0.53	-4.58	-0.43	1.39e-5	Reticulocyte fraction of red cells;
THYM	cis	rs673253	0.710	rs583040	chr1:44060483	G/A	cg24466421	chr1:44070974	PTPRF	-0.6	-5.34	-0.48	6.24e-7	Intelligence (multi-trait analysis);
THYM	cis	rs17253792	0.545	rs12883972	chr14:56018020	A/G	cg01858014	chr14:56050164	KTN1	-1.08	-4.55	-0.42	1.59e-5	Putamen volume;
THYM	cis	rs3916	0.955	rs2066938	chr12:121160615	A/G	cg21892295	chr12:121157589	UNC119B	-0.5	-4.89	-0.45	4.04e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg16850897	chr7:100343110	ZAN	-0.71	-5.39	-0.48	5.2e-7	Other erythrocyte phenotypes;
THYM	cis	rs76878669	0.561	rs2279862	chr11:66135179	C/T	cg18002602	chr11:66138449	SLC29A2	0.49	4.98	0.45	2.86e-6	Educational attainment (years of education);
THYM	cis	rs4509693	0.765	rs10786604	chr10:102495302	C/G	cg15234845	chr10:102496500	NA	0.66	4.64	0.43	1.11e-5	Alzheimer's disease;
THYM	cis	rs13191362	0.507	rs7772787	chr6:163190981	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.71	5.28	0.48	8.25e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs61990749	1.000	rs17106604	chr14:78379156	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.9	4.61	0.43	1.25e-5	Fibroblast growth factor basic levels;
THYM	cis	rs977987	0.843	rs6564259	chr16:75447393	T/G	cg03315344	chr16:75512273	CHST6	0.76	6.16	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg03060546	chr3:49711283	APEH	-0.74	-6.21	-0.54	1.42e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.76	-0.51	1.03e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs4919694	0.901	rs79331374	chr10:104882913	G/A	cg04362960	chr10:104952993	NT5C2	1.14	7.07	0.59	2.65e-10	Arsenic metabolism;
THYM	trans	rs7618501	0.699	rs2777888	chr3:49898000	A/G	cg21582582	chr3:182698605	DCUN1D1	0.83	7.09	0.59	2.31e-10	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs56302600	chr4:119770162	T/C	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs4589258	0.933	rs2508411	chr11:90434890	C/A	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs739401	0.619	rs10766481	chr11:2961512	G/C	cg08508325	chr11:3079039	CARS	-0.51	-6.13	-0.53	2e-8	Longevity;
THYM	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5015933	0.703	rs7037034	chr9:128144637	T/C	cg13590414	chr9:128173245	NA	-0.54	-5.1	-0.46	1.7e-6	Body mass index;
THYM	cis	rs778371	0.723	rs12993791	chr2:233690082	C/T	cg08000102	chr2:233561755	GIGYF2	-0.79	-6.96	-0.58	4.28e-10	Schizophrenia;
THYM	cis	rs9880211	0.563	rs6792630	chr3:135824901	C/A	cg21827317	chr3:136751795	NA	-0.71	-5.16	-0.47	1.33e-6	Body mass index;Height;
THYM	cis	rs8067545	0.611	rs12949481	chr17:20190974	C/A	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4866334	1.000	rs79038611	chr5:18503785	C/T	cg02002538	chr5:17811409	NA	-1.1	-4.55	-0.42	1.61e-5	IgG glycosylation;
THYM	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg22133161	chr19:49891603	CCDC155	0.7	5.01	0.46	2.52e-6	Multiple sclerosis;
THYM	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg24250549	chr1:154909240	PMVK	0.64	4.99	0.46	2.71e-6	Prostate cancer;
THYM	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg02221750	chr19:17393354	ANKLE1	-0.97	-8.6	-0.66	1.61e-13	Systemic lupus erythematosus;
THYM	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-13.67	-0.81	3.63e-24	Height;
THYM	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg02782426	chr3:40428986	ENTPD3	0.53	4.66	0.43	1.04e-5	Renal cell carcinoma;
THYM	cis	rs7072216	0.763	rs6584200	chr10:100170037	A/G	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg21385522	chr1:16154831	NA	-1.31	-14.54	-0.83	6.78e-26	Dilated cardiomyopathy;
THYM	cis	rs8016982	0.674	rs1951614	chr14:81672106	A/G	cg21807262	chr14:81713016	NA	0.57	5.28	0.48	8.05e-7	Schizophrenia;
THYM	cis	rs11614913	0.509	rs12300425	chr12:54395082	G/T	cg27482031	chr12:54402697	HOXC8	-0.52	-4.77	-0.44	6.57e-6	Waist circumference adjusted for body mass index;
THYM	cis	rs7705502	1.000	rs72812826	chr5:173362726	C/T	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs2131877	0.750	rs873120	chr3:194853489	C/G	cg21937377	chr3:194868750	C3orf21	0.42	5.17	0.47	1.31e-6	Non-small cell lung cancer;
THYM	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg12893697	chr11:970389	AP2A2	-0.31	-5.21	-0.47	1.1e-6	Alzheimer's disease (late onset);
THYM	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg22117172	chr7:91764530	CYP51A1	-0.35	-4.47	-0.42	2.12e-5	Breast cancer;
THYM	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg10047753	chr17:41438598	NA	0.97	7.99	0.63	3.21e-12	Menopause (age at onset);
THYM	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	5.52	0.49	2.88e-7	Hip circumference adjusted for BMI;
THYM	cis	rs7020830	0.867	rs56098516	chr9:37362220	A/G	cg14294708	chr9:37120828	ZCCHC7	1.17	14.04	0.82	6.52e-25	Schizophrenia;
THYM	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg18681998	chr4:17616180	MED28	0.91	8.58	0.66	1.75e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs12643440	0.538	rs1581402	chr4:17139877	T/A	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.18	8.62	0.66	1.44e-13	Cognitive test performance;
THYM	cis	rs62045849	0.546	rs12933826	chr16:89165984	T/C	cg06035645	chr16:89190857	ACSF3	0.93	4.76	0.44	6.84e-6	Red blood cell count;
THYM	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg11266682	chr4:10021025	SLC2A9	-0.61	-7.55	-0.61	2.65e-11	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1371867	0.875	rs1612773	chr8:101337818	G/C	cg06636551	chr8:101224915	SPAG1	-0.64	-6.41	-0.55	5.47e-9	Atrioventricular conduction;
THYM	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg24675658	chr1:53192096	ZYG11B	0.76	6.69	0.57	1.53e-9	Monocyte count;
THYM	cis	rs17854409	0.803	rs1048109	chr20:61472120	G/A	cg06598544	chr20:61472147	COL9A3	-1.12	-6.98	-0.58	3.91e-10	Obesity-related traits;
THYM	cis	rs7084402	0.967	rs7921207	chr10:60270235	G/T	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs3087591	0.960	rs4795575	chr17:29452625	A/G	cg24425628	chr17:29625626	OMG;NF1	0.65	5.61	0.5	2e-7	Hip circumference;
THYM	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg10360139	chr7:1886902	MAD1L1	-0.67	-5.79	-0.51	9.16e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs4769475	0.957	rs9553752	chr13:26719102	A/G	cg13319468	chr13:27597730	NA	0.69	5.66	0.5	1.6e-7	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	trans	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.1	8.0	0.63	3.04e-12	Exhaled nitric oxide output;
THYM	cis	rs66569888	0.507	rs67196165	chr2:106886496	C/G	cg16099169	chr2:106886729	NA	-0.72	-8.21	-0.64	1.08e-12	Facial morphology (factor 23);
THYM	cis	rs7078219	0.714	rs12360459	chr10:101286154	A/G	cg17888390	chr10:101282816	NA	-0.53	-5.14	-0.47	1.46e-6	Dental caries;
THYM	cis	rs8033133	0.560	rs1549478	chr15:25332200	T/C	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.64	-4.77	-0.44	6.64e-6	Blood osmolality (transformed sodium);
THYM	cis	rs4523957	0.559	rs216174	chr17:2164898	A/G	cg16513277	chr17:2031491	SMG6	0.66	5.19	0.47	1.19e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg10505658	chr17:80084571	CCDC57	0.72	7.84	0.63	6.62e-12	Life satisfaction;
THYM	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg05855489	chr10:104503620	C10orf26	-0.8	-7.2	-0.59	1.38e-10	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs9534288	0.699	rs1409432	chr13:46668302	C/T	cg15192986	chr13:46630673	CPB2	-0.64	-4.49	-0.42	2.01e-5	Blood protein levels;
THYM	cis	rs1568889	0.838	rs12273631	chr11:28042135	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	7.0	0.58	3.58e-10	Bipolar disorder;
THYM	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs6088590	0.610	rs6088461	chr20:32905161	G/T	cg08999081	chr20:33150536	PIGU	0.64	5.2	0.47	1.14e-6	Coronary artery disease;
THYM	cis	rs13082711	0.522	rs574955	chr3:27351000	T/C	cg02860705	chr3:27208620	NA	0.64	5.03	0.46	2.27e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs7100689	0.784	rs7078075	chr10:82162768	A/G	cg01528321	chr10:82214614	TSPAN14	1.08	8.58	0.66	1.76e-13	Post bronchodilator FEV1;
THYM	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg26769984	chr7:1090371	C7orf50	0.81	5.42	0.49	4.45e-7	Bronchopulmonary dysplasia;
THYM	cis	rs3204270	0.714	rs8074828	chr17:79657136	G/C	cg18367735	chr17:79674897	NA	0.75	4.51	0.42	1.85e-5	Dental caries;
THYM	cis	rs8106542	0.789	rs10420809	chr19:10727014	A/G	cg17848348	chr19:10766748	ILF3	0.64	5.31	0.48	7.27e-7	Platelet distribution width;
THYM	cis	rs17708984	0.606	rs3826722	chr19:16192898	A/G	cg13618979	chr19:16186840	TPM4	0.35	4.67	0.43	1e-5	Platelet count;Platelet distribution width;
THYM	cis	rs7084402	0.967	rs2577393	chr10:60286159	C/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs96067	0.711	rs795047	chr1:36637708	C/T	cg24686825	chr1:36642396	MAP7D1	0.76	6.26	0.54	1.13e-8	Corneal structure;
THYM	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg17757837	chr7:157058334	UBE3C	-0.66	-5.32	-0.48	6.85e-7	Body mass index;
THYM	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg10802521	chr3:52805072	NEK4	-0.75	-6.97	-0.58	4.08e-10	Electroencephalogram traits;
THYM	cis	rs1499972	0.887	rs62264956	chr3:117530775	C/T	cg07612923	chr3:117604196	NA	1.31	5.35	0.48	6.02e-7	Schizophrenia;
THYM	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg23803603	chr1:2058230	PRKCZ	-0.59	-5.17	-0.47	1.29e-6	Height;
THYM	cis	rs1371867	0.875	rs1788178	chr8:101332518	A/C	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs72827839	0.846	rs56407566	chr17:46148155	C/T	cg23391107	chr17:45924227	SP6	0.83	5.6	0.5	2.08e-7	Ease of getting up in the morning;
THYM	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg08736216	chr1:53307985	ZYG11A	-0.73	-6.38	-0.55	6.46e-9	Monocyte count;
THYM	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg05660106	chr1:15850417	CASP9	0.75	6.05	0.53	2.87e-8	Systolic blood pressure;
THYM	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg21028142	chr17:79581711	NPLOC4	0.64	6.74	0.57	1.23e-9	Eye color traits;
THYM	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs7894051	1.000	rs7907603	chr10:135195977	G/A	cg20534287	chr10:135191450	PAOX	-0.66	-4.81	-0.44	5.64e-6	Lifespan;
THYM	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg21775007	chr8:11205619	TDH	-0.7	-5.78	-0.51	9.67e-8	Retinal vascular caliber;
THYM	cis	rs4595586	0.525	rs6580891	chr12:39370127	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg23711669	chr6:146136114	FBXO30	-0.91	-8.61	-0.66	1.5e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9826463	0.582	rs73238173	chr3:142110644	C/G	cg20824294	chr3:142316082	PLS1	0.77	5.31	0.48	7.08e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg02896835	chr1:92012615	NA	0.65	5.74	0.51	1.15e-7	Breast cancer;
THYM	cis	rs9915657	0.660	rs975772	chr17:70067810	T/G	cg06234051	chr17:70120541	SOX9	-0.64	-5.69	-0.5	1.38e-7	Thyroid hormone levels;
THYM	cis	rs7580658	0.963	rs4233583	chr2:128060068	C/A	cg10021288	chr2:128175891	PROC	-0.78	-6.82	-0.57	8.26e-10	Protein C levels;
THYM	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs941408	1.000	rs759068	chr19:2792566	G/A	cg06609049	chr19:2785107	THOP1	0.78	6.48	0.55	3.97e-9	Total cholesterol levels;
THYM	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg11764359	chr7:65958608	NA	-0.8	-6.3	-0.54	9.39e-9	Aortic root size;
THYM	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg00129232	chr17:37814104	STARD3	-0.88	-6.92	-0.58	5.38e-10	Asthma;
THYM	trans	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg06437703	chr8:37914619	EIF4EBP1	-0.81	-8.27	-0.65	8.1e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6876348	0.516	rs2577415	chr5:128327425	A/C	cg25555059	chr5:128301488	SLC27A6	-0.49	-5.26	-0.48	8.75e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg05373962	chr22:49881684	NA	-0.64	-6.22	-0.54	1.31e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6032067	0.929	rs13038355	chr20:43805555	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs2276498	0.751	rs2299712	chr20:52643028	G/T	cg23682609	chr20:52687365	BCAS1	0.56	4.57	0.42	1.45e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.89	7.53	0.61	2.93e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg17845761	chr1:175162550	KIAA0040	-0.36	-4.57	-0.42	1.45e-5	Alcohol dependence;
THYM	cis	rs9443645	0.723	rs9343820	chr6:79480458	T/A	cg18132916	chr6:79620363	NA	-0.52	-4.53	-0.42	1.74e-5	Intelligence (multi-trait analysis);
THYM	cis	rs113835537	0.529	rs79798028	chr11:66199362	T/G	cg24851651	chr11:66362959	CCS	0.64	4.65	0.43	1.09e-5	Airway imaging phenotypes;
THYM	cis	rs2806561	0.929	rs6694445	chr1:23540428	A/G	cg12483005	chr1:23474871	LUZP1	0.54	5.48	0.49	3.52e-7	Height;
THYM	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg20587970	chr11:113659929	NA	-1.37	-8.96	-0.68	2.79e-14	Hip circumference adjusted for BMI;
THYM	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	8.38	0.65	4.65e-13	Lung cancer in ever smokers;
THYM	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg16797656	chr11:68205561	LRP5	0.43	4.55	0.42	1.58e-5	Total body bone mineral density;
THYM	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg02527881	chr3:46936655	PTH1R	-0.86	-8.65	-0.66	1.26e-13	Birth weight;
THYM	cis	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg08835221	chr22:38071607	LGALS1	0.36	5.24	0.47	9.85e-7	Fat distribution (HIV);
THYM	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg24209194	chr3:40518798	ZNF619	0.68	5.69	0.5	1.42e-7	Renal cell carcinoma;
THYM	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg20891283	chr12:69753455	YEATS4	0.83	7.27	0.6	1e-10	Cerebrospinal fluid biomarker levels;
THYM	trans	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg17712092	chr4:129076599	LARP1B	-0.87	-7.26	-0.6	1.07e-10	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg12963246	chr6:28129442	ZNF389	0.64	4.86	0.45	4.62e-6	Parkinson's disease;
THYM	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.69	0.43	9.17e-6	Bipolar disorder;
THYM	cis	rs7582180	0.700	rs11685293	chr2:100976502	A/C	cg14675211	chr2:100938903	LONRF2	0.6	5.68	0.5	1.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7224737	1.000	rs1869365	chr17:40293865	T/C	cg00647820	chr17:40259828	DHX58	-0.66	-4.94	-0.45	3.37e-6	Fibrinogen levels;
THYM	cis	rs1003719	0.715	rs9974494	chr21:38566566	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-4.56	-0.42	1.55e-5	Eye color traits;
THYM	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4648845	0.777	rs2477689	chr1:2395538	G/C	cg02275930	chr1:2372054	NA	-0.71	-5.49	-0.49	3.27e-7	Schizophrenia;
THYM	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.52e-7	Heart rate;
THYM	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg11301795	chr4:187892539	NA	-1.11	-18.94	-0.89	5.16e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs240110	0.588	rs7738319	chr6:101195253	T/C	cg21058520	chr6:100914733	NA	-0.57	-4.51	-0.42	1.86e-5	Neuroticism;
THYM	cis	rs112998813	0.571	rs7332124	chr13:114930057	A/C	cg02694521	chr13:114055881	NA	0.54	4.49	0.42	1.99e-5	Nodular sclerosis Hodgkin lymphoma;
THYM	cis	rs4792901	0.918	rs79158595	chr17:41623212	G/A	cg21940313	chr17:41620911	ETV4	-0.52	-5.51	-0.49	3.08e-7	Dupuytren's disease;
THYM	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg21984481	chr17:79567631	NPLOC4	-0.47	-4.95	-0.45	3.22e-6	Eye color traits;
THYM	cis	rs2742234	0.590	rs2505506	chr10:43645854	C/T	cg06632098	chr10:43605906	RET	-0.79	-5.1	-0.46	1.73e-6	Hirschsprung disease;
THYM	cis	rs4638749	0.680	rs12612935	chr2:108818409	A/G	cg23163573	chr2:108905468	SULT1C2	-0.43	-5.7	-0.51	1.33e-7	Blood pressure;
THYM	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.77	-6.56	-0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.61	4.65	0.43	1.07e-5	Colorectal cancer;
THYM	cis	rs2963155	0.518	rs72801090	chr5:142774692	C/T	cg17617527	chr5:142782415	NR3C1	1.12	6.01	0.52	3.43e-8	Breast cancer;
THYM	cis	rs709400	0.526	rs11622835	chr14:103967504	G/A	cg12935359	chr14:103987150	CKB	-0.62	-5.28	-0.48	8.3e-7	Body mass index;
THYM	cis	rs4595586	0.545	rs11615638	chr12:39364766	A/C	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg04043695	chr12:129287642	SLC15A4	0.63	5.17	0.47	1.3e-6	Systemic lupus erythematosus;
THYM	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg02187348	chr16:89574699	SPG7	0.67	5.27	0.48	8.69e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs1865721	0.771	rs72975986	chr18:73127649	A/G	cg26385618	chr18:73139727	C18orf62	-0.69	-5.19	-0.47	1.18e-6	Intelligence;
THYM	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	8.89	0.67	3.88e-14	Chronic sinus infection;
THYM	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-4.96	-0.45	3.03e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg01966878	chr4:90757139	SNCA	-0.56	-4.46	-0.42	2.26e-5	Neuroticism;
THYM	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg00129232	chr17:37814104	STARD3	0.74	4.99	0.46	2.76e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9814567	0.762	rs13093893	chr3:134292131	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.71	6.01	0.53	3.37e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs1904096	0.506	rs4693381	chr4:95206855	A/T	cg11021082	chr4:95130006	SMARCAD1	0.58	5.2	0.47	1.14e-6	Type 2 diabetes;
THYM	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg03859395	chr2:55845619	SMEK2	0.6	5.52	0.49	2.95e-7	Metabolic syndrome;
THYM	cis	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12118280	0.612	rs591141	chr1:108694894	A/G	cg24323958	chr1:108741884	SLC25A24	-0.67	-4.71	-0.43	8.57e-6	Myeloid white cell count;
THYM	cis	rs262150	0.579	rs4909110	chr7:158787332	C/T	cg19418458	chr7:158789849	NA	0.65	4.73	0.44	7.67e-6	Facial morphology (factor 20);
THYM	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs7267979	1.000	rs6083828	chr20:25369918	T/C	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg14829155	chr15:31115871	NA	-0.52	-4.83	-0.44	5.16e-6	Huntington's disease progression;
THYM	cis	rs7917772	0.545	rs3934960	chr10:104355275	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-5.7	-0.5	1.33e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	5.89	0.52	5.81e-8	Platelet count;
THYM	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs2273669	0.667	rs111523655	chr6:109301664	G/A	cg17117243	chr6:109341365	SESN1	-0.84	-4.94	-0.45	3.41e-6	Prostate cancer;
THYM	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg05738196	chr6:26577821	NA	0.85	8.1	0.64	1.87e-12	Intelligence (multi-trait analysis);
THYM	cis	rs34017685	0.536	rs6707236	chr2:71321941	T/A	cg25705148	chr2:72079498	NA	-1.02	-4.67	-0.43	9.92e-6	Stem cell growth factor beta levels;
THYM	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg21644426	chr2:191273491	MFSD6	0.74	6.15	0.53	1.84e-8	Pulse pressure;
THYM	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg02734326	chr4:10020555	SLC2A9	0.63	5.28	0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg03690763	chr11:133734501	NA	-0.61	-4.73	-0.44	7.77e-6	Childhood ear infection;
THYM	cis	rs9880211	0.898	rs34031772	chr3:136018141	T/C	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs11112613	0.713	rs11112592	chr12:105951702	C/T	cg03607813	chr12:105948248	NA	-0.99	-8.21	-0.64	1.08e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs1050631	0.556	rs4267398	chr18:33767749	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.68	5.64	0.5	1.75e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-5.4	-0.48	4.89e-7	Chronic sinus infection;
THYM	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg20891283	chr12:69753455	YEATS4	0.75	6.43	0.55	5e-9	Blood protein levels;
THYM	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.46	-0.49	3.77e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6840360	0.582	rs2709826	chr4:152332120	G/T	cg17479576	chr4:152424074	FAM160A1	-0.72	-5.46	-0.49	3.74e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9796	0.870	rs10851402	chr15:41263438	C/T	cg21153102	chr15:41252147	NA	-0.68	-6.3	-0.54	9.14e-9	Menopause (age at onset);
THYM	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg06634786	chr22:41940651	POLR3H	-0.66	-4.8	-0.44	5.78e-6	Vitiligo;
THYM	cis	rs6032067	0.929	rs56131549	chr20:43842014	A/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.76	-0.51	1.01e-7	Blood protein levels;
THYM	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg12564285	chr5:131593104	PDLIM4	0.44	4.78	0.44	6.47e-6	Acylcarnitine levels;
THYM	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg10281704	chr16:966864	LMF1	-0.26	-4.46	-0.42	2.24e-5	Height;
THYM	cis	rs7106204	0.748	rs7122986	chr11:24224634	G/A	ch.11.24196551F	chr11:24239977	NA	1.05	7.76	0.62	9.67e-12	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg24375607	chr4:120327624	NA	0.58	4.74	0.44	7.61e-6	Corneal astigmatism;
THYM	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg19346786	chr7:2764209	NA	-0.57	-4.82	-0.44	5.46e-6	Height;
THYM	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	1.05	13.99	0.82	8.49e-25	Birth weight;
THYM	cis	rs1775715	0.835	rs11008701	chr10:32241096	A/G	cg04359828	chr10:32216031	ARHGAP12	0.39	4.87	0.45	4.38e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	ch.11.42038R	chr11:967971	AP2A2	0.59	4.69	0.43	9.28e-6	Alzheimer's disease (late onset);
THYM	cis	rs7917772	0.582	rs10786687	chr10:104336994	A/C	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs5769707	0.706	rs763128	chr22:50018045	G/A	cg05373962	chr22:49881684	NA	-0.69	-6.46	-0.55	4.49e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg11663144	chr21:46675770	NA	-0.72	-10.11	-0.72	9.83e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.94	-5.23	-0.47	1.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7169223	0.653	rs3743057	chr15:79089007	T/C	cg21242079	chr15:79101063	ADAMTS7	0.65	5.97	0.52	4.03e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-5.24	-0.47	9.67e-7	Hemoglobin concentration;
THYM	cis	rs2976388	0.578	rs4736324	chr8:143830462	G/A	cg06565975	chr8:143823917	SLURP1	-0.61	-7.51	-0.61	3.22e-11	Urinary tract infection frequency;
THYM	cis	rs7950696	1	rs7950696	chr11:47481533	T/C	cg20307385	chr11:47447363	PSMC3	0.63	4.68	0.43	9.46e-6	Platelet count;
THYM	cis	rs6430585	0.591	rs72970243	chr2:136484232	G/A	cg23851026	chr2:136556271	LCT	0.57	5.41	0.49	4.68e-7	Corneal structure;
THYM	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	8.89	0.67	3.88e-14	Chronic sinus infection;
THYM	cis	rs35264875	1.000	rs72919409	chr11:68826553	G/C	cg23845249	chr11:68861649	NA	0.53	5.47	0.49	3.65e-7	Blond vs. brown hair color;
THYM	cis	rs6435862	0.593	rs34732883	chr2:215674371	C/T	cg04530015	chr2:215796436	ABCA12	0.55	5.1	0.46	1.74e-6	Neuroblastoma (high-risk);
THYM	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg02527881	chr3:46936655	PTH1R	-0.6	-6.01	-0.52	3.48e-8	Colorectal cancer;
THYM	cis	rs12681287	0.571	rs10097450	chr8:87358677	G/A	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg27535305	chr1:53392650	SCP2	-0.4	-4.52	-0.42	1.78e-5	Monocyte count;
THYM	cis	rs12257961	0.675	rs1914548	chr10:15345755	G/A	cg10616319	chr10:15468812	NA	-0.59	-4.76	-0.44	6.83e-6	Selective IgA deficiency;
THYM	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg00383909	chr3:49044727	WDR6	1.05	5.99	0.52	3.79e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7705042	0.861	rs6860138	chr5:141509985	G/A	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg00129232	chr17:37814104	STARD3	0.78	5.12	0.46	1.6e-6	Glomerular filtration rate (creatinine);
THYM	trans	rs11186	0.630	rs10931393	chr2:189953960	G/T	cg14780845	chr17:41323115	NBR1	0.82	6.87	0.58	6.56e-10	Parkinson's disease;
THYM	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg23583168	chr7:148888333	NA	-1.02	-14.14	-0.82	4.14e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.76	-5.88	-0.52	6.17e-8	Prostate cancer;
THYM	cis	rs13082711	0.911	rs35532045	chr3:27515870	A/G	cg02860705	chr3:27208620	NA	0.72	5.15	0.47	1.39e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg05962950	chr11:130786565	SNX19	0.9	8.67	0.66	1.12e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg05707623	chr12:122985044	ZCCHC8	0.76	5.12	0.46	1.61e-6	Body mass index;
THYM	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg09035930	chr12:129282057	SLC15A4	0.84	10.7	0.74	5.31e-18	Systemic lupus erythematosus;
THYM	cis	rs6918586	0.616	rs198836	chr6:26113616	T/A	cg03517284	chr6:25882590	NA	0.71	5.57	0.5	2.33e-7	Schizophrenia;
THYM	cis	rs4589258	0.788	rs11019164	chr11:90460855	T/C	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.72	-0.44	7.95e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4900538	0.963	rs1190554	chr14:102918686	T/C	cg18135206	chr14:102964638	TECPR2	0.96	8.15	0.64	1.42e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg24642844	chr7:1081250	C7orf50	-1.31	-5.46	-0.49	3.76e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.96	-8.85	-0.67	4.81e-14	Chronic sinus infection;
THYM	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.82	-7.5	-0.61	3.33e-11	Schizophrenia;
THYM	trans	rs208520	0.690	rs176289	chr6:66766522	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-7.98	-0.63	3.3e-12	Exhaled nitric oxide output;
THYM	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg00990874	chr7:1149470	C7orf50	-0.66	-4.78	-0.44	6.33e-6	Bronchopulmonary dysplasia;
THYM	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg05347473	chr6:146136440	FBXO30	-0.56	-4.45	-0.42	2.34e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg22105103	chr4:187893119	NA	0.87	9.13	0.68	1.2e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg20295408	chr7:1910781	MAD1L1	-0.59	-4.67	-0.43	9.94e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs995000	0.931	rs11207969	chr1:62911751	A/G	cg06896770	chr1:63153194	DOCK7	0.92	7.67	0.62	1.48e-11	Triglyceride levels;
THYM	cis	rs965469	0.895	rs6037595	chr20:3401128	T/G	cg25506879	chr20:3388711	C20orf194	-0.82	-5.02	-0.46	2.37e-6	IFN-related cytopenia;
THYM	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg20283391	chr11:68216788	NA	0.59	4.47	0.42	2.16e-5	Total body bone mineral density;
THYM	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	4.96	0.45	3.07e-6	Hip circumference adjusted for BMI;
THYM	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg10518543	chr12:38710700	ALG10B	-0.59	-4.67	-0.43	9.89e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Body mass index;
THYM	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	4.85	0.45	4.74e-6	Total body bone mineral density;
THYM	cis	rs10426930	0.700	rs8106479	chr19:5003940	G/C	cg25246084	chr19:4971487	KDM4B	-0.5	-5.28	-0.48	8e-7	Monocyte percentage of white cells;
THYM	cis	rs1994135	0.669	rs10844628	chr12:33697065	T/C	cg06521331	chr12:34319734	NA	-0.66	-4.94	-0.45	3.29e-6	Resting heart rate;
THYM	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg07362569	chr17:61921086	SMARCD2	-0.65	-6.2	-0.54	1.48e-8	Prudent dietary pattern;
THYM	cis	rs394563	0.690	rs237010	chr6:149758750	G/T	cg03678062	chr6:149772716	ZC3H12D	-0.58	-4.89	-0.45	4.18e-6	Dupuytren's disease;
THYM	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg23989207	chr17:80870107	TBCD	0.58	4.82	0.44	5.54e-6	Glycated hemoglobin levels;
THYM	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Body mass index;
THYM	cis	rs1729951	0.575	rs10935214	chr3:136693485	G/A	cg12473912	chr3:136751656	NA	0.63	5.13	0.47	1.55e-6	Neuroticism;
THYM	cis	rs7107174	1.000	rs2510037	chr11:77966099	A/G	cg19901956	chr11:77921274	USP35	-0.7	-5.37	-0.48	5.53e-7	Testicular germ cell tumor;
THYM	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg13298116	chr11:62369859	EML3;MTA2	-0.67	-8.79	-0.67	6.37e-14	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs7616559	0.924	rs1482860	chr3:156730749	T/A	cg15697575	chr3:156784781	NA	0.4	5.03	0.46	2.35e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs4866334	1.000	rs116117462	chr5:18452827	C/A	cg18608440	chr5:17519013	NA	1.16	5.19	0.47	1.17e-6	IgG glycosylation;
THYM	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg24530246	chr3:53118167	NA	-0.83	-4.74	-0.44	7.62e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg27490568	chr2:178487706	NA	0.62	5.81	0.51	8.17e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg08859206	chr1:53392774	SCP2	-0.81	-9.28	-0.69	5.68e-15	Monocyte count;
THYM	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg20503657	chr10:835505	NA	1.1	7.6	0.61	2.12e-11	Eosinophil percentage of granulocytes;
THYM	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.9	-7.96	-0.63	3.72e-12	Menarche (age at onset);
THYM	cis	rs7247513	0.892	rs2861407	chr19:12711495	T/C	cg01871581	chr19:12707946	ZNF490	-0.95	-11.42	-0.76	1.61e-19	Bipolar disorder;
THYM	cis	rs752010	0.630	rs11210507	chr1:42105488	T/C	cg06885757	chr1:42089581	HIVEP3	0.48	5.83	0.51	7.47e-8	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs713587	0.521	rs6545766	chr2:25077856	C/T	cg01884057	chr2:25150051	NA	0.64	5.69	0.5	1.38e-7	Body mass index in non-asthmatics;
THYM	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg16680214	chr1:154839983	KCNN3	-0.46	-5.14	-0.47	1.48e-6	Prostate cancer;
THYM	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg19875535	chr5:140030758	IK	0.61	4.81	0.44	5.71e-6	Depressive symptoms (multi-trait analysis);
THYM	trans	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg25214090	chr10:38739885	LOC399744	0.93	7.92	0.63	4.43e-12	Corneal astigmatism;
THYM	cis	rs977987	0.902	rs4888430	chr16:75494424	T/C	cg03315344	chr16:75512273	CHST6	0.71	5.75	0.51	1.09e-7	Dupuytren's disease;
THYM	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	5.15	0.47	1.39e-6	Schizophrenia;
THYM	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg22535103	chr8:58192502	C8orf71	-0.95	-6.0	-0.52	3.51e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs6500602	0.928	rs3747581	chr16:4462619	A/G	cg08645402	chr16:4508243	NA	0.64	4.97	0.45	2.91e-6	Schizophrenia;
THYM	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg26149184	chr10:133730230	NA	0.75	4.84	0.44	4.96e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03407747	chr17:6899364	ALOX12	-0.8	-10.63	-0.74	7.32e-18	Tonsillectomy;
THYM	cis	rs28595532	0.920	rs116548907	chr4:119735285	G/A	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs6087990	0.735	rs6087420	chr20:31359391	G/A	cg13636640	chr20:31349939	DNMT3B	0.93	10.19	0.72	6.65e-17	Ulcerative colitis;
THYM	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs2708977	1.000	rs13029764	chr2:97328874	C/T	cg01950434	chr2:97203154	ARID5A	-0.58	-5.31	-0.48	7.17e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg27170947	chr2:26402098	FAM59B	-0.81	-6.49	-0.55	3.93e-9	Gut microbiome composition (summer);
THYM	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg13609457	chr4:120235615	NA	0.51	4.76	0.44	6.87e-6	Corneal astigmatism;
THYM	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg08132940	chr7:1081526	C7orf50	-1.15	-6.58	-0.56	2.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4606347	0.789	rs17415879	chr1:66166337	A/G	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24549020	chr5:56110836	MAP3K1	-0.7	-4.51	-0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg07460842	chr6:66804631	NA	-0.9	-6.58	-0.56	2.6e-9	Exhaled nitric oxide output;
THYM	cis	rs2069837	0.591	rs1524104	chr7:22795153	C/T	cg21239317	chr7:23640510	CCDC126	0.73	4.5	0.42	1.92e-5	Longevity;
THYM	trans	rs11109072	1.000	rs7295287	chr12:97903650	A/T	cg17633015	chr7:2020501	MAD1L1	0.95	7.08	0.59	2.49e-10	Obesity (early onset extreme);
THYM	cis	rs6840360	0.571	rs7678080	chr4:152557350	A/G	cg17479576	chr4:152424074	FAM160A1	-0.78	-5.66	-0.5	1.62e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7582180	0.700	rs11685401	chr2:100976685	A/G	cg21926883	chr2:100939477	LONRF2	-0.66	-6.14	-0.53	1.89e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg27532560	chr4:187881888	NA	-0.95	-11.68	-0.77	4.63e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs950394	0.767	rs11904245	chr2:104991257	C/A	cg20302975	chr2:105468274	NA	-0.61	-4.5	-0.42	1.95e-5	Schizophrenia;
THYM	cis	rs2456568	0.802	rs1108910	chr11:93629677	C/T	cg17595323	chr11:93583763	C11orf90	0.58	6.09	0.53	2.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs3806843	0.900	rs2563280	chr5:140131530	G/C	cg19875535	chr5:140030758	IK	-0.58	-4.52	-0.42	1.76e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs1003719	0.654	rs764175	chr21:38517058	C/T	cg01329690	chr21:38580129	DSCR9	-0.37	-5.09	-0.46	1.83e-6	Eye color traits;
THYM	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs2862064	0.932	rs1553317	chr5:156479424	A/C	cg12943317	chr5:156479607	HAVCR1	-0.84	-5.23	-0.47	9.88e-7	Platelet count;
THYM	cis	rs35306767	0.855	rs72778229	chr10:951991	C/A	cg20503657	chr10:835505	NA	1.33	8.27	0.65	7.99e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.28	-9.46	-0.7	2.36e-15	Gut microbiome composition (summer);
THYM	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22857025	chr5:266934	NA	-1.43	-9.54	-0.7	1.58e-15	Breast cancer;
THYM	cis	rs7017697	0.642	rs3927029	chr8:19681933	G/A	cg01411142	chr8:19674711	INTS10	-0.62	-4.8	-0.44	5.95e-6	Breast cancer;
THYM	cis	rs9807989	0.507	rs4851571	chr2:103019000	C/T	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs9486719	1.000	rs12208884	chr6:96885572	G/A	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs2410601	0.562	rs7846416	chr8:18913273	C/G	cg19414122	chr8:18896631	NA	0.62	4.57	0.42	1.44e-5	Urinary albumin excretion rate in type 1 diabetes;
THYM	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs7124681	0.584	rs12226590	chr11:47571808	T/C	cg18512352	chr11:47633146	NA	0.41	4.67	0.43	1.01e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs7570971	0.792	rs56369224	chr2:136328890	A/T	cg04750100	chr2:136595281	LCT	0.49	4.49	0.42	2.02e-5	Blood metabolite levels;Body mass index;Cholesterol, total;
THYM	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg06238570	chr21:40685208	BRWD1	0.94	6.96	0.58	4.43e-10	Cognitive function;
THYM	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.66	4.7	0.43	8.88e-6	Gut microbiome composition (summer);
THYM	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg06532163	chr17:45867833	NA	0.66	6.75	0.57	1.17e-9	IgG glycosylation;
THYM	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg17063962	chr7:91808500	NA	1.16	13.11	0.8	4.9e-23	Breast cancer;
THYM	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.63	-7.38	-0.6	6.04e-11	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg23428387	chr22:49814324	NA	-0.51	-4.86	-0.45	4.68e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1642645	0.872	rs4660595	chr1:42482052	T/A	cg10197057	chr1:42612518	NA	0.45	4.97	0.45	2.93e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6812193	0.518	rs62300803	chr4:77189418	C/T	cg20311846	chr4:77356250	SHROOM3	0.54	4.78	0.44	6.44e-6	Parkinson's disease;
THYM	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg12310025	chr6:25882481	NA	-0.87	-7.78	-0.62	8.56e-12	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg00684032	chr4:1343700	KIAA1530	-0.61	-5.41	-0.49	4.65e-7	Obesity-related traits;
THYM	cis	rs7942486	0.895	rs11022723	chr11:13270635	G/A	cg13286116	chr11:13302098	ARNTL	-0.72	-8.02	-0.64	2.79e-12	Neuroticism;
THYM	cis	rs4386084	1.000	rs2067885	chr15:50221945	A/G	cg21557108	chr15:50410962	ATP8B4	0.45	4.49	0.42	1.97e-5	Basophil percentage of white cells;Basophil percentage of granulocytes;
THYM	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg03060546	chr3:49711283	APEH	-0.74	-6.21	-0.54	1.42e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg03859395	chr2:55845619	SMEK2	0.64	5.71	0.51	1.29e-7	Metabolic syndrome;
THYM	cis	rs6502050	0.723	rs4789698	chr17:80179786	C/T	cg13939156	chr17:80058883	NA	-0.39	-4.89	-0.45	4.08e-6	Life satisfaction;
THYM	cis	rs8060598	0.745	rs1861758	chr16:50751787	C/T	cg05261686	chr16:50743296	NOD2	0.38	4.7	0.43	8.78e-6	Leprosy;
THYM	cis	rs8018808	1.000	rs12435136	chr14:77856184	G/A	cg20045696	chr14:77926864	AHSA1	-0.59	-5.37	-0.48	5.49e-7	Myeloid white cell count;
THYM	cis	rs16917546	0.967	rs10995246	chr10:64391846	C/A	cg03961010	chr10:64397487	ZNF365	-0.8	-6.76	-0.57	1.13e-9	Basal cell carcinoma;
THYM	cis	rs138918	1.000	rs47341	chr22:43560763	C/T	cg02233750	chr22:43539658	MCAT	0.58	5.09	0.46	1.8e-6	Monocyte count;
THYM	cis	rs1018836	0.923	rs10956720	chr8:91576222	C/T	cg16814680	chr8:91681699	NA	-0.78	-6.41	-0.55	5.5e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg25838465	chr1:92012736	NA	-0.9	-8.55	-0.66	2.09e-13	Breast cancer;
THYM	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg23583168	chr7:148888333	NA	-1.1	-14.67	-0.83	3.81e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs11252926	0.800	rs12763675	chr10:744591	C/T	cg03684893	chr10:554711	DIP2C	0.63	4.69	0.43	9.08e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7107174	1.000	rs2510040	chr11:77944548	T/A	cg02023728	chr11:77925099	USP35	0.72	6.25	0.54	1.14e-8	Testicular germ cell tumor;
THYM	cis	rs4911259	0.552	rs13042651	chr20:31467423	C/T	cg13636640	chr20:31349939	DNMT3B	-0.62	-5.87	-0.52	6.45e-8	Inflammatory bowel disease;
THYM	cis	rs9875589	0.509	rs4685051	chr3:13981760	A/G	cg03204825	chr3:13978759	TPRXL	-0.52	-4.51	-0.42	1.82e-5	Ovarian reserve;
THYM	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg02782426	chr3:40428986	ENTPD3	-0.51	-4.56	-0.42	1.55e-5	Renal cell carcinoma;
THYM	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg22841779	chr14:105766346	BRF1	-0.47	-5.85	-0.51	6.89e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2282300	0.956	rs654710	chr11:30394303	A/G	cg06241208	chr11:30344200	C11orf46	0.79	5.49	0.49	3.4e-7	Morning vs. evening chronotype;
THYM	cis	rs12121840	0.790	rs6696050	chr1:165543477	G/C	cg19407955	chr1:165599744	MGST3	-0.65	-4.64	-0.43	1.12e-5	Interleukin-1-receptor antagonist levels;
THYM	cis	rs995000	0.931	rs11207997	chr1:63061906	C/T	cg06896770	chr1:63153194	DOCK7	0.92	7.77	0.62	9.35e-12	Triglyceride levels;
THYM	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg01264106	chr22:38071602	LGALS1	0.39	4.64	0.43	1.1e-5	Fat distribution (HIV);
THYM	cis	rs36051895	0.695	rs7851556	chr9:5022807	C/T	cg02405213	chr9:5042618	JAK2	-1.05	-11.5	-0.76	1.1e-19	Pediatric autoimmune diseases;
THYM	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg08645402	chr16:4508243	NA	0.77	6.77	0.57	1.04e-9	Schizophrenia;
THYM	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9563576	0.778	rs7996731	chr13:58631962	A/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs6987853	0.527	rs3935698	chr8:42363694	G/A	cg09913449	chr8:42400586	C8orf40	-0.76	-6.56	-0.56	2.77e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8067545	0.750	rs4570919	chr17:20000815	C/T	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.61e-6	Schizophrenia;
THYM	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg18252515	chr7:66147081	NA	-1.45	-8.59	-0.66	1.72e-13	Diabetic kidney disease;
THYM	cis	rs6968419	0.609	rs73716710	chr7:115905744	G/A	cg02561103	chr7:115862891	TES	-0.63	-4.5	-0.42	1.91e-5	Intraocular pressure;
THYM	cis	rs11642862	0.901	rs11642733	chr16:30969061	G/A	cg01070095	chr16:30968205	SETD1A	0.73	4.79	0.44	6.24e-6	Tonsillectomy;
THYM	cis	rs7078219	0.714	rs12413565	chr10:101285116	C/A	cg23904955	chr10:101282759	NA	-0.42	-4.97	-0.45	2.99e-6	Dental caries;
THYM	cis	rs7078219	0.543	rs4919342	chr10:101282553	G/C	cg23904955	chr10:101282759	NA	-0.4	-4.97	-0.45	2.99e-6	Dental caries;
THYM	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs61774743	0.521	rs60144015	chr1:41845246	C/A	cg19619003	chr1:41846758	NA	-0.29	-5.87	-0.52	6.26e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg03405983	chr8:143858548	LYNX1	-0.54	-5.8	-0.51	8.81e-8	Urinary tract infection frequency;
THYM	cis	rs6933660	0.610	rs71549125	chr6:151770796	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.96	-9.76	-0.71	5.5e-16	Menarche (age at onset);
THYM	cis	rs2131877	0.830	rs62290330	chr3:194843755	A/G	cg21937377	chr3:194868750	C3orf21	0.44	4.5	0.42	1.92e-5	Non-small cell lung cancer;
THYM	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg00080972	chr5:178986291	RUFY1	-0.58	-7.36	-0.6	6.46e-11	Lung cancer;
THYM	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg18252515	chr7:66147081	NA	0.63	4.74	0.44	7.37e-6	Aortic root size;
THYM	cis	rs8048589	0.604	rs11646584	chr16:12207975	G/A	cg02910054	chr16:12241554	SNX29	0.8	6.12	0.53	2.08e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs10779751	0.770	rs11121695	chr1:11229515	G/A	cg08854313	chr1:11322531	MTOR	-0.72	-5.55	-0.49	2.6e-7	Body mass index;
THYM	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg04398451	chr17:18023971	MYO15A	0.87	8.64	0.66	1.35e-13	Total body bone mineral density;
THYM	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg08975724	chr8:8085496	FLJ10661	0.63	4.68	0.43	9.39e-6	Mood instability;
THYM	cis	rs6838801	0.538	rs17322488	chr4:77560635	G/A	cg01477861	chr4:77609841	SHROOM3	-0.49	-5.23	-0.47	1e-6	Cleft lip with or without cleft palate;
THYM	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.7	7.02	0.58	3.29e-10	Lymphocyte counts;
THYM	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg03688085	chr1:1910585	KIAA1751	-0.76	-7.12	-0.59	2.05e-10	Severe influenza A (H1N1) infection;
THYM	cis	rs55728055	0.661	rs56411340	chr22:31984476	G/T	cg10537193	chr22:32026975	PISD	-0.66	-4.61	-0.43	1.26e-5	Age-related hearing impairment;
THYM	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs11792861	0.591	rs10979632	chr9:111732140	G/C	cg05043794	chr9:111880884	C9orf5	-0.36	-5.03	-0.46	2.35e-6	Menarche (age at onset);
THYM	cis	rs2282930	0.512	rs2282926	chr7:50718075	G/A	cg08586669	chr7:50727761	GRB10	0.31	4.69	0.43	9.01e-6	Bone mineral density;
THYM	cis	rs2235642	0.701	rs2281230	chr16:1601767	T/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.46	-4.93	-0.45	3.44e-6	Coronary artery disease;
THYM	cis	rs10992471	0.603	rs11792019	chr9:95195229	C/T	cg14631576	chr9:95140430	CENPP	-0.99	-9.94	-0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg16486109	chr11:613632	IRF7	0.51	5.7	0.5	1.34e-7	Systemic lupus erythematosus;
THYM	cis	rs6763768	0.606	rs34774173	chr3:53294445	G/C	cg16894138	chr3:53270350	TKT	0.7	5.26	0.47	9.06e-7	Bacterial meningitis;
THYM	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	7.86	0.63	6.06e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg02018176	chr4:1364513	KIAA1530	0.58	5.07	0.46	1.94e-6	Obesity-related traits;
THYM	cis	rs9486719	1.000	rs67996804	chr6:96884387	C/T	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg03676636	chr4:99064102	C4orf37	0.5	7.59	0.61	2.14e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10463554	0.963	rs3776859	chr5:102352034	A/C	cg23492399	chr5:102201601	PAM	-0.69	-5.14	-0.47	1.5e-6	Parkinson's disease;
THYM	cis	rs8041943	0.643	rs60898719	chr15:79912959	G/A	cg20511832	chr15:78934280	CHRNB4	0.44	4.73	0.44	7.76e-6	Bone mineral density (spine) and age at menarche;
THYM	cis	rs861020	1.000	rs674433	chr1:209964875	A/C	cg05527609	chr1:210001259	C1orf107	-1.02	-7.94	-0.63	3.97e-12	Orofacial clefts;
THYM	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg13010199	chr12:38710504	ALG10B	-0.62	-4.5	-0.42	1.95e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg07570687	chr10:102243282	WNT8B	0.75	6.62	0.56	2.11e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg24209194	chr3:40518798	ZNF619	-0.67	-5.8	-0.51	8.62e-8	Renal cell carcinoma;
THYM	cis	rs217727	0.524	rs7483477	chr11:1920255	G/T	cg21136371	chr11:1991065	NA	0.3	4.99	0.46	2.69e-6	Breast cancer;
THYM	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg25566285	chr7:158114605	PTPRN2	0.78	7.03	0.58	3.19e-10	Response to amphetamines;
THYM	trans	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg20587970	chr11:113659929	NA	-1.38	-8.78	-0.67	6.62e-14	Hip circumference adjusted for BMI;
THYM	cis	rs7264396	0.676	rs6060723	chr20:34549947	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-4.8	-0.44	6.01e-6	Total cholesterol levels;
THYM	cis	rs4237845	0.742	rs6650219	chr12:58289100	T/C	cg22764591	chr12:58329936	NA	1.0	8.13	0.64	1.62e-12	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	5.08	0.46	1.85e-6	Total body bone mineral density;
THYM	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg22166914	chr1:53195759	ZYG11B	-0.68	-6.74	-0.57	1.24e-9	Monocyte count;
THYM	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg08508325	chr11:3079039	CARS	-0.5	-6.35	-0.55	7.43e-9	Longevity;
THYM	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	7.02	0.58	3.32e-10	Electrocardiographic conduction measures;
THYM	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-8.51	-0.66	2.52e-13	Coronary artery disease;
THYM	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs6531209	0.589	rs2090033	chr2:20372497	C/T	cg24416238	chr2:20211868	MATN3	-0.56	-4.57	-0.42	1.44e-5	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs921968	0.565	rs6436086	chr2:219640125	T/C	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg06219351	chr7:158114137	PTPRN2	-0.8	-7.16	-0.59	1.7e-10	Response to amphetamines;
THYM	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg05457628	chr5:178986728	RUFY1	-0.66	-6.74	-0.57	1.24e-9	Lung cancer;
THYM	cis	rs78579285	0.545	rs79311053	chr16:88785206	C/T	cg00973732	chr16:88803885	FAM38A	-0.88	-4.56	-0.42	1.51e-5	Joint mobility (Beighton score);
THYM	trans	rs4866334	0.867	rs78519816	chr5:18463568	G/A	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs9915657	0.870	rs1042678	chr17:70122108	G/A	cg09344028	chr17:70110421	NA	0.47	4.65	0.43	1.09e-5	Thyroid hormone levels;
THYM	cis	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg07460842	chr6:66804631	NA	0.92	5.5	0.49	3.15e-7	Exhaled nitric oxide levels;
THYM	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg24375607	chr4:120327624	NA	-0.62	-5.0	-0.46	2.61e-6	Corneal astigmatism;
THYM	cis	rs665401	0.965	rs35974852	chr6:117229958	A/G	cg20376953	chr6:117187980	NA	0.63	5.12	0.46	1.62e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.32	-0.48	7.02e-7	Monocyte percentage of white cells;
THYM	cis	rs490234	0.966	rs829312	chr9:128377873	C/T	cg14078157	chr9:128172775	NA	-0.59	-4.58	-0.43	1.39e-5	Mean arterial pressure;
THYM	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg05043794	chr9:111880884	C9orf5	0.36	5.04	0.46	2.2e-6	Menarche (age at onset);
THYM	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs10170846	0.861	rs4674677	chr2:223529658	G/A	cg25565276	chr2:223520875	FARSB	0.62	5.03	0.46	2.28e-6	Schizophrenia (inflammation and infection response interaction);
THYM	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg16230307	chr14:35515116	FAM177A1	-0.89	-5.81	-0.51	8.29e-8	Psoriasis;
THYM	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg25703541	chr22:24373054	LOC391322	0.86	7.59	0.61	2.23e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11644478	chr21:40555479	PSMG1	-0.82	-7.39	-0.6	5.7e-11	Cognitive function;
THYM	cis	rs6840360	0.615	rs28659854	chr4:152607442	T/C	cg22705602	chr4:152727874	NA	-0.79	-10.66	-0.74	6.62e-18	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs9543976	0.623	rs7996884	chr13:76172744	T/A	cg01531495	chr13:76123901	UCHL3	0.66	4.8	0.44	5.85e-6	Diabetic retinopathy;
THYM	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2836633	0.929	rs11702165	chr21:40035313	C/T	cg05519781	chr21:40033154	ERG	0.75	7.33	0.6	7.63e-11	Coronary artery disease;
THYM	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg27279351	chr12:120934652	DYNLL1	0.96	8.75	0.67	7.6e-14	High light scatter reticulocyte count;
THYM	cis	rs854765	0.624	rs11657423	chr17:17728574	T/C	cg16928487	chr17:17741425	SREBF1	0.52	4.94	0.45	3.31e-6	Total body bone mineral density;
THYM	cis	rs12765878	0.603	rs9420904	chr10:105666745	G/A	cg11005552	chr10:105648138	OBFC1	-0.52	-4.53	-0.42	1.71e-5	Coronary artery disease;
THYM	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg18876405	chr7:65276391	NA	-0.56	-4.65	-0.43	1.09e-5	Aortic root size;
THYM	cis	rs9611519	0.780	rs1983631	chr22:41644074	C/T	cg03806693	chr22:41940476	POLR3H	-0.82	-6.78	-0.57	9.98e-10	Neuroticism;
THYM	cis	rs12594515	1.000	rs11855562	chr15:45995659	C/T	cg01629716	chr15:45996671	NA	0.53	5.27	0.48	8.45e-7	Waist circumference;Weight;
THYM	cis	rs79149102	0.579	rs12592477	chr15:75292699	C/T	cg17294928	chr15:75287854	SCAMP5	-1.06	-5.68	-0.5	1.49e-7	Lung cancer;
THYM	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-1.21	-9.18	-0.69	9.56e-15	Cognitive test performance;
THYM	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg11803278	chr7:157951799	PTPRN2	0.63	6.17	0.53	1.68e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs1061377	0.560	rs6531690	chr4:39074203	A/G	cg24403649	chr4:39172243	NA	0.57	4.59	0.43	1.35e-5	Uric acid levels;
THYM	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg11461670	chr8:22454935	PDLIM2	-0.35	-6.45	-0.55	4.7e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg12310025	chr6:25882481	NA	-1.05	-9.86	-0.71	3.31e-16	Intelligence (multi-trait analysis);
THYM	cis	rs919433	0.713	rs6719483	chr2:198472886	A/G	cg00792783	chr2:198669748	PLCL1	0.8	5.61	0.5	2.02e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg06618935	chr21:46677482	NA	-0.97	-9.11	-0.68	1.33e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg24578937	chr1:2090814	PRKCZ	-0.79	-8.24	-0.65	9.56e-13	Height;
THYM	cis	rs61931739	0.963	rs12298565	chr12:34036188	C/T	cg06521331	chr12:34319734	NA	0.61	4.76	0.44	6.95e-6	Morning vs. evening chronotype;
THYM	cis	rs6060960	0.537	rs6087787	chr20:30452089	G/A	cg09796376	chr20:30640595	HCK	0.79	4.81	0.44	5.64e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg10224037	chr5:178157518	ZNF354A	0.98	8.02	0.64	2.74e-12	Neutrophil percentage of white cells;
THYM	cis	rs8048589	0.615	rs34147612	chr16:12233188	G/A	cg01990910	chr16:12207648	SNX29	-0.52	-5.82	-0.51	7.86e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs28602670	1	rs28602670	chr15:78768167	C/G	cg18825076	chr15:78729989	IREB2	0.7	5.57	0.5	2.39e-7	Post bronchodilator FEV1;
THYM	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg00129232	chr17:37814104	STARD3	-0.87	-7.09	-0.59	2.33e-10	Asthma;
THYM	cis	rs7917772	0.539	rs12572775	chr10:104285594	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.69	-5.87	-0.52	6.47e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs9902453	0.817	rs1842026	chr17:28188111	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.65	0.43	1.08e-5	Coffee consumption (cups per day);
THYM	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg23711669	chr6:146136114	FBXO30	0.95	9.55	0.7	1.52e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs904251	0.828	rs2797803	chr6:37487340	T/C	cg25019722	chr6:37503610	NA	-0.61	-4.79	-0.44	6.12e-6	Cognitive performance;
THYM	cis	rs2067615	0.599	rs12369214	chr12:107198611	G/A	cg15890332	chr12:107067104	RFX4	0.48	5.63	0.5	1.81e-7	Heart rate;
THYM	cis	rs2637266	0.783	rs7914756	chr10:78476406	A/T	cg18941641	chr10:78392320	NA	-0.71	-5.95	-0.52	4.42e-8	Pulmonary function;
THYM	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg09085632	chr11:111637200	PPP2R1B	1.11	11.06	0.75	9.31e-19	Primary sclerosing cholangitis;
THYM	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg16325326	chr1:53192061	ZYG11B	0.82	7.77	0.62	9e-12	Monocyte count;
THYM	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg15448220	chr1:150897856	SETDB1	0.88	7.49	0.61	3.44e-11	Melanoma;
THYM	cis	rs2439831	0.681	rs2444036	chr15:43694108	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.68	4.7	0.43	8.71e-6	Lung cancer in ever smokers;
THYM	cis	rs1008375	1.000	rs11947857	chr4:17691047	T/C	cg18681998	chr4:17616180	MED28	-0.86	-7.1	-0.59	2.3e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg01324343	chr3:183735012	ABCC5	0.88	13.13	0.8	4.58e-23	Anterior chamber depth;
THYM	cis	rs3126085	0.935	rs4595369	chr1:152248193	G/A	cg26020982	chr1:152196106	HRNR	0.35	4.95	0.45	3.26e-6	Atopic dermatitis;
THYM	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg00147160	chr1:26503991	CNKSR1	0.53	6.98	0.58	3.9e-10	Height;
THYM	cis	rs2658782	0.951	rs2608214	chr11:93148665	C/T	cg16424440	chr11:93231842	C11orf75	-0.73	-4.91	-0.45	3.82e-6	Pulmonary function decline;
THYM	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg11846333	chr4:119757529	SEC24D	1.3	4.54	0.42	1.62e-5	Cannabis dependence symptom count;
THYM	cis	rs2070488	0.965	rs3749386	chr3:38496065	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	7.18	0.59	1.54e-10	Electrocardiographic conduction measures;
THYM	cis	rs1003719	0.715	rs1981433	chr21:38542223	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.51	-4.9	-0.45	3.89e-6	Lymphocyte counts;
THYM	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg23711669	chr6:146136114	FBXO30	-0.9	-8.72	-0.67	9.04e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs36051895	0.664	rs10117501	chr9:5094246	G/A	cg02405213	chr9:5042618	JAK2	-0.99	-10.84	-0.74	2.64e-18	Pediatric autoimmune diseases;
THYM	cis	rs354225	0.544	rs10193692	chr2:54808340	A/T	cg23486701	chr2:54789491	SPTBN1	0.36	4.96	0.45	3.11e-6	Schizophrenia;
THYM	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg03676636	chr4:99064102	C4orf37	-0.44	-6.56	-0.56	2.86e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9876781	1.000	rs1109227	chr3:48479207	C/T	cg06066452	chr3:48470258	PLXNB1	0.27	4.77	0.44	6.64e-6	Longevity;
THYM	cis	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.52	-0.42	1.79e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9420	0.961	rs71484468	chr11:57632799	G/C	cg19752551	chr11:57585705	CTNND1	-0.74	-7.99	-0.63	3.1e-12	Schizophrenia;
THYM	cis	rs4746818	1.000	rs4342912	chr10:70959282	T/C	cg11621586	chr10:70884670	VPS26A	1.26	11.24	0.76	3.91e-19	Left atrial antero-posterior diameter;
THYM	cis	rs4654899	0.865	rs12130664	chr1:21332812	G/T	cg01072550	chr1:21505969	NA	-0.73	-6.62	-0.56	2.08e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs4481887	1.000	rs10736378	chr1:248455769	T/G	cg00666640	chr1:248458726	OR2T12	0.56	4.61	0.43	1.26e-5	Common traits (Other);
THYM	cis	rs17534004	1.000	rs17599764	chr13:31469580	G/A	cg13251181	chr13:31481184	C13orf33	0.55	4.52	0.42	1.77e-5	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg17211192	chr8:82754475	SNX16	-0.82	-7.41	-0.61	5.09e-11	Diastolic blood pressure;
THYM	cis	rs3857067	0.506	rs282450	chr4:95139598	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.06	-0.46	2.08e-6	QT interval;
THYM	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg03929089	chr4:120376271	NA	0.98	10.82	0.74	2.92e-18	Coronary artery disease;
THYM	cis	rs2046867	0.818	rs62249875	chr3:72911858	G/A	cg25664220	chr3:72788482	NA	-0.89	-7.13	-0.59	1.99e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs13242816	1.000	rs56010123	chr7:116173046	C/T	cg16553024	chr7:116138462	CAV2	-1.11	-4.69	-0.43	9.02e-6	P wave duration;
THYM	cis	rs7216064	1.000	rs56148300	chr17:65892752	T/C	cg12091567	chr17:66097778	LOC651250	-0.73	-5.18	-0.47	1.25e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg06981504	chr1:1234844	ACAP3	0.53	4.92	0.45	3.7e-6	Body mass index;
THYM	cis	rs2991971	0.903	rs2991973	chr1:46020632	G/A	cg15605315	chr1:45957053	TESK2	0.62	4.83	0.44	5.2e-6	High light scatter reticulocyte count;
THYM	cis	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-5.83	-0.51	7.47e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg25358565	chr5:93447407	FAM172A	-1.0	-7.31	-0.6	8.27e-11	Diabetic retinopathy;
THYM	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg10803722	chr21:46713166	LOC642852	-0.42	-5.46	-0.49	3.72e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.49	-0.42	2.04e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs12681287	0.752	rs13262673	chr8:87293600	G/A	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg06532163	chr17:45867833	NA	0.63	6.25	0.54	1.15e-8	IgG glycosylation;
THYM	cis	rs654384	0.836	rs12701427	chr7:4176472	A/G	cg13153353	chr7:4175865	SDK1	-0.45	-4.81	-0.44	5.63e-6	Positive affect;
THYM	cis	rs10203711	1.000	rs907112	chr2:239566603	C/G	cg14580085	chr2:239553406	NA	0.68	6.18	0.54	1.6e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg11871910	chr12:69753446	YEATS4	1.01	9.83	0.71	3.8e-16	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2294693	0.945	rs11756893	chr6:41010058	A/C	cg14418226	chr6:40996092	UNC5CL	0.75	6.13	0.53	1.97e-8	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs4455778	0.580	rs4270912	chr7:49112335	T/G	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg12826209	chr6:26865740	GUSBL1	0.92	4.99	0.46	2.68e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs57927100	0.734	rs1436138	chr17:75316880	A/G	cg18271897	chr17:75316784	SEPT9	0.72	11.64	0.77	5.48e-20	Systolic blood pressure;
THYM	cis	rs7614311	0.636	rs3821902	chr3:63941697	T/G	cg22134162	chr3:63841271	THOC7	-0.57	-6.78	-0.57	1.01e-9	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs1003719	0.646	rs2835671	chr21:38581125	T/G	cg01329690	chr21:38580129	DSCR9	-0.36	-4.98	-0.46	2.81e-6	Eye color traits;
THYM	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg10523679	chr1:76189770	ACADM	-1.1	-8.11	-0.64	1.76e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg00484396	chr16:3507460	NAT15	0.71	9.1	0.68	1.41e-14	Tuberculosis;
THYM	cis	rs1421898	0.625	rs17624691	chr5:157968961	C/A	cg06698293	chr5:158690540	UBLCP1	-0.98	-4.64	-0.43	1.13e-5	Inflammatory skin disease;
THYM	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.78	6.29	0.54	9.87e-9	Lymphocyte percentage of white cells;
THYM	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg11327659	chr7:150037044	RARRES2	0.42	4.97	0.45	2.94e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs17666538	0.818	rs62486207	chr8:588932	G/T	cg02524346	chr8:600233	NA	-1.0	-4.52	-0.42	1.8e-5	IgG glycosylation;
THYM	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg16188243	chr19:2783719	SGTA	0.71	5.0	0.46	2.6e-6	Total cholesterol levels;
THYM	cis	rs11771526	0.901	rs10267589	chr7:32280156	T/C	cg13207630	chr7:32358064	NA	0.74	4.99	0.46	2.74e-6	Body mass index;
THYM	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.0	9.72	0.71	6.52e-16	Colorectal cancer;
THYM	cis	rs3796352	1.000	rs11706035	chr3:53011868	A/T	cg24530246	chr3:53118167	NA	-0.81	-4.62	-0.43	1.23e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7264396	0.515	rs2425134	chr20:34339439	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Total cholesterol levels;
THYM	cis	rs7589342	0.801	rs13031068	chr2:106455021	A/G	cg14210321	chr2:106509881	NCK2	-0.75	-5.33	-0.48	6.52e-7	Addiction;
THYM	cis	rs365132	1.000	rs7718874	chr5:176358065	A/G	cg17809377	chr5:176326619	HK3	-0.3	-4.55	-0.42	1.59e-5	Menarche and menopause (age at onset);Menopause (age at onset);
THYM	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg15744005	chr10:104629667	AS3MT	-0.84	-8.32	-0.65	6.21e-13	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03517284	chr6:25882590	NA	-0.76	-5.93	-0.52	4.85e-8	Blood metabolite levels;
THYM	cis	rs2219968	1.000	rs1481511	chr8:78955014	A/G	cg00738934	chr8:78996279	NA	0.91	9.88	0.71	3.04e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2274459	0.841	rs3818526	chr6:33660973	T/C	cg06253072	chr6:33679850	C6orf125	0.49	4.97	0.45	2.98e-6	Obesity (extreme);
THYM	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg14137381	chr5:502291	SLC9A3	-0.65	-4.52	-0.42	1.77e-5	Cystic fibrosis severity;
THYM	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs3733585	0.577	rs28558552	chr4:9964913	G/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-6.28	-0.54	9.94e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4654899	0.865	rs6691824	chr1:21417577	T/G	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.29e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg22920501	chr2:26401640	FAM59B	-1.04	-9.12	-0.68	1.26e-14	Gut microbiome composition (summer);
THYM	cis	rs485842	0.930	rs538636	chr11:96026190	A/G	cg23866687	chr11:96026956	MAML2	0.45	6.36	0.55	6.98e-9	Corneal astigmatism;
THYM	cis	rs4631830	0.863	rs10826127	chr10:51530757	G/A	cg10326726	chr10:51549505	MSMB	-0.62	-6.26	-0.54	1.11e-8	Prostate-specific antigen levels;
THYM	cis	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg09085632	chr11:111637200	PPP2R1B	1.15	11.15	0.75	6.06e-19	Primary sclerosing cholangitis;
THYM	cis	rs1747683	0.966	rs10906348	chr10:13368088	A/G	cg00142036	chr10:13388442	SEPHS1	-0.3	-5.3	-0.48	7.38e-7	IgG glycosylation;
THYM	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg10802521	chr3:52805072	NEK4	-0.64	-5.79	-0.51	9.21e-8	Electroencephalogram traits;
THYM	cis	rs7529073	1.000	rs7529073	chr1:214147889	T/C	cg24083324	chr1:214162604	PROX1	-0.61	-4.61	-0.43	1.27e-5	Schizophrenia;
THYM	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg07424592	chr7:64974309	NA	-1.03	-5.36	-0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs4638749	0.677	rs7595399	chr2:108835943	C/G	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs7553864	0.614	rs1886634	chr1:87614821	C/T	cg17420885	chr1:87600446	LOC339524	0.83	7.0	0.58	3.68e-10	Smoking behavior;
THYM	cis	rs2734839	0.929	rs7131627	chr11:113299829	G/A	cg14159747	chr11:113255604	NA	0.31	6.33	0.54	8.14e-9	Information processing speed;
THYM	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.88	7.98	0.63	3.28e-12	Monocyte percentage of white cells;
THYM	cis	rs9309473	0.519	rs1881246	chr2:73650122	T/A	cg19565262	chr2:73869966	NAT8	0.56	4.73	0.44	7.7e-6	Metabolite levels;
THYM	cis	rs28595532	0.841	rs55744948	chr4:119769243	T/C	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg22920501	chr2:26401640	FAM59B	-0.71	-6.33	-0.54	7.92e-9	Gut microbiome composition (summer);
THYM	cis	rs2354432	0.599	rs6693667	chr1:146817245	A/T	cg25205988	chr1:146714368	CHD1L	1.04	5.79	0.51	9.04e-8	Mitochondrial DNA levels;
THYM	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg08859206	chr1:53392774	SCP2	-0.47	-4.87	-0.45	4.49e-6	Monocyte count;
THYM	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg14196790	chr5:131705035	SLC22A5	0.53	4.77	0.44	6.72e-6	Blood metabolite levels;
THYM	cis	rs11577318	0.853	rs2276712	chr1:26627478	T/C	cg19677267	chr1:26645161	CD52;UBXN11	-0.46	-5.87	-0.52	6.35e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg12573674	chr2:1569213	NA	-1.16	-8.07	-0.64	2.18e-12	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs6429082	0.713	rs867363	chr1:235579727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.63	-5.31	-0.48	7.25e-7	Adiposity;
THYM	cis	rs9443645	0.810	rs7753531	chr6:79789996	A/C	cg18132916	chr6:79620363	NA	-0.56	-4.78	-0.44	6.33e-6	Intelligence (multi-trait analysis);
THYM	trans	rs7952251	0.812	rs1945120	chr11:112417320	G/A	cg14154186	chr1:204970430	NFASC	-0.72	-7.35	-0.6	6.94e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4664308	0.810	rs62175552	chr2:160937220	T/G	cg03641300	chr2:160917029	PLA2R1	-0.78	-6.97	-0.58	4.25e-10	Idiopathic membranous nephropathy;
THYM	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg08213375	chr14:104286397	PPP1R13B	0.53	6.31	0.54	8.83e-9	Schizophrenia;
THYM	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.09	0.59	2.39e-10	Lung cancer in ever smokers;
THYM	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg05738196	chr6:26577821	NA	0.57	4.7	0.43	8.7e-6	Schizophrenia;
THYM	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg18681998	chr4:17616180	MED28	0.91	8.56	0.66	2e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs8073060	0.859	rs17550268	chr17:33874678	T/C	cg24895173	chr17:33825374	SLFN12L	0.65	4.59	0.43	1.34e-5	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg16797656	chr11:68205561	LRP5	-0.45	-4.78	-0.44	6.46e-6	Total body bone mineral density;
THYM	cis	rs12711979	0.765	rs13030772	chr2:3821280	T/C	cg17052675	chr2:3827356	NA	-0.48	-5.19	-0.47	1.19e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.43	0.7	2.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7731657	0.537	rs1989052	chr5:130347413	T/C	cg08523029	chr5:130500466	HINT1	0.76	5.05	0.46	2.09e-6	Fasting plasma glucose;
THYM	cis	rs2354432	0.943	rs6660219	chr1:146691404	A/T	cg25205988	chr1:146714368	CHD1L	1.1	7.31	0.6	8.32e-11	Mitochondrial DNA levels;
THYM	cis	rs939658	0.805	rs6495374	chr15:79434031	C/T	cg17916960	chr15:79447300	NA	-0.69	-8.1	-0.64	1.82e-12	Refractive error;
THYM	cis	rs10193935	0.901	rs2286702	chr2:42555473	C/T	cg27598129	chr2:42591480	NA	-0.75	-4.61	-0.43	1.25e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3780378	0.967	rs1328917	chr9:5049065	G/T	cg02405213	chr9:5042618	JAK2	-0.78	-7.34	-0.6	7.17e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg20283391	chr11:68216788	NA	-0.73	-5.4	-0.48	4.96e-7	Total body bone mineral density;
THYM	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.03	10.73	0.74	4.6e-18	Cognitive ability;
THYM	cis	rs9399401	0.523	rs171915	chr6:142866845	C/T	cg04461802	chr6:142623433	GPR126	0.53	4.73	0.44	7.83e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs739401	0.582	rs7932369	chr11:2958468	A/G	cg03159660	chr11:2078197	NA	0.67	5.0	0.46	2.64e-6	Longevity;
THYM	cis	rs3540	0.597	rs1978150	chr15:91037041	A/G	cg22089800	chr15:90895588	ZNF774	-0.69	-5.4	-0.48	4.91e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs7122539	0.646	rs594313	chr11:66608991	A/G	cg24851651	chr11:66362959	CCS	0.65	5.69	0.5	1.38e-7	HIV-1 susceptibility;
THYM	cis	rs732765	0.689	rs12411	chr14:75409043	T/A	cg15890469	chr14:75408846	PGF	0.65	4.48	0.42	2.07e-5	Non-small cell lung cancer;
THYM	cis	rs6782029	0.550	rs62245781	chr3:11679211	G/A	cg07643000	chr3:11666825	VGLL4	-0.47	-5.19	-0.47	1.21e-6	Anorexia nervosa;
THYM	cis	rs8063160	0.667	rs79139787	chr16:89795360	C/T	cg07984980	chr16:89898383	SPIRE2	1.6	6.42	0.55	5.28e-9	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs9359856	0.913	rs9362663	chr6:90307550	A/C	cg13799429	chr6:90582589	CASP8AP2	0.46	4.46	0.42	2.29e-5	Bipolar disorder;
THYM	cis	rs7119038	0.818	rs77209083	chr11:118607569	A/G	cg19308663	chr11:118741387	NA	0.53	4.87	0.45	4.44e-6	Sjögren's syndrome;
THYM	cis	rs7578361	1.000	rs7578361	chr2:150397218	A/C	cg17961725	chr2:150454027	NA	-0.61	-5.12	-0.46	1.62e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.32	-9.88	-0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs9807841	0.670	rs2738039	chr19:10793749	A/G	cg17848348	chr19:10766748	ILF3	-0.85	-7.48	-0.61	3.69e-11	Inflammatory skin disease;
THYM	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.83	0.67	5.15e-14	Colorectal cancer;
THYM	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg13918804	chr1:2043761	PRKCZ	-0.81	-7.45	-0.61	4.33e-11	Height;
THYM	cis	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg02543101	chr16:74334038	PSMD7	0.62	4.96	0.45	3.04e-6	Energy expenditure (24h);
THYM	cis	rs4866334	1.000	rs80047653	chr5:18411985	C/T	cg18608440	chr5:17519013	NA	0.97	4.72	0.44	8.08e-6	IgG glycosylation;
THYM	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg17554472	chr22:41940697	POLR3H	-0.68	-4.85	-0.45	4.78e-6	Vitiligo;
THYM	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg04362960	chr10:104952993	NT5C2	0.57	4.64	0.43	1.12e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg10856724	chr12:34555212	NA	-0.79	-7.7	-0.62	1.27e-11	Morning vs. evening chronotype;
THYM	cis	rs4430311	0.723	rs2345994	chr1:243932275	T/C	cg25706552	chr1:244017396	NA	-0.59	-5.14	-0.47	1.49e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg08132940	chr7:1081526	C7orf50	-0.96	-5.46	-0.49	3.77e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg03690763	chr11:133734501	NA	0.62	4.75	0.44	7.26e-6	Childhood ear infection;
THYM	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg25072359	chr17:41440525	NA	0.68	4.71	0.43	8.49e-6	Menopause (age at onset);
THYM	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.3	6.14	0.53	1.91e-8	Obesity-related traits;
THYM	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg06808227	chr14:105710500	BRF1	-1.05	-9.15	-0.68	1.07e-14	Mean platelet volume;Platelet distribution width;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg23334507	chr12:46753241	SLC38A2	-1.0	-7.28	-0.6	9.67e-11	Depressive symptoms;
THYM	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs7804356	0.871	rs6951065	chr7:26756162	G/A	cg24979288	chr7:27242424	NA	0.62	4.48	0.42	2.09e-5	Type 1 diabetes;
THYM	cis	rs17253792	0.731	rs28587929	chr14:56097492	C/T	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg00981070	chr1:2046702	PRKCZ	-0.49	-5.92	-0.52	4.99e-8	Height;
THYM	cis	rs6840360	0.550	rs6836343	chr4:152497564	A/G	cg17479576	chr4:152424074	FAM160A1	-0.8	-5.92	-0.52	5.02e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.47	-0.42	2.16e-5	Morning vs. evening chronotype;
THYM	cis	rs7246967	0.551	rs16998998	chr19:22911116	T/C	cg05241461	chr19:22816980	ZNF492	0.61	4.74	0.44	7.63e-6	Bronchopulmonary dysplasia;
THYM	cis	rs67072384	0.901	rs2886366	chr11:72455207	G/C	cg01380194	chr11:72452482	ARAP1	-0.97	-5.26	-0.47	8.93e-7	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg07022442	chr13:21864356	NA	0.74	4.99	0.46	2.68e-6	White matter hyperintensity burden;
THYM	cis	rs4853012	1.000	rs4853012	chr2:74361290	G/A	cg19729930	chr2:74357872	NA	1.31	10.62	0.74	7.81e-18	Gestational age at birth (maternal effect);
THYM	cis	rs56341938	0.935	rs12493032	chr3:168747765	G/C	cg09107232	chr3:169491072	MYNN	0.53	4.47	0.42	2.14e-5	Lung function (FEV1/FVC);
THYM	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.63	-4.51	-0.42	1.88e-5	Colorectal cancer;
THYM	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg03188948	chr7:1209495	NA	0.99	5.67	0.5	1.51e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg23982607	chr1:1823379	GNB1	0.89	9.46	0.7	2.31e-15	Body mass index;
THYM	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg14972814	chr11:95582409	MTMR2	-0.81	-6.68	-0.57	1.6e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg10589385	chr1:150898437	SETDB1	0.66	5.58	0.5	2.27e-7	Tonsillectomy;
THYM	cis	rs10911232	0.507	rs61081633	chr1:182995608	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs7084402	0.935	rs11006192	chr10:60343638	T/C	cg07615347	chr10:60278583	BICC1	0.57	5.33	0.48	6.57e-7	Refractive error;
THYM	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg10193763	chr2:225306901	NA	-0.52	-5.56	-0.5	2.42e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg07362569	chr17:61921086	SMARCD2	0.68	6.09	0.53	2.42e-8	Prudent dietary pattern;
THYM	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs8066596	1.000	rs8066596	chr17:12978842	C/T	cg03529555	chr11:19416751	NAV2	-0.95	-7.11	-0.59	2.14e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs503425	1.000	rs503425	chr11:118692727	C/T	cg07003643	chr11:119217537	C1QTNF5;MFRP	0.69	4.58	0.42	1.43e-5	Systemic lupus erythematosus;
THYM	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg02725872	chr8:58115012	NA	-1.08	-6.65	-0.56	1.83e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs6510489	0.961	rs17705450	chr19:35975567	G/T	cg15078284	chr19:36004994	DMKN	0.46	5.58	0.5	2.24e-7	Bipolar disorder;
THYM	cis	rs1691799	0.867	rs1168297	chr12:66735644	T/C	cg16791601	chr12:66731901	HELB	-0.76	-7.23	-0.6	1.21e-10	White blood cell count (basophil);
THYM	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg04865290	chr3:52927548	TMEM110	-0.89	-4.61	-0.43	1.27e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs11214589	1.000	rs11214589	chr11:113245048	C/T	cg14159747	chr11:113255604	NA	0.37	7.42	0.61	4.9e-11	Neuroticism;
THYM	cis	rs12950390	0.512	rs59396604	chr17:45837777	G/A	cg06532163	chr17:45867833	NA	0.58	4.49	0.42	2e-5	IgG glycosylation;
THYM	cis	rs10504073	0.647	rs59064792	chr8:50018337	A/C	cg00325661	chr8:49890786	NA	0.86	7.69	0.62	1.35e-11	Blood metabolite ratios;
THYM	cis	rs57994353	0.897	rs55824202	chr9:139357273	A/T	cg14115884	chr9:139300582	SDCCAG3	0.68	4.74	0.44	7.42e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs2072499	0.865	rs2758608	chr1:156202860	A/T	cg06970220	chr1:156163860	SLC25A44	0.73	6.03	0.53	3.15e-8	Testicular germ cell tumor;
THYM	cis	rs10089	0.953	rs10463839	chr5:127519675	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.92	5.45	0.49	3.92e-7	Ileal carcinoids;
THYM	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.19	8.83	0.67	5.32e-14	Cognitive test performance;
THYM	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg23708337	chr7:1209742	NA	0.74	5.31	0.48	7.12e-7	Longevity;Endometriosis;
THYM	cis	rs10489202	0.657	rs3767479	chr1:168069840	C/A	cg24449463	chr1:168025552	DCAF6	-0.73	-6.53	-0.56	3.3e-9	Schizophrenia;
THYM	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs951188	0.688	rs73968620	chr2:150411187	C/G	cg17961725	chr2:150454027	NA	-0.99	-5.62	-0.5	1.93e-7	Daytime sleep phenotypes;
THYM	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	6.66	0.56	1.76e-9	Electrocardiographic conduction measures;
THYM	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11890956	chr21:40555474	PSMG1	-0.65	-6.03	-0.53	3.17e-8	Menarche (age at onset);
THYM	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg06558623	chr16:89946397	TCF25	1.34	5.59	0.5	2.16e-7	Skin colour saturation;
THYM	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg16586182	chr3:47516702	SCAP	0.57	4.98	0.45	2.88e-6	Colorectal cancer;
THYM	cis	rs6687430	0.512	rs34575776	chr1:10621061	A/G	cg20482658	chr1:10539492	PEX14	0.48	5.81	0.51	8.29e-8	Hand grip strength;
THYM	cis	rs7586879	0.639	rs3903070	chr2:25123463	C/G	cg01884057	chr2:25150051	NA	0.73	7.9	0.63	4.81e-12	Body mass index;
THYM	cis	rs4731207	0.698	rs4422720	chr7:124499402	C/G	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg12011299	chr4:100065546	ADH4	0.66	5.65	0.5	1.65e-7	Alcohol dependence;
THYM	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg26384229	chr12:38710491	ALG10B	0.95	5.74	0.51	1.12e-7	Bladder cancer;
THYM	cis	rs490234	0.867	rs829181	chr9:128288002	A/G	cg14078157	chr9:128172775	NA	0.6	4.72	0.44	7.99e-6	Mean arterial pressure;
THYM	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg18357526	chr6:26021779	HIST1H4A	0.81	7.02	0.58	3.25e-10	Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg03732007	chr1:2071316	PRKCZ	-0.5	-4.51	-0.42	1.89e-5	Height;
THYM	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg21773646	chr17:80085082	CCDC57	0.31	4.49	0.42	1.97e-5	Life satisfaction;
THYM	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg23989207	chr17:80870107	TBCD	0.62	5.18	0.47	1.24e-6	Glycated hemoglobin levels;
THYM	cis	rs13315871	1.000	rs35621601	chr3:58323174	A/G	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg17328964	chr8:145687451	CYHR1	-0.66	-5.62	-0.5	1.9e-7	Age at first birth;
THYM	cis	rs7084402	0.905	rs7098329	chr10:60276915	C/T	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.57e-7	Refractive error;
THYM	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg13385794	chr1:248469461	NA	0.67	4.6	0.43	1.29e-5	Common traits (Other);
THYM	cis	rs6918586	0.658	rs198826	chr6:26121153	A/G	cg03517284	chr6:25882590	NA	-0.62	-4.83	-0.44	5.27e-6	Schizophrenia;
THYM	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs17604090	0.938	rs28457783	chr7:29687058	T/G	cg19413766	chr7:29689036	LOC646762	-0.94	-5.1	-0.46	1.75e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg03529555	chr11:19416751	NAV2	-0.91	-6.94	-0.58	4.89e-10	Depressive symptoms;
THYM	cis	rs7719624	1.000	rs7719624	chr5:135377566	A/G	cg15329133	chr5:135467951	SMAD5;SMAD5OS	-0.56	-4.92	-0.45	3.61e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs28595532	1.000	rs115004746	chr4:119642137	C/T	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs67460515	0.892	rs34771618	chr3:161059795	A/C	cg03342759	chr3:160939853	NMD3	-0.91	-7.85	-0.63	6.27e-12	Parkinson's disease;
THYM	cis	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg04866029	chr1:2707161	NA	0.43	4.46	0.42	2.25e-5	Ulcerative colitis;
THYM	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg13010199	chr12:38710504	ALG10B	0.76	6.07	0.53	2.59e-8	Heart rate;
THYM	cis	rs483180	0.532	rs561931	chr1:120254506	A/G	cg19096424	chr1:120255104	PHGDH	0.69	5.29	0.48	7.71e-7	Macular telangiectasia type 2;
THYM	cis	rs9902453	0.765	rs6505143	chr17:28150585	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	6.53	0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs7078219	0.576	rs989979	chr10:101322423	C/G	cg07044859	chr10:101282883	NA	-0.45	-4.94	-0.45	3.36e-6	Dental caries;
THYM	cis	rs7940866	0.774	rs7480903	chr11:130832276	A/G	cg23692386	chr11:131799662	NTM	0.45	4.48	0.42	2.07e-5	Schizophrenia;
THYM	cis	rs10924970	1.000	rs10924970	chr1:235362960	A/G	cg26050004	chr1:235667680	B3GALNT2	0.62	4.49	0.42	2.04e-5	Asthma;
THYM	trans	rs8002861	0.967	rs2166301	chr13:44473955	A/T	cg17145862	chr1:211918768	LPGAT1	1.04	12.02	0.78	8.8e-21	Leprosy;
THYM	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg17911788	chr17:44343683	NA	-0.78	-7.26	-0.6	1.08e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg07424592	chr7:64974309	NA	1.03	5.4	0.48	4.94e-7	Diabetic kidney disease;
THYM	cis	rs1348850	0.526	rs6718769	chr2:178450909	T/C	cg27490568	chr2:178487706	NA	0.63	5.2	0.47	1.14e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1971762	0.527	rs2365343	chr12:54038149	C/T	cg16917193	chr12:54089295	NA	-0.76	-7.41	-0.61	5.15e-11	Height;
THYM	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg25358565	chr5:93447407	FAM172A	1.37	9.68	0.7	8.1e-16	Diabetic retinopathy;
THYM	cis	rs289828	0.500	rs6747965	chr2:152157972	C/A	cg05960677	chr2:152117363	RBM43	0.69	6.56	0.56	2.86e-9	Blood protein levels;
THYM	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-12.91	-0.8	1.28e-22	Height;
THYM	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-9.71	-0.71	7e-16	Primary sclerosing cholangitis;
THYM	cis	rs600806	0.850	rs10776806	chr1:109952127	G/A	cg23616212	chr1:109941201	SORT1	-0.49	-4.66	-0.43	1.01e-5	Intelligence (multi-trait analysis);
THYM	cis	rs533581	0.816	rs533406	chr16:88974860	A/G	cg08484992	chr16:88977278	CBFA2T3	0.37	4.65	0.43	1.06e-5	Social autistic-like traits;
THYM	cis	rs986417	1.000	rs11845369	chr14:60944959	A/G	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	14.79	0.83	2.2e-26	Chronic sinus infection;
THYM	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs921968	0.565	rs3770219	chr2:219619766	T/C	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6032067	0.866	rs6104054	chr20:43822771	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.44	-5.26	-0.47	8.99e-7	Blood protein levels;
THYM	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg12963246	chr6:28129442	ZNF389	-0.72	-5.78	-0.51	9.62e-8	Parkinson's disease;
THYM	cis	rs34779708	0.931	rs55724039	chr10:35465397	A/G	cg03585969	chr10:35415529	CREM	0.65	4.51	0.42	1.87e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.23	10.02	0.72	1.49e-16	Platelet count;
THYM	cis	rs6674970	0.748	rs56299877	chr1:151115645	C/T	cg11822372	chr1:151115635	SEMA6C	-1.28	-9.36	-0.69	3.83e-15	Childhood ear infection;
THYM	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg21926883	chr2:100939477	LONRF2	0.65	5.96	0.52	4.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.74	5.66	0.5	1.58e-7	Eosinophil percentage of white cells;
THYM	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg12179176	chr11:130786555	SNX19	0.78	6.67	0.56	1.68e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1843834	0.858	rs2047136	chr2:225511361	A/T	cg22455342	chr2:225449267	CUL3	0.69	5.04	0.46	2.24e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	6.33	0.54	8.19e-9	Platelet count;
THYM	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg26116260	chr4:7069785	GRPEL1	-1.02	-7.61	-0.62	1.97e-11	Monocyte percentage of white cells;
THYM	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.16	-7.92	-0.63	4.35e-12	Schizophrenia;
THYM	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2404602	0.552	rs11630185	chr15:76959783	A/T	cg23625390	chr15:77176239	SCAPER	-0.85	-5.19	-0.47	1.19e-6	Blood metabolite levels;
THYM	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg12826209	chr6:26865740	GUSBL1	0.94	5.02	0.46	2.37e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg18681998	chr4:17616180	MED28	0.98	9.9	0.71	2.68e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg11764359	chr7:65958608	NA	0.67	4.85	0.45	4.84e-6	Aortic root size;
THYM	cis	rs1018836	0.892	rs13267237	chr8:91550820	T/C	cg16814680	chr8:91681699	NA	-0.82	-7.32	-0.6	8.09e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg27532560	chr4:187881888	NA	-0.94	-11.13	-0.75	6.64e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg13699009	chr12:122356056	WDR66	0.47	4.61	0.43	1.27e-5	Mean corpuscular volume;
THYM	cis	rs4638749	0.677	rs12712018	chr2:108853505	A/C	cg06795125	chr2:108905320	SULT1C2	-0.35	-4.6	-0.43	1.33e-5	Blood pressure;
THYM	cis	rs7246967	0.673	rs7249685	chr19:22882379	C/T	cg05241461	chr19:22816980	ZNF492	0.6	4.64	0.43	1.11e-5	Bronchopulmonary dysplasia;
THYM	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg22535103	chr8:58192502	C8orf71	-0.96	-5.47	-0.49	3.7e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs6430585	0.583	rs79176913	chr2:136638113	C/A	cg23851026	chr2:136556271	LCT	0.8	7.65	0.62	1.64e-11	Corneal structure;
THYM	cis	rs7511006	0.859	rs7292228	chr22:50649560	C/G	cg11077631	chr22:50617003	PANX2	-0.54	-5.93	-0.52	4.93e-8	Obesity-related traits;
THYM	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07167872	chr1:205819463	PM20D1	-0.81	-7.23	-0.6	1.2e-10	Monocyte percentage of white cells;
THYM	cis	rs7584330	0.504	rs11883500	chr2:238434434	C/T	cg14458575	chr2:238380390	NA	0.81	4.86	0.45	4.63e-6	Prostate cancer;
THYM	cis	rs6918586	0.658	rs198844	chr6:26108282	C/G	cg03264133	chr6:25882463	NA	0.64	4.94	0.45	3.41e-6	Schizophrenia;
THYM	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs7584330	0.697	rs60278044	chr2:238357118	A/G	cg07705835	chr3:9959128	IL17RC	0.62	7.17	0.59	1.59e-10	Prostate cancer;
THYM	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg10360139	chr7:1886902	MAD1L1	-0.61	-4.63	-0.43	1.15e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg18252515	chr7:66147081	NA	0.6	4.54	0.42	1.63e-5	Aortic root size;
THYM	cis	rs3087591	0.960	rs2952984	chr17:29469614	T/C	cg24425628	chr17:29625626	OMG;NF1	0.62	5.34	0.48	6.25e-7	Hip circumference;
THYM	cis	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.85	-6.88	-0.58	6.36e-10	Platelet distribution width;
THYM	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg26038318	chr20:34205095	SPAG4	0.65	5.25	0.47	9.22e-7	Total cholesterol levels;
THYM	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg16423285	chr20:60520624	NA	-1.15	-9.33	-0.69	4.56e-15	Obesity-related traits;
THYM	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg19677267	chr1:26645161	CD52;UBXN11	-0.45	-5.84	-0.51	7.24e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs67460515	0.563	rs6441362	chr3:160877613	G/A	cg03342759	chr3:160939853	NMD3	-0.65	-4.86	-0.45	4.71e-6	Parkinson's disease;
THYM	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg07537917	chr2:241836409	C2orf54	-0.26	-5.87	-0.52	6.32e-8	Urinary metabolites;
THYM	cis	rs7115242	0.800	rs1320668	chr11:116967666	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.91	5.11	0.46	1.67e-6	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
THYM	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4604732	0.642	rs10802514	chr1:247637749	A/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	4.71	0.43	8.6e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs9399401	0.633	rs262118	chr6:142843054	C/A	cg04461802	chr6:142623433	GPR126	0.59	5.18	0.47	1.24e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs7107770	1.000	rs7107770	chr11:125100438	C/G	cg07747661	chr11:125106135	PKNOX2	-0.84	-5.12	-0.46	1.62e-6	Photic sneeze reflex;
THYM	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg24530246	chr3:53118167	NA	-0.76	-4.57	-0.42	1.47e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs6554196	0.508	rs11727273	chr4:55509748	C/T	cg18836493	chr4:55524333	KIT	-0.54	-4.58	-0.42	1.43e-5	Monocyte count;
THYM	cis	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21191810	chr6:118973309	C6orf204	-0.64	-5.64	-0.5	1.77e-7	Electrocardiographic conduction measures;
THYM	cis	rs9880211	0.898	rs13434116	chr3:136353074	G/C	cg21827317	chr3:136751795	NA	-0.7	-4.55	-0.42	1.6e-5	Body mass index;Height;
THYM	cis	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg07460842	chr6:66804631	NA	0.84	5.48	0.49	3.45e-7	Exhaled nitric oxide output;
THYM	cis	rs611744	0.967	rs569701	chr8:109239207	G/A	cg21045802	chr8:109455806	TTC35	0.59	5.25	0.47	9.08e-7	Dupuytren's disease;
THYM	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9359856	0.564	rs1036853	chr6:90499502	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.89	-8.13	-0.64	1.6e-12	Bipolar disorder;
THYM	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg02725872	chr8:58115012	NA	-0.9	-5.24	-0.47	9.85e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs13315871	0.929	rs13075746	chr3:58293867	G/A	cg12435725	chr3:58293450	RPP14	-0.53	-5.57	-0.5	2.32e-7	Cholesterol, total;
THYM	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.53	-4.87	-0.45	4.42e-6	Lymphocyte counts;
THYM	cis	rs73198271	0.740	rs10092720	chr8:8649117	A/C	cg15556689	chr8:8085844	FLJ10661	-0.75	-4.92	-0.45	3.57e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs1728785	1.000	rs1645935	chr16:68563791	A/C	cg02972257	chr16:68554789	NA	-0.74	-4.54	-0.42	1.63e-5	Ulcerative colitis;
THYM	cis	rs2637266	0.935	rs2583050	chr10:78403615	C/T	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg06112835	chr11:68658793	MRPL21	0.43	6.23	0.54	1.28e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2282300	0.956	rs1717779	chr11:30376698	A/T	cg09906309	chr11:30344399	C11orf46	-0.73	-5.14	-0.47	1.5e-6	Morning vs. evening chronotype;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg26873329	chr5:32522933	NA	1.3	7.47	0.61	3.82e-11	Pulmonary function decline;
THYM	cis	rs501916	0.634	rs3743286	chr15:48065792	A/G	cg20869673	chr15:48010124	SEMA6D	0.63	4.49	0.42	1.99e-5	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs9914544	0.545	rs3764445	chr17:18767923	C/T	cg26378065	chr17:18585709	ZNF286B	0.57	4.49	0.42	2.04e-5	Educational attainment (years of education);
THYM	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs11574514	0.661	rs9922476	chr16:67478924	A/G	cg09738193	chr16:67926317	PSKH1	-0.78	-4.5	-0.42	1.91e-5	Crohn's disease;
THYM	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg19507638	chr5:93509721	C5orf36	-0.68	-4.57	-0.42	1.49e-5	Diabetic retinopathy;
THYM	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg25703541	chr22:24373054	LOC391322	0.86	7.53	0.61	2.89e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs9532580	0.710	rs9577090	chr13:41225228	G/T	cg21288729	chr13:41239152	FOXO1	0.71	5.65	0.5	1.66e-7	Mean corpuscular hemoglobin;
THYM	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4575098	0.681	rs10908824	chr1:161111931	A/G	cg24329783	chr1:161160887	ADAMTS4	-0.63	-5.67	-0.5	1.55e-7	Monocyte percentage of white cells;
THYM	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg23682913	chr1:2080710	PRKCZ	-0.57	-5.35	-0.48	6.05e-7	Height;
THYM	cis	rs12282928	0.959	rs1503192	chr11:48289355	A/G	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22496380	chr5:211416	CCDC127	-1.31	-8.26	-0.65	8.38e-13	Breast cancer;
THYM	cis	rs7264396	0.635	rs6060688	chr20:34516731	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.69	5.26	0.48	8.75e-7	Total cholesterol levels;
THYM	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg13319975	chr6:146136371	FBXO30	-0.61	-4.96	-0.45	3.05e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13315871	1.000	rs28668389	chr3:58323942	G/C	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg00012203	chr2:219082015	ARPC2	0.82	7.47	0.61	3.95e-11	Colorectal cancer;
THYM	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg06028808	chr11:68637592	NA	0.59	6.12	0.53	2.1e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.7	5.63	0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg15247329	chr7:2764246	NA	0.7	5.75	0.51	1.1e-7	Height;
THYM	cis	rs7909791	0.543	rs11191842	chr10:105639808	C/T	cg24587175	chr10:105670608	OBFC1	0.77	7.49	0.61	3.44e-11	White matter hyperintensity burden;
THYM	cis	rs748404	0.578	rs2012467	chr15:43690565	A/G	cg12861797	chr15:43585817	TGM7	0.47	4.98	0.46	2.8e-6	Lung cancer;
THYM	cis	rs713587	0.624	rs1550110	chr2:25124563	T/C	cg15423357	chr2:25149977	NA	0.7	7.61	0.62	2e-11	Body mass index in non-asthmatics;
THYM	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg23682913	chr1:2080710	PRKCZ	0.63	5.67	0.5	1.51e-7	Height;
THYM	cis	rs4589258	0.933	rs1616765	chr11:90440154	C/A	cg26138821	chr11:89956704	CHORDC1	0.7	5.9	0.52	5.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg00071950	chr4:10020882	SLC2A9	0.86	8.92	0.68	3.37e-14	Bone mineral density;
THYM	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs6815814	0.898	rs1106956	chr4:38889811	A/G	cg06935464	chr4:38784597	TLR10	0.71	4.81	0.44	5.76e-6	Breast cancer;
THYM	cis	rs17433780	0.857	rs12140979	chr1:89467242	C/G	cg09516651	chr1:89888402	LOC400759	0.85	6.43	0.55	5.2e-9	Carotid intima media thickness;
THYM	cis	rs7106204	0.764	rs4508205	chr11:24218850	C/T	ch.11.24196551F	chr11:24239977	NA	0.86	4.57	0.42	1.46e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.68	-4.89	-0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs7072216	0.763	rs10732782	chr10:100166506	C/A	cg26618903	chr10:100175079	PYROXD2	-0.48	-4.6	-0.43	1.33e-5	Metabolite levels;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg24585035	chr5:32522852	NA	1.32	7.37	0.6	6.32e-11	Pulmonary function decline;
THYM	cis	rs995000	0.931	rs2131926	chr1:63026011	C/T	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs7809950	0.637	rs3801964	chr7:106836242	T/C	cg23024343	chr7:107201750	COG5	-1.02	-8.45	-0.66	3.29e-13	Coronary artery disease;
THYM	cis	rs6543140	0.964	rs6543138	chr2:103066132	G/A	cg03938978	chr2:103052716	IL18RAP	0.58	5.84	0.51	7.16e-8	Blood protein levels;
THYM	cis	rs4654899	1.000	rs7543126	chr1:21406088	T/G	cg01072550	chr1:21505969	NA	-0.74	-6.86	-0.58	6.89e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	4.93	0.45	3.5e-6	Diabetic retinopathy;
THYM	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.26	7.05	0.59	2.91e-10	Gut microbiome composition (summer);
THYM	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-4.78	-0.44	6.41e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7084402	0.967	rs7098606	chr10:60277089	C/T	cg07615347	chr10:60278583	BICC1	-0.56	-5.15	-0.47	1.39e-6	Refractive error;
THYM	cis	rs12549902	0.800	rs4736999	chr8:41506152	C/G	cg21772509	chr8:41503840	NKX6-3	0.64	5.48	0.49	3.56e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
THYM	cis	rs113835537	0.529	rs61561111	chr11:66275923	T/C	cg24851651	chr11:66362959	CCS	0.7	4.89	0.45	4.04e-6	Airway imaging phenotypes;
THYM	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg25566285	chr7:158114605	PTPRN2	0.88	9.18	0.69	9.29e-15	Calcium levels;
THYM	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	5.49	0.49	3.36e-7	Schizophrenia;
THYM	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg04990556	chr1:26633338	UBXN11	-0.89	-8.52	-0.66	2.34e-13	Obesity-related traits;
THYM	trans	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs2456568	0.802	rs1395386	chr11:93639331	A/G	cg26875233	chr11:93583750	C11orf90	0.53	5.53	0.49	2.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs12039431	0.666	rs215207	chr1:37952524	C/A	cg17933807	chr1:38061675	GNL2	-0.75	-5.41	-0.49	4.69e-7	Epithelial ovarian cancer;
THYM	cis	rs747782	0.528	rs10838881	chr11:48387275	T/C	cg24672777	chr11:48374446	OR4C45	-1.16	-7.24	-0.6	1.16e-10	Intraocular pressure;
THYM	cis	rs7692976	0.503	rs9999824	chr4:110935774	A/C	cg06981781	chr4:110842888	EGF	-0.38	-4.51	-0.42	1.86e-5	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs35660623	0.850	rs9969476	chr8:10670769	G/A	cg12395012	chr8:11607386	GATA4	0.94	5.08	0.46	1.85e-6	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg15212455	chr7:39170539	POU6F2	0.59	5.29	0.48	7.76e-7	IgG glycosylation;
THYM	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg01264106	chr22:38071602	LGALS1	0.41	4.97	0.45	2.94e-6	Fat distribution (HIV);
THYM	cis	rs7072216	0.763	rs6584205	chr10:100173806	C/T	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg03264133	chr6:25882463	NA	0.65	5.09	0.46	1.83e-6	Schizophrenia;
THYM	cis	rs16858210	0.520	rs12636861	chr3:183549788	T/C	cg03417191	chr3:183542750	MAP6D1	-0.87	-4.54	-0.42	1.66e-5	Menopause (age at onset);
THYM	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg00147160	chr1:26503991	CNKSR1	0.53	7.17	0.59	1.65e-10	Height;
THYM	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs11696845	0.604	rs1980577	chr20:43382112	A/G	cg25301532	chr20:43378953	KCNK15	0.65	5.3	0.48	7.55e-7	Obesity-related traits;
THYM	cis	rs4845570	1.000	rs6683364	chr1:151746202	T/A	cg18019451	chr1:151746047	TDRKH	-0.75	-4.58	-0.43	1.41e-5	Coronary artery disease;
THYM	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.31	0.6	8.34e-11	Obesity-related traits;
THYM	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg02018176	chr4:1364513	KIAA1530	0.73	6.82	0.57	8.42e-10	Longevity;
THYM	trans	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg25214090	chr10:38739885	LOC399744	0.93	7.92	0.63	4.43e-12	Corneal astigmatism;
THYM	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg05368731	chr17:41323189	NBR1	1.24	11.23	0.76	4.01e-19	Menopause (age at onset);
THYM	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg00071950	chr4:10020882	SLC2A9	0.86	10.33	0.73	3.3e-17	Bone mineral density;
THYM	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg00278517	chr6:167070616	RPS6KA2	0.35	4.58	0.42	1.44e-5	Crohn's disease;
THYM	cis	rs11731175	1.000	rs11132591	chr4:189848643	G/A	cg00431894	chr4:189871012	NA	-0.81	-6.15	-0.53	1.83e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs11031096	0.678	rs1442727	chr11:4188188	G/T	cg08557956	chr11:4115526	RRM1	0.55	4.99	0.46	2.76e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg06640241	chr16:89574553	SPG7	0.9	8.1	0.64	1.82e-12	Multiple myeloma (IgH translocation);
THYM	cis	rs4294134	0.832	rs11772708	chr7:135264737	A/G	cg08396481	chr7:135194601	CNOT4	-0.8	-4.58	-0.43	1.4e-5	Paget's disease;
THYM	cis	rs3770770	0.903	rs62133082	chr2:37233937	T/C	cg14987922	chr2:37194071	STRN	-0.75	-4.67	-0.43	9.88e-6	QRS duration;
THYM	cis	rs11122895	0.791	rs10864876	chr2:112469991	A/G	cg23262488	chr2:112468472	NA	0.47	5.33	0.48	6.64e-7	Allergic sensitization;
THYM	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg26441486	chr22:50317300	CRELD2	0.44	6.39	0.55	6.13e-9	Schizophrenia;
THYM	cis	rs752010	0.905	rs2038977	chr1:42094659	A/G	cg06885757	chr1:42089581	HIVEP3	0.52	6.5	0.56	3.62e-9	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs860818	1.000	rs858291	chr7:23247361	G/A	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs4363385	0.747	rs2339491	chr1:152985322	T/C	cg13444842	chr1:152974279	SPRR3	-0.58	-4.71	-0.44	8.32e-6	Inflammatory skin disease;
THYM	cis	rs8018808	0.875	rs11159258	chr14:77880593	T/C	cg20045696	chr14:77926864	AHSA1	0.58	5.44	0.49	4.16e-7	Myeloid white cell count;
THYM	cis	rs7078219	0.543	rs7092009	chr10:101277239	A/G	cg04972745	chr10:101287846	NA	-0.52	-4.8	-0.44	5.92e-6	Dental caries;
THYM	cis	rs17776563	0.887	rs7164137	chr15:89136177	C/T	cg01779732	chr15:90015521	RHCG	0.46	4.53	0.42	1.71e-5	Thyroid hormone levels;
THYM	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg15445000	chr17:37608096	MED1	-0.42	-5.08	-0.46	1.91e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs11711311	1.000	rs9288983	chr3:113488699	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.62	-5.52	-0.49	2.89e-7	IgG glycosylation;
THYM	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg03929089	chr4:120376271	NA	-0.95	-10.84	-0.74	2.75e-18	Coronary artery disease;
THYM	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg01236616	chr12:121019343	POP5	-1.29	-9.77	-0.71	5.19e-16	Type 1 diabetes nephropathy;
THYM	cis	rs9913156	0.841	rs56239958	chr17:4600280	G/C	cg19197139	chr17:4613644	ARRB2	0.84	4.97	0.45	2.92e-6	Lymphocyte counts;
THYM	cis	rs877282	0.945	rs71491303	chr10:772884	G/T	cg10556349	chr10:835070	NA	-0.69	-4.81	-0.44	5.75e-6	Uric acid levels;
THYM	cis	rs1878931	0.597	rs37816	chr16:3456371	G/A	cg21433313	chr16:3507492	NAT15	0.6	4.99	0.46	2.68e-6	Body mass index (adult);
THYM	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.73	0.57	1.29e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12282928	0.959	rs7124318	chr11:48338030	C/T	cg22827986	chr11:48284249	OR4X1	0.53	5.59	0.5	2.21e-7	Migraine - clinic-based;
THYM	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg06850241	chr22:41845214	NA	-0.49	-4.66	-0.43	1.04e-5	Vitiligo;
THYM	cis	rs2244613	0.882	rs1974708	chr16:55793837	T/C	cg27396498	chr16:55794478	CES4	0.74	5.07	0.46	1.97e-6	Response to dabigatran etexilate treatment;
THYM	cis	rs6032067	0.632	rs35632684	chr20:43802889	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.52	-5.89	-0.52	5.76e-8	Blood protein levels;
THYM	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg02454025	chr1:11042201	C1orf127	0.85	9.91	0.71	2.54e-16	Ewing sarcoma;
THYM	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7551222	0.752	rs11240756	chr1:204482594	C/T	cg20240347	chr1:204465584	NA	-0.51	-4.54	-0.42	1.64e-5	Schizophrenia;
THYM	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg23711669	chr6:146136114	FBXO30	-0.76	-7.22	-0.6	1.28e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg07424592	chr7:64974309	NA	-1.03	-5.38	-0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs61774743	0.754	rs11581271	chr1:41835061	C/G	cg01193554	chr1:41846683	NA	-0.33	-4.86	-0.45	4.71e-6	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs5759167	1.000	rs5759167	chr22:43500212	A/C	cg08094784	chr22:42976149	RRP7B	-0.49	-4.56	-0.42	1.55e-5	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs854765	0.624	rs12450799	chr17:17730201	T/C	cg16928487	chr17:17741425	SREBF1	0.56	5.18	0.47	1.25e-6	Total body bone mineral density;
THYM	cis	rs6500395	1.000	rs1558817	chr16:48730722	G/A	cg04672837	chr16:48644449	N4BP1	0.49	4.76	0.44	7.03e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs899997	0.773	rs12595461	chr15:78969172	T/G	cg04896959	chr15:78267971	NA	-0.8	-5.61	-0.5	1.97e-7	Coronary artery disease or large artery stroke;
THYM	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg15448220	chr1:150897856	SETDB1	0.9	7.41	0.61	5.04e-11	Melanoma;
THYM	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg18305652	chr10:134549665	INPP5A	0.81	7.11	0.59	2.17e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs80319144	1.000	rs80319144	chr2:159199835	C/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.59	4.73	0.44	7.69e-6	Restless legs syndrome;
THYM	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg26384229	chr12:38710491	ALG10B	1.03	10.33	0.73	3.29e-17	Heart rate;
THYM	cis	rs1986734	0.576	rs2068062	chr4:77417214	A/C	cg20311846	chr4:77356250	SHROOM3	-0.43	-4.66	-0.43	1.01e-5	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
THYM	cis	rs2562456	0.917	rs9304987	chr19:21682274	A/T	cg21751540	chr19:21541537	ZNF738	0.68	4.79	0.44	6.17e-6	Pain;
THYM	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.88	-0.58	6.43e-10	Eye color traits;
THYM	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg02753203	chr1:228287806	NA	0.98	8.36	0.65	5.22e-13	Diastolic blood pressure;
THYM	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg08847533	chr14:75593920	NEK9	-1.01	-11.32	-0.76	2.63e-19	Height;
THYM	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.04	9.25	0.69	6.53e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg23711669	chr6:146136114	FBXO30	-0.9	-8.7	-0.67	9.84e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7209460	0.518	rs2236374	chr17:1989637	C/T	cg15816464	chr17:2026533	SMG6	0.37	4.89	0.45	4.04e-6	Coronary artery disease;Total body bone mineral density;
THYM	cis	rs2404602	0.552	rs11634428	chr15:77084582	T/C	cg23625390	chr15:77176239	SCAPER	-0.86	-5.4	-0.48	4.82e-7	Blood metabolite levels;
THYM	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg07936489	chr17:37558343	FBXL20	-0.67	-4.9	-0.45	3.86e-6	Asthma;
THYM	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg09034736	chr1:150693464	HORMAD1	0.51	4.49	0.42	1.98e-5	Melanoma;
THYM	cis	rs2046867	0.862	rs62251645	chr3:72805733	T/C	cg25664220	chr3:72788482	NA	-0.86	-6.56	-0.56	2.76e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7267979	0.966	rs3002698	chr20:25303379	C/G	cg08601574	chr20:25228251	PYGB	-0.57	-4.59	-0.43	1.35e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4849845	0.925	rs4849841	chr2:121012359	G/T	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs17253792	0.822	rs8009239	chr14:56062490	A/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg07424592	chr7:64974309	NA	1.09	5.01	0.46	2.55e-6	Diabetic kidney disease;
THYM	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs2219968	1.000	rs1073444	chr8:78959671	T/C	cg00738934	chr8:78996279	NA	0.91	9.75	0.71	5.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4383453	0.539	rs11923120	chr3:123101592	A/G	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs58873874	0.737	rs112160357	chr5:156928704	C/G	cg08916508	chr5:156566250	MED7	-1.34	-5.3	-0.48	7.59e-7	Bipolar disorder (body mass index interaction);
THYM	cis	rs4917300	0.605	rs1388800	chr8:143106264	C/T	cg26003909	chr8:143102224	NA	0.31	4.56	0.42	1.55e-5	Amyotrophic lateral sclerosis;
THYM	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.6	4.78	0.44	6.37e-6	Renal function-related traits (BUN);
THYM	cis	rs6541297	0.887	rs4846906	chr1:230284257	C/A	cg20703242	chr1:230279135	GALNT2	0.9	5.32	0.48	6.92e-7	Coronary artery disease;
THYM	cis	rs6430585	0.528	rs111682961	chr2:136653848	C/T	cg07169764	chr2:136633963	MCM6	1.19	11.2	0.75	4.62e-19	Corneal structure;
THYM	cis	rs9810089	0.934	rs10935184	chr3:136153468	T/C	cg12473912	chr3:136751656	NA	0.58	4.78	0.44	6.47e-6	Gestational age at birth (child effect);
THYM	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.03	-4.79	-0.44	6.14e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg18252515	chr7:66147081	NA	-0.63	-4.69	-0.43	8.99e-6	Aortic root size;
THYM	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg03806693	chr22:41940476	POLR3H	1.1	8.83	0.67	5.2e-14	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.18	-0.47	1.23e-6	Mean corpuscular volume;
THYM	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	5.0	0.46	2.6e-6	Height;
THYM	cis	rs4077515	0.967	rs3812558	chr9:139269135	A/G	cg14115884	chr9:139300582	SDCCAG3	0.72	7.01	0.58	3.46e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4803468	1.000	rs878082	chr19:41897674	G/A	cg09537434	chr19:41945824	ATP5SL	-1.12	-10.31	-0.73	3.55e-17	Height;
THYM	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.94	-6.98	-0.58	4.05e-10	Schizophrenia;
THYM	cis	rs7833986	0.501	rs72653921	chr8:56897157	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	6.63	0.56	2.06e-9	Height;
THYM	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg08999081	chr20:33150536	PIGU	-0.78	-7.16	-0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg02018176	chr4:1364513	KIAA1530	0.99	9.76	0.71	5.32e-16	Longevity;
THYM	cis	rs4285028	0.948	rs71329247	chr3:121681523	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg06238570	chr21:40685208	BRWD1	0.92	6.87	0.58	6.76e-10	Cognitive function;
THYM	cis	rs4974559	0.739	rs4333131	chr4:1323789	A/G	cg16185996	chr4:1008614	FGFRL1	-0.42	-4.5	-0.42	1.93e-5	Systolic blood pressure;
THYM	cis	rs11731175	1.000	rs12648386	chr4:189862525	G/A	cg00431894	chr4:189871012	NA	-0.88	-6.8	-0.57	9.29e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.63	-0.5	1.81e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7319311	0.899	rs9521729	chr13:111029970	G/A	cg06243866	chr13:111019493	COL4A2	0.73	6.06	0.53	2.76e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg25767906	chr1:53392781	SCP2	-0.57	-5.67	-0.5	1.51e-7	Monocyte count;
THYM	cis	rs11070747	1.000	rs11070747	chr15:50376439	C/G	cg21557108	chr15:50410962	ATP8B4	-0.44	-5.0	-0.46	2.66e-6	Verbal declarative memory;
THYM	cis	rs916888	0.779	rs199526	chr17:44847707	C/G	cg17911788	chr17:44343683	NA	0.61	5.94	0.52	4.59e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03517284	chr6:25882590	NA	-0.93	-8.1	-0.64	1.81e-12	Intelligence (multi-trait analysis);
THYM	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg09323728	chr8:95962352	TP53INP1	-0.45	-4.48	-0.42	2.11e-5	Type 2 diabetes;
THYM	cis	rs7560272	0.723	rs6744697	chr2:73765438	T/C	cg19565262	chr2:73869966	NAT8	-0.54	-4.62	-0.43	1.19e-5	Schizophrenia;
THYM	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.82	-5.23	-0.47	1e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg23649088	chr2:200775458	C2orf69	0.81	6.14	0.53	1.88e-8	Schizophrenia;
THYM	cis	rs7107174	0.892	rs4291702	chr11:78001248	C/T	cg19901956	chr11:77921274	USP35	-0.62	-4.86	-0.45	4.58e-6	Testicular germ cell tumor;
THYM	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.76	-4.99	-0.46	2.73e-6	Body mass index;
THYM	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg21100191	chr22:23484243	RTDR1	0.72	6.3	0.54	9.05e-9	Bone mineral density;
THYM	cis	rs7177699	0.557	rs7403714	chr15:79118650	C/T	cg15571903	chr15:79123663	NA	-0.57	-6.28	-0.54	1.03e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg15704280	chr7:45808275	SEPT13	-0.99	-11.39	-0.76	1.85e-19	Coronary artery disease;
THYM	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg07747251	chr5:1868357	NA	0.68	5.86	0.52	6.66e-8	Cardiovascular disease risk factors;
THYM	cis	rs9926296	0.557	rs11076618	chr16:89807705	T/C	cg01097406	chr16:89675127	NA	-0.55	-4.46	-0.42	2.24e-5	Vitiligo;
THYM	cis	rs977987	0.835	rs4888380	chr16:75347690	T/C	cg03315344	chr16:75512273	CHST6	0.83	6.84	0.57	7.77e-10	Dupuytren's disease;
THYM	cis	rs36051895	0.632	rs7469563	chr9:5139489	C/T	cg02405213	chr9:5042618	JAK2	-1.02	-11.79	-0.77	2.7e-20	Pediatric autoimmune diseases;
THYM	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.69	-5.72	-0.51	1.23e-7	Lymphocyte counts;
THYM	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg08885076	chr2:99613938	TSGA10	-0.71	-6.69	-0.57	1.51e-9	Chronic sinus infection;
THYM	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg24209194	chr3:40518798	ZNF619	0.57	4.62	0.43	1.2e-5	Renal cell carcinoma;
THYM	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg05962950	chr11:130786565	SNX19	0.92	8.74	0.67	8.09e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.71	5.63	0.5	1.8e-7	Tonsillectomy;
THYM	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg08885076	chr2:99613938	TSGA10	-0.45	-4.53	-0.42	1.7e-5	Fear of minor pain;
THYM	cis	rs9649213	0.593	rs12704982	chr7:97926053	C/T	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.6e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4946717	0.740	rs9480634	chr6:106468486	C/T	cg02270332	chr6:106475062	NA	0.74	10.28	0.73	4.27e-17	Inflammatory bowel disease;
THYM	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg16624210	chr5:671434	TPPP	0.79	6.01	0.52	3.44e-8	Obesity-related traits;
THYM	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.16	-0.75	5.56e-19	Primary sclerosing cholangitis;
THYM	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg13334819	chr7:99746414	C7orf59	0.7	4.84	0.44	5e-6	Coronary artery disease;
THYM	cis	rs597539	0.597	rs35956171	chr11:68602735	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.64	-4.84	-0.44	4.97e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7236492	0.935	rs7239086	chr18:77217030	A/C	cg15644404	chr18:77186268	NFATC1	-1.06	-4.94	-0.45	3.41e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg11494091	chr17:61959527	GH2	0.7	6.46	0.55	4.55e-9	Height;
THYM	cis	rs9326248	0.581	rs10892053	chr11:116857003	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.66	5.37	0.48	5.57e-7	Blood protein levels;
THYM	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg06221963	chr1:154839813	KCNN3	-0.9	-12.82	-0.8	1.94e-22	Prostate cancer;
THYM	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs6424115	0.657	rs519202	chr1:24045820	C/T	cg15997130	chr1:24165203	NA	0.65	5.28	0.48	8e-7	Immature fraction of reticulocytes;
THYM	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg00810483	chr4:3375144	RGS12	0.31	4.7	0.43	8.74e-6	Serum sulfate level;
THYM	cis	rs7651039	0.641	rs2455810	chr3:15657082	A/T	cg16303742	chr3:15540471	COLQ	0.71	7.02	0.58	3.27e-10	Coronary heart disease;
THYM	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg18404041	chr3:52824283	ITIH1	-0.53	-5.23	-0.47	9.96e-7	Bipolar disorder;
THYM	cis	rs490234	0.783	rs10119855	chr9:128271123	A/T	cg14078157	chr9:128172775	NA	-0.67	-5.48	-0.49	3.45e-7	Mean arterial pressure;
THYM	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg23711669	chr6:146136114	FBXO30	0.98	10.25	0.72	4.91e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs476633	0.708	rs3986303	chr15:41443179	A/G	cg21153102	chr15:41252147	NA	0.59	4.61	0.43	1.26e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs6754311	0.551	rs313519	chr2:136439517	A/C	cg20242066	chr2:136595261	LCT	0.55	6.03	0.53	3.1e-8	Mosquito bite size;
THYM	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg04842962	chr6:43655489	MRPS18A	1.28	9.29	0.69	5.41e-15	IgG glycosylation;
THYM	cis	rs4888262	0.564	rs6564147	chr16:74622586	G/A	cg01733217	chr16:74700730	RFWD3	0.82	8.54	0.66	2.2e-13	Testicular germ cell tumor;
THYM	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg14416269	chr4:6271139	WFS1	-0.54	-5.62	-0.5	1.93e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg08133631	chr1:26527909	CATSPER4	-0.61	-5.08	-0.46	1.92e-6	Obesity-related traits;
THYM	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg12826209	chr6:26865740	GUSBL1	0.86	4.93	0.45	3.54e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs778371	0.676	rs11688166	chr2:233566210	A/G	cg08000102	chr2:233561755	GIGYF2	0.8	7.05	0.59	2.91e-10	Schizophrenia;
THYM	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg13609457	chr4:120235615	NA	-0.54	-5.02	-0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs1670533	1.000	rs935972	chr4:1045171	A/G	cg27284194	chr4:1044797	NA	0.63	4.83	0.44	5.19e-6	Recombination rate (females);
THYM	cis	rs4654899	0.643	rs12145181	chr1:21086046	C/A	cg01072550	chr1:21505969	NA	-0.62	-5.66	-0.5	1.62e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs665401	0.965	rs1321371	chr6:117235656	C/G	cg20376953	chr6:117187980	NA	0.6	4.68	0.43	9.69e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg08968635	chr6:28129556	ZNF389	-0.69	-5.11	-0.46	1.64e-6	Depression;
THYM	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7043114	0.563	rs10820988	chr9:95317008	T/C	cg14631576	chr9:95140430	CENPP	-0.77	-7.3	-0.6	8.56e-11	Height;
THYM	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6815814	0.847	rs11725309	chr4:38783848	T/C	cg06935464	chr4:38784597	TLR10	0.72	4.68	0.43	9.65e-6	Breast cancer;
THYM	cis	rs28595532	0.920	rs114751999	chr4:119759651	G/A	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs72627123	0.867	rs118113209	chr14:74432158	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.14	6.41	0.55	5.69e-9	Morning vs. evening chronotype;
THYM	cis	rs5753037	0.838	rs28749829	chr22:30219326	C/T	cg27665648	chr22:30112403	NA	0.5	4.45	0.42	2.35e-5	Type 1 diabetes;
THYM	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg22166914	chr1:53195759	ZYG11B	-0.9	-10.61	-0.74	8.09e-18	Monocyte count;
THYM	cis	rs5985	0.659	rs3024321	chr6:6318126	A/G	cg16530177	chr6:6320324	F13A1	0.7	5.83	0.51	7.44e-8	End-stage coagulation;
THYM	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg23958373	chr8:599963	NA	0.9	4.59	0.43	1.34e-5	IgG glycosylation;
THYM	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg06598544	chr20:61472147	COL9A3	0.9	6.38	0.55	6.32e-9	Obesity-related traits;
THYM	cis	rs4523957	0.928	rs9905529	chr17:2177732	T/C	cg16513277	chr17:2031491	SMG6	-0.79	-7.41	-0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg12288994	chr5:1860383	NA	0.87	7.32	0.6	8.1e-11	Cardiovascular disease risk factors;
THYM	cis	rs10799590	1.000	rs10915696	chr1:224877746	A/C	cg01808320	chr1:224927238	CNIH3	0.53	4.89	0.45	4.02e-6	Opioid dependence;
THYM	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg04025307	chr7:1156635	C7orf50	0.63	5.82	0.51	8.1e-8	Longevity;Endometriosis;
THYM	cis	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg06521331	chr12:34319734	NA	-0.96	-8.88	-0.67	4.06e-14	Morning vs. evening chronotype;
THYM	cis	rs3862030	0.720	rs11593526	chr10:104228017	G/T	cg00122347	chr10:104236741	TMEM180	0.48	7.24	0.6	1.14e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs711830	0.931	rs717852	chr2:177031623	C/T	cg26754761	chr2:177040938	NA	-0.55	-4.56	-0.42	1.52e-5	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg00310523	chr12:86230176	RASSF9	0.59	5.41	0.49	4.71e-7	Major depressive disorder;
THYM	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.47	-0.55	4.25e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6952809	0.532	rs6952152	chr7:2440912	G/A	cg13581527	chr7:1708566	NA	-0.77	-5.3	-0.48	7.55e-7	Multiple sclerosis;
THYM	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg24375607	chr4:120327624	NA	0.64	5.41	0.49	4.71e-7	Corneal astigmatism;
THYM	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg20283391	chr11:68216788	NA	-0.63	-5.08	-0.46	1.88e-6	Total body bone mineral density;
THYM	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-5.01	-0.46	2.49e-6	Hemoglobin concentration;
THYM	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg08847533	chr14:75593920	NEK9	-0.94	-9.76	-0.71	5.51e-16	Height;
THYM	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.76	6.74	0.57	1.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg26695010	chr11:65641043	EFEMP2	0.62	4.54	0.42	1.63e-5	Eosinophil percentage of white cells;
THYM	cis	rs7582180	0.845	rs11683088	chr2:100920667	C/T	cg08017756	chr2:100939284	LONRF2	-0.76	-7.81	-0.63	7.52e-12	Intelligence (multi-trait analysis);
THYM	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Body mass index;
THYM	cis	rs12282928	0.876	rs4980428	chr11:48296661	G/T	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs7474896	0.583	rs12776092	chr10:38015795	G/C	cg07661167	chr10:37990439	NA	-0.66	-4.45	-0.42	2.33e-5	Obesity (extreme);
THYM	cis	rs10743315	0.557	rs74465549	chr12:19344365	A/C	cg02471346	chr12:19282374	PLEKHA5	1.11	4.54	0.42	1.62e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.66	-0.5	1.62e-7	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg10856724	chr12:34555212	NA	-0.84	-7.18	-0.59	1.53e-10	Bladder cancer;
THYM	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs11756438	0.683	rs11754023	chr6:119005785	A/G	cg21191810	chr6:118973309	C6orf204	0.52	4.88	0.45	4.35e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg22841779	chr14:105766346	BRF1	0.47	5.84	0.51	7.16e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg13695892	chr22:41940480	POLR3H	-0.94	-7.28	-0.6	9.46e-11	Vitiligo;
THYM	cis	rs1003719	0.788	rs2251161	chr21:38467857	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.89	0.45	4.11e-6	Eye color traits;
THYM	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg03806693	chr22:41940476	POLR3H	-1.03	-8.5	-0.66	2.66e-13	Vitiligo;
THYM	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg25817165	chr18:72167213	CNDP2	-0.95	-7.9	-0.63	4.91e-12	Refractive error;
THYM	cis	rs7084402	0.967	rs1649049	chr10:60324095	G/A	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.29	8.36	0.65	5.15e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs16857609	0.564	rs12232972	chr2:218257272	C/T	cg15335768	chr2:218268053	DIRC3	-0.52	-7.22	-0.6	1.3e-10	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg05775895	chr3:12838266	CAND2	1.02	10.26	0.72	4.71e-17	QRS complex (12-leadsum);
THYM	cis	rs6956675	0.874	rs10266439	chr7:62647022	G/T	cg27518014	chr7:62859535	LOC100287834	0.59	4.92	0.45	3.58e-6	Obesity-related traits;
THYM	cis	rs7909074	1.000	rs10751361	chr10:45398186	C/A	cg05187965	chr10:45406764	TMEM72	-0.52	-4.98	-0.46	2.83e-6	Mean corpuscular volume;
THYM	trans	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg03929089	chr4:120376271	NA	-1.03	-12.43	-0.79	1.26e-21	Height;
THYM	cis	rs2932538	0.845	rs6682678	chr1:113206920	A/G	cg22162597	chr1:113214053	CAPZA1	-0.65	-5.09	-0.46	1.78e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg23187316	chr7:1099788	C7orf50	-0.48	-5.47	-0.49	3.66e-7	Longevity;Endometriosis;
THYM	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg03433033	chr1:76189801	ACADM	0.79	11.21	0.75	4.52e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs8067545	1.000	rs56142708	chr17:19934963	A/C	cg13482628	chr17:19912719	NA	0.59	4.84	0.44	5.07e-6	Schizophrenia;
THYM	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg22117172	chr7:91764530	CYP51A1	0.37	4.72	0.44	8.16e-6	Breast cancer;
THYM	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.93	-0.45	3.52e-6	Monocyte count;
THYM	cis	rs485842	1.000	rs543104	chr11:96025709	C/T	cg23866687	chr11:96026956	MAML2	0.45	6.3	0.54	9.23e-9	Corneal astigmatism;
THYM	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs8002861	0.641	rs2028813	chr13:44422126	G/T	cg17145862	chr1:211918768	LPGAT1	0.86	7.27	0.6	1.02e-10	Leprosy;
THYM	cis	rs1065852	0.526	rs7290655	chr22:42390225	C/G	cg22189786	chr22:42395067	WBP2NL	0.54	5.55	0.49	2.6e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg17345569	chr6:42928274	GNMT	-0.51	-5.08	-0.46	1.89e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2124969	0.506	rs10497209	chr2:160985586	A/C	cg03641300	chr2:160917029	PLA2R1	-0.65	-4.58	-0.43	1.38e-5	Waist circumference adjusted for body mass index;
THYM	cis	rs7100689	0.556	rs3120976	chr10:82025682	C/A	cg01528321	chr10:82214614	TSPAN14	0.96	7.96	0.63	3.67e-12	Post bronchodilator FEV1;
THYM	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg03060546	chr3:49711283	APEH	-0.67	-5.39	-0.48	5.13e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg04234412	chr22:24373322	LOC391322	-0.91	-9.25	-0.69	6.71e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg13695892	chr22:41940480	POLR3H	-0.98	-7.65	-0.62	1.61e-11	Vitiligo;
THYM	cis	rs10504073	0.647	rs4873312	chr8:49991145	A/G	cg00325661	chr8:49890786	NA	0.93	8.79	0.67	6.32e-14	Blood metabolite ratios;
THYM	cis	rs67460515	0.563	rs13085336	chr3:160880599	G/A	cg03342759	chr3:160939853	NMD3	-0.65	-4.86	-0.45	4.71e-6	Parkinson's disease;
THYM	cis	rs10095849	0.576	rs10088799	chr8:39468849	G/T	cg01911981	chr8:39380341	ADAM3A	-0.59	-5.05	-0.46	2.13e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4930103	1.000	rs4929983	chr11:2024579	C/T	cg18511798	chr11:2018149	H19;MIR675	-0.59	-6.33	-0.54	8e-9	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg13319975	chr6:146136371	FBXO30	-0.66	-5.55	-0.49	2.59e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.53	-0.49	2.8e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg14784868	chr12:69753453	YEATS4	0.79	6.48	0.55	4.06e-9	Blood protein levels;
THYM	cis	rs7100689	0.646	rs7077712	chr10:82134894	A/G	cg01528321	chr10:82214614	TSPAN14	0.79	6.01	0.52	3.47e-8	Post bronchodilator FEV1;
THYM	cis	rs6087771	0.651	rs6060775	chr20:30286191	A/G	cg21427119	chr20:30132790	HM13	-0.62	-5.31	-0.48	7.08e-7	Subcortical brain region volumes;Putamen volume;
THYM	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg06028808	chr11:68637592	NA	0.65	6.8	0.57	9.29e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg14784868	chr12:69753453	YEATS4	0.7	5.75	0.51	1.06e-7	Blood protein levels;
THYM	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg13695892	chr22:41940480	POLR3H	-1.04	-8.51	-0.66	2.47e-13	Vitiligo;
THYM	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg21394778	chr1:3037102	PRDM16	-0.48	-4.72	-0.44	8.03e-6	Height;
THYM	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.8	6.76	0.57	1.09e-9	Lymphocyte percentage of white cells;
THYM	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg06636551	chr8:101224915	SPAG1	-0.67	-6.52	-0.56	3.36e-9	Atrioventricular conduction;
THYM	cis	rs7220711	0.707	rs1107748	chr17:41773814	C/T	cg26893861	chr17:41843967	DUSP3	-0.61	-5.26	-0.47	9.02e-7	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg03188948	chr7:1209495	NA	0.9	5.0	0.46	2.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg20528787	chr7:158032352	PTPRN2	0.43	4.98	0.46	2.81e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs67072384	1.000	rs5008485	chr11:72455152	C/T	cg01380194	chr11:72452482	ARAP1	-0.97	-5.26	-0.47	8.93e-7	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs669446	0.533	rs28833034	chr1:44212942	A/G	cg12599982	chr1:44399894	ARTN	0.52	4.74	0.44	7.55e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs859767	0.741	rs1516991	chr2:135370052	G/A	cg12500956	chr2:135428796	TMEM163	-0.49	-4.95	-0.45	3.25e-6	Neuroticism;
THYM	cis	rs9646944	0.501	rs7586983	chr2:103028066	C/T	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	cis	rs909002	0.800	rs7549590	chr1:32109849	G/A	cg13919466	chr1:32135498	COL16A1	-0.46	-4.62	-0.43	1.21e-5	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg13683864	chr3:40499215	RPL14	-0.83	-7.86	-0.63	5.95e-12	Renal cell carcinoma;
THYM	cis	rs977987	0.836	rs34673655	chr16:75323559	T/C	cg03315344	chr16:75512273	CHST6	0.83	6.93	0.58	5e-10	Dupuytren's disease;
THYM	cis	rs17598306	0.935	rs17598132	chr7:96579339	C/T	cg13449377	chr7:96631089	DLX6AS	0.76	4.78	0.44	6.38e-6	Radiation response;
THYM	cis	rs35883536	1.000	rs4907918	chr1:101094609	A/G	cg06223162	chr1:101003688	GPR88	-0.63	-4.77	-0.44	6.71e-6	Monocyte count;
THYM	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg05527609	chr1:210001259	C1orf107	1.09	9.03	0.68	2e-14	Orofacial clefts;
THYM	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg13695892	chr22:41940480	POLR3H	0.89	7.27	0.6	1.02e-10	Vitiligo;
THYM	cis	rs34638657	0.732	rs7206093	chr16:82201884	G/A	cg09439754	chr16:82129088	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	cis	rs9972944	0.729	rs1541610	chr17:63773836	C/T	cg07283582	chr17:63770753	CCDC46	0.68	5.54	0.49	2.69e-7	Total body bone mineral density;
THYM	cis	rs7843479	0.601	rs2002941	chr8:21834366	A/C	cg17168535	chr8:21777572	XPO7	0.89	8.07	0.64	2.13e-12	Mean corpuscular volume;
THYM	cis	rs2820651	0.522	rs11250519	chr10:1481942	C/T	cg13720710	chr10:1452970	ADARB2	0.7	4.58	0.43	1.43e-5	Migraine with aura;
THYM	cis	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg08807101	chr21:30365312	RNF160	0.93	7.99	0.63	3.1e-12	Dental caries;
THYM	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs662064	0.962	rs2506902	chr1:10563681	C/T	cg20482658	chr1:10539492	PEX14	0.5	5.96	0.52	4.24e-8	Asthma;
THYM	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg18252515	chr7:66147081	NA	-1.37	-8.05	-0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs9814567	0.806	rs4535271	chr3:134321669	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.12e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6995541	0.505	rs11250083	chr8:10706162	C/T	cg13457217	chr8:10683266	MIR1322;PINX1	0.62	4.52	0.42	1.78e-5	Triglyceride levels;
THYM	cis	rs3768617	0.510	rs2296294	chr1:183095596	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs9646944	0.501	rs1403552	chr2:103088777	C/T	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	cis	rs478304	0.651	rs11604462	chr11:65551648	G/A	cg27068330	chr11:65405492	SIPA1	-0.96	-9.31	-0.69	4.93e-15	Acne (severe);
THYM	cis	rs7626444	0.625	rs1718410	chr3:196477660	A/G	cg12930392	chr3:196481615	PAK2	0.4	4.92	0.45	3.58e-6	Monocyte count;
THYM	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26314531	chr2:26401878	FAM59B	-0.76	-4.99	-0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs870825	0.616	rs12498890	chr4:185636096	C/G	cg04058563	chr4:185651563	MLF1IP	-1.07	-9.65	-0.7	9.06e-16	Blood protein levels;
THYM	cis	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg15051221	chr5:177434457	FAM153C	0.61	4.72	0.44	8.1e-6	Methadone dose in opioid dependence;
THYM	cis	rs7833986	0.501	rs2667983	chr8:56894087	T/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	6.4	0.55	5.76e-9	Height;
THYM	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg10661904	chr17:79619235	PDE6G	0.66	6.41	0.55	5.55e-9	Eye color traits;
THYM	cis	rs34638657	0.827	rs2303262	chr16:82203758	C/T	cg09439754	chr16:82129088	HSD17B2	-0.66	-5.77	-0.51	9.97e-8	Lung adenocarcinoma;
THYM	cis	rs4363385	0.818	rs10888524	chr1:153000125	A/G	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg07930552	chr6:133119739	C6orf192	1.03	6.0	0.52	3.63e-8	Type 2 diabetes nephropathy;
THYM	cis	rs7216064	0.953	rs75231441	chr17:65885485	A/G	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs6032067	0.850	rs34274189	chr20:43864298	G/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.68	-6.83	-0.57	8.12e-10	Blood protein levels;
THYM	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg03929089	chr4:120376271	NA	-1.01	-13.71	-0.82	3.1e-24	Height;
THYM	cis	rs34638657	0.673	rs67661146	chr16:82199669	G/A	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.11	-0.64	1.73e-12	Lung adenocarcinoma;
THYM	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.17	0.53	1.69e-8	Coronary artery disease;
THYM	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg12292205	chr6:26970375	C6orf41	0.62	5.33	0.48	6.48e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg05368731	chr17:41323189	NBR1	1.26	11.24	0.76	3.79e-19	Menopause (age at onset);
THYM	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg04234412	chr22:24373322	LOC391322	-0.9	-9.0	-0.68	2.22e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2286885	0.965	rs741024	chr9:129251821	A/G	cg14294646	chr9:129243551	FAM125B	0.59	5.57	0.5	2.37e-7	Intraocular pressure;
THYM	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg27211696	chr2:191398769	TMEM194B	-0.64	-4.56	-0.42	1.55e-5	Diastolic blood pressure;
THYM	cis	rs4242434	0.672	rs2404654	chr8:22484949	T/C	cg01710189	chr8:22454888	PDLIM2	-0.48	-5.12	-0.47	1.56e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg00677455	chr12:58241039	CTDSP2	-0.72	-5.37	-0.48	5.68e-7	Multiple sclerosis;
THYM	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg24818145	chr4:99064322	C4orf37	0.74	5.9	0.52	5.66e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3540	0.597	rs1978151	chr15:91037300	C/T	cg22089800	chr15:90895588	ZNF774	0.7	5.45	0.49	3.91e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs7246657	0.943	rs7255972	chr19:37933841	T/C	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs4363385	0.818	rs61811863	chr1:152995721	T/C	cg13444842	chr1:152974279	SPRR3	-0.61	-5.08	-0.46	1.86e-6	Inflammatory skin disease;
THYM	cis	rs12348691	0.503	rs907576	chr9:100615359	C/T	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Alopecia areata;
THYM	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-4.96	-0.45	3.03e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs28595532	0.920	rs28538455	chr4:119486817	T/C	cg11846333	chr4:119757529	SEC24D	1.37	4.91	0.45	3.85e-6	Cannabis dependence symptom count;
THYM	cis	rs4237845	0.537	rs7969844	chr12:58278271	C/T	cg00677455	chr12:58241039	CTDSP2	0.76	6.03	0.53	3.08e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg00533182	chr8:145726136	PPP1R16A	0.61	4.5	0.42	1.92e-5	Age at first birth;
THYM	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg27068330	chr11:65405492	SIPA1	-0.81	-5.52	-0.49	2.95e-7	Breast cancer;
THYM	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg18252515	chr7:66147081	NA	0.66	4.87	0.45	4.38e-6	Aortic root size;
THYM	cis	rs8180040	0.903	rs11130124	chr3:47292183	T/C	cg16586182	chr3:47516702	SCAP	-0.64	-5.49	-0.49	3.39e-7	Colorectal cancer;
THYM	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg11663144	chr21:46675770	NA	-0.72	-9.62	-0.7	1.1e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7616559	0.820	rs9829700	chr3:156725209	A/C	cg15697575	chr3:156784781	NA	0.4	5.03	0.46	2.35e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs9814567	0.806	rs55835132	chr3:134325256	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.09e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs898549	0.967	rs10899957	chr10:44472469	C/T	cg08683644	chr10:44853092	NA	0.44	4.59	0.43	1.38e-5	Obesity-related traits;
THYM	trans	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg07211511	chr3:129823064	LOC729375	-1.43	-8.55	-0.66	2.02e-13	Blood pressure (smoking interaction);
THYM	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.26	-9.1	-0.68	1.4e-14	Gut microbiome composition (summer);
THYM	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg04654363	chr8:8581213	NA	-0.48	-4.62	-0.43	1.22e-5	Obesity-related traits;
THYM	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg11494091	chr17:61959527	GH2	0.69	6.23	0.54	1.27e-8	Height;
THYM	cis	rs11731175	0.961	rs116322463	chr4:189866929	C/A	cg00431894	chr4:189871012	NA	-0.91	-7.23	-0.6	1.24e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6665290	0.669	rs7552783	chr1:227174145	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.08	-12.43	-0.79	1.26e-21	Myeloid white cell count;
THYM	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg16342193	chr10:102329863	NA	-0.53	-5.28	-0.48	8.09e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2985684	0.894	rs8005990	chr14:50022248	G/A	cg02151108	chr14:50098012	C14orf104	-0.75	-6.18	-0.54	1.57e-8	Carotid intima media thickness;
THYM	cis	rs6906287	0.625	rs7757892	chr6:118844221	G/A	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg24678163	chr13:52769951	THSD1P	0.49	4.57	0.42	1.49e-5	Lewy body disease;
THYM	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg17264618	chr3:40429014	ENTPD3	0.5	4.72	0.44	8.06e-6	Renal cell carcinoma;
THYM	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs4604732	0.642	rs4400652	chr1:247636479	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.58	4.56	0.42	1.51e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs782590	0.967	rs11125579	chr2:55739804	T/C	cg03859395	chr2:55845619	SMEK2	0.5	4.49	0.42	2e-5	Metabolic syndrome;
THYM	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg12386194	chr3:101231763	SENP7	0.65	4.91	0.45	3.75e-6	Colorectal cancer;
THYM	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg23791538	chr6:167370224	RNASET2	-0.78	-6.28	-0.54	1.02e-8	Crohn's disease;
THYM	cis	rs36051895	0.632	rs72701654	chr9:5161453	T/C	cg02405213	chr9:5042618	JAK2	-1.09	-10.97	-0.75	1.44e-18	Pediatric autoimmune diseases;
THYM	cis	rs12410462	0.681	rs79461024	chr1:227568783	G/T	cg23173402	chr1:227635558	NA	0.71	5.61	0.5	1.96e-7	Major depressive disorder;
THYM	cis	rs1863824	0.625	rs11202024	chr10:88168024	C/A	cg06895675	chr10:88137553	NA	0.58	4.96	0.45	3.06e-6	Schizophrenia;
THYM	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg06634786	chr22:41940651	POLR3H	0.72	5.22	0.47	1.04e-6	Vitiligo;
THYM	cis	rs28785552	0.897	rs34244888	chr19:53242228	T/A	cg22067481	chr19:53234126	ZNF611	-0.97	-9.87	-0.71	3.07e-16	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs9517302	0.615	rs7983522	chr13:99098055	C/T	cg22223119	chr13:99095684	FARP1	-0.93	-6.9	-0.58	5.7e-10	Obesity-related traits;
THYM	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg11752832	chr7:134001865	SLC35B4	0.77	5.56	0.5	2.5e-7	Mean platelet volume;
THYM	cis	rs1003719	0.788	rs1155787	chr21:38448069	G/A	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg15704280	chr7:45808275	SEPT13	1.02	11.33	0.76	2.47e-19	Coronary artery disease;
THYM	cis	rs79815064	0.790	rs79629761	chr3:46340630	C/T	cg20674725	chr3:47020919	NBEAL2	0.73	4.63	0.43	1.15e-5	Macrophage inflammatory protein 1b levels;
THYM	cis	rs8064024	0.513	rs1049207	chr16:4934564	C/G	cg08329684	chr16:4932620	PPL	-0.34	-4.58	-0.43	1.42e-5	Cancer;
THYM	cis	rs9534288	0.552	rs2840241	chr13:46658903	T/G	cg15192986	chr13:46630673	CPB2	-0.65	-4.53	-0.42	1.71e-5	Blood protein levels;
THYM	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg10515332	chr4:99064459	C4orf37	0.67	5.33	0.48	6.48e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg02478829	chr6:26598070	ABT1	-0.35	-4.57	-0.42	1.49e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7944584	0.552	rs12361415	chr11:47474146	T/G	cg20307385	chr11:47447363	PSMC3	0.83	5.87	0.52	6.48e-8	Fasting blood glucose;Fasting blood glucose (BMI interaction);
THYM	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.72	-5.85	-0.51	6.87e-8	Systemic lupus erythematosus;
THYM	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg07959070	chr22:50026188	C22orf34	-0.29	-4.95	-0.45	3.21e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs75920871	0.588	rs6589587	chr11:116875338	T/G	cg20608306	chr11:116969690	SIK3	-0.5	-5.41	-0.49	4.69e-7	Subjective well-being;
THYM	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	9.7	0.71	7.1e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1728785	0.892	rs1103955	chr16:68588488	T/G	cg02972257	chr16:68554789	NA	-0.76	-4.63	-0.43	1.14e-5	Ulcerative colitis;
THYM	cis	rs6812193	0.518	rs77937770	chr4:77193208	A/T	cg20311846	chr4:77356250	SHROOM3	0.52	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg14018140	chr10:458528	DIP2C	-0.57	-5.97	-0.52	4.04e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg02569458	chr12:86230093	RASSF9	0.68	5.77	0.51	9.71e-8	Major depressive disorder;
THYM	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-4.62	-0.43	1.22e-5	Crohn's disease;
THYM	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg20891283	chr12:69753455	YEATS4	1.09	12.03	0.78	8.44e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg05660106	chr1:15850417	CASP9	0.71	5.75	0.51	1.07e-7	Systolic blood pressure;
THYM	cis	rs9522267	0.535	rs9515451	chr13:112234382	A/G	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs79387448	0.745	rs7575867	chr2:103120179	C/T	cg09003973	chr2:102972529	NA	0.78	4.85	0.45	4.84e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs728616	0.867	rs116994688	chr10:81738137	G/C	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg23482746	chr15:76478102	C15orf27	-0.38	-4.55	-0.42	1.61e-5	Blood metabolite levels;
THYM	cis	rs995000	0.931	rs6587976	chr1:62945631	C/T	cg06896770	chr1:63153194	DOCK7	0.93	7.76	0.62	9.83e-12	Triglyceride levels;
THYM	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-5.16	-0.47	1.34e-6	Hemoglobin concentration;
THYM	cis	rs72627123	0.867	rs3926910	chr14:74336823	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg23758822	chr17:41437982	NA	1.26	13.23	0.81	2.78e-23	Menopause (age at onset);
THYM	cis	rs6723226	0.764	rs176403	chr2:32637864	C/A	cg02381751	chr2:32503542	YIPF4	-0.61	-5.4	-0.48	4.82e-7	Intelligence (multi-trait analysis);
THYM	cis	rs986417	1.000	rs1956554	chr14:60963775	C/T	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs17401966	1.000	rs12130220	chr1:10359944	T/G	cg20482658	chr1:10539492	PEX14	0.39	4.71	0.44	8.47e-6	Hepatocellular carcinoma;
THYM	trans	rs10118776	0.826	rs13284060	chr9:6202701	A/C	cg02532923	chr16:89110004	NA	1.01	7.85	0.63	6.11e-12	Small cell lung carcinoma;
THYM	cis	rs7084402	0.934	rs1649089	chr10:60289695	T/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs2624839	0.602	rs2526398	chr3:50187596	G/C	cg14019146	chr3:50243930	SLC38A3	-0.79	-7.0	-0.58	3.56e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03517284	chr6:25882590	NA	-0.82	-6.39	-0.55	6.09e-9	Blood metabolite levels;
THYM	cis	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg24672777	chr11:48374446	OR4C45	-0.99	-6.44	-0.55	4.78e-9	Axial length;
THYM	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg09354556	chr3:47051341	NA	-0.51	-5.44	-0.49	4.05e-7	Colorectal cancer;
THYM	cis	rs9611519	0.780	rs2235852	chr22:41661154	G/T	cg03806693	chr22:41940476	POLR3H	-0.74	-5.84	-0.51	7.25e-8	Neuroticism;
THYM	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg18230493	chr5:56204884	C5orf35	-0.89	-5.93	-0.52	4.86e-8	Initial pursuit acceleration;
THYM	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg10523679	chr1:76189770	ACADM	-0.89	-8.32	-0.65	6.27e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs61931739	0.635	rs1486883	chr12:33908740	C/T	cg06521331	chr12:34319734	NA	-0.57	-4.76	-0.44	7e-6	Morning vs. evening chronotype;
THYM	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg07424592	chr7:64974309	NA	1.03	5.4	0.48	4.94e-7	Diabetic kidney disease;
THYM	cis	rs7084402	0.967	rs1593674	chr10:60291908	A/C	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs3812049	0.826	rs6860245	chr5:127367998	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.73	-5.34	-0.48	6.44e-7	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs28595532	0.920	rs114223775	chr4:119775091	C/T	cg21605333	chr4:119757512	SEC24D	1.67	6.17	0.53	1.69e-8	Cannabis dependence symptom count;
THYM	cis	rs1639906	0.895	rs34255795	chr7:2207416	A/G	cg19897017	chr7:2163380	MAD1L1	-0.51	-4.78	-0.44	6.42e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg00495681	chr13:53174319	NA	-0.74	-6.75	-0.57	1.16e-9	Lewy body disease;
THYM	cis	rs9902453	0.904	rs4547389	chr17:28364768	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.22	-0.54	1.3e-8	Coffee consumption (cups per day);
THYM	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg00071950	chr4:10020882	SLC2A9	0.77	7.71	0.62	1.24e-11	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs2282300	0.739	rs1717775	chr11:30350254	T/G	cg06241208	chr11:30344200	C11orf46	-0.78	-5.65	-0.5	1.64e-7	Morning vs. evening chronotype;
THYM	cis	rs11711311	0.955	rs12634241	chr3:113397685	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.57	-4.76	-0.44	7.01e-6	IgG glycosylation;
THYM	cis	rs4930776	0.593	rs453385	chr12:5759609	A/G	cg02086166	chr12:5775618	ANO2	0.59	4.94	0.45	3.37e-6	Plasma clusterin levels;
THYM	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg25358565	chr5:93447407	FAM172A	1.31	11.12	0.75	6.98e-19	Diabetic retinopathy;
THYM	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg25319279	chr11:5960081	NA	-0.64	-5.55	-0.5	2.55e-7	DNA methylation (variation);
THYM	cis	rs4285028	0.948	rs7640872	chr3:121697168	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-5.07	-0.46	2e-6	Multiple sclerosis;
THYM	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg02627286	chr16:89590583	SPG7	0.53	5.4	0.48	4.88e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs9677476	0.779	rs72983683	chr2:232100970	G/T	cg07929768	chr2:232055508	NA	0.6	5.07	0.46	2e-6	Food antigen IgG levels;
THYM	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg12310025	chr6:25882481	NA	-0.92	-8.13	-0.64	1.61e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2997447	0.688	rs17257100	chr1:26439586	C/T	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs6980334	0.911	rs10280628	chr7:137767310	C/T	cg22979093	chr7:137028410	PTN	0.62	4.9	0.45	3.91e-6	Blood metabolite ratios;
THYM	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.86	0.51	6.79e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs886126	0.736	rs59214806	chr12:111684461	A/G	cg10833066	chr12:111807467	FAM109A	0.49	6.06	0.53	2.76e-8	Coronary heart disease;
THYM	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg22681709	chr2:178499509	PDE11A	-0.59	-5.62	-0.5	1.91e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-5.57	-0.5	2.38e-7	Morning vs. evening chronotype;
THYM	trans	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs8070624	0.543	rs4299203	chr17:17878159	T/G	cg16928487	chr17:17741425	SREBF1	-0.51	-4.63	-0.43	1.18e-5	Total body bone mineral density;
THYM	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg14517863	chr17:44321492	NA	0.46	5.11	0.46	1.69e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12478296	1.000	rs12469535	chr2:243044147	G/A	cg06360820	chr2:242988706	NA	-0.94	-5.73	-0.51	1.17e-7	Obesity-related traits;
THYM	cis	rs12478296	1.000	rs66612947	chr2:243035962	A/T	cg06360820	chr2:242988706	NA	-0.9	-5.52	-0.49	2.95e-7	Obesity-related traits;
THYM	cis	rs4523957	0.928	rs452363	chr17:2194028	T/C	cg16513277	chr17:2031491	SMG6	0.79	7.37	0.6	6.32e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4803468	0.967	rs284661	chr19:41932120	C/T	cg09537434	chr19:41945824	ATP5SL	-1.1	-10.47	-0.73	1.66e-17	Height;
THYM	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg00071950	chr4:10020882	SLC2A9	-0.52	-4.55	-0.42	1.56e-5	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4654899	0.680	rs4654881	chr1:21209769	T/C	cg01072550	chr1:21505969	NA	0.73	6.93	0.58	5.13e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg16230307	chr14:35515116	FAM177A1	0.9	5.84	0.51	7.37e-8	Psoriasis;
THYM	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg13114125	chr14:105738426	BRF1	-0.77	-6.19	-0.54	1.53e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-10.85	-0.74	2.51e-18	Primary sclerosing cholangitis;
THYM	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg12373951	chr3:133503437	NA	0.65	7.02	0.58	3.27e-10	Iron status biomarkers;
THYM	cis	rs11711311	1.000	rs62268169	chr3:113493860	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.62	-5.52	-0.49	2.89e-7	IgG glycosylation;
THYM	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11644478	chr21:40555479	PSMG1	0.8	6.91	0.58	5.38e-10	Cognitive function;
THYM	cis	rs2456568	0.802	rs10831139	chr11:93640537	G/A	cg26875233	chr11:93583750	C11orf90	-0.54	-5.78	-0.51	9.51e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs10946292	0.656	rs1740	chr6:170441452	C/T	cg11647478	chr6:170497869	NA	-0.6	-4.54	-0.42	1.66e-5	Obesity-related traits;
THYM	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	10.77	0.74	3.77e-18	Chronic sinus infection;
THYM	cis	rs919433	0.617	rs34632716	chr2:198542619	C/T	cg05783139	chr2:198650985	BOLL	-0.63	-5.0	-0.46	2.58e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4523957	0.819	rs12450354	chr17:2159982	C/T	cg16513277	chr17:2031491	SMG6	0.79	7.41	0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg27494647	chr7:150038898	RARRES2	0.47	5.41	0.49	4.77e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.31	0.6	8.45e-11	Obesity-related traits;
THYM	cis	rs877282	0.945	rs10904550	chr10:774177	C/T	cg10556349	chr10:835070	NA	-0.7	-4.88	-0.45	4.27e-6	Uric acid levels;
THYM	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	9.37	0.69	3.63e-15	Platelet count;
THYM	cis	rs7119	0.651	rs12902898	chr15:77849191	A/G	cg27398640	chr15:77910606	LINGO1	-0.61	-6.11	-0.53	2.21e-8	Type 2 diabetes;
THYM	cis	rs12594515	1.000	rs6493170	chr15:45987019	G/A	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs7523273	0.565	rs2985104	chr1:207892012	C/T	cg22525895	chr1:207977042	MIR29B2	-0.54	-5.12	-0.46	1.62e-6	Schizophrenia;
THYM	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs7084402	0.967	rs1658480	chr10:60289374	C/G	cg09696939	chr10:60272079	BICC1	-0.45	-5.14	-0.47	1.47e-6	Refractive error;
THYM	cis	rs8014204	0.720	rs34752362	chr14:75232306	G/A	cg06637938	chr14:75390232	RPS6KL1	0.55	5.29	0.48	7.79e-7	Caffeine consumption;
THYM	cis	rs12540874	0.529	rs732215	chr7:50544063	A/C	cg18232548	chr7:50535776	DDC	-0.9	-8.57	-0.66	1.85e-13	Systemic sclerosis;
THYM	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	13.76	0.82	2.43e-24	Chronic sinus infection;
THYM	cis	rs4930103	0.935	rs2075744	chr11:2018449	A/G	cg18511798	chr11:2018149	H19;MIR675	-0.57	-5.57	-0.5	2.39e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg20295408	chr7:1910781	MAD1L1	-0.63	-4.54	-0.42	1.67e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.29	4.65	0.43	1.08e-5	Obesity-related traits;
THYM	cis	rs611744	0.608	rs612744	chr8:109245991	G/A	cg21045802	chr8:109455806	TTC35	0.65	5.91	0.52	5.3e-8	Dupuytren's disease;
THYM	cis	rs981844	0.740	rs10009844	chr4:154681576	C/T	cg09973105	chr4:154681532	RNF175	0.51	4.68	0.43	9.46e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs6499129	0.571	rs9939768	chr16:67219107	G/C	cg26912222	chr16:68000829	SLC12A4	0.69	4.58	0.42	1.44e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg26441486	chr22:50317300	CRELD2	0.43	6.57	0.56	2.71e-9	Schizophrenia;
THYM	cis	rs2702888	0.501	rs2738152	chr8:6752085	A/T	cg26795848	chr8:6756730	NA	0.54	4.68	0.43	9.66e-6	Blood pressure;
THYM	cis	rs116095464	1.000	rs56700778	chr5:313186	A/T	cg22857025	chr5:266934	NA	-1.59	-5.22	-0.47	1.06e-6	Breast cancer;
THYM	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6163	0.727	rs284862	chr10:104572081	C/T	cg05855489	chr10:104503620	C10orf26	-0.75	-6.61	-0.56	2.21e-9	Waist circumference;Hip circumference;
THYM	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg22920501	chr2:26401640	FAM59B	-1.04	-9.12	-0.68	1.26e-14	Gut microbiome composition (summer);
THYM	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg08859206	chr1:53392774	SCP2	-0.6	-6.81	-0.57	8.75e-10	Monocyte count;
THYM	cis	rs2502731	0.539	rs3003610	chr9:130985525	G/A	cg13642260	chr9:130955380	CIZ1	0.67	5.27	0.48	8.4e-7	Attention deficit hyperactivity disorder;
THYM	cis	rs4653767	1.000	rs10916030	chr1:226919908	C/T	cg05262829	chr1:226921576	ITPKB	-0.49	-5.03	-0.46	2.34e-6	Parkinson's disease;
THYM	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg04455712	chr21:45112962	RRP1B	0.55	5.01	0.46	2.46e-6	Mean corpuscular volume;
THYM	cis	rs4866334	1.000	rs77743777	chr5:18488452	G/A	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg06784218	chr1:46089804	CCDC17	-0.32	-4.82	-0.44	5.41e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs758324	0.572	rs247294	chr5:131457028	C/T	cg16205897	chr5:131564050	P4HA2	0.49	4.45	0.42	2.36e-5	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg15242686	chr22:24348715	GSTTP1	0.56	4.92	0.45	3.61e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	9.37	0.69	3.63e-15	Platelet count;
THYM	cis	rs2797160	1.000	rs6904069	chr6:125995134	C/T	cg16306078	chr6:126000798	NA	-0.52	-5.29	-0.48	7.67e-7	Endometrial cancer;
THYM	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg14675211	chr2:100938903	LONRF2	0.77	8.32	0.65	6.49e-13	Intelligence (multi-trait analysis);
THYM	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg04731861	chr2:219085781	ARPC2	0.56	5.39	0.48	5.21e-7	Colorectal cancer;
THYM	cis	rs28595532	0.841	rs10019311	chr4:119785458	G/A	cg14228332	chr4:119757509	SEC24D	1.3	4.73	0.44	7.91e-6	Cannabis dependence symptom count;
THYM	cis	rs2742234	0.541	rs12220534	chr10:43734306	G/T	cg06632098	chr10:43605906	RET	-0.74	-4.97	-0.45	2.95e-6	Hirschsprung disease;
THYM	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg03264133	chr6:25882463	NA	0.65	5.06	0.46	2e-6	Schizophrenia;
THYM	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg11764359	chr7:65958608	NA	-0.78	-6.44	-0.55	4.97e-9	Aortic root size;
THYM	cis	rs10068717	1	rs10068717	chr5:141494934	C/T	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs1322639	0.697	rs12661910	chr6:169584388	A/G	cg04662567	chr6:169592167	NA	-0.73	-6.29	-0.54	9.53e-9	Pulse pressure;
THYM	cis	rs2836633	0.929	rs11701577	chr21:40028906	C/T	cg12884169	chr21:40033163	ERG	0.68	8.52	0.66	2.33e-13	Coronary artery disease;
THYM	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg11502198	chr6:26597334	ABT1	0.61	5.08	0.46	1.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg07424592	chr7:64974309	NA	0.99	5.15	0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg01751800	chr4:77820391	ANKRD56	0.56	4.63	0.43	1.15e-5	Emphysema distribution in smoking;
THYM	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg06138931	chr13:21896616	NA	0.63	5.25	0.47	9.25e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs7326068	0.576	rs34880311	chr13:21329255	A/T	cg02792322	chr13:21280448	IL17D	-0.66	-4.61	-0.43	1.27e-5	Schizophrenia, bipolar disorder and depression (combined);
THYM	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg11327659	chr7:150037044	RARRES2	-0.43	-5.27	-0.48	8.39e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs57590327	0.503	rs12152272	chr3:81911684	G/A	cg07356753	chr3:81810745	GBE1	-0.74	-5.43	-0.49	4.33e-7	Extraversion;
THYM	cis	rs4478858	0.735	rs4949393	chr1:31851875	G/A	cg00250761	chr1:31883323	NA	-0.41	-4.57	-0.42	1.48e-5	Alcohol dependence;
THYM	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg24069376	chr3:38537580	EXOG	-0.68	-6.77	-0.57	1.06e-9	Electrocardiographic conduction measures;
THYM	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg24578937	chr1:2090814	PRKCZ	0.57	5.73	0.51	1.16e-7	Height;
THYM	cis	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg07460842	chr6:66804631	NA	-1.21	-14.57	-0.83	5.97e-26	Exhaled nitric oxide output;
THYM	cis	rs6754311	0.593	rs656326	chr2:136428460	A/C	cg23851026	chr2:136556271	LCT	0.59	5.62	0.5	1.87e-7	Mosquito bite size;
THYM	cis	rs2295499	0.660	rs56215402	chr4:2756912	G/A	cg14003022	chr4:3043019	NA	0.55	4.89	0.45	4.16e-6	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg02773041	chr1:40204384	PPIE	0.74	5.72	0.51	1.25e-7	Blood protein levels;
THYM	cis	rs67072384	0.901	rs58076660	chr11:72441495	G/A	cg01380194	chr11:72452482	ARAP1	-0.78	-4.59	-0.43	1.36e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg24209194	chr3:40518798	ZNF619	0.65	5.27	0.48	8.46e-7	Renal cell carcinoma;
THYM	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg18681998	chr4:17616180	MED28	0.81	6.87	0.58	6.5e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs1395	0.710	rs11682913	chr2:27473649	G/A	cg23587288	chr2:27483067	SLC30A3	-0.64	-5.72	-0.51	1.26e-7	Blood metabolite levels;
THYM	cis	rs12318506	1.000	rs12318506	chr12:75718423	G/T	cg04728562	chr12:75699417	CAPS2	-1.6	-6.29	-0.54	9.61e-9	Coronary artery calcification;
THYM	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg23682913	chr1:2080710	PRKCZ	0.57	4.91	0.45	3.79e-6	Height;
THYM	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg07424592	chr7:64974309	NA	1.05	4.76	0.44	6.92e-6	Diabetic kidney disease;
THYM	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg18305652	chr10:134549665	INPP5A	0.75	5.9	0.52	5.46e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	trans	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg25517755	chr10:38738941	LOC399744	-0.77	-7.1	-0.59	2.23e-10	Corneal astigmatism;
THYM	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg17554472	chr22:41940697	POLR3H	-0.63	-4.61	-0.43	1.24e-5	Vitiligo;
THYM	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg12935359	chr14:103987150	CKB	-0.64	-6.43	-0.55	5.1e-9	Body mass index;
THYM	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg04282206	chr17:62833786	PLEKHM1P	0.82	7.53	0.61	2.9100000000000002e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	8.69	0.67	1.02e-13	Monocyte percentage of white cells;
THYM	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.92	0.45	3.58e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg14004847	chr7:1930337	MAD1L1	-0.72	-5.55	-0.49	2.59e-7	Schizophrenia;
THYM	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg26924012	chr15:45694286	SPATA5L1	1.02	9.33	0.69	4.4e-15	Homoarginine levels;
THYM	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs1178127	0.719	rs1178179	chr7:18799782	C/T	cg13420273	chr7:18810212	HDAC9	-0.58	-5.21	-0.47	1.11e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs7078219	0.505	rs4129132	chr10:101284637	T/G	cg23904955	chr10:101282759	NA	-0.36	-4.61	-0.43	1.28e-5	Dental caries;
THYM	cis	rs9677476	0.818	rs16827879	chr2:232092301	C/T	cg27665808	chr2:232055229	NA	0.57	4.69	0.43	9.11e-6	Food antigen IgG levels;
THYM	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-7.11	-0.59	2.12e-10	Systolic blood pressure;
THYM	cis	rs3791406	1.000	rs3791412	chr2:240031088	A/G	cg11903188	chr2:239195602	PER2	-0.43	-4.59	-0.43	1.37e-5	Skin aging (microtopography measurement);
THYM	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg03060546	chr3:49711283	APEH	0.77	6.37	0.55	6.65e-9	Resting heart rate;
THYM	cis	rs1957429	0.901	rs1957434	chr14:65349909	C/T	cg23373153	chr14:65346875	NA	1.07	6.45	0.55	4.75e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs7777677	0.925	rs6956269	chr7:142369136	T/G	cg21785750	chr7:142428317	NA	0.68	5.94	0.52	4.71e-8	Alcoholic chronic pancreatitis;
THYM	cis	rs642803	0.551	rs1308020	chr11:65497558	G/A	cg27068330	chr11:65405492	SIPA1	0.73	5.34	0.48	6.42e-7	Urate levels;
THYM	cis	rs9902453	1.000	rs4581755	chr17:28427898	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.76	0.44	6.86e-6	Coffee consumption (cups per day);
THYM	cis	rs11886999	0.723	rs62153020	chr2:96882128	G/T	cg18419276	chr2:96971862	SNRNP200	-0.5	-4.77	-0.44	6.69e-6	Cardiac Troponin-T levels;
THYM	cis	rs757081	0.514	rs214087	chr11:17298365	G/C	cg15432903	chr11:17409602	KCNJ11	-0.45	-4.59	-0.43	1.34e-5	Systolic blood pressure;
THYM	cis	rs7582180	0.700	rs4851303	chr2:100962064	T/C	cg14675211	chr2:100938903	LONRF2	0.6	5.9	0.52	5.67e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg11752832	chr7:134001865	SLC35B4	0.76	5.72	0.51	1.24e-7	Mean platelet volume;
THYM	cis	rs2625529	0.641	rs11852789	chr15:72265494	G/C	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg27494647	chr7:150038898	RARRES2	-0.48	-5.96	-0.52	4.26e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg10802521	chr3:52805072	NEK4	-0.8	-7.53	-0.61	2.92e-11	Bipolar disorder;
THYM	cis	rs1971762	0.545	rs10783586	chr12:53980821	C/T	cg16917193	chr12:54089295	NA	0.72	6.7	0.57	1.45e-9	Height;
THYM	cis	rs9430161	0.579	rs11576658	chr1:11037736	C/T	cg27631724	chr1:11040367	C1orf127	0.63	5.35	0.48	6.13e-7	Ewing sarcoma;
THYM	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg13531842	chr10:38383804	ZNF37A	-0.54	-4.53	-0.42	1.72e-5	Breast cancer;
THYM	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg24531977	chr5:56204891	C5orf35	-0.64	-4.97	-0.45	2.92e-6	Coronary artery disease;
THYM	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg12826209	chr6:26865740	GUSBL1	0.82	5.83	0.51	7.45e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg03676636	chr4:99064102	C4orf37	0.5	7.65	0.62	1.6e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11785693	0.866	rs11782170	chr8:4976942	A/G	cg26367366	chr8:4980734	NA	-1.16	-5.46	-0.49	3.79e-7	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs17718580	0.536	rs59807161	chr14:51091475	G/C	cg04730355	chr14:51134070	SAV1	0.91	4.94	0.45	3.38e-6	Cognitive performance;
THYM	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg18477163	chr1:228402036	OBSCN	-0.46	-5.01	-0.46	2.54e-6	Diastolic blood pressure;
THYM	cis	rs7781977	0.960	rs17732497	chr7:50336073	C/A	cg01139861	chr7:50343298	IKZF1	0.7	6.7	0.57	1.46e-9	IgG glycosylation;
THYM	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg02018176	chr4:1364513	KIAA1530	0.5	4.58	0.43	1.42e-5	Obesity-related traits;
THYM	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	10.61	0.74	8.08e-18	Platelet count;
THYM	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg26545918	chr15:68124484	LBXCOR1	0.55	4.76	0.44	6.88e-6	Restless legs syndrome;
THYM	cis	rs7200543	1.000	rs1135999	chr16:15131962	A/G	cg01933576	chr16:15083564	PDXDC1	-0.99	-8.04	-0.64	2.48e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs2299587	0.585	rs2285304	chr8:17797931	T/A	cg01800426	chr8:17659068	MTUS1	-0.67	-5.06	-0.46	2.07e-6	Economic and political preferences;
THYM	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.29e-7	Corneal astigmatism;
THYM	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg10523679	chr1:76189770	ACADM	0.89	8.55	0.66	2.05e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg05347473	chr6:146136440	FBXO30	0.57	4.46	0.42	2.22e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17253792	0.822	rs10149408	chr14:56046075	G/A	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg13289132	chr10:30722225	MAP3K8	-0.61	-4.98	-0.45	2.84e-6	Inflammatory bowel disease;
THYM	cis	rs10416265	0.528	rs7249097	chr19:33589144	T/C	cg03563238	chr19:33554763	RHPN2	-0.54	-4.67	-0.43	9.87e-6	Bone properties (heel);
THYM	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg05043794	chr9:111880884	C9orf5	-0.44	-6.39	-0.55	6.03e-9	Menarche (age at onset);
THYM	cis	rs259964	1.000	rs259964	chr20:57824309	A/G	cg09005679	chr20:57875326	EDN3	-0.43	-5.08	-0.46	1.85e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs11148252	0.744	rs77466241	chr13:52862914	C/G	cg00495681	chr13:53174319	NA	0.71	6.69	0.57	1.57e-9	Lewy body disease;
THYM	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg02527881	chr3:46936655	PTH1R	0.59	5.63	0.5	1.83e-7	Colorectal cancer;
THYM	cis	rs6450176	0.909	rs67199213	chr5:53290648	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-6.61	-0.56	2.22e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg05182265	chr7:156933206	UBE3C	0.64	8.1	0.64	1.81e-12	Body mass index;
THYM	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg09877947	chr5:131593287	PDLIM4	0.56	4.56	0.42	1.51e-5	Blood metabolite levels;
THYM	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg21361702	chr7:150065534	REPIN1	0.69	5.85	0.51	6.95e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs1345301	0.552	rs67880537	chr2:102864106	A/G	cg03938978	chr2:103052716	IL18RAP	-0.52	-4.92	-0.45	3.65e-6	Waist circumference;
THYM	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg05973401	chr12:123451056	ABCB9	0.68	4.55	0.42	1.58e-5	Neutrophil percentage of white cells;
THYM	cis	rs9992101	0.501	rs4493565	chr4:77420822	A/C	cg20311846	chr4:77356250	SHROOM3	-0.58	-6.55	-0.56	2.89e-9	Creatinine levels;
THYM	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	6.86	0.58	7.07e-10	Total body bone mineral density;
THYM	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	5.69	0.5	1.4e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg24209194	chr3:40518798	ZNF619	-0.73	-6.31	-0.54	8.87e-9	Renal cell carcinoma;
THYM	cis	rs6840360	0.582	rs11733820	chr4:152316139	T/C	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.22	-0.47	1.05e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8050907	1.000	rs111344533	chr16:4654144	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.34	5.32	0.48	7e-7	Obesity-related traits;
THYM	cis	rs28785552	0.577	rs12463163	chr19:53212821	A/C	cg10871876	chr19:53194124	ZNF83	0.65	5.11	0.46	1.65e-6	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14442939	chr10:27389572	ANKRD26	0.93	4.74	0.44	7.52e-6	Breast cancer;
THYM	cis	rs6866344	0.569	rs56027952	chr5:178150181	C/A	cg03877680	chr5:178157825	ZNF354A	0.81	5.74	0.51	1.12e-7	Neutrophil percentage of white cells;
THYM	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg26384229	chr12:38710491	ALG10B	1.0	7.85	0.63	6.12e-12	Bladder cancer;
THYM	cis	rs7705042	0.826	rs11749731	chr5:141500436	A/C	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	trans	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg10856724	chr12:34555212	NA	-1.02	-9.32	-0.69	4.7e-15	Bladder cancer;
THYM	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg17366294	chr4:99064904	C4orf37	0.57	6.96	0.58	4.44e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs354225	0.544	rs3287	chr2:54807657	T/C	cg23486701	chr2:54789491	SPTBN1	0.36	4.6	0.43	1.31e-5	Schizophrenia;
THYM	cis	rs4843185	0.733	rs1049868	chr16:85706633	A/G	cg08899895	chr16:85684853	KIAA0182	0.61	5.14	0.47	1.46e-6	Platelet distribution width;
THYM	cis	rs4474465	0.850	rs4565922	chr11:78260699	A/G	cg19901956	chr11:77921274	USP35	0.61	4.64	0.43	1.1e-5	Alzheimer's disease (survival time);
THYM	cis	rs9902453	0.904	rs11080115	chr17:28408070	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-6.08	-0.53	2.47e-8	Coffee consumption (cups per day);
THYM	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5167	0.504	rs3760629	chr19:45458146	A/C	cg13119609	chr19:45449297	APOC2	0.6	5.67	0.5	1.54e-7	Blood protein levels;
THYM	cis	rs4866334	0.557	rs116250256	chr5:18457657	A/T	cg18608440	chr5:17519013	NA	1.16	5.19	0.47	1.17e-6	IgG glycosylation;
THYM	cis	rs12410462	1.000	rs16847833	chr1:227626662	G/A	cg04117972	chr1:227635322	NA	0.71	4.8	0.44	5.85e-6	Major depressive disorder;
THYM	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.61e-20	Menopause (age at onset);
THYM	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg04025307	chr7:1156635	C7orf50	0.7	5.73	0.51	1.17e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs988913	0.793	rs9370333	chr6:54738246	A/G	cg18532076	chr6:54711417	FAM83B	0.53	4.86	0.45	4.67e-6	Menarche (age at onset);
THYM	cis	rs4631830	0.900	rs9787697	chr10:51533376	C/T	cg10326726	chr10:51549505	MSMB	-0.62	-6.26	-0.54	1.11e-8	Prostate-specific antigen levels;
THYM	cis	rs58950470	0.887	rs1784223	chr11:65380248	T/C	cg27068330	chr11:65405492	SIPA1	0.63	4.8	0.44	6e-6	Schizophrenia;
THYM	cis	rs4499344	0.589	rs259233	chr19:33127000	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	1.01	7.43	0.61	4.69e-11	Mean platelet volume;
THYM	cis	rs4589258	0.713	rs1792614	chr11:90452512	G/A	cg26138821	chr11:89956704	CHORDC1	-0.58	-4.72	-0.44	8.17e-6	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg27535305	chr1:53392650	SCP2	0.41	4.86	0.45	4.54e-6	Monocyte count;
THYM	cis	rs6719884	0.897	rs2215966	chr2:59017244	G/A	cg09452692	chr2:58468460	FANCL	-0.59	-4.66	-0.43	1.03e-5	Myasthenia gravis;
THYM	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg25767906	chr1:53392781	SCP2	-0.53	-5.2	-0.47	1.13e-6	Monocyte count;
THYM	cis	rs911119	1.000	rs34897231	chr20:23620268	A/G	cg16589663	chr20:23618590	CST3	0.76	4.69	0.43	9.26e-6	Chronic kidney disease;
THYM	cis	rs10197940	0.578	rs2432946	chr2:152306897	G/T	cg19508488	chr2:152266495	RIF1	-0.7	-5.56	-0.5	2.42e-7	Lung cancer;
THYM	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Parkinson's disease;
THYM	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg06481639	chr22:41940642	POLR3H	0.77	5.37	0.48	5.67e-7	Vitiligo;
THYM	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg19729930	chr2:74357872	NA	1.23	13.13	0.8	4.61e-23	Gestational age at birth (maternal effect);
THYM	cis	rs12496230	1.000	rs34508066	chr3:66837509	G/T	cg17646820	chr3:66848679	NA	0.82	4.85	0.45	4.74e-6	Type 2 diabetes;
THYM	cis	rs459571	0.959	rs416390	chr9:136908549	C/G	cg13789015	chr9:136890014	NCRNA00094	-0.84	-7.25	-0.6	1.09e-10	Platelet distribution width;
THYM	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg22709100	chr7:91322751	NA	0.71	5.58	0.5	2.22e-7	Breast cancer;
THYM	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg08045932	chr20:61659980	NA	0.94	10.68	0.74	5.76e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg22841779	chr14:105766346	BRF1	-0.46	-5.72	-0.51	1.25e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs12496230	0.953	rs1036970	chr3:66850707	A/G	cg23477460	chr3:66848765	NA	1.2	6.73	0.57	1.29e-9	Type 2 diabetes;
THYM	cis	rs12681287	0.640	rs13253515	chr8:87458596	T/A	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs9876781	1.000	rs725310	chr3:48418571	C/T	cg06066452	chr3:48470258	PLXNB1	-0.26	-4.95	-0.45	3.23e-6	Longevity;
THYM	cis	rs4631830	0.863	rs4554834	chr10:51530146	A/C	cg16070123	chr10:51489643	NA	-0.49	-4.48	-0.42	2.1e-5	Prostate-specific antigen levels;
THYM	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg03388043	chr17:80084554	CCDC57	-0.73	-6.06	-0.53	2.74e-8	Life satisfaction;
THYM	cis	rs4523957	0.890	rs6503324	chr17:2100512	C/T	cg16513277	chr17:2031491	SMG6	-0.83	-8.36	-0.65	5.1e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs11563648	0.573	rs7786199	chr7:126961541	G/A	cg23081781	chr7:127225937	GCC1	-0.36	-4.93	-0.45	3.5e-6	Resting heart rate;
THYM	cis	rs4460079	0.531	rs62314610	chr4:114834558	A/G	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs6430585	0.646	rs1057031	chr2:136633962	G/A	cg07169764	chr2:136633963	MCM6	1.23	15.07	0.84	6.2e-27	Corneal structure;
THYM	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.61	0.56	2.25e-9	Prudent dietary pattern;
THYM	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13126279	chr21:47581558	C21orf56	0.66	4.53	0.42	1.74e-5	Testicular germ cell tumor;
THYM	cis	rs12410462	0.748	rs1495853	chr1:227657336	A/G	cg23173402	chr1:227635558	NA	-0.56	-5.26	-0.47	8.96e-7	Major depressive disorder;
THYM	cis	rs2046867	0.774	rs9820293	chr3:72876237	T/A	cg25664220	chr3:72788482	NA	-0.85	-6.82	-0.57	8.44e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg09455208	chr3:40491958	NA	0.46	4.73	0.44	7.93e-6	Renal cell carcinoma;
THYM	cis	rs7937682	0.632	rs11823089	chr11:111673539	A/G	cg09085632	chr11:111637200	PPP2R1B	1.22	13.43	0.81	1.13e-23	Primary sclerosing cholangitis;
THYM	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg08975724	chr8:8085496	FLJ10661	0.75	6.22	0.54	1.34e-8	Mood instability;
THYM	cis	rs17407555	0.518	rs16891234	chr4:9946163	A/G	cg00071950	chr4:10020882	SLC2A9	-0.86	-6.81	-0.57	8.85e-10	Schizophrenia (age at onset);
THYM	cis	rs6032067	0.929	rs7344269	chr20:43828668	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	0.52	5.42	0.49	4.56e-7	Blood protein levels;
THYM	cis	rs986417	1.000	rs1956549	chr14:60928201	G/A	cg27398547	chr14:60952738	C14orf39	1.15	5.91	0.52	5.37e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg06640241	chr16:89574553	SPG7	0.61	4.6	0.43	1.3e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs3027234	0.734	rs11650309	chr17:8129538	C/G	cg08322244	chr17:8066669	VAMP2	-0.58	-5.84	-0.51	7.34e-8	Telomere length;
THYM	cis	rs7769051	0.522	rs60631157	chr6:133094817	G/A	cg07930552	chr6:133119739	C6orf192	1.3	5.36	0.48	5.74e-7	Type 2 diabetes nephropathy;
THYM	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg23018236	chr17:30244563	NA	-0.6	-4.45	-0.42	2.3e-5	Hip circumference adjusted for BMI;
THYM	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg26038318	chr20:34205095	SPAG4	0.58	4.6	0.43	1.3e-5	Total cholesterol levels;
THYM	cis	rs6840360	0.593	rs6855883	chr4:152688997	A/G	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs9486719	0.857	rs9285393	chr6:97020917	C/A	cg18709589	chr6:96969512	KIAA0776	-0.63	-4.47	-0.42	2.14e-5	Migraine;Coronary artery disease;
THYM	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24531977	chr5:56204891	C5orf35	-1.01	-8.5	-0.66	2.63e-13	Initial pursuit acceleration;
THYM	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg20290983	chr6:43655470	MRPS18A	1.43	15.6	0.85	6.08e-28	IgG glycosylation;
THYM	cis	rs7246657	0.943	rs10405064	chr19:37861861	C/T	cg22634378	chr19:37742834	NA	0.66	5.43	0.49	4.35e-7	Coronary artery calcification;
THYM	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.06	9.59	0.7	1.27e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs912057	0.833	rs1294426	chr6:6744477	T/C	cg13809441	chr6:6737631	NA	0.43	4.86	0.45	4.62e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg02463440	chr8:22132932	PIWIL2	0.59	5.21	0.47	1.12e-6	Hypertriglyceridemia;
THYM	cis	rs737337	0.623	rs4804155	chr19:11334295	C/G	cg21487509	chr19:11347464	LOC55908;DOCK6	0.57	4.54	0.42	1.66e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg09990169	chr2:241835740	C2orf54	-0.29	-4.85	-0.45	4.85e-6	Urinary metabolites;
THYM	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	5.69	0.5	1.41e-7	Obesity-related traits;
THYM	cis	rs67072384	1.000	rs12272109	chr11:72453850	G/A	cg01380194	chr11:72452482	ARAP1	-0.97	-5.26	-0.47	8.93e-7	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs7546094	0.846	rs55675817	chr1:113166876	C/A	cg25616829	chr1:112535356	NA	-0.58	-4.71	-0.44	8.34e-6	Platelet distribution width;
THYM	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg11905131	chr22:24372483	LOC391322	-0.96	-12.61	-0.79	5.16e-22	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg06481639	chr22:41940642	POLR3H	-0.63	-4.58	-0.43	1.39e-5	Neuroticism;
THYM	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg27534772	chr1:16042836	PLEKHM2	0.56	6.31	0.54	8.77e-9	Systolic blood pressure;
THYM	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Gout;
THYM	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg25036284	chr2:26402008	FAM59B	-0.78	-5.19	-0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs3741151	0.773	rs73544729	chr11:73183418	G/T	cg17517138	chr11:73019481	ARHGEF17	0.94	5.48	0.49	3.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg12963246	chr6:28129442	ZNF389	-0.76	-6.43	-0.55	5.07e-9	Depression;
THYM	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg08901578	chr4:187885870	NA	-0.63	-5.75	-0.51	1.09e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs665401	0.692	rs339315	chr6:117183607	T/C	cg20376953	chr6:117187980	NA	0.61	4.89	0.45	4.05e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg00647820	chr17:40259828	DHX58	-0.62	-4.65	-0.43	1.06e-5	Fibrinogen levels;
THYM	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg12165864	chr7:66369176	NA	-0.81	-5.92	-0.52	5.09e-8	Corneal structure;
THYM	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg01710189	chr8:22454888	PDLIM2	-0.55	-5.88	-0.52	6.08e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg21775007	chr8:11205619	TDH	-0.63	-4.86	-0.45	4.65e-6	Retinal vascular caliber;
THYM	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs13315871	0.929	rs17354606	chr3:58237289	T/C	cg12435725	chr3:58293450	RPP14	-0.57	-5.91	-0.52	5.22e-8	Cholesterol, total;
THYM	cis	rs13064411	0.518	rs9870996	chr3:113238375	A/C	cg18753928	chr3:113234510	CCDC52	-0.78	-7.16	-0.59	1.68e-10	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7781557	0.702	rs7809047	chr7:102496061	T/G	cg06322601	chr7:102330635	NA	0.84	5.3	0.48	7.63e-7	Colorectal adenoma (advanced);
THYM	cis	rs3126085	1.000	rs3126095	chr1:152309683	G/A	cg26020982	chr1:152196106	HRNR	-0.36	-4.95	-0.45	3.19e-6	Atopic dermatitis;
THYM	cis	rs4262150	0.883	rs4958583	chr5:152223531	C/T	cg06854687	chr5:151642065	NA	0.67	4.68	0.43	9.56e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4523957	0.928	rs10852932	chr17:2143460	G/T	cg16513277	chr17:2031491	SMG6	-0.8	-7.55	-0.61	2.58e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg22509189	chr2:225307070	NA	-0.65	-5.15	-0.47	1.4e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs3126085	0.935	rs3126094	chr1:152308243	T/C	cg26020982	chr1:152196106	HRNR	-0.37	-5.09	-0.46	1.79e-6	Atopic dermatitis;
THYM	cis	rs2806561	0.964	rs1757041	chr1:23506063	G/A	cg12483005	chr1:23474871	LUZP1	0.55	5.69	0.5	1.39e-7	Height;
THYM	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.55	0.42	1.57e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg08742575	chr21:47604166	C21orf56	0.64	4.96	0.45	3.1e-6	Testicular germ cell tumor;
THYM	cis	rs9653442	0.863	rs10865035	chr2:100835734	A/G	cg07810366	chr2:100720526	AFF3	-0.36	-4.84	-0.44	4.99e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg06112835	chr11:68658793	MRPL21	0.43	6.08	0.53	2.48e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg26441486	chr22:50317300	CRELD2	0.36	5.19	0.47	1.18e-6	Schizophrenia;
THYM	cis	rs7177699	0.557	rs7165075	chr15:79115965	G/A	cg00540400	chr15:79124168	NA	0.64	6.93	0.58	4.98e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs2241584	0.967	rs11738973	chr5:175945027	T/A	cg27658698	chr5:175955578	RNF44	-0.49	-5.86	-0.52	6.73e-8	Menopause (age at onset);
THYM	cis	rs17744026	0.586	rs74857358	chr11:123752340	C/T	cg00079598	chr11:123676903	OR6M1	-0.48	-4.48	-0.42	2.04e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs61931739	0.892	rs61931711	chr12:34045374	C/T	cg06521331	chr12:34319734	NA	0.61	4.76	0.44	6.95e-6	Morning vs. evening chronotype;
THYM	cis	rs7408868	0.831	rs11672004	chr19:15277282	T/A	cg14696996	chr19:15285081	NOTCH3	0.96	5.54	0.49	2.74e-7	Pulse pressure;
THYM	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg24578937	chr1:2090814	PRKCZ	0.81	8.54	0.66	2.22e-13	Height;
THYM	cis	rs8016982	0.633	rs72695758	chr14:81720146	T/C	cg01989461	chr14:81687754	GTF2A1	0.79	7.12	0.59	2.08e-10	Schizophrenia;
THYM	cis	rs2964802	0.505	rs7729989	chr5:10822246	A/G	cg14521931	chr5:10832172	NA	-0.62	-5.12	-0.46	1.63e-6	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs490234	0.691	rs3104551	chr9:128164279	G/A	cg14078157	chr9:128172775	NA	-0.85	-6.93	-0.58	4.91e-10	Mean arterial pressure;
THYM	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg15448220	chr1:150897856	SETDB1	0.87	7.37	0.6	6.2e-11	Melanoma;
THYM	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.6	-11.28	-0.76	3.1400000000000002e-19	Hemostatic factors and hematological phenotypes;
THYM	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg12165864	chr7:66369176	NA	-0.65	-5.08	-0.46	1.89e-6	Aortic root size;
THYM	cis	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg13443165	chr9:33130375	B4GALT1	-0.87	-7.99	-0.63	3.23e-12	IgG glycosylation;
THYM	cis	rs7043114	0.507	rs10820971	chr9:95161740	G/C	cg14631576	chr9:95140430	CENPP	-0.82	-8.27	-0.65	7.95e-13	Height;
THYM	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg08968635	chr6:28129556	ZNF389	0.71	5.58	0.5	2.28e-7	Parkinson's disease;
THYM	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg18402987	chr7:1209562	NA	1.1	6.73	0.57	1.27e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6992848	0.963	rs68147429	chr8:141162799	A/G	cg22504031	chr8:141147661	TRAPPC9	0.63	4.75	0.44	7.06e-6	Response to amphetamines;
THYM	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg17554472	chr22:41940697	POLR3H	-0.73	-5.0	-0.46	2.59e-6	Vitiligo;
THYM	cis	rs2976388	1.000	rs2976396	chr8:143764001	A/G	cg06565975	chr8:143823917	SLURP1	0.45	5.23	0.47	9.95e-7	Urinary tract infection frequency;
THYM	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.9	-0.45	4.01e-6	Monocyte count;
THYM	cis	rs2133450	0.780	rs2030155	chr3:7361473	C/T	cg19930620	chr3:7340148	GRM7	-0.49	-4.66	-0.43	1.02e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs870825	0.616	rs7674952	chr4:185622327	A/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg04546413	chr19:29218101	NA	1.13	9.17	0.69	9.75e-15	Methadone dose in opioid dependence;
THYM	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11644478	chr21:40555479	PSMG1	-0.56	-4.69	-0.43	9.07e-6	Menarche (age at onset);
THYM	cis	rs748404	0.660	rs2602141	chr15:43724646	A/C	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs427394	0.582	rs274662	chr5:6704860	G/A	cg10857441	chr5:6722123	POLS	-0.7	-7.46	-0.61	3.98e-11	Menopause (age at onset);
THYM	cis	rs1023500	0.956	rs1894713	chr22:42335621	G/A	cg19448990	chr22:41842841	TOB2	-0.75	-4.8	-0.44	5.89e-6	Schizophrenia;
THYM	cis	rs16917546	1.000	rs7905030	chr10:64421600	G/C	cg03961010	chr10:64397487	ZNF365	-0.79	-6.78	-0.57	9.94e-10	Basal cell carcinoma;
THYM	cis	rs7264396	0.635	rs6060681	chr20:34506147	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.13	-0.47	1.53e-6	Total cholesterol levels;
THYM	cis	rs12935418	0.583	rs2549841	chr16:81023572	C/T	cg16651780	chr16:81037892	C16orf61	-0.91	-7.0	-0.58	3.57e-10	Mean corpuscular volume;
THYM	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-4.47	-0.42	2.16e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg24818145	chr4:99064322	C4orf37	0.69	5.37	0.48	5.48e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13732083	chr21:47605072	C21orf56	0.65	4.68	0.43	9.57e-6	Testicular germ cell tumor;
THYM	trans	rs3213961	0.562	rs60739635	chr2:33831794	T/C	cg19997179	chr2:620310	NA	0.53	6.94	0.58	4.82e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
THYM	cis	rs7833986	0.818	rs79824205	chr8:57093233	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	4.98	0.45	2.84e-6	Height;
THYM	cis	rs28595532	0.764	rs115877991	chr4:119728298	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs2072499	0.900	rs2248080	chr1:156195971	T/A	cg24450063	chr1:156163899	SLC25A44	1.15	13.63	0.81	4.43e-24	Testicular germ cell tumor;
THYM	cis	rs2554380	0.843	rs1019665	chr15:84380619	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.63	-4.98	-0.46	2.79e-6	Height;
THYM	cis	rs1550582	0.917	rs7831961	chr8:135507060	C/G	cg17885191	chr8:135476712	NA	-0.77	-5.48	-0.49	3.48e-7	Educational attainment;
THYM	cis	rs61931739	0.817	rs11053071	chr12:34201400	A/G	cg06521331	chr12:34319734	NA	-0.58	-4.86	-0.45	4.58e-6	Morning vs. evening chronotype;
THYM	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg08132940	chr7:1081526	C7orf50	-1.17	-6.67	-0.56	1.7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg20295408	chr7:1910781	MAD1L1	-0.65	-5.16	-0.47	1.37e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg04117972	chr1:227635322	NA	0.68	4.46	0.42	2.26e-5	Major depressive disorder;
THYM	cis	rs860818	1.000	rs858252	chr7:23217872	C/A	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs2130392	1.000	rs873686	chr4:185638876	A/G	cg04058563	chr4:185651563	MLF1IP	-0.62	-6.19	-0.54	1.53e-8	Kawasaki disease;
THYM	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg14186256	chr22:23484241	RTDR1	0.97	9.41	0.69	3e-15	Bone mineral density;
THYM	cis	rs72960926	0.744	rs72967299	chr6:75034041	C/T	cg03266952	chr6:74778945	NA	-0.86	-4.52	-0.42	1.78e-5	Metabolite levels (MHPG);
THYM	cis	rs4455778	0.543	rs4132419	chr7:49066633	A/G	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg15445000	chr17:37608096	MED1	-0.44	-5.1	-0.46	1.72e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4919687	0.577	rs12765459	chr10:104465687	G/C	cg18761893	chr10:103892519	PPRC1	0.6	4.47	0.42	2.16e-5	Colorectal cancer;
THYM	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg15549821	chr19:49342101	PLEKHA4	-1.05	-6.42	-0.55	5.46e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs4638749	0.677	rs10185601	chr2:108828278	A/G	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs6956675	0.915	rs7780762	chr7:62654263	T/C	cg08930214	chr7:62859557	LOC100287834	0.61	4.78	0.44	6.47e-6	Obesity-related traits;
THYM	cis	rs4631830	0.965	rs4306255	chr10:51542444	A/G	cg16070123	chr10:51489643	NA	-0.52	-4.74	-0.44	7.39e-6	Prostate-specific antigen levels;
THYM	cis	rs12188164	0.582	rs72700694	chr5:483267	T/C	cg07601488	chr5:169797	PLEKHG4B	0.51	4.45	0.42	2.32e-5	Cystic fibrosis severity;
THYM	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg18876405	chr7:65276391	NA	0.71	6.58	0.56	2.57e-9	Aortic root size;
THYM	cis	rs73198271	0.613	rs11249892	chr8:8657240	C/T	cg06636001	chr8:8085503	FLJ10661	-0.66	-4.5	-0.42	1.92e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg01097406	chr16:89675127	NA	-0.56	-4.64	-0.43	1.12e-5	Vitiligo;
THYM	cis	rs4642101	0.824	rs9825233	chr3:12843368	A/G	cg05775895	chr3:12838266	CAND2	-0.96	-8.68	-0.67	1.07e-13	QRS complex (12-leadsum);
THYM	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	12.13	0.78	5.13e-21	Chronic sinus infection;
THYM	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg12311346	chr5:56204834	C5orf35	0.62	4.71	0.43	8.56e-6	Initial pursuit acceleration;
THYM	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg15110403	chr19:17392923	ANKLE1	0.57	4.94	0.45	3.36e-6	Systemic lupus erythematosus;
THYM	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.09	0.53	2.35e-8	Coronary artery disease;
THYM	cis	rs11605275	0.581	rs11606785	chr11:20030430	A/C	cg14835545	chr11:20032148	NAV2	-1.47	-6.95	-0.58	4.57e-10	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Body mass index;
THYM	cis	rs863345	0.604	rs11265016	chr1:158503785	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs9560113	0.919	rs11069896	chr13:112178887	C/T	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg10150615	chr22:24372951	LOC391322	1.04	12.58	0.79	6.02e-22	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1691799	0.867	rs1027401	chr12:66760892	C/G	cg16791601	chr12:66731901	HELB	-0.68	-5.92	-0.52	5.07e-8	White blood cell count (basophil);
THYM	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg01341218	chr17:43662625	NA	-1.07	-9.27	-0.69	5.9e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg23711669	chr6:146136114	FBXO30	0.91	8.72	0.67	8.87e-14	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg20088477	chr3:71221584	FOXP1	-0.85	-7.2	-0.59	1.38e-10	Depressive symptoms;
THYM	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg07212818	chr11:638076	DRD4	-0.79	-6.69	-0.57	1.57e-9	Systemic lupus erythematosus;
THYM	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg19875535	chr5:140030758	IK	0.58	4.46	0.42	2.21e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs4718428	1.000	rs1830070	chr7:66349671	T/C	cg18252515	chr7:66147081	NA	-0.7	-5.31	-0.48	7.33e-7	Corneal structure;
THYM	cis	rs9768139	0.634	rs11762383	chr7:158113889	C/T	cg25566285	chr7:158114605	PTPRN2	0.95	12.2	0.78	3.77e-21	Calcium levels;
THYM	cis	rs7312774	0.618	rs12316476	chr12:107343326	C/G	cg16260113	chr12:107380972	MTERFD3	1.3	6.63	0.56	2.04e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs9486715	0.867	rs4131519	chr6:96964939	G/A	cg06623918	chr6:96969491	KIAA0776	1.06	8.48	0.66	2.96e-13	Headache;
THYM	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg07061783	chr6:25882402	NA	-0.88	-7.66	-0.62	1.57e-11	Intelligence (multi-trait analysis);
THYM	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg03733263	chr8:22462867	KIAA1967	1.15	13.54	0.81	6.65e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg20295408	chr7:1910781	MAD1L1	-0.61	-4.85	-0.45	4.9100000000000004e-06	Bipolar disorder and schizophrenia;
THYM	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg24692254	chr21:30365293	RNF160	-0.85	-7.06	-0.59	2.74e-10	Dental caries;
THYM	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.75	-5.89	-0.52	5.81e-8	Systemic lupus erythematosus;
THYM	cis	rs2732480	0.500	rs7315820	chr12:48598938	C/T	cg21466736	chr12:48725269	NA	-0.54	-4.87	-0.45	4.43e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs7829975	0.777	rs6989926	chr8:8547313	A/C	cg06636001	chr8:8085503	FLJ10661	-0.64	-5.36	-0.48	5.7e-7	Mood instability;
THYM	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4363385	0.747	rs4845508	chr1:152968421	G/C	cg13444842	chr1:152974279	SPRR3	-0.57	-4.51	-0.42	1.88e-5	Inflammatory skin disease;
THYM	cis	rs28374715	0.580	rs8030228	chr15:41636867	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.17	-14.19	-0.82	3.41e-25	Ulcerative colitis;
THYM	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg16414030	chr3:133502952	NA	0.66	5.53	0.49	2.81e-7	Iron status biomarkers;
THYM	cis	rs2073300	0.609	rs79250740	chr20:23417165	G/A	cg12062639	chr20:23401060	NAPB	1.1	5.73	0.51	1.16e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg24578937	chr1:2090814	PRKCZ	-0.61	-6.21	-0.54	1.37e-8	Height;
THYM	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg09549813	chr16:4587862	C16orf5	-0.59	-6.68	-0.57	1.59e-9	Schizophrenia;
THYM	trans	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg07393940	chr7:158741817	NA	-1.14	-9.25	-0.69	6.69e-15	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	trans	rs1973993	0.691	rs2985636	chr1:96889884	T/A	cg10631902	chr5:14652156	NA	0.77	9.44	0.7	2.62e-15	Weight;
THYM	cis	rs7428	1.000	rs7428	chr2:85545490	C/T	cg24342717	chr2:85555507	TGOLN2	0.58	4.91	0.45	3.81e-6	Ear protrusion;
THYM	cis	rs11677370	0.574	rs10209122	chr2:3871186	C/A	cg07307994	chr2:3828216	NA	-0.7	-4.63	-0.43	1.17e-5	Type 2 diabetes;
THYM	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg19875535	chr5:140030758	IK	-0.62	-5.46	-0.49	3.83e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg15556689	chr8:8085844	FLJ10661	0.62	5.08	0.46	1.86e-6	Mood instability;
THYM	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6754311	0.731	rs309160	chr2:136685228	C/T	cg04750100	chr2:136595281	LCT	0.59	6.31	0.54	8.79e-9	Mosquito bite size;
THYM	cis	rs1461503	0.934	rs7115651	chr11:122831882	C/T	cg27398637	chr11:122830231	C11orf63	-0.63	-5.25	-0.47	9.24e-7	Menarche (age at onset);
THYM	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg23161317	chr6:28129485	ZNF389	0.94	7.03	0.58	3.18e-10	Parkinson's disease;
THYM	cis	rs2737229	0.543	rs179444	chr8:116672747	G/T	cg04656070	chr8:116661063	TRPS1	-0.58	-6.7	-0.57	1.47e-9	Cholesterol, total;
THYM	trans	rs8002861	0.935	rs4101376	chr13:44469835	C/T	cg17145862	chr1:211918768	LPGAT1	-1.03	-11.89	-0.77	1.66e-20	Leprosy;
THYM	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs807029	0.533	rs3740486	chr10:102750623	T/C	cg14905631	chr10:102746534	C10orf2;MRPL43	0.36	5.05	0.46	2.14e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	5.44	0.49	4.13e-7	Obesity-related traits;
THYM	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg01097406	chr16:89675127	NA	-0.64	-5.33	-0.48	6.54e-7	Vitiligo;
THYM	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs4595586	0.545	rs12815047	chr12:39380901	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg20891283	chr12:69753455	YEATS4	0.98	8.78	0.67	6.53e-14	Blood protein levels;
THYM	cis	rs9393777	0.546	rs35589403	chr6:27219491	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.43	-4.52	-0.42	1.81e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9915657	0.966	rs8071717	chr17:70128705	C/T	cg06234051	chr17:70120541	SOX9	-0.54	-4.67	-0.43	9.98e-6	Thyroid hormone levels;
THYM	cis	rs2742417	0.603	rs2531755	chr3:45772742	T/C	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs4242434	0.819	rs720745	chr8:22471147	G/T	cg03733263	chr8:22462867	KIAA1967	0.97	10.89	0.75	2.14e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs1728785	0.591	rs10775305	chr16:68656460	A/G	cg02972257	chr16:68554789	NA	-0.7	-4.57	-0.42	1.47e-5	Ulcerative colitis;
THYM	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg24692254	chr21:30365293	RNF160	0.65	4.65	0.43	1.06e-5	Selective IgA deficiency;
THYM	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	cis	rs7769051	0.522	rs6911773	chr6:133128848	T/C	cg07930552	chr6:133119739	C6orf192	1.17	4.55	0.42	1.6e-5	Type 2 diabetes nephropathy;
THYM	cis	rs11048434	0.736	rs2377673	chr12:9112551	A/G	cg04155231	chr12:9217510	LOC144571	0.47	4.47	0.42	2.14e-5	Sjögren's syndrome;
THYM	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg02569458	chr12:86230093	RASSF9	0.63	5.56	0.5	2.51e-7	Major depressive disorder;
THYM	cis	rs4731207	0.596	rs1871776	chr7:124674648	A/G	cg05285228	chr7:124571219	POT1	-0.65	-4.98	-0.45	2.9e-6	Cutaneous malignant melanoma;
THYM	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg24154853	chr7:158122151	PTPRN2	0.56	5.04	0.46	2.23e-6	Calcium levels;
THYM	trans	rs10962692	0.608	rs62541920	chr9:16865291	G/A	cg03221025	chr16:88955224	CBFA2T3	0.75	7.2	0.59	1.37e-10	Ovarian cancer in BRCA2 mutation carriers;Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;
THYM	cis	rs3096299	0.866	rs4238829	chr16:89462262	G/A	cg10164272	chr16:89456328	ANKRD11	0.64	4.88	0.45	4.2e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs983545	0.556	rs9844888	chr3:17066421	T/A	cg24159436	chr3:16974681	PLCL2	0.3	4.71	0.44	8.3e-6	Blood protein levels;
THYM	cis	rs9814567	0.752	rs7623567	chr3:134330976	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7607369	0.618	rs62193298	chr2:219655211	T/G	cg02176678	chr2:219576539	TTLL4	-0.6	-5.51	-0.49	3.11e-7	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs17016200	0.513	rs73107735	chr3:78366652	G/A	cg24512093	chr3:78698151	ROBO1	0.99	5.11	0.46	1.63e-6	Facial emotion recognition;
THYM	cis	rs8032315	1.000	rs6227	chr15:91425232	C/T	cg04510874	chr15:91427884	FES	0.65	4.83	0.44	5.2e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs904251	0.737	rs914347	chr6:37484970	A/C	cg01843034	chr6:37503916	NA	-0.64	-4.65	-0.43	1.06e-5	Cognitive performance;
THYM	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg04654363	chr8:8581213	NA	-0.48	-4.62	-0.43	1.22e-5	Obesity-related traits;
THYM	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg06808227	chr14:105710500	BRF1	1.09	9.75	0.71	5.74e-16	Mean platelet volume;Platelet distribution width;
THYM	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg08885076	chr2:99613938	TSGA10	0.65	5.96	0.52	4.31e-8	Chronic sinus infection;
THYM	cis	rs61931739	0.890	rs11053018	chr12:34105962	T/G	cg06521331	chr12:34319734	NA	0.6	4.86	0.45	4.59e-6	Morning vs. evening chronotype;
THYM	trans	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg07211511	chr3:129823064	LOC729375	-0.9	-7.15	-0.59	1.8e-10	Blood pressure (smoking interaction);
THYM	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-15.39	-0.84	1.51e-27	Height;
THYM	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg12165864	chr7:66369176	NA	0.64	4.92	0.45	3.64e-6	Aortic root size;
THYM	cis	rs36051895	0.695	rs10120763	chr9:5002911	C/G	cg02405213	chr9:5042618	JAK2	-1.05	-11.09	-0.75	7.79e-19	Pediatric autoimmune diseases;
THYM	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg08645402	chr16:4508243	NA	0.71	6.43	0.55	5.02e-9	Schizophrenia;
THYM	cis	rs1887430	0.526	rs414972	chr9:4827637	A/T	cg14182974	chr9:4791918	RCL1	0.53	4.47	0.42	2.17e-5	Platelet count;Plateletcrit;
THYM	cis	rs6496667	0.509	rs6496677	chr15:90990358	A/G	cg22089800	chr15:90895588	ZNF774	0.65	4.73	0.44	7.89e-6	Rheumatoid arthritis;
THYM	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg08470875	chr2:26401718	FAM59B	-0.74	-4.63	-0.43	1.17e-5	Gut microbiome composition (summer);
THYM	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg03060546	chr3:49711283	APEH	-0.68	-5.24	-0.47	9.81e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg14983838	chr19:29218262	NA	1.06	8.76	0.67	7.49e-14	Methadone dose in opioid dependence;
THYM	cis	rs2213920	0.619	rs4979528	chr9:118194902	G/A	cg13918206	chr9:118159781	DEC1	0.86	4.9	0.45	3.86e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg09307838	chr4:120376055	NA	0.7	5.27	0.48	8.48e-7	Corneal astigmatism;
THYM	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg18252515	chr7:66147081	NA	-0.62	-4.55	-0.42	1.59e-5	Aortic root size;
THYM	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg07414643	chr4:187882934	NA	0.57	4.95	0.45	3.16e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7432375	0.901	rs4521165	chr3:136369710	T/C	cg12473912	chr3:136751656	NA	-0.62	-5.24	-0.47	9.59e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs155076	0.666	rs4770128	chr13:21881922	A/G	cg11317459	chr13:21872234	NA	1.14	9.11	0.68	1.31e-14	White matter hyperintensity burden;
THYM	cis	rs28647808	0.748	rs28502181	chr9:136257792	T/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.13	-0.47	1.55e-6	Blood protein levels;
THYM	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg03806693	chr22:41940476	POLR3H	1.1	8.94	0.68	3.12e-14	Vitiligo;
THYM	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg18681998	chr4:17616180	MED28	0.91	8.56	0.66	2e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs89107	0.576	rs78757409	chr6:118789259	C/T	cg21191810	chr6:118973309	C6orf204	0.5	5.04	0.46	2.25e-6	Cardiac structure and function;
THYM	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg25072359	chr17:41440525	NA	0.65	4.56	0.42	1.5e-5	Menopause (age at onset);
THYM	cis	rs9486719	1.000	rs2263192	chr6:96873037	C/G	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg19077165	chr18:44547161	KATNAL2	0.5	5.86	0.52	6.62e-8	Personality dimensions;
THYM	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2404602	0.622	rs11632365	chr15:77139080	G/A	cg23625390	chr15:77176239	SCAPER	-0.83	-5.17	-0.47	1.29e-6	Blood metabolite levels;
THYM	cis	rs6565180	0.889	rs8051096	chr16:30347731	A/G	cg17640201	chr16:30407289	ZNF48	-0.83	-7.18	-0.59	1.51e-10	Tonsillectomy;
THYM	cis	rs877282	0.786	rs10904558	chr10:797509	C/T	cg10556349	chr10:835070	NA	-0.78	-5.32	-0.48	6.85e-7	Uric acid levels;
THYM	cis	rs17443541	0.507	rs7594660	chr2:200468594	A/G	cg03741458	chr2:200468445	NA	-0.8	-6.04	-0.53	3.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs17739794	0.517	rs6559193	chr8:775451	C/T	cg01971667	chr8:817044	NA	-0.87	-7.33	-0.6	7.41e-11	Clozapine-induced cytotoxicity;
THYM	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.01	9.45	0.7	2.5e-15	Colorectal cancer;
THYM	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg22907277	chr7:1156413	C7orf50	0.91	8.63	0.66	1.36e-13	Longevity;Endometriosis;
THYM	cis	rs17174870	0.910	rs79433506	chr2:112695056	G/A	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg27129171	chr3:47204927	SETD2	0.8	7.91	0.63	4.58e-12	Colorectal cancer;
THYM	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg14349672	chr11:133703707	NA	-0.52	-4.84	-0.44	5.02e-6	Childhood ear infection;
THYM	cis	rs2235649	0.828	rs9925354	chr16:1849866	G/A	cg03034668	chr16:1723424	CRAMP1L	-0.64	-5.57	-0.5	2.39e-7	Blood metabolite levels;
THYM	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.73	-0.44	7.7e-6	Crohn's disease;
THYM	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg05347473	chr6:146136440	FBXO30	0.81	7.24	0.6	1.13e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg27588902	chr6:42928151	GNMT	-0.53	-5.03	-0.46	2.35e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1003719	0.680	rs2835629	chr21:38521660	A/T	cg01329690	chr21:38580129	DSCR9	-0.37	-5.09	-0.46	1.83e-6	Eye color traits;
THYM	cis	rs7404928	0.651	rs1465195	chr16:23914885	A/G	cg26685404	chr16:23957272	PRKCB	0.66	7.56	0.61	2.52e-11	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg06002616	chr8:101225028	SPAG1	-0.46	-4.79	-0.44	6.22e-6	Atrioventricular conduction;
THYM	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg05872129	chr22:39784769	NA	-0.99	-10.55	-0.73	1.12e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg27532560	chr4:187881888	NA	-0.96	-11.49	-0.76	1.13e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg06636001	chr8:8085503	FLJ10661	0.7	6.09	0.53	2.34e-8	Mood instability;
THYM	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg00944433	chr1:107599041	PRMT6	-0.41	-5.03	-0.46	2.27e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs2066819	1.000	rs11575231	chr12:56744445	T/C	cg26714650	chr12:56694279	CS	-1.34	-6.94	-0.58	4.73e-10	Psoriasis vulgaris;
THYM	cis	rs3845702	0.736	rs3845701	chr2:180826781	A/G	cg01881094	chr2:180872142	CWC22	-0.85	-5.0	-0.46	2.64e-6	Schizophrenia;
THYM	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4443100	0.670	rs3788338	chr22:23412058	G/A	cg14186256	chr22:23484241	RTDR1	0.63	4.48	0.42	2.1e-5	Serum parathyroid hormone levels;
THYM	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg19346786	chr7:2764209	NA	-0.73	-6.16	-0.53	1.71e-8	Height;
THYM	trans	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg05926928	chr17:57297772	GDPD1	1.26	10.02	0.72	1.5e-16	Opioid sensitivity;
THYM	cis	rs4242434	0.747	rs6986550	chr8:22467870	T/A	cg03733263	chr8:22462867	KIAA1967	0.97	10.82	0.74	2.99e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg19912559	chr1:40204330	PPIE	0.62	4.76	0.44	6.98e-6	Blood protein levels;
THYM	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg17063962	chr7:91808500	NA	1.16	13.2	0.8	3.33e-23	Breast cancer;
THYM	cis	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6539288	0.677	rs2287163	chr12:107349294	C/T	cg26297688	chr12:107349093	C12orf23	-0.5	-6.02	-0.53	3.22e-8	Total body bone mineral density;
THYM	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.32	0.48	6.81e-7	Height;
THYM	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg12262378	chr17:6899522	ALOX12	0.65	8.63	0.66	1.38e-13	Tonsillectomy;
THYM	cis	rs7107174	1.000	rs10793303	chr11:78060750	G/A	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs6032067	0.704	rs2223901	chr20:43789924	C/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9915657	0.966	rs1042673	chr17:70121339	A/G	cg06234051	chr17:70120541	SOX9	-0.63	-5.48	-0.49	3.45e-7	Thyroid hormone levels;
THYM	cis	rs55665837	0.961	rs12795972	chr11:14443775	C/T	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg00256281	chr22:41985642	PMM1	0.65	4.91	0.45	3.81e-6	Vitiligo;
THYM	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11890956	chr21:40555474	PSMG1	-0.66	-6.35	-0.55	7.37e-9	Menarche (age at onset);
THYM	cis	rs901683	0.850	rs74874679	chr10:46050733	A/C	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs9906944	0.742	rs4073893	chr17:47118523	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.54	-5.48	-0.49	3.55e-7	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg13683864	chr3:40499215	RPL14	-1.02	-11.19	-0.75	4.78e-19	Renal cell carcinoma;
THYM	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg24060327	chr5:131705240	SLC22A5	0.81	6.65	0.56	1.83e-9	Breast cancer;
THYM	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.66	4.68	0.43	9.5e-6	Aortic root size;
THYM	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg07424592	chr7:64974309	NA	1.16	5.55	0.5	2.55e-7	Diabetic kidney disease;
THYM	cis	rs2458413	0.563	rs2458422	chr8:105332817	C/T	cg21295575	chr8:105352067	TM7SF4	0.3	4.58	0.43	1.43e-5	Paget's disease;
THYM	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg25358565	chr5:93447407	FAM172A	0.96	6.78	0.57	1.01e-9	Diabetic retinopathy;
THYM	cis	rs950880	0.710	rs55742125	chr2:103019782	G/A	cg03938978	chr2:103052716	IL18RAP	-0.53	-4.62	-0.43	1.2e-5	Serum protein levels (sST2);
THYM	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg08885076	chr2:99613938	TSGA10	-0.64	-5.57	-0.5	2.38e-7	Chronic sinus infection;
THYM	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg06970220	chr1:156163860	SLC25A44	0.73	5.7	0.5	1.37e-7	Testicular germ cell tumor;
THYM	cis	rs4589258	1.000	rs10765380	chr11:90460382	T/A	cg26138821	chr11:89956704	CHORDC1	-0.7	-5.64	-0.5	1.74e-7	Intelligence (multi-trait analysis);
THYM	cis	rs250585	0.850	rs7186974	chr16:23545478	G/T	cg00143387	chr16:23521605	GGA2	0.72	4.58	0.42	1.43e-5	Egg allergy;
THYM	trans	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs500891	0.547	rs1170480	chr6:84036345	A/G	cg08257003	chr6:84140564	ME1	0.56	4.47	0.42	2.19e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg11764359	chr7:65958608	NA	-0.7	-4.75	-0.44	7.26e-6	Aortic root size;
THYM	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs12410462	0.581	rs77837509	chr1:227559873	C/T	cg04117972	chr1:227635322	NA	0.83	4.97	0.45	2.92e-6	Major depressive disorder;
THYM	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg03806693	chr22:41940476	POLR3H	-1.21	-10.75	-0.74	4.11e-18	Vitiligo;
THYM	cis	rs10493773	0.609	rs11161651	chr1:86177816	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.59	-9.23	-0.69	7.42e-15	Urate levels in overweight individuals;
THYM	cis	rs763014	0.865	rs2384977	chr16:625388	C/T	cg00908189	chr16:619842	PIGQ	1.02	9.27	0.69	6.03e-15	Height;
THYM	cis	rs62435770	0.929	rs62433594	chr6:169517459	G/A	cg07652237	chr6:170125491	PHF10	0.55	4.91	0.45	3.84e-6	Loneliness;
THYM	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs907612	0.638	rs11041476	chr11:1875067	C/T	cg07277017	chr11:1874093	LSP1	0.51	4.49	0.42	1.98e-5	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
THYM	cis	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs2130392	0.926	rs10428357	chr4:185636217	T/A	cg04058563	chr4:185651563	MLF1IP	0.61	6.1	0.53	2.31e-8	Kawasaki disease;
THYM	cis	rs7193541	0.859	rs12598791	chr16:74500745	A/C	cg01733217	chr16:74700730	RFWD3	0.78	5.81	0.51	8.29e-8	Multiple myeloma;
THYM	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg04842962	chr6:43655489	MRPS18A	0.88	7.39	0.6	5.6e-11	IgG glycosylation;
THYM	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg24530246	chr3:53118167	NA	-0.85	-4.82	-0.44	5.52e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs17030434	0.775	rs4696493	chr4:154680007	T/C	cg14289246	chr4:154710475	SFRP2	0.76	5.42	0.49	4.52e-7	Electrocardiographic conduction measures;
THYM	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg17173187	chr15:85201210	NMB	0.56	5.48	0.49	3.52e-7	Schizophrenia;
THYM	cis	rs782590	0.620	rs7596377	chr2:55888612	T/A	cg18811423	chr2:55921094	PNPT1	-0.57	-5.24	-0.47	9.69e-7	Metabolic syndrome;
THYM	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg01097406	chr16:89675127	NA	0.6	5.42	0.49	4.44e-7	Vitiligo;
THYM	cis	rs9527	0.615	rs17725614	chr10:104685493	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-5.01	-0.46	2.51e-6	Arsenic metabolism;
THYM	cis	rs9814567	0.806	rs9824185	chr3:134324024	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.09e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs950880	0.710	rs11123927	chr2:103058803	C/T	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.71	-0.44	8.33e-6	Serum protein levels (sST2);
THYM	cis	rs6840360	0.571	rs62329101	chr4:152512239	G/T	cg22705602	chr4:152727874	NA	-0.78	-8.16	-0.64	1.38e-12	Intelligence (multi-trait analysis);
THYM	cis	rs883565	0.684	rs811971	chr3:39168283	C/T	cg15678707	chr3:39149194	GORASP1;TTC21A	0.72	5.16	0.47	1.36e-6	Handedness;
THYM	cis	rs6867032	1.000	rs4246753	chr5:2014721	G/A	cg26168224	chr5:2018326	NA	1.29	15.53	0.85	8.25e-28	Gut microbiome composition (winter);
THYM	trans	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.92	4.73	0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg02734326	chr4:10020555	SLC2A9	0.72	6.31	0.54	8.96e-9	Bone mineral density;
THYM	cis	rs9816226	0.591	rs1516725	chr3:185824004	T/C	cg00760338	chr3:185826511	ETV5	0.81	4.54	0.42	1.66e-5	Obesity;Body mass index;
THYM	cis	rs7572733	0.515	rs1356542	chr2:198835702	G/T	cg00792783	chr2:198669748	PLCL1	0.82	5.75	0.51	1.08e-7	Dermatomyositis;
THYM	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs870825	0.616	rs10022818	chr4:185619282	A/G	cg04058563	chr4:185651563	MLF1IP	1.04	9.02	0.68	2.05e-14	Blood protein levels;
THYM	cis	rs763014	0.833	rs3743903	chr16:632736	T/C	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22496380	chr5:211416	CCDC127	-1.28	-7.77	-0.62	9.06e-12	Breast cancer;
THYM	cis	rs6960043	0.502	rs2358157	chr7:15023729	G/A	cg19272540	chr7:15055459	NA	0.48	5.27	0.48	8.34e-7	Type 2 diabetes;
THYM	cis	rs4792901	0.802	rs72833123	chr17:41552403	A/C	cg21940313	chr17:41620911	ETV4	-0.54	-5.13	-0.47	1.5e-6	Dupuytren's disease;
THYM	cis	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg12193833	chr17:30244370	NA	-0.63	-4.58	-0.43	1.41e-5	Hip circumference adjusted for BMI;
THYM	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg06611532	chr13:114900021	NA	0.59	6.41	0.55	5.7e-9	Schizophrenia;
THYM	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs6815814	0.950	rs11725779	chr4:38811668	G/A	cg02016764	chr4:38805732	TLR1	-0.57	-5.49	-0.49	3.41e-7	Breast cancer;
THYM	trans	rs9929218	0.581	rs4783676	chr16:68801077	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.93	9.61	0.7	1.14e-15	Colorectal cancer;
THYM	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg11266682	chr4:10021025	SLC2A9	0.53	6.49	0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg19508488	chr2:152266495	RIF1	0.79	6.49	0.55	3.8e-9	Lung cancer;
THYM	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg24692254	chr21:30365293	RNF160	0.66	4.68	0.43	9.38e-6	Selective IgA deficiency;
THYM	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg17644776	chr2:200775616	C2orf69	0.8	4.82	0.44	5.52e-6	Schizophrenia;
THYM	cis	rs2456568	0.802	rs11020585	chr11:93638493	A/C	cg26875233	chr11:93583750	C11orf90	0.51	5.41	0.49	4.74e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg14829155	chr15:31115871	NA	-0.52	-4.97	-0.45	2.92e-6	Huntington's disease progression;
THYM	cis	rs36051895	0.659	rs12343065	chr9:5083533	C/T	cg02405213	chr9:5042618	JAK2	-1.03	-11.11	-0.75	7.02e-19	Pediatric autoimmune diseases;
THYM	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11890956	chr21:40555474	PSMG1	1.07	10.31	0.73	3.54e-17	Cognitive function;
THYM	cis	rs6087990	0.769	rs17123658	chr20:31390840	C/A	cg13636640	chr20:31349939	DNMT3B	0.97	10.7	0.74	5.31e-18	Ulcerative colitis;
THYM	cis	rs11771526	0.901	rs10239582	chr7:32298116	T/A	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg21862992	chr11:68658383	NA	0.23	4.57	0.42	1.49e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7712401	0.569	rs10080185	chr5:122351856	A/G	cg19808643	chr5:122110361	SNX2	0.61	5.31	0.48	7.22e-7	Mean platelet volume;
THYM	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg02825527	chr7:2087843	MAD1L1	-0.79	-4.93	-0.45	3.45e-6	Neuroticism;
THYM	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4731207	0.596	rs7788458	chr7:124630141	G/A	cg05285228	chr7:124571219	POT1	-0.71	-5.31	-0.48	7.33e-7	Cutaneous malignant melanoma;
THYM	cis	rs12142240	0.738	rs41293275	chr1:46806429	A/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7833986	0.501	rs72653948	chr8:56955689	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.0	0.58	3.62e-10	Height;
THYM	cis	rs28829049	0.597	rs71645438	chr1:19502349	G/A	cg13387374	chr1:19411106	UBR4	0.65	4.86	0.45	4.71e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg22709100	chr7:91322751	NA	-0.64	-4.96	-0.45	3.08e-6	Breast cancer;
THYM	cis	rs4237845	0.837	rs7963992	chr12:58295949	G/C	cg22764591	chr12:58329936	NA	0.99	8.1	0.64	1.83e-12	Intelligence (multi-trait analysis);
THYM	cis	rs921968	0.541	rs55996799	chr2:219558193	C/G	cg02176678	chr2:219576539	TTLL4	-0.73	-7.22	-0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg13852791	chr20:30311386	BCL2L1	0.76	5.6	0.5	2.1e-7	Mean corpuscular hemoglobin;
THYM	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs763014	0.898	rs4984892	chr16:622325	A/G	cg07343612	chr16:622815	PIGQ	-1.08	-11.34	-0.76	2.36e-19	Height;
THYM	cis	rs7610301	1.000	rs6799581	chr3:46644909	T/G	cg22951056	chr3:46887651	NA	-0.79	-5.11	-0.46	1.65e-6	Blood protein levels;
THYM	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg22105103	chr4:187893119	NA	0.88	9.57	0.7	1.35e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg21433313	chr16:3507492	NAT15	0.59	4.96	0.45	3.03e-6	Body mass index (adult);
THYM	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs57590327	0.503	rs11706976	chr3:81899653	C/T	cg07356753	chr3:81810745	GBE1	-0.77	-5.65	-0.5	1.66e-7	Extraversion;
THYM	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg13695892	chr22:41940480	POLR3H	-1.06	-8.59	-0.66	1.69e-13	Vitiligo;
THYM	cis	rs1691799	0.899	rs1168301	chr12:66736771	C/T	cg16791601	chr12:66731901	HELB	-0.76	-7.14	-0.59	1.86e-10	White blood cell count (basophil);
THYM	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg02734326	chr4:10020555	SLC2A9	-0.72	-6.31	-0.54	8.96e-9	Bone mineral density;
THYM	cis	rs919433	1.000	rs6741380	chr2:198165121	A/G	cg00792783	chr2:198669748	PLCL1	0.63	4.45	0.42	2.35e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7078439	0.774	rs4494239	chr10:128431443	A/G	cg06406458	chr10:128810499	DOCK1	0.56	4.45	0.42	2.36e-5	Airway wall thickness;
THYM	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.63	-5.75	-0.51	1.09e-7	Total body bone mineral density;
THYM	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg23711669	chr6:146136114	FBXO30	0.84	7.83	0.63	6.82e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg12826209	chr6:26865740	GUSBL1	0.84	6.07	0.53	2.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg03517284	chr6:25882590	NA	0.65	5.32	0.48	7.02e-7	Blood metabolite levels;
THYM	cis	rs3126085	0.935	rs11204937	chr1:152193851	C/T	cg26020982	chr1:152196106	HRNR	0.38	5.14	0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs6967414	0.579	rs11980762	chr7:6756878	G/A	cg09896999	chr7:6746977	ZNF12	-0.65	-4.86	-0.45	4.67e-6	Hematocrit;Hemoglobin concentration;
THYM	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg02527881	chr3:46936655	PTH1R	0.56	5.42	0.49	4.49e-7	Colorectal cancer;
THYM	cis	rs8025790	0.508	rs12441823	chr15:67912977	C/T	cg24579218	chr15:68104479	NA	-0.73	-6.48	-0.55	4.01e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs9790314	1.000	rs4350933	chr3:160955879	G/T	cg04691961	chr3:161091175	C3orf57	-0.53	-4.55	-0.42	1.56e-5	Morning vs. evening chronotype;
THYM	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg10057126	chr4:77819792	ANKRD56	0.71	6.06	0.53	2.78e-8	Emphysema distribution in smoking;
THYM	cis	rs12586317	0.620	rs76293361	chr14:35570889	G/A	cg05294307	chr14:35346193	BAZ1A	-0.82	-5.51	-0.49	3.06e-7	Psoriasis;
THYM	cis	rs79600951	0.516	rs76729986	chr16:56803706	A/C	cg04945457	chr16:56894587	NA	0.7	4.47	0.42	2.17e-5	HDL cholesterol;
THYM	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4930103	0.935	rs2071094	chr11:2021164	G/T	cg18511798	chr11:2018149	H19;MIR675	-0.57	-5.57	-0.5	2.32e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs9470366	0.527	rs733590	chr6:36645203	A/G	cg08179530	chr6:36648295	CDKN1A	0.72	5.4	0.48	5e-7	QRS duration;
THYM	cis	rs4343996	0.967	rs10268249	chr7:3347074	C/T	cg21248987	chr7:3385318	SDK1	0.41	4.95	0.45	3.17e-6	Motion sickness;
THYM	cis	rs17253792	0.822	rs28392709	chr14:56093685	G/A	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs4523957	0.855	rs143499	chr17:2132324	T/C	cg16513277	chr17:2031491	SMG6	0.8	7.85	0.63	6.16e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg06028605	chr16:24865363	SLC5A11	-0.56	-5.25	-0.47	9.15e-7	Intelligence (multi-trait analysis);
THYM	cis	rs73198271	0.740	rs10092600	chr8:8649023	A/G	cg06636001	chr8:8085503	FLJ10661	-0.8	-5.64	-0.5	1.77e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg16423285	chr20:60520624	NA	-1.16	-9.2	-0.69	8.36e-15	Obesity-related traits;
THYM	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs6430585	0.528	rs7606267	chr2:136668123	T/C	cg23851026	chr2:136556271	LCT	0.77	7.29	0.6	9.12e-11	Corneal structure;
THYM	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.62	5.67	0.5	1.54e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg16325326	chr1:53192061	ZYG11B	0.86	8.55	0.66	2.06e-13	Monocyte count;
THYM	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07157834	chr1:205819609	PM20D1	0.88	8.74	0.67	7.98e-14	Menarche (age at onset);
THYM	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg26769984	chr7:1090371	C7orf50	0.84	5.73	0.51	1.2e-7	Bronchopulmonary dysplasia;
THYM	cis	rs28595532	0.920	rs116366070	chr4:119764180	A/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg15704280	chr7:45808275	SEPT13	-1.06	-15.45	-0.85	1.17e-27	Height;
THYM	cis	rs9914544	0.545	rs8078993	chr17:18797126	A/G	cg26378065	chr17:18585709	ZNF286B	0.58	4.65	0.43	1.05e-5	Educational attainment (years of education);
THYM	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	1.0	9.47	0.7	2.25e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12478296	0.786	rs28802397	chr2:243049730	G/A	cg06360820	chr2:242988706	NA	-0.94	-5.72	-0.51	1.25e-7	Obesity-related traits;
THYM	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs2898681	0.874	rs6852148	chr4:53750002	T/C	cg00791764	chr4:53727839	RASL11B	0.47	5.81	0.51	8.23e-8	Optic nerve measurement (cup area);
THYM	cis	rs7394190	0.748	rs4746146	chr10:75527197	C/T	cg07699608	chr10:75541558	CHCHD1	0.91	4.93	0.45	3.49e-6	Incident atrial fibrillation;
THYM	cis	rs13082711	0.911	rs67104968	chr3:27510304	A/G	cg02860705	chr3:27208620	NA	0.72	5.15	0.47	1.39e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-5.76	-0.51	1.03e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs775227	0.636	rs3773697	chr3:113023509	C/T	cg18753928	chr3:113234510	CCDC52	-0.73	-4.97	-0.45	2.93e-6	Dental caries;
THYM	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg21784768	chr11:537496	LRRC56	-1.09	-5.41	-0.49	4.65e-7	Body mass index;
THYM	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg15445000	chr17:37608096	MED1	0.44	5.07	0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg17294928	chr15:75287854	SCAMP5	-0.94	-5.03	-0.46	2.27e-6	Lung cancer;
THYM	cis	rs67460515	0.563	rs16831981	chr3:160897780	T/C	cg12349858	chr3:160822545	B3GALNT1	0.6	4.8	0.44	5.99e-6	Parkinson's disease;
THYM	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg16031515	chr1:205743344	RAB7L1	-0.53	-5.44	-0.49	4.21e-7	Menarche (age at onset);
THYM	cis	rs11577318	0.853	rs1071849	chr1:26646726	A/G	cg19677267	chr1:26645161	CD52;UBXN11	-0.5	-6.66	-0.56	1.78e-9	Granulocyte percentage of myeloid white cells;
THYM	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg04362960	chr10:104952993	NT5C2	0.58	4.75	0.44	7.17e-6	Arsenic metabolism;
THYM	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg07169764	chr2:136633963	MCM6	-0.64	-5.91	-0.52	5.45e-8	Mosquito bite size;
THYM	cis	rs870825	0.929	rs1405940	chr4:185591481	A/G	cg04058563	chr4:185651563	MLF1IP	1.03	7.36	0.6	6.51e-11	Blood protein levels;
THYM	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg06108461	chr20:60628389	TAF4	-0.78	-6.34	-0.55	7.82e-9	Body mass index;
THYM	cis	rs4638749	0.677	rs6755078	chr2:108818270	T/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs7523273	0.565	rs12733108	chr1:207887210	C/T	cg22525895	chr1:207977042	MIR29B2	0.53	5.05	0.46	2.17e-6	Schizophrenia;
THYM	cis	rs4731207	0.565	rs10954056	chr7:124600534	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.88	5.74	0.51	1.15e-7	Smoking behavior;
THYM	cis	rs12681287	0.640	rs12541793	chr8:87462558	G/A	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs9906944	0.657	rs4643373	chr17:47123423	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.56	-4.45	-0.42	2.3e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg23711669	chr6:146136114	FBXO30	0.95	9.55	0.7	1.52e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg06640241	chr16:89574553	SPG7	0.8	5.46	0.49	3.8e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg16230307	chr14:35515116	FAM177A1	0.93	5.99	0.52	3.67e-8	Psoriasis;
THYM	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs9913711	0.899	rs9913936	chr17:70074148	A/G	cg06234051	chr17:70120541	SOX9	-0.64	-5.73	-0.51	1.17e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6840360	0.615	rs9996320	chr4:152610587	T/G	cg22705602	chr4:152727874	NA	-0.81	-11.18	-0.75	5.16e-19	Intelligence (multi-trait analysis);
THYM	cis	rs6732160	0.932	rs6546802	chr2:73379564	G/A	cg24220031	chr2:73402428	NA	-0.65	-6.38	-0.55	6.44e-9	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.552	rs6953538	chr7:1196974	A/G	cg17775962	chr7:1200435	ZFAND2A	0.5	5.7	0.5	1.35e-7	Longevity;Endometriosis;
THYM	cis	rs901683	1.000	rs34309840	chr10:46039361	A/G	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs10799590	1.000	rs6686604	chr1:224878502	A/G	cg01808320	chr1:224927238	CNIH3	-0.51	-4.56	-0.42	1.52e-5	Opioid dependence;
THYM	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg01191920	chr7:158217561	PTPRN2	-0.9	-8.74	-0.67	8.13e-14	Obesity-related traits;
THYM	cis	rs6035126	1.000	rs13433286	chr20:1931500	A/G	cg07210840	chr20:1927816	NA	1.05	4.82	0.44	5.49e-6	Liver enzyme levels (alanine transaminase);
THYM	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	5.87	0.52	6.23e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7851660	0.967	rs907577	chr9:100615117	C/T	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs28595532	0.841	rs114175487	chr4:119733580	C/G	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg02953382	chr22:24373134	LOC391322	-0.7	-6.35	-0.55	7.34e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg02527881	chr3:46936655	PTH1R	-0.63	-6.29	-0.54	9.52e-9	Colorectal cancer;
THYM	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg08968635	chr6:28129556	ZNF389	0.49	4.73	0.44	7.67e-6	Parkinson's disease;
THYM	trans	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg07211511	chr3:129823064	LOC729375	-1.28	-10.3	-0.73	3.76e-17	Blood pressure (smoking interaction);
THYM	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg05552183	chr6:42928497	GNMT	0.72	5.99	0.52	3.66e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg18681998	chr4:17616180	MED28	0.96	8.19	0.64	1.18e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg01299579	chr2:10830716	NOL10	-0.48	-4.58	-0.43	1.39e-5	Prostate cancer;
THYM	cis	rs10100465	0.961	rs4876727	chr8:118633834	G/A	cg09430518	chr8:118662568	NA	-0.34	-5.39	-0.48	5.09e-7	Leprosy;
THYM	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg11764359	chr7:65958608	NA	0.78	6.31	0.54	8.88e-9	Aortic root size;
THYM	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.57	4.65	0.43	1.06e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs6032067	0.543	rs7272524	chr20:43908694	A/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.58	-5.69	-0.5	1.38e-7	Blood protein levels;
THYM	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg11757124	chr7:157526947	PTPRN2	-0.65	-5.32	-0.48	6.97e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg04398451	chr17:18023971	MYO15A	-0.96	-9.43	-0.7	2.73e-15	Total body bone mineral density;
THYM	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.67	-5.18	-0.47	1.22e-6	Tonsillectomy;
THYM	cis	rs4919694	0.901	rs12251035	chr10:104671459	A/C	cg15744005	chr10:104629667	AS3MT	-0.85	-4.67	-0.43	9.96e-6	Arsenic metabolism;
THYM	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg04944784	chr2:26401820	FAM59B	-1.08	-8.57	-0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.62	0.43	1.23e-5	Obesity-related traits;
THYM	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg17211192	chr8:82754475	SNX16	-0.82	-7.41	-0.61	5.09e-11	Diastolic blood pressure;
THYM	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg07511668	chr11:68622177	NA	0.45	4.55	0.42	1.61e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	trans	rs4596713	0.507	rs10869975	chr9:71795034	C/T	cg16512924	chr15:28394682	HERC2	-0.86	-7.1	-0.59	2.28e-10	Headache;
THYM	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg06219351	chr7:158114137	PTPRN2	-0.8	-7.12	-0.59	2.04e-10	Response to amphetamines;
THYM	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg18477163	chr1:228402036	OBSCN	-0.43	-4.69	-0.43	8.96e-6	Diastolic blood pressure;
THYM	cis	rs7219021	0.892	rs66866087	chr17:46849323	C/T	cg09029085	chr17:47094198	IGF2BP1	0.33	4.48	0.42	2.07e-5	Schizophrenia or bipolar disorder;
THYM	cis	rs2273669	0.504	rs76698413	chr6:109474646	G/A	cg17117243	chr6:109341365	SESN1	-0.85	-4.99	-0.46	2.77e-6	Prostate cancer;
THYM	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg12893697	chr11:970389	AP2A2	-0.31	-5.15	-0.47	1.44e-6	Alzheimer's disease (late onset);
THYM	cis	rs35883536	0.647	rs12026951	chr1:101046273	C/T	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs1371867	0.875	rs1788168	chr8:101324960	G/T	cg06636551	chr8:101224915	SPAG1	-0.63	-6.33	-0.54	8.05e-9	Atrioventricular conduction;
THYM	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg15556689	chr8:8085844	FLJ10661	-0.63	-4.92	-0.45	3.64e-6	Joint mobility (Beighton score);
THYM	cis	rs728616	0.867	rs4633405	chr10:81927446	G/T	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs17739167	0.569	rs6493015	chr15:42225260	G/T	cg20935245	chr15:42234343	EHD4	0.4	4.77	0.44	6.72e-6	Monocyte count;
THYM	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.15	-5.7	-0.5	1.37e-7	Schizophrenia;
THYM	cis	rs2836974	0.583	rs741795	chr21:40718440	T/C	cg11644478	chr21:40555479	PSMG1	0.65	4.76	0.44	7.05e-6	Cognitive function;
THYM	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg25319279	chr11:5960081	NA	-0.64	-5.64	-0.5	1.77e-7	DNA methylation (variation);
THYM	cis	rs3768617	0.510	rs10797844	chr1:183082067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs13010737	1.000	rs13010737	chr2:144200043	G/A	cg17056048	chr2:144271431	ARHGAP15	0.5	4.66	0.43	1.04e-5	Coronary artery disease;
THYM	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg04362960	chr10:104952993	NT5C2	-0.56	-4.57	-0.42	1.49e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg23711669	chr6:146136114	FBXO30	-0.83	-7.91	-0.63	4.62e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4901869	0.932	rs12878445	chr14:59339361	A/G	cg02291164	chr14:59296302	NA	0.8	8.12	0.64	1.64e-12	Panic disorder;
THYM	cis	rs11608355	0.597	rs7300290	chr12:109832545	T/G	cg11367159	chr12:110044531	NA	0.53	4.79	0.44	6.16e-6	Neuroticism;
THYM	cis	rs7809950	1.000	rs2712189	chr7:107195747	G/A	cg23024343	chr7:107201750	COG5	-0.95	-8.79	-0.67	6.29e-14	Coronary artery disease;
THYM	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08109568	chr15:31115862	NA	-0.59	-5.74	-0.51	1.15e-7	Huntington's disease progression;
THYM	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg09455208	chr3:40491958	NA	0.42	4.46	0.42	2.25e-5	Renal cell carcinoma;
THYM	cis	rs7119	0.700	rs4886519	chr15:77893885	A/G	cg10437265	chr15:77819839	NA	-0.55	-5.42	-0.49	4.46e-7	Type 2 diabetes;
THYM	cis	rs28595532	0.920	rs114093638	chr4:119729819	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg13918804	chr1:2043761	PRKCZ	0.76	7.29	0.6	9.36e-11	Height;
THYM	cis	rs7100689	0.784	rs3120977	chr10:82075324	C/G	cg01528321	chr10:82214614	TSPAN14	1.02	7.84	0.63	6.52e-12	Post bronchodilator FEV1;
THYM	cis	rs16912285	0.748	rs7104550	chr11:24345162	A/G	ch.11.24196551F	chr11:24239977	NA	0.82	4.86	0.45	4.58e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	trans	rs4262150	0.883	rs72802891	chr5:152255602	C/G	cg08281791	chr5:76607845	PDE8B	0.92	6.91	0.58	5.62e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs17253792	0.822	rs75999534	chr14:56036413	A/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg07648498	chr16:89883185	FANCA	0.66	4.89	0.45	4.06e-6	Vitiligo;
THYM	cis	rs4750440	0.702	rs7911259	chr10:14031051	T/C	cg27542038	chr10:14027202	FRMD4A	-0.5	-4.45	-0.42	2.36e-5	Adiponectin levels;
THYM	cis	rs4731207	0.651	rs28710776	chr7:124614472	A/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs73198271	0.740	rs10112989	chr8:8647334	A/C	cg06636001	chr8:8085503	FLJ10661	-0.76	-5.06	-0.46	2.01e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03452623	chr4:187889614	NA	-1.17	-20.04	-0.9	6.92e-36	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg10523679	chr1:76189770	ACADM	-0.55	-4.67	-0.43	9.97e-6	Daytime sleep phenotypes;
THYM	cis	rs2806561	0.796	rs1738467	chr1:23506521	C/T	cg19743168	chr1:23544995	NA	0.55	5.59	0.5	2.21e-7	Height;
THYM	cis	rs7432375	0.610	rs28458819	chr3:136522314	A/G	cg21827317	chr3:136751795	NA	0.54	4.64	0.43	1.13e-5	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs12579753	1.000	rs10862372	chr12:82249804	C/T	cg21231944	chr12:82153410	PPFIA2	-0.64	-4.8	-0.44	5.93e-6	Resting heart rate;
THYM	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg17063962	chr7:91808500	NA	1.16	13.14	0.8	4.39e-23	Breast cancer;
THYM	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.77	0.51	1.01e-7	Rheumatoid arthritis;
THYM	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.8	6.76	0.57	1.09e-9	Lymphocyte percentage of white cells;
THYM	cis	rs4891159	0.790	rs59762437	chr18:74153146	G/A	cg24786174	chr18:74118243	ZNF516	-0.87	-9.63	-0.7	1.04e-15	Longevity;
THYM	cis	rs9611565	0.506	rs2024566	chr22:41697338	A/G	cg13695892	chr22:41940480	POLR3H	-0.6	-4.69	-0.43	9.11e-6	Vitiligo;
THYM	cis	rs17407555	0.606	rs73229818	chr4:10019884	C/T	cg00071950	chr4:10020882	SLC2A9	-0.75	-6.01	-0.53	3.37e-8	Schizophrenia (age at onset);
THYM	cis	rs6665290	0.904	rs10495273	chr1:227183359	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs490234	0.702	rs35129945	chr9:128320134	C/T	cg14078157	chr9:128172775	NA	-0.77	-6.1	-0.53	2.27e-8	Mean arterial pressure;
THYM	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg05043794	chr9:111880884	C9orf5	-0.43	-6.35	-0.55	7.29e-9	Menarche (age at onset);
THYM	cis	rs4363385	0.818	rs472076	chr1:153013742	G/T	cg13444842	chr1:152974279	SPRR3	-0.55	-4.49	-0.42	1.96e-5	Inflammatory skin disease;
THYM	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg02527881	chr3:46936655	PTH1R	-0.61	-5.74	-0.51	1.15e-7	Colorectal cancer;
THYM	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg02725872	chr8:58115012	NA	-1.09	-8.15	-0.64	1.43e-12	Developmental language disorder (linguistic errors);
THYM	cis	rs7186908	0.761	rs34714490	chr16:72177099	G/T	cg23815491	chr16:72088622	HP	0.79	6.29	0.54	9.85e-9	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg22535103	chr8:58192502	C8orf71	-1.06	-6.61	-0.56	2.24e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.66	4.71	0.43	8.57e-6	Height;
THYM	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg19761014	chr17:28927070	LRRC37B2	0.86	4.94	0.45	3.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.57	-4.51	-0.42	1.85e-5	Response to fenofibrate (adiponectin levels);
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg25373372	chr6:82462656	FAM46A	1.34	7.29	0.6	9.05e-11	Pulmonary function decline;
THYM	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs9527	0.614	rs2153774	chr10:104881035	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs11577318	0.579	rs11548246	chr1:26697166	G/A	cg00852783	chr1:26633632	UBXN11	-0.68	-4.61	-0.43	1.23e-5	Granulocyte percentage of myeloid white cells;
THYM	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.52	-5.23	-0.47	1e-6	Schizophrenia;
THYM	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	5.53	0.49	2.81e-7	Total body bone mineral density;
THYM	cis	rs12134245	0.874	rs17501937	chr1:92021705	C/T	cg25838465	chr1:92012736	NA	0.57	5.1	0.46	1.7e-6	Breast cancer;
THYM	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.99	-0.75	1.26e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs10186029	0.676	rs4673720	chr2:213941581	G/A	cg08319019	chr2:214017104	IKZF2	0.9	7.42	0.61	4.85e-11	Systemic sclerosis;
THYM	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs986417	0.579	rs1254281	chr14:60854300	T/C	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	6.88	0.58	6.35e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs1018836	0.884	rs7008765	chr8:91632589	C/T	cg16814680	chr8:91681699	NA	-0.85	-7.17	-0.59	1.59e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs1883415	0.553	rs807511	chr6:24540715	A/G	cg00346970	chr6:24499591	ALDH5A1	0.38	4.71	0.44	8.42e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg06618935	chr21:46677482	NA	-0.98	-9.5	-0.7	1.95e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg02038168	chr22:39784481	NA	-0.71	-5.16	-0.47	1.37e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg05340658	chr4:99064831	C4orf37	-0.53	-4.51	-0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4974559	0.790	rs5019560	chr4:1324793	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.44	-5.0	-0.46	2.63e-6	Systolic blood pressure;
THYM	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg14019146	chr3:50243930	SLC38A3	-0.56	-4.68	-0.43	9.51e-6	Body mass index;
THYM	trans	rs10838798	0.523	rs11039543	chr11:48168103	G/A	cg00717180	chr2:96193071	NA	-0.64	-6.94	-0.58	4.86e-10	Height;
THYM	cis	rs1451375	0.669	rs10274172	chr7:50637575	G/A	cg18232548	chr7:50535776	DDC	-0.69	-5.35	-0.48	6.04e-7	Malaria;
THYM	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg06808227	chr14:105710500	BRF1	-1.08	-9.65	-0.7	9.45e-16	Mean platelet volume;Platelet distribution width;
THYM	cis	rs5769707	0.777	rs739243	chr22:50057211	C/T	cg05373962	chr22:49881684	NA	-0.61	-6.46	-0.55	4.53e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6867032	0.917	rs4975719	chr5:2010162	C/T	cg26168224	chr5:2018326	NA	1.18	13.01	0.8	7.82e-23	Gut microbiome composition (winter);
THYM	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg04546413	chr19:29218101	NA	1.09	9.4	0.69	3.15e-15	Methadone dose in opioid dependence;
THYM	cis	rs7578361	0.959	rs7580915	chr2:150438034	G/A	cg17961725	chr2:150454027	NA	0.74	6.08	0.53	2.49e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-5.16	-0.47	1.34e-6	Hemoglobin concentration;
THYM	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg13866156	chr1:1669148	SLC35E2	0.67	6.42	0.55	5.3300000000000004e-09	Body mass index;
THYM	cis	rs4746818	1.000	rs7909631	chr10:70918676	C/T	cg04149295	chr10:70884716	VPS26A	0.78	5.31	0.48	7.18e-7	Left atrial antero-posterior diameter;
THYM	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	7.7	0.62	1.29e-11	Monocyte percentage of white cells;
THYM	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg20887711	chr4:1340912	KIAA1530	0.81	7.09	0.59	2.35e-10	Longevity;
THYM	cis	rs938554	0.571	rs7696092	chr4:10025320	C/A	cg26689780	chr4:10079554	WDR1	-0.41	-4.54	-0.42	1.68e-5	Blood metabolite levels;
THYM	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg22920501	chr2:26401640	FAM59B	-1.1	-8.59	-0.66	1.69e-13	Gut microbiome composition (summer);
THYM	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg09990169	chr2:241835740	C2orf54	-0.38	-5.94	-0.52	4.77e-8	Urinary metabolites;
THYM	cis	rs9906944	1.000	rs9906944	chr17:47091420	C/T	cg11673840	chr17:47092156	IGF2BP1	-0.47	-4.79	-0.44	6.22e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	trans	rs8002861	0.641	rs2325085	chr13:44410060	G/A	cg17145862	chr1:211918768	LPGAT1	0.85	7.64	0.62	1.69e-11	Leprosy;
THYM	cis	rs782590	0.967	rs782588	chr2:55841640	T/C	cg18811423	chr2:55921094	PNPT1	0.73	6.99	0.58	3.79e-10	Metabolic syndrome;
THYM	cis	rs9970807	0.901	rs72664354	chr1:57004417	A/T	cg11959316	chr1:57001742	PPAP2B	0.81	5.91	0.52	5.4e-8	Myocardial infarction;Coronary artery disease;
THYM	cis	rs75908454	1.000	rs75490272	chr6:169900464	C/T	cg19338460	chr6:170058176	WDR27	-1.02	-4.64	-0.43	1.11e-5	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs4660306	0.677	rs781059	chr1:45934562	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.64	-4.59	-0.43	1.34e-5	Homocysteine levels;
THYM	cis	rs988913	1.000	rs6902245	chr6:54813006	C/A	cg18532076	chr6:54711417	FAM83B	0.51	5.02	0.46	2.38e-6	Menarche (age at onset);
THYM	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg19346786	chr7:2764209	NA	-0.7	-5.9	-0.52	5.52e-8	Height;
THYM	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg18681998	chr4:17616180	MED28	0.92	8.85	0.67	4.73e-14	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs12579753	0.913	rs12579018	chr12:82231943	T/C	cg07988820	chr12:82153109	PPFIA2	-0.72	-4.47	-0.42	2.2e-5	Resting heart rate;
THYM	cis	rs11190604	1.000	rs4919471	chr10:102299239	A/G	cg07570687	chr10:102243282	WNT8B	0.84	6.22	0.54	1.3e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg03060546	chr3:49711283	APEH	-0.68	-5.24	-0.47	9.81e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs12802200	0.535	rs12282299	chr11:570009	T/C	cg00645579	chr11:617140	IRF7;MUPCDH	-0.41	-4.74	-0.44	7.6e-6	Systemic lupus erythematosus;
THYM	cis	rs4481887	0.927	rs4244173	chr1:248466899	G/C	cg13385794	chr1:248469461	NA	0.67	4.59	0.43	1.35e-5	Common traits (Other);
THYM	cis	rs17407555	0.697	rs56079809	chr4:10102736	C/A	cg00071950	chr4:10020882	SLC2A9	-0.75	-5.56	-0.5	2.52e-7	Schizophrenia (age at onset);
THYM	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs2270927	1.000	rs4546360	chr5:75577563	T/C	cg13563193	chr19:33072644	PDCD5	1.59	8.77	0.67	6.88e-14	Mean corpuscular volume;
THYM	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-5.05	-0.46	2.12e-6	Lymphocyte counts;
THYM	cis	rs6754311	0.773	rs4988183	chr2:136622046	T/C	cg23851026	chr2:136556271	LCT	0.49	4.47	0.42	2.19e-5	Mosquito bite size;
THYM	cis	rs861020	0.630	rs627069	chr1:210004613	C/G	cg05527609	chr1:210001259	C1orf107	0.85	6.82	0.57	8.53e-10	Orofacial clefts;
THYM	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg24818145	chr4:99064322	C4orf37	0.9	7.36	0.6	6.5e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs75920871	0.528	rs7128772	chr11:116889411	T/A	cg20608306	chr11:116969690	SIK3	-0.53	-5.89	-0.52	5.93e-8	Subjective well-being;
THYM	cis	rs28459962	0.545	rs1708670	chr4:89947254	G/A	cg17769793	chr4:89976368	FAM13A	-0.46	-4.78	-0.44	6.39e-6	Post bronchodilator FEV1;
THYM	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg12310025	chr6:25882481	NA	-0.7	-5.47	-0.49	3.7e-7	Blood metabolite levels;
THYM	cis	rs7106204	0.541	rs78630920	chr11:24291192	C/A	ch.11.24196551F	chr11:24239977	NA	0.91	4.82	0.44	5.49e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg26384229	chr12:38710491	ALG10B	0.9	7.73	0.62	1.12e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs289828	0.507	rs13004590	chr2:152127699	G/T	cg05960677	chr2:152117363	RBM43	0.76	8.1	0.64	1.82e-12	Blood protein levels;
THYM	cis	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg00495681	chr13:53174319	NA	0.74	6.36	0.55	6.93e-9	Lewy body disease;
THYM	cis	rs2404602	0.735	rs2436994	chr15:76801063	G/C	cg23625390	chr15:77176239	SCAPER	-0.63	-4.97	-0.45	2.91e-6	Blood metabolite levels;
THYM	cis	rs2797160	1.000	rs1739363	chr6:126020980	G/A	cg16306078	chr6:126000798	NA	0.52	5.27	0.48	8.53e-7	Endometrial cancer;
THYM	cis	rs1062746	0.683	rs891094	chr16:87378001	C/G	cg02258303	chr16:87377426	FBXO31	0.56	5.17	0.47	1.32e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs17102423	0.685	rs4899161	chr14:65540901	G/A	cg11161011	chr14:65562177	MAX	-0.78	-6.41	-0.55	5.56e-9	Obesity-related traits;
THYM	cis	rs3771570	0.892	rs55751610	chr2:242346057	C/T	cg21155796	chr2:242212141	HDLBP	1.25	6.07	0.53	2.57e-8	Prostate cancer;
THYM	cis	rs2732480	0.500	rs2450989	chr12:48653408	A/G	cg21466736	chr12:48725269	NA	0.53	4.91	0.45	3.78e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs7487075	0.780	rs1873793	chr12:46761324	A/G	cg11146691	chr12:47219737	SLC38A4	-0.45	-4.5	-0.42	1.91e-5	Itch intensity from mosquito bite;
THYM	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg02527881	chr3:46936655	PTH1R	0.63	6.14	0.53	1.91e-8	Colorectal cancer;
THYM	cis	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.86	0.45	4.66e-6	Obesity-related traits;
THYM	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.71	-4.7	-0.43	8.88e-6	Gut microbiome composition (summer);
THYM	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg00981070	chr1:2046702	PRKCZ	0.47	5.21	0.47	1.1e-6	Height;
THYM	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg16342193	chr10:102329863	NA	0.59	6.2	0.54	1.48e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-5.66	-0.5	1.59e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4273100	0.564	rs10445411	chr17:19265797	C/T	cg25447019	chr17:19030144	GRAPL	0.79	6.24	0.54	1.2e-8	Schizophrenia;
THYM	cis	rs1278352	0.767	rs1278363	chr10:127775877	C/T	cg08295661	chr10:127769903	ADAM12	-0.54	-5.43	-0.49	4.35e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03517284	chr6:25882590	NA	1.05	10.1	0.72	1.01e-16	Blood metabolite levels;
THYM	cis	rs1061377	1.000	rs6829234	chr4:39116206	G/C	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs954108	0.809	rs715704	chr13:29369317	C/T	cg11788234	chr13:29393811	NA	-0.58	-4.56	-0.42	1.55e-5	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11031096	0.678	rs61899666	chr11:4178711	C/A	cg22027985	chr11:4115532	RRM1	-0.5	-4.6	-0.43	1.3e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4282339	0.729	rs1979923	chr5:168265891	T/C	cg18364770	chr5:168310523	SLIT3	0.34	4.54	0.42	1.62e-5	Height;
THYM	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg18169835	chr10:134612155	NA	0.6	4.46	0.42	2.25e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs3781426	0.824	rs2289431	chr10:126727353	C/A	cg04494136	chr10:126703576	CTBP2	-0.33	-4.46	-0.42	2.23e-5	Height;
THYM	cis	rs11574514	0.661	rs117696061	chr16:67484841	T/C	cg09738193	chr16:67926317	PSKH1	-0.92	-4.49	-0.42	2e-5	Crohn's disease;
THYM	cis	rs7236492	0.748	rs11663658	chr18:77197555	T/C	cg15644404	chr18:77186268	NFATC1	-1.05	-4.96	-0.45	3.04e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs728616	0.614	rs58606426	chr10:81728312	G/A	cg27452691	chr10:81370291	SFTPA1	0.59	4.6	0.43	1.33e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	trans	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg18335740	chr13:41363409	SLC25A15	0.75	7.93	0.63	4.13e-12	Lewy body disease;
THYM	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg09035930	chr12:129282057	SLC15A4	0.87	11.78	0.77	2.86e-20	Systemic lupus erythematosus;
THYM	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg08885076	chr2:99613938	TSGA10	0.57	5.3	0.48	7.37e-7	Chronic sinus infection;
THYM	cis	rs28595532	0.920	rs55640619	chr4:119761999	C/T	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs941408	1.000	rs1624295	chr19:2792034	G/A	cg19693284	chr19:2783607	SGTA	0.7	5.23	0.47	1.02e-6	Total cholesterol levels;
THYM	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg16586182	chr3:47516702	SCAP	-0.62	-5.28	-0.48	8.32e-7	Colorectal cancer;
THYM	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg00129232	chr17:37814104	STARD3	-0.86	-6.03	-0.53	3.18e-8	Asthma;
THYM	cis	rs7572733	0.534	rs2060488	chr2:198751637	T/G	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg15693483	chr7:1102177	C7orf50	0.54	6.26	0.54	1.1e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.89	0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs9527	0.590	rs11191544	chr10:104827198	C/G	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg22857025	chr5:266934	NA	-1.56	-9.48	-0.7	2.14e-15	Breast cancer;
THYM	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg11189052	chr15:85197271	WDR73	-0.59	-4.69	-0.43	9.18e-6	P wave terminal force;
THYM	cis	rs7247513	0.964	rs4414604	chr19:12702437	C/G	cg01871581	chr19:12707946	ZNF490	-0.87	-9.38	-0.69	3.46e-15	Bipolar disorder;
THYM	cis	rs10752881	1.000	rs12753817	chr1:182970337	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.97	0.45	2.99e-6	Colorectal cancer;
THYM	cis	rs2495707	0.624	rs10883518	chr10:102416555	C/A	cg00272971	chr10:102419564	NA	-0.54	-5.77	-0.51	1.01e-7	Body mass index;
THYM	cis	rs7089973	0.872	rs12773943	chr10:116631184	G/A	cg23260525	chr10:116636907	FAM160B1	0.52	4.66	0.43	1.02e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg05234568	chr11:5960015	NA	-0.57	-4.54	-0.42	1.68e-5	DNA methylation (variation);
THYM	trans	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg01483505	chr11:975446	AP2A2	0.57	4.63	0.43	1.17e-5	Alzheimer's disease (late onset);
THYM	cis	rs3741151	0.773	rs7925226	chr11:73137362	A/G	cg17517138	chr11:73019481	ARHGEF17	0.94	5.48	0.49	3.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg09469691	chr10:81107165	PPIF	0.67	5.32	0.48	6.97e-7	Height;
THYM	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg15744005	chr10:104629667	AS3MT	0.63	4.45	0.42	2.3e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7705502	1.000	rs72812805	chr5:173344153	T/C	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs7578361	0.918	rs4309548	chr2:150377427	C/T	cg17961725	chr2:150454027	NA	-0.79	-6.02	-0.53	3.33e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs6686842	0.965	rs2802566	chr1:41551981	A/G	cg03387723	chr1:41708464	SCMH1	0.44	5.22	0.47	1.04e-6	Height;
THYM	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.32e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2798269	0.544	rs1200030	chr13:22160604	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.62	-4.61	-0.43	1.26e-5	PR segment;
THYM	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7246967	0.673	rs2361260	chr19:22914144	C/T	cg05241461	chr19:22816980	ZNF492	-0.61	-4.75	-0.44	7.2e-6	Bronchopulmonary dysplasia;
THYM	cis	rs240764	0.764	rs2213594	chr6:100931400	G/A	cg21058520	chr6:100914733	NA	0.53	4.74	0.44	7.43e-6	Neuroticism;
THYM	cis	rs11785693	0.862	rs11786595	chr8:5001621	T/G	cg26367366	chr8:4980734	NA	1.16	5.46	0.49	3.79e-7	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs1497406	0.744	rs12057222	chr1:16508534	A/G	cg20430773	chr1:16534157	ARHGEF19	0.5	5.47	0.49	3.67e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1483890	0.723	rs12629224	chr3:69411188	T/C	cg22125112	chr3:69402811	FRMD4B	0.55	6.93	0.58	4.98e-10	Resting heart rate;
THYM	cis	rs1113500	0.614	rs11185243	chr1:108597141	T/C	cg06207961	chr1:108661230	NA	0.67	4.94	0.45	3.28e-6	Growth-regulated protein alpha levels;
THYM	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2806561	0.780	rs12117752	chr1:23360223	T/C	cg19743168	chr1:23544995	NA	-0.57	-5.28	-0.48	8.27e-7	Height;
THYM	cis	rs4731207	0.698	rs10248775	chr7:124444207	T/G	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs5769707	0.706	rs763128	chr22:50018045	G/A	cg23428387	chr22:49814324	NA	-0.56	-5.33	-0.48	6.67e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4866334	1.000	rs114489248	chr5:18478969	C/A	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7927592	0.546	rs683978	chr11:68192421	T/C	cg16797656	chr11:68205561	LRP5	0.54	6.19	0.54	1.52e-8	Total body bone mineral density;
THYM	cis	rs10931896	0.531	rs295118	chr2:201144004	C/T	cg17644776	chr2:200775616	C2orf69	0.66	5.31	0.48	7.26e-7	Systolic blood pressure;
THYM	cis	rs16949788	1.000	rs41315964	chr15:66779698	C/T	cg08120210	chr15:66682733	MAP2K1	-0.77	-4.56	-0.42	1.54e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg09455208	chr3:40491958	NA	0.46	4.73	0.44	7.93e-6	Renal cell carcinoma;
THYM	cis	rs6977660	0.652	rs12673842	chr7:19747437	T/C	cg05791153	chr7:19748676	TWISTNB	1.27	7.31	0.6	8.2e-11	Thyroid stimulating hormone;
THYM	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg12419862	chr22:24373484	LOC391322	-0.99	-12.38	-0.79	1.61e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6430585	0.583	rs58509842	chr2:136586027	G/A	cg23851026	chr2:136556271	LCT	0.77	7.67	0.62	1.48e-11	Corneal structure;
THYM	cis	rs9894429	0.604	rs9912071	chr17:79609654	G/A	cg18240062	chr17:79603768	NPLOC4	0.73	6.22	0.54	1.31e-8	Eye color traits;
THYM	cis	rs78366141	0.649	rs77135481	chr4:89689680	T/C	cg01026744	chr4:89619053	NAP1L5;HERC3	1.25	4.97	0.45	3e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg01416388	chr22:39784598	NA	-0.92	-7.13	-0.59	1.95e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg08859206	chr1:53392774	SCP2	-0.77	-9.4	-0.69	3.24e-15	Monocyte count;
THYM	cis	rs34638657	0.673	rs62045961	chr16:82199723	A/G	cg09439754	chr16:82129088	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg13319975	chr6:146136371	FBXO30	-0.69	-5.7	-0.5	1.37e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg04944784	chr2:26401820	FAM59B	-0.79	-6.18	-0.54	1.61e-8	Gut microbiome composition (summer);
THYM	cis	rs9309473	0.519	rs1815027	chr2:73831840	T/C	cg19565262	chr2:73869966	NAT8	0.54	4.62	0.43	1.18e-5	Metabolite levels;
THYM	cis	rs892961	0.899	rs312911	chr17:75414585	A/C	cg05865280	chr17:75406074	SEPT9	0.49	8.19	0.64	1.19e-12	Airflow obstruction;
THYM	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.92	-8.4	-0.65	4.22e-13	Menarche (age at onset);
THYM	cis	rs7172677	1.000	rs4479194	chr15:75422131	C/T	cg09165964	chr15:75287851	SCAMP5	-0.6	-4.45	-0.42	2.33e-5	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-5.16	-0.47	1.34e-6	Hemoglobin concentration;
THYM	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg09184832	chr6:79620586	NA	-0.56	-4.46	-0.42	2.24e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2282930	0.512	rs2237455	chr7:50724129	C/T	cg08586669	chr7:50727761	GRB10	0.31	4.63	0.43	1.17e-5	Bone mineral density;
THYM	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg10518543	chr12:38710700	ALG10B	-0.56	-4.57	-0.42	1.49e-5	Morning vs. evening chronotype;
THYM	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg04455712	chr21:45112962	RRP1B	0.53	4.78	0.44	6.51e-6	Mean corpuscular volume;
THYM	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.63	5.55	0.5	2.53e-7	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg18876405	chr7:65276391	NA	-0.76	-7.25	-0.6	1.09e-10	Calcium levels;
THYM	cis	rs1557488	0.599	rs10431092	chr11:126728477	C/T	cg03950493	chr11:126582183	KIRREL3	-0.39	-4.56	-0.42	1.52e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs12579753	0.917	rs6539580	chr12:82184765	T/C	cg21231944	chr12:82153410	PPFIA2	-0.68	-5.12	-0.46	1.6e-6	Resting heart rate;
THYM	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.58	4.97	0.45	2.98e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg00271210	chr6:167070053	RPS6KA2	0.7	7.41	0.61	5.11e-11	Crohn's disease;
THYM	cis	rs6430585	0.528	rs10496738	chr2:136751488	C/T	cg07169764	chr2:136633963	MCM6	1.19	11.38	0.76	1.91e-19	Corneal structure;
THYM	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg23187316	chr7:1099788	C7orf50	0.59	4.49	0.42	2.01e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9972944	0.729	rs1895035	chr17:63777711	G/A	cg07283582	chr17:63770753	CCDC46	0.68	5.54	0.49	2.69e-7	Total body bone mineral density;
THYM	cis	rs7567389	1.000	rs7567389	chr2:127982645	A/T	cg09760422	chr2:128146352	NA	-0.5	-6.16	-0.53	1.75e-8	Self-rated health;
THYM	cis	rs7705042	0.865	rs7723666	chr5:141513966	C/T	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg03929089	chr4:120376271	NA	-1.0	-12.64	-0.79	4.61e-22	Height;
THYM	cis	rs10089	1.000	rs7713877	chr5:127428825	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.02	7.11	0.59	2.11e-10	Ileal carcinoids;
THYM	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg08847533	chr14:75593920	NEK9	0.93	9.92	0.71	2.48e-16	Height;
THYM	cis	rs155076	1.000	rs2783107	chr13:21837532	C/A	cg07022442	chr13:21864356	NA	0.71	4.66	0.43	1.03e-5	White matter hyperintensity burden;
THYM	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg08835221	chr22:38071607	LGALS1	0.38	5.04	0.46	2.21e-6	Fat distribution (HIV);
THYM	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg10802521	chr3:52805072	NEK4	-0.77	-6.72	-0.57	1.32e-9	Bipolar disorder;
THYM	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg01097406	chr16:89675127	NA	-0.6	-4.82	-0.44	5.5e-6	Vitiligo;
THYM	cis	rs1922291	0.546	rs35139442	chr2:102841646	T/C	cg13315345	chr2:102803985	IL1RL2	0.62	7.15	0.59	1.81e-10	Blood protein levels;
THYM	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg01236616	chr12:121019343	POP5	1.31	10.47	0.73	1.61e-17	Type 1 diabetes nephropathy;
THYM	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg18758796	chr5:131593413	PDLIM4	0.61	6.04	0.53	2.92e-8	Breast cancer;
THYM	cis	rs1981331	0.609	rs3088287	chr21:48079669	G/A	cg17243659	chr21:48055224	PRMT2	0.86	4.57	0.42	1.46e-5	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs1747683	0.966	rs4750346	chr10:13375013	T/C	cg25835351	chr10:13388524	SEPHS1	-0.35	-5.73	-0.51	1.17e-7	IgG glycosylation;
THYM	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.69	-6.06	-0.53	2.7e-8	Total body bone mineral density;
THYM	cis	rs3812049	0.784	rs2568928	chr5:127487603	C/T	cg05443326	chr5:126853169	PRRC1	0.65	4.49	0.42	2.02e-5	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs2219968	1.000	rs6982916	chr8:78972362	A/G	cg00738934	chr8:78996279	NA	-0.91	-9.74	-0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11890956	chr21:40555474	PSMG1	-0.96	-7.93	-0.63	4.16e-12	Cognitive function;
THYM	cis	rs10037758	0.528	rs258002	chr5:128319288	A/G	cg02841155	chr5:128301328	SLC27A6	-0.51	-5.09	-0.46	1.83e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg13902645	chr11:5959945	NA	-0.53	-4.69	-0.43	9.17e-6	DNA methylation (variation);
THYM	cis	rs7586879	0.639	rs2033653	chr2:25103446	C/T	cg15423357	chr2:25149977	NA	-0.67	-7.36	-0.6	6.68e-11	Body mass index;
THYM	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg14675211	chr2:100938903	LONRF2	0.72	7.72	0.62	1.19e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg10515332	chr4:99064459	C4orf37	0.58	4.54	0.42	1.67e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.75	6.16	0.53	1.75e-8	Schizophrenia;
THYM	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg10505658	chr17:80084571	CCDC57	0.7	8.07	0.64	2.18e-12	Life satisfaction;
THYM	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs112184198	0.915	rs2476966	chr10:102595108	G/T	cg03679755	chr10:101875035	NA	-0.81	-4.54	-0.42	1.68e-5	Systolic blood pressure;
THYM	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	6.09	0.53	2.36e-8	Platelet count;
THYM	cis	rs6582630	0.594	rs7308707	chr12:38450428	G/C	cg10518543	chr12:38710700	ALG10B	-0.59	-4.7	-0.43	8.88e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs12121840	0.790	rs56201005	chr1:165542855	G/A	cg19407955	chr1:165599744	MGST3	-0.65	-4.64	-0.43	1.12e-5	Interleukin-1-receptor antagonist levels;
THYM	cis	rs8064299	0.597	rs3785539	chr17:72775099	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.9	8.6	0.66	1.63e-13	Monocyte count;
THYM	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg18904891	chr8:8559673	CLDN23	0.66	5.34	0.48	6.28e-7	Mood instability;
THYM	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.91	10.22	0.72	5.7e-17	Prudent dietary pattern;
THYM	cis	rs2075230	0.705	rs1641542	chr17:7544272	T/C	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.73	-0.44	7.7e-6	Hormone measurements;
THYM	cis	rs3771570	1.000	rs62193256	chr2:242362168	C/T	cg21155796	chr2:242212141	HDLBP	1.25	6.07	0.53	2.57e-8	Prostate cancer;
THYM	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9359856	0.564	rs55722352	chr6:90365853	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.91	-8.21	-0.64	1.08e-12	Bipolar disorder;
THYM	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg12560992	chr17:57184187	TRIM37	0.93	8.88	0.67	4.06e-14	Intelligence (multi-trait analysis);
THYM	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg16926213	chr1:1841314	NA	0.56	5.62	0.5	1.89e-7	Body mass index;
THYM	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg16325326	chr1:53192061	ZYG11B	0.97	11.07	0.75	8.85e-19	Monocyte count;
THYM	cis	rs7551222	0.752	rs11240754	chr1:204477977	A/G	cg20240347	chr1:204465584	NA	-0.51	-4.54	-0.42	1.64e-5	Schizophrenia;
THYM	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg23711669	chr6:146136114	FBXO30	0.97	10.56	0.73	1.05e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3126085	0.778	rs10788828	chr1:152191879	G/A	cg10321714	chr1:152280068	FLG	0.64	4.6	0.43	1.29e-5	Atopic dermatitis;
THYM	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03517284	chr6:25882590	NA	-0.76	-5.98	-0.52	3.87e-8	Blood metabolite levels;
THYM	cis	rs789852	0.867	rs789846	chr3:194322999	T/C	cg18000598	chr3:194342907	TMEM44	-1.19	-6.93	-0.58	5.11e-10	QT interval;
THYM	cis	rs17473412	1.000	rs6880221	chr5:122739993	C/G	cg18093572	chr5:122598329	NA	0.53	4.45	0.42	2.33e-5	Total body bone mineral density;
THYM	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg03609598	chr5:56110824	MAP3K1	-0.85	-5.83	-0.51	7.62e-8	Initial pursuit acceleration;
THYM	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg05872129	chr22:39784769	NA	-1.09	-12.07	-0.78	6.85e-21	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg22907277	chr7:1156413	C7orf50	0.7	6.52	0.56	3.36e-9	Longevity;Endometriosis;
THYM	cis	rs11148252	0.716	rs2760772	chr13:52780373	C/G	cg00495681	chr13:53174319	NA	0.76	6.95	0.58	4.65e-10	Lewy body disease;
THYM	cis	rs7119	0.717	rs11629835	chr15:77787469	G/T	cg10437265	chr15:77819839	NA	0.56	4.99	0.46	2.78e-6	Type 2 diabetes;
THYM	cis	rs863345	0.604	rs1342950	chr1:158463723	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs6443245	0.963	rs2648573	chr3:9635471	C/T	cg19099050	chr3:9594382	LHFPL4	0.5	4.66	0.43	1.05e-5	Daytime sleep phenotypes;
THYM	cis	rs1878931	0.582	rs27238	chr16:3441223	G/A	cg21433313	chr16:3507492	NAT15	0.57	4.69	0.43	9.14e-6	Body mass index (adult);
THYM	cis	rs6921919	0.515	rs1339898	chr6:28395506	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.58	-4.56	-0.42	1.55e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs35883536	0.609	rs10783142	chr1:101043902	C/G	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg22325292	chr17:80708367	FN3K	0.63	4.56	0.42	1.54e-5	Glycated hemoglobin levels;
THYM	cis	rs7408868	1.000	rs10406754	chr19:15274201	T/A	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg17264618	chr3:40429014	ENTPD3	0.49	4.62	0.43	1.2e-5	Renal cell carcinoma;
THYM	cis	rs1065656	0.581	rs1065663	chr16:1839023	G/A	cg14074117	chr16:1909714	C16orf73	0.6	4.59	0.43	1.37e-5	Insulin-like growth factors;
THYM	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg03806693	chr22:41940476	POLR3H	-1.23	-10.76	-0.74	3.91e-18	Vitiligo;
THYM	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	trans	rs8073060	0.586	rs72829922	chr17:34044809	G/A	cg19694781	chr19:47549865	TMEM160	1.01	8.58	0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg03388043	chr17:80084554	CCDC57	0.71	5.83	0.51	7.47e-8	Life satisfaction;
THYM	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11644478	chr21:40555479	PSMG1	-0.57	-4.77	-0.44	6.72e-6	Menarche (age at onset);
THYM	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg04267008	chr7:1944627	MAD1L1	-0.71	-6.5	-0.56	3.64e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg25036284	chr2:26402008	FAM59B	-0.88	-5.44	-0.49	4.17e-7	Gut microbiome composition (summer);
THYM	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs6748734	0.600	rs10933510	chr2:241826754	G/A	cg07537917	chr2:241836409	C2orf54	-0.21	-4.88	-0.45	4.25e-6	Urinary metabolites;
THYM	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg13683864	chr3:40499215	RPL14	-1.01	-10.37	-0.73	2.73e-17	Renal cell carcinoma;
THYM	cis	rs4790333	0.562	rs2429904	chr17:2260362	T/C	cg02569219	chr17:2266849	SGSM2	0.71	5.99	0.52	3.68e-8	Proinsulin levels;
THYM	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg08999081	chr20:33150536	PIGU	0.62	5.02	0.46	2.41e-6	Coronary artery disease;
THYM	cis	rs6906287	0.647	rs11153752	chr6:118834771	A/T	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs7584330	0.740	rs7586312	chr2:238439389	G/A	cg14458575	chr2:238380390	NA	0.72	5.73	0.51	1.17e-7	Prostate cancer;
THYM	cis	rs12611088	0.571	rs2599447	chr19:44007012	G/A	cg18042043	chr19:44147545	NA	-0.41	-4.79	-0.44	6.17e-6	Plasma amyloid beta peptide concentrations (ABx-42);
THYM	cis	rs912057	0.833	rs1294421	chr6:6743149	A/C	cg06612196	chr6:6737390	NA	0.69	9.8	0.71	4.43e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs2046867	0.568	rs1553376	chr3:72828151	T/C	cg25664220	chr3:72788482	NA	-0.87	-6.62	-0.56	2.14e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs2354432	0.607	rs68080346	chr1:146708484	T/C	cg25205988	chr1:146714368	CHD1L	-1.02	-5.31	-0.48	7.2e-7	Mitochondrial DNA levels;
THYM	cis	rs10492096	0.947	rs10849482	chr12:6635274	G/A	cg13857086	chr12:6580257	VAMP1	0.87	5.27	0.48	8.47e-7	Hip geometry;
THYM	cis	rs6754311	0.550	rs3213889	chr2:136511575	A/G	cg23851026	chr2:136556271	LCT	-0.57	-5.96	-0.52	4.29e-8	Mosquito bite size;
THYM	cis	rs2688608	0.698	rs2633313	chr10:75683865	C/T	cg02947784	chr10:75434997	AGAP5	0.55	5.24	0.47	9.78e-7	Inflammatory bowel disease;
THYM	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg26673648	chr5:177209285	NA	0.8	6.21	0.54	1.38e-8	Methadone dose in opioid dependence;
THYM	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg00376283	chr12:123451042	ABCB9	0.68	5.22	0.47	1.04e-6	Neutrophil percentage of white cells;
THYM	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg07936489	chr17:37558343	FBXL20	-0.79	-5.7	-0.5	1.37e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7084402	1.000	rs6481401	chr10:60268880	A/C	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs4845875	0.557	rs4846054	chr1:11869230	C/T	cg24844545	chr1:11908347	NPPA	0.49	4.87	0.45	4.36e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs9359856	0.564	rs72915904	chr6:90421412	C/A	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg03806693	chr22:41940476	POLR3H	1.08	8.79	0.67	6.34e-14	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs1018836	0.527	rs13268721	chr8:91481549	G/A	cg16814680	chr8:91681699	NA	-0.76	-6.38	-0.55	6.27e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9649465	1.000	rs13225220	chr7:123371026	C/A	cg15443791	chr7:124364398	NA	0.6	4.97	0.45	3.01e-6	Migraine;
THYM	cis	rs28595532	0.920	rs115472708	chr4:119773407	C/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs763014	0.833	rs3743904	chr16:632767	A/G	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	6.89	0.58	5.96e-10	Electrocardiographic conduction measures;
THYM	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg08999081	chr20:33150536	PIGU	-0.77	-6.95	-0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg09877947	chr5:131593287	PDLIM4	0.57	4.75	0.44	7.29e-6	Breast cancer;
THYM	cis	rs2273669	0.667	rs12215344	chr6:109329641	A/C	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	cis	rs4733781	0.583	rs1340022	chr8:131334465	T/C	cg16277922	chr8:131349729	ASAP1	0.62	5.13	0.47	1.56e-6	Tuberculosis;
THYM	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.03	9.03	0.68	1.96e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2133450	0.712	rs35202421	chr3:7365899	C/T	cg19930620	chr3:7340148	GRM7	-0.48	-4.58	-0.43	1.4e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06634786	chr22:41940651	POLR3H	-0.79	-6.08	-0.53	2.5e-8	Vitiligo;
THYM	cis	rs1957429	0.614	rs78603758	chr14:65396648	C/G	cg23373153	chr14:65346875	NA	-1.25	-5.03	-0.46	2.29e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs10501293	0.798	rs2114090	chr11:43137621	A/G	cg03447554	chr11:43094025	NA	-0.74	-5.49	-0.49	3.31e-7	Cognitive performance;
THYM	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg05457628	chr5:178986728	RUFY1	0.56	5.2	0.47	1.14e-6	Lung cancer;
THYM	cis	rs1357245	0.533	rs9811837	chr3:27097787	T/C	cg03895047	chr3:27114861	NA	0.49	4.58	0.43	1.42e-5	Breast cancer;
THYM	cis	rs7226229	0.750	rs7213684	chr17:20919334	T/G	cg21263980	chr17:20946333	USP22	0.67	4.98	0.45	2.88e-6	Blood trace element (Se levels);
THYM	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg25110126	chr1:46999211	NA	0.67	5.21	0.47	1.1e-6	Monobrow;
THYM	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs924712	0.545	rs10948862	chr6:54711471	C/A	cg19716238	chr6:54711378	FAM83B	-0.47	-4.49	-0.42	1.99e-5	Breast cancer;
THYM	cis	rs11039798	1.000	rs7131020	chr11:48642132	A/G	cg24672777	chr11:48374446	OR4C45	-1.1	-6.54	-0.56	3.01e-9	Axial length;
THYM	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg19016782	chr12:123741754	C12orf65	-0.69	-4.5	-0.42	1.94e-5	Neutrophil percentage of white cells;
THYM	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.2e-16	Bone mineral density;
THYM	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg22841779	chr14:105766346	BRF1	-0.48	-5.94	-0.52	4.72e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg13770153	chr20:60521292	NA	-1.24	-10.78	-0.74	3.58e-18	Obesity-related traits;
THYM	cis	rs2294693	0.947	rs9296351	chr6:40988102	T/C	cg14418226	chr6:40996092	UNC5CL	0.67	5.96	0.52	4.34e-8	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs995000	0.931	rs6675401	chr1:63073975	C/T	cg06896770	chr1:63153194	DOCK7	0.92	7.57	0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs2012796	0.665	rs72703728	chr14:81834523	G/A	cg02996355	chr14:81879375	NA	0.82	6.24	0.54	1.19e-8	Night sleep phenotypes;
THYM	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg23711669	chr6:146136114	FBXO30	0.85	8.16	0.64	1.39e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10895275	0.649	rs4561174	chr11:102036375	G/T	cg24447756	chr11:102105824	NA	0.5	4.62	0.43	1.21e-5	Migraine;
THYM	cis	rs28595532	0.920	rs56302600	chr4:119770162	T/C	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs12681287	1.000	rs12681287	chr8:87269536	A/C	cg27223183	chr8:87520930	FAM82B	0.63	4.83	0.44	5.15e-6	Caudate activity during reward;
THYM	cis	rs7224737	1.000	rs35184688	chr17:40272406	G/C	cg00647820	chr17:40259828	DHX58	-0.62	-4.65	-0.43	1.06e-5	Fibrinogen levels;
THYM	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.48	-4.59	-0.43	1.36e-5	Crohn's disease;
THYM	cis	rs10174077	0.874	rs11892439	chr2:152469858	T/A	cg06191203	chr2:152266755	RIF1	-0.71	-4.83	-0.44	5.14e-6	Squamous cell lung carcinoma;
THYM	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg09990169	chr2:241835740	C2orf54	-0.29	-4.85	-0.45	4.85e-6	Urinary metabolites;
THYM	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg04034577	chr2:241836375	C2orf54	-0.44	-8.16	-0.64	1.35e-12	Urinary metabolites;
THYM	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs5760092	0.717	rs5760101	chr22:24248712	T/C	cg23131131	chr22:24373011	LOC391322	-0.69	-5.19	-0.47	1.2e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg26314531	chr2:26401878	FAM59B	-0.74	-4.6	-0.43	1.33e-5	Gut microbiome composition (summer);
THYM	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.06	9.47	0.7	2.24e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs36051895	0.632	rs7040806	chr9:5174782	C/T	cg02405213	chr9:5042618	JAK2	-0.98	-10.74	-0.74	4.37e-18	Pediatric autoimmune diseases;
THYM	cis	rs428668	0.681	rs192193	chr5:150692590	A/G	cg11125805	chr5:150678162	SLC36A3	0.47	5.09	0.46	1.82e-6	Skin aging (microtopography measurement);
THYM	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	6.53	0.56	3.24e-9	Obesity-related traits;
THYM	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg02475777	chr4:1388615	CRIPAK	0.67	4.75	0.44	7.33e-6	Longevity;
THYM	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg05283184	chr6:79620031	NA	-0.94	-9.25	-0.69	6.67e-15	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg24642844	chr7:1081250	C7orf50	-0.73	-5.13	-0.47	1.51e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11997175	0.520	rs6994803	chr8:33817796	A/G	ch.8.33884649F	chr8:33765107	NA	0.7	5.4	0.48	5e-7	Body mass index;
THYM	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-5.12	-0.47	1.59e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.81	-0.63	7.44e-12	Chronic sinus infection;
THYM	cis	rs28595532	0.841	rs114363775	chr4:119765587	G/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	trans	rs1974653	0.672	rs76584826	chr22:20068503	G/T	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs7771547	0.519	rs7773253	chr6:36373451	T/A	cg07856975	chr6:36356162	ETV7	0.65	5.5	0.49	3.13e-7	Platelet distribution width;
THYM	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.47	0.49	3.63e-7	Bipolar disorder;
THYM	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg23188684	chr11:67383651	NA	-0.6	-5.39	-0.48	5.22e-7	Mean corpuscular volume;
THYM	cis	rs7567389	0.600	rs3732209	chr2:128079806	A/G	cg09760422	chr2:128146352	NA	0.41	4.91	0.45	3.73e-6	Self-rated health;
THYM	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg17264618	chr3:40429014	ENTPD3	0.52	4.86	0.45	4.57e-6	Renal cell carcinoma;
THYM	cis	rs6918586	0.615	rs198841	chr6:26111671	G/T	cg12310025	chr6:25882481	NA	0.68	5.49	0.49	3.36e-7	Schizophrenia;
THYM	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg06028808	chr11:68637592	NA	0.66	6.82	0.57	8.49e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-5.58	-0.5	2.24e-7	Monocyte percentage of white cells;
THYM	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg09029085	chr17:47094198	IGF2BP1	0.49	6.98	0.58	4.02e-10	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg22467129	chr15:76604101	ETFA	-0.51	-5.02	-0.46	2.42e-6	Blood metabolite levels;
THYM	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13012494	chr21:47604986	C21orf56	0.69	4.62	0.43	1.23e-5	Testicular germ cell tumor;
THYM	cis	rs28595532	0.920	rs115878132	chr4:119756239	T/A	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs6995541	0.505	rs1991649	chr8:10706273	A/G	cg13457217	chr8:10683266	MIR1322;PINX1	-0.62	-4.52	-0.42	1.78e-5	Triglyceride levels;
THYM	cis	rs600806	0.850	rs3768493	chr1:109935505	C/T	cg23616212	chr1:109941201	SORT1	-0.5	-4.65	-0.43	1.06e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7546094	0.846	rs6537749	chr1:113218503	T/C	cg25616829	chr1:112535356	NA	-0.58	-4.7	-0.43	8.7e-6	Platelet distribution width;
THYM	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg23442198	chr4:187126114	CYP4V2	0.96	4.51	0.42	1.87e-5	Blood protein levels;
THYM	cis	rs2898681	0.739	rs8287	chr4:53732586	T/C	cg21521518	chr4:53727714	RASL11B	0.43	4.89	0.45	4.13e-6	Optic nerve measurement (cup area);
THYM	cis	rs13064411	0.696	rs6768979	chr3:113204149	G/A	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg24375607	chr4:120327624	NA	-0.67	-5.49	-0.49	3.34e-7	Corneal astigmatism;
THYM	cis	rs13082711	0.554	rs13087873	chr3:27392326	C/T	cg02860705	chr3:27208620	NA	0.87	6.18	0.54	1.58e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg17372223	chr3:52568218	NT5DC2	0.42	6.84	0.57	7.57e-10	Electroencephalogram traits;
THYM	cis	rs9649213	0.593	rs6465683	chr7:98026092	C/A	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs931127	0.640	rs4930156	chr11:65405699	C/T	cg27068330	chr11:65405492	SIPA1	0.73	5.52	0.49	2.94e-7	Systemic lupus erythematosus;
THYM	cis	rs931812	0.895	rs4236763	chr8:101913022	G/A	cg07585502	chr8:101912084	NA	-0.6	-4.64	-0.43	1.1e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs5758659	0.716	rs86669	chr22:42680800	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.38	-4.5	-0.42	1.94e-5	Cognitive function;
THYM	cis	rs7084402	0.934	rs1658426	chr10:60331542	A/T	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg18681998	chr4:17616180	MED28	0.99	10.27	0.73	4.28e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg13319975	chr6:146136371	FBXO30	-0.68	-5.44	-0.49	4.16e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg13010199	chr12:38710504	ALG10B	0.58	4.95	0.45	3.24e-6	Heart rate;
THYM	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg11812906	chr14:75593930	NEK9	-0.83	-7.5	-0.61	3.32e-11	Height;
THYM	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg23711669	chr6:146136114	FBXO30	0.91	9.54	0.7	1.6e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2237457	0.543	rs2529388	chr7:50701663	A/G	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.48e-6	Schizophrenia (treatment resistant);
THYM	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg27129171	chr3:47204927	SETD2	-0.81	-7.78	-0.62	8.79e-12	Colorectal cancer;
THYM	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg13319975	chr6:146136371	FBXO30	0.66	5.25	0.47	9.4e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg00256281	chr22:41985642	PMM1	0.57	4.78	0.44	6.28e-6	Vitiligo;
THYM	trans	rs629535	0.862	rs654604	chr8:70048939	C/A	cg21567404	chr3:27674614	NA	1.12	10.86	0.74	2.44e-18	Dupuytren's disease;
THYM	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs1065852	0.906	rs9611734	chr22:42502070	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.65	6.77	0.57	1.08e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg07777115	chr5:623756	CEP72	-0.8	-4.78	-0.44	6.48e-6	Obesity-related traits;
THYM	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2294693	0.947	rs742492	chr6:40996381	G/A	cg14769373	chr6:40998127	UNC5CL	-0.61	-4.9	-0.45	4e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs10231759	0.761	rs6955948	chr7:150508720	C/T	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.57	4.56	0.42	1.55e-5	Height;
THYM	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3819817	0.575	rs4762652	chr12:96351097	A/G	cg26410635	chr12:96350720	AMDHD1	0.53	5.02	0.46	2.38e-6	Vitamin D levels;
THYM	cis	rs62103177	0.564	rs59188178	chr18:77723435	T/C	cg07235805	chr18:78004237	PARD6G	0.45	4.96	0.45	3.02e-6	Opioid sensitivity;
THYM	cis	rs11771526	0.901	rs10264625	chr7:32304205	T/C	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs611744	0.967	rs688746	chr8:109225725	G/A	cg21045802	chr8:109455806	TTC35	0.59	5.15	0.47	1.38e-6	Dupuytren's disease;
THYM	cis	rs3892630	0.878	rs8108621	chr19:33183291	G/A	cg02283691	chr19:33182526	NUDT19	-0.42	-5.24	-0.47	9.75e-7	Red blood cell traits;
THYM	cis	rs12579753	1.000	rs7300900	chr12:82166821	G/T	cg21231944	chr12:82153410	PPFIA2	-0.66	-5.0	-0.46	2.64e-6	Resting heart rate;
THYM	cis	rs728616	0.867	rs56008106	chr10:81953776	T/C	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs2721195	0.845	rs4244611	chr8:145739924	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	0.75	6.13	0.53	1.98e-8	Age at first birth;
THYM	cis	rs1160297	0.585	rs12713230	chr2:53090138	A/G	cg07782112	chr2:53107842	NA	0.77	6.27	0.54	1.05e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs2637266	0.599	rs2395425	chr10:78461920	C/T	cg18941641	chr10:78392320	NA	0.75	6.17	0.53	1.68e-8	Pulmonary function;
THYM	cis	rs7586879	0.639	rs7580081	chr2:25097072	G/C	cg27107076	chr2:25050844	ADCY3	-0.29	-4.62	-0.43	1.2e-5	Body mass index;
THYM	cis	rs7584330	0.554	rs13405619	chr2:238445661	C/T	cg14458575	chr2:238380390	NA	0.74	4.59	0.43	1.34e-5	Prostate cancer;
THYM	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg15921436	chr17:44337874	NA	-0.88	-6.72	-0.57	1.34e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1372520	0.684	rs1442144	chr4:90736113	T/C	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs7084402	0.967	rs1649085	chr10:60292042	T/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg10802521	chr3:52805072	NEK4	-0.66	-6.1	-0.53	2.32e-8	Cognitive function;
THYM	cis	rs2070677	0.932	rs2987786	chr10:135365303	C/T	cg20169779	chr10:135381914	SYCE1	-0.67	-4.97	-0.45	2.93e-6	Gout;
THYM	cis	rs6754311	0.509	rs12616520	chr2:136516748	A/T	cg20242066	chr2:136595261	LCT	-0.56	-6.86	-0.58	7.1e-10	Mosquito bite size;
THYM	cis	rs78761021	0.792	rs62064479	chr17:9794101	G/C	cg26853458	chr17:9805074	RCVRN	0.53	4.49	0.42	2.01e-5	Type 2 diabetes;
THYM	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	7.86	0.63	6.02e-12	Lung cancer in ever smokers;
THYM	cis	rs919433	0.617	rs10931793	chr2:198577585	G/A	cg05783139	chr2:198650985	BOLL	-0.63	-5.0	-0.46	2.58e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg00012203	chr2:219082015	ARPC2	-0.69	-5.87	-0.52	6.36e-8	Colorectal cancer;
THYM	cis	rs11608355	1.000	rs11611370	chr12:109870291	A/G	cg10504392	chr12:110044639	NA	-0.66	-6.11	-0.53	2.19e-8	Neuroticism;
THYM	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg07570687	chr10:102243282	WNT8B	0.74	6.71	0.57	1.37e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg27394845	chr17:28928406	LRRC37B2	0.98	4.93	0.45	3.49e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9880211	0.948	rs34282798	chr3:136143357	G/C	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs6435161	1.000	rs72926990	chr2:203520420	G/A	cg18429434	chr2:203499731	FAM117B	-0.76	-5.01	-0.46	2.49e-6	Total cholesterol levels;
THYM	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg21028142	chr17:79581711	NPLOC4	0.64	6.74	0.57	1.23e-9	Eye color traits;
THYM	cis	rs3862030	0.810	rs5870	chr10:104239100	A/G	cg00122347	chr10:104236741	TMEM180	0.48	7.32	0.6	7.97e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg26384229	chr12:38710491	ALG10B	0.95	7.64	0.62	1.72e-11	Bladder cancer;
THYM	cis	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg20307385	chr11:47447363	PSMC3	0.82	6.69	0.57	1.53e-9	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs36051895	0.622	rs12686652	chr9:5071942	C/G	cg02405213	chr9:5042618	JAK2	-1.03	-11.11	-0.75	7.02e-19	Pediatric autoimmune diseases;
THYM	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7546094	0.846	rs4838959	chr1:113085721	G/T	cg25616829	chr1:112535356	NA	-0.59	-4.91	-0.45	3.73e-6	Platelet distribution width;
THYM	cis	rs262150	0.625	rs117651953	chr7:158780563	G/A	cg12257156	chr7:158823799	VIPR2	0.56	4.6	0.43	1.3e-5	Facial morphology (factor 20);
THYM	cis	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg01191920	chr7:158217561	PTPRN2	-0.98	-10.74	-0.74	4.36e-18	Obesity-related traits;
THYM	cis	rs6575793	1.000	rs8006389	chr14:101033435	A/G	cg13673514	chr14:101035818	BEGAIN	-0.51	-4.93	-0.45	3.55e-6	Menarche (age at onset);
THYM	cis	rs6840360	0.571	rs1822347	chr4:152525319	A/G	cg22705602	chr4:152727874	NA	-0.78	-8.73	-0.67	8.56e-14	Intelligence (multi-trait analysis);
THYM	cis	rs1823778	0.609	rs11663969	chr18:67707490	T/C	cg13164537	chr18:67624071	CD226	1.07	4.74	0.44	7.51e-6	Mean platelet volume;
THYM	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg14416269	chr4:6271139	WFS1	0.49	4.99	0.46	2.75e-6	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs28830936	0.510	rs7174099	chr15:42099059	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.34	-5.79	-0.51	9.12e-8	Diastolic blood pressure;
THYM	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4363385	0.588	rs12082627	chr1:153023650	G/A	cg13444842	chr1:152974279	SPRR3	-0.61	-4.9	-0.45	3.96e-6	Inflammatory skin disease;
THYM	cis	rs459571	0.916	rs467303	chr9:136904835	C/T	cg13789015	chr9:136890014	NCRNA00094	0.82	7.14	0.59	1.84e-10	Platelet distribution width;
THYM	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg22968622	chr17:43663579	NA	1.14	10.29	0.73	4.02e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg00256281	chr22:41985642	PMM1	0.48	4.61	0.43	1.27e-5	Vitiligo;
THYM	cis	rs13315871	0.929	rs77825960	chr3:58318677	A/G	cg00563845	chr3:58318305	PXK	0.58	4.99	0.46	2.73e-6	Cholesterol, total;
THYM	cis	rs686320	1.000	rs679643	chr11:65250590	C/A	cg13044675	chr11:65314161	LTBP3	0.86	4.61	0.43	1.25e-5	Hip circumference adjusted for BMI;
THYM	cis	rs9914988	0.887	rs9895625	chr17:27108516	A/G	cg20469991	chr17:27169893	C17orf63	-0.77	-4.59	-0.43	1.33e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs6076065	0.609	rs3746736	chr20:23424613	T/C	cg11657817	chr20:23433608	CST11	0.4	6.19	0.54	1.53e-8	Facial morphology (factor 15, philtrum width);
THYM	cis	rs72627123	0.867	rs112965033	chr14:74461117	T/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs10231759	0.583	rs4725948	chr7:150516404	T/C	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.63	4.81	0.44	5.77e-6	Height;
THYM	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg21775007	chr8:11205619	TDH	-0.6	-4.87	-0.45	4.52e-6	Retinal vascular caliber;
THYM	cis	rs13102973	0.965	rs28769289	chr4:135878230	T/C	cg14419869	chr4:135874104	NA	-0.83	-7.93	-0.63	4.18e-12	Subjective well-being;
THYM	cis	rs7189233	0.830	rs72801843	chr16:53508802	T/A	cg02965178	chr16:53538660	AKTIP	-0.6	-4.59	-0.43	1.37e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7267979	0.966	rs6083818	chr20:25346082	G/A	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2073300	1.000	rs12625160	chr20:23442008	T/C	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7089973	0.872	rs7918388	chr10:116614563	T/C	cg23260525	chr10:116636907	FAM160B1	0.51	4.57	0.42	1.49e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs6430585	0.583	rs60253740	chr2:136571852	G/T	cg04750100	chr2:136595281	LCT	0.51	4.85	0.45	4.89e-6	Corneal structure;
THYM	cis	rs2898681	0.580	rs41279517	chr4:53729771	T/C	cg03786743	chr4:53727781	RASL11B	0.63	5.65	0.5	1.66e-7	Optic nerve measurement (cup area);
THYM	cis	rs3858704	0.517	rs7297186	chr12:111778178	C/T	cg10833066	chr12:111807467	FAM109A	-0.7	-11.39	-0.76	1.87e-19	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs2898681	0.614	rs62338810	chr4:53678507	G/A	cg21521518	chr4:53727714	RASL11B	0.5	5.34	0.48	6.44e-7	Optic nerve measurement (cup area);
THYM	cis	rs7584330	0.554	rs3751107	chr2:238427251	G/A	cg08992911	chr2:238395768	MLPH	0.85	5.39	0.48	5.19e-7	Prostate cancer;
THYM	cis	rs6866344	0.697	rs62392831	chr5:178134365	A/G	cg03877680	chr5:178157825	ZNF354A	0.72	4.98	0.46	2.79e-6	Neutrophil percentage of white cells;
THYM	trans	rs11186	0.591	rs55633056	chr2:189955694	A/C	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg06028605	chr16:24865363	SLC5A11	0.63	5.03	0.46	2.3e-6	Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg04315214	chr1:2043799	PRKCZ	0.65	5.63	0.5	1.8e-7	Height;
THYM	cis	rs757081	0.667	rs644419	chr11:17212375	C/T	cg15432903	chr11:17409602	KCNJ11	0.53	4.89	0.45	4.09e-6	Systolic blood pressure;
THYM	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.17	0.47	1.31e-6	Bipolar disorder;
THYM	cis	rs3820068	0.580	rs12747696	chr1:16002978	A/G	cg05660106	chr1:15850417	CASP9	0.66	5.37	0.48	5.64e-7	Systolic blood pressure;
THYM	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg18305652	chr10:134549665	INPP5A	0.75	5.92	0.52	5.16e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg03806693	chr22:41940476	POLR3H	-1.14	-9.45	-0.7	2.52e-15	Vitiligo;
THYM	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg12463550	chr7:65579703	CRCP	0.59	4.77	0.44	6.58e-6	Aortic root size;
THYM	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06850241	chr22:41845214	NA	-0.61	-5.38	-0.48	5.23e-7	Vitiligo;
THYM	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg24530246	chr3:53118167	NA	-0.85	-4.82	-0.44	5.52e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2555603	1.000	rs2858132	chr13:33800352	G/A	cg07499182	chr13:33825496	STARD13	-0.51	-4.8	-0.44	5.9e-6	Body mass index in asthmatics;
THYM	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg24209194	chr3:40518798	ZNF619	0.55	4.48	0.42	2.1e-5	Renal cell carcinoma;
THYM	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg24308560	chr3:49941425	MST1R	0.79	6.93	0.58	5.04e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs950880	0.710	rs11678975	chr2:103043739	T/A	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.64	-0.43	1.1e-5	Serum protein levels (sST2);
THYM	cis	rs10911232	0.507	rs4442336	chr1:182982538	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Hypertriglyceridemia;
THYM	cis	rs11096990	0.819	rs2381225	chr4:39160535	G/A	cg24403649	chr4:39172243	NA	-0.6	-5.11	-0.46	1.67e-6	Cognitive function;
THYM	cis	rs995000	0.899	rs1183260	chr1:62945418	A/G	cg06896770	chr1:63153194	DOCK7	-0.92	-7.56	-0.61	2.53e-11	Triglyceride levels;
THYM	cis	rs7586879	0.639	rs3903070	chr2:25123463	C/G	cg15423357	chr2:25149977	NA	0.7	7.74	0.62	1.03e-11	Body mass index;
THYM	cis	rs2273669	0.667	rs78383792	chr6:109312498	A/G	cg17117243	chr6:109341365	SESN1	-0.9	-5.38	-0.48	5.45e-7	Prostate cancer;
THYM	cis	rs754466	0.580	rs11002293	chr10:79537965	C/T	cg17075019	chr10:79541650	NA	-0.69	-5.73	-0.51	1.17e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12474201	0.894	rs4952842	chr2:46925730	C/A	cg09399716	chr2:46890238	NA	-0.51	-4.48	-0.42	2.11e-5	Height;
THYM	cis	rs262150	0.502	rs73167295	chr7:158782949	T/A	cg12257156	chr7:158823799	VIPR2	0.62	5.21	0.47	1.11e-6	Facial morphology (factor 20);
THYM	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg01579765	chr21:45077557	HSF2BP	-0.5	-7.86	-0.63	6e-12	Mean corpuscular volume;
THYM	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg13852791	chr20:30311386	BCL2L1	0.85	6.69	0.57	1.56e-9	Monocyte count;
THYM	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg22841779	chr14:105766346	BRF1	-0.46	-5.71	-0.51	1.27e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs17598306	0.935	rs17598579	chr7:96590472	G/T	cg26766885	chr7:96220185	NA	0.62	5.13	0.47	1.56e-6	Radiation response;
THYM	cis	rs17094448	0.557	rs117276277	chr14:74497463	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.14	6.41	0.55	5.69e-9	Blood protein levels;
THYM	cis	rs13315871	0.929	rs71311853	chr3:58319152	C/T	cg00563845	chr3:58318305	PXK	0.59	5.02	0.46	2.37e-6	Cholesterol, total;
THYM	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg06636001	chr8:8085503	FLJ10661	0.78	8.26	0.65	8.63e-13	Mood instability;
THYM	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg19897017	chr7:2163380	MAD1L1	0.43	4.55	0.42	1.61e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs1978968	0.912	rs5992933	chr22:18457043	G/T	cg01550578	chr22:18484421	MICAL3	0.6	4.62	0.43	1.23e-5	Presence of antiphospholipid antibodies;
THYM	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg12311346	chr5:56204834	C5orf35	-0.84	-6.23	-0.54	1.28e-8	Initial pursuit acceleration;
THYM	cis	rs3126085	0.877	rs3126055	chr1:152266364	G/A	cg26020982	chr1:152196106	HRNR	-0.35	-4.95	-0.45	3.26e-6	Atopic dermatitis;
THYM	cis	rs2120243	0.572	rs2305620	chr3:157127586	C/T	cg24825693	chr3:157122686	VEPH1	-0.47	-4.58	-0.43	1.42e-5	Hepatocellular carcinoma in hepatitis B infection;
THYM	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg16524936	chr4:1340807	KIAA1530	-0.62	-4.86	-0.45	4.67e-6	Longevity;
THYM	cis	rs6032067	0.759	rs3761193	chr20:43885827	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.59	-5.47	-0.49	3.57e-7	Blood protein levels;
THYM	cis	rs728616	0.867	rs17885031	chr10:81696091	G/A	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg16486109	chr11:613632	IRF7	0.51	5.38	0.48	5.39e-7	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs227425	0.525	rs10220692	chr14:70412312	A/G	cg12046056	chr14:71067695	MED6	0.56	4.99	0.46	2.7e-6	Bone mineral density;
THYM	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg13390004	chr1:15929781	NA	0.64	4.85	0.45	4.88e-6	Systolic blood pressure;
THYM	cis	rs6496667	0.557	rs2601203	chr15:90958129	T/G	cg00487526	chr15:90818384	NA	-0.63	-4.68	-0.43	9.51e-6	Rheumatoid arthritis;
THYM	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg11494091	chr17:61959527	GH2	1.07	16.31	0.86	2.76e-29	Prudent dietary pattern;
THYM	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg18252515	chr7:66147081	NA	0.64	4.87	0.45	4.48e-6	Aortic root size;
THYM	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.69	0.43	9.17e-6	Bipolar disorder;
THYM	cis	rs3735485	0.738	rs11771107	chr7:45134135	A/T	cg27050550	chr7:44613552	DDX56	0.76	4.47	0.42	2.14e-5	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
THYM	cis	rs7584330	0.704	rs11884395	chr2:238359366	C/T	cg16989719	chr2:238392110	NA	-0.67	-5.71	-0.51	1.3e-7	Prostate cancer;
THYM	cis	rs2236918	0.710	rs1776174	chr1:242031839	G/T	cg21919602	chr1:242011447	EXO1	-0.6	-4.45	-0.42	2.31e-5	Menopause (age at onset);
THYM	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg08430604	chr3:44902960	MIR564;TMEM42	0.48	4.55	0.42	1.61e-5	Depressive symptoms;
THYM	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg11764359	chr7:65958608	NA	-0.87	-7.46	-0.61	4.01e-11	Aortic root size;
THYM	cis	rs36051895	0.632	rs11788164	chr9:5129395	A/G	cg02405213	chr9:5042618	JAK2	-1.02	-11.29	-0.76	2.97e-19	Pediatric autoimmune diseases;
THYM	cis	rs13064411	0.696	rs7631082	chr3:113208913	C/G	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs10504229	0.593	rs116916898	chr8:57984958	G/A	cg08449448	chr8:58056501	NA	0.99	4.87	0.45	4.46e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg08736216	chr1:53307985	ZYG11A	-0.62	-5.5	-0.49	3.22e-7	Monocyte count;
THYM	cis	rs7100689	0.784	rs1870142	chr10:82182296	G/A	cg01528321	chr10:82214614	TSPAN14	1.13	8.8	0.67	6.09e-14	Post bronchodilator FEV1;
THYM	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg27211696	chr2:191398769	TMEM194B	0.84	8.47	0.66	3.11e-13	Pulse pressure;
THYM	cis	rs6424115	0.679	rs2076345	chr1:24083494	C/T	cg15997130	chr1:24165203	NA	-0.67	-5.16	-0.47	1.32e-6	Immature fraction of reticulocytes;
THYM	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6754311	0.513	rs1438304	chr2:136503157	A/G	cg04750100	chr2:136595281	LCT	-0.55	-6.28	-0.54	1.01e-8	Mosquito bite size;
THYM	cis	rs2456568	0.778	rs2456563	chr11:93678675	C/T	cg26875233	chr11:93583750	C11orf90	-0.51	-4.53	-0.42	1.74e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg27490568	chr2:178487706	NA	0.64	5.81	0.51	8.33e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7917772	0.604	rs4917977	chr10:104363119	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6977660	0.652	rs12673842	chr7:19747437	T/C	cg07541023	chr7:19748670	TWISTNB	1.2	6.7	0.57	1.45e-9	Thyroid stimulating hormone;
THYM	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg23260525	chr10:116636907	FAM160B1	0.5	5.12	0.47	1.58e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9900497	0.783	rs758426	chr17:19620624	A/T	cg22552966	chr17:19620595	SLC47A2	0.74	7.54	0.61	2.82e-11	Response to paliperidone in schizophrenia (CGI-S score);
THYM	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg11764359	chr7:65958608	NA	-0.84	-6.74	-0.57	1.24e-9	Aortic root size;
THYM	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg02820040	chr2:241836501	C2orf54	-0.33	-6.76	-0.57	1.12e-9	Urinary metabolites;
THYM	cis	rs2663905	0.611	rs1509558	chr15:81391244	C/T	cg05624577	chr15:81411055	NA	-0.74	-5.7	-0.5	1.36e-7	QT interval (drug interaction);
THYM	cis	rs9467773	0.506	rs9393709	chr6:26365147	C/T	cg14345882	chr6:26364793	BTN3A2	0.35	4.66	0.43	1.01e-5	Intelligence (multi-trait analysis);
THYM	cis	rs240764	0.717	rs6907444	chr6:101163606	G/T	cg21058520	chr6:100914733	NA	0.57	4.92	0.45	3.69e-6	Neuroticism;
THYM	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.1	-11.12	-0.75	7.01e-19	Primary sclerosing cholangitis;
THYM	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg15604051	chr3:44754201	ZNF502	-0.56	-5.0	-0.46	2.6e-6	Depressive symptoms;
THYM	cis	rs72829446	0.530	rs4796424	chr17:7387973	T/C	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs6032067	1.000	rs62205501	chr20:43864089	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.42	-0.49	4.55e-7	Blood protein levels;
THYM	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg22681709	chr2:178499509	PDE11A	-0.49	-4.51	-0.42	1.87e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg21854759	chr1:92012499	NA	-0.7	-5.67	-0.5	1.5e-7	Breast cancer;
THYM	cis	rs9733	0.650	rs12406712	chr1:150545084	C/A	cg13175981	chr1:150552382	MCL1	0.75	5.32	0.48	6.97e-7	Tonsillectomy;
THYM	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.5	-4.93	-0.45	3.5e-6	Crohn's disease;
THYM	cis	rs10256972	0.706	rs7784559	chr7:1002973	A/G	cg08883853	chr7:1026168	CYP2W1	-0.46	-4.78	-0.44	6.32e-6	Longevity;Endometriosis;
THYM	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg27535305	chr1:53392650	SCP2	-0.54	-6.36	-0.55	7.06e-9	Monocyte count;
THYM	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg05234568	chr11:5960015	NA	-0.56	-4.48	-0.42	2.1e-5	DNA methylation (variation);
THYM	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg21475434	chr5:93447410	FAM172A	-0.92	-5.7	-0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs909002	0.849	rs2271933	chr1:32092525	C/T	cg13919466	chr1:32135498	COL16A1	0.49	4.85	0.45	4.86e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg09085632	chr11:111637200	PPP2R1B	1.16	11.93	0.77	1.35e-20	Primary sclerosing cholangitis;
THYM	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-4.77	-0.44	6.66e-6	Mood instability;
THYM	cis	rs3917265	0.616	rs1960510	chr2:102822265	T/C	cg13315345	chr2:102803985	IL1RL2	0.63	7.5	0.61	3.33e-11	Atopic dermatitis;
THYM	cis	rs2777491	0.957	rs2015781	chr15:41648967	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.08	-11.71	-0.77	3.97e-20	Ulcerative colitis;
THYM	cis	rs775227	0.574	rs36108475	chr3:113038406	C/T	cg18753928	chr3:113234510	CCDC52	-0.75	-5.16	-0.47	1.35e-6	Dental caries;
THYM	cis	rs67311347	0.544	rs9821440	chr3:40342347	T/C	cg13683864	chr3:40499215	RPL14	-0.79	-7.48	-0.61	3.69e-11	Renal cell carcinoma;
THYM	cis	rs911119	1.000	rs2016161	chr20:23621174	G/T	cg16589663	chr20:23618590	CST3	-0.78	-4.83	-0.44	5.31e-6	Chronic kidney disease;
THYM	cis	rs11760633	0.672	rs10950377	chr7:1835894	C/G	cg23422044	chr7:1970798	MAD1L1	0.63	4.53	0.42	1.69e-5	Coronary artery disease;
THYM	cis	rs7809950	0.862	rs12112877	chr7:106941324	T/C	cg23024343	chr7:107201750	COG5	-0.9	-7.89	-0.63	5.13e-12	Coronary artery disease;
THYM	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-6.65	-0.56	1.84e-9	Chronic sinus infection;
THYM	cis	rs9902453	1.000	rs4074170	chr17:28381141	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	trans	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg10856724	chr12:34555212	NA	-0.89	-8.35	-0.65	5.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1011018	0.955	rs7459106	chr7:139439007	A/G	cg06079564	chr7:139468310	HIPK2	-0.72	-5.49	-0.49	3.34e-7	Systolic blood pressure;
THYM	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg15247329	chr7:2764246	NA	-0.69	-5.84	-0.51	7.42e-8	Height;
THYM	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg24675658	chr1:53192096	ZYG11B	0.88	6.66	0.56	1.8e-9	Monocyte count;
THYM	cis	rs6496667	1.000	rs3803538	chr15:90891771	A/G	cg22089800	chr15:90895588	ZNF774	0.74	5.0	0.46	2.65e-6	Rheumatoid arthritis;
THYM	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg20476274	chr7:133979776	SLC35B4	0.66	4.61	0.43	1.25e-5	Mean platelet volume;
THYM	cis	rs9403317	0.654	rs9399380	chr6:142003538	G/A	cg15052665	chr6:141804349	NA	0.74	5.38	0.48	5.31e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg12379764	chr21:47803548	PCNT	-0.71	-4.7	-0.43	8.96e-6	Testicular germ cell tumor;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg08460387	chr1:26000291	MAN1C1	-0.92	-6.97	-0.58	4.08e-10	Depressive symptoms;
THYM	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg12826209	chr6:26865740	GUSBL1	0.85	4.68	0.43	9.63e-6	Urinary tract infection frequency;
THYM	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.47	-4.64	-0.43	1.13e-5	Crohn's disease;
THYM	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg06634786	chr22:41940651	POLR3H	0.71	5.22	0.47	1.07e-6	Vitiligo;
THYM	cis	rs4589258	0.788	rs4237552	chr11:90458539	G/A	cg26138821	chr11:89956704	CHORDC1	-0.57	-4.62	-0.43	1.21e-5	Intelligence (multi-trait analysis);
THYM	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21582582	chr3:182698605	DCUN1D1	0.79	6.95	0.58	4.51e-10	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg08885076	chr2:99613938	TSGA10	-0.66	-6.08	-0.53	2.47e-8	Chronic sinus infection;
THYM	cis	rs7646501	0.677	rs11714016	chr3:24057411	G/C	cg21910673	chr3:24143257	LOC152024	0.49	4.49	0.42	2.04e-5	Cognitive ability;Intelligence;
THYM	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg06238570	chr21:40685208	BRWD1	0.9	6.33	0.54	7.95e-9	Cognitive function;
THYM	cis	rs2154427	0.689	rs2833947	chr21:34124930	T/C	cg21871883	chr21:34145043	C21orf49;C21orf66	1.02	5.35	0.48	6e-7	Bilirubin levels;
THYM	cis	rs7584330	0.737	rs1497128	chr2:238369211	A/G	cg16989719	chr2:238392110	NA	-0.6	-5.7	-0.5	1.37e-7	Prostate cancer;
THYM	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg06636001	chr8:8085503	FLJ10661	0.87	9.13	0.68	1.22e-14	Neuroticism;
THYM	cis	rs4907240	0.961	rs62154845	chr2:97267644	G/A	cg01950434	chr2:97203154	ARID5A	-0.57	-4.81	-0.44	5.71e-6	Event-related brain oscillations;
THYM	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg20283391	chr11:68216788	NA	-0.63	-4.49	-0.42	2.03e-5	Total body bone mineral density;
THYM	cis	rs3791406	0.654	rs3752804	chr2:240029490	C/T	cg14550559	chr2:240039617	HDAC4	-0.53	-5.05	-0.46	2.1e-6	Skin aging (microtopography measurement);
THYM	cis	rs7551222	0.716	rs4245738	chr1:204506107	C/T	cg20240347	chr1:204465584	NA	-0.51	-4.54	-0.42	1.64e-5	Schizophrenia;
THYM	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg18252515	chr7:66147081	NA	-0.71	-5.67	-0.5	1.56e-7	Aortic root size;
THYM	trans	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg20587970	chr11:113659929	NA	-1.26	-9.01	-0.68	2.16e-14	Hip circumference adjusted for BMI;
THYM	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg09165964	chr15:75287851	SCAMP5	-1.06	-10.7	-0.74	5.29e-18	Blood trace element (Zn levels);
THYM	cis	rs7731657	0.537	rs973900	chr5:130362467	G/T	cg08523029	chr5:130500466	HINT1	-0.85	-5.98	-0.52	3.88e-8	Fasting plasma glucose;
THYM	cis	rs950394	0.767	rs73946422	chr2:104991726	C/A	cg20302975	chr2:105468274	NA	-0.66	-4.56	-0.42	1.52e-5	Schizophrenia;
THYM	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg04865290	chr3:52927548	TMEM110	-0.89	-4.65	-0.43	1.08e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg07636037	chr3:49044803	WDR6	0.73	5.35	0.48	6.17e-7	Parkinson's disease;
THYM	cis	rs924712	0.547	rs239815	chr6:54816219	G/A	cg04690482	chr6:54711388	FAM83B	0.5	5.87	0.52	6.25e-8	Breast cancer;
THYM	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg14019146	chr3:50243930	SLC38A3	-0.85	-7.32	-0.6	8.02e-11	Intelligence (multi-trait analysis);
THYM	cis	rs2278491	0.557	rs6469660	chr8:117797719	G/T	cg23513447	chr8:117778558	UTP23	0.62	4.51	0.42	1.84e-5	Body mass index;
THYM	cis	rs3785574	1.000	rs3785574	chr17:61763185	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	5.44	0.49	4.17e-7	Height;
THYM	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.66	4.85	0.45	4.9e-6	Lung cancer in ever smokers;
THYM	cis	rs9527	0.590	rs7074395	chr10:104844928	A/C	cg04362960	chr10:104952993	NT5C2	-0.61	-4.61	-0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg19077165	chr18:44547161	KATNAL2	0.6	7.67	0.62	1.51e-11	Personality dimensions;
THYM	cis	rs17152411	0.895	rs11245420	chr10:126586469	T/C	cg07906193	chr10:126599966	NA	0.68	4.65	0.43	1.08e-5	Height;
THYM	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg25487775	chr2:162093969	NA	0.68	5.82	0.51	8e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.98	-6.68	-0.57	1.62e-9	Platelet count;
THYM	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg12310025	chr6:25882481	NA	0.72	5.86	0.52	6.59e-8	Blood metabolite levels;
THYM	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg18825119	chr6:163149453	PACRG;PARK2	0.68	6.04	0.53	2.94e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6032067	0.516	rs761367	chr20:43913317	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.6	-5.86	-0.52	6.58e-8	Blood protein levels;
THYM	cis	rs4790312	0.905	rs4790311	chr17:1979188	T/C	cg15816464	chr17:2026533	SMG6	0.38	4.99	0.46	2.76e-6	Left atrial antero-posterior diameter;
THYM	trans	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg19862616	chr7:65841803	NCRNA00174	1.02	11.16	0.75	5.58e-19	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11890956	chr21:40555474	PSMG1	-0.7	-6.83	-0.57	7.85e-10	Menarche (age at onset);
THYM	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs7178572	0.568	rs10152181	chr15:77678346	A/G	cg22256960	chr15:77711686	NA	-1.05	-8.4	-0.65	4.29e-13	Type 2 diabetes;
THYM	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs8180040	0.800	rs11921117	chr3:47294000	T/C	cg16586182	chr3:47516702	SCAP	0.69	6.0	0.52	3.63e-8	Colorectal cancer;
THYM	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs877282	0.898	rs11253346	chr10:765313	A/G	cg10556349	chr10:835070	NA	-0.78	-5.06	-0.46	2.06e-6	Uric acid levels;
THYM	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs887829	0.694	rs869283	chr2:234626287	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.73	-5.92	-0.52	5.15e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg12863693	chr15:85201151	NMB	0.52	4.67	0.43	9.88e-6	Schizophrenia;
THYM	cis	rs3733631	0.602	rs763582	chr4:104678175	C/T	cg24090629	chr4:104641072	TACR3	-0.92	-5.48	-0.49	3.53e-7	Menarche (age at onset);
THYM	cis	rs7975161	0.515	rs7299866	chr12:104576197	C/T	cg25273343	chr12:104657179	TXNRD1	-0.71	-4.85	-0.45	4.77e-6	Toenail selenium levels;
THYM	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg07570687	chr10:102243282	WNT8B	0.83	8.03	0.64	2.57e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg27588902	chr6:42928151	GNMT	-0.62	-6.33	-0.54	7.99e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06481639	chr22:41940642	POLR3H	0.82	5.64	0.5	1.77e-7	Vitiligo;
THYM	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg13866156	chr1:1669148	SLC35E2	-0.72	-7.32	-0.6	7.77e-11	Body mass index;
THYM	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg10334053	chr1:2078117	PRKCZ	-0.5	-4.83	-0.44	5.24e-6	Height;
THYM	trans	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg19862616	chr7:65841803	NCRNA00174	1.11	12.92	0.8	1.21e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4663969	0.733	rs6741669	chr2:234653192	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.67	-5.17	-0.47	1.31e-6	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg18105134	chr13:113819100	PROZ	-0.98	-9.05	-0.68	1.79e-14	Platelet distribution width;
THYM	cis	rs2273669	0.667	rs11751295	chr6:109334458	C/G	cg17117243	chr6:109341365	SESN1	-0.91	-5.38	-0.48	5.45e-7	Prostate cancer;
THYM	cis	rs7584330	0.554	rs9646716	chr2:238443784	C/T	cg14458575	chr2:238380390	NA	0.74	4.59	0.43	1.34e-5	Prostate cancer;
THYM	cis	rs9572053	0.502	rs9572066	chr13:69549406	C/T	cg16757992	chr13:69559194	NA	-0.63	-5.09	-0.46	1.82e-6	Subjective well-being;
THYM	cis	rs72828912	0.731	rs9358747	chr6:24069549	A/T	cg26336265	chr6:25042955	NA	-0.86	-5.43	-0.49	4.31e-7	Squamous cell lung carcinoma;
THYM	cis	rs1878931	0.582	rs9937267	chr16:3421073	C/T	cg21433313	chr16:3507492	NAT15	-0.59	-4.99	-0.46	2.75e-6	Body mass index (adult);
THYM	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg25918947	chr17:41365094	TMEM106A	-0.58	-4.77	-0.44	6.65e-6	Menopause (age at onset);
THYM	cis	rs600806	0.850	rs2140924	chr1:109935775	A/C	cg23616212	chr1:109941201	SORT1	-0.49	-4.66	-0.43	1.01e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg01097406	chr16:89675127	NA	0.81	7.14	0.59	1.84e-10	Vitiligo;
THYM	trans	rs877282	1.000	rs71494928	chr10:769134	A/G	cg22713356	chr15:30763199	NA	1.42	12.02	0.78	8.69e-21	Uric acid levels;
THYM	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.71	-4.73	-0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg27129171	chr3:47204927	SETD2	0.8	7.67	0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg13237147	chr3:188745304	NA	-0.69	-4.88	-0.45	4.2e-6	Lung adenocarcinoma;
THYM	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg10360139	chr7:1886902	MAD1L1	-0.67	-5.81	-0.51	8.46e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs10276303	0.502	rs11768500	chr7:3396320	A/G	cg21248987	chr7:3385318	SDK1	-0.4	-4.97	-0.45	3e-6	Dupuytren's disease;
THYM	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg14779329	chr11:130786720	SNX19	0.5	5.0	0.46	2.62e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs11121246	0.518	rs12135416	chr1:8910347	A/G	cg06972019	chr1:8937448	ENO1	-0.64	-5.43	-0.49	4.25e-7	Plateletcrit;
THYM	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.81	-8.07	-0.64	2.12e-12	Chronic sinus infection;
THYM	cis	rs8008758	0.517	rs1772024	chr14:101695220	A/C	cg26393534	chr14:101700091	NA	0.54	7.06	0.59	2.66e-10	Body mass index (alcohol intake interaction);
THYM	cis	rs17174870	1.000	rs75069292	chr2:112668204	T/C	cg17354880	chr2:112658759	MERTK	-0.59	-4.6	-0.43	1.31e-5	Multiple sclerosis;
THYM	cis	rs7089973	0.872	rs41284358	chr10:116622339	A/G	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.14	-0.47	1.5e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	trans	rs629535	0.821	rs660144	chr8:70035629	T/C	cg21567404	chr3:27674614	NA	1.12	10.86	0.74	2.44e-18	Dupuytren's disease;
THYM	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs1298062	0.790	rs25668	chr19:50965272	T/C	cg11430371	chr19:50961752	MYBPC2	0.46	4.57	0.42	1.48e-5	Age of smoking initiation;
THYM	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs8050907	0.744	rs8058798	chr16:4531659	C/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.45	5.39	0.48	5.08e-7	Obesity-related traits;
THYM	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7113850	0.541	rs74832028	chr11:24232359	A/T	ch.11.24196551F	chr11:24239977	NA	0.92	4.92	0.45	3.58e-6	Bone fracture in osteoporosis;
THYM	cis	rs2073300	0.609	rs6137929	chr20:23376357	G/A	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	10.01	0.72	1.59e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg06713675	chr4:122721982	EXOSC9	-0.51	-4.75	-0.44	7.13e-6	Type 2 diabetes;
THYM	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg08999081	chr20:33150536	PIGU	0.57	4.78	0.44	6.41e-6	Coronary artery disease;
THYM	cis	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg02770061	chr7:158046166	PTPRN2	0.58	4.5	0.42	1.9e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg24818145	chr4:99064322	C4orf37	0.77	6.16	0.53	1.77e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs887829	0.569	rs3806596	chr2:234637707	C/T	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	0.55	4.5	0.42	1.89e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs9649213	0.593	rs7812180	chr7:97969140	A/G	cg07830472	chr7:97983916	BAIAP2L1	0.47	4.6	0.43	1.28e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg25036284	chr2:26402008	FAM59B	-0.8	-5.41	-0.48	4.79e-7	Gut microbiome composition (summer);
THYM	trans	rs4262150	0.883	rs113844564	chr5:152317522	G/A	cg08281791	chr5:76607845	PDE8B	0.94	7.04	0.59	3.01e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs4499344	0.556	rs259231	chr19:33129067	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	1.01	7.43	0.61	4.69e-11	Mean platelet volume;
THYM	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg11905131	chr22:24372483	LOC391322	-0.78	-6.17	-0.53	1.68e-8	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs1062746	0.738	rs2303764	chr16:87377455	C/G	cg27365499	chr16:87376795	FBXO31	-0.58	-6.24	-0.54	1.23e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs12220238	1.000	rs4320897	chr10:76017732	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.86	4.65	0.43	1.08e-5	Soluble interleukin-2 receptor subunit alpha;
THYM	cis	rs11645898	0.683	rs72787038	chr16:72066102	A/C	cg03805757	chr16:71968109	PKD1L3	-0.6	-4.5	-0.42	1.9e-5	Blood protein levels;
THYM	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg12923728	chr3:195709715	SDHAP1	-0.7	-5.68	-0.5	1.44e-7	Pancreatic cancer;
THYM	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg23332699	chr15:44069569	ELL3	0.75	4.45	0.42	2.36e-5	Lung cancer in ever smokers;
THYM	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg17143192	chr8:8559678	CLDN23	-0.63	-4.79	-0.44	6.02e-6	Mood instability;
THYM	cis	rs6835098	1.000	rs10031414	chr4:174084953	A/C	cg08422745	chr4:174089978	GALNT7	-1.0	-8.54	-0.66	2.21e-13	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs67981189	0.529	rs2526857	chr14:71412626	A/G	cg15910301	chr14:71632612	NA	-0.56	-4.88	-0.45	4.23e-6	Schizophrenia;
THYM	cis	rs7412746	0.621	rs72704656	chr1:150828307	A/G	cg15448220	chr1:150897856	SETDB1	0.88	7.45	0.61	4.26e-11	Melanoma;
THYM	cis	rs9297145	0.958	rs11975761	chr7:98766688	G/A	cg05967295	chr7:98741636	SMURF1	-0.99	-9.16	-0.69	1.01e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs295137	0.836	rs1217456	chr2:201092279	C/T	cg23649088	chr2:200775458	C2orf69	0.63	5.5	0.49	3.27e-7	Asthma (bronchodilator response);
THYM	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg23682913	chr1:2080710	PRKCZ	0.57	4.91	0.45	3.79e-6	Height;
THYM	cis	rs4343996	0.640	rs1546743	chr7:3456218	A/G	cg21248987	chr7:3385318	SDK1	0.38	4.62	0.43	1.22e-5	Motion sickness;
THYM	cis	rs490234	0.812	rs626208	chr9:128428267	A/G	cg14078157	chr9:128172775	NA	0.64	4.85	0.45	4.75e-6	Mean arterial pressure;
THYM	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg16387850	chr1:46982889	NA	-0.45	-5.61	-0.5	2e-7	Monobrow;
THYM	cis	rs8038465	0.624	rs2127015	chr15:73985223	T/C	cg15420318	chr15:73925796	NPTN	0.65	5.35	0.48	5.99e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	trans	rs8073060	0.586	rs4796098	chr17:33913436	T/C	cg19694781	chr19:47549865	TMEM160	1.01	8.58	0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg02569458	chr12:86230093	RASSF9	-0.56	-4.82	-0.44	5.35e-6	Major depressive disorder;
THYM	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg07570687	chr10:102243282	WNT8B	0.76	6.93	0.58	5.03e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs791888	0.667	rs2762520	chr10:89414845	A/G	cg13926569	chr10:89418898	PAPSS2	-0.57	-5.69	-0.5	1.38e-7	Magnesium levels;
THYM	cis	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs11039798	0.557	rs683180	chr11:48463949	A/G	cg24672777	chr11:48374446	OR4C45	0.97	6.24	0.54	1.22e-8	Axial length;
THYM	cis	rs12765878	0.812	rs10786776	chr10:105662994	A/G	cg11005552	chr10:105648138	OBFC1	-0.62	-5.93	-0.52	4.78e-8	Coronary artery disease;
THYM	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs9470366	0.545	rs4711457	chr6:36633160	T/C	cg08179530	chr6:36648295	CDKN1A	-0.61	-4.5	-0.42	1.9e-5	QRS duration;
THYM	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg19016782	chr12:123741754	C12orf65	-0.7	-4.59	-0.43	1.35e-5	Neutrophil percentage of white cells;
THYM	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg08975724	chr8:8085496	FLJ10661	0.65	4.99	0.46	2.69e-6	Mood instability;
THYM	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg00376283	chr12:123451042	ABCB9	-0.68	-5.22	-0.47	1.04e-6	Neutrophil percentage of white cells;
THYM	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg07061783	chr6:25882402	NA	-0.89	-8.0	-0.63	3.07e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4606347	0.789	rs77074159	chr1:66162685	C/G	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9583531	0.574	rs61971615	chr13:111353111	C/T	cg24331049	chr13:111365604	ING1	-0.72	-6.03	-0.53	3.15e-8	Coronary artery disease;
THYM	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg22875332	chr1:76189707	ACADM	0.9	10.62	0.74	7.94e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs7584330	0.518	rs74970394	chr2:238443483	C/T	cg08992911	chr2:238395768	MLPH	1.16	5.98	0.52	3.88e-8	Prostate cancer;
THYM	cis	rs2219968	0.962	rs9643734	chr8:78950552	C/T	cg00738934	chr8:78996279	NA	0.8	8.43	0.65	3.79e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg06789500	chr7:2109450	MAD1L1	-0.69	-4.74	-0.44	7.53e-6	Bipolar disorder;
THYM	cis	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg09307838	chr4:120376055	NA	0.66	5.27	0.48	8.35e-7	Corneal astigmatism;
THYM	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg11764359	chr7:65958608	NA	0.82	6.56	0.56	2.81e-9	Aortic root size;
THYM	cis	rs4732038	0.526	rs706192	chr7:134270195	G/A	cg06906464	chr7:134288099	NA	-0.46	-4.61	-0.43	1.26e-5	Longevity;
THYM	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs12257961	0.549	rs56276505	chr10:15382499	G/A	cg10616319	chr10:15468812	NA	0.61	5.14	0.47	1.48e-6	Selective IgA deficiency;
THYM	cis	rs7107174	1.000	rs2510045	chr11:77920563	G/T	cg19901956	chr11:77921274	USP35	-0.72	-5.77	-0.51	1.01e-7	Testicular germ cell tumor;
THYM	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs9649465	1.000	rs1468656	chr7:123375505	G/C	cg15443791	chr7:124364398	NA	0.58	4.81	0.44	5.62e-6	Migraine;
THYM	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg27398817	chr8:82754497	SNX16	-0.83	-6.43	-0.55	5.11e-9	Diastolic blood pressure;
THYM	cis	rs11039798	1.000	rs6485908	chr11:48652198	C/T	cg24672777	chr11:48374446	OR4C45	1.1	6.54	0.56	3.01e-9	Axial length;
THYM	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg00981070	chr1:2046702	PRKCZ	-0.46	-5.66	-0.5	1.57e-7	Height;
THYM	cis	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs112990264	0.568	rs3006239	chr1:212985840	A/G	cg01785514	chr1:212988523	TATDN3	-1.04	-5.5	-0.49	3.2e-7	Itch intensity from mosquito bite;
THYM	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9972944	0.702	rs6416947	chr17:63763970	C/A	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs4888262	0.545	rs4072450	chr16:74666634	G/C	cg01733217	chr16:74700730	RFWD3	0.87	8.98	0.68	2.45e-14	Testicular germ cell tumor;
THYM	cis	rs17445774	0.857	rs6435043	chr2:200900974	C/G	cg23649088	chr2:200775458	C2orf69	0.79	6.91	0.58	5.52e-10	LDL cholesterol to HDL cholesterol ratio;
THYM	cis	rs8067545	1.000	rs3909258	chr17:19945819	C/G	cg20830565	chr17:20408647	MGC102966	-0.48	-4.46	-0.42	2.23e-5	Schizophrenia;
THYM	cis	rs6924995	0.501	rs35284971	chr6:16187971	C/T	cg11805552	chr6:16175128	NA	0.55	4.53	0.42	1.74e-5	Response to statins (LDL cholesterol change);
THYM	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg15691649	chr6:25882328	NA	-0.7	-5.47	-0.49	3.69e-7	Intelligence (multi-trait analysis);
THYM	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.9	0.45	3.92e-6	Body mass index;
THYM	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11671005	0.779	rs731259	chr19:58989424	C/T	cg02808233	chr19:58920810	ZNF584	0.57	4.51	0.42	1.89e-5	Mean platelet volume;
THYM	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25427524	chr10:38739819	LOC399744	-0.66	-6.18	-0.54	1.56e-8	Breast cancer;
THYM	cis	rs72772090	0.539	rs55773007	chr5:96124918	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	11.87	0.77	1.82e-20	Chronic sinus infection;
THYM	cis	rs2237457	0.525	rs2465529	chr7:50705169	G/T	cg08586669	chr7:50727761	GRB10	-0.3	-4.92	-0.45	3.61e-6	Schizophrenia (treatment resistant);
THYM	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg09904177	chr6:26538194	HMGN4	0.64	5.4	0.48	4.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs526231	0.511	rs27896	chr5:102488571	T/C	cg23492399	chr5:102201601	PAM	-0.7	-5.23	-0.47	9.9e-7	Primary biliary cholangitis;
THYM	trans	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6763768	0.565	rs11714096	chr3:53396145	G/C	cg16894138	chr3:53270350	TKT	0.72	5.5	0.49	3.2e-7	Bacterial meningitis;
THYM	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg03161606	chr19:29218774	NA	0.84	6.44	0.55	4.96e-9	Methadone dose in opioid dependence;
THYM	cis	rs4638749	0.677	rs34449318	chr2:108827222	T/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg07636037	chr3:49044803	WDR6	0.96	9.85	0.71	3.43e-16	Parkinson's disease;
THYM	cis	rs1829883	0.898	rs2511899	chr5:98776319	G/A	cg08333243	chr5:99726346	NA	-0.51	-4.89	-0.45	4.12e-6	Hemostatic factors and hematological phenotypes;
THYM	cis	rs7582180	0.627	rs4149517	chr2:101014247	C/A	cg08017756	chr2:100939284	LONRF2	-0.71	-7.28	-0.6	9.68e-11	Intelligence (multi-trait analysis);
THYM	cis	rs2487048	0.725	rs2246293	chr9:107690838	C/G	cg14019050	chr9:107690770	ABCA1	0.71	10.79	0.74	3.4e-18	Intraocular pressure;
THYM	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs9329289	0.510	rs12359941	chr10:2547015	G/A	cg07014206	chr10:2547000	NA	-0.59	-5.3	-0.48	7.52e-7	Age-related hearing impairment;
THYM	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg22105103	chr4:187893119	NA	0.92	10.09	0.72	1.04e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs921968	0.565	rs7594046	chr2:219624170	A/G	cg02176678	chr2:219576539	TTLL4	0.47	4.56	0.42	1.55e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.22e-16	Bone mineral density;
THYM	cis	rs1883415	0.534	rs2817205	chr6:24477134	G/A	cg20631270	chr6:24437470	GPLD1	0.53	4.46	0.42	2.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	trans	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs7512552	0.966	rs1122967	chr1:150258838	C/G	cg15654264	chr1:150340011	RPRD2	-0.49	-5.79	-0.51	9.09e-8	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs11031096	0.679	rs12292515	chr11:4206385	T/G	cg18678763	chr11:4115507	RRM1	-0.4	-4.71	-0.44	8.28e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg25036284	chr2:26402008	FAM59B	-0.78	-5.19	-0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs10227331	1.000	rs11979293	chr7:157293586	C/T	cg04156418	chr7:157293606	NA	0.82	7.39	0.6	5.65e-11	Inattentive symptoms;
THYM	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg24642844	chr7:1081250	C7orf50	-1.31	-8.61	-0.66	1.56e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg12560992	chr17:57184187	TRIM37	-0.9	-8.49	-0.66	2.77e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.16	9.25	0.69	6.59e-15	Cognitive test performance;
THYM	cis	rs13088645	0.652	rs13074557	chr3:134153526	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.62	5.55	0.49	2.58e-7	Coronary artery disease;
THYM	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11890956	chr21:40555474	PSMG1	-0.97	-11.28	-0.76	3.16e-19	Cognitive function;
THYM	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg05717871	chr11:638507	DRD4	-0.66	-4.83	-0.44	5.17e-6	Systemic lupus erythematosus;
THYM	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.64	-0.5	1.73e-7	Menopause (age at onset);
THYM	cis	rs7586879	0.789	rs11688754	chr2:25133885	C/T	cg01884057	chr2:25150051	NA	0.52	4.64	0.43	1.12e-5	Body mass index;
THYM	cis	rs901683	1.000	rs78363416	chr10:46046134	T/G	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10847980	0.590	rs79206681	chr12:123281744	A/T	cg25930673	chr12:123319894	HIP1R	1.12	5.07	0.46	1.98e-6	Adiponectin levels;
THYM	cis	rs2985684	0.894	rs6572585	chr14:50021075	A/G	cg02151108	chr14:50098012	C14orf104	-0.76	-6.28	-0.54	9.96e-9	Carotid intima media thickness;
THYM	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg12564285	chr5:131593104	PDLIM4	0.54	5.6	0.5	2.06e-7	Acylcarnitine levels;
THYM	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg08213375	chr14:104286397	PPP1R13B	0.45	4.74	0.44	7.48e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs61990749	0.597	rs2267759	chr14:78147615	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-1.17	-8.02	-0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg21775007	chr8:11205619	TDH	0.63	5.05	0.46	2.16e-6	Retinal vascular caliber;
THYM	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg06600287	chr1:53387719	ECHDC2	-0.3	-4.98	-0.46	2.82e-6	Monocyte count;
THYM	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.26	-0.47	8.87e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11157436	0.918	rs1983518	chr14:22617290	A/T	cg26433554	chr14:23315189	MMP14	0.44	4.55	0.42	1.57e-5	Neurocognitive impairment in HIV-1 infection (continuous);
THYM	trans	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs11031096	0.711	rs4910890	chr11:4153407	C/T	cg18678763	chr11:4115507	RRM1	-0.47	-6.57	-0.56	2.7e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4455778	0.501	rs35433930	chr7:49059052	T/C	cg26309511	chr7:48887640	NA	0.63	5.5	0.49	3.13e-7	Lung cancer in never smokers;
THYM	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.9	6.1	0.53	2.33e-8	Schizophrenia;
THYM	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg10523679	chr1:76189770	ACADM	0.89	8.55	0.66	2.05e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg25566285	chr7:158114605	PTPRN2	0.87	9.85	0.71	3.44e-16	Calcium levels;
THYM	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9788682	0.747	rs12101809	chr15:78779801	C/T	cg18825076	chr15:78729989	IREB2	0.7	5.57	0.5	2.39e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg10589385	chr1:150898437	SETDB1	0.64	5.23	0.47	1.01e-6	Melanoma;
THYM	cis	rs7586879	0.575	rs6706316	chr2:25128351	C/G	cg27107076	chr2:25050844	ADCY3	-0.29	-4.73	-0.44	7.91e-6	Body mass index;
THYM	cis	rs10751667	1.000	rs4074232	chr11:977682	C/G	cg01483505	chr11:975446	AP2A2	0.69	5.59	0.5	2.14e-7	Alzheimer's disease (late onset);
THYM	cis	rs6840360	1.000	rs9995704	chr4:152619069	C/A	cg22705602	chr4:152727874	NA	-0.6	-6.38	-0.55	6.53e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6918586	0.565	rs13196986	chr6:26090452	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.66	-4.64	-0.43	1.09e-5	Schizophrenia;
THYM	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg10053473	chr17:62856997	LRRC37A3	0.92	7.34	0.6	7.17e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg18538332	chr22:24372958	LOC391322	-0.94	-11.36	-0.76	2.12e-19	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg02070205	chr10:30722105	MAP3K8	0.68	6.15	0.53	1.79e-8	Inflammatory bowel disease;
THYM	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg02353165	chr6:42928485	GNMT	0.76	5.5	0.49	3.14e-7	Blood protein levels;
THYM	cis	rs6988636	1.000	rs16898095	chr8:124193523	T/C	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs831571	0.519	rs13059603	chr3:63827381	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.75	5.54	0.49	2.68e-7	Type 2 diabetes;
THYM	cis	rs78456975	0.941	rs28913033	chr2:1523194	T/C	cg14129053	chr2:1895732	MYT1L	1.18	4.47	0.42	2.2e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs7084921	0.552	rs2862990	chr10:101876364	A/G	cg11344164	chr10:101878520	NA	0.59	5.69	0.5	1.4e-7	Bone mineral density;
THYM	cis	rs7177699	0.550	rs7182716	chr15:79123753	T/C	cg00540400	chr15:79124168	NA	0.65	7.03	0.58	3.16e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs6430585	0.528	rs309166	chr2:136667487	C/T	cg23851026	chr2:136556271	LCT	0.67	6.53	0.56	3.16e-9	Corneal structure;
THYM	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4654899	0.643	rs589755	chr1:21099846	A/G	cg01072550	chr1:21505969	NA	-0.62	-5.7	-0.5	1.36e-7	Superior frontal gyrus grey matter volume;
THYM	trans	rs4866334	1.000	rs78447918	chr5:18488634	T/A	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs7119	0.604	rs2682927	chr15:77859168	C/T	cg10437265	chr15:77819839	NA	-0.65	-6.5	-0.55	3.72e-9	Type 2 diabetes;
THYM	cis	rs11096990	0.613	rs12505690	chr4:39169045	G/A	cg24403649	chr4:39172243	NA	0.57	4.94	0.45	3.29e-6	Cognitive function;
THYM	cis	rs3892630	1.000	rs3892630	chr19:33181484	A/G	cg02283691	chr19:33182526	NUDT19	0.43	5.37	0.48	5.51e-7	Red blood cell traits;
THYM	cis	rs1198430	0.683	rs534417	chr1:23784965	A/G	cg01095837	chr1:23763767	ASAP3	0.75	4.59	0.43	1.34e-5	Total cholesterol levels;
THYM	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg26597838	chr10:835615	NA	1.17	8.47	0.66	3.07e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2898681	0.614	rs4864680	chr4:53708421	T/G	cg00338735	chr4:53728038	RASL11B	0.6	5.54	0.49	2.69e-7	Optic nerve measurement (cup area);
THYM	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-5.55	-0.49	2.58e-7	Monocyte percentage of white cells;
THYM	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6570726	0.905	rs375692	chr6:145840368	A/G	cg23711669	chr6:146136114	FBXO30	0.82	7.84	0.63	6.69e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs236907	0.859	rs1045456	chr1:171766564	A/G	cg20598894	chr1:171756153	METTL13	0.73	5.69	0.5	1.42e-7	Mean platelet volume;
THYM	cis	rs6748734	0.857	rs4675857	chr2:241842326	T/C	cg09990169	chr2:241835740	C2orf54	-0.36	-5.85	-0.51	6.97e-8	Urinary metabolites;
THYM	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg08305652	chr11:111469057	NA	-0.53	-4.57	-0.42	1.49e-5	Primary sclerosing cholangitis;
THYM	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg06634786	chr22:41940651	POLR3H	0.73	5.33	0.48	6.69e-7	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs981844	0.753	rs62325149	chr4:154728006	G/C	cg22178613	chr4:154710499	SFRP2	-0.59	-4.93	-0.45	3.48e-6	Response to statins (LDL cholesterol change);
THYM	trans	rs629535	0.814	rs604254	chr8:70059164	A/G	cg21567404	chr3:27674614	NA	1.09	10.87	0.74	2.35e-18	Dupuytren's disease;
THYM	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02788857	chr8:22132959	PIWIL2	0.58	5.36	0.48	5.94e-7	Hypertriglyceridemia;
THYM	cis	rs6032067	0.929	rs17424668	chr20:43809647	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	0.71	6.68	0.57	1.6e-9	Blood protein levels;
THYM	cis	rs7106204	0.514	rs11027789	chr11:24260906	T/C	ch.11.24196551F	chr11:24239977	NA	0.99	7.06	0.59	2.66e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg11366901	chr6:160182831	ACAT2	1.09	10.12	0.72	9.06e-17	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg23730037	chr7:158596552	ESYT2	-0.52	-5.27	-0.48	8.56e-7	Height;
THYM	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg18252515	chr7:66147081	NA	0.64	4.69	0.43	9.21e-6	Aortic root size;
THYM	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg01819759	chr13:79234251	RNF219	0.91	6.57	0.56	2.66e-9	Large artery stroke;
THYM	cis	rs4509693	1.000	rs4509693	chr10:102501571	C/T	cg15234845	chr10:102496500	NA	0.67	4.71	0.44	8.29e-6	Alzheimer's disease;
THYM	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg13010199	chr12:38710504	ALG10B	0.72	5.01	0.46	2.54e-6	Heart rate;
THYM	cis	rs11608355	1.000	rs930356	chr12:109852372	T/C	cg11367159	chr12:110044531	NA	0.65	6.26	0.54	1.09e-8	Neuroticism;
THYM	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06873352	chr17:61820015	STRADA	0.56	5.66	0.5	1.63e-7	Height;
THYM	cis	rs1385374	1.000	rs12311303	chr12:129301592	C/T	cg04043695	chr12:129287642	SLC15A4	-0.8	-4.83	-0.44	5.3e-6	Systemic lupus erythematosus;
THYM	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg19507638	chr5:93509721	C5orf36	-0.66	-4.69	-0.43	9.14e-6	Diabetic retinopathy;
THYM	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9875589	0.509	rs6778884	chr3:14044681	A/G	cg03204825	chr3:13978759	TPRXL	-0.56	-4.95	-0.45	3.23e-6	Ovarian reserve;
THYM	cis	rs7729447	0.566	rs3792765	chr5:32713836	A/G	cg14311471	chr5:32711095	NPR3	0.58	4.79	0.44	6.08e-6	Blood pressure;
THYM	cis	rs7010267	0.596	rs7010043	chr8:120011331	G/T	cg17171407	chr8:119960777	TNFRSF11B	0.62	4.96	0.45	3.05e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.06	9.59	0.7	1.27e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6546324	0.625	rs11126138	chr2:67794476	C/T	cg18237512	chr2:67827392	NA	-0.78	-4.57	-0.42	1.47e-5	Endometriosis;
THYM	cis	rs2425143	0.598	rs2425118	chr20:34324098	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Blood protein levels;
THYM	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2692947	0.655	rs4605406	chr2:96583735	A/C	cg23100626	chr2:96804247	ASTL	0.42	5.29	0.48	7.81e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg10560079	chr2:191398806	TMEM194B	-0.94	-7.79	-0.62	8.48e-12	Diastolic blood pressure;
THYM	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11644478	chr21:40555479	PSMG1	-0.76	-6.51	-0.56	3.49e-9	Cognitive function;
THYM	cis	rs7626444	0.625	rs2686595	chr3:196475142	G/C	cg12930392	chr3:196481615	PAK2	0.43	5.31	0.48	7.26e-7	Monocyte count;
THYM	cis	rs4746818	1.000	rs7893492	chr10:70960448	C/T	cg11621586	chr10:70884670	VPS26A	-1.17	-7.32	-0.6	8.04e-11	Left atrial antero-posterior diameter;
THYM	cis	rs4148883	0.675	rs11724783	chr4:100099688	C/A	cg12011299	chr4:100065546	ADH4	0.66	5.65	0.5	1.65e-7	Alcohol dependence;
THYM	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.75	6.48	0.55	4.04e-9	Hip circumference adjusted for BMI;
THYM	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-8.31	-0.65	6.7e-13	Coronary artery disease;
THYM	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg05368731	chr17:41323189	NBR1	1.21	11.02	0.75	1.14e-18	Menopause (age at onset);
THYM	cis	rs3806843	0.838	rs2337514	chr5:140132732	T/C	cg19875535	chr5:140030758	IK	-0.58	-4.52	-0.42	1.76e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg19774624	chr17:42201019	HDAC5	0.69	5.49	0.49	3.39e-7	Total body bone mineral density;
THYM	cis	rs28595532	0.920	rs114938162	chr4:119756407	T/G	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg10803722	chr21:46713166	LOC642852	-0.42	-5.3	-0.48	7.59e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9500256	0.967	rs1012500	chr6:58304669	G/A	cg16251399	chr6:58287822	GUSBL2	0.68	5.72	0.51	1.22e-7	Eosinophilic esophagitis (pediatric);
THYM	cis	rs2797685	0.945	rs1773138	chr1:7891797	C/T	cg06712362	chr1:7811235	CAMTA1	0.68	4.96	0.45	3.09e-6	Crohn's disease;
THYM	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs2286885	1.000	rs10760438	chr9:129245334	C/A	cg14294646	chr9:129243551	FAM125B	-0.61	-5.44	-0.49	4.19e-7	Intraocular pressure;
THYM	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg03474202	chr17:45855739	NA	-0.74	-6.5	-0.55	3.7e-9	IgG glycosylation;
THYM	cis	rs17102423	0.623	rs4902368	chr14:65612048	A/G	cg11161011	chr14:65562177	MAX	0.57	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg13289132	chr10:30722225	MAP3K8	-0.57	-4.82	-0.44	5.38e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg24060327	chr5:131705240	SLC22A5	-0.82	-6.73	-0.57	1.29e-9	Breast cancer;
THYM	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs35934224	0.783	rs7289343	chr22:19860990	G/T	cg11182965	chr22:19864308	TXNRD2	-0.75	-6.23	-0.54	1.3e-8	Glaucoma (primary open-angle);
THYM	cis	rs818427	0.783	rs153568	chr5:112289001	T/G	cg00577935	chr5:112073348	APC	0.69	4.49	0.42	2.04e-5	Total body bone mineral density;
THYM	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06850241	chr22:41845214	NA	-0.54	-4.68	-0.43	9.37e-6	Vitiligo;
THYM	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg24399712	chr22:39784796	NA	-0.88	-9.32	-0.69	4.8e-15	Intelligence (multi-trait analysis);
THYM	cis	rs1371867	0.817	rs1788179	chr8:101333345	A/G	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs2816062	0.775	rs2816048	chr1:18893763	T/C	cg18795169	chr1:18902165	NA	-0.99	-12.12	-0.78	5.39e-21	Urate levels in lean individuals;
THYM	cis	rs2120991	0.967	rs7305034	chr12:54262854	T/A	cg25550629	chr12:53546895	NA	0.47	4.45	0.42	2.31e-5	Biliary atresia;
THYM	cis	rs7107174	1.000	rs2450123	chr11:77952771	T/C	cg19901956	chr11:77921274	USP35	-0.83	-6.02	-0.53	3.28e-8	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.26	-5.09	-0.46	1.83e-6	Obesity-related traits;
THYM	cis	rs478304	0.934	rs537786	chr11:65494987	C/T	cg27068330	chr11:65405492	SIPA1	0.86	8.3	0.65	7.03e-13	Acne (severe);
THYM	cis	rs5417	0.761	rs6503010	chr17:7180435	C/T	cg14660024	chr17:7154518	C17orf81;DULLARD	0.78	6.18	0.54	1.59e-8	Diastolic blood pressure;
THYM	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg08885076	chr2:99613938	TSGA10	0.62	5.67	0.5	1.5e-7	Chronic sinus infection;
THYM	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.76	-5.52	-0.49	2.97e-7	Body mass index;
THYM	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg15592062	chr6:167189543	RPS6KA2	-0.58	-5.88	-0.52	6.01e-8	Crohn's disease;
THYM	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.92	0.45	3.58e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2806561	1.000	rs1571466	chr1:23449183	T/C	cg12483005	chr1:23474871	LUZP1	0.55	5.63	0.5	1.83e-7	Height;
THYM	cis	rs3960554	0.867	rs10239209	chr7:75804085	G/A	cg17325771	chr7:75508891	RHBDD2	-0.4	-4.48	-0.42	2.1e-5	Eotaxin levels;
THYM	cis	rs2455799	0.613	rs13080234	chr3:15852492	C/T	cg16303742	chr3:15540471	COLQ	-0.56	-5.88	-0.52	6.13e-8	Mean platelet volume;
THYM	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.02	-0.46	2.42e-6	Blood metabolite levels;
THYM	cis	rs12586317	0.620	rs17091786	chr14:35565856	A/T	cg05294307	chr14:35346193	BAZ1A	-0.82	-5.51	-0.49	3.06e-7	Psoriasis;
THYM	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg12311346	chr5:56204834	C5orf35	-0.94	-5.44	-0.49	4.07e-7	Type 2 diabetes;
THYM	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg12756686	chr19:29218302	NA	0.95	7.63	0.62	1.82e-11	Methadone dose in opioid dependence;
THYM	cis	rs924712	0.572	rs6922968	chr6:54707264	T/C	cg19716238	chr6:54711378	FAM83B	-0.48	-4.51	-0.42	1.83e-5	Breast cancer;
THYM	cis	rs778371	0.697	rs62193269	chr2:233560303	A/T	cg08000102	chr2:233561755	GIGYF2	0.84	7.55	0.61	2.64e-11	Schizophrenia;
THYM	cis	rs3741151	0.773	rs73548693	chr11:73286637	G/A	cg12959048	chr11:73096162	RELT	-0.52	-4.58	-0.43	1.43e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs75059851	0.756	rs11223651	chr11:133841034	A/G	cg14047540	chr11:133829660	NA	1.05	6.89	0.58	5.96e-10	Schizophrenia;
THYM	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg17863274	chr19:49399704	TULP2	-0.76	-4.54	-0.42	1.62e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg09021430	chr5:549028	NA	-0.74	-5.53	-0.49	2.78e-7	Obesity-related traits;
THYM	cis	rs7589728	0.563	rs79892776	chr2:88470593	G/A	cg04511125	chr2:88470314	THNSL2	0.66	4.62	0.43	1.21e-5	Plasma clusterin levels;
THYM	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg06582575	chr6:163149167	PACRG;PARK2	1.08	7.64	0.62	1.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs800586	0.868	rs4876612	chr8:116699039	C/T	cg04656070	chr8:116661063	TRPS1	-0.51	-4.76	-0.44	6.9e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs919433	0.519	rs700658	chr2:198655007	A/T	cg05783139	chr2:198650985	BOLL	0.64	5.04	0.46	2.18e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg24692254	chr21:30365293	RNF160	-0.99	-8.66	-0.66	1.23e-13	Dental caries;
THYM	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	7.46	0.61	4.05e-11	Platelet count;
THYM	cis	rs7586879	0.593	rs10198275	chr2:25130542	A/C	cg15423357	chr2:25149977	NA	0.7	7.76	0.62	9.56e-12	Body mass index;
THYM	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg12016809	chr21:47604291	C21orf56	-0.66	-4.83	-0.44	5.24e-6	Testicular germ cell tumor;
THYM	cis	rs61931739	0.817	rs1687002	chr12:34170263	T/C	cg06521331	chr12:34319734	NA	-0.61	-5.02	-0.46	2.45e-6	Morning vs. evening chronotype;
THYM	cis	rs67460515	0.563	rs1585481	chr3:160901481	C/T	cg03342759	chr3:160939853	NMD3	-0.68	-5.11	-0.46	1.64e-6	Parkinson's disease;
THYM	cis	rs1729951	0.575	rs1654926	chr3:136709924	G/A	cg21827317	chr3:136751795	NA	0.73	6.67	0.56	1.7e-9	Neuroticism;
THYM	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg07537917	chr2:241836409	C2orf54	0.26	6.01	0.52	3.45e-8	Urinary metabolites;
THYM	cis	rs4891159	0.790	rs72975930	chr18:74144645	G/A	cg24786174	chr18:74118243	ZNF516	-0.87	-9.72	-0.71	6.43e-16	Longevity;
THYM	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg00898013	chr13:113819073	PROZ	-0.88	-9.0	-0.68	2.24e-14	Platelet distribution width;
THYM	cis	rs4751006	0.543	rs61875505	chr10:128774635	A/G	cg05702161	chr10:128779687	DOCK1	-0.81	-4.45	-0.42	2.34e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg00383909	chr3:49044727	WDR6	1.13	6.67	0.56	1.72e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs2334880	0.680	rs1364210	chr16:71603487	G/A	cg06353428	chr16:71660113	MARVELD3	-1.44	-8.01	-0.64	2.84e-12	Malaria;
THYM	cis	rs9790314	0.663	rs778648	chr3:160708943	A/G	cg04691961	chr3:161091175	C3orf57	-0.56	-4.49	-0.42	2.01e-5	Morning vs. evening chronotype;
THYM	cis	rs4722166	0.603	rs7801406	chr7:22788274	A/G	cg13104385	chr7:22767384	IL6	0.55	4.61	0.43	1.26e-5	Lung cancer;
THYM	cis	rs7078219	0.714	rs10883368	chr10:101289998	A/G	cg17888390	chr10:101282816	NA	-0.56	-5.49	-0.49	3.4e-7	Dental caries;
THYM	cis	rs2340727	0.524	rs6693980	chr1:161943202	A/G	ch.1.159725313R	chr1:161458689	NA	0.78	5.36	0.48	5.9e-7	White blood cell count;Hematology traits;
THYM	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg06481639	chr22:41940642	POLR3H	0.77	5.57	0.5	2.34e-7	Vitiligo;
THYM	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.66	8.98	0.68	2.54e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2688608	0.592	rs12253429	chr10:75496161	C/G	cg23231163	chr10:75533350	FUT11	-0.41	-5.9	-0.52	5.54e-8	Inflammatory bowel disease;
THYM	cis	rs12754538	0.665	rs12037534	chr1:8649924	G/A	cg06159269	chr1:8767347	RERE	0.23	4.69	0.43	9.01e-6	Subjective well-being;
THYM	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg21385522	chr1:16154831	NA	-0.94	-6.85	-0.57	7.39e-10	Dilated cardiomyopathy;
THYM	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg13683864	chr3:40499215	RPL14	-1.02	-10.56	-0.73	1.06e-17	Renal cell carcinoma;
THYM	cis	rs554111	0.613	rs3816455	chr1:21191430	A/G	cg00373020	chr1:21041521	KIF17	-0.53	-4.55	-0.42	1.59e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg09260853	chr1:2094483	PRKCZ	-0.44	-4.6	-0.43	1.31e-5	Height;
THYM	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.06	9.34	0.69	4.26e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg12311346	chr5:56204834	C5orf35	-0.61	-4.67	-0.43	9.99e-6	Initial pursuit acceleration;
THYM	cis	rs3087591	0.960	rs2071009	chr17:29558082	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.6	-5.11	-0.46	1.65e-6	Hip circumference;
THYM	cis	rs400736	0.930	rs226249	chr1:8021778	A/G	cg22678073	chr1:8087421	ERRFI1	0.43	4.59	0.43	1.35e-5	Response to antidepressants and depression;
THYM	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.77	7.59	0.61	2.14e-11	Lymphocyte counts;
THYM	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg20295408	chr7:1910781	MAD1L1	-0.68	-5.09	-0.46	1.78e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg06634786	chr22:41940651	POLR3H	-0.72	-5.59	-0.5	2.16e-7	Vitiligo;
THYM	cis	rs2811415	0.597	rs12695504	chr3:127791388	C/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg17294928	chr15:75287854	SCAMP5	-0.94	-7.94	-0.63	4.01e-12	Blood trace element (Zn levels);
THYM	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg17264618	chr3:40429014	ENTPD3	0.53	5.06	0.46	2.05e-6	Renal cell carcinoma;
THYM	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.67	5.22	0.47	1.06e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11096990	0.855	rs2566170	chr4:39152377	T/A	cg24403649	chr4:39172243	NA	-0.65	-5.53	-0.49	2.82e-7	Cognitive function;
THYM	cis	rs6032067	0.850	rs4566421	chr20:43783761	G/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-4.78	-0.44	6.4e-6	Blood protein levels;
THYM	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg02640540	chr1:67518911	SLC35D1	-0.65	-4.78	-0.44	6.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg24399712	chr22:39784796	NA	-0.87	-7.85	-0.63	6.2e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs1348850	0.757	rs4893954	chr2:178340520	T/G	cg27490568	chr2:178487706	NA	0.61	5.49	0.49	3.38e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs3796352	1.000	rs71301804	chr3:53073314	C/A	cg24530246	chr3:53118167	NA	-0.76	-4.57	-0.42	1.47e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg23281280	chr6:28129359	ZNF389	0.61	4.74	0.44	7.58e-6	Parkinson's disease;
THYM	cis	rs10899021	0.920	rs11236172	chr11:74330888	G/A	cg25880958	chr11:74394337	NA	-0.77	-4.66	-0.43	1.04e-5	Response to metformin (IC50);
THYM	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg27534772	chr1:16042836	PLEKHM2	0.54	5.92	0.52	5.1e-8	Systolic blood pressure;
THYM	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg14458575	chr2:238380390	NA	1.13	8.48	0.66	2.87e-13	Prostate cancer;
THYM	cis	rs17407555	0.683	rs4697999	chr4:10274934	C/G	cg00071950	chr4:10020882	SLC2A9	0.53	4.82	0.44	5.48e-6	Schizophrenia (age at onset);
THYM	trans	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg26384229	chr12:38710491	ALG10B	0.89	6.9	0.58	5.73e-10	Morning vs. evening chronotype;
THYM	cis	rs9788682	0.747	rs2938671	chr15:78732754	A/G	cg18825076	chr15:78729989	IREB2	-0.68	-5.27	-0.48	8.6e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs131777	0.532	rs131747	chr22:51025074	C/T	cg00083937	chr22:51039805	MAPK8IP2	0.56	4.99	0.46	2.7e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7119	0.717	rs12901732	chr15:77818933	G/T	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs6700896	0.931	rs10789192	chr1:66125770	G/A	cg04111102	chr1:66153794	NA	0.56	5.27	0.48	8.45e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs34779708	0.966	rs4934725	chr10:35398236	T/C	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg02527881	chr3:46936655	PTH1R	-0.59	-5.87	-0.52	6.4e-8	Colorectal cancer;
THYM	cis	rs2235573	0.868	rs6001003	chr22:38499932	G/A	cg19171272	chr22:38449367	NA	0.46	4.54	0.42	1.65e-5	Glioblastoma;Glioma;
THYM	cis	rs686320	1.000	rs72643572	chr11:65250967	A/G	cg23743554	chr11:65321226	LTBP3	0.77	4.46	0.42	2.25e-5	Hip circumference adjusted for BMI;
THYM	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg10515332	chr4:99064459	C4orf37	0.6	4.75	0.44	7.27e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs3804749	0.966	rs920900	chr3:122845671	C/G	cg10259872	chr3:122802215	PDIA5	-0.49	-5.46	-0.49	3.85e-7	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg00717180	chr2:96193071	NA	-0.71	-7.41	-0.61	5.21e-11	Coronary artery disease;
THYM	cis	rs9814567	1.000	rs9289478	chr3:134268619	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-8.41	-0.65	4e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7089973	0.872	rs3180654	chr10:116615045	T/C	cg08188268	chr10:116634841	FAM160B1	-0.3	-4.93	-0.45	3.54e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs79387448	0.655	rs17639215	chr2:102953444	G/A	cg09003973	chr2:102972529	NA	1.27	6.33	0.54	7.93e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg18305652	chr10:134549665	INPP5A	0.83	7.51	0.61	3.24e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg15536230	chr21:44985092	HSF2BP	0.4	4.75	0.44	7.13e-6	Mean corpuscular volume;
THYM	cis	rs3126085	0.935	rs12027807	chr1:152253726	C/G	cg26020982	chr1:152196106	HRNR	0.35	4.95	0.45	3.26e-6	Atopic dermatitis;
THYM	cis	rs9788721	0.934	rs1051730	chr15:78894339	G/A	cg04882995	chr15:78912658	CHRNA3	0.55	4.72	0.44	7.96e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg03806693	chr22:41940476	POLR3H	-0.95	-7.84	-0.63	6.61e-12	Vitiligo;
THYM	cis	rs7216064	1.000	rs58551145	chr17:65837235	A/G	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg09021430	chr5:549028	NA	-0.72	-5.32	-0.48	6.89e-7	Lung disease severity in cystic fibrosis;
THYM	cis	rs7731657	0.537	rs2189509	chr5:130316093	A/G	cg08523029	chr5:130500466	HINT1	-0.84	-6.14	-0.53	1.87e-8	Fasting plasma glucose;
THYM	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg05738196	chr6:26577821	NA	0.81	8.1	0.64	1.86e-12	Intelligence (multi-trait analysis);
THYM	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg10862848	chr6:42927986	GNMT	-0.52	-7.06	-0.59	2.68e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs3820068	0.608	rs6668919	chr1:16049893	A/G	cg13390004	chr1:15929781	NA	-0.65	-4.93	-0.45	3.54e-6	Systolic blood pressure;
THYM	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.68	-4.95	-0.45	3.23e-6	Tonsillectomy;
THYM	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs6542838	0.641	rs6724477	chr2:99537074	A/C	cg08885076	chr2:99613938	TSGA10	0.48	4.74	0.44	7.38e-6	Fear of minor pain;
THYM	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg02551604	chr5:131831745	NA	-0.78	-5.88	-0.52	5.99e-8	Asthma (sex interaction);
THYM	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg08999081	chr20:33150536	PIGU	-0.57	-5.09	-0.46	1.8e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs2901656	0.934	rs2285176	chr1:172421744	G/A	cg03748243	chr1:172413542	C1orf105;PIGC	0.53	5.53	0.49	2.84e-7	Red cell distribution width;Platelet distribution width;
THYM	cis	rs9534288	0.742	rs1022953	chr13:46649126	G/T	cg15192986	chr13:46630673	CPB2	-0.65	-4.59	-0.43	1.36e-5	Blood protein levels;
THYM	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs7192750	0.538	rs4788582	chr16:71981806	A/G	cg06353428	chr16:71660113	MARVELD3	0.77	5.72	0.51	1.21e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs6586111	1.000	rs7086576	chr10:82372145	C/G	cg03086067	chr10:82368399	SH2D4B	-0.51	-6.5	-0.56	3.64e-9	Capecitabine sensitivity;
THYM	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg05283184	chr6:79620031	NA	-0.91	-8.88	-0.67	4.11e-14	Intelligence (multi-trait analysis);
THYM	cis	rs9807989	0.507	rs1592458	chr2:103031749	A/T	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg26446133	chr18:72167187	CNDP2	-1.02	-7.49	-0.61	3.5e-11	Refractive error;
THYM	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg27034606	chr17:28928453	LRRC37B2	0.76	5.06	0.46	2.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg11245990	chr11:68621969	NA	0.58	7.58	0.61	2.33e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6901250	0.851	rs339360	chr6:117160872	G/T	cg12892004	chr6:117198278	RFX6	-0.71	-6.97	-0.58	4.22e-10	C-reactive protein levels;
THYM	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg24503407	chr1:205819492	PM20D1	0.96	9.18	0.69	9.34e-15	Menarche (age at onset);
THYM	cis	rs9399401	0.633	rs1329705	chr6:142753338	G/A	cg03128060	chr6:142623767	GPR126	0.64	8.08	0.64	2.04e-12	Chronic obstructive pulmonary disease;
THYM	cis	rs4072705	0.967	rs4838208	chr9:127528035	C/A	cg01786973	chr9:127249749	NR5A1	0.37	4.95	0.45	3.25e-6	Menarche (age at onset);
THYM	cis	rs2075230	0.850	rs60920983	chr17:7478962	A/G	cg16696476	chr17:8191344	RANGRF;SLC25A35	0.29	4.64	0.43	1.09e-5	Hormone measurements;
THYM	cis	rs4851266	0.898	rs13026143	chr2:100865406	A/G	cg14675211	chr2:100938903	LONRF2	-0.66	-5.48	-0.49	3.51e-7	Educational attainment;
THYM	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	7.53	0.61	2.89e-11	Chronic sinus infection;
THYM	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg04607235	chr12:12878440	APOLD1	-0.91	-5.43	-0.49	4.36e-7	Systemic lupus erythematosus;
THYM	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg07061783	chr6:25882402	NA	-1.03	-9.84	-0.71	3.58e-16	Urate levels;
THYM	cis	rs6866344	0.570	rs1132338	chr5:178139442	T/G	cg03877680	chr5:178157825	ZNF354A	0.66	4.55	0.42	1.58e-5	Neutrophil percentage of white cells;
THYM	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg02896835	chr1:92012615	NA	-0.65	-5.88	-0.52	6.18e-8	Breast cancer;
THYM	cis	rs6009824	0.836	rs6009821	chr22:50085697	C/T	cg18178197	chr22:50098317	NA	0.85	6.67	0.56	1.68e-9	Natriuretic peptide levels;
THYM	cis	rs4845459	0.967	rs4845447	chr1:152590886	T/C	cg27206522	chr1:152595629	LCE3A	-0.51	-4.54	-0.42	1.66e-5	Psoriasis;
THYM	cis	rs7255045	0.742	rs6511840	chr19:12954720	C/T	cg26870725	chr19:12978805	MAST1	-0.63	-4.77	-0.44	6.59e-6	Mean corpuscular volume;
THYM	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	trans	rs11109072	1.000	rs11109082	chr12:97908024	A/G	cg17633015	chr7:2020501	MAD1L1	1.0	7.4	0.6	5.45e-11	Obesity (early onset extreme);
THYM	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg19875535	chr5:140030758	IK	-0.64	-5.57	-0.5	2.37e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs9814567	1.000	rs1874883	chr3:134205071	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.85	-8.7	-0.67	9.74e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg05962950	chr11:130786565	SNX19	0.84	7.29	0.6	9.11e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1062746	0.771	rs12447487	chr16:87377036	C/T	cg27365499	chr16:87376795	FBXO31	-0.58	-6.21	-0.54	1.38e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs1371867	0.846	rs1616833	chr8:101271821	C/T	cg00191853	chr8:101177733	SPAG1	0.51	5.03	0.46	2.29e-6	Atrioventricular conduction;
THYM	cis	rs2688608	0.592	rs13013	chr10:75562161	C/A	cg15838173	chr10:75533400	FUT11	-0.54	-5.45	-0.49	3.98e-7	Inflammatory bowel disease;
THYM	cis	rs6510489	1.000	rs7976	chr19:35978299	C/T	cg15078284	chr19:36004994	DMKN	0.42	4.82	0.44	5.41e-6	Bipolar disorder;
THYM	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03517284	chr6:25882590	NA	-0.83	-6.5	-0.56	3.62e-9	Intelligence (multi-trait analysis);
THYM	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg14768367	chr16:72042858	DHODH	0.68	5.29	0.48	7.98e-7	Fibrinogen levels;
THYM	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs1978968	1.000	rs11704733	chr22:18446212	T/G	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg08742575	chr21:47604166	C21orf56	0.73	5.27	0.48	8.44e-7	Testicular germ cell tumor;
THYM	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	4.77	0.44	6.7e-6	Obesity-related traits;
THYM	cis	rs7715811	1.000	rs2896103	chr5:13764419	G/A	cg07548982	chr5:13769939	DNAH5	-0.5	-4.47	-0.42	2.19e-5	Subclinical atherosclerosis traits (other);
THYM	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg23711669	chr6:146136114	FBXO30	0.96	10.44	0.73	1.9e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs365132	0.967	rs353471	chr5:176363429	T/C	cg17809377	chr5:176326619	HK3	-0.3	-4.53	-0.42	1.71e-5	Menarche and menopause (age at onset);Menopause (age at onset);
THYM	cis	rs61931739	0.817	rs304313	chr12:34216898	C/T	cg06521331	chr12:34319734	NA	-0.59	-4.99	-0.46	2.77e-6	Morning vs. evening chronotype;
THYM	cis	rs3008870	1.000	rs3008858	chr1:67390416	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.92	7.43	0.61	4.77e-11	Lymphocyte percentage of white cells;
THYM	cis	rs9420	0.961	rs1647405	chr11:57477889	C/T	cg19752551	chr11:57585705	CTNND1	-0.66	-7.73	-0.62	1.11e-11	Schizophrenia;
THYM	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg18230493	chr5:56204884	C5orf35	-0.64	-4.86	-0.45	4.56e-6	Initial pursuit acceleration;
THYM	trans	rs877282	0.898	rs11253353	chr10:766862	C/A	cg22713356	chr15:30763199	NA	1.38	9.68	0.7	7.8e-16	Uric acid levels;
THYM	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg10047753	chr17:41438598	NA	0.93	6.13	0.53	1.96e-8	Menopause (age at onset);
THYM	cis	rs514406	0.858	rs564640	chr1:53285187	T/C	cg16325326	chr1:53192061	ZYG11B	-0.85	-8.17	-0.64	1.34e-12	Monocyte count;
THYM	cis	rs9324022	0.858	rs1004573	chr14:101178235	G/C	cg18089426	chr14:101175970	NA	0.75	5.12	0.46	1.61e-6	Plateletcrit;
THYM	cis	rs1729407	0.741	rs1263177	chr11:116690712	C/T	cg08985259	chr11:116699649	APOC3	-0.63	-5.49	-0.49	3.33e-7	Apolipoprotein A-IV levels;
THYM	cis	rs3820068	0.608	rs2057304	chr1:16017710	A/G	cg24675056	chr1:15929824	NA	0.76	5.94	0.52	4.65e-8	Systolic blood pressure;
THYM	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.87	-0.45	4.45e-6	Eye color traits;
THYM	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.51	5.32	0.48	6.93e-7	Schizophrenia;
THYM	cis	rs67072384	0.818	rs12284245	chr11:72477668	C/T	cg01380194	chr11:72452482	ARAP1	-0.93	-4.91	-0.45	3.84e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07157834	chr1:205819609	PM20D1	0.61	5.63	0.5	1.79e-7	Menarche (age at onset);
THYM	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg02782426	chr3:40428986	ENTPD3	0.52	4.64	0.43	1.1e-5	Renal cell carcinoma;
THYM	cis	rs11096990	0.613	rs1451821	chr4:39180417	G/T	cg24403649	chr4:39172243	NA	-0.61	-5.43	-0.49	4.24e-7	Cognitive function;
THYM	cis	rs550448	0.841	rs78615563	chr7:28149712	C/T	cg26748583	chr7:27497976	NA	-0.9	-4.7	-0.43	8.71e-6	Type 1 diabetes;
THYM	cis	rs12216545	0.765	rs7787639	chr7:150226616	A/T	cg00323915	chr7:150264987	GIMAP4	-0.49	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4466137	0.645	rs6894022	chr5:82982945	T/C	cg16102102	chr5:83017553	HAPLN1	-1.07	-9.87	-0.71	3.13e-16	Prostate cancer;
THYM	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg25072359	chr17:41440525	NA	0.72	5.24	0.47	9.65e-7	Menopause (age at onset);
THYM	cis	rs713587	0.967	rs10865320	chr2:25159780	A/G	cg15423357	chr2:25149977	NA	0.66	7.21	0.59	1.3100000000000001e-10	Body mass index in non-asthmatics;
THYM	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01570182	chr17:44337453	NA	-0.84	-9.31	-0.69	5.04e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2070488	0.965	rs9829192	chr3:38569463	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.89	-6.51	-0.56	3.57e-9	Electrocardiographic conduction measures;
THYM	cis	rs4731207	0.596	rs1481333	chr7:124643059	G/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg25358565	chr5:93447407	FAM172A	1.34	10.59	0.74	9.3e-18	Diabetic retinopathy;
THYM	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg08999081	chr20:33150536	PIGU	0.55	4.85	0.45	4.82e-6	Height;
THYM	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg10802521	chr3:52805072	NEK4	-0.67	-6.16	-0.53	1.71e-8	Bipolar disorder;
THYM	cis	rs12935418	0.672	rs3784814	chr16:81041257	C/G	cg16651780	chr16:81037892	C16orf61	0.86	6.33	0.54	7.92e-9	Mean corpuscular volume;
THYM	cis	rs1348850	0.602	rs1453373	chr2:178221668	G/A	cg27490568	chr2:178487706	NA	0.49	4.67	0.43	9.78e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9837602	0.938	rs10511177	chr3:99724873	A/G	cg00175735	chr3:99903386	TMEM30C	0.74	4.48	0.42	2.11e-5	Breast cancer;
THYM	cis	rs6951245	0.515	rs78461900	chr7:1007033	C/A	cg02869364	chr7:1081709	C7orf50	-0.79	-5.04	-0.46	2.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3793683	0.858	rs1571145	chr10:134583672	C/G	cg26818010	chr10:134567672	INPP5A	0.64	5.29	0.48	7.68e-7	Migraine;
THYM	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg04990556	chr1:26633338	UBXN11	0.89	8.52	0.66	2.34e-13	Obesity-related traits;
THYM	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.87	4.85	0.45	4.9100000000000004e-06	Initial pursuit acceleration;
THYM	trans	rs629535	0.814	rs545720	chr8:70063370	T/C	cg21567404	chr3:27674614	NA	1.09	10.28	0.73	4.24e-17	Dupuytren's disease;
THYM	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg18811423	chr2:55921094	PNPT1	0.72	6.9	0.58	5.79e-10	Metabolic syndrome;
THYM	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg26441486	chr22:50317300	CRELD2	0.42	7.41	0.61	5.09e-11	Schizophrenia;
THYM	cis	rs1198430	0.929	rs1210852	chr1:23753533	T/C	cg27447006	chr1:23763279	ASAP3	0.83	4.45	0.42	2.29e-5	Total cholesterol levels;
THYM	cis	rs8101881	0.576	rs12462086	chr19:33359079	T/G	cg16861209	chr19:33361127	SLC7A9	0.51	4.74	0.44	7.39e-6	Blood metabolite levels;Urinary metabolites;Urinary metabolites (H-NMR features);
THYM	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.57	4.65	0.43	1.06e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11141652	chr22:24348549	GSTTP1	-0.62	-6.35	-0.55	7.25e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7586879	0.638	rs10203482	chr2:25136916	T/C	cg01884057	chr2:25150051	NA	0.73	7.9	0.63	4.9e-12	Body mass index;
THYM	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg15704280	chr7:45808275	SEPT13	0.9	8.9	0.67	3.79e-14	Height;
THYM	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg12179176	chr11:130786555	SNX19	0.84	7.69	0.62	1.32e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.56	-5.57	-0.5	2.41e-7	Crohn's disease;
THYM	cis	rs994014	0.727	rs2109662	chr4:82272565	A/G	cg17825130	chr4:82283507	NA	-0.51	-4.64	-0.43	1.11e-5	Height;
THYM	cis	rs4589258	0.737	rs1792607	chr11:90435167	A/G	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7809950	0.817	rs2712195	chr7:107127496	C/T	cg23024343	chr7:107201750	COG5	-1.01	-8.76	-0.67	7.29e-14	Coronary artery disease;
THYM	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg18681998	chr4:17616180	MED28	0.97	9.52	0.7	1.74e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.91	0.45	3.8e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9914988	0.778	rs4794837	chr17:27110024	T/C	cg20469991	chr17:27169893	C17orf63	-0.77	-4.59	-0.43	1.33e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg14186256	chr22:23484241	RTDR1	-0.73	-5.35	-0.48	6e-7	Bone mineral density;
THYM	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg27129171	chr3:47204927	SETD2	0.71	6.76	0.57	1.1e-9	Colorectal cancer;
THYM	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg11812906	chr14:75593930	NEK9	-0.82	-7.6	-0.61	2.11e-11	Height;
THYM	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg17333051	chr19:2783644	SGTA	0.55	5.3	0.48	7.46e-7	Total cholesterol levels;
THYM	cis	rs4606347	0.932	rs61779737	chr1:66143570	G/A	cg04111102	chr1:66153794	NA	0.57	4.53	0.42	1.73e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg23711669	chr6:146136114	FBXO30	-0.82	-7.3	-0.6	8.63e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8077889	0.871	rs7212648	chr17:41917962	A/C	cg26893861	chr17:41843967	DUSP3	1.23	10.88	0.74	2.18e-18	Triglycerides;
THYM	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg00277334	chr10:82204260	NA	-0.83	-10.18	-0.72	6.99e-17	Post bronchodilator FEV1;
THYM	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg05347473	chr6:146136440	FBXO30	0.58	4.53	0.42	1.7e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7943358	0.955	rs1542645	chr11:15693314	C/T	cg11966998	chr11:15692519	NA	-0.48	-4.66	-0.43	1.03e-5	Gut microbiome composition (summer);
THYM	cis	rs3091242	0.900	rs35345536	chr1:25766488	A/G	cg00786635	chr1:25594202	NA	0.91	7.63	0.62	1.81e-11	Erythrocyte sedimentation rate;
THYM	cis	rs7255436	0.965	rs11666003	chr19:8452102	G/A	cg10174797	chr19:8464628	RAB11B	0.43	5.19	0.47	1.18e-6	HDL cholesterol;
THYM	cis	rs6939532	0.544	rs10946816	chr6:26361946	C/G	cg14345882	chr6:26364793	BTN3A2	0.4	5.07	0.46	2e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg16049864	chr8:95962084	TP53INP1	0.77	6.45	0.55	4.62e-9	Type 2 diabetes;
THYM	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.64	-4.68	-0.43	9.69e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg11845111	chr2:191398756	TMEM194B	-1.02	-8.14	-0.64	1.56e-12	Diastolic blood pressure;
THYM	cis	rs12216545	0.765	rs7787639	chr7:150226616	A/T	cg08960815	chr7:150264767	GIMAP4	-0.89	-8.27	-0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7267979	1.000	rs7019	chr20:25278278	C/T	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs8050907	1.000	rs8050324	chr16:4613292	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.57	0.42	1.47e-5	Obesity-related traits;
THYM	cis	rs9326248	0.530	rs718847	chr11:116734146	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.92	5.28	0.48	8.11e-7	Blood protein levels;
THYM	cis	rs11760633	0.672	rs11763500	chr7:1826385	T/A	cg23422044	chr7:1970798	MAD1L1	-0.62	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg11861562	chr11:117069780	TAGLN	-0.33	-4.76	-0.44	6.86e-6	Blood protein levels;
THYM	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg18352616	chr4:3374830	RGS12	0.72	7.99	0.63	3.22e-12	Serum sulfate level;
THYM	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.02	-0.46	2.42e-6	Blood metabolite levels;
THYM	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg09307838	chr4:120376055	NA	-0.71	-5.05	-0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg15605315	chr1:45957053	TESK2	0.78	6.5	0.55	3.7e-9	High light scatter reticulocyte count;
THYM	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.48	-6.31	-0.54	8.94e-9	Schizophrenia;
THYM	cis	rs9463078	0.764	rs6910294	chr6:44812565	A/T	cg13991849	chr6:45390099	RUNX2	0.6	4.57	0.42	1.48e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs7578361	0.959	rs10204282	chr2:150421458	A/C	cg17961725	chr2:150454027	NA	-0.78	-6.28	-0.54	1.01e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg26384229	chr12:38710491	ALG10B	-0.72	-5.6	-0.5	2.08e-7	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg17366294	chr4:99064904	C4orf37	-0.59	-7.01	-0.58	3.39e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4631830	0.863	rs2611489	chr10:51524889	C/T	cg16070123	chr10:51489643	NA	-0.5	-4.47	-0.42	2.13e-5	Prostate-specific antigen levels;
THYM	cis	rs4474465	0.850	rs7127028	chr11:78262324	A/G	cg19901956	chr11:77921274	USP35	0.58	4.54	0.42	1.68e-5	Alzheimer's disease (survival time);
THYM	cis	rs1894633	0.574	rs17277918	chr1:172322620	A/G	cg13446689	chr1:172328377	DNM3	0.54	4.92	0.45	3.65e-6	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10824037	0.673	rs11000789	chr10:75595226	T/G	cg18802414	chr10:75757814	VCL	0.9	4.5	0.42	1.93e-5	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg01699819	chr7:1052092	C7orf50	-0.57	-5.13	-0.47	1.54e-6	Longevity;Endometriosis;
THYM	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs6877440	1.000	rs11738247	chr5:109054855	G/A	cg17395555	chr5:108820864	NA	0.55	4.65	0.43	1.09e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs17174870	0.955	rs12469210	chr2:112768991	G/A	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg01097406	chr16:89675127	NA	-0.55	-4.46	-0.42	2.24e-5	Vitiligo;
THYM	cis	rs7078219	0.505	rs6584281	chr10:101286480	A/G	cg04972745	chr10:101287846	NA	-0.5	-4.66	-0.43	1.02e-5	Dental caries;
THYM	cis	rs7688540	0.609	rs77700883	chr4:232532	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.72	4.88	0.45	4.35e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs6733011	0.530	rs7608889	chr2:99481350	C/A	cg08885076	chr2:99613938	TSGA10	-0.49	-4.86	-0.45	4.6e-6	Bipolar disorder;
THYM	cis	rs853679	0.599	rs149949	chr6:28011516	T/C	cg23161317	chr6:28129485	ZNF389	0.97	4.62	0.43	1.23e-5	Depression;
THYM	cis	rs2718058	0.519	rs2598072	chr7:37875319	A/C	cg15028436	chr7:37888078	TXNDC3	0.74	4.78	0.44	6.5e-6	Alzheimer's disease (late onset);
THYM	cis	rs4842666	0.915	rs12579302	chr12:90050503	C/T	cg00757033	chr12:89920650	WDR51B	-0.45	-4.45	-0.42	2.33e-5	Blood pressure;
THYM	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg11366901	chr6:160182831	ACAT2	1.07	9.51	0.7	1.88e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs5417	0.689	rs55868524	chr17:7170665	G/A	cg14660024	chr17:7154518	C17orf81;DULLARD	0.65	4.92	0.45	3.67e-6	Diastolic blood pressure;
THYM	cis	rs3826795	0.530	rs11667159	chr19:46795246	C/A	cg15229275	chr19:46800054	HIF3A	0.93	5.64	0.5	1.77e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs9560113	1.000	rs11069895	chr13:112178824	C/T	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs28595532	0.920	rs116550416	chr4:119753467	A/C	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg25319279	chr11:5960081	NA	-0.61	-4.72	-0.44	8.17e-6	DNA methylation (variation);
THYM	cis	rs11031096	0.617	rs12288918	chr11:4191466	G/T	cg18678763	chr11:4115507	RRM1	-0.42	-4.95	-0.45	3.17e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9314614	0.872	rs2951864	chr8:6709922	G/C	cg27319216	chr8:6693540	XKR5	-0.59	-6.25	-0.54	1.18e-8	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs11089937	0.523	rs4820352	chr22:22543592	T/C	cg21401457	chr22:22472743	NA	0.56	4.75	0.44	7.31e-6	Periodontitis (PAL4Q3);
THYM	cis	rs308403	0.509	rs309357	chr4:123653576	G/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.96	8.67	0.66	1.17e-13	Blood protein levels;
THYM	cis	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg15832577	chr1:197874077	C1orf53	-0.68	-5.0	-0.46	2.62e-6	Depressive symptoms;
THYM	cis	rs8180040	0.835	rs6780013	chr3:47452118	G/A	cg02527881	chr3:46936655	PTH1R	0.53	4.7	0.43	8.84e-6	Colorectal cancer;
THYM	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.79	-6.68	-0.57	1.62e-9	Intelligence (multi-trait analysis);
THYM	cis	rs2235642	0.859	rs9927529	chr16:1619488	C/T	cg10465839	chr16:1584050	IFT140;TMEM204	-0.54	-4.65	-0.43	1.06e-5	Coronary artery disease;
THYM	trans	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Bladder cancer;
THYM	cis	rs6964587	0.626	rs7785941	chr7:91531024	T/C	cg17063962	chr7:91808500	NA	-1.04	-9.11	-0.68	1.3e-14	Breast cancer;
THYM	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.58	-5.88	-0.52	6.01e-8	Crohn's disease;
THYM	cis	rs526231	0.511	rs17154965	chr5:102359566	C/A	cg23492399	chr5:102201601	PAM	-0.7	-5.21	-0.47	1.08e-6	Primary biliary cholangitis;
THYM	cis	rs3820068	0.655	rs72645826	chr1:15889741	A/G	cg05660106	chr1:15850417	CASP9	1.16	10.06	0.72	1.25e-16	Systolic blood pressure;
THYM	cis	rs2455799	0.613	rs13071161	chr3:15958166	C/T	cg16303742	chr3:15540471	COLQ	-0.54	-5.37	-0.48	5.67e-7	Mean platelet volume;
THYM	cis	rs1357245	0.631	rs12330710	chr3:27096806	G/A	cg03895047	chr3:27114861	NA	0.49	4.58	0.43	1.42e-5	Breast cancer;
THYM	cis	rs5015933	0.734	rs10126025	chr9:128146064	C/G	cg13590414	chr9:128173245	NA	-0.5	-4.95	-0.45	3.2e-6	Body mass index;
THYM	cis	rs11690935	0.549	rs2129475	chr2:172916772	A/G	cg13550731	chr2:172543902	DYNC1I2	0.68	5.56	0.5	2.45e-7	Schizophrenia;
THYM	cis	rs10992471	0.528	rs4744133	chr9:95226702	C/T	cg14631576	chr9:95140430	CENPP	-0.84	-8.02	-0.64	2.69e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs13064411	0.735	rs13098166	chr3:113210038	A/G	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg19645103	chr12:69753606	YEATS4	-0.57	-4.55	-0.42	1.6e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs6840360	0.869	rs55668815	chr4:152473828	C/G	cg22705602	chr4:152727874	NA	-0.58	-6.45	-0.55	4.57e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg20608306	chr11:116969690	SIK3	0.52	5.52	0.49	2.95e-7	Blood protein levels;
THYM	cis	rs684232	0.602	rs445268	chr17:563338	G/A	cg15660573	chr17:549704	VPS53	-0.99	-10.95	-0.75	1.54e-18	Prostate cancer;
THYM	cis	rs4662750	0.674	rs777437	chr2:128357647	C/T	cg01966334	chr2:128378434	MYO7B	0.67	6.13	0.53	1.96e-8	Renal cell carcinoma;
THYM	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg10803722	chr21:46713166	LOC642852	-0.41	-5.28	-0.48	8.15e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg06219351	chr7:158114137	PTPRN2	-0.74	-7.14	-0.59	1.86e-10	Calcium levels;
THYM	cis	rs2066819	0.892	rs75274818	chr12:56627619	A/G	cg26714650	chr12:56694279	CS	-1.29	-6.29	-0.54	9.85e-9	Psoriasis vulgaris;
THYM	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg11663144	chr21:46675770	NA	-0.76	-10.98	-0.75	1.34e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg09307838	chr4:120376055	NA	-0.7	-5.04	-0.46	2.24e-6	Corneal astigmatism;
THYM	cis	rs2976388	1.000	rs2920292	chr8:143765699	A/G	cg13446199	chr8:143762866	PSCA	0.51	6.41	0.55	5.48e-9	Urinary tract infection frequency;
THYM	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg18131467	chr2:239335373	ASB1	-1.1	-11.05	-0.75	9.8e-19	Multiple system atrophy;
THYM	cis	rs986417	1.000	rs6573320	chr14:61092022	A/G	cg27398547	chr14:60952738	C14orf39	1.26	6.1	0.53	2.29e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs9790314	0.521	rs1450523	chr3:161077270	G/A	cg04691961	chr3:161091175	C3orf57	-0.59	-4.87	-0.45	4.45e-6	Morning vs. evening chronotype;
THYM	cis	rs4900538	0.819	rs72698595	chr14:102863099	G/A	cg18135206	chr14:102964638	TECPR2	-0.81	-6.24	-0.54	1.2e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7106204	0.748	rs7947388	chr11:24224903	A/G	ch.11.24196551F	chr11:24239977	NA	1.05	7.76	0.62	9.67e-12	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.21	9.47	0.7	2.27e-15	Platelet count;
THYM	cis	rs9826463	1.000	rs7647497	chr3:142322333	G/A	cg20824294	chr3:142316082	PLS1	0.64	4.66	0.43	1.01e-5	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg16586182	chr3:47516702	SCAP	-0.6	-5.11	-0.46	1.63e-6	Colorectal cancer;
THYM	cis	rs2276314	0.857	rs4799409	chr18:33592602	C/T	cg19628046	chr18:33552617	C18orf21	0.74	5.43	0.49	4.29e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs807669	0.903	rs762527	chr22:19183470	A/G	cg02655711	chr22:19163373	SLC25A1	0.97	11.57	0.76	7.63e-20	Metabolite levels;
THYM	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg13010199	chr12:38710504	ALG10B	-0.58	-4.52	-0.42	1.77e-5	Morning vs. evening chronotype;
THYM	cis	rs9880211	1.000	rs13092193	chr3:136240366	T/C	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.25	4.74	0.44	7.46e-6	Obesity-related traits;
THYM	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg07047280	chr21:41516394	DSCAM	-0.66	-4.65	-0.43	1.07e-5	Cognitive function;
THYM	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg08859206	chr1:53392774	SCP2	-0.51	-5.47	-0.49	3.67e-7	Monocyte count;
THYM	cis	rs7192750	0.586	rs8058118	chr16:71959733	T/C	cg06353428	chr16:71660113	MARVELD3	0.72	5.12	0.46	1.62e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs67460515	0.892	rs35310734	chr3:160943209	T/G	cg03342759	chr3:160939853	NMD3	-0.9	-7.96	-0.63	3.6e-12	Parkinson's disease;
THYM	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg01069141	chr11:67398826	TBX10;NUDT8	0.46	4.63	0.43	1.17e-5	Mean corpuscular volume;
THYM	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg20744362	chr22:50050164	C22orf34	0.67	6.06	0.53	2.74e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg17264618	chr3:40429014	ENTPD3	-0.53	-5.15	-0.47	1.38e-6	Renal cell carcinoma;
THYM	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg08736216	chr1:53307985	ZYG11A	-0.58	-5.29	-0.48	7.85e-7	Monocyte count;
THYM	cis	rs10089	0.953	rs4836358	chr5:127376869	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.97	6.65	0.56	1.82e-9	Ileal carcinoids;
THYM	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg10802521	chr3:52805072	NEK4	-0.72	-6.12	-0.53	2.09e-8	Bipolar disorder;
THYM	cis	rs6952809	0.532	rs6956223	chr7:2431331	T/C	cg13581527	chr7:1708566	NA	-0.76	-5.21	-0.47	1.11e-6	Multiple sclerosis;
THYM	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg05182265	chr7:156933206	UBE3C	-0.69	-9.34	-0.69	4.32e-15	Body mass index;
THYM	cis	rs17102423	0.788	rs11158575	chr14:65581665	T/C	cg11161011	chr14:65562177	MAX	-0.85	-7.11	-0.59	2.16e-10	Obesity-related traits;
THYM	cis	rs956237	0.966	rs9999061	chr4:109051625	T/C	cg15700776	chr4:108852048	CYP2U1	0.57	4.62	0.43	1.22e-5	Systemic lupus erythematosus;
THYM	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs4953076	0.573	rs7602070	chr2:44388614	G/A	cg04920474	chr2:44395004	PPM1B	0.63	5.27	0.48	8.46e-7	Height;
THYM	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11690935	0.959	rs10206062	chr2:172577276	A/T	cg13550731	chr2:172543902	DYNC1I2	-0.85	-6.26	-0.54	1.09e-8	Schizophrenia;
THYM	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg19729930	chr2:74357872	NA	1.29	12.85	0.8	1.71e-22	Gestational age at birth (maternal effect);
THYM	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg15592062	chr6:167189543	RPS6KA2	0.59	6.0	0.52	3.58e-8	Crohn's disease;
THYM	cis	rs7107770	1.000	rs12791760	chr11:125091568	C/T	cg04164023	chr11:125106101	PKNOX2	0.82	4.74	0.44	7.6e-6	Photic sneeze reflex;
THYM	cis	rs10799590	1.000	rs10799590	chr1:224822482	C/T	cg01808320	chr1:224927238	CNIH3	-0.54	-4.8	-0.44	5.89e-6	Opioid dependence;
THYM	cis	rs79387448	0.638	rs6759588	chr2:103040159	A/G	cg09003973	chr2:102972529	NA	1.17	6.06	0.53	2.74e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs854765	0.822	rs1889014	chr17:17767165	C/T	cg16928487	chr17:17741425	SREBF1	0.56	5.25	0.47	9.22e-7	Total body bone mineral density;
THYM	cis	rs9527	0.590	rs2274339	chr10:104860053	T/A	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg02018176	chr4:1364513	KIAA1530	0.55	4.7	0.43	8.82e-6	Obesity-related traits;
THYM	cis	rs9522267	0.737	rs9522289	chr13:112232110	G/A	cg10483660	chr13:112241077	NA	-0.62	-6.72	-0.57	1.33e-9	Hepatitis;
THYM	cis	rs4845875	0.600	rs1889293	chr1:11840862	G/A	cg14194983	chr1:11908298	NPPA	0.54	4.98	0.46	2.83e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg00300879	chr1:26503847	CNKSR1	0.4	5.27	0.48	8.61e-7	Height;
THYM	cis	rs4343996	1.000	rs6461994	chr7:3356483	C/G	cg21248987	chr7:3385318	SDK1	-0.39	-4.7	-0.43	8.63e-6	Motion sickness;
THYM	cis	rs4072705	0.904	rs721863	chr9:127536267	A/T	cg13476313	chr9:127244764	NR5A1	0.32	4.68	0.43	9.55e-6	Menarche (age at onset);
THYM	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg13175981	chr1:150552382	MCL1	0.6	4.49	0.42	1.99e-5	Tonsillectomy;
THYM	cis	rs10895275	0.961	rs12790399	chr11:102100039	G/C	cg24447756	chr11:102105824	NA	0.54	4.74	0.44	7.37e-6	Migraine;
THYM	cis	rs7246657	1.000	rs12709812	chr19:37794850	A/G	cg22634378	chr19:37742834	NA	-0.68	-5.74	-0.51	1.14e-7	Coronary artery calcification;
THYM	cis	rs6906287	0.647	rs12199463	chr6:118826695	A/G	cg21191810	chr6:118973309	C6orf204	-0.56	-5.54	-0.49	2.74e-7	Electrocardiographic conduction measures;
THYM	cis	rs7760949	0.852	rs9475801	chr6:13933115	G/A	cg27413430	chr6:13925136	RNF182	0.51	4.52	0.42	1.77e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs12530845	0.673	rs73721607	chr7:135335822	C/T	cg19897172	chr7:135347071	PL-5283	-0.59	-5.31	-0.48	7.23e-7	Red blood cell traits;
THYM	cis	rs4343996	0.967	rs10250444	chr7:3350027	A/G	cg21248987	chr7:3385318	SDK1	-0.41	-4.95	-0.45	3.17e-6	Motion sickness;
THYM	cis	rs11190604	1.000	rs2273695	chr10:102259568	A/G	cg16342193	chr10:102329863	NA	-0.48	-4.69	-0.43	9.13e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg24818145	chr4:99064322	C4orf37	0.71	5.75	0.51	1.09e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg24399712	chr22:39784796	NA	-0.92	-10.94	-0.75	1.67e-18	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.569	rs10252443	chr7:124578931	G/A	cg05285228	chr7:124571219	POT1	-0.77	-5.59	-0.5	2.21e-7	Cutaneous malignant melanoma;
THYM	cis	rs9534288	0.731	rs4942461	chr13:46551023	C/T	cg15192986	chr13:46630673	CPB2	-0.6	-4.52	-0.42	1.8e-5	Blood protein levels;
THYM	cis	rs4606347	0.789	rs61780862	chr1:66162360	G/A	cg04111102	chr1:66153794	NA	0.64	5.11	0.46	1.65e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9534288	0.700	rs7331032	chr13:46609040	C/T	cg15192986	chr13:46630673	CPB2	-0.59	-4.54	-0.42	1.67e-5	Blood protein levels;
THYM	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg07936489	chr17:37558343	FBXL20	0.87	5.78	0.51	9.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12410462	1.000	rs75360545	chr1:227625419	T/C	cg04117972	chr1:227635322	NA	0.71	4.8	0.44	5.85e-6	Major depressive disorder;
THYM	cis	rs59698941	0.943	rs10900812	chr5:132268567	G/A	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg17105886	chr17:28927953	LRRC37B2	1.26	6.38	0.55	6.49e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7336332	0.598	rs10220056	chr13:28003781	T/G	cg22138327	chr13:27999177	GTF3A	0.67	4.97	0.45	3.02e-6	Weight;
THYM	cis	rs10887741	0.624	rs7088341	chr10:89427820	C/T	cg13926569	chr10:89418898	PAPSS2	0.62	6.95	0.58	4.46e-10	Exercise (leisure time);
THYM	cis	rs7267979	1.000	rs6050626	chr20:25428261	T/C	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1348850	0.526	rs1345138	chr2:178387100	A/T	cg27490568	chr2:178487706	NA	0.66	5.31	0.48	7.1e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs28476539	0.640	rs17005892	chr4:83548419	T/C	cg10249074	chr4:83542146	C4orf11	-0.67	-5.27	-0.48	8.44e-7	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg16586182	chr3:47516702	SCAP	0.67	5.62	0.5	1.9e-7	Colorectal cancer;
THYM	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg21856205	chr7:94953877	PON1	-0.71	-6.7	-0.57	1.5e-9	Paraoxonase activity;
THYM	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg17718321	chr1:152188247	HRNR	-0.5	-4.98	-0.46	2.79e-6	Inflammatory skin disease;
THYM	cis	rs3947	0.951	rs1736086	chr8:11704897	C/T	cg26752888	chr8:11627280	NEIL2	-0.71	-4.69	-0.43	9.24e-6	Blood protein levels;
THYM	cis	rs34638657	0.536	rs2967327	chr16:82188657	C/T	cg07307142	chr16:82071433	HSD17B2	-0.74	-6.49	-0.55	3.88e-9	Lung adenocarcinoma;
THYM	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg06728252	chr6:26598149	ABT1	-0.45	-5.26	-0.47	8.87e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg22431228	chr1:16359049	CLCNKA	-0.51	-4.94	-0.45	3.33e-6	Dilated cardiomyopathy;
THYM	cis	rs4631830	0.900	rs10763534	chr10:51534920	C/T	cg16070123	chr10:51489643	NA	-0.52	-4.74	-0.44	7.46e-6	Prostate-specific antigen levels;
THYM	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg27490568	chr2:178487706	NA	0.56	4.89	0.45	4.1e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs3087591	0.666	rs2953016	chr17:29494693	C/G	cg24425628	chr17:29625626	OMG;NF1	0.66	4.96	0.45	3.1e-6	Hip circumference;
THYM	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg18200150	chr17:30822561	MYO1D	0.8	6.83	0.57	8.13e-10	Schizophrenia;
THYM	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg22974920	chr21:40686053	BRWD1	0.59	4.5	0.42	1.95e-5	Cognitive function;
THYM	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg15247329	chr7:2764246	NA	-0.67	-5.55	-0.49	2.62e-7	Height;
THYM	cis	rs1348850	0.651	rs4893931	chr2:178228212	T/C	cg27490568	chr2:178487706	NA	0.5	4.7	0.43	8.95e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs17268829	0.925	rs12704723	chr7:94148992	T/A	cg00347863	chr7:94220697	SGCE	0.65	5.29	0.48	7.95e-7	Breast cancer;
THYM	cis	rs6032067	0.925	rs62208424	chr20:43813341	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs9560113	0.919	rs11069896	chr13:112178887	C/T	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs1401999	0.932	rs4148557	chr3:183733784	A/G	cg20387954	chr3:183756860	HTR3D	0.56	4.63	0.43	1.15e-5	Anterior chamber depth;
THYM	cis	rs2039659	0.719	rs1764958	chr13:86260528	A/G	cg25308322	chr13:86268291	NA	0.66	5.72	0.51	1.21e-7	Blood osmolality (transformed sodium);
THYM	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg10803722	chr21:46713166	LOC642852	-0.43	-5.74	-0.51	1.13e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg03264133	chr6:25882463	NA	-0.66	-4.49	-0.42	2.02e-5	Height;
THYM	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg14780466	chr2:20870812	GDF7	-0.76	-6.09	-0.53	2.36e-8	Abdominal aortic aneurysm;
THYM	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg12310025	chr6:25882481	NA	0.68	5.56	0.5	2.47e-7	Schizophrenia;
THYM	cis	rs4523957	0.671	rs4790070	chr17:2158094	C/G	cg16513277	chr17:2031491	SMG6	0.58	4.47	0.42	2.12e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg11845111	chr2:191398756	TMEM194B	0.97	9.11	0.68	1.34e-14	Pulse pressure;
THYM	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03264133	chr6:25882463	NA	-0.72	-5.52	-0.49	2.99e-7	Blood metabolite levels;
THYM	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg10661904	chr17:79619235	PDE6G	-0.65	-6.24	-0.54	1.19e-8	Eye color traits;
THYM	cis	rs2085601	0.542	rs1513807	chr4:89961290	C/A	cg17769793	chr4:89976368	FAM13A	-0.59	-6.86	-0.58	6.96e-10	Hair greying;
THYM	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg01699819	chr7:1052092	C7orf50	-0.87	-7.73	-0.62	1.1e-11	Bronchopulmonary dysplasia;
THYM	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg17264618	chr3:40429014	ENTPD3	0.52	4.97	0.45	3e-6	Renal cell carcinoma;
THYM	cis	rs4919694	1.000	rs78893207	chr10:104796138	T/C	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg14458575	chr2:238380390	NA	1.0	7.94	0.63	3.96e-12	Prostate cancer;
THYM	cis	rs4975616	0.771	rs3816659	chr5:1317820	A/G	cg07493874	chr5:1342172	CLPTM1L	0.87	8.5	0.66	2.59e-13	Lung cancer;
THYM	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg19748678	chr4:122722346	EXOSC9	0.67	4.58	0.43	1.43e-5	Type 2 diabetes;
THYM	cis	rs965604	1.000	rs1062980	chr15:78792527	T/C	cg18825076	chr15:78729989	IREB2	0.54	4.67	0.43	1.01e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg20966754	chr17:47091339	IGF2BP1	-0.54	-7.37	-0.6	6.11e-11	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg18402987	chr7:1209562	NA	0.73	5.27	0.48	8.58e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17401966	0.838	rs7553228	chr1:10350438	G/C	cg19773385	chr1:10388646	KIF1B	-0.57	-4.49	-0.42	2.04e-5	Hepatocellular carcinoma;
THYM	cis	rs113835537	0.529	rs60358007	chr11:66222353	G/A	cg24851651	chr11:66362959	CCS	0.74	5.16	0.47	1.33e-6	Airway imaging phenotypes;
THYM	cis	rs4383453	0.539	rs903571	chr3:123101250	A/C	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg25036284	chr2:26402008	FAM59B	0.8	5.36	0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs2718058	0.519	rs2598054	chr7:37884640	C/T	cg02531859	chr7:37888154	TXNDC3	-0.89	-5.92	-0.52	5.01e-8	Alzheimer's disease (late onset);
THYM	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg27211696	chr2:191398769	TMEM194B	-0.6	-4.5	-0.42	1.94e-5	Diastolic blood pressure;
THYM	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs7084402	0.967	rs1658424	chr10:60331588	G/A	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg17178900	chr1:205818956	PM20D1	1.1	12.06	0.78	7.32e-21	Menarche (age at onset);
THYM	cis	rs9549260	0.755	rs9549241	chr13:41210041	G/A	cg21288729	chr13:41239152	FOXO1	0.71	5.46	0.49	3.86e-7	Red blood cell count;
THYM	trans	rs8073060	0.660	rs34184070	chr17:34003810	A/G	cg19694781	chr19:47549865	TMEM160	-1.02	-8.69	-0.67	1.01e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg03188948	chr7:1209495	NA	0.9	5.0	0.46	2.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3849570	0.696	rs13092157	chr3:81875332	T/A	cg07356753	chr3:81810745	GBE1	-0.84	-6.24	-0.54	1.22e-8	Waist circumference;Body mass index;
THYM	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.8e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg02869364	chr7:1081709	C7orf50	-0.45	-5.13	-0.47	1.53e-6	Longevity;Endometriosis;
THYM	cis	rs7631605	0.905	rs11711937	chr3:37224838	C/G	cg21328643	chr3:37258149	NA	0.48	4.54	0.42	1.67e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs7119	0.700	rs60701760	chr15:77888152	G/A	cg10437265	chr15:77819839	NA	-0.56	-5.5	-0.49	3.21e-7	Type 2 diabetes;
THYM	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg07636037	chr3:49044803	WDR6	0.88	7.74	0.62	1.04e-11	Menarche (age at onset);
THYM	cis	rs877282	0.945	rs12767287	chr10:787310	A/G	cg10556349	chr10:835070	NA	-0.78	-5.38	-0.48	5.34e-7	Uric acid levels;
THYM	cis	rs34638657	0.789	rs2303264	chr16:82203711	G/T	cg09894383	chr16:82067445	HSD17B2	-0.44	-4.64	-0.43	1.11e-5	Lung adenocarcinoma;
THYM	cis	rs9302690	1.000	rs62037108	chr16:57443171	G/A	cg27017172	chr16:57497170	POLR2C	0.82	4.88	0.45	4.29e-6	Blood protein levels;
THYM	cis	rs6754311	0.834	rs12465802	chr2:136381348	A/G	cg07169764	chr2:136633963	MCM6	-0.71	-5.28	-0.48	8.16e-7	Mosquito bite size;
THYM	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg16031515	chr1:205743344	RAB7L1	0.52	4.51	0.42	1.88e-5	Menarche (age at onset);
THYM	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg23758822	chr17:41437982	NA	-1.22	-13.08	-0.8	5.68e-23	Menopause (age at onset);
THYM	cis	rs10992471	0.528	rs7037194	chr9:95216745	G/A	cg14631576	chr9:95140430	CENPP	-0.84	-8.02	-0.64	2.69e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs1018836	0.632	rs2879361	chr8:91481909	C/T	cg16814680	chr8:91681699	NA	0.74	5.88	0.52	6.1e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs3020418	0.691	rs2474148	chr6:152412904	G/T	cg03627880	chr6:151815985	C6orf97	-0.43	-4.52	-0.42	1.75e-5	Height;
THYM	cis	rs72627123	1.000	rs45559033	chr14:74341124	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs10186029	0.509	rs10203838	chr2:213935900	T/C	cg08319019	chr2:214017104	IKZF2	-0.66	-5.12	-0.47	1.6e-6	Systemic sclerosis;
THYM	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg13683864	chr3:40499215	RPL14	-1.04	-11.36	-0.76	2.12e-19	Renal cell carcinoma;
THYM	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg06219351	chr7:158114137	PTPRN2	0.73	7.71	0.62	1.22e-11	Calcium levels;
THYM	cis	rs9290065	0.519	rs1562465	chr3:160701442	G/A	cg03342759	chr3:160939853	NMD3	-0.59	-4.56	-0.42	1.52e-5	Kawasaki disease;
THYM	cis	rs28595532	0.920	rs55901549	chr4:119770172	T/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg04772025	chr11:68637568	NA	0.63	6.58	0.56	2.59e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg19875535	chr5:140030758	IK	0.58	4.46	0.42	2.21e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg04865290	chr3:52927548	TMEM110	-0.96	-4.97	-0.45	2.97e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg20503657	chr10:835505	NA	1.37	9.33	0.69	4.52e-15	Eosinophil percentage of granulocytes;
THYM	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg04181038	chr4:183730758	NA	0.96	7.89	0.63	5.13e-12	Pediatric autoimmune diseases;
THYM	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg10560079	chr2:191398806	TMEM194B	-0.98	-8.0	-0.63	3e-12	Diastolic blood pressure;
THYM	cis	rs6866344	0.569	rs6870021	chr5:178149667	C/T	cg03877680	chr5:178157825	ZNF354A	0.81	5.69	0.5	1.42e-7	Neutrophil percentage of white cells;
THYM	cis	rs11190604	1.000	rs4244338	chr10:102272802	A/G	cg16342193	chr10:102329863	NA	-0.53	-5.41	-0.48	4.8e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs3771570	0.818	rs73008126	chr2:242443157	A/C	cg21155796	chr2:242212141	HDLBP	1.18	5.77	0.51	9.86e-8	Prostate cancer;
THYM	cis	rs2039659	0.719	rs9602804	chr13:86264680	T/A	cg25308322	chr13:86268291	NA	0.67	5.87	0.52	6.37e-8	Blood osmolality (transformed sodium);
THYM	cis	rs8031584	1.000	rs11634216	chr15:31288670	G/A	cg14829155	chr15:31115871	NA	-0.58	-5.26	-0.47	9.04e-7	Huntington's disease progression;
THYM	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg06028605	chr16:24865363	SLC5A11	0.52	4.51	0.42	1.84e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1558375	0.679	rs31674	chr7:87068464	T/C	cg04996195	chr7:87105398	ABCB4	-0.59	-4.53	-0.42	1.73e-5	Gallbladder cancer;
THYM	cis	rs28595532	0.920	rs116634064	chr4:119736514	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg10589385	chr1:150898437	SETDB1	0.57	4.55	0.42	1.56e-5	Melanoma;
THYM	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg19761014	chr17:28927070	LRRC37B2	0.79	5.06	0.46	2.08e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg09367891	chr1:107599246	PRMT6	-0.69	-4.88	-0.45	4.2e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs6840360	0.642	rs7657670	chr4:152353375	A/G	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11792861	0.566	rs67780641	chr9:111850710	A/G	cg05043794	chr9:111880884	C9orf5	-0.3	-4.47	-0.42	2.18e-5	Menarche (age at onset);
THYM	cis	rs6866344	0.601	rs12187838	chr5:178099833	T/C	cg10224037	chr5:178157518	ZNF354A	0.86	5.63	0.5	1.84e-7	Neutrophil percentage of white cells;
THYM	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg05368731	chr17:41323189	NBR1	1.13	10.0	0.72	1.64e-16	Menopause (age at onset);
THYM	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg15536230	chr21:44985092	HSF2BP	-0.42	-5.04	-0.46	2.26e-6	Mean corpuscular volume;
THYM	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg08873628	chr1:175162347	KIAA0040	0.51	4.65	0.43	1.09e-5	Alcohol dependence;
THYM	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg11812906	chr14:75593930	NEK9	-0.87	-8.2	-0.64	1.16e-12	Height;
THYM	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg08847533	chr14:75593920	NEK9	0.55	4.56	0.42	1.52e-5	Caffeine consumption;
THYM	cis	rs7681440	0.606	rs356192	chr4:90687927	G/A	cg06632027	chr4:90757378	SNCA	0.6	4.71	0.44	8.35e-6	Dementia with Lewy bodies;
THYM	cis	rs990171	0.955	rs4851008	chr2:103026611	G/C	cg13897122	chr2:103039542	IL18RAP	-0.39	-4.72	-0.44	7.96e-6	Lymphocyte counts;
THYM	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg24675658	chr1:53192096	ZYG11B	0.73	6.39	0.55	6.03e-9	Monocyte count;
THYM	cis	rs909002	0.800	rs3134718	chr1:32089839	C/T	cg13919466	chr1:32135498	COL16A1	-0.5	-5.13	-0.47	1.51e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3847687	0.546	rs6486621	chr12:131520208	T/C	cg25772418	chr12:131519998	GPR133	-0.36	-4.8	-0.44	5.88e-6	Longevity;
THYM	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg06697600	chr4:7070879	GRPEL1	-0.54	-4.78	-0.44	6.39e-6	Monocyte percentage of white cells;
THYM	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg22681709	chr2:178499509	PDE11A	-0.55	-5.61	-0.5	2.01e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs9443189	0.527	rs775059	chr6:76370130	G/T	cg01950844	chr6:76311363	SENP6	1.05	6.66	0.56	1.73e-9	Prostate cancer;
THYM	cis	rs1933112	1.000	rs1040509	chr1:168500984	G/T	cg00154920	chr1:168513310	XCL2	-0.46	-4.58	-0.43	1.39e-5	Blood protein levels;
THYM	cis	rs2219968	0.756	rs10283381	chr8:78922806	G/A	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs912057	0.671	rs1294433	chr6:6745163	G/A	cg13809441	chr6:6737631	NA	0.44	5.32	0.48	6.97e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs10489525	0.528	rs360604	chr1:115390019	G/A	cg12756093	chr1:115239321	AMPD1	0.66	5.17	0.47	1.28e-6	Autism;
THYM	cis	rs12208915	0.848	rs9359351	chr6:79492533	A/G	cg05283184	chr6:79620031	NA	0.79	5.28	0.48	8.01e-7	Left atrial antero-posterior diameter;
THYM	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg23066280	chr7:158032496	PTPRN2	0.53	5.72	0.51	1.22e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs17253792	0.822	rs28549152	chr14:56091239	A/G	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg13609457	chr4:120235615	NA	0.54	5.0	0.46	2.61e-6	Corneal astigmatism;
THYM	cis	rs951188	0.649	rs1111663	chr2:150346506	A/C	cg17961725	chr2:150454027	NA	-0.77	-4.74	-0.44	7.64e-6	Daytime sleep phenotypes;
THYM	cis	rs1005224	0.515	rs3784003	chr14:76083582	A/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.56	-4.46	-0.42	2.26e-5	Large artery stroke;
THYM	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs61774743	0.557	rs4660192	chr1:41842350	C/T	cg19619003	chr1:41846758	NA	-0.29	-5.93	-0.52	4.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg03806693	chr22:41940476	POLR3H	-1.21	-10.67	-0.74	6.28e-18	Vitiligo;
THYM	cis	rs3924048	0.559	rs6541039	chr1:12626261	T/C	cg00291366	chr1:12616550	NA	0.34	5.07	0.46	1.93e-6	Optic cup area;
THYM	cis	rs3824535	0.541	rs12348258	chr9:125983554	C/T	cg01693284	chr9:125437568	OR1L3	0.61	4.58	0.43	1.42e-5	Subjective well-being (multi-trait analysis);
THYM	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg22947322	chr17:47091978	IGF2BP1	-0.63	-6.48	-0.55	3.99e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7572733	0.515	rs1401096	chr2:198823828	A/G	cg00792783	chr2:198669748	PLCL1	0.82	5.75	0.51	1.08e-7	Dermatomyositis;
THYM	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg05373962	chr22:49881684	NA	-0.66	-6.78	-0.57	9.95e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9902453	0.791	rs3098950	chr17:27998385	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	6.2	0.54	1.45e-8	Coffee consumption (cups per day);
THYM	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg14768367	chr16:72042858	DHODH	-0.65	-5.1	-0.46	1.76e-6	Fibrinogen levels;
THYM	cis	rs1018836	0.923	rs6986088	chr8:91538474	A/C	cg16814680	chr8:91681699	NA	-0.86	-7.95	-0.63	3.82e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs936229	0.813	rs1350193	chr15:75084281	G/C	cg14664628	chr15:75095509	CSK	-0.99	-8.15	-0.64	1.48e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg07061783	chr6:25882402	NA	-0.89	-7.85	-0.63	6.27e-12	Blood metabolite levels;
THYM	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg08999081	chr20:33150536	PIGU	-0.78	-7.16	-0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg03929089	chr4:120376271	NA	-1.01	-13.73	-0.82	2.83e-24	Height;
THYM	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg13390004	chr1:15929781	NA	0.65	4.86	0.45	4.54e-6	Systolic blood pressure;
THYM	cis	rs2147904	0.704	rs783624	chr1:42366343	G/A	cg16685388	chr1:42384056	HIVEP3	0.58	4.72	0.44	7.98e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
THYM	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs6539288	0.677	rs11113144	chr12:107323422	T/C	cg26297688	chr12:107349093	C12orf23	-0.51	-6.04	-0.53	2.94e-8	Total body bone mineral density;
THYM	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg18105134	chr13:113819100	PROZ	-0.95	-8.7	-0.67	1e-13	Platelet distribution width;
THYM	cis	rs6138458	1.000	rs2387362	chr20:24899906	C/T	cg26195577	chr20:24973756	C20orf3	-1.11	-10.52	-0.73	1.29e-17	Blood protein levels;
THYM	cis	rs7187994	0.895	rs16974453	chr16:84758510	C/T	cg07647771	chr16:84786436	USP10	-0.52	-4.56	-0.42	1.51e-5	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs3126085	0.560	rs11588022	chr1:152316952	A/T	cg10321714	chr1:152280068	FLG	-0.72	-4.88	-0.45	4.34e-6	Atopic dermatitis;
THYM	cis	rs55728055	0.661	rs16989274	chr22:31955908	G/A	cg10537193	chr22:32026975	PISD	-0.92	-5.68	-0.5	1.45e-7	Age-related hearing impairment;
THYM	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.2e-16	Bone mineral density;
THYM	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg01069141	chr11:67398826	TBX10;NUDT8	0.49	5.34	0.48	6.25e-7	Mean corpuscular volume;
THYM	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg23711669	chr6:146136114	FBXO30	0.93	9.39	0.69	3.39e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4076764	0.846	rs7525724	chr1:163426372	G/A	cg06092702	chr1:163392909	NA	-0.58	-4.92	-0.45	3.58e-6	Motion sickness;
THYM	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg16342193	chr10:102329863	NA	-0.59	-6.35	-0.55	7.46e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg23708337	chr7:1209742	NA	0.73	5.28	0.48	8e-7	Longevity;Endometriosis;
THYM	cis	rs747334	0.811	rs10881867	chr10:92715851	A/C	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg24846343	chr22:24311635	DDTL	0.41	4.65	0.43	1.05e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2046867	0.862	rs62252360	chr3:72838551	C/T	cg25664220	chr3:72788482	NA	-0.82	-6.45	-0.55	4.62e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg26354017	chr1:205819088	PM20D1	0.93	9.62	0.7	1.06e-15	Menarche (age at onset);
THYM	cis	rs7567389	0.564	rs10209483	chr2:128158637	C/T	cg09760422	chr2:128146352	NA	-0.4	-4.7	-0.43	8.68e-6	Self-rated health;
THYM	cis	rs2354432	0.607	rs59606861	chr1:146761478	G/A	cg25205988	chr1:146714368	CHD1L	-0.96	-4.72	-0.44	7.97e-6	Mitochondrial DNA levels;
THYM	cis	rs9309473	0.500	rs12996463	chr2:73655496	T/C	cg19565262	chr2:73869966	NAT8	0.64	5.14	0.47	1.47e-6	Metabolite levels;
THYM	cis	rs3923380	0.503	rs10020050	chr4:77467819	A/G	cg07933720	chr4:77468187	SHROOM3	0.36	4.71	0.43	8.57e-6	Craniofacial microsomia;
THYM	cis	rs12149862	1.000	rs719620	chr16:69475828	T/C	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	trans	rs8073060	0.586	rs7214250	chr17:33981704	C/G	cg19694781	chr19:47549865	TMEM160	-1.02	-8.69	-0.67	1.01e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg16342193	chr10:102329863	NA	-0.47	-4.63	-0.43	1.18e-5	Palmitoleic acid (16:1n-7) levels;
THYM	trans	rs9929218	0.953	rs2902323	chr16:68736292	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-7.03	-0.58	3.13e-10	Colorectal cancer;
THYM	cis	rs9928842	0.941	rs1808427	chr16:75241394	T/C	cg09066997	chr16:75300724	BCAR1	0.76	4.52	0.42	1.75e-5	Alcoholic chronic pancreatitis;
THYM	cis	rs939658	0.728	rs12904323	chr15:79412583	A/C	cg17916960	chr15:79447300	NA	-0.6	-6.23	-0.54	1.27e-8	Refractive error;
THYM	cis	rs6450176	1.000	rs4311394	chr5:53300662	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-6.19	-0.54	1.54e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg00599163	chr2:162100495	NA	0.83	7.68	0.62	1.41e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg22764591	chr12:58329936	NA	0.9	7.38	0.6	5.98e-11	Intelligence (multi-trait analysis);
THYM	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg11757124	chr7:157526947	PTPRN2	-0.64	-5.22	-0.47	1.06e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs863345	0.564	rs4614256	chr1:158464611	T/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs6840360	0.615	rs55932132	chr4:152463897	G/T	cg17479576	chr4:152424074	FAM160A1	-0.85	-6.4	-0.55	5.9e-9	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.58	-0.5	2.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg03676636	chr4:99064102	C4orf37	0.39	5.55	0.49	2.57e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6728642	1.000	rs17037402	chr2:98014883	C/T	cg26665480	chr2:98280029	ACTR1B	-1.03	-4.91	-0.45	3.81e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs13185784	0.667	rs6882940	chr5:179648989	A/G	cg02891314	chr5:179741120	GFPT2	-0.69	-4.53	-0.42	1.69e-5	TRAIL levels;
THYM	cis	rs67311347	0.544	rs13098483	chr3:40342743	G/C	cg13683864	chr3:40499215	RPL14	-0.79	-7.48	-0.61	3.69e-11	Renal cell carcinoma;
THYM	cis	rs7731657	0.537	rs1468274	chr5:130363308	T/C	cg08523029	chr5:130500466	HINT1	0.73	4.94	0.45	3.38e-6	Fasting plasma glucose;
THYM	cis	rs11997175	0.583	rs66622174	chr8:33812542	T/G	ch.8.33884649F	chr8:33765107	NA	0.73	5.24	0.47	9.7e-7	Body mass index;
THYM	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg15592062	chr6:167189543	RPS6KA2	0.52	5.37	0.48	5.51e-7	Crohn's disease;
THYM	cis	rs1568889	1.000	rs34337978	chr11:28136746	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.66e-6	Bipolar disorder;
THYM	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg13010199	chr12:38710504	ALG10B	-0.67	-5.16	-0.47	1.33e-6	Morning vs. evening chronotype;
THYM	cis	rs367615	0.679	rs10070786	chr5:108815081	T/G	cg17395555	chr5:108820864	NA	0.74	9.32	0.69	4.68e-15	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs500891	0.525	rs7768550	chr6:84075810	T/G	cg21688264	chr6:84418724	SNAP91	0.78	5.0	0.46	2.6e-6	Platelet-derived growth factor BB levels;
THYM	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs72848980	0.512	rs56984020	chr10:105386275	C/A	cg00126946	chr10:105363258	SH3PXD2A	0.54	5.0	0.46	2.65e-6	White matter hyperintensity burden;
THYM	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg16049864	chr8:95962084	TP53INP1	-0.85	-8.12	-0.64	1.72e-12	Type 2 diabetes;
THYM	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg04772025	chr11:68637568	NA	0.63	6.58	0.56	2.59e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg23711669	chr6:146136114	FBXO30	0.76	6.99	0.58	3.82e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4849845	0.889	rs7578369	chr2:121052451	T/C	cg03575764	chr2:121493832	NA	-0.65	-4.86	-0.45	4.59e-6	Mean platelet volume;
THYM	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg08645402	chr16:4508243	NA	0.72	6.52	0.56	3.36e-9	Schizophrenia;
THYM	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg12179176	chr11:130786555	SNX19	0.82	7.65	0.62	1.61e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs870825	0.860	rs72703527	chr4:185605997	C/A	cg04058563	chr4:185651563	MLF1IP	1.0	7.42	0.61	4.93e-11	Blood protein levels;
THYM	cis	rs807669	0.524	rs11089258	chr22:19162276	C/T	cg02655711	chr22:19163373	SLC25A1	0.64	7.15	0.59	1.78e-10	Metabolite levels;
THYM	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg23708337	chr7:1209742	NA	0.73	5.37	0.48	5.5e-7	Longevity;Endometriosis;
THYM	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg06970220	chr1:156163860	SLC25A44	0.72	5.62	0.5	1.87e-7	Testicular germ cell tumor;
THYM	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.89	-6.54	-0.56	3.14e-9	Multiple sclerosis;
THYM	cis	rs7107174	0.681	rs881337	chr11:78128335	G/C	cg02023728	chr11:77925099	USP35	0.54	4.53	0.42	1.69e-5	Testicular germ cell tumor;
THYM	cis	rs7973719	0.868	rs7315553	chr12:7353838	A/C	cg07052231	chr12:7363540	PEX5	0.61	5.26	0.48	8.71e-7	IgG glycosylation;
THYM	cis	rs2932538	0.922	rs12402929	chr1:113072293	G/C	cg22162597	chr1:113214053	CAPZA1	0.57	4.57	0.42	1.44e-5	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg19077165	chr18:44547161	KATNAL2	-0.62	-7.82	-0.63	7.04e-12	Personality dimensions;
THYM	cis	rs12579753	1.000	rs17692461	chr12:82171755	C/G	cg07988820	chr12:82153109	PPFIA2	-0.79	-5.02	-0.46	2.38e-6	Resting heart rate;
THYM	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg08859206	chr1:53392774	SCP2	0.51	5.62	0.5	1.91e-7	Monocyte count;
THYM	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg22105103	chr4:187893119	NA	0.74	7.2	0.59	1.41e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7772486	0.875	rs2814871	chr6:146312274	G/T	cg13319975	chr6:146136371	FBXO30	-0.72	-6.03	-0.53	3.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7833986	0.941	rs13278255	chr8:57067975	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.55	5.14	0.47	1.44e-6	Height;
THYM	cis	rs7582180	0.675	rs4851313	chr2:101029002	A/G	cg21926883	chr2:100939477	LONRF2	0.64	6.02	0.53	3.28e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7572733	0.576	rs1865586	chr2:198758868	C/T	cg05783139	chr2:198650985	BOLL	-0.62	-4.84	-0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs7178572	0.568	rs1191196	chr15:77646504	C/T	cg22256960	chr15:77711686	NA	1.02	8.04	0.64	2.5e-12	Type 2 diabetes;
THYM	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg08916839	chr5:415575	AHRR	1.28	8.2	0.64	1.16e-12	Fat distribution (HIV);
THYM	cis	rs6980334	0.817	rs3805361	chr7:137794519	C/T	cg18769353	chr7:137028617	PTN	0.64	5.06	0.46	2.01e-6	Blood metabolite ratios;
THYM	cis	rs9443645	0.507	rs1475046	chr6:79461801	G/A	cg05283184	chr6:79620031	NA	-0.61	-4.89	-0.45	4.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg05707623	chr12:122985044	ZCCHC8	0.75	5.1	0.46	1.7e-6	Body mass index;
THYM	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg03188948	chr7:1209495	NA	0.91	5.04	0.46	2.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg24818145	chr4:99064322	C4orf37	0.73	5.8	0.51	8.78e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg21385522	chr1:16154831	NA	0.76	5.61	0.5	2e-7	Dilated cardiomyopathy;
THYM	cis	rs6981523	0.517	rs13251510	chr8:10916974	A/G	cg16664915	chr8:10907788	XKR6	-0.6	-5.07	-0.46	1.95e-6	Neuroticism;
THYM	cis	rs7614311	0.731	rs56263032	chr3:63863022	G/A	cg22134162	chr3:63841271	THOC7	-0.56	-6.61	-0.56	2.18e-9	Lung function (FVC);Lung function (FEV1);
THYM	trans	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs116095464	1.000	rs56075848	chr5:308352	T/C	cg22857025	chr5:266934	NA	-1.3	-4.96	-0.45	3.06e-6	Breast cancer;
THYM	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg24209194	chr3:40518798	ZNF619	0.6	4.91	0.45	3.8e-6	Renal cell carcinoma;
THYM	cis	rs2046867	0.818	rs62251647	chr3:72805789	G/A	cg25664220	chr3:72788482	NA	-0.86	-6.56	-0.56	2.76e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs6942756	1.000	rs12111832	chr7:128889025	G/C	cg02491457	chr7:128862824	NA	-0.44	-4.53	-0.42	1.69e-5	White matter hyperintensity burden;
THYM	cis	rs34684276	1	rs34684276	chr15:78813155	G/A	cg18825076	chr15:78729989	IREB2	-0.6	-5.25	-0.47	9.24e-7	Nicotine dependence;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs28829049	0.539	rs34441374	chr1:19392689	G/C	cg13387374	chr1:19411106	UBR4	0.71	5.59	0.5	2.19e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg07936489	chr17:37558343	FBXL20	-0.81	-5.3	-0.48	7.45e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11890956	chr21:40555474	PSMG1	-0.98	-8.21	-0.64	1.1e-12	Cognitive function;
THYM	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg26384229	chr12:38710491	ALG10B	-0.91	-7.45	-0.61	4.34e-11	Bladder cancer;
THYM	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.77	4.6	0.43	1.3e-5	Diabetic retinopathy;
THYM	cis	rs786425	0.502	rs2271661	chr12:124219910	T/C	cg15249119	chr12:124971054	NCOR2	0.55	5.09	0.46	1.79e-6	Pubertal anthropometrics;
THYM	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.54e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg06108461	chr20:60628389	TAF4	-1.03	-8.14	-0.64	1.49e-12	Body mass index;
THYM	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.73	4.75	0.44	7.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3917265	0.616	rs1922302	chr2:102819049	A/C	cg13315345	chr2:102803985	IL1RL2	0.75	5.06	0.46	2.02e-6	Atopic dermatitis;
THYM	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10992471	0.729	rs6479418	chr9:95064762	G/A	cg14631576	chr9:95140430	CENPP	-0.95	-10.73	-0.74	4.66e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg06618935	chr21:46677482	NA	-0.98	-9.58	-0.7	1.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9534288	0.830	rs1126365	chr13:46633196	T/A	cg15192986	chr13:46630673	CPB2	-0.66	-4.66	-0.43	1.03e-5	Blood protein levels;
THYM	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500395	1.000	rs55671623	chr16:48631154	A/G	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs514406	0.893	rs4584343	chr1:53434539	A/C	cg22166914	chr1:53195759	ZYG11B	-0.77	-7.61	-0.62	1.98e-11	Monocyte count;
THYM	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6089584	0.627	rs34496616	chr20:60561944	G/A	cg24733560	chr20:60626293	TAF4	0.59	5.82	0.51	8.03e-8	Body mass index;
THYM	cis	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg07460842	chr6:66804631	NA	0.76	4.98	0.45	2.9e-6	Exhaled nitric oxide output;
THYM	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg08807101	chr21:30365312	RNF160	-0.81	-6.03	-0.53	3.09e-8	Dental caries;
THYM	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02018176	chr4:1364513	KIAA1530	0.98	9.59	0.7	1.22e-15	Longevity;
THYM	cis	rs3126085	0.935	rs4845734	chr1:152167473	T/C	cg10321714	chr1:152280068	FLG	0.69	5.08	0.46	1.88e-6	Atopic dermatitis;
THYM	cis	rs1499972	0.941	rs62264774	chr3:117647906	C/G	cg07612923	chr3:117604196	NA	1.3	5.07	0.46	1.94e-6	Schizophrenia;
THYM	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg24678163	chr13:52769951	THSD1P	0.49	4.76	0.44	6.89e-6	Lewy body disease;
THYM	cis	rs9902453	1.000	rs4075623	chr17:28386526	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs1048238	0.818	rs2017577	chr1:16350123	C/G	cg22431228	chr1:16359049	CLCNKA	-0.56	-5.31	-0.48	7.21e-7	Systolic blood pressure;
THYM	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg24818145	chr4:99064322	C4orf37	0.7	5.51	0.49	3.09e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6674176	0.561	rs12738136	chr1:44455217	G/A	cg12908607	chr1:44402522	ARTN	-0.55	-4.68	-0.43	9.6e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs2249694	0.600	rs915906	chr10:135343738	C/T	cg20169779	chr10:135381914	SYCE1	0.65	5.08	0.46	1.88e-6	Obesity-related traits;
THYM	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7523273	0.927	rs1891423	chr1:207931913	G/A	cg22525895	chr1:207977042	MIR29B2	0.81	7.7	0.62	1.3e-11	Schizophrenia;
THYM	cis	rs7131987	0.641	rs2015599	chr12:29435480	G/A	cg09582351	chr12:29534625	ERGIC2	-0.47	-4.83	-0.44	5.12e-6	QT interval;
THYM	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg13010199	chr12:38710504	ALG10B	0.71	4.87	0.45	4.46e-6	Morning vs. evening chronotype;
THYM	cis	rs6500602	0.819	rs3747580	chr16:4455675	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	5.47	0.49	3.65e-7	Schizophrenia;
THYM	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg27129171	chr3:47204927	SETD2	0.7	6.7	0.57	1.44e-9	Colorectal cancer;
THYM	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg24874828	chr4:187887005	NA	-0.71	-7.15	-0.59	1.77e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7402982	0.625	rs4966009	chr15:99203496	C/T	cg27438980	chr15:99195143	IGF1R	-0.51	-4.68	-0.43	9.59e-6	Birth weight;
THYM	trans	rs11722228	0.549	rs73212853	chr4:10096230	C/T	cg26043149	chr18:55253948	FECH	1.16	10.82	0.74	2.98e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg08859206	chr1:53392774	SCP2	-0.66	-7.63	-0.62	1.77e-11	Monocyte count;
THYM	cis	rs72717009	0.825	rs7529425	chr1:161479599	G/A	cg15358701	chr1:161410459	NA	-0.92	-4.89	-0.45	4.1e-6	Rheumatoid arthritis;
THYM	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg22875332	chr1:76189707	ACADM	0.71	5.49	0.49	3.28e-7	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg02953382	chr22:24373134	LOC391322	-0.82	-8.94	-0.68	3.02e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs600231	0.708	rs602838	chr11:65253247	T/G	cg17120908	chr11:65337727	SSSCA1	-0.62	-4.77	-0.44	6.53e-6	Bone mineral density;
THYM	cis	rs28595532	0.920	rs114094671	chr4:119753540	G/A	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs16857609	0.564	rs3732009	chr2:218291393	G/A	cg15335768	chr2:218268053	DIRC3	-0.53	-7.53	-0.61	2.94e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	cis	rs73416724	0.544	rs6930150	chr6:43249510	C/A	cg17076780	chr6:43251928	TTBK1	0.63	4.54	0.42	1.62e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9677476	0.528	rs62197317	chr2:232054467	T/C	cg23338755	chr2:231921595	PSMD1	0.82	5.42	0.49	4.54e-7	Food antigen IgG levels;
THYM	cis	rs6032067	0.777	rs80323300	chr20:43785287	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.85	-7.76	-0.62	9.66e-12	Intelligence (multi-trait analysis);
THYM	cis	rs72827839	1.000	rs17695373	chr17:46375467	G/A	cg23391107	chr17:45924227	SP6	0.76	4.58	0.43	1.39e-5	Ease of getting up in the morning;
THYM	cis	rs28374715	0.681	rs7163989	chr15:41614621	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.16	-13.9	-0.82	1.29e-24	Ulcerative colitis;
THYM	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs11077998	1.000	rs11077998	chr17:80483946	C/G	cg11779900	chr17:80519722	FOXK2	0.53	4.51	0.42	1.84e-5	Reticulocyte fraction of red cells;
THYM	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg21644426	chr2:191273491	MFSD6	-0.74	-5.2	-0.47	1.13e-6	Diastolic blood pressure;
THYM	cis	rs6876348	0.516	rs257999	chr5:128318589	G/A	cg25555059	chr5:128301488	SLC27A6	-0.45	-4.74	-0.44	7.63e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	6.14	0.53	1.89e-8	Mean corpuscular hemoglobin;
THYM	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg22433210	chr17:43662623	NA	-1.05	-8.08	-0.64	2e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg03609598	chr5:56110824	MAP3K1	-0.89	-6.07	-0.53	2.63e-8	Initial pursuit acceleration;
THYM	cis	rs595982	0.661	rs657008	chr19:49373632	A/G	cg21252483	chr19:49399788	TULP2	-0.56	-4.99	-0.46	2.68e-6	Red cell distribution width;
THYM	cis	rs4792901	0.722	rs12603085	chr17:41545847	G/A	cg21940313	chr17:41620911	ETV4	-0.51	-5.2	-0.47	1.12e-6	Dupuytren's disease;
THYM	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03264133	chr6:25882463	NA	-0.92	-8.02	-0.64	2.72e-12	Blood metabolite levels;
THYM	cis	rs1198430	0.562	rs7523811	chr1:23789567	C/T	cg19827787	chr1:23763612	ASAP3	-0.56	-4.58	-0.43	1.42e-5	Total cholesterol levels;
THYM	cis	rs4363385	0.531	rs11205188	chr1:153053645	A/T	cg13444842	chr1:152974279	SPRR3	-0.61	-4.82	-0.44	5.41e-6	Inflammatory skin disease;
THYM	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg08773314	chr2:239334832	ASB1	0.65	9.89	0.71	2.85e-16	Multiple system atrophy;
THYM	cis	rs7586879	0.964	rs6545795	chr2:25116783	C/T	cg15423357	chr2:25149977	NA	0.56	5.49	0.49	3.41e-7	Body mass index;
THYM	cis	rs8067545	0.611	rs8078716	chr17:20044291	G/A	cg13482628	chr17:19912719	NA	0.55	4.68	0.43	9.41e-6	Schizophrenia;
THYM	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg10792982	chr14:105748885	BRF1	0.74	7.66	0.62	1.56e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6429082	0.608	rs903348	chr1:235571343	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.62	-4.62	-0.43	1.19e-5	Adiposity;
THYM	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg06028808	chr11:68637592	NA	0.66	7.04	0.59	2.94e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg08885076	chr2:99613938	TSGA10	-0.58	-5.74	-0.51	1.11e-7	Chronic sinus infection;
THYM	cis	rs3126085	0.877	rs12116736	chr1:152167062	C/T	cg10321714	chr1:152280068	FLG	0.65	4.72	0.44	8.02e-6	Atopic dermatitis;
THYM	cis	rs2109514	0.542	rs7796627	chr7:116086716	T/C	cg12739419	chr7:116140593	CAV2	-0.45	-4.49	-0.42	2.03e-5	Prevalent atrial fibrillation;
THYM	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg08999081	chr20:33150536	PIGU	0.78	7.16	0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs904251	0.797	rs1776460	chr6:37485484	A/G	cg01843034	chr6:37503916	NA	-0.64	-4.65	-0.43	1.06e-5	Cognitive performance;
THYM	cis	rs600806	0.850	rs12073497	chr1:109974450	A/C	cg23032129	chr1:109941072	SORT1	-0.54	-4.53	-0.42	1.69e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9527	0.615	rs7096452	chr10:104736563	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-4.68	-0.43	9.59e-6	Arsenic metabolism;
THYM	cis	rs12817549	0.728	rs7975577	chr12:94173682	T/A	cg19571390	chr12:94157676	CRADD	0.55	4.61	0.43	1.25e-5	Hip circumference adjusted for BMI;
THYM	cis	rs28595532	1.000	rs115965820	chr4:119586485	G/A	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08109568	chr15:31115862	NA	-0.59	-5.79	-0.51	9.01e-8	Huntington's disease progression;
THYM	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg14664628	chr15:75095509	CSK	-0.67	-5.08	-0.46	1.87e-6	Breast cancer;
THYM	cis	rs6424115	0.862	rs34845821	chr1:24066486	C/T	cg15997130	chr1:24165203	NA	-0.68	-4.74	-0.44	7.63e-6	Immature fraction of reticulocytes;
THYM	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg17143192	chr8:8559678	CLDN23	0.98	7.54	0.61	2.83e-11	Obesity-related traits;
THYM	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg06028605	chr16:24865363	SLC5A11	0.64	5.21	0.47	1.11e-6	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-11.55	-0.76	8.36e-20	Height;
THYM	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg16006841	chr5:176797999	RGS14	0.53	6.38	0.55	6.33e-9	Hemoglobin concentration;Hematocrit;
THYM	cis	rs9302065	0.681	rs9524903	chr13:95963565	A/G	cg26751094	chr13:95954534	ABCC4	-0.45	-4.99	-0.46	2.76e-6	Blood metabolite levels;
THYM	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg06481639	chr22:41940642	POLR3H	-0.64	-5.16	-0.47	1.33e-6	Neuroticism;
THYM	cis	rs11605275	1.000	rs11604681	chr11:20031042	G/A	cg14835545	chr11:20032148	NAV2	-1.38	-7.35	-0.6	7e-11	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs4654899	0.865	rs4654891	chr1:21286391	T/C	cg01072550	chr1:21505969	NA	-0.75	-6.71	-0.57	1.42e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg18402987	chr7:1209562	NA	0.71	5.06	0.46	2.04e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg09165964	chr15:75287851	SCAMP5	-1.06	-10.81	-0.74	3.17e-18	Blood trace element (Zn levels);
THYM	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-6.98	-0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.46e-7	Heart rate;
THYM	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg14972814	chr11:95582409	MTMR2	-0.64	-5.33	-0.48	6.5e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7107174	1.000	rs9651768	chr11:77996020	C/T	cg02023728	chr11:77925099	USP35	0.7	6.39	0.55	6.03e-9	Testicular germ cell tumor;
THYM	cis	rs10203711	0.966	rs4998692	chr2:239564772	T/G	cg14580085	chr2:239553406	NA	0.68	6.07	0.53	2.58e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	trans	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg10856724	chr12:34555212	NA	-0.86	-7.61	-0.62	2.01e-11	Bladder cancer;
THYM	cis	rs4845875	0.600	rs4846041	chr1:11837051	C/T	cg14194983	chr1:11908298	NPPA	0.54	4.97	0.45	2.93e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg14008862	chr17:28927542	LRRC37B2	0.88	4.55	0.42	1.57e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs2625529	0.586	rs2306489	chr15:72227471	G/A	cg16672083	chr15:72433130	SENP8	0.51	4.71	0.43	8.58e-6	Red blood cell count;
THYM	cis	rs9807841	0.643	rs4435370	chr19:10774623	G/A	cg16900796	chr19:10755136	SLC44A2	0.32	4.87	0.45	4.5e-6	Inflammatory skin disease;
THYM	cis	rs7107174	1.000	rs55761949	chr11:77993860	A/G	cg19901956	chr11:77921274	USP35	-0.72	-5.45	-0.49	4.02e-7	Testicular germ cell tumor;
THYM	cis	rs6430585	0.528	rs309167	chr2:136669264	C/T	cg20242066	chr2:136595261	LCT	0.52	4.89	0.45	4.16e-6	Corneal structure;
THYM	cis	rs4474465	0.512	rs12419623	chr11:78249478	A/T	cg19901956	chr11:77921274	USP35	0.61	4.88	0.45	4.21e-6	Alzheimer's disease (survival time);
THYM	cis	rs2204008	0.567	rs2703685	chr12:38081423	G/C	cg26384229	chr12:38710491	ALG10B	0.72	5.52	0.49	2.98e-7	Bladder cancer;
THYM	cis	rs4499344	0.730	rs28402742	chr19:33099734	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.88	7.54	0.61	2.76e-11	Mean platelet volume;
THYM	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg27284194	chr4:1044797	NA	-0.64	-4.89	-0.45	4.08e-6	Recombination rate (females);
THYM	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg17426766	chr1:2046864	PRKCZ	-0.4	-4.71	-0.44	8.33e-6	Height;
THYM	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg00717180	chr2:96193071	NA	-0.65	-6.88	-0.58	6.46e-10	Height;
THYM	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg00129232	chr17:37814104	STARD3	-0.71	-4.8	-0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9355610	0.727	rs2247315	chr6:167370211	A/C	cg15592062	chr6:167189543	RPS6KA2	0.52	5.37	0.48	5.51e-7	Graves' disease;
THYM	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg27129171	chr3:47204927	SETD2	-0.71	-6.71	-0.57	1.4e-9	Colorectal cancer;
THYM	cis	rs901683	1.000	rs17157928	chr10:46048229	C/T	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg17063962	chr7:91808500	NA	1.16	13.2	0.8	3.33e-23	Breast cancer;
THYM	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg18876405	chr7:65276391	NA	-0.55	-4.73	-0.44	7.84e-6	Aortic root size;
THYM	cis	rs11651000	0.947	rs59216876	chr17:45832965	G/A	cg06532163	chr17:45867833	NA	0.58	4.49	0.42	2e-5	IgG glycosylation;
THYM	trans	rs11689435	0.841	rs34713198	chr2:218310661	G/A	cg08509270	chr14:101513595	MIR889;MIR539	0.83	7.04	0.59	2.99e-10	Metabolite levels (MHPG);
THYM	cis	rs4808199	0.649	rs34755166	chr19:19665581	G/A	cg03709012	chr19:19516395	GATAD2A	1.07	5.33	0.48	6.54e-7	Nonalcoholic fatty liver disease;
THYM	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.35	-0.65	5.58e-13	Mean corpuscular volume;
THYM	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg17279839	chr7:150038598	RARRES2	0.57	5.5	0.49	3.16e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs8028313	0.504	rs2899730	chr15:68172520	G/T	cg24579218	chr15:68104479	NA	0.67	6.32	0.54	8.58e-9	Obesity;
THYM	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg19875535	chr5:140030758	IK	0.64	4.95	0.45	3.24e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.25	5.16	0.47	1.35e-6	Obesity-related traits;
THYM	cis	rs116095464	1.000	rs56235400	chr5:312625	G/A	cg22857025	chr5:266934	NA	-1.41	-5.27	-0.48	8.69e-7	Breast cancer;
THYM	cis	rs870825	0.929	rs871253	chr4:185589234	G/A	cg04058563	chr4:185651563	MLF1IP	0.99	6.84	0.57	7.77e-10	Blood protein levels;
THYM	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg23352942	chr3:46931381	PTH1R	0.59	5.27	0.48	8.6e-7	Birth weight;
THYM	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs4363385	0.747	rs2339495	chr1:152975116	A/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.53	-0.42	1.74e-5	Inflammatory skin disease;
THYM	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg14019146	chr3:50243930	SLC38A3	0.55	4.6	0.43	1.3e-5	Body mass index;
THYM	cis	rs9443645	0.527	rs3902856	chr6:79699837	C/T	cg05283184	chr6:79620031	NA	-0.6	-4.67	-0.43	9.91e-6	Intelligence (multi-trait analysis);
THYM	cis	rs28829049	0.508	rs4578242	chr1:19391565	G/C	cg13387374	chr1:19411106	UBR4	0.7	5.24	0.47	9.48e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs2637266	0.626	rs2588329	chr10:78552782	C/T	cg18941641	chr10:78392320	NA	0.74	5.81	0.51	8.27e-8	Pulmonary function;
THYM	cis	rs901683	1.000	rs35036712	chr10:46046710	C/A	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg24163568	chr5:669837	TPPP	0.58	5.36	0.48	5.76e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs11264213	0.551	rs11263852	chr1:36554442	G/C	cg27506609	chr1:36549197	TEKT2	-1.18	-6.41	-0.55	5.61e-9	Schizophrenia;
THYM	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg23851026	chr2:136556271	LCT	-0.55	-5.55	-0.49	2.62e-7	Mosquito bite size;
THYM	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg27129171	chr3:47204927	SETD2	0.8	7.64	0.62	1.69e-11	Colorectal cancer;
THYM	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs2294693	0.786	rs10456497	chr6:40989057	T/C	cg14418226	chr6:40996092	UNC5CL	0.7	5.72	0.51	1.22e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs9902453	0.753	rs3097118	chr17:27978466	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.43	0.55	5.19e-9	Coffee consumption (cups per day);
THYM	cis	rs7793919	0.764	rs6944865	chr7:4766383	A/T	cg09789173	chr7:4769017	FOXK1	0.87	8.62	0.66	1.46e-13	Mosquito bite size;
THYM	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg08045932	chr20:61659980	NA	0.94	10.68	0.74	5.76e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4845570	0.831	rs11588634	chr1:151780686	T/A	cg07092448	chr1:151763213	TDRKH	-1.05	-5.96	-0.52	4.19e-8	Coronary artery disease;
THYM	cis	rs9329289	0.510	rs9733402	chr10:2551532	G/A	cg07014206	chr10:2547000	NA	-0.57	-5.23	-0.47	1.03e-6	Age-related hearing impairment;
THYM	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg06481639	chr22:41940642	POLR3H	0.77	5.37	0.48	5.67e-7	Vitiligo;
THYM	cis	rs208520	0.690	rs207082	chr6:66773796	G/A	cg07460842	chr6:66804631	NA	-1.09	-7.92	-0.63	4.41e-12	Exhaled nitric oxide output;
THYM	cis	rs9527	0.830	rs11191440	chr10:104641511	G/A	cg15744005	chr10:104629667	AS3MT	-0.66	-4.82	-0.44	5.36e-6	Arsenic metabolism;
THYM	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg25382214	chr1:3105252	PRDM16	-0.55	-4.71	-0.44	8.37e-6	Migraine;
THYM	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg08847533	chr14:75593920	NEK9	1.01	11.32	0.76	2.63e-19	Height;
THYM	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg24818145	chr4:99064322	C4orf37	-0.9	-7.52	-0.61	3.12e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg23711669	chr6:146136114	FBXO30	0.96	9.87	0.71	3.12e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	7.84	0.63	6.39e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs72653721	0.838	rs958712	chr6:11026161	T/C	cg24724428	chr6:11044888	ELOVL2	0.55	4.53	0.42	1.71e-5	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
THYM	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg15352829	chr14:105391018	PLD4	-0.32	-4.62	-0.43	1.2e-5	Rheumatoid arthritis;
THYM	cis	rs12920732	0.583	rs8058755	chr16:84785203	C/T	cg26765084	chr16:85018922	ZDHHC7	-0.44	-4.54	-0.42	1.63e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
THYM	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg09307838	chr4:120376055	NA	0.6	4.54	0.42	1.63e-5	Corneal astigmatism;
THYM	cis	rs10057188	0.569	rs7734765	chr5:77921394	C/A	cg02642549	chr5:77805886	LHFPL2	0.54	4.57	0.42	1.45e-5	Pulse pressure;
THYM	cis	rs7267979	1.000	rs7018	chr20:25278261	A/G	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg06636001	chr8:8085503	FLJ10661	-0.89	-9.22	-0.69	7.67e-15	Neuroticism;
THYM	cis	rs1863824	0.625	rs10887599	chr10:88168780	G/A	cg06895675	chr10:88137553	NA	0.58	4.96	0.45	3.06e-6	Schizophrenia;
THYM	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.64	0.43	1.1e-5	Bipolar disorder;
THYM	cis	rs4820539	0.708	rs5751591	chr22:23489042	G/A	cg14186256	chr22:23484241	RTDR1	0.7	5.1	0.46	1.73e-6	Bone mineral density;
THYM	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg00376283	chr12:123451042	ABCB9	0.92	7.04	0.59	2.94e-10	Platelet count;
THYM	cis	rs10029851	0.627	rs17512211	chr4:109528880	A/T	cg21648245	chr4:109541405	LOC285456;RPL34	-0.64	-4.97	-0.45	2.9e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs7618501	0.501	rs7627864	chr3:49926613	C/G	cg14019146	chr3:50243930	SLC38A3	-0.61	-5.14	-0.47	1.45e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7084402	0.967	rs7897298	chr10:60274606	T/C	cg07615347	chr10:60278583	BICC1	-0.56	-5.15	-0.47	1.42e-6	Refractive error;
THYM	cis	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg13443165	chr9:33130375	B4GALT1	-0.86	-7.83	-0.63	6.79e-12	IgG glycosylation;
THYM	cis	rs911555	0.576	rs8015723	chr14:103895909	A/G	cg12935359	chr14:103987150	CKB	0.51	5.58	0.5	2.29e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1278769	0.786	rs9577175	chr13:113543355	C/T	cg01161842	chr13:113518337	ATP11A	0.67	4.64	0.43	1.13e-5	Interstitial lung disease;
THYM	cis	rs904251	0.861	rs1757171	chr6:37487044	T/C	cg25019722	chr6:37503610	NA	-0.65	-5.43	-0.49	4.32e-7	Cognitive performance;
THYM	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg20469991	chr17:27169893	C17orf63	-0.79	-4.79	-0.44	6.18e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs354225	0.544	rs12713265	chr2:54805409	C/T	cg23486701	chr2:54789491	SPTBN1	0.34	4.49	0.42	2e-5	Schizophrenia;
THYM	cis	rs4242434	0.819	rs2306518	chr8:22470308	A/G	cg21658235	chr8:22456391	C8orf58	0.44	4.56	0.42	1.54e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg03806693	chr22:41940476	POLR3H	1.07	8.31	0.65	6.6e-13	Vitiligo;
THYM	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg03060546	chr3:49711283	APEH	-0.75	-6.24	-0.54	1.21e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg24209194	chr3:40518798	ZNF619	0.55	4.58	0.43	1.43e-5	Renal cell carcinoma;
THYM	cis	rs2050392	0.630	rs303426	chr10:30740379	A/G	cg25182066	chr10:30743637	MAP3K8	0.52	4.54	0.42	1.67e-5	Inflammatory bowel disease;
THYM	cis	rs7119	0.636	rs34020536	chr15:77819586	G/A	cg10437265	chr15:77819839	NA	0.7	6.4	0.55	5.91e-9	Type 2 diabetes;
THYM	cis	rs12310956	0.510	rs10844694	chr12:33865682	A/C	cg10856724	chr12:34555212	NA	-0.65	-5.89	-0.52	5.95e-8	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08704250	chr15:31115839	NA	-0.53	-6.18	-0.54	1.61e-8	Huntington's disease progression;
THYM	cis	rs74417235	0.639	rs7443642	chr5:154053450	A/G	cg05662444	chr5:154026397	NA	-0.55	-4.83	-0.44	5.29e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg18352616	chr4:3374830	RGS12	0.75	8.46	0.66	3.18e-13	Serum sulfate level;
THYM	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg00256281	chr22:41985642	PMM1	0.55	4.63	0.43	1.15e-5	Vitiligo;
THYM	cis	rs6754311	0.593	rs313528	chr2:136445869	G/A	cg23851026	chr2:136556271	LCT	0.59	5.62	0.5	1.91e-7	Mosquito bite size;
THYM	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg13010199	chr12:38710504	ALG10B	0.62	4.46	0.42	2.21e-5	Bladder cancer;
THYM	cis	rs4845875	0.626	rs11121828	chr1:11834454	C/T	cg25341925	chr1:11908058	NPPA	0.44	4.76	0.44	7.01e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs72901758	0.661	rs72909031	chr17:76250235	A/G	cg25512537	chr17:76250053	NA	0.42	5.64	0.5	1.77e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
THYM	cis	rs728616	0.867	rs61860417	chr10:81734727	C/T	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg07460842	chr6:66804631	NA	1.11	8.12	0.64	1.7e-12	Exhaled nitric oxide output;
THYM	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	6.0	0.52	3.6e-8	Schizophrenia;
THYM	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg01017244	chr2:74357527	NA	1.08	9.57	0.7	1.37e-15	Gestational age at birth (maternal effect);
THYM	cis	rs912057	1.000	rs1294407	chr6:6738103	C/G	cg06612196	chr6:6737390	NA	0.68	9.36	0.69	3.91e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs448720	0.811	rs338340	chr15:68202957	T/C	cg24579218	chr15:68104479	NA	-0.52	-4.55	-0.42	1.59e-5	Cognitive performance;
THYM	cis	rs6087990	0.899	rs6087999	chr20:31363774	A/G	cg13636640	chr20:31349939	DNMT3B	0.95	10.42	0.73	2.12e-17	Ulcerative colitis;
THYM	cis	rs4713118	0.619	rs200486	chr6:27779506	C/T	cg08968635	chr6:28129556	ZNF389	0.67	4.68	0.43	9.38e-6	Parkinson's disease;
THYM	cis	rs35883536	0.647	rs12023028	chr1:101042717	C/T	cg06223162	chr1:101003688	GPR88	-0.8	-6.9	-0.58	5.77e-10	Monocyte count;
THYM	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.84e-8	Systolic blood pressure;
THYM	cis	rs9880211	1.000	rs9837158	chr3:136073163	C/T	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs240764	0.746	rs240141	chr6:101084946	G/A	cg21058520	chr6:100914733	NA	-0.57	-5.02	-0.46	2.39e-6	Neuroticism;
THYM	cis	rs1907989	0.521	rs4689941	chr4:4809353	A/C	cg01956386	chr4:5056767	STK32B	-0.4	-4.57	-0.42	1.46e-5	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg00147160	chr1:26503991	CNKSR1	0.53	7.26	0.6	1.08e-10	Height;
THYM	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg07777115	chr5:623756	CEP72	-0.78	-4.58	-0.43	1.38e-5	Obesity-related traits;
THYM	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg26354017	chr1:205819088	PM20D1	0.97	10.36	0.73	2.85e-17	Menarche (age at onset);
THYM	cis	rs684232	0.543	rs4968095	chr17:507539	A/G	cg15660573	chr17:549704	VPS53	-0.91	-8.91	-0.67	3.52e-14	Prostate cancer;
THYM	cis	rs2820651	1.000	rs79849781	chr10:1473961	A/C	cg27404824	chr10:1454848	ADARB2	0.91	4.89	0.45	4.05e-6	Migraine with aura;
THYM	cis	rs9810259	0.582	rs12490265	chr3:12384542	C/T	cg05467012	chr3:12595696	NA	0.55	4.5	0.42	1.94e-5	Platelet count;
THYM	cis	rs61931739	0.890	rs814663	chr12:34106338	C/T	cg10856724	chr12:34555212	NA	-0.6	-5.27	-0.48	8.53e-7	Morning vs. evening chronotype;
THYM	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg02527881	chr3:46936655	PTH1R	0.57	5.1	0.46	1.75e-6	Colorectal cancer;
THYM	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg11845111	chr2:191398756	TMEM194B	-1.04	-8.29	-0.65	7.45e-13	Diastolic blood pressure;
THYM	cis	rs924607	0.583	rs12516251	chr5:608939	C/T	cg24686453	chr5:612880	CEP72	-0.41	-4.74	-0.44	7.35e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs11771526	0.901	rs62457473	chr7:32306990	G/A	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs7572733	0.534	rs700672	chr2:198691455	G/A	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs3781426	0.824	rs10901850	chr10:126707881	C/T	cg04494136	chr10:126703576	CTBP2	-0.43	-6.39	-0.55	6.08e-9	Height;
THYM	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg23711669	chr6:146136114	FBXO30	-0.88	-8.57	-0.66	1.89e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg01324343	chr3:183735012	ABCC5	0.89	12.71	0.79	3.23e-22	Anterior chamber depth;
THYM	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1670533	1.000	rs11724371	chr4:1052125	T/C	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg02887458	chr19:19495540	GATAD2A	0.46	5.1	0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs9902453	1.000	rs4465650	chr17:28396721	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.81	0.44	5.64e-6	Coffee consumption (cups per day);
THYM	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg22709100	chr7:91322751	NA	0.62	4.79	0.44	6.11e-6	Breast cancer;
THYM	cis	rs977987	0.750	rs4888406	chr16:75432334	G/T	cg03315344	chr16:75512273	CHST6	0.73	6.28	0.54	1.02e-8	Dupuytren's disease;
THYM	cis	rs4806103	1	rs4806103	chr19:35674870	A/G	cg24346223	chr19:36279422	SNX26	-0.49	-4.65	-0.43	1.05e-5	Reticulocyte count;
THYM	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg15212455	chr7:39170539	POU6F2	0.66	6.22	0.54	1.33e-8	IgG glycosylation;
THYM	cis	rs2806561	0.964	rs683052	chr1:23514953	T/C	cg12483005	chr1:23474871	LUZP1	0.55	5.69	0.5	1.38e-7	Height;
THYM	cis	rs17127169	1.000	rs76454749	chr1:65430959	G/T	cg12075498	chr1:65428216	JAK1	-0.46	-4.87	-0.45	4.49e-6	Sitting height ratio;
THYM	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg08645402	chr16:4508243	NA	0.58	5.01	0.46	2.53e-6	Schizophrenia;
THYM	cis	rs2898681	0.614	rs11947787	chr4:53705225	C/A	cg21521518	chr4:53727714	RASL11B	0.44	5.08	0.46	1.89e-6	Optic nerve measurement (cup area);
THYM	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg12379764	chr21:47803548	PCNT	-0.8	-5.15	-0.47	1.38e-6	Testicular germ cell tumor;
THYM	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg05335186	chr13:53173507	NA	-0.49	-5.77	-0.51	9.84e-8	Lewy body disease;
THYM	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.65	5.09	0.46	1.8e-6	Chronic sinus infection;
THYM	cis	rs981844	0.885	rs72731673	chr4:154667446	A/G	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg15691649	chr6:25882328	NA	0.73	5.61	0.5	1.97e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg16486109	chr11:613632	IRF7	0.51	5.41	0.49	4.64e-7	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg02353165	chr6:42928485	GNMT	0.83	7.54	0.61	2.73e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs3087591	0.960	rs2905794	chr17:29470002	G/A	cg24425628	chr17:29625626	OMG;NF1	0.64	5.54	0.49	2.68e-7	Hip circumference;
THYM	cis	rs72960926	0.590	rs114287599	chr6:74748504	C/T	cg06106633	chr6:73969316	KHDC1	0.9	4.61	0.43	1.27e-5	Metabolite levels (MHPG);
THYM	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg00256281	chr22:41985642	PMM1	0.56	4.62	0.43	1.19e-5	Vitiligo;
THYM	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg11644478	chr21:40555479	PSMG1	0.95	7.08	0.59	2.45e-10	Cognitive function;
THYM	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg18252515	chr7:66147081	NA	0.72	5.6	0.5	2.03e-7	Aortic root size;
THYM	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg13695892	chr22:41940480	POLR3H	0.93	7.11	0.59	2.14e-10	Vitiligo;
THYM	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg03388043	chr17:80084554	CCDC57	0.68	5.9	0.52	5.52e-8	Life satisfaction;
THYM	cis	rs2663905	0.611	rs2663920	chr15:81396404	A/G	cg05624577	chr15:81411055	NA	-0.61	-4.59	-0.43	1.35e-5	QT interval (drug interaction);
THYM	cis	rs259282	0.574	rs12610727	chr19:33116138	G/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.61	4.75	0.44	7.33e-6	Schizophrenia;
THYM	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg23711669	chr6:146136114	FBXO30	-0.9	-8.7	-0.67	9.84e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2708977	0.901	rs6753667	chr2:97160382	G/A	cg01950434	chr2:97203154	ARID5A	-0.52	-4.56	-0.42	1.52e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs9992101	0.578	rs4859663	chr4:77235756	C/A	cg20311846	chr4:77356250	SHROOM3	-0.5	-5.34	-0.48	6.28e-7	Creatinine levels;
THYM	cis	rs12282928	0.917	rs1601046	chr11:48337656	A/G	cg22827986	chr11:48284249	OR4X1	0.53	5.59	0.5	2.21e-7	Migraine - clinic-based;
THYM	trans	rs9951602	1.000	rs9949784	chr18:76649994	A/G	cg02800362	chr5:177631904	HNRNPAB	1.21	7.03	0.58	3.1e-10	Obesity-related traits;
THYM	cis	rs5769707	0.632	rs135876	chr22:50013573	A/G	cg07959070	chr22:50026188	C22orf34	-0.28	-4.88	-0.45	4.19e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs988913	1.000	rs9367601	chr6:54839162	G/T	cg04690482	chr6:54711388	FAM83B	0.46	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg21984481	chr17:79567631	NPLOC4	-0.55	-5.74	-0.51	1.14e-7	Eye color traits;
THYM	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg13918804	chr1:2043761	PRKCZ	0.91	9.19	0.69	9.05e-15	Height;
THYM	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg12560992	chr17:57184187	TRIM37	-0.9	-8.42	-0.65	3.98e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg03264133	chr6:25882463	NA	0.65	5.09	0.46	1.83e-6	Schizophrenia;
THYM	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg23131131	chr22:24373011	LOC391322	-0.88	-9.96	-0.71	2e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg02734326	chr4:10020555	SLC2A9	-0.6	-4.92	-0.45	3.6e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg10523679	chr1:76189770	ACADM	0.89	8.55	0.66	2.05e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs3087591	1.000	rs2905877	chr17:29543269	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.59	-4.85	-0.45	4.81e-6	Hip circumference;
THYM	cis	rs10089	1.000	rs10478798	chr5:127442394	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg11812906	chr14:75593930	NEK9	0.87	8.3	0.65	7.13e-13	Height;
THYM	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	8.7	0.67	9.84e-14	Chronic sinus infection;
THYM	cis	rs6980334	1.000	rs7787591	chr7:137778203	C/T	cg22979093	chr7:137028410	PTN	0.61	4.91	0.45	3.77e-6	Blood metabolite ratios;
THYM	cis	rs55665837	1.000	rs11023216	chr11:14437153	G/A	cg19336497	chr11:14380999	RRAS2	-0.64	-6.95	-0.58	4.63e-10	Vitamin D levels;
THYM	cis	rs765787	0.530	rs12906537	chr15:45520061	T/C	cg24006582	chr15:45444508	DUOX1	0.81	6.51	0.56	3.6e-9	Uric acid levels;
THYM	cis	rs8033133	0.957	rs7162559	chr15:25352341	C/T	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	0.67	4.82	0.44	5.51e-6	Blood osmolality (transformed sodium);
THYM	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg06238570	chr21:40685208	BRWD1	-1.0	-9.57	-0.7	1.36e-15	Cognitive function;
THYM	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-5.68	-0.5	1.44e-7	Blood protein levels;
THYM	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	4.54	0.42	1.66e-5	Hip circumference adjusted for BMI;
THYM	cis	rs2235649	0.828	rs9938694	chr16:1849872	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.46	-4.95	-0.45	3.2e-6	Blood metabolite levels;
THYM	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	9.44	0.7	2.59e-15	Chronic sinus infection;
THYM	cis	rs13315871	1.000	rs13320620	chr3:58408845	A/G	cg12435725	chr3:58293450	RPP14	-0.46	-4.93	-0.45	3.54e-6	Cholesterol, total;
THYM	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg11764359	chr7:65958608	NA	0.82	6.56	0.56	2.81e-9	Aortic root size;
THYM	cis	rs9790314	0.846	rs9834659	chr3:160980947	A/C	cg03342759	chr3:160939853	NMD3	-0.95	-9.47	-0.7	2.2e-15	Morning vs. evening chronotype;
THYM	cis	rs950776	0.684	rs61012457	chr15:78865694	C/G	cg06917634	chr15:78832804	PSMA4	0.88	7.36	0.6	6.64e-11	Sudden cardiac arrest;
THYM	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg26441486	chr22:50317300	CRELD2	0.4	6.33	0.54	8.22e-9	Schizophrenia;
THYM	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg24578937	chr1:2090814	PRKCZ	0.59	5.88	0.52	6.22e-8	Height;
THYM	cis	rs3768617	0.510	rs10797838	chr1:183077020	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	trans	rs9929218	0.954	rs4485355	chr16:68754730	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-7.53	-0.61	2.92e-11	Colorectal cancer;
THYM	cis	rs11186	0.556	rs72904490	chr2:189951830	T/A	cg11041835	chr2:189156425	GULP1	0.81	4.87	0.45	4.38e-6	Parkinson's disease;
THYM	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg07293736	chr12:132670858	NA	0.44	4.63	0.43	1.16e-5	Anti-saccade response;
THYM	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg18681998	chr4:17616180	MED28	0.8	7.06	0.59	2.76e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6988636	1.000	rs13261100	chr8:124190312	G/A	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg12560992	chr17:57184187	TRIM37	-0.88	-8.3	-0.65	7.04e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg18512352	chr11:47633146	NA	-0.52	-6.14	-0.53	1.92e-8	Subjective well-being;
THYM	cis	rs6988636	1.000	rs9987357	chr8:124187620	T/G	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.6	-0.5	2.08e-7	Type 2 diabetes;
THYM	cis	rs7267979	0.868	rs6138546	chr20:25216534	G/A	cg08601574	chr20:25228251	PYGB	0.62	4.82	0.44	5.44e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4919694	0.901	rs12251035	chr10:104671459	A/C	cg04362960	chr10:104952993	NT5C2	1.14	6.92	0.58	5.36e-10	Arsenic metabolism;
THYM	cis	rs2913737	0.530	rs2963671	chr5:175924139	T/C	cg27658698	chr5:175955578	RNF44	0.59	4.66	0.43	1.03e-5	Obesity-related traits;
THYM	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.52e-7	Heart rate;
THYM	cis	rs3741151	1.000	rs112628073	chr11:73013626	C/T	cg12959048	chr11:73096162	RELT	-0.49	-4.54	-0.42	1.63e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs10779751	1.000	rs2253213	chr1:11265785	A/G	cg08854313	chr1:11322531	MTOR	0.85	6.74	0.57	1.22e-9	Body mass index;
THYM	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg26384229	chr12:38710491	ALG10B	0.98	7.79	0.62	8.42e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg24531977	chr5:56204891	C5orf35	-0.72	-5.83	-0.51	7.64e-8	Initial pursuit acceleration;
THYM	cis	rs1986112	1	rs1986112	chr15:63540572	G/A	cg09251291	chr15:63483946	RAB8B	-0.5	-4.69	-0.43	9.01e-6	Schizophrenia;
THYM	cis	rs9902453	0.967	rs4356528	chr17:28489670	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	4.6	0.43	1.33e-5	Coffee consumption (cups per day);
THYM	trans	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg10856724	chr12:34555212	NA	-0.87	-7.75	-0.62	9.89e-12	Bladder cancer;
THYM	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg24692254	chr21:30365293	RNF160	1.06	9.93	0.71	2.29e-16	Dental caries;
THYM	cis	rs7220711	0.934	rs9909172	chr17:41787521	T/C	cg26893861	chr17:41843967	DUSP3	0.65	5.63	0.5	1.83e-7	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs6032067	0.777	rs2868237	chr20:43794189	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg09359103	chr1:154839909	KCNN3	0.53	5.67	0.5	1.51e-7	Prostate cancer;
THYM	cis	rs7084921	0.549	rs9888058	chr10:101859205	C/T	cg11344164	chr10:101878520	NA	-0.53	-4.51	-0.42	1.89e-5	Bone mineral density;
THYM	cis	rs12367572	0.965	rs1506678	chr12:45249492	A/G	cg03114573	chr12:45410052	DBX2	-0.52	-4.95	-0.45	3.16e-6	Gut microbiome composition (summer);
THYM	cis	rs861020	1.000	rs632746	chr1:209982515	C/T	cg05527609	chr1:210001259	C1orf107	1.02	7.65	0.62	1.6e-11	Orofacial clefts;
THYM	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.3	4.58	0.43	1.42e-5	Obesity-related traits;
THYM	cis	rs12754538	0.850	rs12040962	chr1:8536901	A/C	cg06159269	chr1:8767347	RERE	0.22	4.7	0.43	8.75e-6	Subjective well-being;
THYM	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg13939156	chr17:80058883	NA	0.4	5.29	0.48	7.68e-7	Life satisfaction;
THYM	cis	rs7010267	0.542	rs4618726	chr8:120009385	C/A	cg17171407	chr8:119960777	TNFRSF11B	0.6	4.83	0.44	5.29e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs55871839	0.559	rs7834158	chr8:59843813	C/A	cg07426533	chr8:59803705	TOX	0.62	5.11	0.46	1.63e-6	Pneumonia;
THYM	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-8.52	-0.66	2.33e-13	Schizophrenia;
THYM	cis	rs7523273	0.586	rs2724359	chr1:207935706	A/G	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	cis	rs2282300	0.653	rs12800124	chr11:30239865	A/G	cg25418670	chr11:30344373	C11orf46	-0.81	-6.87	-0.58	6.66e-10	Morning vs. evening chronotype;
THYM	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg14983838	chr19:29218262	NA	1.0	8.15	0.64	1.45e-12	Methadone dose in opioid dependence;
THYM	cis	rs28595532	0.920	rs115688334	chr4:119770805	C/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs7512552	0.839	rs1260459	chr1:150348253	T/G	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg17747265	chr1:1875780	NA	0.57	5.91	0.52	5.25e-8	Body mass index;
THYM	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg05043794	chr9:111880884	C9orf5	-0.36	-5.04	-0.46	2.2e-6	Menarche (age at onset);
THYM	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg09436375	chr6:42928200	GNMT	-0.43	-5.62	-0.5	1.9e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg11335335	chr11:637885	DRD4	-0.63	-5.11	-0.46	1.64e-6	Systemic lupus erythematosus;
THYM	cis	rs11048434	0.736	rs1805722	chr12:9145056	T/C	cg26114124	chr12:9217669	LOC144571	0.47	4.73	0.44	7.93e-6	Sjögren's syndrome;
THYM	cis	rs13232179	1.000	rs1558299	chr7:151121676	C/T	cg01177956	chr7:150756509	SLC4A2;CDK5	-0.81	-4.88	-0.45	4.19e-6	Coronary heart disease;
THYM	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg00463982	chr16:1583984	IFT140;TMEM204	-0.62	-5.29	-0.48	7.82e-7	Coronary artery disease;
THYM	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg04455712	chr21:45112962	RRP1B	0.55	5.01	0.46	2.46e-6	Mean corpuscular volume;
THYM	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg04876069	chr12:132293656	NA	-0.52	-4.64	-0.43	1.1e-5	Migraine;
THYM	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg27170947	chr2:26402098	FAM59B	0.79	6.27	0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg13525197	chr6:28411240	ZSCAN23	-0.67	-5.35	-0.48	5.95e-7	Pubertal anthropometrics;
THYM	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg24642439	chr20:33292090	TP53INP2	0.63	4.96	0.45	3.05e-6	Coronary artery disease;
THYM	cis	rs9527	0.590	rs12246739	chr10:104787019	A/C	cg15744005	chr10:104629667	AS3MT	0.62	4.54	0.42	1.64e-5	Arsenic metabolism;
THYM	cis	rs711830	1.000	rs1051929	chr2:177036754	T/C	cg26754761	chr2:177040938	NA	-0.58	-5.03	-0.46	2.27e-6	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg20503657	chr10:835505	NA	1.37	9.33	0.69	4.52e-15	Eosinophil percentage of granulocytes;
THYM	cis	rs7020830	0.830	rs13296413	chr9:37258105	C/T	cg14294708	chr9:37120828	ZCCHC7	1.24	15.43	0.85	1.29e-27	Schizophrenia;
THYM	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg26384229	chr12:38710491	ALG10B	0.99	7.72	0.62	1.14e-11	Bladder cancer;
THYM	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg15445000	chr17:37608096	MED1	-0.44	-5.22	-0.47	1.07e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg17173187	chr15:85201210	NMB	0.54	5.31	0.48	7.17e-7	Schizophrenia;
THYM	cis	rs1018836	0.663	rs2205151	chr8:91483468	A/C	cg16814680	chr8:91681699	NA	-0.76	-6.51	-0.56	3.6e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg06763375	chr16:89025547	CBFA2T3	0.54	4.58	0.43	1.4e-5	Social autistic-like traits;
THYM	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg20283391	chr11:68216788	NA	-0.62	-4.61	-0.43	1.24e-5	Total body bone mineral density;
THYM	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg15247329	chr7:2764246	NA	-0.7	-5.75	-0.51	1.1e-7	Height;
THYM	trans	rs4650994	0.525	rs4316329	chr1:178509333	C/T	cg05059571	chr16:84539110	KIAA1609	-0.86	-10.04	-0.72	1.33e-16	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg23574427	chr4:122746245	BBS7;CCNA2	-0.56	-5.0	-0.46	2.56e-6	Type 2 diabetes;
THYM	trans	rs208520	0.690	rs207081	chr6:66773742	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-7.96	-0.63	3.63e-12	Exhaled nitric oxide output;
THYM	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	5.57	0.5	2.37e-7	Lung cancer in ever smokers;
THYM	cis	rs2361718	0.631	rs4889989	chr17:78151860	C/G	cg09238746	chr17:78121135	EIF4A3	1.01	8.67	0.66	1.16e-13	Yeast infection;
THYM	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg06728252	chr6:26598149	ABT1	-0.43	-5.08	-0.46	1.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg26031613	chr14:104095156	KLC1	0.75	5.11	0.46	1.63e-6	Body mass index;
THYM	cis	rs4595586	0.545	rs7973338	chr12:39380704	T/C	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs1050631	0.564	rs681757	chr18:33744766	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.62	4.8	0.44	5.94e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg02353165	chr6:42928485	GNMT	1.02	11.21	0.75	4.51e-19	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg04944784	chr2:26401820	FAM59B	-1.08	-8.7	-0.67	1e-13	Gut microbiome composition (summer);
THYM	cis	rs6946131	0.593	rs2699229	chr7:54831632	T/C	cg16668896	chr7:54900801	NA	0.43	4.48	0.42	2.06e-5	Systemic lupus erythematosus;
THYM	cis	rs7809950	1.000	rs2066735	chr7:107188719	G/T	cg23024343	chr7:107201750	COG5	-0.94	-8.59	-0.66	1.7e-13	Coronary artery disease;
THYM	cis	rs988913	0.706	rs12523720	chr6:54943041	A/T	cg18532076	chr6:54711417	FAM83B	0.49	4.62	0.43	1.18e-5	Menarche (age at onset);
THYM	cis	rs4930776	1.000	rs4578482	chr12:5766206	A/G	cg02086166	chr12:5775618	ANO2	-0.58	-5.71	-0.51	1.3e-7	Plasma clusterin levels;
THYM	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.49	0.49	3.33e-7	Platelet count;
THYM	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg17264618	chr3:40429014	ENTPD3	-0.52	-5.0	-0.46	2.6e-6	Renal cell carcinoma;
THYM	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.29e-7	Corneal astigmatism;
THYM	cis	rs11551183	0.556	rs8058802	chr16:9101249	A/G	cg00792185	chr16:9855960	GRIN2A	0.85	4.68	0.43	9.51e-6	Macrophage Migration Inhibitory Factor levels;
THYM	cis	rs4589258	0.504	rs34098308	chr11:90390618	C/T	cg26138821	chr11:89956704	CHORDC1	0.65	4.6	0.43	1.32e-5	Intelligence (multi-trait analysis);
THYM	cis	rs798766	1.000	rs798724	chr4:1704643	C/T	cg00006948	chr4:1768889	NA	-0.92	-4.7	-0.43	8.92e-6	Bladder cancer;Urinary bladder cancer;
THYM	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg11663144	chr21:46675770	NA	-0.69	-9.29	-0.69	5.39e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.23	4.9	0.45	3.95e-6	Obesity-related traits;
THYM	cis	rs9905704	0.647	rs9901655	chr17:56987142	G/A	cg12560992	chr17:57184187	TRIM37	0.68	5.32	0.48	7.03e-7	Testicular germ cell tumor;
THYM	cis	rs8192282	0.698	rs6427729	chr1:154518874	G/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.53	-4.61	-0.43	1.27e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs919433	0.680	rs4685	chr2:198257795	C/T	cg00792783	chr2:198669748	PLCL1	-0.81	-5.62	-0.5	1.9e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22590775	chr19:49891494	CCDC155	0.82	6.64	0.56	1.91e-9	Multiple sclerosis;
THYM	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Gout;
THYM	trans	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg10856724	chr12:34555212	NA	-0.94	-8.13	-0.64	1.61e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7843479	0.965	rs11135741	chr8:21801091	C/T	cg17168535	chr8:21777572	XPO7	0.73	5.25	0.47	9.34e-7	Mean corpuscular volume;
THYM	cis	rs7582180	0.903	rs13008568	chr2:100896242	A/G	cg14675211	chr2:100938903	LONRF2	0.64	5.43	0.49	4.28e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9443189	0.570	rs504446	chr6:76326939	T/C	cg01950844	chr6:76311363	SENP6	1.05	6.66	0.56	1.73e-9	Prostate cancer;
THYM	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.85	0.74	2.52e-18	Chronic sinus infection;
THYM	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg08994789	chr17:28903642	LRRC37B2	0.93	5.0	0.46	2.66e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17253792	0.822	rs10143002	chr14:56074278	G/A	cg01858014	chr14:56050164	KTN1	-1.22	-5.13	-0.47	1.52e-6	Putamen volume;
THYM	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg17105886	chr17:28927953	LRRC37B2	1.31	6.9	0.58	5.83e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg23482746	chr15:76478102	C15orf27	-0.38	-4.55	-0.42	1.61e-5	Blood metabolite levels;
THYM	cis	rs757110	0.770	rs4439492	chr11:17386733	C/T	cg15432903	chr11:17409602	KCNJ11	0.58	6.28	0.54	1.01e-8	Type 2 diabetes;
THYM	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.06	9.59	0.7	1.27e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs36051895	0.659	rs7045491	chr9:5045658	G/A	cg02405213	chr9:5042618	JAK2	-1.04	-10.74	-0.74	4.45e-18	Pediatric autoimmune diseases;
THYM	cis	rs28595532	0.920	rs10025640	chr4:119787451	G/A	cg14228332	chr4:119757509	SEC24D	1.3	4.73	0.44	7.91e-6	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	4.5	0.42	1.9e-5	Aortic root size;
THYM	cis	rs4792901	0.729	rs9891052	chr17:41592519	A/G	cg21940313	chr17:41620911	ETV4	-0.53	-5.03	-0.46	2.28e-6	Dupuytren's disease;
THYM	cis	rs9876781	1.000	rs7634377	chr3:48421258	G/A	cg06066452	chr3:48470258	PLXNB1	0.28	5.14	0.47	1.49e-6	Longevity;
THYM	cis	rs988913	1.000	rs2221334	chr6:54834541	A/C	cg04690482	chr6:54711388	FAM83B	0.46	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.78	-0.44	6.31e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs2273669	0.667	rs12212402	chr6:109306681	T/C	cg17117243	chr6:109341365	SESN1	-0.84	-4.94	-0.45	3.41e-6	Prostate cancer;
THYM	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.45	0.49	3.92e-7	Electroencephalogram traits;
THYM	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg10018233	chr7:150070692	REPIN1	-0.4	-5.7	-0.5	1.35e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg13397359	chr6:42928475	GNMT	0.58	4.93	0.45	3.47e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7000551	0.556	rs12674913	chr8:22263617	G/C	cg12081754	chr8:22256438	SLC39A14	1.14	11.51	0.76	1.03e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs4919044	0.808	rs1339820	chr10:94818382	A/C	cg05127821	chr10:94822908	CYP26C1	1.26	7.07	0.59	2.65e-10	Coronary artery disease;
THYM	cis	rs7843479	1.000	rs13248727	chr8:21842063	T/C	cg17168535	chr8:21777572	XPO7	0.62	4.71	0.43	8.52e-6	Mean corpuscular volume;
THYM	cis	rs75920871	0.528	rs2513097	chr11:116836212	A/G	cg20608306	chr11:116969690	SIK3	-0.52	-5.57	-0.5	2.32e-7	Subjective well-being;
THYM	cis	rs919433	0.927	rs13032495	chr2:198189346	C/T	cg00792783	chr2:198669748	PLCL1	-0.71	-5.21	-0.47	1.11e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs288326	0.561	rs76304059	chr2:183779555	C/G	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs12765878	0.603	rs2475213	chr10:105664459	A/T	cg11005552	chr10:105648138	OBFC1	0.52	4.54	0.42	1.67e-5	Coronary artery disease;
THYM	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg16624210	chr5:671434	TPPP	0.83	6.04	0.53	3.03e-8	Lung disease severity in cystic fibrosis;
THYM	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg27588902	chr6:42928151	GNMT	-0.52	-4.82	-0.44	5.5e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg20887711	chr4:1340912	KIAA1530	0.62	4.73	0.44	7.8e-6	Obesity-related traits;
THYM	cis	rs7084402	0.967	rs7079648	chr10:60273155	C/A	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs457717	0.767	rs10045033	chr5:75923945	A/T	cg08241785	chr5:75919281	F2RL2;IQGAP2	-0.33	-4.72	-0.44	8.09e-6	Hearing impairment;
THYM	cis	rs4242434	0.927	rs746011	chr8:22457804	C/T	cg14690197	chr8:22456421	C8orf58	0.58	5.23	0.47	9.94e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs3020333	0.653	rs851985	chr6:152020390	G/T	cg22157087	chr6:152012887	ESR1	-0.5	-5.7	-0.5	1.34e-7	Total body bone mineral density;
THYM	cis	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg07460842	chr6:66804631	NA	-0.97	-6.96	-0.58	4.44e-10	Exhaled nitric oxide output;
THYM	cis	rs807669	0.548	rs9605957	chr22:19187375	G/A	cg02655711	chr22:19163373	SLC25A1	0.62	6.79	0.57	9.47e-10	Metabolite levels;
THYM	cis	rs887829	0.570	rs45615240	chr2:234599296	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.79	-6.88	-0.58	6.26e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.37	5.27	0.48	8.57e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7626444	0.625	rs843530	chr3:196481024	A/G	cg12930392	chr3:196481615	PAK2	0.4	4.97	0.45	2.97e-6	Monocyte count;
THYM	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs2273669	0.667	rs6916819	chr6:109371129	A/G	cg17117243	chr6:109341365	SESN1	-0.8	-4.63	-0.43	1.15e-5	Prostate cancer;
THYM	cis	rs2073300	1.000	rs6114141	chr20:23460620	T/G	cg12062639	chr20:23401060	NAPB	0.96	4.84	0.45	4.95e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs3126085	0.935	rs4845421	chr1:152173259	G/T	cg10321714	chr1:152280068	FLG	0.69	5.08	0.46	1.88e-6	Atopic dermatitis;
THYM	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.81	-5.52	-0.49	2.91e-7	Body mass index;
THYM	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg20503657	chr10:835505	NA	-1.17	-8.37	-0.65	4.9e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg08645402	chr16:4508243	NA	0.6	4.56	0.42	1.5e-5	Schizophrenia;
THYM	cis	rs11118346	0.640	rs2050594	chr1:219744848	A/T	cg07908999	chr1:219785142	NA	-0.4	-4.48	-0.42	2.11e-5	Height;
THYM	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg09877947	chr5:131593287	PDLIM4	0.61	5.33	0.48	6.7e-7	Breast cancer;
THYM	cis	rs7578361	0.879	rs4667421	chr2:150420805	A/G	cg17961725	chr2:150454027	NA	0.76	6.22	0.54	1.32e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg10560079	chr2:191398806	TMEM194B	-0.84	-7.34	-0.6	7.04e-11	Pulse pressure;
THYM	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22496380	chr5:211416	CCDC127	-1.38	-9.31	-0.69	4.83e-15	Breast cancer;
THYM	cis	rs6840360	0.571	rs4696100	chr4:152514242	C/T	cg22705602	chr4:152727874	NA	-0.78	-8.16	-0.64	1.38e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.71	-0.44	8.38e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg23583168	chr7:148888333	NA	-1.02	-13.87	-0.82	1.48e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg25036284	chr2:26402008	FAM59B	0.81	4.61	0.43	1.23e-5	Gut microbiome composition (summer);
THYM	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs6984449	0.516	rs7830251	chr8:19306522	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.58	4.95	0.45	3.23e-6	Educational attainment;
THYM	cis	rs198389	0.589	rs198401	chr1:11888384	A/G	cg24844545	chr1:11908347	NPPA	-0.5	-4.75	-0.44	7.31e-6	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
THYM	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg17054759	chr22:49844102	NA	-0.51	-4.47	-0.42	2.13e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg27284194	chr4:1044797	NA	0.63	4.73	0.44	7.94e-6	Recombination rate (females);
THYM	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg12016809	chr21:47604291	C21orf56	-0.66	-4.83	-0.44	5.24e-6	Testicular germ cell tumor;
THYM	cis	rs611744	0.686	rs424976	chr8:109120820	C/A	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.06e-6	Dupuytren's disease;
THYM	cis	rs6906287	0.647	rs12215793	chr6:118956857	A/T	cg21191810	chr6:118973309	C6orf204	0.58	5.8	0.51	8.72e-8	Electrocardiographic conduction measures;
THYM	cis	rs6980334	1.000	rs7795946	chr7:137785091	A/G	cg18769353	chr7:137028617	PTN	0.63	5.06	0.46	2.01e-6	Blood metabolite ratios;
THYM	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg23711669	chr6:146136114	FBXO30	0.91	9.21	0.69	8.1e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7953508	0.750	rs7310512	chr12:93976703	C/T	cg13201927	chr12:93977447	NA	0.68	5.11	0.46	1.64e-6	Pubertal anthropometrics;
THYM	cis	rs11771526	0.681	rs62457535	chr7:32358710	C/G	cg13207630	chr7:32358064	NA	1.06	6.2	0.54	1.44e-8	Body mass index;
THYM	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg02640540	chr1:67518911	SLC35D1	0.68	5.18	0.47	1.25e-6	Lymphocyte percentage of white cells;
THYM	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg08132940	chr7:1081526	C7orf50	-1.11	-6.36	-0.55	6.88e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	6.0	0.52	3.63e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4731207	0.698	rs2896361	chr7:124473825	C/T	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-6.89	-0.58	5.92e-10	Alzheimer's disease (late onset);
THYM	cis	rs9938149	0.706	rs7498700	chr16:88320620	T/C	cg09385650	chr16:88018033	BANP	-0.26	-4.74	-0.44	7.63e-6	Corneal structure;Central corneal thickness;
THYM	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg06002616	chr8:101225028	SPAG1	-0.46	-4.79	-0.44	6.22e-6	Atrioventricular conduction;
THYM	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg03474202	chr17:45855739	NA	-0.75	-6.48	-0.55	3.99e-9	IgG glycosylation;
THYM	cis	rs1018836	0.608	rs1033348	chr8:91464169	C/G	cg16814680	chr8:91681699	NA	-0.71	-5.68	-0.5	1.47e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4242434	0.819	rs751680	chr8:22475627	G/A	cg21658235	chr8:22456391	C8orf58	0.46	4.74	0.44	7.51e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7216064	1.000	rs12451707	chr17:65871598	G/A	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs1395	0.922	rs13404446	chr2:27519254	C/T	cg23587288	chr2:27483067	SLC30A3	-0.55	-4.56	-0.42	1.52e-5	Blood metabolite levels;
THYM	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg07061783	chr6:25882402	NA	-0.88	-8.54	-0.66	2.14e-13	Intelligence (multi-trait analysis);
THYM	cis	rs933688	1.000	rs933688	chr5:90762748	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.05	7.75	0.62	1.03e-11	Smoking behavior;
THYM	cis	rs8070740	0.592	rs2189338	chr17:5326341	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.72	6.73	0.57	1.26e-9	Menopause (age at onset);
THYM	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.91	8.16	0.64	1.41e-12	Monocyte percentage of white cells;
THYM	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg03760483	chr17:6899297	ALOX12	-0.71	-8.93	-0.68	3.18e-14	Tonsillectomy;
THYM	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11644478	chr21:40555479	PSMG1	-0.79	-6.94	-0.58	4.72e-10	Cognitive function;
THYM	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg11327659	chr7:150037044	RARRES2	0.42	4.94	0.45	3.34e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs17125944	0.615	rs7151474	chr14:53313680	C/T	cg00686598	chr14:53173677	PSMC6	-1.03	-4.67	-0.43	9.78e-6	Alzheimer's disease (late onset);
THYM	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg01097406	chr16:89675127	NA	0.55	4.91	0.45	3.85e-6	Hemoglobin concentration;
THYM	cis	rs3820068	0.603	rs6695903	chr1:15985940	C/T	cg05660106	chr1:15850417	CASP9	0.77	6.42	0.55	5.37e-9	Systolic blood pressure;
THYM	cis	rs1299926	0.850	rs7197673	chr16:8867423	A/T	cg08365638	chr16:9212442	C16orf72	0.99	4.48	0.42	2.07e-5	Anger;
THYM	cis	rs4907240	0.961	rs12469420	chr2:97243305	A/G	cg01950434	chr2:97203154	ARID5A	0.55	4.61	0.43	1.27e-5	Event-related brain oscillations;
THYM	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg02896835	chr1:92012615	NA	-0.65	-5.74	-0.51	1.15e-7	Breast cancer;
THYM	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg06636001	chr8:8085503	FLJ10661	0.78	7.42	0.61	4.87e-11	Mood instability;
THYM	cis	rs800586	0.500	rs2737241	chr8:116657456	G/A	cg04656070	chr8:116661063	TRPS1	-0.56	-6.66	-0.56	1.75e-9	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg09034736	chr1:150693464	HORMAD1	0.51	4.49	0.42	1.98e-5	Tonsillectomy;
THYM	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg12219531	chr12:120966889	COQ5	0.79	6.37	0.55	6.64e-9	High light scatter reticulocyte count;
THYM	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg04731861	chr2:219085781	ARPC2	-0.54	-4.88	-0.45	4.35e-6	Colorectal cancer;
THYM	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	7.98	0.63	3.34e-12	Platelet count;
THYM	cis	rs900145	0.775	rs7926712	chr11:13303085	A/G	cg13286116	chr11:13302098	ARNTL	-0.59	-4.47	-0.42	2.13e-5	Menarche (age at onset);
THYM	trans	rs877282	0.853	rs7092652	chr10:756109	G/A	cg22713356	chr15:30763199	NA	1.27	9.37	0.69	3.62e-15	Uric acid levels;
THYM	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14240646	chr10:27532245	ACBD5	-0.99	-5.49	-0.49	3.3e-7	Breast cancer;
THYM	cis	rs2495707	0.602	rs75205635	chr10:102416299	G/T	cg07919443	chr10:102419409	NA	-0.61	-5.01	-0.46	2.52e-6	Body mass index;
THYM	cis	rs17407555	0.821	rs55851451	chr4:10139189	G/A	cg00071950	chr4:10020882	SLC2A9	-0.76	-5.68	-0.5	1.45e-7	Schizophrenia (age at onset);
THYM	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg24324837	chr19:49891574	CCDC155	0.71	6.57	0.56	2.66e-9	Multiple sclerosis;
THYM	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg12219531	chr12:120966889	COQ5	0.8	6.55	0.56	2.9e-9	High light scatter reticulocyte count;
THYM	cis	rs4499344	0.633	rs259251	chr19:33149768	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.92	7.75	0.62	1.02e-11	Mean platelet volume;
THYM	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07167872	chr1:205819463	PM20D1	0.98	9.79	0.71	4.69e-16	Menarche (age at onset);
THYM	cis	rs9326248	0.581	rs11216267	chr11:116952392	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.66	5.27	0.48	8.49e-7	Blood protein levels;
THYM	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg10862848	chr6:42927986	GNMT	0.51	6.83	0.57	8.14e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4595586	0.545	rs12828866	chr12:39391925	C/A	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	trans	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg25214090	chr10:38739885	LOC399744	0.97	8.33	0.65	5.98e-13	Corneal astigmatism;
THYM	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg27398817	chr8:82754497	SNX16	-0.69	-5.81	-0.51	8.17e-8	Diastolic blood pressure;
THYM	cis	rs7512552	0.698	rs12028001	chr1:150407820	C/T	cg15654264	chr1:150340011	RPRD2	0.45	5.32	0.48	7.01e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg04398451	chr17:18023971	MYO15A	-0.99	-11.34	-0.76	2.38e-19	Total body bone mineral density;
THYM	cis	rs12310956	0.532	rs1852226	chr12:33962940	G/A	cg10856724	chr12:34555212	NA	-0.72	-6.65	-0.56	1.82e-9	Morning vs. evening chronotype;
THYM	cis	rs9326248	0.652	rs7128382	chr11:117023487	A/C	cg26566898	chr11:117069891	TAGLN	0.39	4.53	0.42	1.69e-5	Blood protein levels;
THYM	cis	rs7027203	0.790	rs10123836	chr9:96584109	G/T	cg14598338	chr9:96623480	NA	-0.49	-5.33	-0.48	6.74e-7	DNA methylation (variation);
THYM	cis	rs600806	0.815	rs10858094	chr1:109950858	T/C	cg23032129	chr1:109941072	SORT1	-0.59	-5.03	-0.46	2.31e-6	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg24257776	chr3:47051546	LOC100129354	-0.42	-4.88	-0.45	4.18e-6	Colorectal cancer;
THYM	cis	rs36051895	0.659	rs59225790	chr9:5042757	G/A	cg02405213	chr9:5042618	JAK2	-1.03	-10.88	-0.74	2.16e-18	Pediatric autoimmune diseases;
THYM	cis	rs8013055	1.000	rs8013055	chr14:105990620	T/A	cg04429589	chr14:105992532	TMEM121	-0.52	-5.39	-0.48	5.17e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs7107174	1.000	rs2450123	chr11:77952771	T/C	cg02023728	chr11:77925099	USP35	0.67	5.4	0.48	4.98e-7	Testicular germ cell tumor;
THYM	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg17554472	chr22:41940697	POLR3H	-0.65	-4.66	-0.43	1.02e-5	Vitiligo;
THYM	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg24253500	chr15:84953950	NA	0.55	4.63	0.43	1.14e-5	Schizophrenia;
THYM	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg06028605	chr16:24865363	SLC5A11	-0.57	-5.3	-0.48	7.62e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg03351412	chr1:154909251	PMVK	0.71	5.6	0.5	2.12e-7	Prostate cancer;
THYM	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4730276	0.674	rs2237682	chr7:107535236	C/G	cg23293999	chr7:106826042	HBP1	-0.6	-4.86	-0.45	4.65e-6	Ulcerative colitis;
THYM	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.21	8.69	0.67	1.03e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg10803722	chr21:46713166	LOC642852	-0.42	-5.58	-0.5	2.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg25319279	chr11:5960081	NA	-0.61	-4.72	-0.44	8.17e-6	DNA methylation (variation);
THYM	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.09e-8	Systolic blood pressure;
THYM	cis	rs12197554	0.542	rs7749581	chr6:130631331	C/T	cg20672187	chr6:130686082	NA	0.61	4.45	0.42	2.32e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);Exploratory eye movement dysfunction in schizophrenia (responsive search score);
THYM	cis	rs34286592	0.929	rs11864180	chr16:29830829	T/C	cg04633683	chr16:29837056	MVP	0.61	4.93	0.45	3.45e-6	Multiple sclerosis;
THYM	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg15549821	chr19:49342101	PLEKHA4	-1.21	-6.43	-0.55	5.11e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg02136620	chr5:178986620	RUFY1	0.57	5.63	0.5	1.85e-7	Lung cancer;
THYM	cis	rs9915657	0.773	rs9912974	chr17:70095963	C/T	cg06234051	chr17:70120541	SOX9	-0.64	-5.78	-0.51	9.45e-8	Thyroid hormone levels;
THYM	cis	rs34912216	0.619	rs13232922	chr7:4131685	G/A	cg03141780	chr7:4150753	SDK1	0.68	5.17	0.47	1.29e-6	Motion sickness;
THYM	cis	rs4148689	0.904	rs12533524	chr7:117187461	T/C	cg17204129	chr7:117119601	CFTR	-0.59	-4.6	-0.43	1.32e-5	Gout;
THYM	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7220711	1.000	rs9897313	chr17:41787558	G/A	cg26893861	chr17:41843967	DUSP3	0.65	5.63	0.5	1.83e-7	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs76878669	0.561	rs7125752	chr11:66162419	C/T	cg18002602	chr11:66138449	SLC29A2	-0.46	-4.54	-0.42	1.66e-5	Educational attainment (years of education);
THYM	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1461503	0.900	rs7107502	chr11:122830214	G/A	cg27398637	chr11:122830231	C11orf63	-0.67	-5.76	-0.51	1.03e-7	Menarche (age at onset);
THYM	cis	rs2777491	1.000	rs11631770	chr15:41737059	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.09	-11.71	-0.77	3.87e-20	Ulcerative colitis;
THYM	cis	rs240764	0.817	rs240113	chr6:101058886	G/A	cg21058520	chr6:100914733	NA	-0.57	-5.05	-0.46	2.12e-6	Neuroticism;
THYM	cis	rs3768617	0.510	rs6424889	chr1:183091796	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg01483505	chr11:975446	AP2A2	0.58	4.73	0.44	7.73e-6	Alzheimer's disease (late onset);
THYM	cis	rs728616	0.764	rs75385771	chr10:81692779	T/C	cg18148530	chr10:81370782	SFTPA1	0.77	4.88	0.45	4.23e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs76878669	0.561	rs4930179	chr11:66157432	C/T	cg18002602	chr11:66138449	SLC29A2	0.47	4.84	0.44	5.1e-6	Educational attainment (years of education);
THYM	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.47	-0.49	3.59e-7	Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg10515332	chr4:99064459	C4orf37	-0.63	-5.02	-0.46	2.42e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg08847533	chr14:75593920	NEK9	-0.97	-10.4	-0.73	2.29e-17	Height;
THYM	cis	rs11641184	0.528	rs34323553	chr16:11708461	C/T	cg09662852	chr16:11707685	NA	-0.46	-5.08	-0.46	1.87e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg23730037	chr7:158596552	ESYT2	0.44	4.64	0.43	1.12e-5	Height;
THYM	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg06221963	chr1:154839813	KCNN3	-0.81	-10.27	-0.73	4.36e-17	Prostate cancer;
THYM	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg20891283	chr12:69753455	YEATS4	1.06	10.14	0.72	8.47e-17	Blood protein levels;
THYM	cis	rs11048434	0.518	rs7136274	chr12:9174956	C/T	cg26114124	chr12:9217669	LOC144571	-0.52	-4.63	-0.43	1.14e-5	Sjögren's syndrome;
THYM	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg26384229	chr12:38710491	ALG10B	-0.87	-8.86	-0.67	4.62e-14	Heart rate;
THYM	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg13319975	chr6:146136371	FBXO30	0.65	5.35	0.48	6.13e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg21226059	chr5:178986404	RUFY1	0.49	4.83	0.44	5.13e-6	Lung cancer;
THYM	cis	rs11779988	0.545	rs436506	chr8:17798243	A/G	cg01800426	chr8:17659068	MTUS1	0.73	5.23	0.47	1.03e-6	Breast cancer;
THYM	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg02569458	chr12:86230093	RASSF9	0.62	5.5	0.49	3.13e-7	Major depressive disorder;
THYM	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs10857712	0.851	rs7913420	chr10:135213854	C/T	cg19623624	chr10:135278901	LOC619207	-0.59	-4.76	-0.44	6.89e-6	Systemic lupus erythematosus;
THYM	cis	rs16866061	1.000	rs34345163	chr2:225459080	A/G	cg12698349	chr2:225449008	CUL3	1.11	9.4	0.69	3.15e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.71	5.63	0.5	1.8e-7	Tonsillectomy;
THYM	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg19913688	chr11:428466	ANO9	-0.86	-4.53	-0.42	1.69e-5	Body mass index;
THYM	cis	rs79149102	0.579	rs7342601	chr15:75306795	G/T	cg17294928	chr15:75287854	SCAMP5	0.98	5.33	0.48	6.65e-7	Lung cancer;
THYM	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg08431931	chr22:42394659	WBP2NL	0.69	4.88	0.45	4.33e-6	Birth weight;
THYM	trans	rs1974653	0.672	rs74576059	chr22:20079973	G/A	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs4237845	0.780	rs3751331	chr12:58290278	G/A	cg00677455	chr12:58241039	CTDSP2	0.66	4.45	0.42	2.32e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.92	-7.95	-0.63	3.81e-12	Menarche (age at onset);
THYM	cis	rs3015497	0.626	rs7150204	chr14:51137355	T/C	cg04730355	chr14:51134070	SAV1	-0.51	-4.48	-0.42	2.08e-5	Mean platelet volume;
THYM	cis	rs7172809	0.548	rs11853625	chr15:77505206	C/T	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs17209837	0.607	rs7793196	chr7:87122847	A/G	cg04996195	chr7:87105398	ABCB4	0.65	4.72	0.44	8e-6	Gallbladder cancer;
THYM	cis	rs35264875	1.000	rs72928644	chr11:68849845	A/G	cg01993067	chr11:68851601	TPCN2	1.0	5.3	0.48	7.4e-7	Blond vs. brown hair color;
THYM	cis	rs2066819	1.000	rs75598973	chr12:56746558	C/T	cg26714650	chr12:56694279	CS	-1.34	-6.94	-0.58	4.73e-10	Psoriasis vulgaris;
THYM	cis	rs6768930	0.527	rs268766	chr3:57903413	G/A	cg24033633	chr3:57945695	NA	-0.39	-5.48	-0.49	3.5e-7	Obesity-related traits;
THYM	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg14416269	chr4:6271139	WFS1	0.54	5.51	0.49	3.07e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs7085104	0.513	rs619824	chr10:104581288	G/T	cg15744005	chr10:104629667	AS3MT	-0.91	-9.63	-0.7	1.04e-15	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7578361	0.959	rs1196663	chr2:150326422	A/G	cg17961725	chr2:150454027	NA	0.6	4.76	0.44	7.02e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4144027	0.875	rs6576010	chr14:104349602	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.43	-4.53	-0.42	1.7e-5	Blood metabolite levels;
THYM	cis	rs1003719	0.788	rs1543748	chr21:38446581	T/C	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs2294693	0.947	rs10155663	chr6:40994301	T/G	cg14769373	chr6:40998127	UNC5CL	-0.57	-4.62	-0.43	1.22e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs2072732	0.861	rs3795262	chr1:2938697	A/C	cg08733933	chr1:2954429	NA	-0.59	-4.46	-0.42	2.26e-5	Plateletcrit;
THYM	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg16325326	chr1:53192061	ZYG11B	0.8	6.9	0.58	5.68e-10	Monocyte count;
THYM	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg07492924	chr16:433825	LOC100134368	0.44	4.86	0.45	4.6e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs13424612	0.839	rs7577635	chr2:240901290	T/C	cg01812947	chr2:240904978	NDUFA10	0.55	4.46	0.42	2.28e-5	Odorant perception (isobutyraldehyde);
THYM	cis	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg00495681	chr13:53174319	NA	0.63	5.75	0.51	1.07e-7	Lewy body disease;
THYM	cis	rs2455799	0.613	rs2470538	chr3:15717124	G/C	cg16303742	chr3:15540471	COLQ	-0.55	-5.63	-0.5	1.81e-7	Mean platelet volume;
THYM	cis	rs4509693	1.000	rs4917908	chr10:102502674	G/C	cg15234845	chr10:102496500	NA	0.67	4.71	0.44	8.29e-6	Alzheimer's disease;
THYM	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg26721908	chr21:47610096	LSS	0.87	6.77	0.57	1.08e-9	Testicular germ cell tumor;
THYM	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg02527881	chr3:46936655	PTH1R	-0.61	-5.7	-0.51	1.32e-7	Colorectal cancer;
THYM	cis	rs13191362	0.507	rs13210000	chr6:163176944	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.75	5.84	0.51	7.35e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12532960	0.659	rs61065083	chr7:42374342	A/G	cg23473276	chr7:42834405	NA	0.87	4.77	0.44	6.71e-6	Inflammatory biomarkers;
THYM	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg24250549	chr1:154909240	PMVK	0.72	5.54	0.49	2.73e-7	Prostate cancer;
THYM	cis	rs9972944	0.651	rs1819910	chr17:63814576	C/A	cg07283582	chr17:63770753	CCDC46	-0.63	-4.9	-0.45	3.94e-6	Total body bone mineral density;
THYM	cis	rs4455778	0.536	rs38774	chr7:48939388	C/T	cg26309511	chr7:48887640	NA	0.64	6.37	0.55	6.75e-9	Lung cancer in never smokers;
THYM	cis	rs6988636	1.000	rs6983795	chr8:124185296	T/C	cg22384356	chr8:124195192	FAM83A	-0.86	-5.15	-0.47	1.41e-6	Urinary uromodulin levels;
THYM	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06634786	chr22:41940651	POLR3H	-0.8	-6.21	-0.54	1.37e-8	Vitiligo;
THYM	cis	rs12476592	0.602	rs10176522	chr2:63722433	T/C	cg17519650	chr2:63277830	OTX1	-0.7	-4.68	-0.43	9.57e-6	Childhood ear infection;
THYM	cis	rs758324	0.732	rs114843061	chr5:131490113	C/G	cg16205897	chr5:131564050	P4HA2	0.58	4.96	0.45	3.03e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs889398	0.835	rs12925429	chr16:69801539	G/A	cg09409435	chr16:70099608	PDXDC2	-0.6	-4.55	-0.42	1.57e-5	Body mass index;
THYM	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg03929089	chr4:120376271	NA	-1.01	-13.5	-0.81	8.17e-24	Height;
THYM	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg18681998	chr4:17616180	MED28	0.79	6.7	0.57	1.49e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7769051	0.522	rs6927991	chr6:133113888	T/G	cg07930552	chr6:133119739	C6orf192	1.14	4.51	0.42	1.82e-5	Type 2 diabetes nephropathy;
THYM	cis	rs11608355	1.000	rs10774692	chr12:109862324	G/T	cg10504392	chr12:110044639	NA	0.67	6.21	0.54	1.41e-8	Neuroticism;
THYM	cis	rs12893597	0.715	rs71429953	chr14:76819480	C/T	cg20290672	chr14:76816747	NA	-0.73	-6.03	-0.53	3.17e-8	Maximal oxygen uptake response;
THYM	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06481639	chr22:41940642	POLR3H	-0.79	-5.36	-0.48	5.85e-7	Vitiligo;
THYM	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6163	0.588	rs12763284	chr10:104508202	C/T	cg05855489	chr10:104503620	C10orf26	-0.85	-8.36	-0.65	5.19e-13	Waist circumference;Hip circumference;
THYM	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg26441486	chr22:50317300	CRELD2	0.45	6.81	0.57	8.85e-10	Schizophrenia;
THYM	cis	rs7187994	1.000	rs7187994	chr16:84753453	A/G	cg07647771	chr16:84786436	USP10	-0.54	-4.89	-0.45	4.04e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.85	-5.32	-0.48	6.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg07061783	chr6:25882402	NA	-0.69	-6.02	-0.53	3.26e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg20891283	chr12:69753455	YEATS4	0.73	6.05	0.53	2.92e-8	Blood protein levels;
THYM	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9814567	0.896	rs6763188	chr3:134349995	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	7.64	0.62	1.72e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs12594515	1.000	rs12594515	chr15:45985071	C/G	cg01629716	chr15:45996671	NA	-0.51	-5.34	-0.48	6.32e-7	Waist circumference;Weight;
THYM	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg25251562	chr2:3704773	ALLC	0.8	5.69	0.5	1.4e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs9543976	1.000	rs8192762	chr13:76176680	A/T	cg01531495	chr13:76123901	UCHL3	0.75	5.05	0.46	2.1e-6	Diabetic retinopathy;
THYM	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg18811423	chr2:55921094	PNPT1	0.79	7.61	0.62	1.97e-11	Metabolic syndrome;
THYM	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-5.42	-0.49	4.47e-7	Mood instability;
THYM	cis	rs7909074	1.000	rs10751360	chr10:45396971	G/A	cg04218760	chr10:45406644	TMEM72	-0.67	-6.01	-0.52	3.42e-8	Mean corpuscular volume;
THYM	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.76	0.44	7.04e-6	Bipolar disorder;
THYM	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg17143192	chr8:8559678	CLDN23	0.91	6.72	0.57	1.33e-9	Obesity-related traits;
THYM	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg10150615	chr22:24372951	LOC391322	-0.98	-12.4	-0.79	1.43e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1198430	0.852	rs909537	chr1:23810063	C/G	cg27447006	chr1:23763279	ASAP3	0.87	4.52	0.42	1.82e-5	Total cholesterol levels;
THYM	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg16325326	chr1:53192061	ZYG11B	0.97	11.07	0.75	8.85e-19	Monocyte count;
THYM	cis	rs9397585	0.626	rs13215045	chr6:153447516	C/T	cg12989544	chr6:153429875	RGS17	0.42	4.48	0.42	2.05e-5	Body mass index;
THYM	cis	rs4891159	0.790	rs4891161	chr18:74142683	A/G	cg24786174	chr18:74118243	ZNF516	-0.94	-12.38	-0.79	1.55e-21	Longevity;
THYM	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg16524936	chr4:1340807	KIAA1530	-0.65	-4.67	-0.43	9.74e-6	Obesity-related traits;
THYM	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9902453	0.619	rs2255489	chr17:28084974	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-5.17	-0.47	1.31e-6	Coffee consumption (cups per day);
THYM	cis	rs4343996	0.506	rs10274978	chr7:3433777	T/C	cg21248987	chr7:3385318	SDK1	0.4	5.17	0.47	1.27e-6	Motion sickness;
THYM	cis	rs4666002	0.789	rs13030973	chr2:27928797	T/C	cg27432699	chr2:27873401	GPN1	0.62	4.71	0.43	8.52e-6	Phospholipid levels (plasma);
THYM	cis	rs965469	0.603	rs6051861	chr20:3415566	A/G	cg25506879	chr20:3388711	C20orf194	-0.65	-5.0	-0.46	2.62e-6	IFN-related cytopenia;
THYM	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg08109568	chr15:31115862	NA	0.54	5.23	0.47	1.02e-6	Huntington's disease progression;
THYM	cis	rs6988636	1.000	rs6983795	chr8:124185296	T/C	cg23067535	chr8:124195133	FAM83A	-1.1	-5.77	-0.51	9.8e-8	Urinary uromodulin levels;
THYM	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg13147721	chr7:65941812	NA	-0.94	-5.74	-0.51	1.13e-7	Diabetic kidney disease;
THYM	cis	rs17102423	0.731	rs7145112	chr14:65534084	A/C	cg11161011	chr14:65562177	MAX	-0.57	-4.69	-0.43	9.07e-6	Obesity-related traits;
THYM	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs13315871	0.929	rs9854438	chr3:58277327	G/A	cg12435725	chr3:58293450	RPP14	-0.47	-5.09	-0.46	1.83e-6	Cholesterol, total;
THYM	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg27588902	chr6:42928151	GNMT	-0.51	-4.93	-0.45	3.48e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg22535103	chr8:58192502	C8orf71	-0.98	-4.87	-0.45	4.49e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs73198271	0.710	rs11779561	chr8:8679988	G/C	cg08975724	chr8:8085496	FLJ10661	-0.71	-4.57	-0.42	1.48e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs11690935	0.879	rs908671	chr2:172690265	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.81	-5.84	-0.51	7.21e-8	Schizophrenia;
THYM	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg15247329	chr7:2764246	NA	0.72	6.17	0.53	1.67e-8	Height;
THYM	cis	rs1030877	0.960	rs3792050	chr2:105902255	T/C	cg02079111	chr2:105885981	TGFBRAP1	-0.52	-4.46	-0.42	2.25e-5	Obesity-related traits;
THYM	cis	rs7843479	0.601	rs2306646	chr8:21846586	C/G	cg17168535	chr8:21777572	XPO7	0.8	7.04	0.59	2.93e-10	Mean corpuscular volume;
THYM	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg11317459	chr13:21872234	NA	-1.2	-9.08	-0.68	1.49e-14	White matter hyperintensity burden;
THYM	cis	rs2637266	1.000	rs7475638	chr10:78358586	G/T	cg18941641	chr10:78392320	NA	-0.74	-6.55	-0.56	2.99e-9	Pulmonary function;
THYM	cis	rs28595532	0.920	rs55649377	chr4:119752745	T/A	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.8	5.2	0.47	1.16e-6	Platelet count;
THYM	cis	rs919433	0.713	rs10178946	chr2:198463090	G/T	cg05783139	chr2:198650985	BOLL	0.58	4.5	0.42	1.94e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg06108461	chr20:60628389	TAF4	-1.07	-9.03	-0.68	1.96e-14	Body mass index;
THYM	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.5	-0.66	2.69e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs1978968	1.000	rs1978968	chr22:18448113	A/G	cg01550578	chr22:18484421	MICAL3	-0.69	-5.21	-0.47	1.1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs4072705	1.000	rs10818987	chr9:127520729	T/C	cg13476313	chr9:127244764	NR5A1	0.34	5.15	0.47	1.43e-6	Menarche (age at onset);
THYM	cis	rs1003719	0.715	rs7280251	chr21:38567911	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-4.53	-0.42	1.72e-5	Eye color traits;
THYM	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	7.48	0.61	3.78e-11	Smoking behavior;
THYM	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg24675658	chr1:53192096	ZYG11B	0.7	6.0	0.52	3.56e-8	Monocyte count;
THYM	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg05335186	chr13:53173507	NA	-0.52	-6.6	-0.56	2.38e-9	Lewy body disease;
THYM	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	8.52	0.66	2.36e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg18131467	chr2:239335373	ASB1	1.1	10.84	0.74	2.74e-18	Multiple system atrophy;
THYM	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg23711669	chr6:146136114	FBXO30	0.83	7.92	0.63	4.52e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2688608	0.592	rs11814282	chr10:75490217	T/C	cg15838173	chr10:75533400	FUT11	-0.5	-5.09	-0.46	1.82e-6	Inflammatory bowel disease;
THYM	cis	rs9470366	0.535	rs762624	chr6:36645588	A/C	cg11920449	chr6:36645608	CDKN1A	-0.81	-7.45	-0.61	4.33e-11	QRS duration;
THYM	cis	rs5771242	0.845	rs2295225	chr22:50618797	C/G	cg16473166	chr22:50639996	SELO	0.74	4.78	0.44	6.38e-6	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
THYM	cis	rs861020	0.630	rs657861	chr1:210006884	C/G	cg05527609	chr1:210001259	C1orf107	0.85	6.82	0.57	8.53e-10	Orofacial clefts;
THYM	trans	rs4866334	1.000	rs116309900	chr5:18430285	G/T	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs10892173	0.545	rs115865940	chr11:117666711	C/T	cg21640587	chr11:117668038	DSCAML1	1.05	9.34	0.69	4.24e-15	Myopia;
THYM	cis	rs2073300	1.000	rs61080017	chr20:23457569	A/G	cg12062639	chr20:23401060	NAPB	0.99	4.96	0.45	3.07e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs1048238	0.545	rs848199	chr1:16292742	C/T	cg22431228	chr1:16359049	CLCNKA	0.42	4.46	0.42	2.26e-5	Systolic blood pressure;
THYM	cis	rs9549260	0.755	rs2151785	chr13:41243660	G/A	cg21288729	chr13:41239152	FOXO1	0.73	5.82	0.51	7.84e-8	Red blood cell count;
THYM	cis	rs6032067	0.777	rs979641	chr20:43786336	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs6429082	0.518	rs1812350	chr1:235659920	C/A	cg26050004	chr1:235667680	B3GALNT2	0.92	8.84	0.67	4.96e-14	Adiposity;
THYM	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg26039829	chr8:22132926	PIWIL2	0.68	5.89	0.52	5.84e-8	Hypertriglyceridemia;
THYM	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg19761014	chr17:28927070	LRRC37B2	0.76	4.76	0.44	6.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg03433033	chr1:76189801	ACADM	0.7	6.7	0.57	1.45e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs887829	0.569	rs6711351	chr2:234634916	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.74	-6.02	-0.53	3.33e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg23791538	chr6:167370224	RNASET2	-0.78	-6.28	-0.54	1.02e-8	Crohn's disease;
THYM	cis	rs2732480	0.557	rs2409004	chr12:48721451	T/C	cg21466736	chr12:48725269	NA	-0.54	-4.91	-0.45	3.72e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs3820068	0.705	rs1800616	chr1:15832229	G/A	cg05660106	chr1:15850417	CASP9	1.1	9.92	0.71	2.48e-16	Systolic blood pressure;
THYM	trans	rs11186	0.556	rs72906316	chr2:189956761	T/C	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs7572733	0.515	rs35730302	chr2:198818626	A/T	cg00792783	chr2:198669748	PLCL1	-0.78	-5.35	-0.48	6.18e-7	Dermatomyositis;
THYM	cis	rs73086581	0.838	rs73088424	chr20:4001006	T/G	cg02187196	chr20:3869020	PANK2	0.46	4.89	0.45	4.04e-6	Response to antidepressants in depression;
THYM	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg18252515	chr7:66147081	NA	1.48	8.83	0.67	5.15e-14	Diabetic kidney disease;
THYM	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg06238570	chr21:40685208	BRWD1	0.96	8.95	0.68	2.83e-14	Cognitive function;
THYM	cis	rs28476539	0.567	rs6813901	chr4:83565150	A/G	cg10249074	chr4:83542146	C4orf11	0.66	5.27	0.48	8.48e-7	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg03929089	chr4:120376271	NA	-0.94	-7.42	-0.61	4.85e-11	Coronary artery disease;
THYM	cis	rs42648	0.837	rs7786771	chr7:89924767	G/A	cg25739043	chr7:89950458	NA	-0.53	-4.53	-0.42	1.72e-5	Homocysteine levels;
THYM	cis	rs2980439	0.807	rs2980438	chr8:8094825	T/C	cg08975724	chr8:8085496	FLJ10661	0.61	4.71	0.44	8.41e-6	Neuroticism;
THYM	cis	rs9814567	1.000	rs1917130	chr3:134313773	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	8.54	0.66	2.19e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg27490568	chr2:178487706	NA	0.59	5.61	0.5	1.99e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg10792982	chr14:105748885	BRF1	0.75	7.82	0.63	7.29e-12	Mean platelet volume;Platelet distribution width;
THYM	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg06640241	chr16:89574553	SPG7	0.89	8.35	0.65	5.51e-13	Multiple myeloma (IgH translocation);
THYM	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11690935	0.921	rs3770445	chr2:172708919	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.81	-5.84	-0.51	7.21e-8	Schizophrenia;
THYM	cis	rs10028773	0.666	rs35231872	chr4:120248376	A/T	cg13609457	chr4:120235615	NA	0.55	5.13	0.47	1.5e-6	Educational attainment;
THYM	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg00376283	chr12:123451042	ABCB9	0.8	6.41	0.55	5.49e-9	Platelet count;
THYM	cis	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg10127162	chr1:197170891	ZBTB41	0.82	5.7	0.5	1.36e-7	Depressive symptoms;
THYM	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2282300	0.910	rs528292	chr11:30389710	A/G	cg25418670	chr11:30344373	C11orf46	0.74	5.84	0.51	7.14e-8	Morning vs. evening chronotype;
THYM	cis	rs7719624	0.870	rs3792900	chr5:135393754	A/G	cg12897067	chr5:135418308	NA	0.57	4.68	0.43	9.61e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg11965913	chr1:205819406	PM20D1	-0.61	-5.57	-0.5	2.38e-7	Menarche (age at onset);
THYM	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg27129171	chr3:47204927	SETD2	-0.86	-7.94	-0.63	4.02e-12	Colorectal cancer;
THYM	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg23791538	chr6:167370224	RNASET2	0.74	5.92	0.52	5.06e-8	Crohn's disease;
THYM	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg11905131	chr22:24372483	LOC391322	-0.93	-9.84	-0.71	3.71e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6596100	0.538	rs67652061	chr5:132280347	T/G	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Breast cancer;
THYM	cis	rs2913737	0.564	rs2963673	chr5:175937373	G/A	cg27658698	chr5:175955578	RNF44	0.59	4.63	0.43	1.15e-5	Obesity-related traits;
THYM	cis	rs986417	0.818	rs2882601	chr14:61096879	A/T	cg27398547	chr14:60952738	C14orf39	0.94	5.21	0.47	1.07e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs16917546	1.000	rs16917546	chr10:64397538	T/C	cg03961010	chr10:64397487	ZNF365	-0.8	-6.77	-0.57	1.08e-9	Basal cell carcinoma;
THYM	cis	rs9479482	1.000	rs9479481	chr6:150357944	A/G	cg25797454	chr6:150327115	RAET1K	0.42	4.46	0.42	2.28e-5	Alopecia areata;
THYM	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg08772003	chr10:104629869	AS3MT	-0.63	-5.45	-0.49	3.96e-7	Arsenic metabolism;
THYM	cis	rs4642101	0.537	rs4997708	chr3:12839603	G/A	cg05775895	chr3:12838266	CAND2	0.9	7.77	0.62	9.16e-12	QRS complex (12-leadsum);
THYM	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.69	0.74	5.59e-18	Chronic sinus infection;
THYM	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs710865	0.519	rs3748759	chr1:19487656	C/T	cg13387374	chr1:19411106	UBR4	-0.66	-5.44	-0.49	4.14e-7	Brain structure;
THYM	cis	rs778371	0.578	rs2675956	chr2:233753340	G/A	cg08000102	chr2:233561755	GIGYF2	-0.71	-6.04	-0.53	2.93e-8	Schizophrenia;
THYM	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg10515332	chr4:99064459	C4orf37	-0.61	-4.9	-0.45	3.92e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg14196790	chr5:131705035	SLC22A5	0.51	4.62	0.43	1.23e-5	Blood metabolite levels;
THYM	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg20607798	chr8:58055168	NA	0.88	4.63	0.43	1.16e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg03517284	chr6:25882590	NA	-0.63	-4.71	-0.44	8.37e-6	Blood metabolite levels;
THYM	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg12564285	chr5:131593104	PDLIM4	0.44	4.78	0.44	6.47e-6	Blood metabolite levels;
THYM	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg08213375	chr14:104286397	PPP1R13B	0.45	4.63	0.43	1.16e-5	Reticulocyte count;
THYM	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg04731861	chr2:219085781	ARPC2	-0.5	-4.5	-0.42	1.93e-5	Colorectal cancer;
THYM	cis	rs6502050	0.723	rs4789698	chr17:80179786	C/T	cg03388043	chr17:80084554	CCDC57	-0.69	-5.58	-0.5	2.29e-7	Life satisfaction;
THYM	cis	rs3093024	0.904	rs3093019	chr6:167539655	C/G	cg09487078	chr6:167525398	CCR6	-0.36	-4.66	-0.43	1.03e-5	Rheumatoid arthritis;
THYM	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs7715811	0.913	rs73749952	chr5:13762518	T/C	cg07548982	chr5:13769939	DNAH5	-0.5	-4.47	-0.42	2.2e-5	Subclinical atherosclerosis traits (other);
THYM	cis	rs986417	0.786	rs1254273	chr14:60843581	C/A	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs7824557	0.628	rs11250129	chr8:11202154	G/A	cg21775007	chr8:11205619	TDH	0.74	6.66	0.56	1.79e-9	Retinal vascular caliber;
THYM	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs995000	0.783	rs6686331	chr1:63182135	C/T	cg06896770	chr1:63153194	DOCK7	-0.7	-4.76	-0.44	6.87e-6	Triglyceride levels;
THYM	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg00898013	chr13:113819073	PROZ	-0.88	-8.96	-0.68	2.83e-14	Platelet distribution width;
THYM	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.28	6.37	0.55	6.77e-9	Obesity-related traits;
THYM	cis	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg08968635	chr6:28129556	ZNF389	0.77	4.95	0.45	3.27e-6	Depression;
THYM	cis	rs791888	0.965	rs791876	chr10:89406527	G/A	cg10377144	chr10:89419177	PAPSS2	-0.38	-5.97	-0.52	4.1e-8	Magnesium levels;
THYM	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg08213375	chr14:104286397	PPP1R13B	0.54	6.47	0.55	4.26e-9	Schizophrenia;
THYM	cis	rs1461503	0.932	rs10892934	chr11:122837950	C/T	cg27398637	chr11:122830231	C11orf63	-0.7	-6.69	-0.57	1.51e-9	Menarche (age at onset);
THYM	cis	rs1729951	0.575	rs1654925	chr3:136690391	C/T	cg12473912	chr3:136751656	NA	-0.63	-5.13	-0.47	1.55e-6	Neuroticism;
THYM	cis	rs293526	0.959	rs293483	chr6:83680779	A/C	cg23278060	chr6:83777448	DOPEY1	0.63	4.67	0.43	9.71e-6	Crohn's disease;
THYM	cis	rs9527	0.590	rs12415388	chr10:104796345	T/C	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs7089973	0.966	rs36089581	chr10:116623059	G/C	cg23260525	chr10:116636907	FAM160B1	0.58	5.3	0.48	7.56e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg05335186	chr13:53173507	NA	-0.51	-6.51	-0.56	3.56e-9	Lewy body disease;
THYM	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.75	-6.14	-0.53	1.9e-8	Schizophrenia;
THYM	cis	rs7953249	0.656	rs2251468	chr12:121405126	A/C	cg14101638	chr12:121416612	HNF1A	0.46	4.78	0.44	6.32e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs921968	0.612	rs4674323	chr2:219517088	T/C	cg01872077	chr2:219646372	CYP27A1	0.58	4.49	0.42	2e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs5769707	0.616	rs6009786	chr22:50015145	A/G	cg23428387	chr22:49814324	NA	-0.58	-5.49	-0.49	3.39e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs1823778	0.609	rs11663969	chr18:67707490	T/C	cg26848442	chr18:67624264	CD226	1.19	4.58	0.43	1.41e-5	Mean platelet volume;
THYM	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-4.76	-0.44	6.82e-6	Gut microbiome composition (summer);
THYM	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg18402987	chr7:1209562	NA	0.92	5.5	0.49	3.22e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12611088	0.541	rs2599445	chr19:44005025	C/G	cg18042043	chr19:44147545	NA	-0.41	-4.9	-0.45	3.9e-6	Plasma amyloid beta peptide concentrations (ABx-42);
THYM	cis	rs728616	0.867	rs61860420	chr10:81739379	G/A	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs35398779	1	rs35398779	chr17:19853094	GA/G	cg20830565	chr17:20408647	MGC102966	-0.53	-4.78	-0.44	6.46e-6	Platelet count;
THYM	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg19774624	chr17:42201019	HDAC5	0.68	5.97	0.52	4.05e-8	Total body bone mineral density;
THYM	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg10360139	chr7:1886902	MAD1L1	-0.62	-5.45	-0.49	3.96e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.606	rs3846446	chr4:99099768	C/A	cg17366294	chr4:99064904	C4orf37	0.5	5.74	0.51	1.15e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7192750	0.563	rs12921084	chr16:71880965	T/C	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg05025164	chr4:1340916	KIAA1530	0.95	7.7	0.62	1.31e-11	Longevity;
THYM	cis	rs12711979	0.740	rs6715434	chr2:3820862	T/G	cg17052675	chr2:3827356	NA	-0.48	-5.19	-0.47	1.19e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg02569458	chr12:86230093	RASSF9	0.62	5.34	0.48	6.31e-7	Major depressive disorder;
THYM	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.77	-6.73	-0.57	1.29e-9	Intelligence (multi-trait analysis);
THYM	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg27286337	chr10:134555280	INPP5A	0.8	5.52	0.49	2.9e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg23711669	chr6:146136114	FBXO30	0.91	9.57	0.7	1.4e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg05368731	chr17:41323189	NBR1	1.19	10.4	0.73	2.28e-17	Menopause (age at onset);
THYM	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg00981070	chr1:2046702	PRKCZ	-0.48	-5.89	-0.52	5.86e-8	Height;
THYM	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg21475434	chr5:93447410	FAM172A	0.96	6.08	0.53	2.55e-8	Diabetic retinopathy;
THYM	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg03186999	chr17:7165420	CLDN7	0.44	4.89	0.45	4.06e-6	Diastolic blood pressure;
THYM	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg10803722	chr21:46713166	LOC642852	-0.41	-5.33	-0.48	6.47e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg08999081	chr20:33150536	PIGU	-0.74	-6.96	-0.58	4.32e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs4919694	1.000	rs10509758	chr10:104681710	T/C	cg04362960	chr10:104952993	NT5C2	1.06	6.61	0.56	2.24e-9	Arsenic metabolism;
THYM	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.81	-6.29	-0.54	9.55e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9527	0.615	rs11191401	chr10:104573403	A/G	cg08772003	chr10:104629869	AS3MT	-0.64	-5.33	-0.48	6.62e-7	Arsenic metabolism;
THYM	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg19626725	chr5:178986131	RUFY1	0.34	5.35	0.48	6.1e-7	Lung cancer;
THYM	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.72	0.51	1.22e-7	Bipolar disorder;
THYM	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg04111992	chr7:158790115	NA	-0.53	-4.69	-0.43	9.29e-6	Facial morphology (factor 20);
THYM	cis	rs1457451	0.850	rs67617590	chr2:65869409	C/G	cg16240816	chr2:65861662	NA	0.59	6.01	0.52	3.49e-8	Iron status biomarkers;
THYM	cis	rs7267979	0.966	rs4815425	chr20:25398876	G/C	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9825379	0.524	rs6440007	chr3:141148143	G/A	cg13411656	chr3:141121016	ZBTB38	-0.49	-4.61	-0.43	1.24e-5	Height;
THYM	cis	rs17641971	0.684	rs1511367	chr8:49949412	T/C	cg00325661	chr8:49890786	NA	0.67	5.17	0.47	1.31e-6	Blood metabolite levels;
THYM	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg13695892	chr22:41940480	POLR3H	0.86	6.33	0.54	8.08e-9	Vitiligo;
THYM	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg10360139	chr7:1886902	MAD1L1	-0.58	-5.14	-0.47	1.5e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12476592	0.602	rs1348805	chr2:63895673	A/G	cg17519650	chr2:63277830	OTX1	-0.72	-4.68	-0.43	9.38e-6	Childhood ear infection;
THYM	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg18876405	chr7:65276391	NA	-0.71	-6.59	-0.56	2.44e-9	Aortic root size;
THYM	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg08968635	chr6:28129556	ZNF389	0.63	4.78	0.44	6.43e-6	Parkinson's disease;
THYM	cis	rs9326248	0.581	rs10892048	chr11:116814596	A/G	cg20608306	chr11:116969690	SIK3	0.61	7.4	0.6	5.53e-11	Blood protein levels;
THYM	cis	rs4845570	0.920	rs6694952	chr1:151760131	T/C	cg07092448	chr1:151763213	TDRKH	0.99	6.73	0.57	1.28e-9	Coronary artery disease;
THYM	cis	rs7746082	0.627	rs11152956	chr6:106503262	C/A	cg02270332	chr6:106475062	NA	-0.65	-5.95	-0.52	4.38e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs55788414	1.000	rs55788414	chr16:81184939	C/T	cg06400318	chr16:81190750	PKD1L2	-1.0	-5.23	-0.47	1.01e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs35934224	0.783	rs7286104	chr22:19861226	T/C	cg11182965	chr22:19864308	TXNRD2	-0.71	-5.85	-0.51	7.1e-8	Glaucoma (primary open-angle);
THYM	cis	rs864643	0.812	rs1606473	chr3:39582924	C/T	cg20142358	chr3:39093977	WDR48	-0.71	-4.93	-0.45	3.43e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.03	-0.46	2.3e-6	Mood instability;
THYM	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4731207	0.844	rs2299903	chr7:124397342	A/G	cg05285228	chr7:124571219	POT1	0.71	5.65	0.5	1.64e-7	Cutaneous malignant melanoma;
THYM	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg13852791	chr20:30311386	BCL2L1	0.79	5.87	0.52	6.5e-8	Mean corpuscular hemoglobin;
THYM	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg04414720	chr1:150670196	GOLPH3L	0.59	4.46	0.42	2.24e-5	Tonsillectomy;
THYM	cis	rs924712	0.522	rs4715486	chr6:54712903	T/G	cg19716238	chr6:54711378	FAM83B	-0.48	-4.46	-0.42	2.21e-5	Breast cancer;
THYM	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.02e-12	Alcohol dependence;
THYM	cis	rs4243830	0.850	rs4908912	chr1:6599558	A/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.06	-6.24	-0.54	1.21e-8	Body mass index;
THYM	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg27398817	chr8:82754497	SNX16	0.84	6.56	0.56	2.79e-9	Diastolic blood pressure;
THYM	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg26031613	chr14:104095156	KLC1	1.21	12.87	0.8	1.52e-22	Body mass index;
THYM	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg00576331	chr11:65640516	EFEMP2	-0.68	-4.58	-0.43	1.42e-5	Crohn's disease;
THYM	cis	rs3784262	0.564	rs34958088	chr15:58328332	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.75	-6.11	-0.53	2.23e-8	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
THYM	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1018836	0.923	rs7840846	chr8:91565501	T/A	cg16814680	chr8:91681699	NA	-0.78	-6.45	-0.55	4.73e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg10802521	chr3:52805072	NEK4	-0.72	-6.16	-0.53	1.77e-8	Bipolar disorder;
THYM	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21659725	chr3:3221576	CRBN	0.88	9.54	0.7	1.55e-15	Intelligence (multi-trait analysis);
THYM	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.12	8.84	0.67	5.07e-14	Cognitive test performance;
THYM	trans	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg10856724	chr12:34555212	NA	-0.9	-8.08	-0.64	2.05e-12	Drug-induced liver injury (flucloxacillin);
THYM	trans	rs9929218	0.551	rs2296408	chr16:68713823	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.1	-15.05	-0.84	6.84e-27	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.26	7.89	0.63	5.03e-12	Gut microbiome composition (summer);
THYM	cis	rs9902453	0.933	rs9303628	chr17:28527228	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	6.59	0.56	2.45e-9	Coffee consumption (cups per day);
THYM	cis	rs665401	0.692	rs1512657	chr6:117117628	G/C	cg20376953	chr6:117187980	NA	-0.6	-4.69	-0.43	8.97e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs4242434	0.889	rs11783129	chr8:22453426	G/A	cg01710189	chr8:22454888	PDLIM2	-0.58	-5.83	-0.51	7.59e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	6.97	0.58	4.15e-10	Smoking behavior;
THYM	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg24209194	chr3:40518798	ZNF619	0.67	5.53	0.49	2.85e-7	Renal cell carcinoma;
THYM	cis	rs67981189	0.896	rs917065	chr14:71397846	G/A	cg15910301	chr14:71632612	NA	-0.5	-4.61	-0.43	1.26e-5	Schizophrenia;
THYM	cis	rs259282	0.628	rs35946544	chr19:33109983	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.72	5.98	0.52	3.87e-8	Schizophrenia;
THYM	trans	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg25517755	chr10:38738941	LOC399744	0.75	7.2	0.59	1.43e-10	Corneal astigmatism;
THYM	cis	rs6906287	0.625	rs7764280	chr6:118692514	A/G	cg21191810	chr6:118973309	C6orf204	0.63	5.99	0.52	3.71e-8	Electrocardiographic conduction measures;
THYM	cis	rs2072499	0.966	rs2244144	chr1:156184598	G/A	cg25208724	chr1:156163844	SLC25A44	1.11	12.12	0.78	5.46e-21	Testicular germ cell tumor;
THYM	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg07169764	chr2:136633963	MCM6	-0.64	-5.91	-0.52	5.45e-8	Mosquito bite size;
THYM	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg04520793	chr17:42248056	ASB16	-0.35	-4.98	-0.45	2.85e-6	Total body bone mineral density;
THYM	cis	rs1983170	1.000	rs1983170	chr1:91986482	G/A	cg25838465	chr1:92012736	NA	0.66	4.55	0.42	1.56e-5	Eosinophil percentage of white cells;
THYM	cis	rs8014204	0.901	rs4899536	chr14:75316614	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.55	-5.34	-0.48	6.42e-7	Caffeine consumption;
THYM	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg11366901	chr6:160182831	ACAT2	1.01	9.01	0.68	2.12e-14	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs10193935	0.901	rs10175378	chr2:42456267	A/C	cg27598129	chr2:42591480	NA	-0.75	-4.6	-0.43	1.29e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11563648	0.553	rs10235028	chr7:126995304	A/T	cg23081781	chr7:127225937	GCC1	-0.36	-4.85	-0.45	4.88e-6	Resting heart rate;
THYM	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg18252515	chr7:66147081	NA	0.64	4.83	0.44	5.12e-6	Aortic root size;
THYM	cis	rs4478037	0.822	rs3924696	chr3:33122013	T/C	cg19404215	chr3:33155277	CRTAP	0.97	6.45	0.55	4.65e-9	Major depressive disorder;
THYM	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg23000734	chr10:126850823	CTBP2	0.73	8.02	0.64	2.78e-12	Menarche (age at onset);
THYM	cis	rs4523957	0.583	rs2641442	chr17:2035071	C/T	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6430585	0.591	rs12466487	chr2:136407078	C/T	cg07169764	chr2:136633963	MCM6	-1.15	-10.74	-0.74	4.37e-18	Corneal structure;
THYM	cis	rs76878669	0.561	rs2279861	chr11:66133336	A/G	cg18002602	chr11:66138449	SLC29A2	0.49	4.98	0.45	2.86e-6	Educational attainment (years of education);
THYM	cis	rs1129187	0.748	rs6458312	chr6:42904274	G/T	cg02353165	chr6:42928485	GNMT	0.75	6.34	0.55	7.54e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg03983476	chr2:10830698	NOL10	-0.61	-5.87	-0.52	6.46e-8	Prostate cancer;
THYM	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg01448562	chr3:133502909	NA	0.82	6.76	0.57	1.12e-9	Iron status biomarkers;
THYM	cis	rs7551222	0.752	rs4951393	chr1:204489557	A/C	cg20240347	chr1:204465584	NA	0.51	4.66	0.43	1.04e-5	Schizophrenia;
THYM	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg13695892	chr22:41940480	POLR3H	0.94	7.28	0.6	9.46e-11	Vitiligo;
THYM	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg02187348	chr16:89574699	SPG7	0.79	6.45	0.55	4.71e-9	Multiple myeloma (IgH translocation);
THYM	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg26924012	chr15:45694286	SPATA5L1	1.06	9.17	0.69	9.7e-15	Homoarginine levels;
THYM	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg00717180	chr2:96193071	NA	-0.7	-7.27	-0.6	9.91e-11	HDL cholesterol;
THYM	cis	rs4765905	0.897	rs7965923	chr12:2341385	C/A	cg09436713	chr12:2323135	CACNA1C	-0.35	-4.75	-0.44	7.34e-6	Schizophrenia;
THYM	cis	rs611744	0.647	rs4735053	chr8:109260776	A/G	cg21045802	chr8:109455806	TTC35	0.65	5.91	0.52	5.3e-8	Dupuytren's disease;
THYM	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs994014	0.727	rs7699396	chr4:82271702	C/A	cg17825130	chr4:82283507	NA	0.51	4.64	0.43	1.11e-5	Height;
THYM	cis	rs4654899	0.802	rs10737452	chr1:21199764	C/T	cg01072550	chr1:21505969	NA	0.71	6.21	0.54	1.41e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg04398451	chr17:18023971	MYO15A	0.9	9.57	0.7	1.36e-15	Total body bone mineral density;
THYM	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg01256987	chr12:42539512	GXYLT1	-0.68	-4.96	-0.45	3.07e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
THYM	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg01699819	chr7:1052092	C7orf50	-0.57	-4.82	-0.44	5.34e-6	Bronchopulmonary dysplasia;
THYM	cis	rs1371867	1.000	rs1371867	chr8:101330209	A/C	cg00191853	chr8:101177733	SPAG1	-0.5	-4.95	-0.45	3.24e-6	Atrioventricular conduction;
THYM	cis	rs539514	0.516	rs2273996	chr13:76410725	A/G	cg08579070	chr13:76210054	LMO7	-0.46	-4.73	-0.44	7.67e-6	Type 1 diabetes;
THYM	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	5.09	0.46	1.8e-6	Menarche (age at onset);
THYM	cis	rs7746082	0.564	rs12203431	chr6:106460879	A/G	cg02270332	chr6:106475062	NA	-0.59	-5.68	-0.5	1.48e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2229238	0.911	rs41269915	chr1:154521584	T/A	cg21262032	chr1:154437693	IL6R	-0.62	-5.23	-0.47	1.01e-6	Coronary heart disease;
THYM	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg11327659	chr7:150037044	RARRES2	0.41	4.94	0.45	3.38e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7590720	0.819	rs1344694	chr2:216893637	T/G	cg12620499	chr2:216877984	MREG	1.02	7.85	0.63	6.35e-12	Alcohol dependence;
THYM	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.66	-5.09	-0.46	1.8e-6	Menarche (age at onset);
THYM	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg01570182	chr17:44337453	NA	-0.6	-6.42	-0.55	5.32e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9868809	0.772	rs12107418	chr3:48689787	A/G	cg00383909	chr3:49044727	WDR6	0.92	4.84	0.44	4.96e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4731207	0.698	rs7799938	chr7:124521391	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26314531	chr2:26401878	FAM59B	-0.76	-4.99	-0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs10203711	0.932	rs4502365	chr2:239597792	G/A	cg14580085	chr2:239553406	NA	0.66	5.88	0.52	5.96e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1466045	0.698	rs1867911	chr11:3158300	T/A	cg14568032	chr11:3122963	OSBPL5	0.54	4.56	0.42	1.53e-5	Cisplatin-induced ototoxicity;
THYM	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.8	6.36	0.55	7.03e-9	Chronic sinus infection;
THYM	cis	rs10911251	0.546	rs1547714	chr1:183114119	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.66	0.43	1.02e-5	Colorectal cancer;
THYM	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.43	1.27e-5	Breast cancer;
THYM	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg10465839	chr16:1584050	IFT140;TMEM204	-0.66	-5.82	-0.51	7.88e-8	Coronary artery disease;
THYM	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg21028142	chr17:79581711	NPLOC4	0.62	6.4	0.55	5.97e-9	Eye color traits;
THYM	cis	rs17174870	0.868	rs77306155	chr2:112767941	A/G	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs1550582	1.000	rs16905157	chr8:135519964	C/T	cg17885191	chr8:135476712	NA	0.75	4.76	0.44	6.96e-6	Educational attainment;
THYM	cis	rs11771526	0.786	rs11768955	chr7:32378706	T/C	cg27532318	chr7:32358331	NA	0.82	4.6	0.43	1.31e-5	Body mass index;
THYM	cis	rs57920188	0.535	rs10915659	chr1:4092949	G/A	cg20703997	chr1:4087676	NA	0.74	5.31	0.48	7.07e-7	Interleukin-17 levels;
THYM	cis	rs7020830	0.505	rs12553878	chr9:37095705	C/T	cg14294708	chr9:37120828	ZCCHC7	0.78	7.26	0.6	1.07e-10	Schizophrenia;
THYM	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg01831904	chr17:28903510	LRRC37B2	-1.04	-5.05	-0.46	2.17e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7428297	1.000	rs7428297	chr3:127078340	A/G	cg21487550	chr3:127056955	NA	-0.72	-4.54	-0.42	1.64e-5	Clozapine-induced agranulocytosis;
THYM	cis	rs12478296	1.000	rs55732177	chr2:243040006	C/T	cg06360820	chr2:242988706	NA	-0.88	-5.54	-0.49	2.72e-7	Obesity-related traits;
THYM	cis	rs959260	0.528	rs9909443	chr17:73308346	C/T	cg14668889	chr17:73230827	NUP85	0.75	4.94	0.45	3.28e-6	Systemic lupus erythematosus;
THYM	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg00290607	chr11:67383545	NA	-0.94	-8.48	-0.66	2.86e-13	Mean corpuscular volume;
THYM	cis	rs1018836	0.892	rs1476428	chr8:91555603	G/T	cg16814680	chr8:91681699	NA	-0.81	-6.95	-0.58	4.56e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs3750817	0.516	rs10736303	chr10:123334457	C/T	cg15049101	chr10:123353889	FGFR2	-0.6	-5.22	-0.47	1.06e-6	Breast cancer;
THYM	trans	rs8002861	0.870	rs1348671	chr13:44449505	C/T	cg17145862	chr1:211918768	LPGAT1	0.94	9.74	0.71	6.04e-16	Leprosy;
THYM	cis	rs9287719	0.810	rs1990612	chr2:10781944	A/G	cg03983476	chr2:10830698	NOL10	-0.58	-5.24	-0.47	9.5e-7	Prostate cancer;
THYM	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg26038318	chr20:34205095	SPAG4	0.58	4.6	0.43	1.3e-5	Total cholesterol levels;
THYM	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg12756686	chr19:29218302	NA	0.95	7.63	0.62	1.82e-11	Methadone dose in opioid dependence;
THYM	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg26031613	chr14:104095156	KLC1	1.23	12.6	0.79	5.44e-22	Body mass index;
THYM	cis	rs7570971	1.000	rs6730157	chr2:135907088	C/T	cg07169764	chr2:136633963	MCM6	-0.71	-5.39	-0.48	5.17e-7	Blood metabolite levels;Body mass index;Cholesterol, total;
THYM	cis	rs9296092	0.517	rs7775914	chr6:33518110	T/C	cg13560919	chr6:33536144	NA	-0.94	-9.31	-0.69	4.9e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg27129171	chr3:47204927	SETD2	0.8	7.64	0.62	1.69e-11	Colorectal cancer;
THYM	trans	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg25214090	chr10:38739885	LOC399744	0.86	7.53	0.61	2.86e-11	Corneal astigmatism;
THYM	trans	rs877282	0.838	rs11253408	chr10:796374	T/C	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs7640424	0.826	rs7635063	chr3:107818777	C/T	cg09227934	chr3:107805635	CD47	-0.87	-7.12	-0.59	2.06e-10	Body mass index;
THYM	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.22e-16	Bone mineral density;
THYM	cis	rs34638657	0.732	rs62045963	chr16:82200661	A/G	cg09439754	chr16:82129088	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	cis	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg06521331	chr12:34319734	NA	0.9	5.98	0.52	3.9e-8	Morning vs. evening chronotype;
THYM	cis	rs6443245	0.591	rs2648382	chr3:9621676	T/C	cg20517764	chr3:9027454	SRGAP3	-0.59	-4.57	-0.42	1.44e-5	Daytime sleep phenotypes;
THYM	cis	rs995000	0.931	rs2366638	chr1:63099577	G/A	cg06896770	chr1:63153194	DOCK7	0.92	7.57	0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg11502198	chr6:26597334	ABT1	0.64	5.68	0.5	1.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg04896959	chr15:78267971	NA	-0.89	-7.15	-0.59	1.8e-10	Coronary artery disease or large artery stroke;
THYM	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs612683	0.690	rs11166440	chr1:100808363	C/T	cg06223162	chr1:101003688	GPR88	-0.62	-5.19	-0.47	1.18e-6	Breast cancer;
THYM	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs6430585	0.528	rs3099429	chr2:136655582	T/A	cg20242066	chr2:136595261	LCT	0.57	5.96	0.52	4.26e-8	Corneal structure;
THYM	cis	rs459571	0.959	rs465724	chr9:136910097	C/T	cg13789015	chr9:136890014	NCRNA00094	0.74	6.1	0.53	2.25e-8	Platelet distribution width;
THYM	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7586879	0.929	rs6545808	chr2:25124388	C/A	cg15423357	chr2:25149977	NA	0.57	5.6	0.5	2.09e-7	Body mass index;
THYM	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg04267008	chr7:1944627	MAD1L1	0.69	6.41	0.55	5.59e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg26384229	chr12:38710491	ALG10B	1.0	7.61	0.62	1.97e-11	Bladder cancer;
THYM	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs17739794	0.517	rs10106028	chr8:783286	C/A	cg01971667	chr8:817044	NA	-0.93	-7.86	-0.63	6.05e-12	Clozapine-induced cytotoxicity;
THYM	cis	rs17641971	0.662	rs1858312	chr8:49996521	G/A	cg00325661	chr8:49890786	NA	0.6	4.79	0.44	6.24e-6	Blood metabolite levels;
THYM	cis	rs11264213	0.515	rs9660657	chr1:36548941	C/T	cg27506609	chr1:36549197	TEKT2	-1.17	-6.6	-0.56	2.31e-9	Schizophrenia;
THYM	trans	rs4596713	0.508	rs4076287	chr9:71755333	A/G	cg16512924	chr15:28394682	HERC2	0.83	7.02	0.58	3.32e-10	Headache;
THYM	trans	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-7.62	-0.62	1.88e-11	Exhaled nitric oxide output;
THYM	cis	rs6430585	0.528	rs16832440	chr2:136754183	G/A	cg23851026	chr2:136556271	LCT	0.78	6.96	0.58	4.39e-10	Corneal structure;
THYM	cis	rs2456568	0.543	rs4144616	chr11:93621900	A/G	cg08514419	chr11:93583937	C11orf90	-0.47	-4.51	-0.42	1.84e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs448720	0.967	rs450466	chr15:68198523	C/T	cg23793686	chr15:68133972	NA	-0.5	-4.63	-0.43	1.17e-5	Cognitive performance;
THYM	cis	rs2964802	0.505	rs6876703	chr5:10831629	G/A	cg14521931	chr5:10832172	NA	-0.66	-5.49	-0.49	3.31e-7	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs2985684	1.000	rs3007031	chr14:50102269	G/C	cg02151108	chr14:50098012	C14orf104	-0.68	-5.33	-0.48	6.74e-7	Carotid intima media thickness;
THYM	cis	rs887829	0.570	rs6736743	chr2:234595950	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-6.64	-0.56	1.98e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-5.15	-0.47	1.43e-6	Longevity;
THYM	cis	rs11825685	0.887	rs4328229	chr11:134566548	G/A	cg02395454	chr11:134605862	NA	-0.98	-4.88	-0.45	4.22e-6	IgG glycosylation;
THYM	cis	rs4631830	0.863	rs57263518	chr10:51519154	A/G	cg16070123	chr10:51489643	NA	-0.48	-4.51	-0.42	1.86e-5	Prostate-specific antigen levels;
THYM	cis	rs11190604	1.000	rs76683169	chr10:102358397	A/T	cg07570687	chr10:102243282	WNT8B	0.73	5.58	0.5	2.22e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs28595532	0.920	rs17324807	chr4:119770638	G/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs2562456	0.874	rs9304986	chr19:21682062	G/A	cg21751540	chr19:21541537	ZNF738	0.7	4.89	0.45	4.11e-6	Pain;
THYM	cis	rs6032067	0.777	rs13037087	chr20:43834313	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs96067	0.652	rs274132	chr1:36581978	C/T	cg27506609	chr1:36549197	TEKT2	0.89	4.69	0.43	9.28e-6	Corneal structure;
THYM	cis	rs8067235	1.000	rs8067235	chr17:79024637	A/G	cg19159404	chr17:79041535	BAIAP2	-0.59	-5.66	-0.5	1.6e-7	Memory performance;
THYM	cis	rs7704138	0.639	rs6870832	chr5:55016978	G/A	cg18456523	chr5:54516805	NA	-0.58	-4.59	-0.43	1.34e-5	Height;
THYM	cis	rs2050392	0.630	rs303427	chr10:30739780	G/A	cg25182066	chr10:30743637	MAP3K8	-0.56	-4.96	-0.45	3.14e-6	Inflammatory bowel disease;
THYM	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg03609598	chr5:56110824	MAP3K1	-0.89	-6.07	-0.53	2.63e-8	Initial pursuit acceleration;
THYM	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs2139634	1.000	rs6762703	chr3:46518318	T/G	cg02332537	chr3:46540019	RTP3	0.47	4.83	0.44	5.22e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg07917127	chr4:99064746	C4orf37	0.59	4.5	0.42	1.93e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg10760299	chr15:45669010	GATM	0.76	5.99	0.52	3.77e-8	Homoarginine levels;
THYM	cis	rs6700896	0.931	rs12034502	chr1:66099831	C/T	cg04111102	chr1:66153794	NA	0.55	5.23	0.47	9.89e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.75e-6	Aortic root size;
THYM	cis	rs6866344	0.598	rs11742176	chr5:178147931	C/T	cg10224037	chr5:178157518	ZNF354A	1.02	8.37	0.65	5.03e-13	Neutrophil percentage of white cells;
THYM	cis	rs9826463	0.582	rs73238187	chr3:142143674	T/C	cg20824294	chr3:142316082	PLS1	0.76	5.3	0.48	7.53e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs79815064	0.850	rs78372062	chr3:46323679	G/A	cg20674725	chr3:47020919	NBEAL2	0.71	4.7	0.43	8.76e-6	Macrophage inflammatory protein 1b levels;
THYM	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg06108461	chr20:60628389	TAF4	-0.84	-7.06	-0.59	2.77e-10	Body mass index;
THYM	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg08439880	chr3:133502540	NA	-0.82	-7.09	-0.59	2.36e-10	Iron status biomarkers;
THYM	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg00300879	chr1:26503847	CNKSR1	0.41	5.32	0.48	6.81e-7	Height;
THYM	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.51	4.77	0.44	6.65e-6	Lymphocyte counts;
THYM	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs7226229	0.797	rs7223388	chr17:20866865	C/T	cg21263980	chr17:20946333	USP22	-0.71	-4.86	-0.45	4.57e-6	Blood trace element (Se levels);
THYM	cis	rs4766646	0.640	rs4766642	chr12:110313754	T/C	cg10794374	chr12:110278745	NA	-0.21	-4.46	-0.42	2.29e-5	Metabolite levels (MHPG);
THYM	cis	rs7772486	0.594	rs6901864	chr6:146023050	C/A	cg23711669	chr6:146136114	FBXO30	-1.0	-10.81	-0.74	3.05e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3008870	1.000	rs3008888	chr1:67368965	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.93	7.13	0.59	1.96e-10	Lymphocyte percentage of white cells;
THYM	cis	rs10924970	0.934	rs2891026	chr1:235429907	A/C	cg26050004	chr1:235667680	B3GALNT2	0.6	4.62	0.43	1.22e-5	Asthma;
THYM	cis	rs990171	1.000	rs7597819	chr2:103092906	A/G	cg13897122	chr2:103039542	IL18RAP	-0.41	-4.93	-0.45	3.49e-6	Lymphocyte counts;
THYM	cis	rs4731207	0.596	rs1600737	chr7:124639547	C/T	cg05285228	chr7:124571219	POT1	-0.68	-5.1	-0.46	1.76e-6	Cutaneous malignant melanoma;
THYM	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg24910161	chr17:38119198	GSDMA	0.46	4.8	0.44	5.85e-6	Self-reported allergy;
THYM	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg27398817	chr8:82754497	SNX16	0.84	6.56	0.56	2.79e-9	Diastolic blood pressure;
THYM	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg04455712	chr21:45112962	RRP1B	0.54	5.04	0.46	2.22e-6	Mean corpuscular volume;
THYM	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.76	5.09	0.46	1.77e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	trans	rs1974653	0.672	rs9606239	chr22:20070285	G/A	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	7.8	0.62	7.81e-12	Platelet count;
THYM	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.67	5.55	0.49	2.57e-7	Blood metabolite levels;
THYM	cis	rs2455799	0.533	rs2470550	chr3:15743721	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-5.63	-0.5	1.83e-7	Mean platelet volume;
THYM	cis	rs3126085	0.877	rs12116736	chr1:152167062	C/T	cg26020982	chr1:152196106	HRNR	0.34	4.52	0.42	1.76e-5	Atopic dermatitis;
THYM	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg11812906	chr14:75593930	NEK9	0.75	6.14	0.53	1.91e-8	Height;
THYM	cis	rs6430585	0.583	rs4594504	chr2:136625113	A/C	cg07169764	chr2:136633963	MCM6	1.24	13.85	0.82	1.58e-24	Corneal structure;
THYM	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg12560992	chr17:57184187	TRIM37	-0.9	-8.19	-0.64	1.2e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg00256281	chr22:41985642	PMM1	0.55	4.48	0.42	2.06e-5	Vitiligo;
THYM	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg06656553	chr16:89960601	TCF25	-0.81	-4.7	-0.43	8.84e-6	Skin colour saturation;
THYM	cis	rs2803122	0.807	rs4977289	chr9:19225188	T/C	cg19584733	chr9:19298547	DENND4C	-0.53	-4.55	-0.42	1.56e-5	Pulse pressure;
THYM	cis	rs4901869	0.966	rs425764	chr14:59334997	A/G	cg02291164	chr14:59296302	NA	0.82	8.22	0.64	1.05e-12	Panic disorder;
THYM	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.97	-5.43	-0.49	4.36e-7	Red cell distribution width;
THYM	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg03609598	chr5:56110824	MAP3K1	-0.89	-6.07	-0.53	2.63e-8	Initial pursuit acceleration;
THYM	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg24397884	chr7:158709396	WDR60	0.44	4.62	0.43	1.22e-5	Height;
THYM	cis	rs4988958	0.548	rs6543127	chr2:103028301	A/C	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma (childhood onset);
THYM	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.77	6.66	0.56	1.78e-9	Menarche (age at onset);
THYM	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg13319975	chr6:146136371	FBXO30	-0.67	-5.46	-0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10779751	1.000	rs2300093	chr1:11266392	G/C	cg08854313	chr1:11322531	MTOR	1.01	9.78	0.71	4.97e-16	Body mass index;
THYM	cis	rs3960554	0.741	rs28446604	chr7:75662518	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-4.56	-0.42	1.51e-5	Eotaxin levels;
THYM	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg17644776	chr2:200775616	C2orf69	-0.73	-5.7	-0.5	1.35e-7	Schizophrenia;
THYM	cis	rs10779751	0.770	rs11581010	chr1:11212458	A/G	cg08854313	chr1:11322531	MTOR	-0.72	-5.45	-0.49	4.03e-7	Body mass index;
THYM	cis	rs2658782	0.756	rs2658777	chr11:93148423	C/T	cg15737290	chr11:93063684	CCDC67	0.96	7.35	0.6	6.87e-11	Pulmonary function decline;
THYM	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg26597838	chr10:835615	NA	1.23	8.86	0.67	4.56e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs7705502	0.890	rs3860770	chr5:173301427	G/A	cg18693985	chr5:173351052	CPEB4	-0.8	-5.74	-0.51	1.13e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.13	-0.53	2.04e-8	Total body bone mineral density;
THYM	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg05373962	chr22:49881684	NA	-0.71	-7.11	-0.59	2.18e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs11723261	0.621	rs61794960	chr4:150459	C/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.87	5.76	0.51	1.05e-7	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg15536230	chr21:44985092	HSF2BP	-0.41	-5.14	-0.47	1.46e-6	Mean corpuscular volume;
THYM	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg07424592	chr7:64974309	NA	0.99	5.15	0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg03388043	chr17:80084554	CCDC57	0.67	5.71	0.51	1.27e-7	Life satisfaction;
THYM	cis	rs490234	0.812	rs4329365	chr9:128445758	A/C	cg14078157	chr9:128172775	NA	-0.67	-5.04	-0.46	2.25e-6	Mean arterial pressure;
THYM	cis	rs2456568	0.548	rs7113080	chr11:93657520	G/A	cg17595323	chr11:93583763	C11orf90	-0.52	-5.59	-0.5	2.21e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg18252515	chr7:66147081	NA	1.37	8.05	0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs425277	0.583	rs3128334	chr1:2038662	G/A	cg00981070	chr1:2046702	PRKCZ	-0.39	-4.62	-0.43	1.23e-5	Height;
THYM	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03762994	chr17:6899332	ALOX12	0.72	10.32	0.73	3.39e-17	Tonsillectomy;
THYM	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg21926883	chr2:100939477	LONRF2	-0.67	-6.24	-0.54	1.19e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7824557	0.614	rs5029571	chr8:11213389	C/T	cg21775007	chr8:11205619	TDH	0.69	6.04	0.53	2.96e-8	Retinal vascular caliber;
THYM	cis	rs3540	0.533	rs2352601	chr15:91053125	G/A	cg22089800	chr15:90895588	ZNF774	-0.68	-5.13	-0.47	1.51e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg26769984	chr7:1090371	C7orf50	0.62	4.52	0.42	1.78e-5	Bronchopulmonary dysplasia;
THYM	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg13683864	chr3:40499215	RPL14	-0.85	-8.31	-0.65	6.51e-13	Renal cell carcinoma;
THYM	cis	rs7508	0.765	rs2898458	chr8:17913813	G/A	cg18067069	chr8:17937731	ASAH1	-0.66	-5.19	-0.47	1.17e-6	Atrial fibrillation;
THYM	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs757081	0.637	rs34941502	chr11:17155432	G/A	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.6	-0.43	1.29e-5	Systolic blood pressure;
THYM	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg08999081	chr20:33150536	PIGU	0.62	5.02	0.46	2.41e-6	Coronary artery disease;
THYM	cis	rs2455799	0.593	rs2470544	chr3:15727234	A/G	cg16303742	chr3:15540471	COLQ	-0.54	-5.62	-0.5	1.92e-7	Mean platelet volume;
THYM	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.78	-0.44	6.31e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg09455208	chr3:40491958	NA	0.49	5.1	0.46	1.75e-6	Renal cell carcinoma;
THYM	cis	rs7226229	0.950	rs1038107	chr17:20921492	C/T	cg21263980	chr17:20946333	USP22	0.65	4.88	0.45	4.33e-6	Blood trace element (Se levels);
THYM	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg00012203	chr2:219082015	ARPC2	-0.64	-5.28	-0.48	8.18e-7	Colorectal cancer;
THYM	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs2456568	0.835	rs8181533	chr11:93638614	C/T	cg17595323	chr11:93583763	C11orf90	-0.58	-6.09	-0.53	2.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7487075	1.000	rs7487075	chr12:46828918	G/A	cg21428710	chr12:47219797	SLC38A4	0.46	4.51	0.42	1.82e-5	Itch intensity from mosquito bite;
THYM	cis	rs12367572	0.623	rs10880718	chr12:45362806	G/C	cg03114573	chr12:45410052	DBX2	-0.49	-4.67	-0.43	9.86e-6	Gut microbiome composition (summer);
THYM	cis	rs919433	0.679	rs67492914	chr2:198523402	T/G	cg05783139	chr2:198650985	BOLL	0.66	4.98	0.46	2.78e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6435161	1.000	rs35202091	chr2:203507663	C/T	cg18429434	chr2:203499731	FAM117B	-0.73	-4.83	-0.44	5.15e-6	Total cholesterol levels;
THYM	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg13683864	chr3:40499215	RPL14	0.94	9.5	0.7	1.91e-15	Renal cell carcinoma;
THYM	cis	rs11574514	1.000	rs117705890	chr16:67714211	G/A	cg09738193	chr16:67926317	PSKH1	-0.91	-4.66	-0.43	1.01e-5	Crohn's disease;
THYM	cis	rs4731207	0.596	rs1481339	chr7:124708237	A/G	cg05285228	chr7:124571219	POT1	-0.65	-5.0	-0.46	2.64e-6	Cutaneous malignant melanoma;
THYM	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg04398451	chr17:18023971	MYO15A	0.83	7.71	0.62	1.22e-11	Total body bone mineral density;
THYM	cis	rs7481584	0.624	rs693687	chr11:3052494	A/G	cg03159660	chr11:2078197	NA	0.62	4.6	0.43	1.3e-5	Calcium levels;
THYM	cis	rs9796	0.689	rs13329537	chr15:41449211	C/G	cg18705301	chr15:41695430	NDUFAF1	0.63	5.08	0.46	1.89e-6	Menopause (age at onset);
THYM	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg09354556	chr3:47051341	NA	0.45	4.58	0.43	1.41e-5	Colorectal cancer;
THYM	cis	rs28595532	0.920	rs55649377	chr4:119752745	T/A	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs79349575	0.783	rs9912829	chr17:46982749	G/C	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2057149	0.776	rs1980531	chr6:110724518	C/T	cg01119278	chr6:110721349	DDO	0.49	4.46	0.42	2.23e-5	Platelet distribution width;Mean platelet volume;
THYM	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg11845111	chr2:191398756	TMEM194B	-1.0	-8.08	-0.64	2.04e-12	Diastolic blood pressure;
THYM	cis	rs6748734	0.625	rs6437372	chr2:241822406	A/G	cg02820040	chr2:241836501	C2orf54	0.23	4.49	0.42	2.04e-5	Urinary metabolites;
THYM	cis	rs4474465	0.790	rs4544031	chr11:78265403	G/C	cg02023728	chr11:77925099	USP35	-0.53	-4.62	-0.43	1.21e-5	Alzheimer's disease (survival time);
THYM	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.34	0.48	6.29e-7	Height;
THYM	cis	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg06521331	chr12:34319734	NA	0.76	5.88	0.52	6.13e-8	Morning vs. evening chronotype;
THYM	cis	rs9318086	0.648	rs4067969	chr13:24469120	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.56	4.62	0.43	1.2e-5	Myopia (pathological);
THYM	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg18681998	chr4:17616180	MED28	0.97	9.45	0.7	2.45e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7100689	0.646	rs6585946	chr10:82118292	G/T	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg04025307	chr7:1156635	C7orf50	0.78	6.67	0.56	1.72e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg11663144	chr21:46675770	NA	-0.69	-8.13	-0.64	1.58e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg14582100	chr15:45693742	SPATA5L1	0.57	4.69	0.43	9.14e-6	Homoarginine levels;
THYM	cis	rs6430585	0.528	rs6430594	chr2:136719173	C/T	cg23851026	chr2:136556271	LCT	-0.76	-7.47	-0.61	3.81e-11	Corneal structure;
THYM	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg18352616	chr4:3374830	RGS12	0.68	7.46	0.61	4e-11	Serum sulfate level;
THYM	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg15921436	chr17:44337874	NA	-0.91	-6.85	-0.58	7.19e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4803468	0.967	rs4605279	chr19:41888131	C/G	cg09537434	chr19:41945824	ATP5SL	-1.11	-10.15	-0.72	7.74e-17	Height;
THYM	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg17264618	chr3:40429014	ENTPD3	0.53	4.93	0.45	3.52e-6	Renal cell carcinoma;
THYM	cis	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg15838173	chr10:75533400	FUT11	-0.6	-5.89	-0.52	5.93e-8	Inflammatory bowel disease;
THYM	cis	rs28374715	0.662	rs11852419	chr15:41456374	A/T	cg18705301	chr15:41695430	NDUFAF1	1.0	8.6	0.66	1.59e-13	Ulcerative colitis;
THYM	cis	rs17376456	0.778	rs10476604	chr5:93461838	C/T	cg25358565	chr5:93447407	FAM172A	0.84	6.3	0.54	9.36e-9	Diabetic retinopathy;
THYM	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg24803719	chr17:45855879	NA	-0.6	-6.36	-0.55	7.19e-9	IgG glycosylation;
THYM	cis	rs13082711	0.911	rs3736312	chr3:27442336	G/A	cg02860705	chr3:27208620	NA	0.67	4.7	0.43	8.96e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs11690935	1.000	rs1554166	chr2:172541609	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.85	-6.24	-0.54	1.23e-8	Schizophrenia;
THYM	cis	rs7465272	1.000	rs35476574	chr8:143683784	C/A	cg10104451	chr8:143696006	ARC	-0.78	-5.42	-0.49	4.45e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs13082711	0.554	rs9310843	chr3:27371260	A/G	cg02860705	chr3:27208620	NA	0.67	5.03	0.46	2.3e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg16342193	chr10:102329863	NA	-0.6	-6.21	-0.54	1.41e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg21427119	chr20:30132790	HM13	-0.73	-4.94	-0.45	3.41e-6	Mean corpuscular hemoglobin;
THYM	cis	rs1003719	0.680	rs8130069	chr21:38552116	A/G	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs6541297	1.000	rs2352723	chr1:230291868	C/T	cg20703242	chr1:230279135	GALNT2	-0.94	-5.59	-0.5	2.15e-7	Coronary artery disease;
THYM	cis	rs9796	0.558	rs6492993	chr15:41526104	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.57	-4.64	-0.43	1.1e-5	Menopause (age at onset);
THYM	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.06	9.51	0.7	1.87e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4750440	0.523	rs4565801	chr10:14032358	G/A	cg27542038	chr10:14027202	FRMD4A	-0.58	-4.81	-0.44	5.57e-6	Adiponectin levels;
THYM	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg14983838	chr19:29218262	NA	1.13	9.44	0.7	2.55e-15	Methadone dose in opioid dependence;
THYM	cis	rs13315871	1.000	rs13063504	chr3:58409854	A/G	cg00563845	chr3:58318305	PXK	0.53	4.67	0.43	9.78e-6	Cholesterol, total;
THYM	cis	rs9302690	1.000	rs75700677	chr16:57480315	G/A	cg27017172	chr16:57497170	POLR2C	0.82	4.88	0.45	4.29e-6	Blood protein levels;
THYM	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.84e-8	Systolic blood pressure;
THYM	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg11752832	chr7:134001865	SLC35B4	0.73	5.5	0.49	3.22e-7	Mean platelet volume;
THYM	cis	rs4888262	0.507	rs9888976	chr16:74580924	C/T	cg01733217	chr16:74700730	RFWD3	0.8	8.31	0.65	6.53e-13	Testicular germ cell tumor;
THYM	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg16325326	chr1:53192061	ZYG11B	-0.86	-8.54	-0.66	2.14e-13	Monocyte count;
THYM	cis	rs2213920	0.749	rs4978637	chr9:118222448	T/A	cg13918206	chr9:118159781	DEC1	0.78	4.45	0.42	2.3e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs4660456	0.529	rs61779237	chr1:41150972	A/T	cg11417323	chr1:41160271	NFYC	0.42	4.66	0.43	1.04e-5	Platelet count;
THYM	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg06808227	chr14:105710500	BRF1	-1.02	-8.8	-0.67	6.1e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg23815491	chr16:72088622	HP	0.84	7.3	0.6	8.9e-11	Fibrinogen levels;
THYM	cis	rs7020830	0.898	rs308495	chr9:37277603	G/T	cg14294708	chr9:37120828	ZCCHC7	1.23	13.88	0.82	1.36e-24	Schizophrenia;
THYM	trans	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs8040855	0.965	rs6496766	chr15:85702375	C/A	cg04831495	chr15:85060580	GOLGA6L5	0.6	4.81	0.44	5.75e-6	Bulimia nervosa;
THYM	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg04944784	chr2:26401820	FAM59B	1.05	8.18	0.64	1.23e-12	Gut microbiome composition (summer);
THYM	cis	rs4845570	1.000	rs1054479	chr1:151746079	A/T	cg18019451	chr1:151746047	TDRKH	-0.75	-4.58	-0.43	1.41e-5	Coronary artery disease;
THYM	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg06481639	chr22:41940642	POLR3H	0.8	5.56	0.5	2.48e-7	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28829049	0.861	rs2147946	chr1:19368887	C/T	cg13387374	chr1:19411106	UBR4	0.67	5.46	0.49	3.87e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg07212818	chr11:638076	DRD4	-0.74	-5.37	-0.48	5.5e-7	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg24209194	chr3:40518798	ZNF619	0.58	4.78	0.44	6.34e-6	Renal cell carcinoma;
THYM	cis	rs7833986	0.501	rs2953910	chr8:56968761	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.4	0.6	5.43e-11	Height;
THYM	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg04731861	chr2:219085781	ARPC2	-0.53	-4.83	-0.44	5.3e-6	Colorectal cancer;
THYM	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg27446573	chr6:127587934	RNF146	0.92	7.36	0.6	6.45e-11	Breast cancer;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg14321343	chr22:29838869	RFPL1S	-0.88	-6.86	-0.58	6.85e-10	Depressive symptoms;
THYM	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1650123	0.677	rs703615	chr12:104019152	T/A	cg23227824	chr12:103980017	STAB2	0.49	5.15	0.47	1.38e-6	IgG glycosylation;
THYM	trans	rs2075230	0.705	rs1641520	chr17:7550157	T/A	cg04140212	chr2:85829138	TMEM150A	-0.57	-6.87	-0.58	6.7e-10	Hormone measurements;
THYM	cis	rs4803468	0.934	rs2317131	chr19:41885151	C/T	cg09537434	chr19:41945824	ATP5SL	-1.08	-10.03	-0.72	1.45e-16	Height;
THYM	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	12.92	0.8	1.2e-22	Height;
THYM	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg09035930	chr12:129282057	SLC15A4	0.86	11.57	0.76	7.67e-20	Systemic lupus erythematosus;
THYM	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg17173187	chr15:85201210	NMB	-0.42	-4.55	-0.42	1.56e-5	P wave terminal force;
THYM	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.66e-11	Aortic root size;
THYM	cis	rs6754311	0.773	rs188680	chr2:136630989	A/G	cg04750100	chr2:136595281	LCT	-0.56	-6.13	-0.53	1.97e-8	Mosquito bite size;
THYM	cis	rs2730245	0.527	rs842707	chr7:158656012	C/T	cg11984989	chr7:158649758	WDR60	1.02	8.59	0.66	1.67e-13	Height;
THYM	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg06238570	chr21:40685208	BRWD1	-0.73	-6.27	-0.54	1.05e-8	Menarche (age at onset);
THYM	cis	rs485842	0.965	rs557277	chr11:96019749	A/G	cg23866687	chr11:96026956	MAML2	0.44	6.23	0.54	1.28e-8	Corneal astigmatism;
THYM	cis	rs8112449	0.861	rs3760650	chr19:10515804	T/C	cg01466491	chr19:10523363	NA	-0.66	-6.3	-0.54	9.36e-9	Multiple sclerosis;Gastritis;
THYM	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Drug-induced liver injury (flucloxacillin);
THYM	trans	rs480407	0.857	rs270965	chr2:161688392	T/C	cg06548410	chr19:1997657	BTBD2	0.7	6.87	0.58	6.79e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1018697	0.518	rs284846	chr10:104557290	T/C	cg04362960	chr10:104952993	NT5C2	-0.73	-5.09	-0.46	1.78e-6	Colorectal adenoma (advanced);
THYM	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg27494647	chr7:150038898	RARRES2	-0.48	-5.94	-0.52	4.59e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7267979	0.966	rs2261785	chr20:25262403	C/T	cg08601574	chr20:25228251	PYGB	0.57	4.62	0.43	1.18e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg23583168	chr7:148888333	NA	-1.02	-14.09	-0.82	5.29e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg13319975	chr6:146136371	FBXO30	0.67	5.32	0.48	7.02e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg14196790	chr5:131705035	SLC22A5	-0.55	-4.93	-0.45	3.55e-6	Blood metabolite levels;
THYM	cis	rs11031096	0.711	rs10835723	chr11:4207566	G/C	cg08557956	chr11:4115526	RRM1	-0.55	-4.86	-0.45	4.68e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7260598	0.642	rs11667910	chr19:24159713	C/T	cg15526094	chr19:24182596	NA	-0.66	-4.72	-0.44	8.28e-6	Response to taxane treatment (placlitaxel);
THYM	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg15704280	chr7:45808275	SEPT13	-1.06	-15.39	-0.84	1.51e-27	Height;
THYM	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg27490568	chr2:178487706	NA	0.68	5.53	0.49	2.77e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg23711669	chr6:146136114	FBXO30	0.95	9.84	0.71	3.6e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9560113	0.580	rs9560116	chr13:112193731	G/A	cg10483660	chr13:112241077	NA	0.67	7.54	0.61	2.8e-11	Menarche (age at onset);
THYM	cis	rs2456568	0.564	rs7119708	chr11:93626641	T/C	cg17347335	chr11:93583973	C11orf90	0.57	6.0	0.52	3.53e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg24060327	chr5:131705240	SLC22A5	-0.66	-4.87	-0.45	4.36e-6	Blood metabolite levels;
THYM	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9677476	0.863	rs10181630	chr2:232091757	C/T	cg07929768	chr2:232055508	NA	0.59	5.99	0.52	3.66e-8	Food antigen IgG levels;
THYM	cis	rs4509693	0.943	rs6584395	chr10:102498008	G/C	cg15234845	chr10:102496500	NA	0.65	4.6	0.43	1.3e-5	Alzheimer's disease;
THYM	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg18252515	chr7:66147081	NA	-0.66	-5.0	-0.46	2.65e-6	Aortic root size;
THYM	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg25427524	chr10:38739819	LOC399744	-0.64	-5.88	-0.52	6.2e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs4077515	0.743	rs3812571	chr9:139275294	G/C	cg14115884	chr9:139300582	SDCCAG3	0.76	8.19	0.64	1.21e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg24818145	chr4:99064322	C4orf37	0.72	5.73	0.51	1.19e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11648796	0.959	rs9928077	chr16:784765	C/T	cg01252526	chr16:711033	WDR90	-0.74	-6.21	-0.54	1.37e-8	Height;
THYM	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg12656391	chr1:43425156	SLC2A1	-0.95	-7.15	-0.59	1.82e-10	Monocyte count;
THYM	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg02725872	chr8:58115012	NA	-0.91	-5.43	-0.49	4.32e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs490234	0.586	rs12553548	chr9:128155261	T/G	cg14078157	chr9:128172775	NA	-0.84	-6.93	-0.58	4.9e-10	Mean arterial pressure;
THYM	cis	rs4638749	0.677	rs9631035	chr2:108818916	C/T	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg00898013	chr13:113819073	PROZ	-0.87	-8.8	-0.67	6.16e-14	Platelet distribution width;
THYM	cis	rs7705042	0.865	rs4912623	chr5:141505462	T/A	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs17125944	0.556	rs7152229	chr14:53313405	T/C	cg00686598	chr14:53173677	PSMC6	-1.06	-4.81	-0.44	5.56e-6	Alzheimer's disease (late onset);
THYM	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22857025	chr5:266934	NA	-1.43	-9.3	-0.69	5.28e-15	Breast cancer;
THYM	cis	rs13177918	0.603	rs2343806	chr5:149831985	A/T	cg14059543	chr5:149831962	NA	-0.87	-7.28	-0.6	9.44e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6866614	0.639	rs1858074	chr5:131371999	A/G	cg00255919	chr5:131827918	IRF1	-0.45	-4.86	-0.45	4.55e-6	Perceived unattractiveness to mosquitoes;
THYM	trans	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.11	8.17	0.64	1.3e-12	Exhaled nitric oxide output;
THYM	cis	rs7487075	0.797	rs10785630	chr12:46880380	G/A	cg21428710	chr12:47219797	SLC38A4	0.49	4.55	0.42	1.58e-5	Itch intensity from mosquito bite;
THYM	cis	rs6754459	1.000	rs6754459	chr2:3707423	C/T	cg00999904	chr2:3704751	ALLC	-0.8	-6.38	-0.55	6.4e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs2637266	0.626	rs846617	chr10:78546881	A/G	cg18941641	chr10:78392320	NA	0.74	5.81	0.51	8.27e-8	Pulmonary function;
THYM	cis	rs4148689	1.000	rs2283057	chr7:117202484	C/G	cg17204129	chr7:117119601	CFTR	-0.62	-4.9	-0.45	3.95e-6	Gout;
THYM	cis	rs9326248	0.559	rs1269329	chr11:116755041	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.67	5.3	0.48	7.39e-7	Blood protein levels;
THYM	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg21475434	chr5:93447410	FAM172A	0.93	5.81	0.51	8.12e-8	Diabetic retinopathy;
THYM	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg02891314	chr5:179741120	GFPT2	-0.81	-6.46	-0.55	4.45e-9	Height;
THYM	cis	rs4363385	0.626	rs6667103	chr1:153064438	A/G	cg07796016	chr1:152779584	LCE1C	-0.53	-4.58	-0.43	1.4e-5	Inflammatory skin disease;
THYM	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.08	7.64	0.62	1.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg21475434	chr5:93447410	FAM172A	0.97	6.06	0.53	2.72e-8	Diabetic retinopathy;
THYM	cis	rs9987353	0.544	rs2929470	chr8:9062490	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-4.56	-0.42	1.52e-5	Recombination measurement;
THYM	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs865483	0.895	rs72828253	chr17:35783416	A/G	cg06716730	chr17:35851459	DUSP14	-0.43	-7.32	-0.6	7.91e-11	Monocyte count;
THYM	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg07167872	chr1:205819463	PM20D1	0.59	4.57	0.42	1.45e-5	Parkinson's disease;
THYM	cis	rs735396	1.000	rs2259816	chr12:121435587	A/C	cg02403541	chr12:121454288	C12orf43	-0.59	-4.74	-0.44	7.63e-6	N-glycan levels;
THYM	cis	rs2276314	0.748	rs4799839	chr18:33597531	T/C	cg19628046	chr18:33552617	C18orf21	0.75	5.33	0.48	6.55e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs17739794	0.545	rs982352	chr8:823449	C/T	cg01971667	chr8:817044	NA	0.76	6.91	0.58	5.44e-10	Clozapine-induced cytotoxicity;
THYM	cis	rs2236918	0.710	rs2797603	chr1:242029027	T/G	cg21919602	chr1:242011447	EXO1	-0.6	-4.45	-0.42	2.35e-5	Menopause (age at onset);
THYM	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.6	-0.5	2.08e-7	Type 2 diabetes;
THYM	cis	rs6570726	0.934	rs9484995	chr6:145781114	T/A	cg13319975	chr6:146136371	FBXO30	0.67	5.63	0.5	1.82e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2404602	0.647	rs2404600	chr15:77173557	C/T	cg23625390	chr15:77176239	SCAPER	-0.81	-5.61	-0.5	1.96e-7	Blood metabolite levels;
THYM	cis	rs34779708	0.931	rs12771399	chr10:35452377	C/T	cg03585969	chr10:35415529	CREM	0.66	4.48	0.42	2.06e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg06728252	chr6:26598149	ABT1	-0.43	-5.11	-0.46	1.63e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg25237894	chr2:233734115	C2orf82	-0.33	-4.5	-0.42	1.89e-5	Coronary artery disease;
THYM	cis	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg10518543	chr12:38710700	ALG10B	-0.57	-4.57	-0.42	1.47e-5	Morning vs. evening chronotype;
THYM	cis	rs7178572	0.568	rs12911371	chr15:77689050	C/T	cg22256960	chr15:77711686	NA	-1.05	-8.4	-0.65	4.29e-13	Type 2 diabetes;
THYM	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg04362960	chr10:104952993	NT5C2	0.58	4.75	0.44	7.17e-6	Arsenic metabolism;
THYM	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg10803722	chr21:46713166	LOC642852	0.38	4.93	0.45	3.44e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3820068	0.603	rs59475085	chr1:15911131	G/A	cg05660106	chr1:15850417	CASP9	0.93	7.32	0.6	7.88e-11	Systolic blood pressure;
THYM	cis	rs901683	0.850	rs73291113	chr10:46095065	G/C	cg18240400	chr10:46168597	ANUBL1	0.63	4.71	0.43	8.58e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.52	-5.16	-0.47	1.36e-6	Schizophrenia;
THYM	cis	rs4285028	0.699	rs4676758	chr3:121583415	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.81	5.78	0.51	9.34e-8	Multiple sclerosis;
THYM	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11644478	chr21:40555479	PSMG1	1.09	9.59	0.7	1.26e-15	Cognitive function;
THYM	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg18105134	chr13:113819100	PROZ	1.07	9.85	0.71	3.52e-16	Platelet distribution width;
THYM	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg11266682	chr4:10021025	SLC2A9	-0.68	-9.72	-0.71	6.47e-16	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs665401	0.692	rs339319	chr6:117188735	A/G	cg20376953	chr6:117187980	NA	-0.62	-4.84	-0.44	5.05e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs4631830	0.600	rs11004246	chr10:51495349	T/C	cg10326726	chr10:51549505	MSMB	0.54	5.28	0.48	8.32e-7	Prostate-specific antigen levels;
THYM	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg04398451	chr17:18023971	MYO15A	0.8	7.75	0.62	1.02e-11	Total body bone mineral density;
THYM	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg15704280	chr7:45808275	SEPT13	-0.98	-11.3	-0.76	2.81e-19	Height;
THYM	cis	rs12310956	0.510	rs4931758	chr12:33871870	C/T	cg06521331	chr12:34319734	NA	-0.57	-4.62	-0.43	1.21e-5	Morning vs. evening chronotype;
THYM	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6539288	0.677	rs10735418	chr12:107343376	T/C	cg26297688	chr12:107349093	C12orf23	-0.5	-6.02	-0.53	3.22e-8	Total body bone mineral density;
THYM	cis	rs888194	0.677	rs7956194	chr12:109877825	C/T	cg10504392	chr12:110044639	NA	0.64	5.96	0.52	4.31e-8	Neuroticism;
THYM	cis	rs12765878	1.000	rs3814220	chr10:105647300	A/G	cg11005552	chr10:105648138	OBFC1	0.85	11.16	0.75	5.73e-19	Coronary artery disease;
THYM	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2505998	0.957	rs2435366	chr10:43571988	T/C	cg06632098	chr10:43605906	RET	-1.05	-9.64	-0.7	9.8e-16	Hirschsprung disease;
THYM	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg23649088	chr2:200775458	C2orf69	0.77	5.06	0.46	2e-6	Schizophrenia;
THYM	cis	rs12935418	1.000	rs62054589	chr16:81068748	T/C	cg16651780	chr16:81037892	C16orf61	0.89	4.76	0.44	7.01e-6	Mean corpuscular volume;
THYM	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs13315871	1.000	rs1131052	chr3:58411530	A/T	cg12435725	chr3:58293450	RPP14	-0.46	-4.93	-0.45	3.54e-6	Cholesterol, total;
THYM	cis	rs2625529	0.590	rs12442886	chr15:72473611	T/C	cg16672083	chr15:72433130	SENP8	0.53	4.79	0.44	6.14e-6	Red blood cell count;
THYM	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.82	-7.05	-0.59	2.84e-10	Systemic lupus erythematosus;
THYM	cis	rs3126085	0.935	rs11584340	chr1:152285930	G/A	cg10321714	chr1:152280068	FLG	-0.68	-4.95	-0.45	3.18e-6	Atopic dermatitis;
THYM	cis	rs7172809	0.548	rs17385352	chr15:77651305	A/G	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs2154427	1.000	rs75419790	chr21:34167092	C/T	cg21871883	chr21:34145043	C21orf49;C21orf66	0.99	4.67	0.43	9.95e-6	Bilirubin levels;
THYM	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg03517284	chr6:25882590	NA	-0.7	-4.7	-0.43	8.76e-6	Height;
THYM	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg17863274	chr19:49399704	TULP2	-1.01	-6.47	-0.55	4.29e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg04043695	chr12:129287642	SLC15A4	0.62	4.98	0.46	2.81e-6	Systemic lupus erythematosus;
THYM	cis	rs4930776	0.593	rs421159	chr12:5757207	C/T	cg02086166	chr12:5775618	ANO2	0.59	4.94	0.45	3.37e-6	Plasma clusterin levels;
THYM	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg18825531	chr11:62321136	NA	-0.45	-5.11	-0.46	1.63e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs990171	0.908	rs731628	chr2:103082571	C/T	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.1	-0.46	1.74e-6	Lymphocyte counts;
THYM	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg16230307	chr14:35515116	FAM177A1	0.9	5.79	0.51	9.23e-8	Psoriasis;
THYM	cis	rs6495367	1.000	rs3851677	chr15:79380869	C/T	cg17916960	chr15:79447300	NA	0.56	6.09	0.53	2.42e-8	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg11764359	chr7:65958608	NA	-0.77	-5.97	-0.52	4.07e-8	Aortic root size;
THYM	cis	rs10779751	0.632	rs2748876	chr1:11134157	T/G	cg08854313	chr1:11322531	MTOR	0.79	5.99	0.52	3.69e-8	Body mass index;
THYM	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg09455208	chr3:40491958	NA	0.44	4.51	0.42	1.85e-5	Renal cell carcinoma;
THYM	cis	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg11266682	chr4:10021025	SLC2A9	0.45	4.62	0.43	1.2e-5	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg27286337	chr10:134555280	INPP5A	-1.02	-9.53	-0.7	1.66e-15	Migraine;
THYM	cis	rs6032067	0.929	rs13043503	chr20:43805835	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg05738196	chr6:26577821	NA	0.92	8.68	0.67	1.07e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4631830	0.863	rs7081532	chr10:51526093	A/G	cg10326726	chr10:51549505	MSMB	-0.59	-5.86	-0.52	6.68e-8	Prostate-specific antigen levels;
THYM	cis	rs8006682	0.541	rs12890235	chr14:69089903	T/C	cg21123519	chr14:69095679	NA	-0.63	-4.78	-0.44	6.46e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs1443512	0.588	rs1838173	chr12:54342822	C/T	cg15261861	chr12:54132255	NA	0.54	4.74	0.44	7.55e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs986417	0.748	rs10142927	chr14:61041956	A/G	cg27398547	chr14:60952738	C14orf39	1.1	6.03	0.53	3.13e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg26149184	chr10:133730230	NA	0.77	4.65	0.43	1.07e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg09165964	chr15:75287851	SCAMP5	0.7	5.0	0.46	2.64e-6	Blood trace element (Zn levels);
THYM	cis	rs11809207	0.501	rs3762460	chr1:26495550	A/G	cg00300879	chr1:26503847	CNKSR1	0.38	4.85	0.45	4.79e-6	Height;
THYM	cis	rs919433	0.680	rs7568250	chr2:198409611	G/A	cg05783139	chr2:198650985	BOLL	0.64	4.93	0.45	3.54e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs6430585	0.528	rs111682961	chr2:136653848	C/T	cg23851026	chr2:136556271	LCT	0.81	7.31	0.6	8.35e-11	Corneal structure;
THYM	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.54	7.14	0.59	1.89e-10	Schizophrenia;
THYM	cis	rs4746818	1.000	rs906218	chr10:70960913	C/T	cg04149295	chr10:70884716	VPS26A	0.78	5.31	0.48	7.18e-7	Left atrial antero-posterior diameter;
THYM	cis	rs938554	0.513	rs3775947	chr4:9995240	C/T	cg26689780	chr4:10079554	WDR1	-0.4	-4.67	-0.43	9.92e-6	Blood metabolite levels;
THYM	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs11690935	0.959	rs3770451	chr2:172668715	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.82	-6.02	-0.53	3.29e-8	Schizophrenia;
THYM	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg12963246	chr6:28129442	ZNF389	0.87	7.7	0.62	1.29e-11	Depression;
THYM	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1113500	0.933	rs11185255	chr1:108633191	T/A	cg06207961	chr1:108661230	NA	0.64	5.09	0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs62244186	0.627	rs3935212	chr3:44460954	G/A	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.51	-5.13	-0.47	1.5e-6	Depressive symptoms;
THYM	cis	rs8028313	0.630	rs7169086	chr15:67934454	C/T	cg26545918	chr15:68124484	LBXCOR1	0.54	4.6	0.43	1.29e-5	Obesity;
THYM	cis	rs11910985	0.546	rs9977877	chr21:48080493	G/A	cg23283320	chr21:48055893	PRMT2	1.27	7.94	0.63	3.95e-12	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg02825527	chr7:2087843	MAD1L1	-0.76	-5.08	-0.46	1.88e-6	Bipolar disorder;
THYM	cis	rs10924970	0.967	rs12035746	chr1:235405654	C/T	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	trans	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17712092	chr4:129076599	LARP1B	0.89	7.29	0.6	9.23e-11	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs6539288	0.901	rs4964506	chr12:107347085	A/G	cg26297688	chr12:107349093	C12orf23	-0.47	-4.96	-0.45	3.1e-6	Total body bone mineral density;
THYM	cis	rs524281	0.773	rs2155201	chr11:65992344	T/C	cg00563793	chr11:65837595	PACS1	0.79	4.71	0.43	8.53e-6	Electroencephalogram traits;
THYM	cis	rs7511006	1.000	rs5771109	chr22:50678571	T/C	cg07895657	chr22:50616420	PANX2	-0.53	-4.61	-0.43	1.27e-5	Obesity-related traits;
THYM	cis	rs6918586	1.000	rs198806	chr6:26133616	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.67	-5.55	-0.49	2.57e-7	Schizophrenia;
THYM	cis	rs3126085	0.515	rs9633409	chr1:152362329	G/T	cg10321714	chr1:152280068	FLG	-0.69	-4.84	-0.44	5.1e-6	Atopic dermatitis;
THYM	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg13609457	chr4:120235615	NA	0.52	4.76	0.44	7.02e-6	Corneal astigmatism;
THYM	cis	rs1421898	0.625	rs62384982	chr5:157944856	C/T	cg06698293	chr5:158690540	UBLCP1	-0.97	-4.6	-0.43	1.28e-5	Inflammatory skin disease;
THYM	trans	rs17685	0.753	rs869806	chr7:75688623	C/T	cg19862616	chr7:65841803	NCRNA00174	1.12	13.73	0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs3093024	1.000	rs3093024	chr6:167532793	C/T	cg09487078	chr6:167525398	CCR6	0.36	4.65	0.43	1.07e-5	Rheumatoid arthritis;
THYM	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg03476357	chr21:30257390	N6AMT1	-0.61	-4.59	-0.43	1.38e-5	Dental caries;
THYM	cis	rs3862030	0.810	rs11593710	chr10:104328719	A/C	cg00122347	chr10:104236741	TMEM180	0.42	6.22	0.54	1.34e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs12519773	0.526	rs4632783	chr5:92528309	A/G	cg18783429	chr5:92414398	NA	0.5	4.94	0.45	3.31e-6	Migraine;
THYM	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg12564285	chr5:131593104	PDLIM4	0.46	5.06	0.46	2.05e-6	Blood metabolite levels;
THYM	cis	rs17511627	0.808	rs9512137	chr13:26743507	C/T	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs4731207	0.698	rs7796150	chr7:124521217	C/T	cg05285228	chr7:124571219	POT1	-0.68	-5.43	-0.49	4.39e-7	Cutaneous malignant melanoma;
THYM	cis	rs13082711	0.911	rs17682229	chr3:27443067	T/C	cg02860705	chr3:27208620	NA	0.67	4.7	0.43	8.96e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs4731207	0.596	rs6980448	chr7:124569418	A/G	cg05285228	chr7:124571219	POT1	-0.68	-5.21	-0.47	1.09e-6	Cutaneous malignant melanoma;
THYM	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.45	-5.52	-0.49	2.93e-7	Schizophrenia;
THYM	cis	rs7107174	0.681	rs10899499	chr11:78124797	A/G	cg02023728	chr11:77925099	USP35	-0.63	-5.98	-0.52	3.83e-8	Testicular germ cell tumor;
THYM	cis	rs1957429	0.614	rs73279834	chr14:65352544	G/A	cg23373153	chr14:65346875	NA	-1.29	-5.55	-0.49	2.56e-7	Pediatric areal bone mineral density (radius);
THYM	cis	rs7107174	1.000	rs2510047	chr11:77988668	C/T	cg19901956	chr11:77921274	USP35	0.63	5.02	0.46	2.39e-6	Testicular germ cell tumor;
THYM	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	7.27	0.6	9.96e-11	Platelet count;
THYM	cis	rs986417	0.901	rs1024224	chr14:60926942	C/G	cg27398547	chr14:60952738	C14orf39	1.15	5.91	0.52	5.37e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	6.53	0.56	3.24e-9	Obesity-related traits;
THYM	cis	rs9420	0.796	rs685149	chr11:57657413	A/G	cg19752551	chr11:57585705	CTNND1	0.5	4.98	0.45	2.89e-6	Schizophrenia;
THYM	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg24375607	chr4:120327624	NA	0.64	5.09	0.46	1.84e-6	Corneal astigmatism;
THYM	cis	rs1003719	0.523	rs1063949	chr21:38574675	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-4.53	-0.42	1.72e-5	Eye color traits;
THYM	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg24733560	chr20:60626293	TAF4	0.51	4.58	0.43	1.41e-5	Body mass index;
THYM	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs12681287	0.752	rs1436628	chr8:87313345	C/G	cg27223183	chr8:87520930	FAM82B	0.68	5.19	0.47	1.2e-6	Caudate activity during reward;
THYM	cis	rs7851660	0.844	rs10119853	chr9:100624981	G/A	cg13688889	chr9:100608707	NA	-0.77	-5.31	-0.48	7.25e-7	Strep throat;
THYM	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg04414720	chr1:150670196	GOLPH3L	0.59	4.46	0.42	2.24e-5	Tonsillectomy;
THYM	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg17863274	chr19:49399704	TULP2	-1.01	-6.47	-0.55	4.29e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7769051	0.522	rs73550455	chr6:133096633	A/G	cg22852734	chr6:133119734	C6orf192	1.44	5.87	0.52	6.36e-8	Type 2 diabetes nephropathy;
THYM	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg24450063	chr1:156163899	SLC25A44	1.17	9.81	0.71	4.12e-16	Testicular germ cell tumor;
THYM	cis	rs9467773	0.526	rs12199613	chr6:26367218	C/T	cg14345882	chr6:26364793	BTN3A2	0.35	4.66	0.43	1.01e-5	Intelligence (multi-trait analysis);
THYM	cis	rs829883	0.664	rs829864	chr12:98850195	C/T	cg25150519	chr12:98850993	NA	0.55	5.49	0.49	3.29e-7	Colorectal adenoma (advanced);
THYM	cis	rs892961	0.836	rs35077273	chr17:75412415	T/C	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg20283391	chr11:68216788	NA	0.56	4.48	0.42	2.12e-5	Total body bone mineral density;
THYM	cis	rs17122693	0.748	rs1009292	chr14:51143683	A/T	cg04730355	chr14:51134070	SAV1	0.94	5.85	0.51	7.11e-8	Cognitive performance;
THYM	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg25427524	chr10:38739819	LOC399744	-0.58	-5.11	-0.46	1.67e-6	Extrinsic epigenetic age acceleration;
THYM	cis	rs12246027	0.788	rs10508202	chr10:308491	A/C	cg16346588	chr10:242978	ZMYND11	-0.63	-4.6	-0.43	1.32e-5	Blood metabolite levels;
THYM	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.29	-0.48	7.75e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1061377	1.000	rs9998481	chr4:39118835	G/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs548181	0.668	rs540555	chr11:125486848	T/C	cg03464685	chr11:125439445	EI24	1.24	7.56	0.61	2.49e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.71e-7	Alzheimer's disease (late onset);
THYM	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs7178572	0.568	rs12910480	chr15:77664212	G/C	cg22256960	chr15:77711686	NA	-1.05	-8.4	-0.65	4.29e-13	Type 2 diabetes;
THYM	cis	rs4780401	0.728	rs7188511	chr16:11773743	G/T	cg01061890	chr16:11836724	TXNDC11	-0.61	-4.48	-0.42	2.08e-5	Rheumatoid arthritis;
THYM	cis	rs89107	0.576	rs4307206	chr6:118813320	A/C	cg21191810	chr6:118973309	C6orf204	-0.5	-5.01	-0.46	2.54e-6	Cardiac structure and function;
THYM	cis	rs10992471	0.756	rs2516568	chr9:95187380	A/T	cg14631576	chr9:95140430	CENPP	-0.93	-9.96	-0.71	2.06e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg27129171	chr3:47204927	SETD2	0.77	7.65	0.62	1.67e-11	Colorectal cancer;
THYM	cis	rs35883536	1.000	rs34441740	chr1:101137046	C/G	cg06223162	chr1:101003688	GPR88	0.63	4.79	0.44	6.24e-6	Monocyte count;
THYM	cis	rs5015933	0.801	rs4837016	chr9:128141809	A/G	cg13590414	chr9:128173245	NA	0.47	4.64	0.43	1.12e-5	Body mass index;
THYM	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg00256281	chr22:41985642	PMM1	0.62	4.67	0.43	1e-5	Vitiligo;
THYM	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs3849570	0.695	rs6792696	chr3:81874009	G/A	cg07356753	chr3:81810745	GBE1	-0.84	-6.42	-0.55	5.45e-9	Waist circumference;Body mass index;
THYM	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg17173187	chr15:85201210	NMB	0.53	5.11	0.46	1.65e-6	Schizophrenia;
THYM	cis	rs4148689	0.903	rs10487368	chr7:117140095	C/T	cg17204129	chr7:117119601	CFTR	-0.63	-5.0	-0.46	2.58e-6	Gout;
THYM	cis	rs4481887	0.741	rs6587462	chr1:248539094	C/T	cg17299007	chr1:248814626	OR2T27	-0.42	-4.55	-0.42	1.62e-5	Common traits (Other);
THYM	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg22307297	chr20:60903441	LAMA5	0.54	4.78	0.44	6.51e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs6032067	0.929	rs6017504	chr20:43818920	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg03161606	chr19:29218774	NA	0.84	7.27	0.6	1.01e-10	Methadone dose in opioid dependence;
THYM	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg01304814	chr3:48885189	PRKAR2A	0.96	4.86	0.45	4.55e-6	Cognitive function;
THYM	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-7.5	-0.61	3.41e-11	Platelet count;
THYM	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.7	5.19	0.47	1.21e-6	Tonsillectomy;
THYM	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg20887711	chr4:1340912	KIAA1530	0.99	9.57	0.7	1.37e-15	Longevity;
THYM	cis	rs2625529	0.824	rs4777480	chr15:72328997	A/C	cg16672083	chr15:72433130	SENP8	-0.55	-4.95	-0.45	3.2e-6	Red blood cell count;
THYM	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg11266682	chr4:10021025	SLC2A9	0.74	12.07	0.78	6.92e-21	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9467773	0.566	rs66972160	chr6:26359306	T/C	cg14345882	chr6:26364793	BTN3A2	0.34	4.6	0.43	1.29e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg05738196	chr6:26577821	NA	0.63	5.11	0.46	1.68e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs490234	0.676	rs4838264	chr9:128225561	T/C	cg14078157	chr9:128172775	NA	-0.78	-6.36	-0.55	7.14e-9	Mean arterial pressure;
THYM	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg13319975	chr6:146136371	FBXO30	-0.63	-5.02	-0.46	2.43e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4866334	1.000	rs114489248	chr5:18478969	C/A	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs514406	0.526	rs835608	chr1:53169758	T/A	cg08859206	chr1:53392774	SCP2	0.49	4.84	0.44	4.97e-6	Monocyte count;
THYM	cis	rs9810089	0.814	rs1279424	chr3:136007333	A/G	cg12473912	chr3:136751656	NA	0.61	5.13	0.47	1.5e-6	Gestational age at birth (child effect);
THYM	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg00990874	chr7:1149470	C7orf50	-0.69	-5.17	-0.47	1.29e-6	Bronchopulmonary dysplasia;
THYM	cis	rs6500395	0.926	rs9936446	chr16:48645807	G/C	cg04672837	chr16:48644449	N4BP1	0.48	4.59	0.43	1.35e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22307029	chr19:49891270	CCDC155	-0.57	-4.6	-0.43	1.3e-5	Multiple sclerosis;
THYM	cis	rs17443541	0.507	rs6725254	chr2:200463248	A/C	cg01795955	chr2:200468626	NA	-0.72	-5.0	-0.46	2.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg27170947	chr2:26402098	FAM59B	-0.8	-6.37	-0.55	6.74e-9	Gut microbiome composition (summer);
THYM	cis	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg09307838	chr4:120376055	NA	0.73	5.51	0.49	3.11e-7	Corneal astigmatism;
THYM	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg08439880	chr3:133502540	NA	-0.66	-5.84	-0.51	7.17e-8	Ankle injury;
THYM	cis	rs6960043	0.818	rs2191349	chr7:15064309	G/T	cg19272540	chr7:15055459	NA	-0.45	-4.96	-0.45	3.09e-6	Type 2 diabetes;
THYM	cis	rs1499972	0.941	rs62263120	chr3:117630253	A/G	cg07612923	chr3:117604196	NA	1.19	5.0	0.46	2.66e-6	Schizophrenia;
THYM	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg03676636	chr4:99064102	C4orf37	0.42	6.16	0.53	1.78e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2898681	0.618	rs7677726	chr4:53739262	A/G	cg00791764	chr4:53727839	RASL11B	-0.64	-6.68	-0.57	1.62e-9	Optic nerve measurement (cup area);
THYM	cis	rs34638657	0.732	rs11859473	chr16:82201072	T/C	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.25	-0.47	9.14e-7	Lung adenocarcinoma;
THYM	cis	rs12310956	0.532	rs10844719	chr12:33987714	A/G	cg06521331	chr12:34319734	NA	-0.92	-8.57	-0.66	1.89e-13	Morning vs. evening chronotype;
THYM	cis	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs7617773	0.780	rs13079728	chr3:48339360	A/G	cg02219026	chr3:48282209	ZNF589	-0.64	-4.54	-0.42	1.62e-5	Coronary artery disease;
THYM	cis	rs6754311	0.731	rs12615624	chr2:136721603	A/G	cg20242066	chr2:136595261	LCT	0.54	6.4	0.55	5.97e-9	Mosquito bite size;
THYM	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg06618935	chr21:46677482	NA	-0.96	-9.01	-0.68	2.21e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1322639	0.614	rs4708414	chr6:169574144	C/G	cg04662567	chr6:169592167	NA	-0.56	-5.18	-0.47	1.24e-6	Pulse pressure;
THYM	cis	rs7512552	0.839	rs1694362	chr1:150366963	T/A	cg15654264	chr1:150340011	RPRD2	0.45	5.2	0.47	1.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs11112613	0.609	rs11112585	chr12:105933442	A/G	cg03607813	chr12:105948248	NA	-0.94	-7.36	-0.6	6.64e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs1467979	0.527	rs12601285	chr17:78061274	C/T	cg04028464	chr17:78073854	GAA;CCDC40	0.9	5.41	0.49	4.67e-7	IgG glycosylation;
THYM	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg19507638	chr5:93509721	C5orf36	-0.68	-4.57	-0.42	1.49e-5	Diabetic retinopathy;
THYM	cis	rs6980334	0.871	rs1025967	chr7:137753091	T/C	cg11874123	chr7:137028198	PTN	0.61	4.67	0.43	9.88e-6	Blood metabolite ratios;
THYM	cis	rs7626444	0.625	rs1798636	chr3:196476604	G/A	cg12930392	chr3:196481615	PAK2	0.4	4.97	0.45	2.97e-6	Monocyte count;
THYM	cis	rs9677476	0.688	rs6738687	chr2:232053167	G/A	cg07929768	chr2:232055508	NA	0.54	5.65	0.5	1.69e-7	Food antigen IgG levels;
THYM	cis	rs7216064	1.000	rs6504548	chr17:65886048	T/C	cg12091567	chr17:66097778	LOC651250	-0.73	-5.08	-0.46	1.86e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg00645579	chr11:617140	IRF7;MUPCDH	-0.52	-6.46	-0.55	4.44e-9	Systemic lupus erythematosus;
THYM	cis	rs7312774	0.881	rs7297923	chr12:107305573	T/C	cg16260113	chr12:107380972	MTERFD3	0.97	5.54	0.49	2.71e-7	Severe influenza A (H1N1) infection;
THYM	cis	rs67981189	0.529	rs17093738	chr14:71586648	C/T	cg15910301	chr14:71632612	NA	0.56	4.88	0.45	4.23e-6	Schizophrenia;
THYM	cis	rs259964	0.874	rs259958	chr20:57828583	C/A	cg20910807	chr20:57875384	EDN3	-0.41	-4.5	-0.42	1.93e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs2933343	0.729	rs1680794	chr3:128620390	A/G	cg11901034	chr3:128598214	ACAD9	-0.68	-5.57	-0.5	2.4e-7	IgG glycosylation;
THYM	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg04772025	chr11:68637568	NA	0.61	6.29	0.54	9.45e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6876348	0.598	rs2526252	chr5:128310259	C/G	cg02841155	chr5:128301328	SLC27A6	-0.52	-5.37	-0.48	5.52e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg25358565	chr5:93447407	FAM172A	0.96	7.16	0.59	1.67e-10	Diabetic retinopathy;
THYM	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs16912285	0.748	rs7952223	chr11:24256443	G/C	ch.11.24196551F	chr11:24239977	NA	0.93	5.4	0.48	4.88e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg16989719	chr2:238392110	NA	0.61	5.4	0.48	5e-7	Prostate cancer;
THYM	cis	rs6011002	1.000	rs79391682	chr20:62297768	A/G	cg08432509	chr20:62317768	RTEL1	0.69	4.49	0.42	2.01e-5	Dental caries;
THYM	cis	rs11085466	0.948	rs76881507	chr19:21762189	A/T	cg23004160	chr19:21646329	NA	-0.65	-4.7	-0.43	8.62e-6	Colorectal or endometrial cancer;
THYM	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs1448094	0.511	rs59668915	chr12:86197170	C/T	cg00310523	chr12:86230176	RASSF9	0.53	4.82	0.44	5.4e-6	Major depressive disorder;
THYM	cis	rs138918	1.000	rs3937387	chr22:43555194	C/G	cg02233750	chr22:43539658	MCAT	-0.5	-4.49	-0.42	2.03e-5	Monocyte count;
THYM	cis	rs6754311	0.678	rs309181	chr2:136614813	C/G	cg07169764	chr2:136633963	MCM6	-0.71	-6.05	-0.53	2.81e-8	Mosquito bite size;
THYM	cis	rs11089937	0.616	rs5757258	chr22:22534038	C/T	cg06866756	chr22:22471216	NA	-0.41	-4.52	-0.42	1.76e-5	Periodontitis (PAL4Q3);
THYM	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg13010199	chr12:38710504	ALG10B	-0.58	-4.53	-0.42	1.72e-5	Morning vs. evening chronotype;
THYM	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg22655196	chr4:3374909	RGS12	0.65	8.19	0.64	1.17e-12	Serum sulfate level;
THYM	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg02018176	chr4:1364513	KIAA1530	0.53	4.56	0.42	1.55e-5	Obesity-related traits;
THYM	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg01483505	chr11:975446	AP2A2	0.58	4.75	0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs7818345	0.967	rs11204040	chr8:19288525	T/A	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.65	0.43	1.09e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs7677751	0.806	rs61320297	chr4:55088175	G/A	cg17187183	chr4:55093834	PDGFRA	0.71	5.49	0.49	3.35e-7	Corneal astigmatism;
THYM	cis	rs7211079	0.879	rs66693363	chr17:78128935	G/A	cg09238746	chr17:78121135	EIF4A3	-0.74	-4.51	-0.42	1.83e-5	Myocardial infarction;
THYM	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg10193763	chr2:225306901	NA	-0.52	-5.56	-0.5	2.42e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9992101	0.870	rs13146355	chr4:77412140	G/A	cg20311846	chr4:77356250	SHROOM3	-0.61	-6.2	-0.54	1.48e-8	Creatinine levels;
THYM	cis	rs10411161	0.657	rs67462252	chr19:52382851	T/C	cg25361850	chr19:52391789	ZNF577	0.72	4.96	0.45	3.09e-6	Breast cancer;
THYM	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs6500395	1.000	rs12599744	chr16:48716729	G/A	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs1971762	0.563	rs3897117	chr12:54077407	T/G	cg16917193	chr12:54089295	NA	0.9	9.19	0.69	8.89e-15	Height;
THYM	cis	rs9916302	0.821	rs4795386	chr17:37746847	A/G	cg00129232	chr17:37814104	STARD3	-0.8	-5.39	-0.48	5.09e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg26721908	chr21:47610096	LSS	0.75	5.43	0.49	4.35e-7	Testicular germ cell tumor;
THYM	cis	rs2071518	1.000	rs6997943	chr8:120463608	G/T	cg15718811	chr8:120427810	NOV	-0.51	-4.79	-0.44	6.16e-6	Pulse pressure;Blood pressure;
THYM	cis	rs669446	0.533	rs11210913	chr1:44222597	G/A	cg15962314	chr1:44399869	ARTN	0.46	5.06	0.46	2.03e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg15962314	chr1:44399869	ARTN	0.53	5.14	0.47	1.44e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11886999	0.812	rs57476471	chr2:96902320	A/C	cg18419276	chr2:96971862	SNRNP200	-0.51	-4.88	-0.45	4.21e-6	Cardiac Troponin-T levels;
THYM	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05901451	chr6:126070800	HEY2	-0.97	-9.76	-0.71	5.32e-16	Brugada syndrome;
THYM	cis	rs7772486	0.811	rs2777475	chr6:146304603	G/A	cg23711669	chr6:146136114	FBXO30	0.74	6.87	0.58	6.51e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11771526	0.892	rs1376282	chr7:32370492	A/G	cg27511599	chr7:32358540	NA	0.75	5.02	0.46	2.42e-6	Body mass index;
THYM	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg13114125	chr14:105738426	BRF1	-0.77	-6.12	-0.53	2.12e-8	Mean platelet volume;Platelet distribution width;
THYM	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21582582	chr3:182698605	DCUN1D1	0.81	7.07	0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg06028808	chr11:68637592	NA	0.68	7.24	0.6	1.18e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	5.35	0.48	6.02e-7	Total body bone mineral density;
THYM	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs7793919	0.726	rs10261971	chr7:4776547	A/G	cg09789173	chr7:4769017	FOXK1	0.82	8.19	0.64	1.19e-12	Mosquito bite size;
THYM	cis	rs6840360	0.571	rs11723395	chr4:152524191	G/A	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	cis	rs6840360	0.571	rs17360385	chr4:152587970	C/A	cg17479576	chr4:152424074	FAM160A1	-0.74	-4.82	-0.44	5.36e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4786125	0.801	rs8057091	chr16:6902148	A/G	cg03623568	chr16:6915990	A2BP1	-0.93	-7.61	-0.62	1.99e-11	Heart rate variability traits (SDNN);
THYM	cis	rs7020830	0.898	rs506981	chr9:37351348	A/T	cg14294708	chr9:37120828	ZCCHC7	-1.11	-12.37	-0.79	1.68e-21	Schizophrenia;
THYM	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg18032289	chr17:61959525	GH2	-0.5	-4.76	-0.44	6.95e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg08999081	chr20:33150536	PIGU	-0.57	-4.95	-0.45	3.25e-6	Height;
THYM	cis	rs34638657	0.872	rs6420437	chr16:82187181	T/C	cg07307142	chr16:82071433	HSD17B2	-1.0	-7.8	-0.63	7.75e-12	Lung adenocarcinoma;
THYM	cis	rs12476592	0.571	rs10865341	chr2:63824050	A/T	cg17519650	chr2:63277830	OTX1	-0.7	-4.71	-0.44	8.46e-6	Childhood ear infection;
THYM	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg25554036	chr4:6271136	WFS1	-0.57	-5.18	-0.47	1.23e-6	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs6163	0.588	rs67506723	chr10:104509064	G/T	cg05855489	chr10:104503620	C10orf26	0.86	8.38	0.65	4.67e-13	Waist circumference;Hip circumference;
THYM	cis	rs9959145	1.000	rs79998152	chr18:12567412	T/C	cg14160804	chr18:12703040	PSMG2;CEP76	-0.91	-4.55	-0.42	1.61e-5	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg12000587	chr17:30186630	C17orf79	0.39	4.48	0.42	2.1e-5	Hip circumference adjusted for BMI;
THYM	cis	rs7523273	0.526	rs2724375	chr1:207997973	C/A	cg22525895	chr1:207977042	MIR29B2	-0.91	-9.34	-0.69	4.19e-15	Schizophrenia;
THYM	cis	rs2430307	0.518	rs67763033	chr7:76517677	A/G	cg15770687	chr7:76625569	PMS2L11	0.83	5.35	0.48	5.96e-7	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs17401966	1.000	rs11121552	chr1:10435324	C/A	cg20482658	chr1:10539492	PEX14	0.39	4.66	0.43	1.05e-5	Hepatocellular carcinoma;
THYM	cis	rs4466137	0.951	rs336958	chr5:82973396	A/G	cg16102102	chr5:83017553	HAPLN1	-0.97	-8.04	-0.64	2.53e-12	Prostate cancer;
THYM	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg06028808	chr11:68637592	NA	0.7	7.59	0.61	2.22e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs72627123	0.867	rs58102735	chr14:74467531	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg06636001	chr8:8085503	FLJ10661	0.62	5.37	0.48	5.66e-7	Mood instability;
THYM	cis	rs7567389	0.785	rs4150474	chr2:128033327	C/A	cg09760422	chr2:128146352	NA	-0.4	-4.53	-0.42	1.69e-5	Self-rated health;
THYM	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-7.12	-0.59	2.08e-10	Bone mineral density;
THYM	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg13010199	chr12:38710504	ALG10B	0.76	6.07	0.53	2.59e-8	Heart rate;
THYM	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-4.99	-0.46	2.75e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4851266	0.833	rs11685491	chr2:100858122	A/G	cg08017756	chr2:100939284	LONRF2	-0.56	-4.45	-0.42	2.31e-5	Educational attainment;
THYM	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg01324343	chr3:183735012	ABCC5	0.88	13.13	0.8	4.58e-23	Anterior chamber depth;
THYM	cis	rs9902453	0.808	rs78154346	chr17:28169493	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.73	0.44	7.7e-6	Coffee consumption (cups per day);
THYM	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg07061783	chr6:25882402	NA	-0.59	-4.56	-0.42	1.51e-5	Blood metabolite levels;
THYM	cis	rs11031096	0.711	rs10767882	chr11:4205841	G/A	cg18678763	chr11:4115507	RRM1	-0.4	-4.71	-0.44	8.28e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs314370	0.818	rs12705091	chr7:100472380	C/T	cg10426581	chr7:100472382	SRRT	1.02	9.77	0.71	5.18e-16	Resting heart rate;
THYM	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.65	-11.83	-0.77	2.19e-20	Hemostatic factors and hematological phenotypes;
THYM	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg18252515	chr7:66147081	NA	-0.67	-4.92	-0.45	3.65e-6	Aortic root size;
THYM	cis	rs4363385	0.747	rs9919333	chr1:152968744	G/T	cg13444842	chr1:152974279	SPRR3	-0.6	-4.79	-0.44	6.16e-6	Inflammatory skin disease;
THYM	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-5.64	-0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.29	-4.65	-0.43	1.08e-5	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg10803722	chr21:46713166	LOC642852	-0.42	-5.58	-0.5	2.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9810089	0.934	rs570621	chr3:136000743	A/G	cg12473912	chr3:136751656	NA	0.61	5.13	0.47	1.5e-6	Gestational age at birth (child effect);
THYM	cis	rs1457451	1.000	rs6726535	chr2:65864710	G/C	cg16240816	chr2:65861662	NA	0.68	7.07	0.59	2.63e-10	Iron status biomarkers;
THYM	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg00376283	chr12:123451042	ABCB9	0.74	5.16	0.47	1.35e-6	Neutrophil percentage of white cells;
THYM	cis	rs72772090	0.539	rs56319744	chr5:96141938	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.84	-5.01	-0.46	2.48e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg24250549	chr1:154909240	PMVK	0.75	6.45	0.55	4.66e-9	Prostate cancer;
THYM	cis	rs994014	0.804	rs11723613	chr4:82227548	G/A	cg17825130	chr4:82283507	NA	0.5	4.45	0.42	2.3e-5	Height;
THYM	cis	rs72772090	0.520	rs56325109	chr5:96112295	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-4.67	-0.43	9.81e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6598955	0.585	rs6659822	chr1:26626408	C/A	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.73	0.44	7.82e-6	Obesity-related traits;
THYM	cis	rs4950928	0.823	rs4950882	chr1:203164848	A/G	cg17014757	chr1:203156097	CHI3L1	-1.11	-6.68	-0.57	1.6e-9	YKL-40 levels;
THYM	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg24253500	chr15:84953950	NA	0.59	4.87	0.45	4.48e-6	Schizophrenia;
THYM	cis	rs4889855	0.530	rs7220588	chr17:78598231	G/A	cg16591659	chr17:78472290	NA	-0.4	-5.08	-0.46	1.9e-6	Fractional excretion of uric acid;
THYM	cis	rs12291225	0.637	rs8570	chr11:14300759	C/G	cg05501817	chr11:14380813	RRAS2	-0.75	-5.72	-0.51	1.24e-7	Sense of smell;
THYM	cis	rs13082711	0.911	rs17019809	chr3:27509080	A/G	cg02860705	chr3:27208620	NA	0.72	5.15	0.47	1.39e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg02269571	chr22:50332266	NA	-0.7	-4.91	-0.45	3.84e-6	Schizophrenia;
THYM	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.41	0.55	5.47e-9	Total body bone mineral density;
THYM	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg12560992	chr17:57184187	TRIM37	-0.92	-8.68	-0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg08999081	chr20:33150536	PIGU	0.65	5.39	0.48	5.14e-7	Coronary artery disease;
THYM	cis	rs7823896	0.929	rs73311385	chr8:110145725	A/G	cg18044723	chr8:109261011	EIF3E	-0.85	-4.49	-0.42	2.01e-5	Myopia (pathological);
THYM	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22496380	chr5:211416	CCDC127	-1.25	-7.51	-0.61	3.27e-11	Breast cancer;
THYM	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg00786635	chr1:25594202	NA	0.81	6.41	0.55	5.5e-9	Erythrocyte sedimentation rate;
THYM	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg17264618	chr3:40429014	ENTPD3	0.52	4.95	0.45	3.22e-6	Renal cell carcinoma;
THYM	cis	rs9653442	0.835	rs11885529	chr2:100746935	A/G	cg22139774	chr2:100720529	AFF3	-0.4	-6.4	-0.55	5.98e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg13010199	chr12:38710504	ALG10B	-0.59	-5.14	-0.47	1.46e-6	Heart rate;
THYM	cis	rs611744	0.967	rs666821	chr8:109204313	T/A	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg02153584	chr22:29168773	CCDC117	0.61	4.76	0.44	6.94e-6	Lymphocyte counts;
THYM	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg01483505	chr11:975446	AP2A2	0.58	4.75	0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg13319975	chr6:146136371	FBXO30	0.68	5.85	0.51	6.88e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2806561	1.000	rs1757048	chr1:23510601	A/C	cg08872493	chr1:23521417	HTR1D	0.38	4.86	0.45	4.59e-6	Height;
THYM	cis	rs11249608	0.600	rs13359570	chr5:178449249	T/G	cg01312482	chr5:178451176	ZNF879	-0.68	-5.27	-0.48	8.43e-7	Pubertal anthropometrics;
THYM	cis	rs7084402	0.967	rs1658493	chr10:60281090	C/T	cg09696939	chr10:60272079	BICC1	0.45	5.4	0.48	4.92e-7	Refractive error;
THYM	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg02038168	chr22:39784481	NA	0.66	5.11	0.46	1.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06481639	chr22:41940642	POLR3H	0.8	5.63	0.5	1.81e-7	Vitiligo;
THYM	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg04944784	chr2:26401820	FAM59B	-1.06	-7.83	-0.63	6.7e-12	Gut microbiome composition (summer);
THYM	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg00786635	chr1:25594202	NA	0.99	8.28	0.65	7.8e-13	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg25566285	chr7:158114605	PTPRN2	-0.71	-6.67	-0.56	1.72e-9	Calcium levels;
THYM	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg13246856	chr1:44399776	ARTN	0.46	4.94	0.45	3.4e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9326248	0.510	rs4938332	chr11:116930798	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.66	5.27	0.48	8.49e-7	Blood protein levels;
THYM	cis	rs210138	1.000	rs210144	chr6:33547430	G/A	cg07679836	chr6:33548423	BAK1	0.47	5.3	0.48	7.36e-7	Testicular germ cell tumor;
THYM	cis	rs13126513	0.708	rs1061271	chr4:100545051	C/G	cg05468953	chr4:100565104	NA	0.65	6.03	0.53	3.14e-8	Metabolite levels (MHPG);
THYM	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg00277334	chr10:82204260	NA	-0.84	-9.59	-0.7	1.25e-15	Post bronchodilator FEV1;
THYM	cis	rs6539288	0.933	rs4964497	chr12:107304489	T/G	cg26297688	chr12:107349093	C12orf23	-0.47	-4.89	-0.45	4.15e-6	Total body bone mineral density;
THYM	cis	rs2250402	0.510	rs75578790	chr15:40332440	A/G	cg14157570	chr15:41231049	DLL4	0.94	4.68	0.43	9.46e-6	Corneal curvature;
THYM	cis	rs9790314	0.967	rs6762645	chr3:160948349	T/G	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs6754311	0.551	rs313526	chr2:136445526	C/T	cg04750100	chr2:136595281	LCT	0.56	5.89	0.52	5.87e-8	Mosquito bite size;
THYM	cis	rs11771526	0.579	rs117934886	chr7:32380547	G/T	cg27532318	chr7:32358331	NA	0.91	4.65	0.43	1.06e-5	Body mass index;
THYM	cis	rs7172809	0.863	rs74026932	chr15:77825729	T/C	cg10437265	chr15:77819839	NA	-0.53	-4.57	-0.42	1.48e-5	Glucose homeostasis traits;
THYM	cis	rs4690686	0.538	rs4690428	chr4:177263665	C/T	cg17059388	chr4:177262070	NA	0.48	6.73	0.57	1.29e-9	Essential tremor;
THYM	cis	rs921968	0.541	rs733925	chr2:219302466	G/A	cg02176678	chr2:219576539	TTLL4	-0.75	-7.66	-0.62	1.55e-11	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg14391382	chr7:866102	UNC84A	0.6	4.85	0.45	4.9100000000000004e-06	Subjective well-being;
THYM	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg24308560	chr3:49941425	MST1R	0.64	5.53	0.49	2.79e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9527	0.615	rs17725614	chr10:104685493	G/C	cg15744005	chr10:104629667	AS3MT	-0.6	-4.58	-0.42	1.43e-5	Arsenic metabolism;
THYM	cis	rs763014	0.898	rs4984896	chr16:625493	C/T	cg09263875	chr16:632152	PIGQ	0.71	6.15	0.53	1.85e-8	Height;
THYM	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6960043	0.743	rs1002061	chr7:15039499	A/T	cg19272540	chr7:15055459	NA	-0.45	-5.01	-0.46	2.51e-6	Type 2 diabetes;
THYM	cis	rs877282	0.945	rs11599043	chr10:777972	C/T	cg10556349	chr10:835070	NA	-0.75	-5.24	-0.47	9.64e-7	Uric acid levels;
THYM	cis	rs6840360	0.571	rs72728182	chr4:152487027	T/C	cg17479576	chr4:152424074	FAM160A1	-0.82	-5.82	-0.51	7.78e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs420259	0.516	rs2369013	chr16:23496346	T/C	cg00143387	chr16:23521605	GGA2	-0.72	-5.14	-0.47	1.45e-6	Bipolar disorder;
THYM	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg13918804	chr1:2043761	PRKCZ	0.88	8.76	0.67	7.5e-14	Height;
THYM	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg00071950	chr4:10020882	SLC2A9	0.88	9.22	0.69	7.56e-15	Bone mineral density;
THYM	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg01324343	chr3:183735012	ABCC5	0.88	13.13	0.8	4.58e-23	Anterior chamber depth;
THYM	cis	rs7104764	0.701	rs3782115	chr11:223272	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	0.87	7.34	0.6	7.34e-11	Menarche (age at onset);
THYM	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs10899021	0.790	rs10899019	chr11:74335162	A/G	cg25880958	chr11:74394337	NA	-0.72	-4.72	-0.44	7.99e-6	Response to metformin (IC50);
THYM	cis	rs4242434	0.787	rs1545837	chr8:22477807	T/C	cg11461670	chr8:22454935	PDLIM2	-0.41	-6.68	-0.57	1.58e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	10.62	0.74	7.85e-18	Chronic sinus infection;
THYM	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg23815491	chr16:72088622	HP	0.86	7.6	0.62	2.05e-11	Fibrinogen levels;
THYM	cis	rs10411161	0.702	rs8113584	chr19:52383874	A/G	cg25361850	chr19:52391789	ZNF577	0.71	4.99	0.46	2.69e-6	Breast cancer;
THYM	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg17644776	chr2:200775616	C2orf69	-0.78	-5.68	-0.5	1.48e-7	Osteoporosis;
THYM	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.15e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2057149	0.738	rs9384739	chr6:110698722	A/G	cg19196401	chr6:110721138	DDO	-0.54	-4.48	-0.42	2.05e-5	Platelet distribution width;Mean platelet volume;
THYM	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg13877915	chr19:58951672	ZNF132	0.9	8.81	0.67	5.8e-14	Uric acid clearance;
THYM	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8050907	0.744	rs12446765	chr16:4569625	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.24	4.89	0.45	4.14e-6	Obesity-related traits;
THYM	cis	rs885814	0.878	rs3767155	chr1:21885195	C/T	cg14781605	chr1:21864896	ALPL	-0.67	-5.15	-0.47	1.42e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg23708337	chr7:1209742	NA	0.75	5.29	0.48	7.69e-7	Longevity;Endometriosis;
THYM	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	7.14	0.59	1.88e-10	Platelet count;
THYM	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.3	6.5	0.55	3.75e-9	Obesity-related traits;
THYM	cis	rs4731207	0.698	rs962863	chr7:124558339	C/T	cg05285228	chr7:124571219	POT1	0.69	5.48	0.49	3.54e-7	Cutaneous malignant melanoma;
THYM	cis	rs2073300	0.609	rs6137919	chr20:23363163	T/C	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg06481639	chr22:41940642	POLR3H	-0.76	-5.4	-0.48	4.97e-7	Vitiligo;
THYM	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg13147721	chr7:65941812	NA	-1.11	-7.16	-0.59	1.67e-10	Diabetic kidney disease;
THYM	cis	rs11227306	0.934	rs2303384	chr11:65640204	C/T	cg00576331	chr11:65640516	EFEMP2	0.71	5.48	0.49	3.49e-7	DNA methylation (variation);
THYM	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg00278517	chr6:167070616	RPS6KA2	0.34	4.64	0.43	1.13e-5	Crohn's disease;
THYM	cis	rs4888262	0.545	rs36097721	chr16:74648267	C/G	cg01733217	chr16:74700730	RFWD3	0.82	8.54	0.66	2.2e-13	Testicular germ cell tumor;
THYM	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg24692254	chr21:30365293	RNF160	0.99	9.36	0.69	3.83e-15	Dental caries;
THYM	trans	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg10856724	chr12:34555212	NA	-1.01	-9.23	-0.69	7.34e-15	Bladder cancer;
THYM	cis	rs8064299	0.967	rs3744208	chr17:72767565	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.62	5.34	0.48	6.29e-7	Monocyte count;
THYM	cis	rs4631830	0.540	rs2926493	chr10:51492131	G/A	cg10326726	chr10:51549505	MSMB	-0.57	-5.65	-0.5	1.66e-7	Prostate-specific antigen levels;
THYM	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg27284194	chr4:1044797	NA	0.62	4.73	0.44	7.81e-6	Recombination rate (females);
THYM	cis	rs6032067	0.929	rs35880287	chr20:43821001	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.64	-0.5	1.76e-7	Blood protein levels;
THYM	cis	rs9359856	0.564	rs56396054	chr6:90360406	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.91	-8.11	-0.64	1.79e-12	Bipolar disorder;
THYM	cis	rs9560113	0.959	rs9555802	chr13:112179504	T/C	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs4845875	0.529	rs6680385	chr1:11831756	A/G	cg24844545	chr1:11908347	NPPA	0.56	4.7	0.43	8.63e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.38	0.55	6.27e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg22634378	chr19:37742834	NA	-0.65	-5.41	-0.49	4.73e-7	Coronary artery calcification;
THYM	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg05362011	chr13:21860987	NA	-0.56	-4.55	-0.42	1.6e-5	White matter hyperintensity burden;
THYM	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg17366294	chr4:99064904	C4orf37	0.57	6.86	0.58	7.12e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs308403	0.600	rs309367	chr4:123662211	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.69	4.71	0.44	8.35e-6	Blood protein levels;
THYM	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg17063962	chr7:91808500	NA	-1.12	-12.68	-0.79	3.85e-22	Breast cancer;
THYM	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg10047753	chr17:41438598	NA	1.2	11.15	0.75	5.87e-19	Menopause (age at onset);
THYM	cis	rs11096990	0.634	rs3733281	chr4:39271913	T/C	cg24403649	chr4:39172243	NA	-0.67	-5.84	-0.51	7.33e-8	Cognitive function;
THYM	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg15448220	chr1:150897856	SETDB1	0.85	7.1	0.59	2.25e-10	Tonsillectomy;
THYM	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg00864171	chr11:67383662	NA	0.7	5.61	0.5	1.95e-7	Mean corpuscular volume;
THYM	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.92	5.02	0.46	2.41e-6	Initial pursuit acceleration;
THYM	cis	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg10856724	chr12:34555212	NA	-0.87	-7.73	-0.62	1.1e-11	Morning vs. evening chronotype;
THYM	cis	rs1050631	0.592	rs1785903	chr18:33711642	G/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.28	0.48	8.32e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs4690686	0.500	rs12498564	chr4:177264827	T/C	cg17059388	chr4:177262070	NA	0.48	6.73	0.57	1.29e-9	Essential tremor;
THYM	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg15556689	chr8:8085844	FLJ10661	0.69	5.91	0.52	5.33e-8	Mood instability;
THYM	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.86	7.4	0.6	5.39e-11	Monocyte percentage of white cells;
THYM	cis	rs10788264	0.621	rs9633734	chr10:124057667	T/C	cg09507567	chr10:124027408	NA	0.48	4.71	0.44	8.35e-6	Total body bone mineral density;
THYM	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg24531977	chr5:56204891	C5orf35	-1.04	-8.69	-0.67	1.05e-13	Initial pursuit acceleration;
THYM	cis	rs6988636	1.000	rs11988157	chr8:124194740	A/G	cg23067535	chr8:124195133	FAM83A	1.07	5.8	0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs7177699	0.526	rs7165042	chr15:79123338	C/G	cg00540400	chr15:79124168	NA	0.65	7.03	0.58	3.16e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6032067	0.704	rs62208374	chr20:43765628	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.47	-5.31	-0.48	7.26e-7	Blood protein levels;
THYM	cis	rs116095464	0.558	rs6962	chr5:256509	G/A	cg22496380	chr5:211416	CCDC127	-1.29	-7.7	-0.62	1.27e-11	Breast cancer;
THYM	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg11395062	chr17:14139857	CDRT15	0.64	5.61	0.5	1.99e-7	Temperament;
THYM	cis	rs1609391	0.567	rs835633	chr3:136676496	T/C	cg12473912	chr3:136751656	NA	0.63	5.12	0.47	1.57e-6	Neuroticism;
THYM	cis	rs11696501	0.688	rs6073850	chr20:44301084	C/T	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.57	-0.42	1.46e-5	Brain structure;
THYM	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg27068330	chr11:65405492	SIPA1	-0.67	-4.49	-0.42	2e-5	Breast cancer;
THYM	cis	rs11096990	0.855	rs2566180	chr4:39159001	A/G	cg24403649	chr4:39172243	NA	-0.6	-5.09	-0.46	1.77e-6	Cognitive function;
THYM	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg12863693	chr15:85201151	NMB	-0.57	-4.93	-0.45	3.54e-6	Schizophrenia;
THYM	cis	rs12310956	0.515	rs115836245	chr12:33951369	T/C	cg06521331	chr12:34319734	NA	-0.88	-8.26	-0.65	8.51e-13	Morning vs. evening chronotype;
THYM	cis	rs10489202	0.632	rs202273	chr1:167919963	A/G	cg24449463	chr1:168025552	DCAF6	-0.81	-8.35	-0.65	5.45e-13	Schizophrenia;
THYM	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.35	0.55	7.35e-9	Tonsillectomy;
THYM	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs6956675	0.915	rs7786464	chr7:62615322	C/A	cg27518014	chr7:62859535	LOC100287834	0.64	4.88	0.45	4.31e-6	Obesity-related traits;
THYM	cis	rs16912285	0.688	rs12277966	chr11:24286633	G/A	ch.11.24196551F	chr11:24239977	NA	1.02	7.28	0.6	9.62e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4285028	0.747	rs4048699	chr3:121404483	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.84	7.2	0.59	1.37e-10	Multiple sclerosis;
THYM	cis	rs17345786	0.520	rs13062677	chr3:101305078	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.56	-4.71	-0.43	8.52e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	7.91	0.63	4.73e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg23743428	chr13:21893420	NA	-0.68	-5.89	-0.52	5.75e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs11997175	0.646	rs4733177	chr8:33691754	A/G	ch.8.33884649F	chr8:33765107	NA	0.66	4.99	0.46	2.67e-6	Body mass index;
THYM	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg23815491	chr16:72088622	HP	-0.86	-7.1	-0.59	2.25e-10	Fibrinogen levels;
THYM	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg19774624	chr17:42201019	HDAC5	0.8	7.52	0.61	3.05e-11	Total body bone mineral density;
THYM	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg05373962	chr22:49881684	NA	-0.66	-6.73	-0.57	1.29e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs28595532	0.920	rs55806110	chr4:119742583	A/G	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs7589342	0.929	rs7590652	chr2:106440306	A/G	cg14210321	chr2:106509881	NCK2	-0.72	-5.15	-0.47	1.4e-6	Addiction;
THYM	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg05368731	chr17:41323189	NBR1	1.21	10.31	0.73	3.52e-17	Menopause (age at onset);
THYM	cis	rs1401999	0.898	rs6443928	chr3:183729487	C/T	cg01324343	chr3:183735012	ABCC5	0.82	11.8	0.77	2.53e-20	Anterior chamber depth;
THYM	cis	rs9359856	0.564	rs17228548	chr6:90439164	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs13102973	0.829	rs55951114	chr4:135897925	T/C	cg14419869	chr4:135874104	NA	0.79	6.71	0.57	1.41e-9	Subjective well-being;
THYM	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg18252515	chr7:66147081	NA	-0.62	-4.55	-0.42	1.59e-5	Aortic root size;
THYM	cis	rs7819412	0.545	rs11985603	chr8:10918393	G/A	cg16664915	chr8:10907788	XKR6	-0.59	-4.87	-0.45	4.41e-6	Triglycerides;
THYM	cis	rs73086581	1.000	rs73086588	chr20:3982224	A/T	cg02187196	chr20:3869020	PANK2	0.5	5.52	0.49	2.94e-7	Response to antidepressants in depression;
THYM	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg15445000	chr17:37608096	MED1	-0.41	-5.04	-0.46	2.26e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg12310025	chr6:25882481	NA	0.86	7.34	0.6	7.17e-11	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg13609457	chr4:120235615	NA	0.54	5.0	0.46	2.63e-6	Corneal astigmatism;
THYM	cis	rs28595532	0.920	rs114659035	chr4:119740028	C/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg11366901	chr6:160182831	ACAT2	0.98	8.67	0.66	1.13e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg22166914	chr1:53195759	ZYG11B	-0.95	-12.16	-0.78	4.4e-21	Monocyte count;
THYM	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg13319975	chr6:146136371	FBXO30	-0.64	-5.35	-0.48	6.1e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg20119798	chr7:94954144	PON1	-0.55	-4.93	-0.45	3.47e-6	Paraoxonase activity;
THYM	cis	rs6430585	0.536	rs60397494	chr2:136470219	C/T	cg07169764	chr2:136633963	MCM6	1.16	11.18	0.75	5.24e-19	Corneal structure;
THYM	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg14018140	chr10:458528	DIP2C	-0.61	-7.19	-0.59	1.49e-10	Psychosis in Alzheimer's disease;
THYM	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg24375607	chr4:120327624	NA	0.62	5.0	0.46	2.63e-6	Corneal astigmatism;
THYM	cis	rs954108	0.584	rs9314922	chr13:29379229	A/G	cg11788234	chr13:29393811	NA	0.62	4.77	0.44	6.69e-6	Obesity-related traits;
THYM	cis	rs9522267	1.000	rs9522266	chr13:112195456	C/T	cg10483660	chr13:112241077	NA	-0.49	-4.96	-0.45	3.04e-6	Hepatitis;
THYM	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg02782426	chr3:40428986	ENTPD3	0.52	4.63	0.43	1.15e-5	Renal cell carcinoma;
THYM	cis	rs10924970	0.935	rs4659674	chr1:235392354	T/A	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs79349575	0.783	rs12453394	chr17:46994970	G/A	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs977987	0.705	rs4888377	chr16:75325686	C/G	cg24429836	chr16:75150744	LDHD	0.51	4.95	0.45	3.16e-6	Dupuytren's disease;
THYM	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.95	8.52	0.66	2.34e-13	Colorectal cancer;
THYM	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.26	0.47	8.97e-7	Lung cancer in ever smokers;
THYM	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg13319975	chr6:146136371	FBXO30	-0.65	-5.27	-0.48	8.43e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6987853	0.931	rs2923399	chr8:42439509	G/A	cg09913449	chr8:42400586	C8orf40	0.87	8.1	0.64	1.82e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs921968	0.541	rs7603816	chr2:219396255	C/T	cg02176678	chr2:219576539	TTLL4	-0.73	-7.24	-0.6	1.18e-10	Mean corpuscular hemoglobin concentration;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg04089644	chr2:54809763	SPTBN1	-0.93	-6.99	-0.58	3.85e-10	Depressive symptoms;
THYM	cis	rs28785552	0.589	rs7257371	chr19:53243910	A/G	cg10871876	chr19:53194124	ZNF83	0.71	5.98	0.52	3.91e-8	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-5.63	-0.5	1.84e-7	Chronic sinus infection;
THYM	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg06600287	chr1:53387719	ECHDC2	-0.34	-5.4	-0.48	4.89e-7	Monocyte count;
THYM	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.73	-5.04	-0.46	2.22e-6	Huntington's disease progression;
THYM	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg22920501	chr2:26401640	FAM59B	-1.05	-8.59	-0.66	1.72e-13	Gut microbiome composition (summer);
THYM	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg19774624	chr17:42201019	HDAC5	-0.85	-8.23	-0.65	9.73e-13	Total body bone mineral density;
THYM	cis	rs7100689	0.646	rs1340374	chr10:82129114	C/T	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg13246856	chr1:44399776	ARTN	0.54	5.44	0.49	4.2e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg03909863	chr11:638404	DRD4	-0.76	-6.04	-0.53	2.95e-8	Systemic lupus erythematosus;
THYM	cis	rs12817549	0.934	rs10745660	chr12:94152476	T/C	cg19571390	chr12:94157676	CRADD	0.57	4.67	0.43	9.8200000000000008e-06	Hip circumference adjusted for BMI;
THYM	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg01579765	chr21:45077557	HSF2BP	0.44	6.67	0.56	1.7e-9	Mean corpuscular volume;
THYM	cis	rs6988636	1.000	rs13260798	chr8:124190192	G/A	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs2133450	0.780	rs13082785	chr3:7358711	G/A	cg19930620	chr3:7340148	GRM7	-0.49	-4.66	-0.43	1.02e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg12463550	chr7:65579703	CRCP	-0.57	-4.76	-0.44	7.01e-6	Aortic root size;
THYM	cis	rs9326248	0.581	rs10892061	chr11:116886114	C/T	cg20608306	chr11:116969690	SIK3	0.64	7.98	0.63	3.34e-12	Blood protein levels;
THYM	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs757110	0.526	rs757081	chr11:17351683	C/G	cg15432903	chr11:17409602	KCNJ11	-0.51	-5.19	-0.47	1.19e-6	Type 2 diabetes;
THYM	cis	rs4383453	0.539	rs4678020	chr3:123102353	C/T	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs11690935	0.959	rs6745143	chr2:172650382	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.82	-6.02	-0.53	3.29e-8	Schizophrenia;
THYM	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg22875332	chr1:76189707	ACADM	0.87	10.83	0.74	2.76e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7246657	0.943	rs4803229	chr19:37864682	T/G	cg22634378	chr19:37742834	NA	0.63	5.15	0.47	1.38e-6	Coronary artery calcification;
THYM	cis	rs7975161	0.630	rs4246264	chr12:104637743	C/G	cg25273343	chr12:104657179	TXNRD1	-0.77	-4.57	-0.42	1.48e-5	Toenail selenium levels;
THYM	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg24838063	chr12:130822603	PIWIL1	-0.91	-7.18	-0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg11526020	chr17:80870163	TBCD	0.44	4.74	0.44	7.58e-6	Breast cancer;
THYM	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg05043794	chr9:111880884	C9orf5	-0.36	-5.04	-0.46	2.2e-6	Menarche (age at onset);
THYM	cis	rs68170813	0.559	rs4730239	chr7:107056960	A/T	cg00661777	chr7:106511741	PIK3CG	-0.67	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg12386194	chr3:101231763	SENP7	0.69	5.15	0.47	1.41e-6	Colorectal cancer;
THYM	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg12311346	chr5:56204834	C5orf35	-0.85	-6.2	-0.54	1.45e-8	Initial pursuit acceleration;
THYM	cis	rs16857609	0.748	rs2618146	chr2:218302013	A/G	cg15335768	chr2:218268053	DIRC3	-0.33	-4.53	-0.42	1.74e-5	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg05234568	chr11:5960015	NA	-0.62	-5.04	-0.46	2.18e-6	DNA methylation (variation);
THYM	cis	rs11186	0.556	rs72906352	chr2:189961592	G/A	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	cis	rs9443189	0.570	rs775072	chr6:76377998	G/A	cg01950844	chr6:76311363	SENP6	-1.05	-6.66	-0.56	1.73e-9	Prostate cancer;
THYM	cis	rs2625529	0.824	rs4777471	chr15:72207804	A/G	cg16672083	chr15:72433130	SENP8	-0.56	-5.03	-0.46	2.35e-6	Red blood cell count;
THYM	cis	rs28595532	0.920	rs115226628	chr4:119639818	A/G	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg17366294	chr4:99064904	C4orf37	-0.58	-6.92	-0.58	5.2400000000000005e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8016982	0.633	rs8015423	chr14:81719357	C/T	cg21807262	chr14:81713016	NA	-0.59	-5.63	-0.5	1.85e-7	Schizophrenia;
THYM	cis	rs8067545	0.750	rs9897653	chr17:19987924	G/A	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.64e-6	Schizophrenia;
THYM	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg08847533	chr14:75593920	NEK9	-0.92	-9.94	-0.71	2.25e-16	Height;
THYM	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg19747945	chr6:42946146	PEX6	-0.34	-4.95	-0.45	3.18e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs67072384	0.786	rs58424437	chr11:72448256	C/T	cg01380194	chr11:72452482	ARAP1	-0.93	-5.07	-0.46	1.98e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg24154853	chr7:158122151	PTPRN2	0.54	4.75	0.44	7.12e-6	Calcium levels;
THYM	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg07570687	chr10:102243282	WNT8B	0.72	6.42	0.55	5.46e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg03452623	chr4:187889614	NA	-1.19	-19.02	-0.89	3.66e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-5.11	-0.46	1.64e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg14893161	chr1:205819251	PM20D1	-0.6	-4.6	-0.43	1.32e-5	Menarche (age at onset);
THYM	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs7671261	0.638	rs6843986	chr4:90019365	A/G	cg17769793	chr4:89976368	FAM13A	0.43	4.61	0.43	1.25e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg17173187	chr15:85201210	NMB	0.54	5.41	0.49	4.71e-7	Schizophrenia;
THYM	cis	rs1215050	0.740	rs2555390	chr4:98999112	A/G	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg04750100	chr2:136595281	LCT	-0.54	-6.51	-0.56	3.59e-9	Mosquito bite size;
THYM	cis	rs728616	1.000	rs12414891	chr10:81690385	G/C	cg18148530	chr10:81370782	SFTPA1	0.77	4.88	0.45	4.23e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg10360139	chr7:1886902	MAD1L1	-0.59	-5.09	-0.46	1.81e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg03188948	chr7:1209495	NA	0.91	5.09	0.46	1.79e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs990171	0.955	rs3817465	chr2:103039584	A/T	cg13897122	chr2:103039542	IL18RAP	-0.39	-4.64	-0.43	1.12e-5	Lymphocyte counts;
THYM	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	6.96	0.58	4.33e-10	Lung cancer in ever smokers;
THYM	cis	rs9356181	0.556	rs4709036	chr6:164479669	T/G	cg21271420	chr6:164527436	NA	0.42	4.46	0.42	2.28e-5	Mean corpuscular volume;
THYM	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg24596788	chr1:163392923	NA	-0.77	-7.03	-0.58	3.18e-10	Motion sickness;
THYM	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.48	-0.42	2.05e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs6032067	0.929	rs56168207	chr20:43803971	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.81	-0.57	8.91e-10	Blood protein levels;
THYM	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg26354017	chr1:205819088	PM20D1	-0.72	-5.69	-0.5	1.39e-7	Menarche (age at onset);
THYM	cis	rs6732160	0.650	rs7560224	chr2:73406182	A/G	cg24220031	chr2:73402428	NA	-0.79	-8.99	-0.68	2.41e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2458413	0.521	rs2458427	chr8:105339594	G/T	cg21295575	chr8:105352067	TM7SF4	0.31	4.57	0.42	1.47e-5	Paget's disease;
THYM	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.71	6.78	0.57	1.03e-9	Lymphocyte counts;
THYM	cis	rs12291225	0.883	rs1864658	chr11:14256444	C/T	cg19336497	chr11:14380999	RRAS2	0.54	5.13	0.47	1.53e-6	Sense of smell;
THYM	cis	rs28785552	0.796	rs8112908	chr19:53248041	C/T	cg22067481	chr19:53234126	ZNF611	-0.91	-7.92	-0.63	4.42e-12	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.38	0.55	6.34e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg20999797	chr1:1681921	NA	0.49	5.41	0.49	4.78e-7	Body mass index;
THYM	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22455342	chr2:225449267	CUL3	0.97	9.01	0.68	2.14e-14	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg16414030	chr3:133502952	NA	-0.95	-9.48	-0.7	2.17e-15	Iron status biomarkers;
THYM	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg06728252	chr6:26598149	ABT1	0.44	5.28	0.48	8.11e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2637266	0.783	rs2588333	chr10:78538952	A/G	cg18941641	chr10:78392320	NA	0.65	5.18	0.47	1.24e-6	Pulmonary function;
THYM	cis	rs2109514	0.765	rs768108	chr7:116108658	A/G	cg12739419	chr7:116140593	CAV2	-0.46	-4.63	-0.43	1.15e-5	Prevalent atrial fibrillation;
THYM	cis	rs11098499	0.532	rs12512646	chr4:120585733	G/A	cg09307838	chr4:120376055	NA	0.7	4.64	0.43	1.1e-5	Corneal astigmatism;
THYM	cis	rs714031	0.934	rs2235342	chr22:40068853	T/C	cg21377881	chr22:40064566	CACNA1I	-0.59	-5.3	-0.48	7.51e-7	Schizophrenia;
THYM	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg06481639	chr22:41940642	POLR3H	0.74	4.85	0.45	4.81e-6	Cannabis dependence symptom count;
THYM	cis	rs11186	0.556	rs72906375	chr2:189965175	T/C	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs79149102	0.579	rs7168638	chr15:75280826	T/C	cg17294928	chr15:75287854	SCAMP5	-1.05	-5.58	-0.5	2.3e-7	Lung cancer;
THYM	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg14458575	chr2:238380390	NA	1.0	7.86	0.63	5.79e-12	Prostate cancer;
THYM	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg25427524	chr10:38739819	LOC399744	-0.66	-6.13	-0.53	1.99e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs4731207	0.698	rs10233589	chr7:124468599	G/A	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06873352	chr17:61820015	STRADA	0.78	9.87	0.71	3.13e-16	Prudent dietary pattern;
THYM	cis	rs16937	0.662	rs12137294	chr1:205182872	A/C	cg17889831	chr1:205181581	DSTYK	-0.39	-4.78	-0.44	6.51e-6	Schizophrenia;
THYM	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg11494091	chr17:61959527	GH2	0.68	6.3	0.54	9.43e-9	Height;
THYM	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg06850241	chr22:41845214	NA	0.54	4.68	0.43	9.37e-6	Vitiligo;
THYM	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs3947	0.951	rs1692814	chr8:11704298	T/C	cg26752888	chr8:11627280	NEIL2	-0.76	-4.91	-0.45	3.72e-6	Blood protein levels;
THYM	cis	rs7677751	0.806	rs1800812	chr4:55094629	G/T	cg17187183	chr4:55093834	PDGFRA	0.73	5.43	0.49	4.25e-7	Corneal astigmatism;
THYM	cis	rs7113019	1	rs7113019	chr11:122819119	A/C	cg27398637	chr11:122830231	C11orf63	-0.6	-5.09	-0.46	1.78e-6	Menarche (age at onset);
THYM	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg10523679	chr1:76189770	ACADM	0.91	9.7	0.71	7.37e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs116139393	0.517	rs17789570	chr7:6724344	G/A	cg03005310	chr7:6897353	NA	-0.63	-4.58	-0.43	1.39e-5	Alzheimer's disease (APOE e4 interaction);
THYM	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.81	6.53	0.56	3.27e-9	Blood protein levels;
THYM	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg20503657	chr10:835505	NA	0.94	5.16	0.47	1.33e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs7216064	1.000	rs11869819	chr17:65868669	A/C	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs7582180	0.602	rs7585582	chr2:100998030	G/C	cg14675211	chr2:100938903	LONRF2	0.59	5.65	0.5	1.67e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.95	-9.67	-0.7	8.24e-16	Menarche (age at onset);
THYM	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg23231163	chr10:75533350	FUT11	-0.4	-5.7	-0.5	1.34e-7	Inflammatory bowel disease;
THYM	cis	rs11696501	0.739	rs6104257	chr20:44262100	G/T	cg11783356	chr20:44313418	WFDC10B	-0.67	-4.52	-0.42	1.77e-5	Brain structure;
THYM	cis	rs9788682	0.747	rs7174190	chr15:78763617	C/T	cg18825076	chr15:78729989	IREB2	0.69	5.51	0.49	3.05e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.25	-5.11	-0.46	1.64e-6	Obesity-related traits;
THYM	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2806561	0.765	rs2806556	chr1:23502850	G/A	cg12483005	chr1:23474871	LUZP1	0.58	6.22	0.54	1.31e-8	Height;
THYM	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.74	-5.99	-0.52	3.7e-8	Prostate cancer;
THYM	cis	rs7586879	0.681	rs6756609	chr2:25121125	C/A	cg27107076	chr2:25050844	ADCY3	-0.29	-4.66	-0.43	1.04e-5	Body mass index;
THYM	cis	rs950881	0.932	rs10179458	chr2:102934974	C/T	cg20060108	chr2:102954350	IL1RL1	0.87	4.77	0.44	6.56e-6	Allergy;
THYM	cis	rs35883536	0.588	rs10465764	chr1:101105030	A/G	cg06223162	chr1:101003688	GPR88	0.62	5.52	0.49	2.96e-7	Monocyte count;
THYM	cis	rs9311676	0.656	rs56384862	chr3:58395863	A/G	cg26110898	chr3:58419937	PDHB	0.45	4.79	0.44	6.17e-6	Systemic lupus erythematosus;
THYM	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg08213375	chr14:104286397	PPP1R13B	0.55	6.82	0.57	8.25e-10	Schizophrenia;
THYM	cis	rs4788570	0.615	rs1058750	chr16:71679057	C/T	cg06353428	chr16:71660113	MARVELD3	1.27	8.51	0.66	2.53e-13	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg07362569	chr17:61921086	SMARCD2	0.69	6.13	0.53	2.02e-8	Prudent dietary pattern;
THYM	cis	rs12476592	0.543	rs1900303	chr2:63897260	C/T	cg17519650	chr2:63277830	OTX1	-0.69	-4.69	-0.43	9.3e-6	Childhood ear infection;
THYM	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg24874828	chr4:187887005	NA	-0.73	-7.32	-0.6	8.05e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28785552	0.554	rs11084184	chr19:53213939	G/A	cg22067481	chr19:53234126	ZNF611	-0.97	-9.5	-0.7	1.97e-15	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs7677751	0.806	rs7679903	chr4:55097373	T/C	cg17187183	chr4:55093834	PDGFRA	0.73	5.43	0.49	4.25e-7	Corneal astigmatism;
THYM	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg10253484	chr15:75165896	SCAMP2	-0.66	-4.59	-0.43	1.38e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg27129171	chr3:47204927	SETD2	0.69	6.63	0.56	2.04e-9	Colorectal cancer;
THYM	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg05368731	chr17:41323189	NBR1	1.25	11.45	0.76	1.35e-19	Menopause (age at onset);
THYM	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg13695892	chr22:41940480	POLR3H	0.86	5.96	0.52	4.19e-8	Vitiligo;
THYM	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg23625390	chr15:77176239	SCAPER	0.7	5.19	0.47	1.19e-6	Blood metabolite levels;
THYM	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg13695892	chr22:41940480	POLR3H	-0.93	-8.1	-0.64	1.85e-12	Vitiligo;
THYM	cis	rs11078597	0.708	rs7503952	chr17:1649259	G/C	cg18436246	chr17:1640651	WDR81	0.64	4.63	0.43	1.14e-5	Serum albumin level;
THYM	trans	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs2133450	0.724	rs1858061	chr3:7361210	C/A	cg19930620	chr3:7340148	GRM7	-0.49	-4.66	-0.43	1.02e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs28795989	0.830	rs1320074	chr4:7904111	T/G	cg00251875	chr4:7801337	AFAP1	0.59	4.75	0.44	7.24e-6	Intraocular pressure;
THYM	cis	rs6060717	0.610	rs2794382	chr20:34613651	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-5.35	-0.48	6.15e-7	Hip circumference adjusted for BMI;
THYM	cis	rs728616	0.867	rs61859763	chr10:81671615	A/T	cg05935833	chr10:81318306	SFTPA2	-0.72	-4.64	-0.43	1.09e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg23260525	chr10:116636907	FAM160B1	0.53	5.33	0.48	6.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs10411161	0.702	rs8113685	chr19:52383890	C/T	cg25361850	chr19:52391789	ZNF577	0.71	4.99	0.46	2.69e-6	Breast cancer;
THYM	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs17102423	1.000	rs4902365	chr14:65602064	T/C	cg11161011	chr14:65562177	MAX	-0.69	-6.03	-0.53	3.06e-8	Obesity-related traits;
THYM	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1557488	0.565	rs1946057	chr11:126685198	G/A	cg03950493	chr11:126582183	KIRREL3	-0.38	-4.53	-0.42	1.75e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg26384229	chr12:38710491	ALG10B	-0.91	-7.58	-0.61	2.33e-11	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg27034606	chr17:28928453	LRRC37B2	0.79	4.89	0.45	4.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg06634786	chr22:41940651	POLR3H	0.7	5.26	0.47	8.85e-7	Vitiligo;
THYM	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11890956	chr21:40555474	PSMG1	1.17	13.15	0.8	4.19e-23	Cognitive function;
THYM	cis	rs7771547	0.519	rs67313027	chr6:36363487	G/C	cg07856975	chr6:36356162	ETV7	0.68	5.93	0.52	4.85e-8	Platelet distribution width;
THYM	cis	rs3764563	1.000	rs4646530	chr19:15735238	A/T	cg20725493	chr19:15740067	CYP4F8	1.02	4.62	0.43	1.2e-5	Inflammatory biomarkers;
THYM	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg03929089	chr4:120376271	NA	-1.03	-12.22	-0.78	3.45e-21	Height;
THYM	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg24818145	chr4:99064322	C4orf37	0.7	5.51	0.49	3.09e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6918586	0.615	rs198841	chr6:26111671	G/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.59	-0.61	2.21e-11	Schizophrenia;
THYM	cis	rs25645	0.502	rs9895948	chr17:38108363	T/C	cg24910161	chr17:38119198	GSDMA	-0.58	-6.31	-0.54	8.93e-9	Myeloid white cell count;
THYM	cis	rs7584330	0.737	rs1497127	chr2:238369282	A/G	cg16989719	chr2:238392110	NA	-0.6	-5.7	-0.5	1.37e-7	Prostate cancer;
THYM	cis	rs11225247	0.536	rs12277853	chr11:102257853	A/G	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg03213289	chr20:61660250	NA	0.91	9.46	0.7	2.34e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg18512352	chr11:47633146	NA	-0.52	-6.49	-0.55	3.8e-9	Subjective well-being;
THYM	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.78	-0.51	9.65e-8	Chronic sinus infection;
THYM	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg02527881	chr3:46936655	PTH1R	-0.52	-4.99	-0.46	2.77e-6	Colorectal cancer;
THYM	cis	rs7100689	0.577	rs1417219	chr10:82041409	C/T	cg09936400	chr10:82049201	MAT1A	0.43	4.54	0.42	1.64e-5	Post bronchodilator FEV1;
THYM	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg13854012	chr2:162103682	NA	-0.65	-5.39	-0.48	5.19e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg21926883	chr2:100939477	LONRF2	-0.65	-6.02	-0.53	3.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs56046484	0.778	rs1606119	chr15:85671379	G/T	cg06618377	chr15:85746050	NA	-0.5	-5.12	-0.47	1.58e-6	Testicular germ cell tumor;
THYM	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.65	-5.71	-0.51	1.3e-7	Platelet count;
THYM	trans	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg10856724	chr12:34555212	NA	-0.94	-8.22	-0.64	1.01e-12	Bladder cancer;
THYM	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg11812906	chr14:75593930	NEK9	-0.87	-8.3	-0.65	7.13e-13	Height;
THYM	cis	rs7246657	0.653	rs4805207	chr19:37673733	G/A	cg23950597	chr19:37808831	NA	-0.81	-4.88	-0.45	4.35e-6	Coronary artery calcification;
THYM	cis	rs12765878	0.603	rs9420904	chr10:105666745	G/A	cg04688330	chr10:105451802	SH3PXD2A	0.37	4.59	0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs6495122	0.699	rs1378941	chr15:75080150	C/A	cg14664628	chr15:75095509	CSK	-0.81	-6.38	-0.55	6.5e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs921968	0.541	rs576901	chr2:219424364	A/G	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs899997	1.000	rs8030335	chr15:79034124	G/A	cg00639195	chr15:79103007	ADAMTS7	-0.79	-5.55	-0.49	2.62e-7	Coronary artery disease or large artery stroke;
THYM	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs6956675	0.831	rs4718878	chr7:62656497	T/C	cg27518014	chr7:62859535	LOC100287834	0.59	4.8	0.44	5.95e-6	Obesity-related traits;
THYM	cis	rs4595586	0.545	rs6580896	chr12:39372223	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01341218	chr17:43662625	NA	1.15	9.87	0.71	3.19e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4820539	0.933	rs2267004	chr22:23459863	G/A	cg14186256	chr22:23484241	RTDR1	0.96	9.08	0.68	1.5e-14	Bone mineral density;
THYM	cis	rs72781680	1.000	rs72781680	chr2:24238928	C/T	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg19761014	chr17:28927070	LRRC37B2	0.82	4.58	0.43	1.41e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3741151	0.686	rs11828904	chr11:73139116	T/C	cg12959048	chr11:73096162	RELT	-0.46	-4.84	-0.45	4.94e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg08000102	chr2:233561755	GIGYF2	-0.68	-6.11	-0.53	2.16e-8	Coronary artery disease;
THYM	cis	rs7078219	0.505	rs10883372	chr10:101292483	T/A	cg04972745	chr10:101287846	NA	-0.52	-4.98	-0.45	2.85e-6	Dental caries;
THYM	cis	rs6074022	0.743	rs13037326	chr20:44692598	C/T	cg20003638	chr20:44687730	SLC12A5	0.75	5.26	0.47	8.85e-7	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
THYM	cis	rs1003719	0.628	rs2252402	chr21:38520720	A/G	cg01329690	chr21:38580129	DSCR9	0.34	4.57	0.42	1.48e-5	Eye color traits;
THYM	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg12379764	chr21:47803548	PCNT	-0.68	-4.85	-0.45	4.9100000000000004e-06	Testicular germ cell tumor;
THYM	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg08847533	chr14:75593920	NEK9	-1.0	-11.26	-0.76	3.48e-19	Height;
THYM	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg27125505	chr17:43679177	LOC644172	0.77	6.97	0.58	4.25e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4595586	0.545	rs7308161	chr12:39363459	A/G	cg13010199	chr12:38710504	ALG10B	0.64	4.93	0.45	3.49e-6	Morning vs. evening chronotype;
THYM	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg27535305	chr1:53392650	SCP2	0.5	5.46	0.49	3.81e-7	Monocyte count;
THYM	cis	rs4363385	0.510	rs11576797	chr1:153049417	T/C	cg13444842	chr1:152974279	SPRR3	-0.6	-4.69	-0.43	9.19e-6	Inflammatory skin disease;
THYM	cis	rs880496	0.625	rs12123347	chr1:224824411	C/T	cg01808320	chr1:224927238	CNIH3	-0.62	-4.64	-0.43	1.13e-5	Cancer;
THYM	cis	rs240764	0.817	rs240164	chr6:101044487	T/A	cg21058520	chr6:100914733	NA	-0.56	-4.75	-0.44	7.12e-6	Neuroticism;
THYM	cis	rs10779751	0.734	rs2791647	chr1:11132801	G/A	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs7809950	0.817	rs2712224	chr7:107181235	C/A	cg23024343	chr7:107201750	COG5	-1.05	-9.25	-0.69	6.47e-15	Coronary artery disease;
THYM	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.57	-0.42	1.47e-5	Morning vs. evening chronotype;
THYM	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg01073479	chr16:3509474	NAT15	-0.68	-5.45	-0.49	4.02e-7	Tuberculosis;
THYM	cis	rs688187	0.805	rs12982533	chr19:39731904	T/C	cg16476317	chr19:39737804	NA	0.41	4.76	0.44	6.85e-6	Mucinous ovarian carcinoma;
THYM	cis	rs1348850	0.526	rs7607073	chr2:178375065	C/A	cg27490568	chr2:178487706	NA	0.66	5.31	0.48	7.1e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg27129171	chr3:47204927	SETD2	-0.76	-7.63	-0.62	1.82e-11	Colorectal cancer;
THYM	cis	rs11096990	0.855	rs2711935	chr4:39162457	A/G	cg24403649	chr4:39172243	NA	-0.64	-5.4	-0.48	4.98e-7	Cognitive function;
THYM	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg11247378	chr22:39784982	NA	-0.92	-8.9	-0.67	3.7e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs2273669	0.667	rs11153139	chr6:109279381	C/T	cg17117243	chr6:109341365	SESN1	-0.85	-4.84	-0.44	5.02e-6	Prostate cancer;
THYM	cis	rs2692947	0.740	rs4907280	chr2:96402126	A/G	cg22654517	chr2:96458247	NA	0.65	5.18	0.47	1.26e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg00495681	chr13:53174319	NA	-0.75	-6.79	-0.57	9.65e-10	Lewy body disease;
THYM	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg23711669	chr6:146136114	FBXO30	0.89	8.61	0.66	1.54e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg10018233	chr7:150070692	REPIN1	-0.45	-7.67	-0.62	1.47e-11	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11112613	0.713	rs11112587	chr12:105941285	G/A	cg03607813	chr12:105948248	NA	1.06	9.14	0.68	1.12e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07157834	chr1:205819609	PM20D1	0.89	8.85	0.67	4.64e-14	Menarche (age at onset);
THYM	cis	rs6754311	0.513	rs1438304	chr2:136503157	A/G	cg23851026	chr2:136556271	LCT	-0.57	-5.96	-0.52	4.29e-8	Mosquito bite size;
THYM	cis	rs12643440	0.538	rs62296685	chr4:17137580	T/C	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg08021120	chr3:195498017	MUC4	0.86	4.6	0.43	1.31e-5	Lung disease severity in cystic fibrosis;
THYM	cis	rs28595532	0.920	rs56364904	chr4:119742504	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs4589258	0.933	rs1792603	chr11:90439410	A/T	cg26138821	chr11:89956704	CHORDC1	0.7	5.9	0.52	5.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2229238	0.911	rs11490956	chr1:154487258	G/T	cg21262032	chr1:154437693	IL6R	-0.6	-5.39	-0.48	5.21e-7	Coronary heart disease;
THYM	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg05373962	chr22:49881684	NA	-0.69	-6.46	-0.55	4.49e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs17253792	0.822	rs80321745	chr14:56162947	T/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs1497406	0.744	rs10907282	chr1:16510139	A/G	cg20430773	chr1:16534157	ARHGEF19	0.49	5.51	0.49	3.02e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg04362960	chr10:104952993	NT5C2	0.58	4.95	0.45	3.18e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.7	-5.72	-0.51	1.25e-7	Blood metabolite levels;
THYM	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg19077165	chr18:44547161	KATNAL2	-0.6	-7.68	-0.62	1.41e-11	Personality dimensions;
THYM	cis	rs8041943	0.643	rs11854796	chr15:79924480	A/G	cg20511832	chr15:78934280	CHRNB4	0.42	4.82	0.44	5.4e-6	Bone mineral density (spine) and age at menarche;
THYM	trans	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg25214090	chr10:38739885	LOC399744	0.94	8.27	0.65	7.91e-13	Corneal astigmatism;
THYM	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg04025307	chr7:1156635	C7orf50	0.76	4.73	0.44	7.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22496380	chr5:211416	CCDC127	-1.33	-7.99	-0.63	3.21e-12	Breast cancer;
THYM	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg12310025	chr6:25882481	NA	-0.69	-5.47	-0.49	3.69e-7	Blood metabolite levels;
THYM	cis	rs9972944	0.651	rs12601958	chr17:63820304	A/G	cg07283582	chr17:63770753	CCDC46	-0.63	-4.9	-0.45	3.94e-6	Total body bone mineral density;
THYM	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg02018176	chr4:1364513	KIAA1530	0.55	4.7	0.43	8.68e-6	Obesity-related traits;
THYM	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.32	0.54	8.42e-9	Platelet count;
THYM	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg02734326	chr4:10020555	SLC2A9	0.73	6.39	0.55	6.19e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg21394778	chr1:3037102	PRDM16	0.49	4.83	0.44	5.22e-6	Height;
THYM	cis	rs6084875	0.896	rs11087657	chr20:4740775	C/A	cg19614321	chr20:4804581	RASSF2	-0.46	-4.66	-0.43	1.04e-5	Systemic lupus erythematosus;
THYM	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs3008870	1.000	rs4655663	chr1:67430103	C/T	cg02640540	chr1:67518911	SLC35D1	0.64	4.68	0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs36051895	0.587	rs16922785	chr9:5200409	C/G	cg02405213	chr9:5042618	JAK2	-0.88	-7.89	-0.63	5.2e-12	Pediatric autoimmune diseases;
THYM	cis	rs34638657	0.789	rs2967363	chr16:82204132	C/G	cg19807685	chr16:82068980	HSD17B2	-0.55	-4.53	-0.42	1.73e-5	Lung adenocarcinoma;
THYM	cis	rs10857712	0.784	rs2265639	chr10:135221576	C/G	cg19904058	chr10:135279010	LOC619207	0.51	4.79	0.44	6.24e-6	Systemic lupus erythematosus;
THYM	cis	rs7909074	0.933	rs879073	chr10:45399882	C/G	cg04218760	chr10:45406644	TMEM72	-0.64	-5.63	-0.5	1.79e-7	Mean corpuscular volume;
THYM	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg13012494	chr21:47604986	C21orf56	-0.61	-4.57	-0.42	1.47e-5	Testicular germ cell tumor;
THYM	cis	rs6429082	0.967	rs834143	chr1:235626406	C/T	cg26050004	chr1:235667680	B3GALNT2	0.54	4.78	0.44	6.47e-6	Adiposity;
THYM	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg05043794	chr9:111880884	C9orf5	-0.32	-4.59	-0.43	1.33e-5	Menarche (age at onset);
THYM	cis	rs13064411	0.696	rs6438161	chr3:113227637	G/A	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.95	0.71	2.08e-16	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11785693	0.862	rs11786657	chr8:5001792	T/C	cg26367366	chr8:4980734	NA	1.16	5.46	0.49	3.79e-7	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg03806693	chr22:41940476	POLR3H	-1.21	-10.54	-0.73	1.17e-17	Vitiligo;
THYM	cis	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg05335186	chr13:53173507	NA	-0.51	-6.51	-0.56	3.56e-9	Lewy body disease;
THYM	cis	rs763014	0.931	rs56048717	chr16:634867	A/G	cg00908189	chr16:619842	PIGQ	1.03	9.46	0.7	2.34e-15	Height;
THYM	cis	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg07460842	chr6:66804631	NA	1.11	8.12	0.64	1.7e-12	Exhaled nitric oxide output;
THYM	cis	rs2811415	0.597	rs67527747	chr3:127803083	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg12011299	chr4:100065546	ADH4	0.68	6.19	0.54	1.53e-8	Alcohol dependence;
THYM	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg15592062	chr6:167189543	RPS6KA2	0.58	5.8	0.51	8.65e-8	Crohn's disease;
THYM	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg16778714	chr17:28903809	LRRC37B2	0.69	4.75	0.44	7.09e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs240764	0.764	rs12208241	chr6:100933472	T/C	cg21058520	chr6:100914733	NA	0.55	4.92	0.45	3.63e-6	Neuroticism;
THYM	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg00576331	chr11:65640516	EFEMP2	0.68	4.58	0.43	1.42e-5	Crohn's disease;
THYM	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9297145	0.585	rs4729521	chr7:98780520	G/T	cg05967295	chr7:98741636	SMURF1	-0.7	-5.5	-0.49	3.18e-7	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs4733781	1.000	rs72722365	chr8:131190914	G/A	cg16277922	chr8:131349729	ASAP1	0.67	4.81	0.44	5.62e-6	Tuberculosis;
THYM	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs7851660	0.933	rs13302470	chr9:100615553	A/G	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg12165864	chr7:66369176	NA	0.67	5.26	0.47	8.99e-7	Aortic root size;
THYM	cis	rs5995756	0.666	rs3788567	chr22:40006035	G/T	cg21377881	chr22:40064566	CACNA1I	-0.56	-4.77	-0.44	6.6e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs8070128	0.688	rs59304093	chr17:17875407	A/G	cg04398451	chr17:18023971	MYO15A	-0.93	-8.84	-0.67	4.97e-14	Total body bone mineral density;
THYM	cis	rs4866334	1.000	rs114114986	chr5:18428605	C/A	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs35934224	0.769	rs17534001	chr22:19842310	A/G	cg11182965	chr22:19864308	TXNRD2	0.89	5.1	0.46	1.73e-6	Glaucoma (primary open-angle);
THYM	cis	rs7084402	0.967	rs1658422	chr10:60331758	G/T	cg09696939	chr10:60272079	BICC1	-0.46	-5.54	-0.49	2.74e-7	Refractive error;
THYM	cis	rs425535	0.757	rs2472655	chr4:74843018	C/T	cg07868155	chr4:74864709	CXCL5	0.61	4.51	0.42	1.82e-5	Blood protein levels;
THYM	cis	rs7264396	0.887	rs224363	chr20:34062710	C/T	cg26038318	chr20:34205095	SPAG4	0.56	4.69	0.43	9.26e-6	Total cholesterol levels;
THYM	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg26314531	chr2:26401878	FAM59B	0.78	5.13	0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs889122	0.531	rs918539	chr19:10013840	C/G	cg07950397	chr19:10022659	OLFM2	-0.35	-4.46	-0.42	2.25e-5	Menarche (age at onset);
THYM	cis	rs2075230	0.642	rs1642797	chr17:7543017	C/T	cg10509001	chr17:7553872	ATP1B2	-0.58	-4.71	-0.44	8.48e-6	Hormone measurements;
THYM	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg23711669	chr6:146136114	FBXO30	-0.93	-9.39	-0.69	3.39e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6980334	1.000	rs7795946	chr7:137785091	A/G	cg03464514	chr7:137028442	PTN	0.56	4.67	0.43	9.74e-6	Blood metabolite ratios;
THYM	cis	rs7584330	0.554	rs7582964	chr2:238385766	C/T	cg08992911	chr2:238395768	MLPH	-0.96	-5.78	-0.51	9.65e-8	Prostate cancer;
THYM	cis	rs3812049	0.667	rs6888037	chr5:127406259	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.43	0.49	4.29e-7	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs79480871	0.667	rs4665716	chr2:24943972	A/G	cg26312337	chr2:25170414	DNAJC27	0.62	5.13	0.47	1.5e-6	Diffuse large B cell lymphoma;
THYM	cis	rs988913	1.000	rs9382403	chr6:54825687	A/C	cg18532076	chr6:54711417	FAM83B	0.49	4.87	0.45	4.53e-6	Menarche (age at onset);
THYM	cis	rs72843506	0.656	rs57040439	chr17:19939835	C/G	cg12065943	chr17:19881925	AKAP10	-0.76	-4.58	-0.43	1.41e-5	Schizophrenia;
THYM	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg26963428	chr7:66367121	NA	-0.57	-4.57	-0.42	1.48e-5	Corneal structure;
THYM	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg16414030	chr3:133502952	NA	-0.58	-4.58	-0.43	1.39e-5	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.69	-5.27	-0.48	8.59e-7	Tonsillectomy;
THYM	cis	rs12681287	0.640	rs7833049	chr8:87445898	T/C	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg19507638	chr5:93509721	C5orf36	0.71	4.79	0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg05762616	chr10:133787150	BNIP3	-0.69	-4.46	-0.42	2.26e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	7.5	0.61	3.29e-11	Platelet count;
THYM	cis	rs7106204	1.000	rs4622259	chr11:24215789	A/G	ch.11.24196551F	chr11:24239977	NA	0.94	5.88	0.52	6.09e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs1775715	0.675	rs2808085	chr10:32148599	C/T	cg04359828	chr10:32216031	ARHGAP12	0.39	5.04	0.46	2.19e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	trans	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg10856724	chr12:34555212	NA	-0.98	-8.46	-0.66	3.16e-13	Bladder cancer;
THYM	cis	rs806215	1.000	rs327512	chr7:127257251	G/A	cg08586737	chr7:127225949	GCC1	0.37	4.52	0.42	1.8e-5	Type 2 diabetes;
THYM	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg07884673	chr3:53033167	SFMBT1	1.25	6.34	0.55	7.83e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs34017685	0.536	rs6757800	chr2:71324045	C/G	cg25705148	chr2:72079498	NA	0.8	4.51	0.42	1.89e-5	Stem cell growth factor beta levels;
THYM	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg15704280	chr7:45808275	SEPT13	-0.96	-7.45	-0.61	4.26e-11	Coronary artery disease;
THYM	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg26384229	chr12:38710491	ALG10B	1.0	7.61	0.62	1.97e-11	Bladder cancer;
THYM	cis	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.73	0.44	7.82e-6	Obesity-related traits;
THYM	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg11752832	chr7:134001865	SLC35B4	0.68	4.92	0.45	3.63e-6	Mean platelet volume;
THYM	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs4732038	0.565	rs55935438	chr7:134278238	C/T	cg06906464	chr7:134288099	NA	-0.52	-5.31	-0.48	7.3e-7	Longevity;
THYM	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg04398451	chr17:18023971	MYO15A	-0.76	-6.93	-0.58	4.99e-10	Total body bone mineral density;
THYM	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg14779329	chr11:130786720	SNX19	0.5	5.19	0.47	1.17e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg10760299	chr15:45669010	GATM	0.76	5.72	0.51	1.23e-7	Homoarginine levels;
THYM	cis	rs4072705	0.967	rs4240486	chr9:127341110	C/T	cg01786973	chr9:127249749	NR5A1	0.34	4.5	0.42	1.9e-5	Menarche (age at onset);
THYM	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg05368731	chr17:41323189	NBR1	1.2	10.84	0.74	2.73e-18	Menopause (age at onset);
THYM	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg10792982	chr14:105748885	BRF1	0.7	7.04	0.59	2.92e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg06221963	chr1:154839813	KCNN3	-0.93	-13.15	-0.8	4.09e-23	Prostate cancer;
THYM	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg15242686	chr22:24348715	GSTTP1	0.54	4.93	0.45	3.45e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.62	-4.58	-0.43	1.42e-5	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg09904177	chr6:26538194	HMGN4	0.64	5.41	0.49	4.78e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7819412	0.526	rs62490742	chr8:10906734	G/A	cg16664915	chr8:10907788	XKR6	0.56	4.52	0.42	1.76e-5	Triglycerides;
THYM	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg24154853	chr7:158122151	PTPRN2	0.56	5.04	0.46	2.25e-6	Calcium levels;
THYM	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.74	-6.58	-0.56	2.6e-9	Personality dimensions;
THYM	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg02353165	chr6:42928485	GNMT	0.85	8.03	0.64	2.61e-12	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	7.03	0.58	3.18e-10	Electrocardiographic conduction measures;
THYM	cis	rs4654899	1.000	rs4654902	chr1:21435056	T/G	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.26e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs7771547	0.519	rs12206445	chr6:36379628	G/A	cg07856975	chr6:36356162	ETV7	0.61	5.14	0.47	1.48e-6	Platelet distribution width;
THYM	cis	rs4332037	0.539	rs4719416	chr7:2106608	G/A	cg02825527	chr7:2087843	MAD1L1	-0.68	-4.55	-0.42	1.6e-5	Bipolar disorder;
THYM	cis	rs2997447	0.761	rs2783711	chr1:26428864	G/A	cg03844060	chr1:26490628	NA	0.66	4.48	0.42	2.09e-5	QRS complex (12-leadsum);
THYM	cis	rs524023	0.914	rs2360872	chr11:64353405	T/C	cg19131476	chr11:64387923	NRXN2	-0.35	-4.84	-0.45	4.95e-6	Urate levels in obese individuals;
THYM	cis	rs7582180	0.700	rs11685293	chr2:100976502	A/C	cg21926883	chr2:100939477	LONRF2	-0.66	-6.14	-0.53	1.89e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1322639	0.531	rs11751421	chr6:169574993	T/C	cg04662567	chr6:169592167	NA	0.57	5.08	0.46	1.86e-6	Pulse pressure;
THYM	cis	rs3820068	0.626	rs61103742	chr1:15909153	A/C	cg27534772	chr1:16042836	PLEKHM2	0.49	4.64	0.43	1.13e-5	Systolic blood pressure;
THYM	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg04499151	chr7:100231278	TFR2	0.62	4.49	0.42	1.98e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7927771	0.560	rs4752858	chr11:47685829	C/T	cg18512352	chr11:47633146	NA	-0.41	-4.51	-0.42	1.85e-5	Subjective well-being;
THYM	cis	rs4919044	1.000	rs17108042	chr10:94770488	A/C	cg05127821	chr10:94822908	CYP26C1	-1.18	-5.88	-0.52	6.18e-8	Coronary artery disease;
THYM	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg00191853	chr8:101177733	SPAG1	-0.57	-5.59	-0.5	2.13e-7	Atrioventricular conduction;
THYM	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg20283391	chr11:68216788	NA	-0.69	-5.14	-0.47	1.49e-6	Total body bone mineral density;
THYM	cis	rs8013055	1.000	rs8013055	chr14:105990620	T/A	cg23356831	chr14:105996513	TMEM121	0.59	5.78	0.51	9.65e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs4919087	0.781	rs7901853	chr10:99082360	T/C	cg19453742	chr10:98862320	SLIT1	-0.64	-5.2	-0.47	1.13e-6	Monocyte count;
THYM	cis	rs1728785	0.901	rs1645934	chr16:68564490	T/A	cg02972257	chr16:68554789	NA	-0.74	-4.54	-0.42	1.63e-5	Ulcerative colitis;
THYM	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg22431228	chr1:16359049	CLCNKA	-0.53	-5.13	-0.47	1.51e-6	Dilated cardiomyopathy;
THYM	cis	rs7131987	0.621	rs6487805	chr12:29457550	A/T	cg09582351	chr12:29534625	ERGIC2	0.53	4.68	0.43	9.37e-6	QT interval;
THYM	cis	rs10089	0.904	rs3087889	chr5:127524944	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.92	5.76	0.51	1.04e-7	Ileal carcinoids;
THYM	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg22875332	chr1:76189707	ACADM	0.89	11.21	0.75	4.4e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs36051895	0.659	rs2149555	chr9:5053743	C/T	cg02405213	chr9:5042618	JAK2	-1.04	-10.96	-0.75	1.52e-18	Pediatric autoimmune diseases;
THYM	cis	rs4654899	0.865	rs6664532	chr1:21515800	G/A	cg01072550	chr1:21505969	NA	-0.76	-6.77	-0.57	1.05e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs11997175	0.575	rs56942690	chr8:33820308	G/A	ch.8.33884649F	chr8:33765107	NA	0.7	5.4	0.48	5e-7	Body mass index;
THYM	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg21856205	chr7:94953877	PON1	-0.73	-6.93	-0.58	4.95e-10	Paraoxonase activity;
THYM	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs10905065	0.866	rs10795547	chr10:5827074	A/G	cg11519256	chr10:5708881	ASB13	-0.47	-4.47	-0.42	2.18e-5	Menopause (age at onset);
THYM	cis	rs7220711	0.967	rs4792909	chr17:41798824	G/T	cg26893861	chr17:41843967	DUSP3	0.65	5.49	0.49	3.34e-7	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs765787	0.530	rs2554456	chr15:45521138	A/C	cg24006582	chr15:45444508	DUOX1	-0.8	-6.7	-0.57	1.45e-9	Uric acid levels;
THYM	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.99	-10.6	-0.74	8.54e-18	Menarche (age at onset);
THYM	cis	rs6450176	1.000	rs5024170	chr5:53300827	C/A	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.14	-0.53	1.94e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg00684032	chr4:1343700	KIAA1530	-0.66	-5.62	-0.5	1.9e-7	Obesity-related traits;
THYM	cis	rs6430585	0.702	rs2304601	chr2:136528034	C/A	cg20242066	chr2:136595261	LCT	0.5	4.7	0.43	8.63e-6	Corneal structure;
THYM	cis	rs7523273	0.505	rs35438924	chr1:207881489	T/G	cg22525895	chr1:207977042	MIR29B2	0.52	4.76	0.44	6.95e-6	Schizophrenia;
THYM	cis	rs7402982	0.625	rs12905392	chr15:99199212	G/A	cg27438980	chr15:99195143	IGF1R	-0.51	-4.54	-0.42	1.66e-5	Birth weight;
THYM	cis	rs220324	0.618	rs9975331	chr21:43559892	T/C	cg09727148	chr21:43560719	UMODL1	0.85	10.15	0.72	7.77e-17	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs2963155	0.518	rs853178	chr5:142634799	C/T	cg17617527	chr5:142782415	NR3C1	1.2	6.6	0.56	2.37e-9	Breast cancer;
THYM	cis	rs11886999	0.812	rs57251156	chr2:96886700	A/C	cg18419276	chr2:96971862	SNRNP200	-0.47	-5.28	-0.48	8.28e-7	Cardiac Troponin-T levels;
THYM	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg18402987	chr7:1209562	NA	1.03	6.06	0.53	2.77e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.9	-7.8	-0.62	8.06e-12	Multiple sclerosis;
THYM	cis	rs11225247	1.000	rs75217705	chr11:102294079	C/T	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs7523273	0.526	rs1204708	chr1:208024062	G/C	cg22525895	chr1:207977042	MIR29B2	-0.91	-9.37	-0.69	3.58e-15	Schizophrenia;
THYM	cis	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg01364799	chr7:75623366	TMEM120A	-0.64	-4.65	-0.43	1.08e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs9810089	0.843	rs650326	chr3:136037707	G/A	cg12473912	chr3:136751656	NA	0.6	4.87	0.45	4.42e-6	Gestational age at birth (child effect);
THYM	cis	rs1018836	0.608	rs2142146	chr8:91464808	T/C	cg16814680	chr8:91681699	NA	-0.71	-5.72	-0.51	1.22e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4845875	0.504	rs198396	chr1:11881320	G/C	cg25341925	chr1:11908058	NPPA	-0.56	-4.53	-0.42	1.74e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs4654899	1.000	rs6426660	chr1:21361640	A/G	cg01072550	chr1:21505969	NA	-0.75	-6.82	-0.57	8.26e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs72781680	0.800	rs72790306	chr2:24111311	T/G	cg08917208	chr2:24149416	ATAD2B	1.09	4.95	0.45	3.16e-6	Lymphocyte counts;
THYM	cis	rs2115536	1.000	rs7163338	chr15:80198408	C/G	cg00225070	chr15:80189496	MTHFS	0.59	5.12	0.47	1.6e-6	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs4481887	0.927	rs4244173	chr1:248466899	G/C	cg00666640	chr1:248458726	OR2T12	0.58	4.71	0.44	8.39e-6	Common traits (Other);
THYM	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg01448562	chr3:133502909	NA	-0.96	-8.2	-0.64	1.11e-12	Iron status biomarkers;
THYM	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.84e-8	Systolic blood pressure;
THYM	cis	rs28595532	0.920	rs115688334	chr4:119770805	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs4646404	0.509	rs1531100	chr17:17464828	G/A	cg11245205	chr17:17398264	RASD1	-0.42	-4.82	-0.44	5.38e-6	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
THYM	cis	rs6076065	0.723	rs6137922	chr20:23363773	G/A	cg11657817	chr20:23433608	CST11	0.33	4.66	0.43	1.03e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs2797160	1.000	rs1777183	chr6:126011995	A/C	cg16306078	chr6:126000798	NA	0.54	5.47	0.49	3.72e-7	Endometrial cancer;
THYM	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg08132940	chr7:1081526	C7orf50	-1.25	-6.98	-0.58	3.96e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg20295408	chr7:1910781	MAD1L1	0.62	4.46	0.42	2.24e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs3741151	0.773	rs61345051	chr11:73112305	T/C	cg12959048	chr11:73096162	RELT	-0.53	-5.08	-0.46	1.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs4595586	0.545	rs4411311	chr12:39363612	C/G	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg24154853	chr7:158122151	PTPRN2	-0.52	-4.81	-0.44	5.6e-6	Calcium levels;
THYM	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg09263875	chr16:632152	PIGQ	0.68	5.84	0.51	7.28e-8	Height;
THYM	cis	rs4769475	1.000	rs4769475	chr13:26731714	T/A	cg13319468	chr13:27597730	NA	-0.6	-4.62	-0.43	1.2e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs6047844	0.569	rs6137550	chr20:22112235	C/A	cg16502866	chr20:23015624	SSTR4	-0.54	-4.6	-0.43	1.29e-5	Male-pattern baldness;
THYM	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs981844	1.000	rs55702511	chr4:154665978	A/C	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	trans	rs4866334	1.000	rs74720949	chr5:18503571	T/C	cg08675002	chr5:90437527	GPR98	-1.55	-7.42	-0.61	4.86e-11	IgG glycosylation;
THYM	cis	rs34734847	1.000	rs2948149	chr12:121162854	T/G	cg10600917	chr12:121163489	ACADS	0.55	4.93	0.45	3.53e-6	Mean corpuscular volume;
THYM	cis	rs4481887	0.888	rs4525076	chr1:248456876	T/G	cg00666640	chr1:248458726	OR2T12	0.56	4.61	0.43	1.26e-5	Common traits (Other);
THYM	cis	rs4295623	0.556	rs10903343	chr8:11695872	T/C	cg11009520	chr8:12052164	FAM86B1	-0.61	-4.46	-0.42	2.26e-5	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg27034606	chr17:28928453	LRRC37B2	0.76	5.06	0.46	2.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg17211192	chr8:82754475	SNX16	-0.88	-6.96	-0.58	4.3e-10	Diastolic blood pressure;
THYM	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg03806693	chr22:41940476	POLR3H	1.1	8.94	0.68	3.12e-14	Vitiligo;
THYM	cis	rs16912285	0.688	rs12805482	chr11:24346955	C/A	ch.11.24196551F	chr11:24239977	NA	0.87	5.88	0.52	5.96e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg12386194	chr3:101231763	SENP7	0.68	5.09	0.46	1.8e-6	Colorectal cancer;
THYM	cis	rs7209460	0.518	rs6503222	chr17:1977862	G/A	cg15816464	chr17:2026533	SMG6	0.37	4.8	0.44	5.94e-6	Coronary artery disease;Total body bone mineral density;
THYM	cis	rs490234	0.841	rs548793	chr9:128301931	C/T	cg14078157	chr9:128172775	NA	0.67	5.28	0.48	8.02e-7	Mean arterial pressure;
THYM	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg25817165	chr18:72167213	CNDP2	-0.98	-10.2	-0.72	6.18e-17	Refractive error;
THYM	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg13397359	chr6:42928475	GNMT	0.63	5.32	0.48	6.76e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9467711	0.651	rs55912630	chr6:25866935	T/C	cg16898833	chr6:26189333	HIST1H4D	1.33	4.6	0.43	1.32e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1345301	0.518	rs1558623	chr2:102862402	T/A	cg03938978	chr2:103052716	IL18RAP	-0.52	-4.91	-0.45	3.76e-6	Waist circumference;
THYM	cis	rs35883536	1.000	rs871151	chr1:101123737	G/A	cg06223162	chr1:101003688	GPR88	0.67	5.12	0.46	1.62e-6	Monocyte count;
THYM	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg09549813	chr16:4587862	C16orf5	-0.57	-5.35	-0.48	6e-7	Schizophrenia;
THYM	cis	rs713587	0.713	rs1982200	chr2:25205427	C/T	cg01884057	chr2:25150051	NA	-0.56	-5.49	-0.49	3.37e-7	Body mass index in non-asthmatics;
THYM	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg06074448	chr4:187884817	NA	-1.0	-13.81	-0.82	1.9e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg26513180	chr16:89883248	FANCA	-0.54	-5.15	-0.47	1.43e-6	Vitiligo;
THYM	cis	rs7312774	0.748	rs4964191	chr12:107306497	G/A	cg16260113	chr12:107380972	MTERFD3	0.97	5.54	0.49	2.71e-7	Severe influenza A (H1N1) infection;
THYM	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg00484396	chr16:3507460	NAT15	0.67	6.45	0.55	4.68e-9	Tuberculosis;
THYM	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg12386194	chr3:101231763	SENP7	0.94	7.62	0.62	1.85e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg00383909	chr3:49044727	WDR6	1.12	6.61	0.56	2.27e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg00801512	chr17:28996047	NA	-0.76	-4.9	-0.45	3.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9902453	0.967	rs12602258	chr17:28317657	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.81	0.44	5.74e-6	Coffee consumption (cups per day);
THYM	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	5.56	0.5	2.43e-7	Eosinophil percentage of white cells;
THYM	cis	rs10504073	0.669	rs341799	chr8:50036574	A/G	cg00325661	chr8:49890786	NA	0.78	7.03	0.59	3.11e-10	Blood metabolite ratios;
THYM	cis	rs6840360	0.548	rs4254751	chr4:152322571	C/T	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.22	-0.47	1.05e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg16586182	chr3:47516702	SCAP	-0.61	-5.16	-0.47	1.32e-6	Colorectal cancer;
THYM	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg00012203	chr2:219082015	ARPC2	-0.69	-5.87	-0.52	6.36e-8	Colorectal cancer;
THYM	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3096299	0.746	rs9931120	chr16:89501357	A/G	cg06640241	chr16:89574553	SPG7	0.77	6.61	0.56	2.21e-9	Multiple myeloma (IgH translocation);
THYM	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg03929089	chr4:120376271	NA	-1.01	-13.75	-0.82	2.5300000000000002e-24	Height;
THYM	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg26131816	chr17:42072204	PYY	0.53	4.6	0.43	1.28e-5	Menopause (age at onset);
THYM	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg26384229	chr12:38710491	ALG10B	1.08	10.82	0.74	2.94e-18	Heart rate;
THYM	cis	rs73086581	1.000	rs6107386	chr20:3972756	A/C	cg02187196	chr20:3869020	PANK2	0.5	5.62	0.5	1.92e-7	Response to antidepressants in depression;
THYM	cis	rs3796352	0.892	rs3821872	chr3:53080555	C/G	cg07884673	chr3:53033167	SFMBT1	-1.1	-6.18	-0.54	1.61e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs6430585	0.527	rs62168833	chr2:136449254	G/A	cg23851026	chr2:136556271	LCT	0.67	5.98	0.52	3.89e-8	Corneal structure;
THYM	cis	rs75804782	0.557	rs10178728	chr2:239360121	T/A	cg18131467	chr2:239335373	ASB1	-0.91	-5.32	-0.48	6.99e-7	Morning vs. evening chronotype;Chronotype;
THYM	cis	rs12444261	1.000	rs12444261	chr16:11734642	A/C	cg09662852	chr16:11707685	NA	0.5	4.65	0.43	1.07e-5	QT interval;
THYM	cis	rs72781680	0.821	rs17045981	chr2:24109316	A/G	cg08917208	chr2:24149416	ATAD2B	0.92	4.78	0.44	6.4e-6	Lymphocyte counts;
THYM	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg00484396	chr16:3507460	NAT15	0.66	6.44	0.55	4.97e-9	Tuberculosis;
THYM	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	10.62	0.74	7.85e-18	Chronic sinus infection;
THYM	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg06558623	chr16:89946397	TCF25	1.09	4.8	0.44	5.92e-6	Skin colour saturation;
THYM	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg21100191	chr22:23484243	RTDR1	-0.75	-6.66	-0.56	1.73e-9	Bone mineral density;
THYM	cis	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg09085632	chr11:111637200	PPP2R1B	1.22	13.43	0.81	1.13e-23	Primary sclerosing cholangitis;
THYM	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg25767906	chr1:53392781	SCP2	-0.64	-6.44	-0.55	4.84e-9	Monocyte count;
THYM	cis	rs9928842	0.722	rs1035540	chr16:75278795	A/G	cg09066997	chr16:75300724	BCAR1	0.7	4.53	0.42	1.72e-5	Alcoholic chronic pancreatitis;
THYM	cis	rs10924970	0.967	rs10754589	chr1:235439755	T/C	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg27196691	chr11:105947405	KBTBD3;AASDHPPT	-0.95	-7.09	-0.59	2.4e-10	Energy expenditure (24h);
THYM	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg14515187	chr3:190284901	IL1RAP	-0.74	-4.92	-0.45	3.65e-6	Lung adenocarcinoma;
THYM	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg27129171	chr3:47204927	SETD2	0.69	6.63	0.56	2.04e-9	Colorectal cancer;
THYM	cis	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg24308560	chr3:49941425	MST1R	0.64	5.54	0.49	2.73e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg13852791	chr20:30311386	BCL2L1	0.83	6.43	0.55	5.21e-9	Mean corpuscular hemoglobin;
THYM	cis	rs2777491	1.000	rs316609	chr15:41743828	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.12	-12.55	-0.79	6.92e-22	Ulcerative colitis;
THYM	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg03929089	chr4:120376271	NA	-0.97	-7.63	-0.62	1.81e-11	Coronary artery disease;
THYM	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg18681998	chr4:17616180	MED28	0.86	7.79	0.62	8.27e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg24531977	chr5:56204891	C5orf35	-1.01	-8.5	-0.66	2.63e-13	Initial pursuit acceleration;
THYM	cis	rs887829	0.569	rs871514	chr2:234628529	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.7	-5.61	-0.5	2e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg26818010	chr10:134567672	INPP5A	-0.78	-6.25	-0.54	1.18e-8	Migraine;
THYM	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg10802521	chr3:52805072	NEK4	-0.71	-6.1	-0.53	2.27e-8	Bipolar disorder;
THYM	cis	rs17006441	0.932	rs1430608	chr3:69859692	C/T	cg18496212	chr3:69797108	MITF	0.65	6.27	0.54	1.08e-8	Hemoglobin concentration;
THYM	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg15242686	chr22:24348715	GSTTP1	0.55	5.14	0.47	1.45e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7152530	0.571	rs1461584	chr14:98637996	A/G	cg05180522	chr14:98101740	NA	-0.59	-4.7	-0.43	8.79e-6	Staphylococcus aureus infection;
THYM	cis	rs4731207	0.596	rs6466971	chr7:124596007	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg01831904	chr17:28903510	LRRC37B2	-1.13	-5.5	-0.49	3.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs56322409	0.561	rs12780161	chr10:97367199	T/C	cg00110277	chr10:97668174	C10orf131	-0.58	-4.91	-0.45	3.72e-6	Blood metabolite levels;
THYM	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg00990874	chr7:1149470	C7orf50	-0.61	-4.82	-0.44	5.35e-6	Bronchopulmonary dysplasia;
THYM	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	4.68	0.43	9.45e-6	Aortic root size;
THYM	cis	rs7178572	0.568	rs7167794	chr15:77635875	T/C	cg22256960	chr15:77711686	NA	-1.04	-8.25	-0.65	9.01e-13	Type 2 diabetes;
THYM	cis	rs7106204	0.514	rs1596280	chr11:24250853	T/C	ch.11.24196551F	chr11:24239977	NA	1.03	7.21	0.59	1.36e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg27286337	chr10:134555280	INPP5A	0.85	6.47	0.55	4.17e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg00801512	chr17:28996047	NA	-0.76	-4.9	-0.45	3.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs34638657	0.732	rs62045964	chr16:82200920	T/C	cg09439754	chr16:82129088	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg08999081	chr20:33150536	PIGU	0.78	7.17	0.59	1.64e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg17178900	chr1:205818956	PM20D1	0.96	9.99	0.72	1.71e-16	Menarche (age at onset);
THYM	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg27129171	chr3:47204927	SETD2	0.78	7.67	0.62	1.47e-11	Colorectal cancer;
THYM	cis	rs2282300	0.696	rs12578061	chr11:30249365	T/A	cg09906309	chr11:30344399	C11orf46	-0.72	-5.34	-0.48	6.24e-7	Morning vs. evening chronotype;
THYM	cis	rs9790314	0.905	rs7611367	chr3:161003182	A/G	cg04691961	chr3:161091175	C3orf57	0.55	4.61	0.43	1.26e-5	Morning vs. evening chronotype;
THYM	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg19761014	chr17:28927070	LRRC37B2	-0.83	-4.91	-0.45	3.8e-6	Body mass index;
THYM	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.43	1.27e-5	Breast cancer;
THYM	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg22307029	chr19:49891270	CCDC155	0.58	5.43	0.49	4.24e-7	Multiple sclerosis;
THYM	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg13385794	chr1:248469461	NA	0.67	4.6	0.43	1.29e-5	Common traits (Other);
THYM	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg21970626	chr13:21893289	NA	-0.69	-6.1	-0.53	2.23e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs3960554	0.808	rs60481386	chr7:75700962	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-4.78	-0.44	6.28e-6	Eotaxin levels;
THYM	cis	rs2985684	0.895	rs4900940	chr14:50075310	A/C	cg02151108	chr14:50098012	C14orf104	-0.67	-5.39	-0.48	5.14e-7	Carotid intima media thickness;
THYM	cis	rs28595532	0.920	rs116149978	chr4:119761069	A/C	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs6754311	0.517	rs1865452	chr2:136539330	C/T	cg23851026	chr2:136556271	LCT	0.64	5.85	0.51	6.99e-8	Mosquito bite size;
THYM	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg27129171	chr3:47204927	SETD2	-0.71	-6.35	-0.55	7.38e-9	Colorectal cancer;
THYM	cis	rs2734839	0.964	rs4938017	chr11:113303929	C/T	cg14159747	chr11:113255604	NA	-0.31	-6.1	-0.53	2.25e-8	Information processing speed;
THYM	cis	rs8112449	0.861	rs34266232	chr19:10502968	T/C	cg01466491	chr19:10523363	NA	-0.7	-6.25	-0.54	1.17e-8	Multiple sclerosis;Gastritis;
THYM	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg18904891	chr8:8559673	CLDN23	0.72	5.37	0.48	5.56e-7	Obesity-related traits;
THYM	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg24579218	chr15:68104479	NA	-0.77	-7.2	-0.59	1.43e-10	Restless legs syndrome;
THYM	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg09359103	chr1:154839909	KCNN3	-0.81	-10.3	-0.73	3.79e-17	Prostate cancer;
THYM	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg17480646	chr11:65405466	SIPA1	0.7	6.27	0.54	1.07e-8	Acne (severe);
THYM	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg03264133	chr6:25882463	NA	0.74	5.71	0.51	1.3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg15693483	chr7:1102177	C7orf50	0.4	5.82	0.51	8.07e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg08885076	chr2:99613938	TSGA10	-0.64	-5.53	-0.49	2.86e-7	Chronic sinus infection;
THYM	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg08999081	chr20:33150536	PIGU	-0.78	-7.16	-0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	trans	rs9951602	0.512	rs4799245	chr18:76653397	T/C	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	trans	rs629535	0.590	rs62513426	chr8:70136843	T/G	cg21567404	chr3:27674614	NA	-0.88	-7.0	-0.58	3.66e-10	Dupuytren's disease;
THYM	cis	rs9403317	0.919	rs9373311	chr6:141804925	G/A	cg15052665	chr6:141804349	NA	0.81	7.95	0.63	3.86e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2963155	0.518	rs853177	chr5:142635460	A/G	cg17617527	chr5:142782415	NR3C1	1.2	6.6	0.56	2.37e-9	Breast cancer;
THYM	cis	rs807669	1.000	rs807669	chr22:19154522	T/C	cg02655711	chr22:19163373	SLC25A1	0.93	10.74	0.74	4.45e-18	Metabolite levels;
THYM	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs80319144	1.000	rs6711808	chr2:159267928	A/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs7487075	0.790	rs4074773	chr12:46919181	C/T	cg17501823	chr12:47219793	SLC38A4	-0.51	-4.73	-0.44	7.85e-6	Itch intensity from mosquito bite;
THYM	cis	rs427394	0.735	rs416689	chr5:6740855	C/T	cg10857441	chr5:6722123	POLS	-0.73	-8.88	-0.67	4.02e-14	Menopause (age at onset);
THYM	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.53	4.93	0.45	3.49e-6	Lymphocyte counts;
THYM	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg06634786	chr22:41940651	POLR3H	0.64	4.97	0.45	2.91e-6	Vitiligo;
THYM	cis	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg18252515	chr7:66147081	NA	0.69	5.23	0.47	1.01e-6	Aortic root size;
THYM	trans	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg18335740	chr13:41363409	SLC25A15	0.69	7.27	0.6	1.02e-10	Lewy body disease;
THYM	cis	rs11711311	1.000	rs6792447	chr3:113508335	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.62	-5.52	-0.49	2.89e-7	IgG glycosylation;
THYM	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.8	-5.44	-0.49	4.14e-7	Body mass index;
THYM	cis	rs9467711	0.591	rs13206501	chr6:26110148	T/C	cg01386294	chr6:25732093	NA	0.9	4.88	0.45	4.34e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg04750100	chr2:136595281	LCT	0.56	6.13	0.53	1.97e-8	Mosquito bite size;
THYM	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg13395646	chr4:1353034	KIAA1530	-0.62	-6.0	-0.52	3.57e-8	Longevity;
THYM	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	9.51	0.7	1.8e-15	Platelet count;
THYM	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg00981070	chr1:2046702	PRKCZ	-0.43	-5.49	-0.49	3.27e-7	Height;
THYM	cis	rs7222240	0.951	rs7220212	chr17:43100566	C/G	cg19407385	chr17:43099144	NA	0.63	4.46	0.42	2.21e-5	Craniofacial microsomia;
THYM	cis	rs6450176	0.904	rs6889847	chr5:53303452	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.14	-0.53	1.94e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg16068833	chr1:26644515	UBXN11;CD52	0.26	4.5	0.42	1.9e-5	Obesity-related traits;
THYM	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg09034736	chr1:150693464	HORMAD1	-0.51	-4.49	-0.42	1.98e-5	Tonsillectomy;
THYM	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg04772025	chr11:68637568	NA	0.65	6.95	0.58	4.61e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg06634786	chr22:41940651	POLR3H	-0.66	-4.8	-0.44	5.78e-6	Vitiligo;
THYM	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg19746536	chr19:49375674	PPP1R15A	0.81	4.59	0.43	1.34e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	4.66	0.43	1.04e-5	Diabetic retinopathy;
THYM	cis	rs10492096	0.945	rs1045546	chr12:6567907	C/T	cg13857086	chr12:6580257	VAMP1	0.89	5.4	0.48	5.01e-7	Hip geometry;
THYM	trans	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg17712092	chr4:129076599	LARP1B	1.12	12.55	0.79	6.88e-22	Eosinophil percentage of white cells;
THYM	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.88	0.63	5.43e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs524023	0.958	rs2021860	chr11:64361384	G/T	cg19131476	chr11:64387923	NRXN2	-0.36	-4.93	-0.45	3.53e-6	Urate levels in obese individuals;
THYM	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg02527881	chr3:46936655	PTH1R	0.6	5.69	0.5	1.42e-7	Colorectal cancer;
THYM	cis	rs988913	0.957	rs9382396	chr6:54760686	G/T	cg19716238	chr6:54711378	FAM83B	0.49	5.04	0.46	2.24e-6	Menarche (age at onset);
THYM	cis	rs67311347	0.568	rs57287242	chr3:40335538	T/C	cg24209194	chr3:40518798	ZNF619	0.55	4.6	0.43	1.29e-5	Renal cell carcinoma;
THYM	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg17757837	chr7:157058334	UBE3C	0.65	5.22	0.47	1.05e-6	Body mass index;
THYM	cis	rs2235573	0.570	rs5995529	chr22:38415721	A/G	cg19171272	chr22:38449367	NA	0.49	4.86	0.45	4.58e-6	Glioblastoma;Glioma;
THYM	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs2692947	0.702	rs6717101	chr2:96505552	C/T	cg22654517	chr2:96458247	NA	0.6	4.48	0.42	2.09e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg00278517	chr6:167070616	RPS6KA2	-0.37	-5.23	-0.47	1.02e-6	Crohn's disease;
THYM	cis	rs1451375	0.583	rs3807555	chr7:50610569	A/G	cg18232548	chr7:50535776	DDC	0.65	4.78	0.44	6.34e-6	Malaria;
THYM	cis	rs7719624	0.545	rs12521108	chr5:135409124	G/A	cg15329133	chr5:135467951	SMAD5;SMAD5OS	-0.54	-4.71	-0.43	8.58e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs995000	0.965	rs1179765	chr1:63010110	G/C	cg06896770	chr1:63153194	DOCK7	-0.89	-7.31	-0.6	8.2e-11	Triglyceride levels;
THYM	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg14004847	chr7:1930337	MAD1L1	-0.67	-5.61	-0.5	1.96e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg16778714	chr17:28903809	LRRC37B2	-0.76	-4.49	-0.42	2.03e-5	Body mass index;
THYM	cis	rs10499694	0.933	rs12718583	chr7:50582631	T/C	cg00647317	chr7:50633725	DDC	0.3	4.56	0.42	1.52e-5	Body mass index;
THYM	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg12573674	chr2:1569213	NA	-1.16	-8.07	-0.64	2.18e-12	IgG glycosylation;
THYM	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.72	5.44	0.49	4.19e-7	Glycated hemoglobin levels;
THYM	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg26149184	chr10:133730230	NA	0.75	4.84	0.44	4.96e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-5.74	-0.51	1.15e-7	Total cholesterol levels;
THYM	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg06634786	chr22:41940651	POLR3H	-0.7	-5.38	-0.48	5.4e-7	Vitiligo;
THYM	cis	rs9915657	0.773	rs9896360	chr17:70099469	C/G	cg06234051	chr17:70120541	SOX9	-0.6	-5.56	-0.5	2.44e-7	Thyroid hormone levels;
THYM	cis	rs5769707	0.632	rs6009782	chr22:50010812	C/G	cg20744362	chr22:50050164	C22orf34	0.8	6.98	0.58	4.01e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7828089	0.582	rs13259873	chr8:22266292	C/T	cg13512537	chr8:22265999	SLC39A14	-0.67	-5.57	-0.5	2.39e-7	Verbal declarative memory;
THYM	cis	rs72627123	0.867	rs72627111	chr14:74329781	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg23205692	chr1:25664452	TMEM50A	0.82	6.43	0.55	5.08e-9	Erythrocyte sedimentation rate;
THYM	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg26441486	chr22:50317300	CRELD2	-0.42	-6.6	-0.56	2.38e-9	Schizophrenia;
THYM	cis	rs12367572	0.663	rs1224436	chr12:45400397	C/T	cg03114573	chr12:45410052	DBX2	-0.56	-5.49	-0.49	3.39e-7	Gut microbiome composition (summer);
THYM	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs9403317	0.919	rs11155185	chr6:141806003	C/T	cg15052665	chr6:141804349	NA	0.75	6.88	0.58	6.33e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.63	4.46	0.42	2.25e-5	Aortic root size;
THYM	cis	rs2859741	0.546	rs2102087	chr1:37482849	G/A	cg09363841	chr1:37513479	NA	-0.66	-5.21	-0.47	1.1e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.02	-9.68	-0.7	8.14e-16	Primary sclerosing cholangitis;
THYM	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03452623	chr4:187889614	NA	-1.17	-20.04	-0.9	6.92e-36	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg27398817	chr8:82754497	SNX16	-0.83	-6.57	-0.56	2.65e-9	Diastolic blood pressure;
THYM	cis	rs989978	0.532	rs10883364	chr10:101287586	A/G	cg23904955	chr10:101282759	NA	-0.42	-4.97	-0.45	2.99e-6	Red blood cell count;
THYM	cis	rs6785206	0.772	rs6439134	chr3:128323504	C/T	cg16766828	chr3:128327626	NA	-0.74	-7.2	-0.59	1.41e-10	Lymphocyte percentage of white cells;
THYM	cis	rs1371867	0.817	rs7846076	chr8:101327629	A/G	cg06636551	chr8:101224915	SPAG1	-0.61	-6.13	-0.53	2.01e-8	Atrioventricular conduction;
THYM	cis	rs4803468	1.000	rs9304593	chr19:41942875	A/C	cg09537434	chr19:41945824	ATP5SL	1.09	10.16	0.72	7.58e-17	Height;
THYM	cis	rs4907240	0.961	rs7580048	chr2:97304180	G/C	cg18419276	chr2:96971862	SNRNP200	-0.4	-4.67	-0.43	9.99e-6	Event-related brain oscillations;
THYM	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg01324343	chr3:183735012	ABCC5	0.9	13.47	0.81	9.06e-24	Anterior chamber depth;
THYM	cis	rs1978968	1.000	rs11704059	chr22:18449543	A/G	cg01550578	chr22:18484421	MICAL3	0.7	5.22	0.47	1.06e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg23428387	chr22:49814324	NA	-0.58	-5.49	-0.49	3.39e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.1	-0.46	1.7e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg04414720	chr1:150670196	GOLPH3L	0.62	4.71	0.44	8.35e-6	Tonsillectomy;
THYM	cis	rs6840360	1.000	rs3749563	chr4:152596508	T/C	cg22705602	chr4:152727874	NA	-0.61	-6.56	-0.56	2.8e-9	Intelligence (multi-trait analysis);
THYM	cis	rs4940575	0.786	rs66836460	chr18:60837508	C/A	cg20947866	chr18:61143580	SERPINB5	0.9	5.34	0.48	6.28e-7	Breast cancer;
THYM	cis	rs1455213	0.544	rs6449106	chr4:15170652	T/C	cg12377275	chr4:15005593	CPEB2	0.54	4.49	0.42	2.02e-5	Parental longevity (mother's age at death);
THYM	trans	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg10856724	chr12:34555212	NA	-1.01	-9.21	-0.69	7.89e-15	Bladder cancer;
THYM	cis	rs208520	0.661	rs207079	chr6:66770462	C/T	cg07460842	chr6:66804631	NA	-1.1	-7.47	-0.61	3.91e-11	Exhaled nitric oxide output;
THYM	cis	rs1003719	0.715	rs7282195	chr21:38508619	C/T	cg01329690	chr21:38580129	DSCR9	-0.38	-5.21	-0.47	1.09e-6	Eye color traits;
THYM	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg00495681	chr13:53174319	NA	0.88	8.75	0.67	7.63e-14	Lewy body disease;
THYM	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg26384229	chr12:38710491	ALG10B	-0.93	-7.72	-0.62	1.16e-11	Bladder cancer;
THYM	cis	rs17253792	0.822	rs77033617	chr14:56129746	T/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs9876781	1.000	rs6784322	chr3:48422235	A/T	cg06066452	chr3:48470258	PLXNB1	0.29	5.13	0.47	1.55e-6	Longevity;
THYM	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.79	-6.44	-0.55	4.84e-9	Chronic sinus infection;
THYM	cis	rs7727544	0.557	rs715285	chr5:131485383	A/G	cg16205897	chr5:131564050	P4HA2	-0.46	-4.74	-0.44	7.53e-6	Blood metabolite levels;
THYM	cis	rs1691799	0.899	rs1168327	chr12:66728842	G/A	cg16791601	chr12:66731901	HELB	-0.76	-7.33	-0.6	7.6e-11	White blood cell count (basophil);
THYM	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg00074818	chr8:8560427	CLDN23	-0.59	-5.51	-0.49	3.05e-7	Obesity-related traits;
THYM	cis	rs829883	0.616	rs249832	chr12:98832387	C/T	cg25150519	chr12:98850993	NA	0.53	5.22	0.47	1.05e-6	Colorectal adenoma (advanced);
THYM	cis	rs2997447	0.761	rs17257093	chr1:26436231	C/A	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs929354	0.566	rs6979947	chr7:157005863	C/T	cg05182265	chr7:156933206	UBE3C	0.61	6.56	0.56	2.8e-9	Body mass index;
THYM	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg27170947	chr2:26402098	FAM59B	0.83	4.96	0.45	3.14e-6	Gut microbiome composition (summer);
THYM	cis	rs6032067	0.925	rs13042522	chr20:43829290	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.66	-5.91	-0.52	5.22e-8	Blood protein levels;
THYM	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg12963246	chr6:28129442	ZNF389	0.77	6.4	0.55	5.74e-9	Parkinson's disease;
THYM	cis	rs1331623	1.000	rs6478404	chr9:122199508	A/G	cg25935911	chr9:122132261	DBC1	0.53	4.83	0.44	5.16e-6	Height;
THYM	cis	rs3892630	0.588	rs2112917	chr19:33317543	C/T	cg22980127	chr19:33182716	NUDT19	1.14	10.63	0.74	7.48e-18	Red blood cell traits;
THYM	cis	rs4690686	0.500	rs72623908	chr4:177261971	A/G	cg17059388	chr4:177262070	NA	0.48	6.73	0.57	1.29e-9	Essential tremor;
THYM	cis	rs9790314	0.690	rs1599390	chr3:160833246	A/G	cg03342759	chr3:160939853	NMD3	-0.6	-4.47	-0.42	2.18e-5	Morning vs. evening chronotype;
THYM	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg23161317	chr6:28129485	ZNF389	0.74	4.9	0.45	3.94e-6	Parkinson's disease;
THYM	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg12419862	chr22:24373484	LOC391322	-0.85	-9.8	-0.71	4.34e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6435161	1.000	rs72926986	chr2:203519264	G/T	cg18429434	chr2:203499731	FAM117B	-0.76	-5.01	-0.46	2.49e-6	Total cholesterol levels;
THYM	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg10589385	chr1:150898437	SETDB1	0.57	4.55	0.42	1.56e-5	Melanoma;
THYM	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg26384229	chr12:38710491	ALG10B	-0.74	-5.81	-0.51	8.33e-8	Bladder cancer;
THYM	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg26752003	chr8:145688521	CYHR1	0.98	8.4	0.65	4.21e-13	Age at first birth;
THYM	cis	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs2637266	1.000	rs1077916	chr10:78381951	G/A	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	trans	rs8002861	0.967	rs7984393	chr13:44484361	T/C	cg17145862	chr1:211918768	LPGAT1	0.99	11.5	0.76	1.07e-19	Leprosy;
THYM	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs889398	0.802	rs9940315	chr16:69876164	A/G	cg09409435	chr16:70099608	PDXDC2	0.66	5.34	0.48	6.36e-7	Body mass index;
THYM	cis	rs7719624	0.967	rs55821461	chr5:135362720	C/T	cg15329133	chr5:135467951	SMAD5;SMAD5OS	0.53	4.49	0.42	1.97e-5	Response to cytidine analogues (gemcitabine);
THYM	cis	rs1451375	0.698	rs11489736	chr7:50645372	G/A	cg18232548	chr7:50535776	DDC	0.69	5.35	0.48	6.03e-7	Malaria;
THYM	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg22535103	chr8:58192502	C8orf71	-0.98	-5.84	-0.51	7.38e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs684232	0.623	rs391002	chr17:535441	T/G	cg15660573	chr17:549704	VPS53	-1.0	-11.2	-0.75	4.65e-19	Prostate cancer;
THYM	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg03859395	chr2:55845619	SMEK2	0.65	6.04	0.53	3.03e-8	Metabolic syndrome;
THYM	cis	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.29	-0.54	9.48e-9	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg13695892	chr22:41940480	POLR3H	-0.78	-6.14	-0.53	1.88e-8	Vitiligo;
THYM	cis	rs748404	0.660	rs2249952	chr15:43720533	G/C	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg17143192	chr8:8559678	CLDN23	0.63	4.78	0.44	6.51e-6	Mood instability;
THYM	cis	rs3126085	0.877	rs4456097	chr1:152229741	G/A	cg10321714	chr1:152280068	FLG	0.64	4.81	0.44	5.57e-6	Atopic dermatitis;
THYM	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs6584283	0.875	rs10748783	chr10:101285872	C/A	cg23904955	chr10:101282759	NA	-0.36	-4.61	-0.43	1.28e-5	Ulcerative colitis;
THYM	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg10117171	chr1:25599238	RHD	-0.67	-4.92	-0.45	3.58e-6	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs4281086	0.582	rs4543507	chr8:10354324	T/C	cg02525722	chr8:10404760	NA	0.54	4.54	0.42	1.68e-5	Obesity-related traits;
THYM	cis	rs1061377	0.932	rs35464499	chr4:39129290	A/G	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg13319975	chr6:146136371	FBXO30	0.65	5.26	0.48	8.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4919694	1.000	rs4917379	chr10:104752831	A/T	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs2811415	0.597	rs13094572	chr3:127772785	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs8050907	0.744	rs8047271	chr16:4536634	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.25	4.73	0.44	7.82e-6	Obesity-related traits;
THYM	cis	rs12216545	0.765	rs4607525	chr7:150229350	A/T	cg00323915	chr7:150264987	GIMAP4	-0.49	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs2294693	0.947	rs9369254	chr6:40989408	T/C	cg14769373	chr6:40998127	UNC5CL	-0.62	-4.93	-0.45	3.47e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs2882667	0.628	rs13171173	chr5:138042464	A/C	cg09476006	chr5:138032270	NA	-0.55	-4.45	-0.42	2.32e-5	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs10743315	0.643	rs75189071	chr12:19329505	C/T	cg02471346	chr12:19282374	PLEKHA5	1.17	4.86	0.45	4.65e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs6500395	0.962	rs1386042	chr16:48600332	G/A	cg04672837	chr16:48644449	N4BP1	0.48	4.58	0.43	1.39e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2073300	0.609	rs1936011	chr20:23341912	G/C	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg03676636	chr4:99064102	C4orf37	0.43	6.32	0.54	8.55e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg23958373	chr8:599963	NA	0.9	4.59	0.43	1.34e-5	IgG glycosylation;
THYM	cis	rs7560272	0.723	rs7585119	chr2:73724679	A/T	cg19565262	chr2:73869966	NAT8	-0.55	-4.68	-0.43	9.33e-6	Schizophrenia;
THYM	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg23711669	chr6:146136114	FBXO30	0.85	8.24	0.65	9.39e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg13114125	chr14:105738426	BRF1	-0.73	-5.68	-0.5	1.47e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg00898013	chr13:113819073	PROZ	-0.87	-8.78	-0.67	6.82e-14	Platelet distribution width;
THYM	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg22968622	chr17:43663579	NA	1.14	10.29	0.73	4.02e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4919044	0.808	rs1238178	chr10:94804043	G/A	cg05127821	chr10:94822908	CYP26C1	-1.23	-6.66	-0.56	1.76e-9	Coronary artery disease;
THYM	cis	rs28785552	0.800	rs1971063	chr19:53232854	G/C	cg10871876	chr19:53194124	ZNF83	0.74	6.24	0.54	1.22e-8	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg12373951	chr3:133503437	NA	0.56	6.17	0.53	1.69e-8	Iron status biomarkers;
THYM	cis	rs4803468	1.000	rs17318666	chr19:41940342	T/G	cg09537434	chr19:41945824	ATP5SL	1.02	8.94	0.68	3.1e-14	Height;
THYM	cis	rs9905704	0.918	rs694720	chr17:56708019	T/C	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.7e-6	Testicular germ cell tumor;
THYM	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.82	-4.55	-0.42	1.56e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs919433	0.617	rs700643	chr2:198601370	A/G	cg05783139	chr2:198650985	BOLL	0.6	4.73	0.44	7.81e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg14829155	chr15:31115871	NA	0.75	6.38	0.55	6.46e-9	Huntington's disease progression;
THYM	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs9796	0.689	rs72737758	chr15:41449778	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.6	-4.64	-0.43	1.13e-5	Menopause (age at onset);
THYM	cis	rs4474465	1.000	rs4945281	chr11:78188627	C/G	cg02023728	chr11:77925099	USP35	0.52	4.5	0.42	1.95e-5	Alzheimer's disease (survival time);
THYM	cis	rs755383	0.604	rs7021646	chr9:860004	C/T	cg14021170	chr9:826657	NA	0.44	4.99	0.46	2.72e-6	Testicular germ cell tumor;Testicular germ cell cancer;Testicular cancer;
THYM	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg07424592	chr7:64974309	NA	-1.04	-4.78	-0.44	6.31e-6	Diabetic kidney disease;
THYM	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg05373962	chr22:49881684	NA	-0.66	-6.77	-0.57	1.07e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg08807101	chr21:30365312	RNF160	-0.81	-6.26	-0.54	1.1e-8	Dental caries;
THYM	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg14008862	chr17:28927542	LRRC37B2	0.94	5.08	0.46	1.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10089	1.000	rs1559263	chr5:127512873	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	5.46	0.49	3.81e-7	Ileal carcinoids;
THYM	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg03929089	chr4:120376271	NA	0.97	10.53	0.73	1.25e-17	Coronary artery disease;
THYM	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg03609598	chr5:56110824	MAP3K1	0.68	5.26	0.47	8.89e-7	Type 2 diabetes;
THYM	cis	rs4474465	0.850	rs4944203	chr11:78220629	A/C	cg19901956	chr11:77921274	USP35	0.66	4.84	0.44	4.99e-6	Alzheimer's disease (survival time);
THYM	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs12257961	0.522	rs10737097	chr10:15398464	G/C	cg10616319	chr10:15468812	NA	-0.54	-4.63	-0.43	1.17e-5	Selective IgA deficiency;
THYM	cis	rs977987	0.806	rs4993969	chr16:75411521	A/T	cg03315344	chr16:75512273	CHST6	0.71	6.13	0.53	1.96e-8	Dupuytren's disease;
THYM	cis	rs7769051	0.711	rs6569847	chr6:133083187	C/A	cg07930552	chr6:133119739	C6orf192	1.03	5.56	0.5	2.5e-7	Type 2 diabetes nephropathy;
THYM	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg10589385	chr1:150898437	SETDB1	0.64	5.4	0.48	4.9e-7	Melanoma;
THYM	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1878931	0.582	rs27238	chr16:3441223	G/A	cg22508957	chr16:3507546	NAT15	0.48	4.92	0.45	3.56e-6	Body mass index (adult);
THYM	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg00024416	chr22:24240387	NA	-0.81	-7.35	-0.6	6.85e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg01097406	chr16:89675127	NA	0.8	7.15	0.59	1.81e-10	Vitiligo;
THYM	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.6	-0.5	2.08e-7	Type 2 diabetes;
THYM	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg02734326	chr4:10020555	SLC2A9	0.77	7.16	0.59	1.73e-10	Bone mineral density;
THYM	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg05043794	chr9:111880884	C9orf5	-0.42	-6.16	-0.53	1.78e-8	Menarche (age at onset);
THYM	cis	rs4986172	0.700	rs71373536	chr17:43221808	G/A	cg00677574	chr17:43221327	ACBD4	0.67	5.39	0.48	5.2e-7	Height;
THYM	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs12765878	0.603	rs1570221	chr10:105656874	G/A	cg11005552	chr10:105648138	OBFC1	-0.52	-4.54	-0.42	1.67e-5	Coronary artery disease;
THYM	cis	rs7084402	1.000	rs12257983	chr10:60266555	A/C	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg17796960	chr10:135278976	LOC619207	-0.54	-4.52	-0.42	1.78e-5	Systemic lupus erythematosus;
THYM	cis	rs2754412	1	rs2754412	chr10:38627834	A/G	cg25951256	chr10:38645740	HSD17B7P2	-0.54	-4.55	-0.42	1.57e-5	Breast cancer;
THYM	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg10515332	chr4:99064459	C4orf37	0.6	4.77	0.44	6.7e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	4.86	0.45	4.63e-6	Obesity-related traits;
THYM	cis	rs240764	0.635	rs2071826	chr6:100928357	G/A	cg21058520	chr6:100914733	NA	0.58	4.75	0.44	7.15e-6	Neuroticism;
THYM	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg19626725	chr5:178986131	RUFY1	-0.31	-4.91	-0.45	3.74e-6	Lung cancer;
THYM	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.86	8.56	0.66	1.92e-13	Prudent dietary pattern;
THYM	cis	rs10431058	1.000	rs35005608	chr11:107478873	G/T	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.73	5.39	0.48	5.03e-7	Common traits (Other);
THYM	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs1942	0.813	rs11070327	chr15:41602866	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.68	-5.5	-0.49	3.15e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.67	4.76	0.44	6.93e-6	Aortic root size;
THYM	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06634786	chr22:41940651	POLR3H	-0.76	-5.54	-0.49	2.73e-7	Vitiligo;
THYM	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs3812049	0.784	rs2250127	chr5:127388844	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.7	-4.9	-0.45	3.87e-6	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs9635324	0.516	rs7165012	chr15:40654038	C/T	cg12699599	chr15:40643142	PHGR1	0.47	4.61	0.43	1.26e-5	Blood metabolite ratios;Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg18252515	chr7:66147081	NA	-1.44	-8.51	-0.66	2.48e-13	Diabetic kidney disease;
THYM	cis	rs7078219	0.523	rs4129134	chr10:101284345	C/G	cg04972745	chr10:101287846	NA	-0.5	-4.65	-0.43	1.09e-5	Dental caries;
THYM	cis	rs58235267	0.591	rs4671457	chr2:63346356	C/T	cg17519650	chr2:63277830	OTX1	0.61	4.89	0.45	4.08e-6	Prostate-specific antigen levels (conditioned on lead SNPs);
THYM	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9314614	0.901	rs2978902	chr8:6690173	C/G	cg27319216	chr8:6693540	XKR5	0.71	8.42	0.65	3.95e-13	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs7580658	0.534	rs2089109	chr2:127951458	G/A	cg10021288	chr2:128175891	PROC	-0.53	-4.49	-0.42	1.99e-5	Protein C levels;
THYM	cis	rs250585	0.850	rs4968016	chr16:23530089	T/C	cg00143387	chr16:23521605	GGA2	-0.72	-4.58	-0.42	1.43e-5	Egg allergy;
THYM	cis	rs6906287	0.631	rs9320665	chr6:118986309	G/A	cg21191810	chr6:118973309	C6orf204	0.64	6.78	0.57	1.03e-9	Electrocardiographic conduction measures;
THYM	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg15557168	chr22:42548783	NA	0.58	4.68	0.43	9.66e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg13695892	chr22:41940480	POLR3H	0.9	7.31	0.6	8.34e-11	Vitiligo;
THYM	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg14129053	chr2:1895732	MYT1L	1.13	4.49	0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs8133932	0.736	rs2839020	chr21:47280001	A/G	cg08707771	chr21:46690014	POFUT2	-0.76	-4.62	-0.43	1.22e-5	Schizophrenia;
THYM	cis	rs11186	0.556	rs72906337	chr2:189959204	G/A	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs960902	0.592	rs6753503	chr2:37736167	T/C	cg25341268	chr2:37734390	NA	-0.7	-6.49	-0.55	3.92e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg06238570	chr21:40685208	BRWD1	0.91	6.77	0.57	1.08e-9	Cognitive function;
THYM	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4595586	0.525	rs7970652	chr12:39374873	T/C	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg05335186	chr13:53173507	NA	-0.47	-6.04	-0.53	2.96e-8	Lewy body disease;
THYM	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg11871910	chr12:69753446	YEATS4	1.01	9.83	0.71	3.8e-16	Cerebrospinal fluid biomarker levels;
THYM	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg06808227	chr14:105710500	BRF1	-1.08	-9.65	-0.7	9.45e-16	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg21028142	chr17:79581711	NPLOC4	0.64	6.74	0.57	1.23e-9	Eye color traits;
THYM	cis	rs654950	0.653	rs2810568	chr1:42054247	A/G	cg06885757	chr1:42089581	HIVEP3	-0.64	-8.37	-0.65	4.91e-13	Airway imaging phenotypes;
THYM	cis	rs11031096	0.711	rs4910890	chr11:4153407	C/T	cg08557956	chr11:4115526	RRM1	-0.5	-4.9	-0.45	3.94e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg06728252	chr6:26598149	ABT1	-0.43	-5.08	-0.46	1.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13177918	0.557	rs12520101	chr5:149810923	C/T	cg14059543	chr5:149831962	NA	-0.96	-7.45	-0.61	4.33e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg07937631	chr13:79184529	NA	-0.66	-4.94	-0.45	3.35e-6	Large artery stroke;
THYM	cis	rs9832461	0.741	rs7632048	chr3:39801185	A/G	cg21490179	chr3:40494492	NA	0.86	4.52	0.42	1.8e-5	Brain structure (temporal lobe volume);
THYM	cis	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg19624444	chr7:2048497	MAD1L1	-0.57	-4.63	-0.43	1.16e-5	Bipolar disorder;
THYM	cis	rs4557020	0.935	rs6545410	chr2:54711543	G/A	cg11007406	chr2:54682859	SPTBN1	-0.37	-4.64	-0.43	1.11e-5	Myopia (pathological);
THYM	cis	rs3741151	0.773	rs11820577	chr11:73261424	C/G	cg17517138	chr11:73019481	ARHGEF17	0.9	4.68	0.43	9.36e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg27534772	chr1:16042836	PLEKHM2	0.56	6.31	0.54	8.77e-9	Systolic blood pressure;
THYM	cis	rs4638749	0.677	rs6755598	chr2:108827674	G/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs7582180	0.669	rs4455176	chr2:100876629	T/A	cg14675211	chr2:100938903	LONRF2	0.53	4.81	0.44	5.63e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1140227	0.502	rs10789304	chr1:41587412	A/T	cg03387723	chr1:41708464	SCMH1	-0.49	-5.13	-0.47	1.52e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6906287	0.647	rs6902812	chr6:118936294	A/G	cg21191810	chr6:118973309	C6orf204	0.58	5.8	0.51	8.72e-8	Electrocardiographic conduction measures;
THYM	cis	rs6840360	0.868	rs6823462	chr4:152708740	G/A	cg22705602	chr4:152727874	NA	-0.59	-6.36	-0.55	7.14e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7260598	0.642	rs66750293	chr19:24180621	T/C	cg15526094	chr19:24182596	NA	-0.66	-4.62	-0.43	1.18e-5	Response to taxane treatment (placlitaxel);
THYM	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg06634786	chr22:41940651	POLR3H	-0.68	-5.0	-0.46	2.65e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg24375607	chr4:120327624	NA	0.64	4.47	0.42	2.18e-5	Corneal astigmatism;
THYM	cis	rs11771526	0.901	rs28709683	chr7:32301989	A/G	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs16937	0.518	rs1172149	chr1:205224758	A/G	cg17889831	chr1:205181581	DSTYK	-0.4	-4.98	-0.46	2.79e-6	Schizophrenia;
THYM	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg17366294	chr4:99064904	C4orf37	0.57	6.65	0.56	1.85e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8077889	0.672	rs1234612	chr17:41840802	A/G	cg26893861	chr17:41843967	DUSP3	1.09	17.09	0.87	9.66e-31	Triglycerides;
THYM	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg02891314	chr5:179741120	GFPT2	-0.92	-6.92	-0.58	5.16e-10	Height;
THYM	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.32e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-7.15	-0.59	1.78e-10	Longevity;Endometriosis;
THYM	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11644478	chr21:40555479	PSMG1	-0.8	-6.88	-0.58	6.34e-10	Cognitive function;
THYM	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22496380	chr5:211416	CCDC127	-1.28	-7.77	-0.62	9.06e-12	Breast cancer;
THYM	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg26384229	chr12:38710491	ALG10B	1.0	7.85	0.63	6.12e-12	Bladder cancer;
THYM	cis	rs4523957	0.583	rs2641443	chr17:2036162	G/A	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11948739	0.610	rs6898224	chr5:130247078	C/T	cg08523029	chr5:130500466	HINT1	0.82	5.88	0.52	6.16e-8	Pediatric bone mineral content (hip);
THYM	trans	rs877282	0.898	rs71489279	chr10:760510	T/C	cg22713356	chr15:30763199	NA	1.36	10.13	0.72	8.77e-17	Uric acid levels;
THYM	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg15448220	chr1:150897856	SETDB1	0.88	7.49	0.61	3.44e-11	Melanoma;
THYM	cis	rs7580658	0.545	rs67996371	chr2:127953417	G/A	cg10021288	chr2:128175891	PROC	-0.52	-4.46	-0.42	2.28e-5	Protein C levels;
THYM	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg18681998	chr4:17616180	MED28	-0.91	-8.61	-0.66	1.55e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg16586182	chr3:47516702	SCAP	-0.62	-5.32	-0.48	6.98e-7	Colorectal cancer;
THYM	cis	rs40363	0.645	rs37774	chr16:3512695	T/C	cg08257088	chr16:3726052	TRAP1	-0.64	-4.55	-0.42	1.59e-5	Tuberculosis;
THYM	cis	rs7078219	0.543	rs10786556	chr10:101278324	C/T	cg17888390	chr10:101282816	NA	-0.46	-4.67	-0.43	9.79e-6	Dental caries;
THYM	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg07424592	chr7:64974309	NA	1.04	5.27	0.48	8.52e-7	Diabetic kidney disease;
THYM	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg11301795	chr4:187892539	NA	-1.11	-18.07	-0.88	1.66e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13016963	0.526	rs1406121	chr2:202195030	T/C	cg12544106	chr2:202507780	ALS2CR4	-0.61	-4.48	-0.42	2.09e-5	Esophageal squamous cell carcinoma;Melanoma;
THYM	cis	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.27	-4.5	-0.42	1.91e-5	Obesity-related traits;
THYM	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg21433313	chr16:3507492	NAT15	0.78	6.7	0.57	1.43e-9	Tuberculosis;
THYM	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg20203395	chr5:56204925	C5orf35	-0.67	-4.58	-0.42	1.44e-5	Initial pursuit acceleration;
THYM	cis	rs12643440	0.538	rs1522080	chr4:17135354	G/C	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg21361702	chr7:150065534	REPIN1	0.68	4.98	0.46	2.8e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs1568889	0.838	rs7131379	chr11:28085789	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	6.81	0.57	8.87e-10	Bipolar disorder;
THYM	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg18876405	chr7:65276391	NA	0.77	7.26	0.6	1.05e-10	Calcium levels;
THYM	cis	rs28595532	0.920	rs115690307	chr4:119768289	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg25358565	chr5:93447407	FAM172A	1.32	9.62	0.7	1.08e-15	Diabetic retinopathy;
THYM	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg09462578	chr12:12878428	APOLD1	0.63	5.34	0.48	6.43e-7	Pulse pressure;
THYM	cis	rs11190604	0.767	rs4919459	chr10:102200371	C/T	cg07570687	chr10:102243282	WNT8B	0.85	8.39	0.65	4.57e-13	Palmitoleic acid (16:1n-7) levels;
THYM	trans	rs9951602	0.512	rs9304070	chr18:76654890	A/C	cg02800362	chr5:177631904	HNRNPAB	1.15	9.84	0.71	3.64e-16	Obesity-related traits;
THYM	cis	rs1061377	1.000	rs1560396	chr4:39113712	A/G	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs4731207	0.591	rs1481336	chr7:124696739	G/C	cg05285228	chr7:124571219	POT1	-0.65	-5.0	-0.46	2.64e-6	Cutaneous malignant melanoma;
THYM	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg02070205	chr10:30722105	MAP3K8	0.52	4.45	0.42	2.29e-5	Inflammatory bowel disease;
THYM	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg20887711	chr4:1340912	KIAA1530	0.66	5.78	0.51	9.48e-8	Longevity;
THYM	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7688540	0.623	rs11735968	chr4:238820	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.72	4.88	0.45	4.35e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs28595532	0.920	rs56150431	chr4:119764786	T/C	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg05393297	chr12:53359155	NA	-0.51	-5.74	-0.51	1.14e-7	Prostate cancer;
THYM	cis	rs3110496	0.650	rs563976	chr17:27905673	A/G	cg05877788	chr17:27899874	TP53I13	-0.45	-5.42	-0.49	4.53e-7	Height;
THYM	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg02640540	chr1:67518911	SLC35D1	-0.65	-4.78	-0.44	6.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg22841779	chr14:105766346	BRF1	-0.46	-5.69	-0.5	1.42e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg08736216	chr1:53307985	ZYG11A	-0.6	-5.56	-0.5	2.5e-7	Monocyte count;
THYM	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg16049864	chr8:95962084	TP53INP1	-0.69	-6.21	-0.54	1.41e-8	Type 2 diabetes;
THYM	cis	rs7822232	0.908	rs6558297	chr8:145143934	C/T	cg12091641	chr8:145180933	NA	-1.01	-4.87	-0.45	4.36e-6	Blood metabolite levels;
THYM	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg14008862	chr17:28927542	LRRC37B2	0.88	4.55	0.42	1.57e-5	Body mass index;
THYM	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4900538	0.821	rs12586673	chr14:102827643	C/T	cg18135206	chr14:102964638	TECPR2	-0.81	-6.08	-0.53	2.51e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg12179176	chr11:130786555	SNX19	0.95	9.72	0.71	6.68e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs28595532	0.920	rs115046587	chr4:119779604	T/C	cg21605333	chr4:119757512	SEC24D	1.67	6.17	0.53	1.69e-8	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67460515	0.563	rs16831886	chr3:160799830	A/C	cg12349858	chr3:160822545	B3GALNT1	0.62	4.89	0.45	4.05e-6	Parkinson's disease;
THYM	cis	rs79565040	1	rs79565040	chr1:8917398	T/TTA	cg06972019	chr1:8937448	ENO1	-0.88	-10.25	-0.72	4.95e-17	White blood cell count (basophil);
THYM	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg06713675	chr4:122721982	EXOSC9	-0.66	-6.36	-0.55	7.11e-9	Type 2 diabetes;
THYM	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.91	10.43	0.73	2.04e-17	Prudent dietary pattern;
THYM	cis	rs7551222	0.752	rs4252685	chr1:204496856	C/A	cg20240347	chr1:204465584	NA	-0.51	-4.54	-0.42	1.64e-5	Schizophrenia;
THYM	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg11742103	chr11:62369870	EML3;MTA2	0.69	9.44	0.7	2.66e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg08772003	chr10:104629869	AS3MT	-0.72	-5.45	-0.49	4.05e-7	Arsenic metabolism;
THYM	cis	rs684232	0.602	rs331014	chr17:532103	C/T	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.38	-4.57	-0.42	1.45e-5	Prostate cancer;
THYM	cis	rs6882076	0.884	rs7717984	chr5:156369171	A/G	cg12943317	chr5:156479607	HAVCR1	0.8	6.97	0.58	4.24e-10	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs728616	0.867	rs76239460	chr10:81723227	C/T	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-5.16	-0.47	1.34e-6	Hemoglobin concentration;
THYM	cis	rs12620999	1.000	rs11689249	chr2:238083542	T/A	cg23555395	chr2:238036564	NA	-0.61	-4.83	-0.44	5.17e-6	Systemic lupus erythematosus;
THYM	cis	rs12802200	0.535	rs35391985	chr11:570280	T/C	cg03909863	chr11:638404	DRD4	-0.67	-4.79	-0.44	6.2e-6	Systemic lupus erythematosus;
THYM	cis	rs7705042	0.865	rs249642	chr5:141524980	G/C	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs526231	0.543	rs257303	chr5:102416727	A/G	cg23492399	chr5:102201601	PAM	-0.67	-4.96	-0.45	3.05e-6	Primary biliary cholangitis;
THYM	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg04043695	chr12:129287642	SLC15A4	0.59	4.6	0.43	1.33e-5	Systemic lupus erythematosus;
THYM	cis	rs922692	0.744	rs2277545	chr15:79083591	T/C	cg15571903	chr15:79123663	NA	-0.49	-4.59	-0.43	1.37e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	5.57	0.5	2.37e-7	Lung cancer in ever smokers;
THYM	cis	rs6138458	0.743	rs3746330	chr20:24999795	A/G	cg26195577	chr20:24973756	C20orf3	0.81	6.82	0.57	8.47e-10	Blood protein levels;
THYM	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg04520793	chr17:42248056	ASB16	0.35	4.78	0.44	6.48e-6	Total body bone mineral density;
THYM	cis	rs72627123	0.867	rs77321049	chr14:74455219	G/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.14	6.41	0.55	5.69e-9	Morning vs. evening chronotype;
THYM	cis	rs2219968	0.525	rs4509310	chr8:78876259	T/C	cg00738934	chr8:78996279	NA	0.61	4.93	0.45	3.5e-6	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs911119	1.000	rs6114208	chr20:23621734	C/G	cg16589663	chr20:23618590	CST3	0.78	4.87	0.45	4.48e-6	Chronic kidney disease;
THYM	cis	rs3126085	0.935	rs4845751	chr1:152208997	T/C	cg10321714	chr1:152280068	FLG	0.63	4.53	0.42	1.68e-5	Atopic dermatitis;
THYM	cis	rs4988958	0.565	rs3771154	chr2:103039360	C/T	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma (childhood onset);
THYM	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg22875332	chr1:76189707	ACADM	0.78	7.29	0.6	9.36e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7818345	0.967	rs12678336	chr8:19280552	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.53	0.42	1.73e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs12474201	0.963	rs3829835	chr2:46925789	C/T	cg09399716	chr2:46890238	NA	-0.51	-4.48	-0.42	2.11e-5	Height;
THYM	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs3771570	1.000	rs56156035	chr2:242205955	T/A	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg27129171	chr3:47204927	SETD2	0.8	7.67	0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs8030485	0.571	rs4778904	chr15:79418856	A/C	cg17916960	chr15:79447300	NA	0.6	6.14	0.53	1.87e-8	Left ventricle wall thickness;
THYM	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg06981504	chr1:1234844	ACAP3	0.54	4.94	0.45	3.29e-6	Body mass index;
THYM	cis	rs10277209	1.000	rs73198438	chr7:109069564	C/T	cg24448523	chr7:109046164	NA	-0.82	-4.55	-0.42	1.57e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs113835537	0.597	rs2075792	chr11:66334556	G/A	cg24851651	chr11:66362959	CCS	0.74	5.19	0.47	1.2e-6	Airway imaging phenotypes;
THYM	cis	rs79349575	0.749	rs2546491	chr17:46977916	A/G	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg12893697	chr11:970389	AP2A2	-0.31	-5.21	-0.47	1.1e-6	Alzheimer's disease (late onset);
THYM	cis	rs7809950	0.723	rs2237662	chr7:106874065	C/G	cg23024343	chr7:107201750	COG5	-0.98	-8.34	-0.65	5.83e-13	Coronary artery disease;
THYM	cis	rs1483890	0.723	rs13077078	chr3:69411402	C/A	cg22125112	chr3:69402811	FRMD4B	0.54	6.85	0.58	7.21e-10	Resting heart rate;
THYM	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg06028808	chr11:68637592	NA	-0.64	-6.63	-0.56	2.06e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6565180	0.632	rs8050812	chr16:30385837	C/T	cg01081883	chr16:30390547	SEPT1	0.69	5.23	0.47	9.94e-7	Tonsillectomy;
THYM	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs75059851	0.756	rs73036086	chr11:133841782	C/T	cg14047540	chr11:133829660	NA	-1.1	-7.34	-0.6	7.1e-11	Schizophrenia;
THYM	cis	rs2069036	0.859	rs10904664	chr10:16067241	T/A	cg26633223	chr10:15133461	NA	0.66	4.76	0.44	6.81e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg03806693	chr22:41940476	POLR3H	-1.24	-10.73	-0.74	4.49e-18	Vitiligo;
THYM	cis	rs7809950	0.954	rs11977187	chr7:107210383	C/T	cg23024343	chr7:107201750	COG5	0.97	8.49	0.66	2.8e-13	Coronary artery disease;
THYM	cis	rs7572733	0.534	rs1518365	chr2:198809410	T/C	cg00792783	chr2:198669748	PLCL1	0.82	5.75	0.51	1.08e-7	Dermatomyositis;
THYM	cis	rs7631605	0.905	rs60490177	chr3:37254925	G/C	cg21328643	chr3:37258149	NA	-0.58	-5.57	-0.5	2.39e-7	Cerebrospinal P-tau181p levels;
THYM	cis	rs2734839	0.927	rs2734837	chr11:113286829	C/T	cg14159747	chr11:113255604	NA	0.31	6.28	0.54	1.01e-8	Information processing speed;
THYM	cis	rs9653442	0.622	rs11685341	chr2:100636757	A/G	cg22139774	chr2:100720529	AFF3	0.32	4.76	0.44	6.98e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg12463550	chr7:65579703	CRCP	-0.57	-4.76	-0.44	7.01e-6	Aortic root size;
THYM	cis	rs8044868	0.541	rs7202268	chr16:72086746	A/G	cg06353428	chr16:71660113	MARVELD3	0.59	4.5	0.42	1.89e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg22105103	chr4:187893119	NA	0.88	9.52	0.7	1.73e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg15445000	chr17:37608096	MED1	-0.42	-5.08	-0.46	1.91e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7614311	0.681	rs6796317	chr3:63927739	A/G	cg22134162	chr3:63841271	THOC7	-0.57	-6.56	-0.56	2.79e-9	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs9393692	0.578	rs806795	chr6:26205293	G/A	cg00631329	chr6:26305371	NA	-0.48	-5.11	-0.46	1.66e-6	Educational attainment;
THYM	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg19912559	chr1:40204330	PPIE	0.64	4.92	0.45	3.61e-6	Blood protein levels;
THYM	cis	rs36051895	0.664	rs3780381	chr9:5114523	A/C	cg02405213	chr9:5042618	JAK2	-1.01	-11.38	-0.76	1.95e-19	Pediatric autoimmune diseases;
THYM	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg26924012	chr15:45694286	SPATA5L1	1.12	10.37	0.73	2.72e-17	Homoarginine levels;
THYM	cis	rs8067545	0.611	rs2526476	chr17:20134289	C/T	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs11118844	0.793	rs4433402	chr1:221946172	A/G	cg04222084	chr1:221915650	DUSP10	-1.0	-5.05	-0.46	2.09e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg24399712	chr22:39784796	NA	-0.93	-10.65	-0.74	6.66e-18	Intelligence (multi-trait analysis);
THYM	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg15921436	chr17:44337874	NA	0.95	6.92	0.58	5.33e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9581857	0.579	rs2780341	chr13:27996401	C/T	cg22138327	chr13:27999177	GTF3A	-1.04	-6.13	-0.53	1.97e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	trans	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg25214090	chr10:38739885	LOC399744	-0.81	-6.94	-0.58	4.79e-10	Corneal astigmatism;
THYM	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg26384229	chr12:38710491	ALG10B	0.91	7.46	0.61	4.14e-11	Bladder cancer;
THYM	cis	rs4731207	0.698	rs4552839	chr7:124499514	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg13770153	chr20:60521292	NA	-0.64	-4.54	-0.42	1.66e-5	Body mass index;
THYM	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg10792982	chr14:105748885	BRF1	0.68	6.87	0.58	6.7e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs868036	0.718	rs4776985	chr15:68123021	T/G	cg24579218	chr15:68104479	NA	-0.77	-8.15	-0.64	1.48e-12	Restless legs syndrome;
THYM	cis	rs7772486	0.902	rs2144476	chr6:146322484	G/A	cg13319975	chr6:146136371	FBXO30	-0.7	-5.88	-0.52	6.22e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg06558623	chr16:89946397	TCF25	1.33	5.65	0.5	1.64e-7	Skin colour saturation;
THYM	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-4.99	-0.46	2.75e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg02475777	chr4:1388615	CRIPAK	0.73	5.23	0.47	1e-6	Longevity;
THYM	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg20291162	chr17:40259547	DHX58	-0.69	-6.44	-0.55	4.96e-9	Fibrinogen levels;
THYM	cis	rs12711979	0.765	rs897069	chr2:3818947	C/T	cg17052675	chr2:3827356	NA	0.49	5.23	0.47	9.93e-7	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg24060327	chr5:131705240	SLC22A5	0.68	5.04	0.46	2.19e-6	Blood metabolite levels;
THYM	cis	rs2294693	0.945	rs68031000	chr6:41008841	G/T	cg14418226	chr6:40996092	UNC5CL	0.75	6.13	0.53	1.97e-8	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs9902453	0.904	rs4528633	chr17:28356136	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.22	-0.54	1.3e-8	Coffee consumption (cups per day);
THYM	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg08999081	chr20:33150536	PIGU	0.58	4.91	0.45	3.84e-6	Height;
THYM	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg17054759	chr22:49844102	NA	-0.51	-4.79	-0.44	6.25e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2455799	0.613	rs12637353	chr3:15831525	T/C	cg16303742	chr3:15540471	COLQ	-0.53	-5.68	-0.5	1.44e-7	Mean platelet volume;
THYM	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.3	6.5	0.55	3.71e-9	Obesity-related traits;
THYM	cis	rs2888875	0.632	rs13013639	chr2:43737063	A/G	cg22033476	chr2:43532275	THADA	0.4	4.56	0.42	1.55e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs2777491	0.874	rs7161772	chr15:41611066	A/T	cg18705301	chr15:41695430	NDUFAF1	-1.14	-12.89	-0.8	1.38e-22	Ulcerative colitis;
THYM	cis	rs17152411	0.895	rs7086128	chr10:126587373	A/G	cg07906193	chr10:126599966	NA	0.68	4.65	0.43	1.08e-5	Height;
THYM	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg22815214	chr1:201083145	CACNA1S	0.79	7.52	0.61	3.02e-11	Permanent tooth development;
THYM	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg10334053	chr1:2078117	PRKCZ	0.45	4.46	0.42	2.21e-5	Height;
THYM	cis	rs11608355	1.000	rs11608355	chr12:109879292	T/C	cg10504392	chr12:110044639	NA	0.66	6.22	0.54	1.35e-8	Neuroticism;
THYM	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg08999081	chr20:33150536	PIGU	-0.73	-6.56	-0.56	2.86e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.96	0.45	3.04e-6	Obesity-related traits;
THYM	cis	rs1808579	0.874	rs1367083	chr18:21100240	C/T	cg14672496	chr18:21087552	C18orf8	0.5	4.52	0.42	1.77e-5	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
THYM	cis	rs4731207	0.569	rs7799535	chr7:124592060	C/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs6918586	0.615	rs198841	chr6:26111671	G/T	cg03517284	chr6:25882590	NA	0.71	5.57	0.5	2.4e-7	Schizophrenia;
THYM	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs1784581	0.588	rs4131681	chr6:162422167	T/G	cg17173639	chr6:162384350	PARK2	0.81	7.48	0.61	3.75e-11	Itch intensity from mosquito bite;
THYM	cis	rs11563648	0.573	rs1419392	chr7:126945510	G/A	cg08586737	chr7:127225949	GCC1	-0.32	-4.53	-0.42	1.71e-5	Resting heart rate;
THYM	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.71	5.31	0.48	7.11e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4845570	1.000	rs3811415	chr1:151763767	C/T	cg07092448	chr1:151763213	TDRKH	-1.0	-6.13	-0.53	2e-8	Coronary artery disease;
THYM	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg06611532	chr13:114900021	NA	0.64	7.17	0.59	1.61e-10	Schizophrenia;
THYM	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg23803603	chr1:2058230	PRKCZ	-0.58	-4.93	-0.45	3.53e-6	Height;
THYM	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs8078723	1.000	rs4794823	chr17:38166265	A/T	cg17467752	chr17:38218738	THRA	0.86	7.09	0.59	2.4e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg03676636	chr4:99064102	C4orf37	0.5	7.59	0.61	2.14e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9790314	0.812	rs7631479	chr3:161139566	C/T	cg03342759	chr3:160939853	NMD3	-0.62	-5.3	-0.48	7.54e-7	Morning vs. evening chronotype;
THYM	cis	rs16949788	0.793	rs78483581	chr15:66769365	C/T	cg08120210	chr15:66682733	MAP2K1	-0.77	-4.56	-0.42	1.54e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg15440763	chr7:158190612	PTPRN2	0.48	4.46	0.42	2.25e-5	Obesity-related traits;
THYM	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg10047753	chr17:41438598	NA	1.01	8.29	0.65	7.22e-13	Menopause (age at onset);
THYM	cis	rs4642101	0.793	rs56082700	chr3:12833833	T/C	cg11882607	chr3:12858926	CAND2	-0.4	-4.53	-0.42	1.74e-5	QRS complex (12-leadsum);
THYM	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg27170947	chr2:26402098	FAM59B	0.81	5.31	0.48	7.05e-7	Gut microbiome composition (summer);
THYM	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg11663144	chr21:46675770	NA	-0.72	-10.48	-0.73	1.54e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6835098	0.961	rs2877748	chr4:174102397	G/A	cg08422745	chr4:174089978	GALNT7	-0.99	-8.26	-0.65	8.41e-13	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs870825	0.616	rs9631782	chr4:185626379	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg19774624	chr17:42201019	HDAC5	-0.85	-8.23	-0.65	9.73e-13	Total body bone mineral density;
THYM	trans	rs8073060	0.586	rs4796100	chr17:33997657	G/T	cg19694781	chr19:47549865	TMEM160	0.96	7.97	0.63	3.46e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg03060546	chr3:49711283	APEH	-0.71	-5.89	-0.52	5.83e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2319125	0.683	rs1401048	chr17:64050062	G/A	cg04446870	chr17:64440273	PRKCA	0.5	4.48	0.42	2.12e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs4919694	1.000	rs12253284	chr10:104665145	G/C	cg15744005	chr10:104629667	AS3MT	-0.78	-4.45	-0.42	2.3e-5	Arsenic metabolism;
THYM	cis	rs1499972	0.941	rs62264766	chr3:117641227	A/G	cg07612923	chr3:117604196	NA	1.19	5.0	0.46	2.66e-6	Schizophrenia;
THYM	cis	rs4731207	0.596	rs10257712	chr7:124598079	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.46	-0.49	3.81e-7	Cutaneous malignant melanoma;
THYM	cis	rs7107174	1.000	rs2256187	chr11:77919768	G/A	cg02023728	chr11:77925099	USP35	0.7	6.21	0.54	1.41e-8	Testicular germ cell tumor;
THYM	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg24503407	chr1:205819492	PM20D1	0.94	9.0	0.68	2.24e-14	Menarche (age at onset);
THYM	cis	rs13256369	0.851	rs11249890	chr8:8565245	G/T	cg00074818	chr8:8560427	CLDN23	0.6	5.53	0.49	2.82e-7	Obesity-related traits;
THYM	cis	rs1915146	0.935	rs1057234	chr10:126850793	C/G	cg23000734	chr10:126850823	CTBP2	0.85	10.93	0.75	1.74e-18	Menarche (age at onset);
THYM	cis	rs6558530	0.799	rs62477060	chr8:1706498	A/T	cg09410841	chr8:1729607	CLN8	0.68	5.14	0.47	1.5e-6	Systolic blood pressure;
THYM	cis	rs8114671	0.836	rs2425006	chr20:33571228	T/G	cg08999081	chr20:33150536	PIGU	-0.55	-4.85	-0.45	4.82e-6	Height;
THYM	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.81	-6.97	-0.58	4.14e-10	Tonsillectomy;
THYM	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg02931644	chr1:25747376	RHCE	0.56	4.47	0.42	2.15e-5	Erythrocyte sedimentation rate;
THYM	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg00495681	chr13:53174319	NA	1.09	13.03	0.8	7.36e-23	Lewy body disease;
THYM	cis	rs6918586	0.615	rs198824	chr6:26122783	T/C	cg03264133	chr6:25882463	NA	0.64	4.95	0.45	3.26e-6	Schizophrenia;
THYM	cis	rs8077889	0.917	rs9901676	chr17:41911818	T/C	cg26893861	chr17:41843967	DUSP3	1.06	10.5	0.73	1.45e-17	Triglycerides;
THYM	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg02018176	chr4:1364513	KIAA1530	0.58	4.53	0.42	1.71e-5	Obesity-related traits;
THYM	cis	rs7640424	0.649	rs13093976	chr3:107864963	A/C	cg09227934	chr3:107805635	CD47	0.52	4.49	0.42	1.99e-5	Body mass index;
THYM	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg05043794	chr9:111880884	C9orf5	-0.35	-4.93	-0.45	3.42e-6	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg12419862	chr22:24373484	LOC391322	-0.73	-6.83	-0.57	7.9e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.785	rs11944120	chr4:99079932	A/C	cg24818145	chr4:99064322	C4orf37	0.87	6.3	0.54	9.13e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7729447	0.813	rs1031648	chr5:32692105	T/A	cg16267343	chr5:32710456	NPR3	0.79	7.16	0.59	1.69e-10	Blood pressure;
THYM	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg09359103	chr1:154839909	KCNN3	-0.69	-8.41	-0.65	4.15e-13	Prostate cancer;
THYM	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg14004847	chr7:1930337	MAD1L1	-0.67	-5.14	-0.47	1.45e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg24920358	chr1:40204285	PPIE	0.6	5.57	0.5	2.39e-7	Blood protein levels;
THYM	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg10515332	chr4:99064459	C4orf37	0.57	4.54	0.42	1.68e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8180040	0.903	rs12487736	chr3:47459679	C/T	cg16586182	chr3:47516702	SCAP	-0.64	-5.64	-0.5	1.76e-7	Colorectal cancer;
THYM	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg13390004	chr1:15929781	NA	0.62	4.72	0.44	8.11e-6	Systolic blood pressure;
THYM	cis	rs600806	0.850	rs10745354	chr1:109931908	C/T	cg16988986	chr1:109941118	SORT1	-0.43	-4.56	-0.42	1.5e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg03605463	chr16:89740564	NA	-0.61	-4.55	-0.42	1.61e-5	Vitiligo;
THYM	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg13175981	chr1:150552382	MCL1	0.78	6.02	0.53	3.25e-8	Tonsillectomy;
THYM	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg07424592	chr7:64974309	NA	1.13	5.18	0.47	1.25e-6	Diabetic kidney disease;
THYM	cis	rs6570726	0.935	rs380433	chr6:145859601	A/T	cg13319975	chr6:146136371	FBXO30	-0.67	-5.64	-0.5	1.78e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs888194	0.677	rs2075431	chr12:109874621	C/T	cg11367159	chr12:110044531	NA	0.53	4.82	0.44	5.39e-6	Neuroticism;
THYM	cis	rs9287719	0.699	rs4669602	chr2:10787967	C/T	cg03983476	chr2:10830698	NOL10	-0.54	-4.53	-0.42	1.71e-5	Prostate cancer;
THYM	cis	rs7187994	0.848	rs12443928	chr16:84780202	G/T	cg07647771	chr16:84786436	USP10	-0.56	-4.86	-0.45	4.56e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs11031096	0.678	rs2044135	chr11:4187233	G/A	cg22027985	chr11:4115532	RRM1	-0.54	-5.04	-0.46	2.21e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs3820068	0.603	rs1980607	chr1:15975237	A/G	cg13390004	chr1:15929781	NA	0.63	4.72	0.44	7.96e-6	Systolic blood pressure;
THYM	cis	rs2976388	0.609	rs2585152	chr8:143786214	A/T	cg06565975	chr8:143823917	SLURP1	0.47	5.22	0.47	1.06e-6	Urinary tract infection frequency;
THYM	cis	rs9435341	0.965	rs55924375	chr1:107566690	C/A	cg09367891	chr1:107599246	PRMT6	0.68	4.45	0.42	2.33e-5	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs6570726	0.967	rs365515	chr6:145802833	C/T	cg23711669	chr6:146136114	FBXO30	-0.74	-6.89	-0.58	5.98e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg13319975	chr6:146136371	FBXO30	-0.72	-6.1	-0.53	2.24e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg11764359	chr7:65958608	NA	-0.75	-6.04	-0.53	2.97e-8	Aortic root size;
THYM	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg23711669	chr6:146136114	FBXO30	0.91	9.21	0.69	8.1e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg26769984	chr7:1090371	C7orf50	0.81	5.62	0.5	1.88e-7	Bronchopulmonary dysplasia;
THYM	cis	rs4919694	1.000	rs80327774	chr10:104656671	T/C	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg15448220	chr1:150897856	SETDB1	0.85	7.1	0.59	2.25e-10	Tonsillectomy;
THYM	cis	rs4638749	0.501	rs2171181	chr2:108750391	G/C	cg25838818	chr2:108905173	SULT1C2	-0.52	-4.89	-0.45	4.13e-6	Blood pressure;
THYM	cis	rs7432375	0.901	rs7616204	chr3:136444589	C/T	cg21827317	chr3:136751795	NA	-0.59	-5.05	-0.46	2.11e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg00012203	chr2:219082015	ARPC2	-0.65	-5.36	-0.48	5.83e-7	Pyoderma gangrenosum in inflammatory bowel disease;
THYM	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg16680214	chr1:154839983	KCNN3	-0.47	-5.4	-0.48	4.94e-7	Prostate cancer;
THYM	cis	rs1348850	0.526	rs78587445	chr2:178461339	G/T	cg27490568	chr2:178487706	NA	-0.72	-5.83	-0.51	7.58e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs8067545	0.611	rs12949481	chr17:20190974	C/A	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-7.18	-0.59	1.55e-10	Gut microbiome composition (summer);
THYM	trans	rs877282	0.945	rs12767287	chr10:787310	A/G	cg22713356	chr15:30763199	NA	1.4	11.86	0.77	1.9e-20	Uric acid levels;
THYM	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg13695892	chr22:41940480	POLR3H	0.85	6.16	0.53	1.72e-8	Vitiligo;
THYM	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10814247	1.000	rs10814247	chr9:35507290	C/T	cg18130437	chr9:35658183	CCDC107;RMRP	0.58	4.6	0.43	1.3e-5	Psoriasis;
THYM	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg14895029	chr7:2775587	GNA12	-0.68	-4.93	-0.45	3.55e-6	Height;
THYM	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg27286337	chr10:134555280	INPP5A	0.93	6.98	0.58	3.98e-10	Migraine;
THYM	cis	rs28374715	0.578	rs10518717	chr15:41623368	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.21	-13.52	-0.81	7.22e-24	Ulcerative colitis;
THYM	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs55665837	0.961	rs60622588	chr11:14456998	T/C	cg19336497	chr11:14380999	RRAS2	-0.64	-7.04	-0.59	3e-10	Vitamin D levels;
THYM	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.89	8.39	0.65	4.48e-13	Menarche (age at onset);
THYM	cis	rs9788721	0.836	rs72738736	chr15:78765122	G/T	cg18825076	chr15:78729989	IREB2	-0.67	-6.41	-0.55	5.7e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs7582180	0.903	rs2309826	chr2:100905274	C/A	cg14675211	chr2:100938903	LONRF2	0.65	5.52	0.49	2.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.01	8.54	0.66	2.21e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg09165964	chr15:75287851	SCAMP5	0.6	4.59	0.43	1.38e-5	Breast cancer;
THYM	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs1797081	0.646	rs7090256	chr10:16851949	T/G	cg23933602	chr10:16859644	RSU1	0.66	5.46	0.49	3.75e-7	Platelet distribution width;
THYM	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg15704280	chr7:45808275	SEPT13	-1.06	-15.41	-0.85	1.38e-27	Height;
THYM	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg12311346	chr5:56204834	C5orf35	-0.61	-4.67	-0.43	9.99e-6	Initial pursuit acceleration;
THYM	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg02773041	chr1:40204384	PPIE	0.77	5.83	0.51	7.67e-8	Blood protein levels;
THYM	cis	rs4733781	0.509	rs1158570	chr8:131331073	C/T	cg16277922	chr8:131349729	ASAP1	-0.69	-6.38	-0.55	6.43e-9	Tuberculosis;
THYM	cis	rs13006833	0.668	rs2582735	chr2:191143798	T/C	cg27211696	chr2:191398769	TMEM194B	0.59	4.86	0.45	4.56e-6	Urinary metabolites;
THYM	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg06713675	chr4:122721982	EXOSC9	-0.86	-9.81	-0.71	4.29e-16	Type 2 diabetes;
THYM	cis	rs6084875	0.840	rs2249483	chr20:4719176	C/T	cg19614321	chr20:4804581	RASSF2	0.45	4.53	0.42	1.7e-5	Systemic lupus erythematosus;
THYM	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg00999904	chr2:3704751	ALLC	-1.25	-9.47	-0.7	2.22e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs11671005	0.735	rs11666303	chr19:58922502	T/G	cg18639983	chr19:58920768	ZNF584	0.59	5.0	0.46	2.63e-6	Mean platelet volume;
THYM	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg25072359	chr17:41440525	NA	0.72	5.26	0.47	8.95e-7	Menopause (age at onset);
THYM	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg02782426	chr3:40428986	ENTPD3	-0.51	-4.56	-0.42	1.55e-5	Renal cell carcinoma;
THYM	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg24692254	chr21:30365293	RNF160	-1.05	-9.9	-0.71	2.65e-16	Dental caries;
THYM	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg09021430	chr5:549028	NA	-0.67	-4.51	-0.42	1.87e-5	Lung disease severity in cystic fibrosis;
THYM	trans	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg10856724	chr12:34555212	NA	-0.78	-7.06	-0.59	2.68e-10	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg24642439	chr20:33292090	TP53INP2	0.62	4.87	0.45	4.38e-6	Coronary artery disease;
THYM	cis	rs10979	1.000	rs1416205	chr6:143889397	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg06064525	chr11:970664	AP2A2	-0.38	-7.42	-0.61	4.81e-11	Alzheimer's disease (late onset);
THYM	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg18477163	chr1:228402036	OBSCN	-0.43	-4.69	-0.43	9.18e-6	Diastolic blood pressure;
THYM	cis	rs2073300	0.609	rs17757442	chr20:23421101	A/G	cg12062639	chr20:23401060	NAPB	-1.1	-5.73	-0.51	1.16e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg01416388	chr22:39784598	NA	-0.94	-8.89	-0.67	3.85e-14	Intelligence (multi-trait analysis);
THYM	cis	rs8030379	0.967	rs7181926	chr15:84549428	G/C	cg15564896	chr15:84287328	SH3GL3	0.57	4.77	0.44	6.57e-6	Waist circumference adjusted for body mass index;Waist circumference;
THYM	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg23758822	chr17:41437982	NA	1.17	11.04	0.75	1.02e-18	Menopause (age at onset);
THYM	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg23803603	chr1:2058230	PRKCZ	-0.59	-5.4	-0.48	4.89e-7	Height;
THYM	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg11871910	chr12:69753446	YEATS4	0.75	6.25	0.54	1.18e-8	Blood protein levels;
THYM	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg08484992	chr16:88977278	CBFA2T3	0.45	5.42	0.49	4.55e-7	Social autistic-like traits;
THYM	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg05425664	chr17:57184151	TRIM37	0.59	4.84	0.44	4.98e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg07636037	chr3:49044803	WDR6	0.93	9.11	0.68	1.3e-14	Parkinson's disease;
THYM	cis	rs988913	1.000	rs6922438	chr6:54841383	A/C	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.75e-6	Menarche (age at onset);
THYM	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg05973401	chr12:123451056	ABCB9	0.68	4.55	0.42	1.58e-5	Neutrophil percentage of white cells;
THYM	cis	rs1122608	0.508	rs73011343	chr19:11058262	A/G	cg17326582	chr19:11976514	ZNF439	0.6	4.62	0.43	1.2e-5	Coronary artery disease or ischemic stroke;Coronary artery disease;Coronary artery disease or large artery stroke;Coronary heart disease;Myocardial infarction (early onset);
THYM	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg15556689	chr8:8085844	FLJ10661	0.73	6.19	0.54	1.53e-8	Mood instability;
THYM	cis	rs7809950	1.000	rs2253146	chr7:107200319	A/G	cg23024343	chr7:107201750	COG5	-0.94	-8.66	-0.66	1.21e-13	Coronary artery disease;
THYM	cis	rs6138458	0.626	rs6050259	chr20:25011423	A/G	cg26195577	chr20:24973756	C20orf3	0.75	6.25	0.54	1.17e-8	Blood protein levels;
THYM	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.67	5.11	0.46	1.69e-6	Tonsillectomy;
THYM	cis	rs308403	0.509	rs13122636	chr4:123671045	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.97	8.23	0.65	9.74e-13	Blood protein levels;
THYM	cis	rs3126085	0.736	rs12747962	chr1:152240456	G/A	cg26020982	chr1:152196106	HRNR	0.36	5.11	0.46	1.64e-6	Atopic dermatitis;
THYM	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg11502198	chr6:26597334	ABT1	0.78	6.91	0.58	5.52e-10	Intelligence (multi-trait analysis);
THYM	cis	rs12612619	0.695	rs10207670	chr2:27243001	C/T	cg20518572	chr2:27988785	NA	0.46	4.55	0.42	1.58e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
THYM	cis	rs6815814	0.950	rs5743795	chr4:38832495	C/T	cg02016764	chr4:38805732	TLR1	-0.51	-5.08	-0.46	1.85e-6	Breast cancer;
THYM	cis	rs10489525	0.583	rs1967711	chr1:115630967	C/T	cg01522456	chr1:115632236	TSPAN2	0.88	5.76	0.51	1.02e-7	Autism;
THYM	cis	rs2997447	0.748	rs112813126	chr1:26432239	A/T	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg19508488	chr2:152266495	RIF1	0.79	6.2	0.54	1.45e-8	Lung cancer;
THYM	cis	rs7582180	0.663	rs2309800	chr2:100992086	C/T	cg21926883	chr2:100939477	LONRF2	-0.65	-6.1	-0.53	2.25e-8	Intelligence (multi-trait analysis);
THYM	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg14972814	chr11:95582409	MTMR2	-0.72	-6.08	-0.53	2.51e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg05187965	chr10:45406764	TMEM72	-0.55	-5.37	-0.48	5.58e-7	Mean corpuscular volume;
THYM	cis	rs2903698	0.585	rs2867917	chr4:76360252	T/C	cg03209871	chr4:76438412	RCHY1;THAP6	0.45	5.3	0.48	7.56e-7	Prion diseases;
THYM	cis	rs7267979	1.000	rs6107033	chr20:25363591	A/G	cg08601574	chr20:25228251	PYGB	-0.57	-4.56	-0.42	1.53e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg26597838	chr10:835615	NA	1.23	8.88	0.67	4.1e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs9527	0.590	rs3781281	chr10:104852648	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.64	4.46	0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg14829155	chr15:31115871	NA	-0.57	-5.05	-0.46	2.17e-6	Huntington's disease progression;
THYM	cis	rs11048434	0.736	rs11048344	chr12:9122609	G/C	cg13575925	chr12:9217583	LOC144571	0.53	4.94	0.45	3.31e-6	Sjögren's syndrome;
THYM	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs4452313	0.532	rs58750701	chr3:17020424	C/T	cg19448816	chr3:16974217	PLCL2	0.58	4.67	0.43	9.9e-6	Rheumatoid arthritis;
THYM	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg19729930	chr2:74357872	NA	1.23	12.42	0.79	1.32e-21	Gestational age at birth (maternal effect);
THYM	cis	rs7610301	1.000	rs7610301	chr3:46646028	G/A	cg22951056	chr3:46887651	NA	-0.79	-5.11	-0.46	1.65e-6	Blood protein levels;
THYM	cis	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg26354017	chr1:205819088	PM20D1	0.8	8.16	0.64	1.35e-12	Menarche (age at onset);
THYM	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg07648498	chr16:89883185	FANCA	0.61	4.47	0.42	2.15e-5	Vitiligo;
THYM	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs988913	0.957	rs6459035	chr6:54757520	A/G	cg04690482	chr6:54711388	FAM83B	0.46	4.85	0.45	4.74e-6	Menarche (age at onset);
THYM	cis	rs9875589	0.509	rs2168718	chr3:14084157	A/G	cg03204825	chr3:13978759	TPRXL	-0.56	-4.95	-0.45	3.23e-6	Ovarian reserve;
THYM	cis	rs13326165	0.531	rs35976326	chr3:52325039	G/A	cg08438690	chr3:52279403	PPM1M	-0.79	-4.68	-0.43	9.54e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg11812906	chr14:75593930	NEK9	0.87	8.3	0.65	7.13e-13	Height;
THYM	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg12560992	chr17:57184187	TRIM37	-0.77	-6.62	-0.56	2.16e-9	Intelligence (multi-trait analysis);
THYM	cis	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg07592830	chr1:198259669	NEK7	-0.77	-5.19	-0.47	1.17e-6	Depressive symptoms;
THYM	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg13319975	chr6:146136371	FBXO30	0.66	5.5	0.49	3.25e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg13010199	chr12:38710504	ALG10B	0.73	5.82	0.51	7.99e-8	Heart rate;
THYM	cis	rs62064224	0.554	rs9889352	chr17:30775761	T/C	cg18200150	chr17:30822561	MYO1D	0.54	4.5	0.42	1.95e-5	Schizophrenia;
THYM	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg07936489	chr17:37558343	FBXL20	-0.79	-5.36	-0.48	5.79e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.8	5.95	0.52	4.49e-8	Height;
THYM	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg18252515	chr7:66147081	NA	-1.6	-8.8	-0.67	6.03e-14	Diabetic kidney disease;
THYM	cis	rs13279522	0.572	rs11993997	chr8:67030128	A/G	cg20171999	chr8:67343066	NA	-0.47	-4.69	-0.43	9.22e-6	Coronary heart disease event reduction (statin therapy interaction);
THYM	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7177699	0.550	rs7182103	chr15:79123946	G/T	cg15571903	chr15:79123663	NA	0.58	6.56	0.56	2.77e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg12564285	chr5:131593104	PDLIM4	-0.44	-4.57	-0.42	1.49e-5	Blood metabolite levels;
THYM	cis	rs7940866	0.804	rs3910266	chr11:130814272	A/C	cg12179176	chr11:130786555	SNX19	0.64	4.91	0.45	3.82e-6	Schizophrenia;
THYM	cis	rs1357245	0.680	rs12330908	chr3:27096833	T/G	cg03895047	chr3:27114861	NA	0.49	4.58	0.43	1.42e-5	Breast cancer;
THYM	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg00129232	chr17:37814104	STARD3	-0.71	-4.8	-0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2835345	0.563	rs76422022	chr21:37824626	T/G	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg01191920	chr7:158217561	PTPRN2	-1.07	-12.34	-0.78	1.91e-21	Obesity-related traits;
THYM	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg15448220	chr1:150897856	SETDB1	0.83	7.01	0.58	3.37e-10	Melanoma;
THYM	cis	rs34638657	0.872	rs7202258	chr16:82195013	T/C	cg09894383	chr16:82067445	HSD17B2	-0.55	-5.81	-0.51	8.4e-8	Lung adenocarcinoma;
THYM	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg27532560	chr4:187881888	NA	-0.95	-11.68	-0.77	4.63e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg08772003	chr10:104629869	AS3MT	-0.63	-5.62	-0.5	1.87e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg17294928	chr15:75287854	SCAMP5	0.65	4.97	0.45	2.99e-6	Breast cancer;
THYM	cis	rs7512552	0.780	rs2794681	chr1:150321951	C/T	cg15654264	chr1:150340011	RPRD2	0.45	5.2	0.47	1.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg12165864	chr7:66369176	NA	0.67	5.24	0.47	9.64e-7	Aortic root size;
THYM	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18876405	chr7:65276391	NA	-0.55	-4.62	-0.43	1.23e-5	Aortic root size;
THYM	cis	rs36051895	0.588	rs12340895	chr9:5076691	C/G	cg02405213	chr9:5042618	JAK2	0.98	10.77	0.74	3.87e-18	Pediatric autoimmune diseases;
THYM	cis	rs516946	1.000	rs35273426	chr8:41524688	C/T	cg19441908	chr8:41529140	ANK1	0.62	4.9	0.45	3.87e-6	Type 2 diabetes;
THYM	cis	rs7487075	0.823	rs34472481	chr12:46836348	C/G	cg21428710	chr12:47219797	SLC38A4	0.46	4.54	0.42	1.63e-5	Itch intensity from mosquito bite;
THYM	cis	rs4803468	1.000	rs284652	chr19:41928652	C/T	cg09537434	chr19:41945824	ATP5SL	-1.05	-9.33	-0.69	4.53e-15	Height;
THYM	cis	rs8063160	0.667	rs79139787	chr16:89795360	C/T	cg27050730	chr16:88968896	CBFA2T3	0.96	4.45	0.42	2.33e-5	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs240764	0.817	rs12207086	chr6:101150463	G/A	cg21058520	chr6:100914733	NA	0.58	5.1	0.46	1.72e-6	Neuroticism;
THYM	cis	rs17661538	0.504	rs34537345	chr10:18458587	A/G	cg03634479	chr10:18430412	CACNB2	0.85	4.96	0.45	3.12e-6	Response to antipsychotic treatment;
THYM	cis	rs11030122	0.702	rs4910866	chr11:3950554	A/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.59	-0.5	2.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs524023	0.914	rs11607663	chr11:64368670	G/C	cg19131476	chr11:64387923	NRXN2	-0.39	-5.61	-0.5	1.98e-7	Urate levels in obese individuals;
THYM	cis	rs7771547	0.519	rs2057351	chr6:36361682	G/A	cg07856975	chr6:36356162	ETV7	0.68	5.86	0.52	6.77e-8	Platelet distribution width;
THYM	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg22974920	chr21:40686053	BRWD1	-0.63	-4.97	-0.45	2.98e-6	Cognitive function;
THYM	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg27286337	chr10:134555280	INPP5A	0.84	5.93	0.52	4.78e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs11792861	0.564	rs3816237	chr9:111718348	T/A	cg05043794	chr9:111880884	C9orf5	-0.35	-4.84	-0.44	4.96e-6	Menarche (age at onset);
THYM	cis	rs4889855	0.505	rs8082303	chr17:78605012	A/G	cg16591659	chr17:78472290	NA	-0.4	-5.09	-0.46	1.83e-6	Fractional excretion of uric acid;
THYM	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg03474202	chr17:45855739	NA	-0.74	-6.48	-0.55	4.1e-9	IgG glycosylation;
THYM	cis	rs2811415	0.597	rs13073261	chr3:127751493	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs1030420	1.000	rs1030420	chr8:67360725	A/G	cg06195829	chr8:66753750	PDE7A	0.79	4.51	0.42	1.87e-5	Blood metabolite levels;
THYM	cis	rs2985684	0.841	rs12894785	chr14:50049755	G/C	cg02151108	chr14:50098012	C14orf104	-0.67	-5.35	-0.48	6.12e-7	Carotid intima media thickness;
THYM	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg05660106	chr1:15850417	CASP9	0.73	6.14	0.53	1.88e-8	Systolic blood pressure;
THYM	cis	rs673253	0.556	rs55666439	chr1:44111212	T/G	cg09903430	chr1:44172605	ST3GAL3	-0.5	-4.54	-0.42	1.65e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg24910161	chr17:38119198	GSDMA	0.48	4.78	0.44	6.29e-6	Self-reported allergy;
THYM	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg26721908	chr21:47610096	LSS	-0.79	-5.48	-0.49	3.41e-7	Testicular germ cell tumor;
THYM	cis	rs10929159	0.928	rs10179607	chr2:236915645	C/G	cg20128773	chr2:236923534	AGAP1	0.34	4.46	0.42	2.22e-5	Parkinson's disease;
THYM	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg09455208	chr3:40491958	NA	0.51	5.27	0.48	8.41e-7	Renal cell carcinoma;
THYM	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs6424115	0.830	rs2502991	chr1:24202318	A/G	cg15997130	chr1:24165203	NA	0.76	6.39	0.55	6.14e-9	Immature fraction of reticulocytes;
THYM	cis	rs79149102	0.579	rs2304904	chr15:75315975	G/A	cg17294928	chr15:75287854	SCAMP5	-1.01	-4.92	-0.45	3.66e-6	Lung cancer;
THYM	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs7043114	0.563	rs10820986	chr9:95312961	T/G	cg14631576	chr9:95140430	CENPP	-0.77	-7.3	-0.6	8.56e-11	Height;
THYM	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg01475377	chr6:109611718	NA	-0.57	-4.88	-0.45	4.28e-6	Reticulocyte fraction of red cells;
THYM	cis	rs6430585	0.527	rs76380759	chr2:136438517	G/A	cg23851026	chr2:136556271	LCT	0.67	5.98	0.52	3.89e-8	Corneal structure;
THYM	cis	rs7084402	1.000	rs36097682	chr10:60269738	G/A	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs12701220	0.689	rs12533004	chr7:1095410	C/T	cg26769984	chr7:1090371	C7orf50	0.84	5.46	0.49	3.75e-7	Bronchopulmonary dysplasia;
THYM	cis	rs870825	0.655	rs6844929	chr4:185653809	C/G	cg04058563	chr4:185651563	MLF1IP	-0.99	-7.67	-0.62	1.46e-11	Blood protein levels;
THYM	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs10170846	0.893	rs10932967	chr2:223544111	C/T	cg25565276	chr2:223520875	FARSB	0.65	4.7	0.43	8.78e-6	Schizophrenia (inflammation and infection response interaction);
THYM	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg19346786	chr7:2764209	NA	-0.54	-4.57	-0.42	1.46e-5	Height;
THYM	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg25811766	chr13:21894605	NA	-0.77	-4.91	-0.45	3.82e-6	White matter hyperintensity burden;
THYM	cis	rs4482178	0.511	rs76360428	chr13:86293994	T/G	cg25308322	chr13:86268291	NA	0.68	4.55	0.42	1.57e-5	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg16928487	chr17:17741425	SREBF1	0.56	5.36	0.48	5.91e-7	Total body bone mineral density;
THYM	cis	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg19693284	chr19:2783607	SGTA	0.7	5.45	0.49	4.01e-7	Total cholesterol levels;
THYM	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/A	cg05922057	chr17:4047571	ZZEF1;CYB5D2	0.85	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs752010	0.967	rs752011	chr1:42092929	C/T	cg22486000	chr1:42919398	ZMYND12	-0.42	-4.89	-0.45	4.07e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs4363385	0.626	rs11205179	chr1:153021399	A/G	cg13444842	chr1:152974279	SPRR3	-0.62	-4.98	-0.45	2.89e-6	Inflammatory skin disease;
THYM	cis	rs6586111	1.000	rs7097564	chr10:82372188	T/C	cg03086067	chr10:82368399	SH2D4B	-0.55	-7.08	-0.59	2.5e-10	Capecitabine sensitivity;
THYM	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06873352	chr17:61820015	STRADA	0.8	9.86	0.71	3.34e-16	Prudent dietary pattern;
THYM	cis	rs10992471	0.631	rs2296667	chr9:95274338	A/G	cg14631576	chr9:95140430	CENPP	-0.8	-7.77	-0.62	9.18e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg06221963	chr1:154839813	KCNN3	-0.77	-9.84	-0.71	3.56e-16	Prostate cancer;
THYM	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg00898013	chr13:113819073	PROZ	-0.88	-8.96	-0.68	2.83e-14	Platelet distribution width;
THYM	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs4919687	0.550	rs11191371	chr10:104459897	G/C	cg05855489	chr10:104503620	C10orf26	0.68	5.35	0.48	5.95e-7	Colorectal cancer;
THYM	cis	rs6763768	0.600	rs11705809	chr3:53363940	T/C	cg22900224	chr3:52804907	NEK4	0.72	4.71	0.43	8.6e-6	Bacterial meningitis;
THYM	cis	rs5758511	0.680	rs17002902	chr22:42625509	C/G	cg08431931	chr22:42394659	WBP2NL	0.69	4.78	0.44	6.32e-6	Birth weight;
THYM	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg10802521	chr3:52805072	NEK4	-0.72	-6.16	-0.53	1.77e-8	Bipolar disorder;
THYM	cis	rs7917772	0.560	rs11595170	chr10:104339851	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-5.7	-0.5	1.33e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg07870213	chr5:140052090	DND1	-0.69	-8.1	-0.64	1.86e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs28647808	0.881	rs7029386	chr9:136263736	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg17863274	chr19:49399704	TULP2	-1.02	-6.56	-0.56	2.8e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs10501293	0.703	rs10768909	chr11:43020427	G/A	cg03447554	chr11:43094025	NA	0.61	4.51	0.42	1.83e-5	Cognitive performance;
THYM	cis	rs273218	1.000	rs156438	chr5:53374120	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.91	7.74	0.62	1.04e-11	Migraine;
THYM	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg22709100	chr7:91322751	NA	0.63	4.95	0.45	3.18e-6	Breast cancer;
THYM	cis	rs1691799	0.867	rs6581677	chr12:66770379	C/G	cg16791601	chr12:66731901	HELB	-0.69	-5.95	-0.52	4.52e-8	White blood cell count (basophil);
THYM	cis	rs901683	0.850	rs112184470	chr10:46093302	G/A	cg18240400	chr10:46168597	ANUBL1	0.64	4.8	0.44	5.9e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs9534288	0.797	rs7996875	chr13:46612836	C/T	cg15192986	chr13:46630673	CPB2	0.6	4.52	0.42	1.8e-5	Blood protein levels;
THYM	cis	rs4273100	0.688	rs28582509	chr17:19165179	T/C	cg25447019	chr17:19030144	GRAPL	-0.79	-6.19	-0.54	1.49e-8	Schizophrenia;
THYM	cis	rs11039798	0.507	rs56994343	chr11:48896970	G/A	cg24672777	chr11:48374446	OR4C45	-0.93	-5.95	-0.52	4.55e-8	Axial length;
THYM	cis	rs2963155	0.518	rs853179	chr5:142634773	G/T	cg17617527	chr5:142782415	NR3C1	1.19	6.6	0.56	2.33e-9	Breast cancer;
THYM	cis	rs10504073	0.584	rs74457150	chr8:49890753	C/G	cg00325661	chr8:49890786	NA	1.04	10.53	0.73	1.2e-17	Blood metabolite ratios;
THYM	cis	rs1005224	0.853	rs6574251	chr14:76136883	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.74	-6.08	-0.53	2.53e-8	Large artery stroke;
THYM	cis	rs1728785	1.000	rs12925177	chr16:68569645	A/G	cg02972257	chr16:68554789	NA	0.72	4.67	0.43	1e-5	Ulcerative colitis;
THYM	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.28	4.5	0.42	1.94e-5	Obesity-related traits;
THYM	cis	rs12478296	0.901	rs58906257	chr2:243028248	T/C	cg06360820	chr2:242988706	NA	-0.96	-6.27	-0.54	1.06e-8	Obesity-related traits;
THYM	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg13609457	chr4:120235615	NA	0.54	5.0	0.46	2.62e-6	Corneal astigmatism;
THYM	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg06028808	chr11:68637592	NA	0.68	7.15	0.59	1.8e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.91	8.32	0.65	6.22e-13	Menarche (age at onset);
THYM	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg16586182	chr3:47516702	SCAP	-0.63	-5.25	-0.47	9.1e-7	Colorectal cancer;
THYM	cis	rs4589258	0.504	rs35387842	chr11:90390503	C/T	cg26138821	chr11:89956704	CHORDC1	0.65	4.6	0.43	1.32e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg18252515	chr7:66147081	NA	-0.88	-6.73	-0.57	1.26e-9	Corneal structure;
THYM	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg12463550	chr7:65579703	CRCP	-0.56	-4.54	-0.42	1.67e-5	Aortic root size;
THYM	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg00744431	chr10:134226547	PWWP2B	-0.62	-4.9	-0.45	3.93e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg18252515	chr7:66147081	NA	-1.46	-7.35	-0.6	7.04e-11	Diabetic kidney disease;
THYM	cis	rs713587	0.713	rs12618252	chr2:25207950	G/A	cg15423357	chr2:25149977	NA	-0.58	-5.94	-0.52	4.62e-8	Body mass index in non-asthmatics;
THYM	cis	rs12142240	0.698	rs68012736	chr1:46839510	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs4499344	0.576	rs259280	chr19:33161452	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.91	7.78	0.62	8.53e-12	Mean platelet volume;
THYM	cis	rs9796	0.689	rs9888710	chr15:41446153	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.59	-4.67	-0.43	9.71e-6	Menopause (age at onset);
THYM	cis	rs711830	0.965	rs6755777	chr2:177043226	T/G	cg26754761	chr2:177040938	NA	-0.55	-4.83	-0.44	5.24e-6	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs988913	0.768	rs9396003	chr6:54741853	A/G	cg19716238	chr6:54711378	FAM83B	0.52	5.19	0.47	1.19e-6	Menarche (age at onset);
THYM	cis	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	7.01	0.58	3.42e-10	Platelet count;
THYM	cis	rs4481887	0.927	rs4381224	chr1:248456826	A/T	cg13385794	chr1:248469461	NA	0.67	4.58	0.43	1.4e-5	Common traits (Other);
THYM	cis	rs2797685	1.000	rs2640908	chr1:7889941	C/T	cg06712362	chr1:7811235	CAMTA1	0.68	4.96	0.45	3.09e-6	Crohn's disease;
THYM	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs9796	0.689	rs7180494	chr15:41451841	T/C	cg21153102	chr15:41252147	NA	0.64	5.3	0.48	7.4e-7	Menopause (age at onset);
THYM	cis	rs2882877	0.610	rs13008848	chr2:190445284	C/G	cg10752008	chr2:190445175	SLC40A1	0.71	5.23	0.47	1e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg23758822	chr17:41437982	NA	1.17	11.04	0.75	1.02e-18	Menopause (age at onset);
THYM	cis	rs736801	0.964	rs17622656	chr5:131820997	A/G	cg00255919	chr5:131827918	IRF1	0.4	4.46	0.42	2.26e-5	Breast cancer;Mosquito bite size;
THYM	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg08999081	chr20:33150536	PIGU	0.73	6.56	0.56	2.86e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg10523679	chr1:76189770	ACADM	0.9	9.47	0.7	2.2e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs35264875	0.898	rs55648928	chr11:68861591	G/T	cg23845249	chr11:68861649	NA	0.55	6.45	0.55	4.67e-9	Blond vs. brown hair color;
THYM	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg25811766	chr13:21894605	NA	0.74	4.81	0.44	5.73e-6	White matter hyperintensity burden;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg09446250	chr11:82430349	NA	-0.98	-6.9	-0.58	5.69e-10	Depressive symptoms;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg11800714	chr1:70873816	NA	-0.88	-6.95	-0.58	4.57e-10	Depressive symptoms;
THYM	cis	rs3826795	0.569	rs73059722	chr19:46796418	G/A	cg15229275	chr19:46800054	HIF3A	0.92	5.54	0.49	2.69e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs2274459	0.841	rs12203688	chr6:33693624	G/T	cg06253072	chr6:33679850	C6orf125	-0.49	-4.89	-0.45	4.14e-6	Obesity (extreme);
THYM	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg22920501	chr2:26401640	FAM59B	-0.75	-6.85	-0.57	7.46e-10	Gut microbiome composition (summer);
THYM	cis	rs7107174	1.000	rs2256464	chr11:77917305	C/A	cg02023728	chr11:77925099	USP35	0.69	6.62	0.56	2.11e-9	Testicular germ cell tumor;
THYM	cis	rs747334	0.811	rs11814844	chr10:92715077	T/C	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs478304	0.654	rs10896029	chr11:65452952	C/T	cg17480646	chr11:65405466	SIPA1	-0.97	-8.99	-0.68	2.44e-14	Acne (severe);
THYM	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg09034736	chr1:150693464	HORMAD1	0.51	4.6	0.43	1.31e-5	Tonsillectomy;
THYM	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs1823778	0.609	rs2117557	chr18:67644013	C/T	cg12929678	chr18:67624393	CD226	1.3	4.63	0.43	1.14e-5	Mean platelet volume;
THYM	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs73198271	0.681	rs35457364	chr8:8649790	T/A	cg06636001	chr8:8085503	FLJ10661	-0.7	-4.77	-0.44	6.56e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4790333	1.000	rs2248821	chr17:2268311	G/A	cg02569219	chr17:2266849	SGSM2	0.74	6.55	0.56	2.93e-9	Proinsulin levels;
THYM	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg03476357	chr21:30257390	N6AMT1	-0.67	-5.02	-0.46	2.4e-6	Cognitive test performance;
THYM	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs9902453	0.868	rs8066602	chr17:28523085	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	6.59	0.56	2.45e-9	Coffee consumption (cups per day);
THYM	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg08645402	chr16:4508243	NA	0.68	5.74	0.51	1.11e-7	Schizophrenia;
THYM	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg04025307	chr7:1156635	C7orf50	0.78	6.72	0.57	1.32e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.68	-4.92	-0.45	3.68e-6	Gut microbiome composition (summer);
THYM	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg18357526	chr6:26021779	HIST1H4A	0.82	6.96	0.58	4.37e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7937682	0.711	rs4938792	chr11:111420936	T/C	cg09085632	chr11:111637200	PPP2R1B	0.85	7.01	0.58	3.38e-10	Primary sclerosing cholangitis;
THYM	cis	rs1994135	0.647	rs1351681	chr12:33698724	G/A	cg06521331	chr12:34319734	NA	-0.72	-4.99	-0.46	2.68e-6	Resting heart rate;
THYM	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg14129053	chr2:1895732	MYT1L	1.16	4.47	0.42	2.2e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg07341220	chr16:1583899	IFT140;TMEM204	-0.57	-4.93	-0.45	3.51e-6	Coronary artery disease;
THYM	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg08736216	chr1:53307985	ZYG11A	0.59	5.54	0.49	2.74e-7	Monocyte count;
THYM	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg26384229	chr12:38710491	ALG10B	0.97	7.44	0.61	4.48e-11	Bladder cancer;
THYM	cis	rs4974559	0.594	rs11946384	chr4:1313566	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.4	-4.68	-0.43	9.61e-6	Systolic blood pressure;
THYM	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg15536230	chr21:44985092	HSF2BP	0.42	5.18	0.47	1.26e-6	Mean corpuscular volume;
THYM	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.75	5.59	0.5	2.16e-7	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg16405210	chr4:1374714	KIAA1530	-1.03	-9.59	-0.7	1.24e-15	Longevity;
THYM	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.88	-9.05	-0.68	1.76e-14	Chronic sinus infection;
THYM	cis	rs600806	0.850	rs3768494	chr1:109935427	A/G	cg02175308	chr1:109941060	SORT1	-0.56	-4.99	-0.46	2.76e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6748734	0.895	rs4417704	chr2:241846573	A/G	cg02820040	chr2:241836501	C2orf54	-0.29	-4.47	-0.42	2.13e-5	Urinary metabolites;
THYM	cis	rs9902453	0.904	rs9905638	chr17:28261022	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.11	0.53	2.19e-8	Coffee consumption (cups per day);
THYM	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs863345	0.604	rs2873595	chr1:158508382	G/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11644478	chr21:40555479	PSMG1	-0.78	-6.84	-0.57	7.68e-10	Cognitive function;
THYM	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg19875535	chr5:140030758	IK	-0.69	-6.02	-0.53	3.29e-8	Depressive symptoms (multi-trait analysis);
THYM	cis	rs35264875	1.000	rs35264875	chr11:68846399	A/T	cg23845249	chr11:68861649	NA	0.54	5.48	0.49	3.53e-7	Blond vs. brown hair color;
THYM	cis	rs72627123	0.867	rs77320708	chr14:74478482	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.86	4.91	0.45	3.77e-6	Morning vs. evening chronotype;
THYM	cis	rs289828	0.501	rs13412131	chr2:152151969	T/C	cg05960677	chr2:152117363	RBM43	0.72	6.74	0.57	1.23e-9	Blood protein levels;
THYM	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg23711669	chr6:146136114	FBXO30	-0.95	-10.22	-0.72	5.58e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2073300	1.000	rs6114101	chr20:23446322	C/T	cg12062639	chr20:23401060	NAPB	1.32	6.06	0.53	2.7e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg01819863	chr10:32635814	EPC1	1.04	6.64	0.56	1.9e-9	Sexual dysfunction (female);
THYM	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg13695892	chr22:41940480	POLR3H	0.77	6.07	0.53	2.63e-8	Vitiligo;
THYM	cis	rs1448094	0.511	rs7976647	chr12:86158766	A/G	cg00310523	chr12:86230176	RASSF9	0.61	5.33	0.48	6.57e-7	Major depressive disorder;
THYM	trans	rs6089829	0.926	rs73921625	chr20:61660891	C/T	cg23505145	chr19:12996616	KLF1	-1.03	-8.42	-0.65	3.97e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3820068	0.626	rs11580170	chr1:15909744	C/T	cg27534772	chr1:16042836	PLEKHM2	0.49	4.64	0.43	1.13e-5	Systolic blood pressure;
THYM	cis	rs6956675	0.881	rs1829737	chr7:62576000	G/A	cg27518014	chr7:62859535	LOC100287834	0.64	4.91	0.45	3.78e-6	Obesity-related traits;
THYM	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg25767906	chr1:53392781	SCP2	-0.58	-5.87	-0.52	6.47e-8	Monocyte count;
THYM	cis	rs9399401	0.626	rs1928528	chr6:142779109	T/G	cg04461802	chr6:142623433	GPR126	0.77	7.26	0.6	1.08e-10	Chronic obstructive pulmonary disease;
THYM	cis	rs7027203	1.000	rs7027203	chr9:96562563	A/C	cg14598338	chr9:96623480	NA	0.44	4.71	0.43	8.55e-6	DNA methylation (variation);
THYM	cis	rs9902453	1.000	rs6505158	chr17:28403348	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-4.62	-0.43	1.2e-5	Coffee consumption (cups per day);
THYM	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg19346786	chr7:2764209	NA	-0.6	-5.2	-0.47	1.12e-6	Height;
THYM	cis	rs2797160	0.967	rs1739355	chr6:126018114	A/G	cg16306078	chr6:126000798	NA	0.54	5.45	0.49	3.96e-7	Endometrial cancer;
THYM	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	18.27	0.88	7.47e-33	Chronic sinus infection;
THYM	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg00495681	chr13:53174319	NA	-0.87	-8.28	-0.65	7.67e-13	Lewy body disease;
THYM	cis	rs34779708	0.931	rs2244100	chr10:35323636	G/A	cg03585969	chr10:35415529	CREM	-0.63	-4.66	-0.43	1.01e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs3181245	0.641	rs3756821	chr6:24646821	C/T	cg18428180	chr6:24646492	KIAA0319	0.65	5.39	0.48	5.09e-7	Colorectal or endometrial cancer;
THYM	trans	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs3892630	0.878	rs2903759	chr19:33195947	A/G	cg22980127	chr19:33182716	NUDT19	1.16	9.64	0.7	9.88e-16	Red blood cell traits;
THYM	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg23352942	chr3:46931381	PTH1R	-0.59	-5.3	-0.48	7.55e-7	Birth weight;
THYM	cis	rs1971762	0.509	rs784567	chr12:53894465	C/T	cg16917193	chr12:54089295	NA	-0.71	-5.98	-0.52	3.97e-8	Height;
THYM	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg22947322	chr17:47091978	IGF2BP1	-0.56	-4.76	-0.44	6.98e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs2456568	0.802	rs1506656	chr11:93639813	G/A	cg26875233	chr11:93583750	C11orf90	-0.53	-5.54	-0.49	2.72e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs12190007	0.604	rs7382308	chr6:169732276	A/C	cg16388071	chr6:169726476	NA	-0.55	-4.53	-0.42	1.69e-5	Obesity-related traits;
THYM	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg00990874	chr7:1149470	C7orf50	-0.69	-5.17	-0.47	1.29e-6	Bronchopulmonary dysplasia;
THYM	cis	rs4478037	0.642	rs77202692	chr3:33115776	A/C	cg19404215	chr3:33155277	CRTAP	0.99	6.87	0.58	6.5e-10	Major depressive disorder;
THYM	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg07022442	chr13:21864356	NA	0.72	4.76	0.44	6.91e-6	White matter hyperintensity burden;
THYM	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg03605463	chr16:89740564	NA	0.86	6.82	0.57	8.41e-10	Vitiligo;
THYM	cis	rs8077889	1.000	rs2066725	chr17:41891473	A/G	cg26893861	chr17:41843967	DUSP3	1.03	9.66	0.7	8.63e-16	Triglycerides;
THYM	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg00717180	chr2:96193071	NA	-0.69	-7.24	-0.6	1.13e-10	HDL cholesterol;
THYM	cis	rs13326165	0.585	rs3886875	chr3:52454262	T/G	cg08438690	chr3:52279403	PPM1M	-0.84	-4.6	-0.43	1.32e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs1050631	0.592	rs1785930	chr18:33723718	A/G	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.58	4.56	0.42	1.54e-5	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs4363385	0.782	rs4845515	chr1:153003871	G/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs4731207	0.698	rs7795492	chr7:124524131	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs16912285	0.535	rs7936178	chr11:24252515	G/T	ch.11.24196551F	chr11:24239977	NA	1.02	7.07	0.59	2.58e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg12826209	chr6:26865740	GUSBL1	0.83	4.86	0.45	4.57e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg09165964	chr15:75287851	SCAMP5	-0.7	-5.0	-0.46	2.64e-6	Blood trace element (Zn levels);
THYM	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg03476357	chr21:30257390	N6AMT1	0.59	4.6	0.43	1.31e-5	Dental caries;
THYM	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769707	0.632	rs135871	chr22:50008969	A/G	cg07959070	chr22:50026188	C22orf34	-0.28	-4.85	-0.45	4.85e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.0	11.31	0.76	2.66e-19	Chronic sinus infection;
THYM	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg04320152	chr17:18167836	SMCR7	0.6	4.63	0.43	1.15e-5	Total body bone mineral density;
THYM	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg17178900	chr1:205818956	PM20D1	1.1	11.95	0.77	1.26e-20	Menarche (age at onset);
THYM	cis	rs10887741	0.690	rs11202503	chr10:89440749	T/G	cg13926569	chr10:89418898	PAPSS2	0.64	6.85	0.57	7.46e-10	Exercise (leisure time);
THYM	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs12681287	0.517	rs34596274	chr8:87517679	C/T	cg27223183	chr8:87520930	FAM82B	-0.71	-5.43	-0.49	4.34e-7	Caudate activity during reward;
THYM	cis	rs921665	0.831	rs4402798	chr2:3190969	G/A	cg16434511	chr2:3151078	NA	-0.79	-5.31	-0.48	7.18e-7	World class endurance athleticism;
THYM	cis	rs2625529	0.730	rs35713471	chr15:72459971	C/A	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs4731207	0.596	rs4624966	chr7:124626471	C/A	cg05285228	chr7:124571219	POT1	-0.7	-5.29	-0.48	7.77e-7	Cutaneous malignant melanoma;
THYM	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg09467607	chr2:36825704	FEZ2	0.48	5.77	0.51	9.78e-8	Height;
THYM	cis	rs6840360	1.000	rs28637056	chr4:152652501	A/G	cg22705602	chr4:152727874	NA	-0.59	-6.36	-0.55	7.09e-9	Intelligence (multi-trait analysis);
THYM	cis	rs4950928	0.887	rs7556099	chr1:203166198	C/G	cg17014757	chr1:203156097	CHI3L1	-1.08	-6.5	-0.55	3.78e-9	YKL-40 levels;
THYM	cis	rs11731175	1.000	rs10009798	chr4:189848478	G/T	cg00431894	chr4:189871012	NA	-0.81	-6.15	-0.53	1.83e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2836974	0.604	rs914156	chr21:40717478	C/A	cg11890956	chr21:40555474	PSMG1	0.71	5.65	0.5	1.64e-7	Cognitive function;
THYM	cis	rs778371	0.723	rs6704763	chr2:233592487	C/T	cg08000102	chr2:233561755	GIGYF2	0.83	7.52	0.61	3.07e-11	Schizophrenia;
THYM	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs137603	0.966	rs126228	chr22:39681436	A/G	cg24268161	chr22:39747459	SYNGR1	-0.54	-4.66	-0.43	1.04e-5	Primary biliary cholangitis;
THYM	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	7.72	0.62	1.17e-11	Platelet count;
THYM	cis	rs4889911	0.544	rs1294081	chr17:77829864	T/C	cg00646381	chr17:77835854	NA	0.47	5.43	0.49	4.26e-7	Electroencephalogram traits;
THYM	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg21926883	chr2:100939477	LONRF2	-0.65	-5.96	-0.52	4.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-5.85	-0.51	7.01e-8	Total body bone mineral density;
THYM	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	5.79	0.51	9.14e-8	Rheumatoid arthritis;
THYM	cis	rs2046867	0.661	rs6790583	chr3:72901701	G/T	cg25664220	chr3:72788482	NA	-0.81	-7.48	-0.61	3.67e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11890956	chr21:40555474	PSMG1	-0.66	-6.38	-0.55	6.51e-9	Menarche (age at onset);
THYM	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg02915803	chr1:1606292	LOC728661;CDK11B	0.63	5.32	0.48	7.01e-7	Body mass index;
THYM	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.55	-5.64	-0.5	1.72e-7	Crohn's disease;
THYM	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg26967526	chr14:35346199	BAZ1A	-0.8	-5.27	-0.48	8.47e-7	Psoriasis;
THYM	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg09904177	chr6:26538194	HMGN4	0.62	5.12	0.46	1.61e-6	Intelligence (multi-trait analysis);
THYM	cis	rs988913	0.706	rs4715489	chr6:54732965	C/T	cg04690482	chr6:54711388	FAM83B	0.44	4.54	0.42	1.66e-5	Menarche (age at onset);
THYM	cis	rs288326	0.561	rs77184695	chr2:183802573	G/A	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	5.53	0.49	2.87e-7	Monocyte percentage of white cells;
THYM	cis	rs55728055	0.661	rs55894054	chr22:31976299	T/C	cg10537193	chr22:32026975	PISD	-0.66	-4.61	-0.43	1.26e-5	Age-related hearing impairment;
THYM	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg15298719	chr17:7165255	CLDN7	0.36	5.33	0.48	6.73e-7	Diastolic blood pressure;
THYM	cis	rs1535500	0.967	rs10947804	chr6:39282036	T/C	cg00012638	chr6:39280541	KCNK17	0.61	8.13	0.64	1.63e-12	Type 2 diabetes;
THYM	cis	rs977987	0.843	rs12149063	chr16:75451758	G/A	cg03315344	chr16:75512273	CHST6	0.76	6.16	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9549260	0.755	rs4429172	chr13:41189143	C/A	cg21288729	chr13:41239152	FOXO1	0.66	5.41	0.48	4.8e-7	Red blood cell count;
THYM	cis	rs2080501	0.628	rs1861656	chr16:49663019	G/T	cg05126388	chr16:49670144	ZNF423	-0.84	-10.88	-0.74	2.24e-18	IgG glycosylation;
THYM	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs1401999	0.714	rs13066518	chr3:183635498	T/A	cg01324343	chr3:183735012	ABCC5	0.62	8.53	0.66	2.31e-13	Anterior chamber depth;
THYM	cis	rs36051895	0.632	rs11791350	chr9:5172907	G/T	cg02405213	chr9:5042618	JAK2	-1.04	-10.48	-0.73	1.59e-17	Pediatric autoimmune diseases;
THYM	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg03433033	chr1:76189801	ACADM	-0.65	-6.0	-0.52	3.54e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs55665837	0.559	rs11023209	chr11:14422600	T/C	cg05501817	chr11:14380813	RRAS2	-0.79	-6.63	-0.56	2e-9	Vitamin D levels;
THYM	cis	rs921968	0.643	rs471846	chr2:219432237	C/T	cg02176678	chr2:219576539	TTLL4	0.64	6.08	0.53	2.49e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-5.32	-0.48	6.76e-7	Heart rate;
THYM	cis	rs7719624	0.870	rs1990199	chr5:135395543	G/C	cg15329133	chr5:135467951	SMAD5;SMAD5OS	0.58	5.03	0.46	2.31e-6	Response to cytidine analogues (gemcitabine);
THYM	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs6956675	0.957	rs10236165	chr7:62596446	T/A	cg27518014	chr7:62859535	LOC100287834	0.66	5.05	0.46	2.14e-6	Obesity-related traits;
THYM	cis	rs7078219	0.714	rs10883363	chr10:101287580	C/T	cg23904955	chr10:101282759	NA	-0.42	-4.97	-0.45	2.99e-6	Dental caries;
THYM	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg03929089	chr4:120376271	NA	-0.99	-12.81	-0.8	2.07e-22	Height;
THYM	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg11673840	chr17:47092156	IGF2BP1	-0.62	-7.77	-0.62	9.09e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg06784218	chr1:46089804	CCDC17	-0.3	-4.64	-0.43	1.1e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.72	-6.61	-0.56	2.2e-9	Personality dimensions;
THYM	cis	rs55728055	0.661	rs73162112	chr22:32045449	G/A	cg10537193	chr22:32026975	PISD	-0.76	-5.4	-0.48	5.01e-7	Age-related hearing impairment;
THYM	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg09537434	chr19:41945824	ATP5SL	-1.09	-10.25	-0.72	4.86e-17	Height;
THYM	cis	rs4730276	0.674	rs6943999	chr7:107531279	A/T	cg23293999	chr7:106826042	HBP1	-0.6	-4.86	-0.45	4.65e-6	Ulcerative colitis;
THYM	cis	rs75920871	0.528	rs7935834	chr11:116944437	C/G	cg20608306	chr11:116969690	SIK3	-0.54	-6.01	-0.52	3.45e-8	Subjective well-being;
THYM	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs8078723	0.901	rs709591	chr17:38175561	T/A	cg17467752	chr17:38218738	THRA	0.83	6.62	0.56	2.15e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs17125944	0.615	rs2357945	chr14:53318434	A/G	cg00686598	chr14:53173677	PSMC6	-1.01	-4.81	-0.44	5.62e-6	Alzheimer's disease (late onset);
THYM	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg18301423	chr5:131593218	PDLIM4	0.51	4.53	0.42	1.69e-5	Acylcarnitine levels;
THYM	cis	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg16898833	chr6:26189333	HIST1H4D	1.33	4.95	0.45	3.27e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg13695892	chr22:41940480	POLR3H	0.94	7.71	0.62	1.24e-11	Vitiligo;
THYM	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg13447684	chr7:1895903	MAD1L1	0.59	4.99	0.46	2.78e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs472402	0.580	rs10060745	chr5:6658003	T/C	cg12648172	chr5:5886274	NA	0.52	4.72	0.44	7.99e-6	Response to amphetamines;
THYM	cis	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg21775007	chr8:11205619	TDH	0.65	5.14	0.47	1.45e-6	Retinal vascular caliber;
THYM	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg01097406	chr16:89675127	NA	-0.86	-7.88	-0.63	5.44e-12	Vitiligo;
THYM	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg25703541	chr22:24373054	LOC391322	-0.86	-9.39	-0.69	3.35e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs112998813	0.571	rs12584203	chr13:114926296	G/A	cg02694521	chr13:114055881	NA	0.58	4.45	0.42	2.31e-5	Nodular sclerosis Hodgkin lymphoma;
THYM	cis	rs12509991	0.582	rs6827559	chr4:127051849	A/C	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs501916	0.796	rs55961203	chr15:48050518	G/T	cg16110827	chr15:48056943	SEMA6D	-0.65	-4.8	-0.44	5.85e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-4.78	-0.44	6.41e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7572733	0.555	rs10202569	chr2:198934726	C/G	cg00792783	chr2:198669748	PLCL1	0.71	4.61	0.43	1.28e-5	Dermatomyositis;
THYM	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg10505658	chr17:80084571	CCDC57	-0.66	-7.14	-0.59	1.86e-10	Life satisfaction;
THYM	cis	rs1568889	1.000	rs6484346	chr11:28040767	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	4.49	0.42	2.03e-5	Bipolar disorder;
THYM	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg09307838	chr4:120376055	NA	0.77	5.56	0.5	2.5e-7	Corneal astigmatism;
THYM	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs7809615	0.901	rs10235235	chr7:99075831	T/C	cg12290671	chr7:99195819	NA	-0.99	-4.83	-0.44	5.27e-6	Blood metabolite ratios;
THYM	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs189798	0.807	rs330905	chr8:8993551	A/T	cg15556689	chr8:8085844	FLJ10661	0.6	4.46	0.42	2.28e-5	Myopia (pathological);
THYM	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs686320	1.000	rs1787666	chr11:65249089	A/C	cg21144158	chr11:65211084	MIR612	0.62	4.53	0.42	1.71e-5	Hip circumference adjusted for BMI;
THYM	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg16325326	chr1:53192061	ZYG11B	0.97	11.07	0.75	8.85e-19	Monocyte count;
THYM	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.86	-0.45	4.62e-6	Eye color traits;
THYM	trans	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg25517755	chr10:38738941	LOC399744	-0.8	-7.87	-0.63	5.58e-12	Corneal astigmatism;
THYM	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg13319975	chr6:146136371	FBXO30	0.67	5.41	0.48	4.79e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7584330	0.554	rs74001383	chr2:238424418	T/C	cg08992911	chr2:238395768	MLPH	0.81	5.13	0.47	1.53e-6	Prostate cancer;
THYM	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	4.67	0.43	1.01e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg03806693	chr22:41940476	POLR3H	-1.06	-9.39	-0.69	3.4e-15	Vitiligo;
THYM	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg24874828	chr4:187887005	NA	-0.72	-7.55	-0.61	2.62e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9915657	0.966	rs8071725	chr17:70128726	C/T	cg06234051	chr17:70120541	SOX9	-0.56	-4.9	-0.45	3.93e-6	Thyroid hormone levels;
THYM	trans	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg10856724	chr12:34555212	NA	-1.01	-9.21	-0.69	7.89e-15	Bladder cancer;
THYM	cis	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg09085632	chr11:111637200	PPP2R1B	1.15	11.77	0.77	2.94e-20	Primary sclerosing cholangitis;
THYM	cis	rs7131987	0.650	rs10843377	chr12:29437053	C/G	cg09582351	chr12:29534625	ERGIC2	0.53	4.74	0.44	7.35e-6	QT interval;
THYM	cis	rs2504916	0.712	rs2450977	chr6:160713848	G/A	cg19643109	chr6:160697625	NA	-0.62	-4.67	-0.43	9.94e-6	Response to hepatitis C treatment;
THYM	cis	rs1953600	0.668	rs3122586	chr10:81950326	C/T	cg11900509	chr10:81946545	ANXA11	0.46	4.75	0.44	7.06e-6	Sarcoidosis;
THYM	cis	rs12096438	0.903	rs4418583	chr1:25893242	T/C	cg08876437	chr1:25228690	RUNX3	-0.52	-4.64	-0.43	1.13e-5	Platelet count;Mean platelet volume;
THYM	cis	rs4533251	0.524	rs10431831	chr15:97247993	C/T	cg14021153	chr15:96884532	NA	0.53	4.69	0.43	9.17e-6	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg07414643	chr4:187882934	NA	0.67	5.92	0.52	5.16e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg11266682	chr4:10021025	SLC2A9	0.71	9.91	0.71	2.51e-16	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.95	0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs6840360	1.000	rs6535813	chr4:152599652	A/T	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs526231	0.578	rs42860	chr5:102428118	G/T	cg23492399	chr5:102201601	PAM	-0.67	-5.18	-0.47	1.26e-6	Primary biliary cholangitis;
THYM	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg05025164	chr4:1340916	KIAA1530	0.91	7.06	0.59	2.68e-10	Longevity;
THYM	cis	rs28595532	0.920	rs28538455	chr4:119486817	T/C	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.21e-7	Cannabis dependence symptom count;
THYM	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs7246657	0.943	rs2112923	chr19:37940327	C/T	cg22634378	chr19:37742834	NA	0.62	5.18	0.47	1.22e-6	Coronary artery calcification;
THYM	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg01699819	chr7:1052092	C7orf50	-0.56	-4.96	-0.45	3.09e-6	Longevity;Endometriosis;
THYM	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg11526020	chr17:80870163	TBCD	-0.43	-4.67	-0.43	9.74e-6	Breast cancer;
THYM	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg14690197	chr8:22456421	C8orf58	0.5	4.91	0.45	3.76e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg05738196	chr6:26577821	NA	-0.65	-5.11	-0.46	1.66e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10847980	0.590	rs839360	chr12:123283841	A/G	cg25930673	chr12:123319894	HIP1R	1.08	5.6	0.5	2.07e-7	Adiponectin levels;
THYM	cis	rs7226229	0.950	rs4985964	chr17:20927277	G/T	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs8014204	0.839	rs6574197	chr14:75331487	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.58	-5.59	-0.5	2.13e-7	Caffeine consumption;
THYM	cis	rs9399401	0.710	rs12197866	chr6:142706063	C/T	cg04461802	chr6:142623433	GPR126	0.77	7.46	0.61	3.98e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs11792861	0.541	rs838824	chr9:111670707	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.64	-4.99	-0.46	2.77e-6	Menarche (age at onset);
THYM	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg16405210	chr4:1374714	KIAA1530	-0.89	-7.73	-0.62	1.09e-11	Longevity;
THYM	cis	rs2932538	0.922	rs6537744	chr1:113096746	C/G	cg22162597	chr1:113214053	CAPZA1	0.66	5.21	0.47	1.09e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg08847533	chr14:75593920	NEK9	-0.95	-9.92	-0.71	2.4e-16	Height;
THYM	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg27129171	chr3:47204927	SETD2	0.8	7.64	0.62	1.69e-11	Colorectal cancer;
THYM	cis	rs11726022	0.927	rs10434310	chr4:188170299	C/T	cg09690449	chr4:187998952	NA	-0.51	-5.15	-0.47	1.41e-6	Systolic blood pressure (cigarette smoking interaction);
THYM	cis	rs12410462	1.000	rs16847833	chr1:227626662	G/A	cg23173402	chr1:227635558	NA	0.68	6.15	0.53	1.79e-8	Major depressive disorder;
THYM	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg13607699	chr17:42295918	UBTF	0.9	9.27	0.69	5.91e-15	Total body bone mineral density;
THYM	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg01579765	chr21:45077557	HSF2BP	-0.46	-7.0	-0.58	3.66e-10	Mean corpuscular volume;
THYM	cis	rs7809950	1.000	rs10276604	chr7:107216738	C/T	cg23024343	chr7:107201750	COG5	0.93	8.32	0.65	6.49e-13	Coronary artery disease;
THYM	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.7	5.33	0.48	6.5e-7	Tonsillectomy;
THYM	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg09060608	chr5:178986726	RUFY1	0.6	6.78	0.57	1e-9	Lung cancer;
THYM	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.82	6.47	0.55	4.23e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1728785	0.681	rs4783647	chr16:68558048	G/A	cg02972257	chr16:68554789	NA	0.79	4.91	0.45	3.76e-6	Ulcerative colitis;
THYM	cis	rs1061377	0.513	rs2712000	chr4:39137082	G/T	cg24403649	chr4:39172243	NA	0.61	4.62	0.43	1.18e-5	Uric acid levels;
THYM	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg11632617	chr15:75315747	PPCDC	-0.54	-4.58	-0.43	1.39e-5	Blood trace element (Zn levels);
THYM	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg24846343	chr22:24311635	DDTL	0.46	5.78	0.51	9.38e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg25072359	chr17:41440525	NA	-0.72	-5.26	-0.47	8.95e-7	Menopause (age at onset);
THYM	cis	rs2273669	0.667	rs76267985	chr6:109326183	A/T	cg17117243	chr6:109341365	SESN1	-0.89	-5.32	-0.48	7.02e-7	Prostate cancer;
THYM	cis	rs2085601	0.542	rs2670624	chr4:89977728	A/G	cg17769793	chr4:89976368	FAM13A	0.59	6.62	0.56	2.17e-9	Hair greying;
THYM	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg18876405	chr7:65276391	NA	0.6	5.15	0.47	1.43e-6	Aortic root size;
THYM	cis	rs9486719	0.948	rs2472904	chr6:96874962	T/G	cg18709589	chr6:96969512	KIAA0776	0.76	4.97	0.45	2.98e-6	Migraine;Coronary artery disease;
THYM	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.75	-6.76	-0.57	1.12e-9	Prudent dietary pattern;
THYM	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg12826209	chr6:26865740	GUSBL1	0.94	5.02	0.46	2.37e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg08132940	chr7:1081526	C7orf50	-1.15	-6.58	-0.56	2.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6539288	0.803	rs2374651	chr12:107328124	A/G	cg26297688	chr12:107349093	C12orf23	-0.52	-6.11	-0.53	2.16e-8	Total body bone mineral density;
THYM	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg17757837	chr7:157058334	UBE3C	0.65	5.24	0.47	9.83e-7	Body mass index;
THYM	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg08270630	chr22:50330655	NA	-0.83	-4.52	-0.42	1.8e-5	Mean platelet volume;
THYM	cis	rs7078219	0.505	rs4129133	chr10:101284570	T/C	cg07044859	chr10:101282883	NA	-0.39	-4.52	-0.42	1.8e-5	Dental caries;
THYM	cis	rs8063160	0.740	rs71396950	chr16:89726550	G/A	cg07984980	chr16:89898383	SPIRE2	1.49	6.02	0.53	3.3e-8	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg02931644	chr1:25747376	RHCE	0.62	4.83	0.44	5.24e-6	Erythrocyte sedimentation rate;
THYM	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg18811423	chr2:55921094	PNPT1	0.73	6.99	0.58	3.79e-10	Metabolic syndrome;
THYM	cis	rs72627123	0.867	rs116568714	chr14:74381477	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.1	6.61	0.56	2.24e-9	Morning vs. evening chronotype;
THYM	cis	rs6840360	0.967	rs4696105	chr4:152606702	T/G	cg22705602	chr4:152727874	NA	-0.63	-6.79	-0.57	9.55e-10	Intelligence (multi-trait analysis);
THYM	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg14779329	chr11:130786720	SNX19	0.49	5.26	0.47	8.97e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs8070740	0.617	rs9908179	chr17:5323631	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.74	6.9	0.58	5.86e-10	Menopause (age at onset);
THYM	cis	rs6598955	0.585	rs6659822	chr1:26626408	C/A	cg08133631	chr1:26527909	CATSPER4	-0.55	-4.47	-0.42	2.17e-5	Obesity-related traits;
THYM	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.67	0.43	9.95e-6	Bipolar disorder;
THYM	cis	rs7084402	0.967	rs2842083	chr10:60329230	A/C	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs72627123	0.867	rs11848920	chr14:74476866	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.86	4.91	0.45	3.77e-6	Morning vs. evening chronotype;
THYM	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg08132940	chr7:1081526	C7orf50	-1.17	-6.67	-0.56	1.7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg12599982	chr1:44399894	ARTN	0.56	4.66	0.43	1.02e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7688540	0.771	rs11729365	chr4:272524	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.68	4.82	0.44	5.43e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs9611519	1.000	rs2273085	chr22:41615376	C/T	cg06481639	chr22:41940642	POLR3H	-0.63	-4.68	-0.43	9.34e-6	Neuroticism;
THYM	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-5.91	-0.52	5.41e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg25554036	chr4:6271136	WFS1	0.56	5.3	0.48	7.65e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs11651000	0.761	rs11079788	chr17:45820723	C/T	cg03474202	chr17:45855739	NA	-0.77	-6.92	-0.58	5.27e-10	IgG glycosylation;
THYM	cis	rs2832077	0.943	rs2832097	chr21:30173340	A/T	cg24692254	chr21:30365293	RNF160	0.75	4.5	0.42	1.93e-5	Cognitive test performance;
THYM	cis	rs7432375	1.000	rs10935186	chr3:136346206	T/C	cg12473912	chr3:136751656	NA	0.62	5.36	0.48	5.86e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg14675211	chr2:100938903	LONRF2	0.71	6.92	0.58	5.31e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.71	5.71	0.51	1.27e-7	Blood metabolite levels;
THYM	cis	rs61990749	0.544	rs2544567	chr14:78181739	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.02	0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs870825	0.616	rs28500698	chr4:185627746	A/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs3126085	0.935	rs6681433	chr1:152277396	T/C	cg10321714	chr1:152280068	FLG	-0.68	-4.95	-0.45	3.18e-6	Atopic dermatitis;
THYM	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg24642844	chr7:1081250	C7orf50	-0.94	-5.23	-0.47	9.98e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8014204	0.836	rs8021280	chr14:75290018	C/G	cg06637938	chr14:75390232	RPS6KL1	0.55	5.34	0.48	6.42e-7	Caffeine consumption;
THYM	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs34620785	0.571	rs13269273	chr8:103430407	C/T	cg09990700	chr8:103251014	RRM2B	-0.74	-4.53	-0.42	1.69e-5	Type 2 diabetes (age of onset);
THYM	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.76	6.46	0.55	4.35e-9	Lymphocyte percentage of white cells;
THYM	cis	rs4951011	0.882	rs7540327	chr1:203761520	C/T	cg24343524	chr1:203763352	ZC3H11A	0.71	6.32	0.54	8.49e-9	Breast cancer;
THYM	cis	rs7943358	1.000	rs7943358	chr11:15685570	A/G	cg11966998	chr11:15692519	NA	-0.46	-4.77	-0.44	6.6e-6	Gut microbiome composition (summer);
THYM	cis	rs1957429	0.901	rs3813422	chr14:65347404	G/A	cg23373153	chr14:65346875	NA	1.07	6.45	0.55	4.75e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs4638749	1.000	rs2219078	chr2:108875198	C/T	cg06795125	chr2:108905320	SULT1C2	-0.41	-5.43	-0.49	4.29e-7	Blood pressure;
THYM	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg15557168	chr22:42548783	NA	-0.59	-4.61	-0.43	1.25e-5	Schizophrenia;
THYM	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.58	0.56	2.61e-9	Total body bone mineral density;
THYM	cis	rs72627123	0.867	rs17094157	chr14:74416665	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.82	4.65	0.43	1.08e-5	Morning vs. evening chronotype;
THYM	cis	rs4246076	0.804	rs3765286	chr6:6589348	T/C	cg11302401	chr6:6688847	NA	0.42	4.71	0.44	8.31e-6	Urate levels in overweight individuals;
THYM	cis	rs17608059	0.566	rs5005684	chr17:13910633	T/C	cg11395062	chr17:14139857	CDRT15	0.67	5.36	0.48	5.77e-7	Temperament;
THYM	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg26384229	chr12:38710491	ALG10B	1.02	8.22	0.64	1.05e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg25703541	chr22:24373054	LOC391322	-0.77	-6.06	-0.53	2.74e-8	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs4919044	0.641	rs56112656	chr10:94678966	A/G	cg05127821	chr10:94822908	CYP26C1	-1.13	-6.96	-0.58	4.37e-10	Coronary artery disease;
THYM	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg23711669	chr6:146136114	FBXO30	0.83	8.07	0.64	2.16e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7107174	1.000	rs1567890	chr11:78101700	T/C	cg02023728	chr11:77925099	USP35	0.63	6.01	0.53	3.35e-8	Testicular germ cell tumor;
THYM	cis	rs3741151	0.686	rs1002127	chr11:73103835	G/C	cg17517138	chr11:73019481	ARHGEF17	0.82	5.1	0.46	1.75e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg22907277	chr7:1156413	C7orf50	0.86	5.31	0.48	7.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4889855	0.556	rs4890043	chr17:78526831	C/T	cg16591659	chr17:78472290	NA	0.42	4.86	0.45	4.54e-6	Fractional excretion of uric acid;
THYM	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.57	-5.62	-0.5	1.87e-7	Longevity;Endometriosis;
THYM	cis	rs9972944	0.729	rs7211481	chr17:63766434	A/C	cg07283582	chr17:63770753	CCDC46	-0.63	-4.93	-0.45	3.51e-6	Total body bone mineral density;
THYM	cis	rs13102973	0.829	rs13126756	chr4:135900185	G/A	cg14419869	chr4:135874104	NA	0.82	6.86	0.58	7.03e-10	Subjective well-being;
THYM	cis	rs10089	1.000	rs10089	chr5:127522543	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.94	5.66	0.5	1.6e-7	Ileal carcinoids;
THYM	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg12386194	chr3:101231763	SENP7	0.73	4.61	0.43	1.27e-5	Colorectal cancer;
THYM	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg11871910	chr12:69753446	YEATS4	-0.62	-4.54	-0.42	1.63e-5	Response to diuretic therapy;
THYM	cis	rs28795989	0.896	rs28734123	chr4:7888412	G/A	cg12728606	chr4:7903970	AFAP1	0.44	4.64	0.43	1.09e-5	Intraocular pressure;
THYM	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs1018836	0.812	rs10808619	chr8:91622916	A/T	cg16814680	chr8:91681699	NA	-0.98	-9.08	-0.68	1.5e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg10523679	chr1:76189770	ACADM	-0.56	-4.78	-0.44	6.31e-6	Daytime sleep phenotypes;
THYM	cis	rs7586879	0.593	rs10198356	chr2:25130592	A/G	cg15423357	chr2:25149977	NA	0.7	7.76	0.62	9.56e-12	Body mass index;
THYM	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg07936489	chr17:37558343	FBXL20	-0.85	-5.64	-0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs933688	1.000	rs186717	chr5:90780467	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.82	5.49	0.49	3.36e-7	Smoking behavior;
THYM	cis	rs9287719	1.000	rs9287719	chr2:10710730	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.89	9.71	0.71	6.8e-16	Prudent dietary pattern;
THYM	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.58	-7.18	-0.59	1.54e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs9527	0.640	rs35195396	chr10:104928770	T/A	cg04362960	chr10:104952993	NT5C2	0.65	5.04	0.46	2.18e-6	Arsenic metabolism;
THYM	cis	rs9633835	0.642	rs28711392	chr11:13349559	T/C	cg13286116	chr11:13302098	ARNTL	0.61	6.34	0.55	7.81e-9	Body mass index;
THYM	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg25072359	chr17:41440525	NA	0.65	4.56	0.42	1.5e-5	Menopause (age at onset);
THYM	cis	rs2040771	0.745	rs2283646	chr22:19273902	A/G	cg02655711	chr22:19163373	SLC25A1	-0.55	-5.89	-0.52	5.92e-8	Metabolite levels (small molecules and protein measures);
THYM	cis	rs7119	0.717	rs12910951	chr15:77806797	A/G	cg27398640	chr15:77910606	LINGO1	-0.52	-5.21	-0.47	1.12e-6	Type 2 diabetes;
THYM	cis	rs11864146	0.557	rs111875323	chr16:84045480	C/G	cg06701800	chr16:84600468	COTL1	1.01	4.52	0.42	1.77e-5	Non-alcoholic fatty liver disease histology (other);
THYM	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg24060327	chr5:131705240	SLC22A5	0.71	5.41	0.49	4.66e-7	Blood metabolite levels;
THYM	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11785693	0.862	rs62491168	chr8:4982290	A/T	cg26367366	chr8:4980734	NA	1.21	6.11	0.53	2.2e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg23583168	chr7:148888333	NA	-1.11	-16.68	-0.86	5.53e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs35063026	1.000	rs35063026	chr16:89736157	C/T	cg07984980	chr16:89898383	SPIRE2	1.49	6.02	0.53	3.3e-8	Facial pigmentation;Squamous cell carcinoma;
THYM	cis	rs12519773	0.576	rs55971857	chr5:92441594	A/C	cg18783429	chr5:92414398	NA	0.52	5.19	0.47	1.19e-6	Migraine;
THYM	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9443189	0.526	rs10943250	chr6:76208445	C/G	cg01950844	chr6:76311363	SENP6	1.15	5.85	0.51	6.9e-8	Prostate cancer;
THYM	cis	rs1580019	0.961	rs2392056	chr7:32498953	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.62	0.56	2.16e-9	Cognitive ability;
THYM	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg13319975	chr6:146136371	FBXO30	-0.64	-5.33	-0.48	6.48e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.88	10.0	0.72	1.67e-16	Prudent dietary pattern;
THYM	cis	rs2404602	0.647	rs11072626	chr15:77090826	A/G	cg23625390	chr15:77176239	SCAPER	-0.82	-6.01	-0.53	3.35e-8	Blood metabolite levels;
THYM	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg01483505	chr11:975446	AP2A2	0.57	4.63	0.43	1.16e-5	Alzheimer's disease (late onset);
THYM	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.64	-5.55	-0.49	2.61e-7	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg09904177	chr6:26538194	HMGN4	0.64	5.41	0.49	4.78e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg10018233	chr7:150070692	REPIN1	0.36	5.14	0.47	1.44e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg14675211	chr2:100938903	LONRF2	0.76	8.18	0.64	1.25e-12	Intelligence (multi-trait analysis);
THYM	cis	rs2235573	0.625	rs3026677	chr22:38432725	C/G	cg19171272	chr22:38449367	NA	-0.51	-5.38	-0.48	5.38e-7	Glioblastoma;Glioma;
THYM	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs11690935	1.000	rs6757773	chr2:172549630	T/A	cg13550731	chr2:172543902	DYNC1I2	0.88	6.48	0.55	4.02e-9	Schizophrenia;
THYM	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.63	5.02	0.46	2.37e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7089973	0.564	rs55671354	chr10:116571281	T/C	cg23260525	chr10:116636907	FAM160B1	0.53	5.41	0.49	4.69e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs8067545	0.611	rs2703812	chr17:20114803	A/G	cg20830565	chr17:20408647	MGC102966	0.49	4.48	0.42	2.05e-5	Schizophrenia;
THYM	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.32	-0.48	7.02e-7	Monocyte percentage of white cells;
THYM	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg08847533	chr14:75593920	NEK9	1.02	11.25	0.76	3.61e-19	Height;
THYM	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg12560992	chr17:57184187	TRIM37	0.93	8.77	0.67	7.1e-14	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg16586182	chr3:47516702	SCAP	0.68	5.65	0.5	1.69e-7	Colorectal cancer;
THYM	cis	rs1011018	0.955	rs10262775	chr7:139464375	A/G	cg06079564	chr7:139468310	HIPK2	-0.77	-5.98	-0.52	3.9e-8	Systolic blood pressure;
THYM	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.89	-6.9	-0.58	5.85e-10	Multiple sclerosis;
THYM	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg06009448	chr7:1102226	C7orf50	0.53	5.55	0.49	2.6e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg03161606	chr19:29218774	NA	0.94	8.06	0.64	2.27e-12	Methadone dose in opioid dependence;
THYM	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.36	0.55	7.09e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg11494091	chr17:61959527	GH2	0.96	12.57	0.79	6.42e-22	Prudent dietary pattern;
THYM	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg21784768	chr11:537496	LRRC56	-1.09	-5.41	-0.49	4.65e-7	Body mass index;
THYM	cis	rs3942852	0.868	rs58407618	chr11:48104167	T/G	cg25800328	chr11:47736132	AGBL2	-0.51	-4.68	-0.43	9.4e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg00277334	chr10:82204260	NA	-0.53	-5.41	-0.49	4.75e-7	Post bronchodilator FEV1;
THYM	cis	rs960902	0.648	rs11124584	chr2:37711857	C/T	cg25341268	chr2:37734390	NA	0.57	4.53	0.42	1.69e-5	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg22907277	chr7:1156413	C7orf50	0.8	4.85	0.45	4.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg24503407	chr1:205819492	PM20D1	0.72	6.39	0.55	6.07e-9	Menarche (age at onset);
THYM	cis	rs2888875	0.561	rs17031100	chr2:43821186	T/G	cg22033476	chr2:43532275	THADA	-0.4	-4.61	-0.43	1.26e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs988913	0.706	rs10948870	chr6:54745098	G/A	cg19716238	chr6:54711378	FAM83B	0.52	5.19	0.47	1.19e-6	Menarche (age at onset);
THYM	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.73	6.78	0.57	1.02e-9	Personality dimensions;
THYM	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.78	7.55	0.61	2.65e-11	Menarche (age at onset);
THYM	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.7	7.02	0.58	3.29e-10	Lymphocyte counts;
THYM	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg27588902	chr6:42928151	GNMT	-0.56	-5.54	-0.49	2.65e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg18904891	chr8:8559673	CLDN23	-0.63	-5.32	-0.48	6.8e-7	Mood instability;
THYM	cis	rs988913	0.629	rs34685175	chr6:54866737	G/C	cg18532076	chr6:54711417	FAM83B	0.54	4.99	0.46	2.74e-6	Menarche (age at onset);
THYM	cis	rs10887741	0.542	rs1969823	chr10:89415425	T/C	cg13926569	chr10:89418898	PAPSS2	-0.62	-5.87	-0.52	6.33e-8	Exercise (leisure time);
THYM	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg10360139	chr7:1886902	MAD1L1	-0.6	-5.19	-0.47	1.18e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg13443165	chr9:33130375	B4GALT1	-0.87	-7.97	-0.63	3.46e-12	IgG glycosylation;
THYM	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs887829	0.570	rs10171367	chr2:234597667	C/G	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.57	-0.42	1.45e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg26384229	chr12:38710491	ALG10B	0.95	7.45	0.61	4.26e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg01570182	chr17:44337453	NA	0.87	9.49	0.7	2e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg18758796	chr5:131593413	PDLIM4	0.51	5.2	0.47	1.14e-6	Lung function (FEV1/FVC);
THYM	cis	rs2334880	0.678	rs57821244	chr16:71553791	G/C	cg06353428	chr16:71660113	MARVELD3	-1.02	-5.08	-0.46	1.84e-6	Malaria;
THYM	cis	rs12310956	0.532	rs11494810	chr12:33952881	C/A	cg06521331	chr12:34319734	NA	-0.92	-8.57	-0.66	1.89e-13	Morning vs. evening chronotype;
THYM	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	7.13	0.59	1.91e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs853679	0.599	rs156743	chr6:27967089	T/C	cg12963246	chr6:28129442	ZNF389	0.93	4.96	0.45	3.12e-6	Depression;
THYM	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs12817211	0.502	rs3741562	chr12:50529736	G/A	cg06168149	chr12:50497778	GPD1	0.31	4.72	0.44	8.07e-6	Colorectal or endometrial cancer;
THYM	cis	rs921665	0.831	rs11682390	chr2:3187698	G/A	cg16434511	chr2:3151078	NA	-0.82	-5.22	-0.47	1.05e-6	World class endurance athleticism;
THYM	cis	rs791888	0.965	rs791875	chr10:89406088	C/T	cg13926569	chr10:89418898	PAPSS2	-0.66	-7.15	-0.59	1.77e-10	Magnesium levels;
THYM	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg18252515	chr7:66147081	NA	-1.45	-8.88	-0.67	4.01e-14	Diabetic kidney disease;
THYM	cis	rs3925075	1.000	rs9673405	chr16:31347599	A/C	cg02846316	chr16:31340340	ITGAM	0.57	5.99	0.52	3.79e-8	IgA nephropathy;
THYM	cis	rs11214589	0.774	rs877137	chr11:113256330	C/T	cg14159747	chr11:113255604	NA	0.38	8.65	0.66	1.25e-13	Neuroticism;
THYM	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg05738196	chr6:26577821	NA	0.69	5.49	0.49	3.27e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7119	0.717	rs12916973	chr15:77808099	C/T	cg27398640	chr15:77910606	LINGO1	0.52	5.21	0.47	1.12e-6	Type 2 diabetes;
THYM	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg13447684	chr7:1895903	MAD1L1	0.54	4.54	0.42	1.62e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg13695892	chr22:41940480	POLR3H	0.89	6.39	0.55	6.2e-9	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs3791406	1.000	rs3791405	chr2:240030284	G/A	cg11903188	chr2:239195602	PER2	-0.43	-4.59	-0.43	1.37e-5	Skin aging (microtopography measurement);
THYM	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Bladder cancer;
THYM	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg05368731	chr17:41323189	NBR1	1.26	10.95	0.75	1.6e-18	Menopause (age at onset);
THYM	cis	rs11089937	0.521	rs6001221	chr22:22539566	C/G	cg06866756	chr22:22471216	NA	-0.47	-5.34	-0.48	6.43e-7	Periodontitis (PAL4Q3);
THYM	cis	rs2235649	0.551	rs57876690	chr16:1810116	C/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.46	-4.5	-0.42	1.92e-5	Blood metabolite levels;
THYM	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg05855489	chr10:104503620	C10orf26	-0.59	-4.62	-0.43	1.23e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs55728055	0.661	rs12168645	chr22:32061014	G/A	cg01338084	chr22:32026380	PISD	1.2	4.86	0.45	4.6e-6	Age-related hearing impairment;
THYM	cis	rs28595532	0.920	rs116717907	chr4:119762568	A/G	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs7267979	1.000	rs2424712	chr20:25416942	T/C	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs758324	0.732	rs152056	chr5:131517482	C/T	cg16205897	chr5:131564050	P4HA2	0.6	5.06	0.46	2.09e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs1048238	0.605	rs1889785	chr1:16348729	G/A	cg22431228	chr1:16359049	CLCNKA	-0.57	-5.5	-0.49	3.19e-7	Systolic blood pressure;
THYM	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg04362960	chr10:104952993	NT5C2	0.57	4.68	0.43	9.7e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	4.93	0.45	3.51e-6	Motion sickness;
THYM	cis	rs200810	0.653	rs10457310	chr6:97983877	C/T	cg16511841	chr6:97730490	C6orf167;MIR548H3	0.79	4.72	0.44	8.28e-6	Body mass index;
THYM	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg18252515	chr7:66147081	NA	0.66	5.09	0.46	1.84e-6	Aortic root size;
THYM	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	14.79	0.83	2.2e-26	Chronic sinus infection;
THYM	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg18032289	chr17:61959525	GH2	-0.49	-4.65	-0.43	1.09e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	6.17	0.54	1.63e-8	Mean corpuscular hemoglobin;
THYM	cis	rs10924970	0.967	rs10754588	chr1:235438205	C/T	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs7084921	0.608	rs2862950	chr10:101844785	A/G	cg11344164	chr10:101878520	NA	-0.55	-4.76	-0.44	6.9e-6	Bone mineral density;
THYM	cis	rs2276498	0.751	rs2072128	chr20:52645646	G/A	cg23682609	chr20:52687365	BCAS1	0.56	4.57	0.42	1.45e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs12540874	0.728	rs3807563	chr7:50566390	C/T	cg00647317	chr7:50633725	DDC	0.37	5.34	0.48	6.3e-7	Systemic sclerosis;
THYM	cis	rs12478296	0.786	rs6721704	chr2:242994923	A/G	cg06360820	chr2:242988706	NA	-1.01	-7.18	-0.59	1.55e-10	Obesity-related traits;
THYM	cis	rs1018836	0.608	rs7843149	chr8:91474961	C/T	cg16814680	chr8:91681699	NA	-0.73	-5.92	-0.52	5.03e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7586879	0.828	rs9631061	chr2:25109804	C/T	cg01884057	chr2:25150051	NA	0.52	4.65	0.43	1.09e-5	Body mass index;
THYM	cis	rs2219968	0.962	rs9643732	chr8:78946230	G/A	cg00738934	chr8:78996279	NA	0.79	8.42	0.65	3.88e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg02734326	chr4:10020555	SLC2A9	0.73	6.39	0.55	6.19e-9	Bone mineral density;
THYM	cis	rs1670533	0.818	rs585735	chr4:1080391	G/C	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs4072705	0.646	rs7865700	chr9:127246184	G/A	cg01786973	chr9:127249749	NR5A1	-0.37	-4.57	-0.42	1.46e-5	Menarche (age at onset);
THYM	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg04944784	chr2:26401820	FAM59B	-0.78	-6.06	-0.53	2.71e-8	Gut microbiome composition (summer);
THYM	cis	rs1904096	0.506	rs13435702	chr4:95167751	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.51	-4.45	-0.42	2.32e-5	Type 2 diabetes;
THYM	cis	rs6785206	0.614	rs2712430	chr3:128337438	A/C	cg16766828	chr3:128327626	NA	-0.75	-7.34	-0.6	7.04e-11	Lymphocyte percentage of white cells;
THYM	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg13319975	chr6:146136371	FBXO30	-0.63	-5.21	-0.47	1.12e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs240764	0.717	rs13208757	chr6:101175014	C/T	cg21058520	chr6:100914733	NA	0.58	4.97	0.45	2.95e-6	Neuroticism;
THYM	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg07362569	chr17:61921086	SMARCD2	0.7	6.23	0.54	1.25e-8	Prudent dietary pattern;
THYM	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg11266682	chr4:10021025	SLC2A9	-0.62	-8.42	-0.65	3.89e-13	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03452623	chr4:187889614	NA	-1.19	-19.33	-0.89	1.1e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9677476	0.863	rs13423632	chr2:232079116	T/C	cg07929768	chr2:232055508	NA	0.63	6.38	0.55	6.5e-9	Food antigen IgG levels;
THYM	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs6546537	0.824	rs3771543	chr2:69784255	C/T	cg10773587	chr2:69614142	GFPT1	-0.63	-4.87	-0.45	4.4e-6	Serum thyroid-stimulating hormone levels;
THYM	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg26022315	chr17:47021804	SNF8	0.51	4.87	0.45	4.44e-6	Type 2 diabetes;
THYM	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg00631329	chr6:26305371	NA	0.63	7.37	0.6	6.26e-11	Educational attainment;
THYM	cis	rs7247513	0.759	rs73002392	chr19:12768391	G/A	cg01871581	chr19:12707946	ZNF490	-0.77	-7.68	-0.62	1.41e-11	Bipolar disorder;
THYM	cis	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg13609457	chr4:120235615	NA	-0.56	-5.24	-0.47	9.65e-7	Corneal astigmatism;
THYM	cis	rs11249608	0.789	rs7704963	chr5:178436854	A/G	cg01312482	chr5:178451176	ZNF879	-0.59	-4.78	-0.44	6.34e-6	Pubertal anthropometrics;
THYM	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg11245990	chr11:68621969	NA	0.55	7.26	0.6	1.03e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg11752832	chr7:134001865	SLC35B4	0.62	4.69	0.43	9.25e-6	Mean platelet volume;
THYM	cis	rs2625529	0.824	rs4777470	chr15:72207518	T/A	cg16672083	chr15:72433130	SENP8	-0.56	-5.03	-0.46	2.35e-6	Red blood cell count;
THYM	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg26038318	chr20:34205095	SPAG4	0.66	5.42	0.49	4.59e-7	Total cholesterol levels;
THYM	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg16586182	chr3:47516702	SCAP	0.63	5.6	0.5	2.12e-7	Colorectal cancer;
THYM	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg00981070	chr1:2046702	PRKCZ	0.47	5.21	0.47	1.1e-6	Height;
THYM	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg00071950	chr4:10020882	SLC2A9	-0.55	-4.89	-0.45	4.17e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg24692254	chr21:30365293	RNF160	-0.84	-7.53	-0.61	2.89e-11	Dental caries;
THYM	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs12472274	0.646	rs34465035	chr2:239114093	C/A	cg17459225	chr2:239074497	NA	0.74	5.11	0.46	1.67e-6	Phospholipid levels (plasma);
THYM	cis	rs7246657	0.882	rs6508719	chr19:37877419	A/G	cg22634378	chr19:37742834	NA	0.61	5.17	0.47	1.32e-6	Coronary artery calcification;
THYM	cis	rs6032067	0.777	rs13039211	chr20:43784396	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	trans	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg06437703	chr8:37914619	EIF4EBP1	0.74	7.05	0.59	2.86e-10	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg05373962	chr22:49881684	NA	-0.67	-6.07	-0.53	2.57e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg15592062	chr6:167189543	RPS6KA2	0.59	6.16	0.53	1.73e-8	Crohn's disease;
THYM	cis	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg21775007	chr8:11205619	TDH	-0.61	-4.87	-0.45	4.5e-6	Retinal vascular caliber;
THYM	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	5.38	0.48	5.34e-7	Height;
THYM	cis	rs3087591	1.000	rs1800845	chr17:29703438	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.61	-5.11	-0.46	1.63e-6	Hip circumference;
THYM	cis	rs8133932	1.000	rs8133932	chr21:47211085	C/T	cg20357416	chr21:47294739	PCBP3	0.77	4.56	0.42	1.54e-5	Schizophrenia;
THYM	cis	rs4654899	0.929	rs7552999	chr1:21314454	T/C	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.26e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg00898013	chr13:113819073	PROZ	1.02	10.0	0.72	1.62e-16	Platelet distribution width;
THYM	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-5.92	-0.52	5.16e-8	Total cholesterol levels;
THYM	cis	rs938554	0.513	rs3775948	chr4:9995182	G/C	cg26689780	chr4:10079554	WDR1	-0.4	-4.59	-0.43	1.33e-5	Blood metabolite levels;
THYM	cis	rs669446	0.533	rs3862228	chr1:44196945	C/T	cg12599982	chr1:44399894	ARTN	0.53	4.87	0.45	4.39e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs9500256	0.934	rs1343391	chr6:58344154	C/G	cg16251399	chr6:58287822	GUSBL2	0.66	5.23	0.47	1.02e-6	Eosinophilic esophagitis (pediatric);
THYM	cis	rs9460635	0.919	rs9466089	chr6:21451676	A/G	cg11817533	chr6:21523501	NA	-0.59	-4.63	-0.43	1.16e-5	Metabolite levels (HVA-5-HIAA Factor score);
THYM	cis	rs1018836	0.923	rs10808615	chr8:91569704	A/T	cg16814680	chr8:91681699	NA	-0.78	-6.45	-0.55	4.73e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg11812906	chr14:75593930	NEK9	-0.77	-7.31	-0.6	8.21e-11	Height;
THYM	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg03474202	chr17:45855739	NA	-0.74	-6.5	-0.55	3.7e-9	IgG glycosylation;
THYM	cis	rs2073300	1.000	rs59283536	chr20:23457575	A/T	cg12062639	chr20:23401060	NAPB	0.99	4.96	0.45	3.07e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg06219351	chr7:158114137	PTPRN2	-0.7	-6.22	-0.54	1.35e-8	Calcium levels;
THYM	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg27129171	chr3:47204927	SETD2	0.69	6.63	0.56	2.04e-9	Colorectal cancer;
THYM	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg18252515	chr7:66147081	NA	0.72	5.6	0.5	2.03e-7	Aortic root size;
THYM	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs7119038	0.774	rs73005423	chr11:118681079	A/G	cg19308663	chr11:118741387	NA	0.54	5.73	0.51	1.18e-7	Sjögren's syndrome;
THYM	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	5.78	0.51	9.52e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg25358565	chr5:93447407	FAM172A	1.3	10.52	0.73	1.3e-17	Diabetic retinopathy;
THYM	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs11756438	0.571	rs4946356	chr6:119020195	G/A	cg21191810	chr6:118973309	C6orf204	0.6	6.2	0.54	1.43e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	12.13	0.78	5.13e-21	Chronic sinus infection;
THYM	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg06009448	chr7:1102226	C7orf50	0.35	4.52	0.42	1.78e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6754311	0.517	rs60453613	chr2:136527120	G/C	cg20242066	chr2:136595261	LCT	0.55	5.64	0.5	1.73e-7	Mosquito bite size;
THYM	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.9	-0.45	3.91e-6	Mean corpuscular volume;
THYM	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg18681998	chr4:17616180	MED28	-0.93	-8.56	-0.66	2e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg06521331	chr12:34319734	NA	-1.02	-10.94	-0.75	1.65e-18	Morning vs. evening chronotype;
THYM	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg26721908	chr21:47610096	LSS	-0.73	-5.02	-0.46	2.42e-6	Testicular germ cell tumor;
THYM	cis	rs71403859	0.730	rs12927768	chr16:71645263	G/A	cg08717414	chr16:71523259	ZNF19	-0.92	-5.01	-0.46	2.5e-6	Post bronchodilator FEV1;
THYM	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg18252515	chr7:66147081	NA	-1.6	-8.8	-0.67	6.03e-14	Diabetic kidney disease;
THYM	trans	rs12195417	0.603	rs613839	chr6:84212790	G/A	cg00797837	chr17:19912916	NA	-0.9	-7.07	-0.59	2.54e-10	Schizophrenia;
THYM	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg22875332	chr1:76189707	ACADM	0.9	10.54	0.73	1.18e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6500395	1.000	rs12934126	chr16:48705951	C/G	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs11771526	0.901	rs10239582	chr7:32298116	T/A	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs6500395	0.926	rs11076572	chr16:48623621	T/G	cg04672837	chr16:48644449	N4BP1	0.48	4.64	0.43	1.13e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg20887711	chr4:1340912	KIAA1530	0.75	6.78	0.57	1e-9	Longevity;
THYM	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg15997130	chr1:24165203	NA	-0.78	-7.03	-0.59	3.11e-10	Immature fraction of reticulocytes;
THYM	cis	rs6964587	0.610	rs4729008	chr7:91457054	G/T	cg22709100	chr7:91322751	NA	0.62	4.47	0.42	2.16e-5	Breast cancer;
THYM	cis	rs7626444	0.625	rs2686599	chr3:196483794	G/A	cg12930392	chr3:196481615	PAK2	0.4	4.97	0.45	2.97e-6	Monocyte count;
THYM	cis	rs1499972	0.938	rs843852	chr3:117721428	A/G	cg07612923	chr3:117604196	NA	-1.5	-5.16	-0.47	1.38e-6	Schizophrenia;
THYM	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg00852783	chr1:26633632	UBXN11	0.83	8.51	0.66	2.46e-13	Obesity-related traits;
THYM	cis	rs748404	0.690	rs2924369	chr15:43777985	G/A	cg12861797	chr15:43585817	TGM7	-0.44	-4.53	-0.42	1.71e-5	Lung cancer;
THYM	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg27534772	chr1:16042836	PLEKHM2	0.53	5.9	0.52	5.65e-8	Systolic blood pressure;
THYM	cis	rs6768930	0.509	rs55645723	chr3:57750240	G/A	cg07735586	chr3:57945651	NA	-0.33	-4.9	-0.45	3.9e-6	Obesity-related traits;
THYM	cis	rs7584330	0.554	rs7558685	chr2:238434943	A/G	cg14458575	chr2:238380390	NA	0.81	4.86	0.45	4.63e-6	Prostate cancer;
THYM	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.16	-0.75	5.56e-19	Primary sclerosing cholangitis;
THYM	cis	rs12579753	0.917	rs11115029	chr12:82202219	C/G	cg21231944	chr12:82153410	PPFIA2	-0.66	-5.01	-0.46	2.51e-6	Resting heart rate;
THYM	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg23583168	chr7:148888333	NA	-1.02	-13.68	-0.81	3.53e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg09904177	chr6:26538194	HMGN4	0.54	4.57	0.42	1.47e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg00278517	chr6:167070616	RPS6KA2	-0.35	-4.81	-0.44	5.73e-6	Crohn's disease;
THYM	cis	rs2675662	0.525	rs12264025	chr10:75494450	A/G	cg19442545	chr10:75533431	FUT11	-0.51	-5.22	-0.47	1.03e-6	Psoriasis vulgaris;Psoriasis;
THYM	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg09260853	chr1:2094483	PRKCZ	-0.46	-4.66	-0.43	1.03e-5	Height;
THYM	cis	rs6558530	0.932	rs4370560	chr8:1708194	G/A	cg09410841	chr8:1729607	CLN8	0.75	5.54	0.49	2.74e-7	Systolic blood pressure;
THYM	cis	rs1395	0.677	rs113353646	chr2:27492674	C/T	cg23587288	chr2:27483067	SLC30A3	-0.61	-5.43	-0.49	4.34e-7	Blood metabolite levels;
THYM	cis	rs6598541	0.890	rs57516305	chr15:99288559	C/T	cg13297560	chr15:99320054	IGF1R	-0.49	-4.48	-0.42	2.11e-5	Urate levels;
THYM	cis	rs360798	0.512	rs2215870	chr2:63132342	C/G	cg17519650	chr2:63277830	OTX1	0.69	4.82	0.44	5.38e-6	Coronary artery disease;
THYM	cis	rs1642645	0.831	rs4660212	chr1:42496399	C/T	cg22816091	chr1:42611670	NA	-0.65	-5.68	-0.5	1.49e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg09260853	chr1:2094483	PRKCZ	-0.44	-4.56	-0.42	1.55e-5	Height;
THYM	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg00256281	chr22:41985642	PMM1	-0.57	-4.69	-0.43	9.08e-6	Vitiligo;
THYM	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs6430585	0.591	rs75223002	chr2:136525309	G/T	cg04750100	chr2:136595281	LCT	0.53	4.86	0.45	4.59e-6	Corneal structure;
THYM	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg08847533	chr14:75593920	NEK9	-1.01	-11.33	-0.76	2.42e-19	Height;
THYM	cis	rs240764	0.548	rs12206838	chr6:101180128	G/A	cg21058520	chr6:100914733	NA	0.56	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs2294693	0.891	rs9369256	chr6:40998344	G/C	cg14769373	chr6:40998127	UNC5CL	-0.61	-4.74	-0.44	7.55e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg08133631	chr1:26527909	CATSPER4	-0.64	-5.4	-0.48	4.94e-7	Obesity-related traits;
THYM	cis	rs11225247	1.000	rs12293834	chr11:102295477	T/C	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs11771526	0.786	rs11768318	chr7:32372965	T/G	cg27511599	chr7:32358540	NA	0.75	5.02	0.46	2.42e-6	Body mass index;
THYM	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg26531700	chr6:26746687	NA	0.56	4.76	0.44	6.91e-6	Intelligence (multi-trait analysis);
THYM	cis	rs684232	0.712	rs2955626	chr17:618100	C/G	cg15660573	chr17:549704	VPS53	0.88	8.03	0.64	2.65e-12	Prostate cancer;
THYM	trans	rs3960554	0.808	rs2302434	chr7:75630183	C/T	cg19862616	chr7:65841803	NCRNA00174	0.96	7.3	0.6	8.89e-11	Eotaxin levels;
THYM	cis	rs1799949	0.832	rs2070835	chr17:41174025	A/C	cg23758822	chr17:41437982	NA	1.17	10.68	0.74	5.83e-18	Menopause (age at onset);
THYM	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg07424592	chr7:64974309	NA	1.07	5.56	0.5	2.48e-7	Diabetic kidney disease;
THYM	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs4900538	0.855	rs72698597	chr14:102868633	C/T	cg18135206	chr14:102964638	TECPR2	-0.81	-6.24	-0.54	1.2e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	trans	rs10233018	0.840	rs1548461	chr7:117567576	A/G	cg21837391	chr1:1159412	SDF4	0.87	7.16	0.59	1.67e-10	Depressive symptoms;Depression;
THYM	cis	rs2816062	0.747	rs2816049	chr1:18893768	A/G	cg18795169	chr1:18902165	NA	-0.98	-11.9	-0.77	1.55e-20	Urate levels in lean individuals;
THYM	cis	rs6960043	0.738	rs10950549	chr7:15057829	G/A	cg19272540	chr7:15055459	NA	0.55	6.11	0.53	2.21e-8	Type 2 diabetes;
THYM	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg04398451	chr17:18023971	MYO15A	-1.0	-10.45	-0.73	1.77e-17	Total body bone mineral density;
THYM	cis	rs13326165	0.585	rs17052053	chr3:52334593	A/G	cg08438690	chr3:52279403	PPM1M	-0.74	-4.72	-0.44	8.05e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs1065852	0.526	rs1062753	chr22:42392811	G/A	cg22189786	chr22:42395067	WBP2NL	0.54	5.55	0.49	2.6e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg24531977	chr5:56204891	C5orf35	-0.72	-5.83	-0.51	7.64e-8	Initial pursuit acceleration;
THYM	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg07061783	chr6:25882402	NA	0.84	7.37	0.6	6.13e-11	Blood metabolite levels;
THYM	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg06784218	chr1:46089804	CCDC17	0.29	4.57	0.42	1.48e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs892961	0.932	rs312853	chr17:75406045	T/G	cg11351908	chr17:75402473	SEPT9	0.63	6.42	0.55	5.3e-9	Airflow obstruction;
THYM	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg12031863	chr16:4587854	C16orf5	-0.41	-4.45	-0.42	2.31e-5	Schizophrenia;
THYM	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs757110	0.648	rs12146443	chr11:17384498	T/C	cg15432903	chr11:17409602	KCNJ11	0.58	6.28	0.54	1.01e-8	Type 2 diabetes;
THYM	cis	rs9549260	0.564	rs9577107	chr13:41271676	A/T	cg21288729	chr13:41239152	FOXO1	0.66	4.9	0.45	3.96e-6	Red blood cell count;
THYM	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg15445000	chr17:37608096	MED1	0.44	5.1	0.46	1.73e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9790314	1.000	rs7653233	chr3:160992033	G/A	cg04691961	chr3:161091175	C3orf57	-0.53	-4.55	-0.42	1.56e-5	Morning vs. evening chronotype;
THYM	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-7.5	-0.61	3.41e-11	Platelet count;
THYM	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg04287289	chr16:89883240	FANCA	0.63	5.71	0.51	1.3e-7	Vitiligo;
THYM	cis	rs36051895	0.623	rs3780383	chr9:5232409	G/C	cg02405213	chr9:5042618	JAK2	-0.95	-9.21	-0.69	8.17e-15	Pediatric autoimmune diseases;
THYM	cis	rs995000	0.899	rs1781221	chr1:63006842	A/C	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs10904908	1.000	rs7903259	chr10:17259642	C/G	cg01003015	chr10:17271136	VIM	0.58	4.94	0.45	3.4e-6	Total cholesterol levels;Cholesterol, total;
THYM	cis	rs981844	1.000	rs17299041	chr4:154673127	T/C	cg09973105	chr4:154681532	RNF175	-0.65	-5.33	-0.48	6.48e-7	Response to statins (LDL cholesterol change);
THYM	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs72772090	0.539	rs72773923	chr5:96117579	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg10515332	chr4:99064459	C4orf37	0.58	4.62	0.43	1.21e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7106204	0.513	rs7131112	chr11:24249402	A/G	ch.11.24196551F	chr11:24239977	NA	0.96	6.74	0.57	1.24e-9	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs4891159	0.790	rs77878087	chr18:74116337	G/A	cg24786174	chr18:74118243	ZNF516	-0.87	-9.75	-0.71	5.54e-16	Longevity;
THYM	cis	rs11650494	0.908	rs11656535	chr17:47425588	C/T	cg08112188	chr17:47440006	ZNF652	1.05	4.51	0.42	1.83e-5	Prostate cancer;
THYM	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22496380	chr5:211416	CCDC127	-1.25	-7.51	-0.61	3.27e-11	Breast cancer;
THYM	cis	rs3112255	1.000	rs2137674	chr2:101305228	C/A	cg01042948	chr2:101319752	NA	0.72	6.32	0.54	8.27e-9	Intelligence (multi-trait analysis);
THYM	trans	rs8073060	0.586	rs225296	chr17:33924847	C/G	cg19694781	chr19:47549865	TMEM160	-1.01	-8.85	-0.67	4.75e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg06521331	chr12:34319734	NA	-0.97	-8.31	-0.65	6.53e-13	Morning vs. evening chronotype;
THYM	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg23711669	chr6:146136114	FBXO30	0.97	10.56	0.73	1.05e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	5.02	0.46	2.37e-6	Height;
THYM	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22857025	chr5:266934	NA	-1.62	-10.42	-0.73	2.1e-17	Breast cancer;
THYM	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg03517284	chr6:25882590	NA	0.82	6.55	0.56	2.89e-9	Intelligence (multi-trait analysis);
THYM	cis	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg02501473	chr3:189909740	NA	-0.79	-5.23	-0.47	9.95e-7	Lung adenocarcinoma;
THYM	cis	rs714027	0.585	rs41171	chr22:30422107	C/G	cg27665648	chr22:30112403	NA	-0.51	-4.55	-0.42	1.6e-5	Lymphocyte counts;
THYM	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg17143192	chr8:8559678	CLDN23	0.61	4.57	0.42	1.48e-5	Mood instability;
THYM	cis	rs11785693	0.862	rs11774044	chr8:4988035	C/G	cg26367366	chr8:4980734	NA	1.21	5.9	0.52	5.46e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs4653767	1.000	rs708775	chr1:226923264	G/A	cg05262829	chr1:226921576	ITPKB	-0.5	-5.0	-0.46	2.63e-6	Parkinson's disease;
THYM	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg15704280	chr7:45808275	SEPT13	-1.09	-13.76	-0.82	2.44e-24	Height;
THYM	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg13385794	chr1:248469461	NA	0.67	4.61	0.43	1.24e-5	Common traits (Other);
THYM	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg03806693	chr22:41940476	POLR3H	-0.77	-5.94	-0.52	4.61e-8	Neuroticism;
THYM	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-9.19	-0.69	9.09e-15	Chronic sinus infection;
THYM	cis	rs2915864	0.784	rs2961694	chr5:141543351	G/A	cg01553231	chr5:141072866	NA	-0.59	-4.99	-0.46	2.76e-6	Facial morphology (factor 20);
THYM	cis	rs28595532	1.000	rs73842212	chr4:119638122	A/G	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg08430604	chr3:44902960	MIR564;TMEM42	0.47	4.53	0.42	1.74e-5	Depressive symptoms;
THYM	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.72	-0.67	9.16e-14	Mean corpuscular volume;
THYM	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg08999081	chr20:33150536	PIGU	-0.74	-6.59	-0.56	2.42e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs11048434	0.761	rs2110192	chr12:9136351	A/T	cg26114124	chr12:9217669	LOC144571	0.47	4.73	0.44	7.93e-6	Sjögren's syndrome;
THYM	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg19913688	chr11:428466	ANO9	-0.88	-4.58	-0.42	1.43e-5	Body mass index;
THYM	cis	rs9326248	0.861	rs11216172	chr11:116749878	G/A	cg20608306	chr11:116969690	SIK3	0.51	5.23	0.47	9.92e-7	Blood protein levels;
THYM	cis	rs7552404	0.672	rs8763	chr1:76229120	T/C	cg03433033	chr1:76189801	ACADM	0.71	5.94	0.52	4.68e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4638749	0.677	rs10208945	chr2:108838593	G/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg18252515	chr7:66147081	NA	-0.6	-4.53	-0.42	1.72e-5	Aortic root size;
THYM	cis	rs11577318	0.579	rs12131370	chr1:26698430	G/A	cg19677267	chr1:26645161	CD52;UBXN11	0.51	5.62	0.5	1.88e-7	Granulocyte percentage of myeloid white cells;
THYM	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.86	-0.45	4.62e-6	Eye color traits;
THYM	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg24818145	chr4:99064322	C4orf37	0.87	7.23	0.6	1.19e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg09035930	chr12:129282057	SLC15A4	0.86	12.0	0.78	9.76e-21	Systemic lupus erythematosus;
THYM	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg00376283	chr12:123451042	ABCB9	0.86	6.89	0.58	6.19e-10	Platelet count;
THYM	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg22433210	chr17:43662623	NA	1.1	8.29	0.65	7.36e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4606347	0.932	rs61779729	chr1:66136838	A/G	cg04111102	chr1:66153794	NA	0.7	5.29	0.48	7.89e-7	Cerebrospinal fluid biomarker levels;
THYM	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg12516959	chr21:47718080	NA	-0.4	-4.89	-0.45	4.05e-6	Testicular germ cell tumor;
THYM	cis	rs4481887	0.741	rs6681758	chr1:248540413	T/A	cg17299007	chr1:248814626	OR2T27	0.43	4.58	0.43	1.41e-5	Common traits (Other);
THYM	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs9583531	0.527	rs3818496	chr13:111358488	G/A	cg24331049	chr13:111365604	ING1	0.75	6.09	0.53	2.39e-8	Coronary artery disease;
THYM	cis	rs365132	1.000	rs365132	chr5:176378574	G/T	cg17809377	chr5:176326619	HK3	-0.3	-4.55	-0.42	1.59e-5	Menarche and menopause (age at onset);Menopause (age at onset);
THYM	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.81	-5.56	-0.5	2.42e-7	Body mass index;
THYM	cis	rs988913	1.000	rs9475106	chr6:54851455	G/T	cg19716238	chr6:54711378	FAM83B	0.5	4.91	0.45	3.76e-6	Menarche (age at onset);
THYM	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg19077165	chr18:44547161	KATNAL2	0.51	5.93	0.52	4.94e-8	Personality dimensions;
THYM	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg10518543	chr12:38710700	ALG10B	0.57	4.66	0.43	1.03e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs654950	0.743	rs115951861	chr1:41992488	C/T	cg06885757	chr1:42089581	HIVEP3	-0.47	-5.62	-0.5	1.92e-7	Airway imaging phenotypes;
THYM	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11077998	0.935	rs9893826	chr17:80511128	C/T	cg10255544	chr17:80519551	FOXK2	0.51	4.49	0.42	2e-5	Reticulocyte fraction of red cells;
THYM	cis	rs4919087	0.926	rs10882884	chr10:99025611	T/A	cg19453742	chr10:98862320	SLIT1	-0.64	-4.82	-0.44	5.36e-6	Monocyte count;
THYM	cis	rs11711311	1.000	rs2566970	chr3:113462123	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.6	5.19	0.47	1.2e-6	IgG glycosylation;
THYM	cis	rs1395	0.778	rs72810794	chr2:27401260	C/T	cg23587288	chr2:27483067	SLC30A3	-0.61	-5.36	-0.48	5.76e-7	Blood metabolite levels;
THYM	cis	rs2404602	0.647	rs116090606	chr15:77075209	A/G	cg23625390	chr15:77176239	SCAPER	-0.85	-6.09	-0.53	2.36e-8	Blood metabolite levels;
THYM	cis	rs2625529	0.586	rs7173626	chr15:72186926	C/A	cg16672083	chr15:72433130	SENP8	0.53	4.66	0.43	1.04e-5	Red blood cell count;
THYM	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg06600287	chr1:53387719	ECHDC2	0.31	5.14	0.47	1.45e-6	Monocyte count;
THYM	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg20887711	chr4:1340912	KIAA1530	0.95	8.77	0.67	6.88e-14	Longevity;
THYM	cis	rs919433	0.889	rs6711624	chr2:198207607	C/G	cg00792783	chr2:198669748	PLCL1	-0.71	-5.14	-0.47	1.46e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg15445000	chr17:37608096	MED1	-0.44	-5.07	-0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg27170947	chr2:26402098	FAM59B	-0.57	-4.65	-0.43	1.07e-5	Gut microbiome composition (summer);
THYM	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg01570182	chr17:44337453	NA	-0.84	-9.31	-0.69	5.04e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9677476	0.863	rs12465477	chr2:232073282	G/A	cg23338755	chr2:231921595	PSMD1	0.71	5.25	0.47	9.43e-7	Food antigen IgG levels;
THYM	cis	rs7107174	1.000	rs4945270	chr11:78068216	A/G	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17253792	0.822	rs17746033	chr14:56061837	G/A	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg17830980	chr10:43048298	ZNF37B	1.04	10.47	0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg09044154	chr16:88155775	NA	-0.64	-4.45	-0.42	2.34e-5	Menopause (age at onset);
THYM	cis	rs4866334	1.000	rs75378321	chr5:18402051	C/T	cg24599790	chr5:18972260	NA	-1.18	-4.51	-0.42	1.84e-5	IgG glycosylation;
THYM	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg04455712	chr21:45112962	RRP1B	0.55	5.2	0.47	1.15e-6	Mean corpuscular volume;
THYM	cis	rs2554380	0.943	rs1477593	chr15:84363045	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.61	-4.97	-0.45	3e-6	Height;
THYM	cis	rs7264396	0.563	rs6058302	chr20:34290037	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.76	-0.44	6.84e-6	Total cholesterol levels;
THYM	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg08847533	chr14:75593920	NEK9	-1.0	-11.26	-0.76	3.48e-19	Height;
THYM	cis	rs4243830	1.000	rs4243830	chr1:6577871	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.06	-5.92	-0.52	5.12e-8	Body mass index;
THYM	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6924995	0.501	rs7760540	chr6:16193416	A/C	cg11805552	chr6:16175128	NA	-0.58	-4.8	-0.44	5.89e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs6138458	1.000	rs2387362	chr20:24899906	C/T	cg06937882	chr20:24974362	C20orf3	0.47	4.54	0.42	1.66e-5	Blood protein levels;
THYM	cis	rs4919694	1.000	rs7100592	chr10:104769098	T/G	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg01831904	chr17:28903510	LRRC37B2	-1.0	-5.11	-0.46	1.65e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2295359	0.892	rs72676058	chr1:67627681	C/A	cg11235152	chr1:67600687	NA	0.68	5.55	0.49	2.57e-7	Psoriasis;
THYM	cis	rs951366	0.531	rs12030754	chr1:205678043	G/C	cg26354017	chr1:205819088	PM20D1	-0.68	-5.14	-0.47	1.45e-6	Menarche (age at onset);
THYM	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg12311346	chr5:56204834	C5orf35	-0.77	-5.59	-0.5	2.18e-7	Initial pursuit acceleration;
THYM	cis	rs7943358	0.774	rs4757348	chr11:15686485	A/G	cg11966998	chr11:15692519	NA	-0.45	-4.69	-0.43	9.12e-6	Gut microbiome composition (summer);
THYM	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg13010199	chr12:38710504	ALG10B	0.73	5.82	0.51	7.99e-8	Heart rate;
THYM	cis	rs910316	0.523	rs4026175	chr14:75502240	C/A	cg11812906	chr14:75593930	NEK9	0.78	6.29	0.54	9.76e-9	Height;
THYM	cis	rs981844	1.000	rs62325093	chr4:154669733	G/A	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs17739794	0.557	rs35400327	chr8:808789	A/G	cg01971667	chr8:817044	NA	0.61	5.46	0.49	3.83e-7	Clozapine-induced cytotoxicity;
THYM	cis	rs9311676	0.656	rs4339119	chr3:58389462	A/G	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs4803468	1.000	rs284657	chr19:41929915	G/C	cg09537434	chr19:41945824	ATP5SL	-1.09	-10.16	-0.72	7.58e-17	Height;
THYM	cis	rs478304	0.754	rs2004649	chr11:65380916	G/A	cg17480646	chr11:65405466	SIPA1	-0.8	-6.84	-0.57	7.73e-10	Acne (severe);
THYM	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	5.61	0.5	2e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg27211696	chr2:191398769	TMEM194B	0.63	4.88	0.45	4.22e-6	Diastolic blood pressure;
THYM	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg21427119	chr20:30132790	HM13	-0.9	-6.24	-0.54	1.24e-8	Mean corpuscular hemoglobin;
THYM	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-4.48	-0.42	2.06e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg00074818	chr8:8560427	CLDN23	0.59	5.42	0.49	4.43e-7	Obesity-related traits;
THYM	cis	rs2976388	0.647	rs2164307	chr8:143788831	A/T	cg13446199	chr8:143762866	PSCA	-0.41	-4.53	-0.42	1.7e-5	Urinary tract infection frequency;
THYM	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg06064525	chr11:970664	AP2A2	0.35	6.68	0.57	1.63e-9	Alzheimer's disease (late onset);
THYM	cis	rs1483890	0.723	rs6807930	chr3:69411662	C/T	cg22125112	chr3:69402811	FRMD4B	0.54	6.85	0.58	7.21e-10	Resting heart rate;
THYM	cis	rs7769051	0.615	rs12209144	chr6:133191064	A/T	cg07930552	chr6:133119739	C6orf192	0.93	4.49	0.42	1.99e-5	Type 2 diabetes nephropathy;
THYM	cis	rs995000	0.868	rs1168102	chr1:63127705	C/T	cg06896770	chr1:63153194	DOCK7	-0.9	-7.2	-0.59	1.43e-10	Triglyceride levels;
THYM	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg05754148	chr16:3507555	NAT15	0.88	7.96	0.63	3.57e-12	Tuberculosis;
THYM	cis	rs4575098	0.681	rs11579514	chr1:161143312	A/G	cg24329783	chr1:161160887	ADAMTS4	-0.6	-5.43	-0.49	4.26e-7	Monocyte percentage of white cells;
THYM	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs981844	0.753	rs62325149	chr4:154728006	G/C	cg09973105	chr4:154681532	RNF175	-0.67	-6.2	-0.54	1.44e-8	Response to statins (LDL cholesterol change);
THYM	cis	rs4227	0.545	rs2302661	chr17:7490379	G/C	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	-0.26	-4.65	-0.43	1.07e-5	IgA nephropathy;
THYM	cis	rs17818399	1.000	rs62136864	chr2:46829124	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.68	4.87	0.45	4.5e-6	Height;
THYM	cis	rs6500395	0.962	rs13331902	chr16:48644989	A/G	cg04672837	chr16:48644449	N4BP1	0.48	4.59	0.43	1.35e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.25	4.83	0.44	5.24e-6	Obesity-related traits;
THYM	cis	rs4148689	1.000	rs2283055	chr7:117132098	T/A	cg17204129	chr7:117119601	CFTR	-0.62	-5.0	-0.46	2.66e-6	Gout;
THYM	cis	rs11785693	0.817	rs62491199	chr8:4997878	G/A	cg26367366	chr8:4980734	NA	1.21	5.72	0.51	1.24e-7	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg12386194	chr3:101231763	SENP7	0.96	7.53	0.61	2.97e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg20503657	chr10:835505	NA	1.37	9.33	0.69	4.52e-15	Eosinophil percentage of granulocytes;
THYM	cis	rs898549	0.555	rs10899971	chr10:44516604	C/T	cg27599783	chr10:45480162	RASSF4	0.49	4.5	0.42	1.96e-5	Obesity-related traits;
THYM	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg08859206	chr1:53392774	SCP2	-0.62	-7.04	-0.59	3.02e-10	Monocyte count;
THYM	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg21926883	chr2:100939477	LONRF2	-0.65	-5.96	-0.52	4.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs76878669	0.561	rs1892940	chr11:66111251	A/G	cg18002602	chr11:66138449	SLC29A2	-0.5	-5.01	-0.46	2.49e-6	Educational attainment (years of education);
THYM	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg01819759	chr13:79234251	RNF219	0.8	5.13	0.47	1.55e-6	Large artery stroke;
THYM	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg26418147	chr1:205743515	RAB7L1	-0.54	-4.58	-0.43	1.39e-5	Menarche (age at onset);
THYM	cis	rs9296092	0.538	rs9469491	chr6:33521545	A/G	cg13560919	chr6:33536144	NA	0.94	9.31	0.69	4.9e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06850241	chr22:41845214	NA	0.6	5.38	0.48	5.25e-7	Vitiligo;
THYM	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg06547715	chr2:218990976	CXCR2	0.48	5.23	0.47	9.92e-7	Ulcerative colitis;
THYM	cis	rs7511006	1.000	rs7364173	chr22:50681029	C/T	cg11077631	chr22:50617003	PANX2	0.52	5.66	0.5	1.58e-7	Obesity-related traits;
THYM	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs11621135	0.567	rs10141056	chr14:71673065	G/C	cg18506020	chr14:71758942	NA	-0.48	-4.54	-0.42	1.62e-5	Hair greying;
THYM	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg10295955	chr4:187884368	NA	1.15	15.81	0.85	2.38e-28	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17345786	0.520	rs1476123	chr3:101313413	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	6.18	0.54	1.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg18252515	chr7:66147081	NA	0.63	4.54	0.42	1.65e-5	Aortic root size;
THYM	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg23711669	chr6:146136114	FBXO30	0.96	9.81	0.71	4.28e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg12560992	chr17:57184187	TRIM37	-0.93	-8.88	-0.67	4.06e-14	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg10803722	chr21:46713166	LOC642852	-0.39	-4.87	-0.45	4.5e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg07061783	chr6:25882402	NA	-0.61	-4.61	-0.43	1.26e-5	Blood metabolite levels;
THYM	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg25208724	chr1:156163844	SLC25A44	1.1	8.39	0.65	4.57e-13	Testicular germ cell tumor;
THYM	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.58	-4.45	-0.42	2.35e-5	Monocyte percentage of white cells;
THYM	cis	rs490234	0.552	rs2841327	chr9:128156503	G/A	cg14078157	chr9:128172775	NA	-0.91	-7.95	-0.63	3.88e-12	Mean arterial pressure;
THYM	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg13880726	chr7:1868755	MAD1L1	0.61	4.5	0.42	1.92e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg27572855	chr1:25598939	RHD	0.62	4.71	0.44	8.49e-6	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs4474465	0.736	rs4945291	chr11:78254413	C/T	cg19901956	chr11:77921274	USP35	0.61	4.64	0.43	1.1e-5	Alzheimer's disease (survival time);
THYM	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg07606381	chr6:8435919	SLC35B3	0.63	4.71	0.43	8.51e-6	Motion sickness;
THYM	cis	rs79349575	0.749	rs46521	chr17:46988529	A/G	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg26384229	chr12:38710491	ALG10B	1.0	7.56	0.61	2.54e-11	Bladder cancer;
THYM	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	4.59	0.43	1.35e-5	Diabetic retinopathy;
THYM	cis	rs7814319	0.674	rs2643339	chr8:97246978	C/A	cg20787634	chr8:97240163	UQCRB	-0.72	-7.2	-0.59	1.43e-10	Lung function (FVC);
THYM	cis	rs9302690	1.000	rs62037110	chr16:57444771	A/G	cg27017172	chr16:57497170	POLR2C	0.82	4.88	0.45	4.29e-6	Blood protein levels;
THYM	cis	rs12410462	0.681	rs4486420	chr1:227572321	T/A	cg23173402	chr1:227635558	NA	0.71	5.61	0.5	1.96e-7	Major depressive disorder;
THYM	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.52	0.73	1.31e-17	Prudent dietary pattern;
THYM	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg17264618	chr3:40429014	ENTPD3	0.48	4.75	0.44	7.17e-6	Renal cell carcinoma;
THYM	cis	rs7617773	0.780	rs7653152	chr3:48362097	G/C	cg02219026	chr3:48282209	ZNF589	-0.68	-4.76	-0.44	7.02e-6	Coronary artery disease;
THYM	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg20387954	chr3:183756860	HTR3D	0.56	4.64	0.43	1.11e-5	Anterior chamber depth;
THYM	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs6430585	0.591	rs3098103	chr2:136656094	T/C	cg04750100	chr2:136595281	LCT	0.54	4.85	0.45	4.9100000000000004e-06	Corneal structure;
THYM	cis	rs34638657	0.827	rs6564996	chr16:82207542	T/C	cg07307142	chr16:82071433	HSD17B2	-0.93	-6.91	-0.58	5.61e-10	Lung adenocarcinoma;
THYM	cis	rs17511627	0.808	rs7990711	chr13:26743956	C/T	cg13319468	chr13:27597730	NA	0.68	5.42	0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs9563576	0.778	rs12585496	chr13:58582511	G/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg06074448	chr4:187884817	NA	-1.01	-13.61	-0.81	4.81e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs800586	0.912	rs2960157	chr8:116795541	G/T	cg04656070	chr8:116661063	TRPS1	-0.48	-4.95	-0.45	3.24e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.7	0.43	8.76e-6	Breast cancer;
THYM	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg06481639	chr22:41940642	POLR3H	0.73	5.29	0.48	7.78e-7	Vitiligo;
THYM	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs665401	0.666	rs143357	chr6:117173577	C/T	cg20376953	chr6:117187980	NA	0.61	4.89	0.45	4.05e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs2109514	0.967	rs10271007	chr7:116145849	A/G	cg12739419	chr7:116140593	CAV2	-0.48	-4.66	-0.43	1.04e-5	Prevalent atrial fibrillation;
THYM	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg06028808	chr11:68637592	NA	0.71	7.61	0.62	1.99e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6754311	0.551	rs313526	chr2:136445526	C/T	cg07169764	chr2:136633963	MCM6	0.7	5.67	0.5	1.55e-7	Mosquito bite size;
THYM	cis	rs6499129	0.702	rs8058861	chr16:67234134	A/G	cg03615565	chr16:67572595	FAM65A	0.56	4.66	0.43	1.02e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00475322	chr7:917719	C7orf20	-0.5	-6.27	-0.54	1.05e-8	Perceived unattractiveness to mosquitoes;
THYM	cis	rs7688540	0.771	rs11723615	chr4:276983	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.68	4.82	0.44	5.43e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs2302063	0.517	rs1637655	chr19:3162538	G/A	cg08486065	chr19:3464875	NA	0.55	4.66	0.43	1.03e-5	Glucose homeostasis traits;
THYM	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs2964802	0.505	rs13180011	chr5:10824615	T/C	cg14521931	chr5:10832172	NA	-0.63	-5.28	-0.48	8.09e-7	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg26818010	chr10:134567672	INPP5A	0.7	5.83	0.51	7.51e-8	Migraine;
THYM	cis	rs6586111	1.000	rs6586111	chr10:82377590	T/C	cg03086067	chr10:82368399	SH2D4B	-0.52	-6.28	-0.54	1.02e-8	Capecitabine sensitivity;
THYM	cis	rs9677476	0.818	rs9973675	chr2:232095484	G/A	cg07929768	chr2:232055508	NA	0.63	6.29	0.54	9.87e-9	Food antigen IgG levels;
THYM	cis	rs865483	0.895	rs4795200	chr17:35817105	A/G	cg06716730	chr17:35851459	DUSP14	0.43	7.3	0.6	8.71e-11	Monocyte count;
THYM	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg14829155	chr15:31115871	NA	0.74	6.19	0.54	1.52e-8	Huntington's disease progression;
THYM	cis	rs7572733	0.534	rs10211202	chr2:198771941	A/G	cg05783139	chr2:198650985	BOLL	0.62	4.89	0.45	4.15e-6	Dermatomyositis;
THYM	cis	rs782590	0.935	rs2586954	chr2:55892261	A/C	cg03859395	chr2:55845619	SMEK2	0.61	5.49	0.49	3.37e-7	Metabolic syndrome;
THYM	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg07747251	chr5:1868357	NA	0.6	5.1	0.46	1.75e-6	Cardiovascular disease risk factors;
THYM	cis	rs877282	0.853	rs7083589	chr10:754494	G/A	cg10556349	chr10:835070	NA	-0.69	-4.49	-0.42	2.03e-5	Uric acid levels;
THYM	cis	rs2964802	0.505	rs7715280	chr5:10809219	C/T	cg14521931	chr5:10832172	NA	-0.62	-5.2	-0.47	1.13e-6	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg05347473	chr6:146136440	FBXO30	-0.56	-4.45	-0.42	2.34e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs747334	0.846	rs10785981	chr10:92722166	A/G	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs7000551	0.689	rs2469753	chr8:22383225	T/C	cg12081754	chr8:22256438	SLC39A14	0.7	6.46	0.55	4.43e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg06481639	chr22:41940642	POLR3H	0.75	5.22	0.47	1.06e-6	Vitiligo;
THYM	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg00071950	chr4:10020882	SLC2A9	-0.52	-4.52	-0.42	1.77e-5	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg04772025	chr11:68637568	NA	0.65	6.95	0.58	4.61e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-6.2	-0.54	1.47e-8	Total body bone mineral density;
THYM	cis	rs3015497	0.789	rs2356457	chr14:51116863	C/T	cg04730355	chr14:51134070	SAV1	-0.51	-4.52	-0.42	1.79e-5	Mean platelet volume;
THYM	cis	rs654950	0.505	rs2475839	chr1:42006005	A/G	cg06885757	chr1:42089581	HIVEP3	-0.48	-5.85	-0.51	6.84e-8	Airway imaging phenotypes;
THYM	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg08999081	chr20:33150536	PIGU	0.77	6.95	0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs7572733	0.534	rs6434943	chr2:198762192	T/G	cg05783139	chr2:198650985	BOLL	0.62	4.89	0.45	4.15e-6	Dermatomyositis;
THYM	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg02527881	chr3:46936655	PTH1R	-0.69	-7.11	-0.59	2.13e-10	Colorectal cancer;
THYM	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg13319975	chr6:146136371	FBXO30	-0.62	-4.99	-0.46	2.73e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4481887	0.927	rs4460676	chr1:248431781	G/A	cg00666640	chr1:248458726	OR2T12	0.57	4.78	0.44	6.46e-6	Common traits (Other);
THYM	cis	rs7084402	0.967	rs1658491	chr10:60281354	C/T	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs13040088	1.000	rs910831	chr20:61558775	T/C	cg23096297	chr20:61557774	DIDO1	1.07	7.38	0.6	6.06e-11	Menopause (age at onset);
THYM	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg19507638	chr5:93509721	C5orf36	0.71	4.79	0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg18252515	chr7:66147081	NA	-0.62	-4.55	-0.42	1.59e-5	Aortic root size;
THYM	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg05552183	chr6:42928497	GNMT	0.71	5.79	0.51	8.9e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7719624	0.870	rs1990201	chr5:135395203	C/T	cg15329133	chr5:135467951	SMAD5;SMAD5OS	-0.57	-5.0	-0.46	2.59e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg03859395	chr2:55845619	SMEK2	0.65	5.95	0.52	4.52e-8	Metabolic syndrome;
THYM	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08704250	chr15:31115839	NA	-0.69	-7.64	-0.62	1.7e-11	Huntington's disease progression;
THYM	cis	rs6076065	0.723	rs4813495	chr20:23391617	A/G	cg11657817	chr20:23433608	CST11	0.31	4.57	0.42	1.48e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs865483	0.895	rs853208	chr17:35826456	C/A	cg06716730	chr17:35851459	DUSP14	0.43	7.3	0.6	8.71e-11	Monocyte count;
THYM	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg24675658	chr1:53192096	ZYG11B	0.73	6.62	0.56	2.14e-9	Monocyte count;
THYM	cis	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg21775007	chr8:11205619	TDH	-0.67	-5.91	-0.52	5.24e-8	Retinal vascular caliber;
THYM	cis	rs9611565	0.506	rs1984839	chr22:41685937	G/C	cg13695892	chr22:41940480	POLR3H	-0.58	-4.53	-0.42	1.69e-5	Vitiligo;
THYM	cis	rs28595532	0.841	rs114385163	chr4:119737058	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs950776	0.714	rs17408276	chr15:78881618	T/C	cg06917634	chr15:78832804	PSMA4	0.88	7.36	0.6	6.64e-11	Sudden cardiac arrest;
THYM	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg19610905	chr11:61596333	FADS2	-0.61	-5.16	-0.47	1.36e-6	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
THYM	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg27129171	chr3:47204927	SETD2	0.77	7.65	0.62	1.67e-11	Colorectal cancer;
THYM	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06850241	chr22:41845214	NA	0.59	5.16	0.47	1.37e-6	Vitiligo;
THYM	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg03684893	chr10:554711	DIP2C	-0.7	-6.21	-0.54	1.38e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/G	cg13327734	chr17:4634568	MED11	-0.98	-5.0	-0.46	2.59e-6	Type 2 diabetes;
THYM	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg15110403	chr19:17392923	ANKLE1	-0.57	-4.94	-0.45	3.36e-6	Systemic lupus erythematosus;
THYM	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg08847533	chr14:75593920	NEK9	-0.97	-10.19	-0.72	6.35e-17	Height;
THYM	cis	rs3820068	0.655	rs11587521	chr1:15839206	T/C	cg05660106	chr1:15850417	CASP9	1.1	9.92	0.71	2.48e-16	Systolic blood pressure;
THYM	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg09260853	chr1:2094483	PRKCZ	-0.45	-4.66	-0.43	1.03e-5	Height;
THYM	cis	rs13102973	0.931	rs4561977	chr4:135848936	T/C	cg14419869	chr4:135874104	NA	0.9	8.46	0.66	3.24e-13	Subjective well-being;
THYM	cis	rs7220711	0.902	rs4793020	chr17:41785377	G/A	cg26893861	chr17:41843967	DUSP3	0.65	5.63	0.5	1.83e-7	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg27534772	chr1:16042836	PLEKHM2	0.53	5.9	0.52	5.65e-8	Systolic blood pressure;
THYM	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg19761014	chr17:28927070	LRRC37B2	0.86	4.97	0.45	2.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg10523679	chr1:76189770	ACADM	-0.59	-5.02	-0.46	2.45e-6	Daytime sleep phenotypes;
THYM	cis	rs1371867	0.875	rs1788184	chr8:101335106	A/G	cg00191853	chr8:101177733	SPAG1	-0.51	-5.03	-0.46	2.29e-6	Atrioventricular conduction;
THYM	cis	rs7941600	0.881	rs2291839	chr11:9182219	A/G	cg21110646	chr11:9336536	TMEM41B	0.94	5.65	0.5	1.7e-7	Coronary artery disease;
THYM	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg02475777	chr4:1388615	CRIPAK	0.67	4.8	0.44	5.81e-6	Longevity;
THYM	cis	rs6087990	0.735	rs4911260	chr20:31376490	T/C	cg13636640	chr20:31349939	DNMT3B	0.9	9.45	0.7	2.54e-15	Ulcerative colitis;
THYM	trans	rs2014511	1.000	rs78947501	chr4:154459955	G/C	cg26834479	chr1:41327090	CITED4	-1.93	-6.85	-0.57	7.16e-10	Platelet distribution width;Mean platelet volume;
THYM	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg00129232	chr17:37814104	STARD3	0.76	5.25	0.47	9.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg17279839	chr7:150038598	RARRES2	0.56	5.43	0.49	4.4e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs240764	0.746	rs151572	chr6:101110984	C/T	cg21058520	chr6:100914733	NA	-0.57	-5.03	-0.46	2.29e-6	Neuroticism;
THYM	cis	rs986417	0.901	rs3759688	chr14:60975579	A/C	cg27398547	chr14:60952738	C14orf39	1.14	5.33	0.48	6.64e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg21984481	chr17:79567631	NPLOC4	0.48	5.05	0.46	2.1e-6	Eye color traits;
THYM	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg24910161	chr17:38119198	GSDMA	0.45	4.49	0.42	1.99e-5	Self-reported allergy;
THYM	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.66	-0.43	1.02e-5	Mean corpuscular volume;
THYM	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg16325326	chr1:53192061	ZYG11B	0.83	7.98	0.63	3.29e-12	Monocyte count;
THYM	cis	rs6732160	0.588	rs28626211	chr2:73378522	G/A	cg24220031	chr2:73402428	NA	-0.73	-5.88	-0.52	6.06e-8	Intelligence (multi-trait analysis);
THYM	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.11e-8	Systolic blood pressure;
THYM	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	7.92	0.63	4.42e-12	Smoking behavior;
THYM	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg06028605	chr16:24865363	SLC5A11	-0.63	-5.02	-0.46	2.43e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg06028808	chr11:68637592	NA	-0.68	-7.24	-0.6	1.18e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11186	0.556	rs55977069	chr2:189964747	G/T	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg23803603	chr1:2058230	PRKCZ	0.59	4.51	0.42	1.86e-5	Height;
THYM	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg16524733	chr11:117070046	TAGLN	-0.43	-4.75	-0.44	7.12e-6	Blood protein levels;
THYM	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg24733560	chr20:60626293	TAF4	0.53	4.77	0.44	6.51e-6	Body mass index;
THYM	cis	rs7119	0.689	rs12916833	chr15:77819778	G/A	cg27398640	chr15:77910606	LINGO1	-0.56	-5.61	-0.5	2.03e-7	Type 2 diabetes;
THYM	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7584330	0.740	rs13404177	chr2:238441412	T/C	cg14458575	chr2:238380390	NA	0.63	4.98	0.46	2.83e-6	Prostate cancer;
THYM	cis	rs10186029	0.509	rs2371793	chr2:213945082	G/C	cg08319019	chr2:214017104	IKZF2	-0.67	-4.97	-0.45	2.98e-6	Systemic sclerosis;
THYM	cis	rs8050907	0.590	rs17883666	chr16:4550153	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.15	4.63	0.43	1.16e-5	Obesity-related traits;
THYM	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg08213375	chr14:104286397	PPP1R13B	0.46	4.85	0.45	4.9e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg04034577	chr2:241836375	C2orf54	-0.42	-7.26	-0.6	1.04e-10	Urinary metabolites;
THYM	cis	rs7829975	0.777	rs6989926	chr8:8547313	A/C	cg18904891	chr8:8559673	CLDN23	-0.59	-4.8	-0.44	5.85e-6	Mood instability;
THYM	cis	rs9796	0.689	rs576336	chr15:41452771	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.63	-4.94	-0.45	3.35e-6	Menopause (age at onset);
THYM	cis	rs300703	0.576	rs3791216	chr2:237142	C/A	cg21211680	chr2:198530	NA	1.33	5.61	0.5	1.97e-7	Blood protein levels;
THYM	cis	rs6687430	0.532	rs2150038	chr1:10609973	G/T	cg20482658	chr1:10539492	PEX14	0.49	6.27	0.54	1.07e-8	Hand grip strength;
THYM	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg05283184	chr6:79620031	NA	-0.87	-8.15	-0.64	1.43e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7647973	0.848	rs4955426	chr3:49143438	C/A	cg07636037	chr3:49044803	WDR6	0.85	5.15	0.47	1.4e-6	Menarche (age at onset);
THYM	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg13319975	chr6:146136371	FBXO30	-0.67	-5.44	-0.49	4.21e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg16006841	chr5:176797999	RGS14	-0.51	-5.74	-0.51	1.11e-7	Urate levels in lean individuals;
THYM	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg01475377	chr6:109611718	NA	-0.58	-4.91	-0.45	3.76e-6	Reticulocyte fraction of red cells;
THYM	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	6.62	0.56	2.11e-9	Cognitive test performance;
THYM	cis	rs12509991	0.582	rs7664376	chr4:127041817	T/C	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs4084127	0.775	rs61881664	chr11:69591809	C/T	cg14578030	chr11:69591383	FGF4	0.56	4.85	0.45	4.89e-6	Type 1 diabetes;
THYM	cis	rs1003719	0.680	rs2835664	chr21:38573429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-4.53	-0.42	1.72e-5	Eye color traits;
THYM	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg11764359	chr7:65958608	NA	-0.77	-6.16	-0.53	1.76e-8	Aortic root size;
THYM	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg18252515	chr7:66147081	NA	0.66	4.87	0.45	4.38e-6	Aortic root size;
THYM	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03452623	chr4:187889614	NA	-1.17	-20.04	-0.9	6.92e-36	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7197653	0.748	rs8063446	chr16:68344363	A/C	cg09835421	chr16:68378352	PRMT7	-0.77	-4.51	-0.42	1.86e-5	Magnesium levels;
THYM	cis	rs4595586	0.545	rs1156705	chr12:39372672	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs10845606	1.000	rs10845610	chr12:12839107	G/A	cg04607235	chr12:12878440	APOLD1	-0.77	-4.71	-0.44	8.45e-6	Systemic lupus erythematosus;
THYM	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.76	-5.06	-0.46	2.05e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg05791153	chr7:19748676	TWISTNB	1.27	9.36	0.69	3.77e-15	Night sleep phenotypes;
THYM	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg03213289	chr20:61660250	NA	0.98	10.7	0.74	5.26e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7255436	0.830	rs4350678	chr19:8447366	A/G	cg10174797	chr19:8464628	RAB11B	0.42	4.97	0.45	2.99e-6	HDL cholesterol;
THYM	cis	rs9311676	0.656	rs56097407	chr3:58378079	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22307029	chr19:49891270	CCDC155	0.83	7.33	0.6	7.45e-11	Multiple sclerosis;
THYM	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.75	-0.67	7.74e-14	Mean corpuscular volume;
THYM	cis	rs6732160	0.774	rs1367291	chr2:73374865	A/T	cg24220031	chr2:73402428	NA	-0.78	-8.4	-0.65	4.26e-13	Intelligence (multi-trait analysis);
THYM	cis	rs778371	0.723	rs6710294	chr2:233579634	T/C	cg08000102	chr2:233561755	GIGYF2	0.83	7.52	0.61	3.07e-11	Schizophrenia;
THYM	cis	rs3741151	0.773	rs7115055	chr11:73227827	T/C	cg17517138	chr11:73019481	ARHGEF17	0.9	4.73	0.44	7.74e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	trans	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg25214090	chr10:38739885	LOC399744	0.97	8.33	0.65	5.98e-13	Corneal astigmatism;
THYM	cis	rs1385374	0.858	rs10847698	chr12:129300222	T/C	cg04043695	chr12:129287642	SLC15A4	-0.8	-4.83	-0.44	5.3e-6	Systemic lupus erythematosus;
THYM	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg04663057	chr3:46933782	PTH1R	0.53	5.07	0.46	1.99e-6	Birth weight;
THYM	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg06219351	chr7:158114137	PTPRN2	0.67	6.66	0.56	1.73e-9	Calcium levels;
THYM	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.27	4.52	0.42	1.78e-5	Obesity-related traits;
THYM	cis	rs6906287	0.559	rs2798322	chr6:118991605	G/T	cg18833306	chr6:118973337	C6orf204	0.52	4.55	0.42	1.58e-5	Electrocardiographic conduction measures;
THYM	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-5.4	-0.48	4.89e-7	Chronic sinus infection;
THYM	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg13397359	chr6:42928475	GNMT	0.64	5.74	0.51	1.15e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs995000	0.931	rs1168050	chr1:62986955	C/T	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs6563842	0.563	rs4575411	chr13:41277794	C/G	cg21288729	chr13:41239152	FOXO1	0.66	4.95	0.45	3.27e-6	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
THYM	cis	rs986417	1.000	rs6573316	chr14:61058029	C/A	cg27398547	chr14:60952738	C14orf39	1.26	6.1	0.53	2.29e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg13010199	chr12:38710504	ALG10B	-0.58	-4.53	-0.42	1.72e-5	Morning vs. evening chronotype;
THYM	cis	rs448720	0.840	rs405390	chr15:68169242	A/G	cg23793686	chr15:68133972	NA	0.52	4.53	0.42	1.69e-5	Cognitive performance;
THYM	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg06636551	chr8:101224915	SPAG1	-0.67	-6.52	-0.56	3.36e-9	Atrioventricular conduction;
THYM	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg23711669	chr6:146136114	FBXO30	-0.91	-8.87	-0.67	4.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	trans	rs561341	0.505	rs548298	chr17:30297494	C/A	cg20587970	chr11:113659929	NA	-1.26	-9.01	-0.68	2.16e-14	Hip circumference adjusted for BMI;
THYM	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-5.05	-0.46	2.12e-6	Lymphocyte counts;
THYM	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg24642439	chr20:33292090	TP53INP2	0.59	4.48	0.42	2.04e-5	Coronary artery disease;
THYM	cis	rs6032067	0.516	rs57047308	chr20:43899974	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.61	-6.91	-0.58	5.45e-10	Blood protein levels;
THYM	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg00484396	chr16:3507460	NAT15	0.61	5.19	0.47	1.19e-6	Tuberculosis;
THYM	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg17173187	chr15:85201210	NMB	0.56	5.66	0.5	1.6e-7	Schizophrenia;
THYM	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg14558262	chr17:40713999	COASY	0.62	4.82	0.44	5.34e-6	Colorectal or endometrial cancer;
THYM	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs9311676	0.632	rs62258129	chr3:58397187	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs7909074	0.766	rs5000415	chr10:45383674	C/T	cg05187965	chr10:45406764	TMEM72	-0.48	-4.55	-0.42	1.58e-5	Mean corpuscular volume;
THYM	cis	rs61990749	0.597	rs176944	chr14:78176211	G/T	cg02301378	chr14:78227641	SNW1;C14orf178	-1.17	-8.02	-0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg11266682	chr4:10021025	SLC2A9	0.7	11.02	0.75	1.14e-18	Bone mineral density;
THYM	cis	rs7719624	0.870	rs1990201	chr5:135395203	C/T	cg12897067	chr5:135418308	NA	-0.56	-4.65	-0.43	1.08e-5	Response to cytidine analogues (gemcitabine);
THYM	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs7119	0.604	rs2458035	chr15:77862806	G/A	cg10437265	chr15:77819839	NA	-0.72	-7.52	-0.61	3.06e-11	Type 2 diabetes;
THYM	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg06634786	chr22:41940651	POLR3H	0.71	5.22	0.47	1.07e-6	Vitiligo;
THYM	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.61	-4.61	-0.43	1.24e-5	Breast cancer;
THYM	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg00786635	chr1:25594202	NA	-0.92	-7.28	-0.6	9.7e-11	Erythrocyte sedimentation rate;
THYM	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg23791538	chr6:167370224	RNASET2	-0.59	-4.45	-0.42	2.35e-5	Crohn's disease;
THYM	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg17054759	chr22:49844102	NA	-0.52	-4.59	-0.43	1.35e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs11771526	0.792	rs28394389	chr7:32298509	C/T	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs72829446	0.530	rs72827503	chr17:7371268	G/T	cg02795151	chr17:7402630	POLR2A	0.55	5.67	0.5	1.56e-7	Androgen levels;
THYM	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg12310025	chr6:25882481	NA	-0.9	-7.84	-0.63	6.55e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7173743	0.784	rs11072811	chr15:79132330	G/T	cg15571903	chr15:79123663	NA	-0.6	-6.78	-0.57	1.03e-9	Coronary artery disease;
THYM	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg21226059	chr5:178986404	RUFY1	0.49	4.83	0.44	5.13e-6	Lung cancer;
THYM	cis	rs524023	0.874	rs492175	chr11:64433078	A/G	cg19131476	chr11:64387923	NRXN2	0.35	4.89	0.45	4.18e-6	Urate levels in obese individuals;
THYM	cis	rs28595532	0.920	rs114639588	chr4:119736176	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs735539	1.000	rs9579929	chr13:21282724	C/T	cg02792322	chr13:21280448	IL17D	0.67	4.95	0.45	3.17e-6	Dental caries;
THYM	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs1158570	0.843	rs3057	chr8:131329837	C/T	cg16277922	chr8:131349729	ASAP1	0.65	5.67	0.5	1.51e-7	Platelet count;
THYM	cis	rs611744	0.967	rs2597654	chr8:109221090	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.25	0.47	9.08e-7	Dupuytren's disease;
THYM	cis	rs4919044	0.808	rs835274	chr10:94796534	A/G	cg05127821	chr10:94822908	CYP26C1	-1.23	-6.66	-0.56	1.76e-9	Coronary artery disease;
THYM	cis	rs760805	1.000	rs11249204	chr1:25261740	C/T	cg22509179	chr1:25234806	RUNX3	0.74	6.79	0.57	9.62e-10	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs977987	0.898	rs12918797	chr16:75493810	T/C	cg03315344	chr16:75512273	CHST6	0.72	5.68	0.5	1.46e-7	Dupuytren's disease;
THYM	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg14779329	chr11:130786720	SNX19	0.5	5.19	0.47	1.17e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	trans	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs10744422	1.000	rs1532835	chr12:123330665	G/A	cg25930673	chr12:123319894	HIP1R	-0.86	-4.84	-0.44	5.09e-6	Schizophrenia;
THYM	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg00191853	chr8:101177733	SPAG1	-0.53	-5.12	-0.46	1.61e-6	Atrioventricular conduction;
THYM	cis	rs6840360	1.000	rs2303866	chr4:152640387	C/T	cg22705602	chr4:152727874	NA	-0.66	-7.23	-0.6	1.19e-10	Intelligence (multi-trait analysis);
THYM	cis	rs919433	0.617	rs700645	chr2:198605514	A/G	cg05783139	chr2:198650985	BOLL	0.6	4.73	0.44	7.81e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs5769765	0.671	rs138817	chr22:50163058	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.94	-6.43	-0.55	5.16e-9	Schizophrenia;
THYM	cis	rs7973719	0.899	rs12424618	chr12:7344802	A/G	cg07052231	chr12:7363540	PEX5	0.57	4.7	0.43	8.82e-6	IgG glycosylation;
THYM	cis	rs6598541	0.558	rs62024539	chr15:99300920	A/G	cg13297560	chr15:99320054	IGF1R	-0.62	-4.74	-0.44	7.62e-6	Urate levels;
THYM	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg21926883	chr2:100939477	LONRF2	-0.6	-5.66	-0.5	1.58e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg05335186	chr13:53173507	NA	0.49	6.25	0.54	1.18e-8	Lewy body disease;
THYM	cis	rs9560113	0.806	rs9560112	chr13:112183320	A/G	cg14154082	chr13:112174009	NA	0.85	7.83	0.63	6.99e-12	Menarche (age at onset);
THYM	cis	rs9677476	0.644	rs12470661	chr2:232060050	A/G	cg23338755	chr2:231921595	PSMD1	0.66	4.74	0.44	7.51e-6	Food antigen IgG levels;
THYM	cis	rs1003719	0.667	rs2835606	chr21:38490851	G/C	cg01329690	chr21:38580129	DSCR9	0.36	4.77	0.44	6.72e-6	Eye color traits;
THYM	cis	rs4478037	1.000	rs58995409	chr3:33161404	T/C	cg19404215	chr3:33155277	CRTAP	1.18	8.15	0.64	1.49e-12	Major depressive disorder;
THYM	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg08847533	chr14:75593920	NEK9	-0.91	-9.52	-0.7	1.8e-15	Height;
THYM	cis	rs2625529	0.652	rs11634608	chr15:72255718	A/G	cg16672083	chr15:72433130	SENP8	0.49	4.48	0.42	2.09e-5	Red blood cell count;
THYM	cis	rs887829	0.569	rs4663333	chr2:234655303	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.67	-5.17	-0.47	1.31e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg19747945	chr6:42946146	PEX6	-0.34	-5.08	-0.46	1.86e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06850241	chr22:41845214	NA	-0.56	-4.96	-0.45	3.08e-6	Vitiligo;
THYM	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg01416388	chr22:39784598	NA	0.93	8.31	0.65	6.76e-13	Intelligence (multi-trait analysis);
THYM	cis	rs34375054	0.526	rs2343638	chr12:125677122	G/C	cg25124228	chr12:125621409	AACS	-0.76	-5.75	-0.51	1.1e-7	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs4523957	0.647	rs12950603	chr17:2194937	T/A	cg16513277	chr17:2031491	SMG6	0.79	7.37	0.6	6.32e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10501293	0.746	rs7924326	chr11:43031752	A/G	cg03447554	chr11:43094025	NA	0.61	4.51	0.42	1.83e-5	Cognitive performance;
THYM	cis	rs6500395	0.963	rs4785248	chr16:48687947	A/G	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9790314	1.000	rs6775627	chr3:160953609	A/G	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg24675658	chr1:53192096	ZYG11B	-0.7	-6.08	-0.53	2.47e-8	Monocyte count;
THYM	cis	rs750460	0.932	rs1550436	chr15:74221157	C/T	cg23484268	chr15:74220776	LOXL1	-0.42	-4.65	-0.43	1.07e-5	Height;
THYM	cis	rs4808199	1.000	rs4808199	chr19:19545099	C/T	cg03709012	chr19:19516395	GATAD2A	1.19	7.25	0.6	1.12e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg23682913	chr1:2080710	PRKCZ	-0.57	-5.29	-0.48	7.92e-7	Height;
THYM	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg17063962	chr7:91808500	NA	1.1	12.12	0.78	5.59e-21	Breast cancer;
THYM	cis	rs3925075	0.966	rs12935192	chr16:31359330	G/A	cg02846316	chr16:31340340	ITGAM	0.6	6.27	0.54	1.05e-8	IgA nephropathy;
THYM	cis	rs7216064	0.953	rs11871285	chr17:65840809	G/T	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg24020549	chr11:64937741	SPDYC	-0.46	-4.46	-0.42	2.26e-5	Eosinophil percentage of white cells;
THYM	cis	rs2625529	0.652	rs9302260	chr15:72174611	T/C	cg16672083	chr15:72433130	SENP8	0.5	4.63	0.43	1.15e-5	Red blood cell count;
THYM	cis	rs6939532	0.522	rs4712981	chr6:26361430	C/T	cg14345882	chr6:26364793	BTN3A2	0.4	5.07	0.46	2e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs56341938	0.866	rs3851376	chr3:168757650	T/G	cg09107232	chr3:169491072	MYNN	0.52	4.45	0.42	2.32e-5	Lung function (FEV1/FVC);
THYM	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.49	-4.73	-0.44	7.9e-6	Primary biliary cholangitis;
THYM	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg00383909	chr3:49044727	WDR6	1.05	5.99	0.52	3.79e-8	Cognitive function;
THYM	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg20290983	chr6:43655470	MRPS18A	0.91	7.05	0.59	2.9e-10	IgG glycosylation;
THYM	cis	rs6840360	0.571	rs72730104	chr4:152543857	A/G	cg22705602	chr4:152727874	NA	-0.78	-8.16	-0.64	1.38e-12	Intelligence (multi-trait analysis);
THYM	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg22683308	chr4:1340831	KIAA1530	-0.61	-4.67	-0.43	9.72e-6	Longevity;
THYM	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7523273	0.606	rs2488254	chr1:207941539	A/G	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg13918804	chr1:2043761	PRKCZ	0.87	8.39	0.65	4.56e-13	Height;
THYM	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg10856724	chr12:34555212	NA	-1.05	-10.53	-0.73	1.24e-17	Morning vs. evening chronotype;
THYM	cis	rs28595532	0.920	rs116821181	chr4:119734892	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg07061783	chr6:25882402	NA	0.84	7.37	0.6	6.13e-11	Blood metabolite levels;
THYM	cis	rs61931739	0.534	rs4547187	chr12:34041259	T/C	cg06521331	chr12:34319734	NA	-0.93	-8.67	-0.66	1.15e-13	Morning vs. evening chronotype;
THYM	cis	rs2273669	0.667	rs12195372	chr6:109284223	A/G	cg17117243	chr6:109341365	SESN1	-0.85	-4.85	-0.45	4.87e-6	Prostate cancer;
THYM	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg11764359	chr7:65958608	NA	-0.82	-6.56	-0.56	2.81e-9	Aortic root size;
THYM	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs859767	0.709	rs4954154	chr2:135370656	G/A	cg12500956	chr2:135428796	TMEM163	-0.49	-4.98	-0.46	2.8e-6	Neuroticism;
THYM	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg18252515	chr7:66147081	NA	-0.66	-4.85	-0.45	4.8e-6	Aortic root size;
THYM	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8038465	0.615	rs6495075	chr15:73981005	A/G	cg15420318	chr15:73925796	NPTN	0.6	5.14	0.47	1.47e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg18252515	chr7:66147081	NA	-0.72	-5.6	-0.5	2.03e-7	Aortic root size;
THYM	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg23978390	chr7:1156363	C7orf50	0.7	5.18	0.47	1.22e-6	Longevity;Endometriosis;
THYM	cis	rs10504073	0.647	rs4348510	chr8:50016027	C/A	cg00325661	chr8:49890786	NA	0.86	7.69	0.62	1.35e-11	Blood metabolite ratios;
THYM	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg13609457	chr4:120235615	NA	0.53	4.81	0.44	5.59e-6	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6504108	0.512	rs12950225	chr17:46145200	C/T	cg01521220	chr17:46233799	MIR1203;SKAP1	-0.53	-4.57	-0.42	1.46e-5	Body mass index;
THYM	cis	rs6732160	0.657	rs10171459	chr2:73434728	A/C	cg24220031	chr2:73402428	NA	-0.79	-9.35	-0.69	3.98e-15	Intelligence (multi-trait analysis);
THYM	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg27286337	chr10:134555280	INPP5A	-0.85	-6.36	-0.55	6.91e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg27170947	chr2:26402098	FAM59B	0.61	4.63	0.43	1.17e-5	Gut microbiome composition (summer);
THYM	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs703842	0.616	rs871871	chr12:58219681	G/A	cg00677455	chr12:58241039	CTDSP2	0.82	5.87	0.52	6.4e-8	Multiple sclerosis;
THYM	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg00990874	chr7:1149470	C7orf50	-0.61	-4.82	-0.44	5.35e-6	Bronchopulmonary dysplasia;
THYM	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.86	5.52	0.49	2.91e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg17644776	chr2:200775616	C2orf69	0.8	4.75	0.44	7.1e-6	Schizophrenia;
THYM	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg08916839	chr5:415575	AHRR	1.14	6.87	0.58	6.77e-10	Fat distribution (HIV);
THYM	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.69	-0.43	9.03e-6	Type 2 diabetes;
THYM	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg06238570	chr21:40685208	BRWD1	-0.73	-6.27	-0.54	1.05e-8	Menarche (age at onset);
THYM	cis	rs4731207	0.698	rs4279518	chr7:124528086	G/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06634786	chr22:41940651	POLR3H	0.84	6.23	0.54	1.29e-8	Vitiligo;
THYM	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	7.45	0.61	4.17e-11	Platelet count;
THYM	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6598955	0.671	rs59143843	chr1:26641595	G/T	cg08133631	chr1:26527909	CATSPER4	-0.63	-5.22	-0.47	1.05e-6	Obesity-related traits;
THYM	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg19761014	chr17:28927070	LRRC37B2	0.71	4.52	0.42	1.77e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs75059851	0.756	rs7127156	chr11:133839857	T/C	cg14047540	chr11:133829660	NA	-1.06	-7.03	-0.58	3.14e-10	Schizophrenia;
THYM	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-15.41	-0.85	1.38e-27	Height;
THYM	cis	rs983545	0.800	rs6783752	chr3:16966387	G/A	cg19448816	chr3:16974217	PLCL2	0.53	4.65	0.43	1.06e-5	Blood protein levels;
THYM	cis	rs6430585	0.527	rs961360	chr2:136393658	A/G	cg07169764	chr2:136633963	MCM6	0.97	8.64	0.66	1.32e-13	Corneal structure;
THYM	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg26384229	chr12:38710491	ALG10B	-0.74	-6.24	-0.54	1.22e-8	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg06558623	chr16:89946397	TCF25	1.48	7.81	0.63	7.43e-12	Skin colour saturation;
THYM	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg23332699	chr15:44069569	ELL3	-0.75	-4.94	-0.45	3.31e-6	Lung cancer in ever smokers;
THYM	cis	rs259282	0.538	rs6510272	chr19:33117842	C/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.61	4.6	0.43	1.29e-5	Schizophrenia;
THYM	cis	rs7089973	0.872	rs7923295	chr10:116625159	C/G	cg23260525	chr10:116636907	FAM160B1	-0.52	-4.72	-0.44	8.04e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs3741151	0.686	rs11822984	chr11:73261467	A/C	cg17517138	chr11:73019481	ARHGEF17	0.9	4.68	0.43	9.36e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs11690935	1.000	rs2138348	chr2:172558172	A/C	cg13550731	chr2:172543902	DYNC1I2	0.88	6.5	0.55	3.76e-9	Schizophrenia;
THYM	cis	rs6032067	0.714	rs2206888	chr20:43882006	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.4	-4.72	-0.44	8.03e-6	Blood protein levels;
THYM	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg10523679	chr1:76189770	ACADM	0.91	9.57	0.7	1.37e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2276498	1.000	rs2276498	chr20:52610496	C/G	cg23682609	chr20:52687365	BCAS1	0.63	4.8	0.44	6e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs8180040	0.903	rs2276854	chr3:47276968	C/T	cg16586182	chr3:47516702	SCAP	-0.64	-5.49	-0.49	3.39e-7	Colorectal cancer;
THYM	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	4.58	0.43	1.39e-5	Hip circumference adjusted for BMI;
THYM	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg01741372	chr11:783889	NA	-0.57	-7.61	-0.62	1.98e-11	Breast cancer;
THYM	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	8.23	0.65	9.73e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	trans	rs11186	0.556	rs72906317	chr2:189956854	C/A	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs1018836	0.637	rs7843684	chr8:91470035	G/C	cg16814680	chr8:91681699	NA	-0.71	-5.68	-0.5	1.47e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.47	0.55	4.29e-9	Total body bone mineral density;
THYM	cis	rs611744	0.647	rs589347	chr8:109253929	T/A	cg21045802	chr8:109455806	TTC35	0.66	5.99	0.52	3.78e-8	Dupuytren's disease;
THYM	cis	rs7567389	0.719	rs4150471	chr2:128034539	A/G	cg09760422	chr2:128146352	NA	-0.4	-4.52	-0.42	1.8e-5	Self-rated health;
THYM	cis	rs665401	0.899	rs1406982	chr6:117236853	T/A	cg20376953	chr6:117187980	NA	0.6	4.67	0.43	9.78e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs858239	0.508	rs7805085	chr7:23190243	C/T	cg09755872	chr7:23245557	NA	-0.5	-4.71	-0.43	8.55e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg05373962	chr22:49881684	NA	-0.66	-6.78	-0.57	9.95e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs12928939	0.637	rs8046629	chr16:71643116	G/A	cg02602352	chr16:70688171	IL34	0.44	4.93	0.45	3.53e-6	Post bronchodilator FEV1;
THYM	cis	rs7408868	1.000	rs10420466	chr19:15261371	G/T	cg14696996	chr19:15285081	NOTCH3	0.97	5.57	0.5	2.37e-7	Pulse pressure;
THYM	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg08772003	chr10:104629869	AS3MT	-0.53	-4.54	-0.42	1.64e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.89	4.92	0.45	3.6e-6	Initial pursuit acceleration;
THYM	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg11752832	chr7:134001865	SLC35B4	0.7	4.89	0.45	4.02e-6	Mean platelet volume;
THYM	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.33	5.05	0.46	2.1e-6	Obesity-related traits;
THYM	cis	rs9329221	0.741	rs55975067	chr8:9806824	C/G	cg19847130	chr8:10466454	RP1L1	0.64	6.26	0.54	1.09e-8	Neuroticism;
THYM	cis	rs11657217	0.677	rs8071194	chr17:77698458	A/C	cg06901238	chr17:77706717	ENPP7	0.79	8.03	0.64	2.61e-12	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
THYM	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg00684032	chr4:1343700	KIAA1530	0.59	5.39	0.48	5.18e-7	Obesity-related traits;
THYM	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg05962950	chr11:130786565	SNX19	0.89	8.62	0.66	1.44e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	trans	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg25214090	chr10:38739885	LOC399744	-0.93	-7.97	-0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.96	6.22	0.54	1.34e-8	Smoking behavior;
THYM	cis	rs752010	0.902	rs60743712	chr1:42076629	G/A	cg06885757	chr1:42089581	HIVEP3	0.53	5.98	0.52	3.89e-8	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg21773646	chr17:80085082	CCDC57	-0.35	-4.95	-0.45	3.2e-6	Life satisfaction;
THYM	cis	rs10540	0.570	rs8176330	chr11:535798	G/A	cg21784768	chr11:537496	LRRC56	-1.21	-5.55	-0.5	2.53e-7	Body mass index;
THYM	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg07930552	chr6:133119739	C6orf192	0.96	5.5	0.49	3.14e-7	Type 2 diabetes nephropathy;
THYM	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg13175981	chr1:150552382	MCL1	0.78	5.82	0.51	7.84e-8	Tonsillectomy;
THYM	cis	rs17030434	1.000	rs1456391	chr4:154720485	A/G	cg14289246	chr4:154710475	SFRP2	-0.76	-5.24	-0.47	9.79e-7	Electrocardiographic conduction measures;
THYM	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg00071950	chr4:10020882	SLC2A9	-0.62	-5.69	-0.5	1.4e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11690935	0.959	rs7572215	chr2:172634228	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.84	-6.16	-0.53	1.77e-8	Schizophrenia;
THYM	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7084402	0.967	rs1658429	chr10:60330422	T/C	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs4664308	0.618	rs17830755	chr2:160888835	T/C	cg03641300	chr2:160917029	PLA2R1	-0.63	-5.47	-0.49	3.57e-7	Idiopathic membranous nephropathy;
THYM	cis	rs1691799	0.899	rs1168306	chr12:66738900	A/G	cg16791601	chr12:66731901	HELB	-0.76	-7.14	-0.59	1.9e-10	White blood cell count (basophil);
THYM	cis	rs2742417	0.603	rs9826208	chr3:45773991	C/T	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs9653442	0.835	rs11694875	chr2:100732845	A/G	cg22139774	chr2:100720529	AFF3	0.34	5.35	0.48	6.03e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs3126085	0.515	rs9633410	chr1:152363922	G/T	cg10321714	chr1:152280068	FLG	-0.69	-4.84	-0.44	5.1e-6	Atopic dermatitis;
THYM	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg13397359	chr6:42928475	GNMT	0.69	6.42	0.55	5.32e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg00129232	chr17:37814104	STARD3	-0.9	-7.45	-0.61	4.27e-11	Glomerular filtration rate (creatinine);
THYM	cis	rs7927771	0.524	rs7943213	chr11:47715524	T/C	cg18512352	chr11:47633146	NA	0.4	4.47	0.42	2.14e-5	Subjective well-being;
THYM	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg12165864	chr7:66369176	NA	-0.67	-5.26	-0.47	8.99e-7	Aortic root size;
THYM	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg22709100	chr7:91322751	NA	0.63	4.86	0.45	4.55e-6	Breast cancer;
THYM	cis	rs981844	0.826	rs1545604	chr4:154682733	C/T	cg09973105	chr4:154681532	RNF175	-0.69	-6.16	-0.53	1.74e-8	Response to statins (LDL cholesterol change);
THYM	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg20203395	chr5:56204925	C5orf35	-0.67	-4.53	-0.42	1.74e-5	Initial pursuit acceleration;
THYM	cis	rs9768139	0.935	rs62480865	chr7:158122307	A/C	cg25566285	chr7:158114605	PTPRN2	-0.85	-10.12	-0.72	9.08e-17	Calcium levels;
THYM	cis	rs1150668	0.699	rs1531681	chr6:28226878	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.51	-4.55	-0.42	1.56e-5	Pubertal anthropometrics;
THYM	cis	rs2033711	0.622	rs975947	chr19:58898193	C/T	cg08504662	chr19:58868256	ZNF497	-0.53	-5.12	-0.47	1.59e-6	Uric acid clearance;
THYM	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-4.69	-0.43	8.99e-6	Longevity;
THYM	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg23216685	chr1:86174607	ZNHIT6	-0.45	-5.14	-0.47	1.45e-6	Urate levels in overweight individuals;
THYM	cis	rs1933112	1.000	rs7529824	chr1:168500458	G/A	cg17186328	chr1:168545835	XCL1	-0.54	-4.58	-0.43	1.43e-5	Blood protein levels;
THYM	cis	rs11169225	0.756	rs377470	chr12:50339290	T/G	cg04450003	chr12:50355995	AQP5	0.78	6.01	0.52	3.4e-8	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs16858210	0.520	rs10460892	chr3:183546124	C/T	cg03417191	chr3:183542750	MAP6D1	-0.77	-4.49	-0.42	2.02e-5	Menopause (age at onset);
THYM	cis	rs13006833	0.668	rs291453	chr2:191160196	G/A	cg21644426	chr2:191273491	MFSD6	0.62	4.49	0.42	2e-5	Urinary metabolites;
THYM	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg13319975	chr6:146136371	FBXO30	-0.63	-4.98	-0.45	2.87e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1863824	0.625	rs12354988	chr10:88155204	G/A	cg06895675	chr10:88137553	NA	0.62	5.65	0.5	1.67e-7	Schizophrenia;
THYM	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg03517284	chr6:25882590	NA	0.74	5.83	0.51	7.58e-8	Blood metabolite levels;
THYM	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg12311346	chr5:56204834	C5orf35	0.99	7.77	0.62	9.17e-12	Initial pursuit acceleration;
THYM	cis	rs2777491	0.507	rs34040639	chr15:41760807	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.17	-13.34	-0.81	1.69e-23	Ulcerative colitis;
THYM	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg13525197	chr6:28411240	ZSCAN23	0.71	5.47	0.49	3.61e-7	Cardiac Troponin-T levels;
THYM	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg19913688	chr11:428466	ANO9	-0.86	-4.53	-0.42	1.69e-5	Body mass index;
THYM	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg08847533	chr14:75593920	NEK9	1.02	11.25	0.76	3.61e-19	Height;
THYM	cis	rs8036030	0.604	rs11852686	chr15:74715205	A/G	cg05926586	chr15:74592786	CCDC33	0.56	5.37	0.48	5.65e-7	Airflow obstruction;
THYM	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7626444	0.625	rs1798634	chr3:196474287	G/A	cg12930392	chr3:196481615	PAK2	0.43	5.3	0.48	7.4e-7	Monocyte count;
THYM	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs11122895	0.967	rs11677976	chr2:112468218	T/C	cg23262488	chr2:112468472	NA	0.67	9.4	0.69	3.21e-15	Allergic sensitization;
THYM	cis	rs635808	0.520	rs656938	chr6:167172048	C/T	cg17732216	chr6:167178280	RPS6KA2	0.63	5.09	0.46	1.79e-6	Dental caries;
THYM	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg07362569	chr17:61921086	SMARCD2	0.66	5.61	0.5	2.03e-7	Prudent dietary pattern;
THYM	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-9.24	-0.69	7.05e-15	Chronic sinus infection;
THYM	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg12963246	chr6:28129442	ZNF389	0.72	6.12	0.53	2.05e-8	Depression;
THYM	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.58	0.43	1.41e-5	Bipolar disorder;
THYM	cis	rs10186029	0.509	rs13426230	chr2:213940447	G/A	cg08319019	chr2:214017104	IKZF2	-0.67	-5.16	-0.47	1.34e-6	Systemic sclerosis;
THYM	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg02466173	chr16:30829666	NA	-0.54	-4.68	-0.43	9.68e-6	Dementia with Lewy bodies;
THYM	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg07362569	chr17:61921086	SMARCD2	-0.74	-6.62	-0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs7512552	1.000	rs7512552	chr1:150265704	T/C	cg15654264	chr1:150340011	RPRD2	-0.49	-5.79	-0.51	9.09e-8	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs10832963	1.000	rs10832956	chr11:18645668	A/G	cg09201001	chr11:18656081	SPTY2D1	1.05	9.35	0.69	4.11e-15	Breast cancer;
THYM	cis	rs192264	0.581	rs8061355	chr16:65995056	C/T	cg02795155	chr16:66785218	DYNC1LI2	0.54	4.45	0.42	2.32e-5	Subjective well-being;
THYM	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg14779329	chr11:130786720	SNX19	0.49	5.07	0.46	1.98e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs13006833	0.668	rs2582735	chr2:191143798	T/C	cg11845111	chr2:191398756	TMEM194B	0.66	4.81	0.44	5.66e-6	Urinary metabolites;
THYM	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg24675658	chr1:53192096	ZYG11B	0.75	5.75	0.51	1.08e-7	Monocyte count;
THYM	cis	rs4662945	0.586	rs67836955	chr2:130177825	G/A	cg05903289	chr2:130345205	NA	-0.57	-5.37	-0.48	5.66e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs4786125	0.596	rs12149100	chr16:6922512	T/G	cg03623568	chr16:6915990	A2BP1	-1.01	-10.06	-0.72	1.22e-16	Heart rate variability traits (SDNN);
THYM	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs6768930	0.509	rs9819294	chr3:57720901	G/C	cg24033633	chr3:57945695	NA	-0.4	-5.66	-0.5	1.59e-7	Obesity-related traits;
THYM	cis	rs1018836	0.608	rs6998106	chr8:91479755	G/T	cg16814680	chr8:91681699	NA	-0.75	-6.01	-0.52	3.49e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg00645579	chr11:617140	IRF7;MUPCDH	-0.53	-6.0	-0.52	3.64e-8	Systemic lupus erythematosus;
THYM	cis	rs1401999	0.628	rs7639048	chr3:183746044	A/G	cg01324343	chr3:183735012	ABCC5	0.8	11.03	0.75	1.05e-18	Anterior chamber depth;
THYM	cis	rs6665290	0.935	rs12409755	chr1:227196949	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Alcohol dependence;
THYM	cis	rs10895275	0.961	rs10895273	chr11:102082676	C/T	cg24447756	chr11:102105824	NA	0.51	4.45	0.42	2.3e-5	Migraine;
THYM	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.78	-5.13	-0.47	1.55e-6	Mean platelet volume;
THYM	cis	rs8016982	0.633	rs7160342	chr14:81713427	G/C	cg01989461	chr14:81687754	GTF2A1	0.8	7.24	0.6	1.14e-10	Schizophrenia;
THYM	cis	rs11779988	0.545	rs397096	chr8:17798848	C/G	cg01800426	chr8:17659068	MTUS1	0.69	4.87	0.45	4.45e-6	Breast cancer;
THYM	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.64	-4.68	-0.43	9.69e-6	Colorectal cancer;
THYM	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg18402987	chr7:1209562	NA	1.02	5.97	0.52	4.03e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg07460842	chr6:66804631	NA	-1.1	-8.28	-0.65	7.54e-13	Exhaled nitric oxide output;
THYM	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg11461670	chr8:22454935	PDLIM2	0.31	5.58	0.5	2.28e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs757081	0.667	rs17561348	chr11:17161615	C/T	cg07093617	chr11:18158918	MRGPRX3	0.49	4.61	0.43	1.23e-5	Systolic blood pressure;
THYM	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs75920871	0.528	rs7109649	chr11:116943544	C/T	cg20608306	chr11:116969690	SIK3	-0.54	-6.01	-0.52	3.45e-8	Subjective well-being;
THYM	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg26384229	chr12:38710491	ALG10B	1.0	9.65	0.7	9.1e-16	Heart rate;
THYM	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg02018176	chr4:1364513	KIAA1530	-0.58	-4.62	-0.43	1.19e-5	Obesity-related traits;
THYM	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg03676636	chr4:99064102	C4orf37	0.5	7.65	0.62	1.6e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg11494091	chr17:61959527	GH2	0.7	6.46	0.55	4.55e-9	Height;
THYM	cis	rs4907240	0.961	rs10460601	chr2:97252444	G/A	cg18419276	chr2:96971862	SNRNP200	-0.4	-4.73	-0.44	7.72e-6	Event-related brain oscillations;
THYM	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg12893697	chr11:970389	AP2A2	-0.32	-5.35	-0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.95	9.99	0.72	1.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs7100689	0.784	rs1972370	chr10:82127180	A/G	cg01528321	chr10:82214614	TSPAN14	0.97	7.39	0.6	5.79e-11	Post bronchodilator FEV1;
THYM	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg02018176	chr4:1364513	KIAA1530	0.91	8.22	0.64	1.02e-12	Longevity;
THYM	cis	rs7760949	0.889	rs9475816	chr6:13935425	T/C	cg27413430	chr6:13925136	RNF182	0.53	4.74	0.44	7.6e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.68	9.11	0.68	1.34e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg18252515	chr7:66147081	NA	-0.59	-4.49	-0.42	2.04e-5	Aortic root size;
THYM	cis	rs35883536	0.545	rs115017855	chr1:101101830	T/A	cg06223162	chr1:101003688	GPR88	0.62	5.52	0.49	2.96e-7	Monocyte count;
THYM	cis	rs789852	0.867	rs1773177	chr3:194316181	A/C	cg18000598	chr3:194342907	TMEM44	-1.12	-6.95	-0.58	4.5e-10	QT interval;
THYM	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg03517284	chr6:25882590	NA	-0.66	-4.97	-0.45	3.02e-6	Height;
THYM	cis	rs2295499	0.773	rs2298961	chr4:2644961	T/A	cg17924901	chr4:3475233	DOK7	0.21	4.49	0.42	2.01e-5	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs7089973	0.836	rs12765350	chr10:116635305	G/A	cg23260525	chr10:116636907	FAM160B1	0.52	4.66	0.43	1.02e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs4285028	0.747	rs7610298	chr3:121419100	T/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.84	-7.2	-0.59	1.37e-10	Multiple sclerosis;
THYM	cis	rs4891159	0.527	rs689642	chr18:74119120	A/C	cg24786174	chr18:74118243	ZNF516	0.96	14.31	0.83	1.94e-25	Longevity;
THYM	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.17	-0.53	1.69e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs9790314	0.560	rs4856701	chr3:161044106	G/T	cg04691961	chr3:161091175	C3orf57	-0.55	-4.56	-0.42	1.53e-5	Morning vs. evening chronotype;
THYM	trans	rs8002861	0.935	rs9533672	chr13:44451180	C/T	cg17145862	chr1:211918768	LPGAT1	0.96	9.83	0.71	3.86e-16	Leprosy;
THYM	cis	rs2133450	0.545	rs12492204	chr3:7350481	T/C	cg19930620	chr3:7340148	GRM7	-0.52	-5.62	-0.5	1.86e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg06521331	chr12:34319734	NA	-1.02	-10.14	-0.72	8.47e-17	Morning vs. evening chronotype;
THYM	cis	rs7258015	1.000	rs7257871	chr19:10449252	T/C	cg01466491	chr19:10523363	NA	0.67	5.33	0.48	6.56e-7	Systemic lupus erythematosus or rheumatoid arthritis;
THYM	cis	rs34526934	0.608	rs728521	chr2:177031683	T/C	cg26754761	chr2:177040938	NA	-0.74	-6.37	-0.55	6.7e-9	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg23803603	chr1:2058230	PRKCZ	-0.63	-5.37	-0.48	5.58e-7	Height;
THYM	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg04772025	chr11:68637568	NA	0.59	5.98	0.52	3.92e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg23281280	chr6:28129359	ZNF389	-0.66	-5.35	-0.48	6.09e-7	Depression;
THYM	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg24768116	chr2:27665128	KRTCAP3	-0.28	-4.6	-0.43	1.29e-5	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
THYM	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg06917634	chr15:78832804	PSMA4	0.83	7.39	0.6	5.74e-11	Sudden cardiac arrest;
THYM	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg23711669	chr6:146136114	FBXO30	0.98	10.25	0.72	4.91e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg17264618	chr3:40429014	ENTPD3	0.49	4.57	0.42	1.49e-5	Renal cell carcinoma;
THYM	cis	rs4638749	0.677	rs2198471	chr2:108844069	C/T	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs4072705	0.835	rs10122154	chr9:127559038	C/T	cg13476313	chr9:127244764	NR5A1	0.32	4.78	0.44	6.29e-6	Menarche (age at onset);
THYM	cis	rs8014204	0.533	rs12889955	chr14:75172999	G/A	cg06637938	chr14:75390232	RPS6KL1	0.57	5.06	0.46	2.02e-6	Caffeine consumption;
THYM	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg16230307	chr14:35515116	FAM177A1	0.95	6.12	0.53	2.06e-8	Psoriasis;
THYM	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg26038318	chr20:34205095	SPAG4	0.58	4.6	0.43	1.3e-5	Total cholesterol levels;
THYM	cis	rs7542375	0.507	rs2484697	chr1:221094718	A/G	cg16008148	chr1:221062819	NA	0.37	5.55	0.49	2.56e-7	Obesity-related traits;
THYM	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.0	0.63	3.07e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4460079	0.531	rs4593205	chr4:114847491	A/G	cg02060584	chr4:113970739	ANK2	0.59	4.93	0.45	3.48e-6	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs7131987	0.650	rs7957339	chr12:29456495	T/C	cg09582351	chr12:29534625	ERGIC2	-0.53	-4.68	-0.43	9.37e-6	QT interval;
THYM	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.92	-7.96	-0.63	3.73e-12	Menarche (age at onset);
THYM	cis	rs807029	0.533	rs722435	chr10:102745062	G/T	cg14905631	chr10:102746534	C10orf2;MRPL43	0.36	4.93	0.45	3.49e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs61990749	0.597	rs59848135	chr14:78129000	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	-1.14	-7.81	-0.63	7.61e-12	Fibroblast growth factor basic levels;
THYM	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg22875332	chr1:76189707	ACADM	-0.75	-6.46	-0.55	4.51e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg17888033	chr8:143858414	LYNX1	-0.45	-5.16	-0.47	1.34e-6	Urinary tract infection frequency;
THYM	cis	rs11153147	0.655	rs74934949	chr6:109494833	G/C	cg17117243	chr6:109341365	SESN1	-0.82	-4.8	-0.44	5.98e-6	Mean corpuscular volume;
THYM	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg03351412	chr1:154909251	PMVK	0.67	4.66	0.43	1.05e-5	Prostate cancer;
THYM	cis	rs4660306	0.961	rs4660868	chr1:45986497	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.43	-0.49	4.37e-7	Homocysteine levels;
THYM	cis	rs9443189	0.762	rs1321162	chr6:76456347	C/T	cg01950844	chr6:76311363	SENP6	0.79	4.59	0.43	1.33e-5	Prostate cancer;
THYM	cis	rs10158481	0.759	rs6600259	chr1:25479890	G/A	cg09264742	chr1:25757510	TMEM57	-0.69	-5.06	-0.46	2.07e-6	Urate levels in obese individuals;
THYM	cis	rs1520896	1.000	rs1520896	chr11:20269390	A/G	cg21745110	chr11:19798742	NAV2	-0.7	-4.47	-0.42	2.15e-5	Response to platinum-based chemotherapy (cisplatin);
THYM	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg12407791	chr17:73824354	UNC13D	-0.42	-4.58	-0.43	1.43e-5	White matter hyperintensity burden;
THYM	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg24060327	chr5:131705240	SLC22A5	0.67	5.63	0.5	1.79e-7	Breast cancer;
THYM	cis	rs8048589	0.604	rs12929519	chr16:12207439	A/G	cg01990910	chr16:12207648	SNX29	0.53	6.05	0.53	2.82e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg27129171	chr3:47204927	SETD2	-0.7	-6.73	-0.57	1.3e-9	Colorectal cancer;
THYM	cis	rs6424115	0.830	rs3003336	chr1:24201448	C/T	cg15997130	chr1:24165203	NA	0.76	6.39	0.55	6.14e-9	Immature fraction of reticulocytes;
THYM	cis	rs12478296	0.901	rs7420176	chr2:243005277	G/A	cg06360820	chr2:242988706	NA	-0.92	-6.13	-0.53	1.98e-8	Obesity-related traits;
THYM	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg11494091	chr17:61959527	GH2	0.7	6.46	0.55	4.55e-9	Height;
THYM	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg15247329	chr7:2764246	NA	0.7	5.91	0.52	5.43e-8	Height;
THYM	cis	rs8067545	0.611	rs11653869	chr17:20197586	T/G	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg12386194	chr3:101231763	SENP7	0.64	4.82	0.44	5.43e-6	Colorectal cancer;
THYM	cis	rs2354432	0.891	rs2165743	chr1:146690319	C/T	cg25205988	chr1:146714368	CHD1L	1.1	7.31	0.6	8.32e-11	Mitochondrial DNA levels;
THYM	cis	rs1007190	0.881	rs8073674	chr17:42969337	A/C	cg15406952	chr17:42872593	NA	0.8	5.57	0.5	2.34e-7	DNA methylation (variation);
THYM	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg05738196	chr6:26577821	NA	0.95	9.91	0.71	2.53e-16	Intelligence (multi-trait analysis);
THYM	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg21775007	chr8:11205619	TDH	-0.64	-4.85	-0.45	4.88e-6	Retinal vascular caliber;
THYM	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.69	-7.42	-0.61	4.85e-11	Crohn's disease;
THYM	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg24530246	chr3:53118167	NA	-0.83	-4.78	-0.44	6.39e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg19507638	chr5:93509721	C5orf36	-0.68	-4.57	-0.42	1.49e-5	Diabetic retinopathy;
THYM	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg08999081	chr20:33150536	PIGU	0.62	5.02	0.46	2.41e-6	Coronary artery disease;
THYM	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg09085632	chr11:111637200	PPP2R1B	1.11	11.08	0.75	8.23e-19	Primary sclerosing cholangitis;
THYM	cis	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg07460842	chr6:66804631	NA	1.11	8.12	0.64	1.7e-12	Exhaled nitric oxide output;
THYM	cis	rs7106204	0.620	rs35008727	chr11:24258035	A/T	ch.11.24196551F	chr11:24239977	NA	0.93	5.71	0.51	1.3e-7	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs365132	0.905	rs10068703	chr5:176377069	T/A	cg17809377	chr5:176326619	HK3	-0.3	-4.45	-0.42	2.31e-5	Menarche and menopause (age at onset);Menopause (age at onset);
THYM	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17818399	0.547	rs35178974	chr2:46763898	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.66	4.58	0.43	1.38e-5	Height;
THYM	cis	rs360798	0.779	rs7590973	chr2:62905339	C/T	cg00752480	chr2:62680940	NA	-0.25	-4.49	-0.42	2e-5	Coronary artery disease;
THYM	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg00999904	chr2:3704751	ALLC	-0.71	-4.85	-0.45	4.75e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg24812749	chr6:127587940	RNF146	0.97	7.72	0.62	1.14e-11	Breast cancer;
THYM	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg24257776	chr3:47051546	LOC100129354	0.41	4.79	0.44	6.1e-6	Colorectal cancer;
THYM	cis	rs4731207	0.596	rs10081290	chr7:124575508	T/C	cg05285228	chr7:124571219	POT1	-0.69	-5.25	-0.47	9.35e-7	Cutaneous malignant melanoma;
THYM	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg18477163	chr1:228402036	OBSCN	-0.51	-5.54	-0.49	2.69e-7	Parkinson's disease;
THYM	cis	rs11264213	0.591	rs399393	chr1:36553673	A/G	cg27506609	chr1:36549197	TEKT2	-1.3	-5.02	-0.46	2.41e-6	Schizophrenia;
THYM	cis	rs912057	0.671	rs1294425	chr6:6744292	G/A	cg13809441	chr6:6737631	NA	0.44	5.32	0.48	6.97e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg21773646	chr17:80085082	CCDC57	0.31	4.49	0.42	2.02e-5	Life satisfaction;
THYM	cis	rs7177699	0.557	rs7176187	chr15:79121373	A/G	cg15571903	chr15:79123663	NA	0.56	6.55	0.56	2.92e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	trans	rs10900020	0.764	rs10900023	chr10:44829089	G/T	cg13581866	chr3:11138138	NA	0.99	6.85	0.57	7.17e-10	Schizophrenia;
THYM	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg01528321	chr10:82214614	TSPAN14	0.63	5.31	0.48	7.07e-7	Post bronchodilator FEV1;
THYM	cis	rs59112743	0.510	rs9476849	chr6:15560583	G/A	cg10111214	chr6:14815676	NA	0.74	4.84	0.44	5.08e-6	Multiple keratinocyte cancers;
THYM	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg25358565	chr5:93447407	FAM172A	0.96	6.78	0.57	1.01e-9	Diabetic retinopathy;
THYM	cis	rs9486719	0.948	rs2472881	chr6:96862562	C/T	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	trans	rs10802346	0.545	rs10802347	chr1:246374268	G/A	cg13514129	chr1:39547527	MACF1	1.02	10.19	0.72	6.4e-17	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs7255436	0.965	rs62117510	chr19:8452613	T/G	cg10174797	chr19:8464628	RAB11B	0.43	5.19	0.47	1.18e-6	HDL cholesterol;
THYM	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg24308560	chr3:49941425	MST1R	-0.76	-6.34	-0.55	7.57e-9	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg08859206	chr1:53392774	SCP2	-0.51	-5.32	-0.48	7.04e-7	Monocyte count;
THYM	cis	rs2625529	0.816	rs8025504	chr15:72294757	C/T	cg16672083	chr15:72433130	SENP8	-0.55	-4.92	-0.45	3.61e-6	Red blood cell count;
THYM	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg18252515	chr7:66147081	NA	0.7	5.35	0.48	5.99e-7	Aortic root size;
THYM	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7119	0.717	rs7180732	chr15:77829921	G/A	cg27398640	chr15:77910606	LINGO1	-0.55	-5.53	-0.49	2.82e-7	Type 2 diabetes;
THYM	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	trans	rs1147813	0.654	rs993232	chr9:25890597	A/G	cg10233744	chr13:74557243	KLF12	-0.99	-6.9	-0.58	5.81e-10	Morning vs. evening chronotype;
THYM	cis	rs9914544	0.505	rs4924774	chr17:18794920	A/C	cg26378065	chr17:18585709	ZNF286B	0.58	4.65	0.43	1.05e-5	Educational attainment (years of education);
THYM	cis	rs1122401	0.515	rs2564981	chr5:53870905	A/G	cg18373318	chr5:53813164	SNX18	0.67	4.54	0.42	1.66e-5	Smoking initiation;
THYM	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg18904891	chr8:8559673	CLDN23	-0.57	-4.89	-0.45	4.15e-6	Mood instability;
THYM	cis	rs2236293	0.755	rs10758325	chr9:35804149	A/G	cg12876594	chr9:35791798	NPR2	-0.4	-4.51	-0.42	1.87e-5	Blood protein levels;
THYM	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg24642439	chr20:33292090	TP53INP2	0.59	4.48	0.42	2.09e-5	Coronary artery disease;
THYM	cis	rs2334880	0.678	rs66778248	chr16:71451424	A/G	cg06353428	chr16:71660113	MARVELD3	-1.08	-5.53	-0.49	2.78e-7	Malaria;
THYM	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7578361	0.959	rs10198177	chr2:150422200	G/C	cg17961725	chr2:150454027	NA	0.77	6.17	0.53	1.7e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs3771570	1.000	rs62190367	chr2:242376276	G/A	cg21155796	chr2:242212141	HDLBP	1.25	6.07	0.53	2.57e-8	Prostate cancer;
THYM	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.01	0.58	3.39e-10	Prudent dietary pattern;
THYM	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg03188948	chr7:1209495	NA	1.11	6.31	0.54	8.7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg25214090	chr10:38739885	LOC399744	0.94	7.92	0.63	4.4e-12	Corneal astigmatism;
THYM	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10979	0.931	rs12191837	chr6:143898200	T/G	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg05754148	chr16:3507555	NAT15	-0.72	-7.11	-0.59	2.18e-10	Tuberculosis;
THYM	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg18132916	chr6:79620363	NA	-0.6	-4.99	-0.46	2.72e-6	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg25214090	chr10:38739885	LOC399744	0.87	7.52	0.61	2.99e-11	Corneal astigmatism;
THYM	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-5.65	-0.5	1.64e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg18681998	chr4:17616180	MED28	0.79	6.77	0.57	1.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9311676	0.632	rs7610312	chr3:58374029	A/G	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg13683864	chr3:40499215	RPL14	1.05	11.56	0.76	7.95e-20	Renal cell carcinoma;
THYM	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg27490568	chr2:178487706	NA	-0.61	-5.63	-0.5	1.82e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4780401	0.703	rs12921129	chr16:11769176	C/T	cg01061890	chr16:11836724	TXNDC11	-0.61	-4.71	-0.43	8.55e-6	Rheumatoid arthritis;
THYM	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg15744692	chr15:45671195	LOC145663;GATM	0.45	4.48	0.42	2.08e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs3733631	0.557	rs80318938	chr4:104702505	T/C	cg24090629	chr4:104641072	TACR3	-0.87	-4.61	-0.43	1.26e-5	Menarche (age at onset);
THYM	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg03929089	chr4:120376271	NA	1.02	8.12	0.64	1.67e-12	Coronary artery disease;
THYM	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg24874828	chr4:187887005	NA	-0.76	-8.24	-0.65	9.29e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9916302	0.706	rs11078894	chr17:37396805	C/G	cg07936489	chr17:37558343	FBXL20	-0.79	-5.08	-0.46	1.92e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs868036	0.918	rs4238411	chr15:68079424	A/T	cg24579218	chr15:68104479	NA	-0.61	-6.19	-0.54	1.53e-8	Restless legs syndrome;
THYM	cis	rs612683	0.524	rs11166456	chr1:100925633	C/T	cg09408571	chr1:101003634	GPR88	0.44	5.02	0.46	2.38e-6	Breast cancer;
THYM	cis	rs4790312	0.729	rs9906546	chr17:1995614	C/G	cg15816464	chr17:2026533	SMG6	0.35	4.62	0.43	1.2e-5	Left atrial antero-posterior diameter;
THYM	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11890956	chr21:40555474	PSMG1	-0.68	-6.42	-0.55	5.42e-9	Menarche (age at onset);
THYM	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg24692254	chr21:30365293	RNF160	-0.75	-5.43	-0.49	4.23e-7	Cognitive test performance;
THYM	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg14675211	chr2:100938903	LONRF2	0.71	6.91	0.58	5.47e-10	Intelligence (multi-trait analysis);
THYM	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.75	5.7	0.5	1.35e-7	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg05283184	chr6:79620031	NA	0.94	9.25	0.69	6.49e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs654950	0.840	rs647146	chr1:41986286	G/A	cg06885757	chr1:42089581	HIVEP3	0.46	5.53	0.49	2.78e-7	Airway imaging phenotypes;
THYM	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg18681998	chr4:17616180	MED28	1.01	10.48	0.73	1.53e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg17105886	chr17:28927953	LRRC37B2	1.25	6.76	0.57	1.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg13147721	chr7:65941812	NA	0.96	5.84	0.51	7.26e-8	Diabetic kidney disease;
THYM	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg02503808	chr4:7069936	GRPEL1	1.0	8.02	0.64	2.69e-12	Monocyte percentage of white cells;
THYM	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg27170947	chr2:26402098	FAM59B	0.79	6.27	0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs4731207	0.735	rs17147494	chr7:124449835	G/A	cg05285228	chr7:124571219	POT1	0.66	5.24	0.47	9.66e-7	Cutaneous malignant melanoma;
THYM	cis	rs6987853	0.901	rs2974344	chr8:42400732	T/G	cg09913449	chr8:42400586	C8orf40	0.94	8.91	0.67	3.56e-14	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11077998	0.967	rs4789790	chr17:80510789	G/A	cg10255544	chr17:80519551	FOXK2	0.5	4.46	0.42	2.21e-5	Reticulocyte fraction of red cells;
THYM	cis	rs7589342	0.929	rs13024715	chr2:106433950	A/G	cg14210321	chr2:106509881	NCK2	-0.72	-5.12	-0.46	1.62e-6	Addiction;
THYM	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg02931644	chr1:25747376	RHCE	0.59	4.62	0.43	1.19e-5	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg05368731	chr17:41323189	NBR1	1.25	11.37	0.76	2.01e-19	Menopause (age at onset);
THYM	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg07537917	chr2:241836409	C2orf54	-0.26	-5.83	-0.51	7.57e-8	Urinary metabolites;
THYM	cis	rs4606347	0.789	rs77011771	chr1:66168846	T/A	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs4474465	1.000	rs10899520	chr11:78183370	C/T	cg19901956	chr11:77921274	USP35	-0.61	-4.63	-0.43	1.18e-5	Alzheimer's disease (survival time);
THYM	cis	rs1160297	0.585	rs12713229	chr2:53090105	T/C	cg07782112	chr2:53107842	NA	0.75	5.94	0.52	4.67e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg19693284	chr19:2783607	SGTA	0.87	6.43	0.55	5.17e-9	Total cholesterol levels;
THYM	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs11096990	0.892	rs6815686	chr4:39199791	A/T	cg24403649	chr4:39172243	NA	-0.62	-5.17	-0.47	1.31e-6	Cognitive function;
THYM	cis	rs6988636	1.000	rs59834873	chr8:124188824	G/T	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-14.22	-0.82	2.89e-25	Height;
THYM	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg10518543	chr12:38710700	ALG10B	0.57	4.5	0.42	1.92e-5	Morning vs. evening chronotype;
THYM	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg26384229	chr12:38710491	ALG10B	1.05	10.43	0.73	1.96e-17	Heart rate;
THYM	cis	rs1559088	1.000	rs28803235	chr19:33561804	G/A	cg03563238	chr19:33554763	RHPN2	-0.5	-4.52	-0.42	1.8e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs67311347	0.544	rs35112505	chr3:40337075	A/G	cg24209194	chr3:40518798	ZNF619	0.55	4.6	0.43	1.29e-5	Renal cell carcinoma;
THYM	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs6032067	0.929	rs6032063	chr20:43854475	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.41	-0.55	5.57e-9	Blood protein levels;
THYM	trans	rs11186	0.556	rs7421643	chr2:189961031	C/T	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	5.78	0.51	9.49e-8	Height;
THYM	cis	rs6500395	0.962	rs9937134	chr16:48577683	T/A	cg04672837	chr16:48644449	N4BP1	0.47	4.46	0.42	2.23e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg16049864	chr8:95962084	TP53INP1	-0.7	-6.01	-0.53	3.36e-8	Type 2 diabetes;
THYM	cis	rs3784262	0.528	rs17820966	chr15:58336662	A/G	cg12031962	chr15:58353849	ALDH1A2	0.65	5.04	0.46	2.24e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
THYM	cis	rs8067545	0.641	rs169412	chr17:19851875	G/T	cg20830565	chr17:20408647	MGC102966	-0.54	-4.95	-0.45	3.16e-6	Schizophrenia;
THYM	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg02569458	chr12:86230093	RASSF9	0.56	4.79	0.44	6.02e-6	Major depressive disorder;
THYM	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg00339695	chr16:24857497	SLC5A11	-0.47	-4.72	-0.44	8.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2296887	0.841	rs945781	chr10:104085921	A/G	cg26089160	chr10:104170217	PSD	0.64	4.84	0.45	4.93e-6	Parkinson's disease;
THYM	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg07424592	chr7:64974309	NA	0.99	5.15	0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22857025	chr5:266934	NA	-1.59	-10.2	-0.72	6.04e-17	Breast cancer;
THYM	cis	rs684232	0.583	rs4968094	chr17:507120	A/T	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.41	-4.89	-0.45	4.14e-6	Prostate cancer;
THYM	cis	rs12530845	0.623	rs73721662	chr7:135341314	G/A	cg23117316	chr7:135346802	PL-5283	-0.73	-5.82	-0.51	7.9e-8	Red blood cell traits;
THYM	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs59698941	0.882	rs67414627	chr5:132258165	A/G	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg06026331	chr20:60912101	LAMA5	-0.62	-4.9	-0.45	3.89e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs17016200	0.513	rs73106298	chr3:78344176	C/T	cg24512093	chr3:78698151	ROBO1	0.97	5.12	0.47	1.58e-6	Facial emotion recognition;
THYM	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg17063962	chr7:91808500	NA	-1.02	-8.33	-0.65	6.16e-13	Breast cancer;
THYM	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs2039659	0.719	rs9531827	chr13:86276176	A/G	cg25308322	chr13:86268291	NA	-0.67	-6.04	-0.53	2.93e-8	Blood osmolality (transformed sodium);
THYM	cis	rs6840360	0.571	rs11099823	chr4:152510565	T/G	cg22705602	chr4:152727874	NA	-0.78	-8.73	-0.67	8.56e-14	Intelligence (multi-trait analysis);
THYM	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.04	6.98	0.58	3.97e-10	Cognitive test performance;
THYM	cis	rs13424612	0.839	rs6716293	chr2:240923146	T/C	cg01812947	chr2:240904978	NDUFA10	0.57	4.69	0.43	9.17e-6	Odorant perception (isobutyraldehyde);
THYM	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs1728785	0.818	rs11648503	chr16:68598938	G/A	cg02972257	chr16:68554789	NA	-0.77	-4.9	-0.45	3.98e-6	Ulcerative colitis;
THYM	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg18512352	chr11:47633146	NA	-0.5	-5.94	-0.52	4.75e-8	Subjective well-being;
THYM	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg00666640	chr1:248458726	OR2T12	0.57	4.75	0.44	7.19e-6	Common traits (Other);
THYM	cis	rs9309711	0.736	rs9309717	chr2:3495078	C/T	cg10845886	chr2:3471009	TTC15	0.6	4.86	0.45	4.69e-6	Neurofibrillary tangles;
THYM	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg09549813	chr16:4587862	C16orf5	-0.59	-6.56	-0.56	2.81e-9	Schizophrenia;
THYM	cis	rs753778	0.570	rs6985866	chr8:142210336	C/T	cg18755752	chr8:142205143	DENND3	0.73	7.24	0.6	1.18e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs6674176	0.932	rs7412307	chr1:44433864	C/G	cg26023051	chr1:45103896	RNF220	-0.67	-4.48	-0.42	2.08e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs1978968	0.654	rs13056749	chr22:18402924	G/A	cg01550578	chr22:18484421	MICAL3	0.61	4.5	0.42	1.9e-5	Presence of antiphospholipid antibodies;
THYM	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg03517284	chr6:25882590	NA	-0.68	-4.52	-0.42	1.76e-5	Height;
THYM	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg00757033	chr12:89920650	WDR51B	0.74	11.52	0.76	9.94e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs887829	0.569	rs7574296	chr2:234638249	A/G	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.6	-4.99	-0.46	2.68e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg02782426	chr3:40428986	ENTPD3	-0.49	-4.46	-0.42	2.21e-5	Renal cell carcinoma;
THYM	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg03806693	chr22:41940476	POLR3H	-0.77	-5.95	-0.52	4.56e-8	Neuroticism;
THYM	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg00677455	chr12:58241039	CTDSP2	0.72	5.29	0.48	7.78e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg00599163	chr2:162100495	NA	-0.66	-6.01	-0.52	3.39e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg03605463	chr16:89740564	NA	0.62	5.01	0.46	2.47e-6	Hemoglobin concentration;
THYM	cis	rs2811415	0.597	rs9854763	chr3:127797890	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg02915803	chr1:1606292	LOC728661;CDK11B	0.6	4.96	0.45	3.05e-6	Body mass index;
THYM	cis	rs36051895	0.659	rs58345215	chr9:5043767	A/T	cg02405213	chr9:5042618	JAK2	-1.03	-10.88	-0.74	2.16e-18	Pediatric autoimmune diseases;
THYM	cis	rs6496667	0.509	rs2253419	chr15:90945875	A/G	cg22089800	chr15:90895588	ZNF774	0.72	5.56	0.5	2.5e-7	Rheumatoid arthritis;
THYM	cis	rs6748734	0.600	rs10202620	chr2:241820912	G/C	cg02820040	chr2:241836501	C2orf54	-0.24	-4.5	-0.42	1.89e-5	Urinary metabolites;
THYM	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs12532960	0.749	rs11979793	chr7:42338326	T/C	cg23473276	chr7:42834405	NA	0.87	4.77	0.44	6.71e-6	Inflammatory biomarkers;
THYM	cis	rs4771122	0.500	rs1049302	chr13:27998769	T/C	cg22138327	chr13:27999177	GTF3A	-0.99	-9.81	-0.71	4.18e-16	Body mass index;
THYM	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg06028605	chr16:24865363	SLC5A11	0.63	5.02	0.46	2.38e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg22535103	chr8:58192502	C8orf71	-0.85	-4.77	-0.44	6.68e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg01616529	chr11:638424	DRD4	-0.78	-6.62	-0.56	2.16e-9	Systemic lupus erythematosus;
THYM	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg18761221	chr20:60518478	NA	0.72	5.76	0.51	1.04e-7	Obesity-related traits;
THYM	cis	rs7681440	0.583	rs2619363	chr4:90759047	G/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.33	-0.48	6.7e-7	Dementia with Lewy bodies;
THYM	cis	rs55882075	0.765	rs34329357	chr5:179130408	G/C	cg00433081	chr5:179719502	MAPK9	-0.63	-4.59	-0.43	1.38e-5	Monocyte percentage of white cells;
THYM	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg14768367	chr16:72042858	DHODH	0.65	4.98	0.46	2.83e-6	Fibrinogen levels;
THYM	cis	rs950881	0.866	rs72823628	chr2:102928617	G/A	cg20060108	chr2:102954350	IL1RL1	0.81	4.47	0.42	2.14e-5	Allergy;
THYM	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg08772003	chr10:104629869	AS3MT	-0.55	-4.88	-0.45	4.23e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg26721908	chr21:47610096	LSS	-0.87	-6.81	-0.57	8.89e-10	Testicular germ cell tumor;
THYM	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg10802521	chr3:52805072	NEK4	0.73	6.43	0.55	5.15e-9	Bipolar disorder;
THYM	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg21361702	chr7:150065534	REPIN1	0.67	4.83	0.44	5.28e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg18200150	chr17:30822561	MYO1D	0.71	6.06	0.53	2.7e-8	Schizophrenia;
THYM	cis	rs72828912	0.764	rs12175687	chr6:24089375	A/G	cg26336265	chr6:25042955	NA	-0.87	-5.53	-0.49	2.85e-7	Squamous cell lung carcinoma;
THYM	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.68	5.59	0.5	2.19e-7	Blood metabolite levels;
THYM	cis	rs2692947	0.795	rs2252697	chr2:96778190	G/C	cg23100626	chr2:96804247	ASTL	-0.34	-4.51	-0.42	1.84e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg23260525	chr10:116636907	FAM160B1	0.53	5.36	0.48	5.92e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs34421088	0.678	rs35928010	chr8:11591876	C/T	cg12395012	chr8:11607386	GATA4	0.57	4.97	0.45	3.01e-6	Neuroticism;
THYM	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg05234568	chr11:5960015	NA	-0.62	-5.78	-0.51	9.33e-8	DNA methylation (variation);
THYM	cis	rs514406	0.858	rs564640	chr1:53285187	T/C	cg22166914	chr1:53195759	ZYG11B	-0.8	-8.11	-0.64	1.78e-12	Monocyte count;
THYM	cis	rs9810089	0.835	rs6791611	chr3:136160590	C/G	cg12473912	chr3:136751656	NA	-0.57	-4.56	-0.42	1.5e-5	Gestational age at birth (child effect);
THYM	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg19318889	chr4:1322082	MAEA	0.63	5.4	0.48	5e-7	Longevity;
THYM	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg06600287	chr1:53387719	ECHDC2	-0.31	-5.1	-0.46	1.76e-6	Monocyte count;
THYM	cis	rs2663905	0.611	rs2663920	chr15:81396404	A/G	cg09888468	chr15:81410853	NA	-0.6	-5.09	-0.46	1.79e-6	QT interval (drug interaction);
THYM	cis	rs990171	0.955	rs3755268	chr2:103038527	C/G	cg13897122	chr2:103039542	IL18RAP	-0.39	-4.64	-0.43	1.12e-5	Lymphocyte counts;
THYM	cis	rs11048434	0.761	rs10842660	chr12:9138897	G/A	cg13575925	chr12:9217583	LOC144571	0.55	5.45	0.49	3.89e-7	Sjögren's syndrome;
THYM	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg18200150	chr17:30822561	MYO1D	0.84	7.34	0.6	7.25e-11	Schizophrenia;
THYM	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg21784768	chr11:537496	LRRC56	-1.16	-5.78	-0.51	9.66e-8	Body mass index;
THYM	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg22875332	chr1:76189707	ACADM	0.9	10.57	0.74	9.87e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.02	0.46	2.4e-6	Prudent dietary pattern;
THYM	trans	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg04025307	chr7:1156635	C7orf50	0.79	5.0	0.46	2.6e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs59698941	0.882	rs68171951	chr5:132290711	T/C	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	trans	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg06437703	chr8:37914619	EIF4EBP1	-0.82	-9.08	-0.68	1.52e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02475777	chr4:1388615	CRIPAK	0.66	4.81	0.44	5.69e-6	Longevity;
THYM	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-5.98	-0.52	3.86e-8	Prostate cancer;
THYM	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg14298792	chr15:30685198	CHRFAM7A	0.78	5.37	0.48	5.47e-7	Huntington's disease progression;
THYM	cis	rs864643	0.738	rs13063581	chr3:39592659	C/G	cg20142358	chr3:39093977	WDR48	-0.64	-4.57	-0.42	1.49e-5	Attention deficit hyperactivity disorder;
THYM	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg00640147	chr17:61958756	GH2	-0.44	-4.68	-0.43	9.62e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs57590327	0.503	rs1524557	chr3:81892031	A/G	cg07356753	chr3:81810745	GBE1	-0.78	-5.78	-0.51	9.26e-8	Extraversion;
THYM	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg13390004	chr1:15929781	NA	0.62	4.72	0.44	8.11e-6	Systolic blood pressure;
THYM	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.94	9.06	0.68	1.68e-14	Cognitive ability;
THYM	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.55	-4.72	-0.44	8.2e-6	Coronary artery disease;
THYM	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	9.99	0.72	1.74e-16	Chronic sinus infection;
THYM	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2408955	0.521	rs7301003	chr12:48550227	A/G	cg21466736	chr12:48725269	NA	-0.47	-4.71	-0.43	8.53e-6	Glycated hemoglobin levels;
THYM	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.36e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg12311346	chr5:56204834	C5orf35	-0.81	-5.9	-0.52	5.54e-8	Initial pursuit acceleration;
THYM	cis	rs782590	0.967	rs4672054	chr2:55773093	C/A	cg18811423	chr2:55921094	PNPT1	0.77	7.26	0.6	1.07e-10	Metabolic syndrome;
THYM	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg12935359	chr14:103987150	CKB	-0.62	-6.48	-0.55	3.97e-9	Body mass index;
THYM	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg26314531	chr2:26401878	FAM59B	-0.76	-5.06	-0.46	2.01e-6	Gut microbiome composition (summer);
THYM	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg14798641	chr3:49314920	USP4;C3orf62	-0.67	-4.51	-0.42	1.83e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs2350702	0.608	rs17489439	chr2:49964349	A/G	cg22592722	chr2:49566210	NA	0.6	4.51	0.42	1.83e-5	Morning vs. evening chronotype;
THYM	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg16188243	chr19:2783719	SGTA	-0.69	-4.83	-0.44	5.16e-6	Total cholesterol levels;
THYM	cis	rs1160297	0.585	rs12713227	chr2:53090018	A/G	cg07782112	chr2:53107842	NA	0.74	5.97	0.52	4.08e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs9677476	0.863	rs3731775	chr2:232063578	G/A	cg20307347	chr2:231734563	ITM2C	-0.54	-4.64	-0.43	1.09e-5	Food antigen IgG levels;
THYM	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg27129171	chr3:47204927	SETD2	0.77	7.66	0.62	1.57e-11	Colorectal cancer;
THYM	cis	rs2075230	0.705	rs1642808	chr17:7545464	G/C	cg27413385	chr17:7515425	FXR2	-0.35	-5.06	-0.46	2.06e-6	Hormone measurements;
THYM	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg18681998	chr4:17616180	MED28	-1.0	-10.49	-0.73	1.52e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	trans	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg25214090	chr10:38739885	LOC399744	0.85	7.16	0.59	1.7e-10	Corneal astigmatism;
THYM	cis	rs12956009	0.518	rs3889651	chr18:44865012	T/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-4.81	-0.44	5.59e-6	Educational attainment (years of education);
THYM	cis	rs1178127	0.574	rs7783171	chr7:18828796	G/T	cg13420273	chr7:18810212	HDAC9	-0.61	-5.48	-0.49	3.44e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg04944784	chr2:26401820	FAM59B	1.09	8.74	0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs921968	0.540	rs6746040	chr2:219588890	G/T	cg02176678	chr2:219576539	TTLL4	-0.47	-4.56	-0.42	1.55e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs778371	0.723	rs4144795	chr2:233562731	C/G	cg08000102	chr2:233561755	GIGYF2	0.8	7.25	0.6	1.12e-10	Schizophrenia;
THYM	cis	rs4363385	0.553	rs1415972	chr1:152953552	A/G	cg13444842	chr1:152974279	SPRR3	0.63	4.65	0.43	1.09e-5	Inflammatory skin disease;
THYM	cis	rs16922576	0.623	rs2093446	chr9:5230371	G/C	cg02405213	chr9:5042618	JAK2	-0.82	-7.34	-0.6	7.31e-11	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg17105886	chr17:28927953	LRRC37B2	1.2	6.56	0.56	2.8e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg12334488	chr2:20871173	GDF7	-0.66	-6.1	-0.53	2.33e-8	Abdominal aortic aneurysm;
THYM	cis	rs11048434	0.761	rs2110190	chr12:9128289	A/C	cg13575925	chr12:9217583	LOC144571	0.53	5.0	0.46	2.59e-6	Sjögren's syndrome;
THYM	cis	rs17767294	0.708	rs77689085	chr6:28072536	G/A	cg08851530	chr6:28072375	NA	1.15	4.46	0.42	2.28e-5	Parkinson's disease;
THYM	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg06715136	chr7:158046025	PTPRN2	0.6	4.69	0.43	9.19e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg06112835	chr11:68658793	MRPL21	0.43	6.08	0.53	2.48e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg27446573	chr6:127587934	RNF146	1.04	9.87	0.71	3.12e-16	Breast cancer;
THYM	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06481639	chr22:41940642	POLR3H	0.72	5.15	0.47	1.42e-6	Vitiligo;
THYM	cis	rs12410462	0.581	rs7547204	chr1:227560909	C/T	cg04117972	chr1:227635322	NA	0.83	4.97	0.45	2.92e-6	Major depressive disorder;
THYM	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.33	9.77	0.71	5.06e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6430585	0.528	rs115469964	chr2:136696608	A/C	cg04750100	chr2:136595281	LCT	0.53	5.07	0.46	1.95e-6	Corneal structure;
THYM	cis	rs57920188	0.585	rs12117500	chr1:4072315	G/A	cg20703997	chr1:4087676	NA	1.05	7.6	0.61	2.11e-11	Interleukin-17 levels;
THYM	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg01097406	chr16:89675127	NA	0.57	4.58	0.43	1.41e-5	Vitiligo;
THYM	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg25767906	chr1:53392781	SCP2	-0.64	-6.44	-0.55	4.84e-9	Monocyte count;
THYM	cis	rs12476592	0.571	rs2604617	chr2:63898663	A/G	cg17519650	chr2:63277830	OTX1	-0.72	-4.68	-0.43	9.38e-6	Childhood ear infection;
THYM	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs62103177	0.564	rs3930043	chr18:77723832	G/A	cg07235805	chr18:78004237	PARD6G	0.41	4.45	0.42	2.34e-5	Opioid sensitivity;
THYM	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg10360139	chr7:1886902	MAD1L1	-0.63	-5.42	-0.49	4.46e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7786877	0.723	rs7812235	chr7:100211486	G/C	cg04499151	chr7:100231278	TFR2	0.62	4.49	0.42	1.98e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg23711669	chr6:146136114	FBXO30	-0.77	-7.24	-0.6	1.14e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9921192	0.967	rs251735	chr16:4320672	G/C	cg00021532	chr16:4324280	TFAP4	0.87	7.85	0.63	6.28e-12	Prostate-specific antigen levels;
THYM	trans	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg26384229	chr12:38710491	ALG10B	1.05	10.57	0.74	9.98e-18	Heart rate;
THYM	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg12311346	chr5:56204834	C5orf35	-0.82	-6.04	-0.53	3.01e-8	Initial pursuit acceleration;
THYM	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg14835575	chr10:16859367	RSU1	0.68	4.97	0.45	2.95e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
THYM	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11890956	chr21:40555474	PSMG1	1.07	10.25	0.72	4.79e-17	Cognitive function;
THYM	cis	rs17407555	0.606	rs73229818	chr4:10019884	C/T	cg13000635	chr4:9523653	NA	0.65	4.45	0.42	2.33e-5	Schizophrenia (age at onset);
THYM	cis	rs6746082	0.519	rs508262	chr2:25761044	G/A	cg23192403	chr2:25781496	DTNB	-0.43	-5.79	-0.51	9.2e-8	Multiple myeloma;
THYM	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg04398451	chr17:18023971	MYO15A	-1.02	-10.98	-0.75	1.36e-18	Total body bone mineral density;
THYM	cis	rs868036	0.645	rs4492996	chr15:68113240	A/G	cg24579218	chr15:68104479	NA	-0.8	-8.53	-0.66	2.24e-13	Restless legs syndrome;
THYM	cis	rs654950	0.901	rs1885654	chr1:42007188	C/A	cg06885757	chr1:42089581	HIVEP3	-0.59	-7.86	-0.63	5.82e-12	Airway imaging phenotypes;
THYM	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg17063962	chr7:91808500	NA	1.1	11.64	0.77	5.63e-20	Breast cancer;
THYM	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13732083	chr21:47605072	C21orf56	-0.64	-4.55	-0.42	1.58e-5	Testicular germ cell tumor;
THYM	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs6754311	0.593	rs4954279	chr2:136409073	G/A	cg23851026	chr2:136556271	LCT	0.6	5.63	0.5	1.85e-7	Mosquito bite size;
THYM	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg18876405	chr7:65276391	NA	0.67	5.92	0.52	5.05e-8	Aortic root size;
THYM	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg08439880	chr3:133502540	NA	-0.73	-6.46	-0.55	4.44e-9	Iron status biomarkers;
THYM	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg14074117	chr16:1909714	C16orf73	-0.71	-4.5	-0.42	1.89e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	5.72	0.51	1.23e-7	Platelet count;
THYM	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg17775962	chr7:1200435	ZFAND2A	0.41	4.49	0.42	1.98e-5	Longevity;Endometriosis;
THYM	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg00024416	chr22:24240387	NA	-0.56	-5.49	-0.49	3.29e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs4363385	0.667	rs399550	chr1:153049917	T/C	cg13444842	chr1:152974279	SPRR3	-0.61	-5.02	-0.46	2.45e-6	Inflammatory skin disease;
THYM	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg14196790	chr5:131705035	SLC22A5	0.51	4.62	0.43	1.23e-5	Blood metabolite levels;
THYM	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg04025307	chr7:1156635	C7orf50	0.72	4.46	0.42	2.27e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7584330	0.704	rs7602387	chr2:238356795	A/G	cg14458575	chr2:238380390	NA	0.89	7.16	0.59	1.67e-10	Prostate cancer;
THYM	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg18105134	chr13:113819100	PROZ	-0.96	-8.77	-0.67	6.94e-14	Platelet distribution width;
THYM	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg01341218	chr17:43662625	NA	-1.07	-9.27	-0.69	5.9e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.91	-6.52	-0.56	3.31e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6598955	0.671	rs17163868	chr1:26648381	A/G	cg16068833	chr1:26644515	UBXN11;CD52	-0.28	-4.66	-0.43	1.01e-5	Obesity-related traits;
THYM	cis	rs12310956	0.532	rs11052920	chr12:33955891	T/G	cg06521331	chr12:34319734	NA	-0.88	-8.26	-0.65	8.51e-13	Morning vs. evening chronotype;
THYM	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.71	5.65	0.5	1.66e-7	Tonsillectomy;
THYM	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs4589258	1.000	rs5009703	chr11:90487844	G/A	cg26138821	chr11:89956704	CHORDC1	-0.68	-5.64	-0.5	1.73e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg09549813	chr16:4587862	C16orf5	0.59	6.59	0.56	2.5e-9	Schizophrenia;
THYM	cis	rs4606347	0.789	rs61780882	chr1:66167832	G/A	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg05347473	chr6:146136440	FBXO30	0.57	4.58	0.43	1.42e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg02524346	chr8:600233	NA	0.91	4.62	0.43	1.2e-5	IgG glycosylation;
THYM	cis	rs7582403	0.763	rs12989087	chr2:148598219	G/C	cg23727674	chr2:148602993	ACVR2A	0.54	4.5	0.42	1.92e-5	Neuroticism;
THYM	cis	rs9549260	0.564	rs4941990	chr13:41299857	A/C	cg21288729	chr13:41239152	FOXO1	0.68	5.14	0.47	1.49e-6	Red blood cell count;
THYM	cis	rs55637147	0.671	rs2155234	chr11:57135173	C/T	cg15971518	chr11:57159174	PRG2	-0.65	-5.32	-0.48	7e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs1467026	0.563	rs12629928	chr3:12811796	C/T	cg11882607	chr3:12858926	CAND2	-0.5	-5.57	-0.5	2.39e-7	P wave duration;
THYM	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg12310025	chr6:25882481	NA	-0.94	-8.57	-0.66	1.9e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6430585	0.583	rs12373779	chr2:136586840	A/C	cg20242066	chr2:136595261	LCT	0.47	4.64	0.43	1.1e-5	Corneal structure;
THYM	cis	rs9866391	0.607	rs9853018	chr3:141101961	C/T	cg13411656	chr3:141121016	ZBTB38	-0.32	-4.63	-0.43	1.17e-5	Myopia;
THYM	cis	rs12509991	0.531	rs67092503	chr4:127051297	A/G	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg11494091	chr17:61959527	GH2	1.07	16.26	0.86	3.42e-29	Prudent dietary pattern;
THYM	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-5.08	-0.46	1.91e-6	Gut microbiome composition (summer);
THYM	cis	rs1729951	0.575	rs361243	chr3:136697786	C/T	cg21827317	chr3:136751795	NA	0.74	6.6	0.56	2.29e-9	Neuroticism;
THYM	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg10518543	chr12:38710700	ALG10B	-0.59	-4.7	-0.43	8.75e-6	Drug-induced liver injury (flucloxacillin);
THYM	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg03929089	chr4:120376271	NA	-1.01	-8.43	-0.65	3.69e-13	Height;
THYM	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg14675211	chr2:100938903	LONRF2	0.76	8.42	0.65	3.99e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4455778	0.580	rs10259971	chr7:49085752	A/G	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.01	-8.95	-0.68	2.83e-14	Homoarginine levels;
THYM	cis	rs71403859	0.803	rs8063455	chr16:71599977	G/A	cg08717414	chr16:71523259	ZNF19	-1.11	-5.87	-0.52	6.29e-8	Post bronchodilator FEV1;
THYM	cis	rs17401966	1.000	rs12129035	chr1:10291166	G/A	cg20482658	chr1:10539492	PEX14	0.37	4.5	0.42	1.91e-5	Hepatocellular carcinoma;
THYM	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg12935359	chr14:103987150	CKB	-0.51	-6.07	-0.53	2.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs35883536	0.584	rs56112014	chr1:101037431	A/G	cg06223162	chr1:101003688	GPR88	-0.83	-6.79	-0.57	9.64e-10	Monocyte count;
THYM	cis	rs6840360	0.550	rs62327349	chr4:152627230	G/C	cg22705602	chr4:152727874	NA	-0.84	-8.55	-0.66	2.04e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg04234412	chr22:24373322	LOC391322	-0.9	-9.07	-0.68	1.58e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs747334	0.713	rs7078592	chr10:92727797	A/T	cg07620928	chr10:92689909	NA	0.6	5.08	0.46	1.85e-6	Fibroblast growth factor basic levels;
THYM	cis	rs12282928	0.918	rs11039656	chr11:48320705	T/G	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs7465272	1.000	rs35476574	chr8:143683784	C/A	cg01509843	chr8:143695822	ARC	0.72	4.85	0.45	4.73e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6754311	0.593	rs6755383	chr2:136416941	C/T	cg23851026	chr2:136556271	LCT	0.59	5.62	0.5	1.91e-7	Mosquito bite size;
THYM	cis	rs7572733	0.534	rs1589162	chr2:198782692	A/G	cg00792783	chr2:198669748	PLCL1	0.84	5.87	0.52	6.41e-8	Dermatomyositis;
THYM	cis	rs4866334	1.000	rs79823740	chr5:18488814	T/C	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs1421811	0.532	rs17540044	chr5:32692238	C/G	cg16267343	chr5:32710456	NPR3	-0.85	-7.04	-0.59	2.98e-10	Blood pressure;
THYM	cis	rs2742234	0.541	rs60845448	chr10:43721462	C/T	cg06632098	chr10:43605906	RET	0.8	5.26	0.47	8.98e-7	Hirschsprung disease;
THYM	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.04	7.56	0.61	2.56e-11	Smoking behavior;
THYM	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.09	-0.64	1.9e-12	Mean corpuscular volume;
THYM	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg21385522	chr1:16154831	NA	0.74	5.44	0.49	4.13e-7	Dilated cardiomyopathy;
THYM	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg23711669	chr6:146136114	FBXO30	0.97	10.56	0.73	1.05e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4481887	0.927	rs6587444	chr1:248438452	C/T	cg00666640	chr1:248458726	OR2T12	-0.53	-4.72	-0.44	8.08e-6	Common traits (Other);
THYM	cis	rs586688	0.625	rs602668	chr1:201657709	A/G	cg14168733	chr1:201708718	NAV1	0.54	5.09	0.46	1.84e-6	Obesity-related traits;
THYM	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg09549813	chr16:4587862	C16orf5	-0.62	-6.93	-0.58	5.08e-10	Schizophrenia;
THYM	cis	rs76878669	0.561	rs2236679	chr11:66108894	G/C	cg18002602	chr11:66138449	SLC29A2	-0.48	-4.74	-0.44	7.42e-6	Educational attainment (years of education);
THYM	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg02734326	chr4:10020555	SLC2A9	0.76	7.25	0.6	1.13e-10	Bone mineral density;
THYM	cis	rs6430585	0.697	rs1050115	chr2:136511817	A/G	cg23851026	chr2:136556271	LCT	0.79	7.53	0.61	2.86e-11	Corneal structure;
THYM	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg27129171	chr3:47204927	SETD2	-0.69	-6.35	-0.55	7.36e-9	Colorectal cancer;
THYM	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg25566285	chr7:158114605	PTPRN2	-0.74	-6.96	-0.58	4.41e-10	Response to amphetamines;
THYM	cis	rs3733631	1.000	rs3775971	chr4:104641920	C/T	cg24090629	chr4:104641072	TACR3	0.86	5.51	0.49	3.1e-7	Menarche (age at onset);
THYM	cis	rs8014204	0.604	rs12147862	chr14:75384471	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.62	-6.06	-0.53	2.72e-8	Caffeine consumption;
THYM	cis	rs2282032	0.550	rs58363992	chr14:90766361	T/C	cg14092571	chr14:90743983	NA	0.66	6.6	0.56	2.29e-9	Longevity;
THYM	cis	rs3947	1.000	rs1736085	chr8:11703659	T/C	cg26752888	chr8:11627280	NEIL2	-0.71	-4.67	-0.43	9.83e-6	Blood protein levels;
THYM	cis	rs12928939	0.768	rs11861296	chr16:71850632	T/C	cg03805757	chr16:71968109	PKD1L3	-0.7	-5.31	-0.48	7.21e-7	Post bronchodilator FEV1;
THYM	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.83	-7.72	-0.62	1.19e-11	Intelligence (multi-trait analysis);
THYM	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg19016782	chr12:123741754	C12orf65	-0.7	-4.55	-0.42	1.6e-5	Neutrophil percentage of white cells;
THYM	cis	rs10911232	0.507	rs10911206	chr1:183012423	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs11087114	0.666	rs6042929	chr20:14785081	C/T	cg04470754	chr20:14904432	MACROD2	0.72	4.62	0.43	1.22e-5	Common carotid intima-media thickness in HIV infection;
THYM	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg03388043	chr17:80084554	CCDC57	-0.73	-6.06	-0.53	2.74e-8	Life satisfaction;
THYM	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg26441486	chr22:50317300	CRELD2	0.42	6.65	0.56	1.83e-9	Schizophrenia;
THYM	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg11752832	chr7:134001865	SLC35B4	0.76	5.72	0.51	1.24e-7	Mean platelet volume;
THYM	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg05294307	chr14:35346193	BAZ1A	-0.82	-5.51	-0.49	3.06e-7	Psoriasis;
THYM	cis	rs8050907	0.744	rs11862204	chr16:4519586	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.3	5.2	0.47	1.16e-6	Obesity-related traits;
THYM	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg11984989	chr7:158649758	WDR60	1.15	13.77	0.82	2.29e-24	Height;
THYM	cis	rs6840360	0.571	rs62327277	chr4:152555905	C/T	cg22705602	chr4:152727874	NA	-0.76	-7.92	-0.63	4.35e-12	Intelligence (multi-trait analysis);
THYM	cis	rs111315781	1	rs111315781	chr2:201738724	T/A	cg08474651	chr2:201729683	CLK1	0.43	5.05	0.46	2.11e-6	Triptolide cytotoxicity;
THYM	cis	rs611744	0.743	rs2514843	chr8:109063434	C/T	cg21045802	chr8:109455806	TTC35	0.58	5.16	0.47	1.38e-6	Dupuytren's disease;
THYM	cis	rs12530845	0.573	rs56411048	chr7:135364748	A/T	cg23117316	chr7:135346802	PL-5283	-0.89	-6.87	-0.58	6.51e-10	Red blood cell traits;
THYM	cis	rs192264	0.614	rs1094980	chr16:65977112	T/C	cg02795155	chr16:66785218	DYNC1LI2	0.61	4.9	0.45	3.96e-6	Subjective well-being;
THYM	cis	rs9393692	0.599	rs9358920	chr6:26292029	C/T	cg00631329	chr6:26305371	NA	-0.47	-4.79	-0.44	6.14e-6	Educational attainment;
THYM	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg18806716	chr10:30721971	MAP3K8	-0.5	-5.06	-0.46	2.09e-6	Inflammatory bowel disease;
THYM	cis	rs10899021	0.704	rs11236177	chr11:74339067	T/C	cg25880958	chr11:74394337	NA	-0.72	-4.72	-0.44	7.99e-6	Response to metformin (IC50);
THYM	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg04398451	chr17:18023971	MYO15A	-0.78	-7.23	-0.6	1.22e-10	Total body bone mineral density;
THYM	cis	rs2888875	0.632	rs35645305	chr2:43796478	T/G	cg22033476	chr2:43532275	THADA	-0.39	-4.49	-0.42	1.99e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg10802521	chr3:52805072	NEK4	-0.71	-5.96	-0.52	4.22e-8	Bipolar disorder;
THYM	cis	rs9807989	0.839	rs4851565	chr2:102971481	C/A	cg03938978	chr2:103052716	IL18RAP	0.63	6.46	0.55	4.36e-9	Asthma;
THYM	cis	rs981844	0.617	rs4077965	chr4:154710520	G/C	cg22178613	chr4:154710499	SFRP2	-0.6	-4.88	-0.45	4.21e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs2658782	1.000	rs2605583	chr11:93164957	T/A	cg16424440	chr11:93231842	C11orf75	-0.74	-4.69	-0.43	9.19e-6	Pulmonary function decline;
THYM	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs7582180	0.614	rs4850931	chr2:101005145	C/T	cg08017756	chr2:100939284	LONRF2	-0.75	-7.69	-0.62	1.37e-11	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7927771	0.524	rs10742814	chr11:47554337	G/A	cg20307385	chr11:47447363	PSMC3	0.61	4.67	0.43	9.88e-6	Subjective well-being;
THYM	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg11189052	chr15:85197271	WDR73	-0.67	-5.5	-0.49	3.13e-7	P wave terminal force;
THYM	cis	rs994014	0.804	rs17499327	chr4:82225021	G/A	cg17825130	chr4:82283507	NA	0.5	4.45	0.42	2.31e-5	Height;
THYM	cis	rs933688	1.000	rs933688	chr5:90762748	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.78	5.01	0.46	2.47e-6	Smoking behavior;
THYM	cis	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg01271726	chr6:26323586	NA	-0.84	-4.51	-0.42	1.85e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7246657	0.943	rs10420430	chr19:37894194	C/G	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs1568889	0.838	rs10835304	chr11:28296529	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs295140	1.000	rs1367856	chr2:201160739	T/A	cg04283868	chr2:201171347	SPATS2L	0.75	5.71	0.51	1.31e-7	QT interval;
THYM	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs1775715	0.737	rs2799015	chr10:32107712	C/T	cg04359828	chr10:32216031	ARHGAP12	0.39	4.96	0.45	3.02e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs13102973	0.965	rs13103954	chr4:135844189	A/G	cg14419869	chr4:135874104	NA	0.9	8.46	0.66	3.24e-13	Subjective well-being;
THYM	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg24818145	chr4:99064322	C4orf37	0.87	7.23	0.6	1.19e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.77	-6.12	-0.53	2.13e-8	Systemic lupus erythematosus;
THYM	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg18758796	chr5:131593413	PDLIM4	0.51	4.81	0.44	5.55e-6	Breast cancer;
THYM	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg01073479	chr16:3509474	NAT15	0.57	5.45	0.49	3.92e-7	Tuberculosis;
THYM	cis	rs669446	0.533	rs3862228	chr1:44196945	C/T	cg15962314	chr1:44399869	ARTN	0.47	5.18	0.47	1.22e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg09307838	chr4:120376055	NA	0.7	5.27	0.48	8.48e-7	Corneal astigmatism;
THYM	cis	rs9419702	0.639	rs4367873	chr10:133533485	C/T	cg20568497	chr10:133558893	NA	0.49	4.58	0.43	1.39e-5	Survival in rectal cancer;
THYM	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.79e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs748404	0.631	rs2412781	chr15:43667900	C/T	cg12861797	chr15:43585817	TGM7	-0.45	-4.62	-0.43	1.19e-5	Lung cancer;
THYM	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg01528321	chr10:82214614	TSPAN14	0.66	5.16	0.47	1.35e-6	Post bronchodilator FEV1;
THYM	cis	rs7692299	0.584	rs4833291	chr4:124700389	C/T	cg11268546	chr4:124983615	NA	-0.77	-4.55	-0.42	1.56e-5	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg08564027	chr20:61660810	NA	0.92	9.77	0.71	5.02e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs7582180	0.739	rs11123822	chr2:100911582	G/T	cg08017756	chr2:100939284	LONRF2	-0.59	-5.35	-0.48	6.11e-7	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.663	rs6502618	chr17:17746741	A/G	cg04398451	chr17:18023971	MYO15A	0.81	7.56	0.61	2.52e-11	Total body bone mineral density;
THYM	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.7	-5.98	-0.52	3.96e-8	Renal function-related traits (BUN);
THYM	cis	rs67311347	0.544	rs6769627	chr3:40327845	G/A	cg13683864	chr3:40499215	RPL14	-0.77	-7.2	-0.59	1.39e-10	Renal cell carcinoma;
THYM	cis	rs7267979	1.000	rs2424704	chr20:25273929	A/G	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	trans	rs7952251	0.711	rs10750000	chr11:112395318	A/G	cg14154186	chr1:204970430	NFASC	-0.7	-7.23	-0.6	1.24e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs3741151	1.000	rs7941454	chr11:73085336	C/T	cg12959048	chr11:73096162	RELT	-0.51	-4.94	-0.45	3.28e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg15247329	chr7:2764246	NA	-0.74	-6.31	-0.54	8.94e-9	Height;
THYM	cis	rs9486719	0.843	rs3849198	chr6:97036539	C/A	cg18709589	chr6:96969512	KIAA0776	-0.67	-4.64	-0.43	1.1e-5	Migraine;Coronary artery disease;
THYM	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2458413	0.500	rs2458418	chr8:105350851	A/G	cg21295575	chr8:105352067	TM7SF4	-0.37	-5.34	-0.48	6.2e-7	Paget's disease;
THYM	cis	rs4705952	0.524	rs2406543	chr5:131860320	C/A	cg13566430	chr5:131992455	IL13	0.54	4.54	0.42	1.66e-5	C-reactive protein levels;
THYM	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg12935359	chr14:103987150	CKB	-0.62	-6.48	-0.55	3.97e-9	Body mass index;
THYM	cis	rs59698941	0.943	rs66500331	chr5:132261693	G/A	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs1933112	1.000	rs2223583	chr1:168525416	C/T	cg00154920	chr1:168513310	XCL2	-0.5	-5.03	-0.46	2.31e-6	Blood protein levels;
THYM	cis	rs12142240	0.698	rs67941619	chr1:46838219	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg22841779	chr14:105766346	BRF1	-0.47	-5.89	-0.52	5.72e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs72627509	0.857	rs55762216	chr4:57765731	G/C	cg26694713	chr4:57773883	REST	0.77	4.68	0.43	9.34e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg18811423	chr2:55921094	PNPT1	0.77	7.34	0.6	7.35e-11	Metabolic syndrome;
THYM	cis	rs921968	0.509	rs556468	chr2:219355794	G/A	cg02176678	chr2:219576539	TTLL4	0.73	7.09	0.59	2.4e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg26924012	chr15:45694286	SPATA5L1	0.65	4.75	0.44	7.34e-6	Response to fenofibrate (adiponectin levels);
THYM	cis	rs7078219	0.743	rs17094148	chr10:101280279	A/G	cg23904955	chr10:101282759	NA	-0.41	-4.89	-0.45	4.15e-6	Dental caries;
THYM	cis	rs10789491	1.000	rs2083485	chr1:47170091	G/C	cg15501359	chr1:47185051	KIAA0494	1.14	8.24	0.65	9.45e-13	Response to hepatitis C treatment;
THYM	cis	rs6732160	0.691	rs13402225	chr2:73416906	T/G	cg24220031	chr2:73402428	NA	-0.77	-8.98	-0.68	2.49e-14	Intelligence (multi-trait analysis);
THYM	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg13246856	chr1:44399776	ARTN	0.48	4.95	0.45	3.27e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg10523679	chr1:76189770	ACADM	-0.95	-12.11	-0.78	5.63e-21	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07167872	chr1:205819463	PM20D1	0.96	9.38	0.69	3.52e-15	Menarche (age at onset);
THYM	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg13114125	chr14:105738426	BRF1	-0.72	-5.61	-0.5	2.01e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs10186029	0.509	rs7566029	chr2:213941189	A/G	cg08319019	chr2:214017104	IKZF2	-0.71	-5.38	-0.48	5.43e-7	Systemic sclerosis;
THYM	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg10553204	chr2:20871195	GDF7	0.69	6.57	0.56	2.74e-9	Abdominal aortic aneurysm;
THYM	cis	rs10847980	0.590	rs58182048	chr12:123287708	C/T	cg25930673	chr12:123319894	HIP1R	1.06	4.89	0.45	4.15e-6	Adiponectin levels;
THYM	cis	rs9906944	0.545	rs2088140	chr17:47094599	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.56	-5.81	-0.51	8.47e-8	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg13447684	chr7:1895903	MAD1L1	0.58	4.87	0.45	4.47e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg03433033	chr1:76189801	ACADM	-0.61	-6.05	-0.53	2.87e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs62435770	1.000	rs62435793	chr6:169481244	G/A	cg07652237	chr6:170125491	PHF10	0.55	4.83	0.44	5.28e-6	Loneliness;
THYM	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg12963246	chr6:28129442	ZNF389	-0.81	-6.81	-0.57	8.86e-10	Depression;
THYM	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.72	5.83	0.51	7.65e-8	Systemic lupus erythematosus;
THYM	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg21394778	chr1:3037102	PRDM16	0.47	4.57	0.42	1.46e-5	Height;
THYM	cis	rs12889267	0.722	rs2319626	chr14:21565149	G/C	cg23374312	chr14:21565335	ZNF219	-0.79	-6.01	-0.53	3.35e-8	Hematocrit;Resting heart rate;
THYM	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg23583168	chr7:148888333	NA	-0.93	-10.45	-0.73	1.8e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-6.68	-0.57	1.63e-9	Alzheimer's disease (late onset);
THYM	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg10360139	chr7:1886902	MAD1L1	0.6	5.2	0.47	1.12e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg10018233	chr7:150070692	REPIN1	0.44	5.93	0.52	4.94e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg06636001	chr8:8085503	FLJ10661	0.73	6.61	0.56	2.23e-9	Mood instability;
THYM	cis	rs4466137	0.868	rs4703962	chr5:82999808	A/G	cg16102102	chr5:83017553	HAPLN1	-1.11	-11.03	-0.75	1.07e-18	Prostate cancer;
THYM	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg08132940	chr7:1081526	C7orf50	-1.24	-7.35	-0.6	6.97e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7267979	0.966	rs6083855	chr20:25405118	A/G	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs10929159	0.928	rs12053257	chr2:236920174	C/T	cg20128773	chr2:236923534	AGAP1	0.36	4.75	0.44	7.13e-6	Parkinson's disease;
THYM	cis	rs782590	0.643	rs5012561	chr2:55742032	G/C	cg18811423	chr2:55921094	PNPT1	-0.56	-5.2	-0.47	1.15e-6	Metabolic syndrome;
THYM	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg07061783	chr6:25882402	NA	0.72	5.75	0.51	1.06e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.785	rs11944120	chr4:99079932	A/C	cg03676636	chr4:99064102	C4orf37	0.49	6.51	0.56	3.53e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg25358565	chr5:93447407	FAM172A	-1.34	-10.59	-0.74	9.3e-18	Diabetic retinopathy;
THYM	cis	rs1062746	0.711	rs8056833	chr16:87378388	G/C	cg27365499	chr16:87376795	FBXO31	0.59	6.86	0.58	6.88e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs6138458	1.000	rs11905625	chr20:24977065	A/C	cg06937882	chr20:24974362	C20orf3	-0.46	-4.64	-0.43	1.11e-5	Blood protein levels;
THYM	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg12408189	chr10:30722286	MAP3K8	0.61	5.12	0.46	1.63e-6	Inflammatory bowel disease;
THYM	cis	rs2276314	0.857	rs8087539	chr18:33631537	C/T	cg05985134	chr18:33552581	C18orf21	0.66	4.84	0.44	5.02e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.52	0.42	1.8e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg16586182	chr3:47516702	SCAP	0.68	5.64	0.5	1.71e-7	Colorectal cancer;
THYM	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs7107174	1.000	rs2292572	chr11:78052864	G/T	cg02023728	chr11:77925099	USP35	0.62	6.08	0.53	2.49e-8	Testicular germ cell tumor;
THYM	cis	rs13014235	0.532	rs3731709	chr2:202246034	G/C	cg12544106	chr2:202507780	ALS2CR4	-0.65	-4.77	-0.44	6.57e-6	Basal cell carcinoma;
THYM	cis	rs6450176	0.633	rs10054623	chr5:53343821	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-7.49	-0.61	3.5e-11	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg14458575	chr2:238380390	NA	0.99	7.2	0.59	1.41e-10	Prostate cancer;
THYM	cis	rs7580658	0.895	rs62157549	chr2:128066007	A/G	cg10021288	chr2:128175891	PROC	-0.72	-6.36	-0.55	7.09e-9	Protein C levels;
THYM	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg20887711	chr4:1340912	KIAA1530	0.6	4.62	0.43	1.21e-5	Obesity-related traits;
THYM	cis	rs2710642	0.586	rs6545961	chr2:62814166	A/T	cg17519650	chr2:63277830	OTX1	0.62	4.54	0.42	1.67e-5	LDL cholesterol levels;LDL cholesterol;
THYM	cis	rs7705042	0.865	rs12655465	chr5:141522213	C/T	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs34779708	0.931	rs12248333	chr10:35362977	A/G	cg03585969	chr10:35415529	CREM	0.63	4.66	0.43	1.01e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08564027	chr20:61660810	NA	-0.88	-9.53	-0.7	1.69e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12142240	0.698	rs17357621	chr1:46807697	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg02569458	chr12:86230093	RASSF9	0.62	5.13	0.47	1.56e-6	Major depressive disorder;
THYM	cis	rs6060717	0.610	rs2794383	chr20:34615152	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-5.41	-0.49	4.66e-7	Hip circumference adjusted for BMI;
THYM	cis	rs7528419	0.895	rs583104	chr1:109821307	G/T	cg00908766	chr1:109817496	CELSR2	0.77	6.26	0.54	1.09e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
THYM	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg16482183	chr6:26056742	HIST1H1C	0.96	5.97	0.52	4.07e-8	Iron status biomarkers;
THYM	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg17366294	chr4:99064904	C4orf37	0.54	6.05	0.53	2.81e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg02551604	chr5:131831745	NA	-0.75	-5.93	-0.52	4.79e-8	Asthma (sex interaction);
THYM	cis	rs1371867	0.839	rs1660313	chr8:101332712	G/A	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs4803468	1.000	rs8105833	chr19:41896145	G/A	cg09537434	chr19:41945824	ATP5SL	-1.12	-10.3	-0.73	3.69e-17	Height;
THYM	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs10832963	0.924	rs10500834	chr11:18638712	A/T	cg20219074	chr11:18656078	SPTY2D1	0.81	6.58	0.56	2.52e-9	Breast cancer;
THYM	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.893	rs6682024	chr1:53439525	T/C	cg06600287	chr1:53387719	ECHDC2	0.31	5.09	0.46	1.84e-6	Monocyte count;
THYM	cis	rs977987	0.806	rs4888420	chr16:75462998	G/C	cg03315344	chr16:75512273	CHST6	0.76	6.17	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs7975161	0.630	rs4964260	chr12:104634270	A/G	cg25273343	chr12:104657179	TXNRD1	-0.77	-4.57	-0.42	1.48e-5	Toenail selenium levels;
THYM	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.7	-0.43	8.77e-6	Prostate cancer;
THYM	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg27170947	chr2:26402098	FAM59B	0.79	6.27	0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.49	0.49	3.33e-7	Platelet count;
THYM	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.66	4.63	0.43	1.18e-5	Aortic root size;
THYM	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg09021430	chr5:549028	NA	-0.73	-5.44	-0.49	4.18e-7	Obesity-related traits;
THYM	cis	rs733592	0.507	rs3825403	chr12:48457159	G/A	cg21466736	chr12:48725269	NA	0.46	4.96	0.45	3.09e-6	Plateletcrit;
THYM	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg00256281	chr22:41985642	PMM1	0.65	4.93	0.45	3.47e-6	Vitiligo;
THYM	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg17063962	chr7:91808500	NA	-1.16	-12.32	-0.78	2.11e-21	Breast cancer;
THYM	cis	rs4866334	0.557	rs116250256	chr5:18457657	A/T	cg24599790	chr5:18972260	NA	-1.14	-4.67	-0.43	9.77e-6	IgG glycosylation;
THYM	trans	rs10462794	0.789	rs7719895	chr5:4490338	C/T	cg02254876	chr3:42922351	NA	0.91	6.86	0.58	6.96e-10	DNA methylation (variation);
THYM	cis	rs12620999	0.941	rs4408676	chr2:238085280	C/T	cg15976283	chr2:238042351	NA	0.63	4.94	0.45	3.33e-6	Systemic lupus erythematosus;
THYM	cis	rs72772090	0.539	rs56120748	chr5:96110622	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-4.67	-0.43	9.81e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs35883536	0.626	rs7536054	chr1:101047849	A/G	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs3812831	0.654	rs367312	chr13:114930195	G/A	cg06611532	chr13:114900021	NA	0.55	6.0	0.52	3.58e-8	Schizophrenia;
THYM	cis	rs600550	0.588	rs2304935	chr11:60102384	C/T	cg05040360	chr11:60102449	MS4A6E	0.5	4.72	0.44	8.13e-6	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs344364	0.552	rs388928	chr16:1909657	G/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.49	5.78	0.51	9.33e-8	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs7582180	0.903	rs13013891	chr2:100896110	T/C	cg14675211	chr2:100938903	LONRF2	0.64	5.43	0.49	4.28e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg14186256	chr22:23484241	RTDR1	0.97	9.56	0.7	1.46e-15	Bone mineral density;
THYM	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg26384229	chr12:38710491	ALG10B	1.06	11.07	0.75	8.9e-19	Heart rate;
THYM	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg09222892	chr1:25734099	RHCE	0.62	4.81	0.44	5.6e-6	Erythrocyte sedimentation rate;
THYM	trans	rs4866334	1.000	rs79459190	chr5:18504469	T/G	cg08675002	chr5:90437527	GPR98	-1.55	-7.42	-0.61	4.86e-11	IgG glycosylation;
THYM	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg18357526	chr6:26021779	HIST1H4A	0.76	6.55	0.56	2.91e-9	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg27129171	chr3:47204927	SETD2	-0.79	-7.87	-0.63	5.61e-12	Colorectal cancer;
THYM	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg05313129	chr8:58192883	C8orf71	-0.75	-4.59	-0.43	1.34e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg17252645	chr8:143867129	LY6D	0.85	10.76	0.74	4.04e-18	Urinary tract infection frequency;
THYM	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.77	-7.01	-0.58	3.49e-10	Personality dimensions;
THYM	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg12667521	chr19:29218732	NA	0.67	4.66	0.43	1.02e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg16342193	chr10:102329863	NA	-0.54	-5.35	-0.48	6.03e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9467160	0.871	rs13205780	chr6:24448687	C/T	cg20631270	chr6:24437470	GPLD1	0.75	5.92	0.52	5.17e-8	Liver enzyme levels;
THYM	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7216064	0.953	rs10445361	chr17:65962238	G/T	cg12091567	chr17:66097778	LOC651250	0.7	4.82	0.44	5.54e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs1474256	0.630	rs79015977	chr15:79450147	G/A	cg17916960	chr15:79447300	NA	0.64	6.82	0.57	8.26e-10	Bronchopulmonary dysplasia;
THYM	cis	rs1003719	0.613	rs9978998	chr21:38535848	T/C	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg13854012	chr2:162103682	NA	-0.64	-5.16	-0.47	1.34e-6	Intelligence (multi-trait analysis);
THYM	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg12311346	chr5:56204834	C5orf35	-0.7	-5.3	-0.48	7.6e-7	Coronary artery disease;
THYM	trans	rs10118776	0.677	rs13291323	chr9:6185360	T/C	cg02532923	chr16:89110004	NA	1.01	7.85	0.63	6.11e-12	Small cell lung carcinoma;
THYM	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs1975974	0.511	rs66766425	chr17:21755307	G/T	cg18423549	chr17:21743878	NA	-0.7	-5.26	-0.48	8.81e-7	Psoriasis;
THYM	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg26446133	chr18:72167187	CNDP2	-1.02	-10.4	-0.73	2.35e-17	Refractive error;
THYM	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg10523679	chr1:76189770	ACADM	-0.55	-4.49	-0.42	1.99e-5	Daytime sleep phenotypes;
THYM	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	cis	rs728616	0.867	rs17884637	chr10:81687922	G/C	cg27452691	chr10:81370291	SFTPA1	0.83	4.49	0.42	2.03e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg08999081	chr20:33150536	PIGU	0.78	7.16	0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg00376283	chr12:123451042	ABCB9	0.69	4.65	0.43	1.09e-5	Neutrophil percentage of white cells;
THYM	cis	rs13315871	0.929	rs11716580	chr3:58228695	G/C	cg12435725	chr3:58293450	RPP14	-0.56	-5.39	-0.48	5.03e-7	Cholesterol, total;
THYM	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg21028142	chr17:79581711	NPLOC4	0.65	6.66	0.56	1.75e-9	Eye color traits;
THYM	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg02725872	chr8:58115012	NA	-1.09	-8.15	-0.64	1.43e-12	Developmental language disorder (linguistic errors);
THYM	cis	rs7260598	0.642	rs10425299	chr19:24178559	C/T	cg15526094	chr19:24182596	NA	-0.7	-5.0	-0.46	2.65e-6	Response to taxane treatment (placlitaxel);
THYM	cis	rs72627123	0.867	rs112464051	chr14:74483975	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs72781680	0.752	rs72796119	chr2:23917179	C/T	cg08917208	chr2:24149416	ATAD2B	1.19	5.46	0.49	3.73e-7	Lymphocyte counts;
THYM	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg07606381	chr6:8435919	SLC35B3	0.66	4.93	0.45	3.51e-6	Motion sickness;
THYM	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.93	7.41	0.61	5.14e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg00639195	chr15:79103007	ADAMTS7	-0.83	-5.99	-0.52	3.81e-8	Coronary artery disease or large artery stroke;
THYM	cis	rs6964587	0.692	rs12536220	chr7:91805595	T/G	cg22709100	chr7:91322751	NA	0.67	5.07	0.46	1.97e-6	Breast cancer;
THYM	cis	rs3820068	0.705	rs2145397	chr1:15896199	G/A	cg05660106	chr1:15850417	CASP9	1.13	9.84	0.71	3.68e-16	Systolic blood pressure;
THYM	cis	rs3923380	0.585	rs6817593	chr4:77461011	T/C	cg07933720	chr4:77468187	SHROOM3	0.37	4.62	0.43	1.22e-5	Craniofacial microsomia;
THYM	cis	rs10744422	0.920	rs3896871	chr12:123333610	G/T	cg25930673	chr12:123319894	HIP1R	-0.86	-4.84	-0.44	5.09e-6	Schizophrenia;
THYM	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg13695892	chr22:41940480	POLR3H	0.89	6.74	0.57	1.2e-9	Vitiligo;
THYM	cis	rs10411161	0.752	rs10402107	chr19:52384600	A/G	cg25361850	chr19:52391789	ZNF577	0.71	4.99	0.46	2.69e-6	Breast cancer;
THYM	cis	rs7669967	0.576	rs1902492	chr4:156054738	A/G	cg17641028	chr4:156585641	NA	-0.57	-5.13	-0.47	1.53e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs11671005	0.735	rs11084544	chr19:58940127	C/G	cg18639983	chr19:58920768	ZNF584	0.6	5.01	0.46	2.48e-6	Mean platelet volume;
THYM	cis	rs8008758	1.000	rs8013718	chr14:101689506	C/T	cg26224664	chr14:101693935	NA	-0.55	-4.53	-0.42	1.73e-5	Body mass index (alcohol intake interaction);
THYM	cis	rs524281	0.692	rs2302884	chr11:65824084	C/T	cg00563793	chr11:65837595	PACS1	0.71	5.0	0.46	2.66e-6	Electroencephalogram traits;
THYM	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs11186	0.556	rs72906321	chr2:189957749	A/C	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs13315871	0.929	rs9837903	chr3:58301906	A/T	cg00563845	chr3:58318305	PXK	0.59	5.03	0.46	2.29e-6	Cholesterol, total;
THYM	cis	rs9311676	0.656	rs68021431	chr3:58403136	A/G	cg26110898	chr3:58419937	PDHB	0.45	4.79	0.44	6.17e-6	Systemic lupus erythematosus;
THYM	trans	rs12439619	0.921	rs56042848	chr15:82527585	A/T	cg04831495	chr15:85060580	GOLGA6L5	-0.83	-7.11	-0.59	2.1e-10	Intelligence (multi-trait analysis);
THYM	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg22841779	chr14:105766346	BRF1	-0.47	-5.86	-0.52	6.74e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs56104184	0.887	rs67286688	chr19:49343329	T/C	cg16594139	chr19:49340574	PLEKHA4;HSD17B14	1.0	6.02	0.53	3.26e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg10518543	chr12:38710700	ALG10B	-0.58	-4.65	-0.43	1.06e-5	Morning vs. evening chronotype;
THYM	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg06074448	chr4:187884817	NA	-1.02	-12.88	-0.8	1.45e-22	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg22875332	chr1:76189707	ACADM	0.91	13.71	0.81	3.06e-24	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs28374715	0.578	rs17730589	chr15:41600878	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.23	-14.01	-0.82	7.75e-25	Ulcerative colitis;
THYM	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	6.03	0.53	3.08e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4833407	0.593	rs4833406	chr4:113304812	G/A	cg27291727	chr4:113473876	C4orf21	-0.55	-4.45	-0.42	2.33e-5	Obesity;
THYM	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg08132940	chr7:1081526	C7orf50	-1.18	-4.78	-0.44	6.48e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs75518195	0.543	rs2347821	chr4:64716881	C/T	cg14706739	chr8:21916355	EPB49	0.76	7.25	0.6	1.09e-10	Triptolide cytotoxicity;
THYM	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs9914544	0.545	rs57035178	chr17:18797767	C/T	cg26378065	chr17:18585709	ZNF286B	0.58	4.65	0.43	1.05e-5	Educational attainment (years of education);
THYM	cis	rs262150	0.579	rs73167299	chr7:158784367	C/T	cg12257156	chr7:158823799	VIPR2	0.67	5.86	0.51	6.79e-8	Facial morphology (factor 20);
THYM	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs1728785	1.000	rs12918861	chr16:68566508	G/A	cg02972257	chr16:68554789	NA	-0.75	-4.57	-0.42	1.47e-5	Ulcerative colitis;
THYM	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg06656553	chr16:89960601	TCF25	-0.95	-4.58	-0.43	1.41e-5	Skin colour saturation;
THYM	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg22535103	chr8:58192502	C8orf71	-0.87	-4.83	-0.44	5.32e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7927592	0.513	rs3853616	chr11:68198252	A/G	cg16797656	chr11:68205561	LRP5	0.54	6.19	0.54	1.52e-8	Total body bone mineral density;
THYM	cis	rs11048434	0.518	rs35176717	chr12:9177766	A/G	cg26114124	chr12:9217669	LOC144571	0.52	4.57	0.42	1.49e-5	Sjögren's syndrome;
THYM	cis	rs3750965	0.920	rs10896421	chr11:68863048	T/C	cg01403660	chr11:68851641	TPCN2	0.73	5.79	0.51	9.21e-8	Hair color;
THYM	cis	rs9549367	0.756	rs9549702	chr13:113881944	T/G	cg00898013	chr13:113819073	PROZ	-0.87	-8.71	-0.67	9.19e-14	Platelet distribution width;
THYM	cis	rs7725337	0.965	rs985296	chr5:88377644	G/A	cg11280525	chr5:87955695	LOC645323	-0.4	-4.52	-0.42	1.78e-5	Total body bone mineral density;
THYM	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg08772003	chr10:104629869	AS3MT	-0.59	-5.35	-0.48	5.97e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg26038318	chr20:34205095	SPAG4	0.58	4.6	0.43	1.3e-5	Total cholesterol levels;
THYM	cis	rs997295	0.592	rs12594849	chr15:67716572	T/A	cg24579218	chr15:68104479	NA	0.58	4.93	0.45	3.47e-6	Motion sickness;
THYM	cis	rs4919694	1.000	rs7099987	chr10:104807926	C/T	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07157834	chr1:205819609	PM20D1	0.91	9.23	0.69	7.35e-15	Menarche (age at onset);
THYM	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg04455712	chr21:45112962	RRP1B	0.54	5.16	0.47	1.32e-6	Mean corpuscular volume;
THYM	cis	rs28785552	0.554	rs10424921	chr19:53211087	T/C	cg10871876	chr19:53194124	ZNF83	0.65	5.14	0.47	1.47e-6	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg04455712	chr21:45112962	RRP1B	0.5	4.57	0.42	1.47e-5	Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg05340658	chr4:99064831	C4orf37	0.54	4.55	0.42	1.58e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6586111	0.647	rs2880655	chr10:82369816	G/T	cg03086067	chr10:82368399	SH2D4B	-0.6	-7.7	-0.62	1.26e-11	Capecitabine sensitivity;
THYM	cis	rs4455778	0.565	rs7809432	chr7:49014472	C/T	cg26309511	chr7:48887640	NA	-0.54	-5.23	-0.47	9.98e-7	Lung cancer in never smokers;
THYM	cis	rs10504073	0.669	rs55948643	chr8:50026403	C/G	cg00325661	chr8:49890786	NA	0.86	7.69	0.62	1.35e-11	Blood metabolite ratios;
THYM	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs55728055	0.661	rs62237763	chr22:31947392	C/G	cg10537193	chr22:32026975	PISD	-0.92	-5.68	-0.5	1.45e-7	Age-related hearing impairment;
THYM	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.6	-0.5	2.08e-7	Type 2 diabetes;
THYM	cis	rs9314614	0.899	rs2977802	chr8:6694845	C/G	cg27319216	chr8:6693540	XKR5	0.68	7.67	0.62	1.46e-11	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.86	0.74	2.46e-18	Chronic sinus infection;
THYM	cis	rs12282928	1.000	rs10838851	chr11:48286231	T/A	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs10781543	0.776	rs4378078	chr9:139375962	A/G	cg14115884	chr9:139300582	SDCCAG3	0.71	6.66	0.56	1.76e-9	Monocyte percentage of white cells;
THYM	cis	rs1569175	0.522	rs3094771	chr2:200886058	A/G	cg23649088	chr2:200775458	C2orf69	-0.72	-5.25	-0.47	9.25e-7	Response to treatment for acute lymphoblastic leukemia;
THYM	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg10518543	chr12:38710700	ALG10B	-0.58	-4.83	-0.44	5.2e-6	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg00898013	chr13:113819073	PROZ	-0.98	-9.41	-0.69	3.03e-15	Platelet distribution width;
THYM	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg27034606	chr17:28928453	LRRC37B2	-0.78	-4.91	-0.45	3.76e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1267303	0.675	rs2476164	chr1:46985274	T/C	cg25110126	chr1:46999211	NA	-0.62	-4.81	-0.44	5.57e-6	Monobrow;
THYM	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg25256661	chr17:7137939	DVL2	0.86	6.3	0.54	9.11e-9	Diastolic blood pressure;
THYM	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg07884673	chr3:53033167	SFMBT1	1.25	6.34	0.55	7.83e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.26	-9.1	-0.68	1.4e-14	Gut microbiome composition (summer);
THYM	cis	rs7769051	0.711	rs7758703	chr6:133085417	T/C	cg22852734	chr6:133119734	C6orf192	1.25	7.58	0.61	2.3e-11	Type 2 diabetes nephropathy;
THYM	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg00310523	chr12:86230176	RASSF9	0.61	5.34	0.48	6.44e-7	Major depressive disorder;
THYM	cis	rs2195525	0.572	rs7932692	chr11:119220012	G/C	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.43	4.83	0.44	5.19e-6	Urate levels;
THYM	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg01324343	chr3:183735012	ABCC5	0.89	13.31	0.81	1.93e-23	Anterior chamber depth;
THYM	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg11166453	chr1:247681781	NA	0.69	5.38	0.48	5.45e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs939658	0.875	rs2177057	chr15:79441441	G/C	cg17916960	chr15:79447300	NA	-0.73	-8.58	-0.66	1.81e-13	Refractive error;
THYM	cis	rs4919694	1.000	rs17881215	chr10:104629236	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.84	-4.67	-0.43	9.98e-6	Arsenic metabolism;
THYM	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg06558623	chr16:89946397	TCF25	1.39	6.78	0.57	1.03e-9	Skin colour saturation;
THYM	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.24	9.45	0.7	2.46e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg07424592	chr7:64974309	NA	1.04	5.27	0.48	8.52e-7	Diabetic kidney disease;
THYM	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg12963246	chr6:28129442	ZNF389	0.77	6.4	0.55	5.74e-9	Parkinson's disease;
THYM	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg15693483	chr7:1102177	C7orf50	0.5	5.79	0.51	8.93e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17102423	0.594	rs1124751	chr14:65567601	C/A	cg11161011	chr14:65562177	MAX	-0.69	-5.58	-0.5	2.31e-7	Obesity-related traits;
THYM	cis	rs9905704	0.881	rs695137	chr17:56776663	G/A	cg12560992	chr17:57184187	TRIM37	0.67	4.68	0.43	9.59e-6	Testicular germ cell tumor;
THYM	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg19761014	chr17:28927070	LRRC37B2	0.8	4.73	0.44	7.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs765787	0.530	rs12440321	chr15:45529385	G/A	cg25801113	chr15:45476975	SHF	-0.39	-4.57	-0.42	1.48e-5	Uric acid levels;
THYM	cis	rs9902453	0.904	rs12103671	chr17:28408217	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-5.97	-0.52	4.12e-8	Coffee consumption (cups per day);
THYM	cis	rs7224314	1.000	rs8072527	chr17:65367220	A/G	cg01507342	chr17:65387096	PITPNC1	-0.9	-9.14	-0.68	1.15e-14	Diisocyanate-induced asthma;
THYM	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.87	0.45	4.53e-6	Bipolar disorder;
THYM	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg24920358	chr1:40204285	PPIE	0.59	5.47	0.49	3.71e-7	Blood protein levels;
THYM	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg08999081	chr20:33150536	PIGU	0.59	4.91	0.45	3.85e-6	Coronary artery disease;
THYM	cis	rs733592	0.507	rs7304428	chr12:48494275	T/G	cg21466736	chr12:48725269	NA	0.45	4.85	0.45	4.83e-6	Plateletcrit;
THYM	cis	rs12534701	0.904	rs3817518	chr7:154672809	C/T	cg24255201	chr7:154684926	DPP6	0.61	4.65	0.43	1.09e-5	Colorectal cancer (diet interaction);
THYM	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.7	-6.53	-0.56	3.28e-9	Total body bone mineral density;
THYM	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.11e-8	Systolic blood pressure;
THYM	cis	rs6700896	0.966	rs4655729	chr1:66082471	A/G	cg04111102	chr1:66153794	NA	0.53	4.64	0.43	1.12e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg16586182	chr3:47516702	SCAP	-0.63	-5.25	-0.47	9.07e-7	Colorectal cancer;
THYM	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg06850241	chr22:41845214	NA	-0.54	-4.85	-0.45	4.87e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs757081	0.648	rs214102	chr11:17288298	G/A	cg15432903	chr11:17409602	KCNJ11	-0.45	-4.46	-0.42	2.27e-5	Systolic blood pressure;
THYM	cis	rs4919044	1.000	rs4919044	chr10:94771895	T/C	cg05127821	chr10:94822908	CYP26C1	-1.18	-5.88	-0.52	6.18e-8	Coronary artery disease;
THYM	cis	rs74417235	0.673	rs6873342	chr5:154051835	A/G	cg05662444	chr5:154026397	NA	-0.57	-5.15	-0.47	1.4e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg07157834	chr1:205819609	PM20D1	-0.67	-6.03	-0.53	3.1e-8	Menarche (age at onset);
THYM	cis	rs9429544	0.568	rs35817608	chr1:114998221	G/C	cg19304150	chr1:114696350	SYT6	0.58	4.48	0.42	2.09e-5	Mean corpuscular hemoglobin;
THYM	cis	rs990171	1.000	rs6716784	chr2:103048467	T/G	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.17	-0.47	1.27e-6	Lymphocyte counts;
THYM	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg00376283	chr12:123451042	ABCB9	0.8	6.41	0.55	5.49e-9	Platelet count;
THYM	cis	rs745080	0.519	rs1824258	chr14:52919930	C/T	cg00686598	chr14:53173677	PSMC6	0.54	4.48	0.42	2.12e-5	Orofacial clefts;
THYM	cis	rs921968	0.607	rs2465100	chr2:219551044	A/T	cg02176678	chr2:219576539	TTLL4	-0.55	-5.46	-0.49	3.79e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs921968	0.643	rs611203	chr2:219472325	G/A	cg02176678	chr2:219576539	TTLL4	0.63	6.11	0.53	2.16e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7264396	0.580	rs6060648	chr20:34456704	A/G	cg26038318	chr20:34205095	SPAG4	0.64	5.0	0.46	2.58e-6	Total cholesterol levels;
THYM	cis	rs3136739	0.764	rs56261655	chr8:42071039	A/G	cg16230352	chr8:42123158	NA	0.69	4.8	0.44	5.85e-6	Plasma plasminogen activator levels;
THYM	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs9790314	1.000	rs6794601	chr3:160946769	C/T	cg04691961	chr3:161091175	C3orf57	-0.53	-4.55	-0.42	1.56e-5	Morning vs. evening chronotype;
THYM	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg02153584	chr22:29168773	CCDC117	0.62	4.8	0.44	5.91e-6	Lymphocyte counts;
THYM	cis	rs13064411	0.542	rs7631335	chr3:113209166	C/T	cg18753928	chr3:113234510	CCDC52	-0.84	-7.97	-0.63	3.49e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs3093024	0.904	rs3093017	chr6:167541258	C/G	cg09487078	chr6:167525398	CCR6	-0.35	-4.5	-0.42	1.92e-5	Rheumatoid arthritis;
THYM	cis	rs990171	1.000	rs2160232	chr2:103046880	G/A	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.17	-0.47	1.27e-6	Lymphocyte counts;
THYM	cis	rs189798	0.738	rs330908	chr8:8995166	A/G	cg06636001	chr8:8085503	FLJ10661	0.61	4.88	0.45	4.28e-6	Myopia (pathological);
THYM	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg14768367	chr16:72042858	DHODH	0.65	4.98	0.46	2.83e-6	Fibrinogen levels;
THYM	cis	rs2637266	1.000	rs2395388	chr10:78357203	C/T	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs931127	0.574	rs7944860	chr11:65406179	C/A	cg27068330	chr11:65405492	SIPA1	0.77	5.9	0.52	5.55e-8	Systemic lupus erythematosus;
THYM	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg15445000	chr17:37608096	MED1	-0.44	-5.22	-0.47	1.07e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg16586182	chr3:47516702	SCAP	-0.67	-5.62	-0.5	1.9e-7	Colorectal cancer;
THYM	cis	rs9807989	0.839	rs10204137	chr2:102968212	A/G	cg03938978	chr2:103052716	IL18RAP	0.63	6.56	0.56	2.81e-9	Asthma;
THYM	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg06618935	chr21:46677482	NA	-0.8	-7.29	-0.6	9.09e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.84e-8	Systolic blood pressure;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg10879958	chr5:68708084	RAD17	-0.93	-6.95	-0.58	4.53e-10	Depressive symptoms;
THYM	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg07636037	chr3:49044803	WDR6	0.97	10.16	0.72	7.46e-17	Parkinson's disease;
THYM	cis	rs1957429	0.731	rs10144554	chr14:65321514	T/G	cg23373153	chr14:65346875	NA	0.92	5.01	0.46	2.47e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs4363385	0.818	rs3806222	chr1:153002606	C/T	cg13444842	chr1:152974279	SPRR3	-0.59	-4.81	-0.44	5.61e-6	Inflammatory skin disease;
THYM	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8048589	0.515	rs12443524	chr16:12239979	A/G	cg02910054	chr16:12241554	SNX29	-0.73	-6.63	-0.56	2.04e-9	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs58722170	0.659	rs4073473	chr1:38092075	G/A	cg17933807	chr1:38061675	GNL2	-0.88	-6.64	-0.56	1.95e-9	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs6032067	1.000	rs6017526	chr20:43871555	A/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.71	-7.45	-0.61	4.33e-11	Blood protein levels;
THYM	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.08	9.29	0.69	5.43e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs96067	0.711	rs272833	chr1:36622870	C/G	cg24686825	chr1:36642396	MAP7D1	-0.81	-6.44	-0.55	4.93e-9	Corneal structure;
THYM	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg09307838	chr4:120376055	NA	0.77	5.56	0.5	2.5e-7	Corneal astigmatism;
THYM	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs131805	1.000	rs131816	chr22:50957462	C/T	cg25309564	chr22:51001381	C22orf41	0.71	5.01	0.46	2.55e-6	Granulocyte percentage of myeloid white cells;
THYM	cis	rs11690935	0.959	rs4667694	chr2:172605399	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.88	-6.55	-0.56	2.87e-9	Schizophrenia;
THYM	cis	rs11563648	0.553	rs11563470	chr7:126964180	C/T	cg23081781	chr7:127225937	GCC1	0.34	4.63	0.43	1.17e-5	Resting heart rate;
THYM	cis	rs7267979	1.000	rs2258884	chr20:25279539	C/T	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-6.98	-0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg23978390	chr7:1156363	C7orf50	-0.67	-5.13	-0.47	1.5e-6	Longevity;Endometriosis;
THYM	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg13010199	chr12:38710504	ALG10B	0.71	5.55	0.49	2.55e-7	Heart rate;
THYM	cis	rs9790314	0.967	rs336586	chr3:161081347	G/A	cg04691961	chr3:161091175	C3orf57	-0.6	-5.23	-0.47	1.02e-6	Morning vs. evening chronotype;
THYM	cis	rs2637266	0.967	rs4553314	chr10:78358244	C/T	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg22852734	chr6:133119734	C6orf192	1.26	7.73	0.62	1.11e-11	Type 2 diabetes nephropathy;
THYM	cis	rs59698941	0.943	rs72801413	chr5:132314105	G/A	cg02081065	chr5:132209139	LEAP2	-0.86	-5.74	-0.51	1.11e-7	Apolipoprotein A-IV levels;
THYM	cis	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg13647721	chr17:30228624	UTP6	0.76	5.0	0.46	2.62e-6	Hip circumference adjusted for BMI;
THYM	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs1728785	0.901	rs821169	chr16:68630184	C/T	cg02972257	chr16:68554789	NA	-0.71	-4.59	-0.43	1.37e-5	Ulcerative colitis;
THYM	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11644478	chr21:40555479	PSMG1	-0.76	-6.49	-0.55	3.85e-9	Cognitive function;
THYM	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11711311	1.000	rs34475696	chr3:113458293	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.27	-0.48	8.41e-7	IgG glycosylation;
THYM	cis	rs6930083	0.713	rs1321309	chr6:36638636	G/A	cg11920449	chr6:36645608	CDKN1A	0.77	6.53	0.56	3.22e-9	Coronary artery disease;
THYM	cis	rs8133932	0.736	rs2839020	chr21:47280001	A/G	cg20357416	chr21:47294739	PCBP3	-0.89	-5.87	-0.52	6.3e-8	Schizophrenia;
THYM	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg16405210	chr4:1374714	KIAA1530	-1.1	-10.45	-0.73	1.81e-17	Longevity;
THYM	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs2730245	0.569	rs842692	chr7:158657228	T/C	cg11984989	chr7:158649758	WDR60	1.11	12.96	0.8	1.01e-22	Height;
THYM	cis	rs4938330	0.681	rs12271169	chr11:116980021	C/G	cg20608306	chr11:116969690	SIK3	-0.51	-5.93	-0.52	4.83e-8	Blood protein levels;
THYM	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg08999081	chr20:33150536	PIGU	-0.76	-6.7	-0.57	1.47e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs2073300	1.000	rs6137977	chr20:23464191	G/T	cg12062639	chr20:23401060	NAPB	1.32	6.2	0.54	1.42e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg21960279	chr19:17905606	B3GNT3	0.62	5.91	0.52	5.4e-8	Tumor biomarkers;
THYM	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg11871910	chr12:69753446	YEATS4	0.73	5.85	0.51	6.88e-8	Response to diuretic therapy;
THYM	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11890956	chr21:40555474	PSMG1	1.17	13.11	0.8	4.95e-23	Cognitive function;
THYM	cis	rs6032067	0.516	rs6032087	chr20:43902305	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.39	-4.7	-0.43	8.91e-6	Blood protein levels;
THYM	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs137603	0.623	rs470075	chr22:39686806	G/A	cg24268161	chr22:39747459	SYNGR1	0.64	5.45	0.49	3.93e-7	Primary biliary cholangitis;
THYM	cis	rs12142240	0.698	rs66483119	chr1:46838389	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg08885076	chr2:99613938	TSGA10	0.52	5.02	0.46	2.4e-6	Chronic sinus infection;
THYM	cis	rs10929159	0.928	rs11890052	chr2:236918533	A/G	cg14895183	chr2:236924282	AGAP1	0.52	4.59	0.43	1.37e-5	Parkinson's disease;
THYM	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.53	0.49	2.84e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg05347473	chr6:146136440	FBXO30	-0.56	-4.45	-0.42	2.34e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1209950	1.000	rs7509960	chr21:40165612	T/C	cg01359822	chr21:40176597	ETS2	0.63	4.93	0.45	3.53e-6	Non-small cell lung cancer (survival);
THYM	cis	rs992157	0.798	rs2382818	chr2:219155907	A/T	cg00012203	chr2:219082015	ARPC2	-0.69	-5.69	-0.5	1.43e-7	Colorectal cancer;
THYM	cis	rs9649213	0.593	rs1132971	chr7:97921533	A/G	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.2e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg17691542	chr6:26056736	HIST1H1C	0.88	5.35	0.48	5.99e-7	Iron status biomarkers;
THYM	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg26384229	chr12:38710491	ALG10B	-0.98	-9.09	-0.68	1.45e-14	Morning vs. evening chronotype;
THYM	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg24250549	chr1:154909240	PMVK	0.79	6.82	0.57	8.33e-10	Prostate cancer;
THYM	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	9.7	0.71	7.1e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg03676636	chr4:99064102	C4orf37	0.46	6.97	0.58	4.18e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg00074818	chr8:8560427	CLDN23	0.57	5.35	0.48	6e-7	Obesity-related traits;
THYM	cis	rs478304	0.619	rs10896028	chr11:65432187	A/T	cg27068330	chr11:65405492	SIPA1	-1.04	-10.52	-0.73	1.26e-17	Acne (severe);
THYM	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg17264618	chr3:40429014	ENTPD3	0.54	5.27	0.48	8.5e-7	Renal cell carcinoma;
THYM	cis	rs13102973	0.965	rs13126242	chr4:135860948	T/C	cg14419869	chr4:135874104	NA	0.9	8.82	0.67	5.39e-14	Subjective well-being;
THYM	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg17366294	chr4:99064904	C4orf37	0.55	6.61	0.56	2.24e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg11764359	chr7:65958608	NA	0.87	7.44	0.61	4.44e-11	Aortic root size;
THYM	cis	rs11039798	0.764	rs10838882	chr11:48393035	T/A	cg24672777	chr11:48374446	OR4C45	-1.16	-7.24	-0.6	1.16e-10	Axial length;
THYM	cis	rs9992101	0.547	rs7674982	chr4:77412997	G/A	cg20311846	chr4:77356250	SHROOM3	-0.45	-4.72	-0.44	8.12e-6	Creatinine levels;
THYM	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg02569458	chr12:86230093	RASSF9	-0.65	-5.33	-0.48	6.59e-7	Major depressive disorder;
THYM	cis	rs870825	0.550	rs57301026	chr4:185646505	C/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg03476357	chr21:30257390	N6AMT1	-0.65	-5.07	-0.46	1.94e-6	Cognitive test performance;
THYM	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs2797160	1.000	rs6569435	chr6:125998186	T/C	cg16306078	chr6:126000798	NA	-0.52	-5.26	-0.47	9.06e-7	Endometrial cancer;
THYM	cis	rs4242434	0.854	rs11782130	chr8:22452357	G/T	cg03733263	chr8:22462867	KIAA1967	1.14	12.95	0.8	1.05e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs10911251	0.546	rs10911260	chr1:183106230	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.61	-4.93	-0.45	3.51e-6	Colorectal cancer;
THYM	cis	rs1802575	0.935	rs10207635	chr2:56040035	A/T	cg22104478	chr2:55845289	SMEK2	0.96	4.53	0.42	1.71e-5	Childhood ear infection;
THYM	cis	rs9807841	0.568	rs3859514	chr19:10748820	T/C	cg16900796	chr19:10755136	SLC44A2	0.4	6.39	0.55	6.18e-9	Inflammatory skin disease;
THYM	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg12560992	chr17:57184187	TRIM37	0.7	5.55	0.49	2.59e-7	Testicular germ cell tumor;
THYM	cis	rs10489202	1.000	rs34774552	chr1:168032245	G/A	cg24449463	chr1:168025552	DCAF6	-0.8	-6.3	-0.54	9.45e-9	Schizophrenia;
THYM	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg23711669	chr6:146136114	FBXO30	0.98	10.25	0.72	4.91e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2933343	0.729	rs1683816	chr3:128651195	G/T	cg11901034	chr3:128598214	ACAD9	0.64	5.13	0.47	1.53e-6	IgG glycosylation;
THYM	cis	rs2289577	0.698	rs17513180	chr6:90634912	A/G	cg22363327	chr6:89828097	SFRS13B	0.56	4.72	0.44	8.13e-6	Cognitive performance;
THYM	cis	rs2639990	1.000	rs655156	chr18:72898181	T/C	cg18449964	chr18:72917101	ZADH2	1.29	6.2	0.54	1.48e-8	Vascular endothelial growth factor levels;
THYM	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg17366294	chr4:99064904	C4orf37	0.54	6.05	0.53	2.81e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs240764	0.736	rs9968897	chr6:100945858	G/A	cg21058520	chr6:100914733	NA	0.57	5.02	0.46	2.38e-6	Neuroticism;
THYM	cis	rs6768930	0.509	rs7634631	chr3:57753419	G/C	cg07735586	chr3:57945651	NA	-0.33	-4.9	-0.45	3.9e-6	Obesity-related traits;
THYM	cis	rs4792901	0.797	rs117711821	chr17:41626145	C/G	cg21940313	chr17:41620911	ETV4	-0.52	-5.51	-0.49	3.08e-7	Dupuytren's disease;
THYM	cis	rs2034088	0.833	rs7219151	chr17:440497	G/A	cg06217071	chr17:408420	NA	0.84	9.01	0.68	2.19e-14	Hip circumference adjusted for BMI;
THYM	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg18301423	chr5:131593218	PDLIM4	0.5	4.7	0.43	8.95e-6	Acylcarnitine levels;
THYM	cis	rs9790314	0.521	rs13084731	chr3:161086020	G/A	cg04691961	chr3:161091175	C3orf57	-0.59	-4.87	-0.45	4.45e-6	Morning vs. evening chronotype;
THYM	cis	rs1499972	0.938	rs846184	chr3:117749852	C/T	cg07612923	chr3:117604196	NA	-1.5	-5.16	-0.47	1.38e-6	Schizophrenia;
THYM	cis	rs9326248	0.539	rs10892065	chr11:116897024	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.67	5.33	0.48	6.64e-7	Blood protein levels;
THYM	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03517284	chr6:25882590	NA	-0.76	-5.98	-0.52	3.87e-8	Blood metabolite levels;
THYM	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg13918804	chr1:2043761	PRKCZ	0.91	9.19	0.69	9.05e-15	Height;
THYM	cis	rs7772486	0.875	rs2180192	chr6:146322284	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.69	-0.5	1.43e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7823896	0.929	rs73313204	chr8:110156833	T/C	cg18044723	chr8:109261011	EIF3E	-0.89	-4.68	-0.43	9.42e-6	Myopia (pathological);
THYM	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9970807	0.748	rs6588635	chr1:56940914	C/T	cg11959316	chr1:57001742	PPAP2B	-0.63	-4.82	-0.44	5.34e-6	Myocardial infarction;Coronary artery disease;
THYM	cis	rs7828089	0.935	rs896378	chr8:22262321	T/C	cg12081754	chr8:22256438	SLC39A14	0.62	5.46	0.49	3.87e-7	Verbal declarative memory;
THYM	cis	rs3806843	0.518	rs2563310	chr5:140015741	A/G	cg19875535	chr5:140030758	IK	-0.52	-4.5	-0.42	1.92e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7084402	0.967	rs11006170	chr10:60276369	T/C	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg19693284	chr19:2783607	SGTA	0.81	5.83	0.51	7.66e-8	Total cholesterol levels;
THYM	cis	rs988913	1.000	rs6922186	chr6:54811092	A/T	cg19716238	chr6:54711378	FAM83B	0.49	5.07	0.46	1.99e-6	Menarche (age at onset);
THYM	cis	rs4950928	0.823	rs7541061	chr1:203163367	G/T	cg14085262	chr1:203155938	CHI3L1	0.77	5.48	0.49	3.42e-7	YKL-40 levels;
THYM	cis	rs13082711	0.522	rs6790344	chr3:27336531	G/C	cg02860705	chr3:27208620	NA	0.65	5.19	0.47	1.21e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg03733263	chr8:22462867	KIAA1967	1.11	13.42	0.81	1.19e-23	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs72717009	0.825	rs9427399	chr1:161476533	T/C	cg23840854	chr1:161414152	NA	-1.03	-5.5	-0.49	3.16e-7	Rheumatoid arthritis;
THYM	trans	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg07393940	chr7:158741817	NA	-1.14	-9.25	-0.69	6.69e-15	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg04287289	chr16:89883240	FANCA	0.65	6.04	0.53	3.01e-8	Vitiligo;
THYM	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs34638657	0.732	rs10514532	chr16:82200337	C/T	cg09894383	chr16:82067445	HSD17B2	0.5	5.82	0.51	7.93e-8	Lung adenocarcinoma;
THYM	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.99	-0.75	1.26e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg11366901	chr6:160182831	ACAT2	1.01	8.95	0.68	2.91e-14	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg15557168	chr22:42548783	NA	0.54	4.54	0.42	1.63e-5	Cognitive function;
THYM	cis	rs9902453	0.967	rs9904336	chr17:28357080	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs1524976	1.000	rs9817894	chr3:65465760	T/A	cg16238336	chr3:65465873	MAGI1	-1.01	-6.57	-0.56	2.74e-9	PR interval;
THYM	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs2109514	0.774	rs6954077	chr7:116129153	G/A	cg12739419	chr7:116140593	CAV2	-0.48	-4.7	-0.43	8.75e-6	Prevalent atrial fibrillation;
THYM	cis	rs72823319	0.842	rs16493	chr17:37273219	C/T	cg19919217	chr17:38248105	THRA	-0.39	-4.47	-0.42	2.17e-5	Verbal memory performance (residualized delayed recall change);
THYM	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg11245990	chr11:68621969	NA	0.53	6.78	0.57	1.03e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg15445000	chr17:37608096	MED1	-0.42	-5.08	-0.46	1.91e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4690686	0.836	rs10003662	chr4:177258951	C/G	cg17059388	chr4:177262070	NA	0.38	5.46	0.49	3.74e-7	Essential tremor;
THYM	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg25208724	chr1:156163844	SLC25A44	1.13	12.98	0.8	8.99e-23	Testicular germ cell tumor;
THYM	cis	rs11608355	0.846	rs12581637	chr12:109855429	G/A	cg10504392	chr12:110044639	NA	0.61	5.2	0.47	1.16e-6	Neuroticism;
THYM	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs6032067	0.929	rs13039108	chr20:43829584	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs11148252	0.683	rs9536006	chr13:52887707	T/G	cg05335186	chr13:53173507	NA	-0.48	-5.99	-0.52	3.78e-8	Lewy body disease;
THYM	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg03405983	chr8:143858548	LYNX1	-0.55	-5.9	-0.52	5.66e-8	Urinary tract infection frequency;
THYM	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg12292205	chr6:26970375	C6orf41	0.53	4.49	0.42	1.99e-5	Schizophrenia;
THYM	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg12524338	chr4:183729343	NA	0.92	6.12	0.53	2.11e-8	Pediatric autoimmune diseases;
THYM	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.64	0.43	1.1e-5	Bipolar disorder;
THYM	trans	rs8073060	0.586	rs7208672	chr17:33989759	G/A	cg19694781	chr19:47549865	TMEM160	-1.0	-8.37	-0.65	5.05e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs5769707	0.604	rs1018814	chr22:50036900	T/C	cg23428387	chr22:49814324	NA	-0.51	-4.86	-0.45	4.68e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg13319975	chr6:146136371	FBXO30	-0.66	-5.35	-0.48	6.11e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg22166914	chr1:53195759	ZYG11B	-0.69	-6.96	-0.58	4.39e-10	Monocyte count;
THYM	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg18169835	chr10:134612155	NA	0.6	4.46	0.42	2.25e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7953249	0.618	rs7954331	chr12:121398657	G/T	cg14101638	chr12:121416612	HNF1A	-0.48	-5.11	-0.46	1.65e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg18477163	chr1:228402036	OBSCN	-0.43	-4.69	-0.43	8.96e-6	Diastolic blood pressure;
THYM	cis	rs28595532	0.920	rs17259173	chr4:119777232	T/C	cg14228332	chr4:119757509	SEC24D	1.59	5.76	0.51	1.02e-7	Cannabis dependence symptom count;
THYM	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg01528321	chr10:82214614	TSPAN14	-0.98	-7.53	-0.61	2.93e-11	Post bronchodilator FEV1;
THYM	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg12310025	chr6:25882481	NA	-0.85	-6.87	-0.58	6.59e-10	Intelligence (multi-trait analysis);
THYM	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs4638749	0.501	rs1486193	chr2:108756025	G/A	cg25838818	chr2:108905173	SULT1C2	-0.52	-4.89	-0.45	4.13e-6	Blood pressure;
THYM	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg08439880	chr3:133502540	NA	-0.74	-6.48	-0.55	4.1e-9	Iron status biomarkers;
THYM	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg17173187	chr15:85201210	NMB	-0.61	-6.27	-0.54	1.05e-8	Schizophrenia;
THYM	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	7.01	0.58	3.49e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg17426766	chr1:2046864	PRKCZ	0.44	5.23	0.47	1.02e-6	Height;
THYM	cis	rs4242434	0.892	rs71513892	chr8:22456517	C/G	cg14690197	chr8:22456421	C8orf58	0.52	4.81	0.44	5.58e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg21926612	chr6:163149169	PACRG;PARK2	1.32	9.95	0.71	2.06e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.87	-0.82	1.48e-24	Height;
THYM	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg12826209	chr6:26865740	GUSBL1	0.84	6.07	0.53	2.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg08975724	chr8:8085496	FLJ10661	0.67	5.45	0.49	4.02e-7	Neuroticism;
THYM	cis	rs9560113	1.000	rs9555804	chr13:112179751	T/C	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	trans	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.99	-7.88	-0.63	5.33e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	4.98	0.45	2.88e-6	Schizophrenia;
THYM	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11890956	chr21:40555474	PSMG1	1.17	12.99	0.8	8.73e-23	Cognitive function;
THYM	cis	rs8038465	0.592	rs899981	chr15:73935329	G/A	cg15420318	chr15:73925796	NPTN	0.62	5.3	0.48	7.57e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2180341	0.595	rs7771391	chr6:127749656	C/G	cg27446573	chr6:127587934	RNF146	0.61	4.85	0.45	4.78e-6	Breast cancer;
THYM	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg06636001	chr8:8085503	FLJ10661	0.77	6.79	0.57	9.68e-10	Mood instability;
THYM	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg01119278	chr6:110721349	DDO	-0.56	-6.11	-0.53	2.21e-8	Platelet distribution width;
THYM	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg11266682	chr4:10021025	SLC2A9	-0.52	-6.42	-0.55	5.41e-9	Bone mineral density;
THYM	cis	rs9880211	1.000	rs4038586	chr3:136363291	T/C	cg21827317	chr3:136751795	NA	-0.69	-4.63	-0.43	1.14e-5	Body mass index;Height;
THYM	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg13147721	chr7:65941812	NA	-0.89	-5.31	-0.48	7.23e-7	Diabetic kidney disease;
THYM	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg18357526	chr6:26021779	HIST1H4A	0.74	5.7	0.5	1.35e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9914544	0.545	rs3803835	chr17:18793061	C/T	cg26378065	chr17:18585709	ZNF286B	0.58	4.65	0.43	1.05e-5	Educational attainment (years of education);
THYM	cis	rs4780401	0.609	rs4781141	chr16:11808769	A/C	cg01061890	chr16:11836724	TXNDC11	-0.66	-5.44	-0.49	4.13e-7	Rheumatoid arthritis;
THYM	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.65	0.56	1.88e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.51	4.69	0.43	9.07e-6	Birth weight;
THYM	cis	rs870825	0.860	rs72703529	chr4:185607351	T/C	cg04058563	chr4:185651563	MLF1IP	1.0	7.42	0.61	4.93e-11	Blood protein levels;
THYM	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg00129232	chr17:37814104	STARD3	0.7	4.93	0.45	3.42e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.71	-5.52	-0.49	2.92e-7	Tonsillectomy;
THYM	cis	rs10895275	0.625	rs10791569	chr11:102088335	A/C	cg24447756	chr11:102105824	NA	0.47	4.74	0.44	7.4e-6	Migraine;
THYM	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg22166914	chr1:53195759	ZYG11B	0.89	10.05	0.72	1.31e-16	Monocyte count;
THYM	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg02569458	chr12:86230093	RASSF9	-0.66	-5.63	-0.5	1.84e-7	Major depressive disorder;
THYM	cis	rs7264396	0.528	rs3787174	chr20:34487921	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-4.64	-0.43	1.1e-5	Total cholesterol levels;
THYM	cis	rs7084402	0.967	rs1649082	chr10:60292434	A/C	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg04750100	chr2:136595281	LCT	0.57	6.84	0.57	7.72e-10	Mosquito bite size;
THYM	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg12573674	chr2:1569213	NA	-1.16	-8.07	-0.64	2.18e-12	IgG glycosylation;
THYM	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg09307838	chr4:120376055	NA	0.78	5.62	0.5	1.92e-7	Corneal astigmatism;
THYM	cis	rs240764	0.658	rs10457849	chr6:101245591	A/G	cg21058520	chr6:100914733	NA	-0.61	-5.42	-0.49	4.54e-7	Neuroticism;
THYM	cis	rs7177699	0.525	rs7402376	chr15:79113570	A/G	cg00540400	chr15:79124168	NA	-0.64	-6.85	-0.58	7.16e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7568458	0.905	rs17026396	chr2:85759127	C/T	cg17127132	chr2:85788382	GGCX	-0.65	-5.25	-0.47	9.44e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs7586879	1.000	rs10175064	chr2:25117537	T/C	cg15423357	chr2:25149977	NA	0.56	5.49	0.49	3.41e-7	Body mass index;
THYM	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg27068330	chr11:65405492	SIPA1	-1.03	-8.88	-0.67	4.17e-14	Acne (severe);
THYM	cis	rs9359856	0.564	rs17292768	chr6:90379311	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.16	-0.64	1.36e-12	Bipolar disorder;
THYM	cis	rs67981189	0.558	rs56043821	chr14:71570552	T/C	cg15910301	chr14:71632612	NA	0.56	4.88	0.45	4.23e-6	Schizophrenia;
THYM	cis	rs7119	0.717	rs12910513	chr15:77817258	C/T	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.57	-5.18	-0.47	1.23e-6	Type 2 diabetes;
THYM	cis	rs289828	0.519	rs34028108	chr2:152154141	C/G	cg05960677	chr2:152117363	RBM43	0.74	7.15	0.59	1.81e-10	Blood protein levels;
THYM	cis	rs12367572	0.930	rs11615964	chr12:45261564	C/T	cg03114573	chr12:45410052	DBX2	-0.57	-5.24	-0.47	9.46e-7	Gut microbiome composition (summer);
THYM	cis	rs10911232	0.507	rs2151669	chr1:183055398	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs892961	0.932	rs12452788	chr17:75406866	T/C	cg05865280	chr17:75406074	SEPT9	0.49	8.36	0.65	5.14e-13	Airflow obstruction;
THYM	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg13683864	chr3:40499215	RPL14	0.95	9.77	0.71	5.1e-16	Renal cell carcinoma;
THYM	cis	rs7599312	0.534	rs10182996	chr2:213404834	T/C	cg16329650	chr2:213403929	ERBB4	1.04	12.32	0.78	2.07e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs28476539	0.568	rs13124143	chr4:83559442	A/C	cg10249074	chr4:83542146	C4orf11	-0.66	-5.27	-0.48	8.48e-7	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14893161	chr1:205819251	PM20D1	1.11	13.21	0.8	3.05e-23	Menarche (age at onset);
THYM	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg18132916	chr6:79620363	NA	-0.6	-5.66	-0.5	1.6e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7267979	1.000	rs2482941	chr20:25361216	T/C	cg08601574	chr20:25228251	PYGB	-0.58	-4.71	-0.43	8.54e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.77	6.15	0.53	1.84e-8	Monocyte percentage of white cells;
THYM	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.3	6.14	0.53	1.91e-8	Obesity-related traits;
THYM	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.66	4.63	0.43	1.18e-5	Aortic root size;
THYM	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06634786	chr22:41940651	POLR3H	-0.74	-5.55	-0.49	2.63e-7	Vitiligo;
THYM	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg22117172	chr7:91764530	CYP51A1	0.36	4.59	0.43	1.37e-5	Breast cancer;
THYM	cis	rs2777491	0.574	rs2730056	chr15:41735785	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.21	-13.25	-0.81	2.61e-23	Ulcerative colitis;
THYM	cis	rs8031584	1.000	rs11634216	chr15:31288670	G/A	cg08109568	chr15:31115862	NA	-0.63	-6.06	-0.53	2.72e-8	Huntington's disease progression;
THYM	cis	rs6009824	0.891	rs6009820	chr22:50085456	C/T	cg27029450	chr22:50098074	NA	0.78	5.0	0.46	2.65e-6	Natriuretic peptide levels;
THYM	cis	rs6754311	0.597	rs6760329	chr2:136544752	A/G	cg23851026	chr2:136556271	LCT	-0.61	-6.01	-0.53	3.36e-8	Mosquito bite size;
THYM	cis	rs4606347	0.720	rs61780876	chr1:66165046	C/A	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2777491	0.874	rs13379756	chr15:41663896	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.08	-11.13	-0.75	6.45e-19	Ulcerative colitis;
THYM	cis	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg05335186	chr13:53173507	NA	-0.47	-5.83	-0.51	7.44e-8	Lewy body disease;
THYM	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.73	-5.23	-0.47	1.02e-6	Body mass index;
THYM	cis	rs4700695	0.719	rs27082	chr5:65436152	A/C	cg21114390	chr5:65439923	SFRS12	-0.78	-4.47	-0.42	2.12e-5	Facial morphology (factor 19);
THYM	cis	rs9329289	0.510	rs9733402	chr10:2551532	G/A	cg15501526	chr10:2543763	NA	0.5	4.58	0.42	1.43e-5	Age-related hearing impairment;
THYM	cis	rs760805	1.000	rs61774728	chr1:25258867	G/C	cg22509179	chr1:25234806	RUNX3	-0.73	-6.72	-0.57	1.34e-9	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg24531977	chr5:56204891	C5orf35	0.72	5.87	0.52	6.25e-8	Initial pursuit acceleration;
THYM	cis	rs4642101	0.535	rs55692304	chr3:12840057	C/T	cg11882607	chr3:12858926	CAND2	-0.44	-4.7	-0.43	8.74e-6	QRS complex (12-leadsum);
THYM	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.12	9.06	0.68	1.73e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg17063962	chr7:91808500	NA	-1.12	-12.68	-0.79	3.85e-22	Breast cancer;
THYM	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg06009448	chr7:1102226	C7orf50	0.52	5.44	0.49	4.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9814567	0.722	rs13083717	chr3:134348796	G/A	cg15484384	chr3:134203672	ANAPC13;CEP63	0.43	4.74	0.44	7.46e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-4.95	-0.45	3.16e-6	Schizophrenia;
THYM	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg21252483	chr19:49399788	TULP2	-0.91	-6.15	-0.53	1.83e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	trans	rs208520	0.690	rs207094	chr6:66799009	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.66	-0.62	1.53e-11	Exhaled nitric oxide output;
THYM	cis	rs4654899	1.000	rs6426656	chr1:21343245	G/C	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.26e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.92	-6.03	-0.53	3.11e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6430585	0.583	rs730005	chr2:136582694	T/C	cg23851026	chr2:136556271	LCT	0.77	7.67	0.62	1.52e-11	Corneal structure;
THYM	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg25918947	chr17:41365094	TMEM106A	-0.62	-4.96	-0.45	3.14e-6	Menopause (age at onset);
THYM	cis	rs7528419	1.000	rs629301	chr1:109818306	G/T	cg00908766	chr1:109817496	CELSR2	0.89	7.14	0.59	1.9e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
THYM	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg26441486	chr22:50317300	CRELD2	-0.42	-6.54	-0.56	3.14e-9	Schizophrenia;
THYM	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg14972814	chr11:95582409	MTMR2	-0.59	-5.36	-0.48	5.87e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4819852	1.000	rs1034565	chr22:19984211	A/G	cg07821417	chr22:19972146	ARVCF	-0.45	-5.16	-0.47	1.37e-6	Pulse pressure;
THYM	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.42	-4.7	-0.43	8.79e-6	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs7084921	0.608	rs7474634	chr10:101863410	A/C	cg11344164	chr10:101878520	NA	0.57	4.93	0.45	3.47e-6	Bone mineral density;
THYM	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg26441486	chr22:50317300	CRELD2	0.45	7.6	0.62	2.04e-11	Schizophrenia;
THYM	cis	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg24672777	chr11:48374446	OR4C45	-0.96	-6.12	-0.53	2.1e-8	Axial length;
THYM	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg00757033	chr12:89920650	WDR51B	0.75	12.02	0.78	8.86e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg23791538	chr6:167370224	RNASET2	0.74	5.92	0.52	5.06e-8	Crohn's disease;
THYM	cis	rs6669072	0.527	rs10801831	chr1:91272391	T/A	cg08895590	chr1:91227319	NA	-0.39	-4.45	-0.42	2.32e-5	Cognitive function;
THYM	cis	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs7192750	0.586	rs2335714	chr16:71897926	A/G	cg06353428	chr16:71660113	MARVELD3	0.63	4.58	0.43	1.38e-5	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg00071950	chr4:10020882	SLC2A9	0.88	9.22	0.69	7.56e-15	Bone mineral density;
THYM	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg12165864	chr7:66369176	NA	-0.81	-6.03	-0.53	3.07e-8	Corneal structure;
THYM	cis	rs72781680	1.000	rs56068891	chr2:24230633	A/G	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	10.26	0.73	4.55e-17	Platelet count;
THYM	cis	rs76878669	0.538	rs1785633	chr11:66107527	C/A	cg18002602	chr11:66138449	SLC29A2	0.5	5.0	0.46	2.62e-6	Educational attainment (years of education);
THYM	cis	rs9915657	0.811	rs35126550	chr17:70118699	G/A	cg06234051	chr17:70120541	SOX9	-0.77	-7.49	-0.61	3.45e-11	Thyroid hormone levels;
THYM	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6032067	0.929	rs2233883	chr20:43835822	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.81	-0.57	8.91e-10	Blood protein levels;
THYM	cis	rs6430585	0.528	rs3112496	chr2:136711064	C/T	cg07169764	chr2:136633963	MCM6	0.96	9.1	0.68	1.36e-14	Corneal structure;
THYM	cis	rs933688	1.000	rs12188467	chr5:90765632	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	7.72	0.62	1.18e-11	Smoking behavior;
THYM	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.64	-0.5	1.73e-7	Menopause (age at onset);
THYM	cis	rs4076764	0.801	rs6675964	chr1:163375960	A/G	cg24596788	chr1:163392923	NA	-0.73	-6.2	-0.54	1.45e-8	Motion sickness;
THYM	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg10760299	chr15:45669010	GATM	-0.74	-5.21	-0.47	1.1e-6	Homoarginine levels;
THYM	cis	rs4606347	0.932	rs11809410	chr1:66147068	A/G	cg04111102	chr1:66153794	NA	0.57	4.53	0.42	1.73e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6840360	1.000	rs6817586	chr4:152643184	G/A	cg22705602	chr4:152727874	NA	-0.59	-6.36	-0.55	7.09e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1061377	1.000	rs2381285	chr4:39114395	A/G	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22857025	chr5:266934	NA	-1.43	-9.54	-0.7	1.58e-15	Breast cancer;
THYM	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg11345693	chr17:79170810	AZI1	-0.54	-4.48	-0.42	2.1e-5	Frontotemporal dementia;
THYM	cis	rs7107174	1.000	rs7104222	chr11:78007169	G/A	cg02023728	chr11:77925099	USP35	0.65	5.91	0.52	5.31e-8	Testicular germ cell tumor;
THYM	cis	rs6546324	0.625	rs2861644	chr2:67799964	A/G	cg18237512	chr2:67827392	NA	-0.78	-4.68	-0.43	9.36e-6	Endometriosis;
THYM	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg15744005	chr10:104629667	AS3MT	0.91	9.71	0.71	6.97e-16	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg22875332	chr1:76189707	ACADM	-0.54	-5.11	-0.46	1.67e-6	Daytime sleep phenotypes;
THYM	cis	rs1018836	0.923	rs13255452	chr8:91582988	A/G	cg16814680	chr8:91681699	NA	-0.74	-6.12	-0.53	2.04e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4766566	0.694	rs3843673	chr12:111746499	A/G	cg10833066	chr12:111807467	FAM109A	0.64	8.93	0.68	3.16e-14	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
THYM	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg23260525	chr10:116636907	FAM160B1	0.51	5.31	0.48	7.16e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg14675211	chr2:100938903	LONRF2	0.77	8.23	0.65	9.81e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4430311	0.723	rs10927081	chr1:243994216	T/C	cg25706552	chr1:244017396	NA	-0.57	-4.81	-0.44	5.58e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs3804749	0.966	rs726681	chr3:122837648	C/T	cg26084141	chr3:122786895	PDIA5	0.45	4.51	0.42	1.83e-5	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs1021993	0.868	rs6661759	chr1:209530799	C/G	cg06155620	chr1:209527581	NA	-0.65	-5.28	-0.48	8.22e-7	Gut microbiome composition (winter);
THYM	cis	rs752010	0.523	rs10890160	chr1:42120011	A/G	cg06885757	chr1:42089581	HIVEP3	0.61	7.51	0.61	3.26e-11	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs7312774	0.618	rs12316286	chr12:107343020	C/A	cg16260113	chr12:107380972	MTERFD3	1.3	6.63	0.56	2.04e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg10193763	chr2:225306901	NA	-0.52	-5.48	-0.49	3.41e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs7610301	1.000	rs35413899	chr3:46643000	A/G	cg22951056	chr3:46887651	NA	-0.77	-5.06	-0.46	2.06e-6	Blood protein levels;
THYM	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.3	-0.48	7.34e-7	Monocyte percentage of white cells;
THYM	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	trans	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg07211511	chr3:129823064	LOC729375	-1.22	-9.75	-0.71	5.63e-16	Blood pressure (smoking interaction);
THYM	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.51	-4.79	-0.44	6.24e-6	Lymphocyte counts;
THYM	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg00071950	chr4:10020882	SLC2A9	0.56	4.95	0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6951245	0.515	rs78461900	chr7:1007033	C/A	cg24642844	chr7:1081250	C7orf50	-1.23	-5.41	-0.49	4.7e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03647317	chr4:187891568	NA	-0.83	-9.1	-0.68	1.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2898681	0.519	rs7670068	chr4:53733984	T/G	cg00791764	chr4:53727839	RASL11B	0.6	6.58	0.56	2.51e-9	Optic nerve measurement (cup area);
THYM	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs3741151	0.773	rs7950375	chr11:73281345	G/A	cg17517138	chr11:73019481	ARHGEF17	0.9	4.68	0.43	9.36e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs950880	0.710	rs55883125	chr2:103024331	G/A	cg03938978	chr2:103052716	IL18RAP	-0.53	-4.62	-0.43	1.2e-5	Serum protein levels (sST2);
THYM	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg06219351	chr7:158114137	PTPRN2	-0.73	-7.14	-0.59	1.87e-10	Calcium levels;
THYM	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs7264396	0.887	rs6060434	chr20:34068382	C/G	cg26038318	chr20:34205095	SPAG4	0.53	4.45	0.42	2.33e-5	Total cholesterol levels;
THYM	cis	rs28595532	0.920	rs115090549	chr4:119753554	T/C	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg26031613	chr14:104095156	KLC1	0.79	5.22	0.47	1.06e-6	Body mass index;
THYM	cis	rs116095464	1.000	rs6873902	chr5:313337	C/G	cg22857025	chr5:266934	NA	-1.41	-5.27	-0.48	8.69e-7	Breast cancer;
THYM	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg05043794	chr9:111880884	C9orf5	-0.39	-5.76	-0.51	1.04e-7	Menarche (age at onset);
THYM	cis	rs9549367	0.659	rs9549703	chr13:113885094	T/TTAG	cg18105134	chr13:113819100	PROZ	-1.12	-9.63	-0.7	1.02e-15	Platelet distribution width;
THYM	cis	rs17534004	1.000	rs35646895	chr13:31469604	C/T	cg13251181	chr13:31481184	C13orf33	0.55	4.52	0.42	1.77e-5	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs4589258	0.687	rs1783793	chr11:90439945	A/C	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg06002616	chr8:101225028	SPAG1	-0.46	-4.79	-0.44	6.22e-6	Atrioventricular conduction;
THYM	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg13695892	chr22:41940480	POLR3H	-0.73	-6.66	-0.56	1.74e-9	Vitiligo;
THYM	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06481639	chr22:41940642	POLR3H	-0.81	-5.61	-0.5	2.03e-7	Vitiligo;
THYM	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg14458575	chr2:238380390	NA	1.01	7.82	0.63	7.34e-12	Prostate cancer;
THYM	cis	rs656319	0.559	rs17689289	chr8:9977980	C/G	cg20181426	chr8:10469310	RP1L1	-0.52	-4.46	-0.42	2.25e-5	Myopia (pathological);
THYM	cis	rs7586879	0.616	rs876186	chr2:25125585	C/T	cg27107076	chr2:25050844	ADCY3	-0.29	-4.72	-0.44	8.01e-6	Body mass index;
THYM	cis	rs870825	0.587	rs7682995	chr4:185640684	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg13010199	chr12:38710504	ALG10B	-0.72	-5.59	-0.5	2.15e-7	Heart rate;
THYM	cis	rs1062746	0.557	rs35441225	chr16:87335498	C/A	cg27365499	chr16:87376795	FBXO31	0.57	5.98	0.52	3.93e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg24069376	chr3:38537580	EXOG	-0.66	-6.36	-0.55	7.17e-9	Electrocardiographic conduction measures;
THYM	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg18252515	chr7:66147081	NA	0.64	4.69	0.43	9.21e-6	Aortic root size;
THYM	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg08859206	chr1:53392774	SCP2	-0.77	-9.43	-0.7	2.75e-15	Monocyte count;
THYM	cis	rs2282300	0.739	rs16920406	chr11:30216158	A/C	cg09906309	chr11:30344399	C11orf46	-0.69	-5.16	-0.47	1.37e-6	Morning vs. evening chronotype;
THYM	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg04455712	chr21:45112962	RRP1B	0.52	4.93	0.45	3.42e-6	Mean corpuscular volume;
THYM	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg19601865	chr12:132687172	GALNT9	0.68	7.02	0.58	3.28e-10	Anti-saccade response;
THYM	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg04034577	chr2:241836375	C2orf54	-0.44	-7.95	-0.63	3.91e-12	Urinary metabolites;
THYM	cis	rs427394	1.000	rs182135	chr5:6747453	G/A	cg10857441	chr5:6722123	POLS	-0.65	-7.59	-0.61	2.17e-11	Menopause (age at onset);
THYM	cis	rs863345	0.604	rs12063320	chr1:158499423	A/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs250677	0.687	rs171636	chr5:148434545	G/A	cg18129178	chr5:148520854	ABLIM3	-0.73	-4.49	-0.42	1.98e-5	Breast cancer;
THYM	cis	rs6503525	0.701	rs28618095	chr17:38109075	T/C	cg26162295	chr17:38119207	GSDMA	-0.42	-5.05	-0.46	2.13e-6	Asthma;
THYM	cis	rs13315871	0.929	rs11717700	chr3:58250876	T/A	cg12435725	chr3:58293450	RPP14	-0.56	-5.87	-0.52	6.32e-8	Cholesterol, total;
THYM	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg07167872	chr1:205819463	PM20D1	0.57	4.62	0.43	1.22e-5	Parkinson's disease;
THYM	cis	rs7224314	1.000	rs7221926	chr17:65352181	A/T	cg01507342	chr17:65387096	PITPNC1	-0.84	-8.55	-0.66	2.03e-13	Diisocyanate-induced asthma;
THYM	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg00012203	chr2:219082015	ARPC2	-0.67	-5.5	-0.49	3.17e-7	Pyoderma gangrenosum in inflammatory bowel disease;
THYM	cis	rs1971762	0.527	rs784568	chr12:53927554	C/A	cg16917193	chr12:54089295	NA	-0.73	-6.52	-0.56	3.45e-9	Height;
THYM	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg15744005	chr10:104629667	AS3MT	0.92	9.72	0.71	6.51e-16	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg15212455	chr7:39170539	POU6F2	0.58	5.32	0.48	6.95e-7	IgG glycosylation;
THYM	cis	rs593982	0.777	rs534414	chr11:65475515	A/G	cg08755490	chr11:65554678	OVOL1	1.29	4.66	0.43	1.03e-5	Atopic dermatitis;
THYM	cis	rs8114671	0.933	rs6087683	chr20:33774444	C/T	cg08999081	chr20:33150536	PIGU	0.52	4.67	0.43	9.71e-6	Height;
THYM	cis	rs1729407	0.565	rs2849173	chr11:116697321	G/C	cg08985259	chr11:116699649	APOC3	-0.61	-5.44	-0.49	4.15e-7	Apolipoprotein A-IV levels;
THYM	cis	rs2734839	0.964	rs4587762	chr11:113306893	G/A	cg14159747	chr11:113255604	NA	0.32	6.26	0.54	1.12e-8	Information processing speed;
THYM	cis	rs9595908	0.900	rs1324415	chr13:33174323	G/A	cg12383807	chr13:33924137	NA	-0.51	-4.58	-0.42	1.43e-5	Body mass index;
THYM	cis	rs9902453	0.808	rs76515799	chr17:28169491	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.73	0.44	7.7e-6	Coffee consumption (cups per day);
THYM	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg08431931	chr22:42394659	WBP2NL	0.85	5.33	0.48	6.65e-7	Birth weight;
THYM	cis	rs778371	0.834	rs778364	chr2:233777859	A/G	cg08000102	chr2:233561755	GIGYF2	0.62	4.66	0.43	1.01e-5	Schizophrenia;
THYM	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg24675658	chr1:53192096	ZYG11B	0.57	4.53	0.42	1.75e-5	Monocyte count;
THYM	cis	rs791888	0.760	rs10788561	chr10:89423245	A/G	cg13926569	chr10:89418898	PAPSS2	0.71	8.37	0.65	4.95e-13	Magnesium levels;
THYM	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg23711669	chr6:146136114	FBXO30	0.91	9.21	0.69	8.1e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9790314	0.779	rs1599376	chr3:160900533	C/G	cg04691961	chr3:161091175	C3orf57	-0.59	-4.83	-0.44	5.31e-6	Morning vs. evening chronotype;
THYM	cis	rs61774743	0.754	rs11578963	chr1:41834183	A/G	cg19619003	chr1:41846758	NA	0.28	5.86	0.52	6.65e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs7809950	1.000	rs2250414	chr7:107140987	T/G	cg23024343	chr7:107201750	COG5	-0.91	-8.24	-0.65	9.37e-13	Coronary artery disease;
THYM	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg00012203	chr2:219082015	ARPC2	-0.65	-5.32	-0.48	6.78e-7	Colorectal cancer;
THYM	cis	rs6005807	0.688	rs16986077	chr22:28548967	A/G	cg02153584	chr22:29168773	CCDC117	-1.21	-4.94	-0.45	3.36e-6	Cerebrospinal T-tau levels;Epithelial ovarian cancer;Cerebrospinal fluid p-Tau181p:AB1-42 ratio;Cerebrospinal P-tau181p levels;Serous invasive ovarian cancer;High-grade serous ovarian cancer;Invasive epithelial ovarian cancer;
THYM	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.01	8.17	0.64	1.3e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6743226	0.901	rs12478458	chr2:242237856	A/G	cg10021735	chr2:242295487	FARP2	0.63	4.49	0.42	1.98e-5	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs1797885	0.564	rs2633443	chr3:12600837	G/A	cg05467012	chr3:12595696	NA	0.54	4.56	0.42	1.53e-5	Immature fraction of reticulocytes;
THYM	cis	rs35934224	0.654	rs58210408	chr22:19863638	C/T	cg11182965	chr22:19864308	TXNRD2	-0.79	-5.01	-0.46	2.55e-6	Glaucoma (primary open-angle);
THYM	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg10515332	chr4:99064459	C4orf37	0.67	5.33	0.48	6.48e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2282300	0.739	rs10835648	chr11:30320506	A/G	cg09906309	chr11:30344399	C11orf46	0.72	5.54	0.49	2.73e-7	Morning vs. evening chronotype;
THYM	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg13918804	chr1:2043761	PRKCZ	0.9	9.01	0.68	2.19e-14	Height;
THYM	cis	rs9677476	0.909	rs7562116	chr2:232108246	A/G	cg07929768	chr2:232055508	NA	0.64	6.38	0.55	6.51e-9	Food antigen IgG levels;
THYM	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs977987	0.843	rs11149820	chr16:75422760	G/A	cg03315344	chr16:75512273	CHST6	0.73	6.29	0.54	9.83e-9	Dupuytren's disease;
THYM	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg05283184	chr6:79620031	NA	-0.91	-8.65	-0.66	1.27e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2120019	0.567	rs12385940	chr15:75168162	C/T	cg17294928	chr15:75287854	SCAMP5	-0.67	-4.59	-0.43	1.38e-5	Blood trace element (Zn levels);
THYM	cis	rs4946717	0.740	rs6941301	chr6:106472457	T/C	cg02270332	chr6:106475062	NA	0.74	10.28	0.73	4.27e-17	Inflammatory bowel disease;
THYM	cis	rs1018836	0.632	rs6995399	chr8:91481629	T/C	cg16814680	chr8:91681699	NA	-0.76	-6.25	-0.54	1.15e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs12579753	0.917	rs12316644	chr12:82205497	C/T	cg21231944	chr12:82153410	PPFIA2	0.66	5.01	0.46	2.51e-6	Resting heart rate;
THYM	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs12257961	0.548	rs10796273	chr10:15340747	C/T	cg10616319	chr10:15468812	NA	-0.59	-4.79	-0.44	6.05e-6	Selective IgA deficiency;
THYM	cis	rs9796	0.835	rs28455998	chr15:41430969	T/A	cg21153102	chr15:41252147	NA	0.69	6.18	0.54	1.6e-8	Menopause (age at onset);
THYM	trans	rs11960314	0.717	rs883848	chr5:170070942	A/C	cg26092564	chr6:66207286	EYS	0.76	6.89	0.58	5.96e-10	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs9302690	1.000	rs62037143	chr16:57486583	T/C	cg27017172	chr16:57497170	POLR2C	0.82	4.88	0.45	4.29e-6	Blood protein levels;
THYM	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg11764359	chr7:65958608	NA	0.64	5.08	0.46	1.91e-6	Aortic root size;
THYM	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg23708337	chr7:1209742	NA	0.87	4.65	0.43	1.08e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6840360	0.904	rs6813516	chr4:152594407	C/G	cg22705602	chr4:152727874	NA	-0.61	-6.55	-0.56	2.89e-9	Intelligence (multi-trait analysis);
THYM	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.27	-0.48	8.61e-7	Hemoglobin concentration;
THYM	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg23803603	chr1:2058230	PRKCZ	-0.67	-5.73	-0.51	1.18e-7	Height;
THYM	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.88	0.52	6.19e-8	Rheumatoid arthritis;
THYM	cis	rs2692947	0.770	rs4527246	chr2:96560303	T/C	cg22654517	chr2:96458247	NA	0.59	4.45	0.42	2.32e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg26597838	chr10:835615	NA	0.81	4.94	0.45	3.34e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs6987853	1.000	rs6987853	chr8:42457450	T/C	cg09913449	chr8:42400586	C8orf40	0.84	7.87	0.63	5.79e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg24308560	chr3:49941425	MST1R	-0.76	-6.31	-0.54	8.82e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9807989	0.839	rs4988957	chr2:102968075	C/T	cg03938978	chr2:103052716	IL18RAP	-0.64	-6.66	-0.56	1.78e-9	Asthma;
THYM	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg14298792	chr15:30685198	CHRFAM7A	0.8	5.6	0.5	2.1e-7	Huntington's disease progression;
THYM	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg16342193	chr10:102329863	NA	-0.54	-5.35	-0.48	6.03e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1278352	0.928	rs1278346	chr10:127771872	C/T	cg08295661	chr10:127769903	ADAM12	-0.43	-4.77	-0.44	6.76e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs344364	0.629	rs9806826	chr16:1894912	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-5.89	-0.52	5.79e-8	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs1371867	0.846	rs1788181	chr8:101334068	C/T	cg06636551	chr8:101224915	SPAG1	-0.63	-6.33	-0.54	8.05e-9	Atrioventricular conduction;
THYM	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg11166453	chr1:247681781	NA	0.69	5.38	0.48	5.45e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs2637266	0.967	rs4581393	chr10:78376123	A/C	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs72627509	0.904	rs56281640	chr4:57765816	G/A	cg26694713	chr4:57773883	REST	0.75	4.83	0.44	5.13e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs11997175	0.846	rs7388664	chr8:33768773	T/G	ch.8.33884649F	chr8:33765107	NA	0.75	6.24	0.54	1.21e-8	Body mass index;
THYM	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg27129171	chr3:47204927	SETD2	0.71	6.76	0.57	1.1e-9	Colorectal cancer;
THYM	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg21658235	chr8:22456391	C8orf58	0.52	5.13	0.47	1.54e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg22764044	chr5:178986830	RUFY1	-0.52	-5.44	-0.49	4.16e-7	Lung cancer;
THYM	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs9543976	1.000	rs9543976	chr13:76136648	G/A	cg01531495	chr13:76123901	UCHL3	0.8	5.17	0.47	1.27e-6	Diabetic retinopathy;
THYM	cis	rs11645898	0.504	rs118034653	chr16:71922944	T/C	cg14768367	chr16:72042858	DHODH	-0.68	-4.68	-0.43	9.34e-6	Blood protein levels;
THYM	cis	rs9649213	0.593	rs2394854	chr7:98027306	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7705042	0.828	rs181826	chr5:141526057	C/A	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.98	-10.67	-0.74	6.18e-18	Menarche (age at onset);
THYM	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg05283184	chr6:79620031	NA	-0.91	-8.64	-0.66	1.36e-13	Intelligence (multi-trait analysis);
THYM	cis	rs10203711	0.933	rs10187441	chr2:239577654	C/G	cg14580085	chr2:239553406	NA	0.68	6.18	0.54	1.58e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.91	-5.98	-0.52	3.94e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg22709100	chr7:91322751	NA	-0.62	-4.77	-0.44	6.6e-6	Breast cancer;
THYM	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg02527881	chr3:46936655	PTH1R	-0.61	-5.71	-0.51	1.28e-7	Colorectal cancer;
THYM	cis	rs7580658	0.680	rs2069931	chr2:128185569	C/T	cg10021288	chr2:128175891	PROC	-0.71	-6.19	-0.54	1.5e-8	Protein C levels;
THYM	cis	rs28595532	0.920	rs115690307	chr4:119768289	C/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	8.06	0.64	2.26e-12	Lung cancer in ever smokers;
THYM	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.67	-5.18	-0.47	1.22e-6	Tonsillectomy;
THYM	cis	rs116095464	1.000	rs62331560	chr5:346785	G/C	cg00420510	chr5:1089571	SLC12A7	0.9	5.12	0.46	1.6e-6	Breast cancer;
THYM	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06481639	chr22:41940642	POLR3H	0.87	5.95	0.52	4.49e-8	Vitiligo;
THYM	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg26850624	chr5:429559	AHRR	-0.72	-5.74	-0.51	1.11e-7	Cystic fibrosis severity;
THYM	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg11764359	chr7:65958608	NA	-0.67	-4.8	-0.44	5.81e-6	Aortic root size;
THYM	cis	rs7651039	0.619	rs924814	chr3:15649550	G/A	cg16303742	chr3:15540471	COLQ	0.71	6.99	0.58	3.76e-10	Coronary heart disease;
THYM	cis	rs6430585	0.583	rs4988201	chr2:136618507	A/G	cg23851026	chr2:136556271	LCT	0.79	7.51	0.61	3.2e-11	Corneal structure;
THYM	cis	rs8067354	0.645	rs9901606	chr17:57811407	A/C	cg20151207	chr17:57696971	CLTC	-0.7	-4.67	-0.43	9.76e-6	Hemoglobin concentration;
THYM	cis	rs1950626	0.750	rs34144313	chr14:101431216	C/G	cg11887864	chr14:101510502	MIR1185-2	0.54	4.52	0.42	1.75e-5	Pelvic organ prolapse (moderate/severe);
THYM	cis	rs7695732	0.595	rs1921679	chr4:89890784	A/G	cg17769793	chr4:89976368	FAM13A	-0.49	-5.39	-0.48	5.23e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6686842	1.000	rs213747	chr1:41628738	A/G	cg03387723	chr1:41708464	SCMH1	0.42	4.96	0.45	3.1e-6	Height;
THYM	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg04756594	chr16:24857601	SLC5A11	0.76	5.51	0.49	3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs35264875	0.898	rs72928701	chr11:68861564	C/T	cg01993067	chr11:68851601	TPCN2	1.0	5.27	0.48	8.46e-7	Blond vs. brown hair color;
THYM	cis	rs8070740	0.836	rs4444392	chr17:5324588	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.74	5.93	0.52	4.84e-8	Menopause (age at onset);
THYM	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg12288994	chr5:1860383	NA	0.86	7.08	0.59	2.44e-10	Cardiovascular disease risk factors;
THYM	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.02e-12	Alcohol dependence;
THYM	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg02353165	chr6:42928485	GNMT	0.84	7.53	0.61	2.96e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg08847533	chr14:75593920	NEK9	-1.01	-11.33	-0.76	2.42e-19	Height;
THYM	cis	rs2903698	0.651	rs10518139	chr4:76417401	T/C	cg03209871	chr4:76438412	RCHY1;THAP6	0.41	4.45	0.42	2.33e-5	Prion diseases;
THYM	cis	rs11031096	0.727	rs2056853	chr11:4142172	C/T	cg18678763	chr11:4115507	RRM1	-0.38	-5.17	-0.47	1.27e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7084402	0.967	rs2114564	chr10:60314729	T/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	trans	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg10856724	chr12:34555212	NA	0.79	6.92	0.58	5.22e-10	Morning vs. evening chronotype;
THYM	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.66	-5.86	-0.52	6.54e-8	Chronic sinus infection;
THYM	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg17366294	chr4:99064904	C4orf37	0.57	6.74	0.57	1.24e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1512268	0.526	rs7005012	chr8:23487874	G/A	cg20272884	chr8:23712762	STC1	-0.47	-4.67	-0.43	9.9e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12476592	0.602	rs262478	chr2:63872386	T/C	cg17519650	chr2:63277830	OTX1	-0.67	-4.47	-0.42	2.19e-5	Childhood ear infection;
THYM	cis	rs8114671	0.836	rs6142280	chr20:33622242	A/C	cg08999081	chr20:33150536	PIGU	-0.57	-4.95	-0.45	3.25e-6	Height;
THYM	cis	rs7980799	0.682	rs10844612	chr12:33603676	T/C	cg06521331	chr12:34319734	NA	0.67	4.55	0.42	1.59e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs12549902	0.897	rs12549294	chr8:41506380	A/G	cg00448191	chr8:41504890	NKX6-3	0.3	4.53	0.42	1.71e-5	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
THYM	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg03159660	chr11:2078197	NA	-0.6	-4.48	-0.42	2.1e-5	Longevity;
THYM	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.43	-0.49	4.24e-7	Mean corpuscular volume;
THYM	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg19748678	chr4:122722346	EXOSC9	0.7	4.89	0.45	4.05e-6	Type 2 diabetes;
THYM	cis	rs12817211	0.548	rs2204684	chr12:50522472	G/T	cg06168149	chr12:50497778	GPD1	0.31	4.69	0.43	9.04e-6	Colorectal or endometrial cancer;
THYM	cis	rs2296887	0.841	rs10883717	chr10:103967590	A/G	cg26089160	chr10:104170217	PSD	-0.61	-4.64	-0.43	1.11e-5	Parkinson's disease;
THYM	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg09904177	chr6:26538194	HMGN4	0.62	4.96	0.45	3.06e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg08439880	chr3:133502540	NA	0.71	6.28	0.54	9.97e-9	Iron status biomarkers;
THYM	cis	rs7084402	0.967	rs1658427	chr10:60331504	G/A	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs478304	0.654	rs11601509	chr11:65456864	T/C	cg17480646	chr11:65405466	SIPA1	-0.97	-8.99	-0.68	2.44e-14	Acne (severe);
THYM	cis	rs4631830	0.720	rs2843560	chr10:51512129	C/G	cg16070123	chr10:51489643	NA	0.49	4.62	0.43	1.21e-5	Prostate-specific antigen levels;
THYM	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7631605	0.967	rs7639607	chr3:37269039	A/G	cg21328643	chr3:37258149	NA	-0.51	-4.88	-0.45	4.18e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.45	-7.4	-0.6	5.4e-11	Obesity-related traits;
THYM	cis	rs11722228	0.522	rs73212880	chr4:10115692	T/A	cg02317251	chr4:10116515	WDR1	-0.54	-4.72	-0.44	7.98e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs73198271	0.740	rs1039911	chr8:8648206	G/A	cg06636001	chr8:8085503	FLJ10661	-0.79	-5.53	-0.49	2.86e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg09469691	chr10:81107165	PPIF	0.71	5.54	0.49	2.72e-7	Height;
THYM	trans	rs2270927	1.000	rs2270927	chr5:75591710	C/G	cg13563193	chr19:33072644	PDCD5	1.54	8.76	0.67	7.21e-14	Mean corpuscular volume;
THYM	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg10803722	chr21:46713166	LOC642852	-0.43	-5.15	-0.47	1.39e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs28374715	0.681	rs28728213	chr15:41653602	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.19	-13.86	-0.82	1.55e-24	Ulcerative colitis;
THYM	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg05368731	chr17:41323189	NBR1	1.2	10.93	0.75	1.72e-18	Menopause (age at onset);
THYM	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg10018233	chr7:150070692	REPIN1	0.39	5.52	0.49	3e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg27534772	chr1:16042836	PLEKHM2	0.56	6.31	0.54	8.77e-9	Systolic blood pressure;
THYM	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg11764359	chr7:65958608	NA	0.81	6.42	0.55	5.45e-9	Aortic root size;
THYM	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.61e-20	Menopause (age at onset);
THYM	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg08213375	chr14:104286397	PPP1R13B	0.54	6.52	0.56	3.32e-9	Schizophrenia;
THYM	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg22117172	chr7:91764530	CYP51A1	-0.38	-4.85	-0.45	4.86e-6	Breast cancer;
THYM	cis	rs3916	0.955	rs2066938	chr12:121160615	A/G	cg10600917	chr12:121163489	ACADS	0.65	5.8	0.51	8.8e-8	Urinary metabolites (H-NMR features);
THYM	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9906944	0.545	rs2088140	chr17:47094599	T/C	cg18128536	chr17:47092178	IGF2BP1	-0.58	-8.48	-0.66	2.87e-13	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs4951018	0.526	rs4601639	chr1:205656583	A/G	cg26354017	chr1:205819088	PM20D1	-0.56	-4.55	-0.42	1.57e-5	Prostate-specific antigen levels;
THYM	cis	rs7100689	0.577	rs9285726	chr10:82035150	A/T	cg09936400	chr10:82049201	MAT1A	0.44	4.65	0.43	1.08e-5	Post bronchodilator FEV1;
THYM	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg06640241	chr16:89574553	SPG7	0.88	7.79	0.62	8.28e-12	Multiple myeloma (IgH translocation);
THYM	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg11245990	chr11:68621969	NA	0.56	7.19	0.59	1.44e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg19610905	chr11:61596333	FADS2	-0.57	-4.71	-0.44	8.45e-6	Trans fatty acid levels;
THYM	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs7107174	0.892	rs1567891	chr11:78101985	A/G	cg19901956	chr11:77921274	USP35	-0.69	-5.7	-0.5	1.35e-7	Testicular germ cell tumor;
THYM	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9876781	1.000	rs6776700	chr3:48496758	G/A	cg06066452	chr3:48470258	PLXNB1	0.27	4.71	0.44	8.4e-6	Longevity;
THYM	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12458462	0.859	rs35493271	chr18:77448793	G/T	cg11879182	chr18:77439856	CTDP1	0.81	7.86	0.63	5.87e-12	Monocyte count;
THYM	cis	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg10911889	chr6:126070802	HEY2	0.58	4.79	0.44	6.16e-6	Brugada syndrome;
THYM	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.69	0.43	9.17e-6	Bipolar disorder;
THYM	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6032067	0.759	rs2868239	chr20:43873368	T/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.36	-0.48	5.9e-7	Blood protein levels;
THYM	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg08847533	chr14:75593920	NEK9	1.0	10.82	0.74	3e-18	Height;
THYM	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg11317459	chr13:21872234	NA	1.22	9.8	0.71	4.47e-16	White matter hyperintensity burden;
THYM	cis	rs3126085	1.000	rs11485508	chr1:152253167	T/G	cg26020982	chr1:152196106	HRNR	0.35	4.95	0.45	3.26e-6	Atopic dermatitis;
THYM	cis	rs2798269	0.604	rs1200034	chr13:22165262	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.63	-4.66	-0.43	1.01e-5	PR segment;
THYM	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg18876405	chr7:65276391	NA	-0.54	-4.81	-0.44	5.73e-6	Calcium levels;
THYM	cis	rs6748734	0.625	rs6741220	chr2:241822432	C/T	cg15164180	chr2:241846931	NA	0.33	4.6	0.43	1.31e-5	Urinary metabolites;
THYM	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7818345	0.935	rs4633071	chr8:19275852	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.53	0.42	1.7e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs4363385	0.668	rs6587717	chr1:152984443	G/C	cg13444842	chr1:152974279	SPRR3	-0.58	-4.71	-0.44	8.32e-6	Inflammatory skin disease;
THYM	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13732083	chr21:47605072	C21orf56	0.68	4.82	0.44	5.46e-6	Testicular germ cell tumor;
THYM	cis	rs860818	1.000	rs6955117	chr7:23234140	G/T	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs8016982	0.674	rs1951615	chr14:81671762	G/A	cg21807262	chr14:81713016	NA	-0.57	-5.28	-0.48	8.05e-7	Schizophrenia;
THYM	cis	rs4076764	0.515	rs4657268	chr1:163376507	A/T	cg24596788	chr1:163392923	NA	-0.63	-5.52	-0.49	2.99e-7	Motion sickness;
THYM	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12310956	0.532	rs11608842	chr12:33951121	C/T	cg06521331	chr12:34319734	NA	-0.87	-8.4	-0.65	4.22e-13	Morning vs. evening chronotype;
THYM	cis	rs6430585	0.591	rs61187091	chr2:136468238	G/A	cg23851026	chr2:136556271	LCT	0.66	5.65	0.5	1.71e-7	Corneal structure;
THYM	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg05340658	chr4:99064831	C4orf37	0.59	5.01	0.46	2.53e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg03188948	chr7:1209495	NA	0.65	4.96	0.45	3.06e-6	Longevity;Endometriosis;
THYM	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	trans	rs3780486	0.522	rs10217770	chr9:33146393	C/A	cg04842962	chr6:43655489	MRPS18A	0.87	7.24	0.6	1.19e-10	IgG glycosylation;
THYM	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg11764359	chr7:65958608	NA	-0.82	-6.6	-0.56	2.29e-9	Aortic root size;
THYM	cis	rs67460515	0.563	rs4494975	chr3:160866768	C/T	cg03342759	chr3:160939853	NMD3	-0.64	-4.74	-0.44	7.54e-6	Parkinson's disease;
THYM	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg23583168	chr7:148888333	NA	-0.99	-12.57	-0.79	6.47e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs899997	0.731	rs58717592	chr15:79030417	T/C	cg04896959	chr15:78267971	NA	-1.05	-8.04	-0.64	2.5e-12	Coronary artery disease or large artery stroke;
THYM	cis	rs7189233	0.955	rs72801817	chr16:53474568	C/T	cg02965178	chr16:53538660	AKTIP	-0.57	-4.53	-0.42	1.72e-5	Intelligence (multi-trait analysis);
THYM	cis	rs738321	0.701	rs11703601	chr22:38598041	C/T	cg25457927	chr22:38595422	NA	-0.57	-5.23	-0.47	9.88e-7	Breast cancer;
THYM	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg13010199	chr12:38710504	ALG10B	-0.6	-4.46	-0.42	2.29e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs4845875	0.559	rs4846047	chr1:11843632	C/G	cg14194983	chr1:11908298	NPPA	0.54	5.05	0.46	2.11e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs12365397	0.526	rs11037263	chr11:43161203	A/C	cg03447554	chr11:43094025	NA	0.58	4.6	0.43	1.28e-5	Migraine;
THYM	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs12291225	0.535	rs16930126	chr11:14404983	C/T	cg19336497	chr11:14380999	RRAS2	0.86	11.8	0.77	2.51e-20	Sense of smell;
THYM	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.53	-5.21	-0.47	1.11e-6	Crohn's disease;
THYM	cis	rs4866334	1.000	rs79459190	chr5:18504469	T/G	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.84e-7	IgG glycosylation;
THYM	cis	rs9653442	0.622	rs11685341	chr2:100636757	A/G	cg07810366	chr2:100720526	AFF3	0.38	5.39	0.48	5.12e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs7688540	0.511	rs61794965	chr4:171669	T/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.93	5.62	0.5	1.93e-7	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg06238570	chr21:40685208	BRWD1	0.9	6.44	0.55	4.94e-9	Cognitive function;
THYM	cis	rs2066819	1.000	rs77131854	chr12:56664231	C/T	cg26714650	chr12:56694279	CS	-1.29	-6.45	-0.55	4.57e-9	Psoriasis vulgaris;
THYM	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg06221963	chr1:154839813	KCNN3	-0.74	-8.92	-0.68	3.29e-14	Prostate cancer;
THYM	cis	rs4589258	0.788	rs7935026	chr11:90466300	C/G	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.81	-0.44	5.58e-6	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.99	0.46	2.67e-6	Prudent dietary pattern;
THYM	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg27286337	chr10:134555280	INPP5A	0.92	6.73	0.57	1.25e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs12791968	0.765	rs2279359	chr11:44999605	A/G	cg11846598	chr11:44996168	LOC221122	0.83	6.29	0.54	9.61e-9	Inhibitory control;
THYM	cis	rs7191439	0.789	rs4598894	chr16:88776141	G/A	cg02389323	chr16:88786976	FAM38A	1.03	6.0	0.52	3.64e-8	Plateletcrit;
THYM	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg13902645	chr11:5959945	NA	-0.55	-5.17	-0.47	1.31e-6	DNA methylation (variation);
THYM	trans	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs1018836	0.599	rs9643295	chr8:91492283	T/G	cg16814680	chr8:91681699	NA	-0.76	-6.27	-0.54	1.06e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs10979	0.965	rs9390111	chr6:143894272	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.49	-4.47	-0.42	2.15e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg00012203	chr2:219082015	ARPC2	-0.64	-5.28	-0.48	8.18e-7	Colorectal cancer;
THYM	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg22920501	chr2:26401640	FAM59B	1.07	9.54	0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.93	8.03	0.64	2.63e-12	Cognitive ability;
THYM	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg20295408	chr7:1910781	MAD1L1	-0.73	-6.1	-0.53	2.26e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.2e-16	Bone mineral density;
THYM	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.34	0.55	7.75e-9	Total body bone mineral density;
THYM	cis	rs526231	0.511	rs1826673	chr5:102345916	G/A	cg23492399	chr5:102201601	PAM	-0.7	-5.21	-0.47	1.08e-6	Primary biliary cholangitis;
THYM	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg13319975	chr6:146136371	FBXO30	-0.66	-5.42	-0.49	4.51e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs1729951	0.575	rs361239	chr3:136701295	G/T	cg12473912	chr3:136751656	NA	0.63	5.15	0.47	1.42e-6	Neuroticism;
THYM	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg14829155	chr15:31115871	NA	-0.58	-5.13	-0.47	1.51e-6	Huntington's disease progression;
THYM	cis	rs1395	1.000	rs6717980	chr2:27452784	T/C	cg23587288	chr2:27483067	SLC30A3	-0.56	-5.03	-0.46	2.35e-6	Blood metabolite levels;
THYM	cis	rs2066819	1.000	rs111885088	chr12:56657216	A/C	cg26714650	chr12:56694279	CS	-1.29	-6.45	-0.55	4.57e-9	Psoriasis vulgaris;
THYM	trans	rs4650994	0.544	rs2811311	chr1:178617337	A/G	cg05059571	chr16:84539110	KIAA1609	0.91	9.77	0.71	5.12e-16	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs7211079	0.664	rs72850889	chr17:78114895	T/A	cg04028464	chr17:78073854	GAA;CCDC40	0.78	5.2	0.47	1.14e-6	Myocardial infarction;
THYM	cis	rs10949662	1.000	rs28716556	chr7:157535368	T/C	cg15733309	chr7:157513707	PTPRN2	0.61	6.17	0.53	1.68e-8	Intelligence (multi-trait analysis);
THYM	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg06028605	chr16:24865363	SLC5A11	0.55	5.15	0.47	1.41e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg04455712	chr21:45112962	RRP1B	0.54	5.04	0.46	2.22e-6	Mean corpuscular volume;
THYM	cis	rs289828	0.519	rs289904	chr2:152085643	C/T	cg05960677	chr2:152117363	RBM43	0.71	7.57	0.61	2.46e-11	Blood protein levels;
THYM	cis	rs2932538	0.961	rs12126494	chr1:113228623	G/A	cg22162597	chr1:113214053	CAPZA1	0.64	4.83	0.44	5.12e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs295137	0.752	rs10931892	chr2:201104997	C/T	cg03447810	chr2:200324230	SATB2	-0.65	-5.03	-0.46	2.3e-6	Asthma (bronchodilator response);
THYM	cis	rs6430585	0.527	rs2289959	chr2:136423904	C/T	cg23851026	chr2:136556271	LCT	0.63	5.92	0.52	5.12e-8	Corneal structure;
THYM	cis	rs10504073	0.647	rs9643394	chr8:50014427	A/G	cg00325661	chr8:49890786	NA	0.86	7.69	0.62	1.35e-11	Blood metabolite ratios;
THYM	cis	rs12579753	1.000	rs10862368	chr12:82244514	C/T	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.67	-0.43	1.01e-5	Resting heart rate;
THYM	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17006441	0.932	rs11919798	chr3:69903734	T/C	cg18496212	chr3:69797108	MITF	0.68	6.83	0.57	8.05e-10	Hemoglobin concentration;
THYM	cis	rs62070183	0.817	rs79640811	chr17:31221317	C/T	cg02981443	chr17:31254875	TMEM98	-0.54	-4.87	-0.45	4.46e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg15704280	chr7:45808275	SEPT13	1.01	11.13	0.75	6.46e-19	Coronary artery disease;
THYM	cis	rs2050392	0.517	rs302423	chr10:30772513	A/G	cg02070205	chr10:30722105	MAP3K8	-0.64	-5.14	-0.47	1.48e-6	Inflammatory bowel disease;
THYM	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg18105134	chr13:113819100	PROZ	-0.98	-9.05	-0.68	1.79e-14	Platelet distribution width;
THYM	cis	rs10191773	0.589	rs6761440	chr2:112959193	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.79	-4.63	-0.43	1.14e-5	Yeast infection;
THYM	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg15556689	chr8:8085844	FLJ10661	0.64	4.86	0.45	4.7e-6	Neuroticism;
THYM	cis	rs9443189	0.570	rs529383	chr6:76297847	T/G	cg01950844	chr6:76311363	SENP6	1.11	5.95	0.52	4.44e-8	Prostate cancer;
THYM	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg11764359	chr7:65958608	NA	0.85	7.0	0.58	3.62e-10	Aortic root size;
THYM	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg13289132	chr10:30722225	MAP3K8	-0.59	-5.01	-0.46	2.55e-6	Inflammatory bowel disease;
THYM	cis	rs13185784	0.667	rs4441844	chr5:179645386	C/T	cg23248424	chr5:179741104	GFPT2	-0.7	-4.57	-0.42	1.48e-5	TRAIL levels;
THYM	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11890956	chr21:40555474	PSMG1	1.07	10.21	0.72	5.92e-17	Cognitive function;
THYM	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs2455799	0.573	rs2455812	chr3:15734096	C/G	cg16303742	chr3:15540471	COLQ	-0.55	-5.76	-0.51	1.02e-7	Mean platelet volume;
THYM	cis	rs4951018	0.526	rs4601639	chr1:205656583	A/G	cg07167872	chr1:205819463	PM20D1	-0.57	-4.47	-0.42	2.12e-5	Prostate-specific antigen levels;
THYM	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.55e-12	Life satisfaction;
THYM	cis	rs3126085	1.000	rs11588170	chr1:152286032	C/T	cg10321714	chr1:152280068	FLG	-0.76	-5.68	-0.5	1.47e-7	Atopic dermatitis;
THYM	cis	rs4595586	0.525	rs35089392	chr12:39414547	T/G	cg26384229	chr12:38710491	ALG10B	0.79	5.69	0.5	1.4e-7	Morning vs. evening chronotype;
THYM	cis	rs12519773	0.526	rs4264926	chr5:92518686	C/T	cg18783429	chr5:92414398	NA	0.5	4.91	0.45	3.72e-6	Migraine;
THYM	cis	rs3924048	0.574	rs11589283	chr1:12612280	G/A	cg00291366	chr1:12616550	NA	0.4	6.33	0.54	7.89e-9	Optic cup area;
THYM	cis	rs7107174	0.892	rs2090095	chr11:78034020	G/A	cg19901956	chr11:77921274	USP35	-0.65	-5.34	-0.48	6.39e-7	Testicular germ cell tumor;
THYM	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg14004847	chr7:1930337	MAD1L1	-0.63	-4.83	-0.44	5.3e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7523273	0.597	rs4844619	chr1:207960708	C/T	cg22525895	chr1:207977042	MIR29B2	-0.76	-5.16	-0.47	1.35e-6	Schizophrenia;
THYM	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg27129171	chr3:47204927	SETD2	-0.71	-6.63	-0.56	2e-9	Colorectal cancer;
THYM	cis	rs16912285	0.892	rs80332091	chr11:24255248	T/A	ch.11.24196551F	chr11:24239977	NA	0.88	4.54	0.42	1.66e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7917772	0.582	rs10883738	chr10:104321721	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs11651000	0.654	rs12451801	chr17:45820975	T/C	cg03474202	chr17:45855739	NA	-0.76	-6.83	-0.57	8.07e-10	IgG glycosylation;
THYM	cis	rs59698941	0.882	rs68171951	chr5:132290711	T/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg09359103	chr1:154839909	KCNN3	-0.76	-9.72	-0.71	6.56e-16	Prostate cancer;
THYM	cis	rs5758511	0.680	rs17002902	chr22:42625509	C/G	cg22189786	chr22:42395067	WBP2NL	0.58	5.11	0.46	1.66e-6	Birth weight;
THYM	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg00376283	chr12:123451042	ABCB9	0.78	6.23	0.54	1.26e-8	Platelet count;
THYM	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs6032067	0.683	rs16989763	chr20:43779963	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.46	-5.66	-0.5	1.58e-7	Blood protein levels;
THYM	cis	rs7809950	0.768	rs62482493	chr7:106951579	T/C	cg23024343	chr7:107201750	COG5	-0.93	-7.08	-0.59	2.43e-10	Coronary artery disease;
THYM	cis	rs28595532	0.688	rs116566508	chr4:119619195	G/A	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs1728785	0.901	rs2862781	chr16:68639234	A/T	cg02972257	chr16:68554789	NA	-0.71	-4.59	-0.43	1.37e-5	Ulcerative colitis;
THYM	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg02725872	chr8:58115012	NA	-1.11	-6.84	-0.57	7.55e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg14456004	chr13:21872349	NA	-1.23	-10.05	-0.72	1.31e-16	White matter hyperintensity burden;
THYM	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs75064307	0.834	rs10511271	chr3:108114572	A/G	cg03329597	chr3:108125523	MYH15	-0.65	-4.64	-0.43	1.1e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg04673462	chr1:38461896	NA	-0.47	-6.11	-0.53	2.21e-8	Coronary artery disease;
THYM	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs7246967	0.673	rs16994997	chr19:22879610	T/G	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs11169225	0.906	rs3782319	chr12:50345079	G/A	cg04450003	chr12:50355995	AQP5	0.93	7.54	0.61	2.73e-11	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs7267979	1.000	rs2184000	chr20:25395878	G/A	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1061377	1.000	rs3733279	chr4:39117245	C/T	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg24060327	chr5:131705240	SLC22A5	-0.76	-5.58	-0.5	2.26e-7	Blood metabolite levels;
THYM	cis	rs87938	0.830	rs11720396	chr3:41162974	G/A	cg02247160	chr3:41243829	CTNNB1	-0.35	-4.73	-0.44	7.77e-6	Bone mineral density (hip);
THYM	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg04944784	chr2:26401820	FAM59B	-1.03	-8.17	-0.64	1.31e-12	Gut microbiome composition (summer);
THYM	cis	rs425535	0.702	rs351997	chr4:74834059	A/G	cg07868155	chr4:74864709	CXCL5	0.67	4.71	0.43	8.5e-6	Blood protein levels;
THYM	cis	rs807669	0.934	rs1780643	chr22:19191725	T/C	cg02655711	chr22:19163373	SLC25A1	0.94	10.72	0.74	4.79e-18	Metabolite levels;
THYM	trans	rs4866334	1.000	rs77743777	chr5:18488452	G/A	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs2219968	0.525	rs6999607	chr8:78874928	A/G	cg00738934	chr8:78996279	NA	0.61	4.93	0.45	3.5e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4986172	0.690	rs11657325	chr17:43242694	C/T	cg00677574	chr17:43221327	ACBD4	0.78	6.91	0.58	5.61e-10	Height;
THYM	cis	rs28595532	0.920	rs114262028	chr4:119734877	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg03909863	chr11:638404	DRD4	-0.78	-5.75	-0.51	1.07e-7	Systemic lupus erythematosus;
THYM	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4148689	1.000	rs6951141	chr7:117154998	A/C	cg17204129	chr7:117119601	CFTR	-0.64	-4.95	-0.45	3.18e-6	Gout;
THYM	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg14074117	chr16:1909714	C16orf73	-0.78	-4.97	-0.45	3.01e-6	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg15247329	chr7:2764246	NA	-0.67	-5.55	-0.5	2.53e-7	Height;
THYM	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg09033563	chr22:24373618	LOC391322	0.62	4.79	0.44	6.12e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs12348691	0.503	rs7849497	chr9:100615660	G/C	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Alopecia areata;
THYM	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg00999904	chr2:3704751	ALLC	-0.71	-4.85	-0.45	4.75e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs3741151	0.773	rs17244596	chr11:73179236	A/G	cg12959048	chr11:73096162	RELT	-0.53	-5.08	-0.46	1.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-5.05	-0.46	2.12e-6	Lymphocyte counts;
THYM	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs1451375	0.729	rs6593017	chr7:50644812	G/A	cg18232548	chr7:50535776	DDC	0.69	5.35	0.48	6.03e-7	Malaria;
THYM	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg21926883	chr2:100939477	LONRF2	-0.66	-6.17	-0.54	1.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9644630	0.696	rs35736969	chr8:19319620	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.69	7.68	0.62	1.43e-11	Oropharynx cancer;
THYM	cis	rs9807841	0.568	rs1560708	chr19:10749236	T/C	cg17848348	chr19:10766748	ILF3	-0.77	-6.35	-0.55	7.2e-9	Inflammatory skin disease;
THYM	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg08901578	chr4:187885870	NA	-0.63	-5.79	-0.51	8.9e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9788721	0.614	rs951984	chr15:78720915	T/A	cg18825076	chr15:78729989	IREB2	-0.6	-5.12	-0.47	1.57e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs6840360	0.615	rs9884167	chr4:152470799	A/G	cg22705602	chr4:152727874	NA	-0.71	-7.94	-0.63	4.03e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	5.64	0.5	1.73e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2976388	0.609	rs2244152	chr8:143784885	C/A	cg06565975	chr8:143823917	SLURP1	0.47	5.22	0.47	1.06e-6	Urinary tract infection frequency;
THYM	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg20295408	chr7:1910781	MAD1L1	-0.64	-4.88	-0.45	4.24e-6	Schizophrenia;
THYM	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	5.44	0.49	4.21e-7	Obesity-related traits;
THYM	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg00475322	chr7:917719	C7orf20	0.59	7.86	0.63	5.97e-12	Perceived unattractiveness to mosquitoes;
THYM	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.21	0.47	1.1e-6	Electroencephalogram traits;
THYM	cis	rs79815064	0.850	rs79539493	chr3:46302938	G/A	cg20674725	chr3:47020919	NBEAL2	0.71	4.7	0.43	8.76e-6	Macrophage inflammatory protein 1b levels;
THYM	cis	rs7586879	0.639	rs2033656	chr2:25100902	C/G	cg27107076	chr2:25050844	ADCY3	-0.3	-4.8	-0.44	5.79e-6	Body mass index;
THYM	cis	rs9314614	0.714	rs2980948	chr8:6713695	A/G	cg27319216	chr8:6693540	XKR5	0.57	5.78	0.51	9.56e-8	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs308403	0.509	rs7690133	chr4:123673809	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.99	8.38	0.65	4.64e-13	Blood protein levels;
THYM	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.8	6.76	0.57	1.09e-9	Lymphocyte percentage of white cells;
THYM	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg05738196	chr6:26577821	NA	0.83	8.34	0.65	5.8e-13	Intelligence (multi-trait analysis);
THYM	cis	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg05335186	chr13:53173507	NA	-0.52	-6.57	-0.56	2.69e-9	Lewy body disease;
THYM	cis	rs262147	0.610	rs2657363	chr7:158684273	C/T	cg11984989	chr7:158649758	WDR60	1.35	7.21	0.59	1.35e-10	Hippocampal volume;
THYM	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg00786635	chr1:25594202	NA	0.88	6.85	0.58	7.14e-10	Erythrocyte sedimentation rate;
THYM	cis	rs1065852	0.526	rs2097561	chr22:42389431	T/C	cg09667013	chr22:42394590	WBP2NL	0.54	4.8	0.44	5.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs2688608	0.620	rs11000767	chr10:75516626	G/T	cg15838173	chr10:75533400	FUT11	-0.59	-5.99	-0.52	3.78e-8	Inflammatory bowel disease;
THYM	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg03806693	chr22:41940476	POLR3H	-0.81	-6.8	-0.57	9.18e-10	Neuroticism;
THYM	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	7.1	0.59	2.3e-10	Platelet count;
THYM	cis	rs6980334	0.817	rs10263205	chr7:137792922	C/T	cg11874123	chr7:137028198	PTN	0.67	5.17	0.47	1.29e-6	Blood metabolite ratios;
THYM	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg08132940	chr7:1081526	C7orf50	-1.16	-6.65	-0.56	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8073060	0.785	rs11659054	chr17:33867678	C/T	cg07895132	chr17:33825172	SLFN12L	0.63	5.78	0.51	9.52e-8	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg01570182	chr17:44337453	NA	0.91	9.94	0.71	2.22e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4919694	1.000	rs4917988	chr10:104752830	T/G	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs490234	0.702	rs35237975	chr9:128313867	A/G	cg14078157	chr9:128172775	NA	-0.77	-6.1	-0.53	2.27e-8	Mean arterial pressure;
THYM	cis	rs28595532	0.920	rs115982145	chr4:119605707	A/G	cg21605333	chr4:119757512	SEC24D	1.42	4.79	0.44	6.16e-6	Cannabis dependence symptom count;
THYM	cis	rs9470366	0.509	rs4713996	chr6:36629714	C/T	cg24425727	chr6:36645648	CDKN1A	0.7	6.63	0.56	2.07e-9	QRS duration;
THYM	cis	rs3862030	0.720	rs2025713	chr10:104230156	A/G	cg00122347	chr10:104236741	TMEM180	0.48	7.03	0.59	3.09e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs7172809	0.615	rs907371	chr15:77844375	C/T	cg22256960	chr15:77711686	NA	0.69	5.07	0.46	1.97e-6	Glucose homeostasis traits;
THYM	cis	rs9807841	0.643	rs3843751	chr19:10748121	C/T	cg17848348	chr19:10766748	ILF3	-0.86	-7.69	-0.62	1.34e-11	Inflammatory skin disease;
THYM	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs3924048	0.574	rs10864561	chr1:12611466	T/A	cg00291366	chr1:12616550	NA	0.4	6.33	0.54	7.89e-9	Optic cup area;
THYM	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg12564285	chr5:131593104	PDLIM4	0.52	5.86	0.52	6.7e-8	Blood metabolite levels;
THYM	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg13395646	chr4:1353034	KIAA1530	-0.46	-4.47	-0.42	2.19e-5	Obesity-related traits;
THYM	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg11812906	chr14:75593930	NEK9	0.89	8.2	0.64	1.11e-12	Height;
THYM	cis	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg00495681	chr13:53174319	NA	0.63	5.75	0.51	1.07e-7	Lewy body disease;
THYM	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg05283184	chr6:79620031	NA	-0.9	-9.11	-0.68	1.3e-14	Intelligence (multi-trait analysis);
THYM	cis	rs8031584	1.000	rs11638409	chr15:31288190	A/C	cg14829155	chr15:31115871	NA	-0.58	-5.26	-0.47	9.04e-7	Huntington's disease progression;
THYM	cis	rs5769707	0.521	rs74351010	chr22:50036820	G/A	cg20744362	chr22:50050164	C22orf34	-0.9	-6.42	-0.55	5.34e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs3741151	0.773	rs73542990	chr11:73134398	C/T	cg17517138	chr11:73019481	ARHGEF17	0.94	5.48	0.49	3.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Body mass index;
THYM	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12756686	chr19:29218302	NA	0.98	8.72	0.67	9.12e-14	Methadone dose in opioid dependence;
THYM	trans	rs8073060	0.614	rs72829932	chr17:34055935	A/G	cg19694781	chr19:47549865	TMEM160	1.01	8.48	0.66	2.84e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7940866	0.801	rs2113928	chr11:130835975	A/G	cg05962950	chr11:130786565	SNX19	0.72	5.45	0.49	3.93e-7	Schizophrenia;
THYM	cis	rs6840360	0.582	rs59714108	chr4:152325939	G/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-5.45	-0.49	4.02e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg25036284	chr2:26402008	FAM59B	-0.78	-5.25	-0.47	9.14e-7	Gut microbiome composition (summer);
THYM	cis	rs2811415	0.597	rs11708842	chr3:127790625	T/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg00631329	chr6:26305371	NA	-0.6	-7.45	-0.61	4.22e-11	Educational attainment;
THYM	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg08017756	chr2:100939284	LONRF2	-0.69	-7.09	-0.59	2.35e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7178572	1.000	rs62007299	chr15:77711719	G/A	cg22256960	chr15:77711686	NA	-0.94	-7.93	-0.63	4.23e-12	Type 2 diabetes;
THYM	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg07424592	chr7:64974309	NA	1.1	5.08	0.46	1.87e-6	Diabetic kidney disease;
THYM	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg26446133	chr18:72167187	CNDP2	-1.0	-7.99	-0.63	3.12e-12	Refractive error;
THYM	cis	rs7586879	0.598	rs6724772	chr2:25128730	T/C	cg15423357	chr2:25149977	NA	0.7	7.76	0.62	9.56e-12	Body mass index;
THYM	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg06238570	chr21:40685208	BRWD1	-0.9	-6.54	-0.56	3.06e-9	Cognitive function;
THYM	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06873352	chr17:61820015	STRADA	-0.78	-9.49	-0.7	2.01e-15	Prudent dietary pattern;
THYM	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg18132916	chr6:79620363	NA	-0.55	-4.84	-0.44	4.98e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10979	0.965	rs9403508	chr6:143887857	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs394563	0.602	rs409111	chr6:149766860	A/G	cg26849637	chr6:150530249	PPP1R14C	-0.41	-4.51	-0.42	1.86e-5	Dupuytren's disease;
THYM	trans	rs34156428	0.858	rs73433598	chr11:16507562	A/C	cg02688867	chr12:133019854	NA	0.54	6.89	0.58	6.12e-10	Coronary artery disease;
THYM	cis	rs34638657	0.827	rs6564996	chr16:82207542	T/C	cg09439754	chr16:82129088	HSD17B2	-0.62	-5.38	-0.48	5.38e-7	Lung adenocarcinoma;
THYM	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg10911889	chr6:126070802	HEY2	0.59	4.67	0.43	9.89e-6	Brugada syndrome;
THYM	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	trans	rs11098499	0.821	rs56155624	chr4:120291026	C/G	cg25214090	chr10:38739885	LOC399744	0.85	7.28	0.6	9.67e-11	Corneal astigmatism;
THYM	cis	rs116139393	0.571	rs3801035	chr7:6735534	C/T	cg03005310	chr7:6897353	NA	-0.63	-4.58	-0.43	1.39e-5	Alzheimer's disease (APOE e4 interaction);
THYM	cis	rs7692976	0.503	rs11569100	chr4:110921374	T/C	cg06981781	chr4:110842888	EGF	-0.39	-4.74	-0.44	7.37e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg00129232	chr17:37814104	STARD3	-0.83	-5.97	-0.52	4.17e-8	Asthma;
THYM	cis	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg24678163	chr13:52769951	THSD1P	0.49	4.58	0.43	1.38e-5	Lewy body disease;
THYM	cis	rs665401	0.965	rs339334	chr6:117212689	A/G	cg20376953	chr6:117187980	NA	0.6	4.82	0.44	5.5e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg09455208	chr3:40491958	NA	0.46	4.92	0.45	3.65e-6	Renal cell carcinoma;
THYM	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-5.81	-0.51	8.27e-8	Total cholesterol levels;
THYM	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg08975724	chr8:8085496	FLJ10661	0.6	5.11	0.46	1.67e-6	Mood instability;
THYM	cis	rs7179456	0.593	rs514049	chr15:59042363	A/C	cg05156742	chr15:59063176	FAM63B	-0.6	-5.32	-0.48	6.83e-7	Asperger disorder;
THYM	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13012494	chr21:47604986	C21orf56	0.86	5.64	0.5	1.78e-7	Testicular germ cell tumor;
THYM	cis	rs2072732	0.808	rs55784203	chr1:2936754	G/T	cg08733933	chr1:2954429	NA	-0.61	-4.64	-0.43	1.13e-5	Plateletcrit;
THYM	cis	rs10193935	1.000	rs13391906	chr2:42538617	C/G	cg27598129	chr2:42591480	NA	-0.75	-4.61	-0.43	1.25e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2041895	0.509	rs1035236	chr12:107310797	C/T	cg13944111	chr12:107296891	NA	0.63	5.02	0.46	2.42e-6	Glaucoma (low intraocular pressure);
THYM	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg18402987	chr7:1209562	NA	1.16	7.29	0.6	9.12e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg10360139	chr7:1886902	MAD1L1	-0.59	-4.76	-0.44	6.82e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12282928	1.000	rs10769338	chr11:48294256	A/G	cg22827986	chr11:48284249	OR4X1	-0.51	-5.43	-0.49	4.28e-7	Migraine - clinic-based;
THYM	cis	rs7943358	0.910	rs12576344	chr11:15712323	A/G	cg11966998	chr11:15692519	NA	-0.48	-4.6	-0.43	1.3e-5	Gut microbiome composition (summer);
THYM	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.72	6.31	0.54	8.93e-9	Calcium levels;
THYM	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg10523679	chr1:76189770	ACADM	0.91	9.7	0.71	7.37e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg03188948	chr7:1209495	NA	0.9	5.02	0.46	2.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg11965913	chr1:205819406	PM20D1	0.95	10.53	0.73	1.25e-17	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1371867	0.846	rs1660317	chr8:101333252	G/T	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.14	-0.47	1.49e-6	Total cholesterol levels;
THYM	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	6.46	0.55	4.49e-9	Obesity-related traits;
THYM	cis	rs490234	0.841	rs2793135	chr9:128338620	A/G	cg14078157	chr9:128172775	NA	0.64	5.3	0.48	7.53e-7	Mean arterial pressure;
THYM	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.89	0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg22920501	chr2:26401640	FAM59B	-0.68	-5.72	-0.51	1.24e-7	Gut microbiome composition (summer);
THYM	cis	rs6430585	0.583	rs60253740	chr2:136571852	G/T	cg07169764	chr2:136633963	MCM6	1.18	13.45	0.81	1.03e-23	Corneal structure;
THYM	cis	rs4974559	0.790	rs5019560	chr4:1324793	G/A	cg16185996	chr4:1008614	FGFRL1	-0.42	-4.5	-0.42	1.93e-5	Systolic blood pressure;
THYM	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg22117172	chr7:91764530	CYP51A1	0.38	4.67	0.43	9.95e-6	Breast cancer;
THYM	cis	rs10463554	0.927	rs34820	chr5:102436868	A/G	cg23492399	chr5:102201601	PAM	-0.67	-5.06	-0.46	2e-6	Parkinson's disease;
THYM	cis	rs7746082	0.563	rs73516754	chr6:106459738	A/C	cg02270332	chr6:106475062	NA	-0.58	-5.54	-0.49	2.64e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg14690197	chr8:22456421	C8orf58	0.46	4.56	0.42	1.5e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7635838	0.684	rs2594966	chr3:11325276	A/G	cg00170343	chr3:11313890	ATG7	-0.57	-4.55	-0.42	1.6e-5	HDL cholesterol;
THYM	cis	rs2803122	0.871	rs10481512	chr9:19230739	C/T	cg19584733	chr9:19298547	DENND4C	-0.54	-4.74	-0.44	7.59e-6	Pulse pressure;
THYM	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg07362569	chr17:61921086	SMARCD2	0.72	6.37	0.55	6.65e-9	Prudent dietary pattern;
THYM	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg04842962	chr6:43655489	MRPS18A	1.41	15.7	0.85	3.85e-28	IgG glycosylation;
THYM	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg25703541	chr22:24373054	LOC391322	-0.86	-9.39	-0.69	3.35e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2033562	0.965	rs10096810	chr8:103545436	C/T	cg20611272	chr8:103548145	NA	0.4	4.99	0.46	2.77e-6	IgA nephropathy;
THYM	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.0	0.63	2.98e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3820068	0.608	rs12734937	chr1:16047726	T/C	cg05660106	chr1:15850417	CASP9	0.72	5.59	0.5	2.2e-7	Systolic blood pressure;
THYM	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg10560079	chr2:191398806	TMEM194B	-0.93	-6.73	-0.57	1.29e-9	Diastolic blood pressure;
THYM	cis	rs77372450	0.551	rs77213903	chr5:157106186	C/G	cg00312553	chr5:157098553	C5orf52	-0.65	-4.66	-0.43	1.03e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg24324837	chr19:49891574	CCDC155	0.67	6.5	0.55	3.72e-9	Multiple sclerosis;
THYM	cis	rs988913	1.000	rs7744592	chr6:54826345	A/G	cg04690482	chr6:54711388	FAM83B	0.46	5.17	0.47	1.31e-6	Menarche (age at onset);
THYM	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg13319975	chr6:146136371	FBXO30	-0.66	-5.29	-0.48	7.89e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg08213375	chr14:104286397	PPP1R13B	0.56	6.87	0.58	6.77e-10	Schizophrenia;
THYM	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.43	-0.49	4.36e-7	Menopause (age at onset);
THYM	cis	rs17376456	0.569	rs7732578	chr5:93410244	C/T	cg25358565	chr5:93447407	FAM172A	-0.8	-5.87	-0.52	6.32e-8	Diabetic retinopathy;
THYM	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.63	-0.66	1.37e-13	Mean corpuscular volume;
THYM	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg15242686	chr22:24348715	GSTTP1	0.67	6.72	0.57	1.35e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg00071950	chr4:10020882	SLC2A9	-0.6	-5.16	-0.47	1.34e-6	Bone mineral density;
THYM	cis	rs4072705	1.000	rs4838207	chr9:127519134	G/A	cg13476313	chr9:127244764	NR5A1	0.35	5.38	0.48	5.26e-7	Menarche (age at onset);
THYM	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg22947322	chr17:47091978	IGF2BP1	-0.61	-6.8	-0.57	9.41e-10	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08109568	chr15:31115862	NA	0.74	7.23	0.6	1.21e-10	Huntington's disease progression;
THYM	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.75	-7.53	-0.61	2.88e-11	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg08772003	chr10:104629869	AS3MT	-0.62	-5.45	-0.49	3.88e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9768139	0.654	rs61474285	chr7:158121276	C/T	cg25566285	chr7:158114605	PTPRN2	0.88	10.07	0.72	1.2e-16	Calcium levels;
THYM	cis	rs7975161	0.535	rs6539138	chr12:104735928	G/A	cg25273343	chr12:104657179	TXNRD1	-0.69	-4.7	-0.43	8.65e-6	Toenail selenium levels;
THYM	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.69	-4.62	-0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs3135718	0.967	rs2936870	chr10:123348902	T/C	cg15049101	chr10:123353889	FGFR2	-0.59	-5.21	-0.47	1.08e-6	Estrogen receptor status in breast cancer;
THYM	cis	rs11711311	0.736	rs13320940	chr3:113400954	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.06	-0.46	2.07e-6	IgG glycosylation;
THYM	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg12386194	chr3:101231763	SENP7	0.71	5.39	0.48	5.17e-7	Colorectal cancer;
THYM	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg08132940	chr7:1081526	C7orf50	-0.77	-5.21	-0.47	1.1e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.71	6.54	0.56	3.07e-9	Personality dimensions;
THYM	cis	rs12681287	0.640	rs12679811	chr8:87465370	T/C	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg20503657	chr10:835505	NA	1.01	5.73	0.51	1.17e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg08132940	chr7:1081526	C7orf50	-1.15	-6.58	-0.56	2.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg15693483	chr7:1102177	C7orf50	0.41	5.93	0.52	4.81e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg24675658	chr1:53192096	ZYG11B	0.83	6.34	0.55	7.62e-9	Monocyte count;
THYM	cis	rs3755605	0.864	rs6789982	chr3:169777563	T/C	cg18444028	chr3:169782040	GPR160	0.58	4.55	0.42	1.56e-5	Testicular germ cell tumor;
THYM	cis	rs12935418	0.672	rs9921914	chr16:81056111	C/A	cg16651780	chr16:81037892	C16orf61	0.78	5.68	0.5	1.46e-7	Mean corpuscular volume;
THYM	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs28595532	1.000	rs115915387	chr4:119640854	C/T	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs7089973	0.872	rs34064819	chr10:116621154	C/A	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.14	-0.47	1.5e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs2227631	1.000	rs2227631	chr7:100769538	A/G	cg08053846	chr7:100769605	SERPINE1	-0.5	-4.95	-0.45	3.25e-6	Plasminogen activator inhibitor type 1 levels (PAI-1);
THYM	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg06064525	chr11:970664	AP2A2	-0.35	-6.59	-0.56	2.45e-9	Alzheimer's disease (late onset);
THYM	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg18252515	chr7:66147081	NA	0.62	4.63	0.43	1.18e-5	Aortic root size;
THYM	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.25	-5.04	-0.46	2.25e-6	Obesity-related traits;
THYM	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg00684032	chr4:1343700	KIAA1530	0.78	6.72	0.57	1.36e-9	Obesity-related traits;
THYM	cis	rs7084402	0.817	rs7099496	chr10:60265242	G/A	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs11030122	0.702	rs10835340	chr11:3960420	A/G	cg22027985	chr11:4115532	RRM1	0.48	4.59	0.43	1.36e-5	Mean platelet volume;Platelet distribution width;
THYM	cis	rs36051895	0.589	rs10122037	chr9:5192874	A/G	cg02405213	chr9:5042618	JAK2	0.92	10.17	0.72	7.27e-17	Pediatric autoimmune diseases;
THYM	cis	rs1389724	0.648	rs1160413	chr1:111315694	C/T	cg25283465	chr1:111323341	NA	-0.58	-4.58	-0.43	1.4e-5	Schizophrenia;
THYM	cis	rs7917772	0.545	rs10786681	chr10:104317357	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	trans	rs10462794	0.789	rs7719895	chr5:4490338	C/T	cg27196691	chr11:105947405	KBTBD3;AASDHPPT	-1.2	-6.91	-0.58	5.55e-10	DNA methylation (variation);
THYM	cis	rs2033711	0.783	rs11671113	chr19:58958087	C/T	cg13877915	chr19:58951672	ZNF132	0.91	8.64	0.66	1.34e-13	Uric acid clearance;
THYM	cis	rs6500395	1.000	rs4493038	chr16:48683920	A/G	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg22875332	chr1:76189707	ACADM	-0.74	-6.34	-0.55	7.84e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9359856	0.564	rs72913954	chr6:90361589	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.91	-8.21	-0.64	1.08e-12	Bipolar disorder;
THYM	cis	rs12935418	0.552	rs2123626	chr16:81021810	T/C	cg16651780	chr16:81037892	C16orf61	-0.82	-6.16	-0.53	1.72e-8	Mean corpuscular volume;
THYM	cis	rs16917546	0.933	rs10995238	chr10:64387108	A/G	cg03961010	chr10:64397487	ZNF365	0.79	6.49	0.55	3.84e-9	Basal cell carcinoma;
THYM	cis	rs3760982	0.813	rs8104447	chr19:44293278	T/C	cg11993925	chr19:44307056	LYPD5	-0.56	-4.46	-0.42	2.26e-5	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.55	-7.06	-0.59	2.68e-10	Monocyte percentage of white cells;
THYM	cis	rs4824093	0.610	rs3761496	chr22:50246466	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.04	-4.72	-0.44	8.11e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg09034736	chr1:150693464	HORMAD1	0.51	4.49	0.42	1.98e-5	Tonsillectomy;
THYM	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg09990169	chr2:241835740	C2orf54	-0.37	-6.3	-0.54	9.4e-9	Urinary metabolites;
THYM	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg17747265	chr1:1875780	NA	-0.8	-9.17	-0.69	9.98e-15	Body mass index;
THYM	cis	rs7829975	0.632	rs28663303	chr8:8556278	T/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.04	-0.46	2.22e-6	Mood instability;
THYM	cis	rs2039659	0.719	rs1538049	chr13:86276135	A/G	cg25308322	chr13:86268291	NA	0.67	6.04	0.53	2.93e-8	Blood osmolality (transformed sodium);
THYM	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs74705753	0.618	rs78404259	chr22:41970104	G/A	cg03806693	chr22:41940476	POLR3H	-1.19	-4.96	-0.45	3.1e-6	Intelligence (multi-trait analysis);
THYM	cis	rs78456975	1.000	rs13431491	chr2:1553808	T/A	cg12573674	chr2:1569213	NA	-1.22	-4.82	-0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs2732480	0.577	rs2732481	chr12:48736985	T/G	cg21466736	chr12:48725269	NA	-0.6	-5.36	-0.48	5.86e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg03388043	chr17:80084554	CCDC57	0.65	5.41	0.49	4.76e-7	Life satisfaction;
THYM	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg24818145	chr4:99064322	C4orf37	0.69	5.37	0.48	5.67e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg12560992	chr17:57184187	TRIM37	-0.91	-8.51	-0.66	2.54e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg12963246	chr6:28129442	ZNF389	0.77	6.4	0.55	5.74e-9	Parkinson's disease;
THYM	cis	rs11608355	0.846	rs4766598	chr12:109853306	A/G	cg10504392	chr12:110044639	NA	0.6	5.08	0.46	1.89e-6	Neuroticism;
THYM	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg07936489	chr17:37558343	FBXL20	0.79	5.7	0.5	1.37e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg05373962	chr22:49881684	NA	-0.67	-6.83	-0.57	7.99e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4940575	0.679	rs7230053	chr18:60836185	T/A	cg24349668	chr18:61441546	SERPINB7	0.75	4.63	0.43	1.15e-5	Breast cancer;
THYM	cis	rs61931739	0.591	rs10743834	chr12:33916129	A/C	cg06521331	chr12:34319734	NA	-0.57	-4.76	-0.44	7e-6	Morning vs. evening chronotype;
THYM	cis	rs7769051	0.803	rs12193474	chr6:133186168	T/C	cg22852734	chr6:133119734	C6orf192	1.12	5.75	0.51	1.07e-7	Type 2 diabetes nephropathy;
THYM	cis	rs4589258	0.933	rs7947602	chr11:90406594	T/A	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs75059851	0.778	rs73034263	chr11:133808038	C/G	cg14047540	chr11:133829660	NA	-1.16	-7.83	-0.63	7.01e-12	Schizophrenia;
THYM	cis	rs6430585	0.528	rs3098102	chr2:136654833	C/T	cg20242066	chr2:136595261	LCT	0.53	5.59	0.5	2.18e-7	Corneal structure;
THYM	cis	rs13256369	0.708	rs9644772	chr8:8557685	G/A	cg00074818	chr8:8560427	CLDN23	0.6	5.58	0.5	2.22e-7	Obesity-related traits;
THYM	cis	rs17433710	0.500	rs10917583	chr1:162630894	C/T	cg19264028	chr1:162630153	DDR2	-0.77	-4.46	-0.42	2.28e-5	Dupuytren's disease;
THYM	cis	rs1847202	0.859	rs4274693	chr3:72949375	A/G	cg25664220	chr3:72788482	NA	-0.67	-5.05	-0.46	2.14e-6	Motion sickness;
THYM	cis	rs9810089	0.814	rs866758	chr3:136117870	G/C	cg12473912	chr3:136751656	NA	0.62	5.29	0.48	7.77e-7	Gestational age at birth (child effect);
THYM	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg23583168	chr7:148888333	NA	-1.01	-13.08	-0.8	5.64e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg10295955	chr4:187884368	NA	1.18	16.71	0.86	5.01e-30	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg10856724	chr12:34555212	NA	-0.9	-8.08	-0.64	2.05e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7107174	0.892	rs4945273	chr11:78096977	T/C	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	trans	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs6450176	0.538	rs12186486	chr5:53306549	T/A	ch.5.1024479R	chr5:53302184	ARL15	-1.2	-10.47	-0.73	1.66e-17	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg13010199	chr12:38710504	ALG10B	0.72	5.76	0.51	1.05e-7	Heart rate;
THYM	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.27	10.84	0.74	2.66e-18	Platelet count;
THYM	cis	rs9303280	0.901	rs9303277	chr17:37976469	C/T	cg24910161	chr17:38119198	GSDMA	0.46	4.8	0.44	5.97e-6	Self-reported allergy;
THYM	cis	rs1322639	0.614	rs6937001	chr6:169565086	C/T	cg04662567	chr6:169592167	NA	0.77	6.08	0.53	2.49e-8	Pulse pressure;
THYM	cis	rs986417	0.688	rs965454	chr14:60960251	T/C	cg27398547	chr14:60952738	C14orf39	1.16	6.51	0.56	3.6e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs919433	0.617	rs13018267	chr2:198545592	G/C	cg05783139	chr2:198650985	BOLL	-0.59	-4.56	-0.42	1.52e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs56104184	0.830	rs73061614	chr19:49343289	T/C	cg16594139	chr19:49340574	PLEKHA4;HSD17B14	1.0	6.02	0.53	3.26e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg24692254	chr21:30365293	RNF160	-0.79	-4.48	-0.42	2.07e-5	Cognitive test performance;
THYM	cis	rs7226229	1.000	rs996065	chr17:20936403	T/C	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs2836633	0.965	rs2836615	chr21:40048039	C/T	cg05519781	chr21:40033154	ERG	0.72	6.84	0.57	7.74e-10	Coronary artery disease;
THYM	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg24324837	chr19:49891574	CCDC155	0.66	6.33	0.54	8.23e-9	Multiple sclerosis;
THYM	cis	rs2859741	0.967	rs494157	chr1:37512995	C/T	cg09363841	chr1:37513479	NA	0.86	9.2	0.69	8.53e-15	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs6840360	0.571	rs4696272	chr4:152528229	A/G	cg17479576	chr4:152424074	FAM160A1	-0.78	-5.74	-0.51	1.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs240764	0.717	rs1039032	chr6:101161931	T/C	cg21058520	chr6:100914733	NA	0.59	5.07	0.46	1.99e-6	Neuroticism;
THYM	cis	rs79565040	1	rs79565040	chr1:8917398	T/TTA	cg19371916	chr1:8874984	RERE	-0.53	-4.96	-0.45	3.13e-6	White blood cell count (basophil);
THYM	cis	rs1395	0.778	rs1439768	chr2:27389660	C/A	cg22903471	chr2:27725779	GCKR	-0.63	-4.63	-0.43	1.17e-5	Blood metabolite levels;
THYM	cis	rs7712401	0.569	rs7709836	chr5:122352833	T/C	cg19808643	chr5:122110361	SNX2	-0.62	-5.33	-0.48	6.58e-7	Mean platelet volume;
THYM	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	5.2	0.47	1.13e-6	Platelet count;
THYM	cis	rs6840360	1.000	rs6841783	chr4:152598876	C/G	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.92	-6.03	-0.53	3.11e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs977987	0.751	rs56004344	chr16:75474189	T/C	cg03315344	chr16:75512273	CHST6	0.74	5.92	0.52	5.07e-8	Dupuytren's disease;
THYM	cis	rs6163	0.508	rs12776506	chr10:104532828	A/G	cg05855489	chr10:104503620	C10orf26	0.73	5.72	0.51	1.23e-7	Waist circumference;Hip circumference;
THYM	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg08975724	chr8:8085496	FLJ10661	-0.67	-5.16	-0.47	1.35e-6	Mood instability;
THYM	cis	rs9790314	1.000	rs336590	chr3:161079583	G/A	cg03342759	chr3:160939853	NMD3	-0.75	-6.76	-0.57	1.14e-9	Morning vs. evening chronotype;
THYM	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg22709100	chr7:91322751	NA	0.71	5.58	0.5	2.22e-7	Breast cancer;
THYM	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18402987	chr7:1209562	NA	0.75	5.49	0.49	3.29e-7	Longevity;Endometriosis;
THYM	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg04267008	chr7:1944627	MAD1L1	-0.67	-6.12	-0.53	2.07e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs2039659	0.679	rs1415396	chr13:86278044	C/T	cg25308322	chr13:86268291	NA	0.67	6.04	0.53	2.93e-8	Blood osmolality (transformed sodium);
THYM	cis	rs6032067	0.586	rs13044116	chr20:43754444	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.41	-0.49	4.61e-7	Blood protein levels;
THYM	cis	rs9902453	0.845	rs2617865	chr17:28049804	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-4.85	-0.45	4.84e-6	Coffee consumption (cups per day);
THYM	cis	rs807669	1.000	rs807670	chr22:19154608	A/C	cg02655711	chr22:19163373	SLC25A1	0.69	8.11	0.64	1.76e-12	Metabolite levels;
THYM	cis	rs1878931	0.554	rs3207360	chr16:3498115	G/T	cg04185382	chr16:4424441	VASN;CORO7	-0.29	-4.45	-0.42	2.31e-5	Body mass index (adult);
THYM	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg20203395	chr5:56204925	C5orf35	-0.67	-4.58	-0.42	1.44e-5	Initial pursuit acceleration;
THYM	cis	rs11792861	0.591	rs7027874	chr9:111717112	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.83	7.14	0.59	1.83e-10	Menarche (age at onset);
THYM	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg03806693	chr22:41940476	POLR3H	-1.11	-9.95	-0.71	2.12e-16	Vitiligo;
THYM	cis	rs988913	0.957	rs932452	chr6:54801928	C/T	cg04690482	chr6:54711388	FAM83B	0.49	5.18	0.47	1.22e-6	Menarche (age at onset);
THYM	cis	rs981844	1.000	rs2606341	chr4:154658702	T/C	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	11.87	0.77	1.82e-20	Chronic sinus infection;
THYM	cis	rs10493773	0.775	rs12756013	chr1:86153532	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.48	-6.24	-0.54	1.19e-8	Urate levels in overweight individuals;
THYM	cis	rs3820068	0.581	rs6429762	chr1:15945595	A/C	cg24675056	chr1:15929824	NA	0.76	6.26	0.54	1.13e-8	Systolic blood pressure;
THYM	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03264133	chr6:25882463	NA	-0.76	-5.83	-0.51	7.72e-8	Blood metabolite levels;
THYM	cis	rs4417704	0.551	rs12479396	chr2:241889171	G/A	cg15164180	chr2:241846931	NA	-0.36	-4.65	-0.43	1.08e-5	Joint mobility (Beighton score);
THYM	cis	rs7940866	0.903	rs2324316	chr11:130872353	G/T	cg05962950	chr11:130786565	SNX19	0.68	5.4	0.48	4.84e-7	Schizophrenia;
THYM	cis	rs6032067	0.852	rs2233882	chr20:43835683	T/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.34	-0.65	5.7e-13	Blood protein levels;
THYM	cis	rs7246657	0.943	rs28402338	chr19:37833923	G/A	cg22634378	chr19:37742834	NA	0.68	5.67	0.5	1.55e-7	Coronary artery calcification;
THYM	cis	rs9595908	0.931	rs55645971	chr13:33189589	C/G	cg12383807	chr13:33924137	NA	-0.53	-4.68	-0.43	9.69e-6	Body mass index;
THYM	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg27572855	chr1:25598939	RHD	0.64	5.01	0.46	2.49e-6	Erythrocyte sedimentation rate;
THYM	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4866334	1.000	rs76258230	chr5:18433807	G/C	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg22325292	chr17:80708367	FN3K	0.63	4.56	0.42	1.54e-5	Glycated hemoglobin levels;
THYM	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg21984481	chr17:79567631	NPLOC4	-0.48	-5.05	-0.46	2.1e-6	Eye color traits;
THYM	cis	rs1421811	0.606	rs62369523	chr5:32713365	T/G	cg16267343	chr5:32710456	NPR3	0.9	7.47	0.61	3.85e-11	Blood pressure;
THYM	cis	rs11225247	0.772	rs11601671	chr11:102250065	C/T	cg06323957	chr11:102217781	BIRC2	1.08	4.83	0.44	5.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs2439831	0.681	rs2444036	chr15:43694108	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	6.89	0.58	5.93e-10	Lung cancer in ever smokers;
THYM	cis	rs6815814	0.950	rs66819621	chr4:38819403	A/G	cg02016764	chr4:38805732	TLR1	-0.55	-5.21	-0.47	1.1e-6	Breast cancer;
THYM	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg24154853	chr7:158122151	PTPRN2	-0.51	-4.69	-0.43	9.17e-6	Calcium levels;
THYM	cis	rs7258465	1.000	rs8105994	chr19:18593553	A/G	cg01380346	chr19:18557039	ELL	-0.45	-4.66	-0.43	1.04e-5	Breast cancer;
THYM	trans	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Bladder cancer;
THYM	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21659725	chr3:3221576	CRBN	-0.88	-9.81	-0.71	4.18e-16	Intelligence (multi-trait analysis);
THYM	cis	rs79387448	0.701	rs11465596	chr2:102987093	C/A	cg09003973	chr2:102972529	NA	1.24	5.81	0.51	8.39e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs7584330	0.740	rs13426236	chr2:238447940	A/G	cg16989719	chr2:238392110	NA	-0.54	-4.88	-0.45	4.32e-6	Prostate cancer;
THYM	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs7937682	0.562	rs10891276	chr11:111370415	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.54	-4.47	-0.42	2.13e-5	Primary sclerosing cholangitis;
THYM	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg00339695	chr16:24857497	SLC5A11	0.7	6.53	0.56	3.28e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg24308560	chr3:49941425	MST1R	-0.79	-6.93	-0.58	5.05e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg06481639	chr22:41940642	POLR3H	0.7	5.21	0.47	1.1e-6	Vitiligo;
THYM	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg03396347	chr1:1875803	NA	-0.64	-6.13	-0.53	2e-8	Body mass index;
THYM	cis	rs4731207	0.591	rs28634794	chr7:124614430	A/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs4911259	0.513	rs4287835	chr20:31457337	T/C	cg13636640	chr20:31349939	DNMT3B	-0.6	-5.73	-0.51	1.16e-7	Inflammatory bowel disease;
THYM	cis	rs2286885	1.000	rs10987296	chr9:129245316	C/T	cg14294646	chr9:129243551	FAM125B	-0.59	-5.35	-0.48	6.09e-7	Intraocular pressure;
THYM	cis	rs447921	0.861	rs67873924	chr17:74429992	C/G	cg17201438	chr17:74438067	UBE2O	0.81	5.85	0.51	6.9e-8	Mitochondrial DNA levels;
THYM	cis	rs4731207	0.570	rs7784616	chr7:124677194	C/G	cg05285228	chr7:124571219	POT1	-0.65	-4.98	-0.45	2.9e-6	Cutaneous malignant melanoma;
THYM	cis	rs662064	0.963	rs1188529	chr1:10525914	A/T	cg20482658	chr1:10539492	PEX14	-0.46	-5.99	-0.52	3.66e-8	Asthma;
THYM	cis	rs1843834	0.858	rs4674933	chr2:225514923	C/T	cg22509189	chr2:225307070	NA	-0.66	-4.63	-0.43	1.15e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs7917772	0.582	rs10786698	chr10:104378750	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg23851026	chr2:136556271	LCT	-0.56	-6.05	-0.53	2.91e-8	Mosquito bite size;
THYM	cis	rs6490294	0.607	rs2339907	chr12:112418146	C/A	cg10833066	chr12:111807467	FAM109A	0.47	5.23	0.47	1.02e-6	Mean platelet volume;
THYM	cis	rs6598955	0.671	rs11247914	chr1:26648838	G/T	cg08133631	chr1:26527909	CATSPER4	-0.63	-5.0	-0.46	2.59e-6	Obesity-related traits;
THYM	cis	rs57590327	0.555	rs3943556	chr3:81738892	G/C	cg07356753	chr3:81810745	GBE1	-0.88	-6.79	-0.57	9.52e-10	Extraversion;
THYM	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg23260525	chr10:116636907	FAM160B1	0.53	5.33	0.48	6.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7043114	0.525	rs7023004	chr9:95098712	A/G	cg14631576	chr9:95140430	CENPP	-0.86	-9.03	-0.68	1.97e-14	Height;
THYM	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11008222	0.934	rs11812218	chr10:31041221	G/A	cg00941203	chr10:31016591	NA	-0.34	-4.71	-0.43	8.49e-6	Congenital left-sided heart lesions (maternal effect);
THYM	cis	rs59197085	0.636	rs754920	chr7:128468412	A/G	cg00734629	chr7:128471146	FLNC	-0.77	-4.61	-0.43	1.27e-5	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
THYM	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg18032289	chr17:61959525	GH2	-0.49	-4.61	-0.43	1.25e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs2302729	0.578	rs10774052	chr12:2772171	C/T	cg19945202	chr12:2788847	CACNA1C	-0.72	-5.84	-0.51	7.27e-8	Sleep quality;
THYM	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1113500	0.548	rs17020971	chr1:108655288	C/A	cg06207961	chr1:108661230	NA	0.63	4.93	0.45	3.44e-6	Growth-regulated protein alpha levels;
THYM	cis	rs10911232	0.542	rs12128323	chr1:183050087	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.07	-8.58	-0.66	1.75e-13	Schizophrenia;
THYM	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg18032289	chr17:61959525	GH2	-0.5	-4.84	-0.44	5.07e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	4.66	0.43	1.04e-5	Diabetic retinopathy;
THYM	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	9.67	0.7	8.34e-16	Platelet count;
THYM	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg19747945	chr6:42946146	PEX6	-0.35	-5.0	-0.46	2.67e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg26028573	chr6:26043587	HIST1H2BB	0.53	4.61	0.43	1.27e-5	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6127978	0.702	rs6127982	chr20:55824367	T/C	cg15851418	chr20:55835831	BMP7	0.68	4.89	0.45	4.12e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg10636054	chr15:40330586	SRP14	1.0	5.31	0.48	7.31e-7	Corneal curvature;
THYM	cis	rs6547741	1.000	rs13026621	chr2:27807624	G/A	cg27432699	chr2:27873401	GPN1	0.68	5.97	0.52	4.14e-8	Oral cavity cancer;
THYM	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg08999081	chr20:33150536	PIGU	0.56	4.82	0.44	5.33e-6	Height;
THYM	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg22907277	chr7:1156413	C7orf50	0.86	5.37	0.48	5.5e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg13390004	chr1:15929781	NA	0.61	4.63	0.43	1.15e-5	Systolic blood pressure;
THYM	cis	rs2637266	0.967	rs4608018	chr10:78376110	T/C	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg11752832	chr7:134001865	SLC35B4	0.76	5.72	0.51	1.23e-7	Mean platelet volume;
THYM	cis	rs3770770	0.903	rs17038861	chr2:37233265	G/T	cg14987922	chr2:37194071	STRN	0.73	4.45	0.42	2.34e-5	QRS duration;
THYM	trans	rs637571	0.544	rs500161	chr11:65695438	C/T	cg17712092	chr4:129076599	LARP1B	1.03	9.83	0.71	3.74e-16	Eosinophil percentage of white cells;
THYM	cis	rs6987853	0.966	rs2923428	chr8:42388301	T/C	cg09913449	chr8:42400586	C8orf40	0.88	8.02	0.64	2.8e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg07169764	chr2:136633963	MCM6	-0.64	-5.9	-0.52	5.48e-8	Mosquito bite size;
THYM	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	13.59	0.81	5.3e-24	Chronic sinus infection;
THYM	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg02478829	chr6:26598070	ABT1	-0.33	-4.46	-0.42	2.27e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9796	0.689	rs28497404	chr15:41449510	A/C	cg21153102	chr15:41252147	NA	0.6	4.91	0.45	3.79e-6	Menopause (age at onset);
THYM	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.96	-8.0	-0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs763014	0.931	rs59476302	chr16:629006	C/T	cg00908189	chr16:619842	PIGQ	1.03	9.46	0.7	2.34e-15	Height;
THYM	cis	rs7616559	0.893	rs6802521	chr3:156718896	G/A	cg15697575	chr3:156784781	NA	0.39	5.08	0.46	1.85e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg16482183	chr6:26056742	HIST1H1C	0.98	5.87	0.52	6.24e-8	Iron status biomarkers;
THYM	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg03877680	chr5:178157825	ZNF354A	0.7	4.85	0.45	4.9100000000000004e-06	Neutrophil percentage of white cells;
THYM	cis	rs7917772	0.582	rs10786684	chr10:104323028	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.77	-6.73	-0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs11711311	1.000	rs9879760	chr3:113457948	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.27	-0.48	8.41e-7	IgG glycosylation;
THYM	cis	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg24672777	chr11:48374446	OR4C45	-0.99	-6.44	-0.55	4.78e-9	Axial length;
THYM	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg12573674	chr2:1569213	NA	-1.19	-4.49	-0.42	2.02e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg20891283	chr12:69753455	YEATS4	0.73	6.09	0.53	2.39e-8	Blood protein levels;
THYM	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg00012203	chr2:219082015	ARPC2	0.83	7.86	0.63	6e-12	Colorectal cancer;
THYM	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg12310025	chr6:25882481	NA	-0.69	-5.57	-0.5	2.39e-7	Blood metabolite levels;
THYM	cis	rs67981189	0.896	rs7153237	chr14:71488654	G/A	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs6450176	0.625	rs16881958	chr5:53288201	C/G	ch.5.1024479R	chr5:53302184	ARL15	-1.01	-8.07	-0.64	2.17e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs9933309	0.839	rs9932423	chr16:88846849	C/A	cg27661460	chr16:88844969	FAM38A	-0.66	-5.98	-0.52	3.87e-8	Glycated hemoglobin levels;
THYM	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg21433313	chr16:3507492	NAT15	-0.72	-5.35	-0.48	6.13e-7	Tuberculosis;
THYM	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg08048268	chr3:133502702	NA	0.64	5.34	0.48	6.41e-7	Iron status biomarkers;
THYM	cis	rs11089937	0.651	rs2330015	chr22:22536956	A/G	cg21401457	chr22:22472743	NA	-0.59	-5.02	-0.46	2.39e-6	Periodontitis (PAL4Q3);
THYM	cis	rs854765	0.647	rs712268	chr17:18025744	C/G	cg04398451	chr17:18023971	MYO15A	-0.97	-10.6	-0.74	8.54e-18	Total body bone mineral density;
THYM	cis	rs297325	0.812	rs11024015	chr11:16721893	G/T	cg20214553	chr11:17278779	NA	0.44	4.53	0.42	1.71e-5	Obesity and osteoporosis;
THYM	cis	rs131777	0.526	rs86337	chr22:51020668	C/A	cg25309564	chr22:51001381	C22orf41	0.61	4.89	0.45	4.02e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg21427119	chr20:30132790	HM13	-0.82	-5.6	-0.5	2.05e-7	Mean corpuscular hemoglobin;
THYM	cis	rs4788815	0.712	rs4788563	chr16:71879868	A/C	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	Metabolite levels;
THYM	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.74	-5.24	-0.47	9.84e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg08999081	chr20:33150536	PIGU	-0.59	-5.28	-0.48	8.16e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs595982	0.527	rs55706579	chr19:49382969	G/A	cg21252483	chr19:49399788	TULP2	-0.77	-5.11	-0.46	1.69e-6	Red cell distribution width;
THYM	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg20295408	chr7:1910781	MAD1L1	-0.67	-5.29	-0.48	7.68e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs2692947	0.727	rs893173	chr2:96789787	T/C	cg23100626	chr2:96804247	ASTL	0.38	5.22	0.47	1.05e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs4589258	0.788	rs4753028	chr11:90477639	G/T	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.83	-0.44	5.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11671005	0.656	rs73066226	chr19:59008213	T/C	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.66	-4.9	-0.45	3.98e-6	Mean platelet volume;
THYM	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg14019146	chr3:50243930	SLC38A3	-0.55	-4.46	-0.42	2.29e-5	Body mass index;
THYM	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	10.0	0.72	1.67e-16	Platelet count;
THYM	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg05182265	chr7:156933206	UBE3C	-0.7	-9.62	-0.7	1.06e-15	Body mass index;
THYM	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg24505687	chr6:33548425	BAK1	0.52	4.8	0.44	5.81e-6	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
THYM	cis	rs4638749	0.677	rs2100407	chr2:108830188	G/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg19442545	chr10:75533431	FUT11	-0.66	-7.01	-0.58	3.4e-10	Inflammatory bowel disease;
THYM	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs951188	0.688	rs74675179	chr2:150399477	T/A	cg17961725	chr2:150454027	NA	-1.0	-5.05	-0.46	2.17e-6	Daytime sleep phenotypes;
THYM	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg06917634	chr15:78832804	PSMA4	0.96	8.76	0.67	7.4e-14	Sudden cardiac arrest;
THYM	cis	rs7107174	1.000	rs2512541	chr11:77981747	A/T	cg19901956	chr11:77921274	USP35	-0.68	-5.25	-0.47	9.31e-7	Testicular germ cell tumor;
THYM	cis	rs1057239	0.510	rs3766694	chr1:175143207	T/C	cg08873628	chr1:175162347	KIAA0040	-0.54	-4.47	-0.42	2.16e-5	Diastolic blood pressure;
THYM	cis	rs728616	0.867	rs7893241	chr10:81954338	C/T	cg18148530	chr10:81370782	SFTPA1	0.76	4.66	0.43	1.02e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4663969	0.541	rs11902131	chr2:234594269	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-6.64	-0.56	1.98e-9	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs761746	0.739	rs5753714	chr22:31990930	G/T	cg01338084	chr22:32026380	PISD	-0.55	-4.76	-0.44	6.91e-6	Intelligence;
THYM	cis	rs6840360	0.554	rs13108359	chr4:152727852	T/C	cg22705602	chr4:152727874	NA	0.82	11.52	0.76	9.67e-20	Intelligence (multi-trait analysis);
THYM	cis	rs57994353	1.000	rs57994353	chr9:139356987	T/C	cg24793265	chr9:139269240	CARD9	-0.57	-4.68	-0.43	9.34e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg01494348	chr8:144660395	NAPRT1	-0.93	-4.49	-0.42	2e-5	Attention deficit hyperactivity disorder;
THYM	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg12560992	chr17:57184187	TRIM37	-0.92	-8.68	-0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg24803719	chr17:45855879	NA	-0.6	-6.31	-0.54	8.89e-9	IgG glycosylation;
THYM	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg09549813	chr16:4587862	C16orf5	-0.6	-6.68	-0.57	1.63e-9	Schizophrenia;
THYM	trans	rs17685	0.753	rs869804	chr7:75688954	A/G	cg19862616	chr7:65841803	NCRNA00174	1.12	13.73	0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs447921	0.861	rs423130	chr17:74416189	A/G	cg17201438	chr17:74438067	UBE2O	-0.81	-5.85	-0.51	6.9e-8	Mitochondrial DNA levels;
THYM	cis	rs7127900	0.561	rs7109219	chr11:2233041	G/A	cg25635251	chr11:2234043	NA	0.7	5.36	0.48	5.7e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs11031096	0.711	rs61899755	chr11:4201317	G/T	cg18678763	chr11:4115507	RRM1	-0.41	-4.82	-0.44	5.4e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2658782	0.951	rs2608214	chr11:93148665	C/T	cg15737290	chr11:93063684	CCDC67	1.01	7.95	0.63	3.81e-12	Pulmonary function decline;
THYM	cis	rs2073300	0.793	rs6048814	chr20:23448411	A/C	cg12062639	chr20:23401060	NAPB	1.2	5.64	0.5	1.73e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs17407555	0.697	rs73212821	chr4:10069451	T/A	cg11266682	chr4:10021025	SLC2A9	-0.57	-5.82	-0.51	7.86e-8	Schizophrenia (age at onset);
THYM	trans	rs208520	0.690	rs207107	chr6:66794385	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.66	-0.62	1.53e-11	Exhaled nitric oxide output;
THYM	cis	rs3750965	0.575	rs3018691	chr11:68884543	C/T	cg01403660	chr11:68851641	TPCN2	0.58	4.48	0.42	2.11e-5	Hair color;
THYM	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11890956	chr21:40555474	PSMG1	-0.68	-6.41	-0.55	5.55e-9	Menarche (age at onset);
THYM	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg16342193	chr10:102329863	NA	-0.59	-6.2	-0.54	1.48e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs8112211	0.911	rs2270095	chr19:38840896	A/G	cg09474229	chr19:39360330	RINL	-0.5	-4.66	-0.43	1.03e-5	Blood protein levels;
THYM	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13082711	0.595	rs17317435	chr3:27339326	A/G	cg02860705	chr3:27208620	NA	0.96	7.32	0.6	8.1e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg13319975	chr6:146136371	FBXO30	-0.7	-5.97	-0.52	4.11e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg19623624	chr10:135278901	LOC619207	-0.66	-5.32	-0.48	6.79e-7	Systemic lupus erythematosus;
THYM	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg17775962	chr7:1200435	ZFAND2A	0.4	4.65	0.43	1.06e-5	Longevity;Endometriosis;
THYM	cis	rs7103648	0.966	rs1534576	chr11:47419663	A/C	cg20307385	chr11:47447363	PSMC3	-0.93	-8.66	-0.66	1.23e-13	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs1003719	0.788	rs61701101	chr21:38450317	G/A	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs12289510	0.512	rs6590125	chr11:124957183	T/G	cg03868193	chr11:124958746	SLC37A2	-0.71	-5.66	-0.5	1.6e-7	Platelet-derived growth factor BB levels;
THYM	cis	rs752010	0.756	rs943374	chr1:42056194	A/G	cg06885757	chr1:42089581	HIVEP3	0.45	5.29	0.48	7.72e-7	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.78	-5.93	-0.52	4.92e-8	Prostate cancer;
THYM	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg17063962	chr7:91808500	NA	1.11	12.24	0.78	3.11e-21	Breast cancer;
THYM	cis	rs9876781	1.000	rs1459242	chr3:48413537	C/T	cg06066452	chr3:48470258	PLXNB1	-0.26	-4.8	-0.44	5.94e-6	Longevity;
THYM	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg13289132	chr10:30722225	MAP3K8	-0.63	-5.21	-0.47	1.11e-6	Inflammatory bowel disease;
THYM	cis	rs35110281	0.567	rs4819219	chr21:44984864	T/C	cg01579765	chr21:45077557	HSF2BP	-0.44	-6.78	-0.57	1.03e-9	Mean corpuscular volume;
THYM	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg02640540	chr1:67518911	SLC35D1	-0.59	-4.64	-0.43	1.09e-5	Lymphocyte percentage of white cells;
THYM	cis	rs6543140	0.964	rs11903551	chr2:103084181	C/G	cg03938978	chr2:103052716	IL18RAP	0.6	5.78	0.51	9.35e-8	Blood protein levels;
THYM	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.8	-6.37	-0.55	6.73e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7193541	0.684	rs4888264	chr16:74681632	T/G	cg01733217	chr16:74700730	RFWD3	0.99	11.69	0.77	4.4e-20	Multiple myeloma;
THYM	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	8.55	0.66	2.03e-13	Cognitive test performance;
THYM	cis	rs611744	0.503	rs13282220	chr8:109263043	T/C	cg21045802	chr8:109455806	TTC35	0.75	6.27	0.54	1.08e-8	Dupuytren's disease;
THYM	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.43	0.7	2.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9388451	0.531	rs9401850	chr6:126151000	T/G	cg05901451	chr6:126070800	HEY2	-0.63	-4.66	-0.43	1.04e-5	Brugada syndrome;
THYM	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg17971929	chr21:40555470	PSMG1	0.71	4.58	0.43	1.4e-5	Cognitive function;
THYM	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg10360139	chr7:1886902	MAD1L1	-0.58	-4.63	-0.43	1.15e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs919433	1.000	rs1429414	chr2:198162430	C/T	cg00792783	chr2:198669748	PLCL1	-0.64	-4.58	-0.43	1.39e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg21475434	chr5:93447410	FAM172A	0.71	4.51	0.42	1.83e-5	Diabetic retinopathy;
THYM	cis	rs17597773	0.638	rs7530074	chr1:220989266	G/A	cg16008148	chr1:221062819	NA	0.41	4.54	0.42	1.62e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2075230	0.705	rs11078702	chr17:7543508	T/G	cg10509001	chr17:7553872	ATP1B2	-0.57	-4.61	-0.43	1.26e-5	Hormone measurements;
THYM	trans	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg25214090	chr10:38739885	LOC399744	0.83	7.11	0.59	2.14e-10	Corneal astigmatism;
THYM	cis	rs2637266	0.626	rs846619	chr10:78545449	A/G	cg18941641	chr10:78392320	NA	0.74	5.81	0.51	8.27e-8	Pulmonary function;
THYM	cis	rs2288884	0.767	rs12462359	chr19:52535421	T/G	cg05974498	chr19:52599256	ZNF841	0.35	4.51	0.42	1.85e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs7119	0.651	rs12905044	chr15:77846215	G/A	cg27398640	chr15:77910606	LINGO1	-0.61	-6.05	-0.53	2.92e-8	Type 2 diabetes;
THYM	cis	rs490234	0.702	rs4838274	chr9:128345994	C/A	cg14078157	chr9:128172775	NA	-0.72	-5.42	-0.49	4.48e-7	Mean arterial pressure;
THYM	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg06636001	chr8:8085503	FLJ10661	0.64	5.46	0.49	3.76e-7	Mood instability;
THYM	cis	rs17253792	0.822	rs78323463	chr14:56045451	T/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg02038168	chr22:39784481	NA	0.54	4.51	0.42	1.85e-5	IgG glycosylation;
THYM	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs757081	0.667	rs1987694	chr11:17107648	G/C	cg15432903	chr11:17409602	KCNJ11	-0.49	-4.58	-0.43	1.43e-5	Systolic blood pressure;
THYM	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs6763768	0.606	rs60287116	chr3:53388457	C/T	cg16894138	chr3:53270350	TKT	0.72	5.41	0.49	4.63e-7	Bacterial meningitis;
THYM	cis	rs10028773	0.666	rs35231872	chr4:120248376	A/T	cg09307838	chr4:120376055	NA	0.67	5.02	0.46	2.37e-6	Educational attainment;
THYM	cis	rs1775715	0.737	rs2151047	chr10:32102110	G/A	cg04359828	chr10:32216031	ARHGAP12	0.39	4.96	0.45	3.02e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs863345	0.625	rs12063360	chr1:158499494	A/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs1451375	0.617	rs1807066	chr7:50543683	T/C	cg18232548	chr7:50535776	DDC	-0.66	-4.99	-0.46	2.69e-6	Malaria;
THYM	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.09	-5.32	-0.48	6.76e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.8e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg08975724	chr8:8085496	FLJ10661	-0.6	-5.01	-0.46	2.54e-6	Mood instability;
THYM	cis	rs9527	0.590	rs11191553	chr10:104851396	G/T	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg03806693	chr22:41940476	POLR3H	-0.8	-6.47	-0.55	4.28e-9	Neuroticism;
THYM	cis	rs2637266	1.000	rs7897061	chr10:78366776	C/T	cg18941641	chr10:78392320	NA	0.78	6.7	0.57	1.47e-9	Pulmonary function;
THYM	cis	rs6500637	0.570	rs1049205	chr16:4942099	C/T	cg08329684	chr16:4932620	PPL	-0.35	-4.69	-0.43	9.3e-6	Cancer;
THYM	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	8.57	0.66	1.88e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06873352	chr17:61820015	STRADA	0.8	10.01	0.72	1.54e-16	Prudent dietary pattern;
THYM	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6835098	0.923	rs7671278	chr4:174095769	A/G	cg08422745	chr4:174089978	GALNT7	-0.99	-8.26	-0.65	8.41e-13	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg16586182	chr3:47516702	SCAP	0.6	5.12	0.47	1.6e-6	Colorectal cancer;
THYM	cis	rs11048434	0.761	rs2377675	chr12:9124765	C/T	cg04155231	chr12:9217510	LOC144571	0.49	4.69	0.43	9.28e-6	Sjögren's syndrome;
THYM	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg26818010	chr10:134567672	INPP5A	-0.76	-6.12	-0.53	2.04e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs11030122	0.702	rs7128762	chr11:3943277	C/G	cg18678763	chr11:4115507	RRM1	-0.44	-5.59	-0.5	2.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg08999081	chr20:33150536	PIGU	-0.62	-5.22	-0.47	1.07e-6	Coronary artery disease;
THYM	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs6087990	0.899	rs1883729	chr20:31363193	G/A	cg13636640	chr20:31349939	DNMT3B	0.92	9.56	0.7	1.47e-15	Ulcerative colitis;
THYM	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg04043695	chr12:129287642	SLC15A4	-0.6	-4.66	-0.43	1.03e-5	Systemic lupus erythematosus;
THYM	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg23682913	chr1:2080710	PRKCZ	-0.57	-4.91	-0.45	3.79e-6	Height;
THYM	cis	rs9796	0.653	rs28516683	chr15:41446645	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.59	-4.67	-0.43	9.71e-6	Menopause (age at onset);
THYM	cis	rs654128	0.640	rs1321367	chr6:117238668	A/C	cg12892004	chr6:117198278	RFX6	-0.73	-5.5	-0.49	3.18e-7	Telomere length;
THYM	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg00012203	chr2:219082015	ARPC2	0.89	8.63	0.66	1.37e-13	Colorectal cancer;
THYM	cis	rs6988636	1.000	rs6988636	chr8:124185970	A/G	cg22384356	chr8:124195192	FAM83A	-0.86	-5.15	-0.47	1.41e-6	Urinary uromodulin levels;
THYM	cis	rs2073300	0.609	rs6132615	chr20:23413200	T/C	cg12062639	chr20:23401060	NAPB	1.11	5.75	0.51	1.1e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs4372836	0.518	rs1128416	chr2:29001691	A/G	cg09522027	chr2:28974177	PPP1CB	-0.58	-4.49	-0.42	2e-5	Body mass index;
THYM	cis	rs59698941	0.943	rs66628697	chr5:132252561	C/T	cg27099455	chr5:132201840	GDF9;UQCRQ	0.62	4.67	0.43	9.89e-6	Apolipoprotein A-IV levels;
THYM	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg16325326	chr1:53192061	ZYG11B	0.85	8.17	0.64	1.35e-12	Monocyte count;
THYM	cis	rs131777	0.575	rs131760	chr22:51011936	T/C	cg25309564	chr22:51001381	C22orf41	0.62	5.0	0.46	2.62e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg23422044	chr7:1970798	MAD1L1	-0.76	-5.24	-0.47	9.64e-7	Bipolar disorder;
THYM	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg21984481	chr17:79567631	NPLOC4	0.61	6.89	0.58	6.13e-10	Eye color traits;
THYM	trans	rs9929218	0.559	rs12923775	chr16:68756450	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.98	11.06	0.75	9.13e-19	Colorectal cancer;
THYM	cis	rs7551222	0.681	rs2045623	chr1:204497413	A/G	cg20240347	chr1:204465584	NA	-0.51	-4.54	-0.42	1.64e-5	Schizophrenia;
THYM	cis	rs6700896	0.931	rs59508186	chr1:66107881	C/A	cg04111102	chr1:66153794	NA	0.53	4.91	0.45	3.85e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs3008870	0.709	rs62883160	chr1:67392889	G/A	cg02640540	chr1:67518911	SLC35D1	0.59	4.58	0.43	1.41e-5	Lymphocyte percentage of white cells;
THYM	cis	rs1642645	0.872	rs642112	chr1:42453317	C/T	cg10197057	chr1:42612518	NA	0.43	4.56	0.42	1.5e-5	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs10927875	0.619	rs1806991	chr1:16129441	T/C	cg21385522	chr1:16154831	NA	-0.75	-6.22	-0.54	1.31e-8	Dilated cardiomyopathy;
THYM	cis	rs7404928	0.651	rs1005878	chr16:23914440	C/A	cg26685404	chr16:23957272	PRKCB	0.66	7.36	0.6	6.48e-11	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.59	-5.17	-0.47	1.28e-6	Coronary artery disease;
THYM	cis	rs11030122	0.702	rs10835399	chr11:3989182	G/A	cg18678763	chr11:4115507	RRM1	-0.44	-5.73	-0.51	1.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg08645402	chr16:4508243	NA	0.73	6.71	0.57	1.39e-9	Schizophrenia;
THYM	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg06387496	chr7:2775674	GNA12	-0.43	-4.49	-0.42	2.04e-5	Height;
THYM	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg06221963	chr1:154839813	KCNN3	-0.87	-10.89	-0.75	2.07e-18	Prostate cancer;
THYM	cis	rs2734839	0.537	rs10891549	chr11:113278447	T/C	cg14159747	chr11:113255604	NA	0.35	7.67	0.62	1.48e-11	Information processing speed;
THYM	cis	rs7681440	0.606	rs356185	chr4:90704617	G/A	cg06632027	chr4:90757378	SNCA	-0.64	-5.02	-0.46	2.42e-6	Dementia with Lewy bodies;
THYM	cis	rs4242434	0.747	rs6986550	chr8:22467870	T/A	cg01710189	chr8:22454888	PDLIM2	-0.5	-5.49	-0.49	3.3e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg03188948	chr7:1209495	NA	0.91	6.93	0.58	5.13e-10	Longevity;Endometriosis;
THYM	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.39	0.6	5.63e-11	Obesity-related traits;
THYM	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg02136620	chr5:178986620	RUFY1	-0.55	-5.65	-0.5	1.66e-7	Lung cancer;
THYM	cis	rs2505998	0.957	rs2506005	chr10:43581980	C/T	cg06632098	chr10:43605906	RET	-1.04	-9.21	-0.69	8.15e-15	Hirschsprung disease;
THYM	cis	rs807669	0.903	rs756651	chr22:19179367	T/C	cg02655711	chr22:19163373	SLC25A1	0.97	11.57	0.76	7.63e-20	Metabolite levels;
THYM	cis	rs4930776	0.966	rs1860952	chr12:5765649	T/G	cg02086166	chr12:5775618	ANO2	-0.58	-5.71	-0.51	1.3e-7	Plasma clusterin levels;
THYM	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.68	-4.57	-0.42	1.44e-5	Menarche (age at onset);
THYM	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg21433313	chr16:3507492	NAT15	0.8	6.87	0.58	6.61e-10	Tuberculosis;
THYM	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.57	5.32	0.48	6.76e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs490234	0.683	rs2841326	chr9:128161768	G/A	cg14078157	chr9:128172775	NA	-0.84	-7.1	-0.59	2.28e-10	Mean arterial pressure;
THYM	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg22681709	chr2:178499509	PDE11A	-0.6	-5.77	-0.51	9.99e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9443645	0.527	rs9361477	chr6:79710806	C/T	cg05283184	chr6:79620031	NA	-0.6	-4.67	-0.43	9.86e-6	Intelligence (multi-trait analysis);
THYM	cis	rs977987	0.806	rs12051326	chr16:75437887	G/A	cg03315344	chr16:75512273	CHST6	0.77	6.31	0.54	8.75e-9	Dupuytren's disease;
THYM	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg12560992	chr17:57184187	TRIM37	0.91	8.46	0.66	3.24e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg16989719	chr2:238392110	NA	0.64	5.54	0.49	2.73e-7	Prostate cancer;
THYM	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg26850624	chr5:429559	AHRR	-0.62	-5.16	-0.47	1.34e-6	Cystic fibrosis severity;
THYM	cis	rs77372450	0.551	rs3749797	chr5:157078475	C/G	cg00312553	chr5:157098553	C5orf52	-0.65	-4.63	-0.43	1.16e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg00999904	chr2:3704751	ALLC	0.78	6.34	0.55	7.6e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs7246657	0.943	rs7255785	chr19:37971683	C/T	cg22634378	chr19:37742834	NA	0.59	4.92	0.45	3.62e-6	Coronary artery calcification;
THYM	cis	rs2189609	0.670	rs2663158	chr16:73993052	A/G	cg05340094	chr16:73095395	NA	0.55	4.51	0.42	1.83e-5	Energy expenditure (24h);
THYM	cis	rs73198271	0.740	rs28521727	chr8:8647217	T/C	cg06636001	chr8:8085503	FLJ10661	-0.76	-5.06	-0.46	2.01e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg00786635	chr1:25594202	NA	0.87	6.79	0.57	9.49e-10	Erythrocyte sedimentation rate;
THYM	cis	rs2070488	1.000	rs17733640	chr3:38446742	G/A	cg24069376	chr3:38537580	EXOG	0.64	6.36	0.55	6.97e-9	Electrocardiographic conduction measures;
THYM	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg26384229	chr12:38710491	ALG10B	0.63	4.76	0.44	6.9e-6	Morning vs. evening chronotype;
THYM	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg01386294	chr6:25732093	NA	0.89	4.51	0.42	1.84e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg14895029	chr7:2775587	GNA12	-0.68	-5.03	-0.46	2.27e-6	Height;
THYM	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg05962950	chr11:130786565	SNX19	0.84	7.29	0.6	9.11e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg20302533	chr7:39170763	POU6F2	0.6	4.5	0.42	1.93e-5	IgG glycosylation;
THYM	cis	rs1003719	0.788	rs2835577	chr21:38457457	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.71	5.03	0.46	2.32e-6	Eye color traits;
THYM	cis	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs6815814	0.898	rs73236646	chr4:38871385	T/C	cg06935464	chr4:38784597	TLR10	0.72	4.96	0.45	3.1e-6	Breast cancer;
THYM	cis	rs6430585	0.697	rs115944351	chr2:136515458	G/A	cg20242066	chr2:136595261	LCT	0.5	4.7	0.43	8.63e-6	Corneal structure;
THYM	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg26384229	chr12:38710491	ALG10B	-0.7	-5.72	-0.51	1.23e-7	Morning vs. evening chronotype;
THYM	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg03188948	chr7:1209495	NA	0.81	4.61	0.43	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg03929089	chr4:120376271	NA	0.95	10.29	0.73	3.95e-17	Coronary artery disease;
THYM	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs9674544	0.556	rs1390154	chr17:47071483	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.44	-4.74	-0.44	7.39e-6	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs10504073	0.584	rs56074306	chr8:49940282	C/T	cg00325661	chr8:49890786	NA	1.08	10.81	0.74	3.14e-18	Blood metabolite ratios;
THYM	cis	rs4747241	0.739	rs4746116	chr10:74072136	C/T	cg07828833	chr10:74069493	NA	0.55	4.57	0.42	1.47e-5	Heschl's gyrus morphology;
THYM	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg09260853	chr1:2094483	PRKCZ	0.51	4.76	0.44	7.02e-6	Height;
THYM	cis	rs611744	0.967	rs662714	chr8:109221659	C/A	cg21045802	chr8:109455806	TTC35	0.59	5.25	0.47	9.08e-7	Dupuytren's disease;
THYM	cis	rs11031096	0.782	rs10767845	chr11:4156922	C/T	cg22027985	chr11:4115532	RRM1	-0.53	-5.45	-0.49	4.02e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg18016565	chr1:150552671	MCL1	-0.55	-4.55	-0.42	1.58e-5	Tonsillectomy;
THYM	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	9.38	0.69	3.49e-15	Chronic sinus infection;
THYM	cis	rs7940866	0.834	rs1594821	chr11:130835883	C/T	cg05962950	chr11:130786565	SNX19	0.72	5.59	0.5	2.18e-7	Schizophrenia;
THYM	cis	rs7769051	0.711	rs9493437	chr6:133088405	A/T	cg22852734	chr6:133119734	C6orf192	1.27	7.83	0.63	6.83e-12	Type 2 diabetes nephropathy;
THYM	cis	rs3892630	0.818	rs80137870	chr19:33182750	C/T	cg22928329	chr19:33183273	NUDT19	-0.76	-5.67	-0.5	1.56e-7	Red blood cell traits;
THYM	cis	rs10203711	0.966	rs6713626	chr2:239566896	C/T	cg14580085	chr2:239553406	NA	0.68	6.18	0.54	1.6e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg23260525	chr10:116636907	FAM160B1	0.53	5.33	0.48	6.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7084402	0.967	rs1658489	chr10:60285924	A/G	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs11811982	0.793	rs41270147	chr1:227406908	G/A	cg09853570	chr1:228403422	OBSCN	1.21	4.67	0.43	9.81e-6	Optic disc area;
THYM	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-4.96	-0.45	3.03e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2276314	0.857	rs6507157	chr18:33631703	A/C	cg05985134	chr18:33552581	C18orf21	0.69	4.88	0.45	4.22e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs3780378	0.967	rs7852988	chr9:5010751	C/A	cg02405213	chr9:5042618	JAK2	-0.74	-6.94	-0.58	4.73e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs1729951	0.575	rs12494558	chr3:136678781	C/G	cg12473912	chr3:136751656	NA	0.63	5.13	0.47	1.55e-6	Neuroticism;
THYM	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2562456	0.724	rs58001930	chr19:21742863	C/T	cg21751540	chr19:21541537	ZNF738	-0.69	-4.75	-0.44	7.1e-6	Pain;
THYM	cis	rs1559088	1.000	rs7256328	chr19:33558705	G/C	cg03563238	chr19:33554763	RHPN2	-0.51	-4.53	-0.42	1.69e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.16	-0.75	5.56e-19	Primary sclerosing cholangitis;
THYM	cis	rs7584330	0.518	rs6715245	chr2:238445803	C/T	cg08992911	chr2:238395768	MLPH	0.98	6.06	0.53	2.74e-8	Prostate cancer;
THYM	cis	rs4866334	0.867	rs76734676	chr5:18487735	G/T	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg04876069	chr12:132293656	NA	0.54	5.03	0.46	2.32e-6	Migraine;
THYM	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7794273	0.963	rs2520355	chr7:18854120	A/G	cg13420273	chr7:18810212	HDAC9	-0.55	-4.47	-0.42	2.14e-5	Night sleep phenotypes;
THYM	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.06	0.64	2.28e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg23791538	chr6:167370224	RNASET2	0.64	5.11	0.46	1.63e-6	Crohn's disease;
THYM	cis	rs7027203	0.828	rs4743934	chr9:96581893	A/G	cg13679303	chr9:96623674	NA	-0.48	-4.99	-0.46	2.74e-6	DNA methylation (variation);
THYM	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs911119	0.657	rs13039144	chr20:23633755	A/G	cg16589663	chr20:23618590	CST3	0.83	4.73	0.44	7.87e-6	Chronic kidney disease;
THYM	cis	rs61931739	0.635	rs1825746	chr12:33939984	C/T	cg06521331	chr12:34319734	NA	-0.57	-4.73	-0.44	7.85e-6	Morning vs. evening chronotype;
THYM	cis	rs295137	0.752	rs10931892	chr2:201104997	C/T	cg23649088	chr2:200775458	C2orf69	-0.63	-5.46	-0.49	3.75e-7	Asthma (bronchodilator response);
THYM	cis	rs2997447	0.761	rs17257120	chr1:26450101	A/G	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg11502198	chr6:26597334	ABT1	-0.62	-5.38	-0.48	5.27e-7	Intelligence (multi-trait analysis);
THYM	cis	rs55728055	0.661	rs9680589	chr22:31853484	G/A	cg10537193	chr22:32026975	PISD	-0.91	-5.27	-0.48	8.59e-7	Age-related hearing impairment;
THYM	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.8	-5.41	-0.49	4.66e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.57	4.49	0.42	2.01e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	5.9	0.52	5.53e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg09263875	chr16:632152	PIGQ	0.73	6.29	0.54	9.69e-9	Height;
THYM	cis	rs6466832	0.568	rs2471181	chr7:122315837	C/T	cg22586324	chr7:123296098	LMOD2	-0.91	-5.09	-0.46	1.83e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6032067	0.852	rs6032046	chr20:43823679	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs2734839	0.929	rs2734835	chr11:113291343	T/G	cg14159747	chr11:113255604	NA	0.32	6.41	0.55	5.69e-9	Information processing speed;
THYM	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg13319975	chr6:146136371	FBXO30	-0.64	-5.35	-0.48	6.1e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9796	0.870	rs1001341	chr15:41261491	T/A	cg18705301	chr15:41695430	NDUFAF1	0.56	4.62	0.43	1.22e-5	Menopause (age at onset);
THYM	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.66	-5.38	-0.48	5.38e-7	Blood metabolite levels;
THYM	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg08736216	chr1:53307985	ZYG11A	-0.6	-5.57	-0.5	2.39e-7	Monocyte count;
THYM	cis	rs5769765	0.505	rs4561759	chr22:50256686	C/T	cg08270630	chr22:50330655	NA	0.72	4.68	0.43	9.6e-6	Schizophrenia;
THYM	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg17372223	chr3:52568218	NT5DC2	0.31	4.78	0.44	6.34e-6	Bipolar disorder;
THYM	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg15921436	chr17:44337874	NA	0.9	6.48	0.55	4.06e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs17776563	0.853	rs11636283	chr15:89143777	A/T	cg01779732	chr15:90015521	RHCG	0.45	4.47	0.42	2.15e-5	Thyroid hormone levels;
THYM	cis	rs7226229	1.000	rs7219244	chr17:20926595	A/C	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.65e-6	Aortic root size;
THYM	cis	rs6430585	0.528	rs499483	chr2:136652524	G/A	cg23851026	chr2:136556271	LCT	0.84	7.9	0.63	4.84e-12	Corneal structure;
THYM	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg27534772	chr1:16042836	PLEKHM2	0.56	6.31	0.54	8.77e-9	Systolic blood pressure;
THYM	cis	rs7191439	0.589	rs11076699	chr16:88756812	A/C	cg02389323	chr16:88786976	FAM38A	-1.14	-5.66	-0.5	1.63e-7	Plateletcrit;
THYM	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.62	5.67	0.5	1.54e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg19077165	chr18:44547161	KATNAL2	0.51	6.09	0.53	2.43e-8	Personality dimensions;
THYM	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.54	-4.52	-0.42	1.8e-5	Renal function-related traits (BUN);
THYM	cis	rs1691799	0.867	rs1168333	chr12:66761377	G/A	cg16791601	chr12:66731901	HELB	-0.64	-5.49	-0.49	3.37e-7	White blood cell count (basophil);
THYM	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg08885076	chr2:99613938	TSGA10	0.63	5.66	0.5	1.57e-7	Chronic sinus infection;
THYM	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg12501888	chr15:85177176	SCAND2	-0.58	-4.64	-0.43	1.13e-5	P wave terminal force;
THYM	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg23161317	chr6:28129485	ZNF389	0.94	7.03	0.58	3.18e-10	Parkinson's disease;
THYM	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.67	6.54	0.56	3.06e-9	Lymphocyte counts;
THYM	cis	rs41005	0.967	rs193927	chr2:8108055	G/A	cg03155496	chr2:8117019	LOC339788	0.96	9.33	0.69	4.45e-15	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs28595532	0.920	rs115320476	chr4:119759680	G/A	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17708984	0.606	rs3786573	chr19:16193785	G/A	cg13618979	chr19:16186840	TPM4	0.36	4.7	0.43	8.62e-6	Platelet count;Platelet distribution width;
THYM	cis	rs17006441	0.932	rs11916348	chr3:69864690	C/T	cg18496212	chr3:69797108	MITF	0.65	6.36	0.55	6.97e-9	Hemoglobin concentration;
THYM	cis	rs5769765	0.658	rs2157536	chr22:50190180	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	4.94	0.45	3.38e-6	Schizophrenia;
THYM	cis	rs7705502	0.890	rs72812846	chr5:173377636	T/A	cg18693985	chr5:173351052	CPEB4	-0.7	-4.94	-0.45	3.31e-6	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg27034606	chr17:28928453	LRRC37B2	0.79	4.89	0.45	4.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-5.43	-0.49	4.26e-7	Gut microbiome composition (summer);
THYM	cis	rs4631830	0.720	rs2611512	chr10:51515534	A/G	cg20129853	chr10:51489980	NA	-0.32	-4.63	-0.43	1.18e-5	Prostate-specific antigen levels;
THYM	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg04455712	chr21:45112962	RRP1B	0.55	5.2	0.47	1.15e-6	Mean corpuscular volume;
THYM	cis	rs9788721	0.592	rs28564957	chr15:78906107	C/A	cg06917634	chr15:78832804	PSMA4	-0.81	-7.07	-0.59	2.56e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs9388451	0.531	rs9401850	chr6:126151000	T/G	cg10911889	chr6:126070802	HEY2	0.63	4.63	0.43	1.18e-5	Brugada syndrome;
THYM	cis	rs986417	0.901	rs1955696	chr14:61028271	A/G	cg27398547	chr14:60952738	C14orf39	1.08	5.95	0.52	4.5e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs67460515	0.892	rs4856769	chr3:161004549	C/A	cg03342759	chr3:160939853	NMD3	-0.9	-7.68	-0.62	1.39e-11	Parkinson's disease;
THYM	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg04025307	chr7:1156635	C7orf50	0.72	4.46	0.42	2.27e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg00684032	chr4:1343700	KIAA1530	0.7	5.74	0.51	1.11e-7	Obesity-related traits;
THYM	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg25918947	chr17:41365094	TMEM106A	0.58	4.95	0.45	3.22e-6	Menopause (age at onset);
THYM	cis	rs4481887	0.617	rs7511986	chr1:248527810	G/A	cg00666640	chr1:248458726	OR2T12	0.54	4.62	0.43	1.2e-5	Common traits (Other);
THYM	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg24690094	chr11:67383802	NA	0.89	7.39	0.6	5.64e-11	Mean corpuscular volume;
THYM	cis	rs7580658	0.929	rs4662575	chr2:128022215	C/T	cg10021288	chr2:128175891	PROC	-0.78	-6.82	-0.57	8.26e-10	Protein C levels;
THYM	cis	rs3015497	0.789	rs3015498	chr14:51112824	T/C	cg04730355	chr14:51134070	SAV1	-0.53	-4.7	-0.43	8.68e-6	Mean platelet volume;
THYM	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg14972814	chr11:95582409	MTMR2	-0.73	-6.13	-0.53	1.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-5.43	-0.49	4.23e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg11984989	chr7:158649758	WDR60	-1.06	-13.56	-0.81	6.19e-24	Height;
THYM	cis	rs67460515	0.563	rs11720263	chr3:160848293	T/C	cg03342759	chr3:160939853	NMD3	-0.63	-4.7	-0.43	8.93e-6	Parkinson's disease;
THYM	cis	rs868036	1.000	rs7168156	chr15:68102933	T/C	cg24579218	chr15:68104479	NA	-0.65	-6.51	-0.56	3.59e-9	Restless legs syndrome;
THYM	cis	rs56104184	0.887	rs55869333	chr19:49342145	T/G	cg26267310	chr19:49340593	PLEKHA4;HSD17B14	0.93	6.03	0.53	3.18e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7152530	0.571	rs72478863	chr14:98635404	A/G	cg05180522	chr14:98101740	NA	-0.59	-4.7	-0.43	8.79e-6	Staphylococcus aureus infection;
THYM	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg04673462	chr1:38461896	NA	0.46	5.88	0.52	6.02e-8	Coronary artery disease;
THYM	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg00339695	chr16:24857497	SLC5A11	0.48	4.79	0.44	6.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1345301	0.518	rs12468355	chr2:102861250	T/G	cg03938978	chr2:103052716	IL18RAP	-0.49	-4.58	-0.43	1.41e-5	Waist circumference;
THYM	cis	rs4595586	0.525	rs35089392	chr12:39414547	T/G	cg13010199	chr12:38710504	ALG10B	0.66	4.55	0.42	1.57e-5	Morning vs. evening chronotype;
THYM	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg24675658	chr1:53192096	ZYG11B	-0.66	-5.22	-0.47	1.04e-6	Monocyte count;
THYM	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.88	7.12	0.59	2.08e-10	Intelligence (multi-trait analysis);
THYM	cis	rs10463554	0.927	rs257304	chr5:102416818	C/G	cg23492399	chr5:102201601	PAM	-0.69	-5.17	-0.47	1.27e-6	Parkinson's disease;
THYM	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg05025164	chr4:1340916	KIAA1530	0.62	4.97	0.45	3e-6	Longevity;
THYM	cis	rs1949733	1.000	rs3103099	chr4:8511567	G/A	cg11789530	chr4:8429930	ACOX3	-0.73	-5.77	-0.51	9.69e-8	Response to antineoplastic agents;
THYM	cis	rs11089937	0.616	rs5995615	chr22:22539640	G/A	cg06866756	chr22:22471216	NA	-0.46	-5.09	-0.46	1.79e-6	Periodontitis (PAL4Q3);
THYM	cis	rs7843479	0.511	rs4379446	chr8:21777595	C/G	cg17168535	chr8:21777572	XPO7	0.95	9.22	0.69	7.66e-15	Mean corpuscular volume;
THYM	cis	rs34172651	0.917	rs11074654	chr16:24813743	A/G	cg06028605	chr16:24865363	SLC5A11	0.57	5.66	0.5	1.62e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7224314	1.000	rs11079691	chr17:65362552	T/A	cg01507342	chr17:65387096	PITPNC1	-0.85	-8.53	-0.66	2.22e-13	Diisocyanate-induced asthma;
THYM	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg18538332	chr22:24372958	LOC391322	0.98	8.83	0.67	5.15e-14	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs9906944	0.657	rs4643373	chr17:47123423	T/C	cg14634687	chr17:47094252	IGF2BP1	0.32	4.74	0.44	7.36e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.69	0.74	5.59e-18	Chronic sinus infection;
THYM	trans	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg07211511	chr3:129823064	LOC729375	-1.25	-9.96	-0.71	2.06e-16	Blood pressure (smoking interaction);
THYM	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11644478	chr21:40555479	PSMG1	0.98	7.75	0.62	1.03e-11	Cognitive function;
THYM	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	4.63	0.43	1.15e-5	Prudent dietary pattern;
THYM	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.84	5.69	0.5	1.4e-7	Gut microbiome composition (summer);
THYM	cis	rs7267979	1.000	rs1888998	chr20:25291826	A/G	cg08601574	chr20:25228251	PYGB	-0.57	-4.51	-0.42	1.87e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7020830	0.867	rs55845273	chr9:37362219	C/T	cg14294708	chr9:37120828	ZCCHC7	1.16	14.0	0.82	8.09e-25	Schizophrenia;
THYM	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.41	-5.2	-0.47	1.15e-6	Monocyte percentage of white cells;
THYM	cis	rs362272	0.545	rs3135145	chr4:3299504	T/C	cg18352616	chr4:3374830	RGS12	0.73	7.94	0.63	4.11e-12	Serum sulfate level;
THYM	cis	rs4731207	0.565	rs12536146	chr7:124600631	T/A	cg05285228	chr7:124571219	POT1	-0.71	-5.45	-0.49	3.91e-7	Cutaneous malignant melanoma;
THYM	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	5.34	0.48	6.37e-7	Bipolar disorder;
THYM	cis	rs34779708	0.931	rs11010082	chr10:35351155	A/G	cg03585969	chr10:35415529	CREM	0.63	4.66	0.43	1.01e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1050631	0.592	rs1789547	chr18:33725705	C/T	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.58	4.56	0.42	1.54e-5	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg23187316	chr7:1099788	C7orf50	0.6	4.6	0.43	1.3e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg15247329	chr7:2764246	NA	-0.7	-5.91	-0.52	5.43e-8	Height;
THYM	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg08807101	chr21:30365312	RNF160	0.94	7.63	0.62	1.82e-11	Dental caries;
THYM	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg19318889	chr4:1322082	MAEA	-0.66	-5.68	-0.5	1.44e-7	Longevity;
THYM	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.14	0.47	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1372520	0.577	rs748849	chr4:90734961	G/A	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg05962950	chr11:130786565	SNX19	-0.92	-8.93	-0.68	3.27e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs13064411	0.542	rs2399477	chr3:113222998	A/G	cg18753928	chr3:113234510	CCDC52	-0.84	-7.87	-0.63	5.58e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs12142240	0.667	rs55887761	chr1:46826587	C/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg19761014	chr17:28927070	LRRC37B2	0.89	4.93	0.45	3.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg27494647	chr7:150038898	RARRES2	-0.43	-5.42	-0.49	4.44e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs9309711	0.922	rs13399524	chr2:3480206	C/G	cg10845886	chr2:3471009	TTC15	-0.61	-5.04	-0.46	2.18e-6	Neurofibrillary tangles;
THYM	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg19743168	chr1:23544995	NA	0.62	6.31	0.54	8.74e-9	Height;
THYM	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg02527881	chr3:46936655	PTH1R	0.65	6.44	0.55	4.94e-9	Colorectal cancer;
THYM	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg26384229	chr12:38710491	ALG10B	0.91	7.46	0.61	4.14e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg07690219	chr3:49449608	TCTA;RHOA	0.69	4.56	0.42	1.52e-5	Menarche (age at onset);
THYM	cis	rs11264213	0.686	rs12041193	chr1:36412760	C/T	cg27506609	chr1:36549197	TEKT2	0.92	4.83	0.44	5.3e-6	Schizophrenia;
THYM	cis	rs6952809	0.561	rs1548598	chr7:2438912	T/C	cg13581527	chr7:1708566	NA	-0.77	-5.29	-0.48	7.79e-7	Multiple sclerosis;
THYM	cis	rs2637266	0.783	rs846597	chr10:78529114	A/G	cg18941641	chr10:78392320	NA	0.69	5.52	0.49	2.99e-7	Pulmonary function;
THYM	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg10523679	chr1:76189770	ACADM	-0.55	-4.49	-0.42	1.99e-5	Daytime sleep phenotypes;
THYM	cis	rs7731657	0.537	rs7725020	chr5:130285115	C/G	cg08523029	chr5:130500466	HINT1	0.76	5.21	0.47	1.11e-6	Fasting plasma glucose;
THYM	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg15557168	chr22:42548783	NA	0.58	4.68	0.43	9.66e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg08439880	chr3:133502540	NA	-0.78	-6.4	-0.55	5.88e-9	Iron status biomarkers;
THYM	trans	rs877282	0.891	rs11595385	chr10:800539	A/G	cg22713356	chr15:30763199	NA	1.38	10.62	0.74	7.91e-18	Uric acid levels;
THYM	cis	rs71403859	0.502	rs17345863	chr16:71523261	C/T	cg08717414	chr16:71523259	ZNF19	-1.45	-7.43	-0.61	4.75e-11	Post bronchodilator FEV1;
THYM	cis	rs28595532	0.920	rs115372254	chr4:119771735	T/C	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs7226229	0.821	rs62058989	chr17:20940652	T/A	cg21263980	chr17:20946333	USP22	0.64	4.72	0.44	8.12e-6	Blood trace element (Se levels);
THYM	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg07341220	chr16:1583899	IFT140;TMEM204	-0.59	-5.17	-0.47	1.28e-6	Coronary artery disease;
THYM	cis	rs6988636	1.000	rs16898084	chr8:124190377	A/T	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs985746	0.568	rs1380424	chr4:36813517	G/A	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg25251562	chr2:3704773	ALLC	-0.83	-5.59	-0.5	2.16e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg06636001	chr8:8085503	FLJ10661	0.58	5.02	0.46	2.43e-6	Joint mobility (Beighton score);
THYM	cis	rs4363385	0.740	rs1338181	chr1:153010301	C/T	cg13444842	chr1:152974279	SPRR3	-0.59	-4.72	-0.44	8.04e-6	Inflammatory skin disease;
THYM	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.54	5.81	0.51	8.44e-8	Schizophrenia;
THYM	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs861020	0.606	rs695140	chr1:210005061	G/A	cg05527609	chr1:210001259	C1orf107	0.85	6.82	0.57	8.53e-10	Orofacial clefts;
THYM	cis	rs4280164	0.551	rs1109152	chr14:24799024	G/C	cg18846074	chr14:24801073	ADCY4	-0.59	-4.62	-0.43	1.21e-5	Parent of origin effect on language impairment (paternal);
THYM	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs559389	0.775	rs11235455	chr11:71862219	A/G	cg23619769	chr11:71952356	PHOX2A	-0.63	-4.46	-0.42	2.27e-5	Pulmonary function in asthmatics;
THYM	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg04234412	chr22:24373322	LOC391322	-0.92	-10.42	-0.73	2.11e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2637266	0.599	rs846574	chr10:78503082	G/A	cg18941641	chr10:78392320	NA	0.73	5.86	0.51	6.78e-8	Pulmonary function;
THYM	cis	rs7160336	0.568	rs10146294	chr14:74681382	A/G	cg01992424	chr14:75593964	NEK9	-0.7	-4.47	-0.42	2.2e-5	Blood protein levels;
THYM	cis	rs10823500	0.748	rs12355080	chr10:71963608	G/A	cg25502086	chr10:71892093	AIFM2	-0.54	-4.89	-0.45	4.14e-6	Blood protein levels;
THYM	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg15557168	chr22:42548783	NA	-0.59	-4.61	-0.43	1.25e-5	Schizophrenia;
THYM	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg05973401	chr12:123451056	ABCB9	0.71	4.79	0.44	6.2e-6	Neutrophil percentage of white cells;
THYM	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg07599136	chr5:415885	AHRR	0.93	5.17	0.47	1.29e-6	Fat distribution (HIV);
THYM	cis	rs4930776	0.897	rs417646	chr12:5763764	C/T	cg02086166	chr12:5775618	ANO2	0.57	5.43	0.49	4.23e-7	Plasma clusterin levels;
THYM	cis	rs3803170	0.513	rs10774622	chr12:111833348	C/T	cg10833066	chr12:111807467	FAM109A	0.42	4.46	0.42	2.27e-5	Mean corpuscular hemoglobin;
THYM	cis	rs899997	0.906	rs6495318	chr15:78992137	G/C	cg22753661	chr15:79092743	ADAMTS7	-0.68	-4.87	-0.45	4.37e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9309473	0.519	rs13027816	chr2:73897691	C/T	cg19565262	chr2:73869966	NAT8	0.54	4.58	0.43	1.43e-5	Metabolite levels;
THYM	cis	rs1728785	0.688	rs698718	chr16:68560185	A/G	cg02972257	chr16:68554789	NA	-0.74	-4.54	-0.42	1.63e-5	Ulcerative colitis;
THYM	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg12262378	chr17:6899522	ALOX12	0.66	8.84	0.67	4.97e-14	Tonsillectomy;
THYM	cis	rs4907240	0.925	rs4907242	chr2:97273113	C/A	cg01950434	chr2:97203154	ARID5A	-0.58	-4.9	-0.45	3.86e-6	Event-related brain oscillations;
THYM	cis	rs4792901	0.802	rs9898286	chr17:41562542	T/G	cg21940313	chr17:41620911	ETV4	-0.54	-5.13	-0.47	1.5e-6	Dupuytren's disease;
THYM	cis	rs8031584	1.000	rs8031584	chr15:31287343	A/T	cg14829155	chr15:31115871	NA	-0.57	-5.13	-0.47	1.54e-6	Huntington's disease progression;
THYM	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs12142240	0.698	rs45449893	chr1:46859024	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg18479299	chr3:125709523	NA	-0.69	-4.91	-0.45	3.72e-6	Blood pressure (smoking interaction);
THYM	cis	rs354225	0.544	rs10208225	chr2:54806049	G/A	cg23486701	chr2:54789491	SPTBN1	0.36	4.69	0.43	9.11e-6	Schizophrenia;
THYM	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg07988820	chr12:82153109	PPFIA2	-0.82	-5.23	-0.47	9.93e-7	Resting heart rate;
THYM	cis	rs4523957	0.620	rs9906467	chr17:2069003	C/T	cg16513277	chr17:2031491	SMG6	-1.04	-9.92	-0.71	2.46e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11696501	0.739	rs6073835	chr20:44286454	C/T	cg11783356	chr20:44313418	WFDC10B	-0.69	-4.73	-0.44	7.72e-6	Brain structure;
THYM	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg06108461	chr20:60628389	TAF4	-1.07	-8.7	-0.67	9.91e-14	Body mass index;
THYM	cis	rs6840360	0.615	rs113052419	chr4:152473008	T/C	cg22705602	chr4:152727874	NA	-0.71	-7.94	-0.63	4.03e-12	Intelligence (multi-trait analysis);
THYM	cis	rs526231	0.511	rs62362558	chr5:102368493	C/T	cg23492399	chr5:102201601	PAM	-0.67	-5.09	-0.46	1.77e-6	Primary biliary cholangitis;
THYM	cis	rs6496667	0.532	rs2601207	chr15:90963542	C/G	cg00425431	chr15:90792223	TTLL13	-0.43	-5.28	-0.48	8.09e-7	Rheumatoid arthritis;
THYM	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg18200150	chr17:30822561	MYO1D	0.86	8.47	0.66	3.11e-13	Schizophrenia;
THYM	cis	rs13070279	0.582	rs67109126	chr3:71799808	C/T	cg19388776	chr3:71835112	PROK2	0.88	5.16	0.47	1.34e-6	Monocyte count;
THYM	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg13010199	chr12:38710504	ALG10B	0.64	4.78	0.44	6.28e-6	Bladder cancer;
THYM	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg23791538	chr6:167370224	RNASET2	0.75	6.03	0.53	3.17e-8	Crohn's disease;
THYM	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg00129232	chr17:37814104	STARD3	0.72	5.14	0.47	1.46e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg15744005	chr10:104629667	AS3MT	-0.82	-7.71	-0.62	1.22e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs259964	0.692	rs259976	chr20:57809343	G/A	cg09005679	chr20:57875326	EDN3	-0.39	-4.66	-0.43	1.03e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs36051895	0.589	rs7874785	chr9:5196695	C/T	cg02405213	chr9:5042618	JAK2	0.92	9.03	0.68	2e-14	Pediatric autoimmune diseases;
THYM	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg11279151	chr3:101281821	RG9MTD1	-0.68	-4.99	-0.46	2.68e-6	Colorectal cancer;
THYM	cis	rs10799590	1.000	rs298735	chr1:224842759	A/G	cg01808320	chr1:224927238	CNIH3	-0.53	-4.73	-0.44	7.81e-6	Opioid dependence;
THYM	cis	rs143283559	1	rs143283559	chr18:77567761	T/G	cg26740109	chr18:77585428	NA	-0.66	-4.74	-0.44	7.43e-6	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg11335335	chr11:637885	DRD4	-0.62	-5.23	-0.47	1.01e-6	Systemic lupus erythematosus;
THYM	cis	rs10208940	0.614	rs58485056	chr2:68828403	G/A	cg09157127	chr2:69201416	GKN1	0.89	4.71	0.43	8.61e-6	Urate levels in lean individuals;
THYM	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg14829155	chr15:31115871	NA	0.74	6.1	0.53	2.26e-8	Huntington's disease progression;
THYM	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg03396347	chr1:1875803	NA	-0.7	-7.28	-0.6	9.69e-11	Body mass index;
THYM	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg09354556	chr3:47051341	NA	0.46	4.74	0.44	7.63e-6	Colorectal cancer;
THYM	cis	rs4930776	1.000	rs251785	chr12:5769857	T/C	cg02086166	chr12:5775618	ANO2	0.57	5.51	0.49	3.1e-7	Plasma clusterin levels;
THYM	cis	rs2066819	1.000	rs2643623	chr12:56689725	G/C	cg26714650	chr12:56694279	CS	1.26	7.39	0.6	5.59e-11	Psoriasis vulgaris;
THYM	cis	rs1322639	0.614	rs9364356	chr6:169567108	G/A	cg04662567	chr6:169592167	NA	-0.82	-6.54	-0.56	3.15e-9	Pulse pressure;
THYM	trans	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg05926928	chr17:57297772	GDPD1	1.03	7.32	0.6	7.91e-11	Opioid sensitivity;
THYM	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg21784768	chr11:537496	LRRC56	-1.05	-4.84	-0.44	5.04e-6	Body mass index;
THYM	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg22166914	chr1:53195759	ZYG11B	0.84	8.13	0.64	1.58e-12	Monocyte count;
THYM	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg11812906	chr14:75593930	NEK9	-0.82	-7.6	-0.61	2.11e-11	Height;
THYM	cis	rs4523957	0.620	rs9900587	chr17:2071097	G/A	cg16513277	chr17:2031491	SMG6	-1.03	-10.05	-0.72	1.27e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs3845702	0.668	rs12693215	chr2:180826007	A/C	cg01881094	chr2:180872142	CWC22	-0.85	-5.0	-0.46	2.64e-6	Schizophrenia;
THYM	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg27394845	chr17:28928406	LRRC37B2	0.98	4.82	0.44	5.45e-6	Body mass index;
THYM	cis	rs7107174	0.688	rs11237489	chr11:78130325	G/A	cg19901956	chr11:77921274	USP35	-0.71	-5.35	-0.48	6.07e-7	Testicular germ cell tumor;
THYM	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg04320152	chr17:18167836	SMCR7	0.6	4.71	0.44	8.41e-6	Total body bone mineral density;
THYM	cis	rs9522267	0.535	rs11069897	chr13:112231319	A/G	cg15979348	chr13:112237479	NA	-0.48	-4.46	-0.42	2.21e-5	Hepatitis;
THYM	cis	rs116095464	0.850	rs73023433	chr5:317670	G/A	cg22857025	chr5:266934	NA	-1.37	-4.98	-0.46	2.8e-6	Breast cancer;
THYM	cis	rs55823223	0.590	rs11870142	chr17:73859002	A/G	cg08125733	chr17:73851984	WBP2	0.85	5.58	0.5	2.24e-7	Psoriasis;
THYM	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs1003719	0.688	rs2835662	chr21:38568967	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-4.53	-0.42	1.72e-5	Eye color traits;
THYM	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg22508957	chr16:3507546	NAT15	0.49	5.24	0.47	9.79e-7	Body mass index (adult);
THYM	cis	rs2456568	0.900	rs2511376	chr11:93670388	C/T	cg26875233	chr11:93583750	C11orf90	-0.5	-4.88	-0.45	4.32e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg26441486	chr22:50317300	CRELD2	0.43	6.57	0.56	2.71e-9	Schizophrenia;
THYM	cis	rs2456568	0.508	rs1607403	chr11:93660514	A/G	cg17595323	chr11:93583763	C11orf90	-0.55	-5.83	-0.51	7.52e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs4383453	0.539	rs903572	chr3:123101144	A/G	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs11608355	1.000	rs3742020	chr12:109883254	T/C	cg10504392	chr12:110044639	NA	0.66	6.22	0.54	1.35e-8	Neuroticism;
THYM	cis	rs7178572	0.568	rs11072643	chr15:77415508	T/A	cg22256960	chr15:77711686	NA	0.97	7.55	0.61	2.63e-11	Type 2 diabetes;
THYM	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs17826219	0.733	rs7221691	chr17:28723619	C/T	cg27034606	chr17:28928453	LRRC37B2	-0.77	-4.5	-0.42	1.89e-5	Body mass index;
THYM	cis	rs35883536	1.000	rs4907921	chr1:101128249	C/T	cg06223162	chr1:101003688	GPR88	0.67	5.14	0.47	1.47e-6	Monocyte count;
THYM	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg25036284	chr2:26402008	FAM59B	0.8	5.36	0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg16928487	chr17:17741425	SREBF1	0.46	4.45	0.42	2.36e-5	Total body bone mineral density;
THYM	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg17796960	chr10:135278976	LOC619207	-0.59	-4.87	-0.45	4.38e-6	Systemic lupus erythematosus;
THYM	cis	rs61931739	0.782	rs3903201	chr12:34248275	G/A	cg06521331	chr12:34319734	NA	-0.64	-5.37	-0.48	5.62e-7	Morning vs. evening chronotype;
THYM	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg14972814	chr11:95582409	MTMR2	-0.59	-4.64	-0.43	1.1e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7177699	0.557	rs12898292	chr15:79112603	A/G	cg15571903	chr15:79123663	NA	0.58	6.5	0.55	3.66e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs2637266	0.714	rs11594217	chr10:78385088	G/T	cg18941641	chr10:78392320	NA	-0.68	-4.63	-0.43	1.18e-5	Pulmonary function;
THYM	cis	rs6430585	0.528	rs79826902	chr2:136670419	G/A	cg20242066	chr2:136595261	LCT	0.56	5.17	0.47	1.28e-6	Corneal structure;
THYM	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg03676636	chr4:99064102	C4orf37	0.42	6.16	0.53	1.78e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg15592062	chr6:167189543	RPS6KA2	0.57	5.64	0.5	1.71e-7	Crohn's disease;
THYM	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg02953382	chr22:24373134	LOC391322	-0.76	-7.9	-0.63	4.97e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2299587	0.607	rs2237848	chr8:17874604	A/C	cg01800426	chr8:17659068	MTUS1	-0.63	-4.83	-0.44	5.26e-6	Economic and political preferences;
THYM	cis	rs4343996	0.934	rs4320450	chr7:3372308	G/C	cg21248987	chr7:3385318	SDK1	-0.41	-4.84	-0.44	4.95e-6	Motion sickness;
THYM	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.24e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg02038168	chr22:39784481	NA	-0.69	-5.57	-0.5	2.38e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1784581	0.722	rs1621456	chr6:162399985	C/T	cg17173639	chr6:162384350	PARK2	-0.87	-7.94	-0.63	4.12e-12	Itch intensity from mosquito bite;
THYM	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.68	-4.57	-0.42	1.44e-5	Menarche (age at onset);
THYM	cis	rs13064411	0.696	rs6798938	chr3:113218206	C/T	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg13609457	chr4:120235615	NA	0.61	5.48	0.49	3.41e-7	Corneal astigmatism;
THYM	cis	rs8073060	0.855	rs12150450	chr17:33868896	A/T	cg24895173	chr17:33825374	SLFN12L	0.62	5.09	0.46	1.78e-6	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg17211192	chr8:82754475	SNX16	0.91	7.3	0.6	8.57e-11	Diastolic blood pressure;
THYM	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg26031613	chr14:104095156	KLC1	0.78	5.2	0.47	1.14e-6	Body mass index;
THYM	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs7084402	0.967	rs1649055	chr10:60320045	T/A	cg07615347	chr10:60278583	BICC1	0.56	5.15	0.47	1.4e-6	Refractive error;
THYM	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg12756686	chr19:29218302	NA	0.71	4.76	0.44	6.8e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs7580658	0.929	rs4150477	chr2:128032546	A/G	cg10021288	chr2:128175891	PROC	0.8	7.06	0.59	2.71e-10	Protein C levels;
THYM	cis	rs7103648	0.966	rs11500477	chr11:47409051	T/A	cg20307385	chr11:47447363	PSMC3	0.94	7.99	0.63	3.11e-12	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg19761014	chr17:28927070	LRRC37B2	0.74	4.66	0.43	1.04e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7809950	0.817	rs11535285	chr7:107143866	A/G	cg23024343	chr7:107201750	COG5	-1.03	-8.96	-0.68	2.81e-14	Coronary artery disease;
THYM	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.24	0.47	9.61e-7	Height;
THYM	cis	rs986417	0.818	rs767602	chr14:61098624	G/T	cg27398547	chr14:60952738	C14orf39	1.08	5.23	0.47	1.01e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs2811415	0.597	rs56211835	chr3:127803232	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs6558530	0.965	rs6558535	chr8:1710632	T/C	cg09410841	chr8:1729607	CLN8	0.83	6.0	0.52	3.61e-8	Systolic blood pressure;
THYM	cis	rs11030122	0.673	rs10767767	chr11:4003678	C/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.83	-0.51	7.45e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs3741151	1.000	rs74795285	chr11:73033387	A/G	cg17517138	chr11:73019481	ARHGEF17	0.98	5.82	0.51	7.95e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs6906287	0.631	rs9320663	chr6:118986172	A/G	cg01113488	chr6:119027122	NA	0.57	4.72	0.44	7.96e-6	Electrocardiographic conduction measures;
THYM	cis	rs763014	0.500	rs11865749	chr16:717971	C/G	cg01446963	chr16:420627	MRPL28	-0.66	-4.9	-0.45	3.94e-6	Height;
THYM	cis	rs62435770	1.000	rs62435802	chr6:169499434	G/A	cg07652237	chr6:170125491	PHF10	0.57	5.21	0.47	1.1e-6	Loneliness;
THYM	cis	rs4664308	0.875	rs2124969	chr2:160989486	T/C	cg03641300	chr2:160917029	PLA2R1	-0.75	-6.87	-0.58	6.63e-10	Idiopathic membranous nephropathy;
THYM	cis	rs62070183	0.817	rs79640811	chr17:31221317	C/T	cg23177095	chr17:30873196	MYO1D	0.64	5.02	0.46	2.41e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg25072359	chr17:41440525	NA	0.64	4.48	0.42	2.05e-5	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg03676636	chr4:99064102	C4orf37	-0.44	-6.56	-0.56	2.86e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg18252515	chr7:66147081	NA	0.6	4.54	0.42	1.63e-5	Aortic root size;
THYM	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg06558623	chr16:89946397	TCF25	1.32	4.68	0.43	9.51e-6	Skin colour saturation;
THYM	cis	rs1883415	0.727	rs9393560	chr6:24502183	A/G	cg00346970	chr6:24499591	ALDH5A1	0.39	5.08	0.46	1.89e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs11771526	0.681	rs62457535	chr7:32358710	C/G	cg27532318	chr7:32358331	NA	0.95	5.63	0.5	1.85e-7	Body mass index;
THYM	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg24692254	chr21:30365293	RNF160	-0.85	-7.06	-0.59	2.74e-10	Dental caries;
THYM	cis	rs921968	0.541	rs72965126	chr2:219330189	C/T	cg02176678	chr2:219576539	TTLL4	-0.73	-7.24	-0.6	1.18e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2235573	0.594	rs11912649	chr22:38415542	C/T	cg19171272	chr22:38449367	NA	-0.5	-5.25	-0.47	9.25e-7	Glioblastoma;Glioma;
THYM	cis	rs35264875	0.796	rs72928657	chr11:68852336	T/C	cg23845249	chr11:68861649	NA	0.55	6.53	0.56	3.22e-9	Blond vs. brown hair color;
THYM	cis	rs754466	0.580	rs2289311	chr10:79565655	G/A	cg17075019	chr10:79541650	NA	-0.63	-5.06	-0.46	2.01e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.65	0.5	1.64e-7	Tonsillectomy;
THYM	cis	rs236352	0.576	rs2116447	chr6:36837364	T/C	cg03410223	chr6:36853544	C6orf89	0.73	5.75	0.51	1.09e-7	Heart rate;
THYM	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg12564285	chr5:131593104	PDLIM4	0.45	4.81	0.44	5.56e-6	Blood metabolite levels;
THYM	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg00339695	chr16:24857497	SLC5A11	-0.68	-6.18	-0.54	1.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg05234568	chr11:5960015	NA	-0.6	-4.84	-0.44	4.97e-6	DNA methylation (variation);
THYM	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg07606381	chr6:8435919	SLC35B3	0.66	4.93	0.45	3.51e-6	Motion sickness;
THYM	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.68	0.5	1.46e-7	Height;
THYM	cis	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg05335186	chr13:53173507	NA	0.49	6.23	0.54	1.28e-8	Lewy body disease;
THYM	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg12310025	chr6:25882481	NA	0.68	5.56	0.5	2.47e-7	Schizophrenia;
THYM	cis	rs1483890	0.723	rs12629229	chr3:69411222	A/G	cg22125112	chr3:69402811	FRMD4B	0.54	6.85	0.58	7.21e-10	Resting heart rate;
THYM	cis	rs4919044	0.641	rs12357515	chr10:94725508	A/G	cg05127821	chr10:94822908	CYP26C1	-1.12	-6.77	-0.57	1.08e-9	Coronary artery disease;
THYM	cis	rs7474896	0.616	rs2505239	chr10:38440765	A/G	cg13531842	chr10:38383804	ZNF37A	-0.73	-4.47	-0.42	2.2e-5	Obesity (extreme);
THYM	cis	rs6163	0.508	rs11191381	chr10:104493444	C/T	cg05855489	chr10:104503620	C10orf26	0.74	5.79	0.51	9.14e-8	Waist circumference;Hip circumference;
THYM	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg23583168	chr7:148888333	NA	-1.03	-13.3	-0.81	2.04e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs289828	0.507	rs56376752	chr2:152118275	A/G	cg05960677	chr2:152117363	RBM43	0.76	7.93	0.63	4.29e-12	Blood protein levels;
THYM	cis	rs9565309	0.579	rs9573977	chr13:77586425	A/G	cg13866767	chr13:78470850	EDNRB	-1.06	-4.81	-0.44	5.76e-6	Morning vs. evening chronotype;
THYM	cis	rs4455778	0.580	rs6583507	chr7:49122261	T/C	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg06784218	chr1:46089804	CCDC17	0.31	4.57	0.42	1.46e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg13918804	chr1:2043761	PRKCZ	0.75	7.08	0.59	2.49e-10	Height;
THYM	cis	rs910187	0.678	rs1046661	chr20:45817149	G/A	cg27589058	chr20:45804311	EYA2	-0.58	-4.97	-0.45	2.96e-6	Migraine;
THYM	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg15536230	chr21:44985092	HSF2BP	0.39	4.75	0.44	7.19e-6	Mean corpuscular volume;
THYM	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18765753	chr7:1198926	ZFAND2A	-0.57	-5.64	-0.5	1.78e-7	Longevity;Endometriosis;
THYM	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg03396347	chr1:1875803	NA	-0.69	-7.42	-0.61	5.01e-11	Body mass index;
THYM	cis	rs10504073	0.584	rs1511368	chr8:49949523	A/T	cg00325661	chr8:49890786	NA	1.06	10.84	0.74	2.75e-18	Blood metabolite ratios;
THYM	cis	rs7124681	0.528	rs74608150	chr11:47696214	A/T	cg20307385	chr11:47447363	PSMC3	0.6	4.51	0.42	1.87e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg09085632	chr11:111637200	PPP2R1B	0.95	8.68	0.67	1.1e-13	Primary sclerosing cholangitis;
THYM	trans	rs75518195	0.543	rs17687835	chr4:64671830	T/C	cg14706739	chr8:21916355	EPB49	0.75	7.37	0.6	6.34e-11	Triptolide cytotoxicity;
THYM	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg24642439	chr20:33292090	TP53INP2	0.6	4.72	0.44	8.18e-6	Coronary artery disease;
THYM	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-5.36	-0.48	5.89e-7	Monocyte percentage of white cells;
THYM	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg18451016	chr1:38461880	NA	-0.43	-5.43	-0.49	4.4e-7	Coronary artery disease;
THYM	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	4.79	0.44	6.04e-6	Menarche (age at onset);
THYM	cis	rs8067545	0.750	rs9896411	chr17:19987610	A/T	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.64e-6	Schizophrenia;
THYM	cis	rs1061377	0.513	rs2566166	chr4:39150024	C/A	cg24403649	chr4:39172243	NA	-0.6	-5.03	-0.46	2.33e-6	Uric acid levels;
THYM	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg15445000	chr17:37608096	MED1	-0.44	-5.1	-0.46	1.72e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	4.54	0.42	1.67e-5	Alzheimer's disease;
THYM	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg09549813	chr16:4587862	C16orf5	-0.5	-5.77	-0.51	9.78e-8	Schizophrenia;
THYM	cis	rs920590	0.796	rs7820505	chr8:19634829	A/G	cg01411142	chr8:19674711	INTS10	-0.73	-5.75	-0.51	1.08e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg26384229	chr12:38710491	ALG10B	-0.89	-9.05	-0.68	1.77e-14	Heart rate;
THYM	cis	rs9486719	0.895	rs12190520	chr6:96928620	A/C	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.94	-0.45	3.39e-6	Migraine;Coronary artery disease;
THYM	cis	rs2046867	0.862	rs62251646	chr3:72805787	T/C	cg25664220	chr3:72788482	NA	-0.86	-6.56	-0.56	2.76e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs2404602	0.598	rs71405204	chr15:76635305	C/G	cg23625390	chr15:77176239	SCAPER	-0.75	-5.3	-0.48	7.36e-7	Blood metabolite levels;
THYM	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg17063962	chr7:91808500	NA	1.1	12.12	0.78	5.59e-21	Breast cancer;
THYM	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg20283391	chr11:68216788	NA	-0.6	-4.54	-0.42	1.62e-5	Total body bone mineral density;
THYM	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg14829155	chr15:31115871	NA	-0.56	-5.17	-0.47	1.29e-6	Huntington's disease progression;
THYM	cis	rs2439831	0.867	rs2260160	chr15:43895643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	6.16	0.53	1.78e-8	Lung cancer in ever smokers;
THYM	cis	rs2219968	0.683	rs7010265	chr8:78907014	A/T	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11249608	0.548	rs2132671	chr5:178457434	A/G	cg01312482	chr5:178451176	ZNF879	0.76	6.3	0.54	9.29e-9	Pubertal anthropometrics;
THYM	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg14416269	chr4:6271139	WFS1	0.54	5.52	0.49	2.88e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs7192750	0.586	rs2018384	chr16:71940825	T/C	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg12386194	chr3:101231763	SENP7	0.95	7.47	0.61	3.85e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg06611532	chr13:114900021	NA	0.63	6.8	0.57	9.04e-10	Schizophrenia;
THYM	cis	rs7649443	0.959	rs2044861	chr3:196949564	C/T	cg20744464	chr3:196756875	MFI2	0.63	4.64	0.43	1.12e-5	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg02753203	chr1:228287806	NA	-0.61	-5.28	-0.48	8.19e-7	Diastolic blood pressure;
THYM	cis	rs12643440	0.538	rs16894418	chr4:17141112	T/C	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs6956675	0.915	rs4285375	chr7:62650353	C/T	cg27518014	chr7:62859535	LOC100287834	0.58	4.74	0.44	7.51e-6	Obesity-related traits;
THYM	cis	rs12282928	0.836	rs1503177	chr11:48269178	A/G	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs11997175	0.646	rs66856932	chr8:33700782	A/G	ch.8.33884649F	chr8:33765107	NA	0.66	4.99	0.46	2.67e-6	Body mass index;
THYM	cis	rs4936891	0.504	rs11219389	chr11:123852381	C/T	cg22125253	chr11:123886957	OR10G4	-0.57	-5.24	-0.47	9.71e-7	Male fertility;
THYM	cis	rs611744	0.901	rs639746	chr8:109234825	T/C	cg21045802	chr8:109455806	TTC35	0.59	5.25	0.47	9.08e-7	Dupuytren's disease;
THYM	cis	rs6429082	0.807	rs4659857	chr1:235581411	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.63	-5.31	-0.48	7.25e-7	Adiposity;
THYM	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg11905131	chr22:24372483	LOC391322	0.96	10.62	0.74	7.96e-18	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7586879	0.521	rs7597332	chr2:25075675	A/G	cg15423357	chr2:25149977	NA	0.62	6.33	0.54	8.22e-9	Body mass index;
THYM	cis	rs6500602	0.653	rs3747579	chr16:4445327	A/G	cg08645402	chr16:4508243	NA	-0.62	-5.21	-0.47	1.11e-6	Schizophrenia;
THYM	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg15744692	chr15:45671195	LOC145663;GATM	0.45	4.48	0.42	2.08e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg02640540	chr1:67518911	SLC35D1	0.57	4.58	0.42	1.44e-5	Lymphocyte percentage of white cells;
THYM	cis	rs4732038	0.510	rs6948014	chr7:134274486	T/C	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs1883415	0.516	rs2744587	chr6:24508511	G/A	cg00346970	chr6:24499591	ALDH5A1	0.4	4.59	0.43	1.37e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2811415	0.597	rs1044843	chr3:127783698	A/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs7725337	1.000	rs10070540	chr5:88401770	T/C	cg11280525	chr5:87955695	LOC645323	-0.4	-4.48	-0.42	2.06e-5	Total body bone mineral density;
THYM	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	13.4	0.81	1.29e-23	Chronic sinus infection;
THYM	cis	rs4891159	0.548	rs689902	chr18:74119969	C/T	cg24786174	chr18:74118243	ZNF516	-0.96	-14.2	-0.82	3.19e-25	Longevity;
THYM	cis	rs490234	0.615	rs2819625	chr9:128156648	A/G	cg14078157	chr9:128172775	NA	-0.85	-6.93	-0.58	4.91e-10	Mean arterial pressure;
THYM	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.12	-0.72	9.21e-17	Primary sclerosing cholangitis;
THYM	cis	rs1003719	0.762	rs3787787	chr21:38463452	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs2835345	0.563	rs74439245	chr21:37824620	G/A	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1933112	1.000	rs1933104	chr1:168528886	G/T	cg00154920	chr1:168513310	XCL2	-0.5	-4.91	-0.45	3.82e-6	Blood protein levels;
THYM	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.53	-4.96	-0.45	3.04e-6	Lymphocyte counts;
THYM	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg20608306	chr11:116969690	SIK3	0.51	5.46	0.49	3.84e-7	Blood protein levels;
THYM	cis	rs240110	0.539	rs6934256	chr6:101338728	G/A	cg21058520	chr6:100914733	NA	-0.57	-4.92	-0.45	3.69e-6	Neuroticism;
THYM	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg23730037	chr7:158596552	ESYT2	0.44	4.64	0.43	1.12e-5	Height;
THYM	cis	rs9399401	0.667	rs6912639	chr6:142770548	T/C	cg03128060	chr6:142623767	GPR126	0.65	8.54	0.66	2.17e-13	Chronic obstructive pulmonary disease;
THYM	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg15921436	chr17:44337874	NA	0.91	6.69	0.57	1.56e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg06636001	chr8:8085503	FLJ10661	0.84	8.58	0.66	1.74e-13	Mood instability;
THYM	cis	rs9314614	1.000	rs2951851	chr8:6693495	T/G	cg27319216	chr8:6693540	XKR5	-0.73	-8.5	-0.66	2.63e-13	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs10277209	0.932	rs4730384	chr7:109039061	G/T	cg24448523	chr7:109046164	NA	-0.88	-4.83	-0.44	5.28e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs13006833	0.635	rs2664251	chr2:191147667	C/T	cg21644426	chr2:191273491	MFSD6	0.63	4.45	0.42	2.33e-5	Urinary metabolites;
THYM	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg26384229	chr12:38710491	ALG10B	0.97	7.44	0.61	4.48e-11	Bladder cancer;
THYM	cis	rs995000	0.899	rs10889337	chr1:62980607	G/A	cg06896770	chr1:63153194	DOCK7	0.92	7.69	0.62	1.32e-11	Triglyceride levels;
THYM	cis	rs57994353	0.865	rs13290734	chr9:139330701	G/A	cg14115884	chr9:139300582	SDCCAG3	0.67	4.59	0.43	1.33e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg06981504	chr1:1234844	ACAP3	0.56	5.09	0.46	1.79e-6	Body mass index;
THYM	cis	rs1894633	0.574	rs56259646	chr1:172330739	A/G	cg13446689	chr1:172328377	DNM3	0.54	4.92	0.45	3.65e-6	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs17209837	0.607	rs1558375	chr7:87079069	T/C	cg04996195	chr7:87105398	ABCB4	0.63	4.81	0.44	5.63e-6	Gallbladder cancer;
THYM	cis	rs13315871	1.000	rs35792042	chr3:58409668	C/T	cg12435725	chr3:58293450	RPP14	-0.46	-4.93	-0.45	3.54e-6	Cholesterol, total;
THYM	cis	rs7267979	1.000	rs2257420	chr20:25275890	C/A	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs17685	0.884	rs8565	chr7:75630274	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.53	5.42	0.49	4.43e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-4.5	-0.42	1.93e-5	Mood instability;
THYM	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg18105134	chr13:113819100	PROZ	-0.95	-8.7	-0.67	1e-13	Platelet distribution width;
THYM	cis	rs4481887	0.927	rs10888343	chr1:248446642	A/G	cg00666640	chr1:248458726	OR2T12	0.54	4.57	0.42	1.48e-5	Common traits (Other);
THYM	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg13695892	chr22:41940480	POLR3H	0.86	6.33	0.54	8.08e-9	Vitiligo;
THYM	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg10802521	chr3:52805072	NEK4	-0.74	-6.55	-0.56	3.01e-9	Bipolar disorder;
THYM	cis	rs9826463	0.582	rs11720007	chr3:142134712	T/G	cg20824294	chr3:142316082	PLS1	0.76	5.3	0.48	7.53e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg20486651	chr6:167070296	RPS6KA2	0.52	4.98	0.45	2.84e-6	Crohn's disease;
THYM	cis	rs7196129	0.932	rs11574938	chr16:30485393	G/C	cg24033122	chr16:30485383	ITGAL	0.4	4.9	0.45	3.92e-6	Monocyte count;
THYM	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg03388043	chr17:80084554	CCDC57	-0.67	-5.71	-0.51	1.26e-7	Life satisfaction;
THYM	cis	rs4654899	0.758	rs6426665	chr1:21382205	T/C	cg01072550	chr1:21505969	NA	-0.72	-6.94	-0.58	4.85e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg27490568	chr2:178487706	NA	0.6	5.32	0.48	6.97e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	5.51	0.49	3.02e-7	Platelet count;
THYM	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg05182265	chr7:156933206	UBE3C	-0.69	-9.34	-0.69	4.32e-15	Body mass index;
THYM	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg15445000	chr17:37608096	MED1	-0.44	-5.22	-0.47	1.05e-6	Glomerular filtration rate (creatinine);
THYM	trans	rs507506	0.771	rs929229	chr17:7105399	C/T	cg15655154	chr3:113604241	GRAMD1C	0.87	7.96	0.63	3.71e-12	Adiponectin levels;
THYM	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg23851026	chr2:136556271	LCT	0.57	5.39	0.48	5.18e-7	Mosquito bite size;
THYM	cis	rs7084402	0.875	rs1593671	chr10:60295969	A/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.65e-7	Refractive error;
THYM	cis	rs55665837	1.000	rs10832275	chr11:14478224	A/C	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg03213289	chr20:61660250	NA	0.91	9.46	0.7	2.34e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg19626725	chr5:178986131	RUFY1	-0.32	-5.06	-0.46	2.06e-6	Lung cancer;
THYM	cis	rs4924935	0.851	rs966811	chr17:18830287	G/A	cg26378065	chr17:18585709	ZNF286B	-0.72	-5.03	-0.46	2.3e-6	Pancreatic cancer;
THYM	cis	rs11645898	0.872	rs55955726	chr16:72213691	G/C	cg14768367	chr16:72042858	DHODH	-0.67	-4.93	-0.45	3.42e-6	Blood protein levels;
THYM	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs4731207	0.596	rs6963594	chr7:124609233	C/T	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs4889855	0.556	rs4297763	chr17:78533626	G/C	cg16591659	chr17:78472290	NA	0.42	4.86	0.45	4.54e-6	Fractional excretion of uric acid;
THYM	cis	rs427394	0.802	rs200841	chr5:6737134	A/G	cg10857441	chr5:6722123	POLS	-0.7	-8.41	-0.65	4.12e-13	Menopause (age at onset);
THYM	cis	rs7107174	1.000	rs7112234	chr11:78102470	G/A	cg02023728	chr11:77925099	USP35	0.64	6.31	0.54	8.63e-9	Testicular germ cell tumor;
THYM	cis	rs2637266	1.000	rs7474960	chr10:78359021	C/T	cg18941641	chr10:78392320	NA	0.72	6.33	0.54	8.03e-9	Pulmonary function;
THYM	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg08213375	chr14:104286397	PPP1R13B	0.44	4.51	0.42	1.82e-5	Reticulocyte count;
THYM	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs12711979	0.509	rs10181286	chr2:3824567	G/A	cg17052675	chr2:3827356	NA	-0.88	-13.79	-0.82	2.09e-24	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg26384229	chr12:38710491	ALG10B	0.97	7.47	0.61	3.8e-11	Bladder cancer;
THYM	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg09085632	chr11:111637200	PPP2R1B	1.19	12.69	0.79	3.69e-22	Primary sclerosing cholangitis;
THYM	cis	rs865483	0.929	rs853194	chr17:35848045	A/C	cg06716730	chr17:35851459	DUSP14	0.45	7.69	0.62	1.36e-11	Monocyte count;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg26716046	chr11:77762238	NA	-0.92	-7.55	-0.61	2.58e-11	Depressive symptoms;
THYM	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg03388043	chr17:80084554	CCDC57	0.69	5.98	0.52	3.85e-8	Life satisfaction;
THYM	cis	rs400736	0.930	rs2745722	chr1:8056669	G/A	cg22678073	chr1:8087421	ERRFI1	0.46	4.89	0.45	4.08e-6	Response to antidepressants and depression;
THYM	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs2456568	0.900	rs877340	chr11:93689292	A/T	cg26875233	chr11:93583750	C11orf90	-0.5	-4.88	-0.45	4.23e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2637266	0.846	rs2637260	chr10:78320346	C/T	cg18941641	chr10:78392320	NA	-0.69	-5.84	-0.51	7.23e-8	Pulmonary function;
THYM	cis	rs3741151	0.773	rs61345051	chr11:73112305	T/C	cg17517138	chr11:73019481	ARHGEF17	0.94	5.48	0.49	3.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg03474202	chr17:45855739	NA	-0.76	-6.7	-0.57	1.46e-9	IgG glycosylation;
THYM	cis	rs3741151	0.773	rs73546720	chr11:73252409	C/T	cg12959048	chr11:73096162	RELT	-0.52	-4.58	-0.43	1.43e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg00102166	chr1:43425337	SLC2A1	-0.75	-4.97	-0.45	3.01e-6	Monocyte count;
THYM	cis	rs526231	0.511	rs34823	chr5:102438291	C/T	cg23492399	chr5:102201601	PAM	0.66	4.86	0.45	4.62e-6	Primary biliary cholangitis;
THYM	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1059312	0.932	rs7960920	chr12:129283149	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.65	-5.18	-0.47	1.23e-6	Systemic lupus erythematosus;
THYM	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.87	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3960554	0.808	rs112962015	chr7:75659303	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-4.56	-0.42	1.51e-5	Eotaxin levels;
THYM	cis	rs7084402	0.967	rs1427223	chr10:60290966	T/C	cg07615347	chr10:60278583	BICC1	0.56	5.04	0.46	2.19e-6	Refractive error;
THYM	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg04320152	chr17:18167836	SMCR7	-0.57	-4.66	-0.43	1.01e-5	Total body bone mineral density;
THYM	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14240646	chr10:27532245	ACBD5	-0.93	-9.16	-0.68	1.05e-14	Breast cancer;
THYM	cis	rs7172677	1.000	rs4243032	chr15:75426884	C/G	cg09165964	chr15:75287851	SCAMP5	-0.6	-4.73	-0.44	7.77e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg18811423	chr2:55921094	PNPT1	0.76	7.16	0.59	1.7e-10	Metabolic syndrome;
THYM	cis	rs4665630	0.764	rs6715626	chr2:23891551	G/A	cg08081869	chr2:24582653	ITSN2	0.76	4.47	0.42	2.19e-5	Hypertension;
THYM	cis	rs7582180	0.613	rs12988464	chr2:100946285	A/G	cg08017756	chr2:100939284	LONRF2	-0.74	-7.68	-0.62	1.41e-11	Intelligence (multi-trait analysis);
THYM	cis	rs3741151	0.892	rs76854106	chr11:73027110	G/A	cg17517138	chr11:73019481	ARHGEF17	0.94	5.6	0.5	2.04e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg26038318	chr20:34205095	SPAG4	0.66	5.46	0.49	3.76e-7	Total cholesterol levels;
THYM	cis	rs4474465	1.000	rs2373199	chr11:78142982	G/A	cg19901956	chr11:77921274	USP35	-0.6	-4.5	-0.42	1.91e-5	Alzheimer's disease (survival time);
THYM	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg14458575	chr2:238380390	NA	0.85	6.44	0.55	4.88e-9	Prostate cancer;
THYM	cis	rs36051895	0.632	rs7029084	chr9:5174638	T/C	cg02405213	chr9:5042618	JAK2	-0.97	-10.47	-0.73	1.68e-17	Pediatric autoimmune diseases;
THYM	cis	rs791590	0.752	rs3118475	chr10:6107265	T/C	cg17191567	chr10:6178319	NA	0.73	5.1	0.46	1.75e-6	Soluble interleukin-2 receptor subunit alpha;
THYM	cis	rs6570726	0.791	rs7765675	chr6:145915077	A/C	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg16524936	chr4:1340807	KIAA1530	-0.66	-4.82	-0.44	5.42e-6	Longevity;
THYM	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg10803722	chr21:46713166	LOC642852	-0.38	-4.75	-0.44	7.19e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs17253792	0.822	rs10142497	chr14:56047948	C/T	cg01858014	chr14:56050164	KTN1	1.23	5.16	0.47	1.36e-6	Putamen volume;
THYM	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg11366901	chr6:160182831	ACAT2	1.02	9.27	0.69	6.04e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg25566285	chr7:158114605	PTPRN2	-0.87	-10.68	-0.74	5.87e-18	Calcium levels;
THYM	cis	rs988913	0.781	rs1963697	chr6:54772814	G/T	cg19716238	chr6:54711378	FAM83B	0.54	5.67	0.5	1.52e-7	Menarche (age at onset);
THYM	cis	rs6939532	0.522	rs6933583	chr6:26355283	A/C	cg14345882	chr6:26364793	BTN3A2	0.4	5.17	0.47	1.29e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7917772	0.582	rs11191352	chr10:104372244	A/G	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	trans	rs629535	0.814	rs654452	chr8:70074344	C/G	cg21567404	chr3:27674614	NA	1.08	10.14	0.72	8.19e-17	Dupuytren's disease;
THYM	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-6.66	-0.56	1.76e-9	Electrocardiographic conduction measures;
THYM	cis	rs988913	0.793	rs9370332	chr6:54727075	A/G	cg18532076	chr6:54711417	FAM83B	0.52	4.71	0.44	8.41e-6	Menarche (age at onset);
THYM	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.57	-0.42	1.45e-5	Prostate cancer;
THYM	cis	rs400736	0.894	rs172811	chr1:8039949	A/G	cg22678073	chr1:8087421	ERRFI1	0.46	4.9	0.45	3.98e-6	Response to antidepressants and depression;
THYM	cis	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg21775007	chr8:11205619	TDH	0.75	6.57	0.56	2.67e-9	Retinal vascular caliber;
THYM	cis	rs7084402	0.967	rs3001714	chr10:60285494	A/G	cg09696939	chr10:60272079	BICC1	-0.46	-5.25	-0.47	9.38e-7	Refractive error;
THYM	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg03855291	chr11:639423	DRD4	-0.64	-4.45	-0.42	2.35e-5	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg21926883	chr2:100939477	LONRF2	-0.61	-5.56	-0.5	2.44e-7	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs28595532	0.920	rs115437723	chr4:119741828	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.52	0.49	2.93e-7	Cannabis dependence symptom count;
THYM	cis	rs9902453	0.872	rs34698290	chr17:28500465	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	4.6	0.43	1.33e-5	Coffee consumption (cups per day);
THYM	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg02527881	chr3:46936655	PTH1R	-0.61	-5.7	-0.51	1.33e-7	Colorectal cancer;
THYM	cis	rs3087591	1.000	rs7226006	chr17:29650656	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.61	-5.1	-0.46	1.73e-6	Hip circumference;
THYM	cis	rs9916302	0.605	rs2879258	chr17:37399379	G/T	cg07936489	chr17:37558343	FBXL20	-0.83	-4.94	-0.45	3.35e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs4733781	0.901	rs4733571	chr8:131290664	T/G	cg16277922	chr8:131349729	ASAP1	0.72	5.09	0.46	1.83e-6	Tuberculosis;
THYM	cis	rs7072216	0.763	rs2147900	chr10:100174721	T/C	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg00071950	chr4:10020882	SLC2A9	0.73	7.27	0.6	9.9e-11	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg23711669	chr6:146136114	FBXO30	-0.98	-10.55	-0.73	1.11e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg15247329	chr7:2764246	NA	-0.69	-5.7	-0.5	1.35e-7	Height;
THYM	cis	rs7078219	0.965	rs7081858	chr10:101274565	G/A	cg23904955	chr10:101282759	NA	-0.44	-5.25	-0.47	9.32e-7	Dental caries;
THYM	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10779751	0.762	rs6671083	chr1:11325910	A/G	cg08854313	chr1:11322531	MTOR	-0.85	-8.11	-0.64	1.75e-12	Body mass index;
THYM	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg20503657	chr10:835505	NA	1.04	7.17	0.59	1.64e-10	Eosinophil percentage of granulocytes;
THYM	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg13609457	chr4:120235615	NA	0.6	5.39	0.48	5.11e-7	Corneal astigmatism;
THYM	cis	rs2354432	0.607	rs6685775	chr1:146744294	A/G	cg25205988	chr1:146714368	CHD1L	-1.08	-5.63	-0.5	1.86e-7	Mitochondrial DNA levels;
THYM	cis	rs2625529	0.652	rs8027164	chr15:72407733	A/T	cg16672083	chr15:72433130	SENP8	0.49	4.52	0.42	1.76e-5	Red blood cell count;
THYM	cis	rs2552220	0.781	rs13264901	chr8:6013914	A/G	cg06481462	chr8:7005678	NA	0.47	5.05	0.46	2.16e-6	Interleukin-8 levels;
THYM	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg13695892	chr22:41940480	POLR3H	-0.88	-7.15	-0.59	1.75e-10	Vitiligo;
THYM	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg23711669	chr6:146136114	FBXO30	0.91	8.87	0.67	4.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.75	6.32	0.54	8.55e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg12011299	chr4:100065546	ADH4	0.85	8.12	0.64	1.67e-12	Alcohol dependence;
THYM	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.55	-5.64	-0.5	1.72e-7	Crohn's disease;
THYM	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg05234568	chr11:5960015	NA	-0.6	-4.84	-0.44	4.97e-6	DNA methylation (variation);
THYM	cis	rs28595532	0.841	rs55744948	chr4:119769243	T/C	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg05340658	chr4:99064831	C4orf37	0.58	4.89	0.45	4.04e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg11757124	chr7:157526947	PTPRN2	-0.65	-5.19	-0.47	1.21e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs16866061	1.000	rs72974203	chr2:225408430	G/A	cg22455342	chr2:225449267	CUL3	0.67	4.84	0.44	4.98e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs2637266	0.935	rs4520537	chr10:78392978	C/T	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs7523273	0.565	rs1998539	chr1:207886596	G/A	cg22525895	chr1:207977042	MIR29B2	0.53	5.05	0.46	2.17e-6	Schizophrenia;
THYM	cis	rs2235649	0.833	rs9927047	chr16:1851927	A/C	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	7.35	0.6	6.91e-11	Platelet count;
THYM	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg26924012	chr15:45694286	SPATA5L1	1.03	9.3	0.69	5.23e-15	Homoarginine levels;
THYM	cis	rs12579753	0.956	rs7965168	chr12:82184467	C/A	cg21231944	chr12:82153410	PPFIA2	-0.67	-5.05	-0.46	2.13e-6	Resting heart rate;
THYM	cis	rs7705042	0.865	rs12656877	chr5:141490091	T/C	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs3862030	0.720	rs11595149	chr10:104235978	C/T	cg00122347	chr10:104236741	TMEM180	0.47	7.23	0.6	1.22e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs2625529	0.824	rs7172309	chr15:72384483	C/T	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs3809566	0.526	rs35829897	chr15:63334688	G/C	cg05507819	chr15:63340323	TPM1	-0.88	-5.63	-0.5	1.84e-7	Platelet count;
THYM	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs10193935	0.901	rs62142561	chr2:42477808	G/C	cg27598129	chr2:42591480	NA	-0.76	-4.61	-0.43	1.23e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3820068	0.608	rs10927836	chr1:16034368	G/C	cg05660106	chr1:15850417	CASP9	0.72	5.59	0.5	2.2e-7	Systolic blood pressure;
THYM	cis	rs7216064	1.000	rs62084248	chr17:65874541	C/T	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg23803603	chr1:2058230	PRKCZ	-0.61	-5.52	-0.49	2.94e-7	Height;
THYM	cis	rs6450176	0.633	rs389525	chr5:53333075	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.93	-8.27	-0.65	8.09e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg12935359	chr14:103987150	CKB	-0.53	-6.3	-0.54	9.24e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg24642844	chr7:1081250	C7orf50	-1.07	-5.92	-0.52	5.12e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4662945	0.603	rs13002385	chr2:130276865	T/C	cg05903289	chr2:130345205	NA	-0.57	-5.42	-0.49	4.45e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs17253792	0.822	rs13379342	chr14:56050452	A/G	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg08885076	chr2:99613938	TSGA10	0.59	5.58	0.5	2.25e-7	Chronic sinus infection;
THYM	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg12935359	chr14:103987150	CKB	-0.51	-6.07	-0.53	2.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg13395646	chr4:1353034	KIAA1530	-0.6	-5.72	-0.51	1.21e-7	Obesity-related traits;
THYM	cis	rs9790314	0.936	rs466399	chr3:161091194	G/T	cg04691961	chr3:161091175	C3orf57	-0.69	-6.08	-0.53	2.48e-8	Morning vs. evening chronotype;
THYM	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg04731861	chr2:219085781	ARPC2	0.49	4.65	0.43	1.07e-5	Colorectal cancer;
THYM	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11644478	chr21:40555479	PSMG1	0.69	5.23	0.47	1.01e-6	Cognitive function;
THYM	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-5.4	-0.48	4.89e-7	Chronic sinus infection;
THYM	cis	rs72627123	1.000	rs2302139	chr14:74362935	A/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.73	4.77	0.44	6.65e-6	Morning vs. evening chronotype;
THYM	cis	rs10782582	0.593	rs12142247	chr1:76235746	C/T	cg03433033	chr1:76189801	ACADM	-0.5	-4.93	-0.45	3.51e-6	Daytime sleep phenotypes;
THYM	cis	rs684232	0.602	rs4968057	chr17:517521	T/A	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.4	-4.8	-0.44	6e-6	Prostate cancer;
THYM	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.02	-0.46	2.42e-6	Blood metabolite levels;
THYM	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg10465839	chr16:1584050	IFT140;TMEM204	-0.61	-5.36	-0.48	5.79e-7	Coronary artery disease;
THYM	cis	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg18512352	chr11:47633146	NA	-0.38	-4.51	-0.42	1.84e-5	HDL cholesterol;
THYM	cis	rs4561483	0.771	rs7202234	chr16:11942322	A/G	cg08843971	chr16:11963173	GSPT1	0.58	4.57	0.42	1.49e-5	Testicular germ cell tumor;
THYM	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs853679	0.599	rs188015	chr6:27877446	T/A	cg23161317	chr6:28129485	ZNF389	1.08	4.71	0.44	8.35e-6	Depression;
THYM	cis	rs995000	0.931	rs634341	chr1:62921422	T/C	cg06896770	chr1:63153194	DOCK7	0.91	7.48	0.61	3.73e-11	Triglyceride levels;
THYM	trans	rs11186	0.556	rs58243388	chr2:189953551	G/A	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg10117171	chr1:25599238	RHD	0.72	5.45	0.49	3.94e-7	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg15838173	chr10:75533400	FUT11	-0.51	-5.2	-0.47	1.15e-6	Inflammatory bowel disease;
THYM	cis	rs483180	0.531	rs539708	chr1:120208503	G/T	cg19096424	chr1:120255104	PHGDH	-0.65	-5.25	-0.47	9.36e-7	Macular telangiectasia type 2;
THYM	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg10802521	chr3:52805072	NEK4	-0.72	-6.16	-0.53	1.77e-8	Bipolar disorder;
THYM	cis	rs800586	0.500	rs1983541	chr8:116654557	C/T	cg04656070	chr8:116661063	TRPS1	-0.55	-6.37	-0.55	6.77e-9	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7851660	0.935	rs4460498	chr9:100620412	T/C	cg13688889	chr9:100608707	NA	-0.84	-7.39	-0.6	5.76e-11	Strep throat;
THYM	cis	rs28595532	0.920	rs56212415	chr4:119737731	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs289828	0.579	rs4665163	chr2:152147365	A/G	cg05960677	chr2:152117363	RBM43	0.72	6.74	0.57	1.23e-9	Blood protein levels;
THYM	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg00129232	chr17:37814104	STARD3	0.76	5.25	0.47	9.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs4975616	0.710	rs27996	chr5:1345474	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.61	-4.91	-0.45	3.71e-6	Lung cancer;
THYM	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg13447684	chr7:1895903	MAD1L1	0.54	4.54	0.42	1.62e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs6840360	0.593	rs4696287	chr4:152606723	C/T	cg22705602	chr4:152727874	NA	-0.81	-10.87	-0.74	2.32e-18	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs11771526	0.901	rs78065961	chr7:32300967	C/T	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs12681288	0.550	rs73176529	chr8:962283	G/C	cg08648136	chr8:956695	NA	0.56	4.92	0.45	3.57e-6	Schizophrenia;
THYM	cis	rs10992471	0.598	rs3174352	chr9:95219248	A/G	cg14631576	chr9:95140430	CENPP	0.65	5.66	0.5	1.61e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs7119	0.745	rs11632602	chr15:77809764	C/G	cg10437265	chr15:77819839	NA	0.79	8.2	0.64	1.12e-12	Type 2 diabetes;
THYM	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg03929089	chr4:120376271	NA	-0.97	-7.63	-0.62	1.81e-11	Coronary artery disease;
THYM	cis	rs7635838	0.617	rs367745	chr3:11309274	T/C	cg00170343	chr3:11313890	ATG7	0.67	5.1	0.46	1.74e-6	HDL cholesterol;
THYM	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.54	5.1	0.46	1.74e-6	Lymphocyte counts;
THYM	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06634786	chr22:41940651	POLR3H	-0.83	-6.18	-0.54	1.59e-8	Vitiligo;
THYM	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg00383909	chr3:49044727	WDR6	1.17	6.29	0.54	9.69e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7107174	1.000	rs10899458	chr11:78007451	A/T	cg19901956	chr11:77921274	USP35	-0.69	-5.3	-0.48	7.42e-7	Testicular germ cell tumor;
THYM	cis	rs9467711	0.591	rs13202688	chr6:25993469	A/G	cg16898833	chr6:26189333	HIST1H4D	1.33	4.61	0.43	1.28e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2562456	0.682	rs11085464	chr19:21751778	C/G	cg21751540	chr19:21541537	ZNF738	-0.68	-4.74	-0.44	7.36e-6	Pain;
THYM	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9326248	0.530	rs7124741	chr11:116752219	A/T	cg01368799	chr11:117014884	PAFAH1B2	0.93	5.25	0.47	9.19e-7	Blood protein levels;
THYM	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg17911788	chr17:44343683	NA	-0.79	-7.48	-0.61	3.65e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.68	-4.87	-0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg24531977	chr5:56204891	C5orf35	-0.75	-6.39	-0.55	6e-9	Type 2 diabetes;
THYM	cis	rs5753037	0.813	rs9614100	chr22:30288339	A/T	cg27665648	chr22:30112403	NA	0.53	4.7	0.43	8.92e-6	Type 1 diabetes;
THYM	cis	rs11077998	0.844	rs12185254	chr17:80498972	C/T	cg11779900	chr17:80519722	FOXK2	-0.53	-4.51	-0.42	1.83e-5	Reticulocyte fraction of red cells;
THYM	cis	rs17401966	0.838	rs4623	chr1:10366692	C/G	cg19773385	chr1:10388646	KIF1B	-0.57	-4.45	-0.42	2.35e-5	Hepatocellular carcinoma;
THYM	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg18131467	chr2:239335373	ASB1	1.1	10.67	0.74	6.26e-18	Multiple system atrophy;
THYM	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg10117171	chr1:25599238	RHD	-0.68	-4.87	-0.45	4.52e-6	Erythrocyte sedimentation rate;
THYM	cis	rs35934224	0.710	rs56298833	chr22:19852438	A/G	cg11182965	chr22:19864308	TXNRD2	-0.76	-4.67	-0.43	9.79e-6	Glaucoma (primary open-angle);
THYM	trans	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs686320	1.000	rs1787666	chr11:65249089	A/C	cg13044675	chr11:65314161	LTBP3	0.85	4.7	0.43	8.66e-6	Hip circumference adjusted for BMI;
THYM	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.3	0.69	5.17e-15	Cognitive test performance;
THYM	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg02527881	chr3:46936655	PTH1R	-0.66	-6.44	-0.55	4.86e-9	Colorectal cancer;
THYM	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg14196790	chr5:131705035	SLC22A5	0.55	4.93	0.45	3.55e-6	Blood metabolite levels;
THYM	cis	rs10924970	0.776	rs72758049	chr1:235465045	G/T	cg26050004	chr1:235667680	B3GALNT2	0.6	4.5	0.42	1.92e-5	Asthma;
THYM	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg22920501	chr2:26401640	FAM59B	-1.05	-9.27	-0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs7586879	0.521	rs1865689	chr2:25108197	C/T	cg15423357	chr2:25149977	NA	-0.58	-5.67	-0.5	1.56e-7	Body mass index;
THYM	cis	rs7216064	0.531	rs6504573	chr17:66015963	C/T	cg12091567	chr17:66097778	LOC651250	-0.66	-5.05	-0.46	2.15e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg07507251	chr3:52567010	NT5DC2	0.39	4.61	0.43	1.25e-5	Bipolar disorder;
THYM	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4455778	0.580	rs6583509	chr7:49122419	A/G	cg26309511	chr7:48887640	NA	-0.64	-5.72	-0.51	1.23e-7	Lung cancer in never smokers;
THYM	cis	rs752010	0.967	rs10890153	chr1:42102060	C/A	cg06885757	chr1:42089581	HIVEP3	0.42	4.57	0.42	1.46e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.6	-7.33	-0.6	7.41e-11	Longevity;Endometriosis;
THYM	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg23750338	chr8:142222470	SLC45A4	0.52	4.87	0.45	4.48e-6	Immature fraction of reticulocytes;
THYM	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg05368731	chr17:41323189	NBR1	1.26	11.5	0.76	1.1e-19	Menopause (age at onset);
THYM	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg18252515	chr7:66147081	NA	-0.66	-5.0	-0.46	2.65e-6	Aortic root size;
THYM	cis	rs490234	0.783	rs13284243	chr9:128381785	A/G	cg14078157	chr9:128172775	NA	-0.66	-5.15	-0.47	1.43e-6	Mean arterial pressure;
THYM	cis	rs686320	0.748	rs481335	chr11:65207469	T/C	cg19332572	chr11:65321591	LTBP3	0.81	4.64	0.43	1.12e-5	Hip circumference adjusted for BMI;
THYM	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.86	-7.39	-0.6	5.65e-11	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs6430585	0.583	rs60253740	chr2:136571852	G/T	cg23851026	chr2:136556271	LCT	0.77	7.67	0.62	1.52e-11	Corneal structure;
THYM	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg08305652	chr11:111469057	NA	0.53	4.58	0.43	1.41e-5	Primary sclerosing cholangitis;
THYM	cis	rs7246967	0.673	rs7249003	chr19:22887934	A/G	cg05241461	chr19:22816980	ZNF492	0.6	4.64	0.43	1.11e-5	Bronchopulmonary dysplasia;
THYM	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg03676636	chr4:99064102	C4orf37	0.42	6.05	0.53	2.84e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg24060327	chr5:131705240	SLC22A5	0.73	5.47	0.49	3.61e-7	Blood metabolite levels;
THYM	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg21784768	chr11:537496	LRRC56	-1.14	-5.7	-0.5	1.33e-7	Body mass index;
THYM	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs75059851	0.756	rs55747998	chr11:133840793	C/T	cg14047540	chr11:133829660	NA	-1.1	-7.34	-0.6	7.1e-11	Schizophrenia;
THYM	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg18252515	chr7:66147081	NA	-0.71	-5.67	-0.5	1.56e-7	Aortic root size;
THYM	cis	rs7119	0.651	rs12909292	chr15:77837982	G/T	cg27398640	chr15:77910606	LINGO1	-0.62	-6.27	-0.54	1.04e-8	Type 2 diabetes;
THYM	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg19507638	chr5:93509721	C5orf36	-0.67	-4.48	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs7626444	0.625	rs1798637	chr3:196476639	C/T	cg12930392	chr3:196481615	PAK2	0.4	4.92	0.45	3.58e-6	Monocyte count;
THYM	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.75	5.74	0.51	1.13e-7	Eosinophil percentage of white cells;
THYM	cis	rs2811415	0.597	rs13062846	chr3:127744292	C/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.75	0.44	7.34e-6	Lung function (FEV1/FVC);
THYM	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg22920501	chr2:26401640	FAM59B	-1.08	-9.81	-0.71	4.15e-16	Gut microbiome composition (summer);
THYM	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg21028142	chr17:79581711	NPLOC4	0.64	6.74	0.57	1.23e-9	Eye color traits;
THYM	cis	rs7078219	0.714	rs10883363	chr10:101287580	C/T	cg17888390	chr10:101282816	NA	-0.53	-5.14	-0.47	1.46e-6	Dental caries;
THYM	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg24209194	chr3:40518798	ZNF619	0.57	4.54	0.42	1.66e-5	Renal cell carcinoma;
THYM	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.46	0.42	2.24e-5	Obesity-related traits;
THYM	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg12698349	chr2:225449008	CUL3	0.73	5.45	0.49	4.03e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg26384229	chr12:38710491	ALG10B	-0.72	-6.0	-0.52	3.63e-8	Morning vs. evening chronotype;
THYM	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs7941600	0.786	rs12099067	chr11:9206279	A/G	cg21110646	chr11:9336536	TMEM41B	-0.95	-5.83	-0.51	7.61e-8	Coronary artery disease;
THYM	cis	rs1971762	0.965	rs1800633	chr12:54063501	G/A	cg16917193	chr12:54089295	NA	0.58	4.47	0.42	2.12e-5	Height;
THYM	cis	rs8070740	0.898	rs9303192	chr17:5324836	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.72	6.03	0.53	3.15e-8	Menopause (age at onset);
THYM	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg00383909	chr3:49044727	WDR6	1.27	7.71	0.62	1.22e-11	Cognitive function;
THYM	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	18.27	0.88	7.47e-33	Chronic sinus infection;
THYM	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.2	0.69	8.45e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs9992101	0.612	rs1876535	chr4:77296600	T/C	cg20311846	chr4:77356250	SHROOM3	-0.54	-5.96	-0.52	4.32e-8	Creatinine levels;
THYM	cis	rs7809950	0.906	rs2395907	chr7:107253304	A/G	cg23024343	chr7:107201750	COG5	0.92	7.65	0.62	1.63e-11	Coronary artery disease;
THYM	trans	rs4596713	0.538	rs6560589	chr9:71749540	A/T	cg16512924	chr15:28394682	HERC2	0.83	7.29	0.6	9.03e-11	Headache;
THYM	cis	rs35934224	0.783	rs35969236	chr22:19860355	T/G	cg11182965	chr22:19864308	TXNRD2	-0.71	-5.85	-0.51	7.1e-8	Glaucoma (primary open-angle);
THYM	cis	rs61990749	0.597	rs8016416	chr14:78213100	T/A	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.04	0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg10523679	chr1:76189770	ACADM	-0.55	-4.67	-0.43	9.97e-6	Daytime sleep phenotypes;
THYM	cis	rs10262624	0.504	rs59865844	chr7:23733040	T/C	cg05804949	chr7:23719620	C7orf46	0.48	5.54	0.49	2.72e-7	Schizophrenia;
THYM	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7582180	0.638	rs9973536	chr2:100942243	C/T	cg14675211	chr2:100938903	LONRF2	0.7	7.34	0.6	7.33e-11	Intelligence (multi-trait analysis);
THYM	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg16486109	chr11:613632	IRF7	0.5	5.37	0.48	5.64e-7	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504073	0.565	rs35282337	chr8:49920994	G/A	cg00325661	chr8:49890786	NA	1.02	10.3	0.73	3.73e-17	Blood metabolite ratios;
THYM	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg12564285	chr5:131593104	PDLIM4	0.6	7.19	0.59	1.48e-10	Acylcarnitine levels;
THYM	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg15744692	chr15:45671195	LOC145663;GATM	0.44	4.46	0.42	2.22e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg12310025	chr6:25882481	NA	-0.86	-7.51	-0.61	3.14e-11	Intelligence (multi-trait analysis);
THYM	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11585357	1.000	rs11585357	chr1:17601165	C/T	cg08277548	chr1:17600880	PADI3	-0.93	-6.22	-0.54	1.3e-8	Hair shape;
THYM	cis	rs28595532	0.844	rs115202072	chr4:119732458	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg21433313	chr16:3507492	NAT15	-0.72	-5.35	-0.48	6.13e-7	Tuberculosis;
THYM	cis	rs4606347	0.932	rs17406429	chr1:66089708	A/G	cg04111102	chr1:66153794	NA	0.59	4.54	0.42	1.67e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs4523957	0.651	rs9906705	chr17:2063714	T/G	cg16513277	chr17:2031491	SMG6	-0.94	-8.42	-0.65	3.95e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs240764	0.555	rs4840150	chr6:101183774	T/C	cg21058520	chr6:100914733	NA	-0.58	-5.05	-0.46	2.11e-6	Neuroticism;
THYM	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-4.85	-0.45	4.85e-6	Total body bone mineral density;
THYM	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.5	-0.56	3.64e-9	Personality dimensions;
THYM	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg26031613	chr14:104095156	KLC1	0.79	5.22	0.47	1.06e-6	Body mass index;
THYM	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg04025307	chr7:1156635	C7orf50	0.6	5.5	0.49	3.21e-7	Longevity;Endometriosis;
THYM	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs7901056	0.901	rs1889692	chr10:26718723	A/C	cg23318538	chr10:26883079	C10orf50	-0.37	-4.96	-0.45	3.12e-6	Lymphocyte counts;
THYM	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg27129171	chr3:47204927	SETD2	0.74	7.2	0.59	1.42e-10	Colorectal cancer;
THYM	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg14196790	chr5:131705035	SLC22A5	0.65	6.66	0.56	1.8e-9	Blood metabolite levels;
THYM	cis	rs11225247	0.881	rs7114048	chr11:102253780	C/T	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs586688	1.000	rs125872	chr1:201635798	C/T	cg14168733	chr1:201708718	NAV1	0.65	6.23	0.54	1.28e-8	Obesity-related traits;
THYM	cis	rs12216545	0.765	rs1916002	chr7:150250894	A/G	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs782590	0.582	rs2627767	chr2:55926815	A/T	cg03859395	chr2:55845619	SMEK2	0.59	4.99	0.46	2.71e-6	Metabolic syndrome;
THYM	cis	rs1950626	0.699	rs12896504	chr14:101467948	A/G	cg11887864	chr14:101510502	MIR1185-2	-0.6	-4.48	-0.42	2.05e-5	Pelvic organ prolapse (moderate/severe);
THYM	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1747683	0.966	rs647253	chr10:13363242	T/C	cg00142036	chr10:13388442	SEPHS1	0.29	5.27	0.48	8.45e-7	IgG glycosylation;
THYM	cis	rs4731207	0.698	rs1904975	chr7:124552802	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7580658	0.750	rs6731176	chr2:128071003	C/T	cg10021288	chr2:128175891	PROC	-0.66	-6.27	-0.54	1.05e-8	Protein C levels;
THYM	cis	rs2976388	0.609	rs2585144	chr8:143800269	A/T	cg06565975	chr8:143823917	SLURP1	0.5	5.62	0.5	1.9e-7	Urinary tract infection frequency;
THYM	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg18252515	chr7:66147081	NA	-1.44	-8.67	-0.66	1.16e-13	Diabetic kidney disease;
THYM	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg12564285	chr5:131593104	PDLIM4	-0.43	-4.64	-0.43	1.13e-5	Breast cancer;
THYM	cis	rs995000	0.899	rs11577840	chr1:62991369	T/C	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs4792901	0.765	rs12600416	chr17:41546558	A/G	cg21940313	chr17:41620911	ETV4	-0.5	-4.85	-0.45	4.74e-6	Dupuytren's disease;
THYM	cis	rs1953600	0.645	rs2573351	chr10:81931441	A/G	cg11900509	chr10:81946545	ANXA11	-0.45	-4.62	-0.43	1.2e-5	Sarcoidosis;
THYM	cis	rs9972944	0.729	rs10083875	chr17:63773303	T/C	cg07283582	chr17:63770753	CCDC46	0.68	5.54	0.49	2.69e-7	Total body bone mineral density;
THYM	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg22117172	chr7:91764530	CYP51A1	-0.35	-4.47	-0.42	2.12e-5	Breast cancer;
THYM	cis	rs9534288	0.797	rs7989351	chr13:46534080	C/A	cg15192986	chr13:46630673	CPB2	-0.6	-4.52	-0.42	1.8e-5	Blood protein levels;
THYM	cis	rs7172809	0.599	rs59386622	chr15:77752693	G/A	cg22256960	chr15:77711686	NA	-0.61	-4.47	-0.42	2.18e-5	Glucose homeostasis traits;
THYM	cis	rs9682041	0.673	rs1511175	chr3:170076006	C/G	cg11886554	chr3:170076028	SKIL	1.38	5.34	0.48	6.34e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs1983170	1.000	rs483532	chr1:91980447	A/G	cg04676771	chr1:91176081	NA	-0.68	-4.88	-0.45	4.32e-6	Eosinophil percentage of white cells;
THYM	cis	rs10924970	0.934	rs56681442	chr1:235466800	G/A	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg03452623	chr4:187889614	NA	-1.19	-19.33	-0.89	1.1e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	9.4	0.69	3.1e-15	Chronic sinus infection;
THYM	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg02825527	chr7:2087843	MAD1L1	-0.76	-5.08	-0.46	1.88e-6	Bipolar disorder;
THYM	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	5.97	0.52	4.01e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2237457	0.543	rs6970413	chr7:50702348	A/G	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.48e-6	Schizophrenia (treatment resistant);
THYM	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg10295955	chr4:187884368	NA	-1.18	-16.62	-0.86	7.18e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs747334	0.846	rs7897603	chr10:92708759	C/G	cg07620928	chr10:92689909	NA	-0.6	-4.79	-0.44	6.09e-6	Fibroblast growth factor basic levels;
THYM	cis	rs6099847	0.636	rs1334110	chr20:56499879	A/T	cg03401480	chr20:57087179	APCDD1L	-0.78	-4.48	-0.42	2.11e-5	Obesity-related traits;
THYM	cis	rs919433	0.617	rs12619333	chr2:198567638	C/G	cg05783139	chr2:198650985	BOLL	-0.63	-5.0	-0.46	2.58e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg05283184	chr6:79620031	NA	-0.89	-8.57	-0.66	1.9e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	8.2	0.64	1.13e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs10788264	0.504	rs4751883	chr10:124018027	A/C	cg09507567	chr10:124027408	NA	0.5	4.85	0.45	4.85e-6	Total body bone mineral density;
THYM	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg03433033	chr1:76189801	ACADM	-0.5	-5.08	-0.46	1.88e-6	Daytime sleep phenotypes;
THYM	cis	rs10208649	0.908	rs7583508	chr2:54255785	C/G	cg04546899	chr2:54196757	PSME4	0.68	4.7	0.43	8.91e-6	Body mass index;
THYM	cis	rs7106204	0.609	rs16912371	chr11:24298455	A/G	ch.11.24196551F	chr11:24239977	NA	0.99	6.09	0.53	2.33e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	6.61	0.56	2.26e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7429990	0.932	rs6766641	chr3:48145224	G/A	cg02219026	chr3:48282209	ZNF589	0.62	4.64	0.43	1.12e-5	Educational attainment (years of education);
THYM	cis	rs807669	0.903	rs1780642	chr22:19170604	T/C	cg02655711	chr22:19163373	SLC25A1	0.98	11.86	0.77	1.93e-20	Metabolite levels;
THYM	cis	rs748404	0.660	rs493377	chr15:43773467	C/T	cg12861797	chr15:43585817	TGM7	0.44	4.58	0.43	1.38e-5	Lung cancer;
THYM	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs514406	0.893	rs4584343	chr1:53434539	A/C	cg06600287	chr1:53387719	ECHDC2	0.31	5.11	0.46	1.68e-6	Monocyte count;
THYM	cis	rs651907	0.640	rs771578	chr3:101613434	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	6.05	0.53	2.91e-8	Colorectal cancer;
THYM	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg23205692	chr1:25664452	TMEM50A	0.83	6.37	0.55	6.66e-9	Erythrocyte sedimentation rate;
THYM	cis	rs73787773	0.866	rs79092804	chr5:111478820	C/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.87	-4.47	-0.42	2.13e-5	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs36051895	0.659	rs10815150	chr9:5067301	C/A	cg02405213	chr9:5042618	JAK2	-1.04	-11.56	-0.76	8.21e-20	Pediatric autoimmune diseases;
THYM	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs2294693	0.947	rs9296351	chr6:40988102	T/C	cg14769373	chr6:40998127	UNC5CL	-0.58	-4.66	-0.43	1.02e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs7106204	0.748	rs4598670	chr11:24236524	G/A	ch.11.24196551F	chr11:24239977	NA	1.0	7.19	0.59	1.5e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs16949788	1.000	rs76847935	chr15:66769613	G/A	cg08120210	chr15:66682733	MAP2K1	-0.77	-4.56	-0.42	1.54e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	trans	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	Neuroticism;
THYM	cis	rs2637266	1.000	rs4979784	chr10:78355476	T/A	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.64	4.6	0.43	1.32e-5	Body mass index (adult);
THYM	cis	rs11078597	0.671	rs62090058	chr17:1645624	G/C	cg18436246	chr17:1640651	WDR81	0.64	4.63	0.43	1.14e-5	Serum albumin level;
THYM	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13732083	chr21:47605072	C21orf56	0.77	5.11	0.46	1.67e-6	Testicular germ cell tumor;
THYM	cis	rs10739663	0.520	rs13294786	chr9:128156961	A/G	cg13590414	chr9:128173245	NA	-0.53	-4.61	-0.43	1.24e-5	Resting heart rate;
THYM	cis	rs11651000	0.894	rs72831632	chr17:45805177	C/T	cg03474202	chr17:45855739	NA	-0.71	-4.67	-0.43	9.87e-6	IgG glycosylation;
THYM	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg05660106	chr1:15850417	CASP9	0.75	6.05	0.53	2.87e-8	Systolic blood pressure;
THYM	cis	rs7927592	0.546	rs554734	chr11:68192518	T/G	cg16797656	chr11:68205561	LRP5	0.54	6.19	0.54	1.52e-8	Total body bone mineral density;
THYM	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg05802129	chr4:122689817	NA	-0.61	-4.99	-0.46	2.75e-6	Type 2 diabetes;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg06895436	chr8:82434543	NA	1.32	7.18	0.59	1.53e-10	Pulmonary function decline;
THYM	cis	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg07460842	chr6:66804631	NA	0.8	5.12	0.47	1.57e-6	Exhaled nitric oxide output;
THYM	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	8.69	0.67	1.02e-13	Chronic sinus infection;
THYM	cis	rs9674544	0.792	rs8076012	chr17:47101989	G/A	cg10950924	chr17:47092072	IGF2BP1	-0.59	-7.26	-0.6	1.07e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg19016782	chr12:123741754	C12orf65	-0.69	-4.5	-0.42	1.94e-5	Neutrophil percentage of white cells;
THYM	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg02228675	chr17:40259724	DHX58	0.65	5.4	0.48	4.83e-7	Fibrinogen levels;
THYM	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07157834	chr1:205819609	PM20D1	0.72	6.54	0.56	3.14e-9	Monocyte percentage of white cells;
THYM	cis	rs7404928	0.957	rs7205440	chr16:23902624	T/G	cg26685404	chr16:23957272	PRKCB	0.48	4.83	0.44	5.27e-6	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs1775715	0.870	rs3847415	chr10:32219456	G/T	cg04359828	chr10:32216031	ARHGAP12	0.4	5.16	0.47	1.37e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs12142240	0.660	rs72890715	chr1:46852077	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs4363385	0.791	rs11205177	chr1:153002502	G/A	cg13444842	chr1:152974279	SPRR3	-0.59	-4.81	-0.44	5.61e-6	Inflammatory skin disease;
THYM	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.81	6.2	0.54	1.49e-8	IgG glycosylation;
THYM	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-4.57	-0.42	1.49e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg22535103	chr8:58192502	C8orf71	-0.96	-5.47	-0.49	3.7e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs478304	0.718	rs1151490	chr11:65390485	A/C	cg17480646	chr11:65405466	SIPA1	0.77	6.65	0.56	1.82e-9	Acne (severe);
THYM	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg26149184	chr10:133730230	NA	0.82	5.1	0.46	1.76e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs6964587	0.626	rs9008	chr7:91502407	C/G	cg22709100	chr7:91322751	NA	-0.64	-4.72	-0.44	8.02e-6	Breast cancer;
THYM	cis	rs12282928	1.000	rs11039667	chr11:48326063	C/G	cg22827986	chr11:48284249	OR4X1	0.51	5.29	0.48	7.88e-7	Migraine - clinic-based;
THYM	cis	rs72627123	0.867	rs3815331	chr14:74482948	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	4.87	0.45	4.38e-6	Morning vs. evening chronotype;
THYM	cis	rs9287719	0.674	rs6432130	chr2:10821557	T/C	cg03983476	chr2:10830698	NOL10	0.61	5.27	0.48	8.48e-7	Prostate cancer;
THYM	cis	rs9549260	0.564	rs9549279	chr13:41315582	C/G	cg21288729	chr13:41239152	FOXO1	-0.68	-4.97	-0.45	3.02e-6	Red blood cell count;
THYM	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg09549813	chr16:4587862	C16orf5	-0.59	-6.65	-0.56	1.84e-9	Schizophrenia;
THYM	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs17006441	0.898	rs13071701	chr3:69902514	T/C	cg18496212	chr3:69797108	MITF	0.68	6.83	0.57	8.05e-10	Hemoglobin concentration;
THYM	cis	rs6840360	0.571	rs11940881	chr4:152501050	C/G	cg17479576	chr4:152424074	FAM160A1	-0.82	-5.82	-0.51	7.78e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg03517284	chr6:25882590	NA	0.71	5.64	0.5	1.75e-7	Schizophrenia;
THYM	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08704250	chr15:31115839	NA	-0.51	-6.06	-0.53	2.68e-8	Huntington's disease progression;
THYM	cis	rs7512552	0.809	rs9436112	chr1:150406449	A/C	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs113825134	0.957	rs60232238	chr12:78217681	G/C	cg26687049	chr12:77459485	E2F7	0.7	4.56	0.42	1.51e-5	Plateletcrit;
THYM	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	5.54	0.49	2.69e-7	Menarche (age at onset);
THYM	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg11502198	chr6:26597334	ABT1	0.63	5.61	0.5	2.02e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.71	9.43	0.7	2.67e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg21280719	chr6:42927975	GNMT	-0.53	-7.25	-0.6	1.12e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs1003719	0.553	rs1063948	chr21:38574674	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-4.53	-0.42	1.72e-5	Eye color traits;
THYM	cis	rs7914606	0.516	rs67298808	chr10:85224395	C/T	cg01558777	chr10:85933798	C10orf99	-1.09	-4.7	-0.43	8.68e-6	Trans fatty acid levels;
THYM	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg00383909	chr3:49044727	WDR6	1.27	7.71	0.62	1.22e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg17143192	chr8:8559678	CLDN23	-0.72	-4.92	-0.45	3.63e-6	Obesity-related traits;
THYM	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg00376283	chr12:123451042	ABCB9	0.78	6.19	0.54	1.55e-8	Platelet count;
THYM	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg13147721	chr7:65941812	NA	0.73	4.58	0.43	1.42e-5	Diabetic kidney disease;
THYM	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg00677455	chr12:58241039	CTDSP2	0.72	4.87	0.45	4.51e-6	Multiple sclerosis;
THYM	cis	rs7000551	0.736	rs10091203	chr8:22356970	G/A	cg12081754	chr8:22256438	SLC39A14	0.64	5.85	0.51	6.94e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9677476	0.909	rs7573577	chr2:232104079	C/T	cg07929768	chr2:232055508	NA	0.63	6.29	0.54	9.87e-9	Food antigen IgG levels;
THYM	cis	rs55883249	1.000	rs10495573	chr2:9712160	T/G	cg23886495	chr2:9695866	ADAM17	0.85	5.28	0.48	8.25e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg22907277	chr7:1156413	C7orf50	0.83	5.1	0.46	1.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8048589	0.660	rs11075054	chr16:12216295	C/A	cg01990910	chr16:12207648	SNX29	-0.55	-5.81	-0.51	8.24e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs10431058	0.930	rs11212297	chr11:107475371	T/C	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.74	5.74	0.51	1.12e-7	Common traits (Other);
THYM	cis	rs13326165	0.585	rs10461027	chr3:52341126	G/A	cg08438690	chr3:52279403	PPM1M	-0.8	-4.69	-0.43	9.03e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs919433	0.510	rs34631382	chr2:198390009	C/T	cg00792783	chr2:198669748	PLCL1	0.86	6.08	0.53	2.49e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg04287289	chr16:89883240	FANCA	0.65	5.94	0.52	4.61e-8	Vitiligo;
THYM	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg19077165	chr18:44547161	KATNAL2	-0.62	-7.8	-0.62	7.87e-12	Personality dimensions;
THYM	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.84	-5.3	-0.48	7.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2463822	0.858	rs2463836	chr11:62126494	A/G	cg06239285	chr11:62104954	ASRGL1	1.44	7.7	0.62	1.3e-11	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg23281280	chr6:28129359	ZNF389	0.66	4.6	0.43	1.32e-5	Depression;
THYM	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg15247329	chr7:2764246	NA	-0.72	-5.95	-0.52	4.37e-8	Height;
THYM	cis	rs4589258	0.788	rs1783801	chr11:90432500	A/C	cg26138821	chr11:89956704	CHORDC1	0.56	4.68	0.43	9.36e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11650494	0.522	rs117821438	chr17:47325867	A/T	cg08112188	chr17:47440006	ZNF652	1.15	4.5	0.42	1.93e-5	Prostate cancer;
THYM	cis	rs9905704	0.846	rs2567894	chr17:56794115	G/A	cg12560992	chr17:57184187	TRIM37	0.64	4.46	0.42	2.28e-5	Testicular germ cell tumor;
THYM	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg10760299	chr15:45669010	GATM	0.88	6.73	0.57	1.28e-9	Homoarginine levels;
THYM	cis	rs2235642	0.525	rs8048290	chr16:1562026	T/C	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.5	-4.73	-0.44	7.95e-6	Coronary artery disease;
THYM	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg12923728	chr3:195709715	SDHAP1	-0.83	-6.1	-0.53	2.31e-8	Pancreatic cancer;
THYM	cis	rs4455778	0.561	rs10243463	chr7:49081185	T/G	cg26309511	chr7:48887640	NA	0.68	5.94	0.52	4.63e-8	Lung cancer in never smokers;
THYM	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg01069141	chr11:67398826	TBX10;NUDT8	0.55	5.94	0.52	4.7e-8	Mean corpuscular volume;
THYM	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Body mass index;
THYM	cis	rs2069036	1.000	rs11253762	chr10:16112933	T/C	cg26633223	chr10:15133461	NA	0.71	5.24	0.47	9.71e-7	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs1808579	0.904	rs1618725	chr18:21126952	C/T	cg14672496	chr18:21087552	C18orf8	0.53	4.88	0.45	4.2e-6	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
THYM	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.0	-7.69	-0.62	1.37e-11	Schizophrenia;
THYM	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.96	-8.0	-0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs981844	0.775	rs17299561	chr4:154765480	C/T	cg09973105	chr4:154681532	RNF175	-0.63	-5.13	-0.47	1.53e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg13918804	chr1:2043761	PRKCZ	0.81	7.2	0.59	1.42e-10	Height;
THYM	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6047844	0.569	rs1415798	chr20:22130529	C/G	cg16502866	chr20:23015624	SSTR4	-0.59	-4.86	-0.45	4.68e-6	Male-pattern baldness;
THYM	cis	rs12681288	0.792	rs12678495	chr8:1000858	C/G	cg04918696	chr8:1004106	NA	-0.46	-4.96	-0.45	3.03e-6	Schizophrenia;
THYM	cis	rs3741151	0.773	rs73548688	chr11:73279544	C/T	cg12959048	chr11:73096162	RELT	-0.52	-4.62	-0.43	1.21e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg03806693	chr22:41940476	POLR3H	-1.22	-11.08	-0.75	8.13e-19	Vitiligo;
THYM	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg06917634	chr15:78832804	PSMA4	0.96	8.76	0.67	7.4e-14	Sudden cardiac arrest;
THYM	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg10150615	chr22:24372951	LOC391322	0.84	9.06	0.68	1.69e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs854765	0.624	rs4925119	chr17:17742904	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.64	-5.49	-0.49	3.41e-7	Total body bone mineral density;
THYM	cis	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg00495681	chr13:53174319	NA	-0.73	-6.77	-0.57	1.06e-9	Lewy body disease;
THYM	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.36	0.69	3.89e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg15164180	chr2:241846931	NA	-0.34	-4.63	-0.43	1.15e-5	Urinary metabolites;
THYM	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.21	8.51	0.66	2.47e-13	Cognitive test performance;
THYM	cis	rs3812831	0.572	rs3118896	chr13:114931769	C/G	cg06611532	chr13:114900021	NA	0.53	5.52	0.49	2.95e-7	Schizophrenia;
THYM	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	5.74	0.51	1.12e-7	Obesity-related traits;
THYM	cis	rs854765	0.583	rs4534911	chr17:17852330	A/G	cg16928487	chr17:17741425	SREBF1	-0.56	-5.33	-0.48	6.66e-7	Total body bone mineral density;
THYM	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg21252483	chr19:49399788	TULP2	-0.96	-7.25	-0.6	1.09e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg27068330	chr11:65405492	SIPA1	-0.95	-8.8	-0.67	6.03e-14	Acne (severe);
THYM	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.91	0.63	4.62e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg22764591	chr12:58329936	NA	0.84	5.9	0.52	5.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs58873874	0.737	rs11746837	chr5:156918146	T/A	cg08916508	chr5:156566250	MED7	-1.32	-5.18	-0.47	1.23e-6	Bipolar disorder (body mass index interaction);
THYM	cis	rs870825	0.587	rs6826883	chr4:185616167	A/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs75920871	0.528	rs11216240	chr11:116899248	A/T	cg20608306	chr11:116969690	SIK3	-0.52	-5.85	-0.51	6.81e-8	Subjective well-being;
THYM	cis	rs735539	0.521	rs1966190	chr13:21409137	A/C	cg02792322	chr13:21280448	IL17D	-0.66	-4.78	-0.44	6.37e-6	Dental caries;
THYM	cis	rs9653442	0.835	rs7565967	chr2:100744683	G/T	cg07810366	chr2:100720526	AFF3	-0.43	-6.52	-0.56	3.44e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs909002	0.742	rs2271928	chr1:32127953	G/A	cg13919466	chr1:32135498	COL16A1	0.55	4.96	0.45	3.04e-6	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg17264618	chr3:40429014	ENTPD3	0.51	4.8	0.44	5.88e-6	Renal cell carcinoma;
THYM	cis	rs7107174	0.792	rs12291726	chr11:78088210	A/G	cg19901956	chr11:77921274	USP35	-0.65	-5.34	-0.48	6.4e-7	Testicular germ cell tumor;
THYM	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg05707623	chr12:122985044	ZCCHC8	-0.73	-4.87	-0.45	4.36e-6	Body mass index;
THYM	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.92	7.17	0.59	1.61e-10	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs76878669	0.561	rs7115577	chr11:66172258	G/T	cg14263139	chr11:66104018	RIN1	0.37	4.54	0.42	1.65e-5	Educational attainment (years of education);
THYM	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg14196790	chr5:131705035	SLC22A5	-0.48	-4.55	-0.42	1.59e-5	Breast cancer;
THYM	cis	rs2108225	0.714	rs929393	chr7:107437048	C/T	cg18560240	chr7:107437656	SLC26A3	-1.0	-7.87	-0.63	5.65e-12	Ulcerative colitis;
THYM	cis	rs875971	1.000	rs1144894	chr7:65542894	A/G	cg18876405	chr7:65276391	NA	-0.66	-5.52	-0.49	2.96e-7	Aortic root size;
THYM	cis	rs2235642	0.964	rs9939655	chr16:1577963	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.61	-5.06	-0.46	2.06e-6	Coronary artery disease;
THYM	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg11812906	chr14:75593930	NEK9	-0.87	-8.3	-0.65	7.13e-13	Height;
THYM	cis	rs6429082	0.818	rs291341	chr1:235663174	G/T	cg26050004	chr1:235667680	B3GALNT2	0.74	6.18	0.54	1.6e-8	Adiposity;
THYM	cis	rs10208940	0.614	rs7594705	chr2:68833842	T/G	cg09157127	chr2:69201416	GKN1	0.9	4.74	0.44	7.58e-6	Urate levels in lean individuals;
THYM	cis	rs9515201	0.627	rs61963197	chr13:111038395	G/A	cg06243866	chr13:111019493	COL4A2	-0.99	-9.86	-0.71	3.22e-16	White matter hyperintensity burden;
THYM	cis	rs77372450	0.551	rs6874196	chr5:157045634	C/G	cg00312553	chr5:157098553	C5orf52	-0.65	-4.63	-0.43	1.16e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg18681998	chr4:17616180	MED28	0.91	8.58	0.66	1.75e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs10979	1.000	rs9386037	chr6:143891950	T/C	cg25407410	chr6:143891975	LOC285740	-0.59	-4.83	-0.44	5.18e-6	Hypospadias;
THYM	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg00191853	chr8:101177733	SPAG1	0.56	5.15	0.47	1.43e-6	Atrioventricular conduction;
THYM	cis	rs67981189	0.896	rs1859468	chr14:71402290	C/G	cg15910301	chr14:71632612	NA	-0.52	-4.76	-0.44	6.91e-6	Schizophrenia;
THYM	cis	rs71636778	0.509	rs56139710	chr1:27269788	C/T	cg16022904	chr1:26870173	RPS6KA1	0.84	4.55	0.42	1.58e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
THYM	cis	rs2663905	0.560	rs1879454	chr15:81377717	C/A	cg25029264	chr15:81426347	C15orf26	-0.73	-4.68	-0.43	9.38e-6	QT interval (drug interaction);
THYM	cis	rs4803480	0.873	rs1476770	chr19:42084385	C/G	cg09848080	chr19:41642064	NA	0.62	4.49	0.42	1.99e-5	Schizophrenia;
THYM	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg06618935	chr21:46677482	NA	-0.97	-8.38	-0.65	4.63e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg12564285	chr5:131593104	PDLIM4	0.62	7.72	0.62	1.19e-11	Acylcarnitine levels;
THYM	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs6430585	0.528	rs309172	chr2:136674028	A/G	cg23851026	chr2:136556271	LCT	0.71	7.18	0.59	1.51e-10	Corneal structure;
THYM	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg24838063	chr12:130822603	PIWIL1	0.91	7.02	0.58	3.27e-10	Menopause (age at onset);
THYM	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg11366901	chr6:160182831	ACAT2	1.0	8.33	0.65	6.14e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg17554472	chr22:41940697	POLR3H	0.68	4.83	0.44	5.3e-6	Vitiligo;
THYM	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg23851026	chr2:136556271	LCT	-0.55	-5.55	-0.49	2.62e-7	Mosquito bite size;
THYM	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg04944784	chr2:26401820	FAM59B	-1.05	-8.18	-0.64	1.23e-12	Gut microbiome composition (summer);
THYM	cis	rs4900538	0.821	rs8016191	chr14:102825340	G/A	cg18135206	chr14:102964638	TECPR2	-0.84	-6.43	-0.55	5.1e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4792901	0.802	rs9895324	chr17:41594168	G/A	cg21940313	chr17:41620911	ETV4	-0.53	-5.03	-0.46	2.28e-6	Dupuytren's disease;
THYM	cis	rs10186029	0.582	rs10497995	chr2:213995346	G/A	cg08319019	chr2:214017104	IKZF2	0.78	6.14	0.53	1.95e-8	Systemic sclerosis;
THYM	cis	rs11608355	1.000	rs7132057	chr12:109880279	A/C	cg11367159	chr12:110044531	NA	0.63	5.98	0.52	3.95e-8	Neuroticism;
THYM	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg09085632	chr11:111637200	PPP2R1B	1.02	9.79	0.71	4.74e-16	Primary sclerosing cholangitis;
THYM	cis	rs6565180	0.926	rs8046445	chr16:30386262	A/G	cg17640201	chr16:30407289	ZNF48	-0.91	-8.58	-0.66	1.76e-13	Tonsillectomy;
THYM	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg23161317	chr6:28129485	ZNF389	0.69	5.78	0.51	9.52e-8	Parkinson's disease;
THYM	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg24818145	chr4:99064322	C4orf37	-0.78	-6.25	-0.54	1.18e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1347297	0.666	rs4404314	chr2:179250840	G/A	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.6	-4.53	-0.42	1.72e-5	Alzheimer disease and age of onset;
THYM	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg12311346	chr5:56204834	C5orf35	-0.61	-4.67	-0.43	9.99e-6	Initial pursuit acceleration;
THYM	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg15536230	chr21:44985092	HSF2BP	-0.41	-4.76	-0.44	7.04e-6	Mean corpuscular volume;
THYM	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs6430585	0.528	rs309152	chr2:136657252	C/T	cg07169764	chr2:136633963	MCM6	-0.91	-8.54	-0.66	2.21e-13	Corneal structure;
THYM	cis	rs11771526	1.000	rs62457533	chr7:32355334	G/A	cg27511599	chr7:32358540	NA	0.77	5.13	0.47	1.51e-6	Body mass index;
THYM	cis	rs12802200	0.535	rs12282299	chr11:570009	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.59	-4.62	-0.43	1.23e-5	Systemic lupus erythematosus;
THYM	cis	rs7100689	0.784	rs10736342	chr10:82130005	A/G	cg01528321	chr10:82214614	TSPAN14	0.97	7.39	0.6	5.79e-11	Post bronchodilator FEV1;
THYM	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs2932538	0.922	rs9429694	chr1:113158289	G/A	cg22162597	chr1:113214053	CAPZA1	0.65	5.32	0.48	6.9e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg17063962	chr7:91808500	NA	-1.08	-11.41	-0.76	1.71e-19	Breast cancer;
THYM	cis	rs2777491	0.522	rs7173571	chr15:41712807	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.69	-5.5	-0.49	3.14e-7	Ulcerative colitis;
THYM	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg27129171	chr3:47204927	SETD2	0.71	6.76	0.57	1.1e-9	Colorectal cancer;
THYM	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg22709100	chr7:91322751	NA	0.73	5.73	0.51	1.2e-7	Breast cancer;
THYM	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg12292205	chr6:26970375	C6orf41	-0.64	-5.19	-0.47	1.19e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg10856724	chr12:34555212	NA	-0.8	-8.0	-0.63	3.04e-12	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs34375054	0.735	rs34961756	chr12:125628598	C/T	cg25124228	chr12:125621409	AACS	-0.72	-5.82	-0.51	7.86e-8	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs12765878	0.564	rs2073338	chr10:105642803	A/C	cg11005552	chr10:105648138	OBFC1	-0.55	-4.79	-0.44	6.15e-6	Coronary artery disease;
THYM	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg17063962	chr7:91808500	NA	1.17	13.25	0.81	2.54e-23	Breast cancer;
THYM	cis	rs6032067	0.929	rs6032070	chr20:43869795	A/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.37	-0.48	5.52e-7	Blood protein levels;
THYM	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg27535305	chr1:53392650	SCP2	0.62	6.8	0.57	9.23e-10	Monocyte count;
THYM	cis	rs7246657	0.943	rs35540940	chr19:38008235	G/A	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs240764	0.817	rs240154	chr6:101065792	G/T	cg21058520	chr6:100914733	NA	-0.57	-5.06	-0.46	2.04e-6	Neuroticism;
THYM	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg05855489	chr10:104503620	C10orf26	0.56	4.49	0.42	1.99e-5	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs12532960	0.731	rs12532955	chr7:42376839	C/T	cg23473276	chr7:42834405	NA	-1.02	-4.56	-0.42	1.54e-5	Inflammatory biomarkers;
THYM	cis	rs3885907	1.000	rs9508832	chr13:31314264	G/A	cg19953038	chr13:31306303	NA	-0.7	-5.53	-0.49	2.83e-7	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
THYM	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.09	0.64	1.96e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3760982	0.565	rs8104300	chr19:44293144	T/C	cg11993925	chr19:44307056	LYPD5	0.64	5.0	0.46	2.64e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg17845761	chr1:175162550	KIAA0040	0.36	4.57	0.42	1.45e-5	Alcohol dependence;
THYM	cis	rs7712401	0.599	rs35128692	chr5:122369014	G/T	cg19808643	chr5:122110361	SNX2	-0.61	-5.57	-0.5	2.34e-7	Mean platelet volume;
THYM	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.45	0.81	1.03e-23	Height;
THYM	cis	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg21775007	chr8:11205619	TDH	-0.68	-5.27	-0.48	8.47e-7	Retinal vascular caliber;
THYM	cis	rs490234	0.932	rs473426	chr9:128406988	G/C	cg14078157	chr9:128172775	NA	0.59	4.85	0.45	4.79e-6	Mean arterial pressure;
THYM	cis	rs11096990	0.855	rs2465243	chr4:39155656	G/T	cg24403649	chr4:39172243	NA	-0.6	-5.09	-0.46	1.77e-6	Cognitive function;
THYM	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg03060546	chr3:49711283	APEH	0.71	5.0	0.46	2.62e-6	Resting heart rate;
THYM	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg20295408	chr7:1910781	MAD1L1	-0.61	-4.85	-0.45	4.9100000000000004e-06	Bipolar disorder and schizophrenia;
THYM	cis	rs7927771	0.524	rs10838732	chr11:47607940	C/G	cg20307385	chr11:47447363	PSMC3	0.62	4.77	0.44	6.53e-6	Subjective well-being;
THYM	cis	rs3960554	0.808	rs79864016	chr7:75655838	A/G	cg17325771	chr7:75508891	RHBDD2	-0.39	-4.48	-0.42	2.07e-5	Eotaxin levels;
THYM	cis	rs12367572	0.620	rs2731054	chr12:45410570	T/C	cg03114573	chr12:45410052	DBX2	-0.61	-5.93	-0.52	4.96e-8	Gut microbiome composition (summer);
THYM	cis	rs7394190	0.748	rs11000764	chr10:75506864	A/G	cg07699608	chr10:75541558	CHCHD1	0.84	4.62	0.43	1.23e-5	Incident atrial fibrillation;
THYM	cis	rs4455778	0.561	rs28742972	chr7:48995176	A/G	cg26309511	chr7:48887640	NA	-0.51	-4.5	-0.42	1.92e-5	Lung cancer in never smokers;
THYM	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.83	-0.67	5.27e-14	Mean corpuscular volume;
THYM	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg18681998	chr4:17616180	MED28	-0.78	-6.4	-0.55	5.94e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.82	-5.8	-0.51	8.69e-8	Ankle injury;
THYM	cis	rs2456568	0.778	rs7944194	chr11:93682413	C/G	cg17595323	chr11:93583763	C11orf90	0.56	5.18	0.47	1.22e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs289828	0.579	rs6752471	chr2:152159298	C/T	cg05960677	chr2:152117363	RBM43	0.7	6.71	0.57	1.43e-9	Blood protein levels;
THYM	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg00599163	chr2:162100495	NA	0.83	7.68	0.62	1.41e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg02640540	chr1:67518911	SLC35D1	0.64	4.68	0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg00129232	chr17:37814104	STARD3	-0.87	-7.07	-0.59	2.61e-10	Asthma;
THYM	cis	rs4319547	0.737	rs10846920	chr12:122943231	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.75	-5.22	-0.47	1.07e-6	Body mass index;
THYM	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg07212818	chr11:638076	DRD4	-0.79	-6.69	-0.57	1.57e-9	Systemic lupus erythematosus;
THYM	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg26750617	chr12:132293702	NA	-0.54	-5.53	-0.49	2.8e-7	Migraine;
THYM	cis	rs6547741	0.935	rs4666004	chr2:27855052	T/A	cg27432699	chr2:27873401	GPN1	0.73	6.5	0.56	3.65e-9	Oral cavity cancer;
THYM	cis	rs6490294	0.659	rs7294578	chr12:112197837	A/C	cg10833066	chr12:111807467	FAM109A	0.5	5.4	0.48	4.84e-7	Mean platelet volume;
THYM	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg09354556	chr3:47051341	NA	0.44	4.57	0.42	1.46e-5	Colorectal cancer;
THYM	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.61	-0.43	1.25e-5	Mean corpuscular volume;
THYM	cis	rs5771225	0.544	rs1555048	chr22:50688348	A/G	cg16473166	chr22:50639996	SELO	0.63	4.55	0.42	1.57e-5	Late-onset Alzheimer's disease;
THYM	cis	rs4690686	0.509	rs61482060	chr4:177264465	A/G	cg17059388	chr4:177262070	NA	0.48	6.7	0.57	1.48e-9	Essential tremor;
THYM	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg02725872	chr8:58115012	NA	-1.08	-8.41	-0.65	4.17e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7216064	1.000	rs2365764	chr17:65857714	G/A	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs1018836	0.892	rs4735210	chr8:91549399	G/T	cg16814680	chr8:91681699	NA	-0.82	-7.23	-0.6	1.22e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs2273669	0.667	rs12197912	chr6:109338147	C/T	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03264133	chr6:25882463	NA	-0.87	-7.32	-0.6	8.06e-11	Intelligence (multi-trait analysis);
THYM	trans	rs8002861	0.935	rs7320988	chr13:44413523	C/T	cg17145862	chr1:211918768	LPGAT1	0.89	9.07	0.68	1.6e-14	Leprosy;
THYM	cis	rs901683	1.000	rs35047800	chr10:46089047	C/T	cg18240400	chr10:46168597	ANUBL1	0.7	4.67	0.43	9.74e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs904251	0.797	rs2776878	chr6:37487273	G/A	cg01843034	chr6:37503916	NA	-0.68	-4.97	-0.45	2.9e-6	Cognitive performance;
THYM	cis	rs6840360	0.582	rs6813735	chr4:152326990	T/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-5.45	-0.49	4.02e-7	Intelligence (multi-trait analysis);
THYM	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg15536230	chr21:44985092	HSF2BP	-0.43	-5.24	-0.47	9.86e-7	Mean corpuscular volume;
THYM	cis	rs12540874	0.698	rs13234331	chr7:50560314	G/T	cg00647317	chr7:50633725	DDC	0.32	4.82	0.44	5.47e-6	Systemic sclerosis;
THYM	cis	rs611744	0.935	rs679077	chr8:109244742	G/T	cg21045802	chr8:109455806	TTC35	0.57	4.97	0.45	2.98e-6	Dupuytren's disease;
THYM	cis	rs11771526	0.901	rs7357161	chr7:32302475	A/C	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg14582100	chr15:45693742	SPATA5L1	0.58	4.67	0.43	9.87e-6	Homoarginine levels;
THYM	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg15448220	chr1:150897856	SETDB1	-0.92	-7.32	-0.6	7.77e-11	Blood protein levels;
THYM	cis	rs1061377	1.000	rs62310332	chr4:39114559	G/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs6665290	0.904	rs1343743	chr1:227183125	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs10203711	1.000	rs12692240	chr2:239558688	A/G	cg14580085	chr2:239553406	NA	0.71	6.63	0.56	1.99e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.75	-6.21	-0.54	1.37e-8	Lung cancer;
THYM	cis	rs295140	1.000	rs7578220	chr2:201183701	A/G	cg04283868	chr2:201171347	SPATS2L	0.74	5.53	0.49	2.81e-7	QT interval;
THYM	cis	rs2806561	0.734	rs1952527	chr1:23400969	T/C	cg19743168	chr1:23544995	NA	0.49	4.74	0.44	7.64e-6	Height;
THYM	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg23161317	chr6:28129485	ZNF389	0.84	6.3	0.54	9.31e-9	Parkinson's disease;
THYM	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg12334488	chr2:20871173	GDF7	0.58	5.86	0.52	6.75e-8	Abdominal aortic aneurysm;
THYM	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs17604090	0.878	rs10262227	chr7:29704073	G/A	cg19413766	chr7:29689036	LOC646762	-1.04	-5.82	-0.51	7.9e-8	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg09904177	chr6:26538194	HMGN4	0.53	4.48	0.42	2.05e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9527	0.590	rs1935323	chr10:104877035	T/C	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg13736514	chr6:26305472	NA	-0.61	-7.55	-0.61	2.66e-11	Educational attainment;
THYM	cis	rs524023	0.914	rs7932437	chr11:64373504	T/C	cg19131476	chr11:64387923	NRXN2	-0.39	-5.61	-0.5	1.98e-7	Urate levels in obese individuals;
THYM	cis	rs7119	0.636	rs11635606	chr15:77819591	A/G	cg27398640	chr15:77910606	LINGO1	-0.52	-4.88	-0.45	4.2e-6	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28595532	0.920	rs116834347	chr4:119774155	C/A	cg21605333	chr4:119757512	SEC24D	1.67	6.17	0.53	1.69e-8	Cannabis dependence symptom count;
THYM	cis	rs6032067	0.714	rs16989820	chr20:43837659	G/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.37	-0.48	5.59e-7	Blood protein levels;
THYM	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	trans	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg05283184	chr6:79620031	NA	-0.91	-8.84	-0.67	4.86e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7512552	0.839	rs2873669	chr1:150426224	C/T	cg15654264	chr1:150340011	RPRD2	-0.45	-5.22	-0.47	1.04e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg06028605	chr16:24865363	SLC5A11	0.56	5.26	0.47	8.84e-7	Intelligence (multi-trait analysis);
THYM	cis	rs12142240	0.698	rs17361833	chr1:46828700	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg22508957	chr16:3507546	NAT15	0.7	7.9	0.63	4.94e-12	Tuberculosis;
THYM	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg27068330	chr11:65405492	SIPA1	0.84	8.34	0.65	5.78e-13	Acne (severe);
THYM	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	5.07	0.46	2e-6	Rheumatoid arthritis;
THYM	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9457247	0.534	rs4710154	chr6:167394634	A/T	cg00271210	chr6:167070053	RPS6KA2	0.48	4.72	0.44	8e-6	Crohn's disease;
THYM	cis	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg13609457	chr4:120235615	NA	0.55	5.19	0.47	1.17e-6	Corneal astigmatism;
THYM	cis	rs919433	0.648	rs787975	chr2:198248128	C/T	cg05783139	chr2:198650985	BOLL	0.66	5.13	0.47	1.53e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs87938	1.000	rs55908060	chr3:41136285	G/A	cg02247160	chr3:41243829	CTNNB1	-0.33	-4.5	-0.42	1.91e-5	Bone mineral density (hip);
THYM	cis	rs72627123	0.867	rs17092737	chr14:74317000	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	5.82	0.51	7.78e-8	Morning vs. evening chronotype;
THYM	cis	rs4589258	1.000	rs10741363	chr11:90484800	A/G	cg26138821	chr11:89956704	CHORDC1	-0.68	-5.64	-0.5	1.73e-7	Intelligence (multi-trait analysis);
THYM	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg03060546	chr3:49711283	APEH	0.77	6.37	0.55	6.65e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg10515332	chr4:99064459	C4orf37	-0.72	-5.77	-0.51	9.88e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs5167	0.781	rs11672748	chr19:45490192	A/G	cg09555818	chr19:45449301	APOC2	0.43	4.46	0.42	2.26e-5	Blood protein levels;
THYM	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg22166914	chr1:53195759	ZYG11B	0.74	6.21	0.54	1.38e-8	Monocyte count;
THYM	cis	rs1003719	0.788	rs2835592	chr21:38464387	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs7828089	0.646	rs2122877	chr8:22282416	T/C	cg13512537	chr8:22265999	SLC39A14	-0.68	-5.39	-0.48	5.12e-7	Verbal declarative memory;
THYM	cis	rs71403859	0.502	rs36122765	chr16:71504183	G/C	cg08717414	chr16:71523259	ZNF19	-1.45	-7.43	-0.61	4.75e-11	Post bronchodilator FEV1;
THYM	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg02403541	chr12:121454288	C12orf43	-0.81	-7.16	-0.59	1.67e-10	N-glycan levels;
THYM	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg13609457	chr4:120235615	NA	0.49	4.76	0.44	7.01e-6	Corneal astigmatism;
THYM	cis	rs8067545	0.641	rs1638525	chr17:19848594	G/C	cg20830565	chr17:20408647	MGC102966	-0.53	-4.83	-0.44	5.29e-6	Schizophrenia;
THYM	cis	rs8133932	0.654	rs379493	chr21:47360778	G/C	cg20357416	chr21:47294739	PCBP3	0.82	5.1	0.46	1.76e-6	Schizophrenia;
THYM	cis	rs12410462	0.681	rs78978081	chr1:227571619	G/A	cg04117972	chr1:227635322	NA	0.8	4.82	0.44	5.36e-6	Major depressive disorder;
THYM	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg12000587	chr17:30186630	C17orf79	0.48	6.98	0.58	4.04e-10	Hip circumference adjusted for BMI;
THYM	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg13609457	chr4:120235615	NA	0.58	5.33	0.48	6.5e-7	Corneal astigmatism;
THYM	cis	rs1994135	0.669	rs2121831	chr12:33697674	G/A	cg06521331	chr12:34319734	NA	-0.76	-5.3	-0.48	7.44e-7	Resting heart rate;
THYM	cis	rs7119	0.745	rs12911649	chr15:77807127	C/T	cg10437265	chr15:77819839	NA	0.76	7.61	0.62	1.98e-11	Type 2 diabetes;
THYM	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9318086	0.712	rs9318099	chr13:24442462	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.54	-4.66	-0.43	1.02e-5	Myopia (pathological);
THYM	cis	rs7688540	0.547	rs11728864	chr4:191307	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.91	5.56	0.5	2.45e-7	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg17644776	chr2:200775616	C2orf69	-0.79	-4.49	-0.42	2.01e-5	Schizophrenia;
THYM	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg13319975	chr6:146136371	FBXO30	-0.63	-5.16	-0.47	1.36e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11608355	0.705	rs6663	chr12:109886603	G/A	cg10504392	chr12:110044639	NA	0.55	4.62	0.43	1.22e-5	Neuroticism;
THYM	cis	rs9297145	0.678	rs62473048	chr7:98775511	T/C	cg05967295	chr7:98741636	SMURF1	0.81	6.03	0.53	3.12e-8	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs2688608	0.592	rs7909802	chr10:75484186	G/C	cg19442545	chr10:75533431	FUT11	-0.51	-5.22	-0.47	1.03e-6	Inflammatory bowel disease;
THYM	cis	rs654950	0.807	rs941970	chr1:41990867	G/A	cg06885757	chr1:42089581	HIVEP3	-0.49	-5.82	-0.51	8.03e-8	Airway imaging phenotypes;
THYM	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg06623918	chr6:96969491	KIAA0776	-1.05	-10.47	-0.73	1.63e-17	Headache;
THYM	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg09060608	chr5:178986726	RUFY1	-0.65	-7.38	-0.6	5.91e-11	Lung cancer;
THYM	cis	rs2294693	0.947	rs4714417	chr6:40987782	A/G	cg14769373	chr6:40998127	UNC5CL	-0.62	-4.93	-0.45	3.47e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg07511668	chr11:68622177	NA	0.43	4.57	0.42	1.45e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6032067	0.929	rs2233883	chr20:43835822	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.76	-0.51	1.01e-7	Blood protein levels;
THYM	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg00129232	chr17:37814104	STARD3	0.75	5.4	0.48	4.93e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs16857609	1.000	rs16857609	chr2:218296508	C/T	cg15335768	chr2:218268053	DIRC3	-0.36	-5.19	-0.47	1.17e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	cis	rs12681287	0.547	rs9942792	chr8:87509046	C/T	cg27223183	chr8:87520930	FAM82B	-0.71	-5.46	-0.49	3.8e-7	Caudate activity during reward;
THYM	cis	rs3126085	1.000	rs11485508	chr1:152253167	T/G	cg10321714	chr1:152280068	FLG	0.67	5.14	0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg11327659	chr7:150037044	RARRES2	0.48	5.38	0.48	5.31e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	5.38	0.48	5.31e-7	Lung cancer in ever smokers;
THYM	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7084402	0.935	rs10740732	chr10:60352888	G/A	cg27040468	chr10:60456715	BICC1	-0.54	-4.64	-0.43	1.11e-5	Refractive error;
THYM	cis	rs1609391	0.543	rs2117009	chr3:136633571	A/T	cg15507776	chr3:136538369	TMEM22	-0.64	-4.9	-0.45	4.02e-6	Neuroticism;
THYM	cis	rs7598759	0.548	rs11686485	chr2:232360697	C/T	cg19187155	chr2:232395269	NMUR1	0.83	7.38	0.6	5.93e-11	Noise-induced hearing loss;
THYM	cis	rs2213920	0.516	rs34302658	chr9:118168158	T/A	cg13918206	chr9:118159781	DEC1	-1.03	-6.0	-0.52	3.51e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg23958373	chr8:599963	NA	1.01	4.8	0.44	5.88e-6	IgG glycosylation;
THYM	cis	rs2404602	0.735	rs11638767	chr15:76655938	T/C	cg23625390	chr15:77176239	SCAPER	-0.65	-4.7	-0.43	8.68e-6	Blood metabolite levels;
THYM	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg15247329	chr7:2764246	NA	-0.69	-5.7	-0.5	1.35e-7	Height;
THYM	cis	rs2294693	0.947	rs742492	chr6:40996381	G/A	cg21128951	chr6:40996213	UNC5CL	0.6	4.95	0.45	3.24e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs6500395	0.925	rs12920170	chr16:48701530	A/G	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg06728252	chr6:26598149	ABT1	-0.43	-4.74	-0.44	7.59e-6	Intelligence (multi-trait analysis);
THYM	cis	rs988913	0.957	rs960835	chr6:54823422	A/G	cg19716238	chr6:54711378	FAM83B	0.5	4.91	0.45	3.76e-6	Menarche (age at onset);
THYM	cis	rs6570726	0.791	rs9403734	chr6:145931459	C/G	cg13319975	chr6:146136371	FBXO30	-0.64	-5.23	-0.47	1e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11776767	0.743	rs67211633	chr8:10691073	G/C	cg13457217	chr8:10683266	MIR1322;PINX1	-0.67	-5.02	-0.46	2.43e-6	Triglycerides;
THYM	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg02782426	chr3:40428986	ENTPD3	0.53	4.66	0.43	1.04e-5	Renal cell carcinoma;
THYM	cis	rs1008375	0.646	rs4235387	chr4:17569327	T/G	cg18681998	chr4:17616180	MED28	0.82	6.44	0.55	4.87e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9788721	0.836	rs1504550	chr15:78766250	A/G	cg18825076	chr15:78729989	IREB2	-0.67	-6.18	-0.54	1.56e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg15556689	chr8:8085844	FLJ10661	0.71	6.46	0.55	4.53e-9	Systolic blood pressure;
THYM	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg10360139	chr7:1886902	MAD1L1	-0.59	-4.46	-0.42	2.27e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7786808	0.552	rs4909205	chr7:158185283	G/A	cg15440763	chr7:158190612	PTPRN2	0.51	4.69	0.43	9.19e-6	Obesity-related traits;
THYM	cis	rs17445774	1.000	rs1509833	chr2:200865225	G/A	cg23649088	chr2:200775458	C2orf69	0.75	6.39	0.55	6.03e-9	LDL cholesterol to HDL cholesterol ratio;
THYM	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11644478	chr21:40555479	PSMG1	1.11	9.99	0.72	1.76e-16	Cognitive function;
THYM	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.85	-0.51	7.09e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg15604051	chr3:44754201	ZNF502	-0.6	-5.32	-0.48	6.91e-7	Depressive symptoms;
THYM	cis	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs208520	0.779	rs208446	chr6:66903515	T/C	cg07460842	chr6:66804631	NA	-0.81	-4.98	-0.46	2.79e-6	Exhaled nitric oxide output;
THYM	cis	rs11771526	0.792	rs11770580	chr7:32305009	T/C	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs7100689	0.646	rs1815650	chr10:82157464	C/T	cg09936400	chr10:82049201	MAT1A	0.43	4.74	0.44	7.43e-6	Post bronchodilator FEV1;
THYM	cis	rs10911232	0.507	rs10797829	chr1:183033228	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.59	-4.72	-0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.71	4.82	0.44	5.46e-6	Height;
THYM	cis	rs728616	0.867	rs41298231	chr10:81682461	C/T	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs10799590	1.000	rs2786558	chr1:224838004	G/T	cg01808320	chr1:224927238	CNIH3	-0.57	-5.16	-0.47	1.35e-6	Opioid dependence;
THYM	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg13390004	chr1:15929781	NA	0.63	4.79	0.44	6.2e-6	Systolic blood pressure;
THYM	cis	rs1729407	0.786	rs5096	chr11:116693095	G/A	cg08985259	chr11:116699649	APOC3	-0.63	-5.48	-0.49	3.47e-7	Apolipoprotein A-IV levels;
THYM	cis	rs990171	0.571	rs3771202	chr2:102772669	C/G	cg13315345	chr2:102803985	IL1RL2	0.56	4.64	0.43	1.13e-5	Lymphocyte counts;
THYM	cis	rs9311676	0.632	rs7624283	chr3:58369897	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs873917	0.620	rs784595	chr1:40135017	C/T	cg06209491	chr1:40138402	NT5C1A	-0.65	-6.12	-0.53	2.08e-8	Amyotrophic lateral sclerosis;
THYM	cis	rs7631605	0.967	rs4678950	chr3:37253682	C/T	cg21328643	chr3:37258149	NA	-0.57	-5.53	-0.49	2.79e-7	Cerebrospinal P-tau181p levels;
THYM	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg24397884	chr7:158709396	WDR60	-0.44	-5.02	-0.46	2.37e-6	Height;
THYM	cis	rs4072705	0.614	rs7020027	chr9:127241414	G/A	cg13476313	chr9:127244764	NR5A1	-0.36	-5.1	-0.46	1.76e-6	Menarche (age at onset);
THYM	cis	rs7172809	0.607	rs79590310	chr15:77842095	A/G	cg10437265	chr15:77819839	NA	-0.51	-4.68	-0.43	9.7e-6	Glucose homeostasis traits;
THYM	cis	rs9915657	0.660	rs2241170	chr17:70070989	G/C	cg09344028	chr17:70110421	NA	0.46	4.62	0.43	1.22e-5	Thyroid hormone levels;
THYM	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg13010199	chr12:38710504	ALG10B	0.76	5.24	0.47	9.7e-7	Heart rate;
THYM	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs1371867	0.846	rs1660346	chr8:101312497	A/G	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.44	5.25	0.47	9.29e-7	Monocyte percentage of white cells;
THYM	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg21394778	chr1:3037102	PRDM16	0.46	4.47	0.42	2.12e-5	Height;
THYM	cis	rs34779708	0.966	rs113170867	chr10:35450147	C/T	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg15445000	chr17:37608096	MED1	0.41	4.97	0.45	2.96e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7251806	1	rs7251806	chr19:16499569	C/T	cg10248733	chr19:16607483	C19orf44;CALR3	0.73	5.01	0.46	2.54e-6	Lymphocyte counts;
THYM	cis	rs12142240	0.698	rs13374893	chr1:46843800	A/G	cg00530320	chr1:46809349	NSUN4	0.78	5.55	0.49	2.62e-7	Menopause (age at onset);
THYM	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg26418147	chr1:205743515	RAB7L1	-0.57	-4.91	-0.45	3.71e-6	Menarche (age at onset);
THYM	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg23574427	chr4:122746245	BBS7;CCNA2	-0.54	-4.9	-0.45	3.9e-6	Type 2 diabetes;
THYM	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg27141850	chr2:20869434	GDF7	0.49	4.96	0.45	3.05e-6	Abdominal aortic aneurysm;
THYM	cis	rs62120679	0.552	rs730417	chr19:2317666	T/C	cg26843498	chr19:2361574	NA	0.58	7.65	0.62	1.61e-11	Parkinson's disease;
THYM	cis	rs9649213	0.574	rs7802541	chr7:97933855	C/A	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.45	0.42	2.32e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg17939001	chr1:197871836	C1orf53	-0.76	-4.83	-0.44	5.17e-6	Depressive symptoms;
THYM	cis	rs10779751	1.000	rs4845854	chr1:11261929	T/C	cg08854313	chr1:11322531	MTOR	1.0	9.32	0.69	4.77e-15	Body mass index;
THYM	cis	rs72828912	0.731	rs9356925	chr6:24058402	A/C	cg26336265	chr6:25042955	NA	-0.86	-5.43	-0.49	4.31e-7	Squamous cell lung carcinoma;
THYM	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg24308560	chr3:49941425	MST1R	-0.76	-6.48	-0.55	4.12e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.99	-4.73	-0.44	7.9e-6	Alzheimer's disease;
THYM	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg10661904	chr17:79619235	PDE6G	-0.57	-5.17	-0.47	1.32e-6	Eye color traits;
THYM	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg24209194	chr3:40518798	ZNF619	-0.73	-6.34	-0.55	7.53e-9	Renal cell carcinoma;
THYM	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg14196790	chr5:131705035	SLC22A5	0.55	4.98	0.45	2.88e-6	Blood metabolite levels;
THYM	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.69	5.65	0.5	1.67e-7	Blood metabolite levels;
THYM	cis	rs4746818	1.000	rs7091695	chr10:70964997	A/G	cg11621586	chr10:70884670	VPS26A	-1.17	-7.32	-0.6	8.04e-11	Left atrial antero-posterior diameter;
THYM	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg00071950	chr4:10020882	SLC2A9	-0.67	-6.97	-0.58	4.17e-10	Bone mineral density;
THYM	cis	rs11190604	1.000	rs3750720	chr10:102248884	C/T	cg16342193	chr10:102329863	NA	-0.48	-4.79	-0.44	6.2e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg10802521	chr3:52805072	NEK4	-0.8	-7.53	-0.61	2.92e-11	Bipolar disorder;
THYM	cis	rs9880211	0.613	rs9653930	chr3:135810314	C/T	cg21827317	chr3:136751795	NA	-0.71	-5.16	-0.47	1.33e-6	Body mass index;Height;
THYM	cis	rs9814567	1.000	rs9856693	chr3:134306913	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.5	-0.66	2.69e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs4604732	0.685	rs4925673	chr1:247636800	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.58	4.56	0.42	1.51e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs2747539	1.000	rs4911368	chr20:32421742	C/T	cg06304546	chr20:32448765	NA	-0.79	-5.03	-0.46	2.36e-6	Dysphagia;
THYM	cis	rs3008870	1.000	rs2755240	chr1:67477339	T/G	cg02640540	chr1:67518911	SLC35D1	0.65	4.83	0.44	5.32e-6	Lymphocyte percentage of white cells;
THYM	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg05182265	chr7:156933206	UBE3C	0.69	9.34	0.69	4.32e-15	Body mass index;
THYM	cis	rs1642645	0.757	rs6600394	chr1:42472453	T/C	cg06092502	chr1:42611687	NA	0.6	4.64	0.43	1.11e-5	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg13175981	chr1:150552382	MCL1	0.7	4.99	0.46	2.72e-6	Tonsillectomy;
THYM	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.58	4.95	0.45	3.25e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg26038318	chr20:34205095	SPAG4	0.59	4.65	0.43	1.08e-5	Total cholesterol levels;
THYM	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.55	-4.69	-0.43	8.99e-6	Platelet count;
THYM	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg17063962	chr7:91808500	NA	1.16	13.14	0.8	4.39e-23	Breast cancer;
THYM	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg10911889	chr6:126070802	HEY2	0.6	4.81	0.44	5.72e-6	Brugada syndrome;
THYM	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.79	7.43	0.61	4.64e-11	Calcium levels;
THYM	cis	rs10927875	0.578	rs10927859	chr1:16141862	C/T	cg21385522	chr1:16154831	NA	-1.32	-13.48	-0.81	9e-24	Dilated cardiomyopathy;
THYM	cis	rs4674676	1	rs4674676	chr2:223529112	A/G	cg25565276	chr2:223520875	FARSB	1.13	8.18	0.64	1.26e-12	Chin dimples;
THYM	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg12935359	chr14:103987150	CKB	-0.6	-6.21	-0.54	1.38e-8	Body mass index;
THYM	cis	rs76878669	0.561	rs1784029	chr11:66099987	C/T	cg18002602	chr11:66138449	SLC29A2	0.49	4.91	0.45	3.74e-6	Educational attainment (years of education);
THYM	cis	rs3126085	0.935	rs12729662	chr1:152185750	G/A	cg10321714	chr1:152280068	FLG	-0.69	-4.93	-0.45	3.52e-6	Atopic dermatitis;
THYM	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.65	5.14	0.47	1.47e-6	Lung cancer in ever smokers;
THYM	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22509189	chr2:225307070	NA	-0.88	-7.52	-0.61	3.1e-11	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg25566285	chr7:158114605	PTPRN2	0.78	7.03	0.58	3.19e-10	Response to amphetamines;
THYM	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg03690763	chr11:133734501	NA	-0.63	-5.22	-0.47	1.06e-6	Childhood ear infection;
THYM	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg18681998	chr4:17616180	MED28	1.04	10.1	0.72	1.01e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs17006441	0.932	rs9864805	chr3:69878488	C/T	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs17125944	0.686	rs55685925	chr14:53334546	A/G	cg00686598	chr14:53173677	PSMC6	-1.08	-4.81	-0.44	5.6e-6	Alzheimer's disease (late onset);
THYM	cis	rs7560272	0.723	rs4346412	chr2:73843571	A/G	cg19565262	chr2:73869966	NAT8	-0.53	-4.58	-0.43	1.39e-5	Schizophrenia;
THYM	cis	rs5758265	1	rs5758265	chr22:41617897	G/A	cg06481639	chr22:41940642	POLR3H	-0.69	-5.15	-0.47	1.41e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg07460842	chr6:66804631	NA	-0.84	-5.65	-0.5	1.68e-7	Exhaled nitric oxide output;
THYM	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg08994789	chr17:28903642	LRRC37B2	-1.09	-5.4	-0.48	4.88e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2898681	0.521	rs6833350	chr4:53740868	A/G	cg21521518	chr4:53727714	RASL11B	0.62	5.61	0.5	1.97e-7	Optic nerve measurement (cup area);
THYM	cis	rs7917772	0.582	rs4917976	chr10:104360518	A/G	cg00122347	chr10:104236741	TMEM180	0.41	5.81	0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4523957	0.820	rs7212249	chr17:2135980	A/T	cg16513277	chr17:2031491	SMG6	-0.82	-8.19	-0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs3820068	0.608	rs12734937	chr1:16047726	T/C	cg13390004	chr1:15929781	NA	0.65	4.81	0.44	5.56e-6	Systolic blood pressure;
THYM	cis	rs3213545	0.700	rs10849829	chr12:121470256	A/G	cg02403541	chr12:121454288	C12orf43	-0.6	-5.08	-0.46	1.87e-6	Subjective well-being;Cardiovascular disease risk factors;
THYM	trans	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17712092	chr4:129076599	LARP1B	0.9	7.57	0.61	2.42e-11	Eosinophil percentage of white cells;
THYM	cis	rs17511627	0.866	rs7327712	chr13:26722921	C/T	cg13319468	chr13:27597730	NA	0.78	6.18	0.54	1.62e-8	Alzheimer's disease;
THYM	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg00012203	chr2:219082015	ARPC2	-0.65	-5.3	-0.48	7.35e-7	Colorectal cancer;
THYM	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06873352	chr17:61820015	STRADA	-0.79	-9.97	-0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg16068833	chr1:26644515	UBXN11;CD52	0.26	4.5	0.42	1.9e-5	Obesity-related traits;
THYM	cis	rs6918586	0.565	rs13196986	chr6:26090452	T/C	cg12310025	chr6:25882481	NA	-0.75	-5.28	-0.48	8.05e-7	Schizophrenia;
THYM	cis	rs2302612	0.528	rs2241130	chr2:102835706	T/C	cg13315345	chr2:102803985	IL1RL2	0.68	4.58	0.43	1.4e-5	Serum protein levels (sST2);
THYM	cis	rs2898681	0.519	rs6554057	chr4:53730147	A/T	cg00791764	chr4:53727839	RASL11B	0.6	6.58	0.56	2.51e-9	Optic nerve measurement (cup area);
THYM	cis	rs9522267	0.535	rs9515447	chr13:112222303	C/T	cg10483660	chr13:112241077	NA	-0.59	-6.61	-0.56	2.22e-9	Hepatitis;
THYM	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg08017756	chr2:100939284	LONRF2	-0.72	-7.35	-0.6	6.77e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7216064	1.000	rs62084251	chr17:65878736	G/A	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg01579765	chr21:45077557	HSF2BP	-0.48	-7.38	-0.6	5.95e-11	Mean corpuscular volume;
THYM	cis	rs7681440	0.606	rs1442146	chr4:90748646	C/G	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs2806561	0.780	rs6650086	chr1:23338384	T/C	cg08872493	chr1:23521417	HTR1D	-0.37	-4.53	-0.42	1.74e-5	Height;
THYM	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg06713675	chr4:122721982	EXOSC9	-0.52	-4.72	-0.44	8.2e-6	Type 2 diabetes;
THYM	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg06481639	chr22:41940642	POLR3H	-0.71	-5.13	-0.47	1.51e-6	Neuroticism;
THYM	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg08508325	chr11:3079039	CARS	0.5	6.44	0.55	4.9e-9	Longevity;
THYM	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg27532560	chr4:187881888	NA	-0.95	-11.68	-0.77	4.63e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs16866061	0.962	rs3845840	chr2:225359100	G/A	cg12698349	chr2:225449008	CUL3	1.1	9.52	0.7	1.78e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.24e-7	Corneal astigmatism;
THYM	cis	rs4889855	0.530	rs11654265	chr17:78602697	G/A	cg16591659	chr17:78472290	NA	0.44	5.13	0.47	1.53e-6	Fractional excretion of uric acid;
THYM	cis	rs236907	0.859	rs6681322	chr1:171773871	A/G	cg20598894	chr1:171756153	METTL13	0.74	5.27	0.48	8.4e-7	Mean platelet volume;
THYM	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	cis	rs7100689	0.577	rs10788545	chr10:82034675	A/G	cg09936400	chr10:82049201	MAT1A	0.44	4.65	0.43	1.08e-5	Post bronchodilator FEV1;
THYM	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs10779751	1.000	rs718206	chr1:11294474	T/A	cg08854313	chr1:11322531	MTOR	0.94	8.23	0.65	9.67e-13	Body mass index;
THYM	cis	rs10484885	0.878	rs72921916	chr6:90555990	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.87	-7.73	-0.62	1.13e-11	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg14517863	chr17:44321492	NA	-0.44	-5.0	-0.46	2.59e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg07636037	chr3:49044803	WDR6	0.96	8.27	0.65	8.24e-13	Menarche (age at onset);
THYM	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg12826209	chr6:26865740	GUSBL1	0.84	4.61	0.43	1.27e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg23422044	chr7:1970798	MAD1L1	-0.81	-5.38	-0.48	5.42e-7	Neuroticism;
THYM	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg09877947	chr5:131593287	PDLIM4	0.58	4.82	0.44	5.38e-6	Blood metabolite levels;
THYM	cis	rs2288884	0.708	rs61574510	chr19:52520607	C/T	cg05974498	chr19:52599256	ZNF841	0.35	4.51	0.42	1.85e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	8.67	0.66	1.13e-13	Monocyte percentage of white cells;
THYM	cis	rs9915657	0.933	rs8075603	chr17:70136833	G/T	cg09344028	chr17:70110421	NA	0.44	4.56	0.42	1.52e-5	Thyroid hormone levels;
THYM	cis	rs34638657	0.872	rs2967349	chr16:82194405	G/C	cg09894383	chr16:82067445	HSD17B2	-0.54	-5.46	-0.49	3.8e-7	Lung adenocarcinoma;
THYM	cis	rs6987853	0.686	rs7818789	chr8:42354257	A/G	cg09913449	chr8:42400586	C8orf40	0.89	8.38	0.65	4.76e-13	Mean corpuscular hemoglobin concentration;
THYM	cis	rs748404	0.631	rs6493086	chr15:43655394	T/C	cg12861797	chr15:43585817	TGM7	0.45	4.65	0.43	1.08e-5	Lung cancer;
THYM	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg11526020	chr17:80870163	TBCD	-0.44	-4.46	-0.42	2.24e-5	Breast cancer;
THYM	cis	rs13326165	0.585	rs7615405	chr3:52351553	T/G	cg08438690	chr3:52279403	PPM1M	-0.8	-4.69	-0.43	9.03e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs597539	0.503	rs7131462	chr11:68610143	G/A	cg06112835	chr11:68658793	MRPL21	-0.37	-4.72	-0.44	8e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg06481639	chr22:41940642	POLR3H	0.84	5.85	0.51	6.94e-8	Vitiligo;
THYM	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.69	4.63	0.43	1.14e-5	Lung cancer in ever smokers;
THYM	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg04043695	chr12:129287642	SLC15A4	0.63	5.22	0.47	1.04e-6	Systemic lupus erythematosus;
THYM	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03517284	chr6:25882590	NA	-0.74	-5.87	-0.52	6.35e-8	Blood metabolite levels;
THYM	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg15744005	chr10:104629667	AS3MT	-0.83	-7.78	-0.62	8.71e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg11189052	chr15:85197271	WDR73	-0.71	-5.62	-0.5	1.93e-7	P wave terminal force;
THYM	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg11211951	chr8:145729740	GPT	-0.55	-4.87	-0.45	4.36e-6	Age at first birth;
THYM	cis	rs4731207	0.507	rs10954052	chr7:124586811	C/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg24549020	chr5:56110836	MAP3K1	0.7	4.58	0.42	1.43e-5	Initial pursuit acceleration;
THYM	cis	rs11098499	0.532	rs12512646	chr4:120585733	G/A	cg13609457	chr4:120235615	NA	0.63	5.4	0.48	4.88e-7	Corneal astigmatism;
THYM	cis	rs7772486	0.654	rs6928007	chr6:146074941	G/A	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9814567	0.964	rs9847788	chr3:134186496	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.87	-0.63	5.61e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7432375	0.901	rs7648531	chr3:136462223	T/A	cg12473912	chr3:136751656	NA	-0.61	-5.13	-0.47	1.55e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg01579765	chr21:45077557	HSF2BP	0.52	8.35	0.65	5.58e-13	Mean corpuscular volume;
THYM	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-4.95	-0.45	3.26e-6	Bipolar disorder;
THYM	cis	rs9921192	0.967	rs233953	chr16:4330570	A/G	cg00021532	chr16:4324280	TFAP4	0.89	7.92	0.63	4.48e-12	Prostate-specific antigen levels;
THYM	cis	rs9311676	0.656	rs7647078	chr3:58369912	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs2504916	0.712	rs2504959	chr6:160748465	T/C	cg19643109	chr6:160697625	NA	-0.65	-4.84	-0.44	5.1e-6	Response to hepatitis C treatment;
THYM	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg09359103	chr1:154839909	KCNN3	-0.73	-9.25	-0.69	6.79e-15	Prostate cancer;
THYM	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg13114125	chr14:105738426	BRF1	-0.72	-5.61	-0.5	2.01e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs72843506	0.656	rs8073875	chr17:19939059	A/G	cg12065943	chr17:19881925	AKAP10	-0.76	-4.58	-0.43	1.41e-5	Schizophrenia;
THYM	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs10744422	1.000	rs3852537	chr12:123361501	T/C	cg25930673	chr12:123319894	HIP1R	-0.9	-5.14	-0.47	1.47e-6	Schizophrenia;
THYM	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg22841779	chr14:105766346	BRF1	-0.47	-5.81	-0.51	8.18e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg05347473	chr6:146136440	FBXO30	0.58	4.52	0.42	1.8e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg09307838	chr4:120376055	NA	0.73	5.02	0.46	2.37e-6	Corneal astigmatism;
THYM	cis	rs10905065	1.000	rs10737013	chr10:5746772	C/G	cg11519256	chr10:5708881	ASB13	0.48	4.65	0.43	1.07e-5	Menopause (age at onset);
THYM	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs7267979	1.000	rs7268053	chr20:25328286	A/T	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6687430	0.543	rs7512495	chr1:10631237	C/T	cg20482658	chr1:10539492	PEX14	-0.37	-4.98	-0.45	2.86e-6	Hand grip strength;
THYM	trans	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg25214090	chr10:38739885	LOC399744	-0.89	-7.5	-0.61	3.3e-11	Corneal astigmatism;
THYM	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg11905131	chr22:24372483	LOC391322	-0.92	-9.9	-0.71	2.74e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg26545918	chr15:68124484	LBXCOR1	0.54	4.6	0.43	1.28e-5	Restless legs syndrome;
THYM	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17407555	0.683	rs6833142	chr4:10275982	A/G	cg00071950	chr4:10020882	SLC2A9	0.57	5.3	0.48	7.52e-7	Schizophrenia (age at onset);
THYM	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.63	-5.33	-0.48	6.66e-7	Coronary artery disease;
THYM	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg18681998	chr4:17616180	MED28	0.94	8.65	0.66	1.25e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4072705	0.614	rs35929043	chr9:127234356	T/C	cg13476313	chr9:127244764	NR5A1	0.33	4.65	0.43	1.06e-5	Menarche (age at onset);
THYM	cis	rs2160908	0.694	rs229522	chr22:37578960	C/T	cg26999345	chr22:37584441	C1QTNF6	-0.39	-4.51	-0.42	1.83e-5	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs11008222	1.000	rs11008222	chr10:31042494	A/G	cg00941203	chr10:31016591	NA	0.36	4.93	0.45	3.43e-6	Congenital left-sided heart lesions (maternal effect);
THYM	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.58	-5.9	-0.52	5.64e-8	Crohn's disease;
THYM	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg17063962	chr7:91808500	NA	-1.16	-12.78	-0.8	2.34e-22	Breast cancer;
THYM	cis	rs754466	0.606	rs11002306	chr10:79591519	A/T	cg17075019	chr10:79541650	NA	-0.72	-6.01	-0.52	3.4e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7264396	0.676	rs6060729	chr20:34557004	G/C	cg26038318	chr20:34205095	SPAG4	0.59	4.81	0.44	5.6e-6	Total cholesterol levels;
THYM	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.6	-5.37	-0.48	5.55e-7	Prudent dietary pattern;
THYM	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg21609526	chr1:3105151	PRDM16	0.66	5.56	0.5	2.52e-7	Migraine;
THYM	cis	rs10484885	0.878	rs1328018	chr6:90297847	A/G	cg13799429	chr6:90582589	CASP8AP2	0.86	7.64	0.62	1.68e-11	QRS interval (sulfonylurea treatment interaction);
THYM	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg15704280	chr7:45808275	SEPT13	1.0	11.19	0.75	4.89e-19	Height;
THYM	cis	rs8031584	1.000	rs890159	chr15:31291634	G/A	cg08109568	chr15:31115862	NA	-0.6	-5.35	-0.48	6.01e-7	Huntington's disease progression;
THYM	cis	rs4722166	0.695	rs56061963	chr7:22800397	T/C	cg05472934	chr7:22766657	IL6	0.66	5.64	0.5	1.72e-7	Lung cancer;
THYM	cis	rs9543976	0.623	rs6562915	chr13:76170886	G/T	cg01531495	chr13:76123901	UCHL3	0.66	4.8	0.44	5.85e-6	Diabetic retinopathy;
THYM	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03517284	chr6:25882590	NA	0.75	6.25	0.54	1.17e-8	Blood metabolite levels;
THYM	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg06108461	chr20:60628389	TAF4	-0.81	-6.42	-0.55	5.36e-9	Body mass index;
THYM	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	5.07	0.46	1.92e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg16325326	chr1:53192061	ZYG11B	-0.73	-7.1	-0.59	2.23e-10	Monocyte count;
THYM	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg06636001	chr8:8085503	FLJ10661	-0.75	-7.1	-0.59	2.28e-10	Mood instability;
THYM	cis	rs2070488	0.932	rs4678604	chr3:38444273	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	6.65	0.56	1.88e-9	Electrocardiographic conduction measures;
THYM	cis	rs9906944	0.713	rs9899580	chr17:47106878	T/G	cg18128536	chr17:47092178	IGF2BP1	-0.43	-4.71	-0.44	8.43e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11225247	0.881	rs12271457	chr11:102247928	C/T	cg06323957	chr11:102217781	BIRC2	1.08	4.83	0.44	5.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg00383909	chr3:49044727	WDR6	1.19	7.36	0.6	6.4e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs67072384	1.000	rs72964185	chr11:72443177	G/A	cg01380194	chr11:72452482	ARAP1	-0.83	-4.59	-0.43	1.35e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.65	5.53	0.49	2.76e-7	Lung disease severity in cystic fibrosis;
THYM	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.46	-5.55	-0.49	2.58e-7	Schizophrenia;
THYM	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.64	5.5	0.49	3.23e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs36051895	0.623	rs11790680	chr9:5248768	C/T	cg02405213	chr9:5042618	JAK2	-0.95	-9.21	-0.69	8.17e-15	Pediatric autoimmune diseases;
THYM	trans	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg13615516	chr5:77269221	NA	-0.89	-8.16	-0.64	1.4e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs131777	0.575	rs963980	chr22:51022117	C/A	cg25309564	chr22:51001381	C22orf41	0.63	5.06	0.46	2.07e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs11696845	0.604	rs1980577	chr20:43382112	A/G	cg09357268	chr20:43379437	KCNK15	0.48	4.74	0.44	7.44e-6	Obesity-related traits;
THYM	cis	rs994014	0.847	rs2058368	chr4:82274989	A/G	cg17825130	chr4:82283507	NA	0.46	4.47	0.42	2.16e-5	Height;
THYM	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg06636001	chr8:8085503	FLJ10661	0.78	7.48	0.61	3.74e-11	Mood instability;
THYM	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg02696790	chr15:75250997	RPP25	0.46	4.72	0.44	7.98e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs7107174	1.000	rs7128666	chr11:78102363	A/T	cg19901956	chr11:77921274	USP35	-0.69	-5.7	-0.5	1.35e-7	Testicular germ cell tumor;
THYM	cis	rs912057	0.526	rs746453	chr6:6734221	C/A	cg06612196	chr6:6737390	NA	0.77	12.3	0.78	2.33e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg00677455	chr12:58241039	CTDSP2	0.73	4.93	0.45	3.5e-6	Multiple sclerosis;
THYM	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg12310025	chr6:25882481	NA	-0.9	-8.69	-0.67	1.06e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2294693	0.947	rs736793	chr6:40997919	A/T	cg21128951	chr6:40996213	UNC5CL	0.6	4.95	0.45	3.24e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	trans	rs112998813	0.571	rs7328349	chr13:114930401	G/A	cg07263694	chr12:111748299	CUX2	1.18	6.91	0.58	5.4e-10	Nodular sclerosis Hodgkin lymphoma;
THYM	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg06521331	chr12:34319734	NA	-0.94	-8.59	-0.66	1.66e-13	Morning vs. evening chronotype;
THYM	cis	rs2658782	0.789	rs2658776	chr11:93147927	A/G	cg15737290	chr11:93063684	CCDC67	0.9	7.24	0.6	1.18e-10	Pulmonary function decline;
THYM	cis	rs9796	0.689	rs9888718	chr15:41446254	T/G	cg21153102	chr15:41252147	NA	0.6	4.91	0.45	3.79e-6	Menopause (age at onset);
THYM	cis	rs6032067	0.759	rs2206889	chr20:43886487	C/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.38	-4.48	-0.42	2.07e-5	Blood protein levels;
THYM	cis	rs8048589	0.604	rs11646584	chr16:12207975	G/A	cg01990910	chr16:12207648	SNX29	-0.55	-5.81	-0.51	8.24e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9302635	0.513	rs3902135	chr16:72175820	C/T	cg23815491	chr16:72088622	HP	0.79	6.29	0.54	9.85e-9	Blood protein levels;
THYM	cis	rs7260598	0.792	rs4635459	chr19:24181822	T/C	cg15526094	chr19:24182596	NA	-0.67	-4.69	-0.43	9.12e-6	Response to taxane treatment (placlitaxel);
THYM	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs10463554	0.963	rs11955683	chr5:102326696	A/G	cg23492399	chr5:102201601	PAM	-0.64	-5.09	-0.46	1.8e-6	Parkinson's disease;
THYM	cis	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg05084668	chr3:125655381	ALG1L	-0.78	-5.14	-0.47	1.48e-6	Blood pressure (smoking interaction);
THYM	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg07648498	chr16:89883185	FANCA	0.66	4.89	0.45	4.06e-6	Vitiligo;
THYM	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg11245990	chr11:68621969	NA	0.52	6.56	0.56	2.75e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg18876405	chr7:65276391	NA	0.61	5.3	0.48	7.49e-7	Aortic root size;
THYM	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg15744005	chr10:104629667	AS3MT	-0.84	-8.33	-0.65	6.07e-13	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs5769707	0.632	rs6009782	chr22:50010812	C/G	cg23428387	chr22:49814324	NA	-0.57	-5.4	-0.48	4.94e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg18252515	chr7:66147081	NA	0.65	4.73	0.44	7.72e-6	Aortic root size;
THYM	cis	rs1003719	0.788	rs2835577	chr21:38457457	T/C	cg01329690	chr21:38580129	DSCR9	0.39	5.25	0.47	9.23e-7	Eye color traits;
THYM	cis	rs10744422	1.000	rs7138398	chr12:123341833	G/C	cg25930673	chr12:123319894	HIP1R	-0.84	-4.72	-0.44	8.03e-6	Schizophrenia;
THYM	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg22841779	chr14:105766346	BRF1	-0.51	-6.63	-0.56	2.08e-9	Platelet count;
THYM	cis	rs807029	0.577	rs3740488	chr10:102754033	A/T	cg14905631	chr10:102746534	C10orf2;MRPL43	0.36	5.05	0.46	2.14e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9807989	0.507	rs2058659	chr2:103054556	A/G	cg03938978	chr2:103052716	IL18RAP	-0.75	-9.86	-0.71	3.25e-16	Asthma;
THYM	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg06917634	chr15:78832804	PSMA4	-0.64	-4.55	-0.42	1.6e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs3796619	1.000	rs2290409	chr4:1067249	C/T	cg27284194	chr4:1044797	NA	-0.52	-4.83	-0.44	5.32e-6	Recombination rate (males);
THYM	cis	rs8050907	0.590	rs17137098	chr16:4560535	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.13	4.76	0.44	6.97e-6	Obesity-related traits;
THYM	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg20891283	chr12:69753455	YEATS4	0.77	6.38	0.55	6.37e-9	Response to diuretic therapy;
THYM	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg19747945	chr6:42946146	PEX6	-0.33	-4.75	-0.44	7.16e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7551222	0.716	rs11240751	chr1:204462050	A/G	cg20240347	chr1:204465584	NA	-0.51	-4.64	-0.43	1.12e-5	Schizophrenia;
THYM	cis	rs3849570	1.000	rs2290081	chr3:81810725	C/T	cg07356753	chr3:81810745	GBE1	-0.93	-7.69	-0.62	1.32e-11	Waist circumference;Body mass index;
THYM	cis	rs1883415	0.727	rs2744579	chr6:24501000	A/C	cg00346970	chr6:24499591	ALDH5A1	0.39	5.08	0.46	1.89e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg12863693	chr15:85201151	NMB	0.65	5.9	0.52	5.46e-8	Schizophrenia;
THYM	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.43	-0.49	4.24e-7	Mean corpuscular volume;
THYM	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs8018808	1.000	rs4903580	chr14:77850978	C/T	cg20045696	chr14:77926864	AHSA1	-0.59	-5.39	-0.48	5.04e-7	Myeloid white cell count;
THYM	cis	rs921665	0.680	rs7571242	chr2:3199025	A/G	cg16434511	chr2:3151078	NA	-0.87	-5.46	-0.49	3.8e-7	World class endurance athleticism;
THYM	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-4.98	-0.45	2.87e-6	Obesity-related traits;
THYM	cis	rs17534004	1.000	rs17534137	chr13:31471920	G/A	cg13251181	chr13:31481184	C13orf33	0.55	4.52	0.42	1.77e-5	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg09877947	chr5:131593287	PDLIM4	0.58	4.87	0.45	4.53e-6	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs877674	0.872	rs909001	chr1:32196647	C/G	cg13438300	chr1:32254265	NA	-0.69	-4.67	-0.43	9.81e-6	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg01299579	chr2:10830716	NOL10	0.49	4.65	0.43	1.06e-5	Prostate cancer;
THYM	cis	rs16944158	0.636	rs2098421	chr16:49639815	G/A	cg05126388	chr16:49670144	ZNF423	0.73	4.85	0.45	4.89e-6	IgG glycosylation;
THYM	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg09359103	chr1:154839909	KCNN3	-0.72	-9.45	-0.7	2.44e-15	Prostate cancer;
THYM	cis	rs7043114	0.525	rs10820964	chr9:95041636	G/A	cg14631576	chr9:95140430	CENPP	-0.85	-9.03	-0.68	1.99e-14	Height;
THYM	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg03433033	chr1:76189801	ACADM	0.77	10.22	0.72	5.5e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1642645	0.831	rs6698877	chr1:42500436	T/C	cg22816091	chr1:42611670	NA	0.63	5.58	0.5	2.31e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg23815491	chr16:72088622	HP	0.69	5.3	0.48	7.58e-7	Fibrinogen levels;
THYM	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg09436375	chr6:42928200	GNMT	-0.45	-5.88	-0.52	6.11e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2213920	0.516	rs13301972	chr9:118158086	C/T	cg13918206	chr9:118159781	DEC1	-1.03	-6.0	-0.52	3.51e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs2252521	0.524	rs317744	chr7:29067293	T/G	cg24222995	chr7:28995786	TRIL	-0.62	-4.46	-0.42	2.28e-5	Cognitive performance;
THYM	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg24692254	chr21:30365293	RNF160	-0.84	-6.98	-0.58	4e-10	Dental caries;
THYM	cis	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg07460842	chr6:66804631	NA	0.79	5.18	0.47	1.25e-6	Exhaled nitric oxide output;
THYM	cis	rs17253792	0.822	rs112374071	chr14:56061919	C/T	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg09455208	chr3:40491958	NA	-0.45	-4.55	-0.42	1.59e-5	Renal cell carcinoma;
THYM	cis	rs17401966	1.000	rs3753037	chr1:10355834	C/T	cg19773385	chr1:10388646	KIF1B	-0.63	-4.57	-0.42	1.44e-5	Hepatocellular carcinoma;
THYM	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg06028605	chr16:24865363	SLC5A11	-0.63	-5.02	-0.46	2.43e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs11087123	0.500	rs1743473	chr20:15120767	A/T	cg09937190	chr20:15177509	MACROD2	0.48	5.38	0.48	5.36e-7	Eating disorders;
THYM	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs16854884	0.632	rs4535221	chr3:143658607	A/G	cg05063096	chr3:143689810	C3orf58	0.74	4.89	0.45	4.17e-6	Economic and political preferences (feminism/equality);
THYM	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg18032289	chr17:61959525	GH2	-0.49	-4.67	-0.43	9.78e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.48	-0.55	4.1e-9	Personality dimensions;
THYM	cis	rs2963155	0.518	rs56150733	chr5:142765099	T/C	cg17617527	chr5:142782415	NR3C1	1.15	4.94	0.45	3.32e-6	Breast cancer;
THYM	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs9563576	0.778	rs12583893	chr13:58582515	A/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg18252515	chr7:66147081	NA	0.72	5.66	0.5	1.59e-7	Aortic root size;
THYM	cis	rs6687430	0.526	rs12117392	chr1:10608583	T/C	cg20482658	chr1:10539492	PEX14	-0.39	-5.36	-0.48	5.84e-7	Hand grip strength;
THYM	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg24642844	chr7:1081250	C7orf50	-1.19	-5.14	-0.47	1.47e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg10792982	chr14:105748885	BRF1	0.75	7.8	0.62	7.96e-12	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2282300	0.653	rs12800124	chr11:30239865	A/G	cg09906309	chr11:30344399	C11orf46	-0.72	-5.34	-0.48	6.24e-7	Morning vs. evening chronotype;
THYM	cis	rs1003719	0.715	rs4261789	chr21:38503762	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-4.48	-0.42	2.1e-5	Eye color traits;
THYM	cis	rs17818399	0.620	rs6739397	chr2:46858321	G/C	cg09399716	chr2:46890238	NA	-0.44	-4.45	-0.42	2.32e-5	Height;
THYM	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg27068330	chr11:65405492	SIPA1	0.84	8.34	0.65	5.78e-13	Acne (severe);
THYM	cis	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg06521331	chr12:34319734	NA	-1.03	-10.3	-0.73	3.74e-17	Morning vs. evening chronotype;
THYM	cis	rs6750795	0.542	rs1797388	chr2:232415981	T/G	cg19187155	chr2:232395269	NMUR1	0.89	8.45	0.66	3.32e-13	Height;
THYM	cis	rs11771526	0.681	rs79578813	chr7:32308867	G/T	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg01416388	chr22:39784598	NA	-0.94	-8.89	-0.67	3.85e-14	Intelligence (multi-trait analysis);
THYM	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.2	8.97	0.68	2.63e-14	Cognitive test performance;
THYM	cis	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-4.75	-0.44	7.2e-6	Recombination measurement;
THYM	cis	rs2033562	0.965	rs4734636	chr8:103542538	A/G	cg20611272	chr8:103548145	NA	0.4	4.99	0.46	2.77e-6	IgA nephropathy;
THYM	cis	rs12188164	0.931	rs72717407	chr5:424653	G/A	cg14137381	chr5:502291	SLC9A3	-0.62	-4.57	-0.42	1.45e-5	Cystic fibrosis severity;
THYM	cis	rs7731657	0.537	rs12332151	chr5:130344771	T/C	cg08523029	chr5:130500466	HINT1	-0.81	-5.6	-0.5	2.04e-7	Fasting plasma glucose;
THYM	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg10047753	chr17:41438598	NA	1.02	8.95	0.68	2.87e-14	Menopause (age at onset);
THYM	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg01579765	chr21:45077557	HSF2BP	-0.54	-9.37	-0.69	3.75e-15	Mean corpuscular volume;
THYM	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs8180040	0.800	rs7632501	chr3:47268306	T/C	cg16586182	chr3:47516702	SCAP	0.69	5.97	0.52	4.02e-8	Colorectal cancer;
THYM	cis	rs778371	0.676	rs4973563	chr2:233716421	C/T	cg08000102	chr2:233561755	GIGYF2	-0.81	-7.19	-0.59	1.49e-10	Schizophrenia;
THYM	cis	rs72627123	0.867	rs1013644	chr14:74367564	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs654950	0.840	rs116241899	chr1:41994546	T/C	cg06885757	chr1:42089581	HIVEP3	-0.44	-5.26	-0.47	9e-7	Airway imaging phenotypes;
THYM	cis	rs10174077	0.874	rs4664490	chr2:152471923	C/G	cg06191203	chr2:152266755	RIF1	0.71	4.83	0.44	5.14e-6	Squamous cell lung carcinoma;
THYM	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.76	-0.44	6.96e-6	Type 2 diabetes;
THYM	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-5.09	-0.46	1.8e-6	Joint mobility (Beighton score);
THYM	cis	rs12931792	0.712	rs56399904	chr16:30166183	C/T	cg17640201	chr16:30407289	ZNF48	0.61	5.08	0.46	1.87e-6	Tonsillectomy;
THYM	cis	rs7542375	0.683	rs1335914	chr1:221107232	C/T	cg16008148	chr1:221062819	NA	-0.45	-4.69	-0.43	9.24e-6	Obesity-related traits;
THYM	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg11984989	chr7:158649758	WDR60	-1.04	-13.58	-0.81	5.57e-24	Height;
THYM	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg18252515	chr7:66147081	NA	-1.62	-8.8	-0.67	5.99e-14	Diabetic kidney disease;
THYM	cis	rs6032067	0.777	rs56191952	chr20:43802487	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.41	-0.65	4.05e-13	Blood protein levels;
THYM	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg04025307	chr7:1156635	C7orf50	0.71	6.15	0.53	1.78e-8	Longevity;Endometriosis;
THYM	cis	rs863345	0.564	rs10908662	chr1:158489200	C/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs883115	0.743	rs1002130	chr1:224800929	C/T	cg01808320	chr1:224927238	CNIH3	-0.51	-4.47	-0.42	2.13e-5	Cancer;
THYM	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg05552183	chr6:42928497	GNMT	0.7	5.76	0.51	1.04e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg01483505	chr11:975446	AP2A2	0.57	4.53	0.42	1.73e-5	Alzheimer's disease (late onset);
THYM	cis	rs1788820	1.000	rs1788820	chr18:21101944	A/G	cg14672496	chr18:21087552	C18orf8	0.76	6.04	0.53	2.97e-8	Body mass index;
THYM	cis	rs6500395	1.000	rs9933329	chr16:48646572	T/C	cg04672837	chr16:48644449	N4BP1	0.5	4.83	0.44	5.27e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs907683	0.533	rs12469789	chr2:220293242	C/T	cg15015639	chr2:220282977	DES	0.39	5.13	0.47	1.53e-6	Resting heart rate;
THYM	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg06850241	chr22:41845214	NA	-0.54	-4.96	-0.45	3.02e-6	Vitiligo;
THYM	cis	rs919433	0.679	rs10497806	chr2:198508951	G/A	cg00792783	chr2:198669748	PLCL1	0.79	5.13	0.47	1.53e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg04101117	chr12:42719598	PPHLN1;ZCRB1	1.02	7.13	0.59	1.98e-10	Depressive symptoms;
THYM	cis	rs1018836	0.884	rs2073640	chr8:91594853	A/G	cg16814680	chr8:91681699	NA	-0.75	-6.3	-0.54	9.1e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	trans	rs4650994	0.967	rs4650998	chr1:178531850	G/A	cg05059571	chr16:84539110	KIAA1609	-0.76	-8.28	-0.65	7.7e-13	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg12893697	chr11:970389	AP2A2	-0.31	-5.15	-0.47	1.42e-6	Alzheimer's disease (late onset);
THYM	cis	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs9457247	0.602	rs2239827	chr6:167490945	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.52	-4.81	-0.44	5.71e-6	Crohn's disease;
THYM	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg05717871	chr11:638507	DRD4	-0.69	-6.03	-0.53	3.1e-8	Systemic lupus erythematosus;
THYM	cis	rs6988636	1.000	rs13260775	chr8:124190167	G/A	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg06238570	chr21:40685208	BRWD1	0.85	6.01	0.53	3.36e-8	Cognitive function;
THYM	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg12963246	chr6:28129442	ZNF389	0.57	5.06	0.46	2.09e-6	Cardiac Troponin-T levels;
THYM	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg03188948	chr7:1209495	NA	0.69	4.76	0.44	6.87e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7432375	0.966	rs6808312	chr3:136371504	C/T	cg12473912	chr3:136751656	NA	-0.62	-5.19	-0.47	1.18e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs273218	1.000	rs156437	chr5:53376454	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.93	7.97	0.63	3.55e-12	Migraine;
THYM	cis	rs2235649	0.789	rs9929803	chr16:1852748	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs7869969	0.509	rs13287066	chr9:96178967	G/A	cg13460858	chr9:96720652	NA	-0.55	-4.56	-0.42	1.51e-5	Childhood body mass index;
THYM	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg24531977	chr5:56204891	C5orf35	-0.93	-7.44	-0.61	4.48e-11	Initial pursuit acceleration;
THYM	cis	rs11089937	0.555	rs6001226	chr22:22541278	C/T	cg06866756	chr22:22471216	NA	-0.46	-5.09	-0.46	1.79e-6	Periodontitis (PAL4Q3);
THYM	cis	rs67072384	0.901	rs67868798	chr11:72480455	T/C	cg01380194	chr11:72452482	ARAP1	-0.88	-4.95	-0.45	3.25e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs7246657	0.943	rs7252325	chr19:37930645	A/G	cg22634378	chr19:37742834	NA	0.63	5.32	0.48	6.75e-7	Coronary artery calcification;
THYM	cis	rs34912216	0.625	rs36066771	chr7:4122701	A/T	cg03141780	chr7:4150753	SDK1	0.6	4.5	0.42	1.9e-5	Motion sickness;
THYM	cis	rs12310956	0.510	rs1825903	chr12:33870437	G/C	cg10856724	chr12:34555212	NA	-0.65	-5.89	-0.52	5.95e-8	Morning vs. evening chronotype;
THYM	cis	rs9527	0.545	rs7894588	chr10:104756030	A/T	cg15744005	chr10:104629667	AS3MT	-0.62	-4.73	-0.44	7.79e-6	Arsenic metabolism;
THYM	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg12000587	chr17:30186630	C17orf79	0.5	7.14	0.59	1.84e-10	Hip circumference adjusted for BMI;
THYM	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg12310025	chr6:25882481	NA	0.77	6.25	0.54	1.15e-8	Intelligence (multi-trait analysis);
THYM	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.65	-11.83	-0.77	2.19e-20	Hemostatic factors and hematological phenotypes;
THYM	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs500891	0.547	rs1144178	chr6:84029716	A/G	cg21688264	chr6:84418724	SNAP91	0.74	4.51	0.42	1.87e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs10799590	1.000	rs7537973	chr1:224831281	T/C	cg01808320	chr1:224927238	CNIH3	-0.56	-5.03	-0.46	2.35e-6	Opioid dependence;
THYM	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs12594515	1.000	rs7173144	chr15:45991196	A/G	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg10523679	chr1:76189770	ACADM	0.86	7.78	0.62	8.6e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg00677455	chr12:58241039	CTDSP2	-0.75	-5.59	-0.5	2.19e-7	Multiple sclerosis;
THYM	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg17105886	chr17:28927953	LRRC37B2	1.21	7.24	0.6	1.14e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.75	-5.5	-0.49	3.17e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg11502198	chr6:26597334	ABT1	-0.64	-5.74	-0.51	1.11e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2970992	0.680	rs11123841	chr2:101335813	T/C	cg01042948	chr2:101319752	NA	0.57	5.5	0.49	3.27e-7	Educational attainment;
THYM	trans	rs629535	0.734	rs542288	chr8:70057149	G/T	cg21567404	chr3:27674614	NA	-1.09	-10.26	-0.73	4.61e-17	Dupuytren's disease;
THYM	cis	rs2692947	0.683	rs62153700	chr2:96581338	C/T	cg23100626	chr2:96804247	ASTL	0.43	4.92	0.45	3.64e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs3126085	0.935	rs4845431	chr1:152227977	A/G	cg26020982	chr1:152196106	HRNR	0.37	5.12	0.47	1.58e-6	Atopic dermatitis;
THYM	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg21475434	chr5:93447410	FAM172A	0.85	5.31	0.48	7.28e-7	Diabetic retinopathy;
THYM	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg06636001	chr8:8085503	FLJ10661	-0.83	-7.06	-0.59	2.76e-10	Joint mobility (Beighton score);
THYM	cis	rs7567389	0.534	rs72845982	chr2:128098570	G/A	cg06038358	chr2:128176007	PROC	0.47	5.28	0.48	8.28e-7	Self-rated health;
THYM	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg27394845	chr17:28928406	LRRC37B2	0.91	4.58	0.42	1.44e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg02187348	chr16:89574699	SPG7	-0.73	-4.83	-0.44	5.18e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs3096299	0.933	rs2965939	chr16:89493043	G/A	cg06640241	chr16:89574553	SPG7	0.71	5.43	0.49	4.25e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg07606381	chr6:8435919	SLC35B3	0.61	4.45	0.42	2.31e-5	Motion sickness;
THYM	cis	rs76662990	0.610	rs10075142	chr5:73926984	G/A	cg13275603	chr5:73927487	ENC1	-0.78	-4.52	-0.42	1.81e-5	Residual cognition;
THYM	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg12011299	chr4:100065546	ADH4	0.85	8.06	0.64	2.26e-12	Alcohol dependence;
THYM	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg07424592	chr7:64974309	NA	1.08	5.61	0.5	2.01e-7	Diabetic kidney disease;
THYM	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-8.1	-0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg13609457	chr4:120235615	NA	0.54	5.0	0.46	2.63e-6	Corneal astigmatism;
THYM	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg02187348	chr16:89574699	SPG7	0.69	5.06	0.46	2.01e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs2354432	0.607	rs6689243	chr1:146710559	A/T	cg25205988	chr1:146714368	CHD1L	-1.1	-5.97	-0.52	4.17e-8	Mitochondrial DNA levels;
THYM	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg18305652	chr10:134549665	INPP5A	0.77	5.91	0.52	5.33e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7777677	0.925	rs6969951	chr7:142369586	A/G	cg21785750	chr7:142428317	NA	-0.69	-6.05	-0.53	2.82e-8	Alcoholic chronic pancreatitis;
THYM	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg02734326	chr4:10020555	SLC2A9	0.61	4.98	0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs34546498	1	rs34546498	chr6:26961280	C/T	cg16898833	chr6:26189333	HIST1H4D	1.3	4.47	0.42	2.14e-5	Breast cancer;
THYM	cis	rs4523957	0.859	rs9891227	chr17:2164311	G/A	cg16513277	chr17:2031491	SMG6	-0.79	-7.41	-0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9814567	0.896	rs6799110	chr3:134206749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.33	-0.65	5.98e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg12524338	chr4:183729343	NA	0.91	5.91	0.52	5.43e-8	Pediatric autoimmune diseases;
THYM	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg17480646	chr11:65405466	SIPA1	-0.97	-9.01	-0.68	2.21e-14	Acne (severe);
THYM	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.86	-5.62	-0.5	1.94e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs4631830	0.900	rs11006274	chr10:51540291	C/T	cg10326726	chr10:51549505	MSMB	0.6	5.96	0.52	4.28e-8	Prostate-specific antigen levels;
THYM	cis	rs11651000	0.625	rs58067360	chr17:45819587	G/C	cg24803719	chr17:45855879	NA	-0.56	-5.95	-0.52	4.46e-8	IgG glycosylation;
THYM	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg23422044	chr7:1970798	MAD1L1	-0.76	-4.93	-0.45	3.48e-6	Bipolar disorder;
THYM	cis	rs1371867	0.846	rs924057	chr8:101266157	A/G	cg00191853	chr8:101177733	SPAG1	0.5	4.86	0.45	4.57e-6	Atrioventricular conduction;
THYM	cis	rs985746	0.614	rs1866108	chr4:36817056	G/T	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs28595532	0.920	rs56162974	chr4:119742333	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg26384229	chr12:38710491	ALG10B	1.0	7.85	0.63	6.12e-12	Bladder cancer;
THYM	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg26384229	chr12:38710491	ALG10B	-0.74	-5.8	-0.51	8.85e-8	Bladder cancer;
THYM	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.72	0.67	8.99e-14	Colorectal cancer;
THYM	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg12310025	chr6:25882481	NA	0.67	5.38	0.48	5.31e-7	Height;
THYM	cis	rs10489202	1.000	rs17557135	chr1:167985888	A/G	cg24449463	chr1:168025552	DCAF6	-0.83	-6.51	-0.56	3.58e-9	Schizophrenia;
THYM	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg26418147	chr1:205743515	RAB7L1	-0.54	-4.74	-0.44	7.42e-6	Menarche (age at onset);
THYM	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.77	0.51	1.01e-7	Rheumatoid arthritis;
THYM	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.67	-0.5	1.54e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg12031863	chr16:4587854	C16orf5	-0.46	-4.96	-0.45	3.09e-6	Schizophrenia;
THYM	cis	rs7586879	0.616	rs6722587	chr2:25132192	C/A	cg01884057	chr2:25150051	NA	0.73	7.92	0.63	4.47e-12	Body mass index;
THYM	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg03929089	chr4:120376271	NA	1.01	8.37	0.65	4.88e-13	Coronary artery disease;
THYM	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg11245990	chr11:68621969	NA	0.57	7.2	0.59	1.41e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs977987	0.788	rs7184525	chr16:75437186	A/G	cg03315344	chr16:75512273	CHST6	0.77	6.31	0.54	8.75e-9	Dupuytren's disease;
THYM	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.6	-0.5	2.11e-7	Menopause (age at onset);
THYM	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg03806693	chr22:41940476	POLR3H	1.16	10.2	0.72	6.06e-17	Vitiligo;
THYM	cis	rs7614311	0.636	rs73117047	chr3:63910779	G/A	cg22134162	chr3:63841271	THOC7	-0.58	-6.84	-0.57	7.69e-10	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9612	1.000	rs12669	chr19:44235535	G/A	cg08581076	chr19:44259116	C19orf61	0.67	4.54	0.42	1.62e-5	Exhaled nitric oxide output;
THYM	cis	rs137603	0.644	rs137619	chr22:39706360	A/C	cg24268161	chr22:39747459	SYNGR1	0.65	5.49	0.49	3.4e-7	Primary biliary cholangitis;
THYM	cis	rs28595532	0.920	rs114547492	chr4:119773078	G/C	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs3087591	0.960	rs2905802	chr17:29520084	T/C	cg24425628	chr17:29625626	OMG;NF1	0.66	5.79	0.51	9.11e-8	Hip circumference;
THYM	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg12408189	chr10:30722286	MAP3K8	-0.66	-5.78	-0.51	9.39e-8	Inflammatory bowel disease;
THYM	cis	rs9549260	0.620	rs12583418	chr13:41195411	G/A	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs1642645	0.831	rs7541929	chr1:42479393	G/A	cg22816091	chr1:42611670	NA	0.62	5.52	0.49	2.99e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	trans	rs877282	1.000	rs877281	chr10:771557	T/G	cg22713356	chr15:30763199	NA	1.38	11.57	0.76	7.71e-20	Uric acid levels;
THYM	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg04654363	chr8:8581213	NA	-0.48	-4.62	-0.43	1.22e-5	Obesity-related traits;
THYM	cis	rs131777	0.577	rs131748	chr22:51024837	A/G	cg00083937	chr22:51039805	MAPK8IP2	-0.55	-5.19	-0.47	1.17e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg08704250	chr15:31115839	NA	-0.49	-6.14	-0.53	1.93e-8	Huntington's disease progression;
THYM	cis	rs6541297	1.000	rs6686054	chr1:230282853	C/T	cg20703242	chr1:230279135	GALNT2	0.92	5.97	0.52	4.17e-8	Coronary artery disease;
THYM	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg15744005	chr10:104629667	AS3MT	-0.86	-8.65	-0.66	1.26e-13	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs11779988	0.503	rs411173	chr8:17768264	G/A	cg01800426	chr8:17659068	MTUS1	-0.68	-4.89	-0.45	4.07e-6	Breast cancer;
THYM	trans	rs11175492	1.000	rs11175485	chr12:65032524	T/G	cg12514734	chr12:3216258	TSPAN9	1.59	7.44	0.61	4.38e-11	Platelet count;
THYM	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.53	-4.98	-0.45	2.85e-6	Lymphocyte counts;
THYM	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg00814883	chr7:100076585	TSC22D4	-0.99	-6.67	-0.56	1.67e-9	Platelet count;
THYM	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg11812906	chr14:75593930	NEK9	-0.83	-7.48	-0.61	3.63e-11	Height;
THYM	cis	rs10992471	0.528	rs3739606	chr9:95237222	G/T	cg14631576	chr9:95140430	CENPP	-0.84	-8.02	-0.64	2.69e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg11764359	chr7:65958608	NA	0.82	6.57	0.56	2.65e-9	Aortic root size;
THYM	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg21385522	chr1:16154831	NA	0.65	4.65	0.43	1.08e-5	Dilated cardiomyopathy;
THYM	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs4243830	0.850	rs1064835	chr1:6585539	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	1.11	7.81	0.63	7.67e-12	Body mass index;
THYM	cis	rs72781680	0.898	rs718139	chr2:23975911	G/A	cg08917208	chr2:24149416	ATAD2B	1.1	4.81	0.44	5.71e-6	Lymphocyte counts;
THYM	cis	rs7246967	0.673	rs3844578	chr19:22880610	G/C	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs919433	0.617	rs13018267	chr2:198545592	G/C	cg00792783	chr2:198669748	PLCL1	-0.82	-5.75	-0.51	1.1e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2404602	0.647	rs4886837	chr15:77156417	A/G	cg23625390	chr15:77176239	SCAPER	-0.82	-5.85	-0.51	6.95e-8	Blood metabolite levels;
THYM	cis	rs981844	0.712	rs10009854	chr4:154741785	C/T	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg06481639	chr22:41940642	POLR3H	-0.75	-5.22	-0.47	1.06e-6	Vitiligo;
THYM	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg18252515	chr7:66147081	NA	-1.62	-8.8	-0.67	5.99e-14	Diabetic kidney disease;
THYM	cis	rs10256972	0.552	rs6953538	chr7:1196974	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.63	-8.53	-0.66	2.26e-13	Longevity;Endometriosis;
THYM	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg03609598	chr5:56110824	MAP3K1	-0.89	-6.07	-0.53	2.63e-8	Initial pursuit acceleration;
THYM	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg18032289	chr17:61959525	GH2	-0.5	-4.84	-0.44	5.07e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs863345	0.604	rs11265009	chr1:158498772	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-5.01	-0.46	2.55e-6	Pneumococcal bacteremia;
THYM	cis	rs1559088	0.895	rs1974784	chr19:33551563	T/G	cg03563238	chr19:33554763	RHPN2	-0.5	-4.48	-0.42	2.04e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg20887711	chr4:1340912	KIAA1530	-0.7	-5.99	-0.52	3.75e-8	Obesity-related traits;
THYM	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg27286337	chr10:134555280	INPP5A	0.94	6.97	0.58	4.24e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs12365397	0.526	rs11607331	chr11:43157244	T/C	cg03447554	chr11:43094025	NA	0.63	5.06	0.46	2.05e-6	Migraine;
THYM	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.71	6.87	0.58	6.73e-10	Lymphocyte counts;
THYM	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg10856724	chr12:34555212	NA	-1.01	-9.32	-0.69	4.76e-15	Bladder cancer;
THYM	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg14972814	chr11:95582409	MTMR2	-0.71	-6.61	-0.56	2.19e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg01097406	chr16:89675127	NA	-0.62	-5.04	-0.46	2.23e-6	Vitiligo;
THYM	cis	rs17122693	0.748	rs61607560	chr14:51143649	C/T	cg04730355	chr14:51134070	SAV1	0.94	5.85	0.51	7.11e-8	Cognitive performance;
THYM	cis	rs34366173	1	rs34366173	chr15:63998914	CTT/C	cg12036633	chr15:63758958	NA	-0.61	-4.59	-0.43	1.33e-5	Reticulocyte fraction of red cells;
THYM	cis	rs9527	0.590	rs1807298	chr10:104870218	G/A	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs2067615	0.579	rs4964486	chr12:107140790	A/G	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs1003719	0.762	rs34273703	chr21:38475019	A/G	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs763014	0.931	rs56048717	chr16:634867	A/G	cg07343612	chr16:622815	PIGQ	-1.08	-11.34	-0.76	2.36e-19	Height;
THYM	cis	rs6500395	1.000	rs904819	chr16:48622583	C/A	cg04672837	chr16:48644449	N4BP1	0.51	4.98	0.45	2.85e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg23711669	chr6:146136114	FBXO30	-0.97	-10.54	-0.73	1.14e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg23587288	chr2:27483067	SLC30A3	-0.57	-4.54	-0.42	1.66e-5	Blood metabolite levels;
THYM	cis	rs68170813	0.559	rs5002976	chr7:107050620	C/G	cg00661777	chr7:106511741	PIK3CG	-0.67	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs986417	0.818	rs10143831	chr14:61081961	G/T	cg27398547	chr14:60952738	C14orf39	1.04	5.74	0.51	1.14e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs6842047	1.000	rs9995366	chr4:187131384	T/C	cg09526685	chr4:187126073	CYP4V2	1.05	5.31	0.48	7.3e-7	Blood protein levels;
THYM	cis	rs7580658	0.637	rs4580338	chr2:127974937	T/C	cg10021288	chr2:128175891	PROC	-0.62	-5.55	-0.49	2.57e-7	Protein C levels;
THYM	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg02734326	chr4:10020555	SLC2A9	0.76	6.89	0.58	6.16e-10	Bone mineral density;
THYM	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg01097406	chr16:89675127	NA	0.87	7.73	0.62	1.13e-11	Vitiligo;
THYM	cis	rs7072216	0.763	rs2147901	chr10:100165496	A/C	cg03852570	chr10:100175106	PYROXD2	-0.36	-4.77	-0.44	6.61e-6	Metabolite levels;
THYM	cis	rs9314614	0.872	rs2951861	chr8:6711693	G/C	cg27319216	chr8:6693540	XKR5	-0.64	-6.92	-0.58	5.3e-10	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg16624210	chr5:671434	TPPP	0.59	5.99	0.52	3.77e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg20503657	chr10:835505	NA	1.15	8.11	0.64	1.78e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs17641971	0.684	rs12545097	chr8:49951977	A/G	cg00325661	chr8:49890786	NA	0.65	4.79	0.44	6.09e-6	Blood metabolite levels;
THYM	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2710642	0.564	rs6545963	chr2:62822891	C/T	cg17519650	chr2:63277830	OTX1	-0.62	-4.54	-0.42	1.67e-5	LDL cholesterol levels;LDL cholesterol;
THYM	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg02725872	chr8:58115012	NA	-1.14	-7.59	-0.61	2.17e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs17331151	0.573	rs11626	chr3:52873984	C/T	cg07884673	chr3:53033167	SFMBT1	0.79	5.03	0.46	2.35e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2637266	0.714	rs7895605	chr10:78454207	G/A	cg18941641	chr10:78392320	NA	0.73	5.86	0.52	6.64e-8	Pulmonary function;
THYM	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg27535305	chr1:53392650	SCP2	0.42	4.82	0.44	5.53e-6	Monocyte count;
THYM	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.91	-7.97	-0.63	3.5e-12	Menarche (age at onset);
THYM	cis	rs526231	0.511	rs45518833	chr5:102342990	T/C	cg23492399	chr5:102201601	PAM	-0.68	-5.21	-0.47	1.12e-6	Primary biliary cholangitis;
THYM	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg23750338	chr8:142222470	SLC45A4	0.52	4.87	0.45	4.48e-6	Immature fraction of reticulocytes;
THYM	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg13319975	chr6:146136371	FBXO30	0.7	5.79	0.51	9.05e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg00376283	chr12:123451042	ABCB9	0.8	6.41	0.55	5.49e-9	Platelet count;
THYM	cis	rs17407555	0.909	rs60318661	chr4:10245247	C/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-4.9	-0.45	4e-6	Schizophrenia (age at onset);
THYM	cis	rs17443541	0.507	rs4675716	chr2:200463370	A/C	cg03741458	chr2:200468445	NA	0.8	6.04	0.53	3.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg26038318	chr20:34205095	SPAG4	0.6	4.7	0.43	8.69e-6	Total cholesterol levels;
THYM	cis	rs9326248	0.861	rs4938348	chr11:117021877	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.72	4.62	0.43	1.2e-5	Blood protein levels;
THYM	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg05660106	chr1:15850417	CASP9	0.76	6.27	0.54	1.06e-8	Systolic blood pressure;
THYM	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg12463550	chr7:65579703	CRCP	0.59	4.77	0.44	6.58e-6	Aortic root size;
THYM	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg26314531	chr2:26401878	FAM59B	-0.76	-5.02	-0.46	2.37e-6	Gut microbiome composition (summer);
THYM	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.45	-5.18	-0.47	1.25e-6	Schizophrenia;
THYM	cis	rs7084921	0.526	rs11595928	chr10:101888640	C/T	cg11344164	chr10:101878520	NA	-0.55	-5.18	-0.47	1.25e-6	Bone mineral density;
THYM	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	8.03	0.64	2.55e-12	Monocyte percentage of white cells;
THYM	cis	rs986417	0.901	rs1010052	chr14:61003071	G/A	cg27398547	chr14:60952738	C14orf39	1.07	6.35	0.55	7.27e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs673253	0.556	rs35393217	chr1:44101648	G/A	cg24466421	chr1:44070974	PTPRF	-0.59	-5.09	-0.46	1.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs752010	0.523	rs10890159	chr1:42118282	A/G	cg06885757	chr1:42089581	HIVEP3	0.6	7.12	0.59	2.09e-10	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg10518543	chr12:38710700	ALG10B	-0.57	-4.59	-0.43	1.36e-5	Morning vs. evening chronotype;
THYM	cis	rs921968	0.541	rs588770	chr2:219494638	T/C	cg02176678	chr2:219576539	TTLL4	0.71	7.08	0.59	2.47e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1971762	0.563	rs10219725	chr12:54080865	T/G	cg16917193	chr12:54089295	NA	0.91	9.3	0.69	5.24e-15	Height;
THYM	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg27170947	chr2:26402098	FAM59B	-0.78	-6.09	-0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs4474465	0.920	rs4474466	chr11:78204406	C/T	cg19901956	chr11:77921274	USP35	0.67	4.92	0.45	3.68e-6	Alzheimer's disease (survival time);
THYM	cis	rs4919694	1.000	rs35159404	chr10:104805610	C/A	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg11764359	chr7:65958608	NA	-0.78	-6.57	-0.56	2.63e-9	Aortic root size;
THYM	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg07511668	chr11:68622177	NA	0.44	4.63	0.43	1.16e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7851660	0.809	rs7032086	chr9:100656402	T/G	cg13688889	chr9:100608707	NA	-0.7	-4.78	-0.44	6.3e-6	Strep throat;
THYM	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg25072359	chr17:41440525	NA	0.64	4.48	0.42	2.05e-5	Menopause (age at onset);
THYM	cis	rs7107174	0.786	rs4945266	chr11:78027488	A/G	cg02023728	chr11:77925099	USP35	0.65	5.83	0.51	7.52e-8	Testicular germ cell tumor;
THYM	cis	rs1775715	0.678	rs2105360	chr10:32210198	C/T	cg04359828	chr10:32216031	ARHGAP12	0.41	5.12	0.46	1.62e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs72772090	0.539	rs11739020	chr5:96113838	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.76	4.79	0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg21138405	chr5:131827807	IRF1	0.87	9.54	0.7	1.59e-15	Asthma (sex interaction);
THYM	trans	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg06636001	chr8:8085503	FLJ10661	0.73	7.12	0.59	2.09e-10	Monocyte count;
THYM	cis	rs6924995	0.501	rs9349998	chr6:16196985	T/A	cg11805552	chr6:16175128	NA	0.57	4.85	0.45	4.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg11764359	chr7:65958608	NA	0.87	7.44	0.61	4.44e-11	Aortic root size;
THYM	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg22535103	chr8:58192502	C8orf71	-0.91	-5.93	-0.52	4.88e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg21427119	chr20:30132790	HM13	-0.96	-7.02	-0.58	3.34e-10	Mean corpuscular hemoglobin;
THYM	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	7.8	0.62	7.81e-12	Platelet count;
THYM	cis	rs62435770	1.000	rs62435772	chr6:169472319	G/A	cg07652237	chr6:170125491	PHF10	0.57	4.91	0.45	3.72e-6	Loneliness;
THYM	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg11530693	chr1:120165357	ZNF697	-1.01	-11.02	-0.75	1.1e-18	Systemic lupus erythematosus;
THYM	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg18252515	chr7:66147081	NA	-1.62	-8.8	-0.67	5.99e-14	Diabetic kidney disease;
THYM	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35883536	0.669	rs1932352	chr1:101161251	G/A	cg06223162	chr1:101003688	GPR88	-0.76	-6.32	-0.54	8.51e-9	Monocyte count;
THYM	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg24154853	chr7:158122151	PTPRN2	0.55	4.82	0.44	5.35e-6	Calcium levels;
THYM	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg11752832	chr7:134001865	SLC35B4	0.77	5.52	0.49	2.95e-7	Mean platelet volume;
THYM	cis	rs4919044	0.866	rs1475366	chr10:94781857	T/C	cg05127821	chr10:94822908	CYP26C1	-1.3	-6.79	-0.57	9.52e-10	Coronary artery disease;
THYM	cis	rs7616559	0.924	rs6779199	chr3:156736901	C/T	cg15697575	chr3:156784781	NA	0.4	5.03	0.46	2.35e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs6047844	0.593	rs12479604	chr20:22091220	A/C	cg16502866	chr20:23015624	SSTR4	-0.59	-4.82	-0.44	5.47e-6	Male-pattern baldness;
THYM	cis	rs6430585	0.528	rs6711493	chr2:136692553	A/G	cg04750100	chr2:136595281	LCT	0.55	5.71	0.51	1.26e-7	Corneal structure;
THYM	cis	rs2797160	1.000	rs1777222	chr6:126021030	C/T	cg16306078	chr6:126000798	NA	0.54	5.57	0.5	2.38e-7	Endometrial cancer;
THYM	cis	rs28595532	0.841	rs114768988	chr4:119744451	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs9913156	0.748	rs55981776	chr17:4561401	T/C	cg19197139	chr17:4613644	ARRB2	0.78	4.92	0.45	3.63e-6	Lymphocyte counts;
THYM	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg08772003	chr10:104629869	AS3MT	-0.59	-5.32	-0.48	6.94e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs6918586	0.636	rs198816	chr6:26127184	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.65	-0.62	1.6e-11	Schizophrenia;
THYM	cis	rs7336332	0.598	rs77055070	chr13:28010516	C/G	cg22138327	chr13:27999177	GTF3A	0.62	4.62	0.43	1.21e-5	Weight;
THYM	cis	rs7084402	0.967	rs1427222	chr10:60290970	A/G	cg07615347	chr10:60278583	BICC1	0.56	5.04	0.46	2.19e-6	Refractive error;
THYM	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs735539	0.521	rs2585906	chr13:21407492	C/G	cg02792322	chr13:21280448	IL17D	-0.66	-4.78	-0.44	6.37e-6	Dental caries;
THYM	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg12751644	chr20:60527061	NA	0.68	4.83	0.44	5.17e-6	Obesity-related traits;
THYM	cis	rs12534701	0.534	rs13235571	chr7:154686531	G/C	cg24255201	chr7:154684926	DPP6	0.72	5.84	0.51	7.38e-8	Colorectal cancer (diet interaction);
THYM	cis	rs35264875	1.000	rs72928652	chr11:68851547	G/A	cg01993067	chr11:68851601	TPCN2	1.0	5.3	0.48	7.4e-7	Blond vs. brown hair color;
THYM	trans	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg25517755	chr10:38738941	LOC399744	-0.8	-7.87	-0.63	5.58e-12	Corneal astigmatism;
THYM	cis	rs9303280	0.618	rs4065986	chr17:38102641	G/A	cg24910161	chr17:38119198	GSDMA	-0.55	-6.61	-0.56	2.27e-9	Self-reported allergy;
THYM	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg06634786	chr22:41940651	POLR3H	0.66	5.15	0.47	1.39e-6	Vitiligo;
THYM	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg00383909	chr3:49044727	WDR6	1.05	5.99	0.52	3.79e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs35934224	0.783	rs6518585	chr22:19849501	C/T	cg11182965	chr22:19864308	TXNRD2	-0.68	-5.74	-0.51	1.11e-7	Glaucoma (primary open-angle);
THYM	cis	rs28595532	0.920	rs116246794	chr4:119732491	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg00383909	chr3:49044727	WDR6	1.05	5.98	0.52	3.82e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg14416269	chr4:6271139	WFS1	0.48	4.65	0.43	1.09e-5	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	trans	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.97	-8.77	-0.67	7.04e-14	Brugada syndrome;
THYM	cis	rs13177918	0.686	rs12654827	chr5:149822090	T/C	cg14059543	chr5:149831962	NA	-0.97	-7.25	-0.6	1.09e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs516946	1.000	rs6989203	chr8:41523745	A/G	cg19441908	chr8:41529140	ANK1	-0.61	-4.84	-0.45	4.94e-6	Type 2 diabetes;
THYM	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg13531842	chr10:38383804	ZNF37A	-0.54	-4.53	-0.42	1.73e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	4.49	0.42	1.98e-5	Bipolar disorder;
THYM	cis	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg12000587	chr17:30186630	C17orf79	0.5	7.14	0.59	1.84e-10	Hip circumference adjusted for BMI;
THYM	cis	rs28647808	0.881	rs7027651	chr9:136232437	G/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.11	-4.86	-0.45	4.64e-6	Blood protein levels;
THYM	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg08847533	chr14:75593920	NEK9	-0.98	-10.57	-0.74	1.01e-17	Height;
THYM	cis	rs2738048	0.545	rs2978950	chr8:6825284	C/G	cg24860332	chr8:6827800	DEFA10P	-0.67	-5.29	-0.48	7.97e-7	IgA nephropathy;
THYM	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg08847533	chr14:75593920	NEK9	0.97	10.6	0.74	8.61e-18	Height;
THYM	cis	rs346785	0.692	rs2279056	chr17:74309474	C/T	cg04798684	chr17:74309056	PRPSAP1	0.52	4.6	0.43	1.29e-5	White matter hyperintensities in ischemic stroke;
THYM	cis	rs13424612	0.801	rs4076744	chr2:240902988	G/C	cg01812947	chr2:240904978	NDUFA10	0.55	4.46	0.42	2.28e-5	Odorant perception (isobutyraldehyde);
THYM	cis	rs425277	0.583	rs3128334	chr1:2038662	G/A	cg24578937	chr1:2090814	PRKCZ	-0.6	-6.18	-0.54	1.62e-8	Height;
THYM	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg13683864	chr3:40499215	RPL14	-1.02	-11.08	-0.75	8.4e-19	Renal cell carcinoma;
THYM	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg26384229	chr12:38710491	ALG10B	-0.91	-7.58	-0.61	2.33e-11	Morning vs. evening chronotype;
THYM	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.36	5.11	0.46	1.64e-6	Obesity-related traits;
THYM	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.36	5.11	0.46	1.64e-6	Obesity-related traits;
THYM	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg06481639	chr22:41940642	POLR3H	-0.74	-4.85	-0.45	4.81e-6	Vitiligo;
THYM	cis	rs11214589	0.747	rs10502172	chr11:113199146	C/T	cg14159747	chr11:113255604	NA	0.3	5.73	0.51	1.18e-7	Neuroticism;
THYM	cis	rs2456568	0.867	rs72962810	chr11:93663619	A/G	cg26875233	chr11:93583750	C11orf90	-0.49	-4.84	-0.44	5.09e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg27394845	chr17:28928406	LRRC37B2	0.91	4.58	0.42	1.44e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs55665837	0.961	rs11023237	chr11:14500334	G/A	cg19336497	chr11:14380999	RRAS2	-0.64	-7.04	-0.59	3e-10	Vitamin D levels;
THYM	cis	rs865483	0.861	rs56186148	chr17:35768827	T/A	cg06716730	chr17:35851459	DUSP14	-0.44	-7.64	-0.62	1.73e-11	Monocyte count;
THYM	cis	rs2219968	0.525	rs1872769	chr8:78876745	A/G	cg00738934	chr8:78996279	NA	0.61	4.93	0.45	3.5e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2730245	0.527	rs62476462	chr7:158686619	A/G	cg24397884	chr7:158709396	WDR60	0.55	5.36	0.48	5.79e-7	Height;
THYM	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg09904177	chr6:26538194	HMGN4	0.53	4.5	0.42	1.95e-5	Intelligence (multi-trait analysis);
THYM	cis	rs34638657	0.827	rs3829548	chr16:82206238	C/A	cg09439754	chr16:82129088	HSD17B2	-0.5	-5.34	-0.48	6.31e-7	Lung adenocarcinoma;
THYM	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg10589385	chr1:150898437	SETDB1	0.68	5.74	0.51	1.12e-7	Blood protein levels;
THYM	cis	rs4891159	0.790	rs72975925	chr18:74143902	G/A	cg24786174	chr18:74118243	ZNF516	-0.87	-9.77	-0.71	5.02e-16	Longevity;
THYM	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg19847130	chr8:10466454	RP1L1	0.49	4.46	0.42	2.26e-5	Neuroticism;
THYM	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg11663144	chr21:46675770	NA	-0.67	-9.04	-0.68	1.84e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg17178900	chr1:205818956	PM20D1	0.92	9.11	0.68	1.3e-14	Menarche (age at onset);
THYM	cis	rs6500395	1.000	rs9936454	chr16:48617782	T/G	cg04672837	chr16:48644449	N4BP1	0.51	4.98	0.45	2.85e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.1	-0.53	2.29e-8	Crohn's disease;
THYM	cis	rs1062753	0.922	rs9611712	chr22:42410993	T/C	cg08431931	chr22:42394659	WBP2NL	0.74	6.08	0.53	2.48e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg08859206	chr1:53392774	SCP2	0.6	6.92	0.58	5.22e-10	Monocyte count;
THYM	cis	rs1885364	0.574	rs134086	chr22:28067235	A/G	cg17187762	chr22:28070120	NA	-0.44	-5.15	-0.47	1.42e-6	Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion);
THYM	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.68	5.24	0.47	9.75e-7	Tonsillectomy;
THYM	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg02527881	chr3:46936655	PTH1R	0.61	5.74	0.51	1.15e-7	Colorectal cancer;
THYM	cis	rs12950390	1.000	rs12950390	chr17:45830948	A/G	cg03474202	chr17:45855739	NA	-0.66	-4.83	-0.44	5.24e-6	IgG glycosylation;
THYM	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg10515332	chr4:99064459	C4orf37	0.66	5.17	0.47	1.29e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg22681709	chr2:178499509	PDE11A	-0.49	-4.51	-0.42	1.87e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2734839	0.537	rs1554929	chr11:113278764	C/T	cg14159747	chr11:113255604	NA	0.35	7.81	0.63	7.61e-12	Information processing speed;
THYM	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg10560079	chr2:191398806	TMEM194B	-0.86	-7.77	-0.62	8.96e-12	Pulse pressure;
THYM	cis	rs526231	0.543	rs27361	chr5:102548967	G/A	cg23492399	chr5:102201601	PAM	-0.71	-5.32	-0.48	6.82e-7	Primary biliary cholangitis;
THYM	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs12042938	0.507	rs1655299	chr1:231732161	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-5.49	-0.49	3.32e-7	Neuranatomic and neurocognitive phenotypes;
THYM	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg00684032	chr4:1343700	KIAA1530	0.67	5.58	0.5	2.22e-7	Obesity-related traits;
THYM	cis	rs7824557	0.578	rs2060458	chr8:11212811	C/A	cg21775007	chr8:11205619	TDH	0.65	5.64	0.5	1.72e-7	Retinal vascular caliber;
THYM	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.65	4.7	0.43	8.75e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg13736514	chr6:26305472	NA	-0.61	-7.55	-0.61	2.66e-11	Educational attainment;
THYM	cis	rs6542838	0.673	rs13005148	chr2:99467538	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-4.46	-0.42	2.24e-5	Fear of minor pain;
THYM	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg22166914	chr1:53195759	ZYG11B	0.8	8.04	0.64	2.5e-12	Monocyte count;
THYM	cis	rs3540	0.512	rs3930162	chr15:91075129	C/T	cg22089800	chr15:90895588	ZNF774	-0.67	-5.02	-0.46	2.42e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19346786	chr7:2764209	NA	-0.78	-6.95	-0.58	4.62e-10	Height;
THYM	cis	rs7843479	0.582	rs11135743	chr8:21803008	A/G	cg17168535	chr8:21777572	XPO7	0.91	8.33	0.65	6.18e-13	Mean corpuscular volume;
THYM	cis	rs11574514	1.000	rs10775302	chr16:67792439	C/T	cg04582263	chr16:67973788	LCAT	1.08	5.08	0.46	1.85e-6	Crohn's disease;
THYM	cis	rs11031096	0.711	rs61899755	chr11:4201317	G/T	cg08557956	chr11:4115526	RRM1	-0.57	-5.17	-0.47	1.27e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg12564285	chr5:131593104	PDLIM4	0.43	4.76	0.44	6.88e-6	Acylcarnitine levels;
THYM	cis	rs912057	0.601	rs1294413	chr6:6739924	C/A	cg06612196	chr6:6737390	NA	0.77	14.62	0.83	4.77e-26	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs12073837	0.784	rs35730037	chr1:220988745	C/G	cg16008148	chr1:221062819	NA	0.41	4.45	0.42	2.32e-5	F-cell distribution;
THYM	cis	rs12540874	0.542	rs4947581	chr7:50565967	G/A	cg18232548	chr7:50535776	DDC	-0.88	-8.38	-0.65	4.66e-13	Systemic sclerosis;
THYM	cis	rs2274459	1.000	rs729376	chr6:33704823	C/T	cg06253072	chr6:33679850	C6orf125	0.51	5.24	0.47	9.77e-7	Obesity (extreme);
THYM	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg08885076	chr2:99613938	TSGA10	-0.66	-6.08	-0.53	2.47e-8	Chronic sinus infection;
THYM	cis	rs611744	0.846	rs405534	chr8:109154408	T/A	cg21045802	chr8:109455806	TTC35	0.57	4.9	0.45	3.99e-6	Dupuytren's disease;
THYM	cis	rs72627123	0.867	rs17094448	chr14:74440119	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.14	6.41	0.55	5.69e-9	Morning vs. evening chronotype;
THYM	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg04944784	chr2:26401820	FAM59B	-1.08	-8.57	-0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	4.75	0.44	7.13e-6	Prudent dietary pattern;
THYM	cis	rs7124681	0.565	rs2203712	chr11:47534964	T/C	cg18512352	chr11:47633146	NA	0.41	4.67	0.43	1.01e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg23758822	chr17:41437982	NA	1.2	11.08	0.75	8.27e-19	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.65	4.58	0.43	1.43e-5	Renal function-related traits (BUN);
THYM	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg05738196	chr6:26577821	NA	0.95	9.38	0.69	3.53e-15	Intelligence (multi-trait analysis);
THYM	cis	rs17125944	0.615	rs17125798	chr14:53319905	G/A	cg00686598	chr14:53173677	PSMC6	1.06	4.78	0.44	6.42e-6	Alzheimer's disease (late onset);
THYM	cis	rs34779708	0.931	rs4934535	chr10:35432721	G/T	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs12410462	0.892	rs75757169	chr1:227629855	A/G	cg04117972	chr1:227635322	NA	0.71	4.8	0.44	5.85e-6	Major depressive disorder;
THYM	cis	rs6450176	1.000	rs67430852	chr5:53290586	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-6.61	-0.56	2.22e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs2046867	0.818	rs62249862	chr3:72867949	G/C	cg25664220	chr3:72788482	NA	-0.95	-7.97	-0.63	3.52e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs8067545	0.611	rs2703777	chr17:20138891	C/T	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg00898013	chr13:113819073	PROZ	-0.88	-9.0	-0.68	2.24e-14	Platelet distribution width;
THYM	cis	rs941408	0.515	rs759066	chr19:2775337	G/T	cg23035555	chr19:3500370	DOHH	-0.82	-4.53	-0.42	1.74e-5	Total cholesterol levels;
THYM	cis	rs208520	0.837	rs208471	chr6:66916749	A/C	cg07460842	chr6:66804631	NA	-0.86	-5.5	-0.49	3.15e-7	Exhaled nitric oxide output;
THYM	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11645898	0.515	rs61747473	chr16:72258743	C/T	cg03805757	chr16:71968109	PKD1L3	-0.63	-4.48	-0.42	2.11e-5	Blood protein levels;
THYM	cis	rs4148689	1.000	rs4148686	chr7:117134517	C/G	cg17204129	chr7:117119601	CFTR	-0.57	-4.57	-0.42	1.44e-5	Gout;
THYM	cis	rs919433	1.000	rs1346649	chr2:198166117	C/A	cg00792783	chr2:198669748	PLCL1	-0.66	-4.7	-0.43	8.63e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6430585	0.528	rs309142	chr2:136715324	T/C	cg07169764	chr2:136633963	MCM6	1.04	11.64	0.77	5.41e-20	Corneal structure;
THYM	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg18825531	chr11:62321136	NA	-0.42	-4.66	-0.43	1.05e-5	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs10045504	0.593	rs10941405	chr5:38756188	A/G	cg07423205	chr5:37834672	GDNF	0.45	4.81	0.44	5.68e-6	Night sleep phenotypes;
THYM	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg23803603	chr1:2058230	PRKCZ	0.64	5.53	0.49	2.77e-7	Height;
THYM	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg20387954	chr3:183756860	HTR3D	0.57	5.41	0.49	4.74e-7	Anterior chamber depth;
THYM	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg06623918	chr6:96969491	KIAA0776	1.09	9.94	0.71	2.21e-16	Headache;
THYM	cis	rs6812193	0.518	rs17236661	chr4:77196476	A/C	cg20311846	chr4:77356250	SHROOM3	0.52	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs3924048	0.547	rs72642661	chr1:12612873	C/G	cg00291366	chr1:12616550	NA	0.41	6.37	0.55	6.58e-9	Optic cup area;
THYM	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg07936489	chr17:37558343	FBXL20	-0.67	-4.9	-0.45	3.86e-6	Asthma;
THYM	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	cis	rs3820068	0.603	rs1980607	chr1:15975237	A/G	cg24675056	chr1:15929824	NA	0.72	5.73	0.51	1.17e-7	Systolic blood pressure;
THYM	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg09436375	chr6:42928200	GNMT	-0.43	-5.9	-0.52	5.67e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg23281280	chr6:28129359	ZNF389	0.65	5.18	0.47	1.26e-6	Depression;
THYM	cis	rs12681287	0.752	rs6985427	chr8:87302745	C/T	cg27223183	chr8:87520930	FAM82B	-0.65	-5.02	-0.46	2.43e-6	Caudate activity during reward;
THYM	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.15	9.02	0.68	2.02e-14	Cognitive test performance;
THYM	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg17366294	chr4:99064904	C4orf37	0.57	6.96	0.58	4.44e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9880211	0.613	rs10222451	chr3:135877413	G/C	cg21827317	chr3:136751795	NA	-0.71	-5.16	-0.47	1.33e-6	Body mass index;Height;
THYM	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg08498830	chr11:832797	CD151	-0.62	-4.51	-0.42	1.82e-5	Mean platelet volume;
THYM	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg08048268	chr3:133502702	NA	-0.66	-5.71	-0.51	1.27e-7	Iron status biomarkers;
THYM	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg07414643	chr4:187882934	NA	0.57	4.94	0.45	3.31e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7200543	1.000	rs1136001	chr16:15131974	G/T	cg01933576	chr16:15083564	PDXDC1	-0.99	-8.04	-0.64	2.48e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs728616	0.717	rs12412999	chr10:82008141	C/T	cg05935833	chr10:81318306	SFTPA2	-0.77	-4.72	-0.44	7.98e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg27446573	chr6:127587934	RNF146	0.7	6.13	0.53	1.99e-8	Breast cancer;
THYM	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg22875332	chr1:76189707	ACADM	-0.54	-5.07	-0.46	1.96e-6	Daytime sleep phenotypes;
THYM	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg05660106	chr1:15850417	CASP9	0.75	6.05	0.53	2.87e-8	Systolic blood pressure;
THYM	cis	rs526231	0.543	rs8488	chr5:102538752	T/C	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Primary biliary cholangitis;
THYM	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.686	rs1004752	chr6:146037822	G/A	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg10560079	chr2:191398806	TMEM194B	0.9	8.12	0.64	1.68e-12	Pulse pressure;
THYM	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg03433033	chr1:76189801	ACADM	0.79	11.19	0.75	4.89e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg05890377	chr2:74357713	NA	1.09	10.23	0.72	5.23e-17	Gestational age at birth (maternal effect);
THYM	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg23711669	chr6:146136114	FBXO30	0.91	9.57	0.7	1.4e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1775715	0.769	rs2799030	chr10:32172935	G/T	cg04359828	chr10:32216031	ARHGAP12	0.41	5.09	0.46	1.78e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg10589385	chr1:150898437	SETDB1	0.62	5.26	0.47	8.86e-7	Tonsillectomy;
THYM	cis	rs1847202	0.859	rs4490296	chr3:72949197	C/A	cg25664220	chr3:72788482	NA	-0.64	-4.8	-0.44	6e-6	Motion sickness;
THYM	cis	rs321358	0.731	rs536579	chr11:111016472	T/C	cg19541147	chr11:111957761	TIMM8B;SDHD	-0.68	-4.51	-0.42	1.86e-5	Body mass index;
THYM	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg24209194	chr3:40518798	ZNF619	0.68	5.75	0.51	1.09e-7	Renal cell carcinoma;
THYM	cis	rs4343996	0.558	rs10281401	chr7:3416173	T/C	cg21248987	chr7:3385318	SDK1	0.4	4.91	0.45	3.72e-6	Motion sickness;
THYM	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg23332699	chr15:44069569	ELL3	0.78	4.64	0.43	1.12e-5	Lung cancer in ever smokers;
THYM	cis	rs4819852	0.958	rs2238784	chr22:19972559	G/A	cg07821417	chr22:19972146	ARVCF	0.49	5.82	0.51	7.96e-8	Pulse pressure;
THYM	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03517284	chr6:25882590	NA	0.84	6.72	0.57	1.37e-9	Intelligence (multi-trait analysis);
THYM	cis	rs11690935	0.550	rs6718013	chr2:172869185	A/G	cg13550731	chr2:172543902	DYNC1I2	0.56	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg18825531	chr11:62321136	NA	-0.47	-5.29	-0.48	7.97e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg16928487	chr17:17741425	SREBF1	-0.56	-5.63	-0.5	1.78e-7	Total body bone mineral density;
THYM	cis	rs11039798	1.000	rs3902927	chr11:48581457	C/T	cg24672777	chr11:48374446	OR4C45	-1.14	-6.95	-0.58	4.55e-10	Axial length;
THYM	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg21775007	chr8:11205619	TDH	-0.7	-5.38	-0.48	5.38e-7	Retinal vascular caliber;
THYM	cis	rs3804749	0.966	rs3792376	chr3:122844951	T/G	cg26084141	chr3:122786895	PDIA5	0.44	4.52	0.42	1.81e-5	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs4430311	0.723	rs10158245	chr1:243833397	A/C	cg25706552	chr1:244017396	NA	-0.53	-4.45	-0.42	2.3e-5	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg24399712	chr22:39784796	NA	-0.87	-9.65	-0.7	9.24e-16	Intelligence (multi-trait analysis);
THYM	cis	rs2933343	0.533	rs11915889	chr3:128700866	A/C	cg11901034	chr3:128598214	ACAD9	-0.69	-4.89	-0.45	4.03e-6	IgG glycosylation;
THYM	cis	rs7666738	0.657	rs13102002	chr4:98617794	T/C	cg24818145	chr4:99064322	C4orf37	0.83	4.88	0.45	4.33e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg04673462	chr1:38461896	NA	0.46	5.74	0.51	1.11e-7	Coronary artery disease;
THYM	cis	rs1034435	0.723	rs713946	chr22:48891376	T/C	cg05992904	chr22:48892994	FAM19A5	-0.82	-8.99	-0.68	2.33e-14	Late-onset Alzheimer's disease;
THYM	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg10518543	chr12:38710700	ALG10B	-0.59	-4.97	-0.45	3.01e-6	Morning vs. evening chronotype;
THYM	cis	rs4343996	0.558	rs7798141	chr7:3413024	A/G	cg21248987	chr7:3385318	SDK1	0.4	4.94	0.45	3.32e-6	Motion sickness;
THYM	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.99	0.58	3.74e-10	Prudent dietary pattern;
THYM	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2046867	0.908	rs6779684	chr3:72787586	G/A	cg25664220	chr3:72788482	NA	-0.83	-6.23	-0.54	1.27e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg13918804	chr1:2043761	PRKCZ	0.84	7.49	0.61	3.51e-11	Height;
THYM	trans	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-5.34	-0.48	6.3e-7	Lymphocyte counts;
THYM	cis	rs470093	0.932	rs138053	chr22:44219108	A/G	cg09142166	chr22:44276013	PNPLA5	-0.57	-5.62	-0.5	1.92e-7	Staphylococcus aureus infection;
THYM	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.29	8.36	0.65	5.15e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7169223	0.653	rs12905740	chr15:79082364	C/T	cg21242079	chr15:79101063	ADAMTS7	-0.53	-4.73	-0.44	7.84e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg20891283	chr12:69753455	YEATS4	0.73	6.09	0.53	2.39e-8	Blood protein levels;
THYM	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg04520793	chr17:42248056	ASB16	0.34	4.78	0.44	6.45e-6	Total body bone mineral density;
THYM	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg10360139	chr7:1886902	MAD1L1	-0.61	-5.33	-0.48	6.65e-7	Bipolar disorder and schizophrenia;
THYM	trans	rs4650994	0.507	rs12141152	chr1:178514165	C/T	cg05059571	chr16:84539110	KIAA1609	-0.92	-10.85	-0.74	2.56e-18	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs791888	0.688	rs1980649	chr10:89422375	T/C	cg10377144	chr10:89419177	PAPSS2	0.45	7.48	0.61	3.78e-11	Magnesium levels;
THYM	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs3796352	1.000	rs13076033	chr3:52898427	T/C	cg07884673	chr3:53033167	SFMBT1	0.94	4.84	0.44	4.98e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs4430311	0.655	rs12744253	chr1:243967674	G/A	cg25706552	chr1:244017396	NA	-0.6	-5.18	-0.47	1.25e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs17006441	0.932	rs9872200	chr3:69875415	T/G	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs3804749	0.966	rs3792378	chr3:122845077	G/A	cg10259872	chr3:122802215	PDIA5	0.51	5.65	0.5	1.67e-7	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs2836633	0.965	rs2836621	chr21:40054149	C/T	cg12884169	chr21:40033163	ERG	0.66	8.21	0.64	1.06e-12	Coronary artery disease;
THYM	cis	rs61931739	0.890	rs1687020	chr12:34137924	G/C	cg06521331	chr12:34319734	NA	-0.67	-5.4	-0.48	4.91e-7	Morning vs. evening chronotype;
THYM	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs10140922	0.966	rs10083375	chr14:35823531	C/T	cg07166546	chr14:35805898	NA	-0.27	-6.45	-0.55	4.68e-9	Hip circumference adjusted for BMI;
THYM	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg18811423	chr2:55921094	PNPT1	0.79	7.61	0.62	1.97e-11	Metabolic syndrome;
THYM	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg12031863	chr16:4587854	C16orf5	-0.45	-4.92	-0.45	3.65e-6	Schizophrenia;
THYM	cis	rs7586879	0.520	rs6718511	chr2:25122324	A/G	cg01884057	chr2:25150051	NA	0.73	7.95	0.63	3.89e-12	Body mass index;
THYM	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10904908	0.733	rs359299	chr10:17334378	G/A	cg01003015	chr10:17271136	VIM	0.56	4.61	0.43	1.24e-5	Total cholesterol levels;Cholesterol, total;
THYM	cis	rs7119	0.717	rs12917314	chr15:77818285	T/C	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.58	10.88	0.74	2.23e-18	Hemostatic factors and hematological phenotypes;
THYM	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-7.23	-0.6	1.2e-10	Schizophrenia;
THYM	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg08999081	chr20:33150536	PIGU	0.65	5.82	0.51	7.8e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14893161	chr1:205819251	PM20D1	0.74	7.48	0.61	3.7e-11	Menarche (age at onset);
THYM	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg16928487	chr17:17741425	SREBF1	-0.51	-4.87	-0.45	4.51e-6	Total body bone mineral density;
THYM	cis	rs4285028	0.747	rs7648340	chr3:121426188	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.84	-7.2	-0.59	1.37e-10	Multiple sclerosis;
THYM	cis	rs4849845	0.925	rs10180465	chr2:121011770	A/G	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs1878931	0.507	rs67218524	chr16:3403057	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.65	-4.46	-0.42	2.28e-5	Body mass index (adult);
THYM	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg22841779	chr14:105766346	BRF1	-0.51	-6.63	-0.56	2.08e-9	Mean platelet volume;Platelet distribution width;
THYM	cis	rs41311933	1.000	rs41259344	chr9:123751648	C/T	cg13567360	chr9:123745713	C5	-0.99	-5.07	-0.46	1.96e-6	Coronary artery disease;
THYM	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg18252515	chr7:66147081	NA	-0.66	-4.87	-0.45	4.38e-6	Aortic root size;
THYM	cis	rs7646881	0.812	rs7624161	chr3:158459914	C/G	cg18349298	chr3:158450550	RARRES1	0.54	4.6	0.43	1.29e-5	Tetralogy of Fallot;
THYM	cis	rs6980334	0.817	rs3805361	chr7:137794519	C/T	cg22979093	chr7:137028410	PTN	0.62	4.95	0.45	3.19e-6	Blood metabolite ratios;
THYM	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.78	-4.68	-0.43	9.48e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg00310523	chr12:86230176	RASSF9	0.56	4.94	0.45	3.29e-6	Major depressive disorder;
THYM	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.26	-9.1	-0.68	1.4e-14	Gut microbiome composition (summer);
THYM	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg18252515	chr7:66147081	NA	-0.63	-4.69	-0.43	8.99e-6	Aortic root size;
THYM	cis	rs9303401	0.703	rs9909925	chr17:57210069	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.72	-5.35	-0.48	6.05e-7	Cognitive test performance;
THYM	cis	rs12541335	0.615	rs4872464	chr8:22153381	G/A	cg02788857	chr8:22132959	PIWIL2	0.57	5.14	0.47	1.49e-6	Hypertriglyceridemia;
THYM	cis	rs7851660	1.000	rs7851660	chr9:100610759	C/A	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs6987853	0.814	rs1349471	chr8:42454011	C/T	cg09913449	chr8:42400586	C8orf40	0.95	9.48	0.7	2.15e-15	Mean corpuscular hemoglobin concentration;
THYM	trans	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg18187862	chr3:45730750	SACM1L	-0.9	-7.25	-0.6	1.09e-10	Primary sclerosing cholangitis;
THYM	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg15744005	chr10:104629667	AS3MT	-0.85	-8.22	-0.64	1.02e-12	Arsenic metabolism;
THYM	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg25208724	chr1:156163844	SLC25A44	1.11	8.57	0.66	1.83e-13	Testicular germ cell tumor;
THYM	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg11494091	chr17:61959527	GH2	0.68	6.25	0.54	1.14e-8	Height;
THYM	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg23711669	chr6:146136114	FBXO30	-0.97	-10.49	-0.73	1.45e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs2507	0.578	rs2415188	chr15:74281962	C/G	cg17221444	chr15:74284820	STOML1	-0.58	-4.81	-0.44	5.69e-6	Coronary artery disease;
THYM	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg15445000	chr17:37608096	MED1	-0.44	-5.1	-0.46	1.73e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs61931739	0.534	rs1852222	chr12:34008665	C/A	cg06521331	chr12:34319734	NA	-0.94	-8.73	-0.67	8.6e-14	Morning vs. evening chronotype;
THYM	cis	rs6732160	0.574	rs7557055	chr2:73472670	G/A	cg24220031	chr2:73402428	NA	-0.82	-9.87	-0.71	3.11e-16	Intelligence (multi-trait analysis);
THYM	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg04362960	chr10:104952993	NT5C2	0.58	4.68	0.43	9.68e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	10.01	0.72	1.59e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9311676	0.632	rs67904096	chr3:58365508	T/A	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg03188948	chr7:1209495	NA	0.91	5.04	0.46	2.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4930776	0.838	rs445467	chr12:5756323	T/G	cg02086166	chr12:5775618	ANO2	0.64	6.51	0.56	3.61e-9	Plasma clusterin levels;
THYM	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg12573674	chr2:1569213	NA	-1.16	-8.07	-0.64	2.18e-12	IgG glycosylation;
THYM	cis	rs10992471	0.603	rs1535755	chr9:95202031	G/T	cg14631576	chr9:95140430	CENPP	-0.99	-9.94	-0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs754466	0.651	rs10824584	chr10:79625947	G/A	cg17075019	chr10:79541650	NA	-0.69	-5.85	-0.51	6.94e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.29	-0.48	7.96e-7	Hemoglobin concentration;
THYM	cis	rs7119	0.717	rs12916822	chr15:77818548	G/T	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg09354556	chr3:47051341	NA	0.46	4.71	0.44	8.3e-6	Colorectal cancer;
THYM	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	cis	rs6087990	0.806	rs1474738	chr20:31380309	G/A	cg13636640	chr20:31349939	DNMT3B	0.94	10.37	0.73	2.71e-17	Ulcerative colitis;
THYM	trans	rs8002861	0.870	rs4942251	chr13:44440048	G/T	cg17145862	chr1:211918768	LPGAT1	0.93	9.72	0.71	6.69e-16	Leprosy;
THYM	cis	rs4455778	0.519	rs10227532	chr7:49048208	A/G	cg26309511	chr7:48887640	NA	0.63	5.47	0.49	3.67e-7	Lung cancer in never smokers;
THYM	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg26384229	chr12:38710491	ALG10B	1.03	9.92	0.71	2.51e-16	Heart rate;
THYM	cis	rs9649213	0.593	rs3779193	chr7:98028466	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg17888033	chr8:143858414	LYNX1	-0.46	-5.26	-0.47	8.94e-7	Urinary tract infection frequency;
THYM	cis	rs9534288	0.742	rs1977395	chr13:46638131	C/T	cg15192986	chr13:46630673	CPB2	-0.65	-4.71	-0.44	8.46e-6	Blood protein levels;
THYM	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg10589385	chr1:150898437	SETDB1	0.66	5.48	0.49	3.44e-7	Melanoma;
THYM	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs2235649	0.623	rs8048162	chr16:1848918	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.93	-0.45	3.45e-6	Blood metabolite levels;
THYM	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg22166914	chr1:53195759	ZYG11B	-0.96	-11.92	-0.77	1.4e-20	Monocyte count;
THYM	cis	rs600550	0.588	rs2304933	chr11:60102507	G/T	cg05040360	chr11:60102449	MS4A6E	-0.5	-4.72	-0.44	8.13e-6	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg10505658	chr17:80084571	CCDC57	0.68	7.46	0.61	4.13e-11	Life satisfaction;
THYM	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg10523679	chr1:76189770	ACADM	-0.86	-7.5	-0.61	3.3e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	trans	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg10856724	chr12:34555212	NA	0.82	7.07	0.59	2.55e-10	Drug-induced liver injury (flucloxacillin);
THYM	trans	rs4596713	0.508	rs7467352	chr9:71766081	G/A	cg16512924	chr15:28394682	HERC2	0.83	6.91	0.58	5.43e-10	Headache;
THYM	cis	rs28595532	0.920	rs28837152	chr4:119782868	G/A	cg14228332	chr4:119757509	SEC24D	1.36	5.22	0.47	1.07e-6	Cannabis dependence symptom count;
THYM	cis	rs4268898	0.662	rs2891382	chr2:24511491	C/G	cg06627628	chr2:24431161	ITSN2	-0.76	-5.34	-0.48	6.39e-7	Asthma;
THYM	cis	rs6964587	0.626	rs7785941	chr7:91531024	T/C	cg22709100	chr7:91322751	NA	-0.63	-4.59	-0.43	1.37e-5	Breast cancer;
THYM	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg04013093	chr6:42928303	GNMT	-0.43	-4.52	-0.42	1.76e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg22166914	chr1:53195759	ZYG11B	-0.76	-8.12	-0.64	1.72e-12	Monocyte count;
THYM	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11890956	chr21:40555474	PSMG1	-0.9	-9.57	-0.7	1.4e-15	Cognitive function;
THYM	cis	rs4919694	1.000	rs76892505	chr10:104719290	G/A	cg15744005	chr10:104629667	AS3MT	-0.85	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg13395646	chr4:1353034	KIAA1530	-0.59	-5.68	-0.5	1.45e-7	Longevity;
THYM	cis	rs2554380	0.843	rs1019667	chr15:84380849	C/A	cg14598478	chr15:84363061	ADAMTSL3	-0.63	-4.98	-0.46	2.79e-6	Height;
THYM	cis	rs5769707	0.609	rs2071890	chr22:50001291	G/A	cg20744362	chr22:50050164	C22orf34	0.77	6.72	0.57	1.34e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4595586	0.545	rs9669705	chr12:39374459	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs6456042	1.000	rs4709098	chr6:166534145	G/A	cg11088901	chr6:166572345	T	-0.51	-4.78	-0.44	6.47e-6	Asthma;
THYM	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg24250549	chr1:154909240	PMVK	0.79	6.73	0.57	1.27e-9	Prostate cancer;
THYM	cis	rs9788721	0.630	rs77681598	chr15:78906103	C/A	cg06917634	chr15:78832804	PSMA4	-0.79	-6.88	-0.58	6.46e-10	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs1728785	1.000	rs8058145	chr16:68584090	G/A	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14159672	chr1:205819179	PM20D1	0.96	9.62	0.7	1.07e-15	Menarche (age at onset);
THYM	cis	rs6546537	1.000	rs6712370	chr2:69855094	C/G	cg10773587	chr2:69614142	GFPT1	0.58	5.1	0.46	1.76e-6	Serum thyroid-stimulating hormone levels;
THYM	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg17294928	chr15:75287854	SCAMP5	-0.94	-7.94	-0.63	4.01e-12	Blood trace element (Zn levels);
THYM	cis	rs8050907	0.744	rs8063084	chr16:4536555	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.25	4.73	0.44	7.82e-6	Obesity-related traits;
THYM	cis	rs941408	1.000	rs941410	chr19:2787329	G/A	cg19693284	chr19:2783607	SGTA	0.78	5.89	0.52	5.85e-8	Total cholesterol levels;
THYM	cis	rs1894633	0.547	rs6674018	chr1:172340661	T/A	cg13446689	chr1:172328377	DNM3	0.54	4.94	0.45	3.32e-6	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg06064525	chr11:970664	AP2A2	-0.36	-6.98	-0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	cis	rs208520	0.754	rs851593	chr6:66875783	C/T	cg07460842	chr6:66804631	NA	0.91	6.41	0.55	5.65e-9	Exhaled nitric oxide output;
THYM	cis	rs11089937	0.616	rs5757244	chr22:22531023	C/T	cg06866756	chr22:22471216	NA	-0.46	-5.0	-0.46	2.59e-6	Periodontitis (PAL4Q3);
THYM	cis	rs7178572	0.625	rs12904553	chr15:77845959	G/A	cg22256960	chr15:77711686	NA	-0.78	-6.98	-0.58	4.04e-10	Type 2 diabetes;
THYM	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg26131816	chr17:42072204	PYY	0.53	4.6	0.43	1.28e-5	Menopause (age at onset);
THYM	cis	rs9326248	0.539	rs660443	chr11:116760693	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.67	5.3	0.48	7.39e-7	Blood protein levels;
THYM	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7677751	0.943	rs9991165	chr4:55124591	A/G	cg17187183	chr4:55093834	PDGFRA	0.77	5.14	0.47	1.46e-6	Corneal astigmatism;
THYM	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg13695892	chr22:41940480	POLR3H	-0.6	-4.69	-0.43	9.11e-6	Neuroticism;
THYM	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.63	-0.5	1.8e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg08885076	chr2:99613938	TSGA10	0.53	5.11	0.46	1.64e-6	Chronic sinus infection;
THYM	cis	rs1691799	0.899	rs1168304	chr12:66738667	A/C	cg16791601	chr12:66731901	HELB	-0.76	-7.14	-0.59	1.9e-10	White blood cell count (basophil);
THYM	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg06532163	chr17:45867833	NA	0.65	6.58	0.56	2.6e-9	IgG glycosylation;
THYM	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1933112	1.000	rs1933104	chr1:168528886	G/T	cg17186328	chr1:168545835	XCL1	-0.55	-4.53	-0.42	1.73e-5	Blood protein levels;
THYM	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg12011299	chr4:100065546	ADH4	0.85	8.03	0.64	2.59e-12	Alcohol dependence;
THYM	cis	rs11209185	0.602	rs6662448	chr1:68447267	G/A	cg22082780	chr1:68452167	NA	0.49	5.87	0.52	6.27e-8	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.79	0.51	9.18e-8	Rheumatoid arthritis;
THYM	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg05754148	chr16:3507555	NAT15	0.88	7.96	0.63	3.57e-12	Tuberculosis;
THYM	cis	rs2933343	0.729	rs1680781	chr3:128612830	C/A	cg11901034	chr3:128598214	ACAD9	-0.71	-5.55	-0.49	2.56e-7	IgG glycosylation;
THYM	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9287719	0.674	rs10929690	chr2:10805974	T/C	cg02196655	chr2:10830764	NOL10	0.51	5.14	0.47	1.48e-6	Prostate cancer;
THYM	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg26384229	chr12:38710491	ALG10B	0.94	7.62	0.62	1.86e-11	Morning vs. evening chronotype;
THYM	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg24531977	chr5:56204891	C5orf35	-1.02	-8.59	-0.66	1.73e-13	Initial pursuit acceleration;
THYM	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.69	-5.95	-0.52	4.55e-8	Renal function-related traits (BUN);
THYM	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg23583168	chr7:148888333	NA	-1.02	-14.09	-0.82	5.29e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg17178900	chr1:205818956	PM20D1	-0.67	-5.11	-0.46	1.67e-6	Menarche (age at onset);
THYM	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg07606381	chr6:8435919	SLC35B3	0.67	5.14	0.47	1.47e-6	Motion sickness;
THYM	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg00684032	chr4:1343700	KIAA1530	0.77	6.61	0.56	2.22e-9	Obesity-related traits;
THYM	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg23815491	chr16:72088622	HP	0.66	5.05	0.46	2.17e-6	Fibrinogen levels;
THYM	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs477692	0.583	rs12415589	chr10:131428336	C/G	cg06209143	chr10:131448811	MGMT	-0.6	-4.98	-0.46	2.84e-6	Response to temozolomide;
THYM	cis	rs36051895	0.659	rs62541539	chr9:5038180	C/T	cg02405213	chr9:5042618	JAK2	-1.01	-10.31	-0.73	3.53e-17	Pediatric autoimmune diseases;
THYM	cis	rs1278352	0.767	rs1278348	chr10:127772329	T/C	cg08295661	chr10:127769903	ADAM12	-0.55	-5.5	-0.49	3.16e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg07936489	chr17:37558343	FBXL20	-0.63	-4.61	-0.43	1.27e-5	Asthma;
THYM	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11644478	chr21:40555479	PSMG1	-0.59	-4.91	-0.45	3.74e-6	Menarche (age at onset);
THYM	cis	rs4803480	0.872	rs2058149	chr19:42086665	C/G	cg09848080	chr19:41642064	NA	0.62	4.49	0.42	1.99e-5	Schizophrenia;
THYM	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg09085632	chr11:111637200	PPP2R1B	1.11	11.2	0.75	4.55e-19	Primary sclerosing cholangitis;
THYM	cis	rs1728785	1.000	rs1170428	chr16:68603988	C/A	cg02972257	chr16:68554789	NA	-0.76	-4.9	-0.45	3.93e-6	Ulcerative colitis;
THYM	cis	rs13418717	1.000	rs951817	chr2:127664894	G/T	cg25501666	chr2:127640322	NA	1.4	6.47	0.55	4.32e-9	Heart failure;
THYM	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.24	-0.47	9.67e-7	Monocyte percentage of white cells;
THYM	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg16031515	chr1:205743344	RAB7L1	-0.74	-7.3	-0.6	8.55e-11	Menarche (age at onset);
THYM	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg07424592	chr7:64974309	NA	1.03	5.4	0.48	4.94e-7	Diabetic kidney disease;
THYM	cis	rs3849570	0.925	rs1464791	chr3:81893929	A/C	cg07356753	chr3:81810745	GBE1	0.84	6.34	0.55	7.84e-9	Waist circumference;Body mass index;
THYM	cis	rs7178572	0.889	rs869301	chr15:77830633	T/C	cg22256960	chr15:77711686	NA	-0.95	-7.89	-0.63	5.05e-12	Type 2 diabetes;
THYM	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg03474202	chr17:45855739	NA	-0.74	-6.5	-0.55	3.7e-9	IgG glycosylation;
THYM	cis	rs2562456	0.837	rs11085462	chr19:21750251	C/G	cg21751540	chr19:21541537	ZNF738	-0.71	-4.97	-0.45	2.9e-6	Pain;
THYM	cis	rs7246657	0.943	rs2303131	chr19:37936025	G/A	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs11252926	0.604	rs12359454	chr10:568081	T/C	cg14018140	chr10:458528	DIP2C	0.49	4.73	0.44	7.79e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs7917772	0.560	rs3862030	chr10:104327584	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs12200560	0.505	rs1334321	chr6:97079571	C/T	cg06623918	chr6:96969491	KIAA0776	-0.74	-5.48	-0.49	3.51e-7	Coronary heart disease;
THYM	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11648796	0.959	rs9928077	chr16:784765	C/T	cg10254923	chr16:769848	FAM173A	0.53	5.67	0.5	1.56e-7	Height;
THYM	cis	rs4455778	0.633	rs2098127	chr7:49007109	A/G	cg26309511	chr7:48887640	NA	-0.53	-4.8	-0.44	5.88e-6	Lung cancer in never smokers;
THYM	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg00801512	chr17:28996047	NA	-0.76	-5.02	-0.46	2.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg24450063	chr1:156163899	SLC25A44	1.16	14.83	0.84	1.8e-26	Testicular germ cell tumor;
THYM	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg27129171	chr3:47204927	SETD2	-0.71	-6.68	-0.57	1.58e-9	Colorectal cancer;
THYM	cis	rs62070183	0.938	rs17781142	chr17:31187216	C/G	cg23177095	chr17:30873196	MYO1D	-0.6	-4.58	-0.43	1.39e-5	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs2552220	1.000	rs13248526	chr8:6008526	T/C	cg06481462	chr8:7005678	NA	0.51	5.21	0.47	1.08e-6	Interleukin-8 levels;
THYM	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg18132916	chr6:79620363	NA	-0.58	-5.27	-0.48	8.5e-7	Intelligence (multi-trait analysis);
THYM	cis	rs12073837	0.784	rs61830289	chr1:220988742	G/A	cg16008148	chr1:221062819	NA	0.41	4.45	0.42	2.32e-5	F-cell distribution;
THYM	cis	rs919433	0.680	rs788017	chr2:198265173	T/A	cg05783139	chr2:198650985	BOLL	0.63	4.93	0.45	3.48e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg18825531	chr11:62321136	NA	-0.45	-5.16	-0.47	1.37e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9522267	0.535	rs56330641	chr13:112233538	C/T	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs12188164	0.930	rs11743825	chr5:475463	C/T	cg26850624	chr5:429559	AHRR	-0.73	-5.34	-0.48	6.21e-7	Cystic fibrosis severity;
THYM	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg04362960	chr10:104952993	NT5C2	0.58	4.68	0.43	9.68e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg02640540	chr1:67518911	SLC35D1	0.65	4.78	0.44	6.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs4474465	0.920	rs12222907	chr11:78219726	C/T	cg19901956	chr11:77921274	USP35	0.66	4.84	0.44	4.99e-6	Alzheimer's disease (survival time);
THYM	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12379764	chr21:47803548	PCNT	0.83	5.8	0.51	8.7e-8	Testicular germ cell tumor;
THYM	cis	rs877282	0.891	rs11253355	chr10:768367	C/G	cg10556349	chr10:835070	NA	-0.84	-5.72	-0.51	1.21e-7	Uric acid levels;
THYM	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg26384229	chr12:38710491	ALG10B	1.01	6.69	0.57	1.54e-9	Bladder cancer;
THYM	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg11301795	chr4:187892539	NA	1.11	16.01	0.85	9.83e-29	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs941408	1.000	rs1624295	chr19:2792034	G/A	cg17333051	chr19:2783644	SGTA	0.58	5.01	0.46	2.53e-6	Total cholesterol levels;
THYM	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg12935359	chr14:103987150	CKB	-0.51	-6.07	-0.53	2.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9399401	0.925	rs1360194	chr6:142752595	A/G	cg04461802	chr6:142623433	GPR126	-0.47	-4.85	-0.45	4.9100000000000004e-06	Chronic obstructive pulmonary disease;
THYM	cis	rs4595586	0.545	rs12828001	chr12:39392208	G/A	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg26886231	chr17:78936889	RPTOR	0.53	4.72	0.44	8.16e-6	Eye color traits;
THYM	cis	rs4638749	0.677	rs7570544	chr2:108848137	C/T	cg25838818	chr2:108905173	SULT1C2	-0.54	-5.2	-0.47	1.13e-6	Blood pressure;
THYM	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg26721908	chr21:47610096	LSS	-0.96	-7.26	-0.6	1.08e-10	Testicular germ cell tumor;
THYM	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg22166914	chr1:53195759	ZYG11B	0.9	10.56	0.73	1.04e-17	Monocyte count;
THYM	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg04025307	chr7:1156635	C7orf50	0.63	5.82	0.51	8.1e-8	Longevity;Endometriosis;
THYM	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg20891283	chr12:69753455	YEATS4	0.69	5.9	0.52	5.51e-8	Response to diuretic therapy;
THYM	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg02574844	chr11:5959923	NA	-0.52	-4.66	-0.43	1.04e-5	DNA methylation (variation);
THYM	cis	rs3008870	1.000	rs2815351	chr1:67477980	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	7.79	0.62	8.16e-12	Lymphocyte percentage of white cells;
THYM	cis	rs17604090	1.000	rs28591682	chr7:29690811	T/C	cg19413766	chr7:29689036	LOC646762	-1.03	-5.72	-0.51	1.25e-7	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	trans	rs10462794	0.789	rs7719895	chr5:4490338	C/T	cg22225685	chr22:38203998	GCAT	1.17	6.9	0.58	5.78e-10	DNA methylation (variation);
THYM	cis	rs6480314	0.636	rs77760458	chr10:70004005	G/A	cg27159792	chr10:69524182	NA	0.81	4.89	0.45	4.06e-6	Optic nerve measurement (disc area);
THYM	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg25918947	chr17:41365094	TMEM106A	-0.68	-5.59	-0.5	2.15e-7	Menopause (age at onset);
THYM	trans	rs637571	0.780	rs677029	chr11:65683531	A/G	cg17712092	chr4:129076599	LARP1B	1.12	12.55	0.79	6.88e-22	Eosinophil percentage of white cells;
THYM	cis	rs6163	0.588	rs67506723	chr10:104509064	G/T	cg15744005	chr10:104629667	AS3MT	-0.77	-7.43	-0.61	4.77e-11	Waist circumference;Hip circumference;
THYM	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg24874828	chr4:187887005	NA	-0.72	-7.22	-0.6	1.26e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3771570	1.000	rs73004354	chr2:242356239	G/T	cg21155796	chr2:242212141	HDLBP	1.25	6.07	0.53	2.62e-8	Prostate cancer;
THYM	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg12863693	chr15:85201151	NMB	0.66	5.81	0.51	8.26e-8	Schizophrenia;
THYM	cis	rs476633	0.708	rs9888708	chr15:41446030	G/C	cg21153102	chr15:41252147	NA	0.59	4.6	0.43	1.28e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs2717559	0.568	rs35093407	chr8:143885501	G/A	cg17252645	chr8:143867129	LY6D	-0.61	-6.19	-0.54	1.52e-8	Urinary tract infection frequency;
THYM	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg04362960	chr10:104952993	NT5C2	0.6	5.11	0.46	1.66e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg24253500	chr15:84953950	NA	0.54	4.56	0.42	1.53e-5	Schizophrenia;
THYM	cis	rs7927771	0.524	rs2242081	chr11:47500267	T/C	cg18512352	chr11:47633146	NA	0.43	4.79	0.44	6.07e-6	Subjective well-being;
THYM	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg20283391	chr11:68216788	NA	-0.6	-4.78	-0.44	6.49e-6	Total body bone mineral density;
THYM	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	7.49	0.61	3.58e-11	Smoking behavior;
THYM	cis	rs2072732	0.898	rs2981856	chr1:2972524	T/C	cg08733933	chr1:2954429	NA	-0.56	-4.46	-0.42	2.28e-5	Plateletcrit;
THYM	cis	rs919433	0.680	rs2605039	chr2:198362851	C/A	cg05783139	chr2:198650985	BOLL	0.63	4.9	0.45	3.96e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7941600	0.708	rs12287120	chr11:9311760	C/T	cg19415743	chr11:9336845	TMEM41B	1.1	5.56	0.5	2.52e-7	Coronary artery disease;
THYM	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg07343612	chr16:622815	PIGQ	-1.08	-10.52	-0.73	1.27e-17	Height;
THYM	cis	rs11065961	1	rs11065961	chr12:112023067	G/A	cg10833066	chr12:111807467	FAM109A	-0.53	-6.09	-0.53	2.43e-8	Platelet distribution width;
THYM	cis	rs4474465	1.000	rs10793314	chr11:78174196	G/C	cg19901956	chr11:77921274	USP35	-0.6	-4.55	-0.42	1.56e-5	Alzheimer's disease (survival time);
THYM	cis	rs9401593	0.904	rs9375195	chr6:98562720	G/A	cg16370642	chr6:99292665	NA	0.54	4.61	0.43	1.24e-5	Educational attainment (years of education);
THYM	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg05182265	chr7:156933206	UBE3C	-0.69	-9.32	-0.69	4.58e-15	Body mass index;
THYM	cis	rs1545348	0.581	rs116487640	chr5:34737990	C/T	cg01146980	chr5:34930244	DNAJC21	-0.76	-4.57	-0.42	1.45e-5	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs13102973	0.965	rs4535381	chr4:135861313	A/T	cg14419869	chr4:135874104	NA	0.89	8.76	0.67	7.5e-14	Subjective well-being;
THYM	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg10523679	chr1:76189770	ACADM	0.91	9.7	0.71	7.37e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg12564285	chr5:131593104	PDLIM4	0.53	5.95	0.52	4.4e-8	Breast cancer;
THYM	cis	rs7819412	0.526	rs62490743	chr8:10906740	C/T	cg16664915	chr8:10907788	XKR6	0.56	4.52	0.42	1.76e-5	Triglycerides;
THYM	cis	rs4654899	0.802	rs76122612	chr1:21243059	C/T	cg01072550	chr1:21505969	NA	-0.7	-6.33	-0.54	8.1e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg08835221	chr22:38071607	LGALS1	0.37	4.95	0.45	3.22e-6	Fat distribution (HIV);
THYM	cis	rs2067615	0.524	rs9971765	chr12:107092299	G/A	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	cis	rs4285028	0.747	rs3772126	chr3:121354583	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.84	-6.89	-0.58	6.09e-10	Multiple sclerosis;
THYM	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg08772003	chr10:104629869	AS3MT	-0.57	-4.92	-0.45	3.66e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs12935418	0.579	rs7197606	chr16:81053519	T/A	cg16651780	chr16:81037892	C16orf61	0.78	5.73	0.51	1.2e-7	Mean corpuscular volume;
THYM	cis	rs2730245	0.527	rs842702	chr7:158696814	C/T	cg24397884	chr7:158709396	WDR60	0.55	5.36	0.48	5.79e-7	Height;
THYM	cis	rs4951011	0.744	rs2365864	chr1:203757044	T/C	cg24343524	chr1:203763352	ZC3H11A	0.69	6.07	0.53	2.67e-8	Breast cancer;
THYM	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg09549813	chr16:4587862	C16orf5	-0.53	-5.49	-0.49	3.37e-7	Schizophrenia;
THYM	cis	rs9470366	0.545	rs4711457	chr6:36633160	T/C	cg11920449	chr6:36645608	CDKN1A	0.66	5.63	0.5	1.84e-7	QRS duration;
THYM	cis	rs11992162	0.613	rs6998690	chr8:11798796	A/T	cg21775007	chr8:11205619	TDH	0.61	4.82	0.44	5.41e-6	Monocyte count;
THYM	cis	rs757081	0.606	rs679201	chr11:17200891	T/C	cg07093617	chr11:18158918	MRGPRX3	-0.49	-4.61	-0.43	1.23e-5	Systolic blood pressure;
THYM	trans	rs4596713	0.507	rs10115283	chr9:71801162	T/G	cg16512924	chr15:28394682	HERC2	0.87	7.25	0.6	1.12e-10	Headache;
THYM	cis	rs2688608	0.592	rs11000758	chr10:75493610	A/T	cg15838173	chr10:75533400	FUT11	-0.5	-5.09	-0.46	1.82e-6	Inflammatory bowel disease;
THYM	cis	rs2637266	0.783	rs1660908	chr10:78494856	T/C	cg18941641	chr10:78392320	NA	0.71	5.69	0.5	1.43e-7	Pulmonary function;
THYM	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg12756686	chr19:29218302	NA	0.85	6.0	0.52	3.52e-8	Methadone dose in opioid dependence;
THYM	cis	rs11574514	1.000	rs79437914	chr16:67578143	C/A	cg09738193	chr16:67926317	PSKH1	-0.92	-4.49	-0.42	2e-5	Crohn's disease;
THYM	cis	rs9359856	0.510	rs74437492	chr6:90338728	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.84	-8.17	-0.64	1.31e-12	Bipolar disorder;
THYM	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	8.2	0.64	1.14e-12	Chronic sinus infection;
THYM	cis	rs5009270	0.553	rs11769472	chr7:112220214	A/C	cg23628563	chr7:112262597	NA	-0.61	-4.69	-0.43	9.32e-6	Osteoarthritis (hip);
THYM	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg03388025	chr16:89894329	SPIRE2	0.52	4.49	0.42	1.99e-5	Vitiligo;
THYM	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg25554036	chr4:6271136	WFS1	0.56	4.93	0.45	3.43e-6	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs7828089	1.000	rs34542820	chr8:22264079	C/T	cg13512537	chr8:22265999	SLC39A14	-0.63	-5.23	-0.47	1.02e-6	Verbal declarative memory;
THYM	cis	rs59698941	0.943	rs72799496	chr5:132290911	T/C	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs7119	0.623	rs11637932	chr15:77847353	T/G	cg27398640	chr15:77910606	LINGO1	-0.61	-6.05	-0.53	2.92e-8	Type 2 diabetes;
THYM	cis	rs28595532	0.841	rs55823625	chr4:119780600	T/A	cg14228332	chr4:119757509	SEC24D	1.46	5.36	0.48	5.83e-7	Cannabis dependence symptom count;
THYM	cis	rs1978968	1.000	rs1110659	chr22:18444675	T/C	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg11245990	chr11:68621969	NA	0.57	7.46	0.61	4.06e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg12863693	chr15:85201151	NMB	-0.57	-4.93	-0.45	3.54e-6	Schizophrenia;
THYM	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg13319975	chr6:146136371	FBXO30	-0.58	-4.66	-0.43	1.02e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg07343612	chr16:622815	PIGQ	-1.08	-11.34	-0.76	2.36e-19	Height;
THYM	cis	rs12765878	0.541	rs7091346	chr10:105608824	C/T	cg04688330	chr10:105451802	SH3PXD2A	0.35	4.52	0.42	1.78e-5	Coronary artery disease;
THYM	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg18230493	chr5:56204884	C5orf35	0.64	4.8	0.44	5.87e-6	Initial pursuit acceleration;
THYM	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg10334053	chr1:2078117	PRKCZ	0.48	4.73	0.44	7.65e-6	Height;
THYM	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg00071950	chr4:10020882	SLC2A9	0.56	4.95	0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs929596	0.501	rs4530361	chr2:234590041	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.81	-6.58	-0.56	2.52e-9	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg09877947	chr5:131593287	PDLIM4	0.61	5.29	0.48	7.92e-7	Breast cancer;
THYM	cis	rs2658782	0.951	rs117384439	chr11:93111478	T/G	cg16424440	chr11:93231842	C11orf75	0.7	4.65	0.43	1.06e-5	Pulmonary function decline;
THYM	cis	rs7107174	1.000	rs6592772	chr11:78015563	A/C	cg19901956	chr11:77921274	USP35	-0.73	-5.39	-0.48	5.16e-7	Testicular germ cell tumor;
THYM	cis	rs6430585	0.528	rs309165	chr2:136667301	T/C	cg20242066	chr2:136595261	LCT	0.51	5.39	0.48	5.21e-7	Corneal structure;
THYM	cis	rs861020	0.606	rs689210	chr1:210013723	A/C	cg05527609	chr1:210001259	C1orf107	0.85	6.82	0.57	8.53e-10	Orofacial clefts;
THYM	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg09549813	chr16:4587862	C16orf5	-0.57	-5.43	-0.49	4.35e-7	Schizophrenia;
THYM	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-5.68	-0.5	1.49e-7	Gut microbiome composition (summer);
THYM	cis	rs2066819	0.892	rs2066807	chr12:56740682	C/G	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg07329149	chr2:201936323	NDUFB3;FAM126B	0.94	6.92	0.58	5.27e-10	Depressive symptoms;
THYM	cis	rs6700896	0.931	rs11208716	chr1:66158825	C/T	cg04111102	chr1:66153794	NA	0.52	4.94	0.45	3.32e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg26354017	chr1:205819088	PM20D1	0.96	10.19	0.72	6.47e-17	Menarche (age at onset);
THYM	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg27129171	chr3:47204927	SETD2	-0.71	-6.59	-0.56	2.43e-9	Colorectal cancer;
THYM	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg22105103	chr4:187893119	NA	0.88	9.57	0.7	1.35e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs9515201	0.627	rs4773173	chr13:111025118	A/G	cg06243866	chr13:111019493	COL4A2	-0.94	-10.44	-0.73	1.93e-17	White matter hyperintensity burden;
THYM	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24549020	chr5:56110836	MAP3K1	0.69	4.52	0.42	1.8e-5	Initial pursuit acceleration;
THYM	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.3	6.49	0.55	3.87e-9	Obesity-related traits;
THYM	cis	rs6918586	0.658	rs198814	chr6:26127759	A/G	cg03517284	chr6:25882590	NA	0.71	5.64	0.5	1.75e-7	Schizophrenia;
THYM	cis	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg01364799	chr7:75623366	TMEM120A	0.61	4.46	0.42	2.27e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg10802521	chr3:52805072	NEK4	-0.73	-6.21	-0.54	1.42e-8	Bipolar disorder;
THYM	cis	rs2806561	0.704	rs7532266	chr1:23551623	A/C	cg19743168	chr1:23544995	NA	-0.59	-5.98	-0.52	3.96e-8	Height;
THYM	cis	rs665401	1.000	rs665401	chr6:117257543	T/C	cg20376953	chr6:117187980	NA	0.55	4.49	0.42	1.99e-5	Neutrophil percentage of granulocytes;
THYM	cis	rs11756438	0.683	rs60497831	chr6:119009327	G/A	cg21191810	chr6:118973309	C6orf204	0.52	4.88	0.45	4.35e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs2229238	0.911	rs61559765	chr1:154518349	T/C	cg21262032	chr1:154437693	IL6R	-0.62	-5.23	-0.47	1.01e-6	Coronary heart disease;
THYM	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	9.4	0.69	3.1e-15	Chronic sinus infection;
THYM	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg03806693	chr22:41940476	POLR3H	1.1	8.83	0.67	5.2e-14	Vitiligo;
THYM	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.6	-0.5	2.08e-7	Type 2 diabetes;
THYM	cis	rs662064	0.962	rs660725	chr1:10557544	A/G	cg20482658	chr1:10539492	PEX14	-0.47	-6.05	-0.53	2.84e-8	Asthma;
THYM	cis	rs8006682	0.541	rs17756615	chr14:69089765	C/T	cg21123519	chr14:69095679	NA	-0.63	-4.78	-0.44	6.46e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs6430585	0.702	rs73958637	chr2:136546927	C/T	cg07169764	chr2:136633963	MCM6	1.19	13.81	0.82	1.9e-24	Corneal structure;
THYM	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg26384229	chr12:38710491	ALG10B	-0.9	-6.97	-0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg00631329	chr6:26305371	NA	-0.55	-6.52	-0.56	3.31e-9	Educational attainment;
THYM	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg24642844	chr7:1081250	C7orf50	-0.73	-5.13	-0.47	1.51e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg19016782	chr12:123741754	C12orf65	-0.69	-4.47	-0.42	2.18e-5	Neutrophil percentage of white cells;
THYM	cis	rs910187	0.605	rs6018324	chr20:45810181	G/C	cg27589058	chr20:45804311	EYA2	-0.59	-5.04	-0.46	2.2e-6	Migraine;
THYM	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg05872129	chr22:39784769	NA	-1.0	-8.37	-0.65	5.09e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg11494091	chr17:61959527	GH2	1.07	17.57	0.87	1.34e-31	Prudent dietary pattern;
THYM	cis	rs6785206	0.892	rs6793907	chr3:128391626	A/G	cg16766828	chr3:128327626	NA	0.69	5.72	0.51	1.23e-7	Lymphocyte percentage of white cells;
THYM	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	5.45	0.49	4.01e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6980334	1.000	rs13243992	chr7:137784790	C/T	cg11874123	chr7:137028198	PTN	0.67	5.24	0.47	9.68e-7	Blood metabolite ratios;
THYM	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.75	-0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs78411303	0.584	rs7611002	chr3:122379295	A/C	cg17380795	chr3:122379686	NA	-0.73	-4.52	-0.42	1.76e-5	Periodontitis (CDC/AAP);
THYM	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg23000734	chr10:126850823	CTBP2	-0.73	-8.03	-0.64	2.6e-12	Menarche (age at onset);
THYM	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg22681709	chr2:178499509	PDE11A	0.59	5.62	0.5	1.91e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs10750766	1	rs10750766	chr11:65473798	C/A	cg24147428	chr11:65409760	SIPA1	0.64	5.29	0.48	7.82e-7	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
THYM	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg02782426	chr3:40428986	ENTPD3	0.52	4.61	0.43	1.27e-5	Renal cell carcinoma;
THYM	cis	rs17127169	1.000	rs77762686	chr1:65426832	C/A	cg12075498	chr1:65428216	JAK1	-0.42	-5.17	-0.47	1.32e-6	Sitting height ratio;
THYM	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg17366294	chr4:99064904	C4orf37	0.58	7.07	0.59	2.6e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg27446573	chr6:127587934	RNF146	0.78	6.36	0.55	6.94e-9	Breast cancer;
THYM	cis	rs295140	1.000	rs13026151	chr2:201164570	T/A	cg04283868	chr2:201171347	SPATS2L	0.75	5.71	0.51	1.31e-7	QT interval;
THYM	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg00981070	chr1:2046702	PRKCZ	-0.48	-5.59	-0.5	2.2e-7	Height;
THYM	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg11141652	chr22:24348549	GSTTP1	0.65	6.42	0.55	5.36e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg13114125	chr14:105738426	BRF1	-0.74	-5.72	-0.51	1.22e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4988958	0.584	rs12712149	chr2:103045193	A/G	cg03938978	chr2:103052716	IL18RAP	0.75	9.8	0.71	4.43e-16	Asthma (childhood onset);
THYM	cis	rs1538970	0.816	rs3790583	chr1:45956828	C/G	cg05343316	chr1:45956843	TESK2	0.85	5.45	0.49	3.93e-7	Platelet count;
THYM	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.38	0.6	5.91e-11	Morning vs. evening chronotype;
THYM	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11711311	0.955	rs34458493	chr3:113396473	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.57	-4.76	-0.44	7.01e-6	IgG glycosylation;
THYM	cis	rs34602589	0.778	rs62206432	chr20:43748038	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.65	-5.65	-0.5	1.67e-7	Parental longevity (mother's age at death);
THYM	cis	rs12496230	1.000	rs36016775	chr3:66838437	A/G	cg23477460	chr3:66848765	NA	1.17	7.57	0.61	2.46e-11	Type 2 diabetes;
THYM	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg06238570	chr21:40685208	BRWD1	-0.69	-5.72	-0.51	1.24e-7	Menarche (age at onset);
THYM	cis	rs1728785	1.000	rs1170436	chr16:68607486	T/A	cg02972257	chr16:68554789	NA	-0.77	-4.75	-0.44	7.14e-6	Ulcerative colitis;
THYM	cis	rs10929159	0.665	rs7599602	chr2:236930373	C/T	cg14895183	chr2:236924282	AGAP1	0.55	4.69	0.43	9.27e-6	Parkinson's disease;
THYM	cis	rs394563	0.717	rs548848	chr6:149782009	A/G	cg26849637	chr6:150530249	PPP1R14C	-0.43	-4.79	-0.44	6.23e-6	Dupuytren's disease;
THYM	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg06074448	chr4:187884817	NA	0.94	10.12	0.72	9.09e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2066819	0.892	rs77415512	chr12:56627300	A/G	cg26714650	chr12:56694279	CS	-1.29	-6.29	-0.54	9.85e-9	Psoriasis vulgaris;
THYM	cis	rs728616	0.867	rs1054054	chr10:81682728	C/T	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22133161	chr19:49891603	CCDC155	0.75	4.97	0.45	2.94e-6	Multiple sclerosis;
THYM	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.91	-6.52	-0.56	3.31e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.69	-5.17	-0.47	1.28e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg08742575	chr21:47604166	C21orf56	-0.66	-5.18	-0.47	1.25e-6	Testicular germ cell tumor;
THYM	cis	rs6964587	0.626	rs4729014	chr7:91550707	A/G	cg17063962	chr7:91808500	NA	-1.02	-9.26	-0.69	6.44e-15	Breast cancer;
THYM	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs113075218	1	rs113075218	chr5:121361750	T/A	cg05256605	chr5:121412184	LOX	0.59	4.47	0.42	2.18e-5	Coronary artery disease;
THYM	cis	rs300703	0.655	rs300798	chr2:105917	A/G	cg21211680	chr2:198530	NA	-1.26	-6.03	-0.53	3.07e-8	Blood protein levels;
THYM	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg27284194	chr4:1044797	NA	0.62	4.69	0.43	8.98e-6	Recombination rate (females);
THYM	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg01528321	chr10:82214614	TSPAN14	0.66	5.16	0.47	1.35e-6	Post bronchodilator FEV1;
THYM	cis	rs7731657	0.537	rs13355768	chr5:130360245	C/T	cg08523029	chr5:130500466	HINT1	-0.81	-5.6	-0.5	2.04e-7	Fasting plasma glucose;
THYM	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg18904891	chr8:8559673	CLDN23	0.72	5.39	0.48	5.14e-7	Obesity-related traits;
THYM	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.03	-9.96	-0.71	2.06e-16	Primary sclerosing cholangitis;
THYM	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.65	0.5	1.7e-7	Height;
THYM	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg02825527	chr7:2087843	MAD1L1	-0.69	-4.62	-0.43	1.19e-5	Bipolar disorder;
THYM	cis	rs6754311	0.510	rs1374329	chr2:136421323	A/G	cg20242066	chr2:136595261	LCT	0.55	5.99	0.52	3.81e-8	Mosquito bite size;
THYM	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.78	6.29	0.54	9.87e-9	Lymphocyte percentage of white cells;
THYM	cis	rs3540	0.533	rs12708585	chr15:91052285	C/T	cg22089800	chr15:90895588	ZNF774	-0.68	-5.14	-0.47	1.47e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs981844	0.712	rs4632640	chr4:154742389	G/C	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs2816062	0.813	rs2816050	chr1:18894432	A/G	cg18795169	chr1:18902165	NA	-0.99	-12.14	-0.78	5.02e-21	Urate levels in lean individuals;
THYM	cis	rs2219968	0.525	rs7815883	chr8:78872381	C/T	cg00738934	chr8:78996279	NA	0.6	4.94	0.45	3.35e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4343996	1.000	rs13230698	chr7:3361125	T/C	cg21248987	chr7:3385318	SDK1	-0.41	-4.91	-0.45	3.77e-6	Motion sickness;
THYM	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg03188948	chr7:1209495	NA	0.9	5.02	0.46	2.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3820068	0.705	rs74054769	chr1:15860147	A/C	cg05660106	chr1:15850417	CASP9	1.11	9.62	0.7	1.09e-15	Systolic blood pressure;
THYM	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg07747251	chr5:1868357	NA	0.68	5.9	0.52	5.49e-8	Cardiovascular disease risk factors;
THYM	cis	rs3771317	1.000	rs12617955	chr2:191558492	C/A	cg17118478	chr2:191543902	NAB1	-0.62	-4.58	-0.43	1.41e-5	Primary biliary cholangitis;
THYM	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg15962314	chr1:44399869	ARTN	0.53	5.14	0.47	1.44e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4343996	0.521	rs10246895	chr7:3427874	A/G	cg21248987	chr7:3385318	SDK1	0.39	4.99	0.46	2.68e-6	Motion sickness;
THYM	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg13395646	chr4:1353034	KIAA1530	-0.75	-7.14	-0.59	1.83e-10	Obesity-related traits;
THYM	cis	rs17209837	0.607	rs4148816	chr7:87087731	G/A	cg04996195	chr7:87105398	ABCB4	0.63	4.84	0.44	5.09e-6	Gallbladder cancer;
THYM	cis	rs4363385	0.791	rs489323	chr1:153006047	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7246967	0.551	rs34907478	chr19:22928831	T/C	cg05241461	chr19:22816980	ZNF492	0.59	4.61	0.43	1.26e-5	Bronchopulmonary dysplasia;
THYM	cis	rs2692947	0.770	rs2315417	chr2:96500289	T/C	cg23100626	chr2:96804247	ASTL	0.35	4.56	0.42	1.52e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs11599315	1.000	rs11599315	chr10:1343017	C/T	cg01270228	chr10:1369114	ADARB2	0.59	4.92	0.45	3.66e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs3916	0.794	rs10431384	chr12:121127347	C/T	cg10600917	chr12:121163489	ACADS	-0.54	-5.4	-0.48	4.85e-7	Urinary metabolites (H-NMR features);
THYM	cis	rs17744026	0.525	rs17682723	chr11:123706758	A/C	cg00079598	chr11:123676903	OR6M1	-0.5	-4.71	-0.44	8.4e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs2276314	0.947	rs3898595	chr18:33565885	T/A	cg05985134	chr18:33552581	C18orf21	0.68	4.77	0.44	6.59e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs11249608	0.548	rs6875622	chr5:178451397	C/T	cg01312482	chr5:178451176	ZNF879	-0.75	-6.25	-0.54	1.19e-8	Pubertal anthropometrics;
THYM	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg08999081	chr20:33150536	PIGU	-0.77	-6.85	-0.57	7.45e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs6871536	0.789	rs10056700	chr5:131967482	T/C	cg13566430	chr5:131992455	IL13	-0.56	-4.49	-0.42	1.97e-5	Asthma (childhood onset);
THYM	cis	rs16870629	0.564	rs326050	chr5:1002620	C/T	cg00278107	chr5:1061253	SLC12A7	0.79	7.13	0.59	1.91e-10	QT interval;
THYM	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg17178900	chr1:205818956	PM20D1	0.99	10.59	0.74	9.28e-18	Menarche (age at onset);
THYM	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg04455712	chr21:45112962	RRP1B	0.51	4.72	0.44	8.23e-6	Mean corpuscular volume;
THYM	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg21926883	chr2:100939477	LONRF2	-0.62	-5.43	-0.49	4.32e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg04520793	chr17:42248056	ASB16	-0.33	-4.56	-0.42	1.54e-5	Total body bone mineral density;
THYM	cis	rs3780378	0.870	rs2149556	chr9:5059440	C/T	cg02405213	chr9:5042618	JAK2	-0.7	-6.48	-0.55	4.02e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs2046867	0.818	rs1502757	chr3:72864161	C/T	cg25664220	chr3:72788482	NA	-0.95	-7.97	-0.63	3.52e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs6032067	0.929	rs7344269	chr20:43828668	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	0.72	6.11	0.53	2.19e-8	Blood protein levels;
THYM	cis	rs4746818	1.000	rs6480384	chr10:70890757	C/T	cg11621586	chr10:70884670	VPS26A	1.31	11.97	0.78	1.11e-20	Left atrial antero-posterior diameter;
THYM	cis	rs5417	0.761	rs6503010	chr17:7180435	C/T	cg03186999	chr17:7165420	CLDN7	-0.53	-5.54	-0.49	2.72e-7	Diastolic blood pressure;
THYM	cis	rs3096299	0.838	rs3102384	chr16:89411661	T/G	cg10164272	chr16:89456328	ANKRD11	0.6	4.46	0.42	2.26e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg19623624	chr10:135278901	LOC619207	-0.64	-5.13	-0.47	1.56e-6	Systemic lupus erythematosus;
THYM	cis	rs34638657	0.732	rs62045964	chr16:82200920	T/C	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.25	-0.47	9.14e-7	Lung adenocarcinoma;
THYM	cis	rs7973719	1.000	rs1839622	chr12:7334534	G/C	cg07052231	chr12:7363540	PEX5	0.61	5.43	0.49	4.28e-7	IgG glycosylation;
THYM	cis	rs4319547	0.626	rs12423420	chr12:122938466	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.66	-4.61	-0.43	1.27e-5	Body mass index;
THYM	cis	rs17345786	0.520	rs13062677	chr3:101305078	G/A	cg12386194	chr3:101231763	SENP7	0.59	5.06	0.46	2.04e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg11764359	chr7:65958608	NA	-0.74	-6.02	-0.53	3.33e-8	Aortic root size;
THYM	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg13695892	chr22:41940480	POLR3H	-0.87	-6.35	-0.55	7.28e-9	Vitiligo;
THYM	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg11663144	chr21:46675770	NA	-0.7	-9.97	-0.71	1.96e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg16928487	chr17:17741425	SREBF1	0.52	5.09	0.46	1.82e-6	Total body bone mineral density;
THYM	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.95	0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg24308560	chr3:49941425	MST1R	0.8	6.84	0.57	7.6e-10	Intelligence (multi-trait analysis);
THYM	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs6918586	1.000	rs6918586	chr6:26097384	T/C	cg12310025	chr6:25882481	NA	-0.66	-5.26	-0.48	8.83e-7	Schizophrenia;
THYM	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.62	-4.5	-0.42	1.93e-5	Colorectal cancer;
THYM	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg02825527	chr7:2087843	MAD1L1	-0.81	-5.11	-0.46	1.64e-6	Neuroticism;
THYM	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg17372223	chr3:52568218	NT5DC2	0.38	6.03	0.53	3.15e-8	Electroencephalogram traits;
THYM	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg02725872	chr8:58115012	NA	-1.09	-8.15	-0.64	1.43e-12	Developmental language disorder (linguistic errors);
THYM	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs4481887	1.000	rs7525344	chr1:248467565	C/T	cg13385794	chr1:248469461	NA	-0.66	-4.66	-0.43	1.04e-5	Common traits (Other);
THYM	cis	rs34638657	0.702	rs12599988	chr16:82200063	T/C	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.25	-0.47	9.14e-7	Lung adenocarcinoma;
THYM	cis	rs2070488	0.965	rs6599206	chr3:38545349	C/T	cg24069376	chr3:38537580	EXOG	-0.69	-6.73	-0.57	1.29e-9	Electrocardiographic conduction measures;
THYM	cis	rs2820651	0.614	rs114139266	chr10:1489054	C/T	cg02445968	chr10:1449028	ADARB2	-1.05	-5.34	-0.48	6.32e-7	Migraine with aura;
THYM	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg05335186	chr13:53173507	NA	-0.5	-6.44	-0.55	4.81e-9	Lewy body disease;
THYM	cis	rs13064411	0.542	rs1463643	chr3:113215447	A/G	cg18753928	chr3:113234510	CCDC52	-0.84	-7.97	-0.63	3.49e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs2985684	0.894	rs4581611	chr14:50043520	A/T	cg02151108	chr14:50098012	C14orf104	-0.74	-6.13	-0.53	1.97e-8	Carotid intima media thickness;
THYM	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg26441486	chr22:50317300	CRELD2	0.47	7.49	0.61	3.46e-11	Schizophrenia;
THYM	cis	rs11030122	0.702	rs12286710	chr11:3967171	T/G	cg18678763	chr11:4115507	RRM1	-0.44	-5.73	-0.51	1.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg16680214	chr1:154839983	KCNN3	-0.58	-7.54	-0.61	2.82e-11	Prostate cancer;
THYM	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs754466	0.580	rs2579176	chr10:79529350	A/G	cg17075019	chr10:79541650	NA	-0.67	-5.49	-0.49	3.27e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11039798	1.000	rs3902928	chr11:48581458	A/T	cg24672777	chr11:48374446	OR4C45	-1.14	-6.95	-0.58	4.55e-10	Axial length;
THYM	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg02734326	chr4:10020555	SLC2A9	0.76	7.25	0.6	1.13e-10	Bone mineral density;
THYM	cis	rs2625529	0.668	rs8192386	chr15:72513148	A/C	cg16672083	chr15:72433130	SENP8	0.53	4.9	0.45	3.87e-6	Red blood cell count;
THYM	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs554111	0.656	rs4654900	chr1:21422021	G/C	cg00373020	chr1:21041521	KIF17	-0.53	-4.47	-0.42	2.14e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs1448094	0.512	rs10779216	chr12:86240315	A/G	cg02569458	chr12:86230093	RASSF9	-0.57	-4.91	-0.45	3.8e-6	Major depressive disorder;
THYM	cis	rs4242434	0.787	rs1545837	chr8:22477807	T/C	cg03733263	chr8:22462867	KIAA1967	1.2	11.61	0.77	6.24e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg17054759	chr22:49844102	NA	-0.48	-4.49	-0.42	2e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs10779751	0.734	rs2791657	chr1:11128001	A/G	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs11645898	0.513	rs55741258	chr16:72112480	C/T	cg03805757	chr16:71968109	PKD1L3	-0.65	-4.97	-0.45	2.97e-6	Blood protein levels;
THYM	cis	rs9902453	0.845	rs7501472	chr17:28010628	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.86	0.45	4.56e-6	Coffee consumption (cups per day);
THYM	cis	rs73198271	0.737	rs506960	chr8:8630269	A/C	cg15556689	chr8:8085844	FLJ10661	-0.66	-4.58	-0.43	1.42e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg13609457	chr4:120235615	NA	0.58	5.18	0.47	1.24e-6	Corneal astigmatism;
THYM	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg02524346	chr8:600233	NA	0.9	4.46	0.42	2.29e-5	IgG glycosylation;
THYM	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg07636037	chr3:49044803	WDR6	0.87	6.17	0.54	1.63e-8	Menarche (age at onset);
THYM	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg17178900	chr1:205818956	PM20D1	0.99	10.59	0.74	9.28e-18	Menarche (age at onset);
THYM	cis	rs9646944	0.501	rs9807934	chr2:103040182	T/G	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.62	-4.78	-0.44	6.49e-6	Intelligence (multi-trait analysis);
THYM	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg04282206	chr17:62833786	PLEKHM1P	0.84	7.74	0.62	1.06e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6988636	1.000	rs7002332	chr8:124185442	G/C	cg26140120	chr8:124219575	FAM83A	0.87	4.81	0.44	5.77e-6	Urinary uromodulin levels;
THYM	cis	rs4642101	0.883	rs11718898	chr3:12848822	T/C	cg05775895	chr3:12838266	CAND2	0.77	5.92	0.52	5.05e-8	QRS complex (12-leadsum);
THYM	cis	rs34638657	0.702	rs12599946	chr16:82199831	T/C	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.11	-0.64	1.73e-12	Lung adenocarcinoma;
THYM	cis	rs924712	0.677	rs2207025	chr6:54794882	A/C	cg04690482	chr6:54711388	FAM83B	0.45	5.39	0.48	5.07e-7	Breast cancer;
THYM	cis	rs113835537	0.529	rs3741360	chr11:66300348	A/G	cg24851651	chr11:66362959	CCS	0.71	4.84	0.44	4.96e-6	Airway imaging phenotypes;
THYM	cis	rs7828089	1.000	rs7837964	chr8:22264417	G/C	cg12081754	chr8:22256438	SLC39A14	0.6	5.26	0.48	8.69e-7	Verbal declarative memory;
THYM	cis	rs3733631	0.557	rs7655298	chr4:104671067	A/G	cg24090629	chr4:104641072	TACR3	-0.85	-4.47	-0.42	2.14e-5	Menarche (age at onset);
THYM	cis	rs17511627	0.808	rs7997849	chr13:26741617	G/C	cg13319468	chr13:27597730	NA	-0.7	-5.5	-0.49	3.14e-7	Alzheimer's disease;
THYM	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg08213375	chr14:104286397	PPP1R13B	0.5	6.09	0.53	2.39e-8	Schizophrenia;
THYM	cis	rs2797160	1.000	rs1935773	chr6:125996475	A/G	cg05901451	chr6:126070800	HEY2	-0.55	-4.67	-0.43	9.88e-6	Endometrial cancer;
THYM	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg01699819	chr7:1052092	C7orf50	-0.6	-5.09	-0.46	1.83e-6	Bronchopulmonary dysplasia;
THYM	cis	rs11792861	0.530	rs1772047	chr9:111679012	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.64	-5.01	-0.46	2.47e-6	Menarche (age at onset);
THYM	cis	rs755383	0.545	rs13295058	chr9:858735	A/G	cg14021170	chr9:826657	NA	0.45	4.98	0.45	2.84e-6	Testicular germ cell tumor;Testicular germ cell cancer;Testicular cancer;
THYM	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg07424592	chr7:64974309	NA	1.04	5.45	0.49	3.9e-7	Diabetic kidney disease;
THYM	cis	rs981844	0.775	rs62323979	chr4:154752935	T/C	cg09973105	chr4:154681532	RNF175	-0.62	-5.1	-0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.34	-0.48	6.24e-7	Monocyte percentage of white cells;
THYM	cis	rs6754311	0.593	rs2034276	chr2:136422171	A/T	cg04750100	chr2:136595281	LCT	0.56	5.89	0.52	5.87e-8	Mosquito bite size;
THYM	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17102423	0.964	rs11627859	chr14:65602384	G/A	cg11161011	chr14:65562177	MAX	-0.74	-6.52	-0.56	3.43e-9	Obesity-related traits;
THYM	cis	rs2562456	0.833	rs2650801	chr19:21635355	C/T	cg21751540	chr19:21541537	ZNF738	-0.81	-4.86	-0.45	4.55e-6	Pain;
THYM	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg08999081	chr20:33150536	PIGU	0.6	5.11	0.46	1.65e-6	Coronary artery disease;
THYM	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.45	-5.59	-0.5	2.16e-7	Monocyte percentage of white cells;
THYM	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg11871910	chr12:69753446	YEATS4	1.06	9.77	0.71	5.12e-16	Blood protein levels;
THYM	cis	rs9517302	0.615	rs3752974	chr13:99097827	T/C	cg22223119	chr13:99095684	FARP1	-1.12	-7.54	-0.61	2.78e-11	Obesity-related traits;
THYM	cis	rs3764563	1.000	rs8107240	chr19:15737392	A/G	cg20725493	chr19:15740067	CYP4F8	-1.02	-4.62	-0.43	1.2e-5	Inflammatory biomarkers;
THYM	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg10360139	chr7:1886902	MAD1L1	-0.61	-5.4	-0.48	4.86e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg22508957	chr16:3507546	NAT15	0.41	4.53	0.42	1.71e-5	Body mass index (adult);
THYM	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg26354017	chr1:205819088	PM20D1	-0.72	-5.69	-0.5	1.39e-7	Menarche (age at onset);
THYM	cis	rs9560113	0.509	rs28608633	chr13:112206880	G/A	cg15979348	chr13:112237479	NA	0.55	4.91	0.45	3.76e-6	Menarche (age at onset);
THYM	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg09703963	chr11:616879	IRF7;MUPCDH	-0.6	-4.67	-0.43	9.92e-6	Systemic lupus erythematosus;
THYM	cis	rs4849845	0.812	rs3931842	chr2:121039392	G/C	cg03575764	chr2:121493832	NA	-0.64	-4.78	-0.44	6.41e-6	Mean platelet volume;
THYM	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg14893161	chr1:205819251	PM20D1	0.82	7.8	0.62	7.91e-12	Monocyte percentage of white cells;
THYM	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs17407555	0.606	rs59871456	chr4:10014441	G/A	cg00071950	chr4:10020882	SLC2A9	-0.78	-6.15	-0.53	1.84e-8	Schizophrenia (age at onset);
THYM	cis	rs11209185	0.545	rs1926284	chr1:68446291	T/C	cg22082780	chr1:68452167	NA	0.52	6.02	0.53	3.27e-8	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg02398342	chr17:80708632	TBCD;FN3K	0.67	4.92	0.45	3.6e-6	Glycated hemoglobin levels;
THYM	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg21926883	chr2:100939477	LONRF2	-0.55	-4.99	-0.46	2.74e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3008870	1.000	rs12041926	chr1:67434602	A/G	cg02640540	chr1:67518911	SLC35D1	0.62	4.5	0.42	1.96e-5	Lymphocyte percentage of white cells;
THYM	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg01448562	chr3:133502909	NA	-0.84	-6.84	-0.57	7.57e-10	Iron status biomarkers;
THYM	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg12573674	chr2:1569213	NA	-1.16	-8.07	-0.64	2.18e-12	IgG glycosylation;
THYM	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg07423050	chr13:99094983	FARP1	-0.46	-5.57	-0.5	2.32e-7	Neuroticism;
THYM	cis	rs1403694	0.695	rs10439971	chr3:186434188	C/T	cg12454167	chr3:186435060	KNG1	0.51	7.04	0.59	2.94e-10	Blood protein levels;
THYM	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg23730037	chr7:158596552	ESYT2	-0.42	-4.51	-0.42	1.89e-5	Height;
THYM	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg08885076	chr2:99613938	TSGA10	0.57	5.28	0.48	8.05e-7	Chronic sinus infection;
THYM	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17102423	0.661	rs45604339	chr14:65543102	C/T	cg11161011	chr14:65562177	MAX	-0.84	-6.62	-0.56	2.1e-9	Obesity-related traits;
THYM	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg04362960	chr10:104952993	NT5C2	0.58	4.93	0.45	3.55e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7524258	0.934	rs6689453	chr1:7288384	C/T	cg07173049	chr1:7289937	CAMTA1	0.66	5.24	0.47	9.75e-7	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs4557020	0.904	rs10496031	chr2:54723203	A/C	cg11007406	chr2:54682859	SPTBN1	0.34	4.62	0.43	1.22e-5	Myopia (pathological);
THYM	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg25817165	chr18:72167213	CNDP2	-0.99	-7.58	-0.61	2.27e-11	Refractive error;
THYM	cis	rs2997447	0.653	rs56134135	chr1:26440718	A/T	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs6430585	0.528	rs309162	chr2:136690783	T/A	cg04750100	chr2:136595281	LCT	0.52	5.03	0.46	2.36e-6	Corneal structure;
THYM	cis	rs75920871	0.528	rs7108912	chr11:116925996	G/A	cg20608306	chr11:116969690	SIK3	-0.54	-6.01	-0.52	3.45e-8	Subjective well-being;
THYM	cis	rs4343996	0.902	rs4719894	chr7:3381789	C/T	cg21248987	chr7:3385318	SDK1	-0.4	-4.85	-0.45	4.87e-6	Motion sickness;
THYM	cis	rs9948	1.000	rs62152834	chr2:97504863	C/G	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.85	-0.45	4.73e-6	Erectile dysfunction and prostate cancer treatment;
THYM	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg20291162	chr17:40259547	DHX58	-0.7	-6.47	-0.55	4.18e-9	Fibrinogen levels;
THYM	cis	rs11785693	0.862	rs62491200	chr8:4998001	A/C	cg26367366	chr8:4980734	NA	1.21	5.9	0.52	5.46e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs4919687	0.550	rs12775883	chr10:104485301	G/A	cg04362960	chr10:104952993	NT5C2	0.59	4.52	0.42	1.78e-5	Colorectal cancer;
THYM	cis	rs10203711	0.933	rs10180937	chr2:239597184	A/G	cg14580085	chr2:239553406	NA	0.66	5.88	0.52	5.96e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11992162	0.550	rs61426048	chr8:11784956	A/G	cg21775007	chr8:11205619	TDH	-0.58	-4.48	-0.42	2.1e-5	Monocyte count;
THYM	cis	rs4383453	0.539	rs12631979	chr3:123097710	A/G	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs2463822	1.000	rs11231050	chr11:62131660	C/G	cg06239285	chr11:62104954	ASRGL1	-1.31	-6.98	-0.58	3.9e-10	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg00254258	chr1:3105189	PRDM16	0.65	5.57	0.5	2.32e-7	Migraine;
THYM	trans	rs12810016	0.667	rs34165699	chr12:83319424	T/G	cg04578774	chr11:44332664	ALX4	1.22	6.87	0.58	6.7e-10	Coronary artery aneurysm in Kawasaki disease;
THYM	cis	rs834811	0.796	rs2349456	chr7:135901545	G/T	cg01726295	chr7:135938950	NA	-0.68	-6.06	-0.53	2.68e-8	Post-traumatic stress disorder;
THYM	cis	rs3862030	0.839	rs2281880	chr10:104269217	G/A	cg00122347	chr10:104236741	TMEM180	0.48	7.33	0.6	7.69e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	trans	rs11722228	0.522	rs77691548	chr4:10136115	T/G	cg26043149	chr18:55253948	FECH	1.21	11.76	0.77	3.08e-20	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg18252515	chr7:66147081	NA	-0.65	-4.82	-0.44	5.35e-6	Aortic root size;
THYM	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg02398342	chr17:80708632	TBCD;FN3K	0.68	5.0	0.46	2.6e-6	Glycated hemoglobin levels;
THYM	cis	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg16898833	chr6:26189333	HIST1H4D	1.33	4.95	0.45	3.27e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg11663144	chr21:46675770	NA	-0.71	-9.92	-0.71	2.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6547741	1.000	rs1919125	chr2:27801403	C/G	cg27432699	chr2:27873401	GPN1	0.68	5.97	0.52	4.14e-8	Oral cavity cancer;
THYM	cis	rs800586	0.917	rs800509	chr8:116797530	A/C	cg04656070	chr8:116661063	TRPS1	0.49	4.7	0.43	8.9e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg10295955	chr4:187884368	NA	-1.22	-17.54	-0.87	1.51e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4646404	0.509	rs744925	chr17:17467501	G/A	cg11245205	chr17:17398264	RASD1	-0.42	-4.82	-0.44	5.38e-6	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
THYM	cis	rs944722	0.511	rs2297520	chr17:26108040	T/C	cg07704981	chr17:26127537	NOS2	-0.6	-5.59	-0.5	2.16e-7	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg16989719	chr2:238392110	NA	-0.64	-5.54	-0.49	2.73e-7	Prostate cancer;
THYM	cis	rs7010267	0.692	rs2073618	chr8:119964052	G/C	cg17171407	chr8:119960777	TNFRSF11B	0.55	4.49	0.42	1.98e-5	Total body bone mineral density (age 45-60);
THYM	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg00024416	chr22:24240387	NA	-0.63	-7.0	-0.58	3.54e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg08188268	chr10:116634841	FAM160B1	-0.25	-4.51	-0.42	1.86e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs1878931	0.517	rs17685105	chr16:3413749	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.92	-8.01	-0.64	2.83e-12	Body mass index (adult);
THYM	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.58	0.56	2.61e-9	Total body bone mineral density;
THYM	cis	rs289828	0.579	rs10201139	chr2:152159193	C/G	cg05960677	chr2:152117363	RBM43	0.69	6.56	0.56	2.86e-9	Blood protein levels;
THYM	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.06	9.59	0.7	1.27e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg04944784	chr2:26401820	FAM59B	0.65	5.01	0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg26924012	chr15:45694286	SPATA5L1	1.06	9.17	0.69	9.7e-15	Homoarginine levels;
THYM	cis	rs56079296	0.929	rs28391435	chr5:121353364	G/A	cg05256605	chr5:121412184	LOX	0.59	4.47	0.42	2.18e-5	Coronary artery disease;
THYM	cis	rs10895275	0.625	rs11225153	chr11:102042299	A/G	cg24447756	chr11:102105824	NA	0.53	4.82	0.44	5.35e-6	Migraine;
THYM	cis	rs58799304	0.618	rs35997354	chr1:156071806	G/A	cg15685922	chr1:156045208	MEX3A	-0.44	-4.47	-0.42	2.13e-5	Ischemic stroke;
THYM	cis	rs12310956	0.532	rs11608842	chr12:33951121	C/T	cg10856724	chr12:34555212	NA	-0.73	-6.92	-0.58	5.17e-10	Morning vs. evening chronotype;
THYM	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg18252515	chr7:66147081	NA	0.64	4.69	0.43	9.21e-6	Aortic root size;
THYM	cis	rs17539620	0.624	rs871068	chr6:154837514	C/A	cg20019720	chr6:154832845	CNKSR3	0.47	4.79	0.44	6.17e-6	Lipoprotein (a) levels;
THYM	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.82	-4.55	-0.42	1.56e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg23187316	chr7:1099788	C7orf50	0.48	5.45	0.49	3.98e-7	Longevity;Endometriosis;
THYM	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg16486109	chr11:613632	IRF7	0.47	5.59	0.5	2.19e-7	Systemic lupus erythematosus;
THYM	cis	rs2310173	0.651	rs10198135	chr2:102674631	G/A	cg12682972	chr2:102444908	MAP4K4	-0.42	-4.5	-0.42	1.9e-5	Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Ulcerative colitis;
THYM	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg25358565	chr5:93447407	FAM172A	1.32	11.24	0.76	3.75e-19	Diabetic retinopathy;
THYM	cis	rs11771526	0.892	rs76035550	chr7:32371359	G/A	cg13207630	chr7:32358064	NA	1.06	6.2	0.54	1.44e-8	Body mass index;
THYM	cis	rs12142240	0.698	rs72679807	chr1:46846490	G/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg08772003	chr10:104629869	AS3MT	0.68	6.44	0.55	4.77e-9	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11771526	1.000	rs11764617	chr7:32339102	T/C	cg27532318	chr7:32358331	NA	0.89	5.46	0.49	3.85e-7	Body mass index;
THYM	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg01966878	chr4:90757139	SNCA	-0.56	-4.46	-0.42	2.26e-5	Neuroticism;
THYM	cis	rs6665290	0.901	rs7535826	chr1:227213968	A/C	cg10327440	chr1:227177885	CDC42BPA	1.03	13.27	0.81	2.33e-23	Myeloid white cell count;
THYM	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg24578937	chr1:2090814	PRKCZ	0.81	8.54	0.66	2.22e-13	Height;
THYM	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg15691649	chr6:25882328	NA	-0.78	-6.62	-0.56	2.13e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7583236	0.500	rs6728352	chr2:70343432	G/A	cg19638749	chr2:70312615	NA	0.84	5.03	0.46	2.3e-6	Obesity-related traits;
THYM	cis	rs3771570	1.000	rs62193205	chr2:242316512	C/T	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg21280719	chr6:42927975	GNMT	0.5	6.57	0.56	2.71e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.98	0.45	2.85e-6	Obesity-related traits;
THYM	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg01699819	chr7:1052092	C7orf50	-0.87	-7.92	-0.63	4.5e-12	Bronchopulmonary dysplasia;
THYM	cis	rs6430585	0.528	rs3112496	chr2:136711064	C/T	cg04750100	chr2:136595281	LCT	0.54	5.46	0.49	3.78e-7	Corneal structure;
THYM	cis	rs6575793	1.000	rs8006176	chr14:101033288	A/G	cg13673514	chr14:101035818	BEGAIN	-0.51	-4.93	-0.45	3.55e-6	Menarche (age at onset);
THYM	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg00684032	chr4:1343700	KIAA1530	-0.68	-5.77	-0.51	1e-7	Obesity-related traits;
THYM	cis	rs67072384	1.000	rs56693670	chr11:72445143	G/T	cg01380194	chr11:72452482	ARAP1	-0.85	-4.84	-0.45	4.92e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs713587	0.967	rs6749422	chr2:25150011	C/G	cg15423357	chr2:25149977	NA	0.72	8.18	0.64	1.28e-12	Body mass index in non-asthmatics;
THYM	cis	rs79149102	0.579	rs59303424	chr15:75370014	G/A	cg17294928	chr15:75287854	SCAMP5	-0.82	-4.47	-0.42	2.17e-5	Lung cancer;
THYM	cis	rs3796352	0.527	rs11715498	chr3:52943551	G/C	cg07884673	chr3:53033167	SFMBT1	0.92	5.5	0.49	3.17e-7	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs1065656	0.553	rs344359	chr16:1838640	T/C	cg14074117	chr16:1909714	C16orf73	0.6	4.59	0.43	1.37e-5	Insulin-like growth factors;
THYM	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-11.55	-0.76	8.36e-20	Height;
THYM	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg04414720	chr1:150670196	GOLPH3L	0.62	4.71	0.44	8.35e-6	Tonsillectomy;
THYM	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg06618935	chr21:46677482	NA	-0.95	-9.03	-0.68	1.91e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs977987	0.806	rs12599361	chr16:75434973	A/T	cg03315344	chr16:75512273	CHST6	0.76	6.24	0.54	1.24e-8	Dupuytren's disease;
THYM	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg14664628	chr15:75095509	CSK	-1.08	-9.57	-0.7	1.35e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs1912528	0.783	rs769658	chr4:140872682	C/T	cg11128457	chr4:140864437	MAML3	0.48	5.07	0.46	1.95e-6	Educational attainment (years of education);
THYM	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg01416388	chr22:39784598	NA	-0.94	-8.89	-0.67	3.85e-14	Intelligence (multi-trait analysis);
THYM	cis	rs4788570	0.697	rs9635524	chr16:71804956	C/G	cg06353428	chr16:71660113	MARVELD3	1.41	8.69	0.67	1.03e-13	Intelligence (multi-trait analysis);
THYM	cis	rs10791323	0.628	rs4937838	chr11:133733406	T/C	cg03690763	chr11:133734501	NA	-0.65	-5.49	-0.49	3.35e-7	Childhood ear infection;
THYM	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg23711669	chr6:146136114	FBXO30	0.98	10.66	0.74	6.54e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg24375607	chr4:120327624	NA	0.66	5.35	0.48	6.01e-7	Corneal astigmatism;
THYM	cis	rs4792901	0.802	rs2271958	chr17:41599383	C/T	cg21940313	chr17:41620911	ETV4	-0.54	-5.0	-0.46	2.67e-6	Dupuytren's disease;
THYM	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg04282206	chr17:62833786	PLEKHM1P	-0.82	-8.22	-0.64	1.02e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.67	-5.18	-0.47	1.22e-6	Tonsillectomy;
THYM	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg03709012	chr19:19516395	GATAD2A	-0.83	-7.12	-0.59	2.02e-10	Tonsillectomy;
THYM	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Bladder cancer;
THYM	cis	rs17253792	0.822	rs17253744	chr14:56161950	C/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg16031515	chr1:205743344	RAB7L1	-0.68	-7.08	-0.59	2.53e-10	Menarche (age at onset);
THYM	cis	rs2456568	0.548	rs6483281	chr11:93661840	G/C	cg17595323	chr11:93583763	C11orf90	-0.52	-5.52	-0.49	2.98e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs4919087	1.000	rs11189127	chr10:99079023	G/A	cg19453742	chr10:98862320	SLIT1	-0.62	-5.11	-0.46	1.67e-6	Monocyte count;
THYM	cis	rs17741873	0.779	rs3812634	chr10:75594486	C/T	cg18802414	chr10:75757814	VCL	0.88	4.5	0.42	1.93e-5	Paclitaxel disposition in epithelial ovarian cancer;
THYM	cis	rs11039798	1.000	rs12223271	chr11:48417420	G/C	cg24672777	chr11:48374446	OR4C45	-1.16	-7.24	-0.6	1.16e-10	Axial length;
THYM	cis	rs4523957	0.583	rs8068508	chr17:2047624	A/G	cg16513277	chr17:2031491	SMG6	-1.02	-9.49	-0.7	2.03e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs17125944	0.505	rs17125762	chr14:53289288	A/G	cg00686598	chr14:53173677	PSMC6	1.37	6.64	0.56	1.91e-9	Alzheimer's disease (late onset);
THYM	cis	rs490234	0.812	rs13288963	chr9:128295198	G/A	cg14078157	chr9:128172775	NA	-0.65	-5.28	-0.48	8.05e-7	Mean arterial pressure;
THYM	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg01299579	chr2:10830716	NOL10	-0.5	-4.79	-0.44	6.23e-6	Prostate cancer;
THYM	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-4.62	-0.43	1.22e-5	Longevity;
THYM	cis	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg10856724	chr12:34555212	NA	-0.79	-7.37	-0.6	6.29e-11	Morning vs. evening chronotype;
THYM	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg06028808	chr11:68637592	NA	0.71	7.61	0.62	1.99e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg05368731	chr17:41323189	NBR1	1.19	10.4	0.73	2.28e-17	Menopause (age at onset);
THYM	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg06521331	chr12:34319734	NA	0.98	8.71	0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs2109514	0.840	rs13223362	chr7:116137006	G/A	cg12739419	chr7:116140593	CAV2	-0.48	-4.61	-0.43	1.24e-5	Prevalent atrial fibrillation;
THYM	cis	rs1788820	0.917	rs1652349	chr18:21142734	A/T	cg14672496	chr18:21087552	C18orf8	0.81	6.51	0.56	3.49e-9	Body mass index;
THYM	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg25358565	chr5:93447407	FAM172A	1.36	10.94	0.75	1.67e-18	Diabetic retinopathy;
THYM	cis	rs7614311	0.681	rs3774708	chr3:63881549	A/C	cg22134162	chr3:63841271	THOC7	-0.58	-7.15	-0.59	1.79e-10	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs7512552	0.839	rs1627235	chr1:150358858	C/T	cg15654264	chr1:150340011	RPRD2	0.45	5.2	0.47	1.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7017697	1.000	rs7017697	chr8:19685909	G/T	cg03894339	chr8:19674705	INTS10	-0.55	-4.83	-0.44	5.29e-6	Breast cancer;
THYM	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg06808227	chr14:105710500	BRF1	-1.03	-8.94	-0.68	3.05e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	7.48	0.61	3.78e-11	Smoking behavior;
THYM	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg23791538	chr6:167370224	RNASET2	-0.76	-5.99	-0.52	3.67e-8	Crohn's disease;
THYM	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg10661904	chr17:79619235	PDE6G	-0.54	-4.79	-0.44	6.25e-6	Eye color traits;
THYM	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg06766960	chr11:133703094	NA	0.54	4.71	0.44	8.41e-6	Childhood ear infection;
THYM	cis	rs2131877	0.830	rs62290344	chr3:194849620	T/C	cg21937377	chr3:194868750	C3orf21	0.42	4.89	0.45	4.03e-6	Non-small cell lung cancer;
THYM	cis	rs1346	0.580	rs10750763	chr11:65368434	A/G	cg27068330	chr11:65405492	SIPA1	0.72	4.7	0.43	8.7e-6	Vertical cup-disc ratio;Optic cup area;
THYM	cis	rs4631830	0.863	rs2843549	chr10:51521247	C/A	cg10326726	chr10:51549505	MSMB	-0.59	-5.86	-0.52	6.68e-8	Prostate-specific antigen levels;
THYM	cis	rs16912285	0.688	rs7109312	chr11:24338974	G/A	ch.11.24196551F	chr11:24239977	NA	0.87	5.81	0.51	8.26e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12379764	chr21:47803548	PCNT	0.64	4.52	0.42	1.76e-5	Testicular germ cell tumor;
THYM	cis	rs2085601	0.566	rs60535906	chr4:89987607	C/T	cg17769793	chr4:89976368	FAM13A	0.59	6.58	0.56	2.55e-9	Hair greying;
THYM	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg06219351	chr7:158114137	PTPRN2	0.72	7.04	0.59	3e-10	Calcium levels;
THYM	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg12908607	chr1:44402522	ARTN	-0.58	-5.01	-0.46	2.51e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7917772	0.690	rs11191369	chr10:104457456	G/A	cg00122347	chr10:104236741	TMEM180	-0.43	-5.77	-0.51	1e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg27534772	chr1:16042836	PLEKHM2	0.53	6.07	0.53	2.6e-8	Systolic blood pressure;
THYM	cis	rs2272306	0.636	rs7298527	chr12:53531372	A/T	cg13236315	chr12:53645720	MFSD5	0.88	4.61	0.43	1.24e-5	Obesity-related traits;
THYM	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg17691542	chr6:26056736	HIST1H1C	0.81	5.21	0.47	1.08e-6	Iron status biomarkers;
THYM	cis	rs763014	0.898	rs4984669	chr16:624713	C/T	cg09263875	chr16:632152	PIGQ	0.71	6.15	0.53	1.85e-8	Height;
THYM	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.75	-4.8	-0.44	5.78e-6	Mean platelet volume;
THYM	cis	rs9419702	0.639	rs9419624	chr10:133534822	G/A	cg04492858	chr10:133558786	NA	0.44	4.57	0.42	1.48e-5	Survival in rectal cancer;
THYM	cis	rs7262634	1.000	rs11905932	chr20:45828254	T/G	cg18599129	chr20:45867857	ZMYND8	0.86	4.94	0.45	3.33e-6	Response to protease inhibitor treatment in hepatitis c (bilirubin toxicity);
THYM	cis	rs4589258	0.933	rs1792610	chr11:90432795	T/A	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg17480646	chr11:65405466	SIPA1	-0.94	-8.85	-0.67	4.72e-14	Acne (severe);
THYM	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg23428387	chr22:49814324	NA	-0.55	-5.65	-0.5	1.65e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg08885076	chr2:99613938	TSGA10	0.65	5.96	0.52	4.31e-8	Chronic sinus infection;
THYM	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg11247378	chr22:39784982	NA	-1.01	-9.58	-0.7	1.32e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs1535500	0.935	rs11753141	chr6:39283083	G/A	cg00012638	chr6:39280541	KCNK17	0.61	8.08	0.64	2.06e-12	Type 2 diabetes;
THYM	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg23743428	chr13:21893420	NA	-0.69	-6.28	-0.54	1.02e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg04034577	chr2:241836375	C2orf54	-0.44	-8.16	-0.64	1.35e-12	Urinary metabolites;
THYM	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg24503407	chr1:205819492	PM20D1	-0.6	-4.67	-0.43	9.85e-6	Prostate-specific antigen levels;
THYM	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs9399401	0.601	rs262130	chr6:142853486	C/T	cg04461802	chr6:142623433	GPR126	0.57	5.09	0.46	1.81e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	4.55	0.42	1.61e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg10792982	chr14:105748885	BRF1	0.72	7.38	0.6	5.93e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg05182265	chr7:156933206	UBE3C	-0.7	-9.62	-0.7	1.06e-15	Body mass index;
THYM	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg18806716	chr10:30721971	MAP3K8	-0.49	-4.63	-0.43	1.16e-5	Inflammatory bowel disease;
THYM	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg03388043	chr17:80084554	CCDC57	0.69	5.98	0.52	3.85e-8	Life satisfaction;
THYM	cis	rs526231	0.543	rs26819	chr5:102529401	G/A	cg23492399	chr5:102201601	PAM	-0.71	-5.33	-0.48	6.54e-7	Primary biliary cholangitis;
THYM	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.62e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg18904891	chr8:8559673	CLDN23	0.64	4.99	0.46	2.73e-6	Neuroticism;
THYM	cis	rs4482178	0.850	rs1764960	chr13:86260359	T/C	cg25308322	chr13:86268291	NA	0.69	4.81	0.44	5.76e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs7246657	0.882	rs28623164	chr19:37913453	G/A	cg22634378	chr19:37742834	NA	0.62	5.18	0.47	1.22e-6	Coronary artery calcification;
THYM	trans	rs8073060	0.586	rs225280	chr17:33976296	C/T	cg19694781	chr19:47549865	TMEM160	-1.0	-8.37	-0.65	5.05e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg06191203	chr2:152266755	RIF1	-0.73	-5.02	-0.46	2.46e-6	Lung cancer;
THYM	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg23574427	chr4:122746245	BBS7;CCNA2	-0.56	-5.08	-0.46	1.88e-6	Type 2 diabetes;
THYM	cis	rs35264875	1.000	rs7110274	chr11:68842704	A/G	cg01993067	chr11:68851601	TPCN2	1.0	4.68	0.43	9.62e-6	Blond vs. brown hair color;
THYM	cis	rs6980334	1.000	rs6980334	chr7:137788492	A/G	cg03464514	chr7:137028442	PTN	-0.56	-4.67	-0.43	9.74e-6	Blood metabolite ratios;
THYM	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg08508325	chr11:3079039	CARS	-0.5	-6.42	-0.55	5.3e-9	Longevity;
THYM	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg21385522	chr1:16154831	NA	0.74	5.44	0.49	4.13e-7	Dilated cardiomyopathy;
THYM	cis	rs2919009	0.551	rs7080781	chr10:122721684	A/G	cg26518861	chr10:122708898	NA	-0.62	-4.92	-0.45	3.68e-6	Obesity-related traits;
THYM	cis	rs3126085	0.877	rs868304	chr1:152178568	G/A	cg10321714	chr1:152280068	FLG	0.68	4.95	0.45	3.2e-6	Atopic dermatitis;
THYM	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg15501526	chr10:2543763	NA	0.78	7.54	0.61	2.78e-11	Age-related hearing impairment;
THYM	cis	rs4642101	0.662	rs1969154	chr3:12829156	A/G	cg05775895	chr3:12838266	CAND2	0.81	6.98	0.58	3.99e-10	QRS complex (12-leadsum);
THYM	cis	rs9560113	0.597	rs1163644	chr13:112241223	C/T	cg10483660	chr13:112241077	NA	-0.67	-8.01	-0.64	2.8e-12	Menarche (age at onset);
THYM	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg24846343	chr22:24311635	DDTL	0.49	6.81	0.57	8.75e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2282930	0.512	rs58587127	chr7:50712441	C/G	cg08586669	chr7:50727761	GRB10	0.31	4.61	0.43	1.27e-5	Bone mineral density;
THYM	cis	rs652260	1.000	rs652260	chr19:7900562	C/T	cg15974673	chr19:7926970	EVI5L	-0.53	-4.81	-0.44	5.57e-6	Menarche (age at onset);
THYM	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg27221674	chr7:232095	FAM20C	-0.48	-4.58	-0.42	1.43e-5	Longevity;Endometriosis;
THYM	cis	rs4662945	0.932	rs10174187	chr2:130200925	A/G	cg05903289	chr2:130345205	NA	-0.57	-5.56	-0.5	2.5e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs7216064	1.000	rs6504543	chr17:65837659	T/C	cg12091567	chr17:66097778	LOC651250	-0.72	-5.0	-0.46	2.59e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs12681287	0.752	rs4472493	chr8:87251914	C/T	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs7827545	0.644	rs3739427	chr8:135524938	T/C	cg17885191	chr8:135476712	NA	-0.75	-5.66	-0.5	1.61e-7	Hypertension (SNP x SNP interaction);
THYM	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg06481639	chr22:41940642	POLR3H	-0.77	-5.37	-0.48	5.67e-7	Vitiligo;
THYM	cis	rs2290159	0.800	rs7636754	chr3:12678725	C/G	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg00376283	chr12:123451042	ABCB9	0.92	7.04	0.59	2.94e-10	Platelet count;
THYM	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.51	5.32	0.48	6.93e-7	Schizophrenia;
THYM	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg06850241	chr22:41845214	NA	0.53	4.56	0.42	1.54e-5	Vitiligo;
THYM	cis	rs17744026	0.586	rs12285115	chr11:123764717	C/T	cg00079598	chr11:123676903	OR6M1	-0.49	-4.49	-0.42	2e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs73198271	0.740	rs10092600	chr8:8649023	A/G	cg15556689	chr8:8085844	FLJ10661	-0.75	-4.92	-0.45	3.57e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs2463822	0.764	rs7125402	chr11:62097259	C/T	cg06239285	chr11:62104954	ASRGL1	1.44	7.77	0.62	9.14e-12	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2806561	0.765	rs1612905	chr1:23510023	G/T	cg12483005	chr1:23474871	LUZP1	0.59	6.31	0.54	9.03e-9	Height;
THYM	cis	rs1021993	1.000	rs2660636	chr1:209481868	C/G	cg06155620	chr1:209527581	NA	0.58	4.67	0.43	9.97e-6	Gut microbiome composition (winter);
THYM	cis	rs7512552	0.809	rs1694377	chr1:150293153	A/G	cg15654264	chr1:150340011	RPRD2	0.45	5.25	0.47	9.45e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg16615211	chr3:44902933	MIR564;TMEM42	0.47	5.17	0.47	1.27e-6	Depressive symptoms;
THYM	cis	rs28829049	0.597	rs1009806	chr1:19500551	T/C	cg13387374	chr1:19411106	UBR4	0.67	4.96	0.45	3.08e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg26031613	chr14:104095156	KLC1	0.79	5.22	0.47	1.06e-6	Body mass index;
THYM	cis	rs2836633	0.895	rs62217513	chr21:40024416	A/T	cg05519781	chr21:40033154	ERG	0.75	7.12	0.59	2.06e-10	Coronary artery disease;
THYM	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg20503657	chr10:835505	NA	1.01	5.76	0.51	1.04e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2067615	0.524	rs4964186	chr12:107080235	C/T	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	cis	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg19677267	chr1:26645161	CD52;UBXN11	0.49	4.49	0.42	2.04e-5	Obesity-related traits;
THYM	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg08975724	chr8:8085496	FLJ10661	0.64	5.21	0.47	1.07e-6	Systolic blood pressure;
THYM	cis	rs62435770	1.000	rs62433598	chr6:169522506	A/G	cg07652237	chr6:170125491	PHF10	0.54	4.82	0.44	5.48e-6	Loneliness;
THYM	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg11764359	chr7:65958608	NA	-0.82	-6.6	-0.56	2.29e-9	Aortic root size;
THYM	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg03983476	chr2:10830698	NOL10	0.61	5.82	0.51	7.94e-8	Prostate cancer;
THYM	cis	rs7638995	0.941	rs1995663	chr3:69182974	G/A	cg26574240	chr3:69171822	LMOD3	-0.62	-5.04	-0.46	2.2e-6	Alzheimer's disease (late onset);
THYM	cis	rs4363385	0.818	rs2651413	chr1:153012068	T/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs2456568	0.803	rs10831141	chr11:93640728	C/T	cg17347335	chr11:93583973	C11orf90	-0.48	-4.63	-0.43	1.18e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg07424592	chr7:64974309	NA	-0.99	-5.15	-0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	5.99	0.52	3.67e-8	Platelet count;
THYM	cis	rs758324	0.732	rs2550973	chr5:131511141	A/T	cg16205897	chr5:131564050	P4HA2	0.57	4.86	0.45	4.56e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs12681287	0.604	rs41469550	chr8:87406544	G/T	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs4888262	0.545	rs7184754	chr16:74667864	C/T	cg01733217	chr16:74700730	RFWD3	0.88	9.41	0.69	2.97e-15	Testicular germ cell tumor;
THYM	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg20887711	chr4:1340912	KIAA1530	-0.69	-6.0	-0.52	3.61e-8	Obesity-related traits;
THYM	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs9649213	0.593	rs2240349	chr7:97984663	C/T	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11997175	0.562	rs72630962	chr8:33761447	C/T	ch.8.33884649F	chr8:33765107	NA	0.79	5.51	0.49	3.1e-7	Body mass index;
THYM	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.71	0.57	1.39e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg20290983	chr6:43655470	MRPS18A	1.44	16.02	0.85	9.41e-29	IgG glycosylation;
THYM	cis	rs2235642	0.964	rs2745181	chr16:1577056	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.61	-5.06	-0.46	2.07e-6	Coronary artery disease;
THYM	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg12292205	chr6:26970375	C6orf41	-0.64	-5.19	-0.47	1.19e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg12311346	chr5:56204834	C5orf35	0.62	4.71	0.43	8.56e-6	Initial pursuit acceleration;
THYM	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg11752832	chr7:134001865	SLC35B4	0.68	4.63	0.43	1.14e-5	Mean platelet volume;
THYM	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg10053473	chr17:62856997	LRRC37A3	0.92	7.34	0.6	7.17e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg09307838	chr4:120376055	NA	0.78	5.62	0.5	1.92e-7	Corneal astigmatism;
THYM	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.56	-5.48	-0.49	3.54e-7	Crohn's disease;
THYM	cis	rs11696501	0.688	rs6104295	chr20:44326917	C/T	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg03929089	chr4:120376271	NA	-0.99	-12.15	-0.78	4.84e-21	Height;
THYM	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg08859206	chr1:53392774	SCP2	0.81	8.47	0.66	3e-13	Monocyte count;
THYM	cis	rs8070128	0.688	rs59304093	chr17:17875407	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	6.7	0.57	1.48e-9	Total body bone mineral density;
THYM	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg23711669	chr6:146136114	FBXO30	-0.96	-10.01	-0.72	1.54e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg26597838	chr10:835615	NA	0.9	5.32	0.48	6.92e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs10929159	0.964	rs3754659	chr2:236950634	C/T	cg14895183	chr2:236924282	AGAP1	-0.53	-4.48	-0.42	2.05e-5	Parkinson's disease;
THYM	cis	rs1775715	0.707	rs1541261	chr10:32179523	G/A	cg04359828	chr10:32216031	ARHGAP12	0.39	5.14	0.47	1.45e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs7727544	0.545	rs743564	chr5:131410879	T/C	cg00255919	chr5:131827918	IRF1	-0.38	-4.49	-0.42	2.04e-5	Blood metabolite levels;
THYM	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2777491	0.707	rs1622914	chr15:41789212	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.04	-11.06	-0.75	9.08e-19	Ulcerative colitis;
THYM	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.76	5.8	0.51	8.8e-8	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg03433033	chr1:76189801	ACADM	0.77	10.21	0.72	6.01e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg19746536	chr19:49375674	PPP1R15A	0.81	4.47	0.42	2.12e-5	Red cell distribution width;
THYM	cis	rs4589258	0.897	rs7112861	chr11:90416679	A/G	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.98	-10.44	-0.73	1.88e-17	Chronic sinus infection;
THYM	cis	rs6496667	1.000	rs3803539	chr15:90891982	A/G	cg22089800	chr15:90895588	ZNF774	0.87	5.22	0.47	1.04e-6	Rheumatoid arthritis;
THYM	cis	rs35079168	0.735	rs3118541	chr9:137307147	C/T	cg00753924	chr9:137298813	RXRA	-0.43	-4.45	-0.42	2.31e-5	Intelligence;
THYM	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs10037758	0.504	rs257900	chr5:128315174	G/C	cg02841155	chr5:128301328	SLC27A6	-0.5	-4.86	-0.45	4.54e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7113850	0.541	rs80336897	chr11:24224545	G/T	ch.11.24196551F	chr11:24239977	NA	1.03	5.41	0.49	4.67e-7	Bone fracture in osteoporosis;
THYM	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg05872129	chr22:39784769	NA	-1.07	-10.58	-0.74	9.68e-18	Intelligence (multi-trait analysis);
THYM	cis	rs1267303	0.642	rs61783087	chr1:46999955	T/C	cg16387850	chr1:46982889	NA	-0.45	-5.49	-0.49	3.34e-7	Monobrow;
THYM	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg20203395	chr5:56204925	C5orf35	-0.66	-4.62	-0.43	1.22e-5	Initial pursuit acceleration;
THYM	cis	rs2797160	1.000	rs6933302	chr6:126016951	T/C	cg16306078	chr6:126000798	NA	0.54	5.56	0.5	2.5e-7	Endometrial cancer;
THYM	cis	rs4930776	0.838	rs406430	chr12:5753920	C/T	cg02086166	chr12:5775618	ANO2	-0.58	-5.37	-0.48	5.68e-7	Plasma clusterin levels;
THYM	cis	rs1003719	0.612	rs2835652	chr21:38557408	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs3136739	0.867	rs10091617	chr8:42126549	C/T	cg12091331	chr8:42065314	PLAT	-0.71	-4.74	-0.44	7.62e-6	Plasma plasminogen activator levels;
THYM	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg17366294	chr4:99064904	C4orf37	0.5	5.71	0.51	1.29e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg09260853	chr1:2094483	PRKCZ	0.46	4.77	0.44	6.66e-6	Height;
THYM	cis	rs1568889	1.000	rs9783375	chr11:28033667	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	4.63	0.43	1.15e-5	Bipolar disorder;
THYM	cis	rs6430585	0.528	rs614193	chr2:136653925	A/T	cg07169764	chr2:136633963	MCM6	0.97	9.05	0.68	1.73e-14	Corneal structure;
THYM	cis	rs3925075	1.000	rs4889543	chr16:31340216	C/T	cg02846316	chr16:31340340	ITGAM	0.58	6.06	0.53	2.69e-8	IgA nephropathy;
THYM	cis	rs7558911	0.801	rs7576306	chr2:202074528	A/G	cg12105450	chr2:202048100	CASP10	0.53	4.78	0.44	6.29e-6	Chronic lymphocytic leukemia;
THYM	cis	rs11608355	0.960	rs11066526	chr12:109854476	G/C	cg10504392	chr12:110044639	NA	0.67	6.23	0.54	1.29e-8	Neuroticism;
THYM	cis	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg18512352	chr11:47633146	NA	-0.38	-4.52	-0.42	1.75e-5	HDL cholesterol;
THYM	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg12386194	chr3:101231763	SENP7	0.68	5.09	0.46	1.8e-6	Colorectal cancer;
THYM	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg12165864	chr7:66369176	NA	-0.63	-5.01	-0.46	2.51e-6	Aortic root size;
THYM	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg18252515	chr7:66147081	NA	-0.72	-5.6	-0.5	2.03e-7	Aortic root size;
THYM	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg10589385	chr1:150898437	SETDB1	-0.64	-5.35	-0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg04944784	chr2:26401820	FAM59B	-1.09	-8.74	-0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	5.72	0.51	1.23e-7	Platelet count;
THYM	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg06713675	chr4:122721982	EXOSC9	-0.86	-9.81	-0.71	4.29e-16	Type 2 diabetes;
THYM	cis	rs11225247	0.881	rs12282486	chr11:102253554	C/G	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2071518	0.715	rs4123837	chr8:120427856	A/G	cg15718811	chr8:120427810	NOV	0.52	4.7	0.43	8.84e-6	Pulse pressure;Blood pressure;
THYM	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.95	-8.69	-0.67	1.06e-13	Body mass index (adult);
THYM	cis	rs7072216	0.763	rs6584200	chr10:100170037	A/G	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03576123	chr11:487126	PTDSS2	-1.29	-6.4	-0.55	5.87e-9	Body mass index;
THYM	cis	rs7191439	0.589	rs11076699	chr16:88756812	A/C	cg27087555	chr16:88793112	FAM38A	1.2	5.32	0.48	6.82e-7	Plateletcrit;
THYM	cis	rs240764	0.853	rs10457808	chr6:100979506	A/T	cg21058520	chr6:100914733	NA	0.57	5.09	0.46	1.8e-6	Neuroticism;
THYM	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13732083	chr21:47605072	C21orf56	0.67	4.65	0.43	1.07e-5	Testicular germ cell tumor;
THYM	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg03188948	chr7:1209495	NA	0.91	6.98	0.58	4.01e-10	Longevity;Endometriosis;
THYM	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg08109568	chr15:31115862	NA	0.54	5.23	0.47	1.02e-6	Huntington's disease progression;
THYM	cis	rs255428	0.522	rs589802	chr5:62860977	A/G	cg13713523	chr5:63802877	RGS7BP	0.55	4.68	0.43	9.57e-6	Major depressive disorder;
THYM	cis	rs17253792	0.822	rs10148122	chr14:56146694	G/T	cg01858014	chr14:56050164	KTN1	-1.06	-4.54	-0.42	1.66e-5	Putamen volume;
THYM	cis	rs7542375	0.534	rs12131897	chr1:221044966	T/C	cg16008148	chr1:221062819	NA	0.45	4.62	0.43	1.19e-5	Obesity-related traits;
THYM	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs5758511	0.689	rs62240864	chr22:42563889	C/T	cg22189786	chr22:42395067	WBP2NL	0.64	4.59	0.43	1.34e-5	Birth weight;
THYM	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg11764359	chr7:65958608	NA	0.87	7.45	0.61	4.16e-11	Aortic root size;
THYM	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.0	7.33	0.6	7.68e-11	Colorectal cancer;
THYM	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg03388043	chr17:80084554	CCDC57	-0.7	-5.85	-0.51	6.95e-8	Life satisfaction;
THYM	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg00024416	chr22:24240387	NA	0.63	6.9	0.58	5.73e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	trans	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg10856724	chr12:34555212	NA	-0.9	-8.53	-0.66	2.28e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs995000	0.535	rs12239736	chr1:63085997	T/A	cg06896770	chr1:63153194	DOCK7	0.96	7.76	0.62	9.57e-12	Triglyceride levels;
THYM	cis	rs28476539	0.640	rs3733229	chr4:83552764	G/A	cg10249074	chr4:83542146	C4orf11	-0.64	-5.06	-0.46	2.03e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg09060608	chr5:178986726	RUFY1	0.58	6.26	0.54	1.09e-8	Lung cancer;
THYM	cis	rs12887734	0.546	rs4906376	chr14:104272165	A/C	cg08213375	chr14:104286397	PPP1R13B	0.47	4.97	0.45	3e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs870825	0.860	rs2705895	chr4:185598404	C/T	cg04058563	chr4:185651563	MLF1IP	-0.95	-6.98	-0.58	3.88e-10	Blood protein levels;
THYM	trans	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg25214090	chr10:38739885	LOC399744	0.86	7.53	0.61	2.86e-11	Corneal astigmatism;
THYM	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg19318889	chr4:1322082	MAEA	0.63	5.45	0.49	3.93e-7	Longevity;
THYM	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg10117171	chr1:25599238	RHD	-0.67	-5.0	-0.46	2.65e-6	Erythrocyte sedimentation rate;
THYM	cis	rs7953249	0.594	rs11065384	chr12:121423285	T/C	cg02403541	chr12:121454288	C12orf43	-0.79	-7.09	-0.59	2.31e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs4654899	0.802	rs1530946	chr1:21182540	A/G	cg01072550	chr1:21505969	NA	0.7	6.41	0.55	5.55e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs189798	0.807	rs12785	chr8:8994936	A/T	cg06636001	chr8:8085503	FLJ10661	0.71	5.59	0.5	2.18e-7	Myopia (pathological);
THYM	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg15691649	chr6:25882328	NA	-0.77	-5.92	-0.52	5e-8	Urate levels;
THYM	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg18305652	chr10:134549665	INPP5A	0.88	8.38	0.65	4.68e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg09354556	chr3:47051341	NA	0.45	4.58	0.43	1.41e-5	Colorectal cancer;
THYM	cis	rs4242434	0.646	rs6988593	chr8:22527440	A/G	cg01710189	chr8:22454888	PDLIM2	0.45	4.61	0.43	1.25e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2274459	0.749	rs12190155	chr6:33663241	G/A	cg06253072	chr6:33679850	C6orf125	0.49	4.97	0.45	2.98e-6	Obesity (extreme);
THYM	cis	rs4638749	0.677	rs998186	chr2:108844237	C/T	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg01528321	chr10:82214614	TSPAN14	0.63	5.29	0.48	7.7300000000000005e-07	Post bronchodilator FEV1;
THYM	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs7677751	0.767	rs6832597	chr4:55076237	C/A	cg17187183	chr4:55093834	PDGFRA	0.67	5.36	0.48	5.82e-7	Corneal astigmatism;
THYM	cis	rs4474465	0.790	rs6592784	chr11:78234790	C/T	cg19901956	chr11:77921274	USP35	0.7	5.2	0.47	1.16e-6	Alzheimer's disease (survival time);
THYM	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg05973401	chr12:123451056	ABCB9	0.68	4.85	0.45	4.83e-6	Platelet count;
THYM	cis	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2970992	0.764	rs2942885	chr2:101322332	C/T	cg01042948	chr2:101319752	NA	0.62	6.27	0.54	1.06e-8	Educational attainment;
THYM	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg26031613	chr14:104095156	KLC1	1.21	12.87	0.8	1.52e-22	Body mass index;
THYM	cis	rs7100689	0.599	rs6585968	chr10:82139807	T/C	cg01528321	chr10:82214614	TSPAN14	0.79	6.01	0.52	3.47e-8	Post bronchodilator FEV1;
THYM	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.68	5.16	0.47	1.33e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	7.32	0.6	7.82e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg03806693	chr22:41940476	POLR3H	1.05	9.54	0.7	1.59e-15	Vitiligo;
THYM	cis	rs11645898	0.504	rs79169855	chr16:71950201	A/G	cg14768367	chr16:72042858	DHODH	-0.68	-4.69	-0.43	9.3e-6	Blood protein levels;
THYM	cis	rs3820068	0.705	rs11584209	chr1:15885041	G/T	cg05660106	chr1:15850417	CASP9	1.15	9.97	0.72	1.88e-16	Systolic blood pressure;
THYM	cis	rs11760633	0.672	rs12669620	chr7:1826878	G/C	cg23422044	chr7:1970798	MAD1L1	-0.62	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs2797160	1.000	rs1739354	chr6:126017808	G/C	cg16306078	chr6:126000798	NA	0.54	5.45	0.49	3.96e-7	Endometrial cancer;
THYM	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg07414643	chr4:187882934	NA	0.63	5.56	0.5	2.42e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.01	0.58	3.39e-10	Prudent dietary pattern;
THYM	cis	rs4654899	0.655	rs4654883	chr1:21213708	C/T	cg01072550	chr1:21505969	NA	0.72	6.9	0.58	5.88e-10	Superior frontal gyrus grey matter volume;
THYM	trans	rs3960554	0.808	rs112372188	chr7:75723376	G/A	cg19862616	chr7:65841803	NCRNA00174	0.94	6.87	0.58	6.49e-10	Eotaxin levels;
THYM	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg23482746	chr15:76478102	C15orf27	-0.39	-4.7	-0.43	8.75e-6	Blood metabolite levels;
THYM	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg18252515	chr7:66147081	NA	0.67	5.04	0.46	2.18e-6	Aortic root size;
THYM	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg00256281	chr22:41985642	PMM1	-0.56	-4.47	-0.42	2.2e-5	Vitiligo;
THYM	cis	rs9915657	0.933	rs17246133	chr17:70140485	A/G	cg06234051	chr17:70120541	SOX9	-0.55	-5.08	-0.46	1.91e-6	Thyroid hormone levels;
THYM	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg10760299	chr15:45669010	GATM	-0.85	-6.64	-0.56	1.95e-9	Homoarginine levels;
THYM	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg27286337	chr10:134555280	INPP5A	0.92	7.78	0.62	8.79e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.74	8.22	0.64	1.02e-12	Eosinophil percentage of white cells;
THYM	cis	rs3917265	0.616	rs12474258	chr2:102816695	C/T	cg13315345	chr2:102803985	IL1RL2	0.65	7.56	0.61	2.53e-11	Atopic dermatitis;
THYM	cis	rs7586879	0.616	rs916485	chr2:25082273	T/C	cg15423357	chr2:25149977	NA	0.66	6.76	0.57	1.1e-9	Body mass index;
THYM	cis	rs7107174	0.892	rs2090095	chr11:78034020	G/A	cg02023728	chr11:77925099	USP35	0.64	6.22	0.54	1.32e-8	Testicular germ cell tumor;
THYM	cis	rs4731207	0.967	rs2299902	chr7:124397814	G/T	cg05285228	chr7:124571219	POT1	0.63	4.84	0.45	4.92e-6	Cutaneous malignant melanoma;
THYM	cis	rs8180040	0.800	rs62248905	chr3:47274082	A/G	cg16586182	chr3:47516702	SCAP	0.69	6.0	0.52	3.63e-8	Colorectal cancer;
THYM	cis	rs3781426	0.765	rs11245465	chr10:126706991	A/T	cg01213599	chr10:126704259	CTBP2	-0.33	-4.63	-0.43	1.18e-5	Height;
THYM	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs12216545	0.662	rs1879872	chr7:150300424	A/G	cg08960815	chr7:150264767	GIMAP4	-0.83	-7.51	-0.61	3.22e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg11663144	chr21:46675770	NA	-0.62	-6.06	-0.53	2.67e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9814567	0.752	rs4605591	chr3:134328361	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg06481639	chr22:41940642	POLR3H	0.79	5.52	0.49	2.89e-7	Vitiligo;
THYM	cis	rs11563648	0.553	rs6979232	chr7:127016217	T/A	cg23081781	chr7:127225937	GCC1	-0.37	-5.12	-0.46	1.61e-6	Resting heart rate;
THYM	cis	rs6700896	0.866	rs6588158	chr1:66160621	T/C	cg04111102	chr1:66153794	NA	-0.52	-4.94	-0.45	3.32e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs28408315	0.958	rs34449854	chr15:79188389	C/T	cg00540400	chr15:79124168	NA	0.63	4.93	0.45	3.43e-6	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;
THYM	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1457451	0.748	rs897870	chr2:65849423	C/G	cg16240816	chr2:65861662	NA	-0.67	-6.53	-0.56	3.24e-9	Iron status biomarkers;
THYM	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.91	-6.52	-0.56	3.31e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs17019602	0.666	rs6693467	chr1:108152151	C/A	cg02990361	chr1:107599529	PRMT6	0.78	4.65	0.43	1.09e-5	IgA nephropathy;
THYM	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg22709100	chr7:91322751	NA	-0.6	-4.8	-0.44	5.84e-6	Breast cancer;
THYM	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg07917127	chr4:99064746	C4orf37	0.59	4.5	0.42	1.93e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs297325	0.812	rs3203295	chr11:16761633	A/C	cg20214553	chr11:17278779	NA	0.4	4.48	0.42	2.09e-5	Obesity and osteoporosis;
THYM	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg27572855	chr1:25598939	RHD	0.67	5.17	0.47	1.3e-6	Erythrocyte sedimentation rate;
THYM	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	4.55	0.42	1.61e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg06713675	chr4:122721982	EXOSC9	-0.87	-9.87	-0.71	3.08e-16	Type 2 diabetes;
THYM	cis	rs240764	0.507	rs9390695	chr6:101266770	A/G	cg21058520	chr6:100914733	NA	-0.59	-4.61	-0.43	1.27e-5	Neuroticism;
THYM	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg24530246	chr3:53118167	NA	-0.83	-4.78	-0.44	6.39e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7119038	0.818	rs11217040	chr11:118680648	C/A	cg19308663	chr11:118741387	NA	0.44	4.78	0.44	6.35e-6	Sjögren's syndrome;
THYM	cis	rs7216064	0.906	rs78452260	chr17:65848522	G/T	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg08431931	chr22:42394659	WBP2NL	0.69	4.74	0.44	7.47e-6	Birth weight;
THYM	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg24531977	chr5:56204891	C5orf35	0.67	5.16	0.47	1.33e-6	Coronary artery disease;
THYM	cis	rs7264396	0.623	rs2425123	chr20:34329547	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Total cholesterol levels;
THYM	cis	rs4072705	0.967	rs10120039	chr9:127406961	A/G	cg01786973	chr9:127249749	NR5A1	0.34	4.62	0.43	1.19e-5	Menarche (age at onset);
THYM	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg05768032	chr16:30646687	NA	0.56	5.58	0.5	2.27e-7	Multiple myeloma;
THYM	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg11366901	chr6:160182831	ACAT2	1.01	8.95	0.68	2.91e-14	Age-related macular degeneration (geographic atrophy);
THYM	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-15.26	-0.84	2.74e-27	Height;
THYM	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.61	-5.99	-0.52	3.79e-8	Prudent dietary pattern;
THYM	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg01324343	chr3:183735012	ABCC5	0.9	13.08	0.8	5.7e-23	Anterior chamber depth;
THYM	cis	rs11696501	0.843	rs6073768	chr20:44130146	A/G	cg11783356	chr20:44313418	WFDC10B	-0.69	-4.61	-0.43	1.26e-5	Brain structure;
THYM	trans	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs988913	0.957	rs9382405	chr6:54836613	T/C	cg18532076	chr6:54711417	FAM83B	0.5	4.69	0.43	9.14e-6	Menarche (age at onset);
THYM	cis	rs6918586	0.565	rs13196986	chr6:26090452	T/C	cg07061783	chr6:25882402	NA	-0.68	-4.77	-0.44	6.55e-6	Schizophrenia;
THYM	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg15556689	chr8:8085844	FLJ10661	0.69	5.56	0.5	2.43e-7	Mood instability;
THYM	cis	rs2299587	0.519	rs3850746	chr8:17787536	C/T	cg01800426	chr8:17659068	MTUS1	0.69	5.38	0.48	5.24e-7	Economic and political preferences;
THYM	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg14690197	chr8:22456421	C8orf58	0.46	4.56	0.42	1.5e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs4575098	0.681	rs11591206	chr1:161111363	C/T	cg24329783	chr1:161160887	ADAMTS4	-0.61	-5.71	-0.51	1.27e-7	Monocyte percentage of white cells;
THYM	cis	rs7191700	1.000	rs7191700	chr16:11406803	C/T	cg00044050	chr16:11439710	C16orf75	0.65	4.48	0.42	2.07e-5	Multiple sclerosis;
THYM	cis	rs7226229	1.000	rs9898265	chr17:20940688	A/G	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg05802129	chr4:122689817	NA	-0.59	-4.65	-0.43	1.08e-5	Type 2 diabetes;
THYM	cis	rs4631830	0.863	rs2843550	chr10:51521452	C/T	cg16070123	chr10:51489643	NA	-0.5	-4.53	-0.42	1.71e-5	Prostate-specific antigen levels;
THYM	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-4.93	-0.45	3.45e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs1551570	0.563	rs4804122	chr19:10241944	C/T	cg00593900	chr19:10206746	ANGPTL6	0.43	4.66	0.43	1.03e-5	Narcolepsy;
THYM	cis	rs35883536	0.875	rs1970227	chr1:101140723	G/A	cg06223162	chr1:101003688	GPR88	-0.67	-5.12	-0.46	1.62e-6	Monocyte count;
THYM	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg18477163	chr1:228402036	OBSCN	-0.46	-5.01	-0.46	2.54e-6	Diastolic blood pressure;
THYM	cis	rs4474465	0.850	rs4944205	chr11:78227790	T/A	cg19901956	chr11:77921274	USP35	0.63	4.7	0.43	8.67e-6	Alzheimer's disease (survival time);
THYM	cis	rs189798	0.807	rs330909	chr8:8995387	A/G	cg06636001	chr8:8085503	FLJ10661	0.67	5.22	0.47	1.04e-6	Myopia (pathological);
THYM	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg27494647	chr7:150038898	RARRES2	0.43	5.35	0.48	6.01e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs986417	0.901	rs1950312	chr14:60989784	A/G	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs6430585	0.527	rs62168792	chr2:136415217	A/G	cg07169764	chr2:136633963	MCM6	0.97	8.76	0.67	7.3e-14	Corneal structure;
THYM	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs2241584	0.692	rs2277068	chr5:175916249	T/C	cg27658698	chr5:175955578	RNF44	0.42	4.79	0.44	6.11e-6	Menopause (age at onset);
THYM	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg23602478	chr1:26503979	CNKSR1	0.36	5.09	0.46	1.79e-6	Height;
THYM	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg00677455	chr12:58241039	CTDSP2	0.66	4.45	0.42	2.32e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9790314	0.967	rs10804790	chr3:161039300	T/A	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs9361491	0.608	rs9350774	chr6:79461603	A/G	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg18811423	chr2:55921094	PNPT1	0.68	5.81	0.51	8.25e-8	Metabolic syndrome;
THYM	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg09035930	chr12:129282057	SLC15A4	0.86	12.01	0.78	9.43e-21	Systemic lupus erythematosus;
THYM	cis	rs6901250	0.851	rs7740481	chr6:117149307	G/C	cg12892004	chr6:117198278	RFX6	0.7	6.85	0.57	7.3e-10	C-reactive protein levels;
THYM	cis	rs9876781	1.000	rs10470686	chr3:48449956	C/T	cg06066452	chr3:48470258	PLXNB1	0.27	4.89	0.45	4.08e-6	Longevity;
THYM	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	trans	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg12893697	chr11:970389	AP2A2	0.32	5.35	0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs7264396	0.790	rs6060518	chr20:34217309	A/C	cg26038318	chr20:34205095	SPAG4	0.64	5.28	0.48	8.13e-7	Total cholesterol levels;
THYM	cis	rs3820068	0.608	rs12091750	chr1:16042766	T/C	cg05660106	chr1:15850417	CASP9	0.72	5.59	0.5	2.2e-7	Systolic blood pressure;
THYM	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg26769984	chr7:1090371	C7orf50	0.81	5.62	0.5	1.88e-7	Bronchopulmonary dysplasia;
THYM	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg23711669	chr6:146136114	FBXO30	0.9	8.95	0.68	2.91e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9290065	0.519	rs6770180	chr3:160703786	C/T	cg03342759	chr3:160939853	NMD3	-0.59	-4.59	-0.43	1.37e-5	Kawasaki disease;
THYM	cis	rs4425211	0.766	rs7624498	chr3:36957719	T/C	cg21328643	chr3:37258149	NA	-0.52	-5.15	-0.47	1.38e-6	Iris color (L* coordinate);
THYM	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.08	-7.42	-0.61	4.86e-11	Schizophrenia;
THYM	cis	rs2070488	1.000	rs7373816	chr3:38490443	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	7.02	0.58	3.32e-10	Electrocardiographic conduction measures;
THYM	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg08999081	chr20:33150536	PIGU	0.62	5.04	0.46	2.25e-6	Coronary artery disease;
THYM	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg16325326	chr1:53192061	ZYG11B	-0.97	-11.08	-0.75	8.23e-19	Monocyte count;
THYM	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg18252515	chr7:66147081	NA	1.61	8.23	0.65	9.63e-13	Diabetic kidney disease;
THYM	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg11266682	chr4:10021025	SLC2A9	0.71	9.77	0.71	5.04e-16	Bone mineral density;
THYM	cis	rs728616	0.867	rs4387301	chr10:81736399	C/T	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2637266	0.935	rs2579720	chr10:78399918	T/C	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs2108225	0.872	rs4618632	chr7:107440952	T/G	cg18560240	chr7:107437656	SLC26A3	-0.87	-6.39	-0.55	6.26e-9	Ulcerative colitis;
THYM	cis	rs13126513	0.519	rs7659550	chr4:100554402	G/T	cg05468953	chr4:100565104	NA	0.69	6.46	0.55	4.41e-9	Metabolite levels (MHPG);
THYM	cis	rs7226229	1.000	rs2127094	chr17:20925319	G/A	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs11608355	0.846	rs4766472	chr12:109853602	C/G	cg10504392	chr12:110044639	NA	0.6	5.08	0.46	1.89e-6	Neuroticism;
THYM	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03576123	chr11:487126	PTDSS2	-1.29	-6.4	-0.55	5.87e-9	Body mass index;
THYM	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg14784868	chr12:69753453	YEATS4	1.12	10.83	0.74	2.79e-18	Blood protein levels;
THYM	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.91	-6.47	-0.55	4.22e-9	Schizophrenia;
THYM	cis	rs7246657	0.943	rs4801803	chr19:37966923	A/G	cg23950597	chr19:37808831	NA	0.74	4.77	0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs9364687	0.639	rs9347760	chr6:163954572	C/T	cg01639524	chr6:163818125	NA	0.49	4.79	0.44	6.12e-6	Body mass index;
THYM	cis	rs1451375	0.572	rs896309	chr7:50545022	A/G	cg18232548	chr7:50535776	DDC	-0.67	-5.07	-0.46	1.94e-6	Malaria;
THYM	cis	rs80319144	1.000	rs78858841	chr2:159251840	T/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.58	4.53	0.42	1.72e-5	Restless legs syndrome;
THYM	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg10018233	chr7:150070692	REPIN1	0.54	7.93	0.63	4.16e-12	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg06623918	chr6:96969491	KIAA0776	-1.08	-10.57	-0.74	9.91e-18	Headache;
THYM	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg00640147	chr17:61958756	GH2	-0.44	-4.82	-0.44	5.49e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs62435770	1.000	rs62435791	chr6:169477451	A/T	cg07652237	chr6:170125491	PHF10	0.55	4.81	0.44	5.64e-6	Loneliness;
THYM	cis	rs11671005	0.651	rs11878203	chr19:58920050	G/A	cg18639983	chr19:58920768	ZNF584	0.59	5.0	0.46	2.63e-6	Mean platelet volume;
THYM	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg12573674	chr2:1569213	NA	-1.39	-9.03	-0.68	1.95e-14	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg13695892	chr22:41940480	POLR3H	0.89	6.74	0.57	1.2e-9	Vitiligo;
THYM	cis	rs10992471	0.756	rs3758229	chr9:95078852	G/T	cg14631576	chr9:95140430	CENPP	-0.95	-10.73	-0.74	4.66e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7771547	0.573	rs10440841	chr6:36399086	G/A	cg07856975	chr6:36356162	ETV7	-0.52	-4.72	-0.44	8.26e-6	Platelet distribution width;
THYM	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg06808227	chr14:105710500	BRF1	1.02	8.79	0.67	6.26e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg13609457	chr4:120235615	NA	0.62	5.44	0.49	4.15e-7	Corneal astigmatism;
THYM	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg19346786	chr7:2764209	NA	-0.7	-5.96	-0.52	4.27e-8	Height;
THYM	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg10117171	chr1:25599238	RHD	-0.7	-5.34	-0.48	6.22e-7	Erythrocyte sedimentation rate;
THYM	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg21110456	chr7:2059412	MAD1L1	-0.45	-4.74	-0.44	7.54e-6	Neuroticism;
THYM	cis	rs9384488	0.524	rs7755448	chr6:157028615	T/C	cg08839808	chr6:156983304	NA	-0.72	-4.79	-0.44	6.15e-6	Alzheimer's disease biomarkers;
THYM	cis	rs4845875	0.600	rs6696752	chr1:11835935	T/C	cg06193043	chr1:11908199	NPPA	0.58	4.95	0.45	3.18e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs57244997	0.725	rs73030431	chr6:162439575	G/A	cg17173639	chr6:162384350	PARK2	-0.74	-4.9	-0.45	3.87e-6	Mosquito bite size;
THYM	cis	rs9906944	0.707	rs1523136	chr17:47144532	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.5	-4.95	-0.45	3.25e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs7584330	0.695	rs7570882	chr2:238435086	G/A	cg14458575	chr2:238380390	NA	0.61	4.78	0.44	6.42e-6	Prostate cancer;
THYM	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6815814	0.950	rs56289835	chr4:38811845	G/C	cg06935464	chr4:38784597	TLR10	0.72	4.71	0.44	8.42e-6	Breast cancer;
THYM	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg11764359	chr7:65958608	NA	-0.87	-7.46	-0.61	4.01e-11	Aortic root size;
THYM	cis	rs7829975	0.777	rs6989926	chr8:8547313	A/C	cg15556689	chr8:8085844	FLJ10661	-0.66	-5.33	-0.48	6.66e-7	Mood instability;
THYM	cis	rs933688	1.000	rs1541674	chr5:90660447	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	5.19	0.47	1.2e-6	Smoking behavior;
THYM	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg08916839	chr5:415575	AHRR	1.28	8.2	0.64	1.16e-12	Fat distribution (HIV);
THYM	cis	rs7084402	0.967	rs1649027	chr10:60280911	T/G	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs17006441	0.932	rs13080248	chr3:69866379	G/A	cg18496212	chr3:69797108	MITF	0.65	6.36	0.55	7.15e-9	Hemoglobin concentration;
THYM	cis	rs4455778	0.600	rs56070219	chr7:49128237	A/T	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg26769984	chr7:1090371	C7orf50	0.83	5.33	0.48	6.68e-7	Bronchopulmonary dysplasia;
THYM	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg23958373	chr8:599963	NA	-1.01	-4.56	-0.42	1.51e-5	IgG glycosylation;
THYM	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg13683864	chr3:40499215	RPL14	-0.83	-7.81	-0.63	7.51e-12	Renal cell carcinoma;
THYM	cis	rs35883536	1.000	rs35883536	chr1:101106534	G/A	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs13394619	1.000	rs2884374	chr2:11731846	C/T	cg07314298	chr2:11723111	GREB1	0.57	5.71	0.51	1.28e-7	Endometriosis;
THYM	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg12560992	chr17:57184187	TRIM37	-0.9	-8.36	-0.65	5.12e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg11861562	chr11:117069780	TAGLN	0.33	4.76	0.44	6.86e-6	Blood protein levels;
THYM	cis	rs10028773	0.632	rs34481394	chr4:120248374	C/T	cg09307838	chr4:120376055	NA	0.67	5.02	0.46	2.37e-6	Educational attainment;
THYM	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.98	-6.68	-0.57	1.62e-9	Platelet count;
THYM	cis	rs6032067	0.641	rs34638860	chr20:43765839	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.64	-5.8	-0.51	8.81e-8	Blood protein levels;
THYM	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg22508957	chr16:3507546	NAT15	0.7	7.9	0.63	4.94e-12	Tuberculosis;
THYM	cis	rs10871290	0.551	rs3863435	chr16:74465396	C/G	cg01733217	chr16:74700730	RFWD3	-0.52	-4.7	-0.43	8.74e-6	Breast cancer;
THYM	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg13695892	chr22:41940480	POLR3H	-0.95	-7.25	-0.6	1.08e-10	Vitiligo;
THYM	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg09455208	chr3:40491958	NA	0.47	4.95	0.45	3.25e-6	Renal cell carcinoma;
THYM	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs669446	0.558	rs620851	chr1:44110489	A/G	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11825685	0.790	rs80204957	chr11:134545553	A/T	cg02395454	chr11:134605862	NA	-0.83	-4.51	-0.42	1.86e-5	IgG glycosylation;
THYM	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	5.93	0.52	4.8e-8	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-5.14	-0.47	1.45e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs921968	0.643	rs1850169	chr2:219487299	A/T	cg02176678	chr2:219576539	TTLL4	0.6	5.89	0.52	5.89e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg00255919	chr5:131827918	IRF1	-0.46	-5.19	-0.47	1.17e-6	Asthma (sex interaction);
THYM	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg24450063	chr1:156163899	SLC25A44	1.21	15.52	0.85	8.47e-28	Testicular germ cell tumor;
THYM	cis	rs4660306	0.614	rs781057	chr1:45936017	C/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.66	4.74	0.44	7.56e-6	Homocysteine levels;
THYM	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg06618935	chr21:46677482	NA	-0.98	-9.5	-0.7	1.95e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg14983838	chr19:29218262	NA	1.07	8.86	0.67	4.42e-14	Methadone dose in opioid dependence;
THYM	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg26384229	chr12:38710491	ALG10B	0.87	6.95	0.58	4.61e-10	Morning vs. evening chronotype;
THYM	cis	rs9311676	0.681	rs4681846	chr3:58332543	T/C	cg26110898	chr3:58419937	PDHB	-0.44	-4.58	-0.43	1.41e-5	Systemic lupus erythematosus;
THYM	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg18876405	chr7:65276391	NA	-0.61	-5.24	-0.47	9.48e-7	Aortic root size;
THYM	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg12016809	chr21:47604291	C21orf56	0.78	5.38	0.48	5.36e-7	Testicular germ cell tumor;
THYM	cis	rs12310956	0.510	rs4931743	chr12:33867588	T/C	cg06521331	chr12:34319734	NA	-0.57	-4.6	-0.43	1.33e-5	Morning vs. evening chronotype;
THYM	cis	rs9549328	0.700	rs2185001	chr13:113616369	G/T	cg17524180	chr13:113633600	MCF2L	-0.52	-4.6	-0.43	1.3e-5	Systolic blood pressure;
THYM	cis	rs539096	0.872	rs3791138	chr1:44050027	A/C	cg00143623	chr1:44495758	SLC6A9	0.65	5.03	0.46	2.29e-6	Intelligence (multi-trait analysis);
THYM	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg03929089	chr4:120376271	NA	-0.98	-12.21	-0.78	3.51e-21	Coronary artery disease;
THYM	cis	rs7572733	0.534	rs4369854	chr2:198800630	T/C	cg00792783	chr2:198669748	PLCL1	0.82	5.75	0.51	1.08e-7	Dermatomyositis;
THYM	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg23711669	chr6:146136114	FBXO30	0.9	9.02	0.68	2.06e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7940866	0.874	rs10894306	chr11:130873882	A/C	cg23692386	chr11:131799662	NTM	0.44	4.55	0.42	1.56e-5	Schizophrenia;
THYM	cis	rs7267979	0.966	rs6050611	chr20:25414419	A/G	cg08601574	chr20:25228251	PYGB	0.59	4.81	0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19346786	chr7:2764209	NA	-0.7	-6.1	-0.53	2.32e-8	Height;
THYM	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg10047753	chr17:41438598	NA	1.2	11.36	0.76	2.13e-19	Menopause (age at onset);
THYM	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg10360139	chr7:1886902	MAD1L1	0.53	4.67	0.43	9.71e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.6	-4.63	-0.43	1.17e-5	Longevity;Endometriosis;
THYM	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg13695892	chr22:41940480	POLR3H	-0.72	-6.07	-0.53	2.56e-8	Vitiligo;
THYM	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs790123	0.842	rs796889	chr3:122398461	T/C	cg15604389	chr3:122379662	NA	0.54	5.0	0.46	2.58e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs1823778	0.609	rs1369290	chr18:67691520	A/C	cg12929678	chr18:67624393	CD226	1.3	4.63	0.43	1.14e-5	Mean platelet volume;
THYM	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg02353165	chr6:42928485	GNMT	1.02	11.21	0.75	4.51e-19	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg11279151	chr3:101281821	RG9MTD1	0.83	6.16	0.53	1.76e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg07211511	chr3:129823064	LOC729375	-1.29	-10.96	-0.75	1.51e-18	Blood pressure (smoking interaction);
THYM	cis	rs887829	0.570	rs4553819	chr2:234594083	A/G	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.59	-0.43	1.36e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg03188948	chr7:1209495	NA	0.9	5.0	0.46	2.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg01483505	chr11:975446	AP2A2	0.58	4.75	0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg03806693	chr22:41940476	POLR3H	-1.24	-10.73	-0.74	4.49e-18	Vitiligo;
THYM	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg01579765	chr21:45077557	HSF2BP	-0.45	-6.62	-0.56	2.09e-9	Mean corpuscular volume;
THYM	cis	rs9399401	0.589	rs2294775	chr6:142766347	C/G	cg03128060	chr6:142623767	GPR126	0.66	8.76	0.67	7.32e-14	Chronic obstructive pulmonary disease;
THYM	cis	rs6768930	0.509	rs6445928	chr3:57758655	T/C	cg07735586	chr3:57945651	NA	-0.33	-4.9	-0.45	3.9e-6	Obesity-related traits;
THYM	cis	rs2278491	0.528	rs4145242	chr8:117728296	C/T	cg23513447	chr8:117778558	UTP23	-0.75	-5.36	-0.48	5.9e-7	Body mass index;
THYM	cis	rs2625529	0.627	rs11858015	chr15:72552492	G/A	cg16672083	chr15:72433130	SENP8	-0.53	-4.86	-0.45	4.6e-6	Red blood cell count;
THYM	cis	rs747334	0.811	rs11812869	chr10:92715068	G/A	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg17845761	chr1:175162550	KIAA0040	0.38	4.86	0.45	4.62e-6	Alcohol dependence;
THYM	cis	rs2749592	0.918	rs4934590	chr10:37877569	T/C	cg25427524	chr10:38739819	LOC399744	0.64	4.77	0.44	6.62e-6	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.69e-11	Aortic root size;
THYM	cis	rs910316	0.819	rs175461	chr14:75581816	G/A	cg11812906	chr14:75593930	NEK9	-0.87	-7.38	-0.6	6.07e-11	Height;
THYM	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg16586182	chr3:47516702	SCAP	0.65	5.58	0.5	2.3e-7	Colorectal cancer;
THYM	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg08736216	chr1:53307985	ZYG11A	-0.62	-5.49	-0.49	3.31e-7	Monocyte count;
THYM	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg05347473	chr6:146136440	FBXO30	0.81	7.17	0.59	1.64e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1030877	1.000	rs1030877	chr2:105910513	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.56	4.8	0.44	5.97e-6	Obesity-related traits;
THYM	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.41	0.49	4.79e-7	Height;
THYM	cis	rs2180341	0.700	rs4598100	chr6:127565314	G/A	cg24812749	chr6:127587940	RNF146	0.8	5.18	0.47	1.22e-6	Breast cancer;
THYM	cis	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.98	0.45	2.85e-6	Obesity-related traits;
THYM	cis	rs10504073	0.647	rs55920380	chr8:50026353	G/A	cg00325661	chr8:49890786	NA	0.92	8.49	0.66	2.72e-13	Blood metabolite ratios;
THYM	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.49	4.56	0.42	1.53e-5	Birth weight;
THYM	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg06481639	chr22:41940642	POLR3H	0.77	5.89	0.52	5.75e-8	Vitiligo;
THYM	cis	rs1113500	0.548	rs11185269	chr1:108647636	T/C	cg06207961	chr1:108661230	NA	0.66	4.82	0.44	5.37e-6	Growth-regulated protein alpha levels;
THYM	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg09307838	chr4:120376055	NA	0.7	5.02	0.46	2.43e-6	Corneal astigmatism;
THYM	cis	rs4243830	0.850	rs932112	chr1:6591937	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.14	-7.67	-0.62	1.45e-11	Body mass index;
THYM	cis	rs9560113	1.000	rs9555809	chr13:112181401	T/C	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs854765	0.624	rs9902941	chr17:17733760	C/T	cg16928487	chr17:17741425	SREBF1	0.54	5.05	0.46	2.16e-6	Total body bone mineral density;
THYM	trans	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg25214090	chr10:38739885	LOC399744	0.93	7.92	0.63	4.43e-12	Corneal astigmatism;
THYM	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg10803722	chr21:46713166	LOC642852	-0.42	-5.57	-0.5	2.4e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9311676	0.656	rs62258102	chr3:58378784	T/C	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	9.57	0.7	1.35e-15	Chronic sinus infection;
THYM	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7712401	0.537	rs10037428	chr5:122347610	A/G	cg19808643	chr5:122110361	SNX2	-0.64	-5.41	-0.49	4.69e-7	Mean platelet volume;
THYM	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.93	-4.78	-0.44	6.49e-6	Alzheimer's disease;
THYM	cis	rs6163	0.588	rs11191392	chr10:104526951	C/A	cg04362960	chr10:104952993	NT5C2	0.55	4.77	0.44	6.52e-6	Waist circumference;Hip circumference;
THYM	cis	rs11711311	1.000	rs9830978	chr3:113455940	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.27	-0.48	8.41e-7	IgG glycosylation;
THYM	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg10802521	chr3:52805072	NEK4	-0.63	-4.63	-0.43	1.14e-5	Bipolar disorder;
THYM	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs12579753	0.956	rs7959951	chr12:82231132	T/C	cg07988820	chr12:82153109	PPFIA2	-0.73	-4.53	-0.42	1.71e-5	Resting heart rate;
THYM	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg18240062	chr17:79603768	NPLOC4	0.73	6.55	0.56	2.9e-9	Eye color traits;
THYM	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs921665	1.000	rs921665	chr2:3174321	A/G	cg16434511	chr2:3151078	NA	-0.82	-5.52	-0.49	2.98e-7	World class endurance athleticism;
THYM	cis	rs7131987	0.650	rs16934135	chr12:29483963	T/G	cg09582351	chr12:29534625	ERGIC2	-0.59	-5.13	-0.47	1.53e-6	QT interval;
THYM	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg24531977	chr5:56204891	C5orf35	-1.01	-8.29	-0.65	7.47e-13	Initial pursuit acceleration;
THYM	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg17830980	chr10:43048298	ZNF37B	-1.09	-10.96	-0.75	1.49e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.95	0.68	2.83e-14	Chronic sinus infection;
THYM	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs6754311	0.593	rs10202489	chr2:136494186	G/A	cg23851026	chr2:136556271	LCT	-0.56	-5.39	-0.48	5.15e-7	Mosquito bite size;
THYM	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg02887458	chr19:19495540	GATAD2A	0.46	5.18	0.47	1.25e-6	Bipolar disorder;
THYM	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg11764359	chr7:65958608	NA	-0.74	-6.15	-0.53	1.85e-8	Aortic root size;
THYM	cis	rs10857712	0.904	rs2265641	chr10:135221869	G/A	cg19904058	chr10:135279010	LOC619207	0.51	4.79	0.44	6.24e-6	Systemic lupus erythematosus;
THYM	cis	rs2276498	0.751	rs6127060	chr20:52635467	G/C	cg23682609	chr20:52687365	BCAS1	0.59	5.03	0.46	2.29e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7107770	0.825	rs4935911	chr11:125084742	G/A	cg07747661	chr11:125106135	PKNOX2	-0.84	-5.19	-0.47	1.21e-6	Photic sneeze reflex;
THYM	cis	rs3796352	1.000	rs35507120	chr3:53053924	C/T	cg07884673	chr3:53033167	SFMBT1	1.25	6.34	0.55	7.83e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg16586182	chr3:47516702	SCAP	-0.64	-5.61	-0.5	2.03e-7	Colorectal cancer;
THYM	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10781543	0.839	rs1127152	chr9:139335599	A/G	cg14115884	chr9:139300582	SDCCAG3	0.66	5.77	0.51	1e-7	Monocyte percentage of white cells;
THYM	cis	rs73198271	0.740	rs3827807	chr8:8679385	G/A	cg06636001	chr8:8085503	FLJ10661	-0.79	-5.53	-0.49	2.86e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs988913	1.000	rs9382408	chr6:54836984	A/G	cg19716238	chr6:54711378	FAM83B	0.49	5.05	0.46	2.09e-6	Menarche (age at onset);
THYM	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg23711669	chr6:146136114	FBXO30	0.85	8.17	0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9948	1.000	rs6576986	chr2:97508320	G/C	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.83	-0.44	5.18e-6	Erectile dysfunction and prostate cancer treatment;
THYM	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg06028808	chr11:68637592	NA	0.7	7.59	0.61	2.22e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4595586	0.545	rs6580895	chr12:39372011	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-5.56	-0.5	2.42e-7	Morning vs. evening chronotype;
THYM	cis	rs7084402	0.934	rs1649021	chr10:60286028	C/T	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg03929089	chr4:120376271	NA	1.03	8.74	0.67	8.32e-14	Coronary artery disease;
THYM	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg03060546	chr3:49711283	APEH	0.75	6.08	0.53	2.55e-8	Resting heart rate;
THYM	cis	rs13315871	1.000	rs71311855	chr3:58320507	A/G	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs10781543	0.839	rs10870071	chr9:139382184	T/C	cg14115884	chr9:139300582	SDCCAG3	0.74	7.1	0.59	2.29e-10	Monocyte percentage of white cells;
THYM	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg24060327	chr5:131705240	SLC22A5	0.81	6.74	0.57	1.24e-9	Breast cancer;
THYM	cis	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg08133631	chr1:26527909	CATSPER4	-0.59	-4.94	-0.45	3.38e-6	Obesity-related traits;
THYM	cis	rs981844	0.735	rs111822747	chr4:154734629	G/C	cg09973105	chr4:154681532	RNF175	-0.62	-5.1	-0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg14008862	chr17:28927542	LRRC37B2	0.94	5.08	0.46	1.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4951011	0.938	rs2095757	chr1:203760115	T/C	cg24343524	chr1:203763352	ZC3H11A	-0.67	-5.56	-0.5	2.43e-7	Breast cancer;
THYM	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg02527881	chr3:46936655	PTH1R	0.65	6.23	0.54	1.3e-8	Colorectal cancer;
THYM	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	4.92	0.45	3.6e-6	Hip circumference adjusted for BMI;
THYM	cis	rs17122693	1.000	rs1018036	chr14:51085429	C/T	cg04730355	chr14:51134070	SAV1	0.83	4.62	0.43	1.18e-5	Cognitive performance;
THYM	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg05182265	chr7:156933206	UBE3C	-0.69	-9.32	-0.69	4.58e-15	Body mass index;
THYM	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg21028142	chr17:79581711	NPLOC4	0.51	5.01	0.46	2.47e-6	Eye color traits;
THYM	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg19897017	chr7:2163380	MAD1L1	0.43	4.46	0.42	2.21e-5	Schizophrenia;
THYM	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg14972814	chr11:95582409	MTMR2	-0.63	-5.31	-0.48	7.33e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10927875	0.615	rs10927886	chr1:16339313	C/G	cg21385522	chr1:16154831	NA	-0.74	-4.8	-0.44	5.93e-6	Dilated cardiomyopathy;
THYM	cis	rs7580658	0.857	rs2896980	chr2:128139959	T/C	cg10021288	chr2:128175891	PROC	-0.76	-6.57	-0.56	2.62e-9	Protein C levels;
THYM	cis	rs11225247	0.881	rs12274405	chr11:102259295	C/T	cg06323957	chr11:102217781	BIRC2	1.07	4.93	0.45	3.48e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs901683	1.000	rs35034867	chr10:46039565	T/C	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg26818010	chr10:134567672	INPP5A	-0.83	-6.8	-0.57	9.14e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg03433033	chr1:76189801	ACADM	0.58	5.8	0.51	8.62e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg08772003	chr10:104629869	AS3MT	-0.55	-4.88	-0.45	4.23e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4849845	0.849	rs7588151	chr2:121020641	A/C	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.92	7.55	0.61	2.6e-11	Lymphocyte percentage of white cells;
THYM	cis	rs11779988	0.545	rs404186	chr8:17795496	A/G	cg01800426	chr8:17659068	MTUS1	-0.75	-5.25	-0.47	9.41e-7	Breast cancer;
THYM	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg04756594	chr16:24857601	SLC5A11	0.8	5.79	0.51	9.08e-8	Intelligence (multi-trait analysis);
THYM	cis	rs684232	0.563	rs12939528	chr17:524391	C/T	cg15660573	chr17:549704	VPS53	-1.01	-11.19	-0.75	4.87e-19	Prostate cancer;
THYM	cis	rs8133932	0.736	rs4819159	chr21:47285605	A/G	cg08707771	chr21:46690014	POFUT2	-0.76	-4.45	-0.42	2.29e-5	Schizophrenia;
THYM	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg27068330	chr11:65405492	SIPA1	-0.96	-9.31	-0.69	4.93e-15	Acne (severe);
THYM	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22857025	chr5:266934	NA	-1.43	-9.54	-0.7	1.58e-15	Breast cancer;
THYM	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.24	-0.47	9.48e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg24692254	chr21:30365293	RNF160	0.94	8.51	0.66	2.47e-13	Dental caries;
THYM	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.78	-6.6	-0.56	2.35e-9	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs2072732	0.861	rs2993479	chr1:2967039	A/T	cg08733933	chr1:2954429	NA	-0.55	-4.54	-0.42	1.64e-5	Plateletcrit;
THYM	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs7264396	0.635	rs6058382	chr20:34553948	C/T	cg26038318	chr20:34205095	SPAG4	0.59	4.81	0.44	5.6e-6	Total cholesterol levels;
THYM	cis	rs1975974	0.511	rs56935892	chr17:21754089	A/G	cg18423549	chr17:21743878	NA	-0.66	-5.49	-0.49	3.32e-7	Psoriasis;
THYM	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06850241	chr22:41845214	NA	-0.59	-5.34	-0.48	6.24e-7	Vitiligo;
THYM	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs6490294	0.687	rs648300	chr12:112175819	C/G	cg10833066	chr12:111807467	FAM109A	0.51	5.55	0.49	2.55e-7	Mean platelet volume;
THYM	cis	rs10992471	0.528	rs7022562	chr9:95216340	A/G	cg14631576	chr9:95140430	CENPP	-0.84	-8.02	-0.64	2.69e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs1971762	1.000	rs3892761	chr12:54070445	A/T	cg22997177	chr12:54070527	ATP5G2	-0.48	-5.15	-0.47	1.38e-6	Height;
THYM	cis	rs2295499	0.727	rs9762293	chr4:2729158	C/G	cg14003022	chr4:3043019	NA	0.52	4.45	0.42	2.3e-5	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs11756438	0.572	rs1844964	chr6:119002528	C/T	cg21191810	chr6:118973309	C6orf204	0.56	5.47	0.49	3.57e-7	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs13177918	0.677	rs2073472	chr5:149824067	T/C	cg14059543	chr5:149831962	NA	-1.0	-7.6	-0.61	2.11e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg06558623	chr16:89946397	TCF25	1.07	5.6	0.5	2.11e-7	Skin colour saturation;
THYM	cis	rs1978968	0.830	rs11089210	chr22:18445692	A/T	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06873352	chr17:61820015	STRADA	0.57	5.68	0.5	1.46e-7	Height;
THYM	cis	rs863345	0.625	rs10908655	chr1:158460899	C/T	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg03929089	chr4:120376271	NA	-0.94	-10.63	-0.74	7.58e-18	Height;
THYM	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg06009448	chr7:1102226	C7orf50	0.53	5.6	0.5	2.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6032067	1.000	rs6017519	chr20:43854677	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.5	-0.49	3.14e-7	Blood protein levels;
THYM	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.77e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg17644776	chr2:200775616	C2orf69	-0.77	-4.5	-0.42	1.95e-5	Schizophrenia;
THYM	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg24209194	chr3:40518798	ZNF619	-0.73	-6.16	-0.53	1.75e-8	Renal cell carcinoma;
THYM	cis	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg03522245	chr20:25566470	NINL	0.63	4.71	0.44	8.35e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg09904177	chr6:26538194	HMGN4	0.66	5.53	0.49	2.77e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10823500	0.640	rs7077538	chr10:71993094	T/G	cg25502086	chr10:71892093	AIFM2	-0.56	-4.9	-0.45	3.95e-6	Blood protein levels;
THYM	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1065852	0.526	rs56234624	chr22:42388826	A/G	cg08431931	chr22:42394659	WBP2NL	0.74	6.08	0.53	2.48e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg07636037	chr3:49044803	WDR6	0.75	4.65	0.43	1.06e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs13006833	0.739	rs6434387	chr2:191205969	C/T	cg11845111	chr2:191398756	TMEM194B	0.67	4.69	0.43	9.13e-6	Urinary metabolites;
THYM	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg15704280	chr7:45808275	SEPT13	-0.77	-7.22	-0.6	1.28e-10	Coronary artery disease;
THYM	cis	rs28595532	0.920	rs114223775	chr4:119775091	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.76	0.51	1.02e-7	Cannabis dependence symptom count;
THYM	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06850241	chr22:41845214	NA	0.59	5.13	0.47	1.55e-6	Vitiligo;
THYM	cis	rs12530845	0.673	rs4269479	chr7:135332379	C/T	cg23117316	chr7:135346802	PL-5283	-0.73	-5.82	-0.51	7.9e-8	Red blood cell traits;
THYM	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg05973401	chr12:123451056	ABCB9	-0.7	-4.72	-0.44	8.25e-6	Neutrophil percentage of white cells;
THYM	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1978968	0.912	rs5992932	chr22:18456254	C/T	cg01550578	chr22:18484421	MICAL3	0.6	4.55	0.42	1.59e-5	Presence of antiphospholipid antibodies;
THYM	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg25208724	chr1:156163844	SLC25A44	1.17	13.26	0.81	2.43e-23	Testicular germ cell tumor;
THYM	cis	rs6946131	0.509	rs12668454	chr7:54774641	G/A	cg16668896	chr7:54900801	NA	0.44	4.52	0.42	1.76e-5	Systemic lupus erythematosus;
THYM	cis	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg10856724	chr12:34555212	NA	-0.92	-9.27	-0.69	6.02e-15	Morning vs. evening chronotype;
THYM	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg15448220	chr1:150897856	SETDB1	0.9	7.47	0.61	3.94e-11	Melanoma;
THYM	cis	rs8050907	0.590	rs17137096	chr16:4558553	C/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.13	4.76	0.44	6.97e-6	Obesity-related traits;
THYM	cis	rs17443541	0.507	rs7558643	chr2:200470709	C/T	cg01795955	chr2:200468626	NA	-0.66	-4.59	-0.43	1.38e-5	Intelligence (multi-trait analysis);
THYM	cis	rs17030434	0.607	rs3747522	chr4:154644929	G/A	cg14289246	chr4:154710475	SFRP2	-0.68	-4.9	-0.45	3.9e-6	Electrocardiographic conduction measures;
THYM	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg15557168	chr22:42548783	NA	0.6	4.82	0.44	5.52e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.71	5.26	0.48	8.78e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9828933	0.808	rs3733125	chr3:63981635	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.97	-4.76	-0.44	6.85e-6	Type 2 diabetes;
THYM	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.83	0.44	5.2e-6	Bipolar disorder;
THYM	cis	rs2976388	0.525	rs2016749	chr8:143836118	G/A	cg17252645	chr8:143867129	LY6D	-0.56	-5.58	-0.5	2.28e-7	Urinary tract infection frequency;
THYM	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.74	-6.91	-0.58	5.62e-10	Personality dimensions;
THYM	cis	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.58	6.09	0.53	2.4e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs36051895	0.587	rs7848872	chr9:5197027	T/A	cg02405213	chr9:5042618	JAK2	-0.87	-8.15	-0.64	1.47e-12	Pediatric autoimmune diseases;
THYM	cis	rs4481887	1.000	rs4372295	chr1:248464871	G/T	cg00666640	chr1:248458726	OR2T12	0.56	4.61	0.43	1.26e-5	Common traits (Other);
THYM	cis	rs1775715	0.870	rs1251400	chr10:32235145	A/G	cg04359828	chr10:32216031	ARHGAP12	0.4	5.16	0.47	1.37e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg12564285	chr5:131593104	PDLIM4	0.43	4.8	0.44	6e-6	Breast cancer;
THYM	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg00645579	chr11:617140	IRF7;MUPCDH	-0.47	-6.04	-0.53	3.05e-8	Systemic lupus erythematosus;
THYM	cis	rs7267979	1.000	rs2259837	chr20:25280205	T/C	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg21385522	chr1:16154831	NA	0.65	4.65	0.43	1.08e-5	Dilated cardiomyopathy;
THYM	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg25767906	chr1:53392781	SCP2	-0.58	-5.87	-0.52	6.47e-8	Monocyte count;
THYM	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg10117171	chr1:25599238	RHD	-0.68	-5.17	-0.47	1.28e-6	Erythrocyte sedimentation rate;
THYM	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg06108461	chr20:60628389	TAF4	-0.79	-6.2	-0.54	1.46e-8	Body mass index;
THYM	cis	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg07460842	chr6:66804631	NA	0.93	5.61	0.5	1.96e-7	Exhaled nitric oxide levels;
THYM	cis	rs6032067	0.759	rs118190342	chr20:43843130	A/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.64	-7.37	-0.6	6.28e-11	Blood protein levels;
THYM	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg26384229	chr12:38710491	ALG10B	0.95	7.55	0.61	2.7e-11	Bladder cancer;
THYM	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg11871910	chr12:69753446	YEATS4	1.01	9.87	0.71	3.09e-16	Cerebrospinal fluid biomarker levels;
THYM	cis	rs12148488	0.966	rs1867148	chr15:75339985	T/C	cg02696790	chr15:75250997	RPP25	-0.48	-4.8	-0.44	5.83e-6	Caffeine consumption;
THYM	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500395	1.000	rs9936004	chr16:48566088	A/G	cg04672837	chr16:48644449	N4BP1	0.49	4.74	0.44	7.38e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs11225247	0.881	rs11225236	chr11:102250098	C/T	cg06323957	chr11:102217781	BIRC2	1.08	4.83	0.44	5.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs7250872	0.619	rs2396359	chr19:1819125	T/C	cg10370574	chr19:1840461	REXO1	-1.03	-9.28	-0.69	5.77e-15	Bipolar disorder;
THYM	cis	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg05335186	chr13:53173507	NA	-0.4	-5.03	-0.46	2.36e-6	Lewy body disease;
THYM	cis	rs7408868	1.000	rs4809030	chr19:15273381	A/G	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg22981736	chr15:31284413	MTMR10	-0.57	-4.77	-0.44	6.64e-6	Huntington's disease progression;
THYM	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg12560992	chr17:57184187	TRIM37	0.7	5.55	0.49	2.59e-7	Testicular germ cell tumor;
THYM	cis	rs289828	0.507	rs11730	chr2:152127011	A/G	cg05960677	chr2:152117363	RBM43	0.76	8.1	0.64	1.82e-12	Blood protein levels;
THYM	cis	rs78707713	0.560	rs61848436	chr10:71247714	C/T	cg08851181	chr10:71228077	TSPAN15	-0.8	-5.95	-0.52	4.4e-8	Venous thromboembolism;
THYM	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg08885076	chr2:99613938	TSGA10	0.62	5.67	0.5	1.5e-7	Chronic sinus infection;
THYM	cis	rs28795989	0.896	rs7687431	chr4:7889492	T/C	cg12728606	chr4:7903970	AFAP1	0.43	4.59	0.43	1.34e-5	Intraocular pressure;
THYM	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg02734326	chr4:10020555	SLC2A9	-0.61	-5.0	-0.46	2.66e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg05657792	chr17:6899758	ALOX12	0.51	5.16	0.47	1.33e-6	Tonsillectomy;
THYM	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg23187316	chr7:1099788	C7orf50	0.59	4.52	0.42	1.76e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs208520	0.674	rs207103	chr6:66795568	G/T	cg07460842	chr6:66804631	NA	-1.06	-7.89	-0.63	5.14e-12	Exhaled nitric oxide output;
THYM	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg06238570	chr21:40685208	BRWD1	-0.96	-9.14	-0.68	1.13e-14	Cognitive function;
THYM	cis	rs9560113	1.000	rs9560110	chr13:112181233	C/T	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs1692580	0.870	rs590367	chr1:2162944	C/T	cg13918804	chr1:2043761	PRKCZ	-0.54	-4.5	-0.42	1.95e-5	Coronary artery disease;
THYM	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg03806693	chr22:41940476	POLR3H	1.07	8.61	0.66	1.55e-13	Vitiligo;
THYM	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35883536	0.868	rs2484535	chr1:101107748	C/T	cg06223162	chr1:101003688	GPR88	-0.67	-5.12	-0.46	1.62e-6	Monocyte count;
THYM	cis	rs892961	0.932	rs11655686	chr17:75419535	G/A	cg05865280	chr17:75406074	SEPT9	0.5	8.45	0.65	3.4e-13	Airflow obstruction;
THYM	cis	rs11048434	0.736	rs7301381	chr12:9123932	T/C	cg13575925	chr12:9217583	LOC144571	0.5	4.77	0.44	6.76e-6	Sjögren's syndrome;
THYM	cis	rs2249694	0.959	rs2987799	chr10:135380499	T/G	cg20169779	chr10:135381914	SYCE1	0.55	4.53	0.42	1.69e-5	Obesity-related traits;
THYM	cis	rs6087771	0.642	rs6060403	chr20:30221104	C/A	cg13852791	chr20:30311386	BCL2L1	0.79	7.38	0.6	5.91e-11	Subcortical brain region volumes;Putamen volume;
THYM	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.6	4.53	0.42	1.75e-5	Renal function-related traits (BUN);
THYM	cis	rs828999	0.688	rs1020173	chr1:108695901	C/T	cg24323958	chr1:108741884	SLC25A24	0.54	5.33	0.48	6.7e-7	Monocyte percentage of white cells;
THYM	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg13918804	chr1:2043761	PRKCZ	0.61	4.55	0.42	1.57e-5	Height;
THYM	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3768617	0.510	rs2296293	chr1:183095477	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs9443189	0.570	rs567903	chr6:76327851	C/T	cg01950844	chr6:76311363	SENP6	1.05	6.66	0.56	1.81e-9	Prostate cancer;
THYM	cis	rs9914988	1.000	rs9895443	chr17:27182944	A/G	cg20469991	chr17:27169893	C17orf63	-0.76	-4.88	-0.45	4.25e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg09462578	chr12:12878428	APOLD1	-0.91	-5.39	-0.48	5.01e-7	Systemic lupus erythematosus;
THYM	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg02640540	chr1:67518911	SLC35D1	0.65	4.78	0.44	6.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg11812906	chr14:75593930	NEK9	-0.75	-6.74	-0.57	1.2e-9	Coronary artery disease;
THYM	cis	rs4523957	0.893	rs11078019	chr17:2162121	G/A	cg16513277	chr17:2031491	SMG6	-0.79	-7.41	-0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9309473	0.519	rs2421667	chr2:73832459	T/C	cg19565262	chr2:73869966	NAT8	0.61	4.96	0.45	3.14e-6	Metabolite levels;
THYM	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg24308560	chr3:49941425	MST1R	0.8	6.84	0.57	7.6e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6725517	0.737	rs7576788	chr2:25083310	A/G	cg01884057	chr2:25150051	NA	0.57	5.45	0.49	3.94e-7	Breast cancer;
THYM	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg03806693	chr22:41940476	POLR3H	-1.15	-9.82	-0.71	4.04e-16	Vitiligo;
THYM	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg12288994	chr5:1860383	NA	0.62	4.69	0.43	9.04e-6	Cardiovascular disease risk factors;
THYM	cis	rs6032067	0.538	rs6017489	chr20:43731932	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.5	-4.53	-0.42	1.68e-5	Blood protein levels;
THYM	cis	rs526231	0.543	rs152123	chr5:102531919	A/G	cg23492399	chr5:102201601	PAM	0.68	5.22	0.47	1.05e-6	Primary biliary cholangitis;
THYM	cis	rs2046867	0.661	rs28599586	chr3:72907185	A/G	cg25664220	chr3:72788482	NA	-0.8	-7.4	-0.6	5.51e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg19626725	chr5:178986131	RUFY1	-0.33	-5.22	-0.47	1.03e-6	Lung cancer;
THYM	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.76	0.44	7.04e-6	Bipolar disorder;
THYM	cis	rs6728642	0.572	rs13403225	chr2:97600827	A/G	cg01990225	chr2:97406019	LMAN2L	-0.77	-4.61	-0.43	1.23e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg17691542	chr6:26056736	HIST1H1C	0.88	5.35	0.48	5.99e-7	Iron status biomarkers;
THYM	cis	rs4788570	0.697	rs11075904	chr16:71816899	G/A	cg06353428	chr16:71660113	MARVELD3	1.41	8.74	0.67	8.32e-14	Intelligence (multi-trait analysis);
THYM	cis	rs4849845	0.849	rs12711940	chr2:121036386	T/A	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg16325326	chr1:53192061	ZYG11B	-0.73	-6.9	-0.58	5.91e-10	Monocyte count;
THYM	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg09359103	chr1:154839909	KCNN3	-0.73	-9.27	-0.69	5.9e-15	Prostate cancer;
THYM	cis	rs12935418	0.616	rs874053	chr16:81006107	A/G	cg16651780	chr16:81037892	C16orf61	0.88	6.52	0.56	3.34e-9	Mean corpuscular volume;
THYM	cis	rs4731207	0.596	rs1006334	chr7:124628307	G/T	cg05285228	chr7:124571219	POT1	-0.67	-5.03	-0.46	2.32e-6	Cutaneous malignant melanoma;
THYM	cis	rs6032067	0.929	rs34412950	chr20:43805132	C/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg12179176	chr11:130786555	SNX19	0.69	5.56	0.5	2.51e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg08645402	chr16:4508243	NA	-0.66	-5.63	-0.5	1.82e-7	Schizophrenia;
THYM	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg02640540	chr1:67518911	SLC35D1	-0.68	-5.18	-0.47	1.25e-6	Lymphocyte percentage of white cells;
THYM	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg09222892	chr1:25734099	RHCE	0.59	4.52	0.42	1.75e-5	Erythrocyte sedimentation rate;
THYM	cis	rs4481887	0.676	rs946764	chr1:248522033	A/C	cg00666640	chr1:248458726	OR2T12	0.55	4.79	0.44	6.14e-6	Common traits (Other);
THYM	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.82	-5.85	-0.51	6.81e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs11722228	0.893	rs6449144	chr4:9944650	T/G	cg11266682	chr4:10021025	SLC2A9	-0.47	-4.67	-0.43	9.72e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs4595586	0.545	rs925829	chr12:39364167	A/G	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs995000	0.931	rs12062275	chr1:62991905	T/C	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs4523957	0.820	rs2209073	chr17:2205664	G/A	cg16513277	chr17:2031491	SMG6	0.78	7.13	0.59	1.99e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg06634786	chr22:41940651	POLR3H	-0.59	-4.59	-0.43	1.36e-5	Vitiligo;
THYM	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg17264618	chr3:40429014	ENTPD3	0.52	4.91	0.45	3.72e-6	Renal cell carcinoma;
THYM	cis	rs12142240	0.698	rs68083747	chr1:46807416	T/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.84	-5.3	-0.48	7.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.61	6.51	0.56	3.61e-9	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2658782	0.654	rs2605617	chr11:93243333	T/C	cg15737290	chr11:93063684	CCDC67	0.98	7.13	0.59	1.93e-10	Pulmonary function decline;
THYM	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg02931644	chr1:25747376	RHCE	0.62	4.84	0.45	4.93e-6	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs7582180	0.663	rs1114595	chr2:100960072	T/A	cg14675211	chr2:100938903	LONRF2	0.6	5.9	0.52	5.67e-8	Intelligence (multi-trait analysis);
THYM	cis	rs72627123	0.867	rs72627115	chr14:74350638	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs1448094	0.511	rs61930588	chr12:86158991	A/G	cg00310523	chr12:86230176	RASSF9	0.61	5.33	0.48	6.57e-7	Major depressive disorder;
THYM	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg15962314	chr1:44399869	ARTN	-0.52	-4.97	-0.45	2.95e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg02734326	chr4:10020555	SLC2A9	0.66	6.11	0.53	2.14e-8	Bone mineral density;
THYM	cis	rs7208859	0.673	rs3816780	chr17:29161358	C/T	cg17105886	chr17:28927953	LRRC37B2	1.15	6.19	0.54	1.55e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7646881	1.000	rs73015649	chr3:158450298	C/G	cg18349298	chr3:158450550	RARRES1	0.49	4.54	0.42	1.66e-5	Tetralogy of Fallot;
THYM	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg21110456	chr7:2059412	MAD1L1	-0.45	-4.7	-0.43	8.66e-6	Neuroticism;
THYM	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg09640425	chr7:158790006	NA	-0.54	-4.55	-0.42	1.58e-5	Facial morphology (factor 20);
THYM	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg01341218	chr17:43662625	NA	1.11	8.94	0.68	2.98e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs447921	0.861	rs36119142	chr17:74454336	T/G	cg17201438	chr17:74438067	UBE2O	0.76	5.44	0.49	4.18e-7	Mitochondrial DNA levels;
THYM	cis	rs6456042	0.964	rs3127418	chr6:166538176	G/T	cg11088901	chr6:166572345	T	-0.55	-5.12	-0.47	1.59e-6	Asthma;
THYM	cis	rs6032067	0.641	rs34811768	chr20:43765800	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.7	-7.59	-0.61	2.14e-11	Blood protein levels;
THYM	cis	rs11039798	0.844	rs11040177	chr11:48976211	G/C	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs4072705	0.585	rs7852843	chr9:127233823	C/T	cg13476313	chr9:127244764	NR5A1	-0.34	-4.91	-0.45	3.75e-6	Menarche (age at onset);
THYM	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg12560992	chr17:57184187	TRIM37	-0.87	-7.55	-0.61	2.64e-11	Intelligence (multi-trait analysis);
THYM	cis	rs6840360	0.571	rs62327272	chr4:152545090	A/C	cg22705602	chr4:152727874	NA	-0.78	-8.16	-0.64	1.38e-12	Intelligence (multi-trait analysis);
THYM	cis	rs2674946	0.644	rs764191	chr17:13039792	A/T	cg12799781	chr17:12569110	MYOCD	-0.56	-5.22	-0.47	1.05e-6	Squamous cell lung carcinoma;
THYM	cis	rs62103177	0.564	rs7228971	chr18:77738025	C/T	cg07235805	chr18:78004237	PARD6G	-0.47	-5.38	-0.48	5.46e-7	Opioid sensitivity;
THYM	cis	rs736801	0.891	rs11242115	chr5:131826413	G/C	cg00255919	chr5:131827918	IRF1	-0.43	-4.74	-0.44	7.44e-6	Breast cancer;Mosquito bite size;
THYM	cis	rs6430585	0.941	rs7589832	chr2:136504101	A/C	cg23851026	chr2:136556271	LCT	0.64	5.85	0.51	6.99e-8	Corneal structure;
THYM	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	5.38	0.48	5.27e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs17174870	0.955	rs79464516	chr2:112757446	A/G	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs10979	1.000	rs7774497	chr6:143889033	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs3126085	0.935	rs10888468	chr1:152181539	C/T	cg26020982	chr1:152196106	HRNR	0.35	4.57	0.42	1.45e-5	Atopic dermatitis;
THYM	cis	rs240764	0.658	rs12213201	chr6:101176285	C/A	cg21058520	chr6:100914733	NA	0.57	5.09	0.46	1.82e-6	Neuroticism;
THYM	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.67	6.02	0.53	3.23e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg00990874	chr7:1149470	C7orf50	-0.66	-5.03	-0.46	2.29e-6	Bronchopulmonary dysplasia;
THYM	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg21658235	chr8:22456391	C8orf58	-0.46	-4.69	-0.43	9.17e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg22166914	chr1:53195759	ZYG11B	-0.82	-8.52	-0.66	2.41e-13	Monocyte count;
THYM	cis	rs600806	0.821	rs417270	chr1:109849144	T/C	cg23032129	chr1:109941072	SORT1	-0.56	-4.7	-0.43	8.68e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg05234568	chr11:5960015	NA	-0.62	-5.59	-0.5	2.18e-7	DNA methylation (variation);
THYM	cis	rs1784581	0.588	rs7451121	chr6:162412344	A/G	cg17173639	chr6:162384350	PARK2	0.81	7.47	0.61	3.78e-11	Itch intensity from mosquito bite;
THYM	cis	rs6430585	1.000	rs73958618	chr2:136500475	A/G	cg07169764	chr2:136633963	MCM6	0.95	8.75	0.67	7.65e-14	Corneal structure;
THYM	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg13736514	chr6:26305472	NA	-0.61	-7.45	-0.61	4.28e-11	Educational attainment;
THYM	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg26769984	chr7:1090371	C7orf50	0.79	4.88	0.45	4.23e-6	Bronchopulmonary dysplasia;
THYM	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.25	4.9	0.45	3.87e-6	Obesity-related traits;
THYM	cis	rs11603151	0.595	rs60121522	chr11:134509305	G/A	cg02395454	chr11:134605862	NA	-0.53	-4.51	-0.42	1.84e-5	Schizophrenia;
THYM	cis	rs6906287	0.647	rs12211576	chr6:118872080	G/A	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg06064525	chr11:970664	AP2A2	-0.35	-6.68	-0.57	1.63e-9	Alzheimer's disease (late onset);
THYM	cis	rs7568458	0.811	rs3755015	chr2:85764041	G/A	cg17127132	chr2:85788382	GGCX	0.7	6.21	0.54	1.36e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg26384229	chr12:38710491	ALG10B	-0.84	-8.45	-0.65	3.42e-13	Heart rate;
THYM	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg00647820	chr17:40259828	DHX58	-0.62	-4.65	-0.43	1.06e-5	Fibrinogen levels;
THYM	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs2403083	0.723	rs4150893	chr8:86104754	C/T	cg13721134	chr8:86350390	CA3	-0.49	-4.83	-0.44	5.2e-6	Plasma amyloid beta peptide concentrations (ABx-40);
THYM	cis	rs2625529	0.652	rs11072350	chr15:72464609	T/G	cg16672083	chr15:72433130	SENP8	0.51	4.62	0.43	1.22e-5	Red blood cell count;
THYM	cis	rs8067545	1.000	rs34291370	chr17:19942335	G/A	cg20830565	chr17:20408647	MGC102966	-0.48	-4.45	-0.42	2.32e-5	Schizophrenia;
THYM	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg23161317	chr6:28129485	ZNF389	0.84	6.3	0.54	9.31e-9	Depression;
THYM	cis	rs2997447	0.706	rs61776574	chr1:26429492	C/T	cg03844060	chr1:26490628	NA	0.7	4.82	0.44	5.34e-6	QRS complex (12-leadsum);
THYM	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg18512352	chr11:47633146	NA	-0.53	-6.34	-0.55	7.84e-9	Body mass index;
THYM	cis	rs9649213	0.614	rs2240348	chr7:97984077	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.7	-5.91	-0.52	5.26e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs62070183	0.766	rs62070232	chr17:31230093	A/C	cg02981443	chr17:31254875	TMEM98	-0.53	-4.72	-0.44	8.17e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg12826209	chr6:26865740	GUSBL1	-0.92	-4.98	-0.45	2.89e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs919433	0.713	rs6714697	chr2:198484486	C/T	cg00792783	chr2:198669748	PLCL1	0.82	5.73	0.51	1.17e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg17264618	chr3:40429014	ENTPD3	0.52	4.95	0.45	3.22e-6	Renal cell carcinoma;
THYM	cis	rs2213920	0.516	rs35976675	chr9:118173444	T/C	cg13918206	chr9:118159781	DEC1	-1.03	-6.0	-0.52	3.51e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg19748678	chr4:122722346	EXOSC9	0.71	4.98	0.45	2.9e-6	Type 2 diabetes;
THYM	cis	rs4975616	0.869	rs31490	chr5:1344458	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.9	-9.05	-0.68	1.76e-14	Lung cancer;
THYM	cis	rs9653442	0.712	rs7582731	chr2:100686486	T/C	cg22139774	chr2:100720529	AFF3	-0.31	-4.85	-0.45	4.73e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs2073300	0.609	rs3827086	chr20:23357331	C/T	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg05973401	chr12:123451056	ABCB9	0.68	4.55	0.42	1.58e-5	Height;Educational attainment;Head circumference (infant);
THYM	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg10360139	chr7:1886902	MAD1L1	-0.62	-5.45	-0.49	3.96e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs6754311	0.551	rs9287442	chr2:136522710	A/G	cg04750100	chr2:136595281	LCT	-0.55	-6.22	-0.54	1.31e-8	Mosquito bite size;
THYM	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg22509189	chr2:225307070	NA	-0.66	-5.36	-0.48	5.94e-7	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs1728785	0.818	rs11075684	chr16:68582365	C/T	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	5.09	0.46	1.81e-6	Total body bone mineral density;
THYM	cis	rs1775715	0.737	rs2808028	chr10:32101189	G/A	cg04359828	chr10:32216031	ARHGAP12	0.37	4.91	0.45	3.75e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs6732160	0.588	rs2043099	chr2:73374156	G/A	cg24220031	chr2:73402428	NA	-0.71	-5.79	-0.51	8.94e-8	Intelligence (multi-trait analysis);
THYM	cis	rs929596	0.563	rs1105879	chr2:234602202	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.81	-6.58	-0.56	2.56e-9	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs9644630	0.841	rs4922035	chr8:19328174	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.71	7.43	0.61	4.6e-11	Oropharynx cancer;
THYM	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg02269571	chr22:50332266	NA	-0.82	-5.81	-0.51	8.33e-8	Schizophrenia;
THYM	cis	rs57244997	0.685	rs1954916	chr6:162447612	A/G	cg17173639	chr6:162384350	PARK2	-0.79	-4.85	-0.45	4.83e-6	Mosquito bite size;
THYM	cis	rs11031096	0.563	rs12289940	chr11:4224589	T/A	cg08557956	chr11:4115526	RRM1	-0.62	-4.95	-0.45	3.24e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg24874828	chr4:187887005	NA	-0.75	-7.9	-0.63	4.98e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9677476	0.863	rs16827863	chr2:232077670	C/T	cg20307347	chr2:231734563	ITM2C	0.51	4.58	0.43	1.4e-5	Food antigen IgG levels;
THYM	cis	rs753955	0.962	rs57766297	chr13:24284374	A/G	cg26748598	chr13:24091341	NA	0.52	4.45	0.42	2.34e-5	Lung cancer;
THYM	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg16558253	chr16:72132732	DHX38	0.53	4.54	0.42	1.67e-5	Fibrinogen levels;
THYM	cis	rs12134245	0.874	rs34842487	chr1:92021611	C/T	cg25838465	chr1:92012736	NA	-0.57	-5.1	-0.46	1.7e-6	Breast cancer;
THYM	cis	rs12282928	1.000	rs4752923	chr11:48288155	A/G	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg24818145	chr4:99064322	C4orf37	0.74	5.9	0.52	5.49e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1448094	0.511	rs34885805	chr12:86155180	A/T	cg02569458	chr12:86230093	RASSF9	0.62	5.13	0.47	1.56e-6	Major depressive disorder;
THYM	cis	rs887829	0.570	rs11680450	chr2:234597483	T/C	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.57	-0.42	1.45e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs2708977	0.933	rs2579502	chr2:97198800	A/G	cg01950434	chr2:97203154	ARID5A	-0.58	-5.2	-0.47	1.17e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs1978968	0.913	rs34272636	chr22:18433603	A/C	cg01550578	chr22:18484421	MICAL3	0.63	4.5	0.42	1.94e-5	Presence of antiphospholipid antibodies;
THYM	cis	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg13852791	chr20:30311386	BCL2L1	0.76	6.05	0.53	2.88e-8	Mean corpuscular hemoglobin;
THYM	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.47	-0.42	2.16e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs332507	0.830	rs2289428	chr3:124412524	T/G	cg04915618	chr3:124304960	KALRN	-0.6	-4.49	-0.42	2.03e-5	Plateletcrit;
THYM	cis	rs9814567	1.000	rs62271514	chr3:134298554	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	8.46	0.66	3.25e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs72828912	0.731	rs9393526	chr6:24072458	C/T	cg19882886	chr6:25043046	NA	-0.82	-4.5	-0.42	1.91e-5	Squamous cell lung carcinoma;
THYM	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg09323728	chr8:95962352	TP53INP1	-0.44	-4.53	-0.42	1.7e-5	Type 2 diabetes;
THYM	cis	rs793108	0.712	rs811572	chr10:31387968	A/T	cg07137701	chr10:31611868	ZEB1	-0.55	-4.83	-0.44	5.24e-6	Multiple sclerosis;Rheumatoid arthritis;
THYM	cis	rs10089	0.904	rs2228112	chr5:127469859	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs9810089	0.708	rs619605	chr3:136087012	G/C	cg21827317	chr3:136751795	NA	0.55	4.58	0.43	1.4e-5	Gestational age at birth (child effect);
THYM	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg20891283	chr12:69753455	YEATS4	0.74	6.01	0.52	3.42e-8	Blood protein levels;
THYM	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg02569458	chr12:86230093	RASSF9	-0.65	-5.57	-0.5	2.32e-7	Major depressive disorder;
THYM	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg17366294	chr4:99064904	C4orf37	0.48	5.43	0.49	4.3e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg04362960	chr10:104952993	NT5C2	0.6	5.11	0.46	1.66e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg13319975	chr6:146136371	FBXO30	-0.66	-5.23	-0.47	9.87e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Gout;
THYM	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.97	8.9	0.67	3.72e-14	Chronic sinus infection;
THYM	cis	rs4940575	0.679	rs17070779	chr18:60835738	C/T	cg24349668	chr18:61441546	SERPINB7	-0.75	-4.63	-0.43	1.15e-5	Breast cancer;
THYM	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03517284	chr6:25882590	NA	1.02	9.37	0.69	3.66e-15	Blood metabolite levels;
THYM	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg13683864	chr3:40499215	RPL14	-1.06	-11.61	-0.77	6.25e-20	Renal cell carcinoma;
THYM	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg16325326	chr1:53192061	ZYG11B	-0.73	-6.92	-0.58	5.19e-10	Monocyte count;
THYM	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs9933309	0.916	rs57953994	chr16:88846803	G/A	cg04602696	chr16:88846723	FAM38A	0.48	4.7	0.43	8.65e-6	Glycated hemoglobin levels;
THYM	cis	rs2742417	0.603	rs2064063	chr3:45759924	T/A	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg16342193	chr10:102329863	NA	-0.51	-5.14	-0.47	1.48e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1971762	0.563	rs4759279	chr12:54064888	C/T	cg16917193	chr12:54089295	NA	0.77	7.03	0.59	3.11e-10	Height;
THYM	cis	rs669446	0.622	rs623965	chr1:44111187	A/G	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.76	6.79	0.57	9.55e-10	Personality dimensions;
THYM	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg08807101	chr21:30365312	RNF160	0.93	7.5	0.61	3.42e-11	Dental caries;
THYM	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg24818145	chr4:99064322	C4orf37	0.74	5.93	0.52	4.8e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02475777	chr4:1388615	CRIPAK	0.67	4.84	0.44	5.09e-6	Longevity;
THYM	cis	rs7580658	0.724	rs4662711	chr2:127990840	G/A	cg10021288	chr2:128175891	PROC	-0.67	-5.96	-0.52	4.26e-8	Protein C levels;
THYM	cis	rs995000	0.899	rs6696502	chr1:63039533	C/T	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg15704280	chr7:45808275	SEPT13	-1.09	-13.76	-0.82	2.47e-24	Height;
THYM	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.16	-5.63	-0.5	1.85e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2625529	0.824	rs2415130	chr15:72242554	G/A	cg16672083	chr15:72433130	SENP8	-0.62	-5.66	-0.5	1.61e-7	Red blood cell count;
THYM	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg04362960	chr10:104952993	NT5C2	0.64	5.3	0.48	7.43e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18252515	chr7:66147081	NA	-0.66	-4.96	-0.45	3.11e-6	Aortic root size;
THYM	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg26441486	chr22:50317300	CRELD2	0.44	6.33	0.54	8.23e-9	Schizophrenia;
THYM	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg00256281	chr22:41985642	PMM1	0.62	5.03	0.46	2.3e-6	Vitiligo;
THYM	cis	rs7849270	1.000	rs10819469	chr9:131882067	G/T	cg14069949	chr9:131965419	NA	0.5	4.52	0.42	1.8e-5	Blood metabolite ratios;
THYM	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg14583973	chr4:3374767	RGS12	0.67	6.2	0.54	1.45e-8	Serum sulfate level;
THYM	cis	rs6430585	0.583	rs11886852	chr2:136589379	G/A	cg23851026	chr2:136556271	LCT	0.67	6.81	0.57	8.94e-10	Corneal structure;
THYM	cis	rs3892630	0.824	rs12327732	chr19:33221767	C/T	cg22928329	chr19:33183273	NUDT19	-0.77	-5.75	-0.51	1.08e-7	Red blood cell traits;
THYM	cis	rs17597773	0.635	rs1494368	chr1:221004168	T/C	cg16008148	chr1:221062819	NA	0.43	4.47	0.42	2.2e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7712401	0.537	rs60418991	chr5:122355827	G/C	cg19808643	chr5:122110361	SNX2	-0.62	-5.24	-0.47	9.63e-7	Mean platelet volume;
THYM	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.69	-6.07	-0.53	2.61e-8	Total body bone mineral density;
THYM	cis	rs7100689	0.784	rs3802637	chr10:82179699	G/C	cg01528321	chr10:82214614	TSPAN14	1.13	8.8	0.67	6.09e-14	Post bronchodilator FEV1;
THYM	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	6.36	0.55	6.98e-9	Total body bone mineral density;
THYM	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg01616529	chr11:638424	DRD4	-0.76	-5.38	-0.48	5.42e-7	Systemic lupus erythematosus;
THYM	cis	rs6866344	0.569	rs6870021	chr5:178149667	C/T	cg10224037	chr5:178157518	ZNF354A	0.98	7.92	0.63	4.34e-12	Neutrophil percentage of white cells;
THYM	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg10295955	chr4:187884368	NA	-1.17	-17.37	-0.87	3.11e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg22709100	chr7:91322751	NA	0.61	4.86	0.45	4.66e-6	Breast cancer;
THYM	cis	rs28595532	0.920	rs17324821	chr4:119770716	A/G	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg15962314	chr1:44399869	ARTN	0.53	5.32	0.48	6.88e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02475777	chr4:1388615	CRIPAK	0.66	4.81	0.44	5.68e-6	Longevity;
THYM	trans	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03264133	chr6:25882463	NA	-0.67	-5.03	-0.46	2.36e-6	Height;
THYM	cis	rs79149102	0.579	rs3812946	chr15:75288610	G/C	cg17294928	chr15:75287854	SCAMP5	-1.0	-4.65	-0.43	1.07e-5	Lung cancer;
THYM	cis	rs2463822	0.583	rs72919472	chr11:62040655	C/T	cg06239285	chr11:62104954	ASRGL1	-1.04	-5.14	-0.47	1.45e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg24060327	chr5:131705240	SLC22A5	-0.82	-6.78	-0.57	1.02e-9	Breast cancer;
THYM	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg24642439	chr20:33292090	TP53INP2	0.59	4.48	0.42	2.04e-5	Coronary artery disease;
THYM	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg21433313	chr16:3507492	NAT15	-0.51	-4.53	-0.42	1.7e-5	Body mass index (adult);
THYM	cis	rs10924970	0.967	rs4659678	chr1:235396697	A/G	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs490234	0.691	rs1472467	chr9:128173121	C/G	cg14078157	chr9:128172775	NA	-0.85	-6.77	-0.57	1.05e-9	Mean arterial pressure;
THYM	cis	rs3812565	0.506	rs8413	chr9:139323311	T/C	cg14115884	chr9:139300582	SDCCAG3	0.65	5.46	0.49	3.88e-7	Granulocyte percentage of myeloid white cells;
THYM	cis	rs61931739	1.000	rs12427279	chr12:34025898	T/G	cg06521331	chr12:34319734	NA	0.61	4.8	0.44	5.92e-6	Morning vs. evening chronotype;
THYM	trans	rs9513868	0.898	rs1831877	chr13:101900235	C/T	cg04067066	chr2:219756890	WNT10A	-0.67	-6.87	-0.58	6.78e-10	Prudent dietary pattern;
THYM	cis	rs713587	0.563	rs10865315	chr2:25100738	C/A	cg15423357	chr2:25149977	NA	0.63	6.19	0.54	1.53e-8	Body mass index in non-asthmatics;
THYM	cis	rs10788264	0.544	rs10788269	chr10:124022870	A/G	cg09507567	chr10:124027408	NA	0.53	5.44	0.49	4.11e-7	Total body bone mineral density;
THYM	cis	rs10799590	1.000	rs298738	chr1:224839522	A/G	cg01808320	chr1:224927238	CNIH3	-0.56	-5.06	-0.46	2.03e-6	Opioid dependence;
THYM	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg23711669	chr6:146136114	FBXO30	-0.98	-10.47	-0.73	1.68e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg18681998	chr4:17616180	MED28	0.95	9.51	0.7	1.88e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg11764359	chr7:65958608	NA	-0.62	-4.73	-0.44	7.94e-6	Aortic root size;
THYM	cis	rs11648796	0.879	rs12448432	chr16:778820	G/A	cg09263875	chr16:632152	PIGQ	0.63	4.91	0.45	3.79e-6	Height;
THYM	cis	rs988913	1.000	rs988913	chr6:54756308	C/T	cg04690482	chr6:54711388	FAM83B	0.47	5.15	0.47	1.4e-6	Menarche (age at onset);
THYM	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg06634786	chr22:41940651	POLR3H	0.64	4.97	0.45	2.91e-6	Vitiligo;
THYM	cis	rs9807841	0.592	rs10415961	chr19:10759981	G/C	cg17848348	chr19:10766748	ILF3	-0.61	-5.07	-0.46	1.97e-6	Inflammatory skin disease;
THYM	cis	rs2235649	0.833	rs9939694	chr16:1852760	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs7100689	0.754	rs10736339	chr10:82059970	G/C	cg01528321	chr10:82214614	TSPAN14	1.02	7.78	0.62	8.75e-12	Post bronchodilator FEV1;
THYM	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg27532560	chr4:187881888	NA	-0.95	-11.61	-0.77	6.5e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7729447	0.776	rs58529247	chr5:32693889	C/T	cg16267343	chr5:32710456	NPR3	0.79	7.16	0.59	1.69e-10	Blood pressure;
THYM	cis	rs6960043	0.502	rs6461145	chr7:15026872	C/T	cg19272540	chr7:15055459	NA	0.48	5.32	0.48	6.87e-7	Type 2 diabetes;
THYM	cis	rs10516089	0.504	rs13359217	chr5:171141491	G/T	cg17535961	chr5:171094783	NA	-0.41	-4.47	-0.42	2.17e-5	Venous thromboembolism (SNP x SNP interaction);
THYM	cis	rs5995756	0.666	rs5750857	chr22:40000221	A/C	cg21377881	chr22:40064566	CACNA1I	0.56	4.77	0.44	6.6e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg22535103	chr8:58192502	C8orf71	-0.94	-6.15	-0.53	1.84e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.69	-0.62	1.33e-11	Personality dimensions;
THYM	cis	rs12817211	0.502	rs7307230	chr12:50512632	C/T	cg06168149	chr12:50497778	GPD1	-0.3	-4.54	-0.42	1.65e-5	Colorectal or endometrial cancer;
THYM	cis	rs7084402	0.902	rs1346300	chr10:60287635	G/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4919694	0.808	rs77521106	chr10:104980726	G/T	cg04362960	chr10:104952993	NT5C2	1.09	6.52	0.56	3.33e-9	Arsenic metabolism;
THYM	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg25358565	chr5:93447407	FAM172A	1.37	10.88	0.74	2.21e-18	Diabetic retinopathy;
THYM	cis	rs10208649	0.908	rs60776154	chr2:54253813	T/A	cg04546899	chr2:54196757	PSME4	0.68	4.73	0.44	7.94e-6	Body mass index;
THYM	cis	rs4866334	1.000	rs116117462	chr5:18452827	C/A	cg24599790	chr5:18972260	NA	-1.14	-4.67	-0.43	9.77e-6	IgG glycosylation;
THYM	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg02887458	chr19:19495540	GATAD2A	0.46	5.18	0.47	1.25e-6	Bipolar disorder;
THYM	cis	rs7528419	0.895	rs602633	chr1:109821511	T/G	cg00908766	chr1:109817496	CELSR2	0.76	6.16	0.53	1.71e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
THYM	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg23711669	chr6:146136114	FBXO30	0.93	9.69	0.7	7.64e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6032067	0.636	rs6032093	chr20:43912167	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.7	-6.46	-0.55	4.41e-9	Blood protein levels;
THYM	cis	rs3091242	0.900	rs35345536	chr1:25766488	A/G	cg27572855	chr1:25598939	RHD	0.63	4.96	0.45	3.14e-6	Erythrocyte sedimentation rate;
THYM	cis	rs8141529	0.778	rs763073	chr22:29215542	G/A	cg02153584	chr22:29168773	CCDC117	0.62	4.77	0.44	6.72e-6	Lymphocyte counts;
THYM	cis	rs11731175	1.000	rs1597226	chr4:189859708	A/G	cg00431894	chr4:189871012	NA	-0.82	-6.24	-0.54	1.2e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9611565	0.525	rs9611549	chr22:41705909	C/G	cg06481639	chr22:41940642	POLR3H	-0.62	-4.78	-0.44	6.36e-6	Vitiligo;
THYM	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.92	7.5	0.61	3.42e-11	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6450176	0.625	rs67656636	chr5:53288455	C/A	ch.5.1024479R	chr5:53302184	ARL15	-1.01	-8.07	-0.64	2.17e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg21231944	chr12:82153410	PPFIA2	0.67	5.05	0.46	2.13e-6	Resting heart rate;
THYM	cis	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg06609049	chr19:2785107	THOP1	0.68	5.75	0.51	1.08e-7	Total cholesterol levels;
THYM	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg21926883	chr2:100939477	LONRF2	-0.61	-5.56	-0.5	2.42e-7	Intelligence (multi-trait analysis);
THYM	cis	rs5758511	0.689	rs17478227	chr22:42654327	C/G	cg22189786	chr22:42395067	WBP2NL	-0.67	-5.11	-0.46	1.69e-6	Birth weight;
THYM	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg18357526	chr6:26021779	HIST1H4A	0.83	6.97	0.58	4.25e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6473252	0.522	rs11779701	chr8:81825326	A/G	cg08595989	chr8:81827712	NA	-0.45	-4.71	-0.44	8.42e-6	Breast cancer;
THYM	cis	rs2486288	0.656	rs12908581	chr15:45548635	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.57	-4.51	-0.42	1.84e-5	Glomerular filtration rate;
THYM	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg04267008	chr7:1944627	MAD1L1	-0.67	-5.41	-0.49	4.75e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs6558530	0.932	rs7846610	chr8:1706675	C/T	cg09410841	chr8:1729607	CLN8	0.65	4.93	0.45	3.53e-6	Systolic blood pressure;
THYM	trans	rs8073060	0.586	rs7221203	chr17:34015532	T/C	cg19694781	chr19:47549865	TMEM160	-1.02	-8.69	-0.67	1.01e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	5.41	0.49	4.67e-7	Platelet count;
THYM	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.65	-0.62	1.6e-11	Schizophrenia;
THYM	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg12524338	chr4:183729343	NA	0.91	5.86	0.52	6.52e-8	Pediatric autoimmune diseases;
THYM	cis	rs988913	0.706	rs74714371	chr6:54959209	A/G	cg18532076	chr6:54711417	FAM83B	0.49	4.67	0.43	9.72e-6	Menarche (age at onset);
THYM	cis	rs863345	0.604	rs11264976	chr1:158446927	G/A	cg12129480	chr1:158549410	OR10X1	-0.47	-4.62	-0.43	1.23e-5	Pneumococcal bacteremia;
THYM	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg25208724	chr1:156163844	SLC25A44	1.11	8.66	0.66	1.22e-13	Testicular germ cell tumor;
THYM	cis	rs7851660	0.935	rs10818124	chr9:100603008	C/T	cg13688889	chr9:100608707	NA	-0.83	-7.31	-0.6	8.28e-11	Strep throat;
THYM	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg13695892	chr22:41940480	POLR3H	-0.64	-4.45	-0.42	2.3e-5	Neuroticism;
THYM	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	9.42	0.69	2.88e-15	Chronic sinus infection;
THYM	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg01448562	chr3:133502909	NA	-0.98	-8.5	-0.66	2.62e-13	Iron status biomarkers;
THYM	cis	rs10489202	0.608	rs10918827	chr1:168077044	A/G	cg24449463	chr1:168025552	DCAF6	0.78	7.4	0.6	5.43e-11	Schizophrenia;
THYM	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg06074448	chr4:187884817	NA	0.97	12.32	0.78	2.08e-21	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7688540	0.511	rs6841415	chr4:197383	A/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.91	5.56	0.5	2.45e-7	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs4478037	1.000	rs4478037	chr3:33160407	G/A	cg19404215	chr3:33155277	CRTAP	-1.3	-8.36	-0.65	5.25e-13	Major depressive disorder;
THYM	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	4.88	0.45	4.24e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2075230	0.850	rs9913914	chr17:7468509	G/A	cg10509001	chr17:7553872	ATP1B2	0.57	4.59	0.43	1.36e-5	Hormone measurements;
THYM	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	5.68	0.5	1.44e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7084402	0.967	rs1896243	chr10:60276291	C/T	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg24399712	chr22:39784796	NA	-0.87	-9.64	-0.7	9.72e-16	Intelligence (multi-trait analysis);
THYM	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg07424592	chr7:64974309	NA	1.04	4.87	0.45	4.36e-6	Diabetic kidney disease;
THYM	cis	rs1005224	1.000	rs1981898	chr14:76175565	C/A	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.73	-5.8	-0.51	8.55e-8	Large artery stroke;
THYM	cis	rs4907240	0.961	rs7580048	chr2:97304180	G/C	cg01950434	chr2:97203154	ARID5A	-0.59	-4.89	-0.45	4.09e-6	Event-related brain oscillations;
THYM	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg07362569	chr17:61921086	SMARCD2	0.73	6.71	0.57	1.42e-9	Prudent dietary pattern;
THYM	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg20503657	chr10:835505	NA	1.17	8.22	0.64	1.04e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg22709100	chr7:91322751	NA	-0.59	-4.77	-0.44	6.76e-6	Breast cancer;
THYM	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg23758822	chr17:41437982	NA	1.12	10.64	0.74	7.25e-18	Menopause (age at onset);
THYM	cis	rs9790314	0.580	rs960212	chr3:161047974	C/T	cg04691961	chr3:161091175	C3orf57	-0.56	-4.69	-0.43	8.97e-6	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg06850241	chr22:41845214	NA	0.54	4.58	0.43	1.42e-5	Vitiligo;
THYM	cis	rs3008870	0.959	rs2815353	chr1:67483372	A/G	cg02640540	chr1:67518911	SLC35D1	0.65	4.83	0.44	5.32e-6	Lymphocyte percentage of white cells;
THYM	cis	rs860818	1.000	rs858301	chr7:23244323	T/C	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs2985684	0.901	rs2354448	chr14:50098296	G/A	cg02151108	chr14:50098012	C14orf104	-0.67	-5.33	-0.48	6.48e-7	Carotid intima media thickness;
THYM	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg16797656	chr11:68205561	LRP5	0.46	4.7	0.43	8.67e-6	Total body bone mineral density;
THYM	trans	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg06636001	chr8:8085503	FLJ10661	0.76	6.85	0.57	7.41e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg12963246	chr6:28129442	ZNF389	0.83	6.71	0.57	1.42e-9	Parkinson's disease;
THYM	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.43	0.49	4.23e-7	Obesity-related traits;
THYM	cis	rs595982	0.527	rs55706579	chr19:49382969	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.89	-4.76	-0.44	7.01e-6	Red cell distribution width;
THYM	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg11764359	chr7:65958608	NA	0.69	4.78	0.44	6.27e-6	Aortic root size;
THYM	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg26384229	chr12:38710491	ALG10B	0.99	7.58	0.61	2.29e-11	Bladder cancer;
THYM	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg13695892	chr22:41940480	POLR3H	-0.93	-7.13	-0.59	1.99e-10	Vitiligo;
THYM	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.7	5.63	0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.15e-7	Obesity-related traits;
THYM	cis	rs3126085	0.935	rs11204952	chr1:152227321	G/A	cg10321714	chr1:152280068	FLG	0.64	4.78	0.44	6.43e-6	Atopic dermatitis;
THYM	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-5.54	-0.49	2.68e-7	Monocyte percentage of white cells;
THYM	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg13918804	chr1:2043761	PRKCZ	-0.68	-5.94	-0.52	4.68e-8	Height;
THYM	cis	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg09307838	chr4:120376055	NA	0.78	5.87	0.52	6.42e-8	Corneal astigmatism;
THYM	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg12826209	chr6:26865740	GUSBL1	0.84	4.58	0.43	1.42e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs924712	0.844	rs7752349	chr6:54727731	A/T	cg19716238	chr6:54711378	FAM83B	-0.46	-4.62	-0.43	1.21e-5	Breast cancer;
THYM	cis	rs7586879	0.789	rs13398155	chr2:25128550	C/T	cg01884057	chr2:25150051	NA	0.52	4.64	0.43	1.12e-5	Body mass index;
THYM	cis	rs9534288	0.700	rs57192057	chr13:46592327	C/G	cg15192986	chr13:46630673	CPB2	-0.65	-4.96	-0.45	3.05e-6	Blood protein levels;
THYM	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2932538	0.922	rs6673930	chr1:113104887	A/G	cg22162597	chr1:113214053	CAPZA1	0.65	5.32	0.48	6.9e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs2637266	0.703	rs2583062	chr10:78558472	T/C	cg18941641	chr10:78392320	NA	0.72	5.7	0.51	1.32e-7	Pulmonary function;
THYM	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs553169	1.000	rs553169	chr5:9979084	A/G	cg09699193	chr5:9457024	SEMA5A	-0.59	-4.61	-0.43	1.23e-5	Age-related macular degeneration (smoking status interaction);
THYM	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg16486109	chr11:613632	IRF7	0.48	5.02	0.46	2.41e-6	Systemic lupus erythematosus;
THYM	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1878931	0.624	rs28089	chr16:3446937	G/A	cg22508957	chr16:3507546	NAT15	0.49	5.1	0.46	1.73e-6	Body mass index (adult);
THYM	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg07606381	chr6:8435919	SLC35B3	-0.91	-6.58	-0.56	2.56e-9	Motion sickness;
THYM	cis	rs6032067	0.929	rs62208428	chr20:43827578	A/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.65	-11.76	-0.77	3.01e-20	Hemostatic factors and hematological phenotypes;
THYM	cis	rs960902	0.747	rs2216117	chr2:37723168	G/A	cg25341268	chr2:37734390	NA	0.57	4.89	0.45	4.18e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs10823500	0.748	rs12355080	chr10:71963608	G/A	cg02100629	chr10:71892760	AIFM2	-0.38	-4.59	-0.43	1.37e-5	Blood protein levels;
THYM	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg25918947	chr17:41365094	TMEM106A	-0.68	-5.79	-0.51	9.15e-8	Menopause (age at onset);
THYM	cis	rs7523273	0.565	rs34355011	chr1:207887322	T/G	cg22525895	chr1:207977042	MIR29B2	0.54	5.12	0.46	1.61e-6	Schizophrenia;
THYM	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg23260525	chr10:116636907	FAM160B1	0.52	5.19	0.47	1.19e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg08257088	chr16:3726052	TRAP1	-0.62	-4.63	-0.43	1.14e-5	Tuberculosis;
THYM	cis	rs7119	0.717	rs12916515	chr15:77818518	G/T	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs12765878	1.000	rs34300861	chr10:105643332	A/C	cg11005552	chr10:105648138	OBFC1	0.85	11.02	0.75	1.12e-18	Coronary artery disease;
THYM	cis	rs950881	0.932	rs10189154	chr2:102937544	C/T	cg20060108	chr2:102954350	IL1RL1	0.87	4.77	0.44	6.56e-6	Allergy;
THYM	cis	rs10781543	0.763	rs10781539	chr9:139320965	G/A	cg14115884	chr9:139300582	SDCCAG3	0.68	5.96	0.52	4.33e-8	Monocyte percentage of white cells;
THYM	cis	rs9902453	0.904	rs7218379	chr17:28402737	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-6.08	-0.53	2.47e-8	Coffee consumption (cups per day);
THYM	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	8.87	0.67	4.33e-14	Chronic sinus infection;
THYM	cis	rs665401	0.965	rs2750416	chr6:117259549	A/G	cg20376953	chr6:117187980	NA	-0.55	-4.49	-0.42	1.99e-5	Neutrophil percentage of granulocytes;
THYM	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg18252515	chr7:66147081	NA	0.64	4.81	0.44	5.7e-6	Aortic root size;
THYM	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	7.8	0.62	7.81e-12	Platelet count;
THYM	cis	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg18512352	chr11:47633146	NA	-0.38	-4.52	-0.42	1.75e-5	HDL cholesterol;
THYM	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg06713675	chr4:122721982	EXOSC9	-0.55	-5.09	-0.46	1.81e-6	Type 2 diabetes;
THYM	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.55	-5.6	-0.5	2.1e-7	Crohn's disease;
THYM	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg21773646	chr17:80085082	CCDC57	0.36	5.07	0.46	1.96e-6	Life satisfaction;
THYM	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg27490568	chr2:178487706	NA	0.66	5.9	0.52	5.5e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg13319975	chr6:146136371	FBXO30	-0.65	-5.35	-0.48	6.13e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg18132916	chr6:79620363	NA	-0.59	-5.52	-0.49	2.98e-7	Intelligence (multi-trait analysis);
THYM	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	4.51	0.42	1.85e-5	Bipolar disorder;
THYM	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs7809950	0.678	rs2301801	chr7:106870746	T/C	cg23024343	chr7:107201750	COG5	-1.0	-8.43	-0.65	3.79e-13	Coronary artery disease;
THYM	trans	rs12760731	0.623	rs12045201	chr1:178399218	A/G	cg06907405	chr16:48400475	SIAH1	-0.97	-6.87	-0.58	6.78e-10	Obesity-related traits;
THYM	cis	rs901683	1.000	rs12762495	chr10:46013615	T/C	cg18240400	chr10:46168597	ANUBL1	0.8	5.16	0.47	1.38e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs2730245	0.527	rs2730237	chr7:158706166	A/G	cg24397884	chr7:158709396	WDR60	0.55	5.36	0.48	5.79e-7	Height;
THYM	cis	rs13315871	0.929	rs9871725	chr3:58292525	T/G	cg00563845	chr3:58318305	PXK	0.59	5.03	0.46	2.29e-6	Cholesterol, total;
THYM	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg15556689	chr8:8085844	FLJ10661	0.69	5.48	0.49	3.42e-7	Mood instability;
THYM	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg04518342	chr5:131593106	PDLIM4	0.49	5.26	0.47	8.91e-7	Acylcarnitine levels;
THYM	cis	rs7909074	0.766	rs5000415	chr10:45383674	C/T	cg04218760	chr10:45406644	TMEM72	-0.63	-5.63	-0.5	1.86e-7	Mean corpuscular volume;
THYM	cis	rs11645898	0.872	rs7206422	chr16:72152652	C/T	cg03805757	chr16:71968109	PKD1L3	-0.74	-5.11	-0.46	1.63e-6	Blood protein levels;
THYM	cis	rs9543976	0.623	rs4885322	chr13:76171331	A/G	cg01531495	chr13:76123901	UCHL3	0.66	4.8	0.44	5.85e-6	Diabetic retinopathy;
THYM	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg08847533	chr14:75593920	NEK9	-1.01	-11.32	-0.76	2.63e-19	Height;
THYM	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.52	-5.14	-0.47	1.44e-6	Eosinophil percentage of white cells;
THYM	cis	rs7084402	0.967	rs1658459	chr10:60299246	C/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.52	-0.49	2.96e-7	Refractive error;
THYM	cis	rs870825	0.616	rs6552809	chr4:185643984	G/A	cg04058563	chr4:185651563	MLF1IP	1.0	9.06	0.68	1.72e-14	Blood protein levels;
THYM	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	4.54	0.42	1.66e-5	Hip circumference adjusted for BMI;
THYM	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.0	0.58	3.57e-10	Prudent dietary pattern;
THYM	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg17644776	chr2:200775616	C2orf69	-0.69	-5.22	-0.47	1.07e-6	LDL cholesterol to HDL cholesterol ratio;
THYM	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg15445000	chr17:37608096	MED1	-0.44	-5.22	-0.47	1.07e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs600806	0.888	rs11102971	chr1:109872370	C/T	cg23032129	chr1:109941072	SORT1	-0.57	-4.84	-0.44	5.11e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2319125	0.683	rs8080587	chr17:64039971	G/C	cg04446870	chr17:64440273	PRKCA	0.5	4.48	0.42	2.12e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg05872129	chr22:39784769	NA	-0.99	-10.62	-0.74	8.04e-18	Intelligence (multi-trait analysis);
THYM	cis	rs9653442	0.593	rs4851273	chr2:100848321	A/G	cg08017756	chr2:100939284	LONRF2	-0.62	-4.66	-0.43	1.05e-5	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs800586	0.871	rs800591	chr8:116811386	T/C	cg04656070	chr8:116661063	TRPS1	0.49	4.7	0.43	8.9e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.77	7.55	0.61	2.63e-11	Lymphocyte counts;
THYM	cis	rs9814567	1.000	rs4367113	chr3:134287975	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	trans	rs58106596	0.800	rs6737601	chr2:232572381	A/G	cg01370599	chr3:116745421	NA	0.95	7.0	0.58	3.59e-10	White blood cell count;Lymphocyte counts;
THYM	cis	rs910316	0.646	rs11546525	chr14:75537381	C/T	cg08847533	chr14:75593920	NEK9	0.87	7.85	0.63	6.25e-12	Height;
THYM	cis	rs28595532	0.920	rs55633605	chr4:119761589	G/A	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs10793273	1	rs10793273	chr11:77742595	T/C	cg09721595	chr11:77773924	THRSP	-0.99	-9.04	-0.68	1.86e-14	Pelvic organ prolapse;
THYM	cis	rs13202913	0.608	rs17054363	chr6:151746586	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.86	-4.76	-0.44	7.02e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg01304814	chr3:48885189	PRKAR2A	0.91	4.5	0.42	1.9e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg18289303	chr11:73146840	FAM168A	-1.01	-7.21	-0.59	1.33e-10	Depressive symptoms;
THYM	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg16230307	chr14:35515116	FAM177A1	0.94	6.02	0.53	3.34e-8	Psoriasis;
THYM	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg20295408	chr7:1910781	MAD1L1	-0.6	-4.47	-0.42	2.13e-5	Schizophrenia;
THYM	cis	rs907683	0.545	rs3755054	chr2:220280974	C/T	cg15015639	chr2:220282977	DES	0.42	5.98	0.52	3.93e-8	Resting heart rate;
THYM	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg02380750	chr20:61661411	NA	0.62	6.02	0.53	3.23e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4792901	0.959	rs72833147	chr17:41626578	C/T	cg21940313	chr17:41620911	ETV4	-0.52	-5.51	-0.49	3.08e-7	Dupuytren's disease;
THYM	cis	rs1007190	0.881	rs12941832	chr17:42987482	G/T	cg15406952	chr17:42872593	NA	0.79	5.46	0.49	3.83e-7	DNA methylation (variation);
THYM	trans	rs4262150	0.883	rs12654450	chr5:152238850	T/C	cg08281791	chr5:76607845	PDE8B	0.92	6.91	0.58	5.62e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg05872129	chr22:39784769	NA	-0.97	-10.14	-0.72	8.3e-17	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg17264618	chr3:40429014	ENTPD3	0.54	5.14	0.47	1.47e-6	Renal cell carcinoma;
THYM	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03576123	chr11:487126	PTDSS2	-1.48	-7.49	-0.61	3.49e-11	Body mass index;
THYM	cis	rs7107174	1.000	rs2512550	chr11:77943848	C/T	cg19901956	chr11:77921274	USP35	-0.76	-5.7	-0.5	1.35e-7	Testicular germ cell tumor;
THYM	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg01699819	chr7:1052092	C7orf50	-0.59	-4.95	-0.45	3.16e-6	Bronchopulmonary dysplasia;
THYM	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.72	7.49	0.61	3.58e-11	Lymphocyte counts;
THYM	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.94	6.09	0.53	2.4e-8	Smoking behavior;
THYM	cis	rs2976388	0.590	rs13254346	chr8:143823863	G/C	cg06565975	chr8:143823917	SLURP1	-0.61	-7.51	-0.61	3.22e-11	Urinary tract infection frequency;
THYM	cis	rs17209837	0.607	rs1473152	chr7:87080350	A/C	cg04996195	chr7:87105398	ABCB4	0.63	4.79	0.44	6.03e-6	Gallbladder cancer;
THYM	cis	rs752010	0.875	rs11210501	chr1:42091634	T/C	cg22486000	chr1:42919398	ZMYND12	-0.5	-5.83	-0.51	7.6e-8	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs11971779	0.793	rs9632774	chr7:139137562	C/T	cg07862535	chr7:139043722	LUC7L2	0.64	4.52	0.42	1.8e-5	Diisocyanate-induced asthma;
THYM	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg24874828	chr4:187887005	NA	-0.73	-7.49	-0.61	3.59e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg21775007	chr8:11205619	TDH	-0.68	-5.27	-0.48	8.47e-7	Retinal vascular caliber;
THYM	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg27284194	chr4:1044797	NA	0.62	4.73	0.44	7.81e-6	Recombination rate (females);
THYM	cis	rs439731	0.518	rs2260241	chr16:1075147	G/A	cg27549619	chr16:374924	AXIN1	0.94	4.99	0.46	2.68e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	trans	rs1920324	0.622	rs35843220	chr3:103893701	G/A	cg01901466	chr14:93388880	CHGA	0.65	6.91	0.58	5.4e-10	Colorectal cancer;
THYM	cis	rs4974559	0.790	rs28712208	chr4:1316695	A/T	cg02980000	chr4:1222292	CTBP1	0.82	5.11	0.46	1.69e-6	Systolic blood pressure;
THYM	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg00012203	chr2:219082015	ARPC2	-0.68	-5.78	-0.51	9.36e-8	Colorectal cancer;
THYM	cis	rs12912251	0.894	rs7183893	chr15:38996981	A/C	cg08274633	chr15:38988533	C15orf53	-0.23	-4.81	-0.44	5.59e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
THYM	cis	rs10779751	0.686	rs1148478	chr1:11174067	A/T	cg08854313	chr1:11322531	MTOR	0.72	5.71	0.51	1.3e-7	Body mass index;
THYM	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg18252515	chr7:66147081	NA	0.64	4.9	0.45	3.89e-6	Aortic root size;
THYM	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg24250549	chr1:154909240	PMVK	0.71	5.54	0.49	2.71e-7	Prostate cancer;
THYM	cis	rs9914544	0.545	rs9898426	chr17:18794071	A/G	cg26378065	chr17:18585709	ZNF286B	0.58	4.65	0.43	1.05e-5	Educational attainment (years of education);
THYM	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg06640241	chr16:89574553	SPG7	0.84	7.29	0.6	9.18e-11	Multiple myeloma (IgH translocation);
THYM	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg08847533	chr14:75593920	NEK9	-1.0	-11.26	-0.76	3.48e-19	Height;
THYM	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11890956	chr21:40555474	PSMG1	-0.66	-6.38	-0.55	6.51e-9	Menarche (age at onset);
THYM	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11890956	chr21:40555474	PSMG1	-0.65	-6.01	-0.53	3.34e-8	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg12011299	chr4:100065546	ADH4	0.69	6.2	0.54	1.46e-8	Alcohol dependence;
THYM	cis	rs36093924	0.646	rs7285557	chr22:42348790	T/C	cg10296410	chr22:42095368	MEI1	0.44	4.49	0.42	1.99e-5	Intelligence;
THYM	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6988636	1.000	rs60362869	chr8:124189971	A/G	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg26354017	chr1:205819088	PM20D1	-0.72	-5.69	-0.5	1.39e-7	Menarche (age at onset);
THYM	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg03909863	chr11:638404	DRD4	-0.78	-5.75	-0.51	1.07e-7	Systemic lupus erythematosus;
THYM	cis	rs41005	1.000	rs41005	chr2:8111231	A/G	cg03155496	chr2:8117019	LOC339788	-0.92	-8.82	-0.67	5.48e-14	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs12519773	0.526	rs7714485	chr5:92515301	A/C	cg18783429	chr5:92414398	NA	0.5	4.91	0.45	3.72e-6	Migraine;
THYM	cis	rs7586879	0.575	rs6744205	chr2:25133148	T/C	cg27107076	chr2:25050844	ADCY3	-0.29	-4.73	-0.44	7.91e-6	Body mass index;
THYM	cis	rs4866334	1.000	rs77574409	chr5:18485477	G/T	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs713587	1.000	rs713587	chr2:25158281	C/T	cg15423357	chr2:25149977	NA	0.65	7.01	0.58	3.5e-10	Body mass index in non-asthmatics;
THYM	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.21	8.51	0.66	2.47e-13	Cognitive test performance;
THYM	cis	rs4499344	0.633	rs259258	chr19:33152523	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.92	7.75	0.62	1.02e-11	Mean platelet volume;
THYM	cis	rs57920188	0.535	rs77116992	chr1:4095498	T/A	cg20703997	chr1:4087676	NA	0.74	5.31	0.48	7.07e-7	Interleukin-17 levels;
THYM	cis	rs11166927	1.000	rs13256625	chr8:140805003	G/T	cg16909799	chr8:140841666	TRAPPC9	0.62	5.51	0.49	3.01e-7	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-4.83	-0.44	5.21e-6	Hemoglobin concentration;
THYM	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg22535103	chr8:58192502	C8orf71	-0.88	-4.93	-0.45	3.51e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg26384229	chr12:38710491	ALG10B	0.7	5.4	0.48	4.87e-7	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg13695892	chr22:41940480	POLR3H	0.86	6.43	0.55	5.06e-9	Vitiligo;
THYM	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg22535103	chr8:58192502	C8orf71	-0.86	-4.82	-0.44	5.4e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs2073300	1.000	rs34449811	chr20:23443771	T/C	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6867032	1.000	rs2129471	chr5:2016236	C/G	cg26168224	chr5:2018326	NA	1.29	15.56	0.85	7.19e-28	Gut microbiome composition (winter);
THYM	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg10515332	chr4:99064459	C4orf37	0.58	4.62	0.43	1.21e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs3733631	0.948	rs28438896	chr4:104625753	C/T	cg24090629	chr4:104641072	TACR3	-0.86	-5.41	-0.49	4.62e-7	Menarche (age at onset);
THYM	cis	rs662064	0.748	rs2506896	chr1:10603716	T/C	cg20482658	chr1:10539492	PEX14	0.48	6.04	0.53	2.97e-8	Asthma;
THYM	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg12373951	chr3:133503437	NA	0.57	6.17	0.53	1.69e-8	Iron status biomarkers;
THYM	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg05932139	chr16:680872	WFIKKN1	-0.59	-4.84	-0.44	5.07e-6	Height;
THYM	cis	rs6570726	0.526	rs9376928	chr6:145724403	T/G	cg23711669	chr6:146136114	FBXO30	-0.61	-4.83	-0.44	5.16e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9902453	0.845	rs72823935	chr17:28008595	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.86	0.45	4.59e-6	Coffee consumption (cups per day);
THYM	cis	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs7267979	1.000	rs6107046	chr20:25442049	G/A	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg14983838	chr19:29218262	NA	0.83	5.48	0.49	3.46e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs7072216	0.727	rs942808	chr10:100168102	C/A	cg03852570	chr10:100175106	PYROXD2	0.38	4.89	0.45	4.04e-6	Metabolite levels;
THYM	cis	rs11247915	0.561	rs12750420	chr1:26608649	G/A	cg00852783	chr1:26633632	UBXN11	0.77	6.08	0.53	2.48e-8	Obesity-related traits;
THYM	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg07389463	chr12:132296394	NA	0.62	5.29	0.48	7.69e-7	Migraine;
THYM	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs9926296	0.744	rs352939	chr16:89710378	G/A	cg03605463	chr16:89740564	NA	0.85	7.02	0.58	3.35e-10	Vitiligo;
THYM	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-6.02	-0.53	3.27e-8	Prostate cancer;
THYM	cis	rs2067615	0.579	rs10778506	chr12:107143260	T/C	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg18105134	chr13:113819100	PROZ	-0.98	-9.11	-0.68	1.32e-14	Platelet distribution width;
THYM	cis	rs11577318	0.853	rs12728971	chr1:26626612	C/T	cg19677267	chr1:26645161	CD52;UBXN11	-0.46	-5.87	-0.52	6.35e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs747334	1.000	rs747334	chr10:92744744	A/G	cg07620928	chr10:92689909	NA	0.55	4.52	0.42	1.79e-5	Fibroblast growth factor basic levels;
THYM	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg27588902	chr6:42928151	GNMT	0.56	5.77	0.51	1.01e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7107174	0.748	rs2063730	chr11:78048524	A/C	cg19901956	chr11:77921274	USP35	-0.67	-5.5	-0.49	3.2e-7	Testicular germ cell tumor;
THYM	cis	rs9915657	0.870	rs918081	chr17:70127808	G/A	cg06234051	chr17:70120541	SOX9	-0.69	-6.47	-0.55	4.2e-9	Thyroid hormone levels;
THYM	cis	rs6988636	0.710	rs17316158	chr8:124157607	A/C	cg23067535	chr8:124195133	FAM83A	-0.99	-4.82	-0.44	5.52e-6	Urinary uromodulin levels;
THYM	cis	rs4849845	0.889	rs2289174	chr2:121045884	G/A	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg11189052	chr15:85197271	WDR73	-0.59	-4.51	-0.42	1.89e-5	P wave terminal force;
THYM	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg16006841	chr5:176797999	RGS14	0.5	5.97	0.52	4.02e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs870825	0.929	rs72689260	chr4:185590656	G/T	cg04058563	chr4:185651563	MLF1IP	0.96	6.73	0.57	1.26e-9	Blood protein levels;
THYM	cis	rs12282928	0.743	rs1109906	chr11:48284033	C/T	cg22827986	chr11:48284249	OR4X1	-0.44	-4.47	-0.42	2.15e-5	Migraine - clinic-based;
THYM	trans	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg10856724	chr12:34555212	NA	-0.95	-8.21	-0.64	1.07e-12	Bladder cancer;
THYM	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg12863693	chr15:85201151	NMB	0.66	5.81	0.51	8.26e-8	Schizophrenia;
THYM	cis	rs986417	1.000	rs10136642	chr14:60946098	G/C	cg27398547	chr14:60952738	C14orf39	1.13	6.34	0.55	7.62e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs7975161	0.630	rs6539128	chr12:104618454	A/G	cg25273343	chr12:104657179	TXNRD1	-0.78	-5.35	-0.48	6.15e-7	Toenail selenium levels;
THYM	cis	rs4557020	1.000	rs4557020	chr2:54718181	A/G	cg11007406	chr2:54682859	SPTBN1	-0.37	-4.66	-0.43	1.03e-5	Myopia (pathological);
THYM	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg13695892	chr22:41940480	POLR3H	0.93	7.09	0.59	2.34e-10	Vitiligo;
THYM	cis	rs9831754	1.000	rs3946823	chr3:78353052	G/A	cg06138941	chr3:78371609	NA	-0.66	-4.5	-0.42	1.95e-5	Calcium levels;
THYM	cis	rs6732160	0.588	rs1430345	chr2:73370682	A/G	cg24220031	chr2:73402428	NA	-0.73	-6.05	-0.53	2.79e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12122100	0.545	rs1984615	chr1:146506206	G/A	cg22671717	chr1:146548657	NA	-0.52	-5.2	-0.47	1.12e-6	HIV-1 control;
THYM	cis	rs10203711	1.000	rs7582256	chr2:239587446	C/T	cg14580085	chr2:239553406	NA	0.62	5.61	0.5	1.96e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12935418	0.552	rs2549842	chr16:81023659	A/G	cg16651780	chr16:81037892	C16orf61	1.0	6.45	0.55	4.74e-9	Mean corpuscular volume;
THYM	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	6.31	0.54	8.98e-9	Smoking behavior;
THYM	cis	rs1642645	0.793	rs4083557	chr1:42478177	C/T	cg06092502	chr1:42611687	NA	0.61	4.74	0.44	7.58e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg10334053	chr1:2078117	PRKCZ	-0.44	-4.45	-0.42	2.3e-5	Height;
THYM	cis	rs7649443	0.959	rs2044860	chr3:196949870	C/T	cg20744464	chr3:196756875	MFI2	0.63	4.64	0.43	1.12e-5	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs8078723	0.714	rs2241245	chr17:38151014	C/T	cg17467752	chr17:38218738	THRA	-0.8	-6.7	-0.57	1.46e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg10856724	chr12:34555212	NA	-1.0	-8.86	-0.67	4.42e-14	Bladder cancer;
THYM	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg19346786	chr7:2764209	NA	-0.68	-5.7	-0.51	1.33e-7	Height;
THYM	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-1.07	-9.37	-0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Body mass index;
THYM	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	trans	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg20587970	chr11:113659929	NA	-1.25	-8.26	-0.65	8.39e-13	Hip circumference adjusted for BMI;
THYM	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg07061783	chr6:25882402	NA	-0.6	-4.55	-0.42	1.59e-5	Blood metabolite levels;
THYM	cis	rs6032067	0.929	rs8126178	chr20:43822581	A/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.63	-7.28	-0.6	9.67e-11	Blood protein levels;
THYM	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg23711669	chr6:146136114	FBXO30	0.93	9.39	0.69	3.36e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg03732007	chr1:2071316	PRKCZ	0.5	4.51	0.42	1.89e-5	Height;
THYM	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03517284	chr6:25882590	NA	-0.77	-6.14	-0.53	1.87e-8	Blood metabolite levels;
THYM	cis	rs728616	0.867	rs76239460	chr10:81723227	C/T	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg09455208	chr3:40491958	NA	-0.46	-4.72	-0.44	8.11e-6	Renal cell carcinoma;
THYM	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.9	10.3	0.73	3.87e-17	Prudent dietary pattern;
THYM	cis	rs11190604	0.767	rs10883477	chr10:102161396	A/G	cg07570687	chr10:102243282	WNT8B	0.81	7.81	0.63	7.43e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg07169764	chr2:136633963	MCM6	-0.68	-6.23	-0.54	1.25e-8	Mosquito bite size;
THYM	cis	rs9302065	0.565	rs2993585	chr13:95961966	G/A	cg26751094	chr13:95954534	ABCC4	-0.49	-5.49	-0.49	3.39e-7	Blood metabolite levels;
THYM	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg19346786	chr7:2764209	NA	0.57	4.82	0.44	5.46e-6	Height;
THYM	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.3	9.51	0.7	1.84e-15	Gut microbiome composition (summer);
THYM	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.31e-5	Retinal vascular caliber;
THYM	cis	rs3204270	0.759	rs8066217	chr17:79672615	C/G	cg13117272	chr17:79681052	SLC25A10	-0.76	-4.76	-0.44	6.85e-6	Dental caries;
THYM	cis	rs728616	0.867	rs17883671	chr10:81695193	C/T	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.54	0.42	1.68e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9959145	1.000	rs28821540	chr18:12558308	G/A	cg14160804	chr18:12703040	PSMG2;CEP76	-0.92	-4.5	-0.42	1.95e-5	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.6	0.5	2.09e-7	Obesity-related traits;
THYM	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg03188948	chr7:1209495	NA	0.68	4.73	0.44	7.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg05234568	chr11:5960015	NA	-0.55	-4.46	-0.42	2.26e-5	DNA methylation (variation);
THYM	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg02454025	chr1:11042201	C1orf127	0.92	11.02	0.75	1.13e-18	Ewing sarcoma;
THYM	cis	rs11840576	0.588	rs331976	chr13:110317769	G/T	cg16896868	chr13:110319562	NA	-0.58	-5.05	-0.46	2.11e-6	Paclitaxel disposition in epithelial ovarian cancer;
THYM	cis	rs7247513	0.964	rs8100964	chr19:12720631	C/T	cg01871581	chr19:12707946	ZNF490	-0.84	-8.63	-0.66	1.36e-13	Bipolar disorder;
THYM	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg22920501	chr2:26401640	FAM59B	-0.71	-6.33	-0.54	7.92e-9	Gut microbiome composition (summer);
THYM	cis	rs9420	0.754	rs631791	chr11:57675410	A/G	cg19752551	chr11:57585705	CTNND1	0.7	7.16	0.59	1.73e-10	Schizophrenia;
THYM	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg09060608	chr5:178986726	RUFY1	0.64	7.17	0.59	1.61e-10	Lung cancer;
THYM	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg19931206	chr6:11138650	LOC221710	-0.83	-7.1	-0.59	2.2e-10	Depressive symptoms;
THYM	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg12501888	chr15:85177176	SCAND2	-0.6	-4.51	-0.42	1.85e-5	P wave terminal force;
THYM	cis	rs6988636	0.579	rs28528232	chr8:124189308	G/A	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs7567389	0.719	rs4150404	chr2:128050000	A/G	cg09760422	chr2:128146352	NA	-0.4	-4.52	-0.42	1.8e-5	Self-rated health;
THYM	cis	rs11690935	0.918	rs11757	chr2:172641045	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.84	-6.16	-0.53	1.77e-8	Schizophrenia;
THYM	cis	rs6840360	0.550	rs7689266	chr4:152561048	T/C	cg17479576	chr4:152424074	FAM160A1	-0.83	-5.86	-0.52	6.62e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6998277	1.000	rs35155104	chr8:103646559	G/T	cg10187029	chr8:103597600	NA	0.57	4.49	0.42	2.04e-5	Migraine;
THYM	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg12016809	chr21:47604291	C21orf56	-0.78	-5.38	-0.48	5.36e-7	Testicular germ cell tumor;
THYM	cis	rs11731175	0.961	rs62341080	chr4:189860724	T/C	cg00431894	chr4:189871012	NA	-0.83	-6.41	-0.55	5.52e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1971762	0.561	rs4759288	chr12:54084006	T/A	cg16917193	chr12:54089295	NA	0.91	9.3	0.69	5.24e-15	Height;
THYM	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12530845	0.623	rs73721673	chr7:135349573	A/T	cg23117316	chr7:135346802	PL-5283	-0.83	-6.23	-0.54	1.29e-8	Red blood cell traits;
THYM	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4499344	0.524	rs259242	chr19:33144248	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.9	6.28	0.54	9.92e-9	Mean platelet volume;
THYM	cis	rs6062788	0.570	rs12624668	chr20:61706117	A/G	cg17296441	chr20:62284078	STMN3	0.61	4.45	0.42	2.35e-5	Body mass index;
THYM	cis	rs4595586	0.545	rs3911798	chr12:39389901	A/G	cg13010199	chr12:38710504	ALG10B	0.59	4.47	0.42	2.16e-5	Morning vs. evening chronotype;
THYM	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.67	-5.18	-0.47	1.22e-6	Tonsillectomy;
THYM	cis	rs8130944	0.893	rs2839577	chr21:44151433	C/T	cg03543861	chr21:44258195	NA	0.5	4.67	0.43	9.71e-6	Perceived unattractiveness to mosquitoes;
THYM	cis	rs6570726	0.935	rs452552	chr6:145820781	G/A	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs796364	0.694	rs1653299	chr2:201075611	A/G	cg17644776	chr2:200775616	C2orf69	0.8	6.65	0.56	1.85e-9	Schizophrenia;
THYM	cis	rs34638657	0.518	rs7196560	chr16:82168162	A/T	cg07307142	chr16:82071433	HSD17B2	-0.75	-6.0	-0.52	3.55e-8	Lung adenocarcinoma;
THYM	cis	rs11997175	0.646	rs6468197	chr8:33734894	G/T	ch.8.33884649F	chr8:33765107	NA	0.68	5.1	0.46	1.76e-6	Body mass index;
THYM	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs72627123	0.867	rs73301477	chr14:74463560	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg20476274	chr7:133979776	SLC35B4	0.67	4.62	0.43	1.22e-5	Mean platelet volume;
THYM	cis	rs6964587	0.597	rs975707	chr7:91874527	C/G	cg17063962	chr7:91808500	NA	0.75	5.7	0.5	1.36e-7	Breast cancer;
THYM	cis	rs2797160	0.967	rs6910786	chr6:126017141	A/T	cg16306078	chr6:126000798	NA	0.54	5.56	0.5	2.5e-7	Endometrial cancer;
THYM	cis	rs7104764	0.957	rs6598064	chr11:243557	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs7107174	0.901	rs990706	chr11:78135704	C/T	cg02023728	chr11:77925099	USP35	0.57	4.84	0.44	5.1e-6	Testicular germ cell tumor;
THYM	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg00074818	chr8:8560427	CLDN23	0.58	5.4	0.48	4.91e-7	Obesity-related traits;
THYM	cis	rs6840360	0.533	rs13119490	chr4:152713412	A/G	cg22705602	chr4:152727874	NA	0.76	9.95	0.71	2.12e-16	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7104764	0.917	rs1045288	chr11:237087	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.14	10.43	0.73	1.95e-17	Menarche (age at onset);
THYM	cis	rs3204270	0.639	rs11871678	chr17:79654285	G/A	cg18367735	chr17:79674897	NA	0.8	4.77	0.44	6.61e-6	Dental caries;
THYM	cis	rs8067235	1.000	rs58337218	chr17:79023953	C/T	cg06969622	chr17:79022798	BAIAP2	0.48	4.48	0.42	2.08e-5	Memory performance;
THYM	trans	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.37	-0.6	6.32e-11	Triglycerides;
THYM	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg08885076	chr2:99613938	TSGA10	0.53	5.11	0.46	1.64e-6	Chronic sinus infection;
THYM	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs921968	0.541	rs3755042	chr2:219317248	T/C	cg02176678	chr2:219576539	TTLL4	-0.74	-7.3	-0.6	8.93e-11	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-5.31	-0.48	7.25e-7	Hemoglobin concentration;
THYM	cis	rs7084402	0.902	rs1658484	chr10:60288543	G/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.66e-7	Refractive error;
THYM	cis	rs2811415	0.597	rs13093679	chr3:127726005	T/C	cg05377949	chr3:127951287	EEFSEC	0.37	4.6	0.43	1.29e-5	Lung function (FEV1/FVC);
THYM	trans	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	8.11	0.64	1.73e-12	Exhaled nitric oxide output;
THYM	cis	rs2903698	0.565	rs13137105	chr4:76416387	A/G	cg03209871	chr4:76438412	RCHY1;THAP6	0.42	4.79	0.44	6.08e-6	Prion diseases;
THYM	cis	rs3784262	0.528	rs11071364	chr15:58334113	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.66	-5.15	-0.47	1.43e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
THYM	cis	rs12532214	0.724	rs79042841	chr7:3160660	T/C	cg19214707	chr7:3157722	NA	-0.74	-4.45	-0.42	2.35e-5	Itch intensity from mosquito bite;
THYM	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg10334053	chr1:2078117	PRKCZ	-0.5	-5.01	-0.46	2.48e-6	Height;
THYM	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg13918804	chr1:2043761	PRKCZ	-0.62	-4.68	-0.43	9.63e-6	Height;
THYM	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg00080972	chr5:178986291	RUFY1	-0.61	-8.39	-0.65	4.6e-13	Lung cancer;
THYM	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg21856205	chr7:94953877	PON1	-0.81	-8.13	-0.64	1.57e-12	Paraoxonase activity;
THYM	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg11812906	chr14:75593930	NEK9	-0.8	-7.19	-0.59	1.48e-10	Height;
THYM	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg03517284	chr6:25882590	NA	0.7	5.53	0.49	2.87e-7	Schizophrenia;
THYM	cis	rs747334	0.818	rs10785977	chr10:92705876	C/T	cg07620928	chr10:92689909	NA	0.54	4.84	0.44	5.04e-6	Fibroblast growth factor basic levels;
THYM	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.47	-0.49	3.59e-7	Mean corpuscular volume;
THYM	cis	rs7584330	0.554	rs2325838	chr2:238386515	C/A	cg08992911	chr2:238395768	MLPH	1.18	7.08	0.59	2.47e-10	Prostate cancer;
THYM	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg07414643	chr4:187882934	NA	-0.57	-4.88	-0.45	4.34e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs2742234	0.541	rs10899778	chr10:43718509	G/C	cg06632098	chr10:43605906	RET	0.8	5.26	0.47	8.98e-7	Hirschsprung disease;
THYM	cis	rs6570726	0.935	rs432086	chr6:145841593	C/T	cg23711669	chr6:146136114	FBXO30	-0.88	-8.85	-0.67	4.7e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4919694	1.000	rs11191545	chr10:104829793	C/T	cg04362960	chr10:104952993	NT5C2	1.14	7.07	0.59	2.65e-10	Arsenic metabolism;
THYM	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg27490568	chr2:178487706	NA	0.6	5.23	0.47	9.91e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1865721	0.771	rs4410169	chr18:73138840	A/G	cg26385618	chr18:73139727	C18orf62	-0.65	-4.75	-0.44	7.3e-6	Intelligence;
THYM	cis	rs62070183	0.938	rs1990825	chr17:31056292	G/A	cg23177095	chr17:30873196	MYO1D	0.66	5.14	0.47	1.48e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg12386194	chr3:101231763	SENP7	0.66	4.93	0.45	3.45e-6	Colorectal cancer;
THYM	trans	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg25517755	chr10:38738941	LOC399744	-0.76	-6.92	-0.58	5.26e-10	Corneal astigmatism;
THYM	cis	rs11785693	0.862	rs11782556	chr8:5002389	C/G	cg26367366	chr8:4980734	NA	1.16	5.46	0.49	3.79e-7	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs6500395	1.000	rs12919520	chr16:48705760	G/C	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg08772003	chr10:104629869	AS3MT	-0.58	-4.84	-0.44	5.09e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs11225247	0.772	rs11501344	chr11:102228252	A/G	cg11690896	chr11:102217788	BIRC2	1.12	5.18	0.47	1.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs9788682	0.633	rs2656070	chr15:78730252	A/G	cg18825076	chr15:78729989	IREB2	-0.66	-5.04	-0.46	2.22e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg23711669	chr6:146136114	FBXO30	-0.83	-7.91	-0.63	4.62e-12	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg13319975	chr6:146136371	FBXO30	-0.63	-4.99	-0.46	2.75e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs778371	0.624	rs6733495	chr2:233616709	A/G	cg08000102	chr2:233561755	GIGYF2	0.83	7.52	0.61	3.07e-11	Schizophrenia;
THYM	cis	rs939658	0.728	rs8031638	chr15:79422726	C/T	cg17916960	chr15:79447300	NA	-0.62	-6.56	-0.56	2.82e-9	Refractive error;
THYM	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-4.87	-0.45	4.47e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg12386194	chr3:101231763	SENP7	-0.68	-5.09	-0.46	1.8e-6	Colorectal cancer;
THYM	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg26967526	chr14:35346199	BAZ1A	-0.8	-5.27	-0.48	8.47e-7	Psoriasis;
THYM	cis	rs4924997	0.772	rs2018675	chr17:19441531	A/G	cg03910582	chr17:19030146	GRAPL	-0.49	-4.58	-0.43	1.39e-5	Lymphocyte counts;
THYM	cis	rs3540	0.512	rs8033818	chr15:91075535	C/T	cg22089800	chr15:90895588	ZNF774	-0.67	-5.06	-0.46	2.02e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs4430311	0.566	rs10927035	chr1:243703982	C/T	cg25706552	chr1:244017396	NA	-0.56	-4.92	-0.45	3.62e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs6754311	0.517	rs60453613	chr2:136527120	G/C	cg07169764	chr2:136633963	MCM6	0.94	8.32	0.65	6.19e-13	Mosquito bite size;
THYM	cis	rs3862030	0.533	rs715440	chr10:104258095	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.68	-5.74	-0.51	1.15e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs72828912	0.764	rs12175687	chr6:24089375	A/G	cg19882886	chr6:25043046	NA	-0.88	-4.58	-0.43	1.42e-5	Squamous cell lung carcinoma;
THYM	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg10802521	chr3:52805072	NEK4	-0.75	-7.03	-0.58	3.15e-10	Electroencephalogram traits;
THYM	cis	rs28595532	0.920	rs114696063	chr4:119760624	T/A	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs2237234	0.580	rs7763910	chr6:26472655	C/T	cg05738196	chr6:26577821	NA	-0.65	-4.68	-0.43	9.41e-6	Autism spectrum disorder or schizophrenia;
THYM	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	6.53	0.56	3.24e-9	Obesity-related traits;
THYM	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg06850241	chr22:41845214	NA	0.54	4.68	0.43	9.37e-6	Vitiligo;
THYM	cis	rs12519773	0.526	rs4242241	chr5:92518370	C/T	cg18783429	chr5:92414398	NA	0.5	4.91	0.45	3.72e-6	Migraine;
THYM	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg12863693	chr15:85201151	NMB	0.66	5.81	0.51	8.26e-8	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6960043	0.818	rs1974620	chr7:15065467	A/G	cg19272540	chr7:15055459	NA	0.42	4.7	0.43	8.87e-6	Type 2 diabetes;
THYM	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg03929089	chr4:120376271	NA	-0.99	-12.81	-0.8	2.07e-22	Height;
THYM	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg05187965	chr10:45406764	TMEM72	-0.56	-5.5	-0.49	3.16e-7	Mean corpuscular volume;
THYM	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg26597838	chr10:835615	NA	1.15	8.25	0.65	8.82e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg00310523	chr12:86230176	RASSF9	0.59	5.41	0.49	4.71e-7	Major depressive disorder;
THYM	cis	rs2069036	0.743	rs9988752	chr10:16075416	C/A	cg26633223	chr10:15133461	NA	0.61	4.7	0.43	8.63e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9419702	0.568	rs7920966	chr10:133555185	G/T	cg04492858	chr10:133558786	NA	0.44	4.47	0.42	2.14e-5	Survival in rectal cancer;
THYM	cis	rs7178572	0.568	rs1125617	chr15:77532711	A/G	cg22256960	chr15:77711686	NA	-1.04	-8.57	-0.66	1.83e-13	Type 2 diabetes;
THYM	cis	rs9929218	0.529	rs11075694	chr16:68730366	C/T	cg01251360	chr16:68772225	CDH1	-0.29	-4.45	-0.42	2.36e-5	Colorectal cancer;
THYM	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg07371521	chr5:154026371	NA	0.57	5.45	0.49	3.96e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs3768617	0.510	rs3768618	chr1:183092491	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg02527881	chr3:46936655	PTH1R	-0.63	-6.29	-0.54	9.52e-9	Colorectal cancer;
THYM	cis	rs6430585	1.000	rs73958618	chr2:136500475	A/G	cg04750100	chr2:136595281	LCT	0.51	5.01	0.46	2.55e-6	Corneal structure;
THYM	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg02493740	chr2:85810744	VAMP5	-0.64	-5.03	-0.46	2.35e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs12049351	0.774	rs1065675	chr1:229622162	A/G	cg11742688	chr1:229674241	ABCB10	-0.54	-4.47	-0.42	2.14e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg24163568	chr5:669837	TPPP	-0.58	-5.41	-0.49	4.63e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	trans	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Bladder cancer;
THYM	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.78	-7.27	-0.6	1.01e-10	Personality dimensions;
THYM	cis	rs59197085	0.534	rs2307039	chr7:128449355	A/G	cg00734629	chr7:128471146	FLNC	0.76	4.51	0.42	1.89e-5	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
THYM	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg03806693	chr22:41940476	POLR3H	-1.22	-11.17	-0.75	5.43e-19	Vitiligo;
THYM	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg21775007	chr8:11205619	TDH	-0.73	-5.66	-0.5	1.63e-7	Retinal vascular caliber;
THYM	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg06713675	chr4:122721982	EXOSC9	-0.83	-9.23	-0.69	7.38e-15	Type 2 diabetes;
THYM	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg01304814	chr3:48885189	PRKAR2A	0.96	4.86	0.45	4.55e-6	Cognitive function;
THYM	cis	rs7589728	0.563	rs80324973	chr2:88447264	T/G	cg04511125	chr2:88470314	THNSL2	0.66	4.62	0.43	1.21e-5	Plasma clusterin levels;
THYM	cis	rs2073300	1.000	rs6048824	chr20:23457645	C/A	cg12062639	chr20:23401060	NAPB	0.99	4.96	0.45	3.07e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6430585	0.528	rs56064699	chr2:136595706	G/A	cg04750100	chr2:136595281	LCT	0.57	5.23	0.47	9.99e-7	Corneal structure;
THYM	cis	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.48	4.67	0.43	9.73e-6	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4242434	0.698	rs10104039	chr8:22538384	A/G	cg03733263	chr8:22462867	KIAA1967	-0.98	-9.9	-0.71	2.68e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs490234	0.702	rs4838279	chr9:128411726	G/A	cg14078157	chr9:128172775	NA	-0.71	-5.43	-0.49	4.24e-7	Mean arterial pressure;
THYM	cis	rs9790314	1.000	rs336583	chr3:161081981	A/T	cg03342759	chr3:160939853	NMD3	0.75	6.76	0.57	1.14e-9	Morning vs. evening chronotype;
THYM	trans	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg25214090	chr10:38739885	LOC399744	0.86	7.53	0.61	2.86e-11	Corneal astigmatism;
THYM	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06481639	chr22:41940642	POLR3H	0.8	4.92	0.45	3.61e-6	Vitiligo;
THYM	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg00898013	chr13:113819073	PROZ	-0.88	-9.0	-0.68	2.24e-14	Platelet distribution width;
THYM	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg20295408	chr7:1910781	MAD1L1	-0.68	-5.09	-0.46	1.78e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg14004847	chr7:1930337	MAD1L1	-0.65	-5.29	-0.48	7.86e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs7465272	1.000	rs35900184	chr8:143693411	C/T	cg01509843	chr8:143695822	ARC	0.71	4.74	0.44	7.47e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg00898013	chr13:113819073	PROZ	-0.81	-7.72	-0.62	1.17e-11	Platelet distribution width;
THYM	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs7575217	0.767	rs13386749	chr2:101746592	C/T	cg23907051	chr2:101730305	TBC1D8	-0.41	-5.5	-0.49	3.25e-7	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs7975161	0.938	rs10400561	chr12:104640920	A/G	cg25273343	chr12:104657179	TXNRD1	-0.68	-4.6	-0.43	1.32e-5	Toenail selenium levels;
THYM	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	cis	rs2734839	0.896	rs11608109	chr11:113303448	G/C	cg14159747	chr11:113255604	NA	0.32	6.22	0.54	1.34e-8	Information processing speed;
THYM	cis	rs9649465	0.704	rs665867	chr7:123432329	A/G	cg15443791	chr7:124364398	NA	-0.6	-5.08	-0.46	1.85e-6	Migraine;
THYM	cis	rs9581857	0.725	rs117947621	chr13:28022267	T/C	cg22138327	chr13:27999177	GTF3A	0.86	4.84	0.44	5e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg10518543	chr12:38710700	ALG10B	-0.57	-4.58	-0.43	1.42e-5	Morning vs. evening chronotype;
THYM	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg11266682	chr4:10021025	SLC2A9	-0.61	-8.27	-0.65	7.99e-13	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7043114	0.507	rs7037075	chr9:95216613	G/A	cg14631576	chr9:95140430	CENPP	-0.82	-8.14	-0.64	1.56e-12	Height;
THYM	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-7.97	-0.63	3.53e-12	Life satisfaction;
THYM	cis	rs7119	0.635	rs867916	chr15:77882860	A/G	cg27398640	chr15:77910606	LINGO1	0.68	7.66	0.62	1.58e-11	Type 2 diabetes;
THYM	cis	rs13185784	0.703	rs35394934	chr5:179677555	T/C	cg13944838	chr5:179740914	GFPT2	0.72	4.86	0.45	4.65e-6	TRAIL levels;
THYM	cis	rs7312774	0.881	rs79048355	chr12:107311169	G/T	cg16260113	chr12:107380972	MTERFD3	0.97	5.63	0.5	1.84e-7	Severe influenza A (H1N1) infection;
THYM	cis	rs1061377	1.000	rs3733277	chr4:39117103	G/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg09877947	chr5:131593287	PDLIM4	0.62	5.48	0.49	3.42e-7	Blood metabolite levels;
THYM	cis	rs747334	0.846	rs10785980	chr10:92718468	A/G	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg24531977	chr5:56204891	C5orf35	1.02	8.49	0.66	2.71e-13	Initial pursuit acceleration;
THYM	cis	rs807029	0.533	rs67813203	chr10:102738551	A/G	cg14905631	chr10:102746534	C10orf2;MRPL43	0.36	4.93	0.45	3.49e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs11122895	0.967	rs11677031	chr2:112471639	C/T	cg23262488	chr2:112468472	NA	0.67	9.57	0.7	1.36e-15	Allergic sensitization;
THYM	cis	rs2742234	0.590	rs2742237	chr10:43621323	C/G	cg06632098	chr10:43605906	RET	-0.77	-4.75	-0.44	7.32e-6	Hirschsprung disease;
THYM	trans	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg07211511	chr3:129823064	LOC729375	1.12	9.65	0.7	9.06e-16	Blood pressure (smoking interaction);
THYM	cis	rs761746	0.960	rs4820982	chr22:31929480	T/C	cg01338084	chr22:32026380	PISD	-0.55	-4.7	-0.43	8.66e-6	Intelligence;
THYM	cis	rs9902453	1.000	rs4328498	chr17:28344276	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.93e-6	Coffee consumption (cups per day);
THYM	cis	rs2075230	0.705	rs2955613	chr17:7549342	T/C	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.28	-4.62	-0.43	1.21e-5	Hormone measurements;
THYM	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg02569458	chr12:86230093	RASSF9	0.58	5.04	0.46	2.22e-6	Major depressive disorder;
THYM	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg01651570	chr14:104194141	ZFYVE21	0.54	4.67	0.43	1.01e-5	Schizophrenia;
THYM	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg12756686	chr19:29218302	NA	0.61	4.59	0.43	1.36e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.23	-10.06	-0.72	1.25e-16	Platelet count;
THYM	cis	rs870825	0.929	rs55635512	chr4:185589982	G/T	cg04058563	chr4:185651563	MLF1IP	0.96	6.66	0.56	1.78e-9	Blood protein levels;
THYM	cis	rs11098499	0.821	rs56155624	chr4:120291026	C/G	cg09307838	chr4:120376055	NA	0.63	4.63	0.43	1.17e-5	Corneal astigmatism;
THYM	cis	rs10887741	0.546	rs4316430	chr10:89443649	G/A	cg13926569	chr10:89418898	PAPSS2	0.62	7.09	0.59	2.38e-10	Exercise (leisure time);
THYM	cis	rs7192750	0.586	rs4788584	chr16:71993386	A/T	cg06353428	chr16:71660113	MARVELD3	0.7	5.16	0.47	1.34e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg08885076	chr2:99613938	TSGA10	-0.76	-7.33	-0.6	7.73e-11	Chronic sinus infection;
THYM	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg23422044	chr7:1970798	MAD1L1	-0.94	-6.44	-0.55	4.84e-9	Bipolar disorder;
THYM	cis	rs600806	0.850	rs4970752	chr1:109930852	C/T	cg23032129	chr1:109941072	SORT1	-0.59	-5.03	-0.46	2.31e-6	Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg04315214	chr1:2043799	PRKCZ	0.66	5.55	0.49	2.56e-7	Height;
THYM	cis	rs7193541	0.564	rs4888274	chr16:74706298	A/T	cg01733217	chr16:74700730	RFWD3	1.02	12.66	0.79	4.15e-22	Multiple myeloma;
THYM	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg03188948	chr7:1209495	NA	0.89	6.91	0.58	5.44e-10	Longevity;Endometriosis;
THYM	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg05294307	chr14:35346193	BAZ1A	-0.89	-7.29	-0.6	9.28e-11	Psoriasis;
THYM	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.24	-4.79	-0.44	6.23e-6	Obesity-related traits;
THYM	cis	rs919433	0.617	rs4850436	chr2:198541398	C/T	cg05783139	chr2:198650985	BOLL	-0.63	-5.0	-0.46	2.58e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg03161606	chr19:29218774	NA	0.94	8.06	0.64	2.27e-12	Methadone dose in opioid dependence;
THYM	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg08885076	chr2:99613938	TSGA10	0.69	5.92	0.52	5.2100000000000003e-08	Chronic sinus infection;
THYM	trans	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg05926928	chr17:57297772	GDPD1	1.24	9.78	0.71	4.95e-16	Opioid sensitivity;
THYM	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9467160	0.651	rs7755403	chr6:24453447	C/G	cg20631270	chr6:24437470	GPLD1	0.58	4.83	0.44	5.27e-6	Liver enzyme levels;
THYM	cis	rs7107174	1.000	rs731600	chr11:77963133	A/G	cg19901956	chr11:77921274	USP35	-0.7	-5.37	-0.48	5.53e-7	Testicular germ cell tumor;
THYM	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg14004847	chr7:1930337	MAD1L1	-0.7	-5.58	-0.5	2.26e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs12466960	0.765	rs7559003	chr2:28577465	A/C	cg11535839	chr2:28582676	NA	0.6	4.79	0.44	6.17e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs56309584	0.673	rs7219471	chr17:8121594	G/T	cg08322244	chr17:8066669	VAMP2	-0.56	-5.31	-0.48	7.15e-7	Initial pursuit acceleration;
THYM	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg08885076	chr2:99613938	TSGA10	0.57	5.28	0.48	8.05e-7	Chronic sinus infection;
THYM	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	9.71	0.71	6.96e-16	Platelet count;
THYM	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs6809651	0.524	rs6444106	chr3:185811495	C/T	cg00760338	chr3:185826511	ETV5	-0.82	-6.6	-0.56	2.32e-9	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
THYM	cis	rs612683	0.735	rs10493923	chr1:100930254	A/G	cg09408571	chr1:101003634	GPR88	-0.41	-4.56	-0.42	1.53e-5	Breast cancer;
THYM	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08704250	chr15:31115839	NA	0.67	7.98	0.63	3.39e-12	Huntington's disease progression;
THYM	cis	rs7247513	0.930	rs28368916	chr19:12701577	T/G	cg01871581	chr19:12707946	ZNF490	-0.87	-9.42	-0.69	2.88e-15	Bipolar disorder;
THYM	cis	rs2286885	1.000	rs7851961	chr9:129249140	G/A	cg14294646	chr9:129243551	FAM125B	-0.59	-5.47	-0.49	3.63e-7	Intraocular pressure;
THYM	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg12310025	chr6:25882481	NA	-0.69	-5.47	-0.49	3.69e-7	Blood metabolite levels;
THYM	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg02475777	chr4:1388615	CRIPAK	0.71	5.11	0.46	1.69e-6	Longevity;
THYM	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg11764359	chr7:65958608	NA	0.81	6.42	0.55	5.45e-9	Aortic root size;
THYM	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg21385522	chr1:16154831	NA	0.64	5.29	0.48	7.97e-7	Systolic blood pressure;
THYM	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg25036284	chr2:26402008	FAM59B	-0.81	-5.18	-0.47	1.24e-6	Gut microbiome composition (summer);
THYM	cis	rs289828	0.560	rs67868855	chr2:152151149	A/G	cg05960677	chr2:152117363	RBM43	0.72	6.74	0.57	1.23e-9	Blood protein levels;
THYM	cis	rs4363385	0.719	rs4845501	chr1:152937401	A/G	cg07796016	chr1:152779584	LCE1C	-0.56	-4.55	-0.42	1.56e-5	Inflammatory skin disease;
THYM	cis	rs7408868	0.764	rs62113791	chr19:15277009	C/T	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs4595586	0.545	rs11609541	chr12:39378331	T/C	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs7119038	0.818	rs76704408	chr11:118683327	G/T	cg19308663	chr11:118741387	NA	0.44	4.63	0.43	1.15e-5	Sjögren's syndrome;
THYM	cis	rs9649213	0.593	rs7807455	chr7:97957622	C/A	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.6e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg17063962	chr7:91808500	NA	-1.15	-12.48	-0.79	9.72e-22	Breast cancer;
THYM	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.8	-0.44	5.86e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs61931739	0.926	rs1995966	chr12:34095420	G/A	cg06521331	chr12:34319734	NA	0.63	4.77	0.44	6.74e-6	Morning vs. evening chronotype;
THYM	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg18681998	chr4:17616180	MED28	0.98	9.9	0.71	2.68e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg22325292	chr17:80708367	FN3K	0.62	4.48	0.42	2.09e-5	Glycated hemoglobin levels;
THYM	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg01874867	chr7:94954059	PON1	-0.8	-6.65	-0.56	1.86e-9	Paraoxonase activity;
THYM	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg24675056	chr1:15929824	NA	0.73	5.89	0.52	5.95e-8	Systolic blood pressure;
THYM	cis	rs870825	0.860	rs55974219	chr4:185600733	G/A	cg04058563	chr4:185651563	MLF1IP	1.05	7.96	0.63	3.6e-12	Blood protein levels;
THYM	cis	rs700651	0.624	rs12105927	chr2:198937258	G/A	cg00792783	chr2:198669748	PLCL1	0.71	4.61	0.43	1.28e-5	Intracranial aneurysm;
THYM	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg26131816	chr17:42072204	PYY	0.54	4.65	0.43	1.07e-5	Menopause (age at onset);
THYM	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-4.55	-0.42	1.58e-5	Chronic sinus infection;
THYM	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs12780046	0.656	rs1539396	chr10:100824035	C/G	cg20566587	chr10:101492029	COX15;CUTC	0.73	4.62	0.43	1.19e-5	Non-glioblastoma glioma;
THYM	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg26850624	chr5:429559	AHRR	-0.72	-5.74	-0.51	1.11e-7	Cystic fibrosis severity;
THYM	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03647317	chr4:187891568	NA	-0.82	-8.81	-0.67	5.87e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6686643	0.868	rs9333471	chr1:165619712	A/G	cg19407955	chr1:165599744	MGST3	-0.76	-4.51	-0.42	1.88e-5	Total ventricular volume;
THYM	cis	rs12208915	0.720	rs9352655	chr6:79503423	T/A	cg05283184	chr6:79620031	NA	0.83	5.46	0.49	3.86e-7	Left atrial antero-posterior diameter;
THYM	cis	rs6543140	0.929	rs7602207	chr2:103032366	C/G	cg03938978	chr2:103052716	IL18RAP	0.61	6.13	0.53	1.96e-8	Blood protein levels;
THYM	cis	rs752010	0.967	rs6675999	chr1:42099024	T/G	cg06885757	chr1:42089581	HIVEP3	0.42	4.57	0.42	1.46e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg07424592	chr7:64974309	NA	1.16	5.55	0.5	2.55e-7	Diabetic kidney disease;
THYM	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg24324837	chr19:49891574	CCDC155	0.55	4.99	0.46	2.74e-6	Multiple sclerosis;
THYM	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg04772025	chr11:68637568	NA	0.6	6.07	0.53	2.59e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1697139	0.935	rs1627990	chr5:66513326	C/T	cg11553311	chr5:66541588	NA	0.46	4.99	0.46	2.71e-6	Breast cancer;
THYM	cis	rs7220711	0.934	rs8068071	chr17:41782779	C/T	cg26893861	chr17:41843967	DUSP3	-0.6	-5.11	-0.46	1.69e-6	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.61	5.43	0.49	4.35e-7	Prudent dietary pattern;
THYM	cis	rs12935418	0.583	rs2549843	chr16:81023745	C/T	cg16651780	chr16:81037892	C16orf61	-0.86	-6.73	-0.57	1.3e-9	Mean corpuscular volume;
THYM	cis	rs12142240	0.660	rs72885163	chr1:46807117	C/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg27211696	chr2:191398769	TMEM194B	-0.65	-5.1	-0.46	1.76e-6	Diastolic blood pressure;
THYM	cis	rs946836	0.562	rs12754783	chr1:48400170	C/T	cg18376692	chr1:48452465	NA	-0.56	-5.17	-0.47	1.27e-6	White matter integrity;
THYM	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.81	7.16	0.59	1.73e-10	Cognitive ability;
THYM	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg27129171	chr3:47204927	SETD2	0.7	6.7	0.57	1.44e-9	Colorectal cancer;
THYM	cis	rs6539288	0.899	rs7298423	chr12:107301980	A/G	cg26297688	chr12:107349093	C12orf23	-0.44	-4.57	-0.42	1.49e-5	Total body bone mineral density;
THYM	cis	rs2637266	1.000	rs12413656	chr10:78379666	A/C	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs2985684	0.948	rs2985685	chr14:50101370	G/A	cg02151108	chr14:50098012	C14orf104	-0.67	-5.33	-0.48	6.48e-7	Carotid intima media thickness;
THYM	cis	rs11563648	0.573	rs10241915	chr7:126949074	C/T	cg08586737	chr7:127225949	GCC1	-0.33	-4.53	-0.42	1.74e-5	Resting heart rate;
THYM	cis	rs752010	0.967	rs752011	chr1:42092929	C/T	cg06885757	chr1:42089581	HIVEP3	0.4	4.47	0.42	2.16e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs6032067	0.714	rs2206887	chr20:43856024	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-6.24	-0.54	1.22e-8	Blood protein levels;
THYM	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg03929089	chr4:120376271	NA	-0.99	-12.83	-0.8	1.9e-22	Height;
THYM	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg24060327	chr5:131705240	SLC22A5	-0.81	-6.71	-0.57	1.4e-9	Acylcarnitine levels;
THYM	cis	rs7078219	0.965	rs11190141	chr10:101292390	C/T	cg23904955	chr10:101282759	NA	-0.44	-5.19	-0.47	1.17e-6	Dental caries;
THYM	cis	rs11603020	0.950	rs28362949	chr11:57371911	G/T	cg19752551	chr11:57585705	CTNND1	-0.59	-4.95	-0.45	3.25e-6	Blood protein levels;
THYM	cis	rs4930776	1.000	rs862393	chr12:5769587	G/T	cg02086166	chr12:5775618	ANO2	0.57	5.51	0.49	3.1e-7	Plasma clusterin levels;
THYM	cis	rs12476592	0.516	rs7558796	chr2:63597108	T/A	cg17519650	chr2:63277830	OTX1	-0.72	-4.71	-0.44	8.3e-6	Childhood ear infection;
THYM	cis	rs1215050	0.740	rs1648568	chr4:98957619	A/G	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg26384229	chr12:38710491	ALG10B	-0.73	-6.01	-0.52	3.42e-8	Morning vs. evening chronotype;
THYM	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-6.18	-0.54	1.57e-8	Bipolar disorder;
THYM	cis	rs34172651	0.917	rs11074651	chr16:24778409	A/G	cg06028605	chr16:24865363	SLC5A11	0.58	5.69	0.5	1.42e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg21773646	chr17:80085082	CCDC57	0.31	4.49	0.42	2.02e-5	Life satisfaction;
THYM	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg04772025	chr11:68637568	NA	0.64	6.68	0.57	1.61e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7187994	0.848	rs7185949	chr16:84779248	T/G	cg07647771	chr16:84786436	USP10	-0.55	-5.06	-0.46	2.03e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg15744005	chr10:104629667	AS3MT	-0.78	-7.33	-0.6	7.48e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs924712	0.677	rs239783	chr6:54754240	A/G	cg04690482	chr6:54711388	FAM83B	0.45	5.37	0.48	5.54e-7	Breast cancer;
THYM	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg10117171	chr1:25599238	RHD	-0.71	-5.16	-0.47	1.34e-6	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs7731657	0.537	rs10051429	chr5:130257549	C/T	cg08523029	chr5:130500466	HINT1	0.82	5.88	0.52	6.03e-8	Fasting plasma glucose;
THYM	cis	rs354225	0.544	rs10182836	chr2:54808504	T/G	cg23486701	chr2:54789491	SPTBN1	0.36	4.96	0.45	3.11e-6	Schizophrenia;
THYM	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg11317459	chr13:21872234	NA	-1.21	-9.22	-0.69	7.83e-15	White matter hyperintensity burden;
THYM	cis	rs259282	0.692	rs17693106	chr19:33125055	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.76	-6.55	-0.56	2.98e-9	Schizophrenia;
THYM	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.6	5.92	0.52	4.99e-8	Schizophrenia;
THYM	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03576123	chr11:487126	PTDSS2	-1.12	-5.77	-0.51	9.7e-8	Body mass index;
THYM	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs1421811	0.606	rs10057069	chr5:32716589	A/G	cg16267343	chr5:32710456	NPR3	0.88	7.25	0.6	1.11e-10	Blood pressure;
THYM	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg23711669	chr6:146136114	FBXO30	0.91	9.55	0.7	1.49e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg22875332	chr1:76189707	ACADM	-0.53	-4.69	-0.43	9.07e-6	Daytime sleep phenotypes;
THYM	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.65	4.7	0.43	8.75e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg14345882	chr6:26364793	BTN3A2	0.55	5.25	0.47	9.42e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg00074818	chr8:8560427	CLDN23	0.59	5.47	0.49	3.61e-7	Obesity-related traits;
THYM	cis	rs7586879	0.616	rs11900505	chr2:25131986	A/C	cg01884057	chr2:25150051	NA	0.73	7.92	0.63	4.47e-12	Body mass index;
THYM	cis	rs2806561	0.754	rs750354	chr1:23297406	T/C	cg19743168	chr1:23544995	NA	-0.61	-5.73	-0.51	1.18e-7	Height;
THYM	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9810089	0.903	rs7427564	chr3:136274435	G/A	cg21827317	chr3:136751795	NA	0.57	4.84	0.44	5.08e-6	Gestational age at birth (child effect);
THYM	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs7084402	0.967	rs1427224	chr10:60290620	G/A	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.7	-0.43	8.7e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6665290	0.935	rs17600669	chr1:227201871	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.15	-16.89	-0.87	2.27e-30	Myeloid white cell count;
THYM	cis	rs8180040	0.800	rs11130126	chr3:47306894	A/G	cg27129171	chr3:47204927	SETD2	-0.75	-7.08	-0.59	2.48e-10	Colorectal cancer;
THYM	cis	rs7078219	0.686	rs12412214	chr10:101276256	G/A	cg17888390	chr10:101282816	NA	-0.5	-4.84	-0.44	4.98e-6	Dental caries;
THYM	cis	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7408868	0.706	rs2238642	chr19:15282237	T/C	cg14696996	chr19:15285081	NOTCH3	0.96	5.54	0.49	2.74e-7	Pulse pressure;
THYM	cis	rs4638749	0.651	rs13385677	chr2:108826152	T/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs1267303	0.642	rs61783087	chr1:46999955	T/C	cg25110126	chr1:46999211	NA	0.77	6.12	0.53	2.1e-8	Monobrow;
THYM	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg01073479	chr16:3509474	NAT15	-0.5	-4.67	-0.43	9.89e-6	Tuberculosis;
THYM	cis	rs10089	1.000	rs77086350	chr5:127494431	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.92	5.76	0.51	1.04e-7	Ileal carcinoids;
THYM	cis	rs67460515	0.529	rs6795586	chr3:160897701	A/C	cg04691961	chr3:161091175	C3orf57	-0.57	-4.6	-0.43	1.33e-5	Parkinson's disease;
THYM	cis	rs6980334	0.911	rs10954602	chr7:137774930	A/G	cg18769353	chr7:137028617	PTN	0.6	4.73	0.44	7.72e-6	Blood metabolite ratios;
THYM	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg17366294	chr4:99064904	C4orf37	0.48	5.43	0.49	4.3e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.569	rs7721668	chr5:93290995	G/A	cg25358565	chr5:93447407	FAM172A	-0.83	-6.11	-0.53	2.18e-8	Diabetic retinopathy;
THYM	cis	rs79387448	0.745	rs17027442	chr2:103164948	A/G	cg09003973	chr2:102972529	NA	-0.75	-4.61	-0.43	1.23e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs7851660	0.809	rs12550872	chr9:100653128	G/A	cg13688889	chr9:100608707	NA	-0.78	-5.67	-0.5	1.53e-7	Strep throat;
THYM	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs1160297	0.575	rs6725912	chr2:53097030	A/G	cg07782112	chr2:53107842	NA	0.79	6.37	0.55	6.61e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs1642645	0.793	rs6695748	chr1:42481707	G/T	cg22816091	chr1:42611670	NA	0.62	5.52	0.49	2.99e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs778371	0.649	rs13021823	chr2:233686862	A/G	cg08000102	chr2:233561755	GIGYF2	-0.79	-6.96	-0.58	4.28e-10	Schizophrenia;
THYM	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg08968635	chr6:28129556	ZNF389	0.59	4.57	0.42	1.46e-5	Parkinson's disease;
THYM	cis	rs1728785	0.901	rs11865339	chr16:68565296	C/T	cg02972257	chr16:68554789	NA	-0.75	-4.57	-0.42	1.47e-5	Ulcerative colitis;
THYM	cis	rs72627123	0.749	rs58199545	chr14:74452495	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	4.87	0.45	4.38e-6	Morning vs. evening chronotype;
THYM	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg09436375	chr6:42928200	GNMT	-0.44	-5.86	-0.52	6.75e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	trans	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg17712092	chr4:129076599	LARP1B	-0.99	-9.06	-0.68	1.66e-14	Eosinophil percentage of white cells;
THYM	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg04166595	chr19:18636596	NA	0.62	4.62	0.43	1.19e-5	Breast cancer;
THYM	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg11764359	chr7:65958608	NA	-0.8	-6.38	-0.55	6.55e-9	Aortic root size;
THYM	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg06970220	chr1:156163860	SLC25A44	0.71	5.52	0.49	2.91e-7	Testicular germ cell tumor;
THYM	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.53	0.49	2.84e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10911251	0.528	rs6669199	chr1:183082421	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Colorectal cancer;
THYM	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg01831904	chr17:28903510	LRRC37B2	-1.0	-5.11	-0.46	1.65e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg03806693	chr22:41940476	POLR3H	1.03	9.17	0.69	9.96e-15	Cannabis dependence symptom count;
THYM	cis	rs4660306	0.614	rs1007859	chr1:45911906	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.64	4.55	0.42	1.61e-5	Homocysteine levels;
THYM	cis	rs877282	0.797	rs7079164	chr10:756363	A/G	cg10556349	chr10:835070	NA	-0.69	-4.49	-0.42	2.03e-5	Uric acid levels;
THYM	cis	rs12142240	0.698	rs67200518	chr1:46835777	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg05340658	chr4:99064831	C4orf37	0.54	4.55	0.42	1.58e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg04025307	chr7:1156635	C7orf50	0.72	4.46	0.42	2.27e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg22676075	chr6:135203613	NA	-0.75	-7.01	-0.58	3.36e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4242434	0.927	rs11136093	chr8:22479988	C/G	cg14690197	chr8:22456421	C8orf58	0.56	5.11	0.46	1.63e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2692947	0.702	rs6717101	chr2:96505552	C/T	cg23100626	chr2:96804247	ASTL	0.35	4.6	0.43	1.28e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs988913	0.918	rs7739399	chr6:54855538	C/T	cg04690482	chr6:54711388	FAM83B	0.49	5.2	0.47	1.16e-6	Menarche (age at onset);
THYM	cis	rs6815814	0.950	rs66979032	chr4:38814700	A/G	cg02016764	chr4:38805732	TLR1	-0.57	-5.41	-0.49	4.63e-7	Breast cancer;
THYM	cis	rs7614311	0.681	rs73117042	chr3:63896543	T/C	cg22134162	chr3:63841271	THOC7	-0.58	-7.03	-0.59	3.13e-10	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg10047753	chr17:41438598	NA	0.85	6.14	0.53	1.88e-8	Menopause (age at onset);
THYM	cis	rs1003719	0.715	rs13046581	chr21:38551985	G/T	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg04362960	chr10:104952993	NT5C2	0.62	5.18	0.47	1.22e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs3796352	0.892	rs35076015	chr3:53026366	C/T	cg07884673	chr3:53033167	SFMBT1	1.27	6.43	0.55	5.06e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg27490568	chr2:178487706	NA	0.68	5.9	0.52	5.53e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9650657	0.615	rs4840519	chr8:10693113	T/C	cg12981288	chr8:11183844	MTMR9	-0.5	-4.71	-0.44	8.34e-6	Neuroticism;
THYM	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg00129232	chr17:37814104	STARD3	0.74	4.99	0.46	2.76e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs6980334	1.000	rs6980334	chr7:137788492	A/G	cg06915773	chr7:137028165	PTN	-0.58	-4.79	-0.44	6.22e-6	Blood metabolite ratios;
THYM	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg15704280	chr7:45808275	SEPT13	-0.98	-11.35	-0.76	2.22e-19	Coronary artery disease;
THYM	cis	rs9361491	0.677	rs9352630	chr6:79462192	T/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	trans	rs9929218	0.817	rs3114405	chr16:68722377	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.94	-7.24	-0.6	1.14e-10	Colorectal cancer;
THYM	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg00898013	chr13:113819073	PROZ	-0.89	-8.91	-0.67	3.46e-14	Platelet distribution width;
THYM	cis	rs147144681	1	rs147144681	chr15:78900908	C/T	cg18825076	chr15:78729989	IREB2	-0.57	-5.05	-0.46	2.14e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs4072705	0.616	rs915033	chr9:127245558	C/G	cg01786973	chr9:127249749	NR5A1	0.4	5.21	0.47	1.09e-6	Menarche (age at onset);
THYM	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.82	-8.18	-0.64	1.25e-12	Blood protein levels;
THYM	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg11812906	chr14:75593930	NEK9	-0.8	-7.19	-0.59	1.45e-10	Height;
THYM	cis	rs7000551	0.581	rs11787182	chr8:22256727	T/C	cg12081754	chr8:22256438	SLC39A14	1.19	12.08	0.78	6.76e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs4363385	0.747	rs885096	chr1:152971313	T/C	cg13444842	chr1:152974279	SPRR3	-0.6	-4.79	-0.44	6.16e-6	Inflammatory skin disease;
THYM	cis	rs9902453	0.845	rs116840018	chr17:28232049	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.6	0.43	1.32e-5	Coffee consumption (cups per day);
THYM	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs990171	1.000	rs6755786	chr2:103048103	C/T	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.17	-0.47	1.27e-6	Lymphocyte counts;
THYM	cis	rs7264396	0.790	rs761826	chr20:34194243	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-5.3	-0.48	7.51e-7	Total cholesterol levels;
THYM	cis	rs665401	0.965	rs610424	chr6:117212258	T/C	cg20376953	chr6:117187980	NA	0.6	4.82	0.44	5.5e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs67981189	0.752	rs221902	chr14:71601079	G/T	cg15910301	chr14:71632612	NA	-0.51	-4.77	-0.44	6.78e-6	Schizophrenia;
THYM	cis	rs61931739	0.927	rs12315970	chr12:34038535	A/G	cg10856724	chr12:34555212	NA	0.63	5.33	0.48	6.57e-7	Morning vs. evening chronotype;
THYM	cis	rs2276314	0.857	rs62101402	chr18:33629435	A/G	cg19628046	chr18:33552617	C18orf21	0.74	5.43	0.49	4.29e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs5769765	0.874	rs11703411	chr22:50258751	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.52	-5.0	-0.46	2.57e-6	Schizophrenia;
THYM	cis	rs4851266	0.865	rs11695996	chr2:100854336	C/T	cg14675211	chr2:100938903	LONRF2	0.67	5.59	0.5	2.15e-7	Educational attainment;
THYM	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg14582100	chr15:45693742	SPATA5L1	0.61	5.06	0.46	2.03e-6	Homoarginine levels;
THYM	cis	rs611744	0.967	rs695028	chr8:109239324	T/C	cg21045802	chr8:109455806	TTC35	0.59	5.25	0.47	9.08e-7	Dupuytren's disease;
THYM	cis	rs761746	0.960	rs1543416	chr22:31925073	A/G	cg10537193	chr22:32026975	PISD	-0.36	-4.88	-0.45	4.27e-6	Intelligence;
THYM	cis	rs8063160	0.688	rs75570604	chr16:89846677	G/C	cg07984980	chr16:89898383	SPIRE2	1.51	6.22	0.54	1.3e-8	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9393692	0.620	rs9393696	chr6:26291591	T/C	cg00631329	chr6:26305371	NA	-0.47	-4.79	-0.44	6.14e-6	Educational attainment;
THYM	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg25358565	chr5:93447407	FAM172A	-1.32	-11.28	-0.76	3.22e-19	Diabetic retinopathy;
THYM	cis	rs870825	1.000	rs870825	chr4:185588045	A/G	cg04058563	chr4:185651563	MLF1IP	0.89	6.43	0.55	4.99e-9	Blood protein levels;
THYM	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg14972814	chr11:95582409	MTMR2	-0.64	-5.4	-0.48	4.89e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg11871910	chr12:69753446	YEATS4	0.73	5.82	0.51	7.78e-8	Cerebrospinal fluid biomarker levels;
THYM	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg10150615	chr22:24372951	LOC391322	-0.84	-6.26	-0.54	1.09e-8	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7705042	0.865	rs6863411	chr5:141513204	A/T	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs7264396	0.563	rs2425120	chr20:34324456	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Total cholesterol levels;
THYM	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-7.24	-0.6	1.15e-10	Schizophrenia;
THYM	cis	rs941408	0.928	rs2741991	chr19:2802092	T/C	cg06609049	chr19:2785107	THOP1	0.69	5.66	0.5	1.63e-7	Total cholesterol levels;
THYM	cis	rs4866334	1.000	rs114400023	chr5:18432893	T/C	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg04414720	chr1:150670196	GOLPH3L	0.59	4.46	0.42	2.24e-5	Tonsillectomy;
THYM	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg16325326	chr1:53192061	ZYG11B	0.74	6.39	0.55	6.2e-9	Monocyte count;
THYM	cis	rs2898681	0.581	rs731073	chr4:53680090	A/G	cg00338735	chr4:53728038	RASL11B	0.59	5.31	0.48	7.09e-7	Optic nerve measurement (cup area);
THYM	cis	rs3781426	0.521	rs3781422	chr10:126708783	T/A	cg04494136	chr10:126703576	CTBP2	0.37	5.11	0.46	1.68e-6	Height;
THYM	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg23583168	chr7:148888333	NA	-1.02	-13.03	-0.8	7.19e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg27490568	chr2:178487706	NA	0.68	5.9	0.52	5.53e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg03806693	chr22:41940476	POLR3H	-0.84	-6.41	-0.55	5.51e-9	Neuroticism;
THYM	cis	rs8114671	0.935	rs6142313	chr20:33780427	A/G	cg08999081	chr20:33150536	PIGU	-0.52	-4.69	-0.43	9.11e-6	Height;
THYM	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.94	6.37	0.55	6.72e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs916888	0.647	rs199519	chr17:44853924	G/A	cg01341218	chr17:43662625	NA	-0.81	-6.97	-0.58	4.15e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg17252645	chr8:143867129	LY6D	0.53	5.24	0.47	9.63e-7	Urinary tract infection frequency;
THYM	cis	rs938554	0.513	rs10939650	chr4:9998440	C/T	cg26689780	chr4:10079554	WDR1	-0.39	-4.53	-0.42	1.7e-5	Blood metabolite levels;
THYM	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg10911889	chr6:126070802	HEY2	0.57	4.52	0.42	1.75e-5	Brugada syndrome;
THYM	cis	rs1629083	0.967	rs73024604	chr11:118120351	C/T	cg25155064	chr11:118100782	MPZL3	-0.57	-5.03	-0.46	2.34e-6	Lung cancer;
THYM	cis	rs2109514	0.902	rs1007751	chr7:116110055	A/T	cg12739419	chr7:116140593	CAV2	-0.48	-4.92	-0.45	3.67e-6	Prevalent atrial fibrillation;
THYM	cis	rs7487075	0.790	rs4074773	chr12:46919181	C/T	cg21428710	chr12:47219797	SLC38A4	-0.49	-4.57	-0.42	1.49e-5	Itch intensity from mosquito bite;
THYM	cis	rs6835098	0.962	rs10014010	chr4:174083230	C/T	cg08422745	chr4:174089978	GALNT7	-0.97	-8.28	-0.65	7.53e-13	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs2734839	1.000	rs2734839	chr11:113286490	C/T	cg14159747	chr11:113255604	NA	0.31	6.28	0.54	1.01e-8	Information processing speed;
THYM	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg27129171	chr3:47204927	SETD2	-0.81	-7.81	-0.63	7.51e-12	Colorectal cancer;
THYM	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg07061783	chr6:25882402	NA	-0.84	-6.99	-0.58	3.7e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg17279839	chr7:150038598	RARRES2	0.55	5.34	0.48	6.26e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4242434	0.757	rs4872531	chr8:22529695	A/G	cg21658235	chr8:22456391	C8orf58	-0.52	-4.67	-0.43	9.73e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7536700	0.642	rs35240348	chr1:153662340	G/A	cg21279955	chr1:153747551	SLC27A3	-0.62	-4.52	-0.42	1.78e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg11764359	chr7:65958608	NA	0.66	4.62	0.43	1.18e-5	Aortic root size;
THYM	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs56161922	0.908	rs55689175	chr1:207859699	G/C	cg09557387	chr1:207818395	CR1L	1.27	5.76	0.51	1.02e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg10856724	chr12:34555212	NA	1.07	8.64	0.66	1.35e-13	Morning vs. evening chronotype;
THYM	cis	rs10979	0.964	rs35205240	chr6:143898676	T/C	cg25407410	chr6:143891975	LOC285740	-0.62	-4.88	-0.45	4.22e-6	Hypospadias;
THYM	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.65	0.56	1.83e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg01238044	chr22:24384105	GSTT1	0.53	4.7	0.43	8.7e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10435719	0.638	rs67146188	chr8:11782433	A/G	cg21775007	chr8:11205619	TDH	-0.59	-4.55	-0.42	1.56e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs7582180	0.700	rs4640404	chr2:100980523	C/T	cg14675211	chr2:100938903	LONRF2	-0.6	-5.68	-0.5	1.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs28595532	0.920	rs114057512	chr4:119750179	G/A	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg18305652	chr10:134549665	INPP5A	-0.66	-5.81	-0.51	8.21e-8	Migraine;
THYM	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg23711669	chr6:146136114	FBXO30	0.99	10.97	0.75	1.41e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8051431	0.544	rs2878492	chr16:71981113	A/T	cg06353428	chr16:71660113	MARVELD3	0.77	5.72	0.51	1.21e-7	LDL cholesterol levels;
THYM	cis	rs912057	0.526	rs201061	chr6:6730512	C/T	cg06612196	chr6:6737390	NA	-0.77	-12.36	-0.79	1.74e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs4845570	1.000	rs7542898	chr1:151753622	T/G	cg07092448	chr1:151763213	TDRKH	-1.05	-6.74	-0.57	1.24e-9	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg11235152	chr1:67600687	NA	0.74	6.36	0.55	7e-9	Psoriasis;
THYM	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs637571	0.510	rs3892696	chr11:65582341	G/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.68	-5.17	-0.47	1.27e-6	Eosinophil percentage of white cells;
THYM	cis	rs514406	0.597	rs1241980	chr1:53286013	A/G	cg24675658	chr1:53192096	ZYG11B	0.85	6.07	0.53	2.58e-8	Monocyte count;
THYM	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs2034088	0.965	rs11653961	chr17:440108	A/C	cg06217071	chr17:408420	NA	0.8	7.7	0.62	1.3e-11	Hip circumference adjusted for BMI;
THYM	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg21385522	chr1:16154831	NA	-0.67	-5.62	-0.5	1.89e-7	Systolic blood pressure;
THYM	cis	rs7809950	0.655	rs4730220	chr7:106809056	A/G	cg23024343	chr7:107201750	COG5	-0.79	-6.73	-0.57	1.26e-9	Coronary artery disease;
THYM	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg09307838	chr4:120376055	NA	0.7	5.27	0.48	8.48e-7	Corneal astigmatism;
THYM	cis	rs600806	0.850	rs10858095	chr1:109962642	G/C	cg23032129	chr1:109941072	SORT1	-0.6	-5.12	-0.46	1.63e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06481639	chr22:41940642	POLR3H	-0.84	-5.94	-0.52	4.61e-8	Vitiligo;
THYM	cis	rs17604090	0.756	rs4000290	chr7:29707487	C/T	cg19413766	chr7:29689036	LOC646762	0.72	4.56	0.42	1.5e-5	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg08773314	chr2:239334832	ASB1	0.65	9.77	0.71	5.07e-16	Multiple system atrophy;
THYM	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg22875332	chr1:76189707	ACADM	0.87	10.93	0.75	1.72e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4849845	0.889	rs6542577	chr2:121013832	G/C	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs2147904	0.934	rs783629	chr1:42363275	C/T	cg16685388	chr1:42384056	HIVEP3	0.56	4.82	0.44	5.45e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
THYM	cis	rs763014	0.931	rs3752567	chr16:628130	A/G	cg09263875	chr16:632152	PIGQ	0.74	6.32	0.54	8.26e-9	Height;
THYM	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg16414030	chr3:133502952	NA	-0.94	-9.47	-0.7	2.22e-15	Iron status biomarkers;
THYM	cis	rs5758511	0.680	rs56111723	chr22:42664883	T/A	cg08431931	chr22:42394659	WBP2NL	0.62	4.59	0.43	1.36e-5	Birth weight;
THYM	cis	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg24672777	chr11:48374446	OR4C45	-0.93	-6.01	-0.52	3.39e-8	Axial length;
THYM	cis	rs4474465	0.850	rs10899536	chr11:78216992	C/A	cg19901956	chr11:77921274	USP35	0.67	4.92	0.45	3.69e-6	Alzheimer's disease (survival time);
THYM	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	6.51	0.56	3.5e-9	Total body bone mineral density;
THYM	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9329289	0.510	rs35854428	chr10:2554280	T/C	cg07014206	chr10:2547000	NA	-0.57	-5.24	-0.47	9.47e-7	Age-related hearing impairment;
THYM	cis	rs2069036	1.000	rs2355245	chr10:16100931	C/A	cg26633223	chr10:15133461	NA	0.68	4.76	0.44	6.94e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	7.98	0.63	3.34e-12	Platelet count;
THYM	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg09085632	chr11:111637200	PPP2R1B	1.04	10.37	0.73	2.62e-17	Primary sclerosing cholangitis;
THYM	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg12310025	chr6:25882481	NA	0.95	8.87	0.67	4.37e-14	Blood metabolite levels;
THYM	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg26924012	chr15:45694286	SPATA5L1	0.96	7.5	0.61	3.34e-11	Homoarginine levels;
THYM	cis	rs7098100	0.738	rs12770228	chr10:21783634	G/A	cg04231319	chr10:21824447	MLLT10	-0.33	-4.66	-0.43	1.02e-5	Breast cancer;
THYM	cis	rs6496667	0.865	rs62019351	chr15:90926557	G/A	cg22089800	chr15:90895588	ZNF774	0.79	4.75	0.44	7.21e-6	Rheumatoid arthritis;
THYM	cis	rs4363385	0.626	rs10888531	chr1:153063406	T/C	cg07796016	chr1:152779584	LCE1C	-0.53	-4.6	-0.43	1.31e-5	Inflammatory skin disease;
THYM	cis	rs113835537	0.529	rs11227510	chr11:66281220	T/C	cg24851651	chr11:66362959	CCS	0.7	4.89	0.45	4.04e-6	Airway imaging phenotypes;
THYM	cis	rs2219968	0.525	rs2054827	chr8:78895069	T/C	cg00738934	chr8:78996279	NA	0.61	4.95	0.45	3.21e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3126085	0.825	rs868303	chr1:152178563	C/A	cg10321714	chr1:152280068	FLG	0.64	4.6	0.43	1.29e-5	Atopic dermatitis;
THYM	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg19507638	chr5:93509721	C5orf36	-0.67	-4.5	-0.42	1.95e-5	Diabetic retinopathy;
THYM	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg26384229	chr12:38710491	ALG10B	-0.73	-5.75	-0.51	1.08e-7	Morning vs. evening chronotype;
THYM	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4842666	0.850	rs11105328	chr12:89942390	A/G	cg00757033	chr12:89920650	WDR51B	0.5	4.68	0.43	9.61e-6	Blood pressure;
THYM	cis	rs2273669	0.667	rs76249006	chr6:109366740	G/A	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg02751453	chr18:77725136	HSBP1L1	0.54	4.52	0.42	1.8e-5	Opioid sensitivity;
THYM	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	trans	rs4596713	0.568	rs7038833	chr9:71748097	C/T	cg16512924	chr15:28394682	HERC2	0.81	7.05	0.59	2.82e-10	Headache;
THYM	trans	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg00530320	chr1:46809349	NSUN4	0.71	5.11	0.46	1.69e-6	Menopause (age at onset);
THYM	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg24692254	chr21:30365293	RNF160	1.06	9.93	0.71	2.29e-16	Dental caries;
THYM	cis	rs2964802	0.505	rs2083232	chr5:10812811	G/A	cg14521931	chr5:10832172	NA	-0.61	-5.08	-0.46	1.87e-6	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs6785206	1.000	rs2712370	chr3:128425204	C/G	cg16766828	chr3:128327626	NA	-0.75	-7.58	-0.61	2.26e-11	Lymphocyte percentage of white cells;
THYM	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg00383909	chr3:49044727	WDR6	1.12	6.66	0.56	1.75e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs4481887	1.000	rs4489592	chr1:248470697	A/T	cg13385794	chr1:248469461	NA	0.65	4.66	0.43	1.04e-5	Common traits (Other);
THYM	cis	rs10887741	0.646	rs12257469	chr10:89437129	G/A	cg13926569	chr10:89418898	PAPSS2	0.62	7.19	0.59	1.47e-10	Exercise (leisure time);
THYM	cis	rs7666738	0.570	rs1921415	chr4:99093804	C/T	cg10515332	chr4:99064459	C4orf37	0.57	4.54	0.42	1.68e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6722750	0.933	rs4671553	chr2:64408476	A/T	cg22352474	chr2:64371530	PELI1	-0.62	-4.68	-0.43	9.7e-6	Neuroticism;
THYM	trans	rs4650994	0.525	rs4651000	chr1:178532223	A/G	cg05059571	chr16:84539110	KIAA1609	-0.89	-10.47	-0.73	1.64e-17	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs9563576	0.756	rs9634882	chr13:58617025	A/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg00814883	chr7:100076585	TSC22D4	-0.95	-6.36	-0.55	6.93e-9	Platelet count;
THYM	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg06784218	chr1:46089804	CCDC17	0.3	4.52	0.42	1.76e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs988913	0.793	rs9370333	chr6:54738246	A/G	cg19716238	chr6:54711378	FAM83B	0.53	5.08	0.46	1.84e-6	Menarche (age at onset);
THYM	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg20295408	chr7:1910781	MAD1L1	-0.61	-4.85	-0.45	4.75e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9527	0.640	rs7089061	chr10:104723015	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-5.01	-0.46	2.51e-6	Arsenic metabolism;
THYM	cis	rs6860806	0.507	rs270615	chr5:131641573	G/C	cg12564285	chr5:131593104	PDLIM4	0.47	5.08	0.46	1.87e-6	Breast cancer;
THYM	cis	rs4482178	0.850	rs1764967	chr13:86257607	A/C	cg25308322	chr13:86268291	NA	-0.76	-5.3	-0.48	7.42e-7	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg24846343	chr22:24311635	DDTL	0.43	5.82	0.51	7.93e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7226229	1.000	rs899335	chr17:20898362	T/C	cg21263980	chr17:20946333	USP22	0.72	4.96	0.45	3.12e-6	Blood trace element (Se levels);
THYM	cis	rs4523957	0.583	rs2760745	chr17:2035591	T/C	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs2133450	0.526	rs12495356	chr3:7348994	T/C	cg19930620	chr3:7340148	GRM7	-0.52	-5.62	-0.5	1.86e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs9972944	0.756	rs9901885	chr17:63769559	T/C	cg07283582	chr17:63770753	CCDC46	-0.67	-5.15	-0.47	1.39e-6	Total body bone mineral density;
THYM	cis	rs273218	1.000	rs156380	chr5:53378450	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.93	7.97	0.63	3.55e-12	Migraine;
THYM	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21582582	chr3:182698605	DCUN1D1	0.78	6.87	0.58	6.69e-10	Intelligence (multi-trait analysis);
THYM	cis	rs12681287	0.577	rs11992955	chr8:87530485	A/G	cg27223183	chr8:87520930	FAM82B	0.71	5.56	0.5	2.44e-7	Caudate activity during reward;
THYM	cis	rs72828912	0.764	rs10946669	chr6:24095059	T/C	cg19882886	chr6:25043046	NA	0.73	4.62	0.43	1.2e-5	Squamous cell lung carcinoma;
THYM	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg18200150	chr17:30822561	MYO1D	0.79	6.54	0.56	3.09e-9	Schizophrenia;
THYM	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs1485395	0.735	rs12818931	chr12:54072180	G/A	cg18787548	chr12:54388411	NA	-0.89	-4.47	-0.42	2.2e-5	Migraine without aura;
THYM	cis	rs10779751	0.770	rs2275527	chr1:11190646	A/G	cg08854313	chr1:11322531	MTOR	0.74	5.79	0.51	9.16e-8	Body mass index;
THYM	cis	rs7267979	1.000	rs910997	chr20:25267301	G/A	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7246967	0.673	rs9677019	chr19:22912659	T/C	cg05241461	chr19:22816980	ZNF492	0.61	4.74	0.44	7.63e-6	Bronchopulmonary dysplasia;
THYM	cis	rs10227331	0.846	rs10237006	chr7:157298250	A/G	cg04156418	chr7:157293606	NA	0.77	6.82	0.57	8.45e-10	Inattentive symptoms;
THYM	cis	rs12216545	0.765	rs10254007	chr7:150253381	C/T	cg08960815	chr7:150264767	GIMAP4	-0.89	-8.27	-0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs470093	0.866	rs138084	chr22:44243774	C/G	cg09142166	chr22:44276013	PNPLA5	-0.57	-5.43	-0.49	4.38e-7	Staphylococcus aureus infection;
THYM	cis	rs8033133	0.881	rs3803328	chr15:25330550	T/A	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.75	-5.39	-0.48	5.2e-7	Blood osmolality (transformed sodium);
THYM	trans	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg25214090	chr10:38739885	LOC399744	0.97	8.2	0.64	1.16e-12	Corneal astigmatism;
THYM	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg10047753	chr17:41438598	NA	1.0	8.45	0.65	3.4e-13	Menopause (age at onset);
THYM	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg10523679	chr1:76189770	ACADM	0.9	7.36	0.6	6.5500000000000006e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs8067545	1.000	rs4925066	chr17:19915292	A/G	cg08626831	chr17:20841558	NA	-0.47	-4.5	-0.42	1.91e-5	Schizophrenia;
THYM	cis	rs78761021	0.720	rs7220089	chr17:9796985	G/A	cg26853458	chr17:9805074	RCVRN	0.53	4.46	0.42	2.24e-5	Type 2 diabetes;
THYM	cis	rs11167764	0.945	rs4912619	chr5:141471847	G/A	cg23435118	chr5:141488016	NDFIP1	-0.52	-4.46	-0.42	2.24e-5	Crohn's disease;
THYM	cis	rs61990749	0.511	rs724263	chr14:78321874	G/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.87	5.4	0.48	5.01e-7	Fibroblast growth factor basic levels;
THYM	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg13395646	chr4:1353034	KIAA1530	0.59	5.31	0.48	7.33e-7	Obesity-related traits;
THYM	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg22920501	chr2:26401640	FAM59B	-0.85	-7.29	-0.6	9.24e-11	Gut microbiome composition (summer);
THYM	cis	rs11785693	0.862	rs17435605	chr8:4987302	A/G	cg26367366	chr8:4980734	NA	0.98	5.32	0.48	6.92e-7	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg17264618	chr3:40429014	ENTPD3	0.53	4.99	0.46	2.69e-6	Renal cell carcinoma;
THYM	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs611744	0.967	rs628843	chr8:109196115	C/G	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-5.84	-0.51	7.42e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs62064224	0.905	rs9891969	chr17:30627085	C/T	cg18200150	chr17:30822561	MYO1D	0.67	5.63	0.5	1.79e-7	Schizophrenia;
THYM	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg09307838	chr4:120376055	NA	0.6	4.54	0.42	1.63e-5	Corneal astigmatism;
THYM	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19346786	chr7:2764209	NA	-0.71	-6.02	-0.53	3.21e-8	Height;
THYM	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg15557168	chr22:42548783	NA	-0.58	-4.68	-0.43	9.66e-6	Schizophrenia;
THYM	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06481639	chr22:41940642	POLR3H	-0.82	-5.96	-0.52	4.18e-8	Vitiligo;
THYM	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg06532163	chr17:45867833	NA	0.64	6.45	0.55	4.65e-9	IgG glycosylation;
THYM	cis	rs790123	1.000	rs790116	chr3:122380923	G/C	cg15604389	chr3:122379662	NA	0.6	5.52	0.49	2.91e-7	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg27535305	chr1:53392650	SCP2	-0.52	-6.06	-0.53	2.7e-8	Monocyte count;
THYM	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs4499344	0.730	rs34270210	chr19:33103945	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.61	0.62	2.02e-11	Mean platelet volume;
THYM	cis	rs9394152	0.845	rs9394153	chr6:33471630	A/C	cg13560919	chr6:33536144	NA	0.73	6.26	0.54	1.09e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs9992101	0.838	rs1398016	chr4:77367688	C/T	cg20311846	chr4:77356250	SHROOM3	-0.57	-5.21	-0.47	1.09e-6	Creatinine levels;
THYM	cis	rs920590	0.684	rs7461774	chr8:19666645	G/A	cg03894339	chr8:19674705	INTS10	0.59	4.46	0.42	2.21e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg06115741	chr20:33292138	TP53INP2	0.7	4.65	0.43	1.06e-5	Coronary artery disease;
THYM	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg23711669	chr6:146136114	FBXO30	0.93	9.7	0.71	7.07e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11971779	0.941	rs28395455	chr7:139035986	A/G	cg07862535	chr7:139043722	LUC7L2	0.7	4.53	0.42	1.74e-5	Diisocyanate-induced asthma;
THYM	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg09222892	chr1:25734099	RHCE	0.63	4.92	0.45	3.7e-6	Erythrocyte sedimentation rate;
THYM	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14442939	chr10:27389572	ANKRD26	0.85	4.45	0.42	2.3e-5	Breast cancer;
THYM	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg18904891	chr8:8559673	CLDN23	-0.59	-4.89	-0.45	4.18e-6	Mood instability;
THYM	cis	rs11731175	1.000	rs76185748	chr4:189858147	C/G	cg00431894	chr4:189871012	NA	-0.81	-6.19	-0.54	1.52e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg21252483	chr19:49399788	TULP2	-0.87	-6.06	-0.53	2.77e-8	Red cell distribution width;
THYM	cis	rs79149102	0.579	rs7174129	chr15:75305040	A/G	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	cis	rs7578361	0.879	rs6718881	chr2:150349748	A/T	cg17961725	chr2:150454027	NA	-0.79	-5.22	-0.47	1.04e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs7818345	0.967	rs4921638	chr8:19274793	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.53	0.42	1.7e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs2057149	0.897	rs9320328	chr6:110724106	A/G	cg19196401	chr6:110721138	DDO	0.5	4.46	0.42	2.21e-5	Platelet distribution width;Mean platelet volume;
THYM	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg21773646	chr17:80085082	CCDC57	-0.34	-4.91	-0.45	3.76e-6	Life satisfaction;
THYM	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs6815814	1.000	rs11722836	chr4:38811529	T/A	cg02016764	chr4:38805732	TLR1	-0.57	-5.49	-0.49	3.41e-7	Breast cancer;
THYM	cis	rs4665630	0.764	rs4665628	chr2:23894344	A/T	cg08081869	chr2:24582653	ITSN2	-0.76	-4.73	-0.44	7.82e-6	Hypertension;
THYM	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg27446573	chr6:127587934	RNF146	1.03	9.77	0.71	5.21e-16	Breast cancer;
THYM	cis	rs9467160	0.871	rs9461014	chr6:24449008	T/G	cg20631270	chr6:24437470	GPLD1	0.75	5.95	0.52	4.43e-8	Liver enzyme levels;
THYM	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg15448220	chr1:150897856	SETDB1	0.89	7.36	0.6	6.64e-11	Melanoma;
THYM	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg08772003	chr10:104629869	AS3MT	-0.64	-5.61	-0.5	2e-7	Arsenic metabolism;
THYM	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.04	8.99	0.68	2.42e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs749052	0.831	rs2679178	chr2:232797861	A/G	cg22331108	chr2:232478452	NA	1.04	4.76	0.44	6.92e-6	Height;
THYM	cis	rs742614	1.000	rs742614	chr20:32482632	A/G	cg06304546	chr20:32448765	NA	-0.62	-4.86	-0.45	4.59e-6	Stearic acid (18:0) levels;
THYM	cis	rs61931739	0.591	rs10743834	chr12:33916129	A/C	cg10856724	chr12:34555212	NA	-0.63	-5.9	-0.52	5.54e-8	Morning vs. evening chronotype;
THYM	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg10589385	chr1:150898437	SETDB1	-0.64	-5.35	-0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.57	4.73	0.44	7.79e-6	Hip circumference adjusted for BMI;
THYM	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg13390004	chr1:15929781	NA	-0.58	-4.47	-0.42	2.15e-5	Systolic blood pressure;
THYM	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg14416269	chr4:6271139	WFS1	0.51	5.08	0.46	1.89e-6	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg21775007	chr8:11205619	TDH	-0.73	-5.68	-0.5	1.49e-7	Retinal vascular caliber;
THYM	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg00981070	chr1:2046702	PRKCZ	-0.49	-5.92	-0.52	4.99e-8	Height;
THYM	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg26039829	chr8:22132926	PIWIL2	0.7	6.29	0.54	9.49e-9	Hypertriglyceridemia;
THYM	cis	rs11168351	0.591	rs4258439	chr12:48468652	A/G	cg21466736	chr12:48725269	NA	0.46	4.98	0.46	2.81e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7078219	0.505	rs10883373	chr10:101292484	G/A	cg23904955	chr10:101282759	NA	-0.36	-4.56	-0.42	1.55e-5	Dental caries;
THYM	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	5.09	0.46	1.82e-6	Motion sickness;
THYM	cis	rs2273669	0.504	rs77107907	chr6:109436345	C/A	cg17117243	chr6:109341365	SESN1	-0.92	-5.47	-0.49	3.63e-7	Prostate cancer;
THYM	cis	rs12893597	0.715	rs12896100	chr14:76825064	C/T	cg20290672	chr14:76816747	NA	-0.69	-5.49	-0.49	3.27e-7	Maximal oxygen uptake response;
THYM	cis	rs1150668	0.799	rs9301	chr6:28292706	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.65	-5.06	-0.46	2.06e-6	Pubertal anthropometrics;
THYM	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg01448562	chr3:133502909	NA	-0.83	-7.15	-0.59	1.82e-10	Iron status biomarkers;
THYM	cis	rs1011939	0.726	rs75996459	chr16:20045314	A/T	cg10078415	chr16:20775011	ACSM3	-0.5	-4.83	-0.44	5.3e-6	Birth weight;
THYM	cis	rs3818717	0.538	rs4925108	chr17:17649423	C/T	cg04398451	chr17:18023971	MYO15A	0.64	5.2	0.47	1.14e-6	Lymphocyte counts;
THYM	cis	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg00646216	chr16:73210822	NA	0.62	4.68	0.43	9.64e-6	Energy expenditure (24h);
THYM	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.7	5.33	0.48	6.5e-7	Tonsillectomy;
THYM	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg15744005	chr10:104629667	AS3MT	-0.86	-8.65	-0.66	1.26e-13	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs10489202	1.000	rs1060041	chr1:167973976	C/T	cg24449463	chr1:168025552	DCAF6	-0.83	-6.51	-0.56	3.58e-9	Schizophrenia;
THYM	cis	rs7323507	0.636	rs6492231	chr13:110583053	T/C	cg07669776	chr13:110975691	COL4A2	-0.51	-4.64	-0.43	1.11e-5	Lung function (FVC);
THYM	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19346786	chr7:2764209	NA	-0.78	-6.94	-0.58	4.89e-10	Height;
THYM	cis	rs7267979	1.000	rs2259873	chr20:25280781	A/G	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2213920	0.679	rs7047851	chr9:118220718	A/G	cg13918206	chr9:118159781	DEC1	-0.81	-4.67	-0.43	9.95e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	trans	rs75518195	0.590	rs62302819	chr4:64733884	A/G	cg14706739	chr8:21916355	EPB49	0.75	7.28	0.6	9.73e-11	Triptolide cytotoxicity;
THYM	cis	rs12478296	1.000	rs66466023	chr2:243046151	T/G	cg06360820	chr2:242988706	NA	-0.93	-5.64	-0.5	1.78e-7	Obesity-related traits;
THYM	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg23583168	chr7:148888333	NA	-1.0	-13.2	-0.8	3.29e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg06009448	chr7:1102226	C7orf50	0.53	5.59	0.5	2.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11039798	0.512	rs11040205	chr11:49007360	G/C	cg24672777	chr11:48374446	OR4C45	-0.97	-6.23	-0.54	1.29e-8	Axial length;
THYM	cis	rs6456156	0.774	rs9347175	chr6:167527644	A/T	cg09487078	chr6:167525398	CCR6	-0.44	-4.9	-0.45	3.9e-6	Primary biliary cholangitis;
THYM	cis	rs7584330	0.554	rs7598035	chr2:238434942	C/T	cg14458575	chr2:238380390	NA	0.81	4.86	0.45	4.63e-6	Prostate cancer;
THYM	cis	rs4595586	0.545	rs969469	chr12:39366775	A/C	cg13010199	chr12:38710504	ALG10B	0.64	4.75	0.44	7.15e-6	Morning vs. evening chronotype;
THYM	cis	rs6138458	1.000	rs227651	chr20:24929834	A/G	cg06937882	chr20:24974362	C20orf3	-0.47	-4.45	-0.42	2.31e-5	Blood protein levels;
THYM	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg07511668	chr11:68622177	NA	0.44	4.63	0.43	1.16e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2235649	1.000	rs2235649	chr16:1837406	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.5	-4.87	-0.45	4.51e-6	Blood metabolite levels;
THYM	cis	rs6964587	0.626	rs2188841	chr7:91522641	A/G	cg22709100	chr7:91322751	NA	-0.62	-4.67	-0.43	9.77e-6	Breast cancer;
THYM	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg24578937	chr1:2090814	PRKCZ	0.81	8.45	0.65	3.41e-13	Height;
THYM	cis	rs673253	0.556	rs2274465	chr1:44121557	C/G	cg24466421	chr1:44070974	PTPRF	0.58	4.93	0.45	3.54e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.66	6.06	0.53	2.79e-8	Personality dimensions;
THYM	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg27534772	chr1:16042836	PLEKHM2	0.53	5.9	0.52	5.65e-8	Systolic blood pressure;
THYM	cis	rs9906944	0.707	rs4794019	chr17:47107290	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.49	-4.47	-0.42	2.15e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg02070205	chr10:30722105	MAP3K8	-0.71	-6.19	-0.54	1.53e-8	Inflammatory bowel disease;
THYM	cis	rs6763768	0.606	rs9812118	chr3:53380053	T/C	cg16894138	chr3:53270350	TKT	0.72	5.47	0.49	3.68e-7	Bacterial meningitis;
THYM	cis	rs11048434	0.761	rs2110190	chr12:9128289	A/C	cg04155231	chr12:9217510	LOC144571	0.48	4.59	0.43	1.34e-5	Sjögren's syndrome;
THYM	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg26769984	chr7:1090371	C7orf50	0.81	5.42	0.49	4.45e-7	Bronchopulmonary dysplasia;
THYM	cis	rs11711311	1.000	rs7633832	chr3:113472292	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.62	-5.52	-0.49	2.89e-7	IgG glycosylation;
THYM	cis	rs6988636	1.000	rs13259806	chr8:124190103	A/T	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2505675	0.961	rs2450300	chr6:2322454	C/T	cg01959516	chr6:2449276	NA	0.54	4.74	0.44	7.43e-6	Tuberculosis;
THYM	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg06728252	chr6:26598149	ABT1	-0.44	-5.24	-0.47	9.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs526231	0.511	rs62362545	chr5:102347452	A/G	cg23492399	chr5:102201601	PAM	-0.7	-5.21	-0.47	1.08e-6	Primary biliary cholangitis;
THYM	cis	rs7586673	1.000	rs16845584	chr2:161923830	C/T	cg22496339	chr2:162101262	NA	-0.64	-5.03	-0.46	2.33e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg09184832	chr6:79620586	NA	-0.57	-4.63	-0.43	1.17e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg27170947	chr2:26402098	FAM59B	-0.54	-4.45	-0.42	2.36e-5	Gut microbiome composition (summer);
THYM	cis	rs4919687	0.550	rs7907503	chr10:104440050	C/T	cg18761893	chr10:103892519	PPRC1	0.59	4.54	0.42	1.63e-5	Colorectal cancer;
THYM	cis	rs1050631	0.592	rs1785900	chr18:33710170	C/T	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.6	4.69	0.43	9.09e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.41	0.55	5.47e-9	Tonsillectomy;
THYM	cis	rs7193541	0.508	rs7188581	chr16:74672901	T/A	cg01733217	chr16:74700730	RFWD3	0.99	11.74	0.77	3.42e-20	Multiple myeloma;
THYM	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg18032289	chr17:61959525	GH2	-0.5	-4.58	-0.43	1.41e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs11771526	0.892	rs62457534	chr7:32357652	G/A	cg27532318	chr7:32358331	NA	0.95	5.63	0.5	1.85e-7	Body mass index;
THYM	cis	rs2637266	1.000	rs2579746	chr10:78327674	C/T	cg18941641	chr10:78392320	NA	0.78	6.67	0.56	1.71e-9	Pulmonary function;
THYM	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg17063962	chr7:91808500	NA	-1.12	-12.68	-0.79	3.85e-22	Breast cancer;
THYM	cis	rs6500395	0.928	rs4785532	chr16:48695500	G/A	cg04672837	chr16:48644449	N4BP1	-0.52	-5.16	-0.47	1.36e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg03354898	chr7:1950403	MAD1L1	-0.5	-4.68	-0.43	9.7e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs17209837	0.607	rs45496691	chr7:87110795	C/A	cg04996195	chr7:87105398	ABCB4	0.65	4.77	0.44	6.62e-6	Gallbladder cancer;
THYM	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg01236616	chr12:121019343	POP5	1.17	9.34	0.69	4.22e-15	Type 1 diabetes nephropathy;
THYM	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.45e-16	Prudent dietary pattern;
THYM	cis	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg07460842	chr6:66804631	NA	1.1	8.11	0.64	1.74e-12	Exhaled nitric oxide output;
THYM	cis	rs2903698	0.539	rs6858804	chr4:76358814	C/G	cg03209871	chr4:76438412	RCHY1;THAP6	0.46	5.37	0.48	5.47e-7	Prion diseases;
THYM	cis	rs4917300	0.626	rs13254582	chr8:143121547	T/G	cg25363559	chr8:143086065	NA	-0.52	-4.68	-0.43	9.34e-6	Amyotrophic lateral sclerosis;
THYM	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs9796	0.870	rs8042088	chr15:41337487	C/T	cg21153102	chr15:41252147	NA	-0.71	-6.41	-0.55	5.47e-9	Menopause (age at onset);
THYM	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg14582100	chr15:45693742	SPATA5L1	0.59	4.91	0.45	3.86e-6	Homoarginine levels;
THYM	cis	rs67460515	0.892	rs4856756	chr3:160999414	G/A	cg03342759	chr3:160939853	NMD3	-0.9	-7.94	-0.63	3.98e-12	Parkinson's disease;
THYM	cis	rs6665290	0.904	rs3738729	chr1:227191227	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg03859395	chr2:55845619	SMEK2	0.6	5.52	0.49	2.95e-7	Metabolic syndrome;
THYM	cis	rs4589502	0.925	rs57729347	chr15:67136438	G/A	cg12317470	chr15:67143691	NA	0.74	4.59	0.43	1.34e-5	Lung cancer (smoking interaction);
THYM	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg24503407	chr1:205819492	PM20D1	0.56	4.73	0.44	7.73e-6	Menarche (age at onset);
THYM	cis	rs2276314	0.762	rs3826600	chr18:33609053	A/G	cg19628046	chr18:33552617	C18orf21	0.74	5.43	0.49	4.29e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg17757837	chr7:157058334	UBE3C	0.62	5.01	0.46	2.52e-6	Body mass index;
THYM	cis	rs2354432	0.607	rs7537483	chr1:146709877	C/G	cg25205988	chr1:146714368	CHD1L	1.0	5.22	0.47	1.06e-6	Mitochondrial DNA levels;
THYM	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg11845111	chr2:191398756	TMEM194B	-1.01	-8.13	-0.64	1.61e-12	Diastolic blood pressure;
THYM	cis	rs9457247	0.534	rs4710149	chr6:167386346	T/C	cg15592062	chr6:167189543	RPS6KA2	0.52	5.32	0.48	6.84e-7	Crohn's disease;
THYM	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg23815491	chr16:72088622	HP	0.84	6.94	0.58	4.78e-10	Fibrinogen levels;
THYM	cis	rs2069837	0.636	rs2390716	chr7:22807922	C/T	cg21239317	chr7:23640510	CCDC126	-0.72	-4.46	-0.42	2.24e-5	Longevity;
THYM	cis	rs8044868	0.586	rs8182213	chr16:72080005	C/T	cg16558253	chr16:72132732	DHX38	-0.55	-4.67	-0.43	1e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs8112211	0.637	rs2270093	chr19:38839859	T/C	cg09474229	chr19:39360330	RINL	-0.71	-5.48	-0.49	3.52e-7	Blood protein levels;
THYM	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg24375607	chr4:120327624	NA	0.6	5.06	0.46	2.04e-6	Corneal astigmatism;
THYM	cis	rs11214589	0.747	rs1893695	chr11:113206085	A/C	cg14159747	chr11:113255604	NA	0.3	5.74	0.51	1.12e-7	Neuroticism;
THYM	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg26441486	chr22:50317300	CRELD2	0.43	6.27	0.54	1.07e-8	Schizophrenia;
THYM	trans	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg25214090	chr10:38739885	LOC399744	-0.96	-8.24	-0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg02176678	chr2:219576539	TTLL4	0.72	7.17	0.59	1.63e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22496380	chr5:211416	CCDC127	-1.33	-7.9	-0.63	4.79e-12	Breast cancer;
THYM	cis	rs7589342	0.839	rs1465639	chr2:106439181	T/C	cg14210321	chr2:106509881	NCK2	-0.69	-4.9	-0.45	4.01e-6	Addiction;
THYM	cis	rs7944735	0.567	rs7111404	chr11:48011283	C/G	cg24672777	chr11:48374446	OR4C45	-0.91	-4.88	-0.45	4.35e-6	Intraocular pressure;
THYM	trans	rs629535	0.859	rs55803226	chr8:70108965	T/C	cg21567404	chr3:27674614	NA	-1.0	-9.06	-0.68	1.69e-14	Dupuytren's disease;
THYM	cis	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg15744005	chr10:104629667	AS3MT	-0.87	-8.46	-0.66	3.24e-13	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs73086581	0.947	rs55794220	chr20:3956402	C/T	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg25427524	chr10:38739819	LOC399744	-0.63	-5.84	-0.51	7.33e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg18357526	chr6:26021779	HIST1H4A	0.59	4.55	0.42	1.61e-5	Blood metabolite levels;
THYM	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg19746536	chr19:49375674	PPP1R15A	0.81	4.6	0.43	1.33e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs950394	0.767	rs56354344	chr2:104989874	G/C	cg20302975	chr2:105468274	NA	-0.66	-4.5	-0.42	1.9e-5	Schizophrenia;
THYM	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21659725	chr3:3221576	CRBN	0.9	9.83	0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.777	rs13038342	chr20:43800232	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.93	-0.58	5.03e-10	Blood protein levels;
THYM	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg11764359	chr7:65958608	NA	0.7	4.89	0.45	4.09e-6	Aortic root size;
THYM	cis	rs612683	0.664	rs6702766	chr1:100997635	A/G	cg09408571	chr1:101003634	GPR88	-0.49	-5.62	-0.5	1.92e-7	Breast cancer;
THYM	trans	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg17830980	chr10:43048298	ZNF37B	-0.82	-6.99	-0.58	3.81e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs9768139	0.683	rs72505558	chr7:158113215	A/G	cg24154853	chr7:158122151	PTPRN2	0.55	4.88	0.45	4.32e-6	Calcium levels;
THYM	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7683537	0.887	rs4540092	chr4:185633546	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Systemic lupus erythematosus;
THYM	cis	rs4460079	0.556	rs13107667	chr4:114834627	C/G	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs686320	0.748	rs673753	chr11:65206017	A/G	cg19332572	chr11:65321591	LTBP3	-0.81	-4.78	-0.44	6.51e-6	Hip circumference adjusted for BMI;
THYM	trans	rs2230624	1.000	rs76823085	chr1:11883548	A/T	cg00206407	chr20:62178943	SRMS	1.08	7.12	0.59	2.05e-10	Mosquito bite size;
THYM	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.41	0.49	4.79e-7	Height;
THYM	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg21394778	chr1:3037102	PRDM16	-0.47	-4.53	-0.42	1.73e-5	Height;
THYM	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg11663144	chr21:46675770	NA	-0.68	-8.3	-0.65	7.02e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9876781	1.000	rs9849509	chr3:48483432	A/G	cg06066452	chr3:48470258	PLXNB1	0.27	4.84	0.44	5e-6	Longevity;
THYM	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs4732038	0.510	rs12673683	chr7:134275850	T/C	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs181553	0.664	rs10775491	chr18:46688467	C/T	cg13634221	chr18:46498533	NA	0.81	5.2	0.47	1.12e-6	Hip circumference adjusted for BMI;
THYM	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.44	0.61	4.48e-11	Bladder cancer;
THYM	cis	rs2991971	1.000	rs9147	chr1:46016687	T/C	cg15605315	chr1:45957053	TESK2	0.65	5.12	0.46	1.6e-6	High light scatter reticulocyte count;
THYM	cis	rs4888262	0.526	rs4888253	chr16:74583146	C/T	cg01733217	chr16:74700730	RFWD3	0.8	8.28	0.65	7.82e-13	Testicular germ cell tumor;
THYM	trans	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg25214090	chr10:38739885	LOC399744	0.97	8.33	0.65	5.98e-13	Corneal astigmatism;
THYM	cis	rs4911259	0.552	rs2014837	chr20:31461082	C/T	cg13636640	chr20:31349939	DNMT3B	0.64	6.14	0.53	1.91e-8	Inflammatory bowel disease;
THYM	cis	rs7809950	0.678	rs4730235	chr7:107022506	T/C	cg23024343	chr7:107201750	COG5	-0.93	-7.62	-0.62	1.86e-11	Coronary artery disease;
THYM	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg05890377	chr2:74357713	NA	1.08	9.09	0.68	1.48e-14	Gestational age at birth (maternal effect);
THYM	cis	rs7084402	0.967	rs1658477	chr10:60289607	A/G	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs7915131	0.965	rs7068164	chr10:64401056	A/C	cg03961010	chr10:64397487	ZNF365	-0.63	-4.62	-0.43	1.21e-5	Schizophrenia;
THYM	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg11764359	chr7:65958608	NA	-0.65	-4.98	-0.45	2.84e-6	Aortic root size;
THYM	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg08305652	chr11:111469057	NA	-0.54	-4.61	-0.43	1.25e-5	Primary sclerosing cholangitis;
THYM	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg17757837	chr7:157058334	UBE3C	0.65	5.24	0.47	9.83e-7	Body mass index;
THYM	cis	rs72627123	1.000	rs72627127	chr14:74370098	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	trans	rs75518195	0.590	rs17688509	chr4:64732043	A/G	cg14706739	chr8:21916355	EPB49	0.74	7.19	0.59	1.47e-10	Triptolide cytotoxicity;
THYM	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg24250549	chr1:154909240	PMVK	0.67	5.39	0.48	5.18e-7	Prostate cancer;
THYM	cis	rs2408955	0.504	rs11168441	chr12:48576054	G/A	cg21466736	chr12:48725269	NA	-0.48	-4.71	-0.44	8.4e-6	Glycated hemoglobin levels;
THYM	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg03388025	chr16:89894329	SPIRE2	0.52	4.47	0.42	2.15e-5	Vitiligo;
THYM	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg20007245	chr22:24372913	LOC391322	-0.73	-6.57	-0.56	2.74e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg00666640	chr1:248458726	OR2T12	0.56	4.53	0.42	1.69e-5	Common traits (Other);
THYM	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg17971929	chr21:40555470	PSMG1	0.74	4.87	0.45	4.39e-6	Cognitive function;
THYM	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg04317338	chr11:64019027	PLCB3	0.93	6.43	0.55	5.17e-9	Mean platelet volume;
THYM	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg15549821	chr19:49342101	PLEKHA4	-1.01	-5.71	-0.51	1.3e-7	Red cell distribution width;
THYM	cis	rs12765878	0.603	rs2475213	chr10:105664459	A/T	cg04688330	chr10:105451802	SH3PXD2A	-0.37	-4.54	-0.42	1.64e-5	Coronary artery disease;
THYM	cis	rs77204473	0.557	rs9971422	chr11:116837373	T/C	cg20608306	chr11:116969690	SIK3	-0.72	-5.21	-0.47	1.09e-6	Eosinophil counts;Sum eosinophil basophil counts;
THYM	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.95	0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg02403541	chr12:121454288	C12orf43	0.8	7.33	0.6	7.47e-11	N-glycan levels;
THYM	cis	rs2252521	0.524	rs2074782	chr7:29070653	C/T	cg24222995	chr7:28995786	TRIL	-0.62	-4.46	-0.42	2.28e-5	Cognitive performance;
THYM	cis	rs7560272	0.669	rs13008860	chr2:73774019	G/A	cg19565262	chr2:73869966	NAT8	-0.55	-4.77	-0.44	6.76e-6	Schizophrenia;
THYM	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-6.1	-0.53	2.32e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.02	0.46	2.4e-6	Obesity-related traits;
THYM	cis	rs986417	1.000	rs12147690	chr14:60924009	A/G	cg27398547	chr14:60952738	C14orf39	1.15	5.91	0.52	5.37e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs10992471	0.580	rs4743875	chr9:95423674	T/C	cg14631576	chr9:95140430	CENPP	-0.94	-7.64	-0.62	1.75e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg09367891	chr1:107599246	PRMT6	0.7	4.7	0.43	8.81e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs11048434	0.736	rs11048338	chr12:9121362	C/G	cg13575925	chr12:9217583	LOC144571	0.53	4.94	0.45	3.31e-6	Sjögren's syndrome;
THYM	cis	rs611744	0.967	rs653633	chr8:109196151	T/G	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg10856724	chr12:34555212	NA	-0.93	-9.28	-0.69	5.8e-15	Morning vs. evening chronotype;
THYM	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg06728252	chr6:26598149	ABT1	-0.42	-4.62	-0.43	1.21e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10095849	0.554	rs10108138	chr8:39439826	A/G	cg01911981	chr8:39380341	ADAM3A	-0.62	-5.13	-0.47	1.51e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg06558623	chr16:89946397	TCF25	1.33	5.65	0.5	1.64e-7	Skin colour saturation;
THYM	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg24692254	chr21:30365293	RNF160	-0.85	-7.06	-0.59	2.74e-10	Dental caries;
THYM	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg16325326	chr1:53192061	ZYG11B	0.8	6.52	0.56	3.35e-9	Monocyte count;
THYM	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.65	-4.66	-0.43	1.04e-5	Gut microbiome composition (summer);
THYM	cis	rs13064411	0.735	rs6438157	chr3:113207316	G/T	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs6430585	0.527	rs76622824	chr2:136411879	A/G	cg23851026	chr2:136556271	LCT	0.63	5.72	0.51	1.24e-7	Corneal structure;
THYM	cis	rs6946131	1.000	rs6946131	chr7:54783373	T/C	cg16668896	chr7:54900801	NA	0.36	4.46	0.42	2.22e-5	Systemic lupus erythematosus;
THYM	cis	rs11148252	0.514	rs1886539	chr13:52726090	C/T	cg00495681	chr13:53174319	NA	0.7	6.01	0.52	3.4e-8	Lewy body disease;
THYM	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7084402	0.967	rs1620186	chr10:60314275	G/A	cg07615347	chr10:60278583	BICC1	0.56	5.15	0.47	1.4e-6	Refractive error;
THYM	cis	rs2294693	0.531	rs2179518	chr6:40938370	C/G	cg14418226	chr6:40996092	UNC5CL	0.72	5.49	0.49	3.4e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs7975161	0.520	rs9739833	chr12:104737430	A/T	cg25273343	chr12:104657179	TXNRD1	-0.74	-4.51	-0.42	1.83e-5	Toenail selenium levels;
THYM	cis	rs3126085	0.877	rs2338431	chr1:152169305	A/G	cg26020982	chr1:152196106	HRNR	0.36	4.7	0.43	8.63e-6	Atopic dermatitis;
THYM	cis	rs7192380	1.000	rs8061052	chr16:69656532	G/A	cg09409435	chr16:70099608	PDXDC2	0.62	4.73	0.44	7.92e-6	Sjögren's syndrome;
THYM	cis	rs995000	0.931	rs1168009	chr1:62943954	G/A	cg06896770	chr1:63153194	DOCK7	-0.91	-7.58	-0.61	2.33e-11	Triglyceride levels;
THYM	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg13114125	chr14:105738426	BRF1	-0.74	-5.72	-0.51	1.22e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1113500	0.836	rs1539553	chr1:108589998	C/T	cg06207961	chr1:108661230	NA	-0.7	-5.58	-0.5	2.25e-7	Growth-regulated protein alpha levels;
THYM	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg23803603	chr1:2058230	PRKCZ	0.64	5.53	0.49	2.81e-7	Height;
THYM	cis	rs9913156	0.748	rs7213896	chr17:4562082	G/A	cg19197139	chr17:4613644	ARRB2	0.78	4.92	0.45	3.63e-6	Lymphocyte counts;
THYM	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg13397359	chr6:42928475	GNMT	0.61	5.46	0.49	3.79e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12282928	1.000	rs6485817	chr11:48250764	T/A	cg22827986	chr11:48284249	OR4X1	-0.53	-5.5	-0.49	3.18e-7	Migraine - clinic-based;
THYM	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg23711669	chr6:146136114	FBXO30	0.88	8.52	0.66	2.41e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1055129	0.655	rs3744006	chr17:73838816	G/A	cg12407791	chr17:73824354	UNC13D	-0.43	-4.93	-0.45	3.5e-6	White matter hyperintensity burden;
THYM	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.21	9.47	0.7	2.27e-15	Platelet count;
THYM	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg05425664	chr17:57184151	TRIM37	0.58	4.53	0.42	1.72e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg20295408	chr7:1910781	MAD1L1	-0.61	-4.85	-0.45	4.9100000000000004e-06	Bipolar disorder and schizophrenia;
THYM	cis	rs17577085	0.597	rs10491398	chr5:141869933	C/T	cg07247133	chr5:142066658	FGF1	0.81	4.58	0.43	1.39e-5	Coronary heart disease;
THYM	cis	rs6748734	0.625	rs9288743	chr2:241821569	C/G	cg07537917	chr2:241836409	C2orf54	-0.21	-4.95	-0.45	3.18e-6	Urinary metabolites;
THYM	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg07606381	chr6:8435919	SLC35B3	0.63	4.64	0.43	1.11e-5	Motion sickness;
THYM	cis	rs3020340	0.817	rs35240111	chr6:152050523	G/C	cg22157087	chr6:152012887	ESR1	0.51	4.97	0.45	2.98e-6	Bone mineral density (Ward's triangle area);
THYM	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3820068	0.603	rs2236215	chr1:15892415	A/C	cg27534772	chr1:16042836	PLEKHM2	0.5	4.48	0.42	2.08e-5	Systolic blood pressure;
THYM	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg16486109	chr11:613632	IRF7	0.48	5.34	0.48	6.21e-7	Systemic lupus erythematosus;
THYM	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg26769984	chr7:1090371	C7orf50	0.83	5.35	0.48	6.11e-7	Bronchopulmonary dysplasia;
THYM	cis	rs7078219	0.543	rs7096296	chr10:101277816	A/G	cg07044859	chr10:101282883	NA	0.42	4.89	0.45	4.03e-6	Dental caries;
THYM	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg14895029	chr7:2775587	GNA12	-0.65	-4.67	-0.43	9.71e-6	Height;
THYM	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg18252515	chr7:66147081	NA	-1.01	-6.68	-0.57	1.62e-9	Diabetic kidney disease;
THYM	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22857025	chr5:266934	NA	-1.59	-10.2	-0.72	6.04e-17	Breast cancer;
THYM	cis	rs2862064	0.613	rs2862060	chr5:156443895	A/C	cg12943317	chr5:156479607	HAVCR1	-0.83	-5.12	-0.46	1.61e-6	Platelet count;
THYM	cis	rs28595532	0.841	rs115924581	chr4:119786333	T/C	cg21605333	chr4:119757512	SEC24D	1.61	5.8	0.51	8.85e-8	Cannabis dependence symptom count;
THYM	trans	rs9951602	0.512	rs61021837	chr18:76648210	A/C	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg04320152	chr17:18167836	SMCR7	-0.64	-5.23	-0.47	1.01e-6	Total body bone mineral density;
THYM	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg23803603	chr1:2058230	PRKCZ	0.66	5.99	0.52	3.74e-8	Height;
THYM	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg19774624	chr17:42201019	HDAC5	-0.85	-8.23	-0.65	9.73e-13	Total body bone mineral density;
THYM	cis	rs6032067	0.516	rs16989916	chr20:43899514	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.59	-5.8	-0.51	8.81e-8	Blood protein levels;
THYM	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg10802521	chr3:52805072	NEK4	0.68	6.23	0.54	1.25e-8	Electroencephalogram traits;
THYM	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.54e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg05804037	chr4:1090086	RNF212	0.42	4.53	0.42	1.68e-5	Recombination rate (males);
THYM	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg01699819	chr7:1052092	C7orf50	-0.59	-5.62	-0.5	1.87e-7	Bronchopulmonary dysplasia;
THYM	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	6.97	0.58	4.11e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs78761021	0.755	rs55660558	chr17:9793811	C/T	cg26853458	chr17:9805074	RCVRN	0.54	4.51	0.42	1.86e-5	Type 2 diabetes;
THYM	cis	rs981844	0.683	rs1037647	chr4:154737991	A/G	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs6918586	0.658	rs198809	chr6:26128766	G/A	cg03264133	chr6:25882463	NA	0.65	5.06	0.46	2e-6	Schizophrenia;
THYM	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg20295408	chr7:1910781	MAD1L1	-0.65	-4.85	-0.45	4.9e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg15691649	chr6:25882328	NA	-0.73	-5.62	-0.5	1.9e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg00129232	chr17:37814104	STARD3	-0.69	-4.51	-0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg22431228	chr1:16359049	CLCNKA	-0.53	-5.17	-0.47	1.28e-6	Dilated cardiomyopathy;
THYM	cis	rs9311676	0.632	rs12487420	chr3:58399511	A/G	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg11526020	chr17:80870163	TBCD	-0.44	-4.56	-0.42	1.53e-5	Breast cancer;
THYM	cis	rs988913	0.706	rs4712087	chr6:54940103	A/T	cg18532076	chr6:54711417	FAM83B	0.49	4.62	0.43	1.18e-5	Menarche (age at onset);
THYM	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg19761014	chr17:28927070	LRRC37B2	0.71	4.52	0.42	1.77e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs11722228	0.508	rs3822246	chr4:10094698	G/A	cg02317251	chr4:10116515	WDR1	-0.56	-4.95	-0.45	3.23e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg16586182	chr3:47516702	SCAP	-0.61	-5.25	-0.47	9.2e-7	Colorectal cancer;
THYM	cis	rs4660456	0.572	rs10789191	chr1:41156491	C/G	cg11417323	chr1:41160271	NFYC	0.41	4.6	0.43	1.31e-5	Platelet count;
THYM	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg07936489	chr17:37558343	FBXL20	-0.83	-5.84	-0.51	7.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg10792982	chr14:105748885	BRF1	0.74	7.74	0.62	1.08e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs863345	0.584	rs10797024	chr1:158497163	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs10851411	0.688	rs62022314	chr15:42754649	T/C	cg04857231	chr15:42782520	NA	-0.57	-5.16	-0.47	1.37e-6	Glucose homeostasis traits;
THYM	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg05182265	chr7:156933206	UBE3C	0.62	7.27	0.6	9.88e-11	Body mass index;
THYM	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg08439880	chr3:133502540	NA	-0.73	-6.46	-0.55	4.44e-9	Iron status biomarkers;
THYM	trans	rs629535	0.773	rs72654090	chr8:70118666	G/A	cg21567404	chr3:27674614	NA	-1.06	-9.7	-0.71	7.35e-16	Dupuytren's disease;
THYM	cis	rs7941600	0.581	rs12278189	chr11:9359844	G/T	cg19415743	chr11:9336845	TMEM41B	0.9	4.63	0.43	1.15e-5	Coronary artery disease;
THYM	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs6866344	0.601	rs4419608	chr5:178097049	C/T	cg10224037	chr5:178157518	ZNF354A	0.85	5.73	0.51	1.19e-7	Neutrophil percentage of white cells;
THYM	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg24812749	chr6:127587940	RNF146	0.98	7.94	0.63	4.04e-12	Breast cancer;
THYM	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg04546413	chr19:29218101	NA	1.06	8.41	0.65	4.01e-13	Methadone dose in opioid dependence;
THYM	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg09263875	chr16:632152	PIGQ	0.73	6.29	0.54	9.69e-9	Height;
THYM	cis	rs4733781	0.933	rs1118887	chr8:131202021	A/T	cg16277922	chr8:131349729	ASAP1	0.63	4.59	0.43	1.37e-5	Tuberculosis;
THYM	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	5.1	0.46	1.75e-6	Bipolar disorder;
THYM	cis	rs919433	0.889	rs12693816	chr2:198208420	T/A	cg00792783	chr2:198669748	PLCL1	-0.71	-5.14	-0.47	1.46e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.62	4.78	0.44	6.3e-6	Chronic sinus infection;
THYM	cis	rs7980799	0.653	rs1384598	chr12:33622899	T/A	cg06521331	chr12:34319734	NA	0.69	4.93	0.45	3.47e-6	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs4849845	0.889	rs6746250	chr2:121058254	A/G	cg03575764	chr2:121493832	NA	-0.65	-4.88	-0.45	4.2e-6	Mean platelet volume;
THYM	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.14	6.64	0.56	1.9e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11771526	0.901	rs7791914	chr7:32296754	A/G	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs8049040	0.609	rs4258624	chr16:71467951	C/T	cg08717414	chr16:71523259	ZNF19	0.68	4.47	0.42	2.19e-5	Blood protein levels;
THYM	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg01097406	chr16:89675127	NA	-0.64	-5.33	-0.48	6.66e-7	Vitiligo;
THYM	cis	rs4851254	0.660	rs74340261	chr2:100696827	C/T	cg22139774	chr2:100720529	AFF3	-0.41	-4.69	-0.43	9.07e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.32e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6815814	0.768	rs2013740	chr4:38891737	A/G	cg06935464	chr4:38784597	TLR10	0.63	4.51	0.42	1.87e-5	Breast cancer;
THYM	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.63	-5.52	-0.49	2.88e-7	Hip circumference adjusted for BMI;
THYM	cis	rs2637266	0.729	rs1099883	chr10:78516158	G/T	cg18941641	chr10:78392320	NA	0.71	5.69	0.5	1.38e-7	Pulmonary function;
THYM	cis	rs7586879	0.551	rs7565460	chr2:25130073	C/T	cg15423357	chr2:25149977	NA	0.7	7.76	0.62	9.56e-12	Body mass index;
THYM	cis	rs1728785	0.901	rs6499186	chr16:68660565	C/T	cg02972257	chr16:68554789	NA	-0.78	-4.61	-0.43	1.24e-5	Ulcerative colitis;
THYM	cis	rs6032067	0.929	rs6017513	chr20:43835232	A/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.34	-0.65	5.7e-13	Blood protein levels;
THYM	cis	rs3126085	0.560	rs67661262	chr1:152368016	A/C	cg10321714	chr1:152280068	FLG	-0.69	-4.84	-0.44	5.1e-6	Atopic dermatitis;
THYM	cis	rs9906944	0.703	rs940088	chr17:47145848	T/C	cg09029085	chr17:47094198	IGF2BP1	0.5	7.22	0.6	1.29e-10	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	8.23	0.64	1e-12	Smoking behavior;
THYM	cis	rs9868809	0.772	rs34096717	chr3:48719453	A/C	cg00383909	chr3:49044727	WDR6	0.95	4.69	0.43	9.21e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs2124969	0.548	rs62175391	chr2:161022588	A/G	cg03641300	chr2:160917029	PLA2R1	-0.65	-4.58	-0.43	1.38e-5	Waist circumference adjusted for body mass index;
THYM	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg04429589	chr14:105992532	TMEM121	-0.48	-5.28	-0.48	8.21e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg14768367	chr16:72042858	DHODH	0.62	4.72	0.44	8.24e-6	Fibrinogen levels;
THYM	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg20290983	chr6:43655470	MRPS18A	0.91	7.06	0.59	2.71e-10	IgG glycosylation;
THYM	cis	rs7586879	0.575	rs6712981	chr2:25126230	A/G	cg15423357	chr2:25149977	NA	0.7	7.74	0.62	1.03e-11	Body mass index;
THYM	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg05754148	chr16:3507555	NAT15	-0.87	-6.93	-0.58	4.92e-10	Tuberculosis;
THYM	cis	rs2916260	0.800	rs6932438	chr6:40389163	A/G	cg08415973	chr6:40346114	TDRG1	0.75	4.71	0.43	8.6e-6	Incident coronary heart disease;
THYM	cis	rs2282300	0.696	rs1222214	chr11:30347695	C/G	cg25418670	chr11:30344373	C11orf46	-0.82	-6.98	-0.58	3.93e-10	Morning vs. evening chronotype;
THYM	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.69	0.5	1.43e-7	Height;
THYM	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg17401067	chr22:41840292	TOB2	-0.49	-4.55	-0.42	1.59e-5	Vitiligo;
THYM	cis	rs9296092	0.538	rs9461887	chr6:33526827	C/T	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg04750100	chr2:136595281	LCT	-0.58	-6.94	-0.58	4.82e-10	Mosquito bite size;
THYM	cis	rs7582180	0.764	rs1967341	chr2:100924559	T/C	cg08017756	chr2:100939284	LONRF2	-0.73	-7.51	-0.61	3.21e-11	Intelligence (multi-trait analysis);
THYM	cis	rs1065852	0.526	rs11090066	chr22:42398195	A/G	cg01059385	chr22:42394853	WBP2NL	0.63	5.16	0.47	1.35e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs17443541	0.507	rs7576031	chr2:200470616	G/A	cg03741458	chr2:200468445	NA	-0.8	-6.04	-0.53	3.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03452623	chr4:187889614	NA	1.18	20.29	0.9	2.66e-36	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1007190	0.881	rs71373521	chr17:42949442	C/T	cg15406952	chr17:42872593	NA	0.8	5.57	0.5	2.34e-7	DNA methylation (variation);
THYM	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10886503	0.614	rs3009908	chr10:121262900	T/C	cg13260278	chr10:121265587	RGS10	0.64	5.89	0.52	5.85e-8	Obstetric antiphospholipid syndrome;
THYM	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg27034606	chr17:28928453	LRRC37B2	0.76	5.06	0.46	2.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4460079	0.531	rs10008482	chr4:114844851	G/A	cg02060584	chr4:113970739	ANK2	0.59	4.93	0.45	3.48e-6	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg09165964	chr15:75287851	SCAMP5	0.6	4.59	0.43	1.38e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg06481639	chr22:41940642	POLR3H	-0.72	-5.25	-0.47	9.4e-7	Neuroticism;
THYM	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg21433313	chr16:3507492	NAT15	-0.72	-5.35	-0.48	6.13e-7	Tuberculosis;
THYM	cis	rs4363385	0.642	rs58124215	chr1:152916375	C/T	cg07796016	chr1:152779584	LCE1C	-0.62	-5.07	-0.46	1.97e-6	Inflammatory skin disease;
THYM	cis	rs10887741	0.690	rs4934358	chr10:89439744	C/A	cg13926569	chr10:89418898	PAPSS2	0.61	6.54	0.56	3.07e-9	Exercise (leisure time);
THYM	cis	rs13082711	0.911	rs4973772	chr3:27450234	G/T	cg02860705	chr3:27208620	NA	0.69	4.91	0.45	3.77e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1007190	0.570	rs8064954	chr17:42867443	A/C	cg15406952	chr17:42872593	NA	-0.83	-5.81	-0.51	8.3e-8	DNA methylation (variation);
THYM	cis	rs35883536	1.000	rs11586815	chr1:101089079	C/T	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs6554196	0.525	rs12504135	chr4:55505933	A/T	cg18836493	chr4:55524333	KIT	-0.54	-4.58	-0.42	1.43e-5	Monocyte count;
THYM	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.78	7.15	0.59	1.82e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs8180040	0.800	rs56250009	chr3:47279497	G/C	cg12976108	chr3:47324180	KIF9;KLHL18	0.5	4.5	0.42	1.92e-5	Colorectal cancer;
THYM	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.11	9.5	0.7	1.96e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg20295408	chr7:1910781	MAD1L1	-0.62	-4.8	-0.44	5.93e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.86	0.45	4.55e-6	Prudent dietary pattern;
THYM	cis	rs9574309	0.522	rs9574311	chr13:79396606	C/A	cg20271865	chr13:80233183	NA	0.36	4.45	0.42	2.35e-5	IgG glycosylation;
THYM	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.64	-4.56	-0.42	1.55e-5	Colorectal cancer;
THYM	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	5.16	0.47	1.36e-6	Schizophrenia;
THYM	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs62229266	0.626	rs2835268	chr21:37449136	C/G	cg12218747	chr21:37451666	NA	-0.69	-6.67	-0.57	1.65e-9	Mitral valve prolapse;
THYM	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg13695892	chr22:41940480	POLR3H	0.86	7.06	0.59	2.77e-10	Vitiligo;
THYM	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg25801113	chr15:45476975	SHF	-0.39	-4.5	-0.42	1.91e-5	Uric acid levels;
THYM	cis	rs72627123	0.737	rs77361581	chr14:74465290	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs11822910	0.871	rs2581928	chr11:57202790	A/G	cg00522883	chr11:57194120	SLC43A3	-0.71	-5.13	-0.47	1.54e-6	Platelet distribution width;
THYM	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.26	0.47	8.97e-7	Lung cancer in ever smokers;
THYM	cis	rs10095849	0.576	rs13260129	chr8:39477848	A/C	cg01911981	chr8:39380341	ADAM3A	-0.59	-5.05	-0.46	2.13e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs55728055	0.661	rs62239169	chr22:32042514	G/A	cg10537193	chr22:32026975	PISD	-0.86	-5.48	-0.49	3.48e-7	Age-related hearing impairment;
THYM	cis	rs12200560	0.505	rs211167	chr6:97069087	T/A	cg06623918	chr6:96969491	KIAA0776	0.76	5.77	0.51	9.9e-8	Coronary heart disease;
THYM	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.71	5.67	0.5	1.52e-7	Blood metabolite levels;
THYM	cis	rs9500256	0.683	rs10458024	chr6:58324089	T/C	cg16251399	chr6:58287822	GUSBL2	0.58	4.53	0.42	1.73e-5	Eosinophilic esophagitis (pediatric);
THYM	cis	rs7200543	1.000	rs4500751	chr16:15140211	C/T	cg01933576	chr16:15083564	PDXDC1	-0.92	-7.41	-0.61	5.11e-11	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs137603	0.623	rs137657	chr22:39733242	G/T	cg24268161	chr22:39747459	SYNGR1	0.64	5.27	0.48	8.65e-7	Primary biliary cholangitis;
THYM	cis	rs3087591	0.887	rs1013946	chr17:29530350	A/C	cg24425628	chr17:29625626	OMG;NF1	0.63	5.6	0.5	2.04e-7	Hip circumference;
THYM	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg24578937	chr1:2090814	PRKCZ	-0.65	-6.85	-0.58	7.29e-10	Height;
THYM	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	6.67	0.56	1.66e-9	Prudent dietary pattern;
THYM	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg02734326	chr4:10020555	SLC2A9	0.71	6.47	0.55	4.23e-9	Bone mineral density;
THYM	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg09033563	chr22:24373618	LOC391322	-0.6	-5.6	-0.5	2.04e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg11266682	chr4:10021025	SLC2A9	-0.74	-10.76	-0.74	3.89e-18	Bone mineral density;
THYM	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg02640540	chr1:67518911	SLC35D1	0.67	5.1	0.46	1.74e-6	Lymphocyte percentage of white cells;
THYM	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg00810483	chr4:3375144	RGS12	0.3	4.51	0.42	1.85e-5	Serum sulfate level;
THYM	cis	rs4523957	0.855	rs9897160	chr17:2121566	A/G	cg16513277	chr17:2031491	SMG6	-0.8	-7.85	-0.63	6.16e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7572733	0.515	rs6726506	chr2:198846486	G/T	cg00792783	chr2:198669748	PLCL1	0.83	5.7	0.5	1.36e-7	Dermatomyositis;
THYM	cis	rs4474465	1.000	rs10899508	chr11:78170708	T/G	cg19901956	chr11:77921274	USP35	-0.6	-4.55	-0.42	1.56e-5	Alzheimer's disease (survival time);
THYM	cis	rs6467136	0.765	rs58894662	chr7:127193533	C/T	cg08586737	chr7:127225949	GCC1	-0.32	-4.57	-0.42	1.48e-5	Type 2 diabetes;
THYM	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg10117171	chr1:25599238	RHD	0.68	4.87	0.45	4.52e-6	Erythrocyte sedimentation rate;
THYM	cis	rs9649213	0.593	rs11766808	chr7:97915376	A/G	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2898681	0.581	rs730247	chr4:53680696	T/G	cg00791764	chr4:53727839	RASL11B	0.44	5.46	0.49	3.81e-7	Optic nerve measurement (cup area);
THYM	cis	rs892961	0.932	rs7223768	chr17:75410521	G/A	cg11351908	chr17:75402473	SEPT9	0.58	5.57	0.5	2.36e-7	Airflow obstruction;
THYM	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg09307838	chr4:120376055	NA	0.68	4.93	0.45	3.43e-6	Corneal astigmatism;
THYM	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg27168131	chr21:44088823	PDE9A	-0.48	-4.88	-0.45	4.23e-6	Mean corpuscular volume;
THYM	cis	rs6087990	0.735	rs2424907	chr20:31359819	C/T	cg13636640	chr20:31349939	DNMT3B	0.87	8.73	0.67	8.35e-14	Ulcerative colitis;
THYM	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg24675658	chr1:53192096	ZYG11B	-0.82	-7.65	-0.62	1.6e-11	Monocyte count;
THYM	cis	rs9814567	0.712	rs4306900	chr3:134334327	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.74	6.92	0.58	5.2e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs10463554	0.892	rs257313	chr5:102420647	A/G	cg23492399	chr5:102201601	PAM	-0.69	-5.17	-0.47	1.27e-6	Parkinson's disease;
THYM	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg07936489	chr17:37558343	FBXL20	-0.7	-5.08	-0.46	1.87e-6	Asthma;
THYM	cis	rs9311676	0.632	rs62258078	chr3:58363432	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.6	0.43	1.29e-5	Systemic lupus erythematosus;
THYM	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg04234412	chr22:24373322	LOC391322	-0.92	-9.31	-0.69	4.89e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11690935	0.595	rs788166	chr2:172915489	G/C	cg13550731	chr2:172543902	DYNC1I2	0.72	5.96	0.52	4.35e-8	Schizophrenia;
THYM	cis	rs986417	1.000	rs8004736	chr14:61053061	T/C	cg27398547	chr14:60952738	C14orf39	1.28	6.18	0.54	1.59e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg09307838	chr4:120376055	NA	0.78	5.64	0.5	1.76e-7	Corneal astigmatism;
THYM	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg03188948	chr7:1209495	NA	0.71	4.96	0.45	3.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6669072	0.703	rs3843306	chr1:91288130	A/T	cg08895590	chr1:91227319	NA	0.51	5.64	0.5	1.76e-7	Cognitive function;
THYM	cis	rs12126655	0.529	rs7517496	chr1:108393995	T/C	cg20016673	chr1:108023366	NTNG1	0.42	4.72	0.44	8.06e-6	Plasma thyroid-stimulating hormone levels;
THYM	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg17279839	chr7:150038598	RARRES2	-0.55	-5.44	-0.49	4.08e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs35883536	1.000	rs6681906	chr1:101086414	C/T	cg06223162	chr1:101003688	GPR88	0.61	4.49	0.42	1.98e-5	Monocyte count;
THYM	cis	rs11039798	1.000	rs7942284	chr11:48520424	A/G	cg24672777	chr11:48374446	OR4C45	0.91	5.46	0.49	3.79e-7	Axial length;
THYM	cis	rs861020	0.630	rs9308411	chr1:210005713	C/T	cg05527609	chr1:210001259	C1orf107	0.85	6.79	0.57	9.76e-10	Orofacial clefts;
THYM	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.87	-4.64	-0.43	1.11e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9926296	0.687	rs258323	chr16:89754694	G/C	cg26513180	chr16:89883248	FANCA	-0.53	-4.61	-0.43	1.27e-5	Vitiligo;
THYM	cis	rs9826463	0.752	rs3821647	chr3:142523349	C/T	cg20824294	chr3:142316082	PLS1	0.6	4.75	0.44	7.13e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs3892630	0.588	rs28787932	chr19:33226229	T/C	cg22928329	chr19:33183273	NUDT19	-0.66	-5.14	-0.47	1.44e-6	Red blood cell traits;
THYM	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg02931644	chr1:25747376	RHCE	0.57	4.47	0.42	2.13e-5	Erythrocyte sedimentation rate;
THYM	cis	rs9810089	0.934	rs570621	chr3:136000743	A/G	cg21827317	chr3:136751795	NA	0.54	4.47	0.42	2.18e-5	Gestational age at birth (child effect);
THYM	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg15704280	chr7:45808275	SEPT13	-0.96	-7.4	-0.6	5.4e-11	Coronary artery disease;
THYM	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.72	0.51	1.23e-7	Lung cancer in ever smokers;
THYM	cis	rs6598955	0.543	rs12125620	chr1:26552238	G/A	cg04990556	chr1:26633338	UBXN11	0.96	6.06	0.53	2.7e-8	Obesity-related traits;
THYM	cis	rs7106204	0.514	rs12293105	chr11:24256048	T/C	ch.11.24196551F	chr11:24239977	NA	1.0	6.88	0.58	6.32e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs10231759	0.530	rs741065	chr7:150500576	A/G	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.67	5.13	0.47	1.56e-6	Height;
THYM	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.71	5.31	0.48	7.11e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg08999081	chr20:33150536	PIGU	0.6	5.2	0.47	1.15e-6	Coronary artery disease;
THYM	cis	rs1395	0.778	rs724311	chr2:27441645	A/G	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.52	-0.49	2.95e-7	Blood metabolite levels;
THYM	cis	rs9527	0.590	rs12246739	chr10:104787019	A/C	cg04362960	chr10:104952993	NT5C2	-0.67	-5.02	-0.46	2.45e-6	Arsenic metabolism;
THYM	cis	rs8133932	0.701	rs3788217	chr21:47287321	T/C	cg20357416	chr21:47294739	PCBP3	-0.84	-5.2	-0.47	1.12e-6	Schizophrenia;
THYM	cis	rs7172809	0.615	rs61306472	chr15:77818094	G/T	cg22256960	chr15:77711686	NA	-0.67	-4.88	-0.45	4.3e-6	Glucose homeostasis traits;
THYM	cis	rs12042107	0.601	rs12133063	chr1:91214714	C/A	cg09267056	chr1:90410109	NA	-0.36	-4.58	-0.43	1.39e-5	Educational attainment;
THYM	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg24060327	chr5:131705240	SLC22A5	-0.76	-5.68	-0.5	1.46e-7	Blood metabolite levels;
THYM	cis	rs9560113	0.556	rs9560128	chr13:112221924	A/G	cg10483660	chr13:112241077	NA	0.69	8.05	0.64	2.37e-12	Menarche (age at onset);
THYM	cis	rs17345786	0.520	rs12638134	chr3:101334609	G/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	6.18	0.54	1.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs713587	0.691	rs754536	chr2:25176200	C/T	cg01884057	chr2:25150051	NA	-0.58	-5.82	-0.51	7.97e-8	Body mass index in non-asthmatics;
THYM	cis	rs9399401	0.626	rs3817928	chr6:142750516	A/G	cg03128060	chr6:142623767	GPR126	0.64	8.07	0.64	2.11e-12	Chronic obstructive pulmonary disease;
THYM	cis	rs6500395	1.000	rs9939103	chr16:48592376	G/C	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg11663144	chr21:46675770	NA	-0.71	-8.52	-0.66	2.34e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2964802	0.505	rs10513058	chr5:10804383	C/T	cg14521931	chr5:10832172	NA	-0.62	-5.19	-0.47	1.21e-6	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.76	0.44	7.03e-6	Obesity-related traits;
THYM	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg11752832	chr7:134001865	SLC35B4	0.72	5.43	0.49	4.28e-7	Mean platelet volume;
THYM	cis	rs13394619	1.000	rs4669752	chr2:11727988	G/C	cg07314298	chr2:11723111	GREB1	-0.61	-6.0	-0.52	3.64e-8	Endometriosis;
THYM	cis	rs17030434	0.954	rs10000558	chr4:154766835	A/T	cg14289246	chr4:154710475	SFRP2	-0.69	-4.67	-0.43	1.01e-5	Electrocardiographic conduction measures;
THYM	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg23758822	chr17:41437982	NA	1.21	11.17	0.75	5.41e-19	Menopause (age at onset);
THYM	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs4363385	0.617	rs5010885	chr1:152973141	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.53	-0.42	1.71e-5	Inflammatory skin disease;
THYM	cis	rs933688	1.000	rs6452951	chr5:90653868	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	8.28	0.65	7.66e-13	Smoking behavior;
THYM	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg22467129	chr15:76604101	ETFA	-0.5	-4.94	-0.45	3.32e-6	Blood metabolite levels;
THYM	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg08017756	chr2:100939284	LONRF2	-0.73	-7.54	-0.61	2.77e-11	Intelligence (multi-trait analysis);
THYM	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg05373962	chr22:49881684	NA	-0.6	-5.55	-0.49	2.57e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg26314531	chr2:26401878	FAM59B	-0.72	-4.46	-0.42	2.27e-5	Gut microbiome composition (summer);
THYM	cis	rs7084402	0.967	rs1649034	chr10:60279324	G/A	cg09696939	chr10:60272079	BICC1	0.47	5.47	0.49	3.63e-7	Refractive error;
THYM	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg17063962	chr7:91808500	NA	1.13	12.54	0.79	7.25e-22	Breast cancer;
THYM	cis	rs765787	0.530	rs10467979	chr15:45521270	G/A	cg24006582	chr15:45444508	DUOX1	-0.79	-6.67	-0.56	1.71e-9	Uric acid levels;
THYM	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.72	-4.65	-0.43	1.07e-5	Lymphocyte percentage of white cells;
THYM	cis	rs2718058	0.519	rs2598047	chr7:37888488	G/T	cg02531859	chr7:37888154	TXNDC3	-0.89	-5.92	-0.52	5.01e-8	Alzheimer's disease (late onset);
THYM	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg22852734	chr6:133119734	C6orf192	-1.3	-7.64	-0.62	1.74e-11	Type 2 diabetes nephropathy;
THYM	cis	rs7727544	0.617	rs3843503	chr5:131466629	T/A	cg12564285	chr5:131593104	PDLIM4	0.43	4.54	0.42	1.62e-5	Blood metabolite levels;
THYM	cis	rs3796352	0.527	rs11715498	chr3:52943551	G/C	cg04865290	chr3:52927548	TMEM110	-0.8	-5.14	-0.47	1.47e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7084402	0.905	rs7098329	chr10:60276915	C/T	cg07615347	chr10:60278583	BICC1	-0.56	-5.21	-0.47	1.07e-6	Refractive error;
THYM	cis	rs752010	0.871	rs10789405	chr1:42101962	C/T	cg06885757	chr1:42089581	HIVEP3	0.42	4.57	0.42	1.46e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg13319975	chr6:146136371	FBXO30	-0.66	-5.23	-0.47	9.87e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6840360	0.935	rs3919716	chr4:152456387	A/G	cg22705602	chr4:152727874	NA	-0.6	-6.4	-0.55	5.91e-9	Intelligence (multi-trait analysis);
THYM	cis	rs595982	0.527	rs35087747	chr19:49377918	G/T	cg21252483	chr19:49399788	TULP2	-0.79	-5.22	-0.47	1.04e-6	Red cell distribution width;
THYM	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg11984989	chr7:158649758	WDR60	1.15	15.43	0.85	1.29e-27	Height;
THYM	cis	rs662064	0.603	rs12065251	chr1:10522289	C/T	cg24365837	chr1:10509935	APITD1;CORT	-0.58	-4.49	-0.42	1.98e-5	Asthma;
THYM	cis	rs11112613	0.609	rs6539218	chr12:105934875	C/T	cg03607813	chr12:105948248	NA	0.79	5.98	0.52	3.95e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg19977866	chr11:92705264	MTNR1B	-0.78	-5.5	-0.49	3.17e-7	Subcortical brain region volumes;
THYM	cis	rs3126085	0.825	rs4298736	chr1:152240269	A/T	cg10321714	chr1:152280068	FLG	0.68	5.18	0.47	1.27e-6	Atopic dermatitis;
THYM	cis	rs7078219	0.714	rs12413565	chr10:101285116	C/A	cg07044859	chr10:101282883	NA	-0.48	-5.23	-0.47	1.01e-6	Dental caries;
THYM	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg16558253	chr16:72132732	DHX38	0.59	5.13	0.47	1.56e-6	Fibrinogen levels;
THYM	cis	rs28795989	0.862	rs55937650	chr4:7888830	C/T	cg12728606	chr4:7903970	AFAP1	0.44	4.64	0.43	1.09e-5	Intraocular pressure;
THYM	cis	rs2039659	0.719	rs7342473	chr13:86287726	T/C	cg25308322	chr13:86268291	NA	0.61	5.14	0.47	1.45e-6	Blood osmolality (transformed sodium);
THYM	cis	rs4919694	0.611	rs75182663	chr10:105058104	A/G	cg04362960	chr10:104952993	NT5C2	0.8	4.49	0.42	2e-5	Arsenic metabolism;
THYM	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03517284	chr6:25882590	NA	-1.09	-10.5	-0.73	1.45e-17	Blood metabolite levels;
THYM	cis	rs10789491	1.000	rs2218191	chr1:47130628	C/T	cg15501359	chr1:47185051	KIAA0494	0.92	7.02	0.58	3.25e-10	Response to hepatitis C treatment;
THYM	cis	rs3796352	1.000	rs11707575	chr3:53113762	G/T	cg24530246	chr3:53118167	NA	-0.77	-4.53	-0.42	1.7e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-1.14	-13.33	-0.81	1.77e-23	Height;
THYM	cis	rs7247513	0.797	rs3815914	chr19:12760664	T/C	cg01871581	chr19:12707946	ZNF490	-0.66	-6.09	-0.53	2.36e-8	Bipolar disorder;
THYM	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg03115019	chr17:80708279	FN3K	0.67	4.7	0.43	8.85e-6	Glycated hemoglobin levels;
THYM	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg21475434	chr5:93447410	FAM172A	0.95	6.03	0.53	3.16e-8	Diabetic retinopathy;
THYM	trans	rs2840044	0.554	rs225267	chr17:33964228	T/C	cg19694781	chr19:47549865	TMEM160	-0.95	-7.8	-0.62	7.8e-12	Response to radiotherapy in cancer (late toxicity);
THYM	cis	rs1823778	0.609	rs7230358	chr18:67706709	T/G	cg12929678	chr18:67624393	CD226	1.24	4.69	0.43	9e-6	Mean platelet volume;
THYM	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg18252515	chr7:66147081	NA	-1.37	-8.05	-0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-5.62	-0.5	1.9e-7	Morning vs. evening chronotype;
THYM	cis	rs9788721	0.902	rs7180002	chr15:78873993	A/T	cg04882995	chr15:78912658	CHRNA3	0.54	4.63	0.43	1.16e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs9875589	0.509	rs6783645	chr3:14024542	T/C	cg03204825	chr3:13978759	TPRXL	-0.51	-4.46	-0.42	2.26e-5	Ovarian reserve;
THYM	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg07424592	chr7:64974309	NA	1.15	5.49	0.49	3.32e-7	Diabetic kidney disease;
THYM	cis	rs11642862	0.901	rs11647243	chr16:30965308	G/A	cg01070095	chr16:30968205	SETD1A	0.73	4.79	0.44	6.24e-6	Tonsillectomy;
THYM	cis	rs2273669	0.667	rs4509156	chr6:109308952	A/C	cg17117243	chr6:109341365	SESN1	0.86	5.23	0.47	1.02e-6	Prostate cancer;
THYM	cis	rs7000551	0.715	rs1530874	chr8:22347777	G/C	cg12081754	chr8:22256438	SLC39A14	0.66	5.81	0.51	8.31e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg25358565	chr5:93447407	FAM172A	1.34	10.76	0.74	4.03e-18	Diabetic retinopathy;
THYM	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg12193833	chr17:30244370	NA	-0.66	-4.78	-0.44	6.37e-6	Hip circumference adjusted for BMI;
THYM	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.51	-0.49	3.11e-7	Obesity-related traits;
THYM	cis	rs6138458	1.000	rs227632	chr20:24913729	G/A	cg06937882	chr20:24974362	C20orf3	-0.47	-4.54	-0.42	1.66e-5	Blood protein levels;
THYM	cis	rs6840360	0.615	rs56319216	chr4:152463716	C/T	cg22705602	chr4:152727874	NA	-0.71	-7.43	-0.61	4.71e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7943203	0.850	rs893279	chr11:108365182	C/T	cg04873221	chr11:107992290	ACAT1	-0.62	-4.51	-0.42	1.88e-5	Red blood cell count;Mean corpuscular volume;
THYM	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg02825527	chr7:2087843	MAD1L1	-0.82	-5.18	-0.47	1.24e-6	Neuroticism;
THYM	cis	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg24672777	chr11:48374446	OR4C45	-0.96	-6.12	-0.53	2.1e-8	Axial length;
THYM	cis	rs9467773	0.526	rs9348710	chr6:26360486	A/C	cg14345882	chr6:26364793	BTN3A2	0.34	4.6	0.43	1.29e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9486719	1.000	rs2472880	chr6:96860130	G/A	cg18709589	chr6:96969512	KIAA0776	0.76	4.99	0.46	2.7e-6	Migraine;Coronary artery disease;
THYM	cis	rs2350702	0.715	rs4255993	chr2:49965161	T/A	cg22592722	chr2:49566210	NA	-0.57	-4.65	-0.43	1.07e-5	Morning vs. evening chronotype;
THYM	cis	rs1670533	0.872	rs11727136	chr4:1051804	G/A	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs7267979	1.000	rs2424710	chr20:25283886	C/G	cg08601574	chr20:25228251	PYGB	0.57	4.48	0.42	2.05e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2274459	1.000	rs12153877	chr6:33765465	G/A	cg06253072	chr6:33679850	C6orf125	0.51	4.54	0.42	1.65e-5	Obesity (extreme);
THYM	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg25801113	chr15:45476975	SHF	-0.39	-4.5	-0.42	1.91e-5	Uric acid levels;
THYM	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg23758822	chr17:41437982	NA	1.15	11.04	0.75	1.01e-18	Menopause (age at onset);
THYM	trans	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Bladder cancer;
THYM	cis	rs4148689	0.951	rs4148696	chr7:117171754	T/C	cg17204129	chr7:117119601	CFTR	-0.68	-5.28	-0.48	8.02e-7	Gout;
THYM	cis	rs7626444	0.625	rs1798635	chr3:196474289	C/T	cg12930392	chr3:196481615	PAK2	0.43	5.3	0.48	7.4e-7	Monocyte count;
THYM	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg19875535	chr5:140030758	IK	-0.63	-5.69	-0.5	1.43e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg21194808	chr1:2205498	SKI	-0.33	-4.49	-0.42	2.03e-5	Height;
THYM	cis	rs2692947	0.526	rs4907225	chr2:96576670	C/T	cg23100626	chr2:96804247	ASTL	0.41	5.15	0.47	1.43e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs116095464	1.000	rs1567956	chr5:315616	C/A	cg22857025	chr5:266934	NA	-1.34	-4.81	-0.44	5.74e-6	Breast cancer;
THYM	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg12310025	chr6:25882481	NA	-0.87	-7.67	-0.62	1.47e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7119	0.604	rs2667781	chr15:77858619	A/C	cg10437265	chr15:77819839	NA	-0.69	-6.97	-0.58	4.18e-10	Type 2 diabetes;
THYM	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg18825531	chr11:62321136	NA	-0.43	-4.73	-0.44	7.79e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs4662945	0.603	rs10168574	chr2:130267823	C/T	cg05903289	chr2:130345205	NA	-0.57	-5.43	-0.49	4.34e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg02753203	chr1:228287806	NA	-0.6	-5.13	-0.47	1.55e-6	Diastolic blood pressure;
THYM	cis	rs17854409	0.803	rs3210314	chr20:61472117	C/A	cg06598544	chr20:61472147	COL9A3	-1.12	-6.98	-0.58	3.91e-10	Obesity-related traits;
THYM	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg14004847	chr7:1930337	MAD1L1	-0.68	-5.52	-0.49	2.95e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs8060598	0.804	rs10521209	chr16:50755709	T/G	cg05261686	chr16:50743296	NOD2	0.36	4.45	0.42	2.31e-5	Leprosy;
THYM	cis	rs172166	0.516	rs1225710	chr6:28100640	C/T	cg13525197	chr6:28411240	ZSCAN23	0.77	6.24	0.54	1.22e-8	Cardiac Troponin-T levels;
THYM	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg17105886	chr17:28927953	LRRC37B2	-1.27	-7.74	-0.62	1.07e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg01324343	chr3:183735012	ABCC5	0.88	13.13	0.8	4.58e-23	Anterior chamber depth;
THYM	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg01751800	chr4:77820391	ANKRD56	0.55	4.49	0.42	2.03e-5	Emphysema distribution in smoking;
THYM	cis	rs7100689	0.577	rs1340385	chr10:82058851	G/A	cg09936400	chr10:82049201	MAT1A	0.46	4.8	0.44	6.01e-6	Post bronchodilator FEV1;
THYM	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg02527881	chr3:46936655	PTH1R	-0.61	-5.7	-0.51	1.33e-7	Colorectal cancer;
THYM	cis	rs7631605	0.875	rs4678937	chr3:37145174	C/T	cg21328643	chr3:37258149	NA	-0.5	-4.7	-0.43	8.86e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg13852791	chr20:30311386	BCL2L1	0.8	6.01	0.52	3.39e-8	Mean corpuscular hemoglobin;
THYM	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg10360139	chr7:1886902	MAD1L1	-0.59	-5.13	-0.47	1.5e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6430585	0.527	rs62168836	chr2:136463117	G/A	cg23851026	chr2:136556271	LCT	0.66	5.94	0.52	4.71e-8	Corneal structure;
THYM	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg10047753	chr17:41438598	NA	1.16	10.76	0.74	3.96e-18	Menopause (age at onset);
THYM	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg11764359	chr7:65958608	NA	-0.6	-4.68	-0.43	9.66e-6	Aortic root size;
THYM	cis	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg06636001	chr8:8085503	FLJ10661	0.56	5.02	0.46	2.43e-6	Neuroticism;
THYM	cis	rs870825	1.000	rs9995633	chr4:185584441	C/T	cg04058563	chr4:185651563	MLF1IP	0.94	6.62	0.56	2.12e-9	Blood protein levels;
THYM	cis	rs3096299	0.781	rs3102381	chr16:89409720	G/C	cg10452248	chr16:89456354	ANKRD11	0.58	4.47	0.42	2.14e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs7818345	0.687	rs13275706	chr8:19327151	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.56	4.86	0.45	4.6e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg23131131	chr22:24373011	LOC391322	-0.83	-8.44	-0.65	3.61e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs9866391	0.607	rs6440006	chr3:141142691	G/A	cg13411656	chr3:141121016	ZBTB38	-0.37	-5.66	-0.5	1.6e-7	Myopia;
THYM	cis	rs981844	0.712	rs55656103	chr4:154757478	T/C	cg22178613	chr4:154710499	SFRP2	-0.57	-4.92	-0.45	3.65e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg10803722	chr21:46713166	LOC642852	-0.42	-5.43	-0.49	4.3e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4654899	0.833	rs3816454	chr1:21191416	T/G	cg01072550	chr1:21505969	NA	0.71	6.47	0.55	4.16e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs2219968	1.000	rs7003597	chr8:78976117	A/G	cg00738934	chr8:78996279	NA	0.91	9.74	0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.78	0.51	9.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3772130	0.961	rs13072618	chr3:121391833	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.75	4.65	0.43	1.08e-5	Cognitive performance;
THYM	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg24690094	chr11:67383802	NA	-0.86	-7.32	-0.6	8.04e-11	Mean corpuscular volume;
THYM	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg00990874	chr7:1149470	C7orf50	-0.64	-4.66	-0.43	1.04e-5	Bronchopulmonary dysplasia;
THYM	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-1.09	-15.49	-0.85	9.8e-28	Birth weight;
THYM	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg09359103	chr1:154839909	KCNN3	-0.68	-8.1	-0.64	1.82e-12	Prostate cancer;
THYM	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12039431	0.746	rs10908354	chr1:38014601	A/G	cg17933807	chr1:38061675	GNL2	-0.8	-5.98	-0.52	3.83e-8	Epithelial ovarian cancer;
THYM	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg25036284	chr2:26402008	FAM59B	-0.81	-5.2	-0.47	1.13e-6	Gut microbiome composition (summer);
THYM	cis	rs10089	1.000	rs13355233	chr5:127425350	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-1.02	-7.11	-0.59	2.11e-10	Ileal carcinoids;
THYM	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg22316451	chr20:60645197	NA	-0.48	-4.58	-0.43	1.4e-5	Body mass index;
THYM	cis	rs28595532	0.920	rs116607127	chr4:119731072	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg14829155	chr15:31115871	NA	0.74	6.19	0.54	1.52e-8	Huntington's disease progression;
THYM	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg25319279	chr11:5960081	NA	-0.64	-5.55	-0.5	2.55e-7	DNA methylation (variation);
THYM	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg07424592	chr7:64974309	NA	1.04	5.31	0.48	7.18e-7	Diabetic kidney disease;
THYM	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.01	-9.8	-0.71	4.35e-16	Primary sclerosing cholangitis;
THYM	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg11752832	chr7:134001865	SLC35B4	0.75	5.66	0.5	1.63e-7	Mean platelet volume;
THYM	cis	rs11574514	1.000	rs79576279	chr16:67958239	C/T	cg09738193	chr16:67926317	PSKH1	-0.93	-4.57	-0.42	1.46e-5	Crohn's disease;
THYM	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg07343612	chr16:622815	PIGQ	-1.08	-11.34	-0.76	2.36e-19	Height;
THYM	cis	rs7578361	0.877	rs12622770	chr2:150376344	C/T	cg17961725	chr2:150454027	NA	-0.71	-5.65	-0.5	1.7e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1559088	1.000	rs11672313	chr19:33563190	C/T	cg03563238	chr19:33554763	RHPN2	-0.5	-4.52	-0.42	1.8e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2133450	0.526	rs62237060	chr3:7346588	T/C	cg19930620	chr3:7340148	GRM7	-0.52	-5.62	-0.5	1.86e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg26031613	chr14:104095156	KLC1	-0.68	-4.59	-0.43	1.37e-5	Body mass index;
THYM	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.19	8.27	0.65	8.03e-13	Cognitive test performance;
THYM	cis	rs73198271	0.740	rs1039912	chr8:8648229	C/T	cg15556689	chr8:8085844	FLJ10661	-0.75	-4.92	-0.45	3.57e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs900145	0.773	rs10832017	chr11:13309671	G/A	cg13286116	chr11:13302098	ARNTL	0.59	4.56	0.42	1.54e-5	Menarche (age at onset);
THYM	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg04362960	chr10:104952993	NT5C2	0.58	4.95	0.45	3.18e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs9515201	0.774	rs9521739	chr13:111038803	A/G	cg15455643	chr13:111040242	COL4A2	0.57	6.83	0.57	7.84e-10	White matter hyperintensity burden;
THYM	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg23682913	chr1:2080710	PRKCZ	-0.62	-5.24	-0.47	9.47e-7	Height;
THYM	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg20887711	chr4:1340912	KIAA1530	0.87	8.5	0.66	2.67e-13	Longevity;
THYM	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg02825527	chr7:2087843	MAD1L1	-0.69	-4.62	-0.43	1.19e-5	Bipolar disorder;
THYM	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg14345882	chr6:26364793	BTN3A2	0.58	5.49	0.49	3.39e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10791097	0.967	rs10894268	chr11:130717153	C/T	cg12179176	chr11:130786555	SNX19	0.68	5.55	0.49	2.62e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1336149	0.901	rs822438	chr1:156894006	C/G	cg04298847	chr1:156447084	MEF2D	-0.35	-4.61	-0.43	1.25e-5	Chin dimples;
THYM	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg25237894	chr2:233734115	C2orf82	-0.36	-5.23	-0.47	9.96e-7	Coronary artery disease;
THYM	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg13010199	chr12:38710504	ALG10B	0.64	4.61	0.43	1.25e-5	Morning vs. evening chronotype;
THYM	cis	rs11249608	0.703	rs7726601	chr5:178444713	A/G	cg01312482	chr5:178451176	ZNF879	0.57	4.62	0.43	1.22e-5	Pubertal anthropometrics;
THYM	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg02503808	chr4:7069936	GRPEL1	0.99	8.48	0.66	2.89e-13	Monocyte percentage of white cells;
THYM	cis	rs12817549	0.791	rs10777536	chr12:94120732	G/A	cg19571390	chr12:94157676	CRADD	0.56	4.75	0.44	7.18e-6	Hip circumference adjusted for BMI;
THYM	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-8.52	-0.66	2.33e-13	Schizophrenia;
THYM	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg21394778	chr1:3037102	PRDM16	0.46	4.48	0.42	2.11e-5	Height;
THYM	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs2046867	0.818	rs17010195	chr3:72872852	A/G	cg25664220	chr3:72788482	NA	0.85	6.82	0.57	8.44e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs2455799	0.634	rs11128765	chr3:15903331	G/T	cg16303742	chr3:15540471	COLQ	-0.55	-5.68	-0.5	1.45e-7	Mean platelet volume;
THYM	cis	rs7264396	0.790	rs761826	chr20:34194243	A/G	cg26038318	chr20:34205095	SPAG4	0.58	4.99	0.46	2.72e-6	Total cholesterol levels;
THYM	cis	rs427394	0.659	rs187295	chr5:6734326	C/T	cg10857441	chr5:6722123	POLS	-0.74	-8.19	-0.64	1.21e-12	Menopause (age at onset);
THYM	cis	rs652260	0.819	rs55656533	chr19:7902976	G/C	cg15974673	chr19:7926970	EVI5L	-0.54	-4.78	-0.44	6.27e-6	Menarche (age at onset);
THYM	cis	rs4690686	0.500	rs4690688	chr4:177264192	G/C	cg17059388	chr4:177262070	NA	0.48	6.73	0.57	1.29e-9	Essential tremor;
THYM	cis	rs61931739	0.635	rs1352208	chr12:33932543	T/C	cg10856724	chr12:34555212	NA	-0.63	-5.9	-0.52	5.54e-8	Morning vs. evening chronotype;
THYM	cis	rs1003719	0.788	rs2835599	chr21:38466937	G/T	cg01329690	chr21:38580129	DSCR9	0.42	5.74	0.51	1.13e-7	Eye color traits;
THYM	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg10523679	chr1:76189770	ACADM	0.9	9.37	0.69	3.62e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs863345	0.608	rs11265013	chr1:158499625	G/A	cg12129480	chr1:158549410	OR10X1	-0.54	-5.21	-0.47	1.12e-6	Pneumococcal bacteremia;
THYM	cis	rs476633	0.708	rs28629856	chr15:41446950	C/T	cg21153102	chr15:41252147	NA	0.59	4.6	0.43	1.28e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs28493229	0.708	rs78084428	chr19:41160097	G/A	cg21869046	chr19:41225005	ITPKC	0.52	4.57	0.42	1.46e-5	Kawasaki disease;
THYM	cis	rs2862064	1.000	rs1354163	chr5:156420703	C/T	cg12943317	chr5:156479607	HAVCR1	-0.87	-4.9	-0.45	4.01e-6	Platelet count;
THYM	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	7.11	0.59	2.1e-10	Platelet count;
THYM	cis	rs7809950	1.000	rs67982599	chr7:107100104	T/G	cg23024343	chr7:107201750	COG5	-0.9	-8.07	-0.64	2.19e-12	Coronary artery disease;
THYM	cis	rs7584330	0.518	rs77789507	chr2:238440972	C/T	cg08992911	chr2:238395768	MLPH	1.11	6.57	0.56	2.65e-9	Prostate cancer;
THYM	cis	rs8133932	0.654	rs407651	chr21:47350587	C/T	cg20357416	chr21:47294739	PCBP3	0.8	4.88	0.45	4.26e-6	Schizophrenia;
THYM	cis	rs4363385	0.747	rs2339490	chr1:152984612	A/G	cg13444842	chr1:152974279	SPRR3	0.64	5.46	0.49	3.73e-7	Inflammatory skin disease;
THYM	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg24308560	chr3:49941425	MST1R	0.79	6.93	0.58	5.05e-10	Intelligence (multi-trait analysis);
THYM	cis	rs17030434	1.000	rs10026531	chr4:154727070	C/T	cg14289246	chr4:154710475	SFRP2	-0.75	-5.1	-0.46	1.72e-6	Electrocardiographic conduction measures;
THYM	cis	rs10832963	0.686	rs11024743	chr11:18653712	A/G	cg20219074	chr11:18656078	SPTY2D1	0.79	6.29	0.54	9.6e-9	Breast cancer;
THYM	cis	rs4950928	0.823	rs946262	chr1:203158229	C/T	cg17014757	chr1:203156097	CHI3L1	1.03	6.01	0.52	3.39e-8	YKL-40 levels;
THYM	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg27414909	chr4:1201492	LOC100130872;LOC100130872-SPON2	0.58	4.54	0.42	1.66e-5	Longevity;
THYM	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg22875332	chr1:76189707	ACADM	0.87	10.83	0.74	2.76e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs17433780	0.504	rs7525985	chr1:89460948	C/T	cg09516651	chr1:89888402	LOC400759	0.71	5.63	0.5	1.8e-7	Carotid intima media thickness;
THYM	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg14349672	chr11:133703707	NA	-0.52	-4.83	-0.44	5.12e-6	Childhood ear infection;
THYM	cis	rs2625529	0.824	rs7170461	chr15:72218599	C/A	cg16672083	chr15:72433130	SENP8	-0.54	-4.79	-0.44	6.03e-6	Red blood cell count;
THYM	cis	rs2562456	0.755	rs2650773	chr19:21644088	A/G	cg21751540	chr19:21541537	ZNF738	0.76	4.98	0.45	2.88e-6	Pain;
THYM	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg12386194	chr3:101231763	SENP7	0.93	7.21	0.59	1.32e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8016982	0.633	rs9944085	chr14:81717620	A/T	cg21807262	chr14:81713016	NA	0.58	5.69	0.5	1.42e-7	Schizophrenia;
THYM	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg06850241	chr22:41845214	NA	0.54	4.68	0.43	9.37e-6	Vitiligo;
THYM	cis	rs3768617	0.510	rs10911242	chr1:183072147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.81	0.44	5.61e-6	Fuchs's corneal dystrophy;
THYM	cis	rs9905704	0.918	rs390524	chr17:56674173	A/G	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.74e-6	Testicular germ cell tumor;
THYM	cis	rs36051895	0.632	rs7022901	chr9:5177680	C/G	cg02405213	chr9:5042618	JAK2	-0.99	-10.93	-0.75	1.72e-18	Pediatric autoimmune diseases;
THYM	cis	rs995000	0.931	rs1168021	chr1:63009900	A/G	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg17366294	chr4:99064904	C4orf37	0.48	5.43	0.49	4.3e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg22508957	chr16:3507546	NAT15	0.41	4.53	0.42	1.71e-5	Body mass index (adult);
THYM	cis	rs35110281	0.641	rs4818861	chr21:45123807	A/G	cg01579765	chr21:45077557	HSF2BP	-0.48	-7.02	-0.58	3.31e-10	Mean corpuscular volume;
THYM	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	5.34	0.48	6.25e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg13319975	chr6:146136371	FBXO30	0.63	5.19	0.47	1.19e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg10856724	chr12:34555212	NA	-0.79	-7.36	-0.6	6.4e-11	Morning vs. evening chronotype;
THYM	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg17294928	chr15:75287854	SCAMP5	-0.98	-5.33	-0.48	6.65e-7	Lung cancer;
THYM	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg02086790	chr16:375327	AXIN1	0.45	5.09	0.46	1.78e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.47	4.5	0.42	1.9e-5	Bone mineral density (hip);Bone mineral density;
THYM	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg19901468	chr14:105411992	AHNAK2	-0.81	-6.57	-0.56	2.64e-9	Rheumatoid arthritis;
THYM	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg13852791	chr20:30311386	BCL2L1	0.94	7.29	0.6	9.28e-11	Mean corpuscular hemoglobin;
THYM	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg11597832	chr14:105993747	TMEM121	-0.5	-4.54	-0.42	1.66e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs8067545	0.750	rs11870111	chr17:19992738	G/A	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.61e-6	Schizophrenia;
THYM	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.65	0.5	1.64e-7	Tonsillectomy;
THYM	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg05872129	chr22:39784769	NA	-0.99	-8.18	-0.64	1.26e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-5.95	-0.52	4.48e-8	Chronic sinus infection;
THYM	cis	rs9515201	0.627	rs11838637	chr13:111029923	G/A	cg15455643	chr13:111040242	COL4A2	0.51	6.21	0.54	1.41e-8	White matter hyperintensity burden;
THYM	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	11.87	0.77	1.82e-20	Chronic sinus infection;
THYM	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	5.44	0.49	4.16e-7	Bipolar disorder;
THYM	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg24308560	chr3:49941425	MST1R	-0.76	-6.48	-0.55	4.1e-9	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11644478	chr21:40555479	PSMG1	-0.83	-7.21	-0.59	1.32e-10	Cognitive function;
THYM	cis	rs870825	0.616	rs2090590	chr4:185647850	A/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg06558623	chr16:89946397	TCF25	1.33	7.05	0.59	2.91e-10	Skin colour saturation;
THYM	cis	rs28595532	0.920	rs114683212	chr4:119760209	A/G	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs36051895	0.664	rs3780372	chr9:5097544	C/T	cg02405213	chr9:5042618	JAK2	-1.0	-11.18	-0.75	5.12e-19	Pediatric autoimmune diseases;
THYM	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-5.74	-0.51	1.12e-7	Systemic lupus erythematosus;
THYM	cis	rs12681287	0.752	rs10435564	chr8:87266239	T/C	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs1018836	0.608	rs2205150	chr8:91483232	G/A	cg16814680	chr8:91681699	NA	-0.76	-6.16	-0.53	1.71e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg25237894	chr2:233734115	C2orf82	-0.35	-5.02	-0.46	2.46e-6	Coronary artery disease;
THYM	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg09367891	chr1:107599246	PRMT6	0.68	4.45	0.42	2.33e-5	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg09877947	chr5:131593287	PDLIM4	0.61	5.29	0.48	7.92e-7	Breast cancer;
THYM	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.74	-5.59	-0.5	2.19e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg13246856	chr1:44399776	ARTN	0.5	4.99	0.46	2.7e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs892961	0.932	rs7216116	chr17:75405078	C/T	cg11351908	chr17:75402473	SEPT9	0.59	5.74	0.51	1.11e-7	Airflow obstruction;
THYM	cis	rs1829883	0.835	rs1464638	chr5:98785846	T/C	cg08333243	chr5:99726346	NA	-0.53	-4.49	-0.42	2.01e-5	Hemostatic factors and hematological phenotypes;
THYM	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.47	-4.48	-0.42	2.1e-5	Crohn's disease;
THYM	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg06108461	chr20:60628389	TAF4	-1.08	-9.25	-0.69	6.77e-15	Body mass index;
THYM	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg00012203	chr2:219082015	ARPC2	0.87	8.52	0.66	2.38e-13	Colorectal cancer;
THYM	cis	rs9814567	0.896	rs4435682	chr3:134344182	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	7.74	0.62	1.08e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	trans	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg10856724	chr12:34555212	NA	-1.0	-8.86	-0.67	4.42e-14	Bladder cancer;
THYM	cis	rs11960314	0.717	rs883848	chr5:170070942	A/C	cg07442040	chr5:169289365	DOCK2	0.8	4.62	0.43	1.21e-5	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs611744	0.967	rs660816	chr8:109178048	C/T	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.72	-0.44	8.14e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg08392591	chr16:89556376	ANKRD11	0.55	4.52	0.42	1.76e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs860818	1.000	rs858232	chr7:23241719	C/G	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg02038168	chr22:39784481	NA	-0.65	-4.78	-0.44	6.29e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs9302065	0.529	rs2992904	chr13:95958173	A/C	cg24476569	chr13:95954382	ABCC4	-0.78	-7.88	-0.63	5.41e-12	Blood metabolite levels;
THYM	cis	rs72627123	0.867	rs113257091	chr14:74461121	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs2903698	0.585	rs35820395	chr4:76381041	A/T	cg03209871	chr4:76438412	RCHY1;THAP6	0.45	5.16	0.47	1.33e-6	Prion diseases;
THYM	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg00677455	chr12:58241039	CTDSP2	0.7	4.68	0.43	9.62e-6	Multiple sclerosis;
THYM	cis	rs2075230	0.588	rs1641530	chr17:7548052	T/C	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	-0.31	-4.55	-0.42	1.61e-5	Hormone measurements;
THYM	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg16926213	chr1:1841314	NA	0.51	5.48	0.49	3.5e-7	Body mass index;
THYM	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg14458575	chr2:238380390	NA	1.13	8.45	0.66	3.32e-13	Prostate cancer;
THYM	cis	rs2050392	0.767	rs1536833	chr10:30699265	C/T	cg18806716	chr10:30721971	MAP3K8	0.53	5.37	0.48	5.49e-7	Inflammatory bowel disease;
THYM	cis	rs9807989	0.507	rs4851579	chr2:103028984	G/A	cg03938978	chr2:103052716	IL18RAP	0.74	9.76	0.71	5.45e-16	Asthma;
THYM	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg11812906	chr14:75593930	NEK9	0.87	8.3	0.65	7.13e-13	Height;
THYM	cis	rs912057	0.833	rs1024245	chr6:6743319	A/G	cg13809441	chr6:6737631	NA	0.43	4.86	0.45	4.62e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs66887589	0.660	rs4833613	chr4:120150156	A/C	cg09307838	chr4:120376055	NA	-0.62	-4.91	-0.45	3.76e-6	Diastolic blood pressure;
THYM	cis	rs75059851	0.756	rs11223647	chr11:133839588	G/A	cg14047540	chr11:133829660	NA	-1.06	-7.03	-0.58	3.14e-10	Schizophrenia;
THYM	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg00080972	chr5:178986291	RUFY1	0.65	8.98	0.68	2.52e-14	Lung cancer;
THYM	trans	rs877282	0.898	rs34490091	chr10:765800	A/C	cg22713356	chr15:30763199	NA	1.37	9.82	0.71	4.02e-16	Uric acid levels;
THYM	cis	rs4383453	0.510	rs16834219	chr3:123099470	A/G	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4930776	1.000	rs4930776	chr12:5767385	T/G	cg02086166	chr12:5775618	ANO2	-0.58	-5.71	-0.51	1.3e-7	Plasma clusterin levels;
THYM	cis	rs1061377	0.965	rs6833654	chr4:39112321	T/C	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs4589258	0.737	rs11019138	chr11:90411906	G/C	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg03264133	chr6:25882463	NA	-1.09	-10.32	-0.73	3.48e-17	Urate levels;
THYM	cis	rs7638995	0.878	rs7620430	chr3:69169602	G/A	cg26574240	chr3:69171822	LMOD3	-0.79	-5.45	-0.49	3.99e-7	Alzheimer's disease (late onset);
THYM	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs17433780	0.836	rs17434342	chr1:89505742	C/G	cg09516651	chr1:89888402	LOC400759	-0.89	-7.58	-0.61	2.33e-11	Carotid intima media thickness;
THYM	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg23791538	chr6:167370224	RNASET2	0.74	5.92	0.52	5.06e-8	Crohn's disease;
THYM	cis	rs2273669	0.667	rs112319185	chr6:109305318	T/C	cg17117243	chr6:109341365	SESN1	-0.84	-4.94	-0.45	3.41e-6	Prostate cancer;
THYM	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg06598544	chr20:61472147	COL9A3	-1.12	-7.43	-0.61	4.62e-11	Obesity-related traits;
THYM	cis	rs142518269	1	rs142518269	chr2:24087095	G/A	cg08917208	chr2:24149416	ATAD2B	1.11	4.97	0.45	2.9e-6	Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61774743	0.681	rs10749805	chr1:41850182	C/T	cg19619003	chr1:41846758	NA	-0.28	-6.03	-0.53	3.13e-8	Intelligence (multi-trait analysis);
THYM	cis	rs892961	0.836	rs35077273	chr17:75412415	T/C	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs7507204	0.767	rs12982509	chr19:3412057	C/T	cg08380311	chr19:3435252	NFIC	-0.93	-7.6	-0.62	2.03e-11	Height;
THYM	cis	rs1346	0.580	rs7932616	chr11:65366240	T/C	cg27068330	chr11:65405492	SIPA1	0.7	4.54	0.42	1.67e-5	Vertical cup-disc ratio;Optic cup area;
THYM	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg16031515	chr1:205743344	RAB7L1	-0.69	-7.18	-0.59	1.51e-10	Menarche (age at onset);
THYM	cis	rs6032067	0.852	rs6032046	chr20:43823679	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs7113850	0.541	rs7102578	chr11:24244671	G/T	ch.11.24196551F	chr11:24239977	NA	0.88	4.69	0.43	9.16e-6	Bone fracture in osteoporosis;
THYM	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	18.68	0.89	1.42e-33	Chronic sinus infection;
THYM	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg00852783	chr1:26633632	UBXN11	0.83	8.39	0.65	4.45e-13	Obesity-related traits;
THYM	cis	rs7408868	1.000	rs8107180	chr19:15275430	T/C	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs9796	0.835	rs2927062	chr15:41302687	A/G	cg21153102	chr15:41252147	NA	0.67	6.02	0.53	3.32e-8	Menopause (age at onset);
THYM	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg22655196	chr4:3374909	RGS12	0.65	8.12	0.64	1.67e-12	Serum sulfate level;
THYM	cis	rs2730245	0.527	rs2527187	chr7:158716912	T/C	cg24397884	chr7:158709396	WDR60	-0.55	-5.43	-0.49	4.4e-7	Height;
THYM	cis	rs4242434	0.854	rs4872007	chr8:22538879	G/A	cg11461670	chr8:22454935	PDLIM2	0.33	5.07	0.46	1.92e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs240764	0.658	rs9390685	chr6:101224725	A/T	cg21058520	chr6:100914733	NA	-0.55	-4.64	-0.43	1.1e-5	Neuroticism;
THYM	cis	rs931127	0.554	rs11227261	chr11:65462843	C/G	cg27068330	chr11:65405492	SIPA1	-0.69	-5.71	-0.51	1.29e-7	Systemic lupus erythematosus;
THYM	cis	rs728616	0.867	rs34870056	chr10:81948055	G/A	cg05935833	chr10:81318306	SFTPA2	-0.77	-4.8	-0.44	5.95e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9788682	0.747	rs28480606	chr15:78762313	A/G	cg18825076	chr15:78729989	IREB2	0.69	5.51	0.49	3.05e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg13683864	chr3:40499215	RPL14	-1.08	-12.04	-0.78	7.87e-21	Renal cell carcinoma;
THYM	cis	rs6430585	0.528	rs660002	chr2:136723504	C/T	cg07169764	chr2:136633963	MCM6	1.04	11.64	0.77	5.41e-20	Corneal structure;
THYM	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg16006841	chr5:176797999	RGS14	0.53	6.08	0.53	2.45e-8	Urate levels in lean individuals;
THYM	cis	rs3126085	1.000	rs4845756	chr1:152254919	T/A	cg26020982	chr1:152196106	HRNR	0.35	4.95	0.45	3.26e-6	Atopic dermatitis;
THYM	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg02782426	chr3:40428986	ENTPD3	0.52	4.64	0.43	1.1e-5	Renal cell carcinoma;
THYM	cis	rs7107174	0.901	rs10899496	chr11:78123831	A/G	cg19901956	chr11:77921274	USP35	-0.59	-4.99	-0.46	2.75e-6	Testicular germ cell tumor;
THYM	cis	rs4866334	1.000	rs114675067	chr5:18448226	G/A	cg04591469	chr5:17810299	NA	-1.12	-4.54	-0.42	1.65e-5	IgG glycosylation;
THYM	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.38	0.55	6.27e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg24955955	chr5:415729	AHRR	1.05	5.89	0.52	5.86e-8	Fat distribution (HIV);
THYM	cis	rs6541297	0.878	rs4846905	chr1:230279582	C/T	cg20703242	chr1:230279135	GALNT2	-0.91	-6.21	-0.54	1.41e-8	Coronary artery disease;
THYM	trans	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg19862616	chr7:65841803	NCRNA00174	1.05	11.42	0.76	1.59e-19	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.58	-0.5	2.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs877282	0.898	rs11253344	chr10:765162	C/T	cg22713356	chr15:30763199	NA	1.36	10.13	0.72	8.77e-17	Uric acid levels;
THYM	cis	rs8038465	0.638	rs12594175	chr15:73973186	C/T	cg15420318	chr15:73925796	NPTN	0.59	5.05	0.46	2.12e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs17125944	0.686	rs7147258	chr14:53337664	G/T	cg00686598	chr14:53173677	PSMC6	-1.08	-5.25	-0.47	9.31e-7	Alzheimer's disease (late onset);
THYM	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg22166914	chr1:53195759	ZYG11B	0.91	10.46	0.73	1.7e-17	Monocyte count;
THYM	cis	rs4499344	0.730	rs7246338	chr19:33099504	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.55	0.61	2.63e-11	Mean platelet volume;
THYM	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.0	-5.11	-0.46	1.65e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg19729930	chr2:74357872	NA	1.25	12.52	0.79	8.21e-22	Gestational age at birth (maternal effect);
THYM	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg03060546	chr3:49711283	APEH	-0.72	-5.78	-0.51	9.62e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs951188	0.688	rs115902229	chr2:150407740	A/G	cg17961725	chr2:150454027	NA	-1.02	-5.39	-0.48	5.12e-7	Daytime sleep phenotypes;
THYM	cis	rs8067545	0.586	rs3850779	chr17:20171872	C/T	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs55728055	0.661	rs55997441	chr22:31627989	A/G	cg10537193	chr22:32026975	PISD	-0.83	-4.49	-0.42	2.01e-5	Age-related hearing impairment;
THYM	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg23758822	chr17:41437982	NA	1.17	11.01	0.75	1.18e-18	Menopause (age at onset);
THYM	cis	rs9911578	0.839	rs7214098	chr17:57204632	C/T	cg12560992	chr17:57184187	TRIM37	0.91	8.45	0.66	3.34e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs754466	0.651	rs11818687	chr10:79637709	C/T	cg17075019	chr10:79541650	NA	-0.69	-5.85	-0.51	6.94e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9296092	0.521	rs56332659	chr6:33537887	T/C	cg13560919	chr6:33536144	NA	-0.88	-7.76	-0.62	9.59e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs346785	0.692	rs2279056	chr17:74309474	C/T	cg09812376	chr17:74270190	QRICH2	0.53	5.87	0.52	6.36e-8	White matter hyperintensities in ischemic stroke;
THYM	cis	rs9653442	0.712	rs6714788	chr2:100686173	A/G	cg22139774	chr2:100720529	AFF3	0.36	5.53	0.49	2.81e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs9527	0.830	rs12249194	chr10:104643698	T/C	cg04362960	chr10:104952993	NT5C2	0.64	4.72	0.44	8.19e-6	Arsenic metabolism;
THYM	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg25554036	chr4:6271136	WFS1	0.52	4.78	0.44	6.32e-6	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs2811415	0.597	rs9821500	chr3:127734929	T/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs6952808	0.572	rs1860826	chr7:2112506	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-4.92	-0.45	3.64e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs8013055	0.699	rs66798104	chr14:105987782	C/G	cg23356831	chr14:105996513	TMEM121	0.61	6.41	0.55	5.68e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs16866061	0.962	rs72972361	chr2:225341550	G/A	cg22455342	chr2:225449267	CUL3	0.68	4.88	0.45	4.23e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg03806693	chr22:41940476	POLR3H	1.1	8.94	0.68	3.12e-14	Vitiligo;
THYM	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	8.52	0.66	2.36e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9560113	0.580	rs9560115	chr13:112193619	G/A	cg10483660	chr13:112241077	NA	0.67	7.54	0.61	2.8e-11	Menarche (age at onset);
THYM	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg04772025	chr11:68637568	NA	0.64	6.59	0.56	2.41e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs10889850	0.675	rs1264338	chr1:70212245	T/C	cg01711146	chr1:70671364	SFRS11;LRRC40	0.76	4.45	0.42	2.35e-5	Body mass index;
THYM	cis	rs6456156	0.742	rs2022000	chr6:167529611	A/G	cg09487078	chr6:167525398	CCR6	-0.44	-4.92	-0.45	3.63e-6	Primary biliary cholangitis;
THYM	cis	rs1371867	0.846	rs1660312	chr8:101330634	C/G	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs9296092	0.560	rs17627049	chr6:33537802	G/T	cg13560919	chr6:33536144	NA	-0.89	-8.62	-0.66	1.45e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg20503657	chr10:835505	NA	1.37	9.33	0.69	4.52e-15	Eosinophil percentage of granulocytes;
THYM	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg15536230	chr21:44985092	HSF2BP	-0.43	-5.25	-0.47	9.18e-7	Mean corpuscular volume;
THYM	trans	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs10992471	0.528	rs2296666	chr9:95274261	C/T	cg14631576	chr9:95140430	CENPP	0.81	7.54	0.61	2.79e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2574704	0.851	rs2574717	chr3:11661280	A/C	cg07643000	chr3:11666825	VGLL4	0.38	4.51	0.42	1.86e-5	Body mass index;
THYM	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg13319975	chr6:146136371	FBXO30	-0.71	-5.8	-0.51	8.56e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6087990	0.966	rs2377667	chr20:31346925	A/G	cg13636640	chr20:31349939	DNMT3B	0.93	9.85	0.71	3.45e-16	Ulcerative colitis;
THYM	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg00981070	chr1:2046702	PRKCZ	0.48	5.9	0.52	5.46e-8	Height;
THYM	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg16797656	chr11:68205561	LRP5	0.42	4.6	0.43	1.3e-5	Total body bone mineral density;
THYM	cis	rs778371	1.000	rs11535	chr2:233743532	G/C	cg08000102	chr2:233561755	GIGYF2	-0.85	-7.09	-0.59	2.34e-10	Schizophrenia;
THYM	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg17063962	chr7:91808500	NA	-1.12	-12.68	-0.79	3.85e-22	Breast cancer;
THYM	cis	rs55701159	0.518	rs73920610	chr2:25140527	G/A	cg01884057	chr2:25150051	NA	0.59	4.46	0.42	2.23e-5	Diastolic blood pressure;
THYM	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.82	0.44	5.4e-6	Bipolar disorder;
THYM	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.19	-9.03	-0.68	1.94e-14	Schizophrenia;
THYM	cis	rs7000551	0.751	rs896379	chr8:22374200	C/T	cg12081754	chr8:22256438	SLC39A14	0.67	5.92	0.52	5e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs6840360	0.554	rs61308159	chr4:152728941	G/A	cg22705602	chr4:152727874	NA	0.8	11.06	0.75	9.16e-19	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg08885076	chr2:99613938	TSGA10	-0.66	-6.08	-0.53	2.47e-8	Chronic sinus infection;
THYM	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg23711669	chr6:146136114	FBXO30	0.91	9.55	0.7	1.49e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs55702914	0.809	rs3097385	chr2:198199297	G/A	cg00792783	chr2:198669748	PLCL1	-0.63	-4.76	-0.44	6.97e-6	Major depression and alcohol dependence;
THYM	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg23711669	chr6:146136114	FBXO30	0.96	9.81	0.71	4.28e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg07022442	chr13:21864356	NA	-0.75	-5.17	-0.47	1.31e-6	White matter hyperintensity burden;
THYM	cis	rs2554380	0.800	rs8034055	chr15:84411895	C/T	cg14598478	chr15:84363061	ADAMTSL3	-0.65	-5.23	-0.47	1.02e-6	Height;
THYM	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg22172494	chr11:2017362	H19	-0.52	-4.61	-0.43	1.24e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs899997	1.000	rs755998	chr15:79032469	C/T	cg22753661	chr15:79092743	ADAMTS7	0.72	4.59	0.43	1.36e-5	Coronary artery disease or large artery stroke;
THYM	cis	rs7264396	0.561	rs66483315	chr20:34573575	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-4.67	-0.43	1e-5	Total cholesterol levels;
THYM	cis	rs713587	0.525	rs11687089	chr2:25082926	T/C	cg15423357	chr2:25149977	NA	0.61	5.86	0.52	6.72e-8	Body mass index in non-asthmatics;
THYM	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6076065	0.723	rs2424541	chr20:23386776	T/C	cg11657817	chr20:23433608	CST11	0.31	4.57	0.42	1.48e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs7078219	1.000	rs11190130	chr10:101275206	C/T	cg07044859	chr10:101282883	NA	-0.49	-5.16	-0.47	1.37e-6	Dental caries;
THYM	cis	rs7584330	0.737	rs1497128	chr2:238369211	A/G	cg14458575	chr2:238380390	NA	0.94	7.81	0.63	7.65e-12	Prostate cancer;
THYM	cis	rs763014	0.714	rs3743901	chr16:632699	C/G	cg09263875	chr16:632152	PIGQ	0.69	5.77	0.51	9.68e-8	Height;
THYM	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg07936489	chr17:37558343	FBXL20	0.8	5.79	0.51	9.24e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg03433033	chr1:76189801	ACADM	0.79	11.21	0.75	4.52e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs3126085	0.935	rs55942250	chr1:152251914	G/A	cg10321714	chr1:152280068	FLG	-0.7	-5.11	-0.46	1.68e-6	Atopic dermatitis;
THYM	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg08736216	chr1:53307985	ZYG11A	-0.61	-5.57	-0.5	2.41e-7	Monocyte count;
THYM	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg23711669	chr6:146136114	FBXO30	0.93	9.21	0.69	8.01e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg10856724	chr12:34555212	NA	-0.91	-8.9	-0.67	3.68e-14	Morning vs. evening chronotype;
THYM	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.03	0.46	2.29e-6	Obesity-related traits;
THYM	cis	rs55788414	0.932	rs12716908	chr16:81186245	T/C	cg06400318	chr16:81190750	PKD1L2	-0.84	-4.47	-0.42	2.2e-5	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs13082711	1.000	rs34234262	chr3:27539188	G/A	cg02860705	chr3:27208620	NA	0.76	4.94	0.45	3.31e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.4	-0.48	4.99e-7	Menopause (age at onset);
THYM	cis	rs7119	0.717	rs11630916	chr15:77821331	G/A	cg27398640	chr15:77910606	LINGO1	-0.56	-5.72	-0.51	1.24e-7	Type 2 diabetes;
THYM	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg16586182	chr3:47516702	SCAP	0.61	5.17	0.47	1.29e-6	Colorectal cancer;
THYM	cis	rs10904908	1.000	rs10904908	chr10:17260290	A/G	cg01003015	chr10:17271136	VIM	-0.73	-6.39	-0.55	6.19e-9	Total cholesterol levels;Cholesterol, total;
THYM	cis	rs3020333	0.875	rs2982571	chr6:152012739	A/T	cg22157087	chr6:152012887	ESR1	-0.41	-4.5	-0.42	1.96e-5	Total body bone mineral density;
THYM	cis	rs6924995	0.501	rs2327951	chr6:16195308	A/G	cg11805552	chr6:16175128	NA	0.58	4.8	0.44	5.89e-6	Response to statins (LDL cholesterol change);
THYM	trans	rs11186	0.556	rs10931395	chr2:189969392	A/G	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	cis	rs483180	0.512	rs866321	chr1:120224469	T/C	cg19096424	chr1:120255104	PHGDH	0.68	5.14	0.47	1.49e-6	Macular telangiectasia type 2;
THYM	cis	rs28595532	0.920	rs115690307	chr4:119768289	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs4808199	0.948	rs968525	chr19:19459215	C/T	cg03709012	chr19:19516395	GATAD2A	1.05	5.98	0.52	3.95e-8	Nonalcoholic fatty liver disease;
THYM	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg12564285	chr5:131593104	PDLIM4	0.43	4.67	0.43	9.75e-6	Breast cancer;
THYM	cis	rs17006441	0.932	rs35759074	chr3:69886263	C/G	cg18496212	chr3:69797108	MITF	0.69	6.98	0.58	3.98e-10	Hemoglobin concentration;
THYM	cis	rs6669072	1.000	rs3845561	chr1:91246342	A/G	cg08895590	chr1:91227319	NA	0.53	6.23	0.54	1.27e-8	Cognitive function;
THYM	cis	rs13177918	0.717	rs6874318	chr5:149842399	C/T	cg14059543	chr5:149831962	NA	0.75	5.37	0.48	5.56e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.89	0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs8014204	0.804	rs2287403	chr14:75259140	C/T	cg06637938	chr14:75390232	RPS6KL1	0.56	5.49	0.49	3.27e-7	Caffeine consumption;
THYM	cis	rs4654899	0.733	rs10799677	chr1:21318456	A/C	cg01072550	chr1:21505969	NA	-0.72	-6.64	-0.56	1.95e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs6867032	0.874	rs4975786	chr5:2004724	T/C	cg26168224	chr5:2018326	NA	-1.14	-10.86	-0.74	2.49e-18	Gut microbiome composition (winter);
THYM	cis	rs3806843	0.868	rs2563281	chr5:140131219	T/A	cg19875535	chr5:140030758	IK	-0.58	-4.52	-0.42	1.76e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs28595532	0.841	rs114965278	chr4:119743694	T/A	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs7828089	0.819	rs12548353	chr8:22243491	T/C	cg12081754	chr8:22256438	SLC39A14	0.63	5.51	0.49	3.08e-7	Verbal declarative memory;
THYM	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg00256281	chr22:41985642	PMM1	-0.6	-5.07	-0.46	1.98e-6	Vitiligo;
THYM	trans	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg13695892	chr22:41940480	POLR3H	0.89	6.37	0.55	6.58e-9	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs9633835	0.707	rs4757142	chr11:13325695	C/T	cg13286116	chr11:13302098	ARNTL	-0.72	-7.42	-0.61	4.85e-11	Body mass index;
THYM	cis	rs6988636	1.000	rs57165742	chr8:124184559	G/A	cg26140120	chr8:124219575	FAM83A	0.87	4.81	0.44	5.77e-6	Urinary uromodulin levels;
THYM	cis	rs7027203	0.595	rs4308796	chr9:96570165	G/A	cg14598338	chr9:96623480	NA	0.42	4.67	0.43	9.77e-6	DNA methylation (variation);
THYM	cis	rs7119	0.651	rs34607443	chr15:77847892	C/T	cg10437265	chr15:77819839	NA	0.68	6.22	0.54	1.33e-8	Type 2 diabetes;
THYM	cis	rs227932	0.614	rs12700458	chr7:23722144	T/C	cg20265043	chr7:23510089	IGF2BP3	-0.67	-4.64	-0.43	1.13e-5	Schizophrenia;
THYM	cis	rs2742417	0.603	rs2742453	chr3:45765858	G/A	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg08772003	chr10:104629869	AS3MT	-0.57	-4.92	-0.45	3.56e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs61931739	0.559	rs4385974	chr12:34313128	G/C	cg06521331	chr12:34319734	NA	-0.64	-5.37	-0.48	5.62e-7	Morning vs. evening chronotype;
THYM	cis	rs4589258	0.788	rs2213089	chr11:90480426	G/A	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.83	-0.44	5.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.2	-11.69	-0.77	4.41e-20	Primary sclerosing cholangitis;
THYM	cis	rs860818	1.000	rs2529002	chr7:23233323	A/G	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs1371867	0.875	rs962451	chr8:101331010	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg06191203	chr2:152266755	RIF1	-0.73	-5.02	-0.46	2.46e-6	Lung cancer;
THYM	cis	rs28595532	0.841	rs114155681	chr4:119736427	A/G	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg06728252	chr6:26598149	ABT1	-0.44	-5.07	-0.46	1.95e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg06009448	chr7:1102226	C7orf50	0.48	4.93	0.45	3.53e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg16006841	chr5:176797999	RGS14	-0.49	-5.43	-0.49	4.4e-7	Urate levels in lean individuals;
THYM	cis	rs6032067	0.850	rs34274189	chr20:43864298	G/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.47	-4.94	-0.45	3.38e-6	Blood protein levels;
THYM	cis	rs7224737	1.000	rs12603327	chr17:40290552	T/C	cg00647820	chr17:40259828	DHX58	-0.6	-4.53	-0.42	1.72e-5	Fibrinogen levels;
THYM	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg24846680	chr1:228362309	C1orf69	0.51	4.61	0.43	1.23e-5	Diastolic blood pressure;
THYM	cis	rs6500395	1.000	rs1106386	chr16:48593065	C/A	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs922692	0.744	rs12899147	chr15:79079512	A/G	cg15571903	chr15:79123663	NA	-0.49	-4.61	-0.43	1.24e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs9362426	1.000	rs414013	chr6:88085866	T/G	cg10393598	chr6:87862264	NA	-0.61	-4.83	-0.44	5.13e-6	Depressive episodes in bipolar disorder;
THYM	cis	rs12620999	0.941	rs2078469	chr2:237983273	C/G	cg15976283	chr2:238042351	NA	-0.61	-4.72	-0.44	8.26e-6	Systemic lupus erythematosus;
THYM	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7695732	0.595	rs6852947	chr4:89892604	A/C	cg17769793	chr4:89976368	FAM13A	-0.5	-5.57	-0.5	2.36e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg11764359	chr7:65958608	NA	-0.7	-4.89	-0.45	4.09e-6	Aortic root size;
THYM	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg08847533	chr14:75593920	NEK9	1.01	11.32	0.76	2.63e-19	Height;
THYM	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg11266682	chr4:10021025	SLC2A9	0.74	10.8	0.74	3.21e-18	Bone mineral density;
THYM	cis	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg18127003	chr8:11614472	GATA4	-0.5	-4.67	-0.43	9.84e-6	Morning vs. evening chronotype;
THYM	cis	rs4746818	1.000	rs6480385	chr10:70904785	A/T	cg04149295	chr10:70884716	VPS26A	0.78	5.31	0.48	7.18e-7	Left atrial antero-posterior diameter;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg27099277	chr6:166779349	BRP44L	-0.94	-7.1	-0.59	2.29e-10	Depressive symptoms;
THYM	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg17830980	chr10:43048298	ZNF37B	-1.01	-10.1	-0.72	1.02e-16	Extrinsic epigenetic age acceleration;
THYM	cis	rs72781680	0.950	rs72796402	chr2:24180104	A/G	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg09455208	chr3:40491958	NA	0.47	4.95	0.45	3.25e-6	Renal cell carcinoma;
THYM	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg05552183	chr6:42928497	GNMT	0.59	4.71	0.44	8.45e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs11785693	0.862	rs73189843	chr8:5000915	C/T	cg26367366	chr8:4980734	NA	1.21	5.9	0.52	5.46e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs10760321	0.644	rs2182660	chr9:126871299	C/T	cg21177396	chr9:126888124	NA	-0.67	-5.59	-0.5	2.19e-7	Polycystic ovary syndrome;
THYM	cis	rs11048434	0.736	rs12812913	chr12:9110836	C/G	cg13575925	chr12:9217583	LOC144571	0.52	4.97	0.45	2.96e-6	Sjögren's syndrome;
THYM	cis	rs11679640	1.000	rs11685652	chr2:43120749	G/A	cg27193366	chr2:43037868	NA	0.8	4.74	0.44	7.37e-6	White matter hyperintensity burden;
THYM	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg17830980	chr10:43048298	ZNF37B	-0.87	-7.78	-0.62	8.89e-12	Breast cancer;
THYM	cis	rs2948294	0.566	rs13261997	chr8:8112295	C/T	cg15556689	chr8:8085844	FLJ10661	0.68	5.44	0.49	4.21e-7	Red cell distribution width;
THYM	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs7553864	0.667	rs1886633	chr1:87610356	G/A	cg17420885	chr1:87600446	LOC339524	-0.85	-7.65	-0.62	1.63e-11	Smoking behavior;
THYM	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg00852783	chr1:26633632	UBXN11	0.86	8.81	0.67	5.74e-14	Obesity-related traits;
THYM	cis	rs12681287	0.640	rs7832493	chr8:87371533	A/C	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs600806	0.821	rs1030522	chr1:109900707	C/G	cg02175308	chr1:109941060	SORT1	-0.59	-5.13	-0.47	1.51e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.714	rs6032076	chr20:43887682	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.56	-5.33	-0.48	6.58e-7	Blood protein levels;
THYM	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11644478	chr21:40555479	PSMG1	-0.56	-4.69	-0.43	9.07e-6	Menarche (age at onset);
THYM	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg11764359	chr7:65958608	NA	-0.75	-6.05	-0.53	2.82e-8	Aortic root size;
THYM	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg02896835	chr1:92012615	NA	-0.65	-5.74	-0.51	1.15e-7	Breast cancer;
THYM	cis	rs4731207	0.564	rs10260039	chr7:124603546	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs7771547	0.607	rs9348997	chr6:36430560	A/G	cg07856975	chr6:36356162	ETV7	-0.57	-5.47	-0.49	3.63e-7	Platelet distribution width;
THYM	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg12826209	chr6:26865740	GUSBL1	0.84	6.07	0.53	2.61e-8	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg15704280	chr7:45808275	SEPT13	-1.06	-15.41	-0.85	1.38e-27	Height;
THYM	cis	rs9790314	1.000	rs28515190	chr3:161028605	G/A	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs79149102	0.579	rs7172715	chr15:75287375	C/G	cg17294928	chr15:75287854	SCAMP5	-1.05	-5.13	-0.47	1.55e-6	Lung cancer;
THYM	cis	rs1865721	0.771	rs8093397	chr18:73136217	C/G	cg26385618	chr18:73139727	C18orf62	-0.68	-5.12	-0.47	1.57e-6	Intelligence;
THYM	cis	rs2273669	0.915	rs1080945	chr6:109304694	A/G	cg17117243	chr6:109341365	SESN1	-0.72	-4.51	-0.42	1.85e-5	Prostate cancer;
THYM	cis	rs986417	0.748	rs10142401	chr14:61039403	A/G	cg27398547	chr14:60952738	C14orf39	0.88	5.12	0.46	1.61e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg21862992	chr11:68658383	NA	0.23	4.51	0.42	1.86e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs728616	0.867	rs55666905	chr10:81953639	C/T	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg06271696	chr7:157225062	NA	-0.6	-4.5	-0.42	1.91e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg04673462	chr1:38461896	NA	-0.42	-5.17	-0.47	1.28e-6	Coronary artery disease;
THYM	cis	rs2033562	0.898	rs10110787	chr8:103545003	T/C	cg20611272	chr8:103548145	NA	0.4	4.99	0.46	2.77e-6	IgA nephropathy;
THYM	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg06558623	chr16:89946397	TCF25	1.33	5.62	0.5	1.94e-7	Skin colour saturation;
THYM	cis	rs4901869	0.966	rs431343	chr14:59345530	C/T	cg02291164	chr14:59296302	NA	0.82	8.17	0.64	1.3e-12	Panic disorder;
THYM	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs790123	1.000	rs2650950	chr3:122382048	C/T	cg15604389	chr3:122379662	NA	0.59	5.54	0.49	2.65e-7	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs11671005	0.735	rs3826684	chr19:58918705	T/C	cg18639983	chr19:58920768	ZNF584	0.59	5.0	0.46	2.63e-6	Mean platelet volume;
THYM	trans	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	Myopia (pathological);
THYM	cis	rs800586	0.957	rs1526460	chr8:116823453	G/T	cg04656070	chr8:116661063	TRPS1	0.48	4.98	0.45	2.88e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs714027	0.585	rs960987	chr22:30343477	C/T	cg27665648	chr22:30112403	NA	0.52	4.7	0.43	8.86e-6	Lymphocyte counts;
THYM	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg15693483	chr7:1102177	C7orf50	0.54	6.31	0.54	8.82e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs861020	0.606	rs657844	chr1:210006873	T/G	cg05527609	chr1:210001259	C1orf107	0.86	6.5	0.56	3.62e-9	Orofacial clefts;
THYM	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg24874828	chr4:187887005	NA	-0.72	-7.22	-0.6	1.26e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg26818010	chr10:134567672	INPP5A	-0.75	-5.83	-0.51	7.69e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7681423	1.000	rs7681423	chr4:155542248	C/T	cg20735720	chr4:155535218	FGG	-0.73	-5.71	-0.51	1.28e-7	Fibrinogen;
THYM	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg00339695	chr16:24857497	SLC5A11	0.68	6.43	0.55	5.15e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7084402	0.967	rs1649081	chr10:60292444	G/A	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs1003719	0.788	rs2835588	chr21:38462716	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs611744	0.836	rs684412	chr8:109210905	T/A	cg21045802	chr8:109455806	TTC35	0.6	5.37	0.48	5.65e-7	Dupuytren's disease;
THYM	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg23428387	chr22:49814324	NA	-0.5	-4.86	-0.45	4.57e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2463822	0.925	rs17157227	chr11:62169772	A/G	cg06239285	chr11:62104954	ASRGL1	1.3	6.14	0.53	1.87e-8	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs55728055	0.661	rs62237791	chr22:31973124	A/G	cg10537193	chr22:32026975	PISD	-0.66	-4.61	-0.43	1.26e-5	Age-related hearing impairment;
THYM	cis	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg19847130	chr8:10466454	RP1L1	-0.51	-4.75	-0.44	7.25e-6	Neuroticism;
THYM	cis	rs66887589	0.627	rs3872807	chr4:120360251	T/A	cg13609457	chr4:120235615	NA	0.47	4.88	0.45	4.28e-6	Diastolic blood pressure;
THYM	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg00383909	chr3:49044727	WDR6	1.12	6.62	0.56	2.13e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs3008870	1.000	rs3008894	chr1:67377739	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	7.25	0.6	1.08e-10	Lymphocyte percentage of white cells;
THYM	cis	rs16866061	0.926	rs1523919	chr2:225403615	G/A	cg22509189	chr2:225307070	NA	-0.66	-4.48	-0.42	2.05e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg26038318	chr20:34205095	SPAG4	0.64	5.18	0.47	1.22e-6	Total cholesterol levels;
THYM	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Bladder cancer;
THYM	cis	rs61990749	0.597	rs28534379	chr14:78172140	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-1.17	-8.02	-0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs1878931	0.507	rs67218524	chr16:3403057	G/T	cg22508957	chr16:3507546	NAT15	0.46	4.96	0.45	3.03e-6	Body mass index (adult);
THYM	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.73	0.51	1.19e-7	Rheumatoid arthritis;
THYM	cis	rs9814567	0.806	rs7626557	chr3:134318213	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.09e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg24642439	chr20:33292090	TP53INP2	0.63	4.88	0.45	4.2e-6	Coronary artery disease;
THYM	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg07511668	chr11:68622177	NA	0.43	4.63	0.43	1.15e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg16482183	chr6:26056742	HIST1H1C	0.96	5.97	0.52	4.07e-8	Iron status biomarkers;
THYM	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7582180	0.726	rs2871340	chr2:100884117	A/C	cg08017756	chr2:100939284	LONRF2	0.62	5.84	0.51	7.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.52e-7	Heart rate;
THYM	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg10802521	chr3:52805072	NEK4	-0.73	-6.43	-0.55	5.15e-9	Bipolar disorder;
THYM	cis	rs7582180	0.638	rs7581011	chr2:100954659	A/G	cg14675211	chr2:100938903	LONRF2	-0.69	-7.0	-0.58	3.68e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg14004847	chr7:1930337	MAD1L1	-0.64	-5.12	-0.46	1.62e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs8070740	0.838	rs3786054	chr17:5339059	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	-0.7	-4.72	-0.44	8.14e-6	Menopause (age at onset);
THYM	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.35	-0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.71	5.32	0.48	7.02e-7	Height;
THYM	cis	rs6430585	0.528	rs115553816	chr2:136692893	G/A	cg23851026	chr2:136556271	LCT	0.78	6.95	0.58	4.47e-10	Corneal structure;
THYM	cis	rs8067545	0.750	rs4005937	chr17:19959828	A/C	cg13482628	chr17:19912719	NA	0.56	4.7	0.43	8.78e-6	Schizophrenia;
THYM	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg19761014	chr17:28927070	LRRC37B2	0.71	4.52	0.42	1.77e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg24060327	chr5:131705240	SLC22A5	-0.83	-6.92	-0.58	5.2e-10	Breast cancer;
THYM	cis	rs11608355	1.000	rs2075439	chr12:109859374	A/G	cg10504392	chr12:110044639	NA	0.67	6.21	0.54	1.41e-8	Neuroticism;
THYM	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg08885076	chr2:99613938	TSGA10	-0.66	-6.08	-0.53	2.47e-8	Chronic sinus infection;
THYM	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg15556689	chr8:8085844	FLJ10661	0.65	4.85	0.45	4.81e-6	Neuroticism;
THYM	cis	rs9787249	0.957	rs12074147	chr1:40203722	T/C	cg02773041	chr1:40204384	PPIE	0.78	5.8	0.51	8.71e-8	Blood protein levels;
THYM	cis	rs1322639	0.657	rs9355135	chr6:169573006	C/T	cg04662567	chr6:169592167	NA	-0.8	-6.63	-0.56	2.03e-9	Pulse pressure;
THYM	cis	rs10269006	0.613	rs12704744	chr7:94373916	A/T	cg00347863	chr7:94220697	SGCE	0.53	4.52	0.42	1.76e-5	Breast cancer;
THYM	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg11764359	chr7:65958608	NA	-0.82	-6.56	-0.56	2.81e-9	Aortic root size;
THYM	cis	rs7567389	0.600	rs11691088	chr2:128131853	A/G	cg06038358	chr2:128176007	PROC	0.46	5.13	0.47	1.52e-6	Self-rated health;
THYM	cis	rs240764	0.764	rs11155472	chr6:100921549	A/T	cg21058520	chr6:100914733	NA	0.53	4.7	0.43	8.63e-6	Neuroticism;
THYM	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10751667	0.925	rs7115336	chr11:988101	C/G	ch.11.42038R	chr11:967971	AP2A2	0.61	4.88	0.45	4.31e-6	Alzheimer's disease (late onset);
THYM	cis	rs870825	0.616	rs1401359	chr4:185640216	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs40363	1.000	rs37771	chr16:3512866	G/T	cg01073479	chr16:3509474	NAT15	0.62	5.13	0.47	1.5e-6	Tuberculosis;
THYM	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg19077165	chr18:44547161	KATNAL2	-0.63	-8.24	-0.65	9.47e-13	Personality dimensions;
THYM	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg27170947	chr2:26402098	FAM59B	-0.8	-6.37	-0.55	6.74e-9	Gut microbiome composition (summer);
THYM	cis	rs2219968	0.683	rs35156511	chr8:78908810	G/A	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6430585	0.528	rs309113	chr2:136737460	C/A	cg07169764	chr2:136633963	MCM6	0.96	9.1	0.68	1.36e-14	Corneal structure;
THYM	cis	rs8036030	0.604	rs11852686	chr15:74715205	A/G	cg10253484	chr15:75165896	SCAMP2	-0.74	-5.21	-0.47	1.1e-6	Airflow obstruction;
THYM	cis	rs3862030	0.720	rs7081467	chr10:104231662	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-5.8	-0.51	8.83e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg18681998	chr4:17616180	MED28	1.0	10.49	0.73	1.52e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9612	1.000	rs9612	chr19:44235517	A/G	cg08581076	chr19:44259116	C19orf61	0.67	4.54	0.42	1.62e-5	Exhaled nitric oxide output;
THYM	cis	rs2404602	0.647	rs11072636	chr15:77185786	A/G	cg23625390	chr15:77176239	SCAPER	-0.83	-5.81	-0.51	8.43e-8	Blood metabolite levels;
THYM	cis	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.76	0.44	7.03e-6	Obesity-related traits;
THYM	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg23205692	chr1:25664452	TMEM50A	0.83	6.37	0.55	6.66e-9	Erythrocyte sedimentation rate;
THYM	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs7584330	0.554	rs9646713	chr2:238443542	T/C	cg14458575	chr2:238380390	NA	0.74	4.59	0.43	1.34e-5	Prostate cancer;
THYM	cis	rs7267979	1.000	rs404394	chr20:25447896	A/G	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs8070740	0.838	rs1050456	chr17:5336188	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.69	5.1	0.46	1.75e-6	Menopause (age at onset);
THYM	cis	rs2276314	0.857	rs28431958	chr18:33578401	T/G	cg19628046	chr18:33552617	C18orf21	0.74	5.22	0.47	1.05e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7177699	0.557	rs7403728	chr15:79112016	T/G	cg00540400	chr15:79124168	NA	-0.64	-6.88	-0.58	6.27e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs899997	0.814	rs28661610	chr15:78985317	G/A	cg04896959	chr15:78267971	NA	-0.96	-8.82	-0.67	5.54e-14	Coronary artery disease or large artery stroke;
THYM	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg08645402	chr16:4508243	NA	0.77	6.96	0.58	4.31e-10	Schizophrenia;
THYM	cis	rs2073300	1.000	rs79255223	chr20:23443559	G/T	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	5.94	0.52	4.77e-8	Hip circumference adjusted for BMI;
THYM	cis	rs12478296	1.000	rs11899408	chr2:243014630	A/G	cg06360820	chr2:242988706	NA	-1.02	-6.85	-0.57	7.35e-10	Obesity-related traits;
THYM	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg27490568	chr2:178487706	NA	-0.64	-5.24	-0.47	9.62e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs12476592	0.516	rs1922421	chr2:63592792	G/A	cg17519650	chr2:63277830	OTX1	-0.7	-4.75	-0.44	7.12e-6	Childhood ear infection;
THYM	cis	rs4930776	0.931	rs862396	chr12:5769529	T/C	cg02086166	chr12:5775618	ANO2	0.57	5.51	0.49	3.1e-7	Plasma clusterin levels;
THYM	cis	rs9796	0.516	rs28473405	chr15:41293170	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.67	-5.75	-0.51	1.08e-7	Menopause (age at onset);
THYM	cis	rs28647808	0.881	rs41316984	chr9:136259231	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg03605463	chr16:89740564	NA	0.88	6.76	0.57	1.13e-9	Vitiligo;
THYM	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg02038168	chr22:39784481	NA	-0.67	-5.43	-0.49	4.32e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4731207	0.564	rs10954057	chr7:124613938	T/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg18402987	chr7:1209562	NA	0.7	5.14	0.47	1.49e-6	Longevity;Endometriosis;
THYM	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg14517863	chr17:44321492	NA	-0.44	-5.0	-0.46	2.59e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg03806693	chr22:41940476	POLR3H	0.89	8.52	0.66	2.41e-13	Vitiligo;
THYM	cis	rs2976388	0.590	rs3736011	chr8:143817789	G/A	cg06565975	chr8:143823917	SLURP1	-0.61	-7.51	-0.61	3.22e-11	Urinary tract infection frequency;
THYM	cis	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg10856724	chr12:34555212	NA	-0.93	-9.34	-0.69	4.18e-15	Morning vs. evening chronotype;
THYM	cis	rs1336149	0.901	rs822430	chr1:156902259	A/G	cg04298847	chr1:156447084	MEF2D	0.36	4.82	0.44	5.46e-6	Chin dimples;
THYM	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg09904177	chr6:26538194	HMGN4	0.64	5.4	0.48	4.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs662064	0.925	rs2847344	chr1:10564675	G/A	cg20482658	chr1:10539492	PEX14	-0.47	-5.94	-0.52	4.74e-8	Asthma;
THYM	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.51	-4.9	-0.45	3.89e-6	Lymphocyte counts;
THYM	cis	rs4242434	0.857	rs11777808	chr8:22462755	A/C	cg11461670	chr8:22454935	PDLIM2	-0.35	-6.34	-0.55	7.66e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7267979	0.932	rs417110	chr20:25458297	T/C	cg03522245	chr20:25566470	NINL	0.57	4.48	0.42	2.1e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg04731861	chr2:219085781	ARPC2	-0.56	-5.2	-0.47	1.13e-6	Colorectal cancer;
THYM	cis	rs4285028	0.948	rs12488334	chr3:121702526	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.73	-5.04	-0.46	2.26e-6	Multiple sclerosis;
THYM	cis	rs6586111	1.000	rs6586107	chr10:82373516	C/T	cg03086067	chr10:82368399	SH2D4B	0.52	6.55	0.56	2.89e-9	Capecitabine sensitivity;
THYM	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg07936489	chr17:37558343	FBXL20	0.87	5.78	0.51	9.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.8	-6.53	-0.56	3.27e-9	Breast cancer;
THYM	cis	rs514406	0.893	rs6682024	chr1:53439525	T/C	cg16325326	chr1:53192061	ZYG11B	-0.8	-7.44	-0.61	4.5e-11	Monocyte count;
THYM	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.76	5.89	0.52	5.93e-8	Eosinophil percentage of white cells;
THYM	cis	rs931812	0.825	rs55818461	chr8:101899229	T/C	cg07239293	chr8:101170671	SPAG1	0.69	4.63	0.43	1.16e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs12643440	0.538	rs1522081	chr4:17135357	T/C	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs71403859	0.502	rs12919417	chr16:71579711	A/G	cg08717414	chr16:71523259	ZNF19	1.13	5.99	0.52	3.77e-8	Post bronchodilator FEV1;
THYM	cis	rs11771526	0.901	rs11761481	chr7:32293994	C/T	cg27532318	chr7:32358331	NA	0.73	4.87	0.45	4.39e-6	Body mass index;
THYM	cis	rs10274279	1.000	rs73163816	chr7:157388126	C/G	cg25259479	chr7:157408632	PTPRN2	-0.81	-4.57	-0.42	1.48e-5	Myopia (pathological);
THYM	cis	rs11190604	0.767	rs11190513	chr10:102165238	A/G	cg07570687	chr10:102243282	WNT8B	0.81	7.68	0.62	1.44e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs854765	0.624	rs12450799	chr17:17730201	T/C	cg04398451	chr17:18023971	MYO15A	0.79	6.83	0.57	7.85e-10	Total body bone mineral density;
THYM	cis	rs4474465	1.000	rs11602360	chr11:78179336	A/G	cg19901956	chr11:77921274	USP35	0.61	4.56	0.42	1.53e-5	Alzheimer's disease (survival time);
THYM	cis	rs2980439	0.807	rs2980438	chr8:8094825	T/C	cg15556689	chr8:8085844	FLJ10661	0.78	6.88	0.58	6.38e-10	Neuroticism;
THYM	cis	rs2806561	0.780	rs12751560	chr1:23407081	C/A	cg19743168	chr1:23544995	NA	-0.55	-5.04	-0.46	2.26e-6	Height;
THYM	cis	rs11809207	0.903	rs17257148	chr1:26526348	G/C	cg03844060	chr1:26490628	NA	0.64	4.74	0.44	7.47e-6	Height;
THYM	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg27284194	chr4:1044797	NA	0.6	4.54	0.42	1.68e-5	Recombination rate (females);
THYM	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg03676636	chr4:99064102	C4orf37	0.39	5.55	0.49	2.57e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.58	-5.88	-0.52	6.01e-8	Crohn's disease;
THYM	cis	rs6087990	0.899	rs4911262	chr20:31393352	G/A	cg13636640	chr20:31349939	DNMT3B	0.92	9.94	0.71	2.22e-16	Ulcerative colitis;
THYM	cis	rs6546537	1.000	rs4852892	chr2:69866769	T/A	cg10773587	chr2:69614142	GFPT1	-0.63	-5.44	-0.49	4.22e-7	Serum thyroid-stimulating hormone levels;
THYM	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.89	-6.55	-0.56	2.9e-9	Electrocardiographic conduction measures;
THYM	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.46	-4.85	-0.45	4.84e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs1448094	0.512	rs7970842	chr12:86243258	C/T	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg05738196	chr6:26577821	NA	0.95	9.91	0.71	2.53e-16	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-4.48	-0.42	2.06e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs13082711	0.863	rs35998108	chr3:27423427	G/A	cg02860705	chr3:27208620	NA	0.67	4.7	0.43	8.87e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs6665290	0.904	rs7541033	chr1:227188371	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.13	-15.82	-0.85	2.26e-28	Myeloid white cell count;
THYM	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.32	9.94	0.71	2.24e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs4474465	0.790	rs10899541	chr11:78245573	A/G	cg19901956	chr11:77921274	USP35	-0.57	-4.49	-0.42	1.97e-5	Alzheimer's disease (survival time);
THYM	cis	rs7187994	0.848	rs16974515	chr16:84782510	T/G	cg07647771	chr16:84786436	USP10	-0.52	-4.85	-0.45	4.73e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg02527881	chr3:46936655	PTH1R	0.57	5.4	0.48	4.99e-7	Colorectal cancer;
THYM	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg14664628	chr15:75095509	CSK	-0.69	-5.34	-0.48	6.44e-7	Breast cancer;
THYM	cis	rs2505998	0.833	rs1800858	chr10:43595968	A/G	cg06632098	chr10:43605906	RET	-1.1	-10.64	-0.74	7.21e-18	Hirschsprung disease;
THYM	trans	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Bladder cancer;
THYM	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg24846343	chr22:24311635	DDTL	0.49	6.95	0.58	4.6e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs6546324	0.625	rs2902023	chr2:67830279	A/G	cg18237512	chr2:67827392	NA	-0.78	-4.63	-0.43	1.16e-5	Endometriosis;
THYM	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg24578937	chr1:2090814	PRKCZ	0.57	5.77	0.51	1e-7	Height;
THYM	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg16586182	chr3:47516702	SCAP	0.63	5.6	0.5	2.12e-7	Colorectal cancer;
THYM	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.62	6.03	0.53	3.06e-8	Prudent dietary pattern;
THYM	cis	rs240764	0.817	rs239230	chr6:101105862	C/A	cg21058520	chr6:100914733	NA	-0.57	-5.07	-0.46	1.96e-6	Neuroticism;
THYM	cis	rs28476539	0.640	rs56396312	chr4:83555639	C/T	cg10249074	chr4:83542146	C4orf11	-0.64	-5.06	-0.46	2.05e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg24154853	chr7:158122151	PTPRN2	-0.51	-4.69	-0.43	9.17e-6	Calcium levels;
THYM	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg26545918	chr15:68124484	LBXCOR1	0.55	4.71	0.44	8.37e-6	Restless legs syndrome;
THYM	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg09035930	chr12:129282057	SLC15A4	0.85	10.44	0.73	1.93e-17	Systemic lupus erythematosus;
THYM	cis	rs192264	0.582	rs254349	chr16:65979999	C/T	cg02795155	chr16:66785218	DYNC1LI2	0.62	5.02	0.46	2.36e-6	Subjective well-being;
THYM	cis	rs6768930	0.509	rs4530498	chr3:57724602	A/G	cg07735586	chr3:57945651	NA	-0.32	-4.85	-0.45	4.8e-6	Obesity-related traits;
THYM	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg03407747	chr17:6899364	ALOX12	0.82	10.8	0.74	3.29e-18	Tonsillectomy;
THYM	cis	rs6496932	0.676	rs7183651	chr15:85895721	A/G	cg19183879	chr15:85880815	NA	-0.5	-4.52	-0.42	1.81e-5	Central corneal thickness;Corneal structure;
THYM	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg14458575	chr2:238380390	NA	0.94	7.83	0.63	7.01e-12	Prostate cancer;
THYM	cis	rs35883536	0.647	rs10875312	chr1:101042320	G/C	cg09408571	chr1:101003634	GPR88	-0.47	-5.17	-0.47	1.29e-6	Monocyte count;
THYM	cis	rs4786125	0.581	rs1473519	chr16:6921533	G/A	cg03623568	chr16:6915990	A2BP1	-0.99	-9.71	-0.71	6.74e-16	Heart rate variability traits (SDNN);
THYM	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg27532560	chr4:187881888	NA	-0.96	-11.4	-0.76	1.72e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1003719	0.762	rs8130846	chr21:38480242	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg26384229	chr12:38710491	ALG10B	1.05	10.43	0.73	1.96e-17	Heart rate;
THYM	cis	rs2625529	0.652	rs2929513	chr15:72229180	G/A	cg16672083	chr15:72433130	SENP8	0.52	4.63	0.43	1.14e-5	Red blood cell count;
THYM	cis	rs6138458	1.000	rs7269416	chr20:24976196	T/G	cg26195577	chr20:24973756	C20orf3	1.09	11.01	0.75	1.16e-18	Blood protein levels;
THYM	cis	rs3857067	0.773	rs10023115	chr4:95095502	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs13064411	0.735	rs6438158	chr3:113217290	C/T	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs6960043	0.818	rs10238161	chr7:15053827	A/T	cg19272540	chr7:15055459	NA	0.55	6.04	0.53	3.05e-8	Type 2 diabetes;
THYM	cis	rs7584330	0.554	rs76519914	chr2:238429818	G/A	cg08992911	chr2:238395768	MLPH	0.92	5.79	0.51	9.04e-8	Prostate cancer;
THYM	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg27170947	chr2:26402098	FAM59B	-0.78	-6.09	-0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg10802521	chr3:52805072	NEK4	-0.75	-7.03	-0.58	3.15e-10	Electroencephalogram traits;
THYM	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.65	-5.2	-0.47	1.16e-6	Blood metabolite levels;
THYM	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.32	0.54	8.42e-9	Platelet count;
THYM	cis	rs6689305	0.685	rs1845310	chr1:100271203	A/G	cg15728779	chr1:99729504	LPPR4	0.41	4.64	0.43	1.12e-5	White matter integrity (bipolar disorder risk interaction);
THYM	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg20744362	chr22:50050164	C22orf34	0.83	8.49	0.66	2.73e-13	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg21385522	chr1:16154831	NA	-1.31	-15.16	-0.84	4.14e-27	Dilated cardiomyopathy;
THYM	cis	rs995000	0.931	rs6587980	chr1:63090858	C/T	cg06896770	chr1:63153194	DOCK7	0.9	7.48	0.61	3.67e-11	Triglyceride levels;
THYM	trans	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg02527881	chr3:46936655	PTH1R	-0.66	-6.44	-0.55	4.76e-9	Colorectal cancer;
THYM	cis	rs7917772	0.560	rs4919664	chr10:104363408	A/C	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg15691649	chr6:25882328	NA	-0.82	-6.86	-0.58	7.09e-10	Intelligence (multi-trait analysis);
THYM	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg12386194	chr3:101231763	SENP7	0.7	5.29	0.48	7.69e-7	Colorectal cancer;
THYM	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg05962950	chr11:130786565	SNX19	0.7	5.53	0.49	2.82e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs654950	0.875	rs687835	chr1:41998904	G/C	cg06885757	chr1:42089581	HIVEP3	0.44	5.26	0.47	9e-7	Airway imaging phenotypes;
THYM	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg09184832	chr6:79620586	NA	-0.56	-4.46	-0.42	2.24e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs11645898	0.935	rs4788614	chr16:72188828	C/T	cg14768367	chr16:72042858	DHODH	0.68	4.88	0.45	4.27e-6	Blood protein levels;
THYM	cis	rs9527	0.590	rs11191578	chr10:104902337	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg00376283	chr12:123451042	ABCB9	0.73	4.87	0.45	4.45e-6	Neutrophil percentage of white cells;
THYM	cis	rs6754311	0.593	rs7608045	chr2:136413359	T/C	cg20242066	chr2:136595261	LCT	0.55	6.04	0.53	3.05e-8	Mosquito bite size;
THYM	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg26149184	chr10:133730230	NA	0.77	4.65	0.43	1.07e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs9649213	0.574	rs36099592	chr7:98002331	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg06219351	chr7:158114137	PTPRN2	-0.77	-8.01	-0.63	2.9e-12	Calcium levels;
THYM	cis	rs1915146	0.656	rs10794201	chr10:126846531	C/T	cg23000734	chr10:126850823	CTBP2	0.63	6.76	0.57	1.09e-9	Menarche (age at onset);
THYM	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.39	0.6	5.63e-11	Obesity-related traits;
THYM	cis	rs34779708	0.966	rs12775759	chr10:35400183	G/T	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11608355	1.000	rs11608355	chr12:109879292	T/C	cg11367159	chr12:110044531	NA	0.63	5.98	0.52	3.95e-8	Neuroticism;
THYM	cis	rs314370	0.951	rs12667888	chr7:100474289	T/C	cg08558340	chr7:100472263	SRRT	0.61	4.99	0.46	2.75e-6	Resting heart rate;
THYM	cis	rs936229	0.813	rs1378938	chr15:75096443	T/C	cg14664628	chr15:75095509	CSK	-1.08	-9.62	-0.7	1.09e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg26149184	chr10:133730230	NA	0.79	4.74	0.44	7.52e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs2806561	1.000	rs1757048	chr1:23510601	A/C	cg12483005	chr1:23474871	LUZP1	0.55	5.68	0.5	1.46e-7	Height;
THYM	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg12935359	chr14:103987150	CKB	-0.64	-6.43	-0.55	5.14e-9	Body mass index;
THYM	cis	rs17030434	0.654	rs10021631	chr4:154646675	A/G	cg14289246	chr4:154710475	SFRP2	-0.68	-4.77	-0.44	6.56e-6	Electrocardiographic conduction measures;
THYM	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.37	6.25	0.54	1.18e-8	Obesity-related traits;
THYM	cis	rs28595532	0.844	rs116721336	chr4:119536538	A/G	cg14228332	chr4:119757509	SEC24D	1.38	4.98	0.45	2.89e-6	Cannabis dependence symptom count;
THYM	cis	rs6060960	0.537	rs75351461	chr20:30458612	C/T	cg09796376	chr20:30640595	HCK	0.71	4.63	0.43	1.14e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs2273669	0.504	rs79971938	chr6:109494473	T/G	cg17117243	chr6:109341365	SESN1	-0.82	-4.8	-0.44	5.98e-6	Prostate cancer;
THYM	cis	rs941408	1.000	rs4807332	chr19:2793289	T/C	cg17333051	chr19:2783644	SGTA	0.6	5.4	0.48	4.82e-7	Total cholesterol levels;
THYM	cis	rs9992101	0.901	rs10019833	chr4:77357592	T/C	cg20311846	chr4:77356250	SHROOM3	-0.62	-6.47	-0.55	4.26e-9	Creatinine levels;
THYM	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg06092702	chr1:163392909	NA	-0.62	-5.65	-0.5	1.69e-7	Motion sickness;
THYM	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg04520793	chr17:42248056	ASB16	0.33	4.56	0.42	1.54e-5	Total body bone mineral density;
THYM	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.09	-0.46	1.83e-6	Life satisfaction;
THYM	cis	rs2085601	0.567	rs6846926	chr4:89949707	C/T	cg17769793	chr4:89976368	FAM13A	-0.53	-5.83	-0.51	7.75e-8	Hair greying;
THYM	cis	rs7719624	1.000	rs4141306	chr5:135375473	A/G	cg15329133	chr5:135467951	SMAD5;SMAD5OS	0.55	4.73	0.44	7.85e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg00990874	chr7:1149470	C7orf50	-0.7	-5.47	-0.49	3.71e-7	Bronchopulmonary dysplasia;
THYM	cis	rs4606347	1.000	rs6665672	chr1:66069020	G/A	cg04111102	chr1:66153794	NA	0.59	4.48	0.42	2.04e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg16797656	chr11:68205561	LRP5	0.45	4.7	0.43	8.67e-6	Total body bone mineral density;
THYM	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg17644776	chr2:200775616	C2orf69	0.9	7.45	0.61	4.33e-11	Osteoporosis;
THYM	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg12310025	chr6:25882481	NA	-0.69	-5.59	-0.5	2.16e-7	Blood metabolite levels;
THYM	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg05043794	chr9:111880884	C9orf5	-0.37	-5.18	-0.47	1.22e-6	Menarche (age at onset);
THYM	cis	rs11008222	0.967	rs7919498	chr10:31047997	C/T	cg00941203	chr10:31016591	NA	-0.36	-4.85	-0.45	4.82e-6	Congenital left-sided heart lesions (maternal effect);
THYM	cis	rs7794273	0.607	rs10245511	chr7:18829835	A/C	cg13420273	chr7:18810212	HDAC9	0.59	5.0	0.46	2.65e-6	Night sleep phenotypes;
THYM	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg03396347	chr1:1875803	NA	-0.6	-5.79	-0.51	9.14e-8	Body mass index;
THYM	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg14779329	chr11:130786720	SNX19	0.56	6.33	0.54	7.99e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg15557168	chr22:42548783	NA	-0.59	-4.73	-0.44	7.93e-6	Schizophrenia;
THYM	cis	rs9486719	0.947	rs11153071	chr6:97039741	G/A	cg18709589	chr6:96969512	KIAA0776	-0.66	-4.47	-0.42	2.17e-5	Migraine;Coronary artery disease;
THYM	cis	rs35160687	0.862	rs13024964	chr2:86511868	G/A	cg10973622	chr2:86423274	IMMT	0.52	4.52	0.42	1.8e-5	Night sleep phenotypes;
THYM	cis	rs7973719	0.966	rs7310539	chr12:7329996	C/G	cg07052231	chr12:7363540	PEX5	0.64	5.57	0.5	2.35e-7	IgG glycosylation;
THYM	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg06640241	chr16:89574553	SPG7	0.67	4.53	0.42	1.74e-5	Multiple myeloma (IgH translocation);
THYM	trans	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg24846680	chr1:228362309	C1orf69	0.58	4.77	0.44	6.7e-6	Diastolic blood pressure;
THYM	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.62	5.61	0.5	2.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg26418147	chr1:205743515	RAB7L1	-0.6	-4.99	-0.46	2.77e-6	Menarche (age at onset);
THYM	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs11771526	0.786	rs11768318	chr7:32372965	T/G	cg27532318	chr7:32358331	NA	0.95	5.63	0.5	1.85e-7	Body mass index;
THYM	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg03676636	chr4:99064102	C4orf37	0.43	6.38	0.55	6.28e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35264875	1.000	rs72928652	chr11:68851547	G/A	cg23845249	chr11:68861649	NA	0.55	6.53	0.56	3.22e-9	Blond vs. brown hair color;
THYM	cis	rs4072705	0.557	rs1886124	chr9:127233207	A/G	cg13476313	chr9:127244764	NR5A1	0.32	4.53	0.42	1.73e-5	Menarche (age at onset);
THYM	cis	rs12701220	0.689	rs12530960	chr7:1095471	G/A	cg01699819	chr7:1052092	C7orf50	-0.83	-6.96	-0.58	4.26e-10	Bronchopulmonary dysplasia;
THYM	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg26769984	chr7:1090371	C7orf50	0.8	5.36	0.48	5.9e-7	Bronchopulmonary dysplasia;
THYM	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg03709012	chr19:19516395	GATAD2A	0.79	6.38	0.55	6.42e-9	Tonsillectomy;
THYM	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg02187348	chr16:89574699	SPG7	0.69	5.06	0.46	2.01e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg26384229	chr12:38710491	ALG10B	0.9	7.73	0.62	1.12e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6089829	0.962	rs2314131	chr20:61665225	A/G	cg08564027	chr20:61660810	NA	0.72	5.94	0.52	4.71e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.69	-5.13	-0.47	1.56e-6	Colorectal cancer;
THYM	cis	rs10819861	0.645	rs10739800	chr9:98853170	C/A	cg14508093	chr9:98862825	NA	-0.24	-4.67	-0.43	9.83e-6	Electrocardiographic traits;
THYM	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg05347473	chr6:146136440	FBXO30	0.81	7.12	0.59	2.04e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	6.55	0.56	2.93e-9	Obesity-related traits;
THYM	cis	rs6490294	0.632	rs10849966	chr12:112100773	T/A	cg10833066	chr12:111807467	FAM109A	0.49	5.55	0.5	2.53e-7	Mean platelet volume;
THYM	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg06618935	chr21:46677482	NA	-1.04	-9.34	-0.69	4.33e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg23583168	chr7:148888333	NA	-1.06	-14.1	-0.82	4.94e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg17830980	chr10:43048298	ZNF37B	-1.02	-10.36	-0.73	2.81e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs4731207	0.564	rs6466992	chr7:124692166	G/A	cg05285228	chr7:124571219	POT1	-0.63	-4.76	-0.44	6.82e-6	Cutaneous malignant melanoma;
THYM	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg22974920	chr21:40686053	BRWD1	-0.58	-4.49	-0.42	2e-5	Cognitive function;
THYM	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg07570687	chr10:102243282	WNT8B	0.75	6.44	0.55	4.81e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs728616	0.867	rs56008106	chr10:81953776	T/C	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6430585	0.591	rs724326	chr2:136485971	T/C	cg07169764	chr2:136633963	MCM6	0.94	9.32	0.69	4.67e-15	Corneal structure;
THYM	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg22079354	chr11:130786696	SNX19	0.53	4.85	0.45	4.9100000000000004e-06	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg08645402	chr16:4508243	NA	-0.72	-6.66	-0.56	1.73e-9	Schizophrenia;
THYM	cis	rs4731207	0.596	rs7794538	chr7:124648850	C/T	cg05285228	chr7:124571219	POT1	-0.72	-5.53	-0.49	2.81e-7	Cutaneous malignant melanoma;
THYM	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg24450063	chr1:156163899	SLC25A44	1.1	9.46	0.7	2.36e-15	Testicular germ cell tumor;
THYM	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg13695892	chr22:41940480	POLR3H	-0.6	-4.69	-0.43	9.11e-6	Vitiligo;
THYM	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg14196790	chr5:131705035	SLC22A5	-0.54	-4.74	-0.44	7.41e-6	Blood metabolite levels;
THYM	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg18357526	chr6:26021779	HIST1H4A	0.75	6.12	0.53	2.06e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg25427524	chr10:38739819	LOC399744	-0.73	-6.77	-0.57	1.04e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg08999081	chr20:33150536	PIGU	0.77	6.95	0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.52	-4.84	-0.44	5.09e-6	Crohn's disease;
THYM	cis	rs2544523	0.511	rs2544535	chr2:15906778	A/G	cg26669897	chr2:15909070	NA	0.72	6.6	0.56	2.33e-9	Asthma or chronic obstructive pulmonary disease;
THYM	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4808199	0.948	rs8108647	chr19:19427623	A/G	cg03709012	chr19:19516395	GATAD2A	1.15	6.81	0.57	8.59e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg06108461	chr20:60628389	TAF4	-1.1	-9.41	-0.69	3.05e-15	Body mass index;
THYM	cis	rs1957429	0.901	rs8008745	chr14:65351593	C/G	cg23373153	chr14:65346875	NA	1.07	6.45	0.55	4.75e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg06481639	chr22:41940642	POLR3H	0.64	5.03	0.46	2.32e-6	Vitiligo;
THYM	cis	rs7246657	0.943	rs2081096	chr19:37964700	G/A	cg22634378	chr19:37742834	NA	0.6	5.08	0.46	1.91e-6	Coronary artery calcification;
THYM	cis	rs1467026	0.584	rs11712581	chr3:12807781	T/C	cg11882607	chr3:12858926	CAND2	-0.5	-5.66	-0.5	1.63e-7	P wave duration;
THYM	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs17255340	0.539	rs1170500	chr6:83991710	T/C	cg21688264	chr6:84418724	SNAP91	0.66	4.46	0.42	2.22e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs425535	0.817	rs552582	chr4:74855858	A/G	cg07868155	chr4:74864709	CXCL5	0.61	5.04	0.46	2.22e-6	Blood protein levels;
THYM	cis	rs977987	0.806	rs35552529	chr16:75405879	G/C	cg03315344	chr16:75512273	CHST6	0.72	6.09	0.53	2.34e-8	Dupuytren's disease;
THYM	cis	rs7944584	0.551	rs12224672	chr11:47500400	C/T	cg20307385	chr11:47447363	PSMC3	0.8	5.55	0.49	2.58e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
THYM	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg10589385	chr1:150898437	SETDB1	0.64	5.4	0.48	4.9e-7	Melanoma;
THYM	cis	rs4523957	0.788	rs11651451	chr17:2098417	C/T	cg16513277	chr17:2031491	SMG6	-0.83	-8.28	-0.65	7.74e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg06600287	chr1:53387719	ECHDC2	-0.29	-4.69	-0.43	9.17e-6	Monocyte count;
THYM	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.14	0.53	1.9e-8	Platelet count;
THYM	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs41311933	1.000	rs41311871	chr9:123753253	T/C	cg13567360	chr9:123745713	C5	-0.96	-5.55	-0.49	2.57e-7	Coronary artery disease;
THYM	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs3741151	1.000	rs74776668	chr11:73065909	G/A	cg12959048	chr11:73096162	RELT	-0.5	-4.78	-0.44	6.38e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg05738196	chr6:26577821	NA	0.95	9.89	0.71	2.78e-16	Intelligence (multi-trait analysis);
THYM	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg12165864	chr7:66369176	NA	-0.67	-5.26	-0.47	8.99e-7	Aortic root size;
THYM	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs10203711	0.966	rs4998694	chr2:239564713	C/T	cg14580085	chr2:239553406	NA	0.68	6.07	0.53	2.58e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.25	-10.33	-0.73	3.19e-17	Platelet count;
THYM	cis	rs28595532	0.920	rs116046128	chr4:119741990	C/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs6732160	0.691	rs13432787	chr2:73430234	T/C	cg24220031	chr2:73402428	NA	-0.79	-9.35	-0.69	3.98e-15	Intelligence (multi-trait analysis);
THYM	cis	rs12711979	0.765	rs6715805	chr2:3821117	T/C	cg17052675	chr2:3827356	NA	-0.48	-5.19	-0.47	1.19e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs4285028	0.851	rs1986368	chr3:121710969	A/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.75	-5.18	-0.47	1.26e-6	Multiple sclerosis;
THYM	cis	rs72717009	0.778	rs9427400	chr1:161477204	C/T	cg23840854	chr1:161414152	NA	-1.03	-5.5	-0.49	3.16e-7	Rheumatoid arthritis;
THYM	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	6.12	0.53	2.13e-8	Platelet count;
THYM	cis	rs12681288	0.550	rs12674921	chr8:957969	A/C	cg08648136	chr8:956695	NA	0.6	5.16	0.47	1.36e-6	Schizophrenia;
THYM	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4950928	0.700	rs946263	chr1:203165381	A/G	cg17014757	chr1:203156097	CHI3L1	1.07	6.13	0.53	2.02e-8	YKL-40 levels;
THYM	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg13246856	chr1:44399776	ARTN	0.5	5.07	0.46	1.95e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg03690763	chr11:133734501	NA	-0.61	-4.73	-0.44	7.77e-6	Childhood ear infection;
THYM	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg24531977	chr5:56204891	C5orf35	-1.01	-8.29	-0.65	7.47e-13	Initial pursuit acceleration;
THYM	cis	rs13326165	0.585	rs76103861	chr3:52286886	C/G	cg08438690	chr3:52279403	PPM1M	-0.83	-4.63	-0.43	1.16e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11771526	1.000	rs11764617	chr7:32339102	T/C	cg13207630	chr7:32358064	NA	1.0	6.04	0.53	2.92e-8	Body mass index;
THYM	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs4660306	1.000	rs882803	chr1:45976147	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.59	-4.7	-0.43	8.86e-6	Homocysteine levels;
THYM	trans	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg10856724	chr12:34555212	NA	-0.78	-7.08	-0.59	2.48e-10	Bladder cancer;
THYM	cis	rs28595532	0.920	rs114678295	chr4:119756281	C/T	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg00990874	chr7:1149470	C7orf50	-0.6	-4.63	-0.43	1.16e-5	Bronchopulmonary dysplasia;
THYM	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg11764359	chr7:65958608	NA	-0.82	-6.44	-0.55	4.81e-9	Aortic root size;
THYM	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg22709100	chr7:91322751	NA	0.61	4.83	0.44	5.26e-6	Breast cancer;
THYM	cis	rs611744	0.625	rs4735055	chr8:109286642	G/A	cg21045802	chr8:109455806	TTC35	0.71	6.5	0.55	3.66e-9	Dupuytren's disease;
THYM	cis	rs4919694	1.000	rs12252500	chr10:104794984	G/C	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg10117171	chr1:25599238	RHD	0.68	4.87	0.45	4.52e-6	Erythrocyte sedimentation rate;
THYM	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg20887711	chr4:1340912	KIAA1530	1.0	9.57	0.7	1.4e-15	Longevity;
THYM	cis	rs2555603	1.000	rs2555603	chr13:33798262	G/T	cg07499182	chr13:33825496	STARD13	0.51	4.8	0.44	5.9e-6	Body mass index in asthmatics;
THYM	cis	rs10982256	0.817	rs2297815	chr9:117266965	C/T	cg15903421	chr9:117267460	DFNB31	-0.55	-5.22	-0.47	1.05e-6	Bipolar disorder;
THYM	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19346786	chr7:2764209	NA	0.78	7.06	0.59	2.68e-10	Height;
THYM	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03264133	chr6:25882463	NA	-0.69	-5.32	-0.48	7.03e-7	Blood metabolite levels;
THYM	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg02734326	chr4:10020555	SLC2A9	0.73	6.31	0.54	8.85e-9	Bone mineral density;
THYM	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg03396347	chr1:1875803	NA	-0.67	-6.81	-0.57	8.73e-10	Body mass index;
THYM	cis	rs9858542	0.537	rs9864406	chr3:49352619	A/G	cg00383909	chr3:49044727	WDR6	0.66	4.55	0.42	1.56e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs448720	0.776	rs1001870	chr15:68151448	C/T	cg24579218	chr15:68104479	NA	-0.6	-5.26	-0.48	8.75e-7	Cognitive performance;
THYM	cis	rs2229238	0.915	rs7514452	chr1:154438084	C/T	cg21262032	chr1:154437693	IL6R	0.58	5.13	0.47	1.51e-6	Coronary heart disease;
THYM	cis	rs10193935	0.792	rs13430031	chr2:42499968	C/T	cg27598129	chr2:42591480	NA	-0.74	-4.45	-0.42	2.34e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg19747945	chr6:42946146	PEX6	-0.33	-4.75	-0.44	7.16e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7246657	0.943	rs2291004	chr19:37997952	C/A	cg22634378	chr19:37742834	NA	0.67	5.48	0.49	3.45e-7	Coronary artery calcification;
THYM	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg07343612	chr16:622815	PIGQ	-1.08	-11.34	-0.76	2.36e-19	Height;
THYM	cis	rs1580019	0.961	rs11768506	chr7:32494788	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.59	0.56	2.42e-9	Cognitive ability;
THYM	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Body mass index;
THYM	cis	rs4907240	0.925	rs7575254	chr2:97275760	T/C	cg01950434	chr2:97203154	ARID5A	-0.58	-4.9	-0.45	3.86e-6	Event-related brain oscillations;
THYM	cis	rs7617773	0.815	rs9825637	chr3:48372282	T/C	cg02219026	chr3:48282209	ZNF589	-0.66	-4.64	-0.43	1.11e-5	Coronary artery disease;
THYM	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg07212818	chr11:638076	DRD4	-0.73	-5.06	-0.46	2.08e-6	Systemic lupus erythematosus;
THYM	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg01699819	chr7:1052092	C7orf50	-0.77	-6.84	-0.57	7.5e-10	Bronchopulmonary dysplasia;
THYM	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg16586182	chr3:47516702	SCAP	0.68	5.69	0.5	1.4e-7	Colorectal cancer;
THYM	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-5.45	-0.49	3.94e-7	Mood instability;
THYM	cis	rs3772130	1.000	rs11714406	chr3:121372513	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.78	4.75	0.44	7.3e-6	Cognitive performance;
THYM	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg03929089	chr4:120376271	NA	-1.01	-13.5	-0.81	8.17e-24	Height;
THYM	cis	rs3087591	0.960	rs12939815	chr17:29430916	G/C	cg24425628	chr17:29625626	OMG;NF1	0.64	5.52	0.49	2.89e-7	Hip circumference;
THYM	cis	rs7226229	1.000	rs9896259	chr17:20927835	A/G	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs4343996	0.967	rs7791820	chr7:3353180	T/G	cg21248987	chr7:3385318	SDK1	-0.41	-5.1	-0.46	1.73e-6	Motion sickness;
THYM	cis	rs2072732	0.808	rs67758087	chr1:2937031	A/G	cg08733933	chr1:2954429	NA	-0.61	-4.64	-0.43	1.13e-5	Plateletcrit;
THYM	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs10463554	0.926	rs26433	chr5:102363858	A/G	cg23492399	chr5:102201601	PAM	-0.66	-4.85	-0.45	4.81e-6	Parkinson's disease;
THYM	cis	rs6032067	0.714	rs6104055	chr20:43822962	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.63	-7.28	-0.6	9.67e-11	Blood protein levels;
THYM	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg11494091	chr17:61959527	GH2	1.08	15.58	0.85	6.62e-28	Prudent dietary pattern;
THYM	cis	rs28595532	0.920	rs55794497	chr4:119764664	A/G	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg06521331	chr12:34319734	NA	-1.03	-11.1	-0.75	7.72e-19	Morning vs. evening chronotype;
THYM	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08109568	chr15:31115862	NA	-0.73	-6.54	-0.56	3.06e-9	Huntington's disease progression;
THYM	cis	rs892961	0.932	rs3987886	chr17:75414980	A/G	cg05865280	chr17:75406074	SEPT9	0.49	8.27	0.65	8.21e-13	Airflow obstruction;
THYM	cis	rs4589258	0.788	rs10741372	chr11:90500327	G/A	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.96	-0.45	3.02e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg04034577	chr2:241836375	C2orf54	-0.43	-7.92	-0.63	4.51e-12	Urinary metabolites;
THYM	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg00990874	chr7:1149470	C7orf50	-0.6	-4.57	-0.42	1.47e-5	Bronchopulmonary dysplasia;
THYM	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg10803722	chr21:46713166	LOC642852	-0.42	-5.45	-0.49	3.95e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6906287	0.647	rs7769001	chr6:118934509	A/G	cg21191810	chr6:118973309	C6orf204	0.58	5.8	0.51	8.72e-8	Electrocardiographic conduction measures;
THYM	cis	rs447921	0.813	rs435892	chr17:74398505	A/T	cg17201438	chr17:74438067	UBE2O	-0.81	-5.85	-0.51	6.9e-8	Mitochondrial DNA levels;
THYM	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs1728785	1.000	rs1615609	chr16:68596401	C/A	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs8070624	0.543	rs7219320	chr17:17880877	A/G	cg04398451	chr17:18023971	MYO15A	-0.93	-8.84	-0.67	4.97e-14	Total body bone mineral density;
THYM	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg07636037	chr3:49044803	WDR6	0.85	5.77	0.51	9.94e-8	Menarche (age at onset);
THYM	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg16615211	chr3:44902933	MIR564;TMEM42	0.58	6.25	0.54	1.14e-8	Depressive symptoms;
THYM	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg16989719	chr2:238392110	NA	-0.61	-5.82	-0.51	8.02e-8	Prostate cancer;
THYM	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs2915864	1.000	rs2961720	chr5:141580230	G/A	cg00542992	chr5:141595654	NA	0.62	4.65	0.43	1.06e-5	Facial morphology (factor 20);
THYM	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.07	-0.46	1.93e-6	Mood instability;
THYM	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.92	-8.31	-0.65	6.66e-13	Primary sclerosing cholangitis;
THYM	cis	rs12765878	0.580	rs55983834	chr10:105601210	C/T	cg04688330	chr10:105451802	SH3PXD2A	0.35	4.61	0.43	1.24e-5	Coronary artery disease;
THYM	cis	rs2688608	0.901	rs2664280	chr10:75617344	A/T	cg15838173	chr10:75533400	FUT11	0.45	4.78	0.44	6.48e-6	Inflammatory bowel disease;
THYM	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs955333	0.601	rs78453013	chr6:154902249	T/A	cg17771515	chr6:154831774	CNKSR3	0.71	5.0	0.46	2.66e-6	Diabetic kidney disease;
THYM	cis	rs11112613	0.762	rs17037308	chr12:105949847	T/G	cg03607813	chr12:105948248	NA	1.07	9.36	0.69	3.87e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs8101881	0.510	rs2287876	chr19:33360652	A/T	cg05467458	chr19:33361032	SLC7A9	-0.57	-5.19	-0.47	1.19e-6	Blood metabolite levels;Urinary metabolites;Urinary metabolites (H-NMR features);
THYM	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg24874828	chr4:187887005	NA	-0.72	-7.44	-0.61	4.48e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10425738	0.830	rs3852872	chr19:41416143	C/T	cg17435250	chr19:41386441	CYP2A7	-0.63	-4.52	-0.42	1.79e-5	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
THYM	cis	rs1018836	0.665	rs7000724	chr8:91516335	A/T	cg16814680	chr8:91681699	NA	-0.78	-6.79	-0.57	9.87e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs1865063	1.000	rs1865063	chr19:11341029	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.8	4.93	0.45	3.43e-6	HDL cholesterol levels;
THYM	cis	rs72717009	0.825	rs7529225	chr1:161479352	G/A	cg23840854	chr1:161414152	NA	-1.01	-5.36	-0.48	5.81e-7	Rheumatoid arthritis;
THYM	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg06850241	chr22:41845214	NA	-0.54	-4.68	-0.43	9.37e-6	Vitiligo;
THYM	cis	rs8077889	0.917	rs72836559	chr17:41913529	C/T	cg26893861	chr17:41843967	DUSP3	1.11	10.19	0.72	6.43e-17	Triglycerides;
THYM	cis	rs7119	0.717	rs62009069	chr15:77817877	T/G	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg02773041	chr1:40204384	PPIE	0.77	5.99	0.52	3.8e-8	Blood protein levels;
THYM	cis	rs10911251	0.527	rs1537520	chr1:183084229	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.68	0.43	9.44e-6	Colorectal cancer;
THYM	cis	rs8192282	0.739	rs6670375	chr1:154494947	G/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs9486719	0.749	rs1009596	chr6:96843688	A/G	cg18709589	chr6:96969512	KIAA0776	0.75	4.49	0.42	2.02e-5	Migraine;Coronary artery disease;
THYM	cis	rs11696501	0.688	rs6130894	chr20:44322673	G/A	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	cis	rs236907	0.859	rs35674909	chr1:171778147	G/A	cg20598894	chr1:171756153	METTL13	-0.73	-5.09	-0.46	1.81e-6	Mean platelet volume;
THYM	cis	rs13064411	0.696	rs13325046	chr3:113104444	C/T	cg10517650	chr3:113235015	CCDC52	-0.6	-5.02	-0.46	2.37e-6	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs11030122	0.661	rs10835561	chr11:4087594	C/T	cg18678763	chr11:4115507	RRM1	-0.41	-5.32	-0.48	6.86e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs6032067	0.543	rs7272524	chr20:43908694	A/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.39	-4.6	-0.43	1.33e-5	Blood protein levels;
THYM	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg03806693	chr22:41940476	POLR3H	-1.03	-8.5	-0.66	2.66e-13	Vitiligo;
THYM	trans	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg17911788	chr17:44343683	NA	0.59	5.92	0.52	5.02e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs17253792	0.822	rs10483643	chr14:56089931	G/C	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg08859206	chr1:53392774	SCP2	-0.66	-7.55	-0.61	2.7e-11	Monocyte count;
THYM	cis	rs9902453	0.765	rs2169810	chr17:28167941	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	6.53	0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg24020549	chr11:64937741	SPDYC	-0.46	-4.45	-0.42	2.34e-5	Eosinophil percentage of white cells;
THYM	cis	rs4474465	0.850	rs4285892	chr11:78243134	C/A	cg19901956	chr11:77921274	USP35	0.57	4.49	0.42	1.97e-5	Alzheimer's disease (survival time);
THYM	cis	rs3087591	0.960	rs2905883	chr17:29550141	G/A	cg24425628	chr17:29625626	OMG;NF1	0.6	5.16	0.47	1.35e-6	Hip circumference;
THYM	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.36	0.48	5.79e-7	Melanoma;
THYM	cis	rs9563576	0.778	rs9569818	chr13:58688345	C/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.67	4.97	0.45	2.97e-6	Body mass index;
THYM	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.83	-4.61	-0.43	1.25e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs4731207	0.596	rs10247349	chr7:124607495	C/T	cg05285228	chr7:124571219	POT1	-0.68	-5.08	-0.46	1.88e-6	Cutaneous malignant melanoma;
THYM	cis	rs7084402	0.967	rs2577392	chr10:60329183	A/G	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs2274459	1.000	rs12204992	chr6:33741724	C/T	cg06253072	chr6:33679850	C6orf125	0.51	4.49	0.42	1.99e-5	Obesity (extreme);
THYM	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg22681709	chr2:178499509	PDE11A	-0.58	-5.44	-0.49	4.12e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs28374715	0.532	rs28897479	chr15:41690851	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.21	-13.27	-0.81	2.41e-23	Ulcerative colitis;
THYM	cis	rs10463554	0.927	rs7717343	chr5:102361983	T/C	cg23492399	chr5:102201601	PAM	-0.67	-5.18	-0.47	1.26e-6	Parkinson's disease;
THYM	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg08000102	chr2:233561755	GIGYF2	-0.83	-7.26	-0.6	1.05e-10	Coronary artery disease;
THYM	cis	rs55728055	0.661	rs75785548	chr22:31991363	C/T	cg10537193	chr22:32026975	PISD	-0.87	-5.53	-0.49	2.78e-7	Age-related hearing impairment;
THYM	cis	rs2997447	0.846	rs61775422	chr1:26395898	C/T	cg03844060	chr1:26490628	NA	0.66	4.5	0.42	1.96e-5	QRS complex (12-leadsum);
THYM	cis	rs17539620	0.624	rs117591255	chr6:154839118	G/A	cg20019720	chr6:154832845	CNKSR3	0.47	4.79	0.44	6.17e-6	Lipoprotein (a) levels;
THYM	cis	rs6430585	0.528	rs75667274	chr2:136682486	C/T	cg23851026	chr2:136556271	LCT	0.76	6.28	0.54	1.02e-8	Corneal structure;
THYM	cis	rs6901250	0.851	rs339313	chr6:117179501	C/T	cg12892004	chr6:117198278	RFX6	-0.7	-6.78	-0.57	9.91e-10	C-reactive protein levels;
THYM	cis	rs526231	0.543	rs26820	chr5:102528092	T/C	cg23492399	chr5:102201601	PAM	-0.71	-5.27	-0.48	8.5e-7	Primary biliary cholangitis;
THYM	cis	rs7580658	0.676	rs4662717	chr2:128013504	C/T	cg10021288	chr2:128175891	PROC	-0.63	-5.9	-0.52	5.69e-8	Protein C levels;
THYM	cis	rs75920871	0.528	rs7950093	chr11:116963519	G/T	cg20608306	chr11:116969690	SIK3	-0.52	-5.67	-0.5	1.51e-7	Subjective well-being;
THYM	cis	rs7772486	0.846	rs1331636	chr6:146338826	T/C	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7851660	0.967	rs3758251	chr9:100613700	G/C	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg05932139	chr16:680872	WFIKKN1	-0.64	-5.31	-0.48	7.21e-7	Height;
THYM	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs72827839	0.894	rs41336845	chr17:46215110	A/G	cg23391107	chr17:45924227	SP6	-0.81	-5.51	-0.49	3.05e-7	Ease of getting up in the morning;
THYM	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	5.44	0.49	4.13e-7	Obesity-related traits;
THYM	cis	rs7107174	1.000	rs6592772	chr11:78015563	A/C	cg02023728	chr11:77925099	USP35	0.68	5.92	0.52	5.19e-8	Testicular germ cell tumor;
THYM	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg09359103	chr1:154839909	KCNN3	-0.69	-8.43	-0.65	3.66e-13	Prostate cancer;
THYM	cis	rs2816062	0.760	rs2244192	chr1:18890939	A/T	cg18795169	chr1:18902165	NA	-0.97	-11.04	-0.75	1.03e-18	Urate levels in lean individuals;
THYM	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg06994016	chr10:45406847	TMEM72	-0.46	-4.54	-0.42	1.66e-5	Mean corpuscular volume;
THYM	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg21394778	chr1:3037102	PRDM16	0.47	4.6	0.43	1.31e-5	Height;
THYM	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg26566898	chr11:117069891	TAGLN	0.41	5.02	0.46	2.43e-6	Blood protein levels;
THYM	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg07532245	chr17:28927093	LRRC37B2	0.71	4.48	0.42	2.04e-5	Body mass index;
THYM	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs289828	0.519	rs12998170	chr2:152153569	A/C	cg05960677	chr2:152117363	RBM43	0.71	6.61	0.56	2.24e-9	Blood protein levels;
THYM	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg21798802	chr22:38057573	PDXP	0.47	5.37	0.48	5.51e-7	Fat distribution (HIV);
THYM	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.59	4.58	0.43	1.4e-5	Height;
THYM	cis	rs55871839	0.547	rs3780001	chr8:59872615	G/T	cg07426533	chr8:59803705	TOX	-0.66	-5.63	-0.5	1.84e-7	Pneumonia;
THYM	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg06634786	chr22:41940651	POLR3H	0.75	6.01	0.52	3.4e-8	Vitiligo;
THYM	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-5.35	-0.48	6.09e-7	Obesity-related traits;
THYM	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg18032289	chr17:61959525	GH2	-0.5	-4.76	-0.44	6.95e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs7875611	1	rs7875611	chr9:95679009	T/C	cg14631576	chr9:95140430	CENPP	-0.59	-4.58	-0.43	1.4e-5	Schizophrenia;
THYM	cis	rs910187	0.605	rs6124960	chr20:45803866	G/C	cg27589058	chr20:45804311	EYA2	-0.7	-6.42	-0.55	5.42e-9	Migraine;
THYM	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06634786	chr22:41940651	POLR3H	-0.75	-5.64	-0.5	1.75e-7	Vitiligo;
THYM	cis	rs11886999	0.680	rs997547	chr2:96859034	A/G	cg10278162	chr2:97193688	NA	-0.71	-4.48	-0.42	2.11e-5	Cardiac Troponin-T levels;
THYM	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg13175981	chr1:150552382	MCL1	0.78	6.02	0.53	3.28e-8	Tonsillectomy;
THYM	cis	rs9810089	0.758	rs12492510	chr3:136151631	G/T	cg21827317	chr3:136751795	NA	0.59	5.05	0.46	2.11e-6	Gestational age at birth (child effect);
THYM	cis	rs116095464	1.000	rs6879758	chr5:350277	G/C	cg00420510	chr5:1089571	SLC12A7	0.78	4.49	0.42	1.98e-5	Breast cancer;
THYM	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg22709100	chr7:91322751	NA	0.69	5.41	0.49	4.7e-7	Breast cancer;
THYM	cis	rs13326165	0.585	rs17052052	chr3:52331793	A/G	cg08438690	chr3:52279403	PPM1M	-0.79	-4.64	-0.43	1.11e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs4790312	0.819	rs4061659	chr17:1997444	C/G	cg15816464	chr17:2026533	SMG6	0.36	4.83	0.44	5.26e-6	Left atrial antero-posterior diameter;
THYM	cis	rs2742417	0.603	rs13059502	chr3:45781380	A/G	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg25287198	chr4:183728479	NA	0.76	4.65	0.43	1.08e-5	Pediatric autoimmune diseases;
THYM	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg17178900	chr1:205818956	PM20D1	0.97	10.11	0.72	9.5e-17	Menarche (age at onset);
THYM	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg12310025	chr6:25882481	NA	-0.68	-5.3	-0.48	7.65e-7	Height;
THYM	cis	rs10214930	0.958	rs28521509	chr7:27762627	G/A	cg04422003	chr7:28448295	CREB5	-0.62	-4.6	-0.43	1.28e-5	Hypospadias;
THYM	cis	rs6956675	0.915	rs6977279	chr7:62630625	C/G	cg08930214	chr7:62859557	LOC100287834	0.61	4.73	0.44	7.65e-6	Obesity-related traits;
THYM	cis	rs3087591	0.960	rs2952976	chr17:29486152	G/A	cg24425628	chr17:29625626	OMG;NF1	0.66	5.79	0.51	9.11e-8	Hip circumference;
THYM	cis	rs7084402	0.967	rs1658446	chr10:60314183	A/C	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg00290607	chr11:67383545	NA	-0.78	-5.38	-0.48	5.41e-7	Mean corpuscular volume;
THYM	cis	rs9649213	0.593	rs6465672	chr7:97963717	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.49	-4.45	-0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg21427119	chr20:30132790	HM13	-0.86	-6.14	-0.53	1.88e-8	Mean corpuscular hemoglobin;
THYM	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs4455778	0.580	rs4529410	chr7:49125486	C/T	cg26309511	chr7:48887640	NA	0.69	6.23	0.54	1.26e-8	Lung cancer in never smokers;
THYM	cis	rs10791323	0.604	rs2723615	chr11:133704567	C/T	cg03690763	chr11:133734501	NA	-0.59	-4.76	-0.44	6.97e-6	Childhood ear infection;
THYM	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6906287	0.625	rs11968351	chr6:118901509	G/A	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs9992101	0.547	rs4318673	chr4:77412338	A/T	cg20311846	chr4:77356250	SHROOM3	-0.45	-4.72	-0.44	8.12e-6	Creatinine levels;
THYM	cis	rs2806561	0.929	rs10917357	chr1:23535161	C/T	cg19743168	chr1:23544995	NA	0.68	7.55	0.61	2.67e-11	Height;
THYM	cis	rs2463822	0.925	rs6863	chr11:62160725	G/T	cg06239285	chr11:62104954	ASRGL1	-1.43	-6.99	-0.58	3.82e-10	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs13177918	0.629	rs2070842	chr5:149824223	T/C	cg14059543	chr5:149831962	NA	-1.0	-7.6	-0.61	2.11e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs1113500	0.933	rs11185250	chr1:108616417	A/G	cg06207961	chr1:108661230	NA	0.66	5.18	0.47	1.24e-6	Growth-regulated protein alpha levels;
THYM	cis	rs9810089	0.527	rs895894	chr3:135955443	C/T	cg12473912	chr3:136751656	NA	0.7	6.4	0.55	5.88e-9	Gestational age at birth (child effect);
THYM	cis	rs12893597	0.715	rs4624098	chr14:76826256	G/A	cg20290672	chr14:76816747	NA	-0.71	-5.69	-0.5	1.39e-7	Maximal oxygen uptake response;
THYM	cis	rs55728055	0.661	rs7285091	chr22:31996363	A/G	cg10537193	chr22:32026975	PISD	-0.87	-5.53	-0.49	2.78e-7	Age-related hearing impairment;
THYM	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.21	8.51	0.66	2.47e-13	Cognitive test performance;
THYM	cis	rs4731207	0.596	rs2017928	chr7:124672323	A/G	cg05285228	chr7:124571219	POT1	-0.65	-4.98	-0.45	2.9e-6	Cutaneous malignant melanoma;
THYM	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg03160526	chr17:80928410	B3GNTL1	-0.49	-4.83	-0.44	5.26e-6	Glycated hemoglobin levels;
THYM	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs7072216	0.763	rs6584204	chr10:100173580	C/G	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg05872129	chr22:39784769	NA	-1.04	-10.98	-0.75	1.35e-18	Intelligence (multi-trait analysis);
THYM	cis	rs865483	0.929	rs853215	chr17:35861133	A/G	cg06716730	chr17:35851459	DUSP14	0.41	6.59	0.56	2.48e-9	Monocyte count;
THYM	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg19748678	chr4:122722346	EXOSC9	0.73	5.15	0.47	1.42e-6	Type 2 diabetes;
THYM	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg06558623	chr16:89946397	TCF25	1.33	5.65	0.5	1.64e-7	Skin colour saturation;
THYM	cis	rs113835537	0.529	rs7950407	chr11:66258006	A/G	cg24851651	chr11:66362959	CCS	0.63	4.51	0.42	1.86e-5	Airway imaging phenotypes;
THYM	cis	rs929354	1.000	rs929354	chr7:157045557	C/T	cg05182265	chr7:156933206	UBE3C	0.63	7.88	0.63	5.39e-12	Body mass index;
THYM	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg24257776	chr3:47051546	LOC100129354	0.41	4.73	0.44	7.73e-6	Colorectal cancer;
THYM	cis	rs831571	0.550	rs153734	chr3:64078009	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.61	-4.45	-0.42	2.31e-5	Type 2 diabetes;
THYM	cis	rs6956675	0.915	rs7795023	chr7:62652291	C/T	cg08930214	chr7:62859557	LOC100287834	0.6	4.69	0.43	9.2e-6	Obesity-related traits;
THYM	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg06611532	chr13:114900021	NA	0.64	7.17	0.59	1.61e-10	Schizophrenia;
THYM	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs3135718	0.935	rs11200014	chr10:123334930	G/A	cg15049101	chr10:123353889	FGFR2	0.53	4.54	0.42	1.66e-5	Estrogen receptor status in breast cancer;
THYM	cis	rs7731657	0.537	rs7735161	chr5:130324105	C/T	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg04034577	chr2:241836375	C2orf54	-0.43	-7.48	-0.61	3.69e-11	Urinary metabolites;
THYM	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.29	4.65	0.43	1.08e-5	Obesity-related traits;
THYM	cis	rs4919044	0.808	rs1222605	chr10:94804200	T/C	cg05127821	chr10:94822908	CYP26C1	-1.23	-6.66	-0.56	1.76e-9	Coronary artery disease;
THYM	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg00129232	chr17:37814104	STARD3	0.71	4.8	0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg04842962	chr6:43655489	MRPS18A	1.17	7.26	0.6	1.05e-10	IgG glycosylation;
THYM	cis	rs12643440	0.538	rs62296683	chr4:17137441	C/G	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg18512352	chr11:47633146	NA	-0.56	-7.3	-0.6	8.87e-11	Subjective well-being;
THYM	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg03295274	chr13:50190584	NA	0.68	5.16	0.47	1.37e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg06238570	chr21:40685208	BRWD1	0.9	6.47	0.55	4.34e-9	Cognitive function;
THYM	cis	rs1451375	0.617	rs896307	chr7:50569060	T/C	cg18232548	chr7:50535776	DDC	-0.69	-5.23	-0.47	9.94e-7	Malaria;
THYM	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.62	0.66	1.45e-13	Cognitive test performance;
THYM	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg00677455	chr12:58241039	CTDSP2	0.75	5.59	0.5	2.19e-7	Multiple sclerosis;
THYM	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-5.1	-0.46	1.75e-6	Gut microbiome composition (summer);
THYM	cis	rs910187	1.000	rs4555399	chr20:45837896	G/A	cg27589058	chr20:45804311	EYA2	-0.58	-4.66	-0.43	1.01e-5	Migraine;
THYM	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.54	-4.78	-0.44	6.47e-6	Type 2 diabetes;
THYM	cis	rs9560113	1.000	rs9555809	chr13:112181401	T/C	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs6032067	0.929	rs56131549	chr20:43842014	A/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.81	-0.57	8.91e-10	Blood protein levels;
THYM	cis	rs7119	0.651	rs12902072	chr15:77848732	T/C	cg27398640	chr15:77910606	LINGO1	-0.57	-5.56	-0.5	2.47e-7	Type 2 diabetes;
THYM	cis	rs7267979	1.000	rs6050542	chr20:25318879	T/C	cg08601574	chr20:25228251	PYGB	-0.57	-4.59	-0.43	1.35e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs11726022	0.927	rs11732567	chr4:188175565	C/T	cg09690449	chr4:187998952	NA	-0.51	-5.15	-0.47	1.41e-6	Systolic blood pressure (cigarette smoking interaction);
THYM	cis	rs921968	0.643	rs62191565	chr2:219482017	C/T	cg02176678	chr2:219576539	TTLL4	0.62	6.11	0.53	2.17e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8063160	1.000	rs8063160	chr16:90054709	T/C	cg07984980	chr16:89898383	SPIRE2	1.11	4.97	0.45	2.91e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs941408	0.515	rs1736193	chr19:2785273	G/C	cg19693284	chr19:2783607	SGTA	0.83	6.02	0.53	3.2e-8	Total cholesterol levels;
THYM	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg06850241	chr22:41845214	NA	0.54	4.68	0.43	9.37e-6	Vitiligo;
THYM	cis	rs6032067	0.929	rs6032055	chr20:43833336	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs887829	0.569	rs3806597	chr2:234637569	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.69	5.49	0.49	3.28e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs7192750	0.586	rs1834035	chr16:71972271	C/G	cg06353428	chr16:71660113	MARVELD3	0.72	5.13	0.47	1.5e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs2882667	0.628	rs13173618	chr5:138139780	T/G	cg09476006	chr5:138032270	NA	0.58	4.46	0.42	2.23e-5	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9361491	0.657	rs9343804	chr6:79468052	G/A	cg04547799	chr6:79944526	HMGN3	-0.67	-4.68	-0.43	9.43e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8114671	0.539	rs2064453	chr20:33460810	T/C	cg08999081	chr20:33150536	PIGU	0.63	5.05	0.46	2.1e-6	Height;
THYM	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg11764359	chr7:65958608	NA	-0.81	-6.42	-0.55	5.45e-9	Aortic root size;
THYM	cis	rs17030434	0.728	rs16998891	chr4:154646419	T/G	cg14289246	chr4:154710475	SFRP2	-0.8	-5.23	-0.47	1.01e-6	Electrocardiographic conduction measures;
THYM	cis	rs12291225	0.679	rs11023170	chr11:14294909	A/G	cg19336497	chr11:14380999	RRAS2	-0.82	-9.53	-0.7	1.67e-15	Sense of smell;
THYM	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg04267008	chr7:1944627	MAD1L1	-0.67	-6.12	-0.53	2.07e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg11764359	chr7:65958608	NA	0.86	7.24	0.6	1.17e-10	Aortic root size;
THYM	cis	rs1799949	0.832	rs2070835	chr17:41174025	A/C	cg25072359	chr17:41440525	NA	0.66	4.5	0.42	1.93e-5	Menopause (age at onset);
THYM	cis	rs6860806	0.531	rs270612	chr5:131637338	G/A	cg12564285	chr5:131593104	PDLIM4	0.46	5.01	0.46	2.49e-6	Breast cancer;
THYM	cis	rs11563648	0.573	rs10241265	chr7:126948370	C/T	cg08586737	chr7:127225949	GCC1	-0.34	-4.59	-0.43	1.36e-5	Resting heart rate;
THYM	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12540874	0.965	rs9791887	chr7:50661170	A/C	cg18232548	chr7:50535776	DDC	-0.58	-4.56	-0.42	1.52e-5	Systemic sclerosis;
THYM	cis	rs4589258	0.788	rs2226920	chr11:90464388	G/A	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.93	-0.45	3.53e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3741151	0.773	rs73543000	chr11:73151774	T/C	cg12959048	chr11:73096162	RELT	-0.53	-5.08	-0.46	1.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs4866334	1.000	rs74851546	chr5:18487135	C/T	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs7804356	0.871	rs4722630	chr7:26773364	G/T	cg24979288	chr7:27242424	NA	0.62	4.48	0.42	2.09e-5	Type 1 diabetes;
THYM	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8114671	0.773	rs3746438	chr20:33584289	C/T	cg08999081	chr20:33150536	PIGU	-0.56	-4.96	-0.45	3.13e-6	Height;
THYM	cis	rs7084402	1.000	rs1863665	chr10:60266640	T/C	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs7172677	0.961	rs12102035	chr15:75418871	A/G	cg09165964	chr15:75287851	SCAMP5	-0.6	-4.45	-0.42	2.33e-5	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg16405210	chr4:1374714	KIAA1530	-0.67	-5.53	-0.49	2.77e-7	Longevity;
THYM	cis	rs6430585	0.941	rs60963894	chr2:136539670	T/G	cg20242066	chr2:136595261	LCT	0.55	5.64	0.5	1.73e-7	Corneal structure;
THYM	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg05707623	chr12:122985044	ZCCHC8	0.75	5.1	0.46	1.7e-6	Body mass index;
THYM	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7000551	0.671	rs7812987	chr8:22289166	G/A	cg12081754	chr8:22256438	SLC39A14	1.03	8.83	0.67	5.27e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9527	0.615	rs7080462	chr10:104736699	T/C	cg15744005	chr10:104629667	AS3MT	-0.61	-4.55	-0.42	1.61e-5	Arsenic metabolism;
THYM	cis	rs7843479	1.000	rs727694	chr8:21849962	T/C	cg17168535	chr8:21777572	XPO7	0.64	4.77	0.44	6.53e-6	Mean corpuscular volume;
THYM	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg15592062	chr6:167189543	RPS6KA2	-0.49	-5.05	-0.46	2.16e-6	Crohn's disease;
THYM	cis	rs56104184	0.779	rs2131093	chr19:49350693	A/T	cg17863274	chr19:49399704	TULP2	-0.83	-4.87	-0.45	4.42e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7669967	0.554	rs11099977	chr4:156058277	C/T	cg17641028	chr4:156585641	NA	-0.59	-5.24	-0.47	9.58e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs11651000	0.857	rs11658383	chr17:45842354	A/C	cg25856473	chr17:45174155	NA	0.57	4.49	0.42	2.03e-5	IgG glycosylation;
THYM	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg06453172	chr10:134556979	INPP5A	-0.63	-4.55	-0.42	1.56e-5	Migraine;
THYM	cis	rs6430585	0.528	rs75667274	chr2:136682486	C/T	cg07169764	chr2:136633963	MCM6	1.16	9.66	0.7	8.72e-16	Corneal structure;
THYM	cis	rs2109514	0.740	rs12706089	chr7:116084367	C/T	cg12739419	chr7:116140593	CAV2	0.49	4.82	0.44	5.46e-6	Prevalent atrial fibrillation;
THYM	cis	rs9324022	0.929	rs9635184	chr14:101173056	C/T	cg18089426	chr14:101175970	NA	0.78	4.88	0.45	4.25e-6	Plateletcrit;
THYM	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	5.61	0.5	1.96e-7	Tonsillectomy;
THYM	cis	rs1670533	1.000	rs2290410	chr4:1052078	A/T	cg27284194	chr4:1044797	NA	0.62	4.51	0.42	1.86e-5	Recombination rate (females);
THYM	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg26412358	chr1:26503933	CNKSR1	0.36	5.01	0.46	2.48e-6	Height;
THYM	cis	rs10779751	0.887	rs6686835	chr1:11305316	G/A	cg08854313	chr1:11322531	MTOR	0.99	8.95	0.68	2.85e-14	Body mass index;
THYM	cis	rs4731207	0.596	rs6466963	chr7:124572288	G/A	cg05285228	chr7:124571219	POT1	-0.69	-5.25	-0.47	9.35e-7	Cutaneous malignant melanoma;
THYM	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7523273	0.925	rs4844394	chr1:208000625	C/T	cg22525895	chr1:207977042	MIR29B2	-0.83	-7.9	-0.63	4.95e-12	Schizophrenia;
THYM	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg01097406	chr16:89675127	NA	0.88	7.87	0.63	5.52e-12	Vitiligo;
THYM	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg14829155	chr15:31115871	NA	0.52	4.88	0.45	4.27e-6	Huntington's disease progression;
THYM	trans	rs11109072	1.000	rs7975704	chr12:97912363	G/C	cg17633015	chr7:2020501	MAD1L1	1.0	7.4	0.6	5.45e-11	Obesity (early onset extreme);
THYM	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg03929089	chr4:120376271	NA	-0.98	-10.36	-0.73	2.8e-17	Coronary artery disease;
THYM	cis	rs2080501	0.601	rs12919799	chr16:49668955	C/T	cg03087880	chr16:49666012	ZNF423	-0.7	-9.06	-0.68	1.71e-14	IgG glycosylation;
THYM	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg26384229	chr12:38710491	ALG10B	0.95	7.55	0.61	2.7e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg05234568	chr11:5960015	NA	-0.6	-4.84	-0.44	4.97e-6	DNA methylation (variation);
THYM	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4713118	0.588	rs200994	chr6:27813813	A/C	cg23161317	chr6:28129485	ZNF389	-0.69	-4.5	-0.42	1.95e-5	Parkinson's disease;
THYM	cis	rs10256972	0.642	rs6961424	chr7:1004113	T/C	cg07930192	chr7:1003750	NA	0.87	7.63	0.62	1.8e-11	Longevity;Endometriosis;
THYM	cis	rs10982256	0.763	rs1535965	chr9:117273208	C/T	cg15903421	chr9:117267460	DFNB31	-0.57	-5.45	-0.49	3.91e-7	Bipolar disorder;
THYM	cis	rs4455778	0.657	rs10233258	chr7:49003132	T/A	cg26309511	chr7:48887640	NA	-0.56	-5.19	-0.47	1.18e-6	Lung cancer in never smokers;
THYM	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg13010199	chr12:38710504	ALG10B	-0.63	-5.06	-0.46	2.06e-6	Morning vs. evening chronotype;
THYM	cis	rs113835537	0.529	rs2279865	chr11:66203025	A/C	cg24851651	chr11:66362959	CCS	0.64	4.65	0.43	1.09e-5	Airway imaging phenotypes;
THYM	cis	rs28374715	0.617	rs16971733	chr15:41562030	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.94	-8.33	-0.65	5.91e-13	Ulcerative colitis;
THYM	cis	rs3768617	0.510	rs7549768	chr1:183097382	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.91	0.45	3.8e-6	Fuchs's corneal dystrophy;
THYM	cis	rs1160297	0.609	rs7577692	chr2:53105969	T/C	cg07782112	chr2:53107842	NA	0.78	6.68	0.57	1.61e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs9583531	0.600	rs6492306	chr13:111361693	G/A	cg24331049	chr13:111365604	ING1	0.72	5.88	0.52	6.16e-8	Coronary artery disease;
THYM	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg00339695	chr16:24857497	SLC5A11	0.7	6.53	0.56	3.28e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4919687	0.550	rs12775883	chr10:104485301	G/A	cg15744005	chr10:104629667	AS3MT	-0.61	-4.71	-0.44	8.29e-6	Colorectal cancer;
THYM	trans	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg18335740	chr13:41363409	SLC25A15	0.7	7.5	0.61	3.31e-11	Lewy body disease;
THYM	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg04731861	chr2:219085781	ARPC2	-0.54	-5.22	-0.47	1.03e-6	Colorectal cancer;
THYM	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg11764359	chr7:65958608	NA	0.61	4.53	0.42	1.7e-5	Aortic root size;
THYM	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg00024416	chr22:24240387	NA	-0.69	-8.01	-0.63	2.91e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg16928487	chr17:17741425	SREBF1	-0.57	-5.63	-0.5	1.79e-7	Total body bone mineral density;
THYM	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.74	8.12	0.64	1.67e-12	Prudent dietary pattern;
THYM	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg16558253	chr16:72132732	DHX38	-0.57	-4.83	-0.44	5.22e-6	Fibrinogen levels;
THYM	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg10589385	chr1:150898437	SETDB1	0.62	5.08	0.46	1.9e-6	Melanoma;
THYM	cis	rs10901296	0.660	rs11991	chr9:133762558	T/C	cg09374774	chr9:134151945	FAM78A	-0.92	-4.48	-0.42	2.08e-5	Bilirubin levels;
THYM	cis	rs9644630	1.000	rs6988743	chr8:19369583	C/A	cg01280390	chr8:19363452	CSGALNACT1	0.78	8.32	0.65	6.36e-13	Oropharynx cancer;
THYM	cis	rs3126085	1.000	rs72696989	chr1:152248674	A/C	cg10321714	chr1:152280068	FLG	-0.76	-5.68	-0.5	1.47e-7	Atopic dermatitis;
THYM	cis	rs67385638	0.862	rs11036641	chr11:5310578	A/G	cg12559170	chr11:5275217	HBG2	0.71	5.82	0.51	7.96e-8	Hemoglobin levels;
THYM	cis	rs2229238	0.911	rs73023339	chr1:154510852	C/T	cg21262032	chr1:154437693	IL6R	-0.63	-5.65	-0.5	1.68e-7	Coronary heart disease;
THYM	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22590775	chr19:49891494	CCDC155	0.63	4.8	0.44	5.89e-6	Multiple sclerosis;
THYM	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.06	9.59	0.7	1.27e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1461503	0.932	rs10790542	chr11:122838243	C/T	cg27398637	chr11:122830231	C11orf63	-0.7	-6.69	-0.57	1.51e-9	Menarche (age at onset);
THYM	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg04607235	chr12:12878440	APOLD1	-0.91	-5.43	-0.49	4.36e-7	Systemic lupus erythematosus;
THYM	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg15592062	chr6:167189543	RPS6KA2	-0.58	-5.81	-0.51	8.31e-8	Crohn's disease;
THYM	cis	rs7267979	1.000	rs1888997	chr20:25298988	G/A	cg08601574	chr20:25228251	PYGB	-0.57	-4.59	-0.43	1.35e-5	Liver enzyme levels (alkaline phosphatase);
THYM	trans	rs7794364	0.658	rs35895632	chr7:117506470	C/G	cg21837391	chr1:1159412	SDF4	0.92	7.57	0.61	2.37e-11	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs2859741	0.546	rs10489413	chr1:37513906	C/T	cg09363841	chr1:37513479	NA	-0.79	-7.0	-0.58	3.66e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs17006441	0.932	rs7624235	chr3:69844879	A/G	cg18496212	chr3:69797108	MITF	0.7	7.17	0.59	1.64e-10	Hemoglobin concentration;
THYM	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg00012203	chr2:219082015	ARPC2	-0.62	-4.89	-0.45	4.02e-6	Pyoderma gangrenosum in inflammatory bowel disease;
THYM	cis	rs62070183	0.882	rs17183628	chr17:31184631	C/T	cg02981443	chr17:31254875	TMEM98	0.54	4.91	0.45	3.73e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs792448	0.603	rs12024665	chr1:212499895	C/T	cg14523881	chr1:213164074	VASH2	0.58	4.62	0.43	1.19e-5	White blood cell count (basophil);
THYM	cis	rs240764	0.764	rs13201976	chr6:100933185	T/A	cg21058520	chr6:100914733	NA	0.53	4.74	0.44	7.43e-6	Neuroticism;
THYM	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg00677455	chr12:58241039	CTDSP2	0.72	5.29	0.48	7.78e-7	Intelligence (multi-trait analysis);
THYM	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg09085632	chr11:111637200	PPP2R1B	1.11	11.2	0.75	4.55e-19	Primary sclerosing cholangitis;
THYM	cis	rs6754311	0.509	rs10188066	chr2:136539513	G/A	cg23851026	chr2:136556271	LCT	-0.61	-6.01	-0.53	3.36e-8	Mosquito bite size;
THYM	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg27572855	chr1:25598939	RHD	0.69	5.34	0.48	6.29e-7	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs2997447	0.761	rs61776585	chr1:26438498	G/C	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs8048589	0.948	rs35318501	chr16:12182531	A/C	cg02910054	chr16:12241554	SNX29	0.66	4.92	0.45	3.62e-6	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs4638749	0.501	rs9653451	chr2:108781858	A/G	cg25838818	chr2:108905173	SULT1C2	-0.51	-4.77	-0.44	6.71e-6	Blood pressure;
THYM	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg24642844	chr7:1081250	C7orf50	-1.13	-7.19	-0.59	1.46e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg11673840	chr17:47092156	IGF2BP1	0.62	8.2	0.64	1.11e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg09307838	chr4:120376055	NA	-0.71	-5.05	-0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs4953076	0.533	rs1551315	chr2:44407618	G/A	cg04920474	chr2:44395004	PPM1B	0.63	5.16	0.47	1.36e-6	Height;
THYM	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg17143192	chr8:8559678	CLDN23	0.92	6.72	0.57	1.37e-9	Obesity-related traits;
THYM	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg17689763	chr4:710664	PCGF3	-1.08	-9.75	-0.71	5.54e-16	White blood cell count;
THYM	cis	rs11677370	0.603	rs11675498	chr2:3850943	G/T	cg17052675	chr2:3827356	NA	-0.71	-6.57	-0.56	2.7e-9	Type 2 diabetes;
THYM	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs9790314	0.846	rs7636941	chr3:160993928	A/G	cg03342759	chr3:160939853	NMD3	-0.95	-9.47	-0.7	2.2e-15	Morning vs. evening chronotype;
THYM	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14159672	chr1:205819179	PM20D1	0.97	10.17	0.72	7.06e-17	Menarche (age at onset);
THYM	cis	rs921968	0.643	rs1055816	chr2:219501328	G/A	cg02176678	chr2:219576539	TTLL4	0.6	5.84	0.51	7.3e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg00012203	chr2:219082015	ARPC2	-0.62	-4.88	-0.45	4.28e-6	Colorectal cancer;
THYM	cis	rs240764	0.658	rs7747014	chr6:101201898	T/G	cg21058520	chr6:100914733	NA	0.6	5.28	0.48	8.25e-7	Neuroticism;
THYM	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg09307838	chr4:120376055	NA	0.71	5.07	0.46	1.98e-6	Corneal astigmatism;
THYM	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.36	0.69	3.89e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4455778	0.561	rs56235551	chr7:49128132	C/T	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg00666640	chr1:248458726	OR2T12	0.56	4.61	0.43	1.26e-5	Common traits (Other);
THYM	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg00129232	chr17:37814104	STARD3	0.69	4.45	0.42	2.32e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg03806693	chr22:41940476	POLR3H	1.21	10.48	0.73	1.56e-17	Vitiligo;
THYM	cis	rs11886999	0.723	rs3852673	chr2:96919642	C/T	cg18419276	chr2:96971862	SNRNP200	-0.51	-4.85	-0.45	4.85e-6	Cardiac Troponin-T levels;
THYM	cis	rs586688	0.625	rs654631	chr1:201658449	C/T	cg14168733	chr1:201708718	NAV1	0.6	5.55	0.49	2.61e-7	Obesity-related traits;
THYM	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg18876405	chr7:65276391	NA	0.77	7.26	0.6	1.05e-10	Aortic root size;
THYM	cis	rs79149102	0.579	rs79916508	chr15:75373721	A/C	cg09165964	chr15:75287851	SCAMP5	-0.92	-5.22	-0.47	1.04e-6	Lung cancer;
THYM	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg10792982	chr14:105748885	BRF1	0.73	7.54	0.61	2.72e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg15744005	chr10:104629667	AS3MT	-0.86	-7.94	-0.63	3.99e-12	Arsenic metabolism;
THYM	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg24375607	chr4:120327624	NA	0.58	4.74	0.44	7.61e-6	Corneal astigmatism;
THYM	cis	rs72781680	1.000	rs72781675	chr2:24232092	G/A	cg08917208	chr2:24149416	ATAD2B	1.07	4.79	0.44	6.13e-6	Lymphocyte counts;
THYM	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg12463550	chr7:65579703	CRCP	-0.57	-4.76	-0.44	7.01e-6	Aortic root size;
THYM	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2075230	0.705	rs1641525	chr17:7549211	A/G	cg27413385	chr17:7515425	FXR2	0.36	5.1	0.46	1.72e-6	Hormone measurements;
THYM	cis	rs9677476	0.779	rs12612219	chr2:232107363	G/T	cg23338755	chr2:231921595	PSMD1	0.76	4.95	0.45	3.17e-6	Food antigen IgG levels;
THYM	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg10760299	chr15:45669010	GATM	0.91	7.05	0.59	2.89e-10	Homoarginine levels;
THYM	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg15997130	chr1:24165203	NA	0.74	6.34	0.55	7.69e-9	Immature fraction of reticulocytes;
THYM	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs1050631	0.564	rs1785925	chr18:33727186	C/A	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.6	4.69	0.43	9.09e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs7181230	1.000	rs11638521	chr15:40360314	T/C	cg20592017	chr15:40364740	NA	-0.58	-5.44	-0.49	4.22e-7	Dehydroepiandrosterone sulphate levels;
THYM	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg02734326	chr4:10020555	SLC2A9	0.76	6.18	0.54	1.58e-8	Bone mineral density;
THYM	cis	rs28595532	0.841	rs115987912	chr4:119737085	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs912057	0.671	rs1294417	chr6:6741932	T/C	cg06612196	chr6:6737390	NA	0.74	12.02	0.78	8.85e-21	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg26513180	chr16:89883248	FANCA	0.54	5.11	0.46	1.65e-6	Vitiligo;
THYM	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg26721908	chr21:47610096	LSS	0.87	6.77	0.57	1.08e-9	Testicular germ cell tumor;
THYM	cis	rs78366141	0.649	rs7666372	chr4:89687531	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	1.2	4.98	0.45	2.85e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-6.98	-0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg06627628	chr2:24431161	ITSN2	-0.73	-5.17	-0.47	1.31e-6	Asthma;
THYM	cis	rs4523957	0.583	rs4349181	chr17:2040963	A/G	cg16513277	chr17:2031491	SMG6	-1.03	-10.01	-0.72	1.6e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2410601	0.562	rs13275125	chr8:18898352	T/A	cg19414122	chr8:18896631	NA	0.7	5.57	0.5	2.41e-7	Urinary albumin excretion rate in type 1 diabetes;
THYM	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg00129232	chr17:37814104	STARD3	-0.88	-7.23	-0.6	1.24e-10	Asthma;
THYM	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg19508488	chr2:152266495	RIF1	0.82	6.77	0.57	1.05e-9	Lung cancer;
THYM	cis	rs11048434	0.761	rs11494570	chr12:9127147	T/C	cg04155231	chr12:9217510	LOC144571	0.49	4.69	0.43	9.28e-6	Sjögren's syndrome;
THYM	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg17401067	chr22:41840292	TOB2	0.52	4.96	0.45	3.14e-6	Vitiligo;
THYM	cis	rs6546537	0.869	rs13035491	chr2:69827456	G/A	cg10773587	chr2:69614142	GFPT1	-0.53	-4.53	-0.42	1.72e-5	Serum thyroid-stimulating hormone levels;
THYM	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg17279839	chr7:150038598	RARRES2	0.55	4.9	0.45	3.88e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs600806	0.815	rs10858089	chr1:109926828	T/C	cg23032129	chr1:109941072	SORT1	-0.59	-5.03	-0.46	2.31e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1401999	0.807	rs9869029	chr3:183735286	C/G	cg20387954	chr3:183756860	HTR3D	0.54	4.59	0.43	1.37e-5	Anterior chamber depth;
THYM	cis	rs4731207	0.661	rs6466956	chr7:124520366	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs11608355	1.000	rs10774695	chr12:109868040	G/A	cg10504392	chr12:110044639	NA	0.67	6.21	0.54	1.41e-8	Neuroticism;
THYM	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.9	0.45	3.94e-6	Prudent dietary pattern;
THYM	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg24209194	chr3:40518798	ZNF619	0.64	5.14	0.47	1.45e-6	Renal cell carcinoma;
THYM	cis	rs986417	1.000	rs713336	chr14:60974958	T/G	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg00071950	chr4:10020882	SLC2A9	-0.61	-5.89	-0.52	5.83e-8	Bone mineral density;
THYM	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg08975724	chr8:8085496	FLJ10661	-0.59	-4.71	-0.44	8.3e-6	Mood instability;
THYM	cis	rs11937061	0.539	rs13130398	chr4:78159988	C/T	cg01930676	chr4:78783082	MRPL1	-0.57	-4.63	-0.43	1.17e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7940866	0.834	rs1594821	chr11:130835883	C/T	cg12179176	chr11:130786555	SNX19	0.61	4.63	0.43	1.17e-5	Schizophrenia;
THYM	cis	rs669446	0.591	rs649504	chr1:44105948	T/C	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs9467711	0.651	rs67491322	chr6:25961352	C/T	cg12826209	chr6:26865740	GUSBL1	1.08	4.52	0.42	1.77e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.71	5.65	0.5	1.69e-7	Tonsillectomy;
THYM	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.56	-5.13	-0.47	1.51e-6	Type 2 diabetes;
THYM	cis	rs4919694	1.000	rs12254254	chr10:104765605	C/T	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	cis	rs41311933	0.901	rs41260544	chr9:123744252	A/G	cg13567360	chr9:123745713	C5	-0.97	-4.94	-0.45	3.34e-6	Coronary artery disease;
THYM	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg09307838	chr4:120376055	NA	0.68	5.14	0.47	1.46e-6	Corneal astigmatism;
THYM	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg13390004	chr1:15929781	NA	0.63	4.79	0.44	6.2e-6	Systolic blood pressure;
THYM	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.69	5.65	0.5	1.67e-7	Blood metabolite levels;
THYM	cis	rs2554380	0.943	rs2562777	chr15:84366066	C/T	cg14598478	chr15:84363061	ADAMTSL3	-0.61	-4.97	-0.45	3e-6	Height;
THYM	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.71	-4.55	-0.42	1.61e-5	Mean platelet volume;
THYM	cis	rs13006833	1.000	rs13006833	chr2:191205499	G/C	cg21644426	chr2:191273491	MFSD6	0.66	4.64	0.43	1.11e-5	Urinary metabolites;
THYM	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	5.79	0.51	8.99e-8	Lung cancer in ever smokers;
THYM	cis	rs6032067	0.925	rs35875037	chr20:43859921	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg14895029	chr7:2775587	GNA12	-0.7	-5.09	-0.46	1.83e-6	Height;
THYM	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.25	-0.47	9.43e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7584330	0.518	rs80282956	chr2:238447929	G/A	cg08992911	chr2:238395768	MLPH	0.9	5.47	0.49	3.65e-7	Prostate cancer;
THYM	cis	rs17001868	0.568	rs73167007	chr22:40734241	G/C	cg07138101	chr22:40742427	ADSL	0.82	4.85	0.45	4.8e-6	Mammographic density (dense area);
THYM	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs3820068	0.705	rs4646022	chr1:15839112	G/A	cg05660106	chr1:15850417	CASP9	1.09	9.77	0.71	5.15e-16	Systolic blood pressure;
THYM	cis	rs877282	0.891	rs11595385	chr10:800539	A/G	cg10556349	chr10:835070	NA	-0.75	-4.84	-0.44	5.05e-6	Uric acid levels;
THYM	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg00990874	chr7:1149470	C7orf50	-0.7	-5.23	-0.47	1.03e-6	Bronchopulmonary dysplasia;
THYM	cis	rs2985684	1.000	rs1957977	chr14:50090603	A/G	cg02151108	chr14:50098012	C14orf104	-0.68	-5.42	-0.49	4.54e-7	Carotid intima media thickness;
THYM	cis	rs72627509	0.904	rs12645070	chr4:57770106	G/A	cg26694713	chr4:57773883	REST	0.77	4.68	0.43	9.34e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg07061783	chr6:25882402	NA	0.73	5.88	0.52	6.22e-8	Intelligence (multi-trait analysis);
THYM	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg17333051	chr19:2783644	SGTA	0.71	6.13	0.53	1.95e-8	Total cholesterol levels;
THYM	cis	rs72949976	0.646	rs13029384	chr2:214029164	G/A	cg08319019	chr2:214017104	IKZF2	0.77	6.51	0.56	3.54e-9	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg03433033	chr1:76189801	ACADM	0.77	9.42	0.69	2.92e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs5758511	0.773	rs11913631	chr22:42347371	G/T	cg08431931	chr22:42394659	WBP2NL	0.71	4.46	0.42	2.25e-5	Birth weight;
THYM	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg00898013	chr13:113819073	PROZ	-0.87	-8.8	-0.67	6.16e-14	Platelet distribution width;
THYM	cis	rs1050631	0.564	rs12185396	chr18:33738496	C/T	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.63	4.91	0.45	3.85e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs1609391	0.561	rs9289523	chr3:136635589	C/G	cg15507776	chr3:136538369	TMEM22	0.64	4.9	0.45	4.02e-6	Neuroticism;
THYM	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg18230493	chr5:56204884	C5orf35	-0.89	-6.53	-0.56	3.25e-9	Initial pursuit acceleration;
THYM	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg08873628	chr1:175162347	KIAA0040	0.51	4.59	0.43	1.34e-5	Alcohol dependence;
THYM	cis	rs4730268	0.768	rs79139176	chr7:107438298	C/G	cg18560240	chr7:107437656	SLC26A3	-0.93	-5.18	-0.47	1.22e-6	IgG glycosylation;
THYM	cis	rs758324	0.687	rs156057	chr5:131478034	T/C	cg16205897	chr5:131564050	P4HA2	0.61	5.04	0.46	2.2e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg09990169	chr2:241835740	C2orf54	-0.37	-6.37	-0.55	6.84e-9	Urinary metabolites;
THYM	cis	rs6754311	0.593	rs4954279	chr2:136409073	G/A	cg04750100	chr2:136595281	LCT	0.56	5.81	0.51	8.48e-8	Mosquito bite size;
THYM	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg12908607	chr1:44402522	ARTN	-0.54	-5.03	-0.46	2.33e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7915131	1.000	rs7915131	chr10:64418656	A/G	cg03961010	chr10:64397487	ZNF365	0.72	5.26	0.48	8.8e-7	Schizophrenia;
THYM	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg18477163	chr1:228402036	OBSCN	0.64	6.29	0.54	9.81e-9	Diastolic blood pressure;
THYM	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg01710189	chr8:22454888	PDLIM2	-0.55	-5.72	-0.51	1.21e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg11764359	chr7:65958608	NA	0.85	7.04	0.59	2.94e-10	Aortic root size;
THYM	cis	rs78366141	0.649	rs78114325	chr4:89682189	T/C	cg01026744	chr4:89619053	NAP1L5;HERC3	1.14	4.83	0.44	5.28e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg22166914	chr1:53195759	ZYG11B	-0.95	-12.16	-0.78	4.4e-21	Monocyte count;
THYM	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg19761014	chr17:28927070	LRRC37B2	0.8	4.73	0.44	7.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3820068	0.608	rs58140482	chr1:16043979	A/G	cg24675056	chr1:15929824	NA	0.78	6.16	0.53	1.73e-8	Systolic blood pressure;
THYM	cis	rs4919694	1.000	rs35159404	chr10:104805610	C/A	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	cis	rs7107174	0.892	rs10431155	chr11:78121978	T/C	cg02023728	chr11:77925099	USP35	0.64	6.0	0.52	3.64e-8	Testicular germ cell tumor;
THYM	cis	rs7584330	0.657	rs10190310	chr2:238352282	C/T	cg14458575	chr2:238380390	NA	0.89	6.93	0.58	4.97e-10	Prostate cancer;
THYM	cis	rs4478037	0.822	rs9827863	chr3:33118951	C/T	cg19404215	chr3:33155277	CRTAP	-1.07	-6.92	-0.58	5.22e-10	Major depressive disorder;
THYM	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg10518543	chr12:38710700	ALG10B	-0.54	-4.54	-0.42	1.65e-5	Morning vs. evening chronotype;
THYM	cis	rs67460515	0.926	rs66508859	chr3:160946351	C/T	cg03342759	chr3:160939853	NMD3	-0.93	-7.98	-0.63	3.34e-12	Parkinson's disease;
THYM	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg03806693	chr22:41940476	POLR3H	-1.02	-9.07	-0.68	1.58e-14	Vitiligo;
THYM	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.41	-6.4	-0.55	5.78e-9	Obesity-related traits;
THYM	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg09035930	chr12:129282057	SLC15A4	0.85	10.44	0.73	1.93e-17	Systemic lupus erythematosus;
THYM	cis	rs863345	0.604	rs10908674	chr1:158503920	A/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg23711669	chr6:146136114	FBXO30	-0.83	-7.72	-0.62	1.18e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg02931644	chr1:25747376	RHCE	0.62	4.83	0.44	5.24e-6	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs7020830	0.931	rs13297576	chr9:37142189	A/C	cg14294708	chr9:37120828	ZCCHC7	1.34	18.37	0.88	4.93e-33	Schizophrenia;
THYM	cis	rs9329289	0.590	rs11251295	chr10:2563183	C/T	cg15501526	chr10:2543763	NA	0.64	6.27	0.54	1.04e-8	Age-related hearing impairment;
THYM	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg04398451	chr17:18023971	MYO15A	-0.95	-10.09	-0.72	1.06e-16	Total body bone mineral density;
THYM	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg02380750	chr20:61661411	NA	0.61	6.14	0.53	1.94e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs752010	0.695	rs10890155	chr1:42107843	C/T	cg06885757	chr1:42089581	HIVEP3	0.49	5.95	0.52	4.46e-8	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs240764	0.658	rs7451736	chr6:101189901	C/T	cg21058520	chr6:100914733	NA	0.56	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg18105134	chr13:113819100	PROZ	0.98	9.05	0.68	1.79e-14	Platelet distribution width;
THYM	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg13695892	chr22:41940480	POLR3H	-0.84	-6.25	-0.54	1.16e-8	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7084402	0.967	rs1649015	chr10:60289031	A/G	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11890956	chr21:40555474	PSMG1	-0.95	-10.91	-0.75	1.91e-18	Cognitive function;
THYM	cis	rs7072216	0.727	rs10748728	chr10:100171198	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs11552708	0.504	rs9890935	chr17:7391282	A/G	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	IgM levels;
THYM	cis	rs3862030	0.720	rs7081110	chr10:104231651	A/G	cg00122347	chr10:104236741	TMEM180	0.46	6.63	0.56	2.04e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg06238570	chr21:40685208	BRWD1	0.91	6.77	0.57	1.08e-9	Cognitive function;
THYM	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg00786635	chr1:25594202	NA	-0.91	-7.63	-0.62	1.81e-11	Erythrocyte sedimentation rate;
THYM	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg25554036	chr4:6271136	WFS1	0.5	4.53	0.42	1.69e-5	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs877282	0.735	rs111609055	chr10:826539	A/G	cg10556349	chr10:835070	NA	-0.76	-5.34	-0.48	6.39e-7	Uric acid levels;
THYM	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs6918586	1.000	rs198806	chr6:26133616	A/G	cg07061783	chr6:25882402	NA	0.57	4.45	0.42	2.36e-5	Schizophrenia;
THYM	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.84	-5.66	-0.5	1.57e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg18681998	chr4:17616180	MED28	0.84	7.05	0.59	2.89e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg11984989	chr7:158649758	WDR60	1.17	15.57	0.85	6.93e-28	Height;
THYM	cis	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg16898833	chr6:26189333	HIST1H4D	1.33	4.95	0.45	3.27e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg23161317	chr6:28129485	ZNF389	-0.9	-6.59	-0.56	2.41e-9	Parkinson's disease;
THYM	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11671005	0.693	rs34230465	chr19:58943576	C/G	cg18639983	chr19:58920768	ZNF584	0.59	4.82	0.44	5.48e-6	Mean platelet volume;
THYM	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.85	0.51	7e-8	Obesity-related traits;
THYM	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg06808227	chr14:105710500	BRF1	-1.02	-8.92	-0.68	3.29e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-6.35	-0.55	7.49e-9	Electrocardiographic conduction measures;
THYM	trans	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs34638657	0.656	rs2911429	chr16:82203443	T/C	cg07307142	chr16:82071433	HSD17B2	-0.91	-7.2	-0.59	1.39e-10	Lung adenocarcinoma;
THYM	cis	rs7264396	0.790	rs761825	chr20:34194054	A/G	cg26038318	chr20:34205095	SPAG4	0.54	4.73	0.44	7.84e-6	Total cholesterol levels;
THYM	cis	rs4788570	0.615	rs10852502	chr16:71652072	C/A	cg06353428	chr16:71660113	MARVELD3	1.38	8.9	0.67	3.63e-14	Intelligence (multi-trait analysis);
THYM	cis	rs17019602	0.585	rs7527807	chr1:108134110	A/G	cg02990361	chr1:107599529	PRMT6	-0.81	-4.74	-0.44	7.47e-6	IgA nephropathy;
THYM	cis	rs10895275	0.625	rs10791566	chr11:102041261	G/A	cg24447756	chr11:102105824	NA	-0.5	-4.69	-0.43	8.96e-6	Migraine;
THYM	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg15693483	chr7:1102177	C7orf50	0.53	6.19	0.54	1.52e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03576123	chr11:487126	PTDSS2	1.29	6.68	0.57	1.6e-9	Body mass index;
THYM	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.74	5.35	0.48	6.19e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7523273	0.606	rs2761433	chr1:207917361	G/A	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs56309584	0.673	rs7219471	chr17:8121594	G/T	cg11257113	chr17:8062204	NA	-0.61	-4.45	-0.42	2.33e-5	Initial pursuit acceleration;
THYM	cis	rs13315871	0.929	rs35004361	chr3:58313394	T/C	cg00563845	chr3:58318305	PXK	0.6	5.3	0.48	7.63e-7	Cholesterol, total;
THYM	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg20503657	chr10:835505	NA	1.37	9.33	0.69	4.52e-15	Eosinophil percentage of granulocytes;
THYM	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg05738196	chr6:26577821	NA	0.57	4.72	0.44	8.2e-6	Schizophrenia;
THYM	cis	rs4930776	1.000	rs251784	chr12:5770190	C/T	cg02086166	chr12:5775618	ANO2	0.59	5.67	0.5	1.52e-7	Plasma clusterin levels;
THYM	cis	rs778371	0.697	rs2344611	chr2:233581937	A/G	cg08000102	chr2:233561755	GIGYF2	0.79	6.96	0.58	4.28e-10	Schizophrenia;
THYM	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg06108461	chr20:60628389	TAF4	-1.06	-9.1	-0.68	1.39e-14	Body mass index;
THYM	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg20887711	chr4:1340912	KIAA1530	0.61	4.94	0.45	3.31e-6	Obesity-related traits;
THYM	cis	rs988913	1.000	rs9475081	chr6:54813738	G/T	cg18532076	chr6:54711417	FAM83B	0.52	4.79	0.44	6.22e-6	Menarche (age at onset);
THYM	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg22907277	chr7:1156413	C7orf50	0.82	4.98	0.46	2.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7084402	0.967	rs1649069	chr10:60303695	A/G	cg09696939	chr10:60272079	BICC1	0.47	5.64	0.5	1.72e-7	Refractive error;
THYM	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg18132916	chr6:79620363	NA	-0.59	-5.32	-0.48	6.79e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg11327659	chr7:150037044	RARRES2	0.42	4.97	0.45	2.94e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg00012203	chr2:219082015	ARPC2	-0.65	-5.32	-0.48	6.78e-7	Colorectal cancer;
THYM	cis	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg03522245	chr20:25566470	NINL	0.63	4.71	0.44	8.35e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg04520793	chr17:42248056	ASB16	0.33	4.72	0.44	8.05e-6	Total body bone mineral density;
THYM	cis	rs4072705	0.586	rs7023736	chr9:127247946	G/A	cg13476313	chr9:127244764	NR5A1	0.39	5.96	0.52	4.23e-8	Menarche (age at onset);
THYM	cis	rs8078723	0.763	rs4433838	chr17:38143532	C/T	cg17467752	chr17:38218738	THRA	-0.81	-6.72	-0.57	1.36e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs7631605	0.905	rs11129752	chr3:37257793	A/G	cg21328643	chr3:37258149	NA	0.58	5.68	0.5	1.45e-7	Cerebrospinal P-tau181p levels;
THYM	cis	rs790123	0.666	rs790124	chr3:122388605	A/G	cg15604389	chr3:122379662	NA	0.58	4.8	0.44	5.91e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg25767906	chr1:53392781	SCP2	-0.58	-5.78	-0.51	9.55e-8	Monocyte count;
THYM	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.97	-5.47	-0.49	3.59e-7	Red cell distribution width;
THYM	cis	rs10789491	1.000	rs11211342	chr1:47163098	T/C	cg15501359	chr1:47185051	KIAA0494	1.14	8.24	0.65	9.45e-13	Response to hepatitis C treatment;
THYM	cis	rs6840360	0.571	rs17275598	chr4:152568478	C/A	cg22705602	chr4:152727874	NA	-0.8	-8.43	-0.65	3.62e-13	Intelligence (multi-trait analysis);
THYM	cis	rs11225247	0.772	rs12270109	chr11:102229310	G/C	cg06323957	chr11:102217781	BIRC2	1.02	4.79	0.44	6.18e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs12449964	0.524	rs4925092	chr17:17568931	A/G	cg04398451	chr17:18023971	MYO15A	-0.57	-4.57	-0.42	1.46e-5	Coronary artery disease or ischemic stroke;
THYM	cis	rs7196129	0.966	rs11150589	chr16:30482494	T/C	cg24033122	chr16:30485383	ITGAL	0.4	4.89	0.45	4.05e-6	Monocyte count;
THYM	cis	rs747334	0.791	rs1334579	chr10:92732950	C/T	cg07620928	chr10:92689909	NA	0.59	5.27	0.48	8.49e-7	Fibroblast growth factor basic levels;
THYM	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs2985684	1.000	rs11157696	chr14:50105746	C/G	cg02151108	chr14:50098012	C14orf104	0.67	5.42	0.49	4.42e-7	Carotid intima media thickness;
THYM	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg11941060	chr3:133502564	NA	0.69	6.0	0.52	3.57e-8	Iron status biomarkers;
THYM	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs11711311	1.000	rs2305545	chr3:113499733	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.62	-5.52	-0.49	2.89e-7	IgG glycosylation;
THYM	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg05738196	chr6:26577821	NA	-0.97	-9.56	-0.7	1.41e-15	Intelligence (multi-trait analysis);
THYM	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg26513180	chr16:89883248	FANCA	0.5	4.61	0.43	1.26e-5	Vitiligo;
THYM	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg08835221	chr22:38071607	LGALS1	0.37	5.14	0.47	1.45e-6	Fat distribution (HIV);
THYM	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg22681709	chr2:178499509	PDE11A	-0.58	-5.45	-0.49	3.91e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7677751	0.806	rs4864858	chr4:55089953	T/A	cg17187183	chr4:55093834	PDGFRA	0.71	5.49	0.49	3.35e-7	Corneal astigmatism;
THYM	cis	rs12282928	0.729	rs7932309	chr11:48345179	T/C	cg22827986	chr11:48284249	OR4X1	0.53	5.59	0.5	2.21e-7	Migraine - clinic-based;
THYM	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg01528321	chr10:82214614	TSPAN14	0.66	5.16	0.47	1.35e-6	Post bronchodilator FEV1;
THYM	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg17279839	chr7:150038598	RARRES2	0.51	4.51	0.42	1.89e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg06027949	chr8:82754900	SNX16	-0.62	-5.07	-0.46	1.95e-6	Diastolic blood pressure;
THYM	cis	rs4580814	0.869	rs4535497	chr5:1107428	G/T	cg13681701	chr5:1103910	SLC12A7	0.52	5.43	0.49	4.29e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9393692	0.620	rs12525187	chr6:26337537	A/G	cg00631329	chr6:26305371	NA	-0.45	-4.53	-0.42	1.72e-5	Educational attainment;
THYM	cis	rs9462846	1.000	rs9471941	chr6:42857827	C/T	cg10862848	chr6:42927986	GNMT	0.43	4.49	0.42	1.97e-5	Blood protein levels;
THYM	cis	rs596169	0.655	rs1700872	chr1:219182679	C/T	cg19270308	chr1:218458869	RRP15	-1.24	-4.52	-0.42	1.81e-5	Intraocular pressure;
THYM	cis	rs1065852	0.526	rs12166549	chr22:42410419	T/C	cg22189786	chr22:42395067	WBP2NL	0.54	5.55	0.49	2.6e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs7107174	1.000	rs2510039	chr11:77944480	G/A	cg19901956	chr11:77921274	USP35	-0.83	-6.25	-0.54	1.14e-8	Testicular germ cell tumor;
THYM	cis	rs7614311	0.555	rs58676857	chr3:63903883	G/A	cg22134162	chr3:63841271	THOC7	-0.59	-7.26	-0.6	1.05e-10	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs61931739	0.513	rs7956626	chr12:33901640	C/T	cg06521331	chr12:34319734	NA	-0.57	-4.63	-0.43	1.18e-5	Morning vs. evening chronotype;
THYM	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg11764359	chr7:65958608	NA	-0.81	-6.42	-0.55	5.45e-9	Aortic root size;
THYM	cis	rs9915657	0.870	rs12601701	chr17:70115358	G/A	cg06234051	chr17:70120541	SOX9	-0.77	-7.48	-0.61	3.63e-11	Thyroid hormone levels;
THYM	cis	rs6840360	0.642	rs7698816	chr4:152352972	C/T	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.26	-0.47	8.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs55728055	0.661	rs16989760	chr22:31951808	A/G	cg10537193	chr22:32026975	PISD	-0.92	-5.68	-0.5	1.45e-7	Age-related hearing impairment;
THYM	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg06634786	chr22:41940651	POLR3H	0.7	4.96	0.45	3.12e-6	Crohn's disease;Inflammatory bowel disease;
THYM	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg01341218	chr17:43662625	NA	-1.07	-9.27	-0.69	5.9e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	18.08	0.88	1.64e-32	Chronic sinus infection;
THYM	cis	rs10186029	0.676	rs4673721	chr2:213941643	T/G	cg08319019	chr2:214017104	IKZF2	0.8	6.53	0.56	3.29e-9	Systemic sclerosis;
THYM	cis	rs889398	0.741	rs6499268	chr16:69906529	G/A	cg09409435	chr16:70099608	PDXDC2	0.67	5.36	0.48	5.83e-7	Body mass index;
THYM	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg12863693	chr15:85201151	NMB	0.53	4.72	0.44	8.06e-6	Schizophrenia;
THYM	cis	rs10197862	0.518	rs35181686	chr2:103092584	C/G	cg01241218	chr2:102972058	NA	0.67	4.65	0.43	1.07e-5	Asthma and hay fever;Asthma;
THYM	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg18252515	chr7:66147081	NA	-0.62	-4.81	-0.44	5.64e-6	Aortic root size;
THYM	cis	rs2463822	0.583	rs17709552	chr11:62040519	A/G	cg06239285	chr11:62104954	ASRGL1	-1.04	-5.14	-0.47	1.45e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg10802521	chr3:52805072	NEK4	-0.8	-7.53	-0.61	2.92e-11	Bipolar disorder;
THYM	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs1003719	0.667	rs3753073	chr21:38466615	A/G	cg01329690	chr21:38580129	DSCR9	0.36	4.77	0.44	6.72e-6	Eye color traits;
THYM	cis	rs11166927	0.548	rs9324514	chr8:140830241	A/G	cg16909799	chr8:140841666	TRAPPC9	0.82	7.96	0.63	3.59e-12	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg12935359	chr14:103987150	CKB	-0.65	-6.4	-0.55	5.78e-9	Body mass index;
THYM	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06873352	chr17:61820015	STRADA	0.57	5.68	0.5	1.46e-7	Height;
THYM	cis	rs7829975	0.748	rs693109	chr8:8640172	C/A	cg08975724	chr8:8085496	FLJ10661	-0.58	-4.83	-0.44	5.15e-6	Mood instability;
THYM	cis	rs977987	0.843	rs67409275	chr16:75457212	T/C	cg03315344	chr16:75512273	CHST6	0.76	6.27	0.54	1.05e-8	Dupuytren's disease;
THYM	cis	rs2070488	0.932	rs1841776	chr3:38480727	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	7.18	0.59	1.57e-10	Electrocardiographic conduction measures;
THYM	cis	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg21775007	chr8:11205619	TDH	-0.65	-5.18	-0.47	1.24e-6	Retinal vascular caliber;
THYM	cis	rs2717559	0.542	rs2585156	chr8:143879795	G/A	cg03405983	chr8:143858548	LYNX1	-0.54	-5.79	-0.51	9.18e-8	Urinary tract infection frequency;
THYM	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg10518543	chr12:38710700	ALG10B	-0.59	-4.97	-0.45	3.01e-6	Morning vs. evening chronotype;
THYM	cis	rs10501293	0.709	rs10742664	chr11:43034588	G/A	cg03447554	chr11:43094025	NA	0.61	4.51	0.42	1.83e-5	Cognitive performance;
THYM	cis	rs887829	0.588	rs4663969	chr2:234655313	C/A	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.57	-4.52	-0.42	1.76e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg08645402	chr16:4508243	NA	0.7	6.17	0.53	1.67e-8	Schizophrenia;
THYM	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg19418458	chr7:158789849	NA	-0.66	-5.78	-0.51	9.26e-8	Facial morphology (factor 20);
THYM	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg23281280	chr6:28129359	ZNF389	0.61	4.94	0.45	3.3e-6	Depression;
THYM	cis	rs9302690	1.000	rs7192201	chr16:57436587	T/C	cg27017172	chr16:57497170	POLR2C	0.82	4.88	0.45	4.29e-6	Blood protein levels;
THYM	cis	rs3772130	0.603	rs35489993	chr3:121411876	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.72	5.92	0.52	5.13e-8	Cognitive performance;
THYM	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs56104184	0.830	rs73061617	chr19:49350984	G/A	cg15549821	chr19:49342101	PLEKHA4	-1.19	-6.09	-0.53	2.39e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs6964587	0.655	rs6965864	chr7:91595596	A/G	cg17063962	chr7:91808500	NA	1.01	9.06	0.68	1.69e-14	Breast cancer;
THYM	cis	rs477692	0.655	rs7906680	chr10:131442671	C/G	cg05714579	chr10:131428358	MGMT	-0.83	-7.01	-0.58	3.51e-10	Response to temozolomide;
THYM	cis	rs7646881	0.904	rs112493023	chr3:158448276	A/G	cg19483011	chr3:158453295	NA	-0.68	-4.73	-0.44	7.86e-6	Tetralogy of Fallot;
THYM	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.76	5.89	0.52	5.93e-8	Eosinophil percentage of white cells;
THYM	cis	rs72829446	0.530	rs7222404	chr17:7384198	G/A	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03517284	chr6:25882590	NA	-0.68	-5.11	-0.46	1.69e-6	Height;
THYM	cis	rs6901250	1.000	rs6901250	chr6:117114025	A/G	cg12892004	chr6:117198278	RFX6	-0.7	-6.41	-0.55	5.7e-9	C-reactive protein levels;
THYM	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg07061783	chr6:25882402	NA	-0.71	-5.85	-0.51	6.86e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7731657	0.537	rs7726927	chr5:130215211	G/T	cg08523029	chr5:130500466	HINT1	-0.86	-5.85	-0.51	6.92e-8	Fasting plasma glucose;
THYM	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1747683	0.966	rs10796059	chr10:13368987	T/C	cg11679871	chr10:13388567	SEPHS1	-0.31	-4.6	-0.43	1.3e-5	IgG glycosylation;
THYM	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg02640540	chr1:67518911	SLC35D1	0.64	4.68	0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	12.82	0.8	1.97e-22	Chronic sinus infection;
THYM	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg27532560	chr4:187881888	NA	-0.95	-11.68	-0.77	4.63e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.39	6.97	0.58	4.15e-10	Obesity-related traits;
THYM	cis	rs12765878	0.603	rs1570221	chr10:105656874	G/A	cg04688330	chr10:105451802	SH3PXD2A	0.37	4.54	0.42	1.64e-5	Coronary artery disease;
THYM	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg06766960	chr11:133703094	NA	-0.52	-4.83	-0.44	5.25e-6	Childhood ear infection;
THYM	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg03709012	chr19:19516395	GATAD2A	0.72	5.55	0.49	2.55e-7	Tonsillectomy;
THYM	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg08132940	chr7:1081526	C7orf50	-0.77	-5.21	-0.47	1.1e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.76	5.18	0.47	1.26e-6	Gut microbiome composition (summer);
THYM	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg24874828	chr4:187887005	NA	0.71	7.05	0.59	2.86e-10	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs314370	0.855	rs17883557	chr7:100494949	G/T	cg08558340	chr7:100472263	SRRT	0.61	4.99	0.46	2.75e-6	Resting heart rate;
THYM	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg00495681	chr13:53174319	NA	0.9	8.86	0.67	4.53e-14	Lewy body disease;
THYM	cis	rs2361718	0.631	rs12601637	chr17:78142455	T/C	cg09238746	chr17:78121135	EIF4A3	-0.94	-7.81	-0.63	7.43e-12	Yeast infection;
THYM	cis	rs9527	0.590	rs12414232	chr10:104914491	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs7589342	0.929	rs2060036	chr2:106436101	G/A	cg14210321	chr2:106509881	NCK2	-0.72	-5.12	-0.46	1.62e-6	Addiction;
THYM	cis	rs1535500	1.000	rs1535500	chr6:39284050	G/T	cg00012638	chr6:39280541	KCNK17	0.61	8.19	0.64	1.19e-12	Type 2 diabetes;
THYM	cis	rs1467026	0.589	rs9876483	chr3:12803792	G/T	cg11882607	chr3:12858926	CAND2	-0.46	-5.08	-0.46	1.91e-6	P wave duration;
THYM	cis	rs7084402	0.967	rs1658439	chr10:60325986	A/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs2806561	0.765	rs681395	chr1:23500314	G/A	cg12483005	chr1:23474871	LUZP1	0.58	6.11	0.53	2.2e-8	Height;
THYM	cis	rs4523957	0.928	rs9899193	chr17:2156917	G/A	cg16513277	chr17:2031491	SMG6	0.79	7.41	0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6032067	0.929	rs13039083	chr20:43878838	T/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.67	-6.07	-0.53	2.65e-8	Blood protein levels;
THYM	cis	rs72712511	0.571	rs3796629	chr4:140762853	T/C	cg15010390	chr4:140216957	NDUFC1	0.62	4.67	0.43	9.92e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7084402	0.934	rs1658453	chr10:60309602	T/C	cg07615347	chr10:60278583	BICC1	0.56	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs131777	0.576	rs131758	chr22:51017082	T/A	cg00083937	chr22:51039805	MAPK8IP2	0.64	5.87	0.52	6.38e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg25358565	chr5:93447407	FAM172A	1.26	10.2	0.72	6.16e-17	Diabetic retinopathy;
THYM	cis	rs2572431	0.505	rs13269118	chr8:11247814	G/A	cg21775007	chr8:11205619	TDH	0.68	5.34	0.48	6.28e-7	Neuroticism;
THYM	cis	rs13177918	0.603	rs2748241	chr5:149827494	C/T	cg14059543	chr5:149831962	NA	-0.84	-7.53	-0.61	2.94e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg23851026	chr2:136556271	LCT	-0.5	-4.76	-0.44	6.97e-6	Mosquito bite size;
THYM	cis	rs6669072	0.739	rs712026	chr1:91251381	T/C	cg08895590	chr1:91227319	NA	0.45	5.24	0.47	9.6e-7	Cognitive function;
THYM	trans	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg10856724	chr12:34555212	NA	-0.89	-8.05	-0.64	2.41e-12	Bladder cancer;
THYM	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.02	5.09	0.46	1.83e-6	Initial pursuit acceleration;
THYM	cis	rs5769765	0.542	rs761878	chr22:50249677	A/G	cg08270630	chr22:50330655	NA	0.73	4.83	0.44	5.24e-6	Schizophrenia;
THYM	cis	rs1371867	0.817	rs1788208	chr8:101312515	T/C	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12379764	chr21:47803548	PCNT	-0.81	-5.54	-0.49	2.66e-7	Testicular germ cell tumor;
THYM	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	7.86	0.63	5.84e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg06636001	chr8:8085503	FLJ10661	0.78	6.9	0.58	5.88e-10	Mood instability;
THYM	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	5.08	0.46	1.9e-6	Diabetic retinopathy;
THYM	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg10589385	chr1:150898437	SETDB1	-0.64	-5.59	-0.5	2.16e-7	Melanoma;
THYM	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-4.5	-0.42	1.92e-5	Hemoglobin concentration;
THYM	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs8112449	0.822	rs7260594	chr19:10548136	C/T	cg01466491	chr19:10523363	NA	-0.62	-5.9	-0.52	5.56e-8	Multiple sclerosis;Gastritis;
THYM	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg13918804	chr1:2043761	PRKCZ	0.9	9.76	0.71	5.4e-16	Height;
THYM	cis	rs2227564	0.620	rs4746143	chr10:75477298	A/G	cg00564723	chr10:75632066	CAMK2G	-0.57	-5.16	-0.47	1.33e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg18402987	chr7:1209562	NA	1.02	6.07	0.53	2.58e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	7.18	0.59	1.57e-10	Electrocardiographic conduction measures;
THYM	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.76	0.44	7.04e-6	Bipolar disorder;
THYM	cis	rs17453880	0.929	rs10071370	chr5:152048813	T/G	cg12297329	chr5:152029980	NA	-0.59	-4.48	-0.42	2.06e-5	Subjective well-being;
THYM	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg07212818	chr11:638076	DRD4	-0.79	-6.69	-0.57	1.57e-9	Systemic lupus erythematosus;
THYM	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg09238746	chr17:78121135	EIF4A3	-1.17	-10.29	-0.73	3.9e-17	Yeast infection;
THYM	cis	rs889398	0.967	rs1437134	chr16:69730426	A/G	cg09409435	chr16:70099608	PDXDC2	0.59	4.54	0.42	1.66e-5	Body mass index;
THYM	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg18132916	chr6:79620363	NA	-0.54	-4.79	-0.44	6.11e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg20203395	chr5:56204925	C5orf35	-0.67	-4.58	-0.42	1.44e-5	Initial pursuit acceleration;
THYM	trans	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	3.97e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg08779649	chr13:50194554	NA	0.58	5.05	0.46	2.16e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg03806693	chr22:41940476	POLR3H	1.11	9.95	0.71	2.12e-16	Vitiligo;
THYM	cis	rs6480314	0.542	rs7894859	chr10:69994377	A/G	cg27159792	chr10:69524182	NA	0.83	4.86	0.45	4.6e-6	Optic nerve measurement (disc area);
THYM	cis	rs886126	1.000	rs3809286	chr12:111664404	C/T	cg10833066	chr12:111807467	FAM109A	0.44	5.46	0.49	3.84e-7	Coronary heart disease;
THYM	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg24324837	chr19:49891574	CCDC155	-0.52	-4.84	-0.45	4.94e-6	Multiple sclerosis;
THYM	cis	rs13202913	0.639	rs9397407	chr6:151748995	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.86	-4.76	-0.44	7.02e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs3772130	0.775	rs6781857	chr3:121560721	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.75	4.64	0.43	1.1e-5	Cognitive performance;
THYM	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg13679303	chr9:96623674	NA	-0.57	-5.86	-0.52	6.61e-8	DNA methylation (variation);
THYM	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	4.98	0.45	2.88e-6	Schizophrenia;
THYM	cis	rs6988636	0.901	rs62521825	chr8:124185786	C/A	cg22384356	chr8:124195192	FAM83A	-0.86	-5.15	-0.47	1.41e-6	Urinary uromodulin levels;
THYM	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg13010199	chr12:38710504	ALG10B	0.65	4.65	0.43	1.06e-5	Morning vs. evening chronotype;
THYM	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11644478	chr21:40555479	PSMG1	-0.58	-4.76	-0.44	6.94e-6	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg25811766	chr13:21894605	NA	-0.76	-4.87	-0.45	4.47e-6	White matter hyperintensity burden;
THYM	cis	rs7177699	0.557	rs7178051	chr15:79118296	A/G	cg15571903	chr15:79123663	NA	0.56	6.28	0.54	9.92e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs9300255	0.722	rs12322888	chr12:123825559	A/G	cg05973401	chr12:123451056	ABCB9	0.72	4.53	0.42	1.68e-5	Neutrophil percentage of white cells;
THYM	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg21862992	chr11:68658383	NA	0.23	4.51	0.42	1.86e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs7681440	0.606	rs2737008	chr4:90747183	G/A	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs11214589	0.651	rs11214595	chr11:113259658	G/T	cg14159747	chr11:113255604	NA	0.37	7.8	0.62	8.01e-12	Neuroticism;
THYM	cis	rs4930776	0.900	rs405541	chr12:5761100	G/A	cg02086166	chr12:5775618	ANO2	0.61	6.07	0.53	2.57e-8	Plasma clusterin levels;
THYM	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg05294307	chr14:35346193	BAZ1A	-0.82	-5.44	-0.49	4.12e-7	Psoriasis;
THYM	cis	rs698833	0.501	rs10194161	chr2:44507213	A/G	cg04920474	chr2:44395004	PPM1B	-0.61	-6.16	-0.53	1.74e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
THYM	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg00310523	chr12:86230176	RASSF9	0.53	4.6	0.43	1.32e-5	Major depressive disorder;
THYM	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg07570687	chr10:102243282	WNT8B	0.76	6.64	0.56	1.94e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg21394778	chr1:3037102	PRDM16	0.46	4.47	0.42	2.12e-5	Height;
THYM	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg18758796	chr5:131593413	PDLIM4	0.5	4.74	0.44	7.49e-6	Breast cancer;
THYM	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg18252515	chr7:66147081	NA	-0.6	-4.53	-0.42	1.69e-5	Aortic root size;
THYM	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg08901578	chr4:187885870	NA	-0.64	-6.03	-0.53	3.1e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	6.9	0.58	5.76e-10	Smoking behavior;
THYM	cis	rs13082711	0.516	rs1388786	chr3:27372222	G/A	cg02860705	chr3:27208620	NA	-0.67	-5.05	-0.46	2.17e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg10856724	chr12:34555212	NA	-0.91	-8.9	-0.67	3.68e-14	Morning vs. evening chronotype;
THYM	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg23711669	chr6:146136114	FBXO30	0.93	9.32	0.69	4.7e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg22535103	chr8:58192502	C8orf71	-1.02	-6.22	-0.54	1.33e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7580658	0.550	rs62160290	chr2:128200695	C/T	cg10021288	chr2:128175891	PROC	-0.67	-5.8	-0.51	8.69e-8	Protein C levels;
THYM	cis	rs7107174	0.892	rs2510042	chr11:77923665	C/T	cg19901956	chr11:77921274	USP35	-0.75	-5.88	-0.52	6.01e-8	Testicular germ cell tumor;
THYM	cis	rs6906287	0.647	rs57813349	chr6:118763858	C/A	cg21191810	chr6:118973309	C6orf204	0.59	5.88	0.52	5.99e-8	Electrocardiographic conduction measures;
THYM	cis	rs9790314	0.632	rs55672403	chr3:160681026	C/A	cg04691961	chr3:161091175	C3orf57	0.57	4.61	0.43	1.27e-5	Morning vs. evening chronotype;
THYM	cis	rs67981189	0.896	rs4391999	chr14:71445413	A/G	cg15910301	chr14:71632612	NA	0.51	4.68	0.43	9.44e-6	Schizophrenia;
THYM	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg05182265	chr7:156933206	UBE3C	-0.69	-9.32	-0.69	4.58e-15	Body mass index;
THYM	cis	rs7828089	0.582	rs13282084	chr8:22266280	T/C	cg13512537	chr8:22265999	SLC39A14	-0.67	-5.57	-0.5	2.39e-7	Verbal declarative memory;
THYM	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg02380750	chr20:61661411	NA	0.61	6.16	0.53	1.78e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7119038	0.629	rs10892272	chr11:118602707	C/G	cg19308663	chr11:118741387	NA	0.47	4.55	0.42	1.58e-5	Sjögren's syndrome;
THYM	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.54	-4.51	-0.42	1.86e-5	Coronary artery disease;
THYM	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.31	8.7	0.67	9.92e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs8025790	0.508	rs35930676	chr15:67827705	G/A	cg24579218	chr15:68104479	NA	-0.64	-5.91	-0.52	5.4e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs910187	0.678	rs3818013	chr20:45816639	A/G	cg27589058	chr20:45804311	EYA2	-0.59	-5.04	-0.46	2.21e-6	Migraine;
THYM	cis	rs13064411	0.696	rs6808394	chr3:113122524	T/G	cg18753928	chr3:113234510	CCDC52	-0.92	-8.29	-0.65	7.27e-13	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7578361	0.959	rs11674815	chr2:150454194	C/T	cg17961725	chr2:150454027	NA	0.74	6.16	0.53	1.72e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg03909863	chr11:638404	DRD4	-0.76	-6.04	-0.53	2.95e-8	Systemic lupus erythematosus;
THYM	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg12560992	chr17:57184187	TRIM37	-0.92	-8.68	-0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-8.08	-0.64	1.99e-12	Coronary artery disease;
THYM	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05901451	chr6:126070800	HEY2	-0.94	-9.73	-0.71	6.24e-16	Brugada syndrome;
THYM	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg20242066	chr2:136595261	LCT	0.61	7.15	0.59	1.78e-10	Mosquito bite size;
THYM	cis	rs11148252	0.514	rs3818422	chr13:52719214	C/T	cg05335186	chr13:53173507	NA	0.39	4.52	0.42	1.79e-5	Lewy body disease;
THYM	cis	rs4866334	1.000	rs79459190	chr5:18504469	T/G	cg24599790	chr5:18972260	NA	-1.15	-4.67	-0.43	9.77e-6	IgG glycosylation;
THYM	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg19016782	chr12:123741754	C12orf65	-0.71	-4.58	-0.42	1.43e-5	Neutrophil percentage of white cells;
THYM	cis	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg13443165	chr9:33130375	B4GALT1	-0.84	-7.7	-0.62	1.31e-11	IgG glycosylation;
THYM	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs12220238	0.558	rs76330316	chr10:76002291	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.85	4.58	0.43	1.41e-5	Soluble interleukin-2 receptor subunit alpha;
THYM	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	4.93	0.45	3.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg27490568	chr2:178487706	NA	0.72	6.15	0.53	1.78e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg02487422	chr3:49467188	NICN1	0.63	4.82	0.44	5.48e-6	Resting heart rate;
THYM	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg18806716	chr10:30721971	MAP3K8	-0.52	-4.72	-0.44	8.07e-6	Inflammatory bowel disease;
THYM	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg09904177	chr6:26538194	HMGN4	0.64	5.4	0.48	4.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg18357526	chr6:26021779	HIST1H4A	0.59	4.55	0.42	1.61e-5	Blood metabolite levels;
THYM	cis	rs6754311	0.593	rs313523	chr2:136432103	G/A	cg04750100	chr2:136595281	LCT	0.56	5.89	0.52	5.87e-8	Mosquito bite size;
THYM	cis	rs3768617	0.528	rs10737242	chr1:183098249	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.7	0.43	8.67e-6	Fuchs's corneal dystrophy;
THYM	cis	rs67981189	0.896	rs2810098	chr14:71433911	A/G	cg15910301	chr14:71632612	NA	-0.5	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	cis	rs7119	0.717	rs7180732	chr15:77829921	G/A	cg10437265	chr15:77819839	NA	0.75	7.41	0.6	5.28e-11	Type 2 diabetes;
THYM	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg13695892	chr22:41940480	POLR3H	0.93	7.09	0.59	2.34e-10	Vitiligo;
THYM	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg23205692	chr1:25664452	TMEM50A	0.84	6.43	0.55	5.09e-9	Erythrocyte sedimentation rate;
THYM	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.91	5.71	0.51	1.3e-7	Yeast infection;
THYM	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg22433210	chr17:43662623	NA	1.12	8.59	0.66	1.69e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg18811423	chr2:55921094	PNPT1	0.73	6.83	0.57	8.01e-10	Metabolic syndrome;
THYM	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-4.49	-0.42	1.98e-5	Monocyte percentage of white cells;
THYM	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg26446133	chr18:72167187	CNDP2	-0.99	-7.36	-0.6	6.48e-11	Refractive error;
THYM	cis	rs5015933	0.736	rs10125995	chr9:128145942	C/T	cg14078157	chr9:128172775	NA	-0.54	-4.59	-0.43	1.36e-5	Body mass index;
THYM	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg02187348	chr16:89574699	SPG7	0.72	5.43	0.49	4.28e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs61931739	0.517	rs10844738	chr12:34059503	T/A	cg10856724	chr12:34555212	NA	-0.79	-7.41	-0.61	5.14e-11	Morning vs. evening chronotype;
THYM	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg18477163	chr1:228402036	OBSCN	-0.43	-4.69	-0.43	8.96e-6	Diastolic blood pressure;
THYM	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	8.04	0.64	2.52e-12	Monocyte percentage of white cells;
THYM	cis	rs2235649	0.828	rs9938694	chr16:1849872	T/C	cg03034668	chr16:1723424	CRAMP1L	-0.64	-5.57	-0.5	2.39e-7	Blood metabolite levels;
THYM	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs17401966	0.894	rs12141201	chr1:10454714	G/A	cg19773385	chr1:10388646	KIF1B	-0.6	-4.7	-0.43	8.88e-6	Hepatocellular carcinoma;
THYM	cis	rs79387448	0.638	rs74731686	chr2:103043981	G/A	cg09003973	chr2:102972529	NA	1.08	6.39	0.55	6.26e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs9814567	0.806	rs4245904	chr3:134321808	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.09e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7177699	0.557	rs72749206	chr15:79122948	G/A	cg00540400	chr15:79124168	NA	-0.64	-6.03	-0.53	3.17e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs13102973	0.640	rs11099301	chr4:135880662	G/T	cg14419869	chr4:135874104	NA	0.85	7.03	0.59	3.1e-10	Subjective well-being;
THYM	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg14972814	chr11:95582409	MTMR2	-0.72	-6.7	-0.57	1.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7523273	0.597	rs11118612	chr1:207979577	T/A	cg22525895	chr1:207977042	MIR29B2	-0.77	-5.11	-0.46	1.68e-6	Schizophrenia;
THYM	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg12756686	chr19:29218302	NA	-0.69	-4.78	-0.44	6.35e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs1021993	0.620	rs1395748	chr1:209475945	G/A	cg24997231	chr1:209527535	NA	0.5	4.55	0.42	1.57e-5	Gut microbiome composition (winter);
THYM	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03452623	chr4:187889614	NA	-1.16	-21.11	-0.91	1.23e-37	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg25072359	chr17:41440525	NA	0.68	4.71	0.44	8.33e-6	Menopause (age at onset);
THYM	cis	rs1331623	0.955	rs4837644	chr9:122196021	C/T	cg25935911	chr9:122132261	DBC1	-0.52	-4.72	-0.44	8.05e-6	Height;
THYM	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg27490568	chr2:178487706	NA	-0.61	-5.72	-0.51	1.24e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg11871910	chr12:69753446	YEATS4	0.61	4.84	0.44	5e-6	Blood protein levels;
THYM	cis	rs6750795	0.569	rs1667313	chr2:232408018	A/C	cg19187155	chr2:232395269	NMUR1	0.9	9.04	0.68	1.87e-14	Height;
THYM	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg00825309	chr19:58991885	ZNF446	-0.6	-4.69	-0.43	9.1e-6	Uric acid clearance;
THYM	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg26924012	chr15:45694286	SPATA5L1	0.65	4.75	0.44	7.21e-6	Response to fenofibrate (adiponectin levels);
THYM	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs7192750	0.586	rs2288031	chr16:71902142	C/A	cg06353428	chr16:71660113	MARVELD3	0.76	5.6	0.5	2.04e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs6998277	0.830	rs6468838	chr8:103609336	T/C	cg10187029	chr8:103597600	NA	0.51	4.54	0.42	1.62e-5	Migraine;
THYM	cis	rs9309473	0.519	rs2421670	chr2:73886661	T/G	cg19565262	chr2:73869966	NAT8	0.56	4.68	0.43	9.48e-6	Metabolite levels;
THYM	cis	rs73198271	0.740	rs1039910	chr8:8648066	T/C	cg15556689	chr8:8085844	FLJ10661	-0.74	-4.83	-0.44	5.24e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs6430585	0.528	rs12476127	chr2:136763242	A/G	cg20242066	chr2:136595261	LCT	0.5	4.86	0.45	4.68e-6	Corneal structure;
THYM	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.58	-4.95	-0.45	3.2e-6	Homoarginine levels;
THYM	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg17426766	chr1:2046864	PRKCZ	0.4	4.78	0.44	6.44e-6	Height;
THYM	cis	rs7631605	0.905	rs72866099	chr3:37259646	C/A	cg21328643	chr3:37258149	NA	-0.58	-5.57	-0.5	2.39e-7	Cerebrospinal P-tau181p levels;
THYM	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg20295408	chr7:1910781	MAD1L1	-0.58	-4.63	-0.43	1.14e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg17294928	chr15:75287854	SCAMP5	0.64	4.54	0.42	1.64e-5	Breast cancer;
THYM	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.7	6.52	0.56	3.4e-9	Total body bone mineral density;
THYM	cis	rs198813	0.611	rs198823	chr6:26122933	G/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.73	-5.92	-0.52	5.04e-8	Intelligence (multi-trait analysis);
THYM	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Body mass index;
THYM	cis	rs11696501	0.739	rs6104250	chr20:44251479	C/T	cg11783356	chr20:44313418	WFDC10B	-0.66	-4.52	-0.42	1.77e-5	Brain structure;
THYM	cis	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg19847130	chr8:10466454	RP1L1	0.5	4.75	0.44	7.15e-6	Neuroticism;
THYM	cis	rs673253	0.710	rs673242	chr1:44062159	C/T	cg24466421	chr1:44070974	PTPRF	-0.6	-5.24	-0.47	9.75e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2046867	0.818	rs9814945	chr3:72803590	C/T	cg25664220	chr3:72788482	NA	-0.87	-7.21	-0.59	1.32e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs3112255	1.000	rs3112255	chr2:101317260	C/A	cg01042948	chr2:101319752	NA	0.68	5.92	0.52	5.2e-8	Intelligence (multi-trait analysis);
THYM	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.65	-4.72	-0.44	8.09e-6	Colorectal cancer;
THYM	cis	rs16976116	0.951	rs13733	chr15:55489104	A/G	cg11288833	chr15:55489084	RSL24D1	0.69	4.49	0.42	2e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12889267	0.770	rs66995536	chr14:21564859	G/A	cg02988727	chr14:21567520	ZNF219;C14orf176	0.5	4.51	0.42	1.85e-5	Hematocrit;Resting heart rate;
THYM	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05901451	chr6:126070800	HEY2	-0.94	-9.57	-0.7	1.34e-15	Brugada syndrome;
THYM	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg11663144	chr21:46675770	NA	-0.64	-8.7	-0.67	9.77e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg24209194	chr3:40518798	ZNF619	0.62	4.91	0.45	3.77e-6	Renal cell carcinoma;
THYM	cis	rs1050631	0.564	rs10153377	chr18:33727984	G/C	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.6	4.69	0.43	9.09e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs9894429	0.604	rs9912071	chr17:79609654	G/A	cg21984481	chr17:79567631	NPLOC4	-0.55	-5.75	-0.51	1.1e-7	Eye color traits;
THYM	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg18758796	chr5:131593413	PDLIM4	0.51	4.83	0.44	5.32e-6	Blood metabolite levels;
THYM	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg16405210	chr4:1374714	KIAA1530	-1.09	-10.29	-0.73	4.03e-17	Longevity;
THYM	cis	rs11756438	0.683	rs4945624	chr6:119017155	G/T	cg01113488	chr6:119027122	NA	0.63	5.11	0.46	1.66e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg13695892	chr22:41940480	POLR3H	-0.9	-7.19	-0.59	1.49e-10	Vitiligo;
THYM	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg12386194	chr3:101231763	SENP7	0.65	4.89	0.45	4.17e-6	Colorectal cancer;
THYM	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg13319975	chr6:146136371	FBXO30	-0.66	-5.23	-0.47	1.01e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7843479	0.932	rs68023663	chr8:21794379	T/C	cg17168535	chr8:21777572	XPO7	0.75	5.24	0.47	9.82e-7	Mean corpuscular volume;
THYM	cis	rs10929159	0.928	rs11890052	chr2:236918533	A/G	cg20128773	chr2:236923534	AGAP1	0.35	4.71	0.44	8.3e-6	Parkinson's disease;
THYM	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg07959070	chr22:50026188	C22orf34	-0.28	-4.95	-0.45	3.17e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs911119	0.779	rs3761280	chr20:23620076	A/G	cg16589663	chr20:23618590	CST3	0.76	4.69	0.43	9.26e-6	Chronic kidney disease;
THYM	cis	rs11249608	0.636	rs6888567	chr5:178449074	C/T	cg01312482	chr5:178451176	ZNF879	0.67	5.48	0.49	3.49e-7	Pubertal anthropometrics;
THYM	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg23260525	chr10:116636907	FAM160B1	0.53	5.33	0.48	6.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.63	-4.48	-0.42	2.05e-5	Gut microbiome composition (summer);
THYM	cis	rs4589258	0.762	rs7925702	chr11:90396603	A/G	cg26138821	chr11:89956704	CHORDC1	0.57	4.76	0.44	7.05e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1957429	0.614	rs62621845	chr14:65403525	T/A	cg23373153	chr14:65346875	NA	-1.25	-5.03	-0.46	2.29e-6	Pediatric areal bone mineral density (radius);
THYM	trans	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg18105134	chr13:113819100	PROZ	-0.99	-9.17	-0.69	9.97e-15	Platelet distribution width;
THYM	cis	rs7617773	0.780	rs7645425	chr3:48362369	A/T	cg02219026	chr3:48282209	ZNF589	-0.69	-4.83	-0.44	5.12e-6	Coronary artery disease;
THYM	cis	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg15448220	chr1:150897856	SETDB1	0.89	7.59	0.61	2.17e-11	Melanoma;
THYM	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg11764359	chr7:65958608	NA	0.87	7.45	0.61	4.16e-11	Aortic root size;
THYM	cis	rs2625529	0.652	rs8023788	chr15:72459847	A/G	cg16672083	chr15:72433130	SENP8	0.49	4.52	0.42	1.76e-5	Red blood cell count;
THYM	cis	rs4845570	1.000	rs4845579	chr1:151770138	C/T	cg07092448	chr1:151763213	TDRKH	-1.2	-8.96	-0.68	2.74e-14	Coronary artery disease;
THYM	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg17173187	chr15:85201210	NMB	0.55	5.5	0.49	3.26e-7	Schizophrenia;
THYM	cis	rs2070488	0.813	rs3749387	chr3:38496193	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.97	7.17	0.59	1.65e-10	Electrocardiographic conduction measures;
THYM	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	5.64	0.5	1.76e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs7216064	1.000	rs1976053	chr17:65833002	C/G	cg12091567	chr17:66097778	LOC651250	-0.7	-4.98	-0.46	2.8e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs9467773	0.587	rs9467722	chr6:26352566	T/C	cg14345882	chr6:26364793	BTN3A2	0.34	4.6	0.43	1.29e-5	Intelligence (multi-trait analysis);
THYM	cis	rs12410462	0.581	rs35141785	chr1:227553496	G/C	cg23173402	chr1:227635558	NA	0.67	5.39	0.48	5.02e-7	Major depressive disorder;
THYM	cis	rs7582180	1.000	rs7582180	chr2:100912463	C/T	cg14675211	chr2:100938903	LONRF2	-0.57	-4.67	-0.43	9.95e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1499972	0.941	rs56256549	chr3:117612102	A/G	cg07612923	chr3:117604196	NA	1.3	5.44	0.49	4.05e-7	Schizophrenia;
THYM	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.41	-5.16	-0.47	1.38e-6	Monocyte percentage of white cells;
THYM	cis	rs6687430	0.532	rs17035305	chr1:10616505	C/A	cg20482658	chr1:10539492	PEX14	0.5	6.43	0.55	5.19e-9	Hand grip strength;
THYM	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg22875332	chr1:76189707	ACADM	0.87	10.83	0.74	2.76e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.87	-7.37	-0.6	6.37e-11	Primary sclerosing cholangitis;
THYM	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.96	0.58	4.38e-10	Prudent dietary pattern;
THYM	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.04	-5.14	-0.47	1.48e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs61931739	0.635	rs6488185	chr12:33933127	G/C	cg06521331	chr12:34319734	NA	-0.57	-4.76	-0.44	7e-6	Morning vs. evening chronotype;
THYM	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg02569458	chr12:86230093	RASSF9	0.58	5.01	0.46	2.52e-6	Major depressive disorder;
THYM	cis	rs986417	1.000	rs1956875	chr14:60846212	T/C	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs919433	0.713	rs2045245	chr2:198485341	A/C	cg00792783	chr2:198669748	PLCL1	0.79	5.38	0.48	5.25e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6427356	0.513	rs11264627	chr1:157141088	G/A	cg27547283	chr1:156698502	C1orf66;ISG20L2	-0.58	-4.49	-0.42	2.02e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs35603048	0.881	rs11637595	chr15:40387728	C/T	cg02313495	chr15:40398007	BMF	-0.66	-5.5	-0.49	3.27e-7	B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
THYM	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg01751800	chr4:77820391	ANKRD56	-0.55	-4.58	-0.42	1.43e-5	Emphysema distribution in smoking;
THYM	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg25566285	chr7:158114605	PTPRN2	0.77	6.92	0.58	5.36e-10	Response to amphetamines;
THYM	cis	rs826838	0.967	rs7965656	chr12:38807244	G/A	cg13010199	chr12:38710504	ALG10B	0.81	6.13	0.53	2.04e-8	Heart rate;
THYM	cis	rs710865	0.516	rs12062540	chr1:19529204	A/G	cg13387374	chr1:19411106	UBR4	0.61	5.4	0.48	4.84e-7	Brain structure;
THYM	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.88	5.64	0.5	1.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs804280	0.525	rs804287	chr8:11618311	C/T	cg23916205	chr8:11614368	GATA4	-0.61	-5.02	-0.46	2.43e-6	Myopia (pathological);
THYM	cis	rs883565	0.655	rs4676628	chr3:39095965	G/A	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	5.0	0.46	2.59e-6	Handedness;
THYM	cis	rs5769765	1.000	rs5770755	chr22:50280136	T/C	cg26441486	chr22:50317300	CRELD2	-0.44	-6.83	-0.57	8.09e-10	Schizophrenia;
THYM	cis	rs1371867	0.846	rs1660332	chr8:101309490	A/G	cg00191853	chr8:101177733	SPAG1	0.5	4.9	0.45	3.87e-6	Atrioventricular conduction;
THYM	cis	rs2882877	0.648	rs726093	chr2:190396659	T/C	cg10752008	chr2:190445175	SLC40A1	0.72	6.14	0.53	1.9e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs3760982	0.585	rs62116964	chr19:44291986	T/C	cg11993925	chr19:44307056	LYPD5	0.64	5.0	0.46	2.64e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs17453880	0.929	rs6859908	chr5:152049109	G/A	cg12297329	chr5:152029980	NA	-0.59	-4.48	-0.42	2.06e-5	Subjective well-being;
THYM	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg02734326	chr4:10020555	SLC2A9	-0.6	-4.85	-0.45	4.9100000000000004e-06	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7172809	0.573	rs75657134	chr15:77532885	C/G	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs2108225	0.872	rs7792139	chr7:107445433	G/A	cg18560240	chr7:107437656	SLC26A3	-0.91	-6.73	-0.57	1.27e-9	Ulcerative colitis;
THYM	cis	rs9565309	0.579	rs76803135	chr13:77588579	C/T	cg13866767	chr13:78470850	EDNRB	1.06	4.81	0.44	5.76e-6	Morning vs. evening chronotype;
THYM	cis	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg04990556	chr1:26633338	UBXN11	-0.87	-7.92	-0.63	4.4e-12	Obesity-related traits;
THYM	cis	rs295140	0.934	rs74853338	chr2:201171651	C/T	cg04283868	chr2:201171347	SPATS2L	0.74	5.53	0.49	2.81e-7	QT interval;
THYM	trans	rs1997103	0.954	rs2177807	chr7:55391002	G/T	cg20935933	chr6:143382018	AIG1	-0.86	-7.07	-0.59	2.64e-10	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs4430311	0.691	rs1531244	chr1:243939970	A/G	cg25706552	chr1:244017396	NA	-0.56	-4.97	-0.45	2.93e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg11494091	chr17:61959527	GH2	1.05	20.89	0.91	2.79e-37	Prudent dietary pattern;
THYM	cis	rs7586879	0.616	rs13410999	chr2:25097939	T/C	cg01884057	chr2:25150051	NA	0.7	7.27	0.6	1.01e-10	Body mass index;
THYM	cis	rs7582180	0.663	rs930374	chr2:100962700	A/G	cg08017756	chr2:100939284	LONRF2	-0.76	-7.81	-0.63	7.51e-12	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg08132940	chr7:1081526	C7orf50	-0.77	-5.19	-0.47	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs490234	0.841	rs1755936	chr9:128388991	C/G	cg14078157	chr9:128172775	NA	-0.66	-5.2	-0.47	1.12e-6	Mean arterial pressure;
THYM	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg21433313	chr16:3507492	NAT15	0.81	8.84	0.67	4.96e-14	Tuberculosis;
THYM	cis	rs7084402	0.967	rs1649026	chr10:60281400	A/G	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg19847130	chr8:10466454	RP1L1	0.51	4.63	0.43	1.15e-5	Triglycerides;
THYM	cis	rs6032067	0.777	rs34073275	chr20:43788917	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg27284194	chr4:1044797	NA	0.62	4.73	0.44	7.81e-6	Recombination rate (females);
THYM	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg09354556	chr3:47051341	NA	-0.44	-4.5	-0.42	1.94e-5	Colorectal cancer;
THYM	cis	rs2367725	1	rs2367725	chr1:44215828	C/T	cg25219246	chr1:44053380	PTPRF	0.41	4.7	0.43	8.71e-6	Aging (time to event);
THYM	cis	rs73198271	0.740	rs67766414	chr8:8649533	C/T	cg06636001	chr8:8085503	FLJ10661	-0.8	-5.65	-0.5	1.7e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg16586182	chr3:47516702	SCAP	-0.6	-5.11	-0.46	1.63e-6	Colorectal cancer;
THYM	cis	rs7100689	0.646	rs10749579	chr10:82140959	C/T	cg01528321	chr10:82214614	TSPAN14	0.78	5.93	0.52	4.97e-8	Post bronchodilator FEV1;
THYM	cis	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg05335186	chr13:53173507	NA	-0.46	-5.89	-0.52	5.78e-8	Lewy body disease;
THYM	cis	rs1669338	1.000	rs1669338	chr3:3199635	A/C	cg16797762	chr3:3221439	CRBN	0.92	5.75	0.51	1.07e-7	White matter integrity;
THYM	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.18	-8.64	-0.66	1.34e-13	Gut microbiome composition (summer);
THYM	cis	rs2976388	0.566	rs4736301	chr8:143829499	T/G	cg06565975	chr8:143823917	SLURP1	-0.61	-7.51	-0.61	3.22e-11	Urinary tract infection frequency;
THYM	cis	rs4788570	0.547	rs7202479	chr16:71759679	A/C	cg06353428	chr16:71660113	MARVELD3	1.39	9.54	0.7	1.57e-15	Intelligence (multi-trait analysis);
THYM	cis	rs921665	0.831	rs6548168	chr2:3181784	T/C	cg16434511	chr2:3151078	NA	-0.78	-5.18	-0.47	1.24e-6	World class endurance athleticism;
THYM	cis	rs2288884	0.767	rs28379522	chr19:52539487	C/T	cg05974498	chr19:52599256	ZNF841	0.35	4.51	0.42	1.85e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	trans	rs1147813	0.654	rs993232	chr9:25890597	A/G	cg17166802	chr3:112709596	GTPBP8	1.07	7.43	0.61	4.65e-11	Morning vs. evening chronotype;
THYM	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.68	-4.55	-0.42	1.59e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7618915	0.962	rs13094687	chr3:52450043	A/G	cg10802521	chr3:52805072	NEK4	-0.66	-4.8	-0.44	5.82e-6	Bipolar disorder;
THYM	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg12165864	chr7:66369176	NA	0.65	5.06	0.46	2.07e-6	Aortic root size;
THYM	cis	rs765787	0.530	rs12905246	chr15:45500841	C/T	cg24006582	chr15:45444508	DUOX1	0.78	6.22	0.54	1.36e-8	Uric acid levels;
THYM	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg13319975	chr6:146136371	FBXO30	0.63	5.17	0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11225247	0.649	rs11607214	chr11:102225224	A/G	cg11690896	chr11:102217788	BIRC2	1.18	4.71	0.44	8.31e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4975616	1.000	rs4975616	chr5:1315660	G/A	cg07493874	chr5:1342172	CLPTM1L	0.77	6.68	0.57	1.65e-9	Lung cancer;
THYM	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg22431228	chr1:16359049	CLCNKA	-0.52	-4.99	-0.46	2.71e-6	Dilated cardiomyopathy;
THYM	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.07	8.36	0.65	5.31e-13	Smoking behavior;
THYM	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs6089829	0.589	rs73921629	chr20:61676036	G/C	cg03213289	chr20:61660250	NA	-0.97	-8.12	-0.64	1.66e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6918586	0.658	rs198837	chr6:26113398	A/T	cg12310025	chr6:25882481	NA	-0.65	-5.18	-0.47	1.26e-6	Schizophrenia;
THYM	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.52	-4.57	-0.42	1.49e-5	Type 2 diabetes;
THYM	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg18252515	chr7:66147081	NA	1.48	8.83	0.67	5.15e-14	Diabetic kidney disease;
THYM	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg14458575	chr2:238380390	NA	1.05	8.65	0.66	1.23e-13	Prostate cancer;
THYM	cis	rs28785552	0.554	rs11084185	chr19:53214600	T/A	cg22067481	chr19:53234126	ZNF611	-0.96	-9.19	-0.69	9.13e-15	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs6032067	0.759	rs1007138	chr20:43816835	A/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.29	-0.48	7.93e-7	Blood protein levels;
THYM	cis	rs11225247	1.000	rs11607908	chr11:102307399	A/G	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg08000102	chr2:233561755	GIGYF2	-0.54	-4.77	-0.44	6.59e-6	Coronary artery disease;
THYM	cis	rs12458462	0.851	rs2169249	chr18:77489649	G/A	cg11879182	chr18:77439856	CTDP1	0.82	7.9	0.63	4.85e-12	Monocyte count;
THYM	cis	rs2455799	0.613	rs6802048	chr3:15883933	A/G	cg16303742	chr3:15540471	COLQ	-0.54	-5.78	-0.51	9.67e-8	Mean platelet volume;
THYM	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg02487422	chr3:49467188	NICN1	0.7	5.42	0.49	4.51e-7	Resting heart rate;
THYM	cis	rs611744	0.870	rs672243	chr8:109098742	G/A	cg21045802	chr8:109455806	TTC35	0.6	5.36	0.48	5.88e-7	Dupuytren's disease;
THYM	cis	rs12681287	0.640	rs4961193	chr8:87486168	C/T	cg27223183	chr8:87520930	FAM82B	0.67	5.05	0.46	2.17e-6	Caudate activity during reward;
THYM	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg05754148	chr16:3507555	NAT15	0.92	8.27	0.65	8.27e-13	Tuberculosis;
THYM	cis	rs516946	1.000	rs28591316	chr8:41524425	A/G	cg19441908	chr8:41529140	ANK1	0.62	4.9	0.45	3.87e-6	Type 2 diabetes;
THYM	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg23791538	chr6:167370224	RNASET2	-0.58	-4.53	-0.42	1.72e-5	Crohn's disease;
THYM	cis	rs1499972	0.878	rs817513	chr3:117733823	A/T	cg07612923	chr3:117604196	NA	-1.5	-5.16	-0.47	1.38e-6	Schizophrenia;
THYM	cis	rs6952809	0.532	rs2057840	chr7:2432797	C/G	cg13581527	chr7:1708566	NA	-0.76	-5.36	-0.48	5.7e-7	Multiple sclerosis;
THYM	cis	rs13177918	0.559	rs3901731	chr5:149816968	T/G	cg14059543	chr5:149831962	NA	-0.92	-8.3	-0.65	6.98e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2085601	0.519	rs1708680	chr4:89976967	T/G	cg17769793	chr4:89976368	FAM13A	-0.59	-6.86	-0.58	6.96e-10	Hair greying;
THYM	cis	rs11648796	0.879	rs12448432	chr16:778820	G/A	cg05638439	chr16:711235	WDR90	-0.61	-5.53	-0.49	2.86e-7	Height;
THYM	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg17366294	chr4:99064904	C4orf37	0.57	6.83	0.57	8.15e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs7762018	0.607	rs75964125	chr6:170054290	T/A	cg19338460	chr6:170058176	WDR27	-1.03	-6.13	-0.53	2.01e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs4731207	0.623	rs12706629	chr7:124574045	A/G	cg05285228	chr7:124571219	POT1	-0.69	-5.25	-0.47	9.35e-7	Cutaneous malignant melanoma;
THYM	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg01448562	chr3:133502909	NA	-0.82	-6.84	-0.57	7.51e-10	Iron status biomarkers;
THYM	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg12311346	chr5:56204834	C5orf35	0.84	6.23	0.54	1.28e-8	Initial pursuit acceleration;
THYM	cis	rs9403317	0.960	rs9389927	chr6:141839717	T/C	cg15052665	chr6:141804349	NA	0.85	8.69	0.67	1.03e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg01579765	chr21:45077557	HSF2BP	-0.49	-7.89	-0.63	5.14e-12	Mean corpuscular volume;
THYM	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg07424592	chr7:64974309	NA	1.04	5.31	0.48	7.18e-7	Diabetic kidney disease;
THYM	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.8	-0.51	8.64e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.08	7.64	0.62	1.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg18402987	chr7:1209562	NA	0.75	5.42	0.49	4.58e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4642101	0.686	rs13085726	chr3:12832672	A/C	cg11882607	chr3:12858926	CAND2	-0.42	-4.61	-0.43	1.23e-5	QRS complex (12-leadsum);
THYM	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg25427524	chr10:38739819	LOC399744	-0.58	-5.11	-0.46	1.69e-6	Extrinsic epigenetic age acceleration;
THYM	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg18240062	chr17:79603768	NPLOC4	-0.73	-6.59	-0.56	2.43e-9	Eye color traits;
THYM	cis	rs6840360	0.571	rs7695866	chr4:152488110	G/A	cg17479576	chr4:152424074	FAM160A1	-0.8	-5.92	-0.52	5.02e-8	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg02527881	chr3:46936655	PTH1R	0.56	5.47	0.49	3.58e-7	Colorectal cancer;
THYM	cis	rs854765	0.587	rs12936927	chr17:17726965	C/T	cg16928487	chr17:17741425	SREBF1	0.53	5.11	0.46	1.69e-6	Total body bone mineral density;
THYM	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.55	-5.64	-0.5	1.72e-7	Crohn's disease;
THYM	cis	rs6980334	0.871	rs3757393	chr7:137759000	T/C	cg18769353	chr7:137028617	PTN	0.56	4.46	0.42	2.21e-5	Blood metabolite ratios;
THYM	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.89	-6.55	-0.56	2.96e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs16854884	0.632	rs4446205	chr3:143682607	A/G	cg05063096	chr3:143689810	C3orf58	0.74	4.94	0.45	3.38e-6	Economic and political preferences (feminism/equality);
THYM	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.77	7.57	0.61	2.4e-11	Lymphocyte counts;
THYM	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4604732	0.603	rs4546958	chr1:247639478	G/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	4.8	0.44	5.87e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg17264618	chr3:40429014	ENTPD3	0.52	4.97	0.45	3e-6	Renal cell carcinoma;
THYM	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg09307838	chr4:120376055	NA	0.7	5.02	0.46	2.43e-6	Corneal astigmatism;
THYM	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg12935359	chr14:103987150	CKB	0.48	5.88	0.52	6.11e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7432375	0.609	rs835637	chr3:136673157	A/T	cg12473912	chr3:136751656	NA	0.58	4.79	0.44	6.12e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs478304	0.934	rs1193496	chr11:65537556	C/T	cg27068330	chr11:65405492	SIPA1	-0.82	-7.91	-0.63	4.72e-12	Acne (severe);
THYM	cis	rs2235649	0.833	rs2011088	chr16:1850091	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs7189233	0.955	rs60420081	chr16:53520804	A/G	cg02965178	chr16:53538660	AKTIP	-0.63	-5.12	-0.46	1.61e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg08508325	chr11:3079039	CARS	-0.52	-6.81	-0.57	8.85e-10	Longevity;
THYM	cis	rs2637266	0.663	rs846581	chr10:78497984	C/T	cg18941641	chr10:78392320	NA	0.71	5.68	0.5	1.46e-7	Pulmonary function;
THYM	cis	rs7189233	0.955	rs72801853	chr16:53516824	A/G	cg02965178	chr16:53538660	AKTIP	-0.58	-4.61	-0.43	1.26e-5	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg16586182	chr3:47516702	SCAP	0.63	5.57	0.5	2.36e-7	Colorectal cancer;
THYM	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg07606381	chr6:8435919	SLC35B3	0.59	4.45	0.42	2.36e-5	Motion sickness;
THYM	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.7	-5.63	-0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg20608306	chr11:116969690	SIK3	0.57	6.09	0.53	2.44e-8	Blood protein levels;
THYM	cis	rs4849845	0.925	rs3980213	chr2:121004979	A/G	cg03575764	chr2:121493832	NA	-0.66	-4.77	-0.44	6.55e-6	Mean platelet volume;
THYM	cis	rs988913	0.874	rs9382398	chr6:54783266	C/T	cg18532076	chr6:54711417	FAM83B	0.52	4.94	0.45	3.36e-6	Menarche (age at onset);
THYM	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg02527881	chr3:46936655	PTH1R	-0.85	-8.46	-0.66	3.21e-13	Birth weight;
THYM	cis	rs7980799	0.654	rs1482987	chr12:33614283	G/C	cg10856724	chr12:34555212	NA	0.6	4.5	0.42	1.93e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg12963246	chr6:28129442	ZNF389	0.77	6.4	0.55	5.74e-9	Parkinson's disease;
THYM	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg12310025	chr6:25882481	NA	0.78	5.9	0.52	5.57e-8	Blood metabolite levels;
THYM	cis	rs11190604	0.767	rs10883491	chr10:102196071	G/T	cg07570687	chr10:102243282	WNT8B	0.85	8.39	0.65	4.57e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg15445000	chr17:37608096	MED1	-0.41	-4.77	-0.44	6.61e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7224737	1.000	rs1122326	chr17:40274873	A/C	cg20291162	chr17:40259547	DHX58	-0.68	-6.22	-0.54	1.33e-8	Fibrinogen levels;
THYM	cis	rs6430585	0.528	rs12464050	chr2:136663110	G/T	cg20242066	chr2:136595261	LCT	0.56	5.17	0.47	1.28e-6	Corneal structure;
THYM	cis	rs4786125	0.636	rs8062299	chr16:6902722	T/C	cg03623568	chr16:6915990	A2BP1	-0.97	-9.45	-0.7	2.46e-15	Heart rate variability traits (SDNN);
THYM	cis	rs28374715	0.532	rs1899	chr15:41689232	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.78	-0.83	2.3e-26	Ulcerative colitis;
THYM	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg07424592	chr7:64974309	NA	0.79	4.89	0.45	4.17e-6	Diabetic kidney disease;
THYM	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg25767906	chr1:53392781	SCP2	-0.57	-5.68	-0.5	1.5e-7	Monocyte count;
THYM	cis	rs7084402	0.934	rs1658441	chr10:60323021	G/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg15242686	chr22:24348715	GSTTP1	-0.54	-4.74	-0.44	7.44e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.61	-6.45	-0.55	4.55e-9	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6754311	0.517	rs1469996	chr2:136542560	A/G	cg20242066	chr2:136595261	LCT	0.56	5.59	0.5	2.16e-7	Mosquito bite size;
THYM	cis	rs11840576	0.643	rs149577	chr13:110318648	G/A	cg16896868	chr13:110319562	NA	-0.8	-6.96	-0.58	4.43e-10	Paclitaxel disposition in epithelial ovarian cancer;
THYM	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg02696790	chr15:75250997	RPP25	-0.46	-4.72	-0.44	8.11e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs2976388	0.609	rs2263092	chr8:143789966	A/G	cg06565975	chr8:143823917	SLURP1	0.47	5.22	0.47	1.06e-6	Urinary tract infection frequency;
THYM	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg17691542	chr6:26056736	HIST1H1C	0.88	5.35	0.48	5.99e-7	Iron status biomarkers;
THYM	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02475777	chr4:1388615	CRIPAK	-0.65	-4.78	-0.44	6.34e-6	Longevity;
THYM	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg03517284	chr6:25882590	NA	-1.02	-9.86	-0.71	3.21e-16	Intelligence (multi-trait analysis);
THYM	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg24531977	chr5:56204891	C5orf35	-0.72	-5.83	-0.51	7.64e-8	Initial pursuit acceleration;
THYM	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs1729951	0.546	rs12054218	chr3:136677496	C/G	cg21827317	chr3:136751795	NA	0.75	6.64	0.56	1.92e-9	Neuroticism;
THYM	cis	rs10929159	0.928	rs2317305	chr2:236922151	G/A	cg14895183	chr2:236924282	AGAP1	0.54	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs2130392	0.926	rs7680323	chr4:185652871	A/T	cg04058563	chr4:185651563	MLF1IP	-0.62	-6.01	-0.52	3.47e-8	Kawasaki disease;
THYM	cis	rs10788972	0.633	rs34374665	chr1:54580106	C/A	cg13191808	chr1:55505327	PCSK9	0.51	4.57	0.42	1.48e-5	Parkinson disease and lewy body pathology;
THYM	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg11266682	chr4:10021025	SLC2A9	0.74	10.8	0.74	3.21e-18	Bone mineral density;
THYM	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg17211192	chr8:82754475	SNX16	-0.9	-7.35	-0.6	6.83e-11	Diastolic blood pressure;
THYM	cis	rs611744	0.967	rs631031	chr8:109190032	G/A	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg05234568	chr11:5960015	NA	0.62	5.55	0.49	2.6e-7	DNA methylation (variation);
THYM	cis	rs6733011	0.578	rs10172158	chr2:99509605	T/C	cg08885076	chr2:99613938	TSGA10	-0.45	-4.48	-0.42	2.1e-5	Bipolar disorder;
THYM	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6754311	0.593	rs10928542	chr2:136410299	G/A	cg07169764	chr2:136633963	MCM6	0.7	5.67	0.5	1.55e-7	Mosquito bite size;
THYM	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg11764359	chr7:65958608	NA	0.7	4.88	0.45	4.21e-6	Aortic root size;
THYM	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg24130564	chr14:104152367	KLC1	-0.66	-5.88	-0.52	6.14e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7000551	0.725	rs2249098	chr8:22400098	T/C	cg12081754	chr8:22256438	SLC39A14	0.69	6.2	0.54	1.42e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg21775007	chr8:11205619	TDH	-0.73	-5.68	-0.5	1.49e-7	Retinal vascular caliber;
THYM	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg07424592	chr7:64974309	NA	0.99	5.03	0.46	2.27e-6	Diabetic kidney disease;
THYM	cis	rs8008758	1.000	rs8008758	chr14:101690045	A/C	cg26224664	chr14:101693935	NA	0.56	4.75	0.44	7.34e-6	Body mass index (alcohol intake interaction);
THYM	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg12311346	chr5:56204834	C5orf35	-0.79	-5.64	-0.5	1.71e-7	Initial pursuit acceleration;
THYM	cis	rs4654899	0.865	rs61779065	chr1:21356474	A/T	cg01072550	chr1:21505969	NA	-0.75	-6.6	-0.56	2.29e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	7.04	0.59	2.93e-10	Smoking behavior;
THYM	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg09165964	chr15:75287851	SCAMP5	-1.0	-9.02	-0.68	2.08e-14	Blood trace element (Zn levels);
THYM	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22433210	chr17:43662623	NA	1.06	8.36	0.65	5.23e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg12564285	chr5:131593104	PDLIM4	0.43	4.66	0.43	1.04e-5	Breast cancer;
THYM	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg26818010	chr10:134567672	INPP5A	-0.91	-7.34	-0.6	7.06e-11	Migraine;
THYM	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg18252515	chr7:66147081	NA	-1.63	-8.86	-0.67	4.45e-14	Diabetic kidney disease;
THYM	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg07621104	chr11:117668040	DSCAML1	0.83	6.82	0.57	8.58e-10	Myopia;
THYM	cis	rs17094222	0.504	rs12267029	chr10:102458677	C/A	cg26540559	chr10:102447443	NA	0.72	6.21	0.54	1.36e-8	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs684232	0.666	rs461521	chr17:622497	G/T	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.39	-4.71	-0.43	8.55e-6	Prostate cancer;
THYM	cis	rs4731207	0.698	rs3815221	chr7:124481245	G/A	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs3008870	0.816	rs1118392	chr1:67366549	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.82	-6.55	-0.56	2.92e-9	Lymphocyte percentage of white cells;
THYM	cis	rs4343996	0.530	rs10262783	chr7:3431165	T/C	cg21248987	chr7:3385318	SDK1	0.4	5.25	0.47	9.31e-7	Motion sickness;
THYM	cis	rs9902453	0.765	rs2729436	chr17:28120670	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.61	-0.43	1.24e-5	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs593982	0.925	rs585272	chr11:65505289	A/G	cg08755490	chr11:65554678	OVOL1	1.36	8.73	0.67	8.51e-14	Atopic dermatitis;
THYM	cis	rs1691799	0.806	rs1168319	chr12:66744857	T/A	cg16791601	chr12:66731901	HELB	-0.75	-7.25	-0.6	1.08e-10	White blood cell count (basophil);
THYM	cis	rs4788570	0.584	rs6499528	chr16:71672762	T/C	cg06353428	chr16:71660113	MARVELD3	1.36	9.32	0.69	4.74e-15	Intelligence (multi-trait analysis);
THYM	cis	rs1569175	0.522	rs2347286	chr2:200946393	T/C	cg23649088	chr2:200775458	C2orf69	-0.73	-5.1	-0.46	1.72e-6	Response to treatment for acute lymphoblastic leukemia;
THYM	cis	rs4930776	0.722	rs3782614	chr12:5775103	G/A	cg02086166	chr12:5775618	ANO2	-0.55	-4.86	-0.45	4.66e-6	Plasma clusterin levels;
THYM	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg18477163	chr1:228402036	OBSCN	-0.43	-4.69	-0.43	8.96e-6	Diastolic blood pressure;
THYM	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg17757837	chr7:157058334	UBE3C	0.66	5.29	0.48	7.81e-7	Body mass index;
THYM	cis	rs887829	0.570	rs10445704	chr2:234600274	G/A	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.54	-4.57	-0.42	1.45e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg18876405	chr7:65276391	NA	0.63	5.53	0.49	2.83e-7	Aortic root size;
THYM	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg22508957	chr16:3507546	NAT15	-0.68	-9.1	-0.68	1.38e-14	Tuberculosis;
THYM	cis	rs55871839	0.684	rs10108037	chr8:59812337	A/C	cg07426533	chr8:59803705	TOX	-0.67	-6.88	-0.58	6.33e-10	Pneumonia;
THYM	cis	rs10274279	1.000	rs2021742	chr7:157381671	T/A	cg25259479	chr7:157408632	PTPRN2	-0.81	-4.56	-0.42	1.52e-5	Myopia (pathological);
THYM	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.7	-5.63	-0.5	1.83e-7	Prostate cancer;
THYM	cis	rs8070740	0.838	rs57745425	chr17:5327528	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.66	4.48	0.42	2.11e-5	Menopause (age at onset);
THYM	cis	rs6429082	0.608	rs4469707	chr1:235570634	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.62	-4.62	-0.43	1.19e-5	Adiposity;
THYM	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg00339695	chr16:24857497	SLC5A11	0.47	4.69	0.43	9.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9807841	0.617	rs892087	chr19:10794793	C/T	cg16900796	chr19:10755136	SLC44A2	0.35	5.59	0.5	2.19e-7	Inflammatory skin disease;
THYM	cis	rs10791097	0.967	rs1944142	chr11:130717440	C/T	cg22079354	chr11:130786696	SNX19	0.5	4.48	0.42	2.11e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg08968635	chr6:28129556	ZNF389	0.79	5.19	0.47	1.2e-6	Depression;
THYM	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg20295408	chr7:1910781	MAD1L1	-0.61	-4.85	-0.45	4.75e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.68	-5.28	-0.48	8.12e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9457247	0.534	rs7750593	chr6:167387359	C/G	cg15592062	chr6:167189543	RPS6KA2	0.52	5.32	0.48	6.84e-7	Crohn's disease;
THYM	cis	rs9677476	0.863	rs16827863	chr2:232077670	C/T	cg27665808	chr2:232055229	NA	-0.53	-4.45	-0.42	2.35e-5	Food antigen IgG levels;
THYM	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg18252515	chr7:66147081	NA	1.37	8.05	0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg12386194	chr3:101231763	SENP7	0.69	5.16	0.47	1.34e-6	Colorectal cancer;
THYM	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg14582100	chr15:45693742	SPATA5L1	0.56	4.63	0.43	1.17e-5	Homoarginine levels;
THYM	cis	rs448720	0.811	rs2458506	chr15:68182610	G/A	cg23793686	chr15:68133972	NA	-0.53	-4.8	-0.44	5.93e-6	Cognitive performance;
THYM	cis	rs4243830	0.850	rs2274553	chr1:6586553	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.06	-6.92	-0.58	5.26e-10	Body mass index;
THYM	cis	rs981844	0.816	rs62325145	chr4:154725687	G/C	cg09973105	chr4:154681532	RNF175	-0.66	-5.45	-0.49	3.98e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg06808227	chr14:105710500	BRF1	-1.03	-8.98	-0.68	2.5e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg06028605	chr16:24865363	SLC5A11	-0.63	-5.12	-0.47	1.59e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg04287289	chr16:89883240	FANCA	0.6	5.28	0.48	8.06e-7	Vitiligo;
THYM	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06634786	chr22:41940651	POLR3H	-0.75	-5.44	-0.49	4.09e-7	Vitiligo;
THYM	cis	rs611744	0.647	rs7016198	chr8:109262752	G/A	cg21045802	chr8:109455806	TTC35	0.63	5.66	0.5	1.62e-7	Dupuytren's disease;
THYM	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg05738196	chr6:26577821	NA	0.86	8.72	0.67	9.13e-14	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19346786	chr7:2764209	NA	-0.84	-7.87	-0.63	5.55e-12	Height;
THYM	cis	rs12310956	0.532	rs1352210	chr12:33983187	A/G	cg06521331	chr12:34319734	NA	-0.89	-8.32	-0.65	6.41e-13	Morning vs. evening chronotype;
THYM	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg17480646	chr11:65405466	SIPA1	-0.91	-8.37	-0.65	5.06e-13	Acne (severe);
THYM	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	9.51	0.7	1.8e-15	Platelet count;
THYM	cis	rs12752838	0.777	rs10864368	chr1:8918313	A/G	cg10211414	chr1:8875053	RERE	-0.66	-6.57	-0.56	2.63e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs6754311	0.509	rs13412397	chr2:136470714	G/A	cg04750100	chr2:136595281	LCT	-0.57	-6.01	-0.52	3.44e-8	Mosquito bite size;
THYM	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg22535103	chr8:58192502	C8orf71	-0.99	-6.27	-0.54	1.05e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs4866334	1.000	rs77016925	chr5:18487933	T/C	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs72843506	0.656	rs2385960	chr17:19938217	C/A	cg12065943	chr17:19881925	AKAP10	-0.76	-4.58	-0.43	1.41e-5	Schizophrenia;
THYM	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg10164272	chr16:89456328	ANKRD11	0.62	4.46	0.42	2.23e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1558375	0.679	rs31672	chr7:87059699	C/T	cg04996195	chr7:87105398	ABCB4	-0.59	-4.53	-0.42	1.73e-5	Gallbladder cancer;
THYM	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg08859206	chr1:53392774	SCP2	0.58	6.59	0.56	2.42e-9	Monocyte count;
THYM	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg05234568	chr11:5960015	NA	-0.62	-5.59	-0.5	2.18e-7	DNA methylation (variation);
THYM	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg13395646	chr4:1353034	KIAA1530	-0.61	-5.22	-0.47	1.03e-6	Obesity-related traits;
THYM	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg17328964	chr8:145687451	CYHR1	-0.89	-9.06	-0.68	1.67e-14	Age at first birth;
THYM	cis	rs6546324	0.625	rs2861689	chr2:67838604	C/G	cg18237512	chr2:67827392	NA	-0.73	-4.51	-0.42	1.82e-5	Endometriosis;
THYM	cis	rs782590	0.870	rs2586950	chr2:55868966	T/G	cg03859395	chr2:55845619	SMEK2	0.61	5.3	0.48	7.63e-7	Metabolic syndrome;
THYM	cis	rs11603020	0.950	rs28362947	chr11:57369008	C/G	cg19752551	chr11:57585705	CTNND1	-0.57	-4.8	-0.44	5.82e-6	Blood protein levels;
THYM	cis	rs2721195	0.816	rs4251689	chr8:145741130	C/T	cg26752003	chr8:145688521	CYHR1	-0.74	-6.0	-0.52	3.65e-8	Age at first birth;
THYM	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg19897017	chr7:2163380	MAD1L1	0.45	4.79	0.44	6.24e-6	Schizophrenia;
THYM	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg08754478	chr10:133766260	PPP2R2D	0.86	5.92	0.52	5.14e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs6684428	1.000	rs12123418	chr1:56383394	C/T	cg11651538	chr1:56320950	NA	0.64	5.13	0.47	1.5e-6	Airflow obstruction;
THYM	cis	rs28595532	0.920	rs114165587	chr4:119779525	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.08	0.46	1.92e-6	Cannabis dependence symptom count;
THYM	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg02527881	chr3:46936655	PTH1R	0.55	5.2	0.47	1.16e-6	Colorectal cancer;
THYM	cis	rs6032067	0.759	rs6104052	chr20:43808783	T/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.67	-7.66	-0.62	1.54e-11	Blood protein levels;
THYM	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg26384229	chr12:38710491	ALG10B	0.92	7.34	0.6	7.32e-11	Bladder cancer;
THYM	cis	rs669446	0.561	rs664728	chr1:44101714	A/T	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs6438424	0.967	rs11715566	chr3:117562436	C/T	cg07190778	chr3:117604296	NA	-0.37	-4.96	-0.45	3.06e-6	Menarche (age at onset);
THYM	cis	rs2439831	0.614	rs2467733	chr15:43693328	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.68	4.7	0.43	8.71e-6	Lung cancer in ever smokers;
THYM	cis	rs9914988	0.943	rs9894335	chr17:27138483	C/A	cg20469991	chr17:27169893	C17orf63	-0.76	-4.9	-0.45	3.96e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs11096990	0.964	rs6835064	chr4:39265966	A/T	cg24403649	chr4:39172243	NA	-0.68	-5.75	-0.51	1.09e-7	Cognitive function;
THYM	cis	rs12530845	0.524	rs7795267	chr7:135308455	C/G	cg23117316	chr7:135346802	PL-5283	-0.65	-4.98	-0.46	2.79e-6	Red blood cell traits;
THYM	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg06618935	chr21:46677482	NA	0.95	9.14	0.68	1.14e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11118993	0.902	rs10863701	chr1:206715716	G/A	cg19452316	chr1:206680966	RASSF5	0.64	5.23	0.47	1.02e-6	Neurofibrillary tangles;
THYM	cis	rs4662750	0.580	rs4662745	chr2:128352863	T/G	cg01966334	chr2:128378434	MYO7B	0.62	5.52	0.49	2.98e-7	Renal cell carcinoma;
THYM	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg13390004	chr1:15929781	NA	0.63	4.79	0.44	6.2e-6	Systolic blood pressure;
THYM	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg20503657	chr10:835505	NA	1.15	8.11	0.64	1.78e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs4513633	0.656	rs12649213	chr4:113450367	G/A	cg27432847	chr4:113444372	NA	-0.56	-4.68	-0.43	9.49e-6	Interleukin-16 levels;
THYM	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.78	-4.94	-0.45	3.4e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6598955	0.671	rs10902735	chr1:26617936	C/T	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.95	0.45	3.22e-6	Obesity-related traits;
THYM	cis	rs4851254	0.660	rs13430705	chr2:100690616	G/A	cg22139774	chr2:100720529	AFF3	-0.41	-4.69	-0.43	9.07e-6	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs115878132	chr4:119756239	T/A	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs12681287	0.673	rs2976178	chr8:87332552	C/G	cg27223183	chr8:87520930	FAM82B	-0.75	-5.49	-0.49	3.31e-7	Caudate activity during reward;
THYM	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs986417	0.688	rs8018111	chr14:60964347	A/G	cg27398547	chr14:60952738	C14orf39	1.16	6.51	0.56	3.6e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs9549260	0.755	rs2721067	chr13:41156708	C/T	cg21288729	chr13:41239152	FOXO1	0.66	5.22	0.47	1.06e-6	Red blood cell count;
THYM	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg18681998	chr4:17616180	MED28	-1.0	-10.49	-0.73	1.52e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg06108461	chr20:60628389	TAF4	-0.81	-6.42	-0.55	5.36e-9	Body mass index;
THYM	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg09904177	chr6:26538194	HMGN4	0.64	5.41	0.49	4.78e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs11096990	0.855	rs1820939	chr4:39171735	C/T	cg24403649	chr4:39172243	NA	-0.66	-5.61	-0.5	1.99e-7	Cognitive function;
THYM	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg08439880	chr3:133502540	NA	0.71	5.59	0.5	2.18e-7	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs7582180	0.568	rs10186134	chr2:100939501	T/A	cg08017756	chr2:100939284	LONRF2	-0.74	-7.68	-0.62	1.41e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg26038318	chr20:34205095	SPAG4	0.65	5.33	0.48	6.57e-7	Total cholesterol levels;
THYM	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg18352616	chr4:3374830	RGS12	0.77	8.74	0.67	8.24e-14	Serum sulfate level;
THYM	cis	rs6921919	0.583	rs6908137	chr6:28370393	A/C	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.5	-0.42	1.89e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10489202	0.634	rs11582396	chr1:168077636	C/T	cg24449463	chr1:168025552	DCAF6	-0.69	-5.96	-0.52	4.22e-8	Schizophrenia;
THYM	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs714027	1.000	rs2412970	chr22:30486826	C/T	cg11564601	chr22:30592435	NA	0.3	5.45	0.49	3.98e-7	Lymphocyte counts;
THYM	cis	rs728616	0.717	rs61860016	chr10:81915889	G/C	cg18148530	chr10:81370782	SFTPA1	0.75	4.85	0.45	4.73e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs1348850	0.526	rs10497504	chr2:178370040	T/C	cg27490568	chr2:178487706	NA	0.67	5.35	0.48	5.99e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6480314	0.831	rs1900007	chr10:69977775	G/A	cg27159792	chr10:69524182	NA	0.72	4.57	0.42	1.49e-5	Optic nerve measurement (disc area);
THYM	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg16060761	chr17:80687452	NA	0.6	4.8	0.44	5.89e-6	Glycated hemoglobin levels;
THYM	cis	rs9470366	0.816	rs7774130	chr6:36623756	C/T	cg11920449	chr6:36645608	CDKN1A	-0.68	-5.29	-0.48	7.7e-7	QRS duration;
THYM	cis	rs289828	0.538	rs35613168	chr2:152153348	A/C	cg05960677	chr2:152117363	RBM43	0.71	6.86	0.58	7.1e-10	Blood protein levels;
THYM	cis	rs1003719	0.725	rs2187101	chr21:38452379	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.7	4.91	0.45	3.82e-6	Eye color traits;
THYM	cis	rs909002	0.849	rs3753611	chr1:32082486	C/T	cg13919466	chr1:32135498	COL16A1	-0.49	-4.56	-0.42	1.54e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg17545662	chr6:170176663	C6orf70	0.64	5.39	0.48	5.2e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg12419862	chr22:24373484	LOC391322	0.75	6.99	0.58	3.72e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3008870	0.920	rs975452	chr1:67480190	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.93	7.76	0.62	9.52e-12	Lymphocyte percentage of white cells;
THYM	cis	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg21775007	chr8:11205619	TDH	0.67	5.45	0.49	4.01e-7	Retinal vascular caliber;
THYM	cis	rs12681287	0.640	rs72606633	chr8:87476236	T/C	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg03060546	chr3:49711283	APEH	0.75	6.08	0.53	2.55e-8	Resting heart rate;
THYM	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg07061783	chr6:25882402	NA	0.72	5.85	0.51	6.84e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg04117972	chr1:227635322	NA	0.89	5.21	0.47	1.07e-6	Major depressive disorder;
THYM	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg08000102	chr2:233561755	GIGYF2	-0.54	-4.87	-0.45	4.52e-6	Coronary artery disease;
THYM	cis	rs36051895	0.603	rs10974972	chr9:5130146	G/A	cg02405213	chr9:5042618	JAK2	-1.01	-10.97	-0.75	1.39e-18	Pediatric autoimmune diseases;
THYM	cis	rs6901250	1.000	rs615199	chr6:117113653	T/C	cg12892004	chr6:117198278	RFX6	0.72	6.64	0.56	1.94e-9	C-reactive protein levels;
THYM	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg22496339	chr2:162101262	NA	0.71	5.37	0.48	5.55e-7	Intelligence (multi-trait analysis);
THYM	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs2562456	0.755	rs2562421	chr19:21631304	T/G	cg21751540	chr19:21541537	ZNF738	0.8	5.29	0.48	7.69e-7	Pain;
THYM	cis	rs2811415	0.597	rs10934844	chr3:127749651	T/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg04944784	chr2:26401820	FAM59B	-1.09	-8.74	-0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs6840360	0.571	rs4696101	chr4:152528513	A/G	cg22705602	chr4:152727874	NA	-0.82	-8.88	-0.67	4.01e-14	Intelligence (multi-trait analysis);
THYM	cis	rs10752881	1.000	rs6658501	chr1:182991417	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.56	-4.48	-0.42	2.09e-5	Colorectal cancer;
THYM	cis	rs1322639	0.575	rs9294966	chr6:169565318	G/T	cg04662567	chr6:169592167	NA	-0.77	-6.08	-0.53	2.49e-8	Pulse pressure;
THYM	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.37	5.27	0.48	8.36e-7	Obesity-related traits;
THYM	cis	rs4474465	0.607	rs7930161	chr11:78268878	C/A	cg19901956	chr11:77921274	USP35	0.69	4.93	0.45	3.49e-6	Alzheimer's disease (survival time);
THYM	cis	rs7144547	0.803	rs8008602	chr14:81890171	T/A	cg02996355	chr14:81879375	NA	-0.95	-9.49	-0.7	2.02e-15	Prudent dietary pattern;
THYM	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9515201	0.774	rs9521739	chr13:111038803	A/G	cg05272587	chr13:111038400	COL4A2	-0.55	-4.5	-0.42	1.9e-5	White matter hyperintensity burden;
THYM	cis	rs6840360	0.642	rs10857260	chr4:152424056	C/G	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs728616	0.867	rs17879726	chr10:81698723	G/A	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg22981736	chr15:31284413	MTMR10	-0.56	-4.85	-0.45	4.84e-6	Huntington's disease progression;
THYM	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg00981070	chr1:2046702	PRKCZ	-0.45	-5.13	-0.47	1.53e-6	Height;
THYM	cis	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.57	-5.82	-0.51	8.08e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2276314	1.000	rs1540042	chr18:33555236	C/T	cg05985134	chr18:33552581	C18orf21	0.68	4.77	0.44	6.59e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg13736514	chr6:26305472	NA	0.65	6.51	0.56	3.58e-9	Mosquito bite size;
THYM	cis	rs4836390	0.656	rs11241969	chr5:128041757	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	4.64	0.43	1.09e-5	Coronary artery disease;
THYM	cis	rs11077998	0.967	rs4789788	chr17:80510285	C/T	cg10255544	chr17:80519551	FOXK2	-0.52	-4.59	-0.43	1.33e-5	Reticulocyte fraction of red cells;
THYM	cis	rs12347191	0.500	rs907582	chr9:100621926	T/C	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Orofacial clefts;
THYM	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg02887458	chr19:19495540	GATAD2A	-0.49	-5.38	-0.48	5.37e-7	Bipolar disorder;
THYM	cis	rs240764	0.658	rs35967345	chr6:101187858	T/G	cg21058520	chr6:100914733	NA	0.56	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.21	-0.64	1.07e-12	Mean corpuscular volume;
THYM	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg06112835	chr11:68658793	MRPL21	0.43	6.08	0.53	2.48e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs28595532	0.920	rs115259971	chr4:119762654	T/C	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs10992471	0.580	rs7030920	chr9:95122952	A/G	cg14631576	chr9:95140430	CENPP	-1.04	-11.32	-0.76	2.57e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs61931739	0.534	rs4547187	chr12:34041259	T/C	cg10856724	chr12:34555212	NA	-0.75	-6.73	-0.57	1.25e-9	Morning vs. evening chronotype;
THYM	cis	rs7020830	0.931	rs9775431	chr9:37130433	G/A	cg14294708	chr9:37120828	ZCCHC7	1.27	14.43	0.83	1.13e-25	Schizophrenia;
THYM	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg14458575	chr2:238380390	NA	0.98	8.37	0.65	5.03e-13	Prostate cancer;
THYM	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg18477163	chr1:228402036	OBSCN	0.66	6.61	0.56	2.24e-9	Diastolic blood pressure;
THYM	cis	rs9420	0.961	rs11606396	chr11:57435211	C/T	cg19752551	chr11:57585705	CTNND1	-0.73	-8.02	-0.64	2.79e-12	Schizophrenia;
THYM	cis	rs1788820	0.917	rs1788785	chr18:21142340	T/C	cg14672496	chr18:21087552	C18orf8	0.8	6.46	0.55	4.43e-9	Body mass index;
THYM	cis	rs8014204	0.566	rs7145575	chr14:75145528	T/A	cg06637938	chr14:75390232	RPS6KL1	0.56	5.06	0.46	2.05e-6	Caffeine consumption;
THYM	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg24375607	chr4:120327624	NA	0.65	5.19	0.47	1.18e-6	Corneal astigmatism;
THYM	cis	rs8102476	0.703	rs4803899	chr19:38727640	A/T	cg08196968	chr19:38746749	PPP1R14A	0.48	5.39	0.48	5.02e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg13683864	chr3:40499215	RPL14	-0.91	-8.72	-0.67	8.93e-14	Renal cell carcinoma;
THYM	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.59	4.45	0.42	2.35e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs4731207	0.564	rs12531996	chr7:124619460	T/C	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs7582180	0.577	rs6542942	chr2:100985378	G/T	cg08017756	chr2:100939284	LONRF2	-0.75	-7.52	-0.61	3e-11	Intelligence (multi-trait analysis);
THYM	cis	rs11657217	0.677	rs8072274	chr17:77701601	A/C	cg06901238	chr17:77706717	ENPP7	0.79	7.63	0.62	1.78e-11	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
THYM	cis	rs899997	1.000	rs755998	chr15:79032469	C/T	cg00639195	chr15:79103007	ADAMTS7	-0.81	-5.72	-0.51	1.24e-7	Coronary artery disease or large artery stroke;
THYM	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.61	4.66	0.43	1.01e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12282928	0.959	rs1483122	chr11:48327186	T/A	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs4654899	0.601	rs6668094	chr1:21464387	C/T	cg01072550	chr1:21505969	NA	0.8	7.91	0.63	4.63e-12	Superior frontal gyrus grey matter volume;
THYM	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg18538332	chr22:24372958	LOC391322	-1.06	-14.14	-0.82	4.22e-25	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg02725872	chr8:58115012	NA	-1.08	-8.26	-0.65	8.3e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7572733	0.534	rs700664	chr2:198671145	C/T	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs6541297	0.941	rs6665258	chr1:230279058	G/A	cg20703242	chr1:230279135	GALNT2	0.92	6.26	0.54	1.13e-8	Coronary artery disease;
THYM	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg12419862	chr22:24373484	LOC391322	-0.81	-8.54	-0.66	2.14e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs490234	0.702	rs13302549	chr9:128284775	T/C	cg14078157	chr9:128172775	NA	-0.76	-6.24	-0.54	1.23e-8	Mean arterial pressure;
THYM	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg06636001	chr8:8085503	FLJ10661	0.66	5.77	0.51	1e-7	Mood instability;
THYM	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs3741151	0.773	rs73542979	chr11:73127526	G/C	cg17517138	chr11:73019481	ARHGEF17	0.94	5.48	0.49	3.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg14186256	chr22:23484241	RTDR1	0.96	9.57	0.7	1.38e-15	Bone mineral density;
THYM	cis	rs1729407	0.709	rs2098453	chr11:116696680	C/T	cg08985259	chr11:116699649	APOC3	-0.61	-5.44	-0.49	4.15e-7	Apolipoprotein A-IV levels;
THYM	cis	rs1784581	0.588	rs6455789	chr6:162417948	C/T	cg17173639	chr6:162384350	PARK2	0.81	7.48	0.61	3.75e-11	Itch intensity from mosquito bite;
THYM	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg19507638	chr5:93509721	C5orf36	-0.67	-4.5	-0.42	1.95e-5	Diabetic retinopathy;
THYM	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	6.04	0.53	2.96e-8	Schizophrenia;
THYM	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.69	5.48	0.49	3.51e-7	Renal function-related traits (BUN);
THYM	cis	rs4938534	0.559	rs1944918	chr11:111261995	A/G	cg18316498	chr11:111250196	POU2AF1	0.54	4.51	0.42	1.86e-5	Primary biliary cholangitis;
THYM	cis	rs7106204	0.748	rs4382909	chr11:24236618	C/T	ch.11.24196551F	chr11:24239977	NA	1.0	7.01	0.58	3.4e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs2273669	0.667	rs1424479	chr6:109355790	G/T	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg18876405	chr7:65276391	NA	0.76	7.24	0.6	1.19e-10	Aortic root size;
THYM	cis	rs3126085	0.935	rs4511113	chr1:152222192	G/A	cg10321714	chr1:152280068	FLG	0.65	4.64	0.43	1.1e-5	Atopic dermatitis;
THYM	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs988913	0.957	rs9382396	chr6:54760686	G/T	cg18532076	chr6:54711417	FAM83B	0.47	4.47	0.42	2.13e-5	Menarche (age at onset);
THYM	cis	rs7084402	1.000	rs6481400	chr10:60268783	T/C	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg08859206	chr1:53392774	SCP2	-0.49	-5.15	-0.47	1.4e-6	Monocyte count;
THYM	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2797160	1.000	rs1832979	chr6:125997436	A/G	cg16306078	chr6:126000798	NA	-0.52	-5.3	-0.48	7.65e-7	Endometrial cancer;
THYM	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg22467129	chr15:76604101	ETFA	-0.57	-5.41	-0.49	4.76e-7	Blood metabolite levels;
THYM	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg17054759	chr22:49844102	NA	-0.55	-5.29	-0.48	7.92e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg27454412	chr7:1067447	C7orf50	0.59	4.91	0.45	3.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10140922	0.966	rs10140133	chr14:35819834	C/G	cg07166546	chr14:35805898	NA	-0.26	-6.41	-0.55	5.56e-9	Hip circumference adjusted for BMI;
THYM	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg11764359	chr7:65958608	NA	0.65	5.05	0.46	2.11e-6	Aortic root size;
THYM	cis	rs4746818	0.892	rs10823298	chr10:70867083	T/C	cg11621586	chr10:70884670	VPS26A	0.91	6.03	0.53	3.09e-8	Left atrial antero-posterior diameter;
THYM	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg11247378	chr22:39784982	NA	-1.08	-13.56	-0.81	6.12e-24	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.596	rs1404898	chr7:124694339	G/T	cg05285228	chr7:124571219	POT1	-0.65	-4.86	-0.45	4.58e-6	Cutaneous malignant melanoma;
THYM	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7591472	1	rs7591472	chr2:201889751	C/T	cg08474651	chr2:201729683	CLK1	0.37	4.75	0.44	7.2e-6	Triptolide cytotoxicity;
THYM	cis	rs11030122	0.569	rs11030781	chr11:4083258	T/C	cg18678763	chr11:4115507	RRM1	-0.41	-5.33	-0.48	6.72e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7267979	0.816	rs8115257	chr20:25207931	A/G	cg03522245	chr20:25566470	NINL	0.66	4.98	0.46	2.79e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg03188948	chr7:1209495	NA	0.59	4.57	0.42	1.48e-5	Longevity;Endometriosis;
THYM	cis	rs713587	0.713	rs11682135	chr2:25205377	G/A	cg01884057	chr2:25150051	NA	-0.56	-5.49	-0.49	3.37e-7	Body mass index in non-asthmatics;
THYM	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg23352942	chr3:46931381	PTH1R	0.89	11.74	0.77	3.37e-20	Birth weight;
THYM	cis	rs8067545	0.750	rs4925085	chr17:20000131	G/T	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.61e-6	Schizophrenia;
THYM	cis	rs611744	0.550	rs1448154	chr8:109281053	T/C	cg21045802	chr8:109455806	TTC35	0.69	6.21	0.54	1.42e-8	Dupuytren's disease;
THYM	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg20608306	chr11:116969690	SIK3	0.51	5.45	0.49	3.96e-7	Blood protein levels;
THYM	cis	rs13256369	0.774	rs13248423	chr8:8577602	C/G	cg18904891	chr8:8559673	CLDN23	0.68	5.1	0.46	1.74e-6	Obesity-related traits;
THYM	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.38	0.48	5.3e-7	Tonsillectomy;
THYM	cis	rs10887741	0.606	rs3824722	chr10:89435723	C/G	cg13926569	chr10:89418898	PAPSS2	0.63	7.28	0.6	9.67e-11	Exercise (leisure time);
THYM	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg26384229	chr12:38710491	ALG10B	0.93	7.31	0.6	8.23e-11	Bladder cancer;
THYM	cis	rs4845570	0.850	rs4618976	chr1:151766588	A/G	cg07092448	chr1:151763213	TDRKH	1.02	6.25	0.54	1.19e-8	Coronary artery disease;
THYM	cis	rs911119	0.954	rs2424582	chr20:23622550	A/G	cg16589663	chr20:23618590	CST3	0.75	4.65	0.43	1.08e-5	Chronic kidney disease;
THYM	cis	rs28595532	0.920	rs115485705	chr4:119733286	G/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg26384229	chr12:38710491	ALG10B	0.97	7.38	0.6	5.91e-11	Morning vs. evening chronotype;
THYM	cis	rs1335645	0.649	rs7550484	chr1:111673355	C/T	cg00321911	chr1:111669324	DRAM2	-1.19	-6.66	-0.56	1.77e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg04602696	chr16:88846723	FAM38A	-0.68	-4.91	-0.45	3.73e-6	Plateletcrit;
THYM	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg03213289	chr20:61660250	NA	0.98	10.7	0.74	5.26e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg12935359	chr14:103987150	CKB	0.48	5.37	0.48	5.52e-7	Intelligence (multi-trait analysis);
THYM	cis	rs28795989	0.931	rs7686202	chr4:7898577	C/T	cg00251875	chr4:7801337	AFAP1	0.58	4.7	0.43	8.64e-6	Intraocular pressure;
THYM	cis	rs7626444	0.625	rs7648479	chr3:196477213	G/C	cg12930392	chr3:196481615	PAK2	0.38	4.54	0.42	1.67e-5	Monocyte count;
THYM	cis	rs2204008	0.594	rs2711545	chr12:38061039	C/T	cg26384229	chr12:38710491	ALG10B	0.72	5.52	0.49	2.98e-7	Bladder cancer;
THYM	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg24812749	chr6:127587940	RNF146	0.87	6.2	0.54	1.44e-8	Breast cancer;
THYM	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg03929089	chr4:120376271	NA	1.03	8.74	0.67	8.32e-14	Height;
THYM	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg22508957	chr16:3507546	NAT15	-0.7	-7.05	-0.59	2.91e-10	Tuberculosis;
THYM	cis	rs7312774	0.748	rs10492211	chr12:107298213	T/C	cg16260113	chr12:107380972	MTERFD3	1.05	5.57	0.5	2.4e-7	Severe influenza A (H1N1) infection;
THYM	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs807669	0.835	rs698423	chr22:19197896	T/C	cg02655711	chr22:19163373	SLC25A1	0.93	10.49	0.73	1.51e-17	Metabolite levels;
THYM	cis	rs8014204	0.575	rs1045430	chr14:75130235	T/G	cg06637938	chr14:75390232	RPS6KL1	0.59	5.44	0.49	4.19e-7	Caffeine consumption;
THYM	cis	rs72627123	0.867	rs57482759	chr14:74485523	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.86	4.91	0.45	3.77e-6	Morning vs. evening chronotype;
THYM	cis	rs7512552	0.803	rs3738487	chr1:150477061	C/T	cg15654264	chr1:150340011	RPRD2	0.45	5.22	0.47	1.06e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2070677	0.935	rs2070676	chr10:135351137	C/G	cg20169779	chr10:135381914	SYCE1	0.79	5.69	0.5	1.4e-7	Gout;
THYM	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-5.13	-0.47	1.55e-6	Lymphocyte counts;
THYM	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg03235661	chr20:60525775	NA	0.53	4.54	0.42	1.68e-5	Obesity-related traits;
THYM	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg00129232	chr17:37814104	STARD3	-0.76	-5.25	-0.47	9.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg04546413	chr19:29218101	NA	1.09	9.4	0.69	3.15e-15	Methadone dose in opioid dependence;
THYM	cis	rs9814567	0.727	rs4543053	chr3:134351724	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-7.37	-0.6	6.34e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs3126085	1.000	rs3126092	chr1:152307955	T/A	cg10321714	chr1:152280068	FLG	-0.72	-5.44	-0.49	4.14e-7	Atopic dermatitis;
THYM	cis	rs36051895	0.658	rs7030260	chr9:5008070	C/A	cg02405213	chr9:5042618	JAK2	-1.04	-11.24	-0.76	3.73e-19	Pediatric autoimmune diseases;
THYM	cis	rs1003719	0.715	rs35199609	chr21:38510262	T/C	cg01329690	chr21:38580129	DSCR9	-0.38	-5.21	-0.47	1.09e-6	Eye color traits;
THYM	cis	rs7119	0.637	rs2667775	chr15:77864802	T/G	cg27398640	chr15:77910606	LINGO1	0.65	7.36	0.6	6.45e-11	Type 2 diabetes;
THYM	cis	rs2033562	0.931	rs10095950	chr8:103545008	A/G	cg20611272	chr8:103548145	NA	0.4	4.99	0.46	2.77e-6	IgA nephropathy;
THYM	cis	rs986417	0.818	rs12883272	chr14:61015153	A/G	cg27398547	chr14:60952738	C14orf39	1.0	5.05	0.46	2.14e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs66887589	0.560	rs9684327	chr4:120365441	A/G	cg13609457	chr4:120235615	NA	0.47	4.88	0.45	4.28e-6	Diastolic blood pressure;
THYM	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.77	-5.02	-0.46	2.45e-6	Mean platelet volume;
THYM	cis	rs5769707	0.642	rs4824070	chr22:50031521	T/C	cg07959070	chr22:50026188	C22orf34	-0.27	-4.87	-0.45	4.48e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.43	1.27e-5	Breast cancer;
THYM	cis	rs7572733	0.534	rs1464209	chr2:198814396	A/G	cg00792783	chr2:198669748	PLCL1	0.82	5.75	0.51	1.08e-7	Dermatomyositis;
THYM	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs3126085	0.935	rs7534716	chr1:152198654	A/G	cg10321714	chr1:152280068	FLG	0.65	4.72	0.44	8.02e-6	Atopic dermatitis;
THYM	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.24	4.92	0.45	3.64e-6	Obesity-related traits;
THYM	cis	rs7122539	0.646	rs608248	chr11:66562248	C/T	cg24851651	chr11:66362959	CCS	-0.65	-5.6	-0.5	2.05e-7	HIV-1 susceptibility;
THYM	trans	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.11	8.17	0.64	1.3e-12	Exhaled nitric oxide output;
THYM	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg13939156	chr17:80058883	NA	0.4	5.3	0.48	7.65e-7	Life satisfaction;
THYM	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg18221576	chr1:22213934	HSPG2	-0.58	-4.88	-0.45	4.32e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9326248	0.539	rs660443	chr11:116760693	T/C	cg20608306	chr11:116969690	SIK3	0.62	7.38	0.6	5.92e-11	Blood protein levels;
THYM	cis	rs3857067	0.806	rs7669168	chr4:95104881	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.48	-0.42	2.07e-5	QT interval;
THYM	cis	rs1031391	0.716	rs10772416	chr12:11170087	T/A	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	0.92	5.93	0.52	4.79e-8	Bitter taste perception;
THYM	cis	rs6840360	0.642	rs1372977	chr4:152452398	G/A	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.31	-0.48	7.1e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs12579753	0.917	rs11610365	chr12:82218108	C/T	cg21231944	chr12:82153410	PPFIA2	-0.7	-5.38	-0.48	5.24e-7	Resting heart rate;
THYM	cis	rs1018836	0.847	rs4735225	chr8:91569100	G/C	cg16814680	chr8:91681699	NA	-0.78	-6.45	-0.55	4.73e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7786808	0.527	rs62478405	chr7:158188528	G/A	cg15440763	chr7:158190612	PTPRN2	0.49	4.61	0.43	1.24e-5	Obesity-related traits;
THYM	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg14456004	chr13:21872349	NA	-1.24	-10.0	-0.72	1.63e-16	White matter hyperintensity burden;
THYM	cis	rs75920871	0.502	rs10790166	chr11:116779499	A/G	cg20608306	chr11:116969690	SIK3	-0.43	-4.48	-0.42	2.04e-5	Subjective well-being;
THYM	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.641	rs35882692	chr20:43763968	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.67	-5.94	-0.52	4.77e-8	Blood protein levels;
THYM	cis	rs10504073	0.605	rs62507176	chr8:49930321	G/A	cg00325661	chr8:49890786	NA	1.04	10.53	0.73	1.2e-17	Blood metabolite ratios;
THYM	cis	rs4242434	0.672	rs11785031	chr8:22486612	A/G	cg03733263	chr8:22462867	KIAA1967	1.0	11.13	0.75	6.58e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg24250549	chr1:154909240	PMVK	0.69	5.08	0.46	1.87e-6	Prostate cancer;
THYM	cis	rs2294693	0.947	rs742492	chr6:40996381	G/A	cg14418226	chr6:40996092	UNC5CL	0.76	6.98	0.58	3.88e-10	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs8041943	0.643	rs2902952	chr15:79909729	T/C	cg20511832	chr15:78934280	CHRNB4	0.46	4.99	0.46	2.73e-6	Bone mineral density (spine) and age at menarche;
THYM	cis	rs12681287	0.547	rs7465511	chr8:87521481	C/T	cg27223183	chr8:87520930	FAM82B	-0.71	-5.47	-0.49	3.66e-7	Caudate activity during reward;
THYM	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg12373951	chr3:133503437	NA	0.56	6.17	0.53	1.69e-8	Iron status biomarkers;
THYM	cis	rs986417	0.892	rs57925468	chr14:60816129	G/A	cg27398547	chr14:60952738	C14orf39	-1.26	-6.29	-0.54	9.47e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs870825	0.616	rs2130393	chr4:185642335	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.69	0.71	7.45e-16	Blood protein levels;
THYM	cis	rs2034650	0.544	rs2289330	chr15:40705105	A/G	cg12699599	chr15:40643142	PHGR1	-0.59	-5.35	-0.48	6.05e-7	Interstitial lung disease;
THYM	cis	rs4455778	0.536	rs887451	chr7:48943352	T/C	cg26309511	chr7:48887640	NA	-0.65	-6.19	-0.54	1.51e-8	Lung cancer in never smokers;
THYM	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg05738196	chr6:26577821	NA	0.95	9.91	0.71	2.53e-16	Intelligence (multi-trait analysis);
THYM	cis	rs9914544	0.545	rs8068683	chr17:18761827	T/G	cg26378065	chr17:18585709	ZNF286B	0.6	4.71	0.43	8.56e-6	Educational attainment (years of education);
THYM	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.46e-7	Heart rate;
THYM	cis	rs7264396	0.528	rs7273880	chr20:34551507	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-4.8	-0.44	6.01e-6	Total cholesterol levels;
THYM	cis	rs1975974	1.000	rs4889732	chr17:21721443	T/C	cg18423549	chr17:21743878	NA	-0.55	-4.48	-0.42	2.07e-5	Psoriasis;
THYM	cis	rs12519773	0.555	rs1845840	chr5:92388210	G/A	cg18783429	chr5:92414398	NA	-0.49	-4.54	-0.42	1.63e-5	Migraine;
THYM	trans	rs10118776	0.677	rs13298301	chr9:6187242	A/G	cg02532923	chr16:89110004	NA	1.01	7.85	0.63	6.11e-12	Small cell lung carcinoma;
THYM	cis	rs17604090	0.775	rs10225523	chr7:29689735	C/A	cg19413766	chr7:29689036	LOC646762	-0.89	-4.92	-0.45	3.62e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs6430585	0.583	rs2304370	chr2:136561735	G/A	cg07169764	chr2:136633963	MCM6	1.07	12.68	0.79	3.76e-22	Corneal structure;
THYM	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg03676636	chr4:99064102	C4orf37	0.5	7.59	0.61	2.14e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2625529	0.824	rs12592044	chr15:72419115	A/G	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg23205692	chr1:25664452	TMEM50A	0.89	6.94	0.58	4.83e-10	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs3892630	0.824	rs35654350	chr19:33223766	T/C	cg22928329	chr19:33183273	NUDT19	-0.77	-5.75	-0.51	1.08e-7	Red blood cell traits;
THYM	cis	rs17784882	0.524	rs7433300	chr3:47120640	G/A	cg27129171	chr3:47204927	SETD2	0.79	7.59	0.61	2.15e-11	QT interval;
THYM	cis	rs1883415	0.727	rs2760129	chr6:24500368	T/G	cg00346970	chr6:24499591	ALDH5A1	0.39	5.08	0.46	1.89e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg18252515	chr7:66147081	NA	1.43	8.6	0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg12564285	chr5:131593104	PDLIM4	0.6	6.79	0.57	9.59e-10	Acylcarnitine levels;
THYM	cis	rs3771570	0.901	rs73008106	chr2:242422446	C/T	cg21155796	chr2:242212141	HDLBP	1.13	5.69	0.5	1.43e-7	Prostate cancer;
THYM	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg17063962	chr7:91808500	NA	1.11	12.24	0.78	3.11e-21	Breast cancer;
THYM	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1483890	0.642	rs9825845	chr3:69404572	C/A	cg22125112	chr3:69402811	FRMD4B	0.53	6.81	0.57	8.98e-10	Resting heart rate;
THYM	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg12165864	chr7:66369176	NA	-0.65	-5.08	-0.46	1.89e-6	Aortic root size;
THYM	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg17127132	chr2:85788382	GGCX	0.7	6.22	0.54	1.32e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg09307838	chr4:120376055	NA	0.77	5.61	0.5	2.02e-7	Corneal astigmatism;
THYM	cis	rs7107174	1.000	rs11601590	chr11:78073288	T/G	cg19901956	chr11:77921274	USP35	-0.65	-5.37	-0.48	5.66e-7	Testicular germ cell tumor;
THYM	cis	rs1021993	0.645	rs5008731	chr1:209470010	A/T	cg24997231	chr1:209527535	NA	0.5	4.55	0.42	1.57e-5	Gut microbiome composition (winter);
THYM	cis	rs250677	0.522	rs3763022	chr5:148381078	A/G	cg18129178	chr5:148520854	ABLIM3	-0.64	-5.04	-0.46	2.22e-6	Breast cancer;
THYM	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg16586182	chr3:47516702	SCAP	0.67	5.66	0.5	1.59e-7	QT interval;
THYM	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg04234412	chr22:24373322	LOC391322	0.92	9.31	0.69	4.89e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg02038168	chr22:39784481	NA	-0.62	-5.1	-0.46	1.73e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4886920	0.894	rs4587942	chr15:78119345	G/T	cg10461261	chr15:78109450	NA	-0.49	-4.83	-0.44	5.15e-6	Neuroticism;
THYM	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg05738196	chr6:26577821	NA	0.62	4.99	0.46	2.72e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs920590	0.796	rs11778257	chr8:19634598	A/T	cg01411142	chr8:19674711	INTS10	0.73	5.75	0.51	1.08e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg04750100	chr2:136595281	LCT	-0.55	-6.19	-0.54	1.51e-8	Mosquito bite size;
THYM	cis	rs2898681	0.614	rs962416	chr4:53695657	G/T	cg21521518	chr4:53727714	RASL11B	-0.47	-5.52	-0.49	2.89e-7	Optic nerve measurement (cup area);
THYM	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.66	-0.43	1.05e-5	Eye color traits;
THYM	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg13319975	chr6:146136371	FBXO30	0.72	6.09	0.53	2.44e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs990171	1.000	rs6750020	chr2:102994714	G/A	cg13897122	chr2:103039542	IL18RAP	-0.39	-4.79	-0.44	6.08e-6	Lymphocyte counts;
THYM	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg05872129	chr22:39784769	NA	-0.97	-10.24	-0.72	5.2e-17	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs7560272	0.695	rs780393	chr2:73701669	T/A	cg19565262	chr2:73869966	NAT8	0.64	5.17	0.47	1.3e-6	Schizophrenia;
THYM	cis	rs10493773	0.609	rs11161660	chr1:86184066	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.59	-9.23	-0.69	7.42e-15	Urate levels in overweight individuals;
THYM	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg00801512	chr17:28996047	NA	-0.75	-4.83	-0.44	5.19e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8078723	1.000	rs59925331	chr17:38169273	C/G	cg17467752	chr17:38218738	THRA	0.86	7.09	0.59	2.4e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs240764	0.635	rs6901854	chr6:100932291	C/T	cg21058520	chr6:100914733	NA	0.58	4.92	0.45	3.57e-6	Neuroticism;
THYM	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs8106542	0.865	rs1560710	chr19:10742443	C/T	cg17848348	chr19:10766748	ILF3	-0.8	-6.65	-0.56	1.88e-9	Platelet distribution width;
THYM	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg06634786	chr22:41940651	POLR3H	0.73	5.36	0.48	5.89e-7	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs9527	0.590	rs3740386	chr10:104931051	C/T	cg04362960	chr10:104952993	NT5C2	0.65	5.04	0.46	2.18e-6	Arsenic metabolism;
THYM	cis	rs1056053	0.514	rs3099268	chr6:166572826	T/C	cg11088901	chr6:166572345	T	-0.59	-5.34	-0.48	6.45e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6500395	0.962	rs7499213	chr16:48680597	T/C	cg04672837	chr16:48644449	N4BP1	0.49	4.76	0.44	7.03e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs4747241	0.593	rs9415064	chr10:74089364	C/T	cg07828833	chr10:74069493	NA	-0.59	-4.82	-0.44	5.49e-6	Heschl's gyrus morphology;
THYM	cis	rs7428	0.527	rs1554110	chr2:85547963	C/T	cg24342717	chr2:85555507	TGOLN2	-0.79	-6.32	-0.54	8.53e-9	Ear protrusion;
THYM	cis	rs3960554	0.808	rs4728587	chr7:75803132	C/T	cg17398381	chr7:75624190	TMEM120A	-0.47	-4.53	-0.42	1.75e-5	Eotaxin levels;
THYM	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg15536230	chr21:44985092	HSF2BP	-0.42	-5.18	-0.47	1.26e-6	Mean corpuscular volume;
THYM	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg18876405	chr7:65276391	NA	-0.64	-5.55	-0.49	2.58e-7	Aortic root size;
THYM	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	4.69	0.43	9e-6	Menarche (age at onset);
THYM	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg04717802	chr22:42394638	WBP2NL	0.74	4.66	0.43	1.02e-5	Birth weight;
THYM	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg19875535	chr5:140030758	IK	-0.67	-5.76	-0.51	1.05e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg17554472	chr22:41940697	POLR3H	0.66	4.69	0.43	9.23e-6	Vitiligo;
THYM	cis	rs6754459	1.000	rs6754459	chr2:3707423	C/T	cg10645314	chr2:3704589	ALLC	-0.78	-6.08	-0.53	2.53e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs7432375	0.933	rs55970317	chr3:136353193	T/G	cg21827317	chr3:136751795	NA	0.57	4.86	0.45	4.62e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs921968	0.565	rs6436072	chr2:219598095	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4940575	0.786	rs4940574	chr18:60837844	G/C	cg20947866	chr18:61143580	SERPINB5	0.9	5.34	0.48	6.28e-7	Breast cancer;
THYM	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg08736216	chr1:53307985	ZYG11A	-0.58	-5.29	-0.48	7.85e-7	Monocyte count;
THYM	cis	rs5760092	0.717	rs5760101	chr22:24248712	T/C	cg11905131	chr22:24372483	LOC391322	-0.76	-5.94	-0.52	4.64e-8	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs9522267	0.535	rs7326875	chr13:112236231	C/T	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs12532960	0.731	rs9638963	chr7:42377336	C/G	cg23473276	chr7:42834405	NA	0.91	4.69	0.43	9.19e-6	Inflammatory biomarkers;
THYM	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg18876405	chr7:65276391	NA	-0.64	-5.57	-0.5	2.32e-7	Aortic root size;
THYM	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-4.97	-0.45	2.92e-6	Hemoglobin concentration;
THYM	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.7	4.71	0.43	8.57e-6	Menarche (age at onset);
THYM	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs7834588	0.544	rs1947483	chr8:63811000	T/C	cg25248160	chr8:63776642	NKAIN3	-0.62	-5.21	-0.47	1.08e-6	Response to Vitamin E supplementation;
THYM	cis	rs36051895	0.664	rs3780373	chr9:5098223	T/C	cg02405213	chr9:5042618	JAK2	-1.0	-11.18	-0.75	5.12e-19	Pediatric autoimmune diseases;
THYM	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg10319629	chr12:132285459	NA	-0.53	-4.87	-0.45	4.36e-6	Migraine;
THYM	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg07157834	chr1:205819609	PM20D1	0.65	5.43	0.49	4.35e-7	Menarche (age at onset);
THYM	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.84	9.32	0.69	4.67e-15	Prudent dietary pattern;
THYM	cis	rs4891159	0.505	rs680253	chr18:74167427	A/C	cg24786174	chr18:74118243	ZNF516	-0.8	-10.54	-0.73	1.16e-17	Longevity;
THYM	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg22117172	chr7:91764530	CYP51A1	0.37	4.84	0.44	5.01e-6	Breast cancer;
THYM	trans	rs8002861	0.901	rs9525867	chr13:44463557	G/A	cg17145862	chr1:211918768	LPGAT1	1.0	10.59	0.74	9.04e-18	Leprosy;
THYM	cis	rs763014	0.898	rs8060921	chr16:635988	C/A	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs2070488	0.761	rs6807940	chr3:38460062	C/G	cg24069376	chr3:38537580	EXOG	0.41	4.46	0.42	2.28e-5	Electrocardiographic conduction measures;
THYM	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.09	-7.74	-0.62	1.06e-11	Platelet count;
THYM	cis	rs28595532	1.000	rs115004746	chr4:119642137	C/T	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs4589258	0.504	rs7128489	chr11:90387210	C/T	cg26138821	chr11:89956704	CHORDC1	0.62	4.49	0.42	1.98e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7107770	1.000	rs4935912	chr11:125090279	T/G	cg07747661	chr11:125106135	PKNOX2	-0.88	-5.0	-0.46	2.6e-6	Photic sneeze reflex;
THYM	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4731207	0.537	rs6466974	chr7:124609510	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs72627123	0.867	rs112464051	chr14:74483975	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg26597838	chr10:835615	NA	-1.23	-8.88	-0.67	4.1e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs12042938	0.600	rs1094656	chr1:231773675	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.7	4.88	0.45	4.23e-6	Neuranatomic and neurocognitive phenotypes;
THYM	cis	rs2229238	0.868	rs73023348	chr1:154513418	G/A	cg21262032	chr1:154437693	IL6R	-0.64	-5.79	-0.51	8.9e-8	Coronary heart disease;
THYM	cis	rs35660623	0.702	rs17152442	chr8:10657726	C/G	cg12395012	chr8:11607386	GATA4	0.96	5.25	0.47	9.42e-7	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs600806	0.850	rs11102976	chr1:109917540	G/C	cg23616212	chr1:109941201	SORT1	-0.49	-4.66	-0.43	1.01e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg11301795	chr4:187892539	NA	-1.12	-16.92	-0.87	2.01e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg27532560	chr4:187881888	NA	-0.96	-11.4	-0.76	1.72e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1569019	1.000	rs1976930	chr12:131576445	A/G	cg25772418	chr12:131519998	GPR133	0.56	4.62	0.43	1.23e-5	Height;
THYM	cis	rs11186	0.556	rs72906317	chr2:189956854	C/A	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs4343996	0.967	rs10224769	chr7:3347166	A/T	cg21248987	chr7:3385318	SDK1	0.4	4.83	0.44	5.22e-6	Motion sickness;
THYM	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg18850929	chr19:1828978	REXO1	-0.55	-4.88	-0.45	4.28e-6	Bipolar disorder;
THYM	cis	rs4601821	0.823	rs17115439	chr11:113264272	T/C	cg14159747	chr11:113255604	NA	0.24	4.45	0.42	2.32e-5	Alcoholic chronic pancreatitis;
THYM	cis	rs28595532	0.841	rs112953035	chr4:119752450	T/C	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg03806693	chr22:41940476	POLR3H	-0.78	-6.77	-0.57	1.05e-9	Neuroticism;
THYM	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg18252515	chr7:66147081	NA	1.48	8.83	0.67	5.15e-14	Diabetic kidney disease;
THYM	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.11	8.07	0.64	2.15e-12	Cognitive test performance;
THYM	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg04896959	chr15:78267971	NA	0.93	7.69	0.62	1.38e-11	Coronary artery disease or large artery stroke;
THYM	cis	rs3096299	0.967	rs2965937	chr16:89488779	A/T	cg02187348	chr16:89574699	SPG7	0.78	6.11	0.53	2.16e-8	Multiple myeloma (IgH translocation);
THYM	cis	rs4866334	1.000	rs77743777	chr5:18488452	G/A	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs9296092	0.538	rs62405942	chr6:33517346	G/A	cg13560919	chr6:33536144	NA	-0.94	-9.16	-0.68	1.03e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs59698941	0.943	rs66483023	chr5:132257748	A/T	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs4455778	0.580	rs35333419	chr7:49120543	A/C	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg26566898	chr11:117069891	TAGLN	0.4	5.16	0.47	1.36e-6	Blood protein levels;
THYM	cis	rs6032067	0.561	rs6032104	chr20:43932412	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.59	-5.14	-0.47	1.46e-6	Blood protein levels;
THYM	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg04607235	chr12:12878440	APOLD1	-0.93	-5.53	-0.49	2.79e-7	Systemic lupus erythematosus;
THYM	cis	rs2997447	0.723	rs56241003	chr1:26435919	C/T	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs7084402	0.967	rs3001714	chr10:60285494	A/G	cg07615347	chr10:60278583	BICC1	0.61	5.57	0.5	2.41e-7	Refractive error;
THYM	cis	rs2625529	0.617	rs8025939	chr15:72460339	T/A	cg16672083	chr15:72433130	SENP8	0.49	4.52	0.42	1.76e-5	Red blood cell count;
THYM	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg08132940	chr7:1081526	C7orf50	-1.16	-6.65	-0.56	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7107174	0.892	rs11601866	chr11:78011153	G/A	cg19901956	chr11:77921274	USP35	-0.69	-5.3	-0.48	7.42e-7	Testicular germ cell tumor;
THYM	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg03159660	chr11:2078197	NA	-0.63	-4.58	-0.43	1.43e-5	Longevity;
THYM	cis	rs8016982	0.633	rs9944085	chr14:81717620	A/T	cg01989461	chr14:81687754	GTF2A1	-0.79	-7.13	-0.59	1.98e-10	Schizophrenia;
THYM	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg23730037	chr7:158596552	ESYT2	-0.53	-5.48	-0.49	3.44e-7	Height;
THYM	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg16325326	chr1:53192061	ZYG11B	-0.82	-8.47	-0.66	3.12e-13	Monocyte count;
THYM	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg23131131	chr22:24373011	LOC391322	-0.82	-8.21	-0.64	1.09e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7586879	0.639	rs2033654	chr2:25103108	C/A	cg15423357	chr2:25149977	NA	0.69	7.48	0.61	3.68e-11	Body mass index;
THYM	cis	rs7572733	0.534	rs6760891	chr2:198768166	T/G	cg05783139	chr2:198650985	BOLL	0.62	4.89	0.45	4.15e-6	Dermatomyositis;
THYM	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg03684893	chr10:554711	DIP2C	-0.7	-6.2	-0.54	1.48e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg24675658	chr1:53192096	ZYG11B	-0.77	-6.23	-0.54	1.25e-8	Monocyte count;
THYM	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg05962950	chr11:130786565	SNX19	0.84	7.29	0.6	9.11e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9560113	0.960	rs1163862	chr13:112174319	C/T	cg14154082	chr13:112174009	NA	0.82	7.93	0.63	4.21e-12	Menarche (age at onset);
THYM	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg16558253	chr16:72132732	DHX38	0.63	5.46	0.49	3.81e-7	Fibrinogen levels;
THYM	cis	rs34638657	0.702	rs62044258	chr16:82199461	C/T	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.28	-0.48	8.32e-7	Lung adenocarcinoma;
THYM	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg20469991	chr17:27169893	C17orf63	-0.76	-4.78	-0.44	6.27e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs7211079	0.626	rs61751628	chr17:78111178	G/C	cg04028464	chr17:78073854	GAA;CCDC40	0.9	4.82	0.44	5.46e-6	Myocardial infarction;
THYM	cis	rs28785552	0.769	rs7253672	chr19:53243212	G/C	cg22067481	chr19:53234126	ZNF611	-0.97	-9.87	-0.71	3.07e-16	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs8133932	0.701	rs3788217	chr21:47287321	T/C	cg08707771	chr21:46690014	POFUT2	-0.76	-4.45	-0.42	2.29e-5	Schizophrenia;
THYM	cis	rs4631830	0.863	rs10826125	chr10:51530505	G/A	cg10326726	chr10:51549505	MSMB	-0.55	-5.57	-0.5	2.32e-7	Prostate-specific antigen levels;
THYM	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-4.68	-0.43	9.61e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg21475434	chr5:93447410	FAM172A	0.83	5.31	0.48	7.13e-7	Diabetic retinopathy;
THYM	cis	rs9318086	0.648	rs9510927	chr13:24467641	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.59	5.07	0.46	1.96e-6	Myopia (pathological);
THYM	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg03188948	chr7:1209495	NA	0.7	4.83	0.44	5.29e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs786425	0.530	rs7300721	chr12:124219595	T/C	cg15249119	chr12:124971054	NCOR2	0.55	5.09	0.46	1.79e-6	Pubertal anthropometrics;
THYM	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg15693483	chr7:1102177	C7orf50	0.5	5.65	0.5	1.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7809950	0.954	rs2520243	chr7:107136973	T/C	cg23024343	chr7:107201750	COG5	-0.91	-8.24	-0.65	9.37e-13	Coronary artery disease;
THYM	cis	rs55728055	0.661	rs16989519	chr22:31725416	C/T	cg01338084	chr22:32026380	PISD	1.35	4.93	0.45	3.5e-6	Age-related hearing impairment;
THYM	cis	rs7937890	0.684	rs12799007	chr11:14426484	T/A	cg19336497	chr11:14380999	RRAS2	-0.44	-4.65	-0.43	1.06e-5	Mitochondrial DNA levels;
THYM	cis	rs42648	0.905	rs42641	chr7:89972764	T/C	cg25739043	chr7:89950458	NA	-0.54	-4.55	-0.42	1.59e-5	Homocysteine levels;
THYM	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg18252515	chr7:66147081	NA	0.65	4.73	0.44	7.72e-6	Aortic root size;
THYM	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	4.59	0.43	1.35e-5	Aortic root size;
THYM	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg18252515	chr7:66147081	NA	0.72	5.62	0.5	1.87e-7	Aortic root size;
THYM	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg21658235	chr8:22456391	C8orf58	0.51	4.92	0.45	3.66e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9549260	0.709	rs9549247	chr13:41220777	G/C	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs4851254	0.626	rs71413861	chr2:100673501	A/G	cg22139774	chr2:100720529	AFF3	-0.41	-4.69	-0.43	9.07e-6	Intelligence (multi-trait analysis);
THYM	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg26818010	chr10:134567672	INPP5A	-0.91	-7.12	-0.59	2.1e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs10129666	0.900	rs8016189	chr14:78681601	G/C	cg07119463	chr14:78630749	NA	0.55	4.5	0.42	1.9e-5	Electrodermal activity;
THYM	cis	rs981844	0.857	rs72731698	chr4:154716353	T/C	cg09973105	chr4:154681532	RNF175	-0.65	-5.58	-0.5	2.27e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs3768617	0.510	rs2296300	chr1:183099701	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs6723226	0.750	rs10182170	chr2:32704186	G/A	cg02381751	chr2:32503542	YIPF4	0.68	5.82	0.51	8e-8	Intelligence (multi-trait analysis);
THYM	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Body mass index;
THYM	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg06850241	chr22:41845214	NA	-0.52	-4.53	-0.42	1.73e-5	Vitiligo;
THYM	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg07424592	chr7:64974309	NA	1.03	5.4	0.48	4.94e-7	Diabetic kidney disease;
THYM	cis	rs870825	0.616	rs28660669	chr4:185623312	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs863345	0.604	rs950260	chr1:158491520	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg14768367	chr16:72042858	DHODH	0.68	5.29	0.48	7.98e-7	Fibrinogen levels;
THYM	cis	rs13315871	1.000	rs13317400	chr3:58408792	T/G	cg00563845	chr3:58318305	PXK	0.53	4.67	0.43	9.78e-6	Cholesterol, total;
THYM	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11890956	chr21:40555474	PSMG1	-0.67	-6.25	-0.54	1.17e-8	Menarche (age at onset);
THYM	cis	rs739496	0.542	rs7312913	chr12:111793552	A/G	cg10833066	chr12:111807467	FAM109A	0.52	5.92	0.52	5e-8	Platelet count;
THYM	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg22920501	chr2:26401640	FAM59B	1.07	9.54	0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs1061377	1.000	rs7675782	chr4:39121668	G/A	cg24403649	chr4:39172243	NA	0.59	4.78	0.44	6.29e-6	Uric acid levels;
THYM	cis	rs10992471	0.756	rs7848055	chr9:95115492	A/C	cg14631576	chr9:95140430	CENPP	-0.97	-10.75	-0.74	4.09e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2067615	0.599	rs3759310	chr12:107166122	C/G	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg22535103	chr8:58192502	C8orf71	-0.98	-6.18	-0.54	1.6e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs3781426	1.000	rs3781416	chr10:126712428	G/A	cg04494136	chr10:126703576	CTBP2	-0.41	-5.61	-0.5	2e-7	Height;
THYM	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg12373951	chr3:133503437	NA	-0.55	-6.21	-0.54	1.36e-8	Iron status biomarkers;
THYM	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg11812906	chr14:75593930	NEK9	-0.86	-7.65	-0.62	1.61e-11	Height;
THYM	cis	rs67981189	0.896	rs12883437	chr14:71464781	T/C	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs11711311	1.000	rs3732793	chr3:113442198	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.62	-5.41	-0.49	4.79e-7	IgG glycosylation;
THYM	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg04287289	chr16:89883240	FANCA	-0.65	-6.04	-0.53	3.01e-8	Vitiligo;
THYM	cis	rs4285028	0.699	rs73855465	chr3:121574219	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.82	-5.8	-0.51	8.78e-8	Multiple sclerosis;
THYM	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg27534772	chr1:16042836	PLEKHM2	0.55	5.99	0.52	3.71e-8	Systolic blood pressure;
THYM	cis	rs9303280	0.901	rs2313430	chr17:37929816	T/C	cg24910161	chr17:38119198	GSDMA	-0.46	-4.8	-0.44	5.97e-6	Self-reported allergy;
THYM	cis	rs611744	0.967	rs660065	chr8:109191932	G/C	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs8030379	0.967	rs12916223	chr15:84552494	C/T	cg15564896	chr15:84287328	SH3GL3	0.57	4.77	0.44	6.57e-6	Waist circumference adjusted for body mass index;Waist circumference;
THYM	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg13683864	chr3:40499215	RPL14	-1.0	-10.76	-0.74	3.95e-18	Renal cell carcinoma;
THYM	cis	rs9527	0.615	rs7089065	chr10:104723022	C/T	cg15744005	chr10:104629667	AS3MT	-0.6	-4.58	-0.42	1.43e-5	Arsenic metabolism;
THYM	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg25703541	chr22:24373054	LOC391322	0.93	12.25	0.78	3e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg02725872	chr8:58115012	NA	-0.9	-6.54	-0.56	3.09e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg22655196	chr4:3374909	RGS12	0.45	5.49	0.49	3.41e-7	Parental longevity (mother's age at death);
THYM	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg14784868	chr12:69753453	YEATS4	0.72	5.93	0.52	4.9e-8	Blood protein levels;
THYM	cis	rs1784581	0.802	rs9365359	chr6:162423945	C/A	cg17173639	chr6:162384350	PARK2	0.8	8.14	0.64	1.52e-12	Itch intensity from mosquito bite;
THYM	cis	rs1670533	0.932	rs13140341	chr4:1054235	T/C	cg27284194	chr4:1044797	NA	0.6	4.54	0.42	1.68e-5	Recombination rate (females);
THYM	cis	rs7189233	1.000	rs62048491	chr16:53456391	G/C	cg02965178	chr16:53538660	AKTIP	-0.61	-4.9	-0.45	3.93e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9359856	0.564	rs36040566	chr6:90372574	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.91	-8.21	-0.64	1.08e-12	Bipolar disorder;
THYM	trans	rs9929218	0.954	rs72785165	chr16:68755635	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-7.53	-0.61	2.92e-11	Colorectal cancer;
THYM	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg06917634	chr15:78832804	PSMA4	0.92	8.46	0.66	3.27e-13	Sudden cardiac arrest;
THYM	cis	rs11096990	0.964	rs3733280	chr4:39271541	A/G	cg24403649	chr4:39172243	NA	-0.66	-5.24	-0.47	9.77e-7	Cognitive function;
THYM	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg00376283	chr12:123451042	ABCB9	0.72	4.88	0.45	4.24e-6	Neutrophil percentage of white cells;
THYM	cis	rs3733631	0.557	rs4535337	chr4:104703172	C/T	cg24090629	chr4:104641072	TACR3	1.01	5.67	0.5	1.51e-7	Menarche (age at onset);
THYM	cis	rs6430585	0.528	rs114760827	chr2:136661110	G/A	cg07169764	chr2:136633963	MCM6	1.18	10.98	0.75	1.39e-18	Corneal structure;
THYM	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg13695892	chr22:41940480	POLR3H	-0.86	-5.96	-0.52	4.19e-8	Vitiligo;
THYM	cis	rs9814567	1.000	rs2370578	chr3:134199612	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.65	-0.62	1.62e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg16524936	chr4:1340807	KIAA1530	-0.63	-5.05	-0.46	2.15e-6	Longevity;
THYM	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg14972814	chr11:95582409	MTMR2	-0.73	-6.88	-0.58	6.21e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7580658	0.963	rs4233584	chr2:128060163	C/T	cg10021288	chr2:128175891	PROC	-0.78	-6.82	-0.57	8.26e-10	Protein C levels;
THYM	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14442939	chr10:27389572	ANKRD26	0.88	4.6	0.43	1.29e-5	Breast cancer;
THYM	cis	rs17253792	0.822	rs10083499	chr14:56066590	T/A	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs6543140	0.964	rs6543143	chr2:103085420	A/C	cg03938978	chr2:103052716	IL18RAP	0.6	5.78	0.51	9.35e-8	Blood protein levels;
THYM	cis	rs9560113	1.000	rs9560109	chr13:112180468	C/T	cg10483660	chr13:112241077	NA	0.54	4.93	0.45	3.49e-6	Menarche (age at onset);
THYM	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg17279839	chr7:150038598	RARRES2	0.55	5.44	0.49	4.08e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2730245	0.527	rs2527197	chr7:158735260	G/A	cg11984989	chr7:158649758	WDR60	-1.03	-8.12	-0.64	1.7e-12	Height;
THYM	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg24642844	chr7:1081250	C7orf50	-1.29	-8.3	-0.65	7.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3008870	1.000	rs2755245	chr1:67487964	C/G	cg02640540	chr1:67518911	SLC35D1	0.65	4.83	0.44	5.32e-6	Lymphocyte percentage of white cells;
THYM	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs13006833	0.739	rs12693568	chr2:191202637	A/G	cg11845111	chr2:191398756	TMEM194B	0.67	4.69	0.43	9.13e-6	Urinary metabolites;
THYM	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg18681998	chr4:17616180	MED28	-0.76	-6.3	-0.54	9.37e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9311676	0.656	rs11714807	chr3:58405431	A/G	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs1003719	0.751	rs55740803	chr21:38542761	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.75e-5	Eye color traits;
THYM	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1045902	0.574	rs1474298	chr2:73466592	C/T	cg24220031	chr2:73402428	NA	-0.6	-5.23	-0.47	1.02e-6	Intelligence (multi-trait analysis);
THYM	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg10802521	chr3:52805072	NEK4	-0.71	-5.78	-0.51	9.42e-8	Bipolar disorder;
THYM	cis	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg12193833	chr17:30244370	NA	-0.7	-4.99	-0.46	2.78e-6	Hip circumference adjusted for BMI;
THYM	cis	rs921968	0.643	rs612874	chr2:219492924	T/C	cg02176678	chr2:219576539	TTLL4	0.63	6.15	0.53	1.85e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg08999081	chr20:33150536	PIGU	-0.77	-6.95	-0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs600550	0.528	rs17154511	chr11:59825585	A/G	cg02771260	chr11:59836817	MS4A3	0.68	5.19	0.47	1.17e-6	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg19761014	chr17:28927070	LRRC37B2	0.82	4.76	0.44	6.98e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs55692411	0.537	rs71326904	chr3:49991060	C/T	cg14019146	chr3:50243930	SLC38A3	-0.59	-4.56	-0.42	1.55e-5	Intelligence (multi-trait analysis);
THYM	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg06028605	chr16:24865363	SLC5A11	0.57	5.55	0.5	2.53e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg24060327	chr5:131705240	SLC22A5	0.8	6.52	0.56	3.35e-9	Breast cancer;
THYM	cis	rs2997447	0.761	rs61776596	chr1:26454968	T/C	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg04546413	chr19:29218101	NA	1.07	8.46	0.66	3.27e-13	Methadone dose in opioid dependence;
THYM	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg08968635	chr6:28129556	ZNF389	0.61	4.59	0.43	1.35e-5	Parkinson's disease;
THYM	cis	rs3820068	0.603	rs6429753	chr1:15900537	A/G	cg24675056	chr1:15929824	NA	0.65	4.57	0.42	1.46e-5	Systolic blood pressure;
THYM	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs7127900	0.950	rs6579002	chr11:2232229	A/G	cg25635251	chr11:2234043	NA	0.74	4.71	0.44	8.43e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs28595532	0.920	rs114789346	chr4:119748652	G/A	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg04842962	chr6:43655489	MRPS18A	1.36	14.18	0.82	3.44e-25	IgG glycosylation;
THYM	cis	rs7027203	0.797	rs7870672	chr9:96606693	A/C	cg13679303	chr9:96623674	NA	-0.5	-5.08	-0.46	1.89e-6	DNA methylation (variation);
THYM	cis	rs3112255	0.901	rs2942892	chr2:101294132	C/T	cg01042948	chr2:101319752	NA	0.7	5.96	0.52	4.3e-8	Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg24578937	chr1:2090814	PRKCZ	-0.57	-5.78	-0.51	9.45e-8	Height;
THYM	cis	rs73198271	0.751	rs617813	chr8:8635888	A/G	cg15556689	chr8:8085844	FLJ10661	-0.7	-4.87	-0.45	4.43e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg06558623	chr16:89946397	TCF25	1.03	5.52	0.49	2.99e-7	Skin colour saturation;
THYM	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg08847533	chr14:75593920	NEK9	1.01	11.32	0.76	2.63e-19	Height;
THYM	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg03213289	chr20:61660250	NA	0.91	9.99	0.72	1.76e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs892961	0.932	rs7216116	chr17:75405078	C/T	cg05865280	chr17:75406074	SEPT9	0.5	8.56	0.66	1.99e-13	Airflow obstruction;
THYM	cis	rs11190604	0.697	rs10748795	chr10:102194818	A/T	cg07570687	chr10:102243282	WNT8B	-0.82	-7.98	-0.63	3.29e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs12620999	0.838	rs7589198	chr2:237967615	C/T	cg15976283	chr2:238042351	NA	-0.59	-4.63	-0.43	1.17e-5	Systemic lupus erythematosus;
THYM	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg27125505	chr17:43679177	LOC644172	0.75	6.93	0.58	4.96e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs13082711	0.911	rs34098124	chr3:27451242	G/T	cg02860705	chr3:27208620	NA	0.71	5.01	0.46	2.54e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs1395	1.000	rs2014252	chr2:27462405	T/A	cg23587288	chr2:27483067	SLC30A3	-0.56	-5.03	-0.46	2.3e-6	Blood metabolite levels;
THYM	cis	rs240764	0.817	rs12199888	chr6:101154419	T/A	cg21058520	chr6:100914733	NA	0.58	5.22	0.47	1.04e-6	Neuroticism;
THYM	cis	rs10823500	0.748	rs2394668	chr10:71943951	G/A	cg25502086	chr10:71892093	AIFM2	-0.51	-4.66	-0.43	1.05e-5	Blood protein levels;
THYM	cis	rs6743226	0.870	rs10933547	chr2:242230443	C/G	cg10021735	chr2:242295487	FARP2	-0.63	-4.49	-0.42	1.98e-5	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg08975724	chr8:8085496	FLJ10661	-0.6	-4.69	-0.43	9e-6	Mood instability;
THYM	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs6424115	0.830	rs2502995	chr1:24199290	T/C	cg15997130	chr1:24165203	NA	0.74	6.34	0.55	7.54e-9	Immature fraction of reticulocytes;
THYM	cis	rs66573146	0.831	rs67665838	chr4:7064870	G/A	cg02503808	chr4:7069936	GRPEL1	-0.96	-4.6	-0.43	1.29e-5	Granulocyte percentage of myeloid white cells;
THYM	cis	rs2075230	0.705	rs1641538	chr17:7545588	C/T	cg27413385	chr17:7515425	FXR2	-0.35	-5.06	-0.46	2.06e-6	Hormone measurements;
THYM	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg07414643	chr4:187882934	NA	0.64	5.77	0.51	9.85e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs62367758	0.683	rs570391	chr5:43099681	C/A	cg06348134	chr5:42991495	NA	-0.65	-4.83	-0.44	5.21e-6	Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion);
THYM	cis	rs13090388	1	rs13090388	chr3:49391082	C/T	cg03060546	chr3:49711283	APEH	-0.66	-4.99	-0.46	2.7e-6	Intelligence (multi-trait analysis);Educational attainment (years of education);
THYM	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.55	-0.49	2.62e-7	Alzheimer's disease (late onset);
THYM	cis	rs17401966	1.000	rs7520935	chr1:10354271	G/T	cg19773385	chr1:10388646	KIF1B	-0.62	-4.47	-0.42	2.13e-5	Hepatocellular carcinoma;
THYM	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg12311346	chr5:56204834	C5orf35	-0.81	-5.9	-0.52	5.54e-8	Initial pursuit acceleration;
THYM	cis	rs3741151	1.000	rs1892855	chr11:73017972	G/T	cg17517138	chr11:73019481	ARHGEF17	1.01	5.83	0.51	7.72e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg08901578	chr4:187885870	NA	-0.64	-6.03	-0.53	3.1e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg10515332	chr4:99064459	C4orf37	0.57	4.56	0.42	1.54e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4888262	0.545	rs8050624	chr16:74686690	A/G	cg01733217	chr16:74700730	RFWD3	-0.89	-9.23	-0.69	7.38e-15	Testicular germ cell tumor;
THYM	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg06713675	chr4:122721982	EXOSC9	-0.5	-4.6	-0.43	1.3e-5	Type 2 diabetes;
THYM	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg27034606	chr17:28928453	LRRC37B2	0.82	5.25	0.47	9.11e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6906287	0.647	rs13219555	chr6:118816364	G/A	cg21191810	chr6:118973309	C6orf204	0.57	5.63	0.5	1.79e-7	Electrocardiographic conduction measures;
THYM	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg04317338	chr11:64019027	PLCB3	0.78	5.28	0.48	8.14e-7	Mean platelet volume;
THYM	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg26597838	chr10:835615	NA	1.05	6.33	0.54	8.17e-9	Eosinophil percentage of granulocytes;
THYM	cis	rs12716977	1	rs12716977	chr16:30482803	T/C	cg24033122	chr16:30485383	ITGAL	0.4	4.89	0.45	4.05e-6	Lymphocyte counts;Lymphocyte percentage of white cells;
THYM	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-4.95	-0.45	3.23e-6	Lymphocyte counts;
THYM	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg02380750	chr20:61661411	NA	0.61	6.16	0.53	1.78e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg02038168	chr22:39784481	NA	-0.66	-5.56	-0.5	2.49e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	trans	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Bladder cancer;
THYM	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg13880726	chr7:1868755	MAD1L1	-0.69	-4.64	-0.43	1.09e-5	Bipolar disorder;
THYM	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs490234	0.934	rs571675	chr9:128297692	C/T	cg14078157	chr9:128172775	NA	0.6	4.72	0.44	7.99e-6	Mean arterial pressure;
THYM	cis	rs7590720	0.731	rs1864253	chr2:216878008	C/G	cg25588852	chr2:216877276	MREG	-0.62	-5.73	-0.51	1.16e-7	Alcohol dependence;
THYM	cis	rs11118844	0.843	rs58850477	chr1:221927229	G/A	cg04222084	chr1:221915650	DUSP10	-0.97	-5.06	-0.46	2.01e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs778371	0.723	rs34707169	chr2:233699459	C/T	cg08000102	chr2:233561755	GIGYF2	-0.79	-6.96	-0.58	4.28e-10	Schizophrenia;
THYM	cis	rs713587	0.607	rs6725517	chr2:25129473	A/G	cg15423357	chr2:25149977	NA	0.64	6.41	0.55	5.48e-9	Body mass index in non-asthmatics;
THYM	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg13246856	chr1:44399776	ARTN	0.48	4.94	0.45	3.41e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs7246967	0.611	rs3931771	chr19:22896820	A/G	cg05241461	chr19:22816980	ZNF492	0.6	4.66	0.43	1.05e-5	Bronchopulmonary dysplasia;
THYM	cis	rs2458413	0.500	rs2251930	chr8:105357764	G/A	cg21295575	chr8:105352067	TM7SF4	-0.29	-4.5	-0.42	1.89e-5	Paget's disease;
THYM	cis	rs12476592	0.602	rs7570031	chr2:63792265	A/G	cg17519650	chr2:63277830	OTX1	-0.7	-4.71	-0.44	8.46e-6	Childhood ear infection;
THYM	cis	rs62120679	0.552	rs4807227	chr19:2318180	C/T	cg26843498	chr19:2361574	NA	-0.58	-7.65	-0.62	1.66e-11	Parkinson's disease;
THYM	cis	rs3780378	0.840	rs10119004	chr9:5071049	C/T	cg02405213	chr9:5042618	JAK2	-0.81	-7.07	-0.59	2.63e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg18876405	chr7:65276391	NA	-0.66	-5.52	-0.49	2.96e-7	Aortic root size;
THYM	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg10911889	chr6:126070802	HEY2	0.58	4.62	0.43	1.19e-5	Brugada syndrome;
THYM	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg22907277	chr7:1156413	C7orf50	0.61	5.39	0.48	5.17e-7	Longevity;Endometriosis;
THYM	cis	rs10493773	0.674	rs414618	chr1:86220418	G/A	cg17807903	chr1:86174739	ZNHIT6	0.42	5.26	0.48	8.8e-7	Urate levels in overweight individuals;
THYM	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg18876405	chr7:65276391	NA	-0.56	-4.65	-0.43	1.09e-5	Aortic root size;
THYM	cis	rs600806	0.888	rs3853500	chr1:109864269	T/C	cg23032129	chr1:109941072	SORT1	-0.57	-4.84	-0.44	5.11e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1568889	1.000	rs12794100	chr11:28332785	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	4.49	0.42	1.99e-5	Bipolar disorder;
THYM	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg13609457	chr4:120235615	NA	0.64	5.08	0.46	1.86e-6	Corneal astigmatism;
THYM	cis	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg06521331	chr12:34319734	NA	-0.72	-4.99	-0.46	2.68e-6	Resting heart rate;
THYM	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg27068330	chr11:65405492	SIPA1	0.84	8.34	0.65	5.78e-13	Acne (severe);
THYM	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	5.43	0.49	4.27e-7	Platelet count;
THYM	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	4.93	0.45	3.5e-6	Diabetic retinopathy;
THYM	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs977987	0.866	rs12932606	chr16:75493944	C/T	cg03315344	chr16:75512273	CHST6	0.72	5.41	0.49	4.78e-7	Dupuytren's disease;
THYM	cis	rs921968	0.565	rs11896209	chr2:219599268	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11723261	0.621	rs11721745	chr4:114934	T/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.86	5.8	0.51	8.53e-8	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs2797685	0.735	rs56204811	chr1:7895069	A/G	cg06712362	chr1:7811235	CAMTA1	1.02	5.91	0.52	5.22e-8	Crohn's disease;
THYM	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg00071950	chr4:10020882	SLC2A9	-0.67	-6.97	-0.58	4.17e-10	Bone mineral density;
THYM	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg14829155	chr15:31115871	NA	-0.58	-5.13	-0.47	1.51e-6	Huntington's disease progression;
THYM	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg13683864	chr3:40499215	RPL14	-0.82	-7.56	-0.61	2.57e-11	Renal cell carcinoma;
THYM	cis	rs6860806	0.507	rs270615	chr5:131641573	G/C	cg18758796	chr5:131593413	PDLIM4	0.55	5.3	0.48	7.64e-7	Breast cancer;
THYM	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.34	-0.48	6.24e-7	Monocyte percentage of white cells;
THYM	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.71	6.54	0.56	3.07e-9	Personality dimensions;
THYM	cis	rs73198271	0.740	rs1039912	chr8:8648229	C/T	cg06636001	chr8:8085503	FLJ10661	-0.8	-5.64	-0.5	1.77e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg11812906	chr14:75593930	NEK9	0.87	8.3	0.65	7.13e-13	Height;
THYM	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg14972814	chr11:95582409	MTMR2	-0.7	-6.18	-0.54	1.56e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9814567	0.896	rs7642266	chr3:134346025	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-8.47	-0.66	3e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2075230	0.705	rs2955611	chr17:7549574	C/A	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.28	-4.62	-0.43	1.21e-5	Hormone measurements;
THYM	cis	rs4237845	0.537	rs4237844	chr12:58267987	A/G	cg00677455	chr12:58241039	CTDSP2	-0.72	-5.4	-0.48	4.96e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11711311	1.000	rs12631232	chr3:113497386	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.18	-0.47	1.22e-6	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg03476357	chr21:30257390	N6AMT1	-0.61	-4.73	-0.44	7.84e-6	Dental caries;
THYM	cis	rs6547741	0.935	rs12714204	chr2:27787540	T/C	cg27432699	chr2:27873401	GPN1	0.67	5.9	0.52	5.47e-8	Oral cavity cancer;
THYM	cis	rs1079204	1.000	rs7600989	chr2:219119134	G/T	cg05728596	chr2:219128475	GPBAR1	1.24	5.67	0.5	1.54e-7	Smooth-surface caries;
THYM	cis	rs3126085	0.877	rs12133847	chr1:152170101	T/G	cg10321714	chr1:152280068	FLG	0.65	4.72	0.44	8.02e-6	Atopic dermatitis;
THYM	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.98	-5.47	-0.49	3.57e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg00786635	chr1:25594202	NA	-0.92	-7.29	-0.6	9.16e-11	Erythrocyte sedimentation rate;
THYM	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs9549260	0.755	rs2755216	chr13:41156938	G/A	cg21288729	chr13:41239152	FOXO1	0.71	5.53	0.49	2.84e-7	Red blood cell count;
THYM	cis	rs17102423	0.755	rs12880781	chr14:65576257	C/T	cg11161011	chr14:65562177	MAX	-0.85	-6.77	-0.57	1.04e-9	Obesity-related traits;
THYM	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs10752881	0.967	rs6695837	chr1:182991462	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Colorectal cancer;
THYM	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg26597838	chr10:835615	NA	1.2	8.57	0.66	1.85e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4589258	0.737	rs1632663	chr11:90430808	T/G	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg24675056	chr1:15929824	NA	0.73	5.89	0.52	5.95e-8	Systolic blood pressure;
THYM	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg27490568	chr2:178487706	NA	0.58	5.05	0.46	2.09e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7757969	1.000	rs9374291	chr6:112114791	A/G	cg08601457	chr6:112115117	FYN	0.42	4.79	0.44	6.23e-6	Schizophrenia;
THYM	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg26384229	chr12:38710491	ALG10B	0.94	7.05	0.59	2.8e-10	Bladder cancer;
THYM	cis	rs714027	0.546	rs5997549	chr22:30265344	C/T	cg27665648	chr22:30112403	NA	0.53	4.7	0.43	8.92e-6	Lymphocyte counts;
THYM	cis	rs4891159	0.790	rs35516239	chr18:74129942	C/T	cg24786174	chr18:74118243	ZNF516	-0.88	-10.16	-0.72	7.56e-17	Longevity;
THYM	cis	rs912057	0.797	rs1294430	chr6:6744698	A/G	cg06612196	chr6:6737390	NA	0.69	9.83	0.71	3.75e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs654128	1.000	rs654128	chr6:117086378	A/C	cg12892004	chr6:117198278	RFX6	-0.89	-5.5	-0.49	3.14e-7	Telomere length;
THYM	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg03264133	chr6:25882463	NA	0.65	5.06	0.46	2e-6	Schizophrenia;
THYM	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg12288994	chr5:1860383	NA	0.82	6.66	0.56	1.79e-9	Cardiovascular disease risk factors;
THYM	cis	rs2408955	0.561	rs11168365	chr12:48421772	A/G	cg21466736	chr12:48725269	NA	0.47	4.51	0.42	1.89e-5	Glycated hemoglobin levels;
THYM	cis	rs11048434	0.518	rs34533518	chr12:9177898	T/C	cg26114124	chr12:9217669	LOC144571	0.52	4.57	0.42	1.49e-5	Sjögren's syndrome;
THYM	cis	rs3845702	0.736	rs72960660	chr2:180832482	A/G	cg01881094	chr2:180872142	CWC22	0.91	5.5	0.49	3.16e-7	Schizophrenia;
THYM	cis	rs6918586	0.658	rs198844	chr6:26108282	C/G	cg07061783	chr6:25882402	NA	0.58	4.57	0.42	1.46e-5	Schizophrenia;
THYM	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg16230307	chr14:35515116	FAM177A1	0.93	6.02	0.53	3.31e-8	Psoriasis;
THYM	cis	rs1593	0.531	rs3822055	chr4:187179678	A/G	cg09526685	chr4:187126073	CYP4V2	0.82	4.72	0.44	7.99e-6	Activated partial thromboplastin time;
THYM	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.07	-10.71	-0.74	5.17e-18	Primary sclerosing cholangitis;
THYM	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg24690094	chr11:67383802	NA	-0.68	-4.45	-0.42	2.31e-5	Mean corpuscular volume;
THYM	cis	rs9905704	0.918	rs35934668	chr17:56894638	A/G	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.89e-6	Testicular germ cell tumor;
THYM	cis	rs1797885	0.524	rs2255648	chr3:12598963	A/G	cg05467012	chr3:12595696	NA	0.56	4.75	0.44	7.12e-6	Immature fraction of reticulocytes;
THYM	cis	rs7586879	0.638	rs13035244	chr2:25134009	T/C	cg27107076	chr2:25050844	ADCY3	-0.29	-4.73	-0.44	7.91e-6	Body mass index;
THYM	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg19346786	chr7:2764209	NA	-0.73	-6.14	-0.53	1.9e-8	Height;
THYM	cis	rs1215050	0.740	rs783924	chr4:98969234	C/T	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26314531	chr2:26401878	FAM59B	0.78	5.13	0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs9420	0.528	rs7102271	chr11:57396825	G/T	cg19752551	chr11:57585705	CTNND1	-0.56	-5.08	-0.46	1.87e-6	Schizophrenia;
THYM	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg12935359	chr14:103987150	CKB	-0.6	-6.21	-0.54	1.41e-8	Body mass index;
THYM	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg01528321	chr10:82214614	TSPAN14	0.66	5.16	0.47	1.35e-6	Post bronchodilator FEV1;
THYM	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg11764359	chr7:65958608	NA	-0.61	-4.58	-0.43	1.42e-5	Aortic root size;
THYM	cis	rs1728785	1.000	rs1170442	chr16:68574064	G/T	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs863345	0.604	rs6697656	chr1:158520737	A/G	cg12129480	chr1:158549410	OR10X1	-0.52	-5.01	-0.46	2.46e-6	Pneumococcal bacteremia;
THYM	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.33	10.11	0.72	9.63e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs860554	0.660	rs832169	chr1:201256771	C/T	cg01022117	chr1:201258280	PKP1	0.66	4.9	0.45	3.93e-6	Panic disorder;
THYM	cis	rs4788570	0.615	rs2334880	chr16:71653637	A/G	cg06353428	chr16:71660113	MARVELD3	1.21	8.23	0.65	9.83e-13	Intelligence (multi-trait analysis);
THYM	cis	rs12935418	0.616	rs1127390	chr16:81010073	C/T	cg16651780	chr16:81037892	C16orf61	0.88	6.52	0.56	3.34e-9	Mean corpuscular volume;
THYM	cis	rs67460515	0.563	rs68166680	chr3:160829735	T/A	cg12349858	chr3:160822545	B3GALNT1	0.57	4.53	0.42	1.71e-5	Parkinson's disease;
THYM	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg13319975	chr6:146136371	FBXO30	0.58	4.62	0.43	1.19e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg01579765	chr21:45077557	HSF2BP	0.49	8.08	0.64	2.09e-12	Mean corpuscular volume;
THYM	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg13266496	chr6:110720918	DDO	-0.48	-5.23	-0.47	1.02e-6	Platelet distribution width;
THYM	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg26597838	chr10:835615	NA	1.22	8.73	0.67	8.59e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs4654899	0.772	rs7548269	chr1:21089472	T/C	cg01072550	chr1:21505969	NA	-0.58	-4.89	-0.45	4.14e-6	Superior frontal gyrus grey matter volume;
THYM	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg26354017	chr1:205819088	PM20D1	0.97	10.36	0.73	2.85e-17	Menarche (age at onset);
THYM	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg22974920	chr21:40686053	BRWD1	-0.63	-4.97	-0.45	2.98e-6	Cognitive function;
THYM	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg24692254	chr21:30365293	RNF160	-0.71	-5.14	-0.47	1.48e-6	Cognitive test performance;
THYM	cis	rs7220401	0.512	rs2289629	chr17:27959903	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	4.97	0.45	3.01e-6	Coronary artery disease;
THYM	cis	rs9411298	0.550	rs4880192	chr9:139927062	A/G	cg09305224	chr9:139927245	C9orf139;FUT7	0.68	6.71	0.57	1.43e-9	Monocyte percentage of white cells;
THYM	cis	rs870825	0.860	rs72689284	chr4:185596680	A/G	cg04058563	chr4:185651563	MLF1IP	1.05	7.96	0.63	3.6e-12	Blood protein levels;
THYM	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg06623918	chr6:96969491	KIAA0776	1.09	10.37	0.73	2.65e-17	Headache;
THYM	cis	rs7487075	0.797	rs10785630	chr12:46880380	G/A	cg17501823	chr12:47219793	SLC38A4	0.51	4.73	0.44	7.85e-6	Itch intensity from mosquito bite;
THYM	cis	rs7909074	0.831	rs2065466	chr10:45384047	T/C	cg04218760	chr10:45406644	TMEM72	-0.63	-5.63	-0.5	1.86e-7	Mean corpuscular volume;
THYM	cis	rs10823500	0.777	rs7919014	chr10:71944577	T/C	cg02100629	chr10:71892760	AIFM2	-0.37	-4.48	-0.42	2.1e-5	Blood protein levels;
THYM	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg08000102	chr2:233561755	GIGYF2	-0.53	-4.68	-0.43	9.6e-6	Coronary artery disease;
THYM	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg21854759	chr1:92012499	NA	0.65	5.03	0.46	2.27e-6	Breast cancer;
THYM	cis	rs7681440	0.606	rs2737005	chr4:90750590	A/G	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg04362960	chr10:104952993	NT5C2	0.58	4.69	0.43	9.04e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg25036284	chr2:26402008	FAM59B	-0.78	-5.19	-0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs8077889	0.917	rs6503479	chr17:41917003	A/G	cg26893861	chr17:41843967	DUSP3	1.06	9.99	0.72	1.7e-16	Triglycerides;
THYM	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg10150615	chr22:24372951	LOC391322	-0.91	-9.51	-0.7	1.82e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg17054759	chr22:49844102	NA	-0.52	-4.6	-0.43	1.29e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs11690935	0.959	rs10803863	chr2:172535337	T/C	cg13550731	chr2:172543902	DYNC1I2	0.85	6.15	0.53	1.8e-8	Schizophrenia;
THYM	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7267979	0.932	rs433352	chr20:25467992	C/T	cg03522245	chr20:25566470	NINL	-0.59	-4.55	-0.42	1.57e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs113123495	0.510	rs2261565	chr19:5712108	C/T	cg26242866	chr19:5711310	LONP1	1.15	4.75	0.44	7.25e-6	Obsessive-compulsive symptoms;
THYM	cis	rs11696845	0.626	rs6073537	chr20:43378270	A/G	cg09357268	chr20:43379437	KCNK15	-0.5	-4.96	-0.45	3.12e-6	Obesity-related traits;
THYM	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs665401	0.932	rs1761879	chr6:117260230	A/G	cg20376953	chr6:117187980	NA	-0.55	-4.49	-0.42	1.99e-5	Neutrophil percentage of granulocytes;
THYM	cis	rs1670533	1.000	rs12645644	chr4:1054159	C/T	cg27284194	chr4:1044797	NA	0.61	4.6	0.43	1.29e-5	Recombination rate (females);
THYM	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg23711669	chr6:146136114	FBXO30	0.9	9.23	0.69	7.15e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17253792	0.822	rs78143160	chr14:56150097	A/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg06238570	chr21:40685208	BRWD1	0.96	8.89	0.67	3.96e-14	Cognitive function;
THYM	cis	rs3771570	0.901	rs35496488	chr2:242434316	G/A	cg21155796	chr2:242212141	HDLBP	1.18	5.77	0.51	9.86e-8	Prostate cancer;
THYM	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg23260525	chr10:116636907	FAM160B1	0.52	5.19	0.47	1.19e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg22683308	chr4:1340831	KIAA1530	-0.63	-5.09	-0.46	1.78e-6	Longevity;
THYM	cis	rs12048904	0.505	rs11166511	chr1:101240686	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.84	-6.29	-0.54	9.53e-9	Multiple sclerosis;
THYM	cis	rs1528010	1.000	rs1822528	chr4:99671044	A/G	cg12371169	chr4:99182555	RAP1GDS1	0.81	4.82	0.44	5.44e-6	Depressive episodes in bipolar disorder;
THYM	cis	rs2281845	0.791	rs1325313	chr1:201076167	C/T	cg17810781	chr1:201082982	CACNA1S	0.55	5.64	0.5	1.75e-7	Permanent tooth development;
THYM	cis	rs985746	0.614	rs6847453	chr4:36823004	G/A	cg04301614	chr4:37585993	C4orf19	0.56	4.55	0.42	1.58e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg06636001	chr8:8085503	FLJ10661	-0.76	-6.98	-0.58	3.97e-10	Triglycerides;
THYM	cis	rs742614	0.533	rs6059496	chr20:32446931	T/C	cg06304546	chr20:32448765	NA	-0.98	-10.72	-0.74	4.79e-18	Stearic acid (18:0) levels;
THYM	cis	rs4731207	0.698	rs11978628	chr7:124449897	C/T	cg05285228	chr7:124571219	POT1	0.66	5.24	0.47	9.66e-7	Cutaneous malignant melanoma;
THYM	cis	rs669446	0.562	rs3791036	chr1:44155383	A/G	cg15962314	chr1:44399869	ARTN	0.43	4.57	0.42	1.46e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.7	6.53	0.56	3.28e-9	Total body bone mineral density;
THYM	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg02487422	chr3:49467188	NICN1	0.63	4.82	0.44	5.48e-6	Resting heart rate;
THYM	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg01097406	chr16:89675127	NA	-0.56	-4.64	-0.43	1.12e-5	Vitiligo;
THYM	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg22709100	chr7:91322751	NA	0.61	4.86	0.45	4.66e-6	Breast cancer;
THYM	cis	rs6500395	1.000	rs7202551	chr16:48728984	A/G	cg04672837	chr16:48644449	N4BP1	-0.52	-5.05	-0.46	2.16e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9905704	0.918	rs302857	chr17:56692387	C/G	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.74e-6	Testicular germ cell tumor;
THYM	cis	rs6840360	0.870	rs7680604	chr4:152469917	C/T	cg22705602	chr4:152727874	NA	-0.58	-6.45	-0.55	4.57e-9	Intelligence (multi-trait analysis);
THYM	cis	rs892961	0.932	rs7222170	chr17:75413096	G/A	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs11148252	0.744	rs77466241	chr13:52862914	C/G	cg05335186	chr13:53173507	NA	-0.42	-5.25	-0.47	9.38e-7	Lewy body disease;
THYM	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg18252515	chr7:66147081	NA	-0.66	-5.01	-0.46	2.55e-6	Aortic root size;
THYM	trans	rs11722228	0.522	rs12504600	chr4:10067138	C/A	cg26043149	chr18:55253948	FECH	1.25	11.26	0.76	3.53e-19	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs910187	0.641	rs3186647	chr20:45817067	T/C	cg27589058	chr20:45804311	EYA2	-0.58	-4.97	-0.45	2.96e-6	Migraine;
THYM	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg06808227	chr14:105710500	BRF1	-1.01	-8.64	-0.66	1.31e-13	Mean platelet volume;Platelet distribution width;
THYM	cis	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg11764359	chr7:65958608	NA	-0.62	-4.71	-0.43	8.57e-6	Aortic root size;
THYM	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg27170947	chr2:26402098	FAM59B	-0.61	-5.04	-0.46	2.25e-6	Gut microbiome composition (summer);
THYM	cis	rs7172809	0.573	rs28437977	chr15:77681453	C/T	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg11245990	chr11:68621969	NA	0.53	6.77	0.57	1.04e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	trans	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Educational attainment;
THYM	cis	rs1883415	0.614	rs4646841	chr6:24507714	A/G	cg00346970	chr6:24499591	ALDH5A1	0.48	6.11	0.53	2.17e-8	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs11031096	0.683	rs55898672	chr11:4189284	G/C	cg18678763	chr11:4115507	RRM1	-0.42	-4.95	-0.45	3.17e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9420	0.807	rs12807357	chr11:57656902	C/T	cg19752551	chr11:57585705	CTNND1	-0.72	-7.34	-0.6	7.26e-11	Schizophrenia;
THYM	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg07362569	chr17:61921086	SMARCD2	0.72	6.35	0.55	7.37e-9	Prudent dietary pattern;
THYM	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg12826209	chr6:26865740	GUSBL1	1.03	6.64	0.56	1.94e-9	Intelligence (multi-trait analysis);
THYM	cis	rs11126435	0.565	rs715407	chr2:74765693	G/T	cg04255230	chr2:74727010	LBX2	0.51	4.46	0.42	2.21e-5	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11644478	chr21:40555479	PSMG1	1.09	9.34	0.69	4.28e-15	Cognitive function;
THYM	cis	rs7107174	1.000	rs2512549	chr11:77940163	A/G	cg02023728	chr11:77925099	USP35	-0.67	-6.46	-0.55	4.39e-9	Testicular germ cell tumor;
THYM	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg19748678	chr4:122722346	EXOSC9	0.75	5.37	0.48	5.52e-7	Type 2 diabetes;
THYM	cis	rs56309584	0.596	rs117854193	chr17:8178467	G/A	cg08322244	chr17:8066669	VAMP2	-0.55	-4.87	-0.45	4.39e-6	Initial pursuit acceleration;
THYM	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg05347473	chr6:146136440	FBXO30	0.78	6.76	0.57	1.1e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg11764359	chr7:65958608	NA	0.89	7.7	0.62	1.31e-11	Aortic root size;
THYM	cis	rs995000	0.839	rs12090886	chr1:62981440	G/A	cg06896770	chr1:63153194	DOCK7	-0.91	-7.48	-0.61	3.62e-11	Triglyceride levels;
THYM	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg23161317	chr6:28129485	ZNF389	0.65	5.74	0.51	1.12e-7	Parkinson's disease;
THYM	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg19774624	chr17:42201019	HDAC5	-0.77	-7.16	-0.59	1.73e-10	Total body bone mineral density;
THYM	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg23352942	chr3:46931381	PTH1R	0.59	5.27	0.48	8.6e-7	Birth weight;
THYM	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg01710189	chr8:22454888	PDLIM2	-0.55	-5.69	-0.5	1.4e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.73	5.49	0.49	3.39e-7	Glycated hemoglobin levels;
THYM	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs5753037	0.803	rs131262	chr22:30133044	G/T	cg27665648	chr22:30112403	NA	0.5	4.56	0.42	1.51e-5	Type 1 diabetes;
THYM	cis	rs3087591	0.960	rs2905803	chr17:29520056	T/C	cg24425628	chr17:29625626	OMG;NF1	0.66	5.79	0.51	9.11e-8	Hip circumference;
THYM	cis	rs8038465	0.638	rs62004615	chr15:73957799	C/A	cg15420318	chr15:73925796	NPTN	0.56	4.79	0.44	6.09e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11096990	0.855	rs2711990	chr4:39151736	A/C	cg24403649	chr4:39172243	NA	-0.63	-5.43	-0.49	4.33e-7	Cognitive function;
THYM	cis	rs9796	0.870	rs2925342	chr15:41305733	A/G	cg21153102	chr15:41252147	NA	-0.66	-5.94	-0.52	4.63e-8	Menopause (age at onset);
THYM	cis	rs7705502	1.000	rs72810989	chr5:173326714	A/G	cg18693985	chr5:173351052	CPEB4	-0.78	-5.64	-0.5	1.71e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg11764359	chr7:65958608	NA	-0.82	-6.6	-0.56	2.29e-9	Aortic root size;
THYM	cis	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg12000587	chr17:30186630	C17orf79	0.5	7.14	0.59	1.84e-10	Hip circumference adjusted for BMI;
THYM	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs9403317	0.700	rs1361161	chr6:141916472	T/C	cg15052665	chr6:141804349	NA	0.76	5.75	0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8067545	0.967	rs1034904	chr17:19927699	A/G	cg13482628	chr17:19912719	NA	-0.6	-5.22	-0.47	1.06e-6	Schizophrenia;
THYM	cis	rs7264396	0.563	rs2050729	chr20:34294409	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.76	4.76	0.44	6.84e-6	Total cholesterol levels;
THYM	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg12165864	chr7:66369176	NA	0.64	4.96	0.45	3.13e-6	Aortic root size;
THYM	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg16989719	chr2:238392110	NA	-0.6	-5.82	-0.51	8.08e-8	Prostate cancer;
THYM	cis	rs7771547	0.607	rs6923993	chr6:36427276	A/G	cg07856975	chr6:36356162	ETV7	0.52	5.01	0.46	2.48e-6	Platelet distribution width;
THYM	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs1267303	0.675	rs1267313	chr1:46986322	G/T	cg25110126	chr1:46999211	NA	-0.64	-5.01	-0.46	2.51e-6	Monobrow;
THYM	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg13319975	chr6:146136371	FBXO30	0.65	5.22	0.47	1.05e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07167872	chr1:205819463	PM20D1	1.15	12.6	0.79	5.61e-22	Menarche (age at onset);
THYM	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg05973401	chr12:123451056	ABCB9	0.71	4.82	0.44	5.46e-6	Neutrophil percentage of white cells;
THYM	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg24675658	chr1:53192096	ZYG11B	-0.63	-4.95	-0.45	3.25e-6	Monocyte count;
THYM	cis	rs9790314	1.000	rs6765269	chr3:160948542	T/C	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs7264396	0.563	rs2425086	chr20:34302873	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.69	-0.43	9.19e-6	Total cholesterol levels;
THYM	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg03188948	chr7:1209495	NA	0.74	5.9	0.52	5.62e-8	Longevity;Endometriosis;
THYM	cis	rs12446552	0.661	rs72781044	chr16:11704903	C/T	cg09662852	chr16:11707685	NA	-0.67	-5.97	-0.52	4.14e-8	Colorectal or endometrial cancer;
THYM	cis	rs926938	0.618	rs1286560	chr1:115375930	C/T	cg12756093	chr1:115239321	AMPD1	-0.63	-5.08	-0.46	1.88e-6	Autism;
THYM	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg00080972	chr5:178986291	RUFY1	0.49	5.82	0.51	7.91e-8	Lung cancer;
THYM	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg07167872	chr1:205819463	PM20D1	-0.64	-4.67	-0.43	9.75e-6	Menarche (age at onset);
THYM	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.51	0.81	7.55e-24	Height;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg00259584	chr2:106986308	NA	-0.96	-7.29	-0.6	9.07e-11	Depressive symptoms;
THYM	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg11752832	chr7:134001865	SLC35B4	0.73	5.5	0.49	3.22e-7	Mean platelet volume;
THYM	cis	rs9880211	0.948	rs34135127	chr3:136226498	T/C	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs9403317	0.612	rs62433158	chr6:142018077	T/C	cg15052665	chr6:141804349	NA	0.74	5.38	0.48	5.31e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs1451375	1.000	rs1966839	chr7:50627101	T/C	cg18232548	chr7:50535776	DDC	0.76	5.85	0.51	7.09e-8	Malaria;
THYM	cis	rs6807915	0.504	rs167467	chr3:12281183	A/G	cg05467012	chr3:12595696	NA	-0.51	-4.65	-0.43	1.09e-5	Leprosy;
THYM	cis	rs10029851	0.627	rs17584324	chr4:109529386	A/G	cg21648245	chr4:109541405	LOC285456;RPL34	-0.64	-4.97	-0.45	2.9e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs9359856	0.564	rs56281344	chr6:90445393	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.9	-7.81	-0.63	7.61e-12	Bipolar disorder;
THYM	cis	rs651907	0.967	rs641432	chr3:101587566	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	5.12	0.46	1.6e-6	Colorectal cancer;
THYM	cis	rs67981189	0.501	rs2810104	chr14:71424813	C/T	cg15910301	chr14:71632612	NA	0.59	5.19	0.47	1.18e-6	Schizophrenia;
THYM	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg00080972	chr5:178986291	RUFY1	-0.57	-7.27	-0.6	9.93e-11	Lung cancer;
THYM	cis	rs80319144	1.000	rs11680774	chr2:159245985	T/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs600231	0.708	rs661403	chr11:65242478	A/G	cg17120908	chr11:65337727	SSSCA1	-0.61	-4.78	-0.44	6.51e-6	Bone mineral density;
THYM	cis	rs11112613	0.653	rs59504344	chr12:105950837	C/T	cg03607813	chr12:105948248	NA	1.02	8.65	0.66	1.27e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg24910161	chr17:38119198	GSDMA	0.42	4.45	0.42	2.31e-5	Self-reported allergy;
THYM	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg05738196	chr6:26577821	NA	0.57	4.7	0.43	8.7e-6	Schizophrenia;
THYM	cis	rs17030434	0.906	rs4696491	chr4:154679865	T/C	cg14289246	chr4:154710475	SFRP2	0.79	5.64	0.5	1.73e-7	Electrocardiographic conduction measures;
THYM	cis	rs7107174	0.892	rs2512540	chr11:77979299	A/G	cg02023728	chr11:77925099	USP35	0.65	5.83	0.51	7.52e-8	Testicular germ cell tumor;
THYM	cis	rs11779988	0.538	rs12541567	chr8:17920077	T/A	cg18067069	chr8:17937731	ASAH1	-0.6	-4.56	-0.42	1.53e-5	Breast cancer;
THYM	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	5.38	0.48	5.27e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs1278352	0.690	rs1278355	chr10:127774028	G/C	cg08295661	chr10:127769903	ADAM12	-0.55	-5.64	-0.5	1.71e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs3825932	0.961	rs10400881	chr15:79234384	G/C	cg25744700	chr15:79237217	CTSH	0.47	4.5	0.42	1.89e-5	Type 1 diabetes;
THYM	cis	rs4343996	0.626	rs4722723	chr7:3398320	C/T	cg21248987	chr7:3385318	SDK1	-0.41	-5.31	-0.48	7.27e-7	Motion sickness;
THYM	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg22841779	chr14:105766346	BRF1	-0.47	-5.81	-0.51	8.18e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6087771	0.821	rs6058444	chr20:30315137	A/G	cg13852791	chr20:30311386	BCL2L1	0.99	9.11	0.68	1.31e-14	Subcortical brain region volumes;Putamen volume;
THYM	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg17775962	chr7:1200435	ZFAND2A	0.51	5.74	0.51	1.11e-7	Longevity;Endometriosis;
THYM	cis	rs28595532	0.925	rs28627331	chr4:119665345	T/C	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg19610905	chr11:61596333	FADS2	-0.61	-5.16	-0.47	1.36e-6	Trans fatty acid levels;
THYM	cis	rs289828	0.868	rs6757821	chr2:152138037	G/A	cg05960677	chr2:152117363	RBM43	0.61	6.05	0.53	2.89e-8	Blood protein levels;
THYM	cis	rs1642645	0.872	rs1408948	chr1:42417706	C/T	cg10197057	chr1:42612518	NA	-0.43	-4.6	-0.43	1.3e-5	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg23803603	chr1:2058230	PRKCZ	0.6	4.69	0.43	9.29e-6	Height;
THYM	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg23711669	chr6:146136114	FBXO30	-0.9	-9.17	-0.69	9.79e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7084402	0.967	rs1820542	chr10:60315643	T/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs7584330	0.657	rs10190310	chr2:238352282	C/T	cg16989719	chr2:238392110	NA	-0.6	-5.42	-0.49	4.42e-7	Prostate cancer;
THYM	cis	rs17511627	0.808	rs1158461	chr13:26745194	C/T	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg01238044	chr22:24384105	GSTT1	-0.54	-4.92	-0.45	3.65e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3862030	0.694	rs2025712	chr10:104230064	T/C	cg00122347	chr10:104236741	TMEM180	0.48	7.03	0.59	3.09e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs9560113	0.550	rs1163632	chr13:112231530	T/C	cg15979348	chr13:112237479	NA	-0.58	-5.51	-0.49	3.05e-7	Menarche (age at onset);
THYM	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg08885076	chr2:99613938	TSGA10	0.57	5.3	0.48	7.37e-7	Chronic sinus infection;
THYM	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg15704280	chr7:45808275	SEPT13	-0.98	-11.3	-0.76	2.81e-19	Height;
THYM	cis	rs61931739	1.000	rs11052989	chr12:34057614	G/A	cg10856724	chr12:34555212	NA	0.6	5.05	0.46	2.16e-6	Morning vs. evening chronotype;
THYM	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg08968635	chr6:28129556	ZNF389	0.61	4.59	0.43	1.35e-5	Parkinson's disease;
THYM	cis	rs28595532	0.920	rs55985953	chr4:119764971	T/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs981844	0.712	rs1037654	chr4:154750300	C/G	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg09238746	chr17:78121135	EIF4A3	-0.69	-4.72	-0.44	8.1e-6	Yeast infection;
THYM	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03647317	chr4:187891568	NA	-0.83	-9.1	-0.68	1.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg14829155	chr15:31115871	NA	0.72	6.65	0.56	1.89e-9	Huntington's disease progression;
THYM	cis	rs728616	0.614	rs10887218	chr10:81711024	G/A	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs1788820	0.917	rs1788762	chr18:21132571	G/C	cg14672496	chr18:21087552	C18orf8	0.81	6.51	0.56	3.49e-9	Body mass index;
THYM	cis	rs7267979	0.873	rs6037062	chr20:25202892	G/A	cg03522245	chr20:25566470	NINL	0.7	5.43	0.49	4.38e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs72827839	0.846	rs72823591	chr17:46122628	C/T	cg23391107	chr17:45924227	SP6	0.8	5.49	0.49	3.4e-7	Ease of getting up in the morning;
THYM	cis	rs7584330	0.554	rs6744807	chr2:238424684	A/G	cg08992911	chr2:238395768	MLPH	0.76	4.68	0.43	9.46e-6	Prostate cancer;
THYM	cis	rs80208956	1.000	rs3862792	chr11:69462856	A/G	cg27021553	chr11:69462783	CCND1	-0.8	-4.52	-0.42	1.78e-5	Major depressive disorder;
THYM	cis	rs227425	0.544	rs10141617	chr14:70416442	G/A	cg12046056	chr14:71067695	MED6	0.53	4.88	0.45	4.33e-6	Bone mineral density;
THYM	cis	rs6840360	0.571	rs4696270	chr4:152498289	G/A	cg22705602	chr4:152727874	NA	-0.77	-8.64	-0.66	1.36e-13	Intelligence (multi-trait analysis);
THYM	cis	rs10911251	0.546	rs2274984	chr1:183107446	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.58	-4.67	-0.43	9.99e-6	Colorectal cancer;
THYM	cis	rs13253111	0.766	rs56232071	chr8:28063230	A/T	cg26534493	chr8:28060551	NA	-0.54	-4.87	-0.45	4.38e-6	Childhood body mass index;
THYM	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg17143192	chr8:8559678	CLDN23	0.59	4.61	0.43	1.26e-5	Mood instability;
THYM	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg27170947	chr2:26402098	FAM59B	0.79	6.27	0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg19770292	chr5:1868693	NA	0.54	4.95	0.45	3.26e-6	Cardiovascular disease risk factors;
THYM	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg22920501	chr2:26401640	FAM59B	-0.77	-6.64	-0.56	1.96e-9	Gut microbiome composition (summer);
THYM	cis	rs6084875	0.840	rs2422933	chr20:4720035	T/C	cg19614321	chr20:4804581	RASSF2	0.44	4.47	0.42	2.19e-5	Systemic lupus erythematosus;
THYM	cis	rs7927771	0.542	rs3886262	chr11:47817010	T/G	cg20307385	chr11:47447363	PSMC3	0.6	4.52	0.42	1.77e-5	Subjective well-being;
THYM	cis	rs10186029	0.667	rs6734174	chr2:213981428	A/C	cg08319019	chr2:214017104	IKZF2	-0.6	-4.55	-0.42	1.6e-5	Systemic sclerosis;
THYM	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg12386194	chr3:101231763	SENP7	0.93	7.22	0.6	1.3e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3885907	1.000	rs3885907	chr13:31314455	C/A	cg19953038	chr13:31306303	NA	0.62	4.6	0.43	1.3e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
THYM	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg02753203	chr1:228287806	NA	0.95	8.14	0.64	1.51e-12	Diastolic blood pressure;
THYM	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg18252515	chr7:66147081	NA	-0.71	-5.67	-0.5	1.56e-7	Aortic root size;
THYM	cis	rs3008870	1.000	rs3008871	chr1:67419089	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-7.93	-0.63	4.17e-12	Lymphocyte percentage of white cells;
THYM	cis	rs9788682	0.747	rs2568499	chr15:78722359	T/C	cg18825076	chr15:78729989	IREB2	-0.67	-5.14	-0.47	1.5e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs10744422	1.000	rs4759382	chr12:123347609	C/T	cg25930673	chr12:123319894	HIP1R	0.87	4.92	0.45	3.57e-6	Schizophrenia;
THYM	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg06002616	chr8:101225028	SPAG1	-0.46	-4.79	-0.44	6.22e-6	Atrioventricular conduction;
THYM	cis	rs12532960	0.908	rs12532413	chr7:42342409	A/G	cg23473276	chr7:42834405	NA	1.03	4.5	0.42	1.89e-5	Inflammatory biomarkers;
THYM	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg20503657	chr10:835505	NA	-1.42	-9.74	-0.71	5.94e-16	Eosinophil percentage of granulocytes;
THYM	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg06028605	chr16:24865363	SLC5A11	0.63	5.22	0.47	1.07e-6	Intelligence (multi-trait analysis);
THYM	cis	rs929354	1.000	rs1182384	chr7:157040642	A/G	cg17757837	chr7:157058334	UBE3C	-0.79	-6.84	-0.57	7.63e-10	Body mass index;
THYM	cis	rs10779751	0.922	rs2295080	chr1:11322628	G/T	cg08854313	chr1:11322531	MTOR	1.02	9.98	0.72	1.8e-16	Body mass index;
THYM	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg09085632	chr11:111637200	PPP2R1B	0.95	8.44	0.65	3.45e-13	Primary sclerosing cholangitis;
THYM	cis	rs72781680	0.898	rs2339851	chr2:23938883	G/A	cg08917208	chr2:24149416	ATAD2B	1.1	4.81	0.44	5.71e-6	Lymphocyte counts;
THYM	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg16031515	chr1:205743344	RAB7L1	-0.73	-7.18	-0.59	1.54e-10	Menarche (age at onset);
THYM	cis	rs11971779	0.938	rs28477480	chr7:139036058	C/T	cg07862535	chr7:139043722	LUC7L2	-0.7	-4.52	-0.42	1.76e-5	Diisocyanate-induced asthma;
THYM	cis	rs68170813	0.559	rs78064065	chr7:106967440	G/A	cg00661777	chr7:106511741	PIK3CG	-0.68	-4.71	-0.44	8.28e-6	Coronary artery disease;
THYM	cis	rs870825	0.655	rs2017101	chr4:185637381	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs10927875	0.541	rs1048334	chr1:16340761	T/C	cg22431228	chr1:16359049	CLCNKA	-0.53	-5.13	-0.47	1.51e-6	Dilated cardiomyopathy;
THYM	cis	rs9653442	0.675	rs12995420	chr2:100652578	T/C	cg07810366	chr2:100720526	AFF3	-0.39	-5.55	-0.5	2.55e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs1371867	0.846	rs1788180	chr8:101333368	A/G	cg06636551	chr8:101224915	SPAG1	-0.63	-6.33	-0.54	8.05e-9	Atrioventricular conduction;
THYM	cis	rs968451	0.619	rs2267407	chr22:39747050	G/A	cg24268161	chr22:39747459	SYNGR1	-0.67	-5.54	-0.49	2.64e-7	Primary biliary cholangitis;
THYM	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs6430585	0.528	rs309120	chr2:136708787	G/C	cg23851026	chr2:136556271	LCT	0.68	6.64	0.56	1.94e-9	Corneal structure;
THYM	trans	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg25517755	chr10:38738941	LOC399744	-0.74	-7.12	-0.59	2.01e-10	Corneal astigmatism;
THYM	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg12826209	chr6:26865740	GUSBL1	0.79	5.62	0.5	1.92e-7	Intelligence (multi-trait analysis);
THYM	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg22968622	chr17:43663579	NA	1.18	10.66	0.74	6.45e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12586317	0.620	rs17091786	chr14:35565856	A/T	cg16230307	chr14:35515116	FAM177A1	0.9	5.84	0.51	7.37e-8	Psoriasis;
THYM	cis	rs6558530	0.836	rs11136424	chr8:1717036	C/T	cg09410841	chr8:1729607	CLN8	0.81	6.11	0.53	2.14e-8	Systolic blood pressure;
THYM	cis	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg13010199	chr12:38710504	ALG10B	-0.59	-4.71	-0.44	8.44e-6	Morning vs. evening chronotype;
THYM	cis	rs713587	0.646	rs2384061	chr2:25135620	C/T	cg01884057	chr2:25150051	NA	0.62	5.95	0.52	4.37e-8	Body mass index in non-asthmatics;
THYM	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs4363385	0.669	rs4845519	chr1:153003916	G/T	cg13444842	chr1:152974279	SPRR3	0.58	4.76	0.44	6.8e-6	Inflammatory skin disease;
THYM	cis	rs9807841	0.670	rs10948	chr19:10754905	G/T	cg17848348	chr19:10766748	ILF3	-0.84	-7.36	-0.6	6.61e-11	Inflammatory skin disease;
THYM	cis	rs17253792	0.822	rs79398217	chr14:56067350	C/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg20307385	chr11:47447363	PSMC3	-0.6	-4.61	-0.43	1.26e-5	Subjective well-being;
THYM	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg07507251	chr3:52567010	NT5DC2	0.41	4.89	0.45	4.17e-6	Bipolar disorder;
THYM	cis	rs1775715	0.737	rs2778661	chr10:32159191	C/T	cg04359828	chr10:32216031	ARHGAP12	0.41	5.12	0.46	1.62e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs7100689	0.646	rs7919380	chr10:82133380	C/T	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs7084402	0.967	rs10763552	chr10:60273977	C/T	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg16240275	chr20:61666158	NCRNA00029	-0.33	-4.47	-0.42	2.2e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg20007245	chr22:24372913	LOC391322	-0.68	-5.95	-0.52	4.5e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs990171	1.000	rs4851584	chr2:103060313	A/G	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.08	-0.46	1.87e-6	Lymphocyte counts;
THYM	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.91	0.45	3.84e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7592578	0.882	rs61117285	chr2:191468986	G/C	cg27211696	chr2:191398769	TMEM194B	-0.62	-4.72	-0.44	8.15e-6	Diastolic blood pressure;
THYM	cis	rs6565180	1.000	rs11646130	chr16:30376959	T/C	cg17640201	chr16:30407289	ZNF48	-0.87	-7.58	-0.61	2.29e-11	Tonsillectomy;
THYM	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	8.52	0.66	2.36e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs514406	0.858	rs564640	chr1:53285187	T/C	cg08859206	chr1:53392774	SCP2	0.6	6.58	0.56	2.6e-9	Monocyte count;
THYM	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg13695892	chr22:41940480	POLR3H	0.91	7.22	0.6	1.25e-10	Vitiligo;
THYM	cis	rs7688540	0.771	rs61795002	chr4:242797	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.72	4.88	0.45	4.35e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs354225	0.544	rs13386146	chr2:54802514	G/C	cg23486701	chr2:54789491	SPTBN1	0.34	4.49	0.42	2e-5	Schizophrenia;
THYM	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg13289132	chr10:30722225	MAP3K8	-0.59	-4.89	-0.45	4.05e-6	Inflammatory bowel disease;
THYM	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg19442545	chr10:75533431	FUT11	-0.58	-6.01	-0.53	3.37e-8	Inflammatory bowel disease;
THYM	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	trans	rs8002861	0.905	rs12874535	chr13:44433565	A/G	cg17145862	chr1:211918768	LPGAT1	-0.85	-7.78	-0.62	8.6e-12	Leprosy;
THYM	cis	rs8067545	0.611	rs11653630	chr17:20189046	C/T	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs2273669	0.588	rs11153151	chr6:109316754	C/G	cg17117243	chr6:109341365	SESN1	-0.9	-5.38	-0.48	5.45e-7	Prostate cancer;
THYM	cis	rs904251	0.828	rs1757174	chr6:37486695	G/A	cg25019722	chr6:37503610	NA	-0.65	-5.57	-0.5	2.37e-7	Cognitive performance;
THYM	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg06850241	chr22:41845214	NA	0.53	4.69	0.43	9.07e-6	Vitiligo;
THYM	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg27170947	chr2:26402098	FAM59B	-0.61	-5.04	-0.46	2.25e-6	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2898681	0.561	rs7699960	chr4:53735661	C/A	cg21521518	chr4:53727714	RASL11B	0.5	4.52	0.42	1.76e-5	Optic nerve measurement (cup area);
THYM	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg06028605	chr16:24865363	SLC5A11	-0.56	-5.24	-0.47	9.74e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg13443165	chr9:33130375	B4GALT1	-0.8	-7.46	-0.61	4.15e-11	IgG glycosylation;
THYM	cis	rs1797885	0.546	rs2450855	chr3:12602494	G/A	cg05467012	chr3:12595696	NA	0.6	5.26	0.47	9.06e-7	Immature fraction of reticulocytes;
THYM	cis	rs6840360	0.571	rs62327275	chr4:152548238	G/T	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	0.500	rs3823631	chr7:2190100	A/G	cg10360139	chr7:1886902	MAD1L1	-0.65	-4.92	-0.45	3.68e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg06028605	chr16:24865363	SLC5A11	-0.63	-4.93	-0.45	3.53e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs35934224	0.783	rs16984299	chr22:19863593	C/T	cg11182965	chr22:19864308	TXNRD2	0.68	5.49	0.49	3.33e-7	Glaucoma (primary open-angle);
THYM	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.19	-9.36	-0.69	3.85e-15	Platelet count;
THYM	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg11764359	chr7:65958608	NA	-0.74	-6.15	-0.53	1.85e-8	Aortic root size;
THYM	cis	rs11089937	0.825	rs5757012	chr22:22489908	C/T	cg21401457	chr22:22472743	NA	0.61	5.1	0.46	1.71e-6	Periodontitis (PAL4Q3);
THYM	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg02887458	chr19:19495540	GATAD2A	-0.42	-5.08	-0.46	1.87e-6	Bipolar disorder;
THYM	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg20503657	chr10:835505	NA	1.14	7.96	0.63	3.64e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs2730245	0.527	rs2657362	chr7:158685095	A/G	cg24397884	chr7:158709396	WDR60	0.55	5.36	0.48	5.79e-7	Height;
THYM	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg09260853	chr1:2094483	PRKCZ	-0.51	-5.03	-0.46	2.3e-6	Height;
THYM	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg00129232	chr17:37814104	STARD3	-0.99	-9.09	-0.68	1.45e-14	Asthma;
THYM	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg16624210	chr5:671434	TPPP	0.74	6.34	0.54	7.87e-9	Obesity-related traits;
THYM	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	4.67	0.43	9.92e-6	Schizophrenia;
THYM	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg14019146	chr3:50243930	SLC38A3	-0.61	-5.26	-0.48	8.81e-7	Intelligence (multi-trait analysis);
THYM	cis	rs17854409	0.803	rs1063247	chr20:61472118	C/G	cg06598544	chr20:61472147	COL9A3	-1.12	-6.98	-0.58	3.91e-10	Obesity-related traits;
THYM	cis	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg12981288	chr8:11183844	MTMR9	-0.47	-4.57	-0.42	1.48e-5	Retinal vascular caliber;
THYM	cis	rs4481887	0.741	rs6421453	chr1:248533285	A/G	cg17299007	chr1:248814626	OR2T27	0.42	4.52	0.42	1.81e-5	Common traits (Other);
THYM	cis	rs9554348	0.541	rs61966906	chr13:96973228	C/A	cg25169784	chr13:96706045	UGGT2	0.85	4.55	0.42	1.58e-5	Schizophrenia;
THYM	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg25811766	chr13:21894605	NA	-0.74	-4.81	-0.44	5.73e-6	White matter hyperintensity burden;
THYM	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.7	-5.35	-0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7115242	0.800	rs10736487	chr11:116950232	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.89	4.88	0.45	4.27e-6	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
THYM	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg12893428	chr3:195717962	SDHAP1	0.51	4.57	0.42	1.49e-5	Pancreatic cancer;
THYM	cis	rs12681287	0.547	rs13249177	chr8:87513034	A/G	cg27223183	chr8:87520930	FAM82B	-0.71	-5.46	-0.49	3.8e-7	Caudate activity during reward;
THYM	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.29	4.46	0.42	2.27e-5	Obesity-related traits;
THYM	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg18105134	chr13:113819100	PROZ	-1.09	-8.84	-0.67	5.06e-14	Platelet distribution width;
THYM	cis	rs6598163	0.517	rs12366296	chr12:132296824	C/G	cg07389463	chr12:132296394	NA	-0.54	-5.06	-0.46	2.08e-6	Migraine;
THYM	cis	rs950776	0.720	rs11633223	chr15:78935476	T/C	cg06917634	chr15:78832804	PSMA4	0.63	4.63	0.43	1.14e-5	Sudden cardiac arrest;
THYM	cis	rs665401	0.692	rs339320	chr6:117191249	G/A	cg20376953	chr6:117187980	NA	0.61	4.89	0.45	4.05e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg05660106	chr1:15850417	CASP9	-0.65	-5.27	-0.48	8.69e-7	Systolic blood pressure;
THYM	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-4.5	-0.42	1.89e-5	Hemoglobin concentration;
THYM	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg18132916	chr6:79620363	NA	-0.59	-5.3	-0.48	7.54e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg12031863	chr16:4587854	C16orf5	-0.46	-4.96	-0.45	3.09e-6	Schizophrenia;
THYM	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg11871910	chr12:69753446	YEATS4	1.01	9.83	0.71	3.8e-16	Cerebrospinal fluid biomarker levels;
THYM	cis	rs3916	0.955	rs34030695	chr12:121156496	G/A	cg21892295	chr12:121157589	UNC119B	-0.51	-5.03	-0.46	2.27e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs7124681	0.584	rs12226590	chr11:47571808	T/C	cg20307385	chr11:47447363	PSMC3	0.61	4.67	0.43	9.88e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs79149102	0.579	rs28394281	chr15:75326754	C/G	cg09165964	chr15:75287851	SCAMP5	-1.11	-6.35	-0.55	7.21e-9	Lung cancer;
THYM	cis	rs12594515	1.000	rs8026221	chr15:45987910	G/T	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg26924012	chr15:45694286	SPATA5L1	1.14	11.19	0.75	4.78e-19	Homoarginine levels;
THYM	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.92	-10.65	-0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-5.15	-0.47	1.38e-6	Chronic sinus infection;
THYM	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg13395646	chr4:1353034	KIAA1530	-0.54	-5.25	-0.47	9.41e-7	Obesity-related traits;
THYM	cis	rs1629083	0.967	rs12364013	chr11:118119575	C/T	cg25155064	chr11:118100782	MPZL3	-0.57	-5.03	-0.46	2.34e-6	Lung cancer;
THYM	cis	rs950394	0.767	rs17029778	chr2:104991388	A/G	cg20302975	chr2:105468274	NA	-0.66	-4.56	-0.42	1.52e-5	Schizophrenia;
THYM	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg14675211	chr2:100938903	LONRF2	0.76	8.03	0.64	2.6e-12	Intelligence (multi-trait analysis);
THYM	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg12310025	chr6:25882481	NA	-0.97	-9.27	-0.69	6.06e-15	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Bladder cancer;
THYM	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg04863758	chr4:1303710	MAEA	-0.39	-4.47	-0.42	2.16e-5	Obesity-related traits;
THYM	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg22841779	chr14:105766346	BRF1	-0.46	-5.72	-0.51	1.23e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs17407555	1.000	rs17407555	chr4:10274994	A/G	cg00071950	chr4:10020882	SLC2A9	-0.65	-4.89	-0.45	4.12e-6	Schizophrenia (age at onset);
THYM	cis	rs924712	0.645	rs239801	chr6:54788252	G/A	cg04690482	chr6:54711388	FAM83B	0.45	5.39	0.48	5.16e-7	Breast cancer;
THYM	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg27535305	chr1:53392650	SCP2	-0.39	-4.46	-0.42	2.26e-5	Monocyte count;
THYM	cis	rs96067	0.711	rs7521145	chr1:36622903	A/G	cg24686825	chr1:36642396	MAP7D1	-0.64	-5.08	-0.46	1.84e-6	Corneal structure;
THYM	cis	rs7586879	0.681	rs6545800	chr2:25118885	A/G	cg27107076	chr2:25050844	ADCY3	0.29	4.66	0.43	1.04e-5	Body mass index;
THYM	cis	rs1401999	0.621	rs1000952	chr3:183755822	G/A	cg01324343	chr3:183735012	ABCC5	0.71	7.55	0.61	2.67e-11	Anterior chamber depth;
THYM	cis	rs10779751	1.000	rs4845856	chr1:11274547	T/C	cg08854313	chr1:11322531	MTOR	1.01	9.78	0.71	4.97e-16	Body mass index;
THYM	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12579753	0.872	rs12319937	chr12:82182545	T/G	cg21231944	chr12:82153410	PPFIA2	-0.68	-5.12	-0.46	1.6e-6	Resting heart rate;
THYM	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg15693483	chr7:1102177	C7orf50	0.49	5.66	0.5	1.63e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs12200782	0.530	rs6929908	chr6:26555289	C/A	cg12826209	chr6:26865740	GUSBL1	0.8	4.82	0.44	5.52e-6	Small cell lung carcinoma;
THYM	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg21028142	chr17:79581711	NPLOC4	0.51	5.01	0.46	2.47e-6	Eye color traits;
THYM	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg26677194	chr12:130822605	PIWIL1	0.8	6.12	0.53	2.13e-8	Menopause (age at onset);
THYM	cis	rs2458413	0.542	rs2853146	chr8:105370179	G/A	cg21295575	chr8:105352067	TM7SF4	-0.35	-5.3	-0.48	7.58e-7	Paget's disease;
THYM	cis	rs2969070	1.000	rs1548594	chr7:2513281	G/C	cg25507518	chr7:2405875	EIF3B	-0.47	-4.54	-0.42	1.68e-5	Diastolic blood pressure;
THYM	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg21773646	chr17:80085082	CCDC57	-0.35	-4.9	-0.45	3.91e-6	Life satisfaction;
THYM	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg03929089	chr4:120376271	NA	-0.98	-10.67	-0.74	6.29e-18	Coronary artery disease;
THYM	cis	rs858239	0.539	rs6461695	chr7:23197784	C/A	cg09755872	chr7:23245557	NA	-0.49	-4.52	-0.42	1.81e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg01380346	chr19:18557039	ELL	-0.47	-4.7	-0.43	8.65e-6	Breast cancer;
THYM	cis	rs1922291	0.546	rs17637748	chr2:102841715	A/G	cg13315345	chr2:102803985	IL1RL2	0.62	7.15	0.59	1.81e-10	Blood protein levels;
THYM	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.69	6.25	0.54	1.14e-8	Chronic sinus infection;
THYM	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg04429589	chr14:105992532	TMEM121	-0.51	-5.6	-0.5	2.08e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg03188948	chr7:1209495	NA	0.9	5.02	0.46	2.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg20607798	chr8:58055168	NA	0.84	4.46	0.42	2.29e-5	Developmental language disorder (linguistic errors);
THYM	trans	rs11109072	1.000	rs11109092	chr12:97915711	T/C	cg17633015	chr7:2020501	MAD1L1	0.95	7.08	0.59	2.49e-10	Obesity (early onset extreme);
THYM	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg00898013	chr13:113819073	PROZ	0.87	8.45	0.65	3.44e-13	Platelet distribution width;
THYM	cis	rs4919694	1.000	rs12257935	chr10:104803062	C/A	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs9880211	0.948	rs13321721	chr3:136209550	A/G	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.81	5.01	0.46	2.56e-6	Diabetic retinopathy;
THYM	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg13447684	chr7:1895903	MAD1L1	0.58	5.07	0.46	2e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs11674184	0.714	rs9789525	chr2:11724580	G/T	cg07314298	chr2:11723111	GREB1	-0.67	-6.23	-0.54	1.27e-8	Endometriosis;
THYM	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg02569458	chr12:86230093	RASSF9	0.64	5.56	0.5	2.46e-7	Major depressive disorder;
THYM	cis	rs72827839	0.779	rs72827844	chr17:46434441	A/G	cg23391107	chr17:45924227	SP6	0.86	5.55	0.5	2.54e-7	Ease of getting up in the morning;
THYM	cis	rs877282	0.945	rs11253388	chr10:787852	A/G	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.77	7.59	0.61	2.14e-11	Lymphocyte counts;
THYM	cis	rs7432375	0.901	rs11919030	chr3:136348599	G/A	cg21827317	chr3:136751795	NA	0.58	5.07	0.46	1.97e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.47	-4.5	-0.42	1.9e-5	Bone mineral density (hip);Bone mineral density;
THYM	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.67	-5.5	-0.49	3.15e-7	Blood metabolite levels;
THYM	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg23173402	chr1:227635558	NA	0.82	6.44	0.55	4.95e-9	Major depressive disorder;
THYM	cis	rs7833986	0.534	rs17814089	chr8:56965563	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.57	-6.97	-0.58	4.25e-10	Height;
THYM	cis	rs2288884	0.708	rs59104696	chr19:52555170	C/T	cg05974498	chr19:52599256	ZNF841	0.36	4.52	0.42	1.78e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs6840360	0.642	rs7666571	chr4:152443273	C/T	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.32	-0.48	6.81e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg23978390	chr7:1156363	C7orf50	0.66	5.16	0.47	1.38e-6	Longevity;Endometriosis;
THYM	cis	rs4285028	0.796	rs12638492	chr3:121711763	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.69	-4.51	-0.42	1.83e-5	Multiple sclerosis;
THYM	cis	rs10214930	1.000	rs10214930	chr7:27784949	G/A	cg04422003	chr7:28448295	CREB5	-0.62	-4.62	-0.43	1.19e-5	Hypospadias;
THYM	cis	rs7681440	0.606	rs2736996	chr4:90754691	A/G	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg16928487	chr17:17741425	SREBF1	-0.55	-5.04	-0.46	2.21e-6	Total body bone mineral density;
THYM	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11890956	chr21:40555474	PSMG1	-0.65	-6.03	-0.53	3.17e-8	Menarche (age at onset);
THYM	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22509189	chr2:225307070	NA	0.88	7.52	0.61	3.1e-11	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs910187	1.000	rs910187	chr20:45841052	A/G	cg27589058	chr20:45804311	EYA2	0.59	4.89	0.45	4.14e-6	Migraine;
THYM	cis	rs11966931	1.000	rs11966931	chr6:108131298	G/A	cg25323841	chr6:108444506	NA	0.65	4.45	0.42	2.35e-5	Neutrophil percentage of white cells;
THYM	cis	rs3020340	0.906	rs12525163	chr6:152040291	T/C	cg22157087	chr6:152012887	ESR1	0.49	4.76	0.44	7.03e-6	Bone mineral density (Ward's triangle area);
THYM	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg14784868	chr12:69753453	YEATS4	1.12	10.85	0.74	2.52e-18	Blood protein levels;
THYM	cis	rs17152411	0.895	rs7080330	chr10:126585673	A/G	cg07906193	chr10:126599966	NA	0.68	4.65	0.43	1.08e-5	Height;
THYM	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg12560992	chr17:57184187	TRIM37	-0.92	-8.68	-0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	trans	rs8002861	0.935	rs9525865	chr13:44459647	A/T	cg17145862	chr1:211918768	LPGAT1	1.03	11.49	0.76	1.12e-19	Leprosy;
THYM	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg17366294	chr4:99064904	C4orf37	0.48	5.41	0.49	4.78e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs600806	0.713	rs12140694	chr1:109998386	C/T	cg02175308	chr1:109941060	SORT1	-0.55	-4.59	-0.43	1.33e-5	Intelligence (multi-trait analysis);
THYM	cis	rs13102973	0.931	rs13128765	chr4:135888141	A/G	cg14419869	chr4:135874104	NA	0.89	8.63	0.66	1.39e-13	Subjective well-being;
THYM	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg19507638	chr5:93509721	C5orf36	-0.65	-4.54	-0.42	1.63e-5	Diabetic retinopathy;
THYM	cis	rs806215	0.951	rs327510	chr7:127257894	G/A	cg08586737	chr7:127225949	GCC1	0.37	4.52	0.42	1.8e-5	Type 2 diabetes;
THYM	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg08305652	chr11:111469057	NA	0.53	4.54	0.42	1.62e-5	Primary sclerosing cholangitis;
THYM	cis	rs7172809	0.897	rs17394448	chr15:77825149	C/A	cg10437265	chr15:77819839	NA	-0.57	-5.0	-0.46	2.56e-6	Glucose homeostasis traits;
THYM	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg08470875	chr2:26401718	FAM59B	-0.78	-4.69	-0.43	9.1e-6	Gut microbiome composition (summer);
THYM	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.36e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs600806	0.850	rs10776807	chr1:109956156	A/G	cg16988986	chr1:109941118	SORT1	0.45	4.89	0.45	4.02e-6	Intelligence (multi-trait analysis);
THYM	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	7.04	0.59	2.93e-10	Smoking behavior;
THYM	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg20295408	chr7:1910781	MAD1L1	-0.72	-6.12	-0.53	2.04e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs13395090	0.606	rs13405419	chr2:3720664	T/C	cg25251562	chr2:3704773	ALLC	-0.55	-4.47	-0.42	2.18e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	trans	rs9929218	0.551	rs2274240	chr16:68725486	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.14	15.76	0.85	3.02e-28	Colorectal cancer;
THYM	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg08885076	chr2:99613938	TSGA10	-0.47	-4.69	-0.43	9.21e-6	Fear of minor pain;
THYM	cis	rs3741151	0.686	rs2298469	chr11:73133030	T/C	cg12959048	chr11:73096162	RELT	-0.46	-4.94	-0.45	3.32e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7626444	0.625	rs2686596	chr3:196475119	T/C	cg12930392	chr3:196481615	PAK2	0.43	5.31	0.48	7.26e-7	Monocyte count;
THYM	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg17264618	chr3:40429014	ENTPD3	0.51	5.06	0.46	2.03e-6	Renal cell carcinoma;
THYM	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg09467607	chr2:36825704	FEZ2	0.38	4.68	0.43	9.43e-6	Height;
THYM	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg17054759	chr22:49844102	NA	-0.53	-4.92	-0.45	3.67e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs11696501	0.688	rs1487310	chr20:44308789	A/G	cg11783356	chr20:44313418	WFDC10B	-0.69	-4.75	-0.44	7.34e-6	Brain structure;
THYM	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg10523679	chr1:76189770	ACADM	0.9	9.47	0.7	2.2e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1639906	0.895	rs6972752	chr7:2196551	G/A	cg19897017	chr7:2163380	MAD1L1	-0.52	-4.93	-0.45	3.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg16322792	chr1:120165303	ZNF697	0.92	11.54	0.76	9.09e-20	Systemic lupus erythematosus;
THYM	cis	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg09085632	chr11:111637200	PPP2R1B	1.16	11.93	0.77	1.35e-20	Primary sclerosing cholangitis;
THYM	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg07414643	chr4:187882934	NA	-0.6	-5.3	-0.48	7.52e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.71	6.25	0.54	1.16e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6565180	0.888	rs8060853	chr16:30403858	A/G	cg17640201	chr16:30407289	ZNF48	0.87	7.05	0.59	2.85e-10	Tonsillectomy;
THYM	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg11494091	chr17:61959527	GH2	1.1	16.61	0.86	7.61e-30	Prudent dietary pattern;
THYM	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-4.5	-0.42	1.93e-5	Aortic root size;
THYM	trans	rs9951602	0.512	rs8084836	chr18:76647841	A/G	cg02800362	chr5:177631904	HNRNPAB	1.09	8.5	0.66	2.58e-13	Obesity-related traits;
THYM	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg08885076	chr2:99613938	TSGA10	0.75	7.01	0.58	3.44e-10	Chronic sinus infection;
THYM	cis	rs6450176	1.000	rs1445887	chr5:53299376	A/T	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.18	-0.54	1.6e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs2933343	0.700	rs2630257	chr3:128644015	T/C	cg11901034	chr3:128598214	ACAD9	-0.69	-5.57	-0.5	2.32e-7	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg06221963	chr1:154839813	KCNN3	-0.9	-12.27	-0.78	2.64e-21	Prostate cancer;
THYM	cis	rs8112211	1.000	rs56849284	chr19:38826947	T/C	cg09474229	chr19:39360330	RINL	-0.52	-4.74	-0.44	7.35e-6	Blood protein levels;
THYM	cis	rs2637266	0.967	rs12254242	chr10:78352934	T/C	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg26384229	chr12:38710491	ALG10B	0.91	6.96	0.58	4.26e-10	Morning vs. evening chronotype;
THYM	cis	rs367615	0.704	rs55956735	chr5:108845042	A/G	cg17395555	chr5:108820864	NA	0.74	8.82	0.67	5.59e-14	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs4631830	0.863	rs7081532	chr10:51526093	A/G	cg16070123	chr10:51489643	NA	-0.5	-4.5	-0.42	1.94e-5	Prostate-specific antigen levels;
THYM	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	trans	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg25214090	chr10:38739885	LOC399744	0.94	8.27	0.65	7.91e-13	Corneal astigmatism;
THYM	cis	rs2463822	0.844	rs72923263	chr11:62161170	C/G	cg06239285	chr11:62104954	ASRGL1	-1.4	-6.65	-0.56	1.86e-9	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs13177918	0.677	rs13181401	chr5:149822596	T/C	cg14059543	chr5:149831962	NA	-1.0	-7.6	-0.61	2.11e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs1065852	0.526	rs11090066	chr22:42398195	A/G	cg22189786	chr22:42395067	WBP2NL	0.6	6.24	0.54	1.2e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg11245990	chr11:68621969	NA	0.56	7.23	0.6	1.2e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg12935359	chr14:103987150	CKB	-0.64	-6.43	-0.55	5.14e-9	Body mass index;
THYM	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.59	5.3	0.48	7.4e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9875589	0.509	rs2129888	chr3:14013826	A/T	cg03204825	chr3:13978759	TPRXL	-0.51	-4.5	-0.42	1.93e-5	Ovarian reserve;
THYM	cis	rs12049351	0.612	rs16849836	chr1:229614462	C/T	cg11742688	chr1:229674241	ABCB10	-0.54	-4.62	-0.43	1.22e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs67478160	0.643	rs11624184	chr14:104240998	A/G	cg08213375	chr14:104286397	PPP1R13B	0.59	7.06	0.59	2.73e-10	Schizophrenia;
THYM	cis	rs778371	0.874	rs1083522	chr2:233745521	C/T	cg08000102	chr2:233561755	GIGYF2	-0.84	-6.97	-0.58	4.18e-10	Schizophrenia;
THYM	cis	rs7572733	0.515	rs12619300	chr2:198786490	A/C	cg05783139	chr2:198650985	BOLL	-0.62	-4.91	-0.45	3.8e-6	Dermatomyositis;
THYM	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg21427119	chr20:30132790	HM13	-0.75	-5.02	-0.46	2.39e-6	Mean corpuscular hemoglobin;
THYM	cis	rs12681287	0.752	rs4641037	chr8:87268379	A/G	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs3812049	0.826	rs17764730	chr5:127357526	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.63	4.53	0.42	1.73e-5	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs9788682	0.747	rs16969894	chr15:78776456	C/T	cg18825076	chr15:78729989	IREB2	0.7	5.57	0.5	2.39e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg08999081	chr20:33150536	PIGU	-0.75	-6.62	-0.56	2.1e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs986417	0.748	rs2179971	chr14:61055466	T/C	cg27398547	chr14:60952738	C14orf39	0.87	5.0	0.46	2.57e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs4733781	0.509	rs1158569	chr8:131331012	A/C	cg16277922	chr8:131349729	ASAP1	0.71	6.31	0.54	8.85e-9	Tuberculosis;
THYM	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg26384229	chr12:38710491	ALG10B	-0.74	-6.24	-0.54	1.22e-8	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg16926213	chr1:1841314	NA	0.55	5.79	0.51	9.21e-8	Body mass index;
THYM	cis	rs116095464	1.000	rs62346511	chr5:208265	C/T	cg22857025	chr5:266934	NA	-1.45	-4.92	-0.45	3.57e-6	Breast cancer;
THYM	trans	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01570182	chr17:44337453	NA	0.91	9.94	0.71	2.22e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg21475434	chr5:93447410	FAM172A	0.83	5.31	0.48	7.13e-7	Diabetic retinopathy;
THYM	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg13319975	chr6:146136371	FBXO30	-0.66	-5.62	-0.5	1.89e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg26384229	chr12:38710491	ALG10B	1.01	9.69	0.7	7.72e-16	Heart rate;
THYM	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg06636001	chr8:8085503	FLJ10661	-0.72	-6.6	-0.56	2.35e-9	Mood instability;
THYM	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg05468064	chr22:46423449	NA	-0.45	-5.5	-0.49	3.19e-7	Dupuytren's disease;
THYM	cis	rs9309473	0.539	rs6732440	chr2:73827099	T/G	cg19565262	chr2:73869966	NAT8	0.62	5.07	0.46	1.98e-6	Metabolite levels;
THYM	cis	rs17331151	0.505	rs13066389	chr3:52565317	C/T	cg17372223	chr3:52568218	NT5DC2	0.57	4.58	0.43	1.42e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg27588902	chr6:42928151	GNMT	-0.56	-5.77	-0.51	1.01e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06873352	chr17:61820015	STRADA	-0.54	-5.48	-0.49	3.55e-7	Height;
THYM	cis	rs7107174	1.000	rs1017908	chr11:77948095	A/G	cg02023728	chr11:77925099	USP35	0.73	6.41	0.55	5.61e-9	Testicular germ cell tumor;
THYM	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs55728055	0.661	rs62237775	chr22:31965401	A/G	cg10537193	chr22:32026975	PISD	-0.68	-4.66	-0.43	1.03e-5	Age-related hearing impairment;
THYM	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg18105134	chr13:113819100	PROZ	-0.99	-9.17	-0.69	9.97e-15	Platelet distribution width;
THYM	cis	rs4595586	0.545	rs2197941	chr12:39402223	G/A	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg19016782	chr12:123741754	C12orf65	-0.69	-4.57	-0.42	1.45e-5	Neutrophil percentage of white cells;
THYM	cis	rs9915657	0.870	rs4140902	chr17:70133750	A/G	cg09344028	chr17:70110421	NA	0.49	4.9	0.45	3.92e-6	Thyroid hormone levels;
THYM	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg20891283	chr12:69753455	YEATS4	0.69	5.59	0.5	2.19e-7	Response to diuretic therapy;
THYM	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg10802521	chr3:52805072	NEK4	-0.73	-6.43	-0.55	5.15e-9	Bipolar disorder;
THYM	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs3843585	0.708	rs3750778	chr10:71715359	G/A	cg14179150	chr10:71641786	COL13A1	0.57	4.47	0.42	2.12e-5	Middle childhood and early adolescence aggressive behavior;
THYM	cis	rs28595532	0.920	rs114210107	chr4:119734491	G/A	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs9549367	0.712	rs2316443	chr13:113864837	G/A	cg00898013	chr13:113819073	PROZ	-0.87	-8.07	-0.64	2.19e-12	Platelet distribution width;
THYM	cis	rs7843479	0.526	rs34802507	chr8:21773853	C/T	cg17168535	chr8:21777572	XPO7	0.87	7.85	0.63	6.11e-12	Mean corpuscular volume;
THYM	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg21784768	chr11:537496	LRRC56	-0.95	-4.86	-0.45	4.66e-6	Body mass index;
THYM	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg14004847	chr7:1930337	MAD1L1	-0.72	-5.51	-0.49	3.04e-7	Schizophrenia;
THYM	cis	rs8112449	0.930	rs11085732	chr19:10533112	C/G	cg01466491	chr19:10523363	NA	-0.66	-6.07	-0.53	2.66e-8	Multiple sclerosis;Gastritis;
THYM	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg26384229	chr12:38710491	ALG10B	0.9	6.93	0.58	5.08e-10	Heart rate;
THYM	cis	rs981844	0.712	rs11099915	chr4:154743624	A/G	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs7119	0.717	rs12911854	chr15:77817288	T/C	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	trans	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg10856724	chr12:34555212	NA	-0.89	-7.93	-0.63	4.21e-12	Bladder cancer;
THYM	cis	rs12765878	1.000	rs11191847	chr10:105650626	G/C	cg11005552	chr10:105648138	OBFC1	0.87	11.39	0.76	1.84e-19	Coronary artery disease;
THYM	cis	rs16866061	1.000	rs11694987	chr2:225397409	C/G	cg12698349	chr2:225449008	CUL3	1.13	10.33	0.73	3.22e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg06219351	chr7:158114137	PTPRN2	-0.71	-6.92	-0.58	5.15e-10	Calcium levels;
THYM	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-4.98	-0.45	2.87e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs274567	0.711	rs404771	chr5:131635092	A/T	cg12564285	chr5:131593104	PDLIM4	0.45	4.77	0.44	6.7e-6	Blood metabolite levels;
THYM	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg02725872	chr8:58115012	NA	-0.84	-5.75	-0.51	1.06e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs57994353	0.826	rs34619169	chr9:139327277	G/A	cg24793265	chr9:139269240	CARD9	-0.57	-4.61	-0.43	1.26e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs76935404	1.000	rs76935404	chr19:41419294	C/T	cg19493303	chr19:41414353	NA	0.57	5.1	0.46	1.74e-6	nicotine metabolite ratio in current smokers;
THYM	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg17480646	chr11:65405466	SIPA1	-0.94	-8.85	-0.67	4.72e-14	Acne (severe);
THYM	cis	rs11997175	0.624	rs4355732	chr8:33676920	A/C	ch.8.33884649F	chr8:33765107	NA	0.66	5.0	0.46	2.57e-6	Body mass index;
THYM	cis	rs988913	0.706	rs6910384	chr6:54743998	G/A	cg19716238	chr6:54711378	FAM83B	0.52	5.19	0.47	1.19e-6	Menarche (age at onset);
THYM	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg23583168	chr7:148888333	NA	-1.0	-13.46	-0.81	9.53e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6694672	1.000	rs2336597	chr1:196993339	C/T	cg13682187	chr1:196946512	CFHR5	-0.8	-4.46	-0.42	2.27e-5	Asthma;
THYM	cis	rs36051895	0.664	rs10117565	chr9:5094461	G/A	cg02405213	chr9:5042618	JAK2	-1.0	-10.94	-0.75	1.67e-18	Pediatric autoimmune diseases;
THYM	cis	rs10743315	0.557	rs10505840	chr12:19403729	G/T	cg02471346	chr12:19282374	PLEKHA5	1.17	4.83	0.44	5.31e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg24399712	chr22:39784796	NA	-0.87	-9.59	-0.7	1.24e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg15741354	chr8:8146129	NA	0.29	4.85	0.45	4.88e-6	Joint mobility (Beighton score);
THYM	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.79	-0.44	6.18e-6	Mean corpuscular volume;
THYM	cis	rs3780378	0.870	rs7034878	chr9:5058991	G/T	cg02405213	chr9:5042618	JAK2	0.65	6.17	0.54	1.63e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg02887458	chr19:19495540	GATAD2A	-0.49	-5.38	-0.48	5.37e-7	Bipolar disorder;
THYM	cis	rs12478296	0.818	rs57194240	chr2:243011545	A/G	cg06360820	chr2:242988706	NA	-0.91	-5.94	-0.52	4.61e-8	Obesity-related traits;
THYM	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg07371521	chr5:154026371	NA	0.57	5.45	0.49	3.96e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg00908189	chr16:619842	PIGQ	1.03	9.46	0.7	2.34e-15	Height;
THYM	cis	rs2285947	0.935	rs10258022	chr7:21583667	A/G	cg04471919	chr7:21584483	DNAH11	0.46	4.5	0.42	1.92e-5	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
THYM	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg18105134	chr13:113819100	PROZ	0.98	9.1	0.68	1.36e-14	Platelet distribution width;
THYM	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg18230493	chr5:56204884	C5orf35	-0.82	-5.98	-0.52	3.83e-8	Initial pursuit acceleration;
THYM	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg13607699	chr17:42295918	UBTF	0.89	8.57	0.66	1.84e-13	Red cell distribution width;Reticulocyte count;
THYM	cis	rs611744	0.967	rs686584	chr8:109192357	G/A	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg03929089	chr4:120376271	NA	-1.03	-12.43	-0.79	1.26e-21	Height;
THYM	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg03388043	chr17:80084554	CCDC57	0.69	5.98	0.52	3.85e-8	Life satisfaction;
THYM	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg23711669	chr6:146136114	FBXO30	0.82	7.34	0.6	7.2e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg09035930	chr12:129282057	SLC15A4	0.86	12.01	0.78	9.43e-21	Systemic lupus erythematosus;
THYM	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg27398817	chr8:82754497	SNX16	0.84	6.56	0.56	2.79e-9	Diastolic blood pressure;
THYM	cis	rs1728785	1.000	rs1364109	chr16:68595505	T/C	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs9419702	0.526	rs9419637	chr10:133548059	T/C	cg23460707	chr10:133558971	NA	0.45	4.69	0.43	9.18e-6	Survival in rectal cancer;
THYM	cis	rs7211079	0.957	rs935117	chr17:78115484	A/C	cg09238746	chr17:78121135	EIF4A3	-0.74	-4.64	-0.43	1.1e-5	Myocardial infarction;
THYM	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg14349672	chr11:133703707	NA	-0.54	-4.86	-0.45	4.63e-6	Childhood ear infection;
THYM	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg23803603	chr1:2058230	PRKCZ	0.66	5.99	0.52	3.8e-8	Height;
THYM	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg13147721	chr7:65941812	NA	-0.74	-4.73	-0.44	7.94e-6	Diabetic kidney disease;
THYM	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02463440	chr8:22132932	PIWIL2	0.58	4.89	0.45	4.15e-6	Hypertriglyceridemia;
THYM	cis	rs7107174	0.892	rs4291702	chr11:78001248	C/T	cg02023728	chr11:77925099	USP35	0.63	5.98	0.52	3.95e-8	Testicular germ cell tumor;
THYM	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.09	-7.74	-0.62	1.06e-11	Platelet count;
THYM	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg02753203	chr1:228287806	NA	0.97	8.27	0.65	8.11e-13	Diastolic blood pressure;
THYM	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	5.59	0.5	2.16e-7	Monocyte percentage of white cells;
THYM	cis	rs10208940	0.614	rs13422390	chr2:68810855	A/C	cg09157127	chr2:69201416	GKN1	-0.77	-4.57	-0.42	1.45e-5	Urate levels in lean individuals;
THYM	cis	rs7582180	0.715	rs11123823	chr2:100916315	A/G	cg14675211	chr2:100938903	LONRF2	0.72	7.03	0.59	3.09e-10	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.93	-0.45	3.52e-6	Monocyte count;
THYM	cis	rs62117911	1	rs62117911	chr19:16241886	G/A	cg03621001	chr19:16221719	RAB8A	-0.69	-4.49	-0.42	1.97e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg00310523	chr12:86230176	RASSF9	-0.57	-5.07	-0.46	1.98e-6	Major depressive disorder;
THYM	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26314531	chr2:26401878	FAM59B	-0.8	-5.35	-0.48	6.14e-7	Gut microbiome composition (summer);
THYM	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg05802129	chr4:122689817	NA	-0.59	-4.65	-0.43	1.08e-5	Type 2 diabetes;
THYM	cis	rs7399018	1.000	rs7399018	chr12:51610365	C/T	cg25754956	chr12:51612065	POU6F1	-1.08	-6.32	-0.54	8.42e-9	Cisplatin-induced ototoxicity;
THYM	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.67	0.43	9.95e-6	Bipolar disorder;
THYM	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg00576331	chr11:65640516	EFEMP2	0.68	4.58	0.43	1.42e-5	Crohn's disease;
THYM	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21659725	chr3:3221576	CRBN	0.9	9.83	0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	5.89	0.52	5.79e-8	Schizophrenia;
THYM	cis	rs6032067	0.866	rs2233901	chr20:43851094	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	0.71	7.53	0.61	2.95e-11	Blood protein levels;
THYM	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg10334053	chr1:2078117	PRKCZ	0.45	4.46	0.42	2.25e-5	Height;
THYM	cis	rs2455799	0.613	rs10510443	chr3:15829127	A/G	cg16303742	chr3:15540471	COLQ	-0.54	-5.78	-0.51	9.67e-8	Mean platelet volume;
THYM	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg00640147	chr17:61958756	GH2	-0.43	-4.54	-0.42	1.64e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg00255919	chr5:131827918	IRF1	-0.46	-5.0	-0.46	2.62e-6	Asthma (sex interaction);
THYM	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg00129232	chr17:37814104	STARD3	0.69	4.51	0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs7078219	0.714	rs10883369	chr10:101291367	C/T	cg07044859	chr10:101282883	NA	-0.51	-5.24	-0.47	9.46e-7	Dental caries;
THYM	cis	rs4731207	1.000	rs4731207	chr7:124396645	G/A	cg05285228	chr7:124571219	POT1	0.63	4.84	0.44	5.04e-6	Cutaneous malignant melanoma;
THYM	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg11764359	chr7:65958608	NA	-0.67	-5.08	-0.46	1.9e-6	Aortic root size;
THYM	cis	rs981844	0.796	rs13140722	chr4:154712203	T/A	cg22178613	chr4:154710499	SFRP2	0.59	4.9	0.45	3.97e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg22907277	chr7:1156413	C7orf50	0.87	7.58	0.61	2.31e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs13064411	0.696	rs9869318	chr3:113146271	T/C	cg18753928	chr3:113234510	CCDC52	-0.91	-8.22	-0.64	1.04e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs10463554	0.963	rs62364876	chr5:102394158	T/C	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs4499344	0.526	rs8111902	chr19:33032243	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.69	-4.54	-0.42	1.64e-5	Mean platelet volume;
THYM	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg17366294	chr4:99064904	C4orf37	0.54	6.05	0.53	2.81e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7000551	0.659	rs2280521	chr8:22271995	G/T	cg13512537	chr8:22265999	SLC39A14	0.64	4.69	0.43	9.02e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs11711311	0.747	rs7638449	chr3:113343646	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.53	-4.5	-0.42	1.95e-5	IgG glycosylation;
THYM	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg03684893	chr10:554711	DIP2C	-0.7	-6.2	-0.54	1.48e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs6840360	0.571	rs4696271	chr4:152509118	G/A	cg17479576	chr4:152424074	FAM160A1	-0.79	-5.56	-0.5	2.45e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg10295955	chr4:187884368	NA	-1.19	-17.25	-0.87	5.06e-31	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg10856724	chr12:34555212	NA	-0.89	-7.81	-0.63	7.68e-12	Bladder cancer;
THYM	cis	rs34638657	0.827	rs6564996	chr16:82207542	T/C	cg19807685	chr16:82068980	HSD17B2	-0.62	-4.67	-0.43	1e-5	Lung adenocarcinoma;
THYM	cis	rs7072216	0.763	rs733346	chr10:100164325	A/C	cg26618903	chr10:100175079	PYROXD2	-0.49	-4.67	-0.43	1.01e-5	Metabolite levels;
THYM	cis	rs9992101	0.645	rs6857452	chr4:77317124	C/T	cg20311846	chr4:77356250	SHROOM3	0.52	5.72	0.51	1.22e-7	Creatinine levels;
THYM	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg16586182	chr3:47516702	SCAP	-0.63	-5.52	-0.49	2.96e-7	Colorectal cancer;
THYM	cis	rs600806	0.815	rs4970730	chr1:109979526	T/C	cg02175308	chr1:109941060	SORT1	-0.56	-4.88	-0.45	4.33e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.28	-5.88	-0.52	6.18e-8	Obesity-related traits;
THYM	trans	rs11109072	0.850	rs7957658	chr12:97897192	C/T	cg17633015	chr7:2020501	MAD1L1	1.0	7.4	0.6	5.5e-11	Obesity (early onset extreme);
THYM	cis	rs4979906	1.000	rs11002241	chr10:79445327	C/T	cg07817648	chr10:79422355	NA	-0.76	-5.64	-0.5	1.77e-7	Mortality in heart failure;
THYM	cis	rs9361491	0.604	rs1158575	chr6:79459206	A/G	cg04547799	chr6:79944526	HMGN3	-0.66	-4.61	-0.43	1.24e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg24596788	chr1:163392923	NA	0.77	7.15	0.59	1.78e-10	Motion sickness;
THYM	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg00310523	chr12:86230176	RASSF9	-0.57	-5.04	-0.46	2.2e-6	Major depressive disorder;
THYM	cis	rs909002	0.704	rs2271927	chr1:32127911	C/T	cg13919466	chr1:32135498	COL16A1	0.55	4.96	0.45	3.04e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg06713675	chr4:122721982	EXOSC9	-0.86	-9.81	-0.71	4.29e-16	Type 2 diabetes;
THYM	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg02953382	chr22:24373134	LOC391322	-0.7	-6.21	-0.54	1.42e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg12179176	chr11:130786555	SNX19	0.95	9.69	0.71	7.59e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4731207	0.698	rs17147583	chr7:124470125	C/G	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs4482178	0.850	rs1764956	chr13:86261588	G/T	cg25308322	chr13:86268291	NA	0.65	4.56	0.42	1.54e-5	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs8114671	0.562	rs2273683	chr20:33509523	C/T	cg08999081	chr20:33150536	PIGU	0.63	5.21	0.47	1.09e-6	Height;
THYM	cis	rs2072499	0.868	rs2758600	chr1:156195205	C/T	cg06970220	chr1:156163860	SLC25A44	0.74	5.73	0.51	1.2e-7	Testicular germ cell tumor;
THYM	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg06221963	chr1:154839813	KCNN3	-0.77	-9.84	-0.71	3.56e-16	Prostate cancer;
THYM	cis	rs12282928	0.959	rs4980426	chr11:48296019	A/G	cg22827986	chr11:48284249	OR4X1	-0.52	-5.43	-0.49	4.4e-7	Migraine - clinic-based;
THYM	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg14004847	chr7:1930337	MAD1L1	-0.61	-4.87	-0.45	4.5e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7523273	0.606	rs10449303	chr1:207961058	A/G	cg22525895	chr1:207977042	MIR29B2	-0.97	-10.43	-0.73	1.98e-17	Schizophrenia;
THYM	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg03709012	chr19:19516395	GATAD2A	0.81	6.63	0.56	2.02e-9	Tonsillectomy;
THYM	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg01557791	chr16:72042693	DHODH	-0.59	-4.69	-0.43	9.31e-6	Prostate cancer;
THYM	cis	rs55665837	1.000	rs4412729	chr11:14439000	A/G	cg19336497	chr11:14380999	RRAS2	-0.63	-6.93	-0.58	5.1e-10	Vitamin D levels;
THYM	cis	rs3791406	1.000	rs3791406	chr2:240030484	A/G	cg05758467	chr2:240035894	HDAC4	0.44	4.51	0.42	1.89e-5	Skin aging (microtopography measurement);
THYM	cis	rs7927771	0.697	rs11039307	chr11:47611152	C/T	cg18512352	chr11:47633146	NA	-0.46	-5.56	-0.5	2.48e-7	Subjective well-being;
THYM	cis	rs7599312	0.534	rs10207878	chr2:213409337	A/G	cg20637307	chr2:213403960	ERBB4	1.04	11.16	0.75	5.66e-19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9581943	0.967	rs4424773	chr13:28470544	C/G	cg16302790	chr13:28498334	PDX1	0.52	4.59	0.43	1.33e-5	Pancreatic cancer;
THYM	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-5.77	-0.51	9.69e-8	Gut microbiome composition (summer);
THYM	cis	rs11997175	0.846	rs6999445	chr8:33732693	G/A	ch.8.33884649F	chr8:33765107	NA	0.69	5.59	0.5	2.17e-7	Body mass index;
THYM	cis	rs2039659	0.641	rs1753772	chr13:86259391	C/T	cg25308322	chr13:86268291	NA	0.65	5.9	0.52	5.56e-8	Blood osmolality (transformed sodium);
THYM	cis	rs2836950	0.501	rs1474490	chr21:40716136	C/A	cg11890956	chr21:40555474	PSMG1	-0.57	-5.0	-0.46	2.6e-6	Menarche (age at onset);
THYM	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.85	-5.32	-0.48	6.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1011018	0.955	rs7782128	chr7:139441661	C/T	cg06079564	chr7:139468310	HIPK2	0.71	5.39	0.48	5.1e-7	Systolic blood pressure;
THYM	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.78	0.44	6.42e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg15556689	chr8:8085844	FLJ10661	0.62	4.72	0.44	8.27e-6	Neuroticism;
THYM	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg25811766	chr13:21894605	NA	-0.77	-4.99	-0.46	2.77e-6	White matter hyperintensity burden;
THYM	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg11905131	chr22:24372483	LOC391322	-0.94	-10.28	-0.73	4.07e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs919433	0.713	rs13411968	chr2:198467141	C/T	cg00792783	chr2:198669748	PLCL1	0.81	5.63	0.5	1.83e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9788682	0.748	rs637137	chr15:78873976	T/A	cg18825076	chr15:78729989	IREB2	0.6	4.83	0.44	5.31e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg14768367	chr16:72042858	DHODH	0.61	4.64	0.43	1.1e-5	Fibrinogen levels;
THYM	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	5.87	0.52	6.41e-8	Rheumatoid arthritis;
THYM	cis	rs6960043	0.936	rs62448618	chr7:15052211	T/A	cg19272540	chr7:15055459	NA	-0.48	-5.81	-0.51	8.28e-8	Type 2 diabetes;
THYM	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg10802521	chr3:52805072	NEK4	-0.74	-6.49	-0.55	3.86e-9	Bipolar disorder;
THYM	cis	rs34638657	0.872	rs2967355	chr16:82200103	G/T	cg07307142	chr16:82071433	HSD17B2	0.99	7.88	0.63	5.45e-12	Lung adenocarcinoma;
THYM	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg01570182	chr17:44337453	NA	0.87	8.96	0.68	2.7e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Electroencephalogram traits;
THYM	cis	rs478304	0.934	rs1193692	chr11:65504069	A/C	cg27068330	chr11:65405492	SIPA1	0.82	7.83	0.63	6.95e-12	Acne (severe);
THYM	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg06917634	chr15:78832804	PSMA4	-0.93	-8.47	-0.66	3.1e-13	Sudden cardiac arrest;
THYM	cis	rs7246657	1.000	rs7247672	chr19:37743928	A/G	cg23950597	chr19:37808831	NA	-0.72	-4.62	-0.43	1.22e-5	Coronary artery calcification;
THYM	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg18512352	chr11:47633146	NA	-0.51	-6.21	-0.54	1.42e-8	Subjective well-being;
THYM	cis	rs763014	0.898	rs35666389	chr16:629458	A/G	cg00908189	chr16:619842	PIGQ	1.01	8.87	0.67	4.3e-14	Height;
THYM	cis	rs2046867	0.818	rs1502758	chr3:72865126	A/G	cg25664220	chr3:72788482	NA	-0.95	-7.97	-0.63	3.52e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg26924012	chr15:45694286	SPATA5L1	1.03	9.11	0.68	1.29e-14	Homoarginine levels;
THYM	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs89107	0.550	rs17226667	chr6:118721628	A/G	cg21191810	chr6:118973309	C6orf204	0.51	5.03	0.46	2.31e-6	Cardiac structure and function;
THYM	cis	rs1729951	0.575	rs16844362	chr3:136704008	T/C	cg12473912	chr3:136751656	NA	0.62	5.03	0.46	2.32e-6	Neuroticism;
THYM	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg05738196	chr6:26577821	NA	0.61	4.94	0.45	3.32e-6	Schizophrenia;
THYM	cis	rs2806561	0.765	rs1757046	chr1:23511821	T/C	cg19743168	chr1:23544995	NA	0.56	5.53	0.49	2.79e-7	Height;
THYM	cis	rs1371867	0.846	rs1788180	chr8:101333368	A/G	cg00191853	chr8:101177733	SPAG1	-0.51	-5.03	-0.46	2.29e-6	Atrioventricular conduction;
THYM	cis	rs3750965	0.959	rs11228490	chr11:68860872	C/G	cg06818126	chr11:68850279	TPCN2	0.66	4.47	0.42	2.14e-5	Hair color;
THYM	cis	rs96067	0.711	rs272811	chr1:36634414	G/A	cg24686825	chr1:36642396	MAP7D1	-0.82	-6.9	-0.58	5.66e-10	Corneal structure;
THYM	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.87e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg17509989	chr5:176798049	RGS14	0.69	6.46	0.55	4.47e-9	Hemoglobin concentration;Hematocrit;
THYM	cis	rs16889362	0.929	rs16889370	chr6:36968063	A/T	cg05466385	chr6:36956891	NA	0.75	5.46	0.49	3.83e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
THYM	cis	rs6956675	0.915	rs7780762	chr7:62654263	T/C	cg27518014	chr7:62859535	LOC100287834	0.59	4.8	0.44	5.95e-6	Obesity-related traits;
THYM	cis	rs55728055	0.661	rs55648708	chr22:32032062	G/A	cg10537193	chr22:32026975	PISD	-0.86	-5.48	-0.49	3.48e-7	Age-related hearing impairment;
THYM	cis	rs6570726	0.526	rs4896805	chr6:145735429	C/A	cg13319975	chr6:146136371	FBXO30	0.59	4.49	0.42	2.03e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10170846	0.893	rs12614976	chr2:223542896	A/T	cg25565276	chr2:223520875	FARSB	0.62	4.93	0.45	3.43e-6	Schizophrenia (inflammation and infection response interaction);
THYM	cis	rs8067545	0.611	rs2703814	chr17:20117151	T/C	cg20830565	chr17:20408647	MGC102966	0.49	4.48	0.42	2.05e-5	Schizophrenia;
THYM	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	4.69	0.43	9.02e-6	Schizophrenia;
THYM	cis	rs4474465	1.000	rs4474465	chr11:78204380	C/T	cg19901956	chr11:77921274	USP35	0.67	4.92	0.45	3.68e-6	Alzheimer's disease (survival time);
THYM	cis	rs986417	0.681	rs1254329	chr14:60912870	G/A	cg27398547	chr14:60952738	C14orf39	-1.08	-5.91	-0.52	5.32e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7223966	1.000	rs6504167	chr17:61693194	G/C	cg00640147	chr17:61958756	GH2	-0.43	-4.57	-0.42	1.48e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs2456568	0.802	rs1574515	chr11:93629643	T/C	cg26875233	chr11:93583750	C11orf90	-0.53	-5.53	-0.49	2.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs4901869	1.000	rs4901869	chr14:59334128	A/G	cg02291164	chr14:59296302	NA	0.8	7.85	0.63	6.35e-12	Panic disorder;
THYM	cis	rs7551222	0.752	rs4245737	chr1:204486242	A/G	cg20240347	chr1:204465584	NA	-0.55	-5.02	-0.46	2.41e-6	Schizophrenia;
THYM	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg18252515	chr7:66147081	NA	-1.61	-8.73	-0.67	8.74e-14	Diabetic kidney disease;
THYM	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg00852783	chr1:26633632	UBXN11	0.86	8.81	0.67	5.74e-14	Obesity-related traits;
THYM	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1443512	0.588	rs1838173	chr12:54342822	C/T	cg26695123	chr12:54132220	NA	0.5	4.53	0.42	1.72e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg10518543	chr12:38710700	ALG10B	-0.57	-4.78	-0.44	6.33e-6	Morning vs. evening chronotype;
THYM	cis	rs1843834	1.000	rs1843834	chr2:225558042	A/G	cg22455342	chr2:225449267	CUL3	0.6	4.67	0.43	9.72e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12509991	0.582	rs7678061	chr4:127040111	A/G	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg23711669	chr6:146136114	FBXO30	0.86	8.21	0.64	1.09e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg01097406	chr16:89675127	NA	0.84	7.57	0.61	2.36e-11	Vitiligo;
THYM	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.6	-4.62	-0.43	1.22e-5	Eosinophil percentage of white cells;
THYM	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.95	8.04	0.64	2.54e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9810089	0.814	rs864437	chr3:136119909	C/G	cg21827317	chr3:136751795	NA	0.62	5.34	0.48	6.38e-7	Gestational age at birth (child effect);
THYM	cis	rs2057149	0.777	rs4945857	chr6:110709576	A/G	cg19196401	chr6:110721138	DDO	-0.55	-4.57	-0.42	1.46e-5	Platelet distribution width;Mean platelet volume;
THYM	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	4.93	0.45	3.5e-6	Diabetic retinopathy;
THYM	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg07362569	chr17:61921086	SMARCD2	0.7	6.23	0.54	1.25e-8	Prudent dietary pattern;
THYM	trans	rs10462794	0.789	rs7719895	chr5:4490338	C/T	cg13411962	chr8:28243934	ZNF395	1.17	7.03	0.58	3.2e-10	DNA methylation (variation);
THYM	cis	rs716316	1.000	rs716316	chr20:14908741	C/T	cg04470754	chr20:14904432	MACROD2	0.67	5.12	0.47	1.57e-6	Advanced glycation end-product levels;
THYM	cis	rs8053891	0.502	rs34679758	chr16:71995427	A/G	cg04254540	chr16:71951199	KIAA0174	-1.04	-4.89	-0.45	4.07e-6	Coronary artery disease;
THYM	cis	rs922692	0.715	rs2277546	chr15:79083376	C/A	cg22753661	chr15:79092743	ADAMTS7	0.65	4.98	0.45	2.86e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg09359103	chr1:154839909	KCNN3	-0.69	-8.43	-0.65	3.66e-13	Prostate cancer;
THYM	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg23018236	chr17:30244563	NA	-0.6	-4.45	-0.42	2.3e-5	Hip circumference adjusted for BMI;
THYM	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg06618935	chr21:46677482	NA	-0.98	-8.08	-0.64	2.01e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.54	-0.42	1.67e-5	Morning vs. evening chronotype;
THYM	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg15744005	chr10:104629667	AS3MT	-0.8	-7.62	-0.62	1.86e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.74	0.67	8.17e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1050631	0.564	rs1785910	chr18:33729871	A/G	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.6	4.69	0.43	9.09e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs7474896	0.583	rs11011347	chr10:38019264	G/A	cg07661167	chr10:37990439	NA	-0.66	-4.45	-0.42	2.33e-5	Obesity (extreme);
THYM	cis	rs13082711	0.516	rs1388785	chr3:27371843	T/C	cg02860705	chr3:27208620	NA	-0.7	-5.39	-0.48	5.2e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg22508957	chr16:3507546	NAT15	0.74	7.44	0.61	4.47e-11	Tuberculosis;
THYM	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs7103648	0.838	rs11039244	chr11:47466442	G/A	cg20307385	chr11:47447363	PSMC3	0.94	7.54	0.61	2.76e-11	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg03909863	chr11:638404	DRD4	-0.78	-5.75	-0.51	1.07e-7	Systemic lupus erythematosus;
THYM	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.75	5.7	0.5	1.35e-7	Eosinophil percentage of white cells;
THYM	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg24060327	chr5:131705240	SLC22A5	-0.76	-5.68	-0.5	1.46e-7	Blood metabolite levels;
THYM	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	6.63	0.56	1.99e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs67981189	0.896	rs2526877	chr14:71433322	T/C	cg15910301	chr14:71632612	NA	-0.5	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	cis	rs761746	0.960	rs5753680	chr22:31930972	A/G	cg10537193	chr22:32026975	PISD	0.42	5.46	0.49	3.83e-7	Intelligence;
THYM	cis	rs1865721	0.771	rs6566093	chr18:73136682	T/C	cg26385618	chr18:73139727	C18orf62	-0.68	-5.12	-0.47	1.57e-6	Intelligence;
THYM	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14442939	chr10:27389572	ANKRD26	-0.79	-4.53	-0.42	1.75e-5	Breast cancer;
THYM	cis	rs2579519	0.547	rs11683523	chr2:96544855	T/C	cg22654517	chr2:96458247	NA	0.69	4.99	0.46	2.72e-6	Diastolic blood pressure;
THYM	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg17294928	chr15:75287854	SCAMP5	-0.98	-5.33	-0.48	6.65e-7	Lung cancer;
THYM	cis	rs7851660	0.805	rs7038998	chr9:100662396	C/G	cg13688889	chr9:100608707	NA	-0.79	-5.71	-0.51	1.28e-7	Strep throat;
THYM	cis	rs3845702	0.736	rs72958863	chr2:180808144	C/T	cg01881094	chr2:180872142	CWC22	0.91	5.5	0.49	3.16e-7	Schizophrenia;
THYM	cis	rs7246657	0.653	rs4805208	chr19:37674259	G/A	cg23950597	chr19:37808831	NA	-0.8	-4.56	-0.42	1.51e-5	Coronary artery calcification;
THYM	cis	rs7432375	0.901	rs7618518	chr3:136370092	C/T	cg12473912	chr3:136751656	NA	-0.62	-5.24	-0.47	9.59e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.67	8.93	0.68	3.13e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1003719	0.788	rs2835597	chr21:38466539	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs12310956	0.510	rs10844694	chr12:33865682	A/C	cg06521331	chr12:34319734	NA	-0.57	-4.58	-0.43	1.42e-5	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg24818145	chr4:99064322	C4orf37	0.77	6.2	0.54	1.45e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg25517755	chr10:38738941	LOC399744	-0.78	-7.12	-0.59	2.07e-10	Educational attainment;
THYM	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22307029	chr19:49891270	CCDC155	0.59	4.72	0.44	8.04e-6	Multiple sclerosis;
THYM	cis	rs2916260	0.800	rs78431593	chr6:40385575	G/A	cg08415973	chr6:40346114	TDRG1	0.76	4.64	0.43	1.1e-5	Incident coronary heart disease;
THYM	cis	rs1994135	0.647	rs11052745	chr12:33695999	G/T	cg10856724	chr12:34555212	NA	-0.63	-4.91	-0.45	3.84e-6	Resting heart rate;
THYM	cis	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg24973591	chr4:10079421	WDR1	-0.47	-4.68	-0.43	9.4e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs10992471	0.580	rs4744143	chr9:95438627	A/C	cg14631576	chr9:95140430	CENPP	-0.94	-7.64	-0.62	1.75e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg24112000	chr20:60950667	NA	-0.63	-5.28	-0.48	8.21e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg27286337	chr10:134555280	INPP5A	0.93	6.98	0.58	3.98e-10	Migraine;
THYM	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg02725872	chr8:58115012	NA	-1.15	-7.43	-0.61	4.64e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs7524258	0.900	rs7514988	chr1:7271651	C/T	cg07173049	chr1:7289937	CAMTA1	0.62	5.05	0.46	2.11e-6	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg07570687	chr10:102243282	WNT8B	-0.76	-6.9	-0.58	5.82e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7940866	0.834	rs10894302	chr11:130861994	C/T	cg12179176	chr11:130786555	SNX19	0.67	5.11	0.46	1.68e-6	Schizophrenia;
THYM	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg04234412	chr22:24373322	LOC391322	-0.91	-8.84	-0.67	4.95e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1395	0.778	rs11693001	chr2:27412744	C/T	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.4	-0.48	4.88e-7	Blood metabolite levels;
THYM	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg00376283	chr12:123451042	ABCB9	-0.9	-7.42	-0.61	4.86e-11	Platelet count;
THYM	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg27398817	chr8:82754497	SNX16	-0.68	-5.76	-0.51	1.03e-7	Diastolic blood pressure;
THYM	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg05335186	chr13:53173507	NA	-0.49	-7.21	-0.59	1.36e-10	Lewy body disease;
THYM	cis	rs16865717	1.000	rs12989595	chr2:7029483	A/G	cg20486407	chr2:7037101	RSAD2	1.22	10.53	0.73	1.23e-17	Venous thromboembolism (SNP x SNP interaction);
THYM	cis	rs11039798	1.000	rs7479655	chr11:48576714	G/T	cg24672777	chr11:48374446	OR4C45	-1.03	-6.15	-0.53	1.83e-8	Axial length;
THYM	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg04025307	chr7:1156635	C7orf50	0.72	4.46	0.42	2.27e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12935418	0.583	rs2244452	chr16:81025372	A/T	cg16651780	chr16:81037892	C16orf61	-0.83	-6.5	-0.55	3.72e-9	Mean corpuscular volume;
THYM	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg22117172	chr7:91764530	CYP51A1	0.38	4.92	0.45	3.66e-6	Breast cancer;
THYM	cis	rs36051895	0.659	rs1322224	chr9:5267889	C/A	cg02405213	chr9:5042618	JAK2	-1.01	-8.76	-0.67	7.37e-14	Pediatric autoimmune diseases;
THYM	cis	rs11031096	0.678	rs17284356	chr11:4189232	G/C	cg08557956	chr11:4115526	RRM1	-0.59	-5.44	-0.49	4.19e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs11648796	0.879	rs12448432	chr16:778820	G/A	cg03287339	chr16:711135	WDR90	-0.55	-4.55	-0.42	1.59e-5	Height;
THYM	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg05368731	chr17:41323189	NBR1	1.25	11.17	0.75	5.29e-19	Menopause (age at onset);
THYM	cis	rs4780401	0.632	rs8055462	chr16:11834821	T/C	cg01061890	chr16:11836724	TXNDC11	-0.61	-4.65	-0.43	1.09e-5	Rheumatoid arthritis;
THYM	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg02228675	chr17:40259724	DHX58	-0.65	-5.45	-0.49	4.02e-7	Fibrinogen levels;
THYM	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg24874828	chr4:187887005	NA	0.66	6.35	0.55	7.27e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs9880211	0.613	rs28669017	chr3:135874932	T/G	cg21827317	chr3:136751795	NA	-0.71	-5.16	-0.47	1.33e-6	Body mass index;Height;
THYM	cis	rs7668190	0.924	rs2114039	chr4:55092626	T/C	cg17187183	chr4:55093834	PDGFRA	0.61	4.61	0.43	1.27e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs936229	0.813	rs2168519	chr15:75080872	T/C	cg14664628	chr15:75095509	CSK	-0.99	-8.15	-0.64	1.48e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs4654899	1.000	rs3767248	chr1:21276854	A/G	cg01072550	chr1:21505969	NA	-0.75	-6.65	-0.56	1.86e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg11366901	chr6:160182831	ACAT2	1.01	8.44	0.65	3.59e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2712184	1.000	rs2712184	chr2:217682779	G/T	cg05032264	chr2:217675019	NA	-0.56	-4.95	-0.45	3.27e-6	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.7	5.65	0.5	1.68e-7	Menarche (age at onset);
THYM	cis	rs11690935	0.921	rs7355523	chr2:172744421	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.8	-5.81	-0.51	8.15e-8	Schizophrenia;
THYM	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-4.73	-0.44	7.66e-6	Mood instability;
THYM	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg03929089	chr4:120376271	NA	-0.94	-10.56	-0.73	1.03e-17	Coronary artery disease;
THYM	cis	rs4273100	0.646	rs11652784	chr17:19217261	C/T	cg25447019	chr17:19030144	GRAPL	0.79	6.24	0.54	1.2e-8	Schizophrenia;
THYM	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg13390004	chr1:15929781	NA	0.63	4.79	0.44	6.2e-6	Systolic blood pressure;
THYM	cis	rs79387448	0.745	rs76746266	chr2:103124920	C/T	cg09003973	chr2:102972529	NA	0.78	4.75	0.44	7.17e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs2242194	0.521	rs10796936	chr1:154999514	T/A	cg12436631	chr1:155007014	DCST1;DCST2	0.88	8.72	0.67	8.92e-14	Schizophrenia;
THYM	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg14784868	chr12:69753453	YEATS4	1.12	10.62	0.74	7.96e-18	Blood protein levels;
THYM	cis	rs2281636	0.540	rs1057491	chr10:101466620	C/T	cg05149213	chr10:101381631	SLC25A28	-0.44	-4.51	-0.42	1.84e-5	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg03159660	chr11:2078197	NA	0.61	4.63	0.43	1.17e-5	Calcium levels;
THYM	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg10515332	chr4:99064459	C4orf37	0.59	4.68	0.43	9.41e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs931127	0.547	rs3886859	chr11:65458310	C/T	cg17480646	chr11:65405466	SIPA1	-0.81	-7.19	-0.59	1.5e-10	Systemic lupus erythematosus;
THYM	cis	rs4746818	0.901	rs4746816	chr10:70874866	G/T	cg11621586	chr10:70884670	VPS26A	1.13	6.77	0.57	1.05e-9	Left atrial antero-posterior diameter;
THYM	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs55871839	0.684	rs7002967	chr8:59816806	T/A	cg07426533	chr8:59803705	TOX	-0.72	-7.5	-0.61	3.37e-11	Pneumonia;
THYM	cis	rs2290159	0.800	rs3730269	chr3:12653233	G/T	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg24069376	chr3:38537580	EXOG	0.68	6.73	0.57	1.26e-9	Electrocardiographic conduction measures;
THYM	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.73	-4.82	-0.44	5.35e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg03929089	chr4:120376271	NA	-0.97	-10.53	-0.73	1.25e-17	Coronary artery disease;
THYM	cis	rs4833103	0.679	rs7696175	chr4:38820986	A/G	cg06935464	chr4:38784597	TLR10	0.65	4.54	0.42	1.63e-5	Diabetes in response to antihypertensive drug treatment (treatment strategy interaction);
THYM	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs3126085	0.935	rs3120660	chr1:152258701	G/T	cg26020982	chr1:152196106	HRNR	-0.35	-4.95	-0.45	3.26e-6	Atopic dermatitis;
THYM	cis	rs36051895	0.695	rs10123873	chr9:5019201	T/G	cg02405213	chr9:5042618	JAK2	-1.0	-9.89	-0.71	2.81e-16	Pediatric autoimmune diseases;
THYM	cis	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg10856724	chr12:34555212	NA	-1.05	-10.84	-0.74	2.69e-18	Morning vs. evening chronotype;
THYM	cis	rs7572733	0.515	rs11887138	chr2:198805838	T/A	cg00792783	chr2:198669748	PLCL1	0.82	5.75	0.51	1.08e-7	Dermatomyositis;
THYM	cis	rs7818345	0.935	rs7016259	chr8:19277530	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.65	0.43	1.07e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs863345	0.604	rs11264977	chr1:158447852	G/T	cg12129480	chr1:158549410	OR10X1	-0.47	-4.62	-0.43	1.23e-5	Pneumococcal bacteremia;
THYM	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg23989207	chr17:80870107	TBCD	0.62	5.1	0.46	1.76e-6	Glycated hemoglobin levels;
THYM	cis	rs6032067	0.777	rs34855539	chr20:43799036	T/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs1568889	1.000	rs12287732	chr11:28120845	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.55e-6	Bipolar disorder;
THYM	cis	rs28374715	0.783	rs11630656	chr15:41570909	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.16	-11.76	-0.77	3.09e-20	Ulcerative colitis;
THYM	cis	rs595982	0.661	rs606400	chr19:49371498	T/C	cg21252483	chr19:49399788	TULP2	-0.55	-4.87	-0.45	4.52e-6	Red cell distribution width;
THYM	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	trans	rs8073060	0.586	rs188959	chr17:34021307	C/A	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	4.75	0.44	7.27e-6	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg06917634	chr15:78832804	PSMA4	-0.64	-4.46	-0.42	2.28e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs899997	1.000	rs8030090	chr15:79034260	A/G	cg22753661	chr15:79092743	ADAMTS7	0.72	4.61	0.43	1.23e-5	Coronary artery disease or large artery stroke;
THYM	cis	rs7582180	0.627	rs6749018	chr2:101001859	G/T	cg14675211	chr2:100938903	LONRF2	0.73	7.53	0.61	2.88e-11	Intelligence (multi-trait analysis);
THYM	cis	rs16866061	0.855	rs11687736	chr2:225405122	A/T	cg12698349	chr2:225449008	CUL3	1.14	10.45	0.73	1.77e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs2085601	0.542	rs6532094	chr4:89946734	G/A	cg17769793	chr4:89976368	FAM13A	-0.53	-5.83	-0.51	7.75e-8	Hair greying;
THYM	cis	rs7404928	0.592	rs11644907	chr16:23909985	C/T	cg26685404	chr16:23957272	PRKCB	0.43	4.54	0.42	1.67e-5	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg00071950	chr4:10020882	SLC2A9	-0.81	-7.9	-0.63	4.83e-12	Bone mineral density;
THYM	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.54	-6.07	-0.53	2.66e-8	Autism spectrum disorder or schizophrenia;
THYM	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22857025	chr5:266934	NA	1.41	9.35	0.69	4e-15	Breast cancer;
THYM	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg02527881	chr3:46936655	PTH1R	0.66	6.8	0.57	9.17e-10	Colorectal cancer;
THYM	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03264133	chr6:25882463	NA	-0.73	-5.82	-0.51	7.95e-8	Blood metabolite levels;
THYM	cis	rs3820068	0.603	rs2236215	chr1:15892415	A/C	cg24675056	chr1:15929824	NA	0.7	4.67	0.43	9.78e-6	Systolic blood pressure;
THYM	cis	rs28374715	0.662	rs1554445	chr15:41503198	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.0	-8.18	-0.64	1.27e-12	Ulcerative colitis;
THYM	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg09549813	chr16:4587862	C16orf5	-0.58	-6.03	-0.53	3.06e-8	Schizophrenia;
THYM	cis	rs9560113	1.000	rs9560104	chr13:112174389	A/G	cg14154082	chr13:112174009	NA	0.86	7.92	0.63	4.35e-12	Menarche (age at onset);
THYM	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg21926883	chr2:100939477	LONRF2	-0.65	-5.96	-0.52	4.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg06558623	chr16:89946397	TCF25	1.51	8.29	0.65	7.35e-13	Skin colour saturation;
THYM	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg10661904	chr17:79619235	PDE6G	-0.57	-5.3	-0.48	7.61e-7	Eye color traits;
THYM	cis	rs13064411	0.735	rs7636128	chr3:113133701	A/T	cg18753928	chr3:113234510	CCDC52	-0.83	-7.29	-0.6	9.08e-11	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs193541	0.565	rs6888751	chr5:122192035	A/G	cg19808643	chr5:122110361	SNX2	-0.58	-4.8	-0.44	5.99e-6	Glucose homeostasis traits;
THYM	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg01483505	chr11:975446	AP2A2	-0.58	-4.73	-0.44	7.73e-6	Alzheimer's disease (late onset);
THYM	cis	rs4285028	0.747	rs9838301	chr3:121375144	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.84	-7.25	-0.6	1.1e-10	Multiple sclerosis;
THYM	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg13695892	chr22:41940480	POLR3H	0.91	6.69	0.57	1.5e-9	Vitiligo;
THYM	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg24818145	chr4:99064322	C4orf37	1.03	6.17	0.53	1.68e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1843834	0.721	rs1601730	chr2:225590153	G/A	cg10193763	chr2:225306901	NA	-0.46	-4.8	-0.44	5.88e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9302690	1.000	rs41351945	chr16:57446809	C/T	cg27017172	chr16:57497170	POLR2C	0.82	4.88	0.45	4.29e-6	Blood protein levels;
THYM	trans	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg25517755	chr10:38738941	LOC399744	-0.77	-7.48	-0.61	3.65e-11	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg17775962	chr7:1200435	ZFAND2A	0.47	5.55	0.5	2.55e-7	Longevity;Endometriosis;
THYM	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7107770	1.000	rs7104532	chr11:125100272	G/A	cg04164023	chr11:125106101	PKNOX2	-0.81	-4.68	-0.43	9.65e-6	Photic sneeze reflex;
THYM	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.57	5.85	0.51	6.89e-8	Eosinophil percentage of white cells;
THYM	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg02478829	chr6:26598070	ABT1	-0.33	-4.49	-0.42	1.97e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1113500	0.836	rs1122158	chr1:108588668	G/T	cg06207961	chr1:108661230	NA	0.7	5.58	0.5	2.25e-7	Growth-regulated protein alpha levels;
THYM	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg06028808	chr11:68637592	NA	0.67	7.26	0.6	1.07e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg14784868	chr12:69753453	YEATS4	0.72	5.38	0.48	5.4e-7	Response to diuretic therapy;
THYM	cis	rs12188164	0.965	rs77101200	chr5:443059	G/T	cg26850624	chr5:429559	AHRR	-0.72	-5.74	-0.51	1.11e-7	Cystic fibrosis severity;
THYM	cis	rs250677	0.522	rs7702695	chr5:148402550	T/A	cg18129178	chr5:148520854	ABLIM3	-0.71	-5.31	-0.48	7.05e-7	Breast cancer;
THYM	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg10334053	chr1:2078117	PRKCZ	-0.45	-4.53	-0.42	1.73e-5	Height;
THYM	cis	rs9814567	0.727	rs7430034	chr3:134342127	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-7.51	-0.61	3.14e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs3806843	0.778	rs2531346	chr5:140126139	T/G	cg19875535	chr5:140030758	IK	-0.58	-4.52	-0.42	1.76e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.26	0.69	6.31e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7731657	0.537	rs9327581	chr5:130311279	T/G	cg08523029	chr5:130500466	HINT1	-0.85	-6.0	-0.52	3.55e-8	Fasting plasma glucose;
THYM	cis	rs9420907	0.892	rs11591710	chr10:105687632	A/C	cg11005552	chr10:105648138	OBFC1	-0.67	-4.63	-0.43	1.16e-5	Telomere length;
THYM	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg22535103	chr8:58192502	C8orf71	-0.98	-6.18	-0.54	1.6e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg22875332	chr1:76189707	ACADM	0.89	12.06	0.78	7.38e-21	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg26043149	chr18:55253948	FECH	1.16	10.82	0.74	2.98e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg14784868	chr12:69753453	YEATS4	0.79	6.48	0.55	4.06e-9	Blood protein levels;
THYM	cis	rs11645898	0.935	rs72787094	chr16:72192613	C/A	cg14768367	chr16:72042858	DHODH	-0.74	-5.36	-0.48	5.94e-7	Blood protein levels;
THYM	cis	rs12765878	0.675	rs3752946	chr10:105670849	A/T	cg11005552	chr10:105648138	OBFC1	0.8	8.86	0.67	4.54e-14	Coronary artery disease;
THYM	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg05856015	chr4:467047	ZNF721;ABCA11P	-0.41	-4.47	-0.42	2.15e-5	White blood cell count;
THYM	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg11752832	chr7:134001865	SLC35B4	0.73	5.5	0.49	3.22e-7	Mean platelet volume;
THYM	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg18252515	chr7:66147081	NA	-0.67	-5.1	-0.46	1.72e-6	Aortic root size;
THYM	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.01	8.17	0.64	1.3e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg02953382	chr22:24373134	LOC391322	-0.82	-8.94	-0.68	3.04e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7224314	1.000	rs7219229	chr17:65380171	C/T	cg01507342	chr17:65387096	PITPNC1	-0.95	-10.71	-0.74	5.15e-18	Diisocyanate-induced asthma;
THYM	cis	rs5769765	0.646	rs9616205	chr22:50309915	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.04	-7.57	-0.61	2.44e-11	Schizophrenia;
THYM	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs2562152	0.744	rs216597	chr16:106777	G/C	cg02949481	chr16:131562	MPG	0.89	5.63	0.5	1.8e-7	Glioblastoma;
THYM	cis	rs4237845	0.837	rs7954591	chr12:58299037	A/G	cg22764591	chr12:58329936	NA	0.98	7.83	0.63	7.02e-12	Intelligence (multi-trait analysis);
THYM	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg12963246	chr6:28129442	ZNF389	-0.78	-7.15	-0.59	1.78e-10	Depression;
THYM	cis	rs28595532	0.920	rs114678295	chr4:119756281	C/T	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs3796352	1.000	rs4478072	chr3:53106125	G/T	cg07884673	chr3:53033167	SFMBT1	1.04	5.26	0.47	8.87e-7	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs17598306	1.000	rs17656761	chr7:96581553	G/A	cg23184042	chr7:96615519	DLX6AS	0.61	4.76	0.44	6.82e-6	Radiation response;
THYM	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg20203395	chr5:56204925	C5orf35	-0.66	-4.62	-0.43	1.22e-5	Initial pursuit acceleration;
THYM	cis	rs11608355	1.000	rs11066523	chr12:109851899	A/G	cg10504392	chr12:110044639	NA	-0.64	-5.98	-0.52	3.86e-8	Neuroticism;
THYM	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg14186256	chr22:23484241	RTDR1	0.96	9.57	0.7	1.38e-15	Bone mineral density;
THYM	cis	rs12579753	0.827	rs7958100	chr12:82200782	G/A	cg21231944	chr12:82153410	PPFIA2	-0.66	-5.01	-0.46	2.51e-6	Resting heart rate;
THYM	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg10150615	chr22:24372951	LOC391322	0.87	9.45	0.7	2.49e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs72827839	0.793	rs112296021	chr17:46101460	G/A	cg23391107	chr17:45924227	SP6	0.8	5.49	0.49	3.4e-7	Ease of getting up in the morning;
THYM	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs9470366	0.848	rs9470361	chr6:36623379	G/A	cg24425727	chr6:36645648	CDKN1A	-0.6	-4.76	-0.44	7.05e-6	QRS duration;
THYM	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.25	-4.74	-0.44	7.61e-6	Obesity-related traits;
THYM	cis	rs6032067	0.683	rs16989769	chr20:43780475	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	0.64	6.42	0.55	5.27e-9	Blood protein levels;
THYM	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.64	-0.62	1.74e-11	Personality dimensions;
THYM	cis	rs2495707	0.624	rs1419177	chr10:102423699	G/C	cg00272971	chr10:102419564	NA	-0.5	-5.65	-0.5	1.66e-7	Body mass index;
THYM	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs909002	0.811	rs11575883	chr1:32085485	G/A	cg13919466	chr1:32135498	COL16A1	-0.49	-4.85	-0.45	4.86e-6	Intelligence (multi-trait analysis);
THYM	cis	rs988913	0.957	rs2064432	chr6:54782652	A/G	cg18532076	chr6:54711417	FAM83B	0.52	4.83	0.44	5.13e-6	Menarche (age at onset);
THYM	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.63	5.02	0.46	2.37e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12681287	0.547	rs9942793	chr8:87509091	C/T	cg27223183	chr8:87520930	FAM82B	-0.71	-5.46	-0.49	3.8e-7	Caudate activity during reward;
THYM	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs9303280	0.685	rs9916765	chr17:38005595	T/C	cg24910161	chr17:38119198	GSDMA	0.46	4.69	0.43	9.15e-6	Self-reported allergy;
THYM	cis	rs2276314	0.857	rs56230698	chr18:33628885	A/G	cg19628046	chr18:33552617	C18orf21	0.74	5.43	0.49	4.29e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4654899	0.758	rs17453044	chr1:21517361	A/G	cg01072550	chr1:21505969	NA	-0.74	-7.08	-0.59	2.43e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs3126085	0.877	rs57597406	chr1:152246619	C/G	cg10321714	chr1:152280068	FLG	0.64	4.81	0.44	5.57e-6	Atopic dermatitis;
THYM	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg00310523	chr12:86230176	RASSF9	-0.55	-4.8	-0.44	5.8e-6	Major depressive disorder;
THYM	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg02187348	chr16:89574699	SPG7	-0.7	-5.51	-0.49	3.11e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg12573674	chr2:1569213	NA	-1.16	-8.07	-0.64	2.18e-12	IgG glycosylation;
THYM	cis	rs56079296	0.929	rs79742050	chr5:121379775	C/T	cg01191064	chr5:121408893	LOX	0.65	4.53	0.42	1.68e-5	Coronary artery disease;
THYM	cis	rs5015933	0.801	rs11999662	chr9:128143928	T/A	cg14078157	chr9:128172775	NA	-0.6	-5.06	-0.46	2.06e-6	Body mass index;
THYM	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg12935359	chr14:103987150	CKB	-0.51	-6.07	-0.53	2.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.14	0.47	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg00810483	chr4:3375144	RGS12	0.31	4.64	0.43	1.12e-5	Serum sulfate level;
THYM	cis	rs12496230	1.000	rs4856828	chr3:66868008	A/T	cg04995300	chr3:66848608	NA	0.93	5.83	0.51	7.54e-8	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg05425664	chr17:57184151	TRIM37	0.58	4.77	0.44	6.54e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg06636001	chr8:8085503	FLJ10661	0.64	5.06	0.46	2.07e-6	Mood instability;
THYM	cis	rs9595908	0.900	rs7327429	chr13:33169396	A/C	cg12383807	chr13:33924137	NA	-0.54	-4.85	-0.45	4.85e-6	Body mass index;
THYM	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg04034577	chr2:241836375	C2orf54	-0.44	-7.3	-0.6	8.65e-11	Urinary metabolites;
THYM	cis	rs7937840	0.581	rs4963461	chr11:61884044	G/A	cg05871569	chr11:61891931	INCENP	0.62	4.72	0.44	8.18e-6	Breast cancer;
THYM	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg06627628	chr2:24431161	ITSN2	-0.75	-5.06	-0.46	2.04e-6	Asthma;
THYM	trans	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg10856724	chr12:34555212	NA	-0.88	-7.68	-0.62	1.44e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2554380	0.800	rs1544876	chr15:84375801	T/A	cg14598478	chr15:84363061	ADAMTSL3	-0.63	-4.98	-0.46	2.79e-6	Height;
THYM	cis	rs28595532	0.920	rs115744897	chr4:119749064	A/G	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs863345	0.604	rs2023632	chr1:158459034	T/C	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg26513180	chr16:89883248	FANCA	0.72	7.16	0.59	1.72e-10	Vitiligo;
THYM	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg14972814	chr11:95582409	MTMR2	-0.59	-5.36	-0.48	5.87e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs877282	0.533	rs10904565	chr10:819991	G/T	cg10556349	chr10:835070	NA	-0.84	-5.48	-0.49	3.43e-7	Uric acid levels;
THYM	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.07	-6.19	-0.54	1.52e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4363385	0.510	rs6689066	chr1:153045154	T/C	cg13444842	chr1:152974279	SPRR3	-0.6	-4.68	-0.43	9.48e-6	Inflammatory skin disease;
THYM	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.59	-8.1	-0.64	1.86e-12	Monocyte percentage of white cells;
THYM	cis	rs950880	0.710	rs11694360	chr2:103061147	G/A	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.71	-0.44	8.33e-6	Serum protein levels (sST2);
THYM	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg07636037	chr3:49044803	WDR6	0.97	10.07	0.72	1.15e-16	Parkinson's disease;
THYM	cis	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg10856724	chr12:34555212	NA	-0.91	-9.08	-0.68	1.57e-14	Morning vs. evening chronotype;
THYM	cis	rs995000	0.839	rs1168026	chr1:62970996	T/C	cg06896770	chr1:63153194	DOCK7	-0.91	-7.48	-0.61	3.62e-11	Triglyceride levels;
THYM	cis	rs9814567	0.806	rs11927540	chr3:134319455	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.12e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg26384229	chr12:38710491	ALG10B	0.94	7.9	0.63	4.92e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg13010199	chr12:38710504	ALG10B	0.71	5.77	0.51	9.75e-8	Heart rate;
THYM	cis	rs11031096	0.655	rs34295904	chr11:4206701	C/A	cg18678763	chr11:4115507	RRM1	-0.4	-4.71	-0.44	8.28e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg23260525	chr10:116636907	FAM160B1	0.53	5.33	0.48	6.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg17178900	chr1:205818956	PM20D1	0.92	9.11	0.68	1.3e-14	Menarche (age at onset);
THYM	cis	rs490647	0.948	rs12083196	chr1:37233430	C/T	cg09088576	chr1:36947785	CSF3R	0.45	4.47	0.42	2.16e-5	Neuroticism;
THYM	cis	rs3844535	1	rs3844535	chr14:81884515	A/G	cg02996355	chr14:81879375	NA	-0.91	-8.87	-0.67	4.21e-14	Plateletcrit;Platelet count;
THYM	cis	rs2228479	0.557	rs62056097	chr16:89933420	A/G	cg06558623	chr16:89946397	TCF25	1.24	5.89	0.52	5.87e-8	Skin colour saturation;
THYM	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg11764359	chr7:65958608	NA	0.63	4.83	0.44	5.31e-6	Aortic root size;
THYM	cis	rs1883415	0.683	rs2760126	chr6:24501769	C/T	cg00346970	chr6:24499591	ALDH5A1	0.39	5.08	0.46	1.89e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg24209194	chr3:40518798	ZNF619	0.55	4.45	0.42	2.36e-5	Renal cell carcinoma;
THYM	cis	rs9429544	0.522	rs71662879	chr1:114951390	T/A	cg19304150	chr1:114696350	SYT6	0.59	4.47	0.42	2.2e-5	Mean corpuscular hemoglobin;
THYM	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-6.16	-0.53	1.75e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg06728252	chr6:26598149	ABT1	-0.43	-5.11	-0.46	1.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs4660531	0.890	rs61229336	chr1:41834935	C/T	cg01193554	chr1:41846683	NA	-0.35	-4.62	-0.43	1.19e-5	Bipolar disorder;
THYM	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg11335335	chr11:637885	DRD4	-0.69	-6.23	-0.54	1.24e-8	Systemic lupus erythematosus;
THYM	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11924390	0.749	rs822363	chr3:186452991	C/G	cg12454167	chr3:186435060	KNG1	0.46	6.08	0.53	2.44e-8	Adiponectin levels;
THYM	cis	rs17253792	0.822	rs79618862	chr14:56093971	C/T	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg00495681	chr13:53174319	NA	0.91	9.49	0.7	2.04e-15	Lewy body disease;
THYM	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg25427524	chr10:38739819	LOC399744	0.52	4.46	0.42	2.21e-5	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.29	-0.48	7.96e-7	Hemoglobin concentration;
THYM	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg04025307	chr7:1156635	C7orf50	0.81	8.62	0.66	1.47e-13	Longevity;Endometriosis;
THYM	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg06623918	chr6:96969491	KIAA0776	1.09	10.37	0.73	2.65e-17	Headache;
THYM	cis	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	trans	rs4866334	1.000	rs80303471	chr5:18478048	A/G	cg08675002	chr5:90437527	GPR98	-1.51	-7.14	-0.59	1.82e-10	IgG glycosylation;
THYM	trans	rs3960554	0.808	rs61303167	chr7:75671175	G/T	cg19862616	chr7:65841803	NCRNA00174	0.95	7.23	0.6	1.21e-10	Eotaxin levels;
THYM	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg03188948	chr7:1209495	NA	0.66	5.11	0.46	1.63e-6	Longevity;Endometriosis;
THYM	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg00376283	chr12:123451042	ABCB9	0.68	5.22	0.47	1.04e-6	Schizophrenia;
THYM	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg00129232	chr17:37814104	STARD3	-0.67	-4.5	-0.42	1.96e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs7107174	1.000	rs10793295	chr11:77996521	C/G	cg02023728	chr11:77925099	USP35	-0.67	-6.24	-0.54	1.24e-8	Testicular germ cell tumor;
THYM	cis	rs1784581	0.588	rs1784606	chr6:162405992	A/T	cg17173639	chr6:162384350	PARK2	-0.68	-5.14	-0.47	1.44e-6	Itch intensity from mosquito bite;
THYM	trans	rs1997103	0.911	rs17777	chr7:55380765	T/C	cg20935933	chr6:143382018	AIG1	0.86	6.96	0.58	4.31e-10	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs9515201	0.774	rs9521739	chr13:111038803	A/G	cg06243866	chr13:111019493	COL4A2	-0.98	-10.55	-0.73	1.09e-17	White matter hyperintensity burden;
THYM	cis	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg05084668	chr3:125655381	ALG1L	-0.71	-4.61	-0.43	1.23e-5	Blood pressure (smoking interaction);
THYM	cis	rs12190007	0.846	rs6905725	chr6:169730253	G/C	cg16388071	chr6:169726476	NA	-0.57	-4.77	-0.44	6.75e-6	Obesity-related traits;
THYM	cis	rs7084402	0.967	rs1649033	chr10:60279634	T/C	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg27572855	chr1:25598939	RHD	0.68	5.27	0.48	8.66e-7	Erythrocyte sedimentation rate;
THYM	cis	rs2276314	0.857	rs16967327	chr18:33587036	C/T	cg19628046	chr18:33552617	C18orf21	0.73	5.32	0.48	6.76e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs9326248	0.520	rs2735183	chr11:117015195	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.86	8.98	0.68	2.44e-14	Blood protein levels;
THYM	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.43	1.27e-5	Breast cancer;
THYM	cis	rs61931739	0.635	rs10743837	chr12:33982162	A/G	cg10856724	chr12:34555212	NA	-0.64	-6.04	-0.53	3.04e-8	Morning vs. evening chronotype;
THYM	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.61	-0.43	1.27e-5	Type 2 diabetes;
THYM	cis	rs11785693	0.862	rs62491202	chr8:5001470	C/A	cg26367366	chr8:4980734	NA	1.18	5.59	0.5	2.16e-7	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs42648	0.869	rs6973816	chr7:89921072	C/T	cg25739043	chr7:89950458	NA	-0.52	-4.47	-0.42	2.2e-5	Homocysteine levels;
THYM	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg10224037	chr5:178157518	ZNF354A	-0.98	-8.09	-0.64	1.9e-12	Neutrophil percentage of white cells;
THYM	cis	rs28595532	0.920	rs114314373	chr4:119639128	G/A	cg14228332	chr4:119757509	SEC24D	1.35	4.52	0.42	1.81e-5	Cannabis dependence symptom count;
THYM	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg07570687	chr10:102243282	WNT8B	0.76	6.7	0.57	1.47e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4924935	1.000	rs2158100	chr17:18811479	A/G	cg26378065	chr17:18585709	ZNF286B	-0.73	-5.42	-0.49	4.42e-7	Pancreatic cancer;
THYM	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg16928487	chr17:17741425	SREBF1	-0.55	-5.39	-0.48	5.05e-7	Total body bone mineral density;
THYM	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg16325326	chr1:53192061	ZYG11B	-0.98	-11.09	-0.75	7.79e-19	Monocyte count;
THYM	cis	rs9914544	0.545	rs12600851	chr17:18767518	T/A	cg26378065	chr17:18585709	ZNF286B	0.6	4.71	0.43	8.56e-6	Educational attainment (years of education);
THYM	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.7	-5.66	-0.5	1.62e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4808199	0.895	rs4808194	chr19:19435680	T/G	cg03709012	chr19:19516395	GATAD2A	1.16	6.87	0.58	6.77e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs10479542	0.766	rs9286047	chr5:178969147	C/A	cg00080972	chr5:178986291	RUFY1	-0.46	-4.98	-0.45	2.87e-6	Lung cancer;
THYM	cis	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs9814567	0.964	rs9841180	chr3:134191880	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-7.43	-0.61	4.74e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs9457247	0.534	rs2757053	chr6:167380338	A/C	cg00271210	chr6:167070053	RPS6KA2	0.48	4.76	0.44	6.87e-6	Crohn's disease;
THYM	cis	rs59112743	0.510	rs9476869	chr6:15618522	A/G	cg10111214	chr6:14815676	NA	0.77	5.0	0.46	2.66e-6	Multiple keratinocyte cancers;
THYM	cis	rs6541297	0.645	rs2103827	chr1:230298285	T/A	cg20703242	chr1:230279135	GALNT2	0.94	5.0	0.46	2.64e-6	Coronary artery disease;
THYM	cis	rs337100	0.521	rs11959350	chr5:122541439	T/G	cg04547002	chr5:122551801	NA	0.61	4.65	0.43	1.09e-5	Pulse pressure;
THYM	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg18252515	chr7:66147081	NA	-0.67	-5.08	-0.46	1.86e-6	Aortic root size;
THYM	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg10505658	chr17:80084571	CCDC57	0.7	7.91	0.63	4.66e-12	Life satisfaction;
THYM	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs6987853	0.933	rs6980507	chr8:42383084	A/G	cg09913449	chr8:42400586	C8orf40	0.89	8.65	0.66	1.29e-13	Mean corpuscular hemoglobin concentration;
THYM	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.41	6.49	0.55	3.84e-9	Obesity-related traits;
THYM	cis	rs977987	0.815	rs11149818	chr16:75419373	G/A	cg03315344	chr16:75512273	CHST6	0.7	6.12	0.53	2.12e-8	Dupuytren's disease;
THYM	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs782590	0.935	rs2627779	chr2:55892356	A/G	cg03859395	chr2:55845619	SMEK2	0.61	5.49	0.49	3.37e-7	Metabolic syndrome;
THYM	cis	rs10979	0.965	rs9390109	chr6:143892806	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg06558623	chr16:89946397	TCF25	1.07	5.6	0.5	2.11e-7	Skin colour saturation;
THYM	cis	rs9581857	0.556	rs9579085	chr13:28041039	G/A	cg22138327	chr13:27999177	GTF3A	0.65	4.55	0.42	1.6e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.01	-5.45	-0.49	4.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1524976	1.000	rs7612710	chr3:65476581	C/T	cg16238336	chr3:65465873	MAGI1	-0.97	-6.24	-0.54	1.19e-8	PR interval;
THYM	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.18	8.91	0.67	3.51e-14	Cognitive test performance;
THYM	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg20283391	chr11:68216788	NA	-0.74	-5.43	-0.49	4.25e-7	Total body bone mineral density;
THYM	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.22e-7	Corneal astigmatism;
THYM	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg07636037	chr3:49044803	WDR6	0.97	9.82	0.71	4.1e-16	Parkinson's disease;
THYM	cis	rs6700896	0.931	rs2154384	chr1:66108517	C/T	cg04111102	chr1:66153794	NA	0.55	5.23	0.47	9.89e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9522267	0.511	rs1163626	chr13:112225200	A/C	cg10483660	chr13:112241077	NA	-0.59	-6.84	-0.57	7.61e-10	Hepatitis;
THYM	cis	rs988913	1.000	rs1503135	chr6:54841672	C/T	cg18532076	chr6:54711417	FAM83B	0.5	4.91	0.45	3.78e-6	Menarche (age at onset);
THYM	cis	rs2898681	0.614	rs11947787	chr4:53705225	C/A	cg00791764	chr4:53727839	RASL11B	0.42	5.3	0.48	7.41e-7	Optic nerve measurement (cup area);
THYM	cis	rs6918586	0.616	rs198836	chr6:26113616	T/A	cg03264133	chr6:25882463	NA	0.64	4.94	0.45	3.34e-6	Schizophrenia;
THYM	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg12826209	chr6:26865740	GUSBL1	0.94	6.54	0.56	3.06e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg18904891	chr8:8559673	CLDN23	-0.6	-4.85	-0.45	4.92e-6	Mood instability;
THYM	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg23161317	chr6:28129485	ZNF389	0.94	7.03	0.58	3.18e-10	Parkinson's disease;
THYM	cis	rs7945718	0.967	rs4757945	chr11:12808718	A/G	cg25843174	chr11:12811716	TEAD1	-0.45	-4.53	-0.42	1.72e-5	Educational attainment (years of education);
THYM	cis	rs28647808	0.786	rs28649804	chr9:136257709	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg26384229	chr12:38710491	ALG10B	1.02	8.22	0.64	1.05e-12	Bladder cancer;
THYM	cis	rs4808199	0.948	rs2301668	chr19:19452249	G/A	cg03709012	chr19:19516395	GATAD2A	1.1	6.32	0.54	8.6e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.67	5.17	0.47	1.32e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs365132	0.967	rs58279426	chr5:176448139	T/C	cg17809377	chr5:176326619	HK3	-0.31	-4.74	-0.44	7.57e-6	Menarche and menopause (age at onset);Menopause (age at onset);
THYM	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg08772003	chr10:104629869	AS3MT	-0.67	-5.92	-0.52	5.2100000000000003e-08	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs9875589	0.509	rs1601870	chr3:14024162	T/C	cg03204825	chr3:13978759	TPRXL	-0.53	-4.71	-0.43	8.55e-6	Ovarian reserve;
THYM	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13012494	chr21:47604986	C21orf56	-0.69	-4.8	-0.44	5.95e-6	Testicular germ cell tumor;
THYM	cis	rs11023332	0.706	rs10766197	chr11:14921880	G/A	cg19336497	chr11:14380999	RRAS2	-0.51	-4.69	-0.43	9.32e-6	Adiponectin levels;Vitamin D levels;
THYM	cis	rs2139634	0.965	rs2280407	chr3:46539963	G/A	cg02332537	chr3:46540019	RTP3	0.46	4.77	0.44	6.53e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg09904177	chr6:26538194	HMGN4	0.64	5.4	0.48	4.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs17102423	0.755	rs8009396	chr14:65573438	C/G	cg11161011	chr14:65562177	MAX	-0.85	-6.77	-0.57	1.04e-9	Obesity-related traits;
THYM	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg10057126	chr4:77819792	ANKRD56	-0.72	-6.26	-0.54	1.11e-8	Emphysema distribution in smoking;
THYM	cis	rs55637147	0.671	rs2276042	chr11:57117385	C/T	cg15971518	chr11:57159174	PRG2	-0.62	-4.79	-0.44	6.21e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg15448220	chr1:150897856	SETDB1	0.86	6.94	0.58	4.73e-10	Tonsillectomy;
THYM	cis	rs240764	0.782	rs239235	chr6:101100528	A/G	cg21058520	chr6:100914733	NA	-0.57	-5.07	-0.46	1.96e-6	Neuroticism;
THYM	trans	rs8002861	0.905	rs12853286	chr13:44446817	A/G	cg17145862	chr1:211918768	LPGAT1	-0.97	-9.31	-0.69	4.82e-15	Leprosy;
THYM	cis	rs2652822	0.530	rs12595312	chr15:63494159	T/C	cg09251291	chr15:63483946	RAB8B	0.55	4.84	0.44	5.08e-6	Metabolic traits;
THYM	cis	rs4589258	0.788	rs7936902	chr11:90492830	A/G	cg26138821	chr11:89956704	CHORDC1	-0.56	-4.49	-0.42	1.98e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1011018	0.955	rs7807797	chr7:139462493	A/G	cg06079564	chr7:139468310	HIPK2	-0.77	-5.98	-0.52	3.9e-8	Systolic blood pressure;
THYM	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg16414030	chr3:133502952	NA	0.58	4.56	0.42	1.54e-5	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs698833	0.521	rs35627501	chr2:44506971	G/C	cg04920474	chr2:44395004	PPM1B	0.63	6.28	0.54	1.01e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
THYM	cis	rs1160297	0.576	rs724860	chr2:53099406	A/G	cg07782112	chr2:53107842	NA	0.79	6.58	0.56	2.52e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg17554472	chr22:41940697	POLR3H	0.68	4.63	0.43	1.16e-5	Vitiligo;
THYM	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg03188948	chr7:1209495	NA	0.82	6.22	0.54	1.31e-8	Longevity;Endometriosis;
THYM	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg15536230	chr21:44985092	HSF2BP	-0.43	-5.4	-0.48	4.83e-7	Mean corpuscular volume;
THYM	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg01616529	chr11:638424	DRD4	-0.78	-6.62	-0.56	2.16e-9	Systemic lupus erythematosus;
THYM	cis	rs6584283	0.713	rs1332100	chr10:101301346	C/T	cg04972745	chr10:101287846	NA	0.54	5.05	0.46	2.14e-6	Ulcerative colitis;
THYM	cis	rs76878669	0.561	rs12420203	chr11:66163794	T/C	cg14263139	chr11:66104018	RIN1	-0.36	-4.46	-0.42	2.29e-5	Educational attainment (years of education);
THYM	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs11674184	0.659	rs59129126	chr2:11728388	T/C	cg07314298	chr2:11723111	GREB1	-0.64	-6.0	-0.52	3.54e-8	Endometriosis;
THYM	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg07061783	chr6:25882402	NA	-0.83	-7.22	-0.6	1.3e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2137111	0.579	rs116951852	chr15:77721319	A/T	cg22256960	chr15:77711686	NA	-0.62	-4.57	-0.42	1.45e-5	Anticoagulant levels;
THYM	cis	rs2797160	1.000	rs2211418	chr6:125995503	G/A	cg05901451	chr6:126070800	HEY2	-0.53	-4.52	-0.42	1.81e-5	Endometrial cancer;
THYM	cis	rs2637266	0.783	rs846633	chr10:78535744	A/C	cg18941641	chr10:78392320	NA	-0.66	-5.35	-0.48	6.08e-7	Pulmonary function;
THYM	cis	rs7020830	0.867	rs7852593	chr9:37332380	A/T	cg14294708	chr9:37120828	ZCCHC7	1.29	17.01	0.87	1.4e-30	Schizophrenia;
THYM	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg21475434	chr5:93447410	FAM172A	0.97	6.1	0.53	2.3e-8	Diabetic retinopathy;
THYM	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg12310025	chr6:25882481	NA	-1.04	-9.58	-0.7	1.32e-15	Intelligence (multi-trait analysis);
THYM	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg15536230	chr21:44985092	HSF2BP	-0.39	-4.69	-0.43	8.98e-6	Mean corpuscular volume;
THYM	cis	rs1670533	0.932	rs935968	chr4:1063187	G/T	cg27284194	chr4:1044797	NA	0.64	4.93	0.45	3.5e-6	Recombination rate (females);
THYM	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs7572733	0.555	rs6434953	chr2:198929693	A/G	cg00792783	chr2:198669748	PLCL1	0.73	4.79	0.44	6.22e-6	Dermatomyositis;
THYM	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg15247329	chr7:2764246	NA	-0.69	-5.68	-0.5	1.46e-7	Height;
THYM	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg10360139	chr7:1886902	MAD1L1	-0.6	-5.11	-0.46	1.63e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs1957429	0.808	rs4899150	chr14:65344400	A/G	cg23373153	chr14:65346875	NA	0.95	5.23	0.47	1.03e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs9403317	1.000	rs9403314	chr6:141831351	A/G	cg15052665	chr6:141804349	NA	-0.85	-8.79	-0.67	6.51e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.97	-5.16	-0.47	1.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.67	4.76	0.44	6.93e-6	Aortic root size;
THYM	cis	rs7178572	0.568	rs4886856	chr15:77510585	A/G	cg22256960	chr15:77711686	NA	-1.04	-8.57	-0.66	1.83e-13	Type 2 diabetes;
THYM	cis	rs11605275	0.818	rs35645523	chr11:20046171	G/A	cg14835545	chr11:20032148	NAV2	-1.15	-5.54	-0.49	2.71e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg19875535	chr5:140030758	IK	-0.58	-4.61	-0.43	1.26e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs67072384	1.000	rs2365442	chr11:72450218	G/A	cg01380194	chr11:72452482	ARAP1	-0.93	-5.07	-0.46	1.98e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg19077165	chr18:44547161	KATNAL2	0.5	5.84	0.51	7.15e-8	Personality dimensions;
THYM	cis	rs2249625	0.545	rs55681410	chr6:72877859	G/A	cg27608224	chr6:72922399	RIMS1	-0.58	-4.9	-0.45	3.94e-6	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
THYM	cis	rs4747241	0.626	rs10762510	chr10:74067286	T/C	cg07828833	chr10:74069493	NA	0.59	5.08	0.46	1.9e-6	Heschl's gyrus morphology;
THYM	cis	rs273218	0.724	rs392714	chr5:53382703	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.9	7.39	0.6	5.67e-11	Migraine;
THYM	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg03517284	chr6:25882590	NA	0.71	5.64	0.5	1.75e-7	Schizophrenia;
THYM	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	4.97	0.45	2.95e-6	Obesity-related traits;
THYM	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg24253500	chr15:84953950	NA	0.59	4.87	0.45	4.48e-6	Schizophrenia;
THYM	cis	rs6754311	0.773	rs309179	chr2:136613780	G/A	cg23851026	chr2:136556271	LCT	-0.5	-4.76	-0.44	6.97e-6	Mosquito bite size;
THYM	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.71	9.43	0.7	2.67e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.43	0.7	2.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg17424134	chr2:27616206	FTHL3;PPM1G	1.31	7.23	0.6	1.22e-10	Pulmonary function decline;
THYM	cis	rs8078723	0.668	rs56030650	chr17:38131187	C/A	cg17467752	chr17:38218738	THRA	0.75	5.63	0.5	1.85e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs192264	0.680	rs377149	chr16:65973530	T/A	cg02795155	chr16:66785218	DYNC1LI2	0.6	4.77	0.44	6.61e-6	Subjective well-being;
THYM	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg07343612	chr16:622815	PIGQ	-1.08	-10.53	-0.73	1.25e-17	Height;
THYM	cis	rs2562456	0.834	rs2173727	chr19:21673957	C/T	cg21751540	chr19:21541537	ZNF738	0.67	4.69	0.43	9.16e-6	Pain;
THYM	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.64	-0.74	7.23e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg09640425	chr7:158790006	NA	0.53	4.79	0.44	6.14e-6	Facial morphology (factor 20);
THYM	cis	rs13082711	0.522	rs674303	chr3:27332177	T/C	cg02860705	chr3:27208620	NA	0.65	5.09	0.46	1.79e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg06766960	chr11:133703094	NA	-0.61	-5.6	-0.5	2.08e-7	Childhood ear infection;
THYM	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg02915803	chr1:1606292	LOC728661;CDK11B	0.62	5.25	0.47	9.16e-7	Body mass index;
THYM	cis	rs7584330	0.704	rs11884395	chr2:238359366	C/T	cg14458575	chr2:238380390	NA	1.05	7.96	0.63	3.59e-12	Prostate cancer;
THYM	cis	rs7584330	0.784	rs6724766	chr2:238413600	A/G	cg14458575	chr2:238380390	NA	0.95	7.41	0.61	5.1e-11	Prostate cancer;
THYM	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg14456004	chr13:21872349	NA	-1.25	-10.18	-0.72	6.67e-17	White matter hyperintensity burden;
THYM	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs36051895	0.664	rs3780371	chr9:5095191	T/A	cg02405213	chr9:5042618	JAK2	-1.0	-10.96	-0.75	1.46e-18	Pediatric autoimmune diseases;
THYM	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs514406	0.893	rs4584343	chr1:53434539	A/C	cg24675658	chr1:53192096	ZYG11B	0.61	4.9	0.45	3.86e-6	Monocyte count;
THYM	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11644478	chr21:40555479	PSMG1	1.03	8.53	0.66	2.25e-13	Cognitive function;
THYM	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg08213375	chr14:104286397	PPP1R13B	0.45	4.82	0.44	5.46e-6	Reticulocyte count;
THYM	cis	rs6980334	1.000	rs7787591	chr7:137778203	C/T	cg03464514	chr7:137028442	PTN	0.56	4.67	0.43	9.74e-6	Blood metabolite ratios;
THYM	cis	rs11563648	0.573	rs115882589	chr7:126953787	C/T	cg23081781	chr7:127225937	GCC1	-0.37	-5.19	-0.47	1.17e-6	Resting heart rate;
THYM	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs4889855	0.530	rs9914854	chr17:78598662	A/G	cg16591659	chr17:78472290	NA	-0.4	-5.08	-0.46	1.9e-6	Fractional excretion of uric acid;
THYM	cis	rs61931739	0.890	rs1705753	chr12:34144594	C/T	cg10856724	chr12:34555212	NA	-0.64	-5.76	-0.51	1.05e-7	Morning vs. evening chronotype;
THYM	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg10295955	chr4:187884368	NA	-1.17	-17.37	-0.87	3.11e-31	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.2	-14.07	-0.82	5.84e-25	Exhaled nitric oxide output;
THYM	cis	rs4589258	0.933	rs7952184	chr11:90410573	G/A	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg20503657	chr10:835505	NA	1.14	8.04	0.64	2.5e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg05347473	chr6:146136440	FBXO30	-0.56	-4.45	-0.42	2.34e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9534288	0.797	rs2404728	chr13:46581862	T/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs1215050	0.740	rs6855827	chr4:99065706	G/A	cg17366294	chr4:99064904	C4orf37	0.43	4.78	0.44	6.43e-6	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs295140	0.507	rs1369842	chr2:201108987	C/A	cg17644776	chr2:200775616	C2orf69	-0.57	-4.63	-0.43	1.15e-5	QT interval;
THYM	cis	rs11711311	1.000	rs11719303	chr3:113494524	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.62	-5.52	-0.49	2.89e-7	IgG glycosylation;
THYM	cis	rs9902453	0.765	rs3102560	chr17:28029938	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	6.53	0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg26408565	chr15:76604113	ETFA	0.52	4.49	0.42	1.97e-5	Blood metabolite levels;
THYM	cis	rs807029	0.577	rs7903239	chr10:102758337	G/T	cg14905631	chr10:102746534	C10orf2;MRPL43	0.37	4.96	0.45	3.08e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7731657	0.537	rs2158352	chr5:130309465	A/G	cg08523029	chr5:130500466	HINT1	0.77	5.3	0.48	7.38e-7	Fasting plasma glucose;
THYM	cis	rs28595532	0.841	rs114976553	chr4:119496056	A/G	cg14228332	chr4:119757509	SEC24D	1.38	4.99	0.46	2.77e-6	Cannabis dependence symptom count;
THYM	cis	rs13315871	0.929	rs35004361	chr3:58313394	T/C	cg12435725	chr3:58293450	RPP14	-0.53	-5.82	-0.51	7.92e-8	Cholesterol, total;
THYM	cis	rs12519773	0.597	rs4342312	chr5:92477890	C/A	cg18783429	chr5:92414398	NA	0.48	4.83	0.44	5.25e-6	Migraine;
THYM	cis	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg21775007	chr8:11205619	TDH	0.73	6.54	0.56	3.07e-9	Retinal vascular caliber;
THYM	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg03929089	chr4:120376271	NA	-1.03	-12.43	-0.79	1.26e-21	Height;
THYM	cis	rs4595586	0.545	rs1349257	chr12:39397139	A/G	cg26384229	chr12:38710491	ALG10B	0.67	5.11	0.46	1.67e-6	Morning vs. evening chronotype;
THYM	cis	rs59112743	0.510	rs9464797	chr6:15556286	C/A	cg10111214	chr6:14815676	NA	0.77	5.0	0.46	2.66e-6	Multiple keratinocyte cancers;
THYM	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs990171	0.913	rs10190555	chr2:102994056	A/G	cg13897122	chr2:103039542	IL18RAP	-0.39	-4.59	-0.43	1.36e-5	Lymphocyte counts;
THYM	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs62064224	0.668	rs11655031	chr17:30833162	C/T	cg18200150	chr17:30822561	MYO1D	0.71	6.03	0.53	3.13e-8	Schizophrenia;
THYM	cis	rs9790314	0.502	rs7647118	chr3:161016165	T/C	cg03342759	chr3:160939853	NMD3	-0.93	-7.98	-0.63	3.34e-12	Morning vs. evening chronotype;
THYM	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg11764359	chr7:65958608	NA	-0.74	-6.15	-0.53	1.85e-8	Aortic root size;
THYM	cis	rs1113500	0.933	rs4590700	chr1:108638344	G/T	cg06207961	chr1:108661230	NA	0.64	5.09	0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg16486109	chr11:613632	IRF7	0.52	5.33	0.48	6.51e-7	Systemic lupus erythematosus;
THYM	cis	rs4619890	0.649	rs7654949	chr4:7784194	A/G	cg19371708	chr4:7070051	GRPEL1	0.65	4.54	0.42	1.64e-5	Glaucoma (primary open-angle);
THYM	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg25554036	chr4:6271136	WFS1	0.59	5.47	0.49	3.68e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs4705952	0.557	rs4588593	chr5:131845333	C/T	cg13566430	chr5:131992455	IL13	0.54	4.54	0.42	1.66e-5	C-reactive protein levels;
THYM	cis	rs4866334	1.000	rs76306109	chr5:18481141	A/C	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg24375607	chr4:120327624	NA	0.65	5.14	0.47	1.45e-6	Corneal astigmatism;
THYM	cis	rs6500395	1.000	rs871903	chr16:48593643	A/C	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs4474465	0.833	rs11606128	chr11:78156960	T/C	cg19901956	chr11:77921274	USP35	-0.61	-4.51	-0.42	1.83e-5	Alzheimer's disease (survival time);
THYM	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7246657	0.943	rs10422074	chr19:37894236	T/C	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg03859395	chr2:55845619	SMEK2	-0.65	-5.47	-0.49	3.61e-7	Metabolic syndrome;
THYM	cis	rs10089	1.000	rs4835944	chr5:127490870	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.96	-5.81	-0.51	8.26e-8	Ileal carcinoids;
THYM	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs12594515	1.000	rs6493168	chr15:45986811	A/C	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23221052	chr5:179740743	GFPT2	-0.85	-6.84	-0.57	7.77e-10	Height;
THYM	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg06636001	chr8:8085503	FLJ10661	0.73	6.4	0.55	5.8e-9	Mood instability;
THYM	cis	rs7149242	0.849	rs10146962	chr14:101170540	A/G	cg18089426	chr14:101175970	NA	0.59	6.33	0.54	8.05e-9	Platelet count;
THYM	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg06728252	chr6:26598149	ABT1	-0.44	-5.24	-0.47	9.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg23711669	chr6:146136114	FBXO30	-0.95	-9.69	-0.71	7.63e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg09165964	chr15:75287851	SCAMP5	-1.1	-6.31	-0.54	8.71e-9	Lung cancer;
THYM	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg04447362	chr2:237654635	NA	0.48	4.49	0.42	2.03e-5	Prostate cancer;
THYM	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg11764359	chr7:65958608	NA	-0.86	-7.24	-0.6	1.17e-10	Aortic root size;
THYM	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs12476592	0.602	rs4671508	chr2:63654140	C/T	cg17519650	chr2:63277830	OTX1	-0.68	-4.49	-0.42	2.03e-5	Childhood ear infection;
THYM	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg12219531	chr12:120966889	COQ5	0.8	6.55	0.56	2.9e-9	High light scatter reticulocyte count;
THYM	cis	rs4866334	1.000	rs76371744	chr5:18441614	T/G	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.59	-4.62	-0.43	1.2e-5	Chronic sinus infection;
THYM	cis	rs9527	0.569	rs10786730	chr10:104724200	G/A	cg04362960	chr10:104952993	NT5C2	0.62	4.7	0.43	8.66e-6	Arsenic metabolism;
THYM	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg14582100	chr15:45693742	SPATA5L1	0.68	5.67	0.5	1.53e-7	Homoarginine levels;
THYM	cis	rs828999	0.638	rs6703282	chr1:108697348	C/A	cg24323958	chr1:108741884	SLC25A24	0.54	5.33	0.48	6.7e-7	Monocyte percentage of white cells;
THYM	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg13397359	chr6:42928475	GNMT	0.61	5.42	0.49	4.58e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg00898013	chr13:113819073	PROZ	-0.89	-9.2	-0.69	8.65e-15	Platelet distribution width;
THYM	cis	rs526231	0.543	rs34784	chr5:102457330	G/C	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.49e-6	Primary biliary cholangitis;
THYM	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg15445000	chr17:37608096	MED1	0.41	5.04	0.46	2.26e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7639513	0.520	rs79141906	chr3:12711977	A/C	cg23032965	chr3:12705835	RAF1	0.99	7.38	0.6	5.9e-11	Itch intensity from mosquito bite;
THYM	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg05373962	chr22:49881684	NA	-0.65	-6.5	-0.55	3.73e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg24818145	chr4:99064322	C4orf37	0.69	5.38	0.48	5.43e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs921968	0.643	rs4674305	chr2:219293326	C/T	cg02176678	chr2:219576539	TTLL4	0.64	6.16	0.53	1.71e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg02640540	chr1:67518911	SLC35D1	-0.64	-4.68	-0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs7975161	0.572	rs4964226	chr12:104570489	A/G	cg25273343	chr12:104657179	TXNRD1	-0.71	-4.86	-0.45	4.55e-6	Toenail selenium levels;
THYM	cis	rs6424115	0.830	rs3003335	chr1:24200052	A/G	cg15997130	chr1:24165203	NA	0.74	6.34	0.55	7.54e-9	Immature fraction of reticulocytes;
THYM	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg04398451	chr17:18023971	MYO15A	-0.76	-6.96	-0.58	4.39e-10	Total body bone mineral density;
THYM	cis	rs3820068	0.580	rs12746773	chr1:16001588	C/T	cg24675056	chr1:15929824	NA	0.68	5.47	0.49	3.59e-7	Systolic blood pressure;
THYM	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg18758796	chr5:131593413	PDLIM4	0.5	4.75	0.44	7.23e-6	Blood metabolite levels;
THYM	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg06634786	chr22:41940651	POLR3H	-0.65	-5.07	-0.46	1.98e-6	Vitiligo;
THYM	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg20007245	chr22:24372913	LOC391322	-0.77	-7.85	-0.63	6.24e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg05890377	chr2:74357713	NA	1.09	10.22	0.72	5.55e-17	Gestational age at birth (maternal effect);
THYM	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg00757033	chr12:89920650	WDR51B	0.75	12.04	0.78	7.96e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs34779708	1.000	rs12769189	chr10:35399668	A/G	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.52e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4654899	0.965	rs61779124	chr1:21513306	C/T	cg01072550	chr1:21505969	NA	-0.71	-6.39	-0.55	6.24e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	10.77	0.74	3.77e-18	Chronic sinus infection;
THYM	cis	rs10924970	0.934	rs12402243	chr1:235431792	A/C	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs73198271	0.740	rs1039910	chr8:8648066	T/C	cg06636001	chr8:8085503	FLJ10661	-0.79	-5.53	-0.49	2.86e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs2806561	0.704	rs6680974	chr1:23376233	A/G	cg19743168	chr1:23544995	NA	0.48	4.69	0.43	9.07e-6	Height;
THYM	cis	rs7084402	1.000	rs7084402	chr10:60265404	C/T	cg09696939	chr10:60272079	BICC1	-0.48	-5.58	-0.5	2.31e-7	Refractive error;
THYM	cis	rs7078219	0.505	rs1548964	chr10:101289653	C/G	cg04972745	chr10:101287846	NA	0.51	4.84	0.44	5.09e-6	Dental caries;
THYM	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg05872129	chr22:39784769	NA	-0.87	-7.17	-0.59	1.64e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg16586182	chr3:47516702	SCAP	-0.63	-5.25	-0.47	9.07e-7	Colorectal cancer;
THYM	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg23758822	chr17:41437982	NA	1.22	11.06	0.75	8.97e-19	Menopause (age at onset);
THYM	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg26116260	chr4:7069785	GRPEL1	1.1	9.3	0.69	5.17e-15	Monocyte percentage of white cells;
THYM	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg24375607	chr4:120327624	NA	0.62	5.0	0.46	2.63e-6	Corneal astigmatism;
THYM	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg27170947	chr2:26402098	FAM59B	0.61	4.63	0.43	1.17e-5	Gut microbiome composition (summer);
THYM	cis	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg13443165	chr9:33130375	B4GALT1	-0.87	-7.99	-0.63	3.23e-12	IgG glycosylation;
THYM	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	5.2	0.47	1.15e-6	Hip circumference adjusted for BMI;
THYM	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg05872129	chr22:39784769	NA	0.94	10.02	0.72	1.51e-16	IgG glycosylation;
THYM	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs2688608	0.592	rs12253429	chr10:75496161	C/G	cg19442545	chr10:75533431	FUT11	-0.51	-5.22	-0.47	1.03e-6	Inflammatory bowel disease;
THYM	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg00129232	chr17:37814104	STARD3	0.69	4.51	0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs6032067	0.543	rs13045693	chr20:43911817	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.6	-5.86	-0.52	6.58e-8	Blood protein levels;
THYM	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg16006841	chr5:176797999	RGS14	-0.52	-5.94	-0.52	4.74e-8	Urate levels in lean individuals;
THYM	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg15549821	chr19:49342101	PLEKHA4	-0.82	-4.55	-0.42	1.56e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs13102973	0.899	rs13126625	chr4:135900322	C/T	cg14419869	chr4:135874104	NA	0.82	6.86	0.58	7.03e-10	Subjective well-being;
THYM	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.25	-4.45	-0.42	2.31e-5	Obesity-related traits;
THYM	cis	rs4731207	0.698	rs35184624	chr7:124469587	G/A	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg26384229	chr12:38710491	ALG10B	1.03	10.33	0.73	3.29e-17	Heart rate;
THYM	cis	rs7264396	0.676	rs6060730	chr20:34558503	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-4.8	-0.44	6.01e-6	Total cholesterol levels;
THYM	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg13319975	chr6:146136371	FBXO30	0.71	5.99	0.52	3.78e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs34779708	0.897	rs16935880	chr10:35415468	C/G	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs863345	0.604	rs7525362	chr1:158493890	G/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg03929089	chr4:120376271	NA	-1.01	-13.5	-0.81	8.23e-24	Height;
THYM	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg22089800	chr15:90895588	ZNF774	0.68	5.26	0.47	9e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs7586879	0.828	rs12986610	chr2:25106265	A/G	cg01884057	chr2:25150051	NA	-0.51	-4.59	-0.43	1.35e-5	Body mass index;
THYM	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg09165964	chr15:75287851	SCAMP5	-1.0	-9.02	-0.68	2.08e-14	Blood trace element (Zn levels);
THYM	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg25358565	chr5:93447407	FAM172A	1.38	10.15	0.72	8.08e-17	Diabetic retinopathy;
THYM	cis	rs3126085	0.935	rs4845745	chr1:152185184	C/T	cg26020982	chr1:152196106	HRNR	0.35	4.57	0.42	1.45e-5	Atopic dermatitis;
THYM	cis	rs2932538	0.922	rs12406906	chr1:113117900	G/T	cg22162597	chr1:113214053	CAPZA1	-0.65	-5.28	-0.48	8.29e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs9807989	0.773	rs72823661	chr2:102968716	G/A	cg03938978	chr2:103052716	IL18RAP	0.63	6.46	0.55	4.36e-9	Asthma;
THYM	cis	rs9972944	0.756	rs2024273	chr17:63768972	A/G	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg01416388	chr22:39784598	NA	-0.93	-9.11	-0.68	1.33e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-4.48	-0.42	2.06e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg07061783	chr6:25882402	NA	-0.82	-6.61	-0.56	2.23e-9	Intelligence (multi-trait analysis);
THYM	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.14	-7.5	-0.61	3.31e-11	Schizophrenia;
THYM	cis	rs924712	0.816	rs971526	chr6:54728129	G/T	cg04690482	chr6:54711388	FAM83B	-0.45	-4.96	-0.45	3.09e-6	Breast cancer;
THYM	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg22508957	chr16:3507546	NAT15	-0.41	-4.53	-0.42	1.71e-5	Body mass index (adult);
THYM	cis	rs887829	0.570	rs4347832	chr2:234593041	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.79	-6.64	-0.56	1.94e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs17818399	0.620	rs7598578	chr2:46857085	T/C	cg09399716	chr2:46890238	NA	-0.44	-4.45	-0.42	2.32e-5	Height;
THYM	cis	rs7599312	0.534	rs10182996	chr2:213404834	T/C	cg20637307	chr2:213403960	ERBB4	1.04	11.16	0.75	5.66e-19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2658782	0.789	rs3019206	chr11:93111073	A/G	cg15737290	chr11:93063684	CCDC67	0.88	6.84	0.57	7.59e-10	Pulmonary function decline;
THYM	cis	rs6768930	0.509	rs7627431	chr3:57723828	T/G	cg24033633	chr3:57945695	NA	-0.4	-5.66	-0.5	1.59e-7	Obesity-related traits;
THYM	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	7.45	0.61	4.17e-11	Platelet count;
THYM	trans	rs4866334	1.000	rs77016925	chr5:18487933	T/C	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs1642645	0.872	rs4660586	chr1:42407229	C/T	cg10197057	chr1:42612518	NA	0.42	4.48	0.42	2.09e-5	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.97	-5.38	-0.48	5.38e-7	Gut microbiome composition (summer);
THYM	cis	rs1865721	0.771	rs72975988	chr18:73128289	T/G	cg26385618	chr18:73139727	C18orf62	-0.69	-5.19	-0.47	1.18e-6	Intelligence;
THYM	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg03709012	chr19:19516395	GATAD2A	-0.82	-6.79	-0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs897984	0.520	rs4889534	chr16:30865440	T/C	cg05768032	chr16:30646687	NA	-0.47	-4.61	-0.43	1.28e-5	Dementia with Lewy bodies;
THYM	cis	rs981844	0.712	rs62325150	chr4:154728117	T/G	cg22178613	chr4:154710499	SFRP2	-0.59	-4.93	-0.45	3.48e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg06636001	chr8:8085503	FLJ10661	0.65	5.66	0.5	1.63e-7	Joint mobility (Beighton score);
THYM	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg00908189	chr16:619842	PIGQ	1.03	9.15	0.68	1.07e-14	Height;
THYM	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg13699009	chr12:122356056	WDR66	0.53	5.66	0.5	1.63e-7	Mean corpuscular volume;
THYM	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.39	-4.45	-0.42	2.37e-5	Depressive symptoms;
THYM	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg04025307	chr7:1156635	C7orf50	0.8	8.1	0.64	1.83e-12	Longevity;Endometriosis;
THYM	cis	rs2276314	1.000	rs9956938	chr18:33567061	A/G	cg05985134	chr18:33552581	C18orf21	0.72	5.0	0.46	2.6e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg02640540	chr1:67518911	SLC35D1	-0.64	-4.68	-0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	6.71	0.57	1.37e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs8114671	0.836	rs6058154	chr20:33585834	C/T	cg08999081	chr20:33150536	PIGU	-0.59	-5.12	-0.46	1.61e-6	Height;
THYM	cis	rs12530845	0.943	rs55889179	chr7:135331631	C/T	cg23117316	chr7:135346802	PL-5283	-0.67	-5.92	-0.52	5.05e-8	Red blood cell traits;
THYM	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg15744692	chr15:45671195	LOC145663;GATM	0.44	4.46	0.42	2.22e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs2072732	0.861	rs12033927	chr1:2937550	A/G	cg08733933	chr1:2954429	NA	-0.65	-4.7	-0.43	8.67e-6	Plateletcrit;
THYM	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg03264133	chr6:25882463	NA	-0.65	-4.81	-0.44	5.56e-6	Height;
THYM	cis	rs354225	0.544	rs12713269	chr2:54809154	C/G	cg23486701	chr2:54789491	SPTBN1	0.36	4.96	0.45	3.11e-6	Schizophrenia;
THYM	cis	rs950881	0.932	rs72823635	chr2:102931612	T/C	cg20060108	chr2:102954350	IL1RL1	0.87	4.77	0.44	6.56e-6	Allergy;
THYM	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg06026331	chr20:60912101	LAMA5	-0.62	-4.85	-0.45	4.84e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg24578937	chr1:2090814	PRKCZ	0.59	5.88	0.52	6.22e-8	Height;
THYM	cis	rs2276498	1.000	rs67617961	chr20:52618367	C/T	cg23682609	chr20:52687365	BCAS1	0.63	4.87	0.45	4.4e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs17253792	0.822	rs10136155	chr14:56049129	G/A	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs2354432	0.607	rs9782976	chr1:146825049	A/G	cg25205988	chr1:146714368	CHD1L	1.04	5.79	0.51	9.04e-8	Mitochondrial DNA levels;
THYM	cis	rs6032067	0.641	rs74174934	chr20:43761331	T/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.41	-0.49	4.61e-7	Blood protein levels;
THYM	cis	rs4731207	0.698	rs4728011	chr7:124481712	C/T	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg13695892	chr22:41940480	POLR3H	-0.94	-7.28	-0.6	9.46e-11	Vitiligo;
THYM	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs9563576	0.778	rs7985226	chr13:58619655	C/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18876405	chr7:65276391	NA	-0.54	-4.46	-0.42	2.25e-5	Aortic root size;
THYM	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg02038168	chr22:39784481	NA	-0.7	-5.1	-0.46	1.7e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg24692254	chr21:30365293	RNF160	-0.95	-8.4	-0.65	4.25e-13	Dental caries;
THYM	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg02725872	chr8:58115012	NA	-1.11	-8.44	-0.65	3.56e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg06238570	chr21:40685208	BRWD1	0.91	6.77	0.57	1.08e-9	Cognitive function;
THYM	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg19024700	chr19:49340765	PLEKHA4;HSD17B14	0.65	4.82	0.44	5.48e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs16912285	0.688	rs59246618	chr11:24315201	G/T	ch.11.24196551F	chr11:24239977	NA	1.0	7.22	0.6	1.29e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs1095368	0.644	rs10906347	chr10:13361421	C/T	cg25835351	chr10:13388524	SEPHS1	-0.31	-5.04	-0.46	2.2e-6	IgG glycosylation;
THYM	cis	rs2235642	0.964	rs9939655	chr16:1577963	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.5	-4.49	-0.42	2.01e-5	Coronary artery disease;
THYM	cis	rs7322722	0.945	rs9544460	chr13:77906583	G/T	cg04565255	chr13:77565759	CLN5	-0.44	-4.49	-0.42	1.98e-5	Preeclampsia;
THYM	cis	rs2404602	0.647	rs10152247	chr15:76942252	T/G	cg23625390	chr15:77176239	SCAPER	-0.86	-6.32	-0.54	8.54e-9	Blood metabolite levels;
THYM	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.7	5.62	0.5	1.89e-7	Menarche (age at onset);
THYM	cis	rs76662990	0.570	rs77403492	chr5:73908080	C/G	cg13275603	chr5:73927487	ENC1	-0.77	-4.53	-0.42	1.71e-5	Residual cognition;
THYM	cis	rs7219021	0.739	rs58376900	chr17:46962853	C/G	cg09029085	chr17:47094198	IGF2BP1	0.36	4.55	0.42	1.61e-5	Schizophrenia or bipolar disorder;
THYM	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg17366294	chr4:99064904	C4orf37	0.57	6.8	0.57	9.22e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28830936	0.625	rs8038764	chr15:41907905	A/C	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	0.46	4.48	0.42	2.11e-5	Diastolic blood pressure;
THYM	cis	rs6424115	0.830	rs2502992	chr1:24201919	T/C	cg15997130	chr1:24165203	NA	0.76	6.39	0.55	6.14e-9	Immature fraction of reticulocytes;
THYM	cis	rs7771547	0.519	rs9654588	chr6:36363923	A/C	cg04289385	chr6:36355825	ETV7	0.55	4.52	0.42	1.75e-5	Platelet distribution width;
THYM	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.66	8.96	0.68	2.76e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg14345882	chr6:26364793	BTN3A2	0.62	5.6	0.5	2.06e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs8067545	0.641	rs397969	chr17:19804247	T/C	cg20830565	chr17:20408647	MGC102966	-0.5	-4.57	-0.42	1.47e-5	Schizophrenia;
THYM	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg10295955	chr4:187884368	NA	-1.22	-17.5	-0.87	1.76e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7078219	1.000	rs11190130	chr10:101275206	C/T	cg23904955	chr10:101282759	NA	-0.44	-5.14	-0.47	1.47e-6	Dental caries;
THYM	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg14784868	chr12:69753453	YEATS4	1.12	10.87	0.74	2.32e-18	Blood protein levels;
THYM	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg07636037	chr3:49044803	WDR6	1.0	10.57	0.73	1.03e-17	Parkinson's disease;
THYM	cis	rs10735851	1	rs10735851	chr12:53743064	G/A	cg26875137	chr12:53738046	NA	0.82	6.34	0.55	7.54e-9	Total body bone mineral density;
THYM	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg27170947	chr2:26402098	FAM59B	-0.79	-6.55	-0.56	2.88e-9	Gut microbiome composition (summer);
THYM	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg26384229	chr12:38710491	ALG10B	0.91	7.47	0.61	3.85e-11	Bladder cancer;
THYM	cis	rs9443189	0.813	rs2133191	chr6:76440761	C/T	cg01950844	chr6:76311363	SENP6	-0.78	-4.52	-0.42	1.81e-5	Prostate cancer;
THYM	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg04944784	chr2:26401820	FAM59B	-1.08	-8.57	-0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs950880	0.710	rs55645612	chr2:103055661	C/T	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.71	-0.44	8.33e-6	Serum protein levels (sST2);
THYM	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg18512352	chr11:47633146	NA	-0.55	-6.8	-0.57	9.37e-10	Subjective well-being;
THYM	cis	rs7173743	0.756	rs4539564	chr15:79128499	G/A	cg00540400	chr15:79124168	NA	0.6	6.52	0.56	3.43e-9	Coronary artery disease;
THYM	cis	rs933688	1.000	rs1363839	chr5:90671274	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	6.24	0.54	1.23e-8	Smoking behavior;
THYM	cis	rs6840360	0.615	rs4696267	chr4:152464500	A/G	cg22705602	chr4:152727874	NA	-0.71	-7.94	-0.63	4.03e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4072705	0.586	rs7023736	chr9:127247946	G/A	cg01786973	chr9:127249749	NR5A1	0.4	5.24	0.47	9.69e-7	Menarche (age at onset);
THYM	cis	rs1163251	0.902	rs839605	chr1:120217524	C/A	cg19096424	chr1:120255104	PHGDH	0.67	5.25	0.47	9.26e-7	Blood metabolite levels;
THYM	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.93	5.12	0.47	1.59e-6	Initial pursuit acceleration;
THYM	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	18.27	0.88	7.47e-33	Chronic sinus infection;
THYM	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg09537434	chr19:41945824	ATP5SL	-1.11	-10.88	-0.74	2.18e-18	Height;
THYM	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg15448220	chr1:150897856	SETDB1	0.9	7.66	0.62	1.56e-11	Melanoma;
THYM	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg10802521	chr3:52805072	NEK4	-0.73	-6.43	-0.55	5.15e-9	Bipolar disorder;
THYM	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1729951	0.546	rs12054219	chr3:136677472	G/A	cg12473912	chr3:136751656	NA	0.63	5.12	0.47	1.57e-6	Neuroticism;
THYM	cis	rs7426056	0.671	rs3116492	chr2:204588382	A/G	cg07930752	chr2:204569955	CD28	-0.67	-4.74	-0.44	7.48e-6	Primary sclerosing cholangitis;
THYM	cis	rs3087591	0.919	rs12603838	chr17:29408059	C/T	cg24425628	chr17:29625626	OMG;NF1	0.65	5.59	0.5	2.16e-7	Hip circumference;
THYM	cis	rs9826463	0.527	rs112722008	chr3:142053561	A/G	cg20824294	chr3:142316082	PLS1	0.76	5.28	0.48	8.31e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.63	0.43	1.14e-5	Lung cancer in ever smokers;
THYM	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg12599982	chr1:44399894	ARTN	0.56	4.48	0.42	2.09e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6542838	0.780	rs981601	chr2:99463882	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.56	-0.42	1.54e-5	Fear of minor pain;
THYM	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg22841779	chr14:105766346	BRF1	-0.47	-5.82	-0.51	7.83e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg17366294	chr4:99064904	C4orf37	0.53	5.9	0.52	5.67e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11997175	0.583	rs7824990	chr8:33779934	A/G	ch.8.33884649F	chr8:33765107	NA	0.74	5.37	0.48	5.5e-7	Body mass index;
THYM	cis	rs7258015	1.000	rs3176766	chr19:10449778	G/A	cg01466491	chr19:10523363	NA	0.67	5.33	0.48	6.56e-7	Systemic lupus erythematosus or rheumatoid arthritis;
THYM	cis	rs7616559	0.637	rs4266145	chr3:156777385	A/G	cg15697575	chr3:156784781	NA	0.42	4.98	0.45	2.85e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22857025	chr5:266934	NA	-1.37	-8.88	-0.67	4.08e-14	Breast cancer;
THYM	cis	rs3750817	0.537	rs2912778	chr10:123338654	G/A	cg15049101	chr10:123353889	FGFR2	-0.59	-5.28	-0.48	8.12e-7	Breast cancer;
THYM	cis	rs1298062	0.790	rs2445841	chr19:50966531	T/A	cg10687087	chr19:50962411	MYBPC2	0.53	4.53	0.42	1.69e-5	Age of smoking initiation;
THYM	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.48	-4.65	-0.43	1.09e-5	Crohn's disease;
THYM	cis	rs4845875	0.626	rs12735869	chr1:11834163	C/T	cg25341925	chr1:11908058	NPPA	0.42	4.52	0.42	1.77e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs10871290	0.881	rs3863436	chr16:74468038	T/C	cg01733217	chr16:74700730	RFWD3	-0.65	-5.57	-0.5	2.38e-7	Breast cancer;
THYM	cis	rs73110464	0.562	rs2363634	chr12:53354683	A/G	cg05393297	chr12:53359155	NA	-0.61	-6.94	-0.58	4.68e-10	Cancer (pleiotropy);
THYM	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg22907277	chr7:1156413	C7orf50	0.62	5.27	0.48	8.61e-7	Longevity;Endometriosis;
THYM	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs7614311	0.731	rs1053338	chr3:63967900	A/G	cg22134162	chr3:63841271	THOC7	-0.56	-6.72	-0.57	1.36e-9	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs2859741	0.528	rs2359647	chr1:37483054	A/T	cg09363841	chr1:37513479	NA	-0.66	-5.21	-0.47	1.1e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs17006441	0.966	rs62250968	chr3:69811900	C/T	cg18496212	chr3:69797108	MITF	0.68	7.29	0.6	9.28e-11	Hemoglobin concentration;
THYM	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.67	5.3	0.48	7.51e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg27211696	chr2:191398769	TMEM194B	-0.6	-4.5	-0.42	1.94e-5	Diastolic blood pressure;
THYM	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg14196790	chr5:131705035	SLC22A5	0.5	4.46	0.42	2.27e-5	Breast cancer;Mosquito bite size;
THYM	cis	rs741677	0.964	rs8077122	chr17:495522	G/A	cg06217071	chr17:408420	NA	-0.55	-4.6	-0.43	1.31e-5	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
THYM	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11937061	0.539	rs17002460	chr4:78157288	C/A	cg01930676	chr4:78783082	MRPL1	-0.58	-4.63	-0.43	1.15e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg21226059	chr5:178986404	RUFY1	-0.61	-7.32	-0.6	7.79e-11	Lung cancer;
THYM	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.53	5.54	0.49	2.75e-7	Schizophrenia;
THYM	cis	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg07460842	chr6:66804631	NA	1.1	8.21	0.64	1.08e-12	Exhaled nitric oxide output;
THYM	cis	rs7818345	1.000	rs11991105	chr8:19290655	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.46	0.42	2.22e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg06009448	chr7:1102226	C7orf50	0.52	5.44	0.49	4.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9768139	0.654	rs61474285	chr7:158121276	C/T	cg24154853	chr7:158122151	PTPRN2	0.56	4.97	0.45	2.92e-6	Calcium levels;
THYM	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.99	12.51	0.79	8.52e-22	Chronic sinus infection;
THYM	cis	rs2953174	0.507	rs2953172	chr2:241525316	C/T	cg27449114	chr2:241501342	DUSP28	0.61	4.82	0.44	5.45e-6	Bipolar disorder;
THYM	cis	rs9527	0.615	rs10883804	chr10:104706520	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-5.08	-0.46	1.85e-6	Arsenic metabolism;
THYM	cis	rs60695258	0.726	rs1471251	chr4:87976359	A/T	cg10685359	chr4:87814065	C4orf36	0.36	4.57	0.42	1.48e-5	Hematocrit;
THYM	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg09307838	chr4:120376055	NA	0.71	5.07	0.46	1.98e-6	Corneal astigmatism;
THYM	cis	rs599083	0.569	rs685095	chr11:68170376	C/T	cg16797656	chr11:68205561	LRP5	-0.49	-5.34	-0.48	6.41e-7	Bone mineral density (spine);
THYM	cis	rs7586879	0.681	rs6545790	chr2:25109302	A/G	cg01884057	chr2:25150051	NA	0.7	7.67	0.62	1.5e-11	Body mass index;
THYM	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg11673840	chr17:47092156	IGF2BP1	-0.54	-5.48	-0.49	3.55e-7	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs524281	0.773	rs2155031	chr11:66030927	C/T	cg00563793	chr11:65837595	PACS1	0.81	4.87	0.45	4.42e-6	Electroencephalogram traits;
THYM	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg26038318	chr20:34205095	SPAG4	0.59	4.68	0.43	9.62e-6	Total cholesterol levels;
THYM	cis	rs12681287	0.711	rs28420256	chr8:87255599	C/T	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs7191439	0.728	rs8043924	chr16:88787704	G/C	cg04602696	chr16:88846723	FAM38A	-0.66	-4.88	-0.45	4.3e-6	Plateletcrit;
THYM	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg05425664	chr17:57184151	TRIM37	0.59	4.75	0.44	7.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg16405210	chr4:1374714	KIAA1530	0.93	8.14	0.64	1.49e-12	Longevity;
THYM	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg18451016	chr1:38461880	NA	0.43	5.26	0.47	8.97e-7	Coronary artery disease;
THYM	cis	rs4731207	0.646	rs67453484	chr7:124454524	T/A	cg05285228	chr7:124571219	POT1	0.6	4.52	0.42	1.76e-5	Cutaneous malignant melanoma;
THYM	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg21028142	chr17:79581711	NPLOC4	-0.61	-6.22	-0.54	1.32e-8	Eye color traits;
THYM	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg18305652	chr10:134549665	INPP5A	0.82	7.2	0.59	1.39e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg03929089	chr4:120376271	NA	-0.9	-8.74	-0.67	8e-14	Coronary artery disease;
THYM	cis	rs10504073	0.584	rs17642664	chr8:49942945	A/G	cg00325661	chr8:49890786	NA	1.09	11.42	0.76	1.62e-19	Blood metabolite ratios;
THYM	cis	rs8017423	0.967	rs1959002	chr14:90670994	T/A	cg04239629	chr14:90701769	NA	-0.59	-4.45	-0.42	2.32e-5	Mortality in heart failure;
THYM	cis	rs868036	0.718	rs922494	chr15:68120644	T/C	cg24579218	chr15:68104479	NA	-0.8	-8.27	-0.65	8.25e-13	Restless legs syndrome;
THYM	cis	rs611744	0.967	rs650437	chr8:109210927	T/G	cg21045802	chr8:109455806	TTC35	0.6	5.37	0.48	5.65e-7	Dupuytren's disease;
THYM	cis	rs735539	0.521	rs1570672	chr13:21408818	C/T	cg02792322	chr13:21280448	IL17D	-0.66	-4.78	-0.44	6.37e-6	Dental caries;
THYM	cis	rs2820651	1.000	rs2820651	chr10:1471765	A/C	cg02445968	chr10:1449028	ADARB2	1.14	6.09	0.53	2.43e-8	Migraine with aura;
THYM	cis	rs4900538	0.927	rs1190544	chr14:102903398	G/A	cg18135206	chr14:102964638	TECPR2	-0.92	-7.62	-0.62	1.88e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg20608306	chr11:116969690	SIK3	0.59	7.92	0.63	4.51e-12	Blood protein levels;
THYM	cis	rs2294693	0.891	rs1072119	chr6:40993072	G/A	cg21128951	chr6:40996213	UNC5CL	0.61	4.8	0.44	5.78e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs2932538	0.922	rs6663922	chr1:113095948	T/C	cg22162597	chr1:113214053	CAPZA1	0.63	5.07	0.46	1.94e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs7115242	0.514	rs4936367	chr11:117042377	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.95	5.34	0.48	6.34e-7	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
THYM	cis	rs17608059	0.901	rs11078215	chr17:13906934	T/C	cg11395062	chr17:14139857	CDRT15	0.74	6.68	0.57	1.61e-9	Temperament;
THYM	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg05802129	chr4:122689817	NA	-0.59	-4.65	-0.43	1.07e-5	Type 2 diabetes;
THYM	cis	rs2070488	1.000	rs34258593	chr3:38464565	T/C	cg24069376	chr3:38537580	EXOG	0.66	6.59	0.56	2.44e-9	Electrocardiographic conduction measures;
THYM	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs61990749	1.000	rs6574411	chr14:78374327	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.91	-4.66	-0.43	1.02e-5	Fibroblast growth factor basic levels;
THYM	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg10523679	chr1:76189770	ACADM	0.92	10.35	0.73	2.94e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg12483005	chr1:23474871	LUZP1	0.58	5.84	0.51	7.3900000000000007e-08	Height;
THYM	cis	rs4792901	0.729	rs12603131	chr17:41538839	G/C	cg21940313	chr17:41620911	ETV4	-0.54	-5.1	-0.46	1.74e-6	Dupuytren's disease;
THYM	cis	rs977747	0.689	rs7545034	chr1:47659445	C/T	cg03885399	chr1:47691550	TAL1	0.53	5.06	0.46	2.01e-6	Body mass index;
THYM	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13732083	chr21:47605072	C21orf56	-0.68	-4.82	-0.44	5.46e-6	Testicular germ cell tumor;
THYM	cis	rs80319144	1.000	rs2193701	chr2:159274227	A/G	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs6496667	1.000	rs4261510	chr15:90890606	G/A	cg22089800	chr15:90895588	ZNF774	0.94	5.57	0.5	2.35e-7	Rheumatoid arthritis;
THYM	cis	rs6754311	0.773	rs4988183	chr2:136622046	T/C	cg04750100	chr2:136595281	LCT	0.5	5.14	0.47	1.48e-6	Mosquito bite size;
THYM	cis	rs208520	1.000	rs208537	chr6:66963544	A/G	cg07460842	chr6:66804631	NA	-0.85	-5.48	-0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs2742234	0.541	rs11528481	chr10:43737767	C/A	cg06632098	chr10:43605906	RET	0.74	4.97	0.45	2.95e-6	Hirschsprung disease;
THYM	cis	rs3960554	0.569	rs10954750	chr7:75664921	C/G	cg01364799	chr7:75623366	TMEM120A	0.66	4.46	0.42	2.25e-5	Eotaxin levels;
THYM	cis	rs2859741	0.935	rs2782410	chr1:37509489	G/C	cg09363841	chr1:37513479	NA	-0.74	-6.92	-0.58	5.2e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs6032067	0.516	rs6104085	chr20:43901302	A/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.39	-4.67	-0.43	9.85e-6	Blood protein levels;
THYM	cis	rs332034	0.546	rs28870140	chr8:8689770	A/G	cg06636001	chr8:8085503	FLJ10661	-0.76	-4.53	-0.42	1.71e-5	Conduct disorder (maternal expressed emotions interaction);
THYM	cis	rs1642645	0.606	rs638734	chr1:42460581	G/A	cg10197057	chr1:42612518	NA	0.44	4.72	0.44	8.15e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs11711311	0.866	rs13313893	chr3:113400856	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.57	-4.76	-0.44	7.01e-6	IgG glycosylation;
THYM	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs2070488	0.965	rs35091896	chr3:38443320	G/A	cg24069376	chr3:38537580	EXOG	0.63	6.41	0.55	5.5e-9	Electrocardiographic conduction measures;
THYM	cis	rs288326	0.561	rs17265894	chr2:183858168	A/G	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs11711311	1.000	rs9288982	chr3:113470149	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.63	-5.49	-0.49	3.29e-7	IgG glycosylation;
THYM	cis	rs35995292	1.000	rs10266891	chr7:38914805	A/G	cg19166347	chr7:37955598	SFRP4	0.57	4.55	0.42	1.58e-5	Subjective well-being (multi-trait analysis);
THYM	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.44e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2637266	1.000	rs1873461	chr10:78338966	A/C	cg18941641	chr10:78392320	NA	-0.8	-6.99	-0.58	3.86e-10	Pulmonary function;
THYM	cis	rs9309711	0.737	rs9284795	chr2:3492065	G/A	cg10845886	chr2:3471009	TTC15	-0.59	-4.78	-0.44	6.48e-6	Neurofibrillary tangles;
THYM	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg15744005	chr10:104629667	AS3MT	-0.78	-7.33	-0.6	7.48e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg00278517	chr6:167070616	RPS6KA2	0.35	4.58	0.42	1.44e-5	Crohn's disease;
THYM	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg00786635	chr1:25594202	NA	0.9	7.27	0.6	1.02e-10	Erythrocyte sedimentation rate;
THYM	cis	rs13006833	0.668	rs906916	chr2:191166212	G/A	cg21644426	chr2:191273491	MFSD6	0.66	4.64	0.43	1.11e-5	Urinary metabolites;
THYM	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg25251562	chr2:3704773	ALLC	-1.26	-9.68	-0.7	8.04e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs7091068	0.532	rs1018634	chr10:95401292	G/A	cg20715218	chr10:95462985	C10orf4	-0.7	-5.06	-0.46	2.06e-6	Urinary tract infection frequency;
THYM	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg10515332	chr4:99064459	C4orf37	0.58	4.65	0.43	1.09e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13082711	0.558	rs640912	chr3:27364092	C/A	cg02860705	chr3:27208620	NA	0.61	4.72	0.44	8.28e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg04362960	chr10:104952993	NT5C2	0.58	4.82	0.44	5.34e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs995000	0.868	rs880694	chr1:63173284	C/T	cg06896770	chr1:63153194	DOCK7	-0.68	-4.86	-0.45	4.62e-6	Triglyceride levels;
THYM	cis	rs17597773	0.674	rs2279638	chr1:221001787	G/A	cg16008148	chr1:221062819	NA	0.43	4.47	0.42	2.2e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6430585	0.527	rs1446586	chr2:136407445	C/T	cg07169764	chr2:136633963	MCM6	-0.97	-9.0	-0.68	2.22e-14	Corneal structure;
THYM	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28595532	0.920	rs17325017	chr4:119774607	A/G	cg11846333	chr4:119757529	SEC24D	1.45	5.08	0.46	1.92e-6	Cannabis dependence symptom count;
THYM	cis	rs7729447	0.813	rs4867470	chr5:32692536	C/A	cg16267343	chr5:32710456	NPR3	0.8	7.25	0.6	1.13e-10	Blood pressure;
THYM	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs7107174	0.579	rs10793299	chr11:78018954	T/A	cg02023728	chr11:77925099	USP35	0.67	5.86	0.52	6.61e-8	Testicular germ cell tumor;
THYM	cis	rs6842047	1.000	rs4862665	chr4:187136142	C/T	cg02012338	chr4:187126139	CYP4V2	-1.02	-4.82	-0.44	5.36e-6	Blood protein levels;
THYM	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg13683864	chr3:40499215	RPL14	0.93	9.65	0.7	9.33e-16	Renal cell carcinoma;
THYM	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs10158481	0.759	rs2143159	chr1:25480280	G/C	cg09264742	chr1:25757510	TMEM57	-0.69	-5.06	-0.46	2.07e-6	Urate levels in obese individuals;
THYM	cis	rs7799006	0.722	rs33981648	chr7:2288669	T/C	cg08027265	chr7:2291960	NA	-0.43	-4.93	-0.45	3.54e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6138458	0.626	rs6050261	chr20:25014206	C/T	cg26195577	chr20:24973756	C20orf3	0.73	5.83	0.51	7.75e-8	Blood protein levels;
THYM	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg09359103	chr1:154839909	KCNN3	-0.84	-10.52	-0.73	1.28e-17	Prostate cancer;
THYM	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg05973401	chr12:123451056	ABCB9	0.65	4.76	0.44	6.99e-6	Platelet count;
THYM	cis	rs17006441	0.866	rs1529584	chr3:69870760	A/T	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs924712	0.844	rs973205	chr6:54729949	C/A	cg04690482	chr6:54711388	FAM83B	-0.45	-4.96	-0.45	3.09e-6	Breast cancer;
THYM	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs11089937	0.857	rs5750580	chr22:22491864	A/T	cg21401457	chr22:22472743	NA	0.58	5.13	0.47	1.55e-6	Periodontitis (PAL4Q3);
THYM	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg18252515	chr7:66147081	NA	-0.65	-4.73	-0.44	7.72e-6	Aortic root size;
THYM	cis	rs58749629	1.000	rs58749629	chr20:44571317	G/A	cg04940435	chr20:44420291	WFDC3;DNTTIP1	-0.58	-5.71	-0.51	1.28e-7	Abdominal aortic aneurysm;
THYM	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg13918804	chr1:2043761	PRKCZ	0.75	7.39	0.6	5.78e-11	Height;
THYM	cis	rs713587	0.563	rs2384057	chr2:25100167	C/G	cg15423357	chr2:25149977	NA	0.62	5.93	0.52	4.94e-8	Body mass index in non-asthmatics;
THYM	trans	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg26043149	chr18:55253948	FECH	1.16	10.82	0.74	2.98e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs6754311	0.731	rs218174	chr2:136658345	C/T	cg04750100	chr2:136595281	LCT	-0.59	-6.31	-0.54	8.84e-9	Mosquito bite size;
THYM	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.71	-4.56	-0.42	1.52e-5	Mean platelet volume;
THYM	cis	rs539096	0.692	rs7549094	chr1:44213178	C/A	cg15962314	chr1:44399869	ARTN	0.47	5.05	0.46	2.16e-6	Intelligence (multi-trait analysis);
THYM	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.76	6.61	0.56	2.23e-9	Aortic root size;
THYM	cis	rs6456042	0.893	rs3127422	chr6:166539070	G/A	cg11088901	chr6:166572345	T	-0.52	-4.9	-0.45	3.93e-6	Asthma;
THYM	cis	rs7122937	1.000	rs12296050	chr11:2489342	C/T	cg27115973	chr11:2481206	KCNQ1	0.57	6.21	0.54	1.38e-8	QT interval;
THYM	cis	rs2820651	0.708	rs17156347	chr10:1478900	A/T	cg02445968	chr10:1449028	ADARB2	-1.03	-5.43	-0.49	4.25e-7	Migraine with aura;
THYM	cis	rs13102973	0.666	rs10007311	chr4:135898716	A/T	cg14419869	chr4:135874104	NA	0.71	5.88	0.52	6.08e-8	Subjective well-being;
THYM	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg17063962	chr7:91808500	NA	-1.13	-12.38	-0.79	1.56e-21	Breast cancer;
THYM	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg08999081	chr20:33150536	PIGU	0.57	4.78	0.44	6.41e-6	Coronary artery disease;
THYM	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg15691649	chr6:25882328	NA	-0.79	-6.03	-0.53	3.06e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg23730037	chr7:158596552	ESYT2	-0.55	-5.54	-0.49	2.73e-7	Height;
THYM	cis	rs863345	0.625	rs6427439	chr1:158460357	C/A	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs6987853	0.966	rs2084709	chr8:42423190	A/G	cg09913449	chr8:42400586	C8orf40	0.85	8.53	0.66	2.3e-13	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7432375	0.901	rs35874192	chr3:136470004	G/C	cg21827317	chr3:136751795	NA	-0.59	-5.0	-0.46	2.58e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-5.77	-0.51	1e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.31	-0.48	7.34e-7	Menopause (age at onset);
THYM	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg04476341	chr5:669733	TPPP	0.48	4.86	0.45	4.54e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs9677476	0.779	rs12612219	chr2:232107363	G/T	cg07929768	chr2:232055508	NA	0.59	5.02	0.46	2.45e-6	Food antigen IgG levels;
THYM	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg00814883	chr7:100076585	TSC22D4	-0.96	-6.44	-0.55	4.85e-9	Platelet count;
THYM	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg23131131	chr22:24373011	LOC391322	-0.74	-5.28	-0.48	8.23e-7	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg24253500	chr15:84953950	NA	0.58	4.81	0.44	5.64e-6	Schizophrenia;
THYM	cis	rs946836	0.537	rs7529370	chr1:48402367	G/A	cg18376692	chr1:48452465	NA	-0.5	-4.97	-0.45	2.94e-6	White matter integrity;
THYM	cis	rs7115242	0.800	rs7131536	chr11:116999446	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.87	4.82	0.44	5.47e-6	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
THYM	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg17105886	chr17:28927953	LRRC37B2	1.25	6.76	0.57	1.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg16031515	chr1:205743344	RAB7L1	-0.48	-4.86	-0.45	4.61e-6	Menarche (age at onset);
THYM	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	4.59	0.43	1.35e-5	Aortic root size;
THYM	cis	rs3771570	1.000	rs56222556	chr2:242364119	G/A	cg21155796	chr2:242212141	HDLBP	1.25	6.07	0.53	2.57e-8	Prostate cancer;
THYM	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg26384229	chr12:38710491	ALG10B	0.94	7.62	0.62	1.86e-11	Bladder cancer;
THYM	cis	rs7106204	0.609	rs16912369	chr11:24297601	C/T	ch.11.24196551F	chr11:24239977	NA	0.99	6.09	0.53	2.41e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg25072359	chr17:41440525	NA	0.66	4.53	0.42	1.7e-5	Menopause (age at onset);
THYM	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg27170947	chr2:26402098	FAM59B	-0.86	-6.63	-0.56	2.07e-9	Gut microbiome composition (summer);
THYM	cis	rs7426056	0.671	rs716611	chr2:204606774	T/C	cg07930752	chr2:204569955	CD28	-0.74	-5.21	-0.47	1.11e-6	Primary sclerosing cholangitis;
THYM	cis	rs800586	0.788	rs800575	chr8:116715389	A/G	cg04656070	chr8:116661063	TRPS1	-0.48	-4.61	-0.43	1.26e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg21433313	chr16:3507492	NAT15	0.53	4.45	0.42	2.34e-5	Body mass index (adult);
THYM	cis	rs2562456	0.917	rs2562466	chr19:21714204	C/T	cg21751540	chr19:21541537	ZNF738	0.67	4.66	0.43	1.04e-5	Pain;
THYM	cis	rs728616	0.867	rs55666905	chr10:81953639	C/T	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4930776	0.865	rs435675	chr12:5764916	A/G	cg02086166	chr12:5775618	ANO2	0.57	5.45	0.49	3.94e-7	Plasma clusterin levels;
THYM	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg16624210	chr5:671434	TPPP	0.83	6.19	0.54	1.54e-8	Obesity-related traits;
THYM	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.17	-9.02	-0.68	2.06e-14	Platelet count;
THYM	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg02527881	chr3:46936655	PTH1R	-0.61	-5.7	-0.51	1.33e-7	Colorectal cancer;
THYM	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-4.63	-0.43	1.15e-5	Mood instability;
THYM	cis	rs713587	0.563	rs7605335	chr2:25109317	G/A	cg15423357	chr2:25149977	NA	0.61	6.11	0.53	2.19e-8	Body mass index in non-asthmatics;
THYM	cis	rs2730245	0.527	rs2527205	chr7:158706393	G/T	cg11984989	chr7:158649758	WDR60	-1.01	-8.5	-0.66	2.65e-13	Height;
THYM	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg06009448	chr7:1102226	C7orf50	0.46	5.2	0.47	1.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.63	4.46	0.42	2.28e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4866334	1.000	rs77016925	chr5:18487933	T/C	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs4851313	0.527	rs10183150	chr2:100939117	A/G	cg08017756	chr2:100939284	LONRF2	-0.74	-7.88	-0.63	5.29e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7404928	0.678	rs28435782	chr16:23925306	A/G	cg26685404	chr16:23957272	PRKCB	0.6	6.79	0.57	9.51e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6570726	0.791	rs10457788	chr6:145921136	T/A	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17253792	0.822	rs74824071	chr14:56095142	T/G	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs3126085	1.000	rs2338556	chr1:152309427	T/A	cg26020982	chr1:152196106	HRNR	-0.36	-4.95	-0.45	3.19e-6	Atopic dermatitis;
THYM	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg10802521	chr3:52805072	NEK4	-0.75	-7.03	-0.58	3.15e-10	Electroencephalogram traits;
THYM	cis	rs2354432	0.556	rs1932979	chr1:146708912	A/G	cg25205988	chr1:146714368	CHD1L	-1.02	-5.31	-0.48	7.2e-7	Mitochondrial DNA levels;
THYM	cis	rs11771526	0.892	rs11764802	chr7:32372978	C/T	cg27511599	chr7:32358540	NA	0.75	5.02	0.46	2.42e-6	Body mass index;
THYM	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.22	-0.47	1.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17604090	0.536	rs112165062	chr7:29687592	C/T	cg19413766	chr7:29689036	LOC646762	-0.93	-5.09	-0.46	1.77e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg15744005	chr10:104629667	AS3MT	0.91	9.63	0.7	1.04e-15	Waist circumference;Hip circumference;
THYM	cis	rs7177699	0.557	rs11072807	chr15:79111517	A/G	cg15571903	chr15:79123663	NA	0.58	6.53	0.56	3.25e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs4788570	0.513	rs2113223	chr16:71607915	A/G	cg06353428	chr16:71660113	MARVELD3	-1.44	-8.01	-0.64	2.84e-12	Intelligence (multi-trait analysis);
THYM	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg13010199	chr12:38710504	ALG10B	0.71	5.77	0.51	9.75e-8	Heart rate;
THYM	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg11752832	chr7:134001865	SLC35B4	-0.68	-4.63	-0.43	1.14e-5	Mean platelet volume;
THYM	cis	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg21775007	chr8:11205619	TDH	-0.67	-5.21	-0.47	1.08e-6	Retinal vascular caliber;
THYM	cis	rs6032067	0.527	rs6017490	chr20:43736369	C/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.51	-4.52	-0.42	1.81e-5	Blood protein levels;
THYM	cis	rs6032067	0.852	rs17424613	chr20:43806441	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg24060327	chr5:131705240	SLC22A5	0.8	6.52	0.56	3.35e-9	Breast cancer;
THYM	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg13880726	chr7:1868755	MAD1L1	-0.68	-4.54	-0.42	1.64e-5	Bipolar disorder;
THYM	cis	rs9807989	0.507	rs6743516	chr2:103036335	A/G	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs2862064	1.000	rs6555787	chr5:156433699	T/C	cg12943317	chr5:156479607	HAVCR1	-0.86	-5.28	-0.48	8.3e-7	Platelet count;
THYM	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg07648498	chr16:89883185	FANCA	0.64	4.74	0.44	7.6e-6	Vitiligo;
THYM	cis	rs8064299	0.597	rs6501736	chr17:72775358	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.88	8.63	0.66	1.37e-13	Monocyte count;
THYM	cis	rs1538970	1.000	rs61791368	chr1:45867944	T/C	cg05343316	chr1:45956843	TESK2	0.72	4.69	0.43	9.29e-6	Platelet count;
THYM	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4664308	0.618	rs4665138	chr2:160890427	C/T	cg03641300	chr2:160917029	PLA2R1	-0.62	-5.35	-0.48	6.02e-7	Idiopathic membranous nephropathy;
THYM	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg25811766	chr13:21894605	NA	0.72	6.13	0.53	1.96e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg07870213	chr5:140052090	DND1	-0.69	-8.1	-0.64	1.86e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7107174	1.000	rs10793303	chr11:78060750	G/A	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs9640161	0.830	rs12703061	chr7:150062545	T/C	cg11327659	chr7:150037044	RARRES2	0.41	4.77	0.44	6.62e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg07075026	chr17:47091521	IGF2BP1	-0.55	-5.82	-0.51	7.91e-8	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs714031	0.867	rs5750868	chr22:40063012	G/A	cg21377881	chr22:40064566	CACNA1I	-0.67	-5.78	-0.51	9.54e-8	Schizophrenia;
THYM	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg06558623	chr16:89946397	TCF25	1.34	5.59	0.5	2.16e-7	Skin colour saturation;
THYM	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg03762994	chr17:6899332	ALOX12	0.75	10.73	0.74	4.6e-18	Tonsillectomy;
THYM	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg12908607	chr1:44402522	ARTN	-0.52	-4.67	-0.43	9.88e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs6456156	0.846	rs204293	chr6:167514481	T/C	cg09487078	chr6:167525398	CCR6	0.46	5.07	0.46	1.96e-6	Primary biliary cholangitis;
THYM	cis	rs12208915	0.848	rs9350786	chr6:79517306	G/T	cg05283184	chr6:79620031	NA	0.73	4.77	0.44	6.59e-6	Left atrial antero-posterior diameter;
THYM	cis	rs854765	0.624	rs7359509	chr17:17741875	A/G	cg04398451	chr17:18023971	MYO15A	0.84	7.62	0.62	1.84e-11	Total body bone mineral density;
THYM	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14893161	chr1:205819251	PM20D1	0.97	10.53	0.73	1.25e-17	Menarche (age at onset);
THYM	cis	rs73086581	0.947	rs73084523	chr20:3875626	T/C	cg02187196	chr20:3869020	PANK2	0.39	4.62	0.43	1.2e-5	Response to antidepressants in depression;
THYM	cis	rs886774	0.526	rs4598195	chr7:107503441	A/C	cg23293999	chr7:106826042	HBP1	-0.59	-4.59	-0.43	1.36e-5	Ulcerative colitis;
THYM	cis	rs9788721	0.836	rs72738718	chr15:78735438	G/C	cg18825076	chr15:78729989	IREB2	-0.66	-6.19	-0.54	1.54e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs6980334	0.679	rs2306847	chr7:137798593	A/T	cg11874123	chr7:137028198	PTN	0.65	4.72	0.44	8.26e-6	Blood metabolite ratios;
THYM	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-6.98	-0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	cis	rs11089937	0.616	rs5757247	chr22:22531572	T/C	cg06866756	chr22:22471216	NA	-0.44	-4.75	-0.44	7.25e-6	Periodontitis (PAL4Q3);
THYM	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9790314	0.690	rs9860738	chr3:160843290	G/A	cg03342759	chr3:160939853	NMD3	-0.6	-4.47	-0.42	2.18e-5	Morning vs. evening chronotype;
THYM	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg06636001	chr8:8085503	FLJ10661	0.62	5.23	0.47	1.01e-6	Mood instability;
THYM	cis	rs3806843	0.900	rs2531341	chr5:140130894	C/T	cg19875535	chr5:140030758	IK	-0.58	-4.52	-0.42	1.76e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.32	0.54	8.42e-9	Platelet count;
THYM	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg13609457	chr4:120235615	NA	0.58	5.2	0.47	1.13e-6	Corneal astigmatism;
THYM	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg26924012	chr15:45694286	SPATA5L1	1.11	9.96	0.71	1.98e-16	Homoarginine levels;
THYM	cis	rs7804356	0.871	rs6461963	chr7:26772491	G/A	cg24979288	chr7:27242424	NA	0.62	4.48	0.42	2.09e-5	Type 1 diabetes;
THYM	cis	rs17767294	0.708	rs72848792	chr6:27997656	A/G	cg08851530	chr6:28072375	NA	1.2	4.72	0.44	7.99e-6	Parkinson's disease;
THYM	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.92	-6.02	-0.53	3.31e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.32e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12620999	1.000	rs10803655	chr2:238075551	C/T	cg15976283	chr2:238042351	NA	0.63	4.94	0.45	3.33e-6	Systemic lupus erythematosus;
THYM	cis	rs6430585	0.583	rs4988145	chr2:136632300	A/C	cg04750100	chr2:136595281	LCT	0.57	5.28	0.48	8.04e-7	Corneal structure;
THYM	cis	rs2762353	0.526	rs3936052	chr6:25715534	A/G	cg03517284	chr6:25882590	NA	-0.66	-4.65	-0.43	1.09e-5	Blood metabolite levels;
THYM	cis	rs7578361	0.879	rs12694153	chr2:150392946	C/T	cg17961725	chr2:150454027	NA	0.92	6.51	0.56	3.61e-9	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs12410462	0.581	rs77430808	chr1:227540880	C/T	cg23173402	chr1:227635558	NA	0.66	5.15	0.47	1.41e-6	Major depressive disorder;
THYM	cis	rs1215050	0.740	rs783945	chr4:99014394	G/A	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2404602	0.684	rs2454451	chr15:76861461	G/T	cg23625390	chr15:77176239	SCAPER	0.78	5.67	0.5	1.56e-7	Blood metabolite levels;
THYM	cis	rs6087990	0.806	rs875041	chr20:31383530	C/T	cg13636640	chr20:31349939	DNMT3B	0.93	10.39	0.73	2.42e-17	Ulcerative colitis;
THYM	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg10047753	chr17:41438598	NA	1.21	11.66	0.77	5.04e-20	Menopause (age at onset);
THYM	cis	rs12200560	0.505	rs9400166	chr6:97077101	G/A	cg06623918	chr6:96969491	KIAA0776	0.78	6.01	0.52	3.39e-8	Coronary heart disease;
THYM	cis	rs2039659	0.679	rs9547334	chr13:86283487	G/A	cg25308322	chr13:86268291	NA	0.61	5.14	0.47	1.45e-6	Blood osmolality (transformed sodium);
THYM	cis	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg07460842	chr6:66804631	NA	0.8	5.12	0.47	1.57e-6	Exhaled nitric oxide output;
THYM	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg00310523	chr12:86230176	RASSF9	0.61	5.31	0.48	7.29e-7	Major depressive disorder;
THYM	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg13010199	chr12:38710504	ALG10B	0.65	4.65	0.43	1.06e-5	Morning vs. evening chronotype;
THYM	cis	rs9324022	0.929	rs9635298	chr14:101172542	C/T	cg18089426	chr14:101175970	NA	0.78	4.88	0.45	4.25e-6	Plateletcrit;
THYM	cis	rs1729951	0.575	rs747842	chr3:136703121	A/C	cg21827317	chr3:136751795	NA	0.76	6.74	0.57	1.23e-9	Neuroticism;
THYM	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-5.42	-0.49	4.49e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs11089937	0.667	rs10483107	chr22:22505429	G/A	cg21401457	chr22:22472743	NA	0.56	4.47	0.42	2.14e-5	Periodontitis (PAL4Q3);
THYM	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg02038168	chr22:39784481	NA	-0.67	-5.43	-0.49	4.32e-7	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg11764359	chr7:65958608	NA	0.8	6.58	0.56	2.51e-9	Aortic root size;
THYM	cis	rs2046867	0.908	rs868336	chr3:72818165	A/C	cg25664220	chr3:72788482	NA	-0.81	-6.15	-0.53	1.81e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.14	0.47	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2963155	0.518	rs72801054	chr5:142687742	T/C	cg17617527	chr5:142782415	NR3C1	1.21	5.49	0.49	3.31e-7	Breast cancer;
THYM	cis	rs11608355	1.000	rs2075439	chr12:109859374	A/G	cg11367159	chr12:110044531	NA	0.66	6.29	0.54	9.83e-9	Neuroticism;
THYM	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg25566285	chr7:158114605	PTPRN2	0.89	10.22	0.72	5.47e-17	Calcium levels;
THYM	cis	rs3008870	1.000	rs2985797	chr1:67431499	C/T	cg02640540	chr1:67518911	SLC35D1	-0.63	-4.54	-0.42	1.65e-5	Lymphocyte percentage of white cells;
THYM	cis	rs12282928	0.959	rs871249	chr11:48284477	G/A	cg22827986	chr11:48284249	OR4X1	0.51	5.43	0.49	4.28e-7	Migraine - clinic-based;
THYM	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7940866	0.838	rs1991898	chr11:130801786	C/G	cg12179176	chr11:130786555	SNX19	-0.71	-5.6	-0.5	2.1e-7	Schizophrenia;
THYM	cis	rs79387448	0.745	rs7582378	chr2:103162263	C/A	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs4343996	0.536	rs1554497	chr7:3415446	G/T	cg21248987	chr7:3385318	SDK1	-0.4	-4.91	-0.45	3.72e-6	Motion sickness;
THYM	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg20476274	chr7:133979776	SLC35B4	0.68	4.55	0.42	1.58e-5	Mean platelet volume;
THYM	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg02725872	chr8:58115012	NA	-1.12	-7.66	-0.62	1.56e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg10518543	chr12:38710700	ALG10B	-0.59	-5.0	-0.46	2.58e-6	Morning vs. evening chronotype;
THYM	cis	rs7616559	0.924	rs9867759	chr3:156725208	G/C	cg15697575	chr3:156784781	NA	0.4	5.03	0.46	2.35e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22496380	chr5:211416	CCDC127	-1.28	-7.77	-0.62	9.06e-12	Breast cancer;
THYM	cis	rs7027203	0.828	rs4344139	chr9:96600298	T/C	cg13679303	chr9:96623674	NA	-0.5	-5.08	-0.46	1.89e-6	DNA methylation (variation);
THYM	cis	rs10208940	0.614	rs12713650	chr2:68835086	T/C	cg09157127	chr2:69201416	GKN1	0.89	4.71	0.43	8.61e-6	Urate levels in lean individuals;
THYM	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg08847533	chr14:75593920	NEK9	-0.99	-10.92	-0.75	1.78e-18	Height;
THYM	cis	rs11225247	0.881	rs79796684	chr11:102257170	T/C	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg06064525	chr11:970664	AP2A2	-0.35	-6.7	-0.57	1.49e-9	Alzheimer's disease (late onset);
THYM	cis	rs7098414	0.530	rs4146515	chr10:82116602	G/A	cg01528321	chr10:82214614	TSPAN14	0.56	4.73	0.44	7.72e-6	Post bronchodilator FEV1;
THYM	cis	rs3857067	0.806	rs4560373	chr4:95113229	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg09165964	chr15:75287851	SCAMP5	1.07	10.24	0.72	5.15e-17	Blood trace element (Zn levels);
THYM	cis	rs2637266	1.000	rs10219107	chr10:78364369	T/C	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs8020441	0.838	rs72681662	chr14:51163884	G/A	cg04730355	chr14:51134070	SAV1	0.63	4.5	0.42	1.93e-5	Cognitive performance;
THYM	cis	rs9515201	0.818	rs9521733	chr13:111034542	C/T	cg05272587	chr13:111038400	COL4A2	0.59	4.96	0.45	3.08e-6	White matter hyperintensity burden;
THYM	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg23711669	chr6:146136114	FBXO30	0.9	8.83	0.67	5.32e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7319311	1.000	rs7319311	chr13:111030578	A/G	cg05272587	chr13:111038400	COL4A2	0.62	5.03	0.46	2.31e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg15242686	chr22:24348715	GSTTP1	-0.53	-4.89	-0.45	4.1e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg00990874	chr7:1149470	C7orf50	0.69	5.18	0.47	1.22e-6	Bronchopulmonary dysplasia;
THYM	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg05738196	chr6:26577821	NA	-0.79	-7.33	-0.6	7.47e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7172809	0.897	rs16968893	chr15:77825082	A/G	cg10437265	chr15:77819839	NA	-0.53	-4.57	-0.42	1.48e-5	Glucose homeostasis traits;
THYM	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg03676636	chr4:99064102	C4orf37	0.5	7.65	0.62	1.6e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg06074448	chr4:187884817	NA	1.0	13.48	0.81	8.89e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.44	-0.49	4.17e-7	Monocyte percentage of white cells;
THYM	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs9902453	0.765	rs3102555	chr17:28044101	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	6.53	0.56	3.17e-9	Coffee consumption (cups per day);
THYM	trans	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg25517755	chr10:38738941	LOC399744	-0.8	-7.86	-0.63	6e-12	Corneal astigmatism;
THYM	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg14345882	chr6:26364793	BTN3A2	0.58	5.49	0.49	3.39e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs17597773	0.755	rs114708296	chr1:221034313	T/G	cg16008148	chr1:221062819	NA	0.46	4.66	0.43	1.04e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9595908	0.900	rs7981943	chr13:33167891	G/T	cg12383807	chr13:33924137	NA	-0.54	-4.85	-0.45	4.85e-6	Body mass index;
THYM	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg19623624	chr10:135278901	LOC619207	-0.66	-5.32	-0.48	6.79e-7	Systemic lupus erythematosus;
THYM	trans	rs17685	0.884	rs3823882	chr7:75631913	T/C	cg19862616	chr7:65841803	NCRNA00174	-1.02	-10.99	-0.75	1.31e-18	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs778371	0.671	rs1104764	chr2:233561743	C/G	cg08000102	chr2:233561755	GIGYF2	0.82	7.45	0.61	4.19e-11	Schizophrenia;
THYM	cis	rs9633835	0.524	rs1481879	chr11:13271768	C/T	cg13286116	chr11:13302098	ARNTL	-0.72	-8.03	-0.64	2.61e-12	Body mass index;
THYM	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg13447684	chr7:1895903	MAD1L1	0.52	4.86	0.45	4.7e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg26408565	chr15:76604113	ETFA	-0.55	-4.85	-0.45	4.73e-6	Blood metabolite levels;
THYM	cis	rs10411161	0.702	rs17778790	chr19:52399559	C/T	cg25361850	chr19:52391789	ZNF577	0.74	4.96	0.45	3.14e-6	Breast cancer;
THYM	cis	rs7937682	0.602	rs503905	chr11:111390762	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.64	-4.99	-0.46	2.73e-6	Primary sclerosing cholangitis;
THYM	cis	rs28595532	0.920	rs116023344	chr4:119760263	A/G	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs1691799	0.867	rs1168343	chr12:66758581	C/T	cg16791601	chr12:66731901	HELB	-0.72	-6.82	-0.57	8.35e-10	White blood cell count (basophil);
THYM	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-10.85	-0.74	2.51e-18	Primary sclerosing cholangitis;
THYM	cis	rs4845570	0.764	rs12141652	chr1:151716711	A/T	cg18019451	chr1:151746047	TDRKH	-0.9	-5.04	-0.46	2.19e-6	Coronary artery disease;
THYM	cis	rs2916260	0.736	rs115702684	chr6:40394119	G/T	cg08415973	chr6:40346114	TDRG1	0.81	5.1	0.46	1.76e-6	Incident coronary heart disease;
THYM	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg00376283	chr12:123451042	ABCB9	0.74	5.11	0.46	1.67e-6	Neutrophil percentage of white cells;
THYM	cis	rs6840360	0.653	rs13136369	chr4:152731283	T/G	cg22705602	chr4:152727874	NA	0.67	7.78	0.62	8.74e-12	Intelligence (multi-trait analysis);
THYM	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	5.89	0.52	5.84e-8	Rheumatoid arthritis;
THYM	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg07606381	chr6:8435919	SLC35B3	0.59	4.49	0.42	1.99e-5	Motion sickness;
THYM	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg00786635	chr1:25594202	NA	0.99	8.22	0.64	1.04e-12	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg12419862	chr22:24373484	LOC391322	-0.7	-5.16	-0.47	1.36e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs3862030	0.694	rs1984795	chr10:104226830	C/T	cg00122347	chr10:104236741	TMEM180	0.48	7.24	0.6	1.14e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22496380	chr5:211416	CCDC127	-1.31	-8.26	-0.65	8.38e-13	Breast cancer;
THYM	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11644478	chr21:40555479	PSMG1	-0.77	-6.71	-0.57	1.41e-9	Cognitive function;
THYM	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15541040	chr2:3486749	NA	-0.57	-4.58	-0.43	1.43e-5	Neurofibrillary tangles;
THYM	cis	rs684232	0.644	rs1227030	chr17:619882	C/T	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.42	-4.94	-0.45	3.37e-6	Prostate cancer;
THYM	cis	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg26384229	chr12:38710491	ALG10B	-0.71	-5.66	-0.5	1.58e-7	Morning vs. evening chronotype;
THYM	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg02734326	chr4:10020555	SLC2A9	-0.74	-6.18	-0.54	1.6e-8	Bone mineral density;
THYM	cis	rs8050907	1.000	rs75117781	chr16:4654204	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.57	0.42	1.47e-5	Obesity-related traits;
THYM	trans	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2276314	0.857	rs59649576	chr18:33616075	G/T	cg19628046	chr18:33552617	C18orf21	0.74	5.43	0.49	4.29e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs11608355	0.552	rs2304549	chr12:109794875	A/G	cg11367159	chr12:110044531	NA	0.53	4.93	0.45	3.46e-6	Neuroticism;
THYM	cis	rs786425	0.530	rs882563	chr12:124210549	A/G	cg15249119	chr12:124971054	NCOR2	-0.51	-4.68	-0.43	9.53e-6	Pubertal anthropometrics;
THYM	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg06115741	chr20:33292138	TP53INP2	0.7	4.65	0.43	1.06e-5	Coronary artery disease;
THYM	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg24692254	chr21:30365293	RNF160	0.99	9.28	0.69	5.71e-15	Dental caries;
THYM	cis	rs4746818	1.000	rs4746817	chr10:70882515	T/C	cg11621586	chr10:70884670	VPS26A	1.2	7.86	0.63	5.83e-12	Left atrial antero-posterior diameter;
THYM	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg24531977	chr5:56204891	C5orf35	-1.03	-8.71	-0.67	9.42e-14	Type 2 diabetes;
THYM	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.7	-5.82	-0.51	7.84e-8	Lung cancer;
THYM	cis	rs8078723	1.000	rs3213762	chr17:38178627	A/G	cg17467752	chr17:38218738	THRA	0.84	6.77	0.57	1.04e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs9992101	0.564	rs12506745	chr4:77220837	A/C	cg20311846	chr4:77356250	SHROOM3	-0.51	-5.64	-0.5	1.71e-7	Creatinine levels;
THYM	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.85	7.62	0.62	1.88e-11	Cognitive ability;
THYM	cis	rs2985684	0.841	rs2281836	chr14:50065717	G/C	cg02151108	chr14:50098012	C14orf104	-0.72	-5.72	-0.51	1.24e-7	Carotid intima media thickness;
THYM	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs12121840	0.736	rs76593835	chr1:165531442	T/A	cg19407955	chr1:165599744	MGST3	-0.65	-4.63	-0.43	1.16e-5	Interleukin-1-receptor antagonist levels;
THYM	cis	rs7100689	0.577	rs7901663	chr10:82153488	C/G	cg01528321	chr10:82214614	TSPAN14	0.84	6.8	0.57	9.07e-10	Post bronchodilator FEV1;
THYM	cis	rs892961	0.806	rs35489990	chr17:75412312	T/C	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg14074117	chr16:1909714	C16orf73	-0.7	-4.45	-0.42	2.3e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs9867325	0.895	rs9879531	chr3:136638975	A/G	cg21827317	chr3:136751795	NA	-0.75	-5.2	-0.47	1.14e-6	Body mass index;
THYM	cis	rs62070183	1.000	rs62070183	chr17:31164367	T/C	cg02981443	chr17:31254875	TMEM98	-0.54	-4.78	-0.44	6.31e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs7610301	1.000	rs4683248	chr3:46643053	C/T	cg22951056	chr3:46887651	NA	-0.77	-5.06	-0.46	2.06e-6	Blood protein levels;
THYM	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg27087555	chr16:88793112	FAM38A	-1.21	-7.36	-0.6	6.56e-11	Plateletcrit;
THYM	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg23711669	chr6:146136114	FBXO30	0.91	8.87	0.67	4.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11118844	0.793	rs17010720	chr1:221946403	A/G	cg04222084	chr1:221915650	DUSP10	-1.02	-5.31	-0.48	7.05e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg04034577	chr2:241836375	C2orf54	-0.43	-8.0	-0.63	3.07e-12	Urinary metabolites;
THYM	trans	rs4866334	1.000	rs77552202	chr5:18489043	A/T	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg00277334	chr10:82204260	NA	-0.83	-10.18	-0.72	6.99e-17	Post bronchodilator FEV1;
THYM	cis	rs17030434	0.784	rs8180349	chr4:154657038	T/C	cg14289246	chr4:154710475	SFRP2	-0.74	-5.52	-0.49	2.93e-7	Electrocardiographic conduction measures;
THYM	cis	rs854765	0.624	rs12450799	chr17:17730201	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-5.43	-0.49	4.27e-7	Total body bone mineral density;
THYM	cis	rs28595532	0.920	rs116401323	chr4:119721727	C/T	cg14228332	chr4:119757509	SEC24D	1.46	5.56	0.5	2.47e-7	Cannabis dependence symptom count;
THYM	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.36	0.69	3.89e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg01304814	chr3:48885189	PRKAR2A	0.96	4.86	0.45	4.55e-6	Cognitive function;
THYM	cis	rs61931739	1.000	rs12298806	chr12:34036528	C/G	cg10856724	chr12:34555212	NA	0.63	5.33	0.48	6.57e-7	Morning vs. evening chronotype;
THYM	cis	rs34375054	0.624	rs4073534	chr12:125671800	C/T	cg25124228	chr12:125621409	AACS	-0.66	-4.73	-0.44	7.7e-6	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg11366901	chr6:160182831	ACAT2	1.0	8.3	0.65	7.06e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7192750	0.562	rs4788573	chr16:71921946	A/C	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs1345301	1.000	rs1420093	chr2:102870458	T/C	cg03938978	chr2:103052716	IL18RAP	-0.6	-6.0	-0.52	3.58e-8	Waist circumference;
THYM	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg18105134	chr13:113819100	PROZ	-0.99	-9.19	-0.69	8.83e-15	Platelet distribution width;
THYM	cis	rs6032067	0.929	rs13039108	chr20:43829584	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg14186256	chr22:23484241	RTDR1	1.07	10.83	0.74	2.84e-18	Bone mineral density;
THYM	cis	rs2404602	0.735	rs2048856	chr15:76800083	C/T	cg23625390	chr15:77176239	SCAPER	-0.63	-4.71	-0.43	8.52e-6	Blood metabolite levels;
THYM	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg13852791	chr20:30311386	BCL2L1	0.71	5.21	0.47	1.09e-6	Mean corpuscular hemoglobin;
THYM	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg03161606	chr19:29218774	NA	0.57	4.7	0.43	8.84e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg18811423	chr2:55921094	PNPT1	-0.69	-6.41	-0.55	5.6e-9	Metabolic syndrome;
THYM	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg22535103	chr8:58192502	C8orf71	-0.86	-4.82	-0.44	5.4e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg15247329	chr7:2764246	NA	-0.74	-6.28	-0.54	1.01e-8	Height;
THYM	cis	rs7172809	0.573	rs2292594	chr15:77515140	T/C	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs11148252	0.766	rs74697307	chr13:52897573	C/T	cg00495681	chr13:53174319	NA	-0.72	-6.48	-0.55	3.97e-9	Lewy body disease;
THYM	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg10803722	chr21:46713166	LOC642852	-0.39	-5.36	-0.48	5.86e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg18876405	chr7:65276391	NA	0.67	5.93	0.52	4.91e-8	Aortic root size;
THYM	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg14784868	chr12:69753453	YEATS4	-0.79	-6.48	-0.55	4.06e-9	Blood protein levels;
THYM	cis	rs950880	0.710	rs17027255	chr2:103090127	C/T	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.74	-0.44	7.54e-6	Serum protein levels (sST2);
THYM	cis	rs6601450	0.522	rs10095190	chr8:10239612	C/G	cg02525722	chr8:10404760	NA	0.5	4.64	0.43	1.09e-5	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs995000	0.899	rs11207974	chr1:62949960	T/C	cg06896770	chr1:63153194	DOCK7	0.93	7.76	0.62	9.83e-12	Triglyceride levels;
THYM	cis	rs9902453	0.967	rs28792710	chr17:28450015	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.83	0.44	5.26e-6	Coffee consumption (cups per day);
THYM	cis	rs7599312	1.000	rs7599312	chr2:213413231	C/T	cg20637307	chr2:213403960	ERBB4	0.7	4.47	0.42	2.2e-5	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	5.54	0.49	2.69e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs10779751	1.000	rs2076655	chr1:11289161	A/G	cg08854313	chr1:11322531	MTOR	-1.01	-9.78	-0.71	4.97e-16	Body mass index;
THYM	cis	rs600231	0.708	rs682845	chr11:65254201	A/G	cg17120908	chr11:65337727	SSSCA1	-0.6	-4.69	-0.43	9.1e-6	Bone mineral density;
THYM	cis	rs16866061	1.000	rs3768886	chr2:225450161	G/C	cg12698349	chr2:225449008	CUL3	1.14	10.47	0.73	1.64e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs4595586	0.545	rs7972590	chr12:39376615	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs7084402	0.967	rs1658418	chr10:60333003	G/A	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg22681709	chr2:178499509	PDE11A	-0.53	-5.09	-0.46	1.79e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4343996	1.000	rs6980323	chr7:3356207	A/G	cg21248987	chr7:3385318	SDK1	-0.39	-4.74	-0.44	7.62e-6	Motion sickness;
THYM	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs36051895	0.625	rs12340333	chr9:5176215	C/G	cg02405213	chr9:5042618	JAK2	-0.99	-10.66	-0.74	6.38e-18	Pediatric autoimmune diseases;
THYM	cis	rs113835537	0.529	rs2305533	chr11:66298623	A/C	cg24851651	chr11:66362959	CCS	0.71	4.84	0.44	4.96e-6	Airway imaging phenotypes;
THYM	cis	rs11651000	0.817	rs11657479	chr17:45822901	T/C	cg25856473	chr17:45174155	NA	0.61	4.73	0.44	7.67e-6	IgG glycosylation;
THYM	cis	rs747782	0.582	rs11039571	chr11:48207259	G/A	cg24672777	chr11:48374446	OR4C45	-1.08	-6.32	-0.54	8.31e-9	Intraocular pressure;
THYM	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.52	4.6	0.43	1.31e-5	Blood metabolite levels;
THYM	cis	rs611744	0.967	rs603571	chr8:109213893	A/C	cg21045802	chr8:109455806	TTC35	0.59	5.21	0.47	1.07e-6	Dupuytren's disease;
THYM	cis	rs9902453	0.753	rs7226121	chr17:28208125	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	5.14	0.47	1.47e-6	Coffee consumption (cups per day);
THYM	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs7809950	1.000	rs17154104	chr7:107090698	C/T	cg23024343	chr7:107201750	COG5	-0.92	-8.11	-0.64	1.73e-12	Coronary artery disease;
THYM	cis	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg13609457	chr4:120235615	NA	0.63	5.07	0.46	1.97e-6	Corneal astigmatism;
THYM	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12379764	chr21:47803548	PCNT	0.7	4.94	0.45	3.31e-6	Testicular germ cell tumor;
THYM	trans	rs4650994	1.000	rs12138541	chr1:178518707	G/A	cg05059571	chr16:84539110	KIAA1609	-0.75	-8.02	-0.64	2.68e-12	HDL cholesterol levels;HDL cholesterol;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg03310691	chr10:34505321	PARD3	-0.94	-7.45	-0.61	4.29e-11	Depressive symptoms;
THYM	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14159672	chr1:205819179	PM20D1	0.83	8.52	0.66	2.38e-13	Menarche (age at onset);
THYM	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg20503657	chr10:835505	NA	1.11	7.73	0.62	1.13e-11	Eosinophil percentage of granulocytes;
THYM	cis	rs7833986	0.501	rs72653941	chr8:56942247	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.55	6.55	0.56	2.92e-9	Height;
THYM	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg08901578	chr4:187885870	NA	0.64	6.03	0.53	3.1e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg26384229	chr12:38710491	ALG10B	-0.61	-4.6	-0.43	1.29e-5	Heart rate;
THYM	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg06271696	chr7:157225062	NA	-0.63	-4.75	-0.44	7.09e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs8050907	0.744	rs9938647	chr16:4572151	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.13	4.76	0.44	6.97e-6	Obesity-related traits;
THYM	trans	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg13615516	chr5:77269221	NA	0.81	7.4	0.6	5.35e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs67981189	0.529	rs2526858	chr14:71412340	T/C	cg15910301	chr14:71632612	NA	-0.56	-4.88	-0.45	4.23e-6	Schizophrenia;
THYM	cis	rs11690935	0.959	rs7586207	chr2:172671094	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.83	-6.52	-0.56	3.44e-9	Schizophrenia;
THYM	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg05872129	chr22:39784769	NA	-1.09	-12.07	-0.78	6.85e-21	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.596	rs7792654	chr7:124653637	A/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs11096990	0.634	rs2381371	chr4:39273034	A/G	cg24403649	chr4:39172243	NA	0.66	5.75	0.51	1.09e-7	Cognitive function;
THYM	cis	rs765787	0.530	rs2554457	chr15:45520926	G/A	cg24006582	chr15:45444508	DUOX1	-0.79	-6.67	-0.56	1.71e-9	Uric acid levels;
THYM	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg20887711	chr4:1340912	KIAA1530	0.68	6.06	0.53	2.77e-8	Longevity;
THYM	cis	rs10979	0.965	rs9496679	chr6:143896741	G/T	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg12564285	chr5:131593104	PDLIM4	0.44	4.78	0.44	6.47e-6	Breast cancer;
THYM	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg17366294	chr4:99064904	C4orf37	0.54	6.31	0.54	8.73e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.56	-4.75	-0.44	7.08e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg23708337	chr7:1209742	NA	0.77	5.93	0.52	4.79e-8	Longevity;Endometriosis;
THYM	cis	rs800586	0.500	rs2737242	chr8:116657727	T/C	cg04656070	chr8:116661063	TRPS1	-0.56	-6.66	-0.56	1.75e-9	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9677476	0.863	rs11558174	chr2:232072912	T/C	cg23338755	chr2:231921595	PSMD1	0.69	5.11	0.46	1.68e-6	Food antigen IgG levels;
THYM	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg25817165	chr18:72167213	CNDP2	-0.99	-10.48	-0.73	1.53e-17	Refractive error;
THYM	cis	rs6032067	0.641	rs17423416	chr20:43758144	G/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.72	-7.65	-0.62	1.63e-11	Blood protein levels;
THYM	cis	rs10791097	0.739	rs735094	chr11:130725109	G/C	cg14779329	chr11:130786720	SNX19	0.5	5.18	0.47	1.22e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg03404566	chr17:6899310	ALOX12	-0.78	-9.22	-0.69	7.52e-15	Tonsillectomy;
THYM	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg06558623	chr16:89946397	TCF25	1.33	5.65	0.5	1.64e-7	Skin colour saturation;
THYM	cis	rs900145	0.773	rs11022755	chr11:13315049	T/C	cg13286116	chr11:13302098	ARNTL	0.59	4.56	0.42	1.54e-5	Menarche (age at onset);
THYM	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg11812906	chr14:75593930	NEK9	0.86	7.67	0.62	1.45e-11	Height;
THYM	cis	rs297325	0.812	rs61881966	chr11:16772832	A/G	cg20214553	chr11:17278779	NA	0.4	4.48	0.42	2.09e-5	Obesity and osteoporosis;
THYM	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg08901578	chr4:187885870	NA	-0.68	-6.63	-0.56	2.07e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28785552	0.966	rs7247272	chr19:53236331	C/T	cg22067481	chr19:53234126	ZNF611	1.06	12.06	0.78	7.32e-21	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs4595586	0.545	rs61939641	chr12:39378001	T/C	cg13010199	chr12:38710504	ALG10B	0.61	4.65	0.43	1.05e-5	Morning vs. evening chronotype;
THYM	cis	rs236352	0.521	rs6457963	chr6:36883540	A/G	cg03410223	chr6:36853544	C6orf89	0.72	6.0	0.52	3.52e-8	Heart rate;
THYM	cis	rs11118346	0.501	rs1932963	chr1:219723599	C/T	cg07908999	chr1:219785142	NA	-0.44	-5.0	-0.46	2.59e-6	Height;
THYM	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg13695892	chr22:41940480	POLR3H	0.85	6.16	0.53	1.72e-8	Vitiligo;
THYM	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg07606381	chr6:8435919	SLC35B3	0.61	4.45	0.42	2.31e-5	Motion sickness;
THYM	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.88	5.64	0.5	1.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17407555	0.657	rs12505144	chr4:10270919	G/C	cg00071950	chr4:10020882	SLC2A9	0.59	5.53	0.49	2.81e-7	Schizophrenia (age at onset);
THYM	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.67	8.52	0.66	2.41e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg00129232	chr17:37814104	STARD3	0.7	4.93	0.45	3.42e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs887829	0.570	rs10175809	chr2:234596865	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-6.51	-0.56	3.47e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg15556689	chr8:8085844	FLJ10661	0.7	6.07	0.53	2.64e-8	Mood instability;
THYM	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.58	-5.08	-0.46	1.85e-6	Coronary artery disease;
THYM	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.43	0.7	2.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs67311347	0.544	rs12054197	chr3:40337562	C/T	cg24209194	chr3:40518798	ZNF619	0.55	4.6	0.43	1.29e-5	Renal cell carcinoma;
THYM	cis	rs6438424	1.000	rs7433864	chr3:117593483	C/A	cg07190778	chr3:117604296	NA	-0.4	-5.58	-0.5	2.3e-7	Menarche (age at onset);
THYM	trans	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	trans	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg18187862	chr3:45730750	SACM1L	0.88	7.2	0.59	1.4e-10	Primary sclerosing cholangitis;
THYM	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.8	8.45	0.65	3.38e-13	Lymphocyte counts;
THYM	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg03517284	chr6:25882590	NA	0.58	4.53	0.42	1.7e-5	Blood metabolite levels;
THYM	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg06873352	chr17:61820015	STRADA	-0.66	-8.23	-0.65	9.79e-13	Prudent dietary pattern;
THYM	cis	rs7772486	0.686	rs4896828	chr6:145953339	A/C	cg13319975	chr6:146136371	FBXO30	-0.65	-5.22	-0.47	1.05e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.73	-4.82	-0.44	5.35e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9972944	0.729	rs62065062	chr17:63777383	G/A	cg07283582	chr17:63770753	CCDC46	0.68	5.54	0.49	2.69e-7	Total body bone mineral density;
THYM	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg19336497	chr11:14380999	RRAS2	-0.55	-5.8	-0.51	8.54e-8	Mitochondrial DNA levels;
THYM	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg16325326	chr1:53192061	ZYG11B	0.83	7.93	0.63	4.14e-12	Monocyte count;
THYM	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg23018236	chr17:30244563	NA	-0.6	-4.45	-0.42	2.3e-5	Hip circumference adjusted for BMI;
THYM	cis	rs3772130	0.564	rs9817555	chr3:121406327	G/A	cg20356878	chr3:121714668	ILDR1	0.63	4.89	0.45	4.07e-6	Cognitive performance;
THYM	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg23958373	chr8:599963	NA	0.9	4.55	0.42	1.58e-5	IgG glycosylation;
THYM	cis	rs939574	1.000	rs11552796	chr2:220108300	T/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.32	5.96	0.52	4.29e-8	Platelet distribution width;
THYM	cis	rs1050631	0.564	rs1789549	chr18:33722425	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.28	0.48	8.32e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg07636037	chr3:49044803	WDR6	0.97	10.07	0.72	1.15e-16	Parkinson's disease;
THYM	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg12011299	chr4:100065546	ADH4	-0.73	-6.91	-0.58	5.53e-10	Alcohol dependence;
THYM	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg11764359	chr7:65958608	NA	0.78	6.09	0.53	2.42e-8	Aortic root size;
THYM	cis	rs12935418	0.672	rs1453327	chr16:81048564	A/C	cg16651780	chr16:81037892	C16orf61	-0.82	-6.36	-0.55	6.89e-9	Mean corpuscular volume;
THYM	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.09	0.53	2.35e-8	Coronary artery disease;
THYM	cis	rs10781543	0.810	rs11145756	chr9:139364585	A/G	cg14115884	chr9:139300582	SDCCAG3	0.69	6.33	0.54	7.93e-9	Monocyte percentage of white cells;
THYM	cis	rs34526934	0.608	rs2301301	chr2:177032267	T/C	cg14324370	chr2:177042789	NA	-0.7	-5.97	-0.52	4.16e-8	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs6815814	0.861	rs12233670	chr4:38787216	C/T	cg06935464	chr4:38784597	TLR10	0.71	5.22	0.47	1.06e-6	Breast cancer;
THYM	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg27394845	chr17:28928406	LRRC37B2	0.91	4.58	0.42	1.44e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg24818145	chr4:99064322	C4orf37	0.69	5.37	0.48	5.48e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4148689	0.951	rs11770639	chr7:117169601	T/A	cg17204129	chr7:117119601	CFTR	-0.68	-5.28	-0.48	8.02e-7	Gout;
THYM	cis	rs61931739	0.929	rs2389272	chr12:34067771	T/C	cg10856724	chr12:34555212	NA	0.6	5.36	0.48	5.8e-7	Morning vs. evening chronotype;
THYM	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg12310025	chr6:25882481	NA	0.77	6.2	0.54	1.44e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9595908	0.965	rs11840502	chr13:33198709	G/A	cg12383807	chr13:33924137	NA	-0.54	-4.78	-0.44	6.39e-6	Body mass index;
THYM	cis	rs72717009	0.825	rs7539468	chr1:161477066	G/A	cg23840854	chr1:161414152	NA	-1.03	-5.5	-0.49	3.16e-7	Rheumatoid arthritis;
THYM	cis	rs4595586	0.545	rs2388176	chr12:39372357	G/A	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg00106254	chr7:1943704	MAD1L1	0.49	4.49	0.42	2.01e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs6495367	1.000	rs13380109	chr15:79378775	G/A	cg17916960	chr15:79447300	NA	0.55	6.01	0.52	3.39e-8	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs860818	1.000	rs1728344	chr7:23250044	C/A	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg10589385	chr1:150898437	SETDB1	-0.63	-5.2	-0.47	1.13e-6	Melanoma;
THYM	cis	rs5167	0.566	rs204905	chr19:45460764	G/A	cg13119609	chr19:45449297	APOC2	0.64	6.12	0.53	2.13e-8	Blood protein levels;
THYM	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg05373962	chr22:49881684	NA	-0.67	-6.8	-0.57	9.16e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2213920	0.749	rs7467654	chr9:118253677	C/T	cg13918206	chr9:118159781	DEC1	0.84	4.63	0.43	1.17e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg12935359	chr14:103987150	CKB	0.58	5.77	0.51	9.99e-8	Bone mineral density;
THYM	cis	rs11098499	0.690	rs7674713	chr4:120322257	T/C	cg01778622	chr4:120419485	PDE5A	-0.59	-4.81	-0.44	5.58e-6	Corneal astigmatism;
THYM	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs5769707	0.632	rs135871	chr22:50008969	A/G	cg05373962	chr22:49881684	NA	-0.7	-6.4	-0.55	5.81e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg02524346	chr8:600233	NA	0.92	4.6	0.43	1.3e-5	IgG glycosylation;
THYM	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2637266	0.846	rs2579773	chr10:78402847	A/C	cg18941641	chr10:78392320	NA	0.6	4.79	0.44	6.07e-6	Pulmonary function;
THYM	cis	rs2637266	0.905	rs60809084	chr10:78374431	A/C	cg18941641	chr10:78392320	NA	0.6	4.79	0.44	6.09e-6	Pulmonary function;
THYM	cis	rs1978968	0.912	rs1110666	chr22:18457720	A/C	cg01550578	chr22:18484421	MICAL3	-0.6	-4.62	-0.43	1.23e-5	Presence of antiphospholipid antibodies;
THYM	cis	rs6558530	0.897	rs7838456	chr8:1707591	T/G	cg09410841	chr8:1729607	CLN8	0.67	4.91	0.45	3.85e-6	Systolic blood pressure;
THYM	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg00686598	chr14:53173677	PSMC6	1.52	7.73	0.62	1.09e-11	Alzheimer's disease (late onset);
THYM	cis	rs34638657	0.872	rs11859599	chr16:82182832	C/G	cg07307142	chr16:82071433	HSD17B2	-1.0	-7.78	-0.62	8.6e-12	Lung adenocarcinoma;
THYM	cis	rs4631830	0.900	rs7914347	chr10:51537431	C/T	cg10326726	chr10:51549505	MSMB	-0.62	-6.27	-0.54	1.07e-8	Prostate-specific antigen levels;
THYM	cis	rs4474465	0.920	rs10899526	chr11:78206157	T/C	cg19901956	chr11:77921274	USP35	0.67	4.94	0.45	3.29e-6	Alzheimer's disease (survival time);
THYM	cis	rs10982256	0.904	rs4527950	chr9:117267472	G/T	cg15903421	chr9:117267460	DFNB31	-0.57	-5.37	-0.48	5.49e-7	Bipolar disorder;
THYM	cis	rs2276314	1.000	rs16967317	chr18:33573400	A/G	cg19628046	chr18:33552617	C18orf21	0.76	5.36	0.48	5.89e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.42	4.49	0.42	2.03e-5	Hemoglobin concentration;
THYM	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg02782426	chr3:40428986	ENTPD3	-0.53	-4.66	-0.43	1.04e-5	Renal cell carcinoma;
THYM	cis	rs6032067	0.561	rs2743317	chr20:43936931	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.4	-4.48	-0.42	2.1e-5	Blood protein levels;
THYM	cis	rs300703	0.935	rs300755	chr2:228505	C/T	cg21211680	chr2:198530	NA	1.33	5.61	0.5	1.97e-7	Blood protein levels;
THYM	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg08999081	chr20:33150536	PIGU	0.73	6.56	0.56	2.86e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs6768930	0.509	rs55645723	chr3:57750240	G/A	cg24033633	chr3:57945695	NA	-0.38	-5.27	-0.48	8.55e-7	Obesity-related traits;
THYM	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg18132916	chr6:79620363	NA	-0.58	-5.27	-0.48	8.5e-7	Intelligence (multi-trait analysis);
THYM	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00908189	chr16:619842	PIGQ	1.06	9.31	0.69	5e-15	Height;
THYM	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg25703541	chr22:24373054	LOC391322	-0.85	-8.9	-0.67	3.62e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4072705	1.000	rs10760371	chr9:127452977	T/G	cg13476313	chr9:127244764	NR5A1	0.3	4.49	0.42	2.03e-5	Menarche (age at onset);
THYM	cis	rs7107174	0.892	rs10899487	chr11:78085474	G/A	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg27534772	chr1:16042836	PLEKHM2	0.53	5.9	0.52	5.65e-8	Systolic blood pressure;
THYM	cis	rs2502731	0.539	rs3003609	chr9:130984755	A/G	cg09976142	chr9:130955436	CIZ1	-0.53	-5.1	-0.46	1.72e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs9543976	1.000	rs2031236	chr13:76169777	C/T	cg01531495	chr13:76123901	UCHL3	-0.76	-4.69	-0.43	8.97e-6	Diabetic retinopathy;
THYM	cis	rs2075230	0.705	rs1619016	chr17:7550553	C/T	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.28	-4.62	-0.43	1.21e-5	Hormone measurements;
THYM	cis	rs988913	0.837	rs9475109	chr6:54861913	T/C	cg04690482	chr6:54711388	FAM83B	0.43	4.45	0.42	2.32e-5	Menarche (age at onset);
THYM	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg20283391	chr11:68216788	NA	0.61	4.85	0.45	4.82e-6	Total body bone mineral density;
THYM	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg00786635	chr1:25594202	NA	0.94	7.75	0.62	9.88e-12	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg27286337	chr10:134555280	INPP5A	0.93	7.66	0.62	1.57e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs17006441	0.834	rs9819188	chr3:69880298	A/G	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs7267979	1.000	rs6138575	chr20:25438952	G/A	cg08601574	chr20:25228251	PYGB	0.57	4.55	0.42	1.6e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9788721	0.836	rs17483721	chr15:78733731	C/T	cg18825076	chr15:78729989	IREB2	0.66	6.19	0.54	1.54e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg15445000	chr17:37608096	MED1	-0.42	-5.07	-0.46	1.93e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg10802521	chr3:52805072	NEK4	-0.73	-6.43	-0.55	5.15e-9	Bipolar disorder;
THYM	cis	rs3008870	0.785	rs10889651	chr1:67463513	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.78	-6.55	-0.56	2.97e-9	Lymphocyte percentage of white cells;
THYM	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg02753203	chr1:228287806	NA	0.86	7.79	0.62	8.26e-12	Diastolic blood pressure;
THYM	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.11	0.68	1.31e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1265879	0.729	rs1265880	chr14:50880437	T/C	cg04730355	chr14:51134070	SAV1	-0.74	-4.82	-0.44	5.36e-6	Cognitive performance;
THYM	cis	rs4474465	0.915	rs12272791	chr11:78159426	G/A	cg19901956	chr11:77921274	USP35	-0.66	-4.91	-0.45	3.71e-6	Alzheimer's disease (survival time);
THYM	cis	rs12118280	0.512	rs7418288	chr1:108754099	G/A	cg11967332	chr1:108735228	SLC25A24	0.89	4.93	0.45	3.48e-6	Myeloid white cell count;
THYM	cis	rs36096196	0.891	rs12081179	chr1:2251119	A/G	cg17974515	chr1:2252516	NA	0.33	4.5	0.42	1.96e-5	Coronary artery disease;
THYM	cis	rs4499344	0.730	rs28416849	chr19:33099758	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.88	7.54	0.61	2.76e-11	Mean platelet volume;
THYM	cis	rs17608059	0.524	rs9897978	chr17:13900256	G/T	cg11395062	chr17:14139857	CDRT15	-0.71	-5.84	-0.51	7.29e-8	Temperament;
THYM	cis	rs10193935	0.901	rs10202848	chr2:42515661	A/G	cg27598129	chr2:42591480	NA	-0.73	-4.52	-0.42	1.76e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg12386194	chr3:101231763	SENP7	0.71	5.39	0.48	5.17e-7	Colorectal cancer;
THYM	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg11335335	chr11:637885	DRD4	-0.56	-4.45	-0.42	2.33e-5	Systemic lupus erythematosus;
THYM	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg15704280	chr7:45808275	SEPT13	1.03	11.84	0.77	2.09e-20	Coronary artery disease;
THYM	cis	rs1747683	0.932	rs1005089	chr10:13387295	G/A	cg25835351	chr10:13388524	SEPHS1	-0.35	-5.9	-0.52	5.49e-8	IgG glycosylation;
THYM	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg07936489	chr17:37558343	FBXL20	0.84	5.79	0.51	8.94e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg03676636	chr4:99064102	C4orf37	0.45	6.84	0.57	7.76e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg10523679	chr1:76189770	ACADM	-0.86	-7.97	-0.63	3.42e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.14	6.64	0.56	1.9e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2456568	0.867	rs10501810	chr11:93666589	C/G	cg26875233	chr11:93583750	C11orf90	-0.5	-4.95	-0.45	3.25e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg03806693	chr22:41940476	POLR3H	-1.03	-8.13	-0.64	1.58e-12	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs765787	0.530	rs4514617	chr15:45535439	A/G	cg24006582	chr15:45444508	DUOX1	-0.84	-7.2	-0.59	1.39e-10	Uric acid levels;
THYM	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.42	-0.49	4.57e-7	Bipolar disorder;
THYM	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg10018233	chr7:150070692	REPIN1	0.37	5.18	0.47	1.22e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7211079	0.581	rs66994322	chr17:78131240	G/T	cg04028464	chr17:78073854	GAA;CCDC40	0.7	4.67	0.43	9.88e-6	Myocardial infarction;
THYM	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg14456004	chr13:21872349	NA	-1.25	-10.18	-0.72	6.85e-17	White matter hyperintensity burden;
THYM	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg06713675	chr4:122721982	EXOSC9	0.51	4.76	0.44	6.92e-6	Type 2 diabetes;
THYM	cis	rs17604090	1.000	rs10272065	chr7:29694236	A/T	cg19413766	chr7:29689036	LOC646762	-1.05	-5.89	-0.52	5.72e-8	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7107174	0.636	rs11237451	chr11:78025459	G/A	cg19901956	chr11:77921274	USP35	0.62	4.79	0.44	6.17e-6	Testicular germ cell tumor;
THYM	cis	rs42648	0.819	rs10953006	chr7:90030153	A/G	cg25739043	chr7:89950458	NA	-0.52	-4.53	-0.42	1.69e-5	Homocysteine levels;
THYM	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg10505658	chr17:80084571	CCDC57	0.7	7.93	0.63	4.3e-12	Life satisfaction;
THYM	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg12564285	chr5:131593104	PDLIM4	0.49	5.49	0.49	3.29e-7	Breast cancer;
THYM	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg13607699	chr17:42295918	UBTF	0.66	5.44	0.49	4.13e-7	Total body bone mineral density;
THYM	cis	rs236907	0.859	rs12565176	chr1:171736641	A/G	cg20598894	chr1:171756153	METTL13	-0.72	-5.04	-0.46	2.23e-6	Mean platelet volume;
THYM	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.67	6.01	0.52	3.42e-8	Calcium levels;
THYM	cis	rs6430585	0.528	rs6750549	chr2:136707480	A/G	cg07169764	chr2:136633963	MCM6	1.23	14.81	0.84	1.97e-26	Corneal structure;
THYM	cis	rs6138458	0.546	rs6050118	chr20:24891895	C/T	cg26195577	chr20:24973756	C20orf3	-0.86	-5.53	-0.49	2.85e-7	Blood protein levels;
THYM	cis	rs2579519	0.547	rs11683523	chr2:96544855	T/C	cg23100626	chr2:96804247	ASTL	0.4	5.0	0.46	2.62e-6	Diastolic blood pressure;
THYM	cis	rs886774	0.526	rs13226753	chr7:107504332	T/C	cg23293999	chr7:106826042	HBP1	-0.59	-4.6	-0.43	1.3e-5	Ulcerative colitis;
THYM	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12216545	0.695	rs10276888	chr7:150230326	T/C	cg00323915	chr7:150264987	GIMAP4	-0.49	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg01710189	chr8:22454888	PDLIM2	-0.49	-5.22	-0.47	1.07e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg06634786	chr22:41940651	POLR3H	-0.7	-5.35	-0.48	6.16e-7	Vitiligo;
THYM	cis	rs9902453	0.765	rs2628167	chr17:28064498	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.12	7.7	0.62	1.28e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg22664400	chr11:66445111	RBM4B	-0.66	-4.47	-0.42	2.14e-5	Crohn's disease;
THYM	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg18252515	chr7:66147081	NA	-0.64	-4.96	-0.45	3.09e-6	Aortic root size;
THYM	cis	rs7119038	0.818	rs10892289	chr11:118646003	C/T	cg19308663	chr11:118741387	NA	0.58	5.47	0.49	3.57e-7	Sjögren's syndrome;
THYM	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.17	11.49	0.76	1.16e-19	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs61931739	0.635	rs1601627	chr12:33962420	G/A	cg10856724	chr12:34555212	NA	-0.64	-6.04	-0.53	3.04e-8	Morning vs. evening chronotype;
THYM	cis	rs7578361	0.877	rs7597580	chr2:150367405	T/C	cg17961725	chr2:150454027	NA	0.72	5.25	0.47	9.22e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1692580	0.840	rs263526	chr1:2173504	T/C	cg21442419	chr1:2182373	SKI	-0.42	-4.62	-0.43	1.22e-5	Coronary artery disease;
THYM	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg27535305	chr1:53392650	SCP2	-0.45	-5.06	-0.46	2.02e-6	Monocyte count;
THYM	cis	rs2806561	0.964	rs683052	chr1:23514953	T/C	cg19743168	chr1:23544995	NA	0.62	6.64	0.56	1.92e-9	Height;
THYM	cis	rs673253	0.710	rs56175694	chr1:44065148	C/T	cg24466421	chr1:44070974	PTPRF	-0.6	-5.24	-0.47	9.75e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg19774624	chr17:42201019	HDAC5	0.71	6.24	0.54	1.23e-8	Total body bone mineral density;
THYM	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22857025	chr5:266934	NA	-1.38	-9.05	-0.68	1.76e-14	Breast cancer;
THYM	cis	rs924712	0.677	rs239837	chr6:54768159	A/G	cg04690482	chr6:54711388	FAM83B	-0.47	-5.66	-0.5	1.58e-7	Breast cancer;
THYM	cis	rs9394152	0.845	rs7747216	chr6:33476718	A/G	cg13560919	chr6:33536144	NA	-0.77	-6.76	-0.57	1.1e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs4363385	0.740	rs4845518	chr1:153003903	A/G	cg13444842	chr1:152974279	SPRR3	-0.59	-4.83	-0.44	5.24e-6	Inflammatory skin disease;
THYM	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg23161317	chr6:28129485	ZNF389	0.98	7.27	0.6	1.03e-10	Parkinson's disease;
THYM	cis	rs11910985	1.000	rs11910985	chr21:48042766	C/T	cg17243659	chr21:48055224	PRMT2	1.02	4.45	0.42	2.33e-5	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg06221963	chr1:154839813	KCNN3	-0.78	-9.74	-0.71	5.93e-16	Prostate cancer;
THYM	cis	rs17125944	0.686	rs7145440	chr14:53333717	A/G	cg00686598	chr14:53173677	PSMC6	-0.93	-4.77	-0.44	6.76e-6	Alzheimer's disease (late onset);
THYM	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg12463550	chr7:65579703	CRCP	-0.56	-4.67	-0.43	9.84e-6	Aortic root size;
THYM	cis	rs10895275	0.625	rs4754836	chr11:102040823	C/T	cg24447756	chr11:102105824	NA	-0.52	-4.98	-0.46	2.83e-6	Migraine;
THYM	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-15.41	-0.85	1.38e-27	Height;
THYM	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg20607798	chr8:58055168	NA	0.83	4.45	0.42	2.34e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs2252521	0.583	rs1846490	chr7:29080827	G/A	cg24222995	chr7:28995786	TRIL	-0.62	-4.46	-0.42	2.28e-5	Cognitive performance;
THYM	cis	rs4951011	0.938	rs12048085	chr1:203761807	C/G	cg24343524	chr1:203763352	ZC3H11A	-0.68	-5.67	-0.5	1.56e-7	Breast cancer;
THYM	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg08645402	chr16:4508243	NA	0.68	5.74	0.51	1.11e-7	Schizophrenia;
THYM	cis	rs34311866	0.808	rs4583705	chr4:973036	C/T	cg11017086	chr4:979022	SLC26A1	0.71	4.71	0.43	8.53e-6	Parkinson's disease;
THYM	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg27394845	chr17:28928406	LRRC37B2	0.91	4.58	0.42	1.44e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs8050907	0.590	rs1362627	chr16:4551505	C/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.13	4.76	0.44	6.97e-6	Obesity-related traits;
THYM	cis	rs2731664	0.792	rs163199	chr5:176890067	A/G	cg14098951	chr5:176875120	PRR7	0.57	5.17	0.47	1.31e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg27129171	chr3:47204927	SETD2	0.71	6.59	0.56	2.43e-9	Colorectal cancer;
THYM	cis	rs9868809	1.000	rs9868809	chr3:48681053	C/T	cg00383909	chr3:49044727	WDR6	1.02	5.01	0.46	2.55e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4631830	0.900	rs7914347	chr10:51537431	C/T	cg16070123	chr10:51489643	NA	-0.53	-4.78	-0.44	6.27e-6	Prostate-specific antigen levels;
THYM	cis	rs500891	0.525	rs1144179	chr6:84026572	C/G	cg08257003	chr6:84140564	ME1	0.56	4.47	0.42	2.19e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-4.49	-0.42	1.99e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg05362011	chr13:21860987	NA	0.6	5.02	0.46	2.4e-6	White matter hyperintensity burden;
THYM	trans	rs10162002	0.572	rs117896237	chr13:24023514	C/T	cg10504632	chr7:40591610	C7orf10	-0.85	-7.1	-0.59	2.22e-10	Hypothyroidism;
THYM	cis	rs6728642	0.572	rs1320147	chr2:97600626	A/C	cg01990225	chr2:97406019	LMAN2L	0.77	4.61	0.43	1.23e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs921968	0.591	rs13421421	chr2:219519286	A/G	cg02176678	chr2:219576539	TTLL4	0.64	6.34	0.55	7.85e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4792901	0.765	rs12601607	chr17:41538783	A/G	cg21940313	chr17:41620911	ETV4	-0.54	-5.1	-0.46	1.74e-6	Dupuytren's disease;
THYM	cis	rs4722585	0.533	rs3753097	chr7:26198207	A/G	cg07876897	chr7:26191696	NFE2L3	0.56	4.47	0.42	2.16e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg04455712	chr21:45112962	RRP1B	0.51	4.62	0.43	1.21e-5	Mean corpuscular volume;
THYM	cis	rs2562456	0.958	rs2562508	chr19:21726281	G/A	cg21751540	chr19:21541537	ZNF738	0.69	4.75	0.44	7.1e-6	Pain;
THYM	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg07936489	chr17:37558343	FBXL20	-0.72	-5.06	-0.46	2.05e-6	Asthma;
THYM	cis	rs2080501	0.571	rs1861657	chr16:49675807	G/T	cg03087880	chr16:49666012	ZNF423	0.69	8.55	0.66	2.04e-13	IgG glycosylation;
THYM	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg16342193	chr10:102329863	NA	-0.53	-5.45	-0.49	4.01e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg07362569	chr17:61921086	SMARCD2	0.75	6.66	0.56	1.73e-9	Prudent dietary pattern;
THYM	cis	rs7404928	0.579	rs1858872	chr16:23923520	G/A	cg26685404	chr16:23957272	PRKCB	-0.62	-7.22	-0.6	1.28e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs12368653	0.641	rs7311632	chr12:58086340	A/C	cg12615879	chr12:58013172	SLC26A10	0.54	5.38	0.48	5.25e-7	Multiple sclerosis;
THYM	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg16342193	chr10:102329863	NA	-0.57	-6.1	-0.53	2.32e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg18240062	chr17:79603768	NPLOC4	-0.73	-6.57	-0.56	2.74e-9	Eye color traits;
THYM	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg17757837	chr7:157058334	UBE3C	-0.66	-5.32	-0.48	6.85e-7	Body mass index;
THYM	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg23711669	chr6:146136114	FBXO30	0.92	9.0	0.68	2.32e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6496667	0.533	rs2601206	chr15:90962699	C/T	cg00487526	chr15:90818384	NA	-0.64	-4.7	-0.43	8.86e-6	Rheumatoid arthritis;
THYM	cis	rs6032067	0.852	rs6032053	chr20:43829935	G/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg23758822	chr17:41437982	NA	1.17	11.09	0.75	7.75e-19	Menopause (age at onset);
THYM	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg14458575	chr2:238380390	NA	1.01	8.02	0.64	2.79e-12	Prostate cancer;
THYM	cis	rs858239	0.601	rs2141307	chr7:23191424	G/C	cg09755872	chr7:23245557	NA	-0.5	-4.77	-0.44	6.74e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg11266682	chr4:10021025	SLC2A9	0.51	6.17	0.53	1.66e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9296092	0.538	rs9469487	chr6:33516943	G/T	cg13560919	chr6:33536144	NA	-0.94	-9.16	-0.68	1.03e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg00640147	chr17:61958756	GH2	-0.43	-4.54	-0.42	1.64e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs28647808	1.000	rs2285484	chr9:136271841	C/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs728616	0.867	rs61860421	chr10:81743399	C/T	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.47	0.49	3.63e-7	Bipolar disorder;
THYM	cis	rs2806561	0.780	rs12409321	chr1:23398065	C/T	cg19743168	chr1:23544995	NA	-0.57	-5.28	-0.48	8.27e-7	Height;
THYM	cis	rs9595908	0.931	rs7998440	chr13:33125206	G/A	cg12383807	chr13:33924137	NA	-0.57	-5.0	-0.46	2.58e-6	Body mass index;
THYM	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg04654363	chr8:8581213	NA	-0.48	-4.62	-0.43	1.22e-5	Obesity-related traits;
THYM	cis	rs1056053	0.514	rs1056051	chr6:166571579	T/G	cg11088901	chr6:166572345	T	-0.58	-5.26	-0.47	9.03e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7809950	1.000	rs2237673	chr7:107131580	T/C	cg23024343	chr7:107201750	COG5	-0.93	-8.3	-0.65	7.11e-13	Coronary artery disease;
THYM	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg18252515	chr7:66147081	NA	-0.72	-5.6	-0.5	2.03e-7	Aortic root size;
THYM	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg03806693	chr22:41940476	POLR3H	1.25	10.88	0.74	2.22e-18	Vitiligo;
THYM	cis	rs782590	0.902	rs7582278	chr2:55742924	C/G	cg03859395	chr2:55845619	SMEK2	0.64	5.82	0.51	8e-8	Metabolic syndrome;
THYM	cis	rs886774	0.507	rs17411033	chr7:107519996	G/A	cg23293999	chr7:106826042	HBP1	-0.62	-4.96	-0.45	3.03e-6	Ulcerative colitis;
THYM	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg06618935	chr21:46677482	NA	-0.96	-9.38	-0.69	3.52e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs986417	1.000	rs4901995	chr14:61090629	C/G	cg27398547	chr14:60952738	C14orf39	1.18	5.36	0.48	5.92e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg13319975	chr6:146136371	FBXO30	-0.67	-5.47	-0.49	3.58e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2456568	0.709	rs1354765	chr11:93637776	G/T	cg17595323	chr11:93583763	C11orf90	0.55	6.11	0.53	2.2e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs11089937	0.523	rs4820352	chr22:22543592	T/C	cg06866756	chr22:22471216	NA	-0.46	-5.28	-0.48	8.24e-7	Periodontitis (PAL4Q3);
THYM	cis	rs3741151	0.686	rs7112924	chr11:73106408	C/T	cg17517138	chr11:73019481	ARHGEF17	0.74	4.69	0.43	9.11e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg16778714	chr17:28903809	LRRC37B2	0.69	4.75	0.44	7.3e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs12496230	1.000	rs13079612	chr3:66840534	T/C	cg04995300	chr3:66848608	NA	0.99	6.14	0.53	1.89e-8	Type 2 diabetes;
THYM	cis	rs17125944	0.615	rs2357944	chr14:53305573	T/G	cg00686598	chr14:53173677	PSMC6	-1.17	-5.3	-0.48	7.4e-7	Alzheimer's disease (late onset);
THYM	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg16230307	chr14:35515116	FAM177A1	0.83	5.29	0.48	7.72e-7	Psoriasis;
THYM	cis	rs10504073	0.647	rs62507252	chr8:50028795	C/G	cg00325661	chr8:49890786	NA	0.88	8.06	0.64	2.23e-12	Blood metabolite ratios;
THYM	trans	rs9951602	0.512	rs9955812	chr18:76650954	T/A	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs5758511	0.680	rs5758687	chr22:42656588	A/T	cg08431931	chr22:42394659	WBP2NL	0.63	4.75	0.44	7.21e-6	Birth weight;
THYM	cis	rs12681287	0.752	rs12681438	chr8:87293089	G/A	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg24818145	chr4:99064322	C4orf37	0.72	5.65	0.5	1.68e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg13010199	chr12:38710504	ALG10B	-0.58	-5.07	-0.46	1.98e-6	Heart rate;
THYM	cis	rs7705042	0.759	rs3765011	chr5:141517665	G/C	cg07392085	chr5:141489673	NDFIP1	0.54	4.52	0.42	1.81e-5	Asthma;
THYM	cis	rs12579753	0.956	rs34747993	chr12:82217777	C/T	cg21231944	chr12:82153410	PPFIA2	-0.65	-4.96	-0.45	3.1e-6	Resting heart rate;
THYM	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-5.43	-0.49	4.26e-7	Gut microbiome composition (summer);
THYM	cis	rs7177699	0.557	rs72749206	chr15:79122948	G/A	cg15571903	chr15:79123663	NA	-0.65	-6.7	-0.57	1.46e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.07	-6.19	-0.54	1.52e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg24503407	chr1:205819492	PM20D1	0.92	8.61	0.66	1.53e-13	Menarche (age at onset);
THYM	cis	rs2120991	0.935	rs2165901	chr12:54270780	T/C	cg25550629	chr12:53546895	NA	0.49	4.57	0.42	1.44e-5	Biliary atresia;
THYM	trans	rs3960554	0.741	rs10232162	chr7:75702505	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	6.95	0.58	4.6e-10	Eotaxin levels;
THYM	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.63	8.71	0.67	9.52e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6840360	0.615	rs6535816	chr4:152614264	T/C	cg22705602	chr4:152727874	NA	-0.8	-10.53	-0.73	1.24e-17	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06634786	chr22:41940651	POLR3H	-0.78	-5.76	-0.51	1.02e-7	Vitiligo;
THYM	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg02782426	chr3:40428986	ENTPD3	0.54	4.78	0.44	6.26e-6	Renal cell carcinoma;
THYM	cis	rs7131987	0.868	rs7958210	chr12:29395181	G/C	cg09582351	chr12:29534625	ERGIC2	-0.48	-4.66	-0.43	1.03e-5	QT interval;
THYM	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg03609598	chr5:56110824	MAP3K1	-0.85	-5.85	-0.51	6.86e-8	Initial pursuit acceleration;
THYM	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg26384229	chr12:38710491	ALG10B	0.89	6.85	0.57	7.32e-10	Heart rate;
THYM	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg08736216	chr1:53307985	ZYG11A	-0.7	-6.06	-0.53	2.72e-8	Monocyte count;
THYM	cis	rs4951011	0.938	rs4951005	chr1:203763325	A/G	cg24343524	chr1:203763352	ZC3H11A	0.7	6.26	0.54	1.11e-8	Breast cancer;
THYM	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg00071950	chr4:10020882	SLC2A9	0.55	4.73	0.44	7.89e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg17264618	chr3:40429014	ENTPD3	0.53	5.02	0.46	2.37e-6	Renal cell carcinoma;
THYM	cis	rs7084402	0.935	rs717453	chr10:60268398	C/T	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs10788264	0.504	rs10749451	chr10:124028040	C/T	cg09507567	chr10:124027408	NA	0.52	5.39	0.48	5.03e-7	Total body bone mineral density;
THYM	cis	rs9361491	0.657	rs1180824	chr6:79433523	G/A	cg04547799	chr6:79944526	HMGN3	-0.64	-4.47	-0.42	2.13e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7968440	1.000	rs2684898	chr12:51046825	C/T	cg20014596	chr12:50898483	DIP2B	0.56	4.55	0.42	1.57e-5	Fibrinogen;
THYM	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg17211192	chr8:82754475	SNX16	0.89	7.25	0.6	1.13e-10	Diastolic blood pressure;
THYM	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg22189786	chr22:42395067	WBP2NL	0.56	5.09	0.46	1.79e-6	Birth weight;
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg24096828	chr13:98604736	IPO5	0.89	7.27	0.6	1.01e-10	Energy expenditure (24h);
THYM	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg21237687	chr17:6899380	ALOX12	-0.75	-9.65	-0.7	9.22e-16	Tonsillectomy;
THYM	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg14228332	chr4:119757509	SEC24D	1.2	4.59	0.43	1.36e-5	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg16586182	chr3:47516702	SCAP	-0.67	-5.61	-0.5	1.99e-7	Colorectal cancer;
THYM	cis	rs11696501	0.947	rs6073759	chr20:44115498	A/T	cg11783356	chr20:44313418	WFDC10B	-0.76	-4.74	-0.44	7.55e-6	Brain structure;
THYM	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg06634786	chr22:41940651	POLR3H	0.73	5.36	0.48	5.89e-7	Vitiligo;
THYM	cis	rs448720	0.811	rs2458506	chr15:68182610	G/A	cg24579218	chr15:68104479	NA	-0.52	-4.46	-0.42	2.2e-5	Cognitive performance;
THYM	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg20887711	chr4:1340912	KIAA1530	0.97	8.89	0.67	3.84e-14	Longevity;
THYM	cis	rs478304	0.651	rs78412025	chr11:65495696	T/C	cg17480646	chr11:65405466	SIPA1	-0.94	-8.68	-0.67	1.07e-13	Acne (severe);
THYM	cis	rs11264213	0.591	rs3754076	chr1:36549157	A/G	cg27506609	chr1:36549197	TEKT2	-1.17	-6.6	-0.56	2.31e-9	Schizophrenia;
THYM	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg23711669	chr6:146136114	FBXO30	0.85	7.94	0.63	4.02e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8135828	0.874	rs2267152	chr22:30088671	A/G	cg16189954	chr22:29138267	HSCB;CHEK2	0.73	4.54	0.42	1.62e-5	Lipid traits;
THYM	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg13609457	chr4:120235615	NA	0.61	5.47	0.49	3.63e-7	Corneal astigmatism;
THYM	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg23422044	chr7:1970798	MAD1L1	-0.76	-5.35	-0.48	5.98e-7	Bipolar disorder;
THYM	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg11366901	chr6:160182831	ACAT2	1.01	9.01	0.68	2.12e-14	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4638749	1.000	rs1466211	chr2:108856412	G/A	cg25838818	chr2:108905173	SULT1C2	-0.6	-6.13	-0.53	1.97e-8	Blood pressure;
THYM	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs10832963	0.847	rs4237722	chr11:18639363	T/C	cg20219074	chr11:18656078	SPTY2D1	0.75	6.22	0.54	1.33e-8	Breast cancer;
THYM	cis	rs17407555	0.865	rs78272916	chr4:10286838	A/G	cg11266682	chr4:10021025	SLC2A9	-0.53	-4.73	-0.44	7.89e-6	Schizophrenia (age at onset);
THYM	cis	rs7845219	0.597	rs7002058	chr8:95873993	G/C	cg16049864	chr8:95962084	TP53INP1	-0.64	-5.74	-0.51	1.11e-7	Type 2 diabetes;
THYM	cis	rs288326	0.561	rs41270217	chr2:183850877	C/T	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs6032067	0.777	rs116517830	chr20:43784872	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg21385522	chr1:16154831	NA	-1.31	-14.68	-0.83	3.56e-26	Dilated cardiomyopathy;
THYM	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3087591	0.960	rs11868459	chr17:29458197	C/T	cg24425628	chr17:29625626	OMG;NF1	0.65	5.52	0.49	2.96e-7	Hip circumference;
THYM	cis	rs7071206	0.740	rs2048781	chr10:79422975	T/C	cg07817648	chr10:79422355	NA	-0.84	-6.48	-0.55	4.04e-9	Bone mineral density;
THYM	cis	rs1003719	0.680	rs2835630	chr21:38521842	A/G	cg01329690	chr21:38580129	DSCR9	-0.41	-5.68	-0.5	1.45e-7	Eye color traits;
THYM	cis	rs4731207	0.698	rs10228682	chr7:124538036	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs9790314	1.000	rs336585	chr3:161081670	A/G	cg03342759	chr3:160939853	NMD3	-0.79	-7.04	-0.59	3.04e-10	Morning vs. evening chronotype;
THYM	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs76935404	0.899	rs73034465	chr19:41419075	A/G	cg19493303	chr19:41414353	NA	0.57	5.1	0.46	1.74e-6	nicotine metabolite ratio in current smokers;
THYM	cis	rs4343996	0.536	rs10270365	chr7:3417373	C/T	cg21248987	chr7:3385318	SDK1	0.4	4.89	0.45	4.11e-6	Motion sickness;
THYM	cis	rs397020	0.904	rs203547	chr20:1195245	T/A	cg16922058	chr20:1206700	RAD21L1	0.79	7.94	0.63	4.04e-12	Multiple sclerosis;
THYM	cis	rs35883536	0.626	rs11799819	chr1:101049382	G/A	cg09408571	chr1:101003634	GPR88	-0.51	-5.63	-0.5	1.84e-7	Monocyte count;
THYM	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01341218	chr17:43662625	NA	-0.88	-7.74	-0.62	1.03e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7705042	0.865	rs6580223	chr5:141489027	G/T	cg07392085	chr5:141489673	NDFIP1	0.54	4.49	0.42	2.03e-5	Asthma;
THYM	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg23187316	chr7:1099788	C7orf50	0.59	4.49	0.42	2.01e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs213032	1.000	rs213028	chr1:21652177	A/G	cg18221576	chr1:22213934	HSPG2	-0.49	-4.49	-0.42	1.96e-5	Obesity-related traits;
THYM	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg09323728	chr8:95962352	TP53INP1	-0.45	-4.55	-0.42	1.59e-5	Type 2 diabetes;
THYM	cis	rs59197085	0.636	rs62479609	chr7:128443492	C/G	cg00734629	chr7:128471146	FLNC	0.78	4.64	0.43	1.13e-5	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
THYM	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	10.29	0.73	3.95e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1629083	0.902	rs57495164	chr11:118095148	T/C	cg25155064	chr11:118100782	MPZL3	-0.57	-5.04	-0.46	2.21e-6	Lung cancer;
THYM	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg18477163	chr1:228402036	OBSCN	0.59	6.41	0.55	5.62e-9	Diastolic blood pressure;
THYM	cis	rs950880	0.710	rs67723747	chr2:102969807	C/T	cg03938978	chr2:103052716	IL18RAP	-0.53	-4.57	-0.42	1.46e-5	Serum protein levels (sST2);
THYM	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06481639	chr22:41940642	POLR3H	0.8	5.63	0.5	1.81e-7	Vitiligo;
THYM	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.56	-0.5	2.44e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs289828	0.579	rs12624156	chr2:152149667	G/A	cg05960677	chr2:152117363	RBM43	0.75	7.25	0.6	1.1e-10	Blood protein levels;
THYM	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg12908607	chr1:44402522	ARTN	0.54	4.63	0.43	1.18e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg21280719	chr6:42927975	GNMT	-0.53	-7.38	-0.6	5.9e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg08847533	chr14:75593920	NEK9	-1.03	-11.28	-0.76	3.11e-19	Height;
THYM	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs9858542	0.537	rs4410472	chr3:49329090	A/T	cg00383909	chr3:49044727	WDR6	0.77	5.05	0.46	2.16e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.97	8.88	0.67	4.01e-14	Colorectal cancer;
THYM	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg07061783	chr6:25882402	NA	0.79	6.56	0.56	2.8e-9	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-6.6	-0.56	2.38e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs2108622	0.640	rs58858790	chr19:15974273	G/A	cg13772218	chr19:15982569	NA	0.53	4.48	0.42	2.06e-5	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs10819861	0.679	rs10819868	chr9:98871378	C/T	cg14508093	chr9:98862825	NA	-0.26	-5.13	-0.47	1.52e-6	Electrocardiographic traits;
THYM	cis	rs148803332	1	rs148803332	chr17:65958250	CAAAAGAAA/C	cg12091567	chr17:66097778	LOC651250	0.7	4.78	0.44	6.39e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;
THYM	cis	rs3126085	0.935	rs6681457	chr1:152297117	C/T	cg10321714	chr1:152280068	FLG	-0.67	-4.65	-0.43	1.08e-5	Atopic dermatitis;
THYM	trans	rs9951602	0.512	rs3859325	chr18:76652175	A/G	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs9583531	0.600	rs1441043	chr13:111367650	A/G	cg24331049	chr13:111365604	ING1	0.69	5.79	0.51	9.24e-8	Coronary artery disease;
THYM	cis	rs2070488	1.000	rs7373805	chr3:38455439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	6.83	0.57	7.89e-10	Electrocardiographic conduction measures;
THYM	cis	rs11644362	0.631	rs12597772	chr16:12963185	C/G	cg06890432	chr16:12997467	SHISA9	-0.52	-4.72	-0.44	8.17e-6	Positive affect;Subjective well-being;
THYM	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	trans	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg23505145	chr19:12996616	KLF1	1.04	10.24	0.72	5.19e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs863345	0.604	rs12041350	chr1:158482048	A/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs9403317	0.960	rs11751835	chr6:141836735	C/T	cg15052665	chr6:141804349	NA	0.85	8.69	0.67	1.03e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10736390	0.640	rs10888858	chr1:55108978	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-1.07	-11.32	-0.76	2.62e-19	Survival in pancreatic cancer;
THYM	cis	rs9796	0.621	rs537244	chr15:41469313	G/T	cg18705301	chr15:41695430	NDUFAF1	0.56	4.61	0.43	1.24e-5	Menopause (age at onset);
THYM	cis	rs2268241	0.938	rs17878783	chr21:34779185	G/A	cg14850771	chr21:34775459	IFNGR2	1.04	6.96	0.58	4.26e-10	Obesity-related traits;
THYM	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg15693483	chr7:1102177	C7orf50	0.4	5.82	0.51	8.07e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6930083	0.510	rs4713994	chr6:36621533	A/G	cg24425727	chr6:36645648	CDKN1A	0.74	6.14	0.53	1.87e-8	Coronary artery disease;
THYM	cis	rs4780401	0.693	rs8191277	chr16:11764082	A/G	cg01061890	chr16:11836724	TXNDC11	-0.62	-4.71	-0.43	8.53e-6	Rheumatoid arthritis;
THYM	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg12193833	chr17:30244370	NA	-0.63	-4.47	-0.42	2.2e-5	Hip circumference adjusted for BMI;
THYM	cis	rs13221852	0.659	rs1554499	chr7:3415818	G/A	cg21248987	chr7:3385318	SDK1	0.4	4.89	0.45	4.11e-6	Acute graft versus host disease in bone marrow transplantation (donor effect);
THYM	cis	rs9296092	0.538	rs9461879	chr6:33516907	C/T	cg13560919	chr6:33536144	NA	-0.94	-9.16	-0.68	1.03e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs28595532	0.920	rs114916728	chr4:119776886	G/A	cg21605333	chr4:119757512	SEC24D	1.67	6.17	0.53	1.69e-8	Cannabis dependence symptom count;
THYM	cis	rs13315871	0.929	rs11130627	chr3:58315749	G/A	cg00563845	chr3:58318305	PXK	0.59	5.02	0.46	2.37e-6	Cholesterol, total;
THYM	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg12310025	chr6:25882481	NA	-0.69	-5.64	-0.5	1.72e-7	Schizophrenia;
THYM	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg23711669	chr6:146136114	FBXO30	0.9	8.82	0.67	5.37e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6546324	0.625	rs2902008	chr2:67802950	T/C	cg18237512	chr2:67827392	NA	-0.78	-4.63	-0.43	1.16e-5	Endometriosis;
THYM	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.22e-7	Corneal astigmatism;
THYM	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg12379764	chr21:47803548	PCNT	-0.83	-5.37	-0.48	5.52e-7	Testicular germ cell tumor;
THYM	cis	rs6980334	0.817	rs10954603	chr7:137794021	A/G	cg11874123	chr7:137028198	PTN	0.67	5.17	0.47	1.29e-6	Blood metabolite ratios;
THYM	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.77	-6.56	-0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg24818145	chr4:99064322	C4orf37	0.75	6.04	0.53	2.94e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg22105103	chr4:187893119	NA	0.95	10.21	0.72	5.86e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1569175	0.522	rs2202923	chr2:200879804	C/T	cg23649088	chr2:200775458	C2orf69	-0.71	-5.03	-0.46	2.34e-6	Response to treatment for acute lymphoblastic leukemia;
THYM	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	9.39	0.69	3.37e-15	Chronic sinus infection;
THYM	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg00786635	chr1:25594202	NA	0.9	7.2	0.59	1.39e-10	Erythrocyte sedimentation rate;
THYM	cis	rs89107	0.576	rs17227124	chr6:118741382	T/C	cg21191810	chr6:118973309	C6orf204	0.48	4.81	0.44	5.7e-6	Cardiac structure and function;
THYM	cis	rs4654899	1.000	rs6700718	chr1:21299363	A/C	cg01072550	chr1:21505969	NA	0.72	6.55	0.56	2.98e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs7542375	0.683	rs1414518	chr1:221091157	T/C	cg16008148	chr1:221062819	NA	0.54	5.51	0.49	3.02e-7	Obesity-related traits;
THYM	cis	rs4285028	0.580	rs1523519	chr3:121631841	C/T	cg20356878	chr3:121714668	ILDR1	-0.58	-5.12	-0.47	1.57e-6	Multiple sclerosis;
THYM	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-10.4	-0.73	2.29e-17	Primary sclerosing cholangitis;
THYM	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg24399712	chr22:39784796	NA	-0.87	-7.99	-0.63	3.22e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs6840360	0.571	rs62327270	chr4:152533618	C/T	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg01304814	chr3:48885189	PRKAR2A	0.88	4.58	0.43	1.39e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs2073300	1.000	rs6048825	chr20:23457671	T/C	cg12062639	chr20:23401060	NAPB	0.99	4.96	0.45	3.07e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	trans	rs561341	1.000	rs546748	chr17:30324293	A/C	cg20587970	chr11:113659929	NA	-1.0	-6.93	-0.58	4.94e-10	Hip circumference adjusted for BMI;
THYM	cis	rs10927875	0.619	rs2102664	chr1:16130169	A/G	cg21385522	chr1:16154831	NA	-0.75	-6.22	-0.54	1.31e-8	Dilated cardiomyopathy;
THYM	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg22681709	chr2:178499509	PDE11A	-0.55	-5.35	-0.48	6.03e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7119	0.717	rs62009069	chr15:77817877	T/G	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs17401966	1.000	rs17401924	chr1:10384439	A/G	cg19773385	chr1:10388646	KIF1B	-0.64	-4.77	-0.44	6.6e-6	Hepatocellular carcinoma;
THYM	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg15604051	chr3:44754201	ZNF502	-0.6	-5.22	-0.47	1.05e-6	Depressive symptoms;
THYM	cis	rs79480871	0.667	rs4665272	chr2:24950337	A/G	cg26312337	chr2:25170414	DNAJC27	0.59	4.67	0.43	9.72e-6	Diffuse large B cell lymphoma;
THYM	cis	rs6500395	1.000	rs7201196	chr16:48674030	C/T	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs778371	0.915	rs938569	chr2:233759695	C/G	cg08000102	chr2:233561755	GIGYF2	0.86	6.89	0.58	5.93e-10	Schizophrenia;
THYM	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.81	-0.63	7.44e-12	Chronic sinus infection;
THYM	cis	rs9831754	0.856	rs9824624	chr3:78407182	G/A	cg06138941	chr3:78371609	NA	-0.63	-4.48	-0.42	2.11e-5	Calcium levels;
THYM	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.07	-0.46	1.97e-6	Bipolar disorder;
THYM	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03517284	chr6:25882590	NA	-0.94	-8.29	-0.65	7.51e-13	Intelligence (multi-trait analysis);
THYM	cis	rs28735056	0.596	rs3744879	chr18:77679006	G/C	cg20368463	chr18:77673604	PQLC1	-0.67	-5.05	-0.46	2.17e-6	Schizophrenia;
THYM	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13185784	0.703	rs35394934	chr5:179677555	T/C	cg23248424	chr5:179741104	GFPT2	0.69	4.6	0.43	1.31e-5	TRAIL levels;
THYM	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg24069376	chr3:38537580	EXOG	0.69	6.79	0.57	9.87e-10	Electrocardiographic conduction measures;
THYM	cis	rs7131987	0.621	rs3782506	chr12:29445422	A/C	cg09582351	chr12:29534625	ERGIC2	0.53	4.68	0.43	9.37e-6	QT interval;
THYM	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg12935359	chr14:103987150	CKB	-0.65	-6.4	-0.55	5.78e-9	Body mass index;
THYM	cis	rs8020441	0.541	rs113935613	chr14:51163847	C/T	cg04730355	chr14:51134070	SAV1	0.86	5.16	0.47	1.37e-6	Cognitive performance;
THYM	trans	rs877282	0.838	rs34778553	chr10:796865	T/C	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg00271210	chr6:167070053	RPS6KA2	-0.54	-5.42	-0.49	4.43e-7	Crohn's disease;
THYM	cis	rs995000	0.931	rs10158897	chr1:62912919	C/T	cg06896770	chr1:63153194	DOCK7	1.0	8.17	0.64	1.31e-12	Triglyceride levels;
THYM	cis	rs4417704	0.551	rs4464265	chr2:241891799	A/G	cg15164180	chr2:241846931	NA	-0.37	-4.76	-0.44	6.94e-6	Joint mobility (Beighton score);
THYM	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.02	0.46	2.4e-6	Prudent dietary pattern;
THYM	cis	rs308403	0.509	rs13117125	chr4:123670824	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.98	8.3	0.65	6.83e-13	Blood protein levels;
THYM	cis	rs6942756	0.513	rs10954224	chr7:128893513	T/A	cg02491457	chr7:128862824	NA	0.41	4.49	0.42	1.97e-5	White matter hyperintensity burden;
THYM	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg19770292	chr5:1868693	NA	0.51	4.68	0.43	9.52e-6	Cardiovascular disease risk factors;
THYM	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg11764359	chr7:65958608	NA	0.68	4.57	0.42	1.48e-5	Aortic root size;
THYM	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg06092702	chr1:163392909	NA	-0.62	-5.65	-0.5	1.69e-7	Motion sickness;
THYM	cis	rs6543140	0.964	rs4851578	chr2:103028951	T/G	cg03938978	chr2:103052716	IL18RAP	0.61	6.16	0.53	1.77e-8	Blood protein levels;
THYM	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg18876405	chr7:65276391	NA	0.57	4.73	0.44	7.67e-6	Aortic root size;
THYM	cis	rs6840360	0.582	rs4696259	chr4:152310788	A/G	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.24	-0.47	9.84e-7	Intelligence (multi-trait analysis);
THYM	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	5.57	0.5	2.36e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs600806	0.854	rs11102974	chr1:109886371	G/A	cg23616212	chr1:109941201	SORT1	-0.49	-4.67	-0.43	9.88e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg19077165	chr18:44547161	KATNAL2	-0.63	-8.24	-0.65	9.47e-13	Personality dimensions;
THYM	cis	rs7575217	0.767	rs10207371	chr2:101763227	C/T	cg23907051	chr2:101730305	TBC1D8	-0.33	-4.47	-0.42	2.13e-5	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg03605463	chr16:89740564	NA	0.9	6.82	0.57	8.37e-10	Vitiligo;
THYM	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg08213375	chr14:104286397	PPP1R13B	0.45	4.63	0.43	1.16e-5	Reticulocyte count;
THYM	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg03709012	chr19:19516395	GATAD2A	-0.74	-5.8	-0.51	8.48e-8	Tonsillectomy;
THYM	cis	rs6430585	0.528	rs6430594	chr2:136719173	C/T	cg07169764	chr2:136633963	MCM6	-1.23	-14.81	-0.84	1.97e-26	Corneal structure;
THYM	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg08999081	chr20:33150536	PIGU	0.55	4.63	0.43	1.16e-5	Coronary artery disease;
THYM	cis	rs11677370	0.561	rs12711973	chr2:3825339	C/G	cg17052675	chr2:3827356	NA	-0.64	-6.3	-0.54	9.25e-9	Type 2 diabetes;
THYM	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg11266682	chr4:10021025	SLC2A9	0.73	12.79	0.8	2.29e-22	Bone mineral density;
THYM	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	5.92	0.52	5.04e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6960043	1.000	rs62448644	chr7:15053485	C/T	cg19272540	chr7:15055459	NA	-0.53	-6.43	-0.55	5.03e-9	Type 2 diabetes;
THYM	cis	rs240764	0.612	rs4840132	chr6:100914602	C/T	cg21058520	chr6:100914733	NA	0.63	5.6	0.5	2.11e-7	Neuroticism;
THYM	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg23583168	chr7:148888333	NA	-1.02	-13.89	-0.82	1.32e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6728642	0.901	rs10179966	chr2:97845100	C/T	cg26665480	chr2:98280029	ACTR1B	-0.77	-4.48	-0.42	2.07e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg26384229	chr12:38710491	ALG10B	-0.92	-7.03	-0.58	3.08e-10	Morning vs. evening chronotype;
THYM	cis	rs754466	0.724	rs11002318	chr10:79633807	G/A	cg17075019	chr10:79541650	NA	-0.69	-5.85	-0.51	6.94e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7474896	0.616	rs2505239	chr10:38440765	A/G	cg25427524	chr10:38739819	LOC399744	-0.74	-4.74	-0.44	7.42e-6	Obesity (extreme);
THYM	cis	rs28647808	0.881	rs4962139	chr9:136267869	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	1.13	5.15	0.47	1.4e-6	Blood protein levels;
THYM	cis	rs9658691	0.646	rs7909414	chr10:90754744	C/T	cg03111039	chr10:90751583	FAS;ACTA2	0.84	4.71	0.44	8.41e-6	Mosquito bite size;
THYM	cis	rs367615	0.537	rs1965670	chr5:108649798	A/T	cg17395555	chr5:108820864	NA	-0.54	-6.57	-0.56	2.62e-9	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs981844	0.775	rs17299246	chr4:154743504	C/T	cg09973105	chr4:154681532	RNF175	-0.69	-5.1	-0.46	1.75e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs308403	0.600	rs309364	chr4:123658859	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.79	-5.14	-0.47	1.48e-6	Blood protein levels;
THYM	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg07636037	chr3:49044803	WDR6	0.85	7.57	0.61	2.36e-11	Menarche (age at onset);
THYM	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg18876405	chr7:65276391	NA	0.73	6.87	0.58	6.52e-10	Aortic root size;
THYM	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg11871910	chr12:69753446	YEATS4	1.01	9.83	0.71	3.8e-16	Cerebrospinal fluid biomarker levels;
THYM	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg00786635	chr1:25594202	NA	0.99	8.22	0.64	1.04e-12	Erythrocyte sedimentation rate;
THYM	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	6.32	0.54	8.27e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg15448220	chr1:150897856	SETDB1	0.89	7.44	0.61	4.54e-11	Melanoma;
THYM	cis	rs62103177	0.564	rs1864529	chr18:77748975	G/A	cg07235805	chr18:78004237	PARD6G	-0.45	-5.41	-0.49	4.67e-7	Opioid sensitivity;
THYM	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg17366294	chr4:99064904	C4orf37	0.54	6.05	0.53	2.81e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg06994016	chr10:45406847	TMEM72	-0.46	-4.54	-0.42	1.66e-5	Mean corpuscular volume;
THYM	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg00256281	chr22:41985642	PMM1	0.63	4.9	0.45	3.93e-6	Vitiligo;
THYM	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg17264618	chr3:40429014	ENTPD3	0.52	4.95	0.45	3.22e-6	Renal cell carcinoma;
THYM	cis	rs155076	0.666	rs4638420	chr13:21872348	A/G	cg25811766	chr13:21894605	NA	0.72	4.89	0.45	4.15e-6	White matter hyperintensity burden;
THYM	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs28795989	0.731	rs13139805	chr4:7917053	A/C	cg00251875	chr4:7801337	AFAP1	-0.61	-4.9	-0.45	3.95e-6	Intraocular pressure;
THYM	cis	rs988913	0.736	rs4588693	chr6:54878219	A/G	cg19716238	chr6:54711378	FAM83B	0.47	4.57	0.42	1.44e-5	Menarche (age at onset);
THYM	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg10589385	chr1:150898437	SETDB1	0.57	4.55	0.42	1.56e-5	Melanoma;
THYM	cis	rs870825	0.616	rs28563856	chr4:185635581	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs4836390	0.656	rs9327484	chr5:128016546	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.82	4.68	0.43	9.53e-6	Coronary artery disease;
THYM	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg01475377	chr6:109611718	NA	-0.55	-4.6	-0.43	1.32e-5	Reticulocyte fraction of red cells;
THYM	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg18681998	chr4:17616180	MED28	0.91	8.56	0.66	2e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7973719	0.865	rs12228393	chr12:7368182	A/G	cg07052231	chr12:7363540	PEX5	-0.58	-4.88	-0.45	4.2e-6	IgG glycosylation;
THYM	cis	rs12530845	0.943	rs78188670	chr7:135335163	T/C	cg23117316	chr7:135346802	PL-5283	-0.66	-5.88	-0.52	6.21e-8	Red blood cell traits;
THYM	cis	rs113835537	0.627	rs11227534	chr11:66336171	C/A	cg10315249	chr11:66235081	PELI3	0.41	4.45	0.42	2.33e-5	Airway imaging phenotypes;
THYM	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg20891283	chr12:69753455	YEATS4	0.76	6.35	0.55	7.22e-9	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6076065	0.723	rs6083095	chr20:23354090	C/T	cg11657817	chr20:23433608	CST11	0.31	4.57	0.42	1.48e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs10911251	0.528	rs2147584	chr1:183074764	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Colorectal cancer;
THYM	cis	rs2898681	0.521	rs115874483	chr4:53728272	G/A	cg00338735	chr4:53728038	RASL11B	0.62	4.59	0.43	1.35e-5	Optic nerve measurement (cup area);
THYM	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg13319975	chr6:146136371	FBXO30	-0.64	-5.18	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	4.51	0.42	1.83e-5	Bipolar disorder;
THYM	cis	rs763014	0.898	rs4984895	chr16:623238	T/C	cg00908189	chr16:619842	PIGQ	1.02	9.27	0.69	6.03e-15	Height;
THYM	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs7688540	0.771	rs11737268	chr4:224452	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.65	4.8	0.44	5.89e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs2456568	0.525	rs6483269	chr11:93620428	C/T	cg09189538	chr11:93579666	C11orf90	0.56	5.13	0.47	1.53e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7124681	0.584	rs10769285	chr11:47709212	C/T	cg20307385	chr11:47447363	PSMC3	0.6	4.51	0.42	1.87e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs4919694	1.000	rs77969925	chr10:104649357	C/T	cg04362960	chr10:104952993	NT5C2	1.06	6.74	0.57	1.22e-9	Arsenic metabolism;
THYM	cis	rs2898681	0.521	rs6833350	chr4:53740868	A/G	cg00791764	chr4:53727839	RASL11B	0.64	6.68	0.57	1.62e-9	Optic nerve measurement (cup area);
THYM	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg23815491	chr16:72088622	HP	0.96	9.29	0.69	5.57e-15	Fibrinogen levels;
THYM	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg22875332	chr1:76189707	ACADM	-0.73	-6.76	-0.57	1.1e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg27034606	chr17:28928453	LRRC37B2	0.76	5.06	0.46	2.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg24803719	chr17:45855879	NA	-0.6	-6.31	-0.54	8.89e-9	IgG glycosylation;
THYM	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg22974920	chr21:40686053	BRWD1	-0.59	-4.59	-0.43	1.34e-5	Cognitive function;
THYM	cis	rs12410462	0.892	rs35341041	chr1:227653885	G/A	cg23173402	chr1:227635558	NA	0.68	6.08	0.53	2.5e-8	Major depressive disorder;
THYM	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg12379764	chr21:47803548	PCNT	-0.83	-5.29	-0.48	7.7e-7	Testicular germ cell tumor;
THYM	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg06766960	chr11:133703094	NA	0.48	4.46	0.42	2.22e-5	Childhood ear infection;
THYM	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg13852791	chr20:30311386	BCL2L1	0.67	4.76	0.44	7.04e-6	Mean corpuscular hemoglobin;
THYM	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.99	-0.75	1.26e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs28595532	0.920	rs115317002	chr4:119722809	T/C	cg21605333	chr4:119757512	SEC24D	1.53	6.07	0.53	2.59e-8	Cannabis dependence symptom count;
THYM	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg08305652	chr11:111469057	NA	-0.53	-4.6	-0.43	1.29e-5	Primary sclerosing cholangitis;
THYM	cis	rs921968	0.643	rs1055816	chr2:219501328	G/A	cg01872077	chr2:219646372	CYP27A1	0.58	4.49	0.42	2e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2073300	1.000	rs6137982	chr20:23468892	T/A	cg12062639	chr20:23401060	NAPB	1.33	6.01	0.52	3.46e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg08645402	chr16:4508243	NA	0.6	5.11	0.46	1.64e-6	Schizophrenia;
THYM	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	4.79	0.44	6.04e-6	Menarche (age at onset);
THYM	cis	rs4638749	1.000	rs10209928	chr2:108863898	C/T	cg23163573	chr2:108905468	SULT1C2	-0.29	-4.47	-0.42	2.15e-5	Blood pressure;
THYM	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.65	5.21	0.47	1.07e-6	Renal function-related traits (BUN);
THYM	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs714027	0.585	rs5763670	chr22:30383758	C/G	cg27665648	chr22:30112403	NA	0.5	4.58	0.43	1.4e-5	Lymphocyte counts;
THYM	cis	rs2901656	0.677	rs2269615	chr1:172415451	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.59	6.22	0.54	1.34e-8	Red cell distribution width;Platelet distribution width;
THYM	cis	rs7781557	1.000	rs2041094	chr7:102495434	C/T	cg06322601	chr7:102330635	NA	0.67	4.99	0.46	2.75e-6	Colorectal adenoma (advanced);
THYM	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg02228675	chr17:40259724	DHX58	-0.62	-5.13	-0.47	1.55e-6	Fibrinogen levels;
THYM	cis	rs12950390	0.512	rs59396604	chr17:45837777	G/A	cg03474202	chr17:45855739	NA	-0.72	-4.87	-0.45	4.42e-6	IgG glycosylation;
THYM	cis	rs4731207	0.698	rs10269011	chr7:124478813	T/C	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg13609457	chr4:120235615	NA	0.56	5.24	0.47	9.58e-7	Corneal astigmatism;
THYM	cis	rs6840360	0.571	rs17275598	chr4:152568478	C/A	cg17479576	chr4:152424074	FAM160A1	-0.77	-5.2	-0.47	1.13e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11628318	0.515	rs4906245	chr14:103088182	G/C	cg27124170	chr14:102829869	TECPR2;CINP	-0.65	-4.47	-0.42	2.15e-5	Platelet count;
THYM	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4466137	0.953	rs974023	chr5:83014848	T/C	cg16102102	chr5:83017553	HAPLN1	-1.11	-11.0	-0.75	1.21e-18	Prostate cancer;
THYM	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03264133	chr6:25882463	NA	0.93	8.24	0.65	9.46e-13	Blood metabolite levels;
THYM	cis	rs4589258	0.737	rs2187537	chr11:90462851	C/G	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.93	-0.45	3.53e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs12681287	0.752	rs10112123	chr8:87302328	T/C	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs236907	0.859	rs10913683	chr1:171758699	T/C	cg20598894	chr1:171756153	METTL13	-0.74	-5.59	-0.5	2.16e-7	Mean platelet volume;
THYM	cis	rs10208649	0.908	rs6719990	chr2:54264652	A/T	cg04546899	chr2:54196757	PSME4	0.68	4.73	0.44	7.94e-6	Body mass index;
THYM	cis	rs11250464	0.794	rs11250487	chr10:1434168	C/A	cg08668359	chr10:1443807	ADARB2	0.61	5.16	0.47	1.35e-6	Radiation response;
THYM	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs600231	0.708	rs1784860	chr11:65240712	C/A	cg17120908	chr11:65337727	SSSCA1	-0.61	-4.75	-0.44	7.14e-6	Bone mineral density;
THYM	cis	rs1461503	0.809	rs7121955	chr11:122845478	A/T	cg27398637	chr11:122830231	C11orf63	-0.71	-6.64	-0.56	1.97e-9	Menarche (age at onset);
THYM	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg04398451	chr17:18023971	MYO15A	0.98	11.5	0.76	1.08e-19	Total body bone mineral density;
THYM	cis	rs3820068	0.705	rs4646096	chr1:15820758	A/G	cg05660106	chr1:15850417	CASP9	1.13	10.23	0.72	5.39e-17	Systolic blood pressure;
THYM	cis	rs12935418	0.552	rs2549847	chr16:81024222	T/G	cg16651780	chr16:81037892	C16orf61	-0.86	-6.73	-0.57	1.3e-9	Mean corpuscular volume;
THYM	cis	rs9399401	0.626	rs3817928	chr6:142750516	A/G	cg04461802	chr6:142623433	GPR126	0.76	7.35	0.6	6.98e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs9399401	0.626	rs6906468	chr6:142769386	A/G	cg03128060	chr6:142623767	GPR126	0.65	9.15	0.68	1.09e-14	Chronic obstructive pulmonary disease;
THYM	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08109568	chr15:31115862	NA	-0.63	-5.99	-0.52	3.8e-8	Huntington's disease progression;
THYM	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg25427524	chr10:38739819	LOC399744	-0.67	-6.07	-0.53	2.57e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs2963155	0.518	rs10482614	chr5:142782402	C/T	cg17617527	chr5:142782415	NR3C1	1.12	6.01	0.52	3.43e-8	Breast cancer;
THYM	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg26384229	chr12:38710491	ALG10B	0.92	7.34	0.6	7.32e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7584099	0.504	rs7593570	chr2:148739393	G/A	cg23727674	chr2:148602993	ACVR2A	0.54	4.73	0.44	7.88e-6	Response to statin therapy;
THYM	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.65	-0.62	1.6e-11	Schizophrenia;
THYM	cis	rs9527	0.544	rs11191549	chr10:104846797	C/T	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs4889855	0.530	rs12603265	chr17:78618637	A/G	cg16591659	chr17:78472290	NA	-0.41	-5.14	-0.47	1.48e-6	Fractional excretion of uric acid;
THYM	cis	rs449303	1	rs449303	chr14:60605788	A/G	cg00846580	chr14:60632234	DHRS7	0.8	5.26	0.48	8.8e-7	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs7119038	0.731	rs10892283	chr11:118636980	A/G	cg19308663	chr11:118741387	NA	0.58	5.41	0.49	4.72e-7	Sjögren's syndrome;
THYM	cis	rs1457451	0.748	rs11900826	chr2:65853229	T/C	cg16240816	chr2:65861662	NA	0.61	6.08	0.53	2.48e-8	Iron status biomarkers;
THYM	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	5.26	0.48	8.71e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg09469691	chr10:81107165	PPIF	0.71	5.82	0.51	7.83e-8	Height;
THYM	cis	rs986417	0.711	rs2224409	chr14:60957216	C/T	cg27398547	chr14:60952738	C14orf39	1.13	5.43	0.49	4.26e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs9560113	0.960	rs9560102	chr13:112173825	G/A	cg10483660	chr13:112241077	NA	0.53	4.76	0.44	6.81e-6	Menarche (age at onset);
THYM	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2041840	0.824	rs7593932	chr2:37567226	C/T	cg25727520	chr2:37576821	QPCT	-0.4	-4.58	-0.43	1.42e-5	Chronic lymphocytic leukemia;
THYM	cis	rs9807989	0.507	rs2287033	chr2:103011237	C/T	cg03938978	chr2:103052716	IL18RAP	-0.74	-9.61	-0.7	1.15e-15	Asthma;
THYM	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg02725872	chr8:58115012	NA	-1.09	-8.15	-0.64	1.43e-12	Developmental language disorder (linguistic errors);
THYM	cis	rs1461503	0.780	rs75981430	chr11:122842469	A/C	cg27398637	chr11:122830231	C11orf63	-0.7	-6.66	-0.56	1.81e-9	Menarche (age at onset);
THYM	cis	rs9486719	1.000	rs12190397	chr6:97036465	G/A	cg18709589	chr6:96969512	KIAA0776	-0.67	-4.64	-0.43	1.1e-5	Migraine;Coronary artery disease;
THYM	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg00024416	chr22:24240387	NA	-0.63	-6.9	-0.58	5.64e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1461503	0.900	rs7115852	chr11:122831830	G/A	cg27398637	chr11:122830231	C11orf63	-0.63	-5.25	-0.47	9.24e-7	Menarche (age at onset);
THYM	cis	rs57590327	0.504	rs13065281	chr3:81693550	G/A	cg07356753	chr3:81810745	GBE1	-0.81	-5.53	-0.49	2.8e-7	Extraversion;
THYM	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.51	5.15	0.47	1.39e-6	Schizophrenia;
THYM	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg15962314	chr1:44399869	ARTN	0.54	5.43	0.49	4.32e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs3849570	1.000	rs9842330	chr3:81814688	G/A	cg07356753	chr3:81810745	GBE1	-0.93	-7.66	-0.62	1.56e-11	Waist circumference;Body mass index;
THYM	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg01831904	chr17:28903510	LRRC37B2	0.98	4.99	0.46	2.78e-6	Body mass index;
THYM	trans	rs10962692	0.530	rs62541923	chr9:16870501	C/A	cg03221025	chr16:88955224	CBFA2T3	0.75	7.2	0.59	1.4e-10	Ovarian cancer in BRCA2 mutation carriers;Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;
THYM	cis	rs4731207	0.698	rs4731223	chr7:124483272	A/T	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg17063962	chr7:91808500	NA	1.13	12.56	0.79	6.81e-22	Breast cancer;
THYM	cis	rs7814319	0.899	rs1878638	chr8:97258719	C/T	cg20787634	chr8:97240163	UQCRB	-0.79	-9.53	-0.7	1.71e-15	Lung function (FVC);
THYM	cis	rs7078219	0.714	rs888208	chr10:101295863	A/G	cg07044859	chr10:101282883	NA	-0.49	-5.26	-0.47	9.05e-7	Dental caries;
THYM	cis	rs4769475	0.957	rs192752	chr13:26711733	A/T	cg13319468	chr13:27597730	NA	-0.67	-5.46	-0.49	3.74e-7	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs36051895	0.664	rs10117459	chr9:5094034	G/A	cg02405213	chr9:5042618	JAK2	-1.0	-10.94	-0.75	1.67e-18	Pediatric autoimmune diseases;
THYM	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg18252515	chr7:66147081	NA	-1.18	-6.43	-0.55	4.99e-9	Diabetic kidney disease;
THYM	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg13114125	chr14:105738426	BRF1	-0.74	-5.72	-0.51	1.22e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg06623918	chr6:96969491	KIAA0776	1.09	9.82	0.71	3.91e-16	Headache;
THYM	cis	rs62070183	0.938	rs75822124	chr17:31037894	C/T	cg23177095	chr17:30873196	MYO1D	0.64	4.92	0.45	3.61e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs7568458	0.846	rs6705839	chr2:85761279	A/T	cg17127132	chr2:85788382	GGCX	0.68	6.1	0.53	2.28e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs1018836	0.923	rs1858674	chr8:91580665	G/T	cg16814680	chr8:91681699	NA	-0.75	-6.25	-0.54	1.16e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6992820	0.967	rs7816303	chr8:56723278	A/G	cg06880721	chr8:56792545	LYN	-0.71	-5.94	-0.52	4.77e-8	Mean platelet volume;
THYM	cis	rs9868809	0.772	rs28452701	chr3:48708575	C/T	cg00383909	chr3:49044727	WDR6	1.04	5.4	0.48	4.88e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs863345	0.604	rs1578761	chr1:158497572	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs7633857	0.532	rs9873705	chr3:160768818	A/T	cg03342759	chr3:160939853	NMD3	-0.63	-4.84	-0.44	5.04e-6	Educational attainment (years of education);
THYM	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg04944784	chr2:26401820	FAM59B	-0.68	-5.09	-0.46	1.78e-6	Gut microbiome composition (summer);
THYM	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg26513180	chr16:89883248	FANCA	0.73	7.24	0.6	1.16e-10	Vitiligo;
THYM	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg13147721	chr7:65941812	NA	-1.0	-6.2	-0.54	1.47e-8	Diabetic kidney disease;
THYM	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg00376283	chr12:123451042	ABCB9	0.68	5.22	0.47	1.04e-6	Height;Educational attainment;Head circumference (infant);
THYM	cis	rs6732160	0.613	rs59979991	chr2:73384422	G/A	cg24220031	chr2:73402428	NA	-0.71	-5.79	-0.51	8.94e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	5.52	0.49	2.88e-7	Hip circumference adjusted for BMI;
THYM	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg00786635	chr1:25594202	NA	0.91	7.6	0.61	2.08e-11	Erythrocyte sedimentation rate;
THYM	cis	rs12410462	0.551	rs2814091	chr1:227636367	G/T	cg22525281	chr1:228134933	WNT9A	-0.59	-4.84	-0.44	5.1e-6	Major depressive disorder;
THYM	cis	rs34112283	0.592	rs5025201	chr2:144206076	T/G	cg17056048	chr2:144271431	ARHGAP15	0.66	6.56	0.56	2.81e-9	Neuroticism;
THYM	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg24060327	chr5:131705240	SLC22A5	0.8	6.52	0.56	3.35e-9	Breast cancer;
THYM	cis	rs3126085	0.935	rs7537637	chr1:152223335	T/A	cg10321714	chr1:152280068	FLG	0.65	4.64	0.43	1.1e-5	Atopic dermatitis;
THYM	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10791097	0.739	rs735094	chr11:130725109	G/C	cg05962950	chr11:130786565	SNX19	0.73	5.92	0.52	4.99e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11039798	1.000	rs8188963	chr11:48685693	C/A	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg24250549	chr1:154909240	PMVK	0.79	6.71	0.57	1.41e-9	Prostate cancer;
THYM	cis	rs662064	0.963	rs1188529	chr1:10525914	A/T	cg05038881	chr1:10490043	APITD1	0.28	4.47	0.42	2.17e-5	Asthma;
THYM	cis	rs901683	0.850	rs12098366	chr10:46091616	G/A	cg18240400	chr10:46168597	ANUBL1	0.68	5.03	0.46	2.31e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg16418258	chr15:42840397	LRRC57;HAUS2	-0.56	-4.5	-0.42	1.95e-5	Lung cancer;
THYM	cis	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg08975724	chr8:8085496	FLJ10661	-0.59	-4.87	-0.45	4.36e-6	Mood instability;
THYM	trans	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg04944784	chr2:26401820	FAM59B	-1.08	-8.57	-0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs80319144	0.521	rs1116969	chr2:159312164	G/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.52	4.99	0.46	2.77e-6	Restless legs syndrome;
THYM	cis	rs1403694	0.695	rs5029975	chr3:186436918	A/G	cg12454167	chr3:186435060	KNG1	-0.51	-7.39	-0.6	5.6e-11	Blood protein levels;
THYM	cis	rs62070183	0.882	rs17780981	chr17:31119037	A/G	cg23177095	chr17:30873196	MYO1D	0.64	5.02	0.46	2.41e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7968440	0.651	rs7309519	chr12:50652280	G/A	cg20014596	chr12:50898483	DIP2B	-0.53	-5.01	-0.46	2.54e-6	Fibrinogen;
THYM	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.09	8.17	0.64	1.33e-12	Smoking behavior;
THYM	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	trans	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg06636001	chr8:8085503	FLJ10661	0.78	6.99	0.58	3.83e-10	Neuroticism;
THYM	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg14458575	chr2:238380390	NA	0.91	7.49	0.61	3.6e-11	Prostate cancer;
THYM	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg06600287	chr1:53387719	ECHDC2	-0.3	-4.78	-0.44	6.39e-6	Monocyte count;
THYM	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs1003719	0.699	rs1015549	chr21:38448880	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.48	4.51	0.42	1.89e-5	Birth weight;
THYM	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg22875332	chr1:76189707	ACADM	0.62	5.58	0.5	2.28e-7	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7635838	0.684	rs346079	chr3:11328139	G/A	cg00170343	chr3:11313890	ATG7	0.57	4.55	0.42	1.6e-5	HDL cholesterol;
THYM	cis	rs988913	0.918	rs7739399	chr6:54855538	C/T	cg18532076	chr6:54711417	FAM83B	0.51	4.74	0.44	7.6e-6	Menarche (age at onset);
THYM	cis	rs34638657	0.872	rs2967355	chr16:82200103	G/T	cg19807685	chr16:82068980	HSD17B2	0.63	4.91	0.45	3.76e-6	Lung adenocarcinoma;
THYM	cis	rs7826238	0.502	rs10503377	chr8:8378422	C/T	cg17143192	chr8:8559678	CLDN23	0.61	4.45	0.42	2.31e-5	Systolic blood pressure;
THYM	cis	rs7084402	0.967	rs1658467	chr10:60295316	A/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.65e-7	Refractive error;
THYM	cis	rs2302612	0.528	rs3755287	chr2:102839856	G/A	cg13315345	chr2:102803985	IL1RL2	0.68	4.58	0.43	1.4e-5	Serum protein levels (sST2);
THYM	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	trans	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs939658	0.805	rs11638625	chr15:79434787	T/G	cg17916960	chr15:79447300	NA	-0.75	-8.62	-0.66	1.48e-13	Refractive error;
THYM	cis	rs17253792	0.822	rs77555779	chr14:56078430	A/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs7106204	0.686	rs12803800	chr11:24258319	A/G	ch.11.24196551F	chr11:24239977	NA	0.93	5.71	0.51	1.3e-7	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs3771570	0.579	rs62190373	chr2:242388685	G/A	cg21155796	chr2:242212141	HDLBP	1.25	6.07	0.53	2.57e-8	Prostate cancer;
THYM	cis	rs28795989	0.896	rs7437940	chr4:7887500	C/T	cg12728606	chr4:7903970	AFAP1	-0.44	-4.64	-0.43	1.09e-5	Intraocular pressure;
THYM	cis	rs7264396	0.790	rs8125090	chr20:34360015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.35	-0.48	6.19e-7	Total cholesterol levels;
THYM	cis	rs7072216	0.763	rs3814142	chr10:100171104	C/G	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs13014235	0.532	rs10497867	chr2:202284867	T/C	cg12544106	chr2:202507780	ALS2CR4	-0.62	-4.59	-0.43	1.37e-5	Basal cell carcinoma;
THYM	cis	rs1488864	0.892	rs1488871	chr11:6350469	G/A	cg12755421	chr11:6342214	PRKCDBP	-0.52	-4.52	-0.42	1.78e-5	Smooth-surface caries;
THYM	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7953249	0.656	rs2251468	chr12:121405126	A/C	cg02403541	chr12:121454288	C12orf43	0.71	6.43	0.55	5.01e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs1395	1.000	rs1275501	chr2:27419282	A/C	cg23587288	chr2:27483067	SLC30A3	0.58	5.09	0.46	1.78e-6	Blood metabolite levels;
THYM	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.74	-5.59	-0.5	2.19e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1003719	0.715	rs2156078	chr21:38546473	T/C	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	4.92	0.45	3.68e-6	Schizophrenia;
THYM	cis	rs13191362	0.507	rs13210000	chr6:163176944	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.71	5.28	0.48	8.25e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg23711669	chr6:146136114	FBXO30	0.93	9.69	0.7	7.64e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2811415	0.597	rs3733158	chr3:127787157	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs7512552	0.839	rs11587575	chr1:150451863	T/C	cg15654264	chr1:150340011	RPRD2	0.44	5.12	0.47	1.58e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg13257436	chr8:145726034	PPP1R16A	-0.59	-4.7	-0.43	8.66e-6	Age at first birth;
THYM	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg07341220	chr16:1583899	IFT140;TMEM204	-0.61	-5.01	-0.46	2.53e-6	Coronary artery disease;
THYM	cis	rs892961	0.932	rs7224116	chr17:75413177	A/G	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs7200543	0.583	rs4985149	chr16:15147338	A/T	cg01933576	chr16:15083564	PDXDC1	-0.95	-7.97	-0.63	3.5e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg13289132	chr10:30722225	MAP3K8	0.57	4.86	0.45	4.56e-6	Inflammatory bowel disease;
THYM	cis	rs11096990	0.634	rs10010352	chr4:39242277	A/G	cg24403649	chr4:39172243	NA	0.67	5.87	0.52	6.24e-8	Cognitive function;
THYM	trans	rs877282	0.898	rs11253341	chr10:765008	G/C	cg22713356	chr15:30763199	NA	1.36	10.13	0.72	8.77e-17	Uric acid levels;
THYM	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg01341218	chr17:43662625	NA	-1.07	-9.27	-0.69	5.9e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11948739	0.538	rs4705991	chr5:130306152	C/G	cg08523029	chr5:130500466	HINT1	-0.84	-5.88	-0.52	6.09e-8	Pediatric bone mineral content (hip);
THYM	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg07636037	chr3:49044803	WDR6	0.76	6.33	0.54	8.19e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg17063962	chr7:91808500	NA	0.99	7.83	0.63	6.74e-12	Breast cancer;
THYM	cis	rs9902453	0.817	rs62068620	chr17:28167674	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.79	0.44	6.08e-6	Coffee consumption (cups per day);
THYM	cis	rs901683	1.000	rs9422651	chr10:46047456	C/T	cg18240400	chr10:46168597	ANUBL1	0.65	4.56	0.42	1.52e-5	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs6089829	0.851	rs10854168	chr20:61669550	A/G	cg08045932	chr20:61659980	NA	0.94	10.05	0.72	1.27e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4887140	1.000	rs4887140	chr15:74046663	G/T	cg11789681	chr15:74046708	NA	0.97	4.59	0.43	1.38e-5	Glucose homeostasis traits;
THYM	cis	rs28595532	0.920	rs115860303	chr4:119734526	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg24733560	chr20:60626293	TAF4	0.6	6.21	0.54	1.37e-8	Body mass index;
THYM	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg24060327	chr5:131705240	SLC22A5	-0.8	-6.52	-0.56	3.35e-9	Breast cancer;
THYM	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg10505658	chr17:80084571	CCDC57	0.66	7.04	0.59	3.01e-10	Life satisfaction;
THYM	cis	rs10489202	0.608	rs7556350	chr1:168077797	C/T	cg24449463	chr1:168025552	DCAF6	-0.7	-6.06	-0.53	2.77e-8	Schizophrenia;
THYM	cis	rs9807841	0.568	rs3859514	chr19:10748820	T/C	cg17848348	chr19:10766748	ILF3	-0.77	-6.35	-0.55	7.2e-9	Inflammatory skin disease;
THYM	cis	rs6918586	0.658	rs198844	chr6:26108282	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.59	-0.61	2.21e-11	Schizophrenia;
THYM	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg04362960	chr10:104952993	NT5C2	0.6	4.92	0.45	3.68e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs17122693	1.000	rs3015444	chr14:51085116	T/C	cg04730355	chr14:51134070	SAV1	0.83	4.62	0.43	1.18e-5	Cognitive performance;
THYM	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg10518543	chr12:38710700	ALG10B	-0.59	-4.67	-0.43	9.89e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs17174870	1.000	rs55728465	chr2:112666096	A/G	cg17354880	chr2:112658759	MERTK	-0.59	-4.6	-0.43	1.31e-5	Multiple sclerosis;
THYM	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05901451	chr6:126070800	HEY2	-0.96	-9.53	-0.7	1.68e-15	Brugada syndrome;
THYM	cis	rs3126085	0.935	rs12408581	chr1:152175211	A/G	cg10321714	chr1:152280068	FLG	-0.76	-5.65	-0.5	1.71e-7	Atopic dermatitis;
THYM	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg18132916	chr6:79620363	NA	0.61	5.63	0.5	1.8e-7	Intelligence (multi-trait analysis);
THYM	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg26384229	chr12:38710491	ALG10B	1.04	10.23	0.72	5.34e-17	Heart rate;
THYM	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg25817165	chr18:72167213	CNDP2	-0.96	-7.96	-0.63	3.71e-12	Refractive error;
THYM	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01341218	chr17:43662625	NA	1.05	8.93	0.68	3.22e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.02	-7.03	-0.59	3.07e-10	Platelet count;
THYM	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4866334	0.850	rs75708102	chr5:18489975	C/A	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs754466	0.651	rs11813532	chr10:79637991	T/C	cg17075019	chr10:79541650	NA	-0.69	-5.85	-0.51	6.94e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg26038318	chr20:34205095	SPAG4	0.59	4.68	0.43	9.62e-6	Total cholesterol levels;
THYM	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6723226	0.699	rs376914	chr2:32508393	G/C	cg02381751	chr2:32503542	YIPF4	0.68	5.71	0.51	1.31e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3767633	0.764	rs2340717	chr1:161822959	C/T	cg27495845	chr1:161693088	FCRLB	-0.67	-4.59	-0.43	1.35e-5	IgG glycosylation;
THYM	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg26149184	chr10:133730230	NA	0.78	4.75	0.44	7.22e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs12935418	0.672	rs9923948	chr16:81047419	A/G	cg16651780	chr16:81037892	C16orf61	0.86	6.29	0.54	9.5e-9	Mean corpuscular volume;
THYM	cis	rs7404928	0.557	rs8057516	chr16:23929483	T/C	cg26685404	chr16:23957272	PRKCB	-0.58	-6.53	-0.56	3.16e-9	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	trans	rs1973993	0.691	rs1980684	chr1:96890636	A/G	cg10631902	chr5:14652156	NA	0.77	9.44	0.7	2.62e-15	Weight;
THYM	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg09034736	chr1:150693464	HORMAD1	-0.57	-4.92	-0.45	3.66e-6	Blood protein levels;
THYM	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg03806693	chr22:41940476	POLR3H	-1.09	-8.62	-0.66	1.45e-13	Vitiligo;
THYM	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg09323728	chr8:95962352	TP53INP1	-0.46	-4.76	-0.44	6.8e-6	Type 2 diabetes;
THYM	cis	rs4900538	0.963	rs1190554	chr14:102918686	T/C	cg23712530	chr14:102964522	TECPR2	0.49	4.72	0.44	8.27e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs901683	1.000	rs36053776	chr10:46088145	C/A	cg18240400	chr10:46168597	ANUBL1	0.73	4.73	0.44	7.89e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg10047753	chr17:41438598	NA	1.18	11.26	0.76	3.4e-19	Menopause (age at onset);
THYM	cis	rs2282032	0.527	rs3742666	chr14:90767860	T/C	cg14092571	chr14:90743983	NA	0.66	6.54	0.56	3.11e-9	Longevity;
THYM	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg27034606	chr17:28928453	LRRC37B2	0.79	4.89	0.45	4.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4974559	0.790	rs11933855	chr4:1315183	C/T	cg02980000	chr4:1222292	CTBP1	0.79	5.09	0.46	1.82e-6	Systolic blood pressure;
THYM	cis	rs7106204	0.534	rs74650605	chr11:24253414	T/C	ch.11.24196551F	chr11:24239977	NA	0.89	4.62	0.43	1.22e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg09455208	chr3:40491958	NA	0.49	5.1	0.46	1.75e-6	Renal cell carcinoma;
THYM	cis	rs988913	0.957	rs4437472	chr6:54838438	C/T	cg19716238	chr6:54711378	FAM83B	0.5	4.91	0.45	3.76e-6	Menarche (age at onset);
THYM	trans	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg14893161	chr1:205819251	PM20D1	0.87	8.72	0.67	9.08e-14	Menarche (age at onset);
THYM	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg08017756	chr2:100939284	LONRF2	-0.75	-7.8	-0.62	7.89e-12	Intelligence (multi-trait analysis);
THYM	cis	rs2502731	1.000	rs2502731	chr9:130976557	A/G	cg07814289	chr9:130981060	DNM1	-0.57	-4.61	-0.43	1.26e-5	Attention deficit hyperactivity disorder;
THYM	cis	rs969413	0.535	rs8077394	chr17:79258787	A/G	cg14413466	chr17:79170920	AZI1	-0.66	-5.93	-0.52	4.85e-8	Frontotemporal dementia;
THYM	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg06784218	chr1:46089804	CCDC17	-0.29	-4.54	-0.42	1.65e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs2354432	0.607	rs6677679	chr1:146803630	C/T	cg25205988	chr1:146714368	CHD1L	-1.03	-5.4	-0.48	4.84e-7	Mitochondrial DNA levels;
THYM	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg26924012	chr15:45694286	SPATA5L1	1.14	10.78	0.74	3.64e-18	Homoarginine levels;
THYM	cis	rs747782	0.583	rs11039666	chr11:48324841	C/G	cg24672777	chr11:48374446	OR4C45	-1.05	-5.38	-0.48	5.43e-7	Intraocular pressure;
THYM	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg08645402	chr16:4508243	NA	0.69	5.6	0.5	2.1e-7	Schizophrenia;
THYM	cis	rs12509991	0.531	rs1905335	chr4:127037185	C/T	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg03676636	chr4:99064102	C4orf37	0.43	6.33	0.54	8.16e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3862030	0.694	rs12781742	chr10:104227469	G/A	cg00122347	chr10:104236741	TMEM180	0.48	7.24	0.6	1.14e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs13315871	0.929	rs34676912	chr3:58320298	C/A	cg00563845	chr3:58318305	PXK	0.58	5.09	0.46	1.82e-6	Cholesterol, total;
THYM	cis	rs6430585	0.527	rs59413285	chr2:136444185	G/T	cg07169764	chr2:136633963	MCM6	1.03	9.12	0.68	1.26e-14	Corneal structure;
THYM	trans	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22496380	chr5:211416	CCDC127	-1.28	-7.77	-0.62	9.06e-12	Breast cancer;
THYM	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9549260	0.739	rs7330614	chr13:41199421	G/A	cg21288729	chr13:41239152	FOXO1	0.72	5.55	0.49	2.61e-7	Red blood cell count;
THYM	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg08017756	chr2:100939284	LONRF2	-0.75	-7.78	-0.62	8.81e-12	Intelligence (multi-trait analysis);
THYM	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg20887711	chr4:1340912	KIAA1530	0.75	6.78	0.57	1e-9	Longevity;
THYM	cis	rs2901656	0.640	rs9425316	chr1:172400860	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.59	6.16	0.53	1.72e-8	Red cell distribution width;Platelet distribution width;
THYM	cis	rs600806	0.888	rs443345	chr1:109849254	A/G	cg23032129	chr1:109941072	SORT1	-0.56	-4.7	-0.43	8.68e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7830933	0.910	rs62500432	chr8:23583628	G/C	cg04349084	chr8:23602677	NA	0.68	7.07	0.59	2.58e-10	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs12410462	0.581	rs6675521	chr1:227544702	C/T	cg23173402	chr1:227635558	NA	0.66	5.21	0.47	1.1e-6	Major depressive disorder;
THYM	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg19770292	chr5:1868693	NA	0.54	4.97	0.45	2.95e-6	Cardiovascular disease risk factors;
THYM	cis	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg13609457	chr4:120235615	NA	-0.56	-5.24	-0.47	9.65e-7	Corneal astigmatism;
THYM	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg01528321	chr10:82214614	TSPAN14	0.64	5.35	0.48	5.99e-7	Post bronchodilator FEV1;
THYM	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg18876405	chr7:65276391	NA	0.63	5.56	0.5	2.48e-7	Aortic root size;
THYM	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	4.53	0.42	1.7e-5	Rheumatoid arthritis;
THYM	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg11245990	chr11:68621969	NA	0.54	6.76	0.57	1.1e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg01699819	chr7:1052092	C7orf50	0.57	4.82	0.44	5.34e-6	Bronchopulmonary dysplasia;
THYM	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg22166914	chr1:53195759	ZYG11B	-0.89	-9.73	-0.71	6.37e-16	Monocyte count;
THYM	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg06064525	chr11:970664	AP2A2	-0.35	-6.67	-0.56	1.69e-9	Alzheimer's disease (late onset);
THYM	cis	rs79149102	0.579	rs58294763	chr15:75299768	G/A	cg17294928	chr15:75287854	SCAMP5	-1.06	-5.68	-0.5	1.49e-7	Lung cancer;
THYM	cis	rs988913	0.768	rs1115159	chr6:54753541	T/C	cg04690482	chr6:54711388	FAM83B	0.52	6.3	0.54	9.33e-9	Menarche (age at onset);
THYM	cis	rs611744	0.967	rs597649	chr8:109187718	T/G	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg23583168	chr7:148888333	NA	-1.1	-16.73	-0.86	4.47e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs17102423	0.826	rs10873181	chr14:65604459	A/C	cg11161011	chr14:65562177	MAX	-0.66	-5.76	-0.51	1.03e-7	Obesity-related traits;
THYM	cis	rs59698941	0.943	rs60042606	chr5:132248170	G/T	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs36051895	0.659	rs7036476	chr9:5063664	T/C	cg02405213	chr9:5042618	JAK2	-1.05	-10.91	-0.75	1.89e-18	Pediatric autoimmune diseases;
THYM	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg15247329	chr7:2764246	NA	-0.69	-5.7	-0.5	1.35e-7	Height;
THYM	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg22664400	chr11:66445111	RBM4B	0.66	4.47	0.42	2.14e-5	Crohn's disease;
THYM	cis	rs4638749	0.677	rs998186	chr2:108844237	C/T	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg18811423	chr2:55921094	PNPT1	0.78	7.29	0.6	9.14e-11	Metabolic syndrome;
THYM	cis	rs6748734	0.625	rs4295000	chr2:241821237	C/T	cg09990169	chr2:241835740	C2orf54	-0.3	-5.01	-0.46	2.56e-6	Urinary metabolites;
THYM	cis	rs2066819	1.000	rs80317430	chr12:56727705	G/A	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs4713118	0.619	rs200486	chr6:27779506	C/T	cg12963246	chr6:28129442	ZNF389	0.67	4.68	0.43	9.36e-6	Parkinson's disease;
THYM	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg23505145	chr19:12996616	KLF1	1.02	9.83	0.71	3.86e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg17294928	chr15:75287854	SCAMP5	0.65	4.97	0.45	2.99e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs9814567	0.964	rs4974480	chr3:134178562	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.57	-0.61	2.44e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7226229	1.000	rs7216786	chr17:20931064	A/G	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs1003719	0.680	rs2835668	chr21:38580151	C/G	cg01329690	chr21:38580129	DSCR9	-0.36	-4.98	-0.46	2.81e-6	Eye color traits;
THYM	cis	rs10992471	0.702	rs10120915	chr9:95547725	A/C	cg14631576	chr9:95140430	CENPP	-0.84	-7.23	-0.6	1.22e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg17063962	chr7:91808500	NA	-1.08	-11.41	-0.76	1.71e-19	Breast cancer;
THYM	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg06640241	chr16:89574553	SPG7	0.65	4.65	0.43	1.05e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24531977	chr5:56204891	C5orf35	-1.04	-7.84	-0.63	6.63e-12	Initial pursuit acceleration;
THYM	cis	rs12579753	1.000	rs12821073	chr12:82183260	G/T	cg21231944	chr12:82153410	PPFIA2	-0.68	-5.12	-0.46	1.6e-6	Resting heart rate;
THYM	cis	rs72627509	0.767	rs6853156	chr4:57774843	C/T	cg26694713	chr4:57773883	REST	0.76	4.85	0.45	4.78e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs2797160	1.000	rs984040	chr6:126021277	A/G	cg16306078	chr6:126000798	NA	0.54	5.57	0.5	2.38e-7	Endometrial cancer;
THYM	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg08975724	chr8:8085496	FLJ10661	0.67	4.87	0.45	4.51e-6	Neuroticism;
THYM	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg20503657	chr10:835505	NA	1.17	8.3	0.65	7.12e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs28595532	0.920	rs56124677	chr4:119772213	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs6960043	0.905	rs7786873	chr7:15060410	A/G	cg19272540	chr7:15055459	NA	-0.53	-6.34	-0.55	7.81e-9	Type 2 diabetes;
THYM	trans	rs9929218	1.000	rs4500718	chr16:68754312	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-7.53	-0.61	2.92e-11	Colorectal cancer;
THYM	cis	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg02734326	chr4:10020555	SLC2A9	0.75	6.89	0.58	6.11e-10	Bone mineral density;
THYM	cis	rs28595532	1.000	rs115915387	chr4:119640854	C/T	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs17641971	0.662	rs1828495	chr8:49945281	C/T	cg00325661	chr8:49890786	NA	0.65	4.79	0.44	6.09e-6	Blood metabolite levels;
THYM	cis	rs12348691	0.503	rs7847259	chr9:100600712	A/G	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Alopecia areata;
THYM	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs193541	0.565	rs7716700	chr5:122341654	T/A	cg19808643	chr5:122110361	SNX2	-0.58	-4.96	-0.45	3.08e-6	Glucose homeostasis traits;
THYM	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg02725872	chr8:58115012	NA	-0.92	-7.03	-0.59	3.08e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.73	-4.82	-0.44	5.35e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg14019146	chr3:50243930	SLC38A3	-0.65	-5.48	-0.49	3.56e-7	Intelligence (multi-trait analysis);
THYM	cis	rs921665	0.680	rs4411731	chr2:3189324	C/A	cg16434511	chr2:3151078	NA	-0.84	-5.24	-0.47	9.7e-7	World class endurance athleticism;
THYM	cis	rs12478296	0.681	rs56357900	chr2:243033966	A/C	cg06360820	chr2:242988706	NA	-0.9	-5.52	-0.49	2.95e-7	Obesity-related traits;
THYM	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.64	4.52	0.42	1.81e-5	Lung cancer in ever smokers;
THYM	cis	rs420259	0.516	rs10153059	chr16:23512383	C/T	cg00143387	chr16:23521605	GGA2	-0.74	-5.31	-0.48	7.21e-7	Bipolar disorder;
THYM	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg19016782	chr12:123741754	C12orf65	-0.7	-4.59	-0.43	1.35e-5	Neutrophil percentage of white cells;
THYM	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg03264133	chr6:25882463	NA	-0.64	-4.77	-0.44	6.59e-6	Height;
THYM	cis	rs9649213	0.593	rs3801255	chr7:98000929	C/T	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4435363	0.794	rs117855633	chr19:47072791	A/G	cg10017888	chr19:47105860	CALM3	0.82	5.39	0.48	5.06e-7	Immature fraction of reticulocytes;P wave terminal force;
THYM	cis	rs478304	0.654	rs7947604	chr11:65442059	G/C	cg27068330	chr11:65405492	SIPA1	-1.05	-10.98	-0.75	1.33e-18	Acne (severe);
THYM	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg02891314	chr5:179741120	GFPT2	-0.88	-7.14	-0.59	1.88e-10	Height;
THYM	cis	rs524281	0.731	rs11227439	chr11:66025679	G/A	cg00563793	chr11:65837595	PACS1	0.79	4.72	0.44	8.2e-6	Electroencephalogram traits;
THYM	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.76	-4.97	-0.45	3e-6	Mean platelet volume;
THYM	cis	rs12410462	0.551	rs2819513	chr1:227630987	G/A	cg22525281	chr1:228134933	WNT9A	0.59	4.84	0.44	5.1e-6	Major depressive disorder;
THYM	cis	rs56775891	0.559	rs11664298	chr18:77578986	G/A	cg25357022	chr18:77495084	CTDP1	-0.68	-4.51	-0.42	1.83e-5	Schizophrenia;
THYM	cis	rs8192282	0.739	rs6662503	chr1:154477069	T/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.6	-5.48	-0.49	3.55e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs7149242	0.696	rs7141210	chr14:101182470	T/C	cg18089426	chr14:101175970	NA	-0.56	-5.48	-0.49	3.56e-7	Platelet count;
THYM	cis	rs887829	0.569	rs3821242	chr2:234637803	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.75	-6.19	-0.54	1.54e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs7144547	0.950	rs8004137	chr14:81884857	A/G	cg02996355	chr14:81879375	NA	-0.95	-9.65	-0.7	9.39e-16	Prudent dietary pattern;
THYM	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg01073479	chr16:3509474	NAT15	0.53	5.25	0.47	9.14e-7	Tuberculosis;
THYM	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg00129232	chr17:37814104	STARD3	-0.69	-4.51	-0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg23711669	chr6:146136114	FBXO30	0.9	8.92	0.68	3.32e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1971762	0.712	rs7302232	chr12:53965423	A/T	cg16917193	chr12:54089295	NA	0.67	6.1	0.53	2.29e-8	Height;
THYM	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg10523679	chr1:76189770	ACADM	0.92	10.35	0.73	2.94e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg02782426	chr3:40428986	ENTPD3	-0.51	-4.54	-0.42	1.67e-5	Renal cell carcinoma;
THYM	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg15247329	chr7:2764246	NA	-0.69	-5.64	-0.5	1.76e-7	Height;
THYM	cis	rs11030122	0.733	rs10835331	chr11:3957365	C/T	cg18678763	chr11:4115507	RRM1	-0.43	-5.53	-0.49	2.79e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9297145	1.000	rs9297145	chr7:98759117	A/C	cg05967295	chr7:98741636	SMURF1	0.95	8.8	0.67	6.15e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs4474465	0.850	rs10899539	chr11:78243743	T/C	cg19901956	chr11:77921274	USP35	0.61	4.6	0.43	1.3e-5	Alzheimer's disease (survival time);
THYM	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg06002616	chr8:101225028	SPAG1	0.46	4.82	0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs6473252	0.584	rs4739765	chr8:81821634	A/C	cg08595989	chr8:81827712	NA	-0.51	-5.6	-0.5	2.12e-7	Breast cancer;
THYM	cis	rs1878931	0.567	rs7196196	chr16:3411855	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	9.17	0.69	9.9e-15	Body mass index (adult);
THYM	cis	rs2932538	0.922	rs3790611	chr1:113067792	A/G	cg22162597	chr1:113214053	CAPZA1	0.6	5.07	0.46	1.96e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs6473252	0.584	rs4739766	chr8:81821656	C/T	cg08595989	chr8:81827712	NA	-0.5	-5.44	-0.49	4.12e-7	Breast cancer;
THYM	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg16405210	chr4:1374714	KIAA1530	-0.68	-5.69	-0.5	1.42e-7	Longevity;
THYM	cis	rs11648796	0.959	rs9928077	chr16:784765	C/T	cg16899442	chr16:776458	CCDC78;HAGHL	0.45	4.67	0.43	1e-5	Height;
THYM	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg13147721	chr7:65941812	NA	-0.99	-6.21	-0.54	1.41e-8	Diabetic kidney disease;
THYM	cis	rs854765	0.583	rs8078138	chr17:17811251	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.34	0.55	7.83e-9	Total body bone mineral density;
THYM	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg13866156	chr1:1669148	SLC35E2	-0.73	-7.08	-0.59	2.45e-10	Body mass index;
THYM	cis	rs7894051	1.000	rs77189950	chr10:135126722	A/T	cg02114346	chr10:135191542	PAOX	0.9	4.59	0.43	1.34e-5	Lifespan;
THYM	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg25427524	chr10:38739819	LOC399744	-0.64	-6.04	-0.53	2.98e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg20607798	chr8:58055168	NA	0.83	4.68	0.43	9.53e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.25	0.47	9.11e-7	Melanoma;
THYM	cis	rs4372836	0.541	rs6710080	chr2:28989975	A/G	cg09522027	chr2:28974177	PPP1CB	-0.62	-4.79	-0.44	6.18e-6	Body mass index;
THYM	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg24920358	chr1:40204285	PPIE	0.6	5.57	0.5	2.39e-7	Blood protein levels;
THYM	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	trans	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg25214090	chr10:38739885	LOC399744	0.87	7.52	0.61	2.99e-11	Corneal astigmatism;
THYM	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7267979	0.966	rs2261784	chr20:25262396	G/C	cg08601574	chr20:25228251	PYGB	0.57	4.62	0.43	1.18e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg10523679	chr1:76189770	ACADM	-0.55	-4.67	-0.43	9.78e-6	Daytime sleep phenotypes;
THYM	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg25208724	chr1:156163844	SLC25A44	1.11	12.72	0.79	3.19e-22	Testicular germ cell tumor;
THYM	cis	rs2075230	0.705	rs1641520	chr17:7550157	T/A	cg27413385	chr17:7515425	FXR2	-0.37	-5.39	-0.48	5.16e-7	Hormone measurements;
THYM	cis	rs854765	0.624	rs7359509	chr17:17741875	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-5.66	-0.5	1.6e-7	Total body bone mineral density;
THYM	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg06112835	chr11:68658793	MRPL21	0.44	6.41	0.55	5.69e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg05340658	chr4:99064831	C4orf37	-0.53	-4.51	-0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg18252515	chr7:66147081	NA	0.64	4.69	0.43	9.21e-6	Aortic root size;
THYM	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg03806693	chr22:41940476	POLR3H	1.08	8.77	0.67	7.1e-14	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs6430585	0.528	rs3112496	chr2:136711064	C/T	cg20242066	chr2:136595261	LCT	0.53	5.59	0.5	2.18e-7	Corneal structure;
THYM	cis	rs600806	0.850	rs4970729	chr1:109979202	G/A	cg02175308	chr1:109941060	SORT1	-0.59	-5.15	-0.47	1.38e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg06609049	chr19:2785107	THOP1	0.76	6.43	0.55	5.1e-9	Total cholesterol levels;
THYM	cis	rs72828912	0.731	rs9366559	chr6:24078056	C/T	cg19882886	chr6:25043046	NA	-0.88	-4.58	-0.43	1.42e-5	Squamous cell lung carcinoma;
THYM	cis	rs9527	0.568	rs12772775	chr10:104702999	C/A	cg04362960	chr10:104952993	NT5C2	0.6	4.62	0.43	1.2e-5	Arsenic metabolism;
THYM	cis	rs1065656	0.591	rs2235648	chr16:1836796	C/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.46	5.79	0.51	9.24e-8	Insulin-like growth factors;
THYM	cis	rs34779708	0.966	rs17500582	chr10:35498788	T/A	cg03585969	chr10:35415529	CREM	0.63	4.48	0.42	2.09e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg14074117	chr16:1909714	C16orf73	-0.7	-4.45	-0.42	2.3e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22509189	chr2:225307070	NA	-0.89	-7.54	-0.61	2.77e-11	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15541040	chr2:3486749	NA	-0.57	-4.58	-0.43	1.43e-5	Neurofibrillary tangles;
THYM	cis	rs35883536	0.740	rs4604711	chr1:101089492	A/C	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs1670533	1.000	rs6812586	chr4:1069851	A/G	cg27284194	chr4:1044797	NA	0.61	4.6	0.43	1.29e-5	Recombination rate (females);
THYM	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg24503407	chr1:205819492	PM20D1	0.97	9.46	0.7	2.35e-15	Menarche (age at onset);
THYM	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.2e-16	Bone mineral density;
THYM	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22133161	chr19:49891603	CCDC155	0.79	5.33	0.48	6.52e-7	Multiple sclerosis;
THYM	cis	rs4654899	0.931	rs3125161	chr1:21126346	A/G	cg01072550	chr1:21505969	NA	0.7	6.41	0.55	5.56e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.74	-4.91	-0.45	3.82e-6	Huntington's disease progression;
THYM	cis	rs7084402	0.905	rs7914888	chr10:60308558	T/C	cg07615347	chr10:60278583	BICC1	-0.56	-5.21	-0.47	1.09e-6	Refractive error;
THYM	cis	rs17401966	1.000	rs17401966	chr1:10385471	C/T	cg19773385	chr1:10388646	KIF1B	0.64	4.77	0.44	6.6e-6	Hepatocellular carcinoma;
THYM	cis	rs2235642	1.000	rs2076438	chr16:1584618	T/C	cg08296037	chr16:1584118	IFT140;TMEM204	-0.54	-4.5	-0.42	1.92e-5	Coronary artery disease;
THYM	cis	rs3126085	0.935	rs2184953	chr1:152280782	A/G	cg26020982	chr1:152196106	HRNR	-0.35	-4.96	-0.45	3.02e-6	Atopic dermatitis;
THYM	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs9435341	0.965	rs2335077	chr1:107573565	A/G	cg09367891	chr1:107599246	PRMT6	0.66	4.48	0.42	2.06e-5	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg24733560	chr20:60626293	TAF4	0.55	4.98	0.46	2.81e-6	Body mass index;
THYM	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg00256281	chr22:41985642	PMM1	0.62	4.85	0.45	4.76e-6	Vitiligo;
THYM	cis	rs3020333	0.875	rs3020336	chr6:152013760	G/T	cg22157087	chr6:152012887	ESR1	0.42	4.58	0.43	1.4e-5	Total body bone mineral density;
THYM	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg10150615	chr22:24372951	LOC391322	-1.02	-12.46	-0.79	1.08e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1003719	0.762	rs9975361	chr21:38450025	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs11098499	0.690	rs7674713	chr4:120322257	T/C	cg09307838	chr4:120376055	NA	0.68	4.91	0.45	3.76e-6	Corneal astigmatism;
THYM	trans	rs8002861	0.905	rs12430629	chr13:44415919	T/A	cg17145862	chr1:211918768	LPGAT1	-0.85	-7.77	-0.62	9e-12	Leprosy;
THYM	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg23583168	chr7:148888333	NA	-1.06	-13.95	-0.82	1.01e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11890956	chr21:40555474	PSMG1	1.07	10.25	0.72	4.79e-17	Cognitive function;
THYM	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg02527881	chr3:46936655	PTH1R	-0.61	-5.7	-0.51	1.33e-7	Colorectal cancer;
THYM	trans	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs12594515	1.000	rs12185095	chr15:45994635	G/T	cg01629716	chr15:45996671	NA	0.53	5.27	0.48	8.45e-7	Waist circumference;Weight;
THYM	cis	rs1003719	0.715	rs8130643	chr21:38551715	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs4866334	1.000	rs4302587	chr5:18484728	T/G	cg18608440	chr5:17519013	NA	-1.07	-4.95	-0.45	3.24e-6	IgG glycosylation;
THYM	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.48	-4.7	-0.43	8.67e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg18132916	chr6:79620363	NA	-0.54	-4.8	-0.44	5.95e-6	Intelligence (multi-trait analysis);
THYM	cis	rs968451	0.547	rs738331	chr22:39714216	A/G	cg24268161	chr22:39747459	SYNGR1	-0.57	-4.46	-0.42	2.25e-5	Primary biliary cholangitis;
THYM	cis	rs4901869	0.966	rs12148052	chr14:59338970	C/T	cg02291164	chr14:59296302	NA	0.8	8.12	0.64	1.64e-12	Panic disorder;
THYM	cis	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg10856724	chr12:34555212	NA	-0.79	-7.37	-0.6	6.29e-11	Morning vs. evening chronotype;
THYM	cis	rs900145	0.691	rs11022756	chr11:13315439	A/C	cg13286116	chr11:13302098	ARNTL	-0.59	-4.73	-0.44	7.89e-6	Menarche (age at onset);
THYM	cis	rs883565	0.771	rs2056613	chr3:39125293	G/T	cg15678707	chr3:39149194	GORASP1;TTC21A	0.77	5.52	0.49	2.95e-7	Handedness;
THYM	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-5.76	-0.51	1.03e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2067615	0.579	rs10778502	chr12:107090201	T/C	cg15890332	chr12:107067104	RFX4	0.46	5.18	0.47	1.24e-6	Heart rate;
THYM	cis	rs7582180	0.663	rs2309800	chr2:100992086	C/T	cg14675211	chr2:100938903	LONRF2	0.59	5.65	0.5	1.67e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6901250	0.851	rs339361	chr6:117162515	C/T	cg12892004	chr6:117198278	RFX6	0.71	6.97	0.58	4.22e-10	C-reactive protein levels;
THYM	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg01073479	chr16:3509474	NAT15	0.57	5.45	0.49	3.92e-7	Tuberculosis;
THYM	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.78	4.62	0.43	1.23e-5	Lung function (FEV1/FVC);
THYM	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg21798802	chr22:38057573	PDXP	0.43	4.86	0.45	4.68e-6	Fat distribution (HIV);
THYM	cis	rs9563576	0.778	rs9634879	chr13:58613180	T/C	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs17125944	0.505	rs2295827	chr14:53174981	C/T	cg00686598	chr14:53173677	PSMC6	1.52	7.7	0.62	1.28e-11	Alzheimer's disease (late onset);
THYM	cis	rs9549260	0.816	rs9532582	chr13:41251207	A/G	cg21288729	chr13:41239152	FOXO1	0.7	5.32	0.48	6.91e-7	Red blood cell count;
THYM	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg13695892	chr22:41940480	POLR3H	-0.83	-5.98	-0.52	3.93e-8	Vitiligo;
THYM	trans	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg03188948	chr7:1209495	NA	0.92	5.18	0.47	1.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs6866344	0.697	rs58549512	chr5:178133204	C/T	cg10224037	chr5:178157518	ZNF354A	0.97	7.89	0.63	5.06e-12	Neutrophil percentage of white cells;
THYM	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg27532560	chr4:187881888	NA	-0.95	-11.42	-0.76	1.6e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg15445000	chr17:37608096	MED1	-0.44	-5.19	-0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	5.76	0.51	1.02e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs735539	0.718	rs7985552	chr13:21280738	A/T	cg02792322	chr13:21280448	IL17D	0.67	4.57	0.42	1.45e-5	Dental caries;
THYM	cis	rs7851660	0.874	rs1955144	chr9:100634589	A/G	cg13688889	chr9:100608707	NA	-0.79	-5.92	-0.52	5.07e-8	Strep throat;
THYM	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11644478	chr21:40555479	PSMG1	-0.56	-4.69	-0.43	9.25e-6	Menarche (age at onset);
THYM	cis	rs7567389	0.740	rs4536600	chr2:128002572	A/G	cg06038358	chr2:128176007	PROC	0.49	5.8	0.51	8.73e-8	Self-rated health;
THYM	cis	rs2404602	0.684	rs57682236	chr15:76868478	G/A	cg23625390	chr15:77176239	SCAPER	-0.92	-6.25	-0.54	1.17e-8	Blood metabolite levels;
THYM	cis	rs7917772	0.582	rs10883744	chr10:104347247	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9527	0.590	rs1807298	chr10:104870218	G/A	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg09395187	chr16:88023319	BANP	-0.65	-4.47	-0.42	2.17e-5	Menopause (age at onset);
THYM	cis	rs7187994	0.848	rs34457873	chr16:84782871	T/G	cg07647771	chr16:84786436	USP10	-0.53	-4.91	-0.45	3.81e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg20891283	chr12:69753455	YEATS4	1.09	12.1	0.78	5.96e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs1003719	0.646	rs9985082	chr21:38501021	A/G	cg01329690	chr21:38580129	DSCR9	-0.38	-5.21	-0.47	1.09e-6	Eye color traits;
THYM	cis	rs4731207	0.596	rs7795199	chr7:124578345	C/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg05215272	chr17:6899095	ALOX12	0.63	8.97	0.68	2.6e-14	Tonsillectomy;
THYM	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg03806693	chr22:41940476	POLR3H	-1.02	-7.83	-0.63	6.94e-12	Vitiligo;
THYM	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg06634786	chr22:41940651	POLR3H	-0.62	-4.7	-0.43	8.7e-6	Vitiligo;
THYM	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.65	-0.62	1.6e-11	Schizophrenia;
THYM	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.12	9.06	0.68	1.73e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg05340658	chr4:99064831	C4orf37	0.53	4.53	0.42	1.74e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg00376283	chr12:123451042	ABCB9	0.77	5.19	0.47	1.19e-6	Neutrophil percentage of white cells;
THYM	cis	rs8077889	1.000	rs2079005	chr17:41865627	T/G	cg26893861	chr17:41843967	DUSP3	1.07	9.57	0.7	1.39e-15	Triglycerides;
THYM	cis	rs4900538	0.855	rs9788420	chr14:102839338	A/G	cg18135206	chr14:102964638	TECPR2	-0.83	-6.48	-0.55	4.13e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs28595532	1.000	rs114778020	chr4:119662584	C/A	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs10256972	0.758	rs7789093	chr7:1002981	T/C	cg07930192	chr7:1003750	NA	0.87	7.62	0.62	1.89e-11	Longevity;Endometriosis;
THYM	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs6496667	0.533	rs2074584	chr15:91009381	C/T	cg22089800	chr15:90895588	ZNF774	0.68	5.07	0.46	1.94e-6	Rheumatoid arthritis;
THYM	cis	rs4790312	0.729	rs9912392	chr17:1995611	G/C	cg15816464	chr17:2026533	SMG6	0.38	5.16	0.47	1.33e-6	Left atrial antero-posterior diameter;
THYM	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg17554472	chr22:41940697	POLR3H	0.67	4.73	0.44	7.66e-6	Vitiligo;
THYM	cis	rs10992471	0.651	rs2296669	chr9:95373790	A/G	cg14631576	chr9:95140430	CENPP	0.98	8.8	0.67	6.06e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg17063962	chr7:91808500	NA	1.16	13.12	0.8	4.77e-23	Breast cancer;
THYM	cis	rs13177918	0.677	rs4841	chr5:149826526	C/T	cg14059543	chr5:149831962	NA	-0.99	-7.58	-0.61	2.25e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs10499694	0.868	rs1470749	chr7:50578023	G/T	cg18232548	chr7:50535776	DDC	-0.62	-5.1	-0.46	1.72e-6	Body mass index;
THYM	cis	rs9913156	0.707	rs11657052	chr17:4570573	C/T	cg19197139	chr17:4613644	ARRB2	-0.74	-4.62	-0.43	1.21e-5	Lymphocyte counts;
THYM	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg06611532	chr13:114900021	NA	0.62	6.79	0.57	9.62e-10	Schizophrenia;
THYM	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg06634786	chr22:41940651	POLR3H	0.7	4.96	0.45	3.12e-6	Vitiligo;
THYM	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg01751800	chr4:77820391	ANKRD56	0.55	4.58	0.42	1.43e-5	Emphysema distribution in smoking;
THYM	cis	rs7828089	1.000	rs7823832	chr8:22264426	A/G	cg12081754	chr8:22256438	SLC39A14	0.6	5.26	0.48	8.69e-7	Verbal declarative memory;
THYM	cis	rs10788264	0.652	rs9633732	chr10:124056473	G/T	cg09507567	chr10:124027408	NA	0.48	4.67	0.43	9.91e-6	Total body bone mineral density;
THYM	cis	rs9443645	0.810	rs7753531	chr6:79789996	A/C	cg05283184	chr6:79620031	NA	-0.91	-8.38	-0.65	4.72e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg25918947	chr17:41365094	TMEM106A	-0.58	-4.95	-0.45	3.22e-6	Menopause (age at onset);
THYM	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg06718696	chr17:78121285	EIF4A3	1.02	7.38	0.6	5.95e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
THYM	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22857025	chr5:266934	NA	-1.5	-9.71	-0.71	6.9e-16	Breast cancer;
THYM	cis	rs9880211	0.613	rs1393786	chr3:135854035	G/T	cg21827317	chr3:136751795	NA	-0.71	-5.16	-0.47	1.33e-6	Body mass index;Height;
THYM	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg09021430	chr5:549028	NA	-0.6	-5.64	-0.5	1.71e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs9906944	0.707	rs4794019	chr17:47107290	G/T	cg09029085	chr17:47094198	IGF2BP1	0.47	6.53	0.56	3.17e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7586879	0.828	rs2384056	chr2:25092649	G/A	cg01884057	chr2:25150051	NA	0.51	4.49	0.42	2.01e-5	Body mass index;
THYM	cis	rs2276314	0.857	rs28530656	chr18:33588700	C/T	cg05985134	chr18:33552581	C18orf21	-0.66	-4.84	-0.44	5.02e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7849270	1.000	rs7036114	chr9:131893406	C/T	cg14069949	chr9:131965419	NA	0.5	4.52	0.42	1.8e-5	Blood metabolite ratios;
THYM	cis	rs7107174	1.000	rs10899452	chr11:77995143	A/C	cg02023728	chr11:77925099	USP35	0.62	5.05	0.46	2.1e-6	Testicular germ cell tumor;
THYM	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg09354556	chr3:47051341	NA	0.46	4.74	0.44	7.63e-6	Colorectal cancer;
THYM	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	8.01	0.64	2.84e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs240764	0.746	rs239197	chr6:101133600	T/C	cg21058520	chr6:100914733	NA	-0.57	-5.21	-0.47	1.1e-6	Neuroticism;
THYM	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	5.09	0.46	1.8e-6	Menarche (age at onset);
THYM	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg26441486	chr22:50317300	CRELD2	0.43	6.57	0.56	2.71e-9	Schizophrenia;
THYM	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs9929218	0.529	rs35854485	chr16:68730855	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.06	12.98	0.8	9.28e-23	Colorectal cancer;
THYM	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg22907277	chr7:1156413	C7orf50	0.82	4.98	0.46	2.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg05335186	chr13:53173507	NA	-0.46	-5.86	-0.52	6.6e-8	Lewy body disease;
THYM	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06873352	chr17:61820015	STRADA	0.79	9.84	0.71	3.66e-16	Prudent dietary pattern;
THYM	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg13319975	chr6:146136371	FBXO30	-0.67	-5.46	-0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9902453	0.933	rs9898353	chr17:28451865	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.83	0.44	5.26e-6	Coffee consumption (cups per day);
THYM	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg05182265	chr7:156933206	UBE3C	-0.69	-9.35	-0.69	4.05e-15	Body mass index;
THYM	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg04476341	chr5:669733	TPPP	0.61	4.48	0.42	2.12e-5	Obesity-related traits;
THYM	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1670533	1.000	rs7660779	chr4:1075940	A/G	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg25811766	chr13:21894605	NA	0.73	5.95	0.52	4.49e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.47	-0.55	4.25e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7246657	0.943	rs8106839	chr19:37958475	C/G	cg23950597	chr19:37808831	NA	-0.76	-5.07	-0.46	1.99e-6	Coronary artery calcification;
THYM	cis	rs4266144	0.562	rs2086667	chr3:156836517	G/A	cg14969094	chr3:156848003	NA	-0.48	-4.62	-0.43	1.21e-5	Coronary artery disease;
THYM	cis	rs34638657	0.673	rs62045961	chr16:82199723	A/G	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.11	-0.64	1.73e-12	Lung adenocarcinoma;
THYM	cis	rs41311933	1.000	rs16910255	chr9:123756983	C/T	cg13567360	chr9:123745713	C5	-0.92	-5.24	-0.47	9.59e-7	Coronary artery disease;
THYM	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.94	-9.65	-0.7	9.32e-16	Height;
THYM	cis	rs7688540	0.723	rs7687112	chr4:243556	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.69	5.07	0.46	1.96e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg06586046	chr17:78038103	CCDC40	-0.43	-4.55	-0.42	1.56e-5	Yeast infection;
THYM	cis	rs11997175	0.646	rs4609158	chr8:33693420	A/G	ch.8.33884649F	chr8:33765107	NA	0.63	4.76	0.44	6.85e-6	Body mass index;
THYM	cis	rs2073300	0.609	rs2281428	chr20:23400050	C/T	cg12062639	chr20:23401060	NAPB	1.1	5.73	0.51	1.16e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs11126435	0.591	rs10779958	chr2:74755778	A/C	cg04255230	chr2:74727010	LBX2	0.53	4.7	0.43	8.84e-6	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg04398451	chr17:18023971	MYO15A	-0.76	-7.18	-0.59	1.56e-10	Total body bone mineral density;
THYM	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.69e-11	Aortic root size;
THYM	cis	rs7704138	0.639	rs6871905	chr5:55016884	C/G	cg18456523	chr5:54516805	NA	0.59	4.72	0.44	7.99e-6	Height;
THYM	cis	rs4074961	0.527	rs2294875	chr1:38052445	C/T	cg17933807	chr1:38061675	GNL2	1.09	14.67	0.83	3.78e-26	Axial length;
THYM	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg17691542	chr6:26056736	HIST1H1C	0.73	4.69	0.43	9.12e-6	Iron status biomarkers;
THYM	cis	rs7586879	0.681	rs6756609	chr2:25121125	C/A	cg01884057	chr2:25150051	NA	0.71	7.7	0.62	1.31e-11	Body mass index;
THYM	trans	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg07211511	chr3:129823064	LOC729375	-1.32	-8.77	-0.67	7.15e-14	Blood pressure (smoking interaction);
THYM	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg06481639	chr22:41940642	POLR3H	-0.74	-4.85	-0.45	4.81e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg18681998	chr4:17616180	MED28	0.98	9.85	0.71	3.43e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg13695892	chr22:41940480	POLR3H	-0.61	-4.72	-0.44	8.23e-6	Neuroticism;
THYM	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg24675056	chr1:15929824	NA	0.73	5.89	0.52	5.95e-8	Systolic blood pressure;
THYM	cis	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs2552220	0.616	rs10503358	chr8:6016142	C/T	cg23638070	chr8:6569043	AGPAT5	-0.54	-4.7	-0.43	8.71e-6	Interleukin-8 levels;
THYM	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg21773646	chr17:80085082	CCDC57	-0.33	-4.6	-0.43	1.33e-5	Life satisfaction;
THYM	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg24209194	chr3:40518798	ZNF619	0.67	5.48	0.49	3.47e-7	Renal cell carcinoma;
THYM	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg13319975	chr6:146136371	FBXO30	0.66	5.45	0.49	3.96e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7512552	0.646	rs1694367	chr1:150329469	T/A	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2195525	0.572	rs7480948	chr11:119220483	G/C	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.43	4.83	0.44	5.19e-6	Urate levels;
THYM	cis	rs2811415	0.597	rs1007233	chr3:127801776	G/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs453301	0.686	rs17702602	chr8:8908596	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-4.8	-0.44	5.96e-6	Joint mobility (Beighton score);
THYM	cis	rs58688157	0.626	rs7941198	chr11:571681	A/G	cg00645579	chr11:617140	IRF7;MUPCDH	-0.4	-4.54	-0.42	1.65e-5	Systemic lupus erythematosus;
THYM	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg15448220	chr1:150897856	SETDB1	0.9	7.49	0.61	3.57e-11	Melanoma;
THYM	cis	rs3771570	0.901	rs35256094	chr2:242439938	A/C	cg21155796	chr2:242212141	HDLBP	1.18	5.77	0.51	9.86e-8	Prostate cancer;
THYM	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg06637938	chr14:75390232	RPS6KL1	0.63	6.36	0.55	6.97e-9	Caffeine consumption;
THYM	cis	rs807669	0.903	rs1780640	chr22:19174597	C/T	cg02655711	chr22:19163373	SLC25A1	0.97	11.57	0.76	7.63e-20	Metabolite levels;
THYM	cis	rs61990749	0.597	rs10148373	chr14:78280199	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.02	0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg20685674	chr1:26233538	STMN1	0.41	4.53	0.42	1.69e-5	Erythrocyte sedimentation rate;
THYM	cis	rs1843834	0.721	rs1601730	chr2:225590153	G/A	cg22455342	chr2:225449267	CUL3	0.6	4.59	0.43	1.38e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg06766960	chr11:133703094	NA	-0.6	-5.63	-0.5	1.82e-7	Childhood ear infection;
THYM	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs7072216	0.763	rs10736129	chr10:100171571	C/T	cg03852570	chr10:100175106	PYROXD2	-0.38	-5.08	-0.46	1.85e-6	Metabolite levels;
THYM	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg17105886	chr17:28927953	LRRC37B2	1.29	7.59	0.61	2.17e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1728785	1.000	rs3203684	chr16:68600440	C/T	cg02972257	chr16:68554789	NA	0.75	4.55	0.42	1.61e-5	Ulcerative colitis;
THYM	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg10164272	chr16:89456328	ANKRD11	0.64	5.21	0.47	1.12e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs7799006	0.606	rs878534	chr7:2314652	G/A	cg08027265	chr7:2291960	NA	-0.42	-5.15	-0.47	1.38e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs16865717	1.000	rs12991466	chr2:7029725	C/A	cg20486407	chr2:7037101	RSAD2	-1.2	-10.56	-0.73	1.05e-17	Venous thromboembolism (SNP x SNP interaction);
THYM	cis	rs6930083	0.527	rs9368950	chr6:36627872	T/C	cg24425727	chr6:36645648	CDKN1A	0.71	5.83	0.51	7.61e-8	Coronary artery disease;
THYM	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg25427524	chr10:38739819	LOC399744	-0.67	-6.15	-0.53	1.85e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.29	9.36	0.69	3.9e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs67460515	0.500	rs9812507	chr3:160723393	G/A	cg12349858	chr3:160822545	B3GALNT1	0.59	4.79	0.44	6.12e-6	Parkinson's disease;
THYM	cis	rs990171	1.000	rs3755274	chr2:103002395	A/G	cg13897122	chr2:103039542	IL18RAP	-0.39	-4.79	-0.44	6.08e-6	Lymphocyte counts;
THYM	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03517284	chr6:25882590	NA	-1.0	-9.89	-0.71	2.8e-16	Intelligence (multi-trait analysis);
THYM	trans	rs4596713	0.508	rs7862404	chr9:71779903	G/A	cg16512924	chr15:28394682	HERC2	0.83	6.92	0.58	5.28e-10	Headache;
THYM	cis	rs4731207	0.596	rs6942997	chr7:124648479	T/C	cg05285228	chr7:124571219	POT1	-0.71	-5.47	-0.49	3.59e-7	Cutaneous malignant melanoma;
THYM	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg06873352	chr17:61820015	STRADA	0.52	4.99	0.46	2.71e-6	Height;
THYM	cis	rs7255045	0.665	rs2014639	chr19:12975021	G/C	cg26870725	chr19:12978805	MAST1	-0.62	-4.73	-0.44	7.73e-6	Mean corpuscular volume;
THYM	cis	rs8067545	0.586	rs2703819	chr17:20121401	A/G	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs7772486	0.790	rs9497425	chr6:146234197	G/A	cg13319975	chr6:146136371	FBXO30	0.75	6.27	0.54	1.07e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6930083	0.713	rs1321308	chr6:36638691	A/C	cg11920449	chr6:36645608	CDKN1A	0.78	6.54	0.56	3.06e-9	Coronary artery disease;
THYM	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg12165864	chr7:66369176	NA	-0.64	-4.91	-0.45	3.72e-6	Aortic root size;
THYM	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg02915803	chr1:1606292	LOC728661;CDK11B	0.64	5.37	0.48	5.52e-7	Body mass index;
THYM	cis	rs9788682	0.747	rs2656073	chr15:78742276	G/T	cg18825076	chr15:78729989	IREB2	0.67	5.25	0.47	9.07e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs7677751	0.806	rs4864862	chr4:55100489	G/A	cg17187183	chr4:55093834	PDGFRA	0.74	5.58	0.5	2.27e-7	Corneal astigmatism;
THYM	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg23711669	chr6:146136114	FBXO30	0.93	9.6	0.7	1.18e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg22133161	chr19:49891603	CCDC155	0.93	6.07	0.53	2.59e-8	Multiple sclerosis;
THYM	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg21211367	chr2:162094118	NA	0.66	5.4	0.48	4.85e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg02018176	chr4:1364513	KIAA1530	0.53	4.54	0.42	1.63e-5	Obesity-related traits;
THYM	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg15997130	chr1:24165203	NA	-0.72	-5.47	-0.49	3.67e-7	Immature fraction of reticulocytes;
THYM	cis	rs600806	0.751	rs7551176	chr1:109961965	C/T	cg02175308	chr1:109941060	SORT1	-0.57	-5.08	-0.46	1.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs6694672	1.000	rs1759009	chr1:197026672	C/T	cg13682187	chr1:196946512	CFHR5	-0.82	-4.5	-0.42	1.89e-5	Asthma;
THYM	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg04520793	chr17:42248056	ASB16	-0.35	-4.98	-0.45	2.85e-6	Total body bone mineral density;
THYM	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs338389	0.586	rs338390	chr15:68259214	A/G	cg07562100	chr15:68569975	FEM1B	0.72	5.1	0.46	1.72e-6	Survival in rectal cancer;
THYM	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg23758822	chr17:41437982	NA	1.2	11.71	0.77	3.95e-20	Menopause (age at onset);
THYM	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg11266682	chr4:10021025	SLC2A9	0.7	9.21	0.69	8.15e-15	Bone mineral density;
THYM	cis	rs13102973	0.640	rs13140829	chr4:135838818	T/C	cg14419869	chr4:135874104	NA	0.72	5.86	0.51	6.78e-8	Subjective well-being;
THYM	cis	rs7617773	0.780	rs13090538	chr3:48370769	A/C	cg02219026	chr3:48282209	ZNF589	-0.65	-4.51	-0.42	1.84e-5	Coronary artery disease;
THYM	cis	rs501916	0.634	rs10851459	chr15:48061510	C/A	cg20869673	chr15:48010124	SEMA6D	0.64	4.63	0.43	1.14e-5	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs2294693	0.947	rs736795	chr6:40998141	G/A	cg14418226	chr6:40996092	UNC5CL	0.76	6.98	0.58	3.88e-10	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06850241	chr22:41845214	NA	0.59	5.41	0.49	4.76e-7	Vitiligo;
THYM	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.73	0.51	1.19e-7	Lung cancer in ever smokers;
THYM	cis	rs4938330	0.629	rs12269901	chr11:116973929	C/G	cg20608306	chr11:116969690	SIK3	-0.52	-5.91	-0.52	5.28e-8	Blood protein levels;
THYM	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-4.71	-0.43	8.61e-6	Longevity;
THYM	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg11266682	chr4:10021025	SLC2A9	0.74	10.8	0.74	3.21e-18	Bone mineral density;
THYM	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.64	-4.59	-0.43	1.35e-5	Aortic root size;
THYM	cis	rs2072732	0.904	rs12044831	chr1:2964397	A/C	cg08733933	chr1:2954429	NA	-0.64	-4.55	-0.42	1.61e-5	Plateletcrit;
THYM	cis	rs41311933	1.000	rs12683026	chr9:123758632	A/G	cg13567360	chr9:123745713	C5	-1.06	-5.62	-0.5	1.91e-7	Coronary artery disease;
THYM	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg02018176	chr4:1364513	KIAA1530	0.55	4.94	0.45	3.29e-6	Obesity-related traits;
THYM	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg27490568	chr2:178487706	NA	0.59	5.69	0.5	1.41e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.57	4.81	0.44	5.69e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2070488	1.000	rs4147024	chr3:38456664	C/T	cg24069376	chr3:38537580	EXOG	0.66	6.49	0.55	3.91e-9	Electrocardiographic conduction measures;
THYM	cis	rs4481887	0.741	rs6587458	chr1:248532290	T/A	cg00666640	chr1:248458726	OR2T12	0.55	4.74	0.44	7.59e-6	Common traits (Other);
THYM	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs6495367	1.000	rs28412916	chr15:79378167	A/C	cg17916960	chr15:79447300	NA	0.56	6.11	0.53	2.17e-8	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs9796	0.866	rs1678750	chr15:41410705	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.58	-4.73	-0.44	7.81e-6	Menopause (age at onset);
THYM	cis	rs4731207	0.596	rs9640828	chr7:124655481	A/C	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	trans	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg18335740	chr13:41363409	SLC25A15	0.68	7.45	0.61	4.37e-11	Lewy body disease;
THYM	cis	rs9653442	0.593	rs2309811	chr2:100862359	A/G	cg08017756	chr2:100939284	LONRF2	-0.68	-5.13	-0.47	1.53e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03517284	chr6:25882590	NA	-1.03	-9.27	-0.69	5.91e-15	Intelligence (multi-trait analysis);
THYM	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg08885076	chr2:99613938	TSGA10	-0.48	-4.81	-0.44	5.68e-6	Fear of minor pain;
THYM	cis	rs7107174	1.000	rs10899479	chr11:78052539	A/G	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg12935359	chr14:103987150	CKB	-0.46	-6.19	-0.54	1.49e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.714	rs35343177	chr20:43845986	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.64	-7.37	-0.6	6.28e-11	Blood protein levels;
THYM	cis	rs728616	0.614	rs10887235	chr10:81715646	T/C	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs3204270	0.810	rs8077959	chr17:79670122	G/A	cg13117272	chr17:79681052	SLC25A10	-0.76	-4.76	-0.44	6.85e-6	Dental caries;
THYM	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg16586182	chr3:47516702	SCAP	-0.67	-5.62	-0.5	1.9e-7	Colorectal cancer;
THYM	cis	rs7017697	1.000	rs10092772	chr8:19686385	A/T	cg01607444	chr8:20232518	NA	-0.37	-4.51	-0.42	1.82e-5	Breast cancer;
THYM	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg02221750	chr19:17393354	ANKLE1	-0.95	-8.73	-0.67	8.39e-14	Systemic lupus erythematosus;
THYM	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg23791538	chr6:167370224	RNASET2	0.82	6.9	0.58	5.9e-10	Crohn's disease;
THYM	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.88	7.81	0.63	7.51e-12	Monocyte percentage of white cells;
THYM	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	6.88	0.58	6.35e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7851660	0.967	rs7847126	chr9:100600635	A/C	cg13688889	chr9:100608707	NA	-0.83	-7.31	-0.6	8.28e-11	Strep throat;
THYM	cis	rs12478296	1.000	rs6732595	chr2:243035338	T/C	cg06360820	chr2:242988706	NA	-0.9	-5.49	-0.49	3.3e-7	Obesity-related traits;
THYM	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg21394778	chr1:3037102	PRDM16	0.48	4.68	0.43	9.64e-6	Height;
THYM	cis	rs11948739	0.501	rs4254896	chr5:130363499	C/T	cg08523029	chr5:130500466	HINT1	-0.85	-5.98	-0.52	3.88e-8	Pediatric bone mineral content (hip);
THYM	cis	rs10979	1.000	rs6905264	chr6:143894378	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs1829883	0.898	rs2963578	chr5:98785417	C/T	cg08333243	chr5:99726346	NA	-0.55	-5.05	-0.46	2.15e-6	Hemostatic factors and hematological phenotypes;
THYM	cis	rs42648	0.642	rs11771963	chr7:89887587	G/T	cg03688058	chr7:89840708	STEAP2	-0.56	-4.45	-0.42	2.32e-5	Homocysteine levels;
THYM	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg21926883	chr2:100939477	LONRF2	-0.55	-4.99	-0.46	2.74e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6547741	1.000	rs1919126	chr2:27801418	C/A	cg27432699	chr2:27873401	GPN1	0.68	5.97	0.52	4.14e-8	Oral cavity cancer;
THYM	cis	rs4919687	0.550	rs17784294	chr10:104479385	G/T	cg05855489	chr10:104503620	C10orf26	0.71	5.66	0.5	1.61e-7	Colorectal cancer;
THYM	cis	rs6987853	0.933	rs2974355	chr8:42414117	C/T	cg09913449	chr8:42400586	C8orf40	0.88	7.95	0.63	3.88e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9534288	0.797	rs2148414	chr13:46582368	G/T	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs2268241	0.877	rs17885509	chr21:34779630	C/T	cg14850771	chr21:34775459	IFNGR2	1.04	6.96	0.58	4.26e-10	Obesity-related traits;
THYM	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg15736062	chr7:158136485	PTPRN2	-0.61	-4.9	-0.45	3.94e-6	Response to amphetamines;
THYM	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs12765878	0.603	rs10786773	chr10:105644275	A/T	cg11005552	chr10:105648138	OBFC1	-0.57	-5.02	-0.46	2.42e-6	Coronary artery disease;
THYM	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg03264133	chr6:25882463	NA	0.65	5.06	0.46	2e-6	Schizophrenia;
THYM	cis	rs11148252	0.514	rs2296347	chr13:52728423	A/C	cg05335186	chr13:53173507	NA	0.39	4.52	0.42	1.79e-5	Lewy body disease;
THYM	cis	rs7523273	0.606	rs761275	chr1:207972154	A/C	cg22525895	chr1:207977042	MIR29B2	-0.95	-9.83	-0.71	3.86e-16	Schizophrenia;
THYM	cis	rs4919044	0.688	rs11187221	chr10:94704990	A/G	cg05127821	chr10:94822908	CYP26C1	-1.13	-6.75	-0.57	1.18e-9	Coronary artery disease;
THYM	cis	rs7264396	0.573	rs55969606	chr20:34075688	T/C	cg26038318	chr20:34205095	SPAG4	0.53	4.47	0.42	2.15e-5	Total cholesterol levels;
THYM	cis	rs1550582	1.000	rs62523710	chr8:135538773	T/C	cg17885191	chr8:135476712	NA	0.75	4.69	0.43	9.31e-6	Educational attainment;
THYM	cis	rs12496230	1.000	rs62258957	chr3:66864153	G/T	cg04995300	chr3:66848608	NA	0.93	5.83	0.51	7.54e-8	Type 2 diabetes;
THYM	cis	rs11608355	0.597	rs12579285	chr12:109832712	T/C	cg11367159	chr12:110044531	NA	0.53	4.79	0.44	6.16e-6	Neuroticism;
THYM	cis	rs7200543	1.000	rs35574015	chr16:15146061	T/C	cg01933576	chr16:15083564	PDXDC1	-1.02	-8.31	-0.65	6.69e-13	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs524023	1.000	rs11602903	chr11:64358241	A/T	cg19131476	chr11:64387923	NRXN2	-0.33	-4.48	-0.42	2.12e-5	Urate levels in obese individuals;
THYM	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs36051895	0.589	rs6476950	chr9:5218416	A/T	cg02405213	chr9:5042618	JAK2	-0.91	-9.63	-0.7	1.01e-15	Pediatric autoimmune diseases;
THYM	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg08439880	chr3:133502540	NA	-0.72	-6.19	-0.54	1.51e-8	Iron status biomarkers;
THYM	cis	rs3741151	1.000	rs112628073	chr11:73013626	C/T	cg17517138	chr11:73019481	ARHGEF17	0.98	5.7	0.5	1.35e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.76	-6.27	-0.54	1.07e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9296092	0.538	rs35381461	chr6:33519751	T/C	cg13560919	chr6:33536144	NA	-0.94	-9.31	-0.69	4.9e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs877282	0.898	rs11253341	chr10:765008	G/C	cg10556349	chr10:835070	NA	-0.78	-5.06	-0.46	2.06e-6	Uric acid levels;
THYM	cis	rs711830	1.000	rs1549334	chr2:177039197	G/A	cg26754761	chr2:177040938	NA	-0.58	-5.03	-0.46	2.27e-6	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg11266682	chr4:10021025	SLC2A9	0.74	12.07	0.78	6.92e-21	Bone mineral density;
THYM	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg06532163	chr17:45867833	NA	0.65	6.55	0.56	2.91e-9	IgG glycosylation;
THYM	cis	rs877282	1.000	rs12773872	chr10:771939	T/C	cg10556349	chr10:835070	NA	-0.77	-5.28	-0.48	8.04e-7	Uric acid levels;
THYM	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg08045932	chr20:61659980	NA	0.94	10.48	0.73	1.56e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7312774	0.748	rs10492214	chr12:107294758	T/C	cg16260113	chr12:107380972	MTERFD3	1.04	4.98	0.45	2.86e-6	Severe influenza A (H1N1) infection;
THYM	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	8.89	0.67	3.88e-14	Chronic sinus infection;
THYM	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg01699819	chr7:1052092	C7orf50	-0.86	-7.74	-0.62	1.04e-11	Bronchopulmonary dysplasia;
THYM	cis	rs2039659	0.719	rs1556773	chr13:86276120	G/C	cg25308322	chr13:86268291	NA	0.66	5.92	0.52	5.07e-8	Blood osmolality (transformed sodium);
THYM	cis	rs523522	0.602	rs7970933	chr12:120862474	G/A	cg27279351	chr12:120934652	DYNLL1	0.7	4.54	0.42	1.64e-5	High light scatter reticulocyte count;
THYM	cis	rs11225247	1.000	rs17349689	chr11:102269050	T/C	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs9828933	0.577	rs704374	chr3:63865947	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.87	5.41	0.49	4.64e-7	Type 2 diabetes;
THYM	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.1	-9.2	-0.69	8.65e-15	Schizophrenia;
THYM	cis	rs113835537	0.529	rs11227499	chr11:66272824	A/G	cg24851651	chr11:66362959	CCS	0.7	4.89	0.45	4.04e-6	Airway imaging phenotypes;
THYM	cis	rs17174870	0.955	rs77226570	chr2:112751534	G/A	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.71	5.58	0.5	2.25e-7	Menarche (age at onset);
THYM	cis	rs1129187	0.748	rs6458312	chr6:42904274	G/T	cg09436375	chr6:42928200	GNMT	-0.47	-6.22	-0.54	1.31e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg24069376	chr3:38537580	EXOG	0.68	6.73	0.57	1.26e-9	Electrocardiographic conduction measures;
THYM	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg03476357	chr21:30257390	N6AMT1	0.62	4.85	0.45	4.75e-6	Cognitive test performance;
THYM	cis	rs7769051	0.711	rs7758531	chr6:133085302	T/C	cg07930552	chr6:133119739	C6orf192	0.97	5.34	0.48	6.46e-7	Type 2 diabetes nephropathy;
THYM	cis	rs7264396	0.790	rs6579255	chr20:34219496	T/C	cg26038318	chr20:34205095	SPAG4	0.64	5.22	0.47	1.05e-6	Total cholesterol levels;
THYM	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg02725872	chr8:58115012	NA	-0.87	-6.17	-0.53	1.69e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs6882716	0.636	rs10043680	chr5:10804522	A/G	cg14521931	chr5:10832172	NA	0.72	6.21	0.54	1.41e-8	Alcohol consumption (maxi-drinks);
THYM	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07157834	chr1:205819609	PM20D1	0.88	8.85	0.67	4.65e-14	Menarche (age at onset);
THYM	cis	rs1061377	1.000	rs10026775	chr4:39116775	A/T	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs7246657	0.943	rs10426666	chr19:37828514	C/G	cg22634378	chr19:37742834	NA	0.68	5.67	0.5	1.55e-7	Coronary artery calcification;
THYM	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11644478	chr21:40555479	PSMG1	1.1	9.84	0.71	3.61e-16	Cognitive function;
THYM	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg24818145	chr4:99064322	C4orf37	0.75	5.91	0.52	5.22e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg20486651	chr6:167070296	RPS6KA2	0.5	4.79	0.44	6.18e-6	Crohn's disease;
THYM	cis	rs1775715	0.513	rs2808089	chr10:32145112	A/T	cg04359828	chr10:32216031	ARHGAP12	0.41	5.12	0.46	1.62e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs11096990	0.855	rs2566172	chr4:39152563	G/A	cg24403649	chr4:39172243	NA	-0.63	-5.35	-0.48	6.18e-7	Cognitive function;
THYM	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.96	-8.0	-0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs9549260	0.755	rs9549255	chr13:41235213	C/T	cg21288729	chr13:41239152	FOXO1	0.73	5.82	0.51	7.84e-8	Red blood cell count;
THYM	cis	rs7177699	0.557	rs34372090	chr15:79110735	C/T	cg00540400	chr15:79124168	NA	-0.65	-6.89	-0.58	6.04e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs6450176	1.000	rs4334836	chr5:53300835	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.14	-0.53	1.94e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs346785	0.610	rs347674	chr17:74278548	C/G	cg10318678	chr17:74308979	PRPSAP1	-0.53	-4.97	-0.45	2.95e-6	White matter hyperintensities in ischemic stroke;
THYM	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg23758822	chr17:41437982	NA	1.21	12.96	0.8	1.02e-22	Menopause (age at onset);
THYM	cis	rs929596	0.556	rs10202865	chr2:234587707	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.82	-6.44	-0.55	4.79e-9	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg04455712	chr21:45112962	RRP1B	0.5	4.85	0.45	4.76e-6	Mean corpuscular volume;
THYM	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg27034606	chr17:28928453	LRRC37B2	0.81	5.4	0.48	4.89e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg12310025	chr6:25882481	NA	-0.66	-4.59	-0.43	1.36e-5	Height;
THYM	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg10760299	chr15:45669010	GATM	0.87	6.78	0.57	1.01e-9	Homoarginine levels;
THYM	cis	rs9649213	0.574	rs6961790	chr7:98007993	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg04518342	chr5:131593106	PDLIM4	-0.48	-5.37	-0.48	5.55e-7	Breast cancer;
THYM	trans	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg13319975	chr6:146136371	FBXO30	-0.69	-5.59	-0.5	2.15e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1003719	0.788	rs9975168	chr21:38450557	A/G	cg01329690	chr21:38580129	DSCR9	-0.37	-5.08	-0.46	1.85e-6	Eye color traits;
THYM	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg17830980	chr10:43048298	ZNF37B	-1.1	-11.0	-0.75	1.23e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs16989760	0.661	rs67935422	chr22:32020413	G/A	cg10537193	chr22:32026975	PISD	-0.68	-4.64	-0.43	1.11e-5	Age-related hearing impairment;
THYM	cis	rs2256039	0.920	rs2256043	chr9:86799337	G/T	cg14555996	chr9:86785905	NA	-0.3	-4.68	-0.43	9.56e-6	Multiple system atrophy;
THYM	cis	rs1864400	0.645	rs2249005	chr10:43627280	A/G	cg06632098	chr10:43605906	RET	-0.76	-4.83	-0.44	5.28e-6	Hirschsprung disease;
THYM	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg21100191	chr22:23484243	RTDR1	0.75	6.66	0.56	1.77e-9	Bone mineral density;
THYM	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg15247329	chr7:2764246	NA	-0.67	-5.56	-0.5	2.44e-7	Height;
THYM	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg08470875	chr2:26401718	FAM59B	0.74	4.59	0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs870825	0.616	rs7678616	chr4:185648714	T/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg20887711	chr4:1340912	KIAA1530	0.99	9.57	0.7	1.37e-15	Longevity;
THYM	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg19693284	chr19:2783607	SGTA	0.68	5.47	0.49	3.56e-7	Total cholesterol levels;
THYM	cis	rs7191439	0.858	rs2340973	chr16:88773396	G/A	cg02389323	chr16:88786976	FAM38A	0.83	4.66	0.43	1.01e-5	Plateletcrit;
THYM	trans	rs480407	0.759	rs12986586	chr2:161758353	C/A	cg06548410	chr19:1997657	BTBD2	0.71	7.09	0.59	2.38e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7523273	0.925	rs2745977	chr1:208017360	C/A	cg22525895	chr1:207977042	MIR29B2	-0.78	-7.59	-0.61	2.14e-11	Schizophrenia;
THYM	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg05215272	chr17:6899095	ALOX12	-0.64	-9.11	-0.68	1.32e-14	Tonsillectomy;
THYM	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg18876405	chr7:65276391	NA	0.63	5.53	0.49	2.83e-7	Aortic root size;
THYM	cis	rs10504073	0.647	rs10105794	chr8:50012793	G/C	cg00325661	chr8:49890786	NA	0.86	7.69	0.62	1.35e-11	Blood metabolite ratios;
THYM	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.63	-5.69	-0.5	1.4e-7	Height;
THYM	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg05738196	chr6:26577821	NA	0.95	9.89	0.71	2.78e-16	Intelligence (multi-trait analysis);
THYM	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg14675211	chr2:100938903	LONRF2	0.73	7.27	0.6	1.02e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9875589	0.509	rs6770928	chr3:14077189	G/C	cg03204825	chr3:13978759	TPRXL	-0.51	-4.46	-0.42	2.26e-5	Ovarian reserve;
THYM	cis	rs6964587	0.692	rs10271430	chr7:91710466	G/C	cg17063962	chr7:91808500	NA	1.0	9.02	0.68	2.03e-14	Breast cancer;
THYM	cis	rs7582180	0.715	rs11123823	chr2:100916315	A/G	cg21926883	chr2:100939477	LONRF2	-0.58	-4.99	-0.46	2.69e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs9467160	0.651	rs9393557	chr6:24453195	C/G	cg20631270	chr6:24437470	GPLD1	0.58	4.83	0.44	5.27e-6	Liver enzyme levels;
THYM	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg03806693	chr22:41940476	POLR3H	-1.02	-8.68	-0.67	1.07e-13	Vitiligo;
THYM	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg23711669	chr6:146136114	FBXO30	0.94	9.83	0.71	3.85e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11096990	0.634	rs60016848	chr4:39283056	A/G	cg24403649	chr4:39172243	NA	-0.64	-5.54	-0.49	2.67e-7	Cognitive function;
THYM	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg19077165	chr18:44547161	KATNAL2	0.59	7.29	0.6	9.19e-11	Personality dimensions;
THYM	cis	rs2692947	0.644	rs1168975	chr2:96814075	G/A	cg23100626	chr2:96804247	ASTL	0.38	4.52	0.42	1.78e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg20295408	chr7:1910781	MAD1L1	-0.64	-5.1	-0.46	1.74e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs11760633	0.672	rs7811019	chr7:1843541	C/G	cg23422044	chr7:1970798	MAD1L1	-0.68	-5.07	-0.46	1.99e-6	Coronary artery disease;
THYM	cis	rs11608355	0.846	rs61934479	chr12:109855111	A/G	cg11367159	chr12:110044531	NA	0.6	5.17	0.47	1.31e-6	Neuroticism;
THYM	cis	rs586688	1.000	rs589855	chr1:201631649	C/A	cg14168733	chr1:201708718	NAV1	0.54	4.62	0.43	1.18e-5	Obesity-related traits;
THYM	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg24209194	chr3:40518798	ZNF619	-0.73	-6.34	-0.55	7.53e-9	Renal cell carcinoma;
THYM	cis	rs9653442	0.675	rs961788	chr2:100641459	T/C	cg22139774	chr2:100720529	AFF3	-0.35	-5.17	-0.47	1.31e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs10779751	0.960	rs11121712	chr1:11320329	G/C	cg08854313	chr1:11322531	MTOR	1.04	10.45	0.73	1.85e-17	Body mass index;
THYM	cis	rs2688608	0.592	rs12253429	chr10:75496161	C/G	cg15838173	chr10:75533400	FUT11	-0.5	-5.09	-0.46	1.82e-6	Inflammatory bowel disease;
THYM	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg05283184	chr6:79620031	NA	-0.91	-8.88	-0.67	4.11e-14	Intelligence (multi-trait analysis);
THYM	cis	rs9486719	1.000	rs9373978	chr6:97056255	T/C	cg18709589	chr6:96969512	KIAA0776	-0.69	-4.95	-0.45	3.16e-6	Migraine;Coronary artery disease;
THYM	cis	rs2637266	0.875	rs115333453	chr10:78369011	G/A	cg18941641	chr10:78392320	NA	0.6	4.79	0.44	6.09e-6	Pulmonary function;
THYM	trans	rs9929218	0.953	rs11075696	chr16:68731365	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.89	-7.79	-0.62	8.46e-12	Colorectal cancer;
THYM	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	trans	rs877282	0.945	rs12776447	chr10:790625	A/G	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg19847130	chr8:10466454	RP1L1	0.51	4.63	0.43	1.14e-5	Neuroticism;
THYM	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg13699009	chr12:122356056	WDR66	0.55	5.98	0.52	3.87e-8	Mean platelet volume;
THYM	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg23649088	chr2:200775458	C2orf69	0.81	6.14	0.53	1.88e-8	Schizophrenia;
THYM	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg13147721	chr7:65941812	NA	-0.94	-5.74	-0.51	1.12e-7	Diabetic kidney disease;
THYM	cis	rs782590	0.774	rs12616629	chr2:55944293	G/C	cg18811423	chr2:55921094	PNPT1	-0.67	-5.84	-0.51	7.27e-8	Metabolic syndrome;
THYM	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs9500256	0.655	rs12191043	chr6:58346483	C/T	cg16251399	chr6:58287822	GUSBL2	0.57	4.48	0.42	2.12e-5	Eosinophilic esophagitis (pediatric);
THYM	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg01097406	chr16:89675127	NA	-0.6	-5.07	-0.46	1.94e-6	Vitiligo;
THYM	cis	rs61931739	0.793	rs609886	chr12:34138160	T/G	cg10856724	chr12:34555212	NA	-0.64	-5.5	-0.49	3.24e-7	Morning vs. evening chronotype;
THYM	cis	rs17255340	0.530	rs6923627	chr6:84064858	G/A	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs7246657	0.943	rs2891699	chr19:37920237	A/G	cg22634378	chr19:37742834	NA	0.62	5.18	0.47	1.22e-6	Coronary artery calcification;
THYM	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.25	-10.33	-0.73	3.19e-17	Platelet count;
THYM	cis	rs10504073	0.584	rs10504070	chr8:49978554	A/G	cg00325661	chr8:49890786	NA	-1.06	-10.54	-0.73	1.17e-17	Blood metabolite ratios;
THYM	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg06636001	chr8:8085503	FLJ10661	-0.72	-6.52	-0.56	3.35e-9	Mood instability;
THYM	cis	rs6570726	0.935	rs367612	chr6:145828987	A/G	cg23711669	chr6:146136114	FBXO30	0.82	7.84	0.63	6.69e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8112449	0.822	rs34246431	chr19:10549968	T/C	cg01466491	chr19:10523363	NA	-0.62	-5.9	-0.52	5.56e-8	Multiple sclerosis;Gastritis;
THYM	cis	rs6032067	0.777	rs34343273	chr20:43795293	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg13939156	chr17:80058883	NA	-0.37	-4.92	-0.45	3.62e-6	Life satisfaction;
THYM	cis	rs2635047	0.648	rs4986203	chr18:44597092	A/G	cg19077165	chr18:44547161	KATNAL2	-0.48	-5.22	-0.47	1.06e-6	Educational attainment;
THYM	cis	rs2439831	0.850	rs16965120	chr15:44100342	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	5.47	0.49	3.6e-7	Lung cancer in ever smokers;
THYM	cis	rs4917300	0.605	rs7820768	chr8:143110823	C/T	cg25363559	chr8:143086065	NA	-0.57	-5.19	-0.47	1.17e-6	Amyotrophic lateral sclerosis;
THYM	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.48	-4.59	-0.43	1.36e-5	Crohn's disease;
THYM	cis	rs2652822	0.530	rs7165016	chr15:63439590	T/A	cg09251291	chr15:63483946	RAB8B	0.56	4.98	0.45	2.87e-6	Metabolic traits;
THYM	cis	rs2273669	0.588	rs12201102	chr6:109317388	A/G	cg17117243	chr6:109341365	SESN1	-0.9	-5.38	-0.48	5.45e-7	Prostate cancer;
THYM	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg00631329	chr6:26305371	NA	-0.72	-7.47	-0.61	3.81e-11	Educational attainment;
THYM	cis	rs4940575	0.786	rs8088100	chr18:60840079	G/T	cg24349668	chr18:61441546	SERPINB7	0.76	4.66	0.43	1.01e-5	Breast cancer;
THYM	cis	rs10779751	0.770	rs11585553	chr1:11233814	G/A	cg08854313	chr1:11322531	MTOR	-0.71	-5.37	-0.48	5.63e-7	Body mass index;
THYM	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg18512352	chr11:47633146	NA	-0.55	-6.8	-0.57	9.37e-10	Subjective well-being;
THYM	cis	rs13102973	0.645	rs6535055	chr4:135886101	A/C	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.23e-13	Subjective well-being;
THYM	cis	rs12282928	0.714	rs1354295	chr11:48232547	A/T	cg22827986	chr11:48284249	OR4X1	-0.46	-4.64	-0.43	1.1e-5	Migraine - clinic-based;
THYM	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg20295408	chr7:1910781	MAD1L1	-0.61	-4.79	-0.44	6.11e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs757110	0.740	rs10832776	chr11:17385224	C/A	cg15432903	chr11:17409602	KCNJ11	0.58	6.28	0.54	1.01e-8	Type 2 diabetes;
THYM	cis	rs8133932	0.654	rs7277632	chr21:47327542	A/G	cg20357416	chr21:47294739	PCBP3	-0.78	-5.07	-0.46	1.98e-6	Schizophrenia;
THYM	cis	rs2554380	0.800	rs2585068	chr15:84404457	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.59	-4.89	-0.45	4.13e-6	Height;
THYM	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg01416388	chr22:39784598	NA	-0.95	-9.15	-0.68	1.11e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs5417	0.689	rs55868524	chr17:7170665	G/A	cg15655154	chr3:113604241	GRAMD1C	-0.89	-7.24	-0.6	1.16e-10	Diastolic blood pressure;
THYM	cis	rs17741873	0.779	rs10509346	chr10:75596014	A/G	cg18802414	chr10:75757814	VCL	-0.87	-4.54	-0.42	1.63e-5	Paclitaxel disposition in epithelial ovarian cancer;
THYM	cis	rs11098499	0.690	rs7674713	chr4:120322257	T/C	cg24375607	chr4:120327624	NA	0.6	4.89	0.45	4.16e-6	Corneal astigmatism;
THYM	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs11809207	0.857	rs11247866	chr1:26517794	A/G	cg03844060	chr1:26490628	NA	0.7	5.01	0.46	2.51e-6	Height;
THYM	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg10018233	chr7:150070692	REPIN1	0.38	5.48	0.49	3.46e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9790314	0.875	rs336582	chr3:161082659	C/T	cg03342759	chr3:160939853	NMD3	-0.73	-6.32	-0.54	8.42e-9	Morning vs. evening chronotype;
THYM	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-4.74	-0.44	7.43e-6	Lung function (FEV1);
THYM	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg22535103	chr8:58192502	C8orf71	-0.93	-5.34	-0.48	6.32e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs35934224	0.783	rs7288170	chr22:19864252	C/G	cg11182965	chr22:19864308	TXNRD2	-0.75	-5.83	-0.51	7.48e-8	Glaucoma (primary open-angle);
THYM	cis	rs6032067	0.777	rs55767422	chr20:43802497	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.93	-0.58	5.03e-10	Blood protein levels;
THYM	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg01073479	chr16:3509474	NAT15	0.57	4.83	0.44	5.33e-6	Tuberculosis;
THYM	cis	rs472402	0.580	rs3733773	chr5:6652252	G/A	cg12648172	chr5:5886274	NA	0.52	4.72	0.44	7.99e-6	Response to amphetamines;
THYM	cis	rs8053891	0.585	rs12926804	chr16:71994932	A/G	cg04254540	chr16:71951199	KIAA0174	-1.04	-4.89	-0.45	4.07e-6	Coronary artery disease;
THYM	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg09526685	chr4:187126073	CYP4V2	-1.15	-5.85	-0.51	6.97e-8	Blood protein levels;
THYM	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.44	-0.49	4.16e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7901056	0.967	rs3006818	chr10:26721012	A/C	cg23318538	chr10:26883079	C10orf50	-0.37	-5.08	-0.46	1.88e-6	Lymphocyte counts;
THYM	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg26597838	chr10:835615	NA	1.58	12.04	0.78	8.01e-21	Eosinophil percentage of granulocytes;
THYM	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg20007245	chr22:24372913	LOC391322	-0.7	-6.16	-0.53	1.73e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg19318889	chr4:1322082	MAEA	0.69	5.99	0.52	3.8e-8	Longevity;
THYM	cis	rs863345	0.625	rs6663286	chr1:158473725	C/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.83	-0.44	5.28e-6	Pneumococcal bacteremia;
THYM	cis	rs11419537	1	rs11419537	chr22:44154000	A/AT	cg09142166	chr22:44276013	PNPLA5	0.35	4.52	0.42	1.78e-5	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7178572	1.000	rs6495240	chr15:77766556	T/C	cg22256960	chr15:77711686	NA	-0.94	-7.93	-0.63	4.23e-12	Type 2 diabetes;
THYM	cis	rs6456156	0.526	rs3093025	chr6:167532731	A/G	cg09487078	chr6:167525398	CCR6	-0.36	-4.63	-0.43	1.18e-5	Primary biliary cholangitis;
THYM	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.71	5.31	0.48	7.11e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg07570687	chr10:102243282	WNT8B	0.83	8.01	0.63	2.92e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6980507	0.523	rs2974294	chr8:42369473	C/T	cg09913449	chr8:42400586	C8orf40	-0.76	-6.57	-0.56	2.7e-9	Glycated hemoglobin levels;
THYM	cis	rs995000	0.895	rs10889348	chr1:63078222	A/T	cg06896770	chr1:63153194	DOCK7	0.97	7.27	0.6	1.02e-10	Triglyceride levels;
THYM	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg24642844	chr7:1081250	C7orf50	-1.28	-8.22	-0.64	1.06e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg27572855	chr1:25598939	RHD	0.69	5.53	0.49	2.76e-7	Erythrocyte sedimentation rate;
THYM	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg12395012	chr8:11607386	GATA4	-0.65	-5.56	-0.5	2.51e-7	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs4262150	0.883	rs72802889	chr5:152254829	T/C	cg08281791	chr5:76607845	PDE8B	0.92	6.91	0.58	5.62e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs9460635	0.959	rs7755046	chr6:21453452	T/G	cg11817533	chr6:21523501	NA	-0.57	-4.49	-0.42	1.98e-5	Metabolite levels (HVA-5-HIAA Factor score);
THYM	cis	rs4747241	0.700	rs7099642	chr10:74052013	G/C	cg07828833	chr10:74069493	NA	0.59	5.03	0.46	2.3e-6	Heschl's gyrus morphology;
THYM	cis	rs2070488	1.000	rs762317	chr3:38497659	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	7.18	0.59	1.57e-10	Electrocardiographic conduction measures;
THYM	cis	rs9906944	0.742	rs4073893	chr17:47118523	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.43	-4.71	-0.44	8.43e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs11077998	0.840	rs9894993	chr17:80481088	T/C	cg10255544	chr17:80519551	FOXK2	0.5	4.46	0.42	2.25e-5	Reticulocyte fraction of red cells;
THYM	cis	rs9658691	0.607	rs12416581	chr10:90780440	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.7	-4.55	-0.42	1.6e-5	Mosquito bite size;
THYM	cis	rs2404602	0.735	rs11072598	chr15:76764788	T/C	cg23482746	chr15:76478102	C15orf27	0.47	4.46	0.42	2.27e-5	Blood metabolite levels;
THYM	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg20503657	chr10:835505	NA	1.17	8.26	0.65	8.45e-13	Eosinophil percentage of granulocytes;
THYM	trans	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg10856724	chr12:34555212	NA	-0.99	-8.99	-0.68	2.34e-14	Bladder cancer;
THYM	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg11663144	chr21:46675770	NA	-0.72	-10.48	-0.73	1.54e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg17105886	chr17:28927953	LRRC37B2	1.26	6.38	0.55	6.49e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg08999081	chr20:33150536	PIGU	-0.77	-6.95	-0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs240768	0.511	rs61289570	chr6:101403098	C/T	cg12253828	chr6:101329408	ASCC3	1.08	6.2	0.54	1.43e-8	Economic and political preferences (immigration/crime);
THYM	cis	rs3799977	0.504	rs227813	chr6:44671471	G/A	cg01816997	chr6:44355194	CDC5L	0.47	4.49	0.42	1.98e-5	Attention deficit hyperactivity disorder;
THYM	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs960902	0.714	rs10198396	chr2:37742142	A/G	cg25341268	chr2:37734390	NA	-0.68	-6.19	-0.54	1.5e-8	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs611744	0.967	rs682007	chr8:109210326	G/C	cg21045802	chr8:109455806	TTC35	0.6	5.37	0.48	5.65e-7	Dupuytren's disease;
THYM	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg05368731	chr17:41323189	NBR1	1.02	6.52	0.56	3.4e-9	Menopause (age at onset);
THYM	cis	rs490234	0.841	rs13291593	chr9:128228483	A/G	cg14078157	chr9:128172775	NA	-0.63	-4.84	-0.44	5.06e-6	Mean arterial pressure;
THYM	cis	rs72627123	0.867	rs3815331	chr14:74482948	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.14	6.41	0.55	5.69e-9	Morning vs. evening chronotype;
THYM	cis	rs17401966	0.800	rs2039778	chr1:10354601	A/G	cg19773385	chr1:10388646	KIF1B	-0.57	-4.49	-0.42	2.04e-5	Hepatocellular carcinoma;
THYM	cis	rs7000551	0.556	rs6998780	chr8:22254639	C/T	cg12081754	chr8:22256438	SLC39A14	1.15	12.01	0.78	9.31e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs892961	0.899	rs747482	chr17:75412109	T/C	cg11351908	chr17:75402473	SEPT9	0.55	5.4	0.48	4.94e-7	Airflow obstruction;
THYM	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6542838	0.702	rs4851167	chr2:99496303	G/C	cg08885076	chr2:99613938	TSGA10	-0.45	-4.47	-0.42	2.15e-5	Fear of minor pain;
THYM	cis	rs17685	0.753	rs8200	chr7:75696606	C/G	cg01364799	chr7:75623366	TMEM120A	0.63	4.48	0.42	2.05e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4595586	0.545	rs2218761	chr12:39393593	A/G	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg04622731	chr7:157956161	PTPRN2	-0.59	-4.88	-0.45	4.31e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg06027949	chr8:82754900	SNX16	-0.64	-5.35	-0.48	6.18e-7	Diastolic blood pressure;
THYM	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg03733263	chr8:22462867	KIAA1967	1.06	9.61	0.7	1.12e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6430585	0.528	rs895285	chr2:136710554	A/G	cg23851026	chr2:136556271	LCT	0.78	6.95	0.58	4.47e-10	Corneal structure;
THYM	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs4919694	1.000	rs12252500	chr10:104794984	G/C	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	trans	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg10856724	chr12:34555212	NA	-1.02	-9.56	-0.7	1.47e-15	Bladder cancer;
THYM	cis	rs6918586	0.658	rs198840	chr6:26112164	T/G	cg12310025	chr6:25882481	NA	0.68	5.49	0.49	3.36e-7	Schizophrenia;
THYM	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg10360139	chr7:1886902	MAD1L1	-0.58	-4.63	-0.43	1.15e-5	Schizophrenia;
THYM	cis	rs6840360	0.571	rs12650655	chr4:152556075	G/A	cg17479576	chr4:152424074	FAM160A1	-0.75	-5.26	-0.48	8.76e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.82	-7.5	-0.61	3.29e-11	Schizophrenia;
THYM	cis	rs447921	0.861	rs62084971	chr17:74425318	T/G	cg17201438	chr17:74438067	UBE2O	-0.81	-5.85	-0.51	6.9e-8	Mitochondrial DNA levels;
THYM	cis	rs922692	0.901	rs12906691	chr15:79068328	G/A	cg15571903	chr15:79123663	NA	-0.58	-5.23	-0.47	1.01e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg13319975	chr6:146136371	FBXO30	-0.71	-5.99	-0.52	3.78e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg10645314	chr2:3704589	ALLC	0.88	6.12	0.53	2.04e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.61e-20	Menopause (age at onset);
THYM	cis	rs2777491	1.000	rs66538814	chr15:41685917	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.07	-11.0	-0.75	1.25e-18	Ulcerative colitis;
THYM	cis	rs636291	0.500	rs655271	chr1:10536635	G/A	cg20482658	chr1:10539492	PEX14	-0.35	-5.25	-0.47	9.19e-7	Prostate cancer;
THYM	cis	rs11731175	1.000	rs3843890	chr4:189857604	G/T	cg00431894	chr4:189871012	NA	-0.89	-6.97	-0.58	4.22e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2742234	0.656	rs1864400	chr10:43610366	G/A	cg06632098	chr10:43605906	RET	-0.8	-5.05	-0.46	2.1e-6	Hirschsprung disease;
THYM	cis	rs6992848	0.727	rs13251796	chr8:141169168	G/A	cg22504031	chr8:141147661	TRAPPC9	0.64	4.95	0.45	3.19e-6	Response to amphetamines;
THYM	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg12310025	chr6:25882481	NA	-0.91	-7.9	-0.63	4.79e-12	Intelligence (multi-trait analysis);
THYM	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs4077515	0.967	rs4567159	chr9:139277059	G/A	cg14115884	chr9:139300582	SDCCAG3	0.73	6.9	0.58	5.79e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg17143192	chr8:8559678	CLDN23	0.91	6.72	0.57	1.33e-9	Obesity-related traits;
THYM	cis	rs28595532	0.688	rs116173135	chr4:119721949	C/T	cg11846333	chr4:119757529	SEC24D	1.48	5.58	0.5	2.24e-7	Cannabis dependence symptom count;
THYM	cis	rs6032067	0.527	rs6104011	chr20:43733503	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.57	-6.3	-0.54	9.23e-9	Blood protein levels;
THYM	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg06623918	chr6:96969491	KIAA0776	-1.1	-11.52	-0.76	9.8e-20	Headache;
THYM	cis	rs7264396	0.836	rs6058276	chr20:34187728	T/G	cg26038318	chr20:34205095	SPAG4	0.57	4.88	0.45	4.22e-6	Total cholesterol levels;
THYM	trans	rs75518195	0.590	rs11131485	chr4:64729820	C/T	cg14706739	chr8:21916355	EPB49	0.75	7.28	0.6	9.73e-11	Triptolide cytotoxicity;
THYM	cis	rs9393692	0.552	rs806789	chr6:26229161	C/A	cg00631329	chr6:26305371	NA	-0.51	-5.47	-0.49	3.61e-7	Educational attainment;
THYM	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg19875535	chr5:140030758	IK	0.58	4.46	0.42	2.21e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7631605	0.905	rs1046512	chr3:37032296	A/C	cg21328643	chr3:37258149	NA	-0.48	-4.58	-0.43	1.41e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs791590	0.752	rs41295055	chr10:6111622	C/T	cg17191567	chr10:6178319	NA	0.69	4.8	0.44	5.92e-6	Soluble interleukin-2 receptor subunit alpha;
THYM	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-6.02	-0.53	3.27e-8	Prostate cancer;
THYM	cis	rs1050631	0.564	rs1785904	chr18:33713132	T/C	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.6	4.69	0.43	9.09e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg12179176	chr11:130786555	SNX19	0.87	8.11	0.64	1.78e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg09085632	chr11:111637200	PPP2R1B	1.21	13.55	0.81	6.48e-24	Primary sclerosing cholangitis;
THYM	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs995000	0.931	rs598253	chr1:62911341	T/C	cg06896770	chr1:63153194	DOCK7	0.91	7.48	0.61	3.73e-11	Triglyceride levels;
THYM	cis	rs6754311	0.551	rs9287442	chr2:136522710	A/G	cg23851026	chr2:136556271	LCT	-0.56	-5.73	-0.51	1.2e-7	Mosquito bite size;
THYM	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9682041	0.696	rs9872796	chr3:170099393	T/G	cg11886554	chr3:170076028	SKIL	1.23	4.71	0.44	8.47e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg06808227	chr14:105710500	BRF1	-1.05	-9.14	-0.68	1.12e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7426056	0.671	rs10515944	chr2:204587269	A/C	cg07930752	chr2:204569955	CD28	0.67	4.74	0.44	7.48e-6	Primary sclerosing cholangitis;
THYM	cis	rs985746	0.568	rs6813156	chr4:36815686	A/G	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1878931	0.520	rs2015640	chr16:3465018	G/C	cg21433313	chr16:3507492	NAT15	0.66	5.87	0.52	6.45e-8	Body mass index (adult);
THYM	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg03676636	chr4:99064102	C4orf37	0.42	6.13	0.53	2.03e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg03806693	chr22:41940476	POLR3H	-0.77	-5.81	-0.51	8.37e-8	Neuroticism;
THYM	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07167872	chr1:205819463	PM20D1	0.97	9.53	0.7	1.65e-15	Menarche (age at onset);
THYM	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	8.78	0.67	6.71e-14	Chronic sinus infection;
THYM	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.7	5.63	0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs870825	0.587	rs58332461	chr4:185639742	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs6987853	0.901	rs2923429	chr8:42389743	A/G	cg09913449	chr8:42400586	C8orf40	0.88	8.02	0.64	2.8e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7586879	0.828	rs13387053	chr2:25103025	G/A	cg01884057	chr2:25150051	NA	0.53	4.7	0.43	8.85e-6	Body mass index;
THYM	cis	rs17407555	0.601	rs73229828	chr4:10026833	A/G	cg00071950	chr4:10020882	SLC2A9	-0.75	-6.01	-0.53	3.37e-8	Schizophrenia (age at onset);
THYM	cis	rs11096990	0.821	rs2711991	chr4:39151353	G/A	cg24403649	chr4:39172243	NA	-0.61	-5.14	-0.47	1.49e-6	Cognitive function;
THYM	cis	rs6598955	0.670	rs10902734	chr1:26617923	G/T	cg04990556	chr1:26633338	UBXN11	0.89	8.52	0.66	2.34e-13	Obesity-related traits;
THYM	cis	rs9633740	0.773	rs7080009	chr10:82269461	T/C	cg01528321	chr10:82214614	TSPAN14	0.94	4.48	0.42	2.08e-5	Post bronchodilator FEV1;
THYM	cis	rs7980799	0.682	rs61927702	chr12:33631695	A/G	cg06521331	chr12:34319734	NA	0.71	5.02	0.46	2.39e-6	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs921968	0.643	rs864990	chr2:219494037	G/A	cg02176678	chr2:219576539	TTLL4	0.63	6.15	0.53	1.85e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	4.92	0.45	3.6e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg13010199	chr12:38710504	ALG10B	0.72	5.78	0.51	9.6e-8	Heart rate;
THYM	cis	rs6723226	0.961	rs13010404	chr2:32848854	T/G	cg02381751	chr2:32503542	YIPF4	-0.62	-5.11	-0.46	1.7e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg04362960	chr10:104952993	NT5C2	0.59	4.69	0.43	8.99e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7000551	0.751	rs2449338	chr8:22369232	A/G	cg12081754	chr8:22256438	SLC39A14	0.64	5.95	0.52	4.51e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.87	0.58	6.55e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg16325326	chr1:53192061	ZYG11B	-0.96	-10.8	-0.74	3.33e-18	Monocyte count;
THYM	cis	rs300703	0.654	rs393277	chr2:121539	G/T	cg21211680	chr2:198530	NA	-1.33	-7.55	-0.61	2.66e-11	Blood protein levels;
THYM	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg03609598	chr5:56110824	MAP3K1	-0.85	-5.85	-0.51	6.86e-8	Initial pursuit acceleration;
THYM	cis	rs6032067	0.538	rs17331776	chr20:43744754	G/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.44	-4.7	-0.43	8.66e-6	Blood protein levels;
THYM	trans	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg26043149	chr18:55253948	FECH	1.2	11.6	0.77	6.65e-20	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08109568	chr15:31115862	NA	-0.59	-5.69	-0.5	1.39e-7	Huntington's disease progression;
THYM	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg15704280	chr7:45808275	SEPT13	-0.98	-11.3	-0.76	2.81e-19	Coronary artery disease;
THYM	cis	rs988913	1.000	rs9396011	chr6:54836739	C/T	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.74e-6	Menarche (age at onset);
THYM	cis	rs11605275	0.901	rs79690581	chr11:20026110	G/C	cg14835545	chr11:20032148	NAV2	-1.28	-6.23	-0.54	1.29e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.47	0.49	3.62e-7	Height;
THYM	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg13147721	chr7:65941812	NA	-0.94	-5.74	-0.51	1.13e-7	Diabetic kidney disease;
THYM	cis	rs9470366	0.535	rs762624	chr6:36645588	A/C	cg08179530	chr6:36648295	CDKN1A	0.64	4.74	0.44	7.55e-6	QRS duration;
THYM	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs6946131	0.509	rs12666973	chr7:54774739	T/G	cg16668896	chr7:54900801	NA	0.44	4.52	0.42	1.76e-5	Systemic lupus erythematosus;
THYM	cis	rs9361491	0.608	rs7740607	chr6:79441290	C/T	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11890956	chr21:40555474	PSMG1	1.04	9.53	0.7	1.68e-15	Cognitive function;
THYM	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg25072359	chr17:41440525	NA	0.74	4.57	0.42	1.49e-5	Menopause (age at onset);
THYM	cis	rs11771526	0.901	rs17161086	chr7:32294254	A/G	cg27532318	chr7:32358331	NA	-0.73	-4.87	-0.45	4.39e-6	Body mass index;
THYM	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg00484396	chr16:3507460	NAT15	0.68	6.6	0.56	2.35e-9	Tuberculosis;
THYM	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg08885076	chr2:99613938	TSGA10	-0.66	-6.08	-0.53	2.47e-8	Chronic sinus infection;
THYM	cis	rs4917300	0.605	rs1388800	chr8:143106264	C/T	cg25363559	chr8:143086065	NA	0.56	5.14	0.47	1.44e-6	Amyotrophic lateral sclerosis;
THYM	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg11871910	chr12:69753446	YEATS4	1.01	9.83	0.71	3.8e-16	Cerebrospinal fluid biomarker levels;
THYM	cis	rs477692	0.596	rs12247555	chr10:131370520	T/C	cg05714579	chr10:131428358	MGMT	-0.56	-4.83	-0.44	5.17e-6	Response to temozolomide;
THYM	cis	rs2235642	0.507	rs2235645	chr16:1597924	C/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.53	-5.1	-0.46	1.75e-6	Coronary artery disease;
THYM	trans	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg10856724	chr12:34555212	NA	-0.99	-8.92	-0.68	3.37e-14	Bladder cancer;
THYM	cis	rs12594515	1.000	rs8029209	chr15:45993489	A/G	cg01629716	chr15:45996671	NA	0.53	5.27	0.48	8.45e-7	Waist circumference;Weight;
THYM	cis	rs981844	0.826	rs4585278	chr4:154684145	A/G	cg09973105	chr4:154681532	RNF175	-0.69	-6.16	-0.53	1.74e-8	Response to statins (LDL cholesterol change);
THYM	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg26038318	chr20:34205095	SPAG4	0.64	5.27	0.48	8.62e-7	Total cholesterol levels;
THYM	cis	rs6828523	0.698	rs75086254	chr4:175851520	T/G	cg14561282	chr4:175839468	ADAM29	0.62	4.51	0.42	1.84e-5	Breast cancer;
THYM	cis	rs611744	0.669	rs13251024	chr8:109258333	T/C	cg21045802	chr8:109455806	TTC35	0.65	5.91	0.52	5.3e-8	Dupuytren's disease;
THYM	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg26149184	chr10:133730230	NA	0.82	5.1	0.46	1.76e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs1371867	0.875	rs1788184	chr8:101335106	A/G	cg06636551	chr8:101224915	SPAG1	-0.63	-6.33	-0.54	8.05e-9	Atrioventricular conduction;
THYM	cis	rs2932538	0.961	rs10745332	chr1:113189053	G/A	cg22162597	chr1:113214053	CAPZA1	-0.65	-5.32	-0.48	6.9e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs1448094	0.512	rs11117057	chr12:86248546	C/T	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.68	-5.92	-0.52	5.15e-8	Total body bone mineral density;
THYM	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg16342193	chr10:102329863	NA	0.62	6.54	0.56	3.03e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg22166914	chr1:53195759	ZYG11B	0.63	5.43	0.49	4.4e-7	Monocyte count;
THYM	trans	rs10802346	0.545	rs1361408	chr1:246410054	T/G	cg22732515	chr19:44031385	ETHE1	1.03	8.89	0.67	3.83e-14	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.77	5.93	0.52	4.88e-8	Height;
THYM	cis	rs4849845	0.889	rs4849848	chr2:121043190	A/T	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs75059851	0.756	rs11223658	chr11:133843216	G/A	cg14047540	chr11:133829660	NA	-1.1	-7.34	-0.6	7.1e-11	Schizophrenia;
THYM	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06481639	chr22:41940642	POLR3H	-0.81	-5.56	-0.5	2.47e-7	Vitiligo;
THYM	cis	rs912057	0.560	rs1294416	chr6:6741327	A/G	cg06612196	chr6:6737390	NA	0.77	14.62	0.83	4.77e-26	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg17279839	chr7:150038598	RARRES2	0.51	4.51	0.42	1.89e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs854765	0.583	rs4553680	chr17:17857722	A/G	cg04398451	chr17:18023971	MYO15A	-0.86	-8.06	-0.64	2.28e-12	Total body bone mineral density;
THYM	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg04317338	chr11:64019027	PLCB3	0.86	5.95	0.52	4.48e-8	Attention deficit hyperactivity disorder;
THYM	cis	rs2290159	0.800	rs6766666	chr3:12690855	A/C	cg23032965	chr3:12705835	RAF1	-0.85	-5.42	-0.49	4.55e-7	Cholesterol, total;
THYM	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg07959070	chr22:50026188	C22orf34	-0.28	-4.95	-0.45	3.17e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7107174	0.681	rs3102742	chr11:77949334	G/T	cg02023728	chr11:77925099	USP35	0.73	6.33	0.54	7.98e-9	Testicular germ cell tumor;
THYM	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg18402987	chr7:1209562	NA	0.64	5.02	0.46	2.4e-6	Longevity;Endometriosis;
THYM	cis	rs2963155	0.518	rs1438732	chr5:142756266	G/C	cg17617527	chr5:142782415	NR3C1	1.12	6.01	0.52	3.43e-8	Breast cancer;
THYM	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg14779329	chr11:130786720	SNX19	0.49	5.07	0.46	1.98e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg04842962	chr6:43655489	MRPS18A	-1.4	-15.42	-0.85	1.3e-27	IgG glycosylation;
THYM	cis	rs7804356	0.871	rs6972378	chr7:26753074	C/T	cg24979288	chr7:27242424	NA	0.62	4.48	0.42	2.09e-5	Type 1 diabetes;
THYM	cis	rs10992471	0.603	rs11794346	chr9:95247288	C/T	cg14631576	chr9:95140430	CENPP	-0.99	-9.94	-0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg10515332	chr4:99064459	C4orf37	0.71	5.67	0.5	1.51e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg06238570	chr21:40685208	BRWD1	-0.73	-6.27	-0.54	1.05e-8	Menarche (age at onset);
THYM	cis	rs238914	0.654	rs2846027	chr11:114003415	C/T	cg18231614	chr11:113558886	TMPRSS5	-0.58	-4.57	-0.42	1.47e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
THYM	cis	rs28595532	0.920	rs115354352	chr4:119750358	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg24112000	chr20:60950667	NA	-0.61	-5.04	-0.46	2.21e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg27284194	chr4:1044797	NA	0.61	4.69	0.43	9.09e-6	Recombination rate (females);
THYM	cis	rs7178572	0.524	rs11853287	chr15:77399371	A/G	cg22256960	chr15:77711686	NA	-0.96	-7.34	-0.6	7.36e-11	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg11871910	chr12:69753446	YEATS4	1.06	9.8	0.71	4.32e-16	Blood protein levels;
THYM	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg13319975	chr6:146136371	FBXO30	0.66	5.42	0.49	4.59e-7	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs561341	0.882	rs563539	chr17:30307958	A/G	cg20587970	chr11:113659929	NA	-1.26	-9.15	-0.68	1.09e-14	Hip circumference adjusted for BMI;
THYM	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg04317338	chr11:64019027	PLCB3	0.86	5.95	0.52	4.48e-8	Mean platelet volume;
THYM	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg27286337	chr10:134555280	INPP5A	0.85	6.36	0.55	6.91e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7840202	0.524	rs4483125	chr8:103312181	C/T	cg09990700	chr8:103251014	RRM2B	-0.94	-4.52	-0.42	1.76e-5	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);
THYM	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg09354556	chr3:47051341	NA	0.47	4.8	0.44	5.93e-6	Colorectal cancer;
THYM	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg21775007	chr8:11205619	TDH	0.69	5.2	0.47	1.15e-6	Retinal vascular caliber;
THYM	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg10515332	chr4:99064459	C4orf37	-0.65	-5.2	-0.47	1.12e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs988913	1.000	rs6902245	chr6:54813006	C/A	cg19716238	chr6:54711378	FAM83B	0.49	5.07	0.46	1.99e-6	Menarche (age at onset);
THYM	cis	rs259282	0.605	rs8101920	chr19:33109270	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.57	4.73	0.44	7.88e-6	Schizophrenia;
THYM	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg10518543	chr12:38710700	ALG10B	-0.57	-4.65	-0.43	1.09e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs8030379	0.967	rs11629657	chr15:84548980	C/G	cg15564896	chr15:84287328	SH3GL3	0.57	4.77	0.44	6.57e-6	Waist circumference adjusted for body mass index;Waist circumference;
THYM	cis	rs7246657	1.000	rs35398388	chr19:37740358	A/G	cg22634378	chr19:37742834	NA	0.64	5.31	0.48	7.33e-7	Coronary artery calcification;
THYM	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.88	9.61	0.7	1.12e-15	Prudent dietary pattern;
THYM	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg02353165	chr6:42928485	GNMT	0.86	7.87	0.63	5.67e-12	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs11190604	0.652	rs76629555	chr10:102191417	T/C	cg07570687	chr10:102243282	WNT8B	0.85	8.46	0.66	3.16e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg26597838	chr10:835615	NA	-1.1	-7.38	-0.6	5.95e-11	Eosinophil percentage of granulocytes;
THYM	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg23711669	chr6:146136114	FBXO30	-0.98	-10.65	-0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4866334	1.000	rs4866334	chr5:18483651	C/T	cg18608440	chr5:17519013	NA	-1.07	-4.95	-0.45	3.24e-6	IgG glycosylation;
THYM	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg02825527	chr7:2087843	MAD1L1	-0.7	-4.55	-0.42	1.58e-5	Bipolar disorder;
THYM	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg01380346	chr19:18557039	ELL	-0.47	-4.69	-0.43	8.97e-6	Breast cancer;
THYM	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3741151	0.773	rs73542960	chr11:73115946	T/C	cg17517138	chr11:73019481	ARHGEF17	0.94	5.48	0.49	3.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg03213289	chr20:61660250	NA	0.94	9.72	0.71	6.59e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs9527	0.567	rs6584539	chr10:104879402	G/C	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg27535305	chr1:53392650	SCP2	0.38	4.55	0.42	1.6e-5	Monocyte count;
THYM	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg13385794	chr1:248469461	NA	0.67	4.61	0.43	1.24e-5	Common traits (Other);
THYM	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg08772003	chr10:104629869	AS3MT	-0.74	-7.11	-0.59	2.16e-10	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg10057126	chr4:77819792	ANKRD56	0.72	6.14	0.53	1.93e-8	Emphysema distribution in smoking;
THYM	cis	rs300890	0.651	rs300917	chr4:144269849	C/G	cg01601573	chr4:144256835	GAB1	-0.38	-4.55	-0.42	1.61e-5	Nasopharyngeal carcinoma;
THYM	cis	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.83	-5.29	-0.48	7.71e-7	Resting heart rate;
THYM	cis	rs2456568	0.570	rs1518579	chr11:93656821	A/G	cg17595323	chr11:93583763	C11orf90	-0.52	-5.59	-0.5	2.21e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs3825932	0.961	rs11856301	chr15:79232330	T/C	cg25744700	chr15:79237217	CTSH	0.48	4.49	0.42	1.98e-5	Type 1 diabetes;
THYM	cis	rs7100689	0.646	rs1340380	chr10:82115619	T/C	cg01528321	chr10:82214614	TSPAN14	0.82	6.28	0.54	9.92e-9	Post bronchodilator FEV1;
THYM	cis	rs7512552	0.839	rs698916	chr1:150388385	A/G	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.54	-0.42	1.64e-5	Fear of minor pain;
THYM	cis	rs10208940	0.541	rs10164991	chr2:68831408	A/G	cg09157127	chr2:69201416	GKN1	0.89	4.71	0.43	8.61e-6	Urate levels in lean individuals;
THYM	cis	rs4523957	0.651	rs9898819	chr17:2076352	G/A	cg16513277	chr17:2031491	SMG6	-0.94	-8.81	-0.67	5.81e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg13609457	chr4:120235615	NA	0.58	5.33	0.48	6.48e-7	Corneal astigmatism;
THYM	cis	rs4731207	0.698	rs11975788	chr7:124497811	T/A	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs995000	0.899	rs4495740	chr1:63124465	T/G	cg06896770	chr1:63153194	DOCK7	1.0	8.13	0.64	1.61e-12	Triglyceride levels;
THYM	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg07636037	chr3:49044803	WDR6	0.88	7.74	0.62	1.04e-11	Menarche (age at onset);
THYM	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg23583168	chr7:148888333	NA	-1.02	-12.84	-0.8	1.76e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs861020	0.630	rs628300	chr1:209998298	C/T	cg05527609	chr1:210001259	C1orf107	0.84	6.74	0.57	1.22e-9	Orofacial clefts;
THYM	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg06634786	chr22:41940651	POLR3H	0.71	5.22	0.47	1.07e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg04025307	chr7:1156635	C7orf50	-0.65	-6.24	-0.54	1.22e-8	Longevity;Endometriosis;
THYM	cis	rs6785206	0.892	rs6439143	chr3:128425132	C/T	cg16766828	chr3:128327626	NA	-0.75	-7.58	-0.61	2.26e-11	Lymphocyte percentage of white cells;
THYM	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg10523679	chr1:76189770	ACADM	0.81	7.62	0.62	1.86e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs728616	0.867	rs118134654	chr10:81744381	G/A	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs790123	1.000	rs790123	chr3:122388993	T/C	cg15604389	chr3:122379662	NA	0.57	5.15	0.47	1.39e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs921968	0.643	rs832801	chr2:219488698	G/A	cg02176678	chr2:219576539	TTLL4	0.6	5.81	0.51	8.39e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg16797656	chr11:68205561	LRP5	0.42	4.47	0.42	2.16e-5	Total body bone mineral density;
THYM	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg01416388	chr22:39784598	NA	-0.95	-9.15	-0.68	1.11e-14	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.688	rs116580819	chr4:119767362	T/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg23682913	chr1:2080710	PRKCZ	0.5	4.52	0.42	1.81e-5	Height;
THYM	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs367615	0.704	rs7705399	chr5:108850351	G/C	cg17395555	chr5:108820864	NA	0.71	8.26	0.65	8.51e-13	Colorectal cancer (SNP x SNP interaction);
THYM	trans	rs8002861	0.810	rs7334812	chr13:44445538	C/T	cg17145862	chr1:211918768	LPGAT1	0.94	9.74	0.71	6.04e-16	Leprosy;
THYM	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.85	-0.51	7.09e-8	Bipolar disorder and schizophrenia;
THYM	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg04842962	chr6:43655489	MRPS18A	-0.98	-8.35	-0.65	5.51e-13	IgG glycosylation;
THYM	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg01528321	chr10:82214614	TSPAN14	0.66	5.16	0.47	1.35e-6	Post bronchodilator FEV1;
THYM	cis	rs7953508	0.711	rs11107116	chr12:93978504	G/T	cg18151635	chr12:93972918	NA	-0.73	-5.04	-0.46	2.21e-6	Pubertal anthropometrics;
THYM	cis	rs4951011	0.938	rs7547815	chr1:203761870	T/G	cg24343524	chr1:203763352	ZC3H11A	0.71	6.32	0.54	8.49e-9	Breast cancer;
THYM	cis	rs10489202	1.000	rs67600256	chr1:167972357	T/C	cg24449463	chr1:168025552	DCAF6	-0.83	-6.51	-0.56	3.58e-9	Schizophrenia;
THYM	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg06481639	chr22:41940642	POLR3H	0.77	5.21	0.47	1.11e-6	Cannabis dependence symptom count;
THYM	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg03929089	chr4:120376271	NA	-0.8	-8.0	-0.63	2.94e-12	Height;
THYM	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg01341218	chr17:43662625	NA	0.96	7.09	0.59	2.36e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg17554472	chr22:41940697	POLR3H	0.7	4.97	0.45	2.97e-6	Vitiligo;
THYM	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg23815491	chr16:72088622	HP	0.69	5.3	0.48	7.58e-7	Fibrinogen levels;
THYM	cis	rs9297145	1.000	rs10953280	chr7:98763405	A/G	cg05967295	chr7:98741636	SMURF1	-0.99	-9.11	-0.68	1.32e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg11871910	chr12:69753446	YEATS4	0.75	6.09	0.53	2.39e-8	Blood protein levels;
THYM	cis	rs865483	0.895	rs2522966	chr17:35816616	A/G	cg06716730	chr17:35851459	DUSP14	-0.42	-7.12	-0.59	2.04e-10	Monocyte count;
THYM	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg26354017	chr1:205819088	PM20D1	-0.71	-5.59	-0.5	2.15e-7	Menarche (age at onset);
THYM	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg12908607	chr1:44402522	ARTN	0.59	4.96	0.45	3.12e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs2034088	0.897	rs11652657	chr17:439124	A/G	cg04370829	chr17:406249	NA	-0.62	-5.1	-0.46	1.76e-6	Hip circumference adjusted for BMI;
THYM	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06634786	chr22:41940651	POLR3H	0.63	4.92	0.45	3.62e-6	Vitiligo;
THYM	cis	rs40363	0.868	rs37772	chr16:3512843	A/G	cg21433313	chr16:3507492	NAT15	0.77	7.71	0.62	1.24e-11	Tuberculosis;
THYM	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg00129232	chr17:37814104	STARD3	-0.71	-4.8	-0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7072216	0.763	rs10748730	chr10:100171440	C/T	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs6842047	0.563	rs6843711	chr4:187212953	T/C	cg09526685	chr4:187126073	CYP4V2	1.02	4.69	0.43	9.23e-6	Blood protein levels;
THYM	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs7408868	1.000	rs2074617	chr19:15276055	C/G	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs6496667	0.533	rs2589949	chr15:90955015	C/T	cg22089800	chr15:90895588	ZNF774	0.68	4.96	0.45	3.08e-6	Rheumatoid arthritis;
THYM	cis	rs2404602	0.647	rs11629727	chr15:77009038	G/C	cg23625390	chr15:77176239	SCAPER	-0.83	-5.7	-0.5	1.36e-7	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg24818145	chr4:99064322	C4orf37	0.75	5.94	0.52	4.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1784581	1.000	rs1615717	chr6:162400612	C/T	cg17173639	chr6:162384350	PARK2	-0.94	-8.79	-0.67	6.3e-14	Itch intensity from mosquito bite;
THYM	cis	rs7246967	0.673	rs8105441	chr19:22891466	T/C	cg05241461	chr19:22816980	ZNF492	0.6	4.64	0.43	1.11e-5	Bronchopulmonary dysplasia;
THYM	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs13064411	0.735	rs2614191	chr3:113269201	C/T	cg18753928	chr3:113234510	CCDC52	-0.69	-5.42	-0.49	4.55e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg18681998	chr4:17616180	MED28	0.86	7.79	0.62	8.27e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.89	0.45	4.08e-6	Mean corpuscular hemoglobin;
THYM	cis	rs6032067	0.929	rs35475980	chr20:43821080	A/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg10053473	chr17:62856997	LRRC37A3	-0.94	-7.34	-0.6	7.09e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg25801113	chr15:45476975	SHF	-0.39	-4.5	-0.42	1.91e-5	Uric acid levels;
THYM	cis	rs79387448	0.745	rs9677607	chr2:103149520	A/T	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs9828933	0.752	rs832192	chr3:63853423	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.93	5.59	0.5	2.16e-7	Type 2 diabetes;
THYM	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.66	8.96	0.68	2.76e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg07537917	chr2:241836409	C2orf54	-0.27	-6.41	-0.55	5.61e-9	Urinary metabolites;
THYM	cis	rs11711311	1.000	rs12637067	chr3:113527606	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.59	-5.13	-0.47	1.52e-6	IgG glycosylation;
THYM	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.75	-6.23	-0.54	1.3e-8	Lung cancer;
THYM	cis	rs7119	0.651	rs35577135	chr15:77840074	C/T	cg27398640	chr15:77910606	LINGO1	-0.61	-6.09	-0.53	2.41e-8	Type 2 diabetes;
THYM	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg10792982	chr14:105748885	BRF1	-0.73	-7.54	-0.61	2.8e-11	Mean platelet volume;Platelet distribution width;
THYM	trans	rs11186	0.591	rs72906354	chr2:189961771	C/T	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	cis	rs9399401	0.667	rs1329707	chr6:142724439	T/C	cg03128060	chr6:142623767	GPR126	0.65	8.79	0.67	6.46e-14	Chronic obstructive pulmonary disease;
THYM	cis	rs2302063	0.603	rs451690	chr19:3156465	G/T	cg14194048	chr19:2462042	NA	-0.63	-4.77	-0.44	6.55e-6	Glucose homeostasis traits;
THYM	cis	rs3087591	1.000	rs7216033	chr17:29574642	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.64	-5.44	-0.49	4.06e-7	Hip circumference;
THYM	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3768617	0.510	rs7542640	chr1:183063738	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.76	0.44	6.83e-6	Fuchs's corneal dystrophy;
THYM	cis	rs2069036	0.855	rs7069992	chr10:16078154	C/T	cg26633223	chr10:15133461	NA	0.6	4.46	0.42	2.23e-5	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg08439880	chr3:133502540	NA	0.82	7.1	0.59	2.26e-10	Iron status biomarkers;
THYM	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg01819863	chr10:32635814	EPC1	1.04	6.64	0.56	1.9e-9	Sexual dysfunction (female);
THYM	cis	rs9314614	0.789	rs4840642	chr8:6712765	T/A	cg27319216	chr8:6693540	XKR5	-0.56	-5.87	-0.52	6.33e-8	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs76878669	0.561	rs1784029	chr11:66099987	C/T	cg15964523	chr11:66469143	SPTBN2	0.58	4.46	0.42	2.23e-5	Educational attainment (years of education);
THYM	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg10802521	chr3:52805072	NEK4	-0.59	-5.12	-0.46	1.63e-6	Electroencephalogram traits;
THYM	cis	rs6876348	0.929	rs1422457	chr5:128118664	C/G	cg25555059	chr5:128301488	SLC27A6	-0.46	-4.95	-0.45	3.19e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28595532	0.920	rs114051506	chr4:119772893	A/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg09307838	chr4:120376055	NA	0.7	5.27	0.48	8.48e-7	Corneal astigmatism;
THYM	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	4.83	0.44	5.17e-6	Bipolar disorder;
THYM	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs4889855	0.530	rs4889863	chr17:78550468	C/T	cg16591659	chr17:78472290	NA	-0.45	-5.14	-0.47	1.46e-6	Fractional excretion of uric acid;
THYM	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg08645402	chr16:4508243	NA	0.58	5.15	0.47	1.39e-6	Schizophrenia;
THYM	cis	rs6665290	0.669	rs3768423	chr1:227177293	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.08	-12.43	-0.79	1.26e-21	Myeloid white cell count;
THYM	cis	rs4077515	0.967	rs10781500	chr9:139269338	A/G	cg14115884	chr9:139300582	SDCCAG3	-0.65	-5.47	-0.49	3.67e-7	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs2350702	0.660	rs1914775	chr2:49951337	C/A	cg22592722	chr2:49566210	NA	-0.56	-4.55	-0.42	1.6e-5	Morning vs. evening chronotype;
THYM	cis	rs12594515	1.000	rs8038058	chr15:45990272	C/T	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.9	0.45	3.94e-6	Prudent dietary pattern;
THYM	cis	rs11886999	0.762	rs72825864	chr2:96888608	C/T	cg18419276	chr2:96971862	SNRNP200	-0.5	-4.77	-0.44	6.69e-6	Cardiac Troponin-T levels;
THYM	cis	rs10799590	1.000	rs12124262	chr1:224824953	C/T	cg01808320	chr1:224927238	CNIH3	-0.6	-5.41	-0.49	4.72e-7	Opioid dependence;
THYM	cis	rs3126085	0.935	rs3126046	chr1:152256925	G/A	cg10321714	chr1:152280068	FLG	-0.67	-5.14	-0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg21926883	chr2:100939477	LONRF2	-0.61	-5.71	-0.51	1.3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs240764	0.755	rs12206564	chr6:100987009	A/G	cg21058520	chr6:100914733	NA	0.59	5.0	0.46	2.61e-6	Neuroticism;
THYM	cis	rs1728785	1.000	rs7192341	chr16:68569224	G/C	cg02972257	chr16:68554789	NA	-0.76	-4.76	-0.44	6.82e-6	Ulcerative colitis;
THYM	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg17173187	chr15:85201210	NMB	0.54	5.31	0.48	7.17e-7	Schizophrenia;
THYM	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg03684893	chr10:554711	DIP2C	-0.66	-5.28	-0.48	8.12e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs2913737	0.530	rs2963660	chr5:175895023	G/A	cg27658698	chr5:175955578	RNF44	0.53	4.54	0.42	1.65e-5	Obesity-related traits;
THYM	cis	rs2276314	0.947	rs16967319	chr18:33573525	A/G	cg05985134	chr18:33552581	C18orf21	0.72	4.95	0.45	3.19e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs1971762	0.527	rs6580952	chr12:53937452	C/T	cg16917193	chr12:54089295	NA	0.7	6.18	0.54	1.6e-8	Height;
THYM	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg10515332	chr4:99064459	C4orf37	0.67	5.33	0.48	6.48e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2915864	0.800	rs17098069	chr5:141499435	A/G	cg03486475	chr5:140796240	PCDHGA4;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	-0.74	-4.45	-0.42	2.32e-5	Facial morphology (factor 20);
THYM	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg26597838	chr10:835615	NA	1.23	8.88	0.67	4.1e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg06808227	chr14:105710500	BRF1	-1.02	-8.81	-0.67	5.84e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2273669	0.667	rs2145763	chr6:109306963	C/A	cg17117243	chr6:109341365	SESN1	-0.84	-4.94	-0.45	3.41e-6	Prostate cancer;
THYM	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg16031515	chr1:205743344	RAB7L1	-0.71	-7.29	-0.6	9.03e-11	Menarche (age at onset);
THYM	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg21773646	chr17:80085082	CCDC57	-0.34	-4.91	-0.45	3.76e-6	Life satisfaction;
THYM	cis	rs2120019	0.508	rs8030528	chr15:75171825	C/T	cg09165964	chr15:75287851	SCAMP5	-0.7	-5.0	-0.46	2.64e-6	Blood trace element (Zn levels);
THYM	cis	rs11048434	0.761	rs12824380	chr12:9132017	A/G	cg04155231	chr12:9217510	LOC144571	0.49	4.69	0.43	9.28e-6	Sjögren's syndrome;
THYM	cis	rs860818	1.000	rs858304	chr7:23243153	G/T	cg05407003	chr7:23246146	NA	1.27	4.72	0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg18252515	chr7:66147081	NA	0.7	5.46	0.49	3.81e-7	Aortic root size;
THYM	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg08847533	chr14:75593920	NEK9	-1.03	-11.14	-0.75	6.16e-19	Height;
THYM	cis	rs595982	0.702	rs638050	chr19:49375676	A/G	cg21252483	chr19:49399788	TULP2	-0.53	-4.64	-0.43	1.1e-5	Red cell distribution width;
THYM	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg02524346	chr8:600233	NA	0.92	4.61	0.43	1.24e-5	IgG glycosylation;
THYM	cis	rs9992101	0.547	rs7654978	chr4:77409945	G/T	cg27417997	chr4:77356416	SHROOM3	-0.37	-4.46	-0.42	2.22e-5	Creatinine levels;
THYM	cis	rs9790314	0.663	rs778642	chr3:160705819	A/G	cg04691961	chr3:161091175	C3orf57	-0.58	-4.63	-0.43	1.15e-5	Morning vs. evening chronotype;
THYM	cis	rs12142240	0.698	rs1475389	chr1:46816429	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs8133932	0.701	rs9653780	chr21:47303774	A/G	cg20357416	chr21:47294739	PCBP3	-0.83	-4.98	-0.46	2.83e-6	Schizophrenia;
THYM	cis	rs986417	1.000	rs1254287	chr14:60861774	C/T	cg27398547	chr14:60952738	C14orf39	-1.17	-6.74	-0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg10523679	chr1:76189770	ACADM	-0.84	-6.96	-0.58	4.4e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs13223928	0.541	rs17132968	chr7:3136074	T/G	cg19214707	chr7:3157722	NA	-0.79	-5.74	-0.51	1.11e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg03517284	chr6:25882590	NA	0.74	5.83	0.51	7.64e-8	Blood metabolite levels;
THYM	cis	rs877282	1.000	rs71491304	chr10:772982	C/T	cg10556349	chr10:835070	NA	-0.69	-4.81	-0.44	5.75e-6	Uric acid levels;
THYM	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg03806693	chr22:41940476	POLR3H	1.19	10.49	0.73	1.46e-17	Vitiligo;
THYM	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.08	8.29	0.65	7.47e-13	Cognitive test performance;
THYM	cis	rs611744	0.647	rs2298603	chr8:109271426	C/T	cg21045802	chr8:109455806	TTC35	0.62	5.45	0.49	4.02e-7	Dupuytren's disease;
THYM	cis	rs8017423	0.740	rs7152196	chr14:90703900	G/T	cg04239629	chr14:90701769	NA	-0.61	-4.53	-0.42	1.68e-5	Mortality in heart failure;
THYM	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg02734326	chr4:10020555	SLC2A9	0.76	6.88	0.58	6.2e-10	Bone mineral density;
THYM	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.5	0.49	3.16e-7	Obesity-related traits;
THYM	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg00686598	chr14:53173677	PSMC6	1.39	7.01	0.58	3.52e-10	Alzheimer's disease (late onset);
THYM	cis	rs76878669	0.538	rs4930360	chr11:66143247	T/A	cg18002602	chr11:66138449	SLC29A2	0.5	5.02	0.46	2.38e-6	Educational attainment (years of education);
THYM	cis	rs17005891	0.730	rs6535363	chr4:83562569	A/G	cg10249074	chr4:83542146	C4orf11	-0.7	-5.81	-0.51	8.38e-8	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs8070624	0.543	rs57728924	chr17:17875342	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	6.7	0.57	1.48e-9	Total body bone mineral density;
THYM	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	4.46	0.42	2.21e-5	Diabetic retinopathy;
THYM	cis	rs4918072	0.667	rs10430666	chr10:105702425	T/C	cg11005552	chr10:105648138	OBFC1	0.58	4.77	0.44	6.69e-6	Coronary artery disease;
THYM	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg07936489	chr17:37558343	FBXL20	-0.67	-4.9	-0.45	3.86e-6	Asthma;
THYM	cis	rs1018836	0.847	rs4735226	chr8:91569238	T/A	cg16814680	chr8:91681699	NA	-0.78	-6.45	-0.55	4.73e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg26531700	chr6:26746687	NA	0.58	4.76	0.44	6.95e-6	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.844	rs55845920	chr4:119490085	C/T	cg14228332	chr4:119757509	SEC24D	1.38	4.98	0.45	2.89e-6	Cannabis dependence symptom count;
THYM	cis	rs7830933	1.000	rs7830933	chr8:23603324	A/G	cg04349084	chr8:23602677	NA	0.65	7.36	0.6	6.49e-11	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg09436375	chr6:42928200	GNMT	-0.44	-5.86	-0.52	6.75e-8	Plasma homocysteine levels (post-methionine load test);
THYM	cis	rs9915657	0.870	rs759499	chr17:70133177	C/T	cg06234051	chr17:70120541	SOX9	-0.68	-6.34	-0.55	7.65e-9	Thyroid hormone levels;
THYM	cis	rs1215050	0.740	rs783949	chr4:99001933	A/G	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs919433	0.679	rs6757632	chr2:198530266	C/T	cg05783139	chr2:198650985	BOLL	0.66	4.98	0.46	2.78e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	trans	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.65	5.14	0.47	1.47e-6	Lung cancer in ever smokers;
THYM	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-4.73	-0.44	7.82e-6	Hemoglobin concentration;
THYM	cis	rs17433780	0.836	rs61798917	chr1:89506093	G/A	cg09516651	chr1:89888402	LOC400759	0.99	8.14	0.64	1.54e-12	Carotid intima media thickness;
THYM	cis	rs3741151	0.892	rs2027761	chr11:73036179	C/T	cg12959048	chr11:73096162	RELT	-0.43	-4.54	-0.42	1.62e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg13010199	chr12:38710504	ALG10B	0.76	6.07	0.53	2.59e-8	Heart rate;
THYM	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg15445000	chr17:37608096	MED1	-0.41	-5.04	-0.46	2.26e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs1003719	0.586	rs2298685	chr21:38533390	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs6430585	0.697	rs6724569	chr2:136516970	G/A	cg20242066	chr2:136595261	LCT	0.5	4.7	0.43	8.63e-6	Corneal structure;
THYM	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg17480646	chr11:65405466	SIPA1	-0.94	-8.68	-0.67	1.07e-13	Acne (severe);
THYM	cis	rs10791097	0.702	rs10894267	chr11:130714861	C/T	cg12179176	chr11:130786555	SNX19	-0.73	-6.17	-0.53	1.67e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs995000	0.868	rs10889360	chr1:63173918	C/T	cg06896770	chr1:63153194	DOCK7	0.84	5.58	0.5	2.31e-7	Triglyceride levels;
THYM	cis	rs950881	0.932	rs13408661	chr2:102955082	G/A	cg20060108	chr2:102954350	IL1RL1	0.85	4.68	0.43	9.48e-6	Allergy;
THYM	cis	rs4638749	0.677	rs12712018	chr2:108853505	A/C	cg25838818	chr2:108905173	SULT1C2	-0.51	-5.06	-0.46	2.04e-6	Blood pressure;
THYM	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg04025307	chr7:1156635	C7orf50	0.77	6.65	0.56	1.86e-9	Longevity;Endometriosis;
THYM	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg06558623	chr16:89946397	TCF25	1.3	6.32	0.54	8.49e-9	Skin colour saturation;
THYM	cis	rs6665290	0.545	rs6426584	chr1:227374949	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.73	-6.87	-0.58	6.62e-10	Myeloid white cell count;
THYM	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.68	6.1	0.53	2.26e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-5.79	-0.51	9.2e-8	Chronic sinus infection;
THYM	cis	rs6456156	0.774	rs6930998	chr6:167526940	A/C	cg09487078	chr6:167525398	CCR6	-0.44	-4.92	-0.45	3.63e-6	Primary biliary cholangitis;
THYM	cis	rs4072705	1.000	rs4072705	chr9:127373463	C/A	cg13476313	chr9:127244764	NR5A1	0.33	5.11	0.46	1.66e-6	Menarche (age at onset);
THYM	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.41	0.55	5.47e-9	Total body bone mineral density;
THYM	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg10295955	chr4:187884368	NA	-1.22	-17.5	-0.87	1.76e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs73787773	0.669	rs73227487	chr5:111462440	A/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.97	-5.7	-0.5	1.34e-7	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg16797656	chr11:68205561	LRP5	-0.45	-4.75	-0.44	7.31e-6	Total body bone mineral density;
THYM	cis	rs295140	1.000	rs10931897	chr2:201162520	T/C	cg04283868	chr2:201171347	SPATS2L	0.75	5.71	0.51	1.31e-7	QT interval;
THYM	cis	rs6542838	0.609	rs12712043	chr2:99541494	C/T	cg08885076	chr2:99613938	TSGA10	-0.48	-4.95	-0.45	3.25e-6	Fear of minor pain;
THYM	cis	rs877282	1.000	rs877281	chr10:771557	T/G	cg10556349	chr10:835070	NA	-0.77	-5.28	-0.48	8.04e-7	Uric acid levels;
THYM	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg04944784	chr2:26401820	FAM59B	-0.79	-6.18	-0.54	1.61e-8	Gut microbiome composition (summer);
THYM	cis	rs9649213	0.593	rs6970801	chr7:97925240	T/C	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.6e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.47	-0.55	4.25e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22857025	chr5:266934	NA	-1.37	-8.88	-0.67	4.08e-14	Breast cancer;
THYM	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg03929089	chr4:120376271	NA	-1.03	-12.43	-0.79	1.26e-21	Height;
THYM	cis	rs4851266	0.898	rs13026143	chr2:100865406	A/G	cg08017756	chr2:100939284	LONRF2	0.57	4.5	0.42	1.9e-5	Educational attainment;
THYM	cis	rs10927875	0.688	rs2009371	chr1:16348083	A/T	cg22431228	chr1:16359049	CLCNKA	-0.51	-4.93	-0.45	3.47e-6	Dilated cardiomyopathy;
THYM	cis	rs6032067	0.640	rs13043809	chr20:43753220	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.33	-0.48	6.56e-7	Blood protein levels;
THYM	cis	rs11030122	0.702	rs67300156	chr11:3953949	C/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.73	-0.51	1.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg06850241	chr22:41845214	NA	0.53	4.72	0.44	8.08e-6	Vitiligo;
THYM	cis	rs11225247	0.881	rs117487227	chr11:102256853	G/T	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs12903896	1	rs12903896	chr15:75052495	C/T	cg14664628	chr15:75095509	CSK	-0.71	-5.33	-0.48	6.7e-7	Red blood cell count;
THYM	cis	rs754466	0.580	rs10824575	chr10:79549047	A/G	cg17075019	chr10:79541650	NA	-0.7	-5.81	-0.51	8.45e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg26384229	chr12:38710491	ALG10B	0.9	7.3	0.6	8.9e-11	Bladder cancer;
THYM	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-6.65	-0.56	1.84e-9	Chronic sinus infection;
THYM	cis	rs240764	0.817	rs6922219	chr6:101153907	G/C	cg21058520	chr6:100914733	NA	0.6	5.37	0.48	5.6e-7	Neuroticism;
THYM	cis	rs4242434	0.819	rs2306518	chr8:22470308	A/G	cg01710189	chr8:22454888	PDLIM2	-0.5	-5.49	-0.49	3.3e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg09184832	chr6:79620586	NA	0.65	5.64	0.5	1.75e-7	Intelligence (multi-trait analysis);
THYM	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg01448562	chr3:133502909	NA	-0.83	-7.15	-0.59	1.82e-10	Iron status biomarkers;
THYM	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9581943	1.000	rs9581943	chr13:28493997	G/A	cg16302790	chr13:28498334	PDX1	0.59	5.29	0.48	7.81e-7	Pancreatic cancer;
THYM	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg11366901	chr6:160182831	ACAT2	1.07	9.53	0.7	1.68e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg06609049	chr19:2785107	THOP1	0.66	5.72	0.51	1.21e-7	Total cholesterol levels;
THYM	cis	rs593982	0.925	rs3953806	chr11:65505153	C/T	cg08755490	chr11:65554678	OVOL1	-1.44	-7.91	-0.63	4.57e-12	Atopic dermatitis;
THYM	cis	rs12829704	0.534	rs4149022	chr12:21295612	G/A	cg12696586	chr12:21590942	PYROXD1	0.59	4.6	0.43	1.33e-5	Blood metabolite levels;
THYM	cis	rs7705502	0.962	rs55850761	chr5:173373488	A/C	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-4.5	-0.42	1.91e-5	Chronic sinus infection;
THYM	cis	rs865483	0.929	rs853225	chr17:35791505	A/C	cg06716730	chr17:35851459	DUSP14	0.43	7.3	0.6	8.71e-11	Monocyte count;
THYM	cis	rs988913	1.000	rs1503136	chr6:54851965	A/C	cg18532076	chr6:54711417	FAM83B	0.5	4.91	0.45	3.78e-6	Menarche (age at onset);
THYM	cis	rs2658782	0.724	rs2248655	chr11:93254612	T/C	cg15737290	chr11:93063684	CCDC67	1.02	7.68	0.62	1.39e-11	Pulmonary function decline;
THYM	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg15556689	chr8:8085844	FLJ10661	0.64	5.35	0.48	6.11e-7	Mood instability;
THYM	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg20587970	chr11:113659929	NA	-1.35	-8.36	-0.65	5.21e-13	Hip circumference adjusted for BMI;
THYM	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg27170947	chr2:26402098	FAM59B	-0.58	-4.89	-0.45	4.18e-6	Gut microbiome composition (summer);
THYM	cis	rs8038465	0.516	rs8037836	chr15:73859855	G/A	cg15420318	chr15:73925796	NPTN	0.81	8.27	0.65	8.09e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.99	-0.46	2.72e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1863824	0.595	rs61859067	chr10:88159997	G/A	cg06895675	chr10:88137553	NA	0.56	5.09	0.46	1.79e-6	Schizophrenia;
THYM	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg26384229	chr12:38710491	ALG10B	0.73	5.35	0.48	6.04e-7	Morning vs. evening chronotype;
THYM	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg20587970	chr11:113659929	NA	-1.25	-9.01	-0.68	2.13e-14	Hip circumference adjusted for BMI;
THYM	cis	rs7246657	0.524	rs10411251	chr19:37428755	C/T	cg22634378	chr19:37742834	NA	0.64	4.62	0.43	1.21e-5	Coronary artery calcification;
THYM	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg20283391	chr11:68216788	NA	-0.58	-4.47	-0.42	2.19e-5	Total body bone mineral density;
THYM	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg16928487	chr17:17741425	SREBF1	0.56	5.57	0.5	2.37e-7	Total body bone mineral density;
THYM	cis	rs9326248	0.581	rs10790167	chr11:116800943	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.67	5.38	0.48	5.42e-7	Blood protein levels;
THYM	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg13319975	chr6:146136371	FBXO30	-0.7	-5.72	-0.51	1.23e-7	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg03929089	chr4:120376271	NA	-1.01	-13.68	-0.81	3.47e-24	Height;
THYM	cis	rs2820651	1.000	rs4448619	chr10:1468196	C/T	cg27404824	chr10:1454848	ADARB2	0.92	4.81	0.44	5.74e-6	Migraine with aura;
THYM	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg01341218	chr17:43662625	NA	1.15	9.87	0.71	3.19e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11078597	0.671	rs1310	chr17:1641715	G/T	cg18436246	chr17:1640651	WDR81	0.64	4.63	0.43	1.14e-5	Serum albumin level;
THYM	cis	rs12040273	0.908	rs12240271	chr1:230207462	A/G	cg04991747	chr1:230207211	GALNT2	0.75	4.83	0.44	5.2e-6	Carotid intima media thickness;
THYM	cis	rs3916	1.000	rs1799958	chr12:121176083	G/A	cg21892295	chr12:121157589	UNC119B	-0.51	-4.88	-0.45	4.32e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs8068544	0.818	rs79892925	chr17:40171819	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.47	-7.41	-0.61	5.18e-11	Reticulocyte fraction of red cells;Reticulocyte count;
THYM	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg07061783	chr6:25882402	NA	0.57	4.48	0.42	2.07e-5	Schizophrenia;
THYM	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11890956	chr21:40555474	PSMG1	-0.66	-6.44	-0.55	4.92e-9	Menarche (age at onset);
THYM	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs524281	0.814	rs10896093	chr11:65958411	C/G	cg00563793	chr11:65837595	PACS1	0.79	4.66	0.43	1.04e-5	Electroencephalogram traits;
THYM	cis	rs6840360	0.571	rs62327271	chr4:152535916	A/G	cg17479576	chr4:152424074	FAM160A1	-0.8	-5.65	-0.5	1.68e-7	Intelligence (multi-trait analysis);
THYM	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg13695892	chr22:41940480	POLR3H	0.85	6.16	0.53	1.72e-8	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4455778	0.580	rs56068416	chr7:49083226	T/C	cg26309511	chr7:48887640	NA	0.68	5.94	0.52	4.63e-8	Lung cancer in never smokers;
THYM	cis	rs7572733	0.534	rs10211202	chr2:198771941	A/G	cg00792783	chr2:198669748	PLCL1	0.84	5.97	0.52	4.15e-8	Dermatomyositis;
THYM	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg09354556	chr3:47051341	NA	0.48	5.0	0.46	2.57e-6	Colorectal cancer;
THYM	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg11965913	chr1:205819406	PM20D1	0.63	5.31	0.48	7.21e-7	Menarche (age at onset);
THYM	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg26597838	chr10:835615	NA	1.23	8.88	0.67	4.1e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg00129232	chr17:37814104	STARD3	-0.89	-7.1	-0.59	2.24e-10	Asthma;
THYM	cis	rs9807989	0.765	rs6751977	chr2:102967430	T/C	cg03938978	chr2:103052716	IL18RAP	0.61	6.04	0.53	3.04e-8	Asthma;
THYM	cis	rs3768617	0.510	rs6424885	chr1:183066254	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.76	0.44	6.83e-6	Fuchs's corneal dystrophy;
THYM	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg19747945	chr6:42946146	PEX6	-0.33	-4.82	-0.44	5.43e-6	Plasma homocysteine levels (post-methionine load test);
THYM	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs35883536	0.587	rs2809799	chr1:101036516	A/G	cg06223162	chr1:101003688	GPR88	0.82	6.96	0.58	4.4e-10	Monocyte count;
THYM	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs995000	0.839	rs12403207	chr1:62993620	T/C	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs12580035	0.945	rs12811035	chr12:1901546	A/C	cg04012082	chr12:1905096	CACNA2D4	-0.51	-4.75	-0.44	7.1e-6	Urate levels in lean individuals;
THYM	cis	rs17021463	0.934	rs28403447	chr4:95257753	G/A	cg11021082	chr4:95130006	SMARCAD1	0.54	4.63	0.43	1.17e-5	Testicular germ cell tumor;
THYM	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg18252515	chr7:66147081	NA	-0.66	-5.03	-0.46	2.34e-6	Aortic root size;
THYM	cis	rs7429990	0.965	rs6770467	chr3:48019232	A/G	cg02219026	chr3:48282209	ZNF589	0.6	4.5	0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs17001868	0.527	rs11913132	chr22:40778778	A/G	cg07138101	chr22:40742427	ADSL	0.74	4.56	0.42	1.54e-5	Mammographic density (dense area);
THYM	cis	rs11997175	0.646	rs67480501	chr8:33736315	C/T	ch.8.33884649F	chr8:33765107	NA	0.68	5.1	0.46	1.76e-6	Body mass index;
THYM	cis	rs6430585	0.583	rs730005	chr2:136582694	T/C	cg04750100	chr2:136595281	LCT	0.51	4.85	0.45	4.89e-6	Corneal structure;
THYM	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs950880	0.710	rs1135354	chr2:103014302	T/G	cg03938978	chr2:103052716	IL18RAP	-0.5	-4.46	-0.42	2.24e-5	Serum protein levels (sST2);
THYM	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg22709100	chr7:91322751	NA	-0.62	-4.77	-0.44	6.6e-6	Breast cancer;
THYM	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg03676636	chr4:99064102	C4orf37	0.4	5.77	0.51	9.89e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7927592	0.513	rs531163	chr11:68194496	A/G	cg16797656	chr11:68205561	LRP5	0.54	6.23	0.54	1.25e-8	Total body bone mineral density;
THYM	cis	rs9814567	0.752	rs4955547	chr3:134334975	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.88	-0.63	5.28e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.77	7.13	0.59	1.95e-10	Personality dimensions;
THYM	cis	rs6424115	1.000	rs6697805	chr1:24151996	C/A	cg15997130	chr1:24165203	NA	-0.77	-7.11	-0.59	2.15e-10	Immature fraction of reticulocytes;
THYM	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg14972814	chr11:95582409	MTMR2	-0.81	-6.68	-0.57	1.6e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2898681	0.580	rs41279517	chr4:53729771	T/C	cg00791764	chr4:53727839	RASL11B	0.65	6.4	0.55	5.74e-9	Optic nerve measurement (cup area);
THYM	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg13147721	chr7:65941812	NA	0.73	4.62	0.43	1.21e-5	Diabetic kidney disease;
THYM	cis	rs7818345	0.967	rs6999786	chr8:19277817	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.65	0.43	1.07e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs13394619	1.000	rs13394619	chr2:11727507	A/G	cg07314298	chr2:11723111	GREB1	0.59	5.55	0.49	2.6e-7	Endometriosis;
THYM	cis	rs757081	0.667	rs12420958	chr11:17100432	G/T	cg15432903	chr11:17409602	KCNJ11	-0.49	-4.58	-0.43	1.43e-5	Systolic blood pressure;
THYM	cis	rs62435770	1.000	rs62433637	chr6:169530865	C/G	cg07652237	chr6:170125491	PHF10	0.55	4.91	0.45	3.84e-6	Loneliness;
THYM	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	8.41	0.65	4.11e-13	Cognitive test performance;
THYM	cis	rs9359856	0.510	rs6937244	chr6:90468465	C/A	cg13799429	chr6:90582589	CASP8AP2	0.85	8.15	0.64	1.43e-12	Bipolar disorder;
THYM	cis	rs4455778	0.580	rs6944916	chr7:49113732	T/A	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs983545	0.586	rs4685404	chr3:16978642	T/C	cg19448816	chr3:16974217	PLCL2	0.56	5.14	0.47	1.45e-6	Blood protein levels;
THYM	cis	rs9527	0.568	rs1926036	chr10:104883812	C/T	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg12386194	chr3:101231763	SENP7	0.71	5.39	0.48	5.17e-7	Colorectal cancer;
THYM	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg13695892	chr22:41940480	POLR3H	0.93	7.11	0.59	2.14e-10	Vitiligo;
THYM	cis	rs35883536	0.588	rs114540631	chr1:101101249	A/G	cg06223162	chr1:101003688	GPR88	0.58	5.16	0.47	1.34e-6	Monocyte count;
THYM	cis	rs7523273	0.597	rs56075814	chr1:207975949	T/C	cg22525895	chr1:207977042	MIR29B2	-0.76	-5.12	-0.46	1.6e-6	Schizophrenia;
THYM	cis	rs9790314	0.580	rs960212	chr3:161047974	C/T	cg03342759	chr3:160939853	NMD3	-0.68	-5.73	-0.51	1.17e-7	Morning vs. evening chronotype;
THYM	cis	rs1061377	0.585	rs12648581	chr4:39055644	A/G	cg24403649	chr4:39172243	NA	0.57	4.57	0.42	1.48e-5	Uric acid levels;
THYM	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg07570687	chr10:102243282	WNT8B	0.84	8.13	0.64	1.59e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg18252515	chr7:66147081	NA	1.61	8.73	0.67	8.74e-14	Diabetic kidney disease;
THYM	cis	rs79387448	0.745	rs72995658	chr2:103176773	A/G	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs9915657	0.870	rs35271702	chr17:70140516	G/A	cg09344028	chr17:70110421	NA	0.49	4.83	0.44	5.18e-6	Thyroid hormone levels;
THYM	cis	rs988913	1.000	rs6941291	chr6:54837376	A/G	cg19716238	chr6:54711378	FAM83B	0.49	5.05	0.46	2.09e-6	Menarche (age at onset);
THYM	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg24209194	chr3:40518798	ZNF619	-0.63	-5.23	-0.47	1.01e-6	Renal cell carcinoma;
THYM	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg19016782	chr12:123741754	C12orf65	-0.68	-4.48	-0.42	2.05e-5	Neutrophil percentage of white cells;
THYM	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg26597838	chr10:835615	NA	1.52	11.37	0.76	2.05e-19	Eosinophil percentage of granulocytes;
THYM	cis	rs16944158	0.636	rs2111233	chr16:49650484	C/T	cg05126388	chr16:49670144	ZNF423	0.75	4.95	0.45	3.16e-6	IgG glycosylation;
THYM	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02018176	chr4:1364513	KIAA1530	0.94	8.82	0.67	5.6e-14	Longevity;
THYM	cis	rs904251	0.797	rs1776460	chr6:37485484	A/G	cg25019722	chr6:37503610	NA	-0.64	-5.12	-0.47	1.59e-6	Cognitive performance;
THYM	cis	rs66479974	1	rs66479974	chr10:95049397	CAG/C	cg00429402	chr10:94833658	CYP26A1	-0.63	-4.84	-0.44	5.06e-6	Intraocular pressure;
THYM	cis	rs7586879	0.616	rs6726199	chr2:25126328	G/C	cg27107076	chr2:25050844	ADCY3	-0.29	-4.72	-0.44	8.01e-6	Body mass index;
THYM	cis	rs2456568	0.548	rs4753113	chr11:93660974	G/A	cg26875233	chr11:93583750	C11orf90	-0.56	-6.24	-0.54	1.22e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs4523957	0.579	rs57130712	chr17:2089035	A/G	cg16513277	chr17:2031491	SMG6	-0.97	-8.83	-0.67	5.35e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs8100891	0.734	rs8104048	chr19:32829306	A/G	cg16662424	chr19:32837316	ZNF507	-0.41	-4.46	-0.42	2.25e-5	Neuroticism;
THYM	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg20891283	chr12:69753455	YEATS4	1.09	12.1	0.78	5.96e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg10856724	chr12:34555212	NA	-0.78	-6.99	-0.58	3.83e-10	Morning vs. evening chronotype;
THYM	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg22431228	chr1:16359049	CLCNKA	-0.42	-4.5	-0.42	1.92e-5	Systolic blood pressure;
THYM	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg05234568	chr11:5960015	NA	-0.59	-4.75	-0.44	7.28e-6	DNA methylation (variation);
THYM	cis	rs3916	0.910	rs7306541	chr12:121130046	A/G	cg10600917	chr12:121163489	ACADS	0.59	5.28	0.48	8.25e-7	Urinary metabolites (H-NMR features);
THYM	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.29	6.33	0.54	8.01e-9	Obesity-related traits;
THYM	cis	rs747334	0.846	rs2178205	chr10:92718227	G/A	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs4886920	0.662	rs4322626	chr15:78105835	A/G	cg16542125	chr15:78894002	CHRNA3	0.6	4.48	0.42	2.05e-5	Neuroticism;
THYM	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.73	5.62	0.5	1.93e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg13393036	chr8:95962371	TP53INP1	-0.46	-4.66	-0.43	1.02e-5	Type 2 diabetes;
THYM	cis	rs1883415	0.824	rs2245668	chr6:24501639	G/C	cg00346970	chr6:24499591	ALDH5A1	0.38	4.67	0.43	9.92e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9810089	0.835	rs655836	chr3:136097576	T/C	cg12473912	chr3:136751656	NA	0.58	4.67	0.43	9.76e-6	Gestational age at birth (child effect);
THYM	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg23711669	chr6:146136114	FBXO30	-0.93	-9.39	-0.69	3.39e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg08439880	chr3:133502540	NA	0.73	6.38	0.55	6.45e-9	Iron status biomarkers;
THYM	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg18200150	chr17:30822561	MYO1D	0.69	6.0	0.52	3.55e-8	Schizophrenia;
THYM	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg24069376	chr3:38537580	EXOG	0.66	6.6	0.56	2.37e-9	Electrocardiographic conduction measures;
THYM	cis	rs34638657	0.872	rs2967349	chr16:82194405	G/C	cg09439754	chr16:82129088	HSD17B2	-0.6	-5.26	-0.48	8.71e-7	Lung adenocarcinoma;
THYM	cis	rs728616	0.867	rs61860041	chr10:81944331	G/A	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg06028605	chr16:24865363	SLC5A11	0.63	5.18	0.47	1.26e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9543976	0.623	rs9544004	chr13:76191884	G/A	cg01531495	chr13:76123901	UCHL3	0.68	4.9	0.45	3.89e-6	Diabetic retinopathy;
THYM	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg06221963	chr1:154839813	KCNN3	-0.93	-13.22	-0.8	3.04e-23	Prostate cancer;
THYM	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg05896524	chr21:47604654	C21orf56	0.79	5.6	0.5	2.05e-7	Testicular germ cell tumor;
THYM	cis	rs10193935	0.901	rs13384885	chr2:42536646	G/C	cg27598129	chr2:42591480	NA	-0.76	-4.61	-0.43	1.23e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7075426	0.512	rs9633738	chr10:88183796	T/A	cg06895675	chr10:88137553	NA	0.52	4.46	0.42	2.27e-5	Migraine without aura;
THYM	cis	rs7968679	1	rs7968679	chr12:9313304	A/G	cg04155231	chr12:9217510	LOC144571	-0.56	-4.62	-0.43	1.21e-5	Myopia;
THYM	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	12.94	0.8	1.11e-22	Height;
THYM	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg08835221	chr22:38071607	LGALS1	0.38	5.35	0.48	6.05e-7	Fat distribution (HIV);
THYM	cis	rs1003719	0.715	rs2156077	chr21:38539357	C/T	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg10589385	chr1:150898437	SETDB1	0.65	5.45	0.49	4.01e-7	Melanoma;
THYM	cis	rs9611519	0.929	rs9611465	chr22:41426139	G/A	cg03806693	chr22:41940476	POLR3H	-0.77	-6.07	-0.53	2.59e-8	Neuroticism;
THYM	cis	rs7840202	0.524	rs36178006	chr8:103311667	T/G	cg09990700	chr8:103251014	RRM2B	-0.93	-4.48	-0.42	2.09e-5	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);
THYM	cis	rs6867032	1.000	rs4398675	chr5:2015816	G/A	cg26168224	chr5:2018326	NA	1.29	15.56	0.85	7.19e-28	Gut microbiome composition (winter);
THYM	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg05872129	chr22:39784769	NA	-0.99	-9.59	-0.7	1.25e-15	Intelligence (multi-trait analysis);
THYM	cis	rs2290159	0.800	rs11711419	chr3:12667784	A/T	cg23032965	chr3:12705835	RAF1	0.87	5.53	0.49	2.86e-7	Cholesterol, total;
THYM	cis	rs6952809	0.532	rs6953297	chr7:2440874	C/G	cg13581527	chr7:1708566	NA	-0.77	-5.3	-0.48	7.55e-7	Multiple sclerosis;
THYM	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg26384229	chr12:38710491	ALG10B	-0.92	-7.34	-0.6	7.32e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs950776	0.518	rs28438420	chr15:78836288	A/T	cg06917634	chr15:78832804	PSMA4	-0.88	-7.94	-0.63	3.97e-12	Sudden cardiac arrest;
THYM	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17122693	1.000	rs72679560	chr14:51067379	C/T	cg04730355	chr14:51134070	SAV1	0.99	5.42	0.49	4.44e-7	Cognitive performance;
THYM	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19346786	chr7:2764209	NA	-0.84	-7.92	-0.63	4.35e-12	Height;
THYM	cis	rs55788414	1.000	rs34242559	chr16:81180138	T/C	cg06400318	chr16:81190750	PKD1L2	-1.0	-4.87	-0.45	4.51e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs7172809	0.561	rs76746801	chr15:77789773	C/T	cg10437265	chr15:77819839	NA	-0.5	-4.57	-0.42	1.47e-5	Glucose homeostasis traits;
THYM	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03517284	chr6:25882590	NA	-0.76	-5.98	-0.52	3.87e-8	Blood metabolite levels;
THYM	cis	rs36051895	0.593	rs2094619	chr9:5167712	G/C	cg02405213	chr9:5042618	JAK2	-0.97	-9.49	-0.7	1.99e-15	Pediatric autoimmune diseases;
THYM	cis	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg06521331	chr12:34319734	NA	1.04	10.04	0.72	1.39e-16	Morning vs. evening chronotype;
THYM	cis	rs13185784	0.703	rs17627536	chr5:179678603	G/A	cg23248424	chr5:179741104	GFPT2	0.72	4.76	0.44	6.87e-6	TRAIL levels;
THYM	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg02953382	chr22:24373134	LOC391322	-0.71	-6.49	-0.55	3.93e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4481887	0.708	rs6688853	chr1:248548006	G/A	cg00666640	chr1:248458726	OR2T12	0.54	4.63	0.43	1.17e-5	Common traits (Other);
THYM	cis	rs526231	0.543	rs34804	chr5:102428239	G/A	cg23492399	chr5:102201601	PAM	-0.74	-5.51	-0.49	3e-7	Primary biliary cholangitis;
THYM	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs1974653	0.672	rs9606252	chr22:20092996	A/G	cg08822737	chr17:71088851	SLC39A11	1.01	7.03	0.58	3.18e-10	Schizophrenia;
THYM	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg07936489	chr17:37558343	FBXL20	0.83	5.84	0.51	7.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs863345	0.604	rs7544134	chr1:158475421	G/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs28595532	0.920	rs114940990	chr4:119758568	A/G	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg10803722	chr21:46713166	LOC642852	-0.5	-6.28	-0.54	1.02e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10779751	1.000	rs11121711	chr1:11317661	A/T	cg08854313	chr1:11322531	MTOR	0.99	9.0	0.68	2.29e-14	Body mass index;
THYM	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg18451016	chr1:38461880	NA	0.57	7.68	0.62	1.41e-11	Coronary artery disease;
THYM	cis	rs6964587	0.692	rs2158138	chr7:91700879	A/G	cg17063962	chr7:91808500	NA	1.0	9.02	0.68	2.03e-14	Breast cancer;
THYM	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg20295408	chr7:1910781	MAD1L1	-0.67	-5.26	-0.48	8.76e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg04520793	chr17:42248056	ASB16	-0.34	-4.75	-0.44	7.17e-6	Total body bone mineral density;
THYM	cis	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg27034606	chr17:28928453	LRRC37B2	0.79	4.89	0.45	4.06e-6	Body mass index;
THYM	cis	rs9913156	0.748	rs55869432	chr17:4562901	A/G	cg19197139	chr17:4613644	ARRB2	0.78	4.92	0.45	3.63e-6	Lymphocyte counts;
THYM	trans	rs59827721	0.556	rs80353776	chr9:13852228	T/C	cg12515942	chr19:49552529	CGB8	0.66	7.03	0.58	3.14e-10	Inflammatory skin disease;
THYM	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg09033563	chr22:24373618	LOC391322	0.6	5.77	0.51	9.94e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg11764359	chr7:65958608	NA	0.67	4.74	0.44	7.41e-6	Aortic root size;
THYM	cis	rs2806561	0.894	rs629107	chr1:23537971	C/T	cg12483005	chr1:23474871	LUZP1	0.54	5.48	0.49	3.47e-7	Height;
THYM	cis	rs7317940	1.000	rs1928522	chr13:78009779	A/T	cg02481778	chr13:77460607	KCTD12	-0.74	-5.09	-0.46	1.8e-6	Age of smoking initiation;
THYM	cis	rs72828912	0.808	rs9358746	chr6:24058264	C/G	cg26336265	chr6:25042955	NA	-0.86	-5.43	-0.49	4.31e-7	Squamous cell lung carcinoma;
THYM	cis	rs453193	0.573	rs2630744	chr2:8464827	A/T	cg12167548	chr2:8464763	NA	-0.42	-4.49	-0.42	1.97e-5	Granulocyte percentage of myeloid white cells;
THYM	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg20891558	chr2:74357851	NA	1.21	12.56	0.79	6.82e-22	Gestational age at birth (maternal effect);
THYM	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg19875535	chr5:140030758	IK	0.58	4.46	0.42	2.21e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg05043794	chr9:111880884	C9orf5	-0.43	-6.35	-0.55	7.29e-9	Menarche (age at onset);
THYM	cis	rs34779708	0.931	rs2384289	chr10:35343525	G/A	cg03585969	chr10:35415529	CREM	0.63	4.66	0.43	1.01e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs11771526	0.901	rs10267589	chr7:32280156	T/C	cg27532318	chr7:32358331	NA	0.75	5.37	0.48	5.5e-7	Body mass index;
THYM	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs4792901	0.759	rs60442473	chr17:41579287	A/G	cg21940313	chr17:41620911	ETV4	-0.54	-5.17	-0.47	1.32e-6	Dupuytren's disease;
THYM	cis	rs28595532	0.688	rs116566508	chr4:119619195	G/A	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.59	4.71	0.44	8.36e-6	Aortic root size;
THYM	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg07212818	chr11:638076	DRD4	-0.73	-5.06	-0.46	2.08e-6	Systemic lupus erythematosus;
THYM	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg26597838	chr10:835615	NA	1.29	8.24	0.65	9.18e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs3126085	0.935	rs1496051	chr1:152164923	G/A	cg26020982	chr1:152196106	HRNR	0.34	4.52	0.42	1.76e-5	Atopic dermatitis;
THYM	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg24209194	chr3:40518798	ZNF619	0.57	4.54	0.42	1.66e-5	Renal cell carcinoma;
THYM	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.64	-7.69	-0.62	1.38e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	trans	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.99	12.51	0.79	8.52e-22	Chronic sinus infection;
THYM	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg00684032	chr4:1343700	KIAA1530	0.54	4.71	0.43	8.55e-6	Obesity-related traits;
THYM	cis	rs977987	0.806	rs1364077	chr16:75396991	C/T	cg03315344	chr16:75512273	CHST6	0.74	6.13	0.53	2.02e-8	Dupuytren's disease;
THYM	cis	rs13070279	0.655	rs11718929	chr3:71792688	G/A	cg19388776	chr3:71835112	PROK2	0.88	5.12	0.46	1.61e-6	Monocyte count;
THYM	cis	rs4731207	0.596	rs115520589	chr7:124635877	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg21862992	chr11:68658383	NA	0.23	4.49	0.42	2.03e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg22875332	chr1:76189707	ACADM	-0.53	-4.69	-0.43	9.07e-6	Daytime sleep phenotypes;
THYM	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg12163867	chr12:51592794	POU6F1	-0.9	-5.77	-0.51	9.69e-8	Cisplatin-induced ototoxicity;
THYM	cis	rs9796	0.621	rs2899013	chr15:41492283	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.59	-4.85	-0.45	4.77e-6	Menopause (age at onset);
THYM	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs6723226	0.593	rs176401	chr2:32636511	A/T	cg02381751	chr2:32503542	YIPF4	-0.67	-6.0	-0.52	3.62e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg00376283	chr12:123451042	ABCB9	-0.8	-6.41	-0.55	5.49e-9	Platelet count;
THYM	cis	rs79518236	1	rs79518236	chr7:98026554	ACT/A	cg09267113	chr7:98030324	BAIAP2L1	-0.65	-5.52	-0.49	2.99e-7	Breast cancer;
THYM	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03576123	chr11:487126	PTDSS2	-1.48	-7.49	-0.61	3.49e-11	Body mass index;
THYM	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.6	-5.01	-0.46	2.5e-6	Coronary artery disease;
THYM	cis	rs17718580	0.536	rs56285552	chr14:51044852	G/C	cg04730355	chr14:51134070	SAV1	0.97	4.72	0.44	8.06e-6	Cognitive performance;
THYM	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg18904891	chr8:8559673	CLDN23	0.67	4.97	0.45	3e-6	Obesity-related traits;
THYM	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg02018176	chr4:1364513	KIAA1530	-0.58	-4.62	-0.43	1.19e-5	Obesity-related traits;
THYM	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg05368731	chr17:41323189	NBR1	1.19	10.4	0.73	2.28e-17	Menopause (age at onset);
THYM	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs7940866	0.804	rs3910267	chr11:130810282	C/T	cg05962950	chr11:130786565	SNX19	0.73	5.79	0.51	9.05e-8	Schizophrenia;
THYM	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg24910161	chr17:38119198	GSDMA	0.47	4.93	0.45	3.55e-6	Self-reported allergy;
THYM	cis	rs7757969	0.941	rs9487723	chr6:112124440	C/T	cg08601457	chr6:112115117	FYN	0.42	4.79	0.44	6.23e-6	Schizophrenia;
THYM	cis	rs2294693	0.947	rs9349176	chr6:40989525	C/T	cg14418226	chr6:40996092	UNC5CL	0.72	6.48	0.55	4.14e-9	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs9814567	0.806	rs4955534	chr3:134319723	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.09e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7106204	0.534	rs78539127	chr11:24256698	T/A	ch.11.24196551F	chr11:24239977	NA	0.91	4.72	0.44	8.27e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg05335186	chr13:53173507	NA	-0.49	-5.89	-0.52	5.94e-8	Lewy body disease;
THYM	cis	rs8180040	0.800	rs6768221	chr3:47296899	C/G	cg16586182	chr3:47516702	SCAP	0.69	6.0	0.52	3.63e-8	Colorectal cancer;
THYM	trans	rs8002861	0.905	rs12429722	chr13:44412466	T/A	cg17145862	chr1:211918768	LPGAT1	-0.85	-7.77	-0.62	9e-12	Leprosy;
THYM	cis	rs7072216	0.763	rs9787550	chr10:100169051	C/T	cg26618903	chr10:100175079	PYROXD2	-0.48	-4.6	-0.43	1.33e-5	Metabolite levels;
THYM	cis	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg01364799	chr7:75623366	TMEM120A	0.63	4.56	0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs17600642	0.526	rs7912588	chr10:72469287	G/C	cg09177132	chr10:72142824	LRRC20	-0.48	-5.04	-0.46	2.24e-6	Bipolar disorder;
THYM	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg17063962	chr7:91808500	NA	1.1	12.12	0.78	5.59e-21	Breast cancer;
THYM	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg11846333	chr4:119757529	SEC24D	-1.28	-4.91	-0.45	3.82e-6	Cannabis dependence symptom count;
THYM	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	4.93	0.45	3.51e-6	Motion sickness;
THYM	trans	rs8073060	0.586	rs225250	chr17:33941963	A/G	cg19694781	chr19:47549865	TMEM160	-1.05	-9.1	-0.68	1.42e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg17063962	chr7:91808500	NA	1.1	10.08	0.72	1.1e-16	Breast cancer;
THYM	cis	rs7953508	0.506	rs12425869	chr12:93961353	A/G	cg18151635	chr12:93972918	NA	-0.78	-5.51	-0.49	3.02e-7	Pubertal anthropometrics;
THYM	cis	rs7944004	1.000	rs7944004	chr11:2311152	G/T	cg11525052	chr11:2321955	C11orf21;TSPAN32	0.41	4.73	0.44	7.89e-6	Chronic lymphocytic leukemia;
THYM	cis	rs12049351	0.774	rs12117468	chr1:229671361	G/T	cg11742688	chr1:229674241	ABCB10	-0.56	-4.51	-0.42	1.88e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs7626444	0.625	rs1486358	chr3:196485590	T/C	cg12930392	chr3:196481615	PAK2	0.4	4.97	0.45	2.97e-6	Monocyte count;
THYM	cis	rs2495707	0.624	rs2489006	chr10:102419893	G/A	cg03943218	chr10:102419600	NA	-0.63	-6.76	-0.57	1.09e-9	Body mass index;
THYM	cis	rs8016982	0.630	rs61980900	chr14:81686436	T/C	cg21807262	chr14:81713016	NA	-0.56	-5.24	-0.47	9.73e-7	Schizophrenia;
THYM	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg09455208	chr3:40491958	NA	0.5	5.21	0.47	1.11e-6	Renal cell carcinoma;
THYM	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg16031515	chr1:205743344	RAB7L1	-0.55	-5.63	-0.5	1.79e-7	Menarche (age at onset);
THYM	cis	rs17125944	1.000	rs17125924	chr14:53391680	A/G	cg00686598	chr14:53173677	PSMC6	1.05	5.05	0.46	2.11e-6	Alzheimer's disease (late onset);
THYM	cis	rs4808199	0.894	rs10418051	chr19:19397789	C/T	cg03709012	chr19:19516395	GATAD2A	1.09	6.33	0.54	8.08e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs1550582	0.662	rs7812708	chr8:135500832	C/T	cg17885191	chr8:135476712	NA	1.11	9.16	0.68	1.05e-14	Educational attainment;
THYM	cis	rs9470366	0.772	rs9918353	chr6:36622677	A/C	cg11920449	chr6:36645608	CDKN1A	-0.68	-5.23	-0.47	1e-6	QRS duration;
THYM	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg12311346	chr5:56204834	C5orf35	0.61	4.73	0.44	7.84e-6	Initial pursuit acceleration;
THYM	cis	rs9549260	0.753	rs9532563	chr13:41160270	T/C	cg21288729	chr13:41239152	FOXO1	0.69	4.87	0.45	4.38e-6	Red blood cell count;
THYM	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.21	-0.47	1.11e-6	Hemoglobin concentration;
THYM	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg18357526	chr6:26021779	HIST1H4A	0.75	5.95	0.52	4.45e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1865721	0.804	rs59187673	chr18:73143964	A/G	cg26385618	chr18:73139727	C18orf62	-0.63	-4.56	-0.42	1.5e-5	Intelligence;
THYM	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg17264618	chr3:40429014	ENTPD3	0.52	5.13	0.47	1.52e-6	Renal cell carcinoma;
THYM	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg14004847	chr7:1930337	MAD1L1	-0.66	-5.36	-0.48	5.79e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs9797861	1	rs9797861	chr19:10743126	C/T	cg17848348	chr19:10766748	ILF3	-0.83	-6.71	-0.57	1.39e-9	Thrombosis;
THYM	cis	rs752010	0.811	rs10749836	chr1:42086860	G/C	cg06885757	chr1:42089581	HIVEP3	0.41	4.47	0.42	2.17e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg24530246	chr3:53118167	NA	-0.81	-4.62	-0.43	1.23e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg22841779	chr14:105766346	BRF1	-0.47	-5.83	-0.51	7.76e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06634786	chr22:41940651	POLR3H	-0.75	-5.76	-0.51	1.03e-7	Vitiligo;
THYM	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg10117171	chr1:25599238	RHD	-0.75	-5.53	-0.49	2.79e-7	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg17366294	chr4:99064904	C4orf37	0.54	6.31	0.54	8.73e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13315871	1.000	rs11715445	chr3:58343888	T/C	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs1729951	0.546	rs12054408	chr3:136677645	T/C	cg12473912	chr3:136751656	NA	0.63	5.13	0.47	1.55e-6	Neuroticism;
THYM	cis	rs3126085	0.935	rs10888466	chr1:152166223	A/C	cg26020982	chr1:152196106	HRNR	-0.37	-5.06	-0.46	2.05e-6	Atopic dermatitis;
THYM	trans	rs10462794	0.789	rs7719895	chr5:4490338	C/T	cg17414733	chr19:21688647	ZNF429	1.2	6.92	0.58	5.36e-10	DNA methylation (variation);
THYM	cis	rs9633835	0.524	rs35601753	chr11:13279149	T/C	cg13286116	chr11:13302098	ARNTL	-0.72	-8.02	-0.64	2.69e-12	Body mass index;
THYM	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg10760299	chr15:45669010	GATM	0.87	6.61	0.56	2.21e-9	Homoarginine levels;
THYM	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg25811766	chr13:21894605	NA	0.73	4.89	0.45	4.02e-6	White matter hyperintensity burden;
THYM	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg21658235	chr8:22456391	C8orf58	0.59	5.47	0.49	3.62e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg03684893	chr10:554711	DIP2C	-0.66	-5.33	-0.48	6.49e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs6089829	0.888	rs4809465	chr20:61671156	G/C	cg03213289	chr20:61660250	NA	0.98	10.61	0.74	8.36e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7833986	0.501	rs72653917	chr8:56892844	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	6.4	0.55	5.76e-9	Height;
THYM	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg26267310	chr19:49340593	PLEKHA4;HSD17B14	-0.97	-6.22	-0.54	1.31e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs8006682	0.541	rs10483815	chr14:69088991	A/T	cg21123519	chr14:69095679	NA	0.64	4.95	0.45	3.25e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs2710642	0.564	rs9989741	chr2:62828377	T/A	cg17519650	chr2:63277830	OTX1	0.65	4.79	0.44	6.13e-6	LDL cholesterol levels;LDL cholesterol;
THYM	trans	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg25214090	chr10:38739885	LOC399744	0.93	7.92	0.63	4.43e-12	Corneal astigmatism;
THYM	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg06481639	chr22:41940642	POLR3H	-0.7	-5.45	-0.49	4.02e-7	Neuroticism;
THYM	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg13683864	chr3:40499215	RPL14	-0.88	-8.62	-0.66	1.5e-13	Renal cell carcinoma;
THYM	cis	rs35123781	0.654	rs356484	chr5:139084438	T/A	cg10513866	chr5:139070639	NA	0.51	4.48	0.42	2.05e-5	Schizophrenia;
THYM	cis	rs56161922	1.000	rs55883147	chr1:207840002	C/T	cg09557387	chr1:207818395	CR1L	1.14	5.13	0.47	1.52e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs4242434	0.699	rs878051	chr8:22483836	T/C	cg03733263	chr8:22462867	KIAA1967	1.01	11.22	0.75	4.28e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs8064299	0.574	rs12452204	chr17:72774128	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.87	8.13	0.64	1.6e-12	Monocyte count;
THYM	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg06917634	chr15:78832804	PSMA4	-0.83	-6.85	-0.58	7.29e-10	Sudden cardiac arrest;
THYM	cis	rs4638749	0.773	rs4676190	chr2:108858619	A/G	cg13968390	chr2:108904812	SULT1C2	-0.68	-5.14	-0.47	1.47e-6	Blood pressure;
THYM	cis	rs9868809	0.764	rs41290686	chr3:48604059	G/A	cg00383909	chr3:49044727	WDR6	1.24	4.95	0.45	3.17e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg05182265	chr7:156933206	UBE3C	0.7	9.62	0.7	1.05e-15	Body mass index;
THYM	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg02869364	chr7:1081709	C7orf50	-0.57	-4.76	-0.44	6.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1018836	0.631	rs9987164	chr8:91470910	T/G	cg16814680	chr8:91681699	NA	-0.69	-5.58	-0.5	2.3e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6815814	0.950	rs66922907	chr4:38812537	A/G	cg02016764	chr4:38805732	TLR1	-0.57	-5.49	-0.49	3.41e-7	Breast cancer;
THYM	cis	rs36051895	0.695	rs12352214	chr9:5018041	G/A	cg02405213	chr9:5042618	JAK2	-1.02	-10.67	-0.74	6.09e-18	Pediatric autoimmune diseases;
THYM	cis	rs7197653	0.586	rs55856208	chr16:68324210	A/T	cg09835421	chr16:68378352	PRMT7	-0.74	-4.51	-0.42	1.83e-5	Magnesium levels;
THYM	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg20242066	chr2:136595261	LCT	-0.6	-7.41	-0.61	5.17e-11	Mosquito bite size;
THYM	cis	rs8070740	1.000	rs8080400	chr17:5328633	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.67	5.26	0.47	8.92e-7	Menopause (age at onset);
THYM	cis	rs3741151	0.892	rs7105681	chr11:73059341	G/A	cg12959048	chr11:73096162	RELT	-0.43	-4.56	-0.42	1.51e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg02136620	chr5:178986620	RUFY1	-0.56	-5.74	-0.51	1.14e-7	Lung cancer;
THYM	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	10.29	0.73	4e-17	Chronic sinus infection;
THYM	cis	rs10504073	0.669	rs62507251	chr8:50028524	T/G	cg00325661	chr8:49890786	NA	0.87	7.77	0.62	9.33e-12	Blood metabolite ratios;
THYM	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg12560992	chr17:57184187	TRIM37	0.91	8.51	0.66	2.54e-13	Intelligence (multi-trait analysis);
THYM	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.68	0.5	1.45e-7	Height;
THYM	cis	rs67460515	0.563	rs4494975	chr3:160866768	C/T	cg12349858	chr3:160822545	B3GALNT1	0.57	4.54	0.42	1.66e-5	Parkinson's disease;
THYM	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg15212455	chr7:39170539	POU6F2	0.64	6.01	0.52	3.44e-8	IgG glycosylation;
THYM	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.88	-7.8	-0.62	8e-12	Menarche (age at onset);
THYM	cis	rs9326248	0.530	rs17120139	chr11:116774201	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.93	-5.14	-0.47	1.46e-6	Blood protein levels;
THYM	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg07424592	chr7:64974309	NA	1.1	5.82	0.51	8.08e-8	Diabetic kidney disease;
THYM	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs652260	0.967	rs569175	chr19:7901160	T/G	cg15974673	chr19:7926970	EVI5L	-0.53	-4.81	-0.44	5.57e-6	Menarche (age at onset);
THYM	cis	rs9814567	0.929	rs2241556	chr3:134183312	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.74	6.73	0.57	1.28e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7084402	0.967	rs1427199	chr10:60274941	C/T	cg09696939	chr10:60272079	BICC1	0.5	5.75	0.51	1.07e-7	Refractive error;
THYM	cis	rs7762018	0.607	rs79355059	chr6:170062157	T/C	cg19338460	chr6:170058176	WDR27	-1.04	-6.21	-0.54	1.42e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg09260853	chr1:2094483	PRKCZ	-0.5	-4.66	-0.43	1.01e-5	Height;
THYM	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.03	10.05	0.72	1.3e-16	Colorectal cancer;
THYM	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg04156016	chr5:1868137	NA	0.53	4.96	0.45	3.13e-6	Cardiovascular disease risk factors;
THYM	cis	rs2288884	0.731	rs11673450	chr19:52540694	G/T	cg05974498	chr19:52599256	ZNF841	0.35	4.51	0.42	1.85e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs7633857	0.512	rs10936215	chr3:160652271	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-4.75	-0.44	7.25e-6	Educational attainment (years of education);
THYM	cis	rs9633835	0.524	rs4756761	chr11:13272616	T/C	cg13286116	chr11:13302098	ARNTL	-0.76	-8.59	-0.66	1.73e-13	Body mass index;
THYM	cis	rs2754412	1	rs2754412	chr10:38627834	A/G	cg25427524	chr10:38739819	LOC399744	-0.7	-6.42	-0.55	5.23e-9	Breast cancer;
THYM	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg23711669	chr6:146136114	FBXO30	0.96	9.81	0.71	4.28e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7177699	0.557	rs11072807	chr15:79111517	A/G	cg00540400	chr15:79124168	NA	0.64	6.88	0.58	6.27e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg12386194	chr3:101231763	SENP7	0.68	5.08	0.46	1.87e-6	Colorectal cancer;
THYM	cis	rs1172149	0.533	rs74139129	chr1:205206960	G/T	cg17889831	chr1:205181581	DSTYK	0.44	4.45	0.42	2.31e-5	Platelet distribution width;
THYM	cis	rs66887589	0.807	rs7694483	chr4:120405929	T/A	cg13609457	chr4:120235615	NA	0.47	4.86	0.45	4.64e-6	Diastolic blood pressure;
THYM	cis	rs877282	1.000	rs10904552	chr10:774326	A/G	cg10556349	chr10:835070	NA	-0.7	-4.88	-0.45	4.27e-6	Uric acid levels;
THYM	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg13695892	chr22:41940480	POLR3H	-0.94	-7.28	-0.6	9.46e-11	Vitiligo;
THYM	cis	rs4731207	0.698	rs11979724	chr7:124451045	G/T	cg05285228	chr7:124571219	POT1	0.66	5.24	0.47	9.66e-7	Cutaneous malignant melanoma;
THYM	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg08704250	chr15:31115839	NA	0.47	5.54	0.49	2.68e-7	Huntington's disease progression;
THYM	cis	rs600806	0.888	rs11102971	chr1:109872370	C/T	cg02175308	chr1:109941060	SORT1	-0.57	-4.96	-0.45	3.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6998277	0.830	rs7017839	chr8:103610769	G/C	cg10187029	chr8:103597600	NA	0.51	4.54	0.42	1.62e-5	Migraine;
THYM	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs6543140	0.964	rs2310301	chr2:103072935	C/T	cg03938978	chr2:103052716	IL18RAP	0.58	5.84	0.51	7.16e-8	Blood protein levels;
THYM	cis	rs4731207	0.624	rs1031955	chr7:124710858	G/C	cg05285228	chr7:124571219	POT1	-0.65	-5.0	-0.46	2.64e-6	Cutaneous malignant melanoma;
THYM	cis	rs4523957	0.855	rs1231206	chr17:2125605	G/A	cg16513277	chr17:2031491	SMG6	-0.79	-7.53	-0.61	2.9e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7246657	0.943	rs10404920	chr19:37881556	T/C	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs55871839	0.619	rs6471756	chr8:59802159	A/G	cg07426533	chr8:59803705	TOX	-0.61	-6.02	-0.53	3.2e-8	Pneumonia;
THYM	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs1351164	1.000	rs10183694	chr2:218279923	T/A	cg15335768	chr2:218268053	DIRC3	-0.4	-5.48	-0.49	3.51e-7	Height;
THYM	cis	rs2806561	1.000	rs1208932	chr1:23429122	T/G	cg12483005	chr1:23474871	LUZP1	-0.55	-5.75	-0.51	1.1e-7	Height;
THYM	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg08645402	chr16:4508243	NA	-0.73	-6.74	-0.57	1.25e-9	Schizophrenia;
THYM	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg24675658	chr1:53192096	ZYG11B	-0.58	-4.58	-0.43	1.4e-5	Monocyte count;
THYM	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03517284	chr6:25882590	NA	-0.76	-5.98	-0.52	3.87e-8	Blood metabolite levels;
THYM	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Body mass index;
THYM	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7677751	0.806	rs6836215	chr4:55102741	T/C	cg17187183	chr4:55093834	PDGFRA	0.71	5.45	0.49	3.99e-7	Corneal astigmatism;
THYM	cis	rs9549260	0.755	rs2755219	chr13:41169625	A/G	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg22467129	chr15:76604101	ETFA	-0.56	-5.37	-0.48	5.47e-7	Blood metabolite levels;
THYM	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs2219968	0.701	rs34965401	chr8:78991957	C/G	cg00738934	chr8:78996279	NA	0.87	8.41	0.65	4.01e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4482178	0.850	rs80090931	chr13:86263041	T/A	cg25308322	chr13:86268291	NA	0.68	4.75	0.44	7.32e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs4460079	0.531	rs9995239	chr4:114840439	A/G	cg02060584	chr4:113970739	ANK2	-0.56	-4.58	-0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03647317	chr4:187891568	NA	-0.84	-9.05	-0.68	1.74e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg10047753	chr17:41438598	NA	1.18	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs6138458	1.000	rs1977540	chr20:24900290	G/T	cg26195577	chr20:24973756	C20orf3	-1.11	-10.52	-0.73	1.29e-17	Blood protein levels;
THYM	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs13185784	0.830	rs17627815	chr5:179693083	T/C	cg23248424	chr5:179741104	GFPT2	0.74	4.48	0.42	2.06e-5	TRAIL levels;
THYM	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	trans	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg25214090	chr10:38739885	LOC399744	0.86	7.44	0.61	4.54e-11	Corneal astigmatism;
THYM	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs2404618	0.624	rs4338133	chr8:1477507	T/C	cg13402656	chr8:1511478	DLGAP2	-0.75	-6.99	-0.58	3.75e-10	Lung cancer;
THYM	cis	rs861020	0.630	rs686582	chr1:210008673	A/C	cg05527609	chr1:210001259	C1orf107	0.85	6.82	0.57	8.53e-10	Orofacial clefts;
THYM	cis	rs78456975	0.550	rs10197874	chr2:1545310	A/G	cg12573674	chr2:1569213	NA	-1.33	-7.98	-0.63	3.24e-12	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	4.98	0.45	2.88e-6	Schizophrenia;
THYM	cis	rs665401	0.965	rs9489066	chr6:117239499	T/C	cg20376953	chr6:117187980	NA	0.6	4.67	0.43	9.78e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg22875332	chr1:76189707	ACADM	-0.88	-10.14	-0.72	8.31e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs35849525	0.633	rs62263602	chr3:50152491	C/T	cg14019146	chr3:50243930	SLC38A3	-0.6	-4.71	-0.43	8.58e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs4654899	0.865	rs72988025	chr1:21351441	A/G	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.29e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs7072216	0.691	rs3829853	chr10:100171174	A/G	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg04414720	chr1:150670196	GOLPH3L	0.62	4.58	0.43	1.41e-5	Tonsillectomy;
THYM	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg07022442	chr13:21864356	NA	0.7	4.64	0.43	1.12e-5	White matter hyperintensity burden;
THYM	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg08772003	chr10:104629869	AS3MT	0.68	6.44	0.55	4.77e-9	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7084402	0.967	rs1365741	chr10:60277489	C/T	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs13177918	0.559	rs12109637	chr5:149834718	G/T	cg14059543	chr5:149831962	NA	-0.91	-7.49	-0.61	3.56e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7429990	0.901	rs6442102	chr3:48152562	A/G	cg02219026	chr3:48282209	ZNF589	0.59	4.46	0.42	2.23e-5	Educational attainment (years of education);
THYM	cis	rs6032067	1.000	rs6017526	chr20:43871555	A/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.72	-6.57	-0.56	2.73e-9	Blood protein levels;
THYM	cis	rs12950390	0.512	rs72831681	chr17:45847174	C/G	cg06532163	chr17:45867833	NA	0.58	4.49	0.42	2e-5	IgG glycosylation;
THYM	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06873352	chr17:61820015	STRADA	0.56	5.6	0.5	2.12e-7	Height;
THYM	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.79e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs1747683	0.932	rs6602648	chr10:13383212	C/T	cg11679871	chr10:13388567	SEPHS1	-0.31	-4.6	-0.43	1.3e-5	IgG glycosylation;
THYM	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg07648498	chr16:89883185	FANCA	0.61	4.58	0.43	1.41e-5	Vitiligo;
THYM	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	9.39	0.69	3.37e-15	Chronic sinus infection;
THYM	cis	rs10492096	1.000	rs11064210	chr12:6576721	C/T	cg13857086	chr12:6580257	VAMP1	0.93	5.67	0.5	1.54e-7	Hip geometry;
THYM	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg06808227	chr14:105710500	BRF1	1.04	9.09	0.68	1.46e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs425535	0.817	rs352009	chr4:74851693	G/A	cg07868155	chr4:74864709	CXCL5	0.66	5.57	0.5	2.41e-7	Blood protein levels;
THYM	cis	rs596169	0.655	rs6702023	chr1:219167752	C/G	cg19270308	chr1:218458869	RRP15	-1.24	-4.52	-0.42	1.81e-5	Intraocular pressure;
THYM	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.53	-5.97	-0.52	4.14e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs7474896	0.583	rs10740950	chr10:38003496	C/T	cg07661167	chr10:37990439	NA	-0.67	-4.54	-0.42	1.62e-5	Obesity (extreme);
THYM	cis	rs7072216	0.690	rs113195335	chr10:100175532	A/C	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg03161606	chr19:29218774	NA	0.82	6.25	0.54	1.15e-8	Methadone dose in opioid dependence;
THYM	cis	rs669446	0.533	rs11210913	chr1:44222597	G/A	cg00143623	chr1:44495758	SLC6A9	0.53	4.5	0.42	1.95e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.74	6.67	0.56	1.67e-9	Prudent dietary pattern;
THYM	cis	rs12118280	0.512	rs11185301	chr1:108741228	G/A	cg11967332	chr1:108735228	SLC25A24	0.92	5.16	0.47	1.34e-6	Myeloid white cell count;
THYM	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg16586182	chr3:47516702	SCAP	0.63	5.6	0.5	2.12e-7	Colorectal cancer;
THYM	cis	rs12149862	0.882	rs28636635	chr16:69475543	G/C	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.61e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.87	-4.64	-0.43	1.11e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4343996	0.558	rs10454314	chr7:3411725	A/G	cg21248987	chr7:3385318	SDK1	0.4	4.94	0.45	3.32e-6	Motion sickness;
THYM	cis	rs800586	0.871	rs9297543	chr8:116704980	C/T	cg04656070	chr8:116661063	TRPS1	0.49	5.19	0.47	1.17e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg26354017	chr1:205819088	PM20D1	1.08	11.69	0.77	4.25e-20	Menarche (age at onset);
THYM	cis	rs17597773	0.674	rs1335919	chr1:221018385	G/T	cg16008148	chr1:221062819	NA	0.44	4.5	0.42	1.96e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg22920501	chr2:26401640	FAM59B	1.01	8.6	0.66	1.63e-13	Gut microbiome composition (summer);
THYM	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs2011503	0.941	rs7257875	chr19:19372150	C/T	cg02887458	chr19:19495540	GATAD2A	-0.43	-5.21	-0.47	1.1e-6	Bipolar disorder;
THYM	cis	rs1215050	0.740	rs13134479	chr4:99067723	G/A	cg17366294	chr4:99064904	C4orf37	0.41	4.55	0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs12282928	0.959	rs12290629	chr11:48298901	G/A	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs6980334	0.911	rs10280628	chr7:137767310	C/T	cg03464514	chr7:137028442	PTN	0.56	4.5	0.42	1.9e-5	Blood metabolite ratios;
THYM	cis	rs7729447	0.776	rs17442964	chr5:32693916	G/A	cg16267343	chr5:32710456	NPR3	0.8	7.2	0.59	1.41e-10	Blood pressure;
THYM	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.13	9.06	0.68	1.65e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs3960554	0.800	rs112463197	chr7:75622912	C/T	cg19862616	chr7:65841803	NCRNA00174	0.98	7.31	0.6	8.37e-11	Eotaxin levels;
THYM	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg22974920	chr21:40686053	BRWD1	-0.59	-4.64	-0.43	1.13e-5	Cognitive function;
THYM	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs28374715	0.783	rs1866399	chr15:41571139	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.09	-10.34	-0.73	3.07e-17	Ulcerative colitis;
THYM	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg03433033	chr1:76189801	ACADM	0.77	10.09	0.72	1.07e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22307029	chr19:49891270	CCDC155	0.6	4.74	0.44	7.4e-6	Multiple sclerosis;
THYM	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg14583973	chr4:3374767	RGS12	0.68	6.65	0.56	1.81e-9	Serum sulfate level;
THYM	cis	rs3126085	0.877	rs4845742	chr1:152183949	G/A	cg26020982	chr1:152196106	HRNR	0.35	4.57	0.42	1.45e-5	Atopic dermatitis;
THYM	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg03213289	chr20:61660250	NA	-0.94	-9.7	-0.71	7.4e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs67311347	0.549	rs60249586	chr3:40246659	G/A	cg09455208	chr3:40491958	NA	0.42	4.48	0.42	2.08e-5	Renal cell carcinoma;
THYM	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg18252515	chr7:66147081	NA	0.62	4.55	0.42	1.59e-5	Aortic root size;
THYM	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7731657	0.509	rs10477723	chr5:130187390	G/A	cg08523029	chr5:130500466	HINT1	-0.67	-4.77	-0.44	6.71e-6	Fasting plasma glucose;
THYM	cis	rs7705042	0.828	rs249677	chr5:141539339	C/A	cg07392085	chr5:141489673	NDFIP1	0.57	4.57	0.42	1.44e-5	Asthma;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg04166405	chr6:53772058	LRRC1	-0.9	-6.91	-0.58	5.47e-10	Depressive symptoms;
THYM	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06850241	chr22:41845214	NA	-0.54	-5.04	-0.46	2.24e-6	Vitiligo;
THYM	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg15212455	chr7:39170539	POU6F2	0.65	6.01	0.52	3.38e-8	IgG glycosylation;
THYM	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03517284	chr6:25882590	NA	-0.99	-9.32	-0.69	4.8e-15	Intelligence (multi-trait analysis);
THYM	cis	rs11264213	0.686	rs645383	chr1:36373823	C/G	cg27506609	chr1:36549197	TEKT2	-1.1	-5.22	-0.47	1.05e-6	Schizophrenia;
THYM	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs10752881	1.000	rs8179262	chr1:182973186	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg11764359	chr7:65958608	NA	-0.85	-7.43	-0.61	4.73e-11	Aortic root size;
THYM	trans	rs9929218	0.861	rs4783667	chr16:68752878	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.9	-7.81	-0.63	7.56e-12	Colorectal cancer;
THYM	cis	rs899997	0.954	rs4887091	chr15:79043580	T/C	cg00639195	chr15:79103007	ADAMTS7	-0.84	-6.03	-0.53	3.12e-8	Coronary artery disease or large artery stroke;
THYM	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg19442545	chr10:75533431	FUT11	-0.5	-5.19	-0.47	1.21e-6	Inflammatory bowel disease;
THYM	cis	rs13315871	1.000	rs74834816	chr3:58321828	G/A	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs8048589	0.559	rs35542345	chr16:12210618	T/C	cg01990910	chr16:12207648	SNX29	-0.55	-5.81	-0.51	8.24e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs7100689	0.556	rs6585971	chr10:82145057	G/C	cg01528321	chr10:82214614	TSPAN14	0.89	6.73	0.57	1.26e-9	Post bronchodilator FEV1;
THYM	cis	rs11039798	0.764	rs4357721	chr11:48354907	G/A	cg24672777	chr11:48374446	OR4C45	1.16	7.24	0.6	1.16e-10	Axial length;
THYM	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg00999904	chr2:3704751	ALLC	-0.73	-4.99	-0.46	2.75e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg11645453	chr3:52864694	ITIH4	0.3	4.69	0.43	8.99e-6	Schizophrenia;
THYM	cis	rs12711979	0.765	rs7559345	chr2:3818523	G/A	cg17052675	chr2:3827356	NA	-0.49	-5.23	-0.47	9.93e-7	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.58	0.43	1.41e-5	Bipolar disorder;
THYM	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg17173187	chr15:85201210	NMB	0.57	5.65	0.5	1.67e-7	Schizophrenia;
THYM	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg09085632	chr11:111637200	PPP2R1B	1.22	15.22	0.84	3.16e-27	Primary sclerosing cholangitis;
THYM	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg13395646	chr4:1353034	KIAA1530	-0.72	-6.59	-0.56	2.4e-9	Obesity-related traits;
THYM	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg18252515	chr7:66147081	NA	-1.39	-8.36	-0.65	5.29e-13	Diabetic kidney disease;
THYM	cis	rs4638749	1.000	rs12616140	chr2:108867728	A/G	cg25838818	chr2:108905173	SULT1C2	-0.6	-6.11	-0.53	2.14e-8	Blood pressure;
THYM	cis	rs889122	0.513	rs10403584	chr19:10013440	G/A	cg07950397	chr19:10022659	OLFM2	0.35	4.46	0.42	2.25e-5	Menarche (age at onset);
THYM	cis	rs13064411	0.696	rs6808394	chr3:113122524	T/G	cg10517650	chr3:113235015	CCDC52	-0.6	-5.04	-0.46	2.22e-6	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs6088590	0.610	rs6059973	chr20:33254329	A/T	cg08999081	chr20:33150536	PIGU	0.69	6.14	0.53	1.9e-8	Coronary artery disease;
THYM	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs6450176	1.000	rs3776707	chr5:53304873	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.13	-0.53	2.01e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg04117972	chr1:227635322	NA	0.8	4.79	0.44	6.09e-6	Major depressive disorder;
THYM	cis	rs61990749	0.597	rs117131659	chr14:78131126	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-1.14	-7.81	-0.63	7.61e-12	Fibroblast growth factor basic levels;
THYM	cis	rs7616559	0.962	rs9839037	chr3:156739425	G/A	cg15697575	chr3:156784781	NA	0.4	5.03	0.46	2.35e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs4970988	0.556	rs2280078	chr1:150600181	C/T	cg10589385	chr1:150898437	SETDB1	-0.58	-4.68	-0.43	9.56e-6	Urate levels;
THYM	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg26022315	chr17:47021804	SNF8	0.51	4.87	0.45	4.44e-6	Type 2 diabetes;
THYM	cis	rs990171	1.000	rs13015714	chr2:102971865	G/T	cg13897122	chr2:103039542	IL18RAP	-0.42	-4.92	-0.45	3.56e-6	Lymphocyte counts;
THYM	cis	rs2882877	0.648	rs13032311	chr2:190397020	T/C	cg10752008	chr2:190445175	SLC40A1	0.72	6.14	0.53	1.9e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg04429589	chr14:105992532	TMEM121	-0.48	-5.28	-0.48	8.21e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs2072499	0.900	rs2248080	chr1:156195971	T/A	cg06970220	chr1:156163860	SLC25A44	0.74	5.73	0.51	1.2e-7	Testicular germ cell tumor;
THYM	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg17105886	chr17:28927953	LRRC37B2	1.25	6.76	0.57	1.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9527	0.569	rs10883801	chr10:104677887	A/C	cg15744005	chr10:104629667	AS3MT	-0.6	-4.58	-0.42	1.43e-5	Arsenic metabolism;
THYM	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs931127	0.505	rs746429	chr11:65417434	G/A	cg17480646	chr11:65405466	SIPA1	-0.95	-9.01	-0.68	2.2e-14	Systemic lupus erythematosus;
THYM	cis	rs1451375	0.583	rs11575320	chr7:50605298	A/G	cg18232548	chr7:50535776	DDC	-0.67	-5.03	-0.46	2.31e-6	Malaria;
THYM	cis	rs6063312	0.518	rs6122718	chr20:47346225	A/G	cg18078177	chr20:47281410	PREX1	-0.62	-4.53	-0.42	1.71e-5	Tonometry;
THYM	cis	rs62103177	0.564	rs3930042	chr18:77723843	G/A	cg02751453	chr18:77725136	HSBP1L1	-0.64	-5.34	-0.48	6.2e-7	Opioid sensitivity;
THYM	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg08470875	chr2:26401718	FAM59B	0.74	4.59	0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg27432699	chr2:27873401	GPN1	0.73	6.36	0.55	7.06e-9	Oral cavity cancer;
THYM	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg07570687	chr10:102243282	WNT8B	0.75	6.92	0.58	5.2e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg09877947	chr5:131593287	PDLIM4	0.61	5.39	0.48	5.19e-7	Breast cancer;
THYM	cis	rs11603020	0.950	rs78624400	chr11:57375463	G/C	cg19752551	chr11:57585705	CTNND1	-0.6	-5.02	-0.46	2.42e-6	Blood protein levels;
THYM	cis	rs9311676	0.586	rs11707019	chr3:58398036	A/C	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs4788570	0.584	rs11075898	chr16:71705215	T/C	cg06353428	chr16:71660113	MARVELD3	1.33	9.11	0.68	1.3e-14	Intelligence (multi-trait analysis);
THYM	cis	rs17641971	0.645	rs4873099	chr8:50025683	G/T	cg00325661	chr8:49890786	NA	0.58	4.48	0.42	2.04e-5	Blood metabolite levels;
THYM	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg14972814	chr11:95582409	MTMR2	-0.63	-5.24	-0.47	9.61e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs3812049	0.826	rs34576922	chr5:127364103	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.72	-5.26	-0.47	8.91e-7	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg09085632	chr11:111637200	PPP2R1B	1.12	11.53	0.76	9.47e-20	Primary sclerosing cholangitis;
THYM	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg00383909	chr3:49044727	WDR6	1.27	7.71	0.62	1.22e-11	Cognitive function;
THYM	cis	rs909341	0.629	rs3761124	chr20:62288752	T/C	cg25157850	chr20:62401287	ZBTB46	0.52	4.51	0.42	1.87e-5	Atopic dermatitis;
THYM	cis	rs11039798	0.588	rs11039781	chr11:48523085	T/G	cg24672777	chr11:48374446	OR4C45	-0.98	-6.39	-0.55	6.21e-9	Axial length;
THYM	cis	rs6840360	0.593	rs1429558	chr4:152685406	A/T	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.929	rs56168207	chr20:43803971	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.76	-0.51	1.01e-7	Blood protein levels;
THYM	cis	rs2235642	1.000	rs2076438	chr16:1584618	T/C	cg10465839	chr16:1584050	IFT140;TMEM204	-0.57	-4.77	-0.44	6.7e-6	Coronary artery disease;
THYM	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg19077165	chr18:44547161	KATNAL2	-0.63	-8.24	-0.65	9.47e-13	Personality dimensions;
THYM	cis	rs6499255	0.951	rs78772829	chr16:69607098	G/A	cg00738113	chr16:70207722	CLEC18C	-0.43	-4.5	-0.42	1.93e-5	IgE levels;
THYM	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg18681998	chr4:17616180	MED28	1.0	9.81	0.71	4.29e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs28595532	0.920	rs55668908	chr4:119769799	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg10803722	chr21:46713166	LOC642852	-0.5	-6.18	-0.54	1.58e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg20887711	chr4:1340912	KIAA1530	0.98	9.39	0.69	3.36e-15	Longevity;
THYM	cis	rs912057	0.585	rs1745341	chr6:6744990	T/C	cg13809441	chr6:6737631	NA	0.44	5.32	0.48	6.97e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs2346160	0.899	rs384974	chr6:167688418	C/T	cg21686812	chr6:168078911	NA	-0.51	-4.68	-0.43	9.65e-6	Parental extreme longevity (95 years and older);
THYM	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg01819863	chr10:32635814	EPC1	1.12	6.59	0.56	2.46e-9	Sexual dysfunction (female);
THYM	cis	rs8130944	1.000	rs2269152	chr21:44144644	A/G	cg03543861	chr21:44258195	NA	0.52	4.87	0.45	4.38e-6	Perceived unattractiveness to mosquitoes;
THYM	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg08847533	chr14:75593920	NEK9	1.01	11.32	0.76	2.63e-19	Height;
THYM	cis	rs2901656	1.000	rs2901656	chr1:172434812	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.46	4.61	0.43	1.27e-5	Red cell distribution width;Platelet distribution width;
THYM	cis	rs7688540	0.511	rs11735723	chr4:199637	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.97	5.95	0.52	4.38e-8	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg02820040	chr2:241836501	C2orf54	0.31	6.23	0.54	1.29e-8	Urinary metabolites;
THYM	cis	rs929596	0.785	rs17862875	chr2:234649302	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.96	-7.96	-0.63	3.58e-12	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs56161922	1.000	rs74401244	chr1:207844799	T/C	cg09557387	chr1:207818395	CR1L	1.14	5.13	0.47	1.52e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs1747683	0.932	rs2027167	chr10:13372390	T/C	cg25835351	chr10:13388524	SEPHS1	-0.34	-5.7	-0.5	1.35e-7	IgG glycosylation;
THYM	cis	rs6840360	0.642	rs1470281	chr4:152431552	A/G	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.26	-0.47	9.04e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg12826209	chr6:26865740	GUSBL1	1.05	5.5	0.49	3.15e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs17376456	0.597	rs11135401	chr5:93365716	G/A	cg21475434	chr5:93447410	FAM172A	-0.68	-4.59	-0.43	1.34e-5	Diabetic retinopathy;
THYM	cis	rs34638657	0.872	rs2967350	chr16:82196130	T/C	cg07307142	chr16:82071433	HSD17B2	-1.0	-8.25	-0.65	8.84e-13	Lung adenocarcinoma;
THYM	cis	rs7107174	0.901	rs1055250	chr11:77925708	C/G	cg02023728	chr11:77925099	USP35	0.76	7.26	0.6	1.07e-10	Testicular germ cell tumor;
THYM	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg02527881	chr3:46936655	PTH1R	-0.64	-6.21	-0.54	1.39e-8	Colorectal cancer;
THYM	cis	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg07460842	chr6:66804631	NA	-0.91	-6.41	-0.55	5.65e-9	Exhaled nitric oxide output;
THYM	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg02953382	chr22:24373134	LOC391322	-0.95	-10.84	-0.74	2.66e-18	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg13695892	chr22:41940480	POLR3H	-0.98	-7.59	-0.61	2.21e-11	Vitiligo;
THYM	cis	rs10492096	0.947	rs12371184	chr12:6632925	A/G	cg13857086	chr12:6580257	VAMP1	0.78	4.91	0.45	3.75e-6	Hip geometry;
THYM	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg19875535	chr5:140030758	IK	-0.61	-5.25	-0.47	9.4e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg02551604	chr5:131831745	NA	0.81	6.25	0.54	1.17e-8	Asthma (sex interaction);
THYM	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg11663144	chr21:46675770	NA	-0.69	-9.29	-0.69	5.39e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1499972	0.887	rs73163707	chr3:117536135	A/T	cg07612923	chr3:117604196	NA	1.31	5.35	0.48	6.1e-7	Schizophrenia;
THYM	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17407555	0.909	rs56133633	chr4:10291351	G/T	cg11266682	chr4:10021025	SLC2A9	-0.52	-4.67	-0.43	9.87e-6	Schizophrenia (age at onset);
THYM	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg10334053	chr1:2078117	PRKCZ	-0.46	-4.86	-0.45	4.61e-6	Height;
THYM	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg12031863	chr16:4587854	C16orf5	0.45	5.09	0.46	1.8e-6	Schizophrenia;
THYM	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg02782426	chr3:40428986	ENTPD3	0.55	4.96	0.45	3.05e-6	Renal cell carcinoma;
THYM	cis	rs870825	0.616	rs7683615	chr4:185618373	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs7078219	0.686	rs12412391	chr10:101288935	A/G	cg07044859	chr10:101282883	NA	-0.48	-5.23	-0.47	1.01e-6	Dental caries;
THYM	cis	rs6840360	0.642	rs2709819	chr4:152383832	A/G	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg07636037	chr3:49044803	WDR6	0.96	9.68	0.7	8e-16	Parkinson's disease;
THYM	cis	rs3862030	0.694	rs12781742	chr10:104227469	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.66	-5.41	-0.49	4.72e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs7830933	0.955	rs13274892	chr8:23586054	G/C	cg04349084	chr8:23602677	NA	0.64	6.73	0.57	1.29e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs7100689	0.646	rs1340382	chr10:82096997	G/C	cg01528321	chr10:82214614	TSPAN14	0.84	6.43	0.55	5.15e-9	Post bronchodilator FEV1;
THYM	cis	rs6558530	0.836	rs7461159	chr8:1716616	A/T	cg09410841	chr8:1729607	CLN8	0.83	6.17	0.53	1.68e-8	Systolic blood pressure;
THYM	cis	rs11166927	1.000	rs13256946	chr8:140805101	G/A	cg16909799	chr8:140841666	TRAPPC9	0.62	5.51	0.49	3.11e-7	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs4930103	0.508	rs217205	chr11:1973205	T/C	cg18511798	chr11:2018149	H19;MIR675	0.48	4.86	0.45	4.58e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg09034736	chr1:150693464	HORMAD1	-0.52	-4.66	-0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs10979	1.000	rs12212011	chr6:143894694	C/A	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg07884673	chr3:53033167	SFMBT1	1.05	5.07	0.46	1.96e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs11039798	0.841	rs11500573	chr11:48713900	T/G	cg24672777	chr11:48374446	OR4C45	-1.12	-6.73	-0.57	1.28e-9	Axial length;
THYM	cis	rs3796619	1.000	rs3796619	chr4:1095281	A/G	cg27284194	chr4:1044797	NA	0.53	4.88	0.45	4.34e-6	Recombination rate (males);
THYM	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.03	-9.96	-0.71	2.06e-16	Primary sclerosing cholangitis;
THYM	cis	rs61990749	0.597	rs17106157	chr14:78146878	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-1.17	-8.02	-0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs8064299	0.655	rs16978176	chr17:72761242	T/C	cg21922841	chr17:72744131	SLC9A3R1	0.37	5.07	0.46	1.95e-6	Monocyte count;
THYM	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg24675658	chr1:53192096	ZYG11B	-0.76	-5.87	-0.52	6.36e-8	Monocyte count;
THYM	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs2445762	0.642	rs8025191	chr15:51623785	A/G	cg07517944	chr15:51633816	GLDN	0.61	4.86	0.45	4.69e-6	Hormone measurements;
THYM	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg05962950	chr11:130786565	SNX19	0.95	9.03	0.68	2e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9595908	0.900	rs9595883	chr13:33167700	A/G	cg12383807	chr13:33924137	NA	-0.51	-4.61	-0.43	1.27e-5	Body mass index;
THYM	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7084402	0.764	rs2393455	chr10:60374898	C/A	cg07615347	chr10:60278583	BICC1	0.55	5.16	0.47	1.34e-6	Refractive error;
THYM	cis	rs3204270	0.759	rs8065104	chr17:79672605	G/A	cg09996840	chr17:79680718	SLC25A10	-0.59	-4.46	-0.42	2.24e-5	Dental caries;
THYM	cis	rs2070488	0.965	rs6796845	chr3:38567771	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-6.55	-0.56	2.97e-9	Electrocardiographic conduction measures;
THYM	cis	rs2073300	0.609	rs3827085	chr20:23356985	A/T	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg22709100	chr7:91322751	NA	0.6	4.65	0.43	1.07e-5	Breast cancer;
THYM	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg17366294	chr4:99064904	C4orf37	0.57	6.68	0.57	1.63e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg17294928	chr15:75287854	SCAMP5	-0.94	-7.94	-0.63	4.01e-12	Blood trace element (Zn levels);
THYM	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-4.49	-0.42	1.99e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs300703	0.935	rs12714403	chr2:273070	A/G	cg21211680	chr2:198530	NA	1.33	5.61	0.5	1.97e-7	Blood protein levels;
THYM	cis	rs17443541	0.507	rs6725254	chr2:200463248	A/C	cg03741458	chr2:200468445	NA	-0.8	-6.04	-0.53	3.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-5.75	-0.51	1.06e-7	Chronic sinus infection;
THYM	cis	rs9858542	0.597	rs56116382	chr3:49606188	A/C	cg00383909	chr3:49044727	WDR6	0.66	4.49	0.42	1.97e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg22508957	chr16:3507546	NAT15	0.7	7.87	0.63	5.61e-12	Tuberculosis;
THYM	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg23958373	chr8:599963	NA	-0.89	-4.64	-0.43	1.1e-5	IgG glycosylation;
THYM	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg02825527	chr7:2087843	MAD1L1	-0.75	-4.96	-0.45	3.06e-6	Bipolar disorder;
THYM	cis	rs7582180	0.669	rs4455176	chr2:100876629	T/A	cg21926883	chr2:100939477	LONRF2	-0.52	-4.49	-0.42	1.97e-5	Intelligence (multi-trait analysis);
THYM	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg09517075	chr8:22133004	PIWIL2	0.64	5.77	0.51	9.95e-8	Hypertriglyceridemia;
THYM	cis	rs7688540	0.511	rs77815676	chr4:189869	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.91	5.56	0.5	2.45e-7	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg13695892	chr22:41940480	POLR3H	0.85	6.16	0.53	1.72e-8	Vitiligo;
THYM	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg15445000	chr17:37608096	MED1	0.43	4.9	0.45	3.87e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg21028142	chr17:79581711	NPLOC4	0.64	6.74	0.57	1.23e-9	Eye color traits;
THYM	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg17279839	chr7:150038598	RARRES2	0.55	4.9	0.45	3.88e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.7	5.33	0.48	6.5e-7	Tonsillectomy;
THYM	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg00129232	chr17:37814104	STARD3	0.7	4.93	0.45	3.42e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg25918947	chr17:41365094	TMEM106A	-0.56	-4.62	-0.43	1.22e-5	Menopause (age at onset);
THYM	cis	rs2235642	1.000	rs2235642	chr16:1584866	T/C	cg08296037	chr16:1584118	IFT140;TMEM204	-0.54	-4.5	-0.42	1.92e-5	Coronary artery disease;
THYM	cis	rs6974574	1.000	rs10280939	chr7:38120073	C/T	cg19166347	chr7:37955598	SFRP4	-0.59	-4.47	-0.42	2.18e-5	Height;
THYM	cis	rs9393777	0.588	rs6941920	chr6:26492149	C/T	cg12826209	chr6:26865740	GUSBL1	1.02	6.88	0.58	6.48e-10	Intelligence (multi-trait analysis);
THYM	cis	rs516946	1.000	rs750625	chr8:41525914	C/T	cg19441908	chr8:41529140	ANK1	0.62	4.9	0.45	3.87e-6	Type 2 diabetes;
THYM	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg05373962	chr22:49881684	NA	-0.64	-6.22	-0.54	1.31e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-4.87	-0.45	4.44e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8018808	0.902	rs176773	chr14:77882456	C/T	cg20045696	chr14:77926864	AHSA1	0.53	4.8	0.44	5.9e-6	Myeloid white cell count;
THYM	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg26597838	chr10:835615	NA	1.6	11.21	0.75	4.49e-19	Eosinophil percentage of granulocytes;
THYM	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg23422044	chr7:1970798	MAD1L1	0.89	6.43	0.55	5.07e-9	Bipolar disorder;
THYM	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg16342193	chr10:102329863	NA	-0.59	-6.2	-0.54	1.48e-8	Palmitoleic acid (16:1n-7) levels;
THYM	trans	rs34156428	0.929	rs7927277	chr11:16499691	T/G	cg02688867	chr12:133019854	NA	0.54	6.89	0.58	6.12e-10	Coronary artery disease;
THYM	cis	rs2658782	0.789	rs3020057	chr11:93118515	C/T	cg15737290	chr11:93063684	CCDC67	0.86	6.72	0.57	1.32e-9	Pulmonary function decline;
THYM	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.91	10.43	0.73	2.04e-17	Prudent dietary pattern;
THYM	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg20966754	chr17:47091339	IGF2BP1	0.59	7.32	0.6	7.93e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg18681998	chr4:17616180	MED28	0.82	7.15	0.59	1.82e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs17193922	0.798	rs7203644	chr16:53547209	C/T	cg09728985	chr16:53543985	NA	-0.59	-4.7	-0.43	8.67e-6	Hip circumference adjusted for BMI;
THYM	cis	rs7781557	1.000	rs727175	chr7:102471780	T/C	cg06322601	chr7:102330635	NA	0.65	4.73	0.44	7.87e-6	Colorectal adenoma (advanced);
THYM	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg13147721	chr7:65941812	NA	-1.0	-6.2	-0.54	1.47e-8	Diabetic kidney disease;
THYM	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg03115019	chr17:80708279	FN3K	-0.65	-5.25	-0.47	9.12e-7	Glycated hemoglobin levels;
THYM	cis	rs7818345	0.967	rs4554480	chr8:19284072	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.53	0.42	1.73e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs57545798	0.895	rs60767084	chr15:100647080	C/G	cg20941820	chr15:100882334	ADAMTS17	0.56	4.68	0.43	9.61e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg27572855	chr1:25598939	RHD	0.69	5.3	0.48	7.64e-7	Erythrocyte sedimentation rate;
THYM	cis	rs6964587	0.758	rs35963176	chr7:91617115	C/T	cg22117172	chr7:91764530	CYP51A1	0.4	4.64	0.43	1.11e-5	Breast cancer;
THYM	cis	rs73787773	0.668	rs59043064	chr5:111491066	C/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.9	-4.83	-0.44	5.3e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs250677	0.522	rs62378210	chr5:148384885	G/A	cg18129178	chr5:148520854	ABLIM3	-0.71	-5.31	-0.48	7.05e-7	Breast cancer;
THYM	cis	rs6669384	0.826	rs4844393	chr1:207994429	T/C	cg22525895	chr1:207977042	MIR29B2	-0.72	-4.73	-0.44	7.77e-6	Immune response to measles vaccine (measles-specific neutralising antibody titre);
THYM	cis	rs7771547	0.573	rs517890	chr6:36397786	G/C	cg07856975	chr6:36356162	ETV7	0.52	4.72	0.44	8.26e-6	Platelet distribution width;
THYM	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg22907277	chr7:1156413	C7orf50	0.8	4.85	0.45	4.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs763014	0.931	rs59476302	chr16:629006	C/T	cg07343612	chr16:622815	PIGQ	-1.08	-11.34	-0.76	2.36e-19	Height;
THYM	cis	rs2806561	0.734	rs1952527	chr1:23400969	T/C	cg12483005	chr1:23474871	LUZP1	0.62	6.51	0.56	3.57e-9	Height;
THYM	cis	rs7851660	0.809	rs10115216	chr9:100657119	G/T	cg13688889	chr9:100608707	NA	0.77	5.59	0.5	2.17e-7	Strep throat;
THYM	cis	rs9810089	0.527	rs838199	chr3:135950090	T/C	cg12473912	chr3:136751656	NA	0.68	6.33	0.54	7.89e-9	Gestational age at birth (child effect);
THYM	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.91	0.63	4.62e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.96	6.22	0.54	1.34e-8	Smoking behavior;
THYM	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs4845570	1.000	rs7416415	chr1:151757798	C/T	cg18019451	chr1:151746047	TDRKH	0.73	4.49	0.42	1.98e-5	Coronary artery disease;
THYM	cis	rs2354432	0.505	rs72691009	chr1:146708397	C/T	cg25205988	chr1:146714368	CHD1L	-1.02	-5.31	-0.48	7.2e-7	Mitochondrial DNA levels;
THYM	cis	rs7119038	0.818	rs57494551	chr11:118661398	C/T	cg19308663	chr11:118741387	NA	0.61	5.98	0.52	3.84e-8	Sjögren's syndrome;
THYM	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg04447362	chr2:237654635	NA	0.48	4.49	0.42	2.03e-5	Prostate cancer;
THYM	cis	rs763014	0.865	rs8675	chr16:633843	A/G	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.15	-0.47	1.4e-6	Total cholesterol levels;
THYM	cis	rs4930776	1.000	rs10774353	chr12:5767174	C/T	cg02086166	chr12:5775618	ANO2	0.58	5.71	0.51	1.3e-7	Plasma clusterin levels;
THYM	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-6.65	-0.56	1.84e-9	Chronic sinus infection;
THYM	cis	rs6076065	0.723	rs6083100	chr20:23358651	G/A	cg11657817	chr20:23433608	CST11	0.31	4.57	0.42	1.48e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs8180040	0.800	rs56250009	chr3:47279497	G/C	cg02527881	chr3:46936655	PTH1R	0.59	5.48	0.49	3.44e-7	Colorectal cancer;
THYM	cis	rs10979	1.000	rs9386034	chr6:143890572	T/G	cg25407410	chr6:143891975	LOC285740	-0.61	-5.13	-0.47	1.5e-6	Hypospadias;
THYM	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg04234412	chr22:24373322	LOC391322	-0.94	-10.52	-0.73	1.26e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10857712	0.950	rs7906765	chr10:135225460	G/T	cg19623624	chr10:135278901	LOC619207	-0.6	-4.74	-0.44	7.47e-6	Systemic lupus erythematosus;
THYM	cis	rs2046867	0.774	rs1393585	chr3:72886722	A/G	cg25664220	chr3:72788482	NA	-0.96	-7.85	-0.63	6.21e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs9486719	1.000	rs12197411	chr6:97039621	G/A	cg18709589	chr6:96969512	KIAA0776	-0.67	-4.64	-0.43	1.1e-5	Migraine;Coronary artery disease;
THYM	cis	rs6545977	0.531	rs2539981	chr2:63104904	T/C	cg17519650	chr2:63277830	OTX1	0.81	6.77	0.57	1.05e-9	Prostate cancer;
THYM	cis	rs7524258	0.868	rs4908610	chr1:7311260	C/A	cg07173049	chr1:7289937	CAMTA1	0.74	5.89	0.52	5.74e-8	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs2279817	0.675	rs1416853	chr1:18024880	G/C	cg21791023	chr1:18019539	ARHGEF10L	0.75	4.73	0.44	7.76e-6	Neuroticism;
THYM	cis	rs11785693	0.862	rs73183606	chr8:4986999	C/T	cg26367366	chr8:4980734	NA	1.21	6.11	0.53	2.2e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg07061783	chr6:25882402	NA	-0.83	-6.76	-0.57	1.12e-9	Intelligence (multi-trait analysis);
THYM	cis	rs16866061	1.000	rs7588380	chr2:225341304	A/T	cg12698349	chr2:225449008	CUL3	-1.1	-9.52	-0.7	1.78e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg03806693	chr22:41940476	POLR3H	1.24	10.81	0.74	3.08e-18	Vitiligo;
THYM	cis	rs12509991	0.582	rs1994151	chr4:127048586	C/T	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06634786	chr22:41940651	POLR3H	0.78	6.01	0.53	3.36e-8	Vitiligo;
THYM	cis	rs3204270	0.684	rs57405099	chr17:79637065	T/C	cg13117272	chr17:79681052	SLC25A10	-0.72	-4.48	-0.42	2.05e-5	Dental caries;
THYM	cis	rs2286885	1.000	rs10733678	chr9:129242280	G/A	cg14294646	chr9:129243551	FAM125B	-0.67	-6.41	-0.55	5.49e-9	Intraocular pressure;
THYM	cis	rs3755605	0.760	rs2302864	chr3:169781887	T/G	cg18444028	chr3:169782040	GPR160	0.57	4.73	0.44	7.8e-6	Testicular germ cell tumor;
THYM	cis	rs1894633	0.574	rs17369011	chr1:172321641	A/T	cg13446689	chr1:172328377	DNM3	0.54	4.92	0.45	3.65e-6	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs11574514	0.661	rs117024179	chr16:67795150	A/G	cg09738193	chr16:67926317	PSKH1	-0.91	-4.66	-0.43	1.01e-5	Crohn's disease;
THYM	cis	rs2734839	0.964	rs2734833	chr11:113292920	G/A	cg14159747	chr11:113255604	NA	0.31	6.39	0.55	6.13e-9	Information processing speed;
THYM	cis	rs4930103	0.935	rs2071094	chr11:2021164	G/T	cg06197492	chr11:2016605	H19	0.63	5.47	0.49	3.69e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs59197085	0.636	rs9791702	chr7:128440185	T/C	cg00734629	chr7:128471146	FLNC	0.77	4.52	0.42	1.79e-5	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
THYM	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.85	-7.3	-0.6	8.54e-11	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg12310025	chr6:25882481	NA	-0.85	-6.91	-0.58	5.48e-10	Intelligence (multi-trait analysis);
THYM	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.75	8.38	0.65	4.74e-13	Eosinophil percentage of white cells;
THYM	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg10505658	chr17:80084571	CCDC57	0.7	8.07	0.64	2.18e-12	Life satisfaction;
THYM	cis	rs854765	0.663	rs6502618	chr17:17746741	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.66	-5.84	-0.51	7.23e-8	Total body bone mineral density;
THYM	trans	rs7794364	0.658	rs12154872	chr7:117512932	A/G	cg21837391	chr1:1159412	SDF4	0.92	7.57	0.61	2.37e-11	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg06009448	chr7:1102226	C7orf50	0.49	5.06	0.46	2.08e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs28595532	1.000	rs115915387	chr4:119640854	C/T	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs9992101	0.645	rs3849577	chr4:77286706	A/G	cg20311846	chr4:77356250	SHROOM3	-0.53	-5.83	-0.51	7.6e-8	Creatinine levels;
THYM	cis	rs17401966	1.000	rs58549151	chr1:10314657	A/C	cg20482658	chr1:10539492	PEX14	0.39	4.66	0.43	1.04e-5	Hepatocellular carcinoma;
THYM	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg23978390	chr7:1156363	C7orf50	0.66	4.94	0.45	3.32e-6	Longevity;Endometriosis;
THYM	cis	rs17739794	0.764	rs2336409	chr8:809079	A/C	cg07178994	chr8:816998	NA	-0.65	-6.12	-0.53	2.04e-8	Clozapine-induced cytotoxicity;
THYM	trans	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs9403317	0.573	rs9403332	chr6:142000328	A/G	cg15052665	chr6:141804349	NA	0.74	5.41	0.49	4.63e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7781977	0.920	rs7805434	chr7:50340750	G/C	cg16697214	chr7:50343361	IKZF1	0.61	4.65	0.43	1.09e-5	IgG glycosylation;
THYM	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg08021120	chr3:195498017	MUC4	0.86	4.65	0.43	1.09e-5	Lung disease severity in cystic fibrosis;
THYM	cis	rs72960926	0.744	rs72964214	chr6:74864851	T/C	cg03266952	chr6:74778945	NA	-0.83	-4.77	-0.44	6.58e-6	Metabolite levels (MHPG);
THYM	cis	rs12282928	0.959	rs1354292	chr11:48264647	G/A	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs7043114	0.525	rs1133908	chr9:95068046	C/T	cg14631576	chr9:95140430	CENPP	-0.85	-9.03	-0.68	1.99e-14	Height;
THYM	cis	rs9916302	0.706	rs9890198	chr17:37457480	A/C	cg07936489	chr17:37558343	FBXL20	0.86	5.49	0.49	3.4e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6763768	0.606	rs6795127	chr3:53376669	C/T	cg22900224	chr3:52804907	NEK4	0.72	4.67	0.43	9.85e-6	Bacterial meningitis;
THYM	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg22875332	chr1:76189707	ACADM	0.89	12.06	0.78	7.38e-21	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2273669	0.665	rs56054577	chr6:109406513	T/G	cg17117243	chr6:109341365	SESN1	-0.78	-4.77	-0.44	6.52e-6	Prostate cancer;
THYM	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.27	-0.65	8.15e-13	Mean corpuscular volume;
THYM	cis	rs314370	0.951	rs13226502	chr7:100506381	C/T	cg08558340	chr7:100472263	SRRT	0.61	4.99	0.46	2.75e-6	Resting heart rate;
THYM	cis	rs7580658	0.864	rs10928761	chr2:128003247	C/T	cg10021288	chr2:128175891	PROC	-0.71	-6.17	-0.54	1.63e-8	Protein C levels;
THYM	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg07537917	chr2:241836409	C2orf54	-0.25	-5.46	-0.49	3.76e-7	Urinary metabolites;
THYM	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg21854759	chr1:92012499	NA	-0.72	-5.93	-0.52	4.84e-8	Breast cancer;
THYM	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg20486651	chr6:167070296	RPS6KA2	0.48	4.71	0.43	8.5e-6	Crohn's disease;
THYM	cis	rs13082711	0.911	rs13097178	chr3:27527920	T/C	cg02860705	chr3:27208620	NA	0.72	5.06	0.46	2.01e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9649213	0.614	rs4729432	chr7:97947055	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.67	-5.66	-0.5	1.57e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2108225	0.872	rs2051955	chr7:107441154	C/T	cg18560240	chr7:107437656	SLC26A3	-0.88	-6.57	-0.56	2.64e-9	Ulcerative colitis;
THYM	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg22166914	chr1:53195759	ZYG11B	-0.76	-7.95	-0.63	3.76e-12	Monocyte count;
THYM	cis	rs10886503	0.777	rs4752317	chr10:121264341	C/A	cg13260278	chr10:121265587	RGS10	-0.66	-6.1	-0.53	2.25e-8	Obstetric antiphospholipid syndrome;
THYM	cis	rs362272	0.545	rs3135145	chr4:3299504	T/C	cg22655196	chr4:3374909	RGS12	0.59	6.95	0.58	4.51e-10	Serum sulfate level;
THYM	cis	rs61931739	0.635	rs10772123	chr12:33975557	C/T	cg10856724	chr12:34555212	NA	-0.7	-6.58	-0.56	2.54e-9	Morning vs. evening chronotype;
THYM	cis	rs13177918	0.626	rs12186649	chr5:149818526	T/A	cg14059543	chr5:149831962	NA	-0.99	-7.41	-0.6	5.27e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.53	-5.0	-0.46	2.67e-6	Lymphocyte counts;
THYM	cis	rs4455778	0.561	rs6952745	chr7:49122762	C/A	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg12179176	chr11:130786555	SNX19	0.77	6.55	0.56	3e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg10803722	chr21:46713166	LOC642852	-0.41	-5.33	-0.48	6.47e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg24549020	chr5:56110836	MAP3K1	0.8	4.89	0.45	4.04e-6	Initial pursuit acceleration;
THYM	cis	rs4638749	0.677	rs2219082	chr2:108854182	C/A	cg25838818	chr2:108905173	SULT1C2	-0.52	-5.18	-0.47	1.25e-6	Blood pressure;
THYM	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg24531977	chr5:56204891	C5orf35	0.9	6.47	0.55	4.22e-9	Initial pursuit acceleration;
THYM	cis	rs8038465	0.622	rs17185525	chr15:73885539	T/C	cg15420318	chr15:73925796	NPTN	0.62	5.32	0.48	6.84e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs863345	0.625	rs4609418	chr1:158464728	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg18876405	chr7:65276391	NA	0.62	5.54	0.49	2.66e-7	Aortic root size;
THYM	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.09	-5.4	-0.48	4.88e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg22508957	chr16:3507546	NAT15	0.69	9.19	0.69	8.75e-15	Tuberculosis;
THYM	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg09640425	chr7:158790006	NA	-0.51	-4.48	-0.42	2.08e-5	Facial morphology (factor 20);
THYM	cis	rs36051895	0.623	rs10975024	chr9:5246403	A/T	cg02405213	chr9:5042618	JAK2	-0.95	-9.57	-0.7	1.4e-15	Pediatric autoimmune diseases;
THYM	cis	rs9915657	0.743	rs9894720	chr17:70097607	C/T	cg06234051	chr17:70120541	SOX9	-0.61	-5.57	-0.5	2.35e-7	Thyroid hormone levels;
THYM	cis	rs7072216	0.763	rs7923729	chr10:100169465	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs11009175	0.615	rs7901543	chr10:33299313	G/A	cg00146027	chr10:33299147	NA	-0.68	-5.13	-0.47	1.55e-6	Depression (quantitative trait);
THYM	cis	rs11190604	0.767	rs4919458	chr10:102177728	G/A	cg07570687	chr10:102243282	WNT8B	-0.82	-7.88	-0.63	5.44e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs10197862	0.518	rs13018263	chr2:103092270	T/C	cg01241218	chr2:102972058	NA	0.65	4.5	0.42	1.94e-5	Asthma and hay fever;Asthma;
THYM	cis	rs6754311	0.593	rs11679508	chr2:136474098	A/T	cg04750100	chr2:136595281	LCT	-0.57	-6.01	-0.52	3.44e-8	Mosquito bite size;
THYM	cis	rs7794273	0.851	rs10251998	chr7:18849259	G/A	cg13420273	chr7:18810212	HDAC9	0.59	4.87	0.45	4.4e-6	Night sleep phenotypes;
THYM	cis	rs11031096	0.782	rs2165728	chr11:4147004	T/C	cg18678763	chr11:4115507	RRM1	-0.42	-5.75	-0.51	1.1e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg14690197	chr8:22456421	C8orf58	0.46	4.56	0.42	1.5e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg14829155	chr15:31115871	NA	0.52	4.88	0.45	4.27e-6	Huntington's disease progression;
THYM	cis	rs61990749	0.597	rs717683	chr14:78255453	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.0	0.63	3.03e-12	Fibroblast growth factor basic levels;
THYM	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg07936489	chr17:37558343	FBXL20	0.85	5.64	0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2219968	0.717	rs4739188	chr8:78912778	G/T	cg00738934	chr8:78996279	NA	-0.81	-8.29	-0.65	7.26e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4460079	0.531	rs4466108	chr4:114839270	T/C	cg02060584	chr4:113970739	ANK2	0.56	4.52	0.42	1.8e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg26384229	chr12:38710491	ALG10B	-0.72	-5.6	-0.5	2.08e-7	Morning vs. evening chronotype;
THYM	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg06766960	chr11:133703094	NA	-0.52	-4.83	-0.44	5.25e-6	Childhood ear infection;
THYM	cis	rs4638749	0.773	rs4676190	chr2:108858619	A/G	cg06795125	chr2:108905320	SULT1C2	-0.54	-6.33	-0.54	7.98e-9	Blood pressure;
THYM	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg12310025	chr6:25882481	NA	-0.99	-9.34	-0.69	4.23e-15	Blood metabolite levels;
THYM	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg00271210	chr6:167070053	RPS6KA2	-0.54	-5.42	-0.49	4.43e-7	Crohn's disease;
THYM	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22857025	chr5:266934	NA	-1.41	-9.08	-0.68	1.5e-14	Breast cancer;
THYM	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg23711669	chr6:146136114	FBXO30	1.0	10.8	0.74	3.33e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs651907	0.737	rs9844218	chr3:101584983	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.7	-5.31	-0.48	7.15e-7	Colorectal cancer;
THYM	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg06238570	chr21:40685208	BRWD1	-0.96	-8.95	-0.68	2.83e-14	Cognitive function;
THYM	cis	rs13082711	0.595	rs6778612	chr3:27370789	T/C	cg02860705	chr3:27208620	NA	-0.79	-5.95	-0.52	4.53e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs11648796	0.765	rs2003832	chr16:769538	G/A	cg02852791	chr16:710674	WDR90	-0.6	-5.57	-0.5	2.38e-7	Height;
THYM	trans	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg25517755	chr10:38738941	LOC399744	-0.79	-7.77	-0.62	9.18e-12	Corneal astigmatism;
THYM	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs7267979	1.000	rs2258719	chr20:25275843	C/T	cg08601574	chr20:25228251	PYGB	0.58	4.71	0.43	8.54e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg18512352	chr11:47633146	NA	-0.51	-6.23	-0.54	1.24e-8	Subjective well-being;
THYM	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg09307838	chr4:120376055	NA	0.73	5.07	0.46	1.96e-6	Corneal astigmatism;
THYM	cis	rs34779708	0.931	rs4934731	chr10:35431636	T/C	cg03585969	chr10:35415529	CREM	0.67	5.01	0.46	2.51e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg27490568	chr2:178487706	NA	0.61	5.41	0.49	4.77e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg11494091	chr17:61959527	GH2	1.05	16.1	0.86	6.81e-29	Prudent dietary pattern;
THYM	cis	rs2933343	0.729	rs1680780	chr3:128612659	G/C	cg11901034	chr3:128598214	ACAD9	-0.71	-5.55	-0.49	2.56e-7	IgG glycosylation;
THYM	cis	rs742614	0.533	rs2747541	chr20:32418772	G/T	cg06304546	chr20:32448765	NA	-0.96	-10.04	-0.72	1.35e-16	Stearic acid (18:0) levels;
THYM	cis	rs34779708	0.931	rs11010077	chr10:35328088	C/T	cg03585969	chr10:35415529	CREM	-0.63	-4.66	-0.43	1.01e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs13064411	0.518	rs6438160	chr3:113217591	A/C	cg18753928	chr3:113234510	CCDC52	-0.78	-7.16	-0.59	1.68e-10	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg08645402	chr16:4508243	NA	0.74	7.08	0.59	2.52e-10	Schizophrenia;
THYM	trans	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.1	8.0	0.63	3.04e-12	Exhaled nitric oxide output;
THYM	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg24846343	chr22:24311635	DDTL	-0.46	-5.78	-0.51	9.38e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg20007245	chr22:24372913	LOC391322	-0.75	-6.78	-0.57	1.03e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg23989207	chr17:80870107	TBCD	0.61	5.13	0.47	1.54e-6	Glycated hemoglobin levels;
THYM	cis	rs11779988	0.545	rs208058	chr8:17820433	G/A	cg01800426	chr8:17659068	MTUS1	-0.74	-5.15	-0.47	1.41e-6	Breast cancer;
THYM	cis	rs9905704	0.756	rs302860	chr17:56695008	C/A	cg12560992	chr17:57184187	TRIM37	0.65	4.51	0.42	1.89e-5	Testicular germ cell tumor;
THYM	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.75	5.7	0.5	1.35e-7	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs4262150	0.883	rs10515678	chr5:152323236	A/G	cg06854687	chr5:151642065	NA	-0.58	-4.46	-0.42	2.24e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg15604051	chr3:44754201	ZNF502	-0.52	-4.75	-0.44	7.07e-6	Depressive symptoms;
THYM	cis	rs2637266	1.000	rs2579747	chr10:78327759	C/T	cg18941641	chr10:78392320	NA	0.8	6.91	0.58	5.42e-10	Pulmonary function;
THYM	cis	rs6840360	0.642	rs6851814	chr4:152346437	G/A	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.3	-0.48	7.43e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg23281280	chr6:28129359	ZNF389	0.61	4.74	0.44	7.58e-6	Parkinson's disease;
THYM	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg17554472	chr22:41940697	POLR3H	-0.61	-4.56	-0.42	1.5e-5	Vitiligo;
THYM	cis	rs2073300	0.609	rs2277765	chr20:23425163	C/T	cg12062639	chr20:23401060	NAPB	1.08	5.67	0.5	1.55e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Body mass index;
THYM	cis	rs6074578	0.648	rs16995685	chr20:139576	G/T	cg16931068	chr20:139680	DEFB127	0.42	4.57	0.42	1.49e-5	Hirschsprung disease;
THYM	cis	rs241257	0.583	rs241263	chr1:4618722	T/C	cg00505606	chr1:3620638	TP73	0.47	4.51	0.42	1.88e-5	Anxiety disorder;
THYM	cis	rs6121246	0.559	rs6121172	chr20:30296095	A/C	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs6669384	0.547	rs2745979	chr1:208018219	G/C	cg22525895	chr1:207977042	MIR29B2	-0.78	-6.38	-0.55	6.49e-9	Immune response to measles vaccine (measles-specific neutralising antibody titre);
THYM	trans	rs4650994	0.935	rs2811289	chr1:178572693	G/A	cg05059571	chr16:84539110	KIAA1609	0.74	7.38	0.6	5.88e-11	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.26	-0.47	8.87e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg06623918	chr6:96969491	KIAA0776	1.09	9.89	0.71	2.89e-16	Headache;
THYM	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg19623624	chr10:135278901	LOC619207	-0.66	-5.32	-0.48	6.79e-7	Systemic lupus erythematosus;
THYM	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg04218760	chr10:45406644	TMEM72	0.69	6.47	0.55	4.15e-9	Mean corpuscular volume;
THYM	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg10360139	chr7:1886902	MAD1L1	0.6	4.75	0.44	7.14e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6989175	0.555	rs1510761	chr8:25076964	C/G	cg20708129	chr8:25316039	KCTD9;CDCA2	0.89	4.48	0.42	2.09e-5	QT interval;
THYM	cis	rs7100689	0.556	rs946893	chr10:82023524	A/G	cg01528321	chr10:82214614	TSPAN14	0.93	7.49	0.61	3.53e-11	Post bronchodilator FEV1;
THYM	cis	rs677665	0.918	rs11590326	chr1:9339205	A/G	cg03265564	chr1:9748971	PIK3CD	-0.24	-4.53	-0.42	1.68e-5	Eosinophil percentage of white cells;
THYM	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-4.84	-0.44	4.98e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg12564285	chr5:131593104	PDLIM4	0.44	4.57	0.42	1.46e-5	Blood metabolite levels;
THYM	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs887829	0.641	rs7586110	chr2:234590527	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.81	-6.58	-0.56	2.52e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg24006582	chr15:45444508	DUOX1	0.77	6.04	0.53	3.05e-8	Uric acid levels;
THYM	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg24846680	chr1:228362309	C1orf69	0.52	4.71	0.43	8.6e-6	Diastolic blood pressure;
THYM	cis	rs12368653	0.666	rs1050045	chr12:58115271	A/G	cg12615879	chr12:58013172	SLC26A10	0.52	5.21	0.47	1.09e-6	Multiple sclerosis;
THYM	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg18169835	chr10:134612155	NA	0.6	4.46	0.42	2.25e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg04043695	chr12:129287642	SLC15A4	0.61	5.09	0.46	1.83e-6	Systemic lupus erythematosus;
THYM	cis	rs526231	0.543	rs34787	chr5:102458903	G/C	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.49e-6	Primary biliary cholangitis;
THYM	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg24675658	chr1:53192096	ZYG11B	-0.82	-7.65	-0.62	1.6e-11	Monocyte count;
THYM	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11644478	chr21:40555479	PSMG1	-0.76	-6.49	-0.55	3.85e-9	Cognitive function;
THYM	cis	rs75557865	1	rs75557865	chr3:121652141	G/A	cg20356878	chr3:121714668	ILDR1	0.86	9.31	0.69	4.94e-15	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7107174	1.000	rs10899475	chr11:78051610	T/C	cg02023728	chr11:77925099	USP35	0.61	5.85	0.51	7e-8	Testicular germ cell tumor;
THYM	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg04772025	chr11:68637568	NA	0.61	6.5	0.56	3.65e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4595586	0.545	rs2218762	chr12:39397762	G/A	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	4.87	0.45	4.49e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg18811423	chr2:55921094	PNPT1	0.73	6.99	0.58	3.79e-10	Metabolic syndrome;
THYM	cis	rs11157436	0.918	rs12586393	chr14:22618769	G/A	cg26433554	chr14:23315189	MMP14	0.44	4.61	0.43	1.24e-5	Neurocognitive impairment in HIV-1 infection (continuous);
THYM	cis	rs6466832	0.568	rs1968147	chr7:122316592	C/T	cg22586324	chr7:123296098	LMOD2	-0.86	-5.02	-0.46	2.38e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg16342193	chr10:102329863	NA	-0.58	-5.99	-0.52	3.78e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs17030434	0.953	rs12639885	chr4:154700374	G/A	cg14289246	chr4:154710475	SFRP2	-0.76	-5.24	-0.47	9.79e-7	Electrocardiographic conduction measures;
THYM	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg24060327	chr5:131705240	SLC22A5	-0.65	-4.8	-0.44	5.83e-6	Blood metabolite levels;
THYM	cis	rs7849270	0.959	rs3124509	chr9:131896999	C/T	cg14069949	chr9:131965419	NA	-0.5	-4.52	-0.42	1.8e-5	Blood metabolite ratios;
THYM	cis	rs2319125	0.683	rs28419707	chr17:64051179	A/G	cg04446870	chr17:64440273	PRKCA	0.5	4.48	0.42	2.12e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg27211696	chr2:191398769	TMEM194B	0.82	8.1	0.64	1.86e-12	Pulse pressure;
THYM	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg27129171	chr3:47204927	SETD2	-0.82	-7.83	-0.63	6.81e-12	Colorectal cancer;
THYM	cis	rs600806	0.778	rs2140923	chr1:110004990	C/T	cg02175308	chr1:109941060	SORT1	-0.55	-4.59	-0.43	1.33e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6687430	0.526	rs7555790	chr1:10613167	A/G	cg20482658	chr1:10539492	PEX14	0.39	5.52	0.49	2.99e-7	Hand grip strength;
THYM	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg03929089	chr4:120376271	NA	-0.98	-12.21	-0.78	3.51e-21	Coronary artery disease;
THYM	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.77	-0.51	9.87e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg07936489	chr17:37558343	FBXL20	0.85	5.64	0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg19774624	chr17:42201019	HDAC5	-0.77	-7.16	-0.59	1.73e-10	Total body bone mineral density;
THYM	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg26545918	chr15:68124484	LBXCOR1	0.55	4.71	0.44	8.37e-6	Restless legs syndrome;
THYM	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg20891283	chr12:69753455	YEATS4	0.79	6.27	0.54	1.08e-8	Response to diuretic therapy;
THYM	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.55	-5.23	-0.47	1e-6	Lymphocyte counts;
THYM	cis	rs9527	0.590	rs10786741	chr10:104939182	G/A	cg04362960	chr10:104952993	NT5C2	0.65	5.04	0.46	2.18e-6	Arsenic metabolism;
THYM	cis	rs4713118	0.699	rs200969	chr6:27859453	T/C	cg08968635	chr6:28129556	ZNF389	0.49	4.74	0.44	7.51e-6	Parkinson's disease;
THYM	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg05283184	chr6:79620031	NA	-0.89	-8.99	-0.68	2.38e-14	Intelligence (multi-trait analysis);
THYM	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg11812906	chr14:75593930	NEK9	-0.8	-7.51	-0.61	3.26e-11	Height;
THYM	cis	rs1152591	0.543	rs1152590	chr14:64681193	C/T	cg05844852	chr14:64010466	PPP2R5E	-0.56	-4.51	-0.42	1.86e-5	Atrial fibrillation;
THYM	cis	rs3916	0.955	rs35599677	chr12:121141458	G/A	cg21892295	chr12:121157589	UNC119B	-0.52	-4.99	-0.46	2.76e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs1129187	0.702	rs2296805	chr6:42928758	T/G	cg27588902	chr6:42928151	GNMT	-0.6	-6.32	-0.54	8.6e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg18876405	chr7:65276391	NA	-0.58	-4.99	-0.46	2.75e-6	Aortic root size;
THYM	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1568889	0.877	rs57202579	chr11:28221677	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.55e-6	Bipolar disorder;
THYM	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg22875332	chr1:76189707	ACADM	-0.75	-6.46	-0.55	4.51e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4589258	1.000	rs4603267	chr11:90505698	G/A	cg26138821	chr11:89956704	CHORDC1	-0.7	-5.64	-0.5	1.74e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg05890377	chr2:74357713	NA	1.06	9.98	0.72	1.83e-16	Gestational age at birth (maternal effect);
THYM	trans	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs3903072	0.652	rs501630	chr11:65637273	A/G	cg26695010	chr11:65641043	EFEMP2	0.61	4.64	0.43	1.13e-5	Breast cancer;
THYM	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	5.17	0.47	1.28e-6	Hip circumference adjusted for BMI;
THYM	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg10047753	chr17:41438598	NA	1.18	11.26	0.76	3.4e-19	Menopause (age at onset);
THYM	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg24375607	chr4:120327624	NA	0.53	4.47	0.42	2.2e-5	Corneal astigmatism;
THYM	cis	rs2133450	0.712	rs1396403	chr3:7365357	A/G	cg19930620	chr3:7340148	GRM7	-0.48	-4.57	-0.42	1.44e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg15744005	chr10:104629667	AS3MT	-0.9	-8.72	-0.67	9.09e-14	Arsenic metabolism;
THYM	cis	rs7119	0.717	rs12898656	chr15:77807995	C/T	cg10437265	chr15:77819839	NA	-0.76	-7.61	-0.62	1.98e-11	Type 2 diabetes;
THYM	cis	rs7084402	0.967	rs1649023	chr10:60285820	C/T	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs35934224	0.783	rs13056219	chr22:19860846	C/T	cg11182965	chr22:19864308	TXNRD2	-0.96	-7.33	-0.6	7.51e-11	Glaucoma (primary open-angle);
THYM	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg23281280	chr6:28129359	ZNF389	-0.68	-5.59	-0.5	2.18e-7	Depression;
THYM	cis	rs9790314	0.846	rs9815222	chr3:160994897	C/T	cg03342759	chr3:160939853	NMD3	-0.95	-9.47	-0.7	2.2e-15	Morning vs. evening chronotype;
THYM	cis	rs4662945	0.504	rs35568023	chr2:130251812	A/T	cg05903289	chr2:130345205	NA	-0.55	-5.12	-0.46	1.62e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg19847130	chr8:10466454	RP1L1	0.5	4.58	0.43	1.42e-5	Neuroticism;
THYM	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.66	-5.11	-0.46	1.68e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs516243	0.871	rs3748687	chr1:10736216	G/A	cg02903756	chr1:10750680	CASZ1	-0.58	-4.67	-0.43	1e-5	Migraine - clinic-based;
THYM	cis	rs4523957	0.855	rs1231209	chr17:2124972	G/A	cg16513277	chr17:2031491	SMG6	-0.8	-7.85	-0.63	6.16e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs330048	0.644	rs10102807	chr8:9104590	C/T	cg15741354	chr8:8146129	NA	0.29	4.7	0.43	8.77e-6	Systemic lupus erythematosus;
THYM	cis	rs9905704	0.846	rs35082135	chr17:56939694	A/G	cg12560992	chr17:57184187	TRIM37	0.64	4.46	0.42	2.28e-5	Testicular germ cell tumor;
THYM	cis	rs3767633	0.612	rs2341472	chr1:161872727	A/G	cg27495845	chr1:161693088	FCRLB	-0.88	-4.78	-0.44	6.48e-6	IgG glycosylation;
THYM	cis	rs960902	0.747	rs13387905	chr2:37728625	A/G	cg25341268	chr2:37734390	NA	0.59	4.97	0.45	2.98e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.56	-5.12	-0.46	1.63e-6	Lymphocyte counts;
THYM	cis	rs7106204	0.609	rs34102968	chr11:24304149	C/T	ch.11.24196551F	chr11:24239977	NA	0.99	6.11	0.53	2.16e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg00757033	chr12:89920650	WDR51B	0.74	11.52	0.76	9.94e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg06789500	chr7:2109450	MAD1L1	-0.65	-4.46	-0.42	2.24e-5	Bipolar disorder;
THYM	cis	rs4930103	0.782	rs10840167	chr11:2022023	G/T	cg21926276	chr11:2035255	NA	0.27	4.53	0.42	1.7e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs35883536	1.000	rs12239531	chr1:101085661	A/G	cg06223162	chr1:101003688	GPR88	0.61	4.49	0.42	1.98e-5	Monocyte count;
THYM	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10889850	0.675	rs10889849	chr1:70204719	C/A	cg01711146	chr1:70671364	SFRS11;LRRC40	0.75	4.46	0.42	2.23e-5	Body mass index;
THYM	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs7178572	0.568	rs12909924	chr15:77551445	T/G	cg22256960	chr15:77711686	NA	-1.03	-8.45	-0.66	3.3e-13	Type 2 diabetes;
THYM	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg27535305	chr1:53392650	SCP2	-0.49	-5.49	-0.49	3.28e-7	Monocyte count;
THYM	cis	rs17253792	0.598	rs71413578	chr14:56018651	T/C	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs293526	0.959	rs293503	chr6:83633665	T/A	cg23278060	chr6:83777448	DOPEY1	0.61	4.49	0.42	2.02e-5	Crohn's disease;
THYM	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg12011299	chr4:100065546	ADH4	0.95	10.16	0.72	7.41e-17	Alcohol dependence;
THYM	cis	rs752010	1.000	rs6664724	chr1:42093821	G/A	cg22486000	chr1:42919398	ZMYND12	-0.42	-4.95	-0.45	3.22e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg23711669	chr6:146136114	FBXO30	-0.89	-9.09	-0.68	1.43e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9467160	0.871	rs9461015	chr6:24449020	C/G	cg20631270	chr6:24437470	GPLD1	-0.75	-5.95	-0.52	4.43e-8	Liver enzyme levels;
THYM	cis	rs7100689	0.784	rs4258322	chr10:82184770	T/C	cg01528321	chr10:82214614	TSPAN14	1.13	8.8	0.67	6.09e-14	Post bronchodilator FEV1;
THYM	cis	rs748404	0.660	rs693510	chr15:43714625	C/G	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg00071950	chr4:10020882	SLC2A9	0.84	8.8	0.67	6.19e-14	Bone mineral density;
THYM	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg05043794	chr9:111880884	C9orf5	-0.4	-5.64	-0.5	1.71e-7	Menarche (age at onset);
THYM	cis	rs4589258	0.737	rs1783787	chr11:90434394	T/G	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7567389	0.504	rs5937	chr2:128184770	T/C	cg06038358	chr2:128176007	PROC	0.44	4.95	0.45	3.17e-6	Self-rated health;
THYM	cis	rs6748734	0.625	rs9288743	chr2:241821569	C/G	cg02820040	chr2:241836501	C2orf54	-0.24	-4.61	-0.43	1.25e-5	Urinary metabolites;
THYM	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.89	-8.79	-0.67	6.49e-14	Lung cancer;
THYM	cis	rs4803468	0.967	rs3826713	chr19:41892269	C/T	cg09537434	chr19:41945824	ATP5SL	-1.13	-10.6	-0.74	8.86e-18	Height;
THYM	cis	rs11039798	1.000	rs7125913	chr11:48984318	G/A	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22509189	chr2:225307070	NA	-0.87	-7.39	-0.6	5.67e-11	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg16926213	chr1:1841314	NA	0.56	5.78	0.51	9.28e-8	Body mass index;
THYM	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg08504662	chr19:58868256	ZNF497	-0.55	-5.42	-0.49	4.53e-7	Uric acid clearance;
THYM	cis	rs7084402	0.967	rs1619284	chr10:60302515	C/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.64	-0.5	1.72e-7	Refractive error;
THYM	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.02	7.48	0.61	3.7e-11	Smoking behavior;
THYM	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	5.92	0.52	5.15e-8	Total body bone mineral density;
THYM	cis	rs2288884	0.708	rs12460617	chr19:52535834	G/A	cg05974498	chr19:52599256	ZNF841	0.35	4.51	0.42	1.85e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg24642844	chr7:1081250	C7orf50	-1.29	-8.3	-0.65	7.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg11764359	chr7:65958608	NA	-0.85	-7.43	-0.61	4.73e-11	Aortic root size;
THYM	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg18477163	chr1:228402036	OBSCN	0.57	6.23	0.54	1.28e-8	Diastolic blood pressure;
THYM	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg02640540	chr1:67518911	SLC35D1	0.64	4.68	0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg00981070	chr1:2046702	PRKCZ	-0.47	-5.83	-0.51	7.64e-8	Height;
THYM	cis	rs9522267	0.502	rs9522297	chr13:112234419	C/T	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg17775962	chr7:1200435	ZFAND2A	0.5	5.48	0.49	3.48e-7	Longevity;Endometriosis;
THYM	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg12288994	chr5:1860383	NA	0.62	4.81	0.44	5.61e-6	Cardiovascular disease risk factors;
THYM	cis	rs7107174	1.000	rs2512533	chr11:77968674	A/C	cg02023728	chr11:77925099	USP35	0.69	6.19	0.54	1.55e-8	Testicular germ cell tumor;
THYM	cis	rs4731207	0.570	rs7784614	chr7:124677191	C/G	cg05285228	chr7:124571219	POT1	-0.63	-4.74	-0.44	7.37e-6	Cutaneous malignant melanoma;
THYM	cis	rs981844	0.683	rs2405423	chr4:154749823	C/A	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs35123781	0.580	rs431184	chr5:138962408	G/A	cg08720517	chr5:138729919	LOC389333	0.56	4.64	0.43	1.13e-5	Schizophrenia;
THYM	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg17294928	chr15:75287854	SCAMP5	0.64	4.54	0.42	1.64e-5	Breast cancer;
THYM	cis	rs490234	0.756	rs1268539	chr9:128195657	C/A	cg14078157	chr9:128172775	NA	-0.74	-5.79	-0.51	9.14e-8	Mean arterial pressure;
THYM	cis	rs8058578	1.000	rs7187359	chr16:30703155	G/A	cg05768032	chr16:30646687	NA	0.56	5.61	0.5	1.98e-7	Multiple myeloma;
THYM	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg06609049	chr19:2785107	THOP1	1.13	11.02	0.75	1.1e-18	Total cholesterol levels;
THYM	cis	rs6546324	0.625	rs2861701	chr2:67855980	T/G	cg18237512	chr2:67827392	NA	-0.78	-4.68	-0.43	9.42e-6	Endometriosis;
THYM	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg24692254	chr21:30365293	RNF160	0.7	5.22	0.47	1.05e-6	Cognitive test performance;
THYM	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.44e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12667521	chr19:29218732	NA	0.73	5.83	0.51	7.5e-8	Methadone dose in opioid dependence;
THYM	cis	rs12449964	0.524	rs7224619	chr17:17572384	C/T	cg04398451	chr17:18023971	MYO15A	0.6	4.96	0.45	3.1e-6	Coronary artery disease or ischemic stroke;
THYM	cis	rs3008870	0.755	rs2815355	chr1:67485034	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.79	6.84	0.57	7.8e-10	Lymphocyte percentage of white cells;
THYM	cis	rs137603	0.562	rs137644	chr22:39728139	A/G	cg24268161	chr22:39747459	SYNGR1	0.64	5.24	0.47	9.5e-7	Primary biliary cholangitis;
THYM	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03576123	chr11:487126	PTDSS2	-1.23	-6.11	-0.53	2.16e-8	Body mass index;
THYM	cis	rs250585	0.850	rs250588	chr16:23400054	T/C	cg00143387	chr16:23521605	GGA2	0.74	5.32	0.48	6.81e-7	Egg allergy;
THYM	cis	rs35883536	0.626	rs10783140	chr1:101042083	A/G	cg09408571	chr1:101003634	GPR88	-0.48	-5.2	-0.47	1.14e-6	Monocyte count;
THYM	cis	rs13102973	0.899	rs13127659	chr4:135900604	G/A	cg14419869	chr4:135874104	NA	0.82	6.86	0.58	7.03e-10	Subjective well-being;
THYM	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.7	-5.83	-0.51	7.67e-8	Renal function-related traits (BUN);
THYM	cis	rs988913	0.957	rs4141552	chr6:54759929	A/G	cg19716238	chr6:54711378	FAM83B	0.51	5.18	0.47	1.22e-6	Menarche (age at onset);
THYM	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs6084875	0.932	rs731001	chr20:4731547	T/C	cg19614321	chr20:4804581	RASSF2	-0.46	-4.63	-0.43	1.16e-5	Systemic lupus erythematosus;
THYM	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg22683308	chr4:1340831	KIAA1530	0.61	4.5	0.42	1.93e-5	Longevity;
THYM	cis	rs977987	0.966	rs11643207	chr16:75498793	C/T	cg03315344	chr16:75512273	CHST6	0.7	5.71	0.51	1.3e-7	Dupuytren's disease;
THYM	cis	rs8016982	0.633	rs55643303	chr14:81708872	A/G	cg21807262	chr14:81713016	NA	-0.55	-4.98	-0.46	2.79e-6	Schizophrenia;
THYM	cis	rs2404602	0.684	rs2047504	chr15:76883516	A/T	cg23625390	chr15:77176239	SCAPER	-0.92	-6.39	-0.55	6.18e-9	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs1978968	1.000	rs7285566	chr22:18445288	G/A	cg01550578	chr22:18484421	MICAL3	0.66	4.89	0.45	4.05e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs483180	0.512	rs598685	chr1:120215269	G/A	cg19096424	chr1:120255104	PHGDH	0.67	5.25	0.47	9.26e-7	Macular telangiectasia type 2;
THYM	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg08859206	chr1:53392774	SCP2	0.51	5.7	0.51	1.32e-7	Monocyte count;
THYM	cis	rs7084402	0.967	rs1365740	chr10:60277549	A/C	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs17539620	0.534	rs7768635	chr6:154827861	C/T	cg20019720	chr6:154832845	CNKSR3	0.6	7.45	0.61	4.24e-11	Lipoprotein (a) levels;
THYM	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg04267008	chr7:1944627	MAD1L1	-0.67	-5.53	-0.49	2.83e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg09904177	chr6:26538194	HMGN4	0.54	4.57	0.42	1.47e-5	Intelligence (multi-trait analysis);
THYM	cis	rs793571	0.544	rs1427282	chr15:58914326	C/T	cg05156742	chr15:59063176	FAM63B	0.63	5.09	0.46	1.79e-6	Schizophrenia;
THYM	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg22508957	chr16:3507546	NAT15	-0.69	-9.09	-0.68	1.46e-14	Tuberculosis;
THYM	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg17554472	chr22:41940697	POLR3H	0.73	5.15	0.47	1.39e-6	Vitiligo;
THYM	cis	rs10779751	1.000	rs4845986	chr1:11288633	G/C	cg08854313	chr1:11322531	MTOR	0.96	8.41	0.65	4.17e-13	Body mass index;
THYM	cis	rs2219968	0.961	rs35174414	chr8:78977693	C/T	cg00738934	chr8:78996279	NA	0.92	10.08	0.72	1.12e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9790314	0.723	rs10936223	chr3:160884313	C/A	cg03342759	chr3:160939853	NMD3	-0.66	-5.18	-0.47	1.23e-6	Morning vs. evening chronotype;
THYM	cis	rs9826463	0.757	rs73238195	chr3:142171525	A/C	cg20824294	chr3:142316082	PLS1	0.64	4.69	0.43	9.09e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs4372836	0.543	rs10204329	chr2:28998077	C/G	cg09522027	chr2:28974177	PPP1CB	-0.62	-4.78	-0.44	6.39e-6	Body mass index;
THYM	cis	rs763014	0.931	rs11643039	chr16:634260	G/A	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs956237	0.966	rs9992763	chr4:109058718	G/T	cg15700776	chr4:108852048	CYP2U1	0.57	4.6	0.43	1.3e-5	Systemic lupus erythematosus;
THYM	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg26597838	chr10:835615	NA	1.58	12.04	0.78	8.01e-21	Eosinophil percentage of granulocytes;
THYM	cis	rs526231	0.578	rs34794	chr5:102423368	T/A	cg23492399	chr5:102201601	PAM	-0.67	-4.96	-0.45	3.05e-6	Primary biliary cholangitis;
THYM	cis	rs1395	1.000	rs7593448	chr2:27449293	C/G	cg23587288	chr2:27483067	SLC30A3	-0.57	-5.16	-0.47	1.36e-6	Blood metabolite levels;
THYM	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-5.83	-0.51	7.7e-8	Total cholesterol levels;
THYM	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1692580	0.846	rs377599	chr1:2164699	C/T	cg21194808	chr1:2205498	SKI	0.32	4.57	0.42	1.45e-5	Coronary artery disease;
THYM	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.01	-6.81	-0.57	8.99e-10	Platelet count;
THYM	cis	rs4986172	0.726	rs12946454	chr17:43208121	A/T	cg00677574	chr17:43221327	ACBD4	0.67	5.55	0.49	2.58e-7	Height;
THYM	cis	rs11690935	0.550	rs62183785	chr2:172866976	G/A	cg13550731	chr2:172543902	DYNC1I2	0.56	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs11997175	0.646	rs12678266	chr8:33689254	A/G	ch.8.33884649F	chr8:33765107	NA	0.66	5.03	0.46	2.33e-6	Body mass index;
THYM	trans	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17712092	chr4:129076599	LARP1B	0.91	7.59	0.61	2.23e-11	Eosinophil percentage of white cells;
THYM	cis	rs12791968	1.000	rs12791968	chr11:45001490	C/T	cg11846598	chr11:44996168	LOC221122	0.93	8.0	0.63	3.08e-12	Inhibitory control;
THYM	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg24818145	chr4:99064322	C4orf37	0.72	5.66	0.5	1.62e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9790314	0.846	rs13083229	chr3:161008125	G/A	cg03342759	chr3:160939853	NMD3	-0.95	-9.47	-0.7	2.2e-15	Morning vs. evening chronotype;
THYM	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg04944784	chr2:26401820	FAM59B	-1.07	-8.38	-0.65	4.66e-13	Gut microbiome composition (summer);
THYM	trans	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg06636001	chr8:8085503	FLJ10661	0.78	6.99	0.58	3.83e-10	Neuroticism;
THYM	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg20007245	chr22:24372913	LOC391322	-0.78	-7.91	-0.63	4.61e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1385374	0.642	rs10847691	chr12:129287449	G/A	cg04043695	chr12:129287642	SLC15A4	-0.79	-4.74	-0.44	7.61e-6	Systemic lupus erythematosus;
THYM	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	10.09	0.72	1.05e-16	Platelet count;
THYM	cis	rs8067545	1.000	rs4925067	chr17:19921222	C/G	cg20830565	chr17:20408647	MGC102966	-0.5	-4.67	-0.43	9.81e-6	Schizophrenia;
THYM	cis	rs1448094	0.512	rs12314274	chr12:86249196	A/G	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg02734326	chr4:10020555	SLC2A9	0.66	5.88	0.52	6.12e-8	Bone mineral density;
THYM	cis	rs4074961	0.565	rs10908362	chr1:38061706	G/C	cg17933807	chr1:38061675	GNL2	1.12	16.56	0.86	9.4e-30	Axial length;
THYM	cis	rs2404602	0.647	rs920712	chr15:77033934	G/A	cg23625390	chr15:77176239	SCAPER	-0.86	-6.08	-0.53	2.47e-8	Blood metabolite levels;
THYM	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg17554472	chr22:41940697	POLR3H	0.7	4.97	0.45	2.97e-6	Cannabis dependence symptom count;
THYM	cis	rs7772486	0.875	rs1929523	chr6:146339989	T/A	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg13736514	chr6:26305472	NA	-0.62	-7.42	-0.61	5.02e-11	Educational attainment;
THYM	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.96e-6	Resting heart rate;
THYM	cis	rs56309584	0.673	rs56256903	chr17:8123128	T/G	cg08322244	chr17:8066669	VAMP2	-0.56	-5.31	-0.48	7.15e-7	Initial pursuit acceleration;
THYM	cis	rs10929159	0.928	rs7557693	chr2:236920713	G/A	cg20128773	chr2:236923534	AGAP1	0.35	4.62	0.43	1.23e-5	Parkinson's disease;
THYM	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg17345569	chr6:42928274	GNMT	-0.48	-4.52	-0.42	1.82e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.22	0.64	1.03e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg16586182	chr3:47516702	SCAP	-0.61	-5.25	-0.47	9.2e-7	Colorectal cancer;
THYM	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg19774624	chr17:42201019	HDAC5	0.66	5.25	0.47	9.36e-7	Total body bone mineral density;
THYM	cis	rs10887741	0.865	rs2281803	chr10:89418564	C/A	cg13926569	chr10:89418898	PAPSS2	-0.66	-7.0	-0.58	3.57e-10	Exercise (leisure time);
THYM	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg26597838	chr10:835615	NA	1.2	8.64	0.66	1.3e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs6942756	1.000	rs13235749	chr7:128879678	C/G	cg02491457	chr7:128862824	NA	-0.44	-4.53	-0.42	1.69e-5	White matter hyperintensity burden;
THYM	cis	rs4919694	1.000	rs111622998	chr10:104953021	C/A	cg04362960	chr10:104952993	NT5C2	1.2	7.45	0.61	4.23e-11	Arsenic metabolism;
THYM	cis	rs7729447	0.776	rs58739438	chr5:32693994	G/C	cg16267343	chr5:32710456	NPR3	0.8	7.2	0.59	1.41e-10	Blood pressure;
THYM	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg04520793	chr17:42248056	ASB16	-0.35	-4.62	-0.43	1.2e-5	Total body bone mineral density;
THYM	cis	rs6956675	0.915	rs7786464	chr7:62615322	C/A	cg08930214	chr7:62859557	LOC100287834	0.62	4.53	0.42	1.71e-5	Obesity-related traits;
THYM	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg19746536	chr19:49375674	PPP1R15A	0.81	4.59	0.43	1.34e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg11266682	chr4:10021025	SLC2A9	0.68	9.74	0.71	5.95e-16	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg18252515	chr7:66147081	NA	-0.66	-5.01	-0.46	2.55e-6	Aortic root size;
THYM	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg11663144	chr21:46675770	NA	-0.7	-9.8	-0.71	4.38e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11723261	0.582	rs4634177	chr4:136837	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.83	5.89	0.52	5.81e-8	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg20387954	chr3:183756860	HTR3D	-0.68	-6.27	-0.54	1.08e-8	Anterior chamber depth;
THYM	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg23173402	chr1:227635558	NA	0.82	6.44	0.55	4.95e-9	Major depressive disorder;
THYM	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17174870	0.910	rs11884693	chr2:112767483	A/G	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg26924012	chr15:45694286	SPATA5L1	0.66	4.86	0.45	4.69e-6	Response to fenofibrate (adiponectin levels);
THYM	cis	rs9583531	0.689	rs9521905	chr13:111352600	G/A	cg24331049	chr13:111365604	ING1	-0.69	-5.34	-0.48	6.35e-7	Coronary artery disease;
THYM	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06481639	chr22:41940642	POLR3H	-0.76	-4.83	-0.44	5.23e-6	Vitiligo;
THYM	cis	rs8133932	0.701	rs9653791	chr21:47303328	G/A	cg20357416	chr21:47294739	PCBP3	-0.88	-5.72	-0.51	1.23e-7	Schizophrenia;
THYM	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg13770153	chr20:60521292	NA	1.31	11.49	0.76	1.14e-19	Obesity-related traits;
THYM	cis	rs939658	0.805	rs11634903	chr15:79436192	C/T	cg17916960	chr15:79447300	NA	0.75	8.77	0.67	6.85e-14	Refractive error;
THYM	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg26384229	chr12:38710491	ALG10B	0.99	7.62	0.62	1.85e-11	Bladder cancer;
THYM	cis	rs12586317	0.576	rs10143314	chr14:35637904	A/T	cg07166546	chr14:35805898	NA	0.19	4.53	0.42	1.68e-5	Psoriasis;
THYM	cis	rs6876348	0.564	rs2577427	chr5:128311818	C/T	cg02841155	chr5:128301328	SLC27A6	-0.54	-5.75	-0.51	1.07e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs728616	0.867	rs61860039	chr10:81939906	G/A	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	trans	rs4650994	1.000	rs4650994	chr1:178515312	A/G	cg05059571	chr16:84539110	KIAA1609	0.72	7.65	0.62	1.64e-11	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.84	-5.3	-0.48	7.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg16928487	chr17:17741425	SREBF1	-0.6	-5.6	-0.5	2.04e-7	Total body bone mineral density;
THYM	cis	rs11690935	1.000	rs312925	chr2:172563922	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.85	-6.26	-0.54	1.09e-8	Schizophrenia;
THYM	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg17279839	chr7:150038598	RARRES2	0.55	5.29	0.48	7.96e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2456568	0.695	rs877341	chr11:93689293	C/T	cg17595323	chr11:93583763	C11orf90	0.51	4.83	0.44	5.33e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg16486109	chr11:613632	IRF7	0.47	5.59	0.5	2.19e-7	Systemic lupus erythematosus;
THYM	cis	rs887829	0.588	rs6715325	chr2:234635241	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.71	-5.64	-0.5	1.74e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9325144	0.723	rs3887436	chr12:39189526	A/C	cg26384229	chr12:38710491	ALG10B	-0.6	-4.62	-0.43	1.18e-5	Morning vs. evening chronotype;
THYM	cis	rs2354432	0.607	rs9661159	chr1:146757923	G/A	cg25205988	chr1:146714368	CHD1L	-1.05	-5.34	-0.48	6.28e-7	Mitochondrial DNA levels;
THYM	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.05	6.85	0.57	7.4e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs863345	0.604	rs12123305	chr1:158498955	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs10493773	0.928	rs12741600	chr1:86191172	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.47	-5.06	-0.46	2.01e-6	Urate levels in overweight individuals;
THYM	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg10254923	chr16:769848	FAM173A	0.54	6.66	0.56	1.8e-9	Height;
THYM	cis	rs870825	0.616	rs7668009	chr4:185641998	A/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs981844	0.712	rs11099914	chr4:154743519	C/T	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.86	0.45	4.66e-6	Obesity-related traits;
THYM	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg06627557	chr7:32535165	LSM5;AVL9	1.03	10.73	0.74	4.6e-18	Cognitive ability;
THYM	cis	rs2562152	0.654	rs216600	chr16:110165	T/C	cg02949481	chr16:131562	MPG	0.75	4.7	0.43	8.82e-6	Glioblastoma;
THYM	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7582180	0.613	rs12988464	chr2:100946285	A/G	cg21926883	chr2:100939477	LONRF2	-0.64	-5.9	-0.52	5.54e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg21280719	chr6:42927975	GNMT	0.53	7.38	0.6	5.9e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9549260	0.564	rs7998724	chr13:41324793	G/T	cg21288729	chr13:41239152	FOXO1	0.7	5.27	0.48	8.56e-7	Red blood cell count;
THYM	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg10452248	chr16:89456354	ANKRD11	0.65	4.71	0.44	8.29e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs10489202	0.634	rs6427119	chr1:168074145	A/G	cg24449463	chr1:168025552	DCAF6	0.71	6.24	0.54	1.2e-8	Schizophrenia;
THYM	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg19346786	chr7:2764209	NA	-0.72	-6.01	-0.52	3.44e-8	Height;
THYM	cis	rs950880	0.710	rs11693955	chr2:103029165	A/T	cg03938978	chr2:103052716	IL18RAP	-0.53	-4.62	-0.43	1.2e-5	Serum protein levels (sST2);
THYM	cis	rs10779751	0.734	rs2748878	chr1:11129434	T/C	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs6980334	0.679	rs1872930	chr7:137801444	C/T	cg11874123	chr7:137028198	PTN	0.63	4.56	0.42	1.53e-5	Blood metabolite ratios;
THYM	cis	rs4930103	1.000	rs4930103	chr11:2024544	G/A	cg06197492	chr11:2016605	H19	0.62	5.44	0.49	4.08e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs6032067	0.777	rs116517830	chr20:43784872	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg20486651	chr6:167070296	RPS6KA2	0.5	4.68	0.43	9.47e-6	Crohn's disease;
THYM	cis	rs7191700	0.836	rs10163410	chr16:11430615	G/C	cg00044050	chr16:11439710	C16orf75	0.67	4.56	0.42	1.53e-5	Multiple sclerosis;
THYM	cis	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.506	rs1883825	chr22:41703408	A/G	cg13695892	chr22:41940480	POLR3H	-0.63	-5.05	-0.46	2.16e-6	Vitiligo;
THYM	cis	rs514406	0.893	rs6588446	chr1:53425260	G/A	cg06600287	chr1:53387719	ECHDC2	0.31	5.1	0.46	1.76e-6	Monocyte count;
THYM	cis	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg00495681	chr13:53174319	NA	0.77	6.95	0.58	4.6e-10	Lewy body disease;
THYM	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg06219351	chr7:158114137	PTPRN2	-0.7	-7.07	-0.59	2.56e-10	Calcium levels;
THYM	cis	rs516946	1.000	rs3802315	chr8:41528178	G/T	cg19441908	chr8:41529140	ANK1	0.61	4.84	0.45	4.92e-6	Type 2 diabetes;
THYM	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg02640540	chr1:67518911	SLC35D1	0.65	4.83	0.44	5.32e-6	Lymphocyte percentage of white cells;
THYM	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg24308560	chr3:49941425	MST1R	0.8	6.84	0.57	7.6e-10	Intelligence (multi-trait analysis);
THYM	cis	rs55637147	0.553	rs894450	chr11:57133371	A/G	cg15971518	chr11:57159174	PRG2	-0.62	-5.12	-0.46	1.62e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs10504073	0.527	rs118032023	chr8:49926296	A/T	cg00325661	chr8:49890786	NA	1.04	10.98	0.75	1.34e-18	Blood metabolite ratios;
THYM	cis	rs981844	1.000	rs2606327	chr4:154653629	C/T	cg09973105	chr4:154681532	RNF175	-0.57	-4.65	-0.43	1.07e-5	Response to statins (LDL cholesterol change);
THYM	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg15501526	chr10:2543763	NA	0.74	6.83	0.57	7.84e-10	Age-related hearing impairment;
THYM	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg17401067	chr22:41840292	TOB2	0.5	4.77	0.44	6.71e-6	Vitiligo;
THYM	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03517284	chr6:25882590	NA	-0.76	-5.98	-0.52	3.87e-8	Blood metabolite levels;
THYM	cis	rs1461503	0.966	rs10790547	chr11:122842110	T/A	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg06238570	chr21:40685208	BRWD1	-0.96	-9.24	-0.69	7.07e-15	Cognitive function;
THYM	cis	rs9902453	0.967	rs8072664	chr17:28333385	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg26384229	chr12:38710491	ALG10B	0.97	7.38	0.6	5.91e-11	Morning vs. evening chronotype;
THYM	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg24803719	chr17:45855879	NA	-0.6	-6.33	-0.54	7.96e-9	IgG glycosylation;
THYM	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg17264618	chr3:40429014	ENTPD3	0.52	4.95	0.45	3.25e-6	Renal cell carcinoma;
THYM	cis	rs34779708	0.966	rs12260130	chr10:35467671	C/T	cg03585969	chr10:35415529	CREM	0.66	4.76	0.44	6.85e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7173743	0.525	rs8027870	chr15:79134045	A/G	cg00540400	chr15:79124168	NA	0.55	5.22	0.47	1.04e-6	Coronary artery disease;
THYM	cis	rs8050907	0.744	rs1345430	chr16:4527961	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.3	5.2	0.47	1.16e-6	Obesity-related traits;
THYM	cis	rs11264213	0.901	rs716925	chr1:36424517	A/G	cg27506609	chr1:36549197	TEKT2	0.92	4.83	0.44	5.3e-6	Schizophrenia;
THYM	cis	rs990171	0.913	rs6718157	chr2:103079814	A/T	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.13	-0.47	1.56e-6	Lymphocyte counts;
THYM	cis	rs78579285	0.510	rs78759106	chr16:88788535	T/C	cg00973732	chr16:88803885	FAM38A	-0.87	-4.49	-0.42	2.02e-5	Joint mobility (Beighton score);
THYM	cis	rs7834588	0.544	rs13277301	chr8:63816442	C/T	cg25248160	chr8:63776642	NKAIN3	-0.62	-5.21	-0.47	1.08e-6	Response to Vitamin E supplementation;
THYM	cis	rs1981331	0.609	rs7279368	chr21:48065999	A/G	cg23283320	chr21:48055893	PRMT2	1.57	7.92	0.63	4.41e-12	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg04267008	chr7:1944627	MAD1L1	-0.66	-5.43	-0.49	4.23e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs9527	0.615	rs12248123	chr10:104735366	A/G	cg15744005	chr10:104629667	AS3MT	-0.6	-4.58	-0.43	1.4e-5	Arsenic metabolism;
THYM	cis	rs11886999	1.000	rs11886999	chr2:96841793	T/C	cg18419276	chr2:96971862	SNRNP200	-0.45	-4.89	-0.45	4.03e-6	Cardiac Troponin-T levels;
THYM	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg00990874	chr7:1149470	C7orf50	-0.61	-5.14	-0.47	1.47e-6	Bronchopulmonary dysplasia;
THYM	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.68	-5.28	-0.48	8.12e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.61e-20	Menopause (age at onset);
THYM	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg15962314	chr1:44399869	ARTN	0.52	4.69	0.43	9.1e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs7027203	1.000	rs7854820	chr9:96526027	A/G	cg14598338	chr9:96623480	NA	0.45	4.81	0.44	5.72e-6	DNA methylation (variation);
THYM	cis	rs988913	0.706	rs10948870	chr6:54745098	G/A	cg04690482	chr6:54711388	FAM83B	0.44	4.58	0.43	1.4e-5	Menarche (age at onset);
THYM	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.82	-6.95	-0.58	4.5e-10	Menarche (age at onset);
THYM	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11890956	chr21:40555474	PSMG1	-0.95	-10.91	-0.75	1.91e-18	Cognitive function;
THYM	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs10899021	0.790	rs10899022	chr11:74339386	C/T	cg25880958	chr11:74394337	NA	-0.72	-4.72	-0.44	7.99e-6	Response to metformin (IC50);
THYM	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg09417038	chr21:47716443	C21orf57	-0.61	-5.13	-0.47	1.55e-6	Testicular germ cell tumor;
THYM	cis	rs684232	0.583	rs2543776	chr17:557149	G/A	cg15660573	chr17:549704	VPS53	-0.9	-9.16	-0.68	1.06e-14	Prostate cancer;
THYM	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg03806693	chr22:41940476	POLR3H	1.25	10.88	0.74	2.22e-18	Vitiligo;
THYM	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs765787	0.530	rs13329228	chr15:45533017	C/T	cg24006582	chr15:45444508	DUOX1	-0.84	-7.2	-0.59	1.39e-10	Uric acid levels;
THYM	cis	rs7719624	0.756	rs2302038	chr5:135397018	A/G	cg15329133	chr5:135467951	SMAD5;SMAD5OS	0.58	5.06	0.46	2.01e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs977987	0.835	rs8046109	chr16:75360096	A/G	cg03315344	chr16:75512273	CHST6	0.88	7.0	0.58	3.59e-10	Dupuytren's disease;
THYM	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg03676636	chr4:99064102	C4orf37	0.5	7.52	0.61	3.06e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.37	6.23	0.54	1.24e-8	Obesity-related traits;
THYM	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg07606381	chr6:8435919	SLC35B3	0.62	4.48	0.42	2.1e-5	Motion sickness;
THYM	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg03159660	chr11:2078197	NA	0.62	4.56	0.42	1.53e-5	Calcium levels;
THYM	cis	rs34779708	0.966	rs10827492	chr10:35429825	A/G	cg03585969	chr10:35415529	CREM	-0.66	-4.76	-0.44	6.85e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7404928	0.707	rs1989647	chr16:23959420	A/G	cg26685404	chr16:23957272	PRKCB	-0.65	-7.25	-0.6	1.11e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg12908607	chr1:44402522	ARTN	-0.54	-4.64	-0.43	1.1e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4786125	1.000	rs4786125	chr16:6900547	G/A	cg03623568	chr16:6915990	A2BP1	-0.8	-6.33	-0.54	7.9e-9	Heart rate variability traits (SDNN);
THYM	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg06634786	chr22:41940651	POLR3H	-0.76	-5.58	-0.5	2.23e-7	Vitiligo;
THYM	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg26384229	chr12:38710491	ALG10B	0.94	7.62	0.62	1.86e-11	Resting heart rate;
THYM	cis	rs9467711	0.651	rs2237228	chr6:26104630	C/T	cg01386294	chr6:25732093	NA	0.88	4.7	0.43	8.83e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6930083	0.605	rs3829964	chr6:36644498	T/C	cg11920449	chr6:36645608	CDKN1A	-0.79	-6.72	-0.57	1.32e-9	Coronary artery disease;
THYM	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11644478	chr21:40555479	PSMG1	-0.82	-7.39	-0.6	5.7e-11	Cognitive function;
THYM	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2066819	1.000	rs59295315	chr12:56708576	G/A	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs912057	0.833	rs1024245	chr6:6743319	A/G	cg06612196	chr6:6737390	NA	0.69	9.83	0.71	3.75e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg23815491	chr16:72088622	HP	0.81	6.62	0.56	2.09e-9	Fibrinogen levels;
THYM	cis	rs6480314	0.636	rs61854790	chr10:70002248	T/G	cg27159792	chr10:69524182	NA	0.81	4.89	0.45	4.06e-6	Optic nerve measurement (disc area);
THYM	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg24375607	chr4:120327624	NA	-0.65	-5.3	-0.48	7.61e-7	Corneal astigmatism;
THYM	cis	rs9355610	0.727	rs2247315	chr6:167370211	A/C	cg00271210	chr6:167070053	RPS6KA2	0.48	4.65	0.43	1.08e-5	Graves' disease;
THYM	cis	rs7104764	1.000	rs10794302	chr11:234102	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.11	9.81	0.71	4.22e-16	Menarche (age at onset);
THYM	cis	rs66887589	0.934	rs56843000	chr4:120516597	T/C	cg13609457	chr4:120235615	NA	-0.47	-4.93	-0.45	3.55e-6	Diastolic blood pressure;
THYM	cis	rs28374715	0.662	rs13329579	chr15:41467435	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.02	-8.4	-0.65	4.27e-13	Ulcerative colitis;
THYM	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg08999081	chr20:33150536	PIGU	0.58	4.78	0.44	6.4e-6	Height;
THYM	cis	rs6032067	0.810	rs62208441	chr20:43839360	T/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.69	-6.65	-0.56	1.88e-9	Blood protein levels;
THYM	cis	rs5985	0.583	rs7758057	chr6:6307578	C/G	cg22185065	chr6:6318785	F13A1	-0.58	-4.55	-0.42	1.56e-5	End-stage coagulation;
THYM	cis	rs9560113	0.573	rs7988040	chr13:112226534	C/G	cg10483660	chr13:112241077	NA	0.7	8.37	0.65	4.93e-13	Menarche (age at onset);
THYM	cis	rs12579753	1.000	rs11115047	chr12:82232773	C/G	cg07988820	chr12:82153109	PPFIA2	-0.72	-4.47	-0.42	2.2e-5	Resting heart rate;
THYM	cis	rs1007190	0.570	rs12185253	chr17:42867957	C/T	cg15406952	chr17:42872593	NA	-0.7	-4.98	-0.46	2.79e-6	DNA methylation (variation);
THYM	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg27211696	chr2:191398769	TMEM194B	-0.64	-4.55	-0.42	1.59e-5	Diastolic blood pressure;
THYM	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg08736216	chr1:53307985	ZYG11A	0.66	5.22	0.47	1.04e-6	Monocyte count;
THYM	cis	rs7084402	0.967	rs1620404	chr10:60327830	G/A	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg13609457	chr4:120235615	NA	0.62	5.4	0.48	4.91e-7	Corneal astigmatism;
THYM	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11890956	chr21:40555474	PSMG1	1.15	12.23	0.78	3.25e-21	Cognitive function;
THYM	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	5.72	0.51	1.23e-7	Platelet count;
THYM	cis	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg26384229	chr12:38710491	ALG10B	0.79	6.07	0.53	2.65e-8	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4866334	1.000	rs79823740	chr5:18488814	T/C	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg26384229	chr12:38710491	ALG10B	0.73	5.59	0.5	2.2e-7	Morning vs. evening chronotype;
THYM	cis	rs9796	0.662	rs8033435	chr15:41436479	C/T	cg21153102	chr15:41252147	NA	0.6	4.93	0.45	3.43e-6	Menopause (age at onset);
THYM	cis	rs4589258	0.933	rs7102581	chr11:90396327	T/C	cg26138821	chr11:89956704	CHORDC1	0.71	6.0	0.52	3.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg16928487	chr17:17741425	SREBF1	-0.55	-5.39	-0.48	5.05e-7	Total body bone mineral density;
THYM	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7399018	0.739	rs7399073	chr12:51614050	C/A	cg10377582	chr12:51612794	POU6F1	-0.6	-4.46	-0.42	2.26e-5	Cisplatin-induced ototoxicity;
THYM	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg20203395	chr5:56204925	C5orf35	-0.65	-4.47	-0.42	2.15e-5	Initial pursuit acceleration;
THYM	cis	rs2797160	1.000	rs1418639	chr6:125999940	C/T	cg16306078	chr6:126000798	NA	-0.53	-5.51	-0.49	3.09e-7	Endometrial cancer;
THYM	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.89	0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs289828	0.507	rs12987765	chr2:152127902	T/C	cg05960677	chr2:152117363	RBM43	0.76	8.1	0.64	1.82e-12	Blood protein levels;
THYM	cis	rs6988636	1.000	rs16898086	chr8:124190445	A/G	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg20203395	chr5:56204925	C5orf35	-0.67	-4.58	-0.42	1.44e-5	Initial pursuit acceleration;
THYM	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg23428387	chr22:49814324	NA	-0.51	-4.91	-0.45	3.78e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7833986	1.000	rs61690651	chr8:57096661	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	4.85	0.45	4.74e-6	Height;
THYM	cis	rs28795989	0.862	rs35661042	chr4:7887427	G/C	cg12728606	chr4:7903970	AFAP1	0.44	4.64	0.43	1.09e-5	Intraocular pressure;
THYM	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg20486651	chr6:167070296	RPS6KA2	-0.46	-4.51	-0.42	1.82e-5	Crohn's disease;
THYM	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11890956	chr21:40555474	PSMG1	1.16	12.2	0.78	3.69e-21	Cognitive function;
THYM	trans	rs8073060	0.516	rs2376177	chr17:33938089	T/G	cg19694781	chr19:47549865	TMEM160	-1.05	-9.1	-0.68	1.42e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17712092	chr4:129076599	LARP1B	0.9	7.57	0.61	2.39e-11	Eosinophil percentage of white cells;
THYM	cis	rs7043114	0.507	rs10761154	chr9:95144086	A/G	cg14631576	chr9:95140430	CENPP	-0.86	-9.03	-0.68	1.97e-14	Height;
THYM	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg00801512	chr17:28996047	NA	-0.76	-5.02	-0.46	2.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7216064	1.000	rs8072225	chr17:65912960	A/G	cg12091567	chr17:66097778	LOC651250	-0.73	-5.18	-0.47	1.25e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	18.96	0.89	4.77e-34	Chronic sinus infection;
THYM	cis	rs533581	0.866	rs502258	chr16:88968547	G/A	cg08484992	chr16:88977278	CBFA2T3	0.45	5.48	0.49	3.52e-7	Social autistic-like traits;
THYM	cis	rs11039798	1.000	rs7942042	chr11:48520270	A/G	cg24672777	chr11:48374446	OR4C45	-1.14	-6.89	-0.58	6.15e-10	Axial length;
THYM	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg23711669	chr6:146136114	FBXO30	0.98	10.47	0.73	1.68e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs62435770	1.000	rs62435789	chr6:169473870	G/A	cg07652237	chr6:170125491	PHF10	0.56	4.87	0.45	4.47e-6	Loneliness;
THYM	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg03474202	chr17:45855739	NA	-0.76	-6.7	-0.57	1.45e-9	IgG glycosylation;
THYM	cis	rs62151617	0.509	rs11689855	chr2:70809571	A/C	cg04871472	chr2:70268913	NA	0.44	4.69	0.43	9.32e-6	Hair shape;
THYM	cis	rs673253	0.556	rs55666439	chr1:44111212	T/G	cg24466421	chr1:44070974	PTPRF	-0.59	-5.09	-0.46	1.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg04398451	chr17:18023971	MYO15A	-0.83	-7.74	-0.62	1.04e-11	Total body bone mineral density;
THYM	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg06600287	chr1:53387719	ECHDC2	-0.29	-4.69	-0.43	9.17e-6	Monocyte count;
THYM	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg10792982	chr14:105748885	BRF1	0.74	7.6	0.62	2.03e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs259282	0.605	rs73028624	chr19:33111758	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.72	6.1	0.53	2.28e-8	Schizophrenia;
THYM	cis	rs7119038	0.818	rs4936441	chr11:118725660	C/G	cg19308663	chr11:118741387	NA	-0.58	-5.56	-0.5	2.52e-7	Sjögren's syndrome;
THYM	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg02734326	chr4:10020555	SLC2A9	0.76	6.89	0.58	6.15e-10	Bone mineral density;
THYM	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg05660106	chr1:15850417	CASP9	0.73	6.14	0.53	1.88e-8	Systolic blood pressure;
THYM	cis	rs9790314	0.747	rs4616689	chr3:160856269	A/G	cg04691961	chr3:161091175	C3orf57	-0.6	-4.63	-0.43	1.14e-5	Morning vs. evening chronotype;
THYM	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg00129232	chr17:37814104	STARD3	0.69	4.51	0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg08999081	chr20:33150536	PIGU	-0.75	-6.5	-0.55	3.72e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs1568889	0.712	rs10835306	chr11:28302410	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs7584330	0.868	rs7571898	chr2:238383028	T/C	cg14458575	chr2:238380390	NA	0.96	7.75	0.62	1.01e-11	Prostate cancer;
THYM	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg18876405	chr7:65276391	NA	0.74	6.93	0.58	5.06e-10	Calcium levels;
THYM	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg13319975	chr6:146136371	FBXO30	-0.69	-5.68	-0.5	1.5e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7127900	0.583	rs11043147	chr11:2234169	C/G	cg25635251	chr11:2234043	NA	0.75	5.7	0.5	1.33e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs3825942	1.000	rs8034403	chr15:74222028	G/A	cg23484268	chr15:74220776	LOXL1	0.5	4.81	0.44	5.74e-6	Glaucoma (exfoliation);
THYM	cis	rs11186	0.524	rs72908338	chr2:189976977	C/T	cg11041835	chr2:189156425	GULP1	0.8	4.52	0.42	1.79e-5	Parkinson's disease;
THYM	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg06009448	chr7:1102226	C7orf50	0.52	5.44	0.49	4.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs939658	0.805	rs34222382	chr15:79440748	C/T	cg17916960	chr15:79447300	NA	-0.75	-8.85	-0.67	4.67e-14	Refractive error;
THYM	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4974559	0.790	rs2293631	chr4:1315917	C/A	cg02980000	chr4:1222292	CTBP1	0.81	5.18	0.47	1.23e-6	Systolic blood pressure;
THYM	cis	rs877282	0.898	rs10904546	chr10:757222	A/G	cg10556349	chr10:835070	NA	-0.77	-4.95	-0.45	3.24e-6	Uric acid levels;
THYM	cis	rs35883536	0.647	rs59667512	chr1:101046712	C/T	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs7546094	1.000	rs3103450	chr1:113197730	G/A	cg22162597	chr1:113214053	CAPZA1	-0.48	-4.9	-0.45	3.87e-6	Platelet distribution width;
THYM	cis	rs10791097	0.728	rs10894265	chr11:130714613	T/C	cg05962950	chr11:130786565	SNX19	-0.7	-5.54	-0.49	2.65e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	6.52	0.56	3.31e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg04772025	chr11:68637568	NA	0.61	6.23	0.54	1.26e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6669072	1.000	rs6669072	chr1:91247345	C/T	cg08895590	chr1:91227319	NA	-0.52	-5.89	-0.52	5.71e-8	Cognitive function;
THYM	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs981844	1.000	rs2606335	chr4:154656536	T/C	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs28476539	0.640	rs7672265	chr4:83554822	G/T	cg10249074	chr4:83542146	C4orf11	-0.64	-5.06	-0.46	2.03e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg12463550	chr7:65579703	CRCP	0.59	4.77	0.44	6.58e-6	Aortic root size;
THYM	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg11764359	chr7:65958608	NA	-0.7	-4.89	-0.45	4.09e-6	Aortic root size;
THYM	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs148406912	1	rs148406912	chr11:116837717	T/C	cg20608306	chr11:116969690	SIK3	-0.72	-5.21	-0.47	1.09e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg00024416	chr22:24240387	NA	0.8	7.81	0.63	7.61e-12	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg18681998	chr4:17616180	MED28	-0.76	-6.53	-0.56	3.15e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9326248	0.530	rs11216171	chr11:116749113	T/A	cg20608306	chr11:116969690	SIK3	0.57	5.86	0.52	6.64e-8	Blood protein levels;
THYM	cis	rs921968	0.565	rs6436073	chr2:219618237	A/C	cg02176678	chr2:219576539	TTLL4	-0.47	-4.56	-0.42	1.55e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg24209194	chr3:40518798	ZNF619	0.55	4.49	0.42	2.02e-5	Renal cell carcinoma;
THYM	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg00271210	chr6:167070053	RPS6KA2	-0.71	-7.66	-0.62	1.54e-11	Crohn's disease;
THYM	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg13319975	chr6:146136371	FBXO30	0.65	5.26	0.48	8.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7584330	0.740	rs7586312	chr2:238439389	G/A	cg16989719	chr2:238392110	NA	-0.49	-4.71	-0.44	8.48e-6	Prostate cancer;
THYM	cis	rs8016982	0.610	rs2371570	chr14:81709686	C/T	cg01989461	chr14:81687754	GTF2A1	0.87	7.71	0.62	1.24e-11	Schizophrenia;
THYM	cis	rs921968	0.541	rs17462853	chr2:219345637	T/G	cg02176678	chr2:219576539	TTLL4	-0.73	-7.24	-0.6	1.18e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11690462	0.534	rs6546949	chr2:26592429	T/C	cg11525280	chr2:26624667	C2orf39	-0.52	-5.18	-0.47	1.27e-6	Coronary artery disease;
THYM	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg10589385	chr1:150898437	SETDB1	0.64	5.48	0.49	3.48e-7	Tonsillectomy;
THYM	cis	rs2219968	0.561	rs1386339	chr8:78877256	A/G	cg00738934	chr8:78996279	NA	0.61	4.93	0.45	3.5e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.79	-6.79	-0.57	9.84e-10	Lung cancer;
THYM	cis	rs10504073	0.647	rs11997959	chr8:50014044	C/T	cg00325661	chr8:49890786	NA	0.86	7.69	0.62	1.35e-11	Blood metabolite ratios;
THYM	cis	rs2806561	0.929	rs641452	chr1:23538386	A/G	cg19743168	chr1:23544995	NA	0.7	7.69	0.62	1.38e-11	Height;
THYM	cis	rs7404928	0.651	rs8055482	chr16:23949999	T/C	cg26685404	chr16:23957272	PRKCB	0.61	7.09	0.59	2.38e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs7267979	1.000	rs6050547	chr20:25326012	C/T	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs644799	0.562	rs671320	chr11:95578780	G/T	cg14972814	chr11:95582409	MTMR2	-0.65	-5.56	-0.5	2.51e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4786125	0.665	rs6500858	chr16:6906111	T/C	cg03623568	chr16:6915990	A2BP1	-1.04	-10.4	-0.73	2.36e-17	Heart rate variability traits (SDNN);
THYM	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12410462	0.581	rs4329477	chr1:227552494	A/G	cg23173402	chr1:227635558	NA	-0.65	-5.17	-0.47	1.31e-6	Major depressive disorder;
THYM	cis	rs10929159	0.894	rs1349729	chr2:236928217	A/G	cg20128773	chr2:236923534	AGAP1	0.35	4.74	0.44	7.39e-6	Parkinson's disease;
THYM	cis	rs6446298	0.738	rs1060970	chr3:49708769	T/C	cg03060546	chr3:49711283	APEH	0.93	6.51	0.56	3.54e-9	Intelligence (multi-trait analysis);
THYM	cis	rs2456568	0.543	rs4144616	chr11:93621900	A/G	cg26875233	chr11:93583750	C11orf90	-0.49	-5.07	-0.46	1.96e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs6121246	0.559	rs6119728	chr20:30413121	G/A	cg13852791	chr20:30311386	BCL2L1	0.87	8.17	0.64	1.31e-12	Mean corpuscular hemoglobin;
THYM	cis	rs79149102	0.579	rs7179097	chr15:75279240	T/G	cg09165964	chr15:75287851	SCAMP5	-1.08	-5.99	-0.52	3.79e-8	Lung cancer;
THYM	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	7.44	0.61	4.46e-11	Platelet count;
THYM	cis	rs58235267	0.544	rs12478556	chr2:63341711	T/A	cg17519650	chr2:63277830	OTX1	0.67	5.46	0.49	3.76e-7	Prostate-specific antigen levels (conditioned on lead SNPs);
THYM	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9429544	0.568	rs71664843	chr1:114978607	G/A	cg19304150	chr1:114696350	SYT6	0.59	4.46	0.42	2.24e-5	Mean corpuscular hemoglobin;
THYM	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg23711669	chr6:146136114	FBXO30	0.92	9.0	0.68	2.32e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4731207	0.724	rs4383910	chr7:124540841	A/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	4.46	0.42	2.21e-5	Diabetic retinopathy;
THYM	cis	rs669446	0.533	rs3791041	chr1:44202991	A/G	cg12599982	chr1:44399894	ARTN	0.52	4.74	0.44	7.55e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg18512352	chr11:47633146	NA	-0.51	-6.09	-0.53	2.34e-8	Subjective well-being;
THYM	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg03806693	chr22:41940476	POLR3H	-1.02	-8.03	-0.64	2.62e-12	Vitiligo;
THYM	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg24209194	chr3:40518798	ZNF619	-0.69	-5.98	-0.52	3.94e-8	Renal cell carcinoma;
THYM	cis	rs1398942	0.522	rs2056012	chr4:89993459	C/T	cg17769793	chr4:89976368	FAM13A	-0.44	-4.66	-0.43	1.02e-5	Post bronchodilator FEV1;
THYM	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg01073479	chr16:3509474	NAT15	0.54	5.23	0.47	1e-6	Tuberculosis;
THYM	cis	rs8105265	1	rs8105265	chr19:2920705	A/G	cg08634464	chr19:2901147	ZNF57	1.37	7.43	0.61	4.8e-11	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.4	0.48	4.9e-7	Melanoma;
THYM	cis	rs1178127	0.608	rs3854289	chr7:18826692	T/C	cg13420273	chr7:18810212	HDAC9	-0.65	-5.69	-0.5	1.43e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs66887589	0.934	rs6817317	chr4:120542827	A/G	cg13609457	chr4:120235615	NA	-0.47	-4.95	-0.45	3.27e-6	Diastolic blood pressure;
THYM	cis	rs611744	0.967	rs603889	chr8:109224232	C/T	cg21045802	chr8:109455806	TTC35	0.59	5.25	0.47	9.08e-7	Dupuytren's disease;
THYM	trans	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs9297145	0.585	rs10953283	chr7:98782750	A/G	cg05967295	chr7:98741636	SMURF1	0.65	5.17	0.47	1.3e-6	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs2282300	0.739	rs1222215	chr11:30347596	C/T	cg09906309	chr11:30344399	C11orf46	-0.73	-5.37	-0.48	5.47e-7	Morning vs. evening chronotype;
THYM	cis	rs921968	0.643	rs484085	chr2:219396684	C/T	cg02176678	chr2:219576539	TTLL4	0.68	6.71	0.57	1.42e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2108622	0.727	rs2158511	chr19:15986647	C/T	cg13772218	chr19:15982569	NA	0.5	4.48	0.42	2.06e-5	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs8064299	0.574	rs1879455	chr17:72774738	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.9	8.72	0.67	8.9e-14	Monocyte count;
THYM	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg06221963	chr1:154839813	KCNN3	-0.8	-8.98	-0.68	2.53e-14	Prostate cancer;
THYM	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs72828912	0.831	rs10806983	chr6:24094895	A/C	cg19882886	chr6:25043046	NA	-0.86	-5.89	-0.52	5.95e-8	Squamous cell lung carcinoma;
THYM	cis	rs16912285	0.636	rs7114960	chr11:24310828	G/A	ch.11.24196551F	chr11:24239977	NA	0.99	7.0	0.58	3.56e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs12476592	0.516	rs6717060	chr2:63568608	G/A	cg17519650	chr2:63277830	OTX1	-0.67	-4.56	-0.42	1.52e-5	Childhood ear infection;
THYM	cis	rs950881	0.932	rs13408569	chr2:102955056	G/C	cg20060108	chr2:102954350	IL1RL1	0.85	4.68	0.43	9.48e-6	Allergy;
THYM	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg06481639	chr22:41940642	POLR3H	-0.69	-5.3	-0.48	7.4e-7	Neuroticism;
THYM	cis	rs6429082	0.967	rs704710	chr1:235621026	A/G	cg26050004	chr1:235667680	B3GALNT2	0.54	4.78	0.44	6.47e-6	Adiposity;
THYM	cis	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg13789015	chr9:136890014	NCRNA00094	0.83	7.04	0.59	3e-10	Platelet distribution width;
THYM	cis	rs3849570	1.000	rs4411908	chr3:81802418	A/C	cg07356753	chr3:81810745	GBE1	-0.78	-5.67	-0.5	1.54e-7	Waist circumference;Body mass index;
THYM	cis	rs4938534	0.559	rs1944919	chr11:111259876	A/C	cg24049888	chr11:111250129	POU2AF1	0.5	4.69	0.43	9.18e-6	Primary biliary cholangitis;
THYM	cis	rs1387259	0.839	rs7487682	chr12:48579665	A/C	cg21466736	chr12:48725269	NA	0.5	4.83	0.44	5.18e-6	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs7586879	0.639	rs3903070	chr2:25123463	C/G	cg27107076	chr2:25050844	ADCY3	-0.29	-4.72	-0.44	8.01e-6	Body mass index;
THYM	cis	rs4631830	0.900	rs11006274	chr10:51540291	C/T	cg16070123	chr10:51489643	NA	0.5	4.48	0.42	2.11e-5	Prostate-specific antigen levels;
THYM	cis	rs6866344	0.697	rs61247551	chr5:178133503	G/A	cg10224037	chr5:178157518	ZNF354A	0.95	7.68	0.62	1.38e-11	Neutrophil percentage of white cells;
THYM	cis	rs4595586	0.545	rs6580892	chr12:39370237	G/C	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs775227	0.574	rs55693215	chr3:113064094	T/C	cg18753928	chr3:113234510	CCDC52	-0.76	-5.24	-0.47	9.81e-7	Dental caries;
THYM	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg26354017	chr1:205819088	PM20D1	0.59	4.79	0.44	6.26e-6	Parkinson's disease;
THYM	cis	rs11039798	0.512	rs3974936	chr11:49005012	C/T	cg24672777	chr11:48374446	OR4C45	-0.93	-5.81	-0.51	8.44e-8	Axial length;
THYM	cis	rs1348850	0.561	rs4893956	chr2:178373452	C/T	cg27490568	chr2:178487706	NA	0.68	5.53	0.49	2.77e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6840360	0.967	rs10028961	chr4:152668224	A/G	cg22705602	chr4:152727874	NA	-0.58	-6.26	-0.54	1.1e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9914988	0.943	rs7224870	chr17:27102620	A/G	cg20469991	chr17:27169893	C17orf63	-0.88	-5.34	-0.48	6.44e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs4076764	0.846	rs7525724	chr1:163426372	G/A	cg24596788	chr1:163392923	NA	-0.74	-6.47	-0.55	4.33e-9	Motion sickness;
THYM	cis	rs8058578	1.000	rs6565197	chr16:30706477	T/C	cg05768032	chr16:30646687	NA	0.56	5.61	0.5	1.98e-7	Multiple myeloma;
THYM	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg23711669	chr6:146136114	FBXO30	-0.85	-8.02	-0.64	2.76e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4845570	1.000	rs6681093	chr1:151755284	C/G	cg07092448	chr1:151763213	TDRKH	-0.8	-5.8	-0.51	8.72e-8	Coronary artery disease;
THYM	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg07606381	chr6:8435919	SLC35B3	0.62	4.62	0.43	1.21e-5	Motion sickness;
THYM	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs977987	0.806	rs6564258	chr16:75447363	G/A	cg03315344	chr16:75512273	CHST6	0.76	6.16	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg24375607	chr4:120327624	NA	0.58	4.74	0.44	7.61e-6	Corneal astigmatism;
THYM	cis	rs2219968	0.743	rs7833315	chr8:78931987	T/C	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg23422044	chr7:1970798	MAD1L1	-0.79	-5.24	-0.47	9.83e-7	Bipolar disorder;
THYM	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg23281280	chr6:28129359	ZNF389	0.61	4.88	0.45	4.21e-6	Depression;
THYM	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs6951245	0.505	rs56117635	chr7:1030034	G/C	cg02778551	chr7:1045947	C7orf50	-0.97	-4.55	-0.42	1.59e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs939658	0.683	rs11634726	chr15:79465894	A/G	cg17916960	chr15:79447300	NA	-0.67	-7.7	-0.62	1.3e-11	Refractive error;
THYM	cis	rs10227331	0.934	rs2302447	chr7:157295985	A/T	cg04156418	chr7:157293606	NA	0.88	8.05	0.64	2.36e-12	Inattentive symptoms;
THYM	cis	rs1728785	0.901	rs7194664	chr16:68643313	T/C	cg02972257	chr16:68554789	NA	-0.71	-4.59	-0.43	1.37e-5	Ulcerative colitis;
THYM	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg15247329	chr7:2764246	NA	-0.75	-6.6	-0.56	2.38e-9	Height;
THYM	cis	rs6901250	0.851	rs339362	chr6:117165370	A/C	cg12892004	chr6:117198278	RFX6	-0.71	-6.97	-0.58	4.22e-10	C-reactive protein levels;
THYM	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg03264133	chr6:25882463	NA	0.67	5.59	0.5	2.19e-7	Blood metabolite levels;
THYM	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg02734326	chr4:10020555	SLC2A9	-0.6	-4.75	-0.44	7.18e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg04398451	chr17:18023971	MYO15A	-0.93	-9.06	-0.68	1.68e-14	Total body bone mineral density;
THYM	cis	rs9318086	0.712	rs1886970	chr13:24440498	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.5	4.47	0.42	2.13e-5	Myopia (pathological);
THYM	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs6748734	0.600	rs10933510	chr2:241826754	G/A	cg09990169	chr2:241835740	C2orf54	-0.31	-5.03	-0.46	2.34e-6	Urinary metabolites;
THYM	cis	rs863345	0.604	rs949397	chr1:158461951	G/T	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg02931644	chr1:25747376	RHCE	0.59	4.5	0.42	1.9e-5	Erythrocyte sedimentation rate;
THYM	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-5.64	-0.5	1.78e-7	Morning vs. evening chronotype;
THYM	cis	rs332507	0.750	rs3755680	chr3:124356460	A/G	cg14688451	chr3:124303035	KALRN	0.59	4.59	0.43	1.35e-5	Plateletcrit;
THYM	cis	rs12530845	0.887	rs6948382	chr7:135323576	G/A	cg23117316	chr7:135346802	PL-5283	-0.69	-6.01	-0.52	3.49e-8	Red blood cell traits;
THYM	cis	rs4845875	0.529	rs6680385	chr1:11831756	A/G	cg06193043	chr1:11908199	NPPA	0.54	4.56	0.42	1.52e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.77	4.68	0.43	9.49e-6	Diabetic retinopathy;
THYM	cis	rs3819817	0.575	rs2043608	chr12:96354455	C/G	cg26410635	chr12:96350720	AMDHD1	0.53	5.01	0.46	2.55e-6	Vitamin D levels;
THYM	cis	rs28795989	0.896	rs7437984	chr4:7887588	T/C	cg12728606	chr4:7903970	AFAP1	0.44	4.64	0.43	1.09e-5	Intraocular pressure;
THYM	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs6430585	0.528	rs309158	chr2:136680534	A/G	cg04750100	chr2:136595281	LCT	0.56	5.87	0.52	6.36e-8	Corneal structure;
THYM	cis	rs9814567	1.000	rs9989967	chr3:134238964	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-8.41	-0.65	4e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.8	-5.41	-0.49	4.66e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg07606381	chr6:8435919	SLC35B3	0.62	4.64	0.43	1.11e-5	Motion sickness;
THYM	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg15556689	chr8:8085844	FLJ10661	0.69	5.91	0.52	5.33e-8	Mood instability;
THYM	cis	rs2288884	0.806	rs59667666	chr19:52586194	A/G	cg05974498	chr19:52599256	ZNF841	0.36	4.67	0.43	9.88e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg07027457	chr16:89025522	CBFA2T3	0.62	5.38	0.48	5.28e-7	Social autistic-like traits;
THYM	cis	rs2797160	1.000	rs78602343	chr6:126019768	T/C	cg16306078	chr6:126000798	NA	0.52	5.19	0.47	1.19e-6	Endometrial cancer;
THYM	cis	rs5758511	0.508	rs2854827	chr22:42461918	G/A	cg01059385	chr22:42394853	WBP2NL	0.7	4.73	0.44	7.72e-6	Birth weight;
THYM	cis	rs28595532	0.920	rs17324884	chr4:119771477	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg18256630	chr15:75040318	CYP1A2	-0.94	-6.92	-0.58	5.28e-10	Depressive symptoms;
THYM	cis	rs1747683	0.932	rs10752298	chr10:13382754	T/C	cg11679871	chr10:13388567	SEPHS1	-0.31	-4.6	-0.43	1.3e-5	IgG glycosylation;
THYM	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg20476274	chr7:133979776	SLC35B4	0.67	4.62	0.43	1.22e-5	Mean platelet volume;
THYM	cis	rs11771526	1.000	rs117890465	chr7:32351009	A/C	cg27511599	chr7:32358540	NA	0.65	4.51	0.42	1.83e-5	Body mass index;
THYM	cis	rs3820068	0.580	rs61169376	chr1:16003832	A/G	cg05660106	chr1:15850417	CASP9	0.72	5.8	0.51	8.78e-8	Systolic blood pressure;
THYM	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg12963246	chr6:28129442	ZNF389	0.51	4.53	0.42	1.72e-5	Parkinson's disease;
THYM	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs7814319	0.600	rs111300519	chr8:97262939	G/A	cg20787634	chr8:97240163	UQCRB	-0.72	-6.45	-0.55	4.65e-9	Lung function (FVC);
THYM	cis	rs10924970	0.934	rs3856241	chr1:235429692	G/A	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs7084402	0.967	rs11006171	chr10:60278487	C/T	cg09696939	chr10:60272079	BICC1	0.47	5.53	0.49	2.84e-7	Refractive error;
THYM	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.78	-0.44	6.31e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7639513	0.767	rs2348201	chr3:12711696	A/G	cg23032965	chr3:12705835	RAF1	0.99	7.86	0.63	5.93e-12	Itch intensity from mosquito bite;
THYM	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg16414030	chr3:133502952	NA	-0.84	-8.47	-0.66	3.08e-13	Iron status biomarkers;
THYM	cis	rs2131877	0.871	rs62290351	chr3:194856979	G/A	cg21937377	chr3:194868750	C3orf21	0.42	5.18	0.47	1.25e-6	Non-small cell lung cancer;
THYM	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07167872	chr1:205819463	PM20D1	0.75	6.75	0.57	1.18e-9	Menarche (age at onset);
THYM	cis	rs7178572	0.568	rs4886850	chr15:77404160	G/C	cg22256960	chr15:77711686	NA	-0.93	-7.23	-0.6	1.24e-10	Type 2 diabetes;
THYM	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg21211367	chr2:162094118	NA	-0.57	-4.92	-0.45	3.59e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs9534288	0.797	rs718530	chr13:46563653	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-4.52	-0.42	1.8e-5	Blood protein levels;
THYM	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs61931739	0.635	rs1405024	chr12:33937939	A/T	cg06521331	chr12:34319734	NA	0.57	4.76	0.44	7e-6	Morning vs. evening chronotype;
THYM	cis	rs4654899	0.758	rs6426667	chr1:21396216	C/A	cg01072550	chr1:21505969	NA	-0.75	-7.23	-0.6	1.25e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg19052272	chr2:3704530	ALLC	0.61	4.72	0.44	8.26e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs10851411	0.695	rs11636577	chr15:42775650	A/G	cg04857231	chr15:42782520	NA	0.42	4.51	0.42	1.86e-5	Glucose homeostasis traits;
THYM	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg22089800	chr15:90895588	ZNF774	0.68	5.26	0.47	9e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg02734326	chr4:10020555	SLC2A9	0.77	6.8	0.57	9.29e-10	Bone mineral density;
THYM	cis	rs6669072	0.565	rs10801830	chr1:91272173	G/A	cg08895590	chr1:91227319	NA	-0.39	-4.45	-0.42	2.32e-5	Cognitive function;
THYM	cis	rs951188	0.688	rs77097900	chr2:150437428	T/C	cg17961725	chr2:150454027	NA	-1.02	-5.39	-0.48	5.12e-7	Daytime sleep phenotypes;
THYM	cis	rs7191700	0.509	rs415595	chr16:11363692	A/G	cg00044050	chr16:11439710	C16orf75	0.66	4.91	0.45	3.76e-6	Multiple sclerosis;
THYM	cis	rs4654899	0.680	rs2305463	chr1:21180181	C/T	cg01072550	chr1:21505969	NA	0.71	6.87	0.58	6.59e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs289828	0.579	rs6433325	chr2:152154547	G/A	cg05960677	chr2:152117363	RBM43	0.69	6.55	0.56	2.88e-9	Blood protein levels;
THYM	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg22920501	chr2:26401640	FAM59B	-1.05	-9.24	-0.69	6.92e-15	Gut microbiome composition (summer);
THYM	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg06565975	chr8:143823917	SLURP1	-0.76	-8.91	-0.67	3.46e-14	Urinary tract infection frequency;
THYM	cis	rs250677	0.522	rs10038913	chr5:148354224	A/G	cg18129178	chr5:148520854	ABLIM3	0.72	5.42	0.49	4.44e-7	Breast cancer;
THYM	cis	rs4589258	0.788	rs4488164	chr11:90465418	T/C	cg26138821	chr11:89956704	CHORDC1	-0.58	-4.8	-0.44	6.01e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2836633	0.929	rs11702165	chr21:40035313	C/T	cg12884169	chr21:40033163	ERG	0.67	8.36	0.65	5.18e-13	Coronary artery disease;
THYM	cis	rs2888875	0.562	rs66702817	chr2:43826080	A/C	cg22033476	chr2:43532275	THADA	-0.4	-4.61	-0.43	1.26e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs7119	0.651	rs8041398	chr15:77839173	A/G	cg10437265	chr15:77819839	NA	0.78	7.77	0.62	9.08e-12	Type 2 diabetes;
THYM	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg03609598	chr5:56110824	MAP3K1	-0.84	-5.73	-0.51	1.16e-7	Initial pursuit acceleration;
THYM	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	4.97	0.45	3e-6	Height;
THYM	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2070433	0.556	rs8129460	chr21:47822544	C/T	cg12379764	chr21:47803548	PCNT	0.81	4.88	0.45	4.34e-6	Lymphocyte counts;
THYM	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg22431228	chr1:16359049	CLCNKA	-0.52	-4.99	-0.46	2.71e-6	Dilated cardiomyopathy;
THYM	cis	rs17854409	0.764	rs8116995	chr20:61475824	A/G	cg06598544	chr20:61472147	COL9A3	-1.13	-7.37	-0.6	6.16e-11	Obesity-related traits;
THYM	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08704250	chr15:31115839	NA	-0.7	-7.88	-0.63	5.33e-12	Huntington's disease progression;
THYM	cis	rs1933112	1.000	rs10753777	chr1:168527787	T/G	cg00154920	chr1:168513310	XCL2	-0.51	-5.07	-0.46	1.94e-6	Blood protein levels;
THYM	cis	rs863345	0.604	rs7548349	chr1:158493726	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg11266682	chr4:10021025	SLC2A9	0.74	10.8	0.74	3.21e-18	Bone mineral density;
THYM	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg07870213	chr5:140052090	DND1	0.69	7.56	0.61	2.49e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg24531977	chr5:56204891	C5orf35	-1.01	-8.29	-0.65	7.47e-13	Initial pursuit acceleration;
THYM	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg06238570	chr21:40685208	BRWD1	0.89	6.46	0.55	4.38e-9	Cognitive function;
THYM	cis	rs4727027	0.704	rs10952805	chr7:148907849	G/A	cg23583168	chr7:148888333	NA	-1.07	-15.64	-0.85	5e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs9790314	1.000	rs6765269	chr3:160948542	T/C	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg18477163	chr1:228402036	OBSCN	-0.43	-4.69	-0.43	8.96e-6	Diastolic blood pressure;
THYM	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs10463554	0.926	rs5855	chr5:102365186	G/A	cg23492399	chr5:102201601	PAM	0.64	4.81	0.44	5.71e-6	Parkinson's disease;
THYM	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg27129171	chr3:47204927	SETD2	0.8	7.64	0.62	1.69e-11	Colorectal cancer;
THYM	cis	rs8016982	0.633	rs55822231	chr14:81708677	C/T	cg01989461	chr14:81687754	GTF2A1	0.88	7.94	0.63	4.02e-12	Schizophrenia;
THYM	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs2085601	0.518	rs2670629	chr4:89968290	G/C	cg17769793	chr4:89976368	FAM13A	-0.59	-6.62	-0.56	2.17e-9	Hair greying;
THYM	cis	rs7769051	0.522	rs7738256	chr6:133113066	C/G	cg22852734	chr6:133119734	C6orf192	1.47	6.85	0.57	7.36e-10	Type 2 diabetes nephropathy;
THYM	cis	rs289828	1.000	rs289828	chr2:152137181	C/T	cg05960677	chr2:152117363	RBM43	0.59	5.56	0.5	2.51e-7	Blood protein levels;
THYM	trans	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs2663905	0.560	rs1879454	chr15:81377717	C/A	cg26546864	chr15:81426434	C15orf26	-0.81	-5.34	-0.48	6.46e-7	QT interval (drug interaction);
THYM	cis	rs17539620	0.624	rs62432746	chr6:154838986	A/G	cg20019720	chr6:154832845	CNKSR3	0.47	4.79	0.44	6.17e-6	Lipoprotein (a) levels;
THYM	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.87	5.92	0.52	5.2e-8	Platelet count;
THYM	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg24006582	chr15:45444508	DUOX1	-0.78	-6.47	-0.55	4.27e-9	Uric acid levels;
THYM	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg08736216	chr1:53307985	ZYG11A	0.58	5.56	0.5	2.5e-7	Monocyte count;
THYM	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg23711669	chr6:146136114	FBXO30	0.96	9.6	0.7	1.17e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs17818399	0.788	rs17818315	chr2:46818992	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.64	4.55	0.42	1.58e-5	Height;
THYM	cis	rs7584330	0.554	rs13431733	chr2:238430275	A/G	cg14458575	chr2:238380390	NA	0.8	4.67	0.43	9.97e-6	Prostate cancer;
THYM	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg18811423	chr2:55921094	PNPT1	0.69	6.41	0.55	5.6e-9	Metabolic syndrome;
THYM	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg21252483	chr19:49399788	TULP2	-0.96	-7.25	-0.6	1.09e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2777491	0.872	rs7176588	chr15:41588872	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.13	-12.36	-0.79	1.77e-21	Ulcerative colitis;
THYM	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg24642439	chr20:33292090	TP53INP2	0.62	4.91	0.45	3.85e-6	Coronary artery disease;
THYM	cis	rs11249608	0.703	rs7726601	chr5:178444713	A/G	cg21905437	chr5:178450457	ZNF879	-0.56	-4.45	-0.42	2.31e-5	Pubertal anthropometrics;
THYM	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500602	0.685	rs62037617	chr16:4435163	G/C	cg08645402	chr16:4508243	NA	0.62	5.42	0.49	4.46e-7	Schizophrenia;
THYM	cis	rs6542838	0.641	rs12467189	chr2:99495820	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-4.47	-0.42	2.14e-5	Fear of minor pain;
THYM	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg00801512	chr17:28996047	NA	-0.76	-5.08	-0.46	1.91e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg08772003	chr10:104629869	AS3MT	-0.53	-4.54	-0.42	1.64e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg18105134	chr13:113819100	PROZ	-0.98	-9.0	-0.68	2.28e-14	Platelet distribution width;
THYM	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg10802521	chr3:52805072	NEK4	-0.73	-6.21	-0.54	1.42e-8	Bipolar disorder;
THYM	cis	rs1348850	0.597	rs4893964	chr2:178447658	G/T	cg27490568	chr2:178487706	NA	0.54	4.75	0.44	7.29e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg07061783	chr6:25882402	NA	0.74	5.97	0.52	4.1e-8	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg24209194	chr3:40518798	ZNF619	0.66	5.33	0.48	6.48e-7	Renal cell carcinoma;
THYM	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg10862848	chr6:42927986	GNMT	-0.52	-6.76	-0.57	1.1e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs990171	1.000	rs1465321	chr2:102986618	T/C	cg13897122	chr2:103039542	IL18RAP	-0.4	-4.76	-0.44	6.87e-6	Lymphocyte counts;
THYM	cis	rs6984449	0.516	rs4921645	chr8:19303736	A/C	cg01280390	chr8:19363452	CSGALNACT1	-0.63	-5.34	-0.48	6.45e-7	Educational attainment;
THYM	cis	rs72627123	0.656	rs17096208	chr14:74555269	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.29	7.08	0.59	2.46e-10	Morning vs. evening chronotype;
THYM	cis	rs919433	0.680	rs6434930	chr2:198369370	A/G	cg00792783	chr2:198669748	PLCL1	0.86	6.08	0.53	2.49e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2070488	1.000	rs3792527	chr3:38493212	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	7.18	0.59	1.57e-10	Electrocardiographic conduction measures;
THYM	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg13147721	chr7:65941812	NA	0.74	4.63	0.43	1.15e-5	Diabetic kidney disease;
THYM	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg18352616	chr4:3374830	RGS12	0.72	7.81	0.63	7.42e-12	Serum sulfate level;
THYM	cis	rs4266144	0.562	rs2086667	chr3:156836517	G/A	cg16248515	chr3:156840234	NA	-0.78	-7.14	-0.59	1.87e-10	Coronary artery disease;
THYM	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg24642844	chr7:1081250	C7orf50	-1.28	-8.22	-0.64	1.06e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs87938	0.830	rs2109633	chr3:41171732	C/T	cg02247160	chr3:41243829	CTNNB1	-0.35	-4.78	-0.44	6.37e-6	Bone mineral density (hip);
THYM	cis	rs7940866	0.678	rs61909201	chr11:130839547	C/T	cg05962950	chr11:130786565	SNX19	0.78	6.51	0.56	3.52e-9	Schizophrenia;
THYM	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg09359103	chr1:154839909	KCNN3	-0.51	-5.16	-0.47	1.36e-6	Prostate cancer;
THYM	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.22	-0.47	1.04e-6	Monocyte percentage of white cells;
THYM	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.62	-5.74	-0.51	1.11e-7	Hip circumference adjusted for BMI;
THYM	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg11317459	chr13:21872234	NA	-1.22	-9.46	-0.7	2.41e-15	White matter hyperintensity burden;
THYM	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg09537434	chr19:41945824	ATP5SL	-1.03	-9.37	-0.69	3.66e-15	Height;
THYM	cis	rs55882075	0.723	rs56227602	chr5:179179472	A/G	cg14593053	chr5:179126677	CANX	0.59	4.62	0.43	1.19e-5	Monocyte percentage of white cells;
THYM	cis	rs4849845	0.889	rs7574745	chr2:121020802	C/T	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs2276314	0.532	rs11081927	chr18:33614282	C/T	cg19628046	chr18:33552617	C18orf21	0.65	4.87	0.45	4.39e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg18357526	chr6:26021779	HIST1H4A	0.79	6.57	0.56	2.67e-9	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs10208649	1.000	rs72904915	chr2:54227350	C/T	cg04546899	chr2:54196757	PSME4	0.67	4.66	0.43	1.05e-5	Body mass index;
THYM	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs17598306	0.873	rs2189774	chr7:96605287	A/G	cg26766885	chr7:96220185	NA	0.62	5.13	0.47	1.56e-6	Radiation response;
THYM	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg24069376	chr3:38537580	EXOG	0.69	6.79	0.57	9.87e-10	Electrocardiographic conduction measures;
THYM	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6456042	1.000	rs3127415	chr6:166537088	C/T	cg11088901	chr6:166572345	T	-0.52	-4.89	-0.45	4.16e-6	Asthma;
THYM	cis	rs4604732	0.642	rs10925047	chr1:247640143	A/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	4.67	0.43	9.83e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs6496667	0.557	rs2601201	chr15:90958000	C/T	cg00487526	chr15:90818384	NA	-0.64	-4.8	-0.44	5.93e-6	Rheumatoid arthritis;
THYM	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg26408565	chr15:76604113	ETFA	-0.55	-4.77	-0.44	6.53e-6	Blood metabolite levels;
THYM	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.68	-5.83	-0.51	7.51e-8	Lymphocyte counts;
THYM	cis	rs9677476	0.818	rs6753393	chr2:232061967	G/C	cg23338755	chr2:231921595	PSMD1	0.71	5.37	0.48	5.59e-7	Food antigen IgG levels;
THYM	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg18252515	chr7:66147081	NA	-0.69	-5.45	-0.49	3.94e-7	Aortic root size;
THYM	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11644478	chr21:40555479	PSMG1	1.1	9.84	0.71	3.61e-16	Cognitive function;
THYM	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg10661904	chr17:79619235	PDE6G	-0.57	-5.3	-0.48	7.61e-7	Eye color traits;
THYM	cis	rs8180040	0.726	rs9843075	chr3:47195630	A/G	cg16586182	chr3:47516702	SCAP	-0.68	-5.64	-0.5	1.76e-7	Colorectal cancer;
THYM	cis	rs5769707	0.681	rs4622843	chr22:50036916	T/G	cg17054759	chr22:49844102	NA	-0.52	-4.77	-0.44	6.52e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg04546413	chr19:29218101	NA	1.0	6.91	0.58	5.57e-10	Methadone dose in opioid dependence;
THYM	cis	rs11122895	0.791	rs11686294	chr2:112470707	G/A	cg23262488	chr2:112468472	NA	0.47	5.33	0.48	6.64e-7	Allergic sensitization;
THYM	cis	rs7027203	1.000	rs13288708	chr9:96509653	T/C	cg14598338	chr9:96623480	NA	0.45	4.81	0.44	5.72e-6	DNA methylation (variation);
THYM	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg08999081	chr20:33150536	PIGU	0.78	7.16	0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg23428387	chr22:49814324	NA	-0.57	-5.86	-0.51	6.8e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs56161922	1.000	rs57587123	chr1:207825415	A/G	cg09557387	chr1:207818395	CR1L	1.14	5.13	0.47	1.52e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs7695732	0.595	rs2704596	chr4:89888092	C/T	cg17769793	chr4:89976368	FAM13A	-0.49	-5.39	-0.48	5.23e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7592578	0.508	rs55919641	chr2:191265414	G/A	cg10560079	chr2:191398806	TMEM194B	-0.75	-5.67	-0.5	1.52e-7	Diastolic blood pressure;
THYM	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs6690583	0.697	rs10873684	chr1:85522196	T/C	cg22153463	chr1:85462885	MCOLN2	-0.68	-4.47	-0.42	2.19e-5	Serum sulfate level;
THYM	cis	rs61931739	0.679	rs10844831	chr12:34311245	G/T	cg06521331	chr12:34319734	NA	-0.64	-5.37	-0.48	5.62e-7	Morning vs. evening chronotype;
THYM	cis	rs36051895	0.658	rs72699574	chr9:5020089	G/A	cg02405213	chr9:5042618	JAK2	-1.0	-9.68	-0.7	7.84e-16	Pediatric autoimmune diseases;
THYM	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg06009448	chr7:1102226	C7orf50	0.53	5.59	0.5	2.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg17264618	chr3:40429014	ENTPD3	-0.47	-4.61	-0.43	1.27e-5	Renal cell carcinoma;
THYM	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg12908607	chr1:44402522	ARTN	-0.52	-4.67	-0.43	9.88e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg08645402	chr16:4508243	NA	-0.76	-6.87	-0.58	6.72e-10	Schizophrenia;
THYM	cis	rs13263959	0.651	rs34584174	chr8:142651285	A/G	cg24384331	chr8:142183860	DENND3	-0.47	-4.57	-0.42	1.49e-5	Hair color;
THYM	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.9	-8.01	-0.63	2.94e-12	Urate levels;
THYM	cis	rs6032067	0.852	rs2868240	chr20:43874039	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	0.72	6.57	0.56	2.73e-9	Blood protein levels;
THYM	cis	rs7172809	0.573	rs1374201	chr15:77477873	G/A	cg22256960	chr15:77711686	NA	-0.65	-4.83	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg08772003	chr10:104629869	AS3MT	-0.63	-5.54	-0.49	2.68e-7	Arsenic metabolism;
THYM	cis	rs7584330	0.554	rs56853932	chr2:238428327	T/C	cg08992911	chr2:238395768	MLPH	0.82	5.08	0.46	1.9e-6	Prostate cancer;
THYM	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg12011299	chr4:100065546	ADH4	0.86	8.3	0.65	6.94e-13	Alcohol dependence;
THYM	cis	rs36051895	0.664	rs10115172	chr9:5098549	C/T	cg02405213	chr9:5042618	JAK2	-1.0	-10.94	-0.75	1.67e-18	Pediatric autoimmune diseases;
THYM	cis	rs3126085	0.935	rs1496045	chr1:152184704	C/T	cg10321714	chr1:152280068	FLG	0.68	4.95	0.45	3.2e-6	Atopic dermatitis;
THYM	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4363385	0.574	rs6683514	chr1:152984397	A/G	cg13444842	chr1:152974279	SPRR3	-0.64	-4.99	-0.46	2.77e-6	Inflammatory skin disease;
THYM	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	4.46	0.42	2.21e-5	Diabetic retinopathy;
THYM	cis	rs34421088	0.603	rs10086064	chr8:11583841	A/G	cg12395012	chr8:11607386	GATA4	-0.63	-5.11	-0.46	1.68e-6	Neuroticism;
THYM	cis	rs28595532	0.920	rs55671478	chr4:119753811	A/G	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs7940866	0.740	rs7131121	chr11:130806424	A/G	cg12179176	chr11:130786555	SNX19	0.67	5.21	0.47	1.09e-6	Schizophrenia;
THYM	cis	rs7191439	0.858	rs4390574	chr16:88776297	T/C	cg02389323	chr16:88786976	FAM38A	0.86	5.16	0.47	1.33e-6	Plateletcrit;
THYM	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg24250549	chr1:154909240	PMVK	0.79	6.73	0.57	1.27e-9	Prostate cancer;
THYM	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg18252515	chr7:66147081	NA	-1.52	-8.02	-0.64	2.72e-12	Diabetic kidney disease;
THYM	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-6.65	-0.56	1.82e-9	Colorectal cancer;
THYM	cis	rs7582403	0.816	rs7558404	chr2:148895307	C/G	cg23727674	chr2:148602993	ACVR2A	-0.62	-5.11	-0.46	1.69e-6	Neuroticism;
THYM	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg10505658	chr17:80084571	CCDC57	-0.74	-8.13	-0.64	1.59e-12	Life satisfaction;
THYM	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg27423445	chr12:12879764	APOLD1	0.53	4.45	0.42	2.3e-5	Systemic lupus erythematosus;
THYM	cis	rs28595532	0.920	rs116550416	chr4:119753467	A/C	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg00383909	chr3:49044727	WDR6	1.28	6.7	0.57	1.48e-9	Cognitive function;
THYM	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg15691649	chr6:25882328	NA	-0.72	-5.52	-0.49	2.91e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2282930	0.512	rs10261940	chr7:50718818	G/T	cg08586669	chr7:50727761	GRB10	-0.31	-4.69	-0.43	9.01e-6	Bone mineral density;
THYM	cis	rs28595532	0.920	rs116106661	chr4:119749794	A/G	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg08859206	chr1:53392774	SCP2	0.48	4.97	0.45	2.96e-6	Monocyte count;
THYM	cis	rs6138458	1.000	rs227658	chr20:24932028	A/G	cg26195577	chr20:24973756	C20orf3	1.11	10.36	0.73	2.84e-17	Blood protein levels;
THYM	cis	rs55728055	0.661	rs7288051	chr22:32013816	C/T	cg01338084	chr22:32026380	PISD	1.51	6.41	0.55	5.48e-9	Age-related hearing impairment;
THYM	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg00908189	chr16:619842	PIGQ	1.03	9.46	0.7	2.34e-15	Height;
THYM	cis	rs8180040	0.800	rs11130126	chr3:47306894	A/G	cg12976108	chr3:47324180	KIF9;KLHL18	0.5	4.5	0.42	1.92e-5	Colorectal cancer;
THYM	cis	rs4788570	0.667	rs9302630	chr16:71789529	A/C	cg06353428	chr16:71660113	MARVELD3	1.43	8.68	0.67	1.09e-13	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.578	rs726748	chr12:33624416	C/T	cg06521331	chr12:34319734	NA	0.62	4.47	0.42	2.13e-5	Morning vs. evening chronotype;
THYM	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg08883853	chr7:1026168	CYP2W1	-0.45	-4.99	-0.46	2.68e-6	Longevity;Endometriosis;
THYM	cis	rs665401	0.965	rs1632019	chr6:117259580	C/T	cg20376953	chr6:117187980	NA	-0.55	-4.49	-0.42	1.99e-5	Neutrophil percentage of granulocytes;
THYM	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg17063962	chr7:91808500	NA	1.1	11.9	0.77	1.56e-20	Breast cancer;
THYM	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg15445000	chr17:37608096	MED1	0.39	4.59	0.43	1.37e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs10193935	0.901	rs13426988	chr2:42604081	G/A	cg27598129	chr2:42591480	NA	-0.79	-4.75	-0.44	7.08e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7582403	0.844	rs6430288	chr2:148849424	G/A	cg23727674	chr2:148602993	ACVR2A	-0.58	-4.79	-0.44	6.24e-6	Neuroticism;
THYM	cis	rs893818	0.606	rs7163406	chr15:74238272	A/G	cg27228563	chr15:74284600	STOML1	-0.66	-4.6	-0.43	1.29e-5	Exfoliation glaucoma or exfoliation syndrome;
THYM	cis	rs4814894	0.527	rs927113	chr20:19752844	A/T	cg08371391	chr20:19739935	NA	0.48	4.45	0.42	2.32e-5	Breast cancer;
THYM	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg22535103	chr8:58192502	C8orf71	-0.93	-6.13	-0.53	1.98e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7072216	0.727	rs942807	chr10:100168219	G/A	cg03852570	chr10:100175106	PYROXD2	0.38	4.89	0.45	4.04e-6	Metabolite levels;
THYM	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg07917127	chr4:99064746	C4orf37	0.59	4.5	0.42	1.93e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7078219	1.000	rs7081330	chr10:101274465	A/G	cg17888390	chr10:101282816	NA	-0.51	-4.9	-0.45	3.94e-6	Dental caries;
THYM	cis	rs12681287	0.752	rs34279109	chr8:87247944	G/A	cg27223183	chr8:87520930	FAM82B	-0.6	-4.64	-0.43	1.1e-5	Caudate activity during reward;
THYM	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg25427524	chr10:38739819	LOC399744	-0.73	-6.77	-0.57	1.04e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs7178572	0.539	rs12594346	chr15:77671966	A/T	cg22256960	chr15:77711686	NA	0.9	6.65	0.56	1.88e-9	Type 2 diabetes;
THYM	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg11764359	chr7:65958608	NA	-0.63	-4.96	-0.45	3.1e-6	Aortic root size;
THYM	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs477692	0.569	rs7087541	chr10:131309979	A/C	cg05714579	chr10:131428358	MGMT	0.58	4.81	0.44	5.56e-6	Response to temozolomide;
THYM	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg17279839	chr7:150038598	RARRES2	0.55	5.2	0.47	1.16e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.02	13.17	0.8	3.81e-23	Chronic sinus infection;
THYM	cis	rs3540	0.576	rs10152871	chr15:91047469	G/A	cg22089800	chr15:90895588	ZNF774	-0.69	-5.32	-0.48	6.82e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03517284	chr6:25882590	NA	1.06	10.0	0.72	1.63e-16	Blood metabolite levels;
THYM	cis	rs7523273	0.586	rs2761425	chr1:207894033	C/T	cg22525895	chr1:207977042	MIR29B2	-0.53	-5.07	-0.46	1.93e-6	Schizophrenia;
THYM	cis	rs12216545	0.765	rs1403222	chr7:150253913	C/T	cg08960815	chr7:150264767	GIMAP4	0.87	7.96	0.63	3.61e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7172809	0.535	rs17385296	chr15:77646338	A/C	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs665401	0.965	rs1321372	chr6:117237524	G/A	cg20376953	chr6:117187980	NA	0.6	4.67	0.43	9.78e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg04317338	chr11:64019027	PLCB3	0.83	5.73	0.51	1.17e-7	Mean platelet volume;
THYM	cis	rs4654899	0.865	rs6665549	chr1:21475884	G/C	cg01072550	chr1:21505969	NA	-0.74	-6.68	-0.57	1.63e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs6543140	0.964	rs4851592	chr2:103087641	C/T	cg03938978	chr2:103052716	IL18RAP	0.6	5.78	0.51	9.35e-8	Blood protein levels;
THYM	cis	rs7626444	0.625	rs843535	chr3:196473064	G/A	cg12930392	chr3:196481615	PAK2	0.43	5.34	0.48	6.22e-7	Monocyte count;
THYM	cis	rs7523273	0.606	rs2724387	chr1:207932617	T/G	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg23031969	chr7:5014415	RNF216L	-1.28	-6.93	-0.58	4.93e-10	Pulmonary function decline;
THYM	cis	rs4866334	1.000	rs77653879	chr5:18449396	A/G	cg18608440	chr5:17519013	NA	1.16	5.19	0.47	1.17e-6	IgG glycosylation;
THYM	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg12011299	chr4:100065546	ADH4	0.92	8.91	0.67	3.59e-14	Alcohol dependence;
THYM	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg27490568	chr2:178487706	NA	0.58	5.35	0.48	6.1e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg24375607	chr4:120327624	NA	-0.61	-5.39	-0.48	5.17e-7	Corneal astigmatism;
THYM	cis	rs7760949	0.889	rs9475816	chr6:13935425	T/C	cg11053062	chr6:13924544	RNF182	-0.48	-4.6	-0.43	1.28e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg16524936	chr4:1340807	KIAA1530	-0.63	-5.07	-0.46	1.93e-6	Longevity;
THYM	cis	rs7107770	0.607	rs12797054	chr11:125092501	C/A	cg07747661	chr11:125106135	PKNOX2	-0.84	-4.85	-0.45	4.82e-6	Photic sneeze reflex;
THYM	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-7.24	-0.6	1.15e-10	Schizophrenia;
THYM	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg22292345	chr3:47051533	LOC100129354	0.43	4.79	0.44	6.04e-6	Colorectal cancer;
THYM	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-5.76	-0.51	1.03e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg11812906	chr14:75593930	NEK9	-0.85	-7.64	-0.62	1.7e-11	Height;
THYM	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg15782153	chr7:917662	C7orf20	0.47	4.94	0.45	3.4e-6	Perceived unattractiveness to mosquitoes;
THYM	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg06238570	chr21:40685208	BRWD1	-0.98	-9.35	-0.69	4.01e-15	Cognitive function;
THYM	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg23711669	chr6:146136114	FBXO30	0.93	9.69	0.7	7.64e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1018836	0.923	rs7007102	chr8:91629730	T/A	cg16814680	chr8:91681699	NA	-0.85	-7.17	-0.59	1.59e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs2281845	0.965	rs3738262	chr1:201083343	A/G	cg17810781	chr1:201082982	CACNA1S	0.71	7.59	0.61	2.14e-11	Permanent tooth development;
THYM	cis	rs673253	0.571	rs61768370	chr1:44111963	A/T	cg24466421	chr1:44070974	PTPRF	-0.59	-5.09	-0.46	1.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.76	8.53	0.66	2.25e-13	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg03676636	chr4:99064102	C4orf37	0.4	5.72	0.51	1.24e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4481887	1.000	rs4474293	chr1:248470438	T/C	cg13385794	chr1:248469461	NA	0.65	4.66	0.43	1.04e-5	Common traits (Other);
THYM	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg22535103	chr8:58192502	C8orf71	-1.02	-6.26	-0.54	1.12e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg08859206	chr1:53392774	SCP2	0.51	5.35	0.48	6.02e-7	Monocyte count;
THYM	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg03806693	chr22:41940476	POLR3H	0.98	8.1	0.64	1.84e-12	Vitiligo;
THYM	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg17264618	chr3:40429014	ENTPD3	0.58	5.6	0.5	2.06e-7	Renal cell carcinoma;
THYM	cis	rs66569888	0.632	rs6728600	chr2:106898653	G/T	cg16099169	chr2:106886729	NA	-0.77	-5.23	-0.47	1.01e-6	Facial morphology (factor 23);
THYM	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs6732160	0.834	rs57456443	chr2:73366441	C/A	cg24220031	chr2:73402428	NA	-0.63	-6.29	-0.54	9.86e-9	Intelligence (multi-trait analysis);
THYM	cis	rs742614	0.533	rs6059497	chr20:32446960	C/G	cg06304546	chr20:32448765	NA	-0.98	-10.72	-0.74	4.79e-18	Stearic acid (18:0) levels;
THYM	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg09469691	chr10:81107165	PPIF	-0.72	-5.85	-0.51	6.87e-8	Height;
THYM	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg17178900	chr1:205818956	PM20D1	0.75	6.8	0.57	9.1e-10	Monocyte percentage of white cells;
THYM	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg13683864	chr3:40499215	RPL14	-0.86	-8.06	-0.64	2.24e-12	Renal cell carcinoma;
THYM	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg15549821	chr19:49342101	PLEKHA4	-0.97	-5.43	-0.49	4.36e-7	Red cell distribution width;
THYM	cis	rs8016982	0.674	rs11159494	chr14:81667611	G/C	cg01989461	chr14:81687754	GTF2A1	0.86	7.64	0.62	1.67e-11	Schizophrenia;
THYM	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg18252515	chr7:66147081	NA	0.66	4.96	0.45	3.11e-6	Aortic root size;
THYM	cis	rs921968	0.643	rs6708683	chr2:219504503	G/A	cg02176678	chr2:219576539	TTLL4	0.6	5.71	0.51	1.28e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs4690686	0.500	rs17062804	chr4:177262892	A/G	cg17059388	chr4:177262070	NA	0.48	6.73	0.57	1.29e-9	Essential tremor;
THYM	cis	rs8133932	0.701	rs9637207	chr21:47283359	A/G	cg08707771	chr21:46690014	POFUT2	-0.76	-4.45	-0.42	2.29e-5	Schizophrenia;
THYM	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg18252515	chr7:66147081	NA	-1.5	-9.13	-0.68	1.2e-14	Diabetic kidney disease;
THYM	cis	rs7695732	0.595	rs6834787	chr4:89912464	C/T	cg17769793	chr4:89976368	FAM13A	-0.49	-5.2	-0.47	1.17e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6700896	0.931	rs2889195	chr1:66156730	C/T	cg04111102	chr1:66153794	NA	0.55	5.31	0.48	7.28e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03264133	chr6:25882463	NA	-0.88	-8.1	-0.64	1.87e-12	Intelligence (multi-trait analysis);
THYM	cis	rs3087591	0.960	rs12949230	chr17:29461899	G/A	cg24425628	chr17:29625626	OMG;NF1	0.64	5.45	0.49	3.96e-7	Hip circumference;
THYM	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg04248312	chr19:17393744	ANKLE1	-1.0	-13.06	-0.8	6.35e-23	Systemic lupus erythematosus;
THYM	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg00958927	chr1:175162553	KIAA0040	0.35	4.88	0.45	4.32e-6	Alcohol dependence;
THYM	cis	rs34638657	0.500	rs12446210	chr16:82185762	G/A	cg09439754	chr16:82129088	HSD17B2	-0.58	-5.83	-0.51	7.49e-8	Lung adenocarcinoma;
THYM	cis	rs11186	0.556	rs13383261	chr2:189913748	T/C	cg11041835	chr2:189156425	GULP1	0.78	4.69	0.43	9.21e-6	Parkinson's disease;
THYM	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs7246657	0.653	rs10414983	chr19:37665732	T/C	cg23950597	chr19:37808831	NA	-0.81	-4.88	-0.45	4.35e-6	Coronary artery calcification;
THYM	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.83	-0.44	5.29e-6	Mean corpuscular volume;
THYM	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg09034736	chr1:150693464	HORMAD1	0.53	4.76	0.44	6.91e-6	Tonsillectomy;
THYM	cis	rs977987	0.835	rs1010630	chr16:75328591	G/T	cg03315344	chr16:75512273	CHST6	0.83	7.05	0.59	2.81e-10	Dupuytren's disease;
THYM	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg15921436	chr17:44337874	NA	0.78	6.3	0.54	9.05e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11771526	0.892	rs62457541	chr7:32372566	G/A	cg13207630	chr7:32358064	NA	1.06	6.2	0.54	1.44e-8	Body mass index;
THYM	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22857025	chr5:266934	NA	-1.37	-8.88	-0.67	4.08e-14	Breast cancer;
THYM	cis	rs12935418	0.672	rs1453328	chr16:81052845	G/A	cg16651780	chr16:81037892	C16orf61	0.78	5.73	0.51	1.2e-7	Mean corpuscular volume;
THYM	cis	rs6921919	0.609	rs67211468	chr6:28391987	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.59	-4.48	-0.42	2.05e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg10334053	chr1:2078117	PRKCZ	-0.46	-4.79	-0.44	6.05e-6	Height;
THYM	cis	rs4631830	0.832	rs2611513	chr10:51515457	A/G	cg10326726	chr10:51549505	MSMB	0.55	5.5	0.49	3.19e-7	Prostate-specific antigen levels;
THYM	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.86	-7.67	-0.62	1.46e-11	Intelligence (multi-trait analysis);
THYM	cis	rs9581857	0.685	rs9581856	chr13:28025615	G/C	cg22138327	chr13:27999177	GTF3A	0.84	4.74	0.44	7.35e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs10905065	0.861	rs10752069	chr10:5752403	A/G	cg11519256	chr10:5708881	ASB13	0.48	4.65	0.43	1.07e-5	Menopause (age at onset);
THYM	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	4.9	0.45	3.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg14675211	chr2:100938903	LONRF2	0.73	7.75	0.62	1e-11	Intelligence (multi-trait analysis);
THYM	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.72	0.51	1.23e-7	Lung cancer in ever smokers;
THYM	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	5.54	0.49	2.68e-7	Hip circumference adjusted for BMI;
THYM	cis	rs2637266	1.000	rs1907317	chr10:78337849	C/A	cg18941641	chr10:78392320	NA	0.81	7.03	0.58	3.16e-10	Pulmonary function;
THYM	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.17	0.47	1.31e-6	Height;
THYM	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.81	7.6	0.61	2.08e-11	Calcium levels;
THYM	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg22875332	chr1:76189707	ACADM	-0.52	-4.8	-0.44	5.96e-6	Daytime sleep phenotypes;
THYM	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg18132916	chr6:79620363	NA	-0.59	-5.16	-0.47	1.34e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6754311	0.517	rs1865452	chr2:136539330	C/T	cg07169764	chr2:136633963	MCM6	0.94	8.32	0.65	6.19e-13	Mosquito bite size;
THYM	cis	rs8133932	0.654	rs402039	chr21:47358809	A/G	cg20357416	chr21:47294739	PCBP3	0.85	5.2	0.47	1.15e-6	Schizophrenia;
THYM	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg24812749	chr6:127587940	RNF146	0.95	7.21	0.59	1.37e-10	Breast cancer;
THYM	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs454510	0.857	rs838990	chr1:120193252	A/G	cg11530693	chr1:120165357	ZNF697	0.63	4.76	0.44	6.94e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
THYM	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.64	0.43	1.12e-5	Obesity-related traits;
THYM	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg08736216	chr1:53307985	ZYG11A	-0.6	-5.44	-0.49	4.07e-7	Monocyte count;
THYM	cis	rs295140	1.000	rs4516413	chr2:201163920	T/C	cg04283868	chr2:201171347	SPATS2L	0.75	5.71	0.51	1.31e-7	QT interval;
THYM	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg06238570	chr21:40685208	BRWD1	-0.73	-6.27	-0.54	1.05e-8	Menarche (age at onset);
THYM	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg14895029	chr7:2775587	GNA12	-0.67	-4.79	-0.44	6.01e-6	Height;
THYM	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.55	-7.31	-0.6	8.48e-11	Monocyte percentage of white cells;
THYM	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg11764359	chr7:65958608	NA	-0.82	-6.65	-0.56	1.85e-9	Aortic root size;
THYM	cis	rs2398893	0.960	rs2153791	chr9:96744928	G/A	cg14459158	chr9:96720562	NA	0.53	4.63	0.43	1.14e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1129187	0.748	rs9471968	chr6:42905235	A/G	cg19747945	chr6:42946146	PEX6	-0.32	-4.62	-0.43	1.19e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1003719	0.708	rs3787788	chr21:38502804	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-4.75	-0.44	7.3e-6	Eye color traits;
THYM	cis	rs7192380	0.964	rs6499231	chr16:69588016	A/G	cg09409435	chr16:70099608	PDXDC2	0.62	4.75	0.44	7.2e-6	Sjögren's syndrome;
THYM	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg10589385	chr1:150898437	SETDB1	0.67	5.55	0.49	2.58e-7	Melanoma;
THYM	cis	rs870825	0.929	rs2310102	chr4:185595141	C/G	cg04058563	chr4:185651563	MLF1IP	-0.98	-7.31	-0.6	8.33e-11	Blood protein levels;
THYM	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg01570182	chr17:44337453	NA	0.87	9.32	0.69	4.78e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.1	-0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2795502	0.564	rs3004259	chr10:43486041	A/G	cg08461752	chr10:43522343	NA	0.79	4.82	0.44	5.45e-6	Blood protein levels;
THYM	cis	rs12532960	0.749	rs12534649	chr7:42368427	G/A	cg23473276	chr7:42834405	NA	0.87	4.77	0.44	6.71e-6	Inflammatory biomarkers;
THYM	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg24818145	chr4:99064322	C4orf37	0.9	7.36	0.6	6.5e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg13319975	chr6:146136371	FBXO30	-0.67	-5.46	-0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg21926883	chr2:100939477	LONRF2	-0.62	-5.43	-0.49	4.32e-7	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.88	9.94	0.71	2.24e-16	Prudent dietary pattern;
THYM	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs1957429	0.901	rs2884308	chr14:65350406	A/T	cg23373153	chr14:65346875	NA	-1.07	-6.53	-0.56	3.2e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs3126085	0.935	rs4845429	chr1:152225376	G/C	cg26020982	chr1:152196106	HRNR	0.37	4.98	0.45	2.89e-6	Atopic dermatitis;
THYM	cis	rs6539288	0.933	rs2075289	chr12:107307638	C/T	cg26297688	chr12:107349093	C12orf23	-0.47	-4.89	-0.45	4.15e-6	Total body bone mineral density;
THYM	cis	rs9309473	0.519	rs2421583	chr2:73898785	C/G	cg19565262	chr2:73869966	NAT8	0.56	4.68	0.43	9.48e-6	Metabolite levels;
THYM	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg21028142	chr17:79581711	NPLOC4	-0.52	-5.13	-0.47	1.52e-6	Eye color traits;
THYM	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg22433210	chr17:43662623	NA	-1.05	-8.08	-0.64	2e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs16866061	1.000	rs72974267	chr2:225454209	T/C	cg22455342	chr2:225449267	CUL3	0.67	4.84	0.44	4.98e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg22166914	chr1:53195759	ZYG11B	-0.79	-8.5	-0.66	2.59e-13	Monocyte count;
THYM	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg13010199	chr12:38710504	ALG10B	0.73	5.76	0.51	1.02e-7	Heart rate;
THYM	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg14196790	chr5:131705035	SLC22A5	0.51	4.62	0.43	1.23e-5	Blood metabolite levels;
THYM	cis	rs763014	0.833	rs4984891	chr16:622234	T/A	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.59	5.3	0.48	7.4e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2319125	0.683	rs28719969	chr17:64051214	A/G	cg04446870	chr17:64440273	PRKCA	0.5	4.48	0.42	2.12e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs763014	0.865	rs8909	chr16:633851	T/C	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08109568	chr15:31115862	NA	-0.59	-5.74	-0.51	1.15e-7	Huntington's disease progression;
THYM	cis	rs7107174	1.000	rs11237456	chr11:78040780	C/G	cg02023728	chr11:77925099	USP35	0.6	5.77	0.51	9.96e-8	Testicular germ cell tumor;
THYM	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg06074448	chr4:187884817	NA	-1.0	-13.91	-0.82	1.19e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs920590	0.641	rs2035889	chr8:19634087	T/A	cg03894339	chr8:19674705	INTS10	0.62	4.61	0.43	1.26e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs8033133	0.514	rs58498746	chr15:25294236	C/G	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.62	-4.84	-0.44	5.1e-6	Blood osmolality (transformed sodium);
THYM	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11186	0.556	rs56408385	chr2:189970654	C/A	cg11041835	chr2:189156425	GULP1	0.8	4.52	0.42	1.79e-5	Parkinson's disease;
THYM	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs35883536	0.647	rs1335765	chr1:101048612	A/T	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg22681709	chr2:178499509	PDE11A	-0.63	-5.98	-0.52	3.88e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9810089	1.000	rs9810089	chr3:135807609	G/T	cg12473912	chr3:136751656	NA	-0.61	-5.22	-0.47	1.03e-6	Gestational age at birth (child effect);
THYM	cis	rs4866334	1.000	rs78178098	chr5:18487497	T/C	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs7614311	0.681	rs73119022	chr3:63979834	T/C	cg22134162	chr3:63841271	THOC7	-0.52	-6.39	-0.55	6.06e-9	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs4866334	1.000	rs6866535	chr5:18431650	G/A	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs1331623	0.710	rs12156553	chr9:122195006	A/G	cg25935911	chr9:122132261	DBC1	-0.52	-4.7	-0.43	8.87e-6	Height;
THYM	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg05347473	chr6:146136440	FBXO30	0.81	7.21	0.59	1.34e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg15736062	chr7:158136485	PTPRN2	-0.63	-5.03	-0.46	2.34e-6	Response to amphetamines;
THYM	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg14004847	chr7:1930337	MAD1L1	-0.63	-4.84	-0.44	5.09e-6	Schizophrenia;
THYM	cis	rs11771526	0.901	rs62457494	chr7:32312299	T/G	cg13207630	chr7:32358064	NA	0.84	5.28	0.48	8.15e-7	Body mass index;
THYM	cis	rs7570971	0.761	rs3940549	chr2:136138627	A/G	cg07169764	chr2:136633963	MCM6	0.69	4.96	0.45	3.1e-6	Blood metabolite levels;Body mass index;Cholesterol, total;
THYM	cis	rs9814567	0.762	rs13079012	chr3:134247706	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.71	6.01	0.53	3.37e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg13319975	chr6:146136371	FBXO30	-0.69	-5.7	-0.5	1.37e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs892961	0.899	rs72896162	chr17:75412521	A/G	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg08736216	chr1:53307985	ZYG11A	-0.62	-5.55	-0.5	2.53e-7	Monocyte count;
THYM	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg24675658	chr1:53192096	ZYG11B	-0.57	-4.54	-0.42	1.63e-5	Monocyte count;
THYM	cis	rs7220711	1.000	rs7220711	chr17:41789965	C/T	cg26893861	chr17:41843967	DUSP3	-0.67	-5.89	-0.52	5.9e-8	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs2976388	1.000	rs2585179	chr8:143774193	G/A	cg06565975	chr8:143823917	SLURP1	-0.46	-5.53	-0.49	2.86e-7	Urinary tract infection frequency;
THYM	cis	rs6933660	0.512	rs13198669	chr6:151799924	A/G	cg03596678	chr6:151814994	C6orf97	0.74	4.88	0.45	4.28e-6	Menarche (age at onset);
THYM	cis	rs8106542	0.906	rs8109681	chr19:10738836	A/G	cg17848348	chr19:10766748	ILF3	-0.81	-6.67	-0.56	1.7e-9	Platelet distribution width;
THYM	cis	rs6430585	0.528	rs721765	chr2:136748779	C/A	cg20242066	chr2:136595261	LCT	0.56	5.2	0.47	1.14e-6	Corneal structure;
THYM	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.81e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg17143192	chr8:8559678	CLDN23	0.91	6.74	0.57	1.2e-9	Obesity-related traits;
THYM	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06873352	chr17:61820015	STRADA	0.57	5.68	0.5	1.46e-7	Height;
THYM	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs796364	0.694	rs1653299	chr2:201075611	A/G	cg23649088	chr2:200775458	C2orf69	0.85	7.91	0.63	4.73e-12	Schizophrenia;
THYM	cis	rs1629083	0.654	rs648682	chr11:118066582	T/C	cg18857871	chr11:118064634	AMICA1	0.43	4.6	0.43	1.31e-5	Lung cancer;
THYM	cis	rs6032067	0.777	rs13038342	chr20:43800232	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.41	-0.65	4.05e-13	Blood protein levels;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg12141746	chr1:218703459	NA	-0.88	-6.95	-0.58	4.62e-10	Depressive symptoms;
THYM	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs2046867	0.862	rs6549483	chr3:72805316	T/G	cg25664220	chr3:72788482	NA	-0.81	-6.15	-0.53	1.81e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs11650494	0.908	rs11650087	chr17:47362923	T/A	cg08112188	chr17:47440006	ZNF652	1.23	5.06	0.46	2.02e-6	Prostate cancer;
THYM	cis	rs4654899	0.785	rs9426656	chr1:21505932	T/G	cg01072550	chr1:21505969	NA	-0.79	-7.7	-0.62	1.29e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg17911788	chr17:44343683	NA	0.71	6.76	0.57	1.09e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs3126085	1.000	rs2338555	chr1:152309380	G/A	cg26020982	chr1:152196106	HRNR	-0.36	-4.95	-0.45	3.19e-6	Atopic dermatitis;
THYM	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg06618935	chr21:46677482	NA	-0.97	-9.14	-0.68	1.12e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	5.06	0.46	2.04e-6	Hip circumference adjusted for BMI;
THYM	cis	rs7927771	0.839	rs3817334	chr11:47650993	C/T	cg18512352	chr11:47633146	NA	-0.46	-5.56	-0.5	2.48e-7	Subjective well-being;
THYM	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg18132916	chr6:79620363	NA	0.59	5.46	0.49	3.8e-7	Intelligence (multi-trait analysis);
THYM	cis	rs892961	0.932	rs11658267	chr17:75411884	C/T	cg11351908	chr17:75402473	SEPT9	-0.56	-5.45	-0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs9403317	0.960	rs9389929	chr6:141840934	T/A	cg15052665	chr6:141804349	NA	0.85	8.69	0.67	1.03e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4595586	0.545	rs12821810	chr12:39375858	T/C	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs7833986	0.501	rs2976018	chr8:57014752	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	6.82	0.57	8.29e-10	Height;
THYM	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg19761014	chr17:28927070	LRRC37B2	0.83	4.66	0.43	1.04e-5	Body mass index;
THYM	cis	rs6665290	0.935	rs17528667	chr1:227201770	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.15	-16.89	-0.87	2.27e-30	Myeloid white cell count;
THYM	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg02734326	chr4:10020555	SLC2A9	-0.6	-4.7	-0.43	8.84e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg03474202	chr17:45855739	NA	-0.76	-6.64	-0.56	1.94e-9	IgG glycosylation;
THYM	cis	rs7000551	0.532	rs4872486	chr8:22256359	G/T	cg12081754	chr8:22256438	SLC39A14	1.18	12.41	0.79	1.35e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs3791556	0.661	rs3791539	chr2:240102327	C/T	cg27074582	chr2:240114406	HDAC4	0.51	4.85	0.45	4.79e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4474465	1.000	rs7124043	chr11:78205644	G/T	cg19901956	chr11:77921274	USP35	0.65	4.8	0.44	5.97e-6	Alzheimer's disease (survival time);
THYM	cis	rs2637266	1.000	rs11001830	chr10:78346396	G/A	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.25	10.13	0.72	8.76e-17	Platelet count;
THYM	cis	rs308447	0.542	rs10084869	chr4:123696907	T/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.85	6.76	0.57	1.12e-9	Perceived unattractiveness to mosquitoes;
THYM	cis	rs500891	0.525	rs750384	chr6:84030422	C/T	cg21688264	chr6:84418724	SNAP91	0.74	4.51	0.42	1.87e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg06453172	chr10:134556979	INPP5A	-0.67	-4.84	-0.44	5.1e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg13683864	chr3:40499215	RPL14	0.69	6.11	0.53	2.19e-8	Renal cell carcinoma;
THYM	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.92	-9.1	-0.68	1.36e-14	Lung cancer;
THYM	cis	rs55728055	0.661	rs62237845	chr22:32027892	G/A	cg10537193	chr22:32026975	PISD	-0.86	-5.48	-0.49	3.48e-7	Age-related hearing impairment;
THYM	cis	rs4919087	1.000	rs12221430	chr10:99061386	C/G	cg19453742	chr10:98862320	SLIT1	-0.63	-4.95	-0.45	3.19e-6	Monocyte count;
THYM	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg07362569	chr17:61921086	SMARCD2	-0.64	-6.11	-0.53	2.17e-8	Prudent dietary pattern;
THYM	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg00255919	chr5:131827918	IRF1	-0.46	-5.19	-0.47	1.17e-6	Asthma (sex interaction);
THYM	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg23262073	chr20:60523788	NA	-0.91	-6.36	-0.55	7.15e-9	Obesity-related traits;
THYM	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	6.61	0.56	2.26e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs728616	0.614	rs55768100	chr10:81724477	C/T	cg27452691	chr10:81370291	SFTPA1	0.59	4.6	0.43	1.33e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2219968	1.000	rs13262830	chr8:78957669	C/T	cg00738934	chr8:78996279	NA	0.88	9.31	0.69	4.91e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7927592	0.513	rs556442	chr11:68192690	G/A	cg16797656	chr11:68205561	LRP5	-0.55	-6.49	-0.55	3.83e-9	Total body bone mineral density;
THYM	cis	rs3733606	0.538	rs11734099	chr4:6891435	G/A	cg05012661	chr4:6891264	NA	0.6	4.54	0.42	1.62e-5	Platelet count;
THYM	cis	rs2066819	1.000	rs76466034	chr12:56719450	G/A	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg25427524	chr10:38739819	LOC399744	-0.67	-6.25	-0.54	1.16e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs7072216	0.763	rs733345	chr10:100164215	G/T	cg26618903	chr10:100175079	PYROXD2	-0.49	-4.67	-0.43	1.01e-5	Metabolite levels;
THYM	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs7119	0.717	rs8032071	chr15:77745762	C/T	cg10437265	chr15:77819839	NA	-0.6	-4.68	-0.43	9.47e-6	Type 2 diabetes;
THYM	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg27572855	chr1:25598939	RHD	0.69	5.33	0.48	6.72e-7	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg24397884	chr7:158709396	WDR60	0.53	5.8	0.51	8.56e-8	Height;
THYM	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg08305652	chr11:111469057	NA	0.53	4.58	0.43	1.41e-5	Primary sclerosing cholangitis;
THYM	cis	rs7113850	0.541	rs7107667	chr11:24224091	T/A	ch.11.24196551F	chr11:24239977	NA	1.03	5.41	0.49	4.67e-7	Bone fracture in osteoporosis;
THYM	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg16797656	chr11:68205561	LRP5	-0.45	-4.83	-0.44	5.26e-6	Total body bone mineral density;
THYM	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.57	-4.88	-0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg16109012	chr1:197124878	ZBTB41	-0.73	-4.91	-0.45	3.75e-6	Depressive symptoms;
THYM	cis	rs1568889	1.000	rs7945367	chr11:28166272	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.55e-6	Bipolar disorder;
THYM	cis	rs35883536	0.609	rs2647327	chr1:101041766	C/T	cg09408571	chr1:101003634	GPR88	0.5	5.52	0.49	2.9e-7	Monocyte count;
THYM	cis	rs2803122	0.777	rs6475326	chr9:19386565	A/G	cg19584733	chr9:19298547	DENND4C	0.61	5.27	0.48	8.38e-7	Pulse pressure;
THYM	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg12419862	chr22:24373484	LOC391322	-0.92	-10.83	-0.74	2.79e-18	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9563576	0.778	rs9316970	chr13:58621461	C/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs2456568	0.548	rs1607402	chr11:93660732	T/G	cg26875233	chr11:93583750	C11orf90	-0.56	-6.24	-0.54	1.22e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg02569458	chr12:86230093	RASSF9	0.57	4.84	0.44	4.95e-6	Major depressive disorder;
THYM	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.63	-6.33	-0.54	7.96e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs3015497	0.554	rs8011039	chr14:51091267	C/T	cg04730355	chr14:51134070	SAV1	-0.53	-4.55	-0.42	1.58e-5	Mean platelet volume;
THYM	cis	rs9443189	0.570	rs504323	chr6:76294965	A/G	cg01950844	chr6:76311363	SENP6	-1.08	-5.85	-0.51	6.82e-8	Prostate cancer;
THYM	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg22166914	chr1:53195759	ZYG11B	0.8	8.04	0.64	2.5e-12	Monocyte count;
THYM	cis	rs11247915	0.501	rs34209692	chr1:26608782	C/T	cg00852783	chr1:26633632	UBXN11	0.77	6.08	0.53	2.48e-8	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.790	rs3924499	chr6:146232978	A/T	cg23711669	chr6:146136114	FBXO30	-0.95	-9.84	-0.71	3.6e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs34638657	0.732	rs12597534	chr16:82200276	G/T	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.25	-0.47	9.14e-7	Lung adenocarcinoma;
THYM	cis	rs7084402	0.967	rs10826199	chr10:60274213	T/C	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs4481887	0.927	rs6587445	chr1:248440915	A/G	cg00666640	chr1:248458726	OR2T12	0.56	4.75	0.44	7.28e-6	Common traits (Other);
THYM	cis	rs79387448	0.701	rs3752659	chr2:103001598	A/G	cg09003973	chr2:102972529	NA	1.01	5.69	0.5	1.41e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg13695892	chr22:41940480	POLR3H	0.85	6.16	0.53	1.72e-8	Cannabis dependence symptom count;
THYM	cis	rs6495367	0.803	rs2870111	chr15:79403585	C/T	cg17916960	chr15:79447300	NA	0.67	7.74	0.62	1.06e-11	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg09165964	chr15:75287851	SCAMP5	0.59	4.55	0.42	1.62e-5	Breast cancer;
THYM	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg12963246	chr6:28129442	ZNF389	0.8	6.39	0.55	6.19e-9	Parkinson's disease;
THYM	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg00256281	chr22:41985642	PMM1	0.5	4.51	0.42	1.84e-5	Vitiligo;
THYM	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg01191920	chr7:158217561	PTPRN2	-0.91	-9.49	-0.7	2e-15	Obesity-related traits;
THYM	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg05872129	chr22:39784769	NA	-1.04	-10.98	-0.75	1.35e-18	Intelligence (multi-trait analysis);
THYM	cis	rs17102423	0.826	rs10873182	chr14:65605408	C/T	cg11161011	chr14:65562177	MAX	-0.74	-6.25	-0.54	1.15e-8	Obesity-related traits;
THYM	cis	rs1957429	0.901	rs59876171	chr14:65384429	C/T	cg23373153	chr14:65346875	NA	-1.04	-6.49	-0.55	3.87e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/A	cg18639983	chr19:58920768	ZNF584	0.6	5.17	0.47	1.31e-6	Mean platelet volume;
THYM	cis	rs7107770	1.000	rs7107770	chr11:125100438	C/G	cg04164023	chr11:125106101	PKNOX2	-0.78	-4.6	-0.43	1.31e-5	Photic sneeze reflex;
THYM	cis	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg26384229	chr12:38710491	ALG10B	-0.71	-5.53	-0.49	2.8e-7	Morning vs. evening chronotype;
THYM	cis	rs7909791	0.632	rs11191853	chr10:105657363	C/G	cg24587175	chr10:105670608	OBFC1	0.76	7.41	0.61	5.2e-11	White matter hyperintensity burden;
THYM	cis	rs4642101	0.597	rs2305397	chr3:12857493	C/T	cg05775895	chr3:12838266	CAND2	1.05	10.13	0.72	8.52e-17	QRS complex (12-leadsum);
THYM	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg06917634	chr15:78832804	PSMA4	-0.96	-8.72	-0.67	9.12e-14	Sudden cardiac arrest;
THYM	cis	rs17401966	0.931	rs1002076	chr1:10438892	G/A	cg19773385	chr1:10388646	KIF1B	-0.6	-4.7	-0.43	8.88e-6	Hepatocellular carcinoma;
THYM	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg16586182	chr3:47516702	SCAP	0.64	5.55	0.5	2.54e-7	Colorectal cancer;
THYM	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-5.32	-0.48	6.76e-7	Heart rate;
THYM	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg03605463	chr16:89740564	NA	0.86	6.66	0.56	1.74e-9	Vitiligo;
THYM	cis	rs35934224	0.783	rs7285948	chr22:19861127	T/C	cg11182965	chr22:19864308	TXNRD2	-0.71	-5.85	-0.51	7.1e-8	Glaucoma (primary open-angle);
THYM	cis	rs13006833	0.668	rs291445	chr2:191176479	G/A	cg27211696	chr2:191398769	TMEM194B	0.56	4.47	0.42	2.19e-5	Urinary metabolites;
THYM	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs13082711	0.911	rs2003886	chr3:27527732	G/T	cg02860705	chr3:27208620	NA	0.72	5.06	0.46	2.01e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs732765	0.602	rs2359192	chr14:75410523	A/C	cg15890469	chr14:75408846	PGF	-0.68	-4.99	-0.46	2.77e-6	Non-small cell lung cancer;
THYM	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2404602	0.611	rs2404734	chr15:76936165	T/C	cg23625390	chr15:77176239	SCAPER	-0.88	-6.17	-0.54	1.64e-8	Blood metabolite levels;
THYM	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg15693483	chr7:1102177	C7orf50	0.54	6.29	0.54	9.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg09580147	chr16:22431764	RRN3P3	0.94	7.07	0.59	2.61e-10	Depressive symptoms;
THYM	cis	rs12935418	0.583	rs1469125	chr16:81029768	G/A	cg16651780	chr16:81037892	C16orf61	-0.84	-6.39	-0.55	6.03e-9	Mean corpuscular volume;
THYM	cis	rs7072216	0.763	rs942805	chr10:100168372	G/A	cg26618903	chr10:100175079	PYROXD2	-0.48	-4.6	-0.43	1.33e-5	Metabolite levels;
THYM	cis	rs600550	0.588	rs10897049	chr11:60100581	C/T	cg05040360	chr11:60102449	MS4A6E	-0.5	-4.72	-0.44	8.13e-6	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs7027203	0.828	rs7037960	chr9:96584028	G/A	cg14598338	chr9:96623480	NA	-0.49	-5.33	-0.48	6.74e-7	DNA methylation (variation);
THYM	cis	rs863345	0.535	rs12064570	chr1:158499631	T/C	cg12129480	chr1:158549410	OR10X1	-0.54	-5.21	-0.47	1.12e-6	Pneumococcal bacteremia;
THYM	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7172809	0.643	rs11855272	chr15:77840790	G/A	cg22256960	chr15:77711686	NA	-0.75	-5.36	-0.48	5.83e-7	Glucose homeostasis traits;
THYM	cis	rs2073300	0.609	rs6137931	chr20:23376875	G/C	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs55665837	1.000	rs10047429	chr11:14439032	C/T	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs2304069	0.659	rs216141	chr5:149443994	A/G	cg12661370	chr5:149340060	SLC26A2	-0.72	-5.28	-0.48	8.09e-7	HIV-1 control;
THYM	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11644478	chr21:40555479	PSMG1	0.64	4.66	0.43	1.04e-5	Cognitive function;
THYM	cis	rs9959145	1.000	rs77321492	chr18:12552123	T/A	cg14160804	chr18:12703040	PSMG2;CEP76	-0.92	-4.53	-0.42	1.74e-5	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg18252515	chr7:66147081	NA	-0.67	-5.09	-0.46	1.82e-6	Aortic root size;
THYM	cis	rs17511627	0.808	rs7982318	chr13:26742798	G/A	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.9	-8.01	-0.63	2.94e-12	Urate levels;
THYM	cis	rs11089937	0.895	rs5756985	chr22:22486240	G/A	cg21401457	chr22:22472743	NA	0.57	4.64	0.43	1.11e-5	Periodontitis (PAL4Q3);
THYM	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg13026072	chr11:65380126	MAP3K11	0.68	5.45	0.49	3.95e-7	Blood pressure (age interaction);
THYM	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg00129232	chr17:37814104	STARD3	-0.69	-4.45	-0.42	2.32e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs669446	0.562	rs10890275	chr1:44194216	T/G	cg15962314	chr1:44399869	ARTN	0.47	5.18	0.47	1.22e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs1163251	0.869	rs487884	chr1:120217330	C/T	cg19096424	chr1:120255104	PHGDH	0.67	5.25	0.47	9.26e-7	Blood metabolite levels;
THYM	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg04896959	chr15:78267971	NA	-0.94	-8.92	-0.67	3.42e-14	Coronary artery disease or large artery stroke;
THYM	cis	rs7553864	0.614	rs4559475	chr1:87614236	T/C	cg17420885	chr1:87600446	LOC339524	-0.83	-7.0	-0.58	3.68e-10	Smoking behavior;
THYM	cis	rs7084402	1.000	rs1427204	chr10:60267640	A/C	cg07615347	chr10:60278583	BICC1	-0.55	-5.0	-0.46	2.63e-6	Refractive error;
THYM	cis	rs10089	1.000	rs72794392	chr5:127490061	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.97	5.9	0.52	5.51e-8	Ileal carcinoids;
THYM	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg18230493	chr5:56204884	C5orf35	-0.64	-4.86	-0.45	4.56e-6	Initial pursuit acceleration;
THYM	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg23428387	chr22:49814324	NA	-0.57	-5.97	-0.52	4.07e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg00376283	chr12:123451042	ABCB9	0.71	4.71	0.44	8.31e-6	Neutrophil percentage of white cells;
THYM	cis	rs747334	0.811	rs2141375	chr10:92717963	C/T	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg24675056	chr1:15929824	NA	0.73	5.79	0.51	9.09e-8	Systolic blood pressure;
THYM	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg22433210	chr17:43662623	NA	1.12	8.23	0.65	9.88e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1978968	1.000	rs5992922	chr22:18445287	A/G	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg26384229	chr12:38710491	ALG10B	-0.74	-5.8	-0.51	8.85e-8	Bladder cancer;
THYM	cis	rs62481355	1.000	rs62481355	chr7:127201664	C/T	cg08586737	chr7:127225949	GCC1	-0.35	-4.53	-0.42	1.71e-5	Type 2 diabetes;
THYM	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7843479	0.582	rs7009693	chr8:21775314	C/T	cg17168535	chr8:21777572	XPO7	0.93	9.08	0.68	1.51e-14	Mean corpuscular volume;
THYM	cis	rs4642101	0.855	rs9873475	chr3:12845422	A/G	cg05775895	chr3:12838266	CAND2	0.94	8.62	0.66	1.49e-13	QRS complex (12-leadsum);
THYM	cis	rs6988636	1.000	rs28513831	chr8:124189208	T/C	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.76	-6.38	-0.55	6.46e-9	Systemic lupus erythematosus;
THYM	cis	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg10856724	chr12:34555212	NA	-0.93	-9.34	-0.69	4.18e-15	Morning vs. evening chronotype;
THYM	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg15921436	chr17:44337874	NA	-0.8	-6.46	-0.55	4.4e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg01579765	chr21:45077557	HSF2BP	-0.44	-5.77	-0.51	9.79e-8	Mean corpuscular hemoglobin;
THYM	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.74	5.97	0.52	4.02e-8	Tonsillectomy;
THYM	cis	rs17598306	0.935	rs17657370	chr7:96606492	C/T	cg23184042	chr7:96615519	DLX6AS	0.61	4.76	0.44	6.82e-6	Radiation response;
THYM	cis	rs6032067	0.929	rs6032063	chr20:43854475	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.71	-7.53	-0.61	2.95e-11	Blood protein levels;
THYM	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.95	0.68	2.83e-14	Chronic sinus infection;
THYM	cis	rs3126085	0.735	rs4845744	chr1:152185095	T/A	cg26020982	chr1:152196106	HRNR	0.35	4.57	0.42	1.45e-5	Atopic dermatitis;
THYM	cis	rs72772090	0.539	rs11747179	chr5:96112969	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.81	-4.56	-0.42	1.54e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7513165	0.935	rs4951319	chr1:204162230	A/G	cg04791601	chr1:204159016	NA	0.38	4.75	0.44	7.13e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
THYM	cis	rs6584283	0.716	rs10786558	chr10:101287610	G/A	cg23904955	chr10:101282759	NA	-0.35	-4.53	-0.42	1.71e-5	Ulcerative colitis;
THYM	cis	rs4951011	0.938	rs4951228	chr1:203761948	C/A	cg24343524	chr1:203763352	ZC3H11A	0.71	6.32	0.54	8.49e-9	Breast cancer;
THYM	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg11812906	chr14:75593930	NEK9	-0.83	-7.68	-0.62	1.42e-11	Height;
THYM	cis	rs72828912	0.731	rs9379635	chr6:24067548	C/T	cg19882886	chr6:25043046	NA	0.92	5.03	0.46	2.34e-6	Squamous cell lung carcinoma;
THYM	trans	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.93	-8.78	-0.67	6.81e-14	Brugada syndrome;
THYM	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg00495681	chr13:53174319	NA	-0.75	-7.52	-0.61	3.11e-11	Lewy body disease;
THYM	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.64	4.58	0.43	1.4e-5	Tonsillectomy;
THYM	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg09307838	chr4:120376055	NA	0.7	5.27	0.48	8.48e-7	Corneal astigmatism;
THYM	cis	rs10214930	1.000	rs1859328	chr7:27878077	A/G	cg04422003	chr7:28448295	CREB5	0.57	4.51	0.42	1.87e-5	Hypospadias;
THYM	cis	rs2463822	0.920	rs72923207	chr11:62117959	A/G	cg06239285	chr11:62104954	ASRGL1	-1.39	-6.58	-0.56	2.58e-9	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg11965913	chr1:205819406	PM20D1	-0.94	-10.47	-0.73	1.63e-17	Menarche (age at onset);
THYM	cis	rs77688320	0.636	rs10197246	chr2:202204741	T/C	cg12544106	chr2:202507780	ALS2CR4	-0.74	-4.69	-0.43	9.16e-6	Breast cancer;
THYM	cis	rs55883249	0.957	rs17453675	chr2:9754407	A/G	cg23886495	chr2:9695866	ADAM17	0.72	4.5	0.42	1.89e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg08045932	chr20:61659980	NA	0.94	10.68	0.74	5.76e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14240646	chr10:27532245	ACBD5	-0.96	-5.37	-0.48	5.66e-7	Breast cancer;
THYM	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg17426766	chr1:2046864	PRKCZ	-0.47	-5.51	-0.49	3.05e-7	Height;
THYM	cis	rs3772130	0.962	rs1318472	chr3:121556899	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs2933343	0.649	rs728839	chr3:128589359	A/G	cg11901034	chr3:128598214	ACAD9	-0.7	-5.68	-0.5	1.47e-7	IgG glycosylation;
THYM	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.8e-10	Alzheimer's disease (late onset);
THYM	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg10117171	chr1:25599238	RHD	0.67	4.92	0.45	3.62e-6	Erythrocyte sedimentation rate;
THYM	cis	rs995000	0.965	rs10789116	chr1:63042738	A/G	cg06896770	chr1:63153194	DOCK7	1.0	8.17	0.64	1.31e-12	Triglyceride levels;
THYM	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg24209194	chr3:40518798	ZNF619	0.62	4.91	0.45	3.77e-6	Renal cell carcinoma;
THYM	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.68	-5.06	-0.46	2.08e-6	Colorectal cancer;
THYM	cis	rs7582180	0.681	rs6754176	chr2:100995691	C/T	cg14675211	chr2:100938903	LONRF2	0.59	5.65	0.5	1.67e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7106204	0.534	rs4923167	chr11:24274441	G/T	ch.11.24196551F	chr11:24239977	NA	0.93	5.71	0.51	1.3e-7	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg19748678	chr4:122722346	EXOSC9	0.71	4.93	0.45	3.44e-6	Type 2 diabetes;
THYM	cis	rs10078	0.559	rs2672725	chr5:434981	G/C	cg24955955	chr5:415729	AHRR	0.75	4.58	0.42	1.43e-5	Fat distribution (HIV);
THYM	cis	rs7404928	0.579	rs8051574	chr16:23925585	C/G	cg26685404	chr16:23957272	PRKCB	-0.57	-6.33	-0.54	8.01e-9	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs10779751	0.649	rs1318348	chr1:11130418	A/G	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs13082711	0.911	rs6775176	chr3:27432475	G/A	cg02860705	chr3:27208620	NA	0.67	4.7	0.43	8.96e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs7584330	0.784	rs1463795	chr2:238412392	C/G	cg16989719	chr2:238392110	NA	0.59	5.47	0.49	3.59e-7	Prostate cancer;
THYM	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg26408565	chr15:76604113	ETFA	-0.55	-4.85	-0.45	4.73e-6	Blood metabolite levels;
THYM	cis	rs55665837	0.559	rs11023210	chr11:14422762	A/G	cg19336497	chr11:14380999	RRAS2	0.84	11.43	0.76	1.49e-19	Vitamin D levels;
THYM	cis	rs6831352	0.879	rs1984362	chr4:100070973	G/A	cg12011299	chr4:100065546	ADH4	-0.82	-7.58	-0.61	2.26e-11	Alcohol dependence;
THYM	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg00376283	chr12:123451042	ABCB9	0.71	4.75	0.44	7.32e-6	Neutrophil percentage of white cells;
THYM	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg24692254	chr21:30365293	RNF160	-0.98	-8.78	-0.67	6.83e-14	Dental caries;
THYM	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg01699819	chr7:1052092	C7orf50	-0.6	-5.75	-0.51	1.06e-7	Bronchopulmonary dysplasia;
THYM	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs2147904	0.704	rs2764839	chr1:42368704	A/G	cg16685388	chr1:42384056	HIVEP3	0.54	4.48	0.42	2.06e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
THYM	cis	rs6840360	0.571	rs7695866	chr4:152488110	G/A	cg22705602	chr4:152727874	NA	-0.77	-8.64	-0.66	1.36e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg06697600	chr4:7070879	GRPEL1	-0.54	-4.78	-0.44	6.39e-6	Monocyte percentage of white cells;
THYM	cis	rs700651	0.789	rs62277902	chr2:198879443	T/A	cg00792783	chr2:198669748	PLCL1	-0.79	-5.35	-0.48	6.05e-7	Intracranial aneurysm;
THYM	cis	rs17021463	0.902	rs2016483	chr4:95229039	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.61	-5.47	-0.49	3.6e-7	Testicular germ cell tumor;
THYM	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg05084668	chr3:125655381	ALG1L	-0.71	-4.61	-0.43	1.23e-5	Blood pressure (smoking interaction);
THYM	cis	rs977987	0.806	rs4888405	chr16:75428196	A/C	cg03315344	chr16:75512273	CHST6	0.73	6.16	0.53	1.73e-8	Dupuytren's disease;
THYM	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg27394845	chr17:28928406	LRRC37B2	0.97	4.66	0.43	1.03e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs828999	0.688	rs6693028	chr1:108694369	C/T	cg24323958	chr1:108741884	SLC25A24	0.5	5.08	0.46	1.89e-6	Monocyte percentage of white cells;
THYM	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg16325326	chr1:53192061	ZYG11B	-0.83	-8.65	-0.66	1.28e-13	Monocyte count;
THYM	cis	rs2286885	0.896	rs62578061	chr9:129248219	C/T	cg14294646	chr9:129243551	FAM125B	-0.59	-5.47	-0.49	3.63e-7	Intraocular pressure;
THYM	cis	rs3845702	0.736	rs72962517	chr2:180861452	G/A	cg01881094	chr2:180872142	CWC22	0.92	5.53	0.49	2.76e-7	Schizophrenia;
THYM	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg18132916	chr6:79620363	NA	-0.6	-5.35	-0.48	6.07e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs2273669	0.667	rs12204576	chr6:109318843	A/G	cg17117243	chr6:109341365	SESN1	-0.91	-5.45	-0.49	4.01e-7	Prostate cancer;
THYM	cis	rs7192750	0.586	rs4788581	chr16:71967695	T/A	cg06353428	chr16:71660113	MARVELD3	0.72	5.13	0.47	1.5e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg23803603	chr1:2058230	PRKCZ	0.59	4.55	0.42	1.61e-5	Height;
THYM	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg18876405	chr7:65276391	NA	-0.57	-4.9	-0.45	3.91e-6	Calcium levels;
THYM	cis	rs2067615	0.579	rs12312782	chr12:107135647	G/A	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs13401104	0.587	rs6431443	chr2:237150311	T/C	cg19324714	chr2:237145437	ASB18	0.62	4.6	0.43	1.31e-5	Educational attainment;
THYM	cis	rs7027203	0.828	rs10122041	chr9:96615517	A/G	cg14598338	chr9:96623480	NA	-0.49	-5.22	-0.47	1.07e-6	DNA methylation (variation);
THYM	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg15247329	chr7:2764246	NA	-0.74	-6.31	-0.54	8.64e-9	Height;
THYM	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg20007245	chr22:24372913	LOC391322	-0.74	-6.29	-0.54	9.77e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg09307838	chr4:120376055	NA	-0.75	-5.41	-0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg10150615	chr22:24372951	LOC391322	0.79	7.11	0.59	2.1e-10	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg09307838	chr4:120376055	NA	-0.73	-5.76	-0.51	1.03e-7	Corneal astigmatism;
THYM	cis	rs4285028	0.747	rs10049060	chr3:121358448	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.84	7.2	0.59	1.37e-10	Multiple sclerosis;
THYM	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg06108461	chr20:60628389	TAF4	-1.03	-8.14	-0.64	1.49e-12	Body mass index;
THYM	cis	rs6988636	0.710	rs62521806	chr8:124161054	C/T	cg23067535	chr8:124195133	FAM83A	-0.99	-4.82	-0.44	5.52e-6	Urinary uromodulin levels;
THYM	cis	rs12681287	0.888	rs2976201	chr8:87335937	T/C	cg27223183	chr8:87520930	FAM82B	-0.61	-4.68	-0.43	9.49e-6	Caudate activity during reward;
THYM	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg06481639	chr22:41940642	POLR3H	-0.59	-4.73	-0.44	7.94e-6	Neuroticism;
THYM	cis	rs7107770	0.600	rs34868999	chr11:125110079	G/A	cg07747661	chr11:125106135	PKNOX2	-0.97	-5.83	-0.51	7.56e-8	Photic sneeze reflex;
THYM	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-5.05	-0.46	2.09e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg09021430	chr5:549028	NA	-0.73	-5.45	-0.49	4.01e-7	Obesity-related traits;
THYM	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.57	4.57	0.42	1.47e-5	Platelet count;
THYM	cis	rs2816062	0.813	rs2816053	chr1:18895819	A/G	cg18795169	chr1:18902165	NA	-0.99	-12.16	-0.78	4.55e-21	Urate levels in lean individuals;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg10167233	chr6:72004311	OGFRL1	-0.94	-6.92	-0.58	5.34e-10	Depressive symptoms;
THYM	cis	rs35934224	0.891	rs34249993	chr22:19872170	G/T	cg11182965	chr22:19864308	TXNRD2	-0.89	-6.63	-0.56	2.06e-9	Glaucoma (primary open-angle);
THYM	cis	rs35883536	0.647	rs17402630	chr1:101046587	C/T	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg03188948	chr7:1209495	NA	0.9	4.99	0.46	2.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8018808	0.935	rs8005759	chr14:77880493	C/T	cg20045696	chr14:77926864	AHSA1	0.5	4.46	0.42	2.27e-5	Myeloid white cell count;
THYM	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg18806716	chr10:30721971	MAP3K8	0.55	5.59	0.5	2.15e-7	Inflammatory bowel disease;
THYM	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05901451	chr6:126070800	HEY2	-0.96	-9.69	-0.71	7.62e-16	Brugada syndrome;
THYM	cis	rs12216545	0.765	rs6980388	chr7:150250709	T/C	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs9790314	1.000	rs9850455	chr3:161017192	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-7.0	-0.58	3.68e-10	Morning vs. evening chronotype;
THYM	cis	rs7107174	0.892	rs2510031	chr11:77969956	T/C	cg19901956	chr11:77921274	USP35	-0.71	-5.46	-0.49	3.75e-7	Testicular germ cell tumor;
THYM	cis	rs10411161	0.702	rs8110073	chr19:52383123	C/A	cg25361850	chr19:52391789	ZNF577	0.72	4.96	0.45	3.09e-6	Breast cancer;
THYM	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg15556689	chr8:8085844	FLJ10661	0.58	4.56	0.42	1.5e-5	Mood instability;
THYM	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg21475434	chr5:93447410	FAM172A	-0.92	-6.14	-0.53	1.93e-8	Diabetic retinopathy;
THYM	cis	rs79349575	0.783	rs832410	chr17:46972865	C/T	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg06558623	chr16:89946397	TCF25	1.36	6.6	0.56	2.33e-9	Skin colour saturation;
THYM	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4919694	1.000	rs12261040	chr10:104665397	T/C	cg04362960	chr10:104952993	NT5C2	1.06	6.61	0.56	2.24e-9	Arsenic metabolism;
THYM	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg20295408	chr7:1910781	MAD1L1	-0.68	-5.09	-0.46	1.78e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg18252515	chr7:66147081	NA	0.66	4.87	0.45	4.38e-6	Aortic root size;
THYM	cis	rs9972944	0.756	rs9907969	chr17:63754860	G/T	cg07283582	chr17:63770753	CCDC46	-0.63	-4.91	-0.45	3.8e-6	Total body bone mineral density;
THYM	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg11366901	chr6:160182831	ACAT2	1.06	9.39	0.69	3.35e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg25358565	chr5:93447407	FAM172A	-0.82	-6.07	-0.53	2.63e-8	Diabetic retinopathy;
THYM	cis	rs12049351	0.507	rs10916484	chr1:229601673	G/A	cg11742688	chr1:229674241	ABCB10	-0.55	-4.59	-0.43	1.38e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg07424592	chr7:64974309	NA	-1.04	-5.27	-0.48	8.52e-7	Diabetic kidney disease;
THYM	cis	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg13443165	chr9:33130375	B4GALT1	-0.86	-7.96	-0.63	3.71e-12	IgG glycosylation;
THYM	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg14983838	chr19:29218262	NA	1.0	8.15	0.64	1.45e-12	Methadone dose in opioid dependence;
THYM	cis	rs67385638	0.925	rs12417960	chr11:5265106	C/A	cg12559170	chr11:5275217	HBG2	0.88	9.02	0.68	2.09e-14	Hemoglobin levels;
THYM	cis	rs9399401	0.710	rs10484733	chr6:142710988	C/G	cg03128060	chr6:142623767	GPR126	0.7	9.31	0.69	4.91e-15	Chronic obstructive pulmonary disease;
THYM	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg15247329	chr7:2764246	NA	-0.7	-5.91	-0.52	5.43e-8	Height;
THYM	cis	rs28595532	0.920	rs116205107	chr4:119730910	G/A	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs1374313	0.807	rs6730710	chr2:120152250	T/C	cg18093372	chr2:119607603	NA	-0.46	-4.7	-0.43	8.81e-6	Obesity-related traits;
THYM	cis	rs4866334	1.000	rs78178098	chr5:18487497	T/C	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg08885076	chr2:99613938	TSGA10	0.66	5.97	0.52	4.17e-8	Chronic sinus infection;
THYM	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg18758796	chr5:131593413	PDLIM4	0.5	4.8	0.44	5.79e-6	Breast cancer;
THYM	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	4.84	0.44	4.97e-6	Menarche (age at onset);
THYM	cis	rs28785552	0.589	rs11669056	chr19:53244443	G/A	cg22067481	chr19:53234126	ZNF611	-0.82	-7.87	-0.63	5.58e-12	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs9677476	0.909	rs10181602	chr2:232121642	G/C	cg07929768	chr2:232055508	NA	0.62	6.15	0.53	1.8e-8	Food antigen IgG levels;
THYM	cis	rs4660306	0.961	rs7539253	chr1:45947420	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.43	-0.49	4.37e-7	Homocysteine levels;
THYM	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg09990169	chr2:241835740	C2orf54	-0.37	-6.3	-0.54	9.42e-9	Urinary metabolites;
THYM	cis	rs6842789	0.510	rs11098727	chr4:124921724	A/G	cg01723706	chr4:124814442	LOC285419	0.69	4.47	0.42	2.14e-5	Neuroticism;
THYM	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg17426766	chr1:2046864	PRKCZ	-0.47	-5.51	-0.49	3.05e-7	Height;
THYM	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg00271210	chr6:167070053	RPS6KA2	0.72	7.96	0.63	3.73e-12	Crohn's disease;
THYM	cis	rs4363385	0.747	rs4845334	chr1:152982998	T/A	cg13444842	chr1:152974279	SPRR3	-0.59	-4.68	-0.43	9.52e-6	Inflammatory skin disease;
THYM	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg10523679	chr1:76189770	ACADM	-0.89	-8.55	-0.66	2.05e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4940575	0.786	rs66836460	chr18:60837508	C/A	cg25271770	chr18:61057090	VPS4B	0.82	4.92	0.45	3.69e-6	Breast cancer;
THYM	cis	rs6840360	0.642	rs2724580	chr4:152372505	A/G	cg17479576	chr4:152424074	FAM160A1	-0.68	-5.17	-0.47	1.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg13902645	chr11:5959945	NA	-0.56	-5.08	-0.46	1.9e-6	DNA methylation (variation);
THYM	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg18252515	chr7:66147081	NA	0.64	4.68	0.43	9.54e-6	Aortic root size;
THYM	cis	rs728616	0.557	rs17107449	chr10:81715696	C/T	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs11563648	0.511	rs11563622	chr7:127057076	T/A	cg23081781	chr7:127225937	GCC1	-0.35	-4.85	-0.45	4.85e-6	Resting heart rate;
THYM	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.69	-0.67	1.03e-13	Monocyte count;
THYM	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg24375607	chr4:120327624	NA	0.53	4.47	0.42	2.2e-5	Corneal astigmatism;
THYM	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg19693284	chr19:2783607	SGTA	0.84	6.19	0.54	1.5e-8	Total cholesterol levels;
THYM	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg21385522	chr1:16154831	NA	0.76	5.61	0.5	2e-7	Dilated cardiomyopathy;
THYM	cis	rs7546094	0.509	rs7415988	chr1:113159730	G/T	cg22162597	chr1:113214053	CAPZA1	-0.63	-4.96	-0.45	3.13e-6	Platelet distribution width;
THYM	cis	rs17407555	0.697	rs73224464	chr4:10387636	T/C	cg11266682	chr4:10021025	SLC2A9	-0.52	-5.11	-0.46	1.68e-6	Schizophrenia (age at onset);
THYM	cis	rs10208940	0.614	rs13391952	chr2:68821925	C/T	cg09157127	chr2:69201416	GKN1	0.93	4.78	0.44	6.3e-6	Urate levels in lean individuals;
THYM	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg22841779	chr14:105766346	BRF1	-0.47	-5.75	-0.51	1.06e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs3091242	0.900	rs35345536	chr1:25766488	A/G	cg23205692	chr1:25664452	TMEM50A	0.79	6.3	0.54	9.43e-9	Erythrocyte sedimentation rate;
THYM	cis	rs7578361	1.000	rs10170236	chr2:150457624	C/T	cg17961725	chr2:150454027	NA	0.71	6.07	0.53	2.63e-8	Acute lymphoblastic leukemia (childhood);
THYM	trans	rs6089829	0.851	rs10854168	chr20:61669550	A/G	cg23505145	chr19:12996616	KLF1	1.02	9.71	0.71	6.74e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11252926	0.931	rs4881399	chr10:567325	A/G	cg14018140	chr10:458528	DIP2C	-0.58	-6.01	-0.53	3.34e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.57	0.56	2.72e-9	Total body bone mineral density;
THYM	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg06532163	chr17:45867833	NA	0.64	6.5	0.55	3.66e-9	IgG glycosylation;
THYM	cis	rs4731207	0.596	rs1481330	chr7:124631363	C/T	cg05285228	chr7:124571219	POT1	-0.68	-5.08	-0.46	1.88e-6	Cutaneous malignant melanoma;
THYM	cis	rs950776	0.720	rs11637890	chr15:78935419	C/G	cg06917634	chr15:78832804	PSMA4	-0.63	-4.63	-0.43	1.14e-5	Sudden cardiac arrest;
THYM	cis	rs4803468	1.000	rs10853751	chr19:41903220	G/A	cg09537434	chr19:41945824	ATP5SL	-1.12	-10.57	-0.74	1.03e-17	Height;
THYM	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9921222	0.786	rs3848365	chr16:374617	C/T	cg02086790	chr16:375327	AXIN1	-0.5	-5.87	-0.52	6.42e-8	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	5.48	0.49	3.45e-7	Schizophrenia;
THYM	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg08645402	chr16:4508243	NA	-0.66	-5.63	-0.5	1.82e-7	Schizophrenia;
THYM	cis	rs853679	0.599	rs188015	chr6:27877446	T/A	cg12963246	chr6:28129442	ZNF389	0.92	4.59	0.43	1.35e-5	Depression;
THYM	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.71	-5.62	-0.5	1.93e-7	Tonsillectomy;
THYM	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg03806693	chr22:41940476	POLR3H	-1.16	-9.9	-0.71	2.75e-16	Vitiligo;
THYM	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03576123	chr11:487126	PTDSS2	-1.29	-6.4	-0.55	5.87e-9	Body mass index;
THYM	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg24596788	chr1:163392923	NA	-0.77	-7.27	-0.6	9.92e-11	Motion sickness;
THYM	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs2235649	0.746	rs113666107	chr16:1848642	C/A	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs1878931	0.554	rs3207360	chr16:3498115	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.7	5.53	0.49	2.84e-7	Body mass index (adult);
THYM	cis	rs89107	0.575	rs11752928	chr6:118977768	C/G	cg01113488	chr6:119027122	NA	0.57	4.9	0.45	3.96e-6	Cardiac structure and function;
THYM	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg14784868	chr12:69753453	YEATS4	0.64	5.0	0.46	2.57e-6	Response to diuretic therapy;
THYM	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg04025307	chr7:1156635	C7orf50	0.55	4.77	0.44	6.54e-6	Longevity;Endometriosis;
THYM	cis	rs2046867	0.818	rs2208	chr3:72871773	A/G	cg25664220	chr3:72788482	NA	0.85	6.82	0.57	8.44e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs6754311	0.593	rs313524	chr2:136444123	C/T	cg07169764	chr2:136633963	MCM6	0.7	5.67	0.5	1.55e-7	Mosquito bite size;
THYM	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg00810483	chr4:3375144	RGS12	0.33	4.92	0.45	3.61e-6	Serum sulfate level;
THYM	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg06634786	chr22:41940651	POLR3H	0.65	4.91	0.45	3.8e-6	Vitiligo;
THYM	cis	rs17019602	0.585	rs7554525	chr1:108135527	C/T	cg02990361	chr1:107599529	PRMT6	0.84	5.0	0.46	2.58e-6	IgA nephropathy;
THYM	cis	rs2932538	0.922	rs12758377	chr1:113137221	C/A	cg22162597	chr1:113214053	CAPZA1	0.65	5.32	0.48	6.9e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg14349672	chr11:133703707	NA	-0.54	-4.74	-0.44	7.5e-6	Childhood ear infection;
THYM	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg04756594	chr16:24857601	SLC5A11	-0.75	-4.88	-0.45	4.19e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg05457628	chr5:178986728	RUFY1	-0.66	-6.85	-0.58	7.29e-10	Lung cancer;
THYM	cis	rs2688608	0.592	rs3849967	chr10:75483366	C/T	cg23231163	chr10:75533350	FUT11	-0.41	-5.9	-0.52	5.54e-8	Inflammatory bowel disease;
THYM	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg26031613	chr14:104095156	KLC1	0.76	5.12	0.47	1.58e-6	Body mass index;
THYM	cis	rs12282928	0.876	rs7937826	chr11:48299348	T/G	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	trans	rs4749080	0.541	rs10828954	chr10:26428160	G/T	cg00192819	chr18:76486611	NA	1.0	7.09	0.59	2.41e-10	Obesity-related traits;
THYM	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg09455208	chr3:40491958	NA	0.5	5.12	0.46	1.62e-6	Renal cell carcinoma;
THYM	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg21862992	chr11:68658383	NA	0.24	4.65	0.43	1.07e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs12310956	0.515	rs1872745	chr12:33985987	G/A	cg06521331	chr12:34319734	NA	-0.92	-8.57	-0.66	1.89e-13	Morning vs. evening chronotype;
THYM	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg27129171	chr3:47204927	SETD2	0.74	7.4	0.6	5.4e-11	Colorectal cancer;
THYM	cis	rs6138458	1.000	rs4273288	chr20:24900873	G/A	cg06937882	chr20:24974362	C20orf3	0.47	4.48	0.42	2.08e-5	Blood protein levels;
THYM	cis	rs7727544	0.544	rs55722650	chr5:131607300	C/T	cg21138405	chr5:131827807	IRF1	-0.48	-4.48	-0.42	2.08e-5	Blood metabolite levels;
THYM	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg02696790	chr15:75250997	RPP25	0.49	4.71	0.44	8.44e-6	Breast cancer;
THYM	cis	rs9420	0.961	rs12805841	chr11:57443842	G/A	cg19752551	chr11:57585705	CTNND1	-0.73	-8.02	-0.64	2.79e-12	Schizophrenia;
THYM	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.68	5.18	0.47	1.27e-6	Multiple sclerosis;
THYM	cis	rs303795	0.562	rs303765	chr12:52264525	A/G	cg06302118	chr12:51785656	GALNT6	0.56	4.74	0.44	7.45e-6	LDL peak particle diameter (total fat intake interaction);
THYM	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg00419117	chr1:228361641	C1orf69	0.47	4.54	0.42	1.67e-5	Diastolic blood pressure;
THYM	cis	rs6956675	1.000	rs1609527	chr7:62599257	C/T	cg08930214	chr7:62859557	LOC100287834	0.66	4.93	0.45	3.51e-6	Obesity-related traits;
THYM	cis	rs6748734	0.625	rs7598309	chr2:241824876	A/T	cg15164180	chr2:241846931	NA	-0.33	-4.53	-0.42	1.69e-5	Urinary metabolites;
THYM	cis	rs10832963	1.000	rs4757676	chr11:18640477	C/T	cg09201001	chr11:18656081	SPTY2D1	1.07	9.63	0.7	1.04e-15	Breast cancer;
THYM	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg06611532	chr13:114900021	NA	0.62	6.79	0.57	9.62e-10	Schizophrenia;
THYM	cis	rs13064411	0.696	rs6768648	chr3:113234141	C/G	cg10517650	chr3:113235015	CCDC52	-0.61	-5.34	-0.48	6.3e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	trans	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg10856724	chr12:34555212	NA	-0.94	-8.13	-0.64	1.61e-12	Bladder cancer;
THYM	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg10515332	chr4:99064459	C4orf37	0.59	4.65	0.43	1.08e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4481887	0.893	rs10736379	chr1:248455876	A/T	cg13385794	chr1:248469461	NA	0.67	4.58	0.43	1.4e-5	Common traits (Other);
THYM	cis	rs28595532	0.920	rs115226628	chr4:119639818	A/G	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs1065656	0.563	rs391546	chr16:1915581	T/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	0.41	4.48	0.42	2.12e-5	Insulin-like growth factors;
THYM	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg12165864	chr7:66369176	NA	-0.63	-4.9	-0.45	3.94e-6	Aortic root size;
THYM	cis	rs12310956	0.532	rs2087270	chr12:33850109	C/T	cg10856724	chr12:34555212	NA	-0.62	-5.59	-0.5	2.18e-7	Morning vs. evening chronotype;
THYM	cis	rs11645898	0.810	rs72787085	chr16:72182564	C/T	cg14768367	chr16:72042858	DHODH	-0.77	-5.59	-0.5	2.21e-7	Blood protein levels;
THYM	cis	rs2439831	0.681	rs2242067	chr15:43699303	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.76	6.2	0.54	1.48e-8	Lung cancer in ever smokers;
THYM	cis	rs870825	0.581	rs28602720	chr4:185630598	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs11608355	1.000	rs10774695	chr12:109868040	G/A	cg11367159	chr12:110044531	NA	0.66	6.29	0.54	9.83e-9	Neuroticism;
THYM	cis	rs2806561	0.929	rs6660880	chr1:23540302	T/C	cg12483005	chr1:23474871	LUZP1	-0.54	-5.48	-0.49	3.52e-7	Height;
THYM	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg05373962	chr22:49881684	NA	-0.7	-6.43	-0.55	5.05e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4731207	0.967	rs3807544	chr7:124400705	G/A	cg05285228	chr7:124571219	POT1	0.63	4.84	0.45	4.92e-6	Cutaneous malignant melanoma;
THYM	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg06636001	chr8:8085503	FLJ10661	0.73	6.95	0.58	4.46e-10	Neuroticism;
THYM	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg11764359	chr7:65958608	NA	-0.65	-4.98	-0.45	2.84e-6	Aortic root size;
THYM	cis	rs61931739	0.500	rs7134491	chr12:34443072	C/T	cg10856724	chr12:34555212	NA	-1.03	-8.62	-0.66	1.46e-13	Morning vs. evening chronotype;
THYM	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs17253792	0.822	rs76918910	chr14:56058762	T/C	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs6732160	0.588	rs7578991	chr2:73376171	A/G	cg24220031	chr2:73402428	NA	-0.71	-5.79	-0.51	8.94e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9790314	1.000	rs464766	chr3:161087592	C/G	cg03342759	chr3:160939853	NMD3	-0.73	-6.57	-0.56	2.67e-9	Morning vs. evening chronotype;
THYM	cis	rs9644630	0.897	rs28671342	chr8:19352420	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.71	-7.06	-0.59	2.78e-10	Oropharynx cancer;
THYM	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg01416388	chr22:39784598	NA	-0.87	-6.83	-0.57	8.07e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs6840360	1.000	rs6535821	chr4:152678974	T/C	cg22705602	chr4:152727874	NA	-0.57	-6.17	-0.53	1.7e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11585357	0.895	rs72633808	chr1:17618665	A/G	cg08277548	chr1:17600880	PADI3	-0.89	-5.36	-0.48	5.87e-7	Hair shape;
THYM	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg15592062	chr6:167189543	RPS6KA2	0.59	6.16	0.53	1.73e-8	Crohn's disease;
THYM	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs7616559	0.512	rs1600978	chr3:156734799	G/C	cg15697575	chr3:156784781	NA	0.36	5.11	0.46	1.64e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs7172809	0.574	rs74026913	chr15:77733083	A/G	cg22256960	chr15:77711686	NA	-0.62	-4.57	-0.42	1.45e-5	Glucose homeostasis traits;
THYM	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7781557	1.000	rs7781557	chr7:102481891	A/G	cg06322601	chr7:102330635	NA	-0.67	-5.05	-0.46	2.1e-6	Colorectal adenoma (advanced);
THYM	cis	rs10463554	0.892	rs34816	chr5:102434645	T/G	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs35264875	0.898	rs55648928	chr11:68861591	G/T	cg01993067	chr11:68851601	TPCN2	1.0	5.27	0.48	8.46e-7	Blond vs. brown hair color;
THYM	cis	rs995000	0.931	rs10889347	chr1:63075826	G/A	cg06896770	chr1:63153194	DOCK7	0.92	7.57	0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs7326068	0.510	rs4432108	chr13:21342151	G/A	cg27499820	chr13:21296301	IL17D	0.61	4.5	0.42	1.91e-5	Schizophrenia, bipolar disorder and depression (combined);
THYM	cis	rs13326165	0.585	rs17052054	chr3:52337754	C/T	cg08438690	chr3:52279403	PPM1M	-0.8	-4.69	-0.43	9.03e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs2273669	0.667	rs11153155	chr6:109359963	G/A	cg17117243	chr6:109341365	SESN1	-0.86	-4.96	-0.45	3.05e-6	Prostate cancer;
THYM	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg02753203	chr1:228287806	NA	-0.61	-5.28	-0.48	8.19e-7	Diastolic blood pressure;
THYM	cis	rs7267979	1.000	rs2027004	chr20:25350618	C/T	cg08601574	chr20:25228251	PYGB	-0.58	-4.71	-0.43	8.54e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18402987	chr7:1209562	NA	0.75	5.38	0.48	5.33e-7	Longevity;Endometriosis;
THYM	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.05	5.32	0.48	6.81e-7	Initial pursuit acceleration;
THYM	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs1568889	1.000	rs7931847	chr11:28175245	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.66e-6	Bipolar disorder;
THYM	cis	rs526231	0.543	rs246901	chr5:102584178	G/A	cg23492399	chr5:102201601	PAM	-0.72	-5.27	-0.48	8.44e-7	Primary biliary cholangitis;
THYM	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.66	5.82	0.51	7.79e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs13326165	0.760	rs59612757	chr3:52299521	T/C	cg08438690	chr3:52279403	PPM1M	-0.65	-4.72	-0.44	8.02e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs7618501	0.521	rs11712056	chr3:49914397	T/C	cg14019146	chr3:50243930	SLC38A3	-0.63	-5.56	-0.5	2.51e-7	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.663	rs1052299	chr17:17750419	A/G	cg16928487	chr17:17741425	SREBF1	0.53	5.11	0.46	1.66e-6	Total body bone mineral density;
THYM	cis	rs763014	0.931	rs11643039	chr16:634260	G/A	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs977987	0.806	rs4888404	chr16:75428097	G/A	cg03315344	chr16:75512273	CHST6	0.73	6.16	0.53	1.73e-8	Dupuytren's disease;
THYM	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22509189	chr2:225307070	NA	-0.9	-7.68	-0.62	1.43e-11	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs2639990	1.000	rs609303	chr18:72895242	C/T	cg18449964	chr18:72917101	ZADH2	1.29	6.2	0.54	1.48e-8	Vascular endothelial growth factor levels;
THYM	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg08000102	chr2:233561755	GIGYF2	-0.79	-6.9	-0.58	5.85e-10	Coronary artery disease;
THYM	cis	rs6473252	0.544	rs10957987	chr8:81819762	A/C	cg08595989	chr8:81827712	NA	-0.51	-5.6	-0.5	2.12e-7	Breast cancer;
THYM	cis	rs2932538	0.922	rs61818800	chr1:113148571	A/G	cg22162597	chr1:113214053	CAPZA1	0.62	4.89	0.45	4.03e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs6754311	0.597	rs2278544	chr2:136546110	A/G	cg20242066	chr2:136595261	LCT	-0.56	-6.86	-0.58	7.1e-10	Mosquito bite size;
THYM	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg18681998	chr4:17616180	MED28	0.8	6.73	0.57	1.29e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg10505658	chr17:80084571	CCDC57	-0.74	-8.13	-0.64	1.59e-12	Life satisfaction;
THYM	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg00898013	chr13:113819073	PROZ	-0.89	-9.2	-0.69	8.65e-15	Platelet distribution width;
THYM	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg15448220	chr1:150897856	SETDB1	0.86	6.94	0.58	4.73e-10	Melanoma;
THYM	cis	rs7954638	1	rs7954638	chr12:96314795	C/A	cg20354882	chr12:96350795	AMDHD1	0.59	5.37	0.48	5.61e-7	Metabolite levels (small molecules and protein measures);
THYM	cis	rs2985684	0.894	rs2883436	chr14:50013822	T/C	cg02151108	chr14:50098012	C14orf104	-0.78	-6.66	-0.56	1.77e-9	Carotid intima media thickness;
THYM	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs7084402	1.000	rs4113952	chr10:60268599	A/G	cg07615347	chr10:60278583	BICC1	0.55	5.09	0.46	1.83e-6	Refractive error;
THYM	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg19346786	chr7:2764209	NA	-0.71	-6.01	-0.53	3.36e-8	Height;
THYM	cis	rs7909791	0.809	rs12570462	chr10:105613329	A/G	cg24587175	chr10:105670608	OBFC1	-0.66	-6.28	-0.54	9.99e-9	White matter hyperintensity burden;
THYM	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg20744362	chr22:50050164	C22orf34	0.67	6.06	0.53	2.74e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs28595532	1.000	rs114682099	chr4:119702004	C/T	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs548181	0.577	rs569766	chr11:125532369	G/A	cg03464685	chr11:125439445	EI24	1.24	7.56	0.61	2.49e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9807841	0.670	rs2569512	chr19:10790162	A/G	cg17848348	chr19:10766748	ILF3	-0.9	-8.24	-0.65	9.54e-13	Inflammatory skin disease;
THYM	cis	rs9470366	0.535	rs762624	chr6:36645588	A/C	cg24425727	chr6:36645648	CDKN1A	-0.59	-5.18	-0.47	1.23e-6	QRS duration;
THYM	cis	rs6570726	0.791	rs6915094	chr6:145883540	C/G	cg13319975	chr6:146136371	FBXO30	-0.64	-5.22	-0.47	1.06e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg12310025	chr6:25882481	NA	-1.11	-11.25	-0.76	3.64e-19	Urate levels;
THYM	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg03859395	chr2:55845619	SMEK2	0.7	6.23	0.54	1.28e-8	Metabolic syndrome;
THYM	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg06453172	chr10:134556979	INPP5A	0.69	4.99	0.46	2.73e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs12282928	1.000	rs6485821	chr11:48292594	C/G	cg22827986	chr11:48284249	OR4X1	0.51	5.24	0.47	9.8e-7	Migraine - clinic-based;
THYM	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.95	-0.52	4.5e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-4.95	-0.45	3.23e-6	Lymphocyte counts;
THYM	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.45	-5.59	-0.5	2.16e-7	Monocyte percentage of white cells;
THYM	cis	rs7975161	0.572	rs10861163	chr12:104568613	C/A	cg25273343	chr12:104657179	TXNRD1	-0.71	-4.86	-0.45	4.55e-6	Toenail selenium levels;
THYM	cis	rs524281	0.773	rs79770412	chr11:66045344	G/C	cg00563793	chr11:65837595	PACS1	0.81	4.87	0.45	4.42e-6	Electroencephalogram traits;
THYM	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg16594139	chr19:49340574	PLEKHA4;HSD17B14	1.01	5.03	0.46	2.33e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg17063962	chr7:91808500	NA	-1.06	-8.97	-0.68	2.59e-14	Breast cancer;
THYM	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg18132916	chr6:79620363	NA	-0.56	-4.85	-0.45	4.75e-6	Intelligence (multi-trait analysis);
THYM	cis	rs600806	0.850	rs1880670	chr1:109941133	C/T	cg16988986	chr1:109941118	SORT1	-0.43	-4.56	-0.42	1.5e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9902453	0.899	rs1979572	chr17:28511978	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.83	0.44	5.26e-6	Coffee consumption (cups per day);
THYM	cis	rs782590	0.721	rs1084525	chr2:55929430	C/T	cg18811423	chr2:55921094	PNPT1	0.73	6.58	0.56	2.55e-9	Metabolic syndrome;
THYM	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg17691542	chr6:26056736	HIST1H1C	0.73	4.69	0.43	9.12e-6	Iron status biomarkers;
THYM	cis	rs7084402	0.967	rs1427223	chr10:60290966	T/C	cg09696939	chr10:60272079	BICC1	-0.5	-5.96	-0.52	4.19e-8	Refractive error;
THYM	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg17105886	chr17:28927953	LRRC37B2	1.25	6.76	0.57	1.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.84	-5.3	-0.48	7.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg10018233	chr7:150070692	REPIN1	0.5	7.76	0.62	9.42e-12	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28595532	0.920	rs114207133	chr4:119755140	T/C	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs4792901	0.802	rs79934399	chr17:41571961	C/T	cg21940313	chr17:41620911	ETV4	-0.54	-5.13	-0.47	1.5e-6	Dupuytren's disease;
THYM	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9790314	0.747	rs9990115	chr3:160838412	C/G	cg04691961	chr3:161091175	C3orf57	-0.61	-4.71	-0.44	8.33e-6	Morning vs. evening chronotype;
THYM	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg26597838	chr10:835615	NA	1.23	8.86	0.67	4.56e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs10037758	0.522	rs257903	chr5:128315434	A/G	cg02841155	chr5:128301328	SLC27A6	-0.51	-5.07	-0.46	1.98e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8030379	0.967	rs6603000	chr15:84551894	C/T	cg15564896	chr15:84287328	SH3GL3	0.57	4.77	0.44	6.57e-6	Waist circumference adjusted for body mass index;Waist circumference;
THYM	cis	rs4266144	0.544	rs13080798	chr3:156832401	G/T	cg16248515	chr3:156840234	NA	-0.58	-5.39	-0.48	5.15e-7	Coronary artery disease;
THYM	cis	rs7107174	1.000	rs9651769	chr11:77996166	T/C	cg02023728	chr11:77925099	USP35	0.66	5.9	0.52	5.46e-8	Testicular germ cell tumor;
THYM	cis	rs2361710	0.611	rs12451471	chr17:78102517	C/T	cg06718696	chr17:78121285	EIF4A3	0.67	5.42	0.49	4.57e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
THYM	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg04362960	chr10:104952993	NT5C2	0.59	5.01	0.46	2.47e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11890956	chr21:40555474	PSMG1	-1.17	-12.72	-0.79	3.2e-22	Cognitive function;
THYM	cis	rs4478037	0.822	rs9825335	chr3:33123292	A/C	cg19404215	chr3:33155277	CRTAP	0.96	6.51	0.56	3.58e-9	Major depressive disorder;
THYM	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.13	0.59	1.95e-10	Prudent dietary pattern;
THYM	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.65	-4.83	-0.44	5.26e-6	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs289828	0.507	rs3771882	chr2:152126966	G/A	cg05960677	chr2:152117363	RBM43	0.76	8.1	0.64	1.82e-12	Blood protein levels;
THYM	cis	rs3733631	1.000	rs3796951	chr4:104628158	A/T	cg24090629	chr4:104641072	TACR3	0.82	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	cis	rs4589258	0.933	rs7102581	chr11:90396327	T/C	cg26834418	chr11:89957033	CHORDC1	0.49	4.45	0.42	2.31e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg12756686	chr19:29218302	NA	0.71	4.76	0.44	6.8e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg26038318	chr20:34205095	SPAG4	0.57	4.49	0.42	2.04e-5	Total cholesterol levels;
THYM	cis	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg19847130	chr8:10466454	RP1L1	0.52	4.46	0.42	2.29e-5	Neuroticism;
THYM	cis	rs6964587	0.547	rs12704628	chr7:91478070	G/A	cg22709100	chr7:91322751	NA	-0.64	-4.7	-0.43	8.91e-6	Breast cancer;
THYM	cis	rs6918586	0.658	rs198822	chr6:26123539	G/C	cg12310025	chr6:25882481	NA	0.68	5.56	0.5	2.47e-7	Schizophrenia;
THYM	cis	rs1729951	0.546	rs835634	chr3:136676303	C/T	cg21827317	chr3:136751795	NA	0.74	6.6	0.56	2.29e-9	Neuroticism;
THYM	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs3857067	0.806	rs72665608	chr4:95093501	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg10360139	chr7:1886902	MAD1L1	-0.6	-5.26	-0.47	8.94e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.752	rs35436270	chr4:99088280	G/A	cg24818145	chr4:99064322	C4orf37	0.82	6.03	0.53	3.12e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs72781680	1.000	rs72796328	chr2:24141343	A/G	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg06387496	chr7:2775674	GNA12	-0.43	-4.47	-0.42	2.2e-5	Height;
THYM	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.21	9.47	0.7	2.27e-15	Platelet count;
THYM	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7100689	0.577	rs2342813	chr10:82046302	T/G	cg01528321	chr10:82214614	TSPAN14	0.82	6.07	0.53	2.66e-8	Post bronchodilator FEV1;
THYM	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06873352	chr17:61820015	STRADA	0.57	5.68	0.5	1.46e-7	Height;
THYM	cis	rs9527	0.615	rs7080462	chr10:104736699	T/C	cg04362960	chr10:104952993	NT5C2	0.63	4.76	0.44	6.9e-6	Arsenic metabolism;
THYM	cis	rs13323323	1.000	rs13323323	chr3:44333324	G/T	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.53	-4.71	-0.43	8.54e-6	IgG glycosylation;
THYM	cis	rs892961	0.932	rs12453822	chr17:75416792	G/A	cg05865280	chr17:75406074	SEPT9	0.48	7.81	0.63	7.44e-12	Airflow obstruction;
THYM	cis	rs17005891	0.549	rs111805711	chr4:83575217	T/C	cg10249074	chr4:83542146	C4orf11	-0.68	-5.44	-0.49	4.19e-7	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs870825	0.520	rs10022842	chr4:185649459	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg10911889	chr6:126070802	HEY2	0.56	4.66	0.43	1.03e-5	Brugada syndrome;
THYM	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg17143192	chr8:8559678	CLDN23	-0.58	-4.54	-0.42	1.65e-5	Myopia (pathological);
THYM	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.21	8.51	0.66	2.47e-13	Cognitive test performance;
THYM	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg00012203	chr2:219082015	ARPC2	0.67	5.5	0.49	3.17e-7	Pyoderma gangrenosum in inflammatory bowel disease;
THYM	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	6.06	0.53	2.73e-8	Obesity-related traits;
THYM	cis	rs354225	0.584	rs13432302	chr2:54813938	A/C	cg23486701	chr2:54789491	SPTBN1	0.35	4.68	0.43	9.65e-6	Schizophrenia;
THYM	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.55	-6.55	-0.56	3e-9	Longevity;Endometriosis;
THYM	cis	rs1215050	0.740	rs1214997	chr4:99041533	A/T	cg17366294	chr4:99064904	C4orf37	0.41	4.55	0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg25072359	chr17:41440525	NA	0.73	5.12	0.46	1.62e-6	Menopause (age at onset);
THYM	cis	rs2811415	0.597	rs55662362	chr3:127774723	A/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg22681709	chr2:178499509	PDE11A	0.58	5.43	0.49	4.31e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6547741	1.000	rs6756238	chr2:27841305	G/A	cg27432699	chr2:27873401	GPN1	0.72	6.29	0.54	9.71e-9	Oral cavity cancer;
THYM	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.02	6.76	0.57	1.11e-9	Smoking behavior;
THYM	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg17279839	chr7:150038598	RARRES2	0.54	5.39	0.48	5.08e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7725337	0.965	rs2217257	chr5:88342592	C/T	cg11280525	chr5:87955695	LOC645323	-0.4	-4.49	-0.42	2.03e-5	Total body bone mineral density;
THYM	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg00271210	chr6:167070053	RPS6KA2	0.68	7.08	0.59	2.45e-10	Crohn's disease;
THYM	cis	rs9290065	0.538	rs9860182	chr3:160768962	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-4.49	-0.42	2.02e-5	Kawasaki disease;
THYM	cis	rs9790314	1.000	rs336589	chr3:161080358	C/T	cg03342759	chr3:160939853	NMD3	-0.73	-6.54	-0.56	3.03e-9	Morning vs. evening chronotype;
THYM	cis	rs7584330	0.518	rs7585969	chr2:238439073	G/A	cg14458575	chr2:238380390	NA	1.0	5.68	0.5	1.47e-7	Prostate cancer;
THYM	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg05738196	chr6:26577821	NA	0.6	4.83	0.44	5.25e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12643440	0.538	rs1357233	chr4:17143376	A/C	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs4808199	0.948	rs2023883	chr19:19405480	G/A	cg03709012	chr19:19516395	GATAD2A	1.15	6.73	0.57	1.28e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs11811982	0.793	rs115643064	chr1:227416153	A/G	cg09853570	chr1:228403422	OBSCN	1.21	4.67	0.43	9.81e-6	Optic disc area;
THYM	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg13395646	chr4:1353034	KIAA1530	-0.54	-4.82	-0.44	5.51e-6	Obesity-related traits;
THYM	cis	rs7546094	1.000	rs6682737	chr1:113136229	T/C	cg22162597	chr1:113214053	CAPZA1	0.45	4.63	0.43	1.17e-5	Platelet distribution width;
THYM	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg27170947	chr2:26402098	FAM59B	-0.57	-4.85	-0.45	4.9100000000000004e-06	Gut microbiome composition (summer);
THYM	cis	rs919433	0.963	rs1896854	chr2:198147776	G/T	cg00792783	chr2:198669748	PLCL1	-0.65	-4.72	-0.44	8e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg01699819	chr7:1052092	C7orf50	-0.79	-6.31	-0.54	8.97e-9	Bronchopulmonary dysplasia;
THYM	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg25208724	chr1:156163844	SLC25A44	1.13	12.94	0.8	1.09e-22	Testicular germ cell tumor;
THYM	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg07606381	chr6:8435919	SLC35B3	0.65	4.96	0.45	3.05e-6	Motion sickness;
THYM	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg20999797	chr1:1681921	NA	0.5	5.51	0.49	3.1e-7	Body mass index;
THYM	cis	rs28595532	0.920	rs73842253	chr4:119721856	G/A	cg21605333	chr4:119757512	SEC24D	1.5	5.52	0.49	2.92e-7	Cannabis dependence symptom count;
THYM	cis	rs988913	0.768	rs2179786	chr6:54753340	G/T	cg04690482	chr6:54711388	FAM83B	0.54	6.6	0.56	2.3e-9	Menarche (age at onset);
THYM	cis	rs35883536	0.588	rs17403878	chr1:101105310	C/T	cg06223162	chr1:101003688	GPR88	0.58	5.09	0.46	1.8e-6	Monocyte count;
THYM	cis	rs7200543	1.000	rs72774845	chr16:15147954	A/C	cg01933576	chr16:15083564	PDXDC1	-0.95	-8.08	-0.64	2.07e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs61841072	0.961	rs6657349	chr1:243124511	G/T	cg02356786	chr1:243265016	LOC731275	0.52	4.7	0.43	8.7e-6	Schizophrenia;
THYM	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg01570182	chr17:44337453	NA	-0.6	-6.42	-0.55	5.32e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg19875535	chr5:140030758	IK	-0.63	-5.69	-0.5	1.43e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg00083206	chr6:110721305	DDO	-0.58	-6.96	-0.58	4.42e-10	Platelet distribution width;
THYM	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	5.26	0.48	8.71e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7584330	0.617	rs10202195	chr2:238352128	A/G	cg16989719	chr2:238392110	NA	-0.6	-5.42	-0.49	4.42e-7	Prostate cancer;
THYM	cis	rs6754311	0.593	rs2034276	chr2:136422171	A/T	cg20242066	chr2:136595261	LCT	0.55	6.04	0.53	3.05e-8	Mosquito bite size;
THYM	cis	rs2882877	0.648	rs13027987	chr2:190389720	C/G	cg10752008	chr2:190445175	SLC40A1	-0.72	-6.09	-0.53	2.41e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg04455712	chr21:45112962	RRP1B	0.54	4.85	0.45	4.79e-6	Mean corpuscular volume;
THYM	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg03609598	chr5:56110824	MAP3K1	-0.89	-6.07	-0.53	2.63e-8	Initial pursuit acceleration;
THYM	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg21385522	chr1:16154831	NA	0.65	4.65	0.43	1.08e-5	Systolic blood pressure;
THYM	cis	rs9581857	0.725	rs1924074	chr13:28015387	C/G	cg22138327	chr13:27999177	GTF3A	-0.89	-4.98	-0.46	2.82e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg21433313	chr16:3507492	NAT15	-0.54	-4.57	-0.42	1.46e-5	Body mass index (adult);
THYM	cis	rs34375054	0.872	rs4622332	chr12:125667376	C/T	cg25124228	chr12:125621409	AACS	-0.73	-5.89	-0.52	5.9e-8	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg15693483	chr7:1102177	C7orf50	0.54	6.26	0.54	1.1e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7731657	0.537	rs72801793	chr5:130376936	A/T	cg08523029	chr5:130500466	HINT1	-0.85	-6.0	-0.52	3.63e-8	Fasting plasma glucose;
THYM	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg26028573	chr6:26043587	HIST1H2BB	0.51	4.47	0.42	2.18e-5	Blood metabolite levels;
THYM	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs2505998	0.868	rs2505991	chr10:43566360	A/G	cg06632098	chr10:43605906	RET	-1.04	-9.23	-0.69	7.14e-15	Hirschsprung disease;
THYM	cis	rs3781426	1.000	rs11245472	chr10:126719263	G/C	cg04494136	chr10:126703576	CTBP2	-0.39	-5.3	-0.48	7.52e-7	Height;
THYM	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg18252515	chr7:66147081	NA	-0.72	-5.6	-0.5	2.03e-7	Aortic root size;
THYM	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg18230493	chr5:56204884	C5orf35	-0.9	-6.78	-0.57	9.95e-10	Initial pursuit acceleration;
THYM	cis	rs11031096	0.754	rs10835611	chr11:4117730	G/C	cg18678763	chr11:4115507	RRM1	-0.39	-5.21	-0.47	1.09e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.21	8.51	0.66	2.47e-13	Cognitive test performance;
THYM	cis	rs4638749	0.627	rs1522020	chr2:108833346	C/G	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs7631605	0.905	rs6809297	chr3:37181591	G/A	cg21328643	chr3:37258149	NA	-0.5	-4.87	-0.45	4.38e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg05501817	chr11:14380813	RRAS2	0.73	5.52	0.49	2.94e-7	Sense of smell;
THYM	cis	rs1021993	0.672	rs1876409	chr1:209481103	C/A	cg24997231	chr1:209527535	NA	0.5	4.55	0.42	1.57e-5	Gut microbiome composition (winter);
THYM	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg00106254	chr7:1943704	MAD1L1	-0.48	-4.46	-0.42	2.26e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg00278517	chr6:167070616	RPS6KA2	-0.34	-4.67	-0.43	9.84e-6	Crohn's disease;
THYM	cis	rs2963155	0.518	rs33389	chr5:142700499	C/T	cg17617527	chr5:142782415	NR3C1	1.06	5.57	0.5	2.32e-7	Breast cancer;
THYM	cis	rs4242434	0.927	rs11136092	chr8:22466488	T/G	cg11461670	chr8:22454935	PDLIM2	-0.38	-6.33	-0.54	7.9e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg01416388	chr22:39784598	NA	-0.94	-8.89	-0.67	3.85e-14	Intelligence (multi-trait analysis);
THYM	cis	rs11756438	0.572	rs902779	chr6:119000593	A/C	cg21191810	chr6:118973309	C6orf204	0.55	5.62	0.5	1.92e-7	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs12410462	0.502	rs75429875	chr1:227957200	A/C	cg23173402	chr1:227635558	NA	0.67	4.86	0.45	4.7e-6	Major depressive disorder;
THYM	cis	rs295140	1.000	rs7584810	chr2:201167772	G/A	cg04283868	chr2:201171347	SPATS2L	0.74	5.53	0.49	2.81e-7	QT interval;
THYM	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg09455208	chr3:40491958	NA	0.51	5.39	0.48	5.03e-7	Renal cell carcinoma;
THYM	cis	rs12956009	0.583	rs12327454	chr18:44863964	C/T	cg19077165	chr18:44547161	KATNAL2	-0.49	-4.57	-0.42	1.49e-5	Educational attainment (years of education);
THYM	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14159672	chr1:205819179	PM20D1	1.05	11.28	0.76	3.17e-19	Menarche (age at onset);
THYM	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs11771526	0.901	rs62457472	chr7:32306885	A/G	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg08885076	chr2:99613938	TSGA10	-0.59	-5.85	-0.51	7.08e-8	Chronic sinus infection;
THYM	cis	rs245880	0.740	rs245885	chr7:29188554	A/G	cg17163760	chr7:29186267	CPVL	-0.59	-4.94	-0.45	3.3e-6	Warfarin maintenance dose;
THYM	cis	rs72828912	0.665	rs3846826	chr6:24097567	T/C	cg26336265	chr6:25042955	NA	-0.8	-5.09	-0.46	1.84e-6	Squamous cell lung carcinoma;
THYM	cis	rs2970992	0.728	rs3112256	chr2:101321822	A/G	cg01042948	chr2:101319752	NA	-0.58	-5.76	-0.51	1.01e-7	Educational attainment;
THYM	cis	rs7584330	0.518	rs78856668	chr2:238438055	A/C	cg08992911	chr2:238395768	MLPH	1.16	6.9	0.58	5.73e-10	Prostate cancer;
THYM	cis	rs11030122	0.661	rs10767811	chr11:4066398	G/A	cg18678763	chr11:4115507	RRM1	-0.42	-5.6	-0.5	2.05e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9914988	0.887	rs34644886	chr17:27168327	T/C	cg20469991	chr17:27169893	C17orf63	-0.78	-4.89	-0.45	4.05e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg00647820	chr17:40259828	DHX58	-0.62	-4.65	-0.43	1.06e-5	Fibrinogen levels;
THYM	cis	rs6032067	0.641	rs34638860	chr20:43765839	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.47	-5.31	-0.48	7.26e-7	Blood protein levels;
THYM	cis	rs28595532	0.920	rs114684527	chr4:119749252	G/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs4918072	0.728	rs7099351	chr10:105710933	A/G	cg11005552	chr10:105648138	OBFC1	0.58	4.79	0.44	6.06e-6	Coronary artery disease;
THYM	cis	rs9831754	0.906	rs7621811	chr3:78388816	G/A	cg06138941	chr3:78371609	NA	-0.64	-4.55	-0.42	1.6e-5	Calcium levels;
THYM	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg11764359	chr7:65958608	NA	-0.75	-6.05	-0.53	2.82e-8	Aortic root size;
THYM	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.06	-0.64	2.28e-12	Mean corpuscular volume;
THYM	cis	rs4072705	1.000	rs4838201	chr9:127460617	C/T	cg01786973	chr9:127249749	NR5A1	0.37	4.89	0.45	4.02e-6	Menarche (age at onset);
THYM	cis	rs950394	0.767	rs73946421	chr2:104991674	A/C	cg20302975	chr2:105468274	NA	-0.66	-4.56	-0.42	1.52e-5	Schizophrenia;
THYM	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg24112000	chr20:60950667	NA	-0.82	-7.55	-0.61	2.7e-11	Colorectal cancer;
THYM	trans	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg10856724	chr12:34555212	NA	-0.99	-8.42	-0.65	3.84e-13	Bladder cancer;
THYM	cis	rs13315871	0.790	rs115288459	chr3:58324283	A/G	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Bladder cancer;
THYM	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg06028808	chr11:68637592	NA	0.68	7.24	0.6	1.18e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14240646	chr10:27532245	ACBD5	-0.78	-4.74	-0.44	7.52e-6	Breast cancer;
THYM	cis	rs2133450	0.526	rs12489404	chr3:7346698	C/T	cg19930620	chr3:7340148	GRM7	-0.52	-5.62	-0.5	1.86e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg09338302	chr7:1325757	NA	0.47	4.46	0.42	2.27e-5	Bipolar disorder;
THYM	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.01	11.08	0.75	8.19e-19	Intelligence (multi-trait analysis);
THYM	cis	rs2075230	0.705	rs2541010	chr17:7551320	T/C	cg27413385	chr17:7515425	FXR2	-0.36	-5.31	-0.48	7.3e-7	Hormone measurements;
THYM	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg24642844	chr7:1081250	C7orf50	-1.19	-5.14	-0.47	1.47e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg11663144	chr21:46675770	NA	-0.71	-9.92	-0.71	2.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3785574	1.000	rs3785574	chr17:61763185	T/C	cg06873352	chr17:61820015	STRADA	0.54	4.85	0.45	4.8e-6	Height;
THYM	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg22709100	chr7:91322751	NA	0.61	4.86	0.45	4.66e-6	Breast cancer;
THYM	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.7	5.16	0.47	1.33e-6	Renal function-related traits (BUN);
THYM	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg10523679	chr1:76189770	ACADM	0.92	10.35	0.73	2.94e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs7584330	0.518	rs74003106	chr2:238447004	A/G	cg14458575	chr2:238380390	NA	0.82	4.53	0.42	1.74e-5	Prostate cancer;
THYM	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.67	-4.49	-0.42	1.98e-5	Menarche (age at onset);
THYM	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg11266682	chr4:10021025	SLC2A9	0.69	10.53	0.73	1.22e-17	Bone mineral density;
THYM	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg19196401	chr6:110721138	DDO	-0.54	-6.03	-0.53	3.16e-8	Platelet distribution width;
THYM	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	4.78	0.44	6.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs870825	0.616	rs7667409	chr4:185650941	C/T	cg04058563	chr4:185651563	MLF1IP	-1.07	-9.65	-0.7	9.06e-16	Blood protein levels;
THYM	cis	rs7106204	0.668	rs7119362	chr11:24218132	G/T	ch.11.24196551F	chr11:24239977	NA	1.04	7.55	0.61	2.59e-11	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg11502198	chr6:26597334	ABT1	0.64	5.68	0.5	1.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg12908607	chr1:44402522	ARTN	-0.6	-5.36	-0.48	5.85e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2235573	0.789	rs4821733	chr22:38449394	A/G	cg19171272	chr22:38449367	NA	0.52	6.03	0.53	3.1e-8	Glioblastoma;Glioma;
THYM	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg11247378	chr22:39784982	NA	-0.95	-9.48	-0.7	2.15e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-5.19	-0.47	1.17e-6	Chronic sinus infection;
THYM	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs4866334	1.000	rs78447918	chr5:18488634	T/A	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs6456042	0.929	rs3127421	chr6:166539059	A/G	cg11088901	chr6:166572345	T	-0.52	-4.9	-0.45	3.93e-6	Asthma;
THYM	cis	rs3750965	0.919	rs12280942	chr11:68859683	A/G	cg01403660	chr11:68851641	TPCN2	-0.75	-6.39	-0.55	6.05e-9	Hair color;
THYM	cis	rs7772486	0.840	rs2814864	chr6:146345046	A/C	cg23711669	chr6:146136114	FBXO30	0.74	6.85	0.57	7.38e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg13695892	chr22:41940480	POLR3H	0.93	7.39	0.6	5.75e-11	Vitiligo;
THYM	cis	rs6032067	1.000	rs34885285	chr20:43804789	C/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs4595586	0.545	rs6580889	chr12:39369742	T/C	cg26384229	chr12:38710491	ALG10B	0.71	5.5	0.49	3.21e-7	Morning vs. evening chronotype;
THYM	cis	rs4660456	0.596	rs1534956	chr1:41186443	G/A	cg11417323	chr1:41160271	NFYC	0.41	4.5	0.42	1.9e-5	Platelet count;
THYM	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg00129232	chr17:37814104	STARD3	0.76	5.25	0.47	9.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs36051895	0.664	rs3824433	chr9:5113577	C/T	cg02405213	chr9:5042618	JAK2	-1.0	-11.2	-0.75	4.62e-19	Pediatric autoimmune diseases;
THYM	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg12386194	chr3:101231763	SENP7	0.64	4.8	0.44	5.91e-6	Colorectal cancer;
THYM	cis	rs793108	0.804	rs2793103	chr10:31411113	C/T	cg07137701	chr10:31611868	ZEB1	-0.51	-4.82	-0.44	5.47e-6	Multiple sclerosis;Rheumatoid arthritis;
THYM	cis	rs936229	0.871	rs2290574	chr15:75135447	T/C	cg14664628	chr15:75095509	CSK	-1.04	-8.16	-0.64	1.36e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg21773646	chr17:80085082	CCDC57	-0.35	-4.95	-0.45	3.2e-6	Life satisfaction;
THYM	cis	rs10887741	0.546	rs7078618	chr10:89440911	A/G	cg13926569	chr10:89418898	PAPSS2	0.62	7.28	0.6	9.55e-11	Exercise (leisure time);
THYM	cis	rs2425143	1.000	rs2425093	chr20:34306875	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.76	-0.44	6.84e-6	Blood protein levels;
THYM	cis	rs11096990	0.656	rs2066788	chr4:39301605	G/C	cg24403649	chr4:39172243	NA	-0.63	-5.43	-0.49	4.29e-7	Cognitive function;
THYM	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg05890377	chr2:74357713	NA	1.06	10.33	0.73	3.21e-17	Gestational age at birth (maternal effect);
THYM	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs11096990	0.552	rs7655170	chr4:39173604	T/G	cg24403649	chr4:39172243	NA	0.57	4.95	0.45	3.28e-6	Cognitive function;
THYM	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg03517284	chr6:25882590	NA	-1.21	-11.36	-0.76	2.1e-19	Intelligence (multi-trait analysis);
THYM	cis	rs863345	0.604	rs10797022	chr1:158494193	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg13319975	chr6:146136371	FBXO30	-0.66	-5.22	-0.47	1.06e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9393692	0.620	rs9379842	chr6:26289310	C/T	cg13736514	chr6:26305472	NA	0.47	4.87	0.45	4.39e-6	Educational attainment;
THYM	cis	rs6728642	0.572	rs60621865	chr2:97598001	T/C	cg01990225	chr2:97406019	LMAN2L	-0.79	-4.68	-0.43	9.64e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg09307838	chr4:120376055	NA	-0.74	-5.26	-0.47	8.88e-7	Corneal astigmatism;
THYM	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg27087555	chr16:88793112	FAM38A	-1.27	-7.89	-0.63	5.1e-12	Plateletcrit;
THYM	cis	rs600550	0.791	rs485333	chr11:59871862	C/G	cg02771260	chr11:59836817	MS4A3	-0.63	-4.59	-0.43	1.34e-5	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg22709100	chr7:91322751	NA	0.6	4.69	0.43	9.3e-6	Breast cancer;
THYM	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg09021430	chr5:549028	NA	-0.72	-5.32	-0.48	6.89e-7	Obesity-related traits;
THYM	cis	rs9326248	0.581	rs6589582	chr11:116829200	A/C	cg20608306	chr11:116969690	SIK3	0.63	7.94	0.63	4.08e-12	Blood protein levels;
THYM	cis	rs10904908	1.000	rs7920002	chr10:17259766	T/A	cg01003015	chr10:17271136	VIM	-0.63	-5.33	-0.48	6.61e-7	Total cholesterol levels;Cholesterol, total;
THYM	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.7	-0.43	8.88e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg10560079	chr2:191398806	TMEM194B	-0.87	-6.55	-0.56	2.88e-9	Diastolic blood pressure;
THYM	cis	rs4266144	0.592	rs1545854	chr3:156840138	A/G	cg16248515	chr3:156840234	NA	0.77	6.95	0.58	4.61e-10	Coronary artery disease;
THYM	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg13114125	chr14:105738426	BRF1	-0.73	-5.75	-0.51	1.09e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg20476274	chr7:133979776	SLC35B4	0.67	4.62	0.43	1.22e-5	Mean platelet volume;
THYM	cis	rs2688608	0.672	rs2688621	chr10:75687849	C/T	cg02947784	chr10:75434997	AGAP5	0.54	5.22	0.47	1.07e-6	Inflammatory bowel disease;
THYM	cis	rs9479482	0.789	rs12204988	chr6:150339315	T/G	cg07578070	chr6:150326732	RAET1K	0.54	4.47	0.42	2.19e-5	Alopecia areata;
THYM	cis	rs4378999	0.660	rs9820606	chr3:50771819	G/A	cg27233566	chr3:49894142	TRAIP	0.77	4.47	0.42	2.16e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs7584330	0.554	rs13392410	chr2:238430273	G/A	cg08992911	chr2:238395768	MLPH	0.9	5.8	0.51	8.78e-8	Prostate cancer;
THYM	cis	rs2404602	0.647	rs11072628	chr15:77107761	C/A	cg23625390	chr15:77176239	SCAPER	-0.87	-6.12	-0.53	2.05e-8	Blood metabolite levels;
THYM	cis	rs7084921	0.608	rs4475856	chr10:101833339	G/T	cg11344164	chr10:101878520	NA	-0.55	-4.76	-0.44	6.9e-6	Bone mineral density;
THYM	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg26031613	chr14:104095156	KLC1	0.77	5.0	0.46	2.67e-6	Body mass index;
THYM	cis	rs240764	0.681	rs12209887	chr6:101156806	G/A	cg21058520	chr6:100914733	NA	0.59	5.07	0.46	1.97e-6	Neuroticism;
THYM	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg07930192	chr7:1003750	NA	-0.58	-4.8	-0.44	5.88e-6	Longevity;Endometriosis;
THYM	cis	rs34638657	0.872	rs2911423	chr16:82188801	C/T	cg19807685	chr16:82068980	HSD17B2	-0.66	-5.08	-0.46	1.85e-6	Lung adenocarcinoma;
THYM	cis	rs9325144	0.723	rs11169535	chr12:39183494	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-4.62	-0.43	1.18e-5	Morning vs. evening chronotype;
THYM	cis	rs12121840	0.790	rs55674257	chr1:165542363	C/A	cg19407955	chr1:165599744	MGST3	-0.65	-4.64	-0.43	1.12e-5	Interleukin-1-receptor antagonist levels;
THYM	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg17294928	chr15:75287854	SCAMP5	-0.99	-9.14	-0.68	1.15e-14	Blood trace element (Zn levels);
THYM	cis	rs1021993	1.000	rs1027823	chr1:209511454	G/A	cg06155620	chr1:209527581	NA	0.58	4.69	0.43	8.99e-6	Gut microbiome composition (winter);
THYM	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg00981070	chr1:2046702	PRKCZ	-0.47	-5.57	-0.5	2.4e-7	Height;
THYM	trans	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg25208724	chr1:156163844	SLC25A44	1.02	8.24	0.65	9.35e-13	Testicular germ cell tumor;
THYM	cis	rs7246657	0.943	rs13343471	chr19:37932130	A/G	cg22634378	chr19:37742834	NA	0.7	5.73	0.51	1.2e-7	Coronary artery calcification;
THYM	cis	rs59698941	0.943	rs55767930	chr5:132203952	G/A	cg02081065	chr5:132209139	LEAP2	-0.85	-5.74	-0.51	1.14e-7	Apolipoprotein A-IV levels;
THYM	cis	rs28595532	1.000	rs115965820	chr4:119586485	G/A	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs870825	0.616	rs2141257	chr4:185609463	C/T	cg04058563	chr4:185651563	MLF1IP	-1.16	-9.67	-0.7	8.28e-16	Blood protein levels;
THYM	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg18681998	chr4:17616180	MED28	0.93	8.79	0.67	6.51e-14	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg07870213	chr5:140052090	DND1	0.73	8.28	0.65	7.61e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg06636001	chr8:8085503	FLJ10661	0.77	6.69	0.57	1.54e-9	Red cell distribution width;
THYM	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13126279	chr21:47581558	C21orf56	-0.66	-4.55	-0.42	1.62e-5	Testicular germ cell tumor;
THYM	cis	rs13064411	0.696	rs36054418	chr3:113204762	G/T	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg05340658	chr4:99064831	C4orf37	0.54	4.51	0.42	1.83e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg08645402	chr16:4508243	NA	0.67	5.35	0.48	6.16e-7	Schizophrenia;
THYM	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg24675658	chr1:53192096	ZYG11B	-0.56	-4.49	-0.42	2e-5	Monocyte count;
THYM	cis	rs7084402	0.967	rs1649072	chr10:60298112	G/A	cg07615347	chr10:60278583	BICC1	0.57	5.36	0.48	5.86e-7	Refractive error;
THYM	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.19	-0.47	1.18e-6	Chronic sinus infection;
THYM	cis	rs600806	0.821	rs3879451	chr1:109909269	C/T	cg02175308	chr1:109941060	SORT1	-0.56	-4.87	-0.45	4.42e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg10661904	chr17:79619235	PDE6G	-0.57	-5.17	-0.47	1.32e-6	Eye color traits;
THYM	cis	rs2235642	0.533	rs2076436	chr16:1608082	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.54	-5.44	-0.49	4.2e-7	Coronary artery disease;
THYM	cis	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg23422044	chr7:1970798	MAD1L1	-0.95	-6.58	-0.56	2.51e-9	Bipolar disorder;
THYM	cis	rs919433	1.000	rs2889363	chr2:198163699	A/G	cg00792783	chr2:198669748	PLCL1	-0.66	-4.7	-0.43	8.63e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2050392	0.799	rs303429	chr10:30708441	C/T	cg02070205	chr10:30722105	MAP3K8	-0.55	-4.83	-0.44	5.25e-6	Inflammatory bowel disease;
THYM	trans	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg10856724	chr12:34555212	NA	-0.8	-7.16	-0.59	1.68e-10	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6768930	0.509	rs6787090	chr3:57751032	A/G	cg07735586	chr3:57945651	NA	-0.33	-4.9	-0.45	3.9e-6	Obesity-related traits;
THYM	cis	rs36051895	0.664	rs4593605	chr9:5107278	C/A	cg02405213	chr9:5042618	JAK2	-1.0	-11.0	-0.75	1.23e-18	Pediatric autoimmune diseases;
THYM	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg21784768	chr11:537496	LRRC56	-1.16	-5.78	-0.51	9.66e-8	Body mass index;
THYM	cis	rs7851660	0.809	rs10739526	chr9:100662671	T/C	cg13688889	chr9:100608707	NA	-0.79	-5.71	-0.51	1.28e-7	Strep throat;
THYM	trans	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg22683308	chr4:1340831	KIAA1530	-0.63	-4.52	-0.42	1.78e-5	Obesity-related traits;
THYM	cis	rs7181230	1.000	rs28587891	chr15:40365106	T/A	cg20592017	chr15:40364740	NA	0.58	5.36	0.48	5.75e-7	Dehydroepiandrosterone sulphate levels;
THYM	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg18357526	chr6:26021779	HIST1H4A	0.78	6.01	0.52	3.41e-8	Urate levels;
THYM	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg03806693	chr22:41940476	POLR3H	-0.84	-6.41	-0.55	5.51e-9	Neuroticism;
THYM	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg10505658	chr17:80084571	CCDC57	-0.72	-7.85	-0.63	6.25e-12	Life satisfaction;
THYM	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg12560992	chr17:57184187	TRIM37	0.93	8.77	0.67	7.1e-14	Intelligence (multi-trait analysis);
THYM	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg14768367	chr16:72042858	DHODH	0.65	4.98	0.46	2.83e-6	Fibrinogen levels;
THYM	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.02	-0.46	2.42e-6	Blood metabolite levels;
THYM	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg00599163	chr2:162100495	NA	0.83	7.68	0.62	1.41e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.57	-5.18	-0.47	1.23e-6	Type 2 diabetes;
THYM	cis	rs7681423	1.000	rs7654093	chr4:155545072	A/T	cg20735720	chr4:155535218	FGG	-0.69	-5.35	-0.48	6.18e-7	Fibrinogen;
THYM	cis	rs1160297	0.601	rs1828337	chr2:53096942	G/T	cg07782112	chr2:53107842	NA	0.77	6.13	0.53	1.99e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs459571	0.959	rs410876	chr9:136893867	C/A	cg13789015	chr9:136890014	NCRNA00094	0.82	7.14	0.59	1.84e-10	Platelet distribution width;
THYM	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs854765	0.647	rs854791	chr17:18029857	C/T	cg04398451	chr17:18023971	MYO15A	-0.98	-10.6	-0.74	8.64e-18	Total body bone mineral density;
THYM	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg24642439	chr20:33292090	TP53INP2	0.59	4.48	0.42	2.04e-5	Coronary artery disease;
THYM	cis	rs1747683	0.677	rs1095368	chr10:13355131	T/C	cg11679871	chr10:13388567	SEPHS1	0.3	4.62	0.43	1.2e-5	IgG glycosylation;
THYM	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg14779329	chr11:130786720	SNX19	0.52	5.66	0.5	1.57e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg11247378	chr22:39784982	NA	-0.97	-10.29	-0.73	4.06e-17	Intelligence (multi-trait analysis);
THYM	cis	rs28829049	0.597	rs2066002	chr1:19504300	G/A	cg13387374	chr1:19411106	UBR4	0.65	4.86	0.45	4.71e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg11266682	chr4:10021025	SLC2A9	0.74	12.07	0.78	6.86e-21	Bone mineral density;
THYM	cis	rs240764	0.621	rs6925840	chr6:101209386	C/T	cg21058520	chr6:100914733	NA	0.6	5.28	0.48	8.25e-7	Neuroticism;
THYM	cis	rs9443645	0.527	rs1415859	chr6:79794858	A/G	cg05283184	chr6:79620031	NA	-0.6	-4.68	-0.43	9.44e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6988636	1.000	rs58741168	chr8:124191852	G/A	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs8077889	0.703	rs72836567	chr17:41945776	G/A	cg26893861	chr17:41843967	DUSP3	0.83	6.0	0.52	3.56e-8	Triglycerides;
THYM	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg08017756	chr2:100939284	LONRF2	-0.74	-7.57	-0.61	2.4e-11	Intelligence (multi-trait analysis);
THYM	cis	rs921665	0.831	rs7578217	chr2:3175376	A/G	cg16434511	chr2:3151078	NA	0.78	4.79	0.44	6.03e-6	World class endurance athleticism;
THYM	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg10803722	chr21:46713166	LOC642852	-0.41	-5.33	-0.48	6.47e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg03909863	chr11:638404	DRD4	-0.66	-4.71	-0.44	8.41e-6	Systemic lupus erythematosus;
THYM	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs11077773	1.000	rs11077773	chr17:73060073	C/T	cg27626185	chr17:73056755	KCTD2	0.78	4.48	0.42	2.1e-5	Information processing speed;
THYM	cis	rs9905704	0.918	rs302858	chr17:56692800	G/T	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.7e-6	Testicular germ cell tumor;
THYM	cis	rs79349575	0.783	rs12603969	chr17:47034419	A/G	cg26022315	chr17:47021804	SNF8	0.51	4.85	0.45	4.88e-6	Type 2 diabetes;
THYM	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26314531	chr2:26401878	FAM59B	-0.83	-5.0	-0.46	2.57e-6	Gut microbiome composition (summer);
THYM	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	4.56	0.42	1.54e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs7512552	0.839	rs1625468	chr1:150321486	G/A	cg15654264	chr1:150340011	RPRD2	0.45	5.2	0.47	1.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg21028142	chr17:79581711	NPLOC4	0.62	6.4	0.55	5.97e-9	Eye color traits;
THYM	cis	rs72828912	0.831	rs2176933	chr6:24094140	A/G	cg19882886	chr6:25043046	NA	0.85	5.46	0.49	3.82e-7	Squamous cell lung carcinoma;
THYM	trans	rs75518195	0.543	rs72641819	chr4:64673243	T/C	cg14706739	chr8:21916355	EPB49	0.75	7.37	0.6	6.34e-11	Triptolide cytotoxicity;
THYM	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.16	-0.47	1.36e-6	Chronic sinus infection;
THYM	cis	rs9959145	0.778	rs77764901	chr18:12567458	G/C	cg14160804	chr18:12703040	PSMG2;CEP76	-0.91	-4.55	-0.42	1.61e-5	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs425277	0.917	rs78395918	chr1:2045876	G/A	cg24578937	chr1:2090814	PRKCZ	0.76	7.24	0.6	1.14e-10	Height;
THYM	cis	rs17021463	0.902	rs2865352	chr4:95253263	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.64	-5.82	-0.51	8.09e-8	Testicular germ cell tumor;
THYM	cis	rs1371867	0.817	rs1788179	chr8:101333345	A/G	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs6809651	0.524	rs4686730	chr3:185805993	C/T	cg00760338	chr3:185826511	ETV5	-0.86	-7.02	-0.58	3.25e-10	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
THYM	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg24308560	chr3:49941425	MST1R	0.79	6.93	0.58	5.05e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.64	0.43	1.1e-5	Bipolar disorder;
THYM	cis	rs9906944	0.678	rs56015440	chr17:47136631	C/G	cg09029085	chr17:47094198	IGF2BP1	0.5	7.06	0.59	2.77e-10	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7107174	1.000	rs1318241	chr11:77930792	C/T	cg02023728	chr11:77925099	USP35	0.75	6.63	0.56	2.04e-9	Testicular germ cell tumor;
THYM	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg27490568	chr2:178487706	NA	0.58	5.35	0.48	6.1e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg26038318	chr20:34205095	SPAG4	0.65	5.25	0.47	9.22e-7	Total cholesterol levels;
THYM	cis	rs7172809	0.599	rs17471431	chr15:77749068	T/C	cg22256960	chr15:77711686	NA	-0.61	-4.47	-0.42	2.18e-5	Glucose homeostasis traits;
THYM	cis	rs4601821	0.895	rs1055075	chr11:113239512	T/C	cg14159747	chr11:113255604	NA	0.26	4.77	0.44	6.72e-6	Alcoholic chronic pancreatitis;
THYM	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg24846343	chr22:24311635	DDTL	-0.46	-5.78	-0.51	9.38e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7851660	0.809	rs7022148	chr9:100660824	T/C	cg13688889	chr9:100608707	NA	-0.79	-5.71	-0.51	1.28e-7	Strep throat;
THYM	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs7187994	0.848	rs12920732	chr16:84780613	C/T	cg07647771	chr16:84786436	USP10	-0.55	-5.06	-0.46	2.03e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	4.72	0.44	8e-6	Prudent dietary pattern;
THYM	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg13695892	chr22:41940480	POLR3H	-0.85	-6.42	-0.55	5.32e-9	Vitiligo;
THYM	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg24209194	chr3:40518798	ZNF619	0.61	5.08	0.46	1.85e-6	Renal cell carcinoma;
THYM	cis	rs7100689	0.646	rs12253992	chr10:82158710	G/A	cg01528321	chr10:82214614	TSPAN14	0.93	7.76	0.62	9.45e-12	Post bronchodilator FEV1;
THYM	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg11764359	chr7:65958608	NA	0.75	6.0	0.52	3.62e-8	Aortic root size;
THYM	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg13114125	chr14:105738426	BRF1	-0.72	-5.62	-0.5	1.91e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6763768	0.606	rs931253	chr3:53298604	A/C	cg22900224	chr3:52804907	NEK4	0.76	4.52	0.42	1.78e-5	Bacterial meningitis;
THYM	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg04944784	chr2:26401820	FAM59B	-1.04	-8.62	-0.66	1.49e-13	Gut microbiome composition (summer);
THYM	cis	rs968451	0.789	rs1569500	chr22:39683515	A/G	cg24268161	chr22:39747459	SYNGR1	-0.63	-4.54	-0.42	1.67e-5	Primary biliary cholangitis;
THYM	cis	rs11112613	0.713	rs12307351	chr12:105955634	T/A	cg03607813	chr12:105948248	NA	1.0	8.16	0.64	1.36e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg08847533	chr14:75593920	NEK9	1.01	11.32	0.76	2.63e-19	Height;
THYM	cis	rs4919687	0.550	rs4264100	chr10:104454113	C/G	cg18761893	chr10:103892519	PPRC1	0.61	4.66	0.43	1.05e-5	Colorectal cancer;
THYM	trans	rs877282	0.898	rs11253356	chr10:768604	G/A	cg22713356	chr15:30763199	NA	1.34	10.9	0.75	1.99e-18	Uric acid levels;
THYM	cis	rs12478296	1.000	rs55814222	chr2:243041166	C/T	cg06360820	chr2:242988706	NA	-0.91	-5.52	-0.49	2.97e-7	Obesity-related traits;
THYM	cis	rs6984449	0.508	rs62496184	chr8:19319423	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.69	7.68	0.62	1.43e-11	Educational attainment;
THYM	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.33	9.84	0.71	3.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg10856724	chr12:34555212	NA	-0.79	-7.41	-0.61	5.14e-11	Morning vs. evening chronotype;
THYM	cis	rs6138458	1.000	rs227631	chr20:24913653	A/G	cg26195577	chr20:24973756	C20orf3	1.11	10.52	0.73	1.29e-17	Blood protein levels;
THYM	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs8073060	0.544	rs1080352	chr17:34002362	A/G	cg19694781	chr19:47549865	TMEM160	-1.02	-8.69	-0.67	1.01e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs960902	0.620	rs6734373	chr2:37735241	C/T	cg25341268	chr2:37734390	NA	-0.65	-5.51	-0.49	3.1e-7	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg09307838	chr4:120376055	NA	0.71	5.41	0.49	4.61e-7	Corneal astigmatism;
THYM	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg23583168	chr7:148888333	NA	-1.06	-13.95	-0.82	1.01e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs477692	0.563	rs12266634	chr10:131412659	G/C	cg05714579	chr10:131428358	MGMT	-0.99	-10.28	-0.73	4.1e-17	Response to temozolomide;
THYM	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg27170947	chr2:26402098	FAM59B	-0.58	-4.9	-0.45	3.87e-6	Gut microbiome composition (summer);
THYM	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg20887711	chr4:1340912	KIAA1530	-0.62	-4.69	-0.43	9.23e-6	Obesity-related traits;
THYM	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg07936489	chr17:37558343	FBXL20	-0.73	-5.04	-0.46	2.22e-6	Asthma;
THYM	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.78	-6.59	-0.56	2.47e-9	Tonsillectomy;
THYM	cis	rs259282	0.524	rs731674	chr19:33132395	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.7	5.95	0.52	4.51e-8	Schizophrenia;
THYM	cis	rs2806561	0.765	rs652783	chr1:23514313	G/T	cg12483005	chr1:23474871	LUZP1	0.59	6.28	0.54	1.01e-8	Height;
THYM	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg15704280	chr7:45808275	SEPT13	0.95	9.62	0.7	1.1e-15	Coronary artery disease;
THYM	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg00255919	chr5:131827918	IRF1	-0.46	-5.19	-0.47	1.17e-6	Asthma (sex interaction);
THYM	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg08772003	chr10:104629869	AS3MT	-0.53	-4.54	-0.42	1.64e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4891159	0.790	rs17059379	chr18:74160316	A/T	cg24786174	chr18:74118243	ZNF516	0.8	8.93	0.68	3.18e-14	Longevity;
THYM	cis	rs4792901	0.722	rs12601849	chr17:41546288	G/T	cg21940313	chr17:41620911	ETV4	-0.52	-5.3	-0.48	7.5e-7	Dupuytren's disease;
THYM	cis	rs60180747	0.865	rs11639144	chr15:66600096	G/A	cg08479319	chr15:66648941	TIPIN	0.66	4.48	0.42	2.05e-5	Testicular germ cell tumor;
THYM	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg07884673	chr3:53033167	SFMBT1	1.25	6.34	0.55	7.83e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg10164272	chr16:89456328	ANKRD11	0.62	4.56	0.42	1.55e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs2637266	1.000	rs12252604	chr10:78352591	T/C	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs11030122	0.702	rs1349583	chr11:3972236	G/A	cg22027985	chr11:4115532	RRM1	-0.48	-4.59	-0.43	1.36e-5	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg26131816	chr17:42072204	PYY	0.54	4.65	0.43	1.07e-5	Menopause (age at onset);
THYM	cis	rs853679	0.666	rs200956	chr6:27839746	A/G	cg23161317	chr6:28129485	ZNF389	0.79	4.63	0.43	1.16e-5	Depression;
THYM	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg08439880	chr3:133502540	NA	0.71	6.05	0.53	2.86e-8	Iron status biomarkers;
THYM	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg26384229	chr12:38710491	ALG10B	-0.83	-8.3	-0.65	6.83e-13	Heart rate;
THYM	cis	rs4654899	0.865	rs6671056	chr1:21488610	G/A	cg01072550	chr1:21505969	NA	-0.74	-6.68	-0.57	1.63e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs2276314	0.857	rs9960670	chr18:33577712	A/G	cg19628046	chr18:33552617	C18orf21	0.74	5.22	0.47	1.05e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg08439880	chr3:133502540	NA	-0.72	-6.04	-0.53	2.97e-8	Iron status biomarkers;
THYM	cis	rs2985684	1.000	rs2147712	chr14:50091684	G/A	cg02151108	chr14:50098012	C14orf104	-0.68	-5.42	-0.49	4.54e-7	Carotid intima media thickness;
THYM	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg24250549	chr1:154909240	PMVK	0.75	6.45	0.55	4.66e-9	Prostate cancer;
THYM	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.86	-0.52	6.67e-8	Chronic sinus infection;
THYM	cis	rs7918232	0.891	rs10443987	chr10:27375377	A/T	cg14240646	chr10:27532245	ACBD5	-0.74	-4.52	-0.42	1.78e-5	Breast cancer;
THYM	cis	rs12946454	0.696	rs4792819	chr17:43247957	A/C	cg06100756	chr17:43221575	NA	0.55	5.31	0.48	7.29e-7	Systolic blood pressure;
THYM	cis	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.55	5.64	0.5	1.72e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg24846680	chr1:228362309	C1orf69	0.51	4.53	0.42	1.74e-5	Diastolic blood pressure;
THYM	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg13114125	chr14:105738426	BRF1	-0.71	-5.51	-0.49	3.08e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.22	0.6	1.28e-10	Obesity-related traits;
THYM	cis	rs1385374	0.858	rs3741615	chr12:129298848	G/A	cg04043695	chr12:129287642	SLC15A4	-0.8	-4.83	-0.44	5.3e-6	Systemic lupus erythematosus;
THYM	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg03161606	chr19:29218774	NA	0.84	6.44	0.55	4.96e-9	Methadone dose in opioid dependence;
THYM	cis	rs7909074	0.831	rs7903412	chr10:45382361	C/T	cg05187965	chr10:45406764	TMEM72	-0.48	-4.55	-0.42	1.58e-5	Mean corpuscular volume;
THYM	cis	rs2625529	0.824	rs12595464	chr15:72294398	C/T	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs12465778	0.550	rs10048784	chr2:144168037	T/C	cg17056048	chr2:144271431	ARHGAP15	-0.51	-5.26	-0.47	8.95e-7	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg00684032	chr4:1343700	KIAA1530	-0.66	-5.62	-0.5	1.9e-7	Obesity-related traits;
THYM	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg07212818	chr11:638076	DRD4	-0.75	-5.71	-0.51	1.28e-7	Systemic lupus erythematosus;
THYM	cis	rs12594515	1.000	rs35182335	chr15:45995184	C/G	cg01629716	chr15:45996671	NA	0.53	5.27	0.48	8.45e-7	Waist circumference;Weight;
THYM	cis	rs1797081	0.967	rs780633	chr10:16863161	C/T	cg23933602	chr10:16859644	RSU1	0.93	10.77	0.74	3.7e-18	Platelet distribution width;
THYM	cis	rs7917772	0.582	rs4408249	chr10:104374653	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	6.54	0.56	3.03e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg12373951	chr3:133503437	NA	0.59	6.4	0.55	5.88e-9	Iron status biomarkers;
THYM	cis	rs669446	0.533	rs7543520	chr1:44243866	T/C	cg15962314	chr1:44399869	ARTN	0.47	5.1	0.46	1.73e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	5.8	0.51	8.5e-8	Schizophrenia;
THYM	cis	rs7404928	0.557	rs195990	chr16:23946385	C/A	cg26685404	chr16:23957272	PRKCB	-0.58	-6.47	-0.55	4.23e-9	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs1728785	0.901	rs1170437	chr16:68607943	C/T	cg02972257	chr16:68554789	NA	-0.77	-4.75	-0.44	7.14e-6	Ulcerative colitis;
THYM	cis	rs7131987	0.903	rs67517901	chr12:29421346	A/G	cg09582351	chr12:29534625	ERGIC2	-0.48	-4.59	-0.43	1.35e-5	QT interval;
THYM	cis	rs8067545	0.750	rs11869616	chr17:19992713	G/A	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.61e-6	Schizophrenia;
THYM	cis	rs3810291	0.964	rs12609406	chr19:47611128	A/G	cg12068280	chr19:46804528	HIF3A	-0.4	-4.49	-0.42	2.03e-5	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);BMI in smokers;Hip circumference;Body mass index;Body mass index in physically active individuals;
THYM	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs11645898	0.748	rs11641424	chr16:72066879	C/T	cg14768367	chr16:72042858	DHODH	-0.81	-5.89	-0.52	5.95e-8	Blood protein levels;
THYM	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg01831904	chr17:28903510	LRRC37B2	-1.05	-5.07	-0.46	1.93e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.84e-8	Systolic blood pressure;
THYM	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg02527881	chr3:46936655	PTH1R	0.6	5.69	0.5	1.42e-7	Colorectal cancer;
THYM	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg05985134	chr18:33552581	C18orf21	0.68	4.77	0.44	6.59e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs28595532	0.920	rs115103359	chr4:119739608	A/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs988913	1.000	rs9475099	chr6:54839070	A/C	cg18532076	chr6:54711417	FAM83B	0.52	4.95	0.45	3.25e-6	Menarche (age at onset);
THYM	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg12386194	chr3:101231763	SENP7	0.93	7.52	0.61	3.11e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	1.000	rs7781597	chr7:91588194	T/C	cg17063962	chr7:91808500	NA	1.06	10.59	0.74	9.17e-18	Breast cancer;
THYM	cis	rs950880	0.710	rs66566526	chr2:103047802	C/T	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.68	-0.43	9.39e-6	Serum protein levels (sST2);
THYM	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg12573674	chr2:1569213	NA	-1.22	-4.82	-0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.81	6.2	0.54	1.49e-8	IgG glycosylation;
THYM	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg13695892	chr22:41940480	POLR3H	-0.95	-7.67	-0.62	1.5e-11	Vitiligo;
THYM	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg05802129	chr4:122689817	NA	-0.63	-5.16	-0.47	1.34e-6	Type 2 diabetes;
THYM	cis	rs61931739	0.534	rs2625897	chr12:34064295	G/A	cg06521331	chr12:34319734	NA	-0.95	-9.13	-0.68	1.19e-14	Morning vs. evening chronotype;
THYM	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg10248100	chr7:872053	UNC84A	0.74	4.99	0.46	2.75e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22857025	chr5:266934	NA	-1.43	-9.3	-0.69	5.28e-15	Breast cancer;
THYM	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	9.67	0.7	8.34e-16	Platelet count;
THYM	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg17971929	chr21:40555470	PSMG1	0.74	4.87	0.45	4.39e-6	Cognitive function;
THYM	cis	rs2239547	0.522	rs9311485	chr3:52987645	T/G	cg11645453	chr3:52864694	ITIH4	-0.29	-4.72	-0.44	8.27e-6	Schizophrenia;
THYM	cis	rs1499972	0.941	rs56051552	chr3:117613726	C/T	cg07612923	chr3:117604196	NA	1.3	5.44	0.49	4.05e-7	Schizophrenia;
THYM	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.7	5.69	0.5	1.38e-7	Blood metabolite levels;
THYM	cis	rs3106136	0.527	rs10030586	chr4:95150805	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.1	-0.46	1.7e-6	Capecitabine sensitivity;
THYM	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.63	0.5	1.81e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9616064	0.924	rs7292319	chr22:46994999	T/A	cg25730555	chr22:47059586	GRAMD4	-0.54	-4.84	-0.44	5.06e-6	Urate levels in obese individuals;
THYM	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg19875535	chr5:140030758	IK	-0.58	-4.53	-0.42	1.69e-5	Depressive symptoms (multi-trait analysis);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg00220575	chr6:46457310	NA	-0.83	-6.96	-0.58	4.27e-10	Depressive symptoms;
THYM	trans	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg25517755	chr10:38738941	LOC399744	0.75	6.84	0.57	7.71e-10	Corneal astigmatism;
THYM	cis	rs17604090	0.793	rs17150665	chr7:29688860	T/G	cg19413766	chr7:29689036	LOC646762	-0.91	-5.02	-0.46	2.37e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg23711669	chr6:146136114	FBXO30	0.99	10.6	0.74	8.81e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs472402	0.580	rs11738248	chr5:6657494	C/T	cg12648172	chr5:5886274	NA	0.52	4.72	0.44	7.99e-6	Response to amphetamines;
THYM	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs79349575	0.783	rs12601955	chr17:47034420	C/T	cg26022315	chr17:47021804	SNF8	0.51	4.85	0.45	4.88e-6	Type 2 diabetes;
THYM	cis	rs7681440	0.538	rs2619351	chr4:90747704	A/G	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs17739794	0.545	rs982352	chr8:823449	C/T	cg07178994	chr8:816998	NA	0.63	6.19	0.54	1.49e-8	Clozapine-induced cytotoxicity;
THYM	cis	rs6840360	0.642	rs7684462	chr4:152348422	T/G	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs477692	0.792	rs12762024	chr10:131441055	G/C	cg05714579	chr10:131428358	MGMT	-0.53	-4.77	-0.44	6.63e-6	Response to temozolomide;
THYM	cis	rs13006833	0.739	rs291468	chr2:191188119	A/G	cg27211696	chr2:191398769	TMEM194B	0.56	4.48	0.42	2.1e-5	Urinary metabolites;
THYM	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs7851660	0.844	rs10984103	chr9:100639275	G/T	cg13688889	chr9:100608707	NA	0.73	5.39	0.48	5.2e-7	Strep throat;
THYM	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg03732007	chr1:2071316	PRKCZ	0.49	4.57	0.42	1.46e-5	Height;
THYM	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg24675658	chr1:53192096	ZYG11B	0.71	6.38	0.55	6.56e-9	Monocyte count;
THYM	cis	rs3126085	0.935	rs3126088	chr1:152305785	A/G	cg10321714	chr1:152280068	FLG	-0.72	-5.44	-0.49	4.14e-7	Atopic dermatitis;
THYM	cis	rs4853012	1.000	rs4853012	chr2:74361290	G/A	cg05890377	chr2:74357713	NA	1.09	8.3	0.65	6.97e-13	Gestational age at birth (maternal effect);
THYM	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.84	-5.3	-0.48	7.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.72	-0.51	1.23e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg18105134	chr13:113819100	PROZ	0.97	8.91	0.67	3.54e-14	Platelet distribution width;
THYM	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg03264133	chr6:25882463	NA	0.65	5.06	0.46	2e-6	Schizophrenia;
THYM	cis	rs6430585	0.583	rs59243420	chr2:136584538	A/T	cg23851026	chr2:136556271	LCT	0.77	7.55	0.61	2.64e-11	Corneal structure;
THYM	cis	rs2625529	0.617	rs13858	chr15:72433144	C/T	cg16672083	chr15:72433130	SENP8	-0.5	-4.62	-0.43	1.19e-5	Red blood cell count;
THYM	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06850241	chr22:41845214	NA	-0.54	-4.78	-0.44	6.37e-6	Vitiligo;
THYM	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg08975724	chr8:8085496	FLJ10661	-0.65	-4.96	-0.45	3.03e-6	Mood instability;
THYM	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg12564285	chr5:131593104	PDLIM4	-0.53	-5.95	-0.52	4.4e-8	Breast cancer;
THYM	cis	rs9926296	0.744	rs352939	chr16:89710378	G/A	cg01097406	chr16:89675127	NA	0.73	6.68	0.57	1.63e-9	Vitiligo;
THYM	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.66e-18	Prudent dietary pattern;
THYM	cis	rs988913	0.957	rs72645372	chr6:54788822	C/T	cg18532076	chr6:54711417	FAM83B	0.52	4.83	0.44	5.13e-6	Menarche (age at onset);
THYM	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg01017244	chr2:74357527	NA	1.0	8.8	0.67	6.08e-14	Gestational age at birth (maternal effect);
THYM	cis	rs1113500	0.862	rs2336129	chr1:108640669	A/G	cg06207961	chr1:108661230	NA	-0.64	-5.09	-0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs72829446	0.530	rs9891297	chr17:7385204	T/C	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg21252483	chr19:49399788	TULP2	-0.88	-6.15	-0.53	1.82e-8	Red cell distribution width;
THYM	cis	rs12282928	0.625	rs12276188	chr11:48350692	G/A	cg22827986	chr11:48284249	OR4X1	0.52	5.31	0.48	7.13e-7	Migraine - clinic-based;
THYM	cis	rs7104764	1.000	rs7128044	chr11:244115	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs1403694	0.734	rs266723	chr3:186447047	A/C	cg12454167	chr3:186435060	KNG1	0.39	4.87	0.45	4.37e-6	Blood protein levels;
THYM	cis	rs9457247	0.534	rs1130033	chr6:167385623	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.49	-4.97	-0.45	2.93e-6	Crohn's disease;
THYM	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-4.73	-0.44	7.65e-6	Alzheimer's disease;
THYM	cis	rs240764	0.645	rs239208	chr6:101139285	G/A	cg21058520	chr6:100914733	NA	-0.55	-4.7	-0.43	8.96e-6	Neuroticism;
THYM	cis	rs7264396	0.563	rs56941405	chr20:34313426	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Total cholesterol levels;
THYM	cis	rs2970992	0.764	rs6542984	chr2:101324884	C/T	cg01042948	chr2:101319752	NA	0.57	5.45	0.49	4.04e-7	Educational attainment;
THYM	cis	rs4638749	0.501	rs12624041	chr2:108763547	C/A	cg25838818	chr2:108905173	SULT1C2	-0.52	-4.89	-0.45	4.13e-6	Blood pressure;
THYM	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg15741354	chr8:8146129	NA	-0.29	-4.84	-0.44	5.09e-6	Joint mobility (Beighton score);
THYM	cis	rs11209185	0.509	rs1938424	chr1:68431722	A/G	cg22082780	chr1:68452167	NA	-0.53	-6.09	-0.53	2.34e-8	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg04025307	chr7:1156635	C7orf50	0.73	4.51	0.42	1.84e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg05973401	chr12:123451056	ABCB9	0.67	4.49	0.42	2.02e-5	Neutrophil percentage of white cells;
THYM	cis	rs678347	1.000	rs678347	chr8:102463602	A/G	cg27484483	chr8:103249853	RRM2B	0.52	4.56	0.42	1.5e-5	Rheumatoid arthritis;
THYM	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg08645402	chr16:4508243	NA	-0.69	-6.0	-0.52	3.58e-8	Schizophrenia;
THYM	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg12031863	chr16:4587854	C16orf5	-0.46	-4.96	-0.45	3.09e-6	Schizophrenia;
THYM	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg03676636	chr4:99064102	C4orf37	-0.44	-6.64	-0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg18252515	chr7:66147081	NA	-1.44	-8.51	-0.66	2.48e-13	Diabetic kidney disease;
THYM	cis	rs36051895	0.559	rs7850228	chr9:5210671	C/G	cg02405213	chr9:5042618	JAK2	0.89	8.66	0.66	1.18e-13	Pediatric autoimmune diseases;
THYM	cis	rs506338	0.517	rs530775	chr11:64426933	A/G	cg19395706	chr11:64412079	NRXN2	0.34	4.51	0.42	1.86e-5	Body mass index;Urate levels;
THYM	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg03709012	chr19:19516395	GATAD2A	0.79	6.1	0.53	2.29e-8	Tonsillectomy;
THYM	cis	rs514406	0.526	rs835608	chr1:53169758	T/A	cg16325326	chr1:53192061	ZYG11B	-0.91	-9.0	-0.68	2.27e-14	Monocyte count;
THYM	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg21773646	chr17:80085082	CCDC57	0.31	4.49	0.42	2.02e-5	Life satisfaction;
THYM	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg15242686	chr22:24348715	GSTTP1	0.72	7.74	0.62	1.07e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg15704280	chr7:45808275	SEPT13	-0.98	-11.3	-0.76	2.81e-19	Height;
THYM	cis	rs13014235	0.532	rs13029007	chr2:202264877	G/T	cg08939942	chr2:202838362	NA	-0.57	-4.52	-0.42	1.78e-5	Basal cell carcinoma;
THYM	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg18641463	chr7:2144579	MAD1L1	0.63	4.59	0.43	1.35e-5	Height;
THYM	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg14784868	chr12:69753453	YEATS4	0.64	5.0	0.46	2.57e-6	Response to diuretic therapy;
THYM	cis	rs7084402	0.935	rs1658492	chr10:60281267	C/T	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs977987	0.843	rs11649638	chr16:75488285	G/A	cg03315344	chr16:75512273	CHST6	0.72	5.99	0.52	3.67e-8	Dupuytren's disease;
THYM	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg13683864	chr3:40499215	RPL14	-1.08	-13.23	-0.81	2.83e-23	Renal cell carcinoma;
THYM	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	4.94	0.45	3.4e-6	Height;
THYM	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg03396347	chr1:1875803	NA	-0.67	-6.72	-0.57	1.33e-9	Body mass index;
THYM	cis	rs4072705	1.000	rs3739760	chr9:127453204	T/C	cg13476313	chr9:127244764	NR5A1	0.34	5.44	0.49	4.05e-7	Menarche (age at onset);
THYM	cis	rs4851254	0.618	rs35300735	chr2:100667829	G/A	cg22139774	chr2:100720529	AFF3	-0.39	-4.49	-0.42	1.99e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg27446573	chr6:127587934	RNF146	1.04	9.87	0.71	3.12e-16	Breast cancer;
THYM	cis	rs4988958	0.584	rs7559845	chr2:103046214	T/G	cg03938978	chr2:103052716	IL18RAP	0.75	9.8	0.71	4.43e-16	Asthma (childhood onset);
THYM	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg00677455	chr12:58241039	CTDSP2	0.72	5.29	0.48	7.78e-7	Intelligence (multi-trait analysis);
THYM	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	5.47	0.49	3.62e-7	Tonsillectomy;
THYM	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg19729930	chr2:74357872	NA	1.25	11.06	0.75	9.12e-19	Gestational age at birth (maternal effect);
THYM	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg23482746	chr15:76478102	C15orf27	-0.38	-4.55	-0.42	1.61e-5	Blood metabolite levels;
THYM	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg23791538	chr6:167370224	RNASET2	0.74	5.92	0.52	5.06e-8	Crohn's disease;
THYM	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg10856724	chr12:34555212	NA	-0.9	-8.53	-0.66	2.28e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4808199	0.948	rs757000	chr19:19448301	A/G	cg03709012	chr19:19516395	GATAD2A	1.1	6.32	0.54	8.6e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs7106204	0.609	rs12785699	chr11:24280489	C/T	ch.11.24196551F	chr11:24239977	NA	0.93	5.71	0.51	1.3e-7	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.59	-7.59	-0.61	2.16e-11	Longevity;Endometriosis;
THYM	cis	rs10799590	1.000	rs2936575	chr1:224841619	A/T	cg01808320	chr1:224927238	CNIH3	-0.53	-4.77	-0.44	6.52e-6	Opioid dependence;
THYM	cis	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg06521331	chr12:34319734	NA	-0.98	-8.55	-0.66	2.09e-13	Morning vs. evening chronotype;
THYM	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg00684032	chr4:1343700	KIAA1530	0.58	4.85	0.45	4.83e-6	Obesity-related traits;
THYM	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg06627557	chr7:32535165	LSM5;AVL9	1.04	10.65	0.74	6.72e-18	Cognitive ability;
THYM	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg16342193	chr10:102329863	NA	-0.54	-5.38	-0.48	5.4e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg08999081	chr20:33150536	PIGU	0.77	6.95	0.58	4.57e-10	Coronary artery disease;
THYM	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg26314531	chr2:26401878	FAM59B	-0.76	-5.02	-0.46	2.37e-6	Gut microbiome composition (summer);
THYM	cis	rs13380717	0.563	rs4268754	chr16:86925490	T/C	cg05661093	chr16:86825505	NA	-0.54	-4.77	-0.44	6.55e-6	Sepsis in extremely premature infants;
THYM	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg13289132	chr10:30722225	MAP3K8	-0.63	-5.21	-0.47	1.11e-6	Inflammatory bowel disease;
THYM	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg03115019	chr17:80708279	FN3K	0.67	4.7	0.43	8.85e-6	Glycated hemoglobin levels;
THYM	cis	rs7246657	1.000	rs6508710	chr19:37749886	A/G	cg22634378	chr19:37742834	NA	0.61	4.99	0.46	2.7e-6	Coronary artery calcification;
THYM	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg09936400	chr10:82049201	MAT1A	-0.46	-4.76	-0.44	7.01e-6	Post bronchodilator FEV1;
THYM	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.81	-5.52	-0.49	2.91e-7	Body mass index;
THYM	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg24846343	chr22:24311635	DDTL	0.48	6.67	0.56	1.66e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7072216	0.763	rs1061437	chr10:100176154	C/T	cg03852570	chr10:100175106	PYROXD2	0.38	5.08	0.46	1.87e-6	Metabolite levels;
THYM	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg27286337	chr10:134555280	INPP5A	0.87	6.74	0.57	1.24e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs12039431	0.706	rs61776179	chr1:37986804	G/T	cg17933807	chr1:38061675	GNL2	-0.76	-5.52	-0.49	2.94e-7	Epithelial ovarian cancer;
THYM	cis	rs983545	0.586	rs4685404	chr3:16978642	T/C	cg24159436	chr3:16974681	PLCL2	0.34	5.34	0.48	6.28e-7	Blood protein levels;
THYM	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg12407791	chr17:73824354	UNC13D	-0.42	-4.6	-0.43	1.3e-5	White matter hyperintensity burden;
THYM	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00864171	chr11:67383662	NA	0.64	5.16	0.47	1.36e-6	Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4788815	0.513	rs7204967	chr16:71804287	A/G	cg06353428	chr16:71660113	MARVELD3	1.41	8.69	0.67	1.03e-13	Metabolite levels;
THYM	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg08645402	chr16:4508243	NA	0.62	5.43	0.49	4.39e-7	Schizophrenia;
THYM	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.88	-0.58	6.43e-10	Eye color traits;
THYM	cis	rs611744	0.905	rs640950	chr8:109157819	T/A	cg21045802	chr8:109455806	TTC35	0.58	4.84	0.44	5e-6	Dupuytren's disease;
THYM	cis	rs1448094	0.549	rs4919770	chr12:86238050	G/T	cg02569458	chr12:86230093	RASSF9	0.63	5.56	0.5	2.51e-7	Major depressive disorder;
THYM	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg13609457	chr4:120235615	NA	0.61	5.25	0.47	9.09e-7	Corneal astigmatism;
THYM	cis	rs9300255	0.722	rs1060105	chr12:123806219	C/T	cg00376283	chr12:123451042	ABCB9	-0.76	-4.45	-0.42	2.35e-5	Neutrophil percentage of white cells;
THYM	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg15556689	chr8:8085844	FLJ10661	-0.65	-5.56	-0.5	2.43e-7	Myopia (pathological);
THYM	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	trans	rs4650994	0.525	rs4650997	chr1:178530744	T/A	cg05059571	chr16:84539110	KIAA1609	-0.93	-11.31	-0.76	2.75e-19	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg01097406	chr16:89675127	NA	-0.6	-5.04	-0.46	2.23e-6	Vitiligo;
THYM	cis	rs7404928	0.515	rs8051390	chr16:23925351	G/A	cg26685404	chr16:23957272	PRKCB	-0.57	-6.33	-0.54	8.01e-9	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg11301795	chr4:187892539	NA	-1.11	-18.94	-0.89	5.16e-34	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Bladder cancer;
THYM	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg02527881	chr3:46936655	PTH1R	-0.61	-5.7	-0.51	1.33e-7	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg08508325	chr11:3079039	CARS	-0.52	-6.39	-0.55	6.11e-9	Longevity;
THYM	cis	rs17407555	0.738	rs73212898	chr4:10121994	C/T	cg14348967	chr4:10160060	NA	0.56	4.48	0.42	2.09e-5	Schizophrenia (age at onset);
THYM	cis	rs34638657	0.536	rs2967327	chr16:82188657	C/T	cg09439754	chr16:82129088	HSD17B2	-0.46	-4.72	-0.44	8.05e-6	Lung adenocarcinoma;
THYM	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg27446573	chr6:127587934	RNF146	0.92	7.31	0.6	8.41e-11	Breast cancer;
THYM	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg06618935	chr21:46677482	NA	-0.97	-9.14	-0.68	1.12e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9287719	0.649	rs58633964	chr2:10736382	T/G	cg01299579	chr2:10830716	NOL10	-0.48	-4.47	-0.42	2.13e-5	Prostate cancer;
THYM	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg02524346	chr8:600233	NA	1.0	4.57	0.42	1.48e-5	IgG glycosylation;
THYM	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg24818145	chr4:99064322	C4orf37	0.87	7.23	0.6	1.19e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg22189786	chr22:42395067	WBP2NL	0.57	5.12	0.47	1.59e-6	Birth weight;
THYM	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.596	rs7799518	chr7:124575684	A/C	cg05285228	chr7:124571219	POT1	-0.69	-5.25	-0.47	9.35e-7	Cutaneous malignant melanoma;
THYM	cis	rs1461503	0.966	rs10790546	chr11:122838426	C/A	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg16586182	chr3:47516702	SCAP	-0.65	-5.62	-0.5	1.94e-7	Colorectal cancer;
THYM	cis	rs4919694	0.908	rs11191523	chr10:104792400	A/G	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg15556689	chr8:8085844	FLJ10661	-0.65	-5.14	-0.47	1.48e-6	Mood instability;
THYM	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg07511668	chr11:68622177	NA	0.44	4.63	0.43	1.16e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg06092702	chr1:163392909	NA	-0.64	-5.88	-0.52	6.04e-8	Motion sickness;
THYM	cis	rs4940575	0.786	rs4940574	chr18:60837844	G/C	cg25271770	chr18:61057090	VPS4B	0.82	4.92	0.45	3.69e-6	Breast cancer;
THYM	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.88	7.98	0.63	3.28e-12	Monocyte percentage of white cells;
THYM	cis	rs2456568	0.803	rs10831141	chr11:93640728	C/T	cg26875233	chr11:93583750	C11orf90	-0.54	-5.78	-0.51	9.51e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs28595532	0.688	rs116053430	chr4:119731375	G/A	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs1729951	0.575	rs361244	chr3:136697506	C/T	cg12473912	chr3:136751656	NA	0.63	5.13	0.47	1.55e-6	Neuroticism;
THYM	cis	rs4730268	1.000	rs4730268	chr7:107443386	C/T	cg18560240	chr7:107437656	SLC26A3	-0.93	-5.22	-0.47	1.07e-6	IgG glycosylation;
THYM	cis	rs514406	0.597	rs1241980	chr1:53286013	A/G	cg08859206	chr1:53392774	SCP2	0.81	8.0	0.63	3.03e-12	Monocyte count;
THYM	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs12960472	0.539	rs7230338	chr18:52312547	A/C	cg26630735	chr18:52626848	CCDC68	-0.71	-4.56	-0.42	1.55e-5	Positive affect;
THYM	cis	rs4866334	1.000	rs74776941	chr5:18489387	T/G	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs9462846	0.845	rs9471959	chr6:42884517	A/G	cg09436375	chr6:42928200	GNMT	-0.4	-4.63	-0.43	1.14e-5	Blood protein levels;
THYM	cis	rs295140	1.000	rs12614621	chr2:201171207	G/C	cg04283868	chr2:201171347	SPATS2L	0.74	5.53	0.49	2.81e-7	QT interval;
THYM	cis	rs4631830	0.720	rs11004422	chr10:51498336	A/G	cg10326726	chr10:51549505	MSMB	0.53	5.15	0.47	1.38e-6	Prostate-specific antigen levels;
THYM	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg02524346	chr8:600233	NA	0.92	4.51	0.42	1.85e-5	IgG glycosylation;
THYM	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg15704280	chr7:45808275	SEPT13	-1.07	-12.69	-0.79	3.6e-22	Height;
THYM	cis	rs6570726	0.764	rs448258	chr6:145869145	C/A	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7119	0.717	rs8042307	chr15:77804013	A/G	cg27398640	chr15:77910606	LINGO1	-0.52	-5.19	-0.47	1.21e-6	Type 2 diabetes;
THYM	cis	rs6867032	0.917	rs10474733	chr5:2004160	A/G	cg26168224	chr5:2018326	NA	-1.13	-11.47	-0.76	1.24e-19	Gut microbiome composition (winter);
THYM	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg02725872	chr8:58115012	NA	-1.1	-8.38	-0.65	4.69e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs2286885	1.000	rs10733679	chr9:129242416	C/T	cg14294646	chr9:129243551	FAM125B	-0.67	-6.41	-0.55	5.49e-9	Intraocular pressure;
THYM	cis	rs6840360	0.509	rs62327273	chr4:152547594	A/G	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7973719	1.000	rs12828040	chr12:7326541	T/C	cg07052231	chr12:7363540	PEX5	0.64	5.58	0.5	2.24e-7	IgG glycosylation;
THYM	cis	rs56775891	1.000	rs6650631	chr18:77566535	G/C	cg26740109	chr18:77585428	NA	-0.67	-4.83	-0.44	5.31e-6	Schizophrenia;
THYM	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg04654363	chr8:8581213	NA	-0.46	-4.48	-0.42	2.07e-5	Obesity-related traits;
THYM	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg27170947	chr2:26402098	FAM59B	-0.59	-4.97	-0.45	3.01e-6	Gut microbiome composition (summer);
THYM	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg11494091	chr17:61959527	GH2	1.07	16.52	0.86	1.13e-29	Prudent dietary pattern;
THYM	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.13	7.89	0.63	5.23e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4767364	0.922	rs7300252	chr12:112430346	C/T	cg10833066	chr12:111807467	FAM109A	0.47	5.23	0.47	1.02e-6	Oral cavity and pharyngeal cancer;
THYM	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.53	4.61	0.43	1.27e-5	Blood metabolite levels;
THYM	cis	rs9326248	0.530	rs236918	chr11:117091609	G/C	cg01368799	chr11:117014884	PAFAH1B2	-0.98	-5.53	-0.49	2.83e-7	Blood protein levels;
THYM	cis	rs2963155	0.518	rs852978	chr5:142690596	T/C	cg17617527	chr5:142782415	NR3C1	1.13	6.29	0.54	9.55e-9	Breast cancer;
THYM	cis	rs4642101	0.680	rs7626609	chr3:12806080	A/G	cg11882607	chr3:12858926	CAND2	0.44	5.31	0.48	7.26e-7	QRS complex (12-leadsum);
THYM	cis	rs2658782	0.789	rs3020073	chr11:93103830	T/C	cg15737290	chr11:93063684	CCDC67	0.9	7.11	0.59	2.15e-10	Pulmonary function decline;
THYM	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg01579765	chr21:45077557	HSF2BP	-0.45	-6.54	-0.56	3.03e-9	Mean corpuscular volume;
THYM	cis	rs12579753	0.917	rs2401002	chr12:82215870	C/T	cg21231944	chr12:82153410	PPFIA2	-0.7	-5.38	-0.48	5.24e-7	Resting heart rate;
THYM	cis	rs596169	0.685	rs659478	chr1:219113227	A/G	cg19270308	chr1:218458869	RRP15	1.24	4.52	0.42	1.81e-5	Intraocular pressure;
THYM	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg24874828	chr4:187887005	NA	-0.72	-7.22	-0.6	1.26e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9644630	0.864	rs4339658	chr8:19347059	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.7	6.69	0.57	1.56e-9	Oropharynx cancer;
THYM	cis	rs4474465	1.000	rs10899505	chr11:78165343	T/C	cg19901956	chr11:77921274	USP35	-0.6	-4.46	-0.42	2.26e-5	Alzheimer's disease (survival time);
THYM	cis	rs7941600	0.643	rs11828205	chr11:9335284	T/A	cg21110646	chr11:9336536	TMEM41B	1.26	7.16	0.59	1.7e-10	Coronary artery disease;
THYM	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg18904891	chr8:8559673	CLDN23	0.66	4.72	0.44	8.16e-6	Obesity-related traits;
THYM	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg24450063	chr1:156163899	SLC25A44	1.21	15.52	0.85	8.47e-28	Testicular germ cell tumor;
THYM	cis	rs6456156	0.586	rs4710176	chr6:167491639	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.52	-5.2	-0.47	1.14e-6	Primary biliary cholangitis;
THYM	cis	rs55883249	0.958	rs17362734	chr2:9730208	A/G	cg23886495	chr2:9695866	ADAM17	0.82	5.32	0.48	6.79e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs6733011	0.578	rs10169003	chr2:99508866	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.53	4.75	0.44	7.18e-6	Bipolar disorder;
THYM	cis	rs7582180	0.663	rs4850930	chr2:100990955	T/C	cg08017756	chr2:100939284	LONRF2	-0.72	-7.39	-0.6	5.75e-11	Intelligence (multi-trait analysis);
THYM	cis	rs2282300	0.956	rs594937	chr11:30390132	A/G	cg25418670	chr11:30344373	C11orf46	0.74	5.84	0.51	7.14e-8	Morning vs. evening chronotype;
THYM	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07157834	chr1:205819609	PM20D1	0.95	9.71	0.71	6.79e-16	Menarche (age at onset);
THYM	cis	rs12935418	0.583	rs2970085	chr16:81028447	T/C	cg16651780	chr16:81037892	C16orf61	-0.8	-6.24	-0.54	1.2e-8	Mean corpuscular volume;
THYM	cis	rs11031096	0.782	rs10767845	chr11:4156922	C/T	cg18678763	chr11:4115507	RRM1	-0.47	-6.57	-0.56	2.7e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg10515332	chr4:99064459	C4orf37	0.71	5.67	0.5	1.51e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg25767906	chr1:53392781	SCP2	0.53	5.39	0.48	5.08e-7	Monocyte count;
THYM	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg18357526	chr6:26021779	HIST1H4A	0.74	5.96	0.52	4.29e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.41	-5.16	-0.47	1.35e-6	Monocyte percentage of white cells;
THYM	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg06784218	chr1:46089804	CCDC17	-0.3	-4.45	-0.42	2.33e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs16866061	0.926	rs17479770	chr2:225335814	A/G	cg22455342	chr2:225449267	CUL3	0.67	4.64	0.43	1.13e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg06618935	chr21:46677482	NA	-0.93	-9.07	-0.68	1.6e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9914988	0.778	rs35398767	chr17:27122960	A/T	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs4951018	0.526	rs4601639	chr1:205656583	A/G	cg14159672	chr1:205819179	PM20D1	-0.61	-4.96	-0.45	3.06e-6	Prostate-specific antigen levels;
THYM	cis	rs12410462	0.681	rs78978081	chr1:227571619	G/A	cg23173402	chr1:227635558	NA	0.71	5.61	0.5	1.96e-7	Major depressive disorder;
THYM	cis	rs78663649	0.540	rs7252709	chr19:16721183	T/G	cg21122529	chr19:16652680	CHERP	-1.21	-4.58	-0.43	1.43e-5	White blood cell count;
THYM	cis	rs13215566	0.789	rs13194649	chr6:89908152	A/G	cg08400210	chr6:89908154	GABRR1	0.98	5.75	0.51	1.09e-7	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg08999081	chr20:33150536	PIGU	-0.73	-6.56	-0.56	2.86e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.25	10.07	0.72	1.18e-16	Platelet count;
THYM	cis	rs2067615	0.579	rs10746066	chr12:107129108	G/A	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs308403	0.509	rs10016979	chr4:123673192	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.97	8.19	0.64	1.18e-12	Blood protein levels;
THYM	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg16558253	chr16:72132732	DHX38	-0.66	-5.88	-0.52	6.13e-8	Fibrinogen levels;
THYM	cis	rs11771526	0.901	rs11761481	chr7:32293994	C/T	cg13207630	chr7:32358064	NA	0.78	5.0	0.46	2.64e-6	Body mass index;
THYM	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg21427119	chr20:30132790	HM13	-0.86	-5.96	-0.52	4.2e-8	Mean corpuscular hemoglobin;
THYM	cis	rs6430585	0.527	rs7592050	chr2:136459227	C/T	cg23851026	chr2:136556271	LCT	-0.66	-5.94	-0.52	4.71e-8	Corneal structure;
THYM	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs6946131	0.710	rs10231452	chr7:54781223	G/T	cg15810747	chr7:54765501	NA	-0.62	-4.84	-0.44	4.98e-6	Systemic lupus erythematosus;
THYM	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg00271210	chr6:167070053	RPS6KA2	0.72	7.96	0.63	3.73e-12	Crohn's disease;
THYM	cis	rs8044995	0.563	rs3743743	chr16:68397775	C/T	cg09835421	chr16:68378352	PRMT7	-0.72	-4.56	-0.42	1.5e-5	Schizophrenia;
THYM	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg10523679	chr1:76189770	ACADM	-0.55	-4.67	-0.43	9.97e-6	Daytime sleep phenotypes;
THYM	cis	rs13137105	0.614	rs10032148	chr4:76409569	G/A	cg03209871	chr4:76438412	RCHY1;THAP6	0.48	5.22	0.47	1.07e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7107174	1.000	rs2510048	chr11:77987464	T/C	cg19901956	chr11:77921274	USP35	-0.69	-5.3	-0.48	7.42e-7	Testicular germ cell tumor;
THYM	cis	rs9500256	0.967	rs1012500	chr6:58304669	G/A	cg17976157	chr6:58263193	GUSBL2	-0.63	-5.05	-0.46	2.15e-6	Eosinophilic esophagitis (pediatric);
THYM	cis	rs4481887	0.893	rs10788774	chr1:248471712	T/C	cg13385794	chr1:248469461	NA	0.62	4.46	0.42	2.29e-5	Common traits (Other);
THYM	cis	rs2282300	0.653	rs67745574	chr11:30234839	C/T	cg09906309	chr11:30344399	C11orf46	-0.67	-4.95	-0.45	3.23e-6	Morning vs. evening chronotype;
THYM	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1065852	0.526	rs8138080	chr22:42396371	A/G	cg01059385	chr22:42394853	WBP2NL	-0.56	-4.46	-0.42	2.25e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg18876405	chr7:65276391	NA	-0.53	-4.54	-0.42	1.68e-5	Aortic root size;
THYM	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg01570182	chr17:44337453	NA	0.7	6.39	0.55	6.08e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12410462	0.582	rs12408978	chr1:227596235	A/T	cg23173402	chr1:227635558	NA	-0.73	-5.91	-0.52	5.26e-8	Major depressive disorder;
THYM	cis	rs4363385	0.818	rs532743	chr1:153011758	T/G	cg13444842	chr1:152974279	SPRR3	-0.57	-4.57	-0.42	1.47e-5	Inflammatory skin disease;
THYM	cis	rs367615	0.512	rs414724	chr5:108670421	A/G	cg17395555	chr5:108820864	NA	0.56	6.99	0.58	3.83e-10	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg03388043	chr17:80084554	CCDC57	-0.66	-5.66	-0.5	1.61e-7	Life satisfaction;
THYM	trans	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.82	9.07	0.68	1.57e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6062788	0.617	rs56354512	chr20:61706111	A/G	cg17296441	chr20:62284078	STMN3	0.61	4.45	0.42	2.35e-5	Body mass index;
THYM	cis	rs6835098	0.961	rs17322893	chr4:174122556	A/G	cg08422745	chr4:174089978	GALNT7	0.98	7.53	0.61	2.86e-11	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg00300879	chr1:26503847	CNKSR1	0.43	5.74	0.51	1.15e-7	Height;
THYM	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg01341218	chr17:43662625	NA	1.1	9.4	0.69	3.24e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg07936489	chr17:37558343	FBXL20	-0.77	-5.03	-0.46	2.28e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2624839	0.639	rs2526389	chr3:50192826	C/T	cg14019146	chr3:50243930	SLC38A3	-0.63	-5.43	-0.49	4.32e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg03676636	chr4:99064102	C4orf37	0.47	6.85	0.58	7.22e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs684232	0.623	rs117314378	chr17:521672	C/T	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.39	-4.64	-0.43	1.1e-5	Prostate cancer;
THYM	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg01416388	chr22:39784598	NA	-0.91	-8.26	-0.65	8.64e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.929	rs17333381	chr20:43804919	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs2273669	0.667	rs12206606	chr6:109353519	C/A	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs78707713	0.511	rs28697194	chr10:71215483	T/C	cg08851181	chr10:71228077	TSPAN15	-0.71	-4.89	-0.45	4.09e-6	Venous thromboembolism;
THYM	cis	rs6430585	0.528	rs2278682	chr2:136743143	G/C	cg20242066	chr2:136595261	LCT	0.56	5.82	0.51	7.85e-8	Corneal structure;
THYM	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg17063962	chr7:91808500	NA	1.16	13.12	0.8	4.77e-23	Breast cancer;
THYM	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	7.86	0.63	6.06e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs34638657	0.732	rs12595971	chr16:82200309	T/C	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.25	-0.47	9.14e-7	Lung adenocarcinoma;
THYM	cis	rs61931739	1.000	rs11502817	chr12:34010676	T/C	cg06521331	chr12:34319734	NA	0.57	4.49	0.42	2.01e-5	Morning vs. evening chronotype;
THYM	cis	rs4930103	0.935	rs2071094	chr11:2021164	G/T	cg21926276	chr11:2035255	NA	0.27	4.54	0.42	1.68e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs7584330	0.518	rs113812061	chr2:238447934	T/C	cg08992911	chr2:238395768	MLPH	0.76	4.75	0.44	7.09e-6	Prostate cancer;
THYM	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg24308560	chr3:49941425	MST1R	-0.76	-6.48	-0.55	4.1e-9	Intelligence (multi-trait analysis);
THYM	cis	rs28647808	1.000	rs2285482	chr9:136271792	G/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg07167872	chr1:205819463	PM20D1	-0.64	-4.68	-0.43	9.68e-6	Menarche (age at onset);
THYM	cis	rs4478037	0.643	rs9875798	chr3:33120448	G/C	cg19404215	chr3:33155277	CRTAP	1.07	6.99	0.58	3.76e-10	Major depressive disorder;
THYM	cis	rs9527	0.590	rs10509766	chr10:104926334	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.49	-0.42	1.98e-5	Arsenic metabolism;
THYM	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg17143192	chr8:8559678	CLDN23	0.94	7.03	0.59	3.1e-10	Obesity-related traits;
THYM	cis	rs59698941	0.943	rs72799498	chr5:132291157	G/A	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg11266682	chr4:10021025	SLC2A9	0.74	10.8	0.74	3.21e-18	Bone mineral density;
THYM	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg22655196	chr4:3374909	RGS12	0.56	6.85	0.58	7.27e-10	Serum sulfate level;
THYM	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg19610905	chr11:61596333	FADS2	0.57	4.71	0.44	8.37e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
THYM	trans	rs8002861	0.935	rs1811464	chr13:44469290	T/G	cg17145862	chr1:211918768	LPGAT1	1.03	11.89	0.77	1.66e-20	Leprosy;
THYM	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg24642844	chr7:1081250	C7orf50	-1.29	-8.31	-0.65	6.62e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg27535305	chr1:53392650	SCP2	-0.4	-4.52	-0.42	1.78e-5	Monocyte count;
THYM	cis	rs7909074	1.000	rs4948927	chr10:45397071	G/A	cg05187965	chr10:45406764	TMEM72	-0.54	-5.12	-0.46	1.62e-6	Mean corpuscular volume;
THYM	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg18252515	chr7:66147081	NA	0.62	4.55	0.42	1.59e-5	Aortic root size;
THYM	cis	rs6754311	0.509	rs12616520	chr2:136516748	A/T	cg23851026	chr2:136556271	LCT	-0.56	-5.73	-0.51	1.2e-7	Mosquito bite size;
THYM	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg13695892	chr22:41940480	POLR3H	0.89	7.27	0.6	1.02e-10	Vitiligo;
THYM	cis	rs4733781	1.000	rs876575	chr8:131210851	A/G	cg16277922	chr8:131349729	ASAP1	0.69	4.85	0.45	4.8e-6	Tuberculosis;
THYM	cis	rs10823500	0.674	rs7089860	chr10:71992848	C/G	cg26699283	chr10:71892715	AIFM2	-0.47	-4.55	-0.42	1.57e-5	Blood protein levels;
THYM	cis	rs13065560	0.594	rs9858516	chr3:38891548	C/T	cg15678707	chr3:39149194	GORASP1;TTC21A	0.57	4.54	0.42	1.64e-5	Interleukin-18 levels;
THYM	cis	rs2235573	0.625	rs1883471	chr22:38417510	T/C	cg19171272	chr22:38449367	NA	-0.52	-5.55	-0.49	2.62e-7	Glioblastoma;Glioma;
THYM	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11644478	chr21:40555479	PSMG1	-0.56	-4.69	-0.43	9.07e-6	Menarche (age at onset);
THYM	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg13319975	chr6:146136371	FBXO30	0.67	5.51	0.49	3.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1669338	0.507	rs4685606	chr3:3177973	T/G	cg16797762	chr3:3221439	CRBN	-0.9	-5.17	-0.47	1.27e-6	White matter integrity;
THYM	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg19761014	chr17:28927070	LRRC37B2	0.71	4.52	0.42	1.77e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2109514	1.000	rs4727833	chr7:116147908	C/G	cg12739419	chr7:116140593	CAV2	-0.48	-4.65	-0.43	1.07e-5	Prevalent atrial fibrillation;
THYM	cis	rs8014204	0.870	rs3742790	chr14:75308758	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.52	-5.11	-0.46	1.69e-6	Caffeine consumption;
THYM	cis	rs12310956	0.510	rs1386936	chr12:33875369	G/A	cg06521331	chr12:34319734	NA	-0.57	-4.6	-0.43	1.33e-5	Morning vs. evening chronotype;
THYM	cis	rs55823223	0.648	rs11867582	chr17:73857306	A/G	cg09253696	chr17:73873529	TRIM47	-0.69	-4.7	-0.43	8.72e-6	Psoriasis;
THYM	cis	rs3741151	1.000	rs79038783	chr11:73038746	C/G	cg17517138	chr11:73019481	ARHGEF17	0.99	5.88	0.52	5.97e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg10802521	chr3:52805072	NEK4	-0.68	-5.58	-0.5	2.28e-7	Bipolar disorder;
THYM	cis	rs7020830	0.571	rs7031314	chr9:37376122	A/T	cg14294708	chr9:37120828	ZCCHC7	-0.98	-7.66	-0.62	1.54e-11	Schizophrenia;
THYM	cis	rs3924048	0.574	rs11121924	chr1:12611629	A/G	cg00291366	chr1:12616550	NA	0.4	6.33	0.54	7.89e-9	Optic cup area;
THYM	cis	rs710216	0.843	rs10890232	chr1:43416514	C/T	cg16738646	chr1:43409193	SLC2A1	-0.56	-5.0	-0.46	2.66e-6	Red cell distribution width;
THYM	cis	rs888194	0.966	rs6606725	chr12:109905368	C/A	cg10504392	chr12:110044639	NA	0.6	5.61	0.5	1.99e-7	Neuroticism;
THYM	cis	rs2371030	1.000	rs10211086	chr2:211575748	C/G	cg18417063	chr2:211583084	NA	-0.53	-4.57	-0.42	1.48e-5	Non-small cell lung cancer;
THYM	cis	rs7404928	0.651	rs28734145	chr16:23949343	C/T	cg26685404	chr16:23957272	PRKCB	0.61	7.05	0.59	2.91e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs7267979	0.844	rs1555330	chr20:25232097	A/C	cg08601574	chr20:25228251	PYGB	0.7	5.75	0.51	1.1e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg12963246	chr6:28129442	ZNF389	0.77	6.4	0.55	5.74e-9	Parkinson's disease;
THYM	cis	rs17030434	0.784	rs4696486	chr4:154651354	T/C	cg14289246	chr4:154710475	SFRP2	-0.68	-5.1	-0.46	1.73e-6	Electrocardiographic conduction measures;
THYM	cis	rs7084402	0.967	rs1623568	chr10:60320446	T/C	cg07615347	chr10:60278583	BICC1	0.56	5.15	0.47	1.4e-6	Refractive error;
THYM	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg19016782	chr12:123741754	C12orf65	-0.69	-4.47	-0.42	2.18e-5	Neutrophil percentage of white cells;
THYM	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg08847533	chr14:75593920	NEK9	0.96	10.31	0.73	3.66e-17	Height;
THYM	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg04414720	chr1:150670196	GOLPH3L	0.59	4.46	0.42	2.24e-5	Melanoma;
THYM	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg00463982	chr16:1583984	IFT140;TMEM204	-0.58	-4.96	-0.45	3.04e-6	Coronary artery disease;
THYM	cis	rs4907240	0.925	rs11164109	chr2:97300833	T/A	cg01950434	chr2:97203154	ARID5A	-0.59	-4.94	-0.45	3.29e-6	Event-related brain oscillations;
THYM	cis	rs9422860	0.666	rs12761049	chr10:127062506	A/T	cg01247788	chr10:126281564	LHPP	1.1	4.65	0.43	1.06e-5	3-hydroxypropylmercapturic acid levels in smokers;
THYM	trans	rs8002861	0.967	rs2325071	chr13:44476793	T/C	cg17145862	chr1:211918768	LPGAT1	0.99	11.5	0.76	1.06e-19	Leprosy;
THYM	cis	rs9361491	0.608	rs9361425	chr6:79454678	C/T	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Body mass index;
THYM	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.8	-5.07	-0.46	1.98e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2147904	0.933	rs783621	chr1:42368035	A/G	cg16685388	chr1:42384056	HIVEP3	0.56	4.58	0.43	1.41e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
THYM	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg19196401	chr6:110721138	DDO	-0.54	-5.84	-0.51	7.16e-8	Platelet distribution width;
THYM	cis	rs477692	0.544	rs12251589	chr10:131417354	C/A	cg06209143	chr10:131448811	MGMT	-0.61	-5.06	-0.46	2.07e-6	Response to temozolomide;
THYM	cis	rs921968	1.000	rs921968	chr2:219272294	G/T	cg02176678	chr2:219576539	TTLL4	0.55	5.31	0.48	7.07e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs989978	0.532	rs10883364	chr10:101287586	A/G	cg07044859	chr10:101282883	NA	-0.48	-5.23	-0.47	1.01e-6	Red blood cell count;
THYM	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg08807101	chr21:30365312	RNF160	-0.68	-4.46	-0.42	2.28e-5	Dental caries;
THYM	cis	rs4319547	0.695	rs1973463	chr12:122938003	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-4.59	-0.43	1.37e-5	Body mass index;
THYM	cis	rs35883536	0.611	rs61070860	chr1:101097628	G/A	cg09408571	chr1:101003634	GPR88	0.43	5.16	0.47	1.34e-6	Monocyte count;
THYM	cis	rs828999	0.586	rs7555404	chr1:108725558	G/A	cg24323958	chr1:108741884	SLC25A24	0.55	5.4	0.48	4.99e-7	Monocyte percentage of white cells;
THYM	cis	rs752010	0.619	rs1123483	chr1:42114198	C/T	cg06885757	chr1:42089581	HIVEP3	-0.71	-10.12	-0.72	9.12e-17	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg11301795	chr4:187892539	NA	-1.11	-16.58	-0.86	8.47e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg16325326	chr1:53192061	ZYG11B	0.92	9.77	0.71	5.06e-16	Monocyte count;
THYM	cis	rs2554380	0.943	rs4843152	chr15:84363542	T/C	cg14598478	chr15:84363061	ADAMTSL3	-0.61	-4.97	-0.45	3e-6	Height;
THYM	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg25767906	chr1:53392781	SCP2	-0.53	-5.2	-0.47	1.13e-6	Monocyte count;
THYM	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	4.87	0.45	4.49e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9814567	0.752	rs13098546	chr3:134333161	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	7.35	0.6	6.76e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg12524338	chr4:183729343	NA	0.92	6.03	0.53	3.18e-8	Pediatric autoimmune diseases;
THYM	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg00908189	chr16:619842	PIGQ	1.03	9.46	0.7	2.34e-15	Height;
THYM	cis	rs9814567	0.727	rs9809344	chr3:134342758	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-7.5	-0.61	3.34e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg17747265	chr1:1875780	NA	-0.8	-9.16	-0.68	1.01e-14	Body mass index;
THYM	cis	rs28595532	0.920	rs114678295	chr4:119756281	C/T	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7572733	0.534	rs58374969	chr2:198764363	C/T	cg05783139	chr2:198650985	BOLL	0.61	4.82	0.44	5.49e-6	Dermatomyositis;
THYM	cis	rs6570726	0.791	rs392612	chr6:145881586	C/G	cg13319975	chr6:146136371	FBXO30	0.63	5.17	0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg24399712	chr22:39784796	NA	-0.8	-7.28	-0.6	9.82e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg23958373	chr8:599963	NA	0.93	5.05	0.46	2.16e-6	IgG glycosylation;
THYM	cis	rs6032067	0.609	rs1011536	chr20:43793370	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.49	-0.49	3.31e-7	Blood protein levels;
THYM	cis	rs1198430	0.714	rs1198437	chr1:23747424	G/C	cg19827787	chr1:23763612	ASAP3	0.58	4.6	0.43	1.32e-5	Total cholesterol levels;
THYM	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg09640425	chr7:158790006	NA	-0.54	-4.85	-0.45	4.86e-6	Facial morphology (factor 20);
THYM	cis	rs995000	0.931	rs1168042	chr1:62974150	A/T	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs2933343	0.729	rs1680786	chr3:128644840	T/C	cg11901034	chr3:128598214	ACAD9	-0.69	-5.57	-0.5	2.32e-7	IgG glycosylation;
THYM	cis	rs6032067	0.777	rs13038275	chr20:43780988	A/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.52	-5.89	-0.52	5.76e-8	Blood protein levels;
THYM	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg02725872	chr8:58115012	NA	-1.11	-8.56	-0.66	1.98e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs4481887	0.676	rs7524978	chr1:248527319	A/T	cg00666640	chr1:248458726	OR2T12	0.53	4.54	0.42	1.64e-5	Common traits (Other);
THYM	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg00898013	chr13:113819073	PROZ	0.83	8.51	0.66	2.52e-13	Platelet distribution width;
THYM	cis	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg21775007	chr8:11205619	TDH	0.76	6.69	0.57	1.5e-9	Retinal vascular caliber;
THYM	cis	rs9314614	0.865	rs2978898	chr8:6692378	T/C	cg16580759	chr8:6693379	XKR5	-0.45	-4.63	-0.43	1.16e-5	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs17209837	0.607	rs45560338	chr7:87111106	T/C	cg04996195	chr7:87105398	ABCB4	0.65	4.77	0.44	6.62e-6	Gallbladder cancer;
THYM	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg21798802	chr22:38057573	PDXP	0.47	5.34	0.48	6.29e-7	Fat distribution (HIV);
THYM	cis	rs8067545	0.516	rs11869258	chr17:20206898	G/A	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.36	5.09	0.46	1.8e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg08859206	chr1:53392774	SCP2	-0.49	-5.14	-0.47	1.47e-6	Monocyte count;
THYM	cis	rs3126085	0.597	rs12047544	chr1:152169922	C/T	cg26020982	chr1:152196106	HRNR	0.34	4.52	0.42	1.76e-5	Atopic dermatitis;
THYM	cis	rs6430585	0.528	rs309154	chr2:136726567	C/T	cg20242066	chr2:136595261	LCT	0.52	4.91	0.45	3.78e-6	Corneal structure;
THYM	cis	rs72627123	0.867	rs17093884	chr14:74482039	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.52	0.56	3.44e-9	Morning vs. evening chronotype;
THYM	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg09034736	chr1:150693464	HORMAD1	-0.52	-4.66	-0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs116095464	1.000	rs61501460	chr5:316811	G/A	cg22857025	chr5:266934	NA	-1.4	-4.92	-0.45	3.65e-6	Breast cancer;
THYM	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg23711669	chr6:146136114	FBXO30	0.93	9.12	0.68	1.24e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1728785	1.000	rs1069288	chr16:68585285	C/G	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg18305652	chr10:134549665	INPP5A	0.88	8.07	0.64	2.13e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg10518543	chr12:38710700	ALG10B	-0.57	-4.58	-0.43	1.42e-5	Morning vs. evening chronotype;
THYM	cis	rs7975161	0.521	rs4630362	chr12:104727744	G/C	cg25273343	chr12:104657179	TXNRD1	-0.75	-4.47	-0.42	2.13e-5	Toenail selenium levels;
THYM	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2273669	0.504	rs79374607	chr6:109398257	C/T	cg17117243	chr6:109341365	SESN1	-0.92	-5.47	-0.49	3.63e-7	Prostate cancer;
THYM	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg16558253	chr16:72132732	DHX38	-0.54	-4.57	-0.42	1.47e-5	Fibrinogen levels;
THYM	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.92	0.45	3.58e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8133932	0.654	rs7280405	chr21:47275611	C/T	cg20357416	chr21:47294739	PCBP3	-0.8	-5.38	-0.48	5.28e-7	Schizophrenia;
THYM	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg04025307	chr7:1156635	C7orf50	0.78	6.67	0.56	1.66e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg10589385	chr1:150898437	SETDB1	0.63	5.18	0.47	1.23e-6	Melanoma;
THYM	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs3820068	0.580	rs12747696	chr1:16002978	A/G	cg27534772	chr1:16042836	PLEKHM2	0.52	5.87	0.52	6.44e-8	Systolic blood pressure;
THYM	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg23791538	chr6:167370224	RNASET2	0.72	5.66	0.5	1.58e-7	Lung cancer;
THYM	cis	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg24308560	chr3:49941425	MST1R	-0.57	-4.48	-0.42	2.05e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg03647317	chr4:187891568	NA	-0.84	-9.05	-0.68	1.74e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg17757837	chr7:157058334	UBE3C	-0.66	-5.32	-0.48	6.85e-7	Body mass index;
THYM	cis	rs1829883	0.835	rs2963576	chr5:98781722	A/G	cg08333243	chr5:99726346	NA	-0.53	-4.49	-0.42	2.01e-5	Hemostatic factors and hematological phenotypes;
THYM	cis	rs757081	0.667	rs3950680	chr11:17138666	G/A	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.6	-0.43	1.29e-5	Systolic blood pressure;
THYM	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg00684032	chr4:1343700	KIAA1530	0.63	5.4	0.48	4.93e-7	Obesity-related traits;
THYM	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg05313129	chr8:58192883	C8orf71	-0.84	-4.83	-0.44	5.22e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg21775007	chr8:11205619	TDH	0.7	6.37	0.55	6.82e-9	Retinal vascular caliber;
THYM	cis	rs42648	0.935	rs2188233	chr7:89958315	G/A	cg25739043	chr7:89950458	NA	-0.58	-5.04	-0.46	2.25e-6	Homocysteine levels;
THYM	cis	rs4595586	0.545	rs7307303	chr12:39368976	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg18806716	chr10:30721971	MAP3K8	-0.54	-5.41	-0.49	4.74e-7	Inflammatory bowel disease;
THYM	cis	rs1847202	0.787	rs13071878	chr3:72951084	G/A	cg25664220	chr3:72788482	NA	-0.67	-5.01	-0.46	2.48e-6	Motion sickness;
THYM	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg04944784	chr2:26401820	FAM59B	-0.76	-6.06	-0.53	2.78e-8	Gut microbiome composition (summer);
THYM	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg02725872	chr8:58115012	NA	-1.14	-7.59	-0.61	2.17e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg16325326	chr1:53192061	ZYG11B	0.69	5.72	0.51	1.21e-7	Monocyte count;
THYM	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg03188948	chr7:1209495	NA	0.92	6.96	0.58	4.27e-10	Longevity;Endometriosis;
THYM	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg08085267	chr17:45401833	C17orf57	-0.66	-4.73	-0.44	7.76e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
THYM	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg14159672	chr1:205819179	PM20D1	-0.73	-5.77	-0.51	9.83e-8	Menarche (age at onset);
THYM	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg00990874	chr7:1149470	C7orf50	-0.71	-5.19	-0.47	1.17e-6	Bronchopulmonary dysplasia;
THYM	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-11.43	-0.76	1.48e-19	Height;
THYM	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.69e-11	Aortic root size;
THYM	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg15445000	chr17:37608096	MED1	-0.44	-5.22	-0.47	1.07e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg27394845	chr17:28928406	LRRC37B2	0.91	4.58	0.42	1.44e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg03806693	chr22:41940476	POLR3H	1.25	10.88	0.74	2.22e-18	Vitiligo;
THYM	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg06766960	chr11:133703094	NA	-0.52	-4.83	-0.44	5.25e-6	Childhood ear infection;
THYM	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg18402987	chr7:1209562	NA	1.03	6.42	0.55	5.36e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2985684	0.625	rs4900931	chr14:50022793	A/T	cg02151108	chr14:50098012	C14orf104	-0.75	-6.22	-0.54	1.31e-8	Carotid intima media thickness;
THYM	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	13.2	0.8	3.23e-23	Height;
THYM	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg05707623	chr12:122985044	ZCCHC8	0.75	5.1	0.46	1.7e-6	Body mass index;
THYM	cis	rs2888875	0.590	rs13022691	chr2:43723977	T/C	cg22033476	chr2:43532275	THADA	-0.41	-4.65	-0.43	1.06e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs3892630	0.824	rs34748593	chr19:33240447	T/C	cg22928329	chr19:33183273	NUDT19	-0.77	-5.75	-0.51	1.08e-7	Red blood cell traits;
THYM	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg13683864	chr3:40499215	RPL14	-1.05	-11.57	-0.76	7.71e-20	Renal cell carcinoma;
THYM	cis	rs9527	0.590	rs11191572	chr10:104893137	A/G	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs4907240	0.961	rs10460601	chr2:97252444	G/A	cg01950434	chr2:97203154	ARID5A	-0.57	-4.81	-0.44	5.71e-6	Event-related brain oscillations;
THYM	cis	rs7027203	0.797	rs4744294	chr9:96612114	C/G	cg13679303	chr9:96623674	NA	-0.5	-5.08	-0.46	1.89e-6	DNA methylation (variation);
THYM	cis	rs796364	0.587	rs7588746	chr2:200986345	A/G	cg17644776	chr2:200775616	C2orf69	0.74	4.75	0.44	7.09e-6	Schizophrenia;
THYM	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg06028808	chr11:68637592	NA	0.66	7.16	0.59	1.72e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7267979	0.966	rs2227890	chr20:25260931	A/G	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7119038	0.818	rs4938572	chr11:118740931	C/T	cg19308663	chr11:118741387	NA	-0.59	-5.53	-0.49	2.78e-7	Sjögren's syndrome;
THYM	cis	rs17604090	0.941	rs114036198	chr7:29676300	C/T	cg19413766	chr7:29689036	LOC646762	-0.94	-5.1	-0.46	1.75e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg06521331	chr12:34319734	NA	-0.84	-6.6	-0.56	2.37e-9	Morning vs. evening chronotype;
THYM	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg03474202	chr17:45855739	NA	-0.76	-6.7	-0.57	1.45e-9	IgG glycosylation;
THYM	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg03452623	chr4:187889614	NA	-1.16	-19.13	-0.89	2.39e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7089973	0.872	rs7074729	chr10:116632257	C/G	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.05	-0.46	2.15e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs13315871	1.000	rs71311857	chr3:58323377	A/G	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.17	-9.02	-0.68	2.06e-14	Platelet count;
THYM	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg13695892	chr22:41940480	POLR3H	0.86	7.06	0.59	2.77e-10	Vitiligo;
THYM	cis	rs3126085	0.935	rs11588174	chr1:152175970	C/T	cg10321714	chr1:152280068	FLG	-0.65	-4.72	-0.44	8.02e-6	Atopic dermatitis;
THYM	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg18032289	chr17:61959525	GH2	-0.49	-4.7	-0.43	8.9e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs2070677	0.935	rs4300354	chr10:135415890	C/T	cg20169779	chr10:135381914	SYCE1	-0.75	-5.76	-0.51	1.03e-7	Gout;
THYM	cis	rs13082711	0.863	rs13062327	chr3:27495573	G/A	cg02860705	chr3:27208620	NA	0.72	5.22	0.47	1.03e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.0	0.46	2.58e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg13447684	chr7:1895903	MAD1L1	0.69	6.6	0.56	2.34e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs12509991	0.582	rs66894662	chr4:127050999	C/A	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg22683308	chr4:1340831	KIAA1530	-0.62	-4.47	-0.42	2.17e-5	Obesity-related traits;
THYM	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg02551604	chr5:131831745	NA	-0.8	-6.1	-0.53	2.26e-8	Asthma (sex interaction);
THYM	cis	rs11648796	0.717	rs10682	chr16:767430	C/G	cg05638439	chr16:711235	WDR90	-0.54	-4.91	-0.45	3.75e-6	Height;
THYM	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg20966754	chr17:47091339	IGF2BP1	-0.64	-7.73	-0.62	1.1e-11	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	5.45	0.49	3.99e-7	Hip circumference adjusted for BMI;
THYM	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg02527881	chr3:46936655	PTH1R	-0.65	-6.63	-0.56	1.99e-9	Colorectal cancer;
THYM	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg15693483	chr7:1102177	C7orf50	0.53	6.2	0.54	1.46e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs7089973	0.668	rs10885622	chr10:116643844	C/T	cg23260525	chr10:116636907	FAM160B1	0.58	5.98	0.52	3.93e-8	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg10940203	chr5:177434438	FAM153C	0.71	5.74	0.51	1.13e-7	Methadone dose in opioid dependence;
THYM	cis	rs9677476	0.863	rs13423632	chr2:232079116	T/C	cg23338755	chr2:231921595	PSMD1	0.7	5.11	0.46	1.65e-6	Food antigen IgG levels;
THYM	cis	rs7829975	0.653	rs13259070	chr8:8690787	C/T	cg08975724	chr8:8085496	FLJ10661	0.75	6.01	0.52	3.45e-8	Mood instability;
THYM	trans	rs4866334	1.000	rs77695209	chr5:18483369	T/C	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs303386	0.581	rs4000190	chr1:99592566	C/T	cg03593336	chr1:99471295	LPPR5	0.42	4.6	0.43	1.32e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
THYM	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.7	5.52	0.49	2.9e-7	Tonsillectomy;
THYM	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg09367891	chr1:107599246	PRMT6	-0.71	-4.85	-0.45	4.85e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs9486719	1.000	rs2499807	chr6:96864053	T/G	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg21280719	chr6:42927975	GNMT	-0.53	-6.8	-0.57	9.39e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9403317	1.000	rs11155189	chr6:141849039	C/T	cg15052665	chr6:141804349	NA	0.86	7.61	0.62	1.94e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	15.13	0.84	4.91e-27	Chronic sinus infection;
THYM	cis	rs524023	0.874	rs475642	chr11:64424691	C/A	cg19131476	chr11:64387923	NRXN2	-0.39	-5.54	-0.49	2.7e-7	Urate levels in obese individuals;
THYM	trans	rs11165623	0.792	rs12132069	chr1:96918809	A/C	cg10631902	chr5:14652156	NA	-0.62	-6.91	-0.58	5.61e-10	Hip circumference;Waist circumference;
THYM	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg06850241	chr22:41845214	NA	0.53	4.56	0.42	1.54e-5	Vitiligo;
THYM	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06481639	chr22:41940642	POLR3H	-0.82	-5.67	-0.5	1.55e-7	Vitiligo;
THYM	cis	rs11603020	0.950	rs11229066	chr11:57374871	C/G	cg19752551	chr11:57585705	CTNND1	-0.59	-4.95	-0.45	3.25e-6	Blood protein levels;
THYM	cis	rs6541297	1.000	rs6682741	chr1:230279090	T/C	cg20703242	chr1:230279135	GALNT2	0.92	6.26	0.54	1.13e-8	Coronary artery disease;
THYM	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg00071950	chr4:10020882	SLC2A9	0.52	4.58	0.43	1.42e-5	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg08132940	chr7:1081526	C7orf50	-1.0	-6.32	-0.54	8.62e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs36051895	0.632	rs10974993	chr9:5182159	C/T	cg02405213	chr9:5042618	JAK2	-1.0	-11.0	-0.75	1.2e-18	Pediatric autoimmune diseases;
THYM	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg23711669	chr6:146136114	FBXO30	0.96	9.87	0.71	3.12e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9876781	1.000	rs2885510	chr3:48418226	C/T	cg06066452	chr3:48470258	PLXNB1	-0.25	-4.77	-0.44	6.73e-6	Longevity;
THYM	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg16486109	chr11:613632	IRF7	0.51	5.7	0.5	1.34e-7	Systemic lupus erythematosus;
THYM	cis	rs1975974	0.511	rs113941161	chr17:21741346	T/C	cg18423549	chr17:21743878	NA	-0.68	-5.61	-0.5	2.01e-7	Psoriasis;
THYM	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11644478	chr21:40555479	PSMG1	1.1	9.84	0.71	3.61e-16	Cognitive function;
THYM	cis	rs10170846	0.861	rs7571732	chr2:223538316	A/C	cg25565276	chr2:223520875	FARSB	-0.66	-5.35	-0.48	6.03e-7	Schizophrenia (inflammation and infection response interaction);
THYM	cis	rs3772130	0.962	rs11715951	chr3:121522968	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.72	4.56	0.42	1.53e-5	Cognitive performance;
THYM	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg24733560	chr20:60626293	TAF4	0.62	6.55	0.56	2.89e-9	Body mass index;
THYM	cis	rs2692947	0.832	rs2438972	chr2:96690873	T/C	cg22654517	chr2:96458247	NA	0.63	4.87	0.45	4.5e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg15921436	chr17:44337874	NA	0.91	6.52	0.56	3.43e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11574514	1.000	rs9929423	chr16:67733113	T/C	cg04582263	chr16:67973788	LCAT	0.94	4.45	0.42	2.31e-5	Crohn's disease;
THYM	trans	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg07211511	chr3:129823064	LOC729375	-1.34	-9.19	-0.69	9.04e-15	Blood pressure (smoking interaction);
THYM	cis	rs11771526	0.901	rs11760534	chr7:32262966	C/T	cg27532318	chr7:32358331	NA	0.73	4.74	0.44	7.61e-6	Body mass index;
THYM	cis	rs11718455	0.961	rs3846068	chr3:44029835	G/A	cg08738300	chr3:44038990	NA	0.69	4.48	0.42	2.1e-5	Coronary artery disease;
THYM	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg24642844	chr7:1081250	C7orf50	-1.26	-8.22	-0.64	1.03e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg25834613	chr7:1915315	MAD1L1	-0.5	-4.52	-0.42	1.81e-5	Bipolar disorder;
THYM	cis	rs6754311	0.597	rs2082729	chr2:136550109	C/T	cg04750100	chr2:136595281	LCT	-0.55	-6.29	-0.54	9.84e-9	Mosquito bite size;
THYM	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg09549813	chr16:4587862	C16orf5	-0.56	-5.91	-0.52	5.33e-8	Schizophrenia;
THYM	cis	rs9644630	0.672	rs4486225	chr8:19313404	A/G	cg06562184	chr8:19319451	CSGALNACT1	0.61	5.52	0.49	2.88e-7	Oropharynx cancer;
THYM	cis	rs4631830	0.720	rs2611475	chr10:51503178	G/A	cg16070123	chr10:51489643	NA	-0.52	-4.8	-0.44	5.87e-6	Prostate-specific antigen levels;
THYM	trans	rs11109072	0.826	rs11109073	chr12:97902788	G/C	cg17633015	chr7:2020501	MAD1L1	0.95	7.15	0.59	1.78e-10	Obesity (early onset extreme);
THYM	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg06453172	chr10:134556979	INPP5A	-0.72	-5.25	-0.47	9.26e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg10117171	chr1:25599238	RHD	-0.75	-5.56	-0.5	2.44e-7	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs34172651	0.917	rs1075987	chr16:24794957	G/A	cg06028605	chr16:24865363	SLC5A11	0.58	5.69	0.5	1.42e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg07936489	chr17:37558343	FBXL20	-0.79	-5.29	-0.48	7.77e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg04398451	chr17:18023971	MYO15A	0.77	7.22	0.6	1.29e-10	Total body bone mineral density;
THYM	cis	rs4242434	0.854	rs3735893	chr8:22452704	A/G	cg11461670	chr8:22454935	PDLIM2	-0.38	-6.79	-0.57	9.82e-10	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1061377	0.621	rs11096974	chr4:39063659	C/T	cg24403649	chr4:39172243	NA	0.57	4.68	0.43	9.67e-6	Uric acid levels;
THYM	cis	rs1267303	0.562	rs2476162	chr1:47007324	G/A	cg25110126	chr1:46999211	NA	0.64	5.06	0.46	2.07e-6	Monobrow;
THYM	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg13683864	chr3:40499215	RPL14	-0.88	-8.71	-0.67	9.58e-14	Renal cell carcinoma;
THYM	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg17143192	chr8:8559678	CLDN23	0.59	4.48	0.42	2.12e-5	Mood instability;
THYM	cis	rs11785693	0.862	rs62491191	chr8:4993460	G/A	cg26367366	chr8:4980734	NA	1.21	5.9	0.52	5.46e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg08736216	chr1:53307985	ZYG11A	-0.62	-5.5	-0.49	3.14e-7	Monocyte count;
THYM	cis	rs78761021	0.829	rs62066057	chr17:9784047	A/G	cg26853458	chr17:9805074	RCVRN	0.51	4.45	0.42	2.36e-5	Type 2 diabetes;
THYM	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg09877947	chr5:131593287	PDLIM4	0.61	5.31	0.48	7.2e-7	Breast cancer;
THYM	cis	rs6429082	0.764	rs2481095	chr1:235695756	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.74	-6.12	-0.53	2.05e-8	Adiposity;
THYM	cis	rs11031096	0.711	rs4910891	chr11:4153408	A/G	cg08557956	chr11:4115526	RRM1	-0.5	-4.9	-0.45	3.94e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg19507638	chr5:93509721	C5orf36	-0.68	-4.57	-0.42	1.49e-5	Diabetic retinopathy;
THYM	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg13319975	chr6:146136371	FBXO30	-0.66	-5.32	-0.48	6.78e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg06766960	chr11:133703094	NA	-0.6	-5.5	-0.49	3.24e-7	Childhood ear infection;
THYM	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs4749080	0.573	rs12781541	chr10:26431677	C/T	cg00192819	chr18:76486611	NA	1.0	7.09	0.59	2.41e-10	Obesity-related traits;
THYM	cis	rs651907	0.588	rs1707608	chr3:101644769	C/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	5.17	0.47	1.32e-6	Colorectal cancer;
THYM	cis	rs921968	0.565	rs4672897	chr2:219588134	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg11301795	chr4:187892539	NA	-1.1	-16.11	-0.86	6.39e-29	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg08296037	chr16:1584118	IFT140;TMEM204	-0.58	-5.08	-0.46	1.85e-6	Coronary artery disease;
THYM	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg19747945	chr6:42946146	PEX6	-0.34	-5.12	-0.46	1.61e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	trans	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg18335740	chr13:41363409	SLC25A15	0.7	7.52	0.61	3.02e-11	Lewy body disease;
THYM	cis	rs888194	0.649	rs10774697	chr12:109875981	A/G	cg11367159	chr12:110044531	NA	0.53	4.82	0.44	5.39e-6	Neuroticism;
THYM	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg26818010	chr10:134567672	INPP5A	-0.85	-6.98	-0.58	3.98e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs2404602	0.735	rs2461871	chr15:76822418	C/G	cg23625390	chr15:77176239	SCAPER	-0.61	-4.48	-0.42	2.1e-5	Blood metabolite levels;
THYM	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg12935359	chr14:103987150	CKB	-0.64	-6.43	-0.55	5.14e-9	Body mass index;
THYM	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06873352	chr17:61820015	STRADA	0.77	9.62	0.7	1.08e-15	Prudent dietary pattern;
THYM	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg21926883	chr2:100939477	LONRF2	-0.65	-5.98	-0.52	3.94e-8	Intelligence (multi-trait analysis);
THYM	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg17644776	chr2:200775616	C2orf69	0.8	4.82	0.44	5.52e-6	Schizophrenia;
THYM	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg21385522	chr1:16154831	NA	-1.3	-14.69	-0.83	3.47e-26	Dilated cardiomyopathy;
THYM	cis	rs11690935	0.632	rs62183783	chr2:172865775	A/G	cg13550731	chr2:172543902	DYNC1I2	0.63	5.12	0.46	1.6e-6	Schizophrenia;
THYM	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg08999081	chr20:33150536	PIGU	-0.78	-7.2	-0.59	1.41e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg18252515	chr7:66147081	NA	-1.61	-8.73	-0.67	8.74e-14	Diabetic kidney disease;
THYM	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4808199	0.895	rs7252888	chr19:19628037	C/T	cg03709012	chr19:19516395	GATAD2A	1.17	6.65	0.56	1.87e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs9880211	0.644	rs35352346	chr3:135881488	G/A	cg21827317	chr3:136751795	NA	-0.72	-5.21	-0.47	1.11e-6	Body mass index;Height;
THYM	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg17143192	chr8:8559678	CLDN23	0.91	6.74	0.57	1.2e-9	Obesity-related traits;
THYM	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg13119609	chr19:45449297	APOC2	0.6	5.72	0.51	1.22e-7	Blood protein levels;
THYM	cis	rs7219021	0.705	rs67174000	chr17:46982380	G/A	cg09029085	chr17:47094198	IGF2BP1	0.33	4.5	0.42	1.91e-5	Schizophrenia or bipolar disorder;
THYM	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg18132916	chr6:79620363	NA	-0.58	-5.27	-0.48	8.5e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs2806561	0.929	rs6669568	chr1:23540469	G/A	cg19743168	chr1:23544995	NA	-0.7	-7.69	-0.62	1.35e-11	Height;
THYM	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg23803603	chr1:2058230	PRKCZ	-0.55	-4.68	-0.43	9.58e-6	Height;
THYM	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg20283391	chr11:68216788	NA	-0.69	-5.14	-0.47	1.49e-6	Total body bone mineral density;
THYM	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg20744362	chr22:50050164	C22orf34	0.81	7.98	0.63	3.36e-12	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9359856	0.600	rs17584763	chr6:90502088	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.89	-8.13	-0.64	1.6e-12	Bipolar disorder;
THYM	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg03433033	chr1:76189801	ACADM	-0.51	-5.31	-0.48	7.2e-7	Daytime sleep phenotypes;
THYM	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg16586182	chr3:47516702	SCAP	0.64	5.37	0.48	5.54e-7	Colorectal cancer;
THYM	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs924712	0.584	rs10948867	chr6:54737821	T/A	cg19716238	chr6:54711378	FAM83B	-0.45	-4.52	-0.42	1.8e-5	Breast cancer;
THYM	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg26384229	chr12:38710491	ALG10B	1.07	10.43	0.73	2.04e-17	Heart rate;
THYM	cis	rs9790314	0.967	rs460165	chr3:161087710	G/A	cg03342759	chr3:160939853	NMD3	-0.7	-6.01	-0.52	3.47e-8	Morning vs. evening chronotype;
THYM	cis	rs34115320	1	rs34115320	chr7:148783936	CT/C	cg23583168	chr7:148888333	NA	-0.99	-11.66	-0.77	5.06e-20	Sum basophil neutrophil counts;Neutrophil count;
THYM	cis	rs919433	0.680	rs2565163	chr2:198354414	T/C	cg05783139	chr2:198650985	BOLL	0.64	4.95	0.45	3.24e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6457821	1.000	rs6903200	chr6:35482031	G/A	cg05593667	chr6:35490744	NA	-0.89	-4.6	-0.43	1.28e-5	Height;
THYM	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg07570687	chr10:102243282	WNT8B	0.84	8.04	0.64	2.45e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7010267	0.902	rs4242592	chr8:119968975	T/G	cg17171407	chr8:119960777	TNFRSF11B	0.6	4.87	0.45	4.36e-6	Total body bone mineral density (age 45-60);
THYM	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.65	-11.83	-0.77	2.19e-20	Hemostatic factors and hematological phenotypes;
THYM	cis	rs7980799	0.711	rs12319055	chr12:33626509	C/T	cg10856724	chr12:34555212	NA	0.6	4.5	0.42	1.93e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs10927875	0.518	rs1763604	chr1:16339772	C/G	cg22431228	chr1:16359049	CLCNKA	-0.52	-5.1	-0.46	1.74e-6	Dilated cardiomyopathy;
THYM	cis	rs2811415	0.597	rs12695506	chr3:127791800	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs1971762	1.000	rs10876481	chr12:54066743	T/C	cg22997177	chr12:54070527	ATP5G2	-0.48	-5.15	-0.47	1.38e-6	Height;
THYM	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs1005224	1.000	rs1158282	chr14:76172916	C/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.73	-5.7	-0.5	1.34e-7	Large artery stroke;
THYM	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg08999081	chr20:33150536	PIGU	-0.6	-5.44	-0.49	4.18e-7	Height;
THYM	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg07362569	chr17:61921086	SMARCD2	-0.58	-5.21	-0.47	1.07e-6	Prudent dietary pattern;
THYM	cis	rs74417235	0.639	rs2396994	chr5:154052750	A/T	cg25588787	chr5:154027256	NA	-0.92	-4.69	-0.43	9.21e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs2235642	0.505	rs56359342	chr16:1654948	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.5	-5.73	-0.51	1.17e-7	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4363385	0.747	rs2225919	chr1:152969603	A/G	cg13444842	chr1:152974279	SPRR3	-0.57	-4.53	-0.42	1.71e-5	Inflammatory skin disease;
THYM	cis	rs4979906	1.000	rs2395494	chr10:79458340	C/T	cg07817648	chr10:79422355	NA	-0.73	-5.3	-0.48	7.48e-7	Mortality in heart failure;
THYM	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg15242686	chr22:24348715	GSTTP1	0.55	4.91	0.45	3.74e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1568889	0.774	rs11030235	chr11:28212375	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs72848980	0.512	rs56033495	chr10:105383611	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.59	5.47	0.49	3.56e-7	White matter hyperintensity burden;
THYM	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg20887711	chr4:1340912	KIAA1530	0.74	6.76	0.57	1.1e-9	Longevity;
THYM	cis	rs7107174	0.892	rs10899490	chr11:78105879	C/T	cg02023728	chr11:77925099	USP35	0.63	6.11	0.53	2.23e-8	Testicular germ cell tumor;
THYM	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg16322792	chr1:120165303	ZNF697	0.92	11.5	0.76	1.09e-19	Systemic lupus erythematosus;
THYM	trans	rs7615952	0.688	rs9754526	chr3:125542866	C/A	cg07211511	chr3:129823064	LOC729375	-0.92	-7.27	-0.6	9.9e-11	Blood pressure (smoking interaction);
THYM	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	10.26	0.73	4.55e-17	Platelet count;
THYM	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg06634786	chr22:41940651	POLR3H	0.67	4.67	0.43	9.84e-6	Vitiligo;
THYM	cis	rs931127	0.658	rs7926512	chr11:65464487	T/A	cg17480646	chr11:65405466	SIPA1	-0.82	-7.31	-0.6	8.51e-11	Systemic lupus erythematosus;
THYM	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	trans	rs561341	1.000	rs506766	chr17:30289659	T/C	cg20587970	chr11:113659929	NA	-1.35	-8.33	-0.65	6.01e-13	Hip circumference adjusted for BMI;
THYM	cis	rs4733781	0.509	rs7008182	chr8:131344745	T/A	cg16277922	chr8:131349729	ASAP1	-0.73	-6.38	-0.55	6.38e-9	Tuberculosis;
THYM	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.16	0.47	1.32e-6	Prudent dietary pattern;
THYM	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg11752832	chr7:134001865	SLC35B4	0.73	5.5	0.49	3.22e-7	Mean platelet volume;
THYM	cis	rs12257961	0.578	rs10796284	chr10:15392276	G/T	cg10616319	chr10:15468812	NA	-0.61	-4.95	-0.45	3.23e-6	Selective IgA deficiency;
THYM	cis	rs4845875	0.564	rs2151655	chr1:11845518	G/C	cg06193043	chr1:11908199	NPPA	0.6	5.14	0.47	1.44e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.76	-0.44	7.03e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs1403694	0.695	rs5029970	chr3:186434491	T/C	cg12454167	chr3:186435060	KNG1	0.53	7.54	0.61	2.83e-11	Blood protein levels;
THYM	cis	rs1371867	0.846	rs2439460	chr8:101312665	C/T	cg06636551	chr8:101224915	SPAG1	-0.63	-6.33	-0.54	8.05e-9	Atrioventricular conduction;
THYM	cis	rs6815814	0.851	rs17582893	chr4:38886420	G/A	cg14665413	chr4:38859728	TLR6	-0.39	-4.67	-0.43	1e-5	Breast cancer;
THYM	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg18252515	chr7:66147081	NA	-1.45	-8.88	-0.67	4.01e-14	Diabetic kidney disease;
THYM	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg18132916	chr6:79620363	NA	-0.58	-5.29	-0.48	7.66e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg23758822	chr17:41437982	NA	1.16	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg24642844	chr7:1081250	C7orf50	-1.29	-8.3	-0.65	7.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7043114	0.563	rs10820990	chr9:95323297	C/T	cg14631576	chr9:95140430	CENPP	0.76	7.28	0.6	9.4e-11	Height;
THYM	cis	rs11755724	0.772	rs3863228	chr6:7127987	A/G	cg24899545	chr6:7112846	RREB1	-0.47	-4.87	-0.45	4.44e-6	Age-related macular degeneration;Multiple sclerosis;
THYM	cis	rs7809950	1.000	rs6976607	chr7:107223401	A/C	cg23024343	chr7:107201750	COG5	0.93	8.32	0.65	6.49e-13	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg17366294	chr4:99064904	C4orf37	0.57	6.82	0.57	8.42e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4478037	0.822	rs9817393	chr3:33117069	A/G	cg19404215	chr3:33155277	CRTAP	1.07	6.96	0.58	4.27e-10	Major depressive disorder;
THYM	cis	rs1682859	0.545	rs10894763	chr11:133799408	A/G	cg08945802	chr11:132946455	OPCML	-0.7	-4.55	-0.42	1.62e-5	Obesity-related traits;
THYM	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.28	4.69	0.43	9.3e-6	Obesity-related traits;
THYM	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.75	6.41	0.55	5.65e-9	Lymphocyte percentage of white cells;
THYM	trans	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg10856724	chr12:34555212	NA	-0.96	-8.66	-0.66	1.22e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg11189052	chr15:85197271	WDR73	-0.59	-4.61	-0.43	1.23e-5	P wave terminal force;
THYM	cis	rs6499255	0.951	rs16958970	chr16:69627793	G/A	cg00738113	chr16:70207722	CLEC18C	-0.48	-4.5	-0.42	1.92e-5	IgE levels;
THYM	trans	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg25214090	chr10:38739885	LOC399744	0.97	8.33	0.65	5.98e-13	Corneal astigmatism;
THYM	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg24812749	chr6:127587940	RNF146	0.98	7.86	0.63	5.91e-12	Breast cancer;
THYM	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg06481639	chr22:41940642	POLR3H	0.77	5.36	0.48	5.75e-7	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg06784218	chr1:46089804	CCDC17	-0.32	-4.73	-0.44	7.83e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6500395	0.775	rs7185541	chr16:48664681	A/G	cg04672837	chr16:48644449	N4BP1	0.47	4.62	0.43	1.18e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg11764359	chr7:65958608	NA	-0.73	-5.55	-0.49	2.63e-7	Aortic root size;
THYM	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.07	-6.19	-0.54	1.52e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg15556689	chr8:8085844	FLJ10661	0.64	5.21	0.47	1.09e-6	Mood instability;
THYM	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg24578937	chr1:2090814	PRKCZ	-0.57	-5.46	-0.49	3.79e-7	Height;
THYM	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg24733560	chr20:60626293	TAF4	0.62	6.55	0.56	2.89e-9	Body mass index;
THYM	cis	rs28595532	0.920	rs114165587	chr4:119779525	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.76	0.51	1.02e-7	Cannabis dependence symptom count;
THYM	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg22764044	chr5:178986830	RUFY1	0.47	4.79	0.44	6.2e-6	Lung cancer;
THYM	cis	rs9549260	0.564	rs6563845	chr13:41318907	A/G	cg21288729	chr13:41239152	FOXO1	0.7	5.27	0.48	8.56e-7	Red blood cell count;
THYM	cis	rs9486715	0.867	rs211159	chr6:97023026	G/A	cg06623918	chr6:96969491	KIAA0776	-1.05	-8.69	-0.67	1.05e-13	Headache;
THYM	cis	rs3820068	0.581	rs68052904	chr1:15916714	T/C	cg05660106	chr1:15850417	CASP9	0.76	6.31	0.54	8.99e-9	Systolic blood pressure;
THYM	cis	rs7582180	0.790	rs13020451	chr2:100927131	T/G	cg14675211	chr2:100938903	LONRF2	0.76	8.22	0.64	1.01e-12	Intelligence (multi-trait analysis);
THYM	cis	rs6430585	0.527	rs1438303	chr2:136429857	C/T	cg23851026	chr2:136556271	LCT	0.63	5.72	0.51	1.24e-7	Corneal structure;
THYM	cis	rs13315871	0.929	rs13097873	chr3:58267924	C/T	cg12435725	chr3:58293450	RPP14	-0.48	-5.21	-0.47	1.11e-6	Cholesterol, total;
THYM	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg24060327	chr5:131705240	SLC22A5	-0.73	-5.47	-0.49	3.61e-7	Blood metabolite levels;
THYM	cis	rs4866334	1.000	rs77552202	chr5:18489043	A/T	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs7020830	0.858	rs1492714	chr9:37141259	T/C	cg14294708	chr9:37120828	ZCCHC7	1.34	18.37	0.88	4.93e-33	Schizophrenia;
THYM	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg16486109	chr11:613632	IRF7	0.44	4.73	0.44	7.84e-6	Systemic lupus erythematosus;
THYM	cis	rs3885907	0.681	rs4769060	chr13:31337877	A/G	cg00632070	chr13:31506324	C13orf26	-0.54	-4.55	-0.42	1.58e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
THYM	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6906287	0.647	rs4946350	chr6:118945433	A/C	cg21191810	chr6:118973309	C6orf204	0.57	5.73	0.51	1.17e-7	Electrocardiographic conduction measures;
THYM	cis	rs7626444	0.585	rs860050	chr3:196474447	T/G	cg12930392	chr3:196481615	PAK2	0.43	5.34	0.48	6.22e-7	Monocyte count;
THYM	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg18105134	chr13:113819100	PROZ	-0.98	-9.0	-0.68	2.28e-14	Platelet distribution width;
THYM	trans	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg20503657	chr10:835505	NA	0.92	5.02	0.46	2.4e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs10504073	0.609	rs17644494	chr8:50019679	T/C	cg00325661	chr8:49890786	NA	0.86	7.69	0.62	1.35e-11	Blood metabolite ratios;
THYM	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg00071950	chr4:10020882	SLC2A9	0.9	10.65	0.74	6.87e-18	Bone mineral density;
THYM	cis	rs8067545	0.750	rs4925080	chr17:19991838	T/A	cg13482628	chr17:19912719	NA	0.57	4.65	0.43	1.07e-5	Schizophrenia;
THYM	cis	rs61774743	0.557	rs4359027	chr1:41848296	G/A	cg01193554	chr1:41846683	NA	-0.37	-5.19	-0.47	1.19e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06481639	chr22:41940642	POLR3H	-0.78	-5.39	-0.48	5.17e-7	Vitiligo;
THYM	cis	rs79149102	0.579	rs7172715	chr15:75287375	C/G	cg09165964	chr15:75287851	SCAMP5	-1.01	-4.96	-0.45	3.06e-6	Lung cancer;
THYM	cis	rs4653767	1.000	rs708773	chr1:226920730	T/C	cg05262829	chr1:226921576	ITPKB	-0.5	-5.12	-0.46	1.62e-6	Parkinson's disease;
THYM	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg26513180	chr16:89883248	FANCA	0.72	7.38	0.6	5.86e-11	Vitiligo;
THYM	cis	rs2067615	0.579	rs3910854	chr12:107165669	T/C	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs807669	0.903	rs2854643	chr22:19189706	T/C	cg02655711	chr22:19163373	SLC25A1	0.95	10.98	0.75	1.35e-18	Metabolite levels;
THYM	cis	rs11030122	0.702	rs10835311	chr11:3949027	G/T	cg18678763	chr11:4115507	RRM1	-0.43	-5.59	-0.5	2.16e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06850241	chr22:41845214	NA	0.59	5.41	0.49	4.76e-7	Vitiligo;
THYM	cis	rs10095849	0.576	rs10099250	chr8:39444134	T/G	cg22755526	chr8:38854673	TM2D2;ADAM9	-0.63	-4.66	-0.43	1.04e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs786425	0.502	rs10773032	chr12:124226063	A/G	cg15249119	chr12:124971054	NCOR2	0.53	4.98	0.46	2.8e-6	Pubertal anthropometrics;
THYM	cis	rs4363385	0.818	rs6587719	chr1:152993409	G/C	cg13444842	chr1:152974279	SPRR3	-0.57	-4.76	-0.44	6.94e-6	Inflammatory skin disease;
THYM	cis	rs2276314	0.857	rs6507157	chr18:33631703	A/C	cg19628046	chr18:33552617	C18orf21	0.75	5.33	0.48	6.55e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs28595532	0.841	rs114107504	chr4:119771080	T/C	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs3540	0.597	rs3539	chr15:91045419	G/T	cg22089800	chr15:90895588	ZNF774	-0.69	-5.31	-0.48	7.26e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs6964587	0.626	rs35849169	chr7:91507313	A/G	cg17063962	chr7:91808500	NA	1.0	8.44	0.65	3.58e-13	Breast cancer;
THYM	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.43	0.7	2.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7681440	0.606	rs2619350	chr4:90747004	A/G	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg14456004	chr13:21872349	NA	-1.25	-10.05	-0.72	1.28e-16	White matter hyperintensity burden;
THYM	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs36051895	0.658	rs10974912	chr9:5010885	A/C	cg02405213	chr9:5042618	JAK2	-1.04	-10.95	-0.75	1.58e-18	Pediatric autoimmune diseases;
THYM	cis	rs2070677	0.935	rs3020502	chr10:135381623	T/C	cg20169779	chr10:135381914	SYCE1	0.77	5.93	0.52	4.93e-8	Gout;
THYM	cis	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg19693284	chr19:2783607	SGTA	0.66	5.24	0.47	9.69e-7	Total cholesterol levels;
THYM	cis	rs9527	0.590	rs12775302	chr10:104911356	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs977987	0.806	rs8057203	chr16:75404974	T/C	cg03315344	chr16:75512273	CHST6	0.73	6.07	0.53	2.66e-8	Dupuytren's disease;
THYM	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg03929089	chr4:120376271	NA	-0.94	-10.63	-0.74	7.58e-18	Height;
THYM	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.73	-5.73	-0.51	1.16e-7	Blood protein levels;
THYM	cis	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg05084668	chr3:125655381	ALG1L	-0.71	-4.61	-0.43	1.23e-5	Blood pressure (smoking interaction);
THYM	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	10.29	0.73	4e-17	Chronic sinus infection;
THYM	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg00631329	chr6:26305371	NA	-0.72	-7.53	-0.61	2.89e-11	Educational attainment;
THYM	cis	rs1371867	0.846	rs1660346	chr8:101312497	A/G	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg00310523	chr12:86230176	RASSF9	-0.53	-4.89	-0.45	4.11e-6	Major depressive disorder;
THYM	cis	rs6748734	0.895	rs4417704	chr2:241846573	A/G	cg04034577	chr2:241836375	C2orf54	-0.46	-6.3	-0.54	9.32e-9	Urinary metabolites;
THYM	cis	rs7586879	1.000	rs10207698	chr2:25117672	C/T	cg15423357	chr2:25149977	NA	0.56	5.49	0.49	3.41e-7	Body mass index;
THYM	cis	rs3741151	1.000	rs76610873	chr11:73084387	C/T	cg12959048	chr11:73096162	RELT	-0.53	-5.13	-0.47	1.52e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg10047753	chr17:41438598	NA	1.12	9.46	0.7	2.34e-15	Menopause (age at onset);
THYM	cis	rs8073060	0.785	rs11659054	chr17:33867678	C/T	cg24895173	chr17:33825374	SLFN12L	0.61	4.93	0.45	3.43e-6	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg13319975	chr6:146136371	FBXO30	-0.69	-5.65	-0.5	1.7e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6032067	0.641	rs13038485	chr20:43767759	T/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.67	-5.94	-0.52	4.77e-8	Blood protein levels;
THYM	cis	rs2120243	0.572	rs6803628	chr3:157125584	G/A	cg24825693	chr3:157122686	VEPH1	-0.48	-4.67	-0.43	9.97e-6	Hepatocellular carcinoma in hepatitis B infection;
THYM	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs1670533	0.872	rs935969	chr4:1062588	A/G	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs13315871	1.000	rs78248959	chr3:58455068	G/A	cg12435725	chr3:58293450	RPP14	-0.48	-4.95	-0.45	3.17e-6	Cholesterol, total;
THYM	cis	rs6032067	0.929	rs11699850	chr20:43809049	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg18402987	chr7:1209562	NA	1.24	7.55	0.61	2.62e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.07	6.92	0.58	5.17e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg06238570	chr21:40685208	BRWD1	-0.69	-6.08	-0.53	2.47e-8	Menarche (age at onset);
THYM	cis	rs80319144	0.521	rs75690826	chr2:159324696	C/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.52	5.07	0.46	1.99e-6	Restless legs syndrome;
THYM	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg18305652	chr10:134549665	INPP5A	0.75	5.9	0.52	5.46e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs863345	0.604	rs11265010	chr1:158498853	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg24642844	chr7:1081250	C7orf50	-1.28	-8.22	-0.64	1.06e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs611744	0.839	rs638238	chr8:109169152	A/G	cg21045802	chr8:109455806	TTC35	0.67	6.47	0.55	4.27e-9	Dupuytren's disease;
THYM	cis	rs4386084	1.000	rs12915576	chr15:50233770	G/A	cg21557108	chr15:50410962	ATP8B4	0.46	4.45	0.42	2.35e-5	Basophil percentage of white cells;Basophil percentage of granulocytes;
THYM	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg10523679	chr1:76189770	ACADM	-0.55	-4.49	-0.42	1.99e-5	Daytime sleep phenotypes;
THYM	cis	rs12474201	0.925	rs1058157	chr2:46988275	G/A	cg09399716	chr2:46890238	NA	-0.54	-4.72	-0.44	7.96e-6	Height;
THYM	trans	rs877282	0.898	rs11253349	chr10:765897	C/G	cg22713356	chr15:30763199	NA	1.36	9.83	0.71	3.89e-16	Uric acid levels;
THYM	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg03859395	chr2:55845619	SMEK2	0.61	5.47	0.49	3.72e-7	Metabolic syndrome;
THYM	trans	rs9951602	0.541	rs12454297	chr18:76654445	A/G	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs7119	0.700	rs57471224	chr15:77888169	A/G	cg10437265	chr15:77819839	NA	-0.56	-5.5	-0.49	3.21e-7	Type 2 diabetes;
THYM	cis	rs72827839	0.846	rs16954204	chr17:46315198	T/C	cg23391107	chr17:45924227	SP6	0.85	5.05	0.46	2.17e-6	Ease of getting up in the morning;
THYM	cis	rs7124681	0.584	rs10769285	chr11:47709212	C/T	cg18512352	chr11:47633146	NA	0.4	4.47	0.42	2.14e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg05973401	chr12:123451056	ABCB9	0.69	4.55	0.42	1.56e-5	Neutrophil percentage of white cells;
THYM	cis	rs919433	0.679	rs10931787	chr2:198520615	A/G	cg05783139	chr2:198650985	BOLL	0.66	4.98	0.46	2.78e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs877282	0.945	rs10904554	chr10:786768	T/C	cg10556349	chr10:835070	NA	-0.78	-5.38	-0.48	5.34e-7	Uric acid levels;
THYM	cis	rs8114671	0.562	rs6087644	chr20:33480917	G/C	cg08999081	chr20:33150536	PIGU	0.61	4.95	0.45	3.22e-6	Height;
THYM	cis	rs295140	1.000	rs11696001	chr2:201162433	G/A	cg04283868	chr2:201171347	SPATS2L	0.74	5.53	0.49	2.81e-7	QT interval;
THYM	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg12165864	chr7:66369176	NA	-0.68	-5.2	-0.47	1.15e-6	Aortic root size;
THYM	cis	rs11048434	0.761	rs2110191	chr12:9136263	G/A	cg04155231	chr12:9217510	LOC144571	0.5	4.95	0.45	3.27e-6	Sjögren's syndrome;
THYM	cis	rs2408955	0.500	rs12816820	chr12:48558325	A/G	cg21466736	chr12:48725269	NA	-0.49	-4.9	-0.45	3.87e-6	Glycated hemoglobin levels;
THYM	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg15997130	chr1:24165203	NA	-0.77	-6.87	-0.58	6.65e-10	Immature fraction of reticulocytes;
THYM	cis	rs9486719	0.802	rs2983896	chr6:97029871	G/A	cg06623918	chr6:96969491	KIAA0776	-0.81	-5.13	-0.47	1.54e-6	Migraine;Coronary artery disease;
THYM	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg18681998	chr4:17616180	MED28	1.0	10.28	0.73	4.24e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7705502	0.962	rs1976074	chr5:173384663	T/A	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg12119029	chr16:89752879	CDK10	-0.45	-5.21	-0.47	1.1e-6	Vitiligo;
THYM	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg04234412	chr22:24373322	LOC391322	-0.9	-8.8	-0.67	6.11e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg27572855	chr1:25598939	RHD	0.68	5.25	0.47	9.33e-7	Erythrocyte sedimentation rate;
THYM	trans	rs629535	0.814	rs614050	chr8:70065642	G/A	cg21567404	chr3:27674614	NA	1.08	10.14	0.72	8.19e-17	Dupuytren's disease;
THYM	cis	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg03060546	chr3:49711283	APEH	-0.68	-5.26	-0.48	8.7e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg02070205	chr10:30722105	MAP3K8	-0.6	-5.29	-0.48	7.75e-7	Inflammatory bowel disease;
THYM	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg22166914	chr1:53195759	ZYG11B	-0.92	-10.91	-0.75	1.93e-18	Monocyte count;
THYM	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg15358701	chr1:161410459	NA	-0.97	-5.37	-0.48	5.56e-7	Rheumatoid arthritis;
THYM	cis	rs7584330	0.504	rs11890307	chr2:238434705	A/G	cg08992911	chr2:238395768	MLPH	0.89	5.81	0.51	8.24e-8	Prostate cancer;
THYM	cis	rs13102973	0.965	rs7656209	chr4:135875550	G/A	cg14419869	chr4:135874104	NA	0.88	8.62	0.66	1.45e-13	Subjective well-being;
THYM	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg05043794	chr9:111880884	C9orf5	-0.42	-6.12	-0.53	2.11e-8	Menarche (age at onset);
THYM	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg27121462	chr16:89883253	FANCA	-0.57	-4.49	-0.42	2.04e-5	Vitiligo;
THYM	cis	rs6728642	0.614	rs113485946	chr2:97866442	T/C	cg26665480	chr2:98280029	ACTR1B	-1.04	-4.77	-0.44	6.53e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs10489202	1.000	rs12727036	chr1:167972147	A/G	cg24449463	chr1:168025552	DCAF6	-0.83	-6.51	-0.56	3.58e-9	Schizophrenia;
THYM	cis	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg12193833	chr17:30244370	NA	-0.7	-4.99	-0.46	2.78e-6	Hip circumference adjusted for BMI;
THYM	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	6.47	0.55	4.21e-9	Obesity-related traits;
THYM	cis	rs11252926	0.800	rs2209625	chr10:747115	A/C	cg16346588	chr10:242978	ZMYND11	-0.6	-4.95	-0.45	3.26e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs863345	0.564	rs12145401	chr1:158494693	A/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	trans	rs75518195	0.566	rs62302823	chr4:64739112	T/A	cg14706739	chr8:21916355	EPB49	0.73	6.98	0.58	3.99e-10	Triptolide cytotoxicity;
THYM	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.74	8.11	0.64	1.79e-12	Eosinophil percentage of white cells;
THYM	cis	rs10851411	0.688	rs17709596	chr15:42767981	C/T	cg04857231	chr15:42782520	NA	-0.58	-5.26	-0.48	8.76e-7	Glucose homeostasis traits;
THYM	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg04602696	chr16:88846723	FAM38A	-0.67	-5.21	-0.47	1.08e-6	Plateletcrit;
THYM	cis	rs1800682	0.528	rs11202918	chr10:90742008	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.57	5.85	0.51	7.01e-8	Chronic lymphocytic leukemia;
THYM	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg01579765	chr21:45077557	HSF2BP	-0.54	-8.88	-0.67	4.14e-14	Mean corpuscular volume;
THYM	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs901683	0.867	rs34144887	chr10:46086393	G/A	cg18240400	chr10:46168597	ANUBL1	0.73	4.73	0.44	7.89e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg04267008	chr7:1944627	MAD1L1	0.61	4.95	0.45	3.27e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg06191203	chr2:152266755	RIF1	0.71	4.71	0.43	8.5e-6	Lung cancer;
THYM	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg24397884	chr7:158709396	WDR60	0.5	5.41	0.49	4.64e-7	Height;
THYM	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg04731861	chr2:219085781	ARPC2	0.54	5.03	0.46	2.27e-6	Colorectal cancer;
THYM	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs9311676	0.656	rs11130634	chr3:58379123	A/C	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs2836633	0.895	rs62217513	chr21:40024416	A/T	cg12884169	chr21:40033163	ERG	0.7	8.72	0.67	8.83e-14	Coronary artery disease;
THYM	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg02782426	chr3:40428986	ENTPD3	0.54	4.79	0.44	6.02e-6	Renal cell carcinoma;
THYM	cis	rs7258015	0.909	rs2304237	chr19:10446568	T/C	cg01466491	chr19:10523363	NA	0.67	5.06	0.46	2.04e-6	Systemic lupus erythematosus or rheumatoid arthritis;
THYM	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg00255919	chr5:131827918	IRF1	0.45	5.17	0.47	1.29e-6	Asthma (sex interaction);
THYM	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg11494091	chr17:61959527	GH2	0.69	6.42	0.55	5.32e-9	Height;
THYM	cis	rs10504073	0.669	rs818558	chr8:50030855	A/G	cg00325661	chr8:49890786	NA	0.78	7.03	0.59	3.11e-10	Blood metabolite ratios;
THYM	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg05340658	chr4:99064831	C4orf37	0.54	4.51	0.42	1.83e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1670533	1.000	rs935971	chr4:1045265	G/A	cg27284194	chr4:1044797	NA	0.66	5.03	0.46	2.27e-6	Recombination rate (females);
THYM	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.8	-5.5	-0.49	3.14e-7	Huntington's disease progression;
THYM	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg15451548	chr1:2144873	NA	-0.47	-4.54	-0.42	1.64e-5	Height;
THYM	cis	rs9796	0.621	rs2578655	chr15:41462809	T/G	cg21153102	chr15:41252147	NA	0.56	4.59	0.43	1.38e-5	Menopause (age at onset);
THYM	cis	rs9467160	0.520	rs2753910	chr6:24442473	C/T	cg20631270	chr6:24437470	GPLD1	-0.64	-5.82	-0.51	7.99e-8	Liver enzyme levels;
THYM	cis	rs11696501	0.688	rs714595	chr20:44330591	G/A	cg11783356	chr20:44313418	WFDC10B	-0.71	-4.79	-0.44	6.07e-6	Brain structure;
THYM	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg04362960	chr10:104952993	NT5C2	0.55	4.53	0.42	1.72e-5	Arsenic metabolism;
THYM	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg01264106	chr22:38071602	LGALS1	0.36	4.52	0.42	1.76e-5	Fat distribution (HIV);
THYM	cis	rs4979906	1.000	rs4979907	chr10:79451969	C/A	cg07817648	chr10:79422355	NA	-0.76	-5.19	-0.47	1.19e-6	Mortality in heart failure;
THYM	cis	rs12216545	0.765	rs2373807	chr7:150249370	G/T	cg00323915	chr7:150264987	GIMAP4	-0.51	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg23442198	chr4:187126114	CYP4V2	-0.96	-4.51	-0.42	1.87e-5	Blood protein levels;
THYM	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg10589385	chr1:150898437	SETDB1	0.57	4.55	0.42	1.56e-5	Melanoma;
THYM	cis	rs7000551	0.751	rs2449329	chr8:22374794	G/T	cg12081754	chr8:22256438	SLC39A14	0.65	5.67	0.5	1.51e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs17253792	0.822	rs77544029	chr14:56087917	T/C	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg23711669	chr6:146136114	FBXO30	0.98	10.66	0.74	6.54e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs752010	0.715	rs4660551	chr1:42099979	T/C	cg06885757	chr1:42089581	HIVEP3	0.75	10.32	0.73	3.46e-17	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs6840360	0.571	rs4696110	chr4:152671325	G/A	cg22705602	chr4:152727874	NA	-0.81	-10.99	-0.75	1.3e-18	Intelligence (multi-trait analysis);
THYM	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg24060327	chr5:131705240	SLC22A5	-0.75	-6.12	-0.53	2.12e-8	Acylcarnitine levels;
THYM	cis	rs2742417	0.609	rs2673066	chr3:45771200	C/T	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs7084402	0.967	rs1658462	chr10:60298284	A/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.64	-0.5	1.72e-7	Refractive error;
THYM	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.71	-6.03	-0.53	3.12e-8	Coronary artery disease;
THYM	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg21280719	chr6:42927975	GNMT	-0.55	-7.23	-0.6	1.21e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2898681	0.874	rs4864691	chr4:53755972	C/T	cg21521518	chr4:53727714	RASL11B	0.48	5.37	0.48	5.64e-7	Optic nerve measurement (cup area);
THYM	cis	rs1843834	0.823	rs2129610	chr2:225505345	G/A	cg22509189	chr2:225307070	NA	-0.68	-4.77	-0.44	6.52e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs6785206	0.730	rs9861429	chr3:128425749	A/G	cg16766828	chr3:128327626	NA	-0.75	-7.58	-0.61	2.26e-11	Lymphocyte percentage of white cells;
THYM	cis	rs12410462	1.000	rs75652886	chr1:227654485	G/T	cg23173402	chr1:227635558	NA	0.67	5.94	0.52	4.59e-8	Major depressive disorder;
THYM	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.33	9.84	0.71	3.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg14993813	chr1:46806288	NSUN4	-0.67	-4.52	-0.42	1.81e-5	Menopause (age at onset);
THYM	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	4.66	0.43	1.02e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.79e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs6754311	0.593	rs10195620	chr2:136495619	A/T	cg04750100	chr2:136595281	LCT	-0.55	-6.19	-0.54	1.52e-8	Mosquito bite size;
THYM	cis	rs3126085	0.935	rs41267154	chr1:152286367	C/A	cg10321714	chr1:152280068	FLG	-0.68	-4.95	-0.45	3.18e-6	Atopic dermatitis;
THYM	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg09549813	chr16:4587862	C16orf5	-0.56	-6.15	-0.53	1.84e-8	Schizophrenia;
THYM	cis	rs11711311	1.000	rs9811746	chr3:113515060	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.63	-5.57	-0.5	2.32e-7	IgG glycosylation;
THYM	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg12379764	chr21:47803548	PCNT	-0.71	-4.84	-0.44	5.11e-6	Testicular germ cell tumor;
THYM	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg24578937	chr1:2090814	PRKCZ	0.81	8.45	0.65	3.41e-13	Height;
THYM	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg05738196	chr6:26577821	NA	0.95	9.91	0.71	2.53e-16	Intelligence (multi-trait analysis);
THYM	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg23161317	chr6:28129485	ZNF389	-1.02	-8.34	-0.65	5.76e-13	Depression;
THYM	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs1061377	0.870	rs73238544	chr4:39138963	A/C	cg24403649	chr4:39172243	NA	0.59	4.78	0.44	6.29e-6	Uric acid levels;
THYM	cis	rs3760776	0.522	rs78060698	chr19:5832773	G/A	cg25387410	chr19:5844109	FUT3	-0.96	-4.96	-0.45	3.08e-6	N-glycan levels;Tumor biomarkers;Vitamin B12 levels;
THYM	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg24397884	chr7:158709396	WDR60	0.53	5.8	0.51	8.48e-8	Height;
THYM	cis	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs3126085	1.000	rs11590365	chr1:152165489	C/A	cg10321714	chr1:152280068	FLG	-0.76	-5.65	-0.5	1.71e-7	Atopic dermatitis;
THYM	cis	rs4589258	0.762	rs4486591	chr11:90464079	G/A	cg26138821	chr11:89956704	CHORDC1	-0.56	-4.49	-0.42	2.02e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg27170947	chr2:26402098	FAM59B	0.79	6.27	0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs250677	0.522	rs6872701	chr5:148359086	C/G	cg18129178	chr5:148520854	ABLIM3	0.72	5.4	0.48	4.94e-7	Breast cancer;
THYM	cis	rs4654899	0.643	rs2053981	chr1:21227083	G/A	cg01072550	chr1:21505969	NA	-0.72	-6.64	-0.56	1.91e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg04673462	chr1:38461896	NA	0.46	5.74	0.51	1.11e-7	Coronary artery disease;
THYM	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg27286337	chr10:134555280	INPP5A	0.95	7.18	0.59	1.56e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06481639	chr22:41940642	POLR3H	0.65	4.77	0.44	6.53e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs9897596	1	rs9897596	chr17:17593453	T/C	cg04398451	chr17:18023971	MYO15A	0.63	5.13	0.47	1.53e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs7917772	0.582	rs10786680	chr10:104317192	A/G	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs977987	0.778	rs11858992	chr16:75411445	A/C	cg03315344	chr16:75512273	CHST6	0.71	6.13	0.53	1.96e-8	Dupuytren's disease;
THYM	cis	rs728616	0.867	rs61860034	chr10:81931848	C/T	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg00999904	chr2:3704751	ALLC	-0.72	-4.95	-0.45	3.24e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs73086581	1.000	rs17214949	chr20:3940952	T/C	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg06877462	chr1:205807181	PM20D1	0.62	4.76	0.44	6.89e-6	Menarche (age at onset);
THYM	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg23161317	chr6:28129485	ZNF389	0.94	7.03	0.58	3.18e-10	Parkinson's disease;
THYM	cis	rs4886920	0.894	rs4886930	chr15:78127406	G/A	cg10461261	chr15:78109450	NA	-0.47	-4.58	-0.43	1.41e-5	Neuroticism;
THYM	cis	rs9311676	0.656	rs55913214	chr3:58388026	A/G	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg11965913	chr1:205819406	PM20D1	1.05	12.51	0.79	8.56e-22	Menarche (age at onset);
THYM	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg11335335	chr11:637885	DRD4	-0.69	-6.23	-0.54	1.24e-8	Systemic lupus erythematosus;
THYM	cis	rs332507	0.789	rs10755078	chr3:124378412	A/G	cg14688451	chr3:124303035	KALRN	0.59	4.45	0.42	2.33e-5	Plateletcrit;
THYM	cis	rs4666002	0.956	rs3749147	chr2:27851918	G/A	cg27432699	chr2:27873401	GPN1	0.6	4.62	0.43	1.21e-5	Phospholipid levels (plasma);
THYM	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg01324343	chr3:183735012	ABCC5	0.9	13.47	0.81	9.06e-24	Anterior chamber depth;
THYM	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.51	4.95	0.45	3.21e-6	Lymphocyte counts;
THYM	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs6746082	0.550	rs682888	chr2:25757709	T/C	cg23192403	chr2:25781496	DTNB	-0.43	-5.82	-0.51	7.98e-8	Multiple myeloma;
THYM	cis	rs4242434	0.819	rs751680	chr8:22475627	G/A	cg01710189	chr8:22454888	PDLIM2	-0.48	-5.16	-0.47	1.33e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03647317	chr4:187891568	NA	-0.82	-8.73	-0.67	8.61e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg17333051	chr19:2783644	SGTA	0.54	5.14	0.47	1.48e-6	Total cholesterol levels;
THYM	cis	rs1747683	0.966	rs4750346	chr10:13375013	T/C	cg00142036	chr10:13388442	SEPHS1	-0.28	-4.99	-0.46	2.75e-6	IgG glycosylation;
THYM	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg19318889	chr4:1322082	MAEA	0.69	6.05	0.53	2.86e-8	Longevity;
THYM	cis	rs3806843	0.900	rs2563279	chr5:140131535	G/A	cg19875535	chr5:140030758	IK	-0.58	-4.55	-0.42	1.58e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs1129187	0.748	rs9471968	chr6:42905235	A/G	cg02353165	chr6:42928485	GNMT	0.75	6.34	0.55	7.54e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg27490568	chr2:178487706	NA	0.6	5.49	0.49	3.3e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs425535	0.817	rs377579	chr4:74851660	T/C	cg07868155	chr4:74864709	CXCL5	0.66	5.57	0.5	2.41e-7	Blood protein levels;
THYM	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg01350728	chr13:21893604	NA	-0.59	-4.45	-0.42	2.36e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg09417038	chr21:47716443	C21orf57	-0.74	-6.77	-0.57	1.05e-9	Testicular germ cell tumor;
THYM	cis	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg10856724	chr12:34555212	NA	-0.75	-6.61	-0.56	2.21e-9	Morning vs. evening chronotype;
THYM	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg21211367	chr2:162094118	NA	0.66	5.4	0.48	4.85e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg17775962	chr7:1200435	ZFAND2A	0.42	4.91	0.45	3.81e-6	Longevity;Endometriosis;
THYM	cis	rs6089829	0.926	rs73921625	chr20:61660891	C/T	cg03213289	chr20:61660250	NA	-0.86	-7.13	-0.59	1.92e-10	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs250677	0.522	rs1007400	chr5:148382635	C/T	cg18129178	chr5:148520854	ABLIM3	0.72	5.4	0.48	4.94e-7	Breast cancer;
THYM	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg00810483	chr4:3375144	RGS12	-0.3	-4.51	-0.42	1.85e-5	Serum sulfate level;
THYM	cis	rs868036	1.000	rs3784719	chr15:68098180	C/T	cg24579218	chr15:68104479	NA	-0.65	-6.51	-0.56	3.59e-9	Restless legs syndrome;
THYM	cis	rs12476592	0.602	rs4671509	chr2:63686004	C/T	cg17519650	chr2:63277830	OTX1	-0.71	-4.83	-0.44	5.29e-6	Childhood ear infection;
THYM	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg27284194	chr4:1044797	NA	0.65	4.94	0.45	3.28e-6	Recombination rate (females);
THYM	cis	rs7209460	0.556	rs4790312	chr17:1981480	T/C	cg27406664	chr17:2294951	MNT	-0.54	-4.7	-0.43	8.71e-6	Coronary artery disease;Total body bone mineral density;
THYM	cis	rs1863824	0.625	rs10887600	chr10:88169072	C/T	cg06895675	chr10:88137553	NA	0.58	4.96	0.45	3.06e-6	Schizophrenia;
THYM	cis	rs5758511	0.514	rs3985938	chr22:42511727	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.66	6.84	0.57	7.82e-10	Birth weight;
THYM	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg27535305	chr1:53392650	SCP2	-0.59	-6.67	-0.56	1.7e-9	Monocyte count;
THYM	cis	rs11641365	0.517	rs73262667	chr16:88779753	C/T	cg00034003	chr16:88779146	CTU2	1.05	7.38	0.6	5.95e-11	Autism spectrum disorder-related traits;
THYM	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg12923728	chr3:195709715	SDHAP1	-0.7	-5.68	-0.5	1.44e-7	Pancreatic cancer;
THYM	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11644478	chr21:40555479	PSMG1	-0.56	-4.69	-0.43	9.07e-6	Menarche (age at onset);
THYM	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.0	8.1	0.64	1.86e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9595908	0.785	rs3848085	chr13:33261664	C/A	cg12383807	chr13:33924137	NA	-0.51	-4.45	-0.42	2.34e-5	Body mass index;
THYM	cis	rs208520	0.874	rs208485	chr6:66925654	T/C	cg07460842	chr6:66804631	NA	-0.86	-5.5	-0.49	3.15e-7	Exhaled nitric oxide output;
THYM	cis	rs12496230	1.000	rs13100186	chr3:66831642	T/C	cg04995300	chr3:66848608	NA	1.11	6.63	0.56	2.07e-9	Type 2 diabetes;
THYM	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg10661904	chr17:79619235	PDE6G	0.54	4.79	0.44	6.25e-6	Eye color traits;
THYM	cis	rs2976388	0.935	rs2976386	chr8:143757409	G/A	cg06565975	chr8:143823917	SLURP1	-0.44	-4.94	-0.45	3.37e-6	Urinary tract infection frequency;
THYM	cis	rs662064	0.962	rs622623	chr1:10555257	C/T	cg20482658	chr1:10539492	PEX14	-0.47	-5.99	-0.52	3.75e-8	Asthma;
THYM	cis	rs112998813	0.571	rs11147317	chr13:114939396	A/G	cg26703057	chr13:114071457	NA	0.71	4.58	0.43	1.4e-5	Nodular sclerosis Hodgkin lymphoma;
THYM	cis	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg13443165	chr9:33130375	B4GALT1	-0.78	-7.25	-0.6	1.09e-10	IgG glycosylation;
THYM	cis	rs9972944	0.756	rs2873818	chr17:63762867	A/T	cg07283582	chr17:63770753	CCDC46	-0.65	-4.99	-0.46	2.68e-6	Total body bone mineral density;
THYM	cis	rs35264875	0.950	rs35337391	chr11:68854012	A/G	cg01993067	chr11:68851601	TPCN2	1.0	5.26	0.47	8.97e-7	Blond vs. brown hair color;
THYM	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg11764359	chr7:65958608	NA	0.64	5.0	0.46	2.58e-6	Aortic root size;
THYM	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7226229	1.000	rs2364332	chr17:20909288	G/A	cg21263980	chr17:20946333	USP22	0.65	4.88	0.45	4.33e-6	Blood trace element (Se levels);
THYM	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg25554036	chr4:6271136	WFS1	0.58	5.26	0.47	8.93e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs9796	0.870	rs1001341	chr15:41261491	T/A	cg21153102	chr15:41252147	NA	-0.68	-6.29	-0.54	9.47e-9	Menopause (age at onset);
THYM	cis	rs7572733	0.514	rs700686	chr2:198721054	G/A	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs7943358	0.955	rs10832502	chr11:15692238	C/T	cg11966998	chr11:15692519	NA	-0.52	-5.42	-0.49	4.59e-7	Gut microbiome composition (summer);
THYM	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg00495681	chr13:53174319	NA	0.73	6.85	0.57	7.36e-10	Lewy body disease;
THYM	cis	rs2976388	1.000	rs2976392	chr8:143762932	G/A	cg06565975	chr8:143823917	SLURP1	-0.45	-5.23	-0.47	9.95e-7	Urinary tract infection frequency;
THYM	cis	rs13223928	0.621	rs10228451	chr7:3150859	C/G	cg19214707	chr7:3157722	NA	0.88	7.44	0.61	4.58e-11	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs62070183	0.766	rs10512441	chr17:31239645	A/G	cg02981443	chr17:31254875	TMEM98	0.52	4.68	0.43	9.42e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg10560079	chr2:191398806	TMEM194B	-0.86	-6.5	-0.56	3.64e-9	Diastolic blood pressure;
THYM	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg21926612	chr6:163149169	PACRG;PARK2	1.3	8.44	0.65	3.47e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg02218324	chr19:46318439	RSPH6A	-0.35	-4.53	-0.42	1.71e-5	Coronary artery disease;
THYM	cis	rs2249694	0.960	rs9630033	chr10:135418505	G/T	cg20169779	chr10:135381914	SYCE1	-0.52	-4.48	-0.42	2.08e-5	Obesity-related traits;
THYM	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg24578937	chr1:2090814	PRKCZ	-0.65	-6.79	-0.57	9.86e-10	Height;
THYM	cis	rs17407555	0.738	rs55731306	chr4:10067885	G/T	cg00071950	chr4:10020882	SLC2A9	-0.76	-5.76	-0.51	1.04e-7	Schizophrenia (age at onset);
THYM	cis	rs4654899	0.580	rs1977296	chr1:21091543	G/T	cg01072550	chr1:21505969	NA	-0.62	-5.66	-0.5	1.62e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg14456004	chr13:21872349	NA	1.25	11.49	0.76	1.13e-19	White matter hyperintensity burden;
THYM	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg17054759	chr22:49844102	NA	-0.52	-4.72	-0.44	8.24e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6456042	1.000	rs6940243	chr6:166534658	C/G	cg11088901	chr6:166572345	T	0.51	4.82	0.44	5.5e-6	Asthma;
THYM	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg27168131	chr21:44088823	PDE9A	-0.48	-4.87	-0.45	4.37e-6	Mean corpuscular volume;
THYM	cis	rs113835537	0.529	rs116867234	chr11:66209024	C/T	cg24851651	chr11:66362959	CCS	0.74	5.16	0.47	1.33e-6	Airway imaging phenotypes;
THYM	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg11327659	chr7:150037044	RARRES2	0.43	5.04	0.46	2.19e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg16586182	chr3:47516702	SCAP	-0.6	-5.11	-0.46	1.63e-6	Colorectal cancer;
THYM	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg23205692	chr1:25664452	TMEM50A	0.87	6.74	0.57	1.21e-9	Erythrocyte sedimentation rate;
THYM	cis	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg07460842	chr6:66804631	NA	1.1	8.21	0.64	1.08e-12	Exhaled nitric oxide output;
THYM	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg00786635	chr1:25594202	NA	1.0	8.23	0.65	9.66e-13	Erythrocyte sedimentation rate;
THYM	cis	rs12310956	0.532	rs10844712	chr12:33961022	G/A	cg06521331	chr12:34319734	NA	-0.92	-8.57	-0.66	1.89e-13	Morning vs. evening chronotype;
THYM	cis	rs6430585	0.528	rs7606267	chr2:136668123	T/C	cg04750100	chr2:136595281	LCT	0.57	5.28	0.48	8.26e-7	Corneal structure;
THYM	cis	rs1451375	0.527	rs6950777	chr7:50597056	G/A	cg18232548	chr7:50535776	DDC	0.67	5.03	0.46	2.33e-6	Malaria;
THYM	trans	rs75518195	0.590	rs113717221	chr4:64720943	C/A	cg14706739	chr8:21916355	EPB49	0.75	7.2	0.59	1.39e-10	Triptolide cytotoxicity;
THYM	cis	rs9902453	0.765	rs62068653	chr17:28212663	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	5.39	0.48	5.11e-7	Coffee consumption (cups per day);
THYM	cis	rs4803468	0.967	rs11670583	chr19:41920440	A/T	cg09537434	chr19:41945824	ATP5SL	-1.06	-9.81	-0.71	4.27e-16	Height;
THYM	cis	rs11096990	0.964	rs6842390	chr4:39263482	C/G	cg24403649	chr4:39172243	NA	-0.66	-5.36	-0.48	5.78e-7	Cognitive function;
THYM	cis	rs7937890	0.681	rs4756784	chr11:14270904	G/A	cg19336497	chr11:14380999	RRAS2	0.55	5.83	0.51	7.63e-8	Mitochondrial DNA levels;
THYM	cis	rs854765	0.583	rs8078583	chr17:17811465	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.47	0.55	4.29e-9	Total body bone mineral density;
THYM	cis	rs9486719	0.843	rs1009597	chr6:96843540	A/T	cg18709589	chr6:96969512	KIAA0776	0.75	4.49	0.42	2.02e-5	Migraine;Coronary artery disease;
THYM	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg08994789	chr17:28903642	LRRC37B2	1.1	6.31	0.54	8.97e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11621135	0.605	rs10141170	chr14:71664249	T/C	cg18506020	chr14:71758942	NA	-0.48	-4.51	-0.42	1.85e-5	Hair greying;
THYM	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg02187348	chr16:89574699	SPG7	0.81	6.85	0.57	7.43e-10	Multiple myeloma (IgH translocation);
THYM	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.26	0.47	8.97e-7	Lung cancer in ever smokers;
THYM	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2070677	0.935	rs12245634	chr10:135420002	A/G	cg20169779	chr10:135381914	SYCE1	-0.75	-5.76	-0.51	1.03e-7	Gout;
THYM	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg24846680	chr1:228362309	C1orf69	0.59	4.78	0.44	6.29e-6	Diastolic blood pressure;
THYM	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg14008862	chr17:28927542	LRRC37B2	0.94	5.08	0.46	1.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7246657	0.943	rs4803347	chr19:37848017	G/A	cg22634378	chr19:37742834	NA	0.64	5.28	0.48	8.18e-7	Coronary artery calcification;
THYM	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg18681998	chr4:17616180	MED28	0.85	7.68	0.62	1.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs477692	0.563	rs12266634	chr10:131412659	G/C	cg06209143	chr10:131448811	MGMT	-0.64	-5.12	-0.47	1.59e-6	Response to temozolomide;
THYM	cis	rs9880211	0.613	rs9834966	chr3:135808620	T/G	cg21827317	chr3:136751795	NA	-0.71	-5.16	-0.47	1.33e-6	Body mass index;Height;
THYM	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4242434	0.854	rs11782130	chr8:22452357	G/T	cg01710189	chr8:22454888	PDLIM2	-0.56	-5.71	-0.51	1.27e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2046867	0.628	rs7356055	chr3:72912878	A/C	cg25664220	chr3:72788482	NA	-0.76	-6.33	-0.54	8.1e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg23711669	chr6:146136114	FBXO30	0.91	9.57	0.7	1.4e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg06238570	chr21:40685208	BRWD1	0.9	6.33	0.54	7.95e-9	Cognitive function;
THYM	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg01579765	chr21:45077557	HSF2BP	-0.44	-6.58	-0.56	2.52e-9	Mean corpuscular volume;
THYM	cis	rs72827839	1.000	rs72827887	chr17:46537636	A/G	cg23391107	chr17:45924227	SP6	0.77	4.61	0.43	1.24e-5	Ease of getting up in the morning;
THYM	cis	rs804280	0.662	rs7826055	chr8:11611723	G/C	cg23916205	chr8:11614368	GATA4	0.54	4.51	0.42	1.88e-5	Myopia (pathological);
THYM	cis	rs4919694	1.000	rs11191439	chr10:104638723	C/T	cg04362960	chr10:104952993	NT5C2	-1.14	-7.07	-0.59	2.65e-10	Arsenic metabolism;
THYM	cis	rs4430311	0.723	rs4590656	chr1:244002773	C/T	cg25706552	chr1:244017396	NA	-0.61	-5.2	-0.47	1.15e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs7771547	0.519	rs12663882	chr6:36362441	G/T	cg07856975	chr6:36356162	ETV7	-0.66	-5.69	-0.5	1.38e-7	Platelet distribution width;
THYM	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg07021052	chr2:20871279	NA	-0.69	-5.65	-0.5	1.66e-7	Abdominal aortic aneurysm;
THYM	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg16049864	chr8:95962084	TP53INP1	-0.68	-6.05	-0.53	2.91e-8	Type 2 diabetes;
THYM	cis	rs2777491	0.915	rs8036498	chr15:41603276	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.14	-12.89	-0.8	1.38e-22	Ulcerative colitis;
THYM	cis	rs6496667	0.865	rs7161929	chr15:90884009	G/A	cg22089800	chr15:90895588	ZNF774	0.76	4.69	0.43	9.31e-6	Rheumatoid arthritis;
THYM	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg11871910	chr12:69753446	YEATS4	1.01	9.85	0.71	3.52e-16	Cerebrospinal fluid biomarker levels;
THYM	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg24838063	chr12:130822603	PIWIL1	0.91	6.92	0.58	5.35e-10	Menopause (age at onset);
THYM	cis	rs4243830	0.850	rs10779787	chr1:6599755	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.06	-6.24	-0.54	1.21e-8	Body mass index;
THYM	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg04772025	chr11:68637568	NA	0.66	6.9	0.58	5.88e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4930776	0.897	rs371609	chr12:5762400	A/T	cg02086166	chr12:5775618	ANO2	0.61	6.07	0.53	2.57e-8	Plasma clusterin levels;
THYM	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg05347473	chr6:146136440	FBXO30	0.6	4.86	0.45	4.66e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs977987	0.835	rs8057535	chr16:75347941	C/T	cg03315344	chr16:75512273	CHST6	0.83	6.84	0.57	7.77e-10	Dupuytren's disease;
THYM	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg01341218	chr17:43662625	NA	0.85	7.37	0.6	6.34e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg09307838	chr4:120376055	NA	0.78	5.62	0.5	1.92e-7	Corneal astigmatism;
THYM	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg06850241	chr22:41845214	NA	0.54	4.77	0.44	6.68e-6	Vitiligo;
THYM	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs13070279	0.786	rs13094390	chr3:71817778	A/G	cg19388776	chr3:71835112	PROK2	0.86	5.15	0.47	1.38e-6	Monocyte count;
THYM	cis	rs80319144	1.000	rs79928267	chr2:159288179	G/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06634786	chr22:41940651	POLR3H	-0.79	-5.87	-0.52	6.38e-8	Vitiligo;
THYM	cis	rs11025559	0.643	rs11025570	chr11:20481109	T/A	cg19653624	chr11:20408972	PRMT3	-0.76	-4.56	-0.42	1.53e-5	Pursuit maintenance gain;
THYM	cis	rs17253792	0.822	rs76264681	chr14:56060447	T/C	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg17178900	chr1:205818956	PM20D1	1.11	12.18	0.78	4.1e-21	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11696501	0.688	rs6073861	chr20:44325708	G/A	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg22709100	chr7:91322751	NA	-0.61	-4.85	-0.45	4.84e-6	Breast cancer;
THYM	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg20744362	chr22:50050164	C22orf34	0.82	8.14	0.64	1.52e-12	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2674946	0.644	rs8077563	chr17:13042365	C/T	cg12799781	chr17:12569110	MYOCD	-0.5	-4.64	-0.43	1.1e-5	Squamous cell lung carcinoma;
THYM	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg00071950	chr4:10020882	SLC2A9	0.86	10.33	0.73	3.3e-17	Bone mineral density;
THYM	cis	rs17153755	0.761	rs804288	chr8:11618179	T/C	cg23916205	chr8:11614368	GATA4	-0.61	-5.02	-0.46	2.43e-6	Testicular germ cell tumor;
THYM	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg09436375	chr6:42928200	GNMT	-0.41	-5.54	-0.49	2.74e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg22974920	chr21:40686053	BRWD1	0.66	4.54	0.42	1.67e-5	Cognitive function;
THYM	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg08773314	chr2:239334832	ASB1	0.4	4.66	0.43	1.04e-5	Multiple system atrophy;
THYM	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11249608	0.600	rs6859767	chr5:178451107	T/C	cg01312482	chr5:178451176	ZNF879	-0.76	-6.36	-0.55	7.14e-9	Pubertal anthropometrics;
THYM	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg23583168	chr7:148888333	NA	-1.0	-13.2	-0.8	3.29e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs924712	0.844	rs7752349	chr6:54727731	A/T	cg04690482	chr6:54711388	FAM83B	-0.45	-4.97	-0.45	2.97e-6	Breast cancer;
THYM	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg08859206	chr1:53392774	SCP2	-0.62	-7.07	-0.59	2.58e-10	Monocyte count;
THYM	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.55	-0.73	1.12e-17	Primary sclerosing cholangitis;
THYM	cis	rs9814567	1.000	rs6800862	chr3:134228628	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-8.41	-0.65	4e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6665290	0.935	rs6704144	chr1:227201030	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.13	-13.82	-0.82	1.86e-24	Myeloid white cell count;
THYM	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.22	-14.33	-0.83	1.74e-25	Exhaled nitric oxide output;
THYM	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.58	4.97	0.45	2.98e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg23711669	chr6:146136114	FBXO30	0.77	7.34	0.6	7.09e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7572733	0.534	rs700684	chr2:198713099	C/T	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg23711669	chr6:146136114	FBXO30	-0.83	-7.91	-0.63	4.68e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4460079	0.531	rs4473715	chr4:114848391	G/A	cg02060584	chr4:113970739	ANK2	0.59	4.99	0.46	2.71e-6	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg16405210	chr4:1374714	KIAA1530	0.87	7.71	0.62	1.25e-11	Obesity-related traits;
THYM	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	4.73	0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	5.53	0.49	2.81e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg05335186	chr13:53173507	NA	-0.4	-5.03	-0.46	2.36e-6	Lewy body disease;
THYM	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg27534772	chr1:16042836	PLEKHM2	0.56	6.31	0.54	8.77e-9	Systolic blood pressure;
THYM	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg22166914	chr1:53195759	ZYG11B	0.8	8.04	0.64	2.5e-12	Monocyte count;
THYM	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1728785	1.000	rs1728773	chr16:68563644	A/C	cg02972257	chr16:68554789	NA	-0.74	-4.54	-0.42	1.63e-5	Ulcerative colitis;
THYM	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg09904177	chr6:26538194	HMGN4	0.53	4.47	0.42	2.16e-5	Intelligence (multi-trait analysis);
THYM	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.17	-0.47	1.28e-6	Joint mobility (Beighton score);
THYM	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg07010633	chr17:73824396	UNC13D	-0.43	-4.61	-0.43	1.28e-5	White matter hyperintensity burden;
THYM	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg06115741	chr20:33292138	TP53INP2	0.7	4.65	0.43	1.06e-5	Coronary artery disease;
THYM	cis	rs7177699	0.557	rs55870734	chr15:79117917	A/T	cg15571903	chr15:79123663	NA	-0.56	-6.28	-0.54	9.92e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.55	-0.73	1.12e-17	Primary sclerosing cholangitis;
THYM	cis	rs10504073	0.584	rs4873306	chr8:49950369	T/C	cg00325661	chr8:49890786	NA	1.06	10.84	0.74	2.75e-18	Blood metabolite ratios;
THYM	cis	rs7172809	0.573	rs2137977	chr15:77575505	T/C	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs2354432	0.825	rs10900347	chr1:146800107	G/C	cg25205988	chr1:146714368	CHD1L	1.29	8.8	0.67	6.06e-14	Mitochondrial DNA levels;
THYM	cis	rs7078219	0.523	rs4129134	chr10:101284345	C/G	cg23904955	chr10:101282759	NA	-0.36	-4.61	-0.43	1.28e-5	Dental caries;
THYM	cis	rs3916	0.911	rs2239758	chr12:121162637	A/G	cg21892295	chr12:121157589	UNC119B	-0.51	-5.01	-0.46	2.48e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg05425664	chr17:57184151	TRIM37	-0.65	-5.21	-0.47	1.1e-6	Intelligence (multi-trait analysis);
THYM	trans	rs1920324	0.622	rs34436570	chr3:103899653	C/T	cg01901466	chr14:93388880	CHGA	0.65	6.91	0.58	5.4e-10	Colorectal cancer;
THYM	cis	rs35123781	1.000	rs13436896	chr5:139067098	G/A	cg10513866	chr5:139070639	NA	0.47	4.58	0.43	1.41e-5	Schizophrenia;
THYM	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg25767906	chr1:53392781	SCP2	-0.53	-5.2	-0.47	1.13e-6	Monocyte count;
THYM	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg18904891	chr8:8559673	CLDN23	0.64	4.62	0.43	1.2e-5	Obesity-related traits;
THYM	cis	rs7487075	0.754	rs10880962	chr12:46773444	C/G	cg11146691	chr12:47219737	SLC38A4	0.5	5.17	0.47	1.27e-6	Itch intensity from mosquito bite;
THYM	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg26384229	chr12:38710491	ALG10B	-0.83	-8.3	-0.65	6.83e-13	Heart rate;
THYM	cis	rs1270639	0.778	rs1465250	chr7:157439075	C/G	cg13357408	chr7:157437802	PTPRN2	0.46	4.92	0.45	3.65e-6	Colorectal cancer;
THYM	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg12311346	chr5:56204834	C5orf35	-0.81	-5.9	-0.52	5.54e-8	Initial pursuit acceleration;
THYM	cis	rs17407555	0.683	rs4697998	chr4:10274626	G/T	cg00071950	chr4:10020882	SLC2A9	0.5	4.66	0.43	1.04e-5	Schizophrenia (age at onset);
THYM	cis	rs1784581	0.674	rs1789990	chr6:162406957	G/T	cg17173639	chr6:162384350	PARK2	-0.84	-7.31	-0.6	8.33e-11	Itch intensity from mosquito bite;
THYM	cis	rs9611565	0.506	rs2024567	chr22:41699206	G/C	cg03806693	chr22:41940476	POLR3H	-0.84	-7.2	-0.59	1.37e-10	Vitiligo;
THYM	cis	rs35883536	0.967	rs1582091	chr1:101177133	G/T	cg06223162	chr1:101003688	GPR88	0.67	5.12	0.46	1.62e-6	Monocyte count;
THYM	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg09323728	chr8:95962352	TP53INP1	-0.45	-4.67	-0.43	9.99e-6	Type 2 diabetes;
THYM	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs2276314	0.857	rs9960670	chr18:33577712	A/G	cg05985134	chr18:33552581	C18orf21	0.69	4.84	0.44	5.07e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg14074117	chr16:1909714	C16orf73	-0.7	-4.45	-0.42	2.3e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02475777	chr4:1388615	CRIPAK	0.66	4.8	0.44	5.82e-6	Longevity;
THYM	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg26384229	chr12:38710491	ALG10B	1.0	8.01	0.63	2.86e-12	Bladder cancer;
THYM	cis	rs13102973	0.614	rs56199725	chr4:135873448	T/C	cg14419869	chr4:135874104	NA	-0.8	-7.56	-0.61	2.58e-11	Subjective well-being;
THYM	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg13918804	chr1:2043761	PRKCZ	-0.82	-7.43	-0.61	4.76e-11	Height;
THYM	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg15691649	chr6:25882328	NA	0.67	5.14	0.47	1.47e-6	Blood metabolite levels;
THYM	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg10360139	chr7:1886902	MAD1L1	-0.83	-7.35	-0.6	7.02e-11	Bipolar disorder and schizophrenia;
THYM	cis	rs9420	0.961	rs11604325	chr11:57497011	C/A	cg19752551	chr11:57585705	CTNND1	-0.73	-8.02	-0.64	2.79e-12	Schizophrenia;
THYM	cis	rs1267303	0.600	rs57100184	chr1:47004710	A/C	cg16387850	chr1:46982889	NA	-0.45	-5.44	-0.49	4.13e-7	Monobrow;
THYM	cis	rs7560272	0.549	rs2421554	chr2:73806202	A/T	cg19565262	chr2:73869966	NAT8	-0.55	-4.76	-0.44	6.97e-6	Schizophrenia;
THYM	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22509189	chr2:225307070	NA	-0.88	-7.52	-0.61	3.1e-11	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	4.97	0.45	3.01e-6	Height;
THYM	cis	rs10904908	1.000	rs10795465	chr10:17260525	C/T	cg01003015	chr10:17271136	VIM	-0.63	-5.55	-0.49	2.59e-7	Total cholesterol levels;Cholesterol, total;
THYM	cis	rs2282300	1.000	rs12799529	chr11:30408552	T/C	cg06241208	chr11:30344200	C11orf46	-0.71	-4.97	-0.45	3.01e-6	Morning vs. evening chronotype;
THYM	cis	rs2219968	0.683	rs62508199	chr8:78909203	C/T	cg00738934	chr8:78996279	NA	0.65	5.22	0.47	1.04e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-4.88	-0.45	4.35e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2456568	0.802	rs11020586	chr11:93638547	G/A	cg17595323	chr11:93583763	C11orf90	-0.58	-6.09	-0.53	2.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.32	9.94	0.71	2.24e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1335645	0.570	rs56200127	chr1:111628519	G/A	cg00321911	chr1:111669324	DRAM2	-1.38	-7.97	-0.63	3.51e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs35123781	0.502	rs261532	chr5:138949362	A/C	cg08720517	chr5:138729919	LOC389333	-0.58	-4.83	-0.44	5.3e-6	Schizophrenia;
THYM	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg08772003	chr10:104629869	AS3MT	-0.57	-4.93	-0.45	3.53e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	ch.11.42038R	chr11:967971	AP2A2	0.55	4.45	0.42	2.32e-5	Alzheimer's disease (late onset);
THYM	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.98	4.89	0.45	4.07e-6	Initial pursuit acceleration;
THYM	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg21926612	chr6:163149169	PACRG;PARK2	1.32	9.94	0.71	2.24e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg11789530	chr4:8429930	ACOX3	-0.74	-5.76	-0.51	1.04e-7	Response to antineoplastic agents;
THYM	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg06634786	chr22:41940651	POLR3H	-0.72	-5.26	-0.48	8.73e-7	Vitiligo;
THYM	cis	rs6424115	0.594	rs7519640	chr1:24069637	G/C	cg15997130	chr1:24165203	NA	0.67	5.5	0.49	3.16e-7	Immature fraction of reticulocytes;
THYM	cis	rs58873874	0.737	rs77273565	chr5:156916555	A/G	cg08916508	chr5:156566250	MED7	-1.31	-4.98	-0.45	2.84e-6	Bipolar disorder (body mass index interaction);
THYM	cis	rs3540	0.512	rs7176518	chr15:91079637	C/T	cg22089800	chr15:90895588	ZNF774	-0.69	-5.42	-0.49	4.43e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs854765	0.686	rs8065497	chr17:17782649	A/G	cg16928487	chr17:17741425	SREBF1	0.62	5.74	0.51	1.13e-7	Total body bone mineral density;
THYM	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.24	-0.47	9.63e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs1983170	1.000	rs12563578	chr1:91993702	T/C	cg25838465	chr1:92012736	NA	0.66	4.55	0.42	1.56e-5	Eosinophil percentage of white cells;
THYM	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg24692254	chr21:30365293	RNF160	1.06	9.9	0.71	2.71e-16	Dental caries;
THYM	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg08975724	chr8:8085496	FLJ10661	0.76	6.33	0.54	8.16e-9	Mood instability;
THYM	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg26408565	chr15:76604113	ETFA	-0.53	-4.64	-0.43	1.13e-5	Blood metabolite levels;
THYM	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13732083	chr21:47605072	C21orf56	-0.68	-4.82	-0.44	5.46e-6	Testicular germ cell tumor;
THYM	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06481639	chr22:41940642	POLR3H	0.79	5.36	0.48	5.85e-7	Vitiligo;
THYM	cis	rs4836390	0.656	rs10059694	chr5:128039687	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	4.64	0.43	1.09e-5	Coronary artery disease;
THYM	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg23574427	chr4:122746245	BBS7;CCNA2	-0.57	-5.18	-0.47	1.23e-6	Type 2 diabetes;
THYM	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg03188948	chr7:1209495	NA	0.91	7.1	0.59	2.21e-10	Longevity;Endometriosis;
THYM	cis	rs10484885	0.553	rs17707975	chr6:90622318	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.69	-5.44	-0.49	4.05e-7	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs1994135	0.647	rs67243558	chr12:33695383	T/C	cg10856724	chr12:34555212	NA	-0.74	-5.54	-0.49	2.74e-7	Resting heart rate;
THYM	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs4866334	1.000	rs77574409	chr5:18485477	G/T	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs4227	0.565	rs1642772	chr17:7504159	A/G	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	-0.27	-4.86	-0.45	4.63e-6	IgA nephropathy;
THYM	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.37	6.57	0.56	2.69e-9	Obesity-related traits;
THYM	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg24675658	chr1:53192096	ZYG11B	0.57	4.7	0.43	8.7e-6	Monocyte count;
THYM	cis	rs11771526	1.000	rs11771526	chr7:32342618	A/G	cg13207630	chr7:32358064	NA	1.03	6.12	0.53	2.13e-8	Body mass index;
THYM	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	4.97	0.45	3e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg24675658	chr1:53192096	ZYG11B	-0.68	-5.47	-0.49	3.57e-7	Monocyte count;
THYM	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs10504073	0.647	rs4493918	chr8:50015937	C/G	cg00325661	chr8:49890786	NA	0.92	8.49	0.66	2.72e-13	Blood metabolite ratios;
THYM	cis	rs3768617	0.510	rs12095664	chr1:183101686	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg21252483	chr19:49399788	TULP2	-0.96	-7.25	-0.6	1.09e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs12579753	1.000	rs2400979	chr12:82197353	T/C	cg21231944	chr12:82153410	PPFIA2	-0.65	-4.96	-0.45	3.1e-6	Resting heart rate;
THYM	cis	rs669446	0.561	rs531459	chr1:44090675	T/C	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7529073	0.683	rs340882	chr1:214145731	C/G	cg24083324	chr1:214162604	PROX1	0.73	5.6	0.5	2.05e-7	Schizophrenia;
THYM	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg21433313	chr16:3507492	NAT15	0.81	8.84	0.67	4.96e-14	Tuberculosis;
THYM	cis	rs11225247	0.881	rs10895292	chr11:102245718	G/C	cg06323957	chr11:102217781	BIRC2	1.07	4.8	0.44	5.87e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs1050631	0.564	rs12185396	chr18:33738496	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.65	5.11	0.46	1.67e-6	Esophageal squamous cell cancer (length of survival);
THYM	trans	rs1973993	0.934	rs588660	chr1:96886604	G/A	cg10631902	chr5:14652156	NA	0.66	7.54	0.61	2.8e-11	Weight;
THYM	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg15744005	chr10:104629667	AS3MT	-0.76	-7.05	-0.59	2.83e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg05552183	chr6:42928497	GNMT	0.57	4.64	0.43	1.11e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg00684032	chr4:1343700	KIAA1530	0.54	4.71	0.43	8.55e-6	Obesity-related traits;
THYM	cis	rs679087	1.000	rs436124	chr12:29916839	C/T	cg14258853	chr12:29935411	TMTC1	0.67	6.14	0.53	1.9e-8	Schizophrenia;
THYM	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg24578937	chr1:2090814	PRKCZ	0.81	8.47	0.66	3e-13	Height;
THYM	cis	rs12282928	1.000	rs10769336	chr11:48292339	T/C	cg22827986	chr11:48284249	OR4X1	-0.51	-5.43	-0.49	4.28e-7	Migraine - clinic-based;
THYM	cis	rs7172809	0.897	rs869302	chr15:77830430	T/C	cg10437265	chr15:77819839	NA	-0.53	-4.49	-0.42	1.99e-5	Glucose homeostasis traits;
THYM	trans	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg25517755	chr10:38738941	LOC399744	-0.79	-7.77	-0.62	9.18e-12	Corneal astigmatism;
THYM	cis	rs13315871	0.929	rs11717783	chr3:58267642	A/T	cg00563845	chr3:58318305	PXK	0.55	4.88	0.45	4.32e-6	Cholesterol, total;
THYM	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg07636037	chr3:49044803	WDR6	-0.93	-9.92	-0.71	2.44e-16	Parkinson's disease;
THYM	cis	rs9611519	0.964	rs2179744	chr22:41621714	G/A	cg03806693	chr22:41940476	POLR3H	-0.81	-6.15	-0.53	1.81e-8	Neuroticism;
THYM	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg22841779	chr14:105766346	BRF1	-0.47	-5.84	-0.51	7.22e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2455799	0.594	rs11928773	chr3:15925135	A/G	cg16303742	chr3:15540471	COLQ	-0.57	-5.77	-0.51	9.82e-8	Mean platelet volume;
THYM	cis	rs17407555	0.586	rs16895836	chr4:10278349	C/T	cg00071950	chr4:10020882	SLC2A9	0.52	4.9	0.45	3.98e-6	Schizophrenia (age at onset);
THYM	cis	rs2806561	1.000	rs2746553	chr1:23493246	T/C	cg19743168	chr1:23544995	NA	0.62	6.64	0.56	1.93e-9	Height;
THYM	cis	rs1395	1.000	rs4665958	chr2:27443196	A/G	cg23587288	chr2:27483067	SLC30A3	-0.56	-5.03	-0.46	2.35e-6	Blood metabolite levels;
THYM	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.7	5.33	0.48	6.5e-7	Tonsillectomy;
THYM	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.76	0.44	7.03e-6	Obesity-related traits;
THYM	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg13695892	chr22:41940480	POLR3H	0.93	7.11	0.59	2.14e-10	Vitiligo;
THYM	cis	rs7580658	0.963	rs12479003	chr2:128118553	C/T	cg10021288	chr2:128175891	PROC	-0.83	-7.08	-0.59	2.5e-10	Protein C levels;
THYM	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs2688608	0.592	rs7076585	chr10:75503692	T/C	cg19442545	chr10:75533431	FUT11	-0.58	-5.96	-0.52	4.22e-8	Inflammatory bowel disease;
THYM	cis	rs17739167	0.550	rs11631075	chr15:42235173	G/A	cg20935245	chr15:42234343	EHD4	0.42	4.85	0.45	4.74e-6	Monocyte count;
THYM	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg04654363	chr8:8581213	NA	-0.46	-4.48	-0.42	2.07e-5	Obesity-related traits;
THYM	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg20891558	chr2:74357851	NA	1.18	12.27	0.78	2.67e-21	Gestational age at birth (maternal effect);
THYM	trans	rs4940575	0.679	rs12606418	chr18:60833672	G/T	cg08454546	chr15:59731340	FAM81A	1.02	6.91	0.58	5.4e-10	Breast cancer;
THYM	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-6.35	-0.55	7.49e-9	Electrocardiographic conduction measures;
THYM	cis	rs2286885	1.000	rs741025	chr9:129251792	C/T	cg14294646	chr9:129243551	FAM125B	-0.59	-5.57	-0.5	2.37e-7	Intraocular pressure;
THYM	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22857025	chr5:266934	NA	-1.37	-8.88	-0.67	4.08e-14	Breast cancer;
THYM	cis	rs899997	0.862	rs57260218	chr15:78973772	C/T	cg04896959	chr15:78267971	NA	-0.88	-7.02	-0.58	3.27e-10	Coronary artery disease or large artery stroke;
THYM	cis	rs270601	0.817	rs460089	chr5:131629772	C/G	cg04518342	chr5:131593106	PDLIM4	0.45	4.68	0.43	9.69e-6	Acylcarnitine levels;
THYM	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg01304814	chr3:48885189	PRKAR2A	0.88	4.58	0.43	1.39e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg04518342	chr5:131593106	PDLIM4	0.48	5.37	0.48	5.55e-7	Breast cancer;
THYM	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.69e-11	Aortic root size;
THYM	cis	rs10782582	0.593	rs11578480	chr1:76208989	T/G	cg22875332	chr1:76189707	ACADM	-0.52	-4.82	-0.44	5.5e-6	Daytime sleep phenotypes;
THYM	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.58	-4.63	-0.43	1.17e-5	Response to bleomycin (chromatid breaks);
THYM	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	ch.11.42038R	chr11:967971	AP2A2	0.61	4.81	0.44	5.58e-6	Alzheimer's disease (late onset);
THYM	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg00129232	chr17:37814104	STARD3	-0.71	-4.8	-0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg01448562	chr3:133502909	NA	-0.84	-7.02	-0.58	3.24e-10	Iron status biomarkers;
THYM	cis	rs790123	1.000	rs790116	chr3:122380923	G/C	cg17380795	chr3:122379686	NA	0.59	5.42	0.49	4.57e-7	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg03690763	chr11:133734501	NA	-0.61	-4.75	-0.44	7.32e-6	Childhood ear infection;
THYM	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg19761014	chr17:28927070	LRRC37B2	0.8	4.73	0.44	7.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg02887458	chr19:19495540	GATAD2A	0.46	5.1	0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg08498830	chr11:832797	CD151	-0.62	-4.51	-0.42	1.82e-5	Mean platelet volume;
THYM	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg17691542	chr6:26056736	HIST1H1C	0.73	4.69	0.43	9.12e-6	Iron status biomarkers;
THYM	cis	rs2073300	1.000	rs6137980	chr20:23466726	G/T	cg12062639	chr20:23401060	NAPB	1.33	6.01	0.52	3.46e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs240764	0.817	rs240146	chr6:101078718	G/A	cg21058520	chr6:100914733	NA	-0.57	-5.06	-0.46	2.04e-6	Neuroticism;
THYM	cis	rs6500395	1.000	rs9936467	chr16:48677983	T/C	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-5.1	-0.46	1.74e-6	Lymphocyte counts;
THYM	cis	rs7769051	0.522	rs11965927	chr6:133101353	T/C	cg22852734	chr6:133119734	C6orf192	1.53	6.61	0.56	2.25e-9	Type 2 diabetes nephropathy;
THYM	trans	rs8073060	0.586	rs226089	chr17:34016935	C/T	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs863345	0.604	rs1873510	chr1:158461418	G/A	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg19761014	chr17:28927070	LRRC37B2	0.89	4.93	0.45	3.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12410462	0.681	rs58496521	chr1:227582375	T/C	cg23173402	chr1:227635558	NA	0.73	6.11	0.53	2.19e-8	Major depressive disorder;
THYM	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg27034606	chr17:28928453	LRRC37B2	0.79	4.89	0.45	4.06e-6	Body mass index;
THYM	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg12483005	chr1:23474871	LUZP1	0.58	5.84	0.51	7.3900000000000007e-08	Height;
THYM	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.81	-8.07	-0.64	2.12e-12	Chronic sinus infection;
THYM	cis	rs8018967	0.622	rs2041073	chr14:73972535	C/T	cg10076968	chr14:74006090	HEATR4;ACOT1	-0.44	-4.72	-0.44	8.19e-6	Blood metabolite ratios;
THYM	cis	rs2932538	0.883	rs6696991	chr1:113095661	C/T	cg22162597	chr1:113214053	CAPZA1	0.63	5.07	0.46	1.94e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	trans	rs877282	0.945	rs34367686	chr10:791868	G/C	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs679087	1.000	rs302315	chr12:29919054	G/C	cg14258853	chr12:29935411	TMTC1	-0.67	-6.12	-0.53	2.12e-8	Schizophrenia;
THYM	cis	rs28493229	0.500	rs45545932	chr19:41190875	G/A	cg21869046	chr19:41225005	ITPKC	0.5	4.94	0.45	3.4e-6	Kawasaki disease;
THYM	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.42	-0.49	4.56e-7	Longevity;
THYM	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg16989719	chr2:238392110	NA	-0.62	-5.14	-0.47	1.46e-6	Prostate cancer;
THYM	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg23332699	chr15:44069569	ELL3	-0.78	-4.64	-0.43	1.12e-5	Lung cancer in ever smokers;
THYM	trans	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg10856724	chr12:34555212	NA	-1.0	-8.86	-0.67	4.42e-14	Bladder cancer;
THYM	cis	rs4919694	1.000	rs11191439	chr10:104638723	C/T	cg15744005	chr10:104629667	AS3MT	0.84	4.64	0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs28735056	0.620	rs12456484	chr18:77677315	C/G	cg20368463	chr18:77673604	PQLC1	0.65	4.65	0.43	1.08e-5	Schizophrenia;
THYM	cis	rs9296092	0.538	rs56199698	chr6:33534505	G/C	cg13560919	chr6:33536144	NA	-0.93	-9.1	-0.68	1.38e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs977102	0.556	rs885110	chr3:67356536	C/T	cg06096184	chr3:66549732	LRIG1	0.7	5.08	0.46	1.88e-6	Response to amphetamines;
THYM	cis	rs4575098	0.681	rs11589567	chr1:161116022	G/T	cg24329783	chr1:161160887	ADAMTS4	-0.63	-5.73	-0.51	1.2e-7	Monocyte percentage of white cells;
THYM	cis	rs6450176	0.556	rs111423662	chr5:53288661	T/C	ch.5.1024479R	chr5:53302184	ARL15	-1.22	-10.23	-0.72	5.39e-17	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg20891283	chr12:69753455	YEATS4	1.06	10.14	0.72	8.47e-17	Blood protein levels;
THYM	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg22875332	chr1:76189707	ACADM	0.8	7.18	0.59	1.58e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg12310025	chr6:25882481	NA	0.67	5.77	0.51	9.89e-8	Blood metabolite levels;
THYM	cis	rs12681287	0.752	rs12677470	chr8:87260559	G/A	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg15445000	chr17:37608096	MED1	0.42	4.91	0.45	3.85e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs710865	0.627	rs10799710	chr1:19483209	A/G	cg13387374	chr1:19411106	UBR4	0.67	5.84	0.51	7.24e-8	Brain structure;
THYM	cis	rs3110496	0.751	rs3115096	chr17:27907486	A/G	cg05877788	chr17:27899874	TP53I13	-0.45	-5.42	-0.49	4.53e-7	Height;
THYM	cis	rs1883415	0.553	rs807528	chr6:24544482	C/G	cg00346970	chr6:24499591	ALDH5A1	0.36	4.6	0.43	1.3e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7551222	0.752	rs4252694	chr1:204499056	A/G	cg20240347	chr1:204465584	NA	-0.49	-4.46	-0.42	2.24e-5	Schizophrenia;
THYM	cis	rs11225247	0.881	rs58250524	chr11:102258184	G/A	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg17366294	chr4:99064904	C4orf37	0.57	6.66	0.56	1.75e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg01579765	chr21:45077557	HSF2BP	-0.48	-7.51	-0.61	3.21e-11	Mean corpuscular volume;
THYM	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg04398451	chr17:18023971	MYO15A	-0.78	-7.23	-0.6	1.22e-10	Total body bone mineral density;
THYM	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg10360139	chr7:1886902	MAD1L1	0.53	4.54	0.42	1.65e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs6815814	0.904	rs67712706	chr4:38820616	A/G	cg02016764	chr4:38805732	TLR1	-0.49	-4.66	-0.43	1.03e-5	Breast cancer;
THYM	cis	rs7173743	0.756	rs8034804	chr15:79129600	C/T	cg15571903	chr15:79123663	NA	0.55	6.25	0.54	1.14e-8	Coronary artery disease;
THYM	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg03806693	chr22:41940476	POLR3H	1.09	8.4	0.65	4.19e-13	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg13010199	chr12:38710504	ALG10B	0.73	5.82	0.51	7.99e-8	Heart rate;
THYM	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg17757837	chr7:157058334	UBE3C	-0.66	-5.32	-0.48	6.85e-7	Body mass index;
THYM	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg03806693	chr22:41940476	POLR3H	-1.23	-11.25	-0.76	3.67e-19	Vitiligo;
THYM	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg07424592	chr7:64974309	NA	1.06	5.48	0.49	3.47e-7	Diabetic kidney disease;
THYM	cis	rs7638995	0.628	rs4855550	chr3:69185740	C/A	cg26574240	chr3:69171822	LMOD3	-0.72	-5.03	-0.46	2.31e-6	Alzheimer's disease (late onset);
THYM	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.7	6.82	0.57	8.42e-10	Lymphocyte counts;
THYM	cis	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg10856724	chr12:34555212	NA	-0.82	-7.06	-0.59	2.78e-10	Morning vs. evening chronotype;
THYM	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg06623918	chr6:96969491	KIAA0776	-1.09	-10.31	-0.73	3.58e-17	Headache;
THYM	cis	rs9329289	0.547	rs4366414	chr10:2561529	C/G	cg15501526	chr10:2543763	NA	-0.69	-6.32	-0.54	8.5e-9	Age-related hearing impairment;
THYM	cis	rs11574514	1.000	rs8052287	chr16:67865073	C/T	cg04582263	chr16:67973788	LCAT	1.03	4.91	0.45	3.76e-6	Crohn's disease;
THYM	cis	rs2688608	1.000	rs2675680	chr10:75658864	T/C	cg15838173	chr10:75533400	FUT11	-0.42	-4.56	-0.42	1.5e-5	Inflammatory bowel disease;
THYM	cis	rs7115242	0.748	rs1035237	chr11:116727850	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.92	5.2	0.47	1.15e-6	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
THYM	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg06917634	chr15:78832804	PSMA4	-0.86	-7.09	-0.59	2.4e-10	Sudden cardiac arrest;
THYM	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg23428387	chr22:49814324	NA	-0.5	-4.77	-0.44	6.53e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs3126085	0.877	rs1552996	chr1:152171104	C/A	cg26020982	chr1:152196106	HRNR	0.37	5.06	0.46	2.05e-6	Atopic dermatitis;
THYM	cis	rs11166927	1.000	rs12549587	chr8:140804310	G/A	cg16909799	chr8:140841666	TRAPPC9	0.62	5.46	0.49	3.78e-7	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs2204008	0.694	rs11179394	chr12:38210389	A/G	cg26384229	chr12:38710491	ALG10B	-0.74	-5.8	-0.51	8.85e-8	Bladder cancer;
THYM	cis	rs7567389	0.600	rs72845979	chr2:128095754	C/A	cg09760422	chr2:128146352	NA	0.4	4.79	0.44	6.04e-6	Self-rated health;
THYM	cis	rs1003719	0.667	rs28666643	chr21:38455999	T/G	cg01329690	chr21:38580129	DSCR9	0.36	4.77	0.44	6.72e-6	Eye color traits;
THYM	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg11764359	chr7:65958608	NA	-0.75	-6.05	-0.53	2.82e-8	Aortic root size;
THYM	cis	rs3816788	0.792	rs10097055	chr8:21872328	A/G	cg17168535	chr8:21777572	XPO7	0.83	7.22	0.6	1.26e-10	Lung cancer in ever smokers;
THYM	cis	rs6032067	0.929	rs17333381	chr20:43804919	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs61925898	1	rs61925898	chr12:66779537	A/G	cg16791601	chr12:66731901	HELB	-0.69	-5.92	-0.52	5.2e-8	Basophil percentage of granulocytes;Basophil percentage of white cells;
THYM	cis	rs9814567	0.806	rs9857242	chr3:134316378	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.79	7.82	0.63	7.09e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	5.51	0.49	3.1e-7	Schizophrenia;
THYM	cis	rs9913156	0.793	rs55782417	chr17:4562845	G/A	cg19197139	chr17:4613644	ARRB2	0.83	5.0	0.46	2.63e-6	Lymphocyte counts;
THYM	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs791888	0.767	rs2255684	chr10:89419971	C/T	cg17916473	chr10:89419373	PAPSS2	-0.44	-4.76	-0.44	6.88e-6	Magnesium levels;
THYM	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg05973401	chr12:123451056	ABCB9	0.68	4.55	0.42	1.58e-5	Neutrophil percentage of white cells;
THYM	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg07936489	chr17:37558343	FBXL20	-0.67	-4.9	-0.45	3.86e-6	Asthma;
THYM	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg04362960	chr10:104952993	NT5C2	-0.63	-4.47	-0.42	2.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg17063962	chr7:91808500	NA	-1.13	-12.38	-0.79	1.56e-21	Breast cancer;
THYM	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg13114125	chr14:105738426	BRF1	-0.74	-5.72	-0.51	1.22e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs921968	0.591	rs6717107	chr2:219588697	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs36051895	0.632	rs111573904	chr9:5169804	A/T	cg02405213	chr9:5042618	JAK2	-1.01	-9.39	-0.69	3.35e-15	Pediatric autoimmune diseases;
THYM	cis	rs34912216	0.580	rs7779346	chr7:4133298	C/G	cg03141780	chr7:4150753	SDK1	0.69	5.03	0.46	2.31e-6	Motion sickness;
THYM	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg20007245	chr22:24372913	LOC391322	-0.7	-6.4	-0.55	5.86e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg07424592	chr7:64974309	NA	1.04	5.48	0.49	3.42e-7	Diabetic kidney disease;
THYM	cis	rs7523273	0.627	rs2724389	chr1:207933648	T/C	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg06481639	chr22:41940642	POLR3H	0.82	5.9	0.52	5.47e-8	Vitiligo;
THYM	cis	rs2288884	0.767	rs3752119	chr19:52551498	C/T	cg05974498	chr19:52599256	ZNF841	0.36	4.52	0.42	1.78e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg12981288	chr8:11183844	MTMR9	-0.45	-4.45	-0.42	2.35e-5	Retinal vascular caliber;
THYM	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg09323728	chr8:95962352	TP53INP1	-0.48	-4.93	-0.45	3.53e-6	Type 2 diabetes;
THYM	cis	rs887829	0.569	rs4399719	chr2:234666461	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.67	-5.17	-0.47	1.31e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs1003719	1.000	rs2835608	chr21:38493455	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.72	5.19	0.47	1.18e-6	Eye color traits;
THYM	cis	rs2334880	0.602	rs12444212	chr16:71437689	T/C	cg06353428	chr16:71660113	MARVELD3	-0.91	-5.44	-0.49	4.18e-7	Malaria;
THYM	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg13393036	chr8:95962371	TP53INP1	-0.48	-4.68	-0.43	9.68e-6	Type 2 diabetes;
THYM	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg03433033	chr1:76189801	ACADM	0.77	10.09	0.72	1.07e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs3796352	1.000	rs13072457	chr3:53102389	G/A	cg24530246	chr3:53118167	NA	-0.82	-4.67	-0.43	9.89e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7107174	1.000	rs7111986	chr11:78102266	G/T	cg19901956	chr11:77921274	USP35	-0.69	-5.7	-0.5	1.37e-7	Testicular germ cell tumor;
THYM	trans	rs9747201	1.000	rs12451470	chr17:80177532	G/A	cg07393940	chr7:158741817	NA	1.1	8.4	0.65	4.38e-13	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg02734326	chr4:10020555	SLC2A9	-0.72	-6.37	-0.55	6.8e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4986811	1.000	rs5030157	chr11:32450825	C/T	cg13301003	chr11:32449254	WT1	0.64	4.75	0.44	7.25e-6	Rubella-specific interleukin-6 secretion;
THYM	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg11301795	chr4:187892539	NA	-1.12	-16.92	-0.87	2.01e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1003719	0.743	rs2835615	chr21:38497303	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-4.61	-0.43	1.26e-5	Eye color traits;
THYM	cis	rs59112743	0.510	rs2743872	chr6:15622613	G/T	cg10111214	chr6:14815676	NA	0.74	4.84	0.44	5.08e-6	Multiple keratinocyte cancers;
THYM	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg02038168	chr22:39784481	NA	-0.7	-5.8	-0.51	8.49e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs13177918	0.629	rs13161261	chr5:149822407	G/A	cg14059543	chr5:149831962	NA	-0.99	-7.46	-0.61	4.05e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs72627123	0.656	rs765720	chr14:74541326	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.29	7.08	0.59	2.46e-10	Morning vs. evening chronotype;
THYM	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg18681998	chr4:17616180	MED28	-0.8	-6.76	-0.57	1.11e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg18105134	chr13:113819100	PROZ	-0.98	-9.05	-0.68	1.79e-14	Platelet distribution width;
THYM	cis	rs11030122	0.673	rs10835474	chr11:4020819	G/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.69	-0.43	9.03e-6	Mean platelet volume;Platelet distribution width;
THYM	cis	rs800586	0.796	rs2694034	chr8:116740823	A/G	cg04656070	chr8:116661063	TRPS1	0.49	5.27	0.48	8.56e-7	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg03806693	chr22:41940476	POLR3H	0.98	8.0	0.63	3.08e-12	Vitiligo;
THYM	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03264133	chr6:25882463	NA	-0.73	-5.82	-0.51	7.95e-8	Blood metabolite levels;
THYM	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg13114125	chr14:105738426	BRF1	-0.77	-6.12	-0.53	2.12e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg24692254	chr21:30365293	RNF160	-0.98	-8.79	-0.67	6.33e-14	Dental caries;
THYM	cis	rs11886999	0.680	rs6576968	chr2:96904127	G/A	cg18419276	chr2:96971862	SNRNP200	-0.55	-5.2	-0.47	1.14e-6	Cardiac Troponin-T levels;
THYM	cis	rs8031584	1.000	rs11638409	chr15:31288190	A/C	cg08109568	chr15:31115862	NA	-0.63	-6.06	-0.53	2.72e-8	Huntington's disease progression;
THYM	cis	rs7000551	0.689	rs6996872	chr8:22316753	T/C	cg12081754	chr8:22256438	SLC39A14	0.62	5.3	0.48	7.6e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs1559088	0.600	rs7246566	chr19:33589618	A/T	cg03563238	chr19:33554763	RHPN2	-0.54	-4.67	-0.43	9.87e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1061377	1.000	rs7676008	chr4:39121774	G/C	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg25358565	chr5:93447407	FAM172A	1.36	11.23	0.76	4.04e-19	Diabetic retinopathy;
THYM	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	7.98	0.63	3.34e-12	Platelet count;
THYM	cis	rs863345	0.604	rs6699473	chr1:158495209	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs4792901	0.879	rs939357	chr17:41650012	A/G	cg21940313	chr17:41620911	ETV4	-0.47	-4.85	-0.45	4.88e-6	Dupuytren's disease;
THYM	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg18904891	chr8:8559673	CLDN23	0.6	4.74	0.44	7.59e-6	Neuroticism;
THYM	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg16797656	chr11:68205561	LRP5	-0.43	-4.54	-0.42	1.62e-5	Total body bone mineral density;
THYM	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.72	-0.44	7.98e-6	Fear of minor pain;
THYM	cis	rs9326248	0.569	rs10047459	chr11:116721826	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.75	4.85	0.45	4.88e-6	Blood protein levels;
THYM	cis	rs7193541	0.965	rs8050262	chr16:74661159	T/C	cg01733217	chr16:74700730	RFWD3	0.8	7.8	0.62	7.96e-12	Multiple myeloma;
THYM	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg26038318	chr20:34205095	SPAG4	-0.63	-5.13	-0.47	1.54e-6	Total cholesterol levels;
THYM	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.44	-0.49	4.16e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2599510	0.703	rs762023	chr2:32713170	G/A	cg02381751	chr2:32503542	YIPF4	0.58	4.48	0.42	2.08e-5	Interleukin-18 levels;
THYM	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg22875332	chr1:76189707	ACADM	0.88	11.22	0.75	4.31e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg18252515	chr7:66147081	NA	-1.61	-8.73	-0.67	8.74e-14	Diabetic kidney disease;
THYM	cis	rs453193	0.800	rs186975	chr2:8442736	C/G	cg12167548	chr2:8464763	NA	-0.45	-4.71	-0.44	8.43e-6	Granulocyte percentage of myeloid white cells;
THYM	cis	rs1823778	0.609	rs7244421	chr18:67685007	C/T	cg13164537	chr18:67624071	CD226	1.11	4.94	0.45	3.28e-6	Mean platelet volume;
THYM	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg00898013	chr13:113819073	PROZ	-0.89	-9.29	-0.69	5.34e-15	Platelet distribution width;
THYM	cis	rs40363	0.645	rs40447	chr16:3514841	G/A	cg00484396	chr16:3507460	NAT15	0.79	10.79	0.74	3.5e-18	Tuberculosis;
THYM	cis	rs11249608	0.548	rs13156530	chr5:178475017	C/T	cg01312482	chr5:178451176	ZNF879	-0.75	-5.91	-0.52	5.39e-8	Pubertal anthropometrics;
THYM	cis	rs76878669	0.561	rs6591215	chr11:66170611	A/C	cg18002602	chr11:66138449	SLC29A2	-0.44	-4.58	-0.43	1.42e-5	Educational attainment (years of education);
THYM	cis	rs7586879	0.616	rs10203386	chr2:25136866	T/A	cg15423357	chr2:25149977	NA	0.68	7.34	0.6	7.31e-11	Body mass index;
THYM	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg03647317	chr4:187891568	NA	-0.83	-9.53	-0.7	1.64e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6429082	0.715	rs9793740	chr1:235595590	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.62	-4.72	-0.44	8.18e-6	Adiposity;
THYM	cis	rs11039798	0.841	rs11039783	chr11:48526828	G/C	cg24672777	chr11:48374446	OR4C45	-1.14	-6.89	-0.58	6.15e-10	Axial length;
THYM	cis	rs6032067	0.714	rs4359712	chr20:43884861	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.57	-5.57	-0.5	2.35e-7	Blood protein levels;
THYM	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs921968	0.613	rs2912737	chr2:219545789	A/G	cg02176678	chr2:219576539	TTLL4	-0.55	-5.46	-0.49	3.79e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2404602	0.735	rs11632222	chr15:76712927	C/G	cg23625390	chr15:77176239	SCAPER	-0.68	-4.75	-0.44	7.34e-6	Blood metabolite levels;
THYM	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg26924012	chr15:45694286	SPATA5L1	0.66	4.86	0.45	4.65e-6	Response to fenofibrate (adiponectin levels);
THYM	cis	rs8077889	0.917	rs4793037	chr17:41914826	C/T	cg26893861	chr17:41843967	DUSP3	1.06	9.9	0.71	2.76e-16	Triglycerides;
THYM	cis	rs7131987	0.903	rs10843367	chr12:29408380	G/A	cg09582351	chr12:29534625	ERGIC2	-0.48	-4.59	-0.43	1.35e-5	QT interval;
THYM	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg00383909	chr3:49044727	WDR6	1.07	6.29	0.54	9.72e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs12188164	1.000	rs12188164	chr5:428236	C/A	cg14137381	chr5:502291	SLC9A3	-0.62	-4.57	-0.42	1.45e-5	Cystic fibrosis severity;
THYM	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg24308560	chr3:49941425	MST1R	0.8	6.84	0.57	7.6e-10	Intelligence (multi-trait analysis);
THYM	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg26446133	chr18:72167187	CNDP2	-0.93	-7.89	-0.63	5.19e-12	Refractive error;
THYM	cis	rs7705042	0.828	rs6580224	chr5:141489306	A/G	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs7746082	0.594	rs11152957	chr6:106503692	T/G	cg02270332	chr6:106475062	NA	-0.65	-5.95	-0.52	4.38e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4664308	0.875	rs60908067	chr2:161004983	T/G	cg03641300	chr2:160917029	PLA2R1	-0.75	-6.87	-0.58	6.63e-10	Idiopathic membranous nephropathy;
THYM	cis	rs4499344	0.521	rs1862214	chr19:33035849	C/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.7	4.59	0.43	1.34e-5	Mean platelet volume;
THYM	cis	rs11112613	0.713	rs73184084	chr12:105952615	T/A	cg03607813	chr12:105948248	NA	0.99	8.2	0.64	1.17e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg17775962	chr7:1200435	ZFAND2A	-0.41	-5.09	-0.46	1.82e-6	Longevity;Endometriosis;
THYM	cis	rs7084402	0.935	rs4948524	chr10:60351224	C/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.72	-0.51	1.25e-7	Refractive error;
THYM	cis	rs9486719	0.948	rs11152952	chr6:96894303	A/G	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg11366901	chr6:160182831	ACAT2	1.01	8.44	0.65	3.57e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs951366	0.531	rs12030754	chr1:205678043	G/C	cg17178900	chr1:205818956	PM20D1	-0.63	-4.63	-0.43	1.14e-5	Menarche (age at onset);
THYM	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.95	0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.22	0.64	1.03e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs8016982	0.610	rs2371570	chr14:81709686	C/T	cg21807262	chr14:81713016	NA	-0.58	-5.3	-0.48	7.62e-7	Schizophrenia;
THYM	cis	rs3540	0.618	rs11636089	chr15:91039527	C/T	cg00487526	chr15:90818384	NA	-0.58	-4.47	-0.42	2.19e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs4732038	0.669	rs6955887	chr7:134263676	A/G	cg06906464	chr7:134288099	NA	-0.44	-4.5	-0.42	1.89e-5	Longevity;
THYM	cis	rs36051895	0.589	rs12682672	chr9:5187941	T/C	cg02405213	chr9:5042618	JAK2	-0.93	-9.84	-0.71	3.58e-16	Pediatric autoimmune diseases;
THYM	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg07570687	chr10:102243282	WNT8B	0.79	7.41	0.61	5.19e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg06238570	chr21:40685208	BRWD1	0.92	6.87	0.58	6.76e-10	Cognitive function;
THYM	cis	rs4938534	0.559	rs1944919	chr11:111259876	A/C	cg19148410	chr11:111250352	POU2AF1	0.5	4.64	0.43	1.11e-5	Primary biliary cholangitis;
THYM	cis	rs10892173	0.678	rs7122817	chr11:117657679	A/G	cg21640587	chr11:117668038	DSCAML1	0.54	4.46	0.42	2.23e-5	Myopia;
THYM	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg06636001	chr8:8085503	FLJ10661	-0.74	-7.34	-0.6	7.35e-11	Triglycerides;
THYM	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	4.93	0.45	3.5e-6	Diabetic retinopathy;
THYM	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.25	-5.11	-0.46	1.64e-6	Obesity-related traits;
THYM	cis	rs35883536	0.611	rs72977390	chr1:101107147	C/T	cg09408571	chr1:101003634	GPR88	0.4	4.9	0.45	3.88e-6	Monocyte count;
THYM	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.27	5.24	0.47	9.8e-7	Obesity-related traits;
THYM	cis	rs348196	0.562	rs34228076	chr1:155589792	G/T	cg02153340	chr1:155202674	NA	-0.66	-4.81	-0.44	5.73e-6	Breast cancer;
THYM	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg00129232	chr17:37814104	STARD3	0.69	4.45	0.42	2.32e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs7078219	0.714	rs11190137	chr10:101287944	G/T	cg07044859	chr10:101282883	NA	0.47	4.99	0.46	2.72e-6	Dental caries;
THYM	cis	rs7267979	1.000	rs6037099	chr20:25356876	T/G	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg08000102	chr2:233561755	GIGYF2	-0.69	-6.26	-0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg08270630	chr22:50330655	NA	-0.83	-4.75	-0.44	7.33e-6	Schizophrenia;
THYM	cis	rs9560113	0.881	rs9560111	chr13:112181289	C/T	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs12643440	0.538	rs6843399	chr4:17140263	A/G	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7481584	0.624	rs451060	chr11:3056389	G/A	cg03159660	chr11:2078197	NA	0.62	4.6	0.43	1.3e-5	Calcium levels;
THYM	cis	rs9354654	0.696	rs9294781	chr6:68647156	A/G	cg03938432	chr6:69345836	BAI3	-0.57	-4.53	-0.42	1.7e-5	Classic bladder exstrophy;
THYM	cis	rs2806561	0.765	rs652706	chr1:23514246	G/A	cg12483005	chr1:23474871	LUZP1	0.59	6.28	0.54	1.01e-8	Height;
THYM	cis	rs2067615	0.507	rs10746063	chr12:107086240	G/T	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg18252515	chr7:66147081	NA	-1.45	-8.82	-0.67	5.41e-14	Diabetic kidney disease;
THYM	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs1569175	0.510	rs55852473	chr2:200709099	T/C	cg23649088	chr2:200775458	C2orf69	-0.88	-4.65	-0.43	1.06e-5	Response to treatment for acute lymphoblastic leukemia;
THYM	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg23711669	chr6:146136114	FBXO30	0.91	9.21	0.69	8.1e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg09359103	chr1:154839909	KCNN3	-0.69	-8.43	-0.65	3.66e-13	Prostate cancer;
THYM	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	0.72	4.5	0.42	1.93e-5	IgG glycosylation;
THYM	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg15704280	chr7:45808275	SEPT13	-1.07	-15.24	-0.84	2.93e-27	Height;
THYM	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg24209194	chr3:40518798	ZNF619	0.66	5.51	0.49	3.1e-7	Renal cell carcinoma;
THYM	cis	rs3784262	0.528	rs8027964	chr15:58335272	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.65	-5.04	-0.46	2.24e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
THYM	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.59	-4.6	-0.43	1.28e-5	Longevity;Endometriosis;
THYM	cis	rs977987	0.581	rs8056141	chr16:75497162	A/T	cg03315344	chr16:75512273	CHST6	0.65	5.09	0.46	1.79e-6	Dupuytren's disease;
THYM	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg13010199	chr12:38710504	ALG10B	0.72	5.61	0.5	1.98e-7	Heart rate;
THYM	cis	rs4866334	1.000	rs74368495	chr5:18483062	T/C	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg08901578	chr4:187885870	NA	-0.63	-5.72	-0.51	1.21e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg06074448	chr4:187884817	NA	-1.02	-13.05	-0.8	6.55e-23	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs13065560	0.594	rs4575820	chr3:38886179	A/G	cg15678707	chr3:39149194	GORASP1;TTC21A	-0.58	-4.62	-0.43	1.18e-5	Interleukin-18 levels;
THYM	cis	rs9314614	1.000	rs2978894	chr8:6693629	G/C	cg16580759	chr8:6693379	XKR5	-0.44	-4.48	-0.42	2.11e-5	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs6840360	0.642	rs7680236	chr4:152409601	A/G	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	4.97	0.45	2.9e-6	Bipolar disorder;
THYM	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg10505658	chr17:80084571	CCDC57	0.7	7.31	0.6	8.39e-11	Life satisfaction;
THYM	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg23682913	chr1:2080710	PRKCZ	-0.59	-5.24	-0.47	9.66e-7	Height;
THYM	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03517284	chr6:25882590	NA	0.84	6.72	0.57	1.37e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1198430	0.636	rs2811963	chr1:23824242	A/C	cg19827787	chr1:23763612	ASAP3	0.68	4.7	0.43	8.65e-6	Total cholesterol levels;
THYM	cis	rs775227	0.574	rs13086266	chr3:113083535	T/A	cg18753928	chr3:113234510	CCDC52	-0.76	-5.11	-0.46	1.64e-6	Dental caries;
THYM	cis	rs2244613	0.882	rs7204940	chr16:55794983	C/G	cg27396498	chr16:55794478	CES4	0.76	5.28	0.48	8.15e-7	Response to dabigatran etexilate treatment;
THYM	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg13246856	chr1:44399776	ARTN	0.51	5.22	0.47	1.06e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs2075230	0.850	rs9908405	chr17:7467461	A/C	cg10509001	chr17:7553872	ATP1B2	0.58	4.62	0.43	1.21e-5	Hormone measurements;
THYM	cis	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.88	-0.45	4.33e-6	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs6032067	0.641	rs74174932	chr20:43756133	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.72	-7.65	-0.62	1.63e-11	Blood protein levels;
THYM	cis	rs9992101	0.547	rs7654754	chr4:77409795	C/T	cg20311846	chr4:77356250	SHROOM3	-0.44	-4.67	-0.43	9.98e-6	Creatinine levels;
THYM	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03576123	chr11:487126	PTDSS2	-1.29	-6.4	-0.55	5.87e-9	Body mass index;
THYM	cis	rs8112211	0.834	rs3178327	chr19:38798086	T/C	cg25820703	chr19:38877220	GGN	-0.5	-4.6	-0.43	1.33e-5	Blood protein levels;
THYM	cis	rs12216545	0.765	rs2373807	chr7:150249370	G/T	cg08960815	chr7:150264767	GIMAP4	-0.87	-7.56	-0.61	2.54e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs6430585	0.528	rs309151	chr2:136661150	C/T	cg07169764	chr2:136633963	MCM6	1.05	9.09	0.68	1.49e-14	Corneal structure;
THYM	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.72	-0.44	7.98e-6	Fear of minor pain;
THYM	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg20607798	chr8:58055168	NA	0.83	4.46	0.42	2.29e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs931127	0.640	rs2448490	chr11:65412035	G/A	cg27068330	chr11:65405492	SIPA1	0.72	5.44	0.49	4.05e-7	Systemic lupus erythematosus;
THYM	cis	rs7731657	0.537	rs9327578	chr5:130181064	C/T	cg08523029	chr5:130500466	HINT1	-0.75	-5.19	-0.47	1.21e-6	Fasting plasma glucose;
THYM	cis	rs7246657	0.823	rs4802236	chr19:37919246	A/G	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg18681998	chr4:17616180	MED28	0.92	7.79	0.62	8.34e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7267979	1.000	rs2257496	chr20:25279315	A/G	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg03159660	chr11:2078197	NA	0.63	4.76	0.44	7e-6	Calcium levels;
THYM	cis	rs1559088	0.545	rs7257431	chr19:33566924	A/G	cg03563238	chr19:33554763	RHPN2	-0.53	-4.64	-0.43	1.12e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs490234	0.616	rs2648318	chr9:128163447	T/C	cg14078157	chr9:128172775	NA	-0.8	-6.55	-0.56	2.87e-9	Mean arterial pressure;
THYM	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg23815491	chr16:72088622	HP	1.0	9.86	0.71	3.35e-16	Fibrinogen levels;
THYM	cis	rs6842789	0.510	rs11098725	chr4:124919843	C/T	cg01723706	chr4:124814442	LOC285419	0.71	4.7	0.43	8.8e-6	Neuroticism;
THYM	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg23791538	chr6:167370224	RNASET2	-0.62	-4.65	-0.43	1.09e-5	Crohn's disease;
THYM	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg24531977	chr5:56204891	C5orf35	0.68	5.57	0.5	2.32e-7	Initial pursuit acceleration;
THYM	trans	rs8073060	0.586	rs225264	chr17:33961335	A/G	cg19694781	chr19:47549865	TMEM160	-0.95	-7.8	-0.62	7.8e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7100689	0.784	rs7089058	chr10:82071263	T/C	cg01528321	chr10:82214614	TSPAN14	1.02	7.78	0.62	8.75e-12	Post bronchodilator FEV1;
THYM	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.6	-0.5	2.08e-7	Type 2 diabetes;
THYM	cis	rs877282	1.000	rs11253369	chr10:773610	C/G	cg10556349	chr10:835070	NA	-0.69	-4.88	-0.45	4.29e-6	Uric acid levels;
THYM	cis	rs295140	0.546	rs295134	chr2:201110223	A/G	cg23649088	chr2:200775458	C2orf69	-0.62	-5.22	-0.47	1.07e-6	QT interval;
THYM	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg20887711	chr4:1340912	KIAA1530	-0.56	-4.68	-0.43	9.41e-6	Obesity-related traits;
THYM	cis	rs17376456	0.569	rs13186432	chr5:93336940	G/A	cg25358565	chr5:93447407	FAM172A	-0.89	-6.54	-0.56	3.06e-9	Diabetic retinopathy;
THYM	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg20283391	chr11:68216788	NA	-0.69	-5.14	-0.47	1.49e-6	Total body bone mineral density;
THYM	cis	rs17453880	0.929	rs4473762	chr5:152065361	T/C	cg12297329	chr5:152029980	NA	-0.61	-4.61	-0.43	1.27e-5	Subjective well-being;
THYM	cis	rs2070677	0.935	rs4335491	chr10:135422460	T/G	cg20169779	chr10:135381914	SYCE1	-0.77	-5.98	-0.52	3.93e-8	Gout;
THYM	cis	rs7171869	1	rs7171869	chr15:78900909	A/G	cg18825076	chr15:78729989	IREB2	-0.58	-4.74	-0.44	7.43e-6	Post bronchodilator FEV1;
THYM	cis	rs2034650	0.563	rs12914710	chr15:40713849	C/T	cg12699599	chr15:40643142	PHGR1	-0.59	-5.56	-0.5	2.45e-7	Interstitial lung disease;
THYM	cis	rs994014	0.655	rs59498284	chr4:82272047	C/A	cg17825130	chr4:82283507	NA	0.51	4.64	0.43	1.11e-5	Height;
THYM	cis	rs4242434	0.854	rs3735893	chr8:22452704	A/G	cg21658235	chr8:22456391	C8orf58	0.52	5.01	0.46	2.5e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg25072359	chr17:41440525	NA	0.68	4.71	0.44	8.33e-6	Menopause (age at onset);
THYM	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg06611532	chr13:114900021	NA	0.61	6.67	0.56	1.7e-9	Schizophrenia;
THYM	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg01483505	chr11:975446	AP2A2	0.58	4.73	0.44	7.73e-6	Alzheimer's disease (late onset);
THYM	cis	rs1728785	0.901	rs1170420	chr16:68635877	G/C	cg02972257	chr16:68554789	NA	-0.71	-4.59	-0.43	1.37e-5	Ulcerative colitis;
THYM	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg00256281	chr22:41985642	PMM1	-0.58	-4.62	-0.43	1.19e-5	Vitiligo;
THYM	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-6.19	-0.54	1.55e-8	Joint mobility (Beighton score);
THYM	cis	rs8180040	0.768	rs11915074	chr3:47309757	A/T	cg12976108	chr3:47324180	KIF9;KLHL18	0.5	4.5	0.42	1.92e-5	Colorectal cancer;
THYM	cis	rs988913	1.000	rs1503142	chr6:54818948	C/T	cg18532076	chr6:54711417	FAM83B	0.49	4.85	0.45	4.72e-6	Menarche (age at onset);
THYM	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg19761014	chr17:28927070	LRRC37B2	0.73	4.46	0.42	2.21e-5	Body mass index;
THYM	cis	rs1784581	0.928	rs1789995	chr6:162396518	C/T	cg17173639	chr6:162384350	PARK2	-0.92	-8.38	-0.65	4.83e-13	Itch intensity from mosquito bite;
THYM	cis	rs6918586	0.658	rs198813	chr6:26128226	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.65	-0.62	1.6e-11	Schizophrenia;
THYM	cis	rs910187	0.678	rs6122562	chr20:45813847	A/G	cg27589058	chr20:45804311	EYA2	-0.62	-5.44	-0.49	4.1e-7	Migraine;
THYM	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2273669	0.667	rs12200531	chr6:109320441	T/C	cg17117243	chr6:109341365	SESN1	-0.91	-5.45	-0.49	4.01e-7	Prostate cancer;
THYM	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg13609457	chr4:120235615	NA	0.59	5.22	0.47	1.04e-6	Corneal astigmatism;
THYM	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	4.63	0.43	1.18e-5	Aortic root size;
THYM	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg17366294	chr4:99064904	C4orf37	0.49	5.43	0.49	4.32e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3096299	0.933	rs2965939	chr16:89493043	G/A	cg02187348	chr16:89574699	SPG7	0.78	6.16	0.53	1.72e-8	Multiple myeloma (IgH translocation);
THYM	cis	rs16866061	0.962	rs16866045	chr2:225413020	G/A	cg22455342	chr2:225449267	CUL3	0.67	4.84	0.44	4.98e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg17509989	chr5:176798049	RGS14	0.67	6.54	0.56	3.15e-9	Urinary electrolytes (magnesium/calcium ratio);
THYM	cis	rs7084921	0.552	rs7098331	chr10:101877961	T/G	cg11344164	chr10:101878520	NA	-0.58	-5.68	-0.5	1.47e-7	Bone mineral density;
THYM	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.76	0.57	1.09e-9	Total body bone mineral density;
THYM	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.43	-0.49	4.24e-7	Mean corpuscular volume;
THYM	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg23332699	chr15:44069569	ELL3	0.73	4.71	0.43	8.55e-6	Lung cancer in ever smokers;
THYM	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg25703541	chr22:24373054	LOC391322	-0.88	-11.09	-0.75	7.92e-19	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg18230493	chr5:56204884	C5orf35	-0.64	-5.0	-0.46	2.57e-6	Type 2 diabetes;
THYM	cis	rs2456568	0.548	rs6483281	chr11:93661840	G/C	cg26875233	chr11:93583750	C11orf90	-0.53	-5.86	-0.52	6.52e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg25358565	chr5:93447407	FAM172A	1.34	10.59	0.74	9.3e-18	Diabetic retinopathy;
THYM	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg18252515	chr7:66147081	NA	1.6	8.71	0.67	9.29e-14	Diabetic kidney disease;
THYM	cis	rs2235649	0.833	rs9939766	chr16:1852808	C/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06634786	chr22:41940651	POLR3H	0.82	6.05	0.53	2.85e-8	Vitiligo;
THYM	cis	rs2282300	0.739	rs35883696	chr11:30246407	A/C	cg25418670	chr11:30344373	C11orf46	-0.81	-6.87	-0.58	6.66e-10	Morning vs. evening chronotype;
THYM	cis	rs13102973	0.965	rs13142779	chr4:135872841	G/T	cg14419869	chr4:135874104	NA	0.88	8.62	0.66	1.45e-13	Subjective well-being;
THYM	cis	rs2456568	0.802	rs7115629	chr11:93635477	G/A	cg26875233	chr11:93583750	C11orf90	-0.53	-5.53	-0.49	2.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs6754311	0.597	rs2082729	chr2:136550109	C/T	cg20242066	chr2:136595261	LCT	-0.57	-7.02	-0.58	3.26e-10	Mosquito bite size;
THYM	cis	rs8180040	0.676	rs1108301	chr3:47029426	G/A	cg02527881	chr3:46936655	PTH1R	0.65	6.52	0.56	3.34e-9	Colorectal cancer;
THYM	cis	rs6842047	0.901	rs2102575	chr4:187131504	G/A	cg09526685	chr4:187126073	CYP4V2	1.26	6.11	0.53	2.13e-8	Blood protein levels;
THYM	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg26149184	chr10:133730230	NA	0.77	4.66	0.43	1.04e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg04034577	chr2:241836375	C2orf54	-0.49	-8.8	-0.67	6.02e-14	Urinary metabolites;
THYM	cis	rs7072216	0.763	rs7091709	chr10:100167605	G/A	cg03852570	chr10:100175106	PYROXD2	0.37	5.02	0.46	2.41e-6	Metabolite levels;
THYM	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	5.24	0.47	9.75e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	18.96	0.89	4.77e-34	Chronic sinus infection;
THYM	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg11965913	chr1:205819406	PM20D1	0.91	9.5	0.7	1.89e-15	Menarche (age at onset);
THYM	cis	rs526231	0.511	rs26255	chr5:102554100	T/A	cg23492399	chr5:102201601	PAM	-0.71	-5.21	-0.47	1.09e-6	Primary biliary cholangitis;
THYM	cis	rs6430585	0.528	rs7573555	chr2:136694905	C/T	cg04750100	chr2:136595281	LCT	-0.53	-5.07	-0.46	1.95e-6	Corneal structure;
THYM	cis	rs2292884	0.505	rs11889660	chr2:238438395	C/T	cg08992911	chr2:238395768	MLPH	1.05	6.53	0.56	3.16e-9	Prostate cancer;
THYM	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg22841779	chr14:105766346	BRF1	-0.47	-5.83	-0.51	7.76e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	5.92	0.52	5.15e-8	Total body bone mineral density;
THYM	cis	rs41005	1.000	rs34505904	chr2:8115159	T/C	cg03155496	chr2:8117019	LOC339788	-0.98	-9.1	-0.68	1.42e-14	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs3803170	0.513	rs10849943	chr12:111819589	A/G	cg10833066	chr12:111807467	FAM109A	-0.44	-4.71	-0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs12142240	0.698	rs7548675	chr1:46809321	C/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	trans	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg00898013	chr13:113819073	PROZ	-0.82	-8.1	-0.64	1.81e-12	Platelet distribution width;
THYM	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.7	-5.63	-0.5	1.83e-7	Prostate cancer;
THYM	cis	rs6430585	0.528	rs309162	chr2:136690783	T/A	cg23851026	chr2:136556271	LCT	0.77	7.76	0.62	9.54e-12	Corneal structure;
THYM	cis	rs447921	0.861	rs117544870	chr17:74415206	T/G	cg17201438	chr17:74438067	UBE2O	0.81	5.85	0.51	6.9e-8	Mitochondrial DNA levels;
THYM	cis	rs7084402	1.000	rs7074778	chr10:60272248	C/T	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs6988636	1.000	rs28624331	chr8:124190768	G/A	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg08772003	chr10:104629869	AS3MT	-0.61	-5.37	-0.48	5.62e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1971762	0.966	rs11170631	chr12:54041192	T/C	cg16917193	chr12:54089295	NA	0.58	4.85	0.45	4.74e-6	Height;
THYM	cis	rs7830933	0.911	rs7001541	chr8:23596394	A/T	cg04349084	chr8:23602677	NA	0.6	6.37	0.55	6.85e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg20295408	chr7:1910781	MAD1L1	-0.67	-5.06	-0.46	2.05e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7119	0.717	rs12910512	chr15:77817253	C/A	cg10437265	chr15:77819839	NA	0.79	8.2	0.64	1.12e-12	Type 2 diabetes;
THYM	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg24450063	chr1:156163899	SLC25A44	1.13	14.2	0.82	3.24e-25	Testicular germ cell tumor;
THYM	cis	rs7772486	0.754	rs6937661	chr6:146113299	T/C	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.43e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg06558623	chr16:89946397	TCF25	1.39	6.78	0.57	1.03e-9	Skin colour saturation;
THYM	cis	rs300703	0.515	rs300694	chr2:182277	G/T	cg21211680	chr2:198530	NA	-0.86	-5.61	-0.5	1.95e-7	Blood protein levels;
THYM	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg12165864	chr7:66369176	NA	-0.68	-5.34	-0.48	6.27e-7	Aortic root size;
THYM	cis	rs7894051	1.000	rs11101724	chr10:135192153	G/A	cg12428399	chr10:135191333	PAOX	1.05	4.54	0.42	1.67e-5	Lifespan;
THYM	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.69	-0.62	1.33e-11	Personality dimensions;
THYM	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg22189786	chr22:42395067	WBP2NL	0.58	5.19	0.47	1.2e-6	Birth weight;
THYM	cis	rs8068544	0.818	rs8079958	chr17:40155467	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.47	-7.45	-0.61	4.22e-11	Reticulocyte fraction of red cells;Reticulocyte count;
THYM	cis	rs6500395	0.963	rs6500404	chr16:48690083	C/T	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9443189	0.615	rs618239	chr6:76350038	A/G	cg01950844	chr6:76311363	SENP6	1.05	6.74	0.57	1.21e-9	Prostate cancer;
THYM	cis	rs2290159	0.800	rs59821954	chr3:12687613	T/C	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs56104184	0.779	rs4802513	chr19:49357656	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.97	-5.11	-0.46	1.67e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2658782	0.724	rs2658769	chr11:93252030	T/C	cg15737290	chr11:93063684	CCDC67	1.02	7.68	0.62	1.39e-11	Pulmonary function decline;
THYM	cis	rs8114671	0.967	rs1415774	chr20:33765616	C/T	cg08999081	chr20:33150536	PIGU	-0.53	-4.77	-0.44	6.63e-6	Height;
THYM	cis	rs3791406	1.000	rs3791412	chr2:240031088	A/G	cg27074582	chr2:240114406	HDAC4	-0.44	-4.48	-0.42	2.05e-5	Skin aging (microtopography measurement);
THYM	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg22709100	chr7:91322751	NA	0.65	5.25	0.47	9.11e-7	Breast cancer;
THYM	cis	rs6450176	0.680	rs255756	chr5:53309364	A/G	ch.5.1024479R	chr5:53302184	ARL15	-1.21	-10.54	-0.73	1.18e-17	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs9902453	0.765	rs2250320	chr17:28128657	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg12011299	chr4:100065546	ADH4	0.85	8.12	0.64	1.67e-12	Alcohol dependence;
THYM	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg06558623	chr16:89946397	TCF25	1.5	8.19	0.64	1.22e-12	Skin colour saturation;
THYM	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs338389	0.586	rs338400	chr15:68254156	C/T	cg07562100	chr15:68569975	FEM1B	0.71	5.26	0.47	8.9e-7	Survival in rectal cancer;
THYM	cis	rs13102973	0.867	rs12501608	chr4:135896365	T/C	cg14419869	chr4:135874104	NA	0.9	7.67	0.62	1.5e-11	Subjective well-being;
THYM	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.92	-6.03	-0.53	3.11e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg08439880	chr3:133502540	NA	0.59	4.59	0.43	1.38e-5	Iron status biomarkers;
THYM	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14240646	chr10:27532245	ACBD5	-0.78	-4.67	-0.43	1e-5	Breast cancer;
THYM	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg20503657	chr10:835505	NA	1.14	7.96	0.63	3.64e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs1878931	0.582	rs10048083	chr16:3417465	A/C	cg22508957	chr16:3507546	NAT15	-0.45	-4.9	-0.45	3.99e-6	Body mass index (adult);
THYM	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg22535103	chr8:58192502	C8orf71	-0.94	-5.62	-0.5	1.86e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs2637266	1.000	rs2579761	chr10:78321040	C/T	cg18941641	chr10:78392320	NA	0.8	6.87	0.58	6.58e-10	Pulmonary function;
THYM	cis	rs526231	0.575	rs62362524	chr5:102314227	G/T	cg23492399	chr5:102201601	PAM	-0.61	-4.63	-0.43	1.14e-5	Primary biliary cholangitis;
THYM	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg05872129	chr22:39784769	NA	-1.02	-10.78	-0.74	3.61e-18	Intelligence (multi-trait analysis);
THYM	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg00376283	chr12:123451042	ABCB9	0.71	4.75	0.44	7.22e-6	Neutrophil percentage of white cells;
THYM	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg10518543	chr12:38710700	ALG10B	-0.58	-4.83	-0.44	5.2e-6	Morning vs. evening chronotype;
THYM	cis	rs7119	0.667	rs907390	chr15:77902419	T/C	cg27398640	chr15:77910606	LINGO1	0.68	8.82	0.67	5.38e-14	Type 2 diabetes;
THYM	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg11663144	chr21:46675770	NA	-0.69	-9.27	-0.69	6.12e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs11186	0.556	rs58289599	chr2:189964389	C/T	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	cis	rs6964587	0.626	rs10243083	chr7:91552530	G/A	cg22709100	chr7:91322751	NA	-0.62	-4.64	-0.43	1.1e-5	Breast cancer;
THYM	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4589258	0.504	rs4753291	chr11:90388052	G/T	cg26138821	chr11:89956704	CHORDC1	0.62	4.45	0.42	2.36e-5	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg21926612	chr6:163149169	PACRG;PARK2	1.32	9.94	0.71	2.24e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg21775007	chr8:11205619	TDH	0.63	5.07	0.46	1.95e-6	Retinal vascular caliber;
THYM	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg26441486	chr22:50317300	CRELD2	0.42	6.58	0.56	2.53e-9	Schizophrenia;
THYM	cis	rs73195822	0.536	rs73191849	chr12:111017205	C/T	cg24010859	chr12:110868153	NA	0.67	4.76	0.44	6.79e-6	Itch intensity from mosquito bite;
THYM	cis	rs1808579	0.904	rs1652348	chr18:21147509	C/T	cg14672496	chr18:21087552	C18orf8	0.53	4.86	0.45	4.63e-6	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
THYM	cis	rs308403	0.532	rs309386	chr4:123665991	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.98	8.84	0.67	4.9e-14	Blood protein levels;
THYM	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg10589385	chr1:150898437	SETDB1	0.64	5.48	0.49	3.48e-7	Tonsillectomy;
THYM	cis	rs2011503	1.000	rs16996127	chr19:19627310	T/G	cg02887458	chr19:19495540	GATAD2A	-0.44	-4.91	-0.45	3.81e-6	Bipolar disorder;
THYM	cis	rs28595532	0.920	rs115334469	chr4:119596194	G/C	cg14228332	chr4:119757509	SEC24D	1.35	4.52	0.42	1.81e-5	Cannabis dependence symptom count;
THYM	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg26597838	chr10:835615	NA	0.84	4.73	0.44	7.71e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs7172809	0.897	rs78412727	chr15:77827185	A/G	cg10437265	chr15:77819839	NA	-0.53	-4.57	-0.42	1.48e-5	Glucose homeostasis traits;
THYM	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg06108461	chr20:60628389	TAF4	-0.8	-6.66	-0.56	1.77e-9	Body mass index;
THYM	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg00383909	chr3:49044727	WDR6	1.27	7.71	0.62	1.22e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs72901758	0.700	rs72909025	chr17:76249015	A/G	cg25512537	chr17:76250053	NA	0.38	5.38	0.48	5.31e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
THYM	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.98	-12.13	-0.78	5.13e-21	Chronic sinus infection;
THYM	cis	rs6490294	0.659	rs601663	chr12:112123284	A/G	cg10833066	chr12:111807467	FAM109A	0.51	5.55	0.49	2.55e-7	Mean platelet volume;
THYM	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg15691649	chr6:25882328	NA	-0.64	-4.65	-0.43	1.08e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4803468	1.000	rs55986560	chr19:41939835	C/T	cg09537434	chr19:41945824	ATP5SL	1.1	10.47	0.73	1.63e-17	Height;
THYM	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-6.7	-0.57	1.43e-9	Total body bone mineral density;
THYM	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	10.22	0.72	5.61e-17	Chronic sinus infection;
THYM	cis	rs6992848	0.791	rs35391756	chr8:141167677	C/T	cg22504031	chr8:141147661	TRAPPC9	0.64	4.95	0.45	3.19e-6	Response to amphetamines;
THYM	cis	rs7695732	0.572	rs12512799	chr4:89905340	A/T	cg17769793	chr4:89976368	FAM13A	-0.49	-5.4	-0.48	4.81e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7631605	1.000	rs7631605	chr3:37234589	C/T	cg21328643	chr3:37258149	NA	-0.47	-4.52	-0.42	1.79e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg18252515	chr7:66147081	NA	-0.65	-4.97	-0.45	3.01e-6	Aortic root size;
THYM	cis	rs854765	0.647	rs854818	chr17:18022039	A/C	cg04398451	chr17:18023971	MYO15A	-0.99	-10.24	-0.72	5.05e-17	Total body bone mineral density;
THYM	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg05802129	chr4:122689817	NA	-0.59	-4.63	-0.43	1.15e-5	Type 2 diabetes;
THYM	cis	rs4866334	1.000	rs76790673	chr5:18502463	G/C	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.84e-7	IgG glycosylation;
THYM	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22590775	chr19:49891494	CCDC155	0.61	4.71	0.43	8.55e-6	Multiple sclerosis;
THYM	cis	rs2133450	0.712	rs1396404	chr3:7365390	T/C	cg19930620	chr3:7340148	GRM7	-0.48	-4.57	-0.42	1.44e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	13.59	0.81	5.3e-24	Chronic sinus infection;
THYM	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg10518543	chr12:38710700	ALG10B	-0.58	-4.77	-0.44	6.77e-6	Morning vs. evening chronotype;
THYM	cis	rs1395	0.778	rs2580759	chr2:27432500	G/T	cg23587288	chr2:27483067	SLC30A3	0.57	5.28	0.48	8.33e-7	Blood metabolite levels;
THYM	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg14784868	chr12:69753453	YEATS4	0.89	7.76	0.62	9.66e-12	Cerebrospinal fluid biomarker levels;
THYM	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg17509989	chr5:176798049	RGS14	0.69	6.1	0.53	2.3e-8	Urate levels in lean individuals;
THYM	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11948739	0.539	rs1119863	chr5:130282399	T/G	cg08523029	chr5:130500466	HINT1	0.76	5.12	0.46	1.6e-6	Pediatric bone mineral content (hip);
THYM	cis	rs149313	0.560	rs151835	chr5:96070982	A/G	cg11214001	chr5:96078430	CAST	-0.75	-5.7	-0.5	1.35e-7	Blood protein levels;
THYM	cis	rs72627123	1.000	rs72627120	chr14:74363480	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-5.79	-0.51	9.2e-8	Chronic sinus infection;
THYM	cis	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg06521331	chr12:34319734	NA	-0.96	-8.88	-0.67	4.06e-14	Morning vs. evening chronotype;
THYM	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg11301795	chr4:187892539	NA	-1.12	-16.65	-0.86	6.34e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13064411	0.501	rs13092925	chr3:113209375	C/G	cg18753928	chr3:113234510	CCDC52	-0.84	-7.97	-0.63	3.49e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs600806	0.850	rs1880670	chr1:109941133	C/T	cg02175308	chr1:109941060	SORT1	-0.6	-5.3	-0.48	7.58e-7	Intelligence (multi-trait analysis);
THYM	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg02038168	chr22:39784481	NA	-0.67	-5.43	-0.49	4.32e-7	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.59	5.54	0.49	2.72e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg18876405	chr7:65276391	NA	-0.63	-5.44	-0.49	4.13e-7	Aortic root size;
THYM	cis	rs9902453	0.817	rs2617881	chr17:28063275	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.75	-5.71	-0.51	1.29e-7	Coffee consumption (cups per day);
THYM	cis	rs6430585	0.528	rs309122	chr2:136761853	A/G	cg07169764	chr2:136633963	MCM6	1.04	11.64	0.77	5.41e-20	Corneal structure;
THYM	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	5.75	0.51	1.08e-7	Blood metabolite levels;
THYM	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9972944	0.729	rs7224482	chr17:63777949	C/A	cg07283582	chr17:63770753	CCDC46	0.68	5.54	0.49	2.69e-7	Total body bone mineral density;
THYM	cis	rs6424115	0.830	rs2501431	chr1:24201643	G/A	cg15997130	chr1:24165203	NA	0.76	6.39	0.55	6.14e-9	Immature fraction of reticulocytes;
THYM	trans	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6541297	0.699	rs12065546	chr1:230295245	C/T	cg20703242	chr1:230279135	GALNT2	0.88	4.48	0.42	2.11e-5	Coronary artery disease;
THYM	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg03609598	chr5:56110824	MAP3K1	0.82	5.57	0.5	2.35e-7	Initial pursuit acceleration;
THYM	cis	rs113835537	0.529	rs10896125	chr11:66288733	G/C	cg24851651	chr11:66362959	CCS	0.71	4.99	0.46	2.78e-6	Airway imaging phenotypes;
THYM	cis	rs6499255	0.951	rs2361838	chr16:69676086	T/C	cg00738113	chr16:70207722	CLEC18C	-0.44	-4.57	-0.42	1.45e-5	IgE levels;
THYM	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg06850241	chr22:41845214	NA	-0.49	-4.73	-0.44	7.72e-6	Vitiligo;
THYM	cis	rs3826795	0.569	rs73059723	chr19:46796502	A/C	cg15229275	chr19:46800054	HIF3A	0.92	5.54	0.49	2.69e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg25703541	chr22:24373054	LOC391322	-0.85	-9.36	-0.69	3.79e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs17005891	0.730	rs7684732	chr4:83575832	A/C	cg10249074	chr4:83542146	C4orf11	-0.66	-5.44	-0.49	4.19e-7	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs10892173	0.703	rs1014034	chr11:117661734	G/C	cg21640587	chr11:117668038	DSCAML1	0.55	4.59	0.43	1.38e-5	Myopia;
THYM	cis	rs35883536	0.647	rs17411209	chr1:101046734	A/G	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs28595532	0.764	rs115986119	chr4:119767785	C/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs17152411	0.895	rs11245419	chr10:126586392	A/T	cg07906193	chr10:126599966	NA	0.68	4.65	0.43	1.08e-5	Height;
THYM	cis	rs240764	0.697	rs9485411	chr6:101261352	A/C	cg21058520	chr6:100914733	NA	-0.61	-4.97	-0.45	2.96e-6	Neuroticism;
THYM	cis	rs10089	1.000	rs10478796	chr5:127436187	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.2e-16	Bone mineral density;
THYM	cis	rs11771526	0.901	rs2191000	chr7:32275098	C/A	cg27532318	chr7:32358331	NA	0.75	4.92	0.45	3.7e-6	Body mass index;
THYM	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg06636001	chr8:8085503	FLJ10661	0.62	5.37	0.48	5.66e-7	Mood instability;
THYM	cis	rs7705042	0.828	rs6877864	chr5:141503839	A/G	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs7104764	0.957	rs3829998	chr11:230751	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.1	9.77	0.71	5.16e-16	Menarche (age at onset);
THYM	cis	rs6430585	0.591	rs12466487	chr2:136407078	C/T	cg23851026	chr2:136556271	LCT	-0.65	-5.48	-0.49	3.48e-7	Corneal structure;
THYM	cis	rs2932538	0.922	rs6658555	chr1:113098534	C/T	cg22162597	chr1:113214053	CAPZA1	0.64	4.83	0.44	5.12e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	7.18	0.59	1.57e-10	Electrocardiographic conduction measures;
THYM	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg22431228	chr1:16359049	CLCNKA	-0.43	-4.66	-0.43	1.03e-5	Systolic blood pressure;
THYM	cis	rs7106204	0.748	rs6484032	chr11:24237153	C/A	ch.11.24196551F	chr11:24239977	NA	1.0	7.01	0.58	3.4e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg25767906	chr1:53392781	SCP2	-0.58	-5.87	-0.52	6.47e-8	Monocyte count;
THYM	cis	rs3780378	0.712	rs2038588	chr9:5196262	C/T	cg02405213	chr9:5042618	JAK2	-0.58	-5.09	-0.46	1.77e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	trans	rs7952251	0.756	rs7101495	chr11:112396795	C/G	cg14154186	chr1:204970430	NFASC	-0.7	-7.23	-0.6	1.24e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg26398791	chr1:38455867	SF3A3	-0.63	-5.18	-0.47	1.26e-6	Coronary artery disease;
THYM	cis	rs911263	0.961	rs7148882	chr14:68740924	A/G	cg18825221	chr14:68749962	RAD51L1	-0.61	-6.86	-0.58	6.96e-10	Primary biliary cholangitis;
THYM	cis	rs12935418	0.616	rs2602453	chr16:81027963	C/T	cg16651780	chr16:81037892	C16orf61	-0.8	-6.24	-0.54	1.2e-8	Mean corpuscular volume;
THYM	cis	rs3126085	0.935	rs6676012	chr1:152213203	G/A	cg10321714	chr1:152280068	FLG	0.69	5.08	0.46	1.85e-6	Atopic dermatitis;
THYM	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg05340658	chr4:99064831	C4orf37	-0.57	-4.76	-0.44	6.88e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-6.68	-0.57	1.63e-9	Alzheimer's disease (late onset);
THYM	cis	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg02454025	chr1:11042201	C1orf127	0.91	10.49	0.73	1.51e-17	Ewing sarcoma;
THYM	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs8133932	0.701	rs6518258	chr21:47281829	C/T	cg20357416	chr21:47294739	PCBP3	-0.89	-5.87	-0.52	6.3e-8	Schizophrenia;
THYM	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	7.13	0.59	1.91e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs921968	0.565	rs7599945	chr2:219641528	G/T	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg08017756	chr2:100939284	LONRF2	-0.71	-7.37	-0.6	6.18e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7769051	0.614	rs17061930	chr6:133223799	T/C	cg22852734	chr6:133119734	C6orf192	0.94	4.46	0.42	2.29e-5	Type 2 diabetes nephropathy;
THYM	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg06697600	chr4:7070879	GRPEL1	-0.54	-4.53	-0.42	1.7e-5	Monocyte percentage of white cells;
THYM	cis	rs7246967	0.673	rs34126042	chr19:22909218	G/A	cg05241461	chr19:22816980	ZNF492	0.61	4.7	0.43	8.92e-6	Bronchopulmonary dysplasia;
THYM	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg18681998	chr4:17616180	MED28	1.0	10.49	0.73	1.52e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs12291225	0.546	rs12291662	chr11:14342949	T/C	cg19336497	chr11:14380999	RRAS2	-0.91	-13.71	-0.82	3.02e-24	Sense of smell;
THYM	cis	rs9790314	0.659	rs13066683	chr3:160847410	A/G	cg04691961	chr3:161091175	C3orf57	-0.66	-5.23	-0.47	9.96e-7	Morning vs. evening chronotype;
THYM	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg25918947	chr17:41365094	TMEM106A	-0.59	-4.92	-0.45	3.66e-6	Menopause (age at onset);
THYM	cis	rs17511627	0.808	rs7985823	chr13:26746467	C/T	cg13319468	chr13:27597730	NA	-0.71	-5.59	-0.5	2.2e-7	Alzheimer's disease;
THYM	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg10760299	chr15:45669010	GATM	-0.86	-6.78	-0.57	1.01e-9	Homoarginine levels;
THYM	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	4.75	0.44	7.27e-6	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg18681998	chr4:17616180	MED28	-0.87	-7.97	-0.63	3.51e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.64	-0.5	1.73e-7	Menopause (age at onset);
THYM	cis	rs1160297	0.576	rs1376570	chr2:53087099	G/A	cg07782112	chr2:53107842	NA	0.77	6.18	0.54	1.56e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg12667521	chr19:29218732	NA	0.76	5.79	0.51	8.94e-8	Methadone dose in opioid dependence;
THYM	cis	rs8016982	0.633	rs55643303	chr14:81708872	A/G	cg01989461	chr14:81687754	GTF2A1	0.84	7.36	0.6	6.67e-11	Schizophrenia;
THYM	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	5.56	0.5	2.42e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4731207	0.535	rs11769711	chr7:124574924	A/T	cg05285228	chr7:124571219	POT1	-0.69	-5.25	-0.47	9.35e-7	Cutaneous malignant melanoma;
THYM	cis	rs2046867	0.908	rs1106310	chr3:72818902	A/T	cg25664220	chr3:72788482	NA	0.78	6.59	0.56	2.49e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs4595586	0.525	rs2892450	chr12:39363678	G/A	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg26924012	chr15:45694286	SPATA5L1	1.03	9.3	0.69	5.23e-15	Homoarginine levels;
THYM	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg12000587	chr17:30186630	C17orf79	-0.48	-6.97	-0.58	4.14e-10	Hip circumference adjusted for BMI;
THYM	cis	rs6032067	0.714	rs2071651	chr20:43853153	T/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.47	-0.49	3.71e-7	Blood protein levels;
THYM	cis	rs67981189	0.821	rs56021283	chr14:71462759	T/G	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.89	0.52	5.81e-8	Obesity-related traits;
THYM	cis	rs11048434	0.761	rs2110191	chr12:9136263	G/A	cg14913610	chr12:9142341	KLRG1	-0.29	-4.45	-0.42	2.33e-5	Sjögren's syndrome;
THYM	cis	rs988913	0.957	rs9475068	chr6:54791581	A/G	cg19716238	chr6:54711378	FAM83B	0.52	5.18	0.47	1.26e-6	Menarche (age at onset);
THYM	cis	rs6918586	0.615	rs198841	chr6:26111671	G/T	cg03264133	chr6:25882463	NA	0.64	4.94	0.45	3.41e-6	Schizophrenia;
THYM	cis	rs208520	0.661	rs150263	chr6:66777620	T/C	cg07460842	chr6:66804631	NA	-1.09	-7.92	-0.63	4.41e-12	Exhaled nitric oxide output;
THYM	cis	rs6754311	0.509	rs3820794	chr2:136505546	C/T	cg07169764	chr2:136633963	MCM6	-0.71	-6.02	-0.53	3.2e-8	Mosquito bite size;
THYM	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.48	-0.55	4.1e-9	Personality dimensions;
THYM	cis	rs3772130	0.962	rs9839617	chr3:121516577	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.56	4.61	0.43	1.24e-5	Lung disease severity in cystic fibrosis;
THYM	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg24818145	chr4:99064322	C4orf37	0.73	5.94	0.52	4.63e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3126085	0.935	rs4845740	chr1:152183310	G/A	cg10321714	chr1:152280068	FLG	0.64	4.6	0.43	1.29e-5	Atopic dermatitis;
THYM	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.9	7.81	0.63	7.43e-12	Multiple sclerosis;
THYM	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.38	0.48	5.3e-7	Tonsillectomy;
THYM	cis	rs4076764	0.846	rs10753616	chr1:163415855	G/T	cg24596788	chr1:163392923	NA	0.75	6.47	0.55	4.26e-9	Motion sickness;
THYM	trans	rs208520	0.690	rs207112	chr6:66792092	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.66	-0.62	1.53e-11	Exhaled nitric oxide output;
THYM	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg01119278	chr6:110721349	DDO	-0.64	-7.54	-0.61	2.78e-11	Platelet distribution width;
THYM	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg20887711	chr4:1340912	KIAA1530	0.96	8.77	0.67	7.02e-14	Longevity;
THYM	cis	rs295140	1.000	rs7580924	chr2:201172628	G/C	cg04283868	chr2:201171347	SPATS2L	0.74	5.53	0.49	2.81e-7	QT interval;
THYM	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg07936489	chr17:37558343	FBXL20	-0.81	-5.38	-0.48	5.26e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.59	-4.49	-0.42	1.98e-5	Breast cancer;
THYM	cis	rs7572733	0.534	rs700670	chr2:198687284	T/C	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs11089937	0.616	rs11705598	chr22:22533227	C/T	cg06866756	chr22:22471216	NA	-0.41	-4.52	-0.42	1.75e-5	Periodontitis (PAL4Q3);
THYM	cis	rs2625529	0.824	rs12917428	chr15:72221998	T/C	cg16672083	chr15:72433130	SENP8	-0.56	-5.03	-0.46	2.35e-6	Red blood cell count;
THYM	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg06060754	chr5:176797920	RGS14	0.44	6.47	0.55	4.2e-9	Urinary electrolytes (magnesium/calcium ratio);
THYM	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg09307838	chr4:120376055	NA	0.72	5.48	0.49	3.51e-7	Corneal astigmatism;
THYM	cis	rs9807989	0.801	rs10173193	chr2:102975050	G/A	cg03938978	chr2:103052716	IL18RAP	0.63	6.55	0.56	2.99e-9	Asthma;
THYM	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg03351412	chr1:154909251	PMVK	0.7	5.38	0.48	5.4e-7	Prostate cancer;
THYM	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg02782426	chr3:40428986	ENTPD3	0.57	5.05	0.46	2.09e-6	Renal cell carcinoma;
THYM	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg23161317	chr6:28129485	ZNF389	0.77	5.57	0.5	2.38e-7	Parkinson's disease;
THYM	cis	rs7786808	0.579	rs12669482	chr7:158188813	G/A	cg01191920	chr7:158217561	PTPRN2	-0.93	-9.5	-0.7	1.93e-15	Obesity-related traits;
THYM	cis	rs818427	0.737	rs2545165	chr5:112153119	C/T	cg04614008	chr5:112630677	MCC	-0.65	-4.69	-0.43	9.24e-6	Total body bone mineral density;
THYM	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg13147721	chr7:65941812	NA	0.73	4.58	0.43	1.42e-5	Diabetic kidney disease;
THYM	cis	rs12310956	0.515	rs1852221	chr12:33945489	G/T	cg06521331	chr12:34319734	NA	-0.92	-8.53	-0.66	2.24e-13	Morning vs. evening chronotype;
THYM	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg12379764	chr21:47803548	PCNT	-0.78	-4.92	-0.45	3.61e-6	Testicular germ cell tumor;
THYM	cis	rs12579753	0.869	rs12366921	chr12:82223024	G/A	cg21231944	chr12:82153410	PPFIA2	-0.66	-4.98	-0.46	2.81e-6	Resting heart rate;
THYM	cis	rs931812	0.895	rs4734493	chr8:101902169	C/T	cg07585502	chr8:101912084	NA	0.6	4.69	0.43	9.31e-6	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs9563576	0.778	rs895282	chr13:58659349	A/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.6	4.5	0.42	1.9e-5	Body mass index;
THYM	cis	rs7927771	0.524	rs10838740	chr11:47679980	A/G	cg18512352	chr11:47633146	NA	0.41	4.51	0.42	1.87e-5	Subjective well-being;
THYM	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg07570687	chr10:102243282	WNT8B	0.75	6.59	0.56	2.4e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg22709100	chr7:91322751	NA	0.62	4.78	0.44	6.51e-6	Breast cancer;
THYM	cis	rs4986172	0.700	rs71373536	chr17:43221808	G/A	cg24180402	chr17:43221464	ACBD4	0.63	4.96	0.45	3.06e-6	Height;
THYM	cis	rs61990749	0.597	rs2267768	chr14:78216014	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.02	0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg03213289	chr20:61660250	NA	0.91	9.43	0.7	2.75e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12765878	1.000	rs61277100	chr10:105643352	A/G	cg11005552	chr10:105648138	OBFC1	0.85	11.02	0.75	1.12e-18	Coronary artery disease;
THYM	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg11812906	chr14:75593930	NEK9	-0.87	-7.95	-0.63	3.92e-12	Height;
THYM	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6121246	0.609	rs6087783	chr20:30421224	T/G	cg13852791	chr20:30311386	BCL2L1	0.89	8.16	0.64	1.35e-12	Mean corpuscular hemoglobin;
THYM	cis	rs728616	0.764	rs56122289	chr10:81746027	G/A	cg18148530	chr10:81370782	SFTPA1	0.74	4.81	0.44	5.69e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg19747945	chr6:42946146	PEX6	-0.34	-4.94	-0.45	3.36e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs67460515	0.563	rs16831886	chr3:160799830	A/C	cg03342759	chr3:160939853	NMD3	-0.65	-4.73	-0.44	7.8e-6	Parkinson's disease;
THYM	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.82	5.13	0.47	1.5e-6	Smoking behavior;
THYM	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg03806693	chr22:41940476	POLR3H	-1.22	-10.16	-0.72	7.41e-17	Vitiligo;
THYM	cis	rs6121246	0.609	rs6060843	chr20:30297047	G/C	cg13852791	chr20:30311386	BCL2L1	0.89	8.22	0.64	1.01e-12	Mean corpuscular hemoglobin;
THYM	cis	rs988913	0.957	rs9382405	chr6:54836613	T/C	cg19716238	chr6:54711378	FAM83B	0.49	4.83	0.44	5.26e-6	Menarche (age at onset);
THYM	cis	rs7106204	0.686	rs16912345	chr11:24283119	A/G	ch.11.24196551F	chr11:24239977	NA	0.95	5.82	0.51	7.9e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs13126513	0.528	rs1442482	chr4:100399736	C/T	cg05468953	chr4:100565104	NA	-0.64	-5.22	-0.47	1.04e-6	Metabolite levels (MHPG);
THYM	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg03929089	chr4:120376271	NA	-1.01	-8.47	-0.66	3.05e-13	Height;
THYM	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg09307838	chr4:120376055	NA	0.6	4.54	0.42	1.63e-5	Corneal astigmatism;
THYM	cis	rs4072705	0.557	rs1886124	chr9:127233207	A/G	cg01786973	chr9:127249749	NR5A1	0.41	5.25	0.47	9.35e-7	Menarche (age at onset);
THYM	cis	rs76878669	0.561	rs7115577	chr11:66172258	G/T	cg18002602	chr11:66138449	SLC29A2	-0.46	-4.66	-0.43	1.02e-5	Educational attainment (years of education);
THYM	cis	rs11577318	0.579	rs35456934	chr1:26686864	G/A	cg19677267	chr1:26645161	CD52;UBXN11	0.53	5.95	0.52	4.51e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs1061377	1.000	rs1036038	chr4:39113003	T/G	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs7523273	0.606	rs2796268	chr1:207925192	G/A	cg22525895	chr1:207977042	MIR29B2	0.94	9.98	0.72	1.81e-16	Schizophrenia;
THYM	cis	rs7072216	0.763	rs10748730	chr10:100171440	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg05340658	chr4:99064831	C4orf37	0.54	4.58	0.43	1.41e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg09307838	chr4:120376055	NA	0.73	4.99	0.46	2.76e-6	Corneal astigmatism;
THYM	cis	rs11574514	1.000	rs28668419	chr16:68010195	C/G	cg04582263	chr16:67973788	LCAT	1.12	5.04	0.46	2.26e-6	Crohn's disease;
THYM	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	trans	rs4866334	1.000	rs80007833	chr5:18489203	G/T	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg12288994	chr5:1860383	NA	0.86	7.08	0.59	2.44e-10	Cardiovascular disease risk factors;
THYM	cis	rs10929159	0.928	rs9636243	chr2:236925259	C/T	cg20128773	chr2:236923534	AGAP1	0.35	4.63	0.43	1.16e-5	Parkinson's disease;
THYM	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg16624210	chr5:671434	TPPP	0.76	5.61	0.5	2.03e-7	Obesity-related traits;
THYM	cis	rs13326165	0.585	rs55676974	chr3:52328024	G/A	cg08438690	chr3:52279403	PPM1M	-0.79	-4.68	-0.43	9.54e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs13082711	0.519	rs13091109	chr3:27229125	G/A	cg02860705	chr3:27208620	NA	0.93	7.38	0.6	5.89e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.63	0.62	1.78e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg02527881	chr3:46936655	PTH1R	-0.68	-7.07	-0.59	2.57e-10	Colorectal cancer;
THYM	cis	rs2195525	0.572	rs7927959	chr11:119218616	A/T	cg16996281	chr11:119217884	MFRP;C1QTNF5	-0.44	-4.91	-0.45	3.7e-6	Urate levels;
THYM	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs208520	0.754	rs851592	chr6:66875175	G/T	cg07460842	chr6:66804631	NA	-0.91	-6.41	-0.55	5.65e-9	Exhaled nitric oxide output;
THYM	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg25588787	chr5:154027256	NA	0.9	4.6	0.43	1.32e-5	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05901451	chr6:126070800	HEY2	-0.98	-10.02	-0.72	1.48e-16	Brugada syndrome;
THYM	cis	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg07460842	chr6:66804631	NA	0.8	5.12	0.47	1.57e-6	Exhaled nitric oxide output;
THYM	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg11366901	chr6:160182831	ACAT2	1.05	9.17	0.69	9.94e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg00129232	chr17:37814104	STARD3	-0.88	-7.23	-0.6	1.24e-10	Asthma;
THYM	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22857025	chr5:266934	NA	-1.43	-9.3	-0.69	5.28e-15	Breast cancer;
THYM	cis	rs6435161	0.959	rs10189685	chr2:203488449	G/A	cg18429434	chr2:203499731	FAM117B	-0.69	-4.51	-0.42	1.82e-5	Total cholesterol levels;
THYM	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-5.95	-0.52	4.48e-8	Chronic sinus infection;
THYM	cis	rs728616	0.867	rs61860043	chr10:81946398	G/A	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs990171	0.607	rs871659	chr2:102771855	C/T	cg13315345	chr2:102803985	IL1RL2	0.54	4.63	0.43	1.15e-5	Lymphocyte counts;
THYM	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.3	-0.48	7.34e-7	Monocyte percentage of white cells;
THYM	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg04731861	chr2:219085781	ARPC2	-0.57	-5.36	-0.48	5.72e-7	Colorectal cancer;
THYM	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11890956	chr21:40555474	PSMG1	1.16	12.76	0.79	2.54e-22	Cognitive function;
THYM	cis	rs7084402	0.902	rs1649044	chr10:60327298	A/C	cg09696939	chr10:60272079	BICC1	-0.48	-5.81	-0.51	8.27e-8	Refractive error;
THYM	cis	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg07460842	chr6:66804631	NA	-1.06	-7.93	-0.63	4.23e-12	Exhaled nitric oxide output;
THYM	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg25838465	chr1:92012736	NA	-0.9	-8.55	-0.66	2.09e-13	Breast cancer;
THYM	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg16928487	chr17:17741425	SREBF1	-0.56	-5.63	-0.5	1.78e-7	Total body bone mineral density;
THYM	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.88	7.81	0.63	7.51e-12	Monocyte percentage of white cells;
THYM	cis	rs2841277	0.720	rs11160827	chr14:105422228	C/T	cg19901468	chr14:105411992	AHNAK2	-1.06	-9.86	-0.71	3.3e-16	Rheumatoid arthritis;
THYM	cis	rs6032067	0.537	rs6032033	chr20:43795081	G/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.49	-0.49	3.31e-7	Blood protein levels;
THYM	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg03476357	chr21:30257390	N6AMT1	0.61	4.64	0.43	1.1e-5	Dental caries;
THYM	cis	rs12580035	0.812	rs6489330	chr12:1907853	A/G	cg04012082	chr12:1905096	CACNA2D4	0.49	5.51	0.49	3.11e-7	Urate levels in lean individuals;
THYM	cis	rs6980334	0.767	rs10274304	chr7:137790882	G/A	cg06915773	chr7:137028165	PTN	0.56	4.5	0.42	1.91e-5	Blood metabolite ratios;
THYM	cis	rs2688608	1.000	rs2688608	chr10:75658349	G/T	cg15838173	chr10:75533400	FUT11	-0.42	-4.56	-0.42	1.51e-5	Inflammatory bowel disease;
THYM	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg09222892	chr1:25734099	RHCE	0.62	4.81	0.44	5.58e-6	Erythrocyte sedimentation rate;
THYM	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.96	0.68	2.8e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6138458	0.828	rs6138466	chr20:24997137	A/G	cg26195577	chr20:24973756	C20orf3	0.96	9.1	0.68	1.41e-14	Blood protein levels;
THYM	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.63	-5.44	-0.49	4.15e-7	Renal function-related traits (BUN);
THYM	trans	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg11764359	chr7:65958608	NA	-0.81	-6.4	-0.55	5.83e-9	Aortic root size;
THYM	cis	rs6906287	0.561	rs2078079	chr6:118705213	G/A	cg21191810	chr6:118973309	C6orf204	0.55	5.41	0.49	4.67e-7	Electrocardiographic conduction measures;
THYM	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.65e-6	Aortic root size;
THYM	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg19336497	chr11:14380999	RRAS2	0.82	9.58	0.7	1.34e-15	Sense of smell;
THYM	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	10.01	0.72	1.59e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg10523679	chr1:76189770	ACADM	-0.87	-8.86	-0.67	4.47e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg19875535	chr5:140030758	IK	0.57	4.52	0.42	1.79e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs782590	0.729	rs706548	chr2:55850106	C/G	cg18811423	chr2:55921094	PNPT1	0.59	5.43	0.49	4.26e-7	Metabolic syndrome;
THYM	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg26384229	chr12:38710491	ALG10B	-0.87	-8.86	-0.67	4.62e-14	Heart rate;
THYM	cis	rs3845702	0.736	rs3843323	chr2:180856459	T/C	cg01881094	chr2:180872142	CWC22	-0.91	-5.44	-0.49	4.07e-7	Schizophrenia;
THYM	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg03806693	chr22:41940476	POLR3H	-0.83	-7.85	-0.63	6.33e-12	Vitiligo;
THYM	cis	rs1878931	0.543	rs1129568	chr16:3483475	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.86	7.42	0.61	4.9e-11	Body mass index (adult);
THYM	cis	rs3857067	0.806	rs10008044	chr4:95092850	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.48	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	6.66	0.56	1.74e-9	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.24	9.45	0.7	2.46e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1978968	0.957	rs55865752	chr22:18444227	G/A	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs7772486	0.743	rs111332144	chr6:146056681	C/T	cg23711669	chr6:146136114	FBXO30	-0.77	-7.15	-0.59	1.81e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg14458575	chr2:238380390	NA	0.95	7.97	0.63	3.54e-12	Prostate cancer;
THYM	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg03806693	chr22:41940476	POLR3H	-1.07	-9.92	-0.71	2.48e-16	Vitiligo;
THYM	cis	rs6032067	0.516	rs6017530	chr20:43899731	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.39	-4.67	-0.43	9.85e-6	Blood protein levels;
THYM	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06481639	chr22:41940642	POLR3H	-0.68	-4.72	-0.44	8.17e-6	Vitiligo;
THYM	cis	rs9572053	0.589	rs9572067	chr13:69549452	C/T	cg16757992	chr13:69559194	NA	-0.63	-5.09	-0.46	1.82e-6	Subjective well-being;
THYM	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg19875535	chr5:140030758	IK	0.58	4.46	0.42	2.21e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs11834862	0.770	rs10444603	chr12:132694910	C/G	cg02410480	chr12:132819930	GALNT9	0.61	5.08	0.46	1.89e-6	Anti-saccade response;
THYM	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg04025307	chr7:1156635	C7orf50	0.87	8.21	0.64	1.11e-12	Longevity;Endometriosis;
THYM	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	trans	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	Myopia (pathological);
THYM	cis	rs72627123	1.000	rs72627119	chr14:74356274	C/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg00645579	chr11:617140	IRF7;MUPCDH	-0.52	-6.46	-0.55	4.44e-9	Systemic lupus erythematosus;
THYM	cis	rs13082711	0.595	rs4973761	chr3:27358620	T/C	cg02860705	chr3:27208620	NA	0.94	7.05	0.59	2.81e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs4731207	0.662	rs7357296	chr7:124532716	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg08439880	chr3:133502540	NA	-0.79	-6.57	-0.56	2.63e-9	Iron status biomarkers;
THYM	cis	rs7394190	0.748	rs78985317	chr10:75514465	C/T	cg07699608	chr10:75541558	CHCHD1	0.96	5.07	0.46	1.97e-6	Incident atrial fibrillation;
THYM	cis	rs3136739	0.510	rs12114934	chr8:42100613	T/G	cg12091331	chr8:42065314	PLAT	-0.7	-5.34	-0.48	6.29e-7	Plasma plasminogen activator levels;
THYM	cis	rs4343996	0.967	rs10228723	chr7:3348120	A/G	cg21248987	chr7:3385318	SDK1	0.4	4.83	0.44	5.22e-6	Motion sickness;
THYM	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg10760299	chr15:45669010	GATM	0.79	5.94	0.52	4.76e-8	Homoarginine levels;
THYM	cis	rs10492096	1.000	rs10849462	chr12:6575992	C/T	cg13857086	chr12:6580257	VAMP1	0.94	5.73	0.51	1.19e-7	Hip geometry;
THYM	cis	rs2898681	0.614	rs10016904	chr4:53694296	C/A	cg21521518	chr4:53727714	RASL11B	0.45	5.16	0.47	1.35e-6	Optic nerve measurement (cup area);
THYM	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg05754148	chr16:3507555	NAT15	0.71	7.17	0.59	1.6e-10	Tuberculosis;
THYM	cis	rs12802200	0.561	rs7940600	chr11:572105	A/G	cg09703963	chr11:616879	IRF7;MUPCDH	-0.58	-4.5	-0.42	1.89e-5	Systemic lupus erythematosus;
THYM	cis	rs7084402	0.967	rs1658454	chr10:60306770	G/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.65e-7	Refractive error;
THYM	cis	rs1847202	0.826	rs1979884	chr3:72948515	T/C	cg25664220	chr3:72788482	NA	-0.64	-4.88	-0.45	4.2e-6	Motion sickness;
THYM	cis	rs1018836	0.884	rs13279263	chr8:91648780	T/C	cg16814680	chr8:91681699	NA	-0.84	-7.11	-0.59	2.12e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs11209185	0.672	rs1926278	chr1:68453859	C/T	cg22082780	chr1:68452167	NA	0.59	7.88	0.63	5.49e-12	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7586879	0.575	rs6721750	chr2:25128719	A/G	cg27107076	chr2:25050844	ADCY3	-0.29	-4.73	-0.44	7.91e-6	Body mass index;
THYM	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg22875332	chr1:76189707	ACADM	-0.86	-10.85	-0.74	2.52e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs8114671	0.935	rs6060282	chr20:33767066	C/T	cg08999081	chr20:33150536	PIGU	0.52	4.67	0.43	9.71e-6	Height;
THYM	cis	rs67397200	0.590	rs12327712	chr19:17424947	T/G	cg04248312	chr19:17393744	ANKLE1	-0.49	-4.54	-0.42	1.64e-5	Breast cancer;Breast Cancer in BRCA1 mutation carriers;Breast cancer (estrogen-receptor negative);
THYM	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3126085	0.935	rs4845741	chr1:152183474	A/G	cg26020982	chr1:152196106	HRNR	0.38	5.14	0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.86	-0.45	4.62e-6	Eye color traits;
THYM	cis	rs9378357	0.850	rs9391986	chr6:3290583	A/G	cg10513992	chr6:3293720	SLC22A23	1.0	5.29	0.48	7.7300000000000005e-07	Obesity-related traits;
THYM	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.82	-4.55	-0.42	1.56e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7705042	0.865	rs9324866	chr5:141497650	A/G	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg00290607	chr11:67383545	NA	-0.76	-5.22	-0.47	1.06e-6	Mean corpuscular volume;
THYM	cis	rs863345	0.604	rs1157524	chr1:158457298	T/C	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg03396347	chr1:1875803	NA	-0.67	-6.81	-0.57	8.91e-10	Body mass index;
THYM	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg02018176	chr4:1364513	KIAA1530	0.5	4.58	0.43	1.42e-5	Obesity-related traits;
THYM	cis	rs12893597	1.000	rs12587221	chr14:76809864	G/A	cg20290672	chr14:76816747	NA	-0.62	-5.08	-0.46	1.89e-6	Maximal oxygen uptake response;
THYM	cis	rs887829	0.588	rs4663969	chr2:234655313	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-6.25	-0.54	1.15e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg03929089	chr4:120376271	NA	-0.98	-12.02	-0.78	9.02e-21	Height;
THYM	cis	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg05901451	chr6:126070800	HEY2	-0.56	-4.63	-0.43	1.16e-5	Endometrial cancer;
THYM	cis	rs7246967	0.673	rs73022763	chr19:22894216	C/T	cg05241461	chr19:22816980	ZNF492	0.6	4.64	0.43	1.11e-5	Bronchopulmonary dysplasia;
THYM	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg01097406	chr16:89675127	NA	0.85	7.67	0.62	1.46e-11	Vitiligo;
THYM	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.81	5.47	0.49	3.7e-7	Smoking behavior;
THYM	cis	rs7192750	0.586	rs4788585	chr16:71993638	A/G	cg06353428	chr16:71660113	MARVELD3	0.79	5.9	0.52	5.7e-8	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs41278232	1.000	rs73153160	chr20:62675410	G/A	cg03065311	chr20:62601662	ZNF512B	0.69	4.91	0.45	3.74e-6	Tonsillectomy;
THYM	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg08859206	chr1:53392774	SCP2	-0.66	-7.55	-0.61	2.7e-11	Monocyte count;
THYM	cis	rs2806561	0.769	rs2235547	chr1:23406485	C/G	cg19743168	chr1:23544995	NA	-0.6	-5.7	-0.51	1.33e-7	Height;
THYM	cis	rs11225247	0.655	rs112276332	chr11:102226953	A/G	cg06323957	chr11:102217781	BIRC2	1.02	4.74	0.44	7.52e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg12311346	chr5:56204834	C5orf35	-0.82	-6.04	-0.53	3.01e-8	Initial pursuit acceleration;
THYM	cis	rs2108225	1.000	rs2108226	chr7:107453279	A/C	cg18560240	chr7:107437656	SLC26A3	-0.87	-6.68	-0.57	1.62e-9	Ulcerative colitis;
THYM	cis	rs2964802	0.505	rs7737359	chr5:10832104	A/G	cg14521931	chr5:10832172	NA	-0.62	-5.47	-0.49	3.57e-7	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.68	5.23	0.47	1.02e-6	Renal function-related traits (BUN);
THYM	cis	rs4731207	0.596	rs1531717	chr7:124644690	G/T	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs12540874	0.698	rs12718574	chr7:50573848	G/C	cg00647317	chr7:50633725	DDC	0.32	4.57	0.42	1.46e-5	Systemic sclerosis;
THYM	cis	rs11030122	0.673	rs4910597	chr11:4094923	G/A	cg18678763	chr11:4115507	RRM1	-0.43	-5.59	-0.5	2.14e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg22875332	chr1:76189707	ACADM	-0.87	-10.77	-0.74	3.75e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7584330	0.518	rs11903073	chr2:238432766	C/T	cg08992911	chr2:238395768	MLPH	0.9	5.8	0.51	8.78e-8	Prostate cancer;
THYM	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg15448220	chr1:150897856	SETDB1	0.9	7.43	0.61	4.6e-11	Melanoma;
THYM	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg06636001	chr8:8085503	FLJ10661	-0.73	-6.25	-0.54	1.15e-8	Joint mobility (Beighton score);
THYM	cis	rs4891159	0.527	rs34956524	chr18:74130480	A/G	cg24786174	chr18:74118243	ZNF516	0.97	14.43	0.83	1.15e-25	Longevity;
THYM	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg22709100	chr7:91322751	NA	-0.6	-4.8	-0.44	5.84e-6	Breast cancer;
THYM	cis	rs7216064	0.953	rs1966410	chr17:65837215	T/C	cg12091567	chr17:66097778	LOC651250	-0.71	-4.76	-0.44	6.86e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs7011507	0.700	rs72637700	chr8:49304624	T/G	cg08774009	chr8:49309094	NA	-0.69	-5.38	-0.48	5.36e-7	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs7523273	0.526	rs12132968	chr1:207884292	T/C	cg22525895	chr1:207977042	MIR29B2	0.55	5.13	0.47	1.51e-6	Schizophrenia;
THYM	cis	rs11264213	0.792	rs709309	chr1:36441148	G/T	cg27506609	chr1:36549197	TEKT2	0.99	5.3	0.48	7.41e-7	Schizophrenia;
THYM	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg14196790	chr5:131705035	SLC22A5	0.55	5.04	0.46	2.21e-6	Blood metabolite levels;
THYM	cis	rs4903604	0.581	rs4899658	chr14:78035392	A/T	cg18872420	chr14:78023429	SPTLC2	-0.53	-4.53	-0.42	1.69e-5	Gut microbiome composition (winter);
THYM	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-6.65	-0.56	1.82e-9	Colorectal cancer;
THYM	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg16342193	chr10:102329863	NA	-0.55	-5.59	-0.5	2.14e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg07636037	chr3:49044803	WDR6	0.84	7.39	0.6	5.67e-11	Menarche (age at onset);
THYM	cis	rs2976388	1.000	rs1045547	chr8:143763757	T/G	cg13446199	chr8:143762866	PSCA	0.51	6.42	0.55	5.46e-9	Urinary tract infection frequency;
THYM	cis	rs9825379	0.643	rs9858405	chr3:141136727	A/C	cg13411656	chr3:141121016	ZBTB38	-0.5	-4.65	-0.43	1.08e-5	Height;
THYM	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	6.03	0.53	3.12e-8	Obesity-related traits;
THYM	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg18681998	chr4:17616180	MED28	0.96	8.93	0.68	3.19e-14	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg08999081	chr20:33150536	PIGU	0.62	5.04	0.46	2.25e-6	Coronary artery disease;
THYM	cis	rs67311347	0.544	rs6804545	chr3:40354040	G/C	cg13683864	chr3:40499215	RPL14	-0.67	-5.89	-0.52	5.93e-8	Renal cell carcinoma;
THYM	trans	rs4650994	0.935	rs4652306	chr1:178528206	T/C	cg05059571	chr16:84539110	KIAA1609	-0.75	-8.15	-0.64	1.43e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg24257776	chr3:47051546	LOC100129354	0.41	4.78	0.44	6.38e-6	Colorectal cancer;
THYM	cis	rs754466	0.580	rs10824573	chr10:79540969	T/C	cg17075019	chr10:79541650	NA	-0.69	-5.73	-0.51	1.17e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg06112835	chr11:68658793	MRPL21	0.45	6.39	0.55	6.21e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7216064	0.765	rs6504550	chr17:65894542	A/G	cg12091567	chr17:66097778	LOC651250	-0.83	-6.17	-0.53	1.65e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-5.88	-0.52	6.14e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg20283391	chr11:68216788	NA	-0.71	-5.27	-0.48	8.44e-7	Total body bone mineral density;
THYM	cis	rs2502731	0.539	rs3003615	chr9:130997892	C/T	cg13642260	chr9:130955380	CIZ1	0.58	4.73	0.44	7.72e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.23	9.89	0.71	2.89e-16	Platelet count;
THYM	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg21028142	chr17:79581711	NPLOC4	0.52	5.13	0.47	1.52e-6	Eye color traits;
THYM	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2046867	0.818	rs62249866	chr3:72878632	T/C	cg25664220	chr3:72788482	NA	-0.96	-7.85	-0.63	6.21e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg16230307	chr14:35515116	FAM177A1	0.9	5.84	0.51	7.37e-8	Psoriasis;
THYM	cis	rs4363385	0.747	rs10399896	chr1:152975083	T/A	cg13444842	chr1:152974279	SPRR3	-0.6	-4.79	-0.44	6.06e-6	Inflammatory skin disease;
THYM	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg02753203	chr1:228287806	NA	-0.6	-5.13	-0.47	1.55e-6	Diastolic blood pressure;
THYM	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg10518543	chr12:38710700	ALG10B	0.57	4.5	0.42	1.92e-5	Morning vs. evening chronotype;
THYM	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg05890377	chr2:74357713	NA	1.09	10.22	0.72	5.55e-17	Gestational age at birth (maternal effect);
THYM	cis	rs7267979	1.000	rs6050629	chr20:25430680	G/A	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs8133932	0.701	rs2150454	chr21:47288142	T/C	cg08707771	chr21:46690014	POFUT2	-0.79	-4.63	-0.43	1.15e-5	Schizophrenia;
THYM	cis	rs7586879	0.616	rs10206196	chr2:25137323	T/C	cg15423357	chr2:25149977	NA	0.7	7.29	0.6	9.27e-11	Body mass index;
THYM	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg05283184	chr6:79620031	NA	-0.94	-9.21	-0.69	7.9e-15	Intelligence (multi-trait analysis);
THYM	cis	rs612683	0.894	rs10875290	chr1:100853755	G/T	cg06223162	chr1:101003688	GPR88	0.69	5.55	0.49	2.63e-7	Breast cancer;
THYM	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg21862992	chr11:68658383	NA	0.23	4.48	0.42	2.07e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	5.51	0.49	3.1e-7	Schizophrenia;
THYM	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg20283391	chr11:68216788	NA	-0.65	-4.65	-0.43	1.07e-5	Total body bone mineral density;
THYM	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg12419862	chr22:24373484	LOC391322	-0.76	-7.85	-0.63	6.09e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2742234	0.503	rs1254968	chr10:43691691	C/T	cg06632098	chr10:43605906	RET	0.79	5.1	0.46	1.73e-6	Hirschsprung disease;
THYM	trans	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs2072499	0.865	rs2758608	chr1:156202860	A/T	cg25208724	chr1:156163844	SLC25A44	0.98	9.88	0.71	3.05e-16	Testicular germ cell tumor;
THYM	cis	rs2463822	1.000	rs2246920	chr11:62104937	T/G	cg06239285	chr11:62104954	ASRGL1	1.44	7.7	0.62	1.3e-11	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg04455712	chr21:45112962	RRP1B	0.51	4.72	0.44	8.23e-6	Mean corpuscular volume;
THYM	cis	rs897984	0.683	rs12926237	chr16:30837596	C/T	cg02466173	chr16:30829666	NA	0.56	4.92	0.45	3.64e-6	Dementia with Lewy bodies;
THYM	cis	rs12291225	0.545	rs11023187	chr11:14345559	T/G	cg19336497	chr11:14380999	RRAS2	-0.91	-13.71	-0.82	3.02e-24	Sense of smell;
THYM	cis	rs12042938	0.600	rs1094655	chr1:231774362	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.72	5.23	0.47	1.02e-6	Neuranatomic and neurocognitive phenotypes;
THYM	cis	rs7220711	1.000	rs59303349	chr17:41793668	A/G	cg26893861	chr17:41843967	DUSP3	0.67	5.79	0.51	8.98e-8	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs3008870	1.000	rs2815361	chr1:67494591	G/T	cg02640540	chr1:67518911	SLC35D1	0.64	4.73	0.44	7.69e-6	Lymphocyte percentage of white cells;
THYM	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.79e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs2458413	0.522	rs2669449	chr8:105372173	A/C	cg21295575	chr8:105352067	TM7SF4	-0.34	-5.12	-0.46	1.61e-6	Paget's disease;
THYM	cis	rs13223928	0.511	rs11773338	chr7:3144508	T/C	cg19214707	chr7:3157722	NA	-0.9	-7.76	-0.62	9.61e-12	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg08975724	chr8:8085496	FLJ10661	0.6	4.76	0.44	7e-6	Mood instability;
THYM	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg19774624	chr17:42201019	HDAC5	-0.77	-7.16	-0.59	1.73e-10	Total body bone mineral density;
THYM	cis	rs28510890	0.536	rs8030062	chr15:93157633	G/A	cg05775517	chr15:93158989	NA	-0.39	-4.61	-0.43	1.27e-5	Lung cancer in ever smokers;
THYM	cis	rs3008870	1.000	rs3008853	chr1:67385488	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.92	7.43	0.61	4.77e-11	Lymphocyte percentage of white cells;
THYM	cis	rs2154427	0.872	rs80141393	chr21:34098304	C/T	cg21871883	chr21:34145043	C21orf49;C21orf66	1.01	5.23	0.47	9.88e-7	Bilirubin levels;
THYM	cis	rs7312774	0.867	rs10492213	chr12:107295841	A/T	cg16260113	chr12:107380972	MTERFD3	-1.05	-5.57	-0.5	2.4e-7	Severe influenza A (H1N1) infection;
THYM	cis	rs9926296	0.715	rs648548	chr16:89749436	C/G	cg26513180	chr16:89883248	FANCA	-0.56	-4.78	-0.44	6.37e-6	Vitiligo;
THYM	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg06009448	chr7:1102226	C7orf50	0.53	5.59	0.5	2.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg02018176	chr4:1364513	KIAA1530	0.7	6.36	0.55	7.08e-9	Longevity;
THYM	cis	rs526231	0.543	rs34770	chr5:102447646	A/C	cg23492399	chr5:102201601	PAM	-0.7	-5.23	-0.47	9.9e-7	Primary biliary cholangitis;
THYM	cis	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg17333051	chr19:2783644	SGTA	0.57	5.22	0.47	1.05e-6	Total cholesterol levels;
THYM	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg13609457	chr4:120235615	NA	0.53	4.89	0.45	4.12e-6	Corneal astigmatism;
THYM	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.85	8.94	0.68	3.08e-14	Blood protein levels;
THYM	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg07570687	chr10:102243282	WNT8B	0.76	6.71	0.57	1.41e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg09033563	chr22:24373618	LOC391322	0.66	5.11	0.46	1.66e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg01097406	chr16:89675127	NA	-0.62	-5.04	-0.46	2.23e-6	Vitiligo;
THYM	cis	rs12594515	1.000	rs57299255	chr15:45996532	C/A	cg01629716	chr15:45996671	NA	0.53	5.27	0.48	8.45e-7	Waist circumference;Weight;
THYM	cis	rs763014	0.898	rs4984893	chr16:623082	A/G	cg07343612	chr16:622815	PIGQ	-1.05	-10.74	-0.74	4.28e-18	Height;
THYM	cis	rs2029213	0.523	rs3773745	chr3:53270424	A/G	cg16894138	chr3:53270350	TKT	-0.83	-7.83	-0.63	6.88e-12	Heart rate;
THYM	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg09904177	chr6:26538194	HMGN4	0.63	5.43	0.49	4.41e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7264396	0.563	rs3827029	chr20:34332784	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.74	4.71	0.43	8.5e-6	Total cholesterol levels;
THYM	cis	rs977987	0.800	rs1011121	chr16:75325933	A/G	cg03315344	chr16:75512273	CHST6	0.83	6.93	0.58	5e-10	Dupuytren's disease;
THYM	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7973719	0.865	rs12820829	chr12:7347534	G/A	cg07052231	chr12:7363540	PEX5	0.61	5.09	0.46	1.84e-6	IgG glycosylation;
THYM	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg06618935	chr21:46677482	NA	-0.98	-9.58	-0.7	1.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7809950	0.637	rs2701685	chr7:107299584	A/G	cg23024343	chr7:107201750	COG5	0.76	6.39	0.55	6.23e-9	Coronary artery disease;
THYM	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs1691799	0.867	rs1027400	chr12:66760922	A/T	cg16791601	chr12:66731901	HELB	-0.68	-5.92	-0.52	5.07e-8	White blood cell count (basophil);
THYM	cis	rs4343996	0.935	rs4385365	chr7:3360860	C/T	cg21248987	chr7:3385318	SDK1	-0.41	-4.91	-0.45	3.77e-6	Motion sickness;
THYM	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.53	5.74	0.51	1.14e-7	Mean corpuscular volume;
THYM	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg05340658	chr4:99064831	C4orf37	0.56	4.64	0.43	1.13e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9633740	1.000	rs1870137	chr10:82269848	C/G	cg01528321	chr10:82214614	TSPAN14	0.94	4.48	0.42	2.08e-5	Post bronchodilator FEV1;
THYM	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg17105886	chr17:28927953	LRRC37B2	1.31	7.95	0.63	3.89e-12	Body mass index;
THYM	cis	rs889398	0.741	rs3790076	chr16:69907445	A/C	cg09409435	chr16:70099608	PDXDC2	-0.6	-4.84	-0.44	5.03e-6	Body mass index;
THYM	cis	rs7487075	0.754	rs10880962	chr12:46773444	C/G	cg11331445	chr12:47219877	SLC38A4	0.5	4.98	0.46	2.8e-6	Itch intensity from mosquito bite;
THYM	cis	rs1670533	1.000	rs13107058	chr4:1054379	G/A	cg27284194	chr4:1044797	NA	0.61	4.6	0.43	1.29e-5	Recombination rate (females);
THYM	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.59	0.66	1.68e-13	Colorectal cancer;
THYM	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs7523273	0.586	rs7518047	chr1:207899332	T/C	cg22525895	chr1:207977042	MIR29B2	-0.53	-5.08	-0.46	1.91e-6	Schizophrenia;
THYM	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg06636001	chr8:8085503	FLJ10661	0.77	7.36	0.6	6.58e-11	Mood instability;
THYM	cis	rs16866061	0.890	rs72972401	chr2:225404668	T/C	cg22455342	chr2:225449267	CUL3	0.67	4.84	0.44	4.98e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs1335645	0.570	rs11805357	chr1:111651660	G/C	cg00321911	chr1:111669324	DRAM2	-1.14	-6.19	-0.54	1.49e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7851660	0.844	rs10119760	chr9:100624602	G/C	cg13688889	chr9:100608707	NA	-0.84	-6.24	-0.54	1.21e-8	Strep throat;
THYM	cis	rs4595586	0.545	rs7952765	chr12:39375325	C/G	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs4845570	1.000	rs3790514	chr1:151744168	T/C	cg07092448	chr1:151763213	TDRKH	-1.03	-6.71	-0.57	1.42e-9	Coronary artery disease;
THYM	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg04267008	chr7:1944627	MAD1L1	-0.69	-6.42	-0.55	5.45e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg09307838	chr4:120376055	NA	0.71	5.07	0.46	1.98e-6	Corneal astigmatism;
THYM	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg14186256	chr22:23484241	RTDR1	-0.96	-9.17	-0.69	9.89e-15	Bone mineral density;
THYM	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg16325326	chr1:53192061	ZYG11B	-0.82	-8.46	-0.66	3.1400000000000003e-13	Monocyte count;
THYM	trans	rs637571	0.565	rs570387	chr11:65637076	T/C	cg17712092	chr4:129076599	LARP1B	-0.94	-8.07	-0.64	2.19e-12	Eosinophil percentage of white cells;
THYM	cis	rs1994135	0.586	rs7308214	chr12:33713834	T/A	cg10856724	chr12:34555212	NA	-0.7	-5.32	-0.48	6.75e-7	Resting heart rate;
THYM	cis	rs7323507	0.636	rs7327098	chr13:110612333	G/C	cg07669776	chr13:110975691	COL4A2	-0.51	-4.65	-0.43	1.07e-5	Lung function (FVC);
THYM	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	15.57	0.85	6.94e-28	Chronic sinus infection;
THYM	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.08	7.64	0.62	1.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9287719	0.674	rs11684157	chr2:10827157	C/A	cg03983476	chr2:10830698	NOL10	0.61	5.27	0.48	8.48e-7	Prostate cancer;
THYM	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg06481639	chr22:41940642	POLR3H	0.72	4.68	0.43	9.65e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs6906287	0.647	rs11755121	chr6:118828124	G/C	cg21191810	chr6:118973309	C6orf204	0.53	5.24	0.47	9.58e-7	Electrocardiographic conduction measures;
THYM	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg16049864	chr8:95962084	TP53INP1	0.77	6.45	0.55	4.62e-9	Type 2 diabetes;
THYM	cis	rs9644630	0.696	rs35736969	chr8:19319620	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.62	5.67	0.5	1.54e-7	Oropharynx cancer;
THYM	cis	rs7809950	0.954	rs62482543	chr7:107080656	G/A	cg23024343	chr7:107201750	COG5	-0.92	-8.11	-0.64	1.73e-12	Coronary artery disease;
THYM	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.49	-0.42	2.04e-5	Bladder cancer;
THYM	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg01570182	chr17:44337453	NA	0.63	6.62	0.56	2.1e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7104764	0.957	rs7116130	chr11:244129	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs250585	0.704	rs11861636	chr16:23439997	T/C	cg00143387	chr16:23521605	GGA2	0.74	5.27	0.48	8.6e-7	Egg allergy;
THYM	cis	rs6700896	0.864	rs7515766	chr1:66167452	G/A	cg04111102	chr1:66153794	NA	-0.59	-5.49	-0.49	3.35e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.85	-5.32	-0.48	6.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7681440	0.606	rs2619353	chr4:90747975	G/C	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.77	-6.56	-0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.96	-6.27	-0.54	1.05e-8	Platelet count;
THYM	cis	rs7106204	0.800	rs7120940	chr11:24236485	C/A	ch.11.24196551F	chr11:24239977	NA	1.0	7.01	0.58	3.4e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg15744005	chr10:104629667	AS3MT	-0.82	-7.64	-0.62	1.71e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4455778	0.538	rs6583513	chr7:49123526	G/A	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg04876069	chr12:132293656	NA	-0.6	-4.94	-0.45	3.3e-6	Migraine;
THYM	cis	rs12530845	0.623	rs7798256	chr7:135344211	C/A	cg19897172	chr7:135347071	PL-5283	-0.63	-5.34	-0.48	6.36e-7	Red blood cell traits;
THYM	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs9915657	0.966	rs8071717	chr17:70128705	C/T	cg09344028	chr17:70110421	NA	0.44	4.46	0.42	2.27e-5	Thyroid hormone levels;
THYM	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg18681998	chr4:17616180	MED28	0.99	10.09	0.72	1.05e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9549367	0.711	rs9994	chr13:113884301	T/C	cg00898013	chr13:113819073	PROZ	-0.91	-8.6	-0.66	1.6e-13	Platelet distribution width;
THYM	trans	rs629535	0.821	rs680993	chr8:70050247	G/A	cg21567404	chr3:27674614	NA	1.11	10.64	0.74	7.17e-18	Dupuytren's disease;
THYM	cis	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg13319975	chr6:146136371	FBXO30	-0.74	-6.33	-0.54	7.91e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2276314	0.600	rs28729782	chr18:33590529	A/G	cg19628046	chr18:33552617	C18orf21	0.64	4.88	0.45	4.2e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg02953382	chr22:24373134	LOC391322	-0.76	-7.83	-0.63	6.87e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7173743	0.756	rs12903668	chr15:79129320	A/G	cg00540400	chr15:79124168	NA	0.57	5.87	0.52	6.5e-8	Coronary artery disease;
THYM	cis	rs7681440	0.566	rs356189	chr4:90691132	T/C	cg06632027	chr4:90757378	SNCA	0.59	4.61	0.43	1.27e-5	Dementia with Lewy bodies;
THYM	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg24308560	chr3:49941425	MST1R	0.79	6.98	0.58	4.02e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7727544	0.740	rs419291	chr5:131633355	T/C	cg24060327	chr5:131705240	SLC22A5	-0.73	-5.17	-0.47	1.27e-6	Blood metabolite levels;
THYM	cis	rs7582180	0.614	rs3748930	chr2:101010082	G/C	cg14675211	chr2:100938903	LONRF2	0.64	6.17	0.53	1.69e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2455799	0.613	rs7620787	chr3:15882826	G/A	cg16303742	chr3:15540471	COLQ	-0.55	-5.72	-0.51	1.25e-7	Mean platelet volume;
THYM	cis	rs6686842	1.000	rs34454389	chr1:41663236	C/G	cg03387723	chr1:41708464	SCMH1	-0.43	-5.15	-0.47	1.38e-6	Height;
THYM	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg09035930	chr12:129282057	SLC15A4	-0.84	-10.7	-0.74	5.31e-18	Systemic lupus erythematosus;
THYM	cis	rs6728642	0.908	rs10207116	chr2:98018281	G/A	cg26665480	chr2:98280029	ACTR1B	-0.83	-5.09	-0.46	1.79e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.11e-8	Systolic blood pressure;
THYM	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg12923728	chr3:195709715	SDHAP1	-0.83	-6.1	-0.53	2.31e-8	Pancreatic cancer;
THYM	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	7.64	0.62	1.73e-11	Smoking behavior;
THYM	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.76	-4.99	-0.46	2.73e-6	Body mass index;
THYM	cis	rs7769051	0.522	rs34688576	chr6:133118214	C/T	cg22852734	chr6:133119734	C6orf192	1.45	6.1	0.53	2.32e-8	Type 2 diabetes nephropathy;
THYM	cis	rs2456568	0.802	rs10765639	chr11:93636194	G/A	cg17347335	chr11:93583973	C11orf90	-0.48	-4.58	-0.43	1.39e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg01616529	chr11:638424	DRD4	-0.74	-5.68	-0.5	1.45e-7	Systemic lupus erythematosus;
THYM	cis	rs12681287	0.640	rs28561640	chr8:87425638	G/A	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs1878931	0.582	rs9921152	chr16:3421199	A/G	cg00484396	chr16:3507460	NAT15	-0.48	-4.62	-0.43	1.2e-5	Body mass index (adult);
THYM	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg08999081	chr20:33150536	PIGU	-0.57	-4.95	-0.45	3.25e-6	Height;
THYM	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	cg12893697	chr11:970389	AP2A2	-0.31	-5.12	-0.47	1.57e-6	Alzheimer's disease (late onset);
THYM	cis	rs2692947	0.673	rs1168965	chr2:96787899	C/G	cg23100626	chr2:96804247	ASTL	-0.39	-4.76	-0.44	6.93e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg18512352	chr11:47633146	NA	-0.5	-5.98	-0.52	3.96e-8	Subjective well-being;
THYM	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg17063962	chr7:91808500	NA	1.13	12.83	0.8	1.9e-22	Breast cancer;
THYM	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg15536230	chr21:44985092	HSF2BP	-0.43	-5.46	-0.49	3.79e-7	Mean corpuscular volume;
THYM	cis	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg00852783	chr1:26633632	UBXN11	0.82	7.95	0.63	3.8e-12	Obesity-related traits;
THYM	cis	rs7806994	1	rs7806994	chr7:56139505	A/T	cg14187409	chr7:56174376	CHCHD2	0.88	5.01	0.46	2.53e-6	PR interval in Tripanosoma cruzi seropositivity;
THYM	cis	rs5771069	0.933	rs137848	chr22:50440296	A/G	cg08241514	chr22:50438769	IL17REL	-0.4	-4.54	-0.42	1.66e-5	Ulcerative colitis;
THYM	cis	rs11630290	0.736	rs4777239	chr15:64148098	T/A	cg12036633	chr15:63758958	NA	0.83	4.46	0.42	2.27e-5	Iris characteristics;
THYM	cis	rs4589258	0.933	rs1783808	chr11:90436805	C/T	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg08885076	chr2:99613938	TSGA10	-0.67	-6.0	-0.52	3.54e-8	Chronic sinus infection;
THYM	cis	rs888194	0.934	rs12314392	chr12:110010866	A/G	cg10504392	chr12:110044639	NA	0.6	5.82	0.51	8.07e-8	Neuroticism;
THYM	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs2219968	0.683	rs936888	chr8:78897829	C/G	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1691799	0.899	rs1168302	chr12:66737518	C/T	cg16791601	chr12:66731901	HELB	-0.75	-7.27	-0.6	1.03e-10	White blood cell count (basophil);
THYM	cis	rs7408868	1.000	rs757472	chr19:15273221	T/C	cg14696996	chr19:15285081	NOTCH3	1.0	5.82	0.51	7.85e-8	Pulse pressure;
THYM	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg20744362	chr22:50050164	C22orf34	0.73	6.71	0.57	1.4e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7614311	0.636	rs67944903	chr3:63871195	A/T	cg22134162	chr3:63841271	THOC7	-0.46	-5.66	-0.5	1.57e-7	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs9565309	0.579	rs9635010	chr13:77576383	G/C	cg13866767	chr13:78470850	EDNRB	1.06	4.81	0.44	5.76e-6	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg12000587	chr17:30186630	C17orf79	-0.4	-4.56	-0.42	1.53e-5	Hip circumference adjusted for BMI;
THYM	cis	rs240764	0.817	rs58266877	chr6:101156284	C/T	cg21058520	chr6:100914733	NA	0.58	5.22	0.47	1.04e-6	Neuroticism;
THYM	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg13683864	chr3:40499215	RPL14	-0.83	-7.81	-0.63	7.51e-12	Renal cell carcinoma;
THYM	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs2730245	0.545	rs2788472	chr7:158649304	T/C	cg23730037	chr7:158596552	ESYT2	-0.45	-4.64	-0.43	1.1e-5	Height;
THYM	cis	rs6430585	0.528	rs309162	chr2:136690783	T/A	cg07169764	chr2:136633963	MCM6	1.12	12.01	0.78	9.39e-21	Corneal structure;
THYM	cis	rs7584330	0.554	rs79213383	chr2:238426890	A/G	cg14458575	chr2:238380390	NA	0.79	4.65	0.43	1.06e-5	Prostate cancer;
THYM	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg02527881	chr3:46936655	PTH1R	-0.69	-7.11	-0.59	2.11e-10	Colorectal cancer;
THYM	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg11764359	chr7:65958608	NA	-0.82	-6.56	-0.56	2.81e-9	Aortic root size;
THYM	cis	rs892961	0.932	rs66886702	chr17:75412714	G/A	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs79349575	0.721	rs1008834	chr17:46968008	G/C	cg26022315	chr17:47021804	SNF8	0.48	4.49	0.42	2e-5	Type 2 diabetes;
THYM	cis	rs1699337	0.896	rs2938388	chr3:12437978	A/G	cg05467012	chr3:12595696	NA	-0.58	-4.69	-0.43	9.06e-6	Cholesterol, total;
THYM	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg23758822	chr17:41437982	NA	1.27	14.18	0.82	3.54e-25	Menopause (age at onset);
THYM	cis	rs9326248	0.539	rs518181	chr11:116772787	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.63	4.94	0.45	3.38e-6	Blood protein levels;
THYM	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	6.35	0.55	7.5e-9	Smoking behavior;
THYM	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg14972814	chr11:95582409	MTMR2	-0.63	-4.86	-0.45	4.64e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs3112255	0.967	rs2971019	chr2:101298126	C/G	cg01042948	chr2:101319752	NA	0.72	6.28	0.54	1.02e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.68	0.43	9.35e-6	Tonsillectomy;
THYM	cis	rs483180	0.512	rs1163251	chr1:120209755	T/C	cg19096424	chr1:120255104	PHGDH	-0.65	-5.25	-0.47	9.36e-7	Macular telangiectasia type 2;
THYM	cis	rs8050907	1.000	rs28505517	chr16:4608099	G/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.34	5.32	0.48	7e-7	Obesity-related traits;
THYM	cis	rs7432375	0.901	rs4408829	chr3:136404683	C/T	cg21827317	chr3:136751795	NA	-0.57	-4.84	-0.44	5.03e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs9807989	0.839	rs11695627	chr2:102970105	A/G	cg03938978	chr2:103052716	IL18RAP	0.63	6.46	0.55	4.36e-9	Asthma;
THYM	cis	rs782590	0.967	rs782588	chr2:55841640	T/C	cg03859395	chr2:55845619	SMEK2	0.65	6.04	0.53	3.03e-8	Metabolic syndrome;
THYM	cis	rs2071303	1.000	rs2071303	chr6:26091336	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.63	-4.96	-0.45	3.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg27034606	chr17:28928453	LRRC37B2	0.7	4.72	0.44	8.26e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg18268492	chr10:99185986	PGAM1	-1.24	-7.01	-0.58	3.51e-10	Pulmonary function decline;
THYM	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg00376283	chr12:123451042	ABCB9	0.69	4.65	0.43	1.09e-5	Neutrophil percentage of white cells;
THYM	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg27068330	chr11:65405492	SIPA1	0.84	8.34	0.65	5.78e-13	Acne (severe);
THYM	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	15.61	0.85	5.73e-28	Chronic sinus infection;
THYM	cis	rs2276314	0.857	rs8087539	chr18:33631537	C/T	cg19628046	chr18:33552617	C18orf21	0.74	5.43	0.49	4.29e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs6720763	0.838	rs67726376	chr2:168032190	A/G	cg10633051	chr2:168042982	XIRP2	-0.69	-4.73	-0.44	7.73e-6	Atopic dermatitis;
THYM	cis	rs4077515	0.967	rs3829110	chr9:139269198	A/G	cg14115884	chr9:139300582	SDCCAG3	0.7	6.74	0.57	1.23e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs919433	0.679	rs13000656	chr2:198522126	T/C	cg05783139	chr2:198650985	BOLL	-0.64	-4.72	-0.44	8.16e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs798766	0.953	rs798751	chr4:1719572	A/G	cg00006948	chr4:1768889	NA	-0.97	-5.13	-0.47	1.54e-6	Bladder cancer;Urinary bladder cancer;
THYM	cis	rs7089973	0.836	rs7895551	chr10:116625481	C/T	cg23260525	chr10:116636907	FAM160B1	0.52	4.72	0.44	8.04e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	trans	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg13615516	chr5:77269221	NA	0.86	7.64	0.62	1.71e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9329289	0.510	rs11251283	chr10:2555784	C/G	cg15501526	chr10:2543763	NA	0.5	4.47	0.42	2.16e-5	Age-related hearing impairment;
THYM	cis	rs35883536	0.846	rs964905	chr1:101087131	T/C	cg06223162	chr1:101003688	GPR88	-0.67	-4.91	-0.45	3.77e-6	Monocyte count;
THYM	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11644478	chr21:40555479	PSMG1	-0.76	-6.49	-0.55	3.85e-9	Cognitive function;
THYM	cis	rs1129187	0.755	rs2296804	chr6:42931261	C/G	cg09436375	chr6:42928200	GNMT	-0.47	-6.42	-0.55	5.27e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg05368731	chr17:41323189	NBR1	1.26	11.54	0.76	9.06e-20	Menopause (age at onset);
THYM	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg12165864	chr7:66369176	NA	0.6	4.66	0.43	1.03e-5	Aortic root size;
THYM	cis	rs1642645	0.831	rs11210563	chr1:42494633	G/T	cg06092502	chr1:42611687	NA	0.61	4.74	0.44	7.58e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg08847533	chr14:75593920	NEK9	-1.01	-11.32	-0.76	2.63e-19	Height;
THYM	cis	rs6988636	1.000	rs28542077	chr8:124190896	T/C	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg11752832	chr7:134001865	SLC35B4	0.72	4.92	0.45	3.6e-6	Mean platelet volume;
THYM	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg19077165	chr18:44547161	KATNAL2	-0.63	-8.26	-0.65	8.52e-13	Personality dimensions;
THYM	cis	rs6541297	1.000	rs4846838	chr1:230281618	G/A	cg20703242	chr1:230279135	GALNT2	0.86	4.93	0.45	3.49e-6	Coronary artery disease;
THYM	cis	rs9581857	0.547	rs74518675	chr13:27972180	A/G	cg22138327	chr13:27999177	GTF3A	1.02	5.82	0.51	7.8e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	trans	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.23	-14.87	-0.84	1.54e-26	Exhaled nitric oxide output;
THYM	cis	rs7246657	0.943	rs7255996	chr19:37971699	G/A	cg22634378	chr19:37742834	NA	0.59	4.92	0.45	3.62e-6	Coronary artery calcification;
THYM	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg27532560	chr4:187881888	NA	-0.95	-11.68	-0.77	4.63e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg16797656	chr11:68205561	LRP5	0.46	4.96	0.45	3.09e-6	Total body bone mineral density;
THYM	cis	rs4766566	0.704	rs10774617	chr12:111755178	T/C	cg10833066	chr12:111807467	FAM109A	0.67	8.28	0.65	7.79e-13	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
THYM	cis	rs12928939	0.954	rs8057568	chr16:71811995	G/A	cg03805757	chr16:71968109	PKD1L3	-0.7	-5.34	-0.48	6.39e-7	Post bronchodilator FEV1;
THYM	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2070488	0.775	rs762318	chr3:38516369	C/A	cg24069376	chr3:38537580	EXOG	0.45	4.59	0.43	1.36e-5	Electrocardiographic conduction measures;
THYM	cis	rs6466832	0.506	rs1968146	chr7:122316653	C/G	cg22586324	chr7:123296098	LMOD2	-0.91	-5.09	-0.46	1.83e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4919687	0.550	rs12259058	chr10:104484799	A/G	cg04362960	chr10:104952993	NT5C2	0.61	4.74	0.44	7.57e-6	Colorectal cancer;
THYM	cis	rs9649213	0.537	rs6465663	chr7:97918883	C/G	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.2e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10847980	0.590	rs1979236	chr12:123325993	G/A	cg25930673	chr12:123319894	HIP1R	1.08	5.36	0.48	5.72e-7	Adiponectin levels;
THYM	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17443541	0.507	rs7558643	chr2:200470709	C/T	cg03741458	chr2:200468445	NA	-0.75	-5.77	-0.51	9.74e-8	Intelligence (multi-trait analysis);
THYM	cis	rs36051895	0.589	rs10491650	chr9:5203054	C/T	cg02405213	chr9:5042618	JAK2	0.89	8.85	0.67	4.76e-14	Pediatric autoimmune diseases;
THYM	cis	rs9649213	0.614	rs1006169	chr7:97938443	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.67	5.68	0.5	1.49e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7512552	0.839	rs1260367	chr1:150344514	C/T	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9814567	0.964	rs3856729	chr3:134200925	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-8.49	-0.66	2.78e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg09034736	chr1:150693464	HORMAD1	0.53	4.85	0.45	4.83e-6	Tonsillectomy;
THYM	cis	rs4595586	0.545	rs2388176	chr12:39372357	G/A	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs2456568	0.803	rs10831140	chr11:93640689	G/A	cg17595323	chr11:93583763	C11orf90	-0.6	-6.33	-0.54	8.23e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg23750338	chr8:142222470	SLC45A4	0.52	4.87	0.45	4.48e-6	Immature fraction of reticulocytes;
THYM	cis	rs61931739	0.853	rs7137146	chr12:34102394	G/A	cg06521331	chr12:34319734	NA	0.6	4.85	0.45	4.82e-6	Morning vs. evening chronotype;
THYM	cis	rs2997447	0.802	rs75786059	chr1:26449327	A/G	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs4843185	0.669	rs889502	chr16:85716832	A/G	cg26571870	chr16:85723150	GINS2	-0.38	-4.63	-0.43	1.15e-5	Platelet distribution width;
THYM	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg11764359	chr7:65958608	NA	0.7	4.86	0.45	4.56e-6	Aortic root size;
THYM	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg13246856	chr1:44399776	ARTN	0.5	4.99	0.46	2.7e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7084402	0.967	rs12242287	chr10:60278340	A/G	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.63e-7	Refractive error;
THYM	cis	rs2124969	0.548	rs62175384	chr2:161011128	C/T	cg03641300	chr2:160917029	PLA2R1	-0.65	-4.58	-0.43	1.38e-5	Waist circumference adjusted for body mass index;
THYM	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg26513180	chr16:89883248	FANCA	0.73	7.24	0.6	1.14e-10	Vitiligo;
THYM	cis	rs995000	0.899	rs1168032	chr1:62967747	A/G	cg06896770	chr1:63153194	DOCK7	-0.91	-7.48	-0.61	3.62e-11	Triglyceride levels;
THYM	cis	rs6496667	0.865	rs62019277	chr15:90880438	C/T	cg22089800	chr15:90895588	ZNF774	0.73	4.5	0.42	1.93e-5	Rheumatoid arthritis;
THYM	cis	rs986417	1.000	rs11158293	chr14:61109020	G/C	cg27398547	chr14:60952738	C14orf39	1.26	6.1	0.53	2.29e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs7267979	0.932	rs449703	chr20:25458559	C/T	cg03522245	chr20:25566470	NINL	0.57	4.48	0.42	2.1e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9880211	1.000	rs9826454	chr3:135953220	A/G	cg21827317	chr3:136751795	NA	-0.66	-4.54	-0.42	1.67e-5	Body mass index;Height;
THYM	cis	rs7633857	0.512	rs1374787	chr3:160700144	C/T	cg03342759	chr3:160939853	NMD3	-0.67	-5.25	-0.47	9.11e-7	Educational attainment (years of education);
THYM	cis	rs1448094	0.512	rs12309296	chr12:86241566	T/C	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs7188861	0.626	rs7193871	chr16:11455606	C/G	cg00044050	chr16:11439710	C16orf75	0.81	5.53	0.49	2.82e-7	HDL cholesterol;
THYM	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg23815491	chr16:72088622	HP	0.68	5.23	0.47	1.01e-6	Fibrinogen levels;
THYM	cis	rs9527	0.590	rs1807298	chr10:104870218	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg10164272	chr16:89456328	ANKRD11	0.6	4.58	0.43	1.42e-5	Multiple myeloma (IgH translocation);
THYM	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg13918804	chr1:2043761	PRKCZ	0.88	8.76	0.67	7.5e-14	Height;
THYM	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg23791538	chr6:167370224	RNASET2	0.77	6.12	0.53	2.1e-8	Crohn's disease;
THYM	cis	rs79349575	0.783	rs28409394	chr17:46998118	T/C	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs559928	0.576	rs750830	chr11:64163446	G/A	cg00022866	chr11:64108440	CCDC88B	0.6	4.45	0.42	2.36e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg12935359	chr14:103987150	CKB	-0.65	-6.4	-0.55	5.78e-9	Body mass index;
THYM	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs7849270	1.000	rs3124513	chr9:131904593	C/T	cg14069949	chr9:131965419	NA	-0.5	-4.52	-0.42	1.8e-5	Blood metabolite ratios;
THYM	trans	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg26043149	chr18:55253948	FECH	1.16	10.82	0.74	2.98e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs6430585	0.528	rs6743537	chr2:136702601	C/T	cg04750100	chr2:136595281	LCT	0.5	4.53	0.42	1.71e-5	Corneal structure;
THYM	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg10792982	chr14:105748885	BRF1	0.7	7.07	0.59	2.55e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg16680214	chr1:154839983	KCNN3	-0.49	-5.76	-0.51	1.05e-7	Prostate cancer;
THYM	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.97	8.79	0.67	6.29e-14	Chronic sinus infection;
THYM	cis	rs7772486	0.790	rs2814880	chr6:146208937	T/G	cg13319975	chr6:146136371	FBXO30	-0.74	-6.33	-0.54	7.91e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11608355	0.960	rs10774691	chr12:109859830	C/T	cg10504392	chr12:110044639	NA	0.67	6.21	0.54	1.41e-8	Neuroticism;
THYM	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg12310025	chr6:25882481	NA	-0.92	-8.34	-0.65	5.62e-13	Blood metabolite levels;
THYM	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg13395646	chr4:1353034	KIAA1530	0.62	5.54	0.49	2.73e-7	Obesity-related traits;
THYM	cis	rs55728055	0.661	rs1018488	chr22:31992376	A/G	cg01338084	chr22:32026380	PISD	1.39	6.92	0.58	5.23e-10	Age-related hearing impairment;
THYM	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg21658235	chr8:22456391	C8orf58	0.47	4.69	0.43	9.2e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs57994353	0.828	rs35135227	chr9:139385099	C/T	cg14115884	chr9:139300582	SDCCAG3	0.73	5.05	0.46	2.11e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs60871478	0.735	rs4721306	chr7:839098	C/T	cg10248100	chr7:872053	UNC84A	0.72	4.61	0.43	1.27e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg07061783	chr6:25882402	NA	-0.9	-8.09	-0.64	1.98e-12	Intelligence (multi-trait analysis);
THYM	cis	rs11605275	1.000	rs74809393	chr11:20031520	C/A	cg14835545	chr11:20032148	NAV2	-1.38	-7.35	-0.6	7e-11	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg26384229	chr12:38710491	ALG10B	-0.91	-7.44	-0.61	4.4e-11	Morning vs. evening chronotype;
THYM	cis	rs236907	0.859	rs2143369	chr1:171767372	A/G	cg20598894	chr1:171756153	METTL13	-0.74	-5.59	-0.5	2.16e-7	Mean platelet volume;
THYM	cis	rs6500395	1.000	rs4517800	chr16:48677404	T/A	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7560272	0.723	rs2421548	chr2:73641240	A/G	cg19565262	chr2:73869966	NAT8	0.64	5.07	0.46	1.96e-6	Schizophrenia;
THYM	cis	rs7119	0.700	rs2867311	chr15:77902191	A/C	cg27398640	chr15:77910606	LINGO1	0.66	8.96	0.68	2.79e-14	Type 2 diabetes;
THYM	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg24209194	chr3:40518798	ZNF619	-0.73	-6.19	-0.54	1.54e-8	Renal cell carcinoma;
THYM	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg21963583	chr11:68658836	MRPL21	0.32	4.51	0.42	1.86e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs3008870	1.000	rs2815351	chr1:67477980	A/G	cg02640540	chr1:67518911	SLC35D1	0.65	4.68	0.43	9.49e-6	Lymphocyte percentage of white cells;
THYM	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg13010199	chr12:38710504	ALG10B	-0.66	-4.78	-0.44	6.27e-6	Bladder cancer;
THYM	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs74417235	0.639	rs2396994	chr5:154052750	A/T	cg07371521	chr5:154026371	NA	-0.58	-5.6	-0.5	2.04e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.58	5.03	0.46	2.3e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg18105134	chr13:113819100	PROZ	-0.99	-9.19	-0.69	8.83e-15	Platelet distribution width;
THYM	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs138918	0.967	rs105585	chr22:43557492	G/A	cg02233750	chr22:43539658	MCAT	0.56	4.87	0.45	4.39e-6	Monocyte count;
THYM	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg03405983	chr8:143858548	LYNX1	-0.53	-5.69	-0.5	1.4e-7	Urinary tract infection frequency;
THYM	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	6.88	0.58	6.35e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg08847533	chr14:75593920	NEK9	1.04	11.72	0.77	3.75e-20	Height;
THYM	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg07362569	chr17:61921086	SMARCD2	0.69	6.16	0.53	1.78e-8	Prudent dietary pattern;
THYM	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg02753203	chr1:228287806	NA	0.74	6.44	0.55	4.87e-9	Diastolic blood pressure;
THYM	cis	rs1788820	0.917	rs1788826	chr18:21154024	G/A	cg14672496	chr18:21087552	C18orf8	0.82	6.62	0.56	2.11e-9	Body mass index;
THYM	cis	rs13064411	0.696	rs9814395	chr3:113188885	C/T	cg10517650	chr3:113235015	CCDC52	-0.56	-4.99	-0.46	2.74e-6	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-4.79	-0.44	6.17e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg11266682	chr4:10021025	SLC2A9	-0.68	-9.74	-0.71	5.95e-16	Bone mineral density;
THYM	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg10295955	chr4:187884368	NA	1.21	16.87	0.87	2.45e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs736801	0.521	rs41525648	chr5:131827775	A/G	cg00255919	chr5:131827918	IRF1	-0.51	-6.54	-0.56	3.03e-9	Breast cancer;Mosquito bite size;
THYM	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs6450176	0.625	rs11747281	chr5:53289047	G/A	ch.5.1024479R	chr5:53302184	ARL15	-1.01	-8.07	-0.64	2.17e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs12042938	0.507	rs1765777	chr1:231731742	C/T	cg04892437	chr1:231737901	TSNAX-DISC1	-0.48	-4.59	-0.43	1.36e-5	Neuranatomic and neurocognitive phenotypes;
THYM	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Body mass index;
THYM	cis	rs1451375	0.698	rs68143668	chr7:50638110	C/T	cg18232548	chr7:50535776	DDC	0.69	5.34	0.48	6.39e-7	Malaria;
THYM	cis	rs72712511	0.571	rs10027514	chr4:140765578	C/G	cg15010390	chr4:140216957	NDUFC1	0.63	4.81	0.44	5.63e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11771526	0.686	rs62457501	chr7:32329946	A/G	cg27532318	chr7:32358331	NA	0.75	4.82	0.44	5.35e-6	Body mass index;
THYM	cis	rs4363385	0.747	rs946097	chr1:152974732	A/G	cg13444842	chr1:152974279	SPRR3	-0.6	-4.78	-0.44	6.32e-6	Inflammatory skin disease;
THYM	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg22709100	chr7:91322751	NA	0.6	4.74	0.44	7.58e-6	Breast cancer;
THYM	cis	rs711830	0.965	rs2857532	chr2:177033283	A/G	cg13092806	chr2:177043255	NA	0.59	4.49	0.42	1.99e-5	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs62103177	0.525	rs612913	chr18:77845882	A/G	cg07235805	chr18:78004237	PARD6G	-0.48	-5.47	-0.49	3.62e-7	Opioid sensitivity;
THYM	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg04025307	chr7:1156635	C7orf50	0.57	5.0	0.46	2.58e-6	Longevity;Endometriosis;
THYM	cis	rs600806	0.850	rs7518013	chr1:109944078	C/T	cg23616212	chr1:109941201	SORT1	0.5	4.78	0.44	6.34e-6	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs1113500	1.000	rs1777483	chr1:108609408	A/C	cg06207961	chr1:108661230	NA	-0.71	-5.81	-0.51	8.13e-8	Growth-regulated protein alpha levels;
THYM	cis	rs939574	0.720	rs6714820	chr2:220071803	C/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.2	-5.46	-0.49	3.84e-7	Platelet distribution width;
THYM	cis	rs2820651	0.614	rs56368317	chr10:1490983	G/A	cg13720710	chr10:1452970	ADARB2	0.79	5.03	0.46	2.28e-6	Migraine with aura;
THYM	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs11112613	0.713	rs17041546	chr12:105950801	G/T	cg03607813	chr12:105948248	NA	-1.03	-8.8	-0.67	5.93e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg12560992	chr17:57184187	TRIM37	-0.87	-7.5	-0.61	3.41e-11	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg13695892	chr22:41940480	POLR3H	-0.85	-6.16	-0.53	1.72e-8	Vitiligo;
THYM	cis	rs4731207	0.671	rs10085867	chr7:124486168	T/C	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg06558623	chr16:89946397	TCF25	1.5	7.17	0.59	1.64e-10	Skin colour saturation;
THYM	cis	rs9361491	0.608	rs4706724	chr6:79462821	G/A	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg24209194	chr3:40518798	ZNF619	0.58	4.79	0.44	6.12e-6	Renal cell carcinoma;
THYM	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg01579765	chr21:45077557	HSF2BP	-0.46	-6.98	-0.58	4.02e-10	Mean corpuscular volume;
THYM	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.85	7.05	0.59	2.87e-10	Systemic lupus erythematosus;
THYM	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg11266682	chr4:10021025	SLC2A9	-0.63	-7.73	-0.62	1.09e-11	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg21028142	chr17:79581711	NPLOC4	0.62	6.13	0.53	1.96e-8	Eye color traits;
THYM	cis	rs10484885	0.775	rs17584945	chr6:90512776	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.87	-7.73	-0.62	1.13e-11	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11890956	chr21:40555474	PSMG1	0.68	5.44	0.49	4.16e-7	Cognitive function;
THYM	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg05717871	chr11:638507	DRD4	-0.69	-6.03	-0.53	3.1e-8	Systemic lupus erythematosus;
THYM	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg00898013	chr13:113819073	PROZ	0.88	8.78	0.67	6.63e-14	Platelet distribution width;
THYM	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg12310025	chr6:25882481	NA	-0.66	-4.58	-0.43	1.4e-5	Height;
THYM	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg23281280	chr6:28129359	ZNF389	0.61	4.94	0.45	3.3e-6	Depression;
THYM	cis	rs7394190	0.748	rs2292307	chr10:75549916	C/A	cg07699608	chr10:75541558	CHCHD1	0.96	5.1	0.46	1.77e-6	Incident atrial fibrillation;
THYM	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg13695892	chr22:41940480	POLR3H	-0.94	-7.71	-0.62	1.24e-11	Vitiligo;
THYM	cis	rs2554380	1.000	rs2730076	chr15:84315985	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.6	-4.65	-0.43	1.05e-5	Height;
THYM	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg21784768	chr11:537496	LRRC56	-1.09	-5.51	-0.49	3.01e-7	Body mass index;
THYM	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg05347473	chr6:146136440	FBXO30	0.61	4.95	0.45	3.24e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10823500	0.748	rs7072230	chr10:71978144	A/G	cg02100629	chr10:71892760	AIFM2	-0.37	-4.46	-0.42	2.27e-5	Blood protein levels;
THYM	cis	rs868036	0.561	rs28376697	chr15:68140315	A/G	cg24579218	chr15:68104479	NA	-0.75	-6.38	-0.55	6.33e-9	Restless legs syndrome;
THYM	cis	rs7843479	0.509	rs899428	chr8:21770763	T/C	cg17168535	chr8:21777572	XPO7	0.83	7.24	0.6	1.15e-10	Mean corpuscular volume;
THYM	cis	rs708547	0.647	rs781668	chr4:57825140	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	0.54	4.58	0.43	1.4e-5	Response to bleomycin (chromatid breaks);
THYM	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg06027949	chr8:82754900	SNX16	-0.64	-5.35	-0.48	6.18e-7	Diastolic blood pressure;
THYM	cis	rs714027	0.605	rs193475	chr22:30450492	T/C	cg27665648	chr22:30112403	NA	-0.52	-4.74	-0.44	7.57e-6	Lymphocyte counts;
THYM	cis	rs7814319	1.000	rs6468495	chr8:97259953	C/A	cg20787634	chr8:97240163	UQCRB	-0.74	-7.89	-0.63	5.1e-12	Lung function (FVC);
THYM	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg17063962	chr7:91808500	NA	1.13	12.47	0.79	1.03e-21	Breast cancer;
THYM	cis	rs3204270	0.759	rs77740144	chr17:79608968	G/A	cg18367735	chr17:79674897	NA	0.8	4.8	0.44	5.82e-6	Dental caries;
THYM	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg18032289	chr17:61959525	GH2	-0.5	-4.84	-0.44	5.07e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	5.52	0.49	2.88e-7	Hip circumference adjusted for BMI;
THYM	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs11249608	0.548	rs13161528	chr5:178452958	C/G	cg01312482	chr5:178451176	ZNF879	-0.76	-6.3	-0.54	9.29e-9	Pubertal anthropometrics;
THYM	cis	rs35883536	0.647	rs34195036	chr1:101040429	C/A	cg09408571	chr1:101003634	GPR88	-0.51	-5.54	-0.49	2.68e-7	Monocyte count;
THYM	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-6.01	-0.53	3.35e-8	Mood instability;
THYM	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg13866156	chr1:1669148	SLC35E2	-0.73	-7.29	-0.6	9.26e-11	Body mass index;
THYM	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg00898013	chr13:113819073	PROZ	0.91	8.96	0.68	2.79e-14	Platelet distribution width;
THYM	cis	rs8180040	0.871	rs11716661	chr3:47517773	G/T	cg02527881	chr3:46936655	PTH1R	0.52	4.96	0.45	3.08e-6	Colorectal cancer;
THYM	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg24642439	chr20:33292090	TP53INP2	0.68	5.17	0.47	1.31e-6	Coronary artery disease;
THYM	trans	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg23505145	chr19:12996616	KLF1	1.04	10.24	0.72	5.19e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.75	-5.41	-0.49	4.72e-7	Body mass index;
THYM	cis	rs12049351	0.613	rs7514990	chr1:229581166	T/C	cg11742688	chr1:229674241	ABCB10	-0.55	-4.62	-0.43	1.2e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg26031613	chr14:104095156	KLC1	0.78	5.2	0.47	1.14e-6	Body mass index;
THYM	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg22105103	chr4:187893119	NA	-0.91	-9.67	-0.7	8.51e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7426056	0.671	rs13390252	chr2:204596729	A/G	cg07930752	chr2:204569955	CD28	-0.66	-4.52	-0.42	1.81e-5	Primary sclerosing cholangitis;
THYM	cis	rs904251	0.828	rs2797803	chr6:37487340	T/C	cg01843034	chr6:37503916	NA	-0.68	-4.97	-0.45	2.9e-6	Cognitive performance;
THYM	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.89	0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg08017756	chr2:100939284	LONRF2	-0.75	-7.8	-0.62	7.89e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9902453	0.845	rs58575982	chr17:28221776	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.64	0.43	1.11e-5	Coffee consumption (cups per day);
THYM	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg14196790	chr5:131705035	SLC22A5	0.51	4.78	0.44	6.26e-6	Breast cancer;Mosquito bite size;
THYM	cis	rs3540	0.597	rs4620932	chr15:91036569	G/A	cg22089800	chr15:90895588	ZNF774	0.69	5.41	0.49	4.77e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg18252515	chr7:66147081	NA	-0.72	-5.6	-0.5	2.03e-7	Aortic root size;
THYM	cis	rs78062588	1.000	rs73001418	chr1:154585594	T/A	cg13098855	chr1:153588927	S100A14	0.58	4.67	0.43	1e-5	Lung cancer;
THYM	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26314531	chr2:26401878	FAM59B	-0.77	-5.03	-0.46	2.27e-6	Gut microbiome composition (summer);
THYM	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg06221963	chr1:154839813	KCNN3	-0.87	-10.89	-0.75	2.07e-18	Prostate cancer;
THYM	cis	rs3825942	1.000	rs1550437	chr15:74221298	A/G	cg01349856	chr15:74220517	LOXL1	-0.65	-4.49	-0.42	2.04e-5	Glaucoma (exfoliation);
THYM	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg12863693	chr15:85201151	NMB	0.62	5.39	0.48	5.18e-7	Schizophrenia;
THYM	cis	rs9876781	1.000	rs6810060	chr3:48434748	T/C	cg06066452	chr3:48470258	PLXNB1	0.25	4.74	0.44	7.42e-6	Longevity;
THYM	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.86	0.74	2.46e-18	Chronic sinus infection;
THYM	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	4.83	0.44	5.26e-6	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3862030	0.720	rs3740414	chr10:104232809	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.71	-5.96	-0.52	4.3e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg26149184	chr10:133730230	NA	0.82	5.1	0.46	1.76e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs7851660	0.870	rs1867278	chr9:100615949	C/A	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs1003719	0.788	rs4411798	chr21:38453183	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.67	4.61	0.43	1.25e-5	Eye color traits;
THYM	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg26038318	chr20:34205095	SPAG4	0.65	5.22	0.47	1.04e-6	Total cholesterol levels;
THYM	cis	rs12478296	1.000	rs55758933	chr2:243040289	T/C	cg06360820	chr2:242988706	NA	-0.87	-5.42	-0.49	4.53e-7	Obesity-related traits;
THYM	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.69e-11	Aortic root size;
THYM	cis	rs34638657	0.732	rs11645372	chr16:82202136	C/T	cg09439754	chr16:82129088	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	cis	rs4803468	0.935	rs284660	chr19:41932084	G/T	cg09537434	chr19:41945824	ATP5SL	-1.08	-9.74	-0.71	5.82e-16	Height;
THYM	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg05738196	chr6:26577821	NA	0.95	9.89	0.71	2.78e-16	Intelligence (multi-trait analysis);
THYM	cis	rs2458413	0.521	rs2458427	chr8:105339594	G/T	cg13045555	chr8:105342365	NA	-0.34	-6.52	-0.56	3.36e-9	Paget's disease;
THYM	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg11663144	chr21:46675770	NA	-0.71	-8.52	-0.66	2.34e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7224314	1.000	rs57672368	chr17:65358688	G/C	cg01507342	chr17:65387096	PITPNC1	-0.83	-8.24	-0.65	9.52e-13	Diisocyanate-induced asthma;
THYM	cis	rs13315871	0.929	rs7643185	chr3:58311158	A/C	cg00563845	chr3:58318305	PXK	-0.56	-5.26	-0.47	8.95e-7	Cholesterol, total;
THYM	cis	rs11760633	0.747	rs11765289	chr7:1833097	C/G	cg13880726	chr7:1868755	MAD1L1	-0.7	-4.83	-0.44	5.25e-6	Coronary artery disease;
THYM	cis	rs1161098	0.625	rs6581756	chr12:67811632	T/C	cg20473420	chr12:67782441	NA	1.0	5.82	0.51	7.97e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg14664628	chr15:75095509	CSK	-1.16	-10.28	-0.73	4.11e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs1971256	0.563	rs74798609	chr6:151792026	T/C	cg24322333	chr6:151646584	AKAP12	0.84	4.94	0.45	3.33e-6	Endometriosis;
THYM	cis	rs9858542	0.537	rs9818758	chr3:49382925	G/A	cg00383909	chr3:49044727	WDR6	0.77	5.05	0.46	2.16e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06481639	chr22:41940642	POLR3H	-0.87	-5.94	-0.52	4.65e-8	Vitiligo;
THYM	cis	rs11096990	0.634	rs1564710	chr4:39292798	G/T	cg24403649	chr4:39172243	NA	-0.64	-5.48	-0.49	3.43e-7	Cognitive function;
THYM	cis	rs12257961	0.675	rs7086171	chr10:15348034	C/T	cg10616319	chr10:15468812	NA	-0.61	-5.02	-0.46	2.4e-6	Selective IgA deficiency;
THYM	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg00310523	chr12:86230176	RASSF9	0.56	4.94	0.45	3.29e-6	Major depressive disorder;
THYM	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg19761014	chr17:28927070	LRRC37B2	0.7	4.47	0.42	2.12e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs73086581	0.945	rs6037715	chr20:3972166	A/T	cg02187196	chr20:3869020	PANK2	0.5	5.62	0.5	1.92e-7	Response to antidepressants in depression;
THYM	cis	rs9796	0.775	rs57393155	chr15:41426251	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.58	-4.74	-0.44	7.44e-6	Menopause (age at onset);
THYM	trans	rs877282	0.786	rs10904558	chr10:797509	C/T	cg22713356	chr15:30763199	NA	1.38	11.62	0.77	6.17e-20	Uric acid levels;
THYM	cis	rs1823778	0.609	rs4891794	chr18:67611543	G/A	cg13164537	chr18:67624071	CD226	1.15	4.8	0.44	5.83e-6	Mean platelet volume;
THYM	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg03709012	chr19:19516395	GATAD2A	1.05	6.22	0.54	1.34e-8	Nonalcoholic fatty liver disease;
THYM	cis	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg07460842	chr6:66804631	NA	-1.23	-15.27	-0.84	2.58e-27	Exhaled nitric oxide output;
THYM	cis	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg07460842	chr6:66804631	NA	1.13	7.99	0.63	3.12e-12	Exhaled nitric oxide output;
THYM	cis	rs9393692	0.620	rs9358927	chr6:26330492	T/G	cg00631329	chr6:26305371	NA	-0.45	-4.53	-0.42	1.72e-5	Educational attainment;
THYM	cis	rs1348850	0.554	rs7595576	chr2:178371921	C/T	cg27490568	chr2:178487706	NA	0.66	5.31	0.48	7.1e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs11031096	0.502	rs720571	chr11:4001328	G/T	cg18678763	chr11:4115507	RRM1	-0.45	-5.92	-0.52	5.06e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg24955955	chr5:415729	AHRR	1.03	5.9	0.52	5.62e-8	Fat distribution (HIV);
THYM	cis	rs7681440	0.583	rs2165614	chr4:90805724	A/C	cg06632027	chr4:90757378	SNCA	-0.62	-4.84	-0.44	4.97e-6	Dementia with Lewy bodies;
THYM	cis	rs3849570	0.695	rs6804587	chr3:81873423	T/C	cg07356753	chr3:81810745	GBE1	-0.84	-6.42	-0.55	5.45e-9	Waist circumference;Body mass index;
THYM	cis	rs7582180	0.676	rs1437969	chr2:100983482	A/C	cg14675211	chr2:100938903	LONRF2	0.6	5.68	0.5	1.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2637266	1.000	rs7905033	chr10:78368212	A/C	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs240764	0.595	rs1039033	chr6:101191397	C/T	cg21058520	chr6:100914733	NA	0.66	5.73	0.51	1.17e-7	Neuroticism;
THYM	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg00080972	chr5:178986291	RUFY1	0.57	7.35	0.6	6.84e-11	Lung cancer;
THYM	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg11266682	chr4:10021025	SLC2A9	-0.62	-7.75	-0.62	1e-11	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg10518543	chr12:38710700	ALG10B	-0.59	-4.67	-0.43	9.89e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg03709012	chr19:19516395	GATAD2A	0.84	7.3	0.6	8.83e-11	Tonsillectomy;
THYM	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg22852734	chr6:133119734	C6orf192	1.29	7.8	0.62	7.96e-12	Type 2 diabetes nephropathy;
THYM	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg24578937	chr1:2090814	PRKCZ	-0.58	-6.21	-0.54	1.37e-8	Height;
THYM	cis	rs10779751	1.000	rs1135172	chr1:11301714	C/T	cg08854313	chr1:11322531	MTOR	-1.0	-8.88	-0.67	4.07e-14	Body mass index;
THYM	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg22907277	chr7:1156413	C7orf50	0.72	6.19	0.54	1.54e-8	Longevity;Endometriosis;
THYM	cis	rs72827839	0.779	rs59386258	chr17:46499918	T/C	cg23391107	chr17:45924227	SP6	0.86	5.55	0.5	2.54e-7	Ease of getting up in the morning;
THYM	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg27490568	chr2:178487706	NA	0.63	5.61	0.5	1.97e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg10515332	chr4:99064459	C4orf37	0.72	5.76	0.51	1.01e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg08017756	chr2:100939284	LONRF2	-0.75	-7.8	-0.62	7.89e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	10.09	0.72	1.05e-16	Platelet count;
THYM	cis	rs2354432	0.556	rs885305	chr1:146786080	G/A	cg25205988	chr1:146714368	CHD1L	-1.03	-5.4	-0.48	4.84e-7	Mitochondrial DNA levels;
THYM	cis	rs2997447	0.761	rs61776575	chr1:26429844	G/A	cg03844060	chr1:26490628	NA	0.7	4.82	0.44	5.34e-6	QRS complex (12-leadsum);
THYM	cis	rs72848980	0.512	rs12359556	chr10:105390677	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.54	5.0	0.46	2.65e-6	White matter hyperintensity burden;
THYM	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs3772130	0.962	rs6789736	chr3:121543084	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs4888262	0.508	rs4888258	chr16:74634198	G/T	cg01733217	chr16:74700730	RFWD3	0.81	8.17	0.64	1.33e-12	Testicular germ cell tumor;
THYM	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg11266682	chr4:10021025	SLC2A9	-0.66	-9.07	-0.68	1.62e-14	Bone mineral density;
THYM	cis	rs995000	0.839	rs1168034	chr1:62963914	G/C	cg06896770	chr1:63153194	DOCK7	-0.94	-7.73	-0.62	1.11e-11	Triglyceride levels;
THYM	cis	rs1395	0.922	rs1561535	chr2:27471025	C/T	cg23587288	chr2:27483067	SLC30A3	-0.58	-5.22	-0.47	1.05e-6	Blood metabolite levels;
THYM	cis	rs7647854	0.502	rs62289842	chr3:184875082	T/C	cg03981074	chr3:183959062	VWA5B2;MIR1224	0.71	4.59	0.43	1.37e-5	Major depressive disorder;
THYM	cis	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg08045932	chr20:61659980	NA	-0.96	-10.53	-0.73	1.21e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7681440	0.583	rs2619339	chr4:90777468	G/C	cg06632027	chr4:90757378	SNCA	-0.66	-5.29	-0.48	7.91e-7	Dementia with Lewy bodies;
THYM	cis	rs28374715	0.733	rs7167706	chr15:41569644	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.21	-12.06	-0.78	7.38e-21	Ulcerative colitis;
THYM	cis	rs9420	0.528	rs7117896	chr11:57388551	G/A	cg19752551	chr11:57585705	CTNND1	-0.58	-5.17	-0.47	1.3e-6	Schizophrenia;
THYM	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg05738196	chr6:26577821	NA	-0.91	-9.17	-0.69	9.75e-15	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg25072359	chr17:41440525	NA	0.65	4.56	0.42	1.5e-5	Menopause (age at onset);
THYM	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-4.87	-0.45	4.47e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6430585	0.646	rs12476116	chr2:136497199	A/G	cg04750100	chr2:136595281	LCT	0.51	4.56	0.42	1.5e-5	Corneal structure;
THYM	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg02734326	chr4:10020555	SLC2A9	-0.71	-6.2	-0.54	1.44e-8	Bone mineral density;
THYM	cis	rs7267979	0.816	rs3746337	chr20:25208272	C/T	cg08601574	chr20:25228251	PYGB	0.66	5.27	0.48	8.49e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg09085632	chr11:111637200	PPP2R1B	-0.93	-8.52	-0.66	2.4e-13	Primary sclerosing cholangitis;
THYM	cis	rs7084402	0.967	rs1626606	chr10:60328088	C/T	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs747334	0.653	rs11186372	chr10:92701773	C/T	cg07620928	chr10:92689909	NA	0.52	4.51	0.42	1.86e-5	Fibroblast growth factor basic levels;
THYM	cis	rs6840360	0.533	rs11099829	chr4:152727299	A/G	cg22705602	chr4:152727874	NA	0.77	9.93	0.71	2.36e-16	Intelligence (multi-trait analysis);
THYM	cis	rs4523957	0.820	rs57307236	chr17:2159502	A/G	cg16513277	chr17:2031491	SMG6	-0.76	-6.56	-0.56	2.75e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2227564	0.700	rs12413039	chr10:75524759	C/G	cg00564723	chr10:75632066	CAMK2G	0.52	4.61	0.43	1.23e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6499255	0.951	rs8054096	chr16:69695886	G/A	cg00738113	chr16:70207722	CLEC18C	-0.44	-4.57	-0.42	1.45e-5	IgE levels;
THYM	cis	rs11096990	0.634	rs12648793	chr4:39286093	T/C	cg24403649	chr4:39172243	NA	-0.66	-5.7	-0.51	1.32e-7	Cognitive function;
THYM	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg24578937	chr1:2090814	PRKCZ	-0.59	-5.88	-0.52	6.22e-8	Height;
THYM	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg11644478	chr21:40555479	PSMG1	0.95	7.08	0.59	2.45e-10	Cognitive function;
THYM	cis	rs240764	0.817	rs239239	chr6:101094554	A/G	cg21058520	chr6:100914733	NA	-0.57	-5.06	-0.46	2.04e-6	Neuroticism;
THYM	cis	rs9296092	0.538	rs75082458	chr6:33524792	C/T	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs9788721	0.836	rs2656052	chr15:78740932	A/C	cg18825076	chr15:78729989	IREB2	-0.66	-6.33	-0.54	8.02e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs4242434	0.927	rs10099846	chr8:22534178	C/T	cg03733263	chr8:22462867	KIAA1967	-1.13	-10.68	-0.74	5.8e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22857025	chr5:266934	NA	-1.57	-9.68	-0.7	8.05e-16	Breast cancer;
THYM	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs36051895	0.559	rs72701682	chr9:5208025	A/G	cg02405213	chr9:5042618	JAK2	-0.91	-8.85	-0.67	4.85e-14	Pediatric autoimmune diseases;
THYM	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg10589385	chr1:150898437	SETDB1	0.58	4.81	0.44	5.55e-6	Melanoma;
THYM	cis	rs2637266	0.655	rs846584	chr10:78495419	G/A	cg18941641	chr10:78392320	NA	0.74	5.86	0.52	6.6e-8	Pulmonary function;
THYM	cis	rs13223928	0.621	rs4722438	chr7:3155813	A/G	cg19214707	chr7:3157722	NA	0.85	7.31	0.6	8.38e-11	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11264213	0.901	rs620956	chr1:36362162	T/C	cg27506609	chr1:36549197	TEKT2	0.92	4.83	0.44	5.3e-6	Schizophrenia;
THYM	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg13289132	chr10:30722225	MAP3K8	0.6	5.18	0.47	1.25e-6	Inflammatory bowel disease;
THYM	cis	rs1933112	1.000	rs1323534	chr1:168503277	A/C	cg17186328	chr1:168545835	XCL1	-0.58	-4.72	-0.44	8.07e-6	Blood protein levels;
THYM	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.72	-5.68	-0.5	1.44e-7	Blood protein levels;
THYM	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg14829155	chr15:31115871	NA	-0.57	-4.99	-0.46	2.76e-6	Huntington's disease progression;
THYM	cis	rs10929159	0.928	rs7598567	chr2:236920673	A/G	cg20128773	chr2:236923534	AGAP1	0.35	4.62	0.43	1.23e-5	Parkinson's disease;
THYM	cis	rs4792901	0.759	rs1382685	chr17:41563151	G/A	cg21940313	chr17:41620911	ETV4	-0.55	-5.3	-0.48	7.47e-7	Dupuytren's disease;
THYM	cis	rs4654899	0.865	rs61779120	chr1:21481230	T/C	cg01072550	chr1:21505969	NA	-0.75	-6.56	-0.56	2.79e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs4845875	0.626	rs4845882	chr1:11843167	A/G	cg25341925	chr1:11908058	NPPA	0.42	4.47	0.42	2.18e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs7809950	0.906	rs2253269	chr7:107201114	C/T	cg23024343	chr7:107201750	COG5	-0.94	-8.66	-0.66	1.21e-13	Coronary artery disease;
THYM	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs2663905	0.611	rs2663924	chr15:81392903	T/G	cg05624577	chr15:81411055	NA	-0.71	-5.48	-0.49	3.56e-7	QT interval (drug interaction);
THYM	cis	rs2997447	0.761	rs61776586	chr1:26438933	T/C	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs870825	0.616	rs4443323	chr4:185629805	C/A	cg04058563	chr4:185651563	MLF1IP	1.16	9.67	0.7	8.28e-16	Blood protein levels;
THYM	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg16325326	chr1:53192061	ZYG11B	-0.83	-8.54	-0.66	2.21e-13	Monocyte count;
THYM	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg07570687	chr10:102243282	WNT8B	0.76	6.9	0.58	5.82e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1401999	0.714	rs13066518	chr3:183635498	T/A	cg20387954	chr3:183756860	HTR3D	0.52	5.11	0.46	1.68e-6	Anterior chamber depth;
THYM	cis	rs7914558	0.902	rs3736922	chr10:104850632	A/G	cg08772003	chr10:104629869	AS3MT	0.52	4.62	0.43	1.2e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg15448220	chr1:150897856	SETDB1	0.86	6.94	0.58	4.73e-10	Melanoma;
THYM	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg22467129	chr15:76604101	ETFA	-0.5	-4.94	-0.45	3.32e-6	Blood metabolite levels;
THYM	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg25251562	chr2:3704773	ALLC	0.8	5.2	0.47	1.12e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs2282300	0.739	rs1222216	chr11:30346052	C/T	cg09906309	chr11:30344399	C11orf46	-0.73	-5.37	-0.48	5.47e-7	Morning vs. evening chronotype;
THYM	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg25072359	chr17:41440525	NA	0.64	4.48	0.42	2.05e-5	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg02038168	chr22:39784481	NA	-0.65	-5.3	-0.48	7.52e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7614311	0.681	rs73130565	chr3:63887135	T/C	cg22134162	chr3:63841271	THOC7	-0.58	-7.03	-0.59	3.13e-10	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs6596100	0.538	rs17594964	chr5:132188712	A/G	cg02081065	chr5:132209139	LEAP2	-0.95	-6.14	-0.53	1.87e-8	Breast cancer;
THYM	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.69	-4.54	-0.42	1.63e-5	Menarche (age at onset);
THYM	cis	rs11048434	0.636	rs7306161	chr12:9059075	T/A	cg13575925	chr12:9217583	LOC144571	0.52	4.72	0.44	8.1e-6	Sjögren's syndrome;
THYM	trans	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg10856724	chr12:34555212	NA	-0.87	-7.55	-0.61	2.65e-11	Bladder cancer;
THYM	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg25918947	chr17:41365094	TMEM106A	-0.62	-5.22	-0.47	1.05e-6	Menopause (age at onset);
THYM	cis	rs41264869	0.760	rs12042196	chr1:205157759	A/G	cg15542880	chr1:205114634	DSTYK	0.54	4.59	0.43	1.37e-5	Blood protein levels;
THYM	cis	rs400736	0.930	rs370812	chr1:8075894	C/T	cg22678073	chr1:8087421	ERRFI1	0.45	4.79	0.44	6.13e-6	Response to antidepressants and depression;
THYM	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs288326	0.561	rs79096460	chr2:183798677	A/G	cg09997497	chr2:183902928	NCKAP1	1.24	5.46	0.49	3.86e-7	Blood protein levels;
THYM	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg08213375	chr14:104286397	PPP1R13B	0.5	6.09	0.53	2.39e-8	Schizophrenia;
THYM	cis	rs752010	0.619	rs6702659	chr1:42112236	T/C	cg06885757	chr1:42089581	HIVEP3	0.69	9.66	0.7	8.74e-16	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs2070677	0.935	rs12256349	chr10:135409632	G/A	cg20169779	chr10:135381914	SYCE1	-0.76	-5.95	-0.52	4.55e-8	Gout;
THYM	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg26384229	chr12:38710491	ALG10B	-0.72	-5.64	-0.5	1.75e-7	Morning vs. evening chronotype;
THYM	cis	rs62103177	0.683	rs62101232	chr18:77722454	T/C	cg07235805	chr18:78004237	PARD6G	0.44	4.9	0.45	3.91e-6	Opioid sensitivity;
THYM	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs6032067	0.673	rs2301366	chr20:43836173	T/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.37	-0.48	5.59e-7	Blood protein levels;
THYM	cis	rs8038465	0.622	rs62004587	chr15:73859016	A/C	cg15420318	chr15:73925796	NPTN	0.6	5.18	0.47	1.24e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2295359	0.824	rs11209003	chr1:67601132	G/T	cg12940439	chr1:67600707	NA	0.54	4.77	0.44	6.58e-6	Psoriasis;
THYM	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg13944838	chr5:179740914	GFPT2	-0.94	-6.96	-0.58	4.26e-10	Height;
THYM	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg21433313	chr16:3507492	NAT15	0.57	4.69	0.43	9.14e-6	Body mass index (adult);
THYM	cis	rs28595532	0.920	rs56027489	chr4:119780882	A/G	cg11846333	chr4:119757529	SEC24D	1.36	4.83	0.44	5.31e-6	Cannabis dependence symptom count;
THYM	cis	rs61931739	0.534	rs1352207	chr12:34036862	C/T	cg10856724	chr12:34555212	NA	0.78	7.22	0.6	1.27e-10	Morning vs. evening chronotype;
THYM	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg18252515	chr7:66147081	NA	0.67	5.18	0.47	1.24e-6	Aortic root size;
THYM	cis	rs61931739	0.612	rs1906137	chr12:33939676	T/A	cg10856724	chr12:34555212	NA	-0.64	-5.94	-0.52	4.64e-8	Morning vs. evening chronotype;
THYM	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.11	7.46	0.61	3.98e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3741151	0.773	rs7115055	chr11:73227827	T/C	cg12959048	chr11:73096162	RELT	-0.51	-4.51	-0.42	1.87e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs3820068	0.871	rs2861484	chr1:15812665	G/T	cg05660106	chr1:15850417	CASP9	1.15	9.08	0.68	1.5e-14	Systolic blood pressure;
THYM	cis	rs10089	0.953	rs1432614	chr5:127416919	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.04	6.87	0.58	6.62e-10	Ileal carcinoids;
THYM	cis	rs7818345	0.967	rs12543061	chr8:19286181	G/T	cg11303988	chr8:19266685	CSGALNACT1	-0.43	-4.77	-0.44	6.55e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs300703	0.935	rs10193882	chr2:246301	A/T	cg21211680	chr2:198530	NA	-1.22	-5.23	-0.47	9.98e-7	Blood protein levels;
THYM	cis	rs2456568	0.741	rs2102332	chr11:93635281	G/T	cg17595323	chr11:93583763	C11orf90	-0.58	-6.09	-0.53	2.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.69	9.49	0.7	2.06e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	trans	rs8002861	0.846	rs12428112	chr13:44475821	C/A	cg17145862	chr1:211918768	LPGAT1	-0.89	-8.33	-0.65	5.95e-13	Leprosy;
THYM	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg20891283	chr12:69753455	YEATS4	0.64	5.26	0.47	8.92e-7	Blood protein levels;
THYM	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg18132916	chr6:79620363	NA	-0.58	-5.27	-0.48	8.5e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1046896	0.628	rs12452314	chr17:80723362	A/G	cg03115019	chr17:80708279	FN3K	0.64	4.54	0.42	1.66e-5	Glycated hemoglobin levels;
THYM	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg00256281	chr22:41985642	PMM1	-0.57	-4.63	-0.43	1.15e-5	Vitiligo;
THYM	trans	rs8002861	0.664	rs9533662	chr13:44435988	T/A	cg17145862	chr1:211918768	LPGAT1	0.85	7.64	0.62	1.69e-11	Leprosy;
THYM	cis	rs7236492	0.748	rs8092987	chr18:77208141	C/T	cg15644404	chr18:77186268	NFATC1	-1.06	-4.97	-0.45	2.96e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg02038168	chr22:39784481	NA	-0.62	-4.88	-0.45	4.33e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg02869364	chr7:1081709	C7orf50	-0.45	-5.13	-0.47	1.53e-6	Longevity;Endometriosis;
THYM	cis	rs255428	0.522	rs665350	chr5:62861196	G/A	cg13713523	chr5:63802877	RGS7BP	0.55	4.68	0.43	9.57e-6	Major depressive disorder;
THYM	cis	rs6424115	0.867	rs10917431	chr1:24174093	T/G	cg15997130	chr1:24165203	NA	-0.7	-5.72	-0.51	1.21e-7	Immature fraction of reticulocytes;
THYM	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg02527881	chr3:46936655	PTH1R	-0.6	-6.01	-0.52	3.48e-8	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	0.668	rs2236313	chr6:167360389	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.53	-5.69	-0.5	1.41e-7	Crohn's disease;
THYM	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg15744005	chr10:104629667	AS3MT	-0.83	-7.78	-0.62	8.71e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	trans	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg16342193	chr10:102329863	NA	-0.59	-6.2	-0.54	1.48e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg15691649	chr6:25882328	NA	0.63	4.86	0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg03354898	chr7:1950403	MAD1L1	-0.5	-4.77	-0.44	6.72e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs5769765	1.000	rs2319458	chr22:50236306	G/A	cg26441486	chr22:50317300	CRELD2	0.43	6.66	0.56	1.76e-9	Schizophrenia;
THYM	cis	rs12956009	0.518	rs983095	chr18:44899258	T/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-4.93	-0.45	3.51e-6	Educational attainment (years of education);
THYM	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg23422044	chr7:1970798	MAD1L1	-0.81	-5.38	-0.48	5.42e-7	Bipolar disorder;
THYM	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg13397359	chr6:42928475	GNMT	0.64	5.59	0.5	2.17e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg18876405	chr7:65276391	NA	0.59	4.93	0.45	3.51e-6	Aortic root size;
THYM	cis	rs6430585	0.528	rs309122	chr2:136761853	A/G	cg23851026	chr2:136556271	LCT	0.69	7.27	0.6	1.02e-10	Corneal structure;
THYM	cis	rs300703	0.935	rs4241316	chr2:252197	A/G	cg21211680	chr2:198530	NA	-1.33	-5.61	-0.5	1.97e-7	Blood protein levels;
THYM	cis	rs12889267	0.770	rs66995536	chr14:21564859	G/A	cg23374312	chr14:21565335	ZNF219	-0.77	-5.37	-0.48	5.51e-7	Hematocrit;Resting heart rate;
THYM	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg11366901	chr6:160182831	ACAT2	1.05	9.69	0.71	7.49e-16	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9649213	0.593	rs12672092	chr7:97986557	C/A	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg08807101	chr21:30365312	RNF160	0.96	8.34	0.65	5.68e-13	Dental caries;
THYM	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg18230493	chr5:56204884	C5orf35	-0.82	-5.98	-0.52	3.83e-8	Initial pursuit acceleration;
THYM	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg22968622	chr17:43663579	NA	-0.82	-7.04	-0.59	2.97e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-5.53	-0.49	2.8e-7	Prostate cancer;
THYM	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg20920097	chr3:127057149	NA	-0.7	-4.82	-0.44	5.53e-6	Interleukin-10 levels;Interleukin-13 levels;
THYM	cis	rs8135828	0.770	rs469363	chr22:29952181	C/G	cg16189954	chr22:29138267	HSCB;CHEK2	0.72	4.71	0.44	8.43e-6	Lipid traits;
THYM	cis	rs11696739	0.866	rs1535882	chr20:1600524	T/C	cg06479032	chr20:1246769	SNPH	-0.6	-4.46	-0.42	2.22e-5	Mean platelet volume;
THYM	cis	rs28595532	0.841	rs114107504	chr4:119771080	T/C	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7267979	1.000	rs6050564	chr20:25344231	G/A	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	trans	rs877282	0.898	rs11253340	chr10:764786	G/T	cg22713356	chr15:30763199	NA	1.36	10.13	0.72	8.77e-17	Uric acid levels;
THYM	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg06618935	chr21:46677482	NA	-0.94	-9.15	-0.68	1.09e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg22709100	chr7:91322751	NA	0.59	4.54	0.42	1.65e-5	Breast cancer;
THYM	cis	rs2219968	0.525	rs11994969	chr8:78871476	A/G	cg00738934	chr8:78996279	NA	0.6	4.94	0.45	3.35e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg16482183	chr6:26056742	HIST1H1C	0.82	5.32	0.48	6.78e-7	Iron status biomarkers;
THYM	cis	rs6596100	0.538	rs59682592	chr5:132196800	C/T	cg02081065	chr5:132209139	LEAP2	-0.95	-6.14	-0.53	1.87e-8	Breast cancer;
THYM	cis	rs9807841	0.790	rs1529744	chr19:10841472	T/C	cg17848348	chr19:10766748	ILF3	-0.71	-5.81	-0.51	8.38e-8	Inflammatory skin disease;
THYM	cis	rs28595532	0.920	rs114057512	chr4:119750179	G/A	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs459571	0.959	rs461462	chr9:136911272	C/T	cg13789015	chr9:136890014	NCRNA00094	0.78	6.65	0.56	1.88e-9	Platelet distribution width;
THYM	cis	rs11190604	0.767	rs3750723	chr10:102172989	T/C	cg07570687	chr10:102243282	WNT8B	0.81	7.68	0.62	1.44e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs10516089	0.504	rs10085151	chr5:171136786	A/T	cg17535961	chr5:171094783	NA	0.41	4.51	0.42	1.86e-5	Venous thromboembolism (SNP x SNP interaction);
THYM	cis	rs988913	0.706	rs6910384	chr6:54743998	G/A	cg15217784	chr6:54722227	FAM83B	-0.52	-4.6	-0.43	1.28e-5	Menarche (age at onset);
THYM	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs6687430	0.580	rs616488	chr1:10566215	A/G	cg20482658	chr1:10539492	PEX14	0.47	5.45	0.49	3.98e-7	Hand grip strength;
THYM	cis	rs8133932	0.701	rs7279887	chr21:47301148	T/C	cg08707771	chr21:46690014	POFUT2	-0.76	-4.62	-0.43	1.22e-5	Schizophrenia;
THYM	cis	rs7584330	0.554	rs74001384	chr2:238424530	T/C	cg08992911	chr2:238395768	MLPH	0.79	5.0	0.46	2.62e-6	Prostate cancer;
THYM	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg15691649	chr6:25882328	NA	-0.81	-6.55	-0.56	2.97e-9	Intelligence (multi-trait analysis);
THYM	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg07777115	chr5:623756	CEP72	0.8	4.78	0.44	6.48e-6	Obesity-related traits;
THYM	trans	rs7572644	0.551	rs12468596	chr2:28503941	C/T	cg02959759	chr12:2801584	CACNA1C	-0.51	-7.3	-0.6	8.74e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
THYM	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg06074448	chr4:187884817	NA	-1.02	-13.14	-0.8	4.26e-23	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9314614	0.933	rs2741098	chr8:6690276	C/T	cg27319216	chr8:6693540	XKR5	0.71	8.41	0.65	4.04e-13	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs1050631	0.592	rs1789548	chr18:33724296	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.32	0.48	6.94e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg13683864	chr3:40499215	RPL14	-1.05	-11.98	-0.78	1.08e-20	Renal cell carcinoma;
THYM	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02463440	chr8:22132932	PIWIL2	0.57	4.87	0.45	4.47e-6	Hypertriglyceridemia;
THYM	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg17252645	chr8:143867129	LY6D	-0.83	-10.13	-0.72	8.64e-17	Urinary tract infection frequency;
THYM	cis	rs4866334	1.000	rs6452352	chr5:18482087	C/G	cg18608440	chr5:17519013	NA	-1.07	-4.95	-0.45	3.24e-6	IgG glycosylation;
THYM	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs7772486	0.720	rs9403757	chr6:146261271	C/T	cg13319975	chr6:146136371	FBXO30	0.73	6.11	0.53	2.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6993813	0.678	rs6469792	chr8:120008371	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.57	4.54	0.42	1.65e-5	Bone mineral density (hip);
THYM	cis	rs9914544	0.564	rs9906799	chr17:18795317	A/G	cg26378065	chr17:18585709	ZNF286B	0.58	4.65	0.43	1.05e-5	Educational attainment (years of education);
THYM	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg10047753	chr17:41438598	NA	1.01	8.18	0.64	1.25e-12	Menopause (age at onset);
THYM	cis	rs616402	0.527	rs10779737	chr1:10580275	C/G	cg20482658	chr1:10539492	PEX14	-0.36	-5.32	-0.48	6.91e-7	Breast size;
THYM	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg05313129	chr8:58192883	C8orf71	-0.84	-4.83	-0.44	5.22e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg06115741	chr20:33292138	TP53INP2	0.7	4.67	0.43	9.98e-6	Coronary artery disease;
THYM	cis	rs11574514	1.000	rs117782866	chr16:68023169	G/A	cg09738193	chr16:67926317	PSKH1	-0.92	-4.53	-0.42	1.69e-5	Crohn's disease;
THYM	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg00786635	chr1:25594202	NA	0.95	8.07	0.64	2.19e-12	Erythrocyte sedimentation rate;
THYM	cis	rs2624839	0.704	rs2526384	chr3:50181136	C/T	cg14019146	chr3:50243930	SLC38A3	-0.8	-6.75	-0.57	1.18e-9	Intelligence (multi-trait analysis);
THYM	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg04234412	chr22:24373322	LOC391322	-0.8	-5.79	-0.51	9.21e-8	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	trans	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.93	-8.78	-0.67	6.81e-14	Brugada syndrome;
THYM	cis	rs8014204	0.935	rs2853779	chr14:75368508	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.58	-5.59	-0.5	2.12e-7	Caffeine consumption;
THYM	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg11317459	chr13:21872234	NA	-1.22	-9.26	-0.69	6.43e-15	White matter hyperintensity burden;
THYM	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.1	-0.53	2.29e-8	Crohn's disease;
THYM	cis	rs752010	1.000	rs752010	chr1:42093015	C/T	cg06885757	chr1:42089581	HIVEP3	0.42	4.7	0.43	8.77e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs75059851	0.756	rs11223654	chr11:133841579	C/T	cg14047540	chr11:133829660	NA	-1.1	-7.34	-0.6	7.1e-11	Schizophrenia;
THYM	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg12893697	chr11:970389	AP2A2	0.31	5.21	0.47	1.08e-6	Alzheimer's disease (late onset);
THYM	cis	rs57590327	0.555	rs7634258	chr3:81799100	T/C	cg07356753	chr3:81810745	GBE1	-0.88	-6.67	-0.56	1.67e-9	Extraversion;
THYM	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg17426766	chr1:2046864	PRKCZ	0.44	5.23	0.47	1.02e-6	Height;
THYM	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg13647721	chr17:30228624	UTP6	-0.73	-4.8	-0.44	5.89e-6	Hip circumference adjusted for BMI;
THYM	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.25	10.07	0.72	1.18e-16	Platelet count;
THYM	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg22875332	chr1:76189707	ACADM	0.89	10.1	0.72	1.02e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	7.25	0.6	1.11e-10	Platelet count;
THYM	cis	rs600231	0.598	rs2508712	chr11:65232261	C/G	cg17120908	chr11:65337727	SSSCA1	-0.61	-4.75	-0.44	7.33e-6	Bone mineral density;
THYM	cis	rs533581	0.873	rs555191	chr16:88978850	C/T	cg08484992	chr16:88977278	CBFA2T3	0.44	5.43	0.49	4.31e-7	Social autistic-like traits;
THYM	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.1	7.82	0.63	7.17e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2120019	0.505	rs77456790	chr15:75330095	G/T	cg17294928	chr15:75287854	SCAMP5	-1.07	-5.23	-0.47	9.89e-7	Blood trace element (Zn levels);
THYM	cis	rs3772130	0.962	rs4280673	chr3:121526107	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg06138931	chr13:21896616	NA	0.62	5.08	0.46	1.87e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs2463822	0.748	rs2513038	chr11:62081329	A/C	cg06239285	chr11:62104954	ASRGL1	1.37	7.54	0.61	2.75e-11	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7919533	0.564	rs9415039	chr10:73522694	A/G	cg14916175	chr10:73529624	CDH23;C10orf54	-0.54	-4.48	-0.42	2.11e-5	Monocyte count;
THYM	cis	rs4072705	0.967	rs4838209	chr9:127528842	C/T	cg01786973	chr9:127249749	NR5A1	0.37	4.95	0.45	3.24e-6	Menarche (age at onset);
THYM	cis	rs7426056	0.671	rs45620941	chr2:204600457	G/T	cg07930752	chr2:204569955	CD28	-0.74	-5.21	-0.47	1.11e-6	Primary sclerosing cholangitis;
THYM	cis	rs778371	0.630	rs13007579	chr2:233725364	G/A	cg08000102	chr2:233561755	GIGYF2	-0.81	-7.21	-0.59	1.36e-10	Schizophrenia;
THYM	cis	rs9554348	0.541	rs11618287	chr13:96949452	T/A	cg25169784	chr13:96706045	UGGT2	0.85	4.66	0.43	1.03e-5	Schizophrenia;
THYM	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg13319975	chr6:146136371	FBXO30	-0.72	-6.23	-0.54	1.25e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17598306	0.935	rs17657370	chr7:96606492	C/T	cg13449377	chr7:96631089	DLX6AS	0.76	4.78	0.44	6.38e-6	Radiation response;
THYM	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg19418458	chr7:158789849	NA	-0.62	-5.35	-0.48	6.14e-7	Facial morphology (factor 20);
THYM	cis	rs9486719	1.000	rs2472890	chr6:96867646	C/T	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs11886999	0.767	rs72825877	chr2:96920893	T/G	cg18419276	chr2:96971862	SNRNP200	-0.51	-4.95	-0.45	3.24e-6	Cardiac Troponin-T levels;
THYM	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg01416388	chr22:39784598	NA	-0.79	-6.23	-0.54	1.25e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs6430585	0.528	rs309167	chr2:136669264	C/T	cg07169764	chr2:136633963	MCM6	1.05	9.09	0.68	1.49e-14	Corneal structure;
THYM	cis	rs8048589	0.577	rs8055516	chr16:12180198	A/T	cg01990910	chr16:12207648	SNX29	-0.43	-5.44	-0.49	4.11e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	trans	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg25214090	chr10:38739885	LOC399744	0.97	8.33	0.65	5.98e-13	Corneal astigmatism;
THYM	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-11.39	-0.76	1.85e-19	Coronary artery disease;
THYM	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	trans	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg25517755	chr10:38738941	LOC399744	-0.78	-7.37	-0.6	6.35e-11	Educational attainment;
THYM	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg18105134	chr13:113819100	PROZ	1.05	9.68	0.7	7.89e-16	Platelet distribution width;
THYM	cis	rs7113850	0.541	rs7101719	chr11:24234947	T/C	ch.11.24196551F	chr11:24239977	NA	0.87	4.66	0.43	1.04e-5	Bone fracture in osteoporosis;
THYM	cis	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.52	-0.42	1.76e-5	Resting heart rate;
THYM	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg03806693	chr22:41940476	POLR3H	-0.84	-7.2	-0.59	1.37e-10	Vitiligo;
THYM	cis	rs8067545	0.611	rs9898080	chr17:20035257	A/G	cg13482628	chr17:19912719	NA	0.56	4.81	0.44	5.57e-6	Schizophrenia;
THYM	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg00645579	chr11:617140	IRF7;MUPCDH	-0.47	-6.04	-0.53	3.05e-8	Systemic lupus erythematosus;
THYM	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg22655196	chr4:3374909	RGS12	-0.58	-6.93	-0.58	4.93e-10	Serum sulfate level;
THYM	cis	rs7828089	1.000	rs7828089	chr8:22264334	T/G	cg12081754	chr8:22256438	SLC39A14	0.6	5.27	0.48	8.52e-7	Verbal declarative memory;
THYM	cis	rs9486719	0.947	rs12210834	chr6:96890407	A/T	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs828999	0.642	rs10881512	chr1:108718059	C/T	cg24323958	chr1:108741884	SLC25A24	0.57	5.61	0.5	1.97e-7	Monocyte percentage of white cells;
THYM	cis	rs2552220	0.647	rs2700714	chr8:5999421	A/G	cg03082247	chr8:6756796	NA	0.52	4.64	0.43	1.11e-5	Interleukin-8 levels;
THYM	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs11574514	1.000	rs28490940	chr16:68010262	G/C	cg04582263	chr16:67973788	LCAT	1.12	5.04	0.46	2.26e-6	Crohn's disease;
THYM	cis	rs4654899	0.802	rs12401413	chr1:21236503	T/C	cg01072550	chr1:21505969	NA	-0.7	-6.33	-0.54	8.1e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs7582403	0.844	rs1234433	chr2:148819000	T/C	cg23727674	chr2:148602993	ACVR2A	0.58	4.79	0.44	6.24e-6	Neuroticism;
THYM	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg00376283	chr12:123451042	ABCB9	0.75	5.19	0.47	1.2e-6	Neutrophil percentage of white cells;
THYM	cis	rs7264396	0.580	rs2064511	chr20:34448810	A/G	cg26038318	chr20:34205095	SPAG4	-0.65	-5.12	-0.47	1.57e-6	Total cholesterol levels;
THYM	cis	rs7809950	1.000	rs2712215	chr7:107188207	A/G	cg23024343	chr7:107201750	COG5	-0.94	-8.59	-0.66	1.7e-13	Coronary artery disease;
THYM	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	4.56	0.42	1.53e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8133932	0.667	rs2839033	chr21:47296381	T/C	cg08707771	chr21:46690014	POFUT2	-0.76	-4.45	-0.42	2.29e-5	Schizophrenia;
THYM	cis	rs8050907	1.000	rs7206416	chr16:4626724	T/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.25	5.1	0.46	1.74e-6	Obesity-related traits;
THYM	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg06238570	chr21:40685208	BRWD1	-0.71	-6.22	-0.54	1.34e-8	Menarche (age at onset);
THYM	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg12863693	chr15:85201151	NMB	0.63	5.45	0.49	3.97e-7	Schizophrenia;
THYM	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg00814883	chr7:100076585	TSC22D4	-1.01	-6.78	-0.57	1.01e-9	Platelet count;
THYM	cis	rs4478037	1.000	rs58864038	chr3:33161355	G/A	cg19404215	chr3:33155277	CRTAP	1.18	8.15	0.64	1.49e-12	Major depressive disorder;
THYM	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg06238570	chr21:40685208	BRWD1	-0.96	-9.26	-0.69	6.43e-15	Cognitive function;
THYM	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg10018233	chr7:150070692	REPIN1	0.43	5.87	0.52	6.26e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.01	-9.8	-0.71	4.35e-16	Primary sclerosing cholangitis;
THYM	cis	rs4606347	0.872	rs41459646	chr1:66106042	A/C	cg04111102	chr1:66153794	NA	0.59	4.54	0.42	1.67e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg26441486	chr22:50317300	CRELD2	0.42	6.65	0.56	1.83e-9	Schizophrenia;
THYM	cis	rs539096	0.918	rs519669	chr1:44075505	G/C	cg08936794	chr1:43833873	ELOVL1	0.67	4.77	0.44	6.73e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	6.09	0.53	2.36e-8	Platelet count;
THYM	cis	rs2797160	1.000	rs1832979	chr6:125997436	A/G	cg05901451	chr6:126070800	HEY2	-0.52	-4.46	-0.42	2.21e-5	Endometrial cancer;
THYM	cis	rs4900538	0.855	rs12587464	chr14:102886561	G/C	cg18135206	chr14:102964638	TECPR2	-0.81	-6.24	-0.54	1.2e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06481639	chr22:41940642	POLR3H	-0.8	-5.55	-0.49	2.63e-7	Vitiligo;
THYM	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg26354017	chr1:205819088	PM20D1	0.91	9.05	0.68	1.79e-14	Menarche (age at onset);
THYM	cis	rs11771526	0.901	rs62457503	chr7:32330980	A/C	cg13207630	chr7:32358064	NA	0.8	4.96	0.45	3.05e-6	Body mass index;
THYM	cis	rs7578361	0.959	rs4530332	chr2:150445221	A/C	cg17961725	chr2:150454027	NA	0.75	6.45	0.55	4.58e-9	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.43e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-5.01	-0.46	2.52e-6	Bipolar disorder;
THYM	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg16586182	chr3:47516702	SCAP	-0.64	-5.61	-0.5	2.03e-7	Colorectal cancer;
THYM	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.69	-5.72	-0.51	1.23e-7	Lymphocyte counts;
THYM	cis	rs72829446	0.530	rs4796420	chr17:7379617	A/T	cg02795151	chr17:7402630	POLR2A	0.58	6.72	0.57	1.31e-9	Androgen levels;
THYM	cis	rs8073060	0.859	rs17550268	chr17:33874678	T/C	cg07895132	chr17:33825172	SLFN12L	0.7	5.69	0.5	1.39e-7	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg12893697	chr11:970389	AP2A2	0.31	5.15	0.47	1.42e-6	Alzheimer's disease (late onset);
THYM	cis	rs761746	0.960	rs3818134	chr22:31926725	C/T	cg01338084	chr22:32026380	PISD	-0.57	-4.86	-0.45	4.63e-6	Intelligence;
THYM	cis	rs11997175	0.510	rs10503953	chr8:33797783	C/T	ch.8.33884649F	chr8:33765107	NA	0.67	5.17	0.47	1.32e-6	Body mass index;
THYM	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg23131131	chr22:24373011	LOC391322	-0.69	-5.31	-0.48	7.32e-7	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs10819861	0.645	rs4443780	chr9:98851767	T/C	cg14508093	chr9:98862825	NA	-0.24	-4.65	-0.43	1.08e-5	Electrocardiographic traits;
THYM	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11644478	chr21:40555479	PSMG1	-0.78	-5.36	-0.48	5.87e-7	Cognitive function;
THYM	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg13609457	chr4:120235615	NA	-0.59	-5.37	-0.48	5.68e-7	Corneal astigmatism;
THYM	cis	rs977987	0.835	rs3851734	chr16:75371920	T/C	cg03315344	chr16:75512273	CHST6	0.83	6.72	0.57	1.34e-9	Dupuytren's disease;
THYM	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg10560079	chr2:191398806	TMEM194B	-0.87	-6.55	-0.56	2.88e-9	Diastolic blood pressure;
THYM	cis	rs1642645	0.793	rs6695748	chr1:42481707	G/T	cg06092502	chr1:42611687	NA	0.61	4.74	0.44	7.58e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs7940866	0.804	rs3910267	chr11:130810282	C/T	cg12179176	chr11:130786555	SNX19	0.63	4.87	0.45	4.42e-6	Schizophrenia;
THYM	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg02725872	chr8:58115012	NA	-0.9	-6.62	-0.56	2.12e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs3087591	0.960	rs2905790	chr17:29476110	A/G	cg24425628	chr17:29625626	OMG;NF1	0.64	5.45	0.49	3.96e-7	Hip circumference;
THYM	cis	rs12478296	0.901	rs56318767	chr2:243046591	T/A	cg06360820	chr2:242988706	NA	-0.95	-5.75	-0.51	1.08e-7	Obesity-related traits;
THYM	cis	rs11627756	0.846	rs1190336	chr14:103108478	A/G	cg27124170	chr14:102829869	TECPR2;CINP	0.63	4.5	0.42	1.89e-5	Mean platelet volume;
THYM	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg27129171	chr3:47204927	SETD2	-0.71	-6.75	-0.57	1.16e-9	Colorectal cancer;
THYM	cis	rs2888875	0.632	rs17031097	chr2:43820549	A/T	cg22033476	chr2:43532275	THADA	-0.4	-4.61	-0.43	1.26e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs61931739	0.890	rs814663	chr12:34106338	C/T	cg06521331	chr12:34319734	NA	-0.6	-4.85	-0.45	4.86e-6	Morning vs. evening chronotype;
THYM	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg15448220	chr1:150897856	SETDB1	0.92	7.76	0.62	9.74e-12	Melanoma;
THYM	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.22e-16	Bone mineral density;
THYM	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg08736216	chr1:53307985	ZYG11A	-0.58	-5.29	-0.48	7.85e-7	Monocyte count;
THYM	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.34	0.48	6.29e-7	Height;
THYM	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/T	cg08883853	chr7:1026168	CYP2W1	-0.7	-4.83	-0.44	5.31e-6	Longevity;Endometriosis;
THYM	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg04772025	chr11:68637568	NA	0.64	6.73	0.57	1.25e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg21862992	chr11:68658383	NA	0.23	4.49	0.42	2.03e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9457247	0.534	rs9366078	chr6:167399512	A/G	cg23791538	chr6:167370224	RNASET2	0.83	7.32	0.6	7.9e-11	Crohn's disease;
THYM	cis	rs7633770	0.841	rs11709020	chr3:46680063	A/G	cg11219411	chr3:46661640	NA	-0.46	-4.91	-0.45	3.77e-6	Coronary artery disease;
THYM	cis	rs593982	0.920	rs618456	chr11:65475620	C/T	cg08755490	chr11:65554678	OVOL1	1.29	4.66	0.43	1.03e-5	Atopic dermatitis;
THYM	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.7	-5.63	-0.5	1.83e-7	Prostate cancer;
THYM	cis	rs9303280	0.934	rs56380902	chr17:38066372	T/C	cg24910161	chr17:38119198	GSDMA	0.48	5.08	0.46	1.9e-6	Self-reported allergy;
THYM	trans	rs9929218	0.906	rs34565494	chr16:68741769	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-7.27	-0.6	1.01e-10	Colorectal cancer;
THYM	cis	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg22681709	chr2:178499509	PDE11A	-0.6	-5.12	-0.47	1.58e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg15212455	chr7:39170539	POU6F2	0.62	5.72	0.51	1.26e-7	IgG glycosylation;
THYM	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg15556689	chr8:8085844	FLJ10661	-0.55	-4.47	-0.42	2.15e-5	Mood instability;
THYM	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4866334	1.000	rs79823740	chr5:18488814	T/C	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02463440	chr8:22132932	PIWIL2	0.58	5.04	0.46	2.26e-6	Hypertriglyceridemia;
THYM	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs938554	0.513	rs4529048	chr4:9997112	G/T	cg26689780	chr4:10079554	WDR1	-0.4	-4.73	-0.44	7.94e-6	Blood metabolite levels;
THYM	cis	rs7106204	0.514	rs2083753	chr11:24255896	A/G	ch.11.24196551F	chr11:24239977	NA	1.0	6.88	0.58	6.32e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22496380	chr5:211416	CCDC127	-1.39	-8.13	-0.64	1.62e-12	Breast cancer;
THYM	cis	rs595982	0.527	rs35023389	chr19:49377873	G/A	cg21252483	chr19:49399788	TULP2	-0.79	-5.22	-0.47	1.04e-6	Red cell distribution width;
THYM	cis	rs7762018	0.769	rs7766146	chr6:170070135	A/T	cg19338460	chr6:170058176	WDR27	-0.71	-4.78	-0.44	6.38e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs7729447	0.813	rs7715571	chr5:32690010	A/C	cg16267343	chr5:32710456	NPR3	0.78	7.15	0.59	1.78e-10	Blood pressure;
THYM	cis	rs4595586	0.545	rs12812750	chr12:39363258	C/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg19052272	chr2:3704530	ALLC	-1.02	-8.19	-0.64	1.22e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg04414720	chr1:150670196	GOLPH3L	0.62	4.58	0.43	1.41e-5	Tonsillectomy;
THYM	cis	rs3741151	1.000	rs74776668	chr11:73065909	G/A	cg17517138	chr11:73019481	ARHGEF17	0.99	5.88	0.52	5.97e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7584330	0.780	rs10176842	chr2:238428256	T/C	cg16989719	chr2:238392110	NA	-0.5	-4.95	-0.45	3.16e-6	Prostate cancer;
THYM	cis	rs57244997	0.544	rs77182940	chr6:162443721	T/C	cg17173639	chr6:162384350	PARK2	-0.79	-4.77	-0.44	6.57e-6	Mosquito bite size;
THYM	trans	rs8002861	0.846	rs12869521	chr13:44478346	A/G	cg17145862	chr1:211918768	LPGAT1	-0.89	-8.3	-0.65	7.11e-13	Leprosy;
THYM	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg01483505	chr11:975446	AP2A2	0.58	4.75	0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs1205863	0.764	rs9470670	chr6:11988081	T/G	cg01709473	chr6:12010960	NA	0.55	4.69	0.43	9.29e-6	Disc degeneration (lumbar);
THYM	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2302063	0.517	rs1637655	chr19:3162538	G/A	cg14194048	chr19:2462042	NA	-0.65	-5.12	-0.47	1.57e-6	Glucose homeostasis traits;
THYM	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg06387496	chr7:2775674	GNA12	-0.44	-4.7	-0.43	8.64e-6	Height;
THYM	cis	rs7178572	0.625	rs12905285	chr15:77845812	T/C	cg22256960	chr15:77711686	NA	-0.77	-6.71	-0.57	1.41e-9	Type 2 diabetes;
THYM	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg11890956	chr21:40555474	PSMG1	-0.63	-5.79	-0.51	9.1e-8	Menarche (age at onset);
THYM	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs10857712	0.950	rs7906765	chr10:135225460	G/T	cg19904058	chr10:135279010	LOC619207	-0.55	-5.12	-0.47	1.57e-6	Systemic lupus erythematosus;
THYM	cis	rs654950	0.807	rs61773660	chr1:41993298	C/T	cg13396354	chr1:41153348	NA	0.44	4.51	0.42	1.87e-5	Airway imaging phenotypes;
THYM	cis	rs2736337	0.530	rs2003422	chr8:11303137	G/C	cg11009520	chr8:12052164	FAM86B1	-0.64	-5.11	-0.46	1.66e-6	Rheumatoid arthritis;
THYM	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg24578937	chr1:2090814	PRKCZ	0.81	8.54	0.66	2.22e-13	Height;
THYM	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.72	-0.51	1.23e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3796352	1.000	rs11720191	chr3:53013839	T/C	cg04865290	chr3:52927548	TMEM110	-0.89	-4.65	-0.43	1.08e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs73198271	0.681	rs35457364	chr8:8649790	T/A	cg15556689	chr8:8085844	FLJ10661	-0.74	-4.91	-0.45	3.75e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7772486	0.776	rs2265467	chr6:146218339	T/A	cg13319975	chr6:146136371	FBXO30	-0.74	-6.33	-0.54	8.16e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9399401	0.601	rs643975	chr6:142844251	C/G	cg04461802	chr6:142623433	GPR126	-0.58	-5.21	-0.47	1.07e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg01416388	chr22:39784598	NA	-0.74	-5.85	-0.51	6.86e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg24060327	chr5:131705240	SLC22A5	0.76	5.58	0.5	2.26e-7	Blood metabolite levels;
THYM	cis	rs4355801	0.524	rs2101752	chr8:119859675	T/G	cg17171407	chr8:119960777	TNFRSF11B	-0.58	-4.46	-0.42	2.22e-5	Bone mineral density;
THYM	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg27572855	chr1:25598939	RHD	0.64	5.04	0.46	2.21e-6	Erythrocyte sedimentation rate;
THYM	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.51	-4.79	-0.44	6.24e-6	Lymphocyte counts;
THYM	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg03929089	chr4:120376271	NA	-1.01	-13.71	-0.82	3.1e-24	Height;
THYM	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg22316451	chr20:60645197	NA	-0.47	-4.53	-0.42	1.71e-5	Body mass index;
THYM	cis	rs7107770	1.000	rs35205839	chr11:125106444	G/A	cg07747661	chr11:125106135	PKNOX2	-0.92	-5.28	-0.48	8.31e-7	Photic sneeze reflex;
THYM	cis	rs3741151	0.773	rs74881062	chr11:73245769	G/A	cg12959048	chr11:73096162	RELT	-0.52	-4.58	-0.43	1.43e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs17376456	0.597	rs7728825	chr5:93384594	T/C	cg25358565	chr5:93447407	FAM172A	-0.83	-6.18	-0.54	1.57e-8	Diabetic retinopathy;
THYM	cis	rs208520	0.874	rs208515	chr6:66945749	A/G	cg07460842	chr6:66804631	NA	-0.85	-5.46	-0.49	3.87e-7	Exhaled nitric oxide output;
THYM	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg02887458	chr19:19495540	GATAD2A	-0.44	-5.16	-0.47	1.33e-6	Bipolar disorder;
THYM	cis	rs877282	0.797	rs11253329	chr10:753200	A/T	cg10556349	chr10:835070	NA	-0.69	-4.49	-0.42	2.03e-5	Uric acid levels;
THYM	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg06713675	chr4:122721982	EXOSC9	-0.54	-5.0	-0.46	2.65e-6	Type 2 diabetes;
THYM	cis	rs860818	1.000	rs858293	chr7:23246324	A/C	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs1322639	0.614	rs6908401	chr6:169564716	A/C	cg04662567	chr6:169592167	NA	0.77	6.08	0.53	2.49e-8	Pulse pressure;
THYM	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	9.4	0.69	3.1e-15	Chronic sinus infection;
THYM	cis	rs6815814	0.851	rs73236644	chr4:38863193	A/G	cg06935464	chr4:38784597	TLR10	0.75	4.63	0.43	1.16e-5	Breast cancer;
THYM	cis	rs28374715	0.662	rs72737793	chr15:41516823	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.01	-8.29	-0.65	7.22e-13	Ulcerative colitis;
THYM	cis	rs11190604	0.943	rs113791644	chr10:102324330	T/G	cg07570687	chr10:102243282	WNT8B	0.76	6.58	0.56	2.61e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs28595532	0.920	rs116205107	chr4:119730910	G/A	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs7508	0.618	rs13266287	chr8:17871598	T/A	cg18067069	chr8:17937731	ASAH1	-0.63	-5.25	-0.47	9.41e-7	Atrial fibrillation;
THYM	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg18876405	chr7:65276391	NA	-0.55	-4.73	-0.44	7.84e-6	Aortic root size;
THYM	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg03929089	chr4:120376271	NA	-1.01	-13.5	-0.81	8.17e-24	Height;
THYM	cis	rs8050907	0.744	rs7191458	chr16:4511752	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.32	5.06	0.46	2.09e-6	Obesity-related traits;
THYM	cis	rs7818345	0.569	rs4484715	chr8:19358296	T/G	cg11303988	chr8:19266685	CSGALNACT1	0.47	4.64	0.43	1.12e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg17063962	chr7:91808500	NA	1.16	12.78	0.8	2.34e-22	Breast cancer;
THYM	cis	rs595982	0.546	rs10401443	chr19:49402059	C/A	cg21252483	chr19:49399788	TULP2	-0.68	-6.8	-0.57	9.39e-10	Red cell distribution width;
THYM	cis	rs7772486	0.790	rs9376968	chr6:146180364	T/C	cg13319975	chr6:146136371	FBXO30	-0.71	-5.81	-0.51	8.44e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9595908	1.000	rs7999125	chr13:33145995	G/A	cg12383807	chr13:33924137	NA	-0.5	-4.47	-0.42	2.2e-5	Body mass index;
THYM	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg16414030	chr3:133502952	NA	0.59	4.74	0.44	7.53e-6	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg06636551	chr8:101224915	SPAG1	0.65	5.89	0.52	5.91e-8	Atrioventricular conduction;
THYM	cis	rs2073300	1.000	rs6132625	chr20:23444671	C/T	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs1163251	0.869	rs629735	chr1:120206932	G/T	cg19096424	chr1:120255104	PHGDH	-0.63	-4.88	-0.45	4.26e-6	Blood metabolite levels;
THYM	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg11375102	chr16:1583810	IFT140;TMEM204	-0.61	-5.17	-0.47	1.3e-6	Coronary artery disease;
THYM	cis	rs17608059	0.504	rs11656981	chr17:13978777	A/G	cg27005118	chr17:13972210	COX10	-0.66	-7.49	-0.61	3.54e-11	Temperament;
THYM	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg12011299	chr4:100065546	ADH4	0.86	8.3	0.65	7.14e-13	Alcohol dependence;
THYM	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.63	-5.48	-0.49	3.51e-7	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10463554	0.892	rs257305	chr5:102417237	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs61931739	0.926	rs13377754	chr12:34051765	T/C	cg10856724	chr12:34555212	NA	0.61	5.07	0.46	1.93e-6	Morning vs. evening chronotype;
THYM	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg26149184	chr10:133730230	NA	0.72	4.55	0.42	1.57e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs6693295	0.536	rs6656404	chr1:246255288	A/T	cg11798871	chr1:246315928	SMYD3	-0.76	-4.55	-0.42	1.57e-5	Migraine - clinic-based;Migraine with aura;
THYM	cis	rs6831352	0.879	rs4699716	chr4:100066125	G/A	cg12011299	chr4:100065546	ADH4	-0.82	-7.62	-0.62	1.91e-11	Alcohol dependence;
THYM	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs208520	0.874	rs208481	chr6:66922636	A/G	cg07460842	chr6:66804631	NA	-0.79	-4.96	-0.45	3.05e-6	Exhaled nitric oxide output;
THYM	cis	rs61931739	0.890	rs1705750	chr12:34142648	C/T	cg10856724	chr12:34555212	NA	-0.7	-6.19	-0.54	1.5e-8	Morning vs. evening chronotype;
THYM	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg08000102	chr2:233561755	GIGYF2	0.69	6.09	0.53	2.35e-8	Coronary artery disease;
THYM	cis	rs17401966	1.000	rs12407992	chr1:10311983	A/C	cg20482658	chr1:10539492	PEX14	0.37	4.5	0.42	1.91e-5	Hepatocellular carcinoma;
THYM	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg13607699	chr17:42295918	UBTF	-0.66	-5.44	-0.49	4.13e-7	Total body bone mineral density;
THYM	cis	rs1642645	0.831	rs6698877	chr1:42500436	T/C	cg06092502	chr1:42611687	NA	0.59	4.49	0.42	2.02e-5	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg00129232	chr17:37814104	STARD3	0.69	4.51	0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs3540	0.597	rs1978149	chr15:91036976	A/G	cg22089800	chr15:90895588	ZNF774	0.69	5.41	0.49	4.77e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg27490568	chr2:178487706	NA	0.71	5.66	0.5	1.63e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg04025307	chr7:1156635	C7orf50	0.79	5.0	0.46	2.6e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7814319	0.833	rs13249716	chr8:97228412	G/T	cg20787634	chr8:97240163	UQCRB	-0.69	-7.82	-0.63	7.32e-12	Lung function (FVC);
THYM	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg03060546	chr3:49711283	APEH	-0.74	-6.21	-0.54	1.42e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg20587970	chr11:113659929	NA	-1.25	-8.91	-0.67	3.53e-14	Hip circumference adjusted for BMI;
THYM	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg05564831	chr3:52568323	NT5DC2	0.46	4.87	0.45	4.47e-6	Hemoglobin concentration;
THYM	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs548181	0.673	rs12288034	chr11:125570941	A/T	cg03464685	chr11:125439445	EI24	-1.28	-7.93	-0.63	4.29e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7107174	0.892	rs2512519	chr11:77953015	C/T	cg02023728	chr11:77925099	USP35	0.72	6.25	0.54	1.15e-8	Testicular germ cell tumor;
THYM	cis	rs7681440	0.606	rs2619342	chr4:90744170	A/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.73	7.27	0.6	1.01e-10	Lymphocyte counts;
THYM	cis	rs1691799	0.899	rs1183272	chr12:66735421	T/C	cg16791601	chr12:66731901	HELB	-0.75	-7.25	-0.6	1.08e-10	White blood cell count (basophil);
THYM	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs524281	0.773	rs2017969	chr11:66039032	G/A	cg00563793	chr11:65837595	PACS1	0.79	4.71	0.43	8.53e-6	Electroencephalogram traits;
THYM	cis	rs13279522	0.536	rs7824630	chr8:67003194	C/G	cg20171999	chr8:67343066	NA	-0.48	-4.81	-0.44	5.73e-6	Coronary heart disease event reduction (statin therapy interaction);
THYM	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.26	-9.1	-0.68	1.4e-14	Gut microbiome composition (summer);
THYM	cis	rs4638749	0.677	rs1522021	chr2:108833263	C/T	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg03060546	chr3:49711283	APEH	0.75	6.08	0.53	2.55e-8	Resting heart rate;
THYM	cis	rs7178572	0.568	rs11632966	chr15:77621805	A/C	cg22256960	chr15:77711686	NA	-1.04	-8.25	-0.65	9.01e-13	Type 2 diabetes;
THYM	cis	rs28476539	0.568	rs6855705	chr4:83556375	C/T	cg10249074	chr4:83542146	C4orf11	-0.64	-5.06	-0.46	2.05e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs6032067	0.929	rs36032462	chr20:43873088	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.37	-0.48	5.52e-7	Blood protein levels;
THYM	cis	rs9677476	0.863	rs12465438	chr2:232073106	G/A	cg23338755	chr2:231921595	PSMD1	0.67	4.91	0.45	3.85e-6	Food antigen IgG levels;
THYM	cis	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs995000	0.931	rs12074528	chr1:63010871	T/C	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11890956	chr21:40555474	PSMG1	1.17	13.11	0.8	4.95e-23	Cognitive function;
THYM	cis	rs6032067	0.714	rs6513969	chr20:43878475	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.66	-7.59	-0.61	2.22e-11	Blood protein levels;
THYM	cis	rs7020830	0.898	rs308521	chr9:37367094	T/C	cg14294708	chr9:37120828	ZCCHC7	1.15	13.21	0.8	3.18e-23	Schizophrenia;
THYM	cis	rs7794273	0.723	rs2588638	chr7:18844596	C/T	cg13420273	chr7:18810212	HDAC9	0.57	4.74	0.44	7.63e-6	Night sleep phenotypes;
THYM	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg15247329	chr7:2764246	NA	-0.74	-6.48	-0.55	4.13e-9	Height;
THYM	cis	rs3768617	0.510	rs2333620	chr1:183100555	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs6500395	0.963	rs961951	chr16:48716720	A/G	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg14784868	chr12:69753453	YEATS4	0.69	5.41	0.49	4.61e-7	Response to diuretic therapy;
THYM	cis	rs2282300	0.739	rs1222211	chr11:30362239	A/C	cg09906309	chr11:30344399	C11orf46	-0.72	-5.11	-0.46	1.66e-6	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4654899	1.000	rs61117207	chr1:21394374	A/C	cg01072550	chr1:21505969	NA	-0.71	-6.29	-0.54	9.47e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs7828089	1.000	rs7838127	chr8:22264561	G/A	cg12081754	chr8:22256438	SLC39A14	0.6	5.26	0.48	8.69e-7	Verbal declarative memory;
THYM	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4808199	0.947	rs1465695	chr19:19588546	A/C	cg03709012	chr19:19516395	GATAD2A	1.19	7.25	0.6	1.12e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs9549260	0.816	rs7337995	chr13:41249040	A/G	cg21288729	chr13:41239152	FOXO1	0.72	5.42	0.49	4.47e-7	Red blood cell count;
THYM	trans	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs877282	0.891	rs12357999	chr10:796468	A/C	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs11209185	0.545	rs11209184	chr1:68421069	C/T	cg22082780	chr1:68452167	NA	0.51	5.53	0.49	2.85e-7	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg10589385	chr1:150898437	SETDB1	0.64	5.28	0.48	8.02e-7	Melanoma;
THYM	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg24209194	chr3:40518798	ZNF619	0.58	4.7	0.43	8.73e-6	Renal cell carcinoma;
THYM	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg18252515	chr7:66147081	NA	0.65	4.73	0.44	7.72e-6	Aortic root size;
THYM	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7106204	0.609	rs34237482	chr11:24295932	G/A	ch.11.24196551F	chr11:24239977	NA	0.99	6.11	0.53	2.16e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs55728055	0.661	rs8142821	chr22:31941240	A/C	cg01338084	chr22:32026380	PISD	1.47	5.89	0.52	5.9e-8	Age-related hearing impairment;
THYM	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg02527881	chr3:46936655	PTH1R	-0.86	-8.66	-0.66	1.21e-13	Birth weight;
THYM	cis	rs11771526	0.901	rs62457467	chr7:32301101	T/A	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs17006441	0.932	rs6804686	chr3:69884405	G/C	cg18496212	chr3:69797108	MITF	0.65	6.36	0.55	7.15e-9	Hemoglobin concentration;
THYM	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg06481639	chr22:41940642	POLR3H	-0.84	-5.89	-0.52	5.93e-8	Vitiligo;
THYM	cis	rs17604090	1.000	rs28420551	chr7:29685353	G/A	cg19413766	chr7:29689036	LOC646762	-0.93	-5.09	-0.46	1.77e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg08847533	chr14:75593920	NEK9	-1.03	-11.29	-0.76	3e-19	Height;
THYM	cis	rs7267979	1.000	rs2856	chr20:25433536	T/C	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg23758822	chr17:41437982	NA	1.18	11.2	0.75	4.58e-19	Menopause (age at onset);
THYM	cis	rs4842666	0.915	rs6538195	chr12:90062376	G/A	cg00757033	chr12:89920650	WDR51B	0.46	4.54	0.42	1.64e-5	Blood pressure;
THYM	cis	rs2997447	0.761	rs61776618	chr1:26456709	A/G	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs17407555	0.606	rs3775945	chr4:10011996	A/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-5.87	-0.52	6.48e-8	Schizophrenia (age at onset);
THYM	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg08439880	chr3:133502540	NA	0.79	6.83	0.57	7.89e-10	Iron status biomarkers;
THYM	cis	rs3849570	0.732	rs11715625	chr3:81875938	A/T	cg07356753	chr3:81810745	GBE1	-0.84	-6.38	-0.55	6.53e-9	Waist circumference;Body mass index;
THYM	cis	rs7849270	1.000	rs10988223	chr9:131903021	T/C	cg14069949	chr9:131965419	NA	0.5	4.52	0.42	1.8e-5	Blood metabolite ratios;
THYM	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg24910161	chr17:38119198	GSDMA	0.45	4.57	0.42	1.44e-5	Self-reported allergy;
THYM	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg04398451	chr17:18023971	MYO15A	-0.9	-8.29	-0.65	7.43e-13	Total body bone mineral density;
THYM	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg04025307	chr7:1156635	C7orf50	0.67	4.64	0.43	1.13e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7072216	0.655	rs3830025	chr10:100176104	A/G	cg03852570	chr10:100175106	PYROXD2	0.39	5.14	0.47	1.44e-6	Metabolite levels;
THYM	cis	rs1691799	0.867	rs1168356	chr12:66750469	A/G	cg16791601	chr12:66731901	HELB	-0.75	-6.98	-0.58	3.96e-10	White blood cell count (basophil);
THYM	cis	rs902774	0.554	rs4503623	chr12:53353759	T/C	cg05393297	chr12:53359155	NA	-0.45	-5.07	-0.46	1.95e-6	Prostate cancer;
THYM	trans	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg10856724	chr12:34555212	NA	-0.94	-8.22	-0.64	1.01e-12	Bladder cancer;
THYM	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg09904177	chr6:26538194	HMGN4	0.62	4.96	0.45	3.06e-6	Intelligence (multi-trait analysis);
THYM	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg11812906	chr14:75593930	NEK9	-0.86	-7.85	-0.63	6.25e-12	Height;
THYM	cis	rs2562152	0.706	rs216596	chr16:105320	A/G	cg02949481	chr16:131562	MPG	0.84	5.21	0.47	1.11e-6	Glioblastoma;
THYM	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg27446573	chr6:127587934	RNF146	-0.74	-5.98	-0.52	3.83e-8	Breast cancer;
THYM	cis	rs7103648	0.838	rs2293576	chr11:47434986	A/G	cg20307385	chr11:47447363	PSMC3	-0.92	-7.54	-0.61	2.72e-11	Diastolic blood pressure;Systolic blood pressure;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg04334564	chr11:118310840	MLL	-0.82	-6.85	-0.57	7.33e-10	Depressive symptoms;
THYM	cis	rs4866334	1.000	rs80007833	chr5:18489203	G/T	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs6754311	0.773	rs309137	chr2:136765951	A/G	cg07169764	chr2:136633963	MCM6	0.66	5.34	0.48	6.33e-7	Mosquito bite size;
THYM	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg09359103	chr1:154839909	KCNN3	-0.75	-8.52	-0.66	2.42e-13	Prostate cancer;
THYM	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00908189	chr16:619842	PIGQ	1.06	9.31	0.69	5e-15	Height;
THYM	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg08736216	chr1:53307985	ZYG11A	-0.63	-5.56	-0.5	2.51e-7	Monocyte count;
THYM	cis	rs11077998	0.967	rs11657886	chr17:80516173	T/C	cg11779900	chr17:80519722	FOXK2	-0.54	-4.69	-0.43	9.03e-6	Reticulocyte fraction of red cells;
THYM	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg09222892	chr1:25734099	RHCE	0.62	4.83	0.44	5.21e-6	Erythrocyte sedimentation rate;
THYM	cis	rs262150	0.545	rs73167302	chr7:158789762	G/A	cg12257156	chr7:158823799	VIPR2	0.7	6.25	0.54	1.18e-8	Facial morphology (factor 20);
THYM	cis	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05901451	chr6:126070800	HEY2	-0.67	-5.8	-0.51	8.61e-8	Migraine;
THYM	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	9.34	0.69	4.33e-15	Platelet count;
THYM	cis	rs9296092	0.517	rs55683509	chr6:33471077	A/G	cg13560919	chr6:33536144	NA	-0.84	-6.92	-0.58	5.15e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs6543140	0.964	rs918000	chr2:103067862	C/T	cg03938978	chr2:103052716	IL18RAP	0.58	5.84	0.51	7.16e-8	Blood protein levels;
THYM	cis	rs273218	1.000	rs156440	chr5:53373656	A/T	ch.5.1024479R	chr5:53302184	ARL15	0.93	8.01	0.63	2.85e-12	Migraine;
THYM	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg12165864	chr7:66369176	NA	-0.62	-4.85	-0.45	4.84e-6	Aortic root size;
THYM	cis	rs4474465	0.920	rs908002	chr11:78144753	T/A	cg19901956	chr11:77921274	USP35	-0.6	-4.5	-0.42	1.96e-5	Alzheimer's disease (survival time);
THYM	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.79	6.34	0.55	7.85e-9	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs1524976	1.000	rs11707527	chr3:65450416	G/A	cg16238336	chr3:65465873	MAGI1	-1.08	-6.99	-0.58	3.81e-10	PR interval;
THYM	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg11317459	chr13:21872234	NA	1.24	10.26	0.73	4.58e-17	White matter hyperintensity burden;
THYM	cis	rs17094222	0.504	rs4917904	chr10:102447292	G/A	cg26540559	chr10:102447443	NA	0.7	6.04	0.53	3.01e-8	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7940866	0.801	rs10894288	chr11:130808679	T/C	cg05962950	chr11:130786565	SNX19	0.75	6.04	0.53	3.04e-8	Schizophrenia;
THYM	cis	rs2354432	0.556	rs4424557	chr1:146871119	A/G	cg25205988	chr1:146714368	CHD1L	0.99	4.64	0.43	1.13e-5	Mitochondrial DNA levels;
THYM	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs909685	1.000	rs2069235	chr22:39747780	C/T	cg24268161	chr22:39747459	SYNGR1	-0.88	-10.33	-0.73	3.25e-17	Rheumatoid arthritis;
THYM	cis	rs12935418	0.583	rs2167889	chr16:81021472	G/A	cg16651780	chr16:81037892	C16orf61	-0.85	-6.53	-0.56	3.16e-9	Mean corpuscular volume;
THYM	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg27286337	chr10:134555280	INPP5A	0.94	7.69	0.62	1.33e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs8077889	0.645	rs1230396	chr17:41843029	A/C	cg26893861	chr17:41843967	DUSP3	-1.18	-20.6	-0.9	8.25e-37	Triglycerides;
THYM	cis	rs9527	0.615	rs9733635	chr10:104711940	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-5.01	-0.46	2.51e-6	Arsenic metabolism;
THYM	cis	rs11650494	0.908	rs77488129	chr17:47448970	G/A	cg08112188	chr17:47440006	ZNF652	1.24	5.37	0.48	5.59e-7	Prostate cancer;
THYM	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg20744362	chr22:50050164	C22orf34	0.82	8.41	0.65	4.07e-13	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2456568	0.802	rs10765639	chr11:93636194	G/A	cg17595323	chr11:93583763	C11orf90	-0.58	-6.09	-0.53	2.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs6951245	0.515	rs78461900	chr7:1007033	C/A	cg08883853	chr7:1026168	CYP2W1	-0.83	-4.83	-0.44	5.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs863345	0.604	rs4313395	chr1:158505135	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg11764359	chr7:65958608	NA	0.78	6.29	0.54	9.72e-9	Aortic root size;
THYM	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	10.68	0.74	6.01e-18	Chronic sinus infection;
THYM	cis	rs7771547	0.519	rs6457912	chr6:36373794	C/A	cg07856975	chr6:36356162	ETV7	0.65	5.5	0.49	3.13e-7	Platelet distribution width;
THYM	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg27534772	chr1:16042836	PLEKHM2	0.56	6.31	0.54	8.77e-9	Systolic blood pressure;
THYM	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg24910161	chr17:38119198	GSDMA	0.45	4.48	0.42	2.06e-5	Lymphocyte counts;
THYM	cis	rs9880211	1.000	rs28641809	chr3:136290489	G/A	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs861020	0.630	rs655713	chr1:210006438	C/T	cg05527609	chr1:210001259	C1orf107	0.85	6.82	0.57	8.53e-10	Orofacial clefts;
THYM	trans	rs3960554	0.808	rs78811105	chr7:75702795	G/A	cg19862616	chr7:65841803	NCRNA00174	0.93	6.95	0.58	4.6e-10	Eotaxin levels;
THYM	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg26384229	chr12:38710491	ALG10B	-0.89	-9.06	-0.68	1.67e-14	Heart rate;
THYM	cis	rs7897654	0.651	rs12783467	chr10:104708312	A/G	cg17812664	chr10:104957217	NA	0.69	4.93	0.45	3.47e-6	Schizophrenia;
THYM	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Body mass index;
THYM	cis	rs17331151	0.505	rs7614424	chr3:52566354	C/T	cg17372223	chr3:52568218	NT5DC2	0.57	4.58	0.43	1.42e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs4654899	1.000	rs10916937	chr1:21439785	A/G	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.26e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg08885076	chr2:99613938	TSGA10	-0.69	-6.44	-0.55	4.84e-9	Chronic sinus infection;
THYM	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg13390004	chr1:15929781	NA	0.63	4.79	0.44	6.2e-6	Systolic blood pressure;
THYM	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.72	-7.49	-0.61	3.58e-11	Lymphocyte counts;
THYM	trans	rs877282	1.000	rs112522746	chr10:772288	T/C	cg22713356	chr15:30763199	NA	1.26	10.12	0.72	9.24e-17	Uric acid levels;
THYM	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg22709100	chr7:91322751	NA	-0.6	-4.8	-0.44	5.84e-6	Breast cancer;
THYM	trans	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg06636001	chr8:8085503	FLJ10661	-0.78	-7.13	-0.59	1.97e-10	Triglycerides;
THYM	cis	rs3741151	0.773	rs58334887	chr11:73171510	A/C	cg17517138	chr11:73019481	ARHGEF17	0.94	5.48	0.49	3.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs7255436	1.000	rs7255436	chr19:8433196	C/A	cg10174797	chr19:8464628	RAB11B	0.42	4.97	0.45	2.99e-6	HDL cholesterol;
THYM	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg17063962	chr7:91808500	NA	1.14	12.62	0.79	4.97e-22	Breast cancer;
THYM	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg18230493	chr5:56204884	C5orf35	-0.89	-6.53	-0.56	3.25e-9	Initial pursuit acceleration;
THYM	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg18512352	chr11:47633146	NA	-0.56	-7.3	-0.6	8.87e-11	Subjective well-being;
THYM	cis	rs986417	1.000	rs2351176	chr14:61073731	A/T	cg27398547	chr14:60952738	C14orf39	1.3	6.11	0.53	2.15e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs17321999	0.904	rs6708792	chr2:30468860	C/T	cg05247661	chr2:30472410	LBH	0.67	4.92	0.45	3.66e-6	Systemic lupus erythematosus;
THYM	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.58	-5.3	-0.48	7.57e-7	Chronic sinus infection;
THYM	cis	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.72	-0.51	1.23e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	trans	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg13615516	chr5:77269221	NA	0.85	7.51	0.61	3.18e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.54	-5.07	-0.46	1.93e-6	Lymphocyte counts;
THYM	cis	rs9534288	0.797	rs7990238	chr13:46578379	T/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg03351412	chr1:154909251	PMVK	0.71	5.6	0.5	2.12e-7	Prostate cancer;
THYM	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg08859206	chr1:53392774	SCP2	-0.61	-6.86	-0.58	6.9e-10	Monocyte count;
THYM	cis	rs7809950	0.723	rs62483634	chr7:106878516	G/A	cg23024343	chr7:107201750	COG5	-0.97	-8.28	-0.65	7.72e-13	Coronary artery disease;
THYM	trans	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg06112835	chr11:68658793	MRPL21	-0.43	-6.02	-0.53	3.32e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1062753	0.922	rs9611712	chr22:42410993	T/C	cg01059385	chr22:42394853	WBP2NL	0.57	4.66	0.43	1.04e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg10047753	chr17:41438598	NA	1.16	10.71	0.74	5.01e-18	Menopause (age at onset);
THYM	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg23711669	chr6:146136114	FBXO30	0.97	10.66	0.74	6.4e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg19346786	chr7:2764209	NA	-0.53	-4.48	-0.42	2.12e-5	Height;
THYM	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg11764359	chr7:65958608	NA	0.64	4.84	0.44	5.08e-6	Aortic root size;
THYM	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg12963246	chr6:28129442	ZNF389	0.77	6.4	0.55	5.74e-9	Parkinson's disease;
THYM	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg04731861	chr2:219085781	ARPC2	0.57	5.69	0.5	1.38e-7	Colorectal cancer;
THYM	cis	rs931812	0.825	rs13271753	chr8:101895491	T/C	cg07239293	chr8:101170671	SPAG1	0.68	4.63	0.43	1.17e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs6032067	0.929	rs6017504	chr20:43818920	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs6754311	0.509	rs12616520	chr2:136516748	A/T	cg04750100	chr2:136595281	LCT	-0.55	-6.22	-0.54	1.31e-8	Mosquito bite size;
THYM	cis	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg02317251	chr4:10116515	WDR1	-0.56	-4.95	-0.45	3.23e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs4589258	0.762	rs10437566	chr11:90463886	A/G	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.93	-0.45	3.53e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg09367891	chr1:107599246	PRMT6	-0.7	-5.02	-0.46	2.42e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs4849845	0.889	rs2278505	chr2:121050560	A/G	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg08994789	chr17:28903642	LRRC37B2	-1.1	-6.12	-0.53	2.11e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs514406	0.893	rs6661115	chr1:53426148	G/A	cg22166914	chr1:53195759	ZYG11B	-0.75	-7.03	-0.59	3.1e-10	Monocyte count;
THYM	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg13319975	chr6:146136371	FBXO30	0.72	6.09	0.53	2.43e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs919433	0.680	rs7582536	chr2:198436103	C/T	cg00792783	chr2:198669748	PLCL1	-0.72	-5.03	-0.46	2.29e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg14186256	chr22:23484241	RTDR1	0.97	9.46	0.7	2.35e-15	Bone mineral density;
THYM	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg16928487	chr17:17741425	SREBF1	-0.54	-5.21	-0.47	1.08e-6	Total body bone mineral density;
THYM	cis	rs7107770	0.739	rs12808899	chr11:125082124	T/C	cg04164023	chr11:125106101	PKNOX2	-0.71	-4.55	-0.42	1.56e-5	Photic sneeze reflex;
THYM	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg06618935	chr21:46677482	NA	-0.98	-9.41	-0.69	3.08e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg08704250	chr15:31115839	NA	-0.52	-6.2	-0.54	1.48e-8	Huntington's disease progression;
THYM	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13732083	chr21:47605072	C21orf56	-0.72	-5.13	-0.47	1.51e-6	Testicular germ cell tumor;
THYM	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg15445000	chr17:37608096	MED1	0.44	5.1	0.46	1.73e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs6686842	0.864	rs6662279	chr1:41553561	T/C	cg03387723	chr1:41708464	SCMH1	0.44	5.22	0.47	1.04e-6	Height;
THYM	cis	rs919433	0.647	rs6741205	chr2:198525997	G/C	cg00792783	chr2:198669748	PLCL1	0.82	5.44	0.49	4.16e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg19052272	chr2:3704530	ALLC	-0.67	-5.0	-0.46	2.62e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs11722228	0.790	rs13126729	chr4:9974186	G/A	cg11266682	chr4:10021025	SLC2A9	-0.49	-4.96	-0.45	3.14e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs888194	0.677	rs2075431	chr12:109874621	C/T	cg10504392	chr12:110044639	NA	0.6	5.49	0.49	3.28e-7	Neuroticism;
THYM	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg27490568	chr2:178487706	NA	0.66	5.3	0.48	7.57e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg15704280	chr7:45808275	SEPT13	1.07	9.88	0.71	2.92e-16	Height;
THYM	cis	rs9470366	0.816	rs4331968	chr6:36623243	A/T	cg24425727	chr6:36645648	CDKN1A	-0.58	-4.73	-0.44	7.82e-6	QRS duration;
THYM	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg04025307	chr7:1156635	C7orf50	0.77	7.36	0.6	6.44e-11	Longevity;Endometriosis;
THYM	cis	rs9470366	0.527	rs10807170	chr6:36629444	C/T	cg11920449	chr6:36645608	CDKN1A	0.66	5.58	0.5	2.26e-7	QRS duration;
THYM	cis	rs2456568	0.503	rs4254038	chr11:93666978	T/C	cg26875233	chr11:93583750	C11orf90	-0.52	-5.74	-0.51	1.11e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg23711669	chr6:146136114	FBXO30	0.96	10.27	0.73	4.48e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4713118	0.699	rs200969	chr6:27859453	T/C	cg23161317	chr6:28129485	ZNF389	0.67	5.95	0.52	4.41e-8	Parkinson's disease;
THYM	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg27535305	chr1:53392650	SCP2	0.4	4.65	0.43	1.09e-5	Monocyte count;
THYM	cis	rs753778	0.962	rs2043422	chr8:142236337	C/T	cg18755752	chr8:142205143	DENND3	-0.63	-4.74	-0.44	7.5e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg18681998	chr4:17616180	MED28	0.82	7.25	0.6	1.09e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.68	-5.91	-0.52	5.35e-8	Lymphocyte counts;
THYM	cis	rs1351164	0.557	rs111945704	chr2:218369566	C/T	cg15335768	chr2:218268053	DIRC3	-0.5	-5.4	-0.48	4.93e-7	Height;
THYM	cis	rs6502050	0.769	rs66670693	chr17:80181799	G/A	cg03388043	chr17:80084554	CCDC57	-0.71	-5.89	-0.52	5.84e-8	Life satisfaction;
THYM	cis	rs2901656	0.934	rs9425311	chr1:172388778	G/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.51	5.37	0.48	5.59e-7	Red cell distribution width;Platelet distribution width;
THYM	cis	rs863345	0.625	rs950487	chr1:158460130	A/T	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg09990169	chr2:241835740	C2orf54	-0.37	-6.3	-0.54	9.4e-9	Urinary metabolites;
THYM	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg16586182	chr3:47516702	SCAP	-0.65	-5.58	-0.5	2.3e-7	Colorectal cancer;
THYM	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg23422044	chr7:1970798	MAD1L1	-0.8	-5.3	-0.48	7.45e-7	Bipolar disorder;
THYM	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg18876405	chr7:65276391	NA	0.62	5.54	0.49	2.66e-7	Aortic root size;
THYM	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg00495681	chr13:53174319	NA	0.88	8.75	0.67	7.63e-14	Lewy body disease;
THYM	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg24253500	chr15:84953950	NA	0.54	4.58	0.42	1.43e-5	Schizophrenia;
THYM	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg14983838	chr19:29218262	NA	0.82	5.16	0.47	1.38e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs4919044	0.808	rs2486680	chr10:94805529	C/T	cg05127821	chr10:94822908	CYP26C1	-1.23	-6.66	-0.56	1.76e-9	Coronary artery disease;
THYM	cis	rs861020	0.606	rs627459	chr1:210004682	C/G	cg05527609	chr1:210001259	C1orf107	0.85	6.82	0.57	8.53e-10	Orofacial clefts;
THYM	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg03433033	chr1:76189801	ACADM	0.77	10.21	0.72	6.01e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.85	9.8	0.71	4.33e-16	Prudent dietary pattern;
THYM	cis	rs89107	0.575	rs10872167	chr6:118988362	C/T	cg21191810	chr6:118973309	C6orf204	-0.58	-6.11	-0.53	2.16e-8	Cardiac structure and function;
THYM	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg14115884	chr9:139300582	SDCCAG3	-0.7	-6.69	-0.57	1.53e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7119	0.666	rs2516302	chr15:77879842	C/G	cg10437265	chr15:77819839	NA	-0.61	-5.83	-0.51	7.54e-8	Type 2 diabetes;
THYM	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg03467027	chr4:99064603	C4orf37	0.82	4.85	0.45	4.8e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11249608	0.548	rs6880315	chr5:178452502	G/A	cg01312482	chr5:178451176	ZNF879	-0.76	-6.23	-0.54	1.26e-8	Pubertal anthropometrics;
THYM	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg11764359	chr7:65958608	NA	0.75	5.99	0.52	3.74e-8	Aortic root size;
THYM	cis	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.55	-5.53	-0.49	2.86e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17490626	0.568	rs12260685	chr10:71215799	C/T	cg08851181	chr10:71228077	TSPAN15	-0.71	-4.89	-0.45	4.09e-6	Thrombosis;
THYM	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg02524346	chr8:600233	NA	1.0	4.69	0.43	8.99e-6	IgG glycosylation;
THYM	cis	rs778371	1.000	rs778371	chr2:233743109	A/G	cg08000102	chr2:233561755	GIGYF2	-0.81	-6.56	-0.56	2.82e-9	Schizophrenia;
THYM	cis	rs11112613	0.609	rs7966960	chr12:106032152	G/A	cg03607813	chr12:105948248	NA	0.76	4.59	0.43	1.36e-5	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs4660306	0.961	rs4660862	chr1:45955056	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.43	-0.49	4.37e-7	Homocysteine levels;
THYM	cis	rs921665	0.831	rs4337500	chr2:3190786	T/C	cg16434511	chr2:3151078	NA	-0.87	-5.46	-0.49	3.8e-7	World class endurance athleticism;
THYM	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg12963246	chr6:28129442	ZNF389	0.65	4.95	0.45	3.26e-6	Parkinson's disease;
THYM	cis	rs1215050	0.740	rs804051	chr4:98935935	A/T	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg05457628	chr5:178986728	RUFY1	0.68	7.05	0.59	2.82e-10	Lung cancer;
THYM	cis	rs8067545	0.750	rs4924803	chr17:19991806	C/T	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.63e-6	Schizophrenia;
THYM	cis	rs17253792	0.732	rs10146604	chr14:56045770	C/G	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg07936489	chr17:37558343	FBXL20	0.83	5.84	0.51	7.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.79	-4.82	-0.44	5.45e-6	Diabetic retinopathy;
THYM	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-7.41	-0.61	5.06e-11	Schizophrenia;
THYM	cis	rs10788264	0.504	rs4751885	chr10:124020305	G/T	cg09507567	chr10:124027408	NA	0.53	5.44	0.49	4.11e-7	Total body bone mineral density;
THYM	cis	rs2109514	0.967	rs4730743	chr7:116145957	A/T	cg12739419	chr7:116140593	CAV2	-0.48	-4.66	-0.43	1.04e-5	Prevalent atrial fibrillation;
THYM	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.63	-4.49	-0.42	2.01e-5	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg05368731	chr17:41323189	NBR1	-1.25	-11.51	-0.76	1.04e-19	Menopause (age at onset);
THYM	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg20503657	chr10:835505	NA	1.34	8.98	0.68	2.55e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg15501526	chr10:2543763	NA	-0.77	-7.64	-0.62	1.7e-11	Age-related hearing impairment;
THYM	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg08188268	chr10:116634841	FAM160B1	0.26	4.48	0.42	2.05e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg05855489	chr10:104503620	C10orf26	0.56	4.54	0.42	1.65e-5	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs642803	0.613	rs489574	chr11:65542739	C/T	cg27068330	chr11:65405492	SIPA1	0.73	5.34	0.48	6.42e-7	Urate levels;
THYM	cis	rs4746818	1.000	rs1506769	chr10:70959710	T/C	cg04149295	chr10:70884716	VPS26A	0.77	5.15	0.47	1.42e-6	Left atrial antero-posterior diameter;
THYM	cis	rs859767	0.519	rs11688414	chr2:135420237	G/A	cg12500956	chr2:135428796	TMEM163	-0.56	-4.83	-0.44	5.2e-6	Neuroticism;
THYM	cis	rs4363385	0.818	rs678960	chr1:153011621	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg20387954	chr3:183756860	HTR3D	0.58	4.73	0.44	7.72e-6	Anterior chamber depth;
THYM	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg04842962	chr6:43655489	MRPS18A	1.41	15.71	0.85	3.75e-28	IgG glycosylation;
THYM	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg09307838	chr4:120376055	NA	0.64	4.63	0.43	1.15e-5	Corneal astigmatism;
THYM	cis	rs10788264	0.621	rs7907952	chr10:124056774	C/T	cg09507567	chr10:124027408	NA	-0.48	-4.67	-0.43	9.98e-6	Total body bone mineral density;
THYM	cis	rs155076	0.666	rs4770128	chr13:21881922	A/G	cg14456004	chr13:21872349	NA	1.23	11.19	0.75	4.98e-19	White matter hyperintensity burden;
THYM	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg04156016	chr5:1868137	NA	0.5	4.63	0.43	1.17e-5	Cardiovascular disease risk factors;
THYM	cis	rs250677	0.522	rs10040598	chr5:148365720	C/A	cg18129178	chr5:148520854	ABLIM3	0.72	5.4	0.48	4.94e-7	Breast cancer;
THYM	cis	rs977987	0.806	rs12930768	chr16:75464500	T/C	cg03315344	chr16:75512273	CHST6	0.73	5.83	0.51	7.5e-8	Dupuytren's disease;
THYM	cis	rs6815814	0.861	rs28393318	chr4:38784267	A/G	cg06935464	chr4:38784597	TLR10	0.68	4.91	0.45	3.75e-6	Breast cancer;
THYM	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.58	0.56	2.61e-9	Total body bone mineral density;
THYM	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.94	6.61	0.56	2.24e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs611744	0.837	rs399131	chr8:109105285	C/T	cg21045802	chr8:109455806	TTC35	-0.59	-5.24	-0.47	9.58e-7	Dupuytren's disease;
THYM	cis	rs1278352	0.894	rs898321	chr10:127771669	C/A	cg08295661	chr10:127769903	ADAM12	-0.43	-4.77	-0.44	6.76e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs2463822	0.925	rs72923272	chr11:62166832	G/A	cg06239285	chr11:62104954	ASRGL1	-1.4	-6.65	-0.56	1.86e-9	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs61931739	0.513	rs2200555	chr12:33899381	C/G	cg10856724	chr12:34555212	NA	-0.67	-5.95	-0.52	4.46e-8	Morning vs. evening chronotype;
THYM	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg11742103	chr11:62369870	EML3;MTA2	-0.68	-8.85	-0.67	4.75e-14	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg06873352	chr17:61820015	STRADA	0.6	5.92	0.52	5.13e-8	Height;
THYM	cis	rs67311347	0.544	rs12633295	chr3:40335292	G/T	cg13683864	chr3:40499215	RPL14	0.73	6.91	0.58	5.47e-10	Renal cell carcinoma;
THYM	cis	rs7572733	0.555	rs2341778	chr2:198776546	G/A	cg05783139	chr2:198650985	BOLL	-0.62	-4.89	-0.45	4.15e-6	Dermatomyositis;
THYM	cis	rs10779751	1.000	rs2016559	chr1:11269917	G/T	cg08854313	chr1:11322531	MTOR	0.89	7.6	0.62	2.03e-11	Body mass index;
THYM	cis	rs10484885	0.752	rs72921948	chr6:90582560	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.91	-9.55	-0.7	1.5e-15	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.65e-6	Aortic root size;
THYM	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg25566285	chr7:158114605	PTPRN2	-0.87	-10.68	-0.74	5.87e-18	Calcium levels;
THYM	cis	rs7010267	0.568	rs2220189	chr8:120007708	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.62	4.83	0.44	5.26e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs6541297	1.000	rs6681042	chr1:230278979	G/A	cg20703242	chr1:230279135	GALNT2	0.92	6.26	0.54	1.13e-8	Coronary artery disease;
THYM	cis	rs13064411	0.735	rs7636128	chr3:113133701	A/T	cg10517650	chr3:113235015	CCDC52	-0.54	-4.64	-0.43	1.13e-5	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs9399401	0.667	rs11759653	chr6:142720354	G/A	cg04461802	chr6:142623433	GPR126	0.77	7.46	0.61	3.98e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	5.47	0.49	3.58e-7	Personality dimensions;
THYM	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg19318889	chr4:1322082	MAEA	0.69	5.93	0.52	4.98e-8	Longevity;
THYM	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg03452623	chr4:187889614	NA	-1.17	-18.46	-0.88	3.44e-33	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7084402	0.967	rs1658439	chr10:60325986	A/G	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg19729930	chr2:74357872	NA	1.29	11.31	0.76	2.68e-19	Gestational age at birth (maternal effect);
THYM	cis	rs8038465	0.623	rs6495073	chr15:73947534	A/T	cg15420318	chr15:73925796	NPTN	0.63	5.49	0.49	3.29e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2463822	0.507	rs72919442	chr11:62028707	A/G	cg06239285	chr11:62104954	ASRGL1	-1.05	-4.8	-0.44	5.85e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg03388043	chr17:80084554	CCDC57	-0.73	-6.06	-0.53	2.74e-8	Life satisfaction;
THYM	cis	rs3892630	0.824	rs35654350	chr19:33223766	T/C	cg02283691	chr19:33182526	NUDT19	-0.41	-4.85	-0.45	4.83e-6	Red blood cell traits;
THYM	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg08645402	chr16:4508243	NA	0.73	7.12	0.59	2.08e-10	Schizophrenia;
THYM	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg15704280	chr7:45808275	SEPT13	-0.98	-11.44	-0.76	1.43e-19	Coronary artery disease;
THYM	cis	rs860295	0.580	rs11264361	chr1:155289545	T/G	cg02153340	chr1:155202674	NA	-0.64	-4.45	-0.42	2.32e-5	Body mass index;
THYM	cis	rs1801251	0.656	rs10211596	chr2:233699415	C/T	cg08000102	chr2:233561755	GIGYF2	-0.77	-6.63	-0.56	2.07e-9	Coronary artery disease;
THYM	cis	rs4474465	1.000	rs7929712	chr11:78158542	T/C	cg19901956	chr11:77921274	USP35	-0.62	-4.63	-0.43	1.15e-5	Alzheimer's disease (survival time);
THYM	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg24675056	chr1:15929824	NA	0.73	5.86	0.52	6.71e-8	Systolic blood pressure;
THYM	cis	rs10979	1.000	rs9390104	chr6:143890978	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs7843479	0.601	rs9969551	chr8:21860007	T/C	cg17168535	chr8:21777572	XPO7	0.81	7.06	0.59	2.76e-10	Mean corpuscular volume;
THYM	cis	rs17376456	0.542	rs6556833	chr5:93104707	T/C	cg25358565	chr5:93447407	FAM172A	0.85	6.01	0.52	3.38e-8	Diabetic retinopathy;
THYM	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg03676636	chr4:99064102	C4orf37	0.43	5.79	0.51	8.87e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22590775	chr19:49891494	CCDC155	0.78	6.32	0.54	8.4e-9	Multiple sclerosis;
THYM	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg24308560	chr3:49941425	MST1R	0.79	6.93	0.58	5.05e-10	Intelligence (multi-trait analysis);
THYM	cis	rs4363385	0.693	rs662506	chr1:153048386	A/C	cg13444842	chr1:152974279	SPRR3	0.61	4.91	0.45	3.81e-6	Inflammatory skin disease;
THYM	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg17509989	chr5:176798049	RGS14	0.67	6.22	0.54	1.35e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg00677455	chr12:58241039	CTDSP2	0.71	5.24	0.47	9.73e-7	Intelligence (multi-trait analysis);
THYM	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg26441486	chr22:50317300	CRELD2	-0.38	-5.63	-0.5	1.85e-7	Schizophrenia;
THYM	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg04398451	chr17:18023971	MYO15A	-0.95	-9.84	-0.71	3.63e-16	Total body bone mineral density;
THYM	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg13010199	chr12:38710504	ALG10B	-0.62	-4.46	-0.42	2.21e-5	Bladder cancer;
THYM	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.64	5.09	0.46	1.83e-6	Total body bone mineral density;
THYM	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	5.38	0.48	5.45e-7	Schizophrenia;
THYM	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg13607699	chr17:42295918	UBTF	-0.66	-5.44	-0.49	4.13e-7	Total body bone mineral density;
THYM	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg08847533	chr14:75593920	NEK9	-0.93	-9.75	-0.71	5.55e-16	Height;
THYM	cis	rs17102423	0.589	rs8011585	chr14:65522223	T/A	cg11161011	chr14:65562177	MAX	-0.55	-4.55	-0.42	1.58e-5	Obesity-related traits;
THYM	cis	rs7119	0.651	rs12904533	chr15:77845928	G/A	cg27398640	chr15:77910606	LINGO1	-0.59	-5.75	-0.51	1.07e-7	Type 2 diabetes;
THYM	cis	rs910187	0.678	rs1046664	chr20:45817223	G/A	cg27589058	chr20:45804311	EYA2	-0.58	-4.97	-0.45	2.96e-6	Migraine;
THYM	cis	rs16866061	1.000	rs72974238	chr2:225432470	C/A	cg22455342	chr2:225449267	CUL3	0.67	4.8	0.44	6e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs17253792	0.822	rs74412558	chr14:56054311	C/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.79e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.68	4.94	0.45	3.32e-6	Renal function-related traits (BUN);
THYM	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	5.52	0.49	2.88e-7	Hip circumference adjusted for BMI;
THYM	cis	rs763014	0.898	rs12917944	chr16:622565	A/G	cg09263875	chr16:632152	PIGQ	0.73	6.29	0.54	9.69e-9	Height;
THYM	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg24531977	chr5:56204891	C5orf35	-1.0	-8.23	-0.65	9.77e-13	Initial pursuit acceleration;
THYM	cis	rs7106204	0.748	rs6484024	chr11:24210079	T/C	ch.11.24196551F	chr11:24239977	NA	0.99	7.0	0.58	3.64e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs6840360	0.809	rs6846809	chr4:152730201	A/G	cg22705602	chr4:152727874	NA	0.66	8.06	0.64	2.3e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg09904177	chr6:26538194	HMGN4	0.64	5.4	0.48	4.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs262150	0.501	rs1017034	chr7:158820460	A/G	cg04111992	chr7:158790115	NA	-0.55	-4.94	-0.45	3.4e-6	Facial morphology (factor 20);
THYM	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg00071950	chr4:10020882	SLC2A9	0.86	10.33	0.73	3.3e-17	Bone mineral density;
THYM	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg12935359	chr14:103987150	CKB	-0.64	-6.43	-0.55	5.14e-9	Body mass index;
THYM	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg08999081	chr20:33150536	PIGU	-0.55	-4.84	-0.44	5.05e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4285028	0.948	rs13089878	chr3:121703895	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.73	-5.04	-0.46	2.26e-6	Multiple sclerosis;
THYM	trans	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg25214090	chr10:38739885	LOC399744	-0.86	-7.44	-0.61	4.49e-11	Corneal astigmatism;
THYM	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg05527609	chr1:210001259	C1orf107	1.01	8.31	0.65	6.7e-13	Orofacial clefts;
THYM	cis	rs2072510	0.569	rs7970524	chr12:96390152	A/G	cg18817487	chr12:96390143	HAL	0.48	6.21	0.54	1.41e-8	Metabolite levels (small molecules and protein measures);
THYM	cis	rs7830933	0.955	rs57220043	chr8:23602763	A/T	cg04349084	chr8:23602677	NA	0.65	7.36	0.6	6.49e-11	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg18681998	chr4:17616180	MED28	0.99	10.27	0.73	4.28e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg04865290	chr3:52927548	TMEM110	-0.88	-4.55	-0.42	1.59e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2463822	1.000	rs2513747	chr11:62098735	T/C	cg06239285	chr11:62104954	ASRGL1	1.44	7.77	0.62	9.14e-12	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs877282	0.733	rs7092976	chr10:756358	G/A	cg10556349	chr10:835070	NA	-0.69	-4.49	-0.42	2.03e-5	Uric acid levels;
THYM	cis	rs9583531	0.600	rs7330080	chr13:111367115	C/T	cg24331049	chr13:111365604	ING1	0.72	5.95	0.52	4.46e-8	Coronary artery disease;
THYM	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07167872	chr1:205819463	PM20D1	0.95	9.06	0.68	1.69e-14	Menarche (age at onset);
THYM	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg22875332	chr1:76189707	ACADM	-0.52	-4.82	-0.44	5.5e-6	Daytime sleep phenotypes;
THYM	cis	rs11039798	0.512	rs1988465	chr11:49011303	C/T	cg24672777	chr11:48374446	OR4C45	-0.97	-6.23	-0.54	1.29e-8	Axial length;
THYM	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg04842962	chr6:43655489	MRPS18A	1.4	15.65	0.85	4.9e-28	IgG glycosylation;
THYM	cis	rs7772486	0.806	rs2253648	chr6:146199296	G/A	cg23711669	chr6:146136114	FBXO30	0.9	8.72	0.67	8.76e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3849570	0.961	rs3772912	chr3:81698481	A/G	cg07356753	chr3:81810745	GBE1	-0.72	-4.96	-0.45	3.12e-6	Waist circumference;Body mass index;
THYM	cis	rs790123	0.842	rs2650958	chr3:122396187	A/T	cg15604389	chr3:122379662	NA	0.52	4.71	0.44	8.38e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.92	0.45	3.58e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg07424592	chr7:64974309	NA	1.01	5.39	0.48	5.1e-7	Diabetic kidney disease;
THYM	cis	rs10140922	0.966	rs10135277	chr14:35823231	A/G	cg07166546	chr14:35805898	NA	0.27	6.45	0.55	4.68e-9	Hip circumference adjusted for BMI;
THYM	cis	rs72949976	0.898	rs6732233	chr2:214022834	C/T	cg08319019	chr2:214017104	IKZF2	-0.69	-5.22	-0.47	1.06e-6	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs9399401	0.710	rs12190271	chr6:142681409	A/G	cg03128060	chr6:142623767	GPR126	-0.69	-9.21	-0.69	8.11e-15	Chronic obstructive pulmonary disease;
THYM	cis	rs4452313	0.547	rs9824172	chr3:16974123	T/G	cg19448816	chr3:16974217	PLCL2	0.63	5.12	0.46	1.6e-6	Rheumatoid arthritis;
THYM	cis	rs1843834	0.721	rs6715655	chr2:225582284	C/T	cg10193763	chr2:225306901	NA	0.43	4.61	0.43	1.25e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg27170947	chr2:26402098	FAM59B	0.61	5.27	0.48	8.49e-7	Gut microbiome composition (summer);
THYM	cis	rs11166927	1.000	rs13260415	chr8:140805137	A/C	cg16909799	chr8:140841666	TRAPPC9	0.62	5.51	0.49	3.11e-7	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg20891558	chr2:74357851	NA	1.19	11.01	0.75	1.17e-18	Gestational age at birth (maternal effect);
THYM	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg18402987	chr7:1209562	NA	0.74	5.36	0.48	5.8e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8112211	0.834	rs3843754	chr19:38807184	G/A	cg25820703	chr19:38877220	GGN	-0.48	-4.56	-0.42	1.5e-5	Blood protein levels;
THYM	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	5.18	0.47	1.25e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4664308	1.000	rs6719686	chr2:160908292	T/G	cg03641300	chr2:160917029	PLA2R1	-0.76	-6.83	-0.57	7.92e-10	Idiopathic membranous nephropathy;
THYM	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.09	-0.64	1.98e-12	Personality dimensions;
THYM	cis	rs919433	0.854	rs787994	chr2:198223121	T/C	cg00792783	chr2:198669748	PLCL1	0.73	5.3	0.48	7.35e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg17077180	chr1:38461687	NA	0.43	4.89	0.45	4.18e-6	Coronary artery disease;
THYM	cis	rs11030122	0.702	rs10500590	chr11:3964724	T/C	cg22027985	chr11:4115532	RRM1	-0.48	-4.59	-0.43	1.36e-5	Mean platelet volume;Platelet distribution width;
THYM	cis	rs17030434	0.654	rs1530105	chr4:154646994	C/T	cg14289246	chr4:154710475	SFRP2	0.68	4.69	0.43	9.1e-6	Electrocardiographic conduction measures;
THYM	cis	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg06521331	chr12:34319734	NA	-0.84	-6.44	-0.55	4.78e-9	Morning vs. evening chronotype;
THYM	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg07884673	chr3:53033167	SFMBT1	1.13	5.83	0.51	7.45e-8	Immune reponse to smallpox (secreted IL-2);
THYM	trans	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg17268801	chr19:24269968	ZNF254	-0.94	-6.85	-0.57	7.41e-10	Lung adenocarcinoma;
THYM	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg15448220	chr1:150897856	SETDB1	0.89	7.36	0.6	6.64e-11	Urate levels;
THYM	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg11764359	chr7:65958608	NA	0.69	4.78	0.44	6.27e-6	Aortic root size;
THYM	cis	rs6546324	0.625	rs11900280	chr2:67840401	T/C	cg18237512	chr2:67827392	NA	-0.8	-4.77	-0.44	6.69e-6	Endometriosis;
THYM	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	4.49	0.42	2.03e-5	Axial length;
THYM	cis	rs1691799	0.899	rs1168292	chr12:66732660	C/T	cg16791601	chr12:66731901	HELB	-0.76	-7.23	-0.6	1.21e-10	White blood cell count (basophil);
THYM	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg13319975	chr6:146136371	FBXO30	0.66	5.42	0.49	4.55e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg16325326	chr1:53192061	ZYG11B	-0.86	-8.54	-0.66	2.14e-13	Monocyte count;
THYM	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg10661904	chr17:79619235	PDE6G	-0.65	-6.34	-0.54	7.88e-9	Eye color traits;
THYM	cis	rs6988636	1.000	rs17323510	chr8:124186089	A/G	cg26140120	chr8:124219575	FAM83A	-0.79	-4.48	-0.42	2.12e-5	Urinary uromodulin levels;
THYM	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.82	0.44	5.36e-6	Alzheimer's disease (late onset);
THYM	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.84	-5.3	-0.48	7.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs3820068	0.705	rs11584398	chr1:15880275	G/A	cg05660106	chr1:15850417	CASP9	1.15	9.97	0.72	1.88e-16	Systolic blood pressure;
THYM	cis	rs11563648	0.553	rs951992	chr7:126986838	G/A	cg08586737	chr7:127225949	GCC1	-0.33	-4.53	-0.42	1.74e-5	Resting heart rate;
THYM	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg11327659	chr7:150037044	RARRES2	-0.43	-5.04	-0.46	2.18e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2120243	0.539	rs4679793	chr3:157122661	A/C	cg24825693	chr3:157122686	VEPH1	0.47	4.52	0.42	1.8e-5	Hepatocellular carcinoma in hepatitis B infection;
THYM	cis	rs7851660	0.874	rs925487	chr9:100636398	C/T	cg13688889	chr9:100608707	NA	-0.68	-4.69	-0.43	9.13e-6	Strep throat;
THYM	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg25817165	chr18:72167213	CNDP2	-0.96	-7.96	-0.63	3.71e-12	Refractive error;
THYM	cis	rs1978968	1.000	rs12158906	chr22:18437382	A/G	cg01550578	chr22:18484421	MICAL3	0.7	5.25	0.47	9.21e-7	Presence of antiphospholipid antibodies;
THYM	cis	rs4383453	0.539	rs2009176	chr3:123100976	C/T	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg15691649	chr6:25882328	NA	0.65	5.01	0.46	2.48e-6	Blood metabolite levels;
THYM	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs17443541	0.507	rs6721266	chr2:200469388	C/T	cg03741458	chr2:200468445	NA	-0.75	-5.77	-0.51	9.74e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg12016809	chr21:47604291	C21orf56	0.66	4.59	0.43	1.36e-5	Testicular germ cell tumor;
THYM	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg03983476	chr2:10830698	NOL10	-0.61	-5.52	-0.49	2.94e-7	Prostate cancer;
THYM	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg11764359	chr7:65958608	NA	0.64	5.0	0.46	2.58e-6	Aortic root size;
THYM	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	9.55	0.7	1.49e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7216064	1.000	rs2365468	chr17:65841318	C/T	cg12091567	chr17:66097778	LOC651250	-0.72	-5.0	-0.46	2.59e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs887829	0.569	rs10179091	chr2:234657983	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.75	-6.21	-0.54	1.41e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs11112613	0.713	rs12580741	chr12:105941328	A/G	cg03607813	chr12:105948248	NA	-1.04	-8.85	-0.67	4.79e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg08439880	chr3:133502540	NA	-0.71	-6.05	-0.53	2.86e-8	Iron status biomarkers;
THYM	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg22166914	chr1:53195759	ZYG11B	-0.82	-8.52	-0.66	2.41e-13	Monocyte count;
THYM	cis	rs10203711	0.600	rs1810138	chr2:239561888	T/C	cg14580085	chr2:239553406	NA	0.71	6.63	0.56	1.99e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.5	-0.49	3.18e-7	Obesity-related traits;
THYM	cis	rs654950	0.875	rs600109	chr1:41998246	A/G	cg06885757	chr1:42089581	HIVEP3	-0.49	-6.01	-0.52	3.46e-8	Airway imaging phenotypes;
THYM	cis	rs2115536	0.967	rs4778734	chr15:80210851	A/G	cg00225070	chr15:80189496	MTHFS	0.61	5.34	0.48	6.3e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs28595532	0.920	rs112097820	chr4:119746532	G/A	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg24818145	chr4:99064322	C4orf37	-0.62	-4.59	-0.43	1.34e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs476633	0.691	rs11858115	chr15:41542591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.66	-5.59	-0.5	2.16e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg08564027	chr20:61660810	NA	0.92	9.78	0.71	4.93e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg11965913	chr1:205819406	PM20D1	-0.68	-6.3	-0.54	9.3e-9	Menarche (age at onset);
THYM	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg15164180	chr2:241846931	NA	-0.35	-4.78	-0.44	6.38e-6	Urinary metabolites;
THYM	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg03609598	chr5:56110824	MAP3K1	-0.81	-5.41	-0.49	4.67e-7	Initial pursuit acceleration;
THYM	cis	rs11645898	0.504	rs75888697	chr16:71985222	A/C	cg03805757	chr16:71968109	PKD1L3	-0.97	-7.13	-0.59	1.95e-10	Blood protein levels;
THYM	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg09307838	chr4:120376055	NA	0.72	5.06	0.46	2.02e-6	Corneal astigmatism;
THYM	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs11605275	1.000	rs78913308	chr11:20027477	A/G	cg14835545	chr11:20032148	NAV2	-1.29	-6.34	-0.55	7.74e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg06656553	chr16:89960601	TCF25	-0.98	-4.53	-0.42	1.74e-5	Skin colour saturation;
THYM	cis	rs9828933	0.766	rs704372	chr3:63867453	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.75	5.45	0.49	3.93e-7	Type 2 diabetes;
THYM	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg07424592	chr7:64974309	NA	1.03	5.4	0.48	4.94e-7	Diabetic kidney disease;
THYM	cis	rs7582403	0.844	rs10928374	chr2:148852035	A/G	cg23727674	chr2:148602993	ACVR2A	-0.58	-4.79	-0.44	6.24e-6	Neuroticism;
THYM	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg02527881	chr3:46936655	PTH1R	-0.69	-7.11	-0.59	2.11e-10	Colorectal cancer;
THYM	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg07690219	chr3:49449608	TCTA;RHOA	0.69	4.62	0.43	1.21e-5	Menarche (age at onset);
THYM	trans	rs8073060	0.544	rs225287	chr17:33929487	G/T	cg19694781	chr19:47549865	TMEM160	-0.99	-8.55	-0.66	2.1e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs1336149	0.529	rs11264612	chr1:157046852	G/T	cg12604331	chr1:156906485	ARHGEF11;MIR765	-0.62	-5.35	-0.48	6.17e-7	Chin dimples;
THYM	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.52e-7	Heart rate;
THYM	cis	rs34638657	0.872	rs2967349	chr16:82194405	G/C	cg07307142	chr16:82071433	HSD17B2	-1.0	-7.94	-0.63	4.09e-12	Lung adenocarcinoma;
THYM	cis	rs6087990	0.871	rs2424905	chr20:31352927	T/C	cg13636640	chr20:31349939	DNMT3B	0.92	8.94	0.68	3.07e-14	Ulcerative colitis;
THYM	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg06618935	chr21:46677482	NA	-0.99	-9.28	-0.69	5.6e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg27129171	chr3:47204927	SETD2	0.77	7.52	0.61	3.08e-11	Colorectal cancer;
THYM	trans	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg25214090	chr10:38739885	LOC399744	0.87	7.54	0.61	2.75e-11	Corneal astigmatism;
THYM	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg19761014	chr17:28927070	LRRC37B2	-0.89	-5.28	-0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs76878669	0.606	rs2282531	chr11:66099494	C/T	cg18002602	chr11:66138449	SLC29A2	-0.49	-4.66	-0.43	1.05e-5	Educational attainment (years of education);
THYM	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg24818145	chr4:99064322	C4orf37	0.9	7.36	0.6	6.5e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg18105134	chr13:113819100	PROZ	1.11	9.66	0.7	8.68e-16	Platelet distribution width;
THYM	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg07959070	chr22:50026188	C22orf34	-0.28	-4.88	-0.45	4.25e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg27121462	chr16:89883253	FANCA	0.59	4.73	0.44	7.9e-6	Vitiligo;
THYM	cis	rs61931739	0.517	rs2636073	chr12:34063049	C/T	cg10856724	chr12:34555212	NA	-0.79	-7.41	-0.61	5.14e-11	Morning vs. evening chronotype;
THYM	cis	rs7177699	0.526	rs7165733	chr15:79123505	G/A	cg00540400	chr15:79124168	NA	0.65	7.03	0.58	3.16e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs714027	1.000	rs757024	chr22:30471679	G/C	cg11564601	chr22:30592435	NA	-0.29	-5.23	-0.47	1e-6	Lymphocyte counts;
THYM	cis	rs17511627	0.808	rs12857368	chr13:26746179	T/A	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs2404602	0.647	rs11634266	chr15:77093461	A/G	cg23625390	chr15:77176239	SCAPER	-0.85	-6.21	-0.54	1.39e-8	Blood metabolite levels;
THYM	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg06600287	chr1:53387719	ECHDC2	-0.31	-4.76	-0.44	7.03e-6	Monocyte count;
THYM	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg17143192	chr8:8559678	CLDN23	-0.94	-7.03	-0.59	3.1e-10	Obesity-related traits;
THYM	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg24675658	chr1:53192096	ZYG11B	0.56	4.66	0.43	1.04e-5	Monocyte count;
THYM	cis	rs6924995	0.501	rs9383120	chr6:16192025	T/C	cg11805552	chr6:16175128	NA	0.58	4.8	0.44	5.89e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg27398817	chr8:82754497	SNX16	-0.72	-5.93	-0.52	4.94e-8	Diastolic blood pressure;
THYM	cis	rs3825942	0.900	rs8042039	chr15:74225518	C/T	cg23484268	chr15:74220776	LOXL1	0.49	4.74	0.44	7.52e-6	Glaucoma (exfoliation);
THYM	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-7.23	-0.6	1.2e-10	Schizophrenia;
THYM	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg22683308	chr4:1340831	KIAA1530	-0.67	-5.32	-0.48	6.77e-7	Longevity;
THYM	cis	rs67981189	0.835	rs2526855	chr14:71413346	T/C	cg15910301	chr14:71632612	NA	-0.5	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.6	-8.2	-0.64	1.13e-12	Monocyte percentage of white cells;
THYM	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg24399712	chr22:39784796	NA	0.91	9.58	0.7	1.29e-15	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg16586182	chr3:47516702	SCAP	0.63	5.15	0.47	1.42e-6	Colorectal cancer;
THYM	cis	rs3126085	1.000	rs3126085	chr1:152300817	G/A	cg10321714	chr1:152280068	FLG	-0.72	-5.44	-0.49	4.14e-7	Atopic dermatitis;
THYM	cis	rs2688608	0.592	rs11000759	chr10:75493726	G/A	cg23231163	chr10:75533350	FUT11	-0.44	-6.22	-0.54	1.34e-8	Inflammatory bowel disease;
THYM	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg18850127	chr7:39170497	POU6F2	0.6	5.66	0.5	1.57e-7	IgG glycosylation;
THYM	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02788857	chr8:22132959	PIWIL2	0.6	5.58	0.5	2.26e-7	Hypertriglyceridemia;
THYM	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	7.35	0.6	6.83e-11	Smoking behavior;
THYM	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg09367891	chr1:107599246	PRMT6	-0.75	-5.53	-0.49	2.77e-7	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.75	6.15	0.53	1.82e-8	Blood metabolite levels;
THYM	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg23281280	chr6:28129359	ZNF389	0.61	4.74	0.44	7.58e-6	Parkinson's disease;
THYM	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg02569458	chr12:86230093	RASSF9	0.69	5.77	0.51	9.84e-8	Major depressive disorder;
THYM	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	10.29	0.73	4e-17	Chronic sinus infection;
THYM	cis	rs10791097	0.702	rs10894267	chr11:130714861	C/T	cg05962950	chr11:130786565	SNX19	-0.7	-5.65	-0.5	1.64e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7246657	0.943	rs1559229	chr19:37876197	T/C	cg22634378	chr19:37742834	NA	0.61	5.17	0.47	1.32e-6	Coronary artery calcification;
THYM	cis	rs57545798	0.963	rs6598301	chr15:100645300	C/T	cg20941820	chr15:100882334	ADAMTS17	-0.61	-5.32	-0.48	6.84e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs684232	0.666	rs2657629	chr17:602261	G/T	cg15660573	chr17:549704	VPS53	-0.87	-8.15	-0.64	1.45e-12	Prostate cancer;
THYM	cis	rs6547741	1.000	rs6706610	chr2:27778091	G/A	cg27432699	chr2:27873401	GPN1	0.68	5.97	0.52	4.06e-8	Oral cavity cancer;
THYM	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9810089	0.814	rs866758	chr3:136117870	G/C	cg21827317	chr3:136751795	NA	0.59	5.18	0.47	1.26e-6	Gestational age at birth (child effect);
THYM	cis	rs2124969	0.548	rs983916	chr2:161015066	T/G	cg03641300	chr2:160917029	PLA2R1	-0.65	-4.58	-0.43	1.38e-5	Waist circumference adjusted for body mass index;
THYM	trans	rs877282	0.853	rs4579862	chr10:753298	A/C	cg22713356	chr15:30763199	NA	1.2	8.66	0.66	1.21e-13	Uric acid levels;
THYM	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg14829155	chr15:31115871	NA	-0.55	-5.04	-0.46	2.26e-6	Huntington's disease progression;
THYM	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg02725872	chr8:58115012	NA	-1.08	-6.65	-0.56	1.83e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7246657	0.943	rs4969487	chr19:37831039	C/T	cg22634378	chr19:37742834	NA	0.68	5.67	0.5	1.55e-7	Coronary artery calcification;
THYM	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg00757033	chr12:89920650	WDR51B	0.77	11.72	0.77	3.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9403317	0.919	rs6905051	chr6:141804428	G/A	cg15052665	chr6:141804349	NA	0.75	6.88	0.58	6.33e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg09307838	chr4:120376055	NA	-0.6	-4.59	-0.43	1.33e-5	Corneal astigmatism;
THYM	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs28374715	0.662	rs28493087	chr15:41486504	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.02	-8.4	-0.65	4.27e-13	Ulcerative colitis;
THYM	cis	rs988913	0.957	rs1503147	chr6:54759483	A/G	cg04690482	chr6:54711388	FAM83B	0.45	4.84	0.44	5.08e-6	Menarche (age at onset);
THYM	trans	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg25214090	chr10:38739885	LOC399744	0.93	7.92	0.63	4.43e-12	Corneal astigmatism;
THYM	cis	rs9583531	0.600	rs1441042	chr13:111365589	T/G	cg24331049	chr13:111365604	ING1	0.7	5.86	0.52	6.69e-8	Coronary artery disease;
THYM	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg21475434	chr5:93447410	FAM172A	-0.74	-5.09	-0.46	1.77e-6	Diabetic retinopathy;
THYM	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg07424592	chr7:64974309	NA	-1.03	-5.36	-0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg21773646	chr17:80085082	CCDC57	-0.33	-4.81	-0.44	5.56e-6	Life satisfaction;
THYM	cis	rs427394	0.659	rs274693	chr5:6734162	G/A	cg10857441	chr5:6722123	POLS	-0.72	-7.89	-0.63	5.24e-12	Menopause (age at onset);
THYM	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.85	-0.51	7.09e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs9915657	0.933	rs4793272	chr17:70139257	A/T	cg09344028	chr17:70110421	NA	0.44	4.49	0.42	1.99e-5	Thyroid hormone levels;
THYM	cis	rs12042938	0.507	rs1655299	chr1:231732161	C/T	cg04892437	chr1:231737901	TSNAX-DISC1	-0.48	-4.59	-0.43	1.38e-5	Neuranatomic and neurocognitive phenotypes;
THYM	cis	rs9814567	0.752	rs7633868	chr3:134331048	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs988913	1.000	rs6922438	chr6:54841383	A/C	cg18532076	chr6:54711417	FAM83B	0.5	4.91	0.45	3.78e-6	Menarche (age at onset);
THYM	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg25767906	chr1:53392781	SCP2	-0.57	-5.69	-0.5	1.41e-7	Monocyte count;
THYM	cis	rs9378357	0.614	rs6421940	chr6:3292317	A/C	cg08754725	chr6:3293098	SLC22A23	-0.77	-5.44	-0.49	4.15e-7	Obesity-related traits;
THYM	cis	rs67981189	0.896	rs28374308	chr14:71501757	G/T	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs7246657	0.943	rs10422074	chr19:37894236	T/C	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs55883249	1.000	rs11692112	chr2:9723732	G/T	cg23886495	chr2:9695866	ADAM17	0.82	5.32	0.48	6.79e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg13695892	chr22:41940480	POLR3H	0.97	7.44	0.61	4.55e-11	Vitiligo;
THYM	cis	rs4474465	1.000	rs11237509	chr11:78173439	C/A	cg19901956	chr11:77921274	USP35	-0.6	-4.46	-0.42	2.25e-5	Alzheimer's disease (survival time);
THYM	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg04362960	chr10:104952993	NT5C2	0.58	4.74	0.44	7.54e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06481639	chr22:41940642	POLR3H	-0.83	-5.64	-0.5	1.74e-7	Vitiligo;
THYM	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg13289132	chr10:30722225	MAP3K8	0.54	4.59	0.43	1.38e-5	Inflammatory bowel disease;
THYM	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg22709100	chr7:91322751	NA	0.6	4.74	0.44	7.58e-6	Breast cancer;
THYM	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg23758822	chr17:41437982	NA	-1.02	-9.62	-0.7	1.08e-15	Menopause (age at onset);
THYM	cis	rs7945718	0.905	rs7935997	chr11:12728651	A/G	cg25843174	chr11:12811716	TEAD1	0.45	4.47	0.42	2.15e-5	Educational attainment (years of education);
THYM	cis	rs1775715	0.705	rs2778651	chr10:32106575	C/T	cg04359828	chr10:32216031	ARHGAP12	0.39	4.96	0.45	3.02e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs9361491	0.579	rs9359350	chr6:79479151	G/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.88e-5	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg27129171	chr3:47204927	SETD2	0.7	6.7	0.57	1.44e-9	Colorectal cancer;
THYM	cis	rs9296092	0.517	rs7743064	chr6:33470529	C/T	cg13560919	chr6:33536144	NA	-0.84	-6.92	-0.58	5.15e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs7084402	1.000	rs7095501	chr10:60271940	T/C	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs897984	0.520	rs4889622	chr16:30870957	A/G	cg05768032	chr16:30646687	NA	-0.47	-4.61	-0.43	1.28e-5	Dementia with Lewy bodies;
THYM	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	6.68	0.57	1.6e-9	Schizophrenia;
THYM	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg09021430	chr5:549028	NA	-0.73	-5.44	-0.49	4.18e-7	Obesity-related traits;
THYM	cis	rs7799006	0.755	rs12534131	chr7:2294123	C/T	cg08027265	chr7:2291960	NA	-0.43	-5.05	-0.46	2.13e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.66e-15	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.758	rs7789093	chr7:1002981	T/C	cg08883853	chr7:1026168	CYP2W1	-0.47	-4.91	-0.45	3.83e-6	Longevity;Endometriosis;
THYM	cis	rs9329289	0.510	rs12356215	chr10:2545390	C/G	cg15501526	chr10:2543763	NA	0.56	5.03	0.46	2.3e-6	Age-related hearing impairment;
THYM	cis	rs12472274	0.646	rs10929269	chr2:239097423	A/G	cg17459225	chr2:239074497	NA	0.75	5.15	0.47	1.41e-6	Phospholipid levels (plasma);
THYM	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg10523679	chr1:76189770	ACADM	-0.57	-4.84	-0.44	5.05e-6	Daytime sleep phenotypes;
THYM	cis	rs6430585	0.702	rs2015532	chr2:136555525	G/T	cg07169764	chr2:136633963	MCM6	-1.18	-13.53	-0.81	6.91e-24	Corneal structure;
THYM	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs59698941	0.943	rs67656232	chr5:132254426	T/C	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs7246657	0.943	rs7255952	chr19:37988797	A/G	cg22634378	chr19:37742834	NA	0.66	5.49	0.49	3.29e-7	Coronary artery calcification;
THYM	cis	rs4654899	1.000	rs7522722	chr1:21481840	G/A	cg01072550	chr1:21505969	NA	-0.74	-6.63	-0.56	2.02e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg06108461	chr20:60628389	TAF4	1.05	7.34	0.6	7.32e-11	Body mass index;
THYM	cis	rs240764	0.817	rs6907240	chr6:101153782	T/C	cg21058520	chr6:100914733	NA	0.6	5.37	0.48	5.6e-7	Neuroticism;
THYM	cis	rs289828	0.868	rs4665159	chr2:152140530	T/C	cg05960677	chr2:152117363	RBM43	0.61	6.05	0.53	2.89e-8	Blood protein levels;
THYM	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg12373951	chr3:133503437	NA	0.56	6.09	0.53	2.42e-8	Iron status biomarkers;
THYM	cis	rs17401966	0.838	rs1556916	chr1:10403482	G/A	cg19773385	chr1:10388646	KIF1B	-0.59	-4.82	-0.44	5.39e-6	Hepatocellular carcinoma;
THYM	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg06808227	chr14:105710500	BRF1	-1.07	-9.59	-0.7	1.27e-15	Mean platelet volume;Platelet distribution width;
THYM	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg18252515	chr7:66147081	NA	0.64	4.83	0.44	5.14e-6	Aortic root size;
THYM	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg03859395	chr2:55845619	SMEK2	0.64	5.61	0.5	1.98e-7	Metabolic syndrome;
THYM	cis	rs901683	1.000	rs34138033	chr10:46046512	T/C	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs6546324	0.625	rs6746394	chr2:67845021	A/C	cg18237512	chr2:67827392	NA	-0.8	-4.77	-0.44	6.69e-6	Endometriosis;
THYM	cis	rs57502260	0.651	rs3781586	chr11:68199393	C/A	cg16797656	chr11:68205561	LRP5	0.51	4.45	0.42	2.29e-5	Total body bone mineral density (age 45-60);
THYM	cis	rs6815814	0.861	rs6843043	chr4:38843136	A/G	cg06935464	chr4:38784597	TLR10	0.67	4.93	0.45	3.54e-6	Breast cancer;
THYM	cis	rs12594515	0.967	rs11070465	chr15:45984899	A/G	cg01629716	chr15:45996671	NA	0.48	4.93	0.45	3.49e-6	Waist circumference;Weight;
THYM	cis	rs758324	0.606	rs804437	chr5:131500700	C/T	cg16205897	chr5:131564050	P4HA2	0.53	4.63	0.43	1.18e-5	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs6964587	0.692	rs4729021	chr7:91758422	C/A	cg22709100	chr7:91322751	NA	0.63	4.58	0.43	1.4e-5	Breast cancer;
THYM	cis	rs854765	0.718	rs7224815	chr17:17845800	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.01	0.52	3.44e-8	Total body bone mineral density;
THYM	cis	rs4343996	1.000	rs12537549	chr7:3361023	T/G	cg21248987	chr7:3385318	SDK1	-0.41	-4.91	-0.45	3.77e-6	Motion sickness;
THYM	cis	rs9309711	0.961	rs11675119	chr2:3476422	C/A	cg10845886	chr2:3471009	TTC15	-0.57	-4.61	-0.43	1.24e-5	Neurofibrillary tangles;
THYM	cis	rs4824093	0.535	rs73441802	chr22:50273916	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.04	-4.76	-0.44	6.85e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs988913	1.000	rs9475106	chr6:54851455	G/T	cg18532076	chr6:54711417	FAM83B	0.52	4.95	0.45	3.25e-6	Menarche (age at onset);
THYM	cis	rs10095849	0.767	rs58299105	chr8:39452447	C/T	cg22755526	chr8:38854673	TM2D2;ADAM9	0.66	4.48	0.42	2.04e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg00684032	chr4:1343700	KIAA1530	-0.68	-5.77	-0.51	1e-7	Obesity-related traits;
THYM	cis	rs73198271	0.740	rs3827807	chr8:8679385	G/A	cg15556689	chr8:8085844	FLJ10661	-0.74	-4.83	-0.44	5.24e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs28595532	0.920	rs116366070	chr4:119764180	A/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs1065852	0.526	rs56234624	chr22:42388826	A/G	cg22189786	chr22:42395067	WBP2NL	0.54	5.55	0.49	2.6e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg03806693	chr22:41940476	POLR3H	-0.81	-6.82	-0.57	8.39e-10	Vitiligo;
THYM	cis	rs9790314	0.740	rs4856767	chr3:161004379	C/T	cg03342759	chr3:160939853	NMD3	-0.95	-9.47	-0.7	2.2e-15	Morning vs. evening chronotype;
THYM	cis	rs72772090	0.539	rs114006288	chr5:96118004	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7429990	0.932	rs6770477	chr3:48019258	A/G	cg02219026	chr3:48282209	ZNF589	0.6	4.5	0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs4727027	0.736	rs12704084	chr7:148915050	C/G	cg23583168	chr7:148888333	NA	-1.0	-12.68	-0.79	3.85e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg07022442	chr13:21864356	NA	0.72	4.78	0.44	6.49e-6	White matter hyperintensity burden;
THYM	cis	rs56309584	0.715	rs3027234	chr17:8136092	C/T	cg08322244	chr17:8066669	VAMP2	-0.58	-5.11	-0.46	1.69e-6	Initial pursuit acceleration;
THYM	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg08000102	chr2:233561755	GIGYF2	-0.81	-7.03	-0.59	3.07e-10	Coronary artery disease;
THYM	cis	rs9866391	0.630	rs7632381	chr3:141106063	A/G	cg13411656	chr3:141121016	ZBTB38	-0.34	-4.89	-0.45	4.09e-6	Myopia;
THYM	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg19318889	chr4:1322082	MAEA	0.63	5.45	0.49	4.01e-7	Longevity;
THYM	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11890956	chr21:40555474	PSMG1	-0.9	-9.57	-0.7	1.4e-15	Cognitive function;
THYM	cis	rs3820068	0.603	rs17448778	chr1:15985306	A/G	cg24675056	chr1:15929824	NA	0.8	6.62	0.56	2.17e-9	Systolic blood pressure;
THYM	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg23711669	chr6:146136114	FBXO30	-0.93	-9.39	-0.69	3.39e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs758324	0.645	rs156033	chr5:131527321	C/T	cg16205897	chr5:131564050	P4HA2	0.57	4.76	0.44	6.85e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs17685	0.753	rs869804	chr7:75688954	A/G	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.56	-0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7220711	0.967	rs1828720	chr17:41797692	A/C	cg26893861	chr17:41843967	DUSP3	0.65	5.46	0.49	3.75e-7	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg10057126	chr4:77819792	ANKRD56	0.7	5.94	0.52	4.59e-8	Emphysema distribution in smoking;
THYM	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg11266682	chr4:10021025	SLC2A9	0.74	10.8	0.74	3.21e-18	Bone mineral density;
THYM	cis	rs3772130	1.000	rs13087578	chr3:121369207	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.77	4.73	0.44	7.83e-6	Cognitive performance;
THYM	cis	rs6840360	0.582	rs4696260	chr4:152318924	T/C	cg17479576	chr4:152424074	FAM160A1	-0.73	-5.45	-0.49	4.02e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg19196401	chr6:110721138	DDO	-0.62	-7.21	-0.59	1.3100000000000001e-10	Platelet distribution width;
THYM	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg06784218	chr1:46089804	CCDC17	-0.32	-4.82	-0.44	5.41e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.78	0.51	9.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6906287	0.631	rs2798321	chr6:118991602	G/T	cg21191810	chr6:118973309	C6orf204	0.66	6.97	0.58	4.11e-10	Electrocardiographic conduction measures;
THYM	cis	rs13177918	0.626	rs2748240	chr5:149828868	A/G	cg14059543	chr5:149831962	NA	-0.87	-7.47	-0.61	3.83e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg00271210	chr6:167070053	RPS6KA2	0.72	7.96	0.63	3.73e-12	Crohn's disease;
THYM	cis	rs12594515	1.000	rs11855509	chr15:45995474	C/T	cg01629716	chr15:45996671	NA	0.53	5.27	0.48	8.66e-7	Waist circumference;Weight;
THYM	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg27398817	chr8:82754497	SNX16	-0.69	-5.81	-0.51	8.17e-8	Diastolic blood pressure;
THYM	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg22709100	chr7:91322751	NA	0.62	4.82	0.44	5.36e-6	Breast cancer;
THYM	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg08999081	chr20:33150536	PIGU	-0.56	-4.92	-0.45	3.59e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs1160297	0.609	rs1597653	chr2:53100420	A/G	cg07782112	chr2:53107842	NA	-0.78	-6.53	-0.56	3.22e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs7089973	0.872	rs7074729	chr10:116632257	C/G	cg23260525	chr10:116636907	FAM160B1	0.52	4.66	0.43	1.02e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs2625529	0.617	rs11633167	chr15:72179178	C/A	cg16672083	chr15:72433130	SENP8	0.51	4.5	0.42	1.93e-5	Red blood cell count;
THYM	cis	rs1957429	0.614	rs79411360	chr14:65378856	T/C	cg23373153	chr14:65346875	NA	-1.25	-5.03	-0.46	2.29e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Electroencephalogram traits;
THYM	cis	rs669446	0.533	rs4660261	chr1:44229597	G/A	cg15962314	chr1:44399869	ARTN	0.47	5.12	0.46	1.61e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7084921	0.579	rs11597870	chr10:101847857	T/C	cg11344164	chr10:101878520	NA	-0.55	-4.76	-0.44	6.9e-6	Bone mineral density;
THYM	cis	rs28595532	0.920	rs115437723	chr4:119741828	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.6	0.5	2.06e-7	Cannabis dependence symptom count;
THYM	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg06558623	chr16:89946397	TCF25	1.16	5.01	0.46	2.5e-6	Skin colour saturation;
THYM	cis	rs9399401	0.634	rs984932	chr6:142803037	C/T	cg03128060	chr6:142623767	GPR126	0.51	6.87	0.58	6.62e-10	Chronic obstructive pulmonary disease;
THYM	cis	rs1003719	0.788	rs4816560	chr21:38487561	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs2885056	0.783	rs12980640	chr19:10640506	G/A	cg04833646	chr19:10679720	CDKN2D	1.06	8.96	0.68	2.82e-14	Red cell distribution width;
THYM	cis	rs1747683	0.605	rs10906352	chr10:13377717	C/T	cg25835351	chr10:13388524	SEPHS1	-0.28	-4.8	-0.44	5.87e-6	IgG glycosylation;
THYM	cis	rs79149102	0.579	rs3812943	chr15:75312715	C/G	cg17294928	chr15:75287854	SCAMP5	-1.01	-4.92	-0.45	3.66e-6	Lung cancer;
THYM	cis	rs919433	0.679	rs6708239	chr2:198525084	A/G	cg05783139	chr2:198650985	BOLL	0.66	4.98	0.46	2.78e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs1593	0.734	rs4862670	chr4:187145423	A/T	cg09526685	chr4:187126073	CYP4V2	1.25	6.03	0.53	3.08e-8	Activated partial thromboplastin time;
THYM	cis	rs4638749	1.000	rs2123694	chr2:108857505	A/G	cg06795125	chr2:108905320	SULT1C2	-0.41	-5.38	-0.48	5.42e-7	Blood pressure;
THYM	cis	rs240764	0.507	rs9404033	chr6:101211541	A/T	cg21058520	chr6:100914733	NA	-0.58	-4.54	-0.42	1.66e-5	Neuroticism;
THYM	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg23711669	chr6:146136114	FBXO30	0.92	9.4	0.69	3.17e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10100465	0.855	rs1396351	chr8:118689728	A/G	cg09430518	chr8:118662568	NA	0.33	4.45	0.42	2.34e-5	Leprosy;
THYM	cis	rs2625529	0.824	rs7170754	chr15:72218594	G/A	cg16672083	chr15:72433130	SENP8	-0.54	-4.79	-0.44	6.03e-6	Red blood cell count;
THYM	cis	rs931127	0.658	rs4930305	chr11:65464000	A/G	cg27068330	chr11:65405492	SIPA1	0.83	7.55	0.61	2.66e-11	Systemic lupus erythematosus;
THYM	cis	rs9611565	0.506	rs1883825	chr22:41703408	A/G	cg03806693	chr22:41940476	POLR3H	-0.85	-7.29	-0.6	9.15e-11	Vitiligo;
THYM	cis	rs7178572	0.568	rs12912050	chr15:77689423	C/T	cg22256960	chr15:77711686	NA	-1.06	-8.31	-0.65	6.6e-13	Type 2 diabetes;
THYM	cis	rs6430585	0.528	rs721765	chr2:136748779	C/A	cg23851026	chr2:136556271	LCT	0.78	6.95	0.58	4.47e-10	Corneal structure;
THYM	cis	rs4986811	1.000	rs11031780	chr11:32452945	C/G	cg13301003	chr11:32449254	WT1	0.65	4.93	0.45	3.5e-6	Rubella-specific interleukin-6 secretion;
THYM	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg06640241	chr16:89574553	SPG7	0.91	8.44	0.65	3.61e-13	Multiple myeloma (IgH translocation);
THYM	cis	rs2070677	0.673	rs3020503	chr10:135381766	C/T	cg20169779	chr10:135381914	SYCE1	0.77	5.93	0.52	4.93e-8	Gout;
THYM	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg18252515	chr7:66147081	NA	0.62	4.6	0.43	1.31e-5	Aortic root size;
THYM	cis	rs10463554	0.963	rs11242484	chr5:102381876	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	5.38	0.48	5.42e-7	Eosinophil percentage of white cells;
THYM	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.81	-6.29	-0.54	9.55e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.53	4.61	0.43	1.27e-5	Blood metabolite levels;
THYM	cis	rs9457247	0.508	rs7760495	chr6:167506795	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.47	-4.45	-0.42	2.32e-5	Crohn's disease;
THYM	cis	rs3810291	0.927	rs4804024	chr19:47609212	C/T	cg12068280	chr19:46804528	HIF3A	-0.4	-4.49	-0.42	2.03e-5	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);BMI in smokers;Hip circumference;Body mass index;Body mass index in physically active individuals;
THYM	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg17294928	chr15:75287854	SCAMP5	-1.01	-9.1	-0.68	1.4e-14	Blood trace element (Zn levels);
THYM	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg27284194	chr4:1044797	NA	0.6	4.54	0.42	1.68e-5	Recombination rate (females);
THYM	cis	rs611744	0.870	rs613179	chr8:109166006	G/A	cg21045802	chr8:109455806	TTC35	0.7	6.78	0.57	1.02e-9	Dupuytren's disease;
THYM	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg22968622	chr17:43663579	NA	-1.1	-9.99	-0.72	1.7e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg26384229	chr12:38710491	ALG10B	0.97	7.89	0.63	5.19e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs17443541	0.507	rs11677019	chr2:200468754	G/C	cg03741458	chr2:200468445	NA	-0.75	-5.77	-0.51	9.74e-8	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg27129171	chr3:47204927	SETD2	-0.8	-7.64	-0.62	1.69e-11	Colorectal cancer;
THYM	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg02353165	chr6:42928485	GNMT	1.01	10.17	0.72	7.04e-17	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg12863693	chr15:85201151	NMB	0.63	5.46	0.49	3.78e-7	Schizophrenia;
THYM	cis	rs4866334	0.850	rs75708102	chr5:18489975	C/A	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.12	9.06	0.68	1.73e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg26441486	chr22:50317300	CRELD2	-0.43	-6.71	-0.57	1.39e-9	Schizophrenia;
THYM	cis	rs4604732	0.588	rs7549955	chr1:247628321	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.69	4.8	0.44	5.99e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs665401	0.965	rs339344	chr6:117217950	C/T	cg20376953	chr6:117187980	NA	0.6	4.82	0.44	5.5e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs679087	1.000	rs679087	chr12:29917265	C/A	cg14258853	chr12:29935411	TMTC1	-0.67	-6.12	-0.53	2.12e-8	Schizophrenia;
THYM	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs17001868	0.614	rs5995849	chr22:40777072	C/G	cg07138101	chr22:40742427	ADSL	-0.77	-4.73	-0.44	7.79e-6	Mammographic density (dense area);
THYM	cis	rs10779751	0.690	rs2791646	chr1:11133242	C/T	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs17401966	0.838	rs12125535	chr1:10350849	T/A	cg19773385	chr1:10388646	KIF1B	-0.57	-4.49	-0.42	2.04e-5	Hepatocellular carcinoma;
THYM	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg03388043	chr17:80084554	CCDC57	0.68	5.74	0.51	1.13e-7	Life satisfaction;
THYM	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6032067	0.704	rs62205505	chr20:43874856	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.71	-7.45	-0.61	4.33e-11	Blood protein levels;
THYM	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg11266682	chr4:10021025	SLC2A9	0.68	9.68	0.7	7.95e-16	Bone mineral density;
THYM	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg12165864	chr7:66369176	NA	-0.64	-4.97	-0.45	2.97e-6	Aortic root size;
THYM	cis	rs42648	0.869	rs3810890	chr7:89908833	G/T	cg25739043	chr7:89950458	NA	-0.53	-4.53	-0.42	1.72e-5	Homocysteine levels;
THYM	cis	rs6918586	0.658	rs198809	chr6:26128766	G/A	cg07061783	chr6:25882402	NA	0.57	4.48	0.42	2.07e-5	Schizophrenia;
THYM	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg04520793	chr17:42248056	ASB16	-0.33	-4.56	-0.42	1.54e-5	Total body bone mineral density;
THYM	cis	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg14019146	chr3:50243930	SLC38A3	-0.84	-7.49	-0.61	3.58e-11	Intelligence (multi-trait analysis);
THYM	cis	rs2302612	0.571	rs34188221	chr2:102850125	C/T	cg13315345	chr2:102803985	IL1RL2	0.72	4.88	0.45	4.28e-6	Serum protein levels (sST2);
THYM	cis	rs9796	0.870	rs10851402	chr15:41263438	C/T	cg18705301	chr15:41695430	NDUFAF1	0.55	4.58	0.43	1.42e-5	Menopause (age at onset);
THYM	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg11764359	chr7:65958608	NA	0.64	5.0	0.46	2.58e-6	Aortic root size;
THYM	cis	rs8014204	0.604	rs7156590	chr14:75388183	C/T	cg11812906	chr14:75593930	NEK9	0.54	4.46	0.42	2.29e-5	Caffeine consumption;
THYM	cis	rs6570726	0.905	rs377143	chr6:145834220	C/T	cg13319975	chr6:146136371	FBXO30	-0.67	-5.64	-0.5	1.78e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7582180	0.607	rs6723909	chr2:100880058	A/T	cg08017756	chr2:100939284	LONRF2	-0.59	-5.48	-0.49	3.53e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.698	rs1468378	chr7:124458359	C/A	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.76	-6.69	-0.57	1.5e-9	Systemic lupus erythematosus;
THYM	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg11752832	chr7:134001865	SLC35B4	0.73	5.5	0.49	3.21e-7	Mean platelet volume;
THYM	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg03929089	chr4:120376271	NA	-0.99	-12.81	-0.8	2.07e-22	Height;
THYM	cis	rs2276314	0.512	rs1789515	chr18:33635893	G/A	cg19628046	chr18:33552617	C18orf21	-0.65	-4.98	-0.46	2.8e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg03806693	chr22:41940476	POLR3H	1.05	9.54	0.7	1.59e-15	Vitiligo;
THYM	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs3741151	0.773	rs73542967	chr11:73123512	C/T	cg17517138	chr11:73019481	ARHGEF17	0.94	5.48	0.49	3.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg18252515	chr7:66147081	NA	-0.66	-5.0	-0.46	2.65e-6	Aortic root size;
THYM	cis	rs6032067	0.777	rs13039211	chr20:43784396	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg00256281	chr22:41985642	PMM1	0.63	4.9	0.45	3.93e-6	Vitiligo;
THYM	cis	rs1670533	1.000	rs935970	chr4:1045323	C/G	cg27284194	chr4:1044797	NA	-0.61	-4.64	-0.43	1.09e-5	Recombination rate (females);
THYM	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg11663144	chr21:46675770	NA	-0.69	-9.22	-0.69	7.77e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg26149184	chr10:133730230	NA	0.75	4.84	0.44	4.96e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.55	0.42	1.57e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs919433	0.680	rs2244271	chr2:198286581	C/T	cg00792783	chr2:198669748	PLCL1	0.82	5.67	0.5	1.54e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7429990	0.965	rs28637561	chr3:48021018	G/A	cg02219026	chr3:48282209	ZNF589	0.6	4.5	0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs7084402	0.967	rs1427199	chr10:60274941	C/T	cg26159090	chr10:60474252	BICC1;LOC728640	-0.43	-4.45	-0.42	2.3e-5	Refractive error;
THYM	cis	rs6700896	0.931	rs12044840	chr1:66115213	C/G	cg04111102	chr1:66153794	NA	0.55	5.23	0.47	9.89e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg24692254	chr21:30365293	RNF160	-0.71	-5.14	-0.47	1.48e-6	Cognitive test performance;
THYM	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg03676636	chr4:99064102	C4orf37	0.39	5.53	0.49	2.76e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	8.85	0.67	4.81e-14	Chronic sinus infection;
THYM	cis	rs9470366	0.816	rs1321311	chr6:36622900	C/A	cg24425727	chr6:36645648	CDKN1A	-0.57	-4.56	-0.42	1.53e-5	QRS duration;
THYM	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg23803603	chr1:2058230	PRKCZ	-0.67	-5.67	-0.5	1.52e-7	Height;
THYM	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg27490568	chr2:178487706	NA	0.57	5.34	0.48	6.43e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2463822	0.688	rs7121684	chr11:62162389	T/C	cg06239285	chr11:62104954	ASRGL1	-1.4	-6.65	-0.56	1.86e-9	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.76	-5.02	-0.46	2.37e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs17443541	0.507	rs4675697	chr2:200450808	C/T	cg01795955	chr2:200468626	NA	-0.73	-4.86	-0.45	4.61e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	6.05	0.53	2.89e-8	Obesity-related traits;
THYM	cis	rs79149102	0.579	rs7174129	chr15:75305040	A/G	cg17294928	chr15:75287854	SCAMP5	-1.06	-5.68	-0.5	1.49e-7	Lung cancer;
THYM	cis	rs7582180	0.627	rs4149517	chr2:101014247	C/A	cg14675211	chr2:100938903	LONRF2	0.58	5.52	0.49	2.9e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg23711669	chr6:146136114	FBXO30	0.83	8.07	0.64	2.16e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg06028808	chr11:68637592	NA	0.7	7.62	0.62	1.89e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg24375607	chr4:120327624	NA	-0.67	-5.37	-0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs8018808	0.869	rs4369582	chr14:77906389	C/T	cg20045696	chr14:77926864	AHSA1	0.51	4.6	0.43	1.29e-5	Myeloid white cell count;
THYM	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22509189	chr2:225307070	NA	-0.86	-7.22	-0.6	1.25e-10	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg11266682	chr4:10021025	SLC2A9	-0.55	-6.53	-0.56	3.24e-9	Bone mineral density;
THYM	cis	rs4243830	0.850	rs12046229	chr1:6580397	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.11	6.21	0.54	1.41e-8	Body mass index;
THYM	cis	rs9583531	0.629	rs7991766	chr13:111380684	A/G	cg24331049	chr13:111365604	ING1	0.63	5.2	0.47	1.12e-6	Coronary artery disease;
THYM	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg12564285	chr5:131593104	PDLIM4	-0.43	-4.66	-0.43	1.04e-5	Blood metabolite levels;
THYM	cis	rs6032067	0.704	rs62205505	chr20:43874856	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.37	-0.48	5.52e-7	Blood protein levels;
THYM	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg22875332	chr1:76189707	ACADM	0.87	10.83	0.74	2.76e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg13695892	chr22:41940480	POLR3H	-0.84	-6.25	-0.54	1.16e-8	Vitiligo;
THYM	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg21394778	chr1:3037102	PRDM16	0.47	4.52	0.42	1.8e-5	Height;
THYM	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg06634786	chr22:41940651	POLR3H	-0.72	-5.22	-0.47	1.04e-6	Vitiligo;
THYM	cis	rs714031	1.000	rs5750869	chr22:40065332	T/C	cg21377881	chr22:40064566	CACNA1I	-0.67	-5.79	-0.51	8.95e-8	Schizophrenia;
THYM	cis	rs4936891	0.557	rs55954258	chr11:123914759	A/G	cg22125253	chr11:123886957	OR10G4	-0.54	-4.56	-0.42	1.53e-5	Male fertility;
THYM	cis	rs9506514	0.617	rs9509352	chr13:21295149	A/G	cg12081946	chr13:21296465	IL17D	-0.46	-4.83	-0.44	5.3e-6	Coronary artery calcification;
THYM	cis	rs12586317	0.620	rs58320987	chr14:35587726	T/C	cg05294307	chr14:35346193	BAZ1A	-0.83	-5.54	-0.49	2.64e-7	Psoriasis;
THYM	cis	rs2282930	0.512	rs2237452	chr7:50720858	C/T	cg08586669	chr7:50727761	GRB10	0.31	4.57	0.42	1.48e-5	Bone mineral density;
THYM	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg14196790	chr5:131705035	SLC22A5	0.55	5.03	0.46	2.34e-6	Blood metabolite levels;
THYM	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.48	-6.05	-0.53	2.9e-8	Schizophrenia;
THYM	cis	rs3015497	0.789	rs10133849	chr14:51121700	A/G	cg04730355	chr14:51134070	SAV1	-0.54	-4.76	-0.44	6.85e-6	Mean platelet volume;
THYM	cis	rs1670533	0.932	rs13137819	chr4:1042115	T/C	cg27284194	chr4:1044797	NA	0.62	4.61	0.43	1.25e-5	Recombination rate (females);
THYM	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg11663144	chr21:46675770	NA	-0.69	-9.39	-0.69	3.4e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6539288	0.933	rs1037012	chr12:107302677	T/C	cg26297688	chr12:107349093	C12orf23	-0.47	-4.91	-0.45	3.79e-6	Total body bone mineral density;
THYM	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg03806693	chr22:41940476	POLR3H	1.11	8.99	0.68	2.33e-14	Vitiligo;
THYM	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg13607699	chr17:42295918	UBTF	0.6	5.03	0.46	2.33e-6	Total body bone mineral density;
THYM	cis	rs7122937	1.000	rs7122937	chr11:2486550	C/T	cg27115973	chr11:2481206	KCNQ1	0.6	6.57	0.56	2.73e-9	QT interval;
THYM	cis	rs62064224	0.589	rs4132610	chr17:30801441	C/T	cg18200150	chr17:30822561	MYO1D	0.54	4.5	0.42	1.95e-5	Schizophrenia;
THYM	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg02527881	chr3:46936655	PTH1R	-0.67	-6.76	-0.57	1.11e-9	Colorectal cancer;
THYM	cis	rs9658691	0.646	rs7079111	chr10:90750982	T/G	cg03111039	chr10:90751583	FAS;ACTA2	0.84	4.71	0.44	8.41e-6	Mosquito bite size;
THYM	cis	rs11048434	0.736	rs12424026	chr12:9110993	T/C	cg13575925	chr12:9217583	LOC144571	0.52	4.97	0.45	2.96e-6	Sjögren's syndrome;
THYM	cis	rs2505998	0.719	rs10900296	chr10:43572507	A/G	cg06632098	chr10:43605906	RET	-1.05	-9.64	-0.7	9.8e-16	Hirschsprung disease;
THYM	cis	rs6430585	0.528	rs115469964	chr2:136696608	A/C	cg23851026	chr2:136556271	LCT	0.76	7.47	0.61	3.81e-11	Corneal structure;
THYM	cis	rs6496667	1.000	rs7162175	chr15:90897473	A/G	cg22089800	chr15:90895588	ZNF774	0.84	4.96	0.45	3.04e-6	Rheumatoid arthritis;
THYM	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg13319975	chr6:146136371	FBXO30	0.67	5.31	0.48	7.2e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs72712511	0.505	rs809478	chr4:140729791	T/A	cg15010390	chr4:140216957	NDUFC1	0.73	6.22	0.54	1.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4523957	0.715	rs6503321	chr17:2096580	G/A	cg16513277	chr17:2031491	SMG6	-0.83	-8.28	-0.65	7.74e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4460079	0.531	rs4311378	chr4:114862320	C/T	cg02060584	chr4:113970739	ANK2	0.56	4.47	0.42	2.15e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg22920501	chr2:26401640	FAM59B	-0.83	-7.3	-0.6	8.69e-11	Gut microbiome composition (summer);
THYM	cis	rs3862030	0.839	rs2274351	chr10:104264107	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.68	-5.74	-0.51	1.15e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs7567389	0.677	rs72845991	chr2:128107907	A/G	cg06038358	chr2:128176007	PROC	0.42	4.49	0.42	2.03e-5	Self-rated health;
THYM	cis	rs7169223	0.615	rs8038189	chr15:79099026	G/C	cg21242079	chr15:79101063	ADAMTS7	0.65	6.03	0.53	3.1e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg22920501	chr2:26401640	FAM59B	-0.79	-7.07	-0.59	2.63e-10	Gut microbiome composition (summer);
THYM	cis	rs10510102	1.000	rs11200181	chr10:123588043	A/G	cg24202772	chr10:124402857	DMBT1	-0.64	-4.65	-0.43	1.06e-5	Breast cancer;
THYM	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	4.84	0.44	4.97e-6	Menarche (age at onset);
THYM	cis	rs1371867	0.846	rs1788196	chr8:101290088	C/T	cg06636551	chr8:101224915	SPAG1	-0.63	-6.29	-0.54	9.77e-9	Atrioventricular conduction;
THYM	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg12963246	chr6:28129442	ZNF389	0.83	7.46	0.61	3.97e-11	Depression;
THYM	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg07936489	chr17:37558343	FBXL20	0.85	5.64	0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs870825	0.616	rs1401362	chr4:185643775	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg02725872	chr8:58115012	NA	-0.78	-5.79	-0.51	9.21e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg23758822	chr17:41437982	NA	1.13	9.81	0.71	4.22e-16	Menopause (age at onset);
THYM	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs2991971	0.869	rs2453404	chr1:46014735	A/G	cg15605315	chr1:45957053	TESK2	0.65	5.13	0.47	1.52e-6	High light scatter reticulocyte count;
THYM	cis	rs11096990	0.634	rs11736790	chr4:39256324	G/A	cg24403649	chr4:39172243	NA	0.66	5.75	0.51	1.09e-7	Cognitive function;
THYM	cis	rs4953076	0.573	rs7595470	chr2:44402467	A/G	cg04920474	chr2:44395004	PPM1B	0.59	4.87	0.45	4.52e-6	Height;
THYM	cis	rs240764	0.817	rs239247	chr6:101088350	T/C	cg21058520	chr6:100914733	NA	-0.57	-5.06	-0.46	2.04e-6	Neuroticism;
THYM	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26314531	chr2:26401878	FAM59B	-0.76	-4.99	-0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg08885076	chr2:99613938	TSGA10	-0.58	-5.74	-0.51	1.11e-7	Chronic sinus infection;
THYM	cis	rs4780401	0.728	rs8191335	chr16:11771353	C/A	cg01061890	chr16:11836724	TXNDC11	-0.65	-4.75	-0.44	7.11e-6	Rheumatoid arthritis;
THYM	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg08772003	chr10:104629869	AS3MT	-0.55	-4.87	-0.45	4.51e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11644478	chr21:40555479	PSMG1	-1.09	-9.31	-0.69	5.05e-15	Cognitive function;
THYM	cis	rs2820651	0.614	rs56385558	chr10:1490864	G/T	cg02445968	chr10:1449028	ADARB2	-1.06	-5.43	-0.49	4.36e-7	Migraine with aura;
THYM	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg12165864	chr7:66369176	NA	-0.8	-6.01	-0.52	3.42e-8	Corneal structure;
THYM	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg13695892	chr22:41940480	POLR3H	-0.81	-6.44	-0.55	4.98e-9	Vitiligo;
THYM	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs990171	0.710	rs2310220	chr2:102951851	G/A	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.04	-0.46	2.25e-6	Lymphocyte counts;
THYM	cis	rs6967414	0.786	rs7804259	chr7:6755448	C/G	cg09896999	chr7:6746977	ZNF12	-0.65	-4.86	-0.45	4.67e-6	Hematocrit;Hemoglobin concentration;
THYM	cis	rs6728302	1.000	rs6728302	chr2:233053961	A/G	cg15348839	chr2:232224846	NA	1.14	4.64	0.43	1.12e-5	Height;
THYM	cis	rs995000	0.931	rs1168085	chr1:63112320	C/G	cg06896770	chr1:63153194	DOCK7	-0.92	-7.54	-0.61	2.71e-11	Triglyceride levels;
THYM	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs208520	0.690	rs851459	chr6:66813989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.66	-0.62	1.53e-11	Exhaled nitric oxide output;
THYM	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8048589	0.615	rs12599107	chr16:12238602	G/A	cg01990910	chr16:12207648	SNX29	-0.5	-5.68	-0.5	1.46e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs13394619	0.936	rs9789414	chr2:11724684	A/G	cg07314298	chr2:11723111	GREB1	-0.62	-6.09	-0.53	2.36e-8	Endometriosis;
THYM	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.25	4.91	0.45	3.72e-6	Obesity-related traits;
THYM	cis	rs2242116	0.743	rs11719795	chr3:46951935	T/C	cg23352942	chr3:46931381	PTH1R	-0.51	-4.5	-0.42	1.94e-5	Birth weight;
THYM	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.7	-5.72	-0.51	1.23e-7	Blood metabolite levels;
THYM	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg13395646	chr4:1353034	KIAA1530	-0.54	-5.23	-0.47	1e-6	Longevity;
THYM	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg10760299	chr15:45669010	GATM	0.75	5.63	0.5	1.79e-7	Homoarginine levels;
THYM	cis	rs7119038	0.818	rs715412	chr11:118684610	G/A	cg19308663	chr11:118741387	NA	0.57	5.61	0.5	2.01e-7	Sjögren's syndrome;
THYM	cis	rs6763768	0.606	rs931253	chr3:53298604	A/C	cg16894138	chr3:53270350	TKT	0.77	5.46	0.49	3.87e-7	Bacterial meningitis;
THYM	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg16624210	chr5:671434	TPPP	0.67	5.5	0.49	3.21e-7	Obesity-related traits;
THYM	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg04317338	chr11:64019027	PLCB3	0.85	5.81	0.51	8.33e-8	Mean platelet volume;
THYM	cis	rs2625529	0.824	rs35167572	chr15:72378960	A/G	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs7084402	0.565	rs1982173	chr10:60334002	G/T	cg09696939	chr10:60272079	BICC1	-0.49	-5.7	-0.5	1.35e-7	Refractive error;
THYM	cis	rs11771526	0.901	rs62457472	chr7:32306885	A/G	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg24060327	chr5:131705240	SLC22A5	-0.6	-4.82	-0.44	5.52e-6	Lung function (FEV1/FVC);
THYM	cis	rs12142240	0.698	rs66911505	chr1:46823298	A/G	cg00530320	chr1:46809349	NSUN4	0.78	5.51	0.49	3.13e-7	Menopause (age at onset);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg00534700	chr11:60196790	MS4A5	-0.97	-6.92	-0.58	5.21e-10	Depressive symptoms;
THYM	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg26597838	chr10:835615	NA	1.52	11.37	0.76	2.05e-19	Eosinophil percentage of granulocytes;
THYM	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg04476341	chr5:669733	TPPP	0.6	4.48	0.42	2.1e-5	Obesity-related traits;
THYM	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg24531977	chr5:56204891	C5orf35	-1.0	-8.33	-0.65	6.15e-13	Initial pursuit acceleration;
THYM	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg15428835	chr7:75027521	TRIM73;TRIM74	0.77	6.51	0.56	3.46e-9	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg26384229	chr12:38710491	ALG10B	1.05	10.43	0.73	1.96e-17	Heart rate;
THYM	cis	rs861020	0.630	rs685248	chr1:210008367	C/G	cg05527609	chr1:210001259	C1orf107	0.85	6.82	0.57	8.53e-10	Orofacial clefts;
THYM	cis	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg09307838	chr4:120376055	NA	-0.64	-4.7	-0.43	8.72e-6	Corneal astigmatism;
THYM	cis	rs17718580	0.536	rs2047150	chr14:51086387	A/G	cg04730355	chr14:51134070	SAV1	0.83	4.62	0.43	1.18e-5	Cognitive performance;
THYM	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg27286337	chr10:134555280	INPP5A	0.89	6.88	0.58	6.33e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs2625529	0.761	rs16956444	chr15:72271235	C/T	cg16672083	chr15:72433130	SENP8	-0.55	-4.92	-0.45	3.61e-6	Red blood cell count;
THYM	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	7.84	0.63	6.39e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7264396	0.635	rs6058363	chr20:34505054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-5.79	-0.51	9.2e-8	Total cholesterol levels;
THYM	cis	rs988913	1.000	rs9349741	chr6:54841709	G/C	cg04690482	chr6:54711388	FAM83B	0.46	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg04865290	chr3:52927548	TMEM110	-0.88	-4.75	-0.44	7.08e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs11726022	0.791	rs7681831	chr4:188161271	A/G	cg09690449	chr4:187998952	NA	-0.53	-5.51	-0.49	3.07e-7	Systolic blood pressure (cigarette smoking interaction);
THYM	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg26119090	chr2:26468346	HADHA;HADHB	0.83	4.46	0.42	2.25e-5	Gut microbiome composition (summer);
THYM	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg23803603	chr1:2058230	PRKCZ	0.59	4.56	0.42	1.52e-5	Height;
THYM	cis	rs34638657	0.797	rs11645045	chr16:82202137	G/A	cg19807685	chr16:82068980	HSD17B2	-0.56	-4.57	-0.42	1.44e-5	Lung adenocarcinoma;
THYM	cis	rs1728785	0.901	rs11075687	chr16:68655894	T/C	cg02972257	chr16:68554789	NA	-0.76	-4.94	-0.45	3.36e-6	Ulcerative colitis;
THYM	cis	rs4953911	0.793	rs3814022	chr2:135047919	C/G	cg18482303	chr2:135041380	MGAT5	-0.29	-5.1	-0.46	1.73e-6	Multiple sclerosis (severity);
THYM	cis	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg09307838	chr4:120376055	NA	-0.75	-5.91	-0.52	5.25e-8	Corneal astigmatism;
THYM	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg14517863	chr17:44321492	NA	0.46	5.11	0.46	1.69e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24549020	chr5:56110836	MAP3K1	0.69	4.52	0.42	1.8e-5	Initial pursuit acceleration;
THYM	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.62	-4.58	-0.43	1.38e-5	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs12817549	0.967	rs1493848	chr12:94152804	T/C	cg19571390	chr12:94157676	CRADD	0.56	4.46	0.42	2.27e-5	Hip circumference adjusted for BMI;
THYM	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg10047753	chr17:41438598	NA	1.19	11.33	0.76	2.52e-19	Menopause (age at onset);
THYM	cis	rs11031096	0.711	rs61899755	chr11:4201317	G/T	cg22027985	chr11:4115532	RRM1	-0.55	-5.06	-0.46	2.06e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	trans	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg25214090	chr10:38739885	LOC399744	0.94	8.27	0.65	7.91e-13	Corneal astigmatism;
THYM	cis	rs9355610	0.892	rs2247314	chr6:167370230	T/C	cg00271210	chr6:167070053	RPS6KA2	0.48	4.65	0.43	1.08e-5	Graves' disease;
THYM	cis	rs56341938	0.835	rs11716285	chr3:168736084	A/C	cg09107232	chr3:169491072	MYNN	0.53	4.49	0.42	1.98e-5	Lung function (FEV1/FVC);
THYM	cis	rs42648	0.667	rs2157793	chr7:89880354	C/G	cg03688058	chr7:89840708	STEAP2	-0.56	-4.47	-0.42	2.18e-5	Homocysteine levels;
THYM	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg23161317	chr6:28129485	ZNF389	1.0	6.68	0.57	1.61e-9	Depression;
THYM	cis	rs7267979	0.966	rs3827014	chr20:25371559	C/T	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg00684032	chr4:1343700	KIAA1530	-0.63	-5.05	-0.46	2.13e-6	Obesity-related traits;
THYM	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg10018233	chr7:150070692	REPIN1	0.47	6.82	0.57	8.33e-10	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs17102423	0.731	rs942629	chr14:65539318	A/G	cg11161011	chr14:65562177	MAX	-0.66	-5.78	-0.51	9.51e-8	Obesity-related traits;
THYM	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg01073479	chr16:3509474	NAT15	-0.68	-5.45	-0.49	4.02e-7	Tuberculosis;
THYM	cis	rs6840360	0.642	rs11726254	chr4:152438850	G/C	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg25072359	chr17:41440525	NA	0.74	5.43	0.49	4.37e-7	Menopause (age at onset);
THYM	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg13175981	chr1:150552382	MCL1	0.81	6.23	0.54	1.25e-8	Tonsillectomy;
THYM	cis	rs3771570	1.000	rs62193175	chr2:242284405	G/A	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg26022315	chr17:47021804	SNF8	0.51	4.87	0.45	4.44e-6	Type 2 diabetes;
THYM	cis	rs79149102	0.579	rs74023908	chr15:75310710	T/C	cg09165964	chr15:75287851	SCAMP5	-1.1	-6.31	-0.54	8.71e-9	Lung cancer;
THYM	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg03188948	chr7:1209495	NA	0.68	4.69	0.43	9.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg24675056	chr1:15929824	NA	0.73	5.86	0.52	6.71e-8	Systolic blood pressure;
THYM	cis	rs2302729	1.000	rs7974589	chr12:2785089	G/A	cg19945202	chr12:2788847	CACNA1C	-0.92	-6.02	-0.53	3.29e-8	Sleep quality;
THYM	cis	rs6840360	0.571	rs4696275	chr4:152530981	C/T	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg22590775	chr19:49891494	CCDC155	0.61	4.67	0.43	9.87e-6	Multiple sclerosis;
THYM	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	13.59	0.81	5.3e-24	Chronic sinus infection;
THYM	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg00383909	chr3:49044727	WDR6	1.12	6.61	0.56	2.27e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg15962314	chr1:44399869	ARTN	0.53	5.14	0.47	1.44e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg10295955	chr4:187884368	NA	-1.17	-16.0	-0.85	1.07e-28	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6546324	0.625	rs1023691	chr2:67868794	G/A	cg18237512	chr2:67827392	NA	-0.77	-4.57	-0.42	1.47e-5	Endometriosis;
THYM	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg05347473	chr6:146136440	FBXO30	0.58	4.52	0.42	1.8e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13082711	0.911	rs13086867	chr3:27529937	G/A	cg02860705	chr3:27208620	NA	0.72	5.06	0.46	2.01e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.81	0.67	5.78e-14	Colorectal cancer;
THYM	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs13315871	1.000	rs28489489	chr3:58443755	C/A	cg12435725	chr3:58293450	RPP14	-0.46	-4.93	-0.45	3.54e-6	Cholesterol, total;
THYM	cis	rs3741151	1.000	rs7122825	chr11:73061324	C/T	cg12959048	chr11:73096162	RELT	-0.5	-4.78	-0.44	6.38e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs4242434	0.672	rs900267	chr8:22485258	T/C	cg01710189	chr8:22454888	PDLIM2	-0.48	-5.12	-0.47	1.56e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs12935418	0.672	rs2549883	chr16:81055878	G/A	cg16651780	chr16:81037892	C16orf61	-0.8	-5.85	-0.51	6.94e-8	Mean corpuscular volume;
THYM	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.94	-7.38	-0.6	6.07e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg10862848	chr6:42927986	GNMT	-0.51	-6.85	-0.57	7.42e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg05660106	chr1:15850417	CASP9	0.75	6.14	0.53	1.87e-8	Systolic blood pressure;
THYM	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg16586182	chr3:47516702	SCAP	-0.61	-5.25	-0.47	9.2e-7	Colorectal cancer;
THYM	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs526231	0.511	rs7731395	chr5:102361761	G/T	cg23492399	chr5:102201601	PAM	-0.67	-5.18	-0.47	1.26e-6	Primary biliary cholangitis;
THYM	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.76	0.57	1.09e-9	Total body bone mineral density;
THYM	cis	rs2932538	0.922	rs112363416	chr1:113107543	T/C	cg22162597	chr1:113214053	CAPZA1	0.67	5.45	0.49	4.01e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg07636037	chr3:49044803	WDR6	0.95	10.1	0.72	1.03e-16	Parkinson's disease;
THYM	cis	rs1994135	0.594	rs10772096	chr12:33732869	A/G	cg10856724	chr12:34555212	NA	-0.57	-4.49	-0.42	2.01e-5	Resting heart rate;
THYM	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg22664400	chr11:66445111	RBM4B	-0.66	-4.47	-0.42	2.14e-5	Crohn's disease;
THYM	cis	rs4919694	0.901	rs10509763	chr10:104776391	G/A	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg06219351	chr7:158114137	PTPRN2	0.68	6.75	0.57	1.17e-9	Calcium levels;
THYM	cis	rs7267979	1.000	rs6050630	chr20:25430745	A/G	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg12310025	chr6:25882481	NA	0.92	8.34	0.65	5.62e-13	Blood metabolite levels;
THYM	cis	rs1535500	0.967	rs11756091	chr6:39282806	G/T	cg00012638	chr6:39280541	KCNK17	0.61	8.08	0.64	2.06e-12	Type 2 diabetes;
THYM	cis	rs6980334	0.679	rs1872930	chr7:137801444	C/T	cg22979093	chr7:137028410	PTN	0.65	5.02	0.46	2.46e-6	Blood metabolite ratios;
THYM	cis	rs2276498	0.751	rs2276491	chr20:52631166	T/C	cg23682609	chr20:52687365	BCAS1	0.61	5.01	0.46	2.49e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6951245	0.515	rs73257955	chr7:1007014	G/A	cg24642844	chr7:1081250	C7orf50	-1.23	-5.47	-0.49	3.7e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9653442	0.511	rs6739695	chr2:100859622	A/G	cg08017756	chr2:100939284	LONRF2	-0.68	-5.13	-0.47	1.53e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs6450176	1.000	rs60492935	chr5:53306240	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.13	-0.53	2.01e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.71	5.31	0.48	7.11e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6732160	0.845	rs13413175	chr2:73389916	T/C	cg24220031	chr2:73402428	NA	-0.8	-8.57	-0.66	1.87e-13	Intelligence (multi-trait analysis);
THYM	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	6.29	0.54	9.84e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12142240	0.659	rs1984491	chr1:46858607	T/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs2273669	0.667	rs117412830	chr6:109336617	A/G	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	cis	rs3820068	0.608	rs7514858	chr1:16035246	G/A	cg13390004	chr1:15929781	NA	0.65	4.81	0.44	5.56e-6	Systolic blood pressure;
THYM	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg03676636	chr4:99064102	C4orf37	0.42	6.37	0.55	6.64e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4730276	0.674	rs13222925	chr7:107583241	C/T	cg23293999	chr7:106826042	HBP1	-0.57	-4.69	-0.43	9.04e-6	Ulcerative colitis;
THYM	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg09307838	chr4:120376055	NA	0.72	5.06	0.46	2.02e-6	Corneal astigmatism;
THYM	cis	rs1950626	0.750	rs35683125	chr14:101454750	T/C	cg11887864	chr14:101510502	MIR1185-2	0.54	4.52	0.42	1.75e-5	Pelvic organ prolapse (moderate/severe);
THYM	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg03235661	chr20:60525775	NA	-0.58	-5.11	-0.46	1.66e-6	Obesity-related traits;
THYM	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg05738196	chr6:26577821	NA	0.84	8.48	0.66	2.87e-13	Intelligence (multi-trait analysis);
THYM	cis	rs73787773	0.867	rs75705984	chr5:111487993	C/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.91	-4.83	-0.44	5.23e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs2361718	0.501	rs12944619	chr17:78144109	T/C	cg09238746	chr17:78121135	EIF4A3	-1.16	-11.43	-0.76	1.51e-19	Yeast infection;
THYM	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg00376283	chr12:123451042	ABCB9	0.69	4.64	0.43	1.12e-5	Neutrophil percentage of white cells;
THYM	cis	rs8073060	1.000	rs8073060	chr17:33875262	T/A	cg24895173	chr17:33825374	SLFN12L	0.6	5.39	0.48	5.23e-7	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg16342193	chr10:102329863	NA	-0.58	-6.04	-0.53	3.02e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1018836	0.923	rs7833025	chr8:91568470	G/C	cg16814680	chr8:91681699	NA	-0.78	-6.45	-0.55	4.73e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs339331	0.517	rs339323	chr6:117193512	G/A	cg20376953	chr6:117187980	NA	0.59	4.76	0.44	6.79e-6	Prostate cancer;
THYM	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg25072359	chr17:41440525	NA	-0.72	-5.26	-0.47	8.95e-7	Menopause (age at onset);
THYM	cis	rs10277209	0.932	rs13309729	chr7:109034692	A/G	cg24448523	chr7:109046164	NA	0.82	4.5	0.42	1.92e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.9	0.45	3.97e-6	Lung cancer in ever smokers;
THYM	cis	rs886126	0.627	rs4766559	chr12:111666984	C/T	cg10833066	chr12:111807467	FAM109A	0.49	5.26	0.47	8.98e-7	Coronary heart disease;
THYM	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg13877915	chr19:58951672	ZNF132	0.85	7.95	0.63	3.77e-12	Uric acid clearance;
THYM	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.97	7.98	0.63	3.37e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs3087591	0.960	rs12942397	chr17:29462498	C/A	cg24425628	chr17:29625626	OMG;NF1	0.64	5.45	0.49	3.96e-7	Hip circumference;
THYM	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg24399712	chr22:39784796	NA	-0.85	-9.78	-0.71	4.86e-16	Intelligence (multi-trait analysis);
THYM	cis	rs6424115	0.830	rs2229585	chr1:24200921	T/C	cg15997130	chr1:24165203	NA	0.76	6.39	0.55	6.14e-9	Immature fraction of reticulocytes;
THYM	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg17105886	chr17:28927953	LRRC37B2	1.34	7.88	0.63	5.49e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg06108461	chr20:60628389	TAF4	-1.1	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-5.81	-0.51	8.27e-8	Total cholesterol levels;
THYM	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg06028808	chr11:68637592	NA	0.7	7.59	0.61	2.22e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg21100191	chr22:23484243	RTDR1	0.75	6.56	0.56	2.76e-9	Bone mineral density;
THYM	cis	rs67311347	0.635	rs73071706	chr3:40288190	C/A	cg13683864	chr3:40499215	RPL14	-0.7	-6.22	-0.54	1.34e-8	Renal cell carcinoma;
THYM	cis	rs2236293	0.754	rs10814276	chr9:35794913	T/A	cg12876594	chr9:35791798	NPR2	0.4	4.45	0.42	2.36e-5	Blood protein levels;
THYM	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg06713675	chr4:122721982	EXOSC9	-0.7	-6.86	-0.58	6.9e-10	Type 2 diabetes;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg27512631	chr3:101292690	PCNP	0.99	6.93	0.58	5.08e-10	Depressive symptoms;
THYM	cis	rs7586879	0.593	rs6733224	chr2:25130907	C/T	cg01884057	chr2:25150051	NA	-0.73	-7.92	-0.63	4.47e-12	Body mass index;
THYM	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9915657	0.660	rs982534	chr17:70081366	T/G	cg06234051	chr17:70120541	SOX9	-0.64	-5.78	-0.51	9.61e-8	Thyroid hormone levels;
THYM	cis	rs17102423	0.602	rs1007914	chr14:65566261	C/A	cg11161011	chr14:65562177	MAX	-0.8	-6.32	-0.54	8.31e-9	Obesity-related traits;
THYM	cis	rs611744	0.967	rs635624	chr8:109197799	G/C	cg21045802	chr8:109455806	TTC35	0.59	5.32	0.48	7e-7	Dupuytren's disease;
THYM	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg22508957	chr16:3507546	NAT15	-0.54	-6.29	-0.54	9.63e-9	Tuberculosis;
THYM	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.7	5.34	0.48	6.41e-7	Tonsillectomy;
THYM	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg20283391	chr11:68216788	NA	-0.65	-5.15	-0.47	1.4e-6	Total body bone mineral density;
THYM	cis	rs2721195	0.816	rs4251689	chr8:145741130	C/T	cg17328964	chr8:145687451	CYHR1	-0.66	-5.84	-0.51	7.29e-8	Age at first birth;
THYM	cis	rs17401966	0.931	rs61778401	chr1:10426474	G/A	cg19773385	chr1:10388646	KIF1B	-0.6	-4.7	-0.43	8.88e-6	Hepatocellular carcinoma;
THYM	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg05347473	chr6:146136440	FBXO30	0.81	7.17	0.59	1.64e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg04166595	chr19:18636596	NA	0.62	4.62	0.43	1.19e-5	Breast cancer;
THYM	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.54	7.21	0.59	1.3100000000000001e-10	Monocyte percentage of white cells;
THYM	cis	rs28595532	0.920	rs116405053	chr4:119739352	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs478304	0.593	rs12576766	chr11:65488556	C/T	cg17480646	chr11:65405466	SIPA1	-0.98	-9.17	-0.69	9.93e-15	Acne (severe);
THYM	cis	rs11186	0.630	rs55850163	chr2:189963786	C/T	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.1	-7.57	-0.61	2.45e-11	Schizophrenia;
THYM	cis	rs6964587	0.626	rs409	chr7:91556355	C/T	cg22709100	chr7:91322751	NA	0.63	4.69	0.43	9.09e-6	Breast cancer;
THYM	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg12311346	chr5:56204834	C5orf35	-0.83	-6.01	-0.53	3.38e-8	Initial pursuit acceleration;
THYM	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs67385638	0.962	rs2071348	chr11:5264146	T/G	cg12559170	chr11:5275217	HBG2	0.87	8.35	0.65	5.47e-13	Hemoglobin levels;
THYM	cis	rs9527	0.590	rs2148200	chr10:104879847	C/A	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs7020830	0.898	rs13290794	chr9:37183628	C/T	cg14294708	chr9:37120828	ZCCHC7	1.24	14.28	0.83	2.2e-25	Schizophrenia;
THYM	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.09	8.45	0.65	3.41e-13	Cognitive test performance;
THYM	cis	rs10992471	0.756	rs10992319	chr9:95127895	G/A	cg14631576	chr9:95140430	CENPP	-0.95	-10.73	-0.74	4.66e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4604732	0.504	rs4634945	chr1:247636015	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.58	-4.45	-0.42	2.36e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs7616559	0.789	rs6797982	chr3:156783095	C/G	cg15697575	chr3:156784781	NA	0.43	5.68	0.5	1.44e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg01528321	chr10:82214614	TSPAN14	0.66	5.16	0.47	1.35e-6	Post bronchodilator FEV1;
THYM	cis	rs17006441	0.932	rs7626629	chr3:69844940	T/C	cg18496212	chr3:69797108	MITF	0.7	7.17	0.59	1.64e-10	Hemoglobin concentration;
THYM	cis	rs1113500	0.932	rs1343205	chr1:108597873	C/G	cg06207961	chr1:108661230	NA	0.7	5.69	0.5	1.43e-7	Growth-regulated protein alpha levels;
THYM	cis	rs11089937	0.616	rs4145537	chr22:22536940	C/T	cg06866756	chr22:22471216	NA	0.45	4.86	0.45	4.64e-6	Periodontitis (PAL4Q3);
THYM	trans	rs10962692	0.608	rs77507622	chr9:16885464	A/G	cg03221025	chr16:88955224	CBFA2T3	0.74	7.08	0.59	2.43e-10	Ovarian cancer in BRCA2 mutation carriers;Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;
THYM	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	5.51	0.49	3.1e-7	Schizophrenia;
THYM	cis	rs42648	0.905	rs42622	chr7:89956824	A/G	cg25739043	chr7:89950458	NA	-0.56	-4.8	-0.44	5.82e-6	Homocysteine levels;
THYM	cis	rs4523957	0.719	rs1532292	chr17:2097483	T/G	cg16513277	chr17:2031491	SMG6	-0.83	-8.28	-0.65	7.74e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg03433033	chr1:76189801	ACADM	-0.52	-5.39	-0.48	5.07e-7	Daytime sleep phenotypes;
THYM	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24549020	chr5:56110836	MAP3K1	0.72	4.66	0.43	1.02e-5	Initial pursuit acceleration;
THYM	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg12863693	chr15:85201151	NMB	0.62	5.57	0.5	2.41e-7	Schizophrenia;
THYM	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg06808227	chr14:105710500	BRF1	-1.02	-8.87	-0.67	4.38e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg21028142	chr17:79581711	NPLOC4	0.55	5.11	0.46	1.63e-6	Eye color traits;
THYM	cis	rs1728785	1.000	rs1094282	chr16:68577260	G/A	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs13358904	0.518	rs10478076	chr5:111609923	G/C	cg01802485	chr5:111723891	EPB41L4A	0.65	4.64	0.43	1.12e-5	Suicide ideation score in major depressive disorder;
THYM	cis	rs17511627	0.808	rs7988263	chr13:26742420	T/A	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs11648796	0.765	rs2003832	chr16:769538	G/A	cg27144592	chr16:783916	NARFL	0.45	4.75	0.44	7.1e-6	Height;
THYM	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg12379764	chr21:47803548	PCNT	0.85	5.47	0.49	3.66e-7	Testicular germ cell tumor;
THYM	cis	rs9309711	0.961	rs11686236	chr2:3471549	G/A	cg10845886	chr2:3471009	TTC15	-0.59	-4.59	-0.43	1.34e-5	Neurofibrillary tangles;
THYM	cis	rs2282930	0.512	rs76969172	chr7:50704124	G/A	cg08586669	chr7:50727761	GRB10	0.33	4.9	0.45	3.95e-6	Bone mineral density;
THYM	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg25319279	chr11:5960081	NA	-0.62	-5.62	-0.5	1.89e-7	DNA methylation (variation);
THYM	cis	rs6754311	0.731	rs687670	chr2:136740900	T/C	cg07169764	chr2:136633963	MCM6	0.7	5.93	0.52	4.84e-8	Mosquito bite size;
THYM	cis	rs4845459	0.967	rs4845453	chr1:152591953	C/G	cg26135325	chr1:152595322	LCE3A	-0.42	-4.83	-0.44	5.16e-6	Psoriasis;
THYM	cis	rs28374715	0.532	rs316606	chr15:41772202	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.15	-12.85	-0.8	1.71e-22	Ulcerative colitis;
THYM	cis	rs67478160	0.619	rs10083370	chr14:104314182	G/A	cg08213375	chr14:104286397	PPP1R13B	-0.57	-6.86	-0.58	7.08e-10	Schizophrenia;
THYM	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg07424592	chr7:64974309	NA	-0.56	-4.47	-0.42	2.16e-5	Calcium levels;
THYM	cis	rs17511627	0.808	rs9512138	chr13:26743598	T/A	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs9906944	0.933	rs12945020	chr17:47082775	G/A	cg18128536	chr17:47092178	IGF2BP1	-0.45	-4.8	-0.44	5.96e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg12516959	chr21:47718080	NA	-0.43	-5.24	-0.47	9.61e-7	Testicular germ cell tumor;
THYM	cis	rs7089973	0.604	rs1924034	chr10:116578539	C/T	cg23260525	chr10:116636907	FAM160B1	0.53	5.38	0.48	5.45e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs870825	0.616	rs12512839	chr4:185610347	G/A	cg04058563	chr4:185651563	MLF1IP	1.16	9.67	0.7	8.28e-16	Blood protein levels;
THYM	cis	rs1784581	0.588	rs9346894	chr6:162430763	T/C	cg17173639	chr6:162384350	PARK2	0.8	7.33	0.6	7.52e-11	Itch intensity from mosquito bite;
THYM	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg11141652	chr22:24348549	GSTTP1	0.61	5.88	0.52	6.07e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11644478	chr21:40555479	PSMG1	-0.56	-4.69	-0.43	9.07e-6	Menarche (age at onset);
THYM	cis	rs9486719	0.843	rs2103539	chr6:96844342	T/A	cg18709589	chr6:96969512	KIAA0776	0.75	4.49	0.42	2.02e-5	Migraine;Coronary artery disease;
THYM	cis	rs11690935	0.694	rs312921	chr2:172567225	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.85	-6.26	-0.54	1.09e-8	Schizophrenia;
THYM	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	5.52	0.49	2.88e-7	Lung cancer in ever smokers;
THYM	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg12219531	chr12:120966889	COQ5	0.8	6.55	0.56	2.9e-9	High light scatter reticulocyte count;
THYM	cis	rs7072216	0.763	rs45523432	chr10:100167436	T/C	cg26618903	chr10:100175079	PYROXD2	-0.48	-4.6	-0.43	1.33e-5	Metabolite levels;
THYM	cis	rs4363385	0.747	rs4845333	chr1:152982877	G/T	cg13444842	chr1:152974279	SPRR3	-0.59	-4.68	-0.43	9.52e-6	Inflammatory skin disease;
THYM	cis	rs7312774	1.000	rs7312774	chr12:107305728	G/A	cg16260113	chr12:107380972	MTERFD3	0.97	5.54	0.49	2.71e-7	Severe influenza A (H1N1) infection;
THYM	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs791888	0.728	rs2255682	chr10:89419873	C/G	cg13926569	chr10:89418898	PAPSS2	-0.71	-8.12	-0.64	1.72e-12	Magnesium levels;
THYM	cis	rs3008870	1.000	rs1925411	chr1:67370292	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.91	7.04	0.59	2.95e-10	Lymphocyte percentage of white cells;
THYM	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg11764359	chr7:65958608	NA	0.75	5.99	0.52	3.7e-8	Aortic root size;
THYM	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg22681709	chr2:178499509	PDE11A	-0.59	-5.11	-0.46	1.65e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg23161317	chr6:28129485	ZNF389	0.69	4.5	0.42	1.92e-5	Parkinson's disease;
THYM	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg26441486	chr22:50317300	CRELD2	0.43	6.57	0.56	2.71e-9	Schizophrenia;
THYM	cis	rs654950	0.775	rs28972757	chr1:41993013	T/C	cg06885757	chr1:42089581	HIVEP3	-0.47	-5.62	-0.5	1.92e-7	Airway imaging phenotypes;
THYM	cis	rs4654899	1.000	rs4654899	chr1:21410231	G/T	cg01072550	chr1:21505969	NA	-0.74	-6.82	-0.57	8.58e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-1.08	-8.4	-0.65	4.36e-13	Cognitive test performance;
THYM	trans	rs75518195	0.566	rs62302820	chr4:64735926	T/A	cg14706739	chr8:21916355	EPB49	0.72	6.91	0.58	5.57e-10	Triptolide cytotoxicity;
THYM	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg18825531	chr11:62321136	NA	-0.46	-5.28	-0.48	8.13e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6687430	0.526	rs6688558	chr1:10611403	A/G	cg20482658	chr1:10539492	PEX14	-0.38	-5.04	-0.46	2.26e-6	Hand grip strength;
THYM	cis	rs11170631	0.507	rs12307701	chr12:54090724	A/C	cg16917193	chr12:54089295	NA	0.94	9.04	0.68	1.83e-14	Height;
THYM	cis	rs6430585	0.591	rs4585083	chr2:136486342	C/T	cg07169764	chr2:136633963	MCM6	1.13	10.27	0.73	4.46e-17	Corneal structure;
THYM	cis	rs59698941	0.765	rs67045943	chr5:132219956	C/T	cg02081065	chr5:132209139	LEAP2	-0.85	-5.74	-0.51	1.14e-7	Apolipoprotein A-IV levels;
THYM	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-4.67	-0.43	9.88e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg03859395	chr2:55845619	SMEK2	0.61	5.47	0.49	3.72e-7	Metabolic syndrome;
THYM	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs986417	0.901	rs4901989	chr14:61014743	G/C	cg27398547	chr14:60952738	C14orf39	1.0	5.05	0.46	2.14e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs6430585	0.583	rs58116536	chr2:136585323	C/T	cg04750100	chr2:136595281	LCT	0.53	5.03	0.46	2.31e-6	Corneal structure;
THYM	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg07424592	chr7:64974309	NA	-1.04	-5.27	-0.48	8.52e-7	Diabetic kidney disease;
THYM	cis	rs16866061	1.000	rs72974263	chr2:225447371	C/T	cg22455342	chr2:225449267	CUL3	0.67	4.86	0.45	4.7e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs7084402	1.000	rs7074778	chr10:60272248	C/T	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-5.84	-0.51	7.42e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs62158800	0.568	rs62161319	chr2:108363138	C/A	cg09155462	chr2:109189131	NA	1.25	4.95	0.45	3.18e-6	Facial morphology (factor 22);
THYM	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg23352942	chr3:46931381	PTH1R	-0.76	-7.43	-0.61	4.74e-11	Birth weight;
THYM	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg18904891	chr8:8559673	CLDN23	0.64	4.99	0.46	2.73e-6	Neuroticism;
THYM	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs192264	0.614	rs92397	chr16:65983517	A/G	cg02795155	chr16:66785218	DYNC1LI2	0.59	4.76	0.44	6.9e-6	Subjective well-being;
THYM	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03264133	chr6:25882463	NA	-0.7	-5.49	-0.49	3.32e-7	Blood metabolite levels;
THYM	cis	rs7582180	0.681	rs6754176	chr2:100995691	C/T	cg21926883	chr2:100939477	LONRF2	-0.65	-6.1	-0.53	2.25e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs16917546	1.000	rs10995250	chr10:64396921	G/A	cg03961010	chr10:64397487	ZNF365	-0.8	-6.74	-0.57	1.19e-9	Basal cell carcinoma;
THYM	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg12963246	chr6:28129442	ZNF389	0.72	6.12	0.53	2.05e-8	Depression;
THYM	cis	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs7582180	0.701	rs4622752	chr2:100892018	A/G	cg21926883	chr2:100939477	LONRF2	0.59	5.2	0.47	1.17e-6	Intelligence (multi-trait analysis);
THYM	cis	rs892961	0.899	rs8071024	chr17:75414067	T/C	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs10992471	0.756	rs10992303	chr9:95082804	A/G	cg14631576	chr9:95140430	CENPP	-0.95	-10.73	-0.74	4.66e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs611744	0.647	rs864166	chr8:109249300	C/G	cg21045802	chr8:109455806	TTC35	0.65	5.91	0.52	5.3e-8	Dupuytren's disease;
THYM	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg00074818	chr8:8560427	CLDN23	0.53	4.83	0.44	5.12e-6	Obesity-related traits;
THYM	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg27129171	chr3:47204927	SETD2	0.69	6.63	0.56	2.04e-9	Colorectal cancer;
THYM	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg10792982	chr14:105748885	BRF1	-0.69	-6.97	-0.58	4.22e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg06784218	chr1:46089804	CCDC17	0.31	4.52	0.42	1.78e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs4642101	0.686	rs9822382	chr3:12828828	T/G	cg05775895	chr3:12838266	CAND2	0.74	6.48	0.55	4.06e-9	QRS complex (12-leadsum);
THYM	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg07343612	chr16:622815	PIGQ	-1.08	-11.34	-0.76	2.36e-19	Height;
THYM	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11890956	chr21:40555474	PSMG1	-0.9	-9.61	-0.7	1.12e-15	Cognitive function;
THYM	cis	rs7804356	0.834	rs7457076	chr7:26793215	C/T	cg24979288	chr7:27242424	NA	0.62	4.46	0.42	2.26e-5	Type 1 diabetes;
THYM	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.73	-0.44	7.73e-6	Mean corpuscular volume;
THYM	cis	rs9393692	0.620	rs9357005	chr6:26336838	C/A	cg00631329	chr6:26305371	NA	-0.46	-4.61	-0.43	1.25e-5	Educational attainment;
THYM	cis	rs8016982	0.651	rs1885601	chr14:81641210	C/T	cg21807262	chr14:81713016	NA	-0.55	-4.9	-0.45	3.88e-6	Schizophrenia;
THYM	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg18357526	chr6:26021779	HIST1H4A	0.71	5.54	0.49	2.69e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7177699	0.557	rs4433781	chr15:79121835	A/T	cg15571903	chr15:79123663	NA	-0.56	-6.28	-0.54	9.92e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs920590	0.641	rs2035889	chr8:19634087	T/A	cg01411142	chr8:19674711	INTS10	0.72	5.57	0.5	2.33e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg09640425	chr7:158790006	NA	-0.57	-4.73	-0.44	7.85e-6	Facial morphology (factor 20);
THYM	cis	rs4285028	0.580	rs12496036	chr3:121640362	G/A	cg20356878	chr3:121714668	ILDR1	-0.57	-5.19	-0.47	1.17e-6	Multiple sclerosis;
THYM	trans	rs8073060	0.544	rs225258	chr17:33956883	C/T	cg19694781	chr19:47549865	TMEM160	-0.98	-8.26	-0.65	8.45e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg17054759	chr22:49844102	NA	-0.53	-4.65	-0.43	1.09e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4889855	0.505	rs12952775	chr17:78607820	A/G	cg16591659	chr17:78472290	NA	-0.4	-5.09	-0.46	1.83e-6	Fractional excretion of uric acid;
THYM	cis	rs7567389	0.677	rs10850	chr2:128063945	T/C	cg06038358	chr2:128176007	PROC	-0.43	-4.53	-0.42	1.7e-5	Self-rated health;
THYM	cis	rs4733781	0.865	rs17284725	chr8:131282724	A/T	cg16277922	chr8:131349729	ASAP1	0.79	5.9	0.52	5.62e-8	Tuberculosis;
THYM	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg24060327	chr5:131705240	SLC22A5	0.68	5.04	0.46	2.19e-6	Blood metabolite levels;
THYM	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg11530693	chr1:120165357	ZNF697	1.08	12.42	0.79	1.33e-21	Systemic lupus erythematosus;
THYM	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg18252515	chr7:66147081	NA	0.64	4.81	0.44	5.74e-6	Aortic root size;
THYM	cis	rs4654899	0.802	rs10916903	chr1:21247944	T/C	cg01072550	chr1:21505969	NA	-0.69	-6.22	-0.54	1.35e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs34526934	0.565	rs34729309	chr2:177034121	G/T	cg26754761	chr2:177040938	NA	-0.74	-6.37	-0.55	6.7e-9	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs4845459	0.933	rs6700181	chr1:152593087	A/G	cg26135325	chr1:152595322	LCE3A	-0.45	-5.13	-0.47	1.54e-6	Psoriasis;
THYM	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg22508957	chr16:3507546	NAT15	0.67	9.28	0.69	5.62e-15	Tuberculosis;
THYM	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg18512352	chr11:47633146	NA	-0.54	-7.07	-0.59	2.54e-10	Subjective well-being;
THYM	cis	rs6032067	0.777	rs13044826	chr20:43801865	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.77	-8.21	-0.64	1.07e-12	Blood protein levels;
THYM	cis	rs4927850	0.958	rs2044599	chr3:195736740	G/A	cg12923728	chr3:195709715	SDHAP1	-0.79	-6.31	-0.54	8.86e-9	Pancreatic cancer;
THYM	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg13010199	chr12:38710504	ALG10B	0.71	5.49	0.49	3.34e-7	Heart rate;
THYM	cis	rs2495707	0.624	rs2489007	chr10:102422046	A/G	cg00272971	chr10:102419564	NA	0.53	5.82	0.51	7.79e-8	Body mass index;
THYM	cis	rs754466	1.000	rs67059283	chr10:79683235	C/T	cg17075019	chr10:79541650	NA	-0.61	-4.53	-0.42	1.7e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7078219	0.965	rs7081858	chr10:101274565	G/A	cg07044859	chr10:101282883	NA	-0.47	-5.14	-0.47	1.45e-6	Dental caries;
THYM	cis	rs3020333	0.875	rs2982572	chr6:152010561	C/T	cg22157087	chr6:152012887	ESR1	0.44	4.85	0.45	4.9e-6	Total body bone mineral density;
THYM	cis	rs2120019	0.608	rs8042558	chr15:75320433	G/T	cg17294928	chr15:75287854	SCAMP5	-0.89	-7.75	-0.62	1.01e-11	Blood trace element (Zn levels);
THYM	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.53	5.25	0.47	9.42e-7	Schizophrenia;
THYM	cis	rs5746492	0.568	rs73151057	chr22:18397913	T/G	cg00227156	chr22:18463646	MICAL3;MIR648	0.52	4.79	0.44	6.14e-6	Eotaxin levels;
THYM	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs7172809	0.599	rs74026912	chr15:77730856	G/A	cg10437265	chr15:77819839	NA	-0.5	-4.56	-0.42	1.5e-5	Glucose homeostasis traits;
THYM	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg19901468	chr14:105411992	AHNAK2	-0.91	-8.15	-0.64	1.45e-12	Rheumatoid arthritis;
THYM	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs946836	0.537	rs10890515	chr1:48419127	T/C	cg18376692	chr1:48452465	NA	-0.55	-5.65	-0.5	1.66e-7	White matter integrity;
THYM	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs800586	0.796	rs800534	chr8:116719898	C/T	cg04656070	chr8:116661063	TRPS1	0.47	5.04	0.46	2.26e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs11048434	0.736	rs12833375	chr12:9112018	A/T	cg13575925	chr12:9217583	LOC144571	0.51	4.87	0.45	4.42e-6	Sjögren's syndrome;
THYM	cis	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg05335186	chr13:53173507	NA	-0.47	-5.92	-0.52	5.1e-8	Lewy body disease;
THYM	cis	rs892961	0.932	rs67719929	chr17:75412605	G/A	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs6486730	1.000	rs7953661	chr12:129275823	T/A	cg09035930	chr12:129282057	SLC15A4	0.48	4.6	0.43	1.32e-5	Systemic lupus erythematosus;
THYM	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg11494091	chr17:61959527	GH2	0.71	6.7	0.57	1.44e-9	Height;
THYM	cis	rs7688540	0.665	rs11731933	chr4:239159	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.68	4.96	0.45	3.03e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs9393692	0.599	rs9358920	chr6:26292029	C/T	cg13736514	chr6:26305472	NA	-0.47	-4.87	-0.45	4.39e-6	Educational attainment;
THYM	cis	rs10501293	0.675	rs10768912	chr11:43034756	C/T	cg03447554	chr11:43094025	NA	0.61	4.51	0.42	1.83e-5	Cognitive performance;
THYM	cis	rs4900538	0.819	rs72700604	chr14:102882307	G/A	cg18135206	chr14:102964638	TECPR2	-0.81	-6.24	-0.54	1.2e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg08901578	chr4:187885870	NA	0.65	6.26	0.54	1.11e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4072705	0.615	rs7869829	chr9:127247177	G/A	cg01786973	chr9:127249749	NR5A1	-0.4	-5.25	-0.47	9.18e-7	Menarche (age at onset);
THYM	cis	rs7323507	0.636	rs4594112	chr13:110604332	C/T	cg07669776	chr13:110975691	COL4A2	-0.51	-4.65	-0.43	1.07e-5	Lung function (FVC);
THYM	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg18252515	chr7:66147081	NA	0.66	4.87	0.45	4.38e-6	Aortic root size;
THYM	cis	rs4343996	1.000	rs4298408	chr7:3358731	T/C	cg21248987	chr7:3385318	SDK1	-0.41	-4.94	-0.45	3.39e-6	Motion sickness;
THYM	cis	rs36051895	0.623	rs76960049	chr9:5064548	G/A	cg02405213	chr9:5042618	JAK2	-1.02	-11.16	-0.75	5.59e-19	Pediatric autoimmune diseases;
THYM	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg13918804	chr1:2043761	PRKCZ	-0.81	-7.45	-0.61	4.35e-11	Height;
THYM	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg17863274	chr19:49399704	TULP2	-1.01	-6.26	-0.54	1.12e-8	Red cell distribution width;
THYM	cis	rs2717559	0.522	rs2572918	chr8:143875721	C/A	cg03405983	chr8:143858548	LYNX1	0.56	6.05	0.53	2.89e-8	Urinary tract infection frequency;
THYM	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.48	-4.86	-0.45	4.64e-6	Crohn's disease;
THYM	cis	rs7809950	1.000	rs4727684	chr7:107226470	C/T	cg23024343	chr7:107201750	COG5	-0.9	-8.03	-0.64	2.56e-12	Coronary artery disease;
THYM	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg24324837	chr19:49891574	CCDC155	0.52	4.79	0.44	6.25e-6	Multiple sclerosis;
THYM	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs7172809	0.599	rs12324795	chr15:77739786	T/C	cg22256960	chr15:77711686	NA	-0.61	-4.47	-0.42	2.18e-5	Glucose homeostasis traits;
THYM	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg27494647	chr7:150038898	RARRES2	0.46	5.82	0.51	8.06e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg08470875	chr2:26401718	FAM59B	0.74	4.59	0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg24154853	chr7:158122151	PTPRN2	0.54	4.75	0.44	7.13e-6	Calcium levels;
THYM	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg03433033	chr1:76189801	ACADM	-0.5	-4.93	-0.45	3.51e-6	Daytime sleep phenotypes;
THYM	cis	rs34638657	0.732	rs12597171	chr16:82200119	A/G	cg07307142	chr16:82071433	HSD17B2	0.91	8.14	0.64	1.53e-12	Lung adenocarcinoma;
THYM	cis	rs3126085	1.000	rs72698906	chr1:152307184	G/A	cg10321714	chr1:152280068	FLG	-0.76	-5.41	-0.49	4.76e-7	Atopic dermatitis;
THYM	cis	rs7584330	0.740	rs12471291	chr2:238441751	T/G	cg16989719	chr2:238392110	NA	-0.47	-4.6	-0.43	1.31e-5	Prostate cancer;
THYM	trans	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.69	-6.91	-0.58	5.55e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	5.84	0.51	7.4e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03264133	chr6:25882463	NA	-0.92	-8.02	-0.64	2.72e-12	Blood metabolite levels;
THYM	trans	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.11	8.17	0.64	1.3e-12	Exhaled nitric oxide output;
THYM	cis	rs791888	0.667	rs2762520	chr10:89414845	A/G	cg10377144	chr10:89419177	PAPSS2	-0.32	-4.69	-0.43	9.23e-6	Magnesium levels;
THYM	cis	rs4849845	0.889	rs3931840	chr2:121041347	A/C	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs7107174	1.000	rs2373115	chr11:78091150	G/T	cg02023728	chr11:77925099	USP35	0.57	5.55	0.49	2.58e-7	Testicular germ cell tumor;
THYM	cis	rs4595586	0.545	rs7980848	chr12:39375166	G/C	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.54	-5.17	-0.47	1.31e-6	Lymphocyte counts;
THYM	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg13319975	chr6:146136371	FBXO30	-0.64	-5.35	-0.48	6.1e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.71	6.25	0.54	1.16e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg11882607	chr3:12858926	CAND2	-0.4	-4.48	-0.42	2.09e-5	QRS complex (12-leadsum);
THYM	cis	rs919433	0.679	rs55656916	chr2:198519628	T/C	cg00792783	chr2:198669748	PLCL1	0.79	5.13	0.47	1.53e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs1568889	1.000	rs7949704	chr11:28373543	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	4.79	0.44	6.08e-6	Bipolar disorder;
THYM	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg19901468	chr14:105411992	AHNAK2	-0.77	-6.26	-0.54	1.1e-8	Rheumatoid arthritis;
THYM	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg15445000	chr17:37608096	MED1	-0.44	-5.19	-0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs61990749	0.597	rs13379065	chr14:78141295	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-1.17	-8.02	-0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6840360	0.607	rs2724547	chr4:152365576	G/A	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.68	-4.99	-0.46	2.68e-6	Colorectal cancer;
THYM	cis	rs1395	0.744	rs62130714	chr2:27532870	A/G	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.3	-0.48	7.55e-7	Blood metabolite levels;
THYM	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg15921436	chr17:44337874	NA	-0.74	-6.03	-0.53	3.13e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs300703	0.592	rs300800	chr2:105493	T/C	cg21211680	chr2:198530	NA	-1.33	-7.27	-0.6	1.03e-10	Blood protein levels;
THYM	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg15536230	chr21:44985092	HSF2BP	-0.42	-5.05	-0.46	2.15e-6	Mean corpuscular volume;
THYM	cis	rs367615	0.679	rs4259216	chr5:108841817	A/G	cg17395555	chr5:108820864	NA	0.76	9.29	0.69	5.53e-15	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg03476357	chr21:30257390	N6AMT1	-0.67	-5.02	-0.46	2.4e-6	Cognitive test performance;
THYM	cis	rs17253792	0.822	rs10147688	chr14:56054642	T/C	cg01858014	chr14:56050164	KTN1	-1.17	-4.89	-0.45	4.1e-6	Putamen volume;
THYM	cis	rs7909074	0.966	rs4268464	chr10:45401081	T/A	cg05187965	chr10:45406764	TMEM72	-0.51	-4.78	-0.44	6.44e-6	Mean corpuscular volume;
THYM	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.81	6.04	0.53	3e-8	Cognitive test performance;
THYM	cis	rs981844	1.000	rs2263434	chr4:154658312	A/G	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs7084402	0.935	rs11006192	chr10:60343638	T/C	cg09696939	chr10:60272079	BICC1	-0.48	-5.67	-0.5	1.56e-7	Refractive error;
THYM	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs8063160	0.621	rs12925026	chr16:89792856	C/T	cg07984980	chr16:89898383	SPIRE2	1.41	5.8	0.51	8.62e-8	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs7189233	0.955	rs72801818	chr16:53476042	C/T	cg02965178	chr16:53538660	AKTIP	-0.6	-4.6	-0.43	1.31e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7200543	0.961	rs1741	chr16:15130351	G/C	cg01933576	chr16:15083564	PDXDC1	-0.99	-8.04	-0.64	2.48e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg15691649	chr6:25882328	NA	-0.68	-5.15	-0.47	1.41e-6	Blood metabolite levels;
THYM	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg05283184	chr6:79620031	NA	-0.88	-8.41	-0.65	4.14e-13	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs854765	0.822	rs1889014	chr17:17767165	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-6.2	-0.54	1.46e-8	Total body bone mineral density;
THYM	cis	rs34286592	0.929	rs1057452	chr16:29833714	A/G	cg04633683	chr16:29837056	MVP	-0.6	-4.93	-0.45	3.42e-6	Multiple sclerosis;
THYM	cis	rs4866334	1.000	rs80303471	chr5:18478048	A/G	cg18608440	chr5:17519013	NA	1.17	5.26	0.47	8.94e-7	IgG glycosylation;
THYM	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg10057126	chr4:77819792	ANKRD56	0.72	6.14	0.53	1.93e-8	Emphysema distribution in smoking;
THYM	cis	rs7020830	0.867	rs13301916	chr9:37361455	A/C	cg14294708	chr9:37120828	ZCCHC7	1.28	15.99	0.85	1.08e-28	Schizophrenia;
THYM	cis	rs7688540	0.771	rs77234191	chr4:258294	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.72	4.88	0.45	4.35e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	4.82	0.44	5.5e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9581857	0.579	rs3759434	chr13:27997700	A/C	cg22138327	chr13:27999177	GTF3A	0.88	6.69	0.57	1.5e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	4.64	0.43	1.13e-5	Bipolar disorder;
THYM	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg13695892	chr22:41940480	POLR3H	0.99	7.48	0.61	3.75e-11	Vitiligo;
THYM	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg08048268	chr3:133502702	NA	-0.67	-5.76	-0.51	1.05e-7	Iron status biomarkers;
THYM	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg24450063	chr1:156163899	SLC25A44	1.1	9.46	0.7	2.36e-15	Testicular germ cell tumor;
THYM	cis	rs6840360	1.000	rs6535810	chr4:152592953	C/T	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg22166914	chr1:53195759	ZYG11B	0.9	10.21	0.72	5.82e-17	Monocyte count;
THYM	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg00071950	chr4:10020882	SLC2A9	0.88	9.22	0.69	7.56e-15	Bone mineral density;
THYM	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg08807101	chr21:30365312	RNF160	-0.81	-6.03	-0.53	3.09e-8	Dental caries;
THYM	cis	rs728616	0.867	rs17886286	chr10:81703852	C/G	cg18148530	chr10:81370782	SFTPA1	0.76	5.29	0.48	7.67e-7	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7107174	1.000	rs10899485	chr11:78072383	C/T	cg02023728	chr11:77925099	USP35	-0.66	-6.35	-0.55	7.29e-9	Testicular germ cell tumor;
THYM	cis	rs41271473	0.526	rs10916337	chr1:228714902	C/T	cg10167378	chr1:228756711	NA	0.77	4.51	0.42	1.89e-5	Chronic lymphocytic leukemia;
THYM	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg05368731	chr17:41323189	NBR1	1.26	11.54	0.76	9.06e-20	Menopause (age at onset);
THYM	cis	rs981844	0.816	rs56413502	chr4:154721784	T/A	cg09973105	chr4:154681532	RNF175	-0.66	-5.45	-0.49	3.98e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg15536230	chr21:44985092	HSF2BP	0.44	5.21	0.47	1.08e-6	Mean corpuscular volume;
THYM	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg08885076	chr2:99613938	TSGA10	0.46	4.63	0.43	1.16e-5	Bipolar disorder;
THYM	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.48	-0.42	2.05e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs35883536	0.588	rs72977389	chr1:101107053	A/C	cg06223162	chr1:101003688	GPR88	0.58	5.16	0.47	1.34e-6	Monocyte count;
THYM	cis	rs2507	0.578	rs7171694	chr15:74278024	T/A	cg17221444	chr15:74284820	STOML1	-0.6	-4.91	-0.45	3.79e-6	Coronary artery disease;
THYM	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg24818145	chr4:99064322	C4orf37	0.67	5.2	0.47	1.13e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6450176	0.564	rs390420	chr5:53326731	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.94	-8.32	-0.65	6.26e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg09307838	chr4:120376055	NA	0.66	4.77	0.44	6.56e-6	Corneal astigmatism;
THYM	cis	rs2742234	0.578	rs2742241	chr10:43625223	G/A	cg06632098	chr10:43605906	RET	-0.76	-4.84	-0.44	4.97e-6	Hirschsprung disease;
THYM	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg12311346	chr5:56204834	C5orf35	-0.66	-4.81	-0.44	5.68e-6	Coronary artery disease;
THYM	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg04398451	chr17:18023971	MYO15A	-0.76	-6.96	-0.58	4.39e-10	Total body bone mineral density;
THYM	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg23982607	chr1:1823379	GNB1	-0.94	-10.26	-0.72	4.7e-17	Body mass index;
THYM	cis	rs6665290	0.935	rs6693535	chr1:227197685	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs7833986	1.000	rs34480844	chr8:57092973	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	4.95	0.45	3.25e-6	Height;
THYM	cis	rs752010	0.619	rs10736421	chr1:42106230	G/A	cg06885757	chr1:42089581	HIVEP3	0.71	10.12	0.72	9.12e-17	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs9677476	0.863	rs3731775	chr2:232063578	G/A	cg23338755	chr2:231921595	PSMD1	0.66	4.74	0.44	7.51e-6	Food antigen IgG levels;
THYM	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11771526	0.892	rs62457534	chr7:32357652	G/A	cg13207630	chr7:32358064	NA	1.06	6.2	0.54	1.44e-8	Body mass index;
THYM	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg03517284	chr6:25882590	NA	-1.23	-13.29	-0.81	2.11e-23	Urate levels;
THYM	cis	rs13082711	0.595	rs34453788	chr3:27330153	T/C	cg02860705	chr3:27208620	NA	0.94	7.1	0.59	2.29e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg22841779	chr14:105766346	BRF1	-0.48	-6.0	-0.52	3.61e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg26850624	chr5:429559	AHRR	-0.71	-5.23	-0.47	1.02e-6	Cystic fibrosis severity;
THYM	cis	rs7119	0.679	rs12914932	chr15:77839051	G/A	cg27398640	chr15:77910606	LINGO1	-0.62	-6.46	-0.55	4.52e-9	Type 2 diabetes;
THYM	cis	rs11167764	0.895	rs6882824	chr5:141474300	A/G	cg23435118	chr5:141488016	NDFIP1	-0.53	-4.51	-0.42	1.85e-5	Crohn's disease;
THYM	cis	rs2658782	0.789	rs2658776	chr11:93147927	A/G	cg16424440	chr11:93231842	C11orf75	-0.65	-4.52	-0.42	1.8e-5	Pulmonary function decline;
THYM	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg02551604	chr5:131831745	NA	0.78	6.17	0.53	1.66e-8	Asthma (sex interaction);
THYM	cis	rs859767	0.741	rs4954156	chr2:135395863	T/C	cg12500956	chr2:135428796	TMEM163	-0.48	-4.88	-0.45	4.29e-6	Neuroticism;
THYM	cis	rs1395	0.778	rs34618115	chr2:27418289	G/A	cg23587288	chr2:27483067	SLC30A3	-0.61	-5.33	-0.48	6.52e-7	Blood metabolite levels;
THYM	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg04320152	chr17:18167836	SMCR7	0.59	4.72	0.44	8.19e-6	Total body bone mineral density;
THYM	cis	rs7103648	1.000	rs2293579	chr11:47440758	G/A	cg20307385	chr11:47447363	PSMC3	0.93	8.6	0.66	1.58e-13	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs10411262	0.506	rs11083845	chr19:47186655	T/C	cg18040997	chr19:47551898	TMEM160	0.72	4.55	0.42	1.56e-5	Tonsillectomy;
THYM	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg26441486	chr22:50317300	CRELD2	0.44	7.57	0.61	2.37e-11	Schizophrenia;
THYM	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg27572855	chr1:25598939	RHD	0.65	4.93	0.45	3.43e-6	Erythrocyte sedimentation rate;
THYM	cis	rs1048238	0.525	rs848214	chr1:16265422	A/G	cg21385522	chr1:16154831	NA	-0.71	-5.88	-0.52	6.18e-8	Systolic blood pressure;
THYM	cis	rs7756236	0.521	rs9394368	chr6:36630525	C/G	cg11920449	chr6:36645608	CDKN1A	0.66	5.63	0.5	1.84e-7	QRS duration;
THYM	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg04025307	chr7:1156635	C7orf50	0.77	6.66	0.56	1.77e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg07343612	chr16:622815	PIGQ	-1.08	-10.53	-0.73	1.25e-17	Height;
THYM	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg20290983	chr6:43655470	MRPS18A	1.43	15.91	0.85	1.54e-28	IgG glycosylation;
THYM	cis	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.1	-0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	7.29	0.6	8.95e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2795502	0.564	rs11239844	chr10:43453365	G/A	cg08461752	chr10:43522343	NA	-0.77	-4.7	-0.43	8.83e-6	Blood protein levels;
THYM	cis	rs1018836	0.828	rs12548806	chr8:91564256	C/T	cg16814680	chr8:91681699	NA	-0.9	-7.92	-0.63	4.38e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.05	-5.39	-0.48	5.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8017423	0.967	rs11628881	chr14:90713833	C/T	cg04239629	chr14:90701769	NA	-0.62	-4.52	-0.42	1.81e-5	Mortality in heart failure;
THYM	cis	rs12711979	0.509	rs13000873	chr2:3823705	T/C	cg17052675	chr2:3827356	NA	-0.88	-13.79	-0.82	2.09e-24	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs3750965	0.575	rs3892895	chr11:68884755	A/G	cg01403660	chr11:68851641	TPCN2	-0.58	-4.77	-0.44	6.7e-6	Hair color;
THYM	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg06656553	chr16:89960601	TCF25	-0.93	-5.27	-0.48	8.6e-7	Skin colour saturation;
THYM	cis	rs4790333	0.692	rs2003969	chr17:2266709	T/C	cg27406664	chr17:2294951	MNT	0.54	4.68	0.43	9.4e-6	Proinsulin levels;
THYM	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg27279351	chr12:120934652	DYNLL1	-0.95	-8.61	-0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs28595532	1.000	rs56000725	chr4:119637675	G/A	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg07424592	chr7:64974309	NA	1.01	5.13	0.47	1.5e-6	Diabetic kidney disease;
THYM	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg17264618	chr3:40429014	ENTPD3	0.53	5.08	0.46	1.86e-6	Renal cell carcinoma;
THYM	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg14983838	chr19:29218262	NA	1.08	9.53	0.7	1.66e-15	Methadone dose in opioid dependence;
THYM	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg08773314	chr2:239334832	ASB1	0.65	9.89	0.71	2.85e-16	Multiple system atrophy;
THYM	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07157834	chr1:205819609	PM20D1	0.6	5.45	0.49	4.02e-7	Menarche (age at onset);
THYM	cis	rs1347297	0.526	rs10201175	chr2:179265348	C/T	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.62	-4.75	-0.44	7.29e-6	Alzheimer disease and age of onset;
THYM	cis	rs17641971	0.599	rs818555	chr8:49999211	A/G	cg00325661	chr8:49890786	NA	-0.91	-8.19	-0.64	1.21e-12	Blood metabolite levels;
THYM	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg03806693	chr22:41940476	POLR3H	0.95	7.85	0.63	6.34e-12	Vitiligo;
THYM	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs919433	0.680	rs1563340	chr2:198414713	A/T	cg00792783	chr2:198669748	PLCL1	0.81	5.51	0.49	3.1e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2135507	0.521	rs2903818	chr4:83537356	T/C	cg10249074	chr4:83542146	C4orf11	-0.58	-4.66	-0.43	1.02e-5	Juvenile osteochondritis dissecans;
THYM	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg12826209	chr6:26865740	GUSBL1	0.86	4.94	0.45	3.4e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg18512352	chr11:47633146	NA	-0.53	-6.56	-0.56	2.75e-9	Subjective well-being;
THYM	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg06808227	chr14:105710500	BRF1	-1.06	-9.4	-0.69	3.18e-15	Mean platelet volume;Platelet distribution width;
THYM	cis	rs728616	0.867	rs56198874	chr10:81686488	C/T	cg18148530	chr10:81370782	SFTPA1	0.77	4.88	0.45	4.23e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs1421898	0.556	rs10475660	chr5:157943212	A/G	cg06698293	chr5:158690540	UBLCP1	-0.97	-4.6	-0.43	1.28e-5	Inflammatory skin disease;
THYM	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.02	0.46	2.4e-6	Obesity-related traits;
THYM	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg24257776	chr3:47051546	LOC100129354	0.41	4.79	0.44	6.12e-6	Colorectal cancer;
THYM	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg08859206	chr1:53392774	SCP2	-0.51	-5.32	-0.48	6.88e-7	Monocyte count;
THYM	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.48	-0.55	4.1e-9	Personality dimensions;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg14295534	chr9:134004811	NUP214	-0.95	-6.94	-0.58	4.89e-10	Depressive symptoms;
THYM	cis	rs7193541	0.595	rs4476202	chr16:74709940	T/C	cg01733217	chr16:74700730	RFWD3	0.91	9.59	0.7	1.23e-15	Multiple myeloma;
THYM	cis	rs6502050	0.835	rs35038106	chr17:80180346	C/T	cg21773646	chr17:80085082	CCDC57	-0.37	-5.17	-0.47	1.29e-6	Life satisfaction;
THYM	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs10203711	1.000	rs907111	chr2:239566426	T/C	cg14580085	chr2:239553406	NA	0.68	6.18	0.54	1.6e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8050907	0.744	rs28629405	chr16:4525933	G/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.3	5.2	0.47	1.16e-6	Obesity-related traits;
THYM	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg22875332	chr1:76189707	ACADM	-0.53	-4.89	-0.45	4.04e-6	Daytime sleep phenotypes;
THYM	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg09877947	chr5:131593287	PDLIM4	-0.67	-5.52	-0.49	2.89e-7	Acylcarnitine levels;
THYM	trans	rs877282	0.898	rs12359731	chr10:759497	A/G	cg22713356	chr15:30763199	NA	1.38	11.24	0.76	3.79e-19	Uric acid levels;
THYM	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.57	-0.42	1.48e-5	Bipolar disorder;
THYM	cis	rs9906944	0.545	rs2088140	chr17:47094599	T/C	cg20966754	chr17:47091339	IGF2BP1	-0.59	-7.39	-0.6	5.64e-11	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg00071950	chr4:10020882	SLC2A9	-0.68	-6.95	-0.58	4.47e-10	Bone mineral density;
THYM	cis	rs12893597	0.580	rs2360999	chr14:76818989	A/C	cg20290672	chr14:76816747	NA	-0.57	-4.59	-0.43	1.37e-5	Maximal oxygen uptake response;
THYM	cis	rs12282928	0.917	rs7942804	chr11:48297076	C/A	cg22827986	chr11:48284249	OR4X1	-0.53	-5.5	-0.49	3.18e-7	Migraine - clinic-based;
THYM	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg22764044	chr5:178986830	RUFY1	0.49	4.67	0.43	9.72e-6	Lung cancer;
THYM	cis	rs11627756	0.958	rs2146430	chr14:103071825	G/T	cg27124170	chr14:102829869	TECPR2;CINP	-0.66	-4.53	-0.42	1.69e-5	Mean platelet volume;
THYM	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs2637266	0.777	rs2637254	chr10:78312002	G/A	cg18941641	chr10:78392320	NA	0.7	5.56	0.5	2.44e-7	Pulmonary function;
THYM	cis	rs34375054	0.558	rs67041765	chr12:125672913	T/G	cg25124228	chr12:125621409	AACS	-0.77	-5.96	-0.52	4.29e-8	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs4746818	1.000	rs4284308	chr10:70884861	C/T	cg04149295	chr10:70884716	VPS26A	0.79	5.49	0.49	3.35e-7	Left atrial antero-posterior diameter;
THYM	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg12963246	chr6:28129442	ZNF389	0.51	4.53	0.42	1.72e-5	Parkinson's disease;
THYM	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.66	-5.26	-0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg23711669	chr6:146136114	FBXO30	-0.83	-7.77	-0.62	9.16e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Body mass index;
THYM	cis	rs3820068	0.705	rs4646083	chr1:15825564	G/A	cg05660106	chr1:15850417	CASP9	1.13	10.23	0.72	5.39e-17	Systolic blood pressure;
THYM	cis	rs228769	1.000	rs12937692	chr17:42256430	G/A	cg19774624	chr17:42201019	HDAC5	-0.75	-6.86	-0.58	7.12e-10	Bone mineral density (hip);Bone mineral density (spine);
THYM	cis	rs4343996	0.967	rs10260145	chr7:3345308	C/T	cg21248987	chr7:3385318	SDK1	0.4	4.83	0.44	5.22e-6	Motion sickness;
THYM	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.74	-0.44	7.64e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs12935418	0.583	rs2316923	chr16:81024821	C/G	cg16651780	chr16:81037892	C16orf61	-0.86	-6.73	-0.57	1.3e-9	Mean corpuscular volume;
THYM	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg06917634	chr15:78832804	PSMA4	0.96	8.89	0.67	3.96e-14	Sudden cardiac arrest;
THYM	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg18876405	chr7:65276391	NA	-0.56	-4.52	-0.42	1.77e-5	Aortic root size;
THYM	cis	rs7220711	0.934	rs4793017	chr17:41780980	A/G	cg26893861	chr17:41843967	DUSP3	0.61	4.99	0.46	2.72e-6	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.79e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg04025307	chr7:1156635	C7orf50	0.82	8.33	0.65	5.94e-13	Longevity;Endometriosis;
THYM	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg05182265	chr7:156933206	UBE3C	-0.68	-9.24	-0.69	6.8e-15	Body mass index;
THYM	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg21784768	chr11:537496	LRRC56	-1.07	-5.36	-0.48	5.7e-7	Body mass index;
THYM	cis	rs995000	0.965	rs10889352	chr1:63099023	T/C	cg06896770	chr1:63153194	DOCK7	0.99	8.07	0.64	2.19e-12	Triglyceride levels;
THYM	cis	rs6723226	0.806	rs2249109	chr2:32750879	G/A	cg02381751	chr2:32503542	YIPF4	0.71	5.83	0.51	7.53e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11563648	0.553	rs10254399	chr7:127012114	G/A	cg23081781	chr7:127225937	GCC1	-0.35	-4.78	-0.44	6.41e-6	Resting heart rate;
THYM	cis	rs8112211	0.750	rs7257537	chr19:38806772	A/T	cg25820703	chr19:38877220	GGN	-0.51	-4.79	-0.44	6.17e-6	Blood protein levels;
THYM	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg23205692	chr1:25664452	TMEM50A	0.84	6.41	0.55	5.63e-9	Erythrocyte sedimentation rate;
THYM	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg06238570	chr21:40685208	BRWD1	0.91	6.77	0.57	1.08e-9	Cognitive function;
THYM	cis	rs12681287	0.752	rs9297861	chr8:87254730	G/C	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs12935418	0.616	rs2549858	chr16:81026994	G/A	cg16651780	chr16:81037892	C16orf61	-0.81	-6.17	-0.53	1.69e-8	Mean corpuscular volume;
THYM	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg05347473	chr6:146136440	FBXO30	0.58	4.52	0.42	1.8e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg25251562	chr2:3704773	ALLC	-0.79	-5.3	-0.48	7.4e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg06558623	chr16:89946397	TCF25	1.09	5.88	0.52	6.15e-8	Skin colour saturation;
THYM	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.69	-4.62	-0.43	1.22e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-5.83	-0.51	7.7e-8	Total cholesterol levels;
THYM	cis	rs11048434	0.736	rs11048345	chr12:9123056	T/G	cg13575925	chr12:9217583	LOC144571	0.53	4.94	0.45	3.31e-6	Sjögren's syndrome;
THYM	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg10334053	chr1:2078117	PRKCZ	-0.47	-4.56	-0.42	1.55e-5	Height;
THYM	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg10803722	chr21:46713166	LOC642852	-0.4	-5.32	-0.48	6.95e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg01191920	chr7:158217561	PTPRN2	0.89	8.56	0.66	2e-13	Obesity-related traits;
THYM	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg08430604	chr3:44902960	MIR564;TMEM42	0.5	4.9	0.45	3.97e-6	Depressive symptoms;
THYM	cis	rs4919687	0.550	rs12784517	chr10:104464970	T/C	cg15744005	chr10:104629667	AS3MT	-0.58	-4.58	-0.43	1.4e-5	Colorectal cancer;
THYM	cis	rs7605378	1.000	rs7605378	chr2:200676926	A/C	cg17644776	chr2:200775616	C2orf69	0.64	4.97	0.45	2.96e-6	Osteoporosis;
THYM	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg00645579	chr11:617140	IRF7;MUPCDH	-0.51	-6.59	-0.56	2.48e-9	Systemic lupus erythematosus;
THYM	cis	rs6084875	0.840	rs2422942	chr20:4726116	A/G	cg19614321	chr20:4804581	RASSF2	0.44	4.46	0.42	2.22e-5	Systemic lupus erythematosus;
THYM	cis	rs7584330	0.697	rs7574337	chr2:238439503	A/G	cg16989719	chr2:238392110	NA	-0.52	-5.18	-0.47	1.23e-6	Prostate cancer;
THYM	cis	rs7043114	0.544	rs7852510	chr9:95316359	T/G	cg14631576	chr9:95140430	CENPP	-0.76	-7.28	-0.6	9.4e-11	Height;
THYM	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg12386194	chr3:101231763	SENP7	0.95	7.35	0.6	7.02e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2976388	0.967	rs2976397	chr8:143764613	G/T	cg06565975	chr8:143823917	SLURP1	-0.53	-5.92	-0.52	5.15e-8	Urinary tract infection frequency;
THYM	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg12288994	chr5:1860383	NA	0.78	6.4	0.55	5.86e-9	Cardiovascular disease risk factors;
THYM	cis	rs9913156	0.748	rs55959711	chr17:4562581	C/A	cg19197139	chr17:4613644	ARRB2	0.83	5.0	0.46	2.63e-6	Lymphocyte counts;
THYM	cis	rs9486715	0.867	rs9372106	chr6:96875058	T/C	cg06623918	chr6:96969491	KIAA0776	1.08	8.95	0.68	2.9e-14	Headache;
THYM	cis	rs35160687	0.640	rs13015186	chr2:86485578	A/G	cg10973622	chr2:86423274	IMMT	0.52	4.54	0.42	1.64e-5	Night sleep phenotypes;
THYM	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg18681998	chr4:17616180	MED28	0.88	8.09	0.64	1.94e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6842047	0.809	rs3087505	chr4:187179486	A/G	cg09526685	chr4:187126073	CYP4V2	1.09	5.27	0.48	8.6e-7	Blood protein levels;
THYM	cis	rs6754311	0.593	rs313523	chr2:136432103	G/A	cg07169764	chr2:136633963	MCM6	0.7	5.67	0.5	1.55e-7	Mosquito bite size;
THYM	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg12863693	chr15:85201151	NMB	-0.57	-4.93	-0.45	3.54e-6	Schizophrenia;
THYM	cis	rs13102973	0.867	rs4521398	chr4:135906934	T/G	cg14419869	chr4:135874104	NA	0.82	6.86	0.58	7.03e-10	Subjective well-being;
THYM	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg24675056	chr1:15929824	NA	0.73	5.79	0.51	9.09e-8	Systolic blood pressure;
THYM	cis	rs2495707	0.602	rs75205635	chr10:102416299	G/T	cg18033436	chr10:102982347	NA	0.63	4.46	0.42	2.22e-5	Body mass index;
THYM	cis	rs865483	0.895	rs878520	chr17:35762107	C/G	cg06716730	chr17:35851459	DUSP14	-0.46	-7.75	-0.62	9.99e-12	Monocyte count;
THYM	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg08132940	chr7:1081526	C7orf50	-1.11	-6.43	-0.55	5.11e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4372836	0.543	rs6742291	chr2:29007349	T/C	cg09522027	chr2:28974177	PPP1CB	-0.58	-4.49	-0.42	2e-5	Body mass index;
THYM	cis	rs453193	1.000	rs453193	chr2:8450521	G/A	cg12167548	chr2:8464763	NA	0.51	5.52	0.49	2.9e-7	Granulocyte percentage of myeloid white cells;
THYM	cis	rs4664308	1.000	rs10929965	chr2:160906931	C/T	cg03641300	chr2:160917029	PLA2R1	0.75	6.95	0.58	4.48e-10	Idiopathic membranous nephropathy;
THYM	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18252515	chr7:66147081	NA	0.64	4.86	0.45	4.57e-6	Aortic root size;
THYM	cis	rs2219968	0.828	rs10808823	chr8:78903013	C/T	cg00738934	chr8:78996279	NA	-0.8	-8.24	-0.65	9.37e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg24920358	chr1:40204285	PPIE	0.6	5.57	0.5	2.39e-7	Blood protein levels;
THYM	cis	rs1829883	0.626	rs2548089	chr5:98910440	A/C	cg08333243	chr5:99726346	NA	0.56	4.82	0.44	5.55e-6	Hemostatic factors and hematological phenotypes;
THYM	cis	rs17102423	0.806	rs4902362	chr14:65582755	G/A	cg11161011	chr14:65562177	MAX	0.67	6.11	0.53	2.19e-8	Obesity-related traits;
THYM	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg12560992	chr17:57184187	TRIM37	-0.92	-8.68	-0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9565309	0.579	rs7982885	chr13:77580732	T/C	cg13866767	chr13:78470850	EDNRB	1.06	4.81	0.44	5.76e-6	Morning vs. evening chronotype;
THYM	cis	rs4900538	0.927	rs1190547	chr14:102905087	G/C	cg18135206	chr14:102964638	TECPR2	-0.92	-7.62	-0.62	1.88e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg14019146	chr3:50243930	SLC38A3	0.54	4.53	0.42	1.73e-5	Menarche (age at onset);
THYM	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg13010199	chr12:38710504	ALG10B	0.7	4.72	0.44	8e-6	Morning vs. evening chronotype;
THYM	cis	rs485842	1.000	rs552585	chr11:96021945	C/T	cg23866687	chr11:96026956	MAML2	0.44	6.23	0.54	1.28e-8	Corneal astigmatism;
THYM	cis	rs11148252	0.514	rs3783242	chr13:52717950	C/T	cg00495681	chr13:53174319	NA	0.68	5.95	0.52	4.54e-8	Lewy body disease;
THYM	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg04398451	chr17:18023971	MYO15A	0.78	7.61	0.62	2.01e-11	Total body bone mineral density;
THYM	cis	rs9381040	0.701	rs6933231	chr6:41163700	T/C	cg03526776	chr6:41159608	TREML2	0.52	4.79	0.44	6.03e-6	Alzheimer's disease (late onset);
THYM	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg08392591	chr16:89556376	ANKRD11	0.55	4.52	0.42	1.76e-5	Multiple myeloma (IgH translocation);
THYM	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg22166914	chr1:53195759	ZYG11B	-0.68	-5.38	-0.48	5.38e-7	Monocyte count;
THYM	cis	rs6430585	0.528	rs309165	chr2:136667301	T/C	cg23851026	chr2:136556271	LCT	0.69	7.1	0.59	2.26e-10	Corneal structure;
THYM	cis	rs4363385	0.782	rs310105	chr1:153022253	A/G	cg13444842	chr1:152974279	SPRR3	-0.63	-5.12	-0.47	1.58e-6	Inflammatory skin disease;
THYM	cis	rs919433	0.679	rs61155920	chr2:198528881	C/T	cg05783139	chr2:198650985	BOLL	0.66	4.98	0.46	2.78e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9403317	0.654	rs11758981	chr6:141958935	A/C	cg15052665	chr6:141804349	NA	0.76	5.72	0.51	1.21e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2070488	0.813	rs3749387	chr3:38496193	G/C	cg24069376	chr3:38537580	EXOG	0.64	5.94	0.52	4.59e-8	Electrocardiographic conduction measures;
THYM	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg13010199	chr12:38710504	ALG10B	-0.6	-5.3	-0.48	7.56e-7	Heart rate;
THYM	cis	rs9894429	0.646	rs7217415	chr17:79618252	G/A	cg21984481	chr17:79567631	NPLOC4	-0.47	-4.97	-0.45	2.92e-6	Eye color traits;
THYM	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg13695892	chr22:41940480	POLR3H	-0.82	-6.71	-0.57	1.43e-9	Vitiligo;
THYM	cis	rs8133932	0.906	rs8128820	chr21:47098766	A/G	cg20357416	chr21:47294739	PCBP3	0.86	4.94	0.45	3.33e-6	Schizophrenia;
THYM	cis	rs78456975	1.000	rs13431491	chr2:1553808	T/A	cg14129053	chr2:1895732	MYT1L	1.13	4.49	0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg17345569	chr6:42928274	GNMT	0.48	4.57	0.42	1.45e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6499255	0.904	rs60010276	chr16:69674805	C/T	cg00738113	chr16:70207722	CLEC18C	-0.44	-4.57	-0.42	1.45e-5	IgE levels;
THYM	cis	rs921943	0.554	rs163132	chr5:78285921	A/G	cg18828365	chr5:78281819	ARSB	0.56	5.23	0.47	9.93e-7	Blood and toenail selenium levels;Blood trace element (Se levels);
THYM	cis	rs4474465	1.000	rs10899521	chr11:78184560	T/A	cg02023728	chr11:77925099	USP35	0.53	4.61	0.43	1.25e-5	Alzheimer's disease (survival time);
THYM	cis	rs17598306	0.873	rs2894085	chr7:96584407	G/C	cg23184042	chr7:96615519	DLX6AS	0.61	4.76	0.44	6.82e-6	Radiation response;
THYM	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg13695892	chr22:41940480	POLR3H	0.96	7.31	0.6	8.29e-11	Vitiligo;
THYM	cis	rs12594515	0.967	rs11070466	chr15:45984955	C/T	cg01629716	chr15:45996671	NA	0.48	4.93	0.45	3.49e-6	Waist circumference;Weight;
THYM	trans	rs28595532	0.920	rs115334469	chr4:119596194	G/C	cg13773247	chr2:42276988	PKDCC	0.89	6.93	0.58	4.92e-10	Cannabis dependence symptom count;
THYM	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg09455208	chr3:40491958	NA	0.5	5.18	0.47	1.24e-6	Renal cell carcinoma;
THYM	cis	rs3892630	0.878	rs6510277	chr19:33183669	C/A	cg22928329	chr19:33183273	NUDT19	-0.78	-5.86	-0.52	6.74e-8	Red blood cell traits;
THYM	cis	rs2652822	0.525	rs8037296	chr15:63516759	A/G	cg09251291	chr15:63483946	RAB8B	0.53	4.89	0.45	4.04e-6	Metabolic traits;
THYM	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	7.8	0.62	7.81e-12	Platelet count;
THYM	cis	rs6876348	0.516	rs185411	chr5:128313024	A/G	cg02841155	chr5:128301328	SLC27A6	-0.51	-5.07	-0.46	1.98e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs4242434	0.889	rs4592028	chr8:22449484	T/C	cg14690197	chr8:22456421	C8orf58	0.53	4.9	0.45	3.89e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs17152411	0.895	rs61872119	chr10:126583534	A/G	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	9.83e-6	Height;
THYM	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg00981070	chr1:2046702	PRKCZ	0.47	5.21	0.47	1.1e-6	Height;
THYM	cis	rs4589258	0.737	rs1783797	chr11:90442251	G/A	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	trans	rs629535	0.767	rs72654073	chr8:70081231	G/A	cg21567404	chr3:27674614	NA	-1.09	-10.28	-0.73	4.24e-17	Dupuytren's disease;
THYM	cis	rs4481887	1.000	rs4372295	chr1:248464871	G/T	cg13385794	chr1:248469461	NA	0.67	4.58	0.43	1.4e-5	Common traits (Other);
THYM	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg03605463	chr16:89740564	NA	0.61	4.49	0.42	2.02e-5	Vitiligo;
THYM	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg23188684	chr11:67383651	NA	0.63	5.49	0.49	3.37e-7	Mean corpuscular volume;
THYM	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg17264618	chr3:40429014	ENTPD3	0.53	4.93	0.45	3.52e-6	Renal cell carcinoma;
THYM	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	7.92	0.63	4.42e-12	Smoking behavior;
THYM	cis	rs12579753	0.869	rs12366920	chr12:82223015	G/A	cg07988820	chr12:82153109	PPFIA2	-0.73	-4.61	-0.43	1.23e-5	Resting heart rate;
THYM	cis	rs1198430	1.000	rs1198430	chr1:23755513	C/T	cg27447006	chr1:23763279	ASAP3	-0.83	-4.45	-0.42	2.29e-5	Total cholesterol levels;
THYM	cis	rs854765	0.624	rs9891957	chr17:17744439	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.66	-5.68	-0.5	1.44e-7	Total body bone mineral density;
THYM	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs9677476	0.909	rs7573577	chr2:232104079	C/T	cg23338755	chr2:231921595	PSMD1	0.69	4.94	0.45	3.31e-6	Food antigen IgG levels;
THYM	cis	rs6901250	0.807	rs339303	chr6:117176691	C/T	cg12892004	chr6:117198278	RFX6	-0.7	-6.78	-0.57	9.91e-10	C-reactive protein levels;
THYM	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06481639	chr22:41940642	POLR3H	0.81	5.81	0.51	8.21e-8	Vitiligo;
THYM	cis	rs748404	0.660	rs509306	chr15:43715171	A/G	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg00024416	chr22:24240387	NA	-0.68	-7.43	-0.61	4.64e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg03676636	chr4:99064102	C4orf37	0.5	7.54	0.61	2.77e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs72772090	0.539	rs56213813	chr5:96112284	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-4.67	-0.43	9.81e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6430585	0.528	rs309161	chr2:136688749	A/G	cg20242066	chr2:136595261	LCT	-0.56	-5.82	-0.51	7.85e-8	Corneal structure;
THYM	cis	rs1003719	0.788	rs1543748	chr21:38446581	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs9554348	0.541	rs11842501	chr13:96990453	A/G	cg25169784	chr13:96706045	UGGT2	0.83	4.48	0.42	2.09e-5	Schizophrenia;
THYM	cis	rs4363385	0.747	rs61811427	chr1:152968419	C/T	cg13444842	chr1:152974279	SPRR3	-0.59	-4.76	-0.44	7.02e-6	Inflammatory skin disease;
THYM	trans	rs877282	0.945	rs877280	chr10:771599	C/T	cg22713356	chr15:30763199	NA	1.38	11.57	0.76	7.71e-20	Uric acid levels;
THYM	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg10792982	chr14:105748885	BRF1	0.7	7.04	0.59	2.92e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg24642844	chr7:1081250	C7orf50	-1.38	-5.93	-0.52	4.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg07930552	chr6:133119739	C6orf192	1.24	5.27	0.48	8.42e-7	Type 2 diabetes nephropathy;
THYM	cis	rs3126085	0.866	rs3126066	chr1:152276871	A/G	cg10321714	chr1:152280068	FLG	-0.7	-5.5	-0.49	3.19e-7	Atopic dermatitis;
THYM	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.97	-7.6	-0.61	2.09e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs28595532	0.920	rs114653217	chr4:119769216	G/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs9302635	0.513	rs7184169	chr16:72152933	C/T	cg23815491	chr16:72088622	HP	0.77	5.93	0.52	4.85e-8	Blood protein levels;
THYM	cis	rs4242434	0.927	rs746011	chr8:22457804	C/T	cg11461670	chr8:22454935	PDLIM2	-0.41	-6.81	-0.57	8.77e-10	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg26597838	chr10:835615	NA	1.52	11.37	0.76	2.05e-19	Eosinophil percentage of granulocytes;
THYM	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg23187316	chr7:1099788	C7orf50	0.45	5.45	0.49	4.04e-7	Longevity;Endometriosis;
THYM	cis	rs4845875	0.626	rs10864542	chr1:11842144	C/G	cg25341925	chr1:11908058	NPPA	0.42	4.49	0.42	1.99e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg27490568	chr2:178487706	NA	0.62	5.61	0.5	1.98e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9581857	0.579	rs76614377	chr13:27974251	A/T	cg22138327	chr13:27999177	GTF3A	1.02	5.82	0.51	7.8e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs2712184	0.967	rs11892032	chr2:217668981	G/A	cg05032264	chr2:217675019	NA	-0.56	-4.79	-0.44	6.05e-6	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs7193541	0.965	rs28616016	chr16:74676964	T/C	cg01733217	chr16:74700730	RFWD3	0.77	7.31	0.6	8.13e-11	Multiple myeloma;
THYM	cis	rs72627123	0.867	rs8015927	chr14:74465756	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	-0.88	-5.03	-0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs11039798	0.764	rs11039929	chr11:48703289	A/G	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs72829446	0.932	rs62059822	chr17:7470560	G/A	cg07091842	chr17:7155530	C17orf81;DULLARD	-0.98	-4.46	-0.42	2.29e-5	Androgen levels;
THYM	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.72	0.57	1.34e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg09060608	chr5:178986726	RUFY1	0.54	5.66	0.5	1.59e-7	Lung cancer;
THYM	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg21427119	chr20:30132790	HM13	-0.73	-4.94	-0.45	3.41e-6	Mean corpuscular hemoglobin;
THYM	cis	rs6427356	0.513	rs4661094	chr1:157149614	A/G	cg27547283	chr1:156698502	C1orf66;ISG20L2	-0.58	-4.47	-0.42	2.16e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs4589258	0.898	rs11019143	chr11:90418632	G/A	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1466662	0.677	rs6811038	chr4:155299346	T/C	cg05574313	chr4:155338166	DCHS2	0.63	4.55	0.42	1.56e-5	Alzheimer's disease (age of onset);
THYM	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg10803722	chr21:46713166	LOC642852	-0.5	-6.17	-0.54	1.63e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7131987	0.683	rs3782511	chr12:29496224	G/A	cg09582351	chr12:29534625	ERGIC2	-0.59	-5.04	-0.46	2.21e-6	QT interval;
THYM	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg08736216	chr1:53307985	ZYG11A	0.66	5.22	0.47	1.04e-6	Monocyte count;
THYM	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-5.12	-0.47	1.59e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs4792901	0.802	rs9894910	chr17:41574306	T/A	cg21940313	chr17:41620911	ETV4	-0.53	-5.03	-0.46	2.28e-6	Dupuytren's disease;
THYM	cis	rs10170846	0.731	rs10180632	chr2:223526384	G/A	cg25565276	chr2:223520875	FARSB	0.61	4.9	0.45	3.94e-6	Schizophrenia (inflammation and infection response interaction);
THYM	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.67	-5.18	-0.47	1.22e-6	Tonsillectomy;
THYM	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.33	10.05	0.72	1.29e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6754311	0.593	rs6755383	chr2:136416941	C/T	cg04750100	chr2:136595281	LCT	0.56	5.89	0.52	5.87e-8	Mosquito bite size;
THYM	cis	rs11030122	0.702	rs10835402	chr11:3990914	T/C	cg22027985	chr11:4115532	RRM1	-0.48	-4.59	-0.43	1.36e-5	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg01069141	chr11:67398826	TBX10;NUDT8	0.52	5.6	0.5	2.07e-7	Mean corpuscular volume;
THYM	cis	rs854765	0.624	rs4925116	chr17:17731200	A/G	cg16928487	chr17:17741425	SREBF1	0.52	4.89	0.45	4.12e-6	Total body bone mineral density;
THYM	cis	rs78456975	1.000	rs10208449	chr2:1563257	G/A	cg12573674	chr2:1569213	NA	-1.37	-4.47	-0.42	2.16e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs9902453	0.780	rs10445384	chr17:28182685	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.72	0.44	8.25e-6	Coffee consumption (cups per day);
THYM	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg10360139	chr7:1886902	MAD1L1	-0.58	-4.63	-0.43	1.15e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23221052	chr5:179740743	GFPT2	-0.88	-7.06	-0.59	2.74e-10	Height;
THYM	cis	rs72627123	0.656	rs11159064	chr14:74614743	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	-1.29	-7.08	-0.59	2.46e-10	Morning vs. evening chronotype;
THYM	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg20503657	chr10:835505	NA	1.11	7.73	0.62	1.13e-11	Eosinophil percentage of granulocytes;
THYM	cis	rs8180040	0.966	rs11914795	chr3:47557722	G/A	cg27129171	chr3:47204927	SETD2	0.7	6.3	0.54	9.04e-9	Colorectal cancer;
THYM	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg18806716	chr10:30721971	MAP3K8	-0.49	-4.56	-0.42	1.55e-5	Inflammatory bowel disease;
THYM	cis	rs9876781	1.000	rs60512868	chr3:48483445	T/G	cg06066452	chr3:48470258	PLXNB1	0.27	4.84	0.44	5e-6	Longevity;
THYM	cis	rs7115242	0.920	rs6589574	chr11:116730638	A/G	cg01368799	chr11:117014884	PAFAH1B2	1.2	5.45	0.49	4.01e-7	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
THYM	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7104764	1.000	rs10902113	chr11:245523	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs2708977	0.965	rs2314109	chr2:97243532	A/G	cg01950434	chr2:97203154	ARID5A	-0.55	-4.97	-0.45	3.02e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg06026331	chr20:60912101	LAMA5	-0.75	-5.34	-0.48	6.46e-7	Colorectal cancer;
THYM	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.68	-5.28	-0.48	8.12e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg17689763	chr4:710664	PCGF3	-1.12	-10.08	-0.72	1.11e-16	White blood cell count;
THYM	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg07570687	chr10:102243282	WNT8B	0.77	6.86	0.58	7.1e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11214589	0.875	rs10891540	chr11:113239082	A/G	cg14159747	chr11:113255604	NA	-0.35	-7.43	-0.61	4.74e-11	Neuroticism;
THYM	cis	rs420259	0.516	rs11642395	chr16:23556561	C/T	cg00143387	chr16:23521605	GGA2	-0.72	-5.18	-0.47	1.26e-6	Bipolar disorder;
THYM	cis	rs113835537	0.529	rs3819247	chr11:66293779	T/C	cg24851651	chr11:66362959	CCS	0.72	4.87	0.45	4.51e-6	Airway imaging phenotypes;
THYM	cis	rs4866334	1.000	rs79038611	chr5:18503785	C/T	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.84e-7	IgG glycosylation;
THYM	cis	rs7216064	1.000	rs7212293	chr17:65847325	A/G	cg12091567	chr17:66097778	LOC651250	-0.7	-4.79	-0.44	6.14e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.75	5.9	0.52	5.58e-8	Total cholesterol levels;
THYM	cis	rs7851660	0.809	rs10818241	chr9:100661972	A/G	cg13688889	chr9:100608707	NA	-0.79	-5.71	-0.51	1.28e-7	Strep throat;
THYM	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.43	0.7	2.73e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6542838	0.583	rs12712040	chr2:99513416	C/G	cg08885076	chr2:99613938	TSGA10	-0.49	-4.56	-0.42	1.52e-5	Fear of minor pain;
THYM	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.94	6.5	0.55	3.77e-9	Schizophrenia;
THYM	cis	rs2073300	0.609	rs6137907	chr20:23344511	C/T	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg06618935	chr21:46677482	NA	-0.97	-9.25	-0.69	6.62e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs1784581	0.722	rs1619122	chr6:162400198	G/T	cg17173639	chr6:162384350	PARK2	-0.89	-7.99	-0.63	3.12e-12	Itch intensity from mosquito bite;
THYM	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg19196401	chr6:110721138	DDO	-0.55	-5.91	-0.52	5.33e-8	Platelet distribution width;
THYM	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.66	-0.43	1.05e-5	Eye color traits;
THYM	cis	rs7746082	0.627	rs6938089	chr6:106470070	A/G	cg02270332	chr6:106475062	NA	0.65	6.21	0.54	1.38e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg16928487	chr17:17741425	SREBF1	0.56	5.36	0.48	5.79e-7	Total body bone mineral density;
THYM	cis	rs7264396	0.635	rs6060682	chr20:34506331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.13	-0.47	1.53e-6	Total cholesterol levels;
THYM	cis	rs738322	0.726	rs5750561	chr22:38595260	A/T	cg25457927	chr22:38595422	NA	0.51	5.31	0.48	7.17e-7	Cutaneous nevi;
THYM	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg27211696	chr2:191398769	TMEM194B	-0.61	-4.56	-0.42	1.55e-5	Diastolic blood pressure;
THYM	cis	rs877282	0.853	rs11596346	chr10:756673	A/T	cg10556349	chr10:835070	NA	-0.69	-4.49	-0.42	2.03e-5	Uric acid levels;
THYM	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs2073300	1.000	rs6137967	chr20:23447108	A/T	cg12062639	chr20:23401060	NAPB	-1.11	-4.9	-0.45	4e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg26354017	chr1:205819088	PM20D1	1.01	11.1	0.75	7.72e-19	Menarche (age at onset);
THYM	cis	rs4509693	1.000	rs6584392	chr10:102497166	G/A	cg15234845	chr10:102496500	NA	0.65	4.6	0.43	1.3e-5	Alzheimer's disease;
THYM	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs58749629	1.000	rs7270354	chr20:44607661	C/T	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.59	-5.59	-0.5	2.14e-7	Abdominal aortic aneurysm;
THYM	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg19318889	chr4:1322082	MAEA	0.63	5.45	0.49	3.93e-7	Longevity;
THYM	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs1642645	0.831	rs3856259	chr1:42475503	T/C	cg22816091	chr1:42611670	NA	0.64	5.76	0.51	1.04e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs7616559	0.606	rs9790244	chr3:156785767	G/A	cg15697575	chr3:156784781	NA	0.46	6.81	0.57	8.89e-10	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg24672777	chr11:48374446	OR4C45	-0.91	-5.57	-0.5	2.31e-7	Axial length;
THYM	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg00686598	chr14:53173677	PSMC6	1.39	7.01	0.58	3.52e-10	Alzheimer's disease (late onset);
THYM	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg13395646	chr4:1353034	KIAA1530	0.59	5.31	0.48	7.33e-7	Obesity-related traits;
THYM	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg17054759	chr22:49844102	NA	-0.52	-4.72	-0.44	8.24e-6	Monocyte count;Monocyte percentage of white cells;
THYM	trans	rs75518195	0.543	rs62302800	chr4:64718272	T/C	cg14706739	chr8:21916355	EPB49	0.76	7.25	0.6	1.09e-10	Triptolide cytotoxicity;
THYM	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.52	0.49	2.99e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg08901578	chr4:187885870	NA	-0.63	-5.79	-0.51	8.9e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9303401	0.646	rs7342863	chr17:57227010	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.68	4.94	0.45	3.35e-6	Cognitive test performance;
THYM	trans	rs9951602	0.512	rs6506874	chr18:76653467	G/T	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs478304	0.593	rs12576766	chr11:65488556	C/T	cg27068330	chr11:65405492	SIPA1	-1.05	-10.64	-0.74	7.09e-18	Acne (severe);
THYM	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg00958927	chr1:175162553	KIAA0040	0.36	4.92	0.45	3.66e-6	Alcohol dependence;
THYM	trans	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg04135372	chr2:99061383	INPP4A	-1.0	-7.49	-0.61	3.6e-11	Lung adenocarcinoma;
THYM	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg26031613	chr14:104095156	KLC1	0.76	5.12	0.47	1.58e-6	Body mass index;
THYM	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs7078219	0.686	rs12412391	chr10:101288935	A/G	cg17888390	chr10:101282816	NA	-0.53	-5.14	-0.47	1.46e-6	Dental caries;
THYM	cis	rs7824557	0.564	rs13268126	chr8:11230574	G/A	cg12981288	chr8:11183844	MTMR9	-0.49	-4.8	-0.44	5.86e-6	Retinal vascular caliber;
THYM	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg02773041	chr1:40204384	PPIE	0.77	5.99	0.52	3.8e-8	Blood protein levels;
THYM	cis	rs4595586	0.545	rs3914596	chr12:39388538	T/C	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.05e-5	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs901683	1.000	rs71499567	chr10:46083956	G/C	cg18240400	chr10:46168597	ANUBL1	0.73	4.73	0.44	7.89e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs116139393	0.517	rs13230987	chr7:6726320	C/G	cg03005310	chr7:6897353	NA	-0.63	-4.58	-0.43	1.39e-5	Alzheimer's disease (APOE e4 interaction);
THYM	trans	rs480407	0.857	rs270973	chr2:161691301	T/A	cg06548410	chr19:1997657	BTBD2	0.71	6.92	0.58	5.23e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs4911259	0.507	rs8118663	chr20:31398876	A/G	cg13636640	chr20:31349939	DNMT3B	0.68	5.96	0.52	4.23e-8	Inflammatory bowel disease;
THYM	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs77372450	0.551	rs62390781	chr5:157061507	G/A	cg00312553	chr5:157098553	C5orf52	-0.65	-4.63	-0.43	1.16e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs7246657	0.891	rs7257495	chr19:37823876	C/G	cg22634378	chr19:37742834	NA	0.65	5.34	0.48	6.2e-7	Coronary artery calcification;
THYM	cis	rs4343996	1.000	rs6966619	chr7:3359491	A/T	cg21248987	chr7:3385318	SDK1	0.42	5.03	0.46	2.31e-6	Motion sickness;
THYM	cis	rs7395662	1.000	rs6485882	chr11:48592435	C/G	cg21721701	chr11:47739669	FNBP4	-0.66	-4.82	-0.44	5.43e-6	HDL cholesterol;
THYM	cis	rs950880	0.710	rs4851570	chr2:103006387	A/G	cg03938978	chr2:103052716	IL18RAP	-0.5	-4.46	-0.42	2.24e-5	Serum protein levels (sST2);
THYM	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg03709012	chr19:19516395	GATAD2A	0.8	6.87	0.58	6.71e-10	Tonsillectomy;
THYM	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg06808227	chr14:105710500	BRF1	-0.99	-8.33	-0.65	6.16e-13	Mean platelet volume;Platelet distribution width;
THYM	cis	rs8018808	0.935	rs963283	chr14:77901456	C/A	cg20045696	chr14:77926864	AHSA1	0.5	4.46	0.42	2.27e-5	Myeloid white cell count;
THYM	cis	rs9790314	1.000	rs975323	chr3:161021322	A/G	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs912057	0.601	rs1294411	chr6:6739034	T/C	cg06612196	chr6:6737390	NA	0.76	14.72	0.83	2.99e-26	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs289828	0.519	rs34548459	chr2:152152542	T/C	cg05960677	chr2:152117363	RBM43	0.72	6.75	0.57	1.17e-9	Blood protein levels;
THYM	cis	rs7833986	0.501	rs72653986	chr8:57035048	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	6.9	0.58	5.65e-10	Height;
THYM	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg04398451	chr17:18023971	MYO15A	-0.93	-10.04	-0.72	1.33e-16	Total body bone mineral density;
THYM	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.63	-5.35	-0.48	6.1e-7	Renal function-related traits (BUN);
THYM	cis	rs7513165	0.935	rs2510	chr1:204161591	T/C	cg04791601	chr1:204159016	NA	0.39	4.91	0.45	3.79e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
THYM	cis	rs6732160	0.564	rs2043096	chr2:73375723	T/C	cg24220031	chr2:73402428	NA	-0.69	-5.48	-0.49	3.55e-7	Intelligence (multi-trait analysis);
THYM	trans	rs10028773	0.666	rs35231872	chr4:120248376	A/T	cg25517755	chr10:38738941	LOC399744	-0.76	-6.9	-0.58	5.85e-10	Educational attainment;
THYM	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg07606381	chr6:8435919	SLC35B3	0.59	4.45	0.42	2.36e-5	Motion sickness;
THYM	cis	rs10781543	0.775	rs10870194	chr9:139327034	A/G	cg14115884	chr9:139300582	SDCCAG3	0.69	6.26	0.54	1.09e-8	Monocyte percentage of white cells;
THYM	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg16325326	chr1:53192061	ZYG11B	-0.81	-7.52	-0.61	3.05e-11	Monocyte count;
THYM	cis	rs7567389	0.719	rs4150471	chr2:128034539	A/G	cg06038358	chr2:128176007	PROC	-0.43	-4.53	-0.42	1.7e-5	Self-rated health;
THYM	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg23205692	chr1:25664452	TMEM50A	0.83	6.37	0.55	6.66e-9	Erythrocyte sedimentation rate;
THYM	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg24209194	chr3:40518798	ZNF619	0.56	4.48	0.42	2.11e-5	Renal cell carcinoma;
THYM	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg06550200	chr5:1325588	CLPTM1L	0.58	4.65	0.43	1.05e-5	Lung cancer;
THYM	cis	rs7107174	0.901	rs901105	chr11:77924607	A/C	cg02023728	chr11:77925099	USP35	0.7	6.19	0.54	1.5e-8	Testicular germ cell tumor;
THYM	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg10334053	chr1:2078117	PRKCZ	0.43	4.51	0.42	1.89e-5	Height;
THYM	cis	rs981844	1.000	rs62325092	chr4:154668674	T/C	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg27494647	chr7:150038898	RARRES2	0.46	5.81	0.51	8.13e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs6456042	0.829	rs3127419	chr6:166538527	A/G	cg11088901	chr6:166572345	T	-0.55	-5.12	-0.47	1.59e-6	Asthma;
THYM	trans	rs59551326	0.517	rs73148813	chr21:26602152	T/C	cg17452615	chr12:122019080	KDM2B	-0.8	-6.84	-0.57	7.67e-10	Alcohol dependence;
THYM	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.25	-4.74	-0.44	7.58e-6	Obesity-related traits;
THYM	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg17279839	chr7:150038598	RARRES2	0.56	5.43	0.49	4.4e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6700896	0.931	rs11809906	chr1:66115064	C/T	cg04111102	chr1:66153794	NA	0.55	5.23	0.47	9.89e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7980799	0.682	rs61927702	chr12:33631695	A/G	cg10856724	chr12:34555212	NA	0.61	4.55	0.42	1.56e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs1451375	0.669	rs4469404	chr7:50647062	C/T	cg18232548	chr7:50535776	DDC	-0.69	-5.35	-0.48	6.04e-7	Malaria;
THYM	cis	rs985746	0.614	rs1026529	chr4:36812287	C/T	cg04301614	chr4:37585993	C4orf19	-0.55	-4.53	-0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs8063160	0.935	rs73283869	chr16:90067184	G/A	cg07984980	chr16:89898383	SPIRE2	1.39	5.63	0.5	1.83e-7	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs28785552	0.554	rs11084178	chr19:53212361	C/T	cg22067481	chr19:53234126	ZNF611	-0.86	-8.16	-0.64	1.37e-12	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.58	-5.14	-0.47	1.5e-6	Total body bone mineral density;
THYM	cis	rs17021463	0.966	rs7657789	chr4:95178589	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.2	-0.47	1.14e-6	Testicular germ cell tumor;
THYM	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg16230307	chr14:35515116	FAM177A1	0.83	5.29	0.48	7.72e-7	Psoriasis;
THYM	cis	rs889398	0.802	rs2291959	chr16:69873992	T/G	cg09409435	chr16:70099608	PDXDC2	0.66	5.34	0.48	6.36e-7	Body mass index;
THYM	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg24531977	chr5:56204891	C5orf35	-1.11	-9.45	-0.7	2.47e-15	Initial pursuit acceleration;
THYM	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	4.98	0.46	2.81e-6	Hip circumference adjusted for BMI;
THYM	cis	rs7216064	1.000	rs62085992	chr17:65923083	T/A	cg12091567	chr17:66097778	LOC651250	-0.69	-4.51	-0.42	1.86e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs7940866	0.770	rs10791104	chr11:130814893	A/T	cg05962950	chr11:130786565	SNX19	0.74	5.91	0.52	5.35e-8	Schizophrenia;
THYM	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg26597838	chr10:835615	NA	1.21	8.65	0.66	1.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg06112835	chr11:68658793	MRPL21	0.43	6.1	0.53	2.3e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs478304	0.654	rs10896035	chr11:65461160	G/A	cg27068330	chr11:65405492	SIPA1	-1.03	-10.31	-0.73	3.55e-17	Acne (severe);
THYM	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg06981504	chr1:1234844	ACAP3	0.56	5.09	0.46	1.79e-6	Body mass index;
THYM	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg02869364	chr7:1081709	C7orf50	-0.62	-5.04	-0.46	2.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg27398817	chr8:82754497	SNX16	-0.71	-6.05	-0.53	2.89e-8	Diastolic blood pressure;
THYM	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg18252515	chr7:66147081	NA	-0.68	-5.24	-0.47	9.46e-7	Aortic root size;
THYM	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35110281	0.607	rs11701518	chr21:44987079	C/T	cg01579765	chr21:45077557	HSF2BP	-0.45	-6.8	-0.57	9.24e-10	Mean corpuscular volume;
THYM	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.68	-0.67	1.07e-13	Mean corpuscular volume;
THYM	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.03	10.73	0.74	4.6e-18	Cognitive ability;
THYM	cis	rs986417	0.901	rs1950316	chr14:61018305	T/C	cg27398547	chr14:60952738	C14orf39	1.12	6.03	0.53	3.17e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs2294693	0.891	rs9369256	chr6:40998344	G/C	cg14418226	chr6:40996092	UNC5CL	0.75	6.61	0.56	2.25e-9	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs3947	0.906	rs1692821	chr8:11699988	C/T	cg26752888	chr8:11627280	NEIL2	-0.64	-4.45	-0.42	2.37e-5	Blood protein levels;
THYM	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg18252515	chr7:66147081	NA	-0.71	-5.67	-0.5	1.56e-7	Aortic root size;
THYM	cis	rs1801251	0.644	rs283473	chr2:233654847	A/G	cg08000102	chr2:233561755	GIGYF2	0.66	5.96	0.52	4.28e-8	Coronary artery disease;
THYM	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg00129232	chr17:37814104	STARD3	-0.88	-7.23	-0.6	1.24e-10	Asthma;
THYM	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg00383909	chr3:49044727	WDR6	1.13	6.67	0.56	1.72e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs8050907	1.000	rs7195763	chr16:4649300	C/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.12	4.53	0.42	1.74e-5	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg27170947	chr2:26402098	FAM59B	0.61	4.63	0.43	1.17e-5	Gut microbiome composition (summer);
THYM	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg24163568	chr5:669837	TPPP	-0.59	-5.39	-0.48	5.16e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs3126085	0.935	rs11204981	chr1:152298212	C/T	cg10321714	chr1:152280068	FLG	-0.68	-4.81	-0.44	5.77e-6	Atopic dermatitis;
THYM	trans	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg25517755	chr10:38738941	LOC399744	-0.77	-7.03	-0.58	3.09e-10	Corneal astigmatism;
THYM	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs9902453	1.000	rs9896062	chr17:28357047	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs10979	0.928	rs6924967	chr6:143906235	C/T	cg25407410	chr6:143891975	LOC285740	-0.58	-4.52	-0.42	1.75e-5	Hypospadias;
THYM	cis	rs4595586	0.545	rs1839402	chr12:39371615	C/T	cg13010199	chr12:38710504	ALG10B	0.61	4.68	0.43	9.49e-6	Morning vs. evening chronotype;
THYM	cis	rs8041943	0.550	rs72730819	chr15:79889853	G/A	cg20511832	chr15:78934280	CHRNB4	0.46	4.53	0.42	1.7e-5	Bone mineral density (spine) and age at menarche;
THYM	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14159672	chr1:205819179	PM20D1	1.1	11.96	0.78	1.18e-20	Menarche (age at onset);
THYM	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg02734326	chr4:10020555	SLC2A9	0.76	7.25	0.6	1.13e-10	Bone mineral density;
THYM	cis	rs1018836	0.892	rs4140680	chr8:91584157	G/A	cg16814680	chr8:91681699	NA	-0.77	-6.25	-0.54	1.14e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs34638657	0.789	rs2967363	chr16:82204132	C/G	cg09439754	chr16:82129088	HSD17B2	-0.62	-6.02	-0.53	3.29e-8	Lung adenocarcinoma;
THYM	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.47	0.49	3.63e-7	Bipolar disorder;
THYM	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg25703541	chr22:24373054	LOC391322	-0.85	-9.19	-0.69	8.88e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11890956	chr21:40555474	PSMG1	-0.9	-9.45	-0.7	2.51e-15	Cognitive function;
THYM	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg02478829	chr6:26598070	ABT1	0.35	4.62	0.43	1.22e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg02070205	chr10:30722105	MAP3K8	-0.69	-6.17	-0.54	1.64e-8	Inflammatory bowel disease;
THYM	cis	rs10499694	0.933	rs7778349	chr7:50593157	C/T	cg00647317	chr7:50633725	DDC	0.3	4.56	0.42	1.52e-5	Body mass index;
THYM	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg22508957	chr16:3507546	NAT15	0.71	7.87	0.63	5.78e-12	Tuberculosis;
THYM	cis	rs863345	0.565	rs7551497	chr1:158444925	T/G	cg12129480	chr1:158549410	OR10X1	-0.47	-4.62	-0.43	1.23e-5	Pneumococcal bacteremia;
THYM	cis	rs1003719	0.762	rs1155786	chr21:38448025	A/G	cg01329690	chr21:38580129	DSCR9	0.42	5.74	0.51	1.13e-7	Eye color traits;
THYM	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg12011299	chr4:100065546	ADH4	0.74	7.23	0.6	1.24e-10	Alcohol dependence;
THYM	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg22709100	chr7:91322751	NA	-0.61	-4.85	-0.45	4.9e-6	Breast cancer;
THYM	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.93	-0.45	3.52e-6	Monocyte count;
THYM	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg00083206	chr6:110721305	DDO	-0.56	-6.7	-0.57	1.44e-9	Platelet distribution width;
THYM	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg24642844	chr7:1081250	C7orf50	-0.71	-4.87	-0.45	4.43e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg14829155	chr15:31115871	NA	-0.76	-6.19	-0.54	1.53e-8	Huntington's disease progression;
THYM	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg07424592	chr7:64974309	NA	1.1	5.08	0.46	1.87e-6	Diabetic kidney disease;
THYM	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg24733560	chr20:60626293	TAF4	-0.62	-6.59	-0.56	2.49e-9	Body mass index;
THYM	cis	rs747334	0.653	rs10881859	chr10:92701594	A/G	cg07620928	chr10:92689909	NA	0.52	4.51	0.42	1.86e-5	Fibroblast growth factor basic levels;
THYM	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg11764359	chr7:65958608	NA	-0.8	-6.38	-0.55	6.55e-9	Aortic root size;
THYM	cis	rs34375054	0.558	rs12578774	chr12:125681761	A/G	cg25124228	chr12:125621409	AACS	0.71	5.38	0.48	5.23e-7	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs4523957	0.928	rs394752	chr17:2199749	C/A	cg16513277	chr17:2031491	SMG6	0.77	6.96	0.58	4.26e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs977987	0.806	rs11149833	chr16:75464002	G/C	cg03315344	chr16:75512273	CHST6	0.73	5.83	0.51	7.5e-8	Dupuytren's disease;
THYM	cis	rs1775715	0.737	rs55859032	chr10:32213239	C/T	cg04359828	chr10:32216031	ARHGAP12	0.39	5.04	0.46	2.19e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg21427119	chr20:30132790	HM13	-0.78	-5.53	-0.49	2.83e-7	Mean corpuscular hemoglobin;
THYM	cis	rs828999	0.620	rs6703140	chr1:108697224	C/T	cg24323958	chr1:108741884	SLC25A24	0.54	5.32	0.48	6.79e-7	Monocyte percentage of white cells;
THYM	cis	rs61931739	0.817	rs2203086	chr12:34232590	T/C	cg10856724	chr12:34555212	NA	-0.62	-5.55	-0.49	2.62e-7	Morning vs. evening chronotype;
THYM	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	7.01	0.58	3.42e-10	Platelet count;
THYM	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg26354017	chr1:205819088	PM20D1	0.58	4.63	0.43	1.18e-5	Parkinson's disease;
THYM	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg20291162	chr17:40259547	DHX58	0.7	6.57	0.56	2.72e-9	Fibrinogen levels;
THYM	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.18	8.77	0.67	7.01e-14	Cognitive test performance;
THYM	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg15962314	chr1:44399869	ARTN	0.52	4.99	0.46	2.72e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs12478296	0.901	rs9653611	chr2:243006956	C/G	cg06360820	chr2:242988706	NA	-0.93	-6.23	-0.54	1.29e-8	Obesity-related traits;
THYM	cis	rs6586111	1.000	rs7093787	chr10:82371127	C/T	cg03086067	chr10:82368399	SH2D4B	-0.55	-7.04	-0.59	3.02e-10	Capecitabine sensitivity;
THYM	cis	rs1003719	0.788	rs9974286	chr21:38456832	A/G	cg01329690	chr21:38580129	DSCR9	-0.38	-5.24	-0.47	9.49e-7	Eye color traits;
THYM	cis	rs4227	0.565	rs1641550	chr17:7503788	G/A	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	-0.27	-4.67	-0.43	9.75e-6	IgA nephropathy;
THYM	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg05347473	chr6:146136440	FBXO30	-0.81	-7.24	-0.6	1.13e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg13695892	chr22:41940480	POLR3H	0.89	6.74	0.57	1.2e-9	Vitiligo;
THYM	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	ch.11.42038R	chr11:967971	AP2A2	0.61	4.81	0.44	5.58e-6	Alzheimer's disease (late onset);
THYM	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg02734326	chr4:10020555	SLC2A9	0.76	6.89	0.58	6.16e-10	Bone mineral density;
THYM	cis	rs5167	0.781	rs2075619	chr19:45495682	A/G	cg09555818	chr19:45449301	APOC2	0.43	4.46	0.42	2.26e-5	Blood protein levels;
THYM	cis	rs1018836	0.892	rs5005585	chr8:91581975	A/G	cg16814680	chr8:91681699	NA	-0.78	-6.43	-0.55	5.14e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6809651	0.524	rs4686728	chr3:185795333	C/T	cg00760338	chr3:185826511	ETV5	0.91	7.2	0.59	1.38e-10	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
THYM	cis	rs7084402	0.967	rs1427200	chr10:60274928	C/T	cg07615347	chr10:60278583	BICC1	-0.53	-4.65	-0.43	1.08e-5	Refractive error;
THYM	cis	rs870825	0.932	rs10034861	chr4:185577450	C/T	cg04058563	chr4:185651563	MLF1IP	1.0	6.98	0.58	3.96e-10	Blood protein levels;
THYM	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg26149184	chr10:133730230	NA	0.78	4.76	0.44	6.86e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs4845875	0.514	rs198406	chr1:11897592	A/G	cg24844545	chr1:11908347	NPPA	-0.49	-4.8	-0.44	5.93e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs858239	0.537	rs2286272	chr7:23224367	T/C	cg09755872	chr7:23245557	NA	-0.52	-4.85	-0.45	4.76e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg26131816	chr17:42072204	PYY	0.52	4.52	0.42	1.75e-5	Menopause (age at onset);
THYM	cis	rs1691799	0.899	rs1168315	chr12:66746694	A/G	cg16791601	chr12:66731901	HELB	-0.75	-7.25	-0.6	1.08e-10	White blood cell count (basophil);
THYM	cis	rs4474465	1.000	rs7131199	chr11:78192148	T/G	cg19901956	chr11:77921274	USP35	-0.69	-5.1	-0.46	1.75e-6	Alzheimer's disease (survival time);
THYM	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg24399712	chr22:39784796	NA	0.88	11.1	0.75	7.67e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs3741151	0.773	rs58334887	chr11:73171510	A/C	cg12959048	chr11:73096162	RELT	-0.53	-5.08	-0.46	1.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg23711669	chr6:146136114	FBXO30	0.91	9.54	0.7	1.6e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs259964	1.000	rs259964	chr20:57824309	A/G	cg16205854	chr20:57875318	EDN3	-0.4	-4.46	-0.42	2.28e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg07537917	chr2:241836409	C2orf54	-0.25	-5.43	-0.49	4.35e-7	Urinary metabolites;
THYM	cis	rs931812	0.858	rs4734017	chr8:101912073	C/T	cg07585502	chr8:101912084	NA	-0.57	-4.62	-0.43	1.21e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs3126085	0.935	rs1390487	chr1:152194601	G/A	cg10321714	chr1:152280068	FLG	0.69	5.04	0.46	2.22e-6	Atopic dermatitis;
THYM	cis	rs9902453	0.934	rs8079028	chr17:28484234	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	6.58	0.56	2.55e-9	Coffee consumption (cups per day);
THYM	cis	rs3020340	0.817	rs1159327	chr6:152048022	C/T	cg22157087	chr6:152012887	ESR1	0.45	4.55	0.42	1.61e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs13082711	0.911	rs73046191	chr3:27454398	T/A	cg02860705	chr3:27208620	NA	0.69	4.99	0.46	2.75e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg17063962	chr7:91808500	NA	-1.08	-11.41	-0.76	1.71e-19	Breast cancer;
THYM	cis	rs10929159	0.928	rs12053257	chr2:236920174	C/T	cg14895183	chr2:236924282	AGAP1	0.54	4.67	0.43	9.81e-6	Parkinson's disease;
THYM	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg22166914	chr1:53195759	ZYG11B	0.8	8.04	0.64	2.5e-12	Monocyte count;
THYM	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.67	-4.76	-0.44	6.93e-6	Aortic root size;
THYM	cis	rs6032067	1.000	rs6032060	chr20:43852454	A/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.41	-0.55	5.57e-9	Blood protein levels;
THYM	cis	rs10788264	0.504	rs4751887	chr10:124029758	G/A	cg09507567	chr10:124027408	NA	0.52	5.39	0.48	5.03e-7	Total body bone mineral density;
THYM	cis	rs1885364	0.967	rs5762316	chr22:28094156	T/C	cg17187762	chr22:28070120	NA	0.39	4.67	0.43	9.73e-6	Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion);
THYM	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg18681998	chr4:17616180	MED28	0.91	8.58	0.66	1.75e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg11494091	chr17:61959527	GH2	0.7	6.45	0.55	4.76e-9	Height;
THYM	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg24675056	chr1:15929824	NA	0.74	6.14	0.53	1.93e-8	Systolic blood pressure;
THYM	cis	rs665401	0.692	rs339321	chr6:117192190	C/T	cg20376953	chr6:117187980	NA	0.62	5.04	0.46	2.26e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	9.78	0.71	4.77e-16	Platelet count;
THYM	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg00631329	chr6:26305371	NA	-0.6	-7.45	-0.61	4.22e-11	Educational attainment;
THYM	cis	rs4455778	0.580	rs4598208	chr7:49084584	G/A	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs1018836	0.773	rs7837109	chr8:91639178	C/T	cg16814680	chr8:91681699	NA	-0.99	-9.24	-0.69	7.07e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs1728785	0.892	rs9928950	chr16:68557114	G/A	cg02972257	chr16:68554789	NA	0.83	5.27	0.48	8.4e-7	Ulcerative colitis;
THYM	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg01448562	chr3:133502909	NA	0.94	8.31	0.65	6.51e-13	Iron status biomarkers;
THYM	cis	rs7822232	0.908	rs4977165	chr8:145139727	C/T	cg12091641	chr8:145180933	NA	-1.01	-4.87	-0.45	4.36e-6	Blood metabolite levels;
THYM	cis	rs6480314	0.542	rs11814858	chr10:70001707	A/G	cg27159792	chr10:69524182	NA	0.81	4.89	0.45	4.06e-6	Optic nerve measurement (disc area);
THYM	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg18230493	chr5:56204884	C5orf35	0.63	4.8	0.44	5.9e-6	Initial pursuit acceleration;
THYM	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg12756686	chr19:29218302	NA	1.0	8.27	0.65	8.26e-13	Methadone dose in opioid dependence;
THYM	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg00677455	chr12:58241039	CTDSP2	0.72	4.87	0.45	4.51e-6	Multiple sclerosis;
THYM	cis	rs931127	1.000	rs931127	chr11:65405300	G/A	cg27068330	chr11:65405492	SIPA1	-0.78	-6.44	-0.55	4.83e-9	Systemic lupus erythematosus;
THYM	cis	rs36051895	0.632	rs10974979	chr9:5131731	C/A	cg02405213	chr9:5042618	JAK2	-1.02	-11.18	-0.75	5.05e-19	Pediatric autoimmune diseases;
THYM	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg13736514	chr6:26305472	NA	-0.61	-7.45	-0.61	4.16e-11	Educational attainment;
THYM	cis	rs1061377	1.000	rs12499266	chr4:39119753	C/T	cg24403649	chr4:39172243	NA	-0.55	-4.46	-0.42	2.28e-5	Uric acid levels;
THYM	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	5.38	0.48	5.27e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2970992	0.728	rs1543104	chr2:101326226	T/C	cg01042948	chr2:101319752	NA	0.57	5.61	0.5	2.02e-7	Educational attainment;
THYM	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4638749	0.734	rs6542756	chr2:108865629	C/G	cg25838818	chr2:108905173	SULT1C2	-0.54	-5.68	-0.5	1.45e-7	Blood pressure;
THYM	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08109568	chr15:31115862	NA	-0.63	-5.99	-0.52	3.8e-8	Huntington's disease progression;
THYM	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	4.95	0.45	3.23e-6	Height;
THYM	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg07870213	chr5:140052090	DND1	-0.66	-7.72	-0.62	1.15e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11696501	0.694	rs6130870	chr20:44263263	T/C	cg11783356	chr20:44313418	WFDC10B	-0.67	-4.63	-0.43	1.17e-5	Brain structure;
THYM	cis	rs12711979	0.765	rs10208316	chr2:3827630	T/C	cg17052675	chr2:3827356	NA	-0.51	-5.46	-0.49	3.74e-7	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	8.57	0.66	1.88e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7586879	0.828	rs4077677	chr2:25122798	G/C	cg01884057	chr2:25150051	NA	0.52	4.59	0.43	1.35e-5	Body mass index;
THYM	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs7246657	0.551	rs28462002	chr19:37634462	A/G	cg22634378	chr19:37742834	NA	0.63	4.53	0.42	1.72e-5	Coronary artery calcification;
THYM	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg12310025	chr6:25882481	NA	-0.9	-7.96	-0.63	3.65e-12	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs870825	0.616	rs4437299	chr4:185643223	T/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs981844	0.683	rs1037655	chr4:154750408	A/G	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs9913156	0.793	rs55974786	chr17:4567564	T/C	cg19197139	chr17:4613644	ARRB2	0.82	4.96	0.45	3.05e-6	Lymphocyte counts;
THYM	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg26384229	chr12:38710491	ALG10B	1.01	9.02	0.68	2.1e-14	Heart rate;
THYM	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg11965913	chr1:205819406	PM20D1	0.94	10.47	0.73	1.63e-17	Menarche (age at onset);
THYM	cis	rs3760047	0.668	rs2858923	chr16:207375	A/T	cg25425005	chr16:202905	HBZ	-0.8	-5.89	-0.52	5.77e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg14018140	chr10:458528	DIP2C	0.52	5.11	0.46	1.69e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg20608306	chr11:116969690	SIK3	0.52	5.48	0.49	3.46e-7	Blood protein levels;
THYM	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs9393692	0.620	rs9393691	chr6:26272829	T/C	cg00631329	chr6:26305371	NA	-0.46	-4.71	-0.44	8.43e-6	Educational attainment;
THYM	cis	rs55728055	0.661	rs61561528	chr22:31983071	A/G	cg10537193	chr22:32026975	PISD	-0.87	-5.53	-0.49	2.78e-7	Age-related hearing impairment;
THYM	cis	rs7178572	0.625	rs907372	chr15:77844516	G/T	cg22256960	chr15:77711686	NA	-0.77	-6.7	-0.57	1.47e-9	Type 2 diabetes;
THYM	cis	rs9527	0.615	rs4919685	chr10:104587362	G/T	cg15744005	chr10:104629667	AS3MT	-0.7	-5.48	-0.49	3.46e-7	Arsenic metabolism;
THYM	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg14196790	chr5:131705035	SLC22A5	-0.48	-4.55	-0.42	1.59e-5	Blood metabolite levels;
THYM	cis	rs28830936	0.510	rs2412640	chr15:42124082	C/T	cg17847044	chr15:42102381	MAPKBP1	0.27	4.6	0.43	1.3e-5	Diastolic blood pressure;
THYM	cis	rs4072705	0.935	rs2184219	chr9:127532904	A/G	cg13476313	chr9:127244764	NR5A1	0.32	4.68	0.43	9.7e-6	Menarche (age at onset);
THYM	cis	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg19847130	chr8:10466454	RP1L1	-0.49	-4.46	-0.42	2.26e-5	Neuroticism;
THYM	cis	rs10992471	0.756	rs2761681	chr9:95186937	A/G	cg14631576	chr9:95140430	CENPP	-0.93	-9.96	-0.71	2.06e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg06713675	chr4:122721982	EXOSC9	0.51	4.75	0.44	7.13e-6	Type 2 diabetes;
THYM	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg18825531	chr11:62321136	NA	-0.46	-5.32	-0.48	6.94e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg19024700	chr19:49340765	PLEKHA4;HSD17B14	0.62	4.45	0.42	2.3e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg02896835	chr1:92012615	NA	-0.68	-5.12	-0.46	1.61e-6	Eosinophil percentage of white cells;
THYM	cis	rs17005891	0.816	rs55825761	chr4:83541628	G/T	cg10249074	chr4:83542146	C4orf11	-0.68	-5.43	-0.49	4.25e-7	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs804280	1.000	rs804280	chr8:11612698	G/T	cg12395012	chr8:11607386	GATA4	-0.55	-5.24	-0.47	9.5e-7	Myopia (pathological);
THYM	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.71	5.11	0.46	1.63e-6	Height;
THYM	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg18252515	chr7:66147081	NA	0.63	4.7	0.43	8.9e-6	Aortic root size;
THYM	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	6.67	0.56	1.66e-9	Prudent dietary pattern;
THYM	cis	rs4747241	0.739	rs4074609	chr10:74069782	C/T	cg07828833	chr10:74069493	NA	0.57	4.75	0.44	7.07e-6	Heschl's gyrus morphology;
THYM	cis	rs892961	0.932	rs7216909	chr17:75405234	A/G	cg11351908	chr17:75402473	SEPT9	0.58	5.73	0.51	1.19e-7	Airflow obstruction;
THYM	cis	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs9902453	0.967	rs1906451	chr17:28515479	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	4.68	0.43	9.35e-6	Coffee consumption (cups per day);
THYM	cis	rs921665	0.505	rs7578008	chr2:3204855	G/A	cg16434511	chr2:3151078	NA	-1.1	-4.93	-0.45	3.55e-6	World class endurance athleticism;
THYM	cis	rs7640424	0.589	rs7612356	chr3:107811037	C/G	cg09227934	chr3:107805635	CD47	-0.71	-4.96	-0.45	3.03e-6	Body mass index;
THYM	cis	rs55728055	0.661	rs16989617	chr22:31839151	T/C	cg10537193	chr22:32026975	PISD	-0.91	-5.25	-0.47	9.24e-7	Age-related hearing impairment;
THYM	cis	rs7695732	0.595	rs28540701	chr4:89898186	A/G	cg17769793	chr4:89976368	FAM13A	-0.49	-5.39	-0.48	5.23e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7582180	0.607	rs6723909	chr2:100880058	A/T	cg21926883	chr2:100939477	LONRF2	-0.53	-4.57	-0.42	1.45e-5	Intelligence (multi-trait analysis);
THYM	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	4.54	0.42	1.66e-5	Rheumatoid arthritis;
THYM	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg22815214	chr1:201083145	CACNA1S	-0.79	-7.4	-0.6	5.42e-11	Permanent tooth development;
THYM	cis	rs7177699	0.557	rs4389113	chr15:79121739	G/A	cg15571903	chr15:79123663	NA	-0.57	-6.28	-0.54	1.03e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs4891159	0.757	rs11665018	chr18:74123589	C/T	cg24786174	chr18:74118243	ZNF516	-0.87	-9.72	-0.71	6.43e-16	Longevity;
THYM	cis	rs9359856	0.564	rs11962292	chr6:90476788	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs4803468	1.000	rs284656	chr19:41929251	T/C	cg09537434	chr19:41945824	ATP5SL	-1.02	-8.91	-0.67	3.55e-14	Height;
THYM	cis	rs7828089	0.819	rs11136021	chr8:22244672	T/C	cg12081754	chr8:22256438	SLC39A14	0.63	5.51	0.49	3.08e-7	Verbal declarative memory;
THYM	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2969070	0.965	rs9691234	chr7:2508415	A/G	cg25507518	chr7:2405875	EIF3B	-0.46	-4.49	-0.42	1.97e-5	Diastolic blood pressure;
THYM	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg16342193	chr10:102329863	NA	-0.48	-4.82	-0.44	5.34e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs7119038	0.818	rs10892287	chr11:118642999	C/T	cg19308663	chr11:118741387	NA	-0.58	-5.76	-0.51	1.03e-7	Sjögren's syndrome;
THYM	cis	rs10504073	0.647	rs4873096	chr8:49995201	A/G	cg00325661	chr8:49890786	NA	0.93	8.79	0.67	6.32e-14	Blood metabolite ratios;
THYM	cis	rs6694672	1.000	rs1576878	chr1:196991325	A/C	cg13682187	chr1:196946512	CFHR5	0.82	4.5	0.42	1.89e-5	Asthma;
THYM	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg22907277	chr7:1156413	C7orf50	0.79	4.57	0.42	1.45e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3540	0.618	rs11609	chr15:91043765	C/G	cg22089800	chr15:90895588	ZNF774	-0.68	-5.12	-0.46	1.63e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs6684428	0.706	rs10493185	chr1:56321789	A/G	cg11651538	chr1:56320950	NA	-0.63	-4.97	-0.45	2.91e-6	Airflow obstruction;
THYM	cis	rs7216064	1.000	rs62084249	chr17:65874998	A/G	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs3126085	1.000	rs4845756	chr1:152254919	T/A	cg10321714	chr1:152280068	FLG	0.67	5.14	0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11644478	chr21:40555479	PSMG1	-0.59	-4.91	-0.45	3.74e-6	Menarche (age at onset);
THYM	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.68	-5.06	-0.46	2.08e-6	Colorectal cancer;
THYM	cis	rs2832077	1.000	rs2832065	chr21:30135362	C/T	cg24692254	chr21:30365293	RNF160	-0.82	-5.03	-0.46	2.31e-6	Cognitive test performance;
THYM	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs2658782	0.789	rs2259633	chr11:93141580	C/A	cg15737290	chr11:93063684	CCDC67	0.9	7.07	0.59	2.57e-10	Pulmonary function decline;
THYM	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg22753661	chr15:79092743	ADAMTS7	0.74	4.74	0.44	7.35e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs3540	0.618	rs11636089	chr15:91039527	C/T	cg22089800	chr15:90895588	ZNF774	0.69	5.4	0.48	4.81e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg23131131	chr22:24373011	LOC391322	0.8	8.24	0.65	9.33e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-4.93	-0.45	3.47e-6	Schizophrenia;
THYM	cis	rs612683	0.602	rs12565245	chr1:101019326	T/G	cg09408571	chr1:101003634	GPR88	0.58	6.94	0.58	4.69e-10	Breast cancer;
THYM	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs34638657	0.702	rs11866709	chr16:82201017	A/G	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.25	-0.47	9.14e-7	Lung adenocarcinoma;
THYM	cis	rs28595532	0.920	rs116799007	chr4:119763562	A/G	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs728616	0.867	rs17879726	chr10:81698723	G/A	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg16928487	chr17:17741425	SREBF1	-0.55	-5.47	-0.49	3.62e-7	Total body bone mineral density;
THYM	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.1	-5.38	-0.48	5.31e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg26384229	chr12:38710491	ALG10B	-0.89	-9.06	-0.68	1.67e-14	Heart rate;
THYM	cis	rs4589258	0.933	rs1783806	chr11:90430132	A/G	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg26441486	chr22:50317300	CRELD2	0.44	6.45	0.55	4.56e-9	Schizophrenia;
THYM	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg09354556	chr3:47051341	NA	0.46	4.71	0.44	8.28e-6	Colorectal cancer;
THYM	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg18131467	chr2:239335373	ASB1	1.07	10.19	0.72	6.48e-17	Multiple system atrophy;
THYM	trans	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg06636001	chr8:8085503	FLJ10661	0.78	6.99	0.58	3.83e-10	Neuroticism;
THYM	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg09359103	chr1:154839909	KCNN3	-0.86	-11.97	-0.78	1.12e-20	Prostate cancer;
THYM	trans	rs877282	0.898	rs12357995	chr10:765739	T/C	cg22713356	chr15:30763199	NA	1.36	9.83	0.71	3.89e-16	Uric acid levels;
THYM	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg22974920	chr21:40686053	BRWD1	-0.58	-4.48	-0.42	2.08e-5	Cognitive function;
THYM	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg11764359	chr7:65958608	NA	0.83	7.0	0.58	3.54e-10	Aortic root size;
THYM	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg22875332	chr1:76189707	ACADM	0.89	11.21	0.75	4.4e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg12963246	chr6:28129442	ZNF389	0.77	6.3	0.54	9.31e-9	Depression;
THYM	cis	rs3845702	0.736	rs6433818	chr2:180810264	A/T	cg01881094	chr2:180872142	CWC22	-0.89	-5.34	-0.48	6.22e-7	Schizophrenia;
THYM	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg09904177	chr6:26538194	HMGN4	0.64	5.4	0.48	4.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2625529	0.652	rs2957724	chr15:72248474	A/C	cg16672083	chr15:72433130	SENP8	0.49	4.49	0.42	1.97e-5	Red blood cell count;
THYM	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg00757033	chr12:89920650	WDR51B	0.76	11.11	0.75	7.17e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs9868809	0.764	rs2633958	chr3:48635432	A/G	cg00383909	chr3:49044727	WDR6	-1.14	-4.67	-0.43	9.72e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg07884673	chr3:53033167	SFMBT1	1.03	5.24	0.47	9.74e-7	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6964587	0.626	rs4729011	chr7:91515419	G/A	cg22709100	chr7:91322751	NA	-0.64	-4.72	-0.44	8e-6	Breast cancer;
THYM	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg03388043	chr17:80084554	CCDC57	0.69	5.98	0.52	3.85e-8	Life satisfaction;
THYM	cis	rs66731853	0.771	rs541244	chr1:20889380	G/A	cg04087271	chr1:20915334	CDA	-0.76	-6.23	-0.54	1.26e-8	Mean corpuscular volume;
THYM	cis	rs9470366	0.545	rs6930083	chr6:36634156	A/G	cg11920449	chr6:36645608	CDKN1A	0.7	5.84	0.51	7.37e-8	QRS duration;
THYM	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg15536230	chr21:44985092	HSF2BP	0.4	4.72	0.44	8.03e-6	Mean corpuscular volume;
THYM	cis	rs7177699	0.557	rs4389112	chr15:79122099	G/A	cg00540400	chr15:79124168	NA	-0.64	-6.03	-0.53	3.17e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg17366294	chr4:99064904	C4orf37	0.57	6.76	0.57	1.09e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg13866156	chr1:1669148	SLC35E2	-0.75	-7.52	-0.61	2.98e-11	Body mass index;
THYM	cis	rs41311933	0.901	rs76481162	chr9:123740526	A/G	cg13567360	chr9:123745713	C5	-0.97	-4.94	-0.45	3.34e-6	Coronary artery disease;
THYM	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg06618935	chr21:46677482	NA	-1.01	-9.39	-0.69	3.29e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7189233	0.955	rs11540358	chr16:53503943	C/G	cg02965178	chr16:53538660	AKTIP	-0.59	-4.65	-0.43	1.06e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg01324343	chr3:183735012	ABCC5	0.88	12.75	0.79	2.73e-22	Anterior chamber depth;
THYM	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg12165864	chr7:66369176	NA	0.67	5.25	0.47	9.34e-7	Aortic root size;
THYM	cis	rs7011507	0.700	rs72639010	chr8:49330321	C/T	cg08774009	chr8:49309094	NA	-0.62	-4.83	-0.44	5.19e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg14983838	chr19:29218262	NA	0.97	6.89	0.58	6.14e-10	Methadone dose in opioid dependence;
THYM	cis	rs938554	0.513	rs1014290	chr4:10001861	G/A	cg26689780	chr4:10079554	WDR1	-0.4	-4.53	-0.42	1.72e-5	Blood metabolite levels;
THYM	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3847687	0.565	rs10848270	chr12:131519664	C/A	cg25772418	chr12:131519998	GPR133	-0.35	-4.51	-0.42	1.89e-5	Longevity;
THYM	cis	rs897984	0.759	rs13708	chr16:31000809	G/A	cg06892815	chr16:30991727	SETD1A	0.51	4.52	0.42	1.79e-5	Dementia with Lewy bodies;
THYM	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg04607235	chr12:12878440	APOLD1	0.63	5.19	0.47	1.21e-6	Pulse pressure;
THYM	cis	rs60180747	0.909	rs11639266	chr15:66600417	G/A	cg08479319	chr15:66648941	TIPIN	0.66	4.48	0.42	2.05e-5	Testicular germ cell tumor;
THYM	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg08772003	chr10:104629869	AS3MT	-0.57	-4.92	-0.45	3.69e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6032067	0.538	rs17422688	chr20:43739119	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.54	-4.75	-0.44	7.25e-6	Blood protein levels;
THYM	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg01416388	chr22:39784598	NA	-0.94	-8.85	-0.67	4.78e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7250872	0.606	rs2289286	chr19:1822668	T/C	cg18850929	chr19:1828978	REXO1	0.56	4.8	0.44	5.98e-6	Bipolar disorder;
THYM	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg25208724	chr1:156163844	SLC25A44	1.17	13.26	0.81	2.43e-23	Testicular germ cell tumor;
THYM	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg27170947	chr2:26402098	FAM59B	0.8	6.37	0.55	6.74e-9	Gut microbiome composition (summer);
THYM	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg24874828	chr4:187887005	NA	-0.72	-7.22	-0.6	1.26e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg10856724	chr12:34555212	NA	-0.74	-5.54	-0.49	2.74e-7	Resting heart rate;
THYM	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg02221750	chr19:17393354	ANKLE1	-0.98	-8.98	-0.68	2.54e-14	Systemic lupus erythematosus;
THYM	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg15448220	chr1:150897856	SETDB1	0.89	7.59	0.61	2.17e-11	Melanoma;
THYM	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg18681998	chr4:17616180	MED28	0.81	6.87	0.58	6.5e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg09549813	chr16:4587862	C16orf5	0.59	6.59	0.56	2.5e-9	Schizophrenia;
THYM	cis	rs10752881	1.000	rs8179282	chr1:182974598	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg22117172	chr7:91764530	CYP51A1	-0.35	-4.47	-0.42	2.12e-5	Breast cancer;
THYM	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg08470875	chr2:26401718	FAM59B	-0.72	-4.46	-0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.59	-0.43	1.37e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs789859	0.611	rs1077729	chr3:194418126	A/G	cg03198678	chr3:194381165	LSG1	0.51	4.63	0.43	1.16e-5	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
THYM	cis	rs611744	0.647	rs615233	chr8:109254262	C/T	cg21045802	chr8:109455806	TTC35	0.66	5.99	0.52	3.78e-8	Dupuytren's disease;
THYM	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	trans	rs629535	0.814	rs549643	chr8:70062884	C/T	cg21567404	chr3:27674614	NA	1.04	9.6	0.7	1.16e-15	Dupuytren's disease;
THYM	cis	rs5769707	0.609	rs2071890	chr22:50001291	G/A	cg05373962	chr22:49881684	NA	-0.63	-5.68	-0.5	1.44e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg15247329	chr7:2764246	NA	-0.69	-5.75	-0.51	1.08e-7	Height;
THYM	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg14298792	chr15:30685198	CHRFAM7A	-0.8	-5.59	-0.5	2.21e-7	Huntington's disease progression;
THYM	cis	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg10911889	chr6:126070802	HEY2	0.55	4.64	0.43	1.1e-5	Brugada syndrome;
THYM	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6430585	0.528	rs309120	chr2:136708787	G/C	cg07169764	chr2:136633963	MCM6	0.96	9.1	0.68	1.36e-14	Corneal structure;
THYM	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg14008862	chr17:28927542	LRRC37B2	0.88	4.64	0.43	1.11e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1270639	0.778	rs1638021	chr7:157438037	A/G	cg13357408	chr7:157437802	PTPRN2	0.47	4.89	0.45	4.1e-6	Colorectal cancer;
THYM	cis	rs7072216	0.763	rs10883091	chr10:100167239	C/T	cg03852570	chr10:100175106	PYROXD2	0.37	4.92	0.45	3.63e-6	Metabolite levels;
THYM	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg10518543	chr12:38710700	ALG10B	-0.57	-4.49	-0.42	2.04e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg23332699	chr15:44069569	ELL3	0.72	4.74	0.44	7.46e-6	Lung cancer in ever smokers;
THYM	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg22875332	chr1:76189707	ACADM	-0.77	-6.75	-0.57	1.18e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2033562	1.000	rs10104124	chr8:103546942	G/C	cg20611272	chr8:103548145	NA	0.4	5.0	0.46	2.6e-6	IgA nephropathy;
THYM	cis	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg21775007	chr8:11205619	TDH	0.68	6.05	0.53	2.83e-8	Retinal vascular caliber;
THYM	cis	rs76878669	1.000	rs76878669	chr11:66092567	C/G	cg18002602	chr11:66138449	SLC29A2	-0.61	-4.94	-0.45	3.29e-6	Educational attainment (years of education);
THYM	cis	rs1808579	0.904	rs1788761	chr18:21133084	A/G	cg14672496	chr18:21087552	C18orf8	0.53	4.86	0.45	4.63e-6	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
THYM	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg23711669	chr6:146136114	FBXO30	0.9	8.82	0.67	5.37e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4595586	0.545	rs12823721	chr12:39386461	G/A	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg02915803	chr1:1606292	LOC728661;CDK11B	-0.59	-4.96	-0.45	3.05e-6	Body mass index;
THYM	cis	rs1003719	0.715	rs2835667	chr21:38579914	G/A	cg01329690	chr21:38580129	DSCR9	-0.36	-4.98	-0.46	2.81e-6	Eye color traits;
THYM	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14159672	chr1:205819179	PM20D1	0.97	10.02	0.72	1.47e-16	Menarche (age at onset);
THYM	cis	rs4655537	0.500	rs7511672	chr1:66178918	A/G	cg04111102	chr1:66153794	NA	0.51	4.68	0.43	9.53e-6	Blood protein levels;
THYM	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.89	8.09	0.64	1.91e-12	Monocyte percentage of white cells;
THYM	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg24578937	chr1:2090814	PRKCZ	-0.55	-5.69	-0.5	1.37e-7	Height;
THYM	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg06547715	chr2:218990976	CXCR2	0.46	5.0	0.46	2.64e-6	Ulcerative colitis;
THYM	cis	rs12216545	0.737	rs10238055	chr7:150249729	G/A	cg00323915	chr7:150264987	GIMAP4	-0.49	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.01	9.61	0.7	1.11e-15	Colorectal cancer;
THYM	cis	rs12476592	0.602	rs1446563	chr2:63898124	T/G	cg17519650	chr2:63277830	OTX1	-0.72	-4.68	-0.43	9.38e-6	Childhood ear infection;
THYM	cis	rs10782582	0.593	rs6664254	chr1:76235084	G/T	cg22875332	chr1:76189707	ACADM	-0.53	-4.69	-0.43	9.07e-6	Daytime sleep phenotypes;
THYM	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.29e-7	Corneal astigmatism;
THYM	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg00864171	chr11:67383662	NA	-0.59	-4.81	-0.44	5.63e-6	Mean corpuscular volume;
THYM	cis	rs4443100	0.535	rs13055979	chr22:23474085	C/T	cg14186256	chr22:23484241	RTDR1	0.59	4.52	0.42	1.77e-5	Serum parathyroid hormone levels;
THYM	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg07870213	chr5:140052090	DND1	-0.69	-8.1	-0.64	1.86e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs3804749	0.966	rs2278668	chr3:122835232	T/C	cg10259872	chr3:122802215	PDIA5	0.47	5.19	0.47	1.2e-6	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	trans	rs6089829	0.888	rs4809471	chr20:61684287	G/A	cg23505145	chr19:12996616	KLF1	1.03	10.07	0.72	1.2e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg10911889	chr6:126070802	HEY2	0.6	4.81	0.44	5.69e-6	Brugada syndrome;
THYM	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg13607699	chr17:42295918	UBTF	-0.84	-7.62	-0.62	1.91e-11	Red cell distribution width;Reticulocyte count;
THYM	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg17691542	chr6:26056736	HIST1H1C	0.73	4.69	0.43	9.12e-6	Iron status biomarkers;
THYM	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg09035930	chr12:129282057	SLC15A4	0.82	10.7	0.74	5.29e-18	Systemic lupus erythematosus;
THYM	cis	rs500891	0.525	rs6454321	chr6:84050941	A/G	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs7729356	0.761	rs10065182	chr5:107475094	T/C	cg12405754	chr5:107005487	EFNA5	-0.53	-4.64	-0.43	1.13e-5	Educational attainment;
THYM	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.58	-0.5	2.23e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs11186	0.524	rs55905390	chr2:189965017	G/C	cg11041835	chr2:189156425	GULP1	0.8	4.58	0.43	1.41e-5	Parkinson's disease;
THYM	cis	rs10992471	0.598	rs2025389	chr9:95157674	A/G	cg14631576	chr9:95140430	CENPP	0.67	5.92	0.52	5.19e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs28510890	0.536	rs8032832	chr15:93158095	C/T	cg05775517	chr15:93158989	NA	0.41	5.04	0.46	2.22e-6	Lung cancer in ever smokers;
THYM	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg03388043	chr17:80084554	CCDC57	-0.69	-5.66	-0.5	1.63e-7	Life satisfaction;
THYM	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg18252515	chr7:66147081	NA	0.62	4.6	0.43	1.31e-5	Aortic root size;
THYM	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03264133	chr6:25882463	NA	0.9	7.52	0.61	3.1e-11	Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg17426766	chr1:2046864	PRKCZ	0.4	4.78	0.44	6.44e-6	Height;
THYM	cis	rs35883536	1.000	rs1932351	chr1:101142049	C/T	cg06223162	chr1:101003688	GPR88	0.67	5.14	0.47	1.47e-6	Monocyte count;
THYM	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.46	0.42	2.28e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs295140	0.506	rs4673855	chr2:201136143	A/G	cg03447810	chr2:200324230	SATB2	-0.61	-4.46	-0.42	2.25e-5	QT interval;
THYM	cis	rs17152411	1.000	rs10901837	chr10:126614618	G/A	cg07906193	chr10:126599966	NA	0.69	4.71	0.44	8.45e-6	Height;
THYM	cis	rs12519773	0.501	rs10428523	chr5:92536365	G/A	cg18783429	chr5:92414398	NA	0.5	4.91	0.45	3.72e-6	Migraine;
THYM	cis	rs7937840	0.501	rs4963459	chr11:61877137	G/A	cg05871569	chr11:61891931	INCENP	0.6	4.67	0.43	9.97e-6	Breast cancer;
THYM	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs7119038	0.818	rs4936444	chr11:118743338	A/G	cg19308663	chr11:118741387	NA	-0.61	-6.01	-0.52	3.42e-8	Sjögren's syndrome;
THYM	cis	rs10214930	0.553	rs6943712	chr7:27917884	T/C	cg04422003	chr7:28448295	CREB5	0.54	4.54	0.42	1.65e-5	Hypospadias;
THYM	cis	rs883565	0.568	rs4616582	chr3:39028854	G/T	cg15678707	chr3:39149194	GORASP1;TTC21A	-0.68	-5.17	-0.47	1.27e-6	Handedness;
THYM	cis	rs10979	1.000	rs9376761	chr6:143887165	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12752838	0.713	rs6577536	chr1:8910110	A/G	cg10211414	chr1:8875053	RERE	-0.66	-6.33	-0.54	8.14e-9	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.66	-5.38	-0.48	5.38e-7	Blood metabolite levels;
THYM	cis	rs11030122	0.673	rs11030639	chr11:4039056	A/G	cg18678763	chr11:4115507	RRM1	-0.45	-5.86	-0.52	6.68e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4654899	0.772	rs61778530	chr1:21087363	G/C	cg01072550	chr1:21505969	NA	-0.64	-5.53	-0.49	2.79e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg01831904	chr17:28903510	LRRC37B2	-1.0	-5.11	-0.46	1.65e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg17105886	chr17:28927953	LRRC37B2	1.31	7.85	0.63	6.35e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg18252515	chr7:66147081	NA	-1.64	-9.3	-0.69	5.17e-15	Diabetic kidney disease;
THYM	cis	rs7264396	0.563	rs2425131	chr20:34337074	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Total cholesterol levels;
THYM	trans	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-4.49	-0.42	2.04e-5	Fear of minor pain;
THYM	cis	rs10895275	0.923	rs11225156	chr11:102059338	C/T	cg24447756	chr11:102105824	NA	0.52	4.55	0.42	1.61e-5	Migraine;
THYM	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg05738196	chr6:26577821	NA	0.6	4.91	0.45	3.71e-6	Schizophrenia;
THYM	cis	rs7631605	0.846	rs68159333	chr3:37259739	G/A	cg21328643	chr3:37258149	NA	-0.58	-5.57	-0.5	2.39e-7	Cerebrospinal P-tau181p levels;
THYM	cis	rs4845875	0.530	rs6667720	chr1:11831615	A/G	cg14194983	chr1:11908298	NPPA	-0.52	-4.72	-0.44	8.21e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs7100689	0.580	rs7083519	chr10:82207524	C/G	cg01528321	chr10:82214614	TSPAN14	0.72	5.72	0.51	1.22e-7	Post bronchodilator FEV1;
THYM	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg17845761	chr1:175162550	KIAA0040	-0.36	-4.57	-0.42	1.45e-5	Alcohol dependence;
THYM	cis	rs58688157	0.626	rs7941198	chr11:571681	A/G	cg16486109	chr11:613632	IRF7	0.49	5.42	0.49	4.56e-7	Systemic lupus erythematosus;
THYM	cis	rs7580658	0.614	rs2896888	chr2:127965811	A/C	cg09152259	chr2:128156114	NA	-0.36	-4.73	-0.44	7.71e-6	Protein C levels;
THYM	cis	rs9311676	0.656	rs11923253	chr3:58376992	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.58	0.43	1.41e-5	Systemic lupus erythematosus;
THYM	cis	rs2862064	0.872	rs6555822	chr5:156473185	A/G	cg12943317	chr5:156479607	HAVCR1	-0.84	-5.23	-0.47	9.88e-7	Platelet count;
THYM	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg14186256	chr22:23484241	RTDR1	0.96	9.43	0.7	2.71e-15	Bone mineral density;
THYM	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg03732007	chr1:2071316	PRKCZ	0.5	4.51	0.42	1.89e-5	Height;
THYM	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg10802521	chr3:52805072	NEK4	-0.65	-5.52	-0.49	2.98e-7	Electroencephalogram traits;
THYM	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.11	8.07	0.64	2.15e-12	Cognitive test performance;
THYM	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs2898681	0.770	rs10032190	chr4:53734940	C/A	cg03786743	chr4:53727781	RASL11B	0.39	4.55	0.42	1.57e-5	Optic nerve measurement (cup area);
THYM	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg26314531	chr2:26401878	FAM59B	0.76	4.57	0.42	1.49e-5	Gut microbiome composition (summer);
THYM	cis	rs9560113	0.881	rs9560111	chr13:112181289	C/T	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs6785206	0.614	rs13095694	chr3:128480065	A/G	cg16766828	chr3:128327626	NA	0.47	4.6	0.43	1.29e-5	Lymphocyte percentage of white cells;
THYM	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg03806693	chr22:41940476	POLR3H	-1.11	-8.99	-0.68	2.33e-14	Vitiligo;
THYM	cis	rs34375054	0.525	rs1080910	chr12:125608492	T/C	cg25124228	chr12:125621409	AACS	-0.78	-6.7	-0.57	1.47e-9	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg05660106	chr1:15850417	CASP9	0.67	5.51	0.49	3.03e-7	Systolic blood pressure;
THYM	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg17757837	chr7:157058334	UBE3C	-0.79	-6.84	-0.57	7.63e-10	Body mass index;
THYM	cis	rs2806561	1.000	rs1571466	chr1:23449183	T/C	cg19743168	chr1:23544995	NA	0.6	6.12	0.53	2.1e-8	Height;
THYM	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03760483	chr17:6899297	ALOX12	0.66	8.82	0.67	5.53e-14	Tonsillectomy;
THYM	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg00484396	chr16:3507460	NAT15	0.74	9.01	0.68	2.2e-14	Tuberculosis;
THYM	cis	rs7551222	0.716	rs4951078	chr1:204491802	A/G	cg20240347	chr1:204465584	NA	-0.51	-4.54	-0.42	1.64e-5	Schizophrenia;
THYM	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg26441486	chr22:50317300	CRELD2	0.42	6.65	0.56	1.83e-9	Schizophrenia;
THYM	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg22920501	chr2:26401640	FAM59B	0.78	5.84	0.51	7.14e-8	Gut microbiome composition (summer);
THYM	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs12282928	1.000	rs7106648	chr11:48283292	A/T	cg22827986	chr11:48284249	OR4X1	-0.49	-5.13	-0.47	1.52e-6	Migraine - clinic-based;
THYM	cis	rs931127	0.666	rs7932857	chr11:65457493	A/C	cg27068330	chr11:65405492	SIPA1	-0.83	-7.52	-0.61	3.07e-11	Systemic lupus erythematosus;
THYM	cis	rs12137294	0.866	rs896318	chr1:205205784	A/G	cg17889831	chr1:205181581	DSTYK	-0.41	-5.05	-0.46	2.13e-6	Red cell distribution width;
THYM	cis	rs7072216	0.763	rs10883090	chr10:100167236	G/C	cg26618903	chr10:100175079	PYROXD2	-0.48	-4.6	-0.43	1.33e-5	Metabolite levels;
THYM	cis	rs7084402	0.967	rs7078900	chr10:60273430	G/A	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs6121246	0.559	rs6058352	chr20:30269179	T/C	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg12564285	chr5:131593104	PDLIM4	0.44	4.78	0.44	6.47e-6	Breast cancer;
THYM	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg17911788	chr17:44343683	NA	-0.79	-7.48	-0.61	3.65e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3768617	0.510	rs20558	chr1:183094547	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06873352	chr17:61820015	STRADA	-0.79	-9.97	-0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs4974559	0.790	rs11933855	chr4:1315183	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.42	-4.85	-0.45	4.74e-6	Systolic blood pressure;
THYM	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26314531	chr2:26401878	FAM59B	0.78	5.13	0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs61841072	0.961	rs12131267	chr1:243138336	G/A	cg02356786	chr1:243265016	LOC731275	0.56	4.6	0.43	1.31e-5	Schizophrenia;
THYM	cis	rs990171	1.000	rs6737668	chr2:103093081	C/T	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.02	-0.46	2.42e-6	Lymphocyte counts;
THYM	cis	rs17443541	0.507	rs6753800	chr2:200462959	G/C	cg03741458	chr2:200468445	NA	-0.8	-6.04	-0.53	3.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs67981189	0.529	rs17108862	chr14:71464666	G/A	cg15910301	chr14:71632612	NA	0.56	4.88	0.45	4.23e-6	Schizophrenia;
THYM	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg07424592	chr7:64974309	NA	1.0	5.2	0.47	1.12e-6	Diabetic kidney disease;
THYM	cis	rs7828089	0.935	rs896378	chr8:22262321	T/C	cg13512537	chr8:22265999	SLC39A14	-0.63	-5.29	-0.48	7.92e-7	Verbal declarative memory;
THYM	cis	rs73086581	0.787	rs67633417	chr20:3868257	C/G	cg02187196	chr20:3869020	PANK2	0.5	5.43	0.49	4.29e-7	Response to antidepressants in depression;
THYM	cis	rs9653442	0.866	rs11123811	chr2:100760172	T/C	cg07810366	chr2:100720526	AFF3	-0.41	-6.24	-0.54	1.19e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs985746	0.614	rs10433865	chr4:36817568	C/T	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs36051895	0.560	rs10975009	chr9:5220397	T/G	cg02405213	chr9:5042618	JAK2	-0.84	-8.39	-0.65	4.51e-13	Pediatric autoimmune diseases;
THYM	cis	rs611744	0.647	rs676654	chr8:109242303	A/G	cg21045802	chr8:109455806	TTC35	0.7	6.26	0.54	1.12e-8	Dupuytren's disease;
THYM	cis	rs231362	0.532	rs231357	chr11:2705175	A/G	cg14051973	chr11:1973545	MRPL23	-0.53	-4.59	-0.43	1.38e-5	Type 2 diabetes;
THYM	cis	rs3093024	0.967	rs1571878	chr6:167540842	C/T	cg09487078	chr6:167525398	CCR6	-0.35	-4.5	-0.42	1.92e-5	Rheumatoid arthritis;
THYM	cis	rs9549260	0.755	rs3892360	chr13:41184078	C/G	cg21288729	chr13:41239152	FOXO1	0.66	5.41	0.48	4.8e-7	Red blood cell count;
THYM	cis	rs7107174	0.786	rs4945269	chr11:78047077	A/G	cg02023728	chr11:77925099	USP35	0.61	5.85	0.51	7e-8	Testicular germ cell tumor;
THYM	cis	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg05084668	chr3:125655381	ALG1L	0.8	5.07	0.46	1.93e-6	Blood pressure (smoking interaction);
THYM	cis	rs3826795	0.569	rs76909958	chr19:46795799	G/C	cg15229275	chr19:46800054	HIF3A	0.92	5.54	0.49	2.69e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs1401999	0.606	rs939335	chr3:183745663	A/G	cg01324343	chr3:183735012	ABCC5	0.8	11.03	0.75	1.05e-18	Anterior chamber depth;
THYM	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.9	5.66	0.5	1.59e-7	Yeast infection;
THYM	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg04944784	chr2:26401820	FAM59B	-1.08	-8.57	-0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg24209194	chr3:40518798	ZNF619	0.67	5.5	0.49	3.17e-7	Renal cell carcinoma;
THYM	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08109568	chr15:31115862	NA	-0.63	-5.99	-0.52	3.8e-8	Huntington's disease progression;
THYM	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.14	-0.64	1.54e-12	Mean corpuscular volume;
THYM	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg17105886	chr17:28927953	LRRC37B2	-1.17	-6.61	-0.56	2.21e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4454254	0.589	rs9987138	chr8:141076623	C/G	cg26048923	chr8:141057285	TRAPPC9	-0.51	-4.54	-0.42	1.63e-5	Pulse pressure;
THYM	cis	rs2229238	0.868	rs72999415	chr1:154513712	C/T	cg21262032	chr1:154437693	IL6R	-0.64	-5.79	-0.51	8.9e-8	Coronary heart disease;
THYM	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg11502198	chr6:26597334	ABT1	0.69	5.81	0.51	8.42e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11214589	0.747	rs7939992	chr11:113229665	T/C	cg14159747	chr11:113255604	NA	0.28	5.56	0.5	2.49e-7	Neuroticism;
THYM	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg10523679	chr1:76189770	ACADM	0.91	9.7	0.71	7.37e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg24308560	chr3:49941425	MST1R	-0.76	-6.48	-0.55	4.1e-9	Intelligence (multi-trait analysis);
THYM	cis	rs112591243	0.685	rs2839362	chr21:48024626	G/A	cg26697654	chr21:47851941	PCNT	0.84	4.64	0.43	1.11e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.13	-0.47	1.53e-6	Total cholesterol levels;
THYM	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.64	-4.68	-0.43	9.45e-6	Aortic root size;
THYM	cis	rs4662750	0.580	rs4662743	chr2:128350808	A/G	cg01966334	chr2:128378434	MYO7B	-0.6	-5.36	-0.48	5.7e-7	Renal cell carcinoma;
THYM	cis	rs854765	0.663	rs2236513	chr17:17747366	A/C	cg04398451	chr17:18023971	MYO15A	0.8	7.38	0.6	5.95e-11	Total body bone mineral density;
THYM	cis	rs4845570	0.850	rs4504897	chr1:151766851	T/A	cg07092448	chr1:151763213	TDRKH	1.17	8.57	0.66	1.86e-13	Coronary artery disease;
THYM	cis	rs71636778	0.509	rs17162387	chr1:27293356	T/G	cg16022904	chr1:26870173	RPS6KA1	0.84	4.55	0.42	1.58e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
THYM	cis	rs367615	0.506	rs246102	chr5:108699695	C/G	cg17395555	chr5:108820864	NA	-0.55	-6.53	-0.56	3.23e-9	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs12643440	0.538	rs4698536	chr4:17142175	C/T	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs7100689	0.646	rs7894762	chr10:82086779	C/G	cg01528321	chr10:82214614	TSPAN14	0.84	6.43	0.55	5.15e-9	Post bronchodilator FEV1;
THYM	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4866334	1.000	rs77653879	chr5:18449396	A/G	cg24599790	chr5:18972260	NA	-1.14	-4.67	-0.43	9.77e-6	IgG glycosylation;
THYM	cis	rs35160687	0.814	rs1863063	chr2:86518249	A/C	cg10973622	chr2:86423274	IMMT	0.49	4.78	0.44	6.39e-6	Night sleep phenotypes;
THYM	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg24253500	chr15:84953950	NA	0.55	4.47	0.42	2.17e-5	Schizophrenia;
THYM	cis	rs7246657	0.943	rs7255407	chr19:37933936	G/A	cg22634378	chr19:37742834	NA	0.62	5.18	0.47	1.22e-6	Coronary artery calcification;
THYM	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	6.54	0.56	3.05e-9	Total body bone mineral density;
THYM	cis	rs986417	1.000	rs1262174	chr14:60887194	C/T	cg27398547	chr14:60952738	C14orf39	1.13	6.31	0.54	8.9e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs78761021	0.867	rs17676097	chr17:9791549	A/G	cg26853458	chr17:9805074	RCVRN	0.52	4.65	0.43	1.08e-5	Type 2 diabetes;
THYM	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.95	0.71	2.08e-16	Colorectal cancer;
THYM	cis	rs2075165	0.901	rs759329	chr1:156230936	A/G	cg20302342	chr1:156215951	PAQR6	0.46	4.61	0.43	1.23e-5	Tonsillectomy;
THYM	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg06074448	chr4:187884817	NA	-1.02	-13.05	-0.8	6.55e-23	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.75	-0.67	7.74e-14	Mean corpuscular volume;
THYM	cis	rs72829446	0.530	rs9906913	chr17:7411360	G/A	cg02795151	chr17:7402630	POLR2A	0.49	4.68	0.43	9.62e-6	Androgen levels;
THYM	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg21100191	chr22:23484243	RTDR1	0.75	6.66	0.56	1.73e-9	Bone mineral density;
THYM	cis	rs11779988	0.545	rs422746	chr8:17784486	C/A	cg01800426	chr8:17659068	MTUS1	-0.76	-5.32	-0.48	6.94e-7	Breast cancer;
THYM	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06481639	chr22:41940642	POLR3H	0.87	6.0	0.52	3.51e-8	Vitiligo;
THYM	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg10360139	chr7:1886902	MAD1L1	-0.85	-7.79	-0.62	8.37e-12	Bipolar disorder and schizophrenia;
THYM	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg13319975	chr6:146136371	FBXO30	-0.62	-4.99	-0.46	2.75e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg06074448	chr4:187884817	NA	-1.01	-13.54	-0.81	6.7e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs854765	0.547	rs9897761	chr17:17912011	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.58	0.56	2.61e-9	Total body bone mineral density;
THYM	cis	rs11190604	0.767	rs77769532	chr10:102193646	T/C	cg07570687	chr10:102243282	WNT8B	0.85	8.46	0.66	3.16e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.08	7.69	0.62	1.35e-11	Schizophrenia;
THYM	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg19507638	chr5:93509721	C5orf36	0.71	4.79	0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs9796	0.804	rs28688742	chr15:41403638	G/A	cg21153102	chr15:41252147	NA	0.64	5.24	0.47	9.66e-7	Menopause (age at onset);
THYM	cis	rs6840360	0.593	rs11723227	chr4:152689717	G/A	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.65	5.62	0.5	1.88e-7	Personality dimensions;
THYM	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg03929089	chr4:120376271	NA	-1.03	-12.19	-0.78	3.85e-21	Height;
THYM	cis	rs954108	0.809	rs1792023	chr13:29368502	G/A	cg11788234	chr13:29393811	NA	-0.58	-4.55	-0.42	1.59e-5	Obesity-related traits;
THYM	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.46e-7	Heart rate;
THYM	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg03806693	chr22:41940476	POLR3H	-0.81	-6.56	-0.56	2.84e-9	Neuroticism;
THYM	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.83	-7.04	-0.59	2.94e-10	Systemic lupus erythematosus;
THYM	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg02403541	chr12:121454288	C12orf43	0.84	7.55	0.61	2.63e-11	N-glycan levels;
THYM	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg18252515	chr7:66147081	NA	1.43	8.6	0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs7769051	0.803	rs34334052	chr6:133231829	C/T	cg07930552	chr6:133119739	C6orf192	0.92	4.77	0.44	6.75e-6	Type 2 diabetes nephropathy;
THYM	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg11764359	chr7:65958608	NA	-0.79	-5.57	-0.5	2.35e-7	Aortic root size;
THYM	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg06108461	chr20:60628389	TAF4	-1.06	-9.1	-0.68	1.39e-14	Body mass index;
THYM	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg23978390	chr7:1156363	C7orf50	0.7	5.17	0.47	1.27e-6	Longevity;Endometriosis;
THYM	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-4.96	-0.45	3.03e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs73198271	0.740	rs28402110	chr8:8647249	C/A	cg15556689	chr8:8085844	FLJ10661	-0.73	-4.58	-0.43	1.39e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	5.07	0.46	1.92e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.47	0.49	3.57e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg03709012	chr19:19516395	GATAD2A	0.72	5.47	0.49	3.6e-7	Tonsillectomy;
THYM	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg15536230	chr21:44985092	HSF2BP	0.38	4.46	0.42	2.27e-5	Mean corpuscular volume;
THYM	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg00684032	chr4:1343700	KIAA1530	0.55	4.8	0.44	5.9e-6	Obesity-related traits;
THYM	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs79387448	0.745	rs76720903	chr2:103162826	G/A	cg09003973	chr2:102972529	NA	0.76	4.71	0.44	8.39e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs11031096	0.782	rs4910904	chr11:4165529	C/T	cg18678763	chr11:4115507	RRM1	0.38	5.17	0.47	1.27e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4523957	0.890	rs2281727	chr17:2117945	A/G	cg16513277	chr17:2031491	SMG6	-0.8	-7.78	-0.62	8.85e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs67981189	0.858	rs17108877	chr14:71473809	G/T	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg18876405	chr7:65276391	NA	0.67	5.93	0.52	4.91e-8	Aortic root size;
THYM	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg13385794	chr1:248469461	NA	0.67	4.58	0.43	1.4e-5	Common traits (Other);
THYM	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg05802129	chr4:122689817	NA	-0.59	-4.65	-0.43	1.08e-5	Type 2 diabetes;
THYM	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg01710189	chr8:22454888	PDLIM2	0.49	5.21	0.47	1.1e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.6	-5.35	-0.48	6.18e-7	Prudent dietary pattern;
THYM	cis	rs4851254	0.660	rs59447631	chr2:100691493	T/C	cg22139774	chr2:100720529	AFF3	-0.42	-4.77	-0.44	6.63e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2404602	0.552	rs11072613	chr15:76961526	A/C	cg23625390	chr15:77176239	SCAPER	-0.74	-4.61	-0.43	1.26e-5	Blood metabolite levels;
THYM	cis	rs2404602	0.735	rs2436996	chr15:76817420	C/T	cg23625390	chr15:77176239	SCAPER	-0.71	-4.92	-0.45	3.63e-6	Blood metabolite levels;
THYM	cis	rs6430585	0.793	rs11684545	chr2:136539122	G/T	cg23851026	chr2:136556271	LCT	-0.57	-5.82	-0.51	7.93e-8	Corneal structure;
THYM	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg14074117	chr16:1909714	C16orf73	-0.7	-4.45	-0.42	2.3e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs9486719	1.000	rs4262195	chr6:96929475	T/C	cg18709589	chr6:96969512	KIAA0776	-0.73	-4.83	-0.44	5.28e-6	Migraine;Coronary artery disease;
THYM	cis	rs1559088	0.947	rs12461297	chr19:33559245	A/G	cg03563238	chr19:33554763	RHPN2	-0.5	-4.52	-0.42	1.8e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg06634786	chr22:41940651	POLR3H	0.62	4.84	0.44	5.12e-6	Vitiligo;
THYM	cis	rs611744	0.870	rs429315	chr8:109094068	A/G	cg21045802	chr8:109455806	TTC35	-0.6	-5.42	-0.49	4.56e-7	Dupuytren's disease;
THYM	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-5.9	-0.52	5.7e-8	Chronic sinus infection;
THYM	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg02018176	chr4:1364513	KIAA1530	0.65	5.2	0.47	1.15e-6	Obesity-related traits;
THYM	cis	rs508977	0.953	rs28404022	chr4:74756385	T/C	cg07318073	chr4:74904359	CXCL3	0.61	4.5	0.42	1.93e-5	Growth-regulated protein alpha levels;
THYM	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg26721908	chr21:47610096	LSS	-0.75	-5.14	-0.47	1.49e-6	Testicular germ cell tumor;
THYM	cis	rs7011507	0.594	rs56054674	chr8:49348188	C/T	cg08774009	chr8:49309094	NA	-0.6	-4.71	-0.44	8.47e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg17757837	chr7:157058334	UBE3C	-0.93	-9.0	-0.68	2.28e-14	Body mass index;
THYM	cis	rs9810089	0.814	rs73226190	chr3:136213310	T/C	cg21827317	chr3:136751795	NA	0.57	4.74	0.44	7.43e-6	Gestational age at birth (child effect);
THYM	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg07936489	chr17:37558343	FBXL20	0.81	5.29	0.48	7.7300000000000005e-07	Glomerular filtration rate (creatinine);
THYM	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg18252515	chr7:66147081	NA	-1.08	-7.38	-0.6	5.85e-11	Diabetic kidney disease;
THYM	cis	rs7781977	0.782	rs1993444	chr7:50338499	G/A	cg01139861	chr7:50343298	IKZF1	0.69	6.47	0.55	4.3e-9	IgG glycosylation;
THYM	cis	rs3008870	0.883	rs2755249	chr1:67493662	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	7.31	0.6	8.51e-11	Lymphocyte percentage of white cells;
THYM	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7523273	0.606	rs2488255	chr1:207941741	C/T	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	cis	rs9534288	0.797	rs2182483	chr13:46582600	C/T	cg15192986	chr13:46630673	CPB2	-0.61	-4.57	-0.42	1.47e-5	Blood protein levels;
THYM	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.33	0.48	6.55e-7	Height;
THYM	cis	rs28795989	0.795	rs17833038	chr4:7918593	A/T	cg00251875	chr4:7801337	AFAP1	-0.62	-4.89	-0.45	4.03e-6	Intraocular pressure;
THYM	cis	rs10871290	0.650	rs2288054	chr16:74491733	A/G	cg01733217	chr16:74700730	RFWD3	0.65	5.23	0.47	9.97e-7	Breast cancer;
THYM	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg02782426	chr3:40428986	ENTPD3	0.51	4.5	0.42	1.95e-5	Renal cell carcinoma;
THYM	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.84	0.44	4.97e-6	Bipolar disorder;
THYM	cis	rs11224069	1.000	rs11224069	chr11:134763071	A/G	cg22202264	chr11:133816022	IGSF9B	0.9	4.53	0.42	1.71e-5	Urinary tract infection frequency;
THYM	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg12560992	chr17:57184187	TRIM37	0.94	8.84	0.67	5.01e-14	Intelligence (multi-trait analysis);
THYM	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03576123	chr11:487126	PTDSS2	-1.24	-5.21	-0.47	1.1e-6	Body mass index;
THYM	cis	rs2276314	0.793	rs77590522	chr18:33629410	C/G	cg05985134	chr18:33552581	C18orf21	0.68	4.84	0.44	5.07e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs216026	0.689	rs216048	chr12:2766700	A/C	cg19945202	chr12:2788847	CACNA1C	0.69	4.6	0.43	1.33e-5	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs6964587	0.626	rs409	chr7:91556355	C/T	cg17063962	chr7:91808500	NA	1.01	8.84	0.67	4.9e-14	Breast cancer;
THYM	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs7953508	0.711	rs11107117	chr12:93979419	T/C	cg13201927	chr12:93977447	NA	0.7	4.95	0.45	3.17e-6	Pubertal anthropometrics;
THYM	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4474465	0.736	rs11237541	chr11:78261703	T/C	cg19901956	chr11:77921274	USP35	0.58	4.54	0.42	1.68e-5	Alzheimer's disease (survival time);
THYM	cis	rs28595532	1.000	rs75497896	chr4:119636703	T/C	cg14228332	chr4:119757509	SEC24D	1.35	4.52	0.42	1.81e-5	Cannabis dependence symptom count;
THYM	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg03733263	chr8:22462867	KIAA1967	-1.12	-12.69	-0.79	3.64e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg08704250	chr15:31115839	NA	0.47	5.54	0.49	2.68e-7	Huntington's disease progression;
THYM	cis	rs9309473	0.500	rs2421582	chr2:73898420	A/G	cg19565262	chr2:73869966	NAT8	0.56	4.68	0.43	9.48e-6	Metabolite levels;
THYM	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg00278517	chr6:167070616	RPS6KA2	-0.34	-4.68	-0.43	9.42e-6	Crohn's disease;
THYM	cis	rs6584283	0.713	rs1332100	chr10:101301346	C/T	cg23319285	chr10:101287752	NA	0.47	4.69	0.43	9.02e-6	Ulcerative colitis;
THYM	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg23708337	chr7:1209742	NA	0.65	4.69	0.43	9.24e-6	Longevity;Endometriosis;
THYM	cis	rs7248779	0.512	rs12610522	chr19:2413228	C/T	cg22729335	chr19:2427816	TIMM13	1.22	12.57	0.79	6.34e-22	Cortisol levels (saliva);
THYM	cis	rs524281	0.692	rs11227395	chr11:65829637	A/C	cg00563793	chr11:65837595	PACS1	0.72	5.05	0.46	2.15e-6	Electroencephalogram traits;
THYM	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg04043695	chr12:129287642	SLC15A4	0.61	5.07	0.46	1.98e-6	Systemic lupus erythematosus;
THYM	cis	rs7582180	0.663	rs2309800	chr2:100992086	C/T	cg08017756	chr2:100939284	LONRF2	-0.72	-7.39	-0.6	5.75e-11	Intelligence (multi-trait analysis);
THYM	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg09877947	chr5:131593287	PDLIM4	0.54	4.59	0.43	1.36e-5	Breast cancer;Mosquito bite size;
THYM	cis	rs7941600	0.655	rs61875699	chr11:9360940	G/A	cg21110646	chr11:9336536	TMEM41B	1.0	5.56	0.5	2.42e-7	Coronary artery disease;
THYM	trans	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg00271210	chr6:167070053	RPS6KA2	-0.54	-5.42	-0.49	4.43e-7	Crohn's disease;
THYM	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.86	-9.57	-0.7	1.4e-15	Prudent dietary pattern;
THYM	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg14008862	chr17:28927542	LRRC37B2	0.92	4.79	0.44	6.05e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3820068	0.608	rs12091644	chr1:16044945	G/A	cg24675056	chr1:15929824	NA	0.78	6.16	0.53	1.73e-8	Systolic blood pressure;
THYM	cis	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg16898833	chr6:26189333	HIST1H4D	1.33	4.61	0.43	1.24e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs901683	0.850	rs73291121	chr10:46097404	A/G	cg18240400	chr10:46168597	ANUBL1	0.64	4.8	0.44	5.9e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg10760299	chr15:45669010	GATM	0.85	6.53	0.56	3.2e-9	Homoarginine levels;
THYM	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg05373962	chr22:49881684	NA	-0.66	-6.6	-0.56	2.35e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg09455208	chr3:40491958	NA	0.46	4.92	0.45	3.65e-6	Renal cell carcinoma;
THYM	cis	rs55883249	1.000	rs17453724	chr2:9764001	A/G	cg23886495	chr2:9695866	ADAM17	0.73	4.54	0.42	1.64e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.94	0.45	3.37e-6	Prudent dietary pattern;
THYM	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg00012203	chr2:219082015	ARPC2	0.63	5.35	0.48	6.15e-7	Colorectal cancer;
THYM	cis	rs2067615	0.560	rs10861671	chr12:107220927	T/C	cg15890332	chr12:107067104	RFX4	0.44	5.05	0.46	2.13e-6	Heart rate;
THYM	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg14820908	chr5:178986412	RUFY1	-0.62	-6.65	-0.56	1.84e-9	Lung cancer;
THYM	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg02018176	chr4:1364513	KIAA1530	0.55	4.7	0.43	8.82e-6	Obesity-related traits;
THYM	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg03161606	chr19:29218774	NA	0.76	5.95	0.52	4.46e-8	Methadone dose in opioid dependence;
THYM	trans	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg07930552	chr6:133119739	C6orf192	1.03	6.0	0.52	3.63e-8	Type 2 diabetes nephropathy;
THYM	cis	rs4919694	1.000	rs112240253	chr10:104753726	C/T	cg15744005	chr10:104629667	AS3MT	-0.84	-4.62	-0.43	1.21e-5	Arsenic metabolism;
THYM	cis	rs2898681	0.511	rs881743	chr4:53727450	A/G	cg03786743	chr4:53727781	RASL11B	0.37	4.7	0.43	8.75e-6	Optic nerve measurement (cup area);
THYM	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg01831904	chr17:28903510	LRRC37B2	-1.13	-5.5	-0.49	3.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg15247329	chr7:2764246	NA	-0.68	-5.59	-0.5	2.19e-7	Height;
THYM	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs977987	0.806	rs4888418	chr16:75460306	C/G	cg03315344	chr16:75512273	CHST6	0.76	6.16	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg04111992	chr7:158790115	NA	-0.6	-5.4	-0.48	4.83e-7	Facial morphology (factor 20);
THYM	cis	rs7584330	0.554	rs62186170	chr2:238425883	C/T	cg14458575	chr2:238380390	NA	0.79	4.65	0.43	1.06e-5	Prostate cancer;
THYM	cis	rs12153160	0.932	rs867674	chr5:152941091	C/T	cg10932939	chr5:153466023	NA	0.71	4.5	0.42	1.89e-5	Middle childhood and early adolescence aggressive behavior;
THYM	cis	rs10158481	0.727	rs7518927	chr1:25483015	C/T	cg09264742	chr1:25757510	TMEM57	-0.67	-4.9	-0.45	3.93e-6	Urate levels in obese individuals;
THYM	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg27446573	chr6:127587934	RNF146	1.04	9.87	0.71	3.12e-16	Breast cancer;
THYM	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg21427119	chr20:30132790	HM13	-0.7	-4.7	-0.43	8.88e-6	Mean corpuscular volume;
THYM	cis	rs3771570	0.901	rs6757876	chr2:242245570	T/C	cg21155796	chr2:242212141	HDLBP	1.09	6.4	0.55	5.95e-9	Prostate cancer;
THYM	cis	rs9880211	0.563	rs1393787	chr3:135854201	G/A	cg21827317	chr3:136751795	NA	-0.72	-5.08	-0.46	1.85e-6	Body mass index;Height;
THYM	cis	rs7216064	1.000	rs62084213	chr17:65842016	A/G	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs9649213	0.593	rs7796611	chr7:97908223	A/G	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3017493	0.786	rs12295625	chr11:70671860	A/G	cg03578926	chr11:70508032	SHANK2	-0.82	-4.91	-0.45	3.78e-6	Renal transplant outcome;
THYM	cis	rs977987	0.528	rs9926933	chr16:75501567	A/G	cg03315344	chr16:75512273	CHST6	-0.72	-4.53	-0.42	1.74e-5	Dupuytren's disease;
THYM	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4606347	0.872	rs61779721	chr1:66133455	G/C	cg04111102	chr1:66153794	NA	0.69	5.21	0.47	1.07e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.54	-0.49	2.74e-7	Menopause (age at onset);
THYM	cis	rs4642101	0.793	rs13320486	chr3:12822069	C/A	cg05775895	chr3:12838266	CAND2	0.76	6.79	0.57	9.61e-10	QRS complex (12-leadsum);
THYM	cis	rs2290159	0.898	rs2290160	chr3:12633083	A/G	cg23032965	chr3:12705835	RAF1	0.7	4.81	0.44	5.59e-6	Cholesterol, total;
THYM	cis	rs9527	0.590	rs763914	chr10:104841587	T/C	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs6429082	0.818	rs291391	chr1:235649955	A/G	cg26050004	chr1:235667680	B3GALNT2	0.76	6.72	0.57	1.36e-9	Adiposity;
THYM	cis	rs2463822	1.000	rs2513071	chr11:62098387	A/C	cg06239285	chr11:62104954	ASRGL1	1.44	7.77	0.62	9.14e-12	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6531209	0.926	rs11678155	chr2:20339792	C/A	cg24416238	chr2:20211868	MATN3	-0.62	-5.02	-0.46	2.38e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06481639	chr22:41940642	POLR3H	0.87	5.95	0.52	4.49e-8	Vitiligo;
THYM	trans	rs7618501	0.699	rs2681781	chr3:49898273	A/G	cg21582582	chr3:182698605	DCUN1D1	0.83	7.09	0.59	2.31e-10	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg27129171	chr3:47204927	SETD2	0.8	7.67	0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg01475377	chr6:109611718	NA	0.56	4.76	0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.25	-5.11	-0.46	1.64e-6	Obesity-related traits;
THYM	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg04944784	chr2:26401820	FAM59B	-1.09	-8.74	-0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs17598306	0.873	rs73402679	chr7:96591973	A/G	cg26766885	chr7:96220185	NA	0.62	5.13	0.47	1.56e-6	Radiation response;
THYM	cis	rs6490294	0.659	rs642898	chr12:112141233	A/G	cg10833066	chr12:111807467	FAM109A	0.51	5.55	0.49	2.55e-7	Mean platelet volume;
THYM	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg26597838	chr10:835615	NA	1.1	6.33	0.54	8e-9	Eosinophil percentage of granulocytes;
THYM	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg00484396	chr16:3507460	NAT15	0.66	6.44	0.55	4.97e-9	Tuberculosis;
THYM	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.69	0.43	9.17e-6	Bipolar disorder;
THYM	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.3	-0.48	7.57e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs67981189	0.896	rs8003227	chr14:71560352	T/C	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs11723261	0.545	rs6812799	chr4:197334	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.91	5.56	0.5	2.45e-7	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs4808199	1.000	rs17288409	chr19:19504167	T/C	cg03709012	chr19:19516395	GATAD2A	1.19	7.25	0.6	1.12e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs501916	0.602	rs472081	chr15:48058652	G/T	cg20869673	chr15:48010124	SEMA6D	0.64	4.63	0.43	1.14e-5	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs17094222	0.504	rs11190661	chr10:102452136	C/T	cg26540559	chr10:102447443	NA	0.71	6.12	0.53	2.12e-8	Body mass index;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6473252	1.000	rs6994674	chr8:81790586	T/C	cg08595989	chr8:81827712	NA	-0.41	-4.56	-0.42	1.54e-5	Breast cancer;
THYM	cis	rs354225	0.584	rs11898032	chr2:54821515	G/A	cg23486701	chr2:54789491	SPTBN1	0.35	4.68	0.43	9.65e-6	Schizophrenia;
THYM	cis	rs9403317	0.609	rs7774144	chr6:142029911	T/C	cg15052665	chr6:141804349	NA	-0.62	-4.78	-0.44	6.43e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6541297	0.941	rs6541294	chr1:230278826	A/G	cg20703242	chr1:230279135	GALNT2	0.92	6.26	0.54	1.13e-8	Coronary artery disease;
THYM	trans	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg25214090	chr10:38739885	LOC399744	0.94	8.0	0.63	2.97e-12	Corneal astigmatism;
THYM	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg17509989	chr5:176798049	RGS14	0.94	10.26	0.73	4.59e-17	Hemoglobin concentration;Hematocrit;
THYM	cis	rs7584330	0.554	rs77380873	chr2:238426551	C/T	cg08992911	chr2:238395768	MLPH	1.15	6.79	0.57	9.88e-10	Prostate cancer;
THYM	cis	rs1728785	0.748	rs889560	chr16:68605784	A/G	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.39e-6	Ulcerative colitis;
THYM	cis	rs2903698	0.585	rs6812261	chr4:76356821	C/T	cg03209871	chr4:76438412	RCHY1;THAP6	-0.43	-4.95	-0.45	3.27e-6	Prion diseases;
THYM	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg07212818	chr11:638076	DRD4	-0.77	-5.92	-0.52	5.09e-8	Systemic lupus erythematosus;
THYM	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Electroencephalogram traits;
THYM	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg24250549	chr1:154909240	PMVK	0.73	5.74	0.51	1.15e-7	Prostate cancer;
THYM	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg19904058	chr10:135279010	LOC619207	-0.56	-5.25	-0.47	9.23e-7	Systemic lupus erythematosus;
THYM	cis	rs611744	0.870	rs613261	chr8:109165949	A/G	cg21045802	chr8:109455806	TTC35	0.7	6.78	0.57	1.02e-9	Dupuytren's disease;
THYM	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg05212892	chr7:158533877	ESYT2	-0.55	-4.76	-0.44	6.95e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs2806561	0.695	rs66592286	chr1:23333649	G/C	cg19743168	chr1:23544995	NA	0.49	4.82	0.44	5.44e-6	Height;
THYM	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg17554472	chr22:41940697	POLR3H	-0.68	-4.86	-0.45	4.66e-6	Vitiligo;
THYM	cis	rs651907	0.588	rs1672380	chr3:101633171	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	5.39	0.48	5.08e-7	Colorectal cancer;
THYM	cis	rs12216545	0.765	rs2373808	chr7:150249391	A/G	cg08960815	chr7:150264767	GIMAP4	-0.87	-7.56	-0.61	2.54e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs3845702	0.736	rs6733426	chr2:180830958	A/G	cg01881094	chr2:180872142	CWC22	-0.85	-5.0	-0.46	2.64e-6	Schizophrenia;
THYM	cis	rs13017997	0.764	rs1405872	chr2:156852897	T/C	cg03339537	chr2:157184816	NR4A2	-0.35	-4.55	-0.42	1.58e-5	Schizophrenia;
THYM	cis	rs89107	0.575	rs72958930	chr6:118983681	G/C	cg21191810	chr6:118973309	C6orf204	0.58	5.96	0.52	4.25e-8	Cardiac structure and function;
THYM	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg20242066	chr2:136595261	LCT	-0.58	-7.42	-0.61	4.87e-11	Mosquito bite size;
THYM	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg04772025	chr11:68637568	NA	0.66	6.9	0.58	5.88e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4148689	1.000	rs4148691	chr7:117150118	G/C	cg17204129	chr7:117119601	CFTR	-0.63	-4.92	-0.45	3.69e-6	Gout;
THYM	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg06623918	chr6:96969491	KIAA0776	1.1	9.91	0.71	2.55e-16	Headache;
THYM	cis	rs6032067	0.516	rs761367	chr20:43913317	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.61	-7.01	-0.58	3.44e-10	Blood protein levels;
THYM	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05901451	chr6:126070800	HEY2	-0.7	-5.82	-0.51	7.96e-8	Brugada syndrome;
THYM	cis	rs7551222	0.721	rs4951080	chr1:204533284	A/G	cg20240347	chr1:204465584	NA	-0.54	-4.91	-0.45	3.81e-6	Schizophrenia;
THYM	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg18252515	chr7:66147081	NA	1.37	8.05	0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4243830	1.000	rs58415361	chr1:6592377	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	1.12	6.29	0.54	9.68e-9	Body mass index;
THYM	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg05855489	chr10:104503620	C10orf26	0.58	4.69	0.43	9.04e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6840360	1.000	rs4696283	chr4:152580516	A/G	cg22705602	chr4:152727874	NA	-0.62	-6.79	-0.57	9.45e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg20295408	chr7:1910781	MAD1L1	-0.65	-5.21	-0.47	1.12e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs72627509	0.904	rs17081933	chr4:57822869	T/A	cg26694713	chr4:57773883	REST	0.75	4.72	0.44	7.97e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs6748734	0.625	rs6437372	chr2:241822406	A/G	cg04034577	chr2:241836375	C2orf54	0.3	4.66	0.43	1.03e-5	Urinary metabolites;
THYM	cis	rs6032067	0.714	rs2206888	chr20:43882006	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.59	-5.71	-0.51	1.29e-7	Blood protein levels;
THYM	cis	rs763014	0.931	rs11643039	chr16:634260	G/A	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg12373951	chr3:133503437	NA	0.57	6.15	0.53	1.78e-8	Iron status biomarkers;
THYM	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7572733	0.534	rs770662	chr2:198729283	T/C	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs4845570	1.000	rs3811415	chr1:151763767	C/T	cg18019451	chr1:151746047	TDRKH	-0.76	-4.52	-0.42	1.75e-5	Coronary artery disease;
THYM	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg27490568	chr2:178487706	NA	0.61	5.63	0.5	1.82e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1451375	0.642	rs6963996	chr7:50559300	T/C	cg18232548	chr7:50535776	DDC	-0.68	-5.19	-0.47	1.21e-6	Malaria;
THYM	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg07936489	chr17:37558343	FBXL20	0.87	5.78	0.51	9.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs2404602	0.647	rs12903331	chr15:77168268	C/G	cg23625390	chr15:77176239	SCAPER	-0.8	-5.61	-0.5	1.95e-7	Blood metabolite levels;
THYM	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg06387496	chr7:2775674	GNA12	-0.43	-4.47	-0.42	2.2e-5	Height;
THYM	cis	rs55882075	0.690	rs12374485	chr5:179131395	G/C	cg14593053	chr5:179126677	CANX	0.61	4.57	0.42	1.48e-5	Monocyte percentage of white cells;
THYM	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9549260	0.755	rs12585875	chr13:41199531	A/G	cg21288729	chr13:41239152	FOXO1	0.72	5.55	0.49	2.61e-7	Red blood cell count;
THYM	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg02018176	chr4:1364513	KIAA1530	0.95	8.86	0.67	4.46e-14	Longevity;
THYM	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg14004847	chr7:1930337	MAD1L1	-0.65	-5.01	-0.46	2.55e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6032067	1.000	rs6017509	chr20:43830362	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.59	-0.5	2.14e-7	Blood protein levels;
THYM	cis	rs6430585	0.528	rs12464050	chr2:136663110	G/T	cg23851026	chr2:136556271	LCT	0.77	6.81	0.57	8.95e-10	Corneal structure;
THYM	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg11266682	chr4:10021025	SLC2A9	-0.69	-10.15	-0.72	7.87e-17	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7610301	1.000	rs7610512	chr3:46646222	G/C	cg22951056	chr3:46887651	NA	-0.78	-5.06	-0.46	2.05e-6	Blood protein levels;
THYM	cis	rs9359856	0.564	rs72915946	chr6:90447924	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.9	-7.81	-0.63	7.61e-12	Bipolar disorder;
THYM	cis	rs7572733	0.534	rs700673	chr2:198692929	A/G	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	trans	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg24596788	chr1:163392923	NA	-0.77	-7.43	-0.61	4.68e-11	Motion sickness;
THYM	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg16325326	chr1:53192061	ZYG11B	-0.97	-11.08	-0.75	8.23e-19	Monocyte count;
THYM	cis	rs1878931	0.597	rs2680221	chr16:3462595	A/G	cg00484396	chr16:3507460	NAT15	0.48	4.46	0.42	2.27e-5	Body mass index (adult);
THYM	trans	rs8002861	0.935	rs9567299	chr13:44456969	G/A	cg17145862	chr1:211918768	LPGAT1	1.03	11.49	0.76	1.12e-19	Leprosy;
THYM	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs2797685	0.773	rs2301489	chr1:7837676	G/C	cg06712362	chr1:7811235	CAMTA1	0.66	4.91	0.45	3.81e-6	Crohn's disease;
THYM	cis	rs2180341	0.594	rs7738385	chr6:127777516	T/C	cg27446573	chr6:127587934	RNF146	0.58	4.54	0.42	1.66e-5	Breast cancer;
THYM	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.68	5.84	0.51	7.34e-8	Birth weight;
THYM	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg14345882	chr6:26364793	BTN3A2	0.62	5.7	0.5	1.34e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs611744	0.901	rs673981	chr8:109191917	G/A	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs3106136	0.527	rs2664872	chr4:95146952	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.1	-0.46	1.7e-6	Capecitabine sensitivity;
THYM	cis	rs35883536	0.647	rs1855630	chr1:101039979	C/G	cg06223162	chr1:101003688	GPR88	-0.81	-6.91	-0.58	5.53e-10	Monocyte count;
THYM	trans	rs4596713	0.538	rs10114369	chr9:71799697	T/A	cg16512924	chr15:28394682	HERC2	0.83	6.93	0.58	5.02e-10	Headache;
THYM	cis	rs9393777	0.547	rs2893910	chr6:27283254	A/T	cg22548220	chr6:27277996	POM121L2	0.83	5.21	0.47	1.11e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2901656	1.000	rs6699095	chr1:172429245	T/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.47	4.75	0.44	7.1e-6	Red cell distribution width;Platelet distribution width;
THYM	cis	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.64	0.43	1.12e-5	Obesity-related traits;
THYM	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg24675658	chr1:53192096	ZYG11B	-0.7	-5.23	-0.47	9.95e-7	Monocyte count;
THYM	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg10911889	chr6:126070802	HEY2	0.55	4.45	0.42	2.34e-5	Brugada syndrome;
THYM	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg08999081	chr20:33150536	PIGU	-0.56	-4.92	-0.45	3.59e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg11764359	chr7:65958608	NA	0.63	4.94	0.45	3.36e-6	Aortic root size;
THYM	cis	rs6665290	0.904	rs3768425	chr1:227178127	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	trans	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.12	8.09	0.64	1.9e-12	Exhaled nitric oxide output;
THYM	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg11845111	chr2:191398756	TMEM194B	-1.0	-8.08	-0.64	2.04e-12	Diastolic blood pressure;
THYM	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg22681709	chr2:178499509	PDE11A	-0.59	-5.62	-0.5	1.91e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs904251	0.797	rs2776878	chr6:37487273	G/A	cg25019722	chr6:37503610	NA	-0.61	-4.79	-0.44	6.12e-6	Cognitive performance;
THYM	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg03433033	chr1:76189801	ACADM	-0.51	-5.31	-0.48	7.2e-7	Daytime sleep phenotypes;
THYM	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg09549813	chr16:4587862	C16orf5	-0.6	-6.33	-0.54	7.92e-9	Schizophrenia;
THYM	cis	rs775227	0.574	rs60131925	chr3:113034768	T/C	cg18753928	chr3:113234510	CCDC52	-0.75	-5.16	-0.47	1.35e-6	Dental caries;
THYM	cis	rs3796352	0.892	rs11718388	chr3:53076415	G/A	cg07884673	chr3:53033167	SFMBT1	1.03	5.24	0.47	9.74e-7	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg27170947	chr2:26402098	FAM59B	-0.61	-5.04	-0.46	2.25e-6	Gut microbiome composition (summer);
THYM	cis	rs10927875	0.541	rs1763599	chr1:16342602	C/T	cg21385522	chr1:16154831	NA	0.65	4.54	0.42	1.65e-5	Dilated cardiomyopathy;
THYM	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg21862992	chr11:68658383	NA	0.23	4.47	0.42	2.16e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs916888	0.647	rs199519	chr17:44853924	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.53	-4.45	-0.42	2.35e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg06238570	chr21:40685208	BRWD1	-0.69	-6.08	-0.53	2.47e-8	Menarche (age at onset);
THYM	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.12	-0.64	1.7e-12	Mean corpuscular volume;
THYM	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	5.42	0.49	4.47e-7	Schizophrenia;
THYM	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg20999797	chr1:1681921	NA	0.49	5.41	0.49	4.78e-7	Body mass index;
THYM	cis	rs17818399	0.547	rs35178974	chr2:46763898	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.66	-4.7	-0.43	8.94e-6	Height;
THYM	cis	rs6450176	0.625	rs35027270	chr5:53289068	T/C	ch.5.1024479R	chr5:53302184	ARL15	-1.01	-8.07	-0.64	2.17e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg04398451	chr17:18023971	MYO15A	0.78	7.21	0.59	1.37e-10	Total body bone mineral density;
THYM	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs1448094	0.511	rs10779210	chr12:86162432	T/C	cg02569458	chr12:86230093	RASSF9	-0.65	-5.53	-0.49	2.75e-7	Major depressive disorder;
THYM	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg20295408	chr7:1910781	MAD1L1	0.61	4.5	0.42	1.9e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs3768617	0.510	rs10911247	chr1:183076993	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.85	0.45	4.89e-6	Fuchs's corneal dystrophy;
THYM	cis	rs4936891	0.563	rs78158860	chr11:123890220	A/G	cg22125253	chr11:123886957	OR10G4	0.51	4.64	0.43	1.12e-5	Male fertility;
THYM	cis	rs11997175	0.583	rs34540455	chr8:33799300	C/T	ch.8.33884649F	chr8:33765107	NA	0.67	4.98	0.45	2.88e-6	Body mass index;
THYM	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.16	-8.93	-0.68	3.25e-14	Platelet count;
THYM	cis	rs7465272	1.000	rs13259747	chr8:143683567	A/C	cg01509843	chr8:143695822	ARC	0.72	4.85	0.45	4.73e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2976388	0.967	rs2976395	chr8:143763750	G/A	cg13446199	chr8:143762866	PSCA	0.51	6.42	0.55	5.46e-9	Urinary tract infection frequency;
THYM	cis	rs17741873	0.779	rs3812635	chr10:75594302	T/G	cg18802414	chr10:75757814	VCL	0.88	4.5	0.42	1.93e-5	Paclitaxel disposition in epithelial ovarian cancer;
THYM	cis	rs7584330	0.554	rs114331205	chr2:238432559	A/C	cg08992911	chr2:238395768	MLPH	0.9	5.8	0.51	8.78e-8	Prostate cancer;
THYM	cis	rs4589258	1.000	rs2213090	chr11:90478149	A/G	cg26138821	chr11:89956704	CHORDC1	-0.69	-5.52	-0.49	3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg17105886	chr17:28927953	LRRC37B2	1.31	7.95	0.63	3.89e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.89	5.72	0.51	1.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs611744	0.967	rs673015	chr8:109191669	C/T	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.63	4.46	0.42	2.25e-5	Aortic root size;
THYM	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.69e-11	Aortic root size;
THYM	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg24642844	chr7:1081250	C7orf50	-1.2	-5.2	-0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs1883415	0.619	rs9366572	chr6:24502142	G/T	cg00346970	chr6:24499591	ALDH5A1	0.4	5.14	0.47	1.45e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs12142240	0.667	rs66990604	chr1:46822073	G/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg02527881	chr3:46936655	PTH1R	-0.66	-6.44	-0.55	4.86e-9	Colorectal cancer;
THYM	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.27	9.43	0.7	2.74e-15	Platelet count;
THYM	cis	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg06565975	chr8:143823917	SLURP1	0.44	4.93	0.45	3.51e-6	Urinary tract infection frequency;
THYM	cis	rs28595532	0.920	rs116821181	chr4:119734892	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs1728785	1.000	rs1728764	chr16:68572292	G/C	cg02972257	chr16:68554789	NA	-0.75	-4.62	-0.43	1.22e-5	Ulcerative colitis;
THYM	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.64	-5.91	-0.52	5.24e-8	Prudent dietary pattern;
THYM	cis	rs886126	0.950	rs6490025	chr12:111691081	T/C	cg10833066	chr12:111807467	FAM109A	0.48	5.93	0.52	4.87e-8	Coronary heart disease;
THYM	cis	rs11190604	1.000	rs10509744	chr10:102271579	C/T	cg16342193	chr10:102329863	NA	-0.52	-5.34	-0.48	6.26e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12893428	chr3:195717962	SDHAP1	0.51	4.5	0.42	1.94e-5	Pancreatic cancer;
THYM	cis	rs4654899	0.865	rs6426658	chr1:21361176	G/A	cg01072550	chr1:21505969	NA	-0.74	-6.72	-0.57	1.35e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.96	-6.76	-0.57	1.12e-9	Schizophrenia;
THYM	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.79	-0.44	6.18e-6	Mean corpuscular volume;
THYM	cis	rs10924970	0.967	rs2185020	chr1:235440289	A/G	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.39	6.98	0.58	3.9e-10	Obesity-related traits;
THYM	cis	rs1957429	0.634	rs59000318	chr14:65419473	C/A	cg23373153	chr14:65346875	NA	-0.92	-5.45	-0.49	3.88e-7	Pediatric areal bone mineral density (radius);
THYM	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg26384229	chr12:38710491	ALG10B	0.9	7.35	0.6	6.77e-11	Bladder cancer;
THYM	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg04234412	chr22:24373322	LOC391322	0.86	8.25	0.65	9.11e-13	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs10744422	1.000	rs4759387	chr12:123377569	C/T	cg25930673	chr12:123319894	HIP1R	-0.84	-4.88	-0.45	4.25e-6	Schizophrenia;
THYM	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs4595586	0.505	rs76485055	chr12:39358294	A/G	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs651907	0.506	rs1513118	chr3:101661789	T/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	5.42	0.49	4.47e-7	Colorectal cancer;
THYM	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.93	-4.56	-0.42	1.53e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg16989719	chr2:238392110	NA	-0.64	-5.45	-0.49	3.99e-7	Prostate cancer;
THYM	cis	rs2637266	0.935	rs2579751	chr10:78339890	G/A	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs13102973	0.720	rs7672296	chr4:135890056	C/G	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	cis	rs1912528	0.783	rs797090	chr4:140867514	A/G	cg11128457	chr4:140864437	MAML3	0.48	5.28	0.48	8.1e-7	Educational attainment (years of education);
THYM	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg14517863	chr17:44321492	NA	-0.44	-5.0	-0.46	2.59e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg11941060	chr3:133502564	NA	-0.72	-6.13	-0.53	1.99e-8	Iron status biomarkers;
THYM	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.5	-4.66	-0.43	1.04e-5	Lymphocyte counts;
THYM	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11905131	chr22:24372483	LOC391322	-0.95	-11.19	-0.75	4.84e-19	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg00645579	chr11:617140	IRF7;MUPCDH	-0.47	-6.04	-0.53	3.05e-8	Systemic lupus erythematosus;
THYM	cis	rs3816788	0.792	rs7013323	chr8:21869024	C/G	cg17168535	chr8:21777572	XPO7	0.83	7.25	0.6	1.08e-10	Lung cancer in ever smokers;
THYM	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	5.56	0.5	2.48e-7	Eosinophil percentage of white cells;
THYM	cis	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.33e-5	Retinal vascular caliber;
THYM	cis	rs4242434	0.699	rs878053	chr8:22483849	T/C	cg03733263	chr8:22462867	KIAA1967	1.04	11.2	0.75	4.73e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14442939	chr10:27389572	ANKRD26	0.82	5.37	0.48	5.63e-7	Breast cancer;
THYM	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg09877947	chr5:131593287	PDLIM4	0.6	5.1	0.46	1.71e-6	Breast cancer;
THYM	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg17264618	chr3:40429014	ENTPD3	0.54	5.13	0.47	1.5e-6	Renal cell carcinoma;
THYM	cis	rs6430585	0.528	rs309154	chr2:136726567	C/T	cg07169764	chr2:136633963	MCM6	1.06	9.37	0.69	3.74e-15	Corneal structure;
THYM	cis	rs6011002	1.000	rs12481186	chr20:62296993	G/A	cg08432509	chr20:62317768	RTEL1	0.69	4.49	0.42	2.01e-5	Dental caries;
THYM	cis	rs526231	0.511	rs55810112	chr5:102362349	C/T	cg23492399	chr5:102201601	PAM	-0.7	-5.21	-0.47	1.08e-6	Primary biliary cholangitis;
THYM	cis	rs9905704	0.671	rs4337355	chr17:56950920	C/T	cg12560992	chr17:57184187	TRIM37	0.7	5.55	0.49	2.59e-7	Testicular germ cell tumor;
THYM	cis	rs11122895	0.509	rs55937046	chr2:112447296	G/A	cg23262488	chr2:112468472	NA	0.5	6.61	0.56	2.25e-9	Allergic sensitization;
THYM	cis	rs6754311	0.593	rs1446584	chr2:136419961	C/T	cg04750100	chr2:136595281	LCT	-0.56	-5.89	-0.52	5.87e-8	Mosquito bite size;
THYM	cis	rs6815814	0.904	rs2101521	chr4:38811551	C/T	cg02016764	chr4:38805732	TLR1	-0.46	-4.73	-0.44	7.81e-6	Breast cancer;
THYM	cis	rs611744	0.935	rs661036	chr8:109213088	C/T	cg21045802	chr8:109455806	TTC35	0.59	5.31	0.48	7.16e-7	Dupuytren's disease;
THYM	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg07648498	chr16:89883185	FANCA	0.61	4.55	0.42	1.57e-5	Vitiligo;
THYM	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg06238570	chr21:40685208	BRWD1	-0.98	-9.35	-0.69	4.01e-15	Cognitive function;
THYM	trans	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.11	8.15	0.64	1.44e-12	Exhaled nitric oxide output;
THYM	trans	rs10962692	0.608	rs10962659	chr9:16883318	G/C	cg03221025	chr16:88955224	CBFA2T3	0.74	7.08	0.59	2.43e-10	Ovarian cancer in BRCA2 mutation carriers;Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;
THYM	cis	rs35883536	1.000	rs9803842	chr1:101134877	G/T	cg06223162	chr1:101003688	GPR88	0.68	5.16	0.47	1.36e-6	Monocyte count;
THYM	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg17830980	chr10:43048298	ZNF37B	-1.09	-10.96	-0.75	1.49e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs740474	1.000	rs740474	chr5:140925362	A/G	cg24137543	chr5:140893634	NA	-0.54	-6.55	-0.56	2.97e-9	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs13082711	0.522	rs646577	chr3:27352225	A/G	cg02860705	chr3:27208620	NA	0.64	5.03	0.46	2.27e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.28	-5.88	-0.52	6.18e-8	Obesity-related traits;
THYM	cis	rs6032067	0.929	rs6017503	chr20:43815103	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.64	-0.5	1.76e-7	Blood protein levels;
THYM	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg17366294	chr4:99064904	C4orf37	0.48	5.43	0.49	4.3e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11096990	0.634	rs2839765	chr4:39295553	T/C	cg24403649	chr4:39172243	NA	-0.64	-5.48	-0.49	3.43e-7	Cognitive function;
THYM	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06634786	chr22:41940651	POLR3H	-0.76	-5.64	-0.5	1.71e-7	Vitiligo;
THYM	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7626444	0.625	rs843540	chr3:196475313	C/A	cg12930392	chr3:196481615	PAK2	0.4	4.97	0.45	2.97e-6	Monocyte count;
THYM	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6430585	1.000	rs6732236	chr2:136501509	T/G	cg23851026	chr2:136556271	LCT	0.61	5.5	0.49	3.14e-7	Corneal structure;
THYM	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg11247378	chr22:39784982	NA	-1.01	-11.33	-0.76	2.42e-19	Intelligence (multi-trait analysis);
THYM	cis	rs9825379	0.643	rs56339671	chr3:141151456	G/A	cg13411656	chr3:141121016	ZBTB38	-0.56	-4.78	-0.44	6.47e-6	Height;
THYM	cis	rs16989760	0.661	rs67935422	chr22:32020413	G/A	cg01338084	chr22:32026380	PISD	1.48	7.33	0.6	7.69e-11	Age-related hearing impairment;
THYM	cis	rs4072705	0.967	rs10818984	chr9:127413551	T/C	cg13476313	chr9:127244764	NR5A1	0.34	5.46	0.49	3.83e-7	Menarche (age at onset);
THYM	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.01	10.25	0.72	4.88e-17	Cognitive ability;
THYM	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	4.96	0.45	3.07e-6	Hip circumference adjusted for BMI;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg18695750	chr6:71135534	FAM135A	-0.93	-6.87	-0.58	6.66e-10	Depressive symptoms;
THYM	cis	rs4919694	0.611	rs76695159	chr10:105070837	C/T	cg04362960	chr10:104952993	NT5C2	0.82	4.87	0.45	4.53e-6	Arsenic metabolism;
THYM	cis	rs4664308	0.935	rs4665148	chr2:160917901	A/G	cg03641300	chr2:160917029	PLA2R1	-0.78	-6.97	-0.58	4.25e-10	Idiopathic membranous nephropathy;
THYM	cis	rs1691799	0.899	rs4762091	chr12:66747863	A/G	cg16791601	chr12:66731901	HELB	-0.73	-6.94	-0.58	4.74e-10	White blood cell count (basophil);
THYM	cis	rs3825942	0.900	rs28522673	chr15:74223716	G/C	cg23484268	chr15:74220776	LOXL1	0.5	4.81	0.44	5.74e-6	Glaucoma (exfoliation);
THYM	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg27068330	chr11:65405492	SIPA1	-0.95	-8.8	-0.67	6.03e-14	Acne (severe);
THYM	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.72	6.86	0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.18	-9.28	-0.69	5.73e-15	Platelet count;
THYM	cis	rs3126085	0.866	rs3126066	chr1:152276871	A/G	cg26020982	chr1:152196106	HRNR	-0.34	-4.78	-0.44	6.45e-6	Atopic dermatitis;
THYM	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg07936489	chr17:37558343	FBXL20	-0.76	-5.33	-0.48	6.57e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-5.93	-0.52	4.8e-8	Gut microbiome composition (summer);
THYM	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg22875332	chr1:76189707	ACADM	0.89	12.06	0.78	7.38e-21	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs13082711	0.954	rs34772035	chr3:27468872	C/G	cg02860705	chr3:27208620	NA	0.85	5.85	0.51	6.89e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs526231	0.543	rs34379	chr5:102398698	C/T	cg23492399	chr5:102201601	PAM	0.69	5.1	0.46	1.76e-6	Primary biliary cholangitis;
THYM	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg22841779	chr14:105766346	BRF1	-0.45	-5.51	-0.49	3.03e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7319311	1.000	rs7320755	chr13:111031092	C/G	cg06243866	chr13:111019493	COL4A2	-0.74	-5.93	-0.52	4.94e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs7084402	0.967	rs1649027	chr10:60280911	T/G	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg24530246	chr3:53118167	NA	-0.83	-4.74	-0.44	7.62e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs6087990	0.735	rs2424906	chr20:31359109	A/G	cg13636640	chr20:31349939	DNMT3B	0.9	9.61	0.7	1.15e-15	Ulcerative colitis;
THYM	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	5.93	0.52	4.96e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs67981189	0.896	rs2810100	chr14:71432172	C/A	cg15910301	chr14:71632612	NA	-0.5	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	cis	rs11886999	0.953	rs6725872	chr2:96874591	T/C	cg18419276	chr2:96971862	SNRNP200	-0.47	-5.28	-0.48	8.28e-7	Cardiac Troponin-T levels;
THYM	cis	rs919433	0.680	rs12621129	chr2:198265350	T/C	cg00792783	chr2:198669748	PLCL1	-0.86	-5.52	-0.49	2.92e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs11186	0.556	rs72908325	chr2:189973658	T/C	cg11041835	chr2:189156425	GULP1	0.8	4.52	0.42	1.79e-5	Parkinson's disease;
THYM	cis	rs4866334	1.000	rs75534671	chr5:18487744	G/A	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg22655196	chr4:3374909	RGS12	0.63	7.73	0.62	1.13e-11	Serum sulfate level;
THYM	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.54	-5.24	-0.47	9.81e-7	Crohn's disease;
THYM	cis	rs7248779	1.000	rs7248779	chr19:2403564	G/T	cg13496660	chr19:2424182	TMPRSS9	-0.52	-4.88	-0.45	4.25e-6	Cortisol levels (saliva);
THYM	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg19761014	chr17:28927070	LRRC37B2	0.78	4.99	0.46	2.76e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10463554	0.892	rs464591	chr5:102447304	T/C	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Parkinson's disease;
THYM	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg13246856	chr1:44399776	ARTN	0.5	5.46	0.49	3.82e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg27394845	chr17:28928406	LRRC37B2	0.91	4.58	0.42	1.44e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs828999	0.688	rs2119344	chr1:108700538	A/G	cg24323958	chr1:108741884	SLC25A24	0.55	5.4	0.48	4.98e-7	Monocyte percentage of white cells;
THYM	cis	rs995000	0.868	rs1168029	chr1:62969402	G/A	cg06896770	chr1:63153194	DOCK7	-0.91	-7.48	-0.61	3.62e-11	Triglyceride levels;
THYM	cis	rs28595532	0.920	rs17324968	chr4:119772316	A/G	cg21605333	chr4:119757512	SEC24D	1.61	6.06	0.53	2.69e-8	Cannabis dependence symptom count;
THYM	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-5.82	-0.51	7.82e-8	Gut microbiome composition (summer);
THYM	cis	rs13314892	0.764	rs4579020	chr3:69878028	A/AT	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	QRS complex (12-leadsum);
THYM	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg12310025	chr6:25882481	NA	0.8	6.64	0.56	1.93e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6754311	0.593	rs7608045	chr2:136413359	T/C	cg23851026	chr2:136556271	LCT	0.59	5.62	0.5	1.91e-7	Mosquito bite size;
THYM	cis	rs6598955	0.671	rs6686100	chr1:26617338	G/C	cg08133631	chr1:26527909	CATSPER4	-0.55	-4.55	-0.42	1.57e-5	Obesity-related traits;
THYM	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg24692254	chr21:30365293	RNF160	1.06	9.89	0.71	2.85e-16	Dental caries;
THYM	cis	rs4455778	0.580	rs3924857	chr7:49121682	C/G	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs12594515	1.000	rs8038320	chr15:45990267	G/C	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg12408189	chr10:30722286	MAP3K8	-0.64	-5.59	-0.5	2.21e-7	Inflammatory bowel disease;
THYM	cis	rs7524258	0.903	rs763197	chr1:7289959	A/G	cg07173049	chr1:7289937	CAMTA1	0.82	6.34	0.55	7.82e-9	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs2806561	0.929	rs2746556	chr1:23524541	G/A	cg08872493	chr1:23521417	HTR1D	0.37	4.51	0.42	1.87e-5	Height;
THYM	cis	rs11992162	0.560	rs13256329	chr8:11782214	G/A	cg21775007	chr8:11205619	TDH	-0.58	-4.46	-0.42	2.21e-5	Monocyte count;
THYM	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg22166914	chr1:53195759	ZYG11B	0.82	8.54	0.66	2.16e-13	Monocyte count;
THYM	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg19507638	chr5:93509721	C5orf36	-0.68	-4.57	-0.42	1.49e-5	Diabetic retinopathy;
THYM	cis	rs11167764	0.895	rs13189044	chr5:141471431	A/C	cg23435118	chr5:141488016	NDFIP1	-0.52	-4.46	-0.42	2.24e-5	Crohn's disease;
THYM	cis	rs921968	0.643	rs485765	chr2:219480804	C/G	cg02176678	chr2:219576539	TTLL4	0.59	5.54	0.49	2.75e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg05335186	chr13:53173507	NA	-0.4	-5.03	-0.46	2.36e-6	Lewy body disease;
THYM	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg08885076	chr2:99613938	TSGA10	-0.75	-7.1	-0.59	2.27e-10	Chronic sinus infection;
THYM	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg16928487	chr17:17741425	SREBF1	-0.56	-5.48	-0.49	3.46e-7	Total body bone mineral density;
THYM	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg05368731	chr17:41323189	NBR1	1.26	11.54	0.76	9.06e-20	Menopause (age at onset);
THYM	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06481639	chr22:41940642	POLR3H	-0.81	-5.61	-0.5	2.03e-7	Vitiligo;
THYM	cis	rs941408	1.000	rs4807332	chr19:2793289	T/C	cg06609049	chr19:2785107	THOP1	0.74	6.12	0.53	2.06e-8	Total cholesterol levels;
THYM	cis	rs7919823	0.661	rs2017681	chr10:21758244	C/T	cg26899113	chr10:22625733	NA	-1.05	-4.59	-0.43	1.35e-5	Subcutaneous adipose tissue;
THYM	cis	rs7107174	1.000	rs4944198	chr11:78032605	T/A	cg02023728	chr11:77925099	USP35	0.62	5.84	0.51	7.32e-8	Testicular germ cell tumor;
THYM	cis	rs2069036	0.855	rs10128280	chr10:16077763	G/A	cg26633223	chr10:15133461	NA	0.65	4.69	0.43	9.18e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs611744	0.647	rs674391	chr8:109242803	A/T	cg21045802	chr8:109455806	TTC35	0.65	5.91	0.52	5.3e-8	Dupuytren's disease;
THYM	cis	rs2046867	0.862	rs62252362	chr3:72855218	A/G	cg25664220	chr3:72788482	NA	-0.82	-6.56	-0.56	2.83e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs870825	0.616	rs7680835	chr4:185652992	C/G	cg04058563	chr4:185651563	MLF1IP	-1.06	-9.32	-0.69	4.75e-15	Blood protein levels;
THYM	cis	rs7578361	0.959	rs4413131	chr2:150433959	C/G	cg17961725	chr2:150454027	NA	0.74	6.08	0.53	2.49e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1729951	0.575	rs1654926	chr3:136709924	G/A	cg12473912	chr3:136751656	NA	0.6	4.96	0.45	3.07e-6	Neuroticism;
THYM	cis	rs13326165	0.715	rs3796343	chr3:52324169	A/G	cg08438690	chr3:52279403	PPM1M	-0.79	-5.29	-0.48	7.99e-7	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs28595532	0.841	rs116521340	chr4:119757415	C/A	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs4148883	0.689	rs1800760	chr4:100065626	A/T	cg12011299	chr4:100065546	ADH4	0.68	5.86	0.51	6.78e-8	Alcohol dependence;
THYM	cis	rs2276314	0.857	rs8097597	chr18:33619448	A/G	cg19628046	chr18:33552617	C18orf21	0.74	5.43	0.49	4.29e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg15536230	chr21:44985092	HSF2BP	0.44	5.43	0.49	4.24e-7	Mean corpuscular volume;
THYM	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4788570	0.624	rs9929985	chr16:71838458	A/G	cg06353428	chr16:71660113	MARVELD3	1.41	8.74	0.67	8.32e-14	Intelligence (multi-trait analysis);
THYM	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg17173187	chr15:85201210	NMB	0.54	5.31	0.48	7.17e-7	Schizophrenia;
THYM	cis	rs7100689	0.577	rs4934038	chr10:82057334	C/A	cg09936400	chr10:82049201	MAT1A	0.46	4.77	0.44	6.64e-6	Post bronchodilator FEV1;
THYM	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg22535103	chr8:58192502	C8orf71	-0.89	-5.1	-0.46	1.73e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg14993813	chr1:46806288	NSUN4	-0.69	-4.75	-0.44	7.24e-6	Menopause (age at onset);
THYM	cis	rs17102423	0.594	rs2781373	chr14:65568215	G/A	cg11161011	chr14:65562177	MAX	-0.7	-5.66	-0.5	1.59e-7	Obesity-related traits;
THYM	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg26963428	chr7:66367121	NA	-0.58	-4.89	-0.45	4.15e-6	Corneal structure;
THYM	cis	rs7582403	0.510	rs13015655	chr2:148873332	C/T	cg23727674	chr2:148602993	ACVR2A	0.65	4.84	0.44	5.04e-6	Neuroticism;
THYM	cis	rs7688540	0.723	rs80316648	chr4:232215	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.68	5.02	0.46	2.36e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg00271210	chr6:167070053	RPS6KA2	0.54	5.42	0.49	4.43e-7	Crohn's disease;
THYM	cis	rs9970807	0.901	rs72664318	chr1:56963627	A/G	cg11959316	chr1:57001742	PPAP2B	0.69	5.16	0.47	1.35e-6	Myocardial infarction;Coronary artery disease;
THYM	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg12408189	chr10:30722286	MAP3K8	-0.58	-4.72	-0.44	7.97e-6	Inflammatory bowel disease;
THYM	cis	rs2882877	0.560	rs11568351	chr2:190445194	C/G	cg10752008	chr2:190445175	SLC40A1	-0.74	-5.22	-0.47	1.04e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.79	-5.94	-0.52	4.69e-8	Menarche (age at onset);
THYM	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg11984989	chr7:158649758	WDR60	1.12	12.86	0.8	1.61e-22	Height;
THYM	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg25554036	chr4:6271136	WFS1	0.59	5.47	0.49	3.68e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs9611565	0.525	rs9611549	chr22:41705909	C/G	cg13695892	chr22:41940480	POLR3H	-0.6	-4.69	-0.43	9.11e-6	Vitiligo;
THYM	cis	rs514406	0.698	rs11206055	chr1:53436632	A/T	cg06600287	chr1:53387719	ECHDC2	0.34	5.37	0.48	5.55e-7	Monocyte count;
THYM	cis	rs7187994	0.836	rs16974519	chr16:84782750	A/C	cg07647771	chr16:84786436	USP10	-0.55	-5.06	-0.46	2.03e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs6495367	1.000	rs1007365	chr15:79379492	T/G	cg17916960	chr15:79447300	NA	0.58	6.35	0.55	7.28e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2797160	0.967	rs2226158	chr6:125995467	C/T	cg05901451	chr6:126070800	HEY2	-0.54	-4.45	-0.42	2.3e-5	Endometrial cancer;
THYM	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs6988636	0.710	rs59229243	chr8:124155673	G/A	cg23067535	chr8:124195133	FAM83A	-0.99	-4.82	-0.44	5.52e-6	Urinary uromodulin levels;
THYM	cis	rs6957923	0.668	rs6956784	chr7:23573998	T/C	cg20265043	chr7:23510089	IGF2BP3	0.48	5.12	0.46	1.6e-6	Height;
THYM	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg15744005	chr10:104629667	AS3MT	-0.78	-7.33	-0.6	7.48e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg11764359	chr7:65958608	NA	0.63	4.92	0.45	3.66e-6	Aortic root size;
THYM	cis	rs4654899	0.895	rs10916866	chr1:21137768	C/A	cg01072550	chr1:21505969	NA	0.72	7.06	0.59	2.7e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg06623918	chr6:96969491	KIAA0776	1.09	9.94	0.71	2.21e-16	Headache;
THYM	cis	rs7000551	0.508	rs11780977	chr8:22245028	G/A	cg12081754	chr8:22256438	SLC39A14	1.13	11.06	0.75	9.37e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg14004847	chr7:1930337	MAD1L1	-0.64	-5.11	-0.46	1.67e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg05347473	chr6:146136440	FBXO30	0.6	4.86	0.45	4.66e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.65	4.96	0.45	3.04e-6	Glycated hemoglobin levels;
THYM	cis	rs2275247	0.609	rs11264165	chr1:35970441	G/T	cg12447066	chr1:35261252	GJA4	-0.89	-4.58	-0.43	1.42e-5	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg03676636	chr4:99064102	C4orf37	0.44	6.48	0.55	4.05e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7614311	0.636	rs73117057	chr3:63915689	A/G	cg22134162	chr3:63841271	THOC7	-0.56	-6.45	-0.55	4.61e-9	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs1557488	0.599	rs7113642	chr11:126732480	A/C	cg03950493	chr11:126582183	KIRREL3	-0.39	-4.63	-0.43	1.18e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs7760949	0.889	rs9396264	chr6:13930342	T/A	cg11053062	chr6:13924544	RNF182	-0.48	-4.6	-0.43	1.28e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1971762	0.527	rs9737721	chr12:54074696	A/T	cg16917193	chr12:54089295	NA	0.87	8.66	0.66	1.21e-13	Height;
THYM	cis	rs7447927	0.950	rs13153461	chr5:138852369	G/A	cg12205435	chr5:138714322	SLC23A1	0.7	5.59	0.5	2.17e-7	Esophageal squamous cell carcinoma;
THYM	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7833986	0.501	rs2953898	chr8:56980803	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.4	0.6	5.43e-11	Height;
THYM	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg26818010	chr10:134567672	INPP5A	-0.82	-6.67	-0.56	1.66e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs28595532	0.920	rs115530096	chr4:119760512	T/G	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs2073300	0.609	rs77908916	chr20:23405626	C/G	cg12062639	chr20:23401060	NAPB	1.02	5.25	0.47	9.42e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	trans	rs1997103	1.000	rs6953494	chr7:55412157	G/A	cg20935933	chr6:143382018	AIG1	0.86	6.91	0.58	5.41e-10	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs931812	1.000	rs4734494	chr8:101917721	T/C	cg07585502	chr8:101912084	NA	-0.56	-4.54	-0.42	1.66e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs10203711	1.000	rs4663941	chr2:239574279	A/G	cg14580085	chr2:239553406	NA	0.63	5.56	0.5	2.46e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.14	0.47	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs28595532	0.764	rs56071514	chr4:119761833	T/C	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg23161317	chr6:28129485	ZNF389	0.98	7.27	0.6	1.03e-10	Parkinson's disease;
THYM	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg06636001	chr8:8085503	FLJ10661	-0.75	-7.07	-0.59	2.6200000000000003e-10	Retinal vascular caliber;
THYM	cis	rs17401966	1.000	rs35766535	chr1:10284659	T/C	cg20482658	chr1:10539492	PEX14	0.4	4.79	0.44	6.2e-6	Hepatocellular carcinoma;
THYM	cis	rs2000999	0.725	rs12924886	chr16:72075593	A/T	cg23815491	chr16:72088622	HP	0.72	5.28	0.48	8.17e-7	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
THYM	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg02018176	chr4:1364513	KIAA1530	0.6	4.98	0.45	2.89e-6	Obesity-related traits;
THYM	cis	rs7646881	1.000	rs7646987	chr3:158453442	A/G	cg19483011	chr3:158453295	NA	0.76	5.46	0.49	3.85e-7	Tetralogy of Fallot;
THYM	cis	rs7246967	0.673	rs4933026	chr19:22874492	A/T	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	trans	rs10802346	0.515	rs1113270	chr1:246423217	A/G	cg22732515	chr19:44031385	ETHE1	1.05	8.96	0.68	2.77e-14	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg13918804	chr1:2043761	PRKCZ	-0.61	-4.62	-0.43	1.19e-5	Height;
THYM	cis	rs828999	0.688	rs11185285	chr1:108695021	T/C	cg24323958	chr1:108741884	SLC25A24	0.54	5.33	0.48	6.59e-7	Monocyte percentage of white cells;
THYM	cis	rs778371	0.723	rs10210953	chr2:233698830	G/A	cg08000102	chr2:233561755	GIGYF2	-0.84	-7.76	-0.62	9.6e-12	Schizophrenia;
THYM	cis	rs4664308	1.000	rs4665147	chr2:160917062	A/G	cg03641300	chr2:160917029	PLA2R1	-0.78	-6.97	-0.58	4.25e-10	Idiopathic membranous nephropathy;
THYM	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg10295955	chr4:187884368	NA	-1.19	-17.25	-0.87	5.06e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg05340658	chr4:99064831	C4orf37	0.54	4.52	0.42	1.78e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2688608	0.592	rs10762560	chr10:75495405	T/G	cg23231163	chr10:75533350	FUT11	-0.41	-5.9	-0.52	5.54e-8	Inflammatory bowel disease;
THYM	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg14779329	chr11:130786720	SNX19	0.54	5.88	0.52	6.2e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg15736062	chr7:158136485	PTPRN2	-0.63	-5.03	-0.46	2.34e-6	Response to amphetamines;
THYM	cis	rs1372520	0.684	rs356162	chr4:90697157	T/C	cg01966878	chr4:90757139	SNCA	0.59	4.52	0.42	1.75e-5	Neuroticism;
THYM	cis	rs67311347	0.910	rs13089215	chr3:40495894	T/C	cg17264618	chr3:40429014	ENTPD3	-0.54	-5.3	-0.48	7.41e-7	Renal cell carcinoma;
THYM	cis	rs7688540	0.771	rs10005733	chr4:292001	C/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.62	4.7	0.43	8.67e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg08968635	chr6:28129556	ZNF389	-0.66	-5.19	-0.47	1.21e-6	Depression;
THYM	cis	rs9880211	0.718	rs56398805	chr3:135932400	A/G	cg21827317	chr3:136751795	NA	-0.7	-4.93	-0.45	3.45e-6	Body mass index;Height;
THYM	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs8114671	0.967	rs4911478	chr20:33782625	A/C	cg08999081	chr20:33150536	PIGU	-0.52	-4.69	-0.43	9.11e-6	Height;
THYM	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg06634786	chr22:41940651	POLR3H	0.7	4.89	0.45	4.14e-6	Cannabis dependence symptom count;
THYM	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs986417	1.000	rs1254318	chr14:60902549	T/C	cg27398547	chr14:60952738	C14orf39	-1.23	-6.08	-0.53	2.55e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs995000	0.931	rs659656	chr1:62912120	C/G	cg06896770	chr1:63153194	DOCK7	0.91	7.48	0.61	3.73e-11	Triglyceride levels;
THYM	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg06074448	chr4:187884817	NA	-1.0	-13.81	-0.82	1.9e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg14798641	chr3:49314920	USP4;C3orf62	-0.66	-4.63	-0.43	1.17e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs10875976	0.647	rs4391887	chr12:50225250	A/G	cg16667475	chr12:50024329	PRPF40B	-0.51	-4.48	-0.42	2.07e-5	Obesity;
THYM	cis	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg10856724	chr12:34555212	NA	-0.85	-7.54	-0.61	2.78e-11	Morning vs. evening chronotype;
THYM	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg00339695	chr16:24857497	SLC5A11	0.49	4.96	0.45	3.08e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2637266	0.597	rs846622	chr10:78543005	G/A	cg18941641	chr10:78392320	NA	0.74	5.81	0.51	8.27e-8	Pulmonary function;
THYM	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2034650	0.544	rs8034416	chr15:40703339	C/T	cg12699599	chr15:40643142	PHGR1	-0.6	-5.48	-0.49	3.46e-7	Interstitial lung disease;
THYM	cis	rs12121840	0.790	rs55957417	chr1:165544992	T/C	cg19407955	chr1:165599744	MGST3	-0.65	-4.77	-0.44	6.66e-6	Interleukin-1-receptor antagonist levels;
THYM	cis	rs8133932	0.906	rs1059010	chr21:47124833	C/T	cg20357416	chr21:47294739	PCBP3	0.8	4.55	0.42	1.56e-5	Schizophrenia;
THYM	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg05373962	chr22:49881684	NA	-0.67	-6.8	-0.57	9.16e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7917772	0.604	rs7908249	chr10:104373300	A/G	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs12478296	0.681	rs55802421	chr2:243033962	C/T	cg06360820	chr2:242988706	NA	-0.9	-5.52	-0.49	2.95e-7	Obesity-related traits;
THYM	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12765878	1.000	rs35223321	chr10:105646395	C/T	cg11005552	chr10:105648138	OBFC1	0.84	10.05	0.72	1.28e-16	Coronary artery disease;
THYM	cis	rs2455799	0.613	rs3924773	chr3:15796853	G/A	cg16303742	chr3:15540471	COLQ	-0.56	-5.73	-0.51	1.18e-7	Mean platelet volume;
THYM	cis	rs8067545	0.641	rs203481	chr17:19828728	C/T	cg20830565	chr17:20408647	MGC102966	-0.54	-4.95	-0.45	3.16e-6	Schizophrenia;
THYM	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg02734326	chr4:10020555	SLC2A9	0.72	6.47	0.55	4.33e-9	Bone mineral density;
THYM	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg02269571	chr22:50332266	NA	-0.71	-5.43	-0.49	4.32e-7	Schizophrenia;
THYM	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg05932139	chr16:680872	WFIKKN1	-0.64	-5.31	-0.48	7.21e-7	Height;
THYM	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.43	-0.49	4.24e-7	Mean corpuscular volume;
THYM	cis	rs36051895	0.695	rs2183137	chr9:5026293	A/G	cg02405213	chr9:5042618	JAK2	-1.02	-10.65	-0.74	6.83e-18	Pediatric autoimmune diseases;
THYM	cis	rs5753037	0.702	rs140143	chr22:30173109	G/T	cg27665648	chr22:30112403	NA	0.5	4.45	0.42	2.3e-5	Type 1 diabetes;
THYM	cis	rs71718386	1	rs71718386	chr13:41224287	CTATA/C	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Eosinophil counts;
THYM	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	cis	rs7586879	0.638	rs13035244	chr2:25134009	T/C	cg15423357	chr2:25149977	NA	0.7	7.76	0.62	9.56e-12	Body mass index;
THYM	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.27	5.56	0.5	2.45e-7	Obesity-related traits;
THYM	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.45	5.59	0.5	2.19e-7	Monocyte percentage of white cells;
THYM	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.81	-7.63	-0.62	1.83e-11	Intelligence (multi-trait analysis);
THYM	cis	rs3784262	0.616	rs2704197	chr15:58323236	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.64	-4.76	-0.44	6.84e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
THYM	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg18904891	chr8:8559673	CLDN23	0.68	5.08	0.46	1.89e-6	Obesity-related traits;
THYM	cis	rs11605275	1.000	rs16937347	chr11:20026717	A/G	cg14835545	chr11:20032148	NAV2	-1.22	-6.31	-0.54	8.99e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg13319975	chr6:146136371	FBXO30	0.61	4.92	0.45	3.68e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg26384229	chr12:38710491	ALG10B	0.97	7.47	0.61	3.8e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs57994353	0.861	rs34936112	chr9:139327062	G/A	cg24793265	chr9:139269240	CARD9	-0.56	-4.46	-0.42	2.21e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs9420	0.961	rs11605731	chr11:57524089	C/G	cg19752551	chr11:57585705	CTNND1	-0.73	-8.02	-0.64	2.79e-12	Schizophrenia;
THYM	cis	rs1775715	0.870	rs7095322	chr10:32248491	C/T	cg04359828	chr10:32216031	ARHGAP12	-0.39	-4.87	-0.45	4.38e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs7267979	1.000	rs2482940	chr20:25349830	C/T	cg08601574	chr20:25228251	PYGB	-0.58	-4.71	-0.43	8.54e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs89107	0.575	rs11153768	chr6:118988152	A/G	cg01113488	chr6:119027122	NA	-0.56	-4.96	-0.45	3.08e-6	Cardiac structure and function;
THYM	cis	rs3892630	0.619	rs61062732	chr19:33304717	T/C	cg22928329	chr19:33183273	NUDT19	-0.68	-5.38	-0.48	5.34e-7	Red blood cell traits;
THYM	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs6032067	0.714	rs3761192	chr20:43885764	C/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.57	-5.5	-0.49	3.17e-7	Blood protein levels;
THYM	cis	rs56161922	0.915	rs12562739	chr1:207856658	T/A	cg09557387	chr1:207818395	CR1L	1.15	5.31	0.48	7.12e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg09549813	chr16:4587862	C16orf5	-0.59	-6.65	-0.56	1.84e-9	Schizophrenia;
THYM	cis	rs6545977	1.000	rs6545977	chr2:63301164	G/A	cg17519650	chr2:63277830	OTX1	-0.82	-7.29	-0.6	9.18e-11	Prostate cancer;
THYM	cis	rs2131877	0.871	rs62290354	chr3:194867296	A/G	cg21937377	chr3:194868750	C3orf21	0.4	4.74	0.44	7.47e-6	Non-small cell lung cancer;
THYM	cis	rs2652822	0.525	rs2053633	chr15:63505649	G/A	cg09251291	chr15:63483946	RAB8B	0.53	4.89	0.45	4.04e-6	Metabolic traits;
THYM	cis	rs586688	0.625	rs481966	chr1:201655746	A/G	cg14168733	chr1:201708718	NAV1	-0.58	-5.38	-0.48	5.32e-7	Obesity-related traits;
THYM	cis	rs4654899	0.758	rs6697284	chr1:21295599	G/A	cg01072550	chr1:21505969	NA	-0.77	-7.5	-0.61	3.31e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs55665837	1.000	rs12364959	chr11:14507435	T/C	cg19336497	chr11:14380999	RRAS2	-0.64	-7.04	-0.59	3e-10	Vitamin D levels;
THYM	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg26818010	chr10:134567672	INPP5A	-0.94	-7.31	-0.6	8.33e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg12386194	chr3:101231763	SENP7	-0.96	-7.69	-0.62	1.34e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3741489	1.000	rs10161328	chr12:133481884	C/A	cg03157182	chr12:132655797	NA	-0.65	-4.73	-0.44	7.78e-6	Cognitive function;
THYM	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13012494	chr21:47604986	C21orf56	0.75	5.19	0.47	1.18e-6	Testicular germ cell tumor;
THYM	cis	rs3126085	0.935	rs7540844	chr1:152230586	A/T	cg10321714	chr1:152280068	FLG	0.64	4.81	0.44	5.57e-6	Atopic dermatitis;
THYM	cis	rs9595908	0.827	rs7321262	chr13:33172079	G/C	cg12383807	chr13:33924137	NA	-0.53	-4.74	-0.44	7.41e-6	Body mass index;
THYM	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs1978968	0.956	rs1110661	chr22:18444734	C/T	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs6541297	1.000	rs1998065	chr1:230286647	T/G	cg20703242	chr1:230279135	GALNT2	0.96	6.3	0.54	9.23e-9	Coronary artery disease;
THYM	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	7.66	0.62	1.54e-11	Platelet count;
THYM	cis	rs4595586	0.505	rs12823590	chr12:39399750	A/T	cg13010199	chr12:38710504	ALG10B	0.6	4.57	0.42	1.46e-5	Morning vs. evening chronotype;
THYM	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg24154853	chr7:158122151	PTPRN2	0.58	5.39	0.48	5.16e-7	Calcium levels;
THYM	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg27170947	chr2:26402098	FAM59B	-0.83	-6.71	-0.57	1.43e-9	Gut microbiome composition (summer);
THYM	cis	rs1003719	0.788	rs2835574	chr21:38455324	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.71	5.03	0.46	2.32e-6	Eye color traits;
THYM	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.43	1.27e-5	Breast cancer;
THYM	cis	rs6563842	0.528	rs56340348	chr13:41296371	C/T	cg21288729	chr13:41239152	FOXO1	0.68	5.14	0.47	1.49e-6	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
THYM	cis	rs4731207	0.564	rs10954060	chr7:124626037	G/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg07424592	chr7:64974309	NA	1.09	5.0	0.46	2.64e-6	Diabetic kidney disease;
THYM	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg18252515	chr7:66147081	NA	-1.57	-8.55	-0.66	2.07e-13	Diabetic kidney disease;
THYM	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg03433033	chr1:76189801	ACADM	-0.65	-6.44	-0.55	4.86e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg22875332	chr1:76189707	ACADM	0.87	10.87	0.74	2.34e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg25427524	chr10:38739819	LOC399744	-0.72	-6.63	-0.56	2.01e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs7078219	0.965	rs11190126	chr10:101271789	A/C	cg17888390	chr10:101282816	NA	-0.52	-4.95	-0.45	3.19e-6	Dental caries;
THYM	cis	rs2075230	0.589	rs2955610	chr17:7549601	G/A	cg27413385	chr17:7515425	FXR2	-0.36	-5.31	-0.48	7.3e-7	Hormone measurements;
THYM	cis	rs1214752	0.935	rs2396027	chr6:43389919	A/T	cg09674015	chr6:43045187	PTK7	-0.51	-4.79	-0.44	6.02e-6	Coronary artery disease;
THYM	trans	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg07211511	chr3:129823064	LOC729375	-1.3	-10.58	-0.74	9.7e-18	Blood pressure (smoking interaction);
THYM	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg07884673	chr3:53033167	SFMBT1	1.25	6.34	0.55	7.83e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7177699	0.557	rs9806363	chr15:79110302	A/G	cg15571903	chr15:79123663	NA	-0.59	-6.78	-0.57	9.9e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs4851266	0.832	rs10865037	chr2:100871361	T/C	cg14675211	chr2:100938903	LONRF2	0.67	5.58	0.5	2.22e-7	Educational attainment;
THYM	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg05368731	chr17:41323189	NBR1	1.29	11.93	0.77	1.37e-20	Menopause (age at onset);
THYM	cis	rs747782	0.646	rs61914719	chr11:48059091	C/T	cg24672777	chr11:48374446	OR4C45	-1.0	-5.35	-0.48	6.03e-7	Intraocular pressure;
THYM	cis	rs12817211	0.502	rs7961112	chr12:50513519	G/T	cg06168149	chr12:50497778	GPD1	0.3	4.54	0.42	1.65e-5	Colorectal or endometrial cancer;
THYM	cis	rs4595586	0.545	rs12816776	chr12:39375817	A/G	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs2213920	0.679	rs7862261	chr9:118187677	A/G	cg13918206	chr9:118159781	DEC1	0.86	4.9	0.45	3.86e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.22e-7	Corneal astigmatism;
THYM	cis	rs4849845	0.849	rs11893180	chr2:121018469	A/G	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs6754311	0.593	rs1446584	chr2:136419961	C/T	cg20242066	chr2:136595261	LCT	-0.55	-6.04	-0.53	3.05e-8	Mosquito bite size;
THYM	cis	rs7953508	0.711	rs11107117	chr12:93979419	T/C	cg18151635	chr12:93972918	NA	-0.75	-5.25	-0.47	9.34e-7	Pubertal anthropometrics;
THYM	cis	rs828999	0.688	rs10881513	chr1:108719199	C/A	cg24323958	chr1:108741884	SLC25A24	0.57	5.61	0.5	1.97e-7	Monocyte percentage of white cells;
THYM	cis	rs73086581	1.000	rs73086510	chr20:3922131	T/C	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	18.27	0.88	7.47e-33	Chronic sinus infection;
THYM	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs354225	0.544	rs13391522	chr2:54805854	T/C	cg23486701	chr2:54789491	SPTBN1	0.36	4.69	0.43	9.11e-6	Schizophrenia;
THYM	cis	rs2803122	0.745	rs9802945	chr9:19385222	T/A	cg19584733	chr9:19298547	DENND4C	0.58	4.9	0.45	3.88e-6	Pulse pressure;
THYM	trans	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg23505145	chr19:12996616	KLF1	1.01	10.01	0.72	1.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs34638657	0.732	rs62045963	chr16:82200661	A/G	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.11	-0.64	1.73e-12	Lung adenocarcinoma;
THYM	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs6430585	0.527	rs76622824	chr2:136411879	A/G	cg07169764	chr2:136633963	MCM6	0.97	8.76	0.67	7.3e-14	Corneal structure;
THYM	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg14829155	chr15:31115871	NA	-0.76	-6.47	-0.55	4.17e-9	Huntington's disease progression;
THYM	cis	rs7567389	0.573	rs11541137	chr2:128145771	C/T	cg09760422	chr2:128146352	NA	0.4	4.57	0.42	1.49e-5	Self-rated health;
THYM	cis	rs12291225	0.645	rs3763950	chr11:14278049	T/A	cg05501817	chr11:14380813	RRAS2	-0.74	-5.63	-0.5	1.82e-7	Sense of smell;
THYM	cis	rs17102423	0.654	rs8008095	chr14:65525794	A/G	cg11161011	chr14:65562177	MAX	-0.57	-4.79	-0.44	6.02e-6	Obesity-related traits;
THYM	cis	rs1639906	0.895	rs35038526	chr7:2213106	A/G	cg19897017	chr7:2163380	MAD1L1	-0.54	-5.02	-0.46	2.42e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	0.534	rs4710154	chr6:167394634	A/T	cg15592062	chr6:167189543	RPS6KA2	0.52	5.32	0.48	6.84e-7	Crohn's disease;
THYM	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg03709012	chr19:19516395	GATAD2A	0.84	7.26	0.6	1.05e-10	Tonsillectomy;
THYM	cis	rs295140	0.546	rs295134	chr2:201110223	A/G	cg03447810	chr2:200324230	SATB2	-0.62	-4.59	-0.43	1.37e-5	QT interval;
THYM	cis	rs9399401	0.601	rs9321870	chr6:142800758	A/T	cg03128060	chr6:142623767	GPR126	0.5	6.71	0.57	1.41e-9	Chronic obstructive pulmonary disease;
THYM	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg19196401	chr6:110721138	DDO	-0.62	-7.23	-0.6	1.21e-10	Platelet distribution width;
THYM	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg11526020	chr17:80870163	TBCD	0.46	4.46	0.42	2.23e-5	Glycated hemoglobin levels;
THYM	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg07636037	chr3:49044803	WDR6	0.87	6.39	0.55	6.07e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg10589385	chr1:150898437	SETDB1	0.6	4.82	0.44	5.42e-6	Melanoma;
THYM	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6992820	1.000	rs6992820	chr8:56764456	A/G	cg06880721	chr8:56792545	LYN	-0.59	-5.12	-0.46	1.62e-6	Mean platelet volume;
THYM	cis	rs7909791	0.743	rs11596104	chr10:105623461	C/A	cg24587175	chr10:105670608	OBFC1	0.7	6.63	0.56	2.03e-9	White matter hyperintensity burden;
THYM	cis	rs7119	0.717	rs11636412	chr15:77767291	C/T	cg10437265	chr15:77819839	NA	0.56	4.99	0.46	2.78e-6	Type 2 diabetes;
THYM	cis	rs8067545	0.750	rs4925069	chr17:19953531	C/G	cg13482628	chr17:19912719	NA	0.54	4.56	0.42	1.51e-5	Schizophrenia;
THYM	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg12292205	chr6:26970375	C6orf41	0.57	4.78	0.44	6.44e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg23791538	chr6:167370224	RNASET2	0.73	5.67	0.5	1.54e-7	Crohn's disease;
THYM	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg03806693	chr22:41940476	POLR3H	-1.18	-10.75	-0.74	4.12e-18	Vitiligo;
THYM	cis	rs36051895	0.659	rs1575285	chr9:5267440	A/G	cg02405213	chr9:5042618	JAK2	-0.92	-8.06	-0.64	2.24e-12	Pediatric autoimmune diseases;
THYM	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg26384229	chr12:38710491	ALG10B	1.02	8.22	0.64	1.05e-12	Bladder cancer;
THYM	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs2040771	0.770	rs9605962	chr22:19233615	C/T	cg02655711	chr22:19163373	SLC25A1	0.57	6.08	0.53	2.5e-8	Metabolite levels (small molecules and protein measures);
THYM	cis	rs6840360	0.617	rs2724563	chr4:152349959	G/C	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs600806	0.850	rs10858092	chr1:109943893	A/G	cg23616212	chr1:109941201	SORT1	0.51	4.75	0.44	7.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9875589	0.509	rs7636901	chr3:14030958	G/A	cg03204825	chr3:13978759	TPRXL	-0.57	-5.07	-0.46	1.95e-6	Ovarian reserve;
THYM	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg18131467	chr2:239335373	ASB1	1.1	10.84	0.74	2.74e-18	Multiple system atrophy;
THYM	cis	rs11264213	0.551	rs172081	chr1:36497498	T/G	cg27506609	chr1:36549197	TEKT2	1.36	5.2	0.47	1.12e-6	Schizophrenia;
THYM	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9914988	0.943	rs9890155	chr17:27125467	A/G	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg07424592	chr7:64974309	NA	-0.99	-5.15	-0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs860818	1.000	rs858292	chr7:23246733	T/C	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-5.4	-0.48	4.92e-7	Hemoglobin concentration;
THYM	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg02640540	chr1:67518911	SLC35D1	0.64	4.68	0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg27129171	chr3:47204927	SETD2	0.81	7.57	0.61	2.37e-11	Colorectal cancer;
THYM	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg12573674	chr2:1569213	NA	-1.35	-8.81	-0.67	5.84e-14	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg00012203	chr2:219082015	ARPC2	0.87	8.3	0.65	6.88e-13	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.01	0.52	3.47e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7119	0.700	rs2867311	chr15:77902191	A/C	cg10437265	chr15:77819839	NA	-0.47	-4.69	-0.43	9.07e-6	Type 2 diabetes;
THYM	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.7	0.71	7.32e-16	Colorectal cancer;
THYM	cis	rs9788682	0.747	rs8042494	chr15:78908010	C/T	cg18825076	chr15:78729989	IREB2	0.63	5.26	0.48	8.82e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg02018176	chr4:1364513	KIAA1530	0.7	6.36	0.55	7.08e-9	Longevity;
THYM	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg13531842	chr10:38383804	ZNF37A	-0.57	-4.7	-0.43	8.81e-6	Extrinsic epigenetic age acceleration;
THYM	cis	rs6570726	0.537	rs1280279	chr6:145884048	G/T	cg05347473	chr6:146136440	FBXO30	0.85	6.93	0.58	5.12e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8014204	0.743	rs35809608	chr14:75254762	A/G	cg06637938	chr14:75390232	RPS6KL1	0.56	5.49	0.49	3.27e-7	Caffeine consumption;
THYM	cis	rs11809207	0.951	rs111772533	chr1:26523404	C/G	cg03844060	chr1:26490628	NA	0.68	4.87	0.45	4.36e-6	Height;
THYM	cis	rs6496667	0.821	rs13329289	chr15:90897454	C/T	cg22089800	chr15:90895588	ZNF774	0.74	5.0	0.46	2.65e-6	Rheumatoid arthritis;
THYM	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg02753203	chr1:228287806	NA	-0.61	-5.15	-0.47	1.4e-6	Diastolic blood pressure;
THYM	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg13852791	chr20:30311386	BCL2L1	0.88	7.11	0.59	2.16e-10	Mean corpuscular hemoglobin;
THYM	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg24154853	chr7:158122151	PTPRN2	0.55	4.82	0.44	5.35e-6	Calcium levels;
THYM	cis	rs4478037	0.749	rs9681623	chr3:33131375	G/T	cg19404215	chr3:33155277	CRTAP	0.82	5.77	0.51	9.77e-8	Major depressive disorder;
THYM	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg26441486	chr22:50317300	CRELD2	-0.43	-6.71	-0.57	1.39e-9	Schizophrenia;
THYM	cis	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg09307838	chr4:120376055	NA	0.73	5.78	0.51	9.65e-8	Corneal astigmatism;
THYM	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.9	-7.84	-0.63	6.69e-12	Multiple sclerosis;
THYM	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg21775007	chr8:11205619	TDH	-0.73	-5.68	-0.5	1.49e-7	Neuroticism;
THYM	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg11764359	chr7:65958608	NA	-0.81	-6.92	-0.58	5.2400000000000005e-10	Aortic root size;
THYM	cis	rs2637266	0.518	rs2579721	chr10:78250890	T/C	cg18941641	chr10:78392320	NA	0.6	4.55	0.42	1.57e-5	Pulmonary function;
THYM	cis	rs4604732	0.631	rs7546720	chr1:247627229	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	4.54	0.42	1.64e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs733592	0.560	rs61918773	chr12:48421774	G/A	cg21466736	chr12:48725269	NA	0.44	4.53	0.42	1.74e-5	Plateletcrit;
THYM	cis	rs4925386	0.559	rs2427291	chr20:60921324	G/A	cg06026331	chr20:60912101	LAMA5	0.92	5.26	0.47	9.03e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs10089	0.909	rs7732599	chr5:127370421	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.97	6.65	0.56	1.82e-9	Ileal carcinoids;
THYM	cis	rs78579285	0.544	rs11549835	chr16:88781073	G/A	cg00973732	chr16:88803885	FAM38A	-0.88	-4.56	-0.42	1.51e-5	Joint mobility (Beighton score);
THYM	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg16624210	chr5:671434	TPPP	0.68	4.91	0.45	3.81e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs4343996	0.543	rs10224159	chr7:3420488	C/T	cg21248987	chr7:3385318	SDK1	0.41	5.06	0.46	2.07e-6	Motion sickness;
THYM	cis	rs2806561	0.929	rs2867315	chr1:23541286	C/T	cg12483005	chr1:23474871	LUZP1	-0.55	-5.65	-0.5	1.66e-7	Height;
THYM	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs12291225	0.585	rs34171876	chr11:14353957	G/C	cg05501817	chr11:14380813	RRAS2	-0.8	-6.64	-0.56	1.91e-9	Sense of smell;
THYM	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg03474202	chr17:45855739	NA	-0.74	-6.5	-0.55	3.7e-9	IgG glycosylation;
THYM	cis	rs4940575	0.679	rs17070777	chr18:60833814	A/C	cg25271770	chr18:61057090	VPS4B	0.78	4.68	0.43	9.43e-6	Breast cancer;
THYM	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg12310025	chr6:25882481	NA	-1.05	-9.27	-0.69	6.1e-15	Intelligence (multi-trait analysis);
THYM	cis	rs6723226	0.803	rs176415	chr2:32649778	G/A	cg02381751	chr2:32503542	YIPF4	-0.65	-5.69	-0.5	1.43e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6089584	0.587	rs3787423	chr20:60555485	G/A	cg06108461	chr20:60628389	TAF4	-0.79	-6.32	-0.54	8.42e-9	Body mass index;
THYM	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg11266682	chr4:10021025	SLC2A9	0.71	10.4	0.73	2.26e-17	Bone mineral density;
THYM	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg04267008	chr7:1944627	MAD1L1	0.63	5.21	0.47	1.09e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg01416388	chr22:39784598	NA	-0.95	-9.15	-0.68	1.11e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.69	4.67	0.43	9.8200000000000008e-06	Lung cancer in ever smokers;
THYM	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9462846	0.853	rs34455103	chr6:42875128	C/G	cg09436375	chr6:42928200	GNMT	-0.37	-4.51	-0.42	1.82e-5	Blood protein levels;
THYM	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.87	0.45	4.53e-6	Bipolar disorder;
THYM	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg18681998	chr4:17616180	MED28	0.88	8.21	0.64	1.09e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs113835537	0.529	rs17065	chr11:66277035	G/A	cg10315249	chr11:66235081	PELI3	0.42	4.53	0.42	1.69e-5	Airway imaging phenotypes;
THYM	cis	rs6748734	0.625	rs7598309	chr2:241824876	A/T	cg02820040	chr2:241836501	C2orf54	-0.24	-4.54	-0.42	1.67e-5	Urinary metabolites;
THYM	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg00012203	chr2:219082015	ARPC2	-0.69	-5.87	-0.52	6.36e-8	Colorectal cancer;
THYM	cis	rs1883415	0.727	rs2245674	chr6:24501421	C/T	cg00346970	chr6:24499591	ALDH5A1	0.39	5.08	0.46	1.89e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg00631329	chr6:26305371	NA	-0.61	-7.35	-0.6	6.96e-11	Educational attainment;
THYM	cis	rs11625487	0.957	rs28820314	chr14:77963272	A/C	cg20045696	chr14:77926864	AHSA1	-0.71	-4.94	-0.45	3.38e-6	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
THYM	cis	rs6430585	0.528	rs309122	chr2:136761853	A/G	cg04750100	chr2:136595281	LCT	0.53	5.67	0.5	1.53e-7	Corneal structure;
THYM	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs34779708	0.931	rs4934721	chr10:35377715	A/G	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg10518543	chr12:38710700	ALG10B	-0.57	-4.59	-0.43	1.36e-5	Morning vs. evening chronotype;
THYM	cis	rs2219968	0.746	rs10957878	chr8:78910939	A/C	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg17366294	chr4:99064904	C4orf37	0.52	6.05	0.53	2.92e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs995000	0.931	rs1168089	chr1:63113719	T/C	cg06896770	chr1:63153194	DOCK7	-0.92	-7.54	-0.61	2.71e-11	Triglyceride levels;
THYM	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg05313129	chr8:58192883	C8orf71	-0.73	-4.47	-0.42	2.18e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs1023500	1.000	rs3752591	chr22:42339516	A/G	cg19448990	chr22:41842841	TOB2	-0.73	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	cis	rs2354432	0.556	rs7516165	chr1:146866418	G/T	cg25205988	chr1:146714368	CHD1L	0.99	4.64	0.43	1.13e-5	Mitochondrial DNA levels;
THYM	cis	rs7582180	0.903	rs6755791	chr2:100895872	G/A	cg12772821	chr2:101768258	TBC1D8	0.59	4.53	0.42	1.75e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg25427524	chr10:38739819	LOC399744	0.66	5.58	0.5	2.26e-7	Extrinsic epigenetic age acceleration;
THYM	cis	rs4731207	0.623	rs34865746	chr7:124639919	T/A	cg05285228	chr7:124571219	POT1	-0.68	-5.08	-0.46	1.88e-6	Cutaneous malignant melanoma;
THYM	cis	rs6121246	0.559	rs6060962	chr20:30397847	A/G	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs4660306	0.744	rs11211114	chr1:45926243	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.61	4.53	0.42	1.73e-5	Homocysteine levels;
THYM	cis	rs7582180	0.627	rs6542947	chr2:100999647	C/G	cg21926883	chr2:100939477	LONRF2	0.65	6.12	0.53	2.11e-8	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg23187316	chr7:1099788	C7orf50	0.48	5.45	0.49	3.98e-7	Longevity;Endometriosis;
THYM	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg10856724	chr12:34555212	NA	-0.89	-7.85	-0.63	6.11e-12	Bladder cancer;
THYM	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg23758822	chr17:41437982	NA	1.22	12.95	0.8	1.06e-22	Menopause (age at onset);
THYM	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.95	6.56	0.56	2.87e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6840360	0.571	rs17360371	chr4:152565374	C/T	cg17479576	chr4:152424074	FAM160A1	-0.79	-5.43	-0.49	4.39e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6430585	0.583	rs3087343	chr2:136622543	T/G	cg04750100	chr2:136595281	LCT	0.57	5.29	0.48	7.86e-7	Corneal structure;
THYM	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg27494647	chr7:150038898	RARRES2	0.41	4.6	0.43	1.31e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs977987	0.843	rs28558946	chr16:75489322	G/T	cg03315344	chr16:75512273	CHST6	0.73	5.99	0.52	3.73e-8	Dupuytren's disease;
THYM	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg09549813	chr16:4587862	C16orf5	-0.59	-6.65	-0.56	1.84e-9	Schizophrenia;
THYM	cis	rs4788570	0.667	rs9929840	chr16:71800942	C/T	cg06353428	chr16:71660113	MARVELD3	-1.42	-8.29	-0.65	7.34e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4363385	0.791	rs10788855	chr1:153002359	A/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg10150615	chr22:24372951	LOC391322	-1.01	-11.54	-0.76	9.13e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	8.56	0.66	1.98e-13	Cognitive test performance;
THYM	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2282526	0.587	rs91424	chr21:44921161	A/G	cg01579765	chr21:45077557	HSF2BP	0.41	5.38	0.48	5.29e-7	Mean corpuscular hemoglobin;
THYM	cis	rs6732160	0.845	rs6546809	chr2:73389681	A/C	cg24220031	chr2:73402428	NA	-0.79	-8.39	-0.65	4.59e-13	Intelligence (multi-trait analysis);
THYM	cis	rs67981189	0.821	rs12896370	chr14:71521340	C/T	cg15910301	chr14:71632612	NA	0.51	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs10779751	0.960	rs4845860	chr1:11324193	A/G	cg08854313	chr1:11322531	MTOR	0.92	7.85	0.63	6.38e-12	Body mass index;
THYM	cis	rs6956675	1.000	rs4718791	chr7:62577991	G/C	cg27518014	chr7:62859535	LOC100287834	0.64	4.96	0.45	3.15e-6	Obesity-related traits;
THYM	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg11752832	chr7:134001865	SLC35B4	0.78	5.71	0.51	1.28e-7	Mean platelet volume;
THYM	trans	rs4650994	1.000	rs4650999	chr1:178532188	A/C	cg05059571	chr16:84539110	KIAA1609	0.77	8.51	0.66	2.51e-13	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs709400	1.000	rs861539	chr14:104165753	G/A	cg26031613	chr14:104095156	KLC1	1.24	12.59	0.79	5.9e-22	Body mass index;
THYM	cis	rs4722166	0.630	rs1829927	chr7:22779918	G/A	cg05472934	chr7:22766657	IL6	0.73	5.55	0.49	2.62e-7	Lung cancer;
THYM	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg09354556	chr3:47051341	NA	0.46	4.71	0.44	8.28e-6	Colorectal cancer;
THYM	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg14798641	chr3:49314920	USP4;C3orf62	-0.66	-4.63	-0.43	1.17e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs901683	1.000	rs9422655	chr10:46051408	T/C	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs6032067	0.714	rs6032075	chr20:43884340	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.59	-5.71	-0.51	1.29e-7	Blood protein levels;
THYM	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg07636037	chr3:49044803	WDR6	0.87	7.94	0.63	4.12e-12	Parkinson's disease;
THYM	cis	rs6032067	0.929	rs2267864	chr20:43805279	C/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.31	-0.48	7.18e-7	Blood protein levels;
THYM	cis	rs2836633	0.895	rs2836598	chr21:40024758	C/G	cg05519781	chr21:40033154	ERG	0.7	6.7	0.57	1.49e-9	Coronary artery disease;
THYM	cis	rs7772486	0.869	rs2777473	chr6:146301494	G/A	cg23711669	chr6:146136114	FBXO30	0.87	8.67	0.66	1.16e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7809950	1.000	rs2808	chr7:107260856	A/G	cg23024343	chr7:107201750	COG5	0.9	7.78	0.62	8.57e-12	Coronary artery disease;
THYM	cis	rs72828912	0.764	rs9379639	chr6:24090993	T/A	cg26336265	chr6:25042955	NA	-0.88	-5.55	-0.49	2.6e-7	Squamous cell lung carcinoma;
THYM	cis	rs870825	0.616	rs9631783	chr4:185626511	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	7.32	0.6	7.96e-11	Platelet count;
THYM	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs7781977	0.782	rs1993444	chr7:50338499	G/A	cg14216940	chr7:50343131	IKZF1	0.55	4.63	0.43	1.15e-5	IgG glycosylation;
THYM	cis	rs4788815	0.552	rs7187129	chr16:71861444	T/C	cg06353428	chr16:71660113	MARVELD3	0.73	5.26	0.47	8.97e-7	Metabolite levels;
THYM	cis	rs12188164	0.747	rs12188321	chr5:428418	C/G	cg16294152	chr5:418696	AHRR	-0.6	-5.26	-0.48	8.78e-7	Cystic fibrosis severity;
THYM	cis	rs9291683	0.679	rs2278122	chr4:10096241	T/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-7.93	-0.63	4.28e-12	Bone mineral density;
THYM	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.67	9.16	0.68	1.04e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7296418	0.630	rs7974099	chr12:123771475	A/G	cg00376283	chr12:123451042	ABCB9	0.79	6.38	0.55	6.44e-9	Platelet count;
THYM	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs10899021	1.000	rs11236190	chr11:74366755	G/T	cg25880958	chr11:74394337	NA	-0.74	-4.54	-0.42	1.64e-5	Response to metformin (IC50);
THYM	cis	rs977987	0.778	rs4888400	chr16:75425596	G/C	cg03315344	chr16:75512273	CHST6	0.73	6.16	0.53	1.73e-8	Dupuytren's disease;
THYM	cis	rs6500395	1.000	rs7190106	chr16:48705542	C/T	cg04672837	chr16:48644449	N4BP1	0.52	5.15	0.47	1.39e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg10047753	chr17:41438598	NA	0.99	7.4	0.6	5.45e-11	Menopause (age at onset);
THYM	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs2067615	0.524	rs7959062	chr12:107107334	G/T	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	trans	rs8073060	0.586	rs6505486	chr17:33996776	G/A	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs12496230	0.855	rs1036971	chr3:66850677	T/A	cg17646820	chr3:66848679	NA	0.84	4.86	0.45	4.56e-6	Type 2 diabetes;
THYM	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs7119038	0.865	rs7117261	chr11:118741157	T/C	cg19308663	chr11:118741387	NA	-0.59	-5.67	-0.5	1.5e-7	Sjögren's syndrome;
THYM	cis	rs10186029	0.657	rs11689895	chr2:213938553	G/T	cg08319019	chr2:214017104	IKZF2	0.81	6.91	0.58	5.54e-10	Systemic sclerosis;
THYM	cis	rs2115630	1.000	rs6496441	chr15:85363348	A/G	cg11189052	chr15:85197271	WDR73	-0.58	-4.45	-0.42	2.3e-5	P wave terminal force;
THYM	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg01341218	chr17:43662625	NA	-0.88	-7.68	-0.62	1.44e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg12379764	chr21:47803548	PCNT	-0.71	-4.7	-0.43	8.84e-6	Testicular germ cell tumor;
THYM	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg16624210	chr5:671434	TPPP	-0.64	-6.62	-0.56	2.15e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs34638657	0.732	rs12102917	chr16:82196808	G/A	cg07307142	chr16:82071433	HSD17B2	-0.8	-7.29	-0.6	9.26e-11	Lung adenocarcinoma;
THYM	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs4474465	1.000	rs4945281	chr11:78188627	C/G	cg19901956	chr11:77921274	USP35	-0.6	-4.54	-0.42	1.66e-5	Alzheimer's disease (survival time);
THYM	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg05043794	chr9:111880884	C9orf5	-0.39	-5.67	-0.5	1.51e-7	Menarche (age at onset);
THYM	trans	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg10856724	chr12:34555212	NA	-0.99	-8.92	-0.68	3.37e-14	Bladder cancer;
THYM	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg05335186	chr13:53173507	NA	-0.47	-5.51	-0.49	3.05e-7	Lewy body disease;
THYM	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg15744692	chr15:45671195	LOC145663;GATM	0.44	4.46	0.42	2.22e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs4889855	0.530	rs12946972	chr17:78618922	A/G	cg16591659	chr17:78472290	NA	-0.4	-5.09	-0.46	1.83e-6	Fractional excretion of uric acid;
THYM	cis	rs62064224	0.589	rs9910731	chr17:30784034	A/G	cg18200150	chr17:30822561	MYO1D	0.54	4.52	0.42	1.81e-5	Schizophrenia;
THYM	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.71	-7.66	-0.62	1.54e-11	Crohn's disease;
THYM	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg12310025	chr6:25882481	NA	0.68	5.56	0.5	2.47e-7	Schizophrenia;
THYM	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg04455712	chr21:45112962	RRP1B	0.55	5.14	0.47	1.46e-6	Mean corpuscular volume;
THYM	cis	rs654128	0.640	rs339333	chr6:117211809	T/G	cg12892004	chr6:117198278	RFX6	-0.72	-5.66	-0.5	1.61e-7	Telomere length;
THYM	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-4.55	-0.42	1.59e-5	Tonsillectomy;
THYM	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg23711669	chr6:146136114	FBXO30	0.8	7.12	0.59	2.02e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs6988636	1.000	rs61422480	chr8:124188940	C/A	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs10203711	0.966	rs4293520	chr2:239567184	A/C	cg14580085	chr2:239553406	NA	0.68	6.18	0.54	1.6e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs490234	0.756	rs6478705	chr9:128216326	G/T	cg14078157	chr9:128172775	NA	-0.71	-5.61	-0.5	1.95e-7	Mean arterial pressure;
THYM	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11644478	chr21:40555479	PSMG1	-0.76	-6.49	-0.55	3.85e-9	Cognitive function;
THYM	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs629535	0.773	rs655299	chr8:70074534	C/T	cg21567404	chr3:27674614	NA	1.08	10.14	0.72	8.19e-17	Dupuytren's disease;
THYM	cis	rs548181	0.621	rs2912098	chr11:125528569	C/T	cg03464685	chr11:125439445	EI24	1.24	7.56	0.61	2.49e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg18252515	chr7:66147081	NA	0.6	4.52	0.42	1.76e-5	Aortic root size;
THYM	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg11764359	chr7:65958608	NA	0.81	6.42	0.55	5.45e-9	Aortic root size;
THYM	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg23711669	chr6:146136114	FBXO30	0.96	9.87	0.71	3.12e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg21784768	chr11:537496	LRRC56	-1.37	-6.17	-0.53	1.7e-8	Body mass index;
THYM	cis	rs16917546	1.000	rs7094595	chr10:64415413	T/A	cg03961010	chr10:64397487	ZNF365	-0.81	-6.91	-0.58	5.62e-10	Basal cell carcinoma;
THYM	cis	rs6684428	0.706	rs12118218	chr1:56320445	C/T	cg11651538	chr1:56320950	NA	-0.65	-5.23	-0.47	9.97e-7	Airflow obstruction;
THYM	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg14349672	chr11:133703707	NA	0.52	4.48	0.42	2.04e-5	Childhood ear infection;
THYM	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg08439880	chr3:133502540	NA	-0.73	-6.46	-0.55	4.44e-9	Iron status biomarkers;
THYM	cis	rs2505998	0.833	rs12767776	chr10:43589513	G/A	cg06632098	chr10:43605906	RET	-1.1	-10.64	-0.74	7.21e-18	Hirschsprung disease;
THYM	cis	rs6754311	0.593	rs4954280	chr2:136420690	C/T	cg20242066	chr2:136595261	LCT	-0.54	-5.99	-0.52	3.8e-8	Mosquito bite size;
THYM	cis	rs8016982	0.674	rs3815953	chr14:81685482	G/A	cg21807262	chr14:81713016	NA	-0.58	-5.39	-0.48	5.05e-7	Schizophrenia;
THYM	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.63	-4.48	-0.42	2.05e-5	Gut microbiome composition (summer);
THYM	cis	rs11031096	0.678	rs11031220	chr11:4197638	G/A	cg08557956	chr11:4115526	RRM1	-0.59	-5.44	-0.49	4.19e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	7.11	0.59	2.1e-10	Platelet count;
THYM	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg02527881	chr3:46936655	PTH1R	0.54	5.21	0.47	1.1e-6	Colorectal cancer;
THYM	cis	rs2718058	0.692	rs2709117	chr7:37787807	A/G	cg15028436	chr7:37888078	TXNDC3	0.61	4.58	0.43	1.4e-5	Alzheimer's disease (late onset);
THYM	cis	rs2041895	0.565	rs10861679	chr12:107322915	T/C	cg26297688	chr12:107349093	C12orf23	-0.5	-5.5	-0.49	3.13e-7	Glaucoma (low intraocular pressure);
THYM	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs7267979	0.873	rs7453	chr20:25207074	A/G	cg03522245	chr20:25566470	NINL	0.69	5.3	0.48	7.35e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7584330	0.554	rs10173100	chr2:238433040	A/G	cg08992911	chr2:238395768	MLPH	0.88	5.73	0.51	1.17e-7	Prostate cancer;
THYM	cis	rs3820068	0.524	rs34094056	chr1:15824154	G/T	cg05660106	chr1:15850417	CASP9	1.12	9.88	0.71	3.03e-16	Systolic blood pressure;
THYM	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03517284	chr6:25882590	NA	-0.98	-8.6	-0.66	1.64e-13	Intelligence (multi-trait analysis);
THYM	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg26818010	chr10:134567672	INPP5A	-0.76	-6.34	-0.55	7.66e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs4718428	0.705	rs4718430	chr7:66432024	G/T	cg12165864	chr7:66369176	NA	-0.78	-5.49	-0.49	3.37e-7	Corneal structure;
THYM	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg01528321	chr10:82214614	TSPAN14	0.63	5.29	0.48	7.7300000000000005e-07	Post bronchodilator FEV1;
THYM	cis	rs3857067	0.806	rs2171384	chr4:95103545	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs714031	0.785	rs11704439	chr22:40069493	T/G	cg21377881	chr22:40064566	CACNA1I	-0.62	-5.29	-0.48	7.83e-7	Schizophrenia;
THYM	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg21605333	chr4:119757512	SEC24D	1.39	5.52	0.49	2.94e-7	Cannabis dependence symptom count;
THYM	cis	rs7705502	0.779	rs56176106	chr5:173296896	C/T	cg18693985	chr5:173351052	CPEB4	-0.79	-5.72	-0.51	1.24e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	trans	rs2136093	0.666	rs10922854	chr1:90860149	A/G	cg21057494	chr3:45066971	CLEC3B	0.54	7.14	0.59	1.87e-10	Response to antidepressants;
THYM	cis	rs11031096	0.727	rs12290828	chr11:4144867	C/G	cg18678763	chr11:4115507	RRM1	-0.38	-5.17	-0.47	1.27e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs3008870	0.583	rs3008892	chr1:67373558	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.72	4.65	0.43	1.07e-5	Lymphocyte percentage of white cells;
THYM	cis	rs17253792	0.822	rs76555508	chr14:56071868	A/G	cg01858014	chr14:56050164	KTN1	-1.22	-5.13	-0.47	1.52e-6	Putamen volume;
THYM	cis	rs11651000	0.761	rs11079788	chr17:45820723	C/T	cg24803719	chr17:45855879	NA	-0.54	-5.58	-0.5	2.29e-7	IgG glycosylation;
THYM	cis	rs981844	0.712	rs1037650	chr4:154737657	G/A	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-4.73	-0.44	7.65e-6	Alzheimer's disease;
THYM	cis	rs924712	0.506	rs62412647	chr6:54711704	A/G	cg19716238	chr6:54711378	FAM83B	-0.47	-4.49	-0.42	1.99e-5	Breast cancer;
THYM	cis	rs240764	0.717	rs183566	chr6:101142605	A/T	cg21058520	chr6:100914733	NA	-0.55	-4.7	-0.43	8.96e-6	Neuroticism;
THYM	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg16524936	chr4:1340807	KIAA1530	-0.67	-5.19	-0.47	1.19e-6	Longevity;
THYM	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg11663144	chr21:46675770	NA	-0.51	-6.34	-0.55	7.67e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs642803	1.000	rs557675	chr11:65566719	G/T	cg27068330	chr11:65405492	SIPA1	-0.69	-5.57	-0.5	2.35e-7	Urate levels;
THYM	cis	rs6032067	0.929	rs2233898	chr20:43850525	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.5	-0.49	3.14e-7	Blood protein levels;
THYM	cis	rs71508903	0.542	rs10821944	chr10:63785089	G/T	cg07520810	chr10:63809149	ARID5B	-0.24	-4.47	-0.42	2.18e-5	Vitiligo;Rheumatoid arthritis;
THYM	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg15744005	chr10:104629667	AS3MT	-0.86	-8.2	-0.64	1.16e-12	Arsenic metabolism;
THYM	cis	rs35264875	1.000	rs72919415	chr11:68827082	G/A	cg23845249	chr11:68861649	NA	0.54	5.48	0.49	3.53e-7	Blond vs. brown hair color;
THYM	cis	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg10856724	chr12:34555212	NA	-0.79	-7.41	-0.61	5.14e-11	Morning vs. evening chronotype;
THYM	cis	rs8078723	0.677	rs11658328	chr17:38149236	T/C	cg17467752	chr17:38218738	THRA	-0.8	-6.7	-0.57	1.46e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg12179176	chr11:130786555	SNX19	0.86	8.24	0.65	9.58e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4866334	1.000	rs76259459	chr5:18456963	A/T	cg18608440	chr5:17519013	NA	1.16	5.19	0.47	1.17e-6	IgG glycosylation;
THYM	cis	rs6060717	0.610	rs6060755	chr20:34606915	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-4.58	-0.42	1.43e-5	Hip circumference adjusted for BMI;
THYM	cis	rs9563576	0.735	rs9634880	chr13:58613296	T/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs10174077	0.687	rs10172023	chr2:152476028	C/G	cg06191203	chr2:152266755	RIF1	-0.78	-5.07	-0.46	1.95e-6	Squamous cell lung carcinoma;
THYM	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.45	4.56	0.42	1.55e-5	Mean corpuscular volume;
THYM	cis	rs12579753	0.871	rs10862362	chr12:82199383	T/G	cg21231944	chr12:82153410	PPFIA2	-0.66	-5.01	-0.46	2.51e-6	Resting heart rate;
THYM	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7119	0.717	rs12915548	chr15:77818042	A/G	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs7512552	0.839	rs17597088	chr1:150475772	A/G	cg15654264	chr1:150340011	RPRD2	0.45	5.2	0.47	1.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.58	-4.83	-0.44	5.18e-6	Renal function-related traits (BUN);
THYM	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg18681998	chr4:17616180	MED28	1.0	10.24	0.72	5.04e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs853679	1.000	rs1778508	chr6:28229881	C/T	cg17849569	chr6:28058911	ZSCAN12L1	-0.71	-4.55	-0.42	1.6e-5	Depression;
THYM	cis	rs8018808	1.000	rs176767	chr14:77865614	A/G	cg20045696	chr14:77926864	AHSA1	0.53	4.73	0.44	7.91e-6	Myeloid white cell count;
THYM	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg10360139	chr7:1886902	MAD1L1	-0.62	-5.45	-0.49	3.96e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg20607798	chr8:58055168	NA	0.83	4.68	0.43	9.53e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg24818145	chr4:99064322	C4orf37	0.82	6.46	0.55	4.38e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17401966	1.000	rs12132635	chr1:10430479	G/A	cg20482658	chr1:10539492	PEX14	0.39	4.72	0.44	8.05e-6	Hepatocellular carcinoma;
THYM	cis	rs7546094	1.000	rs7415820	chr1:113169449	G/A	cg22162597	chr1:113214053	CAPZA1	-0.48	-4.91	-0.45	3.81e-6	Platelet distribution width;
THYM	cis	rs1003719	0.708	rs3787788	chr21:38502804	G/A	cg01329690	chr21:38580129	DSCR9	-0.38	-5.21	-0.47	1.09e-6	Eye color traits;
THYM	cis	rs4930776	1.000	rs251778	chr12:5774124	C/T	cg02086166	chr12:5775618	ANO2	0.57	5.52	0.49	2.89e-7	Plasma clusterin levels;
THYM	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg09455208	chr3:40491958	NA	0.5	5.24	0.47	9.76e-7	Renal cell carcinoma;
THYM	cis	rs1461503	0.966	rs1461502	chr11:122844927	C/G	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg07519536	chr6:26501950	BTN1A1	0.56	5.16	0.47	1.36e-6	Intelligence (multi-trait analysis);
THYM	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg24578937	chr1:2090814	PRKCZ	0.81	8.54	0.66	2.22e-13	Height;
THYM	cis	rs7551222	0.752	rs4951398	chr1:204531876	T/C	cg20240347	chr1:204465584	NA	-0.54	-4.94	-0.45	3.36e-6	Schizophrenia;
THYM	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg04856117	chr22:19949901	COMT	0.49	5.83	0.51	7.71e-8	Blood metabolite levels;
THYM	cis	rs995000	0.965	rs1168022	chr1:63007721	A/T	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs3771570	1.000	rs6752050	chr2:242228780	T/C	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs10895275	0.961	rs7122907	chr11:102085782	G/T	cg24447756	chr11:102105824	NA	-0.53	-4.74	-0.44	7.59e-6	Migraine;
THYM	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg21280719	chr6:42927975	GNMT	-0.52	-7.17	-0.59	1.63e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs675209	0.638	rs6912908	chr6:7080522	C/T	cg23726566	chr6:7051754	NA	-0.6	-4.49	-0.42	1.98e-5	Urate levels;
THYM	cis	rs7809950	0.723	rs62483633	chr7:106876644	T/G	cg23024343	chr7:107201750	COG5	-1.0	-8.43	-0.65	3.79e-13	Coronary artery disease;
THYM	cis	rs36051895	0.632	rs966871	chr9:5121070	A/T	cg02405213	chr9:5042618	JAK2	-1.04	-11.85	-0.77	1.96e-20	Pediatric autoimmune diseases;
THYM	cis	rs7799006	0.634	rs34502289	chr7:2311266	G/A	cg08027265	chr7:2291960	NA	-0.4	-4.53	-0.42	1.7e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs3892630	0.824	rs34748593	chr19:33240447	T/C	cg02283691	chr19:33182526	NUDT19	-0.41	-4.85	-0.45	4.83e-6	Red blood cell traits;
THYM	cis	rs9500256	0.967	rs1012500	chr6:58304669	G/A	cg03371099	chr6:57305889	PRIM2	-0.53	-4.74	-0.44	7.37e-6	Eosinophilic esophagitis (pediatric);
THYM	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg07511668	chr11:68622177	NA	0.43	4.5	0.42	1.94e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg09338302	chr7:1325757	NA	0.48	4.5	0.42	1.96e-5	Bipolar disorder;
THYM	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg12031863	chr16:4587854	C16orf5	-0.46	-4.96	-0.45	3.09e-6	Schizophrenia;
THYM	cis	rs250677	0.522	rs891920	chr5:148369418	G/T	cg18129178	chr5:148520854	ABLIM3	-0.72	-5.38	-0.48	5.29e-7	Breast cancer;
THYM	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg00677455	chr12:58241039	CTDSP2	0.66	4.45	0.42	2.32e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3804749	0.966	rs2278668	chr3:122835232	T/C	cg26084141	chr3:122786895	PDIA5	0.45	4.54	0.42	1.62e-5	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs758324	0.732	rs152055	chr5:131518843	T/C	cg16205897	chr5:131564050	P4HA2	0.61	5.11	0.46	1.64e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs7828089	0.504	rs12676477	chr8:22266425	T/C	cg13512537	chr8:22265999	SLC39A14	-0.67	-5.57	-0.5	2.39e-7	Verbal declarative memory;
THYM	cis	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs7216064	1.000	rs7210027	chr17:65977053	C/T	cg12091567	chr17:66097778	LOC651250	0.74	5.23	0.47	1.02e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs308403	0.608	rs309368	chr4:123662997	A/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.7	4.85	0.45	4.73e-6	Blood protein levels;
THYM	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg12031863	chr16:4587854	C16orf5	-0.46	-4.79	-0.44	6.24e-6	Schizophrenia;
THYM	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg00278107	chr5:1061253	SLC12A7	-0.84	-7.65	-0.62	1.6e-11	QT interval;
THYM	cis	rs12367572	1.000	rs12822444	chr12:45276677	G/A	cg03114573	chr12:45410052	DBX2	-0.53	-4.92	-0.45	3.69e-6	Gut microbiome composition (summer);
THYM	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg03709012	chr19:19516395	GATAD2A	0.84	7.3	0.6	8.83e-11	Tonsillectomy;
THYM	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg24578937	chr1:2090814	PRKCZ	0.79	7.98	0.63	3.3e-12	Height;
THYM	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg26354017	chr1:205819088	PM20D1	0.69	4.85	0.45	4.9e-6	Parkinson's disease;
THYM	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg00786635	chr1:25594202	NA	-0.92	-7.28	-0.6	9.7e-11	Erythrocyte sedimentation rate;
THYM	cis	rs28595532	0.920	rs56389935	chr4:119683571	G/A	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs2346160	0.899	rs1736585	chr6:167688325	G/A	cg21686812	chr6:168078911	NA	-0.51	-4.68	-0.43	9.65e-6	Parental extreme longevity (95 years and older);
THYM	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06634786	chr22:41940651	POLR3H	-0.77	-5.78	-0.51	9.34e-8	Vitiligo;
THYM	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg13683864	chr3:40499215	RPL14	1.07	12.42	0.79	1.31e-21	Renal cell carcinoma;
THYM	cis	rs7000551	0.671	rs11775262	chr8:22291265	C/G	cg12081754	chr8:22256438	SLC39A14	0.95	8.38	0.65	4.69e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg19761014	chr17:28927070	LRRC37B2	0.89	4.93	0.45	3.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs28595532	0.920	rs114547492	chr4:119773078	G/C	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs2795502	0.564	rs72777186	chr10:43430464	C/T	cg08461752	chr10:43522343	NA	-0.73	-4.49	-0.42	2e-5	Blood protein levels;
THYM	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg04731861	chr2:219085781	ARPC2	0.54	5.12	0.47	1.59e-6	Colorectal cancer;
THYM	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs12765878	1.000	rs12765878	chr10:105669622	C/T	cg11005552	chr10:105648138	OBFC1	-0.87	-11.25	-0.76	3.73e-19	Coronary artery disease;
THYM	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg22709100	chr7:91322751	NA	0.62	4.85	0.45	4.77e-6	Breast cancer;
THYM	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg20891283	chr12:69753455	YEATS4	1.09	12.03	0.78	8.44e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs3741151	1.000	rs75912489	chr11:73073846	G/A	cg17517138	chr11:73019481	ARHGEF17	1.0	5.89	0.52	5.75e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.19	0.59	1.47e-10	Obesity-related traits;
THYM	cis	rs67460515	0.563	rs13256	chr3:160796505	G/A	cg03342759	chr3:160939853	NMD3	-0.64	-4.54	-0.42	1.62e-5	Parkinson's disease;
THYM	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	1.04	13.45	0.81	1.02e-23	Subjective well-being;
THYM	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg06618935	chr21:46677482	NA	-0.98	-9.5	-0.7	1.95e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7267979	1.000	rs6050602	chr20:25401203	A/G	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs11048434	0.736	rs1805733	chr12:9089272	A/C	cg13575925	chr12:9217583	LOC144571	0.52	4.94	0.45	3.32e-6	Sjögren's syndrome;
THYM	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg00631329	chr6:26305371	NA	-0.72	-7.52	-0.61	3.12e-11	Educational attainment;
THYM	cis	rs11030122	0.702	rs10835312	chr11:3950253	G/A	cg18678763	chr11:4115507	RRM1	-0.44	-5.73	-0.51	1.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg14768367	chr16:72042858	DHODH	0.65	4.98	0.46	2.83e-6	Fibrinogen levels;
THYM	cis	rs4891159	0.570	rs690132	chr18:74117261	T/C	cg24786174	chr18:74118243	ZNF516	0.97	14.75	0.83	2.65e-26	Longevity;
THYM	cis	rs490234	0.783	rs7852065	chr9:128462023	T/C	cg14078157	chr9:128172775	NA	-0.68	-5.37	-0.48	5.57e-7	Mean arterial pressure;
THYM	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg27129171	chr3:47204927	SETD2	-0.72	-6.82	-0.57	8.56e-10	Colorectal cancer;
THYM	cis	rs42648	0.837	rs10262603	chr7:89909442	G/A	cg25739043	chr7:89950458	NA	-0.53	-4.53	-0.42	1.72e-5	Homocysteine levels;
THYM	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg16680214	chr1:154839983	KCNN3	-0.45	-5.17	-0.47	1.28e-6	Prostate cancer;
THYM	trans	rs4866334	1.000	rs76306109	chr5:18481141	A/C	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs11711311	0.955	rs9851812	chr3:113412362	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.56	-4.75	-0.44	7.12e-6	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs977102	0.556	rs66649021	chr3:67358230	C/T	cg06096184	chr3:66549732	LRIG1	0.67	4.59	0.43	1.38e-5	Response to amphetamines;
THYM	cis	rs977987	0.806	rs1030262	chr16:75491327	C/A	cg03315344	chr16:75512273	CHST6	0.73	6.1	0.53	2.24e-8	Dupuytren's disease;
THYM	cis	rs4766566	0.694	rs1362006	chr12:111742222	A/G	cg10833066	chr12:111807467	FAM109A	0.65	9.05	0.68	1.74e-14	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
THYM	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Coronary heart disease;
THYM	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg23161317	chr6:28129485	ZNF389	0.84	6.3	0.54	9.31e-9	Depression;
THYM	cis	rs886126	0.671	rs7952972	chr12:111646519	A/T	cg10833066	chr12:111807467	FAM109A	-0.41	-4.59	-0.43	1.36e-5	Coronary heart disease;
THYM	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg14004847	chr7:1930337	MAD1L1	-0.68	-5.12	-0.46	1.61e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9399401	0.667	rs34018047	chr6:142790873	G/C	cg04461802	chr6:142623433	GPR126	0.76	7.04	0.59	2.95e-10	Chronic obstructive pulmonary disease;
THYM	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg22709100	chr7:91322751	NA	0.68	5.41	0.49	4.62e-7	Breast cancer;
THYM	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg13319975	chr6:146136371	FBXO30	0.68	5.53	0.49	2.84e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.68	5.0	0.46	2.6e-6	Glycated hemoglobin levels;
THYM	cis	rs12898370	0.651	rs11634056	chr15:77539914	G/A	cg10437265	chr15:77819839	NA	0.66	5.2	0.47	1.17e-6	Risky sexual behaviors (alcohol dependence interaction);
THYM	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	9.71	0.71	6.96e-16	Platelet count;
THYM	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg00383909	chr3:49044727	WDR6	1.21	7.52	0.61	3.1e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs2637266	0.655	rs846595	chr10:78531300	C/T	cg18941641	chr10:78392320	NA	0.74	5.81	0.51	8.27e-8	Pulmonary function;
THYM	cis	rs7551222	0.752	rs10900593	chr1:204470096	G/T	cg20240347	chr1:204465584	NA	-0.55	-5.02	-0.46	2.41e-6	Schizophrenia;
THYM	cis	rs11671005	0.735	rs11084543	chr19:58932701	T/C	cg18639983	chr19:58920768	ZNF584	0.61	5.02	0.46	2.37e-6	Mean platelet volume;
THYM	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.99	-0.75	1.26e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg08704250	chr15:31115839	NA	0.69	7.77	0.62	9.15e-12	Huntington's disease progression;
THYM	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg00256281	chr22:41985642	PMM1	-0.58	-4.61	-0.43	1.25e-5	Vitiligo;
THYM	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg00256281	chr22:41985642	PMM1	0.62	4.67	0.43	1e-5	Vitiligo;
THYM	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg14972814	chr11:95582409	MTMR2	-0.59	-5.36	-0.48	5.87e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg26038318	chr20:34205095	SPAG4	0.59	4.68	0.43	9.66e-6	Total cholesterol levels;
THYM	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7267979	1.000	rs3002702	chr20:25268920	T/C	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7107174	1.000	rs55825352	chr11:78034424	C/T	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.81	-6.93	-0.58	4.99e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg18876405	chr7:65276391	NA	0.59	4.83	0.44	5.29e-6	Aortic root size;
THYM	cis	rs2997447	0.846	rs17257086	chr1:26392535	C/T	cg03844060	chr1:26490628	NA	0.66	4.5	0.42	1.96e-5	QRS complex (12-leadsum);
THYM	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg17178900	chr1:205818956	PM20D1	0.89	8.65	0.66	1.25e-13	Menarche (age at onset);
THYM	cis	rs9515201	0.886	rs55940034	chr13:111043309	A/G	cg15455643	chr13:111040242	COL4A2	0.53	5.72	0.51	1.23e-7	White matter hyperintensity burden;
THYM	cis	rs28595532	1.000	rs55634130	chr4:119655093	C/T	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03576123	chr11:487126	PTDSS2	-1.29	-6.4	-0.55	5.87e-9	Body mass index;
THYM	cis	rs4343996	0.934	rs4607498	chr7:3368197	C/T	cg21248987	chr7:3385318	SDK1	-0.4	-4.83	-0.44	5.26e-6	Motion sickness;
THYM	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg17063962	chr7:91808500	NA	1.16	13.11	0.8	4.9e-23	Breast cancer;
THYM	cis	rs28595532	0.920	rs116149978	chr4:119761069	A/C	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs367615	0.959	rs2201016	chr5:108947287	T/C	cg17395555	chr5:108820864	NA	0.54	4.69	0.43	9.1e-6	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs4363385	0.588	rs12079087	chr1:153023888	T/C	cg13444842	chr1:152974279	SPRR3	-0.61	-4.9	-0.45	3.96e-6	Inflammatory skin disease;
THYM	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22857025	chr5:266934	NA	-1.51	-9.79	-0.71	4.65e-16	Breast cancer;
THYM	cis	rs6918586	0.658	rs13161	chr6:26114702	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.59	-0.61	2.14e-11	Schizophrenia;
THYM	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2976388	0.609	rs2717603	chr8:143803193	T/C	cg06565975	chr8:143823917	SLURP1	0.5	5.62	0.5	1.9e-7	Urinary tract infection frequency;
THYM	cis	rs7618501	0.669	rs3774758	chr3:49938227	C/G	cg24308560	chr3:49941425	MST1R	-0.77	-6.63	-0.56	2.03e-9	Intelligence (multi-trait analysis);
THYM	cis	rs11924390	0.800	rs1648698	chr3:186449582	G/C	cg12454167	chr3:186435060	KNG1	0.44	5.89	0.52	5.76e-8	Adiponectin levels;
THYM	cis	rs6840360	1.000	rs1896883	chr4:152595373	C/T	cg22705602	chr4:152727874	NA	0.61	6.54	0.56	3.02e-9	Intelligence (multi-trait analysis);
THYM	cis	rs4845875	0.600	rs10779765	chr1:11838011	T/C	cg24844545	chr1:11908347	NPPA	0.57	4.77	0.44	6.74e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs6575793	0.967	rs11845605	chr14:101037726	C/T	cg13673514	chr14:101035818	BEGAIN	0.46	4.47	0.42	2.17e-5	Menarche (age at onset);
THYM	cis	rs6840360	0.615	rs12647462	chr4:152607278	C/T	cg22705602	chr4:152727874	NA	-0.79	-10.66	-0.74	6.62e-18	Intelligence (multi-trait analysis);
THYM	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02018176	chr4:1364513	KIAA1530	-0.92	-8.94	-0.68	3.06e-14	Longevity;
THYM	cis	rs1344694	0.566	rs13029765	chr2:216894976	A/T	cg25588852	chr2:216877276	MREG	-0.53	-5.16	-0.47	1.33e-6	Alcohol dependence;
THYM	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg03859395	chr2:55845619	SMEK2	0.67	6.15	0.53	1.84e-8	Metabolic syndrome;
THYM	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg16414030	chr3:133502952	NA	-0.83	-8.16	-0.64	1.38e-12	Iron status biomarkers;
THYM	cis	rs10992471	0.603	rs987553	chr9:95298694	G/T	cg14631576	chr9:95140430	CENPP	-0.97	-8.7	-0.67	9.65e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4481887	0.927	rs9651176	chr1:248447343	A/G	cg00666640	chr1:248458726	OR2T12	0.54	4.57	0.42	1.48e-5	Common traits (Other);
THYM	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg23161317	chr6:28129485	ZNF389	-0.98	-7.68	-0.62	1.43e-11	Depression;
THYM	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	cg20248691	chr11:532330	HRAS	0.45	4.55	0.42	1.59e-5	Alzheimer's disease (late onset);
THYM	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg11764359	chr7:65958608	NA	-0.74	-6.03	-0.53	3.13e-8	Aortic root size;
THYM	cis	rs6495367	1.000	rs4778634	chr15:79380822	C/T	cg17916960	chr15:79447300	NA	0.59	6.17	0.54	1.64e-8	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg11301795	chr4:187892539	NA	-1.12	-16.65	-0.86	6.34e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg02380750	chr20:61661411	NA	0.61	6.14	0.53	1.94e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs800586	0.500	rs2721965	chr8:116662038	A/C	cg04656070	chr8:116661063	TRPS1	-0.59	-6.81	-0.57	8.62e-10	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs35883536	0.528	rs1542837	chr1:101029768	T/C	cg06223162	chr1:101003688	GPR88	0.89	7.6	0.61	2.08e-11	Monocyte count;
THYM	cis	rs10887741	0.865	rs2755425	chr10:89418253	A/C	cg13926569	chr10:89418898	PAPSS2	-0.67	-7.07	-0.59	2.61e-10	Exercise (leisure time);
THYM	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg00277334	chr10:82204260	NA	0.52	5.37	0.48	5.53e-7	Post bronchodilator FEV1;
THYM	cis	rs478304	0.934	rs570954	chr11:65498261	A/G	cg17480646	chr11:65405466	SIPA1	0.7	6.13	0.53	2e-8	Acne (severe);
THYM	cis	rs7940866	0.801	rs10894300	chr11:130845943	A/G	cg23692386	chr11:131799662	NTM	0.51	5.36	0.48	5.81e-7	Schizophrenia;
THYM	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg05962950	chr11:130786565	SNX19	0.96	9.68	0.7	7.81e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03576123	chr11:487126	PTDSS2	-1.3	-6.61	-0.56	2.21e-9	Body mass index;
THYM	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg22875332	chr1:76189707	ACADM	0.86	10.01	0.72	1.6e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs28595532	0.841	rs115907265	chr4:119730593	G/A	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg06618935	chr21:46677482	NA	-0.96	-9.3	-0.69	5.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg09359103	chr1:154839909	KCNN3	-0.81	-10.7	-0.74	5.42e-18	Prostate cancer;
THYM	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg07570687	chr10:102243282	WNT8B	0.75	6.59	0.56	2.4e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7772486	0.764	rs7745696	chr6:146162829	T/C	cg13319975	chr6:146136371	FBXO30	-0.69	-5.65	-0.5	1.7e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg12935359	chr14:103987150	CKB	-0.63	-6.42	-0.55	5.44e-9	Body mass index;
THYM	cis	rs539096	0.749	rs12076635	chr1:44026656	G/C	cg00143623	chr1:44495758	SLC6A9	0.61	4.68	0.43	9.44e-6	Intelligence (multi-trait analysis);
THYM	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg12386194	chr3:101231763	SENP7	0.71	5.39	0.48	5.17e-7	Colorectal cancer;
THYM	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	10.68	0.74	6.01e-18	Chronic sinus infection;
THYM	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2898681	1.000	rs4864690	chr4:53750771	T/A	cg03786743	chr4:53727781	RASL11B	0.44	4.78	0.44	6.49e-6	Optic nerve measurement (cup area);
THYM	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs4940575	0.679	rs60803287	chr18:60830184	A/C	cg25271770	chr18:61057090	VPS4B	0.78	4.56	0.42	1.54e-5	Breast cancer;
THYM	cis	rs4889855	0.556	rs4508465	chr17:78543368	G/A	cg16591659	chr17:78472290	NA	0.44	5.03	0.46	2.33e-6	Fractional excretion of uric acid;
THYM	cis	rs12043259	1.000	rs7537504	chr1:204833630	A/G	cg00664682	chr1:205782872	SLC41A1	-1.12	-4.56	-0.42	1.53e-5	Addiction;
THYM	trans	rs629535	0.699	rs539956	chr8:70033647	G/A	cg21567404	chr3:27674614	NA	1.09	10.27	0.73	4.43e-17	Dupuytren's disease;
THYM	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg18252515	chr7:66147081	NA	-0.66	-4.91	-0.45	3.81e-6	Aortic root size;
THYM	cis	rs10883723	0.962	rs1056739	chr10:104236542	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.48	0.61	3.66e-11	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg15921436	chr17:44337874	NA	-0.91	-6.85	-0.58	7.19e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11209185	0.503	rs4655573	chr1:68438778	C/T	cg22082780	chr1:68452167	NA	-0.53	-6.09	-0.53	2.34e-8	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs2777491	0.574	rs1757468	chr15:41743574	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.23	-14.42	-0.83	1.16e-25	Ulcerative colitis;
THYM	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.69	-4.62	-0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs28595532	1.000	rs56225646	chr4:119651217	T/C	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs5015933	0.703	rs7037034	chr9:128144637	T/C	cg14078157	chr9:128172775	NA	-0.62	-5.2	-0.47	1.13e-6	Body mass index;
THYM	cis	rs4604732	0.588	rs4925552	chr1:247631749	C/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.71	4.74	0.44	7.48e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs7975161	0.565	rs4545635	chr12:104636844	A/C	cg25273343	chr12:104657179	TXNRD1	-0.77	-4.57	-0.42	1.48e-5	Toenail selenium levels;
THYM	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg12935359	chr14:103987150	CKB	-0.62	-6.48	-0.55	3.97e-9	Body mass index;
THYM	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22133161	chr19:49891603	CCDC155	0.77	5.15	0.47	1.38e-6	Multiple sclerosis;
THYM	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	8.7	0.67	9.84e-14	Chronic sinus infection;
THYM	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg19774624	chr17:42201019	HDAC5	-0.77	-7.16	-0.59	1.73e-10	Total body bone mineral density;
THYM	cis	rs9788721	1.000	rs9788721	chr15:78802869	C/T	cg18825076	chr15:78729989	IREB2	0.6	5.62	0.5	1.94e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs4664308	1.000	rs62175515	chr2:160909524	A/T	cg03641300	chr2:160917029	PLA2R1	-0.76	-6.83	-0.57	7.92e-10	Idiopathic membranous nephropathy;
THYM	cis	rs4891159	0.660	rs4891160	chr18:74102135	C/T	cg24786174	chr18:74118243	ZNF516	0.83	9.47	0.7	2.22e-15	Longevity;
THYM	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg06453172	chr10:134556979	INPP5A	-0.67	-4.86	-0.45	4.62e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7296418	0.675	rs1879379	chr12:123727443	G/A	cg00376283	chr12:123451042	ABCB9	0.79	6.23	0.54	1.28e-8	Platelet count;
THYM	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg17757837	chr7:157058334	UBE3C	0.65	5.24	0.47	9.83e-7	Body mass index;
THYM	cis	rs9369640	1.000	rs6925904	chr6:12892486	A/G	cg19458485	chr6:12957800	PHACTR1	0.57	4.69	0.43	9.23e-6	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10847980	0.590	rs1696326	chr12:123311981	A/G	cg25930673	chr12:123319894	HIP1R	-1.08	-5.32	-0.48	6.92e-7	Adiponectin levels;
THYM	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg02187348	chr16:89574699	SPG7	0.82	6.95	0.58	4.55e-10	Multiple myeloma (IgH translocation);
THYM	cis	rs7631605	0.846	rs57863333	chr3:37263719	G/A	cg21328643	chr3:37258149	NA	-0.58	-5.32	-0.48	6.93e-7	Cerebrospinal P-tau181p levels;
THYM	cis	rs75920871	0.588	rs1815788	chr11:116834971	T/C	cg20608306	chr11:116969690	SIK3	-0.47	-4.94	-0.45	3.37e-6	Subjective well-being;
THYM	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg24503407	chr1:205819492	PM20D1	0.92	8.43	0.65	3.7e-13	Menarche (age at onset);
THYM	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg13695892	chr22:41940480	POLR3H	-1.04	-8.38	-0.65	4.84e-13	Vitiligo;
THYM	cis	rs67981189	0.529	rs8014273	chr14:71509830	A/G	cg15910301	chr14:71632612	NA	0.56	4.88	0.45	4.23e-6	Schizophrenia;
THYM	cis	rs4523957	0.583	rs9889861	chr17:2041369	A/G	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs936229	0.784	rs12906946	chr15:75153140	A/G	cg10253484	chr15:75165896	SCAMP2	-0.66	-4.79	-0.44	6.06e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs9462846	1.000	rs2395939	chr6:42851396	G/A	cg10862848	chr6:42927986	GNMT	-0.45	-4.68	-0.43	9.33e-6	Blood protein levels;
THYM	cis	rs9926296	0.568	rs417323	chr16:89746277	T/G	cg01097406	chr16:89675127	NA	0.87	8.11	0.64	1.75e-12	Vitiligo;
THYM	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg22907277	chr7:1156413	C7orf50	0.86	5.31	0.48	7.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13392177	0.543	rs12623716	chr2:219073018	C/T	cg00012203	chr2:219082015	ARPC2	-0.66	-5.36	-0.48	5.76e-7	Pyoderma gangrenosum in inflammatory bowel disease;
THYM	cis	rs11077998	0.844	rs1109123	chr17:80522391	T/C	cg11779900	chr17:80519722	FOXK2	-0.53	-4.53	-0.42	1.71e-5	Reticulocyte fraction of red cells;
THYM	cis	rs1003719	0.654	rs764175	chr21:38517058	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-4.72	-0.44	8.18e-6	Eye color traits;
THYM	cis	rs7681423	1.000	rs2066854	chr4:155535181	T/A	cg20735720	chr4:155535218	FGG	-0.74	-5.81	-0.51	8.33e-8	Fibrinogen;
THYM	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg26597838	chr10:835615	NA	1.2	8.57	0.66	1.85e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg05182265	chr7:156933206	UBE3C	-0.7	-9.62	-0.7	1.06e-15	Body mass index;
THYM	cis	rs10779751	0.734	rs2486920	chr1:11125050	T/C	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg20242066	chr2:136595261	LCT	0.6	6.99	0.58	3.7e-10	Mosquito bite size;
THYM	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.73	-4.5	-0.42	1.93e-5	Alzheimer's disease;
THYM	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.53	0.56	3.27e-9	Total body bone mineral density;
THYM	cis	rs4363385	0.647	rs56158137	chr1:152994380	A/T	cg13444842	chr1:152974279	SPRR3	-0.6	-4.9	-0.45	3.98e-6	Inflammatory skin disease;
THYM	cis	rs6988636	1.000	rs11992152	chr8:124189455	T/A	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs10186029	0.509	rs6435756	chr2:213941279	C/G	cg08319019	chr2:214017104	IKZF2	-0.64	-4.89	-0.45	4.11e-6	Systemic sclerosis;
THYM	cis	rs854765	0.624	rs12938501	chr17:17737258	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-5.22	-0.47	1.05e-6	Total body bone mineral density;
THYM	cis	rs9807989	0.801	rs6734742	chr2:102967857	C/T	cg03938978	chr2:103052716	IL18RAP	0.63	6.56	0.56	2.85e-9	Asthma;
THYM	cis	rs78761021	0.755	rs17744048	chr17:9794996	A/G	cg26853458	chr17:9805074	RCVRN	0.53	4.51	0.42	1.84e-5	Type 2 diabetes;
THYM	cis	rs220324	0.647	rs55877840	chr21:43560383	T/C	cg09727148	chr21:43560719	UMODL1	0.84	9.89	0.71	2.8e-16	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs79149102	0.579	rs78434425	chr15:75304754	C/T	cg17294928	chr15:75287854	SCAMP5	-1.1	-5.3	-0.48	7.57e-7	Lung cancer;
THYM	cis	rs11822910	0.737	rs2584858	chr11:57207077	C/T	cg00522883	chr11:57194120	SLC43A3	0.67	5.1	0.46	1.76e-6	Platelet distribution width;
THYM	cis	rs6430585	0.583	rs12373779	chr2:136586840	A/C	cg23851026	chr2:136556271	LCT	0.77	7.67	0.62	1.48e-11	Corneal structure;
THYM	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.83	-6.94	-0.58	4.68e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03264133	chr6:25882463	NA	-0.7	-5.51	-0.49	3.06e-7	Blood metabolite levels;
THYM	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg00684032	chr4:1343700	KIAA1530	0.81	6.98	0.58	3.97e-10	Obesity-related traits;
THYM	cis	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg01528321	chr10:82214614	TSPAN14	0.82	6.22	0.54	1.34e-8	Post bronchodilator FEV1;
THYM	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7586879	0.616	rs12713422	chr2:25134497	A/C	cg01884057	chr2:25150051	NA	0.73	7.92	0.63	4.47e-12	Body mass index;
THYM	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.66	-5.38	-0.48	5.38e-7	Blood metabolite levels;
THYM	cis	rs986417	0.748	rs11158289	chr14:61032390	C/T	cg27398547	chr14:60952738	C14orf39	1.01	5.77	0.51	1.01e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg03733263	chr8:22462867	KIAA1967	1.11	13.42	0.81	1.19e-23	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg01073479	chr16:3509474	NAT15	0.66	5.29	0.48	7.9e-7	Tuberculosis;
THYM	cis	rs7100689	0.516	rs3862532	chr10:82015725	A/C	cg01528321	chr10:82214614	TSPAN14	0.89	7.03	0.59	3.1e-10	Post bronchodilator FEV1;
THYM	trans	rs561341	1.000	rs560132	chr17:30320019	C/T	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs2811415	0.569	rs1057220	chr3:127799983	A/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs8133932	0.654	rs379501	chr21:47360784	T/C	cg20357416	chr21:47294739	PCBP3	0.82	5.1	0.46	1.76e-6	Schizophrenia;
THYM	cis	rs6450176	1.000	rs6450176	chr5:53298025	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.81	-6.03	-0.53	3.17e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs1403694	0.669	rs10440056	chr3:186433822	C/T	cg12454167	chr3:186435060	KNG1	0.51	7.04	0.59	2.94e-10	Blood protein levels;
THYM	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8038465	0.622	rs60696711	chr15:73873005	C/A	cg15420318	chr15:73925796	NPTN	0.62	5.39	0.48	5.09e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs13177918	0.677	rs13177951	chr5:149825939	C/T	cg14059543	chr5:149831962	NA	-1.01	-7.71	-0.62	1.21e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs1003719	0.715	rs2835646	chr21:38546574	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs9633835	0.524	rs7117317	chr11:13278809	A/G	cg13286116	chr11:13302098	ARNTL	-0.72	-8.02	-0.64	2.69e-12	Body mass index;
THYM	cis	rs12579753	1.000	rs7956826	chr12:82173365	A/G	cg07988820	chr12:82153109	PPFIA2	-0.78	-4.97	-0.45	2.92e-6	Resting heart rate;
THYM	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg10150615	chr22:24372951	LOC391322	1.01	11.87	0.77	1.77e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2067615	0.524	rs10778504	chr12:107120424	C/T	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg13695892	chr22:41940480	POLR3H	-0.93	-7.08	-0.59	2.5e-10	Vitiligo;
THYM	cis	rs921968	0.565	rs3821035	chr2:219620223	T/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg18357526	chr6:26021779	HIST1H4A	0.73	5.65	0.5	1.65e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs13064411	0.627	rs28536176	chr3:113143625	T/C	cg10517650	chr3:113235015	CCDC52	-0.6	-5.06	-0.46	2.06e-6	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg26038318	chr20:34205095	SPAG4	0.65	5.26	0.48	8.7e-7	Total cholesterol levels;
THYM	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg12483005	chr1:23474871	LUZP1	0.58	5.84	0.51	7.3900000000000007e-08	Height;
THYM	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.22	9.78	0.71	4.78e-16	Platelet count;
THYM	cis	rs1014246	0.541	rs2011695	chr10:118507219	A/C	cg14919929	chr10:118506882	NA	-0.64	-5.85	-0.51	7.08e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs9549260	0.755	rs7988604	chr13:41215802	G/T	cg21288729	chr13:41239152	FOXO1	0.73	5.55	0.5	2.52e-7	Red blood cell count;
THYM	cis	rs4792901	0.722	rs7220615	chr17:41540644	G/A	cg21940313	chr17:41620911	ETV4	-0.52	-5.19	-0.47	1.17e-6	Dupuytren's disease;
THYM	cis	rs7851660	0.839	rs10818213	chr9:100648631	T/C	cg13688889	chr9:100608707	NA	-0.7	-4.78	-0.44	6.3e-6	Strep throat;
THYM	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg23750338	chr8:142222470	SLC45A4	-0.5	-4.57	-0.42	1.46e-5	Immature fraction of reticulocytes;
THYM	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs6987853	0.563	rs2923406	chr8:42448873	G/T	cg09913449	chr8:42400586	C8orf40	0.66	5.85	0.51	6.95e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg11871910	chr12:69753446	YEATS4	0.76	6.17	0.54	1.63e-8	Blood protein levels;
THYM	cis	rs28595532	0.920	rs17257945	chr4:119666465	T/A	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg06850241	chr22:41845214	NA	0.53	4.56	0.42	1.54e-5	Vitiligo;
THYM	cis	rs1005224	0.853	rs61980778	chr14:76151532	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	0.71	5.83	0.51	7.54e-8	Large artery stroke;
THYM	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg17691542	chr6:26056736	HIST1H1C	0.92	5.63	0.5	1.83e-7	Iron status biomarkers;
THYM	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg06060754	chr5:176797920	RGS14	0.43	6.16	0.53	1.72e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs9549260	0.755	rs4941987	chr13:41195992	T/C	cg21288729	chr13:41239152	FOXO1	0.69	5.26	0.47	8.95e-7	Red blood cell count;
THYM	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-11.3	-0.76	2.81e-19	Height;
THYM	cis	rs2109514	0.902	rs6980387	chr7:116126882	A/G	cg12739419	chr7:116140593	CAV2	-0.48	-4.71	-0.44	8.4e-6	Prevalent atrial fibrillation;
THYM	cis	rs9355610	0.609	rs9366076	chr6:167373708	C/T	cg15592062	chr6:167189543	RPS6KA2	0.55	4.68	0.43	9.62e-6	Graves' disease;
THYM	cis	rs1568889	0.838	rs11030265	chr11:28296168	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs4474465	1.000	rs10899517	chr11:78180507	A/T	cg19901956	chr11:77921274	USP35	-0.6	-4.55	-0.42	1.59e-5	Alzheimer's disease (survival time);
THYM	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg03609598	chr5:56110824	MAP3K1	-0.85	-5.87	-0.52	6.23e-8	Initial pursuit acceleration;
THYM	cis	rs28595532	0.920	rs116795224	chr4:119734570	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs7772486	0.654	rs4896829	chr6:145953675	T/A	cg23711669	chr6:146136114	FBXO30	0.87	8.34	0.65	5.81e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg05234568	chr11:5960015	NA	-0.6	-4.84	-0.44	4.97e-6	DNA methylation (variation);
THYM	cis	rs600806	0.850	rs4970752	chr1:109930852	C/T	cg02175308	chr1:109941060	SORT1	-0.6	-5.3	-0.48	7.58e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7578361	0.879	rs13024856	chr2:150408665	T/C	cg17961725	chr2:150454027	NA	0.74	5.91	0.52	5.37e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9905704	0.918	rs36071323	chr17:56916804	C/T	cg12560992	chr17:57184187	TRIM37	0.68	4.72	0.44	8.17e-6	Testicular germ cell tumor;
THYM	cis	rs988913	0.915	rs9475107	chr6:54853342	G/A	cg04690482	chr6:54711388	FAM83B	0.49	5.28	0.48	8.01e-7	Menarche (age at onset);
THYM	cis	rs6456156	0.774	rs1012657	chr6:167525142	A/C	cg09487078	chr6:167525398	CCR6	-0.44	-4.82	-0.44	5.43e-6	Primary biliary cholangitis;
THYM	cis	rs28595532	0.920	rs114724233	chr4:119754918	T/A	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs4888262	0.526	rs7201105	chr16:74590603	A/G	cg01733217	chr16:74700730	RFWD3	0.8	8.28	0.65	7.82e-13	Testicular germ cell tumor;
THYM	cis	rs7731657	0.537	rs4377699	chr5:130354830	T/G	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	5.65	0.5	1.69e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg11812906	chr14:75593930	NEK9	-0.87	-8.3	-0.65	7.13e-13	Height;
THYM	cis	rs1267303	0.642	rs114746843	chr1:46999239	C/A	cg16387850	chr1:46982889	NA	-0.45	-5.49	-0.49	3.34e-7	Monobrow;
THYM	cis	rs4654899	0.897	rs710311	chr1:21062001	T/C	cg01072550	chr1:21505969	NA	-0.58	-5.04	-0.46	2.25e-6	Superior frontal gyrus grey matter volume;
THYM	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg04772025	chr11:68637568	NA	0.65	6.87	0.58	6.76e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11585357	0.895	rs72633828	chr1:17632251	G/A	cg08277548	chr1:17600880	PADI3	-0.87	-5.18	-0.47	1.24e-6	Hair shape;
THYM	cis	rs17152411	0.895	rs7084646	chr10:126585738	T/C	cg07906193	chr10:126599966	NA	0.68	4.65	0.43	1.08e-5	Height;
THYM	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg08736216	chr1:53307985	ZYG11A	-0.58	-5.29	-0.48	7.85e-7	Monocyte count;
THYM	cis	rs2806561	0.929	rs2746556	chr1:23524541	G/A	cg12483005	chr1:23474871	LUZP1	0.52	5.12	0.47	1.59e-6	Height;
THYM	cis	rs6840360	0.530	rs11946622	chr4:152486018	C/T	cg22705602	chr4:152727874	NA	-0.81	-8.81	-0.67	5.67e-14	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs4242434	0.698	rs10104039	chr8:22538384	A/G	cg01710189	chr8:22454888	PDLIM2	0.48	4.93	0.45	3.55e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg06636001	chr8:8085503	FLJ10661	-0.64	-5.76	-0.51	1.04e-7	Mood instability;
THYM	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg24375607	chr4:120327624	NA	0.68	5.4	0.48	4.95e-7	Corneal astigmatism;
THYM	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg06600287	chr1:53387719	ECHDC2	-0.33	-4.84	-0.44	5.1e-6	Monocyte count;
THYM	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg09021430	chr5:549028	NA	-0.64	-4.84	-0.44	4.98e-6	Obesity-related traits;
THYM	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.6	0.5	2.04e-7	Height;
THYM	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg11494091	chr17:61959527	GH2	1.07	17.57	0.87	1.34e-31	Prudent dietary pattern;
THYM	cis	rs7152530	0.571	rs7160630	chr14:98637479	A/G	cg05180522	chr14:98101740	NA	-0.59	-4.7	-0.43	8.79e-6	Staphylococcus aureus infection;
THYM	cis	rs2717559	0.522	rs2572918	chr8:143875721	C/A	cg17252645	chr8:143867129	LY6D	0.85	10.44	0.73	1.91e-17	Urinary tract infection frequency;
THYM	cis	rs1075232	0.649	rs67399209	chr15:32223850	T/C	cg01030201	chr15:31746330	NA	-0.98	-4.65	-0.43	1.07e-5	Survival in colorectal cancer (non-distant metastatic);
THYM	trans	rs10752961	0.570	rs4626827	chr1:185996313	A/G	cg05824762	chr9:131533797	ZER1	-0.85	-6.88	-0.58	6.3e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.53	-5.0	-0.46	2.57e-6	Lymphocyte counts;
THYM	cis	rs55728055	0.661	rs62237772	chr22:31964975	A/C	cg01338084	chr22:32026380	PISD	1.48	7.31	0.6	8.42e-11	Age-related hearing impairment;
THYM	cis	rs28476539	0.640	rs17005919	chr4:83555716	C/T	cg10249074	chr4:83542146	C4orf11	-0.62	-4.96	-0.45	3.12e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs7617773	0.707	rs13061269	chr3:48373343	C/T	cg02219026	chr3:48282209	ZNF589	-0.71	-4.97	-0.45	3.01e-6	Coronary artery disease;
THYM	cis	rs8008002	1.000	rs7151624	chr14:75866119	C/T	cg17335494	chr14:75077385	LTBP2	-0.48	-4.57	-0.42	1.46e-5	Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs2456568	0.564	rs4608039	chr11:93624799	C/G	cg17595323	chr11:93583763	C11orf90	0.51	5.35	0.48	6.04e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs763014	0.898	rs4984896	chr16:625493	C/T	cg00908189	chr16:619842	PIGQ	1.02	9.27	0.69	6.03e-15	Height;
THYM	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg16031515	chr1:205743344	RAB7L1	0.53	4.58	0.43	1.43e-5	Menarche (age at onset);
THYM	cis	rs11563648	0.573	rs7803031	chr7:126952552	C/G	cg23081781	chr7:127225937	GCC1	-0.37	-5.13	-0.47	1.55e-6	Resting heart rate;
THYM	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg23711669	chr6:146136114	FBXO30	-0.85	-8.16	-0.64	1.41e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg18252515	chr7:66147081	NA	-0.63	-4.68	-0.43	9.63e-6	Aortic root size;
THYM	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg17691542	chr6:26056736	HIST1H1C	0.92	5.63	0.5	1.83e-7	Iron status biomarkers;
THYM	cis	rs1670533	1.000	rs1670534	chr4:1087265	T/C	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	trans	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.11	8.17	0.64	1.3e-12	Exhaled nitric oxide output;
THYM	cis	rs7177699	0.557	rs12898712	chr15:79112622	G/T	cg00540400	chr15:79124168	NA	0.62	6.51	0.56	3.49e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs754466	0.580	rs2289308	chr10:79579251	G/A	cg17075019	chr10:79541650	NA	-0.69	-5.63	-0.5	1.82e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9796	0.774	rs28866311	chr15:41442195	T/G	cg21153102	chr15:41252147	NA	0.67	5.86	0.52	6.6e-8	Menopause (age at onset);
THYM	cis	rs887829	0.569	rs4124874	chr2:234665659	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.67	-5.2	-0.47	1.13e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs9677476	0.863	rs62197323	chr2:232063714	A/G	cg23338755	chr2:231921595	PSMD1	0.7	5.3	0.48	7.54e-7	Food antigen IgG levels;
THYM	cis	rs1775715	0.870	rs11008696	chr10:32218614	G/A	cg04359828	chr10:32216031	ARHGAP12	0.38	5.04	0.46	2.24e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs11731175	1.000	rs3954005	chr4:189859166	C/T	cg00431894	chr4:189871012	NA	-0.82	-6.24	-0.54	1.2e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs8180040	0.726	rs9843075	chr3:47195630	A/G	cg02527881	chr3:46936655	PTH1R	-0.62	-5.66	-0.5	1.62e-7	Colorectal cancer;
THYM	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06634786	chr22:41940651	POLR3H	-0.81	-5.97	-0.52	4.16e-8	Vitiligo;
THYM	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.59	-4.66	-0.43	1.02e-5	Chronic sinus infection;
THYM	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg18512352	chr11:47633146	NA	0.5	6.42	0.55	5.46e-9	Subjective well-being;
THYM	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg10505658	chr17:80084571	CCDC57	-0.69	-7.95	-0.63	3.78e-12	Life satisfaction;
THYM	cis	rs2354432	1.000	rs2354432	chr1:146693229	C/T	cg25205988	chr1:146714368	CHD1L	1.1	7.31	0.6	8.32e-11	Mitochondrial DNA levels;
THYM	cis	rs9486719	1.000	rs12208011	chr6:96991105	G/A	cg18709589	chr6:96969512	KIAA0776	-0.68	-4.71	-0.44	8.44e-6	Migraine;Coronary artery disease;
THYM	cis	rs6964587	0.620	rs6967588	chr7:91643402	G/T	cg17063962	chr7:91808500	NA	0.94	8.14	0.64	1.53e-12	Breast cancer;
THYM	cis	rs863345	0.565	rs2051665	chr1:158507157	A/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg06521331	chr12:34319734	NA	-1.02	-10.16	-0.72	7.42e-17	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4731207	0.596	rs10954050	chr7:124577901	G/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs611744	0.523	rs13253581	chr8:109343105	A/G	cg21045802	chr8:109455806	TTC35	0.79	7.32	0.6	7.75e-11	Dupuytren's disease;
THYM	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg24812749	chr6:127587940	RNF146	0.87	6.2	0.54	1.44e-8	Breast cancer;
THYM	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg22166914	chr1:53195759	ZYG11B	-0.77	-8.25	-0.65	8.99e-13	Monocyte count;
THYM	cis	rs11252926	0.603	rs11252670	chr10:529152	A/G	cg03684893	chr10:554711	DIP2C	0.6	4.97	0.45	2.96e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs240764	0.782	rs239222	chr6:101112817	T/A	cg21058520	chr6:100914733	NA	-0.57	-5.03	-0.46	2.29e-6	Neuroticism;
THYM	cis	rs9527	0.830	rs10883790	chr10:104640955	A/C	cg04362960	chr10:104952993	NT5C2	0.64	4.72	0.44	8.19e-6	Arsenic metabolism;
THYM	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.6	-7.24	-0.6	1.17e-10	Longevity;Endometriosis;
THYM	cis	rs10992471	0.603	rs10992349	chr9:95233887	T/C	cg14631576	chr9:95140430	CENPP	-0.99	-9.94	-0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs17597773	0.638	rs6541161	chr1:220994264	T/A	cg16008148	chr1:221062819	NA	0.41	4.54	0.42	1.62e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.71	5.32	0.48	7.02e-7	Height;
THYM	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	6.51	0.56	3.5e-9	Total body bone mineral density;
THYM	cis	rs9515201	0.818	rs9521733	chr13:111034542	C/T	cg26053697	chr13:111039873	COL4A2	-0.54	-4.56	-0.42	1.53e-5	White matter hyperintensity burden;
THYM	cis	rs910187	0.678	rs6018329	chr20:45813184	A/G	cg27589058	chr20:45804311	EYA2	-0.59	-5.07	-0.46	1.95e-6	Migraine;
THYM	cis	rs72627123	0.530	rs79371463	chr14:74474856	T/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg23791538	chr6:167370224	RNASET2	-0.62	-4.64	-0.43	1.1e-5	Crohn's disease;
THYM	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12379764	chr21:47803548	PCNT	-0.8	-5.38	-0.48	5.35e-7	Testicular germ cell tumor;
THYM	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg10802521	chr3:52805072	NEK4	-0.63	-4.61	-0.43	1.23e-5	Bipolar disorder;
THYM	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg03732007	chr1:2071316	PRKCZ	0.52	4.74	0.44	7.37e-6	Height;
THYM	cis	rs1113500	0.933	rs4593854	chr1:108638519	A/G	cg06207961	chr1:108661230	NA	0.64	5.09	0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg18252515	chr7:66147081	NA	-0.67	-4.93	-0.45	3.42e-6	Aortic root size;
THYM	cis	rs877282	0.583	rs12356155	chr10:823940	C/T	cg10556349	chr10:835070	NA	-0.8	-5.48	-0.49	3.52e-7	Uric acid levels;
THYM	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg05962950	chr11:130786565	SNX19	-0.92	-8.74	-0.67	8.09e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7589342	0.745	rs11124066	chr2:106516925	T/A	cg14210321	chr2:106509881	NCK2	-0.8	-6.1	-0.53	2.33e-8	Addiction;
THYM	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg26446133	chr18:72167187	CNDP2	-1.02	-7.49	-0.61	3.5e-11	Refractive error;
THYM	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg15448220	chr1:150897856	SETDB1	0.92	7.76	0.62	9.74e-12	Melanoma;
THYM	cis	rs2274459	1.000	rs751095	chr6:33742718	T/G	cg06253072	chr6:33679850	C6orf125	0.51	4.58	0.43	1.39e-5	Obesity (extreme);
THYM	cis	rs4363385	0.818	rs10788853	chr1:153002231	C/T	cg13444842	chr1:152974279	SPRR3	-0.59	-4.81	-0.44	5.61e-6	Inflammatory skin disease;
THYM	trans	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg10856724	chr12:34555212	NA	-0.89	-8.35	-0.65	5.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg00684032	chr4:1343700	KIAA1530	0.59	5.33	0.48	6.64e-7	Obesity-related traits;
THYM	cis	rs4917300	0.626	rs28375965	chr8:143103882	A/G	cg26003909	chr8:143102224	NA	-0.32	-4.65	-0.43	1.08e-5	Amyotrophic lateral sclerosis;
THYM	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg08736216	chr1:53307985	ZYG11A	0.66	5.22	0.47	1.04e-6	Monocyte count;
THYM	cis	rs2495707	0.624	rs10883518	chr10:102416555	C/A	cg07919443	chr10:102419409	NA	-0.61	-5.06	-0.46	2.05e-6	Body mass index;
THYM	cis	rs2067615	0.579	rs10507214	chr12:107194461	G/A	cg15890332	chr12:107067104	RFX4	0.48	5.63	0.5	1.81e-7	Heart rate;
THYM	cis	rs9326248	0.648	rs11216257	chr11:116932561	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.91	6.18	0.54	1.58e-8	Blood protein levels;
THYM	cis	rs67981189	0.529	rs2810096	chr14:71435300	A/G	cg15910301	chr14:71632612	NA	-0.56	-4.88	-0.45	4.23e-6	Schizophrenia;
THYM	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg12292205	chr6:26970375	C6orf41	-0.64	-5.19	-0.47	1.19e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2195525	0.572	rs7358397	chr11:119221078	A/G	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.44	4.78	0.44	6.41e-6	Urate levels;
THYM	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg06481639	chr22:41940642	POLR3H	-0.72	-5.47	-0.49	3.67e-7	Vitiligo;
THYM	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg21110456	chr7:2059412	MAD1L1	-0.47	-5.09	-0.46	1.81e-6	Neuroticism;
THYM	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg26384229	chr12:38710491	ALG10B	0.95	7.55	0.61	2.7e-11	Bladder cancer;
THYM	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg26028573	chr6:26043587	HIST1H2BB	0.53	4.61	0.43	1.27e-5	Blood metabolite levels;
THYM	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg16926213	chr1:1841314	NA	0.53	5.42	0.49	4.48e-7	Body mass index;
THYM	cis	rs2195525	0.572	rs11217245	chr11:119219311	G/A	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.43	4.83	0.44	5.19e-6	Urate levels;
THYM	cis	rs988913	0.957	rs960835	chr6:54823422	A/G	cg04690482	chr6:54711388	FAM83B	0.49	5.28	0.48	8.01e-7	Menarche (age at onset);
THYM	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs2708977	0.901	rs2579505	chr2:97167962	T/C	cg01950434	chr2:97203154	ARID5A	-0.51	-4.51	-0.42	1.88e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg23602478	chr1:26503979	CNKSR1	0.36	4.97	0.45	2.96e-6	Height;
THYM	cis	rs11723261	0.621	rs7692530	chr4:123445	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.85	5.95	0.52	4.45e-8	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs807669	0.903	rs1018764	chr22:19172006	T/C	cg02655711	chr22:19163373	SLC25A1	0.98	11.86	0.77	1.93e-20	Metabolite levels;
THYM	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg11965913	chr1:205819406	PM20D1	1.12	13.9	0.82	1.26e-24	Menarche (age at onset);
THYM	cis	rs2456568	1.000	rs2456568	chr11:93691332	A/T	cg26875233	chr11:93583750	C11orf90	-0.48	-4.73	-0.44	7.87e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2692947	0.800	rs61409777	chr2:96581373	C/A	cg22654517	chr2:96458247	NA	0.59	4.45	0.42	2.32e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg16486109	chr11:613632	IRF7	0.5	5.88	0.52	6.12e-8	Systemic lupus erythematosus;
THYM	cis	rs1451375	0.657	rs12665904	chr7:50635399	A/G	cg18232548	chr7:50535776	DDC	0.69	5.35	0.48	6.04e-7	Malaria;
THYM	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg18252515	chr7:66147081	NA	-1.44	-8.7	-0.67	9.82e-14	Diabetic kidney disease;
THYM	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.89	5.72	0.51	1.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg09165964	chr15:75287851	SCAMP5	-1.0	-9.02	-0.68	2.08e-14	Blood trace element (Zn levels);
THYM	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03452623	chr4:187889614	NA	-1.17	-20.04	-0.9	6.92e-36	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2228479	0.619	rs77847775	chr16:89896243	C/T	cg06558623	chr16:89946397	TCF25	1.22	5.31	0.48	7.11e-7	Skin colour saturation;
THYM	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg24549020	chr5:56110836	MAP3K1	0.7	4.61	0.43	1.28e-5	Initial pursuit acceleration;
THYM	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs7043114	0.525	rs4744134	chr9:95246833	A/G	cg14631576	chr9:95140430	CENPP	0.82	8.18	0.64	1.27e-12	Height;
THYM	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg00684032	chr4:1343700	KIAA1530	0.55	4.88	0.45	4.23e-6	Obesity-related traits;
THYM	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg07414643	chr4:187882934	NA	-0.6	-5.29	-0.48	7.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1912528	0.783	rs809955	chr4:140874760	G/A	cg11128457	chr4:140864437	MAML3	0.49	5.31	0.48	7.25e-7	Educational attainment (years of education);
THYM	cis	rs763014	0.931	rs11648728	chr16:635525	C/T	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	trans	rs10028773	0.700	rs35653026	chr4:120248378	A/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.9	-0.58	5.85e-10	Educational attainment;
THYM	cis	rs17443541	0.507	rs6709301	chr2:200466505	G/A	cg01795955	chr2:200468626	NA	-0.72	-5.0	-0.46	2.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1878931	0.580	rs4785932	chr16:3410456	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.94	8.84	0.67	4.95e-14	Body mass index (adult);
THYM	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.58	0.56	2.61e-9	Total body bone mineral density;
THYM	cis	rs931812	0.825	rs55818461	chr8:101899229	T/C	cg07585502	chr8:101912084	NA	-0.58	-4.6	-0.43	1.31e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs4595586	0.545	rs6580893	chr12:39371885	G/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg10856724	chr12:34555212	NA	-0.88	-8.25	-0.65	8.84e-13	Morning vs. evening chronotype;
THYM	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg12379764	chr21:47803548	PCNT	-0.81	-5.12	-0.46	1.61e-6	Testicular germ cell tumor;
THYM	cis	rs4746818	1.000	rs6480384	chr10:70890757	C/T	cg04149295	chr10:70884716	VPS26A	0.84	5.92	0.52	5.05e-8	Left atrial antero-posterior diameter;
THYM	cis	rs3744028	0.532	rs9903200	chr17:73839498	G/A	cg02627403	chr17:73823769	UNC13D	-0.54	-5.03	-0.46	2.35e-6	White matter hyperintensity burden;
THYM	cis	rs1113500	0.933	rs1419003	chr1:108616955	A/C	cg06207961	chr1:108661230	NA	0.66	5.18	0.47	1.24e-6	Growth-regulated protein alpha levels;
THYM	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg17063962	chr7:91808500	NA	1.16	13.14	0.8	4.39e-23	Breast cancer;
THYM	cis	rs72827839	1.000	rs72827877	chr17:46524904	G/A	cg23391107	chr17:45924227	SP6	0.76	4.58	0.43	1.39e-5	Ease of getting up in the morning;
THYM	cis	rs11077998	0.933	rs4239021	chr17:80531826	T/C	cg10255544	chr17:80519551	FOXK2	0.51	4.49	0.42	2.02e-5	Reticulocyte fraction of red cells;
THYM	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg05872129	chr22:39784769	NA	-1.03	-10.42	-0.73	2.11e-17	Intelligence (multi-trait analysis);
THYM	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	6.13	0.53	1.95e-8	Total body bone mineral density;
THYM	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs3857067	0.806	rs1876918	chr4:95099424	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg10661904	chr17:79619235	PDE6G	-0.57	-5.3	-0.48	7.61e-7	Eye color traits;
THYM	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg17911788	chr17:44343683	NA	0.71	6.76	0.57	1.09e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs57920188	0.585	rs12126679	chr1:4072921	C/T	cg20703997	chr1:4087676	NA	1.05	7.6	0.61	2.11e-11	Interleukin-17 levels;
THYM	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg03709012	chr19:19516395	GATAD2A	0.83	6.77	0.57	1.07e-9	Tonsillectomy;
THYM	cis	rs7537052	0.646	rs6680302	chr1:36653540	C/T	cg24686825	chr1:36642396	MAP7D1	-0.77	-7.16	-0.59	1.73e-10	Schizophrenia;
THYM	trans	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7901056	0.967	rs9299819	chr10:26719882	C/T	cg23318538	chr10:26883079	C10orf50	0.37	5.06	0.46	2.06e-6	Lymphocyte counts;
THYM	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs11608355	1.000	rs11611370	chr12:109870291	A/G	cg11367159	chr12:110044531	NA	-0.65	-6.1	-0.53	2.24e-8	Neuroticism;
THYM	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg13854012	chr2:162103682	NA	-0.65	-5.39	-0.48	5.19e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg04944784	chr2:26401820	FAM59B	1.09	7.65	0.62	1.67e-11	Gut microbiome composition (summer);
THYM	cis	rs4285028	0.747	rs1127412	chr3:121414061	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.79	-6.6	-0.56	2.34e-9	Multiple sclerosis;
THYM	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg10057126	chr4:77819792	ANKRD56	0.72	6.14	0.53	1.93e-8	Emphysema distribution in smoking;
THYM	cis	rs73635312	0.568	rs290898	chr10:8933437	C/T	cg19883813	chr10:8098005	GATA3	-0.58	-4.64	-0.43	1.09e-5	Basal cell carcinoma;
THYM	cis	rs8030485	0.571	rs10775219	chr15:79443894	G/A	cg17916960	chr15:79447300	NA	0.57	5.48	0.49	3.41e-7	Left ventricle wall thickness;
THYM	cis	rs6542838	0.646	rs35077008	chr2:99387660	C/A	cg08885076	chr2:99613938	TSGA10	-0.57	-4.83	-0.44	5.27e-6	Fear of minor pain;
THYM	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11209185	0.509	rs1926279	chr1:68450681	A/G	cg22082780	chr1:68452167	NA	0.54	6.48	0.55	4.12e-9	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	5.9	0.52	5.54e-8	Hip circumference adjusted for BMI;
THYM	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	4.59	0.43	1.35e-5	Hip circumference adjusted for BMI;
THYM	cis	rs877282	0.733	rs11253342	chr10:765072	A/G	cg10556349	chr10:835070	NA	-0.78	-5.06	-0.46	2.06e-6	Uric acid levels;
THYM	cis	rs7771547	0.573	rs544267	chr6:36398302	A/G	cg07856975	chr6:36356162	ETV7	0.52	4.72	0.44	8.26e-6	Platelet distribution width;
THYM	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03264133	chr6:25882463	NA	0.92	8.13	0.64	1.62e-12	Blood metabolite levels;
THYM	cis	rs9302065	0.565	rs2992905	chr13:95958190	C/T	cg26751094	chr13:95954534	ABCC4	-0.5	-5.7	-0.5	1.35e-7	Blood metabolite levels;
THYM	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs990171	0.955	rs11465583	chr2:102982466	C/G	cg13897122	chr2:103039542	IL18RAP	-0.4	-4.76	-0.44	6.87e-6	Lymphocyte counts;
THYM	cis	rs1829883	0.898	rs13184400	chr5:98784722	G/A	cg08333243	chr5:99726346	NA	-0.6	-5.73	-0.51	1.2e-7	Hemostatic factors and hematological phenotypes;
THYM	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg24692254	chr21:30365293	RNF160	-0.85	-7.06	-0.59	2.74e-10	Dental caries;
THYM	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg23851026	chr2:136556271	LCT	-0.56	-6.05	-0.53	2.91e-8	Mosquito bite size;
THYM	cis	rs10193935	0.901	rs12620021	chr2:42477034	T/C	cg27598129	chr2:42591480	NA	-0.75	-4.61	-0.43	1.25e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4766646	0.640	rs4766488	chr12:110296095	G/C	cg10794374	chr12:110278745	NA	-0.23	-4.87	-0.45	4.44e-6	Metabolite levels (MHPG);
THYM	cis	rs3781426	0.960	rs10901851	chr10:126722650	G/T	cg04494136	chr10:126703576	CTBP2	0.38	5.07	0.46	1.99e-6	Height;
THYM	trans	rs208520	0.690	rs864314	chr6:66814830	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.24	-15.07	-0.84	6.22e-27	Exhaled nitric oxide output;
THYM	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg22709100	chr7:91322751	NA	0.63	4.86	0.45	4.55e-6	Breast cancer;
THYM	cis	rs3087591	1.000	rs2051507	chr17:29700101	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.61	-5.11	-0.46	1.63e-6	Hip circumference;
THYM	cis	rs6964587	0.626	rs2106745	chr7:91506635	C/T	cg17063962	chr7:91808500	NA	-1.0	-8.65	-0.66	1.28e-13	Breast cancer;
THYM	cis	rs600806	0.850	rs3931560	chr1:109966718	A/C	cg23032129	chr1:109941072	SORT1	-0.6	-5.12	-0.46	1.63e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg02640540	chr1:67518911	SLC35D1	0.59	4.64	0.43	1.09e-5	Lymphocyte percentage of white cells;
THYM	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.57	-7.25	-0.6	1.12e-10	Monocyte percentage of white cells;
THYM	cis	rs7107174	0.901	rs10899497	chr11:78124534	T/C	cg02023728	chr11:77925099	USP35	0.6	5.59	0.5	2.19e-7	Testicular germ cell tumor;
THYM	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg16680214	chr1:154839983	KCNN3	-0.39	-4.63	-0.43	1.15e-5	Prostate cancer;
THYM	cis	rs72827839	0.846	rs76950846	chr17:46102153	G/A	cg23391107	chr17:45924227	SP6	0.82	5.54	0.49	2.72e-7	Ease of getting up in the morning;
THYM	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg18305652	chr10:134549665	INPP5A	0.82	7.87	0.63	5.75e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs2227564	0.620	rs10740418	chr10:75519322	T/C	cg00564723	chr10:75632066	CAMK2G	-0.54	-4.78	-0.44	6.31e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs57920188	0.584	rs12080562	chr1:4089697	C/A	cg08764037	chr1:3634867	TP73	-0.45	-4.63	-0.43	1.15e-5	Interleukin-17 levels;
THYM	cis	rs6570726	0.577	rs399502	chr6:145805874	A/G	cg13319975	chr6:146136371	FBXO30	-0.66	-5.29	-0.48	7.94e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg24818145	chr4:99064322	C4orf37	0.7	5.51	0.49	3.09e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2235573	0.805	rs5995536	chr22:38500827	G/A	cg19171272	chr22:38449367	NA	0.46	4.54	0.42	1.63e-5	Glioblastoma;Glioma;
THYM	cis	rs28595532	0.920	rs114544767	chr4:119728364	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs8192282	0.739	rs10908844	chr1:154500857	G/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg24818145	chr4:99064322	C4orf37	-0.76	-6.08	-0.53	2.55e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7917772	0.582	rs4917973	chr10:104333700	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg17333051	chr19:2783644	SGTA	0.51	4.55	0.42	1.56e-5	Total cholesterol levels;
THYM	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.78	-5.68	-0.5	1.45e-7	Prostate cancer;
THYM	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg00717180	chr2:96193071	NA	-0.72	-7.45	-0.61	4.21e-11	HDL cholesterol;
THYM	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg13319975	chr6:146136371	FBXO30	0.7	5.77	0.51	1.01e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg09085632	chr11:111637200	PPP2R1B	1.14	11.09	0.75	7.77e-19	Primary sclerosing cholangitis;
THYM	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	6.88	0.58	6.35e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs2635047	0.806	rs9962602	chr18:44599057	G/A	cg19077165	chr18:44547161	KATNAL2	-0.52	-5.56	-0.5	2.48e-7	Educational attainment;
THYM	cis	rs7582403	0.510	rs10207309	chr2:148915190	C/A	cg23727674	chr2:148602993	ACVR2A	0.63	4.61	0.43	1.24e-5	Neuroticism;
THYM	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg19774624	chr17:42201019	HDAC5	0.7	5.83	0.51	7.43e-8	Bone mineral density (hip);Bone mineral density (spine);
THYM	cis	rs78456975	0.941	rs13423300	chr2:1553809	C/A	cg12573674	chr2:1569213	NA	-1.22	-4.82	-0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg18755752	chr8:142205143	DENND3	-0.72	-7.18	-0.59	1.54e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs240764	0.619	rs10872623	chr6:101165047	A/G	cg21058520	chr6:100914733	NA	0.61	5.13	0.47	1.55e-6	Neuroticism;
THYM	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg08132940	chr7:1081526	C7orf50	-1.24	-7.36	-0.6	6.45e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs858239	0.932	rs1637190	chr7:23269065	A/G	cg05407003	chr7:23246146	NA	-0.62	-5.04	-0.46	2.23e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs4455778	0.538	rs13236051	chr7:49097829	T/C	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs4319547	0.656	rs4997380	chr12:122838956	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.76	-5.0	-0.46	2.62e-6	Body mass index;
THYM	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-7.23	-0.6	1.2e-10	Schizophrenia;
THYM	cis	rs12681287	0.640	rs4490816	chr8:87384938	T/C	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg16205897	chr5:131564050	P4HA2	0.48	4.52	0.42	1.76e-5	Blood metabolite levels;
THYM	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg11266682	chr4:10021025	SLC2A9	-0.52	-6.42	-0.55	5.41e-9	Bone mineral density;
THYM	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17598306	0.873	rs2016644	chr7:96596049	C/T	cg26766885	chr7:96220185	NA	0.62	5.13	0.47	1.56e-6	Radiation response;
THYM	cis	rs3741489	1.000	rs10781661	chr12:133431979	G/A	cg03157182	chr12:132655797	NA	-0.57	-4.65	-0.43	1.08e-5	Cognitive function;
THYM	cis	rs9902453	0.791	rs62068629	chr17:28187596	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.65	0.43	1.08e-5	Coffee consumption (cups per day);
THYM	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg20295408	chr7:1910781	MAD1L1	-0.59	-4.63	-0.43	1.15e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg23815491	chr16:72088622	HP	0.87	7.88	0.63	5.38e-12	Fibrinogen levels;
THYM	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg05738196	chr6:26577821	NA	0.75	5.96	0.52	4.36e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg18477163	chr1:228402036	OBSCN	-0.46	-5.0	-0.46	2.64e-6	Diastolic blood pressure;
THYM	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg08017756	chr2:100939284	LONRF2	-0.74	-7.59	-0.61	2.22e-11	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg24375607	chr4:120327624	NA	0.64	5.02	0.46	2.37e-6	Corneal astigmatism;
THYM	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg15448220	chr1:150897856	SETDB1	0.9	7.31	0.6	8.29e-11	Melanoma;
THYM	trans	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg10856724	chr12:34555212	NA	-1.01	-9.23	-0.69	7.34e-15	Bladder cancer;
THYM	cis	rs7941600	0.708	rs10840202	chr11:9320346	G/T	cg19415743	chr11:9336845	TMEM41B	1.12	5.49	0.49	3.31e-7	Coronary artery disease;
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg10233744	chr13:74557243	KLF12	0.88	7.04	0.59	2.99e-10	Energy expenditure (24h);
THYM	cis	rs3804749	0.966	rs726681	chr3:122837648	C/T	cg10259872	chr3:122802215	PDIA5	0.49	5.42	0.49	4.44e-7	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs4237845	0.742	rs3751330	chr12:58290226	T/C	cg22764591	chr12:58329936	NA	0.95	7.93	0.63	4.25e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7072216	0.763	rs10883090	chr10:100167236	G/C	cg03852570	chr10:100175106	PYROXD2	0.38	4.89	0.45	4.04e-6	Metabolite levels;
THYM	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg15556689	chr8:8085844	FLJ10661	0.7	5.84	0.51	7.29e-8	Mood instability;
THYM	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg00981070	chr1:2046702	PRKCZ	-0.43	-5.49	-0.49	3.27e-7	Height;
THYM	cis	rs8092503	0.536	rs12458494	chr18:52460505	A/G	cg07519816	chr18:53447596	NA	-0.74	-4.61	-0.43	1.26e-5	Childhood body mass index;
THYM	cis	rs8008758	1.000	rs12435364	chr14:101690209	G/A	cg26224664	chr14:101693935	NA	-0.55	-4.53	-0.42	1.73e-5	Body mass index (alcohol intake interaction);
THYM	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg00024416	chr22:24240387	NA	-0.63	-7.03	-0.58	3.13e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.74	6.16	0.53	1.77e-8	Tonsillectomy;
THYM	cis	rs804280	0.565	rs1466785	chr8:11623456	C/T	cg12395012	chr8:11607386	GATA4	-0.59	-5.45	-0.49	4.03e-7	Myopia (pathological);
THYM	cis	rs36051895	0.664	rs7857081	chr9:5096728	G/A	cg02405213	chr9:5042618	JAK2	-1.0	-11.3	-0.76	2.84e-19	Pediatric autoimmune diseases;
THYM	cis	rs2742417	0.603	rs2742370	chr3:45782098	T/C	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs7394190	0.748	rs60212594	chr10:75414344	G/C	cg02286717	chr10:75415704	SYNPO2L	-0.74	-4.83	-0.44	5.27e-6	Incident atrial fibrillation;
THYM	cis	rs7772486	0.742	rs4896851	chr6:146278959	T/C	cg23711669	chr6:146136114	FBXO30	-0.78	-7.17	-0.59	1.61e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2295359	0.892	rs4655686	chr1:67638004	T/A	cg11235152	chr1:67600687	NA	0.69	5.69	0.5	1.37e-7	Psoriasis;
THYM	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg08132940	chr7:1081526	C7orf50	-0.78	-5.32	-0.48	6.94e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg24531977	chr5:56204891	C5orf35	0.72	5.87	0.52	6.25e-8	Initial pursuit acceleration;
THYM	cis	rs868036	1.000	rs868036	chr15:68055013	T/A	cg24579218	chr15:68104479	NA	0.65	6.12	0.53	2.07e-8	Restless legs syndrome;
THYM	cis	rs6546324	0.625	rs1430791	chr2:67864800	A/C	cg18237512	chr2:67827392	NA	-0.79	-4.75	-0.44	7.23e-6	Endometriosis;
THYM	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg06481639	chr22:41940642	POLR3H	0.72	5.41	0.49	4.65e-7	Vitiligo;
THYM	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.58	0.5	2.29e-7	Rheumatoid arthritis;
THYM	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg22907277	chr7:1156413	C7orf50	0.82	4.98	0.46	2.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg10518543	chr12:38710700	ALG10B	-0.56	-4.57	-0.42	1.49e-5	Morning vs. evening chronotype;
THYM	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg11812906	chr14:75593930	NEK9	0.88	8.07	0.64	2.1e-12	Height;
THYM	cis	rs1018836	0.923	rs13262354	chr8:91635731	G/A	cg16814680	chr8:91681699	NA	-0.85	-7.26	-0.6	1.08e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	0.9	8.09	0.64	1.93e-12	Menarche (age at onset);
THYM	cis	rs58873874	0.737	rs10476050	chr5:156898874	C/A	cg08916508	chr5:156566250	MED7	-1.17	-4.52	-0.42	1.8e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs17005891	0.818	rs6851819	chr4:83572051	A/G	cg10249074	chr4:83542146	C4orf11	-0.66	-5.22	-0.47	1.07e-6	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg08999081	chr20:33150536	PIGU	0.76	6.73	0.57	1.27e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg24818145	chr4:99064322	C4orf37	0.68	5.26	0.47	8.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg22683308	chr4:1340831	KIAA1530	-0.61	-4.94	-0.45	3.4e-6	Longevity;
THYM	cis	rs9880211	0.848	rs71336069	chr3:136351866	G/C	cg21827317	chr3:136751795	NA	-0.69	-4.67	-0.43	1e-5	Body mass index;Height;
THYM	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg23958373	chr8:599963	NA	1.01	4.84	0.44	5.09e-6	IgG glycosylation;
THYM	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg24308560	chr3:49941425	MST1R	0.6	4.55	0.42	1.59e-5	Body mass index;
THYM	cis	rs4746818	1.000	rs4746818	chr10:70884687	G/T	cg11621586	chr10:70884670	VPS26A	1.31	12.11	0.78	5.65e-21	Left atrial antero-posterior diameter;
THYM	cis	rs28595532	0.688	rs116173135	chr4:119721949	C/T	cg14228332	chr4:119757509	SEC24D	1.46	5.56	0.5	2.47e-7	Cannabis dependence symptom count;
THYM	cis	rs10896135	0.526	rs1987169	chr11:66448044	A/G	cg24851651	chr11:66362959	CCS	-0.87	-7.22	-0.6	1.3e-10	Bipolar disorder;
THYM	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg13683864	chr3:40499215	RPL14	-1.05	-11.77	-0.77	2.9e-20	Renal cell carcinoma;
THYM	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg10589385	chr1:150898437	SETDB1	0.59	4.65	0.43	1.09e-5	Melanoma;
THYM	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg14349672	chr11:133703707	NA	-0.57	-5.32	-0.48	6.99e-7	Childhood ear infection;
THYM	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-6.38	-0.55	6.47e-9	Chronic sinus infection;
THYM	cis	rs9992101	0.645	rs1828538	chr4:77288033	G/A	cg20311846	chr4:77356250	SHROOM3	-0.53	-5.83	-0.51	7.6e-8	Creatinine levels;
THYM	cis	rs4919687	0.550	rs11191372	chr10:104462187	T/C	cg15744005	chr10:104629667	AS3MT	-0.58	-4.58	-0.43	1.4e-5	Colorectal cancer;
THYM	cis	rs4912314	0.903	rs1418978	chr1:56971724	C/T	cg11682697	chr1:56992372	PPAP2B	-0.47	-4.48	-0.42	2.12e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1003719	0.645	rs28503645	chr21:38443674	A/G	cg01329690	chr21:38580129	DSCR9	0.35	4.75	0.44	7.25e-6	Eye color traits;
THYM	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs10193935	0.901	rs9789740	chr2:42486799	A/G	cg27598129	chr2:42591480	NA	-0.75	-4.51	-0.42	1.87e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs73198271	0.737	rs506960	chr8:8630269	A/C	cg06636001	chr8:8085503	FLJ10661	-0.63	-4.55	-0.42	1.59e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs854765	0.624	rs12952723	chr17:17731651	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.59	-4.97	-0.45	2.95e-6	Total body bone mineral density;
THYM	cis	rs791888	0.929	rs2755431	chr10:89415104	C/T	cg10377144	chr10:89419177	PAPSS2	-0.4	-6.3	-0.54	9.38e-9	Magnesium levels;
THYM	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg18876405	chr7:65276391	NA	0.57	4.73	0.44	7.67e-6	Aortic root size;
THYM	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg08645402	chr16:4508243	NA	-0.64	-4.76	-0.44	6.9e-6	Schizophrenia;
THYM	cis	rs1670533	1.000	rs6812596	chr4:1069866	A/G	cg27284194	chr4:1044797	NA	0.61	4.6	0.43	1.29e-5	Recombination rate (females);
THYM	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg18850127	chr7:39170497	POU6F2	0.64	5.44	0.49	4.06e-7	IgG glycosylation;
THYM	trans	rs877282	0.898	rs10904547	chr10:766283	C/T	cg22713356	chr15:30763199	NA	1.37	10.19	0.72	6.35e-17	Uric acid levels;
THYM	cis	rs1551570	0.819	rs11666402	chr19:10219076	A/G	cg07543883	chr19:10213271	ANGPTL6	-0.47	-4.86	-0.45	4.6e-6	Narcolepsy;
THYM	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	8.57	0.66	1.87e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg21775007	chr8:11205619	TDH	-0.68	-5.06	-0.46	2.06e-6	Retinal vascular caliber;
THYM	cis	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg06521331	chr12:34319734	NA	-0.73	-5.66	-0.5	1.59e-7	Morning vs. evening chronotype;
THYM	cis	rs6893300	0.524	rs10516146	chr5:179166974	A/G	cg14593053	chr5:179126677	CANX	0.62	4.82	0.44	5.37e-6	Resting heart rate;
THYM	cis	rs1559088	0.522	rs7254912	chr19:33554151	A/G	cg03563238	chr19:33554763	RHPN2	-0.55	-4.69	-0.43	8.98e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs669446	0.562	rs10890275	chr1:44194216	T/G	cg12599982	chr1:44399894	ARTN	0.53	4.87	0.45	4.39e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg21138405	chr5:131827807	IRF1	-0.85	-9.31	-0.69	4.86e-15	Asthma (sex interaction);
THYM	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg18512352	chr11:47633146	NA	-0.5	-6.15	-0.53	1.83e-8	Subjective well-being;
THYM	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg03806693	chr22:41940476	POLR3H	1.09	8.85	0.67	4.85e-14	Vitiligo;
THYM	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg00757033	chr12:89920650	WDR51B	0.75	12.04	0.78	7.96e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg18876405	chr7:65276391	NA	-0.61	-5.16	-0.47	1.36e-6	Aortic root size;
THYM	cis	rs1298062	0.717	rs78467973	chr19:50995571	T/C	cg11430371	chr19:50961752	MYBPC2	0.45	4.45	0.42	2.34e-5	Age of smoking initiation;
THYM	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05901451	chr6:126070800	HEY2	-0.69	-5.95	-0.52	4.42e-8	Brugada syndrome;
THYM	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg12407791	chr17:73824354	UNC13D	-0.41	-4.54	-0.42	1.63e-5	White matter hyperintensity burden;
THYM	cis	rs6456156	0.586	rs9459862	chr6:167487011	A/G	cg00271210	chr6:167070053	RPS6KA2	0.5	5.07	0.46	1.96e-6	Primary biliary cholangitis;
THYM	cis	rs459482	1.000	rs459498	chr21:42795027	G/A	cg16817229	chr21:42798199	MX1	0.59	4.65	0.43	1.05e-5	IgG glycosylation;
THYM	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	trans	rs112998813	0.571	rs9590395	chr13:114927224	C/G	cg07263694	chr12:111748299	CUX2	1.17	6.87	0.58	6.59e-10	Nodular sclerosis Hodgkin lymphoma;
THYM	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-4.47	-0.42	2.14e-5	Personality dimensions;
THYM	cis	rs2050392	0.894	rs303430	chr10:30706235	C/A	cg02070205	chr10:30722105	MAP3K8	-0.56	-4.98	-0.45	2.86e-6	Inflammatory bowel disease;
THYM	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	7.1	0.59	2.3e-10	Platelet count;
THYM	cis	rs4285028	0.948	rs1920291	chr3:121672440	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs8062405	0.755	rs4149398	chr16:28608938	C/G	cg04193835	chr16:28379378	NA	-0.52	-4.92	-0.45	3.56e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg06784218	chr1:46089804	CCDC17	0.3	4.82	0.44	5.43e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs28595532	0.920	rs114584210	chr4:119773363	G/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs10231759	0.617	rs56077833	chr7:150513046	G/A	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.66	4.97	0.45	3e-6	Height;
THYM	cis	rs1915146	0.546	rs2454055	chr10:126859832	T/C	cg23000734	chr10:126850823	CTBP2	0.74	8.34	0.65	5.64e-13	Menarche (age at onset);
THYM	cis	rs189798	0.807	rs330905	chr8:8993551	A/T	cg06636001	chr8:8085503	FLJ10661	0.73	5.98	0.52	3.86e-8	Myopia (pathological);
THYM	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs3540	0.576	rs1974519	chr15:91036460	A/G	cg22089800	chr15:90895588	ZNF774	0.69	5.41	0.49	4.77e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs1346	0.552	rs11227235	chr11:65366495	A/T	cg27068330	chr11:65405492	SIPA1	0.7	4.54	0.42	1.67e-5	Vertical cup-disc ratio;Optic cup area;
THYM	cis	rs371025208	1	rs371025208	chr20:43928602	TGGGTGTGTGTGTGTAGGG/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.65	-5.93	-0.52	4.89e-8	Parental longevity (mother's age at death);
THYM	cis	rs1003719	0.715	rs2835639	chr21:38537016	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.53	-0.42	1.72e-5	Eye color traits;
THYM	cis	rs8048589	0.948	rs11648228	chr16:12181702	G/T	cg01990910	chr16:12207648	SNX29	-0.45	-5.27	-0.48	8.67e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	13.94	0.82	1.08e-24	Height;
THYM	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg13010199	chr12:38710504	ALG10B	0.74	5.91	0.52	5.32e-8	Heart rate;
THYM	cis	rs6565180	0.963	rs4787642	chr16:30359408	T/C	cg17640201	chr16:30407289	ZNF48	-0.86	-7.43	-0.61	4.79e-11	Tonsillectomy;
THYM	cis	rs1461503	0.534	rs7944405	chr11:122816099	A/G	cg27398637	chr11:122830231	C11orf63	-0.66	-6.02	-0.53	3.28e-8	Menarche (age at onset);
THYM	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg20387954	chr3:183756860	HTR3D	0.59	4.85	0.45	4.87e-6	Anterior chamber depth;
THYM	cis	rs2219968	0.701	rs7015968	chr8:78995994	A/G	cg00738934	chr8:78996279	NA	0.85	8.37	0.65	4.89e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2066819	1.000	rs78149779	chr12:56694817	A/G	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs12476592	0.516	rs6734648	chr2:63801525	A/G	cg17519650	chr2:63277830	OTX1	-0.68	-4.55	-0.42	1.57e-5	Childhood ear infection;
THYM	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg19052272	chr2:3704530	ALLC	-1.02	-8.19	-0.64	1.22e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs490234	0.702	rs1891035	chr9:128258684	T/C	cg14078157	chr9:128172775	NA	-0.76	-6.42	-0.55	5.35e-9	Mean arterial pressure;
THYM	cis	rs6840360	0.593	rs10033405	chr4:152474489	A/G	cg22705602	chr4:152727874	NA	-0.71	-7.94	-0.63	4.03e-12	Intelligence (multi-trait analysis);
THYM	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg06627557	chr7:32535165	LSM5;AVL9	0.85	7.62	0.62	1.88e-11	Cognitive ability;
THYM	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg02038168	chr22:39784481	NA	-0.6	-4.95	-0.45	3.25e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4918072	0.917	rs12571879	chr10:105663346	G/A	cg11005552	chr10:105648138	OBFC1	0.75	6.25	0.54	1.15e-8	Coronary artery disease;
THYM	cis	rs35110281	0.508	rs2838351	chr21:45110784	A/G	cg04455712	chr21:45112962	RRP1B	0.57	5.23	0.47	1e-6	Mean corpuscular volume;
THYM	cis	rs9527	0.590	rs3861984	chr10:104916980	T/C	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg19748678	chr4:122722346	EXOSC9	0.71	4.98	0.45	2.9e-6	Type 2 diabetes;
THYM	cis	rs9479482	0.935	rs5017315	chr6:150333574	C/T	cg25797454	chr6:150327115	RAET1K	0.46	5.03	0.46	2.28e-6	Alopecia areata;
THYM	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	4.47	0.42	2.13e-5	Alzheimer's disease;
THYM	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg08742575	chr21:47604166	C21orf56	0.72	5.89	0.52	5.86e-8	Testicular germ cell tumor;
THYM	cis	rs34638657	0.872	rs7202258	chr16:82195013	T/C	cg19807685	chr16:82068980	HSD17B2	-0.64	-5.06	-0.46	2.06e-6	Lung adenocarcinoma;
THYM	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg25036284	chr2:26402008	FAM59B	-0.77	-5.14	-0.47	1.49e-6	Gut microbiome composition (summer);
THYM	cis	rs11048434	0.518	rs759469	chr12:9175704	A/G	cg26114124	chr12:9217669	LOC144571	-0.51	-4.5	-0.42	1.94e-5	Sjögren's syndrome;
THYM	cis	rs921968	0.643	rs3932856	chr2:219320207	C/A	cg02176678	chr2:219576539	TTLL4	0.68	6.71	0.57	1.42e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9807841	0.592	rs3810155	chr19:10764867	C/G	cg16900796	chr19:10755136	SLC44A2	0.4	6.3	0.54	9.34e-9	Inflammatory skin disease;
THYM	cis	rs6812193	0.518	rs28864163	chr4:77195106	G/C	cg20311846	chr4:77356250	SHROOM3	0.51	4.46	0.42	2.25e-5	Parkinson's disease;
THYM	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg15448220	chr1:150897856	SETDB1	0.84	6.8	0.57	9.11e-10	Melanoma;
THYM	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Body mass index;
THYM	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg10047753	chr17:41438598	NA	1.18	11.26	0.76	3.4e-19	Menopause (age at onset);
THYM	cis	rs7715811	0.913	rs4368727	chr5:13770248	C/T	cg07548982	chr5:13769939	DNAH5	-0.5	-4.48	-0.42	2.1e-5	Subclinical atherosclerosis traits (other);
THYM	cis	rs4919687	0.577	rs12765459	chr10:104465687	G/C	cg15744005	chr10:104629667	AS3MT	-0.6	-4.71	-0.44	8.39e-6	Colorectal cancer;
THYM	cis	rs1696756	0.759	rs1298563	chr17:77834703	G/A	cg00646381	chr17:77835854	NA	0.47	5.54	0.49	2.73e-7	Glucocorticoid-induced osteonecrosis (age 10 years and older);
THYM	cis	rs1371867	0.846	rs1660349	chr8:101319326	G/A	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs7917772	0.636	rs2253709	chr10:104542745	T/A	cg15744005	chr10:104629667	AS3MT	0.65	4.59	0.43	1.34e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg16230307	chr14:35515116	FAM177A1	0.83	5.29	0.48	7.72e-7	Psoriasis;
THYM	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.7	-5.63	-0.5	1.83e-7	Prostate cancer;
THYM	cis	rs137603	0.644	rs470082	chr22:39715140	C/T	cg24268161	chr22:39747459	SYNGR1	0.65	5.49	0.49	3.4e-7	Primary biliary cholangitis;
THYM	cis	rs2702888	0.501	rs2738152	chr8:6752085	A/T	cg03082247	chr8:6756796	NA	0.55	4.65	0.43	1.07e-5	Blood pressure;
THYM	cis	rs13102973	0.932	rs13112935	chr4:135829379	T/C	cg14419869	chr4:135874104	NA	0.91	8.53	0.66	2.28e-13	Subjective well-being;
THYM	cis	rs765787	0.530	rs10851423	chr15:45515950	G/A	cg24006582	chr15:45444508	DUOX1	0.81	6.51	0.56	3.6e-9	Uric acid levels;
THYM	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg14784868	chr12:69753453	YEATS4	0.79	6.5	0.55	3.67e-9	Blood protein levels;
THYM	cis	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg21775007	chr8:11205619	TDH	0.74	6.67	0.57	1.65e-9	Retinal vascular caliber;
THYM	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.03	10.99	0.75	1.32e-18	Intelligence (multi-trait analysis);
THYM	cis	rs9796	0.553	rs7171437	chr15:41315168	G/A	cg21153102	chr15:41252147	NA	0.6	5.14	0.47	1.45e-6	Menopause (age at onset);
THYM	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	5.56	0.5	2.42e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs828999	0.688	rs7535267	chr1:108701706	A/T	cg24323958	chr1:108741884	SLC25A24	0.56	5.58	0.5	2.22e-7	Monocyte percentage of white cells;
THYM	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg16558253	chr16:72132732	DHX38	-0.66	-5.88	-0.52	6.13e-8	Fibrinogen levels;
THYM	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs259282	0.813	rs259250	chr19:33149216	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.75	5.5	0.49	3.23e-7	Schizophrenia;
THYM	cis	rs11608355	0.597	rs7300290	chr12:109832545	T/G	cg10504392	chr12:110044639	NA	0.53	4.66	0.43	1.04e-5	Neuroticism;
THYM	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg26597838	chr10:835615	NA	1.21	8.76	0.67	7.37e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs7584330	0.554	rs77380873	chr2:238426551	C/T	cg14458575	chr2:238380390	NA	1.02	5.32	0.48	6.82e-7	Prostate cancer;
THYM	cis	rs4930776	0.932	rs379170	chr12:5762302	A/G	cg02086166	chr12:5775618	ANO2	0.61	6.07	0.53	2.57e-8	Plasma clusterin levels;
THYM	cis	rs58688157	0.705	rs936468	chr11:607175	G/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.72	-5.66	-0.5	1.62e-7	Systemic lupus erythematosus;
THYM	cis	rs7011507	0.594	rs1123189	chr8:49358439	C/T	cg08774009	chr8:49309094	NA	-0.62	-4.92	-0.45	3.67e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9359856	0.636	rs9344946	chr6:90298371	T/G	cg13799429	chr6:90582589	CASP8AP2	0.78	6.94	0.58	4.78e-10	Bipolar disorder;
THYM	cis	rs8103278	1.000	rs17571725	chr19:46290822	C/T	cg14061069	chr19:46274453	DMPK	-0.57	-5.64	-0.5	1.77e-7	Coronary artery disease;
THYM	cis	rs8017423	0.967	rs2149655	chr14:90707246	T/C	cg04239629	chr14:90701769	NA	-0.62	-4.52	-0.42	1.81e-5	Mortality in heart failure;
THYM	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs1278769	0.786	rs3742238	chr13:113540425	C/T	cg01161842	chr13:113518337	ATP11A	0.69	4.72	0.44	8.24e-6	Interstitial lung disease;
THYM	cis	rs3126085	0.935	rs4845431	chr1:152227977	A/G	cg10321714	chr1:152280068	FLG	0.67	5.12	0.47	1.6e-6	Atopic dermatitis;
THYM	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg14675211	chr2:100938903	LONRF2	0.72	7.72	0.62	1.18e-11	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs9866391	0.607	rs9846396	chr3:141140968	C/T	cg13411656	chr3:141121016	ZBTB38	-0.32	-4.57	-0.42	1.46e-5	Myopia;
THYM	cis	rs2069036	1.000	rs4747257	chr10:16116598	T/A	cg26633223	chr10:15133461	NA	0.68	4.84	0.44	5e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs7119	0.717	rs12902852	chr15:77809016	C/G	cg10437265	chr15:77819839	NA	0.77	7.7	0.62	1.29e-11	Type 2 diabetes;
THYM	cis	rs7264396	0.563	rs7268195	chr20:34339854	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Total cholesterol levels;
THYM	cis	rs17739794	0.517	rs4439155	chr8:781047	C/T	cg01971667	chr8:817044	NA	-0.94	-8.22	-0.64	1.03e-12	Clozapine-induced cytotoxicity;
THYM	cis	rs2898681	0.581	rs730246	chr4:53680719	T/C	cg21521518	chr4:53727714	RASL11B	0.47	5.33	0.48	6.52e-7	Optic nerve measurement (cup area);
THYM	cis	rs13102973	0.965	rs11731021	chr4:135850391	G/T	cg14419869	chr4:135874104	NA	0.9	8.46	0.66	3.24e-13	Subjective well-being;
THYM	cis	rs7572733	0.534	rs2574832	chr2:198704818	T/G	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4474465	1.000	rs7395344	chr11:78202388	A/G	cg19901956	chr11:77921274	USP35	-0.65	-4.8	-0.44	5.97e-6	Alzheimer's disease (survival time);
THYM	cis	rs7851660	0.809	rs9299258	chr9:100666543	T/G	cg13688889	chr9:100608707	NA	-0.79	-5.75	-0.51	1.06e-7	Strep throat;
THYM	cis	rs7100689	0.646	rs1340375	chr10:82129039	C/T	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg03929089	chr4:120376271	NA	-1.03	-12.43	-0.79	1.26e-21	Height;
THYM	cis	rs4654899	0.931	rs58762579	chr1:21257831	G/A	cg01072550	chr1:21505969	NA	-0.66	-5.88	-0.52	5.99e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs7119	0.717	rs8042307	chr15:77804013	A/G	cg10437265	chr15:77819839	NA	0.76	7.57	0.61	2.38e-11	Type 2 diabetes;
THYM	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs9810089	0.843	rs518972	chr3:136039268	C/A	cg12473912	chr3:136751656	NA	0.6	4.88	0.45	4.22e-6	Gestational age at birth (child effect);
THYM	cis	rs7809950	0.678	rs7788271	chr7:106985873	A/G	cg23024343	chr7:107201750	COG5	-0.99	-8.39	-0.65	4.58e-13	Coronary artery disease;
THYM	cis	rs17401966	1.000	rs17411502	chr1:10431158	T/C	cg20482658	chr1:10539492	PEX14	0.39	4.72	0.44	8.05e-6	Hepatocellular carcinoma;
THYM	cis	rs7635838	0.617	rs346085	chr3:11282724	T/C	cg00170343	chr3:11313890	ATG7	0.64	4.87	0.45	4.41e-6	HDL cholesterol;
THYM	cis	rs7264396	0.563	rs6060569	chr20:34290731	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.76	-0.44	6.84e-6	Total cholesterol levels;
THYM	cis	rs870825	0.616	rs28558715	chr4:185627761	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs7187994	0.848	rs34179694	chr16:84776522	A/G	cg07647771	chr16:84786436	USP10	-0.55	-5.12	-0.46	1.61e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs4845875	0.600	rs1889293	chr1:11840862	G/A	cg24844545	chr1:11908347	NPPA	0.57	4.82	0.44	5.44e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg06108461	chr20:60628389	TAF4	-1.07	-9.19	-0.69	9.08e-15	Body mass index;
THYM	cis	rs36051895	0.603	rs1590804	chr9:5177573	T/C	cg02405213	chr9:5042618	JAK2	-1.0	-10.98	-0.75	1.39e-18	Pediatric autoimmune diseases;
THYM	cis	rs7072216	0.763	rs6584204	chr10:100173580	C/G	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg22166914	chr1:53195759	ZYG11B	0.8	8.04	0.64	2.5e-12	Monocyte count;
THYM	cis	rs7217780	0.735	rs4792586	chr17:15197417	T/G	cg21969477	chr17:15166505	PMP22	-0.54	-4.98	-0.46	2.8e-6	Preterm birth (maternal effect);
THYM	cis	rs2046867	0.908	rs62251648	chr3:72806083	A/G	cg25664220	chr3:72788482	NA	-0.86	-6.56	-0.56	2.76e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg01448562	chr3:133502909	NA	-0.84	-7.17	-0.59	1.59e-10	Iron status biomarkers;
THYM	cis	rs6906287	0.609	rs10457342	chr6:118948033	A/G	cg21191810	chr6:118973309	C6orf204	0.58	5.8	0.51	8.72e-8	Electrocardiographic conduction measures;
THYM	cis	rs6956675	0.957	rs28541324	chr7:62608767	G/A	cg27518014	chr7:62859535	LOC100287834	0.64	4.9	0.45	3.9e-6	Obesity-related traits;
THYM	cis	rs7512552	0.809	rs1694363	chr1:150368677	T/G	cg15654264	chr1:150340011	RPRD2	0.45	5.2	0.47	1.15e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg12963246	chr6:28129442	ZNF389	0.72	6.2	0.54	1.44e-8	Parkinson's disease;
THYM	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg12893428	chr3:195717962	SDHAP1	0.51	4.57	0.42	1.49e-5	Pancreatic cancer;
THYM	cis	rs35123781	0.502	rs355160	chr5:138953589	C/T	cg08720517	chr5:138729919	LOC389333	0.57	4.79	0.44	6.19e-6	Schizophrenia;
THYM	cis	rs2718058	0.519	rs2598072	chr7:37875319	A/C	cg02531859	chr7:37888154	TXNDC3	-0.88	-5.75	-0.51	1.06e-7	Alzheimer's disease (late onset);
THYM	cis	rs34638657	0.872	rs6564982	chr16:82167193	C/T	cg09894383	chr16:82067445	HSD17B2	-0.48	-4.77	-0.44	6.63e-6	Lung adenocarcinoma;
THYM	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg18357526	chr6:26021779	HIST1H4A	0.68	5.19	0.47	1.18e-6	Uric acid levels;
THYM	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg14004847	chr7:1930337	MAD1L1	-0.63	-4.47	-0.42	2.19e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs7681440	0.583	rs2736995	chr4:90762197	G/T	cg06632027	chr4:90757378	SNCA	0.66	5.29	0.48	7.91e-7	Dementia with Lewy bodies;
THYM	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg11764359	chr7:65958608	NA	-0.82	-6.45	-0.55	4.58e-9	Aortic root size;
THYM	cis	rs7216064	0.953	rs4791048	chr17:65848994	G/A	cg12091567	chr17:66097778	LOC651250	-0.72	-5.0	-0.46	2.59e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg04362960	chr10:104952993	NT5C2	0.65	5.6	0.5	2.04e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs9560113	1.000	rs11620313	chr13:112179363	G/A	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg00024416	chr22:24240387	NA	-0.7	-7.46	-0.61	4.15e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9810089	0.934	rs1153877	chr3:136004925	C/T	cg21827317	chr3:136751795	NA	0.54	4.47	0.42	2.18e-5	Gestational age at birth (child effect);
THYM	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11644478	chr21:40555479	PSMG1	-0.59	-4.95	-0.45	3.19e-6	Menarche (age at onset);
THYM	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg14458575	chr2:238380390	NA	0.99	7.13	0.59	1.93e-10	Prostate cancer;
THYM	cis	rs1401999	0.864	rs4148563	chr3:183725999	T/C	cg01324343	chr3:183735012	ABCC5	0.85	11.53	0.76	9.24e-20	Anterior chamber depth;
THYM	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg17063962	chr7:91808500	NA	-1.13	-12.74	-0.79	2.8e-22	Breast cancer;
THYM	trans	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg19862616	chr7:65841803	NCRNA00174	1.12	13.73	0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs944002	1.000	rs59643720	chr14:103564807	A/C	cg16996574	chr14:103691482	NA	0.51	4.71	0.44	8.42e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;
THYM	cis	rs1018836	0.798	rs28568272	chr8:91652958	A/G	cg16814680	chr8:91681699	NA	-0.98	-9.71	-0.71	6.91e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg26695010	chr11:65641043	EFEMP2	0.7	5.32	0.48	6.97e-7	Eosinophil percentage of white cells;
THYM	cis	rs9303401	0.632	rs7502541	chr17:57241019	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	5.4	0.48	4.91e-7	Cognitive test performance;
THYM	cis	rs7580658	0.676	rs12465955	chr2:128007074	A/T	cg10021288	chr2:128175891	PROC	-0.63	-5.85	-0.51	6.83e-8	Protein C levels;
THYM	cis	rs7107174	1.000	rs1006441	chr11:77932126	G/C	cg19901956	chr11:77921274	USP35	-0.73	-5.66	-0.5	1.58e-7	Testicular germ cell tumor;
THYM	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg18230493	chr5:56204884	C5orf35	0.91	6.9	0.58	5.71e-10	Initial pursuit acceleration;
THYM	cis	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg23422044	chr7:1970798	MAD1L1	-0.89	-6.61	-0.56	2.22e-9	Bipolar disorder;
THYM	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg10334053	chr1:2078117	PRKCZ	-0.45	-4.8	-0.44	5.83e-6	Height;
THYM	cis	rs1847202	0.859	rs4550778	chr3:72949198	G/A	cg25664220	chr3:72788482	NA	-0.64	-4.8	-0.44	6e-6	Motion sickness;
THYM	cis	rs1346	0.552	rs10791821	chr11:65368323	A/G	cg27068330	chr11:65405492	SIPA1	-0.7	-4.61	-0.43	1.25e-5	Vertical cup-disc ratio;Optic cup area;
THYM	cis	rs6032067	1.000	rs6032069	chr20:43867388	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	0.47	5.15	0.47	1.44e-6	Blood protein levels;
THYM	cis	rs12681287	0.640	rs13282351	chr8:87484669	C/T	cg27223183	chr8:87520930	FAM82B	-0.67	-5.05	-0.46	2.17e-6	Caudate activity during reward;
THYM	cis	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg06521331	chr12:34319734	NA	-0.84	-6.6	-0.56	2.37e-9	Morning vs. evening chronotype;
THYM	cis	rs6542838	0.644	rs7590596	chr2:99467938	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-4.46	-0.42	2.24e-5	Fear of minor pain;
THYM	cis	rs11785693	0.862	rs62489554	chr8:4960685	T/C	cg26367366	chr8:4980734	NA	1.03	5.19	0.47	1.2e-6	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs9875589	0.509	rs1844108	chr3:14024328	A/G	cg03204825	chr3:13978759	TPRXL	-0.55	-4.78	-0.44	6.32e-6	Ovarian reserve;
THYM	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg23708337	chr7:1209742	NA	0.81	4.48	0.42	2.1e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3892630	0.619	rs61062732	chr19:33304717	T/C	cg22980127	chr19:33182716	NUDT19	1.14	10.56	0.73	1.07e-17	Red blood cell traits;
THYM	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg13695892	chr22:41940480	POLR3H	-0.87	-6.35	-0.55	7.28e-9	Vitiligo;
THYM	cis	rs790123	1.000	rs2650950	chr3:122382048	C/T	cg17380795	chr3:122379686	NA	0.57	5.3	0.48	7.36e-7	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14159672	chr1:205819179	PM20D1	0.95	9.55	0.7	1.52e-15	Menarche (age at onset);
THYM	trans	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg25214090	chr10:38739885	LOC399744	0.9	7.17	0.59	1.58e-10	Corneal astigmatism;
THYM	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg27446573	chr6:127587934	RNF146	0.73	6.39	0.55	6.16e-9	Breast cancer;
THYM	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs9326248	0.530	rs6589576	chr11:116735788	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.91	-5.22	-0.47	1.05e-6	Blood protein levels;
THYM	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg15592062	chr6:167189543	RPS6KA2	-0.47	-4.76	-0.44	7.02e-6	Crohn's disease;
THYM	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs2237457	0.543	rs2529389	chr7:50701444	A/G	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.48e-6	Schizophrenia (treatment resistant);
THYM	cis	rs1021993	0.818	rs906349	chr1:209528128	G/T	cg06155620	chr1:209527581	NA	-0.63	-5.34	-0.48	6.36e-7	Gut microbiome composition (winter);
THYM	cis	rs892961	0.932	rs35657663	chr17:75412482	T/C	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs13315871	0.929	rs9857333	chr3:58293551	G/C	cg12435725	chr3:58293450	RPP14	-0.5	-5.35	-0.48	6.13e-7	Cholesterol, total;
THYM	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg18252515	chr7:66147081	NA	0.64	4.69	0.43	9.21e-6	Aortic root size;
THYM	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg10047753	chr17:41438598	NA	-1.14	-10.48	-0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg05962950	chr11:130786565	SNX19	0.96	9.68	0.7	7.81e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg03060546	chr3:49711283	APEH	-0.73	-5.64	-0.5	1.74e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs6500395	1.000	rs1872655	chr16:48670883	A/C	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.69	-0.62	1.33e-11	Personality dimensions;
THYM	cis	rs10889850	0.675	rs61783996	chr1:70219458	A/G	cg01711146	chr1:70671364	SFRS11;LRRC40	-0.76	-4.48	-0.42	2.1e-5	Body mass index;
THYM	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg05890377	chr2:74357713	NA	1.03	8.45	0.66	3.35e-13	Gestational age at birth (maternal effect);
THYM	cis	rs72699765	0.655	rs12593463	chr15:25859669	A/G	cg22934878	chr15:25227003	PAR-SN;SNORD107	-0.94	-4.55	-0.42	1.58e-5	Obstructive sleep apnea trait (average respiratory event duration);
THYM	cis	rs969413	0.624	rs9914093	chr17:79260653	C/G	cg06324037	chr17:79279053	C17orf55	0.45	4.5	0.42	1.95e-5	Frontotemporal dementia;
THYM	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg03388043	chr17:80084554	CCDC57	0.73	6.11	0.53	2.19e-8	Life satisfaction;
THYM	cis	rs9807841	0.670	rs1982075	chr19:10787744	C/G	cg16900796	chr19:10755136	SLC44A2	0.33	5.08	0.46	1.88e-6	Inflammatory skin disease;
THYM	cis	rs13126513	0.708	rs1491233	chr4:100476060	C/T	cg05468953	chr4:100565104	NA	0.64	5.88	0.52	6.06e-8	Metabolite levels (MHPG);
THYM	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg16586182	chr3:47516702	SCAP	0.61	5.29	0.48	7.83e-7	Colorectal cancer;
THYM	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg27532560	chr4:187881888	NA	0.87	9.39	0.69	3.38e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs754466	0.580	rs11002301	chr10:79574078	G/A	cg17075019	chr10:79541650	NA	-0.69	-5.61	-0.5	2.02e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1421898	0.625	rs74590225	chr5:157929064	G/A	cg06698293	chr5:158690540	UBLCP1	-0.95	-4.47	-0.42	2.15e-5	Inflammatory skin disease;
THYM	trans	rs9747201	1.000	rs9303023	chr17:80175920	C/T	cg07393940	chr7:158741817	NA	1.1	8.4	0.65	4.38e-13	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg12373951	chr3:133503437	NA	-0.65	-7.12	-0.59	2.07e-10	Iron status biomarkers;
THYM	cis	rs7814319	0.966	rs2319603	chr8:97270991	G/A	cg20787634	chr8:97240163	UQCRB	-0.79	-9.21	-0.69	8.24e-15	Lung function (FVC);
THYM	trans	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17712092	chr4:129076599	LARP1B	0.92	7.76	0.62	9.49e-12	Eosinophil percentage of white cells;
THYM	cis	rs35160687	0.787	rs10186289	chr2:86512988	G/A	cg10973622	chr2:86423274	IMMT	0.51	4.93	0.45	3.53e-6	Night sleep phenotypes;
THYM	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg23982607	chr1:1823379	GNB1	-0.94	-10.26	-0.72	4.7e-17	Body mass index;
THYM	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg22166914	chr1:53195759	ZYG11B	-0.77	-7.61	-0.62	1.98e-11	Monocyte count;
THYM	cis	rs11886999	0.680	rs62152972	chr2:96842653	C/T	cg18419276	chr2:96971862	SNRNP200	-0.52	-4.74	-0.44	7.6e-6	Cardiac Troponin-T levels;
THYM	cis	rs6074578	0.679	rs1594918	chr20:143754	C/T	cg16931068	chr20:139680	DEFB127	0.4	4.47	0.42	2.19e-5	Hirschsprung disease;
THYM	cis	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.62	0.43	1.23e-5	Obesity-related traits;
THYM	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.33	10.11	0.72	9.63e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg07648498	chr16:89883185	FANCA	0.61	4.49	0.42	2.02e-5	Vitiligo;
THYM	cis	rs6842047	0.706	rs4862667	chr4:187136416	A/G	cg09526685	chr4:187126073	CYP4V2	1.26	6.11	0.53	2.13e-8	Blood protein levels;
THYM	cis	rs600806	0.850	rs3768493	chr1:109935505	C/T	cg16988986	chr1:109941118	SORT1	-0.43	-4.56	-0.42	1.5e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2637266	1.000	rs7900616	chr10:78367075	C/T	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs9677476	0.863	rs5018532	chr2:232077075	A/G	cg20307347	chr2:231734563	ITM2C	-0.51	-4.5	-0.42	1.91e-5	Food antigen IgG levels;
THYM	cis	rs4363385	0.818	rs4576617	chr1:152985729	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.76	-0.44	6.94e-6	Inflammatory skin disease;
THYM	cis	rs1007190	0.881	rs9915066	chr17:42962166	C/T	cg15406952	chr17:42872593	NA	0.8	5.57	0.5	2.34e-7	DNA methylation (variation);
THYM	cis	rs113835537	0.529	rs3892818	chr11:66240191	C/T	cg24851651	chr11:66362959	CCS	0.62	4.48	0.42	2.09e-5	Airway imaging phenotypes;
THYM	cis	rs240764	0.817	rs239207	chr6:101137765	A/C	cg21058520	chr6:100914733	NA	-0.57	-5.21	-0.47	1.1e-6	Neuroticism;
THYM	cis	rs11048434	0.698	rs10842537	chr12:9066158	T/C	cg13575925	chr12:9217583	LOC144571	0.53	4.82	0.44	5.35e-6	Sjögren's syndrome;
THYM	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.76	-0.44	6.98e-6	Crohn's disease;
THYM	cis	rs669446	0.561	rs664336	chr1:44101800	A/G	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.65	4.77	0.44	6.71e-6	Cognitive test performance;
THYM	cis	rs4792901	0.759	rs9907813	chr17:41602858	T/G	cg21940313	chr17:41620911	ETV4	-0.55	-5.42	-0.49	4.55e-7	Dupuytren's disease;
THYM	cis	rs12912251	0.947	rs7177621	chr15:38999394	C/G	cg08274633	chr15:38988533	C15orf53	-0.24	-5.05	-0.46	2.14e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
THYM	cis	rs13380717	0.774	rs58763922	chr16:86908243	A/G	cg05661093	chr16:86825505	NA	-0.53	-4.67	-0.43	1.01e-5	Sepsis in extremely premature infants;
THYM	cis	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg07460842	chr6:66804631	NA	-0.9	-6.58	-0.56	2.6e-9	Exhaled nitric oxide output;
THYM	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg04944784	chr2:26401820	FAM59B	1.09	8.74	0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg18132916	chr6:79620363	NA	0.6	5.34	0.48	6.46e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg14690197	chr8:22456421	C8orf58	0.48	4.58	0.43	1.41e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg23982607	chr1:1823379	GNB1	-0.91	-10.06	-0.72	1.23e-16	Body mass index;
THYM	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg12516959	chr21:47718080	NA	0.38	5.02	0.46	2.4e-6	Testicular germ cell tumor;
THYM	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg00383909	chr3:49044727	WDR6	1.27	7.71	0.62	1.22e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs314370	0.904	rs314373	chr7:100456595	G/A	cg08558340	chr7:100472263	SRRT	0.61	4.98	0.46	2.82e-6	Resting heart rate;
THYM	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg08508325	chr11:3079039	CARS	-0.49	-6.38	-0.55	6.53e-9	Longevity;
THYM	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.7	6.62	0.56	2.17e-9	Lymphocyte counts;
THYM	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg06618935	chr21:46677482	NA	-0.98	-9.5	-0.7	1.95e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs17253792	0.822	rs10129890	chr14:56040413	A/T	cg01858014	chr14:56050164	KTN1	-1.17	-4.89	-0.45	4.1e-6	Putamen volume;
THYM	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg19761014	chr17:28927070	LRRC37B2	0.89	4.93	0.45	3.5e-6	Body mass index;
THYM	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg06600287	chr1:53387719	ECHDC2	-0.37	-6.01	-0.52	3.45e-8	Monocyte count;
THYM	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4909189	0.957	rs11766348	chr7:158135857	G/A	cg06219351	chr7:158114137	PTPRN2	-0.8	-7.17	-0.59	1.64e-10	Response to amphetamines;
THYM	cis	rs8053891	0.615	rs2000999	chr16:72108093	G/A	cg23815491	chr16:72088622	HP	0.71	5.2	0.47	1.15e-6	Coronary artery disease;
THYM	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg13319975	chr6:146136371	FBXO30	-0.68	-5.91	-0.52	5.44e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg00278517	chr6:167070616	RPS6KA2	-0.35	-4.85	-0.45	4.9e-6	Crohn's disease;
THYM	cis	rs909002	0.772	rs12740754	chr1:32083273	G/C	cg13919466	chr1:32135498	COL16A1	-0.5	-5.06	-0.46	2.01e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg09436375	chr6:42928200	GNMT	-0.43	-5.7	-0.51	1.32e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs17321999	0.904	rs59693338	chr2:30473177	T/C	cg05247661	chr2:30472410	LBH	0.65	4.78	0.44	6.4e-6	Systemic lupus erythematosus;
THYM	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg13395646	chr4:1353034	KIAA1530	-0.71	-6.45	-0.55	4.71e-9	Obesity-related traits;
THYM	cis	rs7119	0.604	rs2667781	chr15:77858619	A/C	cg27398640	chr15:77910606	LINGO1	0.63	7.13	0.59	1.93e-10	Type 2 diabetes;
THYM	cis	rs6674176	0.660	rs12726706	chr1:44399942	G/A	cg15962314	chr1:44399869	ARTN	0.53	5.11	0.46	1.64e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs67981189	0.896	rs34731365	chr14:71449594	C/T	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg17888033	chr8:143858414	LYNX1	-0.44	-4.89	-0.45	4.14e-6	Urinary tract infection frequency;
THYM	cis	rs7578361	1.000	rs6744828	chr2:150431338	T/G	cg17961725	chr2:150454027	NA	0.74	6.08	0.53	2.49e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg24578937	chr1:2090814	PRKCZ	-0.59	-6.18	-0.54	1.58e-8	Height;
THYM	cis	rs9527	0.545	rs11191602	chr10:104954219	C/T	cg04362960	chr10:104952993	NT5C2	0.62	4.72	0.44	8.15e-6	Arsenic metabolism;
THYM	cis	rs4595586	0.545	rs11610886	chr12:39390613	C/G	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs9549260	0.755	rs4325426	chr13:41216437	C/A	cg21288729	chr13:41239152	FOXO1	0.73	5.55	0.5	2.52e-7	Red blood cell count;
THYM	cis	rs986417	0.818	rs10873125	chr14:61035024	G/A	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.84e-8	Systolic blood pressure;
THYM	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg15445000	chr17:37608096	MED1	-0.41	-5.04	-0.46	2.26e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg09085632	chr11:111637200	PPP2R1B	1.19	12.69	0.79	3.69e-22	Primary sclerosing cholangitis;
THYM	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.43	0.7	2.73e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg23815491	chr16:72088622	HP	0.81	6.46	0.55	4.54e-9	Fibrinogen levels;
THYM	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg22166914	chr1:53195759	ZYG11B	0.63	5.44	0.49	4.16e-7	Monocyte count;
THYM	cis	rs57244997	0.725	rs7754703	chr6:162440488	T/C	cg17173639	chr6:162384350	PARK2	-0.76	-5.04	-0.46	2.25e-6	Mosquito bite size;
THYM	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg10950924	chr17:47092072	IGF2BP1	-0.68	-8.14	-0.64	1.51e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs595982	0.501	rs112370206	chr19:49396623	C/T	cg19746536	chr19:49375674	PPP1R15A	0.99	9.1	0.68	1.36e-14	Red cell distribution width;
THYM	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg12573674	chr2:1569213	NA	-1.16	-8.07	-0.64	2.18e-12	IgG glycosylation;
THYM	cis	rs904251	0.861	rs2776877	chr6:37487135	G/A	cg01843034	chr6:37503916	NA	-0.71	-5.61	-0.5	1.98e-7	Cognitive performance;
THYM	cis	rs4654899	0.733	rs10799678	chr1:21322785	C/T	cg01072550	chr1:21505969	NA	-0.79	-7.73	-0.62	1.11e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg08885076	chr2:99613938	TSGA10	0.57	5.28	0.48	8.05e-7	Chronic sinus infection;
THYM	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg08999081	chr20:33150536	PIGU	0.77	6.95	0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg15445000	chr17:37608096	MED1	-0.44	-5.19	-0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs6840258	0.660	rs55816619	chr4:87959805	G/A	cg10685359	chr4:87814065	C4orf36	-0.45	-4.51	-0.42	1.84e-5	Mean corpuscular volume;Basophil percentage of granulocytes;
THYM	cis	rs240764	0.578	rs9498252	chr6:101194481	A/G	cg21058520	chr6:100914733	NA	-0.58	-5.05	-0.46	2.11e-6	Neuroticism;
THYM	cis	rs28595532	1.000	rs17258106	chr4:119675406	C/T	cg14228332	chr4:119757509	SEC24D	-1.4	-4.53	-0.42	1.69e-5	Cannabis dependence symptom count;
THYM	cis	rs2354432	0.607	rs3766524	chr1:146729093	A/G	cg25205988	chr1:146714368	CHD1L	-1.04	-5.54	-0.49	2.67e-7	Mitochondrial DNA levels;
THYM	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg08847533	chr14:75593920	NEK9	-0.61	-5.38	-0.48	5.4e-7	Neuroticism;
THYM	cis	rs6988636	1.000	rs13260626	chr8:124190317	C/T	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs111684993	1	rs111684993	chr15:41436737	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.7	-5.49	-0.49	3.32e-7	Coronary artery disease;
THYM	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg05368731	chr17:41323189	NBR1	1.25	11.37	0.76	2.01e-19	Menopause (age at onset);
THYM	trans	rs4460079	0.507	rs6831348	chr4:114792093	A/C	cg25329844	chr11:118015865	SCN4B	0.82	7.07	0.59	2.64e-10	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs9420	0.528	rs73480556	chr11:57400462	G/C	cg19752551	chr11:57585705	CTNND1	-0.56	-5.08	-0.46	1.87e-6	Schizophrenia;
THYM	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg14008862	chr17:28927542	LRRC37B2	0.88	4.64	0.43	1.11e-5	Body mass index;
THYM	cis	rs864643	0.773	rs77852826	chr3:39598328	A/G	cg20142358	chr3:39093977	WDR48	-0.69	-4.79	-0.44	6.04e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs7192750	0.586	rs8063324	chr16:71967599	T/G	cg06353428	chr16:71660113	MARVELD3	0.77	5.72	0.51	1.21e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.65	-4.88	-0.45	4.29e-6	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg15448220	chr1:150897856	SETDB1	0.89	7.54	0.61	2.83e-11	Melanoma;
THYM	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg08968635	chr6:28129556	ZNF389	0.59	4.57	0.42	1.46e-5	Parkinson's disease;
THYM	cis	rs8041943	0.643	rs4779127	chr15:79916800	C/T	cg20511832	chr15:78934280	CHRNB4	0.44	4.94	0.45	3.39e-6	Bone mineral density (spine) and age at menarche;
THYM	cis	rs11096990	0.551	rs2060005	chr4:39162521	A/G	cg24403649	chr4:39172243	NA	0.57	4.81	0.44	5.65e-6	Cognitive function;
THYM	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg12573674	chr2:1569213	NA	1.19	4.49	0.42	2.02e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs7084402	0.967	rs1658451	chr10:60311527	A/T	cg07615347	chr10:60278583	BICC1	0.56	5.15	0.47	1.4e-6	Refractive error;
THYM	cis	rs10463554	0.927	rs257312	chr5:102419627	T/A	cg23492399	chr5:102201601	PAM	-0.69	-5.17	-0.47	1.27e-6	Parkinson's disease;
THYM	cis	rs4383453	0.539	rs12631960	chr3:123097568	A/G	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	6.24	0.54	1.2e-8	Bone mineral density;
THYM	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg22709100	chr7:91322751	NA	-0.6	-4.68	-0.43	9.41e-6	Breast cancer;
THYM	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2070677	0.877	rs1581935	chr10:135360448	T/G	cg20169779	chr10:135381914	SYCE1	0.88	6.55	0.56	3e-9	Gout;
THYM	cis	rs7264396	0.733	rs6060515	chr20:34211779	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-5.65	-0.5	1.67e-7	Total cholesterol levels;
THYM	cis	rs4430311	1.000	rs3008657	chr1:244023667	A/G	cg25706552	chr1:244017396	NA	0.57	4.8	0.44	5.97e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs7546094	1.000	rs11102497	chr1:113109274	T/C	cg22162597	chr1:113214053	CAPZA1	0.45	4.62	0.43	1.21e-5	Platelet distribution width;
THYM	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-4.96	-0.45	3.03e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9560113	0.959	rs9555802	chr13:112179504	T/C	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs35883536	0.967	rs1981134	chr1:101111205	G/T	cg06223162	chr1:101003688	GPR88	-0.65	-4.99	-0.46	2.78e-6	Monocyte count;
THYM	cis	rs7582180	0.903	rs7607170	chr2:100903008	C/G	cg14675211	chr2:100938903	LONRF2	0.65	5.52	0.49	2.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg07570687	chr10:102243282	WNT8B	0.84	8.04	0.64	2.45e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs354225	0.584	rs7586311	chr2:54810762	A/G	cg23486701	chr2:54789491	SPTBN1	0.36	4.96	0.45	3.11e-6	Schizophrenia;
THYM	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg04317338	chr11:64019027	PLCB3	0.86	5.95	0.52	4.48e-8	Mean platelet volume;
THYM	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06481639	chr22:41940642	POLR3H	0.8	5.78	0.51	9.29e-8	Vitiligo;
THYM	trans	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg10856724	chr12:34555212	NA	-0.9	-8.08	-0.64	2.05e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1847202	0.859	rs13068268	chr3:72938132	G/A	cg25664220	chr3:72788482	NA	-0.61	-4.54	-0.42	1.64e-5	Motion sickness;
THYM	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs4509693	0.882	rs7900763	chr10:102492559	A/C	cg24127310	chr10:102502104	NA	0.97	5.36	0.48	5.92e-7	Alzheimer's disease;
THYM	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	7.11	0.59	2.1e-10	Platelet count;
THYM	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg17105886	chr17:28927953	LRRC37B2	1.22	7.38	0.6	5.85e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2737265	0.723	rs2737257	chr8:116665915	C/A	cg04656070	chr8:116661063	TRPS1	-0.58	-6.72	-0.57	1.36e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;
THYM	cis	rs3741151	0.773	rs73544720	chr11:73173496	A/G	cg12959048	chr11:73096162	RELT	-0.51	-4.83	-0.44	5.14e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg06521331	chr12:34319734	NA	-0.96	-8.88	-0.67	4.06e-14	Morning vs. evening chronotype;
THYM	cis	rs7089973	0.966	rs61867966	chr10:116584362	T/C	cg23260525	chr10:116636907	FAM160B1	0.6	5.49	0.49	3.28e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg06850241	chr22:41845214	NA	0.54	4.59	0.43	1.35e-5	Vitiligo;
THYM	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg22875332	chr1:76189707	ACADM	-0.91	-13.71	-0.81	3.06e-24	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg10057126	chr4:77819792	ANKRD56	0.71	6.06	0.53	2.78e-8	Emphysema distribution in smoking;
THYM	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.69	-5.16	-0.47	1.36e-6	Tonsillectomy;
THYM	cis	rs4788570	0.527	rs72791971	chr16:71477297	C/G	cg06353428	chr16:71660113	MARVELD3	-1.01	-5.04	-0.46	2.2e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.564	rs6466970	chr7:124592755	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs2692947	0.770	rs2315417	chr2:96500289	T/C	cg22654517	chr2:96458247	NA	0.64	4.78	0.44	6.3e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs7617773	0.780	rs11718350	chr3:48360992	T/G	cg02219026	chr3:48282209	ZNF589	-0.64	-4.54	-0.42	1.62e-5	Coronary artery disease;
THYM	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg03806693	chr22:41940476	POLR3H	-1.22	-10.52	-0.73	1.3e-17	Vitiligo;
THYM	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24531977	chr5:56204891	C5orf35	-1.0	-8.34	-0.65	5.78e-13	Initial pursuit acceleration;
THYM	cis	rs13315871	1.000	rs13066269	chr3:58449244	T/C	cg12435725	chr3:58293450	RPP14	-0.46	-4.93	-0.45	3.54e-6	Cholesterol, total;
THYM	cis	rs35123781	1.000	rs9687282	chr5:139065988	T/G	cg10513866	chr5:139070639	NA	0.47	4.58	0.43	1.41e-5	Schizophrenia;
THYM	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg27170947	chr2:26402098	FAM59B	-0.78	-6.09	-0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg17264618	chr3:40429014	ENTPD3	-0.5	-4.87	-0.45	4.42e-6	Renal cell carcinoma;
THYM	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg20387954	chr3:183756860	HTR3D	0.56	4.64	0.43	1.11e-5	Anterior chamber depth;
THYM	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg14779329	chr11:130786720	SNX19	0.51	5.54	0.49	2.67e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	5.48	0.49	3.49e-7	Personality dimensions;
THYM	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.58	5.92	0.52	4.99e-8	Eosinophil percentage of white cells;
THYM	cis	rs2219968	1.000	rs1121552	chr8:78958699	T/G	cg00738934	chr8:78996279	NA	0.91	9.75	0.71	5.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3126085	0.560	rs72698932	chr1:152355520	C/T	cg10321714	chr1:152280068	FLG	-0.69	-4.84	-0.44	5.1e-6	Atopic dermatitis;
THYM	cis	rs7264396	0.563	rs6060567	chr20:34288250	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.76	-0.44	6.84e-6	Total cholesterol levels;
THYM	cis	rs16857609	1.000	rs3821098	chr2:218292141	T/C	cg15335768	chr2:218268053	DIRC3	0.35	5.25	0.47	9.31e-7	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	trans	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	trans	rs9951602	0.512	rs9949512	chr18:76641845	T/C	cg02800362	chr5:177631904	HNRNPAB	1.11	8.66	0.66	1.21e-13	Obesity-related traits;
THYM	cis	rs2777491	0.957	rs7181911	chr15:41674060	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.08	-11.71	-0.77	3.97e-20	Ulcerative colitis;
THYM	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg04315214	chr1:2043799	PRKCZ	-0.58	-4.54	-0.42	1.67e-5	Height;
THYM	cis	rs8070740	0.898	rs4605225	chr17:5324136	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.7	5.78	0.51	9.4e-8	Menopause (age at onset);
THYM	cis	rs2637266	0.935	rs2583049	chr10:78403962	T/C	cg18941641	chr10:78392320	NA	0.76	6.37	0.55	6.8e-9	Pulmonary function;
THYM	cis	rs6840360	0.837	rs13146981	chr4:152720703	T/C	cg22705602	chr4:152727874	NA	0.62	6.85	0.57	7.31e-10	Intelligence (multi-trait analysis);
THYM	cis	rs3960554	0.808	rs11983987	chr7:75657850	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-4.52	-0.42	1.77e-5	Eotaxin levels;
THYM	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg22166914	chr1:53195759	ZYG11B	0.97	12.07	0.78	6.85e-21	Monocyte count;
THYM	cis	rs6684428	0.610	rs10493189	chr1:56315657	A/G	cg11651538	chr1:56320950	NA	-0.7	-4.7	-0.43	8.73e-6	Airflow obstruction;
THYM	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg03690763	chr11:133734501	NA	-0.61	-4.73	-0.44	7.77e-6	Childhood ear infection;
THYM	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11890956	chr21:40555474	PSMG1	1.11	11.21	0.75	4.45e-19	Cognitive function;
THYM	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.79e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs476633	0.691	rs28735224	chr15:41537539	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.64	-5.32	-0.48	6.85e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs28595532	0.920	rs115076001	chr4:119764346	T/G	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs113835537	0.529	rs75683511	chr11:66275026	A/G	cg24851651	chr11:66362959	CCS	0.73	5.13	0.47	1.52e-6	Airway imaging phenotypes;
THYM	cis	rs9807989	0.507	rs2293224	chr2:103035779	T/C	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	4.98	0.45	2.88e-6	Schizophrenia;
THYM	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg19875535	chr5:140030758	IK	-0.67	-5.76	-0.51	1.05e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg09537434	chr19:41945824	ATP5SL	1.06	9.53	0.7	1.66e-15	Height;
THYM	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs7104764	0.957	rs56357554	chr11:204715	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	-1.13	-9.93	-0.71	2.28e-16	Menarche (age at onset);
THYM	cis	rs11074306	0.896	rs28636453	chr15:28080420	G/A	cg03462380	chr15:27112902	GABRA5	-0.42	-4.86	-0.45	4.61e-6	Uveal melanoma;
THYM	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg08470875	chr2:26401718	FAM59B	-0.72	-4.46	-0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg23803603	chr1:2058230	PRKCZ	0.62	4.75	0.44	7.21e-6	Height;
THYM	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg24812749	chr6:127587940	RNF146	0.99	8.06	0.64	2.3e-12	Breast cancer;
THYM	cis	rs17125944	0.686	rs77650471	chr14:53364307	C/T	cg00686598	chr14:53173677	PSMC6	1.12	5.02	0.46	2.38e-6	Alzheimer's disease (late onset);
THYM	cis	rs12282928	1.000	rs7130032	chr11:48326963	C/A	cg22827986	chr11:48284249	OR4X1	0.51	5.29	0.48	7.88e-7	Migraine - clinic-based;
THYM	cis	rs6694672	1.000	rs12092294	chr1:196966853	C/T	cg13682187	chr1:196946512	CFHR5	0.81	4.72	0.44	8.07e-6	Asthma;
THYM	cis	rs2070677	0.866	rs2987796	chr10:135379688	C/T	cg20169779	chr10:135381914	SYCE1	0.79	5.76	0.51	1.01e-7	Gout;
THYM	cis	rs662064	0.962	rs607941	chr1:10539543	C/T	cg20482658	chr1:10539492	PEX14	-0.48	-5.85	-0.51	6.92e-8	Asthma;
THYM	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg04362960	chr10:104952993	NT5C2	0.58	4.66	0.43	1.01e-5	Arsenic metabolism;
THYM	cis	rs7824557	0.564	rs13268126	chr8:11230574	G/A	cg21775007	chr8:11205619	TDH	-0.68	-5.26	-0.47	8.84e-7	Retinal vascular caliber;
THYM	cis	rs9828933	0.752	rs12633353	chr3:63970280	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.92	-4.53	-0.42	1.7e-5	Type 2 diabetes;
THYM	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg12386194	chr3:101231763	SENP7	0.69	5.16	0.47	1.34e-6	Colorectal cancer;
THYM	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg15592062	chr6:167189543	RPS6KA2	0.58	6.0	0.52	3.51e-8	Crohn's disease;
THYM	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg03690763	chr11:133734501	NA	-0.61	-4.73	-0.44	7.77e-6	Childhood ear infection;
THYM	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.56	-5.82	-0.51	7.94e-8	Crohn's disease;
THYM	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs10929159	0.928	rs2123513	chr2:236920638	T/C	cg20128773	chr2:236923534	AGAP1	0.36	4.75	0.44	7.13e-6	Parkinson's disease;
THYM	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-1.03	-10.05	-0.72	1.3e-16	Colorectal cancer;
THYM	cis	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg10856724	chr12:34555212	NA	0.85	7.65	0.62	1.61e-11	Morning vs. evening chronotype;
THYM	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg26597838	chr10:835615	NA	1.19	8.47	0.66	3.06e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg09549813	chr16:4587862	C16orf5	-0.59	-6.92	-0.58	5.27e-10	Schizophrenia;
THYM	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg20486651	chr6:167070296	RPS6KA2	-0.48	-4.8	-0.44	5.86e-6	Crohn's disease;
THYM	cis	rs910187	0.678	rs8115769	chr20:45813704	A/C	cg27589058	chr20:45804311	EYA2	-0.59	-5.15	-0.47	1.43e-6	Migraine;
THYM	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg18252515	chr7:66147081	NA	0.6	4.52	0.42	1.76e-5	Aortic root size;
THYM	cis	rs995000	0.931	rs4915840	chr1:62999595	C/G	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs67311347	0.635	rs73071706	chr3:40288190	C/A	cg17264618	chr3:40429014	ENTPD3	0.49	4.87	0.45	4.49e-6	Renal cell carcinoma;
THYM	cis	rs9314614	0.789	rs2951858	chr8:6713809	C/T	cg27319216	chr8:6693540	XKR5	0.54	5.56	0.5	2.45e-7	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs79349575	0.783	rs12453374	chr17:46994846	G/C	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs7582180	0.726	rs4438499	chr2:100876789	A/G	cg08017756	chr2:100939284	LONRF2	0.59	5.48	0.49	3.49e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2811415	0.597	rs9809087	chr3:127761128	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs3771570	0.901	rs3771587	chr2:242409701	A/G	cg21155796	chr2:242212141	HDLBP	1.14	5.7	0.5	1.33e-7	Prostate cancer;
THYM	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg13683864	chr3:40499215	RPL14	-0.87	-8.46	-0.66	3.22e-13	Renal cell carcinoma;
THYM	cis	rs113835537	0.660	rs7116940	chr11:66303895	T/C	cg24851651	chr11:66362959	CCS	0.7	4.69	0.43	9.3e-6	Airway imaging phenotypes;
THYM	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg00290607	chr11:67383545	NA	0.76	5.28	0.48	8.05e-7	Mean corpuscular volume;
THYM	cis	rs75920871	0.588	rs7118591	chr11:116908457	A/C	cg20608306	chr11:116969690	SIK3	0.49	5.34	0.48	6.24e-7	Subjective well-being;
THYM	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg02187348	chr16:89574699	SPG7	0.75	6.08	0.53	2.49e-8	Multiple myeloma (IgH translocation);
THYM	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg21773646	chr17:80085082	CCDC57	-0.37	-5.16	-0.47	1.37e-6	Life satisfaction;
THYM	cis	rs7220711	1.000	rs6503470	chr17:41788360	A/C	cg26893861	chr17:41843967	DUSP3	0.65	5.63	0.5	1.83e-7	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs9549260	0.755	rs9566553	chr13:41174231	A/G	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg26384229	chr12:38710491	ALG10B	0.71	5.51	0.49	3.05e-7	Morning vs. evening chronotype;
THYM	cis	rs4638749	0.677	rs1563112	chr2:108850579	C/T	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs2816062	0.813	rs2816051	chr1:18895460	A/G	cg18795169	chr1:18902165	NA	-0.99	-12.14	-0.78	5.02e-21	Urate levels in lean individuals;
THYM	cis	rs8077889	0.703	rs231531	chr17:41946180	A/C	cg26893861	chr17:41843967	DUSP3	0.64	4.82	0.44	5.35e-6	Triglycerides;
THYM	cis	rs9826463	0.582	rs6440076	chr3:142015067	T/A	cg20824294	chr3:142316082	PLS1	0.68	4.71	0.43	8.59e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg20291162	chr17:40259547	DHX58	-0.7	-6.47	-0.55	4.18e-9	Fibrinogen levels;
THYM	cis	rs6687430	0.532	rs4846235	chr1:10632235	C/T	cg20482658	chr1:10539492	PEX14	0.49	5.97	0.52	4.09e-8	Hand grip strength;
THYM	cis	rs4788570	0.615	rs7193549	chr16:71649416	T/C	cg06353428	chr16:71660113	MARVELD3	1.38	9.28	0.69	5.58e-15	Intelligence (multi-trait analysis);
THYM	trans	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.07e-11	Bladder cancer;
THYM	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg09307838	chr4:120376055	NA	0.77	5.56	0.5	2.5e-7	Corneal astigmatism;
THYM	cis	rs7078219	0.743	rs11190133	chr10:101278725	C/T	cg23904955	chr10:101282759	NA	-0.41	-4.89	-0.45	4.15e-6	Dental caries;
THYM	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg00684032	chr4:1343700	KIAA1530	0.56	4.79	0.44	6.14e-6	Longevity;
THYM	cis	rs5015933	0.801	rs7848571	chr9:128141206	A/T	cg14078157	chr9:128172775	NA	-0.56	-4.76	-0.44	6.85e-6	Body mass index;
THYM	cis	rs56309584	0.521	rs11651599	chr17:8179512	A/G	cg08322244	chr17:8066669	VAMP2	-0.55	-4.87	-0.45	4.39e-6	Initial pursuit acceleration;
THYM	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg10803722	chr21:46713166	LOC642852	-0.37	-4.68	-0.43	9.63e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs62435770	1.000	rs62433643	chr6:169545189	C/T	cg07652237	chr6:170125491	PHF10	0.49	4.53	0.42	1.73e-5	Loneliness;
THYM	trans	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11756438	0.572	rs2638529	chr6:119006459	T/C	cg21191810	chr6:118973309	C6orf204	0.59	5.76	0.51	1.05e-7	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.38	0.6	5.91e-11	Bladder cancer;
THYM	cis	rs981844	0.775	rs17299561	chr4:154765480	C/T	cg10318528	chr4:154702461	SFRP2	-0.46	-4.48	-0.42	2.1e-5	Response to statins (LDL cholesterol change);
THYM	cis	rs7078219	0.743	rs11190128	chr10:101275149	A/C	cg07044859	chr10:101282883	NA	-0.46	-4.94	-0.45	3.34e-6	Dental caries;
THYM	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.81	-7.13	-0.59	1.96e-10	Monocyte percentage of white cells;
THYM	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.46	-0.73	1.74e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg02734326	chr4:10020555	SLC2A9	0.76	6.89	0.58	6.16e-10	Bone mineral density;
THYM	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg12560992	chr17:57184187	TRIM37	0.93	8.65	0.66	1.26e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg09877947	chr5:131593287	PDLIM4	0.6	5.1	0.46	1.71e-6	Breast cancer;
THYM	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg06238570	chr21:40685208	BRWD1	-0.97	-9.35	-0.69	4.03e-15	Cognitive function;
THYM	cis	rs2742234	0.541	rs61845684	chr10:43744983	T/C	cg06632098	chr10:43605906	RET	0.77	5.17	0.47	1.27e-6	Hirschsprung disease;
THYM	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg19678392	chr7:94953810	PON1	-0.71	-5.68	-0.5	1.46e-7	Paraoxonase activity;
THYM	cis	rs12282928	1.000	rs1905287	chr11:48322153	A/C	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg06558623	chr16:89946397	TCF25	1.15	6.38	0.55	6.37e-9	Skin colour saturation;
THYM	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs16912285	0.688	rs35683920	chr11:24358521	A/G	ch.11.24196551F	chr11:24239977	NA	0.83	5.72	0.51	1.21e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs9902453	1.000	rs7221743	chr17:28407876	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-4.62	-0.43	1.2e-5	Coffee consumption (cups per day);
THYM	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg00576331	chr11:65640516	EFEMP2	-0.68	-4.58	-0.43	1.42e-5	Crohn's disease;
THYM	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg24209194	chr3:40518798	ZNF619	0.67	5.53	0.49	2.85e-7	Renal cell carcinoma;
THYM	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg08859206	chr1:53392774	SCP2	-0.66	-7.55	-0.61	2.7e-11	Monocyte count;
THYM	cis	rs1775715	0.737	rs1419171	chr10:32214831	C/A	cg04359828	chr10:32216031	ARHGAP12	0.41	5.12	0.46	1.62e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg21138405	chr5:131827807	IRF1	0.87	9.49	0.7	2.01e-15	Asthma (sex interaction);
THYM	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg23711669	chr6:146136114	FBXO30	0.82	7.84	0.63	6.69e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs34638657	0.872	rs2967350	chr16:82196130	T/C	cg09894383	chr16:82067445	HSD17B2	-0.56	-5.88	-0.52	6e-8	Lung adenocarcinoma;
THYM	cis	rs12347191	0.500	rs1912998	chr9:100621386	T/C	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Orofacial clefts;
THYM	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg08109568	chr15:31115862	NA	-0.78	-6.65	-0.56	1.89e-9	Huntington's disease progression;
THYM	cis	rs7267979	0.933	rs6138571	chr20:25435388	A/G	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg16797656	chr11:68205561	LRP5	0.44	4.52	0.42	1.8e-5	Total body bone mineral density;
THYM	cis	rs61931739	0.591	rs4931764	chr12:33979423	A/G	cg06521331	chr12:34319734	NA	-0.56	-4.69	-0.43	8.97e-6	Morning vs. evening chronotype;
THYM	cis	rs4907240	0.961	rs62154845	chr2:97267644	G/A	cg18419276	chr2:96971862	SNRNP200	-0.4	-4.73	-0.44	7.72e-6	Event-related brain oscillations;
THYM	cis	rs236907	0.859	rs56377810	chr1:171757657	A/C	cg20598894	chr1:171756153	METTL13	-0.73	-5.28	-0.48	8.25e-7	Mean platelet volume;
THYM	cis	rs11190604	0.767	rs12360395	chr10:102194074	A/T	cg07570687	chr10:102243282	WNT8B	0.85	8.46	0.66	3.16e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs12135062	0.687	rs6685614	chr1:3108517	C/T	cg25382214	chr1:3105252	PRDM16	0.57	4.71	0.44	8.33e-6	Migraine;
THYM	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7513165	0.736	rs4889	chr1:204159787	G/C	cg04791601	chr1:204159016	NA	0.4	5.05	0.46	2.12e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
THYM	cis	rs11089937	0.616	rs4991802	chr22:22533421	G/T	cg06866756	chr22:22471216	NA	-0.41	-4.52	-0.42	1.75e-5	Periodontitis (PAL4Q3);
THYM	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg15704280	chr7:45808275	SEPT13	-0.98	-11.44	-0.76	1.43e-19	Coronary artery disease;
THYM	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.87	0.45	4.53e-6	Bipolar disorder;
THYM	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg25517755	chr10:38738941	LOC399744	-0.79	-7.77	-0.62	9.18e-12	Educational attainment;
THYM	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg11941060	chr3:133502564	NA	0.73	6.23	0.54	1.24e-8	Iron status biomarkers;
THYM	cis	rs6964587	0.626	rs6979235	chr7:91511776	T/C	cg17063962	chr7:91808500	NA	-1.0	-8.67	-0.66	1.16e-13	Breast cancer;
THYM	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg26384229	chr12:38710491	ALG10B	0.95	7.06	0.59	2.68e-10	Bladder cancer;
THYM	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg18132916	chr6:79620363	NA	-0.57	-4.78	-0.44	6.48e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	0.507	rs2849534	chr6:163144657	T/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.88	-6.98	-0.58	3.94e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg12863693	chr15:85201151	NMB	0.62	5.57	0.5	2.41e-7	Schizophrenia;
THYM	cis	rs7178572	0.568	rs12906708	chr15:77681444	A/G	cg22256960	chr15:77711686	NA	-1.05	-8.4	-0.65	4.29e-13	Type 2 diabetes;
THYM	cis	rs7107174	1.000	rs2510049	chr11:77985459	G/T	cg19901956	chr11:77921274	USP35	-0.69	-5.3	-0.48	7.42e-7	Testicular germ cell tumor;
THYM	cis	rs9393692	0.620	rs4412193	chr6:26338056	A/G	cg13736514	chr6:26305472	NA	-0.46	-4.7	-0.43	8.63e-6	Educational attainment;
THYM	cis	rs7567389	0.677	rs72846002	chr2:128118147	G/A	cg09760422	chr2:128146352	NA	0.4	4.52	0.42	1.8e-5	Self-rated health;
THYM	cis	rs4363385	0.588	rs1577960	chr1:153025687	G/A	cg13444842	chr1:152974279	SPRR3	-0.62	-4.98	-0.45	2.89e-6	Inflammatory skin disease;
THYM	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg02896835	chr1:92012615	NA	0.6	5.08	0.46	1.86e-6	Breast cancer;
THYM	cis	rs2075230	0.705	rs2541010	chr17:7551320	T/C	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.28	-4.62	-0.43	1.21e-5	Hormone measurements;
THYM	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg11846333	chr4:119757529	SEC24D	1.35	5.12	0.46	1.6e-6	Cannabis dependence symptom count;
THYM	cis	rs2235649	0.789	rs4567715	chr16:1849363	G/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg13385794	chr1:248469461	NA	0.67	4.61	0.43	1.24e-5	Common traits (Other);
THYM	cis	rs12681287	0.927	rs2953517	chr8:87332013	C/T	cg27223183	chr8:87520930	FAM82B	-0.65	-4.76	-0.44	6.8e-6	Caudate activity during reward;
THYM	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg20503657	chr10:835505	NA	1.14	8.04	0.64	2.5e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs6127978	0.646	rs12479884	chr20:55801785	C/T	cg15851418	chr20:55835831	BMP7	0.67	4.83	0.44	5.29e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg11494091	chr17:61959527	GH2	1.05	15.5	0.85	9.5e-28	Prudent dietary pattern;
THYM	cis	rs11089937	0.616	rs6001219	chr22:22538738	A/G	cg06866756	chr22:22471216	NA	-0.46	-5.09	-0.46	1.79e-6	Periodontitis (PAL4Q3);
THYM	cis	rs1568889	1.000	rs7949057	chr11:28255053	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.57e-6	Bipolar disorder;
THYM	cis	rs4842666	0.915	rs11105364	chr12:90069276	T/G	cg00757033	chr12:89920650	WDR51B	0.46	4.58	0.43	1.42e-5	Blood pressure;
THYM	cis	rs3741798	1.000	rs17303178	chr12:12485351	G/A	cg08615371	chr12:12503544	MANSC1	0.88	4.89	0.45	4.17e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg23758822	chr17:41437982	NA	1.15	10.81	0.74	3.1e-18	Menopause (age at onset);
THYM	cis	rs57920188	0.584	rs12068729	chr1:4091650	A/G	cg20703997	chr1:4087676	NA	0.85	5.76	0.51	1.04e-7	Interleukin-17 levels;
THYM	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg26314531	chr2:26401878	FAM59B	0.76	4.96	0.45	3.13e-6	Gut microbiome composition (summer);
THYM	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg17074396	chr22:49843754	NA	-0.4	-4.7	-0.43	8.73e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7043114	0.525	rs1053441	chr9:95147840	T/A	cg14631576	chr9:95140430	CENPP	-0.85	-9.03	-0.68	1.99e-14	Height;
THYM	cis	rs7246657	0.943	rs8109038	chr19:38015709	A/G	cg23950597	chr19:37808831	NA	0.74	4.77	0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs10504073	0.584	rs62507210	chr8:49946601	C/T	cg00325661	chr8:49890786	NA	1.07	10.5	0.73	1.43e-17	Blood metabolite ratios;
THYM	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.12	9.06	0.68	1.73e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg08859206	chr1:53392774	SCP2	-0.65	-7.39	-0.6	5.57e-11	Monocyte count;
THYM	cis	rs13064411	0.696	rs869342	chr3:113226330	C/T	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-4.57	-0.42	1.47e-5	Bladder cancer;
THYM	cis	rs870825	0.860	rs11132253	chr4:185595472	C/T	cg04058563	chr4:185651563	MLF1IP	0.98	7.31	0.6	8.33e-11	Blood protein levels;
THYM	cis	rs4930103	0.935	rs4930098	chr11:2020955	G/C	cg06197492	chr11:2016605	H19	0.63	5.48	0.49	3.56e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.64	-0.74	7.23e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg08999081	chr20:33150536	PIGU	0.62	5.02	0.46	2.41e-6	Coronary artery disease;
THYM	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.34	-0.48	6.28e-7	Menopause (age at onset);
THYM	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg13175981	chr1:150552382	MCL1	0.7	4.99	0.46	2.72e-6	Tonsillectomy;
THYM	cis	rs2072499	0.865	rs2758603	chr1:156198994	T/C	cg25208724	chr1:156163844	SLC25A44	0.97	9.94	0.71	2.21e-16	Testicular germ cell tumor;
THYM	cis	rs9486719	1.000	rs12210146	chr6:96903962	A/G	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs524281	0.773	rs2236651	chr11:66001418	C/T	cg00563793	chr11:65837595	PACS1	0.79	4.71	0.43	8.53e-6	Electroencephalogram traits;
THYM	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg23758822	chr17:41437982	NA	1.15	11.04	0.75	1.01e-18	Menopause (age at onset);
THYM	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg22947322	chr17:47091978	IGF2BP1	-0.54	-4.48	-0.42	2.1e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.95	0.52	4.39e-8	Hip circumference adjusted for BMI;
THYM	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg05738196	chr6:26577821	NA	0.83	7.86	0.63	6e-12	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9314614	0.872	rs2977792	chr8:6711508	G/C	cg27319216	chr8:6693540	XKR5	-0.64	-6.92	-0.58	5.3e-10	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs2932538	0.922	rs6681371	chr1:113101168	A/C	cg22162597	chr1:113214053	CAPZA1	0.63	4.84	0.44	5.12e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg17279839	chr7:150038598	RARRES2	-0.55	-5.31	-0.48	7.06e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs1978968	1.000	rs1079576	chr22:18446318	C/A	cg01550578	chr22:18484421	MICAL3	0.69	5.25	0.47	9.38e-7	Presence of antiphospholipid antibodies;
THYM	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg15556689	chr8:8085844	FLJ10661	0.71	6.07	0.53	2.57e-8	Mood instability;
THYM	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs951188	0.744	rs1196677	chr2:150341051	C/A	cg17961725	chr2:150454027	NA	0.94	4.78	0.44	6.41e-6	Daytime sleep phenotypes;
THYM	trans	rs34156428	1.000	rs7945007	chr11:16494570	A/G	cg02688867	chr12:133019854	NA	0.54	6.89	0.58	6.12e-10	Coronary artery disease;
THYM	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs11776767	0.828	rs1991650	chr8:10706323	C/T	cg13457217	chr8:10683266	MIR1322;PINX1	-0.65	-4.77	-0.44	6.53e-6	Triglycerides;
THYM	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg05962950	chr11:130786565	SNX19	0.92	8.74	0.67	8.09e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs7542375	0.534	rs1580685	chr1:221022394	C/G	cg16008148	chr1:221062819	NA	0.47	4.88	0.45	4.23e-6	Obesity-related traits;
THYM	cis	rs858239	0.699	rs955187	chr7:23194605	A/G	cg18081818	chr7:23246105	NA	0.54	4.83	0.44	5.17e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs8170	1.000	rs34084277	chr19:17387176	A/G	cg21956434	chr19:17377697	C19orf62	0.73	4.48	0.42	2.11e-5	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
THYM	cis	rs1395	0.744	rs9653564	chr2:27472618	G/A	cg23587288	chr2:27483067	SLC30A3	-0.69	-6.19	-0.54	1.53e-8	Blood metabolite levels;
THYM	cis	rs11088226	0.581	rs2236430	chr21:33973408	A/G	cg21642649	chr21:34144118	C21orf66;C21orf49	0.59	4.47	0.42	2.18e-5	Gastritis;
THYM	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.89	-8.78	-0.67	6.71e-14	Lung cancer;
THYM	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg11247378	chr22:39784982	NA	-1.03	-12.63	-0.79	4.69e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	trans	rs3960554	0.808	rs78340819	chr7:75673833	C/G	cg19862616	chr7:65841803	NCRNA00174	0.95	7.23	0.6	1.21e-10	Eotaxin levels;
THYM	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg12826209	chr6:26865740	GUSBL1	0.84	6.07	0.53	2.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs13315871	1.000	rs28668389	chr3:58323942	G/C	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	trans	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg25517755	chr10:38738941	LOC399744	-0.8	-7.87	-0.63	5.58e-12	Educational attainment;
THYM	cis	rs1374313	1.000	rs2100076	chr2:120150778	C/T	cg18093372	chr2:119607603	NA	-0.45	-4.5	-0.42	1.95e-5	Obesity-related traits;
THYM	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg05660106	chr1:15850417	CASP9	0.71	5.75	0.51	1.07e-7	Systolic blood pressure;
THYM	cis	rs2898681	0.874	rs4864691	chr4:53755972	C/T	cg00791764	chr4:53727839	RASL11B	0.5	6.37	0.55	6.81e-9	Optic nerve measurement (cup area);
THYM	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg26384229	chr12:38710491	ALG10B	0.93	7.84	0.63	6.59e-12	Bladder cancer;
THYM	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg13319975	chr6:146136371	FBXO30	0.65	5.35	0.48	6.03e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg02527881	chr3:46936655	PTH1R	-0.69	-7.11	-0.59	2.13e-10	Colorectal cancer;
THYM	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.65	-0.62	1.6e-11	Schizophrenia;
THYM	cis	rs7829975	0.777	rs6989926	chr8:8547313	A/C	cg08975724	chr8:8085496	FLJ10661	-0.64	-4.96	-0.45	3.04e-6	Mood instability;
THYM	cis	rs7106204	0.609	rs12790279	chr11:24286221	C/G	ch.11.24196551F	chr11:24239977	NA	1.01	6.48	0.55	3.97e-9	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg14972814	chr11:95582409	MTMR2	0.61	5.73	0.51	1.19e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg08045932	chr20:61659980	NA	0.95	10.41	0.73	2.18e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4790333	0.813	rs2926992	chr17:2256026	C/A	cg02569219	chr17:2266849	SGSM2	0.75	6.7	0.57	1.46e-9	Proinsulin levels;
THYM	cis	rs4988958	0.584	rs7589142	chr2:103024660	T/C	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma (childhood onset);
THYM	cis	rs9649213	0.614	rs4236537	chr7:97996593	T/C	cg09267113	chr7:98030324	BAIAP2L1	-0.68	-5.75	-0.51	1.08e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8014204	0.550	rs12434356	chr14:75123374	C/A	cg06637938	chr14:75390232	RPS6KL1	0.59	5.46	0.49	3.87e-7	Caffeine consumption;
THYM	cis	rs7107174	1.000	rs58235466	chr11:78030886	T/C	cg02023728	chr11:77925099	USP35	0.67	6.21	0.54	1.38e-8	Testicular germ cell tumor;
THYM	cis	rs7072216	0.691	rs7910973	chr10:100166732	G/A	cg03852570	chr10:100175106	PYROXD2	0.38	4.89	0.45	4.04e-6	Metabolite levels;
THYM	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg17863274	chr19:49399704	TULP2	-0.93	-5.69	-0.5	1.43e-7	Red cell distribution width;
THYM	cis	rs2637266	0.818	rs7894799	chr10:78392012	T/C	cg18941641	chr10:78392320	NA	0.6	4.79	0.44	6.07e-6	Pulmonary function;
THYM	cis	rs8067545	0.611	rs12603372	chr17:20181566	C/T	cg13482628	chr17:19912719	NA	0.53	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg26818010	chr10:134567672	INPP5A	-0.74	-6.17	-0.53	1.7e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs58235267	0.553	rs11890276	chr2:63366191	C/T	cg17519650	chr2:63277830	OTX1	0.68	5.71	0.51	1.31e-7	Prostate-specific antigen levels (conditioned on lead SNPs);
THYM	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg26446133	chr18:72167187	CNDP2	-0.99	-7.91	-0.63	4.64e-12	Refractive error;
THYM	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg08736216	chr1:53307985	ZYG11A	0.66	5.22	0.47	1.04e-6	Monocyte count;
THYM	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg26384229	chr12:38710491	ALG10B	0.98	8.65	0.66	1.29e-13	Morning vs. evening chronotype;
THYM	cis	rs7523273	0.565	rs4081159	chr1:207885479	G/A	cg22525895	chr1:207977042	MIR29B2	0.53	5.03	0.46	2.34e-6	Schizophrenia;
THYM	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-6.2	-0.54	1.47e-8	Total body bone mineral density;
THYM	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg04106633	chr4:1044584	NA	0.49	4.78	0.44	6.3e-6	Recombination rate (males);
THYM	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg24642844	chr7:1081250	C7orf50	-1.29	-8.31	-0.65	6.62e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11563648	0.573	rs2106151	chr7:126957327	A/G	cg23081781	chr7:127225937	GCC1	-0.37	-5.19	-0.47	1.17e-6	Resting heart rate;
THYM	cis	rs9807989	0.839	rs1974675	chr2:102986375	G/A	cg03938978	chr2:103052716	IL18RAP	0.67	7.1	0.59	2.28e-10	Asthma;
THYM	cis	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg21775007	chr8:11205619	TDH	0.71	5.85	0.51	6.91e-8	Retinal vascular caliber;
THYM	cis	rs28595532	0.920	rs115994609	chr4:119777273	G/A	cg11846333	chr4:119757529	SEC24D	1.45	5.08	0.46	1.92e-6	Cannabis dependence symptom count;
THYM	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg16586182	chr3:47516702	SCAP	-0.6	-5.15	-0.47	1.39e-6	Colorectal cancer;
THYM	cis	rs7186908	0.793	rs7191623	chr16:72212044	G/A	cg23815491	chr16:72088622	HP	0.75	5.24	0.47	9.79e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs12681287	0.752	rs4463401	chr8:87250309	C/T	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs7901056	1.000	rs7901056	chr10:26712483	T/G	cg23318538	chr10:26883079	C10orf50	0.37	4.81	0.44	5.62e-6	Lymphocyte counts;
THYM	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6840360	0.550	rs6816471	chr4:152494869	A/G	cg22705602	chr4:152727874	NA	-0.77	-8.05	-0.64	2.4e-12	Intelligence (multi-trait analysis);
THYM	cis	rs863345	0.604	rs1578763	chr1:158497414	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	5.09	0.46	1.8e-6	Menarche (age at onset);
THYM	cis	rs17006441	0.866	rs6805945	chr3:69879759	G/A	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28595532	0.688	rs116053430	chr4:119731375	G/A	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs4631830	0.900	rs4630241	chr10:51532751	G/A	cg10326726	chr10:51549505	MSMB	-0.62	-6.26	-0.54	1.11e-8	Prostate-specific antigen levels;
THYM	cis	rs2033711	0.840	rs4801590	chr19:58961813	G/C	cg13877915	chr19:58951672	ZNF132	0.91	8.64	0.66	1.34e-13	Uric acid clearance;
THYM	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg14298792	chr15:30685198	CHRFAM7A	0.8	5.6	0.5	2.1e-7	Huntington's disease progression;
THYM	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg24069376	chr3:38537580	EXOG	-0.69	-6.73	-0.57	1.29e-9	Electrocardiographic conduction measures;
THYM	cis	rs3768617	0.510	rs2296290	chr1:183079412	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs7582180	0.681	rs6754176	chr2:100995691	C/T	cg08017756	chr2:100939284	LONRF2	-0.72	-7.39	-0.6	5.75e-11	Intelligence (multi-trait analysis);
THYM	cis	rs72627123	0.867	rs59675549	chr14:74469480	A/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs654128	0.506	rs339298	chr6:117222067	C/T	cg12892004	chr6:117198278	RFX6	-0.72	-5.66	-0.5	1.61e-7	Telomere length;
THYM	cis	rs1005224	0.963	rs2302592	chr14:76129287	C/G	cg04684003	chr14:76127793	TTLL5;C14orf1	0.72	5.8	0.51	8.78e-8	Large artery stroke;
THYM	cis	rs28830936	0.510	rs11858843	chr15:42092915	C/A	cg17847044	chr15:42102381	MAPKBP1	-0.37	-6.63	-0.56	2.02e-9	Diastolic blood pressure;
THYM	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg26384229	chr12:38710491	ALG10B	1.0	9.65	0.7	9.1e-16	Heart rate;
THYM	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	5.81	0.51	8.16e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.9	6.1	0.53	2.33e-8	Schizophrenia;
THYM	cis	rs7631605	0.905	rs6550457	chr3:37182198	T/C	cg21328643	chr3:37258149	NA	-0.47	-4.62	-0.43	1.21e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs56104184	1.000	rs56104184	chr19:49370310	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.99	-5.97	-0.52	4.09e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs9902453	0.934	rs12453172	chr17:28441590	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	4.76	0.44	6.96e-6	Coffee consumption (cups per day);
THYM	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs988913	0.957	rs10485136	chr6:54756495	A/G	cg19716238	chr6:54711378	FAM83B	-0.47	-4.8	-0.44	5.78e-6	Menarche (age at onset);
THYM	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7944735	0.517	rs11039520	chr11:48130794	A/G	cg24672777	chr11:48374446	OR4C45	-0.99	-5.4	-0.48	4.85e-7	Intraocular pressure;
THYM	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg24690094	chr11:67383802	NA	-0.71	-4.64	-0.43	1.13e-5	Mean corpuscular volume;
THYM	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg12386194	chr3:101231763	SENP7	0.7	5.24	0.47	9.79e-7	Colorectal cancer;
THYM	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg13609457	chr4:120235615	NA	0.59	5.29	0.48	7.68e-7	Corneal astigmatism;
THYM	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg05313129	chr8:58192883	C8orf71	-0.83	-4.74	-0.44	7.5e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg27572855	chr1:25598939	RHD	0.61	4.81	0.44	5.72e-6	Erythrocyte sedimentation rate;
THYM	cis	rs6500395	1.000	rs3848322	chr16:48620964	C/A	cg04672837	chr16:48644449	N4BP1	0.49	4.83	0.44	5.15e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg26597838	chr10:835615	NA	1.2	8.64	0.66	1.3e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg14129053	chr2:1895732	MYT1L	1.13	4.49	0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	5.51	0.49	3.02e-7	Hip circumference adjusted for BMI;
THYM	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs8020441	0.541	rs2131837	chr14:51154779	A/G	cg04730355	chr14:51134070	SAV1	1.0	5.87	0.52	6.49e-8	Cognitive performance;
THYM	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg03959625	chr15:84868606	LOC388152	0.48	4.59	0.43	1.35e-5	Schizophrenia;
THYM	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg13683864	chr3:40499215	RPL14	1.06	13.36	0.81	1.53e-23	Renal cell carcinoma;
THYM	cis	rs7940866	0.838	rs7949071	chr11:130877478	T/C	cg05962950	chr11:130786565	SNX19	0.61	4.82	0.44	5.4e-6	Schizophrenia;
THYM	cis	rs1018836	0.608	rs1015994	chr8:91465011	T/C	cg16814680	chr8:91681699	NA	-0.71	-5.72	-0.51	1.22e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	trans	rs10962692	0.608	rs62541878	chr9:16861205	A/T	cg03221025	chr16:88955224	CBFA2T3	0.75	7.2	0.59	1.37e-10	Ovarian cancer in BRCA2 mutation carriers;Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;
THYM	cis	rs12367572	0.663	rs1857926	chr12:45344524	C/T	cg03114573	chr12:45410052	DBX2	-0.48	-4.55	-0.42	1.57e-5	Gut microbiome composition (summer);
THYM	cis	rs4947962	0.618	rs6957176	chr7:55101285	C/G	cg23594882	chr7:54487346	NA	0.9	4.7	0.43	8.7e-6	Subjective response to lithium treatment;
THYM	cis	rs28785552	0.554	rs11084182	chr19:53213411	A/G	cg22067481	chr19:53234126	ZNF611	-0.98	-9.54	-0.7	1.56e-15	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs6700896	0.931	rs17127849	chr1:66105512	A/G	cg04111102	chr1:66153794	NA	0.57	5.37	0.48	5.64e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg02018176	chr4:1364513	KIAA1530	0.6	4.69	0.43	9.22e-6	Obesity-related traits;
THYM	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg07343612	chr16:622815	PIGQ	-1.06	-9.96	-0.71	1.99e-16	Height;
THYM	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9549260	0.755	rs59308928	chr13:41245079	C/T	cg21288729	chr13:41239152	FOXO1	0.73	5.82	0.51	7.84e-8	Red blood cell count;
THYM	cis	rs8053891	0.615	rs3794695	chr16:72097827	C/T	cg23815491	chr16:72088622	HP	0.71	5.26	0.48	8.81e-7	Coronary artery disease;
THYM	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg23161317	chr6:28129485	ZNF389	0.84	6.3	0.54	9.31e-9	Parkinson's disease;
THYM	cis	rs34638657	0.732	rs62045964	chr16:82200920	T/C	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.11	-0.64	1.73e-12	Lung adenocarcinoma;
THYM	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9311676	0.656	rs12495490	chr3:58373251	A/G	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	10.27	0.73	4.38e-17	Chronic sinus infection;
THYM	cis	rs6598955	0.671	rs6681452	chr1:26621101	G/A	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.71	0.44	8.29e-6	Obesity-related traits;
THYM	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg24642844	chr7:1081250	C7orf50	-0.7	-4.83	-0.44	5.26e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7943203	0.525	rs920679	chr11:108038477	C/T	cg04873221	chr11:107992290	ACAT1	0.72	4.94	0.45	3.37e-6	Red blood cell count;Mean corpuscular volume;
THYM	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg05025164	chr4:1340916	KIAA1530	0.94	7.61	0.62	1.94e-11	Longevity;
THYM	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg23161317	chr6:28129485	ZNF389	0.68	5.38	0.48	5.35e-7	Parkinson's disease;
THYM	cis	rs12496230	1.000	rs62258957	chr3:66864153	G/T	cg23477460	chr3:66848765	NA	1.04	6.57	0.56	2.68e-9	Type 2 diabetes;
THYM	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg22535103	chr8:58192502	C8orf71	-0.86	-4.82	-0.44	5.4e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.37	5.27	0.48	8.36e-7	Obesity-related traits;
THYM	cis	rs892961	0.932	rs6501954	chr17:75414398	G/C	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs2073300	0.609	rs6137951	chr20:23429459	T/C	cg12062639	chr20:23401060	NAPB	1.18	6.3	0.54	9.34e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg24642844	chr7:1081250	C7orf50	-1.23	-8.17	-0.64	1.31e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs61931739	0.591	rs1608907	chr12:33945435	A/G	cg10856724	chr12:34555212	NA	-0.63	-5.9	-0.52	5.54e-8	Morning vs. evening chronotype;
THYM	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg03806693	chr22:41940476	POLR3H	1.11	8.4	0.65	4.3e-13	Cannabis dependence symptom count;
THYM	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg17063962	chr7:91808500	NA	1.15	12.37	0.79	1.64e-21	Breast cancer;
THYM	cis	rs11711311	0.747	rs2895415	chr3:113345565	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.53	-4.52	-0.42	1.78e-5	IgG glycosylation;
THYM	cis	rs7192750	0.539	rs12599192	chr16:71979097	G/A	cg06353428	chr16:71660113	MARVELD3	0.77	5.72	0.51	1.21e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs9970807	0.901	rs17114036	chr1:56962821	A/G	cg11959316	chr1:57001742	PPAP2B	0.72	5.31	0.48	7.21e-7	Myocardial infarction;Coronary artery disease;
THYM	cis	rs6500395	0.962	rs1039341	chr16:48574869	C/T	cg04672837	chr16:48644449	N4BP1	0.47	4.46	0.42	2.23e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs66887589	0.777	rs4643791	chr4:120265619	A/G	cg13609457	chr4:120235615	NA	-0.48	-4.84	-0.44	5e-6	Diastolic blood pressure;
THYM	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs58530613	0.892	rs10518306	chr4:124736205	A/G	cg11268546	chr4:124983615	NA	-0.72	-4.62	-0.43	1.22e-5	Platelet count;
THYM	cis	rs11096990	0.656	rs7686161	chr4:39284821	A/G	cg24403649	chr4:39172243	NA	-0.66	-5.65	-0.5	1.64e-7	Cognitive function;
THYM	cis	rs76878669	0.917	rs10219183	chr11:66090032	A/C	cg18002602	chr11:66138449	SLC29A2	0.65	5.23	0.47	1.01e-6	Educational attainment (years of education);
THYM	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg17426766	chr1:2046864	PRKCZ	0.45	5.47	0.49	3.71e-7	Height;
THYM	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	4.5	0.42	1.92e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11890956	chr21:40555474	PSMG1	-0.66	-6.38	-0.55	6.51e-9	Menarche (age at onset);
THYM	cis	rs293526	0.959	rs293510	chr6:83642244	C/T	cg23278060	chr6:83777448	DOPEY1	0.61	4.48	0.42	2.1e-5	Crohn's disease;
THYM	cis	rs7027203	0.964	rs7853688	chr9:96523254	C/A	cg14598338	chr9:96623480	NA	0.45	4.81	0.44	5.72e-6	DNA methylation (variation);
THYM	cis	rs72627509	0.904	rs781663	chr4:57781754	A/G	cg26694713	chr4:57773883	REST	0.76	4.85	0.45	4.78e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg18305652	chr10:134549665	INPP5A	0.75	5.9	0.52	5.46e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs6684428	1.000	rs10789010	chr1:56353295	C/G	cg11651538	chr1:56320950	NA	-0.6	-4.54	-0.42	1.63e-5	Airflow obstruction;
THYM	cis	rs3960554	0.808	rs9801125	chr7:75792451	C/T	cg17398381	chr7:75624190	TMEM120A	-0.47	-4.53	-0.42	1.75e-5	Eotaxin levels;
THYM	cis	rs7940866	0.770	rs10791104	chr11:130814893	A/T	cg12179176	chr11:130786555	SNX19	0.64	4.98	0.45	2.86e-6	Schizophrenia;
THYM	cis	rs7084402	0.967	rs1303968	chr10:60298941	G/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.64	-0.5	1.72e-7	Refractive error;
THYM	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg22709100	chr7:91322751	NA	-0.61	-4.85	-0.45	4.84e-6	Breast cancer;
THYM	cis	rs6430585	0.583	rs12475516	chr2:136560761	C/G	cg07169764	chr2:136633963	MCM6	1.07	12.68	0.79	3.76e-22	Corneal structure;
THYM	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg05754148	chr16:3507555	NAT15	0.72	7.34	0.6	7.12e-11	Tuberculosis;
THYM	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg07870213	chr5:140052090	DND1	0.73	8.28	0.65	7.61e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs990171	0.770	rs1420103	chr2:102948632	A/C	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.02	-0.46	2.46e-6	Lymphocyte counts;
THYM	cis	rs4478037	0.555	rs60749629	chr3:33105319	G/A	cg19404215	chr3:33155277	CRTAP	1.13	6.77	0.57	1.06e-9	Major depressive disorder;
THYM	cis	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-5.83	-0.51	7.47e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7103648	0.695	rs12223593	chr11:47789082	T/G	cg20307385	chr11:47447363	PSMC3	0.82	6.53	0.56	3.26e-9	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs6430585	0.583	rs3769001	chr2:136626078	A/G	cg07169764	chr2:136633963	MCM6	1.24	13.85	0.82	1.58e-24	Corneal structure;
THYM	cis	rs73198271	0.700	rs10103282	chr8:8650757	T/G	cg15556689	chr8:8085844	FLJ10661	-0.74	-4.91	-0.45	3.75e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.73	5.98	0.52	3.88e-8	Chronic sinus infection;
THYM	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2445762	0.559	rs4774585	chr15:51616480	G/A	cg07517944	chr15:51633816	GLDN	0.61	4.82	0.44	5.43e-6	Hormone measurements;
THYM	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs920590	0.684	rs3899017	chr8:19669198	A/T	cg03894339	chr8:19674705	INTS10	0.61	4.57	0.42	1.45e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05901451	chr6:126070800	HEY2	-0.87	-8.74	-0.67	8.08e-14	Brugada syndrome;
THYM	cis	rs986417	0.901	rs7150630	chr14:61019458	T/A	cg27398547	chr14:60952738	C14orf39	1.12	6.03	0.53	3.17e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs35883536	0.967	rs9433740	chr1:101133985	G/A	cg06223162	chr1:101003688	GPR88	-0.67	-5.14	-0.47	1.45e-6	Monocyte count;
THYM	cis	rs593982	0.920	rs72922791	chr11:65567395	G/A	cg08755490	chr11:65554678	OVOL1	-1.13	-6.12	-0.53	2.08e-8	Atopic dermatitis;
THYM	cis	rs1847202	0.563	rs13095184	chr3:72951008	A/G	cg25664220	chr3:72788482	NA	-0.67	-5.01	-0.46	2.48e-6	Motion sickness;
THYM	cis	rs220324	0.688	rs56326363	chr21:43560295	G/A	cg09727148	chr21:43560719	UMODL1	0.84	10.06	0.72	1.26e-16	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg06108461	chr20:60628389	TAF4	-0.76	-6.27	-0.54	1.06e-8	Body mass index;
THYM	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	4.98	0.45	2.88e-6	Schizophrenia;
THYM	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg06808227	chr14:105710500	BRF1	-1.02	-8.81	-0.67	5.84e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg24209194	chr3:40518798	ZNF619	-0.66	-5.38	-0.48	5.45e-7	Renal cell carcinoma;
THYM	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg04990556	chr1:26633338	UBXN11	-0.89	-8.52	-0.66	2.34e-13	Obesity-related traits;
THYM	cis	rs4919694	1.000	rs79254677	chr10:104691567	A/G	cg04362960	chr10:104952993	NT5C2	1.04	6.1	0.53	2.28e-8	Arsenic metabolism;
THYM	cis	rs12971120	0.838	rs2241510	chr18:72180739	G/A	cg25817165	chr18:72167213	CNDP2	-0.98	-7.66	-0.62	1.59e-11	Refractive error;
THYM	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg04865290	chr3:52927548	TMEM110	0.88	4.55	0.42	1.59e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs4509693	0.943	rs6584393	chr10:102497206	C/G	cg24127310	chr10:102502104	NA	1.3	10.12	0.72	9.09e-17	Alzheimer's disease;
THYM	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	6.57	0.56	2.74e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs12200782	0.505	rs9295696	chr6:26550288	C/T	cg12826209	chr6:26865740	GUSBL1	0.69	4.69	0.43	9.3e-6	Small cell lung carcinoma;
THYM	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg25237894	chr2:233734115	C2orf82	-0.36	-5.15	-0.47	1.42e-6	Coronary artery disease;
THYM	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg11266682	chr4:10021025	SLC2A9	0.74	10.8	0.74	3.21e-18	Bone mineral density;
THYM	cis	rs1050631	0.563	rs685042	chr18:33743998	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.64	5.05	0.46	2.15e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs2219968	0.962	rs13254874	chr8:78944681	T/C	cg00738934	chr8:78996279	NA	0.79	8.42	0.65	3.88e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9534288	0.783	rs1126366	chr13:46633148	C/G	cg15192986	chr13:46630673	CPB2	-0.66	-4.66	-0.43	1.03e-5	Blood protein levels;
THYM	cis	rs7192750	0.562	rs2335709	chr16:71938442	G/A	cg06353428	chr16:71660113	MARVELD3	0.76	5.59	0.5	2.13e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7695732	0.595	rs10470937	chr4:89902110	A/T	cg17769793	chr4:89976368	FAM13A	-0.49	-5.2	-0.47	1.17e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg26384229	chr12:38710491	ALG10B	0.72	5.56	0.5	2.48e-7	Morning vs. evening chronotype;
THYM	cis	rs6502050	0.835	rs12450154	chr17:80182672	G/A	cg21773646	chr17:80085082	CCDC57	-0.37	-5.31	-0.48	7.27e-7	Life satisfaction;
THYM	cis	rs10149470	0.549	rs9652403	chr14:104036024	G/C	cg12935359	chr14:103987150	CKB	-0.45	-5.25	-0.47	9.4e-7	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.02	9.7	0.71	7.14e-16	Intelligence (multi-trait analysis);
THYM	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg23649088	chr2:200775458	C2orf69	0.81	6.14	0.53	1.88e-8	Schizophrenia;
THYM	cis	rs28595532	0.920	rs116091383	chr4:119635518	A/G	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs4575098	0.681	rs12727614	chr1:161097241	T/A	cg24329783	chr1:161160887	ADAMTS4	-0.63	-5.73	-0.51	1.2e-7	Monocyte percentage of white cells;
THYM	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg18402987	chr7:1209562	NA	1.03	6.06	0.53	2.77e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	6.11	0.53	2.16e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs8014204	1.000	rs10483863	chr14:75322327	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.57	-5.49	-0.49	3.4e-7	Caffeine consumption;
THYM	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs7523273	0.505	rs34277355	chr1:207881491	C/A	cg22525895	chr1:207977042	MIR29B2	0.52	4.76	0.44	6.95e-6	Schizophrenia;
THYM	cis	rs9326248	0.581	rs7121898	chr11:116796846	A/T	cg20608306	chr11:116969690	SIK3	0.66	8.25	0.65	9.14e-13	Blood protein levels;
THYM	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.56	-7.22	-0.6	1.28e-10	Monocyte percentage of white cells;
THYM	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg06713675	chr4:122721982	EXOSC9	-0.51	-4.75	-0.44	7.13e-6	Type 2 diabetes;
THYM	cis	rs12928939	0.723	rs34053338	chr16:71849974	C/T	cg03805757	chr16:71968109	PKD1L3	-0.7	-5.31	-0.48	7.21e-7	Post bronchodilator FEV1;
THYM	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg04082016	chr2:20871401	NA	-0.74	-5.81	-0.51	8.34e-8	Abdominal aortic aneurysm;
THYM	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg06634786	chr22:41940651	POLR3H	0.73	5.33	0.48	6.69e-7	Vitiligo;
THYM	cis	rs12983728	0.536	rs34380569	chr19:58648528	A/G	cg07378217	chr19:58662286	ZNF329	-0.76	-4.99	-0.46	2.78e-6	Cholesterol, total;
THYM	cis	rs7828089	0.792	rs12544610	chr8:22239813	C/T	cg12081754	chr8:22256438	SLC39A14	0.6	5.14	0.47	1.46e-6	Verbal declarative memory;
THYM	cis	rs13082711	0.911	rs34307140	chr3:27467875	A/C	cg02860705	chr3:27208620	NA	0.69	4.99	0.46	2.75e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg27494647	chr7:150038898	RARRES2	0.48	6.0	0.52	3.53e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg26597838	chr10:835615	NA	1.23	8.86	0.67	4.56e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg09549813	chr16:4587862	C16orf5	-0.53	-5.49	-0.49	3.37e-7	Schizophrenia;
THYM	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg05347473	chr6:146136440	FBXO30	0.58	4.74	0.44	7.64e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13006833	0.739	rs291429	chr2:191197941	G/A	cg11845111	chr2:191398756	TMEM194B	0.65	4.48	0.42	2.07e-5	Urinary metabolites;
THYM	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg14582100	chr15:45693742	SPATA5L1	0.6	4.77	0.44	6.64e-6	Homoarginine levels;
THYM	cis	rs3126085	0.560	rs11204986	chr1:152342059	T/C	cg10321714	chr1:152280068	FLG	-0.69	-4.84	-0.44	5.1e-6	Atopic dermatitis;
THYM	trans	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.11	8.17	0.64	1.3e-12	Exhaled nitric oxide output;
THYM	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg13699009	chr12:122356056	WDR66	-0.46	-4.54	-0.42	1.63e-5	Mean corpuscular volume;
THYM	cis	rs988913	1.000	rs4715492	chr6:54835178	C/T	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.75e-6	Menarche (age at onset);
THYM	cis	rs72828912	0.656	rs2139792	chr6:24094347	C/T	cg19882886	chr6:25043046	NA	0.76	4.75	0.44	7.24e-6	Squamous cell lung carcinoma;
THYM	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.72	5.53	0.49	2.8e-7	Height;
THYM	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7107174	1.000	rs11601161	chr11:78073280	A/G	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs3087591	1.000	rs2952980	chr17:29473353	G/A	cg24425628	chr17:29625626	OMG;NF1	0.65	5.57	0.5	2.4e-7	Hip circumference;
THYM	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	7.67	0.62	1.46e-11	Platelet count;
THYM	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg10047753	chr17:41438598	NA	-1.02	-8.95	-0.68	2.87e-14	Menopause (age at onset);
THYM	cis	rs35883536	0.626	rs12135243	chr1:101092955	G/A	cg06223162	chr1:101003688	GPR88	-0.8	-6.59	-0.56	2.43e-9	Monocyte count;
THYM	cis	rs7312774	0.618	rs7953088	chr12:107334539	G/C	cg16260113	chr12:107380972	MTERFD3	1.34	6.39	0.55	6.14e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg13918804	chr1:2043761	PRKCZ	0.76	7.44	0.61	4.5e-11	Height;
THYM	cis	rs10752881	1.000	rs10797811	chr1:182984432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs12935418	0.616	rs11863536	chr16:80969674	C/T	cg16651780	chr16:81037892	C16orf61	0.88	5.56	0.5	2.45e-7	Mean corpuscular volume;
THYM	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg00129232	chr17:37814104	STARD3	0.7	4.79	0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9560113	1.000	rs9560107	chr13:112180146	G/A	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs684232	0.583	rs17677436	chr17:520314	T/C	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.39	-4.77	-0.44	6.73e-6	Prostate cancer;
THYM	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg00129232	chr17:37814104	STARD3	-0.83	-5.68	-0.5	1.45e-7	Asthma;
THYM	cis	rs34779708	0.966	rs57081218	chr10:35434608	A/G	cg03585969	chr10:35415529	CREM	0.67	5.01	0.46	2.51e-6	Inflammatory bowel disease;Crohn's disease;
THYM	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg03929089	chr4:120376271	NA	-0.99	-12.83	-0.8	1.9e-22	Height;
THYM	cis	rs9905704	0.918	rs304293	chr17:56823298	T/G	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.89e-6	Testicular germ cell tumor;
THYM	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg19875535	chr5:140030758	IK	0.58	4.54	0.42	1.63e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg10360139	chr7:1886902	MAD1L1	-0.61	-5.22	-0.47	1.04e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4072705	1.000	rs4838201	chr9:127460617	C/T	cg13476313	chr9:127244764	NR5A1	0.34	5.23	0.47	1e-6	Menarche (age at onset);
THYM	cis	rs10504073	0.584	rs4873300	chr8:49902201	C/G	cg00325661	chr8:49890786	NA	1.04	10.53	0.73	1.2e-17	Blood metabolite ratios;
THYM	cis	rs3750965	0.959	rs3168115	chr11:68858090	A/T	cg01403660	chr11:68851641	TPCN2	-0.73	-5.71	-0.51	1.28e-7	Hair color;
THYM	cis	rs6748734	0.625	rs4295000	chr2:241821237	C/T	cg07537917	chr2:241836409	C2orf54	-0.21	-4.77	-0.44	6.55e-6	Urinary metabolites;
THYM	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11890956	chr21:40555474	PSMG1	-0.93	-10.04	-0.72	1.34e-16	Cognitive function;
THYM	cis	rs6542838	0.703	rs7593332	chr2:99467991	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-4.67	-0.43	9.87e-6	Fear of minor pain;
THYM	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg00484396	chr16:3507460	NAT15	0.75	10.28	0.73	4.24e-17	Tuberculosis;
THYM	cis	rs6748734	0.857	rs4675857	chr2:241842326	T/C	cg02820040	chr2:241836501	C2orf54	-0.33	-6.37	-0.55	6.78e-9	Urinary metabolites;
THYM	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg16850897	chr7:100343110	ZAN	-0.71	-5.37	-0.48	5.67e-7	Other erythrocyte phenotypes;
THYM	cis	rs12780046	0.656	rs7085445	chr10:100858581	C/T	cg20566587	chr10:101492029	COX15;CUTC	0.72	4.53	0.42	1.72e-5	Non-glioblastoma glioma;
THYM	cis	rs8063160	0.756	rs34878706	chr16:89723870	G/A	cg07984980	chr16:89898383	SPIRE2	1.3	5.19	0.47	1.2e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg20608306	chr11:116969690	SIK3	0.52	5.49	0.49	3.32e-7	Blood protein levels;
THYM	cis	rs4747241	0.556	rs4433500	chr10:74068998	G/A	cg07828833	chr10:74069493	NA	0.55	4.8	0.44	5.8e-6	Heschl's gyrus morphology;
THYM	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg05738196	chr6:26577821	NA	0.96	9.75	0.71	5.63e-16	Intelligence (multi-trait analysis);
THYM	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg03709012	chr19:19516395	GATAD2A	0.85	7.08	0.59	2.49e-10	Tonsillectomy;
THYM	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg12826209	chr6:26865740	GUSBL1	-0.86	-6.23	-0.54	1.27e-8	Intelligence (multi-trait analysis);
THYM	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4654899	0.897	rs12121807	chr1:21069129	A/C	cg01072550	chr1:21505969	NA	-0.59	-5.02	-0.46	2.42e-6	Superior frontal gyrus grey matter volume;
THYM	trans	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs7772486	0.811	rs2777475	chr6:146304603	G/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.96	-0.52	4.23e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg06917634	chr15:78832804	PSMA4	0.79	7.0	0.58	3.58e-10	Sudden cardiac arrest;
THYM	cis	rs4731207	0.596	rs12112909	chr7:124584834	C/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs7408868	0.908	rs10416865	chr19:15277601	T/C	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs7578361	1.000	rs10469768	chr2:150427192	C/T	cg17961725	chr2:150454027	NA	0.71	6.03	0.53	3.1e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs7178572	0.524	rs7163503	chr15:77493505	C/A	cg22256960	chr15:77711686	NA	-1.04	-8.57	-0.66	1.83e-13	Type 2 diabetes;
THYM	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs10992471	0.580	rs10992366	chr9:95317214	G/A	cg14631576	chr9:95140430	CENPP	-0.96	-8.92	-0.68	3.33e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.58	4.95	0.45	3.25e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg18132916	chr6:79620363	NA	-0.54	-4.78	-0.44	6.44e-6	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.718	rs6502629	chr17:17869642	A/G	cg04398451	chr17:18023971	MYO15A	-0.78	-6.54	-0.56	3.11e-9	Total body bone mineral density;
THYM	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg17366294	chr4:99064904	C4orf37	0.48	5.43	0.49	4.3e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6430585	0.583	rs4988201	chr2:136618507	A/G	cg20242066	chr2:136595261	LCT	0.51	4.87	0.45	4.44e-6	Corneal structure;
THYM	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg18512352	chr11:47633146	NA	-0.54	-7.07	-0.59	2.54e-10	Subjective well-being;
THYM	cis	rs4930103	0.935	rs2525881	chr11:2019333	T/C	cg06197492	chr11:2016605	H19	0.63	5.48	0.49	3.56e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs931127	0.719	rs7949980	chr11:65445950	T/C	cg17480646	chr11:65405466	SIPA1	-0.78	-6.66	-0.56	1.74e-9	Systemic lupus erythematosus;
THYM	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg02734326	chr4:10020555	SLC2A9	0.64	5.9	0.52	5.59e-8	Bone mineral density;
THYM	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg06634786	chr22:41940651	POLR3H	0.73	5.33	0.48	6.69e-7	Vitiligo;
THYM	cis	rs9470366	0.545	rs4713999	chr6:36633069	A/G	cg24425727	chr6:36645648	CDKN1A	0.73	6.75	0.57	1.19e-9	QRS duration;
THYM	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.64	-5.1	-0.46	1.73e-6	Total body bone mineral density;
THYM	cis	rs7089973	1.000	rs7089973	chr10:116569565	A/C	cg23260525	chr10:116636907	FAM160B1	-0.52	-4.87	-0.45	4.5e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg05552183	chr6:42928497	GNMT	0.72	5.99	0.52	3.66e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg10360139	chr7:1886902	MAD1L1	-0.83	-7.18	-0.59	1.56e-10	Autism spectrum disorder or schizophrenia;
THYM	trans	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg25214090	chr10:38739885	LOC399744	0.8	6.86	0.58	6.83e-10	Corneal astigmatism;
THYM	cis	rs9361491	0.608	rs9350776	chr6:79463845	A/G	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4474465	1.000	rs11604969	chr11:78179293	C/T	cg02023728	chr11:77925099	USP35	-0.52	-4.54	-0.42	1.67e-5	Alzheimer's disease (survival time);
THYM	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg08999081	chr20:33150536	PIGU	-0.57	-5.03	-0.46	2.3e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg18876405	chr7:65276391	NA	-0.66	-5.52	-0.49	2.96e-7	Aortic root size;
THYM	cis	rs6748734	0.625	rs4312489	chr2:241821068	T/A	cg07537917	chr2:241836409	C2orf54	-0.21	-4.61	-0.43	1.24e-5	Urinary metabolites;
THYM	cis	rs1499972	0.887	rs62266061	chr3:117536409	C/T	cg07612923	chr3:117604196	NA	1.31	5.35	0.48	6.02e-7	Schizophrenia;
THYM	cis	rs7084402	0.565	rs7912792	chr10:60335179	C/T	cg09696939	chr10:60272079	BICC1	-0.49	-5.7	-0.5	1.35e-7	Refractive error;
THYM	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg26384229	chr12:38710491	ALG10B	0.73	5.61	0.5	2e-7	Morning vs. evening chronotype;
THYM	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg07636037	chr3:49044803	WDR6	0.96	9.68	0.7	8e-16	Parkinson's disease;
THYM	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg27398817	chr8:82754497	SNX16	0.71	6.05	0.53	2.89e-8	Diastolic blood pressure;
THYM	cis	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg01364799	chr7:75623366	TMEM120A	-0.64	-4.7	-0.43	8.74e-6	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg23711669	chr6:146136114	FBXO30	0.84	8.52	0.66	2.44e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg08883853	chr7:1026168	CYP2W1	-0.45	-5.18	-0.47	1.24e-6	Longevity;Endometriosis;
THYM	cis	rs7599312	0.534	rs6735626	chr2:213403972	G/A	cg16329650	chr2:213403929	ERBB4	1.04	12.32	0.78	2.07e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7772486	0.686	rs9390348	chr6:146044748	C/T	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2237898	0.585	rs34097980	chr11:2875881	T/C	cg12614029	chr11:2160564	INS-IGF2;IGF2AS;IGF2	-1.21	-4.48	-0.42	2.05e-5	Mosquito bite size;
THYM	cis	rs9875589	0.509	rs2731305	chr3:14081342	T/C	cg03204825	chr3:13978759	TPRXL	-0.54	-4.67	-0.43	1.01e-5	Ovarian reserve;
THYM	cis	rs11023332	0.706	rs11023380	chr11:14930058	A/G	cg19336497	chr11:14380999	RRAS2	-0.51	-4.73	-0.44	7.95e-6	Adiponectin levels;Vitamin D levels;
THYM	trans	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg10856724	chr12:34555212	NA	-0.94	-8.13	-0.64	1.61e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg18904891	chr8:8559673	CLDN23	0.58	4.69	0.43	8.98e-6	Joint mobility (Beighton score);
THYM	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg06026331	chr20:60912101	LAMA5	0.74	5.64	0.5	1.75e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	trans	rs561341	0.941	rs736678	chr17:30347423	G/T	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-15.39	-0.84	1.51e-27	Height;
THYM	cis	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg21775007	chr8:11205619	TDH	0.65	5.29	0.48	7.91e-7	Retinal vascular caliber;
THYM	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg04362960	chr10:104952993	NT5C2	-0.63	-4.47	-0.42	2.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs4731207	0.844	rs2267707	chr7:124397026	T/C	cg05285228	chr7:124571219	POT1	0.71	5.65	0.5	1.64e-7	Cutaneous malignant melanoma;
THYM	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg24375607	chr4:120327624	NA	-0.65	-4.96	-0.45	3.1e-6	Corneal astigmatism;
THYM	cis	rs8078723	1.000	rs709592	chr17:38175553	C/T	cg17467752	chr17:38218738	THRA	0.83	6.62	0.56	2.15e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs4845570	1.000	rs6659705	chr1:151769750	T/C	cg18019451	chr1:151746047	TDRKH	-0.77	-4.61	-0.43	1.27e-5	Coronary artery disease;
THYM	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg06219351	chr7:158114137	PTPRN2	-0.8	-7.12	-0.59	2.04e-10	Response to amphetamines;
THYM	cis	rs7404928	1.000	rs8182198	chr16:23905225	G/T	cg26685404	chr16:23957272	PRKCB	0.49	4.86	0.45	4.55e-6	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs4788570	0.537	rs56222754	chr16:71491806	G/A	cg06353428	chr16:71660113	MARVELD3	-1.04	-5.01	-0.46	2.5e-6	Intelligence (multi-trait analysis);
THYM	cis	rs892961	0.932	rs7224442	chr17:75413439	A/G	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg08133631	chr1:26527909	CATSPER4	-0.61	-5.08	-0.46	1.92e-6	Obesity-related traits;
THYM	cis	rs7072216	0.763	rs12763044	chr10:100167451	C/G	cg26618903	chr10:100175079	PYROXD2	-0.48	-4.6	-0.43	1.33e-5	Metabolite levels;
THYM	cis	rs7614311	0.954	rs2291533	chr3:63817430	C/G	cg22134162	chr3:63841271	THOC7	0.48	5.98	0.52	3.89e-8	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg22875332	chr1:76189707	ACADM	-0.73	-6.85	-0.57	7.37e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg18252515	chr7:66147081	NA	-0.72	-5.6	-0.5	2.03e-7	Aortic root size;
THYM	cis	rs9902453	0.578	rs8073217	chr17:28164263	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.21	0.54	1.41e-8	Coffee consumption (cups per day);
THYM	cis	rs2147904	0.934	rs783622	chr1:42366988	C/T	cg16685388	chr1:42384056	HIVEP3	-0.58	-4.77	-0.44	6.63e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
THYM	cis	rs11651000	0.894	rs17250932	chr17:45809307	T/C	cg03474202	chr17:45855739	NA	-0.69	-4.53	-0.42	1.75e-5	IgG glycosylation;
THYM	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.12	7.95	0.63	3.93e-12	Platelet count;
THYM	cis	rs6809651	0.524	rs79262908	chr3:185803594	C/T	cg00760338	chr3:185826511	ETV5	-0.85	-6.6	-0.56	2.33e-9	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
THYM	trans	rs629535	0.862	rs2472141	chr8:70054216	T/C	cg21567404	chr3:27674614	NA	1.11	10.64	0.74	7.17e-18	Dupuytren's disease;
THYM	cis	rs3126085	0.825	rs10788830	chr1:152206898	A/C	cg10321714	chr1:152280068	FLG	0.68	5.07	0.46	1.98e-6	Atopic dermatitis;
THYM	cis	rs10982256	0.789	rs1535964	chr9:117272439	C/G	cg15903421	chr9:117267460	DFNB31	0.56	5.29	0.48	7.79e-7	Bipolar disorder;
THYM	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg10636054	chr15:40330586	SRP14	1.0	5.31	0.48	7.31e-7	Corneal curvature;
THYM	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.66	-0.5	1.62e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg01699819	chr7:1052092	C7orf50	-0.86	-7.86	-0.63	5.96e-12	Bronchopulmonary dysplasia;
THYM	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg11335335	chr11:637885	DRD4	-0.63	-5.11	-0.46	1.64e-6	Systemic lupus erythematosus;
THYM	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg06219351	chr7:158114137	PTPRN2	-0.74	-7.14	-0.59	1.86e-10	Calcium levels;
THYM	cis	rs6430585	0.527	rs60966546	chr2:136401843	C/T	cg07169764	chr2:136633963	MCM6	0.97	8.64	0.66	1.32e-13	Corneal structure;
THYM	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.27	-6.03	-0.53	3.15e-8	Obesity-related traits;
THYM	cis	rs3858526	0.651	rs10838713	chr11:5858434	T/C	cg05234568	chr11:5960015	NA	-0.64	-5.23	-0.47	9.97e-7	DNA methylation (variation);
THYM	cis	rs2180341	0.513	rs12196828	chr6:127696864	C/T	cg24812749	chr6:127587940	RNF146	0.77	5.75	0.51	1.07e-7	Breast cancer;
THYM	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs7677751	0.848	rs4635872	chr4:55099041	C/A	cg17187183	chr4:55093834	PDGFRA	0.74	5.58	0.5	2.27e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2282300	0.739	rs12577729	chr11:30257377	C/T	cg06241208	chr11:30344200	C11orf46	-0.77	-5.59	-0.5	2.15e-7	Morning vs. evening chronotype;
THYM	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg24250549	chr1:154909240	PMVK	0.64	4.98	0.46	2.79e-6	Prostate cancer;
THYM	cis	rs986417	0.818	rs10148116	chr14:61101089	C/T	cg27398547	chr14:60952738	C14orf39	1.04	5.74	0.51	1.14e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Body mass index;
THYM	cis	rs7264396	0.690	rs2425170	chr20:34442672	A/G	cg26038318	chr20:34205095	SPAG4	0.6	4.76	0.44	6.86e-6	Total cholesterol levels;
THYM	cis	rs6840360	0.615	rs1561917	chr4:152479233	G/A	cg17479576	chr4:152424074	FAM160A1	-0.85	-6.4	-0.55	5.9e-9	Intelligence (multi-trait analysis);
THYM	cis	rs10789491	1.000	rs4660956	chr1:47158486	A/G	cg15501359	chr1:47185051	KIAA0494	1.16	8.72	0.67	8.86e-14	Response to hepatitis C treatment;
THYM	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs2562456	0.754	rs55771551	chr19:21746380	C/T	cg21751540	chr19:21541537	ZNF738	-0.67	-4.63	-0.43	1.17e-5	Pain;
THYM	cis	rs9534288	0.912	rs4942468	chr13:46618290	C/A	cg15192986	chr13:46630673	CPB2	-0.64	-4.52	-0.42	1.78e-5	Blood protein levels;
THYM	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg26149184	chr10:133730230	NA	0.77	4.65	0.43	1.05e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs2346177	0.638	rs34186951	chr2:46657659	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-4.48	-0.42	2.06e-5	HDL cholesterol;
THYM	trans	rs75518195	0.543	rs62301950	chr4:64676595	C/T	cg14706739	chr8:21916355	EPB49	0.75	7.37	0.6	6.34e-11	Triptolide cytotoxicity;
THYM	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg16558253	chr16:72132732	DHX38	-0.59	-5.05	-0.46	2.17e-6	Fibrinogen levels;
THYM	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-5.35	-0.48	5.98e-7	Lymphocyte counts;
THYM	cis	rs10276303	0.519	rs11983447	chr7:3399423	T/A	cg21248987	chr7:3385318	SDK1	-0.41	-5.15	-0.47	1.41e-6	Dupuytren's disease;
THYM	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg15691649	chr6:25882328	NA	0.71	5.51	0.49	3.12e-7	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.893	rs6661115	chr1:53426148	G/A	cg06600287	chr1:53387719	ECHDC2	0.32	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs4974559	0.790	rs5019560	chr4:1324793	G/A	cg02980000	chr4:1222292	CTBP1	0.77	4.82	0.44	5.41e-6	Systolic blood pressure;
THYM	cis	rs17253792	0.822	rs77741349	chr14:56097462	C/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs2820651	0.708	rs17156347	chr10:1478900	A/T	cg13720710	chr10:1452970	ADARB2	0.74	4.84	0.45	4.93e-6	Migraine with aura;
THYM	cis	rs10911232	0.507	rs9787327	chr1:182978459	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Hypertriglyceridemia;
THYM	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.71	-5.53	-0.49	2.82e-7	Tonsillectomy;
THYM	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2554380	0.891	rs1896816	chr15:84299371	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.64	-4.99	-0.46	2.72e-6	Height;
THYM	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9633740	1.000	rs7900536	chr10:82253701	G/T	cg01528321	chr10:82214614	TSPAN14	0.94	4.5	0.42	1.9e-5	Post bronchodilator FEV1;
THYM	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg07606381	chr6:8435919	SLC35B3	0.62	4.48	0.42	2.1e-5	Motion sickness;
THYM	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg19508488	chr2:152266495	RIF1	-0.74	-5.1	-0.46	1.73e-6	Lung cancer;
THYM	cis	rs4660306	1.000	rs2356561	chr1:45980862	T/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.59	-4.7	-0.43	8.86e-6	Homocysteine levels;
THYM	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.25	-10.33	-0.73	3.19e-17	Platelet count;
THYM	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg18252515	chr7:66147081	NA	-1.52	-8.02	-0.64	2.72e-12	Diabetic kidney disease;
THYM	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg24733560	chr20:60626293	TAF4	0.52	4.65	0.43	1.07e-5	Body mass index;
THYM	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg03433033	chr1:76189801	ACADM	0.77	10.21	0.72	6.01e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs2637266	0.967	rs12246605	chr10:78352994	G/A	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg19693284	chr19:2783607	SGTA	0.68	5.7	0.51	1.32e-7	Total cholesterol levels;
THYM	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg12379764	chr21:47803548	PCNT	-0.8	-5.15	-0.47	1.38e-6	Testicular germ cell tumor;
THYM	cis	rs960902	0.592	rs7588494	chr2:37736881	C/A	cg25341268	chr2:37734390	NA	-0.7	-6.43	-0.55	5.06e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs7432375	0.901	rs1729951	chr3:136500733	T/G	cg12473912	chr3:136751656	NA	-0.66	-5.45	-0.49	3.93e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg13683864	chr3:40499215	RPL14	-1.05	-11.54	-0.76	8.87e-20	Renal cell carcinoma;
THYM	cis	rs10752881	1.000	rs6697739	chr1:182983333	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs2273669	0.667	rs12215381	chr6:109363217	C/T	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-4.51	-0.42	1.86e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs3741798	1.000	rs61922028	chr12:12487096	A/C	cg08615371	chr12:12503544	MANSC1	0.88	4.9	0.45	3.92e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	6.59	0.56	2.39e-9	Schizophrenia;
THYM	trans	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg10856724	chr12:34555212	NA	-0.96	-8.66	-0.66	1.22e-13	Bladder cancer;
THYM	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg23574427	chr4:122746245	BBS7;CCNA2	-0.56	-5.0	-0.46	2.56e-6	Type 2 diabetes;
THYM	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg13531842	chr10:38383804	ZNF37A	-0.54	-4.53	-0.42	1.73e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs7084921	0.521	rs12772820	chr10:101873824	A/G	cg11344164	chr10:101878520	NA	-0.53	-5.03	-0.46	2.36e-6	Bone mineral density;
THYM	cis	rs6598955	1.000	rs10902728	chr1:26598281	T/C	cg04990556	chr1:26633338	UBXN11	0.95	7.49	0.61	3.51e-11	Obesity-related traits;
THYM	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.02	-0.46	2.42e-6	Blood metabolite levels;
THYM	cis	rs4242434	0.819	rs2291230	chr8:22463697	C/G	cg03733263	chr8:22462867	KIAA1967	0.94	10.44	0.73	1.92e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1113500	0.548	rs3853495	chr1:108643245	A/C	cg06207961	chr1:108661230	NA	0.66	4.75	0.44	7.32e-6	Growth-regulated protein alpha levels;
THYM	cis	rs3126085	0.935	rs3126072	chr1:152279729	C/T	cg26020982	chr1:152196106	HRNR	-0.35	-4.95	-0.45	3.26e-6	Atopic dermatitis;
THYM	cis	rs6665290	0.904	rs1045252	chr1:227181555	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg11871910	chr12:69753446	YEATS4	0.74	6.09	0.53	2.39e-8	Blood protein levels;
THYM	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg13609457	chr4:120235615	NA	0.59	5.21	0.47	1.1e-6	Corneal astigmatism;
THYM	cis	rs10463554	0.927	rs34796	chr5:102424429	T/C	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg15704280	chr7:45808275	SEPT13	-1.09	-16.18	-0.86	4.71e-29	Height;
THYM	cis	rs1011018	0.955	rs66985026	chr7:139457829	G/A	cg06079564	chr7:139468310	HIPK2	-0.77	-5.98	-0.52	3.9e-8	Systolic blood pressure;
THYM	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	9.32	0.69	4.6e-15	Platelet count;
THYM	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	5.92	0.52	5.05e-8	Smoking behavior;
THYM	cis	rs9747201	0.963	rs9747989	chr17:80176092	A/G	cg10505658	chr17:80084571	CCDC57	-0.57	-4.55	-0.42	1.58e-5	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg22496339	chr2:162101262	NA	0.94	9.01	0.68	2.19e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs7584330	0.554	rs13411613	chr2:238437560	T/C	cg08992911	chr2:238395768	MLPH	0.89	5.81	0.51	8.24e-8	Prostate cancer;
THYM	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12923728	chr3:195709715	SDHAP1	-0.78	-6.38	-0.55	6.41e-9	Pancreatic cancer;
THYM	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06634786	chr22:41940651	POLR3H	-0.73	-5.41	-0.49	4.61e-7	Vitiligo;
THYM	cis	rs4077515	0.540	rs4487900	chr9:139303301	A/G	cg14115884	chr9:139300582	SDCCAG3	0.74	6.95	0.58	4.48e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg06784218	chr1:46089804	CCDC17	0.31	4.57	0.42	1.46e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg22105103	chr4:187893119	NA	0.96	10.31	0.73	3.64e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg09165964	chr15:75287851	SCAMP5	-1.08	-10.79	-0.74	3.35e-18	Blood trace element (Zn levels);
THYM	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.14	-0.64	1.51e-12	Personality dimensions;
THYM	cis	rs3126085	0.935	rs4845741	chr1:152183474	A/G	cg10321714	chr1:152280068	FLG	0.69	5.04	0.46	2.22e-6	Atopic dermatitis;
THYM	cis	rs61931739	0.929	rs10844730	chr12:34026721	C/G	cg06521331	chr12:34319734	NA	0.6	4.81	0.44	5.74e-6	Morning vs. evening chronotype;
THYM	cis	rs977987	0.806	rs11865004	chr16:75395777	C/T	cg03315344	chr16:75512273	CHST6	0.73	6.16	0.53	1.73e-8	Dupuytren's disease;
THYM	cis	rs9810089	0.676	rs526574	chr3:136103349	A/G	cg12473912	chr3:136751656	NA	0.6	5.21	0.47	1.09e-6	Gestational age at birth (child effect);
THYM	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg10117171	chr1:25599238	RHD	-0.71	-5.47	-0.49	3.67e-7	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs6565180	1.000	rs11863150	chr16:30385503	C/T	cg17640201	chr16:30407289	ZNF48	0.91	8.4	0.65	4.29e-13	Tonsillectomy;
THYM	cis	rs11096990	0.855	rs1597722	chr4:39174875	C/T	cg24403649	chr4:39172243	NA	0.66	5.61	0.5	1.99e-7	Cognitive function;
THYM	cis	rs1981331	1.000	rs77587985	chr21:47993897	A/G	cg17243659	chr21:48055224	PRMT2	0.99	4.65	0.43	1.09e-5	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs10924970	0.934	rs4288584	chr1:235436631	C/T	cg26050004	chr1:235667680	B3GALNT2	0.6	4.5	0.42	1.92e-5	Asthma;
THYM	cis	rs9302635	0.626	rs34508528	chr16:72215115	C/T	cg23815491	chr16:72088622	HP	0.84	5.78	0.51	9.67e-8	Blood protein levels;
THYM	cis	rs11886999	0.812	rs72825865	chr2:96889900	A/T	cg18419276	chr2:96971862	SNRNP200	-0.51	-4.88	-0.45	4.21e-6	Cardiac Troponin-T levels;
THYM	cis	rs3135724	1.000	rs3135724	chr10:123352220	C/T	cg15049101	chr10:123353889	FGFR2	0.81	5.28	0.48	8.29e-7	Estrogen receptor status in HER2 negative breast cancer;
THYM	cis	rs2898681	0.614	rs962416	chr4:53695657	G/T	cg00791764	chr4:53727839	RASL11B	-0.45	-5.78	-0.51	9.54e-8	Optic nerve measurement (cup area);
THYM	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9938149	0.736	rs7501109	chr16:88320862	C/G	cg05067156	chr16:88591451	ZFPM1	0.43	4.52	0.42	1.81e-5	Corneal structure;Central corneal thickness;
THYM	cis	rs7901056	0.967	rs12783831	chr10:26714435	C/T	cg23318538	chr10:26883079	C10orf50	0.37	4.98	0.46	2.8e-6	Lymphocyte counts;
THYM	cis	rs684232	0.666	rs2657629	chr17:602261	G/T	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.39	-4.72	-0.44	8.25e-6	Prostate cancer;
THYM	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-13.33	-0.81	1.74e-23	Coronary artery disease;
THYM	cis	rs7106204	0.620	rs16912295	chr11:24260162	T/C	ch.11.24196551F	chr11:24239977	NA	0.93	5.71	0.51	1.3e-7	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs28595532	0.920	rs114420700	chr4:119751297	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs12681287	0.640	rs13264364	chr8:87466385	G/T	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs7119	0.700	rs4886519	chr15:77893885	A/G	cg27398640	chr15:77910606	LINGO1	0.68	8.79	0.67	6.21e-14	Type 2 diabetes;
THYM	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg01341218	chr17:43662625	NA	-0.87	-7.55	-0.61	2.7e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg01819863	chr10:32635814	EPC1	1.07	6.94	0.58	4.84e-10	Sexual dysfunction (female);
THYM	cis	rs6531209	0.692	rs115436106	chr2:20365483	T/C	cg24416238	chr2:20211868	MATN3	-0.63	-5.35	-0.48	6.15e-7	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg03235661	chr20:60525775	NA	0.55	4.58	0.43	1.39e-5	Obesity-related traits;
THYM	cis	rs938554	0.578	rs7663032	chr4:9993838	C/T	cg02317251	chr4:10116515	WDR1	-0.55	-4.59	-0.43	1.36e-5	Blood metabolite levels;
THYM	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.6	-5.09	-0.46	1.82e-6	Coronary artery disease;
THYM	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg24324837	chr19:49891574	CCDC155	0.69	5.46	0.49	3.79e-7	Multiple sclerosis;
THYM	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	7.5	0.61	3.28e-11	Platelet count;
THYM	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg11752832	chr7:134001865	SLC35B4	0.67	4.63	0.43	1.15e-5	Mean platelet volume;
THYM	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg00686598	chr14:53173677	PSMC6	1.39	7.01	0.58	3.52e-10	Alzheimer's disease (late onset);
THYM	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg17509989	chr5:176798049	RGS14	-0.67	-5.95	-0.52	4.45e-8	Urate levels in lean individuals;
THYM	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg20476274	chr7:133979776	SLC35B4	0.66	4.61	0.43	1.25e-5	Mean platelet volume;
THYM	cis	rs9911578	0.835	rs3744093	chr17:56492800	T/C	cg12560992	chr17:57184187	TRIM37	-0.74	-5.95	-0.52	4.56e-8	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs684232	0.583	rs2657626	chr17:603052	A/G	cg15660573	chr17:549704	VPS53	-0.87	-8.15	-0.64	1.45e-12	Prostate cancer;
THYM	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Body mass index;
THYM	cis	rs55728055	0.661	rs60324934	chr22:31875654	A/G	cg01338084	chr22:32026380	PISD	1.41	5.12	0.46	1.62e-6	Age-related hearing impairment;
THYM	cis	rs1050631	0.564	rs1625385	chr18:33717364	C/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.28	0.48	8.32e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs10516089	0.504	rs10061323	chr5:171136420	G/T	cg17535961	chr5:171094783	NA	0.41	4.52	0.42	1.78e-5	Venous thromboembolism (SNP x SNP interaction);
THYM	cis	rs9534288	0.716	rs2573304	chr13:46514642	C/T	cg15192986	chr13:46630673	CPB2	0.61	4.52	0.42	1.8e-5	Blood protein levels;
THYM	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg15744692	chr15:45671195	LOC145663;GATM	0.44	4.46	0.42	2.22e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg00684032	chr4:1343700	KIAA1530	0.54	4.7	0.43	8.96e-6	Longevity;
THYM	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg24308560	chr3:49941425	MST1R	0.63	4.78	0.44	6.37e-6	Body mass index;
THYM	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg27534772	chr1:16042836	PLEKHM2	0.51	5.4	0.48	4.81e-7	Systolic blood pressure;
THYM	cis	rs728616	0.867	rs61860044	chr10:81946538	C/G	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs941408	1.000	rs941407	chr19:2812153	A/G	cg06609049	chr19:2785107	THOP1	0.68	5.52	0.49	3e-7	Total cholesterol levels;
THYM	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.85	-5.32	-0.48	6.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12519773	0.526	rs4869191	chr5:92525434	A/T	cg18783429	chr5:92414398	NA	-0.49	-4.79	-0.44	6.17e-6	Migraine;
THYM	cis	rs2637266	1.000	rs7478008	chr10:78355575	T/A	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg11941060	chr3:133502564	NA	-0.74	-6.43	-0.55	5.19e-9	Iron status biomarkers;
THYM	cis	rs7567389	0.677	rs11680877	chr2:128090450	A/G	cg09760422	chr2:128146352	NA	0.4	4.52	0.42	1.8e-5	Self-rated health;
THYM	cis	rs13082711	0.863	rs34611823	chr3:27500344	A/G	cg02860705	chr3:27208620	NA	0.72	5.22	0.47	1.03e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs2239547	0.522	rs7652131	chr3:52997154	C/T	cg11645453	chr3:52864694	ITIH4	0.29	4.48	0.42	2.06e-5	Schizophrenia;
THYM	cis	rs5771242	0.685	rs2341367	chr22:50631226	T/C	cg16473166	chr22:50639996	SELO	0.73	4.82	0.44	5.49e-6	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
THYM	cis	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg06952534	chr1:196946228	CFHR5	-0.69	-4.87	-0.45	4.4e-6	Depressive symptoms;
THYM	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.27	-0.65	8.17e-13	Personality dimensions;
THYM	cis	rs2227564	0.620	rs3911887	chr10:75548026	A/G	cg00564723	chr10:75632066	CAMK2G	-0.54	-4.77	-0.44	6.67e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs55665837	1.000	rs10832271	chr11:14466919	C/G	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs490234	0.841	rs829314	chr9:128415506	A/T	cg14078157	chr9:128172775	NA	0.61	4.72	0.44	7.96e-6	Mean arterial pressure;
THYM	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg21970626	chr13:21893289	NA	-0.64	-5.91	-0.52	5.44e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs1642645	0.831	rs7529102	chr1:42493322	T/C	cg06092502	chr1:42611687	NA	0.61	4.74	0.44	7.58e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs11089937	0.522	rs5757259	chr22:22534039	T/G	cg06866756	chr22:22471216	NA	-0.41	-4.52	-0.42	1.76e-5	Periodontitis (PAL4Q3);
THYM	cis	rs2046867	0.818	rs6786469	chr3:72873809	A/G	cg25664220	chr3:72788482	NA	-0.99	-8.33	-0.65	5.92e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs9905704	0.647	rs12940492	chr17:56954655	C/G	cg12560992	chr17:57184187	TRIM37	0.7	5.55	0.49	2.59e-7	Testicular germ cell tumor;
THYM	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg13852791	chr20:30311386	BCL2L1	0.93	7.14	0.59	1.83e-10	Mean corpuscular hemoglobin;
THYM	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg24846343	chr22:24311635	DDTL	0.46	5.81	0.51	8.43e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg01200585	chr1:228362443	C1orf69	0.42	4.53	0.42	1.71e-5	Diastolic blood pressure;
THYM	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg18402987	chr7:1209562	NA	0.65	4.79	0.44	6.09e-6	Longevity;Endometriosis;
THYM	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	5.2	0.47	1.15e-6	Hip circumference adjusted for BMI;
THYM	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg21427119	chr20:30132790	HM13	-0.72	-4.81	-0.44	5.62e-6	Mean corpuscular hemoglobin;
THYM	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg18850127	chr7:39170497	POU6F2	0.6	5.46	0.49	3.76e-7	IgG glycosylation;
THYM	cis	rs6696239	0.840	rs12097239	chr1:227912474	G/A	cg05053440	chr1:227748442	NA	-0.6	-4.62	-0.43	1.21e-5	Height;
THYM	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg08017756	chr2:100939284	LONRF2	-0.75	-7.8	-0.62	7.89e-12	Intelligence (multi-trait analysis);
THYM	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	6.9	0.58	5.76e-10	Smoking behavior;
THYM	cis	rs9902453	0.868	rs12944395	chr17:28323499	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.85	-6.49	-0.55	3.79e-9	Coffee consumption (cups per day);
THYM	trans	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg10856724	chr12:34555212	NA	-0.99	-8.71	-0.67	9.58e-14	Bladder cancer;
THYM	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg07424592	chr7:64974309	NA	-1.08	-5.73	-0.51	1.2e-7	Diabetic kidney disease;
THYM	cis	rs13102973	0.965	rs4864240	chr4:135856737	T/C	cg14419869	chr4:135874104	NA	-0.82	-7.94	-0.63	4.06e-12	Subjective well-being;
THYM	cis	rs10744422	1.000	rs3852536	chr12:123333824	C/T	cg25930673	chr12:123319894	HIP1R	-0.86	-4.84	-0.44	5.09e-6	Schizophrenia;
THYM	cis	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg09085632	chr11:111637200	PPP2R1B	1.2	12.92	0.8	1.24e-22	Primary sclerosing cholangitis;
THYM	cis	rs4953911	0.793	rs13014122	chr2:135050622	G/A	cg18482303	chr2:135041380	MGAT5	0.29	4.89	0.45	4.15e-6	Multiple sclerosis (severity);
THYM	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg24060327	chr5:131705240	SLC22A5	-0.69	-5.18	-0.47	1.27e-6	Breast cancer;
THYM	cis	rs931127	0.719	rs11227259	chr11:65459404	T/C	cg17480646	chr11:65405466	SIPA1	-0.81	-7.19	-0.59	1.5e-10	Systemic lupus erythematosus;
THYM	cis	rs6570726	0.791	rs9403729	chr6:145907007	C/T	cg13319975	chr6:146136371	FBXO30	-0.64	-5.19	-0.47	1.18e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.87	0.45	4.41e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs358079	0.694	rs358078	chr3:55110151	A/G	cg18010752	chr3:55518091	WNT5A	-0.28	-4.47	-0.42	2.15e-5	Gout;
THYM	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg24692254	chr21:30365293	RNF160	1.01	9.91	0.71	2.52e-16	Dental caries;
THYM	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.6	4.51	0.42	1.88e-5	Renal function-related traits (BUN);
THYM	cis	rs11031096	0.502	rs7935824	chr11:4046900	C/G	cg18678763	chr11:4115507	RRM1	-0.46	-6.1	-0.53	2.29e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs67460515	0.563	rs11720263	chr3:160848293	T/C	cg12349858	chr3:160822545	B3GALNT1	0.57	4.53	0.42	1.71e-5	Parkinson's disease;
THYM	cis	rs12142240	0.698	rs1475388	chr1:46816465	G/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg10334053	chr1:2078117	PRKCZ	-0.5	-4.99	-0.46	2.7e-6	Height;
THYM	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg10505658	chr17:80084571	CCDC57	-0.69	-7.95	-0.63	3.85e-12	Life satisfaction;
THYM	cis	rs986417	0.748	rs8019541	chr14:60929145	A/G	cg27398547	chr14:60952738	C14orf39	1.15	5.91	0.52	5.37e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg08305652	chr11:111469057	NA	0.52	4.46	0.42	2.25e-5	Primary sclerosing cholangitis;
THYM	cis	rs4638749	0.677	rs4396668	chr2:108840364	C/T	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs10752881	0.809	rs3738829	chr1:183113862	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.66	0.43	1.02e-5	Colorectal cancer;
THYM	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.33	0.48	6.55e-7	Height;
THYM	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.69	7.2	0.59	1.41e-10	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs7638995	0.701	rs28591428	chr3:69185601	C/T	cg26574240	chr3:69171822	LMOD3	-0.61	-4.65	-0.43	1.07e-5	Alzheimer's disease (late onset);
THYM	cis	rs7616559	0.962	rs9842862	chr3:156736395	T/G	cg15697575	chr3:156784781	NA	0.42	5.06	0.46	2e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg20503657	chr10:835505	NA	1.37	9.33	0.69	4.52e-15	Eosinophil percentage of granulocytes;
THYM	cis	rs10045504	0.743	rs57488025	chr5:38757173	T/C	cg18182111	chr5:37835111	GDNF	-0.45	-4.6	-0.43	1.29e-5	Night sleep phenotypes;
THYM	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg13695892	chr22:41940480	POLR3H	0.89	6.26	0.54	1.1e-8	Vitiligo;
THYM	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg13010199	chr12:38710504	ALG10B	-0.59	-5.14	-0.47	1.46e-6	Heart rate;
THYM	cis	rs7705042	1.000	rs7705042	chr5:141492419	C/A	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	-0.66	-5.58	-0.5	2.3e-7	Lymphocyte counts;
THYM	trans	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg25214090	chr10:38739885	LOC399744	0.92	7.76	0.62	9.72e-12	Corneal astigmatism;
THYM	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg13695892	chr22:41940480	POLR3H	0.86	5.96	0.52	4.19e-8	Vitiligo;
THYM	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg12564285	chr5:131593104	PDLIM4	0.55	5.99	0.52	3.8e-8	Breast cancer;
THYM	cis	rs9807989	0.765	rs6704565	chr2:102967431	G/A	cg03938978	chr2:103052716	IL18RAP	0.61	6.04	0.53	3.04e-8	Asthma;
THYM	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg07511668	chr11:68622177	NA	0.44	4.63	0.43	1.16e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg08885076	chr2:99613938	TSGA10	0.62	5.67	0.5	1.5e-7	Chronic sinus infection;
THYM	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg18876405	chr7:65276391	NA	0.73	6.86	0.58	6.85e-10	Aortic root size;
THYM	cis	rs4747241	0.810	rs10762506	chr10:74053751	T/C	cg07828833	chr10:74069493	NA	0.58	4.73	0.44	7.73e-6	Heschl's gyrus morphology;
THYM	cis	rs10871290	0.650	rs28484753	chr16:74489395	G/C	cg01733217	chr16:74700730	RFWD3	0.62	4.85	0.45	4.74e-6	Breast cancer;
THYM	cis	rs9560113	0.724	rs4771755	chr13:112170900	G/A	cg14154082	chr13:112174009	NA	-0.76	-7.01	-0.58	3.43e-10	Menarche (age at onset);
THYM	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg06112835	chr11:68658793	MRPL21	0.45	6.34	0.55	7.68e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs67133203	0.554	rs10099	chr12:51487882	T/C	cg14210830	chr12:52218426	NA	-0.36	-4.47	-0.42	2.13e-5	Urinary tract infection frequency;
THYM	cis	rs77372450	0.551	rs11739081	chr5:157087119	C/G	cg00312553	chr5:157098553	C5orf52	-0.65	-4.63	-0.43	1.16e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs10752881	0.775	rs2147585	chr1:183074875	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Colorectal cancer;
THYM	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg10053473	chr17:62856997	LRRC37A3	0.92	7.34	0.6	7.17e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	trans	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg19862616	chr7:65841803	NCRNA00174	1.11	13.27	0.81	2.37e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg13854012	chr2:162103682	NA	0.6	5.33	0.48	6.68e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-5.61	-0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg16486109	chr11:613632	IRF7	0.51	5.7	0.5	1.34e-7	Systemic lupus erythematosus;
THYM	cis	rs763014	0.898	rs4984895	chr16:623238	T/C	cg07343612	chr16:622815	PIGQ	-1.05	-10.74	-0.74	4.28e-18	Height;
THYM	cis	rs16854884	0.632	rs35716467	chr3:143684993	C/A	cg05063096	chr3:143689810	C3orf58	0.68	4.59	0.43	1.34e-5	Economic and political preferences (feminism/equality);
THYM	cis	rs10865397	0.506	rs6546807	chr2:73386212	C/T	cg24220031	chr2:73402428	NA	-0.72	-6.6	-0.56	2.3e-9	Intelligence (multi-trait analysis);
THYM	cis	rs2241584	0.904	rs13159126	chr5:175948548	C/T	cg27658698	chr5:175955578	RNF44	-0.46	-5.45	-0.49	3.89e-7	Menopause (age at onset);
THYM	cis	rs12188164	0.840	rs67665078	chr5:428754	G/A	cg16294152	chr5:418696	AHRR	-0.6	-5.26	-0.48	8.78e-7	Cystic fibrosis severity;
THYM	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs911555	0.570	rs942862	chr14:104022124	G/C	cg24130564	chr14:104152367	KLC1	-0.62	-5.07	-0.46	2e-6	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg12011299	chr4:100065546	ADH4	0.95	9.42	0.7	2.81e-15	Alcohol dependence;
THYM	cis	rs1267303	0.716	rs942255	chr1:46989792	C/T	cg25110126	chr1:46999211	NA	0.71	5.24	0.47	9.66e-7	Monobrow;
THYM	cis	rs7584330	0.554	rs6706729	chr2:238398580	T/C	cg08992911	chr2:238395768	MLPH	1.17	6.68	0.57	1.61e-9	Prostate cancer;
THYM	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg06618935	chr21:46677482	NA	-0.98	-9.58	-0.7	1.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2688608	1.000	rs2675680	chr10:75658864	T/C	cg19442545	chr10:75533431	FUT11	-0.42	-4.63	-0.43	1.16e-5	Inflammatory bowel disease;
THYM	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg16325326	chr1:53192061	ZYG11B	0.82	7.77	0.62	9e-12	Monocyte count;
THYM	cis	rs2115536	1.000	rs2115540	chr15:80190308	A/G	cg00225070	chr15:80189496	MTHFS	0.65	5.77	0.51	9.71e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg05368731	chr17:41323189	NBR1	1.25	11.17	0.75	5.29e-19	Menopause (age at onset);
THYM	cis	rs67460515	0.563	rs16831981	chr3:160897780	T/C	cg03342759	chr3:160939853	NMD3	-0.65	-4.88	-0.45	4.27e-6	Parkinson's disease;
THYM	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg12179176	chr11:130786555	SNX19	0.82	7.66	0.62	1.59e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2932538	0.922	rs7535636	chr1:113101799	C/T	cg22162597	chr1:113214053	CAPZA1	-0.62	-5.09	-0.46	1.83e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg17143192	chr8:8559678	CLDN23	0.63	4.73	0.44	7.81e-6	Mood instability;
THYM	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg24006582	chr15:45444508	DUOX1	0.77	6.04	0.53	3.05e-8	Uric acid levels;
THYM	cis	rs7729447	0.841	rs10941021	chr5:32691144	C/T	cg16267343	chr5:32710456	NPR3	0.78	7.17	0.59	1.64e-10	Blood pressure;
THYM	cis	rs2997447	0.846	rs7520344	chr1:26397286	C/T	cg03844060	chr1:26490628	NA	0.67	4.57	0.42	1.48e-5	QRS complex (12-leadsum);
THYM	cis	rs9913156	0.793	rs4346260	chr17:4567215	A/G	cg19197139	chr17:4613644	ARRB2	-0.85	-5.19	-0.47	1.21e-6	Lymphocyte counts;
THYM	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg18128536	chr17:47092178	IGF2BP1	-0.56	-8.95	-0.68	2.93e-14	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg16342193	chr10:102329863	NA	-0.59	-6.2	-0.54	1.48e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs17401966	1.000	rs7520651	chr1:10329872	G/A	cg20482658	chr1:10539492	PEX14	0.37	4.5	0.42	1.91e-5	Hepatocellular carcinoma;
THYM	cis	rs11098499	0.657	rs10434028	chr4:120294464	T/G	cg09307838	chr4:120376055	NA	0.65	4.79	0.44	6.07e-6	Corneal astigmatism;
THYM	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg18761221	chr20:60518478	NA	0.64	5.09	0.46	1.78e-6	Obesity-related traits;
THYM	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg06640241	chr16:89574553	SPG7	0.87	8.23	0.65	9.72e-13	Multiple myeloma (IgH translocation);
THYM	cis	rs11030122	0.702	rs1452047	chr11:3991648	A/C	cg22027985	chr11:4115532	RRM1	-0.48	-4.59	-0.43	1.36e-5	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9435341	0.930	rs61798463	chr1:107565934	G/A	cg00944433	chr1:107599041	PRMT6	-0.42	-5.0	-0.46	2.58e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg08772003	chr10:104629869	AS3MT	-0.66	-5.79	-0.51	9.01e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4343996	0.870	rs6974075	chr7:3392071	A/G	cg21248987	chr7:3385318	SDK1	-0.4	-4.88	-0.45	4.23e-6	Motion sickness;
THYM	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	5.7	0.5	1.35e-7	Platelet count;
THYM	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg00757033	chr12:89920650	WDR51B	0.75	12.04	0.78	7.96e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs4262150	0.883	rs72802852	chr5:152216893	G/T	cg06854687	chr5:151642065	NA	0.66	4.6	0.43	1.3e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs2350702	0.660	rs12618633	chr2:49958340	G/A	cg22592722	chr2:49566210	NA	-0.59	-4.72	-0.44	8.25e-6	Morning vs. evening chronotype;
THYM	cis	rs765787	0.530	rs1648287	chr15:45516956	T/C	cg24006582	chr15:45444508	DUOX1	-0.84	-7.2	-0.59	1.39e-10	Uric acid levels;
THYM	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg06558623	chr16:89946397	TCF25	1.48	7.81	0.63	7.43e-12	Skin colour saturation;
THYM	cis	rs40363	0.645	rs37774	chr16:3512695	T/C	cg00484396	chr16:3507460	NAT15	0.75	9.47	0.7	2.25e-15	Tuberculosis;
THYM	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg22681709	chr2:178499509	PDE11A	-0.57	-5.4	-0.48	4.83e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs11971779	0.838	rs58074268	chr7:139108925	C/T	cg07862535	chr7:139043722	LUC7L2	0.66	4.68	0.43	9.42e-6	Diisocyanate-induced asthma;
THYM	cis	rs673253	0.571	rs55684236	chr1:44080009	G/A	cg24466421	chr1:44070974	PTPRF	-0.59	-5.12	-0.46	1.62e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13102973	0.899	rs7442212	chr4:135899800	A/G	cg14419869	chr4:135874104	NA	-0.76	-6.42	-0.55	5.46e-9	Subjective well-being;
THYM	cis	rs714027	0.566	rs1548389	chr22:30573552	T/C	cg27665648	chr22:30112403	NA	0.52	4.73	0.44	7.79e-6	Lymphocyte counts;
THYM	cis	rs2554380	0.891	rs2585055	chr15:84281488	A/G	cg15564896	chr15:84287328	SH3GL3	0.88	5.13	0.47	1.52e-6	Height;
THYM	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg17757837	chr7:157058334	UBE3C	0.65	5.24	0.47	9.83e-7	Body mass index;
THYM	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs3126085	0.935	rs3120661	chr1:152294402	A/G	cg10321714	chr1:152280068	FLG	-0.66	-5.07	-0.46	1.97e-6	Atopic dermatitis;
THYM	cis	rs7107174	1.000	rs7128666	chr11:78102363	A/T	cg02023728	chr11:77925099	USP35	0.63	6.01	0.53	3.35e-8	Testicular germ cell tumor;
THYM	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg06640241	chr16:89574553	SPG7	0.91	8.53	0.66	2.29e-13	Multiple myeloma (IgH translocation);
THYM	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg18305652	chr10:134549665	INPP5A	0.73	6.16	0.53	1.71e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs72772090	0.539	rs10515249	chr5:96125259	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg25358565	chr5:93447407	FAM172A	1.36	10.94	0.75	1.62e-18	Diabetic retinopathy;
THYM	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg02734326	chr4:10020555	SLC2A9	-0.6	-4.85	-0.45	4.9100000000000004e-06	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg09877947	chr5:131593287	PDLIM4	-0.73	-6.79	-0.57	9.52e-10	Acylcarnitine levels;
THYM	cis	rs6840360	0.762	rs62327352	chr4:152670780	C/A	cg22705602	chr4:152727874	NA	-0.59	-6.21	-0.54	1.39e-8	Intelligence (multi-trait analysis);
THYM	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg03909863	chr11:638404	DRD4	-0.8	-5.97	-0.52	4.06e-8	Systemic lupus erythematosus;
THYM	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg00012203	chr2:219082015	ARPC2	-0.69	-5.87	-0.52	6.36e-8	Colorectal cancer;
THYM	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg03433033	chr1:76189801	ACADM	0.76	8.16	0.64	1.4e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs8028313	0.630	rs16951105	chr15:67965694	A/G	cg24579218	chr15:68104479	NA	-0.68	-6.05	-0.53	2.9e-8	Obesity;
THYM	cis	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg13443165	chr9:33130375	B4GALT1	-0.86	-7.83	-0.63	6.91e-12	IgG glycosylation;
THYM	cis	rs7731657	0.537	rs9791114	chr5:130361608	A/G	cg08523029	chr5:130500466	HINT1	0.75	5.1	0.46	1.77e-6	Fasting plasma glucose;
THYM	cis	rs7177699	0.525	rs7166770	chr15:79113568	A/G	cg15571903	chr15:79123663	NA	0.57	6.57	0.56	2.72e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs4845875	0.530	rs4846048	chr1:11846252	A/G	cg14194983	chr1:11908298	NPPA	-0.55	-5.14	-0.47	1.5e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg08133631	chr1:26527909	CATSPER4	-0.57	-4.69	-0.43	9.29e-6	Obesity-related traits;
THYM	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg11266682	chr4:10021025	SLC2A9	0.73	12.79	0.8	2.29e-22	Bone mineral density;
THYM	cis	rs7152530	0.571	rs7159904	chr14:98637121	A/C	cg05180522	chr14:98101740	NA	-0.61	-4.74	-0.44	7.57e-6	Staphylococcus aureus infection;
THYM	cis	rs714027	0.566	rs5763751	chr22:30460434	G/T	cg27665648	chr22:30112403	NA	-0.52	-4.73	-0.44	7.79e-6	Lymphocyte counts;
THYM	cis	rs4555082	1.000	rs66777564	chr14:105760245	A/G	cg06808227	chr14:105710500	BRF1	-1.03	-8.95	-0.68	2.92e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.38	-0.48	5.36e-7	Menopause (age at onset);
THYM	cis	rs8018808	1.000	rs4575469	chr14:77860543	G/A	cg20045696	chr14:77926864	AHSA1	-0.53	-4.73	-0.44	7.91e-6	Myeloid white cell count;
THYM	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg00129232	chr17:37814104	STARD3	-0.71	-4.8	-0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs77372450	0.551	rs955967	chr5:157047715	A/G	cg00312553	chr5:157098553	C5orf52	0.62	4.45	0.42	2.3e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs12928939	0.768	rs71386932	chr16:71816191	G/A	cg03805757	chr16:71968109	PKD1L3	-0.7	-5.31	-0.48	7.25e-7	Post bronchodilator FEV1;
THYM	cis	rs5771242	0.685	rs4084289	chr22:50635120	A/G	cg16473166	chr22:50639996	SELO	0.73	4.82	0.44	5.49e-6	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
THYM	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg18402987	chr7:1209562	NA	0.74	5.3	0.48	7.4e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07157834	chr1:205819609	PM20D1	0.92	9.58	0.7	1.29e-15	Menarche (age at onset);
THYM	cis	rs7107770	1.000	rs61912977	chr11:125100184	C/A	cg07747661	chr11:125106135	PKNOX2	-0.85	-5.12	-0.47	1.59e-6	Photic sneeze reflex;
THYM	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03264133	chr6:25882463	NA	0.96	8.41	0.65	4.02e-13	Blood metabolite levels;
THYM	cis	rs977987	0.872	rs1559339	chr16:75318646	A/G	cg03315344	chr16:75512273	CHST6	0.83	7.05	0.59	2.81e-10	Dupuytren's disease;
THYM	cis	rs2688608	0.623	rs2633318	chr10:75690434	T/C	cg02947784	chr10:75434997	AGAP5	0.49	4.64	0.43	1.13e-5	Inflammatory bowel disease;
THYM	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg10057126	chr4:77819792	ANKRD56	0.72	6.14	0.53	1.93e-8	Emphysema distribution in smoking;
THYM	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.37	4.51	0.42	1.82e-5	Schizophrenia;
THYM	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg23978390	chr7:1156363	C7orf50	0.69	4.89	0.45	4.04e-6	Longevity;Endometriosis;
THYM	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	18.27	0.88	7.47e-33	Chronic sinus infection;
THYM	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg26412358	chr1:26503933	CNKSR1	0.36	5.01	0.46	2.48e-6	Height;
THYM	cis	rs273218	0.671	rs27877	chr5:53387784	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.95	5.9	0.52	5.47e-8	Migraine;
THYM	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs10782582	0.569	rs74090722	chr1:76197262	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-5.08	-0.46	1.88e-6	Daytime sleep phenotypes;
THYM	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg21475434	chr5:93447410	FAM172A	0.91	5.64	0.5	1.78e-7	Diabetic retinopathy;
THYM	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-5.74	-0.51	1.12e-7	Systemic lupus erythematosus;
THYM	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg22508957	chr16:3507546	NAT15	0.67	9.28	0.69	5.62e-15	Tuberculosis;
THYM	cis	rs9534288	0.830	rs3783202	chr13:46631869	G/A	cg15192986	chr13:46630673	CPB2	-0.66	-4.66	-0.43	1.03e-5	Blood protein levels;
THYM	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg06609049	chr19:2785107	THOP1	1.14	11.44	0.76	1.47e-19	Total cholesterol levels;
THYM	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg24209194	chr3:40518798	ZNF619	0.67	5.53	0.49	2.85e-7	Renal cell carcinoma;
THYM	cis	rs10463554	0.889	rs246912	chr5:102560841	A/C	cg23492399	chr5:102201601	PAM	-0.67	-5.06	-0.46	2.07e-6	Parkinson's disease;
THYM	cis	rs1609391	0.561	rs6439675	chr3:136625436	G/A	cg15507776	chr3:136538369	TMEM22	0.64	4.9	0.45	4.02e-6	Neuroticism;
THYM	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg08885076	chr2:99613938	TSGA10	-0.69	-5.38	-0.48	5.45e-7	Chronic sinus infection;
THYM	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg23711669	chr6:146136114	FBXO30	0.96	9.87	0.71	3.12e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06873352	chr17:61820015	STRADA	0.56	5.63	0.5	1.81e-7	Height;
THYM	cis	rs72627123	0.867	rs73303129	chr14:74489244	A/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.52	0.56	3.44e-9	Morning vs. evening chronotype;
THYM	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg08807101	chr21:30365312	RNF160	-0.67	-4.87	-0.45	4.5e-6	Dental caries;
THYM	cis	rs554111	0.679	rs906254	chr1:21324760	G/A	cg00373020	chr1:21041521	KIF17	-0.53	-4.47	-0.42	2.14e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg08999081	chr20:33150536	PIGU	0.77	6.95	0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg21784768	chr11:537496	LRRC56	-1.09	-4.91	-0.45	3.76e-6	Body mass index;
THYM	cis	rs9532580	0.553	rs9549250	chr13:41225229	T/G	cg21288729	chr13:41239152	FOXO1	0.71	5.65	0.5	1.66e-7	Mean corpuscular hemoglobin;
THYM	cis	rs6748734	0.857	rs4675857	chr2:241842326	T/C	cg15164180	chr2:241846931	NA	-0.38	-4.98	-0.45	2.87e-6	Urinary metabolites;
THYM	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg27121462	chr16:89883253	FANCA	0.57	4.64	0.43	1.12e-5	Vitiligo;
THYM	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7084402	0.967	rs1658495	chr10:60280153	C/A	cg07615347	chr10:60278583	BICC1	-0.56	-5.15	-0.47	1.4e-6	Refractive error;
THYM	cis	rs752010	0.806	rs10890148	chr1:42091517	T/C	cg06885757	chr1:42089581	HIVEP3	0.55	6.52	0.56	3.4e-9	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg09455208	chr3:40491958	NA	0.5	5.24	0.47	9.76e-7	Renal cell carcinoma;
THYM	cis	rs919433	0.617	rs4850436	chr2:198541398	C/T	cg00792783	chr2:198669748	PLCL1	-0.77	-5.4	-0.48	4.91e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4792901	1.000	rs1010049	chr17:41655679	G/A	cg21940313	chr17:41620911	ETV4	0.45	4.76	0.44	6.89e-6	Dupuytren's disease;
THYM	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs7078219	0.897	rs10883360	chr10:101281158	C/G	cg17888390	chr10:101282816	NA	-0.5	-4.74	-0.44	7.56e-6	Dental caries;
THYM	cis	rs662064	0.962	rs2781232	chr1:10544388	T/C	cg20482658	chr1:10539492	PEX14	-0.49	-6.13	-0.53	2e-8	Asthma;
THYM	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg02782426	chr3:40428986	ENTPD3	0.54	4.79	0.44	6.02e-6	Renal cell carcinoma;
THYM	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg08999081	chr20:33150536	PIGU	0.78	7.16	0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs4481887	1.000	rs4244172	chr1:248466838	A/G	cg00666640	chr1:248458726	OR2T12	0.56	4.65	0.43	1.08e-5	Common traits (Other);
THYM	cis	rs56322409	0.561	rs10786226	chr10:97367803	C/T	cg00110277	chr10:97668174	C10orf131	-0.58	-4.91	-0.45	3.72e-6	Blood metabolite levels;
THYM	cis	rs9397585	0.599	rs685826	chr6:153411255	C/T	cg12989544	chr6:153429875	RGS17	-0.48	-4.67	-0.43	9.89e-6	Body mass index;
THYM	cis	rs9527	0.590	rs726010	chr10:104841977	C/T	cg04362960	chr10:104952993	NT5C2	0.69	5.36	0.48	5.82e-7	Arsenic metabolism;
THYM	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg27129171	chr3:47204927	SETD2	0.71	6.03	0.53	3.19e-8	Birth weight;
THYM	cis	rs11722228	0.521	rs56403947	chr4:10112529	T/G	cg02317251	chr4:10116515	WDR1	-0.56	-4.95	-0.45	3.23e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs4455778	0.580	rs4291221	chr7:49114465	C/T	cg26309511	chr7:48887640	NA	-0.68	-5.87	-0.52	6.3e-8	Lung cancer in never smokers;
THYM	cis	rs6815814	0.950	rs11722813	chr4:38810769	C/T	cg06935464	chr4:38784597	TLR10	0.71	4.5	0.42	1.91e-5	Breast cancer;
THYM	cis	rs4866334	1.000	rs79107423	chr5:18501522	A/G	cg04591469	chr5:17810299	NA	-1.14	-4.6	-0.43	1.28e-5	IgG glycosylation;
THYM	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg08975724	chr8:8085496	FLJ10661	-0.74	-5.91	-0.52	5.44e-8	Mood instability;
THYM	cis	rs13064411	0.627	rs9872168	chr3:113233132	A/C	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs1878931	0.582	rs4785933	chr16:3419741	T/A	cg21433313	chr16:3507492	NAT15	-0.59	-4.99	-0.46	2.75e-6	Body mass index (adult);
THYM	cis	rs6815814	0.950	rs55903115	chr4:38786474	C/A	cg06935464	chr4:38784597	TLR10	0.75	4.99	0.46	2.75e-6	Breast cancer;
THYM	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg08975724	chr8:8085496	FLJ10661	-0.56	-4.46	-0.42	2.28e-5	Myopia (pathological);
THYM	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg22974920	chr21:40686053	BRWD1	-0.61	-4.8	-0.44	5.82e-6	Cognitive function;
THYM	cis	rs11190604	1.000	rs17746014	chr10:102315354	T/C	cg16342193	chr10:102329863	NA	-0.6	-6.24	-0.54	1.22e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs17604090	0.878	rs4000281	chr7:29726287	A/G	cg19413766	chr7:29689036	LOC646762	-0.97	-5.46	-0.49	3.8e-7	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs6032067	1.000	rs6032069	chr20:43867388	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	0.7	6.33	0.54	7.93e-9	Blood protein levels;
THYM	cis	rs6558530	0.932	rs9022	chr8:1710977	A/C	cg09410841	chr8:1729607	CLN8	0.83	6.0	0.52	3.61e-8	Systolic blood pressure;
THYM	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg22467129	chr15:76604101	ETFA	-0.56	-5.26	-0.47	9.01e-7	Blood metabolite levels;
THYM	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs747782	0.528	rs11039674	chr11:48336116	C/T	cg24672777	chr11:48374446	OR4C45	-1.17	-7.15	-0.59	1.78e-10	Intraocular pressure;
THYM	cis	rs559928	0.576	rs750832	chr11:64163302	C/T	cg00022866	chr11:64108440	CCDC88B	-0.6	-4.48	-0.42	2.07e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs2219968	0.884	rs9643433	chr8:78952371	T/A	cg00738934	chr8:78996279	NA	0.8	8.43	0.65	3.79e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs113835537	0.529	rs11227501	chr11:66274072	T/C	cg24851651	chr11:66362959	CCS	0.7	4.89	0.45	4.04e-6	Airway imaging phenotypes;
THYM	cis	rs7567389	0.812	rs6710496	chr2:127976374	A/C	cg09760422	chr2:128146352	NA	-0.49	-5.97	-0.52	4.06e-8	Self-rated health;
THYM	cis	rs8070740	0.617	rs1058115	chr17:5323269	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	-0.76	-7.25	-0.6	1.1e-10	Menopause (age at onset);
THYM	cis	rs2286885	1.000	rs741022	chr9:129252113	C/G	cg14294646	chr9:129243551	FAM125B	-0.59	-5.57	-0.5	2.37e-7	Intraocular pressure;
THYM	cis	rs4237845	0.742	rs3751330	chr12:58290226	T/C	cg00677455	chr12:58241039	CTDSP2	0.62	4.55	0.42	1.56e-5	Intelligence (multi-trait analysis);
THYM	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg04455712	chr21:45112962	RRP1B	-0.5	-4.62	-0.43	1.21e-5	Mean corpuscular volume;
THYM	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg05347473	chr6:146136440	FBXO30	-0.56	-4.45	-0.42	2.34e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg27490568	chr2:178487706	NA	0.64	5.19	0.47	1.17e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg05043794	chr9:111880884	C9orf5	-0.43	-6.35	-0.55	7.29e-9	Menarche (age at onset);
THYM	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg16414030	chr3:133502952	NA	0.59	4.69	0.43	9.11e-6	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs7173743	0.730	rs6495340	chr15:79128396	A/G	cg00540400	chr15:79124168	NA	0.6	6.52	0.56	3.43e-9	Coronary artery disease;
THYM	cis	rs55665837	1.000	rs2305306	chr11:14534999	T/A	cg19336497	chr11:14380999	RRAS2	-0.62	-6.61	-0.56	2.23e-9	Vitamin D levels;
THYM	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg00271210	chr6:167070053	RPS6KA2	-0.54	-5.24	-0.47	9.81e-7	Crohn's disease;
THYM	cis	rs2688608	0.901	rs2664280	chr10:75617344	A/T	cg19442545	chr10:75533431	FUT11	0.43	4.56	0.42	1.54e-5	Inflammatory bowel disease;
THYM	cis	rs4886920	0.894	rs7176895	chr15:78117800	G/A	cg10461261	chr15:78109450	NA	-0.5	-4.91	-0.45	3.82e-6	Neuroticism;
THYM	cis	rs665401	0.652	rs1512655	chr6:117116427	A/G	cg20376953	chr6:117187980	NA	-0.6	-4.69	-0.43	8.97e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs7827545	0.644	rs7386524	chr8:135534005	T/C	cg17885191	chr8:135476712	NA	-0.75	-5.39	-0.48	5.03e-7	Hypertension (SNP x SNP interaction);
THYM	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs10779751	0.575	rs2791655	chr1:11128654	A/G	cg08854313	chr1:11322531	MTOR	-0.74	-6.4	-0.55	5.92e-9	Body mass index;
THYM	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg25767906	chr1:53392781	SCP2	-0.56	-5.33	-0.48	6.59e-7	Monocyte count;
THYM	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg08885076	chr2:99613938	TSGA10	0.52	5.02	0.46	2.4e-6	Chronic sinus infection;
THYM	cis	rs854765	0.929	rs2955360	chr17:17974887	G/A	cg04398451	chr17:18023971	MYO15A	0.89	8.12	0.64	1.7e-12	Total body bone mineral density;
THYM	cis	rs1061377	1.000	rs28465556	chr4:39121189	T/G	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg24818145	chr4:99064322	C4orf37	0.66	5.18	0.47	1.25e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg08847533	chr14:75593920	NEK9	0.97	10.48	0.73	1.56e-17	Height;
THYM	cis	rs10095849	0.576	rs10088799	chr8:39468849	G/T	cg22755526	chr8:38854673	TM2D2;ADAM9	-0.62	-4.61	-0.43	1.24e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg02269571	chr22:50332266	NA	-1.07	-5.81	-0.51	8.2e-8	Schizophrenia;
THYM	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg25811766	chr13:21894605	NA	0.73	5.95	0.52	4.49e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg12463550	chr7:65579703	CRCP	-0.55	-4.51	-0.42	1.88e-5	Aortic root size;
THYM	cis	rs2282300	0.702	rs4379811	chr11:30294760	C/T	cg06241208	chr11:30344200	C11orf46	0.78	5.65	0.5	1.67e-7	Morning vs. evening chronotype;
THYM	cis	rs9790314	0.905	rs4518145	chr3:160950030	T/C	cg03342759	chr3:160939853	NMD3	-0.81	-7.28	-0.6	9.51e-11	Morning vs. evening chronotype;
THYM	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg05717871	chr11:638507	DRD4	-0.64	-5.0	-0.46	2.58e-6	Systemic lupus erythematosus;
THYM	cis	rs2235649	0.663	rs12596160	chr16:1848784	G/A	cg03034668	chr16:1723424	CRAMP1L	-0.61	-5.22	-0.47	1.04e-6	Blood metabolite levels;
THYM	cis	rs34526934	0.672	rs6710142	chr2:177054769	G/A	cg14324370	chr2:177042789	NA	-0.71	-5.68	-0.5	1.46e-7	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs7267979	0.966	rs2387882	chr20:25378802	C/T	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs293526	0.918	rs2783165	chr6:83643612	G/A	cg23278060	chr6:83777448	DOPEY1	0.62	4.54	0.42	1.67e-5	Crohn's disease;
THYM	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg13319975	chr6:146136371	FBXO30	0.6	4.83	0.44	5.32e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11186	0.556	rs72906330	chr2:189958751	T/C	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs2625529	0.938	rs2723343	chr15:72108269	C/T	cg16672083	chr15:72433130	SENP8	-0.61	-4.79	-0.44	6.03e-6	Red blood cell count;
THYM	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	6.47	0.55	4.18e-9	Platelet count;
THYM	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.47	0.49	3.63e-7	Bipolar disorder;
THYM	cis	rs16866061	1.000	rs72974203	chr2:225408430	G/A	cg12698349	chr2:225449008	CUL3	1.14	10.45	0.73	1.77e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs931127	0.640	rs2509948	chr11:65406393	C/T	cg27068330	chr11:65405492	SIPA1	0.73	5.52	0.49	2.94e-7	Systemic lupus erythematosus;
THYM	cis	rs57590327	0.503	rs11711024	chr3:81910207	T/C	cg07356753	chr3:81810745	GBE1	-0.74	-5.43	-0.49	4.33e-7	Extraversion;
THYM	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg24675658	chr1:53192096	ZYG11B	0.88	6.66	0.56	1.8e-9	Monocyte count;
THYM	cis	rs1609391	0.543	rs6800690	chr3:136623026	G/A	cg15507776	chr3:136538369	TMEM22	0.64	4.9	0.45	4.02e-6	Neuroticism;
THYM	cis	rs7084402	0.967	rs1649060	chr10:60310480	C/G	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs9972944	0.756	rs7207587	chr17:63766307	C/T	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs12935418	0.616	rs2549857	chr16:81026958	A/G	cg16651780	chr16:81037892	C16orf61	0.87	6.94	0.58	4.75e-10	Mean corpuscular volume;
THYM	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-6.59	-0.56	2.45e-9	Alzheimer's disease (late onset);
THYM	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11890956	chr21:40555474	PSMG1	-0.92	-10.2	-0.72	6.08e-17	Cognitive function;
THYM	cis	rs7078219	0.505	rs4129132	chr10:101284637	T/G	cg04972745	chr10:101287846	NA	-0.5	-4.65	-0.43	1.09e-5	Dental caries;
THYM	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg08772003	chr10:104629869	AS3MT	-0.63	-5.59	-0.5	2.18e-7	Arsenic metabolism;
THYM	cis	rs4722585	0.533	rs12334205	chr7:26202490	G/A	cg07876897	chr7:26191696	NFE2L3	0.57	4.55	0.42	1.61e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	trans	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg25214090	chr10:38739885	LOC399744	-0.93	-7.86	-0.63	5.93e-12	Corneal astigmatism;
THYM	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg18352616	chr4:3374830	RGS12	0.72	7.72	0.62	1.17e-11	Serum sulfate level;
THYM	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg23161317	chr6:28129485	ZNF389	0.54	5.33	0.48	6.59e-7	Parkinson's disease;
THYM	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg17366294	chr4:99064904	C4orf37	0.53	5.91	0.52	5.24e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1050631	0.592	rs1632169	chr18:33709762	G/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.65	5.24	0.47	9.7e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs13064411	0.735	rs722392	chr3:113228294	A/G	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs2455799	0.573	rs2455793	chr3:15743844	A/G	cg16303742	chr3:15540471	COLQ	-0.53	-5.86	-0.52	6.65e-8	Mean platelet volume;
THYM	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.99	9.59	0.7	1.25e-15	Body mass index (adult);
THYM	cis	rs11574514	0.744	rs28580313	chr16:67806351	G/A	cg04582263	chr16:67973788	LCAT	1.08	5.09	0.46	1.82e-6	Crohn's disease;
THYM	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg14779329	chr11:130786720	SNX19	0.53	5.25	0.47	9.17e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9646944	0.501	rs10197310	chr2:103020030	A/T	cg01241218	chr2:102972058	NA	-0.81	-5.49	-0.49	3.4e-7	Blood protein levels;
THYM	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg15704280	chr7:45808275	SEPT13	1.02	8.31	0.65	6.7e-13	Coronary artery disease;
THYM	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	5.45	0.49	3.96e-7	Lung cancer in ever smokers;
THYM	cis	rs1113500	0.933	rs10881500	chr1:108638895	C/T	cg06207961	chr1:108661230	NA	0.64	5.09	0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs6980334	0.906	rs10264658	chr7:137779000	T/C	cg03464514	chr7:137028442	PTN	0.56	4.67	0.43	9.74e-6	Blood metabolite ratios;
THYM	cis	rs35883536	0.528	rs1855800	chr1:101030641	G/A	cg06223162	chr1:101003688	GPR88	0.85	6.84	0.57	7.49e-10	Monocyte count;
THYM	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05901451	chr6:126070800	HEY2	-0.91	-9.29	-0.69	5.34e-15	Brugada syndrome;
THYM	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg00271210	chr6:167070053	RPS6KA2	0.72	7.96	0.63	3.73e-12	Crohn's disease;
THYM	cis	rs4595586	0.545	rs12814188	chr12:39380853	C/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs3540	0.597	rs4620932	chr15:91036569	G/A	cg00487526	chr15:90818384	NA	-0.58	-4.47	-0.42	2.19e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs1978968	1.000	rs1076541	chr22:18440026	C/T	cg01550578	chr22:18484421	MICAL3	0.66	4.83	0.44	5.27e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg01416388	chr22:39784598	NA	-0.85	-7.67	-0.62	1.48e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg19761014	chr17:28927070	LRRC37B2	0.73	4.46	0.42	2.21e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9807989	0.507	rs6726985	chr2:103048580	G/A	cg03938978	chr2:103052716	IL18RAP	0.75	9.8	0.71	4.43e-16	Asthma;
THYM	cis	rs10089	0.951	rs736969	chr5:127466347	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs600806	0.888	rs444387	chr1:109851127	A/G	cg23032129	chr1:109941072	SORT1	-0.56	-4.7	-0.43	8.68e-6	Intelligence (multi-trait analysis);
THYM	cis	rs16857609	0.917	rs11693806	chr2:218292158	C/G	cg15335768	chr2:218268053	DIRC3	0.35	5.48	0.49	3.53e-7	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	cis	rs514406	0.698	rs11206055	chr1:53436632	A/T	cg27535305	chr1:53392650	SCP2	0.54	6.36	0.55	7.06e-9	Monocyte count;
THYM	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg16414030	chr3:133502952	NA	-0.79	-7.25	-0.6	1.1e-10	Iron status biomarkers;
THYM	cis	rs662064	0.748	rs2480777	chr1:10597551	C/T	cg20482658	chr1:10539492	PEX14	0.5	6.32	0.54	8.53e-9	Asthma;
THYM	cis	rs7927771	0.832	rs10838697	chr11:47384484	T/A	cg18512352	chr11:47633146	NA	-0.51	-5.88	-0.52	5.99e-8	Subjective well-being;
THYM	cis	rs9875589	0.509	rs1873005	chr3:14060223	G/A	cg03204825	chr3:13978759	TPRXL	-0.51	-4.46	-0.42	2.26e-5	Ovarian reserve;
THYM	cis	rs7668190	1.000	rs7668190	chr4:55096270	A/T	cg17187183	chr4:55093834	PDGFRA	0.61	4.61	0.43	1.27e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10095849	0.680	rs13276944	chr8:39457035	G/A	cg01911981	chr8:39380341	ADAM3A	-0.59	-5.01	-0.46	2.47e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs17708984	0.561	rs10424913	chr19:16191338	C/T	cg13618979	chr19:16186840	TPM4	0.36	4.78	0.44	6.39e-6	Platelet count;Platelet distribution width;
THYM	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg19912559	chr1:40204330	PPIE	0.64	4.87	0.45	4.45e-6	Blood protein levels;
THYM	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg06112835	chr11:68658793	MRPL21	0.43	6.02	0.53	3.32e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.53	4.84	0.44	4.99e-6	Schizophrenia;
THYM	cis	rs2625529	0.824	rs12595228	chr15:72267215	T/C	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg17264618	chr3:40429014	ENTPD3	-0.53	-5.15	-0.47	1.38e-6	Renal cell carcinoma;
THYM	cis	rs10744422	1.000	rs7294991	chr12:123286780	C/T	cg25930673	chr12:123319894	HIP1R	-0.85	-5.05	-0.46	2.13e-6	Schizophrenia;
THYM	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg26384229	chr12:38710491	ALG10B	-0.91	-7.45	-0.61	4.34e-11	Bladder cancer;
THYM	cis	rs17604090	0.775	rs76480599	chr7:29689180	A/G	cg19413766	chr7:29689036	LOC646762	-0.87	-4.7	-0.43	8.78e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg12893697	chr11:970389	AP2A2	-0.31	-5.21	-0.47	1.08e-6	Alzheimer's disease (late onset);
THYM	cis	rs28595532	0.920	rs115472708	chr4:119773407	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs10411161	0.702	rs11879436	chr19:52397815	T/A	cg25361850	chr19:52391789	ZNF577	0.74	4.96	0.45	3.14e-6	Breast cancer;
THYM	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs988913	0.957	rs9296771	chr6:54782274	T/A	cg04690482	chr6:54711388	FAM83B	0.51	5.38	0.48	5.24e-7	Menarche (age at onset);
THYM	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs995000	0.899	rs11207985	chr1:63013786	A/G	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg24818145	chr4:99064322	C4orf37	0.75	5.93	0.52	4.94e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.53	0.56	3.27e-9	Total body bone mineral density;
THYM	cis	rs9831754	0.526	rs6548551	chr3:78342292	C/T	cg06138941	chr3:78371609	NA	0.67	5.24	0.47	9.49e-7	Calcium levels;
THYM	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg14779329	chr11:130786720	SNX19	0.54	5.88	0.52	6.2e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9832461	0.843	rs17076570	chr3:39776225	C/T	cg09883745	chr3:40086528	MYRIP	0.68	4.6	0.43	1.31e-5	Brain structure (temporal lobe volume);
THYM	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg05025164	chr4:1340916	KIAA1530	0.94	7.7	0.62	1.28e-11	Longevity;
THYM	cis	rs4148689	0.951	rs1429566	chr7:117170774	G/A	cg17204129	chr7:117119601	CFTR	-0.62	-4.79	-0.44	6.23e-6	Gout;
THYM	cis	rs763014	0.931	rs11643039	chr16:634260	G/A	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs500891	0.525	rs1145902	chr6:84038531	A/G	cg21688264	chr6:84418724	SNAP91	0.74	4.51	0.42	1.87e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs800586	0.868	rs179456	chr8:116695112	C/T	cg04656070	chr8:116661063	TRPS1	-0.51	-4.76	-0.44	6.9e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs6543140	0.964	rs62154972	chr2:103048738	G/A	cg03938978	chr2:103052716	IL18RAP	0.61	6.13	0.53	1.96e-8	Blood protein levels;
THYM	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg11597832	chr14:105993747	TMEM121	-0.5	-4.54	-0.42	1.66e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg12311346	chr5:56204834	C5orf35	-0.83	-6.19	-0.54	1.52e-8	Initial pursuit acceleration;
THYM	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg10515332	chr4:99064459	C4orf37	0.64	5.05	0.46	2.12e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8067545	0.750	rs35003563	chr17:19989218	G/A	cg13482628	chr17:19912719	NA	0.58	4.77	0.44	6.57e-6	Schizophrenia;
THYM	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03576123	chr11:487126	PTDSS2	-1.29	-6.4	-0.55	5.87e-9	Body mass index;
THYM	cis	rs7567389	0.638	rs12105051	chr2:127990177	T/G	cg06038358	chr2:128176007	PROC	-0.49	-4.97	-0.45	2.97e-6	Self-rated health;
THYM	cis	rs7264396	0.561	rs6060741	chr20:34571484	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.62	4.52	0.42	1.78e-5	Total cholesterol levels;
THYM	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.36	0.48	5.75e-7	Height;
THYM	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg10515332	chr4:99064459	C4orf37	0.57	4.56	0.42	1.54e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg21773646	chr17:80085082	CCDC57	0.31	4.49	0.42	2.02e-5	Life satisfaction;
THYM	cis	rs12540874	0.698	rs12718574	chr7:50573848	G/C	cg18232548	chr7:50535776	DDC	-0.88	-7.91	-0.63	4.63e-12	Systemic sclerosis;
THYM	cis	rs611744	0.507	rs1579924	chr8:109324884	G/T	cg21045802	chr8:109455806	TTC35	0.86	7.25	0.6	1.11e-10	Dupuytren's disease;
THYM	cis	rs3126085	0.935	rs1390490	chr1:152161354	T/C	cg10321714	chr1:152280068	FLG	0.67	4.69	0.43	9.24e-6	Atopic dermatitis;
THYM	cis	rs6906287	0.647	rs2356492	chr6:118809437	C/G	cg21191810	chr6:118973309	C6orf204	0.58	5.78	0.51	9.61e-8	Electrocardiographic conduction measures;
THYM	cis	rs61931739	0.890	rs1197560	chr12:34121447	G/C	cg06521331	chr12:34319734	NA	-0.6	-4.84	-0.44	4.98e-6	Morning vs. evening chronotype;
THYM	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg08431931	chr22:42394659	WBP2NL	0.69	4.59	0.43	1.34e-5	Birth weight;
THYM	cis	rs1933112	1.000	rs1024176	chr1:168526103	C/T	cg00154920	chr1:168513310	XCL2	-0.5	-5.02	-0.46	2.38e-6	Blood protein levels;
THYM	cis	rs1448094	0.512	rs12305828	chr12:86249153	C/G	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg16325326	chr1:53192061	ZYG11B	0.95	10.66	0.74	6.45e-18	Monocyte count;
THYM	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg00647820	chr17:40259828	DHX58	0.6	4.53	0.42	1.72e-5	Fibrinogen levels;
THYM	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs10411161	0.690	rs7252336	chr19:52389514	C/T	cg25361850	chr19:52391789	ZNF577	0.74	5.18	0.47	1.22e-6	Breast cancer;
THYM	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg13319975	chr6:146136371	FBXO30	0.7	5.77	0.51	9.81e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11186	0.556	rs7425294	chr2:189968175	G/A	cg11041835	chr2:189156425	GULP1	0.8	4.58	0.43	1.41e-5	Parkinson's disease;
THYM	cis	rs7809615	0.901	rs6947826	chr7:99156520	C/T	cg12290671	chr7:99195819	NA	-0.99	-4.83	-0.44	5.27e-6	Blood metabolite ratios;
THYM	cis	rs1568889	1.000	rs66857704	chr11:28212346	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.66e-6	Bipolar disorder;
THYM	cis	rs2702888	0.503	rs2741714	chr8:6759967	C/A	cg03082247	chr8:6756796	NA	-0.59	-5.0	-0.46	2.67e-6	Blood pressure;
THYM	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg13246856	chr1:44399776	ARTN	0.5	5.46	0.49	3.82e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1629083	0.967	rs1715456	chr11:118123517	A/G	cg25155064	chr11:118100782	MPZL3	-0.56	-5.01	-0.46	2.49e-6	Lung cancer;
THYM	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg05283184	chr6:79620031	NA	-0.91	-8.88	-0.67	4.11e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7177699	0.557	rs8035093	chr15:79120670	T/C	cg00540400	chr15:79124168	NA	0.63	6.89	0.58	6.04e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs3916	0.794	rs10431386	chr12:121128926	A/G	cg21892295	chr12:121157589	UNC119B	0.49	5.26	0.47	8.84e-7	Urinary metabolites (H-NMR features);
THYM	cis	rs901683	0.850	rs12774453	chr10:46038921	G/A	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg23711669	chr6:146136114	FBXO30	-0.97	-9.96	-0.71	2.04e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs35883536	1.000	rs1855798	chr1:101114191	T/C	cg06223162	chr1:101003688	GPR88	0.67	5.2	0.47	1.15e-6	Monocyte count;
THYM	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.86	0.45	4.65e-6	Prudent dietary pattern;
THYM	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg03959625	chr15:84868606	LOC388152	0.48	4.56	0.42	1.5e-5	Schizophrenia;
THYM	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.82	-4.55	-0.42	1.56e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	5.64	0.5	1.76e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg09737314	chr17:6899359	ALOX12	0.8	10.59	0.74	9.09e-18	Tonsillectomy;
THYM	cis	rs6570726	0.764	rs366673	chr6:145814628	T/A	cg23711669	chr6:146136114	FBXO30	0.95	9.55	0.7	1.52e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.69	5.35	0.48	5.98e-7	Tonsillectomy;
THYM	cis	rs12474201	0.507	rs6714451	chr2:47017743	G/C	cg03034696	chr2:47400023	CALM2	0.27	4.5	0.42	1.94e-5	Height;
THYM	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg18252515	chr7:66147081	NA	1.48	8.83	0.67	5.15e-14	Diabetic kidney disease;
THYM	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	6.27	0.54	1.05e-8	Platelet count;
THYM	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg15247329	chr7:2764246	NA	-0.69	-5.76	-0.51	1.02e-7	Height;
THYM	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-4.54	-0.42	1.63e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs7072216	0.726	rs4474372	chr10:100164571	C/T	cg26618903	chr10:100175079	PYROXD2	-0.49	-4.67	-0.43	1.01e-5	Metabolite levels;
THYM	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg16049864	chr8:95962084	TP53INP1	-0.7	-6.01	-0.53	3.36e-8	Type 2 diabetes;
THYM	cis	rs4866334	1.000	rs76258230	chr5:18433807	G/C	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg06028605	chr16:24865363	SLC5A11	0.63	5.12	0.47	1.59e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6138458	1.000	rs6106984	chr20:24977006	T/C	cg26195577	chr20:24973756	C20orf3	1.09	11.01	0.75	1.16e-18	Blood protein levels;
THYM	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg20242066	chr2:136595261	LCT	0.47	5.4	0.48	4.84e-7	Mosquito bite size;
THYM	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg08975724	chr8:8085496	FLJ10661	-0.75	-5.9	-0.52	5.48e-8	Mood instability;
THYM	cis	rs4988958	0.565	rs10206291	chr2:103038863	T/C	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma (childhood onset);
THYM	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg25703541	chr22:24373054	LOC391322	0.88	9.55	0.7	1.49e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2294693	0.580	rs4711653	chr6:40942996	T/C	cg14418226	chr6:40996092	UNC5CL	0.72	5.42	0.49	4.49e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs3820068	0.705	rs4646103	chr1:15819827	T/A	cg05660106	chr1:15850417	CASP9	1.15	10.57	0.74	9.96e-18	Systolic blood pressure;
THYM	cis	rs12476592	0.602	rs262505	chr2:63861786	C/T	cg17519650	chr2:63277830	OTX1	-0.7	-4.68	-0.43	9.57e-6	Childhood ear infection;
THYM	cis	rs1823778	0.609	rs11663969	chr18:67707490	T/C	cg20768743	chr18:67624846	CD226	1.16	4.74	0.44	7.56e-6	Mean platelet volume;
THYM	cis	rs240764	0.578	rs6928418	chr6:101175347	T/C	cg21058520	chr6:100914733	NA	-0.61	-4.86	-0.45	4.54e-6	Neuroticism;
THYM	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg02869364	chr7:1081709	C7orf50	-0.62	-4.99	-0.46	2.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06481639	chr22:41940642	POLR3H	0.85	5.83	0.51	7.73e-8	Vitiligo;
THYM	cis	rs9403317	0.573	rs975858	chr6:142028607	C/T	cg15052665	chr6:141804349	NA	0.62	5.06	0.46	2.08e-6	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs8002861	0.664	rs2218497	chr13:44428793	G/A	cg17145862	chr1:211918768	LPGAT1	0.85	7.64	0.62	1.69e-11	Leprosy;
THYM	cis	rs986417	0.818	rs4901993	chr14:61081453	G/A	cg27398547	chr14:60952738	C14orf39	0.94	5.21	0.47	1.07e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg15110403	chr19:17392923	ANKLE1	-0.58	-4.96	-0.45	3.05e-6	Systemic lupus erythematosus;
THYM	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs3741151	0.687	rs724111	chr11:73238645	G/A	cg12959048	chr11:73096162	RELT	-0.51	-4.51	-0.42	1.87e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.67	-8.76	-0.67	7.26e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs11677370	0.561	rs10084170	chr2:3820204	G/C	cg17052675	chr2:3827356	NA	-0.66	-6.48	-0.55	4.03e-9	Type 2 diabetes;
THYM	cis	rs4766646	0.619	rs4766638	chr12:110298858	T/C	cg10794374	chr12:110278745	NA	-0.22	-4.93	-0.45	3.43e-6	Metabolite levels (MHPG);
THYM	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg18681998	chr4:17616180	MED28	0.97	9.8	0.71	4.41e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs3771570	0.901	rs4675964	chr2:242324760	A/C	cg21155796	chr2:242212141	HDLBP	1.09	6.4	0.55	5.95e-9	Prostate cancer;
THYM	cis	rs240764	0.817	rs239204	chr6:101135580	T/C	cg21058520	chr6:100914733	NA	-0.57	-5.21	-0.47	1.1e-6	Neuroticism;
THYM	cis	rs73219805	0.671	rs13267955	chr8:26224593	C/G	cg22461835	chr8:26723365	ADRA1A	-0.53	-4.56	-0.42	1.55e-5	Schizophrenia;
THYM	cis	rs7267979	0.934	rs2482913	chr20:25405086	T/A	cg08601574	chr20:25228251	PYGB	-0.58	-4.69	-0.43	8.97e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg13695892	chr22:41940480	POLR3H	0.99	7.48	0.61	3.75e-11	Vitiligo;
THYM	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg27129171	chr3:47204927	SETD2	0.77	7.67	0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs12257961	0.640	rs10906887	chr10:15375654	C/T	cg10616319	chr10:15468812	NA	-0.6	-4.9	-0.45	3.99e-6	Selective IgA deficiency;
THYM	cis	rs6456042	0.965	rs6927190	chr6:166539539	G/A	cg11088901	chr6:166572345	T	-0.52	-4.9	-0.45	3.93e-6	Asthma;
THYM	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg24838063	chr12:130822603	PIWIL1	-0.74	-5.51	-0.49	3.09e-7	Menopause (age at onset);
THYM	cis	rs892961	0.899	rs747482	chr17:75412109	T/C	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.55e-12	Airflow obstruction;
THYM	cis	rs2229238	0.911	rs12405637	chr1:154501285	C/T	cg21262032	chr1:154437693	IL6R	-0.63	-5.65	-0.5	1.68e-7	Coronary heart disease;
THYM	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.67	-5.23	-0.47	1.01e-6	Tonsillectomy;
THYM	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg24846343	chr22:24311635	DDTL	0.47	5.95	0.52	4.42e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg17143192	chr8:8559678	CLDN23	0.91	6.72	0.57	1.33e-9	Obesity-related traits;
THYM	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs9796	0.870	rs2925342	chr15:41305733	A/G	cg18705301	chr15:41695430	NDUFAF1	0.56	4.57	0.42	1.49e-5	Menopause (age at onset);
THYM	cis	rs7705042	0.828	rs10875596	chr5:141495715	T/C	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg15744005	chr10:104629667	AS3MT	-0.86	-8.17	-0.64	1.33e-12	Arsenic metabolism;
THYM	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	Neuroticism;
THYM	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg10295955	chr4:187884368	NA	-1.17	-17.37	-0.87	3.11e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7828089	0.934	rs12544427	chr8:22263115	C/T	cg12081754	chr8:22256438	SLC39A14	-0.63	-5.57	-0.5	2.38e-7	Verbal declarative memory;
THYM	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03264133	chr6:25882463	NA	-0.9	-8.04	-0.64	2.46e-12	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs981844	1.000	rs116588966	chr4:154664794	T/C	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs11087123	0.500	rs410068	chr20:15121236	T/G	cg09937190	chr20:15177509	MACROD2	-0.47	-5.15	-0.47	1.42e-6	Eating disorders;
THYM	cis	rs10487112	0.625	rs714498	chr7:90167839	A/T	cg26441104	chr7:90822169	CDK14	0.51	4.85	0.45	4.83e-6	Perceived unattractiveness to mosquitoes;
THYM	cis	rs9790314	0.521	rs1450522	chr3:161077630	A/G	cg03342759	chr3:160939853	NMD3	-0.9	-7.84	-0.63	6.69e-12	Morning vs. evening chronotype;
THYM	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg23711669	chr6:146136114	FBXO30	0.83	8.25	0.65	8.95e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6754311	0.593	rs4954279	chr2:136409073	G/A	cg20242066	chr2:136595261	LCT	0.55	5.9	0.52	5.66e-8	Mosquito bite size;
THYM	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg05283184	chr6:79620031	NA	-0.87	-8.15	-0.64	1.43e-12	Intelligence (multi-trait analysis);
THYM	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg20744362	chr22:50050164	C22orf34	0.82	8.14	0.64	1.52e-12	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs4642101	0.662	rs9840766	chr3:12821870	G/A	cg05775895	chr3:12838266	CAND2	1.04	9.77	0.71	5.02e-16	QRS complex (12-leadsum);
THYM	cis	rs2625529	0.652	rs2415128	chr15:72191073	T/C	cg16672083	chr15:72433130	SENP8	0.52	4.84	0.44	4.99e-6	Red blood cell count;
THYM	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg27490568	chr2:178487706	NA	-0.62	-5.53	-0.49	2.84e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9828933	0.752	rs17069507	chr3:63924956	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.86	-4.49	-0.42	1.97e-5	Type 2 diabetes;
THYM	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs28595532	0.920	rs56252481	chr4:119754023	C/T	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.07	11.15	0.75	6.06e-19	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg08859206	chr1:53392774	SCP2	-0.64	-7.27	-0.6	9.99e-11	Monocyte count;
THYM	cis	rs61990749	0.544	rs12435761	chr14:78246077	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	1.16	7.96	0.63	3.68e-12	Fibroblast growth factor basic levels;
THYM	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg18252515	chr7:66147081	NA	-0.67	-5.08	-0.46	1.86e-6	Aortic root size;
THYM	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg02478829	chr6:26598070	ABT1	-0.33	-4.49	-0.42	1.97e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.54	-5.17	-0.47	1.31e-6	Lymphocyte counts;
THYM	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg00786635	chr1:25594202	NA	-0.92	-7.28	-0.6	9.7e-11	Erythrocyte sedimentation rate;
THYM	cis	rs9403317	0.666	rs1361160	chr6:141895084	T/C	cg15052665	chr6:141804349	NA	0.76	5.75	0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg20387954	chr3:183756860	HTR3D	0.56	4.64	0.43	1.11e-5	Anterior chamber depth;
THYM	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-7.23	-0.6	1.23e-10	Gut microbiome composition (summer);
THYM	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg13010199	chr12:38710504	ALG10B	0.74	6.11	0.53	2.22e-8	Heart rate;
THYM	cis	rs6490294	0.659	rs11066028	chr12:112245170	A/C	cg10833066	chr12:111807467	FAM109A	0.48	5.13	0.47	1.53e-6	Mean platelet volume;
THYM	cis	rs17685	0.753	rs10476	chr7:75696420	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.59	6.01	0.52	3.45e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg03517284	chr6:25882590	NA	-0.69	-4.65	-0.43	1.06e-5	Height;
THYM	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg06558623	chr16:89946397	TCF25	1.22	5.31	0.48	7.11e-7	Skin colour saturation;
THYM	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg04673462	chr1:38461896	NA	0.46	5.74	0.51	1.11e-7	Coronary artery disease;
THYM	cis	rs7635838	0.587	rs347591	chr3:11290122	G/T	cg00170343	chr3:11313890	ATG7	0.62	4.74	0.44	7.47e-6	HDL cholesterol;
THYM	cis	rs2625529	0.730	rs12908882	chr15:72437572	G/A	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs1270639	0.778	rs1796272	chr7:157437832	C/T	cg00847544	chr7:157439651	PTPRN2	-0.58	-4.51	-0.42	1.84e-5	Colorectal cancer;
THYM	cis	rs7729447	0.566	rs1421811	chr5:32714270	C/G	cg16267343	chr5:32710456	NPR3	0.8	6.97	0.58	4.09e-10	Blood pressure;
THYM	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg07424592	chr7:64974309	NA	1.08	5.73	0.51	1.2e-7	Diabetic kidney disease;
THYM	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg12863693	chr15:85201151	NMB	-0.57	-4.93	-0.45	3.54e-6	Schizophrenia;
THYM	cis	rs6960043	0.818	rs6967891	chr7:15065074	T/C	cg19272540	chr7:15055459	NA	-0.44	-4.69	-0.43	9.08e-6	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10979	1.000	rs13211390	chr6:143888010	A/T	cg25407410	chr6:143891975	LOC285740	-0.63	-5.16	-0.47	1.36e-6	Hypospadias;
THYM	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg08772003	chr10:104629869	AS3MT	-0.57	-4.95	-0.45	3.23e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6138458	1.000	rs227627	chr20:24912107	T/C	cg06937882	chr20:24974362	C20orf3	-0.47	-4.54	-0.42	1.66e-5	Blood protein levels;
THYM	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg06112835	chr11:68658793	MRPL21	0.43	6.08	0.53	2.48e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg04287289	chr16:89883240	FANCA	0.64	6.03	0.53	3.08e-8	Vitiligo;
THYM	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg27398817	chr8:82754497	SNX16	-0.8	-6.37	-0.55	6.59e-9	Diastolic blood pressure;
THYM	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg22974920	chr21:40686053	BRWD1	-0.58	-4.58	-0.43	1.4e-5	Cognitive function;
THYM	cis	rs360798	0.512	rs12989754	chr2:63020970	A/G	cg17519650	chr2:63277830	OTX1	-0.66	-4.67	-0.43	9.96e-6	Coronary artery disease;
THYM	cis	rs7584330	0.554	rs880931	chr2:238396741	G/A	cg08992911	chr2:238395768	MLPH	1.11	6.67	0.56	1.72e-9	Prostate cancer;
THYM	cis	rs6980334	1.000	rs6980334	chr7:137788492	A/G	cg26979473	chr7:137028389	PTN	-0.61	-4.5	-0.42	1.92e-5	Blood metabolite ratios;
THYM	cis	rs10463554	0.963	rs34828	chr5:102442913	C/A	cg23492399	chr5:102201601	PAM	-0.69	-5.04	-0.46	2.26e-6	Parkinson's disease;
THYM	cis	rs11030122	0.661	rs963998	chr11:4062803	A/G	cg18678763	chr11:4115507	RRM1	-0.44	-5.74	-0.51	1.11e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg24642439	chr20:33292090	TP53INP2	0.7	5.46	0.49	3.77e-7	Coronary artery disease;
THYM	cis	rs9311676	0.632	rs56033718	chr3:58446398	A/G	cg26110898	chr3:58419937	PDHB	0.45	4.79	0.44	6.17e-6	Systemic lupus erythematosus;
THYM	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg05347473	chr6:146136440	FBXO30	-0.56	-4.45	-0.42	2.34e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6831352	0.765	rs35361391	chr4:100069281	A/T	cg12011299	chr4:100065546	ADH4	-0.82	-7.62	-0.62	1.91e-11	Alcohol dependence;
THYM	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg05973401	chr12:123451056	ABCB9	0.68	4.58	0.43	1.39e-5	Neutrophil percentage of white cells;
THYM	cis	rs6032067	0.714	rs6104069	chr20:43852243	C/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.64	-7.41	-0.61	5.15e-11	Blood protein levels;
THYM	cis	rs10992471	0.756	rs10123342	chr9:95087824	T/G	cg14631576	chr9:95140430	CENPP	-0.95	-10.73	-0.74	4.66e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7551222	0.752	rs4252718	chr1:204512195	A/T	cg20240347	chr1:204465584	NA	0.54	4.94	0.45	3.36e-6	Schizophrenia;
THYM	cis	rs346785	0.692	rs4789273	chr17:74286082	A/G	cg09812376	chr17:74270190	QRICH2	0.44	4.47	0.42	2.17e-5	White matter hyperintensities in ischemic stroke;
THYM	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg22166914	chr1:53195759	ZYG11B	0.91	10.46	0.73	1.7e-17	Monocyte count;
THYM	cis	rs4780401	0.728	rs4781136	chr16:11767978	G/T	cg01061890	chr16:11836724	TXNDC11	-0.61	-4.71	-0.43	8.59e-6	Rheumatoid arthritis;
THYM	cis	rs11225247	0.881	rs117275062	chr11:102309494	A/G	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg10523679	chr1:76189770	ACADM	-0.87	-9.03	-0.68	1.96e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4474465	0.850	rs10751292	chr11:78242201	C/G	cg19901956	chr11:77921274	USP35	0.59	4.54	0.42	1.65e-5	Alzheimer's disease (survival time);
THYM	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg07414643	chr4:187882934	NA	0.66	5.79	0.51	9.15e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4580814	0.869	rs4535497	chr5:1107428	G/T	cg01551729	chr5:1099476	SLC12A7	0.61	5.16	0.47	1.36e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6089829	0.926	rs73921625	chr20:61660891	C/T	cg08045932	chr20:61659980	NA	-0.87	-7.55	-0.61	2.68e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg02921923	chr11:92651425	NA	-0.81	-5.49	-0.49	3.3e-7	Subcortical brain region volumes;
THYM	cis	rs11048434	0.761	rs11494570	chr12:9127147	T/C	cg26114124	chr12:9217669	LOC144571	0.46	4.57	0.42	1.44e-5	Sjögren's syndrome;
THYM	cis	rs5771069	0.871	rs137840	chr22:50431414	C/T	cg27467552	chr22:50353597	PIM3	-0.44	-4.69	-0.43	9.32e-6	Ulcerative colitis;
THYM	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg12386194	chr3:101231763	SENP7	0.96	7.58	0.61	2.33e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg14196790	chr5:131705035	SLC22A5	0.55	5.03	0.46	2.34e-6	Blood metabolite levels;
THYM	cis	rs714027	0.566	rs4823076	chr22:30519414	G/A	cg27665648	chr22:30112403	NA	-0.52	-4.73	-0.44	7.79e-6	Lymphocyte counts;
THYM	cis	rs77320796	1.000	rs7542907	chr1:40391752	A/G	cg05657805	chr1:40942785	ZNF642	-0.79	-4.79	-0.44	6.13e-6	Platelet count;
THYM	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg12011299	chr4:100065546	ADH4	0.81	8.21	0.64	1.1e-12	Alcohol dependence;
THYM	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.73	0.57	1.29e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1003719	0.688	rs2835660	chr21:38568882	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.33	9.84	0.71	3.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6924995	0.501	rs9370871	chr6:16196894	G/A	cg11805552	chr6:16175128	NA	0.57	4.85	0.45	4.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06873352	chr17:61820015	STRADA	0.57	5.65	0.5	1.67e-7	Height;
THYM	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg17264618	chr3:40429014	ENTPD3	0.54	5.19	0.47	1.17e-6	Renal cell carcinoma;
THYM	cis	rs12519773	1.000	rs7711868	chr5:92461247	T/A	cg18783429	chr5:92414398	NA	0.48	4.54	0.42	1.64e-5	Migraine;
THYM	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7216064	1.000	rs4271626	chr17:65930133	G/A	cg12091567	chr17:66097778	LOC651250	-0.69	-4.56	-0.42	1.51e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg04034577	chr2:241836375	C2orf54	-0.43	-7.39	-0.6	5.73e-11	Urinary metabolites;
THYM	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg06850241	chr22:41845214	NA	0.54	4.77	0.44	6.68e-6	Vitiligo;
THYM	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg07022442	chr13:21864356	NA	0.72	4.78	0.44	6.49e-6	White matter hyperintensity burden;
THYM	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs12579753	1.000	rs34894912	chr12:82228721	A/G	cg21231944	chr12:82153410	PPFIA2	-0.65	-4.83	-0.44	5.17e-6	Resting heart rate;
THYM	cis	rs17407555	0.683	rs4698000	chr4:10277467	C/T	cg00071950	chr4:10020882	SLC2A9	-0.52	-4.9	-0.45	3.98e-6	Schizophrenia (age at onset);
THYM	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg06634786	chr22:41940651	POLR3H	-0.7	-4.92	-0.45	3.59e-6	Vitiligo;
THYM	cis	rs758324	0.732	rs114870893	chr5:131460597	G/A	cg16205897	chr5:131564050	P4HA2	0.54	4.67	0.43	9.94e-6	Alzheimer's disease in APOE e4- carriers;
THYM	trans	rs1973993	0.691	rs1980683	chr1:96890379	A/G	cg10631902	chr5:14652156	NA	0.79	9.76	0.71	5.43e-16	Weight;
THYM	cis	rs67311347	0.544	rs13098483	chr3:40342743	G/C	cg24209194	chr3:40518798	ZNF619	0.55	4.6	0.43	1.3e-5	Renal cell carcinoma;
THYM	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg09549813	chr16:4587862	C16orf5	-0.6	-6.93	-0.58	5.03e-10	Schizophrenia;
THYM	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg12826209	chr6:26865740	GUSBL1	0.79	5.62	0.5	1.92e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg10661904	chr17:79619235	PDE6G	-0.54	-4.79	-0.44	6.25e-6	Eye color traits;
THYM	cis	rs4363385	0.510	rs6689510	chr1:153048039	G/A	cg13444842	chr1:152974279	SPRR3	-0.6	-4.74	-0.44	7.54e-6	Inflammatory skin disease;
THYM	cis	rs7107174	1.000	rs1399196	chr11:78071876	A/G	cg02023728	chr11:77925099	USP35	0.64	6.31	0.54	8.65e-9	Testicular germ cell tumor;
THYM	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg08645402	chr16:4508243	NA	0.66	5.52	0.49	2.97e-7	Schizophrenia;
THYM	cis	rs72828912	0.764	rs10946669	chr6:24095059	T/C	cg26336265	chr6:25042955	NA	0.69	5.17	0.47	1.29e-6	Squamous cell lung carcinoma;
THYM	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg13866156	chr1:1669148	SLC35E2	-0.71	-7.14	-0.59	1.86e-10	Body mass index;
THYM	cis	rs3796352	1.000	rs34121720	chr3:53072167	C/T	cg07884673	chr3:53033167	SFMBT1	1.03	5.24	0.47	9.74e-7	Immune reponse to smallpox (secreted IL-2);
THYM	trans	rs9929218	0.551	rs2296406	chr16:68721340	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.15	16.76	0.86	3.99e-30	Colorectal cancer;
THYM	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg18511798	chr11:2018149	H19;MIR675	-0.49	-4.84	-0.44	4.99e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg11247378	chr22:39784982	NA	-1.04	-12.97	-0.8	9.75e-23	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg11663144	chr21:46675770	NA	-0.7	-9.69	-0.7	7.75e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg03188948	chr7:1209495	NA	0.78	6.29	0.54	9.51e-9	Longevity;Endometriosis;
THYM	cis	rs7823896	0.929	rs60785810	chr8:110146965	G/A	cg18044723	chr8:109261011	EIF3E	-0.89	-4.68	-0.43	9.42e-6	Myopia (pathological);
THYM	cis	rs72827839	0.947	rs72827814	chr17:46366960	A/G	cg23391107	chr17:45924227	SP6	0.76	4.58	0.43	1.39e-5	Ease of getting up in the morning;
THYM	cis	rs59698941	0.943	rs60042606	chr5:132248170	G/T	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs2625529	0.652	rs2957750	chr15:72332258	C/T	cg16672083	chr15:72433130	SENP8	0.52	4.81	0.44	5.72e-6	Red blood cell count;
THYM	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg18105134	chr13:113819100	PROZ	-0.99	-9.19	-0.69	8.83e-15	Platelet distribution width;
THYM	cis	rs12410462	0.681	rs4614224	chr1:227574966	C/T	cg23173402	chr1:227635558	NA	0.71	5.61	0.5	1.96e-7	Major depressive disorder;
THYM	cis	rs1371867	0.875	rs2439456	chr8:101336874	C/T	cg06636551	chr8:101224915	SPAG1	-0.64	-6.55	-0.56	2.91e-9	Atrioventricular conduction;
THYM	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.21	8.51	0.66	2.47e-13	Cognitive test performance;
THYM	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11890956	chr21:40555474	PSMG1	1.08	7.17	0.59	1.61e-10	Cognitive function;
THYM	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	4.47	0.42	2.13e-5	Alzheimer's disease;
THYM	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg23602478	chr1:26503979	CNKSR1	0.34	4.56	0.42	1.5e-5	Height;
THYM	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg10053473	chr17:62856997	LRRC37A3	0.92	7.34	0.6	7.17e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs67311347	0.544	rs67533651	chr3:40338367	T/A	cg13683864	chr3:40499215	RPL14	-0.79	-7.44	-0.61	4.43e-11	Renal cell carcinoma;
THYM	cis	rs3785574	0.650	rs7406102	chr17:62004749	G/A	cg11494091	chr17:61959527	GH2	-0.75	-7.62	-0.62	1.9e-11	Height;
THYM	cis	rs7246657	0.943	rs34603719	chr19:37794528	T/G	cg23950597	chr19:37808831	NA	-0.71	-4.49	-0.42	1.97e-5	Coronary artery calcification;
THYM	cis	rs4523957	0.928	rs216183	chr17:2173923	A/G	cg16513277	chr17:2031491	SMG6	0.79	7.41	0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10744422	1.000	rs897385	chr12:123341297	A/G	cg25930673	chr12:123319894	HIP1R	-0.86	-4.84	-0.44	5.09e-6	Schizophrenia;
THYM	cis	rs1784581	0.588	rs7453474	chr6:162421736	C/T	cg17173639	chr6:162384350	PARK2	0.81	7.48	0.61	3.75e-11	Itch intensity from mosquito bite;
THYM	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg14433983	chr11:636460	DRD4	-0.63	-4.55	-0.42	1.6e-5	Systemic lupus erythematosus;
THYM	cis	rs9532580	0.778	rs34373380	chr13:41244217	T/A	cg21288729	chr13:41239152	FOXO1	0.66	4.98	0.46	2.83e-6	Mean corpuscular hemoglobin;
THYM	cis	rs9467711	0.651	rs72834677	chr6:26106604	C/A	cg01386294	chr6:25732093	NA	0.88	4.7	0.43	8.83e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg24733560	chr20:60626293	TAF4	0.62	6.6	0.56	2.35e-9	Body mass index;
THYM	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1395	0.778	rs62128743	chr2:27390169	A/G	cg23587288	chr2:27483067	SLC30A3	-0.6	-5.25	-0.47	9.17e-7	Blood metabolite levels;
THYM	cis	rs10887741	0.532	rs791881	chr10:89408246	C/T	cg13926569	chr10:89418898	PAPSS2	-0.63	-5.85	-0.51	7.1e-8	Exercise (leisure time);
THYM	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.34	0.48	6.29e-7	Height;
THYM	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17006441	0.932	rs6794889	chr3:69879405	A/G	cg18496212	chr3:69797108	MITF	0.67	6.54	0.56	3.15e-9	Hemoglobin concentration;
THYM	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11890956	chr21:40555474	PSMG1	1.17	12.99	0.8	8.73e-23	Cognitive function;
THYM	cis	rs4638749	0.677	rs6711297	chr2:108818357	A/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs4638749	0.953	rs12475415	chr2:108860477	G/A	cg25838818	chr2:108905173	SULT1C2	-0.61	-6.18	-0.54	1.6e-8	Blood pressure;
THYM	cis	rs79149102	0.579	rs7172989	chr15:75295905	C/T	cg17294928	chr15:75287854	SCAMP5	-1.06	-5.68	-0.5	1.49e-7	Lung cancer;
THYM	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9311676	0.632	rs6774577	chr3:58361716	A/G	cg26110898	chr3:58419937	PDHB	0.44	4.56	0.42	1.54e-5	Systemic lupus erythematosus;
THYM	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg03433033	chr1:76189801	ACADM	-0.76	-9.82	-0.71	3.96e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg24818145	chr4:99064322	C4orf37	0.71	5.75	0.51	1.09e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7394190	0.748	rs2075641	chr10:75562108	G/A	cg07699608	chr10:75541558	CHCHD1	0.96	5.1	0.46	1.77e-6	Incident atrial fibrillation;
THYM	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg02696790	chr15:75250997	RPP25	0.5	4.56	0.42	1.53e-5	Breast cancer;
THYM	cis	rs995000	0.965	rs11207981	chr1:63006087	C/A	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg05234568	chr11:5960015	NA	-0.62	-5.51	-0.49	3.06e-7	DNA methylation (variation);
THYM	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg15736062	chr7:158136485	PTPRN2	0.56	4.72	0.44	8.25e-6	Calcium levels;
THYM	cis	rs1003719	0.582	rs2835634	chr21:38528270	T/A	cg01329690	chr21:38580129	DSCR9	-0.37	-5.09	-0.46	1.83e-6	Eye color traits;
THYM	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg05962950	chr11:130786565	SNX19	0.96	9.68	0.7	7.96e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1878931	0.543	rs17612463	chr16:3420479	G/C	cg22508957	chr16:3507546	NAT15	-0.49	-5.2	-0.47	1.13e-6	Body mass index (adult);
THYM	cis	rs12681287	0.752	rs7822268	chr8:87306440	G/T	cg27223183	chr8:87520930	FAM82B	-0.68	-5.19	-0.47	1.2e-6	Caudate activity during reward;
THYM	cis	rs11250079	0.703	rs56978698	chr8:10699068	C/A	cg13457217	chr8:10683266	MIR1322;PINX1	-0.63	-4.55	-0.42	1.6e-5	Lymphocyte counts;
THYM	cis	rs2797685	1.000	rs1689904	chr1:7890801	C/T	cg06712362	chr1:7811235	CAMTA1	0.68	4.96	0.45	3.09e-6	Crohn's disease;
THYM	cis	rs36051895	0.626	rs10283563	chr9:5075603	C/T	cg02405213	chr9:5042618	JAK2	-1.06	-11.43	-0.76	1.49e-19	Pediatric autoimmune diseases;
THYM	cis	rs7582180	0.967	rs2033748	chr2:100916306	A/G	cg14675211	chr2:100938903	LONRF2	0.6	4.61	0.43	1.26e-5	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg20887711	chr4:1340912	KIAA1530	0.58	4.46	0.42	2.27e-5	Obesity-related traits;
THYM	cis	rs3126085	0.935	rs11204943	chr1:152203906	A/C	cg10321714	chr1:152280068	FLG	0.63	4.51	0.42	1.88e-5	Atopic dermatitis;
THYM	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg02551604	chr5:131831745	NA	0.84	6.68	0.57	1.59e-9	Asthma (sex interaction);
THYM	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg20283391	chr11:68216788	NA	0.61	4.58	0.43	1.41e-5	Total body bone mineral density;
THYM	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.09	-0.46	1.83e-6	Life satisfaction;
THYM	cis	rs9814567	0.731	rs34797591	chr3:134192516	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.68	5.79	0.51	9.21e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs4722166	0.508	rs2069832	chr7:22767433	A/G	cg13104385	chr7:22767384	IL6	0.53	4.79	0.44	6.07e-6	Lung cancer;
THYM	cis	rs6531656	0.633	rs4833085	chr4:38688919	C/T	cg24279243	chr4:38676559	KLF3	0.86	7.91	0.63	4.72e-12	Lymphocyte counts;
THYM	cis	rs983545	0.800	rs1441039	chr3:16959319	G/A	cg19448816	chr3:16974217	PLCL2	0.55	4.8	0.44	5.86e-6	Blood protein levels;
THYM	cis	rs2075230	0.705	rs1642809	chr17:7545496	T/C	cg27413385	chr17:7515425	FXR2	-0.35	-5.06	-0.46	2.06e-6	Hormone measurements;
THYM	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7757969	1.000	rs2064700	chr6:112141908	A/G	cg08601457	chr6:112115117	FYN	0.41	4.83	0.44	5.33e-6	Schizophrenia;
THYM	cis	rs6032067	0.759	rs2868239	chr20:43873368	T/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.66	-7.59	-0.61	2.22e-11	Blood protein levels;
THYM	cis	rs10089	1.000	rs4836369	chr5:127486462	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.02	7.11	0.59	2.11e-10	Ileal carcinoids;
THYM	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.0	0.63	2.98e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs208520	0.690	rs207082	chr6:66773796	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-7.96	-0.63	3.63e-12	Exhaled nitric oxide output;
THYM	cis	rs9583531	0.600	rs4773241	chr13:111363021	A/G	cg24331049	chr13:111365604	ING1	0.7	5.86	0.52	6.69e-8	Coronary artery disease;
THYM	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg00898013	chr13:113819073	PROZ	0.83	8.42	0.65	3.93e-13	Platelet distribution width;
THYM	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2637266	1.000	rs34483246	chr10:78342790	G/A	cg18941641	chr10:78392320	NA	0.72	6.33	0.54	8.03e-9	Pulmonary function;
THYM	cis	rs7000551	0.725	rs2469756	chr8:22360423	G/A	cg12081754	chr8:22256438	SLC39A14	0.65	5.72	0.51	1.22e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg08994789	chr17:28903642	LRRC37B2	-1.05	-5.39	-0.48	5.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs10118776	0.677	rs34282845	chr9:6173499	G/C	cg02532923	chr16:89110004	NA	1.01	7.85	0.63	6.11e-12	Small cell lung carcinoma;
THYM	cis	rs7572733	0.534	rs58374969	chr2:198764363	C/T	cg00792783	chr2:198669748	PLCL1	0.83	5.86	0.52	6.56e-8	Dermatomyositis;
THYM	cis	rs6547741	0.967	rs4665986	chr2:27755168	G/A	cg27432699	chr2:27873401	GPN1	0.68	5.96	0.52	4.25e-8	Oral cavity cancer;
THYM	cis	rs9790314	1.000	rs336548	chr3:161058412	T/C	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs10892173	0.545	rs115865940	chr11:117666711	C/T	cg21014159	chr11:117668035	DSCAML1	0.68	4.92	0.45	3.7e-6	Myopia;
THYM	cis	rs28595532	0.920	rs56302493	chr4:119772382	A/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg25287198	chr4:183728479	NA	0.78	4.8	0.44	5.81e-6	Pediatric autoimmune diseases;
THYM	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg22467129	chr15:76604101	ETFA	-0.54	-5.02	-0.46	2.36e-6	Blood metabolite levels;
THYM	cis	rs7224737	1.000	rs12603330	chr17:40290589	T/A	cg02228675	chr17:40259724	DHX58	-0.62	-5.13	-0.47	1.55e-6	Fibrinogen levels;
THYM	cis	rs6430585	0.583	rs58509842	chr2:136586027	G/A	cg07169764	chr2:136633963	MCM6	1.2	14.22	0.82	2.98e-25	Corneal structure;
THYM	cis	rs7226229	1.000	rs6587109	chr17:20917818	T/C	cg21263980	chr17:20946333	USP22	0.67	5.02	0.46	2.38e-6	Blood trace element (Se levels);
THYM	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg24530246	chr3:53118167	NA	-0.81	-4.62	-0.43	1.23e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs6430585	0.528	rs12464050	chr2:136663110	G/T	cg07169764	chr2:136633963	MCM6	1.18	10.98	0.75	1.39e-18	Corneal structure;
THYM	cis	rs9467160	0.651	rs9393557	chr6:24453195	C/G	cg00346970	chr6:24499591	ALDH5A1	0.31	4.55	0.42	1.59e-5	Liver enzyme levels;
THYM	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12711979	0.765	rs13028529	chr2:3825467	C/T	cg17052675	chr2:3827356	NA	-0.5	-5.3	-0.48	7.58e-7	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs3026101	0.624	rs1806261	chr17:5317008	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	5.22	0.47	1.03e-6	Body mass index;
THYM	trans	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.7	-7.08	-0.59	2.47e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg07636037	chr3:49044803	WDR6	0.92	7.94	0.63	4.07e-12	Menarche (age at onset);
THYM	cis	rs9902453	0.967	rs62070344	chr17:28476997	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	4.6	0.43	1.33e-5	Coffee consumption (cups per day);
THYM	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg17074396	chr22:49843754	NA	-0.39	-4.58	-0.43	1.4e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg06917634	chr15:78832804	PSMA4	-0.96	-8.72	-0.67	9.12e-14	Sudden cardiac arrest;
THYM	cis	rs7192750	0.586	rs11648353	chr16:71986764	G/A	cg06353428	chr16:71660113	MARVELD3	0.72	5.4	0.48	4.87e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg05657792	chr17:6899758	ALOX12	-0.46	-4.58	-0.43	1.42e-5	Tonsillectomy;
THYM	cis	rs28595532	0.920	rs28797314	chr4:119783044	A/G	cg14228332	chr4:119757509	SEC24D	1.36	5.22	0.47	1.07e-6	Cannabis dependence symptom count;
THYM	cis	rs800586	0.609	rs4876611	chr8:116671848	A/G	cg04656070	chr8:116661063	TRPS1	0.57	5.78	0.51	9.32e-8	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.83	-0.44	5.28e-6	Mean corpuscular volume;
THYM	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg11663144	chr21:46675770	NA	-0.67	-9.15	-0.68	1.1e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.6	-0.56	2.37e-9	Chronic sinus infection;
THYM	cis	rs2074585	0.647	rs2601188	chr15:90929563	A/G	cg22089800	chr15:90895588	ZNF774	-0.71	-5.63	-0.5	1.84e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
THYM	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg25208724	chr1:156163844	SLC25A44	1.1	8.39	0.65	4.57e-13	Testicular germ cell tumor;
THYM	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg15691649	chr6:25882328	NA	0.67	5.16	0.47	1.33e-6	Blood metabolite levels;
THYM	cis	rs17153755	0.761	rs804288	chr8:11618179	T/C	cg12395012	chr8:11607386	GATA4	-0.64	-5.26	-0.47	9.01e-7	Testicular germ cell tumor;
THYM	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg04476341	chr5:669733	TPPP	0.61	4.56	0.42	1.5e-5	Lung disease severity in cystic fibrosis;
THYM	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.64	8.83	0.67	5.25e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6032067	0.777	rs35434469	chr20:43778544	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.82	-0.51	7.78e-8	Blood protein levels;
THYM	cis	rs12530845	0.945	rs12540273	chr7:135333854	T/G	cg23117316	chr7:135346802	PL-5283	-0.66	-5.88	-0.52	6.21e-8	Red blood cell traits;
THYM	cis	rs9790314	0.846	rs6441371	chr3:161008727	C/A	cg03342759	chr3:160939853	NMD3	-0.81	-7.28	-0.6	9.51e-11	Morning vs. evening chronotype;
THYM	cis	rs990171	1.000	rs1035127	chr2:103019919	C/T	cg13897122	chr2:103039542	IL18RAP	0.39	4.72	0.44	7.96e-6	Lymphocyte counts;
THYM	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg23161317	chr6:28129485	ZNF389	0.76	5.42	0.49	4.54e-7	Parkinson's disease;
THYM	cis	rs6988636	1.000	rs16898088	chr8:124190501	G/A	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.85	-5.32	-0.48	6.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg23221052	chr5:179740743	GFPT2	-0.75	-5.9	-0.52	5.66e-8	Height;
THYM	cis	rs3126085	0.935	rs4421596	chr1:152181673	G/A	cg26020982	chr1:152196106	HRNR	0.35	4.57	0.42	1.45e-5	Atopic dermatitis;
THYM	cis	rs17253792	0.822	rs76192881	chr14:56034654	C/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs931812	1.000	rs4734495	chr8:101917817	C/A	cg07585502	chr8:101912084	NA	-0.57	-4.49	-0.42	2.03e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs10158481	0.713	rs4649067	chr1:25475418	C/T	cg09264742	chr1:25757510	TMEM57	0.66	4.68	0.43	9.41e-6	Urate levels in obese individuals;
THYM	cis	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs3796619	1.000	rs1466214	chr4:1073760	C/T	cg27284194	chr4:1044797	NA	0.54	4.92	0.45	3.69e-6	Recombination rate (males);
THYM	cis	rs41005	1.000	rs12692349	chr2:8114312	G/A	cg03155496	chr2:8117019	LOC339788	-0.97	-9.1	-0.68	1.39e-14	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg02887458	chr19:19495540	GATAD2A	-0.42	-5.08	-0.46	1.87e-6	Bipolar disorder;
THYM	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs35883536	0.647	rs17402665	chr1:101046940	C/T	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg21773646	chr17:80085082	CCDC57	0.33	4.8	0.44	5.78e-6	Life satisfaction;
THYM	cis	rs1267303	0.675	rs1267308	chr1:46987718	A/G	cg25110126	chr1:46999211	NA	-0.77	-5.84	-0.51	7.19e-8	Monobrow;
THYM	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.56	-5.55	-0.49	2.61e-7	Longevity;Endometriosis;
THYM	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg16006841	chr5:176797999	RGS14	0.45	4.93	0.45	3.48e-6	Urate levels in lean individuals;
THYM	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg03929089	chr4:120376271	NA	-1.02	-8.78	-0.67	6.68e-14	Coronary artery disease;
THYM	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg02825527	chr7:2087843	MAD1L1	0.76	5.08	0.46	1.88e-6	Bipolar disorder;
THYM	cis	rs4638749	0.734	rs6542756	chr2:108865629	C/G	cg06795125	chr2:108905320	SULT1C2	-0.34	-4.58	-0.42	1.43e-5	Blood pressure;
THYM	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg03433033	chr1:76189801	ACADM	-0.62	-6.16	-0.53	1.76e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs4478239	1.000	rs6553052	chr4:188190219	G/T	cg02596645	chr4:187628413	FAT1	-0.79	-4.46	-0.42	2.22e-5	Major depressive disorder;
THYM	cis	rs7731657	0.537	rs6877851	chr5:130356413	C/G	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs472402	0.580	rs3822430	chr5:6651970	A/G	cg12648172	chr5:5886274	NA	0.52	4.72	0.44	7.99e-6	Response to amphetamines;
THYM	cis	rs8067545	0.563	rs3850780	chr17:20181902	A/C	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs9790314	1.000	rs7638668	chr3:161047283	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg04455712	chr21:45112962	RRP1B	0.51	4.71	0.44	8.41e-6	Mean corpuscular volume;
THYM	cis	rs2131877	0.830	rs62290331	chr3:194843799	C/T	cg21937377	chr3:194868750	C3orf21	0.44	4.48	0.42	2.07e-5	Non-small cell lung cancer;
THYM	cis	rs7523273	0.568	rs55935450	chr1:208018779	T/A	cg22525895	chr1:207977042	MIR29B2	-0.68	-4.67	-0.43	9.72e-6	Schizophrenia;
THYM	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg08847533	chr14:75593920	NEK9	-0.96	-10.3	-0.73	3.86e-17	Height;
THYM	cis	rs459571	0.959	rs456205	chr9:136911146	G/A	cg13789015	chr9:136890014	NCRNA00094	0.84	7.22	0.6	1.29e-10	Platelet distribution width;
THYM	cis	rs2976388	0.590	rs11785290	chr8:143814849	A/G	cg06565975	chr8:143823917	SLURP1	-0.61	-7.37	-0.6	6.26e-11	Urinary tract infection frequency;
THYM	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11644478	chr21:40555479	PSMG1	0.94	7.05	0.59	2.82e-10	Cognitive function;
THYM	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg08498830	chr11:832797	CD151	-0.62	-4.51	-0.42	1.82e-5	Mean platelet volume;
THYM	cis	rs7084402	0.967	rs3001717	chr10:60329125	A/G	cg09696939	chr10:60272079	BICC1	-0.46	-5.54	-0.49	2.74e-7	Refractive error;
THYM	cis	rs12478296	0.792	rs6755390	chr2:243012998	C/T	cg06360820	chr2:242988706	NA	-0.92	-5.74	-0.51	1.11e-7	Obesity-related traits;
THYM	cis	rs10752881	1.000	rs4593781	chr1:182984983	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.79	0.44	6.13e-6	Colorectal cancer;
THYM	cis	rs6427356	0.513	rs12092484	chr1:157148247	A/G	cg27547283	chr1:156698502	C1orf66;ISG20L2	-0.58	-4.49	-0.42	2.02e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9527	0.615	rs7080462	chr10:104736699	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-4.68	-0.43	9.59e-6	Arsenic metabolism;
THYM	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg18252515	chr7:66147081	NA	-1.48	-8.83	-0.67	5.15e-14	Diabetic kidney disease;
THYM	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg17718321	chr1:152188247	HRNR	-0.51	-4.85	-0.45	4.73e-6	Inflammatory skin disease;
THYM	cis	rs7100689	0.646	rs1538819	chr10:82122523	A/G	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg14517863	chr17:44321492	NA	0.46	5.11	0.46	1.69e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2456568	0.564	rs7119708	chr11:93626641	T/C	cg17595323	chr11:93583763	C11orf90	0.55	5.84	0.51	7.22e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs9832461	0.843	rs2887917	chr3:39773028	T/A	cg09883745	chr3:40086528	MYRIP	0.7	4.73	0.44	7.73e-6	Brain structure (temporal lobe volume);
THYM	cis	rs7044106	1.000	rs7044106	chr9:123494062	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	4.79	0.44	6.11e-6	Hip circumference adjusted for BMI;
THYM	cis	rs9311676	0.656	rs6445973	chr3:58336595	G/T	cg26110898	chr3:58419937	PDHB	-0.46	-4.53	-0.42	1.72e-5	Systemic lupus erythematosus;
THYM	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs67981189	0.896	rs2526846	chr14:71424255	G/A	cg15910301	chr14:71632612	NA	-0.5	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	cis	rs863345	0.604	rs1342948	chr1:158463294	A/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs652260	0.967	rs667295	chr19:7901634	G/A	cg15974673	chr19:7926970	EVI5L	-0.55	-5.08	-0.46	1.88e-6	Menarche (age at onset);
THYM	cis	rs11048434	0.761	rs12828902	chr12:9132231	C/T	cg13575925	chr12:9217583	LOC144571	0.52	5.04	0.46	2.24e-6	Sjögren's syndrome;
THYM	cis	rs60780116	1	rs60780116	chr4:185708807	T/C	cg27112742	chr4:185696749	ACSL1	-0.9	-5.5	-0.49	3.23e-7	Type 2 diabetes;
THYM	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg08847533	chr14:75593920	NEK9	-0.95	-9.92	-0.71	2.4e-16	Height;
THYM	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg00684032	chr4:1343700	KIAA1530	0.8	6.88	0.58	6.2e-10	Obesity-related traits;
THYM	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg01475377	chr6:109611718	NA	0.56	4.76	0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg02734326	chr4:10020555	SLC2A9	-0.72	-6.37	-0.55	6.8e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs8013055	0.846	rs35723046	chr14:105970548	C/T	cg04429589	chr14:105992532	TMEM121	-0.45	-4.86	-0.45	4.65e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs983545	0.800	rs1441039	chr3:16959319	G/A	cg24159436	chr3:16974681	PLCL2	0.32	4.73	0.44	7.91e-6	Blood protein levels;
THYM	cis	rs12530845	0.673	rs73725437	chr7:135327853	G/A	cg19897172	chr7:135347071	PL-5283	-0.59	-5.31	-0.48	7.23e-7	Red blood cell traits;
THYM	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg14675211	chr2:100938903	LONRF2	0.73	7.27	0.6	1.02e-10	Intelligence (multi-trait analysis);
THYM	cis	rs4595586	0.545	rs12811619	chr12:39392196	T/C	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs300703	0.542	rs443419	chr2:189800	C/T	cg21211680	chr2:198530	NA	-0.92	-6.36	-0.55	6.87e-9	Blood protein levels;
THYM	cis	rs612683	0.826	rs7556246	chr1:100828914	A/G	cg06223162	chr1:101003688	GPR88	0.68	5.48	0.49	3.42e-7	Breast cancer;
THYM	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	4.93	0.45	3.5e-6	Diabetic retinopathy;
THYM	cis	rs9902453	0.845	rs3115099	chr17:28019293	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.85	0.45	4.84e-6	Coffee consumption (cups per day);
THYM	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08109568	chr15:31115862	NA	-0.76	-6.77	-0.57	1.05e-9	Huntington's disease progression;
THYM	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg10047753	chr17:41438598	NA	1.2	10.92	0.75	1.85e-18	Menopause (age at onset);
THYM	cis	rs1728785	1.000	rs698712	chr16:68561879	G/A	cg02972257	chr16:68554789	NA	-0.74	-4.6	-0.43	1.31e-5	Ulcerative colitis;
THYM	cis	rs4888262	0.508	rs4462623	chr16:74692426	C/T	cg01733217	chr16:74700730	RFWD3	0.87	9.37	0.69	3.62e-15	Testicular germ cell tumor;
THYM	trans	rs877282	1.000	rs12219807	chr10:772870	A/C	cg22713356	chr15:30763199	NA	1.26	10.12	0.72	9.24e-17	Uric acid levels;
THYM	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg17264618	chr3:40429014	ENTPD3	0.52	5.13	0.47	1.5e-6	Renal cell carcinoma;
THYM	cis	rs921968	0.528	rs13022583	chr2:219589175	T/C	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14442939	chr10:27389572	ANKRD26	0.86	4.61	0.43	1.25e-5	Breast cancer;
THYM	cis	rs7688540	0.771	rs11248009	chr4:220149	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.72	4.88	0.45	4.35e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs600806	0.850	rs1343465	chr1:109937426	T/C	cg02175308	chr1:109941060	SORT1	-0.6	-5.3	-0.48	7.58e-7	Intelligence (multi-trait analysis);
THYM	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg08885076	chr2:99613938	TSGA10	-0.76	-6.77	-0.57	1.08e-9	Chronic sinus infection;
THYM	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg23711669	chr6:146136114	FBXO30	-0.89	-8.4	-0.65	4.24e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8067545	0.611	rs757494	chr17:20150340	C/T	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs4474465	0.920	rs7113559	chr11:78205703	T/G	cg19901956	chr11:77921274	USP35	0.64	4.75	0.44	7.2e-6	Alzheimer's disease (survival time);
THYM	cis	rs17443541	0.507	rs4234081	chr2:200457562	C/T	cg03741458	chr2:200468445	NA	0.8	6.04	0.53	3.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg27129171	chr3:47204927	SETD2	-0.8	-7.67	-0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg05335186	chr13:53173507	NA	0.51	6.51	0.56	3.56e-9	Lewy body disease;
THYM	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg08772003	chr10:104629869	AS3MT	-0.61	-5.55	-0.49	2.58e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs16854884	0.632	rs1910691	chr3:143656905	G/A	cg05063096	chr3:143689810	C3orf58	0.68	4.52	0.42	1.78e-5	Economic and political preferences (feminism/equality);
THYM	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg00852783	chr1:26633632	UBXN11	0.7	5.88	0.52	6.16e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs2976388	1.000	rs2294008	chr8:143761931	C/T	cg06565975	chr8:143823917	SLURP1	-0.45	-5.21	-0.47	1.09e-6	Urinary tract infection frequency;
THYM	cis	rs6876348	0.964	rs1363462	chr5:128119501	C/T	cg25555059	chr5:128301488	SLC27A6	0.46	4.94	0.45	3.35e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg00376283	chr12:123451042	ABCB9	-0.68	-5.22	-0.47	1.04e-6	Neutrophil percentage of white cells;
THYM	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg13010199	chr12:38710504	ALG10B	0.65	4.55	0.42	1.58e-5	Bladder cancer;
THYM	cis	rs6500395	0.925	rs9933148	chr16:48672099	C/T	cg04672837	chr16:48644449	N4BP1	0.48	4.74	0.44	7.39e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs12142240	0.698	rs17361936	chr1:46862893	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7705502	0.692	rs72810906	chr5:173271866	A/G	cg18693985	chr5:173351052	CPEB4	-0.69	-4.56	-0.42	1.51e-5	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	5.65	0.5	1.65e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1729951	0.575	rs361248	chr3:136709066	G/A	cg21827317	chr3:136751795	NA	0.73	6.67	0.56	1.7e-9	Neuroticism;
THYM	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg13695892	chr22:41940480	POLR3H	0.89	6.37	0.55	6.58e-9	Vitiligo;
THYM	cis	rs2797160	0.935	rs60515555	chr6:126000638	T/G	cg16306078	chr6:126000798	NA	-0.54	-5.54	-0.49	2.66e-7	Endometrial cancer;
THYM	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg20476274	chr7:133979776	SLC35B4	0.68	4.55	0.42	1.58e-5	Mean platelet volume;
THYM	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg08736216	chr1:53307985	ZYG11A	-0.56	-5.21	-0.47	1.07e-6	Monocyte count;
THYM	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg24399712	chr22:39784796	NA	-0.75	-6.83	-0.57	7.87e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg06618935	chr21:46677482	NA	0.98	9.5	0.7	1.95e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3126085	0.877	rs3126055	chr1:152266364	G/A	cg10321714	chr1:152280068	FLG	-0.67	-5.14	-0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs11153147	0.502	rs79116221	chr6:109445587	A/G	cg17117243	chr6:109341365	SESN1	-0.82	-4.8	-0.44	5.98e-6	Mean corpuscular volume;
THYM	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg24060327	chr5:131705240	SLC22A5	-0.69	-5.18	-0.47	1.25e-6	Breast cancer;
THYM	cis	rs554111	0.656	rs17450586	chr1:21254593	T/G	cg01072550	chr1:21505969	NA	0.59	5.16	0.47	1.36e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg08885076	chr2:99613938	TSGA10	-0.71	-6.69	-0.57	1.51e-9	Chronic sinus infection;
THYM	cis	rs6987853	0.787	rs2923437	chr8:42425399	A/C	cg09913449	chr8:42400586	C8orf40	1.07	12.64	0.79	4.53e-22	Mean corpuscular hemoglobin concentration;
THYM	cis	rs861020	0.630	rs592694	chr1:210009533	G/T	cg05527609	chr1:210001259	C1orf107	0.85	6.82	0.57	8.53e-10	Orofacial clefts;
THYM	cis	rs3743104	0.510	rs16973303	chr15:33020928	A/C	cg07179000	chr15:33023586	GREM1	-0.64	-6.04	-0.53	3.02e-8	Hypospadias;
THYM	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs7084921	0.608	rs12773948	chr10:101865115	T/A	cg11344164	chr10:101878520	NA	-0.57	-4.93	-0.45	3.47e-6	Bone mineral density;
THYM	trans	rs2270927	1.000	rs13174383	chr5:75580416	T/G	cg13563193	chr19:33072644	PDCD5	1.58	8.69	0.67	1.04e-13	Mean corpuscular volume;
THYM	cis	rs2862064	0.932	rs1553316	chr5:156479509	A/G	cg12943317	chr5:156479607	HAVCR1	-0.84	-5.23	-0.47	9.88e-7	Platelet count;
THYM	cis	rs3924048	0.574	rs11121930	chr1:12616956	C/A	cg00291366	chr1:12616550	NA	0.38	5.85	0.51	7.04e-8	Optic cup area;
THYM	cis	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.68	-4.71	-0.43	8.54e-6	Arsenic metabolism;
THYM	cis	rs9560113	0.509	rs4771758	chr13:112201573	C/G	cg10483660	chr13:112241077	NA	0.65	7.12	0.59	2.05e-10	Menarche (age at onset);
THYM	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg16325326	chr1:53192061	ZYG11B	0.82	7.77	0.62	9e-12	Monocyte count;
THYM	cis	rs3806843	0.712	rs2530244	chr5:140109155	A/G	cg19875535	chr5:140030758	IK	-0.69	-5.84	-0.51	7.41e-8	Depressive symptoms (multi-trait analysis);
THYM	cis	rs4363385	0.791	rs372490	chr1:153008971	A/G	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs7124681	0.585	rs10838773	chr11:47834346	G/A	cg20307385	chr11:47447363	PSMC3	0.59	4.45	0.42	2.31e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs7973719	1.000	rs12828421	chr12:7335217	C/T	cg07052231	chr12:7363540	PEX5	-0.62	-5.46	-0.49	3.83e-7	IgG glycosylation;
THYM	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-4.98	-0.46	2.82e-6	Hemoglobin concentration;
THYM	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg14129053	chr2:1895732	MYT1L	1.13	4.49	0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs6696239	0.840	rs10799445	chr1:227911883	A/C	cg05053440	chr1:227748442	NA	-0.6	-4.62	-0.43	1.21e-5	Height;
THYM	cis	rs12496230	1.000	rs3899502	chr3:66856411	A/G	cg23477460	chr3:66848765	NA	-1.13	-7.65	-0.62	1.66e-11	Type 2 diabetes;
THYM	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg18252515	chr7:66147081	NA	-0.66	-5.01	-0.46	2.55e-6	Aortic root size;
THYM	cis	rs3892630	0.588	rs7245709	chr19:33242755	C/T	cg22980127	chr19:33182716	NUDT19	1.14	10.49	0.73	1.46e-17	Red blood cell traits;
THYM	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg03959625	chr15:84868606	LOC388152	0.48	4.56	0.42	1.5e-5	Schizophrenia;
THYM	cis	rs6840360	0.571	rs11931934	chr4:152552082	A/G	cg17479576	chr4:152424074	FAM160A1	-0.79	-5.55	-0.49	2.59e-7	Intelligence (multi-trait analysis);
THYM	cis	rs76878669	0.561	rs3177514	chr11:66130358	T/G	cg18002602	chr11:66138449	SLC29A2	0.49	4.93	0.45	3.44e-6	Educational attainment (years of education);
THYM	cis	rs7000551	0.751	rs1482337	chr8:22395509	A/G	cg12081754	chr8:22256438	SLC39A14	-0.65	-5.86	-0.52	6.6e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg03806693	chr22:41940476	POLR3H	-0.77	-6.07	-0.53	2.59e-8	Neuroticism;
THYM	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg13390004	chr1:15929781	NA	0.62	4.72	0.44	8.11e-6	Systolic blood pressure;
THYM	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg06640241	chr16:89574553	SPG7	0.88	7.79	0.62	8.28e-12	Multiple myeloma (IgH translocation);
THYM	cis	rs2742234	0.541	rs11238483	chr10:43728780	A/G	cg06632098	chr10:43605906	RET	0.8	5.26	0.47	8.98e-7	Hirschsprung disease;
THYM	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg07460842	chr6:66804631	NA	-1.19	-13.34	-0.81	1.68e-23	Exhaled nitric oxide output;
THYM	cis	rs7119038	0.865	rs11217044	chr11:118696022	T/C	cg19308663	chr11:118741387	NA	0.46	4.76	0.44	7.03e-6	Sjögren's syndrome;
THYM	cis	rs12282928	1.000	rs11039676	chr11:48337188	T/C	cg22827986	chr11:48284249	OR4X1	0.53	5.59	0.5	2.21e-7	Migraine - clinic-based;
THYM	cis	rs7943203	0.850	rs751343	chr11:108366449	A/C	cg04873221	chr11:107992290	ACAT1	-0.65	-4.62	-0.43	1.21e-5	Red blood cell count;Mean corpuscular volume;
THYM	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg17757837	chr7:157058334	UBE3C	0.66	5.29	0.48	7.81e-7	Body mass index;
THYM	cis	rs66887589	0.967	rs2892869	chr4:120521297	T/C	cg13609457	chr4:120235615	NA	-0.47	-4.93	-0.45	3.5e-6	Diastolic blood pressure;
THYM	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.25	6.12	0.53	2.12e-8	Obesity-related traits;
THYM	cis	rs747782	0.527	rs7129364	chr11:48150576	G/A	cg24672777	chr11:48374446	OR4C45	-0.98	-5.37	-0.48	5.58e-7	Intraocular pressure;
THYM	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg06112835	chr11:68658793	MRPL21	0.45	6.39	0.55	6.21e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs5758511	0.817	rs133291	chr22:42269628	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.48	4.59	0.43	1.37e-5	Birth weight;
THYM	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg04944784	chr2:26401820	FAM59B	-0.79	-6.18	-0.54	1.61e-8	Gut microbiome composition (summer);
THYM	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg02524346	chr8:600233	NA	0.92	4.48	0.42	2.05e-5	IgG glycosylation;
THYM	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	8.21	0.64	1.09e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs3892630	0.878	rs114224536	chr19:33211232	A/G	cg02283691	chr19:33182526	NUDT19	-0.4	-4.82	-0.44	5.36e-6	Red blood cell traits;
THYM	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg07936489	chr17:37558343	FBXL20	0.83	5.84	0.51	7.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs62158800	0.568	rs62161319	chr2:108363138	C/A	cg27431625	chr2:107679531	NA	1.03	4.85	0.45	4.75e-6	Facial morphology (factor 22);
THYM	cis	rs4851254	0.660	rs34714421	chr2:100692175	T/C	cg22139774	chr2:100720529	AFF3	-0.41	-4.69	-0.43	9.07e-6	Intelligence (multi-trait analysis);
THYM	trans	rs8002861	0.905	rs6561150	chr13:44460470	C/T	cg17145862	chr1:211918768	LPGAT1	0.97	9.35	0.69	4.09e-15	Leprosy;
THYM	cis	rs3820068	0.608	rs7519899	chr1:16045579	A/G	cg24675056	chr1:15929824	NA	0.76	6.12	0.53	2.08e-8	Systolic blood pressure;
THYM	cis	rs600806	0.850	rs4970751	chr1:109896600	A/C	cg02175308	chr1:109941060	SORT1	-0.59	-5.13	-0.47	1.51e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7078219	0.505	rs7077040	chr10:101281014	C/G	cg23904955	chr10:101282759	NA	-0.4	-4.98	-0.45	2.89e-6	Dental caries;
THYM	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs765787	0.530	rs10851423	chr15:45515950	G/A	cg25801113	chr15:45476975	SHF	-0.38	-4.53	-0.42	1.68e-5	Uric acid levels;
THYM	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg19628046	chr18:33552617	C18orf21	0.77	5.47	0.49	3.68e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs8180040	0.800	rs7632501	chr3:47268306	T/C	cg02527881	chr3:46936655	PTH1R	0.59	5.46	0.49	3.74e-7	Colorectal cancer;
THYM	cis	rs3136739	0.867	rs9298619	chr8:42085572	C/A	cg12091331	chr8:42065314	PLAT	-0.73	-5.27	-0.48	8.56e-7	Plasma plasminogen activator levels;
THYM	cis	rs12928939	0.911	rs77823468	chr16:71828616	C/T	cg03805757	chr16:71968109	PKD1L3	-0.7	-5.31	-0.48	7.25e-7	Post bronchodilator FEV1;
THYM	cis	rs9560113	1.000	rs4773384	chr13:112177987	A/G	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg27535305	chr1:53392650	SCP2	-0.4	-4.52	-0.42	1.78e-5	Monocyte count;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg05729499	chr6:27832945	HIST1H2AL	1.0	7.58	0.61	2.24e-11	Depressive symptoms;
THYM	cis	rs7769051	0.522	rs6927991	chr6:133113888	T/G	cg22852734	chr6:133119734	C6orf192	1.45	6.1	0.53	2.32e-8	Type 2 diabetes nephropathy;
THYM	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7731657	0.537	rs4705883	chr5:130358471	A/G	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs800586	0.628	rs2737263	chr8:116667539	G/T	cg04656070	chr8:116661063	TRPS1	-0.56	-5.72	-0.51	1.21e-7	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs10493773	0.775	rs12739713	chr1:86150378	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.48	-6.24	-0.54	1.19e-8	Urate levels in overweight individuals;
THYM	cis	rs12752838	0.777	rs10864368	chr1:8918313	A/G	cg06972019	chr1:8937448	ENO1	-0.87	-11.07	-0.75	8.74e-19	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg04865290	chr3:52927548	TMEM110	-0.97	-5.07	-0.46	1.97e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7633857	0.512	rs13098529	chr3:160657053	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-4.76	-0.44	6.88e-6	Educational attainment (years of education);
THYM	cis	rs9807841	0.538	rs8113029	chr19:10849194	C/T	cg16900796	chr19:10755136	SLC44A2	0.29	4.69	0.43	9.06e-6	Inflammatory skin disease;
THYM	cis	rs11078917	1	rs11078917	chr17:37746359	A/C	cg00129232	chr17:37814104	STARD3	-0.8	-5.48	-0.49	3.54e-7	Mean corpuscular volume;
THYM	cis	rs7084402	0.967	rs7921371	chr10:60330531	G/C	cg09696939	chr10:60272079	BICC1	0.46	5.53	0.49	2.75e-7	Refractive error;
THYM	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg26116260	chr4:7069785	GRPEL1	1.09	10.34	0.73	3.05e-17	Monocyte percentage of white cells;
THYM	cis	rs2075230	0.705	rs1641540	chr17:7545187	C/T	cg27413385	chr17:7515425	FXR2	-0.35	-5.06	-0.46	2.06e-6	Hormone measurements;
THYM	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg09307838	chr4:120376055	NA	-0.74	-5.63	-0.5	1.81e-7	Corneal astigmatism;
THYM	cis	rs2294693	0.679	rs10947942	chr6:40958205	G/A	cg14418226	chr6:40996092	UNC5CL	0.71	5.47	0.49	3.59e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg18681998	chr4:17616180	MED28	0.85	7.68	0.62	1.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg06873352	chr17:61820015	STRADA	-0.51	-5.02	-0.46	2.43e-6	Height;
THYM	cis	rs3126085	0.799	rs11589532	chr1:152176539	G/A	cg10321714	chr1:152280068	FLG	-0.7	-5.07	-0.46	1.95e-6	Atopic dermatitis;
THYM	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg22907277	chr7:1156413	C7orf50	0.87	7.59	0.61	2.16e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2749592	0.611	rs2505199	chr10:38392457	G/A	cg25427524	chr10:38739819	LOC399744	-0.72	-6.09	-0.53	2.4e-8	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11039798	0.588	rs7483361	chr11:48593786	G/A	cg24672777	chr11:48374446	OR4C45	-0.93	-6.01	-0.52	3.39e-8	Axial length;
THYM	cis	rs12289510	0.539	rs3808995	chr11:124955977	A/G	cg03868193	chr11:124958746	SLC37A2	0.63	4.86	0.45	4.68e-6	Platelet-derived growth factor BB levels;
THYM	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06850241	chr22:41845214	NA	-0.54	-4.9	-0.45	4.01e-6	Vitiligo;
THYM	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7264396	0.563	rs2425094	chr20:34306974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.76	-0.44	6.84e-6	Total cholesterol levels;
THYM	cis	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg13647721	chr17:30228624	UTP6	0.73	4.71	0.44	8.48e-6	Hip circumference adjusted for BMI;
THYM	cis	rs7216064	1.000	rs7216064	chr17:65898809	G/A	cg12091567	chr17:66097778	LOC651250	-0.69	-4.56	-0.42	1.51e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs4455778	0.894	rs4292636	chr7:49078125	C/A	cg26309511	chr7:48887640	NA	0.51	4.48	0.42	2.1e-5	Lung cancer in never smokers;
THYM	cis	rs6032067	0.673	rs36019441	chr20:43892401	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.66	-5.9	-0.52	5.68e-8	Blood protein levels;
THYM	cis	rs8063160	0.610	rs12931267	chr16:89818732	C/G	cg07984980	chr16:89898383	SPIRE2	1.61	5.99	0.52	3.7e-8	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg26384229	chr12:38710491	ALG10B	-0.93	-7.55	-0.61	2.69e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg13695892	chr22:41940480	POLR3H	0.86	6.33	0.54	8.08e-9	Vitiligo;
THYM	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg18252515	chr7:66147081	NA	-0.88	-6.71	-0.57	1.4e-9	Corneal structure;
THYM	cis	rs9515201	1.000	rs9515201	chr13:111040798	A/C	cg15455643	chr13:111040242	COL4A2	-0.48	-4.96	-0.45	3.1e-6	White matter hyperintensity burden;
THYM	cis	rs3771570	1.000	rs1984598	chr2:242284824	G/A	cg21155796	chr2:242212141	HDLBP	1.09	6.4	0.55	5.95e-9	Prostate cancer;
THYM	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg15693483	chr7:1102177	C7orf50	0.54	6.29	0.54	9.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9646944	0.501	rs36049530	chr2:103079988	T/C	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs1348850	0.554	rs1374438	chr2:178376684	A/G	cg27490568	chr2:178487706	NA	0.68	5.53	0.49	2.77e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg14664628	chr15:75095509	CSK	-0.63	-4.86	-0.45	4.63e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs8050907	0.744	rs17879291	chr16:4526104	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.3	5.2	0.47	1.16e-6	Obesity-related traits;
THYM	cis	rs2625529	0.824	rs12916951	chr15:72252498	C/T	cg16672083	chr15:72433130	SENP8	-0.51	-4.64	-0.43	1.1e-5	Red blood cell count;
THYM	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.75	5.13	0.47	1.55e-6	Height;
THYM	trans	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg19862616	chr7:65841803	NCRNA00174	1.04	11.41	0.76	1.64e-19	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs11112613	0.713	rs12316204	chr12:105944244	G/A	cg03607813	chr12:105948248	NA	1.07	9.36	0.69	3.87e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg03909863	chr11:638404	DRD4	-0.76	-6.04	-0.53	2.95e-8	Systemic lupus erythematosus;
THYM	cis	rs11771526	0.901	rs11764193	chr7:32272200	C/T	cg27532318	chr7:32358331	NA	0.76	5.44	0.49	4.16e-7	Body mass index;
THYM	cis	rs2806561	0.929	rs628096	chr1:23537676	C/G	cg08872493	chr1:23521417	HTR1D	0.36	4.45	0.42	2.34e-5	Height;
THYM	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg26418147	chr1:205743515	RAB7L1	-0.54	-4.69	-0.43	9.32e-6	Menarche (age at onset);
THYM	cis	rs17255340	0.520	rs1145912	chr6:83994757	G/C	cg21688264	chr6:84418724	SNAP91	0.66	4.46	0.42	2.22e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg02569458	chr12:86230093	RASSF9	-0.65	-5.33	-0.48	6.59e-7	Major depressive disorder;
THYM	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg22968622	chr17:43663579	NA	1.18	10.66	0.74	6.45e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg22709100	chr7:91322751	NA	0.59	4.65	0.43	1.07e-5	Breast cancer;
THYM	cis	rs12282928	0.759	rs7395503	chr11:48344386	C/T	cg22827986	chr11:48284249	OR4X1	0.53	5.59	0.5	2.21e-7	Migraine - clinic-based;
THYM	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.73	7.01	0.58	3.48e-10	Lymphocyte counts;
THYM	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs10992471	0.533	rs331381	chr9:95249859	A/G	cg14631576	chr9:95140430	CENPP	0.6	4.91	0.45	3.83e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg06558623	chr16:89946397	TCF25	1.51	8.29	0.65	7.35e-13	Skin colour saturation;
THYM	cis	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg21775007	chr8:11205619	TDH	-0.7	-5.78	-0.51	9.67e-8	Retinal vascular caliber;
THYM	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg20486651	chr6:167070296	RPS6KA2	0.47	4.5	0.42	1.95e-5	Crohn's disease;
THYM	cis	rs11648796	0.879	rs12448432	chr16:778820	G/A	cg02852791	chr16:710674	WDR90	-0.61	-5.63	-0.5	1.85e-7	Height;
THYM	cis	rs752010	0.841	rs58737163	chr1:42079821	G/T	cg06885757	chr1:42089581	HIVEP3	0.41	4.45	0.42	2.36e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs12594515	1.000	rs8033148	chr15:45997929	G/A	cg01629716	chr15:45996671	NA	0.53	5.27	0.48	8.47e-7	Waist circumference;Weight;
THYM	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs11645898	0.622	rs4788463	chr16:72223716	G/T	cg03805757	chr16:71968109	PKD1L3	-0.73	-5.61	-0.5	2e-7	Blood protein levels;
THYM	cis	rs11969893	0.649	rs9390699	chr6:101306502	C/G	cg12253828	chr6:101329408	ASCC3	0.71	4.47	0.42	2.19e-5	Economic and political preferences (immigration/crime);
THYM	cis	rs4499344	0.920	rs752719	chr19:33086091	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.77	-5.45	-0.49	3.92e-7	Mean platelet volume;
THYM	cis	rs11089937	0.616	rs4991800	chr22:22533332	A/G	cg06866756	chr22:22471216	NA	-0.46	-4.86	-0.45	4.66e-6	Periodontitis (PAL4Q3);
THYM	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg00310523	chr12:86230176	RASSF9	-0.56	-4.92	-0.45	3.56e-6	Major depressive disorder;
THYM	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06481639	chr22:41940642	POLR3H	-0.8	-5.55	-0.49	2.63e-7	Vitiligo;
THYM	trans	rs4650994	0.544	rs2811314	chr1:178619183	C/T	cg05059571	chr16:84539110	KIAA1609	0.84	8.56	0.66	1.99e-13	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg03264133	chr6:25882463	NA	0.65	5.06	0.46	2.03e-6	Schizophrenia;
THYM	trans	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs10823500	0.777	rs7919014	chr10:71944577	T/C	cg04118878	chr10:71993077	PPA1	0.61	4.46	0.42	2.23e-5	Blood protein levels;
THYM	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.51e-15	Intelligence (multi-trait analysis);
THYM	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.15e-7	Intelligence (multi-trait analysis);
THYM	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg04772025	chr11:68637568	NA	0.63	6.85	0.58	7.17e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg06850241	chr22:41845214	NA	0.54	4.85	0.45	4.87e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs2050392	0.517	rs160018	chr10:30772703	T/C	cg13289132	chr10:30722225	MAP3K8	-0.67	-5.43	-0.49	4.39e-7	Inflammatory bowel disease;
THYM	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.33	0.48	6.55e-7	Height;
THYM	cis	rs919433	0.783	rs2565158	chr2:198236103	T/A	cg05783139	chr2:198650985	BOLL	0.56	4.5	0.42	1.96e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9796	0.870	rs2927061	chr15:41302219	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.56	-4.52	-0.42	1.77e-5	Menopause (age at onset);
THYM	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg07532245	chr17:28927093	LRRC37B2	-0.64	-4.66	-0.43	1.04e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg08885076	chr2:99613938	TSGA10	0.53	5.14	0.47	1.46e-6	Chronic sinus infection;
THYM	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg08508325	chr11:3079039	CARS	-0.49	-5.98	-0.52	3.87e-8	Longevity;
THYM	cis	rs763014	0.833	rs3743903	chr16:632736	T/C	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg18305652	chr10:134549665	INPP5A	0.79	6.5	0.55	3.69e-9	Migraine;
THYM	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Bladder cancer;
THYM	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg18512352	chr11:47633146	NA	-0.51	-6.31	-0.54	8.88e-9	Subjective well-being;
THYM	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg12311346	chr5:56204834	C5orf35	0.88	6.21	0.54	1.41e-8	Initial pursuit acceleration;
THYM	cis	rs4638749	0.677	rs34449318	chr2:108827222	T/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs8067545	0.611	rs11868116	chr17:20029593	T/C	cg13482628	chr17:19912719	NA	0.55	4.7	0.43	8.82e-6	Schizophrenia;
THYM	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg10018233	chr7:150070692	REPIN1	0.43	5.87	0.52	6.26e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg21658235	chr8:22456391	C8orf58	0.5	4.96	0.45	3.12e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7084402	0.967	rs1658483	chr10:60288933	C/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	trans	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs986417	1.000	rs10130255	chr14:60944435	C/T	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05901451	chr6:126070800	HEY2	0.84	8.28	0.65	7.8e-13	Brugada syndrome;
THYM	cis	rs2249625	0.545	rs10498880	chr6:72882183	G/T	cg27608224	chr6:72922399	RIMS1	-0.58	-4.9	-0.45	3.94e-6	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
THYM	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.2	8.02	0.64	2.74e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg17063962	chr7:91808500	NA	1.16	13.12	0.8	4.77e-23	Breast cancer;
THYM	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg05896524	chr21:47604654	C21orf56	0.65	4.56	0.42	1.53e-5	Testicular germ cell tumor;
THYM	cis	rs11078597	0.767	rs874424	chr17:1640034	G/A	cg18436246	chr17:1640651	WDR81	0.64	4.63	0.43	1.14e-5	Serum albumin level;
THYM	cis	rs7578361	0.959	rs6721261	chr2:150455120	C/T	cg17961725	chr2:150454027	NA	0.75	6.2	0.54	1.47e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs7432375	0.901	rs6802702	chr3:136489563	G/A	cg12473912	chr3:136751656	NA	-0.6	-4.89	-0.45	4.06e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs13082711	0.911	rs36101969	chr3:27438181	G/A	cg02860705	chr3:27208620	NA	0.67	4.7	0.43	8.96e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg00640147	chr17:61958756	GH2	-0.43	-4.54	-0.42	1.64e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs354225	0.544	rs7556752	chr2:54810044	G/C	cg23486701	chr2:54789491	SPTBN1	0.36	4.9	0.45	3.93e-6	Schizophrenia;
THYM	cis	rs4786125	0.639	rs7200754	chr16:6897636	A/G	cg03623568	chr16:6915990	A2BP1	0.82	7.24	0.6	1.18e-10	Heart rate variability traits (SDNN);
THYM	cis	rs11048434	0.761	rs12827055	chr12:9130861	G/T	cg26114124	chr12:9217669	LOC144571	0.46	4.51	0.42	1.85e-5	Sjögren's syndrome;
THYM	cis	rs6032067	0.777	rs13042694	chr20:43799368	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.52	-5.89	-0.52	5.83e-8	Blood protein levels;
THYM	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs7851660	0.772	rs6478471	chr9:100664382	A/G	cg13688889	chr9:100608707	NA	-0.72	-4.97	-0.45	3.01e-6	Strep throat;
THYM	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg07424592	chr7:64974309	NA	1.09	5.01	0.46	2.55e-6	Diabetic kidney disease;
THYM	cis	rs35934224	0.831	rs13057374	chr22:19871097	C/G	cg11182965	chr22:19864308	TXNRD2	-0.93	-6.94	-0.58	4.79e-10	Glaucoma (primary open-angle);
THYM	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg03676636	chr4:99064102	C4orf37	0.4	5.62	0.5	1.91e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7103648	0.966	rs10769263	chr11:47417183	A/C	cg20307385	chr11:47447363	PSMC3	0.94	8.51	0.66	2.49e-13	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-5.49	-0.49	3.39e-7	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs11563648	0.573	rs2106151	chr7:126957327	A/G	cg08586737	chr7:127225949	GCC1	-0.33	-4.53	-0.42	1.74e-5	Resting heart rate;
THYM	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg04317338	chr11:64019027	PLCB3	0.83	5.07	0.46	1.94e-6	Mean platelet volume;
THYM	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg03517284	chr6:25882590	NA	-0.67	-4.47	-0.42	2.14e-5	Height;
THYM	cis	rs2413151	0.655	rs130303	chr22:33236572	G/C	cg18989477	chr22:32435639	NA	0.56	5.0	0.46	2.58e-6	Blood protein levels;
THYM	cis	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg08133631	chr1:26527909	CATSPER4	-0.55	-4.59	-0.43	1.34e-5	Obesity-related traits;
THYM	cis	rs6964587	0.610	rs6942852	chr7:91437883	A/C	cg17063962	chr7:91808500	NA	1.0	8.47	0.66	3.06e-13	Breast cancer;
THYM	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg23750338	chr8:142222470	SLC45A4	0.52	4.87	0.45	4.48e-6	Immature fraction of reticulocytes;
THYM	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs775227	0.574	rs13068107	chr3:113029530	A/C	cg18753928	chr3:113234510	CCDC52	-0.75	-5.16	-0.47	1.35e-6	Dental caries;
THYM	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg21280719	chr6:42927975	GNMT	-0.52	-7.31	-0.6	8.5e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06634786	chr22:41940651	POLR3H	-0.74	-5.69	-0.5	1.38e-7	Vitiligo;
THYM	cis	rs12422267	0.793	rs78667940	chr12:132492152	C/T	cg19981660	chr12:132434166	EP400	-1.24	-4.61	-0.43	1.23e-5	Plasma amyloid beta peptide concentrations (ABx-40);
THYM	cis	rs748404	0.631	rs2467745	chr15:43722742	A/G	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg14458575	chr2:238380390	NA	1.09	8.79	0.67	6.36e-14	Prostate cancer;
THYM	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg03563238	chr19:33554763	RHPN2	0.53	4.51	0.42	1.87e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03517284	chr6:25882590	NA	-1.18	-11.8	-0.77	2.53e-20	Intelligence (multi-trait analysis);
THYM	trans	rs9951602	0.512	rs9953258	chr18:76651199	A/C	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg13319975	chr6:146136371	FBXO30	-0.67	-5.47	-0.49	3.58e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	10.09	0.72	1.05e-16	Platelet count;
THYM	cis	rs899997	0.906	rs1994018	chr15:79025584	G/A	cg04896959	chr15:78267971	NA	-1.05	-7.86	-0.63	5.86e-12	Coronary artery disease or large artery stroke;
THYM	cis	rs7705502	1.000	rs59755656	chr5:173378180	A/G	cg18693985	chr5:173351052	CPEB4	-0.75	-5.7	-0.5	1.35e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs902774	0.530	rs11834907	chr12:53350985	C/T	cg14581129	chr12:53358946	NA	-0.99	-4.56	-0.42	1.5e-5	Prostate cancer;
THYM	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.29	-0.48	7.96e-7	Hemoglobin concentration;
THYM	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg13683864	chr3:40499215	RPL14	-0.85	-8.05	-0.64	2.31e-12	Renal cell carcinoma;
THYM	cis	rs7000551	0.606	rs7844699	chr8:22248920	G/T	cg12081754	chr8:22256438	SLC39A14	-0.99	-9.33	-0.69	4.4e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9287719	0.753	rs1990613	chr2:10781975	C/T	cg02196655	chr2:10830764	NOL10	0.48	4.91	0.45	3.74e-6	Prostate cancer;
THYM	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs829880	0.789	rs1096146	chr12:98850966	A/G	cg25150519	chr12:98850993	NA	0.53	4.71	0.44	8.36e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg26384229	chr12:38710491	ALG10B	-0.89	-9.05	-0.68	1.77e-14	Heart rate;
THYM	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg13695892	chr22:41940480	POLR3H	0.88	6.87	0.58	6.5e-10	Vitiligo;
THYM	cis	rs17604090	0.756	rs113829432	chr7:29725069	C/T	cg19413766	chr7:29689036	LOC646762	-0.95	-5.37	-0.48	5.65e-7	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2562456	0.917	rs2681389	chr19:21692575	G/A	cg21751540	chr19:21541537	ZNF738	0.7	4.89	0.45	4.11e-6	Pain;
THYM	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg13319975	chr6:146136371	FBXO30	0.66	5.42	0.49	4.51e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg18305652	chr10:134549665	INPP5A	0.78	6.35	0.55	7.31e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs656319	0.559	rs55683917	chr8:9976479	C/G	cg20181426	chr8:10469310	RP1L1	0.54	4.72	0.44	8.16e-6	Myopia (pathological);
THYM	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg22875332	chr1:76189707	ACADM	-0.53	-5.02	-0.46	2.42e-6	Daytime sleep phenotypes;
THYM	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg20891558	chr2:74357851	NA	1.15	11.89	0.77	1.62e-20	Gestational age at birth (maternal effect);
THYM	cis	rs9640161	0.789	rs10248490	chr7:150051418	C/G	cg10018233	chr7:150070692	REPIN1	0.48	6.93	0.58	5.13e-10	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg12564285	chr5:131593104	PDLIM4	0.43	4.76	0.44	6.88e-6	Breast cancer;
THYM	cis	rs36093924	0.646	rs5996092	chr22:42344408	A/G	cg10296410	chr22:42095368	MEI1	0.44	4.49	0.42	1.99e-5	Intelligence;
THYM	cis	rs36051895	0.559	rs12342390	chr9:5211297	G/A	cg02405213	chr9:5042618	JAK2	-0.87	-8.5	-0.66	2.64e-13	Pediatric autoimmune diseases;
THYM	trans	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Bladder cancer;
THYM	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg23482746	chr15:76478102	C15orf27	-0.38	-4.55	-0.42	1.61e-5	Blood metabolite levels;
THYM	cis	rs2242116	0.743	rs11719795	chr3:46951935	T/C	cg02527881	chr3:46936655	PTH1R	-0.79	-7.89	-0.63	5.11e-12	Birth weight;
THYM	cis	rs10864302	0.515	rs6679411	chr1:7458393	G/A	cg08923594	chr1:7462176	CAMTA1	-0.46	-5.28	-0.48	8.17e-7	Photic sneeze reflex;
THYM	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg10950924	chr17:47092072	IGF2BP1	-0.52	-4.76	-0.44	6.91e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg05425664	chr17:57184151	TRIM37	-0.61	-4.93	-0.45	3.42e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12935418	0.552	rs2549835	chr16:81022610	G/C	cg16651780	chr16:81037892	C16orf61	-0.85	-6.38	-0.55	6.29e-9	Mean corpuscular volume;
THYM	cis	rs12643440	0.538	rs16894428	chr4:17142974	A/G	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs654950	0.875	rs632166	chr1:41995681	T/C	cg13396354	chr1:41153348	NA	0.46	4.74	0.44	7.53e-6	Airway imaging phenotypes;
THYM	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg10047753	chr17:41438598	NA	1.01	7.93	0.63	4.2e-12	Menopause (age at onset);
THYM	cis	rs6570726	0.846	rs6899900	chr6:145883873	T/G	cg23711669	chr6:146136114	FBXO30	0.86	8.19	0.64	1.22e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1981331	0.867	rs76188425	chr21:48002207	C/T	cg23283320	chr21:48055893	PRMT2	1.37	6.24	0.54	1.2e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg11764359	chr7:65958608	NA	0.78	6.31	0.54	8.68e-9	Aortic root size;
THYM	cis	rs4363385	0.720	rs6680624	chr1:152983872	A/G	cg13444842	chr1:152974279	SPRR3	-0.58	-4.71	-0.44	8.32e-6	Inflammatory skin disease;
THYM	cis	rs4930103	0.874	rs80047492	chr11:2025032	A/T	cg06197492	chr11:2016605	H19	0.6	5.36	0.48	5.73e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg06481639	chr22:41940642	POLR3H	0.8	5.56	0.5	2.48e-7	Vitiligo;
THYM	cis	rs7224314	1.000	rs62084078	chr17:65386886	T/C	cg01507342	chr17:65387096	PITPNC1	-0.91	-10.3	-0.73	3.76e-17	Diisocyanate-induced asthma;
THYM	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	5.59	0.5	2.16e-7	Monocyte percentage of white cells;
THYM	cis	rs2836633	0.929	rs8130434	chr21:40036243	C/T	cg12884169	chr21:40033163	ERG	-0.67	-8.4	-0.65	4.19e-13	Coronary artery disease;
THYM	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg00339695	chr16:24857497	SLC5A11	0.68	6.41	0.55	5.69e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.21	8.51	0.66	2.47e-13	Cognitive test performance;
THYM	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs17174870	0.628	rs57297275	chr2:112740598	T/G	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9682041	1.000	rs9682041	chr3:170091902	C/T	cg11886554	chr3:170076028	SKIL	1.3	5.11	0.46	1.63e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs11031096	0.678	rs12223062	chr11:4180178	G/T	cg08557956	chr11:4115526	RRM1	-0.52	-4.68	-0.43	9.36e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs941408	1.000	rs1736181	chr19:2797703	C/T	cg17333051	chr19:2783644	SGTA	0.55	4.86	0.45	4.58e-6	Total cholesterol levels;
THYM	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg08807101	chr21:30365312	RNF160	-0.67	-4.87	-0.45	4.5e-6	Dental caries;
THYM	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg16342193	chr10:102329863	NA	-0.58	-6.04	-0.53	3.02e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7904368	0.568	rs10752061	chr10:16853900	A/G	cg23933602	chr10:16859644	RSU1	0.74	6.37	0.55	6.81e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
THYM	cis	rs4654899	1.000	rs6683542	chr1:21369610	T/C	cg01072550	chr1:21505969	NA	-0.75	-6.82	-0.57	8.26e-10	Superior frontal gyrus grey matter volume;
THYM	trans	rs9929218	0.551	rs9888942	chr16:68727572	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.06	13.08	0.8	5.64e-23	Colorectal cancer;
THYM	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg03405983	chr8:143858548	LYNX1	-0.55	-6.02	-0.53	3.33e-8	Urinary tract infection frequency;
THYM	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg06074448	chr4:187884817	NA	-0.99	-12.8	-0.8	2.14e-22	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg13010199	chr12:38710504	ALG10B	0.73	5.81	0.51	8.29e-8	Heart rate;
THYM	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.68	5.59	0.5	2.19e-7	Blood metabolite levels;
THYM	trans	rs8177376	0.906	rs522486	chr11:126059949	C/T	cg03985801	chr1:202182603	LGR6	0.82	7.5	0.61	3.33e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs7568458	0.905	rs59877521	chr2:85759494	C/T	cg17127132	chr2:85788382	GGCX	0.64	5.22	0.47	1.04e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs988913	1.000	rs9370345	chr6:54825167	C/T	cg19716238	chr6:54711378	FAM83B	0.49	4.85	0.45	4.85e-6	Menarche (age at onset);
THYM	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.76	-6.38	-0.55	6.46e-9	Systemic lupus erythematosus;
THYM	cis	rs12410462	1.000	rs76233861	chr1:227673909	G/A	cg23173402	chr1:227635558	NA	0.67	5.94	0.52	4.64e-8	Major depressive disorder;
THYM	cis	rs4466137	0.953	rs1585153	chr5:83000385	A/T	cg16102102	chr5:83017553	HAPLN1	-1.11	-11.03	-0.75	1.07e-18	Prostate cancer;
THYM	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg27211696	chr2:191398769	TMEM194B	0.85	8.79	0.67	6.5e-14	Pulse pressure;
THYM	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg26513180	chr16:89883248	FANCA	-0.49	-4.62	-0.43	1.2e-5	Vitiligo;
THYM	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-4.93	-0.45	3.53e-6	Hemoglobin concentration;
THYM	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg12311346	chr5:56204834	C5orf35	0.62	4.76	0.44	6.83e-6	Initial pursuit acceleration;
THYM	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs6754311	0.773	rs309179	chr2:136613780	G/A	cg07169764	chr2:136633963	MCM6	-0.71	-6.05	-0.53	2.81e-8	Mosquito bite size;
THYM	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.62	-5.15	-0.47	1.39e-6	Renal function-related traits (BUN);
THYM	cis	rs6867032	0.876	rs1552435	chr5:2018378	A/G	cg26168224	chr5:2018326	NA	1.34	16.98	0.87	1.55e-30	Gut microbiome composition (winter);
THYM	cis	rs11696501	0.688	rs6073855	chr20:44309670	C/T	cg11783356	chr20:44313418	WFDC10B	-0.69	-4.73	-0.44	7.72e-6	Brain structure;
THYM	cis	rs4938534	0.559	rs1944919	chr11:111259876	A/C	cg18316498	chr11:111250196	POU2AF1	0.64	5.9	0.52	5.46e-8	Primary biliary cholangitis;
THYM	cis	rs9563576	0.778	rs9634881	chr13:58616978	G/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	trans	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs939658	0.805	rs939661	chr15:79431063	A/G	cg17916960	chr15:79447300	NA	-0.73	-8.4	-0.65	4.34e-13	Refractive error;
THYM	cis	rs1823778	0.609	rs2117557	chr18:67644013	C/T	cg13164537	chr18:67624071	CD226	1.15	4.8	0.44	5.83e-6	Mean platelet volume;
THYM	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-5.55	-0.49	2.58e-7	Monocyte percentage of white cells;
THYM	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg01097406	chr16:89675127	NA	-0.57	-5.12	-0.46	1.63e-6	Vitiligo;
THYM	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg15549821	chr19:49342101	PLEKHA4	1.32	9.13	0.68	1.22e-14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	trans	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs2286885	1.000	rs2286886	chr9:129246177	T/C	cg14294646	chr9:129243551	FAM125B	-0.6	-5.55	-0.49	2.61e-7	Intraocular pressure;
THYM	cis	rs921665	0.831	rs7566188	chr2:3199057	C/T	cg16434511	chr2:3151078	NA	-0.87	-5.64	-0.5	1.72e-7	World class endurance athleticism;
THYM	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg06850241	chr22:41845214	NA	0.52	4.49	0.42	2.01e-5	Vitiligo;
THYM	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.55	-5.23	-0.47	1e-6	Lymphocyte counts;
THYM	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg20887711	chr4:1340912	KIAA1530	0.94	8.43	0.65	3.74e-13	Longevity;
THYM	cis	rs782590	0.517	rs13013133	chr2:55889466	G/A	cg18811423	chr2:55921094	PNPT1	-0.62	-5.58	-0.5	2.23e-7	Metabolic syndrome;
THYM	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.15	7.41	0.61	5.26e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg11494091	chr17:61959527	GH2	0.71	6.65	0.56	1.81e-9	Height;
THYM	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg11764359	chr7:65958608	NA	-0.74	-6.15	-0.53	1.85e-8	Aortic root size;
THYM	cis	rs7089973	0.872	rs7072356	chr10:116634651	T/C	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.05	-0.46	2.15e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg23583168	chr7:148888333	NA	1.1	16.73	0.86	4.47e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs79149102	0.579	rs2304904	chr15:75315975	G/A	cg09165964	chr15:75287851	SCAMP5	-1.0	-4.96	-0.45	3.08e-6	Lung cancer;
THYM	cis	rs854765	0.724	rs2955371	chr17:17967397	G/A	cg04398451	chr17:18023971	MYO15A	0.86	8.81	0.67	5.89e-14	Total body bone mineral density;
THYM	cis	rs7107770	1.000	rs61912981	chr11:125106352	G/A	cg07747661	chr11:125106135	PKNOX2	-0.92	-5.28	-0.48	8.31e-7	Photic sneeze reflex;
THYM	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg24675658	chr1:53192096	ZYG11B	-0.74	-6.03	-0.53	3.17e-8	Monocyte count;
THYM	cis	rs6450176	0.909	rs11742688	chr5:53291081	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-6.61	-0.56	2.22e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs4589258	0.737	rs2212350	chr11:90411292	C/T	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2495707	0.532	rs2495709	chr10:102416833	C/T	cg07099331	chr10:102419617	NA	-0.46	-5.11	-0.46	1.65e-6	Body mass index;
THYM	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg01386294	chr6:25732093	NA	0.9	4.57	0.42	1.49e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs12681287	0.640	rs2953516	chr8:87332545	C/T	cg27223183	chr8:87520930	FAM82B	-0.74	-5.43	-0.49	4.26e-7	Caudate activity during reward;
THYM	cis	rs12476592	0.602	rs1348803	chr2:63895617	C/T	cg17519650	chr2:63277830	OTX1	-0.72	-4.68	-0.43	9.38e-6	Childhood ear infection;
THYM	cis	rs3862030	0.720	rs7081110	chr10:104231651	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-5.8	-0.51	8.83e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs6964587	0.605	rs6956022	chr7:91553199	A/G	cg22709100	chr7:91322751	NA	-0.62	-4.64	-0.43	1.1e-5	Breast cancer;
THYM	cis	rs8064299	0.597	rs4789097	chr17:72781208	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.89	-8.83	-0.67	5.26e-14	Monocyte count;
THYM	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg02569458	chr12:86230093	RASSF9	-0.66	-5.63	-0.5	1.84e-7	Major depressive disorder;
THYM	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg04267008	chr7:1944627	MAD1L1	-0.61	-5.02	-0.46	2.39e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs3087591	1.000	rs2905795	chr17:29547601	A/G	cg24425628	chr17:29625626	OMG;NF1	0.63	5.52	0.49	2.96e-7	Hip circumference;
THYM	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg02527881	chr3:46936655	PTH1R	0.61	5.7	0.51	1.33e-7	Colorectal cancer;
THYM	cis	rs4242434	0.672	rs10113779	chr8:22485934	G/C	cg03733263	chr8:22462867	KIAA1967	1.02	10.27	0.73	4.38e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs4918072	0.917	rs61861158	chr10:105661686	A/G	cg11005552	chr10:105648138	OBFC1	0.75	6.25	0.54	1.15e-8	Coronary artery disease;
THYM	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg10523679	chr1:76189770	ACADM	0.9	7.36	0.6	6.5500000000000006e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg01416388	chr22:39784598	NA	-0.86	-8.31	-0.65	6.67e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg11301795	chr4:187892539	NA	-1.1	-16.1	-0.86	6.87e-29	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7772486	0.790	rs2265469	chr6:146219049	T/C	cg23711669	chr6:146136114	FBXO30	0.91	9.21	0.69	8.1e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7572733	0.534	rs696817	chr2:198722225	A/G	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs240764	0.659	rs240765	chr6:100953883	C/T	cg21058520	chr6:100914733	NA	0.6	4.7	0.43	8.79e-6	Neuroticism;
THYM	cis	rs1113500	0.565	rs11185226	chr1:108548051	G/A	cg06207961	chr1:108661230	NA	0.62	4.92	0.45	3.58e-6	Growth-regulated protein alpha levels;
THYM	cis	rs2412459	0.635	rs509200	chr15:40254332	T/C	cg16127683	chr15:40268777	EIF2AK4	0.53	4.63	0.43	1.16e-5	Response to haloperidol in psychosis;
THYM	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg24675658	chr1:53192096	ZYG11B	-0.7	-5.23	-0.47	9.95e-7	Monocyte count;
THYM	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg25072359	chr17:41440525	NA	0.75	5.4	0.48	4.82e-7	Menopause (age at onset);
THYM	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg20744362	chr22:50050164	C22orf34	0.77	6.97	0.58	4.25e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	4.54	0.42	1.67e-5	Alzheimer's disease;
THYM	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg10253484	chr15:75165896	SCAMP2	-0.67	-4.53	-0.42	1.73e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-6.0	-0.52	3.63e-8	Prostate cancer;
THYM	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.81	-4.97	-0.45	2.91e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg20891283	chr12:69753455	YEATS4	0.79	6.23	0.54	1.24e-8	Response to diuretic therapy;
THYM	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs6430585	0.583	rs78364332	chr2:136640101	T/C	cg04750100	chr2:136595281	LCT	0.56	5.26	0.47	8.94e-7	Corneal structure;
THYM	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg13319975	chr6:146136371	FBXO30	0.65	5.24	0.47	9.85e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7107174	0.901	rs11237459	chr11:78056273	A/C	cg02023728	chr11:77925099	USP35	0.64	6.31	0.54	8.65e-9	Testicular germ cell tumor;
THYM	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg01364799	chr7:75623366	TMEM120A	0.64	4.75	0.44	7.32e-6	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg19016782	chr12:123741754	C12orf65	-0.69	-4.47	-0.42	2.18e-5	Neutrophil percentage of white cells;
THYM	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs7020830	0.898	rs495863	chr9:37346955	T/C	cg14294708	chr9:37120828	ZCCHC7	1.14	13.84	0.82	1.66e-24	Schizophrenia;
THYM	cis	rs4769475	0.912	rs9512129	chr13:26733047	C/T	cg13319468	chr13:27597730	NA	-0.63	-5.07	-0.46	1.96e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg05901451	chr6:126070800	HEY2	-0.55	-4.61	-0.43	1.27e-5	Endometrial cancer;
THYM	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs995000	0.931	rs10889350	chr1:63085266	C/T	cg06896770	chr1:63153194	DOCK7	0.92	7.57	0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs9595908	1.000	rs7332763	chr13:33147888	T/G	cg12383807	chr13:33924137	NA	-0.55	-4.87	-0.45	4.38e-6	Body mass index;
THYM	cis	rs2069036	0.951	rs6602074	chr10:16094113	G/A	cg26633223	chr10:15133461	NA	0.66	4.65	0.43	1.08e-5	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs116095464	0.867	rs10061296	chr5:312253	G/A	cg22857025	chr5:266934	NA	-1.37	-5.17	-0.47	1.3e-6	Breast cancer;
THYM	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg21475434	chr5:93447410	FAM172A	0.71	4.51	0.42	1.83e-5	Diabetic retinopathy;
THYM	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg18477163	chr1:228402036	OBSCN	-0.43	-4.69	-0.43	8.96e-6	Diastolic blood pressure;
THYM	cis	rs2811415	0.597	rs9834124	chr3:127741260	C/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg04944784	chr2:26401820	FAM59B	-1.05	-8.18	-0.64	1.23e-12	Gut microbiome composition (summer);
THYM	cis	rs885814	0.960	rs12128419	chr1:21864879	T/C	cg14781605	chr1:21864896	ALPL	-0.68	-5.14	-0.47	1.44e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.61	4.82	0.44	5.41e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg22166914	chr1:53195759	ZYG11B	0.91	10.7	0.74	5.4e-18	Monocyte count;
THYM	cis	rs28595532	0.920	rs115797971	chr4:119779620	A/G	cg21605333	chr4:119757512	SEC24D	1.67	6.17	0.53	1.69e-8	Cannabis dependence symptom count;
THYM	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg09260853	chr1:2094483	PRKCZ	0.47	4.84	0.44	4.99e-6	Height;
THYM	cis	rs765787	0.530	rs11636404	chr15:45535861	C/G	cg24006582	chr15:45444508	DUOX1	-0.84	-7.2	-0.59	1.39e-10	Uric acid levels;
THYM	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg20891558	chr2:74357851	NA	1.23	11.42	0.76	1.5700000000000001e-19	Gestational age at birth (maternal effect);
THYM	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.62	-4.94	-0.45	3.28e-6	Lung cancer;
THYM	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg07959070	chr22:50026188	C22orf34	-0.25	-4.68	-0.43	9.42e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1018697	0.518	rs2482506	chr10:104563743	C/G	cg04362960	chr10:104952993	NT5C2	-0.73	-5.09	-0.46	1.78e-6	Colorectal adenoma (advanced);
THYM	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Body mass index;
THYM	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.34	-0.48	6.24e-7	Monocyte percentage of white cells;
THYM	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg13852791	chr20:30311386	BCL2L1	0.79	5.87	0.52	6.5e-8	Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2235649	0.704	rs1742425	chr16:1904524	G/A	cg03034668	chr16:1723424	CRAMP1L	-0.63	-4.91	-0.45	3.8e-6	Blood metabolite levels;
THYM	cis	rs62103177	0.535	rs34299914	chr18:77949236	C/A	cg07235805	chr18:78004237	PARD6G	0.54	6.55	0.56	2.98e-9	Opioid sensitivity;
THYM	cis	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg10856724	chr12:34555212	NA	-0.91	-9.08	-0.68	1.57e-14	Morning vs. evening chronotype;
THYM	cis	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg09549813	chr16:4587862	C16orf5	-0.59	-6.65	-0.56	1.84e-9	Schizophrenia;
THYM	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg15448220	chr1:150897856	SETDB1	0.9	7.49	0.61	3.57e-11	Melanoma;
THYM	cis	rs10911251	0.508	rs2296297	chr1:183105324	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.81	0.44	5.7e-6	Colorectal cancer;
THYM	cis	rs4866334	0.850	rs75263301	chr5:18463357	T/G	cg18608440	chr5:17519013	NA	1.21	5.31	0.48	7.19e-7	IgG glycosylation;
THYM	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg18538332	chr22:24372958	LOC391322	-1.05	-13.05	-0.8	6.64e-23	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg20887711	chr4:1340912	KIAA1530	0.67	5.71	0.51	1.31e-7	Longevity;
THYM	cis	rs6466832	0.568	rs17144752	chr7:122359692	A/G	cg22586324	chr7:123296098	LMOD2	0.85	4.66	0.43	1.01e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4866334	1.000	rs77695209	chr5:18483369	T/C	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs3847687	1.000	rs78233646	chr12:131520170	G/T	cg25772418	chr12:131519998	GPR133	-0.49	-7.31	-0.6	8.17e-11	Longevity;
THYM	cis	rs13256369	0.511	rs7012395	chr8:8538009	T/C	cg17143192	chr8:8559678	CLDN23	-0.74	-5.01	-0.46	2.49e-6	Obesity-related traits;
THYM	cis	rs4595586	0.505	rs12827467	chr12:39374014	A/G	cg13010199	chr12:38710504	ALG10B	0.61	4.65	0.43	1.05e-5	Morning vs. evening chronotype;
THYM	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs4845459	0.967	rs1886734	chr1:152591142	A/C	cg27206522	chr1:152595629	LCE3A	-0.51	-4.54	-0.42	1.66e-5	Psoriasis;
THYM	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg12908607	chr1:44402522	ARTN	-0.52	-4.67	-0.43	9.88e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11792861	0.505	rs12377869	chr9:111907803	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	4.99	0.46	2.69e-6	Menarche (age at onset);
THYM	cis	rs3796352	1.000	rs35163227	chr3:53127876	A/G	cg07884673	chr3:53033167	SFMBT1	1.03	4.98	0.46	2.8e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg25427524	chr10:38739819	LOC399744	-0.64	-5.9	-0.52	5.56e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg24812749	chr6:127587940	RNF146	0.97	7.72	0.62	1.14e-11	Breast cancer;
THYM	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg06074448	chr4:187884817	NA	1.0	13.81	0.82	1.9e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs9359856	0.564	rs72917989	chr6:90470385	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs6570726	0.526	rs4896805	chr6:145735429	C/A	cg23711669	chr6:146136114	FBXO30	-0.6	-4.79	-0.44	6.15e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg21609526	chr1:3105151	PRDM16	-0.66	-5.56	-0.5	2.52e-7	Migraine;
THYM	cis	rs10911232	0.507	rs4072709	chr1:183028855	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs2041895	0.527	rs10861681	chr12:107334262	C/T	cg26297688	chr12:107349093	C12orf23	-0.5	-5.5	-0.49	3.13e-7	Glaucoma (low intraocular pressure);
THYM	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg23791538	chr6:167370224	RNASET2	0.58	4.53	0.42	1.72e-5	Crohn's disease;
THYM	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg09436375	chr6:42928200	GNMT	-0.43	-5.63	-0.5	1.82e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6575793	1.000	rs7141087	chr14:101036052	T/C	cg13673514	chr14:101035818	BEGAIN	-0.48	-4.51	-0.42	1.87e-5	Menarche (age at onset);
THYM	cis	rs28595532	1.000	rs116030177	chr4:119650768	T/C	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg10760299	chr15:45669010	GATM	0.72	5.03	0.46	2.27e-6	Homoarginine levels;
THYM	cis	rs4343996	0.869	rs6651070	chr7:3465411	G/C	cg21248987	chr7:3385318	SDK1	0.39	4.66	0.43	1.03e-5	Motion sickness;
THYM	cis	rs13315871	0.929	rs11720747	chr3:58267833	G/A	cg12435725	chr3:58293450	RPP14	-0.54	-5.71	-0.51	1.3e-7	Cholesterol, total;
THYM	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06873352	chr17:61820015	STRADA	0.56	5.63	0.5	1.81e-7	Height;
THYM	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg00071950	chr4:10020882	SLC2A9	-0.75	-7.49	-0.61	3.45e-11	Bone mineral density;
THYM	cis	rs8114671	0.967	rs6142322	chr20:33788538	C/A	cg08999081	chr20:33150536	PIGU	-0.52	-4.68	-0.43	9.4e-6	Height;
THYM	cis	rs79387448	0.505	rs17027327	chr2:103122513	C/A	cg09003973	chr2:102972529	NA	0.76	4.68	0.43	9.37e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs2811415	0.597	rs13092555	chr3:127738638	T/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs4243830	0.850	rs4434862	chr1:6602241	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.11	-7.56	-0.61	2.57e-11	Body mass index;
THYM	trans	rs629535	0.814	rs55873935	chr8:70081646	G/A	cg21567404	chr3:27674614	NA	-1.09	-10.28	-0.73	4.24e-17	Dupuytren's disease;
THYM	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg02221750	chr19:17393354	ANKLE1	0.94	8.56	0.66	1.92e-13	Systemic lupus erythematosus;
THYM	cis	rs11696501	0.688	rs8123346	chr20:44309987	A/T	cg11783356	chr20:44313418	WFDC10B	-0.66	-4.49	-0.42	1.97e-5	Brain structure;
THYM	cis	rs6840360	0.642	rs2709822	chr4:152351500	A/G	cg17479576	chr4:152424074	FAM160A1	-0.74	-5.66	-0.5	1.6e-7	Intelligence (multi-trait analysis);
THYM	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg26446133	chr18:72167187	CNDP2	-1.01	-7.92	-0.63	4.47e-12	Refractive error;
THYM	cis	rs7267979	1.000	rs2482931	chr20:25334445	G/A	cg08601574	chr20:25228251	PYGB	-0.58	-4.71	-0.43	8.54e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs11096990	0.634	rs6829064	chr4:39291812	G/A	cg24403649	chr4:39172243	NA	-0.64	-5.48	-0.49	3.43e-7	Cognitive function;
THYM	cis	rs924712	0.674	rs2207026	chr6:54763173	T/C	cg04690482	chr6:54711388	FAM83B	0.44	5.22	0.47	1.03e-6	Breast cancer;
THYM	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg04518342	chr5:131593106	PDLIM4	0.47	5.06	0.46	2.05e-6	Blood metabolite levels;
THYM	cis	rs2637266	1.000	rs7896379	chr10:78366247	C/T	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs9644630	0.504	rs62496181	chr8:19318989	A/T	cg06562184	chr8:19319451	CSGALNACT1	0.61	5.52	0.49	2.88e-7	Oropharynx cancer;
THYM	cis	rs9399401	0.667	rs6903424	chr6:142699948	A/C	cg04461802	chr6:142623433	GPR126	0.69	7.1	0.59	2.27e-10	Chronic obstructive pulmonary disease;
THYM	cis	rs8030379	0.811	rs7162542	chr15:84514290	C/G	cg15564896	chr15:84287328	SH3GL3	0.64	5.12	0.47	1.6e-6	Waist circumference adjusted for body mass index;Waist circumference;
THYM	cis	rs17122693	1.000	rs72679549	chr14:51050822	G/A	cg04730355	chr14:51134070	SAV1	0.97	4.72	0.44	8.06e-6	Cognitive performance;
THYM	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg25703541	chr22:24373054	LOC391322	-0.84	-8.79	-0.67	6.37e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg10911889	chr6:126070802	HEY2	0.59	4.73	0.44	7.77e-6	Brugada syndrome;
THYM	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg01097406	chr16:89675127	NA	0.53	4.76	0.44	6.95e-6	Hemoglobin concentration;
THYM	cis	rs6035126	1.000	rs6045603	chr20:1929582	C/G	cg07210840	chr20:1927816	NA	0.97	4.54	0.42	1.62e-5	Liver enzyme levels (alanine transaminase);
THYM	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg12923728	chr3:195709715	SDHAP1	-0.78	-6.47	-0.55	4.3e-9	Pancreatic cancer;
THYM	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg23574427	chr4:122746245	BBS7;CCNA2	-0.56	-5.0	-0.46	2.56e-6	Type 2 diabetes;
THYM	cis	rs910187	0.591	rs13041142	chr20:45788979	C/T	cg27589058	chr20:45804311	EYA2	-0.54	-4.52	-0.42	1.79e-5	Migraine;
THYM	cis	rs2625529	0.652	rs2929525	chr15:72287856	G/A	cg16672083	chr15:72433130	SENP8	0.51	4.71	0.44	8.47e-6	Red blood cell count;
THYM	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	7.27	0.6	9.96e-11	Platelet count;
THYM	cis	rs9677476	0.731	rs28690417	chr2:232064182	G/A	cg07929768	chr2:232055508	NA	0.59	5.09	0.46	1.79e-6	Food antigen IgG levels;
THYM	trans	rs2270927	1.000	rs31243	chr5:75594360	A/G	cg13563193	chr19:33072644	PDCD5	1.54	8.76	0.67	7.21e-14	Mean corpuscular volume;
THYM	cis	rs4731207	0.596	rs1600739	chr7:124639606	A/G	cg05285228	chr7:124571219	POT1	0.7	5.28	0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg23803603	chr1:2058230	PRKCZ	-0.58	-4.95	-0.45	3.22e-6	Height;
THYM	cis	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg06636001	chr8:8085503	FLJ10661	0.71	6.45	0.55	4.58e-9	Joint mobility (Beighton score);
THYM	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg27494647	chr7:150038898	RARRES2	0.46	5.81	0.51	8.13e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6840360	0.582	rs2724553	chr4:152321881	T/C	cg22705602	chr4:152727874	NA	-0.52	-5.22	-0.47	1.03e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3112255	0.517	rs10180350	chr2:101336803	G/A	cg01042948	chr2:101319752	NA	0.56	5.36	0.48	5.91e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg02725872	chr8:58115012	NA	-1.11	-8.56	-0.66	1.98e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	5.41	0.49	4.67e-7	Platelet count;
THYM	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg08772003	chr10:104629869	AS3MT	-0.61	-5.2	-0.47	1.15e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg22718636	chr4:961658	DGKQ	0.58	4.53	0.42	1.7e-5	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
THYM	cis	rs9796	0.689	rs28409432	chr15:41447454	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.59	-4.67	-0.43	9.71e-6	Menopause (age at onset);
THYM	cis	rs453301	0.574	rs10081437	chr8:8948979	T/C	cg06636001	chr8:8085503	FLJ10661	-0.64	-5.21	-0.47	1.1e-6	Joint mobility (Beighton score);
THYM	cis	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg11336294	chr1:197115979	ASPM	0.7	4.59	0.43	1.35e-5	Depressive symptoms;
THYM	cis	rs17407555	0.647	rs55811736	chr4:10014221	G/A	cg13000635	chr4:9523653	NA	0.67	4.56	0.42	1.52e-5	Schizophrenia (age at onset);
THYM	cis	rs6952809	0.532	rs6953297	chr7:2440874	C/G	cg23289794	chr7:2394357	EIF3B	-0.76	-4.72	-0.44	8.17e-6	Multiple sclerosis;
THYM	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs317689	0.600	rs478863	chr12:69639207	G/A	cg20891283	chr12:69753455	YEATS4	0.62	4.55	0.42	1.59e-5	Response to diuretic therapy;
THYM	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg24531977	chr5:56204891	C5orf35	0.67	5.42	0.49	4.52e-7	Initial pursuit acceleration;
THYM	cis	rs6750795	0.765	rs6742387	chr2:232354832	G/T	cg19187155	chr2:232395269	NMUR1	0.86	7.76	0.62	9.62e-12	Height;
THYM	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg05335186	chr13:53173507	NA	0.53	6.8	0.57	9.37e-10	Lewy body disease;
THYM	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	7.27	0.6	9.98e-11	Smoking behavior;
THYM	cis	rs2299587	0.689	rs1847154	chr8:17780338	A/G	cg01800426	chr8:17659068	MTUS1	-0.57	-4.59	-0.43	1.38e-5	Economic and political preferences;
THYM	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg09307838	chr4:120376055	NA	0.77	5.56	0.5	2.5e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg24818145	chr4:99064322	C4orf37	0.69	5.37	0.48	5.48e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg26384229	chr12:38710491	ALG10B	-0.91	-7.22	-0.6	1.26e-10	Bladder cancer;
THYM	cis	rs338419	0.786	rs72742010	chr15:60482372	G/A	cg02404349	chr15:60862256	RORA	0.67	4.55	0.42	1.61e-5	Blood protein levels;
THYM	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg06634786	chr22:41940651	POLR3H	0.71	4.98	0.46	2.8e-6	Crohn's disease;Inflammatory bowel disease;
THYM	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.87	-0.82	1.48e-24	Height;
THYM	cis	rs6087990	0.765	rs6058900	chr20:31400673	T/C	cg13636640	chr20:31349939	DNMT3B	0.84	8.86	0.67	4.51e-14	Ulcerative colitis;
THYM	cis	rs17641971	0.684	rs7011891	chr8:49983538	A/C	cg00325661	chr8:49890786	NA	0.6	4.79	0.44	6.24e-6	Blood metabolite levels;
THYM	cis	rs7404928	0.651	rs3785390	chr16:23956658	T/C	cg26685404	chr16:23957272	PRKCB	0.68	8.12	0.64	1.7e-12	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs28595532	0.920	rs116739193	chr4:119771024	G/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg10047753	chr17:41438598	NA	1.19	11.15	0.75	5.97e-19	Menopause (age at onset);
THYM	cis	rs1535500	0.905	rs2146262	chr6:39283793	C/T	cg00012638	chr6:39280541	KCNK17	0.56	7.44	0.61	4.53e-11	Type 2 diabetes;
THYM	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg03859395	chr2:55845619	SMEK2	0.6	5.52	0.49	2.95e-7	Metabolic syndrome;
THYM	trans	rs629535	0.773	rs568159	chr8:70032908	C/G	cg21567404	chr3:27674614	NA	1.12	10.86	0.74	2.44e-18	Dupuytren's disease;
THYM	cis	rs7172809	0.599	rs2307141	chr15:77756418	A/G	cg22256960	chr15:77711686	NA	-0.61	-4.47	-0.42	2.18e-5	Glucose homeostasis traits;
THYM	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg06618935	chr21:46677482	NA	-0.99	-9.28	-0.69	5.6e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11671005	0.568	rs73068329	chr19:59080325	C/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.62	-4.95	-0.45	3.16e-6	Mean platelet volume;
THYM	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	5.72	0.51	1.23e-7	Platelet count;
THYM	trans	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg20587970	chr11:113659929	NA	-1.26	-9.15	-0.68	1.07e-14	Hip circumference adjusted for BMI;
THYM	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg04154034	chr17:28927549	LRRC37B2	0.88	4.53	0.42	1.73e-5	Body mass index;
THYM	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.38	0.6	5.91e-11	Morning vs. evening chronotype;
THYM	cis	rs12532960	0.642	rs2190516	chr7:42378019	A/C	cg23473276	chr7:42834405	NA	0.99	4.65	0.43	1.08e-5	Inflammatory biomarkers;
THYM	cis	rs631288	0.793	rs10900331	chr1:146733128	C/G	cg25205988	chr1:146714368	CHD1L	1.18	4.7	0.43	8.71e-6	PR interval in Tripanosoma cruzi seropositivity;
THYM	cis	rs420259	0.516	rs531805	chr16:23466035	C/T	cg00143387	chr16:23521605	GGA2	0.8	5.77	0.51	9.71e-8	Bipolar disorder;
THYM	cis	rs7084402	0.967	rs2438182	chr10:60314815	A/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs9534288	0.762	rs1571053	chr13:46554854	G/A	cg15192986	chr13:46630673	CPB2	-0.6	-4.52	-0.42	1.8e-5	Blood protein levels;
THYM	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg04918696	chr8:1004106	NA	-0.43	-4.75	-0.44	7.23e-6	Schizophrenia;
THYM	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06634786	chr22:41940651	POLR3H	-0.76	-5.64	-0.5	1.71e-7	Vitiligo;
THYM	cis	rs6121246	0.567	rs6120890	chr20:30207659	T/G	cg21427119	chr20:30132790	HM13	-0.84	-5.75	-0.51	1.1e-7	Mean corpuscular hemoglobin;
THYM	cis	rs4845875	0.626	rs10779764	chr1:11832311	G/C	cg24844545	chr1:11908347	NPPA	0.45	4.6	0.43	1.28e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.11	0.46	1.64e-6	Obesity-related traits;
THYM	cis	rs34783982	0.881	rs34286613	chr15:89496283	G/C	cg26213453	chr15:89455860	MFGE8	0.49	4.5	0.42	1.9e-5	Squamous cell lung carcinoma;
THYM	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg17775962	chr7:1200435	ZFAND2A	0.42	5.16	0.47	1.32e-6	Longevity;Endometriosis;
THYM	cis	rs892961	0.932	rs3987887	chr17:75414862	T/C	cg05865280	chr17:75406074	SEPT9	0.48	8.22	0.64	1.06e-12	Airflow obstruction;
THYM	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg12564285	chr5:131593104	PDLIM4	0.44	4.76	0.44	6.83e-6	Breast cancer;
THYM	cis	rs6500395	1.000	rs11641458	chr16:48670845	C/T	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg18681998	chr4:17616180	MED28	0.99	10.18	0.72	6.74e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs36051895	0.664	rs3780369	chr9:5095095	A/C	cg02405213	chr9:5042618	JAK2	-1.0	-10.94	-0.75	1.67e-18	Pediatric autoimmune diseases;
THYM	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg02317251	chr4:10116515	WDR1	-0.56	-4.95	-0.45	3.23e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs7523273	0.606	rs1474742	chr1:207976666	A/C	cg22525895	chr1:207977042	MIR29B2	0.95	10.15	0.72	8.09e-17	Schizophrenia;
THYM	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg13395646	chr4:1353034	KIAA1530	-0.61	-6.01	-0.52	3.45e-8	Longevity;
THYM	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06873352	chr17:61820015	STRADA	0.56	5.63	0.5	1.84e-7	Height;
THYM	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg04282206	chr17:62833786	PLEKHM1P	0.82	7.53	0.61	2.9100000000000002e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs13242816	1.000	rs73208106	chr7:116173263	G/A	cg16553024	chr7:116138462	CAV2	-1.25	-5.56	-0.5	2.5e-7	P wave duration;
THYM	cis	rs6032067	0.929	rs55726011	chr20:43855229	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.72	-7.65	-0.62	1.6e-11	Blood protein levels;
THYM	cis	rs34375054	0.525	rs10846829	chr12:125595058	G/C	cg25124228	chr12:125621409	AACS	-0.83	-6.96	-0.58	4.33e-10	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg27494647	chr7:150038898	RARRES2	0.43	5.35	0.48	6.01e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg18252515	chr7:66147081	NA	-0.89	-6.7	-0.57	1.46e-9	Corneal structure;
THYM	cis	rs321358	0.731	rs576877	chr11:111018196	G/A	cg19541147	chr11:111957761	TIMM8B;SDHD	-0.68	-4.51	-0.42	1.86e-5	Body mass index;
THYM	cis	rs9565309	0.579	rs9573972	chr13:77569672	T/C	cg13866767	chr13:78470850	EDNRB	0.93	4.51	0.42	1.85e-5	Morning vs. evening chronotype;
THYM	cis	rs7187994	0.515	rs7199123	chr16:84776178	A/T	cg26765084	chr16:85018922	ZDHHC7	-0.45	-4.66	-0.43	1.04e-5	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs2141079	0.509	rs17387330	chr1:54119578	G/A	cg00454274	chr1:54200587	GLIS1	0.32	4.49	0.42	2e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg20966754	chr17:47091339	IGF2BP1	-0.57	-7.19	-0.59	1.45e-10	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg27588902	chr6:42928151	GNMT	-0.56	-5.77	-0.51	1.01e-7	Plasma homocysteine levels (post-methionine load test);
THYM	cis	rs72627123	0.867	rs73303107	chr14:74477284	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs4919044	0.733	rs12413378	chr10:94759305	A/G	cg05127821	chr10:94822908	CYP26C1	-1.19	-5.88	-0.52	6.17e-8	Coronary artery disease;
THYM	cis	rs6598955	0.671	rs11247914	chr1:26648838	G/T	cg16068833	chr1:26644515	UBXN11;CD52	0.29	4.71	0.44	8.45e-6	Obesity-related traits;
THYM	cis	rs7575217	0.767	rs28371411	chr2:101754723	C/T	cg23907051	chr2:101730305	TBC1D8	-0.41	-5.5	-0.49	3.25e-7	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg03806693	chr22:41940476	POLR3H	-1.04	-7.62	-0.62	1.86e-11	Vitiligo;
THYM	cis	rs2458413	0.500	rs2514666	chr8:105351943	C/T	cg21295575	chr8:105352067	TM7SF4	-0.37	-5.34	-0.48	6.2e-7	Paget's disease;
THYM	cis	rs1403694	0.515	rs5030058	chr3:186452415	T/G	cg12454167	chr3:186435060	KNG1	0.46	6.08	0.53	2.55e-8	Blood protein levels;
THYM	cis	rs7084402	0.967	rs1649030	chr10:60279830	G/A	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs651907	0.935	rs2926538	chr3:101587585	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	5.12	0.46	1.6e-6	Colorectal cancer;
THYM	cis	rs981844	0.961	rs62325108	chr4:154679767	G/A	cg09973105	chr4:154681532	RNF175	-0.63	-4.87	-0.45	4.39e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg22508957	chr16:3507546	NAT15	0.7	7.9	0.63	4.94e-12	Tuberculosis;
THYM	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg14008862	chr17:28927542	LRRC37B2	0.88	4.47	0.42	2.17e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg06970220	chr1:156163860	SLC25A44	0.71	5.52	0.49	2.91e-7	Testicular germ cell tumor;
THYM	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg19774624	chr17:42201019	HDAC5	0.66	5.75	0.51	1.1e-7	Total body bone mineral density;
THYM	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs7584330	0.554	rs3751111	chr2:238426953	G/T	cg14458575	chr2:238380390	NA	0.79	4.65	0.43	1.06e-5	Prostate cancer;
THYM	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg13609457	chr4:120235615	NA	-0.51	-4.8	-0.44	5.83e-6	Corneal astigmatism;
THYM	cis	rs10924970	0.967	rs4659784	chr1:235482463	C/T	cg26050004	chr1:235667680	B3GALNT2	0.59	4.48	0.42	2.06e-5	Asthma;
THYM	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg07606381	chr6:8435919	SLC35B3	0.63	4.67	0.43	9.8e-6	Motion sickness;
THYM	cis	rs7106204	0.748	rs7101572	chr11:24213982	A/G	ch.11.24196551F	chr11:24239977	NA	0.99	7.0	0.58	3.64e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs13253111	1.000	rs62500888	chr8:28061823	A/G	cg26534493	chr8:28060551	NA	-0.53	-4.79	-0.44	6.2e-6	Childhood body mass index;
THYM	cis	rs7572733	0.534	rs700687	chr2:198721560	A/T	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs35883536	0.967	rs4908090	chr1:101135177	A/G	cg06223162	chr1:101003688	GPR88	0.67	5.2	0.47	1.14e-6	Monocyte count;
THYM	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg10515332	chr4:99064459	C4orf37	0.67	5.33	0.48	6.48e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2806561	0.734	rs667211	chr1:23516142	T/C	cg19743168	chr1:23544995	NA	0.55	5.64	0.5	1.77e-7	Height;
THYM	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	8.11	0.64	1.75e-12	Lung cancer in ever smokers;
THYM	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg05283184	chr6:79620031	NA	-0.94	-8.49	-0.66	2.83e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6669072	0.647	rs814546	chr1:91239355	G/T	cg08895590	chr1:91227319	NA	-0.65	-8.27	-0.65	8.27e-13	Cognitive function;
THYM	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg13852791	chr20:30311386	BCL2L1	0.67	4.76	0.44	7.04e-6	Mean corpuscular hemoglobin;
THYM	cis	rs78382112	0.504	rs6684423	chr1:181560367	G/T	cg22019955	chr1:182297893	NA	-0.75	-4.61	-0.43	1.27e-5	Intelligence (multi-trait analysis);
THYM	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg19418458	chr7:158789849	NA	-0.6	-5.69	-0.5	1.39e-7	Facial morphology (factor 20);
THYM	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.9	-9.4	-0.69	3.1e-15	Chronic sinus infection;
THYM	cis	rs240764	0.853	rs2062635	chr6:101002659	G/A	cg21058520	chr6:100914733	NA	0.57	5.07	0.46	1.95e-6	Neuroticism;
THYM	cis	rs2702888	0.503	rs2702931	chr8:6758979	A/C	cg26795848	chr8:6756730	NA	-0.67	-6.06	-0.53	2.73e-8	Blood pressure;
THYM	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg23187316	chr7:1099788	C7orf50	0.59	4.52	0.42	1.76e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4788570	0.547	rs6499538	chr16:71762285	A/C	cg06353428	chr16:71660113	MARVELD3	1.34	8.71	0.67	9.43e-14	Intelligence (multi-trait analysis);
THYM	cis	rs4523957	0.583	rs2641444	chr17:2037402	T/C	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4849845	0.925	rs6723584	chr2:121011162	T/C	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg26736099	chr17:61989275	CSHL1	0.28	4.47	0.42	2.2e-5	Prudent dietary pattern;
THYM	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg23161317	chr6:28129485	ZNF389	0.8	5.63	0.5	1.86e-7	Parkinson's disease;
THYM	cis	rs7953508	0.636	rs10859535	chr12:93979892	A/G	cg18151635	chr12:93972918	NA	-0.76	-5.26	-0.48	8.81e-7	Pubertal anthropometrics;
THYM	cis	rs877282	0.583	rs11595057	chr10:819203	A/C	cg10556349	chr10:835070	NA	-0.69	-4.57	-0.42	1.47e-5	Uric acid levels;
THYM	cis	rs6840360	0.593	rs59350867	chr4:152695935	G/A	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs9296092	0.517	rs76361685	chr6:33536458	G/C	cg13560919	chr6:33536144	NA	-0.93	-9.1	-0.68	1.38e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs936229	0.861	rs3935077	chr15:75120211	C/G	cg14664628	chr15:75095509	CSK	-1.13	-10.16	-0.72	7.47e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs673253	0.556	rs35290231	chr1:44103033	G/A	cg09903430	chr1:44172605	ST3GAL3	-0.5	-4.54	-0.42	1.65e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3126085	0.935	rs10888473	chr1:152220235	G/A	cg26020982	chr1:152196106	HRNR	0.34	4.52	0.42	1.76e-5	Atopic dermatitis;
THYM	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-5.65	-0.5	1.71e-7	Gut microbiome composition (summer);
THYM	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	4.47	0.42	2.13e-5	Alzheimer's disease;
THYM	cis	rs3733631	1.000	rs6831087	chr4:104619090	C/A	cg24090629	chr4:104641072	TACR3	-0.87	-5.51	-0.49	3.08e-7	Menarche (age at onset);
THYM	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs87938	0.863	rs6772565	chr3:41157267	A/G	cg02247160	chr3:41243829	CTNNB1	-0.34	-4.56	-0.42	1.53e-5	Bone mineral density (hip);
THYM	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.48	-4.86	-0.45	4.64e-6	Crohn's disease;
THYM	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg06108461	chr20:60628389	TAF4	-0.97	-7.44	-0.61	4.49e-11	Body mass index;
THYM	cis	rs12922040	1.000	rs12922040	chr16:15869466	C/T	cg01933576	chr16:15083564	PDXDC1	0.61	4.79	0.44	6.23e-6	Serum uric acid levels in response to allopurinol in gout;
THYM	cis	rs73787773	0.867	rs7731129	chr5:111495510	C/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.88	-4.76	-0.44	6.87e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg16414030	chr3:133502952	NA	0.84	8.35	0.65	5.49e-13	Iron status biomarkers;
THYM	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg22841779	chr14:105766346	BRF1	-0.46	-5.72	-0.51	1.25e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9788682	0.747	rs3743078	chr15:78894759	C/G	cg18825076	chr15:78729989	IREB2	-0.57	-4.52	-0.42	1.77e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg02725872	chr8:58115012	NA	-1.11	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-4.96	-0.45	3.03e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs11078597	0.614	rs62090057	chr17:1645526	C/T	cg18436246	chr17:1640651	WDR81	0.64	4.63	0.43	1.14e-5	Serum albumin level;
THYM	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7107174	1.000	rs10793302	chr11:78040961	C/T	cg02023728	chr11:77925099	USP35	0.67	6.46	0.55	4.53e-9	Testicular germ cell tumor;
THYM	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg12011299	chr4:100065546	ADH4	0.69	6.2	0.54	1.46e-8	Alcohol dependence;
THYM	cis	rs6543140	0.964	rs7561351	chr2:103077780	A/G	cg03938978	chr2:103052716	IL18RAP	0.58	5.84	0.51	7.16e-8	Blood protein levels;
THYM	cis	rs11031096	0.711	rs10835694	chr11:4178757	G/C	cg08557956	chr11:4115526	RRM1	-0.52	-4.68	-0.43	9.36e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg08470875	chr2:26401718	FAM59B	0.74	4.59	0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg13683864	chr3:40499215	RPL14	-0.87	-8.34	-0.65	5.88e-13	Renal cell carcinoma;
THYM	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	8.23	0.65	9.9e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg17105886	chr17:28927953	LRRC37B2	1.32	6.56	0.56	2.79e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3916	0.955	rs35525135	chr12:121140064	T/C	cg21892295	chr12:121157589	UNC119B	-0.53	-5.18	-0.47	1.25e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs600806	0.850	rs10858095	chr1:109962642	G/C	cg23616212	chr1:109941201	SORT1	-0.51	-4.75	-0.44	7.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9913156	0.793	rs72835644	chr17:4573667	G/A	cg19197139	chr17:4613644	ARRB2	0.82	4.96	0.45	3.05e-6	Lymphocyte counts;
THYM	cis	rs9311676	0.656	rs56028017	chr3:58372508	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs34779708	0.966	rs35814343	chr10:35427714	G/T	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.34	-0.48	6.28e-7	Menopause (age at onset);
THYM	cis	rs6956675	0.915	rs1608134	chr7:62653607	A/C	cg27518014	chr7:62859535	LOC100287834	0.61	5.07	0.46	2e-6	Obesity-related traits;
THYM	cis	rs1003719	0.788	rs11911508	chr21:38470504	T/C	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs7683537	0.692	rs56368159	chr4:185654827	T/G	cg04058563	chr4:185651563	MLF1IP	1.09	7.62	0.62	1.92e-11	Systemic lupus erythematosus;
THYM	cis	rs7980799	0.682	rs1601005	chr12:33634658	A/G	cg10856724	chr12:34555212	NA	0.61	4.55	0.42	1.56e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs3847687	1.000	rs3847687	chr12:131525053	C/T	cg13586425	chr12:131519906	GPR133	-0.32	-5.18	-0.47	1.26e-6	Longevity;
THYM	cis	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs7107770	1.000	rs66665027	chr11:125109381	A/G	cg04164023	chr11:125106101	PKNOX2	-0.86	-4.87	-0.45	4.48e-6	Photic sneeze reflex;
THYM	cis	rs4474465	1.000	rs11237495	chr11:78155090	A/G	cg19901956	chr11:77921274	USP35	-0.62	-4.63	-0.43	1.15e-5	Alzheimer's disease (survival time);
THYM	cis	rs4660306	0.961	rs1494813	chr1:45957290	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.43	-0.49	4.37e-7	Homocysteine levels;
THYM	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg24375607	chr4:120327624	NA	0.67	5.44	0.49	4.06e-7	Corneal astigmatism;
THYM	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7610301	1.000	rs35795952	chr3:46645694	C/T	cg10242476	chr3:46619364	LRRC2;TDGF1	0.45	4.48	0.42	2.07e-5	Blood protein levels;
THYM	cis	rs2276498	0.751	rs6127062	chr20:52636755	C/T	cg23682609	chr20:52687365	BCAS1	0.59	5.03	0.46	2.29e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs13082711	0.522	rs820617	chr3:27335510	T/C	cg02860705	chr3:27208620	NA	0.65	5.19	0.47	1.21e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs7127900	0.950	rs7121039	chr11:2232911	C/G	cg25635251	chr11:2234043	NA	0.74	4.71	0.44	8.43e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg07061783	chr6:25882402	NA	-0.86	-7.58	-0.61	2.3e-11	Intelligence (multi-trait analysis);
THYM	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg15110403	chr19:17392923	ANKLE1	-0.57	-5.04	-0.46	2.26e-6	Systemic lupus erythematosus;
THYM	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg10360139	chr7:1886902	MAD1L1	-0.6	-5.18	-0.47	1.27e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	6.0	0.52	3.54e-8	Hip circumference adjusted for BMI;
THYM	cis	rs12935418	0.616	rs1469123	chr16:81029549	A/G	cg16651780	chr16:81037892	C16orf61	-0.81	-6.26	-0.54	1.09e-8	Mean corpuscular volume;
THYM	cis	rs7178572	0.568	rs12901739	chr15:77395491	C/T	cg22256960	chr15:77711686	NA	-0.93	-7.23	-0.6	1.24e-10	Type 2 diabetes;
THYM	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg09549813	chr16:4587862	C16orf5	0.55	6.19	0.54	1.55e-8	Schizophrenia;
THYM	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg08847533	chr14:75593920	NEK9	1.02	11.25	0.76	3.61e-19	Height;
THYM	cis	rs4595586	0.545	rs11611625	chr12:39387207	T/C	cg26384229	chr12:38710491	ALG10B	0.69	5.35	0.48	6.11e-7	Morning vs. evening chronotype;
THYM	cis	rs7172809	0.599	rs74666689	chr15:77786731	C/T	cg10437265	chr15:77819839	NA	-0.5	-4.57	-0.42	1.47e-5	Glucose homeostasis traits;
THYM	cis	rs4523957	0.583	rs2984939	chr17:2023965	T/C	cg16513277	chr17:2031491	SMG6	-0.96	-8.72	-0.67	9.17e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs405460	0.517	rs443654	chr14:59305709	A/C	cg02291164	chr14:59296302	NA	-0.64	-5.7	-0.5	1.33e-7	Obesity-related traits;
THYM	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg02153584	chr22:29168773	CCDC117	-0.6	-4.63	-0.43	1.15e-5	Lymphocyte counts;
THYM	cis	rs742614	0.576	rs2747537	chr20:32405217	A/G	cg06304546	chr20:32448765	NA	-0.95	-9.26	-0.69	6.44e-15	Stearic acid (18:0) levels;
THYM	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg00256281	chr22:41985642	PMM1	0.58	4.92	0.45	3.65e-6	Vitiligo;
THYM	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg02269571	chr22:50332266	NA	-0.71	-4.91	-0.45	3.78e-6	Schizophrenia;
THYM	cis	rs36051895	0.658	rs72699568	chr9:5007138	C/T	cg02405213	chr9:5042618	JAK2	-1.05	-11.29	-0.76	2.95e-19	Pediatric autoimmune diseases;
THYM	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12039431	0.706	rs61779866	chr1:37978897	G/A	cg17933807	chr1:38061675	GNL2	-0.75	-5.48	-0.49	3.45e-7	Epithelial ovarian cancer;
THYM	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg13695892	chr22:41940480	POLR3H	-0.76	-6.43	-0.55	5.02e-9	Vitiligo;
THYM	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg02773041	chr1:40204384	PPIE	0.77	6.01	0.52	3.46e-8	Blood protein levels;
THYM	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg23711669	chr6:146136114	FBXO30	-0.98	-10.47	-0.73	1.68e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs250677	0.522	rs10040798	chr5:148367324	A/G	cg18129178	chr5:148520854	ABLIM3	0.72	5.4	0.48	4.94e-7	Breast cancer;
THYM	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg27121462	chr16:89883253	FANCA	0.57	4.54	0.42	1.65e-5	Vitiligo;
THYM	cis	rs10911232	0.507	rs35782443	chr1:183051502	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs11779988	0.545	rs208753	chr8:17814915	A/G	cg01800426	chr8:17659068	MTUS1	-0.73	-4.96	-0.45	3.13e-6	Breast cancer;
THYM	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg27432699	chr2:27873401	GPN1	0.72	6.3	0.54	9.14e-9	Oral cavity cancer;
THYM	cis	rs13315871	0.858	rs78946071	chr3:58318523	G/T	cg00563845	chr3:58318305	PXK	0.59	5.02	0.46	2.37e-6	Cholesterol, total;
THYM	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs3126085	0.544	rs3126074	chr1:152279841	G/C	cg26020982	chr1:152196106	HRNR	-0.35	-4.95	-0.45	3.26e-6	Atopic dermatitis;
THYM	cis	rs11614913	0.509	rs12300425	chr12:54395082	G/T	cg03037150	chr12:54402717	HOXC8	-0.54	-4.81	-0.44	5.61e-6	Waist circumference adjusted for body mass index;
THYM	cis	rs72627123	0.737	rs72627106	chr14:74312458	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.13	5.88	0.52	5.96e-8	Morning vs. evening chronotype;
THYM	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg08999081	chr20:33150536	PIGU	0.73	6.56	0.56	2.86e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg24209194	chr3:40518798	ZNF619	0.58	4.68	0.43	9.35e-6	Renal cell carcinoma;
THYM	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg13175981	chr1:150552382	MCL1	0.81	6.23	0.54	1.25e-8	Tonsillectomy;
THYM	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs1160297	0.576	rs6754423	chr2:53096730	G/A	cg07782112	chr2:53107842	NA	0.79	6.37	0.55	6.61e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg06238570	chr21:40685208	BRWD1	0.92	6.85	0.57	7.35e-10	Cognitive function;
THYM	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg23791538	chr6:167370224	RNASET2	0.74	5.92	0.52	5.06e-8	Crohn's disease;
THYM	cis	rs4988958	0.565	rs12712146	chr2:103008714	C/T	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma (childhood onset);
THYM	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg03733263	chr8:22462867	KIAA1967	1.16	13.91	0.82	1.23e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.67	0.5	1.54e-7	Obesity-related traits;
THYM	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg26384229	chr12:38710491	ALG10B	1.06	11.01	0.75	1.2e-18	Heart rate;
THYM	cis	rs4919087	0.892	rs10882881	chr10:99010067	T/A	cg19453742	chr10:98862320	SLIT1	-0.61	-4.47	-0.42	2.15e-5	Monocyte count;
THYM	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg17426766	chr1:2046864	PRKCZ	-0.4	-4.62	-0.43	1.21e-5	Height;
THYM	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg11502198	chr6:26597334	ABT1	0.62	5.51	0.49	3.03e-7	Intelligence (multi-trait analysis);
THYM	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg20887711	chr4:1340912	KIAA1530	0.72	6.53	0.56	3.28e-9	Longevity;
THYM	cis	rs10911232	0.507	rs10797816	chr1:182998486	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.6	0.43	1.3e-5	Hypertriglyceridemia;
THYM	cis	rs6987853	0.966	rs1901282	chr8:42392942	C/G	cg09913449	chr8:42400586	C8orf40	0.88	8.02	0.64	2.8e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9527	0.590	rs3861984	chr10:104916980	T/C	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs11886999	1.000	rs61697794	chr2:96902604	C/T	cg18419276	chr2:96971862	SNRNP200	-0.48	-5.41	-0.49	4.64e-7	Cardiac Troponin-T levels;
THYM	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs7264396	0.887	rs736032	chr20:34048661	C/T	cg26038318	chr20:34205095	SPAG4	0.53	4.47	0.42	2.15e-5	Total cholesterol levels;
THYM	cis	rs1335645	0.570	rs2278578	chr1:111659792	G/T	cg00321911	chr1:111669324	DRAM2	-1.38	-8.12	-0.64	1.71e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7681423	0.951	rs35147053	chr4:155517842	A/G	cg20735720	chr4:155535218	FGG	-0.64	-4.95	-0.45	3.22e-6	Fibrinogen;
THYM	cis	rs9297145	0.565	rs12705030	chr7:98765041	A/G	cg05967295	chr7:98741636	SMURF1	-0.72	-5.97	-0.52	4.06e-8	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg05182265	chr7:156933206	UBE3C	0.59	7.11	0.59	2.15e-10	Body mass index;
THYM	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg24675056	chr1:15929824	NA	0.73	5.89	0.52	5.95e-8	Systolic blood pressure;
THYM	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.97	7.98	0.63	3.37e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.76	-4.99	-0.46	2.73e-6	Body mass index;
THYM	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg01579765	chr21:45077557	HSF2BP	-0.5	-7.6	-0.61	2.09e-11	Mean corpuscular volume;
THYM	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg20587970	chr11:113659929	NA	-1.25	-9.01	-0.68	2.13e-14	Hip circumference adjusted for BMI;
THYM	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg27211696	chr2:191398769	TMEM194B	-0.65	-5.18	-0.47	1.26e-6	Diastolic blood pressure;
THYM	cis	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg21775007	chr8:11205619	TDH	-0.65	-5.08	-0.46	1.9e-6	Retinal vascular caliber;
THYM	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	6.55	0.56	2.93e-9	Obesity-related traits;
THYM	cis	rs6547741	0.717	rs2178197	chr2:27860551	C/T	cg27432699	chr2:27873401	GPN1	0.89	8.22	0.64	1.05e-12	Oral cavity cancer;
THYM	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg07167872	chr1:205819463	PM20D1	0.64	4.64	0.43	1.1e-5	Menarche (age at onset);
THYM	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg12165864	chr7:66369176	NA	0.82	6.13	0.53	1.99e-8	Corneal structure;
THYM	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg05872129	chr22:39784769	NA	-0.92	-7.7	-0.62	1.31e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg20744362	chr22:50050164	C22orf34	0.79	6.87	0.58	6.62e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.68	8.72	0.67	9.16e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg00666640	chr1:248458726	OR2T12	0.58	4.72	0.44	8.11e-6	Common traits (Other);
THYM	cis	rs7107770	1.000	rs61911056	chr11:125088380	A/T	cg07747661	chr11:125106135	PKNOX2	-0.82	-5.13	-0.47	1.53e-6	Photic sneeze reflex;
THYM	cis	rs3796352	0.527	rs11716506	chr3:52944328	C/T	cg07884673	chr3:53033167	SFMBT1	0.92	5.5	0.49	3.17e-7	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7394190	0.630	rs78845904	chr10:75517249	C/A	cg07699608	chr10:75541558	CHCHD1	0.91	4.9	0.45	3.9e-6	Incident atrial fibrillation;
THYM	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg18446336	chr7:2847575	GNA12	-0.45	-4.81	-0.44	5.68e-6	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs898549	0.520	rs1352999	chr10:44513936	A/G	cg27599783	chr10:45480162	RASSF4	0.49	4.5	0.42	1.96e-5	Obesity-related traits;
THYM	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.55	-5.23	-0.47	1e-6	Lymphocyte counts;
THYM	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg08132940	chr7:1081526	C7orf50	-1.15	-4.47	-0.42	2.2e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg26384229	chr12:38710491	ALG10B	-0.87	-8.86	-0.67	4.62e-14	Heart rate;
THYM	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	trans	rs480407	0.857	rs270997	chr2:161671391	T/G	cg06548410	chr19:1997657	BTBD2	0.72	7.08	0.59	2.46e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	trans	rs7615952	0.736	rs9866347	chr3:125669925	C/T	cg07211511	chr3:129823064	LOC729375	-1.32	-7.83	-0.63	6.77e-12	Blood pressure (smoking interaction);
THYM	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg26566898	chr11:117069891	TAGLN	0.39	4.92	0.45	3.56e-6	Blood protein levels;
THYM	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg14983838	chr19:29218262	NA	1.09	9.77	0.71	5e-16	Methadone dose in opioid dependence;
THYM	cis	rs67311347	0.544	rs2278929	chr3:40351008	C/G	cg24209194	chr3:40518798	ZNF619	-0.54	-4.64	-0.43	1.11e-5	Renal cell carcinoma;
THYM	cis	rs12579753	0.917	rs7138895	chr12:82203280	T/G	cg21231944	chr12:82153410	PPFIA2	-0.66	-5.01	-0.46	2.51e-6	Resting heart rate;
THYM	cis	rs738321	0.671	rs3761446	chr22:38595483	G/A	cg25457927	chr22:38595422	NA	-0.56	-5.31	-0.48	7.27e-7	Breast cancer;
THYM	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg06808227	chr14:105710500	BRF1	-1.02	-8.64	-0.66	1.35e-13	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	4.75	0.44	7.16e-6	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg25841348	chr2:218032832	NA	0.49	4.57	0.42	1.49e-5	Thyroid cancer;
THYM	cis	rs2237457	0.543	rs2529390	chr7:50701355	G/A	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.42e-6	Schizophrenia (treatment resistant);
THYM	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Body mass index;
THYM	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.53	0.56	3.27e-9	Total body bone mineral density;
THYM	cis	rs561341	0.700	rs886223	chr17:30229877	G/T	cg12000587	chr17:30186630	C17orf79	-0.47	-6.9	-0.58	5.82e-10	Hip circumference adjusted for BMI;
THYM	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs956237	0.966	rs55664149	chr4:109050652	A/C	cg15700776	chr4:108852048	CYP2U1	0.57	4.62	0.43	1.22e-5	Systemic lupus erythematosus;
THYM	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.71	5.28	0.48	8.21e-7	Lung cancer in ever smokers;
THYM	cis	rs13418717	0.793	rs7425345	chr2:127640396	C/T	cg25501666	chr2:127640322	NA	1.51	7.81	0.63	7.64e-12	Heart failure;
THYM	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg18758796	chr5:131593413	PDLIM4	-0.49	-4.64	-0.43	1.13e-5	Blood metabolite levels;
THYM	cis	rs870825	0.655	rs7683556	chr4:185632019	T/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs13394619	0.775	rs10200851	chr2:11722082	C/T	cg07314298	chr2:11723111	GREB1	-0.6	-5.68	-0.5	1.46e-7	Endometriosis;
THYM	cis	rs7584330	0.780	rs10176842	chr2:238428256	T/C	cg14458575	chr2:238380390	NA	0.66	5.34	0.48	6.45e-7	Prostate cancer;
THYM	cis	rs7107174	1.000	rs7941617	chr11:78021146	C/T	cg02023728	chr11:77925099	USP35	0.67	6.21	0.54	1.38e-8	Testicular germ cell tumor;
THYM	cis	rs2404602	0.647	rs12904149	chr15:77043652	A/C	cg23625390	chr15:77176239	SCAPER	-0.86	-5.88	-0.52	6.21e-8	Blood metabolite levels;
THYM	cis	rs752010	0.806	rs10890148	chr1:42091517	T/C	cg22486000	chr1:42919398	ZMYND12	-0.43	-4.83	-0.44	5.16e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs901683	1.000	rs12763285	chr10:46082869	A/G	cg18240400	chr10:46168597	ANUBL1	0.73	4.53	0.42	1.69e-5	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.69	-5.16	-0.47	1.36e-6	Tonsillectomy;
THYM	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg03433033	chr1:76189801	ACADM	0.77	10.21	0.72	6.01e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4930103	0.935	rs2525881	chr11:2019333	T/C	cg18511798	chr11:2018149	H19;MIR675	-0.57	-5.57	-0.5	2.39e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs6570726	0.875	rs416243	chr6:145868081	A/T	cg13319975	chr6:146136371	FBXO30	-0.66	-5.62	-0.5	1.89e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7408868	0.764	rs12610803	chr19:15260682	A/C	cg14696996	chr19:15285081	NOTCH3	0.97	5.57	0.5	2.37e-7	Pulse pressure;
THYM	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg07690219	chr3:49449608	TCTA;RHOA	0.68	4.51	0.42	1.83e-5	Menarche (age at onset);
THYM	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21659725	chr3:3221576	CRBN	0.88	9.81	0.71	4.18e-16	Intelligence (multi-trait analysis);
THYM	cis	rs8013055	0.796	rs11628497	chr14:105970789	C/T	cg23356831	chr14:105996513	TMEM121	0.57	6.17	0.53	1.69e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs11731175	0.961	rs74710904	chr4:189858024	G/A	cg00431894	chr4:189871012	NA	-0.81	-6.19	-0.54	1.52e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs3126085	0.935	rs6587651	chr1:152193121	G/T	cg10321714	chr1:152280068	FLG	0.69	5.04	0.46	2.22e-6	Atopic dermatitis;
THYM	cis	rs9905704	0.831	rs12939500	chr17:56848677	T/C	cg12560992	chr17:57184187	TRIM37	0.66	4.54	0.42	1.67e-5	Testicular germ cell tumor;
THYM	cis	rs4908768	0.657	rs4908778	chr1:8804888	C/G	cg06972019	chr1:8937448	ENO1	-0.55	-4.52	-0.42	1.76e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
THYM	trans	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg07936489	chr17:37558343	FBXL20	-0.79	-5.7	-0.5	1.37e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6768930	0.509	rs7634631	chr3:57753419	G/C	cg24033633	chr3:57945695	NA	-0.38	-5.27	-0.48	8.55e-7	Obesity-related traits;
THYM	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg12826209	chr6:26865740	GUSBL1	0.9	5.12	0.47	1.59e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs526231	0.578	rs34786	chr5:102458113	C/G	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.49e-6	Primary biliary cholangitis;
THYM	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-1.05	-7.32	-0.6	7.96e-11	Platelet count;
THYM	cis	rs2639990	1.000	rs1702831	chr18:72897368	C/A	cg11568697	chr18:72916393	ZADH2	1.2	5.71	0.51	1.29e-7	Vascular endothelial growth factor levels;
THYM	cis	rs2413151	0.606	rs4504	chr22:33236544	G/A	cg18989477	chr22:32435639	NA	0.56	5.0	0.46	2.58e-6	Blood protein levels;
THYM	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg03929089	chr4:120376271	NA	0.98	10.85	0.74	2.62e-18	Coronary artery disease;
THYM	cis	rs700651	0.789	rs10184395	chr2:198894285	G/A	cg00792783	chr2:198669748	PLCL1	0.83	5.9	0.52	5.65e-8	Intracranial aneurysm;
THYM	cis	rs1387259	0.690	rs1601985	chr12:48761914	A/G	cg21466736	chr12:48725269	NA	-0.6	-5.43	-0.49	4.29e-7	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs4732038	0.510	rs6967100	chr7:134262085	A/G	cg06906464	chr7:134288099	NA	-0.44	-4.5	-0.42	1.89e-5	Longevity;
THYM	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg08048268	chr3:133502702	NA	0.68	5.75	0.51	1.09e-7	Iron status biomarkers;
THYM	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg11764359	chr7:65958608	NA	0.82	6.56	0.56	2.81e-9	Aortic root size;
THYM	cis	rs2811415	0.597	rs6808774	chr3:127759090	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg18200150	chr17:30822561	MYO1D	0.86	7.53	0.61	2.97e-11	Schizophrenia;
THYM	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs28595532	0.920	rs115294251	chr4:119772833	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs688020	1.000	rs673500	chr7:4229445	C/G	cg02004499	chr7:4244250	SDK1	-0.67	-5.53	-0.49	2.83e-7	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
THYM	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg21926883	chr2:100939477	LONRF2	-0.6	-5.46	-0.49	3.87e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7106204	0.748	rs36092013	chr11:24211987	C/T	ch.11.24196551F	chr11:24239977	NA	0.99	7.0	0.58	3.64e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg13695892	chr22:41940480	POLR3H	0.92	7.95	0.63	3.79e-12	Vitiligo;
THYM	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.61	4.82	0.44	5.41e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg16325326	chr1:53192061	ZYG11B	0.96	10.87	0.74	2.35e-18	Monocyte count;
THYM	cis	rs56161922	1.000	rs72468035	chr1:207812405	C/T	cg09557387	chr1:207818395	CR1L	1.14	5.23	0.47	9.96e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs10463554	0.963	rs32840	chr5:102479150	A/C	cg23492399	chr5:102201601	PAM	-0.69	-5.11	-0.46	1.7e-6	Parkinson's disease;
THYM	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg27034606	chr17:28928453	LRRC37B2	0.85	5.59	0.5	2.16e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1729951	0.575	rs1654923	chr3:136692620	A/T	cg21827317	chr3:136751795	NA	0.75	6.64	0.56	1.92e-9	Neuroticism;
THYM	cis	rs4363385	0.747	rs2075739	chr1:152975495	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.53	-0.42	1.74e-5	Inflammatory skin disease;
THYM	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg27129171	chr3:47204927	SETD2	0.77	7.67	0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs3741151	0.773	rs73542979	chr11:73127526	G/C	cg12959048	chr11:73096162	RELT	-0.53	-5.08	-0.46	1.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg23711669	chr6:146136114	FBXO30	0.96	10.29	0.73	3.99e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	7.62	0.62	1.93e-11	Lung cancer in ever smokers;
THYM	cis	rs7651039	0.641	rs2455823	chr3:15666856	T/C	cg16303742	chr3:15540471	COLQ	0.65	6.26	0.54	1.11e-8	Coronary heart disease;
THYM	cis	rs10927875	0.632	rs7535248	chr1:16129598	C/T	cg21385522	chr1:16154831	NA	-1.32	-13.48	-0.81	9e-24	Dilated cardiomyopathy;
THYM	cis	rs3916	0.911	rs12829722	chr12:121155622	C/T	cg10600917	chr12:121163489	ACADS	0.59	4.97	0.45	3.02e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg26384229	chr12:38710491	ALG10B	-0.9	-7.35	-0.6	6.77e-11	Morning vs. evening chronotype;
THYM	cis	rs10089	1.000	rs1560636	chr5:127447987	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.02	7.11	0.59	2.11e-10	Ileal carcinoids;
THYM	cis	rs3799378	0.579	rs9348715	chr6:26375642	C/G	cg14345882	chr6:26364793	BTN3A2	0.4	5.13	0.47	1.51e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12817211	0.502	rs11169282	chr12:50529971	C/T	cg06168149	chr12:50497778	GPD1	-0.3	-4.6	-0.43	1.3e-5	Colorectal or endometrial cancer;
THYM	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg16989719	chr2:238392110	NA	-0.6	-5.82	-0.51	8.08e-8	Prostate cancer;
THYM	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg20290983	chr6:43655470	MRPS18A	-1.44	-15.94	-0.85	1.35e-28	IgG glycosylation;
THYM	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22857025	chr5:266934	NA	1.46	9.76	0.71	5.38e-16	Breast cancer;
THYM	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg10802521	chr3:52805072	NEK4	-0.78	-7.52	-0.61	3.08e-11	Bipolar disorder;
THYM	cis	rs28595532	0.920	rs114724233	chr4:119754918	T/A	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg05738196	chr6:26577821	NA	0.6	4.91	0.45	3.71e-6	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg03929089	chr4:120376271	NA	-0.8	-8.05	-0.64	2.34e-12	Height;
THYM	cis	rs4654899	0.680	rs3890762	chr1:21198265	G/A	cg01072550	chr1:21505969	NA	0.72	6.91	0.58	5.4e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs3008870	0.651	rs2815376	chr1:67508531	G/A	cg02640540	chr1:67518911	SLC35D1	0.6	4.83	0.44	5.28e-6	Lymphocyte percentage of white cells;
THYM	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg14004847	chr7:1930337	MAD1L1	-0.75	-6.07	-0.53	2.65e-8	Schizophrenia;
THYM	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg00310523	chr12:86230176	RASSF9	0.56	4.94	0.45	3.29e-6	Major depressive disorder;
THYM	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg00981070	chr1:2046702	PRKCZ	-0.42	-5.16	-0.47	1.33e-6	Height;
THYM	cis	rs6032067	0.929	rs17334064	chr20:43839197	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.34	-0.65	5.7e-13	Blood protein levels;
THYM	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs7757969	1.000	rs6921229	chr6:112148293	C/T	cg08601457	chr6:112115117	FYN	0.41	4.51	0.42	1.84e-5	Schizophrenia;
THYM	cis	rs8133932	0.667	rs2839033	chr21:47296381	T/C	cg20357416	chr21:47294739	PCBP3	-0.84	-5.2	-0.47	1.12e-6	Schizophrenia;
THYM	cis	rs600806	0.815	rs10745356	chr1:109960270	C/A	cg02175308	chr1:109941060	SORT1	-0.57	-5.08	-0.46	1.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg25358565	chr5:93447407	FAM172A	1.37	10.93	0.75	1.76e-18	Diabetic retinopathy;
THYM	cis	rs10203711	1.000	rs10191070	chr2:239565413	A/G	cg14580085	chr2:239553406	NA	0.66	5.76	0.51	1.01e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg03859395	chr2:55845619	SMEK2	0.7	6.23	0.54	1.28e-8	Metabolic syndrome;
THYM	cis	rs3087591	0.960	rs12940303	chr17:29604862	C/T	cg24425628	chr17:29625626	OMG;NF1	0.63	5.33	0.48	6.51e-7	Hip circumference;
THYM	cis	rs12643440	0.538	rs970428	chr4:17136795	C/A	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg18105134	chr13:113819100	PROZ	-0.98	-9.05	-0.68	1.79e-14	Platelet distribution width;
THYM	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg09455208	chr3:40491958	NA	0.5	5.24	0.47	9.76e-7	Renal cell carcinoma;
THYM	cis	rs863345	0.604	rs11264981	chr1:158455890	C/T	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	trans	rs10880689	1	rs10880689	chr12:37930102	A/G	cg10856724	chr12:34555212	NA	-0.87	-7.75	-0.62	9.89e-12	Resting heart rate;
THYM	cis	rs9381040	0.701	rs4711658	chr6:41162891	C/T	cg03526776	chr6:41159608	TREML2	-0.52	-4.77	-0.44	6.68e-6	Alzheimer's disease (late onset);
THYM	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	4.72	0.44	7.96e-6	Prudent dietary pattern;
THYM	cis	rs6087990	0.735	rs2424915	chr20:31378448	C/T	cg13636640	chr20:31349939	DNMT3B	0.94	10.33	0.73	3.21e-17	Ulcerative colitis;
THYM	cis	rs524281	0.773	rs7951079	chr11:65980550	C/T	cg00563793	chr11:65837595	PACS1	0.82	4.69	0.43	9.04e-6	Electroencephalogram traits;
THYM	cis	rs2034650	0.544	rs8034217	chr15:40721700	C/T	cg12699599	chr15:40643142	PHGR1	0.58	5.18	0.47	1.24e-6	Interstitial lung disease;
THYM	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg18876405	chr7:65276391	NA	0.6	5.16	0.47	1.33e-6	Aortic root size;
THYM	cis	rs2997447	0.846	rs3008233	chr1:26403991	C/T	cg03844060	chr1:26490628	NA	0.67	4.55	0.42	1.59e-5	QRS complex (12-leadsum);
THYM	cis	rs12681287	0.608	rs1135451	chr8:87483608	T/C	cg27223183	chr8:87520930	FAM82B	-0.67	-5.05	-0.46	2.17e-6	Caudate activity during reward;
THYM	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11141652	chr22:24348549	GSTTP1	0.65	6.38	0.55	6.41e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22455342	chr2:225449267	CUL3	0.97	9.01	0.68	2.12e-14	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs4642101	0.561	rs4560285	chr3:12809066	G/A	cg11882607	chr3:12858926	CAND2	-0.43	-4.94	-0.45	3.3e-6	QRS complex (12-leadsum);
THYM	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg02153584	chr22:29168773	CCDC117	0.58	4.56	0.42	1.52e-5	Lymphocyte counts;
THYM	cis	rs5769707	0.642	rs4824070	chr22:50031521	T/C	cg17054759	chr22:49844102	NA	-0.52	-4.72	-0.44	8.26e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1448094	0.512	rs2405632	chr12:86252456	A/G	cg00310523	chr12:86230176	RASSF9	0.53	4.78	0.44	6.41e-6	Major depressive disorder;
THYM	cis	rs4242434	0.672	rs10113779	chr8:22485934	G/C	cg11461670	chr8:22454935	PDLIM2	-0.35	-6.2	-0.54	1.47e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg18446336	chr7:2847575	GNA12	0.46	4.79	0.44	6.02e-6	Loneliness (linear analysis);
THYM	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	7.51	0.61	3.24e-11	Platelet count;
THYM	cis	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg13531842	chr10:38383804	ZNF37A	-0.54	-4.58	-0.42	1.44e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.68	8.87	0.67	4.28e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7246657	0.941	rs12982333	chr19:37794724	A/G	cg22634378	chr19:37742834	NA	0.63	5.28	0.48	8.18e-7	Coronary artery calcification;
THYM	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.97	8.88	0.67	4.01e-14	Colorectal cancer;
THYM	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg16006841	chr5:176797999	RGS14	0.52	6.22	0.54	1.36e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs9959145	1.000	rs77079191	chr18:12549378	C/T	cg14160804	chr18:12703040	PSMG2;CEP76	-0.92	-4.53	-0.42	1.74e-5	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg10760299	chr15:45669010	GATM	0.75	5.63	0.5	1.79e-7	Homoarginine levels;
THYM	cis	rs2018683	0.707	rs4722877	chr7:28972906	A/G	cg27487796	chr7:28973253	NA	-0.27	-4.69	-0.43	8.99e-6	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
THYM	cis	rs4595586	0.545	rs7967295	chr12:39376866	G/A	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs346785	0.692	rs2279052	chr17:74287204	C/G	cg09812376	chr17:74270190	QRICH2	-0.5	-5.08	-0.46	1.85e-6	White matter hyperintensities in ischemic stroke;
THYM	cis	rs73787773	0.799	rs7730334	chr5:111495150	A/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.88	-4.76	-0.44	6.87e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.6	0.43	1.32e-5	Breast cancer;
THYM	cis	rs4803480	0.935	rs758349	chr19:42085106	T/C	cg09848080	chr19:41642064	NA	0.62	4.49	0.42	1.99e-5	Schizophrenia;
THYM	cis	rs6835098	0.887	rs12644699	chr4:174142874	A/G	cg08422745	chr4:174089978	GALNT7	0.94	7.17	0.59	1.6e-10	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs6840360	0.571	rs4696278	chr4:152558978	A/G	cg17479576	chr4:152424074	FAM160A1	-0.79	-5.55	-0.49	2.59e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10479542	0.766	rs2411380	chr5:178973780	T/C	cg21226059	chr5:178986404	RUFY1	-0.47	-4.6	-0.43	1.29e-5	Lung cancer;
THYM	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg05347473	chr6:146136440	FBXO30	0.6	4.85	0.45	4.74e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs997295	0.556	rs10468041	chr15:67773203	G/T	cg24579218	chr15:68104479	NA	0.55	4.73	0.44	7.79e-6	Motion sickness;
THYM	cis	rs6815814	0.950	rs5743795	chr4:38832495	C/T	cg06935464	chr4:38784597	TLR10	0.72	4.97	0.45	2.94e-6	Breast cancer;
THYM	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg06636001	chr8:8085503	FLJ10661	0.71	6.48	0.55	4.03e-9	Joint mobility (Beighton score);
THYM	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg13683864	chr3:40499215	RPL14	-0.7	-6.12	-0.53	2.12e-8	Renal cell carcinoma;
THYM	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg12165864	chr7:66369176	NA	-0.81	-6.09	-0.53	2.36e-8	Corneal structure;
THYM	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	10.29	0.73	4e-17	Chronic sinus infection;
THYM	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.05	7.59	0.61	2.15e-11	Smoking behavior;
THYM	cis	rs9534288	0.797	rs2896951	chr13:46581185	A/G	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs6840360	0.571	rs2406976	chr4:152541056	G/C	cg17479576	chr4:152424074	FAM160A1	-0.78	-5.74	-0.51	1.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11690935	0.851	rs6433319	chr2:172830953	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.63	-4.79	-0.44	6.04e-6	Schizophrenia;
THYM	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg24642844	chr7:1081250	C7orf50	-1.28	-8.22	-0.64	1.06e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6430585	0.941	rs60963894	chr2:136539670	T/G	cg07169764	chr2:136633963	MCM6	0.94	8.32	0.65	6.19e-13	Corneal structure;
THYM	cis	rs2282930	0.512	rs7792550	chr7:50707415	A/T	cg08586669	chr7:50727761	GRB10	0.3	4.61	0.43	1.23e-5	Bone mineral density;
THYM	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.27	6.27	0.54	1.04e-8	Obesity-related traits;
THYM	cis	rs1538970	0.739	rs4660863	chr1:45955868	T/C	cg05343316	chr1:45956843	TESK2	0.85	5.45	0.49	3.93e-7	Platelet count;
THYM	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg06108461	chr20:60628389	TAF4	0.81	6.72	0.57	1.34e-9	Body mass index;
THYM	cis	rs9399401	0.921	rs7754638	chr6:142780251	A/T	cg04461802	chr6:142623433	GPR126	0.47	4.64	0.43	1.11e-5	Chronic obstructive pulmonary disease;
THYM	cis	rs6840360	0.642	rs1443088	chr4:152450126	G/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-5.66	-0.5	1.6e-7	Intelligence (multi-trait analysis);
THYM	cis	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg13609457	chr4:120235615	NA	0.51	4.82	0.44	5.44e-6	Diastolic blood pressure;
THYM	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7524258	0.868	rs4243824	chr1:7289777	G/A	cg07173049	chr1:7289937	CAMTA1	0.76	5.97	0.52	4.11e-8	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs6598955	0.543	rs6698557	chr1:26561220	G/C	cg04990556	chr1:26633338	UBXN11	0.91	5.82	0.51	7.95e-8	Obesity-related traits;
THYM	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg15536230	chr21:44985092	HSF2BP	-0.38	-4.53	-0.42	1.73e-5	Mean corpuscular volume;
THYM	cis	rs12291225	0.753	rs1431374	chr11:14303975	T/C	cg19336497	chr11:14380999	RRAS2	-0.82	-9.66	-0.7	8.92e-16	Sense of smell;
THYM	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg08213375	chr14:104286397	PPP1R13B	0.43	4.52	0.42	1.81e-5	Reticulocyte count;
THYM	cis	rs2742234	0.579	rs2503881	chr10:43686026	T/C	cg06632098	chr10:43605906	RET	-0.79	-5.1	-0.46	1.73e-6	Hirschsprung disease;
THYM	cis	rs3820068	0.705	rs11587541	chr1:15899478	T/C	cg05660106	chr1:15850417	CASP9	1.06	9.28	0.69	5.78e-15	Systolic blood pressure;
THYM	cis	rs36051895	0.559	rs7858422	chr9:5209797	G/T	cg02405213	chr9:5042618	JAK2	-0.88	-8.68	-0.66	1.11e-13	Pediatric autoimmune diseases;
THYM	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.31e-5	Retinal vascular caliber;
THYM	cis	rs1298062	0.563	rs2445828	chr19:50941807	A/G	cg10687087	chr19:50962411	MYBPC2	0.56	4.77	0.44	6.63e-6	Age of smoking initiation;
THYM	cis	rs7474896	0.583	rs12783272	chr10:38024885	T/G	cg07661167	chr10:37990439	NA	-0.68	-4.53	-0.42	1.71e-5	Obesity (extreme);
THYM	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19346786	chr7:2764209	NA	-0.78	-7.06	-0.59	2.68e-10	Height;
THYM	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg10257693	chr21:44515416	U2AF1	0.52	4.45	0.42	2.36e-5	Mean corpuscular volume;
THYM	cis	rs4731207	0.565	rs6977613	chr7:124681791	G/A	cg05285228	chr7:124571219	POT1	-0.65	-4.98	-0.45	2.9e-6	Cutaneous malignant melanoma;
THYM	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg24692254	chr21:30365293	RNF160	-0.95	-8.06	-0.64	2.21e-12	Dental caries;
THYM	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg10018233	chr7:150070692	REPIN1	0.38	5.33	0.48	6.63e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg03115019	chr17:80708279	FN3K	0.68	4.79	0.44	6.06e-6	Glycated hemoglobin levels;
THYM	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg03388043	chr17:80084554	CCDC57	0.69	5.98	0.52	3.85e-8	Life satisfaction;
THYM	cis	rs13191362	0.573	rs9365499	chr6:163271833	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.75	5.64	0.5	1.71e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg19507638	chr5:93509721	C5orf36	-0.67	-4.48	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs672413	0.739	rs336526	chr5:78287579	T/G	cg02582925	chr5:78281734	ARSB	-0.52	-4.54	-0.42	1.63e-5	Blood and toenail selenium levels;Blood protein levels;
THYM	cis	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.62	0.43	1.23e-5	Obesity-related traits;
THYM	cis	rs7177026	0.500	rs72732716	chr15:79928691	A/C	cg20511832	chr15:78934280	CHRNB4	0.44	5.03	0.46	2.27e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs1048238	0.506	rs698889	chr1:16267040	A/C	cg21385522	chr1:16154831	NA	-0.71	-5.86	-0.52	6.63e-8	Systolic blood pressure;
THYM	cis	rs11098499	0.532	rs4833624	chr4:120585497	C/T	cg09307838	chr4:120376055	NA	0.7	4.64	0.43	1.1e-5	Corneal astigmatism;
THYM	cis	rs1267303	0.675	rs1267309	chr1:46987342	G/A	cg16387850	chr1:46982889	NA	0.45	5.73	0.51	1.19e-7	Monobrow;
THYM	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg00071950	chr4:10020882	SLC2A9	0.87	9.47	0.7	2.27e-15	Bone mineral density;
THYM	cis	rs10504073	0.669	rs12548464	chr8:50023867	C/T	cg00325661	chr8:49890786	NA	0.86	7.69	0.62	1.35e-11	Blood metabolite ratios;
THYM	cis	rs490234	0.702	rs1339499	chr9:128406453	T/C	cg14078157	chr9:128172775	NA	-0.77	-5.97	-0.52	4.01e-8	Mean arterial pressure;
THYM	cis	rs2806561	0.808	rs2235546	chr1:23409538	A/G	cg19743168	chr1:23544995	NA	0.57	5.28	0.48	8.27e-7	Height;
THYM	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg16325326	chr1:53192061	ZYG11B	0.85	8.47	0.66	2.98e-13	Monocyte count;
THYM	cis	rs8067545	0.611	rs2042046	chr17:20018841	A/G	cg13482628	chr17:19912719	NA	0.56	4.68	0.43	9.33e-6	Schizophrenia;
THYM	cis	rs59698941	0.943	rs67268447	chr5:132303194	G/A	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg08132940	chr7:1081526	C7orf50	-1.17	-6.67	-0.56	1.7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg27398817	chr8:82754497	SNX16	-0.68	-5.63	-0.5	1.85e-7	Diastolic blood pressure;
THYM	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg07606381	chr6:8435919	SLC35B3	0.7	5.27	0.48	8.36e-7	Motion sickness;
THYM	cis	rs11190604	1.000	rs2489053	chr10:102353341	A/G	cg16342193	chr10:102329863	NA	-0.59	-5.66	-0.5	1.61e-7	Palmitoleic acid (16:1n-7) levels;
THYM	trans	rs7952251	0.812	rs1945114	chr11:112402907	A/C	cg14154186	chr1:204970430	NFASC	0.73	7.54	0.61	2.79e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7428	0.545	rs2366404	chr2:85551779	G/A	cg24342717	chr2:85555507	TGOLN2	-0.77	-6.63	-0.56	2.06e-9	Ear protrusion;
THYM	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg02734326	chr4:10020555	SLC2A9	0.72	6.31	0.54	8.96e-9	Bone mineral density;
THYM	cis	rs7688540	0.771	rs78343340	chr4:267437	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.68	4.82	0.44	5.43e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs4343996	0.566	rs55940354	chr7:3431534	C/T	cg21248987	chr7:3385318	SDK1	0.4	5.17	0.47	1.27e-6	Motion sickness;
THYM	cis	rs7981781	1.000	rs7326283	chr13:28479685	A/G	cg14660839	chr13:28674720	FLT3	-0.62	-4.56	-0.42	1.52e-5	Fasting plasma glucose;
THYM	cis	rs7589342	0.801	rs13411829	chr2:106466101	G/C	cg14210321	chr2:106509881	NCK2	-0.75	-5.43	-0.49	4.33e-7	Addiction;
THYM	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg16342193	chr10:102329863	NA	-0.56	-5.52	-0.49	2.92e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs7089973	0.872	rs34683721	chr10:116619849	G/A	cg23260525	chr10:116636907	FAM160B1	0.52	4.72	0.44	8.04e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs6930083	0.605	rs3829964	chr6:36644498	T/C	cg24425727	chr6:36645648	CDKN1A	-0.75	-6.9	-0.58	5.69e-10	Coronary artery disease;
THYM	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs6032067	0.929	rs6032049	chr20:43825556	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs9814567	1.000	rs62271513	chr3:134298412	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	8.46	0.66	3.25e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg19346786	chr7:2764209	NA	-0.57	-4.75	-0.44	7.19e-6	Height;
THYM	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg24399712	chr22:39784796	NA	-0.95	-10.92	-0.75	1.82e-18	Intelligence (multi-trait analysis);
THYM	cis	rs662064	0.852	rs1411402	chr1:10579545	G/T	cg20482658	chr1:10539492	PEX14	0.48	5.91	0.52	5.45e-8	Asthma;
THYM	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg10803722	chr21:46713166	LOC642852	-0.39	-4.86	-0.45	4.62e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7809950	0.906	rs62483723	chr7:107186358	A/C	cg23024343	chr7:107201750	COG5	-0.93	-8.53	-0.66	2.33e-13	Coronary artery disease;
THYM	cis	rs9814567	1.000	rs934093	chr3:134195885	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-8.49	-0.66	2.78e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.6	4.7	0.43	8.62e-6	Renal function-related traits (BUN);
THYM	cis	rs7776786	0.870	rs12540224	chr7:18830489	C/T	cg13420273	chr7:18810212	HDAC9	-0.69	-7.52	-0.61	3.11e-11	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs1564271	0.506	rs1148163	chr10:26929671	G/C	cg24343755	chr10:26987087	PDSS1	-0.6	-4.72	-0.44	8.18e-6	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
THYM	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.37	-0.48	5.48e-7	Menopause (age at onset);
THYM	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg02931644	chr1:25747376	RHCE	0.58	4.45	0.42	2.29e-5	Erythrocyte sedimentation rate;
THYM	cis	rs7078219	0.505	rs4129133	chr10:101284570	T/C	cg23904955	chr10:101282759	NA	-0.36	-4.61	-0.43	1.28e-5	Dental caries;
THYM	cis	rs9486719	0.901	rs760619	chr6:96857431	A/G	cg18709589	chr6:96969512	KIAA0776	0.76	4.97	0.45	2.95e-6	Migraine;Coronary artery disease;
THYM	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg06618935	chr21:46677482	NA	-0.91	-8.79	-0.67	6.28e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg07936489	chr17:37558343	FBXL20	-0.68	-5.01	-0.46	2.51e-6	Asthma;
THYM	cis	rs7187994	0.848	rs60566983	chr16:84774799	A/G	cg07647771	chr16:84786436	USP10	-0.54	-5.1	-0.46	1.72e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs9583531	0.600	rs9555726	chr13:111368316	C/T	cg24331049	chr13:111365604	ING1	0.72	5.82	0.51	8.01e-8	Coronary artery disease;
THYM	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg11871910	chr12:69753446	YEATS4	0.75	6.25	0.54	1.18e-8	Blood protein levels;
THYM	cis	rs12950390	1.000	rs12950390	chr17:45830948	A/G	cg06532163	chr17:45867833	NA	0.6	5.08	0.46	1.92e-6	IgG glycosylation;
THYM	cis	rs4970988	0.556	rs6695123	chr1:150563483	T/C	cg15448220	chr1:150897856	SETDB1	-0.8	-6.03	-0.53	3.18e-8	Urate levels;
THYM	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg20203395	chr5:56204925	C5orf35	-0.66	-4.62	-0.43	1.22e-5	Initial pursuit acceleration;
THYM	cis	rs7084402	0.967	rs7094882	chr10:60276829	C/T	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs8068544	0.748	rs75881902	chr17:40156612	C/A	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.47	-7.45	-0.61	4.22e-11	Reticulocyte fraction of red cells;Reticulocyte count;
THYM	cis	rs1336900	0.544	rs10888386	chr1:150611957	A/G	cg10589385	chr1:150898437	SETDB1	-0.66	-5.21	-0.47	1.09e-6	Blood protein levels;
THYM	cis	rs863345	0.604	rs10908657	chr1:158465243	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs3136739	0.764	rs56261655	chr8:42071039	A/G	cg12091331	chr8:42065314	PLAT	-0.64	-4.85	-0.45	4.89e-6	Plasma plasminogen activator levels;
THYM	cis	rs28595532	0.920	rs115484560	chr4:119756781	T/G	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12516959	chr21:47718080	NA	-0.46	-5.59	-0.5	2.17e-7	Testicular germ cell tumor;
THYM	cis	rs3771570	1.000	rs57196672	chr2:242235193	G/A	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs28595532	0.920	rs112097820	chr4:119746532	G/A	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg10515332	chr4:99064459	C4orf37	0.64	5.04	0.46	2.23e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg04944784	chr2:26401820	FAM59B	-0.71	-5.5	-0.49	3.21e-7	Gut microbiome composition (summer);
THYM	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs16866061	1.000	rs72974267	chr2:225454209	T/C	cg12698349	chr2:225449008	CUL3	1.14	10.45	0.73	1.77e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg27068330	chr11:65405492	SIPA1	-0.97	-9.38	-0.69	3.41e-15	Acne (severe);
THYM	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg15247329	chr7:2764246	NA	-0.68	-5.51	-0.49	3.03e-7	Height;
THYM	cis	rs870825	0.616	rs2310110	chr4:185647902	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg03929089	chr4:120376271	NA	-0.99	-12.81	-0.8	2.07e-22	Height;
THYM	cis	rs1178127	0.765	rs1178155	chr7:18782969	T/A	cg13420273	chr7:18810212	HDAC9	0.61	4.82	0.44	5.53e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg13319975	chr6:146136371	FBXO30	-0.66	-5.23	-0.47	1.01e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs41278232	0.925	rs73916684	chr20:62661274	T/C	cg03065311	chr20:62601662	ZNF512B	0.71	5.37	0.48	5.49e-7	Tonsillectomy;
THYM	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	5.71	0.51	1.3e-7	Platelet count;
THYM	cis	rs477692	0.517	rs871026	chr10:131293145	A/G	cg05714579	chr10:131428358	MGMT	-0.58	-4.62	-0.43	1.21e-5	Response to temozolomide;
THYM	cis	rs919433	0.783	rs2565158	chr2:198236103	T/A	cg00792783	chr2:198669748	PLCL1	0.78	5.6	0.5	2.12e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs1065656	0.563	rs391546	chr16:1915581	T/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.53	6.22	0.54	1.32e-8	Insulin-like growth factors;
THYM	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.58	-5.14	-0.47	1.46e-6	Coronary artery disease;
THYM	cis	rs8078723	0.674	rs9303284	chr17:38205793	C/T	cg17467752	chr17:38218738	THRA	-0.95	-7.33	-0.6	7.41e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs7968679	1	rs7968679	chr12:9313304	A/G	cg23795048	chr12:9217529	LOC144571	-0.55	-4.53	-0.42	1.72e-5	Myopia;
THYM	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg26446133	chr18:72167187	CNDP2	-1.0	-9.97	-0.72	1.88e-16	Refractive error;
THYM	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg06728252	chr6:26598149	ABT1	-0.45	-4.91	-0.45	3.82e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03264133	chr6:25882463	NA	-0.7	-5.49	-0.49	3.3e-7	Blood metabolite levels;
THYM	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg23583168	chr7:148888333	NA	-1.02	-13.89	-0.82	1.32e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-6.65	-0.56	1.84e-9	Chronic sinus infection;
THYM	cis	rs6539288	0.899	rs7956807	chr12:107300526	C/T	cg26297688	chr12:107349093	C12orf23	-0.44	-4.57	-0.42	1.49e-5	Total body bone mineral density;
THYM	cis	rs28595532	0.920	rs114653217	chr4:119769216	G/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs782590	0.967	rs1975487	chr2:55809054	A/G	cg18811423	chr2:55921094	PNPT1	0.68	6.36	0.55	6.93e-9	Metabolic syndrome;
THYM	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg06618935	chr21:46677482	NA	-0.97	-8.09	-0.64	1.92e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7084402	0.967	rs1649039	chr10:60330041	C/T	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs9296092	0.517	rs56206922	chr6:33522567	C/T	cg13560919	chr6:33536144	NA	-0.94	-9.31	-0.69	4.9e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs669446	0.561	rs559575	chr1:44089940	A/G	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs763014	0.865	rs8675	chr16:633843	A/G	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg20486651	chr6:167070296	RPS6KA2	0.5	4.79	0.44	6.18e-6	Crohn's disease;
THYM	cis	rs10089	1.000	rs883074	chr5:127445823	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.97	-6.15	-0.53	1.8e-8	Ileal carcinoids;
THYM	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg25358565	chr5:93447407	FAM172A	-0.95	-6.86	-0.58	6.92e-10	Diabetic retinopathy;
THYM	cis	rs6964587	0.655	rs6465351	chr7:91773213	T/C	cg22709100	chr7:91322751	NA	0.67	5.07	0.46	1.97e-6	Breast cancer;
THYM	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg23711669	chr6:146136114	FBXO30	-0.89	-8.76	-0.67	7.32e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2072732	0.821	rs7339938	chr1:2963493	G/C	cg08733933	chr1:2954429	NA	-0.56	-4.46	-0.42	2.28e-5	Plateletcrit;
THYM	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg03388025	chr16:89894329	SPIRE2	0.54	4.54	0.42	1.67e-5	Vitiligo;
THYM	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.36	0.69	3.89e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg14690197	chr8:22456421	C8orf58	0.49	4.65	0.43	1.08e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6441961	0.602	rs3138042	chr3:46401032	A/G	cg22951056	chr3:46887651	NA	-0.62	-4.5	-0.42	1.9e-5	Celiac disease;
THYM	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg11494091	chr17:61959527	GH2	1.08	15.84	0.85	2.13e-28	Prudent dietary pattern;
THYM	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg00255919	chr5:131827918	IRF1	-0.45	-5.04	-0.46	2.26e-6	Asthma (sex interaction);
THYM	cis	rs7851660	0.874	rs1955143	chr9:100634579	A/T	cg13688889	chr9:100608707	NA	-0.72	-5.03	-0.46	2.32e-6	Strep throat;
THYM	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg07492924	chr16:433825	LOC100134368	0.44	4.89	0.45	4.12e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs28647808	1.000	rs28504382	chr9:136275674	A/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg26038318	chr20:34205095	SPAG4	0.65	5.26	0.48	8.7e-7	Total cholesterol levels;
THYM	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4666002	0.789	rs13023094	chr2:27910706	G/T	cg27432699	chr2:27873401	GPN1	-0.64	-4.94	-0.45	3.32e-6	Phospholipid levels (plasma);
THYM	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg01416388	chr22:39784598	NA	0.89	9.27	0.69	6.06e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	trans	rs59551326	0.517	rs11087947	chr21:26593307	T/C	cg17452615	chr12:122019080	KDM2B	-0.8	-6.84	-0.57	7.67e-10	Alcohol dependence;
THYM	cis	rs10789491	1.000	rs618505	chr1:47144532	T/C	cg15501359	chr1:47185051	KIAA0494	1.16	8.72	0.67	8.86e-14	Response to hepatitis C treatment;
THYM	cis	rs11838725	1	rs11838725	chr13:41671085	C/T	cg08713116	chr13:41885295	NAA16	-0.65	-4.63	-0.43	1.14e-5	CSF tryptophan concentration in tuberculous meningitis;
THYM	cis	rs7336332	0.511	rs7998978	chr13:27999457	T/C	cg27031448	chr13:27998168	GTF3A	0.37	4.82	0.44	5.52e-6	Weight;
THYM	cis	rs6988636	1.000	rs59601467	chr8:124193488	C/T	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg12893428	chr3:195717962	SDHAP1	-0.52	-4.68	-0.43	9.63e-6	Pancreatic cancer;
THYM	cis	rs12681287	0.711	rs28506490	chr8:87246118	T/C	cg27223183	chr8:87520930	FAM82B	-0.6	-4.64	-0.43	1.1e-5	Caudate activity during reward;
THYM	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg25358565	chr5:93447407	FAM172A	-1.0	-7.31	-0.6	8.27e-11	Diabetic retinopathy;
THYM	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	6.05	0.53	2.89e-8	Obesity-related traits;
THYM	cis	rs7651039	0.641	rs2455827	chr3:15662906	C/G	cg16303742	chr3:15540471	COLQ	0.71	7.02	0.58	3.27e-10	Coronary heart disease;
THYM	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg27398817	chr8:82754497	SNX16	-0.84	-6.75	-0.57	1.15e-9	Diastolic blood pressure;
THYM	cis	rs7584330	0.666	rs72620818	chr2:238354652	G/A	cg16989719	chr2:238392110	NA	-0.64	-4.94	-0.45	3.3e-6	Prostate cancer;
THYM	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg21252483	chr19:49399788	TULP2	-0.88	-6.15	-0.53	1.82e-8	Red cell distribution width;
THYM	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg07570687	chr10:102243282	WNT8B	0.72	6.28	0.54	1.02e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg16325326	chr1:53192061	ZYG11B	0.69	5.72	0.51	1.21e-7	Monocyte count;
THYM	trans	rs8073060	0.586	rs225307	chr17:33918311	A/G	cg19694781	chr19:47549865	TMEM160	0.98	8.52	0.66	2.45e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg02725872	chr8:58115012	NA	-1.11	-7.53	-0.61	2.9e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg02187348	chr16:89574699	SPG7	0.81	6.86	0.58	7.05e-10	Multiple myeloma (IgH translocation);
THYM	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg04025307	chr7:1156635	C7orf50	0.63	5.15	0.47	1.42e-6	Longevity;Endometriosis;
THYM	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg23711669	chr6:146136114	FBXO30	0.95	9.55	0.7	1.52e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs295140	0.605	rs159320	chr2:201187775	A/G	cg23649088	chr2:200775458	C2orf69	0.61	5.01	0.46	2.53e-6	QT interval;
THYM	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.58	0.43	1.41e-5	Bipolar disorder;
THYM	cis	rs4580814	0.869	rs4535497	chr5:1107428	G/T	cg13592947	chr5:1111049	SLC12A7	0.62	7.76	0.62	9.42e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	5.1	0.46	1.7e-6	Schizophrenia;
THYM	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg26384229	chr12:38710491	ALG10B	0.94	7.45	0.61	4.24e-11	Bladder cancer;
THYM	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg01191920	chr7:158217561	PTPRN2	-0.99	-10.9	-0.75	2.03e-18	Obesity-related traits;
THYM	cis	rs2627019	0.546	rs1823447	chr2:148876603	G/A	cg23727674	chr2:148602993	ACVR2A	0.63	4.61	0.43	1.24e-5	Neuroticism;
THYM	cis	rs6964587	0.626	rs10266424	chr7:91503228	C/T	cg17063962	chr7:91808500	NA	-1.0	-8.65	-0.66	1.28e-13	Breast cancer;
THYM	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7586879	0.828	rs1968482	chr2:25086858	T/C	cg01884057	chr2:25150051	NA	0.51	4.49	0.42	2.01e-5	Body mass index;
THYM	cis	rs2085601	0.542	rs1708684	chr4:89961779	A/C	cg17769793	chr4:89976368	FAM13A	0.58	6.72	0.57	1.33e-9	Hair greying;
THYM	cis	rs870825	0.929	rs72689269	chr4:185592085	T/C	cg04058563	chr4:185651563	MLF1IP	1.01	7.12	0.59	2.08e-10	Blood protein levels;
THYM	cis	rs7107174	0.901	rs2510053	chr11:77959435	T/C	cg19901956	chr11:77921274	USP35	-0.77	-5.78	-0.51	9.66e-8	Testicular germ cell tumor;
THYM	cis	rs3771570	1.000	rs4346380	chr2:242263223	G/A	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg27446573	chr6:127587934	RNF146	1.03	9.77	0.71	5.21e-16	Breast cancer;
THYM	cis	rs13082711	0.554	rs34066402	chr3:27387987	G/A	cg02860705	chr3:27208620	NA	0.92	6.63	0.56	2.02e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs78579285	0.544	rs4782321	chr16:88780175	G/A	cg04002220	chr16:89598305	SPG7	0.65	4.73	0.44	7.78e-6	Joint mobility (Beighton score);
THYM	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg18252515	chr7:66147081	NA	1.6	8.71	0.67	9.29e-14	Diabetic kidney disease;
THYM	cis	rs4638749	0.677	rs12712014	chr2:108812044	A/G	cg25838818	chr2:108905173	SULT1C2	0.55	5.53	0.49	2.86e-7	Blood pressure;
THYM	cis	rs6032067	0.852	rs6032053	chr20:43829935	G/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	trans	rs4749080	0.573	rs11014983	chr10:26462557	G/A	cg00192819	chr18:76486611	NA	0.99	6.94	0.58	4.75e-10	Obesity-related traits;
THYM	cis	rs3768617	0.510	rs3768624	chr1:183079252	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg14458575	chr2:238380390	NA	0.96	7.46	0.61	4.11e-11	Prostate cancer;
THYM	cis	rs13326165	0.585	rs11706515	chr3:52396944	G/A	cg08438690	chr3:52279403	PPM1M	-0.84	-4.6	-0.43	1.32e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs17401966	0.867	rs7546364	chr1:10418815	G/A	cg19773385	chr1:10388646	KIF1B	-0.57	-4.58	-0.43	1.4e-5	Hepatocellular carcinoma;
THYM	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-5.76	-0.51	1.03e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs1061377	1.000	rs11727875	chr4:39135319	T/G	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs7107174	0.892	rs2512540	chr11:77979299	A/G	cg19901956	chr11:77921274	USP35	-0.69	-5.3	-0.48	7.42e-7	Testicular germ cell tumor;
THYM	cis	rs10911232	0.507	rs4652765	chr1:182994147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg27286337	chr10:134555280	INPP5A	0.79	5.29	0.48	7.75e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg11752832	chr7:134001865	SLC35B4	0.73	5.5	0.49	3.21e-7	Mean platelet volume;
THYM	cis	rs977987	0.806	rs11862582	chr16:75431295	T/C	cg03315344	chr16:75512273	CHST6	0.73	6.16	0.53	1.73e-8	Dupuytren's disease;
THYM	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.76	8.46	0.66	3.17e-13	Eosinophil percentage of white cells;
THYM	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	4.47	0.42	2.13e-5	Alzheimer's disease;
THYM	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg10523679	chr1:76189770	ACADM	-0.57	-4.83	-0.44	5.17e-6	Daytime sleep phenotypes;
THYM	cis	rs9902453	0.817	rs2617880	chr17:28106118	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-4.73	-0.44	7.7e-6	Coffee consumption (cups per day);
THYM	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg04414720	chr1:150670196	GOLPH3L	0.62	4.58	0.43	1.41e-5	Melanoma;
THYM	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg16928487	chr17:17741425	SREBF1	0.55	5.45	0.49	3.93e-7	Total body bone mineral density;
THYM	trans	rs2270927	0.510	rs6453213	chr5:75579518	A/G	cg13563193	chr19:33072644	PDCD5	1.54	7.25	0.6	1.09e-10	Mean corpuscular volume;
THYM	cis	rs6089584	0.566	rs3787422	chr20:60555346	G/A	cg22316451	chr20:60645197	NA	-0.46	-4.45	-0.42	2.29e-5	Body mass index;
THYM	cis	rs10752881	0.875	rs10752894	chr1:183050610	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Colorectal cancer;
THYM	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg27129171	chr3:47204927	SETD2	0.69	6.63	0.56	2.04e-9	Colorectal cancer;
THYM	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.73	7.09	0.59	2.35e-10	Lymphocyte counts;
THYM	cis	rs4072705	0.615	rs6478666	chr9:127249343	C/G	cg01786973	chr9:127249749	NR5A1	-0.4	-5.41	-0.49	4.71e-7	Menarche (age at onset);
THYM	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg06009448	chr7:1102226	C7orf50	0.46	5.3	0.48	7.39e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg15445000	chr17:37608096	MED1	-0.42	-5.08	-0.46	1.91e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg12935359	chr14:103987150	CKB	-0.65	-6.4	-0.55	5.78e-9	Body mass index;
THYM	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg08470875	chr2:26401718	FAM59B	-0.72	-4.46	-0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.03	-9.75	-0.71	5.67e-16	Primary sclerosing cholangitis;
THYM	cis	rs4363385	0.679	rs6686286	chr1:152984562	T/C	cg13444842	chr1:152974279	SPRR3	-0.61	-4.98	-0.45	2.84e-6	Inflammatory skin disease;
THYM	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg18681998	chr4:17616180	MED28	0.97	9.8	0.71	4.41e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs13315871	1.000	rs11709976	chr3:58325347	A/G	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12756686	chr19:29218302	NA	0.97	8.54	0.66	2.17e-13	Methadone dose in opioid dependence;
THYM	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg17971929	chr21:40555470	PSMG1	0.74	4.84	0.44	5.09e-6	Cognitive function;
THYM	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg07936489	chr17:37558343	FBXL20	0.8	5.79	0.51	9.24e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs17127169	0.730	rs6663109	chr1:65425747	A/G	cg12075498	chr1:65428216	JAK1	0.37	5.38	0.48	5.36e-7	Sitting height ratio;
THYM	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg18252515	chr7:66147081	NA	0.67	5.24	0.47	9.7e-7	Aortic root size;
THYM	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg25358565	chr5:93447407	FAM172A	-0.97	-7.06	-0.59	2.76e-10	Diabetic retinopathy;
THYM	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01570182	chr17:44337453	NA	0.84	9.34	0.69	4.25e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6060717	0.571	rs6060761	chr20:34612487	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-5.28	-0.48	8.08e-7	Hip circumference adjusted for BMI;
THYM	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg17063962	chr7:91808500	NA	1.1	12.12	0.78	5.59e-21	Breast cancer;
THYM	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11723261	0.621	rs11733385	chr4:140461	T/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.86	5.68	0.5	1.48e-7	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs863345	0.604	rs11264985	chr1:158465166	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs7646881	0.504	rs67305172	chr3:158464274	A/G	cg18349298	chr3:158450550	RARRES1	0.53	4.67	0.43	9.81e-6	Tetralogy of Fallot;
THYM	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg13918804	chr1:2043761	PRKCZ	-0.63	-4.77	-0.44	6.78e-6	Height;
THYM	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.14	-0.47	1.49e-6	Total cholesterol levels;
THYM	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg17211192	chr8:82754475	SNX16	-0.82	-7.41	-0.61	5.09e-11	Diastolic blood pressure;
THYM	cis	rs9902453	0.904	rs7208579	chr17:28263067	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.11	0.53	2.19e-8	Coffee consumption (cups per day);
THYM	cis	rs4262150	0.846	rs56313315	chr5:152307156	C/T	cg06854687	chr5:151642065	NA	0.68	4.82	0.44	5.35e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg09877947	chr5:131593287	PDLIM4	0.61	5.0	0.46	2.64e-6	Breast cancer;
THYM	cis	rs72792324	0.793	rs17097226	chr5:140736474	T/G	cg21929183	chr5:140807225	PCDHGA4;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB8P;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	-0.92	-4.6	-0.43	1.3e-5	Mean platelet volume;
THYM	cis	rs13315871	0.929	rs2056120	chr3:58309436	A/T	cg12435725	chr3:58293450	RPP14	-0.51	-5.58	-0.5	2.26e-7	Cholesterol, total;
THYM	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.06	-0.46	2.04e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs17006441	0.866	rs1529583	chr3:69870775	G/A	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg12963246	chr6:28129442	ZNF389	-0.86	-7.97	-0.63	3.4e-12	Depression;
THYM	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg06009448	chr7:1102226	C7orf50	0.52	5.44	0.49	4.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4481887	0.893	rs4512685	chr1:248446246	C/T	cg00666640	chr1:248458726	OR2T12	0.54	4.57	0.42	1.48e-5	Common traits (Other);
THYM	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg26314531	chr2:26401878	FAM59B	-0.76	-5.02	-0.46	2.37e-6	Gut microbiome composition (summer);
THYM	cis	rs988913	0.874	rs9382398	chr6:54783266	C/T	cg04690482	chr6:54711388	FAM83B	0.5	5.39	0.48	5.11e-7	Menarche (age at onset);
THYM	cis	rs2033562	0.965	rs1347318	chr8:103542791	T/C	cg20611272	chr8:103548145	NA	0.4	4.99	0.46	2.77e-6	IgA nephropathy;
THYM	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03264133	chr6:25882463	NA	-1.17	-11.47	-0.76	1.28e-19	Urate levels;
THYM	cis	rs7189233	1.000	rs62048544	chr16:53537741	C/T	cg02965178	chr16:53538660	AKTIP	-0.66	-5.32	-0.48	6.86e-7	Intelligence (multi-trait analysis);
THYM	cis	rs886126	1.000	rs7969686	chr12:111665388	G/A	cg10833066	chr12:111807467	FAM109A	0.42	5.16	0.47	1.36e-6	Coronary heart disease;
THYM	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg05872129	chr22:39784769	NA	-0.92	-7.7	-0.62	1.31e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs12310956	0.532	rs11052951	chr12:33986181	T/A	cg06521331	chr12:34319734	NA	-0.89	-8.32	-0.65	6.41e-13	Morning vs. evening chronotype;
THYM	cis	rs12142240	0.698	rs72890727	chr1:46860237	G/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.84	-6.63	-0.56	2.06e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg11984989	chr7:158649758	WDR60	1.12	12.86	0.8	1.61e-22	Height;
THYM	cis	rs2637266	0.655	rs2588335	chr10:78510229	C/G	cg18941641	chr10:78392320	NA	0.73	5.86	0.51	6.78e-8	Pulmonary function;
THYM	cis	rs7119	0.651	rs35577135	chr15:77840074	C/T	cg10437265	chr15:77819839	NA	0.75	7.13	0.59	1.98e-10	Type 2 diabetes;
THYM	cis	rs17122693	0.748	rs17122714	chr14:51104741	C/T	cg04730355	chr14:51134070	SAV1	0.94	5.99	0.52	3.73e-8	Cognitive performance;
THYM	cis	rs62229266	0.626	rs2835268	chr21:37449136	C/G	cg08632701	chr21:37451849	NA	-0.69	-6.96	-0.58	4.35e-10	Mitral valve prolapse;
THYM	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg27129171	chr3:47204927	SETD2	0.8	7.93	0.63	4.18e-12	Colorectal cancer;
THYM	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg07570687	chr10:102243282	WNT8B	0.84	8.04	0.64	2.45e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs360798	0.532	rs360799	chr2:62953166	G/A	cg17519650	chr2:63277830	OTX1	-0.68	-4.57	-0.42	1.44e-5	Coronary artery disease;
THYM	cis	rs7851660	0.874	rs13299924	chr9:100627562	C/T	cg13688889	chr9:100608707	NA	-0.79	-5.92	-0.52	5.07e-8	Strep throat;
THYM	cis	rs4888262	0.604	rs12935075	chr16:74676033	A/T	cg01733217	chr16:74700730	RFWD3	0.88	9.41	0.69	2.97e-15	Testicular germ cell tumor;
THYM	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22496380	chr5:211416	CCDC127	-1.3	-8.28	-0.65	7.84e-13	Breast cancer;
THYM	trans	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg19862616	chr7:65841803	NCRNA00174	1.12	13.73	0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4731207	0.596	rs2170353	chr7:124595169	T/G	cg05285228	chr7:124571219	POT1	-0.71	-5.45	-0.49	3.91e-7	Cutaneous malignant melanoma;
THYM	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg03476357	chr21:30257390	N6AMT1	-0.61	-4.64	-0.43	1.1e-5	Dental caries;
THYM	cis	rs9875589	0.509	rs1488377	chr3:14073178	C/G	cg03204825	chr3:13978759	TPRXL	-0.52	-4.56	-0.42	1.53e-5	Ovarian reserve;
THYM	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg16405210	chr4:1374714	KIAA1530	-0.61	-4.71	-0.44	8.31e-6	Obesity-related traits;
THYM	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg02891314	chr5:179741120	GFPT2	-0.92	-6.98	-0.58	3.89e-10	Height;
THYM	cis	rs870825	0.860	rs10015194	chr4:185598925	C/T	cg04058563	chr4:185651563	MLF1IP	0.91	6.95	0.58	4.63e-10	Blood protein levels;
THYM	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg03806693	chr22:41940476	POLR3H	-1.22	-11.17	-0.75	5.43e-19	Vitiligo;
THYM	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03517284	chr6:25882590	NA	-0.99	-9.03	-0.68	1.99e-14	Intelligence (multi-trait analysis);
THYM	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg05425664	chr17:57184151	TRIM37	0.61	4.97	0.45	2.98e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7107174	1.000	rs10899495	chr11:78123293	C/T	cg02023728	chr11:77925099	USP35	0.62	5.82	0.51	7.88e-8	Testicular germ cell tumor;
THYM	cis	rs3917265	0.627	rs1997502	chr2:102844249	A/G	cg13315345	chr2:102803985	IL1RL2	0.53	5.17	0.47	1.3e-6	Atopic dermatitis;
THYM	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.47	0.49	3.63e-7	Bipolar disorder;
THYM	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs4654899	0.931	rs10799671	chr1:21196764	C/T	cg01072550	chr1:21505969	NA	0.71	6.58	0.56	2.61e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs910316	0.819	rs175461	chr14:75581816	G/A	cg08847533	chr14:75593920	NEK9	-1.0	-9.81	-0.71	4.22e-16	Height;
THYM	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg17401067	chr22:41840292	TOB2	0.52	4.86	0.45	4.61e-6	Vitiligo;
THYM	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs2903698	0.585	rs28520516	chr4:76357047	T/C	cg03209871	chr4:76438412	RCHY1;THAP6	0.44	5.11	0.46	1.68e-6	Prion diseases;
THYM	trans	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg25214090	chr10:38739885	LOC399744	0.85	7.16	0.59	1.7e-10	Corneal astigmatism;
THYM	cis	rs7246657	0.943	rs9676967	chr19:37928089	G/C	cg22634378	chr19:37742834	NA	0.62	5.18	0.47	1.22e-6	Coronary artery calcification;
THYM	cis	rs7463256	1.000	rs7463256	chr8:23101620	T/C	cg14349055	chr8:23104193	CHMP7	-1.03	-12.64	-0.79	4.59e-22	Attention deficit hyperactivity disorder;
THYM	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg13393036	chr8:95962371	TP53INP1	-0.46	-4.61	-0.43	1.25e-5	Type 2 diabetes;
THYM	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Bladder cancer;
THYM	cis	rs2806561	0.929	rs627304	chr1:23537555	A/G	cg19743168	chr1:23544995	NA	0.67	7.25	0.6	1.11e-10	Height;
THYM	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg05896524	chr21:47604654	C21orf56	0.73	4.91	0.45	3.73e-6	Testicular germ cell tumor;
THYM	cis	rs7513165	1.000	rs11240695	chr1:204158132	C/A	cg04791601	chr1:204159016	NA	0.39	4.94	0.45	3.32e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
THYM	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg02820040	chr2:241836501	C2orf54	-0.3	-5.57	-0.5	2.36e-7	Urinary metabolites;
THYM	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg01017244	chr2:74357527	NA	1.03	9.24	0.69	6.82e-15	Gestational age at birth (maternal effect);
THYM	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg14019146	chr3:50243930	SLC38A3	0.59	5.0	0.46	2.61e-6	Body mass index;
THYM	cis	rs7731657	0.537	rs4705851	chr5:130220592	A/G	cg08523029	chr5:130500466	HINT1	0.75	5.02	0.46	2.44e-6	Fasting plasma glucose;
THYM	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg07936489	chr17:37558343	FBXL20	-0.83	-5.84	-0.51	7.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg20608306	chr11:116969690	SIK3	0.52	6.75	0.57	1.16e-9	Blood protein levels;
THYM	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg02527881	chr3:46936655	PTH1R	0.84	8.34	0.65	5.7e-13	Birth weight;
THYM	cis	rs72627123	0.867	rs75773875	chr14:74498053	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs343604	0.681	rs12410345	chr1:111356299	T/C	cg22165175	chr1:111148915	KCNA2	0.88	4.77	0.44	6.56e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg06453172	chr10:134556979	INPP5A	-0.65	-4.66	-0.43	1.01e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs10789491	1.000	rs7547522	chr1:47179918	C/G	cg15501359	chr1:47185051	KIAA0494	1.14	8.24	0.65	9.45e-13	Response to hepatitis C treatment;
THYM	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg18512352	chr11:47633146	NA	-0.52	-6.09	-0.53	2.34e-8	Subjective well-being;
THYM	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.67	-5.18	-0.47	1.22e-6	Tonsillectomy;
THYM	cis	rs7078219	0.714	rs12413565	chr10:101285116	C/A	cg17888390	chr10:101282816	NA	-0.53	-5.14	-0.47	1.46e-6	Dental caries;
THYM	cis	rs11031096	0.711	rs10767881	chr11:4205122	C/G	cg18678763	chr11:4115507	RRM1	-0.41	-4.84	-0.44	5.12e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs6763768	0.577	rs35536048	chr3:53388950	C/G	cg16894138	chr3:53270350	TKT	0.72	5.41	0.49	4.63e-7	Bacterial meningitis;
THYM	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg02569458	chr12:86230093	RASSF9	-0.66	-5.63	-0.5	1.84e-7	Major depressive disorder;
THYM	cis	rs73195822	0.542	rs73206866	chr12:110816505	A/G	cg24010859	chr12:110868153	NA	0.63	4.51	0.42	1.88e-5	Itch intensity from mosquito bite;
THYM	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg06640241	chr16:89574553	SPG7	0.91	8.34	0.65	5.62e-13	Multiple myeloma (IgH translocation);
THYM	trans	rs4866334	1.000	rs79038611	chr5:18503785	C/T	cg08675002	chr5:90437527	GPR98	-1.55	-7.42	-0.61	4.86e-11	IgG glycosylation;
THYM	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg25487775	chr2:162093969	NA	0.68	5.82	0.51	8e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg17105886	chr17:28927953	LRRC37B2	1.18	6.23	0.54	1.25e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg04455712	chr21:45112962	RRP1B	0.58	5.41	0.49	4.75e-7	Mean corpuscular volume;
THYM	cis	rs3784262	0.528	rs1994926	chr15:58334587	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.63	-4.75	-0.44	7.21e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
THYM	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg26924012	chr15:45694286	SPATA5L1	1.14	11.12	0.75	6.83e-19	Homoarginine levels;
THYM	cis	rs2806561	0.765	rs2806557	chr1:23503372	T/A	cg08872493	chr1:23521417	HTR1D	0.36	4.63	0.43	1.16e-5	Height;
THYM	cis	rs10095849	0.680	rs62511873	chr8:39449799	T/G	cg22755526	chr8:38854673	TM2D2;ADAM9	0.66	4.48	0.42	2.04e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg10802521	chr3:52805072	NEK4	-0.69	-6.32	-0.54	8.62e-9	Intelligence (multi-trait analysis);
THYM	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg14349672	chr11:133703707	NA	0.56	4.95	0.45	3.17e-6	Childhood ear infection;
THYM	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.27	-5.73	-0.51	1.2e-7	Obesity-related traits;
THYM	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg24733560	chr20:60626293	TAF4	0.51	4.5	0.42	1.94e-5	Body mass index;
THYM	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg00684032	chr4:1343700	KIAA1530	0.7	5.74	0.51	1.12e-7	Obesity-related traits;
THYM	cis	rs4455778	0.579	rs6969891	chr7:49123598	T/G	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs8077889	0.917	rs72836545	chr17:41892602	A/G	cg26893861	chr17:41843967	DUSP3	1.09	9.96	0.71	2.04e-16	Triglycerides;
THYM	cis	rs4713118	0.662	rs156744	chr6:27967274	G/A	cg12963246	chr6:28129442	ZNF389	0.66	5.25	0.47	9.43e-7	Parkinson's disease;
THYM	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	7.5	0.61	3.29e-11	Platelet count;
THYM	cis	rs8180040	0.800	rs2088135	chr3:47280018	T/C	cg16586182	chr3:47516702	SCAP	0.69	6.0	0.52	3.63e-8	Colorectal cancer;
THYM	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24549020	chr5:56110836	MAP3K1	0.7	4.56	0.42	1.55e-5	Initial pursuit acceleration;
THYM	cis	rs669446	0.561	rs641351	chr1:44083519	G/A	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs3087591	1.000	rs12600974	chr17:29589360	A/G	cg24425628	chr17:29625626	OMG;NF1	0.68	5.88	0.52	6.13e-8	Hip circumference;
THYM	cis	rs7020830	0.931	rs13288178	chr9:37107799	A/G	cg14294708	chr9:37120828	ZCCHC7	1.28	15.01	0.84	8.39e-27	Schizophrenia;
THYM	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg17063962	chr7:91808500	NA	1.1	10.03	0.72	1.41e-16	Breast cancer;
THYM	cis	rs2412459	0.635	rs1436276	chr15:40253743	G/T	cg16127683	chr15:40268777	EIF2AK4	0.53	4.63	0.43	1.16e-5	Response to haloperidol in psychosis;
THYM	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg09307838	chr4:120376055	NA	0.62	4.83	0.44	5.16e-6	Corneal astigmatism;
THYM	cis	rs34638657	0.797	rs7203990	chr16:82185320	A/G	cg09894383	chr16:82067445	HSD17B2	-0.5	-4.95	-0.45	3.27e-6	Lung adenocarcinoma;
THYM	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg06850241	chr22:41845214	NA	0.54	4.85	0.45	4.87e-6	Vitiligo;
THYM	cis	rs6723226	0.750	rs3769597	chr2:32691400	T/G	cg02381751	chr2:32503542	YIPF4	0.59	4.57	0.42	1.48e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg23422044	chr7:1970798	MAD1L1	0.9	6.23	0.54	1.25e-8	Bipolar disorder;
THYM	cis	rs7843479	0.601	rs6557712	chr8:21826421	C/T	cg17168535	chr8:21777572	XPO7	0.95	8.73	0.67	8.37e-14	Mean corpuscular volume;
THYM	cis	rs7639513	0.767	rs9861271	chr3:12707620	A/C	cg23032965	chr3:12705835	RAF1	0.99	7.86	0.63	5.93e-12	Itch intensity from mosquito bite;
THYM	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.49	-4.72	-0.44	8.04e-6	Crohn's disease;
THYM	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs11031096	0.621	rs11031159	chr11:4179695	T/G	cg08557956	chr11:4115526	RRM1	-0.56	-5.2	-0.47	1.13e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	trans	rs916888	0.779	rs199526	chr17:44847707	C/G	cg01341218	chr17:43662625	NA	-0.9	-7.64	-0.62	1.72e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1461503	0.548	rs7114175	chr11:122813983	A/T	cg27398637	chr11:122830231	C11orf63	-0.59	-5.19	-0.47	1.21e-6	Menarche (age at onset);
THYM	cis	rs1021993	0.868	rs906347	chr1:209528407	G/A	cg24997231	chr1:209527535	NA	-0.56	-4.45	-0.42	2.34e-5	Gut microbiome composition (winter);
THYM	cis	rs12681288	0.523	rs73176528	chr8:961962	G/A	cg08648136	chr8:956695	NA	0.56	4.92	0.45	3.57e-6	Schizophrenia;
THYM	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg00786635	chr1:25594202	NA	0.88	6.85	0.58	7.26e-10	Erythrocyte sedimentation rate;
THYM	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg16989719	chr2:238392110	NA	-0.61	-5.92	-0.52	5.19e-8	Prostate cancer;
THYM	cis	rs9902453	0.769	rs7210288	chr17:28243473	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.6	0.43	1.32e-5	Coffee consumption (cups per day);
THYM	cis	rs752010	0.875	rs11210502	chr1:42093712	A/C	cg06885757	chr1:42089581	HIVEP3	0.51	6.36	0.55	7.19e-9	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg02725872	chr8:58115012	NA	-1.06	-6.37	-0.55	6.61e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg26384229	chr12:38710491	ALG10B	0.7	5.28	0.48	8.04e-7	Morning vs. evening chronotype;
THYM	cis	rs4285028	0.747	rs1463736	chr3:121400725	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.84	-7.2	-0.59	1.37e-10	Multiple sclerosis;
THYM	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg12386194	chr3:101231763	SENP7	0.67	4.99	0.46	2.75e-6	Colorectal cancer;
THYM	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg06636001	chr8:8085503	FLJ10661	-0.62	-5.28	-0.48	8.27e-7	Joint mobility (Beighton score);
THYM	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg03433033	chr1:76189801	ACADM	0.77	10.2	0.72	6.32e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg23260525	chr10:116636907	FAM160B1	0.53	5.33	0.48	6.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs1003719	0.788	rs2835599	chr21:38466937	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.67	4.61	0.43	1.25e-5	Eye color traits;
THYM	cis	rs921968	0.643	rs3770218	chr2:219525335	C/T	cg01872077	chr2:219646372	CYP27A1	0.58	4.49	0.42	2e-5	Mean corpuscular hemoglobin concentration;
THYM	trans	rs637571	0.726	rs669371	chr11:65674153	G/T	cg17712092	chr4:129076599	LARP1B	-1.01	-10.04	-0.72	1.36e-16	Eosinophil percentage of white cells;
THYM	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg25072359	chr17:41440525	NA	0.65	4.56	0.42	1.5e-5	Menopause (age at onset);
THYM	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg03161606	chr19:29218774	NA	0.75	6.1	0.53	2.24e-8	Methadone dose in opioid dependence;
THYM	cis	rs1912528	0.745	rs6852749	chr4:140864455	C/T	cg11128457	chr4:140864437	MAML3	0.48	5.28	0.48	8.1e-7	Educational attainment (years of education);
THYM	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg17063962	chr7:91808500	NA	1.08	11.35	0.76	2.25e-19	Breast cancer;
THYM	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg24250549	chr1:154909240	PMVK	0.79	6.71	0.57	1.41e-9	Prostate cancer;
THYM	cis	rs912057	0.833	rs1294424	chr6:6744135	G/A	cg06612196	chr6:6737390	NA	0.69	9.83	0.71	3.75e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs2154427	1.000	rs2833963	chr21:34175553	C/T	cg21871883	chr21:34145043	C21orf49;C21orf66	0.98	4.62	0.43	1.22e-5	Bilirubin levels;
THYM	cis	rs2345546	1	rs2345546	chr16:25427472	C/T	cg08360281	chr16:25269390	ZKSCAN2	1.11	7.51	0.61	3.14e-11	Major depression and alcohol dependence;
THYM	cis	rs7020830	0.898	rs6476617	chr9:37200103	G/A	cg14294708	chr9:37120828	ZCCHC7	1.23	14.77	0.83	2.38e-26	Schizophrenia;
THYM	cis	rs295140	0.605	rs159321	chr2:201184713	C/T	cg23649088	chr2:200775458	C2orf69	-0.61	-5.01	-0.46	2.46e-6	QT interval;
THYM	cis	rs7851660	0.844	rs10759975	chr9:100625193	C/T	cg13688889	chr9:100608707	NA	0.77	5.31	0.48	7.25e-7	Strep throat;
THYM	cis	rs4690686	0.500	rs12498752	chr4:177265451	T/C	cg17059388	chr4:177262070	NA	0.48	6.73	0.57	1.29e-9	Essential tremor;
THYM	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg17888033	chr8:143858414	LYNX1	-0.46	-5.13	-0.47	1.55e-6	Urinary tract infection frequency;
THYM	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg18252515	chr7:66147081	NA	0.64	4.69	0.43	9.21e-6	Aortic root size;
THYM	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03452623	chr4:187889614	NA	1.16	19.04	0.89	3.4e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs985746	0.614	rs1459695	chr4:36820357	A/G	cg04301614	chr4:37585993	C4orf19	0.56	4.55	0.42	1.58e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14442939	chr10:27389572	ANKRD26	0.85	4.46	0.42	2.24e-5	Breast cancer;
THYM	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7781557	1.000	rs17135875	chr7:102519031	T/C	cg06322601	chr7:102330635	NA	0.6	4.5	0.42	1.93e-5	Colorectal adenoma (advanced);
THYM	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg13695892	chr22:41940480	POLR3H	-0.92	-7.27	-0.6	9.83e-11	Vitiligo;
THYM	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg24675658	chr1:53192096	ZYG11B	-0.82	-7.65	-0.62	1.6e-11	Monocyte count;
THYM	cis	rs10992471	0.702	rs10820967	chr9:95101729	C/G	cg14631576	chr9:95140430	CENPP	-0.94	-10.4	-0.73	2.37e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4919694	1.000	rs78214351	chr10:104822688	A/G	cg15744005	chr10:104629667	AS3MT	-0.85	-4.67	-0.43	9.96e-6	Arsenic metabolism;
THYM	cis	rs1034435	0.755	rs6007869	chr22:48894213	A/G	cg05992904	chr22:48892994	FAM19A5	-0.81	-8.83	-0.67	5.15e-14	Late-onset Alzheimer's disease;
THYM	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	trans	rs17685	0.753	rs8200	chr7:75696606	C/G	cg19862616	chr7:65841803	NCRNA00174	-1.11	-13.06	-0.8	6.41e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs12200560	0.505	rs211164	chr6:97068140	G/T	cg06623918	chr6:96969491	KIAA0776	0.76	5.77	0.51	9.9e-8	Coronary heart disease;
THYM	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg16989719	chr2:238392110	NA	-0.61	-5.98	-0.52	3.91e-8	Prostate cancer;
THYM	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg22974920	chr21:40686053	BRWD1	-0.6	-4.63	-0.43	1.15e-5	Cognitive function;
THYM	cis	rs981844	0.961	rs56288418	chr4:154668228	C/A	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg06521331	chr12:34319734	NA	-1.03	-10.3	-0.73	3.74e-17	Morning vs. evening chronotype;
THYM	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg11317459	chr13:21872234	NA	-1.21	-9.11	-0.68	1.32e-14	White matter hyperintensity burden;
THYM	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg24818145	chr4:99064322	C4orf37	0.69	5.37	0.48	5.48e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8048589	0.526	rs71388721	chr16:12212164	G/A	cg02910054	chr16:12241554	SNX29	0.73	6.2	0.54	1.48e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	5.65	0.5	1.67e-7	Lung cancer in ever smokers;
THYM	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg08847533	chr14:75593920	NEK9	-0.97	-10.4	-0.73	2.29e-17	Height;
THYM	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg00129232	chr17:37814104	STARD3	-0.71	-4.8	-0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4243830	0.850	rs4908558	chr1:6584101	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.79	-4.49	-0.42	2.02e-5	Body mass index;
THYM	cis	rs11711311	0.712	rs3773683	chr3:113341007	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.53	-4.49	-0.42	1.96e-5	IgG glycosylation;
THYM	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.49	-4.83	-0.44	5.32e-6	Schizophrenia;
THYM	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs739401	0.595	rs2073843	chr11:2970855	A/G	cg03159660	chr11:2078197	NA	-0.66	-4.85	-0.45	4.81e-6	Longevity;
THYM	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg20891283	chr12:69753455	YEATS4	0.68	5.68	0.5	1.46e-7	Blood protein levels;
THYM	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.92	0.45	3.58e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11112613	0.713	rs73184083	chr12:105952593	T/A	cg03607813	chr12:105948248	NA	0.99	8.2	0.64	1.17e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs6964587	0.655	rs6465351	chr7:91773213	T/C	cg17063962	chr7:91808500	NA	0.98	8.49	0.66	2.78e-13	Breast cancer;
THYM	cis	rs8044868	0.521	rs7203821	chr16:72101165	T/C	cg16558253	chr16:72132732	DHX38	-0.54	-4.57	-0.42	1.46e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg03690763	chr11:133734501	NA	0.64	4.82	0.44	5.36e-6	Childhood ear infection;
THYM	cis	rs28595532	0.925	rs56200441	chr4:119497440	T/G	cg21605333	chr4:119757512	SEC24D	1.44	5.22	0.47	1.03e-6	Cannabis dependence symptom count;
THYM	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg01699819	chr7:1052092	C7orf50	-0.56	-4.96	-0.45	3.09e-6	Longevity;Endometriosis;
THYM	cis	rs7084402	0.967	rs2170779	chr10:60277249	G/A	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.28	10.65	0.74	6.95e-18	Platelet count;
THYM	cis	rs5769707	0.609	rs2071890	chr22:50001291	G/A	cg17054759	chr22:49844102	NA	-0.52	-4.55	-0.42	1.61e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg02466173	chr16:30829666	NA	-0.52	-4.48	-0.42	2.09e-5	Dementia with Lewy bodies;
THYM	cis	rs9462846	0.853	rs7741552	chr6:42873823	A/G	cg09436375	chr6:42928200	GNMT	-0.37	-4.51	-0.42	1.82e-5	Blood protein levels;
THYM	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg19761014	chr17:28927070	LRRC37B2	0.89	4.93	0.45	3.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28595532	0.920	rs56150431	chr4:119764786	T/C	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg10856724	chr12:34555212	NA	-0.67	-5.32	-0.48	6.82e-7	Resting heart rate;
THYM	cis	rs6424115	0.830	rs2501426	chr1:24199364	G/A	cg15997130	chr1:24165203	NA	0.74	6.34	0.55	7.54e-9	Immature fraction of reticulocytes;
THYM	cis	rs59698941	0.943	rs67160603	chr5:132285618	G/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22857025	chr5:266934	NA	-1.59	-10.2	-0.72	6.04e-17	Breast cancer;
THYM	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg06481639	chr22:41940642	POLR3H	-0.82	-5.61	-0.5	1.97e-7	Vitiligo;
THYM	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.59	-0.43	1.33e-5	Bipolar disorder;
THYM	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg18032289	chr17:61959525	GH2	-0.49	-4.7	-0.43	8.9e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7646881	1.000	rs73015651	chr3:158450922	C/T	cg18349298	chr3:158450550	RARRES1	0.52	4.73	0.44	7.91e-6	Tetralogy of Fallot;
THYM	cis	rs4430311	0.655	rs12141946	chr1:243811634	T/G	cg25706552	chr1:244017396	NA	-0.55	-4.64	-0.43	1.1e-5	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs2276314	0.553	rs4799842	chr18:33627968	C/A	cg19628046	chr18:33552617	C18orf21	0.66	4.95	0.45	3.22e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7152530	0.571	rs28488824	chr14:98634874	G/A	cg05180522	chr14:98101740	NA	-0.61	-4.74	-0.44	7.57e-6	Staphylococcus aureus infection;
THYM	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg00684032	chr4:1343700	KIAA1530	0.61	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg05182265	chr7:156933206	UBE3C	-0.69	-9.32	-0.69	4.58e-15	Body mass index;
THYM	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs7851660	0.809	rs12004762	chr9:100652755	A/G	cg13688889	chr9:100608707	NA	-0.78	-5.67	-0.5	1.53e-7	Strep throat;
THYM	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg23161317	chr6:28129485	ZNF389	0.68	5.38	0.48	5.35e-7	Parkinson's disease;
THYM	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Urate levels;
THYM	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg14768367	chr16:72042858	DHODH	0.67	5.27	0.48	8.41e-7	Fibrinogen levels;
THYM	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg03929089	chr4:120376271	NA	1.02	8.12	0.64	1.67e-12	Coronary artery disease;
THYM	cis	rs8033133	0.881	rs3803328	chr15:25330550	T/A	cg14481604	chr15:25334117	SNORD116-22	-0.69	-4.5	-0.42	1.95e-5	Blood osmolality (transformed sodium);
THYM	cis	rs12681288	0.723	rs12545453	chr8:970582	C/T	cg08648136	chr8:956695	NA	0.68	6.02	0.53	3.26e-8	Schizophrenia;
THYM	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg03060546	chr3:49711283	APEH	-0.67	-5.08	-0.46	1.85e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg04398451	chr17:18023971	MYO15A	0.9	9.71	0.71	6.98e-16	Total body bone mineral density;
THYM	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs920590	0.684	rs57837509	chr8:19670088	A/G	cg01411142	chr8:19674711	INTS10	0.68	5.37	0.48	5.48e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs12289510	0.573	rs11219893	chr11:124953917	A/C	cg03868193	chr11:124958746	SLC37A2	-0.7	-5.61	-0.5	1.95e-7	Platelet-derived growth factor BB levels;
THYM	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg10164272	chr16:89456328	ANKRD11	0.58	4.51	0.42	1.88e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs763014	0.833	rs3743902	chr16:632728	T/C	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs7178572	0.568	rs1446312	chr15:77412189	G/C	cg22256960	chr15:77711686	NA	-0.99	-7.65	-0.62	1.64e-11	Type 2 diabetes;
THYM	cis	rs9543976	0.858	rs8192763	chr13:76179170	A/T	cg01531495	chr13:76123901	UCHL3	0.75	5.05	0.46	2.1e-6	Diabetic retinopathy;
THYM	cis	rs72627123	0.867	rs57731447	chr14:74487521	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs6815814	0.851	rs11466617	chr4:38780471	T/C	cg02016764	chr4:38805732	TLR1	-0.58	-5.16	-0.47	1.37e-6	Breast cancer;
THYM	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg04287289	chr16:89883240	FANCA	0.5	4.73	0.44	7.94e-6	Vitiligo;
THYM	cis	rs2235649	0.956	rs3829540	chr16:1836393	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.49	-4.93	-0.45	3.54e-6	Blood metabolite levels;
THYM	cis	rs728616	0.867	rs17886286	chr10:81703852	C/G	cg05935833	chr10:81318306	SFTPA2	-0.77	-5.06	-0.46	2.06e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4523957	0.583	rs7503141	chr17:2044645	T/C	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs995000	0.965	rs11207977	chr1:62977307	C/T	cg06896770	chr1:63153194	DOCK7	1.0	8.17	0.64	1.31e-12	Triglyceride levels;
THYM	cis	rs61990749	0.511	rs10146144	chr14:78325300	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.87	5.4	0.48	5.01e-7	Fibroblast growth factor basic levels;
THYM	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs1371867	0.875	rs1619759	chr8:101337560	T/C	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg16414030	chr3:133502952	NA	0.85	8.38	0.65	4.78e-13	Iron status biomarkers;
THYM	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7181230	1.000	rs9972424	chr15:40365851	A/G	cg20592017	chr15:40364740	NA	0.61	5.51	0.49	3.04e-7	Dehydroepiandrosterone sulphate levels;
THYM	cis	rs9790314	0.521	rs1376122	chr3:161087857	A/G	cg04691961	chr3:161091175	C3orf57	-0.59	-4.87	-0.45	4.45e-6	Morning vs. evening chronotype;
THYM	cis	rs2281845	0.826	rs4915214	chr1:201076290	T/A	cg22815214	chr1:201083145	CACNA1S	0.64	5.94	0.52	4.74e-8	Permanent tooth development;
THYM	cis	rs7156960	0.540	rs4903393	chr14:76734188	A/C	cg13981132	chr14:76734493	NA	-0.45	-4.97	-0.45	2.91e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg16342193	chr10:102329863	NA	-0.47	-4.53	-0.42	1.72e-5	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg17105886	chr17:28927953	LRRC37B2	1.18	6.23	0.54	1.25e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg18252515	chr7:66147081	NA	-1.48	-8.83	-0.67	5.15e-14	Diabetic kidney disease;
THYM	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg14582100	chr15:45693742	SPATA5L1	0.61	5.06	0.46	2.03e-6	Homoarginine levels;
THYM	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg25358565	chr5:93447407	FAM172A	1.39	10.46	0.73	1.72e-17	Diabetic retinopathy;
THYM	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg16405210	chr4:1374714	KIAA1530	-0.63	-5.21	-0.47	1.08e-6	Longevity;
THYM	cis	rs12444261	1.000	rs60493856	chr16:11739851	A/C	cg09662852	chr16:11707685	NA	-0.49	-4.66	-0.43	1.05e-5	QT interval;
THYM	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg14456004	chr13:21872349	NA	-1.25	-10.18	-0.72	6.85e-17	White matter hyperintensity burden;
THYM	cis	rs78366141	0.536	rs78517451	chr4:89650437	C/A	cg01026744	chr4:89619053	NAP1L5;HERC3	1.39	5.74	0.51	1.14e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs4784054	0.803	rs7204324	chr16:58750869	A/T	cg26293512	chr16:58010433	TEPP	0.75	4.63	0.43	1.16e-5	Blood metabolite levels;
THYM	cis	rs981844	0.712	rs4292309	chr4:154745178	C/A	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs7100689	0.784	rs10736341	chr10:82061206	C/G	cg01528321	chr10:82214614	TSPAN14	1.02	7.78	0.62	8.75e-12	Post bronchodilator FEV1;
THYM	cis	rs651907	0.554	rs10470501	chr3:101630497	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	4.55	0.42	1.58e-5	Colorectal cancer;
THYM	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs16858210	0.520	rs34190894	chr3:183550412	A/T	cg03417191	chr3:183542750	MAP6D1	-0.84	-4.97	-0.45	2.97e-6	Menopause (age at onset);
THYM	cis	rs2652822	0.525	rs1910094	chr15:63485527	G/C	cg09251291	chr15:63483946	RAB8B	0.59	5.34	0.48	6.36e-7	Metabolic traits;
THYM	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg08885076	chr2:99613938	TSGA10	0.56	5.6	0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg06634786	chr22:41940651	POLR3H	-0.69	-5.66	-0.5	1.58e-7	Vitiligo;
THYM	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	5.62	0.5	1.89e-7	Schizophrenia;
THYM	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg25072359	chr17:41440525	NA	0.7	4.92	0.45	3.6e-6	Menopause (age at onset);
THYM	cis	rs665401	0.965	rs339302	chr6:117224641	A/T	cg20376953	chr6:117187980	NA	0.6	4.82	0.44	5.5e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs11039798	0.623	rs635632	chr11:48399532	T/C	cg24672777	chr11:48374446	OR4C45	0.96	6.27	0.54	1.05e-8	Axial length;
THYM	cis	rs6743226	0.748	rs12620606	chr2:242154015	A/G	cg23350296	chr2:242663858	ING5	-0.46	-4.49	-0.42	1.98e-5	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs71403859	0.730	rs12922775	chr16:71584354	C/T	cg08717414	chr16:71523259	ZNF19	-1.2	-6.38	-0.55	6.44e-9	Post bronchodilator FEV1;
THYM	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg27170947	chr2:26402098	FAM59B	0.77	4.98	0.46	2.81e-6	Gut microbiome composition (summer);
THYM	cis	rs12681287	0.640	rs13251006	chr8:87469105	C/T	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs921968	0.643	rs3931102	chr2:219520405	C/T	cg01872077	chr2:219646372	CYP27A1	0.58	4.49	0.42	2e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8067545	0.720	rs6587206	chr17:19881587	T/C	cg20830565	chr17:20408647	MGC102966	-0.55	-5.16	-0.47	1.35e-6	Schizophrenia;
THYM	cis	rs34912216	0.542	rs4607516	chr7:4130004	A/G	cg26550874	chr7:4183528	SDK1	0.6	4.46	0.42	2.22e-5	Motion sickness;
THYM	cis	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg07460842	chr6:66804631	NA	1.11	8.12	0.64	1.7e-12	Exhaled nitric oxide output;
THYM	cis	rs9467160	0.581	rs760903	chr6:24474658	A/G	cg00346970	chr6:24499591	ALDH5A1	0.35	4.69	0.43	9.25e-6	Liver enzyme levels;
THYM	cis	rs7940866	0.801	rs2113929	chr11:130835974	G/A	cg23692386	chr11:131799662	NTM	0.48	5.08	0.46	1.91e-6	Schizophrenia;
THYM	cis	rs78761021	0.720	rs79348078	chr17:9795771	T/A	cg26853458	chr17:9805074	RCVRN	0.53	4.46	0.42	2.24e-5	Type 2 diabetes;
THYM	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg08999081	chr20:33150536	PIGU	0.76	6.7	0.57	1.47e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg10802521	chr3:52805072	NEK4	-0.73	-6.43	-0.55	5.15e-9	Bipolar disorder;
THYM	cis	rs7107174	1.000	rs2512550	chr11:77943848	C/T	cg02023728	chr11:77925099	USP35	0.72	6.46	0.55	4.54e-9	Testicular germ cell tumor;
THYM	cis	rs79387448	0.745	rs17027413	chr2:103153667	A/G	cg09003973	chr2:102972529	NA	-0.77	-4.45	-0.42	2.31e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg18512352	chr11:47633146	NA	-0.53	-6.56	-0.56	2.75e-9	Subjective well-being;
THYM	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg24812749	chr6:127587940	RNF146	0.8	5.99	0.52	3.74e-8	Breast cancer;
THYM	cis	rs2282300	0.667	rs10734405	chr11:30273750	T/C	cg06241208	chr11:30344200	C11orf46	0.78	5.65	0.5	1.67e-7	Morning vs. evening chronotype;
THYM	cis	rs11577318	0.579	rs12131370	chr1:26698430	G/A	cg16664472	chr1:26644822	UBXN11;CD52	0.33	4.7	0.43	8.78e-6	Granulocyte percentage of myeloid white cells;
THYM	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11890956	chr21:40555474	PSMG1	-0.97	-11.28	-0.76	3.16e-19	Cognitive function;
THYM	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg19747945	chr6:42946146	PEX6	-0.32	-4.82	-0.44	5.38e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7173743	0.756	rs4551997	chr15:79130433	G/A	cg00540400	chr15:79124168	NA	0.62	6.53	0.56	3.29e-9	Coronary artery disease;
THYM	cis	rs13256369	0.756	rs13280759	chr8:8562995	G/T	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs11690935	0.595	rs788170	chr2:172919958	T/C	cg13550731	chr2:172543902	DYNC1I2	0.72	5.96	0.52	4.35e-8	Schizophrenia;
THYM	cis	rs6980334	0.817	rs10263205	chr7:137792922	C/T	cg22979093	chr7:137028410	PTN	0.62	4.95	0.45	3.19e-6	Blood metabolite ratios;
THYM	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs2219968	0.676	rs10156234	chr8:78835777	C/T	cg00738934	chr8:78996279	NA	-0.7	-6.24	-0.54	1.23e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg12698349	chr2:225449008	CUL3	1.13	13.32	0.81	1.86e-23	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg27286337	chr10:134555280	INPP5A	0.84	5.93	0.52	4.78e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs3820068	0.608	rs7552400	chr1:16035892	A/G	cg24675056	chr1:15929824	NA	0.78	6.16	0.53	1.73e-8	Systolic blood pressure;
THYM	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg06636001	chr8:8085503	FLJ10661	0.61	5.08	0.46	1.84e-6	Neuroticism;
THYM	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.43	0.7	2.73e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs34638657	0.872	rs8051436	chr16:82171979	G/C	cg09894383	chr16:82067445	HSD17B2	-0.47	-4.81	-0.44	5.62e-6	Lung adenocarcinoma;
THYM	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs2115630	0.902	rs8023276	chr15:85219638	C/T	cg11189052	chr15:85197271	WDR73	-0.64	-4.82	-0.44	5.49e-6	P wave terminal force;
THYM	cis	rs12216545	0.737	rs10238055	chr7:150249729	G/A	cg08960815	chr7:150264767	GIMAP4	-0.89	-8.27	-0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg06784218	chr1:46089804	CCDC17	-0.34	-5.03	-0.46	2.28e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs9876781	0.933	rs6442124	chr3:48505302	A/G	cg06066452	chr3:48470258	PLXNB1	0.26	4.47	0.42	2.18e-5	Longevity;
THYM	cis	rs2811415	0.627	rs9820691	chr3:127750866	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs1457451	0.646	rs2045431	chr2:65863527	A/G	cg16240816	chr2:65861662	NA	0.68	8.18	0.64	1.25e-12	Iron status biomarkers;
THYM	trans	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg26043149	chr18:55253948	FECH	1.25	11.26	0.76	3.53e-19	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs666930	0.519	rs532303	chr1:120265444	A/G	cg19096424	chr1:120255104	PHGDH	0.92	8.21	0.64	1.08e-12	Breast cancer;
THYM	cis	rs10927875	0.541	rs1048245	chr1:16341354	T/G	cg22431228	chr1:16359049	CLCNKA	-0.53	-5.15	-0.47	1.4e-6	Dilated cardiomyopathy;
THYM	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs250585	0.736	rs250579	chr16:23425585	A/G	cg00143387	chr16:23521605	GGA2	0.74	5.27	0.48	8.6e-7	Egg allergy;
THYM	cis	rs73206853	0.925	rs28670753	chr12:110826463	C/T	cg24703420	chr12:111373904	NA	0.71	4.52	0.42	1.75e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
THYM	cis	rs9419702	0.526	rs9419637	chr10:133548059	T/C	cg20568497	chr10:133558893	NA	0.47	4.73	0.44	7.93e-6	Survival in rectal cancer;
THYM	cis	rs4638749	0.677	rs2378098	chr2:108849381	T/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.74	-6.92	-0.58	5.17e-10	Personality dimensions;
THYM	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.67	5.84	0.51	7.4e-8	Lung disease severity in cystic fibrosis;
THYM	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg24578937	chr1:2090814	PRKCZ	0.81	8.54	0.66	2.22e-13	Height;
THYM	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06850241	chr22:41845214	NA	-0.59	-5.34	-0.48	6.24e-7	Vitiligo;
THYM	cis	rs6867032	1.000	rs10462750	chr5:2012963	A/G	cg26168224	chr5:2018326	NA	1.26	15.12	0.84	4.92e-27	Gut microbiome composition (winter);
THYM	cis	rs2717559	0.522	rs2585160	chr8:143875204	G/A	cg17252645	chr8:143867129	LY6D	0.82	10.04	0.72	1.38e-16	Urinary tract infection frequency;
THYM	cis	rs3741151	1.000	rs78433080	chr11:73067565	G/A	cg17517138	chr11:73019481	ARHGEF17	0.99	5.88	0.52	5.97e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2294693	0.945	rs13216361	chr6:41007046	C/T	cg21128951	chr6:40996213	UNC5CL	0.61	4.58	0.43	1.38e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs2227564	0.597	rs12256103	chr10:75545251	A/G	cg00564723	chr10:75632066	CAMK2G	-0.54	-4.8	-0.44	5.78e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs10832963	0.924	rs10500834	chr11:18638712	A/T	cg09201001	chr11:18656081	SPTY2D1	1.07	9.63	0.7	1.04e-15	Breast cancer;
THYM	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs889398	0.967	rs35967356	chr16:69581354	C/T	cg09409435	chr16:70099608	PDXDC2	-0.61	-4.85	-0.45	4.85e-6	Body mass index;
THYM	cis	rs11864453	0.793	rs7197869	chr16:72079352	G/C	cg23815491	chr16:72088622	HP	0.97	9.39	0.69	3.3e-15	Fibrinogen levels;
THYM	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg04025307	chr7:1156635	C7orf50	0.63	5.8	0.51	8.84e-8	Longevity;Endometriosis;
THYM	cis	rs4523957	0.522	rs8081921	chr17:2021490	C/A	cg16513277	chr17:2031491	SMG6	-0.96	-8.72	-0.67	9.17e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg12031863	chr16:4587854	C16orf5	-0.44	-4.9	-0.45	3.89e-6	Schizophrenia;
THYM	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.1	-0.46	1.7e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg19875535	chr5:140030758	IK	0.58	4.61	0.43	1.26e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs3806843	1.000	rs4451093	chr5:140158542	A/G	cg19875535	chr5:140030758	IK	-0.58	-4.65	-0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg05340658	chr4:99064831	C4orf37	0.54	4.51	0.42	1.83e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2403083	0.578	rs12549289	chr8:86076437	C/T	cg13721134	chr8:86350390	CA3	0.46	4.46	0.42	2.29e-5	Plasma amyloid beta peptide concentrations (ABx-40);
THYM	cis	rs10887741	0.646	rs1358865	chr10:89432645	C/A	cg13926569	chr10:89418898	PAPSS2	0.62	6.97	0.58	4.19e-10	Exercise (leisure time);
THYM	cis	rs208520	0.802	rs851600	chr6:66893754	T/C	cg07460842	chr6:66804631	NA	-0.84	-5.65	-0.5	1.68e-7	Exhaled nitric oxide output;
THYM	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs36051895	0.659	rs12337134	chr9:5061578	G/A	cg02405213	chr9:5042618	JAK2	-1.01	-11.2	-0.75	4.73e-19	Pediatric autoimmune diseases;
THYM	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7572733	0.534	rs734037	chr2:198749269	G/A	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs11690935	0.688	rs7600835	chr2:172521827	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.63	-5.0	-0.46	2.63e-6	Schizophrenia;
THYM	cis	rs4523957	0.928	rs216220	chr17:2148821	G/T	cg16513277	chr17:2031491	SMG6	0.79	7.42	0.61	4.95e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11031096	0.711	rs10835719	chr11:4203906	A/G	cg08557956	chr11:4115526	RRM1	0.52	4.74	0.44	7.4e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7809950	0.817	rs17154091	chr7:107084790	T/C	cg23024343	chr7:107201750	COG5	-1.02	-8.69	-0.67	1.02e-13	Coronary artery disease;
THYM	cis	rs2625529	0.652	rs2957736	chr15:72265344	A/G	cg16672083	chr15:72433130	SENP8	0.49	4.48	0.42	2.09e-5	Red blood cell count;
THYM	cis	rs1790761	0.587	rs4930430	chr11:67294198	A/G	cg01069141	chr11:67398826	TBX10;NUDT8	0.47	5.04	0.46	2.2e-6	Mean corpuscular volume;
THYM	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg00129232	chr17:37814104	STARD3	-0.92	-7.23	-0.6	1.22e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs7264396	0.563	rs6060592	chr20:34352414	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-4.55	-0.42	1.56e-5	Total cholesterol levels;
THYM	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs6964587	0.626	rs34404183	chr7:91551249	T/C	cg22709100	chr7:91322751	NA	-0.62	-4.64	-0.43	1.1e-5	Breast cancer;
THYM	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg11663144	chr21:46675770	NA	0.72	10.04	0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2820651	0.614	rs114139266	chr10:1489054	C/T	cg27404824	chr10:1454848	ADARB2	0.88	4.75	0.44	7.06e-6	Migraine with aura;
THYM	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs75920871	0.588	rs4620758	chr11:116945718	G/A	cg20608306	chr11:116969690	SIK3	-0.52	-5.72	-0.51	1.2e-7	Subjective well-being;
THYM	cis	rs1957429	0.808	rs4902325	chr14:65330843	A/G	cg23373153	chr14:65346875	NA	-0.95	-5.17	-0.47	1.28e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4589258	0.933	rs12806535	chr11:90425578	C/G	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs3741151	0.892	rs7105705	chr11:73012319	T/G	cg12959048	chr11:73096162	RELT	-0.42	-4.49	-0.42	1.97e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg15247329	chr7:2764246	NA	-0.7	-5.75	-0.51	1.1e-7	Height;
THYM	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.59	4.99	0.46	2.73e-6	Hemoglobin concentration;
THYM	cis	rs55883249	1.000	rs62119429	chr2:9743585	G/C	cg23886495	chr2:9695866	ADAM17	0.83	5.36	0.48	5.85e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs2016266	0.859	rs4759061	chr12:53738214	C/T	cg26875137	chr12:53738046	NA	-0.78	-5.78	-0.51	9.62e-8	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs61774743	0.557	rs4660192	chr1:41842350	C/T	cg08462924	chr1:41848221	NA	0.82	9.21	0.69	8.01e-15	Intelligence (multi-trait analysis);
THYM	cis	rs4638749	0.588	rs13401731	chr2:108885340	C/T	cg25838818	chr2:108905173	SULT1C2	-0.51	-5.59	-0.5	2.2e-7	Blood pressure;
THYM	cis	rs11696501	0.688	rs6065866	chr20:44323440	G/A	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg15556689	chr8:8085844	FLJ10661	-0.63	-5.25	-0.47	9.17e-7	Mood instability;
THYM	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg06600287	chr1:53387719	ECHDC2	-0.3	-4.9	-0.45	3.86e-6	Monocyte count;
THYM	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg16405210	chr4:1374714	KIAA1530	-0.64	-5.3	-0.48	7.4e-7	Longevity;
THYM	cis	rs9581857	0.579	rs75326986	chr13:27997758	C/T	cg22138327	chr13:27999177	GTF3A	1.04	6.13	0.53	1.97e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg11247378	chr22:39784982	NA	-1.06	-13.37	-0.81	1.49e-23	Intelligence (multi-trait analysis);
THYM	cis	rs13082711	0.911	rs6797389	chr3:27502070	G/T	cg02860705	chr3:27208620	NA	0.72	5.14	0.47	1.46e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs1215050	0.740	rs6854802	chr4:99065480	A/C	cg17366294	chr4:99064904	C4orf37	0.41	4.55	0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs887829	0.570	rs6759892	chr2:234601669	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.79	6.88	0.58	6.26e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs9677476	0.863	rs12465438	chr2:232073106	G/A	cg07929768	chr2:232055508	NA	0.63	6.38	0.55	6.48e-9	Food antigen IgG levels;
THYM	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg09323728	chr8:95962352	TP53INP1	-0.48	-4.93	-0.45	3.53e-6	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg03351412	chr1:154909251	PMVK	0.7	5.38	0.48	5.4e-7	Prostate cancer;
THYM	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.67	4.9	0.45	3.93e-6	Glycated hemoglobin levels;
THYM	cis	rs9297145	0.565	rs56132062	chr7:98778198	C/T	cg05967295	chr7:98741636	SMURF1	-0.72	-5.74	-0.51	1.12e-7	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs17255340	0.520	rs1170501	chr6:83991861	C/A	cg21688264	chr6:84418724	SNAP91	0.66	4.46	0.42	2.22e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg09263875	chr16:632152	PIGQ	-0.58	-4.69	-0.43	9.26e-6	Height;
THYM	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg08000102	chr2:233561755	GIGYF2	-0.69	-6.26	-0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs2046867	0.862	rs67961837	chr3:72840877	T/G	cg25664220	chr3:72788482	NA	-0.93	-7.35	-0.6	6.79e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg02734326	chr4:10020555	SLC2A9	0.69	5.64	0.5	1.73e-7	Bone mineral density;
THYM	cis	rs9972944	0.729	rs12939140	chr17:63777249	T/A	cg07283582	chr17:63770753	CCDC46	0.68	5.54	0.49	2.69e-7	Total body bone mineral density;
THYM	cis	rs1894633	0.574	rs61806089	chr1:172338301	A/G	cg13446689	chr1:172328377	DNM3	0.54	4.94	0.45	3.32e-6	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4242434	0.927	rs11136093	chr8:22479988	C/G	cg03733263	chr8:22462867	KIAA1967	1.17	11.8	0.77	2.49e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg14664628	chr15:75095509	CSK	-1.08	-9.57	-0.7	1.35e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg24531977	chr5:56204891	C5orf35	-1.01	-8.29	-0.65	7.47e-13	Initial pursuit acceleration;
THYM	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg13289132	chr10:30722225	MAP3K8	-0.67	-5.39	-0.48	5.22e-7	Inflammatory bowel disease;
THYM	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg08017756	chr2:100939284	LONRF2	-0.74	-7.74	-0.62	1.06e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7010267	0.935	rs10955915	chr8:119963547	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.6	4.87	0.45	4.36e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs2439831	0.681	rs884704	chr15:43691150	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	6.89	0.58	5.93e-10	Lung cancer in ever smokers;
THYM	cis	rs988913	1.000	rs9367600	chr6:54837977	T/C	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.75e-6	Menarche (age at onset);
THYM	cis	rs2302612	0.528	rs3771186	chr2:102840411	G/A	cg13315345	chr2:102803985	IL1RL2	0.68	4.71	0.43	8.61e-6	Serum protein levels (sST2);
THYM	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg22307297	chr20:60903441	LAMA5	0.53	4.57	0.42	1.45e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs7523273	0.565	rs3927459	chr1:207883907	A/C	cg22525895	chr1:207977042	MIR29B2	0.53	4.89	0.45	4.07e-6	Schizophrenia;
THYM	cis	rs12540874	0.931	rs4245555	chr7:50661409	A/G	cg18232548	chr7:50535776	DDC	-0.58	-4.65	-0.43	1.07e-5	Systemic sclerosis;
THYM	cis	rs12216545	0.765	rs7792574	chr7:150224206	T/C	cg00323915	chr7:150264987	GIMAP4	-0.49	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs12579753	1.000	rs11519754	chr12:82209181	A/T	cg07988820	chr12:82153109	PPFIA2	-0.72	-4.47	-0.42	2.15e-5	Resting heart rate;
THYM	cis	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs3126085	0.935	rs1466757	chr1:152212469	G/A	cg10321714	chr1:152280068	FLG	0.68	5.07	0.46	1.98e-6	Atopic dermatitis;
THYM	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg11266682	chr4:10021025	SLC2A9	0.74	12.07	0.78	6.92e-21	Bone mineral density;
THYM	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg08885076	chr2:99613938	TSGA10	0.66	6.18	0.54	1.6e-8	Chronic sinus infection;
THYM	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg07022442	chr13:21864356	NA	0.72	4.78	0.44	6.49e-6	White matter hyperintensity burden;
THYM	cis	rs9649213	0.593	rs13246868	chr7:97986453	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6429082	0.715	rs2172718	chr1:235580727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.63	-5.31	-0.48	7.25e-7	Adiposity;
THYM	cis	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg07460842	chr6:66804631	NA	1.1	8.21	0.64	1.08e-12	Exhaled nitric oxide output;
THYM	cis	rs6748734	0.625	rs4312489	chr2:241821068	T/A	cg15164180	chr2:241846931	NA	-0.34	-4.63	-0.43	1.16e-5	Urinary metabolites;
THYM	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs42648	0.617	rs11563435	chr7:89900207	A/C	cg25739043	chr7:89950458	NA	-0.53	-4.49	-0.42	2.01e-5	Homocysteine levels;
THYM	cis	rs1986734	0.576	rs4624677	chr4:77420406	T/C	cg20311846	chr4:77356250	SHROOM3	-0.43	-4.66	-0.43	1.01e-5	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
THYM	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg14004847	chr7:1930337	MAD1L1	-0.63	-5.05	-0.46	2.16e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs1497406	0.744	rs4233540	chr1:16507384	A/G	cg20430773	chr1:16534157	ARHGEF19	-0.48	-5.5	-0.49	3.14e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg11279151	chr3:101281821	RG9MTD1	0.89	6.75	0.57	1.15e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2219968	0.828	rs60036550	chr8:78911936	G/A	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs16912285	0.748	rs7104694	chr11:24280281	A/C	ch.11.24196551F	chr11:24239977	NA	0.99	7.06	0.59	2.74e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg02353165	chr6:42928485	GNMT	-0.74	-5.33	-0.48	6.74e-7	Blood protein levels;
THYM	cis	rs11723261	0.582	rs11735742	chr4:142550	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	-0.79	-5.86	-0.52	6.74e-8	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs75920871	0.588	rs721783	chr11:116907449	C/T	cg20608306	chr11:116969690	SIK3	-0.49	-5.34	-0.48	6.24e-7	Subjective well-being;
THYM	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg20469991	chr17:27169893	C17orf63	-0.76	-4.78	-0.44	6.27e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg10862848	chr6:42927986	GNMT	-0.51	-6.83	-0.57	8.14e-10	Plasma homocysteine levels (post-methionine load test);
THYM	cis	rs490647	0.894	rs6425999	chr1:37228201	T/C	cg09088576	chr1:36947785	CSF3R	-0.47	-4.59	-0.43	1.38e-5	Neuroticism;
THYM	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg24920358	chr1:40204285	PPIE	0.6	5.55	0.5	2.53e-7	Blood protein levels;
THYM	cis	rs8067545	0.616	rs203470	chr17:19858626	C/T	cg20830565	chr17:20408647	MGC102966	-0.5	-4.57	-0.42	1.46e-5	Schizophrenia;
THYM	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg27170947	chr2:26402098	FAM59B	0.79	6.27	0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	10.29	0.73	4e-17	Chronic sinus infection;
THYM	cis	rs995000	0.929	rs2029763	chr1:63013134	A/G	cg06896770	chr1:63153194	DOCK7	1.0	8.17	0.64	1.31e-12	Triglyceride levels;
THYM	cis	rs12928939	0.723	rs28667298	chr16:71855134	T/G	cg03805757	chr16:71968109	PKD1L3	-0.82	-5.88	-0.52	6.1e-8	Post bronchodilator FEV1;
THYM	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg13902645	chr11:5959945	NA	-0.55	-4.84	-0.44	4.99e-6	DNA methylation (variation);
THYM	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg02953382	chr22:24373134	LOC391322	-0.7	-6.19	-0.54	1.52e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2985684	1.000	rs2985697	chr14:50092902	A/G	cg02151108	chr14:50098012	C14orf104	-0.67	-5.42	-0.49	4.42e-7	Carotid intima media thickness;
THYM	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs4733781	0.509	rs12550365	chr8:131136046	A/T	cg16277922	chr8:131349729	ASAP1	0.64	5.99	0.52	3.7e-8	Tuberculosis;
THYM	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.84	4.66	0.43	1.04e-5	Initial pursuit acceleration;
THYM	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg00129232	chr17:37814104	STARD3	-0.78	-5.15	-0.47	1.39e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg25767906	chr1:53392781	SCP2	0.72	6.48	0.55	4.15e-9	Monocyte count;
THYM	cis	rs1535500	0.967	rs12663159	chr6:39282277	C/A	cg00012638	chr6:39280541	KCNK17	0.61	8.08	0.64	2.06e-12	Type 2 diabetes;
THYM	cis	rs7772486	0.846	rs1854901	chr6:146325685	T/C	cg23711669	chr6:146136114	FBXO30	0.9	8.92	0.68	3.32e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg04518342	chr5:131593106	PDLIM4	0.47	5.2	0.47	1.16e-6	Blood metabolite levels;
THYM	cis	rs11031096	0.678	rs970329	chr11:4189803	G/T	cg08557956	chr11:4115526	RRM1	-0.59	-5.44	-0.49	4.19e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4285028	0.948	rs35737776	chr3:121677856	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11644478	chr21:40555479	PSMG1	-0.56	-4.69	-0.43	9.07e-6	Menarche (age at onset);
THYM	cis	rs800586	0.500	rs179442	chr8:116669769	C/T	cg04656070	chr8:116661063	TRPS1	-0.55	-6.59	-0.56	2.5e-9	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg24675056	chr1:15929824	NA	0.74	5.78	0.51	9.65e-8	Systolic blood pressure;
THYM	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg04267008	chr7:1944627	MAD1L1	-0.7	-6.55	-0.56	2.95e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg00256281	chr22:41985642	PMM1	0.62	4.85	0.45	4.76e-6	Vitiligo;
THYM	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg11871910	chr12:69753446	YEATS4	0.75	6.25	0.54	1.18e-8	Blood protein levels;
THYM	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg24818145	chr4:99064322	C4orf37	0.67	5.2	0.47	1.13e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6748734	0.625	rs6741220	chr2:241822432	C/T	cg07537917	chr2:241836409	C2orf54	0.22	5.0	0.46	2.6e-6	Urinary metabolites;
THYM	cis	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg13443165	chr9:33130375	B4GALT1	-0.7	-4.64	-0.43	1.13e-5	IgG glycosylation;
THYM	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg00684032	chr4:1343700	KIAA1530	-0.7	-5.81	-0.51	8.47e-8	Obesity-related traits;
THYM	cis	rs34375054	0.724	rs4517581	chr12:125667394	A/G	cg25124228	chr12:125621409	AACS	-0.66	-4.87	-0.45	4.5e-6	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg22535103	chr8:58192502	C8orf71	0.88	5.02	0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs17598306	0.935	rs2894086	chr7:96584416	A/G	cg23184042	chr7:96615519	DLX6AS	0.61	4.76	0.44	6.82e-6	Radiation response;
THYM	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg17105886	chr17:28927953	LRRC37B2	1.32	6.56	0.56	2.79e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg09222892	chr1:25734099	RHCE	0.61	4.78	0.44	6.43e-6	Erythrocyte sedimentation rate;
THYM	trans	rs11186	0.556	rs56843866	chr2:189956222	T/C	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs1198430	0.562	rs7546989	chr1:23789698	C/G	cg19827787	chr1:23763612	ASAP3	0.58	4.74	0.44	7.43e-6	Total cholesterol levels;
THYM	cis	rs89107	0.544	rs11968176	chr6:118900940	C/A	cg21191810	chr6:118973309	C6orf204	0.51	5.1	0.46	1.71e-6	Cardiac structure and function;
THYM	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.05	-0.46	2.09e-6	Mood instability;
THYM	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg27034606	chr17:28928453	LRRC37B2	0.82	5.25	0.47	9.11e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.43	1.27e-5	Breast cancer;
THYM	cis	rs4606347	0.872	rs61779669	chr1:66128499	T/C	cg04111102	chr1:66153794	NA	0.69	5.21	0.47	1.07e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9527	0.590	rs7087459	chr10:104790999	T/C	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg18811423	chr2:55921094	PNPT1	-0.78	-7.28	-0.6	9.58e-11	Metabolic syndrome;
THYM	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.37	0.55	6.72e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg22841779	chr14:105766346	BRF1	-0.46	-5.69	-0.5	1.42e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg07460842	chr6:66804631	NA	0.92	5.5	0.49	3.15e-7	Exhaled nitric oxide levels;
THYM	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06481639	chr22:41940642	POLR3H	-0.78	-5.39	-0.48	5.17e-7	Vitiligo;
THYM	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg16615211	chr3:44902933	MIR564;TMEM42	0.56	6.23	0.54	1.26e-8	Depressive symptoms;
THYM	cis	rs3771570	1.000	rs73002111	chr2:242277833	C/T	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs7639513	0.545	rs55977822	chr3:12704438	C/A	cg23032965	chr3:12705835	RAF1	0.88	6.54	0.56	3.03e-9	Itch intensity from mosquito bite;
THYM	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs4731207	0.724	rs2057907	chr7:124443684	G/A	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs1448094	0.533	rs4412812	chr12:86151238	G/A	cg02569458	chr12:86230093	RASSF9	-0.63	-5.42	-0.49	4.52e-7	Major depressive disorder;
THYM	cis	rs705145	0.519	rs705141	chr10:125223672	T/C	cg11653519	chr10:125222790	NA	0.41	4.67	0.43	9.85e-6	Motion sickness;
THYM	cis	rs12368653	0.583	rs7952989	chr12:58095989	T/C	cg12615879	chr12:58013172	SLC26A10	0.54	5.36	0.48	5.75e-7	Multiple sclerosis;
THYM	cis	rs56341938	0.874	rs11718785	chr3:168732981	A/T	cg09107232	chr3:169491072	MYNN	0.56	4.87	0.45	4.44e-6	Lung function (FEV1/FVC);
THYM	cis	rs9913156	0.617	rs2255888	chr17:4545581	C/T	cg19197139	chr17:4613644	ARRB2	-0.78	-4.72	-0.44	8.18e-6	Lymphocyte counts;
THYM	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg13695892	chr22:41940480	POLR3H	-0.58	-4.54	-0.42	1.67e-5	Neuroticism;
THYM	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg21280719	chr6:42927975	GNMT	-0.54	-7.07	-0.59	2.63e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.58	0.5	2.29e-7	Rheumatoid arthritis;
THYM	cis	rs61774743	0.557	rs4359027	chr1:41848296	G/A	cg19619003	chr1:41846758	NA	-0.29	-5.87	-0.52	6.26e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg04362960	chr10:104952993	NT5C2	0.63	4.47	0.42	2.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg01304814	chr3:48885189	PRKAR2A	0.94	4.8	0.44	5.79e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg00744431	chr10:134226547	PWWP2B	-0.6	-4.73	-0.44	7.73e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg18681998	chr4:17616180	MED28	0.99	10.08	0.72	1.09e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg23711669	chr6:146136114	FBXO30	0.97	10.62	0.74	7.88e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg27141850	chr2:20869434	GDF7	-0.56	-5.09	-0.46	1.8e-6	Abdominal aortic aneurysm;
THYM	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg22920501	chr2:26401640	FAM59B	-0.75	-6.57	-0.56	2.73e-9	Gut microbiome composition (summer);
THYM	cis	rs7178572	0.524	rs1473922	chr15:77656798	G/T	cg22256960	chr15:77711686	NA	-1.05	-8.4	-0.65	4.29e-13	Type 2 diabetes;
THYM	cis	rs7246657	0.943	rs10415937	chr19:37830064	T/G	cg22634378	chr19:37742834	NA	0.65	5.34	0.48	6.2e-7	Coronary artery calcification;
THYM	cis	rs9394438	0.529	rs10947681	chr6:37547073	C/A	cg00985040	chr6:37553208	NA	-0.51	-5.73	-0.51	1.17e-7	IgG glycosylation;
THYM	cis	rs6480314	0.831	rs1900009	chr10:69977697	G/A	cg27159792	chr10:69524182	NA	0.73	4.59	0.43	1.35e-5	Optic nerve measurement (disc area);
THYM	cis	rs981844	0.712	rs4525952	chr4:154746606	G/T	cg09973105	chr4:154681532	RNF175	-0.52	-4.98	-0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs4866334	1.000	rs76259459	chr5:18456963	A/T	cg04591469	chr5:17810299	NA	-1.12	-4.54	-0.42	1.65e-5	IgG glycosylation;
THYM	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg06600287	chr1:53387719	ECHDC2	-0.28	-4.56	-0.42	1.53e-5	Monocyte count;
THYM	cis	rs2294693	0.945	rs932399	chr6:41011266	C/T	cg14418226	chr6:40996092	UNC5CL	0.67	5.07	0.46	1.93e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs3540	0.533	rs1869179	chr15:90895564	A/C	cg22089800	chr15:90895588	ZNF774	0.84	7.11	0.59	2.14e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21582582	chr3:182698605	DCUN1D1	0.81	7.07	0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.98	7.9	0.63	4.86e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg05738196	chr6:26577821	NA	0.95	9.38	0.69	3.53e-15	Intelligence (multi-trait analysis);
THYM	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg04518342	chr5:131593106	PDLIM4	0.52	6.04	0.53	2.96e-8	Acylcarnitine levels;
THYM	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg03929089	chr4:120376271	NA	-0.98	-12.21	-0.78	3.51e-21	Coronary artery disease;
THYM	cis	rs733175	0.855	rs10022499	chr4:10006537	C/A	cg11266682	chr4:10021025	SLC2A9	0.52	4.6	0.43	1.31e-5	Psychosis and Alzheimer's disease;
THYM	cis	rs6570726	0.791	rs374478	chr6:145840022	C/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.44	-0.49	4.16e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4481887	0.741	rs28616194	chr1:248531904	T/A	cg00666640	chr1:248458726	OR2T12	0.55	4.74	0.44	7.59e-6	Common traits (Other);
THYM	cis	rs7078219	0.965	rs11190126	chr10:101271789	A/C	cg07044859	chr10:101282883	NA	-0.5	-5.32	-0.48	7.02e-7	Dental caries;
THYM	cis	rs2130392	0.562	rs876838	chr4:185655487	G/T	cg04058563	chr4:185651563	MLF1IP	-0.5	-4.45	-0.42	2.3e-5	Kawasaki disease;
THYM	cis	rs4481887	0.708	rs6587463	chr1:248544452	G/C	cg17299007	chr1:248814626	OR2T27	0.43	4.58	0.43	1.41e-5	Common traits (Other);
THYM	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	9.83	0.71	3.84e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs360798	0.532	rs189671	chr2:62959308	T/A	cg17519650	chr2:63277830	OTX1	-0.7	-4.53	-0.42	1.7e-5	Coronary artery disease;
THYM	cis	rs10751667	0.925	rs7115336	chr11:988101	C/G	cg01483505	chr11:975446	AP2A2	0.63	4.9	0.45	4.01e-6	Alzheimer's disease (late onset);
THYM	cis	rs9527	0.590	rs1926037	chr10:104878010	A/C	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs10214930	1.000	rs4719906	chr7:27772852	C/T	cg04422003	chr7:28448295	CREB5	-0.62	-4.62	-0.43	1.19e-5	Hypospadias;
THYM	cis	rs12367572	0.620	rs2731053	chr12:45410728	G/A	cg03114573	chr12:45410052	DBX2	-0.61	-5.93	-0.52	4.96e-8	Gut microbiome composition (summer);
THYM	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg06238570	chr21:40685208	BRWD1	0.9	6.67	0.56	1.72e-9	Cognitive function;
THYM	cis	rs1061377	1.000	rs35116118	chr4:39128913	C/T	cg24403649	chr4:39172243	NA	0.55	4.46	0.42	2.28e-5	Uric acid levels;
THYM	cis	rs786425	0.532	rs7397746	chr12:124218044	T/C	cg15249119	chr12:124971054	NCOR2	0.53	4.98	0.46	2.8e-6	Pubertal anthropometrics;
THYM	trans	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs2295359	1.000	rs736197	chr1:67607135	G/T	cg11235152	chr1:67600687	NA	0.59	4.93	0.45	3.42e-6	Psoriasis;
THYM	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg06219351	chr7:158114137	PTPRN2	-0.92	-9.84	-0.71	3.66e-16	Calcium levels;
THYM	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.56	-0.42	1.54e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg13319975	chr6:146136371	FBXO30	0.7	5.73	0.51	1.15e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2625529	0.689	rs2957742	chr15:72302894	C/G	cg16672083	chr15:72433130	SENP8	0.49	4.47	0.42	2.18e-5	Red blood cell count;
THYM	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs988913	0.957	rs9475098	chr6:54833177	A/G	cg04690482	chr6:54711388	FAM83B	0.5	5.42	0.49	4.58e-7	Menarche (age at onset);
THYM	cis	rs1348850	0.837	rs12619074	chr2:178472336	G/A	cg22681709	chr2:178499509	PDE11A	-0.53	-4.59	-0.43	1.34e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2299587	0.623	rs7009476	chr8:17770376	T/C	cg01800426	chr8:17659068	MTUS1	-0.56	-4.54	-0.42	1.66e-5	Economic and political preferences;
THYM	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg18252515	chr7:66147081	NA	-0.66	-5.2	-0.47	1.16e-6	Aortic root size;
THYM	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.21	8.69	0.67	1.03e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11997175	0.646	rs6984073	chr8:33700070	G/A	ch.8.33884649F	chr8:33765107	NA	0.66	4.99	0.46	2.67e-6	Body mass index;
THYM	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg00383909	chr3:49044727	WDR6	1.16	6.87	0.58	6.56e-10	Cognitive function;
THYM	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg05717871	chr11:638507	DRD4	-0.64	-5.11	-0.46	1.69e-6	Systemic lupus erythematosus;
THYM	cis	rs28595532	0.920	rs56150431	chr4:119764786	T/C	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs4530754	0.662	rs1382329	chr5:122939448	A/G	cg20708411	chr5:122847581	CSNK1G3	-0.39	-5.05	-0.46	2.14e-6	LDL cholesterol;Total cholesterol levels;Cholesterol, total;LDL cholesterol levels;
THYM	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg00640147	chr17:61958756	GH2	-0.42	-4.57	-0.42	1.44e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs747782	0.528	rs16905753	chr11:48285906	C/T	cg24672777	chr11:48374446	OR4C45	-1.17	-7.15	-0.59	1.78e-10	Intraocular pressure;
THYM	cis	rs7100689	0.784	rs17678947	chr10:82136333	T/C	cg01528321	chr10:82214614	TSPAN14	0.97	7.37	0.6	6.38e-11	Post bronchodilator FEV1;
THYM	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg27125505	chr17:43679177	LOC644172	0.75	6.93	0.58	4.96e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11890956	chr21:40555474	PSMG1	1.1	10.98	0.75	1.36e-18	Cognitive function;
THYM	cis	rs4866334	1.000	rs77699507	chr5:18481057	A/G	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs61990749	0.597	rs176943	chr14:78175797	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	-1.17	-8.04	-0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg11764359	chr7:65958608	NA	0.74	6.02	0.53	3.33e-8	Aortic root size;
THYM	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg04398451	chr17:18023971	MYO15A	0.9	9.71	0.71	6.98e-16	Total body bone mineral density;
THYM	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.75e-6	Aortic root size;
THYM	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	6.43	0.55	4.99e-9	Smoking behavior;
THYM	cis	rs4148689	0.951	rs2188159	chr7:117155843	A/G	cg17204129	chr7:117119601	CFTR	-0.62	-4.8	-0.44	5.98e-6	Gout;
THYM	cis	rs526231	0.543	rs34791	chr5:102462104	C/A	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.49e-6	Primary biliary cholangitis;
THYM	cis	rs5769707	0.592	rs6009783	chr22:50011001	C/G	cg20744362	chr22:50050164	C22orf34	0.8	7.01	0.58	3.38e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg16405210	chr4:1374714	KIAA1530	-1.11	-10.82	-0.74	2.89e-18	Longevity;
THYM	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg23131131	chr22:24373011	LOC391322	-0.81	-7.73	-0.62	1.11e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11096990	0.593	rs1026235	chr4:39228249	G/A	cg24403649	chr4:39172243	NA	0.62	5.42	0.49	4.43e-7	Cognitive function;
THYM	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg11166453	chr1:247681781	NA	0.68	5.26	0.47	8.98e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg11327659	chr7:150037044	RARRES2	0.42	5.17	0.47	1.29e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg20295408	chr7:1910781	MAD1L1	-0.68	-5.09	-0.46	1.81e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7771547	0.542	rs597153	chr6:36395997	C/T	cg07856975	chr6:36356162	ETV7	0.52	4.72	0.44	8.26e-6	Platelet distribution width;
THYM	cis	rs10504073	0.584	rs7818507	chr8:49918423	G/T	cg00325661	chr8:49890786	NA	1.04	10.98	0.75	1.34e-18	Blood metabolite ratios;
THYM	cis	rs9522267	0.535	rs4773392	chr13:112227358	A/G	cg10483660	chr13:112241077	NA	0.6	6.98	0.58	3.9e-10	Hepatitis;
THYM	cis	rs7100689	0.516	rs10887711	chr10:82034842	A/G	cg09936400	chr10:82049201	MAT1A	0.45	5.01	0.46	2.49e-6	Post bronchodilator FEV1;
THYM	cis	rs1797885	0.564	rs2596822	chr3:12596844	C/T	cg05467012	chr3:12595696	NA	-0.56	-4.69	-0.43	8.99e-6	Immature fraction of reticulocytes;
THYM	cis	rs447921	0.817	rs346811	chr17:74403926	T/C	cg17201438	chr17:74438067	UBE2O	-0.81	-5.85	-0.51	6.9e-8	Mitochondrial DNA levels;
THYM	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg13902645	chr11:5959945	NA	0.64	5.94	0.52	4.69e-8	DNA methylation (variation);
THYM	cis	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05901451	chr6:126070800	HEY2	0.81	8.0	0.63	3.02e-12	Brugada syndrome;
THYM	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg24818145	chr4:99064322	C4orf37	0.7	5.55	0.49	2.63e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2970992	0.589	rs35151806	chr2:101337495	G/A	cg01042948	chr2:101319752	NA	0.46	4.57	0.42	1.47e-5	Educational attainment;
THYM	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg11266682	chr4:10021025	SLC2A9	0.7	11.24	0.76	3.78e-19	Bone mineral density;
THYM	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	8.1	0.64	1.82e-12	Platelet count;
THYM	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg24060327	chr5:131705240	SLC22A5	0.81	6.65	0.56	1.82e-9	Blood metabolite levels;
THYM	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9311676	0.656	rs11917591	chr3:58368449	C/T	cg26110898	chr3:58419937	PDHB	-0.44	-4.51	-0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.23	8.93	0.68	3.2e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs713587	0.967	rs6749422	chr2:25150011	C/G	cg01884057	chr2:25150051	NA	0.75	8.4	0.65	4.28e-13	Body mass index in non-asthmatics;
THYM	cis	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs11048434	0.736	rs35870866	chr12:9129091	C/A	cg04155231	chr12:9217510	LOC144571	0.49	4.69	0.43	9.28e-6	Sjögren's syndrome;
THYM	cis	rs977987	0.742	rs34624768	chr16:75331572	G/A	cg03315344	chr16:75512273	CHST6	0.83	6.93	0.58	5e-10	Dupuytren's disease;
THYM	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs761746	0.705	rs2092905	chr22:31966274	T/C	cg10537193	chr22:32026975	PISD	0.36	4.63	0.43	1.16e-5	Intelligence;
THYM	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg18252515	chr7:66147081	NA	-0.69	-5.46	-0.49	3.79e-7	Aortic root size;
THYM	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg09307838	chr4:120376055	NA	-0.7	-5.24	-0.47	9.74e-7	Corneal astigmatism;
THYM	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg13147721	chr7:65941812	NA	-0.87	-4.93	-0.45	3.46e-6	Diabetic kidney disease;
THYM	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg25358565	chr5:93447407	FAM172A	-1.36	-10.83	-0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	15.13	0.84	4.91e-27	Chronic sinus infection;
THYM	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg19507638	chr5:93509721	C5orf36	0.71	4.79	0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg18131467	chr2:239335373	ASB1	0.94	8.25	0.65	9.14e-13	Multiple system atrophy;
THYM	cis	rs870825	0.860	rs72689277	chr4:185593699	G/A	cg04058563	chr4:185651563	MLF1IP	1.05	7.92	0.63	4.51e-12	Blood protein levels;
THYM	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg25036284	chr2:26402008	FAM59B	-0.78	-5.19	-0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs9549260	0.755	rs9577091	chr13:41227865	G/A	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg03806693	chr22:41940476	POLR3H	-0.99	-7.63	-0.62	1.82e-11	Vitiligo;
THYM	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Blood metabolite levels;
THYM	trans	rs877282	0.945	rs11253396	chr10:789754	C/T	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg16342193	chr10:102329863	NA	-0.54	-5.64	-0.5	1.77e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs883565	0.655	rs4676670	chr3:39049594	A/C	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	5.0	0.46	2.59e-6	Handedness;
THYM	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs4654899	0.897	rs3736880	chr1:21097727	G/A	cg01072550	chr1:21505969	NA	-0.58	-5.05	-0.46	2.14e-6	Superior frontal gyrus grey matter volume;
THYM	cis	rs72827839	0.779	rs16954581	chr17:46359502	C/T	cg23391107	chr17:45924227	SP6	-0.87	-5.54	-0.49	2.68e-7	Ease of getting up in the morning;
THYM	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg27129171	chr3:47204927	SETD2	-0.8	-7.67	-0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs4851254	0.618	rs35730185	chr2:100648085	G/A	cg22139774	chr2:100720529	AFF3	-0.39	-4.46	-0.42	2.21e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg02176678	chr2:219576539	TTLL4	0.72	7.17	0.59	1.63e-10	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs73194058	1	rs73194058	chr21:34764288	C/A	cg14850771	chr21:34775459	IFNGR2	0.79	4.61	0.43	1.25e-5	Rheumatoid arthritis;
THYM	cis	rs4731207	0.564	rs6960622	chr7:124654080	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.53	-0.49	2.81e-7	Cutaneous malignant melanoma;
THYM	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg11764359	chr7:65958608	NA	0.8	6.5	0.55	3.78e-9	Aortic root size;
THYM	cis	rs7681423	0.951	rs6825454	chr4:155501188	T/C	cg20735720	chr4:155535218	FGG	-0.67	-4.92	-0.45	3.64e-6	Fibrinogen;
THYM	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg18252515	chr7:66147081	NA	-0.66	-4.87	-0.45	4.38e-6	Aortic root size;
THYM	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg04518342	chr5:131593106	PDLIM4	0.49	5.12	0.47	1.6e-6	Blood metabolite levels;
THYM	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg02569458	chr12:86230093	RASSF9	0.58	4.99	0.46	2.75e-6	Major depressive disorder;
THYM	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg26312807	chr3:127057048	NA	-0.78	-6.17	-0.54	1.63e-8	Interleukin-10 levels;Interleukin-13 levels;
THYM	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg04320152	chr17:18167836	SMCR7	0.59	4.74	0.44	7.38e-6	Total body bone mineral density;
THYM	cis	rs7715811	1.000	rs6554813	chr5:13763039	G/A	cg07548982	chr5:13769939	DNAH5	-0.52	-4.6	-0.43	1.32e-5	Subclinical atherosclerosis traits (other);
THYM	cis	rs11731175	1.000	rs80301150	chr4:189860439	A/G	cg00431894	chr4:189871012	NA	-0.8	-5.96	-0.52	4.25e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs548181	0.604	rs11608103	chr11:125627917	G/A	cg03464685	chr11:125439445	EI24	-1.23	-8.33	-0.65	5.91e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg23682913	chr1:2080710	PRKCZ	-0.6	-5.14	-0.47	1.49e-6	Height;
THYM	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg24399712	chr22:39784796	NA	-0.93	-11.11	-0.75	7.13e-19	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.63	-4.89	-0.45	4.06e-6	Longevity;Endometriosis;
THYM	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg08411435	chr17:37784024	PPP1R1B	-0.32	-4.48	-0.42	2.08e-5	Asthma;
THYM	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06634786	chr22:41940651	POLR3H	-0.72	-5.25	-0.47	9.37e-7	Vitiligo;
THYM	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg02820040	chr2:241836501	C2orf54	-0.33	-6.58	-0.56	2.59e-9	Urinary metabolites;
THYM	cis	rs889398	0.933	rs6499240	chr16:69686912	A/G	cg09409435	chr16:70099608	PDXDC2	0.63	4.88	0.45	4.23e-6	Body mass index;
THYM	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg03597347	chr6:28058909	ZSCAN12L1	0.62	4.55	0.42	1.62e-5	Cardiac Troponin-T levels;
THYM	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg07570687	chr10:102243282	WNT8B	0.77	7.0	0.58	3.65e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4499344	0.526	rs10412141	chr19:33034189	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.71	-4.79	-0.44	6.07e-6	Mean platelet volume;
THYM	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg27129171	chr3:47204927	SETD2	0.7	6.7	0.57	1.44e-9	Colorectal cancer;
THYM	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs75059851	0.756	rs11223648	chr11:133840412	C/T	cg14047540	chr11:133829660	NA	-1.1	-7.34	-0.6	7.1e-11	Schizophrenia;
THYM	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg23711669	chr6:146136114	FBXO30	0.96	10.01	0.72	1.54e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.17e-16	Bone mineral density;
THYM	cis	rs9866391	0.607	rs1344674	chr3:141125186	A/G	cg13411656	chr3:141121016	ZBTB38	-0.35	-5.24	-0.47	9.73e-7	Myopia;
THYM	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg05340658	chr4:99064831	C4orf37	0.54	4.52	0.42	1.78e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6598955	0.543	rs881578	chr1:26536141	G/A	cg04990556	chr1:26633338	UBXN11	0.96	6.06	0.53	2.7e-8	Obesity-related traits;
THYM	trans	rs8002861	0.967	rs7999434	chr13:44482961	T/C	cg17145862	chr1:211918768	LPGAT1	0.99	11.5	0.76	1.07e-19	Leprosy;
THYM	cis	rs478304	0.903	rs12293022	chr11:65531698	C/T	cg27068330	chr11:65405492	SIPA1	0.82	7.91	0.63	4.72e-12	Acne (severe);
THYM	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg13319975	chr6:146136371	FBXO30	-0.64	-5.33	-0.48	6.48e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7119	0.604	rs2682921	chr15:77865459	C/T	cg27398640	chr15:77910606	LINGO1	0.65	7.36	0.6	6.45e-11	Type 2 diabetes;
THYM	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	12.13	0.78	5.13e-21	Chronic sinus infection;
THYM	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg26131816	chr17:42072204	PYY	0.53	4.6	0.43	1.28e-5	Menopause (age at onset);
THYM	cis	rs6840360	0.615	rs55932132	chr4:152463897	G/T	cg22705602	chr4:152727874	NA	-0.71	-7.43	-0.61	4.71e-11	Intelligence (multi-trait analysis);
THYM	cis	rs2702888	0.501	rs2738161	chr8:6748597	C/T	cg03082247	chr8:6756796	NA	-0.65	-5.29	-0.48	7.81e-7	Blood pressure;
THYM	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22496380	chr5:211416	CCDC127	-1.39	-8.13	-0.64	1.62e-12	Breast cancer;
THYM	cis	rs4363385	0.747	rs4845330	chr1:152981505	A/G	cg13444842	chr1:152974279	SPRR3	-0.59	-4.68	-0.43	9.52e-6	Inflammatory skin disease;
THYM	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	5.75	0.51	1.08e-7	Blood metabolite levels;
THYM	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg19746536	chr19:49375674	PPP1R15A	0.81	4.59	0.43	1.34e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg18512352	chr11:47633146	NA	-0.53	-6.56	-0.56	2.75e-9	Subjective well-being;
THYM	cis	rs6596100	0.538	rs34592321	chr5:132181675	G/C	cg02081065	chr5:132209139	LEAP2	-0.95	-6.14	-0.53	1.87e-8	Breast cancer;
THYM	cis	rs11030122	0.632	rs4910596	chr11:4084604	A/G	cg18678763	chr11:4115507	RRM1	-0.43	-5.6	-0.5	2.12e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.68	5.6	0.5	2.08e-7	Lung disease severity in cystic fibrosis;
THYM	cis	rs9457247	0.534	rs7750593	chr6:167387359	C/G	cg23791538	chr6:167370224	RNASET2	0.83	7.32	0.6	7.9e-11	Crohn's disease;
THYM	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg22590775	chr19:49891494	CCDC155	0.64	5.39	0.48	5.14e-7	Multiple sclerosis;
THYM	cis	rs7944735	0.517	rs1827503	chr11:48225115	G/T	cg24672777	chr11:48374446	OR4C45	-1.15	-6.73	-0.57	1.29e-9	Intraocular pressure;
THYM	cis	rs752010	0.645	rs1109254	chr1:42091770	T/C	cg06885757	chr1:42089581	HIVEP3	0.77	11.03	0.75	1.05e-18	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg10523679	chr1:76189770	ACADM	-0.85	-7.95	-0.63	3.77e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6127978	0.702	rs6123684	chr20:55827085	A/C	cg15851418	chr20:55835831	BMP7	0.67	4.66	0.43	1.03e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg22903471	chr2:27725779	GCKR	0.52	4.46	0.42	2.25e-5	Total body bone mineral density;
THYM	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg22166914	chr1:53195759	ZYG11B	0.75	6.97	0.58	4.09e-10	Monocyte count;
THYM	cis	rs3135718	1.000	rs3135718	chr10:123353869	C/T	cg15049101	chr10:123353889	FGFR2	-0.59	-5.03	-0.46	2.34e-6	Estrogen receptor status in breast cancer;
THYM	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.88	0.58	6.24e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg13010199	chr12:38710504	ALG10B	-0.59	-4.72	-0.44	8.19e-6	Morning vs. evening chronotype;
THYM	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg26384229	chr12:38710491	ALG10B	0.69	5.2	0.47	1.13e-6	Morning vs. evening chronotype;
THYM	cis	rs4880487	0.888	rs10794730	chr10:1247022	C/T	cg26245549	chr10:559468	DIP2C	0.39	4.64	0.43	1.11e-5	Migraine;
THYM	cis	rs10823500	0.777	rs10762348	chr10:71952322	C/A	cg04118878	chr10:71993077	PPA1	0.61	4.46	0.42	2.23e-5	Blood protein levels;
THYM	cis	rs6748734	0.553	rs7340215	chr2:241805851	A/G	cg02820040	chr2:241836501	C2orf54	-0.24	-4.98	-0.45	2.88e-6	Urinary metabolites;
THYM	cis	rs9534288	0.830	rs2897027	chr13:46636235	A/G	cg15192986	chr13:46630673	CPB2	-0.66	-4.66	-0.43	1.03e-5	Blood protein levels;
THYM	cis	rs4731207	0.596	rs1481327	chr7:124628282	G/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs7100689	0.784	rs7078075	chr10:82162768	A/G	cg03086067	chr10:82368399	SH2D4B	-0.48	-4.55	-0.42	1.58e-5	Post bronchodilator FEV1;
THYM	cis	rs995000	0.899	rs12136083	chr1:63163073	T/C	cg06896770	chr1:63153194	DOCK7	0.85	5.54	0.49	2.72e-7	Triglyceride levels;
THYM	cis	rs289828	0.868	rs6718415	chr2:152140795	T/C	cg05960677	chr2:152117363	RBM43	0.61	6.05	0.53	2.89e-8	Blood protein levels;
THYM	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg04025307	chr7:1156635	C7orf50	0.78	6.62	0.56	2.1e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg00310523	chr12:86230176	RASSF9	0.53	4.79	0.44	6.05e-6	Major depressive disorder;
THYM	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-5.13	-0.47	1.55e-6	Lymphocyte counts;
THYM	cis	rs7809950	0.678	rs6949634	chr7:106984684	G/T	cg23024343	chr7:107201750	COG5	-1.0	-8.35	-0.65	5.42e-13	Coronary artery disease;
THYM	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg08736216	chr1:53307985	ZYG11A	-0.63	-5.56	-0.5	2.51e-7	Monocyte count;
THYM	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg13683864	chr3:40499215	RPL14	-0.91	-8.72	-0.67	8.93e-14	Renal cell carcinoma;
THYM	trans	rs11722228	0.508	rs3756227	chr4:10087995	C/A	cg26043149	chr18:55253948	FECH	1.1	10.03	0.72	1.44e-16	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs425535	0.702	rs1836663	chr4:74842572	C/T	cg07868155	chr4:74864709	CXCL5	0.65	4.95	0.45	3.24e-6	Blood protein levels;
THYM	cis	rs7267979	1.000	rs1888999	chr20:25291848	C/T	cg08601574	chr20:25228251	PYGB	0.57	4.51	0.42	1.87e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs754466	0.580	rs12354903	chr10:79536465	T/C	cg17075019	chr10:79541650	NA	-0.7	-5.9	-0.52	5.7e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs75920871	0.502	rs7124996	chr11:116928006	C/T	cg20608306	chr11:116969690	SIK3	-0.54	-6.01	-0.52	3.45e-8	Subjective well-being;
THYM	cis	rs858239	0.568	rs6970694	chr7:23250828	T/C	cg09755872	chr7:23245557	NA	-0.52	-4.85	-0.45	4.76e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg07511668	chr11:68622177	NA	0.43	4.56	0.42	1.52e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs36059107	0.891	rs71419954	chr14:34242327	A/G	cg09224393	chr14:34268920	NPAS3	0.64	4.53	0.42	1.7e-5	Schizophrenia;
THYM	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg05855489	chr10:104503620	C10orf26	-0.6	-4.68	-0.43	9.37e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs747782	0.640	rs11039603	chr11:48256786	G/A	cg24672777	chr11:48374446	OR4C45	-1.05	-5.38	-0.48	5.43e-7	Intraocular pressure;
THYM	cis	rs7429990	0.932	rs13085054	chr3:48134137	C/T	cg02219026	chr3:48282209	ZNF589	0.59	4.46	0.42	2.23e-5	Educational attainment (years of education);
THYM	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg27129171	chr3:47204927	SETD2	-0.72	-6.87	-0.58	6.72e-10	Colorectal cancer;
THYM	cis	rs7843479	0.509	rs3758156	chr8:21770796	A/G	cg17168535	chr8:21777572	XPO7	0.81	7.11	0.59	2.13e-10	Mean corpuscular volume;
THYM	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Parkinson's disease;
THYM	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg20503657	chr10:835505	NA	1.34	8.98	0.68	2.55e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs11118993	0.936	rs11587643	chr1:206714520	G/A	cg19452316	chr1:206680966	RASSF5	0.64	5.27	0.48	8.52e-7	Neurofibrillary tangles;
THYM	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg13852791	chr20:30311386	BCL2L1	0.74	5.35	0.48	6.15e-7	Mean corpuscular hemoglobin;
THYM	cis	rs13064411	0.696	rs9808893	chr3:113228444	G/A	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs240764	0.604	rs705583	chr6:101261408	C/A	cg21058520	chr6:100914733	NA	-0.6	-5.32	-0.48	6.98e-7	Neuroticism;
THYM	cis	rs863345	0.604	rs11265003	chr1:158490631	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg25767906	chr1:53392781	SCP2	0.51	5.04	0.46	2.22e-6	Monocyte count;
THYM	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg00814883	chr7:100076585	TSC22D4	-0.98	-6.62	-0.56	2.15e-9	Platelet count;
THYM	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg16586182	chr3:47516702	SCAP	0.66	5.57	0.5	2.33e-7	Colorectal cancer;
THYM	cis	rs593982	1.000	rs576663	chr11:65498942	G/T	cg08755490	chr11:65554678	OVOL1	1.36	8.73	0.67	8.51e-14	Atopic dermatitis;
THYM	cis	rs752010	0.838	rs11210505	chr1:42104731	G/C	cg04490934	chr1:41978749	HIVEP3	-0.55	-4.52	-0.42	1.8e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs7824557	0.591	rs2060457	chr8:11213250	C/T	cg21775007	chr8:11205619	TDH	0.69	6.04	0.53	2.96e-8	Retinal vascular caliber;
THYM	cis	rs921968	0.565	rs7562426	chr2:219605118	G/A	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7524258	0.835	rs2412150	chr1:7303343	A/C	cg07173049	chr1:7289937	CAMTA1	0.81	6.33	0.54	8.04e-9	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs6867032	1.000	rs61177713	chr5:2017255	G/A	cg26168224	chr5:2018326	NA	1.29	15.56	0.85	7.19e-28	Gut microbiome composition (winter);
THYM	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg04518342	chr5:131593106	PDLIM4	0.52	6.04	0.53	2.96e-8	Acylcarnitine levels;
THYM	cis	rs17253792	0.822	rs74935793	chr14:56143277	G/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg12615879	chr12:58013172	SLC26A10	-0.62	-5.63	-0.5	1.84e-7	Multiple sclerosis;
THYM	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg07167872	chr1:205819463	PM20D1	0.61	4.72	0.44	8.14e-6	Parkinson's disease;
THYM	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg03609598	chr5:56110824	MAP3K1	-0.85	-5.83	-0.51	7.62e-8	Initial pursuit acceleration;
THYM	cis	rs11711311	0.911	rs9817327	chr3:113478500	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.58	-5.13	-0.47	1.55e-6	IgG glycosylation;
THYM	cis	rs763014	0.802	rs4262946	chr16:632138	C/T	cg07343612	chr16:622815	PIGQ	-1.15	-12.09	-0.78	6.29e-21	Height;
THYM	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg17644776	chr2:200775616	C2orf69	-0.79	-4.49	-0.42	2.01e-5	Schizophrenia;
THYM	cis	rs815815	0.608	rs6751198	chr2:47396274	C/T	cg27223769	chr2:47403360	CALM2	-0.8	-4.81	-0.44	5.7e-6	Dialysis-related mortality;
THYM	cis	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg03476357	chr21:30257390	N6AMT1	-0.67	-5.02	-0.46	2.4e-6	Cognitive test performance;
THYM	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs400736	0.860	rs371452	chr1:8084051	C/T	cg22678073	chr1:8087421	ERRFI1	0.45	4.63	0.43	1.14e-5	Response to antidepressants and depression;
THYM	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg00990874	chr7:1149470	C7orf50	-0.6	-4.63	-0.43	1.16e-5	Bronchopulmonary dysplasia;
THYM	cis	rs8030485	0.571	rs7182751	chr15:79430135	G/A	cg17916960	chr15:79447300	NA	0.58	5.74	0.51	1.14e-7	Left ventricle wall thickness;
THYM	cis	rs921968	0.643	rs6708683	chr2:219504503	G/A	cg01872077	chr2:219646372	CYP27A1	0.62	4.83	0.44	5.3e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2290159	0.706	rs7643321	chr3:12663233	A/G	cg23032965	chr3:12705835	RAF1	0.87	5.17	0.47	1.28e-6	Cholesterol, total;
THYM	cis	rs7771547	0.573	rs522179	chr6:36391605	G/A	cg07856975	chr6:36356162	ETV7	0.52	4.72	0.44	8.26e-6	Platelet distribution width;
THYM	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg02527881	chr3:46936655	PTH1R	0.6	5.7	0.5	1.35e-7	Colorectal cancer;
THYM	cis	rs6032067	0.673	rs991048	chr20:43898227	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	0.64	6.6	0.56	2.35e-9	Blood protein levels;
THYM	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg03433033	chr1:76189801	ACADM	0.77	10.21	0.72	6.01e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs12282928	0.921	rs7933408	chr11:48246824	G/A	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs13315871	0.929	rs71311853	chr3:58319152	C/T	cg12435725	chr3:58293450	RPP14	-0.53	-5.51	-0.49	3.09e-7	Cholesterol, total;
THYM	cis	rs362272	0.524	rs6819202	chr4:3368264	G/A	cg18352616	chr4:3374830	RGS12	0.69	7.58	0.61	2.32e-11	Serum sulfate level;
THYM	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.95	0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs6732160	0.774	rs11890053	chr2:73373448	G/A	cg24220031	chr2:73402428	NA	-0.78	-8.4	-0.65	4.26e-13	Intelligence (multi-trait analysis);
THYM	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg14018140	chr10:458528	DIP2C	-0.48	-4.72	-0.44	8.22e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg03806693	chr22:41940476	POLR3H	-1.04	-7.62	-0.62	1.86e-11	Vitiligo;
THYM	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs4606347	0.872	rs61779715	chr1:66131172	T/C	cg04111102	chr1:66153794	NA	0.69	5.21	0.47	1.07e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg06026331	chr20:60912101	LAMA5	0.76	5.85	0.51	7.06e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	trans	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17712092	chr4:129076599	LARP1B	0.87	7.11	0.59	2.11e-10	Eosinophil percentage of white cells;
THYM	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg03909863	chr11:638404	DRD4	-0.85	-6.09	-0.53	2.41e-8	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs2273669	0.667	rs9688896	chr6:109364698	T/C	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs6840360	0.642	rs12647555	chr4:152401098	A/T	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg27170947	chr2:26402098	FAM59B	0.78	5.12	0.46	1.6e-6	Gut microbiome composition (summer);
THYM	cis	rs921968	0.643	rs585859	chr2:219383121	C/T	cg02176678	chr2:219576539	TTLL4	0.64	6.08	0.53	2.49e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs778371	0.647	rs4144797	chr2:233562197	T/C	cg08000102	chr2:233561755	GIGYF2	0.81	7.41	0.61	5.26e-11	Schizophrenia;
THYM	cis	rs778371	0.676	rs2293780	chr2:233635213	T/C	cg08000102	chr2:233561755	GIGYF2	0.83	7.52	0.61	3.07e-11	Schizophrenia;
THYM	cis	rs912057	0.560	rs1294416	chr6:6741327	A/G	cg13809441	chr6:6737631	NA	0.53	6.74	0.57	1.19e-9	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.0	0.63	2.98e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg13609457	chr4:120235615	NA	0.56	5.24	0.47	9.58e-7	Corneal astigmatism;
THYM	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg22907277	chr7:1156413	C7orf50	0.57	4.82	0.44	5.36e-6	Longevity;Endometriosis;
THYM	cis	rs960902	0.818	rs4353628	chr2:37739512	A/G	cg25341268	chr2:37734390	NA	-0.66	-5.83	-0.51	7.68e-8	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg10523679	chr1:76189770	ACADM	-0.58	-4.79	-0.44	6.03e-6	Daytime sleep phenotypes;
THYM	cis	rs4631830	0.720	rs12763717	chr10:51500874	C/G	cg10326726	chr10:51549505	MSMB	0.54	5.15	0.47	1.43e-6	Prostate-specific antigen levels;
THYM	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs6584283	0.846	rs11190135	chr10:101286848	A/G	cg23904955	chr10:101282759	NA	-0.36	-4.53	-0.42	1.73e-5	Ulcerative colitis;
THYM	cis	rs12458462	0.892	rs12456692	chr18:77482189	C/T	cg11879182	chr18:77439856	CTDP1	0.81	7.96	0.63	3.57e-12	Monocyte count;
THYM	cis	rs67460515	0.563	rs34630898	chr3:160827038	A/G	cg12349858	chr3:160822545	B3GALNT1	0.57	4.53	0.42	1.71e-5	Parkinson's disease;
THYM	cis	rs9733	0.596	rs12086630	chr1:150650955	T/C	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs11085466	0.948	rs11668453	chr19:21759357	C/A	cg23026602	chr19:21646605	NA	-0.66	-4.84	-0.45	4.94e-6	Colorectal or endometrial cancer;
THYM	cis	rs2073300	0.826	rs6048809	chr20:23443788	C/T	cg12062639	chr20:23401060	NAPB	1.33	6.21	0.54	1.41e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs346785	0.666	rs379503	chr17:74308358	A/C	cg09812376	chr17:74270190	QRICH2	-0.52	-5.8	-0.51	8.56e-8	White matter hyperintensities in ischemic stroke;
THYM	cis	rs2637266	1.000	rs1907314	chr10:78337948	G/A	cg18941641	chr10:78392320	NA	0.81	7.03	0.58	3.16e-10	Pulmonary function;
THYM	cis	rs7926906	0.967	rs7112148	chr11:90525925	C/G	cg26138821	chr11:89956704	CHORDC1	-0.51	-4.58	-0.43	1.41e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg05457628	chr5:178986728	RUFY1	-0.63	-6.6	-0.56	2.32e-9	Lung cancer;
THYM	cis	rs9633740	0.947	rs1878036	chr10:82280137	T/G	cg01528321	chr10:82214614	TSPAN14	0.94	4.46	0.42	2.24e-5	Post bronchodilator FEV1;
THYM	cis	rs10186029	0.676	rs12614406	chr2:213955803	A/G	cg08319019	chr2:214017104	IKZF2	-0.9	-7.43	-0.61	4.63e-11	Systemic sclerosis;
THYM	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs11992162	0.636	rs4841645	chr8:11798684	G/T	cg21775007	chr8:11205619	TDH	-0.61	-4.82	-0.44	5.41e-6	Monocyte count;
THYM	cis	rs11023332	0.706	rs11023379	chr11:14929960	C/T	cg19336497	chr11:14380999	RRAS2	-0.51	-4.73	-0.44	7.95e-6	Adiponectin levels;Vitamin D levels;
THYM	cis	rs7578361	0.959	rs6713737	chr2:150448976	A/G	cg17961725	chr2:150454027	NA	0.75	6.45	0.55	4.58e-9	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs12410462	0.581	rs7541809	chr1:227547299	G/A	cg23173402	chr1:227635558	NA	0.68	5.44	0.49	4.2e-7	Major depressive disorder;
THYM	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-11.56	-0.76	8.27e-20	Height;
THYM	cis	rs2069036	0.903	rs4748238	chr10:16067703	C/T	cg26633223	chr10:15133461	NA	0.6	4.56	0.42	1.52e-5	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs3741151	1.000	rs3741151	chr11:73020846	G/T	cg17517138	chr11:73019481	ARHGEF17	0.99	5.88	0.52	5.97e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7246657	0.882	rs10422667	chr19:37937876	T/C	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs1729407	0.695	rs1263176	chr11:116690123	T/C	cg08985259	chr11:116699649	APOC3	-0.61	-5.44	-0.49	4.22e-7	Apolipoprotein A-IV levels;
THYM	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg17757837	chr7:157058334	UBE3C	-0.66	-5.32	-0.48	6.85e-7	Body mass index;
THYM	cis	rs9875589	0.509	rs6775534	chr3:14051001	C/T	cg03204825	chr3:13978759	TPRXL	-0.55	-4.84	-0.45	4.93e-6	Ovarian reserve;
THYM	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg08885076	chr2:99613938	TSGA10	0.52	5.02	0.46	2.4e-6	Chronic sinus infection;
THYM	cis	rs4595586	0.545	rs2388177	chr12:39364403	T/C	cg26384229	chr12:38710491	ALG10B	0.69	5.35	0.48	6.11e-7	Morning vs. evening chronotype;
THYM	cis	rs2072499	0.833	rs2758605	chr1:156200445	G/C	cg06970220	chr1:156163860	SLC25A44	0.71	5.8	0.51	8.5e-8	Testicular germ cell tumor;
THYM	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg16486109	chr11:613632	IRF7	0.51	5.7	0.5	1.34e-7	Systemic lupus erythematosus;
THYM	cis	rs7107174	0.786	rs4945262	chr11:77990831	T/C	cg19901956	chr11:77921274	USP35	-0.73	-5.52	-0.49	2.91e-7	Testicular germ cell tumor;
THYM	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg00022866	chr11:64108440	CCDC88B	-0.51	-4.51	-0.42	1.85e-5	Platelet count;
THYM	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7107174	1.000	rs7116698	chr11:77995191	T/C	cg19901956	chr11:77921274	USP35	-0.73	-5.52	-0.49	2.97e-7	Testicular germ cell tumor;
THYM	cis	rs4851254	0.660	rs10209201	chr2:100672808	C/T	cg22139774	chr2:100720529	AFF3	-0.41	-4.69	-0.43	9.07e-6	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg21475434	chr5:93447410	FAM172A	0.94	5.32	0.48	6.98e-7	Diabetic retinopathy;
THYM	cis	rs1278352	0.798	rs1676711	chr10:127775663	T/C	cg08295661	chr10:127769903	ADAM12	-0.54	-5.43	-0.49	4.35e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs28595532	0.841	rs56046449	chr4:119769302	T/C	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	8.52	0.66	2.36e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.7	-5.72	-0.51	1.23e-7	Blood metabolite levels;
THYM	cis	rs4148689	1.000	rs6977764	chr7:117173455	T/G	cg17204129	chr7:117119601	CFTR	-0.65	-4.94	-0.45	3.3e-6	Gout;
THYM	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg16342193	chr10:102329863	NA	-0.58	-5.99	-0.52	3.78e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs13006833	0.668	rs2136569	chr2:191167414	C/T	cg27211696	chr2:191398769	TMEM194B	-0.56	-4.46	-0.42	2.24e-5	Urinary metabolites;
THYM	cis	rs854765	0.693	rs9915776	chr17:17749056	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-5.87	-0.52	6.25e-8	Total body bone mineral density;
THYM	cis	rs8006682	0.541	rs12882449	chr14:69088405	C/T	cg21123519	chr14:69095679	NA	-0.63	-4.78	-0.44	6.46e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs2625529	0.590	rs12904652	chr15:72548765	T/C	cg16672083	chr15:72433130	SENP8	-0.55	-4.91	-0.45	3.71e-6	Red blood cell count;
THYM	cis	rs877282	0.853	rs11595510	chr10:756757	C/G	cg17470449	chr10:769945	NA	0.52	4.5	0.42	1.95e-5	Uric acid levels;
THYM	cis	rs13185784	0.667	rs4309929	chr5:179650988	A/C	cg06495631	chr5:178692806	ADAMTS2	-0.4	-4.51	-0.42	1.84e-5	TRAIL levels;
THYM	cis	rs11640436	0.584	rs1428853	chr16:77308601	G/A	cg06128999	chr16:77247126	NA	-0.4	-5.07	-0.46	1.96e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17001868	0.568	rs9611328	chr22:40791972	C/T	cg07138101	chr22:40742427	ADSL	0.92	5.69	0.5	1.42e-7	Mammographic density (dense area);
THYM	cis	rs6840360	0.593	rs1877185	chr4:152690348	C/T	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs59698941	0.943	rs66685494	chr5:132291056	A/G	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs354225	0.584	rs10206143	chr2:54817453	A/T	cg23486701	chr2:54789491	SPTBN1	0.35	4.68	0.43	9.65e-6	Schizophrenia;
THYM	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	5.88	0.52	6.2e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6763768	0.606	rs9812118	chr3:53380053	T/C	cg22900224	chr3:52804907	NEK4	0.72	4.71	0.43	8.6e-6	Bacterial meningitis;
THYM	cis	rs12579753	1.000	rs10862371	chr12:82249298	C/T	cg21231944	chr12:82153410	PPFIA2	-0.6	-4.65	-0.43	1.07e-5	Resting heart rate;
THYM	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg17366294	chr4:99064904	C4orf37	0.57	6.68	0.57	1.63e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs611744	0.901	rs655320	chr8:109197482	T/A	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs72772090	0.539	rs11747148	chr5:96112863	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-4.67	-0.43	9.81e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg13683864	chr3:40499215	RPL14	-0.87	-8.19	-0.64	1.2e-12	Renal cell carcinoma;
THYM	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg22709100	chr7:91322751	NA	-0.61	-4.91	-0.45	3.84e-6	Breast cancer;
THYM	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg20891283	chr12:69753455	YEATS4	1.06	10.24	0.72	5.15e-17	Blood protein levels;
THYM	cis	rs2070677	0.935	rs12255182	chr10:135404096	G/A	cg20169779	chr10:135381914	SYCE1	-0.77	-5.94	-0.52	4.64e-8	Gout;
THYM	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-7.81	-0.63	7.56e-12	Lymphocyte percentage of white cells;
THYM	cis	rs17006441	0.932	rs11923382	chr3:69901613	C/T	cg18496212	chr3:69797108	MITF	-0.65	-6.36	-0.55	7.04e-9	Hemoglobin concentration;
THYM	cis	rs16949788	1.000	rs11071894	chr15:66773733	A/C	cg08120210	chr15:66682733	MAP2K1	0.97	5.41	0.49	4.67e-7	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg18538332	chr22:24372958	LOC391322	-1.03	-15.76	-0.85	2.98e-28	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs3741151	0.773	rs73542960	chr11:73115946	T/C	cg12959048	chr11:73096162	RELT	-0.53	-5.08	-0.46	1.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg24642844	chr7:1081250	C7orf50	-1.31	-8.53	-0.66	2.28e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg15693483	chr7:1102177	C7orf50	0.54	6.26	0.54	1.1e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7192750	0.586	rs12447045	chr16:71914617	C/G	cg06353428	chr16:71660113	MARVELD3	0.69	4.89	0.45	4.16e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs9517313	0.707	rs9517298	chr13:99095003	C/T	cg07423050	chr13:99094983	FARP1	-0.45	-5.31	-0.48	7.2e-7	Neuroticism;
THYM	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3126085	0.544	rs3126074	chr1:152279841	G/C	cg10321714	chr1:152280068	FLG	-0.67	-5.14	-0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg00129232	chr17:37814104	STARD3	0.72	5.14	0.47	1.46e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2797160	1.000	rs1739374	chr6:126011825	C/T	cg16306078	chr6:126000798	NA	0.53	5.41	0.49	4.66e-7	Endometrial cancer;
THYM	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg00080972	chr5:178986291	RUFY1	0.49	5.82	0.51	7.91e-8	Lung cancer;
THYM	cis	rs2282032	0.527	rs41309248	chr14:90767386	C/T	cg14092571	chr14:90743983	NA	0.63	6.26	0.54	1.11e-8	Longevity;
THYM	cis	rs919433	0.617	rs700645	chr2:198605514	A/G	cg00792783	chr2:198669748	PLCL1	0.81	5.67	0.5	1.51e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg21433313	chr16:3507492	NAT15	0.51	4.53	0.42	1.7e-5	Body mass index (adult);
THYM	cis	rs10929159	0.665	rs7599602	chr2:236930373	C/T	cg20128773	chr2:236923534	AGAP1	0.35	4.55	0.42	1.58e-5	Parkinson's disease;
THYM	cis	rs1385374	0.858	rs11059923	chr12:129293057	G/A	cg04043695	chr12:129287642	SLC15A4	-0.8	-4.83	-0.44	5.3e-6	Systemic lupus erythematosus;
THYM	cis	rs7586879	0.593	rs11689543	chr2:25130440	A/T	cg27107076	chr2:25050844	ADCY3	-0.29	-4.56	-0.42	1.53e-5	Body mass index;
THYM	cis	rs7940866	0.738	rs10894308	chr11:130891895	G/A	cg05962950	chr11:130786565	SNX19	0.79	6.68	0.57	1.61e-9	Schizophrenia;
THYM	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg06191203	chr2:152266755	RIF1	-0.73	-5.02	-0.46	2.46e-6	Lung cancer;
THYM	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.57	-5.53	-0.49	2.79e-7	Crohn's disease;
THYM	cis	rs13232179	1.000	rs7797900	chr7:151117495	C/T	cg01177956	chr7:150756509	SLC4A2;CDK5	-0.76	-4.53	-0.42	1.74e-5	Coronary heart disease;
THYM	cis	rs2692947	0.832	rs62153679	chr2:96558400	C/T	cg22654517	chr2:96458247	NA	0.59	4.45	0.42	2.32e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg08885076	chr2:99613938	TSGA10	0.57	5.3	0.48	7.37e-7	Chronic sinus infection;
THYM	cis	rs9359856	0.879	rs4707552	chr6:90300841	A/G	cg13799429	chr6:90582589	CASP8AP2	0.47	4.51	0.42	1.84e-5	Bipolar disorder;
THYM	trans	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	3.97e-12	Bladder cancer;
THYM	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.87	7.81	0.63	7.38e-12	Monocyte percentage of white cells;
THYM	cis	rs4363385	0.720	rs1338179	chr1:152981548	T/C	cg13444842	chr1:152974279	SPRR3	-0.59	-4.68	-0.43	9.52e-6	Inflammatory skin disease;
THYM	cis	rs1003719	0.751	rs2835585	chr21:38460488	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs2276314	0.802	rs58906216	chr18:33630297	T/C	cg05985134	chr18:33552581	C18orf21	0.69	4.88	0.45	4.22e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg13699009	chr12:122356056	WDR66	0.49	4.53	0.42	1.74e-5	Mean corpuscular volume;
THYM	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg25036284	chr2:26402008	FAM59B	-0.78	-5.19	-0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.19	8.92	0.68	3.36e-14	Cognitive test performance;
THYM	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg21475434	chr5:93447410	FAM172A	0.86	5.57	0.5	2.35e-7	Diabetic retinopathy;
THYM	cis	rs76662990	0.610	rs16872141	chr5:73939265	C/T	cg13275603	chr5:73927487	ENC1	0.78	4.52	0.42	1.81e-5	Residual cognition;
THYM	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs2072510	0.683	rs2246972	chr12:96427889	C/T	cg18817487	chr12:96390143	HAL	0.34	4.56	0.42	1.5e-5	Metabolite levels (small molecules and protein measures);
THYM	cis	rs4788570	0.566	rs72795867	chr16:71484465	A/G	cg06353428	chr16:71660113	MARVELD3	-1.04	-5.01	-0.46	2.5e-6	Intelligence (multi-trait analysis);
THYM	cis	rs900145	0.814	rs1481891	chr11:13310718	T/C	cg13286116	chr11:13302098	ARNTL	-0.59	-4.73	-0.44	7.89e-6	Menarche (age at onset);
THYM	cis	rs2562456	0.876	rs62110163	chr19:21728822	G/A	cg21751540	chr19:21541537	ZNF738	-0.69	-4.75	-0.44	7.1e-6	Pain;
THYM	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg08999081	chr20:33150536	PIGU	0.56	4.66	0.43	1.03e-5	Height;
THYM	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg24209194	chr3:40518798	ZNF619	0.73	6.22	0.54	1.33e-8	Renal cell carcinoma;
THYM	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg00376283	chr12:123451042	ABCB9	0.72	4.94	0.45	3.36e-6	Neutrophil percentage of white cells;
THYM	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg17328964	chr8:145687451	CYHR1	0.86	8.27	0.65	7.97e-13	Age at first birth;
THYM	cis	rs2933343	0.700	rs883602	chr3:128653952	A/G	cg11901034	chr3:128598214	ACAD9	-0.68	-5.57	-0.5	2.4e-7	IgG glycosylation;
THYM	cis	rs11122895	0.720	rs3860381	chr2:112464649	G/A	cg23262488	chr2:112468472	NA	0.47	5.33	0.48	6.64e-7	Allergic sensitization;
THYM	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.99	-0.46	2.74e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg10589385	chr1:150898437	SETDB1	0.62	5.08	0.46	1.9e-6	Melanoma;
THYM	cis	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg02317251	chr4:10116515	WDR1	-0.56	-4.95	-0.45	3.23e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.67	6.02	0.53	3.23e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg06636001	chr8:8085503	FLJ10661	0.71	6.27	0.54	1.04e-8	Mood instability;
THYM	cis	rs4499344	0.604	rs259275	chr19:33159693	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.91	7.79	0.62	8.31e-12	Mean platelet volume;
THYM	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg08885076	chr2:99613938	TSGA10	-0.76	-7.33	-0.6	7.73e-11	Chronic sinus infection;
THYM	cis	rs2034088	0.802	rs12937004	chr17:413728	T/C	cg06217071	chr17:408420	NA	0.73	7.36	0.6	6.43e-11	Hip circumference adjusted for BMI;
THYM	cis	rs912057	0.526	rs737449	chr6:6733729	A/G	cg13809441	chr6:6737631	NA	-0.55	-6.45	-0.55	4.57e-9	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs17125944	0.615	rs7151643	chr14:53313661	G/C	cg00686598	chr14:53173677	PSMC6	-1.03	-4.67	-0.43	9.78e-6	Alzheimer's disease (late onset);
THYM	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.03	10.05	0.72	1.3e-16	Colorectal cancer;
THYM	cis	rs16866061	0.962	rs72972361	chr2:225341550	G/A	cg12698349	chr2:225449008	CUL3	1.1	9.52	0.7	1.78e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs6499255	0.951	rs12232410	chr16:69736851	G/A	cg00738113	chr16:70207722	CLEC18C	-0.45	-4.57	-0.42	1.49e-5	IgE levels;
THYM	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg02176678	chr2:219576539	TTLL4	0.73	7.25	0.6	1.09e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.86	8.18	0.64	1.27e-12	Menarche (age at onset);
THYM	cis	rs7584330	0.554	rs9646716	chr2:238443784	C/T	cg08992911	chr2:238395768	MLPH	0.71	4.69	0.43	9.14e-6	Prostate cancer;
THYM	cis	rs990171	1.000	rs6713618	chr2:103048437	A/T	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.17	-0.47	1.27e-6	Lymphocyte counts;
THYM	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18876405	chr7:65276391	NA	0.56	4.63	0.43	1.16e-5	Aortic root size;
THYM	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg02503808	chr4:7069936	GRPEL1	0.99	8.48	0.66	2.89e-13	Monocyte percentage of white cells;
THYM	cis	rs950880	0.710	rs1474309	chr2:103091001	C/T	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.74	-0.44	7.54e-6	Serum protein levels (sST2);
THYM	cis	rs9906944	0.707	rs1523136	chr17:47144532	A/G	cg09029085	chr17:47094198	IGF2BP1	0.5	7.22	0.6	1.29e-10	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg08859206	chr1:53392774	SCP2	0.51	5.35	0.48	6.02e-7	Monocyte count;
THYM	cis	rs2888875	0.632	rs17031056	chr2:43797619	C/T	cg22033476	chr2:43532275	THADA	-0.39	-4.49	-0.42	1.99e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs7072216	0.690	rs113195335	chr10:100175532	A/C	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7638995	0.701	rs34550101	chr3:69185670	C/T	cg26574240	chr3:69171822	LMOD3	-0.79	-5.26	-0.47	9.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs2692947	0.655	rs2315668	chr2:96429562	T/C	cg22654517	chr2:96458247	NA	0.78	5.65	0.5	1.7e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg07414643	chr4:187882934	NA	0.58	5.13	0.47	1.54e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	5.18	0.47	1.25e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg06481639	chr22:41940642	POLR3H	0.8	5.56	0.5	2.48e-7	Vitiligo;
THYM	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.54	-0.42	1.67e-5	Morning vs. evening chronotype;
THYM	cis	rs17443541	0.507	rs6742907	chr2:200455180	C/A	cg01795955	chr2:200468626	NA	-0.71	-4.69	-0.43	9.29e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2139634	0.965	rs11130094	chr3:46541503	A/G	cg02332537	chr3:46540019	RTP3	-0.51	-5.31	-0.48	7.11e-7	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9674544	0.792	rs8076012	chr17:47101989	G/A	cg18128536	chr17:47092178	IGF2BP1	-0.53	-8.16	-0.64	1.4e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs9297145	0.761	rs12534399	chr7:98746401	A/G	cg05967295	chr7:98741636	SMURF1	0.88	6.53	0.56	3.19e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs55728055	0.661	rs8139560	chr22:32003798	C/T	cg01338084	chr22:32026380	PISD	1.36	5.56	0.5	2.44e-7	Age-related hearing impairment;
THYM	cis	rs61931739	0.517	rs2101396	chr12:34048927	T/A	cg06521331	chr12:34319734	NA	-0.93	-8.67	-0.66	1.15e-13	Morning vs. evening chronotype;
THYM	cis	rs28595532	0.920	rs116668854	chr4:119707642	A/G	cg21605333	chr4:119757512	SEC24D	1.42	4.79	0.44	6.16e-6	Cannabis dependence symptom count;
THYM	cis	rs11825685	0.790	rs56657264	chr11:134543459	C/T	cg02395454	chr11:134605862	NA	-0.83	-4.51	-0.42	1.86e-5	IgG glycosylation;
THYM	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	6.77	0.57	1.05e-9	Prudent dietary pattern;
THYM	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg27494647	chr7:150038898	RARRES2	0.47	5.68	0.5	1.47e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs13064411	0.518	rs7646188	chr3:113219272	C/T	cg18753928	chr3:113234510	CCDC52	-0.78	-7.16	-0.59	1.68e-10	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg18357526	chr6:26021779	HIST1H4A	0.74	6.49	0.55	3.91e-9	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg25214090	chr10:38739885	LOC399744	0.91	7.93	0.63	4.24e-12	Corneal astigmatism;
THYM	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg22189786	chr22:42395067	WBP2NL	0.67	5.35	0.48	6.07e-7	Birth weight;
THYM	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.73	5.39	0.48	5.04e-7	Huntington's disease progression;
THYM	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg23587288	chr2:27483067	SLC30A3	-0.67	-5.55	-0.5	2.52e-7	Blood metabolite levels;
THYM	cis	rs67460515	0.531	rs13060601	chr3:160823159	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-4.7	-0.43	8.8e-6	Parkinson's disease;
THYM	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg22875332	chr1:76189707	ACADM	-0.56	-5.2	-0.47	1.16e-6	Daytime sleep phenotypes;
THYM	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9948	1.000	rs1320146	chr2:97507727	T/C	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.83	-0.44	5.18e-6	Erectile dysfunction and prostate cancer treatment;
THYM	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg16342193	chr10:102329863	NA	-0.53	-5.45	-0.49	4.01e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs920590	0.876	rs3907477	chr8:19657744	C/T	cg01411142	chr8:19674711	INTS10	0.58	4.5	0.42	1.91e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.74	-5.24	-0.47	9.85e-7	Huntington's disease progression;
THYM	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg11752832	chr7:134001865	SLC35B4	0.76	5.72	0.51	1.24e-7	Mean platelet volume;
THYM	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg10856724	chr12:34555212	NA	0.79	6.9	0.58	5.77e-10	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2290159	0.800	rs9849807	chr3:12675026	A/G	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg17554472	chr22:41940697	POLR3H	-0.72	-4.65	-0.43	1.07e-5	Vitiligo;
THYM	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6032067	0.852	rs6032064	chr20:43854827	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.49	-0.49	3.31e-7	Blood protein levels;
THYM	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg16586182	chr3:47516702	SCAP	0.65	5.62	0.5	1.94e-7	Colorectal cancer;
THYM	cis	rs7834588	0.544	rs1947483	chr8:63811000	T/C	cg20602954	chr8:63776762	NKAIN3	-0.63	-5.23	-0.47	9.91e-7	Response to Vitamin E supplementation;
THYM	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	cg01483505	chr11:975446	AP2A2	-0.63	-4.93	-0.45	3.5e-6	Alzheimer's disease (late onset);
THYM	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.43	-0.49	4.24e-7	Mean corpuscular volume;
THYM	cis	rs17433780	0.897	rs17434151	chr1:89500526	G/T	cg09516651	chr1:89888402	LOC400759	0.96	7.66	0.62	1.58e-11	Carotid intima media thickness;
THYM	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg16586182	chr3:47516702	SCAP	-0.62	-5.42	-0.49	4.52e-7	Colorectal cancer;
THYM	cis	rs10197940	0.578	rs6718653	chr2:152346118	C/A	cg19508488	chr2:152266495	RIF1	0.72	5.66	0.5	1.57e-7	Lung cancer;
THYM	cis	rs4474465	0.920	rs10899535	chr11:78216237	G/A	cg19901956	chr11:77921274	USP35	0.67	4.99	0.46	2.71e-6	Alzheimer's disease (survival time);
THYM	cis	rs6732160	0.691	rs4536673	chr2:73413462	A/T	cg24220031	chr2:73402428	NA	-0.77	-8.98	-0.68	2.49e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2235642	0.592	rs743963	chr16:1657350	A/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.39	-4.48	-0.42	2.07e-5	Coronary artery disease;
THYM	cis	rs9972944	0.651	rs8080916	chr17:63816368	G/C	cg07283582	chr17:63770753	CCDC46	-0.64	-5.01	-0.46	2.54e-6	Total body bone mineral density;
THYM	cis	rs10911232	0.507	rs4397624	chr1:183053131	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg12564285	chr5:131593104	PDLIM4	0.43	4.71	0.44	8.47e-6	Blood metabolite levels;
THYM	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.16	9.2	0.69	8.54e-15	Cognitive test performance;
THYM	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg07884673	chr3:53033167	SFMBT1	1.25	6.36	0.55	6.97e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg06766960	chr11:133703094	NA	-0.61	-5.6	-0.5	2.08e-7	Childhood ear infection;
THYM	cis	rs12049351	0.774	rs4148760	chr1:229673934	G/C	cg11742688	chr1:229674241	ABCB10	-0.56	-4.51	-0.42	1.88e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg17173187	chr15:85201210	NMB	-0.39	-4.46	-0.42	2.25e-5	P wave terminal force;
THYM	cis	rs9420	0.961	rs71484461	chr11:57488890	G/A	cg19752551	chr11:57585705	CTNND1	-0.73	-8.02	-0.64	2.79e-12	Schizophrenia;
THYM	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg12373951	chr3:133503437	NA	0.57	6.02	0.53	3.28e-8	Iron status biomarkers;
THYM	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg16031515	chr1:205743344	RAB7L1	-0.68	-7.03	-0.59	3.07e-10	Menarche (age at onset);
THYM	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg27535305	chr1:53392650	SCP2	-0.39	-4.45	-0.42	2.34e-5	Monocyte count;
THYM	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg00990874	chr7:1149470	C7orf50	-0.68	-4.8	-0.44	5.95e-6	Bronchopulmonary dysplasia;
THYM	cis	rs9364687	0.664	rs9364688	chr6:163901391	A/C	cg01639524	chr6:163818125	NA	0.49	4.86	0.45	4.57e-6	Body mass index;
THYM	cis	rs4866334	1.000	rs76836105	chr5:18467089	T/G	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg00024416	chr22:24240387	NA	-0.68	-7.19	-0.59	1.49e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs3087591	1.000	rs2051506	chr17:29699860	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.61	-5.11	-0.46	1.63e-6	Hip circumference;
THYM	cis	rs9902453	0.791	rs3115100	chr17:28045744	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	6.53	0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg08901578	chr4:187885870	NA	-0.68	-6.86	-0.58	6.97e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13064411	0.696	rs13066742	chr3:113208423	T/C	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs11190604	0.767	rs11190520	chr10:102175309	T/C	cg07570687	chr10:102243282	WNT8B	0.81	7.68	0.62	1.44e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs10503871	0.545	rs6991816	chr8:30487344	C/T	cg12158488	chr8:31336998	NA	0.39	4.58	0.43	1.38e-5	Metabolite levels  (X-11787);
THYM	cis	rs7119038	0.686	rs55894437	chr11:118607417	C/T	cg19308663	chr11:118741387	NA	0.45	4.53	0.42	1.74e-5	Sjögren's syndrome;
THYM	trans	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg25214090	chr10:38739885	LOC399744	0.83	7.11	0.59	2.14e-10	Corneal astigmatism;
THYM	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg22105103	chr4:187893119	NA	0.9	9.35	0.69	4.03e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg00071950	chr4:10020882	SLC2A9	-0.82	-7.76	-0.62	9.48e-12	Bone mineral density;
THYM	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg03929089	chr4:120376271	NA	1.02	8.18	0.64	1.26e-12	Coronary artery disease;
THYM	cis	rs4072705	0.967	rs4836986	chr9:127408059	C/T	cg01786973	chr9:127249749	NR5A1	0.35	4.69	0.43	9.25e-6	Menarche (age at onset);
THYM	cis	rs4601821	0.858	rs7945132	chr11:113262473	A/T	cg14159747	chr11:113255604	NA	0.25	4.68	0.43	9.54e-6	Alcoholic chronic pancreatitis;
THYM	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.68	-4.87	-0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs863345	0.604	rs11264991	chr1:158472861	T/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs863345	0.604	rs12025831	chr1:158496282	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.82	-0.44	5.46e-6	Pneumococcal bacteremia;
THYM	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg27494647	chr7:150038898	RARRES2	0.4	4.59	0.43	1.35e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg02463440	chr8:22132932	PIWIL2	0.58	5.03	0.46	2.28e-6	Hypertriglyceridemia;
THYM	cis	rs7246967	0.673	rs7245540	chr19:22881504	C/G	cg05241461	chr19:22816980	ZNF492	0.59	4.76	0.44	6.88e-6	Bronchopulmonary dysplasia;
THYM	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg24375607	chr4:120327624	NA	0.64	5.09	0.46	1.82e-6	Corneal astigmatism;
THYM	cis	rs6121246	0.567	rs7266471	chr20:30220599	T/A	cg13852791	chr20:30311386	BCL2L1	0.7	4.99	0.46	2.76e-6	Mean corpuscular hemoglobin;
THYM	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg02569458	chr12:86230093	RASSF9	0.62	5.34	0.48	6.31e-7	Major depressive disorder;
THYM	cis	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs4589258	0.601	rs1792605	chr11:90435258	A/T	cg26138821	chr11:89956704	CHORDC1	0.56	4.68	0.43	9.36e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg12863693	chr15:85201151	NMB	0.62	5.39	0.48	5.18e-7	Schizophrenia;
THYM	cis	rs2302612	0.528	rs13416449	chr2:102842665	A/G	cg13315345	chr2:102803985	IL1RL2	0.72	4.88	0.45	4.28e-6	Serum protein levels (sST2);
THYM	cis	rs9807989	0.507	rs13021177	chr2:103056493	A/G	cg03938978	chr2:103052716	IL18RAP	0.75	9.86	0.71	3.25e-16	Asthma;
THYM	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs3820068	0.580	rs36100011	chr1:16046920	C/T	cg13390004	chr1:15929781	NA	0.64	4.86	0.45	4.68e-6	Systolic blood pressure;
THYM	cis	rs7178572	0.568	rs12900433	chr15:77495028	T/C	cg22256960	chr15:77711686	NA	-1.04	-8.57	-0.66	1.83e-13	Type 2 diabetes;
THYM	cis	rs11608355	0.846	rs61934479	chr12:109855111	A/G	cg10504392	chr12:110044639	NA	0.61	5.2	0.47	1.16e-6	Neuroticism;
THYM	cis	rs7000551	0.751	rs2461481	chr8:22382780	A/G	cg12081754	chr8:22256438	SLC39A14	-0.67	-6.16	-0.53	1.76e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs868036	0.681	rs28626095	chr15:68066729	T/C	cg24579218	chr15:68104479	NA	-0.81	-8.58	-0.66	1.78e-13	Restless legs syndrome;
THYM	cis	rs1267303	0.642	rs6670699	chr1:46997270	C/T	cg16387850	chr1:46982889	NA	-0.45	-5.49	-0.49	3.34e-7	Monobrow;
THYM	cis	rs1018836	0.828	rs4734250	chr8:91591239	C/G	cg16814680	chr8:91681699	NA	0.88	7.62	0.62	1.88e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.09e-8	Systolic blood pressure;
THYM	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7572733	0.534	rs770662	chr2:198729283	T/C	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs7610301	1.000	rs35444533	chr3:46644257	C/T	cg10242476	chr3:46619364	LRRC2;TDGF1	0.46	4.54	0.42	1.65e-5	Blood protein levels;
THYM	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg14675211	chr2:100938903	LONRF2	0.76	8.01	0.64	2.81e-12	Intelligence (multi-trait analysis);
THYM	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg26597838	chr10:835615	NA	0.86	5.28	0.48	8.33e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs2932538	0.922	rs12402469	chr1:113076625	G/A	cg22162597	chr1:113214053	CAPZA1	0.6	4.82	0.44	5.52e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs1691799	0.867	rs1168309	chr12:66726439	A/G	cg16791601	chr12:66731901	HELB	0.74	7.04	0.59	2.97e-10	White blood cell count (basophil);
THYM	cis	rs854765	0.583	rs7207395	chr17:17819335	C/T	cg16928487	chr17:17741425	SREBF1	-0.54	-5.21	-0.47	1.08e-6	Total body bone mineral density;
THYM	cis	rs7818345	0.534	rs34221121	chr8:19319625	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.66	5.54	0.49	2.74e-7	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg16928487	chr17:17741425	SREBF1	-0.56	-5.57	-0.5	2.37e-7	Total body bone mineral density;
THYM	cis	rs6047844	0.569	rs6113525	chr20:22094206	C/T	cg16502866	chr20:23015624	SSTR4	-0.57	-4.53	-0.42	1.69e-5	Male-pattern baldness;
THYM	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs1978968	1.000	rs5992135	chr22:18447114	C/T	cg01550578	chr22:18484421	MICAL3	0.68	5.16	0.47	1.37e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg15448220	chr1:150897856	SETDB1	0.86	6.94	0.58	4.73e-10	Melanoma;
THYM	cis	rs775227	0.706	rs808951	chr3:113002150	A/G	cg18753928	chr3:113234510	CCDC52	0.62	4.86	0.45	4.68e-6	Dental caries;
THYM	cis	rs9403317	0.573	rs9389941	chr6:141990680	T/C	cg15052665	chr6:141804349	NA	0.74	5.58	0.5	2.29e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4474465	1.000	rs7106080	chr11:78150592	G/A	cg19901956	chr11:77921274	USP35	-0.59	-4.52	-0.42	1.8e-5	Alzheimer's disease (survival time);
THYM	cis	rs4595586	0.545	rs7307303	chr12:39368976	A/G	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs9796	0.674	rs6492978	chr15:41317702	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.57	-4.67	-0.43	9.79e-6	Menopause (age at onset);
THYM	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.54	-6.0	-0.52	3.58e-8	Autism spectrum disorder or schizophrenia;
THYM	cis	rs654950	0.875	rs632166	chr1:41995681	T/C	cg06885757	chr1:42089581	HIVEP3	-0.43	-4.95	-0.45	3.19e-6	Airway imaging phenotypes;
THYM	cis	rs2806561	0.929	rs641452	chr1:23538386	A/G	cg12483005	chr1:23474871	LUZP1	0.54	5.48	0.49	3.47e-7	Height;
THYM	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs11997175	0.545	rs7818001	chr8:33807682	G/T	ch.8.33884649F	chr8:33765107	NA	0.67	5.0	0.46	2.61e-6	Body mass index;
THYM	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg00071950	chr4:10020882	SLC2A9	0.76	7.91	0.63	4.56e-12	Bone mineral density;
THYM	cis	rs854765	0.583	rs8080823	chr17:17864048	T/C	cg16928487	chr17:17741425	SREBF1	-0.54	-5.12	-0.46	1.63e-6	Total body bone mineral density;
THYM	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs11731175	1.000	rs11731175	chr4:189861251	A/C	cg00431894	chr4:189871012	NA	0.78	5.53	0.49	2.85e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg16049864	chr8:95962084	TP53INP1	-0.68	-6.05	-0.53	2.91e-8	Type 2 diabetes;
THYM	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg23711669	chr6:146136114	FBXO30	0.9	9.2	0.69	8.44e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg04546413	chr19:29218101	NA	0.69	5.19	0.47	1.17e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs870825	0.616	rs7678849	chr4:185648868	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs7940866	0.646	rs10894293	chr11:130824213	C/T	cg05962950	chr11:130786565	SNX19	-0.79	-6.69	-0.57	1.56e-9	Schizophrenia;
THYM	cis	rs367615	0.552	rs7720036	chr5:108710699	A/G	cg17395555	chr5:108820864	NA	-0.53	-6.19	-0.54	1.51e-8	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs1499972	0.941	rs55734908	chr3:117613268	A/T	cg07612923	chr3:117604196	NA	1.3	5.44	0.49	4.05e-7	Schizophrenia;
THYM	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.49	4.63	0.43	1.18e-5	Birth weight;
THYM	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg11366901	chr6:160182831	ACAT2	1.0	8.3	0.65	7.06e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg13402656	chr8:1511478	DLGAP2	-0.75	-6.86	-0.58	7e-10	Lung cancer;
THYM	cis	rs986417	0.818	rs10133871	chr14:61063771	A/C	cg27398547	chr14:60952738	C14orf39	0.93	5.06	0.46	2.07e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs7107770	1.000	rs66665027	chr11:125109381	A/G	cg07747661	chr11:125106135	PKNOX2	-0.93	-5.5	-0.49	3.25e-7	Photic sneeze reflex;
THYM	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg03609598	chr5:56110824	MAP3K1	0.74	4.5	0.42	1.91e-5	Initial pursuit acceleration;
THYM	cis	rs10493773	0.609	rs10873716	chr1:86178347	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.59	-9.23	-0.69	7.42e-15	Urate levels in overweight individuals;
THYM	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg19346786	chr7:2764209	NA	-0.56	-4.61	-0.43	1.26e-5	Height;
THYM	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs3096299	0.738	rs9929606	chr16:89527537	C/T	cg06640241	chr16:89574553	SPG7	0.87	7.29	0.6	9.1e-11	Multiple myeloma (IgH translocation);
THYM	trans	rs877282	0.891	rs11253406	chr10:796297	G/A	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.67	-0.62	1.5e-11	Personality dimensions;
THYM	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg08999081	chr20:33150536	PIGU	-0.77	-6.95	-0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	trans	rs2340727	1.000	rs2340727	chr1:161946727	C/T	cg11641254	chr5:68665600	RAD17;TAF9	1.3	7.27	0.6	1.03e-10	White blood cell count;Hematology traits;
THYM	cis	rs4372836	0.729	rs6547873	chr2:28981983	G/A	cg09522027	chr2:28974177	PPP1CB	-0.65	-5.15	-0.47	1.39e-6	Body mass index;
THYM	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg09487078	chr6:167525398	CCR6	0.4	4.46	0.42	2.26e-5	Crohn's disease;
THYM	cis	rs79349575	0.870	rs12941262	chr17:46967037	T/A	cg26022315	chr17:47021804	SNF8	0.5	4.64	0.43	1.11e-5	Type 2 diabetes;
THYM	cis	rs4664308	0.618	rs62175487	chr2:160892521	C/T	cg03641300	chr2:160917029	PLA2R1	-0.66	-5.58	-0.5	2.24e-7	Idiopathic membranous nephropathy;
THYM	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg04455712	chr21:45112962	RRP1B	0.49	4.47	0.42	2.2e-5	Mean corpuscular volume;
THYM	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg09455208	chr3:40491958	NA	0.47	4.93	0.45	3.41e-6	Renal cell carcinoma;
THYM	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14893161	chr1:205819251	PM20D1	1.02	11.86	0.77	1.87e-20	Menarche (age at onset);
THYM	trans	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.77	-7.67	-0.62	1.47e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg00024416	chr22:24240387	NA	0.63	7.0	0.58	3.54e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7131987	0.683	rs7954278	chr12:29459290	G/A	cg09582351	chr12:29534625	ERGIC2	-0.6	-5.2	-0.47	1.12e-6	QT interval;
THYM	cis	rs11711311	0.824	rs9876528	chr3:113357196	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.59	-5.0	-0.46	2.62e-6	IgG glycosylation;
THYM	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg25072359	chr17:41440525	NA	0.65	4.56	0.42	1.5e-5	Menopause (age at onset);
THYM	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg06808227	chr14:105710500	BRF1	-1.06	-9.42	-0.7	2.84e-15	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2708977	1.000	rs1011040	chr2:97212755	A/G	cg01950434	chr2:97203154	ARID5A	-0.57	-5.05	-0.46	2.1e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs28595532	0.844	rs115411027	chr4:119490685	T/C	cg21605333	chr4:119757512	SEC24D	1.44	5.22	0.47	1.03e-6	Cannabis dependence symptom count;
THYM	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg13852791	chr20:30311386	BCL2L1	0.67	4.65	0.43	1.08e-5	Mean corpuscular hemoglobin;
THYM	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg07061783	chr6:25882402	NA	0.57	4.49	0.42	1.99e-5	Schizophrenia;
THYM	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg08085267	chr17:45401833	C17orf57	-0.61	-4.79	-0.44	6.12e-6	Glaucoma (primary open-angle);
THYM	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg20891283	chr12:69753455	YEATS4	0.73	6.09	0.53	2.39e-8	Blood protein levels;
THYM	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg18105134	chr13:113819100	PROZ	-0.96	-8.77	-0.67	6.94e-14	Platelet distribution width;
THYM	cis	rs863345	0.604	rs879635	chr1:158462908	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs4808199	0.689	rs12979148	chr19:19406869	T/C	cg03709012	chr19:19516395	GATAD2A	1.21	6.31	0.54	8.9e-9	Nonalcoholic fatty liver disease;
THYM	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg15704280	chr7:45808275	SEPT13	1.02	8.22	0.64	1.04e-12	Coronary artery disease;
THYM	cis	rs4788570	0.584	rs6499534	chr16:71755278	C/G	cg06353428	chr16:71660113	MARVELD3	1.39	9.52	0.7	1.78e-15	Intelligence (multi-trait analysis);
THYM	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg15247329	chr7:2764246	NA	-0.7	-5.95	-0.52	4.52e-8	Height;
THYM	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg00129232	chr17:37814104	STARD3	-0.87	-7.23	-0.6	1.23e-10	Asthma;
THYM	cis	rs10501293	0.643	rs10837996	chr11:43028439	A/G	cg03447554	chr11:43094025	NA	0.61	4.51	0.42	1.83e-5	Cognitive performance;
THYM	cis	rs8050907	0.744	rs10438587	chr16:4522160	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.58	0.43	1.38e-5	Obesity-related traits;
THYM	cis	rs892961	0.932	rs8066646	chr17:75414192	C/T	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs7512552	0.839	rs11577843	chr1:150398258	A/G	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg21100191	chr22:23484243	RTDR1	0.72	6.3	0.54	9.05e-9	Bone mineral density;
THYM	cis	rs11186	0.556	rs60762885	chr2:189953679	T/G	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-4.69	-0.43	9.25e-6	Total body bone mineral density;
THYM	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg22907277	chr7:1156413	C7orf50	0.86	7.5	0.61	3.29e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6500395	1.000	rs8052073	chr16:48682696	T/C	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9649213	1.000	rs9649213	chr7:98021211	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.59	-5.21	-0.47	1.08e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg06108461	chr20:60628389	TAF4	-0.81	-6.74	-0.57	1.22e-9	Body mass index;
THYM	cis	rs1018836	0.923	rs4734266	chr8:91628147	C/T	cg16814680	chr8:91681699	NA	-0.85	-7.17	-0.59	1.59e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg12599982	chr1:44399894	ARTN	0.59	4.84	0.44	5e-6	Intelligence (multi-trait analysis);
THYM	cis	rs17152411	1.000	rs12569940	chr10:126592684	T/C	cg07906193	chr10:126599966	NA	0.69	4.72	0.44	8.28e-6	Height;
THYM	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg03676636	chr4:99064102	C4orf37	0.45	6.81	0.57	8.96e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.26	-10.46	-0.73	1.73e-17	Platelet count;
THYM	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.58	-7.96	-0.63	3.69e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg06766960	chr11:133703094	NA	-0.49	-4.67	-0.43	9.84e-6	Childhood ear infection;
THYM	cis	rs713587	0.776	rs1172294	chr2:25169200	A/G	cg01884057	chr2:25150051	NA	0.58	5.81	0.51	8.21e-8	Body mass index in non-asthmatics;
THYM	cis	rs6754311	0.512	rs12998387	chr2:136507039	A/G	cg04750100	chr2:136595281	LCT	-0.55	-6.28	-0.54	1.01e-8	Mosquito bite size;
THYM	cis	rs335206	1.000	rs335204	chr5:122506260	C/A	cg16368670	chr5:122501738	PRDM6	-0.56	-4.55	-0.42	1.56e-5	QRS duration;
THYM	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs7584330	0.554	rs6740834	chr2:238423442	T/C	cg08992911	chr2:238395768	MLPH	0.74	4.69	0.43	9.01e-6	Prostate cancer;
THYM	cis	rs10832963	1.000	rs10128711	chr11:18632984	A/G	cg20219074	chr11:18656078	SPTY2D1	0.82	6.73	0.57	1.3e-9	Breast cancer;
THYM	cis	rs7572733	0.555	rs13395030	chr2:198750806	A/G	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs9443645	0.527	rs9359362	chr6:79723756	T/C	cg05283184	chr6:79620031	NA	-0.58	-4.51	-0.42	1.84e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg06713675	chr4:122721982	EXOSC9	-0.49	-4.55	-0.42	1.59e-5	Type 2 diabetes;
THYM	cis	rs7944735	0.567	rs76477746	chr11:48103368	G/C	cg24672777	chr11:48374446	OR4C45	-0.96	-4.68	-0.43	9.61e-6	Intraocular pressure;
THYM	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.78	0.51	9.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg05283184	chr6:79620031	NA	-1.01	-9.47	-0.7	2.22e-15	Intelligence (multi-trait analysis);
THYM	cis	rs4631830	0.932	rs4581397	chr10:51532367	A/G	cg10326726	chr10:51549505	MSMB	-0.59	-5.9	-0.52	5.56e-8	Prostate-specific antigen levels;
THYM	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg27034606	chr17:28928453	LRRC37B2	0.76	5.06	0.46	2.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2688608	0.592	rs11814282	chr10:75490217	T/C	cg19442545	chr10:75533431	FUT11	-0.51	-5.22	-0.47	1.03e-6	Inflammatory bowel disease;
THYM	cis	rs10819861	0.575	rs10760780	chr9:98872791	A/G	cg14508093	chr9:98862825	NA	0.26	5.22	0.47	1.07e-6	Electrocardiographic traits;
THYM	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02018176	chr4:1364513	KIAA1530	0.99	10.1	0.72	1.02e-16	Longevity;
THYM	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18252515	chr7:66147081	NA	-0.62	-4.68	-0.43	9.6e-6	Aortic root size;
THYM	cis	rs483180	0.531	rs662243	chr1:120209564	A/C	cg19096424	chr1:120255104	PHGDH	0.63	4.91	0.45	3.84e-6	Macular telangiectasia type 2;
THYM	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg07362569	chr17:61921086	SMARCD2	0.76	6.86	0.58	7.12e-10	Prudent dietary pattern;
THYM	cis	rs3771570	1.000	rs59536819	chr2:242272388	A/G	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	6.25	0.54	1.16e-8	Smoking behavior;
THYM	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg13695892	chr22:41940480	POLR3H	-0.99	-7.51	-0.61	3.24e-11	Vitiligo;
THYM	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg15693483	chr7:1102177	C7orf50	0.45	5.63	0.5	1.81e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg12310025	chr6:25882481	NA	-0.74	-5.74	-0.51	1.15e-7	Blood metabolite levels;
THYM	cis	rs354225	0.544	rs13399656	chr2:54802696	T/G	cg23486701	chr2:54789491	SPTBN1	0.34	4.57	0.42	1.48e-5	Schizophrenia;
THYM	cis	rs7246967	0.673	rs2194112	chr19:22926189	A/C	cg05241461	chr19:22816980	ZNF492	0.59	4.61	0.43	1.26e-5	Bronchopulmonary dysplasia;
THYM	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg17211192	chr8:82754475	SNX16	-0.84	-7.19	-0.59	1.46e-10	Diastolic blood pressure;
THYM	cis	rs17433780	0.897	rs12142922	chr1:89489915	A/G	cg09516651	chr1:89888402	LOC400759	0.97	7.66	0.62	1.57e-11	Carotid intima media thickness;
THYM	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg14196790	chr5:131705035	SLC22A5	0.55	5.05	0.46	2.15e-6	Blood metabolite levels;
THYM	cis	rs6964587	0.626	rs7807765	chr7:91531974	C/A	cg17063962	chr7:91808500	NA	-0.98	-8.65	-0.66	1.25e-13	Breast cancer;
THYM	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg26022315	chr17:47021804	SNF8	0.51	4.87	0.45	4.44e-6	Type 2 diabetes;
THYM	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg06453172	chr10:134556979	INPP5A	-0.6	-4.45	-0.42	2.34e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	trans	rs8002861	0.870	rs12865116	chr13:44440441	C/G	cg17145862	chr1:211918768	LPGAT1	-0.87	-7.85	-0.63	6.13e-12	Leprosy;
THYM	cis	rs6754311	0.551	rs313526	chr2:136445526	C/T	cg23851026	chr2:136556271	LCT	0.59	5.62	0.5	1.91e-7	Mosquito bite size;
THYM	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.63	4.83	0.44	5.28e-6	Tonsillectomy;
THYM	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg02753203	chr1:228287806	NA	1.02	9.0	0.68	2.24e-14	Diastolic blood pressure;
THYM	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.68	4.92	0.45	3.64e-6	Height;
THYM	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg04520793	chr17:42248056	ASB16	-0.35	-4.98	-0.45	2.85e-6	Total body bone mineral density;
THYM	cis	rs4409675	0.527	rs1884469	chr1:28239434	G/A	cg23691781	chr1:28212827	C1orf38	0.44	4.53	0.42	1.71e-5	Corneal astigmatism;
THYM	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	5.32	0.48	6.9e-7	Schizophrenia;
THYM	cis	rs7213347	0.581	rs4790881	chr17:2068932	C/A	cg16513277	chr17:2031491	SMG6	-0.64	-5.04	-0.46	2.22e-6	Total body bone mineral density;
THYM	cis	rs1065852	0.526	rs9623490	chr22:42398266	G/C	cg01059385	chr22:42394853	WBP2NL	0.57	4.66	0.43	1.04e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	trans	rs7618501	1.000	rs2247036	chr3:49882349	C/T	cg21582582	chr3:182698605	DCUN1D1	0.79	6.84	0.57	7.58e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg23791538	chr6:167370224	RNASET2	0.73	5.67	0.5	1.54e-7	Crohn's disease;
THYM	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.68	5.16	0.47	1.33e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs10089	1.000	rs13357268	chr5:127423051	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.02	6.68	0.57	1.58e-9	Ileal carcinoids;
THYM	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.7	-5.63	-0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg24209194	chr3:40518798	ZNF619	0.58	4.7	0.43	8.73e-6	Renal cell carcinoma;
THYM	cis	rs7255436	0.965	rs11668346	chr19:8450854	A/T	cg10174797	chr19:8464628	RAB11B	0.43	5.19	0.47	1.21e-6	HDL cholesterol;
THYM	cis	rs7567389	1.000	rs7567389	chr2:127982645	A/T	cg06038358	chr2:128176007	PROC	-0.45	-4.85	-0.45	4.89e-6	Self-rated health;
THYM	cis	rs67072384	0.818	rs7926287	chr11:72464525	A/G	cg01380194	chr11:72452482	ARAP1	-0.81	-4.57	-0.42	1.49e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs7084402	0.935	rs4948523	chr10:60339098	A/C	cg07615347	chr10:60278583	BICC1	0.57	5.33	0.48	6.7e-7	Refractive error;
THYM	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg26721908	chr21:47610096	LSS	0.73	5.25	0.47	9.16e-7	Testicular germ cell tumor;
THYM	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg21926883	chr2:100939477	LONRF2	-0.65	-5.97	-0.52	4.11e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg08994789	chr17:28903642	LRRC37B2	1.09	5.23	0.47	1e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs250677	0.522	rs4431331	chr5:148353574	A/C	cg18129178	chr5:148520854	ABLIM3	-0.69	-5.17	-0.47	1.32e-6	Breast cancer;
THYM	cis	rs7575217	0.588	rs7572457	chr2:101675808	A/G	cg12594615	chr2:101643137	TBC1D8	0.58	4.91	0.45	3.71e-6	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg09359103	chr1:154839909	KCNN3	-0.85	-10.91	-0.75	1.87e-18	Prostate cancer;
THYM	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg26513180	chr16:89883248	FANCA	-0.71	-7.26	-0.6	1.04e-10	Vitiligo;
THYM	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg16989719	chr2:238392110	NA	-0.6	-5.82	-0.51	8.08e-8	Prostate cancer;
THYM	cis	rs67460515	0.926	rs11715591	chr3:161043137	C/T	cg03342759	chr3:160939853	NMD3	-0.93	-7.94	-0.63	3.98e-12	Parkinson's disease;
THYM	cis	rs611744	0.647	rs615126	chr8:109247619	C/T	cg21045802	chr8:109455806	TTC35	0.66	5.99	0.52	3.78e-8	Dupuytren's disease;
THYM	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg20486651	chr6:167070296	RPS6KA2	0.5	4.79	0.44	6.18e-6	Crohn's disease;
THYM	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg19761014	chr17:28927070	LRRC37B2	0.82	4.6	0.43	1.31e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs868036	0.561	rs28376697	chr15:68140315	A/G	cg23793686	chr15:68133972	NA	-0.57	-4.66	-0.43	1.04e-5	Restless legs syndrome;
THYM	cis	rs6840360	1.000	rs1877187	chr4:152605621	C/T	cg22705602	chr4:152727874	NA	-0.63	-7.01	-0.58	3.47e-10	Intelligence (multi-trait analysis);
THYM	cis	rs146972365	1	rs146972365	chr16:90022693	T/C	cg07984980	chr16:89898383	SPIRE2	1.48	5.83	0.51	7.45e-8	Brown vs. non-brown hair color;Red vs non-red hair color;Light vs. dark hair color;
THYM	cis	rs9486719	1.000	rs1303852	chr6:96864523	C/T	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs2625529	0.652	rs2278987	chr15:72409769	T/C	cg16672083	chr15:72433130	SENP8	0.49	4.52	0.42	1.76e-5	Red blood cell count;
THYM	cis	rs57920188	0.703	rs10915642	chr1:4089244	T/C	cg20703997	chr1:4087676	NA	0.74	5.29	0.48	7.79e-7	Interleukin-17 levels;
THYM	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg17264618	chr3:40429014	ENTPD3	-0.5	-4.87	-0.45	4.46e-6	Renal cell carcinoma;
THYM	cis	rs6032067	0.929	rs17425504	chr20:43880089	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.71	-7.45	-0.61	4.33e-11	Blood protein levels;
THYM	cis	rs6500395	0.962	rs9934626	chr16:48602761	G/C	cg04672837	chr16:48644449	N4BP1	0.48	4.64	0.43	1.11e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs80319144	0.855	rs115894713	chr2:159291278	G/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg13939156	chr17:80058883	NA	0.4	5.29	0.48	7.68e-7	Life satisfaction;
THYM	cis	rs4731207	0.698	rs6415362	chr7:124530650	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg06558623	chr16:89946397	TCF25	1.33	6.02	0.53	3.25e-8	Skin colour saturation;
THYM	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg26818010	chr10:134567672	INPP5A	-0.85	-6.98	-0.58	3.98e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg18402987	chr7:1209562	NA	0.64	5.02	0.46	2.4e-6	Longevity;Endometriosis;
THYM	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg03264133	chr6:25882463	NA	0.64	4.94	0.45	3.34e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs9790314	0.936	rs336572	chr3:161068014	G/A	cg03342759	chr3:160939853	NMD3	-0.77	-6.69	-0.57	1.52e-9	Morning vs. evening chronotype;
THYM	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	6.38	0.55	6.5e-9	Electrocardiographic conduction measures;
THYM	cis	rs2862064	1.000	rs7715467	chr5:156468654	C/G	cg12943317	chr5:156479607	HAVCR1	-0.86	-5.28	-0.48	8e-7	Platelet count;
THYM	cis	rs501916	0.796	rs75186419	chr15:48043934	G/A	cg20869673	chr15:48010124	SEMA6D	0.71	5.27	0.48	8.37e-7	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs4589258	0.788	rs7943744	chr11:90493644	T/A	cg26138821	chr11:89956704	CHORDC1	-0.56	-4.49	-0.42	1.98e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs17030434	1.000	rs12645134	chr4:154713430	T/C	cg14289246	chr4:154710475	SFRP2	-0.76	-5.24	-0.47	9.79e-7	Electrocardiographic conduction measures;
THYM	cis	rs4731207	0.596	rs10256218	chr7:124609982	C/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs7620457	1.000	rs7620457	chr3:183747266	A/G	cg20387954	chr3:183756860	HTR3D	-0.76	-5.24	-0.47	9.69e-7	Body mass index;
THYM	cis	rs2456568	0.900	rs2456559	chr11:93668858	A/T	cg26875233	chr11:93583750	C11orf90	-0.47	-4.64	-0.43	1.13e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2050392	0.929	rs10826798	chr10:30700904	G/A	cg02070205	chr10:30722105	MAP3K8	0.54	4.87	0.45	4.44e-6	Inflammatory bowel disease;
THYM	cis	rs354225	0.544	rs4455200	chr2:54801591	T/A	cg23486701	chr2:54789491	SPTBN1	0.37	4.88	0.45	4.18e-6	Schizophrenia;
THYM	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg07636037	chr3:49044803	WDR6	0.96	10.22	0.72	5.62e-17	Parkinson's disease;
THYM	cis	rs56309584	0.673	rs12451139	chr17:8119626	G/T	cg08322244	chr17:8066669	VAMP2	-0.56	-5.31	-0.48	7.15e-7	Initial pursuit acceleration;
THYM	cis	rs7364180	0.582	rs139568	chr22:42210985	C/T	cg03806693	chr22:41940476	POLR3H	0.61	4.74	0.44	7.64e-6	Alzheimer's disease biomarkers;
THYM	cis	rs2976388	0.647	rs2082801	chr8:143786461	A/G	cg06565975	chr8:143823917	SLURP1	0.44	4.93	0.45	3.51e-6	Urinary tract infection frequency;
THYM	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg06636001	chr8:8085503	FLJ10661	0.85	8.01	0.64	2.81e-12	Joint mobility (Beighton score);
THYM	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg05802129	chr4:122689817	NA	-0.57	-4.47	-0.42	2.17e-5	Type 2 diabetes;
THYM	cis	rs7084402	0.967	rs1427197	chr10:60275150	A/G	cg07615347	chr10:60278583	BICC1	-0.56	-5.15	-0.47	1.42e-6	Refractive error;
THYM	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg22535103	chr8:58192502	C8orf71	-0.98	-4.87	-0.45	4.49e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs3087591	0.919	rs2953011	chr17:29412046	A/G	cg24425628	chr17:29625626	OMG;NF1	0.65	5.59	0.5	2.16e-7	Hip circumference;
THYM	cis	rs2712184	0.875	rs35925637	chr2:217676628	T/A	cg05032264	chr2:217675019	NA	0.59	5.16	0.47	1.36e-6	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg11764359	chr7:65958608	NA	0.82	6.56	0.56	2.81e-9	Aortic root size;
THYM	cis	rs6763768	0.606	rs12490667	chr3:53293986	G/A	cg16894138	chr3:53270350	TKT	0.74	5.25	0.47	9.38e-7	Bacterial meningitis;
THYM	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg21427119	chr20:30132790	HM13	-0.86	-5.96	-0.52	4.2e-8	Mean corpuscular hemoglobin;
THYM	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs990171	1.000	rs2058623	chr2:102986170	C/T	cg13897122	chr2:103039542	IL18RAP	-0.4	-4.76	-0.44	6.87e-6	Lymphocyte counts;
THYM	cis	rs9650682	0.784	rs1058252	chr9:15472411	A/G	cg20696139	chr9:15510574	PSIP1	-0.92	-4.65	-0.43	1.09e-5	Schizophrenia;
THYM	cis	rs7914606	0.516	rs11592572	chr10:85225375	C/T	cg01558777	chr10:85933798	C10orf99	-1.09	-4.7	-0.43	8.68e-6	Trans fatty acid levels;
THYM	cis	rs2000999	0.778	rs12445401	chr16:72148419	A/G	cg23815491	chr16:72088622	HP	0.69	5.0	0.46	2.63e-6	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
THYM	cis	rs936229	0.813	rs2168519	chr15:75080872	T/C	cg10253484	chr15:75165896	SCAMP2	-0.66	-4.59	-0.43	1.38e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs11048434	0.761	rs1805765	chr12:9094548	A/G	cg13575925	chr12:9217583	LOC144571	0.53	4.94	0.45	3.31e-6	Sjögren's syndrome;
THYM	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.42	4.47	0.42	2.17e-5	Hemoglobin concentration;
THYM	cis	rs1018836	0.637	rs6471113	chr8:91519735	A/G	cg16814680	chr8:91681699	NA	-0.77	-6.47	-0.55	4.25e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg09359103	chr1:154839909	KCNN3	-0.72	-9.45	-0.7	2.44e-15	Prostate cancer;
THYM	trans	rs877282	1.000	rs12779159	chr10:772143	T/C	cg22713356	chr15:30763199	NA	1.32	10.32	0.73	3.37e-17	Uric acid levels;
THYM	cis	rs2073300	0.609	rs6137930	chr20:23376732	G/A	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs4731207	0.596	rs6959632	chr7:124691046	A/T	cg05285228	chr7:124571219	POT1	-0.65	-5.0	-0.46	2.64e-6	Cutaneous malignant melanoma;
THYM	cis	rs10929159	0.928	rs7569558	chr2:236924309	G/A	cg20128773	chr2:236923534	AGAP1	0.35	4.78	0.44	6.31e-6	Parkinson's disease;
THYM	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg02551604	chr5:131831745	NA	-0.63	-4.92	-0.45	3.64e-6	Breast cancer;Mosquito bite size;
THYM	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg05295671	chr13:79234353	RNF219	0.85	5.71	0.51	1.27e-7	Large artery stroke;
THYM	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs1538970	0.774	rs67683090	chr1:45977803	T/G	cg05343316	chr1:45956843	TESK2	0.85	5.42	0.49	4.57e-7	Platelet count;
THYM	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg16342193	chr10:102329863	NA	-0.57	-6.1	-0.53	2.32e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs35883536	0.647	rs12043865	chr1:101042651	G/A	cg06223162	chr1:101003688	GPR88	-0.8	-6.9	-0.58	5.77e-10	Monocyte count;
THYM	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg02640540	chr1:67518911	SLC35D1	0.65	4.78	0.44	6.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg22709100	chr7:91322751	NA	-0.64	-4.96	-0.45	3.08e-6	Breast cancer;
THYM	cis	rs7786808	0.552	rs4909205	chr7:158185283	G/A	cg01191920	chr7:158217561	PTPRN2	-0.98	-10.22	-0.72	5.51e-17	Obesity-related traits;
THYM	cis	rs2458413	0.669	rs12681140	chr8:105346112	A/C	cg04554929	chr8:105342491	NA	0.42	5.92	0.52	5.03e-8	Paget's disease;
THYM	cis	rs16854884	0.632	rs34071449	chr3:143662861	C/T	cg05063096	chr3:143689810	C3orf58	0.74	4.89	0.45	4.17e-6	Economic and political preferences (feminism/equality);
THYM	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg05340658	chr4:99064831	C4orf37	0.54	4.52	0.42	1.78e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs2282300	0.667	rs10734405	chr11:30273750	T/C	cg09906309	chr11:30344399	C11orf46	0.73	5.38	0.48	5.3e-7	Morning vs. evening chronotype;
THYM	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg09085632	chr11:111637200	PPP2R1B	1.11	11.2	0.75	4.58e-19	Primary sclerosing cholangitis;
THYM	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg17279839	chr7:150038598	RARRES2	0.56	5.45	0.49	3.92e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs12347191	0.500	rs925485	chr9:100619561	G/C	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Orofacial clefts;
THYM	cis	rs96067	0.805	rs6425966	chr1:36611287	C/T	cg24686825	chr1:36642396	MAP7D1	0.68	4.71	0.44	8.32e-6	Corneal structure;
THYM	cis	rs7731657	0.537	rs2419936	chr5:130316560	T/C	cg08523029	chr5:130500466	HINT1	-0.84	-6.14	-0.53	1.87e-8	Fasting plasma glucose;
THYM	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg17366294	chr4:99064904	C4orf37	0.57	6.8	0.57	9.22e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2294693	0.945	rs742494	chr6:41007835	A/T	cg21128951	chr6:40996213	UNC5CL	0.61	4.58	0.43	1.38e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.78	0.44	6.51e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6138458	1.000	rs6707	chr20:24944166	C/T	cg06937882	chr20:24974362	C20orf3	-0.47	-4.45	-0.42	2.31e-5	Blood protein levels;
THYM	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg03467027	chr4:99064603	C4orf37	0.59	4.49	0.42	1.97e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4851254	0.618	rs35840153	chr2:100669829	A/G	cg22139774	chr2:100720529	AFF3	-0.39	-4.49	-0.42	1.99e-5	Intelligence (multi-trait analysis);
THYM	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg14507445	chr22:49886340	NA	-0.51	-4.56	-0.42	1.52e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg13319975	chr6:146136371	FBXO30	0.66	5.42	0.49	4.51e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4660531	1.000	rs4660531	chr1:41839822	G/T	cg01193554	chr1:41846683	NA	-0.35	-4.63	-0.43	1.15e-5	Bipolar disorder;
THYM	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg23161317	chr6:28129485	ZNF389	0.72	4.79	0.44	6.09e-6	Parkinson's disease;
THYM	cis	rs2034088	0.833	rs4968120	chr17:431364	T/G	cg06217071	chr17:408420	NA	0.83	8.9	0.67	3.63e-14	Hip circumference adjusted for BMI;
THYM	cis	rs778371	0.697	rs6717048	chr2:233586427	T/C	cg08000102	chr2:233561755	GIGYF2	0.83	7.52	0.61	3.07e-11	Schizophrenia;
THYM	cis	rs2273669	0.667	rs75675305	chr6:109324353	T/C	cg17117243	chr6:109341365	SESN1	-0.9	-5.38	-0.48	5.45e-7	Prostate cancer;
THYM	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg02725872	chr8:58115012	NA	-0.9	-5.24	-0.47	9.85e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs9527	0.544	rs1572578	chr10:104822431	C/G	cg04362960	chr10:104952993	NT5C2	0.6	4.55	0.42	1.56e-5	Arsenic metabolism;
THYM	trans	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs9388451	0.531	rs9321057	chr6:126156943	G/A	cg10911889	chr6:126070802	HEY2	0.63	4.8	0.44	5.85e-6	Brugada syndrome;
THYM	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg17911788	chr17:44343683	NA	-0.6	-6.03	-0.53	3.12e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.42	-4.98	-0.45	2.88e-6	Schizophrenia;
THYM	cis	rs9361491	0.608	rs9352617	chr6:79441654	A/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg18402987	chr7:1209562	NA	0.64	4.95	0.45	3.15e-6	Longevity;Endometriosis;
THYM	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg24812749	chr6:127587940	RNF146	0.76	5.71	0.51	1.27e-7	Breast cancer;
THYM	cis	rs6584283	0.846	rs10883370	chr10:101291472	T/C	cg04972745	chr10:101287846	NA	-0.51	-4.85	-0.45	4.73e-6	Ulcerative colitis;
THYM	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg02153584	chr22:29168773	CCDC117	0.61	4.76	0.44	6.94e-6	Lymphocyte counts;
THYM	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03264133	chr6:25882463	NA	-0.71	-5.8	-0.51	8.6e-8	Blood metabolite levels;
THYM	cis	rs928736	0.557	rs2834083	chr21:34436973	A/G	cg10915739	chr21:34405733	NA	0.48	4.88	0.45	4.3e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	trans	rs208520	0.661	rs704519	chr6:66801136	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-7.45	-0.61	4.26e-11	Exhaled nitric oxide output;
THYM	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	5.39	0.48	5.1e-7	Monocyte percentage of white cells;
THYM	cis	rs4084127	1.000	rs4084127	chr11:69596523	C/T	cg14578030	chr11:69591383	FGF4	0.5	4.56	0.42	1.51e-5	Type 1 diabetes;
THYM	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg18681998	chr4:17616180	MED28	0.99	10.09	0.72	1.05e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs877282	0.891	rs11599917	chr10:762288	G/A	cg10556349	chr10:835070	NA	-0.78	-5.04	-0.46	2.24e-6	Uric acid levels;
THYM	trans	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg25214090	chr10:38739885	LOC399744	0.85	7.16	0.59	1.7e-10	Corneal astigmatism;
THYM	cis	rs7819412	0.534	rs11250113	chr8:10907479	C/T	cg16664915	chr8:10907788	XKR6	0.56	4.52	0.42	1.76e-5	Triglycerides;
THYM	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg27446573	chr6:127587934	RNF146	1.02	9.5	0.7	1.93e-15	Breast cancer;
THYM	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg11764359	chr7:65958608	NA	0.85	7.0	0.58	3.62e-10	Aortic root size;
THYM	cis	rs2710642	0.525	rs1601673	chr2:62842559	G/C	cg17519650	chr2:63277830	OTX1	0.62	4.61	0.43	1.25e-5	LDL cholesterol levels;LDL cholesterol;
THYM	cis	rs13014235	0.532	rs11681592	chr2:202263901	C/G	cg12544106	chr2:202507780	ALS2CR4	-0.66	-4.77	-0.44	6.66e-6	Basal cell carcinoma;
THYM	cis	rs2276498	0.751	rs2299702	chr20:52659089	A/T	cg23682609	chr20:52687365	BCAS1	0.56	4.55	0.42	1.6e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs4660306	0.961	rs11211138	chr1:46015157	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.69	-5.23	-0.47	1e-6	Homocysteine levels;
THYM	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.63	4.46	0.42	2.25e-5	Aortic root size;
THYM	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg23989207	chr17:80870107	TBCD	0.58	4.82	0.44	5.54e-6	Glycated hemoglobin levels;
THYM	cis	rs6032067	0.929	rs6032055	chr20:43833336	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs3820068	0.608	rs10927831	chr1:16028373	T/G	cg13390004	chr1:15929781	NA	0.65	4.81	0.44	5.56e-6	Systolic blood pressure;
THYM	cis	rs4454254	0.518	rs6578062	chr8:141058722	A/T	cg05910124	chr8:141057427	TRAPPC9	-0.6	-4.67	-0.43	1.01e-5	Pulse pressure;
THYM	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg08085267	chr17:45401833	C17orf57	-0.61	-4.79	-0.44	6.12e-6	Glaucoma (primary open-angle);
THYM	trans	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg05896524	chr21:47604654	C21orf56	-0.69	-4.87	-0.45	4.4e-6	Testicular germ cell tumor;
THYM	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.66	5.85	0.51	6.94e-8	Total body bone mineral density;
THYM	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg04673462	chr1:38461896	NA	0.44	5.24	0.47	9.75e-7	Coronary artery disease;
THYM	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg03351412	chr1:154909251	PMVK	-0.74	-5.89	-0.52	5.76e-8	Prostate cancer;
THYM	cis	rs1568889	0.838	rs11030187	chr11:28044391	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs12579753	1.000	rs11115030	chr12:82203021	A/T	cg21231944	chr12:82153410	PPFIA2	-0.65	-4.96	-0.45	3.1e-6	Resting heart rate;
THYM	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg10802521	chr3:52805072	NEK4	-0.8	-7.5	-0.61	3.34e-11	Electroencephalogram traits;
THYM	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg10047753	chr17:41438598	NA	1.15	10.46	0.73	1.72e-17	Menopause (age at onset);
THYM	cis	rs240764	0.853	rs11155496	chr6:100988939	T/C	cg21058520	chr6:100914733	NA	0.58	5.07	0.46	1.97e-6	Neuroticism;
THYM	cis	rs61931739	0.746	rs1687003	chr12:34170099	T/A	cg06521331	chr12:34319734	NA	-0.66	-5.48	-0.49	3.51e-7	Morning vs. evening chronotype;
THYM	cis	rs6032067	1.000	rs6032066	chr20:43857700	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.42	-0.49	4.55e-7	Blood protein levels;
THYM	cis	rs240764	0.717	rs151640	chr6:101111521	A/C	cg21058520	chr6:100914733	NA	-0.58	-4.89	-0.45	4.08e-6	Neuroticism;
THYM	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06481639	chr22:41940642	POLR3H	0.8	5.63	0.5	1.81e-7	Vitiligo;
THYM	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg16325326	chr1:53192061	ZYG11B	0.87	8.72	0.67	9.17e-14	Monocyte count;
THYM	cis	rs9915657	0.933	rs8075603	chr17:70136833	G/T	cg06234051	chr17:70120541	SOX9	-0.62	-5.81	-0.51	8.42e-8	Thyroid hormone levels;
THYM	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg23711669	chr6:146136114	FBXO30	-0.91	-8.87	-0.67	4.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9788682	0.747	rs11637630	chr15:78899719	G/A	cg18825076	chr15:78729989	IREB2	-0.57	-4.72	-0.44	7.97e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs78456975	0.568	rs115482599	chr2:1571960	A/G	cg12573674	chr2:1569213	NA	-1.32	-6.92	-0.58	5.34e-10	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg16230307	chr14:35515116	FAM177A1	0.93	5.99	0.52	3.67e-8	Psoriasis;
THYM	cis	rs941408	0.515	rs1736193	chr19:2785273	G/C	cg06609049	chr19:2785107	THOP1	1.2	12.48	0.79	9.64e-22	Total cholesterol levels;
THYM	cis	rs1371867	0.875	rs962452	chr8:101331369	G/A	cg06636551	chr8:101224915	SPAG1	-0.63	-6.33	-0.54	8.05e-9	Atrioventricular conduction;
THYM	cis	rs35110281	0.508	rs2838351	chr21:45110784	A/G	cg01579765	chr21:45077557	HSF2BP	-0.44	-6.38	-0.55	6.43e-9	Mean corpuscular volume;
THYM	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg20295408	chr7:1910781	MAD1L1	-0.66	-4.94	-0.45	3.3e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg09307838	chr4:120376055	NA	0.68	4.93	0.45	3.47e-6	Corneal astigmatism;
THYM	cis	rs77372450	0.551	rs60235007	chr5:157069349	G/C	cg00312553	chr5:157098553	C5orf52	-0.65	-4.63	-0.43	1.16e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs3204270	0.543	rs34034499	chr17:79638568	G/C	cg13117272	chr17:79681052	SLC25A10	-0.75	-4.74	-0.44	7.39e-6	Dental caries;
THYM	cis	rs1878931	0.624	rs27241	chr16:3447282	C/G	cg21433313	chr16:3507492	NAT15	0.56	4.58	0.43	1.42e-5	Body mass index (adult);
THYM	cis	rs7078219	0.543	rs7092009	chr10:101277239	A/G	cg17888390	chr10:101282816	NA	-0.48	-4.94	-0.45	3.4e-6	Dental caries;
THYM	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs7578361	0.959	rs4299305	chr2:150441215	A/G	cg17961725	chr2:150454027	NA	-0.75	-6.19	-0.54	1.54e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg06850241	chr22:41845214	NA	0.54	4.58	0.43	1.42e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs1160297	0.576	rs67939368	chr2:53093152	G/C	cg07782112	chr2:53107842	NA	0.77	6.24	0.54	1.19e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.34	-0.65	5.7e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg00645579	chr11:617140	IRF7;MUPCDH	-0.45	-5.02	-0.46	2.41e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9311676	0.656	rs6775710	chr3:58336201	A/G	cg26110898	chr3:58419937	PDHB	-0.44	-4.58	-0.43	1.41e-5	Systemic lupus erythematosus;
THYM	cis	rs10158481	0.727	rs4649068	chr1:25481041	G/A	cg09264742	chr1:25757510	TMEM57	-0.68	-4.9	-0.45	3.99e-6	Urate levels in obese individuals;
THYM	cis	rs57590327	0.555	rs3772884	chr3:81802720	G/T	cg07356753	chr3:81810745	GBE1	-0.85	-6.44	-0.55	4.84e-9	Extraversion;
THYM	cis	rs6424115	0.830	rs1106	chr1:24200772	C/G	cg15997130	chr1:24165203	NA	0.76	6.39	0.55	6.14e-9	Immature fraction of reticulocytes;
THYM	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.28	0.48	8.08e-7	Bipolar disorder;
THYM	cis	rs2718058	0.613	rs2718037	chr7:37777846	G/C	cg15028436	chr7:37888078	TXNDC3	0.65	4.99	0.46	2.72e-6	Alzheimer's disease (late onset);
THYM	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs9677476	0.779	rs10177091	chr2:232109889	C/T	cg23338755	chr2:231921595	PSMD1	0.73	4.71	0.43	8.61e-6	Food antigen IgG levels;
THYM	cis	rs995000	0.868	rs11208007	chr1:63176083	A/T	cg06896770	chr1:63153194	DOCK7	0.84	5.58	0.5	2.31e-7	Triglyceride levels;
THYM	cis	rs1401999	0.899	rs2313211	chr3:183738626	T/A	cg01324343	chr3:183735012	ABCC5	0.85	11.92	0.77	1.39e-20	Anterior chamber depth;
THYM	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg02734326	chr4:10020555	SLC2A9	0.78	6.67	0.56	1.68e-9	Bone mineral density;
THYM	cis	rs6754311	0.689	rs192822	chr2:136682274	A/T	cg20242066	chr2:136595261	LCT	0.56	6.55	0.56	2.97e-9	Mosquito bite size;
THYM	cis	rs4930103	0.874	rs80047492	chr11:2025032	A/T	cg18511798	chr11:2018149	H19;MIR675	-0.57	-5.84	-0.51	7.32e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs11792861	0.591	rs10979613	chr9:111687584	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.83	7.29	0.6	9.15e-11	Menarche (age at onset);
THYM	cis	rs73198271	0.737	rs535094	chr8:8633928	A/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-4.71	-0.44	8.29e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg11266682	chr4:10021025	SLC2A9	-0.69	-10.15	-0.72	7.87e-17	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11723261	0.621	rs7440274	chr4:155713	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	-0.78	-5.71	-0.51	1.28e-7	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs2282300	0.702	rs2211018	chr11:30330079	C/T	cg09906309	chr11:30344399	C11orf46	0.73	5.37	0.48	5.47e-7	Morning vs. evening chronotype;
THYM	cis	rs8014204	0.806	rs11159104	chr14:75293374	A/G	cg06637938	chr14:75390232	RPS6KL1	0.55	5.34	0.48	6.42e-7	Caffeine consumption;
THYM	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg07424592	chr7:64974309	NA	-1.04	-5.27	-0.48	8.52e-7	Diabetic kidney disease;
THYM	cis	rs79149102	0.579	rs12594117	chr15:75323648	C/G	cg09165964	chr15:75287851	SCAMP5	-1.11	-6.35	-0.55	7.21e-9	Lung cancer;
THYM	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg22508957	chr16:3507546	NAT15	0.7	7.9	0.63	4.94e-12	Tuberculosis;
THYM	cis	rs786425	0.585	rs10773034	chr12:124234253	A/G	cg15249119	chr12:124971054	NCOR2	0.52	4.77	0.44	6.73e-6	Pubertal anthropometrics;
THYM	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	8.9	0.67	3.71e-14	Cognitive test performance;
THYM	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg06028605	chr16:24865363	SLC5A11	0.63	5.02	0.46	2.38e-6	Intelligence (multi-trait analysis);
THYM	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg17757837	chr7:157058334	UBE3C	0.66	5.32	0.48	6.85e-7	Body mass index;
THYM	cis	rs4243830	0.826	rs12565181	chr1:6620545	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	1.12	6.95	0.58	4.48e-10	Body mass index;
THYM	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	trans	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.12	-13.73	-0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg04731861	chr2:219085781	ARPC2	0.56	5.39	0.48	5.21e-7	Colorectal cancer;
THYM	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.75	-0.44	7.15e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg14517863	chr17:44321492	NA	-0.44	-5.0	-0.46	2.59e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs654384	0.898	rs1077472	chr7:4175323	G/A	cg13153353	chr7:4175865	SDK1	0.47	4.52	0.42	1.77e-5	Positive affect;
THYM	cis	rs10186029	0.616	rs12616255	chr2:213978895	T/A	cg08319019	chr2:214017104	IKZF2	0.8	6.46	0.55	4.39e-9	Systemic sclerosis;
THYM	cis	rs524281	0.773	rs10750781	chr11:66037270	A/G	cg00563793	chr11:65837595	PACS1	0.79	4.71	0.43	8.53e-6	Electroencephalogram traits;
THYM	cis	rs6541297	1.000	rs6658942	chr1:230287517	A/C	cg20703242	chr1:230279135	GALNT2	1.0	6.58	0.56	2.53e-9	Coronary artery disease;
THYM	cis	rs988913	0.706	rs9396034	chr6:54930109	C/T	cg18532076	chr6:54711417	FAM83B	0.49	4.59	0.43	1.33e-5	Menarche (age at onset);
THYM	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg00801512	chr17:28996047	NA	-0.84	-5.46	-0.49	3.83e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs990171	1.000	rs11694658	chr2:103045020	A/G	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.17	-0.47	1.27e-6	Lymphocyte counts;
THYM	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg12963246	chr6:28129442	ZNF389	0.51	4.53	0.42	1.72e-5	Parkinson's disease;
THYM	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Bladder cancer;
THYM	cis	rs11771526	0.901	rs10271047	chr7:32289660	A/C	cg27532318	chr7:32358331	NA	-0.74	-5.27	-0.48	8.43e-7	Body mass index;
THYM	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.24	9.45	0.7	2.46e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg25072359	chr17:41440525	NA	0.72	5.24	0.47	9.65e-7	Menopause (age at onset);
THYM	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.69	-4.71	-0.44	8.39e-6	Cardiac Troponin-T levels;
THYM	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg12935359	chr14:103987150	CKB	-0.62	-6.36	-0.55	7.08e-9	Body mass index;
THYM	cis	rs10791097	0.967	rs10894268	chr11:130717153	C/T	cg14779329	chr11:130786720	SNX19	0.54	5.68	0.5	1.45e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg23711669	chr6:146136114	FBXO30	0.9	8.82	0.67	5.37e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg18252515	chr7:66147081	NA	-1.58	-8.32	-0.65	6.48e-13	Diabetic kidney disease;
THYM	cis	rs2070488	1.000	rs13058903	chr3:38513365	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.91	-6.8	-0.57	9.39e-10	Electrocardiographic conduction measures;
THYM	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05901451	chr6:126070800	HEY2	-0.96	-9.9	-0.71	2.65e-16	Brugada syndrome;
THYM	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg23711669	chr6:146136114	FBXO30	-0.83	-7.91	-0.63	4.62e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg11941060	chr3:133502564	NA	-0.73	-6.42	-0.55	5.36e-9	Iron status biomarkers;
THYM	cis	rs9810089	0.934	rs696520	chr3:136056861	T/C	cg12473912	chr3:136751656	NA	0.61	4.99	0.46	2.73e-6	Gestational age at birth (child effect);
THYM	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg00677455	chr12:58241039	CTDSP2	0.72	4.87	0.45	4.51e-6	Multiple sclerosis;
THYM	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg08992911	chr2:238395768	MLPH	0.72	4.76	0.44	6.94e-6	Prostate cancer;
THYM	cis	rs747334	0.846	rs1544217	chr10:92724285	A/G	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs782590	0.837	rs2627769	chr2:55927288	G/C	cg03859395	chr2:55845619	SMEK2	0.62	5.45	0.49	3.89e-7	Metabolic syndrome;
THYM	cis	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg06521331	chr12:34319734	NA	-0.99	-9.11	-0.68	1.32e-14	Morning vs. evening chronotype;
THYM	trans	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs10504073	0.584	rs4873307	chr8:49950417	C/T	cg00325661	chr8:49890786	NA	1.08	10.81	0.74	3.14e-18	Blood metabolite ratios;
THYM	cis	rs12549902	0.966	rs17659386	chr8:41513531	T/C	cg21772509	chr8:41503840	NKX6-3	0.69	6.34	0.55	7.6e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
THYM	cis	rs3780378	0.935	rs2149560	chr9:5082106	G/T	cg02405213	chr9:5042618	JAK2	-0.71	-6.64	-0.56	1.92e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	trans	rs4262150	0.883	rs111770575	chr5:152242327	C/T	cg08281791	chr5:76607845	PDE8B	0.93	6.87	0.58	6.5e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg23018236	chr17:30244563	NA	-0.59	-4.46	-0.42	2.27e-5	Hip circumference adjusted for BMI;
THYM	cis	rs11030122	0.673	rs10835596	chr11:4099666	C/T	cg18678763	chr11:4115507	RRM1	-0.43	-5.6	-0.5	2.05e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg04025307	chr7:1156635	C7orf50	0.63	5.25	0.47	9.15e-7	Longevity;Endometriosis;
THYM	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg03160526	chr17:80928410	B3GNTL1	-0.49	-4.89	-0.45	4.16e-6	Glycated hemoglobin levels;
THYM	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg04034577	chr2:241836375	C2orf54	-0.44	-7.84	-0.63	6.6e-12	Urinary metabolites;
THYM	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg26408565	chr15:76604113	ETFA	-0.53	-4.55	-0.42	1.59e-5	Blood metabolite levels;
THYM	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg17264618	chr3:40429014	ENTPD3	0.49	4.7	0.43	8.65e-6	Renal cell carcinoma;
THYM	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	trans	rs1973993	0.544	rs2800427	chr1:97002766	A/C	cg10631902	chr5:14652156	NA	0.64	7.0	0.58	3.53e-10	Weight;
THYM	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg07636037	chr3:49044803	WDR6	0.87	7.66	0.62	1.53e-11	Menarche (age at onset);
THYM	cis	rs761746	0.960	rs3818134	chr22:31926725	C/T	cg10537193	chr22:32026975	PISD	0.38	5.07	0.46	1.94e-6	Intelligence;
THYM	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg13683864	chr3:40499215	RPL14	-0.82	-7.56	-0.61	2.57e-11	Renal cell carcinoma;
THYM	cis	rs13006833	0.668	rs291458	chr2:191181481	A/C	cg11845111	chr2:191398756	TMEM194B	0.65	4.51	0.42	1.88e-5	Urinary metabolites;
THYM	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs490234	0.702	rs13285587	chr9:128233058	G/T	cg14078157	chr9:128172775	NA	-0.69	-5.59	-0.5	2.21e-7	Mean arterial pressure;
THYM	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg03806693	chr22:41940476	POLR3H	1.08	8.77	0.67	7.1e-14	Vitiligo;
THYM	cis	rs11696501	0.739	rs6073784	chr20:44201931	T/A	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.57	-0.42	1.46e-5	Brain structure;
THYM	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg00686598	chr14:53173677	PSMC6	1.52	7.73	0.62	1.09e-11	Alzheimer's disease (late onset);
THYM	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs7106204	0.534	rs75423384	chr11:24273691	A/T	ch.11.24196551F	chr11:24239977	NA	0.92	4.75	0.44	7.06e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7224314	1.000	rs62084082	chr17:65388046	A/G	cg01507342	chr17:65387096	PITPNC1	-0.97	-10.88	-0.74	2.26e-18	Diisocyanate-induced asthma;
THYM	cis	rs17345786	0.520	rs1476123	chr3:101313413	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.56	-4.71	-0.43	8.52e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7786808	0.552	rs4909207	chr7:158187136	G/A	cg15440763	chr7:158190612	PTPRN2	0.49	4.61	0.43	1.24e-5	Obesity-related traits;
THYM	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.47	0.49	3.63e-7	Bipolar disorder;
THYM	cis	rs1957429	1.000	rs1957429	chr14:65354033	C/T	cg23373153	chr14:65346875	NA	1.06	6.31	0.54	8.93e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg11764359	chr7:65958608	NA	0.82	6.56	0.56	2.81e-9	Aortic root size;
THYM	cis	rs3760776	0.522	rs76899991	chr19:5822370	G/T	cg25387410	chr19:5844109	FUT3	-1.01	-4.85	-0.45	4.89e-6	N-glycan levels;Tumor biomarkers;Vitamin B12 levels;
THYM	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg03159660	chr11:2078197	NA	0.62	4.61	0.43	1.26e-5	Calcium levels;
THYM	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg08772003	chr10:104629869	AS3MT	-0.53	-4.54	-0.42	1.64e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg18016565	chr1:150552671	MCL1	-0.55	-4.55	-0.42	1.58e-5	Tonsillectomy;
THYM	trans	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg10803722	chr21:46713166	LOC642852	-0.4	-5.14	-0.47	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10029851	0.627	rs2880787	chr4:109553331	A/G	cg21648245	chr4:109541405	LOC285456;RPL34	-0.64	-5.01	-0.46	2.47e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs17407555	0.865	rs115163648	chr4:10331926	G/T	cg00071950	chr4:10020882	SLC2A9	-0.64	-4.69	-0.43	9.02e-6	Schizophrenia (age at onset);
THYM	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg20242066	chr2:136595261	LCT	-0.6	-7.41	-0.61	5.17e-11	Mosquito bite size;
THYM	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg27572855	chr1:25598939	RHD	0.59	4.69	0.43	9.14e-6	Erythrocyte sedimentation rate;
THYM	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	5.81	0.51	8.16e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg07424592	chr7:64974309	NA	1.07	5.56	0.5	2.48e-7	Diabetic kidney disease;
THYM	cis	rs4919694	1.000	rs12268849	chr10:104737682	G/A	cg15744005	chr10:104629667	AS3MT	-0.78	-4.45	-0.42	2.3e-5	Arsenic metabolism;
THYM	cis	rs7572733	0.534	rs700692	chr2:198728500	T/C	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg20295408	chr7:1910781	MAD1L1	-0.68	-5.09	-0.46	1.78e-6	Schizophrenia;
THYM	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg03060546	chr3:49711283	APEH	0.77	6.37	0.55	6.65e-9	Resting heart rate;
THYM	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg03690763	chr11:133734501	NA	-0.63	-5.15	-0.47	1.43e-6	Childhood ear infection;
THYM	cis	rs16889362	1.000	rs77757126	chr6:36956903	G/A	cg05466385	chr6:36956891	NA	-0.73	-5.03	-0.46	2.28e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
THYM	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg25918947	chr17:41365094	TMEM106A	-0.56	-4.62	-0.43	1.22e-5	Menopause (age at onset);
THYM	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg27423445	chr12:12879764	APOLD1	0.47	5.3	0.48	7.54e-7	Lymphocyte counts;
THYM	cis	rs7719624	0.756	rs13188659	chr5:135396468	T/A	cg15329133	chr5:135467951	SMAD5;SMAD5OS	0.54	4.82	0.44	5.49e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs4731207	0.698	rs6961292	chr7:124503189	A/G	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs2219968	0.828	rs4077569	chr8:78918381	C/A	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4077515	0.806	rs11145839	chr9:139285137	A/C	cg14115884	chr9:139300582	SDCCAG3	0.74	7.68	0.62	1.42e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg10803722	chr21:46713166	LOC642852	-0.49	-6.39	-0.55	6e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg13175981	chr1:150552382	MCL1	0.7	4.99	0.46	2.72e-6	Tonsillectomy;
THYM	cis	rs1971762	0.527	rs6580958	chr12:54073483	A/G	cg16917193	chr12:54089295	NA	0.92	9.46	0.7	2.32e-15	Height;
THYM	cis	rs1971762	1.000	rs10783594	chr12:54067135	A/C	cg22997177	chr12:54070527	ATP5G2	-0.49	-5.19	-0.47	1.19e-6	Height;
THYM	trans	rs4650994	1.000	rs4076205	chr1:178534157	G/A	cg05059571	chr16:84539110	KIAA1609	-0.76	-8.28	-0.65	7.7e-13	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg24257776	chr3:47051546	LOC100129354	0.4	4.58	0.43	1.39e-5	Colorectal cancer;
THYM	cis	rs6531656	0.796	rs2927270	chr4:38674260	C/G	cg24279243	chr4:38676559	KLF3	0.81	5.49	0.49	3.3e-7	Lymphocyte counts;
THYM	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg10515332	chr4:99064459	C4orf37	0.58	4.56	0.42	1.52e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11585357	0.895	rs72646797	chr1:17613838	C/G	cg08277548	chr1:17600880	PADI3	-0.9	-5.43	-0.49	4.38e-7	Hair shape;
THYM	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg02640540	chr1:67518911	SLC35D1	-0.64	-4.59	-0.43	1.37e-5	Lymphocyte percentage of white cells;
THYM	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg05717871	chr11:638507	DRD4	-0.64	-5.11	-0.46	1.69e-6	Systemic lupus erythematosus;
THYM	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-5.08	-0.46	1.85e-6	Chronic sinus infection;
THYM	cis	rs11792861	0.591	rs4978763	chr9:111728067	C/T	cg05043794	chr9:111880884	C9orf5	-0.35	-4.98	-0.46	2.79e-6	Menarche (age at onset);
THYM	cis	rs6032067	0.714	rs3761192	chr20:43885764	C/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.59	-6.61	-0.56	2.25e-9	Blood protein levels;
THYM	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg18105134	chr13:113819100	PROZ	1.02	9.35	0.69	4.08e-15	Platelet distribution width;
THYM	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg17264618	chr3:40429014	ENTPD3	-0.55	-5.44	-0.49	4.17e-7	Renal cell carcinoma;
THYM	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg18252515	chr7:66147081	NA	-1.42	-8.45	-0.66	3.31e-13	Diabetic kidney disease;
THYM	cis	rs6754311	0.551	rs2304599	chr2:136528004	C/G	cg04750100	chr2:136595281	LCT	-0.51	-5.24	-0.47	9.53e-7	Mosquito bite size;
THYM	cis	rs665401	0.692	rs339310	chr6:117178383	T/G	cg20376953	chr6:117187980	NA	0.61	4.89	0.45	4.05e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.66	5.8	0.51	8.69e-8	Bipolar disorder;
THYM	cis	rs611744	0.967	rs684093	chr8:109199355	G/C	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.61	-0.43	1.27e-5	Type 2 diabetes;
THYM	cis	rs7575217	0.552	rs13006193	chr2:101665915	G/A	cg12594615	chr2:101643137	TBC1D8	0.56	4.5	0.42	1.94e-5	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs6988636	0.901	rs2602001	chr8:124195974	T/C	cg22384356	chr8:124195192	FAM83A	0.73	4.67	0.43	9.73e-6	Urinary uromodulin levels;
THYM	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg00191853	chr8:101177733	SPAG1	0.57	5.63	0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg15448220	chr1:150897856	SETDB1	0.85	7.1	0.59	2.25e-10	Tonsillectomy;
THYM	cis	rs8050907	0.661	rs111579187	chr16:4603709	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.25	4.57	0.42	1.48e-5	Obesity-related traits;
THYM	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg16506815	chr2:162101123	NA	0.72	5.84	0.51	7.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12756686	chr19:29218302	NA	0.98	8.72	0.67	9.12e-14	Methadone dose in opioid dependence;
THYM	cis	rs782590	0.748	rs782634	chr2:55897700	T/C	cg18811423	chr2:55921094	PNPT1	0.77	7.24	0.6	1.14e-10	Metabolic syndrome;
THYM	cis	rs11235843	1.000	rs6590	chr11:73373552	C/T	cg27005935	chr11:73371801	PLEKHB1	0.57	4.57	0.42	1.49e-5	Hand grip strength;
THYM	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.64	-0.5	1.73e-7	Menopause (age at onset);
THYM	cis	rs1957429	0.808	rs8009510	chr14:65351338	T/G	cg23373153	chr14:65346875	NA	1.07	6.45	0.55	4.75e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.09	-7.74	-0.62	1.06e-11	Platelet count;
THYM	cis	rs7264396	1.000	rs224415	chr20:34135629	G/A	cg26038318	chr20:34205095	SPAG4	0.52	4.51	0.42	1.83e-5	Total cholesterol levels;
THYM	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.65	-11.83	-0.77	2.19e-20	Hemostatic factors and hematological phenotypes;
THYM	cis	rs9326248	0.530	rs11216171	chr11:116749113	T/A	cg01368799	chr11:117014884	PAFAH1B2	0.66	4.74	0.44	7.39e-6	Blood protein levels;
THYM	cis	rs2985684	0.894	rs2281837	chr14:50065359	C/G	cg02151108	chr14:50098012	C14orf104	-0.73	-5.92	-0.52	5.2e-8	Carotid intima media thickness;
THYM	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg14004847	chr7:1930337	MAD1L1	-0.71	-5.27	-0.48	8.66e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs1728785	1.000	rs1645938	chr16:68595197	G/A	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs2915864	0.800	rs57547939	chr5:141534741	C/T	cg03486475	chr5:140796240	PCDHGA4;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	0.73	4.46	0.42	2.21e-5	Facial morphology (factor 20);
THYM	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg15110403	chr19:17392923	ANKLE1	-0.57	-4.94	-0.45	3.36e-6	Systemic lupus erythematosus;
THYM	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs7903847	0.596	rs11189203	chr10:99159096	C/A	cg13903378	chr10:98272504	TLL2	0.55	4.45	0.42	2.31e-5	Granulocyte percentage of myeloid white cells;
THYM	cis	rs457717	0.798	rs3797412	chr5:75927954	A/G	cg00415993	chr5:75919188	F2RL2;IQGAP2	-0.31	-4.62	-0.43	1.18e-5	Hearing impairment;
THYM	cis	rs2836950	0.545	rs2836949	chr21:40602456	C/A	cg11890956	chr21:40555474	PSMG1	-0.7	-6.75	-0.57	1.19e-9	Menarche (age at onset);
THYM	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg08859206	chr1:53392774	SCP2	0.51	5.7	0.51	1.32e-7	Monocyte count;
THYM	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs9470366	0.848	rs66761782	chr6:36636080	T/C	cg24425727	chr6:36645648	CDKN1A	-0.62	-4.94	-0.45	3.34e-6	QRS duration;
THYM	cis	rs7107174	1.000	rs7119933	chr11:78049750	A/C	cg02023728	chr11:77925099	USP35	0.61	5.9	0.52	5.68e-8	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06850241	chr22:41845214	NA	-0.61	-5.46	-0.49	3.87e-7	Vitiligo;
THYM	cis	rs7084402	0.902	rs1346300	chr10:60287635	G/C	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11651000	0.857	rs57171311	chr17:45826168	A/G	cg25856473	chr17:45174155	NA	0.62	4.81	0.44	5.7e-6	IgG glycosylation;
THYM	cis	rs870825	0.616	rs28620459	chr4:185627132	G/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs7572733	0.534	rs700683	chr2:198712332	G/A	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg06028605	chr16:24865363	SLC5A11	-0.58	-5.69	-0.5	1.42e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg13114125	chr14:105738426	BRF1	-0.74	-5.88	-0.52	6.07e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2495707	0.624	rs2489008	chr10:102422934	C/T	cg07099331	chr10:102419617	NA	-0.46	-5.37	-0.48	5.62e-7	Body mass index;
THYM	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg19626725	chr5:178986131	RUFY1	0.33	5.05	0.46	2.14e-6	Lung cancer;
THYM	trans	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg01121180	chr19:51302454	C19orf48;SNORD88B	0.81	7.09	0.59	2.36e-10	Bone mineral density;
THYM	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.54	-4.51	-0.42	1.86e-5	Coronary artery disease;
THYM	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-4.96	-0.45	3.11e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg19897017	chr7:2163380	MAD1L1	0.43	4.55	0.42	1.61e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs10823500	0.777	rs10999196	chr10:71982305	T/C	cg02100629	chr10:71892760	AIFM2	-0.37	-4.46	-0.42	2.27e-5	Blood protein levels;
THYM	trans	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg07211511	chr3:129823064	LOC729375	-1.22	-9.75	-0.71	5.63e-16	Blood pressure (smoking interaction);
THYM	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg08873628	chr1:175162347	KIAA0040	0.51	4.59	0.43	1.34e-5	Alcohol dependence;
THYM	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg13852791	chr20:30311386	BCL2L1	-0.88	-7.22	-0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs362296	0.511	rs2857861	chr4:3323767	C/T	cg18352616	chr4:3374830	RGS12	0.51	5.31	0.48	7.31e-7	Parental longevity (mother's age at death);
THYM	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg08901578	chr4:187885870	NA	-0.68	-6.61	-0.56	2.18e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg08772003	chr10:104629869	AS3MT	-0.57	-4.92	-0.45	3.56e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9457247	0.534	rs9347170	chr6:167405187	C/T	cg23791538	chr6:167370224	RNASET2	0.83	7.32	0.6	7.9e-11	Crohn's disease;
THYM	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg00024416	chr22:24240387	NA	-0.61	-6.14	-0.53	1.88e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg08901578	chr4:187885870	NA	-0.68	-6.61	-0.56	2.18e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6430585	0.528	rs895285	chr2:136710554	A/G	cg20242066	chr2:136595261	LCT	0.56	5.2	0.47	1.14e-6	Corneal structure;
THYM	cis	rs1669338	0.588	rs3846135	chr3:3195574	C/T	cg16797762	chr3:3221439	CRBN	-0.97	-5.43	-0.49	4.36e-7	White matter integrity;
THYM	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg08213375	chr14:104286397	PPP1R13B	0.43	4.52	0.42	1.81e-5	Reticulocyte count;
THYM	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs616402	0.527	rs604369	chr1:10567208	C/A	cg20482658	chr1:10539492	PEX14	-0.34	-5.11	-0.46	1.68e-6	Breast size;
THYM	cis	rs7560272	0.723	rs1320374	chr2:73828310	T/C	cg19565262	chr2:73869966	NAT8	0.57	4.81	0.44	5.65e-6	Schizophrenia;
THYM	cis	rs919433	0.963	rs1366837	chr2:198160501	T/C	cg00792783	chr2:198669748	PLCL1	-0.68	-4.85	-0.45	4.83e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg18876405	chr7:65276391	NA	0.76	7.05	0.59	2.79e-10	Calcium levels;
THYM	cis	rs2354432	0.556	rs7520661	chr1:146793149	A/G	cg25205988	chr1:146714368	CHD1L	-0.97	-5.05	-0.46	2.13e-6	Mitochondrial DNA levels;
THYM	trans	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg20587970	chr11:113659929	NA	-1.24	-7.96	-0.63	3.73e-12	Hip circumference adjusted for BMI;
THYM	cis	rs7771547	0.573	rs9470274	chr6:36397229	G/A	cg07856975	chr6:36356162	ETV7	0.52	4.72	0.44	8.26e-6	Platelet distribution width;
THYM	cis	rs13082711	0.522	rs479302	chr3:27363033	A/G	cg02860705	chr3:27208620	NA	0.6	4.69	0.43	9.1e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs8070624	0.543	rs57728924	chr17:17875342	A/G	cg16928487	chr17:17741425	SREBF1	-0.51	-4.63	-0.43	1.18e-5	Total body bone mineral density;
THYM	cis	rs944002	1.000	rs56956502	chr14:103565044	G/A	cg16996574	chr14:103691482	NA	0.51	4.65	0.43	1.09e-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;
THYM	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7119	0.637	rs12913005	chr15:77856571	T/A	cg27398640	chr15:77910606	LINGO1	-0.62	-7.24	-0.6	1.16e-10	Type 2 diabetes;
THYM	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg00256281	chr22:41985642	PMM1	0.58	4.45	0.42	2.31e-5	Vitiligo;
THYM	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg18512352	chr11:47633146	NA	-0.55	-7.17	-0.59	1.65e-10	Subjective well-being;
THYM	cis	rs4227	0.565	rs2270341	chr17:7480547	T/A	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	-0.25	-4.59	-0.43	1.35e-5	IgA nephropathy;
THYM	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg16506815	chr2:162101123	NA	0.72	5.84	0.51	7.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg14129053	chr2:1895732	MYT1L	-1.16	-4.47	-0.42	2.2e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs9515201	0.627	rs9521730	chr13:111031180	C/T	cg06243866	chr13:111019493	COL4A2	-0.93	-10.18	-0.72	6.67e-17	White matter hyperintensity burden;
THYM	cis	rs2985684	0.894	rs10147029	chr14:50020232	G/T	cg02151108	chr14:50098012	C14orf104	0.75	6.31	0.54	8.87e-9	Carotid intima media thickness;
THYM	cis	rs7586879	0.789	rs13035239	chr2:25134000	T/A	cg01884057	chr2:25150051	NA	0.52	4.64	0.43	1.12e-5	Body mass index;
THYM	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg14779329	chr11:130786720	SNX19	0.52	5.43	0.49	4.41e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg06656553	chr16:89960601	TCF25	-0.82	-4.48	-0.42	2.08e-5	Skin colour saturation;
THYM	cis	rs4930103	0.782	rs10840167	chr11:2022023	G/T	cg18511798	chr11:2018149	H19;MIR675	-0.57	-5.57	-0.5	2.39e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg15247329	chr7:2764246	NA	-0.7	-5.92	-0.52	5.06e-8	Height;
THYM	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg18252515	chr7:66147081	NA	-0.7	-5.44	-0.49	4.07e-7	Aortic root size;
THYM	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	14.79	0.83	2.2e-26	Chronic sinus infection;
THYM	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg17372223	chr3:52568218	NT5DC2	0.33	4.94	0.45	3.37e-6	Bipolar disorder;
THYM	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg22907277	chr7:1156413	C7orf50	0.74	6.27	0.54	1.06e-8	Longevity;Endometriosis;
THYM	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg18512352	chr11:47633146	NA	0.51	6.11	0.53	2.21e-8	Subjective well-being;
THYM	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg03517284	chr6:25882590	NA	-0.67	-4.47	-0.42	2.14e-5	Height;
THYM	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.31e-5	Retinal vascular caliber;
THYM	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08109568	chr15:31115862	NA	-0.62	-5.94	-0.52	4.67e-8	Huntington's disease progression;
THYM	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg06027949	chr8:82754900	SNX16	0.64	5.35	0.48	6.18e-7	Diastolic blood pressure;
THYM	cis	rs7119	0.717	rs62007350	chr15:77804590	G/A	cg10437265	chr15:77819839	NA	0.76	7.61	0.62	1.98e-11	Type 2 diabetes;
THYM	cis	rs9905704	0.918	rs302852	chr17:56685214	C/T	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.74e-6	Testicular germ cell tumor;
THYM	cis	rs920590	0.758	rs1907799	chr8:19664668	A/G	cg01411142	chr8:19674711	INTS10	-0.66	-5.19	-0.47	1.21e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs16917546	1.000	rs10995258	chr10:64408787	C/T	cg03961010	chr10:64397487	ZNF365	-0.81	-6.71	-0.57	1.38e-9	Basal cell carcinoma;
THYM	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.73	-4.5	-0.42	1.93e-5	Alzheimer's disease;
THYM	cis	rs28595532	0.841	rs115233595	chr4:119744214	T/C	cg21605333	chr4:119757512	SEC24D	1.64	6.45	0.55	4.71e-9	Cannabis dependence symptom count;
THYM	cis	rs4262150	0.767	rs4958596	chr5:152327668	A/G	cg06854687	chr5:151642065	NA	-0.77	-4.97	-0.45	2.94e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs28595532	0.764	rs116788606	chr4:119748849	G/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg27170947	chr2:26402098	FAM59B	0.82	6.57	0.56	2.7e-9	Gut microbiome composition (summer);
THYM	cis	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg11266682	chr4:10021025	SLC2A9	-0.52	-5.99	-0.52	3.77e-8	Bone mineral density;
THYM	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg10047753	chr17:41438598	NA	1.2	11.56	0.76	8.14e-20	Menopause (age at onset);
THYM	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg11327659	chr7:150037044	RARRES2	0.47	5.29	0.48	7.8e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg04447362	chr2:237654635	NA	0.48	4.49	0.42	2.03e-5	Prostate cancer;
THYM	cis	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg07460842	chr6:66804631	NA	1.27	16.22	0.86	3.99e-29	Exhaled nitric oxide output;
THYM	cis	rs17433780	0.892	rs72726528	chr1:89455980	C/A	cg09516651	chr1:89888402	LOC400759	0.86	6.56	0.56	2.81e-9	Carotid intima media thickness;
THYM	cis	rs11039798	1.000	rs10838918	chr11:48507449	A/G	cg24672777	chr11:48374446	OR4C45	-1.16	-7.17	-0.59	1.64e-10	Axial length;
THYM	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg05738196	chr6:26577821	NA	0.93	9.24	0.69	6.9e-15	Intelligence (multi-trait analysis);
THYM	cis	rs12291225	0.585	rs4517475	chr11:14386145	A/G	cg19336497	chr11:14380999	RRAS2	-0.91	-13.68	-0.81	3.58e-24	Sense of smell;
THYM	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg22508957	chr16:3507546	NAT15	-0.41	-4.54	-0.42	1.64e-5	Body mass index (adult);
THYM	cis	rs6032067	0.929	rs56131549	chr20:43842014	A/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.34	-0.65	5.7e-13	Blood protein levels;
THYM	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.7	-0.5	1.37e-7	Prostate cancer;
THYM	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg13319975	chr6:146136371	FBXO30	0.67	5.68	0.5	1.47e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6499255	0.951	rs74026882	chr16:69635059	A/G	cg00738113	chr16:70207722	CLEC18C	-0.45	-4.45	-0.42	2.32e-5	IgE levels;
THYM	cis	rs7640424	0.649	rs11917909	chr3:107864673	G/A	cg09227934	chr3:107805635	CD47	-0.52	-4.49	-0.42	1.99e-5	Body mass index;
THYM	cis	rs921968	0.613	rs2556388	chr2:219541056	T/C	cg02176678	chr2:219576539	TTLL4	-0.55	-5.46	-0.49	3.86e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6539288	0.901	rs4964507	chr12:107348757	T/C	cg26297688	chr12:107349093	C12orf23	-0.47	-4.96	-0.45	3.1e-6	Total body bone mineral density;
THYM	cis	rs981844	1.000	rs62325085	chr4:154663283	A/G	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg27535305	chr1:53392650	SCP2	-0.41	-4.73	-0.44	7.7e-6	Monocyte count;
THYM	cis	rs10489202	1.000	rs7538251	chr1:168001752	C/G	cg24449463	chr1:168025552	DCAF6	-0.83	-6.51	-0.56	3.58e-9	Schizophrenia;
THYM	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg26116260	chr4:7069785	GRPEL1	1.11	9.82	0.71	3.92e-16	Monocyte percentage of white cells;
THYM	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg01699819	chr7:1052092	C7orf50	-0.57	-4.82	-0.44	5.34e-6	Bronchopulmonary dysplasia;
THYM	cis	rs786425	0.532	rs34247974	chr12:124224211	A/G	cg15249119	chr12:124971054	NCOR2	0.53	4.98	0.46	2.8e-6	Pubertal anthropometrics;
THYM	cis	rs12200560	0.505	rs211177	chr6:97074088	C/T	cg06623918	chr6:96969491	KIAA0776	0.76	5.87	0.52	6.31e-8	Coronary heart disease;
THYM	cis	rs728616	0.867	rs117139504	chr10:81734207	C/A	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4849845	0.889	rs17050072	chr2:121048712	T/C	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs714031	0.934	rs4820386	chr22:40068051	C/T	cg21377881	chr22:40064566	CACNA1I	-0.59	-5.32	-0.48	6.98e-7	Schizophrenia;
THYM	cis	rs240764	0.659	rs240772	chr6:101007895	C/T	cg21058520	chr6:100914733	NA	0.61	5.01	0.46	2.52e-6	Neuroticism;
THYM	cis	rs924712	0.677	rs3125283	chr6:54839594	A/G	cg04690482	chr6:54711388	FAM83B	0.43	5.15	0.47	1.39e-6	Breast cancer;
THYM	cis	rs72627123	0.867	rs73301477	chr14:74463560	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg15242686	chr22:24348715	GSTTP1	0.67	7.26	0.6	1.04e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg03452623	chr4:187889614	NA	-0.96	-11.2	-0.75	4.56e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg26384229	chr12:38710491	ALG10B	0.94	7.9	0.63	4.92e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs3781426	0.960	rs12357688	chr10:126711516	A/G	cg04494136	chr10:126703576	CTBP2	0.41	5.4	0.48	4.81e-7	Height;
THYM	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg04155289	chr7:94953770	PON1	0.61	5.47	0.49	3.58e-7	Paraoxonase activity;
THYM	cis	rs1697139	1.000	rs1705397	chr5:66511062	G/T	cg11553311	chr5:66541588	NA	-0.48	-5.23	-0.47	1.02e-6	Breast cancer;
THYM	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg00484396	chr16:3507460	NAT15	0.66	6.44	0.55	4.97e-9	Tuberculosis;
THYM	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Body mass index;
THYM	cis	rs1357245	0.631	rs17434103	chr3:27119537	A/C	cg03895047	chr3:27114861	NA	0.49	4.45	0.42	2.29e-5	Breast cancer;
THYM	cis	rs9796	0.717	rs476633	chr15:41392134	C/G	cg21153102	chr15:41252147	NA	0.6	4.85	0.45	4.79e-6	Menopause (age at onset);
THYM	cis	rs11252926	0.605	rs10904075	chr10:425667	A/G	cg14018140	chr10:458528	DIP2C	0.59	5.59	0.5	2.13e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs308403	0.509	rs1849430	chr4:123674701	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.98	8.36	0.65	5.28e-13	Blood protein levels;
THYM	cis	rs2050392	0.687	rs608693	chr10:30734971	G/A	cg02070205	chr10:30722105	MAP3K8	-0.57	-4.52	-0.42	1.8e-5	Inflammatory bowel disease;
THYM	cis	rs2625529	0.824	rs11072338	chr15:72245447	T/C	cg16672083	chr15:72433130	SENP8	-0.55	-4.89	-0.45	4.1e-6	Red blood cell count;
THYM	cis	rs7872515	0.536	rs6479397	chr9:94769170	G/A	cg13922115	chr9:95397568	IPPK	0.88	4.46	0.42	2.25e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs11252926	0.565	rs4881308	chr10:484983	G/T	cg03684893	chr10:554711	DIP2C	-0.72	-5.99	-0.52	3.72e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs3820068	0.705	rs72643683	chr1:15824905	C/A	cg05660106	chr1:15850417	CASP9	1.13	10.23	0.72	5.39e-17	Systolic blood pressure;
THYM	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg18681998	chr4:17616180	MED28	-0.8	-7.06	-0.59	2.76e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg27284194	chr4:1044797	NA	0.62	4.73	0.44	7.81e-6	Recombination rate (females);
THYM	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg13852791	chr20:30311386	BCL2L1	0.79	5.78	0.51	9.27e-8	Mean corpuscular hemoglobin;
THYM	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg18904891	chr8:8559673	CLDN23	0.62	4.72	0.44	8.27e-6	Obesity-related traits;
THYM	cis	rs870825	0.860	rs2705899	chr4:185596219	A/G	cg04058563	chr4:185651563	MLF1IP	0.98	7.31	0.6	8.33e-11	Blood protein levels;
THYM	cis	rs859767	0.812	rs842358	chr2:135345109	C/T	cg12500956	chr2:135428796	TMEM163	0.53	5.24	0.47	9.86e-7	Neuroticism;
THYM	cis	rs478304	0.934	rs603645	chr11:65533000	A/C	cg27068330	chr11:65405492	SIPA1	0.82	7.91	0.63	4.72e-12	Acne (severe);
THYM	cis	rs9810089	1.000	rs1279831	chr3:135933264	A/G	cg21827317	chr3:136751795	NA	0.52	4.5	0.42	1.93e-5	Gestational age at birth (child effect);
THYM	cis	rs2806561	0.704	rs1757039	chr1:23508657	A/G	cg19743168	chr1:23544995	NA	0.55	5.6	0.5	2.09e-7	Height;
THYM	cis	rs72781680	0.898	rs72796166	chr2:23939311	G/C	cg08917208	chr2:24149416	ATAD2B	1.1	4.81	0.44	5.71e-6	Lymphocyte counts;
THYM	cis	rs870825	0.616	rs10022834	chr4:185649431	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs8074700	0.581	rs890435	chr17:46719399	C/T	cg06602723	chr17:46693336	HOXB8	0.49	4.66	0.43	1.04e-5	Body mass index in non-asthmatics;
THYM	cis	rs2073300	0.609	rs1076776	chr20:23427399	C/T	cg12062639	chr20:23401060	NAPB	-1.08	-5.67	-0.5	1.55e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs1050631	0.564	rs589213	chr18:33743610	G/A	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.63	4.88	0.45	4.27e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs16857609	1.000	rs16857611	chr2:218296732	C/T	cg15335768	chr2:218268053	DIRC3	-0.36	-5.19	-0.47	1.17e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	cis	rs61931739	0.929	rs1844524	chr12:34094709	A/T	cg06521331	chr12:34319734	NA	0.6	4.86	0.45	4.64e-6	Morning vs. evening chronotype;
THYM	cis	rs786425	0.530	rs7399128	chr12:124225211	G/A	cg15249119	chr12:124971054	NCOR2	0.55	5.09	0.46	1.79e-6	Pubertal anthropometrics;
THYM	cis	rs742614	0.533	rs736953	chr20:32415089	G/T	cg06304546	chr20:32448765	NA	-0.96	-9.95	-0.71	2.14e-16	Stearic acid (18:0) levels;
THYM	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg24503407	chr1:205819492	PM20D1	1.01	10.07	0.72	1.15e-16	Menarche (age at onset);
THYM	cis	rs7635838	0.617	rs346075	chr3:11294027	T/G	cg00170343	chr3:11313890	ATG7	0.68	5.14	0.47	1.45e-6	HDL cholesterol;
THYM	cis	rs1448094	0.511	rs61930035	chr12:86153695	G/A	cg00310523	chr12:86230176	RASSF9	0.53	4.6	0.43	1.32e-5	Major depressive disorder;
THYM	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.25	9.0	0.68	2.26e-14	Gut microbiome composition (summer);
THYM	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs4664308	0.692	rs13009231	chr2:160964057	G/T	cg03641300	chr2:160917029	PLA2R1	-0.59	-5.23	-0.47	9.99e-7	Idiopathic membranous nephropathy;
THYM	cis	rs8013055	0.796	rs4075105	chr14:106000231	C/T	cg04429589	chr14:105992532	TMEM121	-0.53	-5.7	-0.5	1.34e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg08859206	chr1:53392774	SCP2	-0.65	-7.37	-0.6	6.31e-11	Monocyte count;
THYM	cis	rs2295359	1.000	rs4655682	chr1:67610967	C/T	cg11235152	chr1:67600687	NA	0.59	4.93	0.45	3.42e-6	Psoriasis;
THYM	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg10515332	chr4:99064459	C4orf37	0.65	5.35	0.48	6.19e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg04990556	chr1:26633338	UBXN11	-0.89	-8.52	-0.66	2.34e-13	Obesity-related traits;
THYM	cis	rs4889855	0.530	rs4890052	chr17:78564245	G/T	cg16591659	chr17:78472290	NA	0.45	5.14	0.47	1.46e-6	Fractional excretion of uric acid;
THYM	cis	rs7772486	0.743	rs62433835	chr6:146032688	C/G	cg13319975	chr6:146136371	FBXO30	0.65	5.35	0.48	6.13e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg03709012	chr19:19516395	GATAD2A	0.76	6.05	0.53	2.87e-8	Tonsillectomy;
THYM	cis	rs6815814	0.861	rs6843043	chr4:38843136	A/G	cg14665413	chr4:38859728	TLR6	-0.36	-4.46	-0.42	2.23e-5	Breast cancer;
THYM	cis	rs72827839	0.948	rs72827882	chr17:46532624	G/T	cg23391107	chr17:45924227	SP6	0.76	4.58	0.43	1.39e-5	Ease of getting up in the morning;
THYM	cis	rs55728055	0.661	rs62237796	chr22:31976578	T/G	cg01338084	chr22:32026380	PISD	1.36	5.56	0.5	2.44e-7	Age-related hearing impairment;
THYM	cis	rs877282	0.891	rs10904557	chr10:797490	C/T	cg10556349	chr10:835070	NA	0.79	5.5	0.49	3.16e-7	Uric acid levels;
THYM	cis	rs7211079	0.917	rs4243251	chr17:78112610	T/A	cg09238746	chr17:78121135	EIF4A3	-0.74	-4.64	-0.43	1.1e-5	Myocardial infarction;
THYM	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.65e-6	Aortic root size;
THYM	cis	rs4523957	0.553	rs2131702	chr17:2025458	T/C	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg27494647	chr7:150038898	RARRES2	0.41	4.6	0.43	1.31e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11078597	0.767	rs4525526	chr17:1650125	T/C	cg18436246	chr17:1640651	WDR81	0.64	4.63	0.43	1.14e-5	Serum albumin level;
THYM	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg01191920	chr7:158217561	PTPRN2	0.9	8.78	0.67	6.83e-14	Obesity-related traits;
THYM	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg04398451	chr17:18023971	MYO15A	0.9	9.71	0.71	6.98e-16	Total body bone mineral density;
THYM	cis	rs7240777	0.935	rs1539948	chr18:71155088	C/T	cg23685965	chr18:71958448	CYB5A	0.37	4.72	0.44	7.97e-6	Thyroid hormone levels;
THYM	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg00376283	chr12:123451042	ABCB9	0.79	6.38	0.55	6.44e-9	Platelet count;
THYM	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11890956	chr21:40555474	PSMG1	-0.97	-11.03	-0.75	1.05e-18	Cognitive function;
THYM	cis	rs600806	0.815	rs10858094	chr1:109950858	T/C	cg23616212	chr1:109941201	SORT1	-0.5	-4.65	-0.43	1.06e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg10360139	chr7:1886902	MAD1L1	-0.59	-4.76	-0.44	6.82e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12466960	0.846	rs868232	chr2:28572731	C/A	cg11535839	chr2:28582676	NA	0.59	4.69	0.43	9.04e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg02931644	chr1:25747376	RHCE	0.62	4.83	0.44	5.3e-6	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs10489202	0.826	rs202255	chr1:167988653	A/G	cg24449463	chr1:168025552	DCAF6	-0.82	-6.96	-0.58	4.38e-10	Schizophrenia;
THYM	cis	rs9302065	0.681	rs9524903	chr13:95963565	A/G	cg24476569	chr13:95954382	ABCC4	-0.77	-7.92	-0.63	4.49e-12	Blood metabolite levels;
THYM	cis	rs28459962	0.545	rs2090031	chr4:90005855	C/T	cg17769793	chr4:89976368	FAM13A	0.48	5.02	0.46	2.42e-6	Post bronchodilator FEV1;
THYM	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg00852783	chr1:26633632	UBXN11	0.83	8.39	0.65	4.45e-13	Obesity-related traits;
THYM	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-4.55	-0.42	1.59e-5	Tonsillectomy;
THYM	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg17689763	chr4:710664	PCGF3	-1.09	-9.94	-0.71	2.2e-16	White blood cell count;
THYM	cis	rs1823778	0.618	rs1583438	chr18:67700180	G/A	cg12929678	chr18:67624393	CD226	1.3	4.63	0.43	1.14e-5	Mean platelet volume;
THYM	cis	rs870825	0.929	rs72689272	chr4:185592515	T/C	cg04058563	chr4:185651563	MLF1IP	1.01	7.12	0.59	2.08e-10	Blood protein levels;
THYM	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs1451375	0.669	rs4512339	chr7:50646977	C/T	cg18232548	chr7:50535776	DDC	-0.69	-5.35	-0.48	6.04e-7	Malaria;
THYM	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.53	-5.2	-0.47	1.16e-6	Crohn's disease;
THYM	cis	rs250585	0.736	rs193937	chr16:23436358	C/T	cg00143387	chr16:23521605	GGA2	0.74	5.25	0.47	9.16e-7	Egg allergy;
THYM	cis	rs2985684	0.948	rs7143010	chr14:50081803	T/C	cg02151108	chr14:50098012	C14orf104	-0.66	-5.02	-0.46	2.41e-6	Carotid intima media thickness;
THYM	cis	rs13089722	1	rs13089722	chr3:128306757	G/A	cg16766828	chr3:128327626	NA	0.57	4.81	0.44	5.76e-6	White blood cell count (eosinophil);
THYM	cis	rs1775715	0.737	rs2778650	chr10:32106851	A/G	cg04359828	chr10:32216031	ARHGAP12	0.37	4.91	0.45	3.75e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg15693483	chr7:1102177	C7orf50	0.53	6.19	0.54	1.52e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3772130	1.000	rs13083794	chr3:121464928	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.74	4.67	0.43	9.91e-6	Cognitive performance;
THYM	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg04398451	chr17:18023971	MYO15A	0.8	7.33	0.6	7.5e-11	Total body bone mineral density;
THYM	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg02725872	chr8:58115012	NA	-0.9	-6.54	-0.56	3.09e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7695732	0.595	rs2704574	chr4:89896393	T/C	cg17769793	chr4:89976368	FAM13A	-0.49	-5.42	-0.49	4.59e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg06784218	chr1:46089804	CCDC17	0.3	4.64	0.43	1.1e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs988913	0.619	rs3857606	chr6:54961364	A/G	cg18532076	chr6:54711417	FAM83B	0.49	4.67	0.43	9.72e-6	Menarche (age at onset);
THYM	cis	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg06521331	chr12:34319734	NA	-0.96	-8.88	-0.67	4.06e-14	Morning vs. evening chronotype;
THYM	cis	rs7681440	0.560	rs2737014	chr4:90745456	A/C	cg06632027	chr4:90757378	SNCA	-0.63	-5.19	-0.47	1.21e-6	Dementia with Lewy bodies;
THYM	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg24675658	chr1:53192096	ZYG11B	-0.67	-5.26	-0.47	8.84e-7	Monocyte count;
THYM	cis	rs7695732	0.595	rs11737182	chr4:89898476	T/C	cg17769793	chr4:89976368	FAM13A	-0.49	-5.39	-0.48	5.23e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs9419702	0.568	rs7093241	chr10:133556596	G/A	cg20568497	chr10:133558893	NA	0.48	4.64	0.43	1.09e-5	Survival in rectal cancer;
THYM	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg22166914	chr1:53195759	ZYG11B	0.8	8.04	0.64	2.5e-12	Monocyte count;
THYM	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg15592062	chr6:167189543	RPS6KA2	0.59	6.16	0.53	1.73e-8	Crohn's disease;
THYM	cis	rs55871839	0.640	rs4738734	chr8:59814330	A/T	cg07426533	chr8:59803705	TOX	-0.67	-6.88	-0.58	6.33e-10	Pneumonia;
THYM	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.31	-0.48	7.2e-7	Monocyte percentage of white cells;
THYM	cis	rs7523273	1.000	rs12184327	chr1:207978780	A/G	cg22525895	chr1:207977042	MIR29B2	-0.85	-8.08	-0.64	2.03e-12	Schizophrenia;
THYM	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg12560992	chr17:57184187	TRIM37	0.94	8.84	0.67	5.01e-14	Intelligence (multi-trait analysis);
THYM	cis	rs4722166	0.630	rs6461667	chr7:22796743	A/G	cg13104385	chr7:22767384	IL6	0.54	4.73	0.44	7.68e-6	Lung cancer;
THYM	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.68	-5.28	-0.48	8.12e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg09307838	chr4:120376055	NA	0.78	5.89	0.52	5.7e-8	Corneal astigmatism;
THYM	cis	rs863345	0.604	rs949398	chr1:158461983	A/G	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	trans	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg10856724	chr12:34555212	NA	-1.01	-9.4	-0.69	3.13e-15	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg06481639	chr22:41940642	POLR3H	-0.86	-6.07	-0.53	2.65e-8	Vitiligo;
THYM	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.48	-0.55	4.1e-9	Personality dimensions;
THYM	cis	rs763014	0.932	rs4984898	chr16:641164	G/T	cg00908189	chr16:619842	PIGQ	1.16	11.2	0.75	4.63e-19	Height;
THYM	cis	rs10823500	0.523	rs12774848	chr10:71932436	T/C	cg02100629	chr10:71892760	AIFM2	-0.38	-4.7	-0.43	8.68e-6	Blood protein levels;
THYM	cis	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg11189052	chr15:85197271	WDR73	-0.62	-4.8	-0.44	5.91e-6	P wave terminal force;
THYM	cis	rs3135718	0.967	rs1219648	chr10:123346190	A/G	cg15049101	chr10:123353889	FGFR2	0.59	5.22	0.47	1.04e-6	Estrogen receptor status in breast cancer;
THYM	cis	rs6867032	0.958	rs4246754	chr5:2014776	A/C	cg26168224	chr5:2018326	NA	1.32	14.86	0.84	1.6e-26	Gut microbiome composition (winter);
THYM	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg00129232	chr17:37814104	STARD3	-0.96	-7.56	-0.61	2.57e-11	Asthma;
THYM	cis	rs7177699	0.557	rs3971829	chr15:79109052	A/G	cg00540400	chr15:79124168	NA	0.66	6.99	0.58	3.72e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs921665	0.831	rs2167961	chr2:3177617	C/G	cg16434511	chr2:3151078	NA	-0.84	-5.24	-0.47	9.7e-7	World class endurance athleticism;
THYM	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg22431228	chr1:16359049	CLCNKA	-0.53	-5.13	-0.47	1.51e-6	Dilated cardiomyopathy;
THYM	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg03859395	chr2:55845619	SMEK2	0.64	5.71	0.51	1.29e-7	Metabolic syndrome;
THYM	cis	rs4849845	0.889	rs4849849	chr2:121046573	A/G	cg03575764	chr2:121493832	NA	-0.68	-4.99	-0.46	2.71e-6	Mean platelet volume;
THYM	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg12573674	chr2:1569213	NA	-1.22	-4.82	-0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg04731861	chr2:219085781	ARPC2	0.56	5.39	0.48	5.21e-7	Colorectal cancer;
THYM	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06002616	chr8:101225028	SPAG1	0.6	6.8	0.57	9.3e-10	Atrioventricular conduction;
THYM	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg14196790	chr5:131705035	SLC22A5	0.51	4.62	0.43	1.23e-5	Blood metabolite levels;
THYM	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.64	-4.56	-0.42	1.55e-5	Colorectal cancer;
THYM	cis	rs747334	0.846	rs6583740	chr10:92720926	A/C	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs17052344	0.543	rs2342183	chr17:21738349	G/T	cg18423549	chr17:21743878	NA	-0.69	-5.7	-0.5	1.34e-7	Cutaneous psoriasis;
THYM	cis	rs11031096	0.782	rs2284450	chr11:4149214	A/T	cg08557956	chr11:4115526	RRM1	-0.5	-4.9	-0.45	3.94e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs8014204	0.935	rs1799900	chr14:75367740	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.58	-5.59	-0.5	2.12e-7	Caffeine consumption;
THYM	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg23281280	chr6:28129359	ZNF389	-0.66	-5.36	-0.48	5.92e-7	Depression;
THYM	cis	rs2933343	0.700	rs6787833	chr3:128656184	A/G	cg11901034	chr3:128598214	ACAD9	-0.68	-5.57	-0.5	2.4e-7	IgG glycosylation;
THYM	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg05962950	chr11:130786565	SNX19	0.7	5.57	0.5	2.41e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4803468	0.901	rs3745292	chr19:41888506	A/G	cg09537434	chr19:41945824	ATP5SL	-1.08	-9.69	-0.7	7.75e-16	Height;
THYM	trans	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg18335740	chr13:41363409	SLC25A15	0.71	8.29	0.65	7.45e-13	Lewy body disease;
THYM	cis	rs8044868	0.586	rs12917999	chr16:72089451	T/C	cg16558253	chr16:72132732	DHX38	-0.54	-4.58	-0.43	1.39e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs13102973	0.614	rs7693794	chr4:135886753	C/G	cg14419869	chr4:135874104	NA	-0.77	-6.46	-0.55	4.35e-9	Subjective well-being;
THYM	cis	rs2282300	0.956	rs1717773	chr11:30383154	T/C	cg06241208	chr11:30344200	C11orf46	-0.81	-5.62	-0.5	1.88e-7	Morning vs. evening chronotype;
THYM	cis	rs6754459	1.000	rs6754459	chr2:3707423	C/T	cg19052272	chr2:3704530	ALLC	-0.72	-6.15	-0.53	1.8e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs7267979	1.000	rs2258201	chr20:25272490	G/C	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg26314531	chr2:26401878	FAM59B	-0.76	-4.99	-0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs10411161	0.702	rs8100716	chr19:52384061	T/C	cg25361850	chr19:52391789	ZNF577	0.71	4.99	0.46	2.69e-6	Breast cancer;
THYM	cis	rs9326248	0.813	rs588534	chr11:117068504	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.68	4.86	0.45	4.72e-6	Blood protein levels;
THYM	cis	rs11089937	0.651	rs6001217	chr22:22538194	A/G	cg21401457	chr22:22472743	NA	0.58	4.88	0.45	4.28e-6	Periodontitis (PAL4Q3);
THYM	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs5995756	0.555	rs2003151	chr22:39991016	C/T	cg21377881	chr22:40064566	CACNA1I	-0.55	-4.59	-0.43	1.38e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg08470875	chr2:26401718	FAM59B	-0.78	-4.69	-0.43	9.1e-6	Gut microbiome composition (summer);
THYM	cis	rs2188554	0.785	rs213938	chr7:117164439	T/C	cg25509184	chr7:117119382	CFTR	0.52	4.54	0.42	1.63e-5	Esophageal adenocarcinoma;
THYM	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg10802521	chr3:52805072	NEK4	0.71	6.15	0.53	1.84e-8	Bipolar disorder;
THYM	cis	rs11948739	0.610	rs2189511	chr5:130321378	T/C	cg08523029	chr5:130500466	HINT1	-0.81	-5.87	-0.52	6.45e-8	Pediatric bone mineral content (hip);
THYM	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs420259	0.556	rs7187920	chr16:23563501	C/T	cg00143387	chr16:23521605	GGA2	-0.72	-5.18	-0.47	1.26e-6	Bipolar disorder;
THYM	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs742614	0.533	rs2103804	chr20:32425403	A/G	cg06304546	chr20:32448765	NA	0.96	10.23	0.72	5.43e-17	Stearic acid (18:0) levels;
THYM	cis	rs8016982	0.674	rs28890880	chr14:81708031	A/G	cg01989461	chr14:81687754	GTF2A1	0.82	7.49	0.61	3.5e-11	Schizophrenia;
THYM	cis	rs36051895	0.530	rs6476951	chr9:5221614	A/G	cg02405213	chr9:5042618	JAK2	-0.82	-8.24	-0.65	9.54e-13	Pediatric autoimmune diseases;
THYM	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg01097406	chr16:89675127	NA	0.88	7.88	0.63	5.43e-12	Vitiligo;
THYM	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg10193763	chr2:225306901	NA	-0.52	-5.56	-0.5	2.42e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg15744005	chr10:104629667	AS3MT	-0.78	-7.44	-0.61	4.38e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs35825582	0.544	rs12612084	chr2:144178400	C/T	cg17056048	chr2:144271431	ARHGAP15	-0.62	-6.98	-0.58	3.94e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg03605463	chr16:89740564	NA	0.65	4.79	0.44	6.22e-6	Vitiligo;
THYM	cis	rs4242434	0.698	rs10104039	chr8:22538384	A/G	cg11461670	chr8:22454935	PDLIM2	0.34	6.08	0.53	2.5e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg24678163	chr13:52769951	THSD1P	0.49	4.58	0.43	1.38e-5	Lewy body disease;
THYM	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg13852791	chr20:30311386	BCL2L1	0.67	4.72	0.44	8.17e-6	Mean corpuscular hemoglobin;
THYM	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg06112835	chr11:68658793	MRPL21	0.43	6.08	0.53	2.48e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg08736216	chr1:53307985	ZYG11A	-0.6	-5.56	-0.5	2.46e-7	Monocyte count;
THYM	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg16325326	chr1:53192061	ZYG11B	0.79	6.42	0.55	5.39e-9	Monocyte count;
THYM	cis	rs9393692	0.552	rs806789	chr6:26229161	C/A	cg13736514	chr6:26305472	NA	-0.58	-6.81	-0.57	8.92e-10	Educational attainment;
THYM	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg10505658	chr17:80084571	CCDC57	-0.74	-8.13	-0.64	1.59e-12	Life satisfaction;
THYM	cis	rs7731657	0.509	rs6870590	chr5:130249954	A/G	cg08523029	chr5:130500466	HINT1	0.88	5.67	0.5	1.51e-7	Fasting plasma glucose;
THYM	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.0	9.3	0.69	5.08e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg03877680	chr5:178157825	ZNF354A	0.74	5.09	0.46	1.8e-6	Neutrophil percentage of white cells;
THYM	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg22907277	chr7:1156413	C7orf50	0.63	5.61	0.5	2.02e-7	Longevity;Endometriosis;
THYM	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17253792	0.822	rs10483650	chr14:56145312	A/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs7586879	0.593	rs11689546	chr2:25130451	A/G	cg01884057	chr2:25150051	NA	0.75	7.96	0.63	3.73e-12	Body mass index;
THYM	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg25797454	chr6:150327115	RAET1K	0.46	5.03	0.46	2.28e-6	Alopecia areata;
THYM	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg06582575	chr6:163149167	PACRG;PARK2	1.2	8.28	0.65	7.89e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg22325292	chr17:80708367	FN3K	0.63	4.53	0.42	1.71e-5	Glycated hemoglobin levels;
THYM	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg13609457	chr4:120235615	NA	-0.51	-4.93	-0.45	3.42e-6	Corneal astigmatism;
THYM	cis	rs8018808	1.000	rs12432247	chr14:77856321	T/C	cg20045696	chr14:77926864	AHSA1	-0.53	-4.73	-0.44	7.91e-6	Myeloid white cell count;
THYM	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg01073479	chr16:3509474	NAT15	0.63	5.26	0.48	8.71e-7	Tuberculosis;
THYM	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg04731861	chr2:219085781	ARPC2	0.55	5.26	0.47	8.86e-7	Colorectal cancer;
THYM	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg00810483	chr4:3375144	RGS12	0.31	4.73	0.44	7.9e-6	Serum sulfate level;
THYM	cis	rs747782	0.527	rs2270993	chr11:48145166	G/A	cg24672777	chr11:48374446	OR4C45	-1.01	-5.56	-0.5	2.46e-7	Intraocular pressure;
THYM	cis	rs477692	0.544	rs12251589	chr10:131417354	C/A	cg05714579	chr10:131428358	MGMT	-0.97	-10.42	-0.73	2.07e-17	Response to temozolomide;
THYM	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg11764359	chr7:65958608	NA	-0.69	-4.78	-0.44	6.27e-6	Aortic root size;
THYM	cis	rs2806561	0.704	rs1757039	chr1:23508657	A/G	cg12483005	chr1:23474871	LUZP1	0.59	6.31	0.54	9.03e-9	Height;
THYM	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.09	-7.38	-0.6	5.96e-11	Body mass index;
THYM	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10982256	0.817	rs10817631	chr9:117267942	G/T	cg15903421	chr9:117267460	DFNB31	-0.57	-5.37	-0.48	5.49e-7	Bipolar disorder;
THYM	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg26031613	chr14:104095156	KLC1	1.08	9.75	0.71	5.73e-16	Body mass index;
THYM	cis	rs79387448	0.614	rs6719130	chr2:102958236	C/T	cg09003973	chr2:102972529	NA	1.24	7.17	0.59	1.64e-10	Gut microbiota (bacterial taxa);
THYM	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg07424592	chr7:64974309	NA	1.07	5.56	0.5	2.48e-7	Diabetic kidney disease;
THYM	cis	rs4845875	0.535	rs198408	chr1:11898130	T/A	cg24844545	chr1:11908347	NPPA	-0.49	-4.8	-0.44	5.93e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs9534288	0.763	rs34175925	chr13:46611800	G/A	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg03474202	chr17:45855739	NA	0.74	6.44	0.55	4.93e-9	IgG glycosylation;
THYM	cis	rs2108225	0.934	rs2283045	chr7:107440714	G/A	cg18560240	chr7:107437656	SLC26A3	-0.74	-5.11	-0.46	1.64e-6	Ulcerative colitis;
THYM	cis	rs425277	0.583	rs3128334	chr1:2038662	G/A	cg23803603	chr1:2058230	PRKCZ	-0.68	-6.2	-0.54	1.48e-8	Height;
THYM	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg13319975	chr6:146136371	FBXO30	-0.67	-5.46	-0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg12963246	chr6:28129442	ZNF389	0.72	6.12	0.53	2.05e-8	Depression;
THYM	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg11266682	chr4:10021025	SLC2A9	-0.69	-9.44	-0.7	2.63e-15	Bone mineral density;
THYM	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg26031613	chr14:104095156	KLC1	0.75	5.11	0.46	1.63e-6	Body mass index;
THYM	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg11335335	chr11:637885	DRD4	-0.63	-5.11	-0.46	1.64e-6	Systemic lupus erythematosus;
THYM	cis	rs13279522	0.536	rs13264487	chr8:67008429	A/G	cg20171999	chr8:67343066	NA	-0.47	-4.74	-0.44	7.46e-6	Coronary heart disease event reduction (statin therapy interaction);
THYM	cis	rs9399401	0.667	rs11155242	chr6:142691549	A/C	cg04461802	chr6:142623433	GPR126	0.76	7.33	0.6	7.72e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg13175981	chr1:150552382	MCL1	0.7	4.99	0.46	2.72e-6	Tonsillectomy;
THYM	cis	rs6723226	0.679	rs116617324	chr2:32622709	C/T	cg02381751	chr2:32503542	YIPF4	-0.57	-4.8	-0.44	5.88e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2456568	0.548	rs1607402	chr11:93660732	T/G	cg17595323	chr11:93583763	C11orf90	-0.55	-5.83	-0.51	7.52e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg02734326	chr4:10020555	SLC2A9	0.76	7.25	0.6	1.1e-10	Bone mineral density;
THYM	cis	rs986417	0.901	rs10150982	chr14:60987006	T/G	cg27398547	chr14:60952738	C14orf39	1.14	5.33	0.48	6.64e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs6570726	0.791	rs418701	chr6:145889992	C/T	cg23711669	chr6:146136114	FBXO30	0.96	9.87	0.71	3.12e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs11677370	0.561	rs13015012	chr2:3821252	C/G	cg17052675	chr2:3827356	NA	0.66	6.41	0.55	5.51e-9	Type 2 diabetes;
THYM	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-1.09	-12.36	-0.79	1.72e-21	Height;
THYM	cis	rs739496	0.542	rs10219736	chr12:111788402	C/T	cg10833066	chr12:111807467	FAM109A	0.52	5.92	0.52	5e-8	Platelet count;
THYM	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.85	0.74	2.52e-18	Chronic sinus infection;
THYM	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg04025307	chr7:1156635	C7orf50	0.84	7.57	0.61	2.41e-11	Longevity;Endometriosis;
THYM	cis	rs72772090	0.539	rs72773989	chr5:96163613	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.79	-4.49	-0.42	2.04e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6840360	0.571	rs11944139	chr4:152505291	T/C	cg22705602	chr4:152727874	NA	-0.83	-8.96	-0.68	2.81e-14	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	14.35	0.83	1.61e-25	Chronic sinus infection;
THYM	cis	rs7078219	0.965	rs11190134	chr10:101282200	C/T	cg23904955	chr10:101282759	NA	-0.44	-5.1	-0.46	1.77e-6	Dental caries;
THYM	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg00484396	chr16:3507460	NAT15	0.74	9.01	0.68	2.2e-14	Tuberculosis;
THYM	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.63	0.5	1.86e-7	Rheumatoid arthritis;
THYM	cis	rs7769051	0.711	rs9493437	chr6:133088405	A/T	cg07930552	chr6:133119739	C6orf192	0.96	5.35	0.48	6.18e-7	Type 2 diabetes nephropathy;
THYM	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg16006841	chr5:176797999	RGS14	-0.52	-5.94	-0.52	4.74e-8	Urate levels in lean individuals;
THYM	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1843834	0.721	rs6436507	chr2:225598242	T/A	cg10193763	chr2:225306901	NA	-0.44	-4.67	-0.43	9.9e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs13202913	0.837	rs3734800	chr6:151766552	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.81	-4.54	-0.42	1.65e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs7262634	1.000	rs60943953	chr20:45840108	C/G	cg18599129	chr20:45867857	ZMYND8	0.82	4.83	0.44	5.14e-6	Response to protease inhibitor treatment in hepatitis c (bilirubin toxicity);
THYM	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg18681998	chr4:17616180	MED28	0.97	9.8	0.71	4.41e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4077515	0.806	rs3812564	chr9:139271190	A/G	cg14115884	chr9:139300582	SDCCAG3	0.75	7.97	0.63	3.47e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12956009	0.583	rs9653018	chr18:44895853	A/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-4.93	-0.45	3.51e-6	Educational attainment (years of education);
THYM	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg22974920	chr21:40686053	BRWD1	-0.6	-4.63	-0.43	1.15e-5	Cognitive function;
THYM	cis	rs6988636	1.000	rs28670850	chr8:124189125	A/G	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg13395646	chr4:1353034	KIAA1530	-0.74	-6.89	-0.58	6.11e-10	Obesity-related traits;
THYM	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg09455208	chr3:40491958	NA	0.46	4.87	0.45	4.42e-6	Renal cell carcinoma;
THYM	cis	rs3096299	0.900	rs4785666	chr16:89462771	C/G	cg02187348	chr16:89574699	SPG7	0.68	4.97	0.45	2.94e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.65	0.5	1.69e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg23803603	chr1:2058230	PRKCZ	-0.6	-5.43	-0.49	4.39e-7	Height;
THYM	cis	rs34638657	0.872	rs11859599	chr16:82182832	C/G	cg09894383	chr16:82067445	HSD17B2	-0.47	-4.56	-0.42	1.54e-5	Lung adenocarcinoma;
THYM	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg22117172	chr7:91764530	CYP51A1	0.38	4.92	0.45	3.65e-6	Breast cancer;
THYM	cis	rs4731207	0.671	rs7811607	chr7:124447843	T/G	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs611744	0.967	rs684904	chr8:109199417	G/A	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg17554472	chr22:41940697	POLR3H	-0.56	-4.47	-0.42	2.16e-5	Vitiligo;
THYM	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.7	-5.27	-0.48	8.35e-7	Tonsillectomy;
THYM	cis	rs10992471	0.603	rs7868013	chr9:95240173	G/A	cg14631576	chr9:95140430	CENPP	-0.99	-9.94	-0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs12282928	0.959	rs11039635	chr11:48299098	T/A	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs10819861	0.611	rs10124975	chr9:98847030	T/C	cg14508093	chr9:98862825	NA	-0.24	-4.61	-0.43	1.23e-5	Electrocardiographic traits;
THYM	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg11327659	chr7:150037044	RARRES2	0.42	5.0	0.46	2.59e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11039798	0.623	rs584851	chr11:48416321	A/G	cg24672777	chr11:48374446	OR4C45	1.16	7.24	0.6	1.16e-10	Axial length;
THYM	cis	rs6543140	0.964	rs10196334	chr2:103090041	T/C	cg03938978	chr2:103052716	IL18RAP	0.62	6.01	0.52	3.42e-8	Blood protein levels;
THYM	cis	rs17407555	0.738	rs73212898	chr4:10121994	C/T	cg11266682	chr4:10021025	SLC2A9	-0.61	-5.58	-0.5	2.26e-7	Schizophrenia (age at onset);
THYM	cis	rs59698941	0.943	rs66685494	chr5:132291056	A/G	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs870825	0.929	rs72689256	chr4:185590174	C/T	cg04058563	chr4:185651563	MLF1IP	0.99	6.98	0.58	3.95e-10	Blood protein levels;
THYM	cis	rs6876348	0.964	rs1363462	chr5:128119501	C/T	cg02841155	chr5:128301328	SLC27A6	0.46	4.46	0.42	2.22e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg00744431	chr10:134226547	PWWP2B	-0.6	-4.75	-0.44	7.12e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg19862616	chr7:65841803	NCRNA00174	1.12	13.73	0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs72772090	0.539	rs11749811	chr5:96115925	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs17102423	0.594	rs1271582	chr14:65564703	T/G	cg11161011	chr14:65562177	MAX	-0.76	-6.25	-0.54	1.14e-8	Obesity-related traits;
THYM	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg10360139	chr7:1886902	MAD1L1	-0.86	-7.83	-0.63	6.99e-12	Bipolar disorder and schizophrenia;
THYM	cis	rs7731657	0.537	rs7709977	chr5:130367086	A/T	cg08523029	chr5:130500466	HINT1	-0.85	-5.98	-0.52	3.88e-8	Fasting plasma glucose;
THYM	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg15744005	chr10:104629667	AS3MT	-0.83	-7.65	-0.62	1.61e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg23574427	chr4:122746245	BBS7;CCNA2	-0.55	-5.06	-0.46	2.05e-6	Type 2 diabetes;
THYM	cis	rs1551570	0.766	rs55752217	chr19:10218434	C/T	cg07543883	chr19:10213271	ANGPTL6	-0.48	-4.94	-0.45	3.35e-6	Narcolepsy;
THYM	cis	rs6840360	0.571	rs62327269	chr4:152527973	G/C	cg17479576	chr4:152424074	FAM160A1	-0.8	-5.65	-0.5	1.68e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs9902453	1.000	rs11080114	chr17:28407287	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-4.62	-0.43	1.2e-5	Coffee consumption (cups per day);
THYM	cis	rs11648796	0.879	rs12448432	chr16:778820	G/A	cg27144592	chr16:783916	NARFL	0.45	4.58	0.43	1.43e-5	Height;
THYM	cis	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg08772003	chr10:104629869	AS3MT	-0.61	-5.55	-0.49	2.58e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg11247378	chr22:39784982	NA	-1.08	-13.56	-0.81	6.12e-24	Intelligence (multi-trait analysis);
THYM	cis	rs7953508	0.700	rs10083107	chr12:93996035	T/A	cg18151635	chr12:93972918	NA	-0.64	-4.59	-0.43	1.37e-5	Pubertal anthropometrics;
THYM	cis	rs7590720	1.000	rs4674051	chr2:216907512	G/C	cg12620499	chr2:216877984	MREG	0.83	5.65	0.5	1.68e-7	Alcohol dependence;
THYM	cis	rs11711311	0.955	rs12630791	chr3:113387717	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.54	4.45	0.42	2.3e-5	IgG glycosylation;
THYM	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg09035930	chr12:129282057	SLC15A4	0.86	11.57	0.76	7.67e-20	Systemic lupus erythematosus;
THYM	cis	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.98	0.45	2.85e-6	Obesity-related traits;
THYM	cis	rs3820068	0.562	rs10927841	chr1:16045261	T/C	cg27534772	chr1:16042836	PLEKHM2	0.53	5.4	0.48	4.86e-7	Systolic blood pressure;
THYM	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg02269571	chr22:50332266	NA	-0.64	-4.83	-0.44	5.14e-6	Schizophrenia;
THYM	cis	rs4589258	0.966	rs4381333	chr11:90502479	T/A	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.93	-0.45	3.5e-6	Intelligence (multi-trait analysis);
THYM	cis	rs995000	0.929	rs12042319	chr1:63049819	C/T	cg06896770	chr1:63153194	DOCK7	1.0	8.24	0.65	9.31e-13	Triglyceride levels;
THYM	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg10047753	chr17:41438598	NA	1.19	11.33	0.76	2.52e-19	Menopause (age at onset);
THYM	cis	rs9419702	0.568	rs7093241	chr10:133556596	G/A	cg23460707	chr10:133558971	NA	0.44	4.54	0.42	1.65e-5	Survival in rectal cancer;
THYM	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	6.97	0.58	4.11e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg13114125	chr14:105738426	BRF1	-0.76	-6.06	-0.53	2.7e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	8.22	0.64	1.02e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2130392	0.886	rs2077205	chr4:185637418	C/T	cg04058563	chr4:185651563	MLF1IP	0.58	5.67	0.5	1.54e-7	Kawasaki disease;
THYM	cis	rs4654899	0.796	rs77366434	chr1:21520069	C/T	cg01072550	chr1:21505969	NA	-0.74	-6.68	-0.57	1.63e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg00898013	chr13:113819073	PROZ	0.88	9.0	0.68	2.24e-14	Platelet distribution width;
THYM	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg27034606	chr17:28928453	LRRC37B2	0.65	4.52	0.42	1.78e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17253792	0.822	rs75437558	chr14:56066798	C/T	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs2075230	0.705	rs1641522	chr17:7549851	C/T	cg27413385	chr17:7515425	FXR2	-0.36	-5.31	-0.48	7.3e-7	Hormone measurements;
THYM	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg12963246	chr6:28129442	ZNF389	0.78	6.75	0.57	1.15e-9	Depression;
THYM	cis	rs6754311	0.593	rs313522	chr2:136430866	T/A	cg20242066	chr2:136595261	LCT	0.55	6.04	0.53	3.05e-8	Mosquito bite size;
THYM	cis	rs4782309	0.544	rs8060579	chr16:88751667	G/C	cg27087555	chr16:88793112	FAM38A	-1.35	-6.15	-0.53	1.78e-8	Hair color;
THYM	cis	rs1728785	1.000	rs1645923	chr16:68581051	G/A	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.99	5.09	0.46	1.79e-6	Initial pursuit acceleration;
THYM	cis	rs9393692	0.620	rs12525187	chr6:26337537	A/G	cg13736514	chr6:26305472	NA	-0.46	-4.7	-0.43	8.63e-6	Educational attainment;
THYM	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg12179176	chr11:130786555	SNX19	0.86	8.24	0.65	9.58e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2237457	0.543	rs2245966	chr7:50700650	C/T	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.48e-6	Schizophrenia (treatment resistant);
THYM	cis	rs11711311	1.000	rs13061150	chr3:113506734	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.61	-5.45	-0.49	4.02e-7	IgG glycosylation;
THYM	cis	rs9876781	1.000	rs7653691	chr3:48419689	C/T	cg06066452	chr3:48470258	PLXNB1	-0.27	-5.01	-0.46	2.47e-6	Longevity;
THYM	cis	rs7695732	0.595	rs10028596	chr4:89901274	C/T	cg17769793	chr4:89976368	FAM13A	-0.49	-5.39	-0.48	5.23e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg15741354	chr8:8146129	NA	-0.29	-5.0	-0.46	2.61e-6	Joint mobility (Beighton score);
THYM	cis	rs4690686	0.836	rs10015351	chr4:177258952	A/G	cg17059388	chr4:177262070	NA	0.38	5.46	0.49	3.74e-7	Essential tremor;
THYM	cis	rs4919694	1.000	rs3740394	chr10:104634474	A/G	cg04362960	chr10:104952993	NT5C2	1.07	6.26	0.54	1.09e-8	Arsenic metabolism;
THYM	cis	rs6840360	0.642	rs2709818	chr4:152382634	A/G	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg00908189	chr16:619842	PIGQ	1.03	9.46	0.7	2.34e-15	Height;
THYM	cis	rs3087591	1.000	rs2040791	chr17:29627297	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.68	-5.88	-0.52	6.13e-8	Hip circumference;
THYM	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg04990556	chr1:26633338	UBXN11	-0.87	-8.24	-0.65	9.45e-13	Obesity-related traits;
THYM	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs2502731	0.584	rs3003578	chr9:130994179	C/T	cg09976142	chr9:130955436	CIZ1	0.5	4.8	0.44	5.82e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg13736514	chr6:26305472	NA	-0.63	-7.46	-0.61	4.03e-11	Educational attainment;
THYM	cis	rs425535	0.757	rs1898002	chr4:74807490	G/A	cg07868155	chr4:74864709	CXCL5	0.64	4.61	0.43	1.24e-5	Blood protein levels;
THYM	cis	rs600806	0.888	rs443345	chr1:109849254	A/G	cg02175308	chr1:109941060	SORT1	-0.56	-4.87	-0.45	4.5e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg08132940	chr7:1081526	C7orf50	-1.22	-5.82	-0.51	7.79e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11096990	0.656	rs9993224	chr4:39300198	C/T	cg24403649	chr4:39172243	NA	-0.64	-5.48	-0.49	3.43e-7	Cognitive function;
THYM	cis	rs763014	0.898	rs4984893	chr16:623082	A/G	cg00908189	chr16:619842	PIGQ	1.02	9.27	0.69	6.03e-15	Height;
THYM	cis	rs8044868	0.606	rs7189591	chr16:72099011	G/T	cg06353428	chr16:71660113	MARVELD3	0.61	4.55	0.42	1.57e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs9790314	0.967	rs463928	chr3:161087734	A/T	cg03342759	chr3:160939853	NMD3	-0.7	-5.98	-0.52	3.86e-8	Morning vs. evening chronotype;
THYM	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.65	9.24	0.69	6.82e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2319125	0.683	rs1443277	chr17:64051379	G/T	cg04446870	chr17:64440273	PRKCA	0.5	4.48	0.42	2.12e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg12564285	chr5:131593104	PDLIM4	-0.44	-4.75	-0.44	7.15e-6	Breast cancer;
THYM	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg13246856	chr1:44399776	ARTN	0.51	4.99	0.46	2.77e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs533123	0.668	rs414491	chr1:29170159	C/G	cg08366446	chr1:29138936	OPRD1	1.12	5.75	0.51	1.06e-7	Schizophrenia;
THYM	cis	rs1018836	0.884	rs7823461	chr8:91581075	T/C	cg16814680	chr8:91681699	NA	-0.78	-6.45	-0.55	4.73e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg22920501	chr2:26401640	FAM59B	-1.04	-9.12	-0.68	1.26e-14	Gut microbiome composition (summer);
THYM	cis	rs28595532	0.764	rs55704595	chr4:119780607	G/A	cg14228332	chr4:119757509	SEC24D	1.46	5.36	0.48	5.83e-7	Cannabis dependence symptom count;
THYM	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg03576123	chr11:487126	PTDSS2	-1.11	-4.78	-0.44	6.51e-6	Body mass index;
THYM	cis	rs4589258	0.698	rs2508413	chr11:90433840	T/A	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs500891	0.525	rs1144177	chr6:84029793	A/G	cg08257003	chr6:84140564	ME1	0.56	4.47	0.42	2.19e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs807029	0.533	rs3824783	chr10:102750851	C/T	cg14905631	chr10:102746534	C10orf2;MRPL43	0.36	5.05	0.46	2.14e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs10216189	1.000	rs7799665	chr7:5527501	G/A	cg08928675	chr7:5528044	FBXL18	0.46	4.62	0.43	1.23e-5	Relative hand skill in reading disability;
THYM	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg10792982	chr14:105748885	BRF1	0.74	7.65	0.62	1.66e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6591341	0.515	rs599301	chr11:68189945	G/C	cg16797656	chr11:68205561	LRP5	0.52	6.17	0.53	1.65e-8	Lean body mass;
THYM	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Gout;
THYM	cis	rs6087990	1.000	rs2018002	chr20:31351623	A/T	cg13636640	chr20:31349939	DNMT3B	0.93	10.38	0.73	2.51e-17	Ulcerative colitis;
THYM	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg02018176	chr4:1364513	KIAA1530	-0.59	-4.56	-0.42	1.51e-5	Obesity-related traits;
THYM	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs4363385	0.747	rs6671524	chr1:152974247	C/G	cg13444842	chr1:152974279	SPRR3	-0.57	-4.53	-0.42	1.74e-5	Inflammatory skin disease;
THYM	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg26384229	chr12:38710491	ALG10B	-0.71	-6.39	-0.55	6.22e-9	Heart rate;
THYM	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.26	0.47	8.97e-7	Lung cancer in ever smokers;
THYM	cis	rs9970807	0.792	rs72664355	chr1:57007791	T/C	cg11959316	chr1:57001742	PPAP2B	0.81	5.68	0.5	1.46e-7	Myocardial infarction;Coronary artery disease;
THYM	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	4.98	0.45	2.88e-6	Schizophrenia;
THYM	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs7894051	0.764	rs12242667	chr10:135192346	G/C	cg20534287	chr10:135191450	PAOX	-0.66	-4.82	-0.44	5.54e-6	Lifespan;
THYM	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.74	5.66	0.5	1.61e-7	Eosinophil percentage of white cells;
THYM	cis	rs35934224	0.783	rs35554477	chr22:19856561	G/A	cg11182965	chr22:19864308	TXNRD2	-0.79	-6.19	-0.54	1.5e-8	Glaucoma (primary open-angle);
THYM	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg27170947	chr2:26402098	FAM59B	-0.58	-4.88	-0.45	4.35e-6	Gut microbiome composition (summer);
THYM	cis	rs6835098	1.000	rs10011724	chr4:174088865	A/G	cg08422745	chr4:174089978	GALNT7	-1.02	-8.74	-0.67	8.01e-14	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs10736390	1.000	rs11206402	chr1:55104317	G/C	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.83	-7.56	-0.61	2.5e-11	Survival in pancreatic cancer;
THYM	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg15358701	chr1:161410459	NA	-0.97	-5.37	-0.48	5.56e-7	Rheumatoid arthritis;
THYM	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.62	0.74	7.83e-18	Prudent dietary pattern;
THYM	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg24006582	chr15:45444508	DUOX1	-0.83	-7.16	-0.59	1.7e-10	Uric acid levels;
THYM	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg23743428	chr13:21893420	NA	-0.68	-5.89	-0.52	5.75e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg03959625	chr15:84868606	LOC388152	0.48	4.59	0.43	1.34e-5	Schizophrenia;
THYM	cis	rs28647808	0.881	rs28602295	chr9:136267471	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg23840854	chr1:161414152	NA	-1.03	-5.72	-0.51	1.23e-7	Rheumatoid arthritis;
THYM	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.88	-0.58	6.43e-10	Eye color traits;
THYM	trans	rs1997103	1.000	rs10249105	chr7:55412405	A/G	cg20935933	chr6:143382018	AIG1	-0.86	-6.99	-0.58	3.79e-10	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06634786	chr22:41940651	POLR3H	-0.76	-5.54	-0.49	2.73e-7	Vitiligo;
THYM	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg23758822	chr17:41437982	NA	1.17	10.72	0.74	4.92e-18	Menopause (age at onset);
THYM	cis	rs17718580	0.609	rs59767247	chr14:51044774	C/A	cg04730355	chr14:51134070	SAV1	0.97	4.72	0.44	8.06e-6	Cognitive performance;
THYM	cis	rs9399401	0.593	rs262117	chr6:142807093	G/A	cg04461802	chr6:142623433	GPR126	0.66	6.33	0.54	8.23e-9	Chronic obstructive pulmonary disease;
THYM	cis	rs7216064	1.000	rs12602912	chr17:65870073	C/T	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs8050907	0.590	rs11860985	chr16:4555965	G/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.15	4.63	0.43	1.16e-5	Obesity-related traits;
THYM	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg12311346	chr5:56204834	C5orf35	-0.81	-5.9	-0.52	5.54e-8	Initial pursuit acceleration;
THYM	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg10018233	chr7:150070692	REPIN1	0.38	5.42	0.49	4.46e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs236352	0.576	rs3778017	chr6:36842183	C/T	cg03410223	chr6:36853544	C6orf89	0.71	5.65	0.5	1.69e-7	Heart rate;
THYM	cis	rs13315871	0.929	rs77487951	chr3:58290892	G/A	cg00563845	chr3:58318305	PXK	0.59	5.03	0.46	2.29e-6	Cholesterol, total;
THYM	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg13732083	chr21:47605072	C21orf56	0.69	4.49	0.42	2.02e-5	Testicular germ cell tumor;
THYM	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg20486651	chr6:167070296	RPS6KA2	0.5	4.68	0.43	9.47e-6	Crohn's disease;
THYM	cis	rs6430585	0.697	rs1050115	chr2:136511817	A/G	cg20242066	chr2:136595261	LCT	0.5	4.7	0.43	8.63e-6	Corneal structure;
THYM	cis	rs1697139	0.583	rs17289614	chr5:66541592	G/A	cg11553311	chr5:66541588	NA	0.71	7.38	0.6	5.98e-11	Breast cancer;
THYM	cis	rs883565	0.568	rs6599004	chr3:39095678	C/T	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	5.0	0.46	2.59e-6	Handedness;
THYM	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg02734326	chr4:10020555	SLC2A9	0.73	6.39	0.55	6.19e-9	Bone mineral density;
THYM	cis	rs4919687	0.679	rs12762176	chr10:104499232	A/T	cg15744005	chr10:104629667	AS3MT	-0.61	-4.82	-0.44	5.48e-6	Colorectal cancer;
THYM	cis	rs2073300	1.000	rs6048826	chr20:23458050	C/A	cg12062639	chr20:23401060	NAPB	0.99	4.96	0.45	3.07e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg07636037	chr3:49044803	WDR6	0.78	5.69	0.5	1.39e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs526231	0.543	rs75913944	chr5:102479503	G/C	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.49e-6	Primary biliary cholangitis;
THYM	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg22709100	chr7:91322751	NA	0.61	4.83	0.44	5.26e-6	Breast cancer;
THYM	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg16558253	chr16:72132732	DHX38	-0.58	-5.02	-0.46	2.46e-6	Fibrinogen levels;
THYM	cis	rs4654899	0.965	rs61781115	chr1:21322860	C/T	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.26e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs12579753	1.000	rs11519754	chr12:82209181	A/T	cg21231944	chr12:82153410	PPFIA2	-0.65	-4.87	-0.45	4.42e-6	Resting heart rate;
THYM	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg02551604	chr5:131831745	NA	0.81	6.39	0.55	6.2e-9	Asthma (sex interaction);
THYM	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg01341218	chr17:43662625	NA	-0.87	-7.53	-0.61	2.93e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg13695892	chr22:41940480	POLR3H	-0.87	-6.35	-0.55	7.28e-9	Vitiligo;
THYM	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg03605463	chr16:89740564	NA	-0.82	-6.25	-0.54	1.17e-8	Vitiligo;
THYM	cis	rs11096990	0.964	rs56284364	chr4:39256648	A/G	cg24403649	chr4:39172243	NA	-0.68	-5.77	-0.51	9.87e-8	Cognitive function;
THYM	cis	rs2668423	1.000	rs2668419	chr19:1366994	A/G	cg02639931	chr19:1387894	NDUFS7	-0.51	-5.95	-0.52	4.5e-8	Nonalcoholic fatty liver disease;
THYM	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg10560079	chr2:191398806	TMEM194B	-0.94	-7.79	-0.62	8.48e-12	Diastolic blood pressure;
THYM	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg22841779	chr14:105766346	BRF1	-0.47	-5.81	-0.51	8.18e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg12373951	chr3:133503437	NA	-0.64	-7.09	-0.59	2.31e-10	Iron status biomarkers;
THYM	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs55665837	0.583	rs78843135	chr11:14411254	T/G	cg05501817	chr11:14380813	RRAS2	-0.74	-6.09	-0.53	2.43e-8	Vitamin D levels;
THYM	cis	rs4638749	0.677	rs13398290	chr2:108833853	G/T	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs61931739	1.000	rs12304768	chr12:34000986	T/G	cg06521331	chr12:34319734	NA	0.57	4.49	0.42	2.01e-5	Morning vs. evening chronotype;
THYM	cis	rs6430585	0.528	rs3098102	chr2:136654833	C/T	cg23851026	chr2:136556271	LCT	0.68	6.64	0.56	1.94e-9	Corneal structure;
THYM	cis	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs728616	0.867	rs61860042	chr10:81946238	G/A	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs3820068	0.705	rs72645803	chr1:15868232	G/A	cg05660106	chr1:15850417	CASP9	1.14	9.89	0.71	2.91e-16	Systolic blood pressure;
THYM	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg24399712	chr22:39784796	NA	-0.84	-8.89	-0.67	3.94e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg13695892	chr22:41940480	POLR3H	0.87	6.18	0.54	1.56e-8	Vitiligo;
THYM	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg11752832	chr7:134001865	SLC35B4	0.72	5.47	0.49	3.57e-7	Mean platelet volume;
THYM	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg06766960	chr11:133703094	NA	-0.52	-4.83	-0.44	5.25e-6	Childhood ear infection;
THYM	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg09260853	chr1:2094483	PRKCZ	-0.51	-4.8	-0.44	5.88e-6	Height;
THYM	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg06115741	chr20:33292138	TP53INP2	0.7	4.67	0.43	9.98e-6	Coronary artery disease;
THYM	trans	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg06636001	chr8:8085503	FLJ10661	-0.8	-7.42	-0.61	4.85e-11	Neuroticism;
THYM	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg27129171	chr3:47204927	SETD2	0.71	6.66	0.56	1.81e-9	Colorectal cancer;
THYM	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.7	6.78	0.57	1.03e-9	Lymphocyte counts;
THYM	cis	rs7772486	0.840	rs2474355	chr6:146312540	C/G	cg13319975	chr6:146136371	FBXO30	-0.68	-5.69	-0.5	1.43e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6754311	0.551	rs6739713	chr2:136488978	A/G	cg07169764	chr2:136633963	MCM6	0.69	4.8	0.44	5.79e-6	Mosquito bite size;
THYM	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.67	-4.49	-0.42	1.98e-5	Childhood ear infection;
THYM	cis	rs9443189	0.570	rs661229	chr6:76293793	G/A	cg01950844	chr6:76311363	SENP6	1.1	6.88	0.58	6.48e-10	Prostate cancer;
THYM	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03517284	chr6:25882590	NA	-1.03	-9.99	-0.72	1.71e-16	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs76878669	0.561	rs10750784	chr11:66110666	A/G	cg18002602	chr11:66138449	SLC29A2	-0.48	-4.72	-0.44	8.12e-6	Educational attainment (years of education);
THYM	cis	rs12817211	0.502	rs59262224	chr12:50510947	C/A	cg06168149	chr12:50497778	GPD1	0.3	4.54	0.42	1.65e-5	Colorectal or endometrial cancer;
THYM	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg17426766	chr1:2046864	PRKCZ	0.44	5.23	0.47	1.02e-6	Height;
THYM	cis	rs2836974	0.931	rs2989330	chr21:40716209	A/G	cg22974920	chr21:40686053	BRWD1	0.79	5.2	0.47	1.15e-6	Cognitive function;
THYM	cis	rs28595532	0.920	rs56283736	chr4:119747268	A/G	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg12165864	chr7:66369176	NA	0.65	5.06	0.46	2.07e-6	Aortic root size;
THYM	cis	rs28595532	0.920	rs114462478	chr4:119752656	T/C	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs8114671	0.586	rs734111	chr20:33533736	A/C	cg08999081	chr20:33150536	PIGU	0.6	5.03	0.46	2.29e-6	Height;
THYM	cis	rs1461503	0.966	rs7110154	chr11:122843300	A/G	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs7781977	0.782	rs9886239	chr7:50336551	A/C	cg14216940	chr7:50343131	IKZF1	0.54	4.6	0.43	1.3e-5	IgG glycosylation;
THYM	cis	rs600806	0.850	rs12073497	chr1:109974450	A/C	cg02175308	chr1:109941060	SORT1	-0.57	-4.97	-0.45	3.01e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg13147721	chr7:65941812	NA	-1.1	-7.08	-0.59	2.51e-10	Diabetic kidney disease;
THYM	cis	rs2991971	0.810	rs2356413	chr1:45914048	A/T	cg15605315	chr1:45957053	TESK2	-0.66	-5.33	-0.48	6.62e-7	High light scatter reticulocyte count;
THYM	cis	rs7731657	0.537	rs12516770	chr5:130222575	T/C	cg08523029	chr5:130500466	HINT1	-0.75	-5.02	-0.46	2.44e-6	Fasting plasma glucose;
THYM	cis	rs9653442	1.000	rs1160542	chr2:100832155	A/G	cg07810366	chr2:100720526	AFF3	0.37	4.91	0.45	3.76e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs11711311	1.000	rs9855613	chr3:113448455	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.59	-5.19	-0.47	1.2e-6	IgG glycosylation;
THYM	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg04362960	chr10:104952993	NT5C2	0.58	4.82	0.44	5.34e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg02569458	chr12:86230093	RASSF9	0.66	5.6	0.5	2.11e-7	Major depressive disorder;
THYM	cis	rs9970807	0.901	rs72664335	chr1:56986978	G/T	cg11959316	chr1:57001742	PPAP2B	0.8	5.84	0.51	7.12e-8	Myocardial infarction;Coronary artery disease;
THYM	cis	rs7980799	0.682	rs1384599	chr12:33624579	G/A	cg10856724	chr12:34555212	NA	0.62	4.58	0.43	1.39e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs13082711	0.595	rs13075389	chr3:27339586	C/T	cg02860705	chr3:27208620	NA	0.95	7.19	0.59	1.47e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs1348850	0.526	rs2218575	chr2:178368997	C/A	cg27490568	chr2:178487706	NA	0.68	5.53	0.49	2.77e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg25072359	chr17:41440525	NA	0.69	4.83	0.44	5.17e-6	Menopause (age at onset);
THYM	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.19	-9.36	-0.69	3.85e-15	Platelet count;
THYM	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg02527881	chr3:46936655	PTH1R	0.62	6.09	0.53	2.34e-8	Colorectal cancer;
THYM	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg04673462	chr1:38461896	NA	0.44	5.24	0.47	9.75e-7	Coronary artery disease;
THYM	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg04362960	chr10:104952993	NT5C2	0.59	4.94	0.45	3.36e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg26149184	chr10:133730230	NA	0.77	4.65	0.43	1.07e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg05373962	chr22:49881684	NA	-0.65	-6.5	-0.55	3.73e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7578361	0.918	rs12468484	chr2:150370944	C/G	cg17961725	chr2:150454027	NA	-0.8	-6.14	-0.53	1.94e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1129187	0.755	rs2296804	chr6:42931261	C/G	cg02353165	chr6:42928485	GNMT	0.76	6.73	0.57	1.27e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6138458	0.887	rs227622	chr20:24910597	T/C	cg06937882	chr20:24974362	C20orf3	-0.47	-4.54	-0.42	1.66e-5	Blood protein levels;
THYM	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg13609457	chr4:120235615	NA	0.6	5.34	0.48	6.23e-7	Corneal astigmatism;
THYM	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg12908607	chr1:44402522	ARTN	0.63	5.52	0.49	2.93e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg22709100	chr7:91322751	NA	-0.62	-4.69	-0.43	9.13e-6	Breast cancer;
THYM	cis	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg12564285	chr5:131593104	PDLIM4	0.43	4.76	0.44	6.88e-6	Breast cancer;
THYM	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg24006582	chr15:45444508	DUOX1	-0.83	-7.16	-0.59	1.7e-10	Uric acid levels;
THYM	cis	rs6430585	0.528	rs6430594	chr2:136719173	C/T	cg04750100	chr2:136595281	LCT	-0.53	-5.07	-0.46	1.95e-6	Corneal structure;
THYM	cis	rs11711311	0.955	rs67550112	chr3:113401988	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.57	-4.78	-0.44	6.38e-6	IgG glycosylation;
THYM	cis	rs3126085	1.000	rs114304428	chr1:152254010	T/C	cg10321714	chr1:152280068	FLG	-0.76	-5.68	-0.5	1.47e-7	Atopic dermatitis;
THYM	cis	rs4499344	0.633	rs411328	chr19:33140178	T/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.95	8.42	0.65	3.96e-13	Mean platelet volume;
THYM	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg26818010	chr10:134567672	INPP5A	-0.93	-7.48	-0.61	3.71e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg10760299	chr15:45669010	GATM	0.83	6.25	0.54	1.19e-8	Homoarginine levels;
THYM	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg00814883	chr7:100076585	TSC22D4	-1.0	-6.8	-0.57	9.22e-10	Platelet count;
THYM	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg03806693	chr22:41940476	POLR3H	1.09	8.4	0.65	4.19e-13	Vitiligo;
THYM	cis	rs68170813	0.562	rs78181351	chr7:106999301	A/G	cg00661777	chr7:106511741	PIK3CG	-0.66	-4.61	-0.43	1.25e-5	Coronary artery disease;
THYM	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg09034736	chr1:150693464	HORMAD1	0.57	4.92	0.45	3.66e-6	Urate levels;
THYM	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg03213289	chr20:61660250	NA	0.91	9.46	0.7	2.34e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs61931739	0.534	rs2636072	chr12:34062386	C/T	cg10856724	chr12:34555212	NA	-0.79	-7.41	-0.61	5.14e-11	Morning vs. evening chronotype;
THYM	cis	rs8044868	0.586	rs8182213	chr16:72080005	C/T	cg06353428	chr16:71660113	MARVELD3	0.6	4.56	0.42	1.54e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs9549367	0.789	rs35569628	chr13:113872712	T/C	cg00898013	chr13:113819073	PROZ	-0.87	-8.8	-0.67	6.16e-14	Platelet distribution width;
THYM	cis	rs6882076	0.925	rs4704826	chr5:156392082	C/A	cg12943317	chr5:156479607	HAVCR1	-0.71	-5.85	-0.51	6.9e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.34	-0.65	5.69e-13	Chronic sinus infection;
THYM	cis	rs13040088	1.000	rs12480117	chr20:61558274	G/A	cg23096297	chr20:61557774	DIDO1	1.1	7.5	0.61	3.32e-11	Menopause (age at onset);
THYM	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg03806693	chr22:41940476	POLR3H	1.1	8.41	0.65	4.11e-13	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs10203711	0.705	rs4663946	chr2:239610287	C/T	cg14580085	chr2:239553406	NA	-0.52	-4.49	-0.42	1.98e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4363385	0.747	rs6587716	chr1:152966705	C/T	cg13444842	chr1:152974279	SPRR3	-0.6	-4.62	-0.43	1.22e-5	Inflammatory skin disease;
THYM	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg02753203	chr1:228287806	NA	-0.61	-5.28	-0.48	8.19e-7	Diastolic blood pressure;
THYM	cis	rs6448317	0.954	rs35276311	chr4:24923493	C/T	cg22968281	chr4:24586266	DHX15	0.66	4.53	0.42	1.69e-5	Heschl's gyrus morphology;
THYM	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg06656553	chr16:89960601	TCF25	-0.93	-5.27	-0.48	8.6e-7	Skin colour saturation;
THYM	cis	rs877282	0.853	rs10904544	chr10:756966	A/G	cg10556349	chr10:835070	NA	-0.73	-4.77	-0.44	6.74e-6	Uric acid levels;
THYM	cis	rs6424115	0.708	rs12755062	chr1:24185025	T/A	cg15997130	chr1:24165203	NA	-0.71	-5.32	-0.48	6.76e-7	Immature fraction of reticulocytes;
THYM	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg18105134	chr13:113819100	PROZ	-1.12	-10.05	-0.72	1.28e-16	Platelet distribution width;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg09136695	chr1:111722281	CEPT1	-0.9	-6.89	-0.58	6.1e-10	Depressive symptoms;
THYM	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg24069376	chr3:38537580	EXOG	-0.64	-6.5	-0.55	3.65e-9	Electrocardiographic conduction measures;
THYM	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg12179176	chr11:130786555	SNX19	-0.71	-5.76	-0.51	1.02e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4731207	0.698	rs4463363	chr7:124513770	A/G	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7705042	0.897	rs4912807	chr5:141519296	G/C	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg25754956	chr12:51612065	POU6F1	1.03	7.36	0.6	6.7e-11	Cisplatin-induced ototoxicity;
THYM	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg00757033	chr12:89920650	WDR51B	0.75	10.23	0.72	5.28e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs8141529	0.732	rs11556025	chr22:29168755	T/C	cg02153584	chr22:29168773	CCDC117	0.68	5.27	0.48	8.69e-7	Lymphocyte counts;
THYM	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs9549260	0.564	rs7998086	chr13:41268924	T/C	cg21288729	chr13:41239152	FOXO1	0.67	5.07	0.46	1.94e-6	Red blood cell count;
THYM	cis	rs10927875	0.864	rs1976402	chr1:16143779	G/A	cg21385522	chr1:16154831	NA	-1.31	-10.36	-0.73	2.84e-17	Dilated cardiomyopathy;
THYM	cis	rs7626444	0.625	rs843529	chr3:196480595	A/G	cg12930392	chr3:196481615	PAK2	-0.4	-4.92	-0.45	3.58e-6	Monocyte count;
THYM	cis	rs7152530	0.571	rs28691243	chr14:98634937	T/C	cg05180522	chr14:98101740	NA	-0.61	-4.74	-0.44	7.57e-6	Staphylococcus aureus infection;
THYM	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg17509989	chr5:176798049	RGS14	0.69	6.41	0.55	5.47e-9	Hemoglobin concentration;Hematocrit;
THYM	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25427524	chr10:38739819	LOC399744	-0.73	-6.77	-0.57	1.04e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg12516959	chr21:47718080	NA	-0.38	-5.02	-0.46	2.4e-6	Testicular germ cell tumor;
THYM	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg11663144	chr21:46675770	NA	-0.72	-10.48	-0.73	1.54e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg15556689	chr8:8085844	FLJ10661	-0.63	-4.97	-0.45	2.96e-6	Mood instability;
THYM	cis	rs7681440	0.606	rs2619361	chr4:90757735	C/A	cg06632027	chr4:90757378	SNCA	-0.67	-5.33	-0.48	6.7e-7	Dementia with Lewy bodies;
THYM	cis	rs28374715	0.629	rs2118740	chr15:41577232	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.14	-10.46	-0.73	1.75e-17	Ulcerative colitis;
THYM	cis	rs59698941	0.943	rs59484796	chr5:132293543	C/T	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs6546324	0.625	rs1430790	chr2:67864912	G/T	cg18237512	chr2:67827392	NA	0.82	5.05	0.46	2.11e-6	Endometriosis;
THYM	cis	rs1003719	0.788	rs1543750	chr21:38446918	A/G	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs4285028	0.948	rs2091664	chr3:121684749	T/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg21427119	chr20:30132790	HM13	-0.94	-6.64	-0.56	1.97e-9	Mean corpuscular hemoglobin;
THYM	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg08508325	chr11:3079039	CARS	-0.54	-6.91	-0.58	5.63e-10	Longevity;
THYM	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg20295408	chr7:1910781	MAD1L1	-0.72	-5.8	-0.51	8.65e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg21475434	chr5:93447410	FAM172A	0.93	5.81	0.51	8.12e-8	Diabetic retinopathy;
THYM	trans	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs4606347	0.652	rs61780874	chr1:66164913	A/T	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs7584330	0.780	rs2292884	chr2:238443226	A/G	cg16989719	chr2:238392110	NA	-0.51	-4.79	-0.44	6.18e-6	Prostate cancer;
THYM	cis	rs9875589	0.509	rs7653289	chr3:13986333	C/T	cg03204825	chr3:13978759	TPRXL	-0.56	-4.74	-0.44	7.52e-6	Ovarian reserve;
THYM	cis	rs2046867	0.583	rs13316962	chr3:72911994	T/C	cg25664220	chr3:72788482	NA	-0.75	-6.57	-0.56	2.72e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs11696501	0.895	rs6065823	chr20:44114873	C/T	cg11783356	chr20:44313418	WFDC10B	0.76	4.74	0.44	7.55e-6	Brain structure;
THYM	cis	rs1642645	0.831	rs6600396	chr1:42489534	G/A	cg06092502	chr1:42611687	NA	0.61	4.74	0.44	7.58e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs4076764	0.535	rs4409627	chr1:163382050	A/G	cg24596788	chr1:163392923	NA	0.6	5.33	0.48	6.57e-7	Motion sickness;
THYM	cis	rs208520	0.874	rs208456	chr6:66907942	A/G	cg07460842	chr6:66804631	NA	-0.81	-4.98	-0.46	2.79e-6	Exhaled nitric oxide output;
THYM	cis	rs8067545	0.611	rs2526477	chr17:20131193	A/G	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.74	-0.67	8.04e-14	Mean corpuscular volume;
THYM	cis	rs9814567	1.000	rs4955485	chr3:134295843	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.43	-0.65	3.72e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2444217	0.868	rs2601792	chr16:4043980	G/A	cg09300795	chr16:4042428	ADCY9	0.62	4.74	0.44	7.64e-6	Body mass index;
THYM	cis	rs9311676	0.632	rs11705721	chr3:58400414	T/C	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs6840360	0.615	rs3828546	chr4:152679816	A/G	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg04455712	chr21:45112962	RRP1B	0.52	4.54	0.42	1.67e-5	Mean corpuscular volume;
THYM	cis	rs6430585	0.527	rs2289959	chr2:136423904	C/T	cg04750100	chr2:136595281	LCT	0.53	5.2	0.47	1.16e-6	Corneal structure;
THYM	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg09455208	chr3:40491958	NA	0.5	5.15	0.47	1.39e-6	Renal cell carcinoma;
THYM	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg25554036	chr4:6271136	WFS1	0.59	5.47	0.49	3.68e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.23	4.9	0.45	3.97e-6	Obesity-related traits;
THYM	cis	rs3892630	0.878	rs8108621	chr19:33183291	G/A	cg22980127	chr19:33182716	NUDT19	1.11	9.12	0.68	1.28e-14	Red blood cell traits;
THYM	cis	rs11112613	0.762	rs17037312	chr12:105950085	C/T	cg03607813	chr12:105948248	NA	1.07	9.36	0.69	3.87e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg25214090	chr10:38739885	LOC399744	0.86	7.53	0.61	2.86e-11	Corneal astigmatism;
THYM	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg00801512	chr17:28996047	NA	-0.76	-4.9	-0.45	3.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9970807	1.000	rs72664341	chr1:56990753	A/C	cg11959316	chr1:57001742	PPAP2B	0.8	5.84	0.51	7.12e-8	Myocardial infarction;Coronary artery disease;
THYM	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg11663144	chr21:46675770	NA	-0.68	-8.3	-0.65	6.95e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs13082711	0.522	rs551621	chr3:27336325	G/C	cg02860705	chr3:27208620	NA	0.65	5.19	0.47	1.21e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg16342193	chr10:102329863	NA	-0.53	-5.45	-0.49	4.01e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs28595532	0.920	rs116514715	chr4:119756280	G/T	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs67460515	0.563	rs7618924	chr3:160855599	A/G	cg12349858	chr3:160822545	B3GALNT1	0.57	4.58	0.43	1.39e-5	Parkinson's disease;
THYM	cis	rs11671005	0.656	rs55928441	chr19:59009674	T/C	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.66	-4.9	-0.45	3.98e-6	Mean platelet volume;
THYM	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7584330	0.554	rs13431733	chr2:238430275	A/G	cg08992911	chr2:238395768	MLPH	0.9	5.8	0.51	8.78e-8	Prostate cancer;
THYM	cis	rs3106136	0.527	rs2664894	chr4:95153831	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.1	-0.46	1.7e-6	Capecitabine sensitivity;
THYM	cis	rs9929218	0.581	rs7203337	chr16:68774800	C/G	cg01251360	chr16:68772225	CDH1	-0.3	-4.66	-0.43	1.04e-5	Colorectal cancer;
THYM	cis	rs2282300	1.000	rs12796693	chr11:30429583	A/C	cg06241208	chr11:30344200	C11orf46	-0.69	-4.8	-0.44	5.94e-6	Morning vs. evening chronotype;
THYM	cis	rs9595908	1.000	rs718444	chr13:33147052	C/T	cg12383807	chr13:33924137	NA	-0.55	-4.87	-0.45	4.38e-6	Body mass index;
THYM	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg06728252	chr6:26598149	ABT1	-0.43	-5.11	-0.46	1.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02018176	chr4:1364513	KIAA1530	0.94	8.73	0.67	8.68e-14	Longevity;
THYM	cis	rs11671005	0.735	rs12981875	chr19:58935130	A/C	cg18639983	chr19:58920768	ZNF584	0.61	5.02	0.46	2.37e-6	Mean platelet volume;
THYM	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg03929089	chr4:120376271	NA	-0.94	-9.89	-0.71	2.79e-16	Coronary artery disease;
THYM	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg26545918	chr15:68124484	LBXCOR1	0.55	4.71	0.44	8.37e-6	Restless legs syndrome;
THYM	cis	rs752010	0.714	rs6664708	chr1:42083070	G/A	cg06885757	chr1:42089581	HIVEP3	0.61	7.92	0.63	4.42e-12	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs1113500	0.614	rs6677839	chr1:108599341	G/T	cg06207961	chr1:108661230	NA	-0.67	-4.94	-0.45	3.28e-6	Growth-regulated protein alpha levels;
THYM	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg21926883	chr2:100939477	LONRF2	-0.55	-4.99	-0.46	2.74e-6	Intelligence (multi-trait analysis);
THYM	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Body mass index;
THYM	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs9527	0.545	rs35756290	chr10:104585572	G/A	cg04362960	chr10:104952993	NT5C2	0.63	4.96	0.45	3.09e-6	Arsenic metabolism;
THYM	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.48	-0.42	2.05e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9581857	0.615	rs9581848	chr13:28003997	C/T	cg22138327	chr13:27999177	GTF3A	0.98	5.58	0.5	2.25e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22433210	chr17:43662623	NA	0.87	7.03	0.58	3.2e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg05084668	chr3:125655381	ALG1L	-0.71	-4.61	-0.43	1.23e-5	Blood pressure (smoking interaction);
THYM	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg13683864	chr3:40499215	RPL14	-0.88	-8.67	-0.66	1.14e-13	Renal cell carcinoma;
THYM	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg13319975	chr6:146136371	FBXO30	-0.67	-5.53	-0.49	2.77e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg13695892	chr22:41940480	POLR3H	0.99	7.48	0.61	3.75e-11	Vitiligo;
THYM	cis	rs17539620	0.519	rs871071	chr6:154837667	T/C	cg20019720	chr6:154832845	CNKSR3	0.61	6.8	0.57	9.42e-10	Lipoprotein (a) levels;
THYM	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg14829155	chr15:31115871	NA	-0.55	-5.07	-0.46	1.95e-6	Huntington's disease progression;
THYM	cis	rs7572733	0.515	rs1518368	chr2:198839145	G/A	cg00792783	chr2:198669748	PLCL1	0.82	5.63	0.5	1.79e-7	Dermatomyositis;
THYM	cis	rs2108225	0.658	rs1476673	chr7:107435945	C/G	cg18560240	chr7:107437656	SLC26A3	-1.02	-8.08	-0.64	2.02e-12	Ulcerative colitis;
THYM	cis	rs1801251	0.963	rs13424351	chr2:233573629	A/G	cg08000102	chr2:233561755	GIGYF2	0.68	6.32	0.54	8.3e-9	Coronary artery disease;
THYM	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg03609598	chr5:56110824	MAP3K1	-0.81	-5.41	-0.49	4.67e-7	Initial pursuit acceleration;
THYM	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg09021430	chr5:549028	NA	-0.64	-4.84	-0.44	4.98e-6	Obesity-related traits;
THYM	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg07414643	chr4:187882934	NA	0.56	4.79	0.44	6.23e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4589258	0.788	rs10830570	chr11:90491914	G/T	cg26138821	chr11:89956704	CHORDC1	-0.56	-4.49	-0.42	1.98e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg10560079	chr2:191398806	TMEM194B	-0.86	-6.5	-0.56	3.64e-9	Diastolic blood pressure;
THYM	trans	rs4596713	0.538	rs10869961	chr9:71787071	C/T	cg16512924	chr15:28394682	HERC2	0.83	7.08	0.59	2.49e-10	Headache;
THYM	cis	rs7582180	0.676	rs10048665	chr2:100933085	A/G	cg21926883	chr2:100939477	LONRF2	-0.6	-5.39	-0.48	5.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs921968	0.643	rs522377	chr2:219437476	T/C	cg02176678	chr2:219576539	TTLL4	0.64	6.08	0.53	2.49e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.97	-7.14	-0.59	1.88e-10	Platelet count;
THYM	cis	rs3806843	0.966	rs4141841	chr5:140203432	C/T	cg19875535	chr5:140030758	IK	0.61	4.81	0.44	5.71e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7084402	0.967	rs7087998	chr10:60271531	A/G	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs36051895	0.664	rs3780374	chr9:5099677	G/A	cg02405213	chr9:5042618	JAK2	-1.0	-10.94	-0.75	1.67e-18	Pediatric autoimmune diseases;
THYM	cis	rs4072705	1.000	rs10986391	chr9:127428235	C/T	cg13476313	chr9:127244764	NR5A1	0.32	4.99	0.46	2.77e-6	Menarche (age at onset);
THYM	cis	rs919433	0.617	rs4850809	chr2:198583403	C/T	cg05783139	chr2:198650985	BOLL	-0.63	-5.0	-0.46	2.58e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg10803722	chr21:46713166	LOC642852	-0.38	-4.75	-0.44	7.19e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07157834	chr1:205819609	PM20D1	0.9	9.21	0.69	8.11e-15	Menarche (age at onset);
THYM	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg08430604	chr3:44902960	MIR564;TMEM42	0.52	4.94	0.45	3.4e-6	Depressive symptoms;
THYM	cis	rs12579753	0.917	rs11612874	chr12:82212649	A/C	cg21231944	chr12:82153410	PPFIA2	0.7	4.95	0.45	3.15e-6	Resting heart rate;
THYM	cis	rs17401966	1.000	rs60743860	chr1:10442926	G/C	cg19773385	chr1:10388646	KIF1B	-0.65	-4.89	-0.45	4.1e-6	Hepatocellular carcinoma;
THYM	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg21385522	chr1:16154831	NA	0.67	5.62	0.5	1.89e-7	Systolic blood pressure;
THYM	cis	rs2552220	0.818	rs13280300	chr8:6012420	A/G	cg06481462	chr8:7005678	NA	0.48	5.1	0.46	1.7e-6	Interleukin-8 levels;
THYM	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg06766960	chr11:133703094	NA	-0.59	-5.56	-0.5	2.51e-7	Childhood ear infection;
THYM	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg07061783	chr6:25882402	NA	0.57	4.48	0.42	2.07e-5	Schizophrenia;
THYM	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg14582100	chr15:45693742	SPATA5L1	0.59	4.91	0.45	3.79e-6	Homoarginine levels;
THYM	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg27129171	chr3:47204927	SETD2	0.76	7.41	0.61	5.11e-11	Colorectal cancer;
THYM	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg20295408	chr7:1910781	MAD1L1	-0.64	-4.51	-0.42	1.86e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.74	-7.33	-0.6	7.54e-11	Lymphocyte counts;
THYM	cis	rs1371867	0.875	rs1660344	chr8:101324659	A/G	cg06002616	chr8:101225028	SPAG1	-0.47	-4.86	-0.45	4.6e-6	Atrioventricular conduction;
THYM	cis	rs7226229	0.950	rs1044410	chr17:20904669	A/G	cg21263980	chr17:20946333	USP22	0.65	4.88	0.45	4.33e-6	Blood trace element (Se levels);
THYM	cis	rs3008870	0.755	rs2815362	chr1:67496803	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.78	6.29	0.54	9.87e-9	Lymphocyte percentage of white cells;
THYM	cis	rs5995756	0.555	rs2413602	chr22:39989216	A/G	cg21377881	chr22:40064566	CACNA1I	-0.55	-4.61	-0.43	1.26e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11690935	0.959	rs6754817	chr2:172663394	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.78	-5.51	-0.49	3.01e-7	Schizophrenia;
THYM	cis	rs4731207	0.564	rs2127972	chr7:124665545	A/T	cg05285228	chr7:124571219	POT1	-0.6	-4.52	-0.42	1.77e-5	Cutaneous malignant melanoma;
THYM	cis	rs10992471	0.603	rs10114932	chr9:95307901	C/A	cg14631576	chr9:95140430	CENPP	-0.96	-8.92	-0.68	3.33e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2235642	0.601	rs2235647	chr16:1601331	C/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.46	-4.93	-0.45	3.44e-6	Coronary artery disease;
THYM	cis	rs951188	0.744	rs1116380	chr2:150336316	T/C	cg17961725	chr2:150454027	NA	0.94	4.78	0.44	6.41e-6	Daytime sleep phenotypes;
THYM	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	5.3	0.48	7.48e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7719624	1.000	rs1989972	chr5:135377802	A/C	cg12897067	chr5:135418308	NA	0.6	4.88	0.45	4.28e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs7822232	0.908	rs6558295	chr8:145139522	C/G	cg12091641	chr8:145180933	NA	-1.01	-4.87	-0.45	4.36e-6	Blood metabolite levels;
THYM	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg00024416	chr22:24240387	NA	-0.75	-7.36	-0.6	6.48e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7119	1.000	rs7119	chr15:77777632	C/T	cg27398640	chr15:77910606	LINGO1	-0.46	-4.81	-0.44	5.59e-6	Type 2 diabetes;
THYM	cis	rs9486719	0.522	rs4839683	chr6:96851933	A/G	cg06623918	chr6:96969491	KIAA0776	0.79	4.75	0.44	7.22e-6	Migraine;Coronary artery disease;
THYM	cis	rs1883415	0.727	rs2760114	chr6:24504363	A/C	cg00346970	chr6:24499591	ALDH5A1	0.42	5.64	0.5	1.73e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	-0.68	-5.83	-0.51	7.51e-8	Lymphocyte counts;
THYM	cis	rs72627123	1.000	rs72627113	chr14:74340141	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs870825	0.860	rs34985821	chr4:185599489	G/A	cg04058563	chr4:185651563	MLF1IP	1.05	7.96	0.63	3.6e-12	Blood protein levels;
THYM	cis	rs6032067	0.561	rs6032104	chr20:43932412	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.54	-5.22	-0.47	1.04e-6	Blood protein levels;
THYM	cis	rs10992471	0.603	rs6479422	chr9:95190694	G/T	cg14631576	chr9:95140430	CENPP	-0.99	-9.94	-0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7705042	0.686	rs2338819	chr5:141540017	C/T	cg07392085	chr5:141489673	NDFIP1	-0.65	-4.67	-0.43	9.91e-6	Asthma;
THYM	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg26850624	chr5:429559	AHRR	-0.72	-5.68	-0.5	1.45e-7	Cystic fibrosis severity;
THYM	cis	rs12142240	0.698	rs966907	chr1:46817125	C/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs6687430	0.562	rs12139169	chr1:10635328	C/T	cg20482658	chr1:10539492	PEX14	-0.37	-4.96	-0.45	3.13e-6	Hand grip strength;
THYM	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6964587	0.626	rs4422709	chr7:91510968	A/G	cg22709100	chr7:91322751	NA	-0.62	-4.56	-0.42	1.51e-5	Breast cancer;
THYM	cis	rs26232	0.521	rs3776855	chr5:102358815	A/C	cg23492399	chr5:102201601	PAM	-0.71	-5.32	-0.48	6.82e-7	Rheumatoid arthritis;
THYM	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg15445000	chr17:37608096	MED1	0.44	5.1	0.46	1.73e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4845570	0.850	rs11204892	chr1:151768048	A/G	cg07092448	chr1:151763213	TDRKH	1.17	8.57	0.66	1.86e-13	Coronary artery disease;
THYM	cis	rs1957429	0.614	rs1957416	chr14:65369329	C/T	cg23373153	chr14:65346875	NA	-1.25	-5.03	-0.46	2.29e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg26446133	chr18:72167187	CNDP2	-0.88	-7.38	-0.6	5.87e-11	Refractive error;
THYM	cis	rs4786125	0.622	rs1492372	chr16:6920965	C/T	cg03623568	chr16:6915990	A2BP1	-0.98	-9.62	-0.7	1.07e-15	Heart rate variability traits (SDNN);
THYM	cis	rs9549260	0.564	rs9549280	chr13:41322660	T/C	cg21288729	chr13:41239152	FOXO1	0.63	4.75	0.44	7.33e-6	Red blood cell count;
THYM	cis	rs2859741	0.546	rs2133910	chr1:37478785	G/T	cg09363841	chr1:37513479	NA	-0.66	-5.15	-0.47	1.4e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg27211696	chr2:191398769	TMEM194B	0.84	8.28	0.65	7.62e-13	Pulse pressure;
THYM	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg15557168	chr22:42548783	NA	0.58	4.68	0.43	9.66e-6	Schizophrenia;
THYM	cis	rs981844	1.000	rs2606325	chr4:154652681	C/T	cg09973105	chr4:154681532	RNF175	-0.59	-4.83	-0.44	5.3e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs1322639	0.614	rs7768154	chr6:169565470	A/G	cg04662567	chr6:169592167	NA	-0.77	-6.08	-0.53	2.49e-8	Pulse pressure;
THYM	cis	rs6882076	1.000	rs7724832	chr5:156381370	C/T	cg06200339	chr5:157079404	SOX30	0.46	4.64	0.43	1.12e-5	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs42648	0.837	rs6970750	chr7:89938191	G/A	cg25739043	chr7:89950458	NA	-0.53	-4.53	-0.42	1.72e-5	Homocysteine levels;
THYM	cis	rs1797885	0.646	rs299652	chr3:12547657	G/A	cg05467012	chr3:12595696	NA	0.55	4.89	0.45	4.03e-6	Immature fraction of reticulocytes;
THYM	cis	rs7107174	0.892	rs2512548	chr11:77962116	A/G	cg19901956	chr11:77921274	USP35	-0.74	-5.72	-0.51	1.25e-7	Testicular germ cell tumor;
THYM	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	10.62	0.74	7.85e-18	Chronic sinus infection;
THYM	cis	rs67311347	0.544	rs7644181	chr3:40355665	A/G	cg13683864	chr3:40499215	RPL14	0.7	6.46	0.55	4.54e-9	Renal cell carcinoma;
THYM	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg22907277	chr7:1156413	C7orf50	0.82	4.98	0.46	2.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg15242686	chr22:24348715	GSTTP1	0.6	6.12	0.53	2.04e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9486719	0.656	rs4839826	chr6:96853616	A/G	cg06623918	chr6:96969491	KIAA0776	-0.86	-5.49	-0.49	3.31e-7	Migraine;Coronary artery disease;
THYM	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg00757033	chr12:89920650	WDR51B	0.74	11.52	0.76	9.94e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg19077165	chr18:44547161	KATNAL2	0.66	8.28	0.65	7.58e-13	Personality dimensions;
THYM	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.87	0.45	4.53e-6	Bipolar disorder;
THYM	cis	rs10425738	0.830	rs1820025	chr19:41436546	C/G	cg17435250	chr19:41386441	CYP2A7	0.63	4.52	0.42	1.79e-5	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
THYM	cis	rs3796352	1.000	rs11706035	chr3:53011868	A/T	cg07884673	chr3:53033167	SFMBT1	1.19	6.0	0.52	3.59e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg00256281	chr22:41985642	PMM1	0.66	5.11	0.46	1.64e-6	Vitiligo;
THYM	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Gout;
THYM	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.48	4.52	0.42	1.76e-5	Birth weight;
THYM	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg24209194	chr3:40518798	ZNF619	-0.68	-5.85	-0.51	6.96e-8	Renal cell carcinoma;
THYM	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg21926883	chr2:100939477	LONRF2	-0.61	-5.67	-0.5	1.54e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg09060608	chr5:178986726	RUFY1	-0.59	-6.37	-0.55	6.84e-9	Lung cancer;
THYM	cis	rs9876781	1.000	rs13314659	chr3:48449149	A/G	cg06066452	chr3:48470258	PLXNB1	-0.27	-4.89	-0.45	4.08e-6	Longevity;
THYM	cis	rs804280	0.525	rs809204	chr8:11619163	A/G	cg23916205	chr8:11614368	GATA4	-0.61	-5.02	-0.46	2.43e-6	Myopia (pathological);
THYM	cis	rs4731207	0.596	rs7787605	chr7:124659982	A/G	cg05285228	chr7:124571219	POT1	-0.66	-4.97	-0.45	2.95e-6	Cutaneous malignant melanoma;
THYM	cis	rs76878669	0.561	rs12420203	chr11:66163794	T/C	cg18002602	chr11:66138449	SLC29A2	0.47	4.84	0.44	5.1e-6	Educational attainment (years of education);
THYM	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02475777	chr4:1388615	CRIPAK	0.68	4.8	0.44	5.97e-6	Longevity;
THYM	cis	rs11089937	0.584	rs6001213	chr22:22536498	A/G	cg06866756	chr22:22471216	NA	-0.47	-5.35	-0.48	6.11e-7	Periodontitis (PAL4Q3);
THYM	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.69	6.36	0.55	7.1e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs4780401	0.728	rs7198518	chr16:11771094	C/G	cg01061890	chr16:11836724	TXNDC11	-0.61	-4.71	-0.43	8.55e-6	Rheumatoid arthritis;
THYM	cis	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05901451	chr6:126070800	HEY2	0.58	4.69	0.43	8.97e-6	Endometrial cancer;
THYM	cis	rs728616	0.867	rs61860412	chr10:81728486	G/A	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg20295408	chr7:1910781	MAD1L1	-0.67	-5.29	-0.48	7.8e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg09359103	chr1:154839909	KCNN3	-0.83	-11.18	-0.75	5.17e-19	Prostate cancer;
THYM	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg20887711	chr4:1340912	KIAA1530	0.58	4.46	0.42	2.27e-5	Obesity-related traits;
THYM	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg13683864	chr3:40499215	RPL14	-1.05	-11.49	-0.76	1.13e-19	Renal cell carcinoma;
THYM	cis	rs1551570	0.819	rs11666402	chr19:10219076	A/G	cg07753644	chr19:10222175	PPAN-P2RY11;P2RY11	-0.41	-4.46	-0.42	2.27e-5	Narcolepsy;
THYM	cis	rs6496667	0.509	rs2657948	chr15:90948617	G/A	cg00425431	chr15:90792223	TTLL13	0.38	4.49	0.42	1.97e-5	Rheumatoid arthritis;
THYM	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg27129171	chr3:47204927	SETD2	0.7	6.7	0.57	1.44e-9	Colorectal cancer;
THYM	cis	rs137603	0.933	rs137593	chr22:39690021	C/T	cg24268161	chr22:39747459	SYNGR1	0.57	5.08	0.46	1.87e-6	Primary biliary cholangitis;
THYM	cis	rs6499188	0.571	rs1645975	chr16:68564448	C/T	cg02972257	chr16:68554789	NA	-0.74	-4.54	-0.42	1.63e-5	Ulcerative colitis;
THYM	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg01570182	chr17:44337453	NA	-0.84	-8.65	-0.66	1.26e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6686842	1.000	rs2749418	chr1:41509674	T/C	cg03387723	chr1:41708464	SCMH1	0.42	5.0	0.46	2.61e-6	Height;
THYM	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg05754148	chr16:3507555	NAT15	0.72	6.82	0.57	8.39e-10	Tuberculosis;
THYM	cis	rs6496667	0.865	rs7178854	chr15:90884634	G/A	cg22089800	chr15:90895588	ZNF774	0.76	4.68	0.43	9.33e-6	Rheumatoid arthritis;
THYM	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg09517075	chr8:22133004	PIWIL2	0.65	5.74	0.51	1.11e-7	Hypertriglyceridemia;
THYM	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-6.98	-0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	cis	rs61990749	0.544	rs2544566	chr14:78181738	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.02	0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs9362426	0.895	rs242292	chr6:88078074	C/T	cg10393598	chr6:87862264	NA	-0.61	-4.85	-0.45	4.78e-6	Depressive episodes in bipolar disorder;
THYM	cis	rs1018836	0.923	rs13254212	chr8:91582355	T/C	cg16814680	chr8:91681699	NA	-0.74	-6.12	-0.53	2.1e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs2549003	0.811	rs10035166	chr5:131823927	C/T	cg02551604	chr5:131831745	NA	0.78	4.53	0.42	1.71e-5	Asthma (sex interaction);
THYM	cis	rs1978968	0.701	rs9618179	chr22:18476909	C/T	cg01550578	chr22:18484421	MICAL3	0.58	4.48	0.42	2.06e-5	Presence of antiphospholipid antibodies;
THYM	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg22907277	chr7:1156413	C7orf50	0.69	6.48	0.55	4.04e-9	Longevity;Endometriosis;
THYM	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg21394778	chr1:3037102	PRDM16	-0.44	-4.6	-0.43	1.31e-5	Height;
THYM	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg24846343	chr22:24311635	DDTL	0.46	5.97	0.52	4.1e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1211375	0.606	rs1203977	chr16:256278	A/C	cg17291625	chr16:236080	NA	0.61	5.21	0.47	1.1e-6	Hematology traits;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4930776	0.966	rs430061	chr12:5769173	T/C	cg02086166	chr12:5775618	ANO2	0.57	5.51	0.49	3.1e-7	Plasma clusterin levels;
THYM	cis	rs736801	0.891	rs10900809	chr5:131826322	G/A	cg00255919	chr5:131827918	IRF1	-0.43	-4.74	-0.44	7.44e-6	Breast cancer;Mosquito bite size;
THYM	cis	rs16912285	0.688	rs1899541	chr11:24339624	T/C	ch.11.24196551F	chr11:24239977	NA	0.93	6.5	0.55	3.7e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs11118346	0.934	rs11118347	chr1:219744249	G/T	cg07908999	chr1:219785142	NA	-0.39	-4.47	-0.42	2.16e-5	Height;
THYM	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.69	-5.13	-0.47	1.56e-6	Colorectal cancer;
THYM	cis	rs4845570	1.000	rs7542898	chr1:151753622	T/G	cg18019451	chr1:151746047	TDRKH	-0.75	-4.58	-0.43	1.41e-5	Coronary artery disease;
THYM	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg10360139	chr7:1886902	MAD1L1	-0.59	-4.76	-0.44	6.82e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7727544	0.544	rs55722650	chr5:131607300	C/T	cg04518342	chr5:131593106	PDLIM4	0.43	4.59	0.43	1.35e-5	Blood metabolite levels;
THYM	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.71	5.19	0.47	1.19e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7851660	0.844	rs13287360	chr9:100637681	A/G	cg13688889	chr9:100608707	NA	-0.75	-5.12	-0.47	1.59e-6	Strep throat;
THYM	cis	rs911263	0.961	rs3784099	chr14:68749927	A/G	cg18825221	chr14:68749962	RAD51L1	0.53	5.92	0.52	5.15e-8	Primary biliary cholangitis;
THYM	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-5.47	-0.49	3.63e-7	Total cholesterol levels;
THYM	cis	rs6500395	0.928	rs4553627	chr16:48708801	A/T	cg04672837	chr16:48644449	N4BP1	-0.48	-4.72	-0.44	8.24e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs75064307	0.834	rs4855561	chr3:108116331	T/C	cg03329597	chr3:108125523	MYH15	0.62	4.63	0.43	1.16e-5	Intelligence (multi-trait analysis);
THYM	trans	rs1974653	0.672	rs9606256	chr22:20108500	G/A	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs4242434	0.672	rs6993302	chr8:22527457	T/C	cg21658235	chr8:22456391	C8orf58	-0.45	-4.51	-0.42	1.88e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2997447	0.655	rs11247852	chr1:26383125	C/G	cg19633962	chr1:26362018	EXTL1	0.73	4.73	0.44	7.84e-6	QRS complex (12-leadsum);
THYM	cis	rs7084402	0.967	rs1303970	chr10:60298477	G/T	cg07615347	chr10:60278583	BICC1	0.57	5.36	0.48	5.86e-7	Refractive error;
THYM	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg11905131	chr22:24372483	LOC391322	-0.96	-11.34	-0.76	2.39e-19	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs611744	0.573	rs629996	chr8:109255206	C/T	cg21045802	chr8:109455806	TTC35	0.75	7.25	0.6	1.13e-10	Dupuytren's disease;
THYM	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg02073558	chr3:44770973	ZNF501	0.67	5.39	0.48	5.15e-7	Depressive symptoms;
THYM	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.93	-0.45	3.52e-6	Monocyte count;
THYM	cis	rs17407555	0.710	rs10489071	chr4:10273549	A/G	cg00071950	chr4:10020882	SLC2A9	-0.49	-4.62	-0.43	1.21e-5	Schizophrenia (age at onset);
THYM	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg16558253	chr16:72132732	DHX38	-0.54	-4.57	-0.42	1.47e-5	Fibrinogen levels;
THYM	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03760483	chr17:6899297	ALOX12	0.68	9.18	0.69	9.55e-15	Tonsillectomy;
THYM	cis	rs988913	1.000	rs7744592	chr6:54826345	A/G	cg18532076	chr6:54711417	FAM83B	0.49	4.87	0.45	4.53e-6	Menarche (age at onset);
THYM	cis	rs4732038	0.510	rs57309811	chr7:134279208	G/A	cg06906464	chr7:134288099	NA	-0.56	-5.49	-0.49	3.31e-7	Longevity;
THYM	cis	rs4731207	0.662	rs10246553	chr7:124494934	A/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs4845875	0.600	rs4846039	chr1:11836868	A/G	cg24844545	chr1:11908347	NPPA	0.57	4.77	0.44	6.74e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs6543140	0.964	rs2160200	chr2:103033963	G/T	cg03938978	chr2:103052716	IL18RAP	0.61	6.13	0.53	1.96e-8	Blood protein levels;
THYM	cis	rs513349	1.000	rs210145	chr6:33547440	G/C	cg07679836	chr6:33548423	BAK1	0.35	4.73	0.44	7.88e-6	Platelet count;
THYM	cis	rs4606347	0.872	rs2154383	chr1:66108534	A/G	cg04111102	chr1:66153794	NA	0.59	4.54	0.42	1.67e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg00639195	chr15:79103007	ADAMTS7	0.69	4.9	0.45	3.95e-6	Diastolic blood pressure;
THYM	cis	rs926938	1.000	rs926938	chr1:115239816	A/G	cg12756093	chr1:115239321	AMPD1	-0.69	-5.79	-0.51	9.13e-8	Autism;
THYM	cis	rs4482178	0.850	rs1764955	chr13:86226160	A/G	cg25308322	chr13:86268291	NA	-0.65	-4.73	-0.44	7.88e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg06636001	chr8:8085503	FLJ10661	-0.63	-5.23	-0.47	1.01e-6	Mood instability;
THYM	cis	rs1728785	1.000	rs1749793	chr16:68569312	C/T	cg02972257	chr16:68554789	NA	-0.76	-4.76	-0.44	6.82e-6	Ulcerative colitis;
THYM	cis	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg23422044	chr7:1970798	MAD1L1	-0.77	-4.99	-0.46	2.71e-6	Bipolar disorder;
THYM	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg23422044	chr7:1970798	MAD1L1	-0.79	-5.24	-0.47	9.83e-7	Bipolar disorder;
THYM	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.18	8.61	0.66	1.54e-13	Cognitive test performance;
THYM	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.8e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs72772090	0.539	rs11135480	chr5:96110582	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-4.67	-0.43	9.81e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs56341938	0.935	rs62273762	chr3:168742523	A/G	cg09107232	chr3:169491072	MYNN	0.54	4.58	0.43	1.42e-5	Lung function (FEV1/FVC);
THYM	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs17604090	0.887	rs850013	chr7:29666530	T/C	cg19413766	chr7:29689036	LOC646762	-0.78	-4.81	-0.44	5.68e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg17063962	chr7:91808500	NA	1.1	11.9	0.77	1.56e-20	Breast cancer;
THYM	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg21644426	chr2:191273491	MFSD6	0.73	5.97	0.52	4.07e-8	Pulse pressure;
THYM	cis	rs7258465	1.000	rs8103622	chr19:18572834	C/T	cg04166595	chr19:18636596	NA	0.62	4.62	0.43	1.19e-5	Breast cancer;
THYM	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg06558623	chr16:89946397	TCF25	1.33	6.71	0.57	1.4e-9	Skin colour saturation;
THYM	cis	rs7804356	0.871	rs6964817	chr7:26756424	G/C	cg24979288	chr7:27242424	NA	0.62	4.48	0.42	2.09e-5	Type 1 diabetes;
THYM	cis	rs28595532	0.925	rs115651057	chr4:119486708	A/G	cg11846333	chr4:119757529	SEC24D	1.27	5.39	0.48	5.09e-7	Cannabis dependence symptom count;
THYM	cis	rs28595532	0.920	rs114094671	chr4:119753540	G/A	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg10760299	chr15:45669010	GATM	0.88	6.87	0.58	6.66e-10	Homoarginine levels;
THYM	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1122608	0.580	rs4804554	chr19:11083210	A/C	cg17326582	chr19:11976514	ZNF439	-0.62	-4.77	-0.44	6.65e-6	Coronary artery disease or ischemic stroke;Coronary artery disease;Coronary artery disease or large artery stroke;Coronary heart disease;Myocardial infarction (early onset);
THYM	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg27490568	chr2:178487706	NA	0.61	5.63	0.5	1.82e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg13736514	chr6:26305472	NA	-0.66	-6.8	-0.57	9.14e-10	Educational attainment;
THYM	cis	rs1823778	0.609	rs3934438	chr18:67604812	A/G	cg12929678	chr18:67624393	CD226	1.38	4.91	0.45	3.83e-6	Mean platelet volume;
THYM	cis	rs7000551	0.725	rs1075534	chr8:22374074	A/G	cg12081754	chr8:22256438	SLC39A14	0.64	5.88	0.52	6.04e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs116095464	1.000	rs55671190	chr5:287422	G/A	cg22857025	chr5:266934	NA	-1.45	-5.27	-0.48	8.45e-7	Breast cancer;
THYM	cis	rs17052344	0.582	rs111876736	chr17:21747067	A/G	cg18423549	chr17:21743878	NA	-0.68	-5.56	-0.5	2.45e-7	Cutaneous psoriasis;
THYM	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg08901578	chr4:187885870	NA	-0.64	-6.03	-0.53	3.1e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7000551	0.751	rs2449340	chr8:22389900	T/G	cg12081754	chr8:22256438	SLC39A14	0.65	5.66	0.5	1.59e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.6	-4.63	-0.43	1.17e-5	Longevity;Endometriosis;
THYM	cis	rs7084402	1.000	rs12250013	chr10:60265957	C/A	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg18105134	chr13:113819100	PROZ	-0.98	-9.05	-0.68	1.79e-14	Platelet distribution width;
THYM	cis	rs7107174	1.000	rs10899483	chr11:78061057	G/C	cg02023728	chr11:77925099	USP35	0.6	5.77	0.51	9.96e-8	Testicular germ cell tumor;
THYM	cis	rs4808199	0.947	rs7250658	chr19:19571100	A/G	cg03709012	chr19:19516395	GATAD2A	1.19	7.25	0.6	1.12e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12379764	chr21:47803548	PCNT	0.7	4.94	0.45	3.31e-6	Testicular germ cell tumor;
THYM	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg18402987	chr7:1209562	NA	1.25	8.14	0.64	1.54e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg10560079	chr2:191398806	TMEM194B	0.9	8.45	0.65	3.42e-13	Pulse pressure;
THYM	cis	rs11190604	0.767	rs3829162	chr10:102172752	T/G	cg07570687	chr10:102243282	WNT8B	0.81	7.68	0.62	1.44e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg10802521	chr3:52805072	NEK4	-0.73	-6.33	-0.54	7.99e-9	Bipolar disorder;
THYM	cis	rs4662945	1.000	rs7603887	chr2:130216073	C/T	cg05903289	chr2:130345205	NA	0.53	5.2	0.47	1.14e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs295140	0.507	rs4673814	chr2:201108133	G/A	cg17644776	chr2:200775616	C2orf69	-0.57	-4.63	-0.43	1.15e-5	QT interval;
THYM	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg11663144	chr21:46675770	NA	-0.64	-8.53	-0.66	2.28e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11840576	0.588	rs332311	chr13:110319646	C/T	cg24915592	chr13:110319578	NA	-0.78	-6.22	-0.54	1.36e-8	Paclitaxel disposition in epithelial ovarian cancer;
THYM	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11644478	chr21:40555479	PSMG1	-0.54	-4.53	-0.42	1.72e-5	Menarche (age at onset);
THYM	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg22535103	chr8:58192502	C8orf71	-0.89	-5.1	-0.46	1.73e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs11030122	0.673	rs4910590	chr11:4018619	C/T	cg18678763	chr11:4115507	RRM1	-0.45	-5.78	-0.51	9.37e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs752010	0.714	rs2148635	chr1:42082452	C/T	cg06885757	chr1:42089581	HIVEP3	-0.61	-8.13	-0.64	1.58e-12	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs35995292	0.963	rs10239557	chr7:38950137	C/T	cg19166347	chr7:37955598	SFRP4	0.61	4.85	0.45	4.8e-6	Subjective well-being (multi-trait analysis);
THYM	cis	rs4595586	0.545	rs7310463	chr12:39368927	T/C	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs2290159	0.571	rs7637392	chr3:12696433	A/G	cg23032965	chr3:12705835	RAF1	0.89	5.65	0.5	1.65e-7	Cholesterol, total;
THYM	cis	rs12134245	0.776	rs13447464	chr1:91968278	G/A	cg21854759	chr1:92012499	NA	-0.68	-5.27	-0.48	8.34e-7	Breast cancer;
THYM	cis	rs5769707	0.632	rs135876	chr22:50013573	A/G	cg23428387	chr22:49814324	NA	-0.58	-5.49	-0.49	3.39e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7575217	0.588	rs11675224	chr2:101670955	C/T	cg12594615	chr2:101643137	TBC1D8	0.59	4.77	0.44	6.63e-6	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.29	0.48	7.97e-7	Menopause (age at onset);
THYM	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg10117171	chr1:25599238	RHD	-0.75	-5.56	-0.5	2.44e-7	Plateletcrit;Mean corpuscular volume;
THYM	trans	rs10802346	0.545	rs2362253	chr1:246371676	G/A	cg13514129	chr1:39547527	MACF1	1.0	10.4	0.73	2.28e-17	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13315871	0.615	rs13066167	chr3:58340175	G/A	cg12435725	chr3:58293450	RPP14	-0.38	-4.85	-0.45	4.75e-6	Cholesterol, total;
THYM	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg12573674	chr2:1569213	NA	-1.22	-4.82	-0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg01570182	chr17:44337453	NA	-0.84	-9.31	-0.69	5.04e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg21226059	chr5:178986404	RUFY1	0.5	5.01	0.46	2.47e-6	Lung cancer;
THYM	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.58	-0.5	2.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs990171	0.913	rs2075185	chr2:103070988	A/G	cg13897122	chr2:103039542	IL18RAP	-0.43	-5.16	-0.47	1.33e-6	Lymphocyte counts;
THYM	cis	rs9807989	0.507	rs4479442	chr2:103054074	A/T	cg03938978	chr2:103052716	IL18RAP	0.75	9.86	0.71	3.25e-16	Asthma;
THYM	cis	rs7107174	0.688	rs10899501	chr11:78131408	C/T	cg02023728	chr11:77925099	USP35	0.54	4.53	0.42	1.69e-5	Testicular germ cell tumor;
THYM	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs600806	0.850	rs10858092	chr1:109943893	A/G	cg23032129	chr1:109941072	SORT1	0.6	5.12	0.46	1.63e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg11366901	chr6:160182831	ACAT2	1.01	9.03	0.68	1.91e-14	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs870825	0.698	rs2696046	chr4:185599972	G/A	cg04058563	chr4:185651563	MLF1IP	-0.98	-7.31	-0.6	8.33e-11	Blood protein levels;
THYM	cis	rs7078219	0.505	rs7916751	chr10:101285650	T/A	cg07044859	chr10:101282883	NA	-0.41	-4.71	-0.43	8.53e-6	Dental caries;
THYM	trans	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs34172651	0.917	rs11646987	chr16:24832408	G/T	cg06028605	chr16:24865363	SLC5A11	0.57	5.66	0.5	1.58e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs919433	0.783	rs787980	chr2:198239225	C/T	cg00792783	chr2:198669748	PLCL1	0.82	5.84	0.51	7.37e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2080501	0.540	rs7184732	chr16:49685986	C/T	cg03087880	chr16:49666012	ZNF423	-0.63	-7.28	-0.6	9.58e-11	IgG glycosylation;
THYM	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg18252515	chr7:66147081	NA	-0.67	-5.08	-0.46	1.86e-6	Aortic root size;
THYM	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4919087	0.923	rs11189038	chr10:98974765	A/T	cg25902810	chr10:99078978	FRAT1	0.72	4.72	0.44	8.08e-6	Monocyte count;
THYM	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs67460515	0.563	rs11717272	chr3:160810355	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-4.61	-0.43	1.27e-5	Parkinson's disease;
THYM	cis	rs1011018	0.628	rs4074826	chr7:139415943	G/A	cg06079564	chr7:139468310	HIPK2	-0.75	-4.84	-0.44	5.09e-6	Systolic blood pressure;
THYM	cis	rs1065852	0.526	rs2413663	chr22:42402399	T/A	cg08431931	chr22:42394659	WBP2NL	0.74	6.08	0.53	2.48e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg17863274	chr19:49399704	TULP2	-0.77	-4.57	-0.42	1.49e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7106204	0.534	rs7928616	chr11:24296060	T/C	ch.11.24196551F	chr11:24239977	NA	1.01	7.28	0.6	9.79e-11	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg21773646	chr17:80085082	CCDC57	-0.35	-4.89	-0.45	4.17e-6	Life satisfaction;
THYM	cis	rs714515	0.546	rs9425573	chr1:172330437	G/T	cg01573306	chr1:172330400	DNM3	-0.61	-5.43	-0.49	4.28e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs892961	0.965	rs2411111	chr17:75402540	A/T	cg11351908	chr17:75402473	SEPT9	0.62	6.12	0.53	2.13e-8	Airflow obstruction;
THYM	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg17264618	chr3:40429014	ENTPD3	0.53	5.07	0.46	1.96e-6	Renal cell carcinoma;
THYM	cis	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg10856724	chr12:34555212	NA	-0.85	-7.83	-0.63	6.91e-12	Morning vs. evening chronotype;
THYM	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg26022315	chr17:47021804	SNF8	0.51	4.87	0.45	4.44e-6	Type 2 diabetes;
THYM	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg13385794	chr1:248469461	NA	0.69	4.71	0.43	8.6e-6	Common traits (Other);
THYM	cis	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg09013696	chr11:91954554	NA	-0.73	-4.83	-0.44	5.16e-6	Subcortical brain region volumes;
THYM	cis	rs9807989	0.571	rs10208293	chr2:102966310	G/A	cg03938978	chr2:103052716	IL18RAP	0.6	5.0	0.46	2.67e-6	Asthma;
THYM	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.72	0.51	1.23e-7	Lung cancer in ever smokers;
THYM	cis	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg10856724	chr12:34555212	NA	-0.83	-7.48	-0.61	3.64e-11	Morning vs. evening chronotype;
THYM	cis	rs300703	0.654	rs401364	chr2:119493	G/A	cg21211680	chr2:198530	NA	-1.34	-7.54	-0.61	2.74e-11	Blood protein levels;
THYM	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg13395646	chr4:1353034	KIAA1530	-0.6	-5.88	-0.52	6.14e-8	Longevity;
THYM	cis	rs7809950	0.598	rs2283038	chr7:106835410	C/T	cg23024343	chr7:107201750	COG5	-1.02	-8.45	-0.66	3.29e-13	Coronary artery disease;
THYM	cis	rs887829	0.569	rs4148326	chr2:234673462	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.72	-5.74	-0.51	1.11e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs981844	0.961	rs62325084	chr4:154662603	C/T	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs9768139	0.658	rs73746486	chr7:158113191	A/G	cg24154853	chr7:158122151	PTPRN2	0.55	4.88	0.45	4.32e-6	Calcium levels;
THYM	cis	rs1568889	1.000	rs10767693	chr11:28093926	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	6.55	0.56	2.94e-9	Bipolar disorder;
THYM	cis	rs4975709	0.798	rs4975757	chr5:1882579	G/A	cg12288994	chr5:1860383	NA	0.6	4.51	0.42	1.83e-5	Cardiovascular disease risk factors;
THYM	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg08736216	chr1:53307985	ZYG11A	-0.6	-5.46	-0.49	3.79e-7	Monocyte count;
THYM	cis	rs7274811	0.901	rs1074683	chr20:32304653	C/G	cg08240466	chr20:32847653	ASIP	-0.56	-4.8	-0.44	6.01e-6	Height;
THYM	cis	rs8170	0.603	rs3810204	chr19:17448660	T/C	cg04749549	chr19:17459798	NA	-0.42	-5.12	-0.47	1.6e-6	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
THYM	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg08999081	chr20:33150536	PIGU	-0.76	-6.89	-0.58	5.96e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10905875	0.872	rs10905879	chr10:6177083	C/T	cg17191567	chr10:6178319	NA	0.61	4.46	0.42	2.24e-5	Selective IgA deficiency;
THYM	cis	rs1335645	1.000	rs4839104	chr1:111708627	G/A	cg00321911	chr1:111669324	DRAM2	-1.21	-6.15	-0.53	1.83e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs3126085	1.000	rs55957623	chr1:152223196	T/A	cg10321714	chr1:152280068	FLG	-0.76	-5.65	-0.5	1.71e-7	Atopic dermatitis;
THYM	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg18850127	chr7:39170497	POU6F2	0.53	4.82	0.44	5.39e-6	IgG glycosylation;
THYM	cis	rs12928939	0.517	rs12149307	chr16:71968091	A/C	cg03805757	chr16:71968109	PKD1L3	-1.1	-11.02	-0.75	1.11e-18	Post bronchodilator FEV1;
THYM	cis	rs9457247	0.534	rs2757053	chr6:167380338	A/C	cg15592062	chr6:167189543	RPS6KA2	0.53	5.44	0.49	4.09e-7	Crohn's disease;
THYM	cis	rs9807989	0.839	rs6543123	chr2:102977196	C/T	cg03938978	chr2:103052716	IL18RAP	0.63	6.55	0.56	2.99e-9	Asthma;
THYM	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14159672	chr1:205819179	PM20D1	-0.97	-10.33	-0.73	3.31e-17	Menarche (age at onset);
THYM	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg23982607	chr1:1823379	GNB1	-0.94	-10.03	-0.72	1.42e-16	Body mass index;
THYM	cis	rs4654899	1.000	rs10799685	chr1:21465930	A/C	cg01072550	chr1:21505969	NA	0.74	6.82	0.57	8.58e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg23711669	chr6:146136114	FBXO30	0.96	9.87	0.71	3.12e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6032067	0.929	rs17424868	chr20:43818519	T/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs13185784	0.632	rs4469167	chr5:179650964	C/T	cg23248424	chr5:179741104	GFPT2	-0.7	-4.51	-0.42	1.83e-5	TRAIL levels;
THYM	cis	rs912057	0.582	rs1294412	chr6:6739854	A/G	cg13809441	chr6:6737631	NA	0.53	6.74	0.57	1.19e-9	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg05025164	chr4:1340916	KIAA1530	0.91	7.09	0.59	2.37e-10	Longevity;
THYM	cis	rs8067235	1.000	rs58337218	chr17:79023953	C/T	cg19159404	chr17:79041535	BAIAP2	0.59	5.6	0.5	2.12e-7	Memory performance;
THYM	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg10862848	chr6:42927986	GNMT	-0.52	-6.88	-0.58	6.36e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs17443541	0.507	rs4675698	chr2:200451350	T/C	cg01795955	chr2:200468626	NA	-0.73	-4.86	-0.45	4.61e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.777	rs17332620	chr20:43777506	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.93	-0.58	5.03e-10	Blood protein levels;
THYM	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg05738196	chr6:26577821	NA	-0.58	-4.64	-0.43	1.12e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs143283559	1	rs143283559	chr18:77567761	T/G	cg13263691	chr18:77568018	NA	0.61	4.61	0.43	1.24e-5	Intelligence (multi-trait analysis);
THYM	cis	rs612683	0.764	rs558035	chr1:100939777	T/C	cg06223162	chr1:101003688	GPR88	-0.59	-5.12	-0.46	1.6e-6	Breast cancer;
THYM	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg03388043	chr17:80084554	CCDC57	-0.66	-5.67	-0.5	1.53e-7	Life satisfaction;
THYM	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg19875535	chr5:140030758	IK	0.63	5.59	0.5	2.16e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg17509989	chr5:176798049	RGS14	0.64	5.96	0.52	4.25e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg08885076	chr2:99613938	TSGA10	0.69	6.47	0.55	4.31e-9	Chronic sinus infection;
THYM	trans	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs2742234	0.541	rs7096500	chr10:43712095	C/T	cg06632098	chr10:43605906	RET	0.8	5.26	0.47	8.98e-7	Hirschsprung disease;
THYM	cis	rs977987	0.806	rs11864102	chr16:75442360	C/T	cg03315344	chr16:75512273	CHST6	0.76	6.0	0.52	3.57e-8	Dupuytren's disease;
THYM	cis	rs357618	0.531	rs7723079	chr5:150886616	G/A	cg24040989	chr5:149979572	SYNPO	-0.46	-4.71	-0.44	8.43e-6	Basophil percentage of white cells;
THYM	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs7524258	0.900	rs7544004	chr1:7314529	A/C	cg07173049	chr1:7289937	CAMTA1	0.71	5.62	0.5	1.88e-7	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs1403694	0.695	rs3774291	chr3:186433471	C/T	cg12454167	chr3:186435060	KNG1	0.51	7.04	0.59	2.94e-10	Blood protein levels;
THYM	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg02825527	chr7:2087843	MAD1L1	-0.7	-4.55	-0.42	1.58e-5	Bipolar disorder;
THYM	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.83	0.67	5.15e-14	Colorectal cancer;
THYM	cis	rs4901869	0.966	rs60800733	chr14:59337778	A/G	cg02291164	chr14:59296302	NA	0.8	7.85	0.63	6.35e-12	Panic disorder;
THYM	cis	rs1018836	0.923	rs6999898	chr8:91650549	G/A	cg16814680	chr8:91681699	NA	-1.02	-9.94	-0.71	2.24e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg10295955	chr4:187884368	NA	1.17	16.12	0.86	6.25e-29	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg16524733	chr11:117070046	TAGLN	-0.42	-4.85	-0.45	4.83e-6	Blood protein levels;
THYM	cis	rs17407555	0.909	rs73222546	chr4:10244074	A/G	cg11266682	chr4:10021025	SLC2A9	-0.53	-4.91	-0.45	3.75e-6	Schizophrenia (age at onset);
THYM	cis	rs6032067	0.777	rs34073275	chr20:43788917	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg13447684	chr7:1895903	MAD1L1	-0.55	-5.1	-0.46	1.76e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg22875332	chr1:76189707	ACADM	-0.91	-9.4	-0.69	3.19e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	trans	rs1974653	0.631	rs41281423	chr22:20097730	C/T	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.61	5.3	0.48	7.56e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7584330	0.554	rs77648388	chr2:238431832	G/C	cg08992911	chr2:238395768	MLPH	1.15	6.79	0.57	9.88e-10	Prostate cancer;
THYM	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg06636001	chr8:8085503	FLJ10661	-0.75	-7.2	-0.59	1.43e-10	Neuroticism;
THYM	cis	rs6981523	0.524	rs4326351	chr8:10907154	G/A	cg16664915	chr8:10907788	XKR6	0.56	4.52	0.42	1.76e-5	Neuroticism;
THYM	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg06558623	chr16:89946397	TCF25	1.15	6.38	0.55	6.37e-9	Skin colour saturation;
THYM	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs5760092	0.717	rs5760101	chr22:24248712	T/C	cg10150615	chr22:24372951	LOC391322	-0.9	-7.54	-0.61	2.71e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs2074585	0.713	rs2589941	chr15:90931457	C/T	cg22089800	chr15:90895588	ZNF774	0.69	5.4	0.48	5e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
THYM	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg23711669	chr6:146136114	FBXO30	0.97	10.74	0.74	4.42e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg02734326	chr4:10020555	SLC2A9	-0.7	-6.19	-0.54	1.54e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg07362569	chr17:61921086	SMARCD2	0.72	6.37	0.55	6.65e-9	Prudent dietary pattern;
THYM	cis	rs950880	0.710	rs12469506	chr2:102965871	C/T	cg03938978	chr2:103052716	IL18RAP	-0.53	-4.62	-0.43	1.23e-5	Serum protein levels (sST2);
THYM	cis	rs7107174	1.000	rs2511178	chr11:77923220	C/T	cg02023728	chr11:77925099	USP35	0.67	6.04	0.53	3.04e-8	Testicular germ cell tumor;
THYM	cis	rs3819817	0.575	rs7961807	chr12:96356807	C/T	cg26410635	chr12:96350720	AMDHD1	0.53	5.02	0.46	2.38e-6	Vitamin D levels;
THYM	cis	rs12348691	0.503	rs7848950	chr9:100612774	T/C	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Alopecia areata;
THYM	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg02463440	chr8:22132932	PIWIL2	0.59	5.02	0.46	2.41e-6	Hypertriglyceridemia;
THYM	cis	rs909002	0.800	rs3753612	chr1:32082410	C/G	cg13919466	chr1:32135498	COL16A1	-0.5	-5.06	-0.46	2.01e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7177699	0.557	rs7178051	chr15:79118296	A/G	cg00540400	chr15:79124168	NA	0.64	6.81	0.57	8.61e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs977987	0.762	rs1364079	chr16:75393131	C/A	cg03315344	chr16:75512273	CHST6	0.71	6.08	0.53	2.54e-8	Dupuytren's disease;
THYM	cis	rs4072705	1.000	rs10818983	chr9:127411577	T/A	cg13476313	chr9:127244764	NR5A1	0.32	5.0	0.46	2.6e-6	Menarche (age at onset);
THYM	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg16850897	chr7:100343110	ZAN	-0.71	-5.46	-0.49	3.85e-7	Other erythrocyte phenotypes;
THYM	cis	rs3862030	0.668	rs12781718	chr10:104227433	G/A	cg00122347	chr10:104236741	TMEM180	0.48	7.24	0.6	1.14e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs55728055	0.661	rs62237798	chr22:31976839	G/T	cg10537193	chr22:32026975	PISD	-0.87	-5.53	-0.49	2.78e-7	Age-related hearing impairment;
THYM	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.96	-8.0	-0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs7781977	0.695	rs6583437	chr7:50350267	C/T	cg01139861	chr7:50343298	IKZF1	0.62	5.9	0.52	5.68e-8	IgG glycosylation;
THYM	cis	rs6138458	1.000	rs6114981	chr20:24974401	C/T	cg06937882	chr20:24974362	C20orf3	0.46	4.58	0.43	1.43e-5	Blood protein levels;
THYM	cis	rs748404	0.690	rs2467737	chr15:43737188	G/A	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg07460842	chr6:66804631	NA	0.81	4.87	0.45	4.52e-6	Exhaled nitric oxide output;
THYM	trans	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10779751	0.881	rs2744815	chr1:11360957	C/T	cg08854313	chr1:11322531	MTOR	0.88	8.07	0.64	2.15e-12	Body mass index;
THYM	trans	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg08470875	chr2:26401718	FAM59B	0.74	4.59	0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg07648498	chr16:89883185	FANCA	-0.61	-4.58	-0.43	1.41e-5	Vitiligo;
THYM	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg19875535	chr5:140030758	IK	0.58	4.46	0.42	2.21e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg18305652	chr10:134549665	INPP5A	0.81	6.6	0.56	2.3e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg13607699	chr17:42295918	UBTF	-0.57	-4.8	-0.44	5.97e-6	Total body bone mineral density;
THYM	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg13683864	chr3:40499215	RPL14	-0.88	-8.67	-0.66	1.14e-13	Renal cell carcinoma;
THYM	cis	rs977747	0.872	rs12145836	chr1:47672289	A/T	cg03885399	chr1:47691550	TAL1	-0.47	-4.47	-0.42	2.14e-5	Body mass index;
THYM	cis	rs6570726	0.791	rs448939	chr6:145808320	T/C	cg23711669	chr6:146136114	FBXO30	0.88	8.31	0.65	6.52e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs79349575	0.783	rs62075820	chr17:46983171	G/C	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg24675658	chr1:53192096	ZYG11B	0.78	7.02	0.58	3.33e-10	Monocyte count;
THYM	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg03351412	chr1:154909251	PMVK	0.71	5.6	0.5	2.12e-7	Prostate cancer;
THYM	cis	rs17102423	1.000	rs4902364	chr14:65602006	G/A	cg11161011	chr14:65562177	MAX	-0.74	-6.52	-0.56	3.43e-9	Obesity-related traits;
THYM	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	8.42	0.65	3.98e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.04	7.56	0.61	2.56e-11	Smoking behavior;
THYM	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg17143192	chr8:8559678	CLDN23	0.65	4.85	0.45	4.78e-6	Mood instability;
THYM	cis	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.76	0.44	7.03e-6	Obesity-related traits;
THYM	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg00677455	chr12:58241039	CTDSP2	0.72	5.27	0.48	8.57e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg07414643	chr4:187882934	NA	0.57	4.95	0.45	3.16e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs34779708	0.966	rs12774834	chr10:35400070	A/T	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg13531842	chr10:38383804	ZNF37A	0.58	4.81	0.44	5.74e-6	Extrinsic epigenetic age acceleration;
THYM	cis	rs3780378	0.875	rs7032785	chr9:5042046	C/T	cg02405213	chr9:5042618	JAK2	-0.78	-7.34	-0.6	7.17e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs3780378	1.000	rs7847294	chr9:5097281	A/C	cg02405213	chr9:5042618	JAK2	-0.71	-5.8	-0.51	8.65e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs6815814	0.898	rs6848423	chr4:38887933	C/T	cg14665413	chr4:38859728	TLR6	-0.4	-4.82	-0.44	5.43e-6	Breast cancer;
THYM	cis	rs12282928	1.000	rs10838845	chr11:48280299	C/T	cg22827986	chr11:48284249	OR4X1	0.52	5.49	0.49	3.27e-7	Migraine - clinic-based;
THYM	cis	rs7020830	0.898	rs2047010	chr9:37077947	A/G	cg14294708	chr9:37120828	ZCCHC7	1.28	16.29	0.86	2.92e-29	Schizophrenia;
THYM	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg06112835	chr11:68658793	MRPL21	0.43	6.43	0.55	5.19e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.23	-10.06	-0.72	1.25e-16	Platelet count;
THYM	cis	rs34526934	0.608	rs72927183	chr2:177033779	C/T	cg26754761	chr2:177040938	NA	-0.74	-6.44	-0.55	4.95e-9	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.05	10.71	0.74	5.06e-18	Intelligence (multi-trait analysis);
THYM	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	8.21	0.64	1.1e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7107174	1.000	rs11601196	chr11:78043431	A/C	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs1371867	0.846	rs1660349	chr8:101319326	G/A	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg10295955	chr4:187884368	NA	-1.19	-17.25	-0.87	5.06e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs67981189	1.000	rs67981189	chr14:71472226	A/G	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.0	10.07	0.72	1.18e-16	Cognitive ability;
THYM	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg00191853	chr8:101177733	SPAG1	0.65	6.81	0.57	8.98e-10	Atrioventricular conduction;
THYM	cis	rs7428	0.527	rs3184780	chr2:85549547	C/T	cg24342717	chr2:85555507	TGOLN2	-0.77	-6.63	-0.56	2.06e-9	Ear protrusion;
THYM	cis	rs28795989	0.795	rs4696746	chr4:7904945	G/T	cg00251875	chr4:7801337	AFAP1	0.61	4.93	0.45	3.53e-6	Intraocular pressure;
THYM	trans	rs12439619	0.883	rs62012045	chr15:82521707	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.83	-7.11	-0.59	2.1e-10	Intelligence (multi-trait analysis);
THYM	cis	rs4940575	0.679	rs7230053	chr18:60836185	T/A	cg20947866	chr18:61143580	SERPINB5	0.87	5.15	0.47	1.38e-6	Breast cancer;
THYM	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg00383909	chr3:49044727	WDR6	1.12	6.62	0.56	2.13e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg23018236	chr17:30244563	NA	-0.6	-4.45	-0.42	2.3e-5	Hip circumference adjusted for BMI;
THYM	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg18876405	chr7:65276391	NA	0.76	7.17	0.59	1.61e-10	Aortic root size;
THYM	cis	rs12257961	0.548	rs10796274	chr10:15341575	T/C	cg10616319	chr10:15468812	NA	-0.59	-4.79	-0.44	6.05e-6	Selective IgA deficiency;
THYM	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg06558623	chr16:89946397	TCF25	1.33	5.65	0.5	1.64e-7	Skin colour saturation;
THYM	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg09877947	chr5:131593287	PDLIM4	0.52	4.63	0.43	1.16e-5	Blood metabolite levels;
THYM	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg00645579	chr11:617140	IRF7;MUPCDH	-0.52	-6.46	-0.55	4.44e-9	Systemic lupus erythematosus;
THYM	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg16586182	chr3:47516702	SCAP	-0.63	-5.6	-0.5	2.12e-7	Colorectal cancer;
THYM	cis	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg09307838	chr4:120376055	NA	0.69	4.64	0.43	1.1e-5	Corneal astigmatism;
THYM	cis	rs6430585	0.640	rs58301703	chr2:136532225	G/A	cg23851026	chr2:136556271	LCT	0.79	7.53	0.61	2.86e-11	Corneal structure;
THYM	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg12935359	chr14:103987150	CKB	-0.65	-6.4	-0.55	5.78e-9	Body mass index;
THYM	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.12	-6.13	-0.53	2.02e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7607369	0.637	rs17462630	chr2:219286541	C/G	cg02176678	chr2:219576539	TTLL4	-0.66	-5.73	-0.51	1.19e-7	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs12478296	0.901	rs67951957	chr2:243004901	A/G	cg06360820	chr2:242988706	NA	-0.97	-6.62	-0.56	2.16e-9	Obesity-related traits;
THYM	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg00024416	chr22:24240387	NA	0.72	7.69	0.62	1.32e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs17597773	0.674	rs10863568	chr1:221018079	C/G	cg16008148	chr1:221062819	NA	0.45	4.54	0.42	1.67e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg10856724	chr12:34555212	NA	-1.06	-10.24	-0.72	4.96e-17	Morning vs. evening chronotype;
THYM	cis	rs995000	0.868	rs9787151	chr1:63179138	C/T	cg06896770	chr1:63153194	DOCK7	-0.69	-4.89	-0.45	4.15e-6	Triglyceride levels;
THYM	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg09359103	chr1:154839909	KCNN3	-0.51	-5.16	-0.47	1.36e-6	Prostate cancer;
THYM	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-5.4	-0.48	4.89e-7	Chronic sinus infection;
THYM	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs67460515	0.892	rs73026974	chr3:160963231	A/C	cg03342759	chr3:160939853	NMD3	-0.93	-7.98	-0.63	3.34e-12	Parkinson's disease;
THYM	cis	rs4953076	0.573	rs6544746	chr2:44407985	C/T	cg04920474	chr2:44395004	PPM1B	0.66	5.76	0.51	1.05e-7	Height;
THYM	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7843479	1.000	rs67385415	chr8:21853733	T/C	cg17168535	chr8:21777572	XPO7	0.7	5.06	0.46	2.07e-6	Mean corpuscular volume;
THYM	cis	rs983545	0.548	rs34149515	chr3:16953337	A/G	cg24159436	chr3:16974681	PLCL2	0.31	5.02	0.46	2.4e-6	Blood protein levels;
THYM	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg19077165	chr18:44547161	KATNAL2	-0.66	-8.3	-0.65	7.02e-13	Personality dimensions;
THYM	cis	rs4589258	0.762	rs4360665	chr11:90409950	T/C	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2637266	0.756	rs2245335	chr10:78553265	T/C	cg18941641	chr10:78392320	NA	0.72	5.69	0.5	1.4e-7	Pulmonary function;
THYM	cis	rs8014204	0.566	rs12587457	chr14:75164141	C/T	cg06637938	chr14:75390232	RPS6KL1	0.57	5.06	0.46	2.02e-6	Caffeine consumption;
THYM	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	4.92	0.45	3.59e-6	Prudent dietary pattern;
THYM	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg12179176	chr11:130786555	SNX19	0.89	8.25	0.65	8.93e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg03060546	chr3:49711283	APEH	-0.67	-5.39	-0.48	5.13e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs1018836	0.923	rs13268594	chr8:91588545	G/T	cg16814680	chr8:91681699	NA	-0.76	-6.33	-0.54	7.97e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6980334	1.000	rs6977075	chr7:137775867	C/T	cg18769353	chr7:137028617	PTN	-0.63	-5.06	-0.46	2.01e-6	Blood metabolite ratios;
THYM	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	14.79	0.83	2.2e-26	Chronic sinus infection;
THYM	cis	rs9814567	1.000	rs6806417	chr3:134211446	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.98	8.4	0.65	4.31e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7432375	0.901	rs1681817	chr3:136473728	C/T	cg21827317	chr3:136751795	NA	-0.61	-5.58	-0.5	2.29e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs7267979	1.000	rs2257991	chr20:25270339	C/T	cg08601574	chr20:25228251	PYGB	-0.57	-4.61	-0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2282930	0.512	rs9886137	chr7:50706927	C/T	cg08586669	chr7:50727761	GRB10	0.31	4.77	0.44	6.66e-6	Bone mineral density;
THYM	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg13695892	chr22:41940480	POLR3H	-0.89	-7.18	-0.59	1.57e-10	Vitiligo;
THYM	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg00129232	chr17:37814104	STARD3	-0.87	-7.23	-0.6	1.23e-10	Asthma;
THYM	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg16586182	chr3:47516702	SCAP	-0.6	-5.12	-0.46	1.6e-6	Colorectal cancer;
THYM	cis	rs10992471	0.535	rs10117041	chr9:95282331	A/G	cg14631576	chr9:95140430	CENPP	-0.96	-9.19	-0.69	9.02e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.6	-7.54	-0.61	2.81e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs2073300	1.000	rs6114098	chr20:23444276	G/A	cg12062639	chr20:23401060	NAPB	1.32	6.06	0.53	2.7e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7584330	0.518	rs74003109	chr2:238448150	C/T	cg08992911	chr2:238395768	MLPH	0.9	5.44	0.49	4.18e-7	Prostate cancer;
THYM	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg13319975	chr6:146136371	FBXO30	-0.66	-5.33	-0.48	6.53e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17321999	1.000	rs4952115	chr2:30478386	G/T	cg05247661	chr2:30472410	LBH	0.65	4.77	0.44	6.63e-6	Systemic lupus erythematosus;
THYM	cis	rs7917772	0.582	rs10786695	chr10:104368756	A/C	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs665401	0.692	rs2274911	chr6:117130704	G/A	cg20376953	chr6:117187980	NA	-0.61	-4.77	-0.44	6.56e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	7.96	0.63	3.67e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg22166914	chr1:53195759	ZYG11B	0.81	8.58	0.66	1.76e-13	Monocyte count;
THYM	cis	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.56	-0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7894051	0.764	rs1049951	chr10:135184126	G/A	cg12428399	chr10:135191333	PAOX	-0.97	-4.53	-0.42	1.7e-5	Lifespan;
THYM	cis	rs4866334	1.000	rs75023127	chr5:18487706	A/G	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs17453880	0.929	rs4385197	chr5:152047146	G/A	cg12297329	chr5:152029980	NA	-0.59	-4.48	-0.42	2.06e-5	Subjective well-being;
THYM	cis	rs76798021	0.745	rs11707976	chr3:53668708	A/G	cg21503701	chr3:53781065	CACNA1D	-0.62	-4.71	-0.44	8.47e-6	Lung function (FEV1/FVC);
THYM	cis	rs11711311	1.000	rs4362695	chr3:113534856	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.62	-5.39	-0.48	5.11e-7	IgG glycosylation;
THYM	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg21361702	chr7:150065534	REPIN1	0.65	4.76	0.44	6.91e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs76878669	0.561	rs11227465	chr11:66115879	T/A	cg18002602	chr11:66138449	SLC29A2	-0.49	-4.81	-0.44	5.56e-6	Educational attainment (years of education);
THYM	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg25588787	chr5:154027256	NA	-0.9	-4.6	-0.43	1.32e-5	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs6547741	1.000	rs10165098	chr2:27796526	C/T	cg27432699	chr2:27873401	GPN1	0.68	5.97	0.52	4.14e-8	Oral cavity cancer;
THYM	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg08916839	chr5:415575	AHRR	1.16	7.02	0.58	3.25e-10	Fat distribution (HIV);
THYM	cis	rs2976388	0.609	rs2585145	chr8:143799457	G/A	cg06565975	chr8:143823917	SLURP1	0.5	5.62	0.5	1.9e-7	Urinary tract infection frequency;
THYM	cis	rs8014204	0.935	rs2300596	chr14:75353855	C/T	cg06637938	chr14:75390232	RPS6KL1	0.59	5.9	0.52	5.57e-8	Caffeine consumption;
THYM	cis	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs7103648	0.669	rs7114011	chr11:47811309	A/C	cg20307385	chr11:47447363	PSMC3	0.81	6.61	0.56	2.2e-9	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs2404602	0.622	rs11632670	chr15:76974055	A/G	cg23625390	chr15:77176239	SCAPER	-0.77	-5.54	-0.49	2.64e-7	Blood metabolite levels;
THYM	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg18252515	chr7:66147081	NA	0.72	5.64	0.5	1.73e-7	Aortic root size;
THYM	cis	rs12946454	0.621	rs11651809	chr17:43255681	C/G	cg00677574	chr17:43221327	ACBD4	0.56	4.7	0.43	8.62e-6	Systolic blood pressure;
THYM	cis	rs887829	0.569	rs4663965	chr2:234650604	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.64	-4.95	-0.45	3.25e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs11148252	0.514	rs2296347	chr13:52728423	A/C	cg00495681	chr13:53174319	NA	-0.68	-5.95	-0.52	4.54e-8	Lewy body disease;
THYM	cis	rs9814567	1.000	rs7433991	chr3:134312292	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.5	-0.66	2.69e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6450176	0.909	rs1541681	chr5:53304620	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-6.2	-0.54	1.45e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs12643440	0.538	rs2041441	chr4:17136036	C/T	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs4866334	0.867	rs78373067	chr5:18463912	A/G	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg04362960	chr10:104952993	NT5C2	0.59	4.95	0.45	3.16e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg04398451	chr17:18023971	MYO15A	0.82	7.91	0.63	4.72e-12	Total body bone mineral density;
THYM	cis	rs4242434	0.819	rs6558167	chr8:22473850	T/C	cg21658235	chr8:22456391	C8orf58	0.43	4.5	0.42	1.95e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs684232	0.666	rs838371	chr17:609275	T/C	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.39	-4.72	-0.44	8.25e-6	Prostate cancer;
THYM	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs9880211	1.000	rs9809988	chr3:136522221	C/G	cg21827317	chr3:136751795	NA	-0.71	-4.84	-0.44	5.12e-6	Body mass index;Height;
THYM	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	9.4	0.69	3.1e-15	Chronic sinus infection;
THYM	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs7586879	0.551	rs7565460	chr2:25130073	C/T	cg27107076	chr2:25050844	ADCY3	-0.29	-4.73	-0.44	7.91e-6	Body mass index;
THYM	cis	rs10463554	0.963	rs17154959	chr5:102356291	G/A	cg23492399	chr5:102201601	PAM	-0.69	-5.24	-0.47	9.68e-7	Parkinson's disease;
THYM	cis	rs34638657	0.872	rs2967349	chr16:82194405	G/C	cg19807685	chr16:82068980	HSD17B2	-0.66	-5.14	-0.47	1.47e-6	Lung adenocarcinoma;
THYM	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg23791538	chr6:167370224	RNASET2	-0.59	-4.66	-0.43	1.04e-5	Crohn's disease;
THYM	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg22535103	chr8:58192502	C8orf71	-1.02	-6.26	-0.54	1.12e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg03859395	chr2:55845619	SMEK2	0.65	6.04	0.53	3.03e-8	Metabolic syndrome;
THYM	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg00012203	chr2:219082015	ARPC2	-0.65	-5.32	-0.48	6.78e-7	Colorectal cancer;
THYM	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs41271473	0.526	rs942852	chr1:228730748	A/G	cg10167378	chr1:228756711	NA	0.77	4.58	0.43	1.38e-5	Chronic lymphocytic leukemia;
THYM	cis	rs9814567	0.806	rs9839705	chr3:134323819	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.09e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7809950	0.798	rs2701684	chr7:107299527	C/T	cg23024343	chr7:107201750	COG5	0.65	5.59	0.5	2.19e-7	Coronary artery disease;
THYM	cis	rs72772090	0.539	rs11748519	chr5:96119328	C/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg06221963	chr1:154839813	KCNN3	-0.73	-8.8	-0.67	6.09e-14	Prostate cancer;
THYM	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg21394778	chr1:3037102	PRDM16	0.46	4.47	0.42	2.12e-5	Height;
THYM	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg18850127	chr7:39170497	POU6F2	0.56	5.2	0.47	1.15e-6	IgG glycosylation;
THYM	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg18681998	chr4:17616180	MED28	0.97	9.52	0.7	1.74e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg10515332	chr4:99064459	C4orf37	0.66	5.17	0.47	1.29e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg17366294	chr4:99064904	C4orf37	0.54	6.33	0.54	8.05e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs870825	0.655	rs28726376	chr4:185638954	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.64	0.56	1.92e-9	Prudent dietary pattern;
THYM	cis	rs4363385	0.765	rs3806221	chr1:153002555	G/T	cg13444842	chr1:152974279	SPRR3	-0.59	-4.81	-0.44	5.61e-6	Inflammatory skin disease;
THYM	cis	rs7909074	0.832	rs10793564	chr10:45386352	C/A	cg04218760	chr10:45406644	TMEM72	-0.68	-6.12	-0.53	2.07e-8	Mean corpuscular volume;
THYM	cis	rs4285028	0.948	rs13083557	chr3:121687613	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs11792861	0.591	rs11791855	chr9:111684139	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.81	6.56	0.56	2.82e-9	Menarche (age at onset);
THYM	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg03433033	chr1:76189801	ACADM	-0.65	-6.0	-0.52	3.54e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6835098	1.000	rs10027708	chr4:174083116	T/C	cg08422745	chr4:174089978	GALNT7	-0.97	-8.28	-0.65	7.55e-13	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg23711669	chr6:146136114	FBXO30	0.96	10.29	0.73	3.99e-17	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.35	-0.73	2.93e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg06713675	chr4:122721982	EXOSC9	-0.86	-9.81	-0.71	4.29e-16	Type 2 diabetes;
THYM	cis	rs6980334	1.000	rs7787591	chr7:137778203	C/T	cg06915773	chr7:137028165	PTN	0.58	4.79	0.44	6.22e-6	Blood metabolite ratios;
THYM	cis	rs9486719	0.947	rs12213375	chr6:96902134	A/G	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg01751800	chr4:77820391	ANKRD56	0.56	4.68	0.43	9.67e-6	Emphysema distribution in smoking;
THYM	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg06636001	chr8:8085503	FLJ10661	0.64	5.28	0.48	8.07e-7	Mood instability;
THYM	cis	rs7616559	0.629	rs1482857	chr3:156754537	G/A	cg15697575	chr3:156784781	NA	0.46	6.65	0.56	1.82e-9	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg13319975	chr6:146136371	FBXO30	0.7	5.77	0.51	1.01e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2562456	0.917	rs2681392	chr19:21695987	T/G	cg21751540	chr19:21541537	ZNF738	0.7	4.89	0.45	4.11e-6	Pain;
THYM	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg23711669	chr6:146136114	FBXO30	0.85	7.92	0.63	4.52e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28829049	0.861	rs67113006	chr1:19376566	A/G	cg13387374	chr1:19411106	UBR4	0.67	5.54	0.49	2.65e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-5.1	-0.46	1.74e-6	Lymphocyte counts;
THYM	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	trans	rs9929218	1.000	rs12446575	chr16:68791644	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.84	-6.86	-0.58	6.96e-10	Colorectal cancer;
THYM	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg17063962	chr7:91808500	NA	1.16	12.78	0.8	2.34e-22	Breast cancer;
THYM	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg12667521	chr19:29218732	NA	0.86	7.18	0.59	1.56e-10	Methadone dose in opioid dependence;
THYM	cis	rs4363385	0.553	rs28924721	chr1:152974254	C/T	cg13444842	chr1:152974279	SPRR3	-0.64	-4.86	-0.45	4.7e-6	Inflammatory skin disease;
THYM	cis	rs981844	0.816	rs62325147	chr4:154727568	G/A	cg09973105	chr4:154681532	RNF175	-0.66	-5.45	-0.49	3.98e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg13683864	chr3:40499215	RPL14	-0.91	-8.85	-0.67	4.82e-14	Renal cell carcinoma;
THYM	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg21775007	chr8:11205619	TDH	0.69	5.32	0.48	6.98e-7	Retinal vascular caliber;
THYM	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg27534772	chr1:16042836	PLEKHM2	0.56	6.22	0.54	1.32e-8	Systolic blood pressure;
THYM	cis	rs12368653	0.582	rs2307095	chr12:58026001	G/A	cg12615879	chr12:58013172	SLC26A10	0.62	6.27	0.54	1.06e-8	Multiple sclerosis;
THYM	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.56	-5.25	-0.47	9.2e-7	Lymphocyte counts;
THYM	cis	rs6785206	0.614	rs13065032	chr3:128510594	A/G	cg16766828	chr3:128327626	NA	0.46	4.54	0.42	1.62e-5	Lymphocyte percentage of white cells;
THYM	cis	rs12216545	0.765	rs1851435	chr7:150228785	A/T	cg08960815	chr7:150264767	GIMAP4	-0.89	-8.27	-0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs3126085	0.935	rs1552995	chr1:152171427	A/G	cg26020982	chr1:152196106	HRNR	0.37	5.06	0.46	2.05e-6	Atopic dermatitis;
THYM	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg04842962	chr6:43655489	MRPS18A	0.88	7.39	0.6	5.6e-11	IgG glycosylation;
THYM	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg27534772	chr1:16042836	PLEKHM2	0.56	6.24	0.54	1.23e-8	Systolic blood pressure;
THYM	cis	rs7246657	0.943	rs7253091	chr19:37967214	C/T	cg22634378	chr19:37742834	NA	0.6	5.05	0.46	2.1e-6	Coronary artery calcification;
THYM	cis	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.64	0.43	1.12e-5	Obesity-related traits;
THYM	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.94	0.58	4.68e-10	Prudent dietary pattern;
THYM	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.2	8.28	0.65	7.89e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4974559	0.585	rs1680025	chr4:1265477	T/C	cg02980000	chr4:1222292	CTBP1	-0.7	-4.47	-0.42	2.2e-5	Systolic blood pressure;
THYM	cis	rs425535	0.757	rs599746	chr4:74778235	C/T	cg07868155	chr4:74864709	CXCL5	0.66	4.67	0.43	1.01e-5	Blood protein levels;
THYM	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg06547715	chr2:218990976	CXCR2	0.46	4.85	0.45	4.9e-6	Ulcerative colitis;
THYM	cis	rs593982	1.000	rs56257941	chr11:65505641	C/T	cg08755490	chr11:65554678	OVOL1	-1.44	-7.91	-0.63	4.57e-12	Atopic dermatitis;
THYM	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg14829155	chr15:31115871	NA	0.52	4.88	0.45	4.27e-6	Huntington's disease progression;
THYM	cis	rs1568889	1.000	rs11826837	chr11:28322566	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.69	-4.5	-0.42	1.95e-5	Bipolar disorder;
THYM	cis	rs8067545	0.611	rs2526466	chr17:20165251	C/T	cg13482628	chr17:19912719	NA	-0.56	-4.6	-0.43	1.32e-5	Schizophrenia;
THYM	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg00277334	chr10:82204260	NA	-0.54	-5.51	-0.49	3.03e-7	Post bronchodilator FEV1;
THYM	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg11812906	chr14:75593930	NEK9	-0.8	-7.19	-0.59	1.48e-10	Height;
THYM	cis	rs4731207	0.724	rs10257255	chr7:124479678	C/T	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg12863693	chr15:85201151	NMB	-0.63	-5.57	-0.5	2.34e-7	Schizophrenia;
THYM	cis	rs909002	0.886	rs11807225	chr1:32083193	G/C	cg13919466	chr1:32135498	COL16A1	-0.49	-4.56	-0.42	1.54e-5	Intelligence (multi-trait analysis);
THYM	cis	rs951188	0.793	rs79127914	chr2:150350496	G/A	cg17961725	chr2:150454027	NA	-0.98	-4.95	-0.45	3.23e-6	Daytime sleep phenotypes;
THYM	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg23730037	chr7:158596552	ESYT2	0.42	4.51	0.42	1.89e-5	Height;
THYM	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.1	-6.31	-0.54	8.97e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1692120	0.669	rs10897172	chr11:61427469	G/A	cg23976388	chr11:61510081	DAGLA	0.5	4.5	0.42	1.94e-5	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
THYM	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs6591182	0.503	rs11227241	chr11:65389890	G/C	cg27068330	chr11:65405492	SIPA1	-0.9	-8.27	-0.65	7.96e-13	Non-alcoholic fatty liver disease histology (lobular);
THYM	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg08847533	chr14:75593920	NEK9	-0.95	-9.91	-0.71	2.54e-16	Height;
THYM	cis	rs7940866	0.903	rs2324316	chr11:130872353	G/T	cg23692386	chr11:131799662	NTM	0.45	4.78	0.44	6.45e-6	Schizophrenia;
THYM	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg11663144	chr21:46675770	NA	-0.71	-9.92	-0.71	2.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs629535	0.814	rs652483	chr8:70055083	G/A	cg21567404	chr3:27674614	NA	1.11	10.64	0.74	7.17e-18	Dupuytren's disease;
THYM	cis	rs6500395	0.926	rs1039343	chr16:48577507	T/G	cg04672837	chr16:48644449	N4BP1	0.49	4.79	0.44	6.02e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs889398	0.802	rs12921407	chr16:69860933	T/C	cg09409435	chr16:70099608	PDXDC2	-0.62	-4.89	-0.45	4.03e-6	Body mass index;
THYM	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-4.5	-0.42	1.92e-5	Hemoglobin concentration;
THYM	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11644478	chr21:40555479	PSMG1	1.1	9.84	0.71	3.61e-16	Cognitive function;
THYM	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7941600	0.708	rs12287120	chr11:9311760	C/T	cg21110646	chr11:9336536	TMEM41B	1.33	7.96	0.63	3.58e-12	Coronary artery disease;
THYM	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg26384229	chr12:38710491	ALG10B	1.03	9.92	0.71	2.51e-16	Heart rate;
THYM	cis	rs2115630	1.000	rs11854291	chr15:85363708	T/C	cg11189052	chr15:85197271	WDR73	-0.6	-4.59	-0.43	1.35e-5	P wave terminal force;
THYM	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg24324837	chr19:49891574	CCDC155	0.65	6.24	0.54	1.22e-8	Multiple sclerosis;
THYM	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg12310025	chr6:25882481	NA	0.94	8.66	0.66	1.23e-13	Blood metabolite levels;
THYM	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg21028142	chr17:79581711	NPLOC4	0.65	6.66	0.56	1.75e-9	Eye color traits;
THYM	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7973719	0.966	rs1450962	chr12:7320545	A/G	cg07052231	chr12:7363540	PEX5	0.64	5.44	0.49	4.15e-7	IgG glycosylation;
THYM	cis	rs7326068	0.610	rs8000601	chr13:21339384	G/A	cg02792322	chr13:21280448	IL17D	-0.64	-4.46	-0.42	2.27e-5	Schizophrenia, bipolar disorder and depression (combined);
THYM	cis	rs2862064	1.000	rs11747316	chr5:156422948	A/G	cg12943317	chr5:156479607	HAVCR1	-0.84	-5.0	-0.46	2.58e-6	Platelet count;
THYM	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.95	8.52	0.66	2.34e-13	Colorectal cancer;
THYM	cis	rs10463554	0.963	rs7721530	chr5:102362192	T/C	cg23492399	chr5:102201601	PAM	-0.67	-5.18	-0.47	1.26e-6	Parkinson's disease;
THYM	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.68	0.43	9.51e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12472274	0.646	rs11688732	chr2:239096622	G/T	cg17459225	chr2:239074497	NA	0.74	5.12	0.47	1.57e-6	Phospholipid levels (plasma);
THYM	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg20476274	chr7:133979776	SLC35B4	0.67	4.62	0.43	1.22e-5	Mean platelet volume;
THYM	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg00533182	chr8:145726136	PPP1R16A	-0.61	-4.67	-0.43	9.78e-6	Age at first birth;
THYM	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg23711669	chr6:146136114	FBXO30	0.91	9.57	0.7	1.4e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg02734326	chr4:10020555	SLC2A9	-0.62	-5.04	-0.46	2.21e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7941600	0.581	rs11042273	chr11:9322132	T/G	cg19415743	chr11:9336845	TMEM41B	1.12	5.54	0.49	2.65e-7	Coronary artery disease;
THYM	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9527	0.615	rs3897401	chr10:104696379	T/C	cg04362960	chr10:104952993	NT5C2	0.6	4.62	0.43	1.2e-5	Arsenic metabolism;
THYM	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg23730037	chr7:158596552	ESYT2	-0.5	-5.07	-0.46	1.98e-6	Height;
THYM	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg14345882	chr6:26364793	BTN3A2	0.62	5.7	0.5	1.34e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg10505658	chr17:80084571	CCDC57	0.68	7.62	0.62	1.85e-11	Life satisfaction;
THYM	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13394619	1.000	rs2358040	chr2:11731774	G/T	cg07314298	chr2:11723111	GREB1	0.59	5.99	0.52	3.8e-8	Endometriosis;
THYM	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs12142240	0.667	rs45524035	chr1:46862780	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg26384229	chr12:38710491	ALG10B	-0.74	-5.69	-0.5	1.42e-7	Bladder cancer;
THYM	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18252515	chr7:66147081	NA	0.64	4.86	0.45	4.57e-6	Aortic root size;
THYM	cis	rs7772486	0.681	rs9390343	chr6:146010527	A/T	cg23711669	chr6:146136114	FBXO30	-0.81	-7.37	-0.6	6.22e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8067545	0.611	rs12936443	chr17:20033446	T/G	cg13482628	chr17:19912719	NA	0.55	4.7	0.43	8.82e-6	Schizophrenia;
THYM	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg06640241	chr16:89574553	SPG7	0.91	8.32	0.65	6.22e-13	Multiple myeloma (IgH translocation);
THYM	cis	rs1843834	0.688	rs2396149	chr2:225601985	G/A	cg10193763	chr2:225306901	NA	-0.44	-4.67	-0.43	9.9e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9914988	0.943	rs2043031	chr17:27085564	A/G	cg20469991	chr17:27169893	C17orf63	-0.79	-4.79	-0.44	6.18e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	6.03	0.53	3.12e-8	Obesity-related traits;
THYM	cis	rs7178572	1.000	rs952471	chr15:77776498	C/G	cg22256960	chr15:77711686	NA	-0.94	-7.93	-0.63	4.23e-12	Type 2 diabetes;
THYM	cis	rs1331623	1.000	rs12156491	chr9:122195169	T/C	cg25935911	chr9:122132261	DBC1	-0.52	-4.72	-0.44	8.05e-6	Height;
THYM	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg10523679	chr1:76189770	ACADM	0.87	7.4	0.6	5.44e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs10191773	0.589	rs11676628	chr2:112953355	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	0.78	4.72	0.44	8.19e-6	Yeast infection;
THYM	cis	rs7084402	0.967	rs1649035	chr10:60332701	A/T	cg07615347	chr10:60278583	BICC1	0.54	5.01	0.46	2.52e-6	Refractive error;
THYM	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg19318889	chr4:1322082	MAEA	0.68	5.84	0.51	7.31e-8	Longevity;
THYM	cis	rs11722228	0.508	rs9732	chr4:10076658	T/C	cg02317251	chr4:10116515	WDR1	-0.55	-4.99	-0.46	2.76e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg26384229	chr12:38710491	ALG10B	0.97	7.44	0.61	4.48e-11	Bladder cancer;
THYM	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg22764044	chr5:178986830	RUFY1	0.52	5.42	0.49	4.45e-7	Lung cancer;
THYM	cis	rs3741151	0.773	rs11235770	chr11:73184002	C/T	cg17517138	chr11:73019481	ARHGEF17	0.74	4.68	0.43	9.57e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg07936489	chr17:37558343	FBXL20	0.81	5.53	0.49	2.79e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg12011299	chr4:100065546	ADH4	0.85	8.06	0.64	2.26e-12	Alcohol dependence;
THYM	cis	rs1003719	0.715	rs2835644	chr21:38545610	G/T	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.91	-4.82	-0.44	5.49e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12291225	0.877	rs11023160	chr11:14264225	T/A	cg19336497	chr11:14380999	RRAS2	-0.63	-5.88	-0.52	6.17e-8	Sense of smell;
THYM	cis	rs6815814	0.898	rs17582830	chr4:38867427	A/G	cg06935464	chr4:38784597	TLR10	0.68	4.54	0.42	1.64e-5	Breast cancer;
THYM	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg06627557	chr7:32535165	LSM5;AVL9	1.0	10.13	0.72	8.93e-17	Cognitive ability;
THYM	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg19729930	chr2:74357872	NA	1.23	12.42	0.79	1.32e-21	Gestational age at birth (maternal effect);
THYM	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg04082016	chr2:20871401	NA	-0.77	-6.3	-0.54	9.41e-9	Abdominal aortic aneurysm;
THYM	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11792861	0.555	rs4978767	chr9:111762925	C/T	cg05043794	chr9:111880884	C9orf5	-0.38	-5.26	-0.48	8.78e-7	Menarche (age at onset);
THYM	cis	rs41311933	0.803	rs41312871	chr9:123733630	C/T	cg13567360	chr9:123745713	C5	-0.95	-4.81	-0.44	5.68e-6	Coronary artery disease;
THYM	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs1933112	0.966	rs4656605	chr1:168525897	A/T	cg00154920	chr1:168513310	XCL2	-0.51	-4.97	-0.45	2.99e-6	Blood protein levels;
THYM	cis	rs4907240	0.922	rs4907246	chr2:97326286	T/C	cg01950434	chr2:97203154	ARID5A	-0.62	-5.18	-0.47	1.22e-6	Event-related brain oscillations;
THYM	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg23260525	chr10:116636907	FAM160B1	0.53	5.33	0.48	6.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg09035930	chr12:129282057	SLC15A4	-0.58	-5.4	-0.48	4.97e-7	Systemic lupus erythematosus;
THYM	cis	rs28595532	0.841	rs115233595	chr4:119744214	T/C	cg11846333	chr4:119757529	SEC24D	1.48	5.59	0.5	2.15e-7	Cannabis dependence symptom count;
THYM	cis	rs7769051	0.803	rs56148066	chr6:133230115	G/A	cg22852734	chr6:133119734	C6orf192	1.13	6.8	0.57	9.08e-10	Type 2 diabetes nephropathy;
THYM	cis	rs9649213	0.555	rs34695842	chr7:97931062	G/T	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.6e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs137603	0.502	rs137627	chr22:39716341	G/A	cg24268161	chr22:39747459	SYNGR1	0.65	5.49	0.49	3.4e-7	Primary biliary cholangitis;
THYM	cis	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-5.43	-0.49	4.23e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs11031096	0.678	rs10767872	chr11:4184239	T/G	cg08557956	chr11:4115526	RRM1	-0.52	-4.67	-0.43	9.71e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg10589385	chr1:150898437	SETDB1	0.64	5.48	0.49	3.48e-7	Tonsillectomy;
THYM	cis	rs2731664	0.792	rs2630765	chr5:176876825	T/C	cg14098951	chr5:176875120	PRR7	0.57	5.02	0.46	2.45e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4722166	0.630	rs12700391	chr7:22777327	C/A	cg05472934	chr7:22766657	IL6	0.73	5.55	0.49	2.62e-7	Lung cancer;
THYM	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg23231163	chr10:75533350	FUT11	-0.44	-6.23	-0.54	1.29e-8	Inflammatory bowel disease;
THYM	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.07	-0.82	5.85e-25	Height;
THYM	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs7843479	0.601	rs10866837	chr8:21861663	G/C	cg17168535	chr8:21777572	XPO7	0.84	7.46	0.61	4.13e-11	Mean corpuscular volume;
THYM	cis	rs1823778	0.609	rs11663969	chr18:67707490	T/C	cg12929678	chr18:67624393	CD226	1.34	5.23	0.47	1.01e-6	Mean platelet volume;
THYM	cis	rs2276314	1.000	rs4799832	chr18:33559646	T/C	cg05985134	chr18:33552581	C18orf21	0.68	4.77	0.44	6.59e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs11690935	0.959	rs10167419	chr2:172649826	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.81	-6.0	-0.52	3.53e-8	Schizophrenia;
THYM	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.65e-6	Aortic root size;
THYM	cis	rs7731657	0.538	rs2107335	chr5:130292853	C/A	cg08523029	chr5:130500466	HINT1	-0.76	-5.21	-0.47	1.11e-6	Fasting plasma glucose;
THYM	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg11764359	chr7:65958608	NA	-0.74	-6.15	-0.53	1.85e-8	Aortic root size;
THYM	cis	rs6502050	0.723	rs4789698	chr17:80179786	C/T	cg10505658	chr17:80084571	CCDC57	-0.7	-7.36	-0.6	6.41e-11	Life satisfaction;
THYM	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.41	-5.16	-0.47	1.35e-6	Monocyte percentage of white cells;
THYM	cis	rs7772486	0.719	rs702307	chr6:145993454	C/G	cg23711669	chr6:146136114	FBXO30	-0.98	-10.65	-0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg06636001	chr8:8085503	FLJ10661	-0.83	-7.06	-0.59	2.76e-10	Joint mobility (Beighton score);
THYM	cis	rs55871839	0.708	rs12114218	chr8:59817454	T/C	cg07426533	chr8:59803705	TOX	-0.71	-7.3	-0.6	8.84e-11	Pneumonia;
THYM	trans	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs600806	0.850	rs6537757	chr1:109936682	G/A	cg02175308	chr1:109941060	SORT1	-0.56	-4.99	-0.46	2.76e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg10117171	chr1:25599238	RHD	-0.72	-5.18	-0.47	1.22e-6	Erythrocyte sedimentation rate;
THYM	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg11301795	chr4:187892539	NA	-1.1	-17.47	-0.87	2e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg05283184	chr6:79620031	NA	-0.94	-9.21	-0.69	7.9e-15	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg22166914	chr1:53195759	ZYG11B	0.95	11.47	0.76	1.28e-19	Monocyte count;
THYM	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg09904177	chr6:26538194	HMGN4	-0.54	-4.57	-0.42	1.47e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9311676	0.632	rs11925533	chr3:58429908	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs12579753	1.000	rs7975863	chr12:82227288	C/T	cg07988820	chr12:82153109	PPFIA2	-0.73	-4.53	-0.42	1.71e-5	Resting heart rate;
THYM	cis	rs367615	0.552	rs2115511	chr5:108725403	A/T	cg17395555	chr5:108820864	NA	-0.51	-5.97	-0.52	4.11e-8	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs2124969	0.506	rs10497210	chr2:160985549	G/A	cg03641300	chr2:160917029	PLA2R1	-0.65	-4.58	-0.43	1.38e-5	Waist circumference adjusted for body mass index;
THYM	cis	rs9394438	0.628	rs4714080	chr6:37544618	A/G	cg00985040	chr6:37553208	NA	0.42	4.58	0.43	1.41e-5	IgG glycosylation;
THYM	cis	rs9314614	1.000	rs2951851	chr8:6693495	T/G	cg16580759	chr8:6693379	XKR5	-0.47	-4.78	-0.44	6.32e-6	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg11764359	chr7:65958608	NA	0.62	4.73	0.44	7.94e-6	Aortic root size;
THYM	cis	rs10911232	0.507	rs12037585	chr1:183000041	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs854765	0.663	rs3744115	chr17:17749822	G/A	cg16928487	chr17:17741425	SREBF1	0.55	5.26	0.48	8.83e-7	Total body bone mineral density;
THYM	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg10518543	chr12:38710700	ALG10B	-0.55	-4.5	-0.42	1.93e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11771526	0.901	rs62457502	chr7:32330797	C/T	cg13207630	chr7:32358064	NA	0.77	4.86	0.45	4.72e-6	Body mass index;
THYM	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7578361	1.000	rs4536618	chr2:150446676	G/A	cg17961725	chr2:150454027	NA	0.71	6.3	0.54	9.23e-9	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.32	-0.48	7.02e-7	Monocyte percentage of white cells;
THYM	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg08885076	chr2:99613938	TSGA10	0.65	5.96	0.52	4.31e-8	Chronic sinus infection;
THYM	cis	rs1345301	0.518	rs2110661	chr2:102863221	C/T	cg03938978	chr2:103052716	IL18RAP	-0.52	-4.89	-0.45	4.1e-6	Waist circumference;
THYM	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg12165864	chr7:66369176	NA	0.64	4.92	0.45	3.64e-6	Aortic root size;
THYM	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6496667	1.000	rs8026533	chr15:90893228	A/C	cg22089800	chr15:90895588	ZNF774	0.74	5.0	0.46	2.65e-6	Rheumatoid arthritis;
THYM	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg13695892	chr22:41940480	POLR3H	0.87	6.35	0.55	7.28e-9	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs10463554	0.927	rs158404	chr5:102415910	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg15110403	chr19:17392923	ANKLE1	-0.59	-5.06	-0.46	2.08e-6	Systemic lupus erythematosus;
THYM	cis	rs7570971	1.000	rs7570971	chr2:135837906	C/A	cg07169764	chr2:136633963	MCM6	0.7	5.21	0.47	1.09e-6	Blood metabolite levels;Body mass index;Cholesterol, total;
THYM	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-5.71	-0.51	1.31e-7	Total cholesterol levels;
THYM	cis	rs7193541	0.929	rs12933037	chr16:74660174	G/A	cg01733217	chr16:74700730	RFWD3	0.83	8.1	0.64	1.83e-12	Multiple myeloma;
THYM	cis	rs9905704	0.846	rs302877	chr17:56764018	G/A	cg12560992	chr17:57184187	TRIM37	0.66	4.9	0.45	4.01e-6	Testicular germ cell tumor;
THYM	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg05043794	chr9:111880884	C9orf5	-0.39	-5.67	-0.5	1.51e-7	Menarche (age at onset);
THYM	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	18.27	0.88	7.47e-33	Chronic sinus infection;
THYM	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg00074818	chr8:8560427	CLDN23	0.58	5.36	0.48	5.79e-7	Obesity-related traits;
THYM	cis	rs7582180	0.663	rs2053263	chr2:100971407	A/G	cg08017756	chr2:100939284	LONRF2	-0.73	-7.46	-0.61	4.01e-11	Intelligence (multi-trait analysis);
THYM	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg21280719	chr6:42927975	GNMT	-0.53	-7.28	-0.6	9.53e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2585417	0.756	rs6091837	chr20:52847428	C/T	cg14415559	chr20:52836060	PFDN4	-0.51	-4.51	-0.42	1.82e-5	Obesity-related traits;
THYM	cis	rs6700896	0.931	rs11208715	chr1:66154414	G/T	cg04111102	chr1:66153794	NA	0.59	5.83	0.51	7.66e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs10498870	0.553	rs2502561	chr6:70595224	T/A	cg03001484	chr6:70507230	LMBRD1	0.29	4.74	0.44	7.63e-6	Subjective well-being (multi-trait analysis);
THYM	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg26513180	chr16:89883248	FANCA	0.67	6.65	0.56	1.87e-9	Vitiligo;
THYM	cis	rs9814567	0.896	rs1357764	chr3:134344928	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	7.74	0.62	1.08e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg23758822	chr17:41437982	NA	1.24	13.19	0.8	3.4e-23	Menopause (age at onset);
THYM	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06634786	chr22:41940651	POLR3H	0.69	5.31	0.48	7.18e-7	Vitiligo;
THYM	cis	rs7771547	0.519	rs4713973	chr6:36382044	A/G	cg07856975	chr6:36356162	ETV7	0.63	5.31	0.48	7.34e-7	Platelet distribution width;
THYM	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg13119609	chr19:45449297	APOC2	0.6	5.73	0.51	1.17e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
THYM	cis	rs1122608	0.540	rs73011374	chr19:11082009	A/G	cg17326582	chr19:11976514	ZNF439	0.6	4.62	0.43	1.19e-5	Coronary artery disease or ischemic stroke;Coronary artery disease;Coronary artery disease or large artery stroke;Coronary heart disease;Myocardial infarction (early onset);
THYM	cis	rs4788570	0.578	rs9934789	chr16:71662467	A/G	cg06353428	chr16:71660113	MARVELD3	1.37	9.59	0.7	1.22e-15	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg08901578	chr4:187885870	NA	-0.64	-6.03	-0.53	3.1e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg16006841	chr5:176797999	RGS14	0.51	6.14	0.53	1.87e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03647317	chr4:187891568	NA	-0.85	-9.12	-0.68	1.26e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2075230	0.866	rs1143015	chr17:7485206	A/G	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	-0.34	-5.32	-0.48	7.02e-7	Hormone measurements;
THYM	cis	rs12496230	0.953	rs4856960	chr3:66843301	T/C	cg23477460	chr3:66848765	NA	1.25	7.67	0.62	1.51e-11	Type 2 diabetes;
THYM	cis	rs4455778	0.580	rs7808082	chr7:49124973	T/C	cg26309511	chr7:48887640	NA	0.67	5.88	0.52	6.18e-8	Lung cancer in never smokers;
THYM	cis	rs4664308	1.000	rs4664308	chr2:160917497	A/G	cg03641300	chr2:160917029	PLA2R1	-0.78	-6.97	-0.58	4.25e-10	Idiopathic membranous nephropathy;
THYM	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	5.57	0.5	2.41e-7	Obesity-related traits;
THYM	cis	rs990171	1.000	rs2110735	chr2:103050925	A/G	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.17	-0.47	1.27e-6	Lymphocyte counts;
THYM	cis	rs59698941	0.943	rs67460003	chr5:132289501	C/G	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg24846343	chr22:24311635	DDTL	0.43	5.82	0.51	7.94e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg24675056	chr1:15929824	NA	0.73	5.9	0.52	5.62e-8	Systolic blood pressure;
THYM	cis	rs10463554	0.963	rs34777	chr5:102452258	C/T	cg23492399	chr5:102201601	PAM	-0.69	-5.07	-0.46	1.92e-6	Parkinson's disease;
THYM	cis	rs7829975	0.632	rs28663303	chr8:8556278	T/C	cg15556689	chr8:8085844	FLJ10661	-0.57	-4.83	-0.44	5.27e-6	Mood instability;
THYM	cis	rs67072384	0.892	rs67034709	chr11:72451004	T/C	cg01380194	chr11:72452482	ARAP1	-0.97	-5.26	-0.47	8.93e-7	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg22920501	chr2:26401640	FAM59B	0.86	7.47	0.61	3.96e-11	Gut microbiome composition (summer);
THYM	cis	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.59	6.1	0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11225247	0.764	rs78166284	chr11:102252087	A/G	cg06323957	chr11:102217781	BIRC2	1.08	4.83	0.44	5.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	trans	rs480407	0.857	rs270974	chr2:161691710	G/A	cg06548410	chr19:1997657	BTBD2	0.71	6.92	0.58	5.23e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7226229	0.950	rs899341	chr17:20924270	T/G	cg21263980	chr17:20946333	USP22	0.66	4.88	0.45	4.25e-6	Blood trace element (Se levels);
THYM	cis	rs7187994	0.848	rs34327141	chr16:84776991	C/T	cg07647771	chr16:84786436	USP10	-0.54	-5.1	-0.46	1.72e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg13609457	chr4:120235615	NA	0.63	5.49	0.49	3.28e-7	Educational attainment;
THYM	cis	rs526231	0.543	rs3776863	chr5:102327869	G/C	cg23492399	chr5:102201601	PAM	-0.66	-5.15	-0.47	1.4e-6	Primary biliary cholangitis;
THYM	cis	rs9916302	0.706	rs2879259	chr17:37410892	C/G	cg07936489	chr17:37558343	FBXL20	-0.87	-5.75	-0.51	1.06e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg08968635	chr6:28129556	ZNF389	0.59	4.57	0.42	1.46e-5	Parkinson's disease;
THYM	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.69	0.43	9.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg15704280	chr7:45808275	SEPT13	-1.04	-14.07	-0.82	5.85e-25	Height;
THYM	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg24818145	chr4:99064322	C4orf37	-0.75	-6.03	-0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs600806	0.821	rs3879451	chr1:109909269	C/T	cg23616212	chr1:109941201	SORT1	-0.48	-4.55	-0.42	1.57e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg00898013	chr13:113819073	PROZ	-0.88	-9.0	-0.68	2.24e-14	Platelet distribution width;
THYM	cis	rs9522267	0.737	rs9515455	chr13:112239671	A/G	cg10483660	chr13:112241077	NA	0.59	6.23	0.54	1.26e-8	Hepatitis;
THYM	cis	rs992157	1.000	rs13003334	chr2:219124921	T/A	cg04731861	chr2:219085781	ARPC2	-0.5	-4.5	-0.42	1.93e-5	Colorectal cancer;
THYM	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg18252515	chr7:66147081	NA	-0.67	-5.09	-0.46	1.82e-6	Aortic root size;
THYM	cis	rs4824093	0.610	rs28473584	chr22:50315413	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-4.7	-0.43	8.84e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg15693483	chr7:1102177	C7orf50	0.41	5.93	0.52	4.81e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg00757033	chr12:89920650	WDR51B	0.75	12.04	0.78	7.96e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7216064	0.953	rs11868959	chr17:65840810	T/C	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs4866334	1.000	rs116499870	chr5:18479009	G/A	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs9814567	1.000	rs62271515	chr3:134300507	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.5	-0.66	2.69e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	4.62	0.43	1.18e-5	Hip circumference adjusted for BMI;
THYM	cis	rs1278352	0.767	rs1278361	chr10:127775470	T/C	cg08295661	chr10:127769903	ADAM12	-0.54	-5.43	-0.49	4.35e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.51	-6.53	-0.56	3.26e-9	Monocyte percentage of white cells;
THYM	cis	rs4455778	0.600	rs4244233	chr7:49130572	T/A	cg26309511	chr7:48887640	NA	0.6	4.6	0.43	1.3e-5	Lung cancer in never smokers;
THYM	cis	rs7659604	0.643	rs6839375	chr4:122663610	G/C	cg06713675	chr4:122721982	EXOSC9	-0.56	-5.04	-0.46	2.22e-6	Type 2 diabetes;
THYM	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg10018233	chr7:150070692	REPIN1	0.5	7.8	0.62	7.97e-12	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg24955955	chr5:415729	AHRR	1.02	5.72	0.51	1.21e-7	Fat distribution (HIV);
THYM	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg09549813	chr16:4587862	C16orf5	0.56	6.19	0.54	1.49e-8	Schizophrenia;
THYM	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg02353165	chr6:42928485	GNMT	0.87	8.22	0.64	1.02e-12	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.53	-4.93	-0.45	3.48e-6	Lymphocyte counts;
THYM	cis	rs9443645	0.527	rs7756996	chr6:79509367	A/C	cg05283184	chr6:79620031	NA	-0.61	-4.77	-0.44	6.62e-6	Intelligence (multi-trait analysis);
THYM	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg21862992	chr11:68658383	NA	-0.25	-4.54	-0.42	1.65e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9486719	0.843	rs976357	chr6:96849679	C/T	cg18709589	chr6:96969512	KIAA0776	0.75	4.49	0.42	2.02e-5	Migraine;Coronary artery disease;
THYM	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg08048268	chr3:133502702	NA	-0.69	-5.66	-0.5	1.59e-7	Iron status biomarkers;
THYM	trans	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg25214090	chr10:38739885	LOC399744	0.92	7.76	0.62	9.72e-12	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs919433	0.680	rs7590010	chr2:198400668	C/T	cg00792783	chr2:198669748	PLCL1	0.86	6.08	0.53	2.49e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9563576	0.518	rs9569732	chr13:58314096	T/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.63	4.89	0.45	4.04e-6	Body mass index;
THYM	cis	rs1747683	0.966	rs584285	chr10:13366237	C/T	cg25835351	chr10:13388524	SEPHS1	0.34	5.59	0.5	2.14e-7	IgG glycosylation;
THYM	cis	rs2692947	0.770	rs62153678	chr2:96558346	C/T	cg23100626	chr2:96804247	ASTL	0.41	5.15	0.47	1.43e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg19729930	chr2:74357872	NA	1.16	11.01	0.75	1.15e-18	Gestational age at birth (maternal effect);
THYM	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg18758796	chr5:131593413	PDLIM4	0.49	4.48	0.42	2.09e-5	Breast cancer;Mosquito bite size;
THYM	cis	rs67981189	0.529	rs8010063	chr14:71510125	T/A	cg15910301	chr14:71632612	NA	0.56	4.88	0.45	4.23e-6	Schizophrenia;
THYM	cis	rs7084402	1.000	rs12259315	chr10:60266152	T/C	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs877282	0.898	rs11253349	chr10:765897	C/G	cg10556349	chr10:835070	NA	-0.79	-5.05	-0.46	2.14e-6	Uric acid levels;
THYM	cis	rs36051895	0.632	rs62541899	chr9:5143291	C/T	cg02405213	chr9:5042618	JAK2	-1.02	-10.39	-0.73	2.41e-17	Pediatric autoimmune diseases;
THYM	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22857025	chr5:266934	NA	-1.37	-8.88	-0.67	4.08e-14	Breast cancer;
THYM	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg08000102	chr2:233561755	GIGYF2	0.69	6.09	0.53	2.35e-8	Coronary artery disease;
THYM	trans	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg00944433	chr1:107599041	PRMT6	0.4	5.19	0.47	1.18e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs1421811	0.509	rs7733428	chr5:32689850	G/A	cg16267343	chr5:32710456	NPR3	0.86	6.86	0.58	6.92e-10	Blood pressure;
THYM	cis	rs2288884	0.731	rs11673398	chr19:52540697	C/T	cg05974498	chr19:52599256	ZNF841	0.35	4.51	0.42	1.85e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs12681287	0.927	rs7003059	chr8:87330713	C/T	cg00550725	chr8:87521180	FAM82B	0.57	4.58	0.42	1.44e-5	Caudate activity during reward;
THYM	cis	rs2072510	0.569	rs17677343	chr12:96397081	T/A	cg18817487	chr12:96390143	HAL	0.47	5.68	0.5	1.44e-7	Metabolite levels (small molecules and protein measures);
THYM	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg01416388	chr22:39784598	NA	-0.93	-8.69	-0.67	1.02e-13	Intelligence (multi-trait analysis);
THYM	cis	rs714027	0.565	rs9614099	chr22:30288338	A/T	cg27665648	chr22:30112403	NA	0.53	4.7	0.43	8.92e-6	Lymphocyte counts;
THYM	cis	rs2456568	0.802	rs10831139	chr11:93640537	G/A	cg17347335	chr11:93583973	C11orf90	-0.48	-4.63	-0.43	1.18e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs863345	0.604	rs60104403	chr1:158500847	G/A	cg12129480	chr1:158549410	OR10X1	-0.51	-5.01	-0.46	2.52e-6	Pneumococcal bacteremia;
THYM	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg07636037	chr3:49044803	WDR6	0.87	7.94	0.63	4.12e-12	Parkinson's disease;
THYM	cis	rs2455799	0.634	rs13085226	chr3:15923750	C/T	cg16303742	chr3:15540471	COLQ	-0.54	-5.54	-0.49	2.74e-7	Mean platelet volume;
THYM	cis	rs597539	0.597	rs35956171	chr11:68602735	G/C	cg06112835	chr11:68658793	MRPL21	-0.4	-5.07	-0.46	1.94e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2976388	0.934	rs2920279	chr8:143762135	A/C	cg13446199	chr8:143762866	PSCA	0.51	6.42	0.55	5.46e-9	Urinary tract infection frequency;
THYM	cis	rs11966931	1.000	rs17589005	chr6:108140282	A/G	cg25323841	chr6:108444506	NA	-0.67	-4.65	-0.43	1.07e-5	Neutrophil percentage of white cells;
THYM	cis	rs7264396	0.690	rs2425157	chr20:34419083	T/C	cg26038318	chr20:34205095	SPAG4	0.64	4.87	0.45	4.38e-6	Total cholesterol levels;
THYM	cis	rs1559088	0.576	rs7251626	chr19:33578470	C/A	cg03563238	chr19:33554763	RHPN2	-0.51	-4.46	-0.42	2.23e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	5.03	0.46	2.33e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg26028573	chr6:26043587	HIST1H2BB	-0.5	-4.5	-0.42	1.94e-5	Blood metabolite levels;
THYM	cis	rs2625529	0.824	rs4776586	chr15:72430503	C/A	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs12594515	1.000	rs6493167	chr15:45986809	G/A	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs2229238	0.823	rs61275241	chr1:154504887	T/G	cg21262032	chr1:154437693	IL6R	-0.63	-5.65	-0.5	1.68e-7	Coronary heart disease;
THYM	cis	rs7107174	0.901	rs2450136	chr11:77925273	T/G	cg02023728	chr11:77925099	USP35	0.67	6.32	0.54	8.25e-9	Testicular germ cell tumor;
THYM	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4733781	0.842	rs1123205	chr8:131349110	C/G	cg16277922	chr8:131349729	ASAP1	0.62	4.68	0.43	9.59e-6	Tuberculosis;
THYM	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg23815491	chr16:72088622	HP	0.68	5.23	0.47	1.01e-6	Fibrinogen levels;
THYM	cis	rs6448317	1.000	rs11938296	chr4:24938861	A/G	cg22968281	chr4:24586266	DHX15	0.7	4.79	0.44	6.02e-6	Heschl's gyrus morphology;
THYM	cis	rs11992162	0.573	rs13275808	chr8:11782815	T/C	cg21775007	chr8:11205619	TDH	-0.59	-4.55	-0.42	1.56e-5	Monocyte count;
THYM	cis	rs7394190	0.748	rs12572278	chr10:75504513	C/A	cg07699608	chr10:75541558	CHCHD1	0.87	4.75	0.44	7.17e-6	Incident atrial fibrillation;
THYM	cis	rs4919044	0.599	rs10882124	chr10:94665826	A/G	cg05127821	chr10:94822908	CYP26C1	-1.11	-6.86	-0.58	6.87e-10	Coronary artery disease;
THYM	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg06582575	chr6:163149167	PACRG;PARK2	1.12	7.7	0.62	1.28e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg14784868	chr12:69753453	YEATS4	0.79	6.39	0.55	6.01e-9	Blood protein levels;
THYM	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9914988	0.943	rs4794836	chr17:27082710	C/G	cg20469991	chr17:27169893	C17orf63	0.91	5.43	0.49	4.37e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs4803468	0.967	rs1077856	chr19:41885221	T/C	cg09537434	chr19:41945824	ATP5SL	-1.08	-10.03	-0.72	1.45e-16	Height;
THYM	cis	rs17433780	0.928	rs12127787	chr1:89458761	T/C	cg09516651	chr1:89888402	LOC400759	0.85	6.43	0.55	5.2e-9	Carotid intima media thickness;
THYM	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg14018140	chr10:458528	DIP2C	0.58	5.55	0.49	2.62e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs922692	0.696	rs1809420	chr15:79056769	A/G	cg15571903	chr15:79123663	NA	-0.65	-5.16	-0.47	1.34e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6674176	0.569	rs11210935	chr1:44369444	G/A	cg12908607	chr1:44402522	ARTN	-0.56	-4.71	-0.44	8.35e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs208520	0.690	rs851464	chr6:66839802	C/T	cg07460842	chr6:66804631	NA	-0.96	-6.88	-0.58	6.25e-10	Exhaled nitric oxide output;
THYM	cis	rs4970988	0.527	rs12067556	chr1:150614535	G/A	cg15448220	chr1:150897856	SETDB1	0.92	7.32	0.6	7.77e-11	Urate levels;
THYM	cis	rs11574514	0.661	rs116856853	chr16:67984804	G/A	cg09738193	chr16:67926317	PSKH1	-0.92	-4.53	-0.42	1.69e-5	Crohn's disease;
THYM	cis	rs7618501	0.699	rs11713193	chr3:49924424	G/A	cg24308560	chr3:49941425	MST1R	-0.77	-6.51	-0.56	3.57e-9	Intelligence (multi-trait analysis);
THYM	cis	rs4363385	0.597	rs55667413	chr1:152976849	G/T	cg13444842	chr1:152974279	SPRR3	-0.59	-4.68	-0.43	9.41e-6	Inflammatory skin disease;
THYM	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg08000102	chr2:233561755	GIGYF2	0.68	6.02	0.53	3.22e-8	Coronary artery disease;
THYM	cis	rs17443541	0.507	rs6711524	chr2:200462940	T/C	cg01795955	chr2:200468626	NA	-0.72	-5.0	-0.46	2.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2273669	0.667	rs12196024	chr6:109302258	C/T	cg17117243	chr6:109341365	SESN1	-0.85	-5.09	-0.46	1.79e-6	Prostate cancer;
THYM	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	7.18	0.59	1.57e-10	Electrocardiographic conduction measures;
THYM	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg19774624	chr17:42201019	HDAC5	0.65	5.35	0.48	6.04e-7	Total body bone mineral density;
THYM	cis	rs6842047	1.000	rs1511800	chr4:187135556	C/T	cg09526685	chr4:187126073	CYP4V2	1.14	5.71	0.51	1.26e-7	Blood protein levels;
THYM	cis	rs240764	0.658	rs6909880	chr6:101179354	A/C	cg21058520	chr6:100914733	NA	0.6	5.32	0.48	6.98e-7	Neuroticism;
THYM	cis	rs4595586	0.545	rs1607042	chr12:39368028	A/G	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg17173187	chr15:85201210	NMB	0.54	5.31	0.48	7.17e-7	Schizophrenia;
THYM	cis	rs11585357	0.895	rs72633803	chr1:17616758	G/A	cg08277548	chr1:17600880	PADI3	-0.9	-5.43	-0.49	4.38e-7	Hair shape;
THYM	cis	rs600806	0.850	rs3879452	chr1:109929237	G/A	cg23032129	chr1:109941072	SORT1	-0.59	-5.03	-0.46	2.31e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.61	-4.9	-0.45	3.93e-6	Lung cancer;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg13491045	chr11:101646253	NA	-0.96	-7.08	-0.59	2.52e-10	Depressive symptoms;
THYM	cis	rs11247915	0.583	rs34058882	chr1:26659794	C/T	cg00852783	chr1:26633632	UBXN11	0.73	6.08	0.53	2.54e-8	Obesity-related traits;
THYM	cis	rs11690935	0.851	rs10201430	chr2:172813241	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.63	-4.79	-0.44	6.04e-6	Schizophrenia;
THYM	cis	rs1113500	0.933	rs3909076	chr1:108631760	T/C	cg06207961	chr1:108661230	NA	0.66	5.17	0.47	1.28e-6	Growth-regulated protein alpha levels;
THYM	cis	rs11264213	0.591	rs1967782	chr1:36543783	C/T	cg27506609	chr1:36549197	TEKT2	-0.98	-5.23	-0.47	1.01e-6	Schizophrenia;
THYM	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg04016957	chr4:1044486	NA	-0.54	-4.45	-0.42	2.3e-5	Recombination rate (males);
THYM	cis	rs985746	0.614	rs9683431	chr4:36788024	T/G	cg04301614	chr4:37585993	C4orf19	0.55	4.47	0.42	2.16e-5	Bone mineral density (Ward's triangle area);
THYM	trans	rs629535	0.783	rs658407	chr8:70035247	T/C	cg21567404	chr3:27674614	NA	1.12	10.86	0.74	2.44e-18	Dupuytren's disease;
THYM	cis	rs71636778	0.509	rs34473788	chr1:27271519	A/G	cg16022904	chr1:26870173	RPS6KA1	0.84	4.55	0.42	1.58e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
THYM	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg01238044	chr22:24384105	GSTT1	0.53	4.6	0.43	1.28e-5	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7523273	0.597	rs4844392	chr1:207991209	C/G	cg22525895	chr1:207977042	MIR29B2	-0.78	-5.2	-0.47	1.15e-6	Schizophrenia;
THYM	cis	rs4455778	0.561	rs13243449	chr7:49129765	T/C	cg26309511	chr7:48887640	NA	0.64	5.72	0.51	1.23e-7	Lung cancer in never smokers;
THYM	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.05	-0.59	2.83e-10	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9467711	0.538	rs7766531	chr6:25886577	T/C	cg12826209	chr6:26865740	GUSBL1	0.92	4.45	0.42	2.36e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs477692	0.544	rs7923750	chr10:131446895	G/C	cg06209143	chr10:131448811	MGMT	-0.56	-4.46	-0.42	2.26e-5	Response to temozolomide;
THYM	cis	rs6596100	0.500	rs67904956	chr5:132274044	A/G	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Breast cancer;
THYM	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14159672	chr1:205819179	PM20D1	0.98	10.2	0.72	6.32e-17	Menarche (age at onset);
THYM	cis	rs2040771	0.740	rs9605960	chr22:19214636	G/C	cg02655711	chr22:19163373	SLC25A1	0.54	5.71	0.51	1.27e-7	Metabolite levels (small molecules and protein measures);
THYM	cis	rs2282300	0.739	rs1765133	chr11:30339400	C/T	cg25418670	chr11:30344373	C11orf46	-0.82	-6.98	-0.58	3.93e-10	Morning vs. evening chronotype;
THYM	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg01699819	chr7:1052092	C7orf50	-0.87	-7.91	-0.63	4.74e-12	Bronchopulmonary dysplasia;
THYM	cis	rs2403083	0.578	rs7829050	chr8:86051394	A/T	cg13721134	chr8:86350390	CA3	0.45	4.46	0.42	2.26e-5	Plasma amyloid beta peptide concentrations (ABx-40);
THYM	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg07217954	chr7:1067459	C7orf50	0.59	4.69	0.43	9.14e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg17911788	chr17:44343683	NA	-0.79	-7.48	-0.61	3.65e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg00686598	chr14:53173677	PSMC6	-1.54	-7.5	-0.61	3.35e-11	Alzheimer's disease (late onset);
THYM	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg20007245	chr22:24372913	LOC391322	-0.8	-7.88	-0.63	5.34e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg23758822	chr17:41437982	NA	1.22	13.08	0.8	5.68e-23	Menopause (age at onset);
THYM	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg01579765	chr21:45077557	HSF2BP	0.51	7.89	0.63	5.21e-12	Mean corpuscular volume;
THYM	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg07936489	chr17:37558343	FBXL20	-0.67	-4.82	-0.44	5.53e-6	Asthma;
THYM	cis	rs1691799	0.899	rs2951656	chr12:66732273	T/G	cg16791601	chr12:66731901	HELB	-0.76	-7.14	-0.59	1.86e-10	White blood cell count (basophil);
THYM	cis	rs8013055	0.796	rs11628497	chr14:105970789	C/T	cg04429589	chr14:105992532	TMEM121	-0.46	-5.08	-0.46	1.87e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs295140	0.566	rs295141	chr2:201163556	C/T	cg17644776	chr2:200775616	C2orf69	-0.59	-4.52	-0.42	1.76e-5	QT interval;
THYM	cis	rs295140	1.000	rs295140	chr2:201160699	T/C	cg04283868	chr2:201171347	SPATS2L	-0.67	-5.23	-0.47	1.02e-6	QT interval;
THYM	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg08847533	chr14:75593920	NEK9	1.04	11.41	0.76	1.69e-19	Height;
THYM	cis	rs7172677	0.508	rs12917120	chr15:75329091	T/C	cg10253484	chr15:75165896	SCAMP2	-0.64	-4.97	-0.45	2.91e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.49	-0.49	3.35e-7	Menopause (age at onset);
THYM	cis	rs7264396	0.887	rs1570841	chr20:34048161	C/T	cg26038318	chr20:34205095	SPAG4	0.53	4.47	0.42	2.15e-5	Total cholesterol levels;
THYM	cis	rs12216545	0.765	rs7785909	chr7:150222230	A/T	cg08960815	chr7:150264767	GIMAP4	-0.89	-8.27	-0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs3760982	0.585	rs61013802	chr19:44292142	A/T	cg11993925	chr19:44307056	LYPD5	0.64	5.0	0.46	2.64e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs1065852	0.526	rs9611700	chr22:42401514	C/T	cg22189786	chr22:42395067	WBP2NL	0.54	5.55	0.49	2.6e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg06713675	chr4:122721982	EXOSC9	-0.88	-10.36	-0.73	2.77e-17	Type 2 diabetes;
THYM	cis	rs34779708	0.966	rs17591163	chr10:35465279	G/C	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9788721	0.900	rs4243084	chr15:78911672	G/C	cg18825076	chr15:78729989	IREB2	-0.56	-5.1	-0.46	1.73e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.27	5.48	0.49	3.41e-7	Obesity-related traits;
THYM	cis	rs9992101	0.547	rs10029860	chr4:77411101	C/A	cg27417997	chr4:77356416	SHROOM3	-0.37	-4.46	-0.42	2.22e-5	Creatinine levels;
THYM	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.49	0.49	3.33e-7	Platelet count;
THYM	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg21475434	chr5:93447410	FAM172A	0.95	6.03	0.53	3.16e-8	Diabetic retinopathy;
THYM	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg22709100	chr7:91322751	NA	0.65	4.56	0.42	1.5e-5	Breast cancer;
THYM	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg10523679	chr1:76189770	ACADM	0.91	7.63	0.62	1.77e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4363385	0.818	rs679378	chr1:153011716	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.57	-0.42	1.44e-5	Inflammatory skin disease;
THYM	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg23708337	chr7:1209742	NA	0.63	4.82	0.44	5.39e-6	Longevity;Endometriosis;
THYM	cis	rs113835537	0.529	rs4542420	chr11:66277610	G/C	cg24851651	chr11:66362959	CCS	0.7	4.82	0.44	5.46e-6	Airway imaging phenotypes;
THYM	cis	rs9902453	0.740	rs2254414	chr17:28061130	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.31	-0.54	8.9e-9	Coffee consumption (cups per day);
THYM	cis	rs9318086	0.712	rs12875437	chr13:24453956	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.53	4.54	0.42	1.64e-5	Myopia (pathological);
THYM	cis	rs3020333	0.875	rs3020334	chr6:152012956	A/G	cg22157087	chr6:152012887	ESR1	0.44	4.94	0.45	3.36e-6	Total body bone mineral density;
THYM	cis	rs7917772	0.582	rs4919663	chr10:104363293	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1904096	0.506	rs114312933	chr4:95216802	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.2	-0.47	1.14e-6	Type 2 diabetes;
THYM	cis	rs420259	0.516	rs7405145	chr16:23537772	A/G	cg00143387	chr16:23521605	GGA2	-0.75	-5.37	-0.48	5.57e-7	Bipolar disorder;
THYM	cis	rs2718058	0.613	rs2597272	chr7:37759710	C/G	cg15028436	chr7:37888078	TXNDC3	-0.59	-4.5	-0.42	1.95e-5	Alzheimer's disease (late onset);
THYM	cis	rs8048589	1.000	rs9925009	chr16:12186352	T/A	cg02910054	chr16:12241554	SNX29	0.69	5.44	0.49	4.19e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs2862064	0.932	rs1393208	chr5:156477725	G/A	cg12943317	chr5:156479607	HAVCR1	-0.84	-5.23	-0.47	9.88e-7	Platelet count;
THYM	cis	rs4266144	0.632	rs56268334	chr3:156848024	C/T	cg16248515	chr3:156840234	NA	-0.78	-6.26	-0.54	1.13e-8	Coronary artery disease;
THYM	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg03806693	chr22:41940476	POLR3H	1.03	9.17	0.69	9.96e-15	Vitiligo;
THYM	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg12379764	chr21:47803548	PCNT	-0.8	-5.15	-0.47	1.38e-6	Testicular germ cell tumor;
THYM	cis	rs55728055	0.661	rs7293143	chr22:32013365	A/G	cg01338084	chr22:32026380	PISD	-1.39	-6.92	-0.58	5.23e-10	Age-related hearing impairment;
THYM	cis	rs240764	0.817	rs12216304	chr6:101174161	A/G	cg21058520	chr6:100914733	NA	0.58	5.22	0.47	1.06e-6	Neuroticism;
THYM	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg06191203	chr2:152266755	RIF1	-0.71	-4.71	-0.43	8.5e-6	Lung cancer;
THYM	cis	rs1461503	0.932	rs10790544	chr11:122838330	T/C	cg27398637	chr11:122830231	C11orf63	-0.7	-6.69	-0.57	1.51e-9	Menarche (age at onset);
THYM	cis	rs899997	0.814	rs28661610	chr15:78985317	G/A	cg00639195	chr15:79103007	ADAMTS7	0.7	5.07	0.46	1.97e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg03159660	chr11:2078197	NA	-0.65	-4.91	-0.45	3.83e-6	Longevity;
THYM	cis	rs6543140	0.964	rs1523205	chr2:103070176	G/T	cg03938978	chr2:103052716	IL18RAP	0.61	6.13	0.53	2.03e-8	Blood protein levels;
THYM	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg05283184	chr6:79620031	NA	-0.88	-8.41	-0.65	4.12e-13	Intelligence (multi-trait analysis);
THYM	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg06064525	chr11:970664	AP2A2	-0.38	-7.23	-0.6	1.22e-10	Alzheimer's disease (late onset);
THYM	cis	rs7172809	0.599	rs17472200	chr15:77783812	C/G	cg10437265	chr15:77819839	NA	-0.5	-4.57	-0.42	1.47e-5	Glucose homeostasis traits;
THYM	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg19346786	chr7:2764209	NA	-0.71	-6.01	-0.53	3.36e-8	Height;
THYM	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.3	-4.73	-0.44	7.83e-6	Obesity-related traits;
THYM	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg00129232	chr17:37814104	STARD3	0.75	5.4	0.48	4.93e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs11608355	1.000	rs7969719	chr12:109883577	C/T	cg10504392	chr12:110044639	NA	0.69	6.37	0.55	6.69e-9	Neuroticism;
THYM	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg02269571	chr22:50332266	NA	-0.71	-4.91	-0.45	3.78e-6	Schizophrenia;
THYM	cis	rs34172651	0.917	rs6497756	chr16:24798291	G/T	cg06028605	chr16:24865363	SLC5A11	0.58	5.69	0.5	1.42e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg09549813	chr16:4587862	C16orf5	-0.61	-6.42	-0.55	5.23e-9	Schizophrenia;
THYM	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg11871910	chr12:69753446	YEATS4	0.66	5.31	0.48	7.08e-7	Response to diuretic therapy;
THYM	cis	rs3204270	0.543	rs34034499	chr17:79638568	G/C	cg18367735	chr17:79674897	NA	0.8	4.89	0.45	4.12e-6	Dental caries;
THYM	cis	rs7084402	0.967	rs1649057	chr10:60318114	C/T	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs7917772	0.582	rs10786684	chr10:104323028	A/C	cg00122347	chr10:104236741	TMEM180	0.41	5.81	0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4731207	0.671	rs12530981	chr7:124521722	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs728616	0.867	rs116994688	chr10:81738137	G/C	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg07959070	chr22:50026188	C22orf34	-0.28	-4.91	-0.45	3.82e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs526231	0.511	rs4421079	chr5:102369076	C/T	cg23492399	chr5:102201601	PAM	-0.67	-5.09	-0.46	1.77e-6	Primary biliary cholangitis;
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg01625761	chr6:107075197	RTN4IP1	0.82	6.86	0.58	7.11e-10	Energy expenditure (24h);
THYM	cis	rs6430585	0.583	rs73957037	chr2:136588031	C/A	cg04750100	chr2:136595281	LCT	0.56	5.92	0.52	5.03e-8	Corneal structure;
THYM	cis	rs4523957	0.583	rs9907384	chr17:2045375	A/C	cg16513277	chr17:2031491	SMG6	-1.04	-9.84	-0.71	3.58e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs977987	0.806	rs11149832	chr16:75462713	C/T	cg03315344	chr16:75512273	CHST6	0.76	6.17	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg09455208	chr3:40491958	NA	-0.45	-4.55	-0.42	1.59e-5	Renal cell carcinoma;
THYM	cis	rs791888	0.965	rs791873	chr10:89405558	C/T	cg13926569	chr10:89418898	PAPSS2	-0.66	-7.15	-0.59	1.77e-10	Magnesium levels;
THYM	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg06766960	chr11:133703094	NA	-0.49	-4.67	-0.43	9.84e-6	Childhood ear infection;
THYM	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg07414643	chr4:187882934	NA	0.64	5.75	0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg10856724	chr12:34555212	NA	-0.74	-5.54	-0.49	2.74e-7	Resting heart rate;
THYM	cis	rs7084921	0.579	rs2862947	chr10:101863817	C/G	cg11344164	chr10:101878520	NA	-0.74	-5.4	-0.48	4.98e-7	Bone mineral density;
THYM	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg02569458	chr12:86230093	RASSF9	0.62	5.13	0.47	1.56e-6	Major depressive disorder;
THYM	cis	rs9807989	0.811	rs67088699	chr2:102968751	C/T	cg03938978	chr2:103052716	IL18RAP	0.63	6.46	0.55	4.36e-9	Asthma;
THYM	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg03676636	chr4:99064102	C4orf37	0.42	6.16	0.53	1.78e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.07	-10.85	-0.74	2.51e-18	Primary sclerosing cholangitis;
THYM	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg22968622	chr17:43663579	NA	-0.83	-7.12	-0.59	2.01e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs42648	0.869	rs12704518	chr7:89914388	G/T	cg25739043	chr7:89950458	NA	-0.53	-4.53	-0.42	1.72e-5	Homocysteine levels;
THYM	cis	rs6674176	0.593	rs3791120	chr1:44431715	T/C	cg13246856	chr1:44399776	ARTN	0.47	4.86	0.45	4.68e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs459571	0.959	rs460888	chr9:136913123	C/G	cg13789015	chr9:136890014	NCRNA00094	0.84	7.22	0.6	1.29e-10	Platelet distribution width;
THYM	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.46	-4.54	-0.42	1.65e-5	Crohn's disease;
THYM	cis	rs863345	0.604	rs6666805	chr1:158498305	G/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs6952809	0.504	rs1978169	chr7:2434522	G/A	cg13581527	chr7:1708566	NA	-0.76	-5.36	-0.48	5.7e-7	Multiple sclerosis;
THYM	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg20387954	chr3:183756860	HTR3D	0.54	5.21	0.47	1.09e-6	Anterior chamber depth;
THYM	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg00898013	chr13:113819073	PROZ	-1.04	-10.24	-0.72	5.14e-17	Platelet distribution width;
THYM	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg18758796	chr5:131593413	PDLIM4	0.61	6.05	0.53	2.91e-8	Breast cancer;
THYM	cis	rs4509693	0.891	rs10748797	chr10:102502173	A/C	cg24127310	chr10:102502104	NA	1.32	10.1	0.72	1.03e-16	Alzheimer's disease;
THYM	cis	rs10927875	0.541	rs1048237	chr1:16341733	T/C	cg21385522	chr1:16154831	NA	0.65	4.65	0.43	1.08e-5	Dilated cardiomyopathy;
THYM	cis	rs4849845	0.925	rs934725	chr2:121012902	C/T	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.22e-7	Corneal astigmatism;
THYM	cis	rs12110303	1	rs12110303	chr5:90662839	G/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	8.32	0.65	6.38e-13	Breast cancer;
THYM	cis	rs12216545	0.765	rs12538773	chr7:150250055	A/G	cg00323915	chr7:150264987	GIMAP4	-0.49	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg04398451	chr17:18023971	MYO15A	0.86	8.05	0.64	2.33e-12	Total body bone mineral density;
THYM	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg14582100	chr15:45693742	SPATA5L1	0.59	4.91	0.45	3.79e-6	Homoarginine levels;
THYM	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10540	1.000	rs61742833	chr11:490035	C/T	cg21784768	chr11:537496	LRRC56	-1.17	-5.17	-0.47	1.28e-6	Body mass index;
THYM	cis	rs11771526	0.892	rs62457541	chr7:32372566	G/A	cg27532318	chr7:32358331	NA	0.95	5.63	0.5	1.85e-7	Body mass index;
THYM	cis	rs4919087	0.961	rs11189120	chr10:99069493	G/T	cg19453742	chr10:98862320	SLIT1	-0.63	-5.17	-0.47	1.31e-6	Monocyte count;
THYM	cis	rs6500395	1.000	rs3919552	chr16:48716328	C/T	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs6754311	0.597	rs2278544	chr2:136546110	A/G	cg04750100	chr2:136595281	LCT	-0.55	-6.22	-0.54	1.31e-8	Mosquito bite size;
THYM	cis	rs6032067	0.759	rs6032043	chr20:43817897	A/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.29	-0.48	7.93e-7	Blood protein levels;
THYM	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.01	7.9	0.63	4.97e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs56104184	0.887	rs16982311	chr19:49342188	C/T	cg15549821	chr19:49342101	PLEKHA4	-1.27	-8.9	-0.67	3.62e-14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7722022	0.542	rs1363558	chr5:172904469	A/T	cg18512156	chr5:172661970	NKX2-5	-0.55	-4.63	-0.43	1.16e-5	Adiponectin levels;
THYM	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.53	5.0	0.46	2.57e-6	Lymphocyte counts;
THYM	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg11905131	chr22:24372483	LOC391322	-0.92	-9.62	-0.7	1.06e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs986417	0.818	rs1254325	chr14:60909689	A/G	cg27398547	chr14:60952738	C14orf39	-1.07	-5.72	-0.51	1.21e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg22709100	chr7:91322751	NA	-0.62	-4.77	-0.44	6.6e-6	Breast cancer;
THYM	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg18876405	chr7:65276391	NA	-0.57	-4.92	-0.45	3.56e-6	Aortic root size;
THYM	cis	rs6906287	0.647	rs7773274	chr6:118934740	C/G	cg21191810	chr6:118973309	C6orf204	0.58	5.8	0.51	8.72e-8	Electrocardiographic conduction measures;
THYM	cis	rs4731207	0.596	rs13224820	chr7:124655399	G/T	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs4642101	0.561	rs6766744	chr3:12801843	C/T	cg05775895	chr3:12838266	CAND2	0.72	5.67	0.5	1.52e-7	QRS complex (12-leadsum);
THYM	cis	rs9527	0.590	rs6584537	chr10:104778267	C/G	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-6.77	-0.57	1.04e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.92	5.02	0.46	2.41e-6	Initial pursuit acceleration;
THYM	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	6.6	0.56	2.34e-9	Smoking behavior;
THYM	cis	rs9880211	0.613	rs6439629	chr3:135901270	G/A	cg21827317	chr3:136751795	NA	-0.73	-5.09	-0.46	1.78e-6	Body mass index;Height;
THYM	cis	rs892961	0.899	rs72896163	chr17:75412525	C/T	cg11351908	chr17:75402473	SEPT9	0.56	5.5	0.49	3.23e-7	Airflow obstruction;
THYM	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg15693483	chr7:1102177	C7orf50	0.4	5.82	0.51	8.07e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg26384229	chr12:38710491	ALG10B	0.94	7.9	0.63	4.92e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg12463550	chr7:65579703	CRCP	-0.55	-4.5	-0.42	1.95e-5	Aortic root size;
THYM	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg01570182	chr17:44337453	NA	0.62	6.48	0.55	4.01e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1957429	0.901	rs17102320	chr14:65384693	T/C	cg23373153	chr14:65346875	NA	-1.04	-6.49	-0.55	3.87e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs12540874	0.542	rs4947582	chr7:50566090	C/T	cg18232548	chr7:50535776	DDC	-0.88	-8.38	-0.65	4.66e-13	Systemic sclerosis;
THYM	cis	rs9549328	0.577	rs4907477	chr13:113618484	A/G	cg10588471	chr13:113632644	MCF2L	-0.66	-4.62	-0.43	1.22e-5	Systolic blood pressure;
THYM	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg26818010	chr10:134567672	INPP5A	-0.63	-5.21	-0.47	1.07e-6	Migraine;
THYM	cis	rs28647808	1.000	rs28756699	chr9:136273527	G/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg14768367	chr16:72042858	DHODH	0.68	5.29	0.48	7.98e-7	Fibrinogen levels;
THYM	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg13695892	chr22:41940480	POLR3H	0.89	6.74	0.57	1.2e-9	Vitiligo;
THYM	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-6.77	-0.57	1.08e-9	Strep throat;
THYM	cis	rs1008375	1.000	rs13148861	chr4:17688338	G/A	cg18681998	chr4:17616180	MED28	-0.85	-6.97	-0.58	4.15e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg07424592	chr7:64974309	NA	-0.99	-5.15	-0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs11148252	0.740	rs7983971	chr13:52790700	C/T	cg00495681	chr13:53174319	NA	0.76	6.96	0.58	4.33e-10	Lewy body disease;
THYM	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg14196790	chr5:131705035	SLC22A5	-0.54	-4.74	-0.44	7.41e-6	Blood metabolite levels;
THYM	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs28785552	0.776	rs12978372	chr19:53242074	C/T	cg10871876	chr19:53194124	ZNF83	0.64	5.37	0.48	5.65e-7	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg18105134	chr13:113819100	PROZ	-0.98	-9.11	-0.68	1.32e-14	Platelet distribution width;
THYM	cis	rs9549367	0.713	rs3024746	chr13:113821777	G/A	cg18105134	chr13:113819100	PROZ	-1.09	-8.84	-0.67	5.06e-14	Platelet distribution width;
THYM	cis	rs2404602	0.647	rs55778276	chr15:77136590	T/A	cg23625390	chr15:77176239	SCAPER	-0.83	-5.85	-0.51	6.84e-8	Blood metabolite levels;
THYM	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg04476341	chr5:669733	TPPP	0.63	5.44	0.49	4.07e-7	Obesity-related traits;
THYM	cis	rs3826795	0.569	rs73059724	chr19:46796767	T/C	cg15229275	chr19:46800054	HIF3A	0.92	5.54	0.49	2.69e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs2069036	0.903	rs1361588	chr10:16079451	T/G	cg26633223	chr10:15133461	NA	0.64	4.52	0.42	1.8e-5	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg22920501	chr2:26401640	FAM59B	-0.68	-5.72	-0.51	1.24e-7	Gut microbiome composition (summer);
THYM	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg12031863	chr16:4587854	C16orf5	0.47	4.95	0.45	3.18e-6	Schizophrenia;
THYM	cis	rs28785552	0.554	rs11084185	chr19:53214600	T/A	cg10871876	chr19:53194124	ZNF83	0.71	5.52	0.49	2.9e-7	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg09035930	chr12:129282057	SLC15A4	0.86	12.0	0.78	9.76e-21	Systemic lupus erythematosus;
THYM	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg21775007	chr8:11205619	TDH	0.6	4.94	0.45	3.4e-6	Retinal vascular caliber;
THYM	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg16405210	chr4:1374714	KIAA1530	-0.7	-5.69	-0.5	1.4e-7	Longevity;
THYM	trans	rs629535	0.954	rs559245	chr8:70009238	T/A	cg21567404	chr3:27674614	NA	-1.1	-10.04	-0.72	1.36e-16	Dupuytren's disease;
THYM	cis	rs2016266	0.859	rs11170506	chr12:53730759	G/T	cg26875137	chr12:53738046	NA	-0.73	-5.27	-0.48	8.44e-7	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6977660	0.652	rs58559474	chr7:19751569	C/T	cg07541023	chr7:19748670	TWISTNB	1.2	6.7	0.57	1.45e-9	Thyroid stimulating hormone;
THYM	cis	rs4792901	0.765	rs9913605	chr17:41592510	G/A	cg21940313	chr17:41620911	ETV4	-0.53	-5.03	-0.46	2.28e-6	Dupuytren's disease;
THYM	cis	rs8063160	0.756	rs35026726	chr16:89791279	C/T	cg27050730	chr16:88968896	CBFA2T3	0.96	4.45	0.42	2.33e-5	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs2836633	1.000	rs2836631	chr21:40065906	G/T	cg05519781	chr21:40033154	ERG	-0.66	-6.22	-0.54	1.35e-8	Coronary artery disease;
THYM	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg14983838	chr19:29218262	NA	1.09	9.77	0.71	5e-16	Methadone dose in opioid dependence;
THYM	cis	rs8013055	0.796	rs35592422	chr14:105996593	G/C	cg04429589	chr14:105992532	TMEM121	-0.48	-5.22	-0.47	1.04e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs28785552	0.931	rs10406850	chr19:53240807	A/C	cg22067481	chr19:53234126	ZNF611	-0.97	-9.68	-0.7	7.8e-16	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs1568889	1.000	rs35697240	chr11:28287342	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.66e-6	Bipolar disorder;
THYM	cis	rs10489202	1.000	rs11587594	chr1:167989180	A/T	cg24449463	chr1:168025552	DCAF6	-0.83	-6.51	-0.56	3.58e-9	Schizophrenia;
THYM	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg07636037	chr3:49044803	WDR6	0.98	10.27	0.73	4.41e-17	Parkinson's disease;
THYM	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-4.48	-0.42	2.11e-5	Body mass index (adult);
THYM	cis	rs4474465	0.790	rs10793331	chr11:78270000	C/T	cg19901956	chr11:77921274	USP35	0.63	4.68	0.43	9.44e-6	Alzheimer's disease (survival time);
THYM	cis	rs7772486	0.686	rs9399565	chr6:146081906	G/T	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs34779708	0.966	rs11010095	chr10:35395948	A/G	cg03585969	chr10:35415529	CREM	0.67	5.01	0.46	2.51e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs9326248	0.559	rs4938334	chr11:116931042	G/C	cg20608306	chr11:116969690	SIK3	0.64	7.97	0.63	3.42e-12	Blood protein levels;
THYM	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs4654899	1.000	rs6682368	chr1:21506914	G/A	cg01072550	chr1:21505969	NA	-0.74	-6.63	-0.56	2.02e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg14196790	chr5:131705035	SLC22A5	-0.56	-5.21	-0.47	1.12e-6	Blood metabolite levels;
THYM	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs7901056	0.967	rs9299820	chr10:26722622	C/T	cg23318538	chr10:26883079	C10orf50	-0.37	-4.96	-0.45	3.12e-6	Lymphocyte counts;
THYM	trans	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg21427119	chr20:30132790	HM13	-0.86	-5.96	-0.52	4.2e-8	Mean corpuscular hemoglobin;
THYM	cis	rs7762018	0.607	rs6907814	chr6:170058206	G/A	cg19338460	chr6:170058176	WDR27	-1.04	-6.21	-0.54	1.42e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg07936489	chr17:37558343	FBXL20	0.83	5.69	0.5	1.41e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7553864	0.589	rs7516494	chr1:87613268	G/A	cg17420885	chr1:87600446	LOC339524	-0.91	-7.88	-0.63	5.49e-12	Smoking behavior;
THYM	cis	rs7072216	0.770	rs1061123	chr10:100176997	A/G	cg26618903	chr10:100175079	PYROXD2	-0.45	-4.51	-0.42	1.84e-5	Metabolite levels;
THYM	cis	rs28374715	0.528	rs7178360	chr15:41631175	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.78	-0.83	2.3e-26	Ulcerative colitis;
THYM	cis	rs6500596	0.570	rs758045	chr16:4434198	A/G	cg09549813	chr16:4587862	C16orf5	-0.49	-4.82	-0.44	5.55e-6	Schizophrenia;
THYM	cis	rs11779988	0.516	rs426498	chr8:17897158	T/C	cg01800426	chr8:17659068	MTUS1	-0.66	-4.83	-0.44	5.23e-6	Breast cancer;
THYM	cis	rs62045849	0.557	rs6500534	chr16:89190313	C/T	cg06035645	chr16:89190857	ACSF3	-0.88	-5.57	-0.5	2.39e-7	Red blood cell count;
THYM	cis	rs654128	0.640	rs339337	chr6:117214675	G/A	cg12892004	chr6:117198278	RFX6	-0.72	-5.66	-0.5	1.61e-7	Telomere length;
THYM	cis	rs611744	0.837	rs403200	chr8:109103375	C/T	cg21045802	chr8:109455806	TTC35	0.59	5.24	0.47	9.78e-7	Dupuytren's disease;
THYM	cis	rs10779751	0.770	rs12075896	chr1:11200350	C/A	cg08854313	chr1:11322531	MTOR	-0.76	-5.88	-0.52	6.08e-8	Body mass index;
THYM	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.3	0.73	3.8e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg22875332	chr1:76189707	ACADM	-0.54	-5.07	-0.46	1.96e-6	Daytime sleep phenotypes;
THYM	cis	rs236352	0.576	rs3756905	chr6:36843777	C/T	cg03410223	chr6:36853544	C6orf89	0.71	5.65	0.5	1.69e-7	Heart rate;
THYM	cis	rs4731207	0.623	rs4506149	chr7:124626473	G/A	cg05285228	chr7:124571219	POT1	-0.7	-5.29	-0.48	7.77e-7	Cutaneous malignant melanoma;
THYM	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg08431931	chr22:42394659	WBP2NL	0.71	4.98	0.46	2.81e-6	Birth weight;
THYM	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg06917634	chr15:78832804	PSMA4	0.96	8.76	0.67	7.4e-14	Sudden cardiac arrest;
THYM	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs1371867	0.875	rs1619759	chr8:101337560	T/C	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs3760982	0.813	rs8111664	chr19:44295092	G/A	cg11993925	chr19:44307056	LYPD5	-0.56	-4.47	-0.42	2.13e-5	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg04944784	chr2:26401820	FAM59B	0.64	4.8	0.44	5.97e-6	Gut microbiome composition (summer);
THYM	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg19077165	chr18:44547161	KATNAL2	-0.67	-8.66	-0.66	1.19e-13	Personality dimensions;
THYM	cis	rs4474465	0.850	rs10793327	chr11:78256841	A/C	cg19901956	chr11:77921274	USP35	0.58	4.54	0.42	1.68e-5	Alzheimer's disease (survival time);
THYM	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg13010199	chr12:38710504	ALG10B	-0.59	-4.72	-0.44	8.19e-6	Morning vs. evening chronotype;
THYM	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg27446573	chr6:127587934	RNF146	0.87	6.7	0.57	1.45e-9	Breast cancer;
THYM	cis	rs669446	0.533	rs2158956	chr1:44211697	T/C	cg12599982	chr1:44399894	ARTN	0.52	4.74	0.44	7.55e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs2040771	0.804	rs2073754	chr22:19221406	G/T	cg02655711	chr22:19163373	SLC25A1	-0.54	-5.71	-0.51	1.27e-7	Metabolite levels (small molecules and protein measures);
THYM	cis	rs9646944	0.501	rs2075186	chr2:103057251	G/T	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg10802521	chr3:52805072	NEK4	-0.71	-6.18	-0.54	1.57e-8	Bipolar disorder;
THYM	cis	rs7586879	0.616	rs12713422	chr2:25134497	A/C	cg15423357	chr2:25149977	NA	0.7	7.76	0.62	9.56e-12	Body mass index;
THYM	cis	rs2811415	0.597	rs9837457	chr3:127777040	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs76878669	0.793	rs7924580	chr11:66080770	C/T	cg18002602	chr11:66138449	SLC29A2	-0.66	-5.7	-0.5	1.37e-7	Educational attainment (years of education);
THYM	cis	rs7582180	0.663	rs2309794	chr2:100954270	G/A	cg08017756	chr2:100939284	LONRF2	-0.74	-7.88	-0.63	5.29e-12	Intelligence (multi-trait analysis);
THYM	trans	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.11	8.17	0.64	1.3e-12	Exhaled nitric oxide output;
THYM	cis	rs7940866	0.834	rs10791105	chr11:130839161	A/G	cg12179176	chr11:130786555	SNX19	0.63	4.84	0.44	5e-6	Schizophrenia;
THYM	trans	rs11109072	1.000	rs7956279	chr12:97902092	A/G	cg17633015	chr7:2020501	MAD1L1	0.9	6.88	0.58	6.35e-10	Obesity (early onset extreme);
THYM	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	5.37	0.48	5.68e-7	Obesity-related traits;
THYM	cis	rs7246657	0.525	rs997516	chr19:37474264	T/C	cg22634378	chr19:37742834	NA	0.66	4.83	0.44	5.32e-6	Coronary artery calcification;
THYM	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg00129232	chr17:37814104	STARD3	-0.77	-5.27	-0.48	8.58e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs4389656	0.826	rs395939	chr5:6734245	T/C	cg10857441	chr5:6722123	POLS	-0.44	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.77	-5.05	-0.46	2.13e-6	Mean platelet volume;
THYM	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg11518657	chr1:67396239	MIER1	0.63	4.56	0.42	1.55e-5	Lymphocyte percentage of white cells;
THYM	cis	rs7572733	0.534	rs770657	chr2:198674184	C/A	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg21433313	chr16:3507492	NAT15	0.58	4.89	0.45	4.06e-6	Body mass index (adult);
THYM	cis	rs7683537	0.692	rs56317358	chr4:185659470	G/A	cg04058563	chr4:185651563	MLF1IP	1.09	7.62	0.62	1.92e-11	Systemic lupus erythematosus;
THYM	cis	rs6840360	0.571	rs4696279	chr4:152560449	G/A	cg17479576	chr4:152424074	FAM160A1	-0.79	-5.55	-0.49	2.59e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03264133	chr6:25882463	NA	-0.74	-5.87	-0.52	6.46e-8	Blood metabolite levels;
THYM	cis	rs6743226	0.901	rs7599888	chr2:242248033	C/G	cg10021735	chr2:242295487	FARP2	-0.63	-4.56	-0.42	1.5e-5	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs4076764	0.914	rs12123378	chr1:163377846	C/T	cg24596788	chr1:163392923	NA	-0.8	-7.45	-0.61	4.17e-11	Motion sickness;
THYM	cis	rs2073300	1.000	rs6036411	chr20:23441706	A/C	cg12062639	chr20:23401060	NAPB	1.32	6.15	0.53	1.81e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs9677476	0.863	rs16827863	chr2:232077670	C/T	cg23338755	chr2:231921595	PSMD1	-0.68	-5.2	-0.47	1.14e-6	Food antigen IgG levels;
THYM	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.47	0.49	3.63e-7	Bipolar disorder;
THYM	cis	rs11574514	1.000	rs8054034	chr16:67773652	C/A	cg04582263	chr16:67973788	LCAT	0.94	4.45	0.42	2.31e-5	Crohn's disease;
THYM	cis	rs17443541	0.516	rs1450569	chr2:200443111	A/T	cg01795955	chr2:200468626	NA	-0.69	-4.57	-0.42	1.45e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1697139	0.583	rs11739727	chr5:66540940	G/A	cg11553311	chr5:66541588	NA	0.72	7.5	0.61	3.36e-11	Breast cancer;
THYM	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg00786635	chr1:25594202	NA	0.92	7.28	0.6	9.7e-11	Erythrocyte sedimentation rate;
THYM	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg24399712	chr22:39784796	NA	-0.82	-8.35	-0.65	5.41e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg26384229	chr12:38710491	ALG10B	0.94	7.38	0.6	5.97e-11	Bladder cancer;
THYM	cis	rs644799	0.582	rs1727149	chr11:95497171	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.68	-5.51	-0.49	3.03e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7681440	0.606	rs2583980	chr4:90751109	T/G	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs17744026	0.649	rs11219307	chr11:123686185	G/T	cg00079598	chr11:123676903	OR6M1	-0.51	-4.63	-0.43	1.15e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs7267979	0.966	rs6037083	chr20:25290543	T/C	cg08601574	chr20:25228251	PYGB	-0.57	-4.61	-0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg03476357	chr21:30257390	N6AMT1	0.6	4.6	0.43	1.31e-5	Dental caries;
THYM	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg26850624	chr5:429559	AHRR	0.53	4.5	0.42	1.93e-5	Cystic fibrosis severity;
THYM	cis	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.1	-0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg08017756	chr2:100939284	LONRF2	0.75	7.8	0.62	7.89e-12	Intelligence (multi-trait analysis);
THYM	cis	rs977987	0.815	rs4887829	chr16:75488935	C/T	cg03315344	chr16:75512273	CHST6	0.72	5.99	0.52	3.67e-8	Dupuytren's disease;
THYM	cis	rs11997175	0.967	rs11993169	chr8:33738004	G/T	ch.8.33884649F	chr8:33765107	NA	0.63	4.94	0.45	3.35e-6	Body mass index;
THYM	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg23161317	chr6:28129485	ZNF389	0.84	6.3	0.54	9.31e-9	Depression;
THYM	cis	rs4285028	0.948	rs34566912	chr3:121679626	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs4919694	1.000	rs12245343	chr10:104774050	A/G	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	cis	rs9419702	0.568	rs11156445	chr10:133542301	T/C	cg20568497	chr10:133558893	NA	0.46	4.58	0.43	1.43e-5	Survival in rectal cancer;
THYM	cis	rs10489202	0.632	rs203779	chr1:167877647	T/G	cg24449463	chr1:168025552	DCAF6	-0.9	-9.11	-0.68	1.35e-14	Schizophrenia;
THYM	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	7.5	0.61	3.28e-11	Platelet count;
THYM	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg02782426	chr3:40428986	ENTPD3	-0.51	-4.56	-0.42	1.55e-5	Renal cell carcinoma;
THYM	cis	rs34912216	0.542	rs4607516	chr7:4130004	A/G	cg03141780	chr7:4150753	SDK1	0.69	5.03	0.46	2.31e-6	Motion sickness;
THYM	trans	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg18335740	chr13:41363409	SLC25A15	0.75	7.34	0.6	7.31e-11	Lewy body disease;
THYM	cis	rs4474465	1.000	rs7935180	chr11:78169785	C/T	cg19901956	chr11:77921274	USP35	-0.6	-4.55	-0.42	1.56e-5	Alzheimer's disease (survival time);
THYM	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg05347473	chr6:146136440	FBXO30	0.81	7.21	0.59	1.34e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7246657	0.653	rs28701616	chr19:37681098	G/A	cg23950597	chr19:37808831	NA	-0.81	-4.88	-0.45	4.35e-6	Coronary artery calcification;
THYM	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg00271210	chr6:167070053	RPS6KA2	-0.5	-4.96	-0.45	3.07e-6	Rheumatoid arthritis;
THYM	cis	rs240764	0.631	rs12195369	chr6:101204106	G/A	cg21058520	chr6:100914733	NA	0.6	5.25	0.47	9.27e-7	Neuroticism;
THYM	cis	rs752010	1.000	rs752010	chr1:42093015	C/T	cg22486000	chr1:42919398	ZMYND12	-0.42	-4.95	-0.45	3.25e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11890956	chr21:40555474	PSMG1	0.97	11.03	0.75	1.05e-18	Cognitive function;
THYM	cis	rs7246657	0.943	rs1382357	chr19:37977609	G/A	cg22634378	chr19:37742834	NA	0.62	5.18	0.47	1.22e-6	Coronary artery calcification;
THYM	cis	rs7849270	0.879	rs7042928	chr9:131855275	G/T	cg14069949	chr9:131965419	NA	-0.5	-4.46	-0.42	2.28e-5	Blood metabolite ratios;
THYM	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg24675658	chr1:53192096	ZYG11B	0.69	6.11	0.53	2.18e-8	Monocyte count;
THYM	cis	rs7084402	0.935	rs2393449	chr10:60343030	A/G	cg07615347	chr10:60278583	BICC1	0.57	5.33	0.48	6.57e-7	Refractive error;
THYM	cis	rs9534288	0.797	rs994351	chr13:46588194	A/G	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs2070433	0.539	rs56157650	chr21:47957959	T/C	cg12379764	chr21:47803548	PCNT	0.67	4.91	0.45	3.84e-6	Lymphocyte counts;
THYM	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg03433033	chr1:76189801	ACADM	0.7	6.7	0.57	1.45e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9916302	0.706	rs3744349	chr17:37414842	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-5.58	-0.5	2.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs728616	0.764	rs75385771	chr10:81692779	T/C	cg27452691	chr10:81370291	SFTPA1	0.83	4.49	0.42	2.03e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg13114125	chr14:105738426	BRF1	0.7	5.45	0.49	4e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4481887	0.676	rs7520659	chr1:248527586	C/A	cg00666640	chr1:248458726	OR2T12	0.54	4.62	0.43	1.2e-5	Common traits (Other);
THYM	cis	rs7224737	1.000	rs12603330	chr17:40290589	T/A	cg20291162	chr17:40259547	DHX58	-0.69	-6.44	-0.55	4.96e-9	Fibrinogen levels;
THYM	cis	rs7584330	0.737	rs6431539	chr2:238360708	G/T	cg04447362	chr2:237654635	NA	0.49	4.49	0.42	2e-5	Prostate cancer;
THYM	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg12379764	chr21:47803548	PCNT	-0.83	-5.37	-0.48	5.52e-7	Testicular germ cell tumor;
THYM	cis	rs8050907	0.661	rs28535861	chr16:4620608	G/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.57	0.42	1.47e-5	Obesity-related traits;
THYM	cis	rs13065560	0.594	rs4234134	chr3:38887970	A/T	cg15678707	chr3:39149194	GORASP1;TTC21A	-0.59	-4.62	-0.43	1.19e-5	Interleukin-18 levels;
THYM	cis	rs11650494	0.908	rs77338752	chr17:47372328	A/C	cg08112188	chr17:47440006	ZNF652	1.25	5.41	0.49	4.62e-7	Prostate cancer;
THYM	cis	rs11096990	0.855	rs2566173	chr4:39152731	G/C	cg24403649	chr4:39172243	NA	-0.6	-5.09	-0.46	1.77e-6	Cognitive function;
THYM	cis	rs9611519	1.000	rs3818003	chr22:41609690	C/T	cg06481639	chr22:41940642	POLR3H	-0.62	-4.6	-0.43	1.28e-5	Neuroticism;
THYM	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg24675658	chr1:53192096	ZYG11B	-0.77	-6.93	-0.58	5.04e-10	Monocyte count;
THYM	trans	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	3.97e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs8016982	0.963	rs7149672	chr14:81657336	A/G	cg01989461	chr14:81687754	GTF2A1	0.61	4.46	0.42	2.25e-5	Schizophrenia;
THYM	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg15962314	chr1:44399869	ARTN	0.54	5.78	0.51	9.62e-8	Intelligence (multi-trait analysis);
THYM	cis	rs586688	0.556	rs981309	chr1:201674081	A/G	cg22488259	chr1:201708500	NAV1	-0.38	-4.51	-0.42	1.87e-5	Obesity-related traits;
THYM	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs12142240	0.731	rs6681857	chr1:46850124	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs10779751	0.727	rs4845852	chr1:11233559	C/T	cg08854313	chr1:11322531	MTOR	0.83	7.47	0.61	3.81e-11	Body mass index;
THYM	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.16	-5.63	-0.5	1.85e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1568889	0.775	rs35243076	chr11:28250618	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs2290159	0.800	rs9809947	chr3:12655944	T/C	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.68	0.5	1.45e-7	Height;
THYM	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.41	-0.49	4.69e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9467711	0.651	rs34043431	chr6:25875084	T/C	cg16898833	chr6:26189333	HIST1H4D	1.33	4.6	0.43	1.32e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg13246856	chr1:44399776	ARTN	-0.5	-4.8	-0.44	5.97e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs4866334	1.000	rs76371744	chr5:18441614	T/G	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-1.12	-9.2	-0.69	8.38e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg00684032	chr4:1343700	KIAA1530	0.62	5.57	0.5	2.37e-7	Obesity-related traits;
THYM	cis	rs988913	1.000	rs9349741	chr6:54841709	G/C	cg18532076	chr6:54711417	FAM83B	0.5	4.91	0.45	3.78e-6	Menarche (age at onset);
THYM	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg08772003	chr10:104629869	AS3MT	-0.72	-5.49	-0.49	3.31e-7	Arsenic metabolism;
THYM	cis	rs6586111	1.000	rs7071690	chr10:82376017	C/T	cg03086067	chr10:82368399	SH2D4B	-0.52	-6.55	-0.56	2.91e-9	Capecitabine sensitivity;
THYM	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg12863693	chr15:85201151	NMB	0.63	5.5	0.49	3.17e-7	Schizophrenia;
THYM	cis	rs9972944	0.756	rs6504353	chr17:63768013	T/C	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg21773646	chr17:80085082	CCDC57	0.31	4.49	0.42	2.02e-5	Life satisfaction;
THYM	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg25358565	chr5:93447407	FAM172A	1.31	11.12	0.75	6.98e-19	Diabetic retinopathy;
THYM	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg08017756	chr2:100939284	LONRF2	-0.77	-7.76	-0.62	9.52e-12	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg18252515	chr7:66147081	NA	0.66	4.87	0.45	4.38e-6	Aortic root size;
THYM	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg13114125	chr14:105738426	BRF1	-0.75	-5.91	-0.52	5.39e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs919433	0.889	rs788001	chr2:198213720	C/T	cg00792783	chr2:198669748	PLCL1	0.76	5.36	0.48	5.86e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs951188	0.744	rs72992991	chr2:150347296	G/C	cg17961725	chr2:150454027	NA	-0.77	-4.74	-0.44	7.64e-6	Daytime sleep phenotypes;
THYM	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg27398817	chr8:82754497	SNX16	-0.83	-6.57	-0.56	2.65e-9	Diastolic blood pressure;
THYM	cis	rs7107770	1.000	rs4935913	chr11:125103146	C/G	cg04164023	chr11:125106101	PKNOX2	-0.77	-4.63	-0.43	1.16e-5	Photic sneeze reflex;
THYM	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg18512352	chr11:47633146	NA	-0.55	-6.84	-0.57	7.79e-10	Subjective well-being;
THYM	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.76	-4.94	-0.45	3.31e-6	Mean platelet volume;
THYM	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14893161	chr1:205819251	PM20D1	0.9	9.23	0.69	7.34e-15	Menarche (age at onset);
THYM	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg25358565	chr5:93447407	FAM172A	-0.96	-6.78	-0.57	1.01e-9	Diabetic retinopathy;
THYM	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg03351412	chr1:154909251	PMVK	0.67	4.65	0.43	1.07e-5	Prostate cancer;
THYM	cis	rs80319144	0.953	rs74504705	chr2:159165286	T/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.6	0.43	1.29e-5	Restless legs syndrome;
THYM	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.67	6.24	0.54	1.23e-8	Prudent dietary pattern;
THYM	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg08885076	chr2:99613938	TSGA10	0.54	4.92	0.45	3.68e-6	Chronic sinus infection;
THYM	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-6.93	-0.58	4.9e-10	Neuroticism;
THYM	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg23758822	chr17:41437982	NA	1.17	11.09	0.75	7.92e-19	Menopause (age at onset);
THYM	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs6430585	0.583	rs73957037	chr2:136588031	C/A	cg07169764	chr2:136633963	MCM6	1.09	12.73	0.79	3.04e-22	Corneal structure;
THYM	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg18252515	chr7:66147081	NA	-0.66	-4.85	-0.45	4.8e-6	Aortic root size;
THYM	cis	rs12653946	0.811	rs10866527	chr5:1891800	C/T	cg22472608	chr5:1891194	NA	-0.74	-5.85	-0.51	7.06e-8	Prostate cancer;
THYM	cis	rs757081	0.867	rs2521999	chr11:17333183	G/A	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.54	-0.42	1.68e-5	Systolic blood pressure;
THYM	cis	rs4792901	0.802	rs12602059	chr17:41573730	A/G	cg21940313	chr17:41620911	ETV4	-0.54	-5.08	-0.46	1.92e-6	Dupuytren's disease;
THYM	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg07570687	chr10:102243282	WNT8B	0.74	6.71	0.57	1.37e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2456568	0.525	rs6483269	chr11:93620428	C/T	cg08514419	chr11:93583937	C11orf90	0.48	4.64	0.43	1.1e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg23711669	chr6:146136114	FBXO30	0.86	8.21	0.64	1.07e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg24675658	chr1:53192096	ZYG11B	-0.75	-5.77	-0.51	9.84e-8	Monocyte count;
THYM	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg18252515	chr7:66147081	NA	-1.57	-8.55	-0.66	2.07e-13	Diabetic kidney disease;
THYM	cis	rs59698941	0.943	rs67806898	chr5:132296771	A/G	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg26384229	chr12:38710491	ALG10B	-0.64	-4.84	-0.44	5.01e-6	Drug-induced liver injury (flucloxacillin);
THYM	trans	rs877282	1.000	rs10904552	chr10:774326	A/G	cg22713356	chr15:30763199	NA	1.27	10.33	0.73	3.32e-17	Uric acid levels;
THYM	cis	rs8067545	0.562	rs2526481	chr17:20127018	T/C	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg08132940	chr7:1081526	C7orf50	-1.16	-6.62	-0.56	2.1e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg10523679	chr1:76189770	ACADM	0.83	7.78	0.62	8.78e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7119	0.717	rs62009071	chr15:77817886	C/G	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg02953382	chr22:24373134	LOC391322	0.73	6.6	0.56	2.36e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs714027	1.000	rs4823073	chr22:30512258	G/A	cg11564601	chr22:30592435	NA	-0.3	-5.45	-0.49	3.98e-7	Lymphocyte counts;
THYM	cis	rs7584330	0.826	rs7604315	chr2:238381729	C/G	cg16989719	chr2:238392110	NA	-0.63	-5.46	-0.49	3.73e-7	Prostate cancer;
THYM	cis	rs12928939	0.911	rs7202840	chr16:71824714	C/T	cg03805757	chr16:71968109	PKD1L3	-0.7	-5.31	-0.48	7.25e-7	Post bronchodilator FEV1;
THYM	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	10.29	0.73	3.95e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs76662990	0.610	rs9942348	chr5:73944997	G/A	cg13275603	chr5:73927487	ENC1	-0.71	-4.45	-0.42	2.33e-5	Residual cognition;
THYM	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg26597838	chr10:835615	NA	1.19	8.57	0.66	1.83e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg20503657	chr10:835505	NA	1.13	7.89	0.63	5.22e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg02018176	chr4:1364513	KIAA1530	0.53	4.56	0.42	1.51e-5	Obesity-related traits;
THYM	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.44	6.67	0.56	1.66e-9	Obesity-related traits;
THYM	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-6.55	-0.56	2.97e-9	Electrocardiographic conduction measures;
THYM	cis	rs10751667	0.621	rs7396049	chr11:1001561	G/A	cg20946044	chr11:1010712	AP2A2	-0.57	-4.83	-0.44	5.27e-6	Alzheimer's disease (late onset);
THYM	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg20486651	chr6:167070296	RPS6KA2	-0.49	-4.7	-0.43	8.94e-6	Crohn's disease;
THYM	cis	rs1642645	0.793	rs7546128	chr1:42473659	C/A	cg06092502	chr1:42611687	NA	0.61	4.76	0.44	7.05e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg24069376	chr3:38537580	EXOG	0.58	6.0	0.52	3.53e-8	Electrocardiographic conduction measures;
THYM	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.57	-5.57	-0.5	2.41e-7	Lymphocyte counts;
THYM	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg12165864	chr7:66369176	NA	-0.81	-5.92	-0.52	5.09e-8	Corneal structure;
THYM	cis	rs9677476	0.818	rs28678038	chr2:232063997	A/T	cg07929768	chr2:232055508	NA	0.63	6.28	0.54	1.01e-8	Food antigen IgG levels;
THYM	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg27286337	chr10:134555280	INPP5A	0.87	6.67	0.56	1.7e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs4589258	0.966	rs4631841	chr11:90456337	A/C	cg26138821	chr11:89956704	CHORDC1	-0.63	-4.99	-0.46	2.74e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg17063962	chr7:91808500	NA	1.16	12.78	0.8	2.34e-22	Breast cancer;
THYM	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.62	-5.17	-0.47	1.27e-6	Homoarginine levels;
THYM	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.9	7.41	0.61	5.04e-11	Menarche (age at onset);
THYM	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg05373962	chr22:49881684	NA	-0.6	-5.47	-0.49	3.61e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03517284	chr6:25882590	NA	-0.71	-5.34	-0.48	6.32e-7	Height;
THYM	cis	rs7575217	0.654	rs62155196	chr2:101701022	A/G	cg23907051	chr2:101730305	TBC1D8	0.41	5.63	0.5	1.83e-7	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg18252515	chr7:66147081	NA	-1.44	-8.7	-0.67	9.82e-14	Diabetic kidney disease;
THYM	cis	rs10463554	0.927	rs40061	chr5:102403116	G/A	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs7119	0.931	rs11630540	chr15:77833625	G/A	cg27398640	chr15:77910606	LINGO1	-0.57	-5.64	-0.5	1.74e-7	Type 2 diabetes;
THYM	cis	rs4638749	0.677	rs2100407	chr2:108830188	G/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg04267008	chr7:1944627	MAD1L1	-0.66	-5.43	-0.49	4.23e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg02524346	chr8:600233	NA	0.92	4.48	0.42	2.05e-5	IgG glycosylation;
THYM	cis	rs2070677	0.877	rs2987791	chr10:135370060	G/C	cg20169779	chr10:135381914	SYCE1	0.87	6.56	0.56	2.85e-9	Gout;
THYM	cis	rs42648	0.567	rs12669304	chr7:89891040	T/C	cg03688058	chr7:89840708	STEAP2	-0.54	-4.45	-0.42	2.36e-5	Homocysteine levels;
THYM	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg16586182	chr3:47516702	SCAP	0.58	5.03	0.46	2.35e-6	Colorectal cancer;
THYM	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg23161317	chr6:28129485	ZNF389	0.75	5.76	0.51	1.03e-7	Cardiac Troponin-T levels;
THYM	cis	rs2820651	1.000	rs79446083	chr10:1476044	T/A	cg13720710	chr10:1452970	ADARB2	0.78	4.63	0.43	1.16e-5	Migraine with aura;
THYM	cis	rs13070279	0.786	rs11716884	chr3:71809397	A/C	cg19388776	chr3:71835112	PROK2	0.88	4.93	0.45	3.49e-6	Monocyte count;
THYM	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg27087555	chr16:88793112	FAM38A	-1.28	-7.35	-0.6	6.77e-11	Plateletcrit;
THYM	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg16586182	chr3:47516702	SCAP	0.6	5.12	0.47	1.6e-6	Colorectal cancer;
THYM	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg11366901	chr6:160182831	ACAT2	1.04	8.69	0.67	1.03e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg23205692	chr1:25664452	TMEM50A	0.84	6.54	0.56	3.13e-9	Erythrocyte sedimentation rate;
THYM	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg04429589	chr14:105992532	TMEM121	-0.48	-5.33	-0.48	6.64e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg26384229	chr12:38710491	ALG10B	-0.71	-5.64	-0.5	1.78e-7	Morning vs. evening chronotype;
THYM	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg18512352	chr11:47633146	NA	-0.53	-6.23	-0.54	1.27e-8	Subjective well-being;
THYM	cis	rs4824093	0.610	rs58888255	chr22:50315627	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-4.68	-0.43	9.37e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg17366294	chr4:99064904	C4orf37	0.55	6.57	0.56	2.7e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs198389	0.589	rs535107	chr1:11889468	C/T	cg24844545	chr1:11908347	NPPA	0.48	4.69	0.43	9.23e-6	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
THYM	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22857025	chr5:266934	NA	-1.43	-9.2	-0.69	8.52e-15	Breast cancer;
THYM	cis	rs752010	0.838	rs11210505	chr1:42104731	G/C	cg06885757	chr1:42089581	HIVEP3	0.42	4.72	0.44	7.98e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg11965913	chr1:205819406	PM20D1	0.95	10.38	0.73	2.57e-17	Menarche (age at onset);
THYM	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg07636037	chr3:49044803	WDR6	0.99	10.39	0.73	2.45e-17	Parkinson's disease;
THYM	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg11335335	chr11:637885	DRD4	-0.69	-6.23	-0.54	1.24e-8	Systemic lupus erythematosus;
THYM	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18876405	chr7:65276391	NA	-0.57	-4.7	-0.43	8.76e-6	Aortic root size;
THYM	cis	rs1692120	0.545	rs962370	chr11:61408401	A/T	cg19838087	chr11:61442541	NA	0.52	5.97	0.52	4.17e-8	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
THYM	cis	rs2637266	0.749	rs4979831	chr10:78457588	G/T	cg18941641	chr10:78392320	NA	0.81	6.55	0.56	2.92e-9	Pulmonary function;
THYM	cis	rs72781680	0.799	rs2551332	chr2:23988950	T/C	cg08917208	chr2:24149416	ATAD2B	0.85	4.5	0.42	1.96e-5	Lymphocyte counts;
THYM	cis	rs11585357	0.947	rs72646795	chr1:17612120	C/T	cg08277548	chr1:17600880	PADI3	-0.92	-6.03	-0.53	3.17e-8	Hair shape;
THYM	cis	rs7211079	0.582	rs72852528	chr17:78136089	T/C	cg04028464	chr17:78073854	GAA;CCDC40	0.71	4.67	0.43	9.71e-6	Myocardial infarction;
THYM	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg05738196	chr6:26577821	NA	-0.57	-4.73	-0.44	7.64e-6	Schizophrenia;
THYM	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg02527881	chr3:46936655	PTH1R	-0.6	-5.74	-0.51	1.12e-7	Colorectal cancer;
THYM	cis	rs8114671	0.935	rs6058198	chr20:33748253	T/A	cg08999081	chr20:33150536	PIGU	0.55	4.92	0.45	3.63e-6	Height;
THYM	cis	rs1971762	0.545	rs4759280	chr12:54064958	C/A	cg16917193	chr12:54089295	NA	0.84	8.06	0.64	2.3e-12	Height;
THYM	cis	rs1883415	0.530	rs3765311	chr6:24503862	G/T	cg00346970	chr6:24499591	ALDH5A1	-0.37	-5.98	-0.52	3.89e-8	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs921665	0.680	rs7591433	chr2:3180126	A/C	cg16434511	chr2:3151078	NA	-0.78	-4.93	-0.45	3.48e-6	World class endurance athleticism;
THYM	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs4975616	0.771	rs3816659	chr5:1317820	A/G	cg06550200	chr5:1325588	CLPTM1L	0.7	5.77	0.51	9.8e-8	Lung cancer;
THYM	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg25554036	chr4:6271136	WFS1	0.56	5.29	0.48	7.94e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03452623	chr4:187889614	NA	-1.15	-17.46	-0.87	2.12e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg25072359	chr17:41440525	NA	0.72	5.31	0.48	7.04e-7	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg03709012	chr19:19516395	GATAD2A	0.78	6.2	0.54	1.44e-8	Tonsillectomy;
THYM	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg03433033	chr1:76189801	ACADM	0.76	8.95	0.68	2.88e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs10208940	0.614	rs7593112	chr2:68808208	A/G	cg09157127	chr2:69201416	GKN1	0.78	4.61	0.43	1.24e-5	Urate levels in lean individuals;
THYM	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.87	-6.47	-0.55	4.16e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.24	-10.02	-0.72	1.53e-16	Platelet count;
THYM	cis	rs2273669	0.504	rs75423558	chr6:109499130	T/C	cg17117243	chr6:109341365	SESN1	-0.77	-4.56	-0.42	1.5e-5	Prostate cancer;
THYM	cis	rs2933343	0.729	rs789224	chr3:128598231	A/C	cg11901034	chr3:128598214	ACAD9	-0.7	-5.68	-0.5	1.47e-7	IgG glycosylation;
THYM	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg07570687	chr10:102243282	WNT8B	0.75	6.59	0.56	2.4e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9825379	0.643	rs9869102	chr3:141138833	A/G	cg13411656	chr3:141121016	ZBTB38	-0.49	-4.51	-0.42	1.86e-5	Height;
THYM	cis	rs4237845	0.537	rs10747786	chr12:58260601	G/T	cg00677455	chr12:58241039	CTDSP2	0.8	6.91	0.58	5.45e-10	Intelligence (multi-trait analysis);
THYM	trans	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.12	8.09	0.64	1.9e-12	Exhaled nitric oxide output;
THYM	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg02782426	chr3:40428986	ENTPD3	0.55	4.96	0.45	3.05e-6	Renal cell carcinoma;
THYM	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs72828912	0.731	rs55691906	chr6:24068410	C/T	cg26336265	chr6:25042955	NA	-0.86	-5.43	-0.49	4.31e-7	Squamous cell lung carcinoma;
THYM	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs995000	0.839	rs1168028	chr1:62969431	G/A	cg06896770	chr1:63153194	DOCK7	-0.91	-7.48	-0.61	3.62e-11	Triglyceride levels;
THYM	cis	rs7107174	0.688	rs869202	chr11:78127914	A/G	cg19901956	chr11:77921274	USP35	-0.71	-5.35	-0.48	6.07e-7	Testicular germ cell tumor;
THYM	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11890956	chr21:40555474	PSMG1	-0.9	-9.45	-0.7	2.51e-15	Cognitive function;
THYM	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg21394778	chr1:3037102	PRDM16	0.46	4.47	0.42	2.12e-5	Height;
THYM	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg10515332	chr4:99064459	C4orf37	0.63	5.07	0.46	1.97e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6754311	0.593	rs12619365	chr2:136398174	C/T	cg20242066	chr2:136595261	LCT	0.55	6.04	0.53	3.05e-8	Mosquito bite size;
THYM	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.72	6.79	0.57	9.58e-10	Lymphocyte counts;
THYM	cis	rs9876781	1.000	rs6442117	chr3:48419897	C/T	cg06066452	chr3:48470258	PLXNB1	-0.25	-4.77	-0.44	6.73e-6	Longevity;
THYM	cis	rs1034435	0.755	rs5768680	chr22:48892919	T/C	cg05992904	chr22:48892994	FAM19A5	-0.81	-8.89	-0.67	3.91e-14	Late-onset Alzheimer's disease;
THYM	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg07747251	chr5:1868357	NA	0.64	5.4	0.48	4.92e-7	Cardiovascular disease risk factors;
THYM	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg10760299	chr15:45669010	GATM	0.87	6.78	0.57	1.03e-9	Homoarginine levels;
THYM	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-4.93	-0.45	3.42e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs921968	0.612	rs496908	chr2:219357742	A/T	cg02176678	chr2:219576539	TTLL4	0.68	6.33	0.54	7.91e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7246967	0.611	rs7246424	chr19:22882185	A/G	cg05241461	chr19:22816980	ZNF492	0.6	4.64	0.43	1.11e-5	Bronchopulmonary dysplasia;
THYM	cis	rs7071206	0.853	rs57420220	chr10:79428886	C/T	cg07817648	chr10:79422355	NA	-1.0	-7.48	-0.61	3.64e-11	Bone mineral density;
THYM	cis	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg08133631	chr1:26527909	CATSPER4	-0.61	-5.08	-0.46	1.92e-6	Obesity-related traits;
THYM	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs216026	0.689	rs216049	chr12:2766711	C/T	cg19945202	chr12:2788847	CACNA1C	0.7	4.77	0.44	6.52e-6	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg04111992	chr7:158790115	NA	0.59	5.38	0.48	5.45e-7	Facial morphology (factor 20);
THYM	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg13609457	chr4:120235615	NA	-0.6	-5.37	-0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs2070677	0.935	rs11101887	chr10:135418062	G/A	cg20169779	chr10:135381914	SYCE1	-0.75	-5.76	-0.51	1.03e-7	Gout;
THYM	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg19507638	chr5:93509721	C5orf36	-0.64	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg15242686	chr22:24348715	GSTTP1	0.58	5.83	0.51	7.44e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs13185784	0.667	rs4309929	chr5:179650988	A/C	cg23248424	chr5:179741104	GFPT2	-0.7	-4.5	-0.42	1.93e-5	TRAIL levels;
THYM	cis	rs7226229	1.000	rs4985953	chr17:20897584	T/C	cg21263980	chr17:20946333	USP22	0.72	4.96	0.45	3.12e-6	Blood trace element (Se levels);
THYM	cis	rs2404602	0.647	rs12910081	chr15:77022959	G/C	cg23625390	chr15:77176239	SCAPER	-0.81	-5.67	-0.5	1.54e-7	Blood metabolite levels;
THYM	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg11752832	chr7:134001865	SLC35B4	0.74	5.65	0.5	1.69e-7	Mean platelet volume;
THYM	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg10589385	chr1:150898437	SETDB1	0.62	5.26	0.47	8.86e-7	Tonsillectomy;
THYM	cis	rs17174870	0.955	rs7578057	chr2:112718094	A/G	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg24675658	chr1:53192096	ZYG11B	0.74	6.65	0.56	1.82e-9	Monocyte count;
THYM	cis	rs7830933	0.955	rs7004910	chr8:23595990	T/C	cg04349084	chr8:23602677	NA	0.6	6.44	0.55	4.86e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg08470875	chr2:26401718	FAM59B	0.74	4.59	0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs59698941	0.943	rs55746968	chr5:132298188	T/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg24874828	chr4:187887005	NA	-0.69	-6.72	-0.57	1.36e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg00339695	chr16:24857497	SLC5A11	0.48	4.79	0.44	6.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9914988	0.943	rs4313850	chr17:27080768	T/C	cg20469991	chr17:27169893	C17orf63	-0.76	-4.47	-0.42	2.18e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg20203395	chr5:56204925	C5orf35	-0.69	-4.75	-0.44	7.14e-6	Initial pursuit acceleration;
THYM	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	5.54	0.49	2.69e-7	Menarche (age at onset);
THYM	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg18681998	chr4:17616180	MED28	-0.79	-7.0	-0.58	3.65e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6032067	1.000	rs6032052	chr20:43829883	C/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs6995541	0.529	rs2292371	chr8:10690244	T/C	cg13457217	chr8:10683266	MIR1322;PINX1	-0.67	-5.02	-0.46	2.39e-6	Triglyceride levels;
THYM	cis	rs9905704	0.723	rs71372848	chr17:56736598	G/C	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.7e-6	Testicular germ cell tumor;
THYM	cis	rs870825	0.860	rs2696044	chr4:185595988	C/G	cg04058563	chr4:185651563	MLF1IP	0.98	7.31	0.6	8.33e-11	Blood protein levels;
THYM	cis	rs6840360	0.571	rs11931934	chr4:152552082	A/G	cg22705602	chr4:152727874	NA	-0.76	-7.92	-0.63	4.35e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4077515	1.000	rs4077515	chr9:139266496	C/T	cg14115884	chr9:139300582	SDCCAG3	0.7	6.74	0.57	1.23e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg04455712	chr21:45112962	RRP1B	0.57	5.39	0.48	5.02e-7	Mean corpuscular volume;
THYM	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg27286337	chr10:134555280	INPP5A	0.95	7.78	0.62	8.82e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg08133631	chr1:26527909	CATSPER4	-0.63	-5.22	-0.47	1.05e-6	Obesity-related traits;
THYM	cis	rs6546324	0.615	rs7598280	chr2:67815313	A/T	cg18237512	chr2:67827392	NA	-0.78	-4.63	-0.43	1.16e-5	Endometriosis;
THYM	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg27446573	chr6:127587934	RNF146	1.03	9.99	0.72	1.71e-16	Breast cancer;
THYM	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11905131	chr22:24372483	LOC391322	0.9	10.61	0.74	8.19e-18	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg13683864	chr3:40499215	RPL14	-0.87	-8.33	-0.65	6.11e-13	Renal cell carcinoma;
THYM	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Body mass index;
THYM	cis	rs3096299	0.900	rs744327	chr16:89439270	C/T	cg10452248	chr16:89456354	ANKRD11	0.6	4.59	0.43	1.33e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs72827839	0.740	rs72825548	chr17:46231108	A/G	cg23391107	chr17:45924227	SP6	0.83	5.6	0.5	2.08e-7	Ease of getting up in the morning;
THYM	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg11245990	chr11:68621969	NA	0.57	7.46	0.61	4.06e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg22508957	chr16:3507546	NAT15	0.73	7.48	0.61	3.63e-11	Tuberculosis;
THYM	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg11764359	chr7:65958608	NA	0.63	4.92	0.45	3.66e-6	Aortic root size;
THYM	cis	rs9364687	0.628	rs4709720	chr6:163924305	C/T	cg01639524	chr6:163818125	NA	0.49	4.84	0.44	4.97e-6	Body mass index;
THYM	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.8	-6.37	-0.55	6.73e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.39	0.48	5.05e-7	Height;
THYM	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6704768	0.545	rs5004510	chr2:233679275	A/C	cg08000102	chr2:233561755	GIGYF2	-0.79	-6.88	-0.58	6.42e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7089973	0.872	rs17092542	chr10:116630289	G/A	cg23260525	chr10:116636907	FAM160B1	0.52	4.72	0.44	8.04e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs12620999	0.887	rs6723783	chr2:237963572	C/A	cg02317832	chr2:237172964	ASB18	0.4	4.64	0.43	1.11e-5	Systemic lupus erythematosus;
THYM	cis	rs6988636	1.000	rs57165742	chr8:124184559	G/A	cg23067535	chr8:124195133	FAM83A	-1.1	-5.77	-0.51	9.8e-8	Urinary uromodulin levels;
THYM	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg12219531	chr12:120966889	COQ5	0.82	6.72	0.57	1.36e-9	High light scatter reticulocyte count;
THYM	cis	rs2346160	0.867	rs2989556	chr6:167704404	T/A	cg21686812	chr6:168078911	NA	-0.51	-4.51	-0.42	1.82e-5	Parental extreme longevity (95 years and older);
THYM	cis	rs2456568	0.802	rs10831139	chr11:93640537	G/A	cg17595323	chr11:93583763	C11orf90	-0.6	-6.33	-0.54	8.23e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg00684032	chr4:1343700	KIAA1530	0.78	6.72	0.57	1.36e-9	Obesity-related traits;
THYM	cis	rs58722170	0.627	rs12039431	chr1:38082122	G/A	cg17933807	chr1:38061675	GNL2	-0.9	-6.91	-0.58	5.62e-10	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg26384229	chr12:38710491	ALG10B	0.98	7.15	0.59	1.8e-10	Bladder cancer;
THYM	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-4.67	-0.43	9.94e-6	Hemoglobin concentration;
THYM	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg23205692	chr1:25664452	TMEM50A	0.83	6.58	0.56	2.53e-9	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.12	-0.64	1.72e-12	Mean corpuscular volume;
THYM	cis	rs526821	0.595	rs504661	chr11:55312683	A/G	cg26866625	chr11:55406191	OR4P4	-0.49	-4.47	-0.42	2.14e-5	Pediatric bone mineral density (spine);
THYM	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs11641184	0.528	rs13330449	chr16:11706727	T/C	cg09662852	chr16:11707685	NA	-0.43	-4.83	-0.44	5.2e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg21773646	chr17:80085082	CCDC57	-0.34	-4.75	-0.44	7.12e-6	Life satisfaction;
THYM	cis	rs2340727	0.660	rs6427642	chr1:161944753	C/G	ch.1.159725313R	chr1:161458689	NA	-0.75	-5.05	-0.46	2.14e-6	White blood cell count;Hematology traits;
THYM	cis	rs6032067	0.641	rs6032006	chr20:43755053	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.64	-5.8	-0.51	8.81e-8	Blood protein levels;
THYM	cis	rs28595532	0.764	rs115916994	chr4:119688758	A/G	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs2346177	0.605	rs7598712	chr2:46660452	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.62	5.07	0.46	1.96e-6	HDL cholesterol;
THYM	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.02	6.98	0.58	4.02e-10	Smoking behavior;
THYM	cis	rs3752962	0.588	rs903164	chr17:1939502	G/A	cg24156229	chr17:1948635	NA	-0.61	-5.14	-0.47	1.48e-6	Itch intensity from mosquito bite;
THYM	cis	rs6840360	0.593	rs4696107	chr4:152606823	G/A	cg22705602	chr4:152727874	NA	-0.81	-10.87	-0.74	2.32e-18	Intelligence (multi-trait analysis);
THYM	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	4.69	0.43	8.99e-6	Height;
THYM	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg05855489	chr10:104503620	C10orf26	-0.8	-7.2	-0.59	1.38e-10	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg06481639	chr22:41940642	POLR3H	0.8	5.56	0.5	2.48e-7	Vitiligo;
THYM	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg25754956	chr12:51612065	POU6F1	0.93	7.0	0.58	3.58e-10	Cisplatin-induced ototoxicity;
THYM	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg10117171	chr1:25599238	RHD	-0.66	-4.78	-0.44	6.35e-6	Erythrocyte sedimentation rate;
THYM	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13732083	chr21:47605072	C21orf56	0.66	4.67	0.43	1.01e-5	Testicular germ cell tumor;
THYM	cis	rs4731207	0.596	rs7802210	chr7:124632460	A/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs986417	0.901	rs1884098	chr14:61038944	A/T	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8060598	0.745	rs8045009	chr16:50735941	C/T	cg05261686	chr16:50743296	NOD2	0.37	4.57	0.42	1.48e-5	Leprosy;
THYM	cis	rs7814319	0.966	rs13276829	chr8:97274990	G/A	cg20787634	chr8:97240163	UQCRB	-0.76	-8.21	-0.64	1.1e-12	Lung function (FVC);
THYM	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg17845761	chr1:175162550	KIAA0040	-0.36	-4.57	-0.42	1.45e-5	Alcohol dependence;
THYM	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs920590	0.796	rs7820520	chr8:19634864	A/G	cg01411142	chr8:19674711	INTS10	-0.73	-5.75	-0.51	1.07e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs4792901	0.802	rs9908678	chr17:41581545	T/C	cg21940313	chr17:41620911	ETV4	-0.53	-5.03	-0.46	2.28e-6	Dupuytren's disease;
THYM	cis	rs3820068	0.603	rs59475085	chr1:15911131	G/A	cg27534772	chr1:16042836	PLEKHM2	0.49	4.63	0.43	1.16e-5	Systolic blood pressure;
THYM	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.57	-5.18	-0.47	1.23e-6	Type 2 diabetes;
THYM	cis	rs4766566	0.609	rs1344438	chr12:111735954	C/G	cg10833066	chr12:111807467	FAM109A	0.63	8.47	0.66	3.11e-13	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
THYM	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg27490568	chr2:178487706	NA	0.6	5.49	0.49	3.3e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs3126085	0.877	rs11204968	chr1:152250211	A/T	cg10321714	chr1:152280068	FLG	0.64	4.81	0.44	5.57e-6	Atopic dermatitis;
THYM	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg19610905	chr11:61596333	FADS2	-0.55	-4.49	-0.42	2.01e-5	Trans fatty acid levels;
THYM	cis	rs72627123	0.867	rs17092878	chr14:74321322	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg09323728	chr8:95962352	TP53INP1	-0.45	-4.67	-0.43	9.99e-6	Type 2 diabetes;
THYM	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg24020549	chr11:64937741	SPDYC	-0.46	-4.45	-0.42	2.29e-5	Eosinophil percentage of white cells;
THYM	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.24e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs13102973	0.899	rs17496	chr4:135900227	C/T	cg14419869	chr4:135874104	NA	-0.76	-6.42	-0.55	5.46e-9	Subjective well-being;
THYM	cis	rs2816062	0.760	rs2745319	chr1:18895078	G/A	cg18795169	chr1:18902165	NA	-0.99	-12.14	-0.78	5.02e-21	Urate levels in lean individuals;
THYM	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.83	-6.9	-0.58	5.78e-10	Systemic lupus erythematosus;
THYM	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.89	5.63	0.5	1.82e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7107174	1.000	rs2512538	chr11:77972461	T/G	cg19901956	chr11:77921274	USP35	-0.76	-5.83	-0.51	7.53e-8	Testicular germ cell tumor;
THYM	cis	rs7487075	0.790	rs4074773	chr12:46919181	C/T	cg15584813	chr12:47219626	SLC38A4	-0.5	-4.65	-0.43	1.06e-5	Itch intensity from mosquito bite;
THYM	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg00277334	chr10:82204260	NA	-0.52	-5.28	-0.48	8.04e-7	Post bronchodilator FEV1;
THYM	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg08847533	chr14:75593920	NEK9	0.97	10.53	0.73	1.25e-17	Height;
THYM	cis	rs7336332	0.598	rs76249173	chr13:28010445	A/G	cg22138327	chr13:27999177	GTF3A	0.62	4.62	0.43	1.21e-5	Weight;
THYM	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg06074448	chr4:187884817	NA	-1.01	-13.54	-0.81	6.7e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7584330	0.740	rs11896232	chr2:238438124	T/C	cg16989719	chr2:238392110	NA	-0.48	-4.7	-0.43	8.62e-6	Prostate cancer;
THYM	cis	rs2652822	0.525	rs11634159	chr15:63507422	C/T	cg09251291	chr15:63483946	RAB8B	0.53	4.89	0.45	4.04e-6	Metabolic traits;
THYM	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg25036284	chr2:26402008	FAM59B	-0.78	-5.19	-0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.69e-11	Aortic root size;
THYM	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg06697600	chr4:7070879	GRPEL1	-0.55	-4.45	-0.42	2.35e-5	Monocyte percentage of white cells;
THYM	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg02725872	chr8:58115012	NA	-1.16	-7.47	-0.61	3.94e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg10589385	chr1:150898437	SETDB1	0.64	5.4	0.48	4.9e-7	Melanoma;
THYM	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs901683	1.000	rs34195613	chr10:46030374	G/C	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs11771526	0.901	rs11767773	chr7:32272342	T/G	cg27532318	chr7:32358331	NA	0.76	5.44	0.49	4.16e-7	Body mass index;
THYM	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg11789530	chr4:8429930	ACOX3	0.74	5.99	0.52	3.74e-8	Response to antineoplastic agents;
THYM	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg06009448	chr7:1102226	C7orf50	0.53	5.59	0.5	2.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	5.57	0.5	2.37e-7	Lung cancer in ever smokers;
THYM	cis	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg17392043	chr3:188495102	LPP	-0.74	-4.58	-0.43	1.4e-5	Lung adenocarcinoma;
THYM	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7809950	0.817	rs10224503	chr7:107075569	A/C	cg23024343	chr7:107201750	COG5	-0.92	-7.73	-0.62	1.11e-11	Coronary artery disease;
THYM	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg25358565	chr5:93447407	FAM172A	0.96	6.78	0.57	1.01e-9	Diabetic retinopathy;
THYM	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg07424592	chr7:64974309	NA	1.05	4.76	0.44	6.92e-6	Diabetic kidney disease;
THYM	cis	rs7098100	0.706	rs6650130	chr10:22280664	A/T	cg10900703	chr10:21824407	MLLT10	0.42	4.69	0.43	9.23e-6	Breast cancer;
THYM	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg05283184	chr6:79620031	NA	-0.94	-9.26	-0.69	6.41e-15	Intelligence (multi-trait analysis);
THYM	trans	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg07211511	chr3:129823064	LOC729375	-1.2	-9.65	-0.7	9.11e-16	Blood pressure (smoking interaction);
THYM	cis	rs113835537	0.529	rs17147644	chr11:66256660	C/T	cg10315249	chr11:66235081	PELI3	0.42	4.52	0.42	1.76e-5	Airway imaging phenotypes;
THYM	cis	rs7552404	0.672	rs8763	chr1:76229120	T/C	cg22875332	chr1:76189707	ACADM	0.8	6.24	0.54	1.22e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg26038318	chr20:34205095	SPAG4	0.66	5.33	0.48	6.74e-7	Total cholesterol levels;
THYM	cis	rs1190596	0.526	rs8003556	chr14:102659667	T/C	cg08231664	chr14:102516632	DYNC1H1	0.41	4.92	0.45	3.58e-6	Behavioural disinhibition (generation interaction);
THYM	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg07936489	chr17:37558343	FBXL20	-0.82	-5.61	-0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg01616529	chr11:638424	DRD4	-0.74	-5.68	-0.5	1.45e-7	Systemic lupus erythematosus;
THYM	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs6466832	0.537	rs12537488	chr7:122368617	C/G	cg22586324	chr7:123296098	LMOD2	-0.89	-4.89	-0.45	4.04e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs1451375	0.572	rs11575463	chr7:50547173	A/G	cg18232548	chr7:50535776	DDC	-0.67	-5.07	-0.46	1.94e-6	Malaria;
THYM	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg24642844	chr7:1081250	C7orf50	-1.29	-8.3	-0.65	7.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg08736216	chr1:53307985	ZYG11A	-0.62	-5.49	-0.49	3.31e-7	Monocyte count;
THYM	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg03159660	chr11:2078197	NA	-0.6	-4.48	-0.42	2.1e-5	Longevity;
THYM	cis	rs4242434	0.819	rs7843128	chr8:22473465	T/C	cg21658235	chr8:22456391	C8orf58	0.43	4.5	0.42	1.95e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9818758	0.556	rs9872660	chr3:49378832	G/T	cg00383909	chr3:49044727	WDR6	0.77	5.05	0.46	2.16e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg08213375	chr14:104286397	PPP1R13B	0.53	6.48	0.55	4.02e-9	Schizophrenia;
THYM	cis	rs79387448	0.745	rs7601773	chr2:103120483	G/T	cg09003973	chr2:102972529	NA	0.78	4.85	0.45	4.84e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs4631830	0.863	rs3101227	chr10:51520203	C/A	cg16070123	chr10:51489643	NA	-0.5	-4.56	-0.42	1.5e-5	Prostate-specific antigen levels;
THYM	cis	rs4148883	0.504	rs9307238	chr4:100136182	A/G	cg12011299	chr4:100065546	ADH4	-0.56	-4.92	-0.45	3.63e-6	Alcohol dependence;
THYM	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg07636037	chr3:49044803	WDR6	0.94	9.83	0.71	3.81e-16	Parkinson's disease;
THYM	cis	rs2842992	0.714	rs2475564	chr6:160123673	A/G	cg11366901	chr6:160182831	ACAT2	1.06	9.68	0.7	8.16e-16	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg24692254	chr21:30365293	RNF160	0.65	4.63	0.43	1.15e-5	Selective IgA deficiency;
THYM	cis	rs8103278	1.000	rs9676288	chr19:46292060	G/T	cg14061069	chr19:46274453	DMPK	-0.57	-5.64	-0.5	1.77e-7	Coronary artery disease;
THYM	cis	rs28647808	1.000	rs4962140	chr9:136272507	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs2688608	0.592	rs7909544	chr10:75484004	G/C	cg23231163	chr10:75533350	FUT11	-0.44	-6.22	-0.54	1.34e-8	Inflammatory bowel disease;
THYM	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg16744531	chr19:17905626	B3GNT3	0.58	6.0	0.52	3.59e-8	Tumor biomarkers;
THYM	cis	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg00495681	chr13:53174319	NA	-0.72	-6.68	-0.57	1.64e-9	Lewy body disease;
THYM	cis	rs10936602	0.527	rs9878316	chr3:169533717	T/A	cg17737146	chr3:169530037	LRRC34	0.5	4.75	0.44	7.09e-6	Renal cell carcinoma;
THYM	cis	rs6674176	0.569	rs34830883	chr1:44405339	T/C	cg12908607	chr1:44402522	ARTN	-0.68	-5.81	-0.51	8.29e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2777491	0.789	rs1655557	chr15:41787972	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.04	-11.1	-0.75	7.61e-19	Ulcerative colitis;
THYM	cis	rs6138458	1.000	rs4273288	chr20:24900873	G/A	cg26195577	chr20:24973756	C20orf3	-1.12	-10.51	-0.73	1.38e-17	Blood protein levels;
THYM	cis	rs6450176	0.638	rs11746856	chr5:53291295	A/C	ch.5.1024479R	chr5:53302184	ARL15	-1.22	-10.84	-0.74	2.64e-18	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs600806	0.821	rs3879447	chr1:109891403	C/T	cg23032129	chr1:109941072	SORT1	-0.57	-4.83	-0.44	5.22e-6	Intelligence (multi-trait analysis);
THYM	trans	rs8002861	0.934	rs9533685	chr13:44468331	A/G	cg17145862	chr1:211918768	LPGAT1	1.03	11.49	0.76	1.13e-19	Leprosy;
THYM	cis	rs6768930	0.509	rs11926924	chr3:57799360	A/C	cg07735586	chr3:57945651	NA	-0.34	-5.13	-0.47	1.56e-6	Obesity-related traits;
THYM	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	12.82	0.8	1.97e-22	Chronic sinus infection;
THYM	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg12698349	chr2:225449008	CUL3	0.73	5.47	0.49	3.64e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs6596100	0.538	rs17516673	chr5:132196711	C/T	cg02081065	chr5:132209139	LEAP2	-0.95	-6.14	-0.53	1.87e-8	Breast cancer;
THYM	cis	rs56104184	0.779	rs2131093	chr19:49350693	A/T	cg26267310	chr19:49340593	PLEKHA4;HSD17B14	0.8	4.64	0.43	1.1e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs4478037	0.558	rs57225144	chr3:33078354	G/C	cg19404215	chr3:33155277	CRTAP	1.12	6.04	0.53	2.99e-8	Major depressive disorder;
THYM	cis	rs2820651	0.614	rs55691140	chr10:1491025	G/A	cg02445968	chr10:1449028	ADARB2	-1.05	-5.33	-0.48	6.52e-7	Migraine with aura;
THYM	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg10523679	chr1:76189770	ACADM	0.92	7.16	0.59	1.71e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg22920501	chr2:26401640	FAM59B	-0.77	-6.9	-0.58	5.83e-10	Gut microbiome composition (summer);
THYM	cis	rs58873874	0.737	rs11134766	chr5:156908317	C/T	cg08916508	chr5:156566250	MED7	-1.31	-4.98	-0.45	2.84e-6	Bipolar disorder (body mass index interaction);
THYM	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03517284	chr6:25882590	NA	1.01	9.24	0.69	6.85e-15	Blood metabolite levels;
THYM	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg00012203	chr2:219082015	ARPC2	0.82	7.47	0.61	3.95e-11	Colorectal cancer;
THYM	cis	rs55728055	0.661	rs62237773	chr22:31965054	A/G	cg01338084	chr22:32026380	PISD	1.47	5.87	0.52	6.32e-8	Age-related hearing impairment;
THYM	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg11663144	chr21:46675770	NA	0.58	5.69	0.5	1.4e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg08439880	chr3:133502540	NA	-0.78	-6.4	-0.55	5.88e-9	Iron status biomarkers;
THYM	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg07959070	chr22:50026188	C22orf34	-0.25	-4.69	-0.43	9.18e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg10505658	chr17:80084571	CCDC57	0.7	8.07	0.64	2.18e-12	Life satisfaction;
THYM	cis	rs1524976	0.941	rs9854638	chr3:65477793	C/T	cg16238336	chr3:65465873	MAGI1	-1.02	-6.53	-0.56	3.16e-9	PR interval;
THYM	cis	rs4343996	0.869	rs4544975	chr7:3385384	G/T	cg21248987	chr7:3385318	SDK1	-0.4	-4.88	-0.45	4.23e-6	Motion sickness;
THYM	cis	rs2125062	0.715	rs4917723	chr10:97982575	A/C	cg07577957	chr10:98803188	SLIT1	0.59	4.56	0.42	1.55e-5	Colorectal adenoma (advanced);
THYM	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg24692254	chr21:30365293	RNF160	-0.71	-5.14	-0.47	1.48e-6	Cognitive test performance;
THYM	cis	rs1538970	0.816	rs11211124	chr1:45962409	T/C	cg05343316	chr1:45956843	TESK2	0.85	5.45	0.49	3.93e-7	Platelet count;
THYM	cis	rs73086581	0.947	rs17287577	chr20:3966254	C/T	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg05340658	chr4:99064831	C4orf37	0.54	4.51	0.42	1.83e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4731207	0.698	rs6945104	chr7:124557915	A/G	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	trans	rs10802346	0.545	rs4478780	chr1:246372241	T/C	cg22732515	chr19:44031385	ETHE1	1.06	9.28	0.69	5.61e-15	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg17054759	chr22:49844102	NA	-0.52	-4.55	-0.42	1.6e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1843834	0.858	rs12105685	chr2:225513164	A/G	cg22455342	chr2:225449267	CUL3	0.68	4.93	0.45	3.45e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs4363385	0.510	rs1500937	chr1:153045483	G/C	cg13444842	chr1:152974279	SPRR3	-0.6	-4.66	-0.43	1.03e-5	Inflammatory skin disease;
THYM	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg01236616	chr12:121019343	POP5	-1.27	-8.49	-0.66	2.82e-13	Type 1 diabetes nephropathy;
THYM	cis	rs951188	0.688	rs77473706	chr2:150415006	T/C	cg17961725	chr2:150454027	NA	-0.96	-5.16	-0.47	1.36e-6	Daytime sleep phenotypes;
THYM	cis	rs11574514	1.000	rs7195415	chr16:67689057	G/A	cg04582263	chr16:67973788	LCAT	0.97	4.56	0.42	1.54e-5	Crohn's disease;
THYM	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg20387954	chr3:183756860	HTR3D	0.58	4.81	0.44	5.56e-6	Anterior chamber depth;
THYM	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.72	-0.51	1.25e-7	Prostate cancer;
THYM	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-4.98	-0.46	2.8e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs533581	0.844	rs548591	chr16:88974516	A/G	cg08484992	chr16:88977278	CBFA2T3	0.37	4.65	0.43	1.06e-5	Social autistic-like traits;
THYM	cis	rs1747683	0.585	rs10752296	chr10:13369506	A/G	cg25835351	chr10:13388524	SEPHS1	-0.28	-4.89	-0.45	4.14e-6	IgG glycosylation;
THYM	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg12379764	chr21:47803548	PCNT	-0.79	-5.07	-0.46	1.95e-6	Testicular germ cell tumor;
THYM	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg08885076	chr2:99613938	TSGA10	0.57	5.3	0.48	7.37e-7	Chronic sinus infection;
THYM	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg04944784	chr2:26401820	FAM59B	0.74	5.02	0.46	2.38e-6	Gut microbiome composition (summer);
THYM	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.46	0.49	3.85e-7	Platelet count;
THYM	cis	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg21775007	chr8:11205619	TDH	0.7	5.36	0.48	5.79e-7	Retinal vascular caliber;
THYM	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-8.4	-0.65	4.35e-13	Gut microbiome composition (summer);
THYM	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs478304	0.593	rs6591188	chr11:65467953	T/C	cg17480646	chr11:65405466	SIPA1	-0.97	-8.99	-0.68	2.44e-14	Acne (severe);
THYM	cis	rs2011503	1.000	rs1036215	chr19:19657198	C/T	cg02887458	chr19:19495540	GATAD2A	-0.48	-4.98	-0.45	2.89e-6	Bipolar disorder;
THYM	cis	rs3892630	0.817	rs35408716	chr19:33187961	A/C	cg22928329	chr19:33183273	NUDT19	-0.77	-5.83	-0.51	7.74e-8	Red blood cell traits;
THYM	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg22974920	chr21:40686053	BRWD1	-0.61	-4.81	-0.44	5.69e-6	Cognitive function;
THYM	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg22433210	chr17:43662623	NA	1.09	8.4	0.65	4.4e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs4654899	1.000	rs7521675	chr1:21424070	T/C	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.26e-9	Superior frontal gyrus grey matter volume;
THYM	trans	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg10856724	chr12:34555212	NA	-0.97	-8.74	-0.67	8.22e-14	Bladder cancer;
THYM	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg04546413	chr19:29218101	NA	1.09	9.4	0.69	3.15e-15	Methadone dose in opioid dependence;
THYM	cis	rs651907	1.000	rs662792	chr3:101599608	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.52	4.51	0.42	1.86e-5	Colorectal cancer;
THYM	cis	rs11577318	0.853	rs7416513	chr1:26647949	G/C	cg00852783	chr1:26633632	UBXN11	0.66	5.39	0.48	5.09e-7	Granulocyte percentage of myeloid white cells;
THYM	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6430585	0.528	rs309165	chr2:136667301	T/C	cg07169764	chr2:136633963	MCM6	1.04	11.13	0.75	6.52e-19	Corneal structure;
THYM	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	6.93	0.58	5.11e-10	Smoking behavior;
THYM	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg01570182	chr17:44337453	NA	0.62	6.48	0.55	4.01e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs8067235	1.000	rs58337218	chr17:79023953	C/T	cg12472449	chr17:79022879	BAIAP2	0.67	6.22	0.54	1.32e-8	Memory performance;
THYM	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.72	-5.83	-0.51	7.65e-8	Systemic lupus erythematosus;
THYM	cis	rs2109514	0.840	rs2402080	chr7:116135016	G/C	cg12739419	chr7:116140593	CAV2	-0.48	-4.72	-0.44	8.06e-6	Prevalent atrial fibrillation;
THYM	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-6.9	-0.58	5.67e-10	Chronic sinus infection;
THYM	cis	rs4766566	0.704	rs11065861	chr12:111752211	A/G	cg10833066	chr12:111807467	FAM109A	0.65	8.22	0.64	1.04e-12	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
THYM	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg00071950	chr4:10020882	SLC2A9	0.9	10.65	0.74	6.87e-18	Bone mineral density;
THYM	cis	rs11651000	0.761	rs11657388	chr17:45820707	C/G	cg03474202	chr17:45855739	NA	-0.77	-6.92	-0.58	5.27e-10	IgG glycosylation;
THYM	cis	rs7481584	0.624	rs80871	chr11:3049843	A/C	cg03159660	chr11:2078197	NA	0.62	4.6	0.43	1.3e-5	Calcium levels;
THYM	cis	rs2354432	0.607	rs66486822	chr1:146802653	T/A	cg25205988	chr1:146714368	CHD1L	-1.03	-5.4	-0.48	4.84e-7	Mitochondrial DNA levels;
THYM	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg24530246	chr3:53118167	NA	-0.82	-4.66	-0.43	1.04e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg08975724	chr8:8085496	FLJ10661	0.76	6.33	0.54	8.16e-9	Mood instability;
THYM	cis	rs6918586	1.000	rs198811	chr6:26128446	A/G	cg07061783	chr6:25882402	NA	-0.57	-4.45	-0.42	2.35e-5	Schizophrenia;
THYM	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg01350728	chr13:21893604	NA	-0.59	-4.47	-0.42	2.12e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.76	-0.44	6.98e-6	Crohn's disease;
THYM	trans	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-8.13	-0.64	1.6e-12	Exhaled nitric oxide output;
THYM	cis	rs6987853	0.749	rs2974367	chr8:42431194	G/C	cg09913449	chr8:42400586	C8orf40	1.06	11.6	0.77	6.75e-20	Mean corpuscular hemoglobin concentration;
THYM	trans	rs877282	0.945	rs10904550	chr10:774177	C/T	cg22713356	chr15:30763199	NA	1.27	10.33	0.73	3.32e-17	Uric acid levels;
THYM	cis	rs9486719	0.948	rs12203657	chr6:96883285	G/A	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg07636037	chr3:49044803	WDR6	1.0	10.78	0.74	3.59e-18	Parkinson's disease;
THYM	cis	rs7267979	1.000	rs6083805	chr20:25317356	T/C	cg08601574	chr20:25228251	PYGB	-0.57	-4.59	-0.43	1.35e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg09359103	chr1:154839909	KCNN3	-0.79	-9.62	-0.7	1.06e-15	Prostate cancer;
THYM	cis	rs28595532	1.000	rs114912871	chr4:119697004	G/C	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs7084402	0.967	rs1658463	chr10:60298208	C/T	cg07615347	chr10:60278583	BICC1	0.57	5.36	0.48	5.86e-7	Refractive error;
THYM	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg24692254	chr21:30365293	RNF160	1.05	9.9	0.71	2.65e-16	Dental caries;
THYM	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg08859206	chr1:53392774	SCP2	-0.49	-5.15	-0.47	1.4e-6	Monocyte count;
THYM	cis	rs2806561	0.765	rs2776815	chr1:23510584	C/T	cg19743168	chr1:23544995	NA	-0.55	-5.6	-0.5	2.09e-7	Height;
THYM	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg08999081	chr20:33150536	PIGU	0.78	7.16	0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs79149102	0.579	rs9788648	chr15:75300284	A/G	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	cis	rs7793919	0.668	rs6946034	chr7:4767112	A/T	cg09789173	chr7:4769017	FOXK1	0.8	7.87	0.63	5.67e-12	Mosquito bite size;
THYM	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06850241	chr22:41845214	NA	0.49	4.62	0.43	1.21e-5	Vitiligo;
THYM	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg23281280	chr6:28129359	ZNF389	0.61	4.88	0.45	4.21e-6	Depression;
THYM	cis	rs9394152	0.781	rs9380362	chr6:33467734	T/C	cg13560919	chr6:33536144	NA	0.72	6.21	0.54	1.37e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08045932	chr20:61659980	NA	0.92	10.35	0.73	2.9e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg27211696	chr2:191398769	TMEM194B	0.84	8.32	0.65	6.43e-13	Pulse pressure;
THYM	cis	rs2625529	0.816	rs4777467	chr15:72138478	T/C	cg16672083	chr15:72433130	SENP8	-0.56	-4.98	-0.45	2.85e-6	Red blood cell count;
THYM	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg23131131	chr22:24373011	LOC391322	-0.84	-8.04	-0.64	2.47e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg22467129	chr15:76604101	ETFA	-0.52	-5.02	-0.46	2.4e-6	Blood metabolite levels;
THYM	cis	rs4589258	0.788	rs4472902	chr11:90464105	C/T	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.93	-0.45	3.53e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg12573674	chr2:1569213	NA	-1.22	-4.82	-0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs11039798	0.920	rs12292685	chr11:48571032	G/T	cg24672777	chr11:48374446	OR4C45	-1.14	-6.95	-0.58	4.55e-10	Axial length;
THYM	cis	rs6582630	0.538	rs12304844	chr12:38335870	C/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.47	-0.42	2.16e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg08048268	chr3:133502702	NA	-0.66	-5.59	-0.5	2.15e-7	Iron status biomarkers;
THYM	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg18898632	chr2:242989856	NA	-0.68	-4.7	-0.43	8.72e-6	Obesity-related traits;
THYM	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg21028142	chr17:79581711	NPLOC4	0.49	4.82	0.44	5.34e-6	Eye color traits;
THYM	cis	rs2742234	0.541	rs871763	chr10:43734188	C/T	cg06632098	chr10:43605906	RET	0.74	4.97	0.45	2.95e-6	Hirschsprung disease;
THYM	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.59	-0.5	2.2e-7	Menopause (age at onset);
THYM	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg27129171	chr3:47204927	SETD2	0.74	7.2	0.59	1.42e-10	Colorectal cancer;
THYM	cis	rs6722750	0.967	rs17754672	chr2:64400608	A/G	cg22352474	chr2:64371530	PELI1	-0.68	-5.33	-0.48	6.56e-7	Neuroticism;
THYM	cis	rs10779751	1.000	rs6670821	chr1:11308762	T/C	cg08854313	chr1:11322531	MTOR	0.94	8.23	0.65	9.67e-13	Body mass index;
THYM	cis	rs11039798	0.698	rs78553793	chr11:48947336	C/A	cg24672777	chr11:48374446	OR4C45	-1.08	-5.95	-0.52	4.42e-8	Axial length;
THYM	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg23989207	chr17:80870107	TBCD	0.61	5.13	0.47	1.54e-6	Glycated hemoglobin levels;
THYM	cis	rs6121246	0.697	rs8118150	chr20:30436088	G/A	cg13852791	chr20:30311386	BCL2L1	0.83	6.19	0.54	1.55e-8	Mean corpuscular hemoglobin;
THYM	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	7.32	0.6	7.96e-11	Platelet count;
THYM	cis	rs7193541	0.585	rs3851729	chr16:74485529	A/G	cg01733217	chr16:74700730	RFWD3	-0.9	-9.86	-0.71	3.33e-16	Multiple myeloma;
THYM	cis	rs7953508	0.506	rs2200160	chr12:93963873	C/T	cg18151635	chr12:93972918	NA	-0.87	-6.12	-0.53	2.07e-8	Pubertal anthropometrics;
THYM	cis	rs10463554	0.655	rs152138	chr5:102559428	C/G	cg23492399	chr5:102201601	PAM	-0.67	-4.94	-0.45	3.33e-6	Parkinson's disease;
THYM	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg08048268	chr3:133502702	NA	0.57	4.48	0.42	2.08e-5	Iron status biomarkers;
THYM	cis	rs977987	0.931	rs1424013	chr16:75495986	T/C	cg03315344	chr16:75512273	CHST6	0.73	5.69	0.5	1.39e-7	Dupuytren's disease;
THYM	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg16524733	chr11:117070046	TAGLN	-0.44	-4.87	-0.45	4.52e-6	Blood protein levels;
THYM	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.87	7.67	0.62	1.49e-11	Monocyte percentage of white cells;
THYM	cis	rs12681287	0.640	rs7830480	chr8:87403137	T/C	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs3741151	1.000	rs75007932	chr11:73080336	G/A	cg17517138	chr11:73019481	ARHGEF17	1.0	5.89	0.52	5.75e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg09359103	chr1:154839909	KCNN3	-0.72	-9.45	-0.7	2.44e-15	Prostate cancer;
THYM	cis	rs6456042	1.000	rs3127408	chr6:166530659	T/A	cg11088901	chr6:166572345	T	-0.52	-4.9	-0.45	3.9e-6	Asthma;
THYM	cis	rs7953249	0.656	rs1732391	chr12:121392341	C/T	cg02403541	chr12:121454288	C12orf43	-0.73	-6.71	-0.57	1.37e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg11764359	chr7:65958608	NA	-0.81	-6.42	-0.55	5.45e-9	Aortic root size;
THYM	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.74	-6.6	-0.56	2.3e-9	Lung cancer;
THYM	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg27535305	chr1:53392650	SCP2	0.39	4.49	0.42	2.02e-5	Monocyte count;
THYM	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.88	5.74	0.51	1.15e-7	Smoking behavior;
THYM	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.62	-4.5	-0.42	1.93e-5	Colorectal cancer;
THYM	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg03609598	chr5:56110824	MAP3K1	-0.83	-5.57	-0.5	2.35e-7	Initial pursuit acceleration;
THYM	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	6.07	0.53	2.66e-8	Platelet count;
THYM	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg04362960	chr10:104952993	NT5C2	0.6	5.11	0.46	1.66e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg22535103	chr8:58192502	C8orf71	-0.93	-4.66	-0.43	1.02e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs6032067	0.714	rs2206888	chr20:43882006	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.61	-6.81	-0.57	8.9e-10	Blood protein levels;
THYM	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg06640241	chr16:89574553	SPG7	0.7	4.7	0.43	8.94e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg22117172	chr7:91764530	CYP51A1	0.37	4.72	0.44	8.16e-6	Breast cancer;
THYM	cis	rs7688540	0.771	rs61795006	chr4:253601	C/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.67	4.9	0.45	3.93e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg22709100	chr7:91322751	NA	-0.61	-4.85	-0.45	4.9e-6	Breast cancer;
THYM	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg06009448	chr7:1102226	C7orf50	0.46	4.92	0.45	3.56e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	8.51	0.66	2.52e-13	Cognitive test performance;
THYM	cis	rs1775715	0.870	rs1755072	chr10:32266642	A/G	cg04359828	chr10:32216031	ARHGAP12	-0.38	-4.83	-0.44	5.18e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs7523273	0.526	rs1204706	chr1:208021060	G/T	cg22525895	chr1:207977042	MIR29B2	-0.91	-9.37	-0.69	3.58e-15	Schizophrenia;
THYM	cis	rs4660306	0.744	rs11211113	chr1:45923668	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.62	4.55	0.42	1.58e-5	Homocysteine levels;
THYM	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg00786635	chr1:25594202	NA	0.89	7.61	0.62	1.99e-11	Erythrocyte sedimentation rate;
THYM	cis	rs9682041	0.688	rs7621787	chr3:170146862	T/A	cg11886554	chr3:170076028	SKIL	1.37	5.27	0.48	8.68e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg08999081	chr20:33150536	PIGU	0.56	4.66	0.43	1.03e-5	Height;
THYM	cis	rs8067545	0.934	rs34848191	chr17:19918626	G/T	cg20830565	chr17:20408647	MGC102966	-0.52	-4.66	-0.43	1.05e-5	Schizophrenia;
THYM	cis	rs860554	0.705	rs832175	chr1:201259645	G/A	cg01022117	chr1:201258280	PKP1	0.66	4.9	0.45	3.93e-6	Panic disorder;
THYM	cis	rs1018836	0.892	rs11776824	chr8:91553256	T/C	cg16814680	chr8:91681699	NA	-0.83	-7.26	-0.6	1.08e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg05347473	chr6:146136440	FBXO30	0.8	7.02	0.58	3.32e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7246657	0.943	rs6508711	chr19:37815134	G/T	cg22634378	chr19:37742834	NA	0.65	5.34	0.48	6.2e-7	Coronary artery calcification;
THYM	cis	rs7584330	0.554	rs6705908	chr2:238433965	A/G	cg20365190	chr2:238923346	UBE2F	0.55	4.78	0.44	6.3e-6	Prostate cancer;
THYM	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg05368731	chr17:41323189	NBR1	1.25	11.37	0.76	2.01e-19	Menopause (age at onset);
THYM	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg09354556	chr3:47051341	NA	0.45	4.64	0.43	1.11e-5	Colorectal cancer;
THYM	cis	rs4481887	0.708	rs6587463	chr1:248544452	G/C	cg00666640	chr1:248458726	OR2T12	0.55	4.73	0.44	7.65e-6	Common traits (Other);
THYM	cis	rs10089	1.000	rs3816006	chr5:127450581	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg00495681	chr13:53174319	NA	0.97	9.92	0.71	2.43e-16	Lewy body disease;
THYM	cis	rs6722750	0.933	rs4671554	chr2:64411122	T/A	cg22352474	chr2:64371530	PELI1	-0.64	-4.72	-0.44	8.22e-6	Neuroticism;
THYM	cis	rs1729951	0.575	rs2163896	chr3:136691177	G/A	cg21827317	chr3:136751795	NA	0.75	6.64	0.56	1.92e-9	Neuroticism;
THYM	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs12681287	0.752	rs4310184	chr8:87245253	T/C	cg27223183	chr8:87520930	FAM82B	-0.6	-4.64	-0.43	1.1e-5	Caudate activity during reward;
THYM	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.92e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10779751	0.690	rs743577	chr1:11119135	G/A	cg08854313	chr1:11322531	MTOR	0.82	7.08	0.59	2.44e-10	Body mass index;
THYM	cis	rs612683	0.602	rs2030048	chr1:101006577	C/T	cg06223162	chr1:101003688	GPR88	-0.82	-7.71	-0.62	1.22e-11	Breast cancer;
THYM	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg27034606	chr17:28928453	LRRC37B2	0.75	4.55	0.42	1.61e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg11502198	chr6:26597334	ABT1	0.69	6.13	0.53	2.02e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6456042	0.893	rs1134481	chr6:166571164	T/G	cg11088901	chr6:166572345	T	-0.56	-5.39	-0.48	5.06e-7	Asthma;
THYM	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg05373962	chr22:49881684	NA	-0.67	-6.83	-0.57	7.99e-10	Monocyte count;Monocyte percentage of white cells;
THYM	trans	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg19862616	chr7:65841803	NCRNA00174	1.11	13.16	0.8	3.94e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	trans	rs6089829	0.888	rs4809471	chr20:61684287	G/A	cg13615516	chr5:77269221	NA	0.83	7.37	0.6	6.19e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9814567	1.000	rs4423809	chr3:134300107	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	8.54	0.66	2.19e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs3087591	0.887	rs12150521	chr17:29595108	C/T	cg24425628	chr17:29625626	OMG;NF1	0.63	5.4	0.48	4.98e-7	Hip circumference;
THYM	cis	rs4845570	0.764	rs12141652	chr1:151716711	A/T	cg07092448	chr1:151763213	TDRKH	-0.98	-5.27	-0.48	8.55e-7	Coronary artery disease;
THYM	cis	rs861020	0.563	rs12046618	chr1:210043135	C/T	cg05527609	chr1:210001259	C1orf107	0.88	6.0	0.52	3.51e-8	Orofacial clefts;
THYM	cis	rs9515201	0.740	rs9555695	chr13:111033125	C/T	cg06243866	chr13:111019493	COL4A2	-0.99	-11.13	-0.75	6.65e-19	White matter hyperintensity burden;
THYM	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs806215	1.000	rs806216	chr7:127237862	C/A	cg08586737	chr7:127225949	GCC1	-0.41	-5.04	-0.46	2.18e-6	Type 2 diabetes;
THYM	cis	rs611744	0.967	rs597992	chr8:109193808	A/T	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg00757033	chr12:89920650	WDR51B	0.75	12.04	0.78	7.96e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg18850127	chr7:39170497	POU6F2	0.56	5.19	0.47	1.19e-6	IgG glycosylation;
THYM	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg21926883	chr2:100939477	LONRF2	-0.58	-4.99	-0.46	2.76e-6	Intelligence (multi-trait analysis);
THYM	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	5.65	0.5	1.64e-7	Schizophrenia;
THYM	cis	rs78579285	0.545	rs79311053	chr16:88785206	C/T	cg04002220	chr16:89598305	SPG7	0.65	4.73	0.44	7.78e-6	Joint mobility (Beighton score);
THYM	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.94	-7.34	-0.6	7.09e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs314370	0.904	rs314373	chr7:100456595	G/A	cg10426581	chr7:100472382	SRRT	1.13	9.05	0.68	1.81e-14	Resting heart rate;
THYM	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg13319975	chr6:146136371	FBXO30	-0.65	-5.3	-0.48	7.51e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9902453	0.619	rs2617866	chr17:28076217	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.8	-0.57	9.08e-10	Coffee consumption (cups per day);
THYM	cis	rs7084402	0.967	rs1649080	chr10:60293294	C/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs943437	0.557	rs59856565	chr6:112164441	A/G	cg20596647	chr6:112163498	FYN	0.42	4.46	0.42	2.22e-5	Parkinson's disease;
THYM	cis	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg10856724	chr12:34555212	NA	0.85	7.65	0.62	1.61e-11	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg13695892	chr22:41940480	POLR3H	0.84	6.25	0.54	1.16e-8	Vitiligo;
THYM	cis	rs113835537	0.529	rs7950790	chr11:66258053	G/A	cg24851651	chr11:66362959	CCS	0.71	4.98	0.45	2.85e-6	Airway imaging phenotypes;
THYM	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.07	11.36	0.76	2.13e-19	Intelligence (multi-trait analysis);
THYM	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg00484396	chr16:3507460	NAT15	-0.62	-5.38	-0.48	5.46e-7	Tuberculosis;
THYM	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg27535305	chr1:53392650	SCP2	-0.41	-4.71	-0.44	8.48e-6	Monocyte count;
THYM	cis	rs6032067	0.929	rs6017513	chr20:43835232	A/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.76	-0.51	1.01e-7	Blood protein levels;
THYM	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg23428387	chr22:49814324	NA	-0.58	-6.04	-0.53	2.99e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2692947	0.832	rs2579519	chr2:96675166	T/C	cg22654517	chr2:96458247	NA	0.6	4.56	0.42	1.51e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg19507638	chr5:93509721	C5orf36	-0.68	-4.57	-0.42	1.49e-5	Diabetic retinopathy;
THYM	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg17509989	chr5:176798049	RGS14	-0.94	-10.26	-0.73	4.59e-17	Hemoglobin concentration;Hematocrit;
THYM	cis	rs6500395	1.000	rs9938633	chr16:48682093	G/C	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	trans	rs2540647	0.706	rs2518805	chr22:18975587	A/G	cg19521646	chr19:15197788	OR1I1	1.02	6.88	0.58	6.37e-10	Blood metabolite ratios;
THYM	cis	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.33e-5	Retinal vascular caliber;
THYM	cis	rs9810089	0.903	rs7427564	chr3:136274435	G/A	cg12473912	chr3:136751656	NA	0.61	5.18	0.47	1.26e-6	Gestational age at birth (child effect);
THYM	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg22117172	chr7:91764530	CYP51A1	-0.35	-4.49	-0.42	1.97e-5	Breast cancer;
THYM	cis	rs7508	0.511	rs2237853	chr8:17877880	G/A	cg01800426	chr8:17659068	MTUS1	-0.8	-5.74	-0.51	1.11e-7	Atrial fibrillation;
THYM	cis	rs8049040	0.547	rs12929335	chr16:71435752	G/A	cg08717414	chr16:71523259	ZNF19	-0.72	-4.46	-0.42	2.27e-5	Blood protein levels;
THYM	cis	rs11969893	0.737	rs1854483	chr6:101378117	G/A	cg12253828	chr6:101329408	ASCC3	1.1	6.47	0.55	4.17e-9	Economic and political preferences (immigration/crime);
THYM	cis	rs10924970	0.967	rs10495362	chr1:235390396	T/C	cg26050004	chr1:235667680	B3GALNT2	0.6	4.57	0.42	1.45e-5	Asthma;
THYM	cis	rs2282300	0.739	rs34224414	chr11:30251041	T/G	cg06241208	chr11:30344200	C11orf46	-0.77	-5.59	-0.5	2.15e-7	Morning vs. evening chronotype;
THYM	cis	rs9359856	0.564	rs17735590	chr6:90330268	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.85	-7.45	-0.61	4.31e-11	Bipolar disorder;
THYM	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg03929089	chr4:120376271	NA	-0.96	-7.48	-0.61	3.69e-11	Coronary artery disease;
THYM	cis	rs4664308	0.870	rs55959207	chr2:161016981	A/C	cg03641300	chr2:160917029	PLA2R1	-0.74	-6.47	-0.55	4.18e-9	Idiopathic membranous nephropathy;
THYM	cis	rs8070740	0.898	rs4578712	chr17:5324431	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.72	6.03	0.53	3.15e-8	Menopause (age at onset);
THYM	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs490234	0.812	rs12341150	chr9:128340770	C/T	cg14078157	chr9:128172775	NA	-0.62	-4.83	-0.44	5.3e-6	Mean arterial pressure;
THYM	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg23131131	chr22:24373011	LOC391322	-0.9	-10.56	-0.73	1.05e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs728616	1.000	rs12414891	chr10:81690385	G/C	cg27452691	chr10:81370291	SFTPA1	0.83	4.49	0.42	2.03e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.76	-6.28	-0.54	1.03e-8	Lung cancer;
THYM	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg10661904	chr17:79619235	PDE6G	0.57	5.3	0.48	7.61e-7	Eye color traits;
THYM	cis	rs7119038	0.818	rs73003215	chr11:118649512	G/A	cg19308663	chr11:118741387	NA	0.44	4.68	0.43	9.33e-6	Sjögren's syndrome;
THYM	cis	rs9810089	0.934	rs684195	chr3:135993599	A/C	cg12473912	chr3:136751656	NA	0.61	5.13	0.47	1.5e-6	Gestational age at birth (child effect);
THYM	cis	rs66887589	0.967	rs13104219	chr4:120438174	G/T	cg13609457	chr4:120235615	NA	0.47	4.92	0.45	3.59e-6	Diastolic blood pressure;
THYM	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg17173187	chr15:85201210	NMB	0.54	5.31	0.48	7.17e-7	Schizophrenia;
THYM	cis	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg08133631	chr1:26527909	CATSPER4	-0.61	-5.08	-0.46	1.92e-6	Obesity-related traits;
THYM	cis	rs240764	0.658	rs12210255	chr6:101187540	G/C	cg21058520	chr6:100914733	NA	0.56	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs13102973	0.640	rs6829739	chr4:135835789	G/A	cg14419869	chr4:135874104	NA	0.7	5.72	0.51	1.26e-7	Subjective well-being;
THYM	cis	rs7107174	1.000	rs10899489	chr11:78095373	G/T	cg02023728	chr11:77925099	USP35	0.62	6.11	0.53	2.22e-8	Testicular germ cell tumor;
THYM	cis	rs4786125	0.665	rs1873704	chr16:6907021	C/G	cg03623568	chr16:6915990	A2BP1	-1.04	-10.4	-0.73	2.36e-17	Heart rate variability traits (SDNN);
THYM	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.2e-16	Bone mineral density;
THYM	cis	rs2637266	0.756	rs7079818	chr10:78469935	T/A	cg18941641	chr10:78392320	NA	0.76	6.05	0.53	2.82e-8	Pulmonary function;
THYM	cis	rs7107174	1.000	rs7116611	chr11:78030046	A/G	cg19901956	chr11:77921274	USP35	-0.68	-5.2	-0.47	1.16e-6	Testicular germ cell tumor;
THYM	cis	rs1784581	0.851	rs1784591	chr6:162388893	C/G	cg17173639	chr6:162384350	PARK2	-0.96	-9.61	-0.7	1.15e-15	Itch intensity from mosquito bite;
THYM	cis	rs981844	1.000	rs2405430	chr4:154658391	A/G	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg26116260	chr4:7069785	GRPEL1	-0.97	-7.15	-0.59	1.79e-10	Monocyte percentage of white cells;
THYM	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.84	0.44	4.97e-6	Bipolar disorder;
THYM	cis	rs11696501	0.739	rs2281210	chr20:44243172	T/G	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.57	-0.42	1.46e-5	Brain structure;
THYM	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg09165964	chr15:75287851	SCAMP5	-1.1	-6.31	-0.54	8.71e-9	Lung cancer;
THYM	cis	rs9972944	0.729	rs1541609	chr17:63773564	G/A	cg07283582	chr17:63770753	CCDC46	0.68	5.54	0.49	2.69e-7	Total body bone mineral density;
THYM	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11644478	chr21:40555479	PSMG1	-0.82	-7.39	-0.6	5.7e-11	Cognitive function;
THYM	cis	rs10203711	0.901	rs907104	chr2:239564564	T/G	cg14580085	chr2:239553406	NA	0.68	6.07	0.53	2.58e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17122693	0.551	rs3015456	chr14:51059923	T/C	cg04730355	chr14:51134070	SAV1	1.02	7.1	0.59	2.29e-10	Cognitive performance;
THYM	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg02675527	chr2:114030824	PAX8;LOC440839	-0.69	-5.72	-0.51	1.23e-7	Lymphocyte counts;
THYM	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg17366294	chr4:99064904	C4orf37	0.54	6.05	0.53	2.81e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.95	0.71	2.16e-16	Mean corpuscular hemoglobin;
THYM	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg05025164	chr4:1340916	KIAA1530	0.68	4.98	0.45	2.89e-6	Longevity;
THYM	cis	rs4631830	0.720	rs2611475	chr10:51503178	G/A	cg10326726	chr10:51549505	MSMB	-0.59	-5.97	-0.52	4.13e-8	Prostate-specific antigen levels;
THYM	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg05890377	chr2:74357713	NA	1.09	10.23	0.72	5.23e-17	Gestational age at birth (maternal effect);
THYM	cis	rs13315871	1.000	rs11717423	chr3:58330177	C/G	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg24675658	chr1:53192096	ZYG11B	0.83	7.77	0.62	9.08e-12	Monocyte count;
THYM	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg11245990	chr11:68621969	NA	0.57	7.2	0.59	1.41e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg04287289	chr16:89883240	FANCA	0.63	5.72	0.51	1.25e-7	Vitiligo;
THYM	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg16797656	chr11:68205561	LRP5	-0.42	-4.51	-0.42	1.87e-5	Total body bone mineral density;
THYM	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg10518543	chr12:38710700	ALG10B	-0.54	-4.54	-0.42	1.64e-5	Morning vs. evening chronotype;
THYM	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	6.65	0.56	1.87e-9	Platelet count;
THYM	cis	rs1670533	1.000	rs629260	chr4:1086764	A/G	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs8067545	0.518	rs7222987	chr17:20055765	A/G	cg13482628	chr17:19912719	NA	0.56	4.81	0.44	5.57e-6	Schizophrenia;
THYM	cis	rs7104764	0.673	rs3782118	chr11:222620	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	0.87	7.4	0.6	5.4e-11	Menarche (age at onset);
THYM	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg08645402	chr16:4508243	NA	0.71	6.39	0.55	6.12e-9	Schizophrenia;
THYM	cis	rs11039798	0.764	rs12277213	chr11:48782176	G/A	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs6838801	0.823	rs7691621	chr4:77589959	A/G	cg01477861	chr4:77609841	SHROOM3	0.48	4.8	0.44	6.01e-6	Cleft lip with or without cleft palate;
THYM	cis	rs939658	0.683	rs1560895	chr15:79468082	A/G	cg17916960	chr15:79447300	NA	-0.69	-7.94	-0.63	4.07e-12	Refractive error;
THYM	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg18252515	chr7:66147081	NA	-1.44	-8.51	-0.66	2.48e-13	Diabetic kidney disease;
THYM	cis	rs9677476	0.644	rs12470661	chr2:232060050	A/G	cg20307347	chr2:231734563	ITM2C	-0.54	-4.64	-0.43	1.09e-5	Food antigen IgG levels;
THYM	cis	rs4662750	0.580	rs4662742	chr2:128350744	C/A	cg01966334	chr2:128378434	MYO7B	0.59	5.4	0.48	5e-7	Renal cell carcinoma;
THYM	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06850241	chr22:41845214	NA	-0.58	-5.19	-0.47	1.18e-6	Vitiligo;
THYM	cis	rs12594515	1.000	rs8039974	chr15:45986665	A/G	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs7216064	0.601	rs35453056	chr17:66039668	A/G	cg12091567	chr17:66097778	LOC651250	0.98	8.02	0.64	2.7e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg15691649	chr6:25882328	NA	-0.69	-5.37	-0.48	5.64e-7	Intelligence (multi-trait analysis);
THYM	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg04111992	chr7:158790115	NA	-0.53	-4.73	-0.44	7.67e-6	Facial morphology (factor 20);
THYM	cis	rs6032067	0.777	rs35434469	chr20:43778544	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.73	-8.01	-0.64	2.81e-12	Blood protein levels;
THYM	cis	rs8038465	0.615	rs62004616	chr15:73961176	C/T	cg15420318	chr15:73925796	NPTN	0.6	5.17	0.47	1.29e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs775227	0.574	rs16861158	chr3:113261709	G/T	cg18753928	chr3:113234510	CCDC52	-0.78	-5.53	-0.49	2.8e-7	Dental caries;
THYM	cis	rs13082711	0.911	rs35605663	chr3:27515754	C/T	cg02860705	chr3:27208620	NA	0.72	5.15	0.47	1.39e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg20891558	chr2:74357851	NA	1.17	12.06	0.78	7.44e-21	Gestational age at birth (maternal effect);
THYM	cis	rs4731207	0.596	rs10231355	chr7:124581218	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs4664308	0.905	rs62177860	chr2:160960571	C/T	cg03641300	chr2:160917029	PLA2R1	-0.75	-6.87	-0.58	6.63e-10	Idiopathic membranous nephropathy;
THYM	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg19747945	chr6:42946146	PEX6	-0.32	-4.65	-0.43	1.06e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	6.96	0.58	4.33e-10	Lung cancer in ever smokers;
THYM	cis	rs67385638	0.802	rs7119142	chr11:5309078	A/G	cg12559170	chr11:5275217	HBG2	0.72	6.37	0.55	6.68e-9	Hemoglobin levels;
THYM	cis	rs72627123	0.867	rs80083802	chr14:74456996	C/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	4.87	0.45	4.38e-6	Morning vs. evening chronotype;
THYM	cis	rs7523273	0.606	rs2724382	chr1:207928635	G/C	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	cis	rs13401104	0.587	rs7581196	chr2:237151098	A/C	cg19324714	chr2:237145437	ASB18	-0.65	-5.02	-0.46	2.42e-6	Educational attainment;
THYM	cis	rs2245008	0.774	rs253136	chr16:83979601	A/C	cg27171569	chr16:83987465	OSGIN1	-0.7	-6.16	-0.53	1.71e-8	Pursuit maintenance gain;
THYM	cis	rs28595532	0.920	rs114243409	chr4:119756585	C/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs17433780	0.964	rs10493821	chr1:89475135	C/T	cg09516651	chr1:89888402	LOC400759	0.81	6.27	0.54	1.07e-8	Carotid intima media thickness;
THYM	trans	rs28595532	0.920	rs115982145	chr4:119605707	A/G	cg13773247	chr2:42276988	PKDCC	0.89	6.93	0.58	4.92e-10	Cannabis dependence symptom count;
THYM	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg02176678	chr2:219576539	TTLL4	0.72	7.17	0.59	1.63e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg04315214	chr1:2043799	PRKCZ	0.65	5.29	0.48	7.9e-7	Height;
THYM	cis	rs9880211	1.000	rs6767889	chr3:136365455	T/A	cg21827317	chr3:136751795	NA	-0.69	-4.63	-0.43	1.14e-5	Body mass index;Height;
THYM	cis	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg23422044	chr7:1970798	MAD1L1	0.75	5.14	0.47	1.48e-6	Bipolar disorder;
THYM	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg09455208	chr3:40491958	NA	0.46	4.66	0.43	1.02e-5	Renal cell carcinoma;
THYM	cis	rs7941600	0.708	rs4537761	chr11:9323353	T/C	cg19415743	chr11:9336845	TMEM41B	1.12	5.54	0.49	2.65e-7	Coronary artery disease;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg16576895	chr18:43842240	C18orf25	-0.97	-6.95	-0.58	4.66e-10	Depressive symptoms;
THYM	cis	rs986417	0.748	rs10150234	chr14:61031284	C/G	cg27398547	chr14:60952738	C14orf39	-1.1	-6.18	-0.54	1.59e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg26384229	chr12:38710491	ALG10B	1.01	9.69	0.7	7.72e-16	Heart rate;
THYM	cis	rs9807989	0.801	rs72823663	chr2:102968738	G/C	cg03938978	chr2:103052716	IL18RAP	0.63	6.46	0.55	4.36e-9	Asthma;
THYM	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg11247378	chr22:39784982	NA	-1.04	-13.86	-0.82	1.53e-24	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg00981070	chr1:2046702	PRKCZ	0.47	5.63	0.5	1.85e-7	Height;
THYM	cis	rs4750440	0.702	rs7918501	chr10:14029895	C/T	cg27542038	chr10:14027202	FRMD4A	-0.5	-4.45	-0.42	2.36e-5	Adiponectin levels;
THYM	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg06627628	chr2:24431161	ITSN2	-0.68	-4.51	-0.42	1.86e-5	Asthma;
THYM	cis	rs9902453	0.933	rs7216487	chr17:28502642	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.83	0.44	5.26e-6	Coffee consumption (cups per day);
THYM	cis	rs7173743	0.525	rs7166501	chr15:79133739	C/T	cg00540400	chr15:79124168	NA	0.63	6.22	0.54	1.3e-8	Coronary artery disease;
THYM	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg19507638	chr5:93509721	C5orf36	0.67	4.49	0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs6754311	0.638	rs2322659	chr2:136555659	A/G	cg04750100	chr2:136595281	LCT	-0.56	-6.53	-0.56	3.28e-9	Mosquito bite size;
THYM	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg13319975	chr6:146136371	FBXO30	-0.72	-6.1	-0.53	2.24e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9646944	0.501	rs10166330	chr2:103050390	C/T	cg01241218	chr2:102972058	NA	0.76	4.86	0.45	4.55e-6	Blood protein levels;
THYM	cis	rs2282930	0.512	rs6593077	chr7:50705770	A/C	cg08586669	chr7:50727761	GRB10	-0.31	-4.77	-0.44	6.66e-6	Bone mineral density;
THYM	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg00129232	chr17:37814104	STARD3	0.71	4.8	0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	trans	rs1974653	0.672	rs9606243	chr22:20080927	A/G	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg15536230	chr21:44985092	HSF2BP	-0.41	-5.14	-0.47	1.46e-6	Mean corpuscular volume;
THYM	cis	rs4663969	0.873	rs759174	chr2:234668245	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.65	-5.06	-0.46	2.06e-6	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg23708337	chr7:1209742	NA	0.87	4.67	0.43	9.79e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12928939	0.517	rs12149325	chr16:71968147	G/C	cg03805757	chr16:71968109	PKD1L3	-1.09	-11.04	-0.75	1.02e-18	Post bronchodilator FEV1;
THYM	cis	rs7020830	0.898	rs12554874	chr9:37073902	C/T	cg14294708	chr9:37120828	ZCCHC7	1.28	16.29	0.86	2.92e-29	Schizophrenia;
THYM	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg22535103	chr8:58192502	C8orf71	-1.05	-6.58	-0.56	2.55e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg13695892	chr22:41940480	POLR3H	-0.8	-6.71	-0.57	1.38e-9	Vitiligo;
THYM	cis	rs17102423	0.594	rs8010213	chr14:65552182	C/T	cg11161011	chr14:65562177	MAX	-0.69	-5.58	-0.5	2.31e-7	Obesity-related traits;
THYM	cis	rs700651	0.821	rs700666	chr2:198673544	G/A	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Intracranial aneurysm;
THYM	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg26441486	chr22:50317300	CRELD2	0.44	7.57	0.61	2.37e-11	Schizophrenia;
THYM	cis	rs3741151	0.687	rs56857598	chr11:73234173	G/A	cg17517138	chr11:73019481	ARHGEF17	0.9	4.73	0.44	7.74e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	5.72	0.51	1.22e-7	Schizophrenia;
THYM	cis	rs904251	0.797	rs1757181	chr6:37485728	A/G	cg01843034	chr6:37503916	NA	0.66	5.1	0.46	1.77e-6	Cognitive performance;
THYM	cis	rs4285028	0.948	rs10934565	chr3:121664661	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs4077515	0.874	rs3812560	chr9:139269905	T/C	cg14115884	chr9:139300582	SDCCAG3	0.76	8.11	0.64	1.79e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4363385	0.510	rs6677674	chr1:153037601	A/G	cg13444842	chr1:152974279	SPRR3	-0.61	-4.82	-0.44	5.4e-6	Inflammatory skin disease;
THYM	cis	rs13177918	0.677	rs13161156	chr5:149822586	A/G	cg14059543	chr5:149831962	NA	-1.0	-7.6	-0.61	2.11e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2354432	0.556	rs12568866	chr1:146718430	A/C	cg25205988	chr1:146714368	CHD1L	-1.04	-5.54	-0.49	2.67e-7	Mitochondrial DNA levels;
THYM	cis	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg09307838	chr4:120376055	NA	0.78	5.87	0.52	6.42e-8	Corneal astigmatism;
THYM	cis	rs12208915	0.559	rs4706738	chr6:79514153	A/G	cg05283184	chr6:79620031	NA	0.67	6.04	0.53	2.94e-8	Left atrial antero-posterior diameter;
THYM	cis	rs28595532	0.920	rs116098781	chr4:119771613	G/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg23205692	chr1:25664452	TMEM50A	0.86	6.69	0.57	1.54e-9	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.06	9.48	0.7	2.16e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg25251562	chr2:3704773	ALLC	-0.81	-5.41	-0.49	4.62e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs61931739	0.927	rs12315970	chr12:34038535	A/G	cg06521331	chr12:34319734	NA	0.61	4.76	0.44	6.95e-6	Morning vs. evening chronotype;
THYM	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg14196790	chr5:131705035	SLC22A5	0.55	5.05	0.46	2.15e-6	Blood metabolite levels;
THYM	cis	rs1797885	0.585	rs2255655	chr3:12598839	C/G	cg05467012	chr3:12595696	NA	0.54	4.56	0.42	1.53e-5	Immature fraction of reticulocytes;
THYM	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg18758796	chr5:131593413	PDLIM4	0.6	5.9	0.52	5.68e-8	Acylcarnitine levels;
THYM	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg01416388	chr22:39784598	NA	0.9	8.2	0.64	1.17e-12	Intelligence (multi-trait analysis);
THYM	cis	rs2933343	0.621	rs789249	chr3:128578453	T/C	cg11901034	chr3:128598214	ACAD9	-0.7	-5.68	-0.5	1.47e-7	IgG glycosylation;
THYM	cis	rs514406	0.893	rs6682024	chr1:53439525	T/C	cg08859206	chr1:53392774	SCP2	0.66	7.64	0.62	1.72e-11	Monocyte count;
THYM	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg03806693	chr22:41940476	POLR3H	-1.19	-10.43	-0.73	2.03e-17	Vitiligo;
THYM	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg03264133	chr6:25882463	NA	0.67	5.59	0.5	2.19e-7	Blood metabolite levels;
THYM	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg02640540	chr1:67518911	SLC35D1	0.59	4.64	0.43	1.09e-5	Lymphocyte percentage of white cells;
THYM	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.21	-0.47	1.09e-6	Mood instability;
THYM	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg14784868	chr12:69753453	YEATS4	0.81	6.43	0.55	5.14e-9	Blood protein levels;
THYM	cis	rs2806561	0.929	rs10917357	chr1:23535161	C/T	cg08872493	chr1:23521417	HTR1D	0.36	4.45	0.42	2.34e-5	Height;
THYM	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.7	5.23	0.47	1.01e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.58	-4.45	-0.42	2.35e-5	Monocyte percentage of white cells;
THYM	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs1113500	0.933	rs2077259	chr1:108629551	T/C	cg06207961	chr1:108661230	NA	0.66	5.17	0.47	1.28e-6	Growth-regulated protein alpha levels;
THYM	cis	rs36093924	0.646	rs4822069	chr22:42351481	T/C	cg10296410	chr22:42095368	MEI1	0.44	4.61	0.43	1.26e-5	Intelligence;
THYM	cis	rs3768617	0.510	rs3768619	chr1:183092404	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg25287198	chr4:183728479	NA	0.76	4.66	0.43	1.03e-5	Pediatric autoimmune diseases;
THYM	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg20203395	chr5:56204925	C5orf35	-0.69	-4.75	-0.44	7.14e-6	Initial pursuit acceleration;
THYM	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	4.54	0.42	1.66e-5	Hip circumference adjusted for BMI;
THYM	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg20587970	chr11:113659929	NA	-1.37	-8.96	-0.68	2.79e-14	Hip circumference adjusted for BMI;
THYM	cis	rs728616	0.867	rs1923534	chr10:81710485	A/G	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3820068	0.705	rs11577225	chr1:15864242	T/C	cg05660106	chr1:15850417	CASP9	1.14	9.89	0.71	2.91e-16	Systolic blood pressure;
THYM	cis	rs10911232	0.507	rs4483371	chr1:182988352	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs6674176	0.628	rs7556565	chr1:44416090	C/T	cg12908607	chr1:44402522	ARTN	-0.54	-4.64	-0.43	1.1e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs3135718	0.935	rs2981584	chr10:123350216	A/C	cg15049101	chr10:123353889	FGFR2	-0.58	-5.17	-0.47	1.32e-6	Estrogen receptor status in breast cancer;
THYM	cis	rs6882076	1.000	rs6882076	chr5:156390297	T/C	cg12943317	chr5:156479607	HAVCR1	-0.7	-5.88	-0.52	6.2e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs1160297	0.609	rs12713232	chr2:53108308	A/T	cg07782112	chr2:53107842	NA	-0.74	-6.4	-0.55	5.79e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg24672777	chr11:48374446	OR4C45	-0.93	-5.95	-0.52	4.55e-8	Axial length;
THYM	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg19052272	chr2:3704530	ALLC	0.72	6.36	0.55	6.94e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg20469991	chr17:27169893	C17orf63	-0.76	-4.78	-0.44	6.27e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg02725872	chr8:58115012	NA	-1.1	-8.38	-0.65	4.69e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg16586182	chr3:47516702	SCAP	0.6	5.09	0.46	1.8e-6	Colorectal cancer;
THYM	cis	rs2273669	0.667	rs12196010	chr6:109302173	C/A	cg17117243	chr6:109341365	SESN1	-0.84	-4.94	-0.45	3.41e-6	Prostate cancer;
THYM	cis	rs8013055	0.846	rs10139744	chr14:105974696	G/A	cg04429589	chr14:105992532	TMEM121	-0.51	-5.35	-0.48	6.17e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg11752832	chr7:134001865	SLC35B4	0.73	5.5	0.49	3.21e-7	Mean platelet volume;
THYM	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg09367891	chr1:107599246	PRMT6	0.71	5.22	0.47	1.07e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs2073300	1.000	rs6132626	chr20:23444672	T/C	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6840360	0.582	rs11732918	chr4:152319045	C/T	cg17479576	chr4:152424074	FAM160A1	-0.74	-5.57	-0.5	2.36e-7	Intelligence (multi-trait analysis);
THYM	trans	rs11640439	1.000	rs11640439	chr16:57303194	C/T	cg21757872	chr12:107974453	BTBD11	0.8	7.94	0.63	4.07e-12	Sleep duration;
THYM	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg02931644	chr1:25747376	RHCE	0.58	4.45	0.42	2.29e-5	Erythrocyte sedimentation rate;
THYM	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.89	-8.78	-0.67	6.71e-14	Lung cancer;
THYM	cis	rs11008222	0.902	rs10826862	chr10:31041134	A/G	cg00941203	chr10:31016591	NA	-0.36	-5.13	-0.47	1.51e-6	Congenital left-sided heart lesions (maternal effect);
THYM	cis	rs2963155	0.518	rs864355	chr5:142633229	A/G	cg17617527	chr5:142782415	NR3C1	1.2	6.6	0.56	2.37e-9	Breast cancer;
THYM	cis	rs911263	0.961	rs2208397	chr14:68753287	T/G	cg18825221	chr14:68749962	RAD51L1	0.58	6.05	0.53	2.91e-8	Primary biliary cholangitis;
THYM	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg03983476	chr2:10830698	NOL10	-0.59	-5.71	-0.51	1.29e-7	Prostate cancer;
THYM	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs4273100	0.607	rs8072587	chr17:19211073	C/G	cg25447019	chr17:19030144	GRAPL	0.79	6.24	0.54	1.2e-8	Schizophrenia;
THYM	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg26384229	chr12:38710491	ALG10B	-0.89	-7.67	-0.62	1.49e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg24733560	chr20:60626293	TAF4	0.52	4.69	0.43	9.24e-6	Body mass index;
THYM	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs1335645	0.502	rs618089	chr1:111625277	T/C	cg00321911	chr1:111669324	DRAM2	1.0	5.55	0.49	2.62e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg10515332	chr4:99064459	C4orf37	0.65	5.22	0.47	1.06e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg04865290	chr3:52927548	TMEM110	-0.96	-4.97	-0.45	2.97e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs6876348	0.516	rs257898	chr5:128314586	A/G	cg02841155	chr5:128301328	SLC27A6	-0.5	-4.86	-0.45	4.54e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg14784868	chr12:69753453	YEATS4	1.13	12.26	0.78	2.8e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg26769984	chr7:1090371	C7orf50	-0.84	-5.73	-0.51	1.2e-7	Bronchopulmonary dysplasia;
THYM	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.69	-7.42	-0.61	4.85e-11	Crohn's disease;
THYM	cis	rs5758511	0.689	rs17478227	chr22:42654327	C/G	cg08431931	chr22:42394659	WBP2NL	-0.81	-4.77	-0.44	6.66e-6	Birth weight;
THYM	cis	rs2820651	0.614	rs76389357	chr10:1482550	C/T	cg02445968	chr10:1449028	ADARB2	-1.07	-5.44	-0.49	4.17e-7	Migraine with aura;
THYM	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg18904891	chr8:8559673	CLDN23	0.68	5.72	0.51	1.23e-7	Neuroticism;
THYM	cis	rs2797160	1.000	rs1739347	chr6:126014157	C/T	cg16306078	chr6:126000798	NA	0.54	5.53	0.49	2.75e-7	Endometrial cancer;
THYM	cis	rs977987	0.806	rs11644306	chr16:75490053	T/C	cg03315344	chr16:75512273	CHST6	0.73	5.99	0.52	3.73e-8	Dupuytren's disease;
THYM	cis	rs67460515	0.506	rs935497	chr3:160600563	A/G	cg12349858	chr3:160822545	B3GALNT1	0.56	4.59	0.43	1.38e-5	Parkinson's disease;
THYM	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.1	8.39	0.65	4.46e-13	Cognitive test performance;
THYM	cis	rs763014	0.898	rs4984892	chr16:622325	A/G	cg09263875	chr16:632152	PIGQ	0.73	6.29	0.54	9.69e-9	Height;
THYM	cis	rs4888262	0.526	rs8057279	chr16:74627303	C/T	cg01733217	chr16:74700730	RFWD3	0.82	8.54	0.66	2.2e-13	Testicular germ cell tumor;
THYM	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg14895029	chr7:2775587	GNA12	-0.68	-4.95	-0.45	3.24e-6	Height;
THYM	cis	rs7078219	0.714	rs12414770	chr10:101288238	G/T	cg17888390	chr10:101282816	NA	-0.53	-5.14	-0.47	1.46e-6	Dental caries;
THYM	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg13866156	chr1:1669148	SLC35E2	0.64	6.18	0.54	1.6e-8	Body mass index;
THYM	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg05962950	chr11:130786565	SNX19	0.85	7.33	0.6	7.42e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg27129171	chr3:47204927	SETD2	0.71	6.44	0.55	4.86e-9	Colorectal cancer;
THYM	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg13010199	chr12:38710504	ALG10B	-0.62	-4.5	-0.42	1.95e-5	Bladder cancer;
THYM	cis	rs4919669	0.546	rs4919647	chr10:104250754	A/C	cg00122347	chr10:104236741	TMEM180	-0.59	-4.8	-0.44	5.93e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
THYM	cis	rs73198271	0.601	rs11997731	chr8:8649848	C/T	cg15556689	chr8:8085844	FLJ10661	-0.74	-4.91	-0.45	3.75e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs6032067	0.929	rs35869085	chr20:43805134	G/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs7818345	0.569	rs4631483	chr8:19357923	G/C	cg01280390	chr8:19363452	CSGALNACT1	0.61	5.03	0.46	2.32e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs11651000	0.894	rs41519545	chr17:45811549	G/T	cg03474202	chr17:45855739	NA	-0.69	-4.5	-0.42	1.91e-5	IgG glycosylation;
THYM	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg06238570	chr21:40685208	BRWD1	0.89	6.24	0.54	1.19e-8	Cognitive function;
THYM	cis	rs7681440	0.606	rs2583984	chr4:90754153	C/T	cg06632027	chr4:90757378	SNCA	0.67	5.36	0.48	5.93e-7	Dementia with Lewy bodies;
THYM	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg22535103	chr8:58192502	C8orf71	-0.95	-6.0	-0.52	3.51e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs4273100	0.573	rs4924783	chr17:19253981	A/G	cg25447019	chr17:19030144	GRAPL	0.79	6.24	0.54	1.2e-8	Schizophrenia;
THYM	cis	rs2276314	0.748	rs4799839	chr18:33597531	T/C	cg05985134	chr18:33552581	C18orf21	0.69	4.88	0.45	4.22e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg00129232	chr17:37814104	STARD3	0.75	5.4	0.48	4.93e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs854765	0.624	rs8078756	chr17:17744725	T/C	cg16928487	chr17:17741425	SREBF1	0.51	4.61	0.43	1.24e-5	Total body bone mineral density;
THYM	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg22535103	chr8:58192502	C8orf71	-0.96	-5.47	-0.49	3.7e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg21657705	chr17:61574500	ACE	0.43	4.65	0.43	1.06e-5	Prudent dietary pattern;
THYM	cis	rs6430585	0.583	rs9636213	chr2:136589278	G/A	cg07169764	chr2:136633963	MCM6	-1.04	-11.48	-0.76	1.18e-19	Corneal structure;
THYM	cis	rs9649213	0.593	rs12728	chr7:97922851	C/T	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12472274	0.536	rs12619455	chr2:239080149	A/C	cg17459225	chr2:239074497	NA	0.72	4.89	0.45	4.02e-6	Phospholipid levels (plasma);
THYM	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.71	-7.68	-0.62	1.42e-11	Crohn's disease;
THYM	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg22431228	chr1:16359049	CLCNKA	-0.53	-5.13	-0.47	1.51e-6	Dilated cardiomyopathy;
THYM	cis	rs75920871	0.588	rs4938321	chr11:116852507	C/T	cg20608306	chr11:116969690	SIK3	-0.49	-5.33	-0.48	6.49e-7	Subjective well-being;
THYM	cis	rs7107174	1.000	rs2512537	chr11:77971947	T/C	cg02023728	chr11:77925099	USP35	0.69	6.19	0.54	1.55e-8	Testicular germ cell tumor;
THYM	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-13.94	-0.82	1.07e-24	Height;
THYM	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg12516959	chr21:47718080	NA	0.38	5.02	0.46	2.4e-6	Testicular germ cell tumor;
THYM	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs921968	0.613	rs1427445	chr2:219555573	C/A	cg02176678	chr2:219576539	TTLL4	-0.55	-5.46	-0.49	3.79e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6430585	0.583	rs12475516	chr2:136560761	C/G	cg04750100	chr2:136595281	LCT	0.46	4.68	0.43	9.64e-6	Corneal structure;
THYM	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg01699819	chr7:1052092	C7orf50	-0.68	-5.7	-0.5	1.37e-7	Bronchopulmonary dysplasia;
THYM	cis	rs3017493	0.786	rs59579317	chr11:70684569	A/G	cg21202716	chr11:70508022	SHANK2	1.01	4.85	0.45	4.85e-6	Renal transplant outcome;
THYM	cis	rs7192380	0.965	rs9938213	chr16:69640590	T/C	cg09409435	chr16:70099608	PDXDC2	0.62	4.73	0.44	7.92e-6	Sjögren's syndrome;
THYM	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg10802521	chr3:52805072	NEK4	-0.75	-7.03	-0.58	3.15e-10	Electroencephalogram traits;
THYM	cis	rs2456568	0.548	rs1607402	chr11:93660732	T/G	cg14065697	chr11:93583672	C11orf90	-0.48	-4.52	-0.42	1.77e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs12142240	0.698	rs72677600	chr1:46834449	G/A	cg00530320	chr1:46809349	NSUN4	0.8	5.5	0.49	3.16e-7	Menopause (age at onset);
THYM	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg06618935	chr21:46677482	NA	-0.96	-9.38	-0.69	3.52e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1008375	0.618	rs6842764	chr4:17568420	C/T	cg16339924	chr4:17578868	LAP3	-0.64	-4.53	-0.42	1.69e-5	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg14507445	chr22:49886340	NA	-0.54	-4.84	-0.44	5.08e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	9.63	0.7	1.02e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs17122693	0.748	rs8014572	chr14:51095780	C/A	cg04730355	chr14:51134070	SAV1	0.98	6.28	0.54	1.03e-8	Cognitive performance;
THYM	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg22852734	chr6:133119734	C6orf192	1.26	7.73	0.62	1.11e-11	Type 2 diabetes nephropathy;
THYM	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg24531977	chr5:56204891	C5orf35	-0.89	-5.16	-0.47	1.34e-6	Type 2 diabetes;
THYM	cis	rs870825	0.616	rs10006828	chr4:185651416	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg26384229	chr12:38710491	ALG10B	0.95	7.06	0.59	2.68e-10	Bladder cancer;
THYM	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg06627628	chr2:24431161	ITSN2	0.73	5.15	0.47	1.42e-6	Asthma;
THYM	cis	rs899997	1.000	rs12899201	chr15:79033534	G/A	cg04896959	chr15:78267971	NA	0.88	7.15	0.59	1.76e-10	Coronary artery disease or large artery stroke;
THYM	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.61	4.95	0.45	3.22e-6	Renal function-related traits (BUN);
THYM	cis	rs1050631	0.574	rs1789507	chr18:33732354	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.28	0.48	8.32e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs2072732	0.706	rs12564456	chr1:2936386	C/G	cg08733933	chr1:2954429	NA	-0.61	-4.64	-0.43	1.13e-5	Plateletcrit;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg07603881	chr1:21065497	NA	-0.99	-7.23	-0.6	1.21e-10	Depressive symptoms;
THYM	cis	rs800586	0.912	rs808982	chr8:116800251	T/G	cg04656070	chr8:116661063	TRPS1	0.49	4.7	0.43	8.9e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg06521331	chr12:34319734	NA	-0.73	-5.66	-0.5	1.59e-7	Morning vs. evening chronotype;
THYM	cis	rs77236434	0.649	rs1729136	chr8:13180159	C/A	cg06835018	chr8:12272982	NA	0.75	4.86	0.45	4.68e-6	Familial hepatitis B virus-related hepatocellular carcinoma;
THYM	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg22316451	chr20:60645197	NA	-0.48	-4.58	-0.43	1.4e-5	Body mass index;
THYM	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg02725872	chr8:58115012	NA	-1.15	-7.43	-0.61	4.64e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs9649213	0.593	rs34129434	chr7:97926464	C/T	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.6e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg26686753	chr3:189841551	LEPREL1	-0.86	-5.87	-0.52	6.23e-8	Lung adenocarcinoma;
THYM	cis	rs7107174	1.000	rs72931642	chr11:78037862	A/T	cg02023728	chr11:77925099	USP35	0.61	5.81	0.51	8.17e-8	Testicular germ cell tumor;
THYM	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg24874828	chr4:187887005	NA	-0.72	-7.22	-0.6	1.27e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9467711	0.538	rs7750960	chr6:25887217	A/C	cg12826209	chr6:26865740	GUSBL1	0.92	4.45	0.42	2.36e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg03609598	chr5:56110824	MAP3K1	-0.85	-5.83	-0.51	7.62e-8	Initial pursuit acceleration;
THYM	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg13852791	chr20:30311386	BCL2L1	-0.88	-7.22	-0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg05084668	chr3:125655381	ALG1L	-0.74	-4.68	-0.43	9.36e-6	Blood pressure (smoking interaction);
THYM	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg01448562	chr3:133502909	NA	-0.82	-6.84	-0.57	7.51e-10	Iron status biomarkers;
THYM	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg08017756	chr2:100939284	LONRF2	-0.75	-7.76	-0.62	9.51e-12	Intelligence (multi-trait analysis);
THYM	cis	rs870825	0.616	rs12502860	chr4:185636105	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg26597838	chr10:835615	NA	1.11	7.5	0.61	3.36e-11	Eosinophil percentage of granulocytes;
THYM	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.69	-6.15	-0.53	1.82e-8	Personality dimensions;
THYM	cis	rs1395	0.778	rs1978881	chr2:27400850	C/A	cg23587288	chr2:27483067	SLC30A3	-0.61	-5.36	-0.48	5.76e-7	Blood metabolite levels;
THYM	cis	rs4713118	0.955	rs9468203	chr6:27688667	A/G	cg08968635	chr6:28129556	ZNF389	0.75	5.95	0.52	4.53e-8	Parkinson's disease;
THYM	cis	rs7523273	0.526	rs12132176	chr1:207884287	A/T	cg22525895	chr1:207977042	MIR29B2	0.55	5.13	0.47	1.51e-6	Schizophrenia;
THYM	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg18512352	chr11:47633146	NA	-0.49	-5.89	-0.52	5.76e-8	Subjective well-being;
THYM	cis	rs868036	1.000	rs4633663	chr15:68106378	G/C	cg24579218	chr15:68104479	NA	-0.65	-6.51	-0.56	3.59e-9	Restless legs syndrome;
THYM	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg15704280	chr7:45808275	SEPT13	-1.08	-13.87	-0.82	1.48e-24	Height;
THYM	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg15247329	chr7:2764246	NA	-0.67	-5.46	-0.49	3.83e-7	Height;
THYM	cis	rs1978968	1.000	rs1076539	chr22:18439598	A/G	cg01550578	chr22:18484421	MICAL3	0.68	5.16	0.47	1.33e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs11186	0.556	rs72906307	chr2:189955684	G/C	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg20848291	chr7:100343083	ZAN	0.62	4.55	0.42	1.6e-5	Other erythrocyte phenotypes;
THYM	cis	rs4638749	0.501	rs9917180	chr2:108747645	A/C	cg25838818	chr2:108905173	SULT1C2	0.49	4.88	0.45	4.3e-6	Blood pressure;
THYM	cis	rs72827839	0.744	rs16955463	chr17:46399497	G/T	cg23391107	chr17:45924227	SP6	0.86	5.55	0.5	2.54e-7	Ease of getting up in the morning;
THYM	cis	rs10929159	0.928	rs13025044	chr2:236916549	G/A	cg20128773	chr2:236923534	AGAP1	0.36	4.68	0.43	9.32e-6	Parkinson's disease;
THYM	cis	rs13256369	0.851	rs11786125	chr8:8564570	T/G	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs36051895	0.659	rs3780365	chr9:5068520	T/C	cg02405213	chr9:5042618	JAK2	-1.02	-11.11	-0.75	7.02e-19	Pediatric autoimmune diseases;
THYM	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg23743428	chr13:21893420	NA	-0.68	-5.89	-0.52	5.75e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs68170813	0.562	rs7810216	chr7:107000353	G/A	cg00661777	chr7:106511741	PIK3CG	-0.68	-4.71	-0.44	8.28e-6	Coronary artery disease;
THYM	cis	rs7578035	1.000	rs7578035	chr2:99382892	T/G	cg02307953	chr2:99797349	MRPL30;MITD1	0.65	4.61	0.43	1.28e-5	Bipolar disorder;
THYM	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg16928487	chr17:17741425	SREBF1	-0.55	-5.38	-0.48	5.28e-7	Total body bone mineral density;
THYM	cis	rs8099917	0.943	rs8109889	chr19:39742770	C/T	cg16476317	chr19:39737804	NA	0.42	4.48	0.42	2.1e-5	Response to hepatitis C treatment;Chronic hepatitis C infection;
THYM	cis	rs611744	0.967	rs627019	chr8:109222544	G/A	cg21045802	chr8:109455806	TTC35	0.59	5.25	0.47	9.08e-7	Dupuytren's disease;
THYM	cis	rs1371867	0.846	rs1660353	chr8:101250907	C/T	cg00191853	chr8:101177733	SPAG1	0.5	4.74	0.44	7.61e-6	Atrioventricular conduction;
THYM	cis	rs4940575	0.679	rs55825601	chr18:60835819	C/T	cg20947866	chr18:61143580	SERPINB5	0.87	5.15	0.47	1.38e-6	Breast cancer;
THYM	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg08968635	chr6:28129556	ZNF389	-0.69	-5.7	-0.5	1.34e-7	Depression;
THYM	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg11211951	chr8:145729740	GPT	-0.51	-4.82	-0.44	5.44e-6	Age at first birth;
THYM	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg08645402	chr16:4508243	NA	-0.7	-6.24	-0.54	1.21e-8	Schizophrenia;
THYM	cis	rs447921	0.861	rs72860804	chr17:74413903	G/A	cg17201438	chr17:74438067	UBE2O	0.81	5.85	0.51	6.9e-8	Mitochondrial DNA levels;
THYM	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-6.28	-0.54	1.03e-8	Total body bone mineral density;
THYM	cis	rs4731207	0.596	rs1600745	chr7:124585183	G/C	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs12579753	0.917	rs7132465	chr12:82205840	C/T	cg21231944	chr12:82153410	PPFIA2	-0.66	-5.01	-0.46	2.51e-6	Resting heart rate;
THYM	cis	rs2803122	0.871	rs10733360	chr9:19221578	G/A	cg19584733	chr9:19298547	DENND4C	-0.52	-4.48	-0.42	2.12e-5	Pulse pressure;
THYM	cis	rs1018836	0.632	rs7017295	chr8:91482356	C/T	cg16814680	chr8:91681699	NA	0.75	6.06	0.53	2.78e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4589258	0.788	rs10741368	chr11:90491476	C/T	cg26138821	chr11:89956704	CHORDC1	-0.56	-4.49	-0.42	1.98e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7725337	0.929	rs35120171	chr5:88346579	G/T	cg11280525	chr5:87955695	LOC645323	-0.4	-4.49	-0.42	2.03e-5	Total body bone mineral density;
THYM	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06850241	chr22:41845214	NA	0.53	4.56	0.42	1.54e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4383453	0.539	rs931575	chr3:123098842	G/C	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg18252515	chr7:66147081	NA	-0.67	-5.08	-0.46	1.89e-6	Aortic root size;
THYM	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg18758796	chr5:131593413	PDLIM4	0.51	4.83	0.44	5.32e-6	Breast cancer;
THYM	cis	rs365132	0.875	rs2456178	chr5:176413570	C/G	cg17809377	chr5:176326619	HK3	-0.3	-4.55	-0.42	1.59e-5	Menarche and menopause (age at onset);Menopause (age at onset);
THYM	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg18850127	chr7:39170497	POU6F2	0.62	5.7	0.5	1.36e-7	IgG glycosylation;
THYM	cis	rs11605275	1.000	rs73434177	chr11:20023995	G/A	cg14835545	chr11:20032148	NAV2	-1.38	-6.36	-0.55	6.98e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs13185784	0.667	rs62406986	chr5:179644055	G/A	cg23248424	chr5:179741104	GFPT2	0.73	4.62	0.43	1.22e-5	TRAIL levels;
THYM	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg06728252	chr6:26598149	ABT1	-0.44	-5.24	-0.47	9.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2294693	0.945	rs9369253	chr6:40986538	A/G	cg14418226	chr6:40996092	UNC5CL	0.69	5.65	0.5	1.7e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs12681287	0.604	rs13279589	chr8:87477723	C/T	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs1461503	0.966	rs11218905	chr11:122840303	A/G	cg27398637	chr11:122830231	C11orf63	0.7	6.65	0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs12496230	1.000	rs36016775	chr3:66838437	A/G	cg17646820	chr3:66848679	NA	0.79	4.81	0.44	5.66e-6	Type 2 diabetes;
THYM	cis	rs9462846	0.652	rs77807794	chr6:42906242	C/T	cg21280719	chr6:42927975	GNMT	-0.42	-4.54	-0.42	1.65e-5	Blood protein levels;
THYM	cis	rs3785574	0.650	rs7406102	chr17:62004749	G/A	cg06873352	chr17:61820015	STRADA	-0.5	-5.01	-0.46	2.47e-6	Height;
THYM	cis	rs6815814	0.861	rs10004195	chr4:38784724	T/A	cg06935464	chr4:38784597	TLR10	0.68	4.82	0.44	5.35e-6	Breast cancer;
THYM	cis	rs12122100	0.651	rs12127461	chr1:146551888	C/G	cg03526459	chr1:146549940	NA	-0.66	-4.49	-0.42	1.97e-5	HIV-1 control;
THYM	cis	rs72901758	0.669	rs17641275	chr17:76247796	A/C	cg25512537	chr17:76250053	NA	-0.44	-6.58	-0.56	2.62e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
THYM	cis	rs1003719	0.641	rs13046844	chr21:38517603	A/G	cg01329690	chr21:38580129	DSCR9	-0.37	-5.09	-0.46	1.83e-6	Eye color traits;
THYM	cis	rs11030122	0.702	rs2898947	chr11:3977572	G/A	cg18678763	chr11:4115507	RRM1	-0.44	-5.73	-0.51	1.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg11905131	chr22:24372483	LOC391322	-0.93	-10.22	-0.72	5.59e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs28669119	0.778	rs674747	chr5:88079010	G/T	cg11309685	chr5:87564951	TMEM161B	0.74	4.5	0.42	1.94e-5	Schizophrenia;
THYM	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs2858942	0.818	rs1203979	chr16:261866	T/A	cg08400316	chr16:204221	HBZ	-0.6	-5.16	-0.47	1.36e-6	Mean corpuscular hemoglobin;
THYM	cis	rs6733011	0.519	rs6739097	chr2:99458601	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.48	-0.42	2.11e-5	Bipolar disorder;
THYM	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	6.96	0.58	4.45e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1395	0.922	rs6547521	chr2:27488432	G/C	cg23587288	chr2:27483067	SLC30A3	-0.56	-4.99	-0.46	2.78e-6	Blood metabolite levels;
THYM	cis	rs2067615	0.507	rs11113083	chr12:107073316	C/A	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg14690197	chr8:22456421	C8orf58	0.48	4.68	0.43	9.65e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg08859206	chr1:53392774	SCP2	-0.66	-7.4	-0.6	5.39e-11	Monocyte count;
THYM	cis	rs7107174	1.000	rs10899452	chr11:77995143	A/C	cg19901956	chr11:77921274	USP35	-0.71	-5.04	-0.46	2.22e-6	Testicular germ cell tumor;
THYM	trans	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.58	-4.67	-0.43	9.9e-6	Lung cancer;
THYM	cis	rs7216064	1.000	rs6504555	chr17:65940727	A/G	cg12091567	chr17:66097778	LOC651250	0.73	5.18	0.47	1.25e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs10186029	0.509	rs10203749	chr2:213935855	T/A	cg08319019	chr2:214017104	IKZF2	-0.66	-5.12	-0.47	1.6e-6	Systemic sclerosis;
THYM	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs17193922	0.876	rs17194040	chr16:53550898	C/T	cg09728985	chr16:53543985	NA	-0.56	-4.62	-0.43	1.21e-5	Hip circumference adjusted for BMI;
THYM	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg05962950	chr11:130786565	SNX19	0.92	8.66	0.66	1.22e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	4.46	0.42	2.21e-5	Diabetic retinopathy;
THYM	cis	rs4888262	0.508	rs6564153	chr16:74658723	A/C	cg01733217	chr16:74700730	RFWD3	0.93	9.74	0.71	5.85e-16	Testicular germ cell tumor;
THYM	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg00852783	chr1:26633632	UBXN11	0.84	8.57	0.66	1.85e-13	Obesity-related traits;
THYM	cis	rs11792861	0.546	rs7873569	chr9:111796753	A/T	cg05043794	chr9:111880884	C9orf5	-0.31	-4.6	-0.43	1.32e-5	Menarche (age at onset);
THYM	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg27129171	chr3:47204927	SETD2	0.75	7.27	0.6	9.95e-11	Colorectal cancer;
THYM	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg03909863	chr11:638404	DRD4	-0.76	-6.04	-0.53	2.95e-8	Systemic lupus erythematosus;
THYM	cis	rs1129187	0.755	rs2296804	chr6:42931261	C/G	cg21280719	chr6:42927975	GNMT	-0.53	-7.41	-0.61	5.24e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg16414030	chr3:133502952	NA	-0.84	-8.47	-0.66	3.08e-13	Iron status biomarkers;
THYM	cis	rs427394	0.796	rs274683	chr5:6747950	T/A	cg10857441	chr5:6722123	POLS	-0.62	-6.72	-0.57	1.33e-9	Menopause (age at onset);
THYM	trans	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.22	-14.33	-0.83	1.74e-25	Exhaled nitric oxide output;
THYM	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs7084402	0.967	rs1427196	chr10:60278573	C/T	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs35264875	0.898	rs56140802	chr11:68861631	G/A	cg23845249	chr11:68861649	NA	0.55	6.45	0.55	4.67e-9	Blond vs. brown hair color;
THYM	cis	rs6598955	0.543	rs112752634	chr1:26534217	G/A	cg04990556	chr1:26633338	UBXN11	0.96	6.06	0.53	2.7e-8	Obesity-related traits;
THYM	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.25	-4.74	-0.44	7.58e-6	Obesity-related traits;
THYM	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg07570687	chr10:102243282	WNT8B	0.74	6.34	0.55	7.57e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg03676636	chr4:99064102	C4orf37	0.45	6.87	0.58	6.55e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg00484396	chr16:3507460	NAT15	-0.62	-5.38	-0.48	5.46e-7	Tuberculosis;
THYM	cis	rs782590	0.935	rs2586954	chr2:55892261	A/C	cg18811423	chr2:55921094	PNPT1	0.75	7.13	0.59	1.94e-10	Metabolic syndrome;
THYM	cis	rs870825	0.616	rs7683537	chr4:185631998	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	5.41	0.49	4.62e-7	Rheumatoid arthritis;
THYM	cis	rs66887589	0.934	rs12648182	chr4:120503891	T/A	cg13609457	chr4:120235615	NA	-0.47	-4.92	-0.45	3.59e-6	Diastolic blood pressure;
THYM	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.64	-6.72	-0.57	1.33e-9	Longevity;Endometriosis;
THYM	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg02275930	chr1:2372054	NA	-1.04	-9.08	-0.68	1.5e-14	Non-obstructive azoospermia;
THYM	cis	rs12282928	0.885	rs1503176	chr11:48269191	C/T	cg22827986	chr11:48284249	OR4X1	-0.53	-5.48	-0.49	3.41e-7	Migraine - clinic-based;
THYM	cis	rs2279817	0.863	rs2270976	chr1:18023690	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.78	5.01	0.46	2.51e-6	Neuroticism;
THYM	cis	rs2806561	0.765	rs4333826	chr1:23517514	C/T	cg12483005	chr1:23474871	LUZP1	0.59	6.29	0.54	9.59e-9	Height;
THYM	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.73	-5.02	-0.46	2.43e-6	Body mass index;
THYM	cis	rs420259	0.516	rs12162020	chr16:23613191	A/G	cg00143387	chr16:23521605	GGA2	0.67	4.72	0.44	8.09e-6	Bipolar disorder;
THYM	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg04663057	chr3:46933782	PTH1R	0.53	5.07	0.46	1.99e-6	Birth weight;
THYM	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Bladder cancer;
THYM	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	5.23	0.47	1.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.86	-5.67	-0.5	1.56e-7	Body mass index;
THYM	cis	rs10203711	1.000	rs907102	chr2:239564503	G/A	cg14580085	chr2:239553406	NA	0.68	6.07	0.53	2.58e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg00256281	chr22:41985642	PMM1	0.62	4.67	0.43	1e-5	Vitiligo;
THYM	cis	rs904251	0.766	rs1757175	chr6:37486694	T/C	cg01843034	chr6:37503916	NA	-0.71	-5.61	-0.5	1.98e-7	Cognitive performance;
THYM	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs2710642	0.564	rs6545962	chr2:62821318	G/A	cg17519650	chr2:63277830	OTX1	0.63	4.64	0.43	1.12e-5	LDL cholesterol levels;LDL cholesterol;
THYM	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs6686842	0.965	rs10889792	chr1:41490885	A/C	cg03387723	chr1:41708464	SCMH1	0.43	4.93	0.45	3.43e-6	Height;
THYM	cis	rs17030434	0.906	rs57446135	chr4:154679331	A/G	cg14289246	chr4:154710475	SFRP2	-0.82	-5.45	-0.49	3.98e-7	Electrocardiographic conduction measures;
THYM	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs7681423	1.000	rs2066861	chr4:155527436	C/T	cg20735720	chr4:155535218	FGG	-0.74	-5.81	-0.51	8.33e-8	Fibrinogen;
THYM	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg03161606	chr19:29218774	NA	0.65	4.58	0.43	1.39e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs1003719	0.788	rs60447195	chr21:38448600	A/T	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg04287289	chr16:89883240	FANCA	0.65	5.87	0.52	6.49e-8	Vitiligo;
THYM	cis	rs988913	0.957	rs2397177	chr6:54834133	A/G	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.75e-6	Menarche (age at onset);
THYM	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.39	5.98	0.52	3.93e-8	Obesity-related traits;
THYM	cis	rs6763768	0.606	rs6795127	chr3:53376669	C/T	cg16894138	chr3:53270350	TKT	0.71	5.38	0.48	5.32e-7	Bacterial meningitis;
THYM	cis	rs12121840	0.736	rs16847570	chr1:165573298	C/T	cg19407955	chr1:165599744	MGST3	-0.77	-5.84	-0.51	7.19e-8	Interleukin-1-receptor antagonist levels;
THYM	cis	rs4919694	1.000	rs11191445	chr10:104651055	C/T	cg04362960	chr10:104952993	NT5C2	1.14	7.07	0.59	2.65e-10	Arsenic metabolism;
THYM	cis	rs9399401	0.961	rs9403381	chr6:142661156	A/C	cg04461802	chr6:142623433	GPR126	-0.48	-4.68	-0.43	9.47e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg08859206	chr1:53392774	SCP2	0.6	6.95	0.58	4.64e-10	Monocyte count;
THYM	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg03929089	chr4:120376271	NA	-0.95	-9.79	-0.71	4.61e-16	Coronary artery disease;
THYM	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.72	-4.75	-0.44	7.2e-6	Body mass index;
THYM	cis	rs7586879	0.687	rs11892869	chr2:25096692	A/T	cg27107076	chr2:25050844	ADCY3	-0.29	-4.62	-0.43	1.2e-5	Body mass index;
THYM	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg02475777	chr4:1388615	CRIPAK	0.58	4.47	0.42	2.14e-5	Longevity;
THYM	cis	rs7085104	0.513	rs619824	chr10:104581288	G/T	cg05855489	chr10:104503620	C10orf26	0.75	6.57	0.56	2.69e-9	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs10819861	0.679	rs4743525	chr9:98849009	A/G	cg14508093	chr9:98862825	NA	0.24	4.76	0.44	6.99e-6	Electrocardiographic traits;
THYM	cis	rs6459804	1.000	rs73163880	chr7:157508755	C/T	cg15733309	chr7:157513707	PTPRN2	0.58	6.21	0.54	1.38e-8	Bipolar disorder and schizophrenia;
THYM	trans	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.72	-0.62	1.18e-11	Exhaled nitric oxide output;
THYM	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg10802521	chr3:52805072	NEK4	-0.71	-5.96	-0.52	4.22e-8	Bipolar disorder;
THYM	trans	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg17712092	chr4:129076599	LARP1B	-1.03	-10.39	-0.73	2.49e-17	Eosinophil percentage of white cells;
THYM	cis	rs34779708	0.931	rs34876468	chr10:35424450	G/A	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6835098	1.000	rs4561909	chr4:174086937	A/T	cg08422745	chr4:174089978	GALNT7	-0.98	-7.52	-0.61	3e-11	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg13609457	chr4:120235615	NA	0.63	5.59	0.5	2.13e-7	Corneal astigmatism;
THYM	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg23161317	chr6:28129485	ZNF389	-1.02	-8.5	-0.66	2.63e-13	Depression;
THYM	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg24642844	chr7:1081250	C7orf50	-1.24	-7.83	-0.63	7e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9527	0.545	rs7095304	chr10:104954795	G/A	cg04362960	chr10:104952993	NT5C2	0.62	4.72	0.44	8.15e-6	Arsenic metabolism;
THYM	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	4.93	0.45	3.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg23428387	chr22:49814324	NA	-0.56	-5.33	-0.48	6.67e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4731207	0.596	rs3903522	chr7:124668142	G/A	cg05285228	chr7:124571219	POT1	-0.62	-4.73	-0.44	7.68e-6	Cutaneous malignant melanoma;
THYM	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg11266682	chr4:10021025	SLC2A9	-0.83	-7.26	-0.6	1.04e-10	Bone mineral density;
THYM	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg13918804	chr1:2043761	PRKCZ	-0.68	-5.94	-0.52	4.68e-8	Height;
THYM	cis	rs4845570	1.000	rs4845356	chr1:151759223	T/A	cg18019451	chr1:151746047	TDRKH	0.73	4.52	0.42	1.75e-5	Coronary artery disease;
THYM	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg13877915	chr19:58951672	ZNF132	0.9	8.63	0.66	1.38e-13	Uric acid clearance;
THYM	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg12826209	chr6:26865740	GUSBL1	1.06	6.87	0.58	6.53e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6032067	0.704	rs62208390	chr20:43794844	A/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs7909074	0.832	rs10793564	chr10:45386352	C/A	cg05187965	chr10:45406764	TMEM72	-0.52	-5.0	-0.46	2.63e-6	Mean corpuscular volume;
THYM	cis	rs11671005	0.693	rs11669665	chr19:58931885	G/A	cg18639983	chr19:58920768	ZNF584	0.61	5.02	0.46	2.37e-6	Mean platelet volume;
THYM	cis	rs459482	1.000	rs459498	chr21:42795027	G/A	cg16733866	chr21:42792609	MX1	0.56	4.88	0.45	4.2e-6	IgG glycosylation;
THYM	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg25237894	chr2:233734115	C2orf82	-0.35	-5.02	-0.46	2.37e-6	Coronary artery disease;
THYM	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.99	0.46	2.67e-6	Prudent dietary pattern;
THYM	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	5.31	0.48	7.32e-7	Joint mobility (Beighton score);
THYM	cis	rs7809950	1.000	rs12667527	chr7:107086969	T/C	cg23024343	chr7:107201750	COG5	-0.92	-8.11	-0.64	1.73e-12	Coronary artery disease;
THYM	cis	rs6430585	0.640	rs6716070	chr2:136544651	G/T	cg04750100	chr2:136595281	LCT	-0.5	-4.72	-0.44	8.2e-6	Corneal structure;
THYM	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg19774624	chr17:42201019	HDAC5	-0.76	-7.12	-0.59	2.05e-10	Total body bone mineral density;
THYM	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg23161317	chr6:28129485	ZNF389	0.94	7.03	0.58	3.18e-10	Parkinson's disease;
THYM	cis	rs28595532	0.920	rs114564223	chr4:119729953	A/G	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs4986811	0.929	rs5030180	chr11:32448239	G/A	cg13301003	chr11:32449254	WT1	0.66	4.85	0.45	4.81e-6	Rubella-specific interleukin-6 secretion;
THYM	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg20007245	chr22:24372913	LOC391322	0.81	8.25	0.65	8.76e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs887829	0.569	rs4663963	chr2:234650193	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.67	-5.12	-0.47	1.59e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs9644630	0.862	rs7830404	chr8:19357346	A/T	cg01280390	chr8:19363452	CSGALNACT1	0.75	7.5	0.61	3.39e-11	Oropharynx cancer;
THYM	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg00383909	chr3:49044727	WDR6	1.12	6.61	0.56	2.27e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs1483890	0.723	rs13075664	chr3:69411365	G/A	cg22125112	chr3:69402811	FRMD4B	0.54	6.85	0.58	7.21e-10	Resting heart rate;
THYM	cis	rs500891	0.525	rs1145901	chr6:84038605	T/C	cg08257003	chr6:84140564	ME1	0.56	4.47	0.42	2.19e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg19761014	chr17:28927070	LRRC37B2	0.82	4.58	0.43	1.41e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg15704280	chr7:45808275	SEPT13	-1.06	-15.39	-0.84	1.51e-27	Height;
THYM	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.19	-9.36	-0.69	3.85e-15	Platelet count;
THYM	cis	rs11167764	0.895	rs9324865	chr5:141488792	T/C	cg23435118	chr5:141488016	NDFIP1	-0.52	-4.52	-0.42	1.79e-5	Crohn's disease;
THYM	cis	rs6087990	0.735	rs1040554	chr20:31380073	C/T	cg13636640	chr20:31349939	DNMT3B	0.93	9.6	0.7	1.18e-15	Ulcerative colitis;
THYM	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs7688540	0.771	rs61794996	chr4:209328	C/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.76	5.16	0.47	1.33e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs9649465	1.000	rs3807634	chr7:123382290	C/T	cg15443791	chr7:124364398	NA	0.6	4.97	0.45	3.01e-6	Migraine;
THYM	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.66	-0.5	1.62e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2637266	0.791	rs2395392	chr10:78359933	C/A	cg18941641	chr10:78392320	NA	0.7	5.55	0.49	2.55e-7	Pulmonary function;
THYM	cis	rs8112449	0.964	rs10854116	chr19:10523086	T/C	cg01466491	chr19:10523363	NA	-0.68	-6.58	-0.56	2.59e-9	Multiple sclerosis;Gastritis;
THYM	cis	rs7582180	0.614	rs1030901	chr2:101007314	G/A	cg08017756	chr2:100939284	LONRF2	-0.73	-7.29	-0.6	9.05e-11	Intelligence (multi-trait analysis);
THYM	cis	rs1784581	0.651	rs1784588	chr6:162390027	T/A	cg17173639	chr6:162384350	PARK2	-0.82	-7.32	-0.6	8.07e-11	Itch intensity from mosquito bite;
THYM	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.64	-0.5	1.73e-7	Menopause (age at onset);
THYM	cis	rs7631605	0.905	rs6786584	chr3:37225728	T/C	cg21328643	chr3:37258149	NA	-0.48	-4.54	-0.42	1.67e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs67460515	0.563	rs6772723	chr3:160895074	C/G	cg03342759	chr3:160939853	NMD3	-0.63	-4.47	-0.42	2.19e-5	Parkinson's disease;
THYM	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg02725872	chr8:58115012	NA	-1.14	-7.59	-0.61	2.17e-11	Developmental language disorder (linguistic errors);
THYM	trans	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg19862616	chr7:65841803	NCRNA00174	1.08	12.75	0.79	2.77e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7727544	0.544	rs55722650	chr5:131607300	C/T	cg09877947	chr5:131593287	PDLIM4	0.56	4.67	0.43	1e-5	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23248424	chr5:179741104	GFPT2	-0.85	-6.61	-0.56	2.27e-9	Height;
THYM	cis	rs2806561	0.765	rs2806556	chr1:23502850	G/A	cg08872493	chr1:23521417	HTR1D	0.36	4.63	0.43	1.16e-5	Height;
THYM	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg08125733	chr17:73851984	WBP2	0.85	5.96	0.52	4.23e-8	Psoriasis;
THYM	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg05890377	chr2:74357713	NA	1.08	8.84	0.67	5.02e-14	Gestational age at birth (maternal effect);
THYM	cis	rs1395	0.922	rs4665376	chr2:27509032	T/C	cg23587288	chr2:27483067	SLC30A3	-0.61	-5.16	-0.47	1.37e-6	Blood metabolite levels;
THYM	cis	rs35934224	0.681	rs1005132	chr22:19858867	G/C	cg11182965	chr22:19864308	TXNRD2	-0.62	-5.1	-0.46	1.73e-6	Glaucoma (primary open-angle);
THYM	cis	rs4409675	0.576	rs6700473	chr1:28236682	C/T	cg23691781	chr1:28212827	C1orf38	0.46	4.47	0.42	2.15e-5	Corneal astigmatism;
THYM	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg13390004	chr1:15929781	NA	0.61	4.63	0.43	1.15e-5	Systolic blood pressure;
THYM	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg13683864	chr3:40499215	RPL14	0.89	8.94	0.68	2.98e-14	Renal cell carcinoma;
THYM	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg16325326	chr1:53192061	ZYG11B	-0.98	-11.09	-0.75	7.79e-19	Monocyte count;
THYM	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg23758822	chr17:41437982	NA	1.18	11.2	0.75	4.58e-19	Menopause (age at onset);
THYM	cis	rs35883536	0.967	rs2783689	chr1:101092411	C/G	cg06223162	chr1:101003688	GPR88	-0.63	-4.8	-0.44	5.92e-6	Monocyte count;
THYM	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg03929089	chr4:120376271	NA	-1.03	-12.27	-0.78	2.71e-21	Height;
THYM	cis	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs7677751	0.806	rs1800813	chr4:55094467	G/A	cg17187183	chr4:55093834	PDGFRA	0.7	5.3	0.48	7.62e-7	Corneal astigmatism;
THYM	cis	rs10992471	0.651	rs13296623	chr9:95301627	T/C	cg14631576	chr9:95140430	CENPP	-0.76	-7.07	-0.59	2.55e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs662064	0.692	rs12129512	chr1:10572967	G/T	cg20482658	chr1:10539492	PEX14	0.45	5.0	0.46	2.6e-6	Asthma;
THYM	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg06238570	chr21:40685208	BRWD1	0.91	6.52	0.56	3.39e-9	Cognitive function;
THYM	cis	rs11731175	0.961	rs4863425	chr4:189866273	C/T	cg00431894	chr4:189871012	NA	-0.91	-7.23	-0.6	1.24e-10	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.64	-4.68	-0.43	9.45e-6	Aortic root size;
THYM	cis	rs9381107	0.615	rs7757541	chr6:9432485	A/C	cg27283345	chr6:10416531	TFAP2A	-0.46	-4.72	-0.44	8.2e-6	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs4474465	1.000	rs10899522	chr11:78190763	C/G	cg19901956	chr11:77921274	USP35	0.64	4.73	0.44	7.73e-6	Alzheimer's disease (survival time);
THYM	cis	rs539096	0.566	rs3011220	chr1:44308867	A/G	cg15962314	chr1:44399869	ARTN	0.52	5.36	0.48	5.71e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg00757033	chr12:89920650	WDR51B	0.75	10.23	0.72	5.28e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg14196790	chr5:131705035	SLC22A5	-0.55	-5.04	-0.46	2.21e-6	Blood metabolite levels;
THYM	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg26384229	chr12:38710491	ALG10B	0.99	7.63	0.62	1.81e-11	Bladder cancer;
THYM	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg13289132	chr10:30722225	MAP3K8	-0.67	-5.39	-0.48	5.22e-7	Inflammatory bowel disease;
THYM	cis	rs611744	0.870	rs429884	chr8:109115122	T/C	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.06e-6	Dupuytren's disease;
THYM	cis	rs4654899	0.865	rs7541923	chr1:21403582	G/C	cg01072550	chr1:21505969	NA	-0.75	-6.83	-0.57	8.17e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs67478160	0.654	rs4906365	chr14:104229230	G/C	cg08213375	chr14:104286397	PPP1R13B	0.51	6.1	0.53	2.25e-8	Schizophrenia;
THYM	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.55	4.68	0.43	9.44e-6	Blood metabolite levels;
THYM	cis	rs854765	0.583	rs8078138	chr17:17811251	C/T	cg04398451	chr17:18023971	MYO15A	-0.83	-7.74	-0.62	1.04e-11	Total body bone mineral density;
THYM	cis	rs6815814	0.950	rs56408159	chr4:38812116	T/A	cg02016764	chr4:38805732	TLR1	-0.57	-5.49	-0.49	3.41e-7	Breast cancer;
THYM	cis	rs9486719	0.857	rs2983897	chr6:97033780	C/T	cg06623918	chr6:96969491	KIAA0776	-0.74	-5.27	-0.48	8.37e-7	Migraine;Coronary artery disease;
THYM	cis	rs5769765	1.000	rs2319458	chr22:50236306	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.99	-6.88	-0.58	6.31e-10	Schizophrenia;
THYM	cis	rs1371867	0.846	rs924057	chr8:101266157	A/G	cg06636551	chr8:101224915	SPAG1	0.61	5.79	0.51	9.03e-8	Atrioventricular conduction;
THYM	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10751667	0.600	rs7394783	chr11:1005108	C/T	cg20946044	chr11:1010712	AP2A2	0.55	4.63	0.43	1.18e-5	Alzheimer's disease (late onset);
THYM	trans	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg05926928	chr17:57297772	GDPD1	1.26	10.02	0.72	1.5e-16	Opioid sensitivity;
THYM	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg13695892	chr22:41940480	POLR3H	0.99	7.48	0.61	3.75e-11	Vitiligo;
THYM	cis	rs981844	0.922	rs2118863	chr4:154657579	C/T	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs17152411	0.895	rs61872120	chr10:126583588	T/G	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	9.83e-6	Height;
THYM	cis	rs2280630	0.898	rs1828679	chr3:39195507	C/T	cg15678707	chr3:39149194	GORASP1;TTC21A	0.56	4.7	0.43	8.93e-6	Verbal declarative memory;
THYM	cis	rs7084402	0.967	rs1658458	chr10:60301382	T/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.64	-0.5	1.72e-7	Refractive error;
THYM	cis	rs9326248	0.559	rs10892052	chr11:116834313	G/A	cg20608306	chr11:116969690	SIK3	0.63	7.95	0.63	3.79e-12	Blood protein levels;
THYM	cis	rs17102423	0.685	rs7156617	chr14:65541381	G/A	cg11161011	chr14:65562177	MAX	-0.78	-6.41	-0.55	5.56e-9	Obesity-related traits;
THYM	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs57339844	1	rs57339844	chr2:86118276	GTT/G	cg07214715	chr2:86114883	ST3GAL5	-0.45	-4.54	-0.42	1.65e-5	Mean platelet volume;
THYM	cis	rs17001868	0.568	rs74424549	chr22:40736938	A/C	cg07138101	chr22:40742427	ADSL	0.94	5.71	0.51	1.3e-7	Mammographic density (dense area);
THYM	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg06618935	chr21:46677482	NA	-0.95	-8.15	-0.64	1.45e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs87938	0.901	rs62259232	chr3:41112656	G/A	cg02247160	chr3:41243829	CTNNB1	-0.32	-4.52	-0.42	1.78e-5	Bone mineral density (hip);
THYM	cis	rs642803	1.000	rs642803	chr11:65560620	C/T	cg27068330	chr11:65405492	SIPA1	0.73	5.59	0.5	2.14e-7	Urate levels;
THYM	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg07570687	chr10:102243282	WNT8B	0.72	6.12	0.53	2.12e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1349547	0.510	rs3852338	chr8:39496970	C/T	cg01911981	chr8:39380341	ADAM3A	-0.52	-4.55	-0.42	1.6e-5	HIV-1 susceptibility;
THYM	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg15676542	chr6:26421231	BTN2A3	0.32	4.58	0.43	1.42e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg17105886	chr17:28927953	LRRC37B2	1.21	6.83	0.57	8.03e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg10661904	chr17:79619235	PDE6G	-0.65	-6.24	-0.54	1.19e-8	Eye color traits;
THYM	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg08312369	chr19:10679775	CDKN2D	0.65	4.69	0.43	9.03e-6	Red cell distribution width;
THYM	cis	rs912057	0.671	rs1024246	chr6:6743505	A/T	cg06612196	chr6:6737390	NA	0.71	11.9	0.77	1.57e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs1983170	0.935	rs578155	chr1:91976541	G/A	cg04676771	chr1:91176081	NA	-0.68	-4.88	-0.45	4.32e-6	Eosinophil percentage of white cells;
THYM	cis	rs8133932	0.654	rs369245	chr21:47337821	G/A	cg20357416	chr21:47294739	PCBP3	0.8	4.88	0.45	4.26e-6	Schizophrenia;
THYM	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg21453420	chr1:198122196	NA	-0.86	-5.92	-0.52	5.03e-8	Depressive symptoms;
THYM	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg02753203	chr1:228287806	NA	0.76	6.53	0.56	3.21e-9	Diastolic blood pressure;
THYM	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg21644426	chr2:191273491	MFSD6	-0.78	-6.28	-0.54	9.92e-9	Pulse pressure;
THYM	cis	rs1728785	1.000	rs1624718	chr16:68580385	A/G	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22496380	chr5:211416	CCDC127	-1.39	-8.13	-0.64	1.62e-12	Breast cancer;
THYM	cis	rs7677751	0.806	rs7682912	chr4:55085620	T/G	cg17187183	chr4:55093834	PDGFRA	0.72	5.59	0.5	2.19e-7	Corneal astigmatism;
THYM	cis	rs12476592	0.571	rs6546005	chr2:63672071	G/A	cg17519650	chr2:63277830	OTX1	-0.68	-4.51	-0.42	1.83e-5	Childhood ear infection;
THYM	cis	rs5766691	0.644	rs6007607	chr22:47529288	C/G	cg15757745	chr22:47558489	TBC1D22A	-0.73	-5.85	-0.51	6.95e-8	Longevity;
THYM	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.56	0.81	6.23e-24	Height;
THYM	cis	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs10208940	0.614	rs13415763	chr2:68759471	T/G	cg09157127	chr2:69201416	GKN1	0.88	4.87	0.45	4.46e-6	Urate levels in lean individuals;
THYM	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg22920501	chr2:26401640	FAM59B	1.07	9.54	0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg18252515	chr7:66147081	NA	0.63	4.54	0.42	1.65e-5	Aortic root size;
THYM	cis	rs9880211	0.898	rs1052620	chr3:136574521	C/T	cg21827317	chr3:136751795	NA	-0.76	-5.12	-0.47	1.57e-6	Body mass index;Height;
THYM	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18402987	chr7:1209562	NA	0.75	5.49	0.49	3.29e-7	Longevity;Endometriosis;
THYM	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg24910161	chr17:38119198	GSDMA	0.46	4.65	0.43	1.07e-5	Self-reported allergy;
THYM	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg08999081	chr20:33150536	PIGU	0.79	7.48	0.61	3.72e-11	Coronary artery disease;
THYM	cis	rs8008758	0.517	rs1772028	chr14:101693861	C/G	cg26393534	chr14:101700091	NA	-0.47	-5.9	-0.52	5.64e-8	Body mass index (alcohol intake interaction);
THYM	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg04287289	chr16:89883240	FANCA	0.65	5.93	0.52	4.8e-8	Vitiligo;
THYM	cis	rs2688608	0.592	rs7080579	chr10:75504029	T/A	cg19442545	chr10:75533431	FUT11	-0.51	-5.22	-0.47	1.03e-6	Inflammatory bowel disease;
THYM	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs2734839	0.964	rs12800853	chr11:113302514	C/T	cg14159747	chr11:113255604	NA	0.32	6.25	0.54	1.14e-8	Information processing speed;
THYM	cis	rs7809950	0.954	rs2520242	chr7:107136320	G/T	cg23024343	chr7:107201750	COG5	0.93	8.3	0.65	7.11e-13	Coronary artery disease;
THYM	cis	rs17739794	0.557	rs7816977	chr8:814612	A/G	cg07178994	chr8:816998	NA	0.49	4.99	0.46	2.76e-6	Clozapine-induced cytotoxicity;
THYM	cis	rs3796352	0.527	rs11716506	chr3:52944328	C/T	cg24530246	chr3:53118167	NA	-0.66	-4.57	-0.42	1.44e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg19761014	chr17:28927070	LRRC37B2	0.78	4.99	0.46	2.76e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg01483505	chr11:975446	AP2A2	0.57	4.53	0.42	1.73e-5	Alzheimer's disease (late onset);
THYM	trans	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg19862616	chr7:65841803	NCRNA00174	1.13	13.2	0.8	3.22e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	trans	rs8073060	0.586	rs117573546	chr17:33909588	G/A	cg19694781	chr19:47549865	TMEM160	1.01	8.58	0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg08968635	chr6:28129556	ZNF389	0.72	5.58	0.5	2.24e-7	Parkinson's disease;
THYM	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg05347473	chr6:146136440	FBXO30	-0.58	-4.63	-0.43	1.15e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg00376283	chr12:123451042	ABCB9	0.68	5.22	0.47	1.04e-6	Neutrophil percentage of white cells;
THYM	cis	rs76878669	0.917	rs10444359	chr11:66102807	G/A	cg18002602	chr11:66138449	SLC29A2	-0.62	-5.21	-0.47	1.09e-6	Educational attainment (years of education);
THYM	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.64	8.83	0.67	5.25e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs12681287	0.752	rs7846635	chr8:87304281	G/A	cg27223183	chr8:87520930	FAM82B	-0.68	-5.19	-0.47	1.2e-6	Caudate activity during reward;
THYM	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg12373951	chr3:133503437	NA	-0.59	-6.56	-0.56	2.8e-9	Iron status biomarkers;
THYM	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg03060546	chr3:49711283	APEH	-0.75	-6.11	-0.53	2.18e-8	Resting heart rate;
THYM	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg15691649	chr6:25882328	NA	-0.74	-6.13	-0.53	2.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12137294	0.866	rs1172156	chr1:205220087	C/T	cg17889831	chr1:205181581	DSTYK	-0.4	-4.83	-0.44	5.16e-6	Red cell distribution width;
THYM	cis	rs11208722	0.604	rs17416384	chr1:66179064	A/G	cg04111102	chr1:66153794	NA	0.51	4.68	0.43	9.53e-6	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg06970220	chr1:156163860	SLC25A44	0.74	5.67	0.5	1.53e-7	Testicular germ cell tumor;
THYM	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg08999081	chr20:33150536	PIGU	-0.61	-5.13	-0.47	1.51e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg08807101	chr21:30365312	RNF160	-0.81	-6.03	-0.53	3.09e-8	Dental caries;
THYM	cis	rs17122693	0.551	rs1812181	chr14:51052669	C/T	cg04730355	chr14:51134070	SAV1	1.02	7.24	0.6	1.18e-10	Cognitive performance;
THYM	cis	rs7567389	0.600	rs7590030	chr2:128055967	G/A	cg06038358	chr2:128176007	PROC	-0.47	-5.31	-0.48	7.16e-7	Self-rated health;
THYM	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg22508957	chr16:3507546	NAT15	0.67	9.28	0.69	5.62e-15	Tuberculosis;
THYM	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg22709100	chr7:91322751	NA	-0.61	-4.85	-0.45	4.9e-6	Breast cancer;
THYM	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg02353165	chr6:42928485	GNMT	1.04	10.79	0.74	3.44e-18	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg11062466	chr8:58055876	NA	0.9	4.5	0.42	1.95e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg01751800	chr4:77820391	ANKRD56	0.56	4.63	0.43	1.15e-5	Emphysema distribution in smoking;
THYM	cis	rs3135718	1.000	rs2420946	chr10:123351324	T/C	cg15049101	chr10:123353889	FGFR2	-0.59	-5.28	-0.48	8.15e-7	Estrogen receptor status in breast cancer;
THYM	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg06221963	chr1:154839813	KCNN3	0.89	12.52	0.79	8.19e-22	Prostate cancer;
THYM	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.33	0.48	6.55e-7	Height;
THYM	cis	rs7078219	0.965	rs10883358	chr10:101273857	C/T	cg07044859	chr10:101282883	NA	-0.47	-5.14	-0.47	1.45e-6	Dental caries;
THYM	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg04731861	chr2:219085781	ARPC2	0.56	5.39	0.48	5.21e-7	Colorectal cancer;
THYM	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs8077889	0.619	rs1230399	chr17:41845403	C/T	cg26893861	chr17:41843967	DUSP3	-1.13	-16.67	-0.86	5.74e-30	Triglycerides;
THYM	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.82	-0.67	5.38e-14	Mean corpuscular volume;
THYM	cis	rs6748734	0.600	rs10933510	chr2:241826754	G/A	cg15164180	chr2:241846931	NA	-0.33	-4.53	-0.42	1.69e-5	Urinary metabolites;
THYM	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.73	6.1	0.53	2.33e-8	Lymphocyte percentage of white cells;
THYM	cis	rs13315871	1.000	rs11709976	chr3:58325347	A/G	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg16586182	chr3:47516702	SCAP	0.62	5.27	0.48	8.42e-7	Colorectal cancer;
THYM	cis	rs9302635	0.513	rs12928732	chr16:72188683	C/T	cg23815491	chr16:72088622	HP	0.81	6.34	0.55	7.72e-9	Blood protein levels;
THYM	cis	rs17030434	0.784	rs17370965	chr4:154650948	C/T	cg14289246	chr4:154710475	SFRP2	-0.74	-5.29	-0.48	7.96e-7	Electrocardiographic conduction measures;
THYM	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg11764359	chr7:65958608	NA	-0.67	-4.8	-0.44	5.81e-6	Aortic root size;
THYM	cis	rs34602589	0.778	rs62206432	chr20:43748038	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.7	-7.21	-0.59	1.32e-10	Parental longevity (mother's age at death);
THYM	cis	rs2073300	1.000	rs6106669	chr20:23460328	C/T	cg12062639	chr20:23401060	NAPB	1.11	5.45	0.49	3.89e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs8072100	0.537	rs9912450	chr17:45402208	C/T	cg08085267	chr17:45401833	C17orf57	-0.69	-5.57	-0.5	2.34e-7	Very long-chain saturated fatty acid levels (fatty acid 20:0);
THYM	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg17426766	chr1:2046864	PRKCZ	-0.43	-4.97	-0.45	2.9e-6	Height;
THYM	cis	rs2404602	0.647	rs8025991	chr15:77155268	C/T	cg23625390	chr15:77176239	SCAPER	-0.77	-5.54	-0.49	2.64e-7	Blood metabolite levels;
THYM	cis	rs981844	0.775	rs56101345	chr4:154764261	C/T	cg09973105	chr4:154681532	RNF175	-0.62	-5.1	-0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs1797885	0.564	rs2454422	chr3:12603900	C/T	cg05467012	chr3:12595696	NA	0.56	4.68	0.43	9.39e-6	Immature fraction of reticulocytes;
THYM	cis	rs3741151	1.000	rs74346863	chr11:73054772	C/T	cg17517138	chr11:73019481	ARHGEF17	1.0	5.84	0.51	7.28e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.58	0.5	2.29e-7	Rheumatoid arthritis;
THYM	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg01304814	chr3:48885189	PRKAR2A	1.01	4.55	0.42	1.57e-5	Cognitive function;
THYM	cis	rs2130392	0.924	rs873687	chr4:185638853	G/A	cg04058563	chr4:185651563	MLF1IP	-0.59	-5.64	-0.5	1.78e-7	Kawasaki disease;
THYM	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg24503407	chr1:205819492	PM20D1	1.15	12.17	0.78	4.34e-21	Menarche (age at onset);
THYM	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg13683864	chr3:40499215	RPL14	0.95	9.88	0.71	2.92e-16	Renal cell carcinoma;
THYM	cis	rs2963155	0.518	rs174048	chr5:142650404	T/C	cg17617527	chr5:142782415	NR3C1	1.19	6.61	0.56	2.25e-9	Breast cancer;
THYM	cis	rs1003719	0.715	rs2835658	chr21:38565201	A/G	cg01329690	chr21:38580129	DSCR9	-0.36	-5.01	-0.46	2.55e-6	Eye color traits;
THYM	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg26061582	chr7:22766209	IL6	0.62	4.77	0.44	6.72e-6	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
THYM	cis	rs7799006	0.606	rs12669625	chr7:2315950	C/T	cg08027265	chr7:2291960	NA	-0.41	-5.23	-0.47	1e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.85	0.74	2.52e-18	Chronic sinus infection;
THYM	cis	rs986417	0.901	rs1955692	chr14:61008408	C/A	cg27398547	chr14:60952738	C14orf39	1.0	5.05	0.46	2.14e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs10089	0.552	rs1351141	chr5:127550055	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.72	-4.61	-0.43	1.23e-5	Ileal carcinoids;
THYM	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.22	9.08	0.68	1.54e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs11031096	0.502	rs4910875	chr11:4047855	C/G	cg22027985	chr11:4115532	RRM1	-0.47	-4.54	-0.42	1.68e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg07424592	chr7:64974309	NA	-1.04	-5.27	-0.48	8.52e-7	Diabetic kidney disease;
THYM	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs1003719	0.708	rs8126491	chr21:38551219	T/C	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs4732038	0.510	rs10245625	chr7:134279424	A/G	cg06906464	chr7:134288099	NA	-0.46	-4.61	-0.43	1.26e-5	Longevity;
THYM	cis	rs2282300	1.000	rs12799529	chr11:30408552	T/C	cg09906309	chr11:30344399	C11orf46	-0.63	-4.48	-0.42	2.04e-5	Morning vs. evening chronotype;
THYM	cis	rs6541297	1.000	rs6665367	chr1:230279169	G/A	cg20703242	chr1:230279135	GALNT2	0.92	6.26	0.54	1.13e-8	Coronary artery disease;
THYM	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg19626725	chr5:178986131	RUFY1	-0.34	-5.75	-0.51	1.08e-7	Lung cancer;
THYM	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg25287198	chr4:183728479	NA	0.74	4.62	0.43	1.23e-5	Pediatric autoimmune diseases;
THYM	cis	rs250585	0.850	rs152460	chr16:23573833	A/C	cg00143387	chr16:23521605	GGA2	0.72	5.18	0.47	1.26e-6	Egg allergy;
THYM	cis	rs67460515	0.531	rs1585483	chr3:160843111	G/A	cg12349858	chr3:160822545	B3GALNT1	0.57	4.63	0.43	1.17e-5	Parkinson's disease;
THYM	cis	rs662064	0.544	rs12725704	chr1:10613351	T/C	cg20482658	chr1:10539492	PEX14	0.49	5.69	0.5	1.38e-7	Asthma;
THYM	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg05932139	chr16:680872	WFIKKN1	-0.64	-5.31	-0.48	7.21e-7	Height;
THYM	cis	rs12928939	0.911	rs8051878	chr16:71818431	C/G	cg03805757	chr16:71968109	PKD1L3	-0.7	-5.31	-0.48	7.25e-7	Post bronchodilator FEV1;
THYM	cis	rs986417	0.901	rs1884095	chr14:61017024	C/G	cg27398547	chr14:60952738	C14orf39	1.0	5.05	0.46	2.14e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs988913	1.000	rs1503134	chr6:54836224	G/A	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.75e-6	Menarche (age at onset);
THYM	cis	rs9394931	1.000	rs9394931	chr6:42873245	C/T	cg02353165	chr6:42928485	GNMT	-0.62	-4.8	-0.44	5.94e-6	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
THYM	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg23161317	chr6:28129485	ZNF389	0.87	6.22	0.54	1.31e-8	Depression;
THYM	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg09824328	chr1:43425412	SLC2A1	-1.07	-7.36	-0.6	6.45e-11	Monocyte count;
THYM	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg26384229	chr12:38710491	ALG10B	0.8	5.8	0.51	8.65e-8	Bladder cancer;
THYM	cis	rs11096990	0.855	rs2566168	chr4:39151673	G/A	cg24403649	chr4:39172243	NA	-0.62	-5.3	-0.48	7.5e-7	Cognitive function;
THYM	cis	rs12912251	0.895	rs35795311	chr15:38998669	C/G	cg08274633	chr15:38988533	C15orf53	-0.25	-5.02	-0.46	2.41e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
THYM	cis	rs1747683	0.932	rs10752298	chr10:13382754	T/C	cg00142036	chr10:13388442	SEPHS1	-0.29	-5.17	-0.47	1.27e-6	IgG glycosylation;
THYM	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	6.09	0.53	2.42e-8	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs17253792	0.731	rs8008528	chr14:56062052	C/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg18758796	chr5:131593413	PDLIM4	0.6	5.53	0.49	2.78e-7	Acylcarnitine levels;
THYM	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg11235152	chr1:67600687	NA	-0.67	-5.47	-0.49	3.56e-7	Psoriasis;
THYM	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg10515332	chr4:99064459	C4orf37	0.58	4.67	0.43	9.88e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg05182265	chr7:156933206	UBE3C	-0.7	-9.62	-0.7	1.06e-15	Body mass index;
THYM	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.7	5.63	0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs74417235	0.639	rs7443642	chr5:154053450	A/G	cg07371521	chr5:154026371	NA	-0.57	-5.45	-0.49	3.96e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg14186256	chr22:23484241	RTDR1	0.96	9.4	0.69	3.09e-15	Bone mineral density;
THYM	cis	rs4523957	0.928	rs8074850	chr17:2187931	C/A	cg16513277	chr17:2031491	SMG6	-0.8	-7.64	-0.62	1.69e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7572733	0.534	rs700664	chr2:198671145	C/T	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.47	-0.49	3.59e-7	Mean corpuscular volume;
THYM	cis	rs6763768	0.606	rs1001222	chr3:53352099	G/A	cg22900224	chr3:52804907	NEK4	0.71	4.6	0.43	1.32e-5	Bacterial meningitis;
THYM	cis	rs7586879	1.000	rs7586879	chr2:25116977	C/T	cg01884057	chr2:25150051	NA	0.63	6.3	0.54	9.31e-9	Body mass index;
THYM	cis	rs665401	0.692	rs339305	chr6:117176757	A/C	cg20376953	chr6:117187980	NA	0.61	4.89	0.45	4.05e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg23711669	chr6:146136114	FBXO30	0.92	9.08	0.68	1.54e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg05738196	chr6:26577821	NA	0.57	4.7	0.43	8.72e-6	Schizophrenia;
THYM	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg13609457	chr4:120235615	NA	0.5	4.76	0.44	6.95e-6	Corneal astigmatism;
THYM	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg00786635	chr1:25594202	NA	-0.86	-6.5	-0.56	3.64e-9	Erythrocyte sedimentation rate;
THYM	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg14820908	chr5:178986412	RUFY1	-0.64	-7.19	-0.59	1.46e-10	Lung cancer;
THYM	cis	rs6700896	0.931	rs1938497	chr1:66100450	G/A	cg04111102	chr1:66153794	NA	0.55	5.23	0.47	9.89e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7220711	0.967	rs4793022	chr17:41798855	C/G	cg26893861	chr17:41843967	DUSP3	0.65	5.51	0.49	3.1e-7	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg11764359	chr7:65958608	NA	0.66	4.69	0.43	8.98e-6	Aortic root size;
THYM	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg26038318	chr20:34205095	SPAG4	0.63	5.13	0.47	1.54e-6	Total cholesterol levels;
THYM	cis	rs35883536	0.647	rs10875314	chr1:101043207	G/C	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs9486719	1.000	rs12530462	chr6:97053514	C/T	cg18709589	chr6:96969512	KIAA0776	-0.69	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs9359856	0.600	rs1179899	chr6:90320258	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.77	-7.08	-0.59	2.53e-10	Bipolar disorder;
THYM	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg11905131	chr22:24372483	LOC391322	-0.94	-10.63	-0.74	7.62e-18	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs859767	1.000	rs842361	chr2:135340840	C/G	cg12500956	chr2:135428796	TMEM163	0.56	5.38	0.48	5.35e-7	Neuroticism;
THYM	cis	rs6754311	0.731	rs309164	chr2:136691825	T/C	cg07169764	chr2:136633963	MCM6	0.68	5.97	0.52	4.08e-8	Mosquito bite size;
THYM	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg00012203	chr2:219082015	ARPC2	-0.65	-5.32	-0.48	6.78e-7	Colorectal cancer;
THYM	cis	rs7084402	0.565	rs4948522	chr10:60334575	T/C	cg09696939	chr10:60272079	BICC1	-0.49	-5.7	-0.5	1.35e-7	Refractive error;
THYM	cis	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg05335186	chr13:53173507	NA	0.46	5.8	0.51	8.66e-8	Lewy body disease;
THYM	cis	rs28595532	1.000	rs114039398	chr4:119631627	T/C	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg02353165	chr6:42928485	GNMT	0.93	8.63	0.66	1.42e-13	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg11494091	chr17:61959527	GH2	0.69	6.32	0.54	8.45e-9	Height;
THYM	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.84	-6.31	-0.54	8.9e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7173743	0.756	rs6495339	chr15:79128272	T/C	cg00540400	chr15:79124168	NA	0.6	6.52	0.56	3.43e-9	Coronary artery disease;
THYM	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8062405	0.723	rs762633	chr16:28608341	T/C	cg04193835	chr16:28379378	NA	-0.51	-4.81	-0.44	5.76e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg07936489	chr17:37558343	FBXL20	0.83	5.84	0.51	7.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.62	0.56	2.1e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs220324	0.688	rs9975332	chr21:43559902	C/T	cg09727148	chr21:43560719	UMODL1	-0.84	-10.33	-0.73	3.31e-17	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs907612	0.639	rs56014530	chr11:1876157	G/A	cg26158194	chr11:1874320	LSP1	0.51	4.87	0.45	4.48e-6	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
THYM	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg02380750	chr20:61661411	NA	0.61	6.16	0.53	1.78e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs909002	0.849	rs10753257	chr1:32086089	G/A	cg13919466	chr1:32135498	COL16A1	-0.49	-4.84	-0.45	4.94e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg22815214	chr1:201083145	CACNA1S	0.8	7.61	0.62	1.95e-11	Permanent tooth development;
THYM	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg11245990	chr11:68621969	NA	0.55	7.14	0.59	1.89e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs8014204	0.836	rs7154256	chr14:75252587	A/G	cg06637938	chr14:75390232	RPS6KL1	0.56	5.49	0.49	3.27e-7	Caffeine consumption;
THYM	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg15693483	chr7:1102177	C7orf50	0.54	6.29	0.54	9.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7640424	0.659	rs7639774	chr3:107816216	T/G	cg09227934	chr3:107805635	CD47	-0.65	-4.99	-0.46	2.68e-6	Body mass index;
THYM	cis	rs11563648	0.553	rs10954148	chr7:127006996	A/G	cg23081781	chr7:127225937	GCC1	-0.34	-4.61	-0.43	1.28e-5	Resting heart rate;
THYM	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg02734326	chr4:10020555	SLC2A9	-0.77	-6.59	-0.56	2.48e-9	Bone mineral density;
THYM	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg25767906	chr1:53392781	SCP2	-0.7	-6.71	-0.57	1.39e-9	Monocyte count;
THYM	cis	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg07460842	chr6:66804631	NA	-0.97	-6.96	-0.58	4.44e-10	Exhaled nitric oxide output;
THYM	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg15445000	chr17:37608096	MED1	-0.44	-5.1	-0.46	1.73e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	7.45	0.61	4.17e-11	Platelet count;
THYM	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg13147721	chr7:65941812	NA	0.71	4.45	0.42	2.33e-5	Diabetic kidney disease;
THYM	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg24642844	chr7:1081250	C7orf50	-1.16	-8.14	-0.64	1.55e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1278352	0.728	rs1278347	chr10:127771938	T/C	cg08295661	chr10:127769903	ADAM12	-0.55	-5.5	-0.49	3.16e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs714027	0.605	rs193471	chr22:30447305	A/G	cg20249462	chr22:29784778	AP1B1	-0.54	-4.49	-0.42	2.02e-5	Lymphocyte counts;
THYM	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg01097406	chr16:89675127	NA	-0.89	-8.32	-0.65	6.23e-13	Vitiligo;
THYM	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg08280861	chr8:58055591	NA	0.84	4.49	0.42	2e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg10047753	chr17:41438598	NA	1.21	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs7107174	0.901	rs11237459	chr11:78056273	A/C	cg19901956	chr11:77921274	USP35	-0.64	-5.3	-0.48	7.43e-7	Testicular germ cell tumor;
THYM	cis	rs2227564	0.533	rs3870402	chr10:75473787	A/C	cg00564723	chr10:75632066	CAMK2G	-0.57	-5.16	-0.47	1.33e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs3771570	0.901	rs55764424	chr2:242407467	C/T	cg21155796	chr2:242212141	HDLBP	1.06	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs7524258	0.900	rs6689574	chr1:7288534	C/G	cg07173049	chr1:7289937	CAMTA1	0.68	5.46	0.49	3.85e-7	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg04772025	chr11:68637568	NA	0.61	6.33	0.54	8.18e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg12863693	chr15:85201151	NMB	0.53	4.73	0.44	7.81e-6	Schizophrenia;
THYM	cis	rs10979	1.000	rs1054752	chr6:143890097	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs4986172	0.726	rs12946454	chr17:43208121	A/T	cg27395066	chr17:43221220	ACBD4	0.59	4.58	0.43	1.38e-5	Height;
THYM	cis	rs73198271	0.740	rs10103163	chr8:8650675	T/C	cg15556689	chr8:8085844	FLJ10661	-0.74	-4.91	-0.45	3.75e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg06115741	chr20:33292138	TP53INP2	0.7	4.65	0.43	1.06e-5	Coronary artery disease;
THYM	cis	rs6840360	0.530	rs12645029	chr4:152650032	T/C	cg17479576	chr4:152424074	FAM160A1	-0.74	-4.75	-0.44	7.3e-6	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs114410095	chr4:119731110	G/A	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs1568889	0.838	rs7933991	chr11:28059761	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	6.81	0.57	8.87e-10	Bipolar disorder;
THYM	cis	rs448720	0.875	rs28680569	chr15:68201944	G/A	cg24579218	chr15:68104479	NA	0.53	4.73	0.44	7.66e-6	Cognitive performance;
THYM	cis	rs1448094	0.511	rs17345975	chr12:86202318	T/A	cg00310523	chr12:86230176	RASSF9	0.53	4.82	0.44	5.4e-6	Major depressive disorder;
THYM	cis	rs909002	0.962	rs10798883	chr1:32140305	C/T	cg13919466	chr1:32135498	COL16A1	-0.52	-5.31	-0.48	7.05e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2455799	0.574	rs2102212	chr3:15704223	C/T	cg16303742	chr3:15540471	COLQ	-0.58	-5.59	-0.5	2.17e-7	Mean platelet volume;
THYM	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg04156016	chr5:1868137	NA	0.55	5.21	0.47	1.1e-6	Cardiovascular disease risk factors;
THYM	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg07414643	chr4:187882934	NA	0.57	4.97	0.45	3.01e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.3	-0.48	7.37e-7	Monocyte percentage of white cells;
THYM	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg18904891	chr8:8559673	CLDN23	0.64	4.99	0.46	2.73e-6	Neuroticism;
THYM	cis	rs9290065	0.519	rs10936216	chr3:160698314	G/C	cg03342759	chr3:160939853	NMD3	-0.59	-4.59	-0.43	1.37e-5	Kawasaki disease;
THYM	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.2e-16	Bone mineral density;
THYM	cis	rs9309473	0.519	rs6746971	chr2:73669462	A/G	cg19565262	chr2:73869966	NAT8	-0.65	-5.36	-0.48	5.81e-7	Metabolite levels;
THYM	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg11494091	chr17:61959527	GH2	1.1	17.33	0.87	3.6e-31	Prudent dietary pattern;
THYM	cis	rs80319144	1.000	rs17808235	chr2:159123724	C/G	cg24986868	chr2:159312599	PKP4;CCDC148	-0.57	-4.61	-0.43	1.26e-5	Restless legs syndrome;
THYM	cis	rs17739794	0.517	rs4439155	chr8:781047	C/T	cg07178994	chr8:816998	NA	-0.79	-7.6	-0.61	2.11e-11	Clozapine-induced cytotoxicity;
THYM	cis	rs1331623	1.000	rs1412071	chr9:122199800	G/A	cg25935911	chr9:122132261	DBC1	-0.53	-4.83	-0.44	5.16e-6	Height;
THYM	cis	rs12519773	1.000	rs6880789	chr5:92451777	A/G	cg18783429	chr5:92414398	NA	0.48	4.55	0.42	1.59e-5	Migraine;
THYM	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg02640540	chr1:67518911	SLC35D1	0.59	4.64	0.43	1.09e-5	Lymphocyte percentage of white cells;
THYM	cis	rs12908161	0.853	rs11633788	chr15:85305142	T/A	cg12863693	chr15:85201151	NMB	0.54	4.54	0.42	1.66e-5	Schizophrenia;
THYM	cis	rs921665	0.681	rs6548169	chr2:3183752	A/G	cg16434511	chr2:3151078	NA	-0.99	-5.41	-0.49	4.79e-7	World class endurance athleticism;
THYM	cis	rs1122608	0.508	rs35140030	chr19:11061315	G/A	cg17326582	chr19:11976514	ZNF439	0.6	4.9	0.45	3.91e-6	Coronary artery disease or ischemic stroke;Coronary artery disease;Coronary artery disease or large artery stroke;Coronary heart disease;Myocardial infarction (early onset);
THYM	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.68	0.5	1.46e-7	Height;
THYM	cis	rs995000	0.931	rs1168097	chr1:63120371	C/T	cg06896770	chr1:63153194	DOCK7	-0.92	-7.54	-0.61	2.71e-11	Triglyceride levels;
THYM	cis	rs7572733	0.576	rs4850441	chr2:198913413	A/G	cg00792783	chr2:198669748	PLCL1	-0.71	-4.63	-0.43	1.15e-5	Dermatomyositis;
THYM	cis	rs34526934	0.608	rs13017511	chr2:177035395	A/G	cg26754761	chr2:177040938	NA	-0.76	-6.58	-0.56	2.53e-9	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.67e-7	Corneal astigmatism;
THYM	cis	rs1904096	0.506	rs6532476	chr4:95192461	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.2	-0.47	1.14e-6	Type 2 diabetes;
THYM	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg27125505	chr17:43679177	LOC644172	0.75	6.93	0.58	4.96e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg13695892	chr22:41940480	POLR3H	0.91	7.35	0.6	6.82e-11	Vitiligo;
THYM	cis	rs2235573	0.625	rs8142174	chr22:38427963	C/T	cg19171272	chr22:38449367	NA	-0.5	-5.2	-0.47	1.13e-6	Glioblastoma;Glioma;
THYM	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg11871910	chr12:69753446	YEATS4	1.06	9.74	0.71	5.98e-16	Blood protein levels;
THYM	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2742234	0.590	rs2435339	chr10:43642173	G/C	cg06632098	chr10:43605906	RET	-0.77	-4.96	-0.45	3.09e-6	Hirschsprung disease;
THYM	cis	rs3804749	0.934	rs13314114	chr3:122836000	T/C	cg10259872	chr3:122802215	PDIA5	0.49	5.5	0.49	3.14e-7	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.22	9.08	0.68	1.54e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7940866	0.834	rs10894302	chr11:130861994	C/T	cg23692386	chr11:131799662	NTM	0.49	5.12	0.47	1.58e-6	Schizophrenia;
THYM	cis	rs9311676	0.656	rs3191903	chr3:58382846	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg07343612	chr16:622815	PIGQ	-1.08	-10.53	-0.73	1.25e-17	Height;
THYM	cis	rs34779708	0.931	rs35388511	chr10:35296616	A/G	cg03585969	chr10:35415529	CREM	0.64	4.5	0.42	1.93e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs710216	0.843	rs3768043	chr1:43419354	C/A	cg16738646	chr1:43409193	SLC2A1	0.56	5.0	0.46	2.66e-6	Red cell distribution width;
THYM	cis	rs4718428	0.960	rs6460317	chr7:66390255	A/G	cg26963428	chr7:66367121	NA	-0.57	-4.91	-0.45	3.76e-6	Corneal structure;
THYM	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg09517075	chr8:22133004	PIWIL2	0.64	5.94	0.52	4.64e-8	Hypertriglyceridemia;
THYM	cis	rs17024684	1.000	rs10510249	chr3:3057771	C/T	cg22818988	chr3:3168509	TRNT1	-1.01	-4.51	-0.42	1.82e-5	Brain connectivity;
THYM	cis	rs9565309	0.579	rs76924563	chr13:77587949	G/A	cg13866767	chr13:78470850	EDNRB	1.06	4.81	0.44	5.76e-6	Morning vs. evening chronotype;
THYM	cis	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.62	0.43	1.23e-5	Obesity-related traits;
THYM	cis	rs1050631	0.592	rs1789508	chr18:33736845	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.32	0.48	6.94e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.02	-0.46	2.42e-6	Blood metabolite levels;
THYM	cis	rs72717009	0.825	rs9427397	chr1:161476204	C/T	cg23840854	chr1:161414152	NA	-1.03	-5.5	-0.49	3.16e-7	Rheumatoid arthritis;
THYM	cis	rs10929159	0.928	rs7596780	chr2:236924303	C/T	cg20128773	chr2:236923534	AGAP1	0.35	4.78	0.44	6.31e-6	Parkinson's disease;
THYM	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg07424592	chr7:64974309	NA	0.99	5.15	0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg26441486	chr22:50317300	CRELD2	0.44	6.78	0.57	9.98e-10	Schizophrenia;
THYM	cis	rs8048589	1.000	rs12599090	chr16:12187341	C/G	cg02910054	chr16:12241554	SNX29	0.71	5.55	0.49	2.58e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.98	0.45	2.85e-6	Obesity-related traits;
THYM	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs2354432	0.607	rs3820130	chr1:146724003	A/G	cg25205988	chr1:146714368	CHD1L	-1.04	-5.54	-0.49	2.67e-7	Mitochondrial DNA levels;
THYM	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg00071950	chr4:10020882	SLC2A9	-0.68	-7.07	-0.59	2.61e-10	Bone mineral density;
THYM	cis	rs6995541	0.529	rs2409649	chr8:10690769	G/A	cg13457217	chr8:10683266	MIR1322;PINX1	-0.67	-5.02	-0.46	2.39e-6	Triglyceride levels;
THYM	cis	rs7586879	0.593	rs10198275	chr2:25130542	A/C	cg01884057	chr2:25150051	NA	0.73	7.92	0.63	4.47e-12	Body mass index;
THYM	cis	rs7589728	0.514	rs78204719	chr2:88460747	G/C	cg04511125	chr2:88470314	THNSL2	0.66	4.62	0.43	1.21e-5	Plasma clusterin levels;
THYM	cis	rs7705502	1.000	rs72812811	chr5:173350990	G/A	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	13.05	0.8	6.7e-23	Chronic sinus infection;
THYM	cis	rs757110	0.690	rs35271178	chr11:17411020	C/T	cg15432903	chr11:17409602	KCNJ11	0.58	6.81	0.57	8.89e-10	Type 2 diabetes;
THYM	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg05283184	chr6:79620031	NA	-0.94	-9.25	-0.69	6.49e-15	Intelligence (multi-trait analysis);
THYM	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg02953382	chr22:24373134	LOC391322	0.82	8.94	0.68	3.02e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs17818399	0.888	rs2346419	chr2:46845069	G/C	cg09399716	chr2:46890238	NA	-0.5	-4.83	-0.44	5.3e-6	Height;
THYM	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg24675658	chr1:53192096	ZYG11B	-0.57	-4.68	-0.43	9.68e-6	Monocyte count;
THYM	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg18402987	chr7:1209562	NA	0.68	5.34	0.48	6.32e-7	Longevity;Endometriosis;
THYM	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg21028142	chr17:79581711	NPLOC4	0.64	6.74	0.57	1.23e-9	Eye color traits;
THYM	cis	rs4589258	0.504	rs61905327	chr11:90387448	C/T	cg26138821	chr11:89956704	CHORDC1	0.62	4.49	0.42	1.98e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7523273	1.000	rs7541230	chr1:207957555	T/C	cg22525895	chr1:207977042	MIR29B2	-0.81	-7.7	-0.62	1.3e-11	Schizophrenia;
THYM	cis	rs12540874	0.522	rs4947641	chr7:50489038	C/T	cg18232548	chr7:50535776	DDC	-0.9	-7.8	-0.62	7.87e-12	Systemic sclerosis;
THYM	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.61e-20	Menopause (age at onset);
THYM	cis	rs7771547	0.642	rs668499	chr6:36496379	A/G	cg07856975	chr6:36356162	ETV7	0.51	4.75	0.44	7.19e-6	Platelet distribution width;
THYM	cis	rs2282300	0.739	rs10835647	chr11:30313268	A/G	cg25418670	chr11:30344373	C11orf46	-0.83	-7.1	-0.59	2.28e-10	Morning vs. evening chronotype;
THYM	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg17143192	chr8:8559678	CLDN23	0.98	7.54	0.61	2.83e-11	Obesity-related traits;
THYM	cis	rs314370	0.951	rs3757868	chr7:100482720	G/A	cg08558340	chr7:100472263	SRRT	0.61	4.99	0.46	2.75e-6	Resting heart rate;
THYM	cis	rs1065656	0.581	rs344353	chr16:1846636	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.7	5.0	0.46	2.64e-6	Insulin-like growth factors;
THYM	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-4.99	-0.46	2.75e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9399401	0.601	rs262113	chr6:142824950	T/G	cg03128060	chr6:142623767	GPR126	0.55	6.75	0.57	1.16e-9	Chronic obstructive pulmonary disease;
THYM	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs7084402	0.967	rs1658421	chr10:60331928	A/T	cg09696939	chr10:60272079	BICC1	-0.46	-5.54	-0.49	2.74e-7	Refractive error;
THYM	cis	rs7189233	0.955	rs7189726	chr16:53497774	C/T	cg02965178	chr16:53538660	AKTIP	-0.58	-4.55	-0.42	1.61e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7258465	0.965	rs1560118	chr19:18570035	G/A	cg01380346	chr19:18557039	ELL	-0.47	-4.69	-0.43	8.97e-6	Breast cancer;
THYM	cis	rs611744	0.647	rs1448150	chr8:109276161	T/C	cg21045802	chr8:109455806	TTC35	0.65	5.55	0.49	2.56e-7	Dupuytren's disease;
THYM	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg03433033	chr1:76189801	ACADM	-0.51	-5.31	-0.48	7.2e-7	Daytime sleep phenotypes;
THYM	cis	rs9403317	1.000	rs62430845	chr6:141862596	G/A	cg15052665	chr6:141804349	NA	0.83	7.58	0.61	2.27e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8077889	1.000	rs2880329	chr17:41866168	T/A	cg26893861	chr17:41843967	DUSP3	1.07	9.57	0.7	1.39e-15	Triglycerides;
THYM	cis	rs9595908	0.900	rs7994229	chr13:33160705	C/A	cg12383807	chr13:33924137	NA	-0.54	-4.78	-0.44	6.39e-6	Body mass index;
THYM	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs238914	0.563	rs926075	chr11:114000727	C/T	cg18231614	chr11:113558886	TMPRSS5	-0.58	-4.58	-0.43	1.39e-5	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
THYM	cis	rs7771547	0.507	rs6457918	chr6:36414308	A/T	cg07856975	chr6:36356162	ETV7	-0.52	-5.02	-0.46	2.39e-6	Platelet distribution width;
THYM	cis	rs4589258	0.788	rs7930201	chr11:90465225	G/A	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.72	-0.44	7.95e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4746818	1.000	rs10733850	chr10:70959617	C/T	cg11621586	chr10:70884670	VPS26A	1.17	7.32	0.6	8.04e-11	Left atrial antero-posterior diameter;
THYM	cis	rs346785	0.692	rs6501880	chr17:74289705	A/G	cg09812376	chr17:74270190	QRICH2	-0.48	-4.88	-0.45	4.35e-6	White matter hyperintensities in ischemic stroke;
THYM	cis	rs6933660	0.512	rs9383905	chr6:151804296	C/T	cg03596678	chr6:151814994	C6orf97	-0.76	-4.91	-0.45	3.72e-6	Menarche (age at onset);
THYM	cis	rs28374715	0.532	rs11070328	chr15:41651569	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.78	-0.83	2.3e-26	Ulcerative colitis;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg14223017	chr19:2151266	AP3D1	-0.99	-7.19	-0.59	1.46e-10	Depressive symptoms;
THYM	cis	rs2067615	0.560	rs10467028	chr12:107076405	A/G	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg14784868	chr12:69753453	YEATS4	0.79	6.34	0.55	7.68e-9	Blood protein levels;
THYM	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg13319975	chr6:146136371	FBXO30	0.63	5.11	0.46	1.67e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3764563	0.877	rs4646526	chr19:15729773	A/G	cg20725493	chr19:15740067	CYP4F8	-1.02	-4.62	-0.43	1.2e-5	Inflammatory biomarkers;
THYM	cis	rs977987	0.705	rs4888377	chr16:75325686	C/G	cg07303275	chr16:75499416	TMEM170A	0.61	4.84	0.44	5.07e-6	Dupuytren's disease;
THYM	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg25237894	chr2:233734115	C2orf82	-0.36	-5.23	-0.47	9.96e-7	Coronary artery disease;
THYM	cis	rs995000	0.868	rs6682423	chr1:63171063	C/T	cg06896770	chr1:63153194	DOCK7	-0.68	-4.86	-0.45	4.62e-6	Triglyceride levels;
THYM	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg17294928	chr15:75287854	SCAMP5	0.64	4.93	0.45	3.54e-6	Breast cancer;
THYM	cis	rs2777491	0.507	rs11854081	chr15:41646398	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.78	-0.83	2.3e-26	Ulcerative colitis;
THYM	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs892961	0.932	rs11657725	chr17:75405501	G/C	cg11351908	chr17:75402473	SEPT9	0.59	5.74	0.51	1.11e-7	Airflow obstruction;
THYM	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg05283184	chr6:79620031	NA	0.91	8.91	0.67	3.59e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2811415	0.597	rs67786346	chr3:127794654	C/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg11757124	chr7:157526947	PTPRN2	-0.64	-5.22	-0.47	1.06e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg00255919	chr5:131827918	IRF1	-0.46	-5.2	-0.47	1.15e-6	Asthma (sex interaction);
THYM	cis	rs6430585	0.528	rs309151	chr2:136661150	C/T	cg20242066	chr2:136595261	LCT	0.52	4.89	0.45	4.16e-6	Corneal structure;
THYM	cis	rs2038227	1	rs2038227	chr16:539140	C/A	cg02296627	chr16:508045	RAB11FIP3	-0.54	-5.9	-0.52	5.56e-8	Venous thromboembolism (SNP x SNP interaction);
THYM	cis	rs9430161	0.579	rs7542158	chr1:11040193	G/A	cg02454025	chr1:11042201	C1orf127	0.85	9.91	0.71	2.54e-16	Ewing sarcoma;
THYM	cis	rs9825379	0.708	rs6776991	chr3:141142391	C/G	cg13411656	chr3:141121016	ZBTB38	-0.49	-4.54	-0.42	1.62e-5	Height;
THYM	cis	rs9486719	1.000	rs3906199	chr6:97049899	C/A	cg18709589	chr6:96969512	KIAA0776	-0.67	-4.64	-0.43	1.1e-5	Migraine;Coronary artery disease;
THYM	cis	rs2139634	0.965	rs10865941	chr3:46508547	A/G	cg02332537	chr3:46540019	RTP3	0.47	4.81	0.44	5.7e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06634786	chr22:41940651	POLR3H	0.78	6.01	0.53	3.36e-8	Vitiligo;
THYM	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg23018236	chr17:30244563	NA	-0.6	-4.45	-0.42	2.3e-5	Hip circumference adjusted for BMI;
THYM	cis	rs2463822	0.920	rs28678254	chr11:62151875	G/C	cg06239285	chr11:62104954	ASRGL1	-1.41	-7.07	-0.59	2.63e-10	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03264133	chr6:25882463	NA	-0.76	-5.8	-0.51	8.5e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12142240	0.698	rs6703374	chr1:46862332	C/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs2658782	0.789	rs2658775	chr11:93126799	C/T	cg15737290	chr11:93063684	CCDC67	0.9	7.12	0.59	2.06e-10	Pulmonary function decline;
THYM	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg15448220	chr1:150897856	SETDB1	0.88	7.18	0.59	1.51e-10	Melanoma;
THYM	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg03433033	chr1:76189801	ACADM	0.79	11.21	0.75	4.52e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1843834	0.517	rs1908252	chr2:225484736	G/A	cg10193763	chr2:225306901	NA	-0.46	-5.36	-0.48	5.93e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs1797885	0.763	rs299630	chr3:12568425	A/C	cg05467012	chr3:12595696	NA	0.54	4.59	0.43	1.35e-5	Immature fraction of reticulocytes;
THYM	cis	rs1559088	0.947	rs12461219	chr19:33550633	C/G	cg03563238	chr19:33554763	RHPN2	-0.5	-4.48	-0.42	2.04e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs2997447	0.761	rs61776582	chr1:26437262	A/C	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	trans	rs629535	0.814	rs488231	chr8:70064993	T/C	cg21567404	chr3:27674614	NA	1.08	10.14	0.72	8.19e-17	Dupuytren's disease;
THYM	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg26384229	chr12:38710491	ALG10B	0.98	7.54	0.61	2.79e-11	Bladder cancer;
THYM	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg27125505	chr17:43679177	LOC644172	0.77	6.97	0.58	4.25e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4766566	0.651	rs933307	chr12:111735537	A/C	cg10833066	chr12:111807467	FAM109A	-0.64	-8.72	-0.67	8.98e-14	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
THYM	cis	rs79149102	0.579	rs7168638	chr15:75280826	T/C	cg09165964	chr15:75287851	SCAMP5	-1.08	-5.99	-0.52	3.79e-8	Lung cancer;
THYM	cis	rs12208915	0.731	rs9443630	chr6:79661777	G/T	cg05283184	chr6:79620031	NA	0.63	4.61	0.43	1.27e-5	Left atrial antero-posterior diameter;
THYM	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg00256281	chr22:41985642	PMM1	0.62	4.78	0.44	6.4e-6	Vitiligo;
THYM	cis	rs72627123	1.000	rs72627126	chr14:74370024	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg04156016	chr5:1868137	NA	0.5	4.63	0.43	1.17e-5	Cardiovascular disease risk factors;
THYM	cis	rs981844	0.712	rs1456398	chr4:154738266	G/A	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs4824093	0.610	rs73443974	chr22:50314316	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.03	-4.99	-0.46	2.68e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg19875535	chr5:140030758	IK	-0.58	-4.92	-0.45	3.6e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg05768032	chr16:30646687	NA	0.56	5.58	0.5	2.27e-7	Multiple myeloma;
THYM	cis	rs713587	0.563	rs2033655	chr2:25101092	C/T	cg15423357	chr2:25149977	NA	0.63	6.36	0.55	6.88e-9	Body mass index in non-asthmatics;
THYM	cis	rs7626444	0.626	rs5021325	chr3:196477629	A/T	cg12930392	chr3:196481615	PAK2	0.4	4.92	0.45	3.58e-6	Monocyte count;
THYM	cis	rs554111	0.656	rs10916930	chr1:21395357	C/T	cg00373020	chr1:21041521	KIF17	0.53	4.49	0.42	2e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs11650494	0.908	rs78208413	chr17:47398282	G/A	cg08112188	chr17:47440006	ZNF652	1.25	5.41	0.49	4.62e-7	Prostate cancer;
THYM	cis	rs2130392	0.962	rs7660116	chr4:185626542	G/A	cg04058563	chr4:185651563	MLF1IP	0.58	5.67	0.5	1.54e-7	Kawasaki disease;
THYM	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg06634786	chr22:41940651	POLR3H	0.68	5.0	0.46	2.65e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg07930552	chr6:133119739	C6orf192	0.95	5.13	0.47	1.56e-6	Type 2 diabetes nephropathy;
THYM	cis	rs7605378	1.000	rs2577852	chr2:200687248	C/T	cg17644776	chr2:200775616	C2orf69	0.64	4.97	0.45	2.96e-6	Osteoporosis;
THYM	cis	rs72827839	0.802	rs16953925	chr17:46294498	C/T	cg23391107	chr17:45924227	SP6	0.85	5.05	0.46	2.17e-6	Ease of getting up in the morning;
THYM	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg23649088	chr2:200775458	C2orf69	0.81	6.14	0.53	1.88e-8	Schizophrenia;
THYM	cis	rs2688608	0.592	rs7080579	chr10:75504029	T/A	cg15838173	chr10:75533400	FUT11	-0.5	-5.09	-0.46	1.82e-6	Inflammatory bowel disease;
THYM	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.48	-4.73	-0.44	7.84e-6	Crohn's disease;
THYM	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg00129232	chr17:37814104	STARD3	-0.69	-4.45	-0.42	2.32e-5	Glomerular filtration rate (creatinine);
THYM	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg22433210	chr17:43662623	NA	1.09	8.4	0.65	4.4e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs57590327	0.508	rs7621968	chr3:81951460	A/G	cg07356753	chr3:81810745	GBE1	-0.71	-4.84	-0.44	5.09e-6	Extraversion;
THYM	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg13175981	chr1:150552382	MCL1	0.72	5.34	0.48	6.24e-7	Tonsillectomy;
THYM	cis	rs4474465	0.833	rs10899540	chr11:78245549	T/A	cg19901956	chr11:77921274	USP35	0.57	4.49	0.42	1.97e-5	Alzheimer's disease (survival time);
THYM	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg21862992	chr11:68658383	NA	0.23	4.49	0.42	2.03e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs3772130	0.624	rs56382357	chr3:121452339	T/C	cg20356878	chr3:121714668	ILDR1	0.63	4.89	0.45	4.07e-6	Cognitive performance;
THYM	cis	rs9640161	0.789	rs10248490	chr7:150051418	C/G	cg27494647	chr7:150038898	RARRES2	0.42	4.87	0.45	4.43e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs763014	0.898	rs4984893	chr16:623082	A/G	cg09263875	chr16:632152	PIGQ	0.71	6.15	0.53	1.85e-8	Height;
THYM	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg10803722	chr21:46713166	LOC642852	-0.39	-5.0	-0.46	2.63e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1003719	0.680	rs2835619	chr21:38505380	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-4.75	-0.44	7.3e-6	Eye color traits;
THYM	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg03396347	chr1:1875803	NA	-0.67	-6.72	-0.57	1.33e-9	Body mass index;
THYM	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs9479482	1.000	rs9479403	chr6:150337746	C/T	cg25797454	chr6:150327115	RAET1K	-0.45	-4.73	-0.44	7.65e-6	Alopecia areata;
THYM	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg05043794	chr9:111880884	C9orf5	-0.43	-6.21	-0.54	1.39e-8	Menarche (age at onset);
THYM	cis	rs61931739	0.591	rs1608907	chr12:33945435	A/G	cg06521331	chr12:34319734	NA	-0.57	-4.76	-0.44	7e-6	Morning vs. evening chronotype;
THYM	cis	rs7772486	0.743	rs9390344	chr6:146012755	C/G	cg23711669	chr6:146136114	FBXO30	-0.83	-7.91	-0.63	4.71e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg14784868	chr12:69753453	YEATS4	1.13	12.3	0.78	2.31e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs4845875	0.600	rs4846041	chr1:11837051	C/T	cg24844545	chr1:11908347	NPPA	0.57	4.77	0.44	6.74e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs59698941	0.943	rs60545802	chr5:132204577	T/G	cg02081065	chr5:132209139	LEAP2	-0.85	-5.74	-0.51	1.14e-7	Apolipoprotein A-IV levels;
THYM	cis	rs1568889	0.838	rs7952717	chr11:28261658	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs7809950	1.000	rs2293658	chr7:107270567	C/T	cg23024343	chr7:107201750	COG5	-0.97	-8.63	-0.66	1.4e-13	Coronary artery disease;
THYM	cis	rs2976388	0.609	rs2257796	chr8:143808667	T/C	cg06565975	chr8:143823917	SLURP1	0.5	5.62	0.5	1.9e-7	Urinary tract infection frequency;
THYM	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg06219351	chr7:158114137	PTPRN2	0.69	6.87	0.58	6.7e-10	Calcium levels;
THYM	cis	rs758324	0.732	rs156034	chr5:131527714	C/T	cg16205897	chr5:131564050	P4HA2	0.61	5.11	0.46	1.64e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs9816226	0.938	rs55742087	chr3:185830488	C/T	cg00760338	chr3:185826511	ETV5	-0.72	-4.5	-0.42	1.95e-5	Obesity;Body mass index;
THYM	trans	rs10802346	0.515	rs1113270	chr1:246423217	A/G	cg13514129	chr1:39547527	MACF1	1.06	11.2	0.75	4.75e-19	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg09085632	chr11:111637200	PPP2R1B	-0.98	-9.83	-0.71	3.91e-16	Primary sclerosing cholangitis;
THYM	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg08736216	chr1:53307985	ZYG11A	-0.58	-5.29	-0.48	7.85e-7	Monocyte count;
THYM	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.63	-4.48	-0.42	2.05e-5	Gut microbiome composition (summer);
THYM	cis	rs7731657	0.537	rs17621442	chr5:130205555	T/C	cg08523029	chr5:130500466	HINT1	-0.74	-5.05	-0.46	2.14e-6	Fasting plasma glucose;
THYM	cis	rs11190604	0.767	rs872290	chr10:102198879	G/A	cg07570687	chr10:102243282	WNT8B	0.85	8.39	0.65	4.57e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg10792982	chr14:105748885	BRF1	0.66	6.65	0.56	1.88e-9	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg10295955	chr4:187884368	NA	-1.2	-17.1	-0.87	9.26e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9549367	0.713	rs3024747	chr13:113821787	C/G	cg00898013	chr13:113819073	PROZ	-0.99	-8.94	-0.68	3.01e-14	Platelet distribution width;
THYM	cis	rs483180	0.531	rs541503	chr1:120208297	A/G	cg19096424	chr1:120255104	PHGDH	-0.65	-5.25	-0.47	9.36e-7	Macular telangiectasia type 2;
THYM	cis	rs7084921	0.608	rs11598979	chr10:101833720	C/T	cg11344164	chr10:101878520	NA	-0.56	-4.81	-0.44	5.61e-6	Bone mineral density;
THYM	cis	rs4481887	0.751	rs28607212	chr1:248520358	T/C	cg00666640	chr1:248458726	OR2T12	0.52	4.59	0.43	1.37e-5	Common traits (Other);
THYM	cis	rs2806561	0.664	rs4620508	chr1:23307438	C/T	cg19743168	chr1:23544995	NA	0.49	4.7	0.43	8.64e-6	Height;
THYM	cis	rs6840360	0.571	rs875668	chr4:152525661	C/T	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg08916839	chr5:415575	AHRR	1.14	6.76	0.57	1.12e-9	Fat distribution (HIV);
THYM	cis	rs216026	0.638	rs12312322	chr12:2771806	A/G	cg19945202	chr12:2788847	CACNA1C	-0.72	-4.94	-0.45	3.41e-6	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs7607369	0.648	rs7599984	chr2:219656713	T/G	cg02176678	chr2:219576539	TTLL4	-0.6	-5.51	-0.49	3.11e-7	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs11648796	0.717	rs10682	chr16:767430	C/G	cg02852791	chr16:710674	WDR90	-0.56	-5.27	-0.48	8.4e-7	Height;
THYM	cis	rs9470366	0.883	rs12199346	chr6:36641546	C/A	cg11920449	chr6:36645608	CDKN1A	-0.75	-5.81	-0.51	8.39e-8	QRS duration;
THYM	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.45	-5.56	-0.5	2.49e-7	Monocyte percentage of white cells;
THYM	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs9649213	0.614	rs9641236	chr7:97998124	T/A	cg09267113	chr7:98030324	BAIAP2L1	-0.68	-5.75	-0.51	1.08e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1023500	1.000	rs1023498	chr22:42340569	C/T	cg19448990	chr22:41842841	TOB2	-0.76	-4.89	-0.45	4.06e-6	Schizophrenia;
THYM	cis	rs2916260	0.866	rs746652	chr6:40382018	T/C	cg08415973	chr6:40346114	TDRG1	0.83	5.05	0.46	2.13e-6	Incident coronary heart disease;
THYM	cis	rs7681440	0.630	rs356195	chr4:90683168	T/C	cg06632027	chr4:90757378	SNCA	0.58	4.46	0.42	2.28e-5	Dementia with Lewy bodies;
THYM	cis	rs425535	0.941	rs187080	chr4:74856663	T/C	cg07868155	chr4:74864709	CXCL5	0.61	5.05	0.46	2.12e-6	Blood protein levels;
THYM	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg07599136	chr5:415885	AHRR	0.93	5.17	0.47	1.29e-6	Fat distribution (HIV);
THYM	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg08835221	chr22:38071607	LGALS1	0.35	4.96	0.45	3.13e-6	Fat distribution (HIV);
THYM	cis	rs6430585	0.528	rs6750549	chr2:136707480	A/G	cg23851026	chr2:136556271	LCT	0.76	7.47	0.61	3.81e-11	Corneal structure;
THYM	cis	rs6906287	0.647	rs2077162	chr6:118687469	G/A	cg21191810	chr6:118973309	C6orf204	0.52	5.02	0.46	2.36e-6	Electrocardiographic conduction measures;
THYM	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg17264618	chr3:40429014	ENTPD3	0.54	5.14	0.47	1.47e-6	Renal cell carcinoma;
THYM	cis	rs73787773	0.867	rs73227492	chr5:111473369	A/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.88	-4.76	-0.44	6.87e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg10802521	chr3:52805072	NEK4	-0.71	-5.78	-0.51	9.42e-8	Bipolar disorder;
THYM	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11890956	chr21:40555474	PSMG1	-0.66	-6.38	-0.55	6.51e-9	Menarche (age at onset);
THYM	cis	rs600806	0.850	rs10858095	chr1:109962642	G/C	cg02175308	chr1:109941060	SORT1	-0.61	-5.38	-0.48	5.35e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg20608306	chr11:116969690	SIK3	0.57	7.4	0.6	5.35e-11	Blood protein levels;
THYM	cis	rs7084402	0.565	rs10826200	chr10:60333847	T/C	cg09696939	chr10:60272079	BICC1	-0.49	-5.7	-0.5	1.35e-7	Refractive error;
THYM	cis	rs9902453	0.791	rs28492945	chr17:28223982	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	5.39	0.48	5.11e-7	Coffee consumption (cups per day);
THYM	cis	rs2997447	0.846	rs72886619	chr1:26452604	G/A	cg03844060	chr1:26490628	NA	0.7	4.89	0.45	4.04e-6	QRS complex (12-leadsum);
THYM	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg18538332	chr22:24372958	LOC391322	-1.05	-13.06	-0.8	6.35e-23	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg11663144	chr21:46675770	NA	-0.71	-9.92	-0.71	2.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs420259	0.516	rs11074565	chr16:23533008	G/A	cg00143387	chr16:23521605	GGA2	-0.72	-5.18	-0.47	1.26e-6	Bipolar disorder;
THYM	cis	rs858239	0.665	rs6964665	chr7:23211352	G/A	cg09755872	chr7:23245557	NA	-0.51	-4.86	-0.45	4.54e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6435161	1.000	rs7568438	chr2:203547106	C/T	cg18429434	chr2:203499731	FAM117B	-0.76	-5.01	-0.46	2.49e-6	Total cholesterol levels;
THYM	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg21427119	chr20:30132790	HM13	0.98	7.3	0.6	8.89e-11	Mean corpuscular hemoglobin;
THYM	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg02527881	chr3:46936655	PTH1R	-0.69	-7.1	-0.59	2.23e-10	Colorectal cancer;
THYM	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs753778	0.963	rs3739234	chr8:142229178	G/A	cg18755752	chr8:142205143	DENND3	-0.64	-4.72	-0.44	8.02e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs420259	0.516	rs430208	chr16:23458485	A/G	cg00143387	chr16:23521605	GGA2	0.8	5.88	0.52	5.96e-8	Bipolar disorder;
THYM	cis	rs3892630	0.878	rs114224536	chr19:33211232	A/G	cg22928329	chr19:33183273	NUDT19	-0.77	-5.88	-0.52	6e-8	Red blood cell traits;
THYM	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg18876405	chr7:65276391	NA	0.61	5.16	0.47	1.36e-6	Aortic root size;
THYM	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs870825	0.929	rs72689265	chr4:185590982	A/G	cg04058563	chr4:185651563	MLF1IP	0.96	6.73	0.57	1.26e-9	Blood protein levels;
THYM	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg00071950	chr4:10020882	SLC2A9	-0.65	-5.99	-0.52	3.67e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs2290159	0.800	rs60953453	chr3:12654921	C/A	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs5771069	0.966	rs137853	chr22:50443449	C/T	cg27467552	chr22:50353597	PIM3	-0.46	-4.87	-0.45	4.5e-6	Ulcerative colitis;
THYM	cis	rs4919694	1.000	rs77827514	chr10:104822009	C/T	cg15744005	chr10:104629667	AS3MT	-0.85	-4.67	-0.43	9.96e-6	Arsenic metabolism;
THYM	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg12560992	chr17:57184187	TRIM37	-0.92	-8.68	-0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg10523679	chr1:76189770	ACADM	-0.55	-4.65	-0.43	1.06e-5	Daytime sleep phenotypes;
THYM	cis	rs7772486	0.764	rs9399569	chr6:146242942	C/T	cg13319975	chr6:146136371	FBXO30	0.75	6.26	0.54	1.11e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs57920188	0.585	rs12124643	chr1:4071209	C/T	cg20703997	chr1:4087676	NA	1.05	7.32	0.6	8.02e-11	Interleukin-17 levels;
THYM	cis	rs2836633	0.929	rs58120977	chr21:40037346	C/T	cg05519781	chr21:40033154	ERG	0.79	7.8	0.62	7.93e-12	Coronary artery disease;
THYM	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	9.4	0.69	3.1e-15	Chronic sinus infection;
THYM	cis	rs7267979	0.739	rs6138555	chr20:25242910	G/A	cg08601574	chr20:25228251	PYGB	0.7	5.75	0.51	1.1e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs216205	0.547	rs2641431	chr17:2030507	C/G	cg16513277	chr17:2031491	SMG6	-0.9	-5.85	-0.51	7.02e-8	Mitral valve prolapse;
THYM	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg14416269	chr4:6271139	WFS1	0.54	5.62	0.5	1.93e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.6	-0.5	2.08e-7	Type 2 diabetes;
THYM	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.54	-4.51	-0.42	1.86e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6089584	0.627	rs6089303	chr20:60565797	G/A	cg06108461	chr20:60628389	TAF4	-0.78	-5.95	-0.52	4.46e-8	Body mass index;
THYM	cis	rs28595532	0.920	rs116834347	chr4:119774155	C/A	cg14228332	chr4:119757509	SEC24D	1.59	5.76	0.51	1.02e-7	Cannabis dependence symptom count;
THYM	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg06481639	chr22:41940642	POLR3H	0.84	6.06	0.53	2.69e-8	Vitiligo;
THYM	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.04	-0.46	2.24e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.61	5.3	0.48	7.56e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17433780	1.000	rs17433780	chr1:89474818	C/T	cg09516651	chr1:89888402	LOC400759	-0.77	-5.88	-0.52	6.22e-8	Carotid intima media thickness;
THYM	cis	rs804280	0.638	rs36038176	chr8:11609995	C/T	cg12395012	chr8:11607386	GATA4	0.66	5.25	0.47	9.29e-7	Myopia (pathological);
THYM	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg24874828	chr4:187887005	NA	-0.72	-7.44	-0.61	4.48e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2276314	1.000	rs9304154	chr18:33562227	C/T	cg05985134	chr18:33552581	C18orf21	0.72	5.0	0.46	2.6e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg22307297	chr20:60903441	LAMA5	0.53	4.59	0.43	1.38e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg14416269	chr4:6271139	WFS1	0.57	5.67	0.5	1.53e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg19913688	chr11:428466	ANO9	-0.88	-4.6	-0.43	1.3e-5	Body mass index;
THYM	cis	rs6924995	0.501	rs9370870	chr6:16196759	C/T	cg11805552	chr6:16175128	NA	0.57	4.85	0.45	4.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs7649443	0.918	rs7619429	chr3:196999090	G/T	cg20744464	chr3:196756875	MFI2	0.62	4.56	0.42	1.53e-5	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs6754311	0.593	rs656326	chr2:136428460	A/C	cg04750100	chr2:136595281	LCT	0.56	5.91	0.52	5.3e-8	Mosquito bite size;
THYM	cis	rs7428	0.527	rs6547612	chr2:85551184	C/T	cg24342717	chr2:85555507	TGOLN2	-0.83	-7.09	-0.59	2.37e-10	Ear protrusion;
THYM	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg25072359	chr17:41440525	NA	0.67	4.64	0.43	1.1e-5	Menopause (age at onset);
THYM	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg02725872	chr8:58115012	NA	1.11	7.58	0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg16414030	chr3:133502952	NA	0.93	9.35	0.69	4.1e-15	Iron status biomarkers;
THYM	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg27446573	chr6:127587934	RNF146	1.01	9.7	0.71	7.13e-16	Breast cancer;
THYM	cis	rs6754311	0.593	rs656326	chr2:136428460	A/C	cg20242066	chr2:136595261	LCT	0.55	6.05	0.53	2.89e-8	Mosquito bite size;
THYM	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg26384229	chr12:38710491	ALG10B	0.93	7.35	0.6	6.77e-11	Bladder cancer;
THYM	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg09323728	chr8:95962352	TP53INP1	-0.44	-4.56	-0.42	1.53e-5	Type 2 diabetes;
THYM	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg14972814	chr11:95582409	MTMR2	-0.63	-5.31	-0.48	7.33e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg05552183	chr6:42928497	GNMT	0.59	4.69	0.43	9.17e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg03859395	chr2:55845619	SMEK2	0.61	5.55	0.49	2.6e-7	Metabolic syndrome;
THYM	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg27490568	chr2:178487706	NA	0.63	6.02	0.53	3.29e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg05872129	chr22:39784769	NA	-1.04	-10.74	-0.74	4.42e-18	Intelligence (multi-trait analysis);
THYM	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg27494647	chr7:150038898	RARRES2	0.44	5.51	0.49	3.09e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11122895	0.791	rs11122894	chr2:112469117	C/T	cg23262488	chr2:112468472	NA	0.47	5.33	0.48	6.62e-7	Allergic sensitization;
THYM	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg07936489	chr17:37558343	FBXL20	-0.81	-5.53	-0.49	2.76e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs4363385	0.818	rs377768	chr1:153016594	T/C	cg13444842	chr1:152974279	SPRR3	-0.55	-4.45	-0.42	2.35e-5	Inflammatory skin disease;
THYM	cis	rs1029738	0.615	rs3757447	chr7:22894735	A/T	cg22407942	chr7:22894828	SNORD93	-0.38	-4.47	-0.42	2.18e-5	Fibrinogen levels;
THYM	cis	rs9560113	1.000	rs9560106	chr13:112179605	A/G	cg10483660	chr13:112241077	NA	0.56	5.07	0.46	1.95e-6	Menarche (age at onset);
THYM	cis	rs7567389	0.677	rs72845975	chr2:128086274	C/T	cg09760422	chr2:128146352	NA	0.4	4.52	0.42	1.8e-5	Self-rated health;
THYM	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03517284	chr6:25882590	NA	-0.71	-5.34	-0.48	6.32e-7	Height;
THYM	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg18105134	chr13:113819100	PROZ	-1.16	-10.42	-0.73	2.11e-17	Platelet distribution width;
THYM	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs2249694	0.620	rs9418990	chr10:135337966	C/T	cg20169779	chr10:135381914	SYCE1	0.65	4.89	0.45	4.11e-6	Obesity-related traits;
THYM	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg17911788	chr17:44343683	NA	-0.79	-7.24	-0.6	1.19e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4474465	0.850	rs4945294	chr11:78256864	G/A	cg19901956	chr11:77921274	USP35	0.61	4.64	0.43	1.1e-5	Alzheimer's disease (survival time);
THYM	cis	rs7940866	0.740	rs2162060	chr11:130830763	A/G	cg05962950	chr11:130786565	SNX19	0.7	5.41	0.49	4.66e-7	Schizophrenia;
THYM	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14159672	chr1:205819179	PM20D1	0.97	10.02	0.72	1.47e-16	Menarche (age at onset);
THYM	cis	rs4474465	1.000	rs10899506	chr11:78168705	C/T	cg19901956	chr11:77921274	USP35	-0.61	-4.57	-0.42	1.48e-5	Alzheimer's disease (survival time);
THYM	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg16342193	chr10:102329863	NA	-0.58	-6.13	-0.53	1.96e-8	Palmitoleic acid (16:1n-7) levels;
THYM	trans	rs28595532	0.557	rs28657902	chr4:119305491	C/T	cg26518628	chr1:97050305	NA	-1.13	-8.44	-0.65	3.62e-13	Cannabis dependence symptom count;
THYM	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg21926883	chr2:100939477	LONRF2	-0.65	-6.02	-0.53	3.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs72781680	0.898	rs72782117	chr2:24026921	G/A	cg08917208	chr2:24149416	ATAD2B	1.11	4.97	0.45	2.9e-6	Lymphocyte counts;
THYM	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-7.13	-0.59	1.99e-10	Chronic sinus infection;
THYM	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg03060546	chr3:49711283	APEH	0.68	4.58	0.43	1.39e-5	Resting heart rate;
THYM	cis	rs55871839	0.684	rs4738729	chr8:59808617	T/C	cg07426533	chr8:59803705	TOX	-0.64	-6.4	-0.55	5.92e-9	Pneumonia;
THYM	cis	rs7211079	0.957	rs58120535	chr17:78116024	G/A	cg09238746	chr17:78121135	EIF4A3	-0.74	-4.64	-0.43	1.1e-5	Myocardial infarction;
THYM	cis	rs7843479	1.000	rs10503715	chr8:21850687	G/A	cg17168535	chr8:21777572	XPO7	0.64	4.77	0.44	6.53e-6	Mean corpuscular volume;
THYM	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg20587970	chr11:113659929	NA	-1.37	-8.96	-0.68	2.79e-14	Hip circumference adjusted for BMI;
THYM	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03576123	chr11:487126	PTDSS2	-1.29	-6.68	-0.57	1.6e-9	Body mass index;
THYM	cis	rs4919694	1.000	rs77827514	chr10:104822009	C/T	cg04362960	chr10:104952993	NT5C2	1.14	6.92	0.58	5.36e-10	Arsenic metabolism;
THYM	cis	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg03732007	chr1:2071316	PRKCZ	0.49	4.57	0.42	1.46e-5	Height;
THYM	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg01097406	chr16:89675127	NA	-0.64	-5.33	-0.48	6.66e-7	Vitiligo;
THYM	cis	rs6570726	1.000	rs405622	chr6:145871897	G/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.8	-0.51	8.64e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7727544	0.582	rs10478998	chr5:131516531	G/A	cg16205897	chr5:131564050	P4HA2	-0.45	-4.51	-0.42	1.83e-5	Blood metabolite levels;
THYM	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg24874828	chr4:187887005	NA	0.75	7.9	0.63	4.98e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs262150	0.545	rs73167302	chr7:158789762	G/A	cg23058037	chr7:158824108	VIPR2	0.54	5.0	0.46	2.65e-6	Facial morphology (factor 20);
THYM	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg10523679	chr1:76189770	ACADM	-0.55	-4.53	-0.42	1.74e-5	Daytime sleep phenotypes;
THYM	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg04896959	chr15:78267971	NA	-1.11	-11.38	-0.76	1.89e-19	Diastolic blood pressure;
THYM	cis	rs8067545	0.641	rs203458	chr17:19816898	A/C	cg20830565	chr17:20408647	MGC102966	-0.54	-4.95	-0.45	3.2e-6	Schizophrenia;
THYM	cis	rs4866334	1.000	rs80012640	chr5:18455247	C/T	cg02002538	chr5:17811409	NA	-1.09	-4.54	-0.42	1.67e-5	IgG glycosylation;
THYM	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg17105886	chr17:28927953	LRRC37B2	1.2	6.56	0.56	2.8e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7089973	0.872	rs34683721	chr10:116619849	G/A	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.14	-0.47	1.5e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Bladder cancer;
THYM	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg17366294	chr4:99064904	C4orf37	0.52	6.01	0.52	3.45e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs55692411	0.537	rs62262118	chr3:50003586	G/A	cg14019146	chr3:50243930	SLC38A3	-0.59	-4.56	-0.42	1.55e-5	Intelligence (multi-trait analysis);
THYM	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs9560113	1.000	rs9555811	chr13:112181532	A/C	cg14154082	chr13:112174009	NA	0.86	7.89	0.63	5.23e-12	Menarche (age at onset);
THYM	cis	rs79349575	0.685	rs1124829	chr17:46967797	C/A	cg26022315	chr17:47021804	SNF8	0.48	4.49	0.42	2e-5	Type 2 diabetes;
THYM	cis	rs12216545	0.737	rs1916006	chr7:150240556	T/C	cg00323915	chr7:150264987	GIMAP4	-0.49	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs6754311	0.773	rs309179	chr2:136613780	G/A	cg04750100	chr2:136595281	LCT	-0.56	-6.13	-0.53	1.97e-8	Mosquito bite size;
THYM	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Crohn's disease;
THYM	cis	rs859767	0.741	rs4954159	chr2:135426782	A/G	cg12500956	chr2:135428796	TMEM163	-0.51	-5.31	-0.48	7.1e-7	Neuroticism;
THYM	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg24955955	chr5:415729	AHRR	1.02	5.72	0.51	1.21e-7	Fat distribution (HIV);
THYM	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg25703541	chr22:24373054	LOC391322	-0.9	-11.69	-0.77	4.37e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6687430	0.562	rs6676491	chr1:10633421	A/C	cg20482658	chr1:10539492	PEX14	-0.35	-4.91	-0.45	3.78e-6	Hand grip strength;
THYM	cis	rs9527	0.590	rs11191540	chr10:104822809	G/C	cg04362960	chr10:104952993	NT5C2	0.6	4.55	0.42	1.56e-5	Arsenic metabolism;
THYM	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg02820040	chr2:241836501	C2orf54	-0.3	-5.84	-0.51	7.13e-8	Urinary metabolites;
THYM	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg27394845	chr17:28928406	LRRC37B2	0.98	4.71	0.43	8.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg01073479	chr16:3509474	NAT15	0.57	5.45	0.49	3.92e-7	Tuberculosis;
THYM	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg09549813	chr16:4587862	C16orf5	-0.62	-7.09	-0.59	2.36e-10	Schizophrenia;
THYM	cis	rs4363385	0.818	rs559236	chr1:153010510	T/C	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	trans	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs9527	0.615	rs10883800	chr10:104671212	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-5.01	-0.46	2.51e-6	Arsenic metabolism;
THYM	cis	rs7917772	0.582	rs12782153	chr10:104368294	A/G	cg00122347	chr10:104236741	TMEM180	0.42	6.22	0.54	1.34e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs67311347	0.544	rs4974047	chr3:40339653	G/T	cg24209194	chr3:40518798	ZNF619	0.55	4.6	0.43	1.29e-5	Renal cell carcinoma;
THYM	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg03676636	chr4:99064102	C4orf37	0.5	7.59	0.61	2.14e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg24642844	chr7:1081250	C7orf50	-1.2	-5.2	-0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg24060327	chr5:131705240	SLC22A5	-0.69	-5.25	-0.47	9.42e-7	Breast cancer;
THYM	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg24503407	chr1:205819492	PM20D1	-0.64	-5.36	-0.48	5.75e-7	Menarche (age at onset);
THYM	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg27398817	chr8:82754497	SNX16	-0.81	-6.46	-0.55	4.49e-9	Diastolic blood pressure;
THYM	cis	rs192264	0.614	rs1094982	chr16:65977720	G/T	cg02795155	chr16:66785218	DYNC1LI2	0.58	4.68	0.43	9.41e-6	Subjective well-being;
THYM	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg27211696	chr2:191398769	TMEM194B	-0.83	-8.06	-0.64	2.24e-12	Pulse pressure;
THYM	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.92	5.02	0.46	2.41e-6	Initial pursuit acceleration;
THYM	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs684232	0.602	rs416662	chr17:535699	A/G	cg15660573	chr17:549704	VPS53	-1.0	-11.2	-0.75	4.65e-19	Prostate cancer;
THYM	cis	rs981844	0.712	rs6535957	chr4:154749862	C/A	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs3741798	1.000	rs2160588	chr12:12487447	C/T	cg08615371	chr12:12503544	MANSC1	0.88	4.9	0.45	3.92e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs428668	0.681	rs430961	chr5:150700559	C/G	cg11125805	chr5:150678162	SLC36A3	0.48	4.96	0.45	3.12e-6	Skin aging (microtopography measurement);
THYM	cis	rs9902453	0.808	rs76039587	chr17:28233760	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.64	0.43	1.11e-5	Coffee consumption (cups per day);
THYM	cis	rs733175	0.855	rs10016075	chr4:10006663	G/T	cg11266682	chr4:10021025	SLC2A9	0.51	4.45	0.42	2.34e-5	Psychosis and Alzheimer's disease;
THYM	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	8.57	0.66	1.88e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9948	1.000	rs6753987	chr2:97521820	C/T	cg01990225	chr2:97406019	LMAN2L	-0.94	-5.11	-0.46	1.66e-6	Erectile dysfunction and prostate cancer treatment;
THYM	cis	rs12130333	0.652	rs61775956	chr1:63124040	G/A	cg06896770	chr1:63153194	DOCK7	0.97	4.6	0.43	1.3e-5	Triglycerides;
THYM	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.77	5.17	0.47	1.28e-6	Smoking behavior;
THYM	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg12011299	chr4:100065546	ADH4	0.66	5.65	0.5	1.65e-7	Alcohol dependence;
THYM	cis	rs11608355	0.573	rs7970666	chr12:109793495	T/G	cg11367159	chr12:110044531	NA	0.53	5.05	0.46	2.14e-6	Neuroticism;
THYM	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg24579218	chr15:68104479	NA	-0.86	-8.33	-0.65	6.04e-13	Restless legs syndrome;
THYM	cis	rs4845459	0.967	rs4845450	chr1:152591200	T/C	cg26135325	chr1:152595322	LCE3A	-0.45	-5.21	-0.47	1.09e-6	Psoriasis;
THYM	cis	rs78366141	0.649	rs61737091	chr4:89671721	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	1.14	4.83	0.44	5.28e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs28595532	0.920	rs114223775	chr4:119775091	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.08	0.46	1.92e-6	Cannabis dependence symptom count;
THYM	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg03060546	chr3:49711283	APEH	-0.67	-5.08	-0.46	1.85e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs988913	1.000	rs6941796	chr6:54837621	A/T	cg04690482	chr6:54711388	FAM83B	0.46	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	cis	rs1466662	0.814	rs2130714	chr4:155314758	A/T	cg05574313	chr4:155338166	DCHS2	-0.66	-4.65	-0.43	1.07e-5	Alzheimer's disease (age of onset);
THYM	cis	rs2354432	0.607	rs10453880	chr1:146693689	T/C	cg25205988	chr1:146714368	CHD1L	1.11	4.98	0.46	2.83e-6	Mitochondrial DNA levels;
THYM	cis	rs61774743	0.681	rs10889959	chr1:41849735	T/C	cg01193554	chr1:41846683	NA	-0.34	-4.85	-0.45	4.9e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9527	0.615	rs12248123	chr10:104735366	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-5.08	-0.46	1.89e-6	Arsenic metabolism;
THYM	cis	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg01364799	chr7:75623366	TMEM120A	0.66	4.78	0.44	6.45e-6	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4243830	0.649	rs11579888	chr1:6609896	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.09	-7.38	-0.6	5.96e-11	Body mass index;
THYM	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg08885076	chr2:99613938	TSGA10	-0.58	-5.61	-0.5	1.99e-7	Chronic sinus infection;
THYM	cis	rs7119	0.689	rs11630926	chr15:77819582	T/C	cg10437265	chr15:77819839	NA	0.7	6.4	0.55	5.91e-9	Type 2 diabetes;
THYM	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.76	-6.38	-0.55	6.46e-9	Systemic lupus erythematosus;
THYM	cis	rs3729931	0.507	rs79945102	chr3:12711975	A/C	cg23032965	chr3:12705835	RAF1	0.99	7.38	0.6	5.9e-11	Cardiac hypertrophy;
THYM	cis	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg09085632	chr11:111637200	PPP2R1B	1.16	11.93	0.77	1.35e-20	Primary sclerosing cholangitis;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg02254876	chr3:42922351	NA	-0.77	-6.96	-0.58	4.31e-10	Depressive symptoms;
THYM	cis	rs9486719	0.741	rs976356	chr6:96849437	T/A	cg18709589	chr6:96969512	KIAA0776	0.75	4.49	0.42	2.02e-5	Migraine;Coronary artery disease;
THYM	cis	rs793571	0.502	rs395601	chr15:59063196	G/C	cg05156742	chr15:59063176	FAM63B	0.57	4.85	0.45	4.9e-6	Schizophrenia;
THYM	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg05738196	chr6:26577821	NA	0.85	7.85	0.63	6.1e-12	Intelligence (multi-trait analysis);
THYM	cis	rs2041895	0.527	rs10861678	chr12:107319661	C/T	cg26297688	chr12:107349093	C12orf23	-0.49	-4.88	-0.45	4.25e-6	Glaucoma (low intraocular pressure);
THYM	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2034088	0.897	rs4968124	chr17:436900	T/C	cg06217071	chr17:408420	NA	0.72	6.34	0.55	7.58e-9	Hip circumference adjusted for BMI;
THYM	cis	rs4789939	1.000	rs4789939	chr17:76881703	T/C	cg26927190	chr17:76875678	TIMP2	-0.81	-5.14	-0.47	1.48e-6	Dupuytren's disease;
THYM	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9527	0.640	rs6584541	chr10:104929124	A/G	cg04362960	chr10:104952993	NT5C2	0.6	4.6	0.43	1.32e-5	Arsenic metabolism;
THYM	cis	rs7598759	0.527	rs12987949	chr2:232367511	A/G	cg19187155	chr2:232395269	NMUR1	0.84	7.65	0.62	1.62e-11	Noise-induced hearing loss;
THYM	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.96	8.75	0.67	7.92e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg24818145	chr4:99064322	C4orf37	0.66	5.03	0.46	2.33e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg24308560	chr3:49941425	MST1R	0.63	4.78	0.44	6.37e-6	Body mass index;
THYM	cis	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg12395012	chr8:11607386	GATA4	-0.65	-5.56	-0.5	2.51e-7	Morning vs. evening chronotype;
THYM	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg14129053	chr2:1895732	MYT1L	1.13	4.49	0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg23711669	chr6:146136114	FBXO30	-0.96	-10.01	-0.72	1.54e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4746818	0.892	rs2394505	chr10:70871598	A/G	cg11621586	chr10:70884670	VPS26A	-0.93	-6.34	-0.55	7.75e-9	Left atrial antero-posterior diameter;
THYM	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.61	0.56	2.28e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.52	0.49	2.99e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.39	0.69	3.28e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg18135555	chr8:22132992	PIWIL2	0.55	4.64	0.43	1.11e-5	Hypertriglyceridemia;
THYM	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg05896524	chr21:47604654	C21orf56	-0.65	-4.55	-0.42	1.57e-5	Testicular germ cell tumor;
THYM	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg26131816	chr17:42072204	PYY	0.56	4.66	0.43	1.03e-5	Menopause (age at onset);
THYM	cis	rs11225247	0.536	rs11605915	chr11:102237187	C/T	cg06323957	chr11:102217781	BIRC2	1.02	4.74	0.44	7.52e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg15536230	chr21:44985092	HSF2BP	-0.38	-4.65	-0.43	1.07e-5	Mean corpuscular volume;
THYM	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg24006582	chr15:45444508	DUOX1	-0.82	-6.89	-0.58	5.91e-10	Uric acid levels;
THYM	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg23815491	chr16:72088622	HP	0.84	6.94	0.58	4.78e-10	Fibrinogen levels;
THYM	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg18357526	chr6:26021779	HIST1H4A	0.76	5.66	0.5	1.6e-7	Intelligence (multi-trait analysis);
THYM	cis	rs236907	0.859	rs7536142	chr1:171770336	A/G	cg20598894	chr1:171756153	METTL13	-0.74	-5.48	-0.49	3.46e-7	Mean platelet volume;
THYM	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg01264106	chr22:38071602	LGALS1	0.41	4.97	0.45	2.94e-6	Fat distribution (HIV);
THYM	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg15445000	chr17:37608096	MED1	0.44	5.07	0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs791888	0.723	rs1980648	chr10:89422369	T/C	cg13926569	chr10:89418898	PAPSS2	0.72	8.15	0.64	1.44e-12	Magnesium levels;
THYM	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg06618935	chr21:46677482	NA	0.88	7.97	0.63	3.5e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg07460842	chr6:66804631	NA	1.21	14.69	0.83	3.4e-26	Exhaled nitric oxide output;
THYM	cis	rs539096	0.872	rs3791137	chr1:44050004	G/A	cg00143623	chr1:44495758	SLC6A9	0.65	5.03	0.46	2.29e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4930103	0.904	rs4929984	chr11:2024683	A/C	cg03175030	chr11:2018143	H19;MIR675	0.44	4.6	0.43	1.32e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg19626725	chr5:178986131	RUFY1	0.34	5.67	0.5	1.52e-7	Lung cancer;
THYM	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg12560992	chr17:57184187	TRIM37	0.83	7.39	0.6	5.71e-11	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg06618935	chr21:46677482	NA	-0.97	-8.09	-0.64	1.92e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13732083	chr21:47605072	C21orf56	-0.7	-4.92	-0.45	3.56e-6	Testicular germ cell tumor;
THYM	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg04990556	chr1:26633338	UBXN11	-0.89	-8.55	-0.66	2.02e-13	Obesity-related traits;
THYM	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs7688540	0.771	rs11726829	chr4:224948	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.65	4.8	0.44	5.89e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs28595532	0.764	rs115916994	chr4:119688758	A/G	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.65	-4.46	-0.42	2.23e-5	Gut microbiome composition (summer);
THYM	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg17143192	chr8:8559678	CLDN23	0.59	4.48	0.42	2.12e-5	Mood instability;
THYM	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg24812749	chr6:127587940	RNF146	0.76	5.71	0.51	1.27e-7	Breast cancer;
THYM	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg00981070	chr1:2046702	PRKCZ	-0.47	-5.85	-0.51	6.95e-8	Height;
THYM	cis	rs4243830	0.850	rs4908911	chr1:6599523	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.06	-6.24	-0.54	1.21e-8	Body mass index;
THYM	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg10047753	chr17:41438598	NA	0.97	7.99	0.63	3.21e-12	Menopause (age at onset);
THYM	cis	rs2806561	1.000	rs2776822	chr1:23492782	A/G	cg19743168	chr1:23544995	NA	-0.59	-5.95	-0.52	4.5e-8	Height;
THYM	trans	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9595908	0.785	rs3912038	chr13:33256198	T/G	cg12383807	chr13:33924137	NA	-0.51	-4.45	-0.42	2.34e-5	Body mass index;
THYM	cis	rs6700896	0.897	rs11208701	chr1:66134698	C/T	cg04111102	chr1:66153794	NA	0.56	5.27	0.48	8.45e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9462846	0.845	rs9471964	chr6:42885664	C/A	cg09436375	chr6:42928200	GNMT	-0.37	-4.46	-0.42	2.25e-5	Blood protein levels;
THYM	cis	rs9913156	0.748	rs72835626	chr17:4560326	C/A	cg19197139	chr17:4613644	ARRB2	0.78	4.92	0.45	3.63e-6	Lymphocyte counts;
THYM	cis	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs6582630	0.555	rs61932279	chr12:38349096	C/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.47	-0.42	2.17e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs28647808	1.000	rs6597630	chr9:136279935	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs10779751	0.770	rs2788543	chr1:11344629	T/C	cg08854313	chr1:11322531	MTOR	-0.99	-9.09	-0.68	1.47e-14	Body mass index;
THYM	cis	rs12765878	1.000	rs11191848	chr10:105650837	T/C	cg11005552	chr10:105648138	OBFC1	0.87	11.39	0.76	1.84e-19	Coronary artery disease;
THYM	cis	rs9915657	0.870	rs720244	chr17:70131643	G/T	cg06234051	chr17:70120541	SOX9	-0.71	-6.56	-0.56	2.8e-9	Thyroid hormone levels;
THYM	cis	rs6502050	0.835	rs12450154	chr17:80182672	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.06	-0.64	2.21e-12	Life satisfaction;
THYM	cis	rs240764	0.817	rs240145	chr6:101079610	A/C	cg21058520	chr6:100914733	NA	-0.57	-5.06	-0.46	2.04e-6	Neuroticism;
THYM	cis	rs6456042	0.893	rs3099312	chr6:166557339	T/C	cg11088901	chr6:166572345	T	-0.51	-4.9	-0.45	3.86e-6	Asthma;
THYM	cis	rs4930776	0.932	rs454736	chr12:5758620	A/G	cg02086166	chr12:5775618	ANO2	0.62	6.17	0.53	1.69e-8	Plasma clusterin levels;
THYM	cis	rs12130333	0.617	rs12117388	chr1:63119256	T/C	cg06896770	chr1:63153194	DOCK7	0.97	4.6	0.43	1.3e-5	Triglycerides;
THYM	cis	rs3791406	1.000	rs3791405	chr2:240030284	G/A	cg14550559	chr2:240039617	HDAC4	-0.6	-5.42	-0.49	4.58e-7	Skin aging (microtopography measurement);
THYM	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg08885076	chr2:99613938	TSGA10	0.52	5.04	0.46	2.24e-6	Chronic sinus infection;
THYM	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg11526020	chr17:80870163	TBCD	0.46	4.49	0.42	1.98e-5	Glycated hemoglobin levels;
THYM	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg01097406	chr16:89675127	NA	0.61	5.55	0.49	2.55e-7	Hemoglobin concentration;
THYM	cis	rs11628318	0.515	rs1190343	chr14:103100348	G/A	cg27124170	chr14:102829869	TECPR2;CINP	-0.67	-4.61	-0.43	1.23e-5	Platelet count;
THYM	cis	rs2160908	0.694	rs9286	chr22:37576486	A/G	cg26999345	chr22:37584441	C1QTNF6	-0.38	-4.52	-0.42	1.76e-5	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs1775715	0.870	rs11008702	chr10:32244818	T/G	cg04359828	chr10:32216031	ARHGAP12	0.39	4.87	0.45	4.38e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.69	-0.62	1.33e-11	Personality dimensions;
THYM	cis	rs1499972	0.941	rs1456182	chr3:117659680	C/T	cg07612923	chr3:117604196	NA	1.29	5.02	0.46	2.46e-6	Schizophrenia;
THYM	cis	rs912057	1.000	rs1294414	chr6:6740366	A/G	cg13809441	chr6:6737631	NA	0.43	4.81	0.44	5.61e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg15448220	chr1:150897856	SETDB1	0.87	7.14	0.59	1.9e-10	Blood protein levels;
THYM	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg01097406	chr16:89675127	NA	0.59	4.85	0.45	4.8e-6	Vitiligo;
THYM	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg24209194	chr3:40518798	ZNF619	0.57	4.61	0.43	1.28e-5	Renal cell carcinoma;
THYM	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg24209194	chr3:40518798	ZNF619	0.55	4.49	0.42	2.02e-5	Renal cell carcinoma;
THYM	cis	rs1971762	0.509	rs1247955	chr12:53964133	G/T	cg16917193	chr12:54089295	NA	-0.75	-6.9	-0.58	5.81e-10	Height;
THYM	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg11812906	chr14:75593930	NEK9	-0.87	-7.93	-0.63	4.14e-12	Height;
THYM	cis	rs6430585	0.536	rs60397494	chr2:136470219	C/T	cg23851026	chr2:136556271	LCT	0.67	5.8	0.51	8.5e-8	Corneal structure;
THYM	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.66e-11	Aortic root size;
THYM	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg17143192	chr8:8559678	CLDN23	-0.61	-4.8	-0.44	5.93e-6	Mood instability;
THYM	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg20295408	chr7:1910781	MAD1L1	-0.6	-4.78	-0.44	6.27e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg07532245	chr17:28927093	LRRC37B2	0.7	4.47	0.42	2.14e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg26384229	chr12:38710491	ALG10B	-0.9	-7.35	-0.6	6.77e-11	Morning vs. evening chronotype;
THYM	cis	rs4619206	1	rs4619206	chr12:1002857	T/C	cg26282236	chr12:1025755	RAD52	0.41	4.98	0.45	2.84e-6	Lung cancer in ever smokers;
THYM	cis	rs28595532	0.920	rs115986613	chr4:119752156	G/A	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs35892873	0.501	rs4299436	chr3:126096047	C/T	cg01955286	chr3:125475060	NA	-0.59	-4.46	-0.42	2.27e-5	Male-pattern baldness;
THYM	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg14779329	chr11:130786720	SNX19	0.55	5.83	0.51	7.58e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg02734326	chr4:10020555	SLC2A9	-0.61	-5.09	-0.46	1.8e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6942756	1.000	rs11769045	chr7:128895335	A/G	cg02491457	chr7:128862824	NA	-0.44	-4.53	-0.42	1.69e-5	White matter hyperintensity burden;
THYM	cis	rs11112613	0.713	rs10507192	chr12:105948247	A/G	cg03607813	chr12:105948248	NA	1.06	9.74	0.71	5.82e-16	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs2067615	0.579	rs10778510	chr12:107162965	A/G	cg15890332	chr12:107067104	RFX4	-0.49	-5.75	-0.51	1.1e-7	Heart rate;
THYM	cis	rs526231	0.511	rs1011453	chr5:102368027	C/T	cg23492399	chr5:102201601	PAM	-0.67	-5.09	-0.46	1.77e-6	Primary biliary cholangitis;
THYM	cis	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg18132916	chr6:79620363	NA	-0.55	-4.78	-0.44	6.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg09307838	chr4:120376055	NA	0.69	5.08	0.46	1.86e-6	Corneal astigmatism;
THYM	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.9	-0.45	3.86e-6	Monocyte count;
THYM	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	6.29	0.54	9.84e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs10504906	0.643	rs9297897	chr8:92420753	G/A	cg09373786	chr8:93156639	NA	1.29	4.52	0.42	1.76e-5	Fat distribution (HIV);
THYM	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg17294928	chr15:75287854	SCAMP5	-0.93	-7.89	-0.63	5.21e-12	Blood trace element (Zn levels);
THYM	cis	rs17407555	0.738	rs56402960	chr4:10086473	T/A	cg00071950	chr4:10020882	SLC2A9	-0.73	-5.39	-0.48	5.09e-7	Schizophrenia (age at onset);
THYM	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg14004847	chr7:1930337	MAD1L1	-0.71	-5.51	-0.49	3.02e-7	Schizophrenia;
THYM	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg08975724	chr8:8085496	FLJ10661	0.59	4.73	0.44	7.91e-6	Neuroticism;
THYM	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg00129232	chr17:37814104	STARD3	0.77	5.27	0.48	8.58e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg10505658	chr17:80084571	CCDC57	0.68	7.45	0.61	4.18e-11	Life satisfaction;
THYM	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg23281280	chr6:28129359	ZNF389	0.61	4.94	0.45	3.3e-6	Parkinson's disease;
THYM	trans	rs1997103	1.000	rs10279035	chr7:55412055	C/T	cg20935933	chr6:143382018	AIG1	0.86	6.91	0.58	5.41e-10	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs1345301	0.518	rs1558624	chr2:102862233	A/G	cg03938978	chr2:103052716	IL18RAP	-0.5	-4.68	-0.43	9.59e-6	Waist circumference;
THYM	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.82	-7.31	-0.6	8.42e-11	Monocyte percentage of white cells;
THYM	cis	rs7084921	0.521	rs12782269	chr10:101875210	T/C	cg11344164	chr10:101878520	NA	-0.58	-5.66	-0.5	1.61e-7	Bone mineral density;
THYM	trans	rs8002861	0.902	rs1445557	chr13:44464827	C/T	cg17145862	chr1:211918768	LPGAT1	1.03	11.49	0.76	1.13e-19	Leprosy;
THYM	cis	rs6032067	0.527	rs35828065	chr20:43732374	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.58	-6.58	-0.56	2.56e-9	Blood protein levels;
THYM	cis	rs1163251	0.837	rs517533	chr1:120229170	T/G	cg19096424	chr1:120255104	PHGDH	0.68	5.0	0.46	2.61e-6	Blood metabolite levels;
THYM	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-4.5	-0.42	1.91e-5	Mean corpuscular volume;
THYM	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg09455208	chr3:40491958	NA	0.46	4.59	0.43	1.35e-5	Renal cell carcinoma;
THYM	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg02574844	chr11:5959923	NA	-0.53	-4.67	-0.43	9.86e-6	DNA methylation (variation);
THYM	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg18252515	chr7:66147081	NA	-1.45	-8.82	-0.67	5.41e-14	Diabetic kidney disease;
THYM	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg17757837	chr7:157058334	UBE3C	0.65	5.24	0.47	9.83e-7	Body mass index;
THYM	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg03188948	chr7:1209495	NA	0.9	5.0	0.46	2.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6032067	0.538	rs62206431	chr20:43737073	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.6	-6.08	-0.53	2.48e-8	Blood protein levels;
THYM	cis	rs2299587	0.650	rs12548412	chr8:17796970	G/T	cg01800426	chr8:17659068	MTUS1	-0.67	-5.06	-0.46	2.07e-6	Economic and political preferences;
THYM	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg22508957	chr16:3507546	NAT15	-0.7	-7.05	-0.59	2.91e-10	Tuberculosis;
THYM	cis	rs288326	0.561	rs17265866	chr2:183822374	G/C	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03264133	chr6:25882463	NA	0.72	5.97	0.52	4.09e-8	Blood metabolite levels;
THYM	cis	rs593982	0.858	rs537385	chr11:65504900	G/A	cg08755490	chr11:65554678	OVOL1	1.36	8.73	0.67	8.51e-14	Atopic dermatitis;
THYM	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg04896959	chr15:78267971	NA	0.9	8.27	0.65	7.99e-13	Coronary artery disease or large artery stroke;
THYM	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	6.02	0.53	3.28e-8	Schizophrenia;
THYM	cis	rs7000551	0.751	rs1116084	chr8:22395309	C/T	cg12081754	chr8:22256438	SLC39A14	0.68	6.14	0.53	1.9e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs9649213	0.593	rs6465677	chr7:98003552	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4780401	0.587	rs9931332	chr16:11807517	G/C	cg01061890	chr16:11836724	TXNDC11	-0.66	-5.44	-0.49	4.13e-7	Rheumatoid arthritis;
THYM	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg13319975	chr6:146136371	FBXO30	-0.7	-5.88	-0.52	6.22e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2235573	0.653	rs3026670	chr22:38426774	T/C	cg19171272	chr22:38449367	NA	-0.53	-5.54	-0.49	2.67e-7	Glioblastoma;Glioma;
THYM	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg17143192	chr8:8559678	CLDN23	-0.62	-4.92	-0.45	3.63e-6	Mood instability;
THYM	cis	rs1524976	0.760	rs11706564	chr3:65443720	G/C	cg16238336	chr3:65465873	MAGI1	-0.99	-6.04	-0.53	2.98e-8	PR interval;
THYM	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	7.66	0.62	1.54e-11	Platelet count;
THYM	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg20503657	chr10:835505	NA	1.42	9.74	0.71	5.94e-16	Eosinophil percentage of granulocytes;
THYM	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg03526776	chr6:41159608	TREML2	-0.51	-4.85	-0.45	4.77e-6	Alzheimer's disease (late onset);
THYM	cis	rs35883536	1.000	rs2050472	chr1:101125560	T/C	cg06223162	chr1:101003688	GPR88	0.67	5.14	0.47	1.47e-6	Monocyte count;
THYM	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg00814883	chr7:100076585	TSC22D4	-0.95	-6.36	-0.55	6.93e-9	Platelet count;
THYM	cis	rs12802200	0.561	rs7940600	chr11:572105	A/G	cg00645579	chr11:617140	IRF7;MUPCDH	-0.4	-4.54	-0.42	1.65e-5	Systemic lupus erythematosus;
THYM	cis	rs6815814	0.861	rs7658651	chr4:38786002	A/C	cg06935464	chr4:38784597	TLR10	0.71	5.22	0.47	1.06e-6	Breast cancer;
THYM	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg13395646	chr4:1353034	KIAA1530	-0.58	-5.47	-0.49	3.64e-7	Obesity-related traits;
THYM	cis	rs1160297	0.609	rs10164801	chr2:53096014	C/T	cg07782112	chr2:53107842	NA	0.79	6.37	0.55	6.61e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs12681287	0.547	rs35871312	chr8:87543219	T/C	cg27223183	chr8:87520930	FAM82B	0.71	5.56	0.5	2.44e-7	Caudate activity during reward;
THYM	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg08999081	chr20:33150536	PIGU	0.57	4.95	0.45	3.25e-6	Height;
THYM	cis	rs7084402	0.935	rs10763556	chr10:60341398	A/G	cg09696939	chr10:60272079	BICC1	0.47	5.72	0.51	1.25e-7	Refractive error;
THYM	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg12386194	chr3:101231763	SENP7	0.69	5.13	0.47	1.52e-6	Colorectal cancer;
THYM	cis	rs11785693	0.862	rs11783719	chr8:4991311	G/T	cg26367366	chr8:4980734	NA	1.21	5.9	0.52	5.46e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs6089829	0.888	rs4809471	chr20:61684287	G/A	cg08045932	chr20:61659980	NA	0.93	10.18	0.72	6.94e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg16325326	chr1:53192061	ZYG11B	0.81	7.53	0.61	2.93e-11	Monocyte count;
THYM	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg12165864	chr7:66369176	NA	-0.67	-5.26	-0.47	8.99e-7	Aortic root size;
THYM	cis	rs9486719	1.000	rs2472886	chr6:96864876	C/T	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg22907277	chr7:1156413	C7orf50	-0.66	-5.99	-0.52	3.79e-8	Longevity;Endometriosis;
THYM	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs7267979	0.932	rs2260997	chr20:25256266	A/C	cg08601574	chr20:25228251	PYGB	-0.57	-4.69	-0.43	9.26e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg01616529	chr11:638424	DRD4	-0.77	-5.68	-0.5	1.47e-7	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs11997175	0.550	rs7459534	chr8:33836623	G/C	ch.8.33884649F	chr8:33765107	NA	0.67	5.17	0.47	1.29e-6	Body mass index;
THYM	cis	rs2708977	0.965	rs13019986	chr2:97243058	C/T	cg01950434	chr2:97203154	ARID5A	0.56	4.96	0.45	3.09e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg06453172	chr10:134556979	INPP5A	-0.69	-4.96	-0.45	3.04e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs3781426	1.000	rs60306160	chr10:126703761	C/T	cg04494136	chr10:126703576	CTBP2	-0.34	-4.59	-0.43	1.34e-5	Height;
THYM	cis	rs4638749	0.677	rs4676186	chr2:108842640	T/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg23428387	chr22:49814324	NA	-0.55	-5.65	-0.5	1.65e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg14196790	chr5:131705035	SLC22A5	0.5	4.47	0.42	2.15e-5	Blood metabolite levels;
THYM	cis	rs4663969	0.733	rs6741669	chr2:234653192	A/G	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.47	-0.42	2.13e-5	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg14675211	chr2:100938903	LONRF2	0.77	8.11	0.64	1.79e-12	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	5.37	0.48	5.69e-7	Obesity-related traits;
THYM	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg04731861	chr2:219085781	ARPC2	-0.46	-4.5	-0.42	1.95e-5	Colorectal cancer;
THYM	cis	rs11696845	0.666	rs6103849	chr20:43365687	C/T	cg09357268	chr20:43379437	KCNK15	-0.46	-4.7	-0.43	8.88e-6	Obesity-related traits;
THYM	cis	rs8114671	0.562	rs4911164	chr20:33479488	G/C	cg08999081	chr20:33150536	PIGU	0.63	5.21	0.47	1.09e-6	Height;
THYM	cis	rs2237457	0.525	rs2715112	chr7:50706122	G/T	cg08586669	chr7:50727761	GRB10	-0.3	-4.92	-0.45	3.61e-6	Schizophrenia (treatment resistant);
THYM	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg00684032	chr4:1343700	KIAA1530	0.54	4.67	0.43	9.81e-6	Obesity-related traits;
THYM	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg04287289	chr16:89883240	FANCA	-0.62	-5.83	-0.51	7.68e-8	Vitiligo;
THYM	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4280164	0.551	rs3212243	chr14:24810370	T/C	cg22990158	chr14:24802150	ADCY4	0.55	4.86	0.45	4.64e-6	Parent of origin effect on language impairment (paternal);
THYM	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg26384229	chr12:38710491	ALG10B	0.97	7.44	0.61	4.48e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg11266682	chr4:10021025	SLC2A9	0.73	11.88	0.77	1.74e-20	Bone mineral density;
THYM	cis	rs6500395	0.962	rs9923371	chr16:48628015	C/T	cg04672837	chr16:48644449	N4BP1	0.51	4.98	0.45	2.85e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.39	6.97	0.58	4.15e-10	Obesity-related traits;
THYM	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06481639	chr22:41940642	POLR3H	-0.81	-5.49	-0.49	3.4e-7	Vitiligo;
THYM	cis	rs9644630	0.841	rs4292704	chr8:19329303	G/C	cg01280390	chr8:19363452	CSGALNACT1	0.71	7.43	0.61	4.6e-11	Oropharynx cancer;
THYM	cis	rs7586879	0.593	rs10198356	chr2:25130592	A/G	cg01884057	chr2:25150051	NA	0.73	7.92	0.63	4.47e-12	Body mass index;
THYM	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg06917634	chr15:78832804	PSMA4	-0.68	-4.63	-0.43	1.14e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-4.74	-0.44	7.42e-6	Myopia;Myopia (pathological);
THYM	cis	rs7567389	0.677	rs72846002	chr2:128118147	G/A	cg06038358	chr2:128176007	PROC	0.43	4.53	0.42	1.7e-5	Self-rated health;
THYM	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg01324343	chr3:183735012	ABCC5	0.88	13.13	0.8	4.58e-23	Anterior chamber depth;
THYM	cis	rs7586673	0.866	rs747003	chr2:161916409	C/T	cg22496339	chr2:162101262	NA	-0.58	-4.63	-0.43	1.17e-5	Intelligence (multi-trait analysis);
THYM	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg12419862	chr22:24373484	LOC391322	0.81	6.65	0.56	1.87e-9	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs10208940	0.541	rs10182193	chr2:68829504	C/G	cg09157127	chr2:69201416	GKN1	0.89	4.71	0.43	8.61e-6	Urate levels in lean individuals;
THYM	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg00071950	chr4:10020882	SLC2A9	-0.66	-5.9	-0.52	5.59e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs644799	0.562	rs654345	chr11:95581865	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	5.54	0.49	2.68e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg01710189	chr8:22454888	PDLIM2	-0.53	-5.4	-0.48	4.93e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs778371	0.723	rs11689851	chr2:233567342	A/G	cg08000102	chr2:233561755	GIGYF2	0.8	7.05	0.59	2.91e-10	Schizophrenia;
THYM	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.69	-5.76	-0.51	1.04e-7	Calcium levels;
THYM	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	6.89	0.58	5.96e-10	Electrocardiographic conduction measures;
THYM	cis	rs2730245	0.527	rs924910	chr7:158672272	C/T	cg01219135	chr7:158766336	NA	0.56	4.49	0.42	2.01e-5	Height;
THYM	cis	rs2976388	1.000	rs2978982	chr8:143763490	T/C	cg06565975	chr8:143823917	SLURP1	-0.45	-5.23	-0.47	9.95e-7	Urinary tract infection frequency;
THYM	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7637230	0.541	rs2449493	chr3:101454514	A/T	cg12932813	chr3:101280753	RG9MTD1	1.4	7.14	0.59	1.87e-10	Psoriasis vulgaris;Psoriasis;
THYM	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg23758822	chr17:41437982	NA	1.23	13.11	0.8	4.87e-23	Menopause (age at onset);
THYM	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg22535103	chr8:58192502	C8orf71	-0.85	-4.77	-0.44	6.68e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg08916839	chr5:415575	AHRR	1.14	6.87	0.58	6.77e-10	Fat distribution (HIV);
THYM	cis	rs7432375	0.966	rs7618871	chr3:136400420	G/T	cg12473912	chr3:136751656	NA	-0.62	-5.22	-0.47	1.05e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs2505998	0.871	rs2505987	chr10:43560079	C/T	cg06632098	chr10:43605906	RET	-0.92	-7.71	-0.62	1.22e-11	Hirschsprung disease;
THYM	cis	rs7666738	0.819	rs13139560	chr4:99081188	C/T	cg24818145	chr4:99064322	C4orf37	0.87	6.32	0.54	8.63e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs2933343	0.729	rs813945	chr3:128660937	A/G	cg11901034	chr3:128598214	ACAD9	-0.69	-5.37	-0.48	5.65e-7	IgG glycosylation;
THYM	cis	rs4936891	0.542	rs10790620	chr11:123863989	C/T	cg22125253	chr11:123886957	OR10G4	-0.58	-5.13	-0.47	1.52e-6	Male fertility;
THYM	cis	rs7814319	0.966	rs6993518	chr8:97256341	T/A	cg20787634	chr8:97240163	UQCRB	-0.78	-9.49	-0.7	2.01e-15	Lung function (FVC);
THYM	cis	rs11148252	0.514	rs9526843	chr13:52730056	C/T	cg00495681	chr13:53174319	NA	0.7	6.0	0.52	3.5e-8	Lewy body disease;
THYM	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	7.48	0.61	3.64e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg03517284	chr6:25882590	NA	-0.66	-4.97	-0.45	3.02e-6	Height;
THYM	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg24692254	chr21:30365293	RNF160	-0.85	-7.06	-0.59	2.74e-10	Dental caries;
THYM	cis	rs11048434	0.518	rs1805707	chr12:9181706	T/C	cg26114124	chr12:9217669	LOC144571	0.51	4.5	0.42	1.94e-5	Sjögren's syndrome;
THYM	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg11663144	chr21:46675770	NA	-0.69	-9.52	-0.7	1.71e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg27588902	chr6:42928151	GNMT	-0.56	-5.77	-0.51	1.01e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.48	-0.42	2.05e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg20119798	chr7:94954144	PON1	-0.56	-5.03	-0.46	2.31e-6	Paraoxonase activity;
THYM	cis	rs11030122	0.702	rs1452047	chr11:3991648	A/C	cg18678763	chr11:4115507	RRM1	-0.44	-5.73	-0.51	1.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9486719	0.843	rs2499792	chr6:96846264	A/C	cg18709589	chr6:96969512	KIAA0776	0.75	4.49	0.42	2.02e-5	Migraine;Coronary artery disease;
THYM	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg27423445	chr12:12879764	APOLD1	0.53	4.52	0.42	1.78e-5	Systemic lupus erythematosus;
THYM	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs28785552	0.577	rs12463163	chr19:53212821	A/C	cg22067481	chr19:53234126	ZNF611	-0.87	-8.15	-0.64	1.43e-12	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg01699819	chr7:1052092	C7orf50	-0.81	-6.78	-0.57	1.03e-9	Bronchopulmonary dysplasia;
THYM	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg00640147	chr17:61958756	GH2	-0.43	-4.61	-0.43	1.24e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg18252515	chr7:66147081	NA	-0.69	-5.39	-0.48	5.11e-7	Aortic root size;
THYM	cis	rs6840360	0.809	rs6847303	chr4:152730221	G/A	cg22705602	chr4:152727874	NA	0.66	8.06	0.64	2.3e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26314531	chr2:26401878	FAM59B	-0.8	-5.31	-0.48	7.28e-7	Gut microbiome composition (summer);
THYM	cis	rs34368983	0.681	rs11013264	chr10:23321054	A/G	cg17782713	chr10:22613360	BMI1	0.88	4.47	0.42	2.14e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs807669	0.807	rs807431	chr22:19242361	G/A	cg02655711	chr22:19163373	SLC25A1	0.64	7.22	0.59	1.3e-10	Metabolite levels;
THYM	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg11266682	chr4:10021025	SLC2A9	0.67	8.59	0.66	1.69e-13	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg12011299	chr4:100065546	ADH4	0.75	7.3	0.6	8.58e-11	Alcohol dependence;
THYM	cis	rs2229238	0.911	rs58881140	chr1:154515193	C/T	cg21262032	chr1:154437693	IL6R	-0.64	-5.79	-0.51	8.9e-8	Coronary heart disease;
THYM	cis	rs4363385	0.588	rs6698361	chr1:153023184	T/G	cg13444842	chr1:152974279	SPRR3	-0.61	-4.9	-0.45	3.96e-6	Inflammatory skin disease;
THYM	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg00944433	chr1:107599041	PRMT6	0.4	5.19	0.47	1.18e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg10018233	chr7:150070692	REPIN1	0.38	5.41	0.48	4.8e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg09165964	chr15:75287851	SCAMP5	-1.06	-10.7	-0.74	5.29e-18	Blood trace element (Zn levels);
THYM	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg03676636	chr4:99064102	C4orf37	0.47	6.85	0.58	7.22e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2985684	0.901	rs57119148	chr14:50097226	T/C	cg02151108	chr14:50098012	C14orf104	-0.67	-5.36	-0.48	5.88e-7	Carotid intima media thickness;
THYM	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg26721908	chr21:47610096	LSS	0.72	4.69	0.43	9.27e-6	Testicular germ cell tumor;
THYM	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.44	5.41	0.49	4.66e-7	Monocyte percentage of white cells;
THYM	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg12373951	chr3:133503437	NA	0.57	6.22	0.54	1.35e-8	Iron status biomarkers;
THYM	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.21	8.69	0.67	1.03e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg10856724	chr12:34555212	NA	-0.95	-8.45	-0.66	3.39e-13	Bladder cancer;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg23417131	chr11:92866768	NA	-0.92	-6.9	-0.58	5.76e-10	Depressive symptoms;
THYM	cis	rs7104764	1.000	rs2272565	chr11:244414	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs10208940	0.614	rs13398850	chr2:68749526	T/C	cg09157127	chr2:69201416	GKN1	0.84	4.73	0.44	7.89e-6	Urate levels in lean individuals;
THYM	cis	rs929596	0.755	rs6742078	chr2:234672639	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.9	7.49	0.61	3.52e-11	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs11186	0.556	rs72906363	chr2:189962922	A/G	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	cis	rs600806	0.850	rs11102981	chr1:109967323	G/C	cg23032129	chr1:109941072	SORT1	-0.6	-5.12	-0.46	1.63e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2991971	1.000	rs606542	chr1:46013933	T/C	cg15605315	chr1:45957053	TESK2	0.65	5.13	0.47	1.52e-6	High light scatter reticulocyte count;
THYM	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg11845111	chr2:191398756	TMEM194B	-0.95	-7.05	-0.59	2.89e-10	Diastolic blood pressure;
THYM	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg06219351	chr7:158114137	PTPRN2	0.68	6.75	0.57	1.17e-9	Calcium levels;
THYM	cis	rs11048434	0.761	rs2377675	chr12:9124765	C/T	cg13575925	chr12:9217583	LOC144571	0.52	5.04	0.46	2.24e-6	Sjögren's syndrome;
THYM	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg19746536	chr19:49375674	PPP1R15A	0.81	4.59	0.43	1.34e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg23428387	chr22:49814324	NA	-0.59	-6.19	-0.54	1.55e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg11845111	chr2:191398756	TMEM194B	-0.99	-7.07	-0.59	2.6e-10	Diastolic blood pressure;
THYM	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.77	0.51	1.01e-7	Rheumatoid arthritis;
THYM	cis	rs7836436	0.606	rs7836028	chr8:121042360	G/T	cg05020510	chr8:120428057	NOV	0.92	4.8	0.44	5.94e-6	HIV-1 viral setpoint;
THYM	cis	rs8016982	0.674	rs1957549	chr14:81706179	G/A	cg21807262	chr14:81713016	NA	-0.56	-5.15	-0.47	1.39e-6	Schizophrenia;
THYM	cis	rs3096299	0.933	rs2930219	chr16:89492049	G/A	cg02187348	chr16:89574699	SPG7	0.77	6.2	0.54	1.45e-8	Multiple myeloma (IgH translocation);
THYM	cis	rs870825	0.616	rs35818632	chr4:185649661	G/T	cg04058563	chr4:185651563	MLF1IP	1.13	9.37	0.69	3.7e-15	Blood protein levels;
THYM	cis	rs611744	0.967	rs627604	chr8:109189819	C/G	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs2334880	0.678	rs34400718	chr16:71455852	G/A	cg06353428	chr16:71660113	MARVELD3	-0.84	-4.61	-0.43	1.26e-5	Malaria;
THYM	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg18252515	chr7:66147081	NA	0.63	4.54	0.42	1.65e-5	Aortic root size;
THYM	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg24209194	chr3:40518798	ZNF619	0.62	4.91	0.45	3.77e-6	Renal cell carcinoma;
THYM	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg20469991	chr17:27169893	C17orf63	-0.76	-4.78	-0.44	6.27e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg20290983	chr6:43655470	MRPS18A	1.44	15.94	0.85	1.35e-28	IgG glycosylation;
THYM	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg24818145	chr4:99064322	C4orf37	0.67	5.23	0.47	1.01e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1823778	0.609	rs1004623	chr18:67664150	A/T	cg12929678	chr18:67624393	CD226	1.3	4.63	0.43	1.14e-5	Mean platelet volume;
THYM	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg23815491	chr16:72088622	HP	-0.76	-6.58	-0.56	2.51e-9	Prostate cancer;
THYM	cis	rs9902453	0.791	rs2729451	chr17:28131334	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-4.73	-0.44	7.7e-6	Coffee consumption (cups per day);
THYM	cis	rs10492096	0.853	rs7300092	chr12:6607364	T/C	cg13857086	chr12:6580257	VAMP1	0.87	5.27	0.48	8.47e-7	Hip geometry;
THYM	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg19875535	chr5:140030758	IK	-0.58	-4.54	-0.42	1.63e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs1455213	0.544	rs2702559	chr4:15168985	C/A	cg12377275	chr4:15005593	CPEB2	0.54	4.49	0.42	2.02e-5	Parental longevity (mother's age at death);
THYM	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg15557168	chr22:42548783	NA	0.58	4.68	0.43	9.66e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg17426766	chr1:2046864	PRKCZ	-0.39	-4.59	-0.43	1.36e-5	Height;
THYM	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg18681998	chr4:17616180	MED28	0.86	7.7	0.62	1.31e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg23750338	chr8:142222470	SLC45A4	0.52	4.87	0.45	4.48e-6	Immature fraction of reticulocytes;
THYM	cis	rs4845570	1.000	rs11585294	chr1:151769887	A/C	cg18019451	chr1:151746047	TDRKH	-0.76	-4.52	-0.42	1.75e-5	Coronary artery disease;
THYM	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg15592062	chr6:167189543	RPS6KA2	0.59	6.16	0.53	1.73e-8	Crohn's disease;
THYM	cis	rs4746818	1.000	rs1506769	chr10:70959710	T/C	cg11621586	chr10:70884670	VPS26A	1.29	11.14	0.75	6.19e-19	Left atrial antero-posterior diameter;
THYM	cis	rs2797160	1.000	rs13328298	chr6:126016580	G/A	cg16306078	chr6:126000798	NA	0.54	5.56	0.5	2.5e-7	Endometrial cancer;
THYM	cis	rs7616559	0.849	rs7649798	chr3:156773367	A/G	cg15697575	chr3:156784781	NA	0.42	5.37	0.48	5.54e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg13609457	chr4:120235615	NA	0.64	5.49	0.49	3.35e-7	Corneal astigmatism;
THYM	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.69	6.36	0.55	7.15e-9	Personality dimensions;
THYM	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg00852783	chr1:26633632	UBXN11	-0.86	-8.81	-0.67	5.74e-14	Obesity-related traits;
THYM	trans	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg04546413	chr19:29218101	NA	1.09	9.4	0.69	3.15e-15	Methadone dose in opioid dependence;
THYM	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg06968155	chr5:131705112	SLC22A5	-0.59	-4.61	-0.43	1.23e-5	Blood metabolite levels;
THYM	cis	rs2154427	1.000	rs2833954	chr21:34162885	G/C	cg21871883	chr21:34145043	C21orf49;C21orf66	0.99	4.67	0.43	9.95e-6	Bilirubin levels;
THYM	cis	rs17030434	0.954	rs17030570	chr4:154755186	A/G	cg14289246	chr4:154710475	SFRP2	0.84	5.66	0.5	1.61e-7	Electrocardiographic conduction measures;
THYM	cis	rs4638749	0.677	rs2198471	chr2:108844069	C/T	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs13315871	0.929	rs6769216	chr3:58238877	C/T	cg12435725	chr3:58293450	RPP14	-0.53	-5.68	-0.5	1.47e-7	Cholesterol, total;
THYM	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg13010199	chr12:38710504	ALG10B	0.75	5.87	0.52	6.41e-8	Heart rate;
THYM	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg25208724	chr1:156163844	SLC25A44	1.17	13.26	0.81	2.43e-23	Testicular germ cell tumor;
THYM	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg08847533	chr14:75593920	NEK9	-0.99	-10.52	-0.73	1.27e-17	Height;
THYM	cis	rs4474465	0.915	rs12274873	chr11:78183015	C/G	cg19901956	chr11:77921274	USP35	-0.59	-4.49	-0.42	2.03e-5	Alzheimer's disease (survival time);
THYM	cis	rs13064411	0.696	rs7631082	chr3:113208913	C/G	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs10463554	1.000	rs6596529	chr5:102317042	C/T	cg23492399	chr5:102201601	PAM	-0.63	-4.94	-0.45	3.36e-6	Parkinson's disease;
THYM	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg20891558	chr2:74357851	NA	1.02	8.01	0.63	2.93e-12	Gestational age at birth (maternal effect);
THYM	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg06074448	chr4:187884817	NA	-1.02	-13.05	-0.8	6.55e-23	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg11764359	chr7:65958608	NA	0.81	6.73	0.57	1.28e-9	Aortic root size;
THYM	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg26924012	chr15:45694286	SPATA5L1	1.1	10.04	0.72	1.34e-16	Homoarginine levels;
THYM	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg12756686	chr19:29218302	NA	0.82	5.83	0.51	7.63e-8	Methadone dose in opioid dependence;
THYM	cis	rs3741151	0.773	rs17244616	chr11:73293112	C/T	cg12959048	chr11:73096162	RELT	-0.52	-4.58	-0.43	1.43e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	6.11	0.53	2.21e-8	Obesity-related traits;
THYM	cis	rs12579753	0.597	rs2244802	chr12:82153749	C/G	cg07988820	chr12:82153109	PPFIA2	0.62	4.48	0.42	2.1e-5	Resting heart rate;
THYM	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg21226059	chr5:178986404	RUFY1	-0.59	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	cis	rs3741151	0.773	rs73544767	chr11:73204619	C/T	cg17517138	chr11:73019481	ARHGEF17	0.91	5.2	0.47	1.14e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs4243830	1.000	rs12401795	chr1:6594773	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	1.13	6.32	0.54	8.56e-9	Body mass index;
THYM	cis	rs3126085	0.935	rs1858480	chr1:152301735	A/G	cg26020982	chr1:152196106	HRNR	-0.37	-5.09	-0.46	1.79e-6	Atopic dermatitis;
THYM	cis	rs10504073	0.647	rs28685207	chr8:50003484	A/G	cg00325661	chr8:49890786	NA	0.88	7.93	0.63	4.22e-12	Blood metabolite ratios;
THYM	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03576123	chr11:487126	PTDSS2	-1.06	-5.27	-0.48	8.49e-7	Body mass index;
THYM	cis	rs9361491	0.548	rs9350777	chr6:79464181	A/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7084402	1.000	rs12257983	chr10:60266555	A/C	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg06028605	chr16:24865363	SLC5A11	-0.67	-5.04	-0.46	2.24e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4690686	0.964	rs1840270	chr4:177246288	G/C	cg17059388	chr4:177262070	NA	0.39	5.62	0.5	1.94e-7	Essential tremor;
THYM	cis	rs478304	0.900	rs502468	chr11:65525119	T/G	cg17480646	chr11:65405466	SIPA1	0.7	6.27	0.54	1.07e-8	Acne (severe);
THYM	cis	rs11603020	0.950	rs3824988	chr11:57377968	C/T	cg19752551	chr11:57585705	CTNND1	0.6	5.02	0.46	2.42e-6	Blood protein levels;
THYM	cis	rs2862064	1.000	rs2902128	chr5:156421347	C/T	cg12943317	chr5:156479607	HAVCR1	-0.84	-5.0	-0.46	2.58e-6	Platelet count;
THYM	cis	rs9970807	0.901	rs2404715	chr1:57008778	C/T	cg11959316	chr1:57001742	PPAP2B	0.81	5.91	0.52	5.4e-8	Myocardial infarction;Coronary artery disease;
THYM	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg18305652	chr10:134549665	INPP5A	0.74	5.83	0.51	7.5e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs1593	0.734	rs4253407	chr4:187193308	A/T	cg09526685	chr4:187126073	CYP4V2	1.09	5.37	0.48	5.5e-7	Activated partial thromboplastin time;
THYM	cis	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.33e-5	Retinal vascular caliber;
THYM	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs11677370	0.603	rs11696104	chr2:3849512	C/G	cg17052675	chr2:3827356	NA	-0.71	-6.57	-0.56	2.7e-9	Type 2 diabetes;
THYM	cis	rs9486719	0.857	rs4486027	chr6:96911886	T/C	cg18709589	chr6:96969512	KIAA0776	-0.7	-4.76	-0.44	6.87e-6	Migraine;Coronary artery disease;
THYM	cis	rs747782	0.528	rs11039669	chr11:48328818	C/T	cg24672777	chr11:48374446	OR4C45	-1.17	-7.15	-0.59	1.78e-10	Intraocular pressure;
THYM	cis	rs8078723	0.668	rs3859191	chr17:38128714	G/A	cg17467752	chr17:38218738	THRA	0.73	5.48	0.49	3.47e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.87	-4.64	-0.43	1.11e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7027203	0.964	rs6479512	chr9:96556985	G/A	cg14598338	chr9:96623480	NA	0.47	4.94	0.45	3.3e-6	DNA methylation (variation);
THYM	cis	rs4664308	1.000	rs16844715	chr2:160915106	A/G	cg03641300	chr2:160917029	PLA2R1	0.7	6.47	0.55	4.19e-9	Idiopathic membranous nephropathy;
THYM	cis	rs7267979	0.714	rs6132825	chr20:25238309	A/T	cg08601574	chr20:25228251	PYGB	0.59	4.79	0.44	6.11e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12681287	0.640	rs7460650	chr8:87474085	A/G	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.39	-4.45	-0.42	2.37e-5	Depressive symptoms;
THYM	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs12496230	0.951	rs34954762	chr3:66853890	A/G	cg17646820	chr3:66848679	NA	0.95	6.02	0.53	3.2e-8	Type 2 diabetes;
THYM	cis	rs7084402	0.967	rs1427198	chr10:60274970	T/G	cg09696939	chr10:60272079	BICC1	0.5	5.75	0.51	1.07e-7	Refractive error;
THYM	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg00898013	chr13:113819073	PROZ	0.89	8.35	0.65	5.57e-13	Platelet distribution width;
THYM	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg10802521	chr3:52805072	NEK4	-0.71	-5.96	-0.52	4.22e-8	Bipolar disorder;
THYM	cis	rs6815814	0.950	rs11727978	chr4:38811051	T/A	cg02016764	chr4:38805732	TLR1	-0.5	-4.55	-0.42	1.56e-5	Breast cancer;
THYM	cis	rs6964587	0.541	rs6947170	chr7:91451471	A/G	cg22709100	chr7:91322751	NA	0.62	4.47	0.42	2.19e-5	Breast cancer;
THYM	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4499344	0.519	rs259226	chr19:33134965	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.93	6.54	0.56	3.01e-9	Mean platelet volume;
THYM	cis	rs3126085	0.932	rs11204949	chr1:152219797	A/C	cg10321714	chr1:152280068	FLG	-0.76	-5.65	-0.5	1.71e-7	Atopic dermatitis;
THYM	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs7513165	0.932	rs12040580	chr1:204148168	T/C	cg04791601	chr1:204159016	NA	0.38	4.74	0.44	7.64e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
THYM	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg10636054	chr15:40330586	SRP14	1.03	5.3	0.48	7.65e-7	Corneal curvature;
THYM	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg20891283	chr12:69753455	YEATS4	1.06	10.19	0.72	6.52e-17	Blood protein levels;
THYM	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg26516362	chr5:178986906	RUFY1	-0.4	-5.05	-0.46	2.16e-6	Lung cancer;
THYM	cis	rs477692	0.544	rs7894836	chr10:131442595	T/A	cg06209143	chr10:131448811	MGMT	-0.57	-4.49	-0.42	2.03e-5	Response to temozolomide;
THYM	cis	rs9677476	0.779	rs7569597	chr2:232102754	G/A	cg23338755	chr2:231921595	PSMD1	0.76	4.95	0.45	3.17e-6	Food antigen IgG levels;
THYM	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg00631329	chr6:26305371	NA	-0.72	-7.52	-0.61	3.12e-11	Educational attainment;
THYM	cis	rs72772090	0.539	rs72773947	chr5:96125533	T/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg02569458	chr12:86230093	RASSF9	-0.65	-5.5	-0.49	3.17e-7	Major depressive disorder;
THYM	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	5.28	0.48	8.21e-7	Hip circumference adjusted for BMI;
THYM	trans	rs8073060	0.586	rs225303	chr17:33922149	A/G	cg19694781	chr19:47549865	TMEM160	0.96	8.21	0.64	1.07e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs4481887	0.893	rs10888347	chr1:248448566	T/C	cg00666640	chr1:248458726	OR2T12	0.54	4.57	0.42	1.48e-5	Common traits (Other);
THYM	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg24531977	chr5:56204891	C5orf35	1.02	8.49	0.66	2.71e-13	Initial pursuit acceleration;
THYM	cis	rs713587	0.624	rs1550110	chr2:25124563	T/C	cg01884057	chr2:25150051	NA	0.73	7.85	0.63	6.12e-12	Body mass index in non-asthmatics;
THYM	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg02038168	chr22:39784481	NA	-0.65	-4.99	-0.46	2.76e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs2403083	0.723	rs4150897	chr8:86105268	G/C	cg13721134	chr8:86350390	CA3	0.49	4.83	0.44	5.2e-6	Plasma amyloid beta peptide concentrations (ABx-40);
THYM	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg08048268	chr3:133502702	NA	0.62	4.84	0.44	5.08e-6	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg03388025	chr16:89894329	SPIRE2	-0.58	-5.1	-0.46	1.75e-6	Vitiligo;
THYM	cis	rs988913	0.662	rs11754240	chr6:54921499	T/G	cg18532076	chr6:54711417	FAM83B	0.51	4.75	0.44	7.32e-6	Menarche (age at onset);
THYM	cis	rs7084402	0.967	rs1649041	chr10:60328782	T/C	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs11771526	0.901	rs62456036	chr7:32266182	C/T	cg13207630	chr7:32358064	NA	0.72	4.73	0.44	7.69e-6	Body mass index;
THYM	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs2777491	0.915	rs7178777	chr15:41634588	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.14	-12.89	-0.8	1.38e-22	Ulcerative colitis;
THYM	cis	rs612683	0.518	rs660945	chr1:100831830	A/T	cg06223162	chr1:101003688	GPR88	-0.68	-5.81	-0.51	8.21e-8	Breast cancer;
THYM	cis	rs988913	1.000	rs7753255	chr6:54832973	C/T	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.75e-6	Menarche (age at onset);
THYM	cis	rs34311866	0.808	rs3755958	chr4:963042	C/A	cg11017086	chr4:979022	SLC26A1	0.71	4.65	0.43	1.08e-5	Parkinson's disease;
THYM	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11771526	0.901	rs62457471	chr7:32306737	A/C	cg13207630	chr7:32358064	NA	0.79	4.94	0.45	3.3e-6	Body mass index;
THYM	cis	rs900145	0.859	rs4603287	chr11:13301335	T/G	cg13286116	chr11:13302098	ARNTL	-0.61	-4.58	-0.43	1.38e-5	Menarche (age at onset);
THYM	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg26441486	chr22:50317300	CRELD2	0.44	7.57	0.61	2.37e-11	Schizophrenia;
THYM	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs919433	0.680	rs3792159	chr2:198403697	A/G	cg00792783	chr2:198669748	PLCL1	-0.83	-5.73	-0.51	1.18e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4557020	1.000	rs7605221	chr2:54720903	C/T	cg11007406	chr2:54682859	SPTBN1	0.37	4.54	0.42	1.65e-5	Myopia (pathological);
THYM	cis	rs7917772	0.604	rs7908249	chr10:104373300	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg24692254	chr21:30365293	RNF160	1.03	10.08	0.72	1.14e-16	Dental caries;
THYM	cis	rs4589258	0.788	rs10765383	chr11:90482036	A/G	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.83	-0.44	5.15e-6	Intelligence (multi-trait analysis);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg19668597	chr12:46786365	NA	-1.0	-7.11	-0.59	2.15e-10	Depressive symptoms;
THYM	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2552220	1.000	rs2552219	chr8:5999117	C/G	cg23638070	chr8:6569043	AGPAT5	0.54	4.51	0.42	1.88e-5	Interleukin-8 levels;
THYM	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg07167872	chr1:205819463	PM20D1	0.59	5.07	0.46	2e-6	Menarche (age at onset);
THYM	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg03060546	chr3:49711283	APEH	0.76	6.18	0.54	1.57e-8	Resting heart rate;
THYM	cis	rs901683	0.850	rs113722818	chr10:46093208	G/A	cg18240400	chr10:46168597	ANUBL1	0.64	4.8	0.44	5.9e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs1568889	0.838	rs11030185	chr11:28041904	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	7.0	0.58	3.58e-10	Bipolar disorder;
THYM	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.94	-6.48	-0.55	4.15e-9	Schizophrenia;
THYM	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg03929089	chr4:120376271	NA	-0.98	-7.88	-0.63	5.32e-12	Coronary artery disease;
THYM	cis	rs2456568	0.802	rs8181578	chr11:93637442	G/A	cg17347335	chr11:93583973	C11orf90	-0.48	-4.58	-0.43	1.39e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg11764359	chr7:65958608	NA	-0.72	-5.49	-0.49	3.38e-7	Aortic root size;
THYM	cis	rs13102973	0.640	rs34037497	chr4:135833698	C/G	cg14419869	chr4:135874104	NA	0.7	5.72	0.51	1.26e-7	Subjective well-being;
THYM	cis	rs9522267	0.535	rs4644738	chr13:112235995	G/A	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs9992101	0.645	rs56367238	chr4:77342159	G/C	cg20311846	chr4:77356250	SHROOM3	-0.55	-6.02	-0.53	3.22e-8	Creatinine levels;
THYM	trans	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg19862616	chr7:65841803	NCRNA00174	1.06	11.85	0.77	2e-20	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs3126085	0.935	rs10888468	chr1:152181539	C/T	cg10321714	chr1:152280068	FLG	0.68	4.95	0.45	3.2e-6	Atopic dermatitis;
THYM	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg18681998	chr4:17616180	MED28	0.86	7.8	0.62	7.94e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg12963246	chr6:28129442	ZNF389	0.86	6.53	0.56	3.17e-9	Depression;
THYM	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	8.42	0.65	3.98e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2276498	0.574	rs2299698	chr20:52666010	A/G	cg23682609	chr20:52687365	BCAS1	0.67	5.13	0.47	1.53e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs55665837	1.000	rs10766182	chr11:14499536	A/G	cg19336497	chr11:14380999	RRAS2	-0.64	-7.04	-0.59	3e-10	Vitamin D levels;
THYM	trans	rs117004340	0.502	rs17217551	chr8:13260285	T/A	cg10588425	chr20:62492820	C20orf135	0.96	6.87	0.58	6.51e-10	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs8063160	0.935	rs113891247	chr16:90047757	T/A	cg07984980	chr16:89898383	SPIRE2	1.49	5.91	0.52	5.36e-8	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg12311346	chr5:56204834	C5orf35	0.62	4.71	0.43	8.56e-6	Initial pursuit acceleration;
THYM	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg04362960	chr10:104952993	NT5C2	-0.63	-5.48	-0.49	3.49e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg04267008	chr7:1944627	MAD1L1	-0.6	-4.95	-0.45	3.19e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	4.78	0.44	6.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg03433033	chr1:76189801	ACADM	-0.66	-6.32	-0.54	8.39e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7678296	0.649	rs4585313	chr4:37240236	C/T	cg06805348	chr4:37245195	KIAA1239	-1.03	-5.19	-0.47	1.19e-6	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs2050392	0.687	rs608693	chr10:30734971	G/A	cg13289132	chr10:30722225	MAP3K8	-0.59	-4.63	-0.43	1.15e-5	Inflammatory bowel disease;
THYM	cis	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg09085632	chr11:111637200	PPP2R1B	1.16	11.93	0.77	1.35e-20	Primary sclerosing cholangitis;
THYM	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg11764359	chr7:65958608	NA	-0.81	-6.42	-0.55	5.45e-9	Aortic root size;
THYM	cis	rs654128	0.590	rs339346	chr6:117218693	T/G	cg12892004	chr6:117198278	RFX6	-0.72	-5.66	-0.5	1.61e-7	Telomere length;
THYM	cis	rs988913	1.000	rs9367600	chr6:54837977	T/C	cg18532076	chr6:54711417	FAM83B	0.5	4.91	0.45	3.78e-6	Menarche (age at onset);
THYM	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs6424115	0.830	rs3003333	chr1:24194014	A/T	cg15997130	chr1:24165203	NA	-0.72	-6.37	-0.55	6.82e-9	Immature fraction of reticulocytes;
THYM	cis	rs314370	0.951	rs12666989	chr7:100486754	G/C	cg10426581	chr7:100472382	SRRT	1.13	8.97	0.68	2.57e-14	Resting heart rate;
THYM	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg12379764	chr21:47803548	PCNT	-0.79	-5.07	-0.46	1.95e-6	Testicular germ cell tumor;
THYM	cis	rs11771526	1.000	rs10231440	chr7:32299435	C/A	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs5985	0.659	rs3024322	chr6:6318073	G/C	cg16530177	chr6:6320324	F13A1	0.7	5.83	0.51	7.44e-8	End-stage coagulation;
THYM	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.8e-7	Monocyte count;
THYM	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg21100191	chr22:23484243	RTDR1	0.73	6.49	0.55	3.82e-9	Bone mineral density;
THYM	cis	rs4654899	1.000	rs6426669	chr1:21430584	C/A	cg01072550	chr1:21505969	NA	-0.74	-6.82	-0.57	8.58e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg25767906	chr1:53392781	SCP2	-0.56	-5.33	-0.48	6.59e-7	Monocyte count;
THYM	cis	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg02825527	chr7:2087843	MAD1L1	-0.7	-4.55	-0.42	1.58e-5	Bipolar disorder;
THYM	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg02869364	chr7:1081709	C7orf50	-0.61	-4.91	-0.45	3.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs34638657	0.702	rs35865749	chr16:82199677	T/C	cg09439754	chr16:82129088	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	cis	rs4499344	0.556	rs259228	chr19:33134635	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.9	6.17	0.54	1.64e-8	Mean platelet volume;
THYM	cis	rs614226	0.935	rs77955762	chr12:121009948	T/C	cg01236616	chr12:121019343	POP5	-1.28	-9.66	-0.7	8.63e-16	Type 1 diabetes nephropathy;
THYM	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg21984481	chr17:79567631	NPLOC4	-0.49	-5.34	-0.48	6.4e-7	Eye color traits;
THYM	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg23730037	chr7:158596552	ESYT2	-0.46	-4.86	-0.45	4.64e-6	Height;
THYM	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03517284	chr6:25882590	NA	-0.98	-8.83	-0.67	5.21e-14	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg10047753	chr17:41438598	NA	1.18	11.26	0.76	3.4e-19	Menopause (age at onset);
THYM	cis	rs2120019	0.608	rs4886414	chr15:75308650	C/T	cg17294928	chr15:75287854	SCAMP5	0.9	7.63	0.62	1.76e-11	Blood trace element (Zn levels);
THYM	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06634786	chr22:41940651	POLR3H	0.78	6.01	0.53	3.36e-8	Vitiligo;
THYM	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg09877947	chr5:131593287	PDLIM4	0.66	5.5	0.49	3.21e-7	Blood metabolite levels;
THYM	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg18200150	chr17:30822561	MYO1D	0.66	5.69	0.5	1.4e-7	Schizophrenia;
THYM	cis	rs3087591	0.960	rs4795593	chr17:29613600	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.68	-5.95	-0.52	4.46e-8	Hip circumference;
THYM	cis	rs11850957	0.502	rs17109380	chr14:25441067	T/C	cg26846476	chr14:24838993	NFATC4	0.93	4.77	0.44	6.66e-6	Subcutaneous adipose tissue;
THYM	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11890956	chr21:40555474	PSMG1	0.66	6.38	0.55	6.51e-9	Menarche (age at onset);
THYM	cis	rs7119	0.678	rs12914098	chr15:77823013	C/T	cg27398640	chr15:77910606	LINGO1	-0.56	-5.61	-0.5	2.03e-7	Type 2 diabetes;
THYM	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	6.54	0.56	3.02e-9	Schizophrenia;
THYM	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg09367891	chr1:107599246	PRMT6	-0.68	-4.63	-0.43	1.14e-5	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs4343996	0.967	rs4722674	chr7:3357188	C/G	cg21248987	chr7:3385318	SDK1	-0.41	-4.92	-0.45	3.64e-6	Motion sickness;
THYM	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03517284	chr6:25882590	NA	-0.99	-8.89	-0.67	3.85e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg09904177	chr6:26538194	HMGN4	0.55	4.63	0.43	1.18e-5	Intelligence (multi-trait analysis);
THYM	cis	rs59698941	0.943	rs4705980	chr5:132286084	T/C	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs2354432	0.607	rs11587707	chr1:146707186	T/C	cg25205988	chr1:146714368	CHD1L	-1.05	-5.61	-0.5	1.95e-7	Mitochondrial DNA levels;
THYM	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg14779329	chr11:130786720	SNX19	0.52	5.43	0.49	4.41e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-9.21	-0.69	7.91e-15	Chronic sinus infection;
THYM	cis	rs6547741	0.844	rs9941696	chr2:27920064	C/T	cg27432699	chr2:27873401	GPN1	-0.89	-8.13	-0.64	1.63e-12	Oral cavity cancer;
THYM	cis	rs2302612	0.528	rs3213734	chr2:102808683	G/A	cg13315345	chr2:102803985	IL1RL2	0.69	4.76	0.44	6.86e-6	Serum protein levels (sST2);
THYM	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03264133	chr6:25882463	NA	-0.73	-5.75	-0.51	1.09e-7	Intelligence (multi-trait analysis);
THYM	cis	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-6.09	-0.53	2.38e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg19346786	chr7:2764209	NA	-0.71	-5.97	-0.52	4.05e-8	Height;
THYM	cis	rs2658782	0.724	rs2658770	chr11:93261886	A/G	cg15737290	chr11:93063684	CCDC67	1.02	7.56	0.61	2.49e-11	Pulmonary function decline;
THYM	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg11189052	chr15:85197271	WDR73	-0.67	-5.56	-0.5	2.52e-7	P wave terminal force;
THYM	cis	rs3008870	0.755	rs3736905	chr1:67392614	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.76	6.27	0.54	1.06e-8	Lymphocyte percentage of white cells;
THYM	cis	rs6840360	0.607	rs1561918	chr4:152446832	T/A	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22496380	chr5:211416	CCDC127	-1.28	-8.11	-0.64	1.75e-12	Breast cancer;
THYM	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7831492	0.564	rs11787479	chr8:41613496	A/G	cg17182837	chr8:41585554	ANK1	-0.58	-5.11	-0.46	1.67e-6	Colorectal cancer;
THYM	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg21115891	chr6:26101465	NA	-0.61	-4.71	-0.43	8.51e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12142240	0.730	rs56030283	chr1:46823093	C/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg08999081	chr20:33150536	PIGU	0.67	5.88	0.52	6.08e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg19442545	chr10:75533431	FUT11	-0.58	-6.01	-0.53	3.37e-8	Inflammatory bowel disease;
THYM	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg06064525	chr11:970664	AP2A2	-0.34	-6.57	-0.56	2.62e-9	Alzheimer's disease (late onset);
THYM	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg00071950	chr4:10020882	SLC2A9	-0.75	-7.49	-0.61	3.45e-11	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg14829155	chr15:31115871	NA	0.52	4.88	0.45	4.27e-6	Huntington's disease progression;
THYM	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg14895029	chr7:2775587	GNA12	-0.68	-4.91	-0.45	3.78e-6	Height;
THYM	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg23583168	chr7:148888333	NA	-1.03	-13.26	-0.81	2.41e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs7107174	1.000	rs1485483	chr11:77930138	T/C	cg19901956	chr11:77921274	USP35	-0.84	-6.48	-0.55	4.03e-9	Testicular germ cell tumor;
THYM	cis	rs17270561	0.943	rs4478398	chr6:25694684	T/C	cg16482183	chr6:26056742	HIST1H1C	0.71	4.85	0.45	4.82e-6	Iron status biomarkers;
THYM	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg15557168	chr22:42548783	NA	-0.61	-4.75	-0.44	7.12e-6	Schizophrenia;
THYM	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg24675658	chr1:53192096	ZYG11B	-0.57	-4.69	-0.43	9.32e-6	Monocyte count;
THYM	cis	rs4363385	0.818	rs6661791	chr1:152994113	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.76	-0.44	6.94e-6	Inflammatory skin disease;
THYM	cis	rs4786125	0.573	rs7201500	chr16:6897659	A/G	cg03623568	chr16:6915990	A2BP1	-0.81	-7.02	-0.58	3.3e-10	Heart rate variability traits (SDNN);
THYM	cis	rs4499344	0.730	rs7247597	chr19:33102257	C/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.61	0.62	2.02e-11	Mean platelet volume;
THYM	cis	rs4866334	1.000	rs76883636	chr5:18488763	G/T	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs10887741	0.532	rs2038680	chr10:89415755	A/G	cg13926569	chr10:89418898	PAPSS2	-0.62	-5.87	-0.52	6.33e-8	Exercise (leisure time);
THYM	cis	rs11031096	0.621	rs12282967	chr11:4191477	A/T	cg18678763	chr11:4115507	RRM1	-0.42	-4.95	-0.45	3.17e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg23711669	chr6:146136114	FBXO30	0.99	10.16	0.72	7.58e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg15838173	chr10:75533400	FUT11	0.56	5.78	0.51	9.27e-8	Inflammatory bowel disease;
THYM	trans	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs4243830	1.000	rs11811007	chr1:6584657	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	1.11	6.34	0.55	7.69e-9	Body mass index;
THYM	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg26924012	chr15:45694286	SPATA5L1	0.62	4.51	0.42	1.84e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs262150	0.579	rs73167299	chr7:158784367	C/T	cg19418458	chr7:158789849	NA	0.65	4.79	0.44	6.07e-6	Facial morphology (factor 20);
THYM	cis	rs56309584	0.715	rs11651199	chr17:8142644	G/A	cg08322244	chr17:8066669	VAMP2	-0.59	-5.17	-0.47	1.29e-6	Initial pursuit acceleration;
THYM	cis	rs10899021	0.512	rs2186955	chr11:74375475	C/T	cg25880958	chr11:74394337	NA	0.63	5.94	0.52	4.59e-8	Response to metformin (IC50);
THYM	cis	rs2273669	0.667	rs11757168	chr6:109301091	A/G	cg17117243	chr6:109341365	SESN1	-0.86	-4.9	-0.45	3.88e-6	Prostate cancer;
THYM	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.66	5.88	0.52	6.13e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs950776	0.714	rs3743074	chr15:78909480	G/A	cg06917634	chr15:78832804	PSMA4	-0.79	-6.67	-0.56	1.73e-9	Sudden cardiac arrest;
THYM	cis	rs12310956	0.532	rs10844712	chr12:33961022	G/A	cg10856724	chr12:34555212	NA	-0.75	-6.8	-0.57	9.1e-10	Morning vs. evening chronotype;
THYM	cis	rs8180040	0.966	rs11914795	chr3:47557722	G/A	cg16586182	chr3:47516702	SCAP	-0.65	-5.49	-0.49	3.29e-7	Colorectal cancer;
THYM	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	5.54	0.49	2.69e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7412746	0.611	rs4319334	chr1:150766822	G/A	cg10589385	chr1:150898437	SETDB1	0.58	4.74	0.44	7.54e-6	Melanoma;
THYM	cis	rs593982	0.719	rs11606668	chr11:65472758	A/G	cg08755490	chr11:65554678	OVOL1	-1.15	-6.38	-0.55	6.55e-9	Atopic dermatitis;
THYM	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg26031613	chr14:104095156	KLC1	0.75	5.11	0.46	1.63e-6	Body mass index;
THYM	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg25072359	chr17:41440525	NA	0.66	4.63	0.43	1.17e-5	Menopause (age at onset);
THYM	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg03517284	chr6:25882590	NA	-0.67	-4.47	-0.42	2.14e-5	Height;
THYM	cis	rs34779708	0.897	rs11010131	chr10:35513316	A/C	cg03585969	chr10:35415529	CREM	0.63	4.48	0.42	2.09e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs1003719	0.680	rs767998	chr21:38525652	T/G	cg01329690	chr21:38580129	DSCR9	-0.37	-5.09	-0.46	1.83e-6	Eye color traits;
THYM	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg24874828	chr4:187887005	NA	-0.72	-7.22	-0.6	1.26e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg20007245	chr22:24372913	LOC391322	0.77	7.87	0.63	5.6e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs9378357	0.850	rs9391986	chr6:3290583	A/G	cg08754725	chr6:3293098	SLC22A23	0.94	4.99	0.46	2.76e-6	Obesity-related traits;
THYM	cis	rs4242434	0.927	rs10099846	chr8:22534178	C/T	cg14690197	chr8:22456421	C8orf58	-0.51	-4.53	-0.42	1.73e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2637266	1.000	rs12783273	chr10:78353221	T/C	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs7894051	1.000	rs7074435	chr10:135190570	G/T	cg02114346	chr10:135191542	PAOX	0.89	4.52	0.42	1.76e-5	Lifespan;
THYM	cis	rs4731207	0.596	rs2219953	chr7:124671915	A/C	cg05285228	chr7:124571219	POT1	-0.61	-4.58	-0.43	1.39e-5	Cutaneous malignant melanoma;
THYM	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg12599982	chr1:44399894	ARTN	-0.58	-5.04	-0.46	2.18e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2072732	0.861	rs12046233	chr1:2960608	A/G	cg08733933	chr1:2954429	NA	-0.65	-4.7	-0.43	8.67e-6	Plateletcrit;
THYM	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg23281280	chr6:28129359	ZNF389	-0.62	-5.15	-0.47	1.39e-6	Depression;
THYM	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28595532	0.920	rs115154263	chr4:119765307	G/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs9790314	1.000	rs336569	chr3:161072346	T/G	cg03342759	chr3:160939853	NMD3	-0.73	-6.54	-0.56	3.03e-9	Morning vs. evening chronotype;
THYM	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg04865290	chr3:52927548	TMEM110	-0.88	-4.75	-0.44	7.08e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg21658235	chr8:22456391	C8orf58	0.5	5.06	0.46	2.04e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7512552	0.803	rs2454286	chr1:150355538	G/A	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.68	5.07	0.46	1.95e-6	Tonsillectomy;
THYM	cis	rs1387259	0.929	rs2956703	chr12:48670294	C/T	cg21466736	chr12:48725269	NA	-0.53	-4.91	-0.45	3.78e-6	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs1823778	0.609	rs11660872	chr18:67686635	T/G	cg12929678	chr18:67624393	CD226	1.3	4.63	0.43	1.14e-5	Mean platelet volume;
THYM	cis	rs1005224	0.895	rs6574252	chr14:76141834	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.71	-5.8	-0.51	8.86e-8	Large artery stroke;
THYM	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1551570	0.766	rs55752217	chr19:10218434	C/T	cg16327482	chr19:10226339	EIF3G	0.39	5.44	0.49	4.22e-7	Narcolepsy;
THYM	trans	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg19862616	chr7:65841803	NCRNA00174	1.05	11.42	0.76	1.59e-19	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs10896135	0.526	rs484262	chr11:66399681	C/T	cg15964523	chr11:66469143	SPTBN2	0.81	6.64	0.56	1.92e-9	Bipolar disorder;
THYM	cis	rs11711311	0.712	rs10804510	chr3:113340700	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.55	-4.58	-0.42	1.44e-5	IgG glycosylation;
THYM	cis	rs7216064	0.532	rs3890640	chr17:66053028	C/T	cg12091567	chr17:66097778	LOC651250	0.94	7.63	0.62	1.84e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg06611532	chr13:114900021	NA	0.62	6.98	0.58	3.95e-10	Schizophrenia;
THYM	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg21926883	chr2:100939477	LONRF2	0.64	5.97	0.52	4.12e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg19761014	chr17:28927070	LRRC37B2	0.86	4.94	0.45	3.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7814319	0.933	rs13260865	chr8:97238472	A/T	cg20787634	chr8:97240163	UQCRB	-0.78	-9.51	-0.7	1.84e-15	Lung function (FVC);
THYM	trans	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs9972944	0.702	rs6416946	chr17:63763967	C/T	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	trans	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg10856724	chr12:34555212	NA	-0.91	-8.12	-0.64	1.72e-12	Bladder cancer;
THYM	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08564027	chr20:61660810	NA	-0.95	-9.99	-0.72	1.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs295140	0.967	rs4673906	chr2:201163812	G/T	cg04283868	chr2:201171347	SPATS2L	0.75	5.71	0.51	1.31e-7	QT interval;
THYM	cis	rs7814319	0.700	rs35290014	chr8:97263930	T/C	cg20787634	chr8:97240163	UQCRB	-0.74	-7.04	-0.59	3.03e-10	Lung function (FVC);
THYM	cis	rs4072705	0.615	rs7028021	chr9:127249022	A/G	cg13476313	chr9:127244764	NR5A1	0.39	6.03	0.53	3.08e-8	Menarche (age at onset);
THYM	cis	rs1568889	0.838	rs7131053	chr11:28143312	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs9807989	0.507	rs7584093	chr2:102997721	C/T	cg03938978	chr2:103052716	IL18RAP	0.73	9.33	0.69	4.55e-15	Asthma;
THYM	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg24060327	chr5:131705240	SLC22A5	-0.63	-4.69	-0.43	9.05e-6	Blood metabolite levels;
THYM	cis	rs12653946	0.846	rs10866528	chr5:1891821	A/G	cg22472608	chr5:1891194	NA	-0.71	-5.63	-0.5	1.81e-7	Prostate cancer;
THYM	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.97	7.98	0.63	3.37e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg14690197	chr8:22456421	C8orf58	0.54	4.91	0.45	3.79e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg11645453	chr3:52864694	ITIH4	0.29	4.46	0.42	2.23e-5	Schizophrenia;
THYM	cis	rs28595532	0.841	rs116452272	chr4:119770802	T/C	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs9522267	0.535	rs4773393	chr13:112229755	A/G	cg15979348	chr13:112237479	NA	-0.48	-4.46	-0.42	2.21e-5	Hepatitis;
THYM	cis	rs883565	0.655	rs6778963	chr3:39091812	T/G	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	5.0	0.46	2.59e-6	Handedness;
THYM	cis	rs951366	0.553	rs10900522	chr1:205684067	T/C	cg07157834	chr1:205819609	PM20D1	-0.61	-4.58	-0.43	1.42e-5	Menarche (age at onset);
THYM	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg14008862	chr17:28927542	LRRC37B2	-0.85	-4.47	-0.42	2.18e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg21475434	chr5:93447410	FAM172A	0.96	6.1	0.53	2.29e-8	Diabetic retinopathy;
THYM	cis	rs7772486	0.743	rs1292339	chr6:145967086	C/T	cg13319975	chr6:146136371	FBXO30	0.65	5.35	0.48	6.13e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.64	4.52	0.42	1.81e-5	Lung cancer in ever smokers;
THYM	cis	rs308403	0.608	rs309362	chr4:123658154	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.7	4.87	0.45	4.49e-6	Blood protein levels;
THYM	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg09307838	chr4:120376055	NA	0.7	5.27	0.48	8.48e-7	Corneal astigmatism;
THYM	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg13683864	chr3:40499215	RPL14	-0.87	-8.09	-0.64	1.97e-12	Renal cell carcinoma;
THYM	cis	rs612683	0.894	rs10875290	chr1:100853755	G/T	cg09408571	chr1:101003634	GPR88	0.43	4.55	0.42	1.6e-5	Breast cancer;
THYM	cis	rs2991971	1.000	rs518365	chr1:46010652	A/G	cg15605315	chr1:45957053	TESK2	0.76	6.45	0.55	4.73e-9	High light scatter reticulocyte count;
THYM	cis	rs10489202	1.000	rs17485889	chr1:168018840	G/T	cg24449463	chr1:168025552	DCAF6	-0.83	-6.51	-0.56	3.58e-9	Schizophrenia;
THYM	cis	rs4903604	0.581	rs41347855	chr14:78037909	C/T	cg18872420	chr14:78023429	SPTLC2	0.53	4.48	0.42	2.11e-5	Gut microbiome composition (winter);
THYM	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg10360139	chr7:1886902	MAD1L1	-0.59	-5.15	-0.47	1.4e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg00376283	chr12:123451042	ABCB9	0.72	4.94	0.45	3.36e-6	Neutrophil percentage of white cells;
THYM	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg15605315	chr1:45957053	TESK2	0.79	6.68	0.57	1.61e-9	High light scatter reticulocyte count;
THYM	cis	rs892961	0.867	rs1079354	chr17:75415713	C/T	cg11351908	chr17:75402473	SEPT9	0.58	5.66	0.5	1.62e-7	Airflow obstruction;
THYM	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg22920501	chr2:26401640	FAM59B	1.07	9.54	0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.58	4.97	0.45	2.98e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-5.91	-0.52	5.44e-8	Bone mineral density;
THYM	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg00310523	chr12:86230176	RASSF9	-0.54	-4.89	-0.45	4.08e-6	Major depressive disorder;
THYM	cis	rs986417	0.818	rs10142842	chr14:61085205	C/T	cg27398547	chr14:60952738	C14orf39	-0.94	-5.21	-0.47	1.07e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg19077165	chr18:44547161	KATNAL2	-0.51	-5.95	-0.52	4.48e-8	Personality dimensions;
THYM	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-13.87	-0.82	1.48e-24	Height;
THYM	cis	rs8077889	0.645	rs1230393	chr17:41842592	A/G	cg26893861	chr17:41843967	DUSP3	-1.18	-20.6	-0.9	8.25e-37	Triglycerides;
THYM	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.75	8.21	0.64	1.06e-12	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.39	0.6	5.63e-11	Obesity-related traits;
THYM	cis	rs7833986	0.501	rs2719255	chr8:57036658	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	6.68	0.57	1.58e-9	Height;
THYM	cis	rs7681440	0.538	rs2737015	chr4:90745283	T/C	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	trans	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg26043149	chr18:55253948	FECH	1.2	11.74	0.77	3.41e-20	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06634786	chr22:41940651	POLR3H	0.78	6.01	0.53	3.36e-8	Vitiligo;
THYM	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg05368731	chr17:41323189	NBR1	1.19	10.4	0.73	2.28e-17	Menopause (age at onset);
THYM	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg04111992	chr7:158790115	NA	-0.55	-4.94	-0.45	3.41e-6	Facial morphology (factor 20);
THYM	cis	rs526231	0.543	rs40092	chr5:102424213	A/G	cg23492399	chr5:102201601	PAM	-0.7	-5.18	-0.47	1.23e-6	Primary biliary cholangitis;
THYM	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-5.89	-0.52	5.93e-8	Total cholesterol levels;
THYM	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg12292205	chr6:26970375	C6orf41	0.53	4.54	0.42	1.63e-5	Schizophrenia;
THYM	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.75	-0.44	7.15e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6032067	0.777	rs62208385	chr20:43789823	A/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg16342193	chr10:102329863	NA	-0.54	-5.64	-0.5	1.77e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg26924012	chr15:45694286	SPATA5L1	0.96	7.5	0.61	3.34e-11	Homoarginine levels;
THYM	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11890956	chr21:40555474	PSMG1	0.99	8.4	0.65	4.29e-13	Cognitive function;
THYM	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03517284	chr6:25882590	NA	-0.77	-6.14	-0.53	1.87e-8	Blood metabolite levels;
THYM	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg03732007	chr1:2071316	PRKCZ	0.52	4.74	0.44	7.37e-6	Height;
THYM	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg11965913	chr1:205819406	PM20D1	0.91	9.68	0.7	8.07e-16	Menarche (age at onset);
THYM	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg19746536	chr19:49375674	PPP1R15A	0.81	4.59	0.43	1.34e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7584330	0.554	rs4420668	chr2:238444793	G/A	cg08992911	chr2:238395768	MLPH	0.71	4.69	0.43	9.14e-6	Prostate cancer;
THYM	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg10792982	chr14:105748885	BRF1	0.74	7.65	0.62	1.66e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4664293	0.631	rs13024749	chr2:160656117	T/G	cg08347373	chr2:160653686	CD302	0.52	4.45	0.42	2.34e-5	Monocyte percentage of white cells;
THYM	cis	rs17818399	0.547	rs12997164	chr2:46758746	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.69	4.76	0.44	6.92e-6	Height;
THYM	cis	rs4262150	0.883	rs12153071	chr5:152247852	C/A	cg06854687	chr5:151642065	NA	0.64	4.46	0.42	2.27e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs8044868	0.586	rs12917999	chr16:72089451	T/C	cg06353428	chr16:71660113	MARVELD3	0.59	4.5	0.42	1.89e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs6032067	0.852	rs2233882	chr20:43835683	T/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.81	-0.57	8.91e-10	Blood protein levels;
THYM	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg18252515	chr7:66147081	NA	-0.66	-4.91	-0.45	3.8e-6	Aortic root size;
THYM	cis	rs67072384	1.000	rs12289259	chr11:72446731	A/C	cg01380194	chr11:72452482	ARAP1	-0.89	-4.94	-0.45	3.4e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs3741151	0.881	rs12099129	chr11:73091318	T/G	cg12959048	chr11:73096162	RELT	-0.53	-5.13	-0.47	1.54e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2668423	0.502	rs7254913	chr19:1388320	A/G	cg02639931	chr19:1387894	NDUFS7	0.58	9.46	0.7	2.37e-15	Nonalcoholic fatty liver disease;
THYM	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg18825531	chr11:62321136	NA	-0.46	-5.32	-0.48	6.94e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs919433	0.680	rs788023	chr2:198283305	T/C	cg00792783	chr2:198669748	PLCL1	0.82	5.67	0.5	1.54e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.77	-7.27	-0.6	1.02e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg25358565	chr5:93447407	FAM172A	-1.36	-10.75	-0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg00647820	chr17:40259828	DHX58	-0.6	-4.53	-0.42	1.72e-5	Fibrinogen levels;
THYM	cis	rs11677370	0.574	rs10190477	chr2:3862738	A/G	cg17052675	chr2:3827356	NA	0.71	6.75	0.57	1.16e-9	Type 2 diabetes;
THYM	cis	rs6570726	0.791	rs436156	chr6:145874873	A/G	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs16866061	1.000	rs72974219	chr2:225423784	G/C	cg22455342	chr2:225449267	CUL3	0.67	4.84	0.44	4.98e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs9527	0.615	rs10883810	chr10:104727224	A/C	cg15744005	chr10:104629667	AS3MT	-0.61	-4.55	-0.42	1.61e-5	Arsenic metabolism;
THYM	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs1878931	0.582	rs4785933	chr16:3419741	T/A	cg00484396	chr16:3507460	NAT15	-0.48	-4.62	-0.43	1.2e-5	Body mass index (adult);
THYM	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg07021052	chr2:20871279	NA	0.61	5.45	0.49	4.01e-7	Abdominal aortic aneurysm;
THYM	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg07157834	chr1:205819609	PM20D1	-0.62	-4.77	-0.44	6.69e-6	Menarche (age at onset);
THYM	cis	rs9914988	0.576	rs11080075	chr17:27322441	A/C	cg26182037	chr17:27055700	NEK8	-0.92	-5.26	-0.48	8.83e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg05768032	chr16:30646687	NA	0.53	5.37	0.48	5.69e-7	Multiple myeloma;
THYM	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs67311347	0.544	rs60329764	chr3:40334621	C/T	cg13683864	chr3:40499215	RPL14	0.77	7.23	0.6	1.22e-10	Renal cell carcinoma;
THYM	cis	rs986417	1.000	rs10151958	chr14:60977275	T/C	cg27398547	chr14:60952738	C14orf39	1.13	6.34	0.55	7.62e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs4363385	0.509	rs11581802	chr1:152936164	G/A	cg13444842	chr1:152974279	SPRR3	-0.66	-4.72	-0.44	8.26e-6	Inflammatory skin disease;
THYM	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg22920501	chr2:26401640	FAM59B	-0.83	-7.3	-0.6	8.69e-11	Gut microbiome composition (summer);
THYM	cis	rs11048434	0.723	rs12820395	chr12:9137096	T/G	cg26114124	chr12:9217669	LOC144571	0.47	4.73	0.44	7.93e-6	Sjögren's syndrome;
THYM	cis	rs367615	0.660	rs10061221	chr5:108839038	C/T	cg17395555	chr5:108820864	NA	0.76	9.29	0.69	5.53e-15	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6546324	0.580	rs4410279	chr2:67850620	A/C	cg18237512	chr2:67827392	NA	-0.79	-4.75	-0.44	7.23e-6	Endometriosis;
THYM	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg24692254	chr21:30365293	RNF160	0.9	7.83	0.63	6.85e-12	Dental caries;
THYM	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg13695892	chr22:41940480	POLR3H	0.85	6.98	0.58	4.06e-10	Vitiligo;
THYM	cis	rs9677476	0.909	rs60240472	chr2:232131217	A/G	cg23338755	chr2:231921595	PSMD1	0.67	4.83	0.44	5.2e-6	Food antigen IgG levels;
THYM	cis	rs7172809	0.599	rs17471697	chr15:77762493	A/G	cg10437265	chr15:77819839	NA	0.5	4.57	0.42	1.47e-5	Glucose homeostasis traits;
THYM	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg20966754	chr17:47091339	IGF2BP1	-0.6	-7.59	-0.61	2.22e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs72627509	0.904	rs7687767	chr4:57824932	C/T	cg26694713	chr4:57773883	REST	-0.72	-4.56	-0.42	1.55e-5	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.78	-6.48	-0.55	4.12e-9	Lung cancer;
THYM	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg08508325	chr11:3079039	CARS	-0.52	-6.47	-0.55	4.17e-9	Longevity;
THYM	cis	rs9915657	0.870	rs12601701	chr17:70115358	G/A	cg09344028	chr17:70110421	NA	0.47	4.61	0.43	1.25e-5	Thyroid hormone levels;
THYM	cis	rs11756438	0.547	rs2798327	chr6:119005353	C/T	cg21191810	chr6:118973309	C6orf204	0.56	5.47	0.49	3.57e-7	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs2249625	0.508	rs60020363	chr6:72844706	C/T	cg27608224	chr6:72922399	RIMS1	-0.58	-4.9	-0.45	3.94e-6	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
THYM	cis	rs72627123	0.867	rs17094056	chr14:74398030	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	-1.11	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1933112	1.000	rs1040509	chr1:168500984	G/T	cg17186328	chr1:168545835	XCL1	-0.54	-4.58	-0.43	1.43e-5	Blood protein levels;
THYM	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-5.95	-0.52	4.48e-8	Chronic sinus infection;
THYM	cis	rs2046867	0.908	rs2322613	chr3:72819453	A/C	cg25664220	chr3:72788482	NA	-0.81	-6.15	-0.53	1.81e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs920590	0.684	rs57462676	chr8:19670848	G/C	cg01411142	chr8:19674711	INTS10	0.68	5.37	0.48	5.48e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1483890	1.000	rs900671	chr3:69406527	C/A	cg22125112	chr3:69402811	FRMD4B	0.48	6.32	0.54	8.53e-9	Resting heart rate;
THYM	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg21252483	chr19:49399788	TULP2	0.81	5.67	0.5	1.56e-7	Red cell distribution width;
THYM	cis	rs3020340	1.000	rs3020340	chr6:152043290	A/G	cg22157087	chr6:152012887	ESR1	0.45	4.55	0.42	1.61e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg08999081	chr20:33150536	PIGU	-0.78	-7.16	-0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.7	6.28	0.54	9.9e-9	Personality dimensions;
THYM	cis	rs7224737	1.000	rs8074708	chr17:40286354	A/G	cg00647820	chr17:40259828	DHX58	0.62	4.7	0.43	8.71e-6	Fibrinogen levels;
THYM	cis	rs2495707	0.624	rs2489008	chr10:102422934	C/T	cg07919443	chr10:102419409	NA	-0.65	-5.66	-0.5	1.63e-7	Body mass index;
THYM	cis	rs10463554	1.000	rs12656131	chr5:102325878	C/T	cg23492399	chr5:102201601	PAM	0.67	4.82	0.44	5.36e-6	Parkinson's disease;
THYM	cis	rs72627123	0.867	rs73303122	chr14:74486797	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.86	4.91	0.45	3.77e-6	Morning vs. evening chronotype;
THYM	cis	rs8031584	1.000	rs12906054	chr15:31292023	A/C	cg08704250	chr15:31115839	NA	-0.55	-6.07	-0.53	2.65e-8	Huntington's disease progression;
THYM	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg02753203	chr1:228287806	NA	-0.61	-5.28	-0.48	8.19e-7	Diastolic blood pressure;
THYM	cis	rs9814567	0.806	rs7648616	chr3:134318074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.09e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.88	5.64	0.5	1.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg04455712	chr21:45112962	RRP1B	0.49	4.48	0.42	2.07e-5	Mean corpuscular volume;
THYM	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg03806693	chr22:41940476	POLR3H	1.16	10.2	0.72	6.06e-17	Vitiligo;
THYM	cis	rs4595586	0.545	rs7976609	chr12:39394317	T/C	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg05335186	chr13:53173507	NA	-0.58	-7.53	-0.61	2.9100000000000002e-11	Lewy body disease;
THYM	cis	rs865483	0.860	rs860468	chr17:35793286	G/C	cg06716730	chr17:35851459	DUSP14	0.43	7.3	0.6	8.71e-11	Monocyte count;
THYM	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg02725872	chr8:58115012	NA	-0.83	-5.68	-0.5	1.5e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	9.75	0.71	5.57e-16	Platelet count;
THYM	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg09549813	chr16:4587862	C16orf5	-0.58	-6.54	-0.56	3.03e-9	Schizophrenia;
THYM	cis	rs524023	0.874	rs519090	chr11:64456240	G/C	cg19131476	chr11:64387923	NRXN2	-0.35	-4.89	-0.45	4.18e-6	Urate levels in obese individuals;
THYM	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.46	0.42	2.21e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs72828912	0.731	rs9393522	chr6:24066174	A/G	cg19882886	chr6:25043046	NA	-0.86	-4.47	-0.42	2.14e-5	Squamous cell lung carcinoma;
THYM	cis	rs6598163	0.517	rs12366296	chr12:132296824	C/G	cg04876069	chr12:132293656	NA	0.52	4.68	0.43	9.49e-6	Migraine;
THYM	cis	rs514406	0.893	rs6661115	chr1:53426148	G/A	cg24675658	chr1:53192096	ZYG11B	0.59	4.58	0.43	1.4e-5	Monocyte count;
THYM	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg24163568	chr5:669837	TPPP	-0.58	-5.41	-0.49	4.63e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs6840360	0.642	rs7682770	chr4:152390413	A/C	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9790314	1.000	rs336589	chr3:161080358	C/T	cg04691961	chr3:161091175	C3orf57	-0.6	-5.27	-0.48	8.6e-7	Morning vs. evening chronotype;
THYM	cis	rs9290065	0.519	rs7644586	chr3:160674133	T/C	cg03342759	chr3:160939853	NMD3	-0.58	-4.57	-0.42	1.44e-5	Kawasaki disease;
THYM	cis	rs2219968	1.000	rs12056614	chr8:78962648	A/T	cg00738934	chr8:78996279	NA	0.91	9.75	0.71	5.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs67460515	1.000	rs67460515	chr3:161068566	T/C	cg03342759	chr3:160939853	NMD3	-0.9	-7.93	-0.63	4.25e-12	Parkinson's disease;
THYM	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg25811766	chr13:21894605	NA	-0.77	-4.99	-0.46	2.77e-6	White matter hyperintensity burden;
THYM	cis	rs59112743	0.510	rs2205852	chr6:15561257	T/C	cg10111214	chr6:14815676	NA	0.74	4.84	0.44	5.08e-6	Multiple keratinocyte cancers;
THYM	cis	rs6980334	0.679	rs3816829	chr7:137792420	A/G	cg11874123	chr7:137028198	PTN	0.67	5.17	0.47	1.29e-6	Blood metabolite ratios;
THYM	cis	rs12367572	0.641	rs4285943	chr12:45404768	A/C	cg03114573	chr12:45410052	DBX2	0.51	4.7	0.43	8.77e-6	Gut microbiome composition (summer);
THYM	cis	rs3096299	0.900	rs4785666	chr16:89462771	C/G	cg10164272	chr16:89456328	ANKRD11	0.63	4.63	0.43	1.14e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs7487075	0.754	rs10880962	chr12:46773444	C/G	cg17501823	chr12:47219793	SLC38A4	0.55	5.52	0.49	2.97e-7	Itch intensity from mosquito bite;
THYM	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs9378357	0.850	rs9392473	chr6:3291236	C/T	cg11647493	chr6:4134485	PECI	-0.69	-4.77	-0.44	6.68e-6	Obesity-related traits;
THYM	cis	rs10924970	0.967	rs3845566	chr1:235449757	T/A	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg23131131	chr22:24373011	LOC391322	-0.88	-8.77	-0.67	6.89e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg03264133	chr6:25882463	NA	-1.09	-9.23	-0.69	7.17e-15	Intelligence (multi-trait analysis);
THYM	cis	rs4891159	0.548	rs690423	chr18:74117984	G/A	cg24786174	chr18:74118243	ZNF516	0.96	14.31	0.83	1.94e-25	Longevity;
THYM	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.47	-0.42	2.13e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg04025307	chr7:1156635	C7orf50	0.76	4.77	0.44	6.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06873352	chr17:61820015	STRADA	0.78	9.87	0.71	3.13e-16	Prudent dietary pattern;
THYM	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs11792861	0.525	rs2417975	chr9:111860185	A/C	cg05043794	chr9:111880884	C9orf5	-0.3	-4.47	-0.42	2.18e-5	Menarche (age at onset);
THYM	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg19024700	chr19:49340765	PLEKHA4;HSD17B14	0.72	4.54	0.42	1.65e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07167872	chr1:205819463	PM20D1	0.98	9.9	0.71	2.74e-16	Menarche (age at onset);
THYM	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.83	-6.92	-0.58	5.27e-10	Systemic lupus erythematosus;
THYM	cis	rs258322	0.606	rs164752	chr16:89722390	G/A	cg03809021	chr16:89831123	FANCA	-0.72	-4.55	-0.42	1.56e-5	Melanoma;Black vs. red hair color;
THYM	cis	rs73086581	1.000	rs113812453	chr20:3963193	T/C	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg00129232	chr17:37814104	STARD3	0.71	4.8	0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.66	5.22	0.47	1.07e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1551570	0.755	rs2290687	chr19:10229521	C/T	cg07543883	chr19:10213271	ANGPTL6	-0.48	-4.99	-0.46	2.73e-6	Narcolepsy;
THYM	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg03806693	chr22:41940476	POLR3H	0.96	7.95	0.63	3.85e-12	Vitiligo;
THYM	cis	rs2985684	1.000	rs2985684	chr14:50101682	C/G	cg02151108	chr14:50098012	C14orf104	-0.67	-5.33	-0.48	6.48e-7	Carotid intima media thickness;
THYM	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg17264618	chr3:40429014	ENTPD3	0.53	5.06	0.46	2.05e-6	Renal cell carcinoma;
THYM	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-11.19	-0.75	4.77e-19	Height;
THYM	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg02389323	chr16:88786976	FAM38A	1.03	6.2	0.54	1.48e-8	Plateletcrit;
THYM	cis	rs1878931	0.582	rs27239	chr16:3442140	T/C	cg00484396	chr16:3507460	NAT15	0.48	4.53	0.42	1.69e-5	Body mass index (adult);
THYM	cis	rs995000	0.931	rs11207983	chr1:63012107	C/T	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs2235573	0.673	rs5756894	chr22:38450136	C/A	cg19171272	chr22:38449367	NA	-0.55	-6.26	-0.54	1.12e-8	Glioblastoma;Glioma;
THYM	cis	rs67981189	0.896	rs1018977	chr14:71400653	G/T	cg15910301	chr14:71632612	NA	-0.5	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg19626725	chr5:178986131	RUFY1	0.33	5.22	0.47	1.03e-6	Lung cancer;
THYM	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.99	-4.9	-0.45	3.96e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.1	-0.53	2.33e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg25237894	chr2:233734115	C2orf82	-0.36	-5.11	-0.46	1.64e-6	Coronary artery disease;
THYM	cis	rs7100689	0.646	rs2050824	chr10:82123563	G/A	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs921968	0.541	rs7583449	chr2:219403022	A/C	cg02176678	chr2:219576539	TTLL4	-0.73	-7.24	-0.6	1.18e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg07930552	chr6:133119739	C6orf192	0.96	5.32	0.48	6.9e-7	Type 2 diabetes nephropathy;
THYM	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs4930776	0.778	rs96745	chr12:5774209	G/A	cg02086166	chr12:5775618	ANO2	0.6	6.13	0.53	2.02e-8	Plasma clusterin levels;
THYM	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg00300879	chr1:26503847	CNKSR1	0.43	5.74	0.51	1.15e-7	Height;
THYM	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	4.73	0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6987853	0.787	rs2974354	chr8:42413943	A/G	cg09913449	chr8:42400586	C8orf40	1.08	11.32	0.76	2.65e-19	Mean corpuscular hemoglobin concentration;
THYM	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs7507204	0.723	rs12610998	chr19:3413653	T/C	cg08380311	chr19:3435252	NFIC	0.93	7.6	0.62	2.03e-11	Height;
THYM	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg27034606	chr17:28928453	LRRC37B2	0.73	4.85	0.45	4.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg05025164	chr4:1340916	KIAA1530	-0.88	-6.98	-0.58	4.02e-10	Longevity;
THYM	trans	rs877282	0.898	rs2004478	chr10:770709	C/A	cg22713356	chr15:30763199	NA	1.26	10.07	0.72	1.17e-16	Uric acid levels;
THYM	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg15445000	chr17:37608096	MED1	-0.44	-5.19	-0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs888194	0.966	rs7313797	chr12:109896165	A/G	cg11367159	chr12:110044531	NA	0.49	4.53	0.42	1.71e-5	Neuroticism;
THYM	cis	rs2282930	0.512	rs3901371	chr7:50700936	C/T	cg08586669	chr7:50727761	GRB10	0.33	4.86	0.45	4.58e-6	Bone mineral density;
THYM	cis	rs67385638	0.962	rs2187608	chr11:5269931	G/C	cg12559170	chr11:5275217	HBG2	0.87	8.9	0.67	3.77e-14	Hemoglobin levels;
THYM	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg12311346	chr5:56204834	C5orf35	0.6	4.65	0.43	1.09e-5	Initial pursuit acceleration;
THYM	cis	rs7553864	0.667	rs10873820	chr1:87605973	C/G	cg17420885	chr1:87600446	LOC339524	0.84	7.64	0.62	1.68e-11	Smoking behavior;
THYM	cis	rs6138458	1.000	rs1977540	chr20:24900290	G/T	cg06937882	chr20:24974362	C20orf3	0.47	4.54	0.42	1.66e-5	Blood protein levels;
THYM	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg11279151	chr3:101281821	RG9MTD1	0.67	4.9	0.45	3.87e-6	Colorectal cancer;
THYM	cis	rs6840360	0.550	rs4696269	chr4:152481704	T/A	cg22705602	chr4:152727874	NA	-0.77	-8.05	-0.64	2.4e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4242434	0.672	rs3758041	chr8:22486987	A/G	cg21658235	chr8:22456391	C8orf58	0.45	4.57	0.42	1.48e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs921968	0.612	rs2384950	chr2:219499719	T/C	cg02176678	chr2:219576539	TTLL4	0.63	6.02	0.53	3.27e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs236907	0.859	rs2294718	chr1:171750854	C/G	cg20598894	chr1:171756153	METTL13	-0.73	-5.28	-0.48	8.25e-7	Mean platelet volume;
THYM	cis	rs6687430	0.512	rs11121587	chr1:10618109	A/G	cg20482658	chr1:10539492	PEX14	0.48	6.06	0.53	2.73e-8	Hand grip strength;
THYM	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg26597838	chr10:835615	NA	1.23	8.88	0.67	4.1e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs7100689	0.646	rs1934696	chr10:82124966	T/C	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg04455712	chr21:45112962	RRP1B	0.57	5.24	0.47	9.84e-7	Mean corpuscular volume;
THYM	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg06808227	chr14:105710500	BRF1	-1.02	-8.82	-0.67	5.58e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs7843479	0.601	rs11780532	chr8:21838670	T/A	cg17168535	chr8:21777572	XPO7	0.83	7.55	0.61	2.67e-11	Mean corpuscular volume;
THYM	trans	rs4596713	0.538	rs4592105	chr9:71754305	T/G	cg16512924	chr15:28394682	HERC2	0.82	7.06	0.59	2.74e-10	Headache;
THYM	cis	rs208520	0.742	rs208454	chr6:66907783	T/C	cg07460842	chr6:66804631	NA	-0.81	-4.98	-0.46	2.79e-6	Exhaled nitric oxide output;
THYM	cis	rs6430585	0.583	rs2304371	chr2:136561557	A/G	cg04750100	chr2:136595281	LCT	0.47	4.75	0.44	7.17e-6	Corneal structure;
THYM	cis	rs1018836	0.923	rs756569	chr8:91610957	G/A	cg16814680	chr8:91681699	NA	-0.88	-7.68	-0.62	1.44e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4372836	0.505	rs6710082	chr2:28989977	A/C	cg09522027	chr2:28974177	PPP1CB	-0.62	-4.79	-0.44	6.18e-6	Body mass index;
THYM	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg07424592	chr7:64974309	NA	-1.04	-5.32	-0.48	6.9e-7	Diabetic kidney disease;
THYM	cis	rs4417704	0.551	rs4675789	chr2:241875481	A/G	cg15164180	chr2:241846931	NA	0.36	4.62	0.43	1.22e-5	Joint mobility (Beighton score);
THYM	cis	rs2455799	0.553	rs12495958	chr3:15941439	G/T	cg16303742	chr3:15540471	COLQ	-0.52	-5.35	-0.48	6.19e-7	Mean platelet volume;
THYM	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg12310025	chr6:25882481	NA	-1.19	-12.62	-0.79	4.99e-22	Urate levels;
THYM	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg03806693	chr22:41940476	POLR3H	1.25	11.31	0.76	2.71e-19	Vitiligo;
THYM	cis	rs854765	0.663	rs3744113	chr17:17748645	T/C	cg16928487	chr17:17741425	SREBF1	0.55	5.21	0.47	1.12e-6	Total body bone mineral density;
THYM	cis	rs2916260	0.800	rs78379039	chr6:40390831	T/A	cg08415973	chr6:40346114	TDRG1	0.75	4.71	0.43	8.6e-6	Incident coronary heart disease;
THYM	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg17264618	chr3:40429014	ENTPD3	0.52	4.95	0.45	3.22e-6	Renal cell carcinoma;
THYM	cis	rs7246657	0.943	rs7246993	chr19:37890154	C/T	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs7078219	1.000	rs7078219	chr10:101274365	A/G	cg07044859	chr10:101282883	NA	0.47	5.14	0.47	1.45e-6	Dental caries;
THYM	cis	rs9486719	0.947	rs9386648	chr6:97035656	T/C	cg18709589	chr6:96969512	KIAA0776	-0.67	-4.64	-0.43	1.1e-5	Migraine;Coronary artery disease;
THYM	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg22681709	chr2:178499509	PDE11A	-0.55	-5.61	-0.5	2.01e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg08968635	chr6:28129556	ZNF389	-0.69	-5.59	-0.5	2.13e-7	Depression;
THYM	cis	rs2963155	0.518	rs10515522	chr5:142758394	A/G	cg17617527	chr5:142782415	NR3C1	1.15	4.94	0.45	3.32e-6	Breast cancer;
THYM	cis	rs4951011	0.938	rs4951008	chr1:203763707	C/T	cg24343524	chr1:203763352	ZC3H11A	0.71	6.38	0.55	6.4e-9	Breast cancer;
THYM	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg08847533	chr14:75593920	NEK9	-0.93	-10.67	-0.74	6.31e-18	Height;
THYM	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.97	-7.62	-0.62	1.88e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	8.87	0.67	4.33e-14	Chronic sinus infection;
THYM	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg17888033	chr8:143858414	LYNX1	-0.46	-5.26	-0.47	8.94e-7	Urinary tract infection frequency;
THYM	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	4.97	0.45	3e-6	Height;
THYM	cis	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg08133631	chr1:26527909	CATSPER4	-0.55	-4.47	-0.42	2.17e-5	Obesity-related traits;
THYM	cis	rs941408	1.000	rs1736182	chr19:2798686	T/G	cg17333051	chr19:2783644	SGTA	0.57	5.17	0.47	1.27e-6	Total cholesterol levels;
THYM	cis	rs989128	0.600	rs9913677	chr17:48628581	T/A	cg16068336	chr17:48637367	CACNA1G	-0.59	-4.51	-0.42	1.82e-5	Type 2 diabetes;
THYM	cis	rs2811415	0.628	rs13067034	chr3:127750310	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs2075230	0.705	rs1641542	chr17:7544272	T/C	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	-0.31	-4.51	-0.42	1.82e-5	Hormone measurements;
THYM	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg13695892	chr22:41940480	POLR3H	-0.91	-7.25	-0.6	1.09e-10	Vitiligo;
THYM	cis	rs7582180	0.677	rs2067783	chr2:100877370	T/C	cg14675211	chr2:100938903	LONRF2	0.67	6.21	0.54	1.37e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7833986	0.501	rs72653990	chr8:57037115	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	6.68	0.57	1.58e-9	Height;
THYM	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg23682913	chr1:2080710	PRKCZ	0.58	4.6	0.43	1.31e-5	Height;
THYM	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.42	0.55	5.28e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg03929089	chr4:120376271	NA	1.03	8.74	0.67	8.32e-14	Coronary artery disease;
THYM	cis	rs3820068	0.603	rs7536654	chr1:15989141	C/G	cg13390004	chr1:15929781	NA	0.63	4.87	0.45	4.53e-6	Systolic blood pressure;
THYM	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg06618935	chr21:46677482	NA	-0.98	-9.58	-0.7	1.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg24818145	chr4:99064322	C4orf37	0.76	6.09	0.53	2.35e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1113500	0.933	rs1414674	chr1:108625947	A/G	cg06207961	chr1:108661230	NA	0.66	5.18	0.47	1.24e-6	Growth-regulated protein alpha levels;
THYM	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-4.81	-0.44	5.55e-6	Chronic sinus infection;
THYM	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg22875332	chr1:76189707	ACADM	0.8	7.35	0.6	6.86e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.27	4.47	0.42	2.16e-5	Obesity-related traits;
THYM	cis	rs2734839	0.964	rs2587548	chr11:113292212	G/C	cg14159747	chr11:113255604	NA	0.32	6.41	0.55	5.69e-9	Information processing speed;
THYM	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg09549813	chr16:4587862	C16orf5	-0.59	-6.65	-0.56	1.84e-9	Schizophrenia;
THYM	cis	rs4731207	0.596	rs6466987	chr7:124677731	C/A	cg05285228	chr7:124571219	POT1	-0.63	-4.74	-0.44	7.37e-6	Cutaneous malignant melanoma;
THYM	cis	rs7107174	1.000	rs10899468	chr11:78016650	C/T	cg02023728	chr11:77925099	USP35	0.67	5.86	0.52	6.61e-8	Testicular germ cell tumor;
THYM	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	6.93	0.58	5.11e-10	Smoking behavior;
THYM	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs17708984	0.562	rs17641735	chr19:16190912	G/A	cg13618979	chr19:16186840	TPM4	0.35	4.65	0.43	1.08e-5	Platelet count;Platelet distribution width;
THYM	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg17063962	chr7:91808500	NA	-1.13	-12.74	-0.79	2.8e-22	Breast cancer;
THYM	cis	rs80319144	0.951	rs11684127	chr2:159190841	G/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.6	4.79	0.44	6.06e-6	Restless legs syndrome;
THYM	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.86	-0.45	4.62e-6	Eye color traits;
THYM	cis	rs7614311	0.906	rs832198	chr3:63870352	T/G	cg22134162	chr3:63841271	THOC7	-0.41	-5.14	-0.47	1.48e-6	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs11710567	0.509	rs13070936	chr3:57721147	G/T	cg24033633	chr3:57945695	NA	0.41	4.69	0.43	9.32e-6	Granulocyte percentage of myeloid white cells;
THYM	cis	rs4281086	0.603	rs6601475	chr8:10354972	A/G	cg02525722	chr8:10404760	NA	0.54	4.54	0.42	1.68e-5	Obesity-related traits;
THYM	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg00631329	chr6:26305371	NA	-0.72	-7.52	-0.61	3.12e-11	Educational attainment;
THYM	cis	rs6840360	0.593	rs6847844	chr4:152693246	C/T	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs1729951	0.575	rs168635	chr3:136699078	A/G	cg12473912	chr3:136751656	NA	0.63	5.15	0.47	1.4e-6	Neuroticism;
THYM	cis	rs12472274	0.941	rs36066920	chr2:239074480	T/G	cg17459225	chr2:239074497	NA	0.77	5.45	0.49	3.99e-7	Phospholipid levels (plasma);
THYM	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg24250549	chr1:154909240	PMVK	0.69	5.08	0.46	1.87e-6	Prostate cancer;
THYM	cis	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs11645898	0.687	rs56129242	chr16:72098260	C/G	cg03805757	chr16:71968109	PKD1L3	-0.6	-4.57	-0.42	1.49e-5	Blood protein levels;
THYM	cis	rs3750965	1.000	rs61881024	chr11:68837794	A/G	cg01403660	chr11:68851641	TPCN2	0.74	5.89	0.52	5.83e-8	Hair color;
THYM	cis	rs4824093	0.610	rs73441745	chr22:50237606	G/A	cg26441486	chr22:50317300	CRELD2	0.46	4.59	0.43	1.38e-5	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs7980799	0.682	rs4931719	chr12:33602986	G/A	cg06521331	chr12:34319734	NA	0.67	4.55	0.42	1.59e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs354225	0.544	rs10169954	chr2:54808117	C/G	cg23486701	chr2:54789491	SPTBN1	0.36	4.96	0.45	3.11e-6	Schizophrenia;
THYM	cis	rs1371867	0.846	rs1660338	chr8:101242757	C/G	cg06636551	chr8:101224915	SPAG1	-0.63	-6.19	-0.54	1.49e-8	Atrioventricular conduction;
THYM	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg03433033	chr1:76189801	ACADM	0.77	10.11	0.72	9.77e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg00645579	chr11:617140	IRF7;MUPCDH	-0.53	-6.33	-0.54	7.97e-9	Systemic lupus erythematosus;
THYM	trans	rs75518195	0.543	rs17687811	chr4:64671810	G/A	cg14706739	chr8:21916355	EPB49	0.75	7.37	0.6	6.34e-11	Triptolide cytotoxicity;
THYM	cis	rs11771526	0.892	rs62457540	chr7:32372199	A/G	cg13207630	chr7:32358064	NA	1.06	6.2	0.54	1.44e-8	Body mass index;
THYM	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg08048268	chr3:133502702	NA	-0.66	-5.59	-0.5	2.13e-7	Iron status biomarkers;
THYM	cis	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg07460842	chr6:66804631	NA	-1.14	-13.96	-0.82	9.54e-25	Exhaled nitric oxide output;
THYM	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg09222892	chr1:25734099	RHCE	0.58	4.48	0.42	2.1e-5	Erythrocyte sedimentation rate;
THYM	cis	rs11723261	0.582	rs11248006	chr4:166703	G/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.87	5.76	0.51	1.05e-7	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs4863692	0.547	rs795988	chr4:140747153	A/G	cg15010390	chr4:140216957	NDUFC1	0.69	5.48	0.49	3.53e-7	Educational attainment (years of education);
THYM	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.2e-16	Bone mineral density;
THYM	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.55	4.49	0.42	2e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs3892630	0.588	rs12610342	chr19:33250690	C/T	cg22928329	chr19:33183273	NUDT19	-0.67	-5.24	-0.47	9.74e-7	Red blood cell traits;
THYM	cis	rs7224737	1.000	rs739636	chr17:40281063	T/G	cg08577293	chr17:40253614	DHX58	-0.55	-4.49	-0.42	1.99e-5	Fibrinogen levels;
THYM	cis	rs4731207	0.689	rs2054585	chr7:124552447	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs1823778	0.609	rs12608079	chr18:67651050	C/G	cg13164537	chr18:67624071	CD226	1.11	4.94	0.45	3.28e-6	Mean platelet volume;
THYM	cis	rs665401	0.640	rs339312	chr6:117178688	A/G	cg20376953	chr6:117187980	NA	0.61	4.89	0.45	4.05e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg05717871	chr11:638507	DRD4	-0.69	-6.03	-0.53	3.1e-8	Systemic lupus erythematosus;
THYM	cis	rs665401	1.000	rs662657	chr6:117258200	A/G	cg20376953	chr6:117187980	NA	0.55	4.49	0.42	1.99e-5	Neutrophil percentage of granulocytes;
THYM	cis	rs10100465	0.737	rs218017	chr8:118706776	G/T	cg09430518	chr8:118662568	NA	0.3	4.74	0.44	7.53e-6	Leprosy;
THYM	cis	rs761746	0.960	rs5998035	chr22:31939612	G/A	cg01338084	chr22:32026380	PISD	0.53	4.54	0.42	1.65e-5	Intelligence;
THYM	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg03213289	chr20:61660250	NA	0.91	9.46	0.7	2.34e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg00083206	chr6:110721305	DDO	0.49	5.6	0.5	2.11e-7	Platelet distribution width;
THYM	cis	rs834811	0.831	rs834810	chr7:135879825	T/C	cg01726295	chr7:135938950	NA	0.63	5.34	0.48	6.28e-7	Post-traumatic stress disorder;
THYM	cis	rs4731207	0.596	rs1481331	chr7:124577325	C/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg02353165	chr6:42928485	GNMT	0.86	7.87	0.63	5.67e-12	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg10518543	chr12:38710700	ALG10B	-0.57	-4.54	-0.42	1.67e-5	Morning vs. evening chronotype;
THYM	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs3924048	0.559	rs4075304	chr1:12626803	C/T	cg00291366	chr1:12616550	NA	0.31	4.83	0.44	5.23e-6	Optic cup area;
THYM	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03264133	chr6:25882463	NA	-0.9	-7.5	-0.61	3.44e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.14	-0.47	1.49e-6	Total cholesterol levels;
THYM	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg09263875	chr16:632152	PIGQ	0.73	5.95	0.52	4.44e-8	Height;
THYM	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg26384229	chr12:38710491	ALG10B	0.95	7.55	0.61	2.7e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9527	0.590	rs2148198	chr10:104915310	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	4.57	0.42	1.45e-5	Arsenic metabolism;
THYM	cis	rs612683	0.658	rs12407689	chr1:100999585	C/G	cg06223162	chr1:101003688	GPR88	0.86	7.85	0.63	6.29e-12	Breast cancer;
THYM	cis	rs28374715	0.662	rs513280	chr15:41482800	T/C	cg18705301	chr15:41695430	NDUFAF1	1.04	8.69	0.67	1.05e-13	Ulcerative colitis;
THYM	cis	rs684232	0.666	rs838372	chr17:566428	C/T	cg15660573	chr17:549704	VPS53	-0.88	-8.37	-0.65	4.88e-13	Prostate cancer;
THYM	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg18252515	chr7:66147081	NA	0.64	4.83	0.44	5.14e-6	Aortic root size;
THYM	cis	rs7582403	0.844	rs7569629	chr2:148870703	A/C	cg23727674	chr2:148602993	ACVR2A	-0.59	-4.86	-0.45	4.57e-6	Neuroticism;
THYM	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg12599982	chr1:44399894	ARTN	0.56	4.66	0.43	1.02e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.91	0.45	3.84e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg03929089	chr4:120376271	NA	-1.01	-8.43	-0.65	3.69e-13	Height;
THYM	cis	rs289828	0.579	rs6433327	chr2:152154732	A/G	cg05960677	chr2:152117363	RBM43	0.69	6.55	0.56	2.88e-9	Blood protein levels;
THYM	cis	rs3825932	0.961	rs11072815	chr15:79232319	C/T	cg25744700	chr15:79237217	CTSH	-0.48	-4.49	-0.42	1.98e-5	Type 1 diabetes;
THYM	cis	rs516946	1.000	rs515071	chr8:41519462	C/T	cg19441908	chr8:41529140	ANK1	0.62	4.77	0.44	6.69e-6	Type 2 diabetes;
THYM	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg22105103	chr4:187893119	NA	0.9	9.33	0.69	4.48e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6450176	1.000	rs3776703	chr5:53305259	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.13	-0.53	2.01e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs96067	0.711	rs4653164	chr1:36627542	A/G	cg24686825	chr1:36642396	MAP7D1	0.68	5.38	0.48	5.23e-7	Corneal structure;
THYM	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg13683864	chr3:40499215	RPL14	1.07	12.42	0.79	1.31e-21	Renal cell carcinoma;
THYM	cis	rs2562152	0.786	rs216594	chr16:103009	A/T	cg02949481	chr16:131562	MPG	0.81	5.03	0.46	2.31e-6	Glioblastoma;
THYM	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.29	8.36	0.65	5.15e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg05962950	chr11:130786565	SNX19	0.95	9.03	0.68	2e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs36051895	0.555	rs6476953	chr9:5248742	C/T	cg02405213	chr9:5042618	JAK2	-0.93	-9.48	-0.7	2.14e-15	Pediatric autoimmune diseases;
THYM	cis	rs11186	0.556	rs72902385	chr2:189922920	A/T	cg11041835	chr2:189156425	GULP1	0.8	4.67	0.43	9.73e-6	Parkinson's disease;
THYM	cis	rs8070740	0.617	rs1058119	chr17:5323125	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.74	6.9	0.58	5.86e-10	Menopause (age at onset);
THYM	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg27221674	chr7:232095	FAM20C	-0.44	-4.45	-0.42	2.33e-5	Longevity;Endometriosis;
THYM	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg16325326	chr1:53192061	ZYG11B	0.79	6.81	0.57	9e-10	Monocyte count;
THYM	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.83	0.82	1.75e-24	Height;
THYM	cis	rs1455213	0.562	rs28567921	chr4:15170365	G/A	cg12377275	chr4:15005593	CPEB2	0.54	4.49	0.42	2.02e-5	Parental longevity (mother's age at death);
THYM	cis	rs1003719	0.788	rs4572679	chr21:38453227	T/C	cg01329690	chr21:38580129	DSCR9	0.39	5.25	0.47	9.23e-7	Eye color traits;
THYM	cis	rs7631605	0.905	rs7649344	chr3:37006396	C/T	cg17445812	chr3:36986805	TRANK1	-0.47	-4.55	-0.42	1.61e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg14675211	chr2:100938903	LONRF2	0.77	8.23	0.65	9.81e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.75	-6.23	-0.54	1.3e-8	Lung cancer;
THYM	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg25237894	chr2:233734115	C2orf82	0.34	4.52	0.42	1.79e-5	Coronary artery disease;
THYM	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs919433	1.000	rs2195510	chr2:198161195	A/G	cg00792783	chr2:198669748	PLCL1	-0.67	-4.82	-0.44	5.36e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg03188948	chr7:1209495	NA	0.68	4.69	0.43	9.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs36051895	0.664	rs10815153	chr9:5092864	G/C	cg02405213	chr9:5042618	JAK2	-1.0	-11.3	-0.76	2.84e-19	Pediatric autoimmune diseases;
THYM	cis	rs9486719	1.000	rs11757063	chr6:96884886	C/T	cg18709589	chr6:96969512	KIAA0776	-0.73	-4.84	-0.44	5.11e-6	Migraine;Coronary artery disease;
THYM	cis	rs6918586	0.658	rs198826	chr6:26121153	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.79	7.3	0.6	8.74e-11	Schizophrenia;
THYM	cis	rs8077889	0.956	rs58242860	chr17:41847300	T/C	cg26893861	chr17:41843967	DUSP3	1.02	8.77	0.67	6.88e-14	Triglycerides;
THYM	cis	rs6840360	0.571	rs17360371	chr4:152565374	C/T	cg22705602	chr4:152727874	NA	-0.81	-8.44	-0.65	3.55e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg12165864	chr7:66369176	NA	-0.81	-6.08	-0.53	2.47e-8	Corneal structure;
THYM	cis	rs2458413	0.669	rs12681140	chr8:105346112	A/C	cg13045555	chr8:105342365	NA	0.26	4.64	0.43	1.13e-5	Paget's disease;
THYM	cis	rs8017423	0.967	rs11159957	chr14:90715972	A/G	cg04239629	chr14:90701769	NA	0.62	4.52	0.42	1.81e-5	Mortality in heart failure;
THYM	cis	rs12282928	1.000	rs1905285	chr11:48326024	A/G	cg22827986	chr11:48284249	OR4X1	0.51	5.29	0.48	7.88e-7	Migraine - clinic-based;
THYM	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg22875332	chr1:76189707	ACADM	-0.74	-6.34	-0.55	7.84e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg08133631	chr1:26527909	CATSPER4	-0.56	-4.52	-0.42	1.78e-5	Granulocyte percentage of myeloid white cells;
THYM	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg21784768	chr11:537496	LRRC56	-1.07	-4.95	-0.45	3.2e-6	Body mass index;
THYM	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg07636037	chr3:49044803	WDR6	0.98	9.91	0.71	2.6e-16	Parkinson's disease;
THYM	cis	rs7177699	0.557	rs3971829	chr15:79109052	A/G	cg15571903	chr15:79123663	NA	0.6	6.71	0.57	1.42e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg10360139	chr7:1886902	MAD1L1	-0.85	-7.79	-0.62	8.37e-12	Bipolar disorder and schizophrenia;
THYM	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg11366901	chr6:160182831	ACAT2	1.05	9.61	0.7	1.11e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg18681998	chr4:17616180	MED28	-0.84	-7.02	-0.58	3.24e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg19507638	chr5:93509721	C5orf36	-0.65	-4.54	-0.42	1.63e-5	Diabetic retinopathy;
THYM	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03264133	chr6:25882463	NA	-0.68	-5.18	-0.47	1.24e-6	Blood metabolite levels;
THYM	cis	rs7584330	0.554	rs76980036	chr2:238426750	G/A	cg14458575	chr2:238380390	NA	0.79	4.65	0.43	1.06e-5	Prostate cancer;
THYM	cis	rs1003719	0.612	rs2835652	chr21:38557408	G/T	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs208520	1.000	rs208529	chr6:66957549	T/C	cg07460842	chr6:66804631	NA	-0.78	-5.07	-0.46	1.96e-6	Exhaled nitric oxide output;
THYM	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg11335335	chr11:637885	DRD4	-0.69	-6.23	-0.54	1.24e-8	Systemic lupus erythematosus;
THYM	cis	rs9875589	0.509	rs4685058	chr3:14030384	T/C	cg03204825	chr3:13978759	TPRXL	-0.55	-4.98	-0.46	2.83e-6	Ovarian reserve;
THYM	cis	rs9788721	0.836	rs2009746	chr15:78754102	A/G	cg18825076	chr15:78729989	IREB2	-0.67	-6.41	-0.55	5.7e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg08213375	chr14:104286397	PPP1R13B	0.46	5.53	0.49	2.78e-7	Schizophrenia;
THYM	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg13010199	chr12:38710504	ALG10B	0.76	6.07	0.53	2.59e-8	Heart rate;
THYM	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg18538332	chr22:24372958	LOC391322	-0.86	-8.85	-0.67	4.65e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs611744	0.967	rs602384	chr8:109188185	G/C	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg03690763	chr11:133734501	NA	-0.64	-4.99	-0.46	2.74e-6	Childhood ear infection;
THYM	cis	rs2806561	0.929	rs10917357	chr1:23535161	C/T	cg12483005	chr1:23474871	LUZP1	0.52	5.23	0.47	1.01e-6	Height;
THYM	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg24818145	chr4:99064322	C4orf37	0.67	5.2	0.47	1.13e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg05340658	chr4:99064831	C4orf37	0.54	4.5	0.42	1.96e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10789491	1.000	rs1371834	chr1:47176894	G/A	cg15501359	chr1:47185051	KIAA0494	1.14	8.24	0.65	9.45e-13	Response to hepatitis C treatment;
THYM	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg15962314	chr1:44399869	ARTN	0.51	4.64	0.43	1.13e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg00012203	chr2:219082015	ARPC2	-0.64	-5.28	-0.48	8.26e-7	Colorectal cancer;
THYM	trans	rs877282	0.797	rs7079164	chr10:756363	A/G	cg22713356	chr15:30763199	NA	1.27	9.37	0.69	3.62e-15	Uric acid levels;
THYM	cis	rs2932538	0.922	rs12143068	chr1:113138110	A/G	cg22162597	chr1:113214053	CAPZA1	0.65	5.32	0.48	6.9e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg13683864	chr3:40499215	RPL14	-1.02	-11.08	-0.75	8.4e-19	Renal cell carcinoma;
THYM	cis	rs988913	1.000	rs1503134	chr6:54836224	G/A	cg18532076	chr6:54711417	FAM83B	0.5	4.91	0.45	3.78e-6	Menarche (age at onset);
THYM	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	trans	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg18876405	chr7:65276391	NA	0.76	7.19	0.59	1.44e-10	Aortic root size;
THYM	trans	rs7952251	0.718	rs1945104	chr11:112398853	A/G	cg14154186	chr1:204970430	NFASC	-0.71	-7.2	-0.59	1.41e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs13102973	0.682	rs7441468	chr4:135886736	C/T	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg05347473	chr6:146136440	FBXO30	0.58	4.52	0.42	1.8e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	6.47	0.55	4.26e-9	Obesity-related traits;
THYM	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg05283184	chr6:79620031	NA	-0.94	-9.25	-0.69	6.67e-15	Intelligence (multi-trait analysis);
THYM	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg21984481	chr17:79567631	NPLOC4	-0.49	-5.34	-0.48	6.4e-7	Eye color traits;
THYM	cis	rs7000551	0.527	rs11783730	chr8:22244897	C/T	cg12081754	chr8:22256438	SLC39A14	1.15	11.29	0.76	2.96e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	5.78	0.51	9.45e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4604732	0.536	rs7528219	chr1:247628307	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.69	4.8	0.44	5.99e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs3791406	1.000	rs3791405	chr2:240030284	G/A	cg20627572	chr2:239991813	HDAC4	-0.46	-4.49	-0.42	2.04e-5	Skin aging (microtopography measurement);
THYM	cis	rs11997175	0.583	rs67830367	chr8:33833788	G/C	ch.8.33884649F	chr8:33765107	NA	0.67	5.0	0.46	2.61e-6	Body mass index;
THYM	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03264133	chr6:25882463	NA	0.95	8.5	0.66	2.63e-13	Blood metabolite levels;
THYM	cis	rs9302635	0.513	rs13334151	chr16:72189727	A/C	cg16558253	chr16:72132732	DHX38	-0.55	-4.53	-0.42	1.7e-5	Blood protein levels;
THYM	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg02782426	chr3:40428986	ENTPD3	-0.57	-5.23	-0.47	1.02e-6	Renal cell carcinoma;
THYM	cis	rs9875589	0.509	rs2607757	chr3:14081948	A/G	cg03204825	chr3:13978759	TPRXL	0.51	4.46	0.42	2.26e-5	Ovarian reserve;
THYM	cis	rs9420	0.961	rs12804972	chr11:57463767	T/C	cg19752551	chr11:57585705	CTNND1	-0.73	-8.02	-0.64	2.79e-12	Schizophrenia;
THYM	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg02380750	chr20:61661411	NA	0.62	6.45	0.55	4.58e-9	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2109514	0.967	rs55883210	chr7:116160524	G/A	cg12739419	chr7:116140593	CAV2	-0.47	-4.57	-0.42	1.44e-5	Prevalent atrial fibrillation;
THYM	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg04990556	chr1:26633338	UBXN11	-0.89	-8.5	-0.66	2.62e-13	Obesity-related traits;
THYM	cis	rs1457614	0.694	rs33915800	chr12:13639388	A/T	cg16488639	chr12:12966464	DDX47	-0.79	-4.46	-0.42	2.24e-5	Major depressive disorder;
THYM	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg22166914	chr1:53195759	ZYG11B	0.81	8.11	0.64	1.74e-12	Monocyte count;
THYM	cis	rs2115630	0.936	rs11073663	chr15:85260268	A/G	cg11189052	chr15:85197271	WDR73	-0.62	-4.82	-0.44	5.54e-6	P wave terminal force;
THYM	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg25036284	chr2:26402008	FAM59B	0.85	5.28	0.48	8e-7	Gut microbiome composition (summer);
THYM	cis	rs2273669	0.667	rs76747161	chr6:109305456	G/A	cg17117243	chr6:109341365	SESN1	-0.84	-4.94	-0.45	3.41e-6	Prostate cancer;
THYM	trans	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Educational attainment;
THYM	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg24250549	chr1:154909240	PMVK	0.75	6.45	0.55	4.66e-9	Prostate cancer;
THYM	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs9527	0.590	rs7910900	chr10:104829898	C/T	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg07424592	chr7:64974309	NA	-1.03	-5.38	-0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg24675658	chr1:53192096	ZYG11B	-0.7	-6.08	-0.53	2.47e-8	Monocyte count;
THYM	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg15691649	chr6:25882328	NA	-0.69	-5.42	-0.49	4.55e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.31	-9.87	-0.71	3.08e-16	Gut microbiome composition (summer);
THYM	cis	rs7968440	1.000	rs2731434	chr12:51109875	C/T	cg20014596	chr12:50898483	DIP2B	0.54	4.46	0.42	2.29e-5	Fibrinogen;
THYM	cis	rs35883536	0.513	rs6577180	chr1:101016939	G/A	cg06223162	chr1:101003688	GPR88	0.9	7.72	0.62	1.19e-11	Monocyte count;
THYM	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg27490568	chr2:178487706	NA	0.6	5.49	0.49	3.3e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs600806	0.850	rs1343465	chr1:109937426	T/C	cg16988986	chr1:109941118	SORT1	-0.43	-4.56	-0.42	1.5e-5	Intelligence (multi-trait analysis);
THYM	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg01570182	chr17:44337453	NA	0.87	9.49	0.7	2e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg13736514	chr6:26305472	NA	-0.6	-7.56	-0.61	2.48e-11	Educational attainment;
THYM	cis	rs12216545	0.765	rs1851435	chr7:150228785	A/T	cg00323915	chr7:150264987	GIMAP4	-0.49	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs9399401	0.589	rs2294775	chr6:142766347	C/G	cg04461802	chr6:142623433	GPR126	0.77	7.67	0.62	1.5e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7084402	0.967	rs1649082	chr10:60292434	A/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg22709100	chr7:91322751	NA	0.6	4.7	0.43	8.94e-6	Breast cancer;
THYM	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs8067545	0.750	rs7223305	chr17:19990986	A/G	cg13482628	chr17:19912719	NA	0.58	4.85	0.45	4.75e-6	Schizophrenia;
THYM	cis	rs12681287	0.752	rs10111095	chr8:87250984	T/C	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg13609457	chr4:120235615	NA	0.51	4.8	0.44	5.83e-6	Corneal astigmatism;
THYM	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg02574844	chr11:5959923	NA	-0.51	-4.51	-0.42	1.87e-5	DNA methylation (variation);
THYM	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg04772025	chr11:68637568	NA	0.6	6.29	0.54	9.69e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12752838	0.777	rs10864368	chr1:8918313	A/G	cg19371916	chr1:8874984	RERE	-0.54	-5.29	-0.48	7.76e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs7681440	0.606	rs990088	chr4:90755225	A/G	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	trans	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg25214090	chr10:38739885	LOC399744	0.97	8.33	0.65	5.98e-13	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs892961	0.932	rs11650011	chr17:75412334	A/G	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg07061783	chr6:25882402	NA	0.84	7.17	0.59	1.58e-10	Blood metabolite levels;
THYM	cis	rs75920871	0.528	rs12274388	chr11:116946238	C/T	cg20608306	chr11:116969690	SIK3	-0.52	-5.78	-0.51	9.38e-8	Subjective well-being;
THYM	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg23711669	chr6:146136114	FBXO30	0.83	7.72	0.62	1.17e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.78	-6.74	-0.57	1.22e-9	Intelligence (multi-trait analysis);
THYM	cis	rs870825	0.616	rs4264873	chr4:185624336	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	trans	rs12810016	0.667	rs17727130	chr12:83323342	C/T	cg04578774	chr11:44332664	ALX4	1.22	6.87	0.58	6.7e-10	Coronary artery aneurysm in Kawasaki disease;
THYM	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg11764359	chr7:65958608	NA	0.88	7.53	0.61	2.88e-11	Aortic root size;
THYM	cis	rs6543140	0.964	rs6543142	chr2:103082006	T/C	cg03938978	chr2:103052716	IL18RAP	0.6	5.78	0.51	9.35e-8	Blood protein levels;
THYM	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg11845111	chr2:191398756	TMEM194B	-0.96	-7.18	-0.59	1.53e-10	Diastolic blood pressure;
THYM	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg21100191	chr22:23484243	RTDR1	0.73	6.5	0.55	3.66e-9	Bone mineral density;
THYM	cis	rs995000	0.931	rs1168013	chr1:62996838	C/G	cg06896770	chr1:63153194	DOCK7	0.92	7.57	0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6499255	0.904	rs2161631	chr16:69556948	C/A	cg00738113	chr16:70207722	CLEC18C	-0.47	-4.65	-0.43	1.08e-5	IgE levels;
THYM	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg24308560	chr3:49941425	MST1R	0.79	6.98	0.58	4.02e-10	Intelligence (multi-trait analysis);
THYM	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs4660306	1.000	rs6429567	chr1:45956700	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.43	-0.49	4.37e-7	Homocysteine levels;
THYM	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg27535305	chr1:53392650	SCP2	0.66	7.27	0.6	9.92e-11	Monocyte count;
THYM	cis	rs6456042	1.000	rs3099293	chr6:166530658	A/C	cg11088901	chr6:166572345	T	-0.52	-4.9	-0.45	3.9e-6	Asthma;
THYM	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg07511668	chr11:68622177	NA	0.44	4.63	0.43	1.16e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg09455208	chr3:40491958	NA	0.47	4.93	0.45	3.41e-6	Renal cell carcinoma;
THYM	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg09455208	chr3:40491958	NA	-0.46	-4.81	-0.44	5.57e-6	Renal cell carcinoma;
THYM	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06481639	chr22:41940642	POLR3H	-0.74	-4.99	-0.46	2.75e-6	Vitiligo;
THYM	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg26597838	chr10:835615	NA	0.99	5.41	0.49	4.77e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs9457247	0.638	rs239933	chr6:167413230	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.48	-4.8	-0.44	5.89e-6	Crohn's disease;
THYM	cis	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg10856724	chr12:34555212	NA	0.84	7.32	0.6	7.94e-11	Morning vs. evening chronotype;
THYM	cis	rs4285028	0.656	rs2141487	chr3:121482765	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.87	6.37	0.55	6.7e-9	Multiple sclerosis;
THYM	cis	rs6450176	0.633	rs25858	chr5:53339518	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-7.49	-0.61	3.5e-11	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs2888875	0.632	rs34154601	chr2:43790448	A/C	cg22033476	chr2:43532275	THADA	-0.39	-4.49	-0.42	1.99e-5	Glomerular filtration rate (creatinine);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg10044466	chr11:10328911	ADM	0.98	6.86	0.58	6.82e-10	Depressive symptoms;
THYM	cis	rs4713118	0.866	rs9468217	chr6:27726467	G/A	cg08968635	chr6:28129556	ZNF389	0.67	5.09	0.46	1.83e-6	Parkinson's disease;
THYM	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg14972814	chr11:95582409	MTMR2	-0.59	-5.36	-0.48	5.87e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg17644776	chr2:200775616	C2orf69	0.77	5.4	0.48	5.01e-7	Schizophrenia;
THYM	cis	rs6032067	0.929	rs7344269	chr20:43828668	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	0.75	7.54	0.61	2.8e-11	Blood protein levels;
THYM	cis	rs4409675	0.576	rs1474908	chr1:28213213	C/T	cg23691781	chr1:28212827	C1orf38	-0.45	-4.62	-0.43	1.19e-5	Corneal astigmatism;
THYM	cis	rs4731207	0.536	rs34630567	chr7:124630663	G/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg17173187	chr15:85201210	NMB	0.55	5.36	0.48	5.82e-7	Schizophrenia;
THYM	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs4849845	0.849	rs6739106	chr2:121053244	G/C	cg03575764	chr2:121493832	NA	-0.65	-4.86	-0.45	4.59e-6	Mean platelet volume;
THYM	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06850241	chr22:41845214	NA	0.54	5.04	0.46	2.24e-6	Vitiligo;
THYM	cis	rs7731657	0.537	rs10073197	chr5:130373090	C/T	cg08523029	chr5:130500466	HINT1	-0.81	-5.62	-0.5	1.92e-7	Fasting plasma glucose;
THYM	cis	rs2224309	0.903	rs6575469	chr14:95334687	C/T	cg00814780	chr14:95331232	NA	-0.57	-4.93	-0.45	3.48e-6	Nose size;
THYM	trans	rs877282	0.898	rs11253347	chr10:765769	A/G	cg22713356	chr15:30763199	NA	1.36	9.83	0.71	3.89e-16	Uric acid levels;
THYM	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg26597838	chr10:835615	NA	1.19	8.47	0.66	3.06e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs35883536	0.935	rs1577510	chr1:101114295	G/A	cg06223162	chr1:101003688	GPR88	-0.67	-5.12	-0.46	1.62e-6	Monocyte count;
THYM	cis	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg26924012	chr15:45694286	SPATA5L1	1.04	9.2	0.69	8.56e-15	Homoarginine levels;
THYM	cis	rs6754311	0.593	rs10195620	chr2:136495619	A/T	cg23851026	chr2:136556271	LCT	-0.55	-5.47	-0.49	3.63e-7	Mosquito bite size;
THYM	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg13852791	chr20:30311386	BCL2L1	0.87	6.96	0.58	4.36e-10	Mean corpuscular hemoglobin;
THYM	cis	rs2521263	0.642	rs2521261	chr11:2307073	A/T	cg11419064	chr11:2291264	ASCL2	-0.76	-4.62	-0.43	1.23e-5	Obesity-related traits;
THYM	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg24642439	chr20:33292090	TP53INP2	0.59	4.48	0.42	2.04e-5	Coronary artery disease;
THYM	cis	rs28595532	0.920	rs115681185	chr4:119757700	G/A	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs11118844	0.843	rs11118847	chr1:221922614	A/G	cg04222084	chr1:221915650	DUSP10	-1.02	-5.4	-0.48	4.88e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs8101881	0.576	rs7254042	chr19:33362148	A/G	cg16861209	chr19:33361127	SLC7A9	-0.51	-4.73	-0.44	7.71e-6	Blood metabolite levels;Urinary metabolites;Urinary metabolites (H-NMR features);
THYM	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg00071950	chr4:10020882	SLC2A9	0.54	4.61	0.43	1.24e-5	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs62435770	1.000	rs62433640	chr6:169539204	T/C	cg07652237	chr6:170125491	PHF10	0.51	4.5	0.42	1.96e-5	Loneliness;
THYM	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg06634786	chr22:41940651	POLR3H	-0.62	-4.85	-0.45	4.84e-6	Vitiligo;
THYM	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.44	7.34	0.6	7.07e-11	Obesity-related traits;
THYM	cis	rs6701037	0.625	rs67332874	chr1:175128537	G/A	cg17845761	chr1:175162550	KIAA0040	-0.36	-4.57	-0.42	1.45e-5	Alcohol dependence;
THYM	cis	rs7940866	0.740	rs2162060	chr11:130830763	A/G	cg12179176	chr11:130786555	SNX19	0.63	4.82	0.44	5.52e-6	Schizophrenia;
THYM	cis	rs1075232	0.649	rs66700609	chr15:32226062	G/A	cg01030201	chr15:31746330	NA	-0.96	-4.54	-0.42	1.68e-5	Survival in colorectal cancer (non-distant metastatic);
THYM	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs10089	1.000	rs2054444	chr5:127493206	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.92	-5.6	-0.5	2.09e-7	Ileal carcinoids;
THYM	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg16524936	chr4:1340807	KIAA1530	-0.6	-4.7	-0.43	8.67e-6	Longevity;
THYM	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22307029	chr19:49891270	CCDC155	0.59	4.72	0.44	8.04e-6	Multiple sclerosis;
THYM	cis	rs600806	0.815	rs10745356	chr1:109960270	C/A	cg23616212	chr1:109941201	SORT1	-0.5	-4.78	-0.44	6.34e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg21231944	chr12:82153410	PPFIA2	-0.62	-4.52	-0.42	1.78e-5	Resting heart rate;
THYM	cis	rs7584330	0.740	rs11891348	chr2:238440449	T/G	cg14458575	chr2:238380390	NA	0.93	6.71	0.57	1.38e-9	Prostate cancer;
THYM	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg13609457	chr4:120235615	NA	0.51	4.74	0.44	7.55e-6	Educational attainment;
THYM	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg04267008	chr7:1944627	MAD1L1	-0.61	-5.05	-0.46	2.09e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	5.71	0.51	1.3e-7	Platelet count;
THYM	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg22189786	chr22:42395067	WBP2NL	0.56	5.08	0.46	1.87e-6	Birth weight;
THYM	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg06873352	chr17:61820015	STRADA	0.57	5.6	0.5	2.05e-7	Height;
THYM	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg04876606	chr3:49977596	RBM6	-0.56	-4.47	-0.42	2.14e-5	Parkinson's disease;
THYM	cis	rs7216064	0.954	rs9907491	chr17:65949993	G/A	cg12091567	chr17:66097778	LOC651250	0.72	5.05	0.46	2.15e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs1018836	0.851	rs12548741	chr8:91628878	G/A	cg16814680	chr8:91681699	NA	-0.85	-7.17	-0.59	1.59e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg06784218	chr1:46089804	CCDC17	0.29	4.62	0.43	1.18e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs854765	0.547	rs7209003	chr17:17907393	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.58	0.56	2.61e-9	Total body bone mineral density;
THYM	cis	rs67981189	0.542	rs17109053	chr14:71609698	G/C	cg15910301	chr14:71632612	NA	0.62	5.55	0.5	2.54e-7	Schizophrenia;
THYM	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg07061783	chr6:25882402	NA	-0.88	-8.34	-0.65	5.64e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg06850241	chr22:41845214	NA	0.49	4.63	0.43	1.14e-5	Vitiligo;
THYM	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10895275	0.625	rs12222063	chr11:102042791	C/G	cg24447756	chr11:102105824	NA	0.49	4.62	0.43	1.19e-5	Migraine;
THYM	cis	rs909002	0.830	rs10914460	chr1:32113216	T/C	cg13919466	chr1:32135498	COL16A1	-0.5	-5.01	-0.46	2.5e-6	Intelligence (multi-trait analysis);
THYM	cis	rs786425	0.530	rs7398851	chr12:124215004	A/G	cg15249119	chr12:124971054	NCOR2	0.53	4.89	0.45	4.04e-6	Pubertal anthropometrics;
THYM	cis	rs10489202	0.632	rs203781	chr1:167880518	A/C	cg24449463	chr1:168025552	DCAF6	-0.9	-9.12	-0.68	1.26e-14	Schizophrenia;
THYM	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.62	-4.46	-0.42	2.27e-5	Gut microbiome composition (summer);
THYM	cis	rs3741151	1.000	rs79778136	chr11:73041339	T/C	cg12959048	chr11:73096162	RELT	-0.5	-4.78	-0.44	6.38e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg06074448	chr4:187884817	NA	-1.01	-13.54	-0.81	6.7e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg10360139	chr7:1886902	MAD1L1	-0.63	-5.46	-0.49	3.78e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg23583168	chr7:148888333	NA	-0.96	-11.93	-0.77	1.34e-20	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs554111	0.613	rs10753510	chr1:21412248	G/A	cg00373020	chr1:21041521	KIF17	-0.55	-4.65	-0.43	1.06e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs11077998	0.967	rs12185229	chr17:80499065	G/C	cg10255544	chr17:80519551	FOXK2	0.51	4.48	0.42	2.05e-5	Reticulocyte fraction of red cells;
THYM	cis	rs9902453	0.868	rs9902340	chr17:28476458	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-6.42	-0.55	5.34e-9	Coffee consumption (cups per day);
THYM	cis	rs13287066	0.935	rs10821124	chr9:96178115	T/A	cg13460858	chr9:96720652	NA	-0.55	-4.56	-0.42	1.51e-5	Intelligence (multi-trait analysis);
THYM	cis	rs877282	0.945	rs877280	chr10:771599	C/T	cg10556349	chr10:835070	NA	-0.77	-5.28	-0.48	8.04e-7	Uric acid levels;
THYM	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg04520793	chr17:42248056	ASB16	-0.33	-4.56	-0.42	1.54e-5	Total body bone mineral density;
THYM	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg11752832	chr7:134001865	SLC35B4	0.72	4.92	0.45	3.6e-6	Mean platelet volume;
THYM	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.54	-0.56	3.08e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg06917634	chr15:78832804	PSMA4	-0.82	-7.22	-0.6	1.3e-10	Sudden cardiac arrest;
THYM	cis	rs7119	0.651	rs34607443	chr15:77847892	C/T	cg27398640	chr15:77910606	LINGO1	-0.59	-5.84	-0.51	7.15e-8	Type 2 diabetes;
THYM	cis	rs13185784	0.703	rs1127580	chr5:179661528	C/T	cg13944838	chr5:179740914	GFPT2	0.74	5.25	0.47	9.17e-7	TRAIL levels;
THYM	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg15691649	chr6:25882328	NA	-0.7	-5.53	-0.49	2.77e-7	Intelligence (multi-trait analysis);
THYM	cis	rs735396	1.000	rs735396	chr12:121438844	T/C	cg02403541	chr12:121454288	C12orf43	0.59	4.73	0.44	7.87e-6	N-glycan levels;
THYM	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg14583973	chr4:3374767	RGS12	0.7	6.97	0.58	4.12e-10	Serum sulfate level;
THYM	cis	rs2933343	0.649	rs1683786	chr3:128626952	T/C	cg11901034	chr3:128598214	ACAD9	-0.68	-5.57	-0.5	2.4e-7	IgG glycosylation;
THYM	cis	rs7809950	0.678	rs13230144	chr7:106909172	T/C	cg23024343	chr7:107201750	COG5	-1.0	-8.43	-0.65	3.79e-13	Coronary artery disease;
THYM	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg22875332	chr1:76189707	ACADM	-0.54	-5.15	-0.47	1.42e-6	Daytime sleep phenotypes;
THYM	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11890956	chr21:40555474	PSMG1	-0.93	-10.04	-0.72	1.34e-16	Cognitive function;
THYM	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg10224037	chr5:178157518	ZNF354A	1.0	8.22	0.64	1.04e-12	Neutrophil percentage of white cells;
THYM	cis	rs8044995	0.563	rs61746794	chr16:68387457	C/T	cg09835421	chr16:68378352	PRMT7	-0.72	-4.56	-0.42	1.5e-5	Schizophrenia;
THYM	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg11764359	chr7:65958608	NA	0.64	5.08	0.46	1.88e-6	Aortic root size;
THYM	cis	rs67311347	0.544	rs1902073	chr3:40333497	C/T	cg13683864	chr3:40499215	RPL14	-0.8	-7.44	-0.61	4.52e-11	Renal cell carcinoma;
THYM	cis	rs11608355	0.846	rs35393419	chr12:109881809	C/T	cg10504392	chr12:110044639	NA	0.62	5.28	0.48	8.16e-7	Neuroticism;
THYM	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg23682913	chr1:2080710	PRKCZ	-0.55	-5.05	-0.46	2.09e-6	Height;
THYM	cis	rs11756438	0.547	rs1343287	chr6:119001805	T/C	cg21191810	chr6:118973309	C6orf204	0.56	5.51	0.49	3.1e-7	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.11	0.53	2.16e-8	Total body bone mineral density;
THYM	cis	rs9677476	0.517	rs55970645	chr2:232052494	G/A	cg07929768	chr2:232055508	NA	0.43	4.47	0.42	2.17e-5	Food antigen IgG levels;
THYM	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg24818145	chr4:99064322	C4orf37	-0.7	-5.43	-0.49	4.3e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10193935	0.901	rs7570083	chr2:42517859	G/A	cg27598129	chr2:42591480	NA	-0.71	-4.56	-0.42	1.5e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28595532	0.920	rs115506655	chr4:119757667	A/G	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg17264618	chr3:40429014	ENTPD3	0.53	4.88	0.45	4.31e-6	Renal cell carcinoma;
THYM	cis	rs6598955	0.671	rs6686100	chr1:26617338	G/C	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.62	0.43	1.2e-5	Obesity-related traits;
THYM	cis	rs892961	0.806	rs312910	chr17:75413961	A/C	cg05865280	chr17:75406074	SEPT9	0.49	8.19	0.64	1.19e-12	Airflow obstruction;
THYM	cis	rs17030434	0.906	rs12641631	chr4:154665279	A/G	cg14289246	chr4:154710475	SFRP2	-0.86	-5.63	-0.5	1.84e-7	Electrocardiographic conduction measures;
THYM	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.6	5.1	0.46	1.76e-6	Prudent dietary pattern;
THYM	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs1883415	0.648	rs2817223	chr6:24506864	C/T	cg00346970	chr6:24499591	ALDH5A1	0.48	6.11	0.53	2.17e-8	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg25554036	chr4:6271136	WFS1	0.56	5.27	0.48	8.6e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg16744531	chr19:17905626	B3GNT3	0.62	6.21	0.54	1.41e-8	Tumor biomarkers;
THYM	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22455342	chr2:225449267	CUL3	0.94	8.56	0.66	2.01e-13	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs72828912	0.831	rs4574616	chr6:24094037	C/G	cg19882886	chr6:25043046	NA	-0.83	-5.3	-0.48	7.44e-7	Squamous cell lung carcinoma;
THYM	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg24375607	chr4:120327624	NA	0.53	4.47	0.42	2.2e-5	Corneal astigmatism;
THYM	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg13319975	chr6:146136371	FBXO30	-0.63	-4.98	-0.45	2.87e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs995000	0.931	rs11207986	chr1:63018170	T/C	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs10931896	0.531	rs296801	chr2:201142812	C/T	cg23649088	chr2:200775458	C2orf69	0.66	5.7	0.51	1.33e-7	Systolic blood pressure;
THYM	cis	rs919433	0.783	rs3097383	chr2:198236887	A/G	cg05783139	chr2:198650985	BOLL	0.56	4.5	0.42	1.96e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg03060546	chr3:49711283	APEH	0.83	6.89	0.58	5.91e-10	Resting heart rate;
THYM	trans	rs7584330	0.704	rs7602387	chr2:238356795	A/G	cg07705835	chr3:9959128	IL17RC	0.58	6.87	0.58	6.53e-10	Prostate cancer;
THYM	cis	rs4363385	0.747	rs1015996	chr1:152976108	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.53	-0.42	1.74e-5	Inflammatory skin disease;
THYM	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg11764359	chr7:65958608	NA	0.67	4.85	0.45	4.84e-6	Aortic root size;
THYM	cis	rs9420	0.961	rs11604333	chr11:57467035	C/G	cg19752551	chr11:57585705	CTNND1	-0.73	-8.02	-0.64	2.79e-12	Schizophrenia;
THYM	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg02953382	chr22:24373134	LOC391322	-0.88	-9.64	-0.7	9.62e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs9902453	0.904	rs9894893	chr17:28270350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.11	0.53	2.19e-8	Coffee consumption (cups per day);
THYM	cis	rs9287719	0.625	rs7567304	chr2:10790029	T/C	cg03983476	chr2:10830698	NOL10	0.64	5.3	0.48	7.45e-7	Prostate cancer;
THYM	cis	rs9302635	0.513	rs13334151	chr16:72189727	A/C	cg23815491	chr16:72088622	HP	0.81	6.34	0.55	7.72e-9	Blood protein levels;
THYM	cis	rs9814567	1.000	rs7611611	chr3:134307877	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.5	-0.66	2.69e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	trans	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs25645	0.502	rs8065126	chr17:38099035	C/T	cg26162295	chr17:38119207	GSDMA	0.43	5.17	0.47	1.32e-6	Myeloid white cell count;
THYM	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg23711669	chr6:146136114	FBXO30	-0.9	-8.74	-0.67	8.26e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12509991	0.582	rs2062209	chr4:127045418	A/G	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs6430585	0.583	rs4594504	chr2:136625113	A/C	cg23851026	chr2:136556271	LCT	0.79	7.51	0.61	3.2e-11	Corneal structure;
THYM	cis	rs7580658	0.724	rs12623948	chr2:128001342	G/A	cg10021288	chr2:128175891	PROC	-0.66	-6.06	-0.53	2.73e-8	Protein C levels;
THYM	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg03959625	chr15:84868606	LOC388152	0.49	4.77	0.44	6.64e-6	Schizophrenia;
THYM	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg22709100	chr7:91322751	NA	0.67	5.35	0.48	6.19e-7	Breast cancer;
THYM	cis	rs6032067	1.000	rs6032059	chr20:43852443	A/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.5	-0.49	3.14e-7	Blood protein levels;
THYM	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg08017756	chr2:100939284	LONRF2	-0.75	-7.8	-0.62	7.89e-12	Intelligence (multi-trait analysis);
THYM	cis	rs55637147	0.671	rs4939140	chr11:57130473	G/T	cg15971518	chr11:57159174	PRG2	-0.65	-5.32	-0.48	6.78e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg03929089	chr4:120376271	NA	-0.94	-10.4	-0.73	2.34e-17	Coronary artery disease;
THYM	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg15164180	chr2:241846931	NA	-0.37	-4.96	-0.45	3.07e-6	Urinary metabolites;
THYM	cis	rs2290159	0.800	rs11128607	chr3:12673275	A/G	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs2456568	0.695	rs908748	chr11:93690148	G/A	cg17595323	chr11:93583763	C11orf90	0.51	4.83	0.44	5.33e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg08847533	chr14:75593920	NEK9	1.02	10.91	0.75	1.92e-18	Height;
THYM	cis	rs7512552	0.839	rs11590787	chr1:150398531	G/A	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg10057126	chr4:77819792	ANKRD56	0.71	6.1	0.53	2.32e-8	Emphysema distribution in smoking;
THYM	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	7.52	0.61	3.02e-11	Lung cancer in ever smokers;
THYM	cis	rs9393777	0.588	rs6933213	chr6:26493909	T/C	cg12826209	chr6:26865740	GUSBL1	1.04	7.1	0.59	2.2e-10	Intelligence (multi-trait analysis);
THYM	cis	rs870825	0.616	rs7700216	chr4:185648510	G/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs950880	0.710	rs57081652	chr2:103075381	G/C	cg03938978	chr2:103052716	IL18RAP	-0.56	-4.77	-0.44	6.57e-6	Serum protein levels (sST2);
THYM	cis	rs11696501	0.739	rs6104249	chr20:44250487	C/G	cg11783356	chr20:44313418	WFDC10B	0.66	4.52	0.42	1.77e-5	Brain structure;
THYM	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	6.88	0.58	6.35e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs3796352	1.000	rs13072818	chr3:53074263	C/T	cg07884673	chr3:53033167	SFMBT1	1.03	5.24	0.47	9.74e-7	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg02569458	chr12:86230093	RASSF9	-0.66	-5.63	-0.5	1.84e-7	Major depressive disorder;
THYM	cis	rs10193935	0.792	rs2053349	chr2:42516205	G/A	cg27598129	chr2:42591480	NA	-0.71	-4.56	-0.42	1.5e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7246657	0.943	rs10413602	chr19:37891492	T/C	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	trans	rs1445130	0.786	rs16985390	chr2:18837158	C/A	cg26863750	chr16:1350103	NA	0.52	7.0	0.58	3.59e-10	Bulimia nervosa;
THYM	cis	rs3820068	0.532	rs74057713	chr1:15944620	G/C	cg13390004	chr1:15929781	NA	0.64	4.84	0.45	4.94e-6	Systolic blood pressure;
THYM	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg06618935	chr21:46677482	NA	-0.97	-9.37	-0.69	3.76e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10463554	0.889	rs246899	chr5:102577139	T/A	cg23492399	chr5:102201601	PAM	-0.59	-4.51	-0.42	1.84e-5	Parkinson's disease;
THYM	cis	rs1797885	0.624	rs299644	chr3:12574897	A/G	cg05467012	chr3:12595696	NA	0.55	4.67	0.43	1.01e-5	Immature fraction of reticulocytes;
THYM	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg18709589	chr6:96969512	KIAA0776	-0.55	-4.52	-0.42	1.75e-5	Headache;
THYM	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs6570726	0.935	rs7757387	chr6:145816726	G/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.91	-0.52	5.44e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1395	0.922	rs11693052	chr2:27484620	A/G	cg23587288	chr2:27483067	SLC30A3	-0.57	-5.11	-0.46	1.63e-6	Blood metabolite levels;
THYM	cis	rs7980799	0.711	rs1482993	chr12:33594515	G/A	cg06521331	chr12:34319734	NA	0.67	4.61	0.43	1.26e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg13246856	chr1:44399776	ARTN	0.51	4.95	0.45	3.16e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs76137255	1.000	rs76137255	chr19:40783832	T/G	cg01564640	chr19:41129962	LTBP4	1.13	4.82	0.44	5.4e-6	Cerebrospinal fluid t-tau:AB1-42 ratio;Cerebrospinal T-tau levels;
THYM	cis	rs10216189	1.000	rs7799970	chr7:5527714	G/C	cg22586569	chr7:5524963	FBXL18	0.59	5.49	0.49	3.28e-7	Relative hand skill in reading disability;
THYM	cis	rs4242434	0.927	rs11136093	chr8:22479988	C/G	cg21658235	chr8:22456391	C8orf58	0.58	5.39	0.48	5.06e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs854765	0.693	rs9915776	chr17:17749056	A/G	cg16928487	chr17:17741425	SREBF1	0.54	5.16	0.47	1.34e-6	Total body bone mineral density;
THYM	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg23161317	chr6:28129485	ZNF389	1.02	7.95	0.63	3.81e-12	Depression;
THYM	cis	rs11756438	0.607	rs1688631	chr6:119019064	A/T	cg21191810	chr6:118973309	C6orf204	0.59	5.86	0.52	6.62e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg08975724	chr8:8085496	FLJ10661	0.75	6.08	0.53	2.52e-8	Mood instability;
THYM	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg11494091	chr17:61959527	GH2	0.68	6.25	0.54	1.14e-8	Height;
THYM	cis	rs34779708	0.931	rs12767414	chr10:35390193	C/T	cg03585969	chr10:35415529	CREM	0.67	5.01	0.46	2.51e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg17264618	chr3:40429014	ENTPD3	0.49	4.74	0.44	7.64e-6	Renal cell carcinoma;
THYM	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg17143192	chr8:8559678	CLDN23	0.91	6.52	0.56	3.35e-9	Obesity-related traits;
THYM	cis	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg06521331	chr12:34319734	NA	-0.94	-8.59	-0.66	1.66e-13	Morning vs. evening chronotype;
THYM	cis	rs10162002	1.000	rs10162002	chr13:24042510	G/A	cg00158254	chr13:24040743	NA	0.69	4.8	0.44	5.81e-6	Hypothyroidism;
THYM	cis	rs11059635	0.570	rs80063446	chr12:128738368	C/T	cg16444942	chr12:129309117	SLC15A4	0.75	4.46	0.42	2.21e-5	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
THYM	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.41	-0.49	4.69e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.79	6.4	0.55	5.82e-9	Blood protein levels;
THYM	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06634786	chr22:41940651	POLR3H	-0.79	-6.08	-0.53	2.5e-8	Vitiligo;
THYM	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg06219351	chr7:158114137	PTPRN2	-0.74	-7.21	-0.59	1.32e-10	Calcium levels;
THYM	cis	rs4731207	0.596	rs2402763	chr7:124709732	A/G	cg05285228	chr7:124571219	POT1	-0.63	-4.6	-0.43	1.31e-5	Cutaneous malignant melanoma;
THYM	cis	rs6448317	1.000	rs6448317	chr4:24949220	C/T	cg22968281	chr4:24586266	DHX15	0.75	5.18	0.47	1.22e-6	Heschl's gyrus morphology;
THYM	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg13319975	chr6:146136371	FBXO30	-0.72	-6.02	-0.53	3.33e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg08773314	chr2:239334832	ASB1	0.56	8.03	0.64	2.65e-12	Multiple system atrophy;
THYM	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.55	0.49	2.56e-7	Tonsillectomy;
THYM	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg24675056	chr1:15929824	NA	0.74	6.14	0.53	1.93e-8	Systolic blood pressure;
THYM	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg22709100	chr7:91322751	NA	0.6	4.69	0.43	9.3e-6	Breast cancer;
THYM	cis	rs1348850	0.540	rs10172355	chr2:178443225	A/G	cg27490568	chr2:178487706	NA	0.56	4.6	0.43	1.32e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg03929089	chr4:120376271	NA	-0.98	-12.02	-0.78	9.02e-21	Coronary artery disease;
THYM	cis	rs7599312	0.586	rs4404217	chr2:213385817	G/A	cg16329650	chr2:213403929	ERBB4	0.62	4.85	0.45	4.75e-6	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7705502	0.962	rs56245789	chr5:173365310	T/C	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg02896835	chr1:92012615	NA	-0.65	-5.74	-0.51	1.15e-7	Breast cancer;
THYM	cis	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg01364799	chr7:75623366	TMEM120A	0.63	4.56	0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2249625	0.545	rs9791273	chr6:72891016	G/T	cg27608224	chr6:72922399	RIMS1	-0.53	-4.48	-0.42	2.04e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
THYM	cis	rs6032067	0.929	rs1997892	chr20:43810961	A/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg21028142	chr17:79581711	NPLOC4	0.61	6.22	0.54	1.32e-8	Eye color traits;
THYM	cis	rs11574514	1.000	rs11865098	chr16:67857436	A/G	cg04582263	chr16:67973788	LCAT	1.03	4.91	0.45	3.76e-6	Crohn's disease;
THYM	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg10518543	chr12:38710700	ALG10B	-0.59	-4.97	-0.45	3.01e-6	Morning vs. evening chronotype;
THYM	cis	rs10203711	1.000	rs907100	chr2:239563579	G/C	cg14580085	chr2:239553406	NA	0.71	6.63	0.56	1.99e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg26384229	chr12:38710491	ALG10B	0.95	7.98	0.63	3.38e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs13080594	0.660	rs7340751	chr3:7414354	G/T	cg20936920	chr3:7782210	GRM7	-0.49	-4.75	-0.44	7.29e-6	Personality traits in bipolar disorder;
THYM	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg11266682	chr4:10021025	SLC2A9	0.74	12.07	0.78	6.92e-21	Bone mineral density;
THYM	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg11279151	chr3:101281821	RG9MTD1	0.64	4.68	0.43	9.69e-6	Colorectal cancer;
THYM	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg12564285	chr5:131593104	PDLIM4	0.52	5.78	0.51	9.58e-8	Breast cancer;
THYM	cis	rs4523957	0.651	rs9910413	chr17:2081419	G/A	cg16513277	chr17:2031491	SMG6	-0.95	-8.69	-0.67	1.05e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs62120679	0.552	rs4807227	chr19:2318180	C/T	cg07474816	chr19:2321113	NA	0.53	4.48	0.42	2.05e-5	Parkinson's disease;
THYM	cis	rs10744422	1.000	rs897386	chr12:123341289	A/C	cg25930673	chr12:123319894	HIP1R	-0.89	-5.17	-0.47	1.31e-6	Schizophrenia;
THYM	cis	rs28595532	0.920	rs114414928	chr4:119728188	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg08736216	chr1:53307985	ZYG11A	0.59	5.54	0.49	2.74e-7	Monocyte count;
THYM	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg03877680	chr5:178157825	ZNF354A	0.75	5.0	0.46	2.57e-6	Neutrophil percentage of white cells;
THYM	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.84	0.51	7.19e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg19346786	chr7:2764209	NA	-0.72	-6.08	-0.53	2.55e-8	Height;
THYM	cis	rs11585357	0.793	rs11588418	chr1:17616445	A/G	cg08277548	chr1:17600880	PADI3	-0.9	-5.43	-0.49	4.38e-7	Hair shape;
THYM	cis	rs17152411	1.000	rs11245423	chr10:126588435	C/A	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg14972814	chr11:95582409	MTMR2	-0.68	-6.12	-0.53	2.12e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	5.72	0.51	1.23e-7	Platelet count;
THYM	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-5.98	-0.52	3.88e-8	Chronic sinus infection;
THYM	cis	rs7683537	0.673	rs1401363	chr4:185643862	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.69	0.71	7.45e-16	Systemic lupus erythematosus;
THYM	cis	rs4654899	1.000	rs12133780	chr1:21270808	G/A	cg01072550	chr1:21505969	NA	-0.73	-6.55	-0.56	2.95e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs6768930	0.509	rs7627431	chr3:57723828	T/G	cg07735586	chr3:57945651	NA	-0.33	-5.05	-0.46	2.13e-6	Obesity-related traits;
THYM	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg27118825	chr19:46318748	RSPH6A;SYMPK	-0.33	-4.66	-0.43	1.03e-5	Coronary artery disease;
THYM	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7103648	0.630	rs7120548	chr11:47662932	A/G	cg20307385	chr11:47447363	PSMC3	0.89	7.26	0.6	1.03e-10	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs791888	1.000	rs2762521	chr10:89414923	T/A	cg13926569	chr10:89418898	PAPSS2	-0.66	-7.22	-0.59	1.3100000000000001e-10	Magnesium levels;
THYM	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.16	-5.63	-0.5	1.85e-7	Body mass index;
THYM	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg06108461	chr20:60628389	TAF4	-1.06	-9.1	-0.68	1.39e-14	Body mass index;
THYM	cis	rs28476539	0.640	rs7698041	chr4:83555141	A/T	cg10249074	chr4:83542146	C4orf11	-0.64	-5.06	-0.46	2.03e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg26384229	chr12:38710491	ALG10B	0.96	7.58	0.61	2.27e-11	Bladder cancer;
THYM	cis	rs9880211	0.731	rs116443932	chr3:135971750	G/T	cg21827317	chr3:136751795	NA	-0.72	-4.78	-0.44	6.32e-6	Body mass index;Height;
THYM	cis	rs7264396	0.563	rs2425119	chr20:34324216	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Total cholesterol levels;
THYM	cis	rs17253792	0.822	rs76205307	chr14:56166038	C/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg26384229	chr12:38710491	ALG10B	0.95	7.53	0.61	2.89e-11	Bladder cancer;
THYM	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg09263875	chr16:632152	PIGQ	0.73	6.29	0.54	9.69e-9	Height;
THYM	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg17372223	chr3:52568218	NT5DC2	0.35	5.33	0.48	6.58e-7	Electroencephalogram traits;
THYM	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg07636037	chr3:49044803	WDR6	0.69	5.98	0.52	3.85e-8	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs886144	0.622	rs75770669	chr15:91718355	C/G	cg21594043	chr15:92491578	SLCO3A1	-0.48	-4.59	-0.43	1.33e-5	Metabolite levels;
THYM	cis	rs16854884	0.632	rs34038325	chr3:143685097	G/A	cg05063096	chr3:143689810	C3orf58	0.72	4.8	0.44	5.9e-6	Economic and political preferences (feminism/equality);
THYM	cis	rs7404928	0.678	rs3785394	chr16:23926474	C/T	cg26685404	chr16:23957272	PRKCB	-0.68	-8.04	-0.64	2.51e-12	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg04455712	chr21:45112962	RRP1B	-0.52	-4.88	-0.45	4.28e-6	Mean corpuscular volume;
THYM	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg18876405	chr7:65276391	NA	0.57	4.72	0.44	8.27e-6	Aortic root size;
THYM	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs6502050	0.835	rs8064935	chr17:80180178	T/C	cg21773646	chr17:80085082	CCDC57	-0.33	-4.76	-0.44	6.99e-6	Life satisfaction;
THYM	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg05962950	chr11:130786565	SNX19	0.95	9.03	0.68	2e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7727544	0.582	rs116749111	chr5:131462918	G/T	cg16205897	chr5:131564050	P4HA2	-0.45	-4.62	-0.43	1.2e-5	Blood metabolite levels;
THYM	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg05738196	chr6:26577821	NA	0.95	9.89	0.71	2.78e-16	Intelligence (multi-trait analysis);
THYM	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg23205692	chr1:25664452	TMEM50A	-0.83	-6.23	-0.54	1.24e-8	Erythrocyte sedimentation rate;
THYM	cis	rs61931739	0.507	rs4638394	chr12:33813585	C/T	cg06521331	chr12:34319734	NA	-0.62	-4.58	-0.43	1.39e-5	Morning vs. evening chronotype;
THYM	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg03264133	chr6:25882463	NA	-1.09	-10.32	-0.73	3.48e-17	Urate levels;
THYM	cis	rs7777677	0.925	rs4726546	chr7:142368318	T/C	cg21785750	chr7:142428317	NA	0.67	5.88	0.52	6.1e-8	Alcoholic chronic pancreatitis;
THYM	cis	rs950880	0.710	rs3732129	chr2:102957532	T/C	cg03938978	chr2:103052716	IL18RAP	-0.53	-4.64	-0.43	1.1e-5	Serum protein levels (sST2);
THYM	cis	rs3733631	0.557	rs17034070	chr4:104683261	A/G	cg24090629	chr4:104641072	TACR3	-0.95	-5.28	-0.48	8.08e-7	Menarche (age at onset);
THYM	cis	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg00495681	chr13:53174319	NA	0.74	6.83	0.57	8.16e-10	Lewy body disease;
THYM	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Gout;
THYM	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg00149659	chr3:10157352	C3orf10	1.38	4.81	0.44	5.73e-6	Alzheimer's disease;
THYM	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.65	-0.5	1.65e-7	Bone mineral density;
THYM	cis	rs2806561	0.606	rs218341	chr1:23294153	G/C	cg12483005	chr1:23474871	LUZP1	0.57	5.63	0.5	1.83e-7	Height;
THYM	cis	rs4343996	0.902	rs12540305	chr7:3376072	A/T	cg21248987	chr7:3385318	SDK1	-0.4	-4.82	-0.44	5.49e-6	Motion sickness;
THYM	cis	rs6967414	0.786	rs9639026	chr7:6746736	A/G	cg09896999	chr7:6746977	ZNF12	-0.64	-5.06	-0.46	2.06e-6	Hematocrit;Hemoglobin concentration;
THYM	cis	rs4474465	0.915	rs12274873	chr11:78183015	C/G	cg02023728	chr11:77925099	USP35	0.54	4.7	0.43	8.74e-6	Alzheimer's disease (survival time);
THYM	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg00129232	chr17:37814104	STARD3	-0.89	-7.01	-0.58	3.49e-10	Asthma;
THYM	cis	rs17604090	0.877	rs57253003	chr7:29686556	T/C	cg19413766	chr7:29689036	LOC646762	-0.93	-5.09	-0.46	1.77e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg23161317	chr6:28129485	ZNF389	0.69	5.6	0.5	2.06e-7	Cardiac Troponin-T levels;
THYM	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06873352	chr17:61820015	STRADA	0.56	5.6	0.5	2.06e-7	Height;
THYM	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg17509989	chr5:176798049	RGS14	-0.64	-5.48	-0.49	3.45e-7	Urate levels in lean individuals;
THYM	cis	rs11223731	0.672	rs57534561	chr11:134137451	G/C	cg18040241	chr11:134201582	GLB1L2	-0.71	-4.5	-0.42	1.89e-5	Verbal declarative memory;
THYM	cis	rs929596	0.614	rs10929302	chr2:234665782	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.97	-8.3	-0.65	7.15e-13	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs17253792	0.642	rs10483648	chr14:56104278	T/C	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.45	7.51	0.61	3.25e-11	Obesity-related traits;
THYM	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	9.2	0.69	8.51e-15	Platelet count;
THYM	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg24399712	chr22:39784796	NA	-0.85	-8.74	-0.67	8.02e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs470093	0.877	rs138128	chr22:44274814	G/A	cg09142166	chr22:44276013	PNPLA5	-0.52	-5.23	-0.47	1e-6	Staphylococcus aureus infection;
THYM	cis	rs2274459	1.000	rs3806107	chr6:33767413	C/T	cg06253072	chr6:33679850	C6orf125	0.51	4.75	0.44	7.1e-6	Obesity (extreme);
THYM	cis	rs9291683	0.655	rs2278121	chr4:10096134	G/A	cg02734326	chr4:10020555	SLC2A9	-0.64	-5.67	-0.5	1.56e-7	Bone mineral density;
THYM	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg23482746	chr15:76478102	C15orf27	-0.42	-4.97	-0.45	2.91e-6	Blood metabolite levels;
THYM	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs2404602	0.575	rs11633309	chr15:76962349	C/A	cg23625390	chr15:77176239	SCAPER	-0.79	-4.87	-0.45	4.41e-6	Blood metabolite levels;
THYM	cis	rs7772486	0.686	rs4896833	chr6:145965673	T/G	cg23711669	chr6:146136114	FBXO30	0.85	8.17	0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28595532	0.841	rs114966236	chr4:119733437	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs1568889	1.000	rs12804198	chr11:28143114	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.66e-6	Bipolar disorder;
THYM	cis	rs12216545	0.765	rs4725916	chr7:150251860	G/A	cg08960815	chr7:150264767	GIMAP4	-0.87	-7.96	-0.63	3.61e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs12318506	0.826	rs17804612	chr12:75671271	T/C	cg04728562	chr12:75699417	CAPS2	-1.2	-4.83	-0.44	5.13e-6	Coronary artery calcification;
THYM	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7000551	0.725	rs7430	chr8:22398414	C/G	cg12081754	chr8:22256438	SLC39A14	0.7	6.19	0.54	1.54e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2072499	0.932	rs2540183	chr1:156164885	C/G	cg06970220	chr1:156163860	SLC25A44	0.75	5.69	0.5	1.4e-7	Testicular germ cell tumor;
THYM	cis	rs6748734	0.625	rs7598309	chr2:241824876	A/T	cg09990169	chr2:241835740	C2orf54	-0.31	-5.03	-0.46	2.34e-6	Urinary metabolites;
THYM	cis	rs3760982	0.585	rs67648499	chr19:44294055	G/A	cg11993925	chr19:44307056	LYPD5	0.64	5.0	0.46	2.58e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs36051895	0.695	rs10815147	chr9:5016145	C/T	cg02405213	chr9:5042618	JAK2	-1.03	-10.57	-0.74	9.88e-18	Pediatric autoimmune diseases;
THYM	cis	rs2820651	1.000	rs76865516	chr10:1469531	G/A	cg02445968	chr10:1449028	ADARB2	-1.22	-6.14	-0.53	1.93e-8	Migraine with aura;
THYM	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs6032067	0.704	rs62208374	chr20:43765628	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.64	-5.8	-0.51	8.81e-8	Blood protein levels;
THYM	cis	rs11731175	1.000	rs9999148	chr4:189850468	C/T	cg00431894	chr4:189871012	NA	-0.82	-6.25	-0.54	1.15e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs72772090	0.539	rs11748328	chr5:96169916	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.79	-4.49	-0.42	2.04e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2072499	0.932	rs2736613	chr1:156196016	T/C	cg06970220	chr1:156163860	SLC25A44	0.72	5.57	0.5	2.32e-7	Testicular germ cell tumor;
THYM	cis	rs2439831	0.867	rs2255051	chr15:43846161	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	6.75	0.57	1.14e-9	Lung cancer in ever smokers;
THYM	cis	rs7267979	1.000	rs34645895	chr20:25368373	A/G	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs870825	0.655	rs28661636	chr4:185634218	A/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.63	-4.48	-0.42	2.05e-5	Gut microbiome composition (summer);
THYM	cis	rs2237457	0.543	rs2529384	chr7:50702188	C/T	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.48e-6	Schizophrenia (treatment resistant);
THYM	cis	rs7567389	0.510	rs1473623	chr2:128196220	T/C	cg09760422	chr2:128146352	NA	-0.46	-6.1	-0.53	2.29e-8	Self-rated health;
THYM	cis	rs1347297	0.526	rs728005	chr2:179251006	C/T	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.62	-4.77	-0.44	6.68e-6	Alzheimer disease and age of onset;
THYM	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg25427524	chr10:38739819	LOC399744	-0.63	-5.82	-0.51	8.07e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-6.98	-0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	cis	rs9326248	0.530	rs7112513	chr11:117037361	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.95	5.34	0.48	6.34e-7	Blood protein levels;
THYM	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	trans	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg10856724	chr12:34555212	NA	-1.01	-9.17	-0.69	9.95e-15	Bladder cancer;
THYM	cis	rs12530845	1.000	rs12531468	chr7:135336264	T/G	cg23117316	chr7:135346802	PL-5283	-0.66	-5.88	-0.52	6.21e-8	Red blood cell traits;
THYM	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg06558623	chr16:89946397	TCF25	1.33	5.62	0.5	1.94e-7	Skin colour saturation;
THYM	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg17264618	chr3:40429014	ENTPD3	0.46	4.47	0.42	2.2e-5	Renal cell carcinoma;
THYM	cis	rs11148252	0.634	rs66849828	chr13:52714837	C/A	cg00495681	chr13:53174319	NA	0.57	4.93	0.45	3.53e-6	Lewy body disease;
THYM	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg00012203	chr2:219082015	ARPC2	-0.64	-5.28	-0.48	8.18e-7	Colorectal cancer;
THYM	cis	rs4660306	1.000	rs4660870	chr1:45995231	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.57	-4.47	-0.42	2.12e-5	Homocysteine levels;
THYM	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.36	0.69	3.89e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg15556689	chr8:8085844	FLJ10661	0.62	4.49	0.42	1.98e-5	Mood instability;
THYM	cis	rs4597304	1	rs4597304	chr16:85055741	G/C	cg01715842	chr16:85045600	ZDHHC7	-0.54	-5.19	-0.47	1.21e-6	Dysphagia;
THYM	cis	rs28647808	1.000	rs28460103	chr9:136278763	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg25566285	chr7:158114605	PTPRN2	0.92	11.54	0.76	9.07e-20	Calcium levels;
THYM	cis	rs4072705	0.904	rs4593661	chr9:127410515	C/A	cg13476313	chr9:127244764	NR5A1	-0.33	-4.85	-0.45	4.76e-6	Menarche (age at onset);
THYM	cis	rs2692947	0.770	rs11689832	chr2:96554851	A/C	cg22654517	chr2:96458247	NA	0.71	5.17	0.47	1.28e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg24375607	chr4:120327624	NA	0.68	5.5	0.49	3.15e-7	Corneal astigmatism;
THYM	cis	rs950880	0.710	rs3771162	chr2:102997174	A/T	cg03938978	chr2:103052716	IL18RAP	-0.5	-4.46	-0.42	2.24e-5	Serum protein levels (sST2);
THYM	cis	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg07460842	chr6:66804631	NA	-1.06	-7.89	-0.63	5.14e-12	Exhaled nitric oxide output;
THYM	cis	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg06521331	chr12:34319734	NA	-0.85	-6.18	-0.54	1.57e-8	Morning vs. evening chronotype;
THYM	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg10150615	chr22:24372951	LOC391322	-1.04	-12.67	-0.79	3.92e-22	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9733	0.596	rs6669369	chr1:150695892	C/T	cg09034736	chr1:150693464	HORMAD1	0.53	4.85	0.45	4.83e-6	Tonsillectomy;
THYM	cis	rs11039798	0.536	rs112223280	chr11:48145077	C/G	cg24672777	chr11:48374446	OR4C45	-1.11	-5.37	-0.48	5.5e-7	Axial length;
THYM	cis	rs7322722	0.945	rs727839	chr13:77793372	T/C	cg04565255	chr13:77565759	CLN5	-0.44	-4.49	-0.42	2.03e-5	Preeclampsia;
THYM	cis	rs11792861	0.591	rs4978763	chr9:111728067	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.78	6.55	0.56	2.93e-9	Menarche (age at onset);
THYM	cis	rs9902453	0.874	rs7213517	chr17:28401740	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-6.08	-0.53	2.47e-8	Coffee consumption (cups per day);
THYM	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg15448220	chr1:150897856	SETDB1	0.85	6.76	0.57	1.1e-9	Melanoma;
THYM	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg10193763	chr2:225306901	NA	0.49	5.11	0.46	1.67e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg07936489	chr17:37558343	FBXL20	-0.73	-5.03	-0.46	2.32e-6	Asthma;
THYM	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg13695892	chr22:41940480	POLR3H	-0.88	-6.16	-0.53	1.73e-8	Vitiligo;
THYM	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg07636037	chr3:49044803	WDR6	0.97	9.94	0.71	2.24e-16	Parkinson's disease;
THYM	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg24308560	chr3:49941425	MST1R	0.63	4.78	0.44	6.37e-6	Body mass index;
THYM	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg14458575	chr2:238380390	NA	1.01	7.82	0.63	7.34e-12	Prostate cancer;
THYM	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg11752832	chr7:134001865	SLC35B4	0.74	5.65	0.5	1.69e-7	Mean platelet volume;
THYM	cis	rs6570726	0.846	rs6914304	chr6:145921017	T/C	cg23711669	chr6:146136114	FBXO30	0.86	8.06	0.64	2.28e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8048589	0.948	rs11648468	chr16:12181510	A/G	cg02910054	chr16:12241554	SNX29	-0.71	-6.07	-0.53	2.56e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg03474202	chr17:45855739	NA	-0.75	-6.59	-0.56	2.43e-9	IgG glycosylation;
THYM	cis	rs6701037	0.681	rs1057246	chr1:175127534	C/G	cg17845761	chr1:175162550	KIAA0040	0.36	4.48	0.42	2.06e-5	Alcohol dependence;
THYM	cis	rs7429990	0.932	rs2166772	chr3:48047874	C/T	cg02219026	chr3:48282209	ZNF589	0.6	4.5	0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.73	-0.44	7.65e-6	Diabetic retinopathy;
THYM	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs6903823	0.508	rs1150726	chr6:28243042	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.68	-5.08	-0.46	1.87e-6	Pulmonary function;
THYM	cis	rs4654899	1.000	rs4654905	chr1:21509558	A/G	cg01072550	chr1:21505969	NA	-0.74	-6.63	-0.56	2.02e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs1267303	0.675	rs1267312	chr1:46986748	C/G	cg16387850	chr1:46982889	NA	0.44	5.6	0.5	2.05e-7	Monobrow;
THYM	cis	rs67311347	0.544	rs7644181	chr3:40355665	A/G	cg24209194	chr3:40518798	ZNF619	-0.54	-4.6	-0.43	1.29e-5	Renal cell carcinoma;
THYM	cis	rs1322639	0.571	rs13204417	chr6:169575355	G/A	cg04662567	chr6:169592167	NA	0.57	5.2	0.47	1.12e-6	Pulse pressure;
THYM	cis	rs17511627	0.808	rs1158462	chr13:26744925	A/C	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg13147721	chr7:65941812	NA	-0.94	-5.74	-0.51	1.13e-7	Diabetic kidney disease;
THYM	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs9814567	0.964	rs6805388	chr3:134173534	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.74	-6.81	-0.57	8.8e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs17006441	0.932	rs1529586	chr3:69870154	C/A	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs362272	0.545	rs3135145	chr4:3299504	T/C	cg14583973	chr4:3374767	RGS12	0.65	6.21	0.54	1.39e-8	Serum sulfate level;
THYM	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg06481639	chr22:41940642	POLR3H	0.71	5.15	0.47	1.43e-6	Vitiligo;
THYM	cis	rs10992471	0.580	rs10992304	chr9:95085365	G/A	cg14631576	chr9:95140430	CENPP	-1.04	-11.32	-0.76	2.57e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg13010199	chr12:38710504	ALG10B	0.72	5.78	0.51	9.3e-8	Heart rate;
THYM	cis	rs1045902	0.537	rs1018342	chr2:73471653	A/C	cg24220031	chr2:73402428	NA	-0.58	-5.15	-0.47	1.39e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg06238570	chr21:40685208	BRWD1	-0.95	-8.85	-0.67	4.7e-14	Cognitive function;
THYM	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.76	5.97	0.52	4.17e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11048434	0.518	rs11048496	chr12:9172421	G/A	cg26114124	chr12:9217669	LOC144571	0.53	4.49	0.42	2.01e-5	Sjögren's syndrome;
THYM	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg06640241	chr16:89574553	SPG7	0.7	4.71	0.44	8.48e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.88	0.63	5.43e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4478037	0.822	rs9826234	chr3:33123832	A/C	cg19404215	chr3:33155277	CRTAP	0.96	6.51	0.56	3.58e-9	Major depressive disorder;
THYM	cis	rs448720	0.806	rs11071966	chr15:68163774	G/A	cg24579218	chr15:68104479	NA	0.68	5.81	0.51	8.18e-8	Cognitive performance;
THYM	cis	rs713587	0.691	rs754536	chr2:25176200	C/T	cg15423357	chr2:25149977	NA	-0.61	-6.55	-0.56	2.91e-9	Body mass index in non-asthmatics;
THYM	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg18252515	chr7:66147081	NA	1.16	8.13	0.64	1.59e-12	Diabetic kidney disease;
THYM	cis	rs985746	0.614	rs7676351	chr4:36818670	A/T	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs5769765	0.671	rs138817	chr22:50163058	G/A	cg26441486	chr22:50317300	CRELD2	0.38	5.72	0.51	1.21e-7	Schizophrenia;
THYM	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs17030434	0.871	rs6847648	chr4:154729700	G/A	cg14289246	chr4:154710475	SFRP2	-0.67	-4.98	-0.45	2.86e-6	Electrocardiographic conduction measures;
THYM	cis	rs1847202	0.826	rs11925587	chr3:72952227	A/G	cg25664220	chr3:72788482	NA	0.62	4.71	0.43	8.55e-6	Motion sickness;
THYM	cis	rs9467773	0.587	rs10946812	chr6:26344975	G/C	cg14345882	chr6:26364793	BTN3A2	0.36	4.88	0.45	4.29e-6	Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg24578937	chr1:2090814	PRKCZ	-0.61	-6.21	-0.54	1.37e-8	Height;
THYM	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg09035930	chr12:129282057	SLC15A4	0.86	12.01	0.78	9.43e-21	Systemic lupus erythematosus;
THYM	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg16434002	chr17:42200994	HDAC5	-0.66	-4.92	-0.45	3.66e-6	Total body bone mineral density;
THYM	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg23711669	chr6:146136114	FBXO30	0.85	7.9	0.63	4.99e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2274459	0.749	rs2281831	chr6:33695815	G/A	cg06253072	chr6:33679850	C6orf125	0.46	4.52	0.42	1.81e-5	Obesity (extreme);
THYM	cis	rs8053891	0.615	rs2287997	chr16:72140553	G/A	cg23815491	chr16:72088622	HP	0.8	5.7	0.5	1.34e-7	Coronary artery disease;
THYM	cis	rs4919087	1.000	rs4919087	chr10:99072507	C/T	cg19453742	chr10:98862320	SLIT1	0.63	5.17	0.47	1.31e-6	Monocyte count;
THYM	cis	rs10484885	0.877	rs17735389	chr6:90323139	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.91	-8.31	-0.65	6.5e-13	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-4.94	-0.45	3.29e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs1065656	0.571	rs2745170	chr16:1835231	G/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.43	5.22	0.47	1.05e-6	Insulin-like growth factors;
THYM	cis	rs9435341	0.965	rs1335053	chr1:107622823	C/T	cg00944433	chr1:107599041	PRMT6	0.42	5.42	0.49	4.52e-7	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs6430585	0.583	rs2304371	chr2:136561557	A/G	cg23851026	chr2:136556271	LCT	0.74	8.15	0.64	1.47e-12	Corneal structure;
THYM	cis	rs6988636	1.000	rs28600861	chr8:124189063	C/T	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg10505658	chr17:80084571	CCDC57	-0.72	-8.0	-0.63	3.03e-12	Life satisfaction;
THYM	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg09990169	chr2:241835740	C2orf54	-0.37	-5.89	-0.52	5.87e-8	Urinary metabolites;
THYM	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg10360139	chr7:1886902	MAD1L1	-0.56	-5.06	-0.46	2.07e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg10515332	chr4:99064459	C4orf37	0.63	5.09	0.46	1.78e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6840360	0.642	rs1470280	chr4:152431770	C/T	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.89	5.72	0.51	1.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg12373951	chr3:133503437	NA	0.57	6.19	0.54	1.51e-8	Iron status biomarkers;
THYM	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg09323728	chr8:95962352	TP53INP1	-0.47	-4.65	-0.43	1.08e-5	Type 2 diabetes;
THYM	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg26384229	chr12:38710491	ALG10B	0.97	7.47	0.61	3.8e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg13114125	chr14:105738426	BRF1	-0.71	-5.48	-0.49	3.45e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg06618935	chr21:46677482	NA	-0.98	-9.5	-0.7	1.95e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11039798	0.841	rs12221667	chr11:48548549	G/T	cg24672777	chr11:48374446	OR4C45	-1.08	-5.95	-0.52	4.42e-8	Axial length;
THYM	cis	rs9677476	0.689	rs6761645	chr2:232055153	T/A	cg23338755	chr2:231921595	PSMD1	0.73	5.43	0.49	4.37e-7	Food antigen IgG levels;
THYM	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg27129171	chr3:47204927	SETD2	0.74	7.2	0.59	1.42e-10	Colorectal cancer;
THYM	cis	rs6429082	0.683	rs868815	chr1:235584543	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.62	-4.69	-0.43	9.14e-6	Adiposity;
THYM	cis	rs765787	0.530	rs11636395	chr15:45535684	G/C	cg24006582	chr15:45444508	DUOX1	-0.79	-6.49	-0.55	3.85e-9	Uric acid levels;
THYM	cis	rs611744	0.967	rs650401	chr8:109196854	C/T	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg03690763	chr11:133734501	NA	-0.61	-4.75	-0.44	7.32e-6	Childhood ear infection;
THYM	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.25	-9.1	-0.68	1.37e-14	Gut microbiome composition (summer);
THYM	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg00495681	chr13:53174319	NA	0.73	7.22	0.6	1.25e-10	Lewy body disease;
THYM	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.61e-20	Menopause (age at onset);
THYM	cis	rs3126085	0.935	rs1858478	chr1:152257457	C/T	cg10321714	chr1:152280068	FLG	-0.64	-4.81	-0.44	5.57e-6	Atopic dermatitis;
THYM	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg15247329	chr7:2764246	NA	-0.73	-6.2	-0.54	1.46e-8	Height;
THYM	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg13736514	chr6:26305472	NA	-0.54	-6.42	-0.55	5.41e-9	Educational attainment;
THYM	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg03806693	chr22:41940476	POLR3H	1.17	10.14	0.72	8.43e-17	Vitiligo;
THYM	cis	rs9420	0.961	rs7117205	chr11:57641883	A/G	cg19752551	chr11:57585705	CTNND1	-0.72	-7.34	-0.6	7.26e-11	Schizophrenia;
THYM	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg24531977	chr5:56204891	C5orf35	-0.72	-5.83	-0.51	7.64e-8	Initial pursuit acceleration;
THYM	cis	rs7584330	0.740	rs10184904	chr2:238428186	G/C	cg14458575	chr2:238380390	NA	0.66	5.34	0.48	6.45e-7	Prostate cancer;
THYM	cis	rs17739794	0.517	rs34109064	chr8:772796	T/C	cg07178994	chr8:816998	NA	-0.68	-6.5	-0.55	3.71e-9	Clozapine-induced cytotoxicity;
THYM	cis	rs9403317	0.573	rs4896550	chr6:142029174	T/C	cg15052665	chr6:141804349	NA	-0.66	-5.23	-0.47	9.97e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg22709100	chr7:91322751	NA	-0.6	-4.68	-0.43	9.41e-6	Breast cancer;
THYM	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg11266682	chr4:10021025	SLC2A9	-0.52	-7.0	-0.58	3.57e-10	Bone mineral density;
THYM	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg17063962	chr7:91808500	NA	-1.12	-12.68	-0.79	3.85e-22	Breast cancer;
THYM	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg13319975	chr6:146136371	FBXO30	-0.61	-4.94	-0.45	3.36e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs34286592	0.929	rs8058824	chr16:29828710	C/G	cg04633683	chr16:29837056	MVP	0.61	4.93	0.45	3.45e-6	Multiple sclerosis;
THYM	cis	rs1942	0.837	rs12440045	chr15:41782684	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.71	-5.78	-0.51	9.65e-8	Eosinophil percentage of granulocytes;
THYM	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.83	0.67	5.34e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg03806693	chr22:41940476	POLR3H	1.11	9.95	0.71	2.12e-16	Vitiligo;
THYM	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg00684032	chr4:1343700	KIAA1530	0.54	4.68	0.43	9.41e-6	Obesity-related traits;
THYM	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg20744362	chr22:50050164	C22orf34	0.8	6.92	0.58	5.17e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-7.93	-0.63	4.19e-12	Life satisfaction;
THYM	cis	rs13126513	0.519	rs12641768	chr4:100558594	C/A	cg05468953	chr4:100565104	NA	0.68	6.46	0.55	4.5e-9	Metabolite levels (MHPG);
THYM	cis	rs2730245	0.527	rs2527202	chr7:158738849	T/C	cg11984989	chr7:158649758	WDR60	-0.97	-6.8	-0.57	9.35e-10	Height;
THYM	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg03161606	chr19:29218774	NA	0.87	7.71	0.62	1.23e-11	Methadone dose in opioid dependence;
THYM	cis	rs3816788	0.774	rs11784816	chr8:21773500	C/T	cg17168535	chr8:21777572	XPO7	-0.81	-7.13	-0.59	1.96e-10	Lung cancer in ever smokers;
THYM	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg26354017	chr1:205819088	PM20D1	0.94	9.63	0.7	1e-15	Menarche (age at onset);
THYM	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs12681287	0.752	rs67615966	chr8:87255203	C/A	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs4474465	1.000	rs10899514	chr11:78172695	A/G	cg19901956	chr11:77921274	USP35	-0.62	-4.66	-0.43	1.02e-5	Alzheimer's disease (survival time);
THYM	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	trans	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17712092	chr4:129076599	LARP1B	0.91	7.63	0.62	1.8e-11	Eosinophil percentage of white cells;
THYM	cis	rs80319144	0.953	rs2883853	chr2:159202835	G/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.59	4.73	0.44	7.69e-6	Restless legs syndrome;
THYM	cis	rs7567389	0.744	rs6430934	chr2:128000833	T/C	cg06038358	chr2:128176007	PROC	-0.46	-4.89	-0.45	4.09e-6	Self-rated health;
THYM	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg00129232	chr17:37814104	STARD3	0.69	4.45	0.42	2.32e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs9921192	1.000	rs251736	chr16:4318455	A/G	cg00021532	chr16:4324280	TFAP4	0.91	8.21	0.64	1.06e-12	Prostate-specific antigen levels;
THYM	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg08470875	chr2:26401718	FAM59B	0.74	4.59	0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs3916	0.794	rs10431386	chr12:121128926	A/G	cg10600917	chr12:121163489	ACADS	-0.55	-5.22	-0.47	1.03e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs9500256	0.655	rs12208465	chr6:58330881	C/T	cg16251399	chr6:58287822	GUSBL2	0.58	4.53	0.42	1.73e-5	Eosinophilic esophagitis (pediatric);
THYM	cis	rs7487075	0.930	rs7308910	chr12:46838242	T/C	cg21428710	chr12:47219797	SLC38A4	0.47	4.69	0.43	9.19e-6	Itch intensity from mosquito bite;
THYM	cis	rs3126085	0.935	rs11204980	chr1:152296191	G/C	cg10321714	chr1:152280068	FLG	-0.65	-4.49	-0.42	2.04e-5	Atopic dermatitis;
THYM	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs8013055	0.846	rs10152050	chr14:105984145	C/G	cg23356831	chr14:105996513	TMEM121	0.61	6.21	0.54	1.42e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs9486719	0.857	rs2971606	chr6:97043025	C/G	cg06623918	chr6:96969491	KIAA0776	-0.79	-5.51	-0.49	3.1e-7	Migraine;Coronary artery disease;
THYM	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg21926883	chr2:100939477	LONRF2	-0.65	-5.96	-0.52	4.24e-8	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs2639990	1.000	rs632157	chr18:72911548	G/A	cg18449964	chr18:72917101	ZADH2	1.36	6.05	0.53	2.82e-8	Vascular endothelial growth factor levels;
THYM	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9549260	0.564	rs9549271	chr13:41295477	T/C	cg21288729	chr13:41239152	FOXO1	0.62	4.64	0.43	1.11e-5	Red blood cell count;
THYM	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg06636001	chr8:8085503	FLJ10661	-0.66	-5.98	-0.52	3.98e-8	Mood instability;
THYM	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg00744431	chr10:134226547	PWWP2B	-0.57	-4.73	-0.44	7.67e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs684232	0.623	rs2543779	chr17:576362	C/A	cg15660573	chr17:549704	VPS53	-0.87	-8.12	-0.64	1.72e-12	Prostate cancer;
THYM	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg24250549	chr1:154909240	PMVK	0.81	6.33	0.54	8.17e-9	Prostate cancer;
THYM	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg12165864	chr7:66369176	NA	-0.64	-5.04	-0.46	2.26e-6	Aortic root size;
THYM	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg03433033	chr1:76189801	ACADM	-0.64	-5.88	-0.52	6.11e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9788721	0.836	rs11858836	chr15:78783277	G/A	cg18825076	chr15:78729989	IREB2	-0.66	-6.04	-0.53	3e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs28595532	0.920	rs10018977	chr4:119785229	C/T	cg21605333	chr4:119757512	SEC24D	1.58	6.06	0.53	2.73e-8	Cannabis dependence symptom count;
THYM	cis	rs67460515	0.892	rs13059340	chr3:161062631	T/C	cg03342759	chr3:160939853	NMD3	-0.88	-7.52	-0.61	3e-11	Parkinson's disease;
THYM	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg18512352	chr11:47633146	NA	-0.56	-7.3	-0.6	8.87e-11	Subjective well-being;
THYM	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg20887711	chr4:1340912	KIAA1530	0.6	4.62	0.43	1.21e-5	Obesity-related traits;
THYM	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg11764359	chr7:65958608	NA	0.58	4.48	0.42	2.07e-5	Aortic root size;
THYM	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs868036	0.681	rs13329582	chr15:68104608	G/C	cg24579218	chr15:68104479	NA	-0.82	-8.85	-0.67	4.77e-14	Restless legs syndrome;
THYM	cis	rs17253792	0.822	rs28681420	chr14:56088403	G/T	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg26384229	chr12:38710491	ALG10B	0.7	6.14	0.53	1.89e-8	Heart rate;
THYM	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs240764	0.725	rs7740826	chr6:101153665	A/G	cg21058520	chr6:100914733	NA	0.59	5.12	0.46	1.62e-6	Neuroticism;
THYM	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg07532245	chr17:28927093	LRRC37B2	0.71	4.48	0.42	2.04e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12368653	0.789	rs17852479	chr12:58126234	C/A	cg12615879	chr12:58013172	SLC26A10	0.55	5.06	0.46	2.08e-6	Multiple sclerosis;
THYM	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg27588902	chr6:42928151	GNMT	-0.55	-5.62	-0.5	1.89e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs13315871	0.929	rs17059171	chr3:58302586	A/G	cg00563845	chr3:58318305	PXK	0.56	4.83	0.44	5.15e-6	Cholesterol, total;
THYM	cis	rs9807841	0.670	rs2360942	chr19:10780802	G/A	cg16900796	chr19:10755136	SLC44A2	0.33	5.08	0.46	1.88e-6	Inflammatory skin disease;
THYM	cis	rs12216545	0.765	rs10238068	chr7:150249758	G/T	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg20486651	chr6:167070296	RPS6KA2	-0.47	-4.5	-0.42	1.92e-5	Crohn's disease;
THYM	cis	rs4589258	0.933	rs116135663	chr11:90409791	C/A	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs16912285	0.688	rs12801480	chr11:24270146	G/A	ch.11.24196551F	chr11:24239977	NA	1.0	7.09	0.59	2.34e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs987710	0.568	rs4287862	chr22:22486735	A/G	cg15020611	chr22:21984399	YDJC	-0.97	-4.5	-0.42	1.96e-5	Iron status biomarkers;Iron deficiency;
THYM	cis	rs7192750	0.586	rs9806882	chr16:71925511	G/T	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg12560992	chr17:57184187	TRIM37	0.93	8.88	0.67	4.06e-14	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg24209194	chr3:40518798	ZNF619	0.67	5.5	0.49	3.17e-7	Renal cell carcinoma;
THYM	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg00383909	chr3:49044727	WDR6	1.27	7.71	0.62	1.22e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs8114671	0.562	rs4911450	chr20:33512406	C/T	cg08999081	chr20:33150536	PIGU	0.63	5.21	0.47	1.09e-6	Height;
THYM	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg26384229	chr12:38710491	ALG10B	0.92	7.03	0.58	3.08e-10	Morning vs. evening chronotype;
THYM	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg00376283	chr12:123451042	ABCB9	0.72	4.88	0.45	4.24e-6	Neutrophil percentage of white cells;
THYM	cis	rs11723261	0.621	rs57013142	chr4:135738	T/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.86	5.68	0.5	1.48e-7	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs10089	1.000	rs10061367	chr5:127449021	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs758324	0.732	rs193685	chr5:131512277	G/A	cg16205897	chr5:131564050	P4HA2	0.52	4.6	0.43	1.29e-5	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg18402987	chr7:1209562	NA	1.03	6.06	0.53	2.77e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs4285028	0.948	rs73855481	chr3:121676951	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.87	-0.45	4.5e-6	Multiple sclerosis;
THYM	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg16049864	chr8:95962084	TP53INP1	-0.69	-6.21	-0.54	1.41e-8	Type 2 diabetes;
THYM	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg04944784	chr2:26401820	FAM59B	-1.07	-8.38	-0.65	4.66e-13	Gut microbiome composition (summer);
THYM	cis	rs568617	1.000	rs10791830	chr11:65661291	C/T	cg15429732	chr11:64851957	ZFPL1;CDCA5	-0.77	-4.53	-0.42	1.69e-5	Crohn's disease;
THYM	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg01324343	chr3:183735012	ABCC5	0.9	13.47	0.81	9.06e-24	Anterior chamber depth;
THYM	cis	rs10095849	0.576	rs4376471	chr8:39458399	A/G	cg01911981	chr8:39380341	ADAM3A	0.59	5.05	0.46	2.13e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg23260525	chr10:116636907	FAM160B1	0.52	5.26	0.47	8.94e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg23711669	chr6:146136114	FBXO30	0.98	10.25	0.72	4.91e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.893	rs10888759	chr1:53433274	A/G	cg08736216	chr1:53307985	ZYG11A	0.61	5.57	0.5	2.41e-7	Monocyte count;
THYM	cis	rs4746818	1.000	rs7901617	chr10:70904063	C/T	cg11621586	chr10:70884670	VPS26A	1.27	10.59	0.74	8.99e-18	Left atrial antero-posterior diameter;
THYM	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg16928487	chr17:17741425	SREBF1	-0.56	-5.57	-0.5	2.37e-7	Total body bone mineral density;
THYM	cis	rs754466	0.651	rs10824582	chr10:79603688	T/C	cg17075019	chr10:79541650	NA	-0.68	-5.69	-0.5	1.41e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9902453	0.780	rs57037139	chr17:28173283	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.66	0.43	1.03e-5	Coffee consumption (cups per day);
THYM	cis	rs4866334	1.000	rs77523779	chr5:18486747	C/A	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg04772025	chr11:68637568	NA	0.64	6.62	0.56	2.1e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg13246856	chr1:44399776	ARTN	0.49	4.95	0.45	3.26e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4664308	1.000	rs62175517	chr2:160911575	C/T	cg03641300	chr2:160917029	PLA2R1	-0.76	-6.83	-0.57	7.92e-10	Idiopathic membranous nephropathy;
THYM	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg22907277	chr7:1156413	C7orf50	0.82	4.98	0.46	2.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	10.09	0.72	1.05e-16	Platelet count;
THYM	cis	rs9560113	1.000	rs9560105	chr13:112175363	A/T	cg10483660	chr13:112241077	NA	-0.53	-4.76	-0.44	6.81e-6	Menarche (age at onset);
THYM	cis	rs10089	1.000	rs1864922	chr5:127420700	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs4833407	0.513	rs62316106	chr4:113302741	C/T	cg25935669	chr4:113448283	NA	-0.55	-4.96	-0.45	3.13e-6	Obesity;
THYM	cis	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg24375607	chr4:120327624	NA	0.59	4.68	0.43	9.43e-6	Corneal astigmatism;
THYM	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.87	-8.55	-0.66	2.03e-13	Lung cancer;
THYM	cis	rs4455778	0.580	rs4336559	chr7:49125213	G/C	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg11764359	chr7:65958608	NA	0.7	4.89	0.45	4.09e-6	Aortic root size;
THYM	cis	rs4909189	1.000	rs11764065	chr7:158135974	T/C	cg25566285	chr7:158114605	PTPRN2	0.77	6.92	0.58	5.36e-10	Response to amphetamines;
THYM	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3006802	1	rs3006802	chr10:26736240	T/C	cg23318538	chr10:26883079	C10orf50	-0.39	-4.95	-0.45	3.15e-6	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs11096990	0.634	rs10029074	chr4:39292502	T/G	cg24403649	chr4:39172243	NA	-0.64	-5.48	-0.49	3.43e-7	Cognitive function;
THYM	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg15693483	chr7:1102177	C7orf50	0.46	4.89	0.45	4.05e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12701220	0.842	rs10236293	chr7:1032637	G/A	cg01699819	chr7:1052092	C7orf50	-0.76	-6.11	-0.53	2.22e-8	Bronchopulmonary dysplasia;
THYM	trans	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6084875	0.840	rs6052816	chr20:4725086	T/C	cg19614321	chr20:4804581	RASSF2	0.44	4.47	0.42	2.19e-5	Systemic lupus erythematosus;
THYM	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg19761014	chr17:28927070	LRRC37B2	0.77	5.07	0.46	1.98e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs8078723	1.000	rs2227336	chr17:38174855	T/G	cg17467752	chr17:38218738	THRA	0.83	6.68	0.57	1.59e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.97	8.88	0.67	4.01e-14	Colorectal cancer;
THYM	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.16	-8.93	-0.68	3.25e-14	Platelet count;
THYM	cis	rs6429082	0.660	rs10737818	chr1:235542023	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.63	-4.69	-0.43	9.16e-6	Adiposity;
THYM	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg07636037	chr3:49044803	WDR6	0.94	9.88	0.71	2.95e-16	Parkinson's disease;
THYM	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg17863274	chr19:49399704	TULP2	-1.01	-6.47	-0.55	4.29e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9826463	0.759	rs17623058	chr3:142344039	G/A	cg20824294	chr3:142316082	PLS1	0.68	4.48	0.42	2.1e-5	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs12216545	0.765	rs2140140	chr7:150249354	C/T	cg08960815	chr7:150264767	GIMAP4	-0.87	-7.56	-0.61	2.54e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	trans	rs916888	0.647	rs199523	chr17:44848517	C/A	cg01341218	chr17:43662625	NA	-0.8	-6.85	-0.57	7.15e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg09307838	chr4:120376055	NA	-0.74	-5.8	-0.51	8.52e-8	Corneal astigmatism;
THYM	cis	rs1885364	0.967	rs5762315	chr22:28094047	T/C	cg17187762	chr22:28070120	NA	0.39	4.67	0.43	9.73e-6	Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion);
THYM	cis	rs956237	0.832	rs61399930	chr4:109089824	C/G	cg15700776	chr4:108852048	CYP2U1	0.6	4.81	0.44	5.76e-6	Systemic lupus erythematosus;
THYM	cis	rs7731657	0.537	rs4705997	chr5:130356026	C/A	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.54	-0.49	2.71e-7	Menopause (age at onset);
THYM	cis	rs6598955	0.671	rs10902735	chr1:26617936	C/T	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.67	0.43	9.71e-6	Obesity-related traits;
THYM	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg12923728	chr3:195709715	SDHAP1	-0.79	-6.49	-0.55	3.84e-9	Pancreatic cancer;
THYM	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg12863693	chr15:85201151	NMB	0.55	4.74	0.44	7.47e-6	Schizophrenia;
THYM	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs34912216	0.619	rs34024211	chr7:4131773	T/G	cg03141780	chr7:4150753	SDK1	0.68	5.17	0.47	1.29e-6	Motion sickness;
THYM	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.58	0.56	2.61e-9	Total body bone mineral density;
THYM	cis	rs1011018	0.955	rs1015122	chr7:139454843	A/G	cg06079564	chr7:139468310	HIPK2	-0.77	-6.04	-0.53	3.05e-8	Systolic blood pressure;
THYM	cis	rs919433	0.713	rs55642934	chr2:198491110	C/T	cg00792783	chr2:198669748	PLCL1	0.83	5.8	0.51	8.63e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg18105134	chr13:113819100	PROZ	-0.98	-9.11	-0.68	1.32e-14	Platelet distribution width;
THYM	cis	rs611744	0.631	rs627392	chr8:109254677	C/T	cg21045802	chr8:109455806	TTC35	0.66	5.99	0.52	3.78e-8	Dupuytren's disease;
THYM	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg06850241	chr22:41845214	NA	0.54	4.6	0.43	1.33e-5	Cannabis dependence symptom count;
THYM	cis	rs73086581	0.891	rs55871214	chr20:3965706	A/C	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs9359856	0.517	rs17506515	chr6:90507332	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.89	-8.13	-0.64	1.6e-12	Bipolar disorder;
THYM	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.46e-7	Heart rate;
THYM	cis	rs12540874	0.698	rs10899736	chr7:50546925	C/T	cg18232548	chr7:50535776	DDC	-0.9	-8.59	-0.66	1.73e-13	Systemic sclerosis;
THYM	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06481639	chr22:41940642	POLR3H	-0.82	-5.67	-0.5	1.55e-7	Vitiligo;
THYM	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs4366490	0.848	rs4963335	chr11:62817083	G/T	cg13684444	chr11:63753508	OTUB1	0.9	4.46	0.42	2.23e-5	Conotruncal heart defects;
THYM	cis	rs9457247	0.508	rs6918286	chr6:167505829	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.48	-4.61	-0.43	1.24e-5	Crohn's disease;
THYM	cis	rs3862260	0.509	rs1045827	chr1:120162442	C/T	cg16322792	chr1:120165303	ZNF697	-0.87	-10.3	-0.73	3.88e-17	Systemic lupus erythematosus;
THYM	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg13319975	chr6:146136371	FBXO30	0.66	5.33	0.48	6.53e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9595908	0.965	rs7335710	chr13:33135424	C/T	cg12383807	chr13:33924137	NA	-0.56	-5.03	-0.46	2.28e-6	Body mass index;
THYM	cis	rs3733631	0.948	rs3733632	chr4:104640935	A/G	cg24090629	chr4:104641072	TACR3	-0.86	-5.51	-0.49	3.1e-7	Menarche (age at onset);
THYM	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg00074818	chr8:8560427	CLDN23	0.5	4.8	0.44	5.85e-6	Obesity-related traits;
THYM	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg25838465	chr1:92012736	NA	-0.9	-8.55	-0.66	2.09e-13	Breast cancer;
THYM	cis	rs2797160	1.000	rs9491471	chr6:125991715	C/T	cg16306078	chr6:126000798	NA	-0.52	-5.34	-0.48	6.31e-7	Endometrial cancer;
THYM	cis	rs7009516	0.819	rs12682329	chr8:24220798	T/C	cg01759110	chr8:24241694	ADAMDEC1	-0.5	-4.45	-0.42	2.35e-5	Hair greying;
THYM	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg16049864	chr8:95962084	TP53INP1	-0.75	-6.69	-0.57	1.54e-9	Type 2 diabetes;
THYM	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg04315214	chr1:2043799	PRKCZ	0.55	4.64	0.43	1.12e-5	Height;
THYM	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	4.83	0.44	5.15e-6	Schizophrenia;
THYM	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg11941060	chr3:133502564	NA	-0.83	-7.14	-0.59	1.83e-10	Iron status biomarkers;
THYM	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs6089829	0.888	rs4809465	chr20:61671156	G/C	cg08045932	chr20:61659980	NA	0.94	10.38	0.73	2.54e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9826463	0.702	rs56397702	chr3:142304764	C/T	cg20824294	chr3:142316082	PLS1	0.63	4.58	0.43	1.42e-5	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs995000	0.931	rs1748200	chr1:63046039	T/C	cg06896770	chr1:63153194	DOCK7	-0.89	-7.31	-0.6	8.2e-11	Triglyceride levels;
THYM	cis	rs57590327	0.508	rs4622918	chr3:81965382	A/G	cg07356753	chr3:81810745	GBE1	-0.68	-4.55	-0.42	1.56e-5	Extraversion;
THYM	cis	rs1878931	0.580	rs8062722	chr16:3409161	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.96	8.89	0.67	3.85e-14	Body mass index (adult);
THYM	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs713587	0.875	rs6746013	chr2:25143649	C/G	cg01884057	chr2:25150051	NA	0.74	8.12	0.64	1.7e-12	Body mass index in non-asthmatics;
THYM	cis	rs4589258	0.788	rs2226918	chr11:90467691	T/C	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.81	-0.44	5.58e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg13175981	chr1:150552382	MCL1	0.7	4.99	0.46	2.72e-6	Tonsillectomy;
THYM	cis	rs2637266	0.846	rs2637263	chr10:78322442	G/A	cg18941641	chr10:78392320	NA	0.69	5.95	0.52	4.51e-8	Pulmonary function;
THYM	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-5.97	-0.52	4.14e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2637266	1.000	rs2637270	chr10:78336901	C/T	cg18941641	chr10:78392320	NA	0.72	6.33	0.54	8.03e-9	Pulmonary function;
THYM	cis	rs4268898	0.662	rs72795832	chr2:24441855	C/A	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg08704250	chr15:31115839	NA	-0.42	-5.05	-0.46	2.17e-6	Huntington's disease progression;
THYM	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg00908189	chr16:619842	PIGQ	1.03	9.46	0.7	2.34e-15	Height;
THYM	cis	rs920590	0.684	rs59565447	chr8:19668430	A/T	cg03894339	chr8:19674705	INTS10	0.62	4.79	0.44	6.22e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1499972	0.938	rs861673	chr3:117733019	A/G	cg07612923	chr3:117604196	NA	-1.5	-5.16	-0.47	1.38e-6	Schizophrenia;
THYM	cis	rs1451375	1.000	rs2329342	chr7:50624971	A/G	cg18232548	chr7:50535776	DDC	-0.73	-5.57	-0.5	2.35e-7	Malaria;
THYM	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.14	0.47	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	4.93	0.45	3.5e-6	Diabetic retinopathy;
THYM	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs9560113	0.550	rs1163633	chr13:112231561	G/T	cg10483660	chr13:112241077	NA	-0.66	-7.74	-0.62	1.04e-11	Menarche (age at onset);
THYM	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg05043794	chr9:111880884	C9orf5	-0.35	-4.93	-0.45	3.42e-6	Menarche (age at onset);
THYM	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg18305652	chr10:134549665	INPP5A	0.75	5.9	0.52	5.46e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs61931739	0.513	rs1608906	chr12:33894986	T/C	cg06521331	chr12:34319734	NA	-0.58	-4.62	-0.43	1.2e-5	Morning vs. evening chronotype;
THYM	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg16586182	chr3:47516702	SCAP	-0.62	-5.25	-0.47	9.36e-7	Colorectal cancer;
THYM	cis	rs7246657	0.943	rs7252346	chr19:37914682	G/A	cg22634378	chr19:37742834	NA	0.62	5.18	0.47	1.22e-6	Coronary artery calcification;
THYM	cis	rs977987	0.750	rs4888407	chr16:75432390	T/C	cg03315344	chr16:75512273	CHST6	0.73	6.16	0.53	1.73e-8	Dupuytren's disease;
THYM	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg20291162	chr17:40259547	DHX58	-0.7	-6.47	-0.55	4.18e-9	Fibrinogen levels;
THYM	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg00898013	chr13:113819073	PROZ	-1.02	-10.0	-0.72	1.62e-16	Platelet distribution width;
THYM	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	5.56	0.5	2.43e-7	Breast cancer;
THYM	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs4731207	0.698	rs7794631	chr7:124551925	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg05347473	chr6:146136440	FBXO30	0.55	4.49	0.42	2.02e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.66	-5.21	-0.47	1.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7584330	0.518	rs77789507	chr2:238440972	C/T	cg14458575	chr2:238380390	NA	1.03	5.54	0.49	2.71e-7	Prostate cancer;
THYM	cis	rs34421088	0.624	rs6986736	chr8:11584503	T/A	cg12395012	chr8:11607386	GATA4	0.63	5.09	0.46	1.78e-6	Neuroticism;
THYM	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg27490568	chr2:178487706	NA	0.59	5.26	0.48	8.77e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg18132916	chr6:79620363	NA	-0.6	-5.35	-0.48	6.15e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg14675211	chr2:100938903	LONRF2	0.76	8.01	0.64	2.81e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7084402	0.967	rs1658434	chr10:60328756	G/C	cg09696939	chr10:60272079	BICC1	-0.46	-5.41	-0.49	4.65e-7	Refractive error;
THYM	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg14196790	chr5:131705035	SLC22A5	0.56	5.27	0.48	8.63e-7	Blood metabolite levels;
THYM	cis	rs367615	0.550	rs10060801	chr5:108881782	A/G	cg17395555	chr5:108820864	NA	0.47	5.47	0.49	3.69e-7	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs7681440	0.606	rs2583974	chr4:90748297	T/C	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs7010267	0.805	rs2062375	chr8:119977792	G/C	cg17171407	chr8:119960777	TNFRSF11B	0.59	4.84	0.44	4.99e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg22709100	chr7:91322751	NA	0.62	4.82	0.44	5.36e-6	Breast cancer;
THYM	cis	rs7359257	1.000	rs11071952	chr15:67694780	A/T	cg24579218	chr15:68104479	NA	0.54	4.6	0.43	1.32e-5	Menarche (age at onset);
THYM	cis	rs3796352	1.000	rs13072818	chr3:53074263	C/T	cg24530246	chr3:53118167	NA	-0.76	-4.57	-0.42	1.47e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	5.86	0.52	6.64e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs10203711	0.966	rs9287635	chr2:239582267	C/T	cg14580085	chr2:239553406	NA	0.68	6.18	0.54	1.58e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg21280719	chr6:42927975	GNMT	-0.53	-7.38	-0.6	5.9e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs807029	0.533	rs3740487	chr10:102750783	C/A	cg14905631	chr10:102746534	C10orf2;MRPL43	0.36	5.05	0.46	2.14e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs1775715	0.737	rs2808090	chr10:32143208	A/C	cg04359828	chr10:32216031	ARHGAP12	0.41	5.12	0.46	1.62e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg06558623	chr16:89946397	TCF25	-0.94	-5.06	-0.46	2.06e-6	Skin colour saturation;
THYM	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg06108461	chr20:60628389	TAF4	-1.06	-9.1	-0.68	1.39e-14	Body mass index;
THYM	cis	rs1728785	0.901	rs1103286	chr16:68578625	C/T	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs62051538	0.602	rs9921592	chr16:31538459	G/A	cg10091996	chr16:31548640	NA	-0.5	-4.5	-0.42	1.96e-5	Mean corpuscular hemoglobin;
THYM	cis	rs144345632	1	rs144345632	chr6:96886894	T/TA	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs11771526	0.892	rs62457504	chr7:32336097	G/A	cg13207630	chr7:32358064	NA	0.99	5.93	0.52	4.8e-8	Body mass index;
THYM	cis	rs2637266	0.745	rs241	chr10:78444456	G/T	cg18941641	chr10:78392320	NA	0.74	6.0	0.52	3.53e-8	Pulmonary function;
THYM	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg15536230	chr21:44985092	HSF2BP	-0.39	-4.62	-0.43	1.22e-5	Mean corpuscular volume;
THYM	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg10047753	chr17:41438598	NA	1.18	10.87	0.74	2.37e-18	Menopause (age at onset);
THYM	cis	rs6032067	0.929	rs2267864	chr20:43805279	C/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.65	-6.32	-0.54	8.44e-9	Blood protein levels;
THYM	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg18758796	chr5:131593413	PDLIM4	-0.52	-5.45	-0.49	3.89e-7	Breast cancer;
THYM	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.61	5.29	0.48	7.85e-7	Personality dimensions;
THYM	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg01119278	chr6:110721349	DDO	-0.64	-7.54	-0.61	2.78e-11	Platelet distribution width;
THYM	cis	rs7172809	0.573	rs55881066	chr15:77507674	T/C	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4383453	0.539	rs4677887	chr3:123100223	A/C	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00475322	chr7:917719	C7orf20	0.49	6.19	0.54	1.55e-8	Perceived unattractiveness to mosquitoes;
THYM	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg26354017	chr1:205819088	PM20D1	-0.96	-10.41	-0.73	2.19e-17	Menarche (age at onset);
THYM	trans	rs877282	1.000	rs7100358	chr10:773681	G/A	cg22713356	chr15:30763199	NA	1.26	10.12	0.72	9.24e-17	Uric acid levels;
THYM	cis	rs28795989	0.795	rs34179701	chr4:7916182	T/C	cg00251875	chr4:7801337	AFAP1	-0.61	-4.9	-0.45	3.95e-6	Intraocular pressure;
THYM	cis	rs9290065	0.558	rs9846254	chr3:160770370	C/T	cg03342759	chr3:160939853	NMD3	-0.62	-4.74	-0.44	7.44e-6	Kawasaki disease;
THYM	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg10802521	chr3:52805072	NEK4	0.75	7.03	0.58	3.15e-10	Electroencephalogram traits;
THYM	cis	rs9361491	0.578	rs9359345	chr6:79469916	A/C	cg04547799	chr6:79944526	HMGN3	-0.7	-4.91	-0.45	3.73e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg15110403	chr19:17392923	ANKLE1	-0.57	-4.94	-0.45	3.36e-6	Systemic lupus erythematosus;
THYM	cis	rs4866334	1.000	rs114114986	chr5:18428605	C/A	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs28476539	0.640	rs7655583	chr4:83554656	T/C	cg10249074	chr4:83542146	C4orf11	-0.64	-5.06	-0.46	2.03e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	7.77	0.62	9.07e-12	Smoking behavior;
THYM	cis	rs9329221	0.621	rs12156350	chr8:10268516	T/G	cg02178032	chr8:11213424	TDH	0.54	4.8	0.44	5.85e-6	Neuroticism;
THYM	cis	rs9486719	1.000	rs3798295	chr6:97052164	C/T	cg18709589	chr6:96969512	KIAA0776	-0.67	-4.64	-0.43	1.1e-5	Migraine;Coronary artery disease;
THYM	trans	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg06636001	chr8:8085503	FLJ10661	0.78	6.99	0.58	3.83e-10	Neuroticism;
THYM	cis	rs7772486	0.558	rs702316	chr6:146004677	C/A	cg05347473	chr6:146136440	FBXO30	-0.86	-6.86	-0.58	6.83e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	4.75	0.44	7.27e-6	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg22920501	chr2:26401640	FAM59B	1.07	9.54	0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg20203395	chr5:56204925	C5orf35	-0.66	-4.62	-0.43	1.22e-5	Initial pursuit acceleration;
THYM	cis	rs17539620	0.624	rs74551216	chr6:154840524	T/C	cg20019720	chr6:154832845	CNKSR3	0.49	4.85	0.45	4.81e-6	Lipoprotein (a) levels;
THYM	cis	rs28595532	0.920	rs55901549	chr4:119770172	T/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg03388043	chr17:80084554	CCDC57	0.69	5.98	0.52	3.85e-8	Life satisfaction;
THYM	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg13114125	chr14:105738426	BRF1	-0.71	-5.48	-0.49	3.45e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs35164067	1.000	rs73923215	chr19:10514842	A/C	cg01466491	chr19:10523363	NA	-0.65	-5.08	-0.46	1.92e-6	Inflammatory bowel disease;
THYM	cis	rs11645898	0.935	rs4788614	chr16:72188828	C/T	cg03805757	chr16:71968109	PKD1L3	0.62	4.49	0.42	2.01e-5	Blood protein levels;
THYM	cis	rs2219968	1.000	rs6473085	chr8:78974505	T/A	cg00738934	chr8:78996279	NA	0.91	9.74	0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10504073	0.584	rs10957337	chr8:49959027	G/T	cg00325661	chr8:49890786	NA	1.07	10.28	0.73	4.26e-17	Blood metabolite ratios;
THYM	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06850241	chr22:41845214	NA	-0.59	-5.36	-0.48	5.85e-7	Vitiligo;
THYM	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg18758796	chr5:131593413	PDLIM4	0.5	4.8	0.44	5.79e-6	Breast cancer;
THYM	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.15	-0.47	1.4e-6	Total cholesterol levels;
THYM	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg23205692	chr1:25664452	TMEM50A	0.83	6.44	0.55	4.85e-9	Erythrocyte sedimentation rate;
THYM	cis	rs4595586	0.545	rs2388174	chr12:39389237	G/A	cg13010199	chr12:38710504	ALG10B	0.61	4.47	0.42	2.16e-5	Morning vs. evening chronotype;
THYM	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12756686	chr19:29218302	NA	0.96	8.21	0.64	1.08e-12	Methadone dose in opioid dependence;
THYM	cis	rs864643	0.773	rs11129838	chr3:39599187	A/C	cg20142358	chr3:39093977	WDR48	0.7	4.92	0.45	3.66e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs10492096	0.947	rs10849484	chr12:6637941	C/T	cg13857086	chr12:6580257	VAMP1	0.86	4.99	0.46	2.74e-6	Hip geometry;
THYM	cis	rs6840360	0.608	rs2724556	chr4:152341717	G/A	cg22705602	chr4:152727874	NA	-0.52	-5.22	-0.47	1.04e-6	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.73	5.62	0.5	1.93e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg17211192	chr8:82754475	SNX16	-0.9	-7.34	-0.6	7.07e-11	Diastolic blood pressure;
THYM	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg12386194	chr3:101231763	SENP7	0.67	4.99	0.46	2.75e-6	Colorectal cancer;
THYM	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg06026331	chr20:60912101	LAMA5	-0.62	-4.87	-0.45	4.52e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs2235642	0.826	rs8048410	chr16:1614097	A/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.65	-5.41	-0.48	4.8e-7	Coronary artery disease;
THYM	cis	rs854765	0.624	rs11657130	chr17:17733826	T/C	cg04398451	chr17:18023971	MYO15A	0.87	7.92	0.63	4.37e-12	Total body bone mineral density;
THYM	cis	rs1061377	1.000	rs1560397	chr4:39113885	T/C	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs10089	0.951	rs56066100	chr5:127460571	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg12165864	chr7:66369176	NA	-0.81	-6.08	-0.53	2.47e-8	Corneal structure;
THYM	cis	rs924712	0.844	rs7765721	chr6:54734941	C/A	cg19716238	chr6:54711378	FAM83B	-0.46	-4.66	-0.43	1.05e-5	Breast cancer;
THYM	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg21433313	chr16:3507492	NAT15	0.81	6.9	0.58	5.87e-10	Tuberculosis;
THYM	cis	rs4606347	0.872	rs61783276	chr1:66112473	A/T	cg04111102	chr1:66153794	NA	0.59	4.54	0.42	1.67e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	5.75	0.51	1.06e-7	Platelet count;
THYM	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg13319975	chr6:146136371	FBXO30	-0.64	-5.34	-0.48	6.3e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg00495681	chr13:53174319	NA	0.6	5.68	0.5	1.44e-7	Lewy body disease;
THYM	cis	rs6500395	1.000	rs12447645	chr16:48694440	A/G	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs747334	0.782	rs7906208	chr10:92703482	C/T	cg07620928	chr10:92689909	NA	0.54	4.84	0.44	5.04e-6	Fibroblast growth factor basic levels;
THYM	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg13319975	chr6:146136371	FBXO30	-0.67	-5.89	-0.52	5.9e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg05234568	chr11:5960015	NA	-0.61	-4.98	-0.46	2.82e-6	DNA methylation (variation);
THYM	cis	rs10484885	0.824	rs72919954	chr6:90515665	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.87	-7.73	-0.62	1.13e-11	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs4262150	0.883	rs12186623	chr5:152214254	T/C	cg06854687	chr5:151642065	NA	0.66	4.6	0.43	1.3e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg24675658	chr1:53192096	ZYG11B	-0.87	-8.37	-0.65	5.08e-13	Monocyte count;
THYM	cis	rs3126085	0.935	rs12144058	chr1:152170216	C/T	cg26020982	chr1:152196106	HRNR	0.34	4.52	0.42	1.76e-5	Atopic dermatitis;
THYM	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg18301423	chr5:131593218	PDLIM4	0.48	4.49	0.42	2.04e-5	Breast cancer;
THYM	cis	rs2976388	1.000	rs2920294	chr8:143765326	C/G	cg06565975	chr8:143823917	SLURP1	-0.45	-5.16	-0.47	1.38e-6	Urinary tract infection frequency;
THYM	cis	rs28595532	0.688	rs116566508	chr4:119619195	G/A	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs2066819	1.000	rs57279772	chr12:56698960	G/A	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg23711669	chr6:146136114	FBXO30	0.96	9.87	0.71	3.12e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6430585	0.583	rs3769012	chr2:136556480	C/T	cg04750100	chr2:136595281	LCT	0.5	4.82	0.44	5.53e-6	Corneal structure;
THYM	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs17030434	0.863	rs17030382	chr4:154650887	A/G	cg14289246	chr4:154710475	SFRP2	-0.89	-5.55	-0.5	2.53e-7	Electrocardiographic conduction measures;
THYM	cis	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg10518543	chr12:38710700	ALG10B	-0.57	-4.57	-0.42	1.47e-5	Morning vs. evening chronotype;
THYM	cis	rs4845875	0.540	rs10864543	chr1:11844330	C/T	cg25341925	chr1:11908058	NPPA	0.47	4.94	0.45	3.3e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs791888	1.000	rs791882	chr10:89408258	C/T	cg13926569	chr10:89418898	PAPSS2	-0.66	-7.22	-0.59	1.3100000000000001e-10	Magnesium levels;
THYM	cis	rs1003719	0.680	rs8130069	chr21:38552116	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs6722750	0.840	rs6712700	chr2:64374041	A/G	cg22352474	chr2:64371530	PELI1	0.81	6.87	0.58	6.49e-10	Neuroticism;
THYM	cis	rs11089937	0.626	rs5757056	chr22:22496884	C/G	cg21401457	chr22:22472743	NA	0.57	4.73	0.44	7.76e-6	Periodontitis (PAL4Q3);
THYM	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg03433033	chr1:76189801	ACADM	-0.51	-5.33	-0.48	6.53e-7	Daytime sleep phenotypes;
THYM	cis	rs4718428	1.000	rs1830070	chr7:66349671	T/C	cg12165864	chr7:66369176	NA	-0.72	-5.55	-0.49	2.63e-7	Corneal structure;
THYM	cis	rs11247915	0.622	rs34370465	chr1:26670609	C/T	cg00852783	chr1:26633632	UBXN11	0.76	6.08	0.53	2.47e-8	Obesity-related traits;
THYM	cis	rs7681440	0.606	rs2737004	chr4:90750722	A/G	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	trans	rs75518195	0.543	rs62301949	chr4:64676573	A/C	cg14706739	chr8:21916355	EPB49	0.75	7.37	0.6	6.34e-11	Triptolide cytotoxicity;
THYM	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs921665	0.915	rs11127382	chr2:3185675	A/T	cg16434511	chr2:3151078	NA	-0.76	-5.18	-0.47	1.24e-6	World class endurance athleticism;
THYM	cis	rs7631605	0.905	rs6773752	chr3:37225837	C/T	cg21328643	chr3:37258149	NA	-0.53	-5.15	-0.47	1.42e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg03732007	chr1:2071316	PRKCZ	0.52	4.78	0.44	6.28e-6	Height;
THYM	cis	rs7412746	0.611	rs1889740	chr1:150799755	C/T	cg15448220	chr1:150897856	SETDB1	0.83	6.83	0.57	8.08e-10	Melanoma;
THYM	cis	rs1978968	0.912	rs28478894	chr22:18454600	G/A	cg01550578	chr22:18484421	MICAL3	0.61	4.65	0.43	1.09e-5	Presence of antiphospholipid antibodies;
THYM	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg14972814	chr11:95582409	MTMR2	-0.72	-6.08	-0.53	2.51e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7322722	0.945	rs12869227	chr13:77846136	A/T	cg04565255	chr13:77565759	CLN5	-0.45	-4.47	-0.42	2.12e-5	Preeclampsia;
THYM	cis	rs500891	0.525	rs1144179	chr6:84026572	C/G	cg21688264	chr6:84418724	SNAP91	0.74	4.51	0.42	1.87e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.56	4.55	0.42	1.56e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs3804749	0.966	rs9820435	chr3:122846881	C/T	cg10259872	chr3:122802215	PDIA5	0.47	5.23	0.47	1.03e-6	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg23711669	chr6:146136114	FBXO30	-0.91	-8.87	-0.67	4.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12282928	0.807	rs4980429	chr11:48298148	G/A	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7843479	0.965	rs17616085	chr8:21857267	C/T	cg17168535	chr8:21777572	XPO7	0.64	4.77	0.44	6.53e-6	Mean corpuscular volume;
THYM	cis	rs4474465	1.000	rs7121283	chr11:78149340	T/A	cg19901956	chr11:77921274	USP35	-0.6	-4.5	-0.42	1.91e-5	Alzheimer's disease (survival time);
THYM	cis	rs806215	1.000	rs327511	chr7:127257261	G/T	cg08586737	chr7:127225949	GCC1	0.37	4.52	0.42	1.8e-5	Type 2 diabetes;
THYM	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg21475434	chr5:93447410	FAM172A	0.85	5.41	0.49	4.61e-7	Diabetic retinopathy;
THYM	cis	rs911119	0.955	rs35610040	chr20:23616469	T/C	cg16589663	chr20:23618590	CST3	0.78	4.79	0.44	6.1e-6	Chronic kidney disease;
THYM	cis	rs6815814	0.950	rs5743795	chr4:38832495	C/T	cg14665413	chr4:38859728	TLR6	-0.41	-4.87	-0.45	4.51e-6	Breast cancer;
THYM	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.94	6.27	0.54	1.05e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg09549813	chr16:4587862	C16orf5	-0.58	-6.42	-0.55	5.23e-9	Schizophrenia;
THYM	cis	rs4654899	0.758	rs1354792	chr1:21391875	C/T	cg01072550	chr1:21505969	NA	0.72	6.94	0.58	4.85e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs11096990	0.576	rs2008679	chr4:39268005	A/C	cg24403649	chr4:39172243	NA	-0.67	-5.84	-0.51	7.33e-8	Cognitive function;
THYM	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	8.07	0.64	2.11e-12	Smoking behavior;
THYM	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg13319975	chr6:146136371	FBXO30	-0.68	-5.69	-0.5	1.43e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs921968	0.613	rs556497	chr2:219446477	G/A	cg02176678	chr2:219576539	TTLL4	0.67	6.66	0.56	1.78e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg14779329	chr11:130786720	SNX19	0.47	4.94	0.45	3.41e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg04842962	chr6:43655489	MRPS18A	1.41	15.71	0.85	3.75e-28	IgG glycosylation;
THYM	cis	rs897984	0.520	rs4889614	chr16:30862135	G/A	cg03418659	chr16:31128414	MYST1	0.64	4.68	0.43	9.46e-6	Dementia with Lewy bodies;
THYM	cis	rs6987853	0.787	rs2974358	chr8:42434403	T/C	cg09913449	chr8:42400586	C8orf40	1.06	11.6	0.77	6.75e-20	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs9326248	0.530	rs7940310	chr11:117024481	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.95	5.34	0.48	6.34e-7	Blood protein levels;
THYM	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg10117171	chr1:25599238	RHD	0.68	4.87	0.45	4.52e-6	Erythrocyte sedimentation rate;
THYM	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg22133161	chr19:49891603	CCDC155	0.74	4.88	0.45	4.29e-6	Multiple sclerosis;
THYM	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg00129232	chr17:37814104	STARD3	-0.98	-9.01	-0.68	2.12e-14	Asthma;
THYM	cis	rs4790333	0.757	rs2429909	chr17:2270284	G/A	cg02569219	chr17:2266849	SGSM2	0.64	5.15	0.47	1.39e-6	Proinsulin levels;
THYM	cis	rs7677751	0.806	rs4864863	chr4:55100831	A/G	cg17187183	chr4:55093834	PDGFRA	0.74	5.58	0.5	2.27e-7	Corneal astigmatism;
THYM	cis	rs7107174	1.000	rs2511185	chr11:77982496	C/A	cg02023728	chr11:77925099	USP35	0.68	6.38	0.55	6.54e-9	Testicular germ cell tumor;
THYM	cis	rs7399018	0.739	rs7399073	chr12:51614050	C/A	cg25754956	chr12:51612065	POU6F1	0.98	7.29	0.6	9.28e-11	Cisplatin-induced ototoxicity;
THYM	cis	rs700651	0.789	rs882954	chr2:198907444	A/G	cg00792783	chr2:198669748	PLCL1	0.72	4.82	0.44	5.37e-6	Intracranial aneurysm;
THYM	trans	rs1974653	0.672	rs9606234	chr22:20067517	T/G	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs7119	0.717	rs12916642	chr15:77818426	G/T	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg06238570	chr21:40685208	BRWD1	-0.72	-6.28	-0.54	9.9e-9	Menarche (age at onset);
THYM	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg22307029	chr19:49891270	CCDC155	0.83	6.95	0.58	4.67e-10	Multiple sclerosis;
THYM	cis	rs10208940	0.614	rs75436646	chr2:68752098	G/A	cg09157127	chr2:69201416	GKN1	0.89	4.71	0.43	8.61e-6	Urate levels in lean individuals;
THYM	cis	rs1568889	0.838	rs4572130	chr11:28371794	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	6.91	0.58	5.53e-10	Bipolar disorder;
THYM	cis	rs11651000	0.841	rs11650451	chr17:45809822	G/A	cg24803719	chr17:45855879	NA	-0.71	-5.58	-0.5	2.25e-7	IgG glycosylation;
THYM	cis	rs6502050	0.723	rs66871014	chr17:80181874	G/A	cg03388043	chr17:80084554	CCDC57	-0.71	-5.79	-0.51	9.15e-8	Life satisfaction;
THYM	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg03474202	chr17:45855739	NA	-0.72	-6.3	-0.54	9.36e-9	IgG glycosylation;
THYM	cis	rs885814	0.843	rs12025623	chr1:21892479	C/T	cg14781605	chr1:21864896	ALPL	-0.61	-4.69	-0.43	9.29e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs2811415	0.597	rs2276867	chr3:127786675	T/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs735539	0.521	rs716480	chr13:21418094	T/G	cg02792322	chr13:21280448	IL17D	-0.66	-4.78	-0.44	6.37e-6	Dental caries;
THYM	cis	rs448720	0.811	rs383041	chr15:68184481	C/G	cg23793686	chr15:68133972	NA	-0.53	-4.81	-0.44	5.57e-6	Cognitive performance;
THYM	cis	rs35264875	1.000	rs72917389	chr11:68822831	C/T	cg01993067	chr11:68851601	TPCN2	1.02	4.76	0.44	6.85e-6	Blond vs. brown hair color;
THYM	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg08847533	chr14:75593920	NEK9	-1.01	-11.33	-0.76	2.42e-19	Height;
THYM	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg18252515	chr7:66147081	NA	-0.66	-5.0	-0.46	2.65e-6	Aortic root size;
THYM	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs7572733	0.534	rs2574832	chr2:198704818	T/G	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs662064	0.962	rs683864	chr1:10561954	T/C	cg20482658	chr1:10539492	PEX14	0.46	5.62	0.5	1.86e-7	Asthma;
THYM	cis	rs6987853	0.933	rs2974341	chr8:42398302	T/A	cg09913449	chr8:42400586	C8orf40	0.88	8.02	0.64	2.8e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs55665837	1.000	rs12295723	chr11:14450201	T/C	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg19761014	chr17:28927070	LRRC37B2	0.72	4.53	0.42	1.72e-5	Body mass index;
THYM	trans	rs8073060	0.586	rs225257	chr17:33956625	G/A	cg19694781	chr19:47549865	TMEM160	-0.95	-7.8	-0.62	7.8e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs4974559	0.739	rs4333131	chr4:1323789	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.44	-5.0	-0.46	2.63e-6	Systolic blood pressure;
THYM	cis	rs3819817	0.575	rs4762653	chr12:96351378	T/C	cg26410635	chr12:96350720	AMDHD1	0.53	5.02	0.46	2.38e-6	Vitamin D levels;
THYM	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg11663144	chr21:46675770	NA	-0.69	-9.58	-0.7	1.33e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11890956	chr21:40555474	PSMG1	0.92	10.06	0.72	1.24e-16	Cognitive function;
THYM	cis	rs1784581	0.546	rs1954917	chr6:162447490	C/T	cg17173639	chr6:162384350	PARK2	0.83	7.55	0.61	2.7e-11	Itch intensity from mosquito bite;
THYM	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg04918696	chr8:1004106	NA	-0.41	-4.63	-0.43	1.15e-5	Schizophrenia;
THYM	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg18876405	chr7:65276391	NA	-0.61	-5.2	-0.47	1.13e-6	Aortic root size;
THYM	cis	rs4731207	0.594	rs6968500	chr7:124431722	G/C	cg05285228	chr7:124571219	POT1	-0.67	-5.33	-0.48	6.75e-7	Cutaneous malignant melanoma;
THYM	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-4.96	-0.45	3.08e-6	Hemoglobin concentration;
THYM	cis	rs61931739	0.782	rs1197569	chr12:34186733	A/T	cg10856724	chr12:34555212	NA	-0.6	-5.47	-0.49	3.6e-7	Morning vs. evening chronotype;
THYM	cis	rs9611565	1.000	rs5758314	chr22:41762523	T/G	cg03806693	chr22:41940476	POLR3H	-0.9	-8.09	-0.64	1.95e-12	Vitiligo;
THYM	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg22117172	chr7:91764530	CYP51A1	0.35	4.46	0.42	2.27e-5	Breast cancer;
THYM	cis	rs11190604	0.697	rs4559619	chr10:102199884	C/T	cg16342193	chr10:102329863	NA	0.49	4.98	0.46	2.81e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs2552220	1.000	rs13254297	chr8:6006228	C/T	cg06481462	chr8:7005678	NA	0.48	4.8	0.44	5.93e-6	Interleukin-8 levels;
THYM	cis	rs6894268	1.000	rs6894268	chr5:179032488	A/G	cg26135573	chr5:179059668	NA	0.6	4.46	0.42	2.22e-5	Eating disorders;
THYM	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg23187316	chr7:1099788	C7orf50	0.48	5.45	0.49	3.98e-7	Longevity;Endometriosis;
THYM	cis	rs4911259	0.533	rs6058931	chr20:31471012	C/T	cg13636640	chr20:31349939	DNMT3B	-0.61	-5.89	-0.52	5.86e-8	Inflammatory bowel disease;
THYM	cis	rs7084402	0.967	rs1649035	chr10:60332701	A/T	cg09696939	chr10:60272079	BICC1	-0.42	-4.98	-0.46	2.79e-6	Refractive error;
THYM	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg03351412	chr1:154909251	PMVK	0.68	5.08	0.46	1.89e-6	Prostate cancer;
THYM	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs288326	0.561	rs79804181	chr2:183710898	T/C	cg09997497	chr2:183902928	NCKAP1	1.06	4.79	0.44	6.12e-6	Blood protein levels;
THYM	cis	rs7172809	0.643	rs61483316	chr15:77834147	C/T	cg22256960	chr15:77711686	NA	-0.75	-5.57	-0.5	2.4e-7	Glucose homeostasis traits;
THYM	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg00684032	chr4:1343700	KIAA1530	0.56	4.83	0.44	5.24e-6	Obesity-related traits;
THYM	cis	rs9807989	0.571	rs10208293	chr2:102966310	G/A	cg09003973	chr2:102972529	NA	0.67	4.99	0.46	2.78e-6	Asthma;
THYM	cis	rs10752881	0.935	rs10797834	chr1:183048749	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Colorectal cancer;
THYM	cis	rs6840360	1.000	rs1864300	chr4:152663326	T/C	cg22705602	chr4:152727874	NA	-0.58	-6.26	-0.54	1.1e-8	Intelligence (multi-trait analysis);
THYM	cis	rs72627123	0.867	rs17094157	chr14:74416665	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.1	6.43	0.55	5.04e-9	Morning vs. evening chronotype;
THYM	cis	rs853679	0.882	rs9380069	chr6:28203300	A/G	cg12963246	chr6:28129442	ZNF389	0.75	5.0	0.46	2.61e-6	Depression;
THYM	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03264133	chr6:25882463	NA	-0.69	-5.32	-0.48	7.03e-7	Blood metabolite levels;
THYM	cis	rs7704138	0.639	rs4865979	chr5:55016150	G/A	cg18456523	chr5:54516805	NA	-0.58	-4.59	-0.43	1.34e-5	Height;
THYM	cis	rs9649213	0.593	rs7778015	chr7:97920270	T/C	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg24881330	chr22:46731750	TRMU	0.85	5.16	0.47	1.37e-6	LDL cholesterol;Cholesterol, total;
THYM	cis	rs13315871	1.000	rs9821570	chr3:58335919	C/G	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg25358565	chr5:93447407	FAM172A	0.98	7.16	0.59	1.71e-10	Diabetic retinopathy;
THYM	cis	rs9733	0.596	rs11807058	chr1:150640475	G/A	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.72	6.55	0.56	2.99e-9	Personality dimensions;
THYM	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9486719	1.000	rs12529248	chr6:96895377	T/G	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs977987	0.806	rs12448947	chr16:75462954	G/A	cg03315344	chr16:75512273	CHST6	0.76	6.17	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs9581857	0.579	rs3759433	chr13:27997999	C/T	cg27031448	chr13:27998168	GTF3A	0.37	4.57	0.42	1.46e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs7107174	1.000	rs11237480	chr11:78110385	C/A	cg02023728	chr11:77925099	USP35	0.63	6.11	0.53	2.23e-8	Testicular germ cell tumor;
THYM	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	5.7	0.5	1.37e-7	Schizophrenia;
THYM	cis	rs59112743	0.510	rs9464793	chr6:15525863	C/T	cg10111214	chr6:14815676	NA	-0.74	-4.99	-0.46	2.71e-6	Multiple keratinocyte cancers;
THYM	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-4.94	-0.45	3.39e-6	Lymphocyte counts;
THYM	trans	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg23505145	chr19:12996616	KLF1	1.02	10.2	0.72	6.2e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs2692947	0.683	rs62153700	chr2:96581338	C/T	cg22654517	chr2:96458247	NA	0.71	4.53	0.42	1.73e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs11217036	1	rs11217036	chr11:118675772	C/T	cg19308663	chr11:118741387	NA	0.57	5.87	0.52	6.34e-8	Allergy;
THYM	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg23791538	chr6:167370224	RNASET2	-0.72	-5.66	-0.5	1.58e-7	Crohn's disease;
THYM	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg26384229	chr12:38710491	ALG10B	1.02	8.46	0.66	3.1400000000000003e-13	Heart rate;
THYM	cis	rs2249694	0.960	rs7075572	chr10:135404358	T/C	cg20169779	chr10:135381914	SYCE1	-0.54	-4.53	-0.42	1.69e-5	Obesity-related traits;
THYM	cis	rs1883415	0.614	rs2817225	chr6:24507728	A/G	cg00346970	chr6:24499591	ALDH5A1	0.48	6.11	0.53	2.17e-8	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg23583168	chr7:148888333	NA	-0.98	-13.39	-0.81	1.35e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs2969070	1.000	rs2969070	chr7:2512545	C/T	cg25507518	chr7:2405875	EIF3B	-0.47	-4.54	-0.42	1.68e-5	Diastolic blood pressure;
THYM	cis	rs673253	0.556	rs660899	chr1:44117006	G/T	cg24466421	chr1:44070974	PTPRF	-0.56	-4.62	-0.43	1.2e-5	Intelligence (multi-trait analysis);
THYM	cis	rs16857609	0.600	rs10932715	chr2:218259783	A/G	cg15335768	chr2:218268053	DIRC3	-0.51	-7.38	-0.6	5.99e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	cis	rs227425	0.525	rs227420	chr14:70458755	G/C	cg12046056	chr14:71067695	MED6	0.56	4.58	0.43	1.43e-5	Bone mineral density;
THYM	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg05283184	chr6:79620031	NA	-0.91	-8.88	-0.67	4.11e-14	Intelligence (multi-trait analysis);
THYM	cis	rs9527	1.000	rs4919690	chr10:104616500	C/T	cg04362960	chr10:104952993	NT5C2	-0.67	-4.74	-0.44	7.61e-6	Arsenic metabolism;
THYM	cis	rs2299587	0.637	rs7832527	chr8:17889343	C/A	cg01800426	chr8:17659068	MTUS1	-0.57	-4.52	-0.42	1.81e-5	Economic and political preferences;
THYM	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg02725872	chr8:58115012	NA	-0.87	-6.17	-0.53	1.69e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	7.98	0.63	3.34e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg20476274	chr7:133979776	SLC35B4	0.75	4.81	0.44	5.58e-6	Mean platelet volume;
THYM	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg24209194	chr3:40518798	ZNF619	0.62	4.94	0.45	3.3e-6	Renal cell carcinoma;
THYM	cis	rs960902	0.620	rs11694646	chr2:37738067	A/G	cg25341268	chr2:37734390	NA	0.66	5.31	0.48	7.24e-7	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg11984989	chr7:158649758	WDR60	-1.02	-13.15	-0.8	4.22e-23	Height;
THYM	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.16	-0.75	5.56e-19	Primary sclerosing cholangitis;
THYM	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg07777115	chr5:623756	CEP72	-0.8	-4.78	-0.44	6.48e-6	Obesity-related traits;
THYM	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg09667013	chr22:42394590	WBP2NL	0.72	5.04	0.46	2.18e-6	Birth weight;
THYM	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg15556689	chr8:8085844	FLJ10661	0.64	4.85	0.45	4.8e-6	Neuroticism;
THYM	cis	rs10992471	0.576	rs9409664	chr9:95070095	A/G	cg14631576	chr9:95140430	CENPP	-0.71	-6.39	-0.55	6.05e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg12981288	chr8:11183844	MTMR9	-0.47	-4.61	-0.43	1.27e-5	Retinal vascular caliber;
THYM	cis	rs7917772	0.582	rs10786683	chr10:104320476	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg25358565	chr5:93447407	FAM172A	1.34	10.69	0.74	5.53e-18	Diabetic retinopathy;
THYM	cis	rs12681288	0.550	rs4272405	chr8:959014	C/G	cg08648136	chr8:956695	NA	0.58	5.0	0.46	2.57e-6	Schizophrenia;
THYM	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg06623918	chr6:96969491	KIAA0776	1.09	9.94	0.71	2.21e-16	Headache;
THYM	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg04455712	chr21:45112962	RRP1B	0.49	4.48	0.42	2.07e-5	Mean corpuscular volume;
THYM	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg25204440	chr1:209979598	IRF6	0.65	5.8	0.51	8.53e-8	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
THYM	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2262909	0.548	rs6511312	chr19:22205349	A/T	cg07498013	chr19:22123504	NA	0.48	4.78	0.44	6.49e-6	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
THYM	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg22852734	chr6:133119734	C6orf192	1.19	7.65	0.62	1.67e-11	Type 2 diabetes nephropathy;
THYM	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.86	7.4	0.6	5.39e-11	Monocyte percentage of white cells;
THYM	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg03676636	chr4:99064102	C4orf37	0.43	6.38	0.55	6.28e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg22166914	chr1:53195759	ZYG11B	0.69	5.65	0.5	1.67e-7	Monocyte count;
THYM	cis	rs4455778	0.508	rs38776	chr7:48938570	G/C	cg26309511	chr7:48887640	NA	0.65	6.1	0.53	2.27e-8	Lung cancer in never smokers;
THYM	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg10360139	chr7:1886902	MAD1L1	-0.59	-5.15	-0.47	1.4e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03576123	chr11:487126	PTDSS2	-1.24	-6.12	-0.53	2.05e-8	Body mass index;
THYM	cis	rs596169	0.655	rs12068857	chr1:219154170	C/T	cg19270308	chr1:218458869	RRP15	-1.24	-4.52	-0.42	1.81e-5	Intraocular pressure;
THYM	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg02725872	chr8:58115012	NA	-0.89	-5.38	-0.48	5.33e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.88	-6.06	-0.53	2.73e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	10.3	0.73	3.73e-17	Chronic sinus infection;
THYM	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg11266682	chr4:10021025	SLC2A9	0.71	9.91	0.71	2.51e-16	Bone mineral density;
THYM	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg18758796	chr5:131593413	PDLIM4	0.51	4.83	0.44	5.32e-6	Blood metabolite levels;
THYM	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.31e-5	Retinal vascular caliber;
THYM	cis	rs4690686	0.500	rs3921993	chr4:177263284	A/G	cg17059388	chr4:177262070	NA	0.48	6.73	0.57	1.29e-9	Essential tremor;
THYM	cis	rs1050631	0.564	rs1785934	chr18:33718326	A/C	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.6	4.69	0.43	9.09e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs12367572	0.601	rs10880730	chr12:45422443	G/A	cg03114573	chr12:45410052	DBX2	-0.52	-4.84	-0.44	5.08e-6	Gut microbiome composition (summer);
THYM	cis	rs7917772	0.582	rs4917973	chr10:104333700	C/T	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9911578	0.805	rs1811202	chr17:56454435	T/G	cg12560992	chr17:57184187	TRIM37	-0.74	-6.15	-0.53	1.84e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg11366901	chr6:160182831	ACAT2	1.08	9.54	0.7	1.56e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg06074448	chr4:187884817	NA	-1.02	-13.05	-0.8	6.55e-23	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	7.12	0.59	2.09e-10	Cognitive test performance;
THYM	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg24818145	chr4:99064322	C4orf37	0.75	5.96	0.52	4.35e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2075230	0.589	rs2955610	chr17:7549601	G/A	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.28	-4.62	-0.43	1.21e-5	Hormone measurements;
THYM	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg14582100	chr15:45693742	SPATA5L1	0.57	4.45	0.42	2.36e-5	Homoarginine levels;
THYM	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg09165964	chr15:75287851	SCAMP5	-1.06	-10.7	-0.74	5.29e-18	Blood trace element (Zn levels);
THYM	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg13736514	chr6:26305472	NA	-0.61	-7.55	-0.61	2.66e-11	Educational attainment;
THYM	cis	rs11792861	0.589	rs2176692	chr9:111927723	G/A	cg05043794	chr9:111880884	C9orf5	-0.38	-5.68	-0.5	1.46e-7	Menarche (age at onset);
THYM	cis	rs77372450	0.551	rs62387681	chr5:157107531	G/C	cg00312553	chr5:157098553	C5orf52	-0.66	-4.63	-0.43	1.14e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs12579753	0.830	rs12825476	chr12:82238350	G/A	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.67	-0.43	1.01e-5	Resting heart rate;
THYM	cis	rs7084402	0.934	rs1658455	chr10:60306089	G/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.65e-7	Refractive error;
THYM	cis	rs10504073	0.584	rs72641612	chr8:49947986	C/T	cg00325661	chr8:49890786	NA	1.1	11.16	0.75	5.58e-19	Blood metabolite ratios;
THYM	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg00080972	chr5:178986291	RUFY1	0.47	5.7	0.5	1.37e-7	Lung cancer;
THYM	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg03690763	chr11:133734501	NA	-0.65	-5.4	-0.48	5e-7	Childhood ear infection;
THYM	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg18876405	chr7:65276391	NA	-0.71	-6.62	-0.56	2.12e-9	Aortic root size;
THYM	cis	rs2072510	0.569	rs2540488	chr12:96426745	G/A	cg18817487	chr12:96390143	HAL	0.45	5.49	0.49	3.35e-7	Metabolite levels (small molecules and protein measures);
THYM	cis	rs8133932	0.667	rs3788218	chr21:47287332	A/G	cg08707771	chr21:46690014	POFUT2	-0.76	-4.45	-0.42	2.29e-5	Schizophrenia;
THYM	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg13609457	chr4:120235615	NA	0.5	4.76	0.44	6.95e-6	Corneal astigmatism;
THYM	cis	rs9560113	1.000	rs4773387	chr13:112180955	T/C	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg17105886	chr17:28927953	LRRC37B2	1.21	7.24	0.6	1.14e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg06623918	chr6:96969491	KIAA0776	-1.1	-11.31	-0.76	2.69e-19	Headache;
THYM	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg12908607	chr1:44402522	ARTN	0.56	4.91	0.45	3.74e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg09307838	chr4:120376055	NA	0.62	4.73	0.44	7.88e-6	Corneal astigmatism;
THYM	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs62435770	1.000	rs62435799	chr6:169498498	G/A	cg07652237	chr6:170125491	PHF10	0.57	5.0	0.46	2.59e-6	Loneliness;
THYM	cis	rs4243830	0.522	rs11122086	chr1:6601246	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.13	-7.7	-0.62	1.31e-11	Body mass index;
THYM	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg18128536	chr17:47092178	IGF2BP1	-0.61	-9.38	-0.69	3.53e-15	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg26384229	chr12:38710491	ALG10B	-0.82	-8.16	-0.64	1.37e-12	Heart rate;
THYM	cis	rs9880211	0.948	rs9813691	chr3:136260722	T/G	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs1401999	0.606	rs939335	chr3:183745663	A/G	cg20387954	chr3:183756860	HTR3D	0.56	4.76	0.44	6.98e-6	Anterior chamber depth;
THYM	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg09904177	chr6:26538194	HMGN4	-0.63	-5.14	-0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7830933	0.780	rs1561105	chr8:23610799	T/G	cg04349084	chr8:23602677	NA	0.6	6.62	0.56	2.1e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg02734326	chr4:10020555	SLC2A9	0.77	7.16	0.59	1.73e-10	Bone mineral density;
THYM	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.61	4.52	0.42	1.76e-5	Aortic root size;
THYM	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.81	-5.48	-0.49	3.45e-7	Body mass index;
THYM	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg03929089	chr4:120376271	NA	-1.01	-13.68	-0.81	3.47e-24	Height;
THYM	cis	rs10992471	0.603	rs1980848	chr9:95248571	A/G	cg14631576	chr9:95140430	CENPP	0.99	9.94	0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg02478829	chr6:26598070	ABT1	-0.35	-4.57	-0.42	1.49e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7076689	0.702	rs1408536	chr10:130677746	A/G	cg18038372	chr10:131404769	MGMT	-1.09	-4.67	-0.43	1e-5	Survival in pancreatic cancer;
THYM	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg17366294	chr4:99064904	C4orf37	0.54	6.05	0.53	2.81e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs713587	0.521	rs35177510	chr2:25089594	C/A	cg01884057	chr2:25150051	NA	0.63	5.99	0.52	3.78e-8	Body mass index in non-asthmatics;
THYM	cis	rs7917772	0.582	rs4285804	chr10:104386309	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.65	-5.64	-0.5	1.73e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4523957	0.584	rs7219557	chr17:2086200	G/A	cg16513277	chr17:2031491	SMG6	-0.95	-6.88	-0.58	6.44e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg19748678	chr4:122722346	EXOSC9	0.71	4.98	0.45	2.9e-6	Type 2 diabetes;
THYM	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg24910161	chr17:38119198	GSDMA	0.42	4.45	0.42	2.31e-5	Self-reported allergy;
THYM	cis	rs4891159	0.548	rs2554830	chr18:74127702	A/G	cg24786174	chr18:74118243	ZNF516	0.97	14.43	0.83	1.15e-25	Longevity;
THYM	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg02825527	chr7:2087843	MAD1L1	-0.8	-5.07	-0.46	1.94e-6	Neuroticism;
THYM	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg03651054	chr13:50194643	NA	0.47	4.48	0.42	2.06e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs6430585	0.528	rs309123	chr2:136761175	C/G	cg04750100	chr2:136595281	LCT	0.56	5.95	0.52	4.54e-8	Corneal structure;
THYM	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg03433033	chr1:76189801	ACADM	0.77	9.42	0.69	2.92e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg10802521	chr3:52805072	NEK4	-0.65	-5.56	-0.5	2.43e-7	Electroencephalogram traits;
THYM	cis	rs6964587	0.621	rs38798	chr7:92044539	C/A	cg17063962	chr7:91808500	NA	-0.82	-6.86	-0.58	6.88e-10	Breast cancer;
THYM	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg13852791	chr20:30311386	BCL2L1	0.72	5.55	0.5	2.55e-7	Mean corpuscular hemoglobin;
THYM	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs2932538	0.922	rs12138335	chr1:113122760	T/C	cg22162597	chr1:113214053	CAPZA1	0.63	4.96	0.45	3.13e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs892961	0.932	rs747481	chr17:75412143	A/G	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs8114671	0.967	rs2065978	chr20:33767291	C/T	cg08999081	chr20:33150536	PIGU	0.52	4.67	0.43	9.71e-6	Height;
THYM	cis	rs7084921	0.526	rs1077821	chr10:101888520	C/T	cg11344164	chr10:101878520	NA	-0.55	-5.18	-0.47	1.25e-6	Bone mineral density;
THYM	cis	rs9355610	0.609	rs62436424	chr6:167374258	A/G	cg15592062	chr6:167189543	RPS6KA2	0.55	4.68	0.43	9.62e-6	Graves' disease;
THYM	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg21028142	chr17:79581711	NPLOC4	-0.61	-6.22	-0.54	1.33e-8	Eye color traits;
THYM	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs1978968	0.956	rs35972244	chr22:18434038	C/G	cg01550578	chr22:18484421	MICAL3	0.63	4.5	0.42	1.94e-5	Presence of antiphospholipid antibodies;
THYM	cis	rs4430311	0.721	rs4610997	chr1:243946917	T/A	cg25706552	chr1:244017396	NA	-0.57	-4.97	-0.45	2.93e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs9311676	0.656	rs11130632	chr3:58369324	C/T	cg26110898	chr3:58419937	PDHB	0.43	4.59	0.43	1.36e-5	Systemic lupus erythematosus;
THYM	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.41	5.2	0.47	1.15e-6	Monocyte percentage of white cells;
THYM	cis	rs66887589	0.934	rs41464847	chr4:120532401	A/G	cg13609457	chr4:120235615	NA	-0.52	-4.57	-0.42	1.45e-5	Diastolic blood pressure;
THYM	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg02782426	chr3:40428986	ENTPD3	0.53	4.66	0.43	1.04e-5	Renal cell carcinoma;
THYM	cis	rs4523957	0.928	rs12453323	chr17:2160214	T/C	cg16513277	chr17:2031491	SMG6	0.79	7.41	0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	5.11	0.46	1.68e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg02753203	chr1:228287806	NA	0.76	6.55	0.56	2.91e-9	Diastolic blood pressure;
THYM	cis	rs2999052	1.000	rs4857878	chr3:127948149	T/C	cg04335449	chr3:127842704	RUVBL1	-0.58	-4.52	-0.42	1.81e-5	Hypospadias;
THYM	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg19774624	chr17:42201019	HDAC5	0.66	5.75	0.51	1.1e-7	Total body bone mineral density;
THYM	cis	rs2637266	0.905	rs1978925	chr10:78399879	C/T	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg04944784	chr2:26401820	FAM59B	-1.08	-6.93	-0.58	4.95e-10	Gut microbiome composition (summer);
THYM	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.61	-0.5	1.98e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05901451	chr6:126070800	HEY2	0.6	4.84	0.44	5.1e-6	Endometrial cancer;
THYM	cis	rs13102973	0.965	rs13106621	chr4:135854975	A/T	cg14419869	chr4:135874104	NA	0.9	8.82	0.67	5.39e-14	Subjective well-being;
THYM	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg13607699	chr17:42295918	UBTF	0.6	4.82	0.44	5.38e-6	Total body bone mineral density;
THYM	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10911232	0.507	rs10911196	chr1:182995233	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs921968	0.540	rs7582329	chr2:219620909	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2811415	0.597	rs11715883	chr3:127726465	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg02734326	chr4:10020555	SLC2A9	-0.69	-5.92	-0.52	5.16e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11756438	0.683	rs57237379	chr6:119018319	G/A	cg21191810	chr6:118973309	C6orf204	0.52	4.88	0.45	4.35e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg16989719	chr2:238392110	NA	-0.62	-5.34	-0.48	6.27e-7	Prostate cancer;
THYM	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg06221963	chr1:154839813	KCNN3	-0.54	-5.24	-0.47	9.5e-7	Prostate cancer;
THYM	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs9906944	1.000	rs9906944	chr17:47091420	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.49	-4.56	-0.42	1.52e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg05347473	chr6:146136440	FBXO30	-0.56	-4.45	-0.42	2.34e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11096990	0.634	rs12651217	chr4:39273584	C/T	cg24403649	chr4:39172243	NA	0.67	5.84	0.51	7.33e-8	Cognitive function;
THYM	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg03396347	chr1:1875803	NA	-0.67	-6.87	-0.58	6.58e-10	Body mass index;
THYM	cis	rs11690935	0.843	rs9784070	chr2:172785007	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.71	-5.03	-0.46	2.27e-6	Schizophrenia;
THYM	cis	rs763014	0.833	rs4984891	chr16:622234	T/A	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg00463982	chr16:1583984	IFT140;TMEM204	-0.61	-5.1	-0.46	1.77e-6	Coronary artery disease;
THYM	cis	rs1639906	0.895	rs78469080	chr7:2200729	G/A	cg19897017	chr7:2163380	MAD1L1	-0.52	-4.93	-0.45	3.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg00074818	chr8:8560427	CLDN23	0.59	5.51	0.49	3.05e-7	Obesity-related traits;
THYM	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg14779329	chr11:130786720	SNX19	-0.52	-5.53	-0.49	2.79e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg26850624	chr5:429559	AHRR	-0.64	-5.0	-0.46	2.62e-6	Cystic fibrosis severity;
THYM	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs11696501	0.739	rs6073822	chr20:44251880	A/G	cg11783356	chr20:44313418	WFDC10B	-0.66	-4.52	-0.42	1.77e-5	Brain structure;
THYM	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.5	-4.46	-0.42	2.23e-5	Fear of minor pain;
THYM	cis	rs11997175	0.646	rs6993892	chr8:33729200	T/C	ch.8.33884649F	chr8:33765107	NA	0.68	5.1	0.46	1.76e-6	Body mass index;
THYM	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9527	0.590	rs1475642	chr10:104546183	C/T	cg15744005	chr10:104629667	AS3MT	0.74	6.13	0.53	2.03e-8	Arsenic metabolism;
THYM	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg24818145	chr4:99064322	C4orf37	0.74	5.93	0.52	4.8e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg23356831	chr14:105996513	TMEM121	0.58	6.17	0.54	1.64e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs2294693	0.947	rs9369254	chr6:40989408	T/C	cg21128951	chr6:40996213	UNC5CL	0.61	4.95	0.45	3.24e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg08431931	chr22:42394659	WBP2NL	0.7	4.91	0.45	3.72e-6	Birth weight;
THYM	cis	rs7412746	0.611	rs1889741	chr1:150869045	T/C	cg15448220	chr1:150897856	SETDB1	0.86	6.94	0.58	4.73e-10	Melanoma;
THYM	cis	rs988913	0.678	rs9367615	chr6:54991283	A/G	cg18532076	chr6:54711417	FAM83B	0.49	4.54	0.42	1.64e-5	Menarche (age at onset);
THYM	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg10018233	chr7:150070692	REPIN1	0.37	5.3	0.48	7.38e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs61931739	0.635	rs10743837	chr12:33982162	A/G	cg06521331	chr12:34319734	NA	-0.56	-4.69	-0.43	8.97e-6	Morning vs. evening chronotype;
THYM	cis	rs7646881	1.000	rs59217052	chr3:158452456	C/T	cg19483011	chr3:158453295	NA	-0.77	-5.54	-0.49	2.65e-7	Tetralogy of Fallot;
THYM	cis	rs9534288	0.762	rs9534285	chr13:46601902	T/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg22508957	chr16:3507546	NAT15	-0.49	-5.48	-0.49	3.5e-7	Body mass index (adult);
THYM	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22857025	chr5:266934	NA	-1.43	-9.54	-0.7	1.58e-15	Breast cancer;
THYM	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg17554472	chr22:41940697	POLR3H	-0.65	-4.73	-0.44	7.66e-6	Vitiligo;
THYM	cis	rs7264396	0.790	rs6060518	chr20:34217309	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-5.65	-0.5	1.67e-7	Total cholesterol levels;
THYM	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg06558623	chr16:89946397	TCF25	1.36	6.57	0.56	2.68e-9	Skin colour saturation;
THYM	cis	rs12681287	0.640	rs13253261	chr8:87458500	T/C	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs35883536	0.708	rs34689792	chr1:101097753	A/G	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs4363385	0.693	rs56347903	chr1:152932175	T/G	cg07796016	chr1:152779584	LCE1C	-0.58	-4.76	-0.44	6.79e-6	Inflammatory skin disease;
THYM	cis	rs4719841	0.662	rs9639523	chr7:25991977	A/C	cg10085138	chr7:25991722	NA	0.59	4.66	0.43	1.03e-5	Triglyceride levels;
THYM	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg17863274	chr19:49399704	TULP2	-0.95	-5.5	-0.49	3.26e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg17211192	chr8:82754475	SNX16	-0.9	-7.35	-0.6	6.83e-11	Diastolic blood pressure;
THYM	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg13010199	chr12:38710504	ALG10B	0.65	4.65	0.43	1.06e-5	Morning vs. evening chronotype;
THYM	cis	rs1451375	0.712	rs11974297	chr7:50618260	A/G	cg18232548	chr7:50535776	DDC	0.68	5.31	0.48	7.16e-7	Malaria;
THYM	cis	rs17598306	0.935	rs17657370	chr7:96606492	C/T	cg26766885	chr7:96220185	NA	0.62	5.13	0.47	1.56e-6	Radiation response;
THYM	cis	rs2811415	0.597	rs3774796	chr3:127780473	C/T	cg05377949	chr3:127951287	EEFSEC	-0.38	-4.74	-0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg26850624	chr5:429559	AHRR	-0.7	-5.6	-0.5	2.07e-7	Cystic fibrosis severity;
THYM	cis	rs6496667	1.000	rs1971898	chr15:90890836	C/G	cg22089800	chr15:90895588	ZNF774	0.74	5.0	0.46	2.65e-6	Rheumatoid arthritis;
THYM	cis	rs854765	0.624	rs12946746	chr17:17741669	T/C	cg16928487	chr17:17741425	SREBF1	0.55	5.12	0.47	1.59e-6	Total body bone mineral density;
THYM	cis	rs1395	0.922	rs13404327	chr2:27519153	G/T	cg23587288	chr2:27483067	SLC30A3	-0.6	-5.0	-0.46	2.59e-6	Blood metabolite levels;
THYM	cis	rs28374715	0.635	rs28557159	chr15:41657353	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.17	-14.19	-0.82	3.41e-25	Ulcerative colitis;
THYM	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03264133	chr6:25882463	NA	0.74	5.71	0.51	1.3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.65	-4.72	-0.44	8.09e-6	Colorectal cancer;
THYM	cis	rs12540874	0.895	rs4245556	chr7:50661661	C/T	cg18232548	chr7:50535776	DDC	-0.67	-5.21	-0.47	1.08e-6	Systemic sclerosis;
THYM	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg24253500	chr15:84953950	NA	0.56	4.56	0.42	1.54e-5	Schizophrenia;
THYM	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.71	6.64	0.56	1.93e-9	Personality dimensions;
THYM	cis	rs4789939	0.528	rs2377003	chr17:76878902	T/C	cg20532887	chr17:76871251	TIMP2	-0.85	-4.88	-0.45	4.34e-6	Dupuytren's disease;
THYM	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9527	0.590	rs1541213	chr10:104885330	A/G	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs951188	0.688	rs74392275	chr2:150415020	G/A	cg17961725	chr2:150454027	NA	-0.96	-5.16	-0.47	1.36e-6	Daytime sleep phenotypes;
THYM	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg10760299	chr15:45669010	GATM	0.77	5.73	0.51	1.2e-7	Homoarginine levels;
THYM	trans	rs8066596	1.000	rs8066596	chr17:12978842	C/T	cg08498597	chr11:67163067	RAD9A	0.75	6.84	0.57	7.57e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs289828	0.519	rs289907	chr2:152087603	A/G	cg05960677	chr2:152117363	RBM43	-0.71	-7.57	-0.61	2.46e-11	Blood protein levels;
THYM	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg05347473	chr6:146136440	FBXO30	0.58	4.51	0.42	1.85e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-4.75	-0.44	7.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg10515332	chr4:99064459	C4orf37	0.57	4.56	0.42	1.54e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.58	-5.03	-0.46	2.34e-6	Hip circumference adjusted for BMI;
THYM	cis	rs4919687	0.550	rs10748828	chr10:104456794	C/T	cg18761893	chr10:103892519	PPRC1	-0.61	-4.65	-0.43	1.05e-5	Colorectal cancer;
THYM	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg04362960	chr10:104952993	NT5C2	0.58	4.93	0.45	3.52e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg18252515	chr7:66147081	NA	-0.59	-4.49	-0.42	2.04e-5	Calcium levels;
THYM	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg08508325	chr11:3079039	CARS	-0.52	-6.47	-0.55	4.17e-9	Longevity;
THYM	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg16049864	chr8:95962084	TP53INP1	-0.82	-7.41	-0.6	5.27e-11	Type 2 diabetes;
THYM	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg07507251	chr3:52567010	NT5DC2	0.4	4.54	0.42	1.66e-5	Electroencephalogram traits;
THYM	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg22166914	chr1:53195759	ZYG11B	0.77	7.32	0.6	8.1e-11	Monocyte count;
THYM	cis	rs1113500	0.565	rs1777455	chr1:108590288	C/A	cg06207961	chr1:108661230	NA	-0.61	-4.46	-0.42	2.27e-5	Growth-regulated protein alpha levels;
THYM	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs1023500	1.000	rs6002552	chr22:42338351	G/A	cg19448990	chr22:41842841	TOB2	-0.75	-4.8	-0.44	5.89e-6	Schizophrenia;
THYM	cis	rs12600053	0.687	rs8058664	chr16:84849100	A/G	cg09249803	chr16:84846936	NA	0.44	4.71	0.44	8.36e-6	Asthma (childhood onset);
THYM	cis	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg22379573	chr1:197704774	DENND1B	-0.84	-5.84	-0.51	7.3e-8	Depressive symptoms;
THYM	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg15693483	chr7:1102177	C7orf50	0.4	5.82	0.51	8.07e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg12310025	chr6:25882481	NA	-0.89	-7.78	-0.62	8.78e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	7.38	0.6	5.83e-11	Platelet count;
THYM	cis	rs28595532	0.920	rs116094766	chr4:119729291	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.5	-4.81	-0.44	5.66e-6	Longevity;Endometriosis;
THYM	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg22166914	chr1:53195759	ZYG11B	0.73	6.2	0.54	1.46e-8	Monocyte count;
THYM	cis	rs4606347	0.789	rs78711727	chr1:66165566	A/T	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg22907277	chr7:1156413	C7orf50	0.75	6.36	0.55	6.9e-9	Longevity;Endometriosis;
THYM	cis	rs4731207	0.698	rs6966415	chr7:124531469	G/A	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs11112613	0.775	rs10861462	chr12:106019898	C/T	cg03607813	chr12:105948248	NA	-0.75	-4.86	-0.45	4.55e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg09904177	chr6:26538194	HMGN4	0.63	5.08	0.46	1.88e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3862030	0.836	rs12771867	chr10:104246691	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.66	-5.58	-0.5	2.24e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs870825	0.929	rs72689263	chr4:185590961	C/T	cg04058563	chr4:185651563	MLF1IP	0.96	6.73	0.57	1.26e-9	Blood protein levels;
THYM	cis	rs10886503	0.920	rs3009906	chr10:121261656	C/A	cg13260278	chr10:121265587	RGS10	0.65	6.04	0.53	3.05e-8	Obstetric antiphospholipid syndrome;
THYM	cis	rs61931739	0.513	rs4931760	chr12:33898361	T/C	cg06521331	chr12:34319734	NA	-0.57	-4.61	-0.43	1.23e-5	Morning vs. evening chronotype;
THYM	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.88	8.14	0.64	1.5e-12	Menarche (age at onset);
THYM	cis	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg00071950	chr4:10020882	SLC2A9	0.84	9.41	0.69	2.96e-15	Bone mineral density;
THYM	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg22907277	chr7:1156413	C7orf50	0.85	5.26	0.48	8.77e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs34638657	0.827	rs2303262	chr16:82203758	C/T	cg09894383	chr16:82067445	HSD17B2	-0.51	-4.98	-0.45	2.88e-6	Lung adenocarcinoma;
THYM	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg02527881	chr3:46936655	PTH1R	0.52	4.99	0.46	2.77e-6	Colorectal cancer;
THYM	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg22166914	chr1:53195759	ZYG11B	0.82	8.9	0.67	3.66e-14	Monocyte count;
THYM	cis	rs35883536	0.647	rs7535762	chr1:101047534	A/G	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs892961	1.000	rs11077907	chr17:75400706	G/A	cg11351908	chr17:75402473	SEPT9	0.58	5.66	0.5	1.62e-7	Airflow obstruction;
THYM	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22857025	chr5:266934	NA	-1.43	-9.3	-0.69	5.28e-15	Breast cancer;
THYM	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg22467129	chr15:76604101	ETFA	-0.51	-5.02	-0.46	2.42e-6	Blood metabolite levels;
THYM	cis	rs35883536	0.528	rs1414414	chr1:101028907	T/C	cg09408571	chr1:101003634	GPR88	0.6	6.63	0.56	2.06e-9	Monocyte count;
THYM	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg11812906	chr14:75593930	NEK9	-0.84	-7.92	-0.63	4.49e-12	Height;
THYM	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg00677455	chr12:58241039	CTDSP2	0.85	6.64	0.56	1.93e-9	Multiple sclerosis;
THYM	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg07424592	chr7:64974309	NA	1.16	5.55	0.5	2.55e-7	Diabetic kidney disease;
THYM	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs12950390	0.548	rs62076098	chr17:45860584	C/T	cg06532163	chr17:45867833	NA	0.56	6.03	0.53	3.08e-8	IgG glycosylation;
THYM	cis	rs981844	0.743	rs17371461	chr4:154759220	C/T	cg09973105	chr4:154681532	RNF175	-0.62	-5.1	-0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs8103278	1.000	rs725660	chr19:46262286	C/A	cg14061069	chr19:46274453	DMPK	-0.58	-5.78	-0.51	9.54e-8	Coronary artery disease;
THYM	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg03929089	chr4:120376271	NA	-1.01	-13.71	-0.82	3.1e-24	Height;
THYM	cis	rs7727544	0.508	rs11739935	chr5:131380658	C/T	cg00255919	chr5:131827918	IRF1	-0.45	-4.86	-0.45	4.55e-6	Blood metabolite levels;
THYM	cis	rs1158570	0.500	rs7846376	chr8:131155443	G/A	cg16277922	chr8:131349729	ASAP1	0.66	5.54	0.49	2.71e-7	Platelet count;
THYM	cis	rs67072384	1.000	rs72964198	chr11:72446464	C/T	cg01380194	chr11:72452482	ARAP1	-0.89	-4.94	-0.45	3.4e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs4919044	0.866	rs11187247	chr10:94794319	G/T	cg05127821	chr10:94822908	CYP26C1	-1.21	-6.28	-0.54	9.93e-9	Coronary artery disease;
THYM	cis	rs61931739	0.591	rs4931764	chr12:33979423	A/G	cg10856724	chr12:34555212	NA	-0.64	-6.04	-0.53	3.04e-8	Morning vs. evening chronotype;
THYM	cis	rs887829	0.569	rs4663333	chr2:234655303	G/T	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.47	-0.42	2.13e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg16926213	chr1:1841314	NA	0.55	5.76	0.51	1.04e-7	Body mass index;
THYM	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg06238570	chr21:40685208	BRWD1	0.91	6.77	0.57	1.08e-9	Cognitive function;
THYM	cis	rs7172809	0.574	rs907398	chr15:77772003	G/A	cg10437265	chr15:77819839	NA	-0.5	-4.57	-0.42	1.47e-5	Glucose homeostasis traits;
THYM	cis	rs9814567	0.806	rs4519744	chr3:134321523	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.09e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs11264213	0.901	rs6665591	chr1:36411737	A/G	cg27506609	chr1:36549197	TEKT2	0.86	4.63	0.43	1.15e-5	Schizophrenia;
THYM	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg10802521	chr3:52805072	NEK4	-0.64	-4.8	-0.44	5.94e-6	Bipolar disorder;
THYM	cis	rs56309584	0.560	rs3027169	chr17:8058814	A/C	cg08322244	chr17:8066669	VAMP2	-0.55	-5.11	-0.46	1.69e-6	Initial pursuit acceleration;
THYM	cis	rs4843185	0.769	rs12149168	chr16:85705611	A/C	cg08899895	chr16:85684853	KIAA0182	-0.57	-4.81	-0.44	5.68e-6	Platelet distribution width;
THYM	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.59	4.45	0.42	2.35e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs514406	0.825	rs12089511	chr1:53436427	A/T	cg16325326	chr1:53192061	ZYG11B	-0.81	-7.52	-0.61	3.05e-11	Monocyte count;
THYM	cis	rs56079296	0.866	rs7736099	chr5:121280216	G/A	cg05256605	chr5:121412184	LOX	-0.6	-4.6	-0.43	1.31e-5	Coronary artery disease;
THYM	cis	rs986417	0.901	rs8020867	chr14:61093246	A/T	cg27398547	chr14:60952738	C14orf39	1.08	5.23	0.47	1.01e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.75	8.37	0.65	4.89e-13	Eosinophil percentage of white cells;
THYM	cis	rs13006833	0.668	rs291445	chr2:191176479	G/A	cg11845111	chr2:191398756	TMEM194B	0.65	4.65	0.43	1.09e-5	Urinary metabolites;
THYM	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg24818145	chr4:99064322	C4orf37	0.67	5.36	0.48	5.88e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg23711669	chr6:146136114	FBXO30	0.93	9.55	0.7	1.53e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg00191853	chr8:101177733	SPAG1	-0.56	-5.59	-0.5	2.15e-7	Atrioventricular conduction;
THYM	cis	rs6980334	0.817	rs10228366	chr7:137794905	T/A	cg18769353	chr7:137028617	PTN	0.64	5.06	0.46	2.01e-6	Blood metabolite ratios;
THYM	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs28595532	0.920	rs114213539	chr4:119758794	G/C	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg20290983	chr6:43655470	MRPS18A	1.44	16.17	0.86	4.93e-29	IgG glycosylation;
THYM	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	9.47	0.7	2.24e-15	Platelet count;
THYM	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4523957	0.620	rs9912385	chr17:2062591	T/G	cg16513277	chr17:2031491	SMG6	-0.94	-8.42	-0.65	3.95e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg03732007	chr1:2071316	PRKCZ	0.5	4.51	0.42	1.89e-5	Height;
THYM	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.49	-0.55	3.89e-9	Chronic sinus infection;
THYM	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7646881	1.000	rs73015655	chr3:158451882	A/C	cg18349298	chr3:158450550	RARRES1	0.51	4.95	0.45	3.15e-6	Tetralogy of Fallot;
THYM	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.65	-5.19	-0.47	1.2e-6	Platelet count;
THYM	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg00898013	chr13:113819073	PROZ	1.04	8.43	0.65	3.71e-13	Platelet distribution width;
THYM	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg03258749	chr1:151040405	MLLT11	-0.66	-5.4	-0.48	4.85e-7	Blood trace element (Cu levels);
THYM	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg24818145	chr4:99064322	C4orf37	0.64	4.85	0.45	4.77e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg18876405	chr7:65276391	NA	0.58	4.66	0.43	1.03e-5	Aortic root size;
THYM	cis	rs9913156	0.793	rs72835642	chr17:4573407	T/C	cg19197139	chr17:4613644	ARRB2	0.82	4.96	0.45	3.05e-6	Lymphocyte counts;
THYM	cis	rs10484885	0.824	rs112817281	chr6:90555658	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.87	-7.73	-0.62	1.13e-11	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs2672886	0.747	rs2672887	chr17:78781804	A/T	cg14474966	chr17:77808999	CBX4	-0.5	-4.67	-0.43	9.77e-6	Airway responsiveness in chronic obstructive pulmonary disease;
THYM	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg22709100	chr7:91322751	NA	0.69	5.12	0.46	1.6e-6	Breast cancer;
THYM	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07167872	chr1:205819463	PM20D1	-0.73	-6.6	-0.56	2.28e-9	Monocyte percentage of white cells;
THYM	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg27572855	chr1:25598939	RHD	-0.65	-4.93	-0.45	3.42e-6	Erythrocyte sedimentation rate;
THYM	cis	rs354225	0.544	rs4616509	chr2:54807982	T/C	cg23486701	chr2:54789491	SPTBN1	0.36	4.77	0.44	6.58e-6	Schizophrenia;
THYM	cis	rs4654899	0.785	rs9426736	chr1:21505931	T/G	cg01072550	chr1:21505969	NA	-0.79	-7.7	-0.62	1.29e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs7512552	0.839	rs696616	chr1:150336173	G/A	cg15654264	chr1:150340011	RPRD2	0.45	5.2	0.47	1.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7226229	1.000	rs2364328	chr17:20939409	T/C	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg18477163	chr1:228402036	OBSCN	-0.43	-4.69	-0.43	8.96e-6	Diastolic blood pressure;
THYM	cis	rs9500256	0.934	rs1343391	chr6:58344154	C/G	cg17976157	chr6:58263193	GUSBL2	-0.6	-4.47	-0.42	2.17e-5	Eosinophilic esophagitis (pediatric);
THYM	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Gout;
THYM	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg06481639	chr22:41940642	POLR3H	-0.72	-5.4	-0.48	4.97e-7	Vitiligo;
THYM	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg26022315	chr17:47021804	SNF8	0.51	4.87	0.45	4.44e-6	Type 2 diabetes;
THYM	cis	rs34526934	0.566	rs1374325	chr2:177043971	G/A	cg26754761	chr2:177040938	NA	-0.73	-6.4	-0.55	5.75e-9	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs2302729	0.545	rs10161181	chr12:2770730	A/C	cg19945202	chr12:2788847	CACNA1C	-0.68	-5.22	-0.47	1.05e-6	Sleep quality;
THYM	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-5.48	-0.49	3.53e-7	Total cholesterol levels;
THYM	cis	rs4523957	0.855	rs9896535	chr17:2133205	C/T	cg16513277	chr17:2031491	SMG6	-0.8	-8.0	-0.63	2.95e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg12599982	chr1:44399894	ARTN	0.57	4.51	0.42	1.85e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg17426766	chr1:2046864	PRKCZ	-0.39	-4.59	-0.43	1.36e-5	Height;
THYM	cis	rs6540559	1.000	rs6696825	chr1:209982372	A/G	cg22029157	chr1:209979665	IRF6	0.63	4.79	0.44	6.14e-6	Cleft lip with or without cleft palate;
THYM	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg15549821	chr19:49342101	PLEKHA4	-0.83	-4.61	-0.43	1.25e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg13695892	chr22:41940480	POLR3H	0.87	6.35	0.55	7.28e-9	Vitiligo;
THYM	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg14004847	chr7:1930337	MAD1L1	-0.64	-5.12	-0.46	1.62e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9943465	0.688	rs4750798	chr10:132070047	T/C	cg02700606	chr10:131763134	EBF3	0.7	4.48	0.42	2.09e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg19077165	chr18:44547161	KATNAL2	-0.66	-8.36	-0.65	5.29e-13	Personality dimensions;
THYM	cis	rs12935418	0.583	rs2113197	chr16:81025506	T/A	cg16651780	chr16:81037892	C16orf61	-0.84	-6.56	-0.56	2.82e-9	Mean corpuscular volume;
THYM	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg12311346	chr5:56204834	C5orf35	-0.97	-7.77	-0.62	9.08e-12	Initial pursuit acceleration;
THYM	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg24530246	chr3:53118167	NA	0.83	4.78	0.44	6.39e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs1372520	0.684	rs356191	chr4:90688120	G/A	cg01966878	chr4:90757139	SNCA	0.59	4.52	0.42	1.75e-5	Neuroticism;
THYM	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg09238746	chr17:78121135	EIF4A3	1.2	11.25	0.76	3.62e-19	Yeast infection;
THYM	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg13699009	chr12:122356056	WDR66	-0.51	-5.71	-0.51	1.26e-7	Mean corpuscular volume;
THYM	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg25703541	chr22:24373054	LOC391322	-0.86	-10.83	-0.74	2.77e-18	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7524258	0.903	rs6577424	chr1:7292417	C/T	cg07173049	chr1:7289937	CAMTA1	-0.82	-6.34	-0.55	7.82e-9	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs6956675	1.000	rs7801458	chr7:62597651	A/G	cg27518014	chr7:62859535	LOC100287834	0.66	5.05	0.46	2.14e-6	Obesity-related traits;
THYM	cis	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg06521331	chr12:34319734	NA	0.8	5.67	0.5	1.52e-7	Morning vs. evening chronotype;
THYM	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg21475434	chr5:93447410	FAM172A	0.9	5.21	0.47	1.11e-6	Diabetic retinopathy;
THYM	cis	rs17016200	0.513	rs73107724	chr3:78363632	A/G	cg24512093	chr3:78698151	ROBO1	0.99	5.11	0.46	1.63e-6	Facial emotion recognition;
THYM	cis	rs57590327	0.528	rs13086292	chr3:81705368	G/A	cg07356753	chr3:81810745	GBE1	-0.87	-6.25	-0.54	1.17e-8	Extraversion;
THYM	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.84	-5.79	-0.51	9.16e-8	Body mass index;
THYM	cis	rs6980334	0.767	rs10274304	chr7:137790882	G/A	cg11874123	chr7:137028198	PTN	0.62	4.61	0.43	1.25e-5	Blood metabolite ratios;
THYM	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.51	-4.93	-0.45	3.44e-6	Crohn's disease;
THYM	cis	rs2836633	0.929	rs2836602	chr21:40039169	A/T	cg12884169	chr21:40033163	ERG	-0.7	-8.71	-0.67	9.28e-14	Coronary artery disease;
THYM	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg01200585	chr1:228362443	C1orf69	0.42	4.53	0.42	1.71e-5	Diastolic blood pressure;
THYM	cis	rs12142240	0.698	rs1057533	chr1:46815836	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs4654899	0.758	rs6658679	chr1:21376451	T/C	cg01072550	chr1:21505969	NA	-0.72	-6.94	-0.58	4.85e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs28595532	0.841	rs114965278	chr4:119743694	T/A	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg07601488	chr5:169797	PLEKHG4B	-0.53	-4.55	-0.42	1.61e-5	Cystic fibrosis severity;
THYM	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg06481639	chr22:41940642	POLR3H	0.82	5.68	0.5	1.49e-7	Vitiligo;
THYM	cis	rs6723226	0.804	rs17428810	chr2:32736043	T/C	cg02381751	chr2:32503542	YIPF4	-0.63	-5.14	-0.47	1.44e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg01324343	chr3:183735012	ABCC5	0.88	13.13	0.8	4.58e-23	Anterior chamber depth;
THYM	cis	rs11039798	0.920	rs12417899	chr11:49017552	G/A	cg24672777	chr11:48374446	OR4C45	-1.1	-6.15	-0.53	1.81e-8	Axial length;
THYM	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg13609457	chr4:120235615	NA	0.59	5.2	0.47	1.13e-6	Corneal astigmatism;
THYM	cis	rs6032067	0.571	rs6017536	chr20:43907369	G/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.42	-4.61	-0.43	1.27e-5	Blood protein levels;
THYM	cis	rs41005	0.967	rs13430914	chr2:8114648	A/G	cg03155496	chr2:8117019	LOC339788	1.02	9.38	0.69	3.52e-15	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs7757969	1.000	rs2881040	chr6:112114308	C/T	cg08601457	chr6:112115117	FYN	0.42	4.79	0.44	6.23e-6	Schizophrenia;
THYM	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03517284	chr6:25882590	NA	-0.94	-7.63	-0.62	1.82e-11	Intelligence (multi-trait analysis);
THYM	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg00012203	chr2:219082015	ARPC2	-0.75	-6.65	-0.56	1.87e-9	Colorectal cancer;
THYM	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg10792982	chr14:105748885	BRF1	0.73	7.39	0.6	5.81e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2495707	0.532	rs2495709	chr10:102416833	C/T	cg18033436	chr10:102982347	NA	0.64	4.59	0.43	1.36e-5	Body mass index;
THYM	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg16405210	chr4:1374714	KIAA1530	-1.07	-10.24	-0.72	4.99e-17	Longevity;
THYM	cis	rs8192282	0.739	rs6427716	chr1:154497329	G/T	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs9565309	0.579	rs76251632	chr13:77584408	C/G	cg13866767	chr13:78470850	EDNRB	1.06	4.81	0.44	5.76e-6	Morning vs. evening chronotype;
THYM	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.59	-0.43	1.34e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs7849270	0.692	rs4397510	chr9:131854950	G/A	cg14069949	chr9:131965419	NA	0.5	4.46	0.42	2.28e-5	Blood metabolite ratios;
THYM	cis	rs448720	0.811	rs383041	chr15:68184481	C/G	cg24579218	chr15:68104479	NA	-0.52	-4.53	-0.42	1.72e-5	Cognitive performance;
THYM	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg18252515	chr7:66147081	NA	-1.6	-8.8	-0.67	6.03e-14	Diabetic kidney disease;
THYM	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg03161606	chr19:29218774	NA	0.84	7.27	0.6	1.01e-10	Methadone dose in opioid dependence;
THYM	cis	rs2050392	0.767	rs1536833	chr10:30699265	C/T	cg13289132	chr10:30722225	MAP3K8	0.57	4.86	0.45	4.56e-6	Inflammatory bowel disease;
THYM	cis	rs11166927	0.901	rs7827091	chr8:140812044	G/C	cg16909799	chr8:140841666	TRAPPC9	0.61	5.61	0.5	1.96e-7	Pediatric non-alcoholic fatty liver disease activity score;
THYM	trans	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg16049864	chr8:95962084	TP53INP1	0.7	6.37	0.55	6.85e-9	Type 2 diabetes;
THYM	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06481639	chr22:41940642	POLR3H	-0.81	-5.49	-0.49	3.4e-7	Vitiligo;
THYM	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	6.03	0.53	3.12e-8	Obesity-related traits;
THYM	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06634786	chr22:41940651	POLR3H	0.78	6.01	0.53	3.36e-8	Vitiligo;
THYM	cis	rs728616	0.510	rs34817075	chr10:81749740	A/G	cg27452691	chr10:81370291	SFTPA1	0.64	4.47	0.42	2.12e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.89	5.72	0.51	1.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-6.68	-0.57	1.62e-9	Platelet count;
THYM	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg07169764	chr2:136633963	MCM6	0.71	6.05	0.53	2.81e-8	Mosquito bite size;
THYM	cis	rs6480314	0.831	rs11813125	chr10:69975033	A/G	cg27159792	chr10:69524182	NA	-0.73	-4.8	-0.44	5.97e-6	Optic nerve measurement (disc area);
THYM	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg11764359	chr7:65958608	NA	-0.67	-4.77	-0.44	6.52e-6	Aortic root size;
THYM	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg22117172	chr7:91764530	CYP51A1	-0.35	-4.47	-0.42	2.12e-5	Breast cancer;
THYM	cis	rs478304	0.654	rs11601509	chr11:65456864	T/C	cg27068330	chr11:65405492	SIPA1	-1.03	-10.31	-0.73	3.55e-17	Acne (severe);
THYM	cis	rs72949976	0.564	rs4673730	chr2:214024836	G/T	cg08319019	chr2:214017104	IKZF2	0.82	7.28	0.6	9.55e-11	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.67	-4.49	-0.42	1.98e-5	Menarche (age at onset);
THYM	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg01416388	chr22:39784598	NA	-0.93	-9.07	-0.68	1.63e-14	Intelligence (multi-trait analysis);
THYM	cis	rs600806	0.850	rs3768493	chr1:109935505	C/T	cg23032129	chr1:109941072	SORT1	-0.59	-5.03	-0.46	2.31e-6	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs116612909	chr4:119749823	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs11039798	0.698	rs6485805	chr11:48101723	C/T	cg24672777	chr11:48374446	OR4C45	-0.98	-5.27	-0.48	8.63e-7	Axial length;
THYM	cis	rs6496932	0.755	rs4842875	chr15:85889244	C/A	cg19183879	chr15:85880815	NA	-0.5	-4.49	-0.42	1.98e-5	Central corneal thickness;Corneal structure;
THYM	cis	rs1198430	0.759	rs946267	chr1:23747703	A/T	cg19827787	chr1:23763612	ASAP3	0.58	4.6	0.43	1.32e-5	Total cholesterol levels;
THYM	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.78	-6.87	-0.58	6.69e-10	Intelligence (multi-trait analysis);
THYM	cis	rs11085466	1.000	rs73552479	chr19:21778816	G/T	cg23026602	chr19:21646605	NA	-0.64	-4.74	-0.44	7.64e-6	Colorectal or endometrial cancer;
THYM	cis	rs11555872	0.560	rs9614177	chr22:43925090	C/T	cg19629120	chr22:43924705	EFCAB6	-0.59	-5.08	-0.46	1.88e-6	Itch intensity from mosquito bite adjusted by bite size;Itch intensity from mosquito bite;
THYM	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.16	9.01	0.68	2.12e-14	Cognitive test performance;
THYM	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg21427119	chr20:30132790	HM13	-0.78	-5.04	-0.46	2.25e-6	Mean corpuscular hemoglobin;
THYM	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs6930083	0.713	rs1321309	chr6:36638636	G/A	cg24425727	chr6:36645648	CDKN1A	0.75	6.83	0.57	8.16e-10	Coronary artery disease;
THYM	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg13695892	chr22:41940480	POLR3H	0.89	6.37	0.55	6.58e-9	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg15962314	chr1:44399869	ARTN	0.53	5.39	0.48	5.01e-7	Intelligence (multi-trait analysis);
THYM	cis	rs8067545	1.000	rs8071730	chr17:19932731	C/T	cg08626831	chr17:20841558	NA	-0.49	-4.7	-0.43	8.84e-6	Schizophrenia;
THYM	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.9	-0.45	4.01e-6	Monocyte count;
THYM	cis	rs4888262	0.526	rs4404098	chr16:74570050	G/A	cg01733217	chr16:74700730	RFWD3	0.78	8.33	0.65	6.03e-13	Testicular germ cell tumor;
THYM	cis	rs7943203	0.568	rs4615991	chr11:108295205	C/T	cg04873221	chr11:107992290	ACAT1	-0.72	-4.71	-0.43	8.56e-6	Red blood cell count;Mean corpuscular volume;
THYM	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs13082711	0.911	rs11716531	chr3:27457208	G/A	cg02860705	chr3:27208620	NA	0.69	4.91	0.45	3.77e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg05373962	chr22:49881684	NA	-0.65	-6.14	-0.53	1.94e-8	Monocyte count;Monocyte percentage of white cells;
THYM	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg07870213	chr5:140052090	DND1	0.71	8.17	0.64	1.32e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg18904891	chr8:8559673	CLDN23	0.68	5.08	0.46	1.89e-6	Obesity-related traits;
THYM	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg06808227	chr14:105710500	BRF1	-1.01	-8.73	-0.67	8.48e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg16579431	chr16:433439	TMEM8A;LOC100134368	0.7	5.45	0.49	4.02e-7	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs1062753	0.527	rs62240998	chr22:42354701	T/A	cg11601000	chr22:42348013	LOC339674	-0.43	-4.6	-0.43	1.31e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs2282300	0.739	rs7942129	chr11:30224692	G/A	cg25418670	chr11:30344373	C11orf46	-0.8	-6.95	-0.58	4.48e-10	Morning vs. evening chronotype;
THYM	cis	rs11264213	0.901	rs688833	chr1:36455600	C/T	cg27506609	chr1:36549197	TEKT2	0.89	4.63	0.43	1.15e-5	Schizophrenia;
THYM	cis	rs6539288	0.677	rs10778515	chr12:107332481	A/G	cg26297688	chr12:107349093	C12orf23	-0.51	-6.04	-0.53	2.94e-8	Total body bone mineral density;
THYM	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	6.98	0.58	3.88e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg16850897	chr7:100343110	ZAN	-0.71	-5.46	-0.49	3.85e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1524976	0.738	rs62252647	chr3:65438217	C/T	cg16238336	chr3:65465873	MAGI1	-0.92	-5.22	-0.47	1.07e-6	PR interval;
THYM	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg00814883	chr7:100076585	TSC22D4	-1.0	-6.82	-0.57	8.43e-10	Platelet count;
THYM	cis	rs600806	0.813	rs6664236	chr1:109986672	C/A	cg23032129	chr1:109941072	SORT1	-0.57	-4.82	-0.44	5.54e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg00071950	chr4:10020882	SLC2A9	-0.75	-6.73	-0.57	1.25e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11031096	0.678	rs970329	chr11:4189803	G/T	cg22027985	chr11:4115532	RRM1	-0.56	-5.25	-0.47	9.12e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg06221963	chr1:154839813	KCNN3	-0.88	-11.91	-0.77	1.51e-20	Prostate cancer;
THYM	cis	rs10751667	0.961	rs6597954	chr11:987677	G/A	ch.11.42038R	chr11:967971	AP2A2	0.61	4.88	0.45	4.31e-6	Alzheimer's disease (late onset);
THYM	cis	rs977987	0.843	rs11149824	chr16:75431830	C/G	cg03315344	chr16:75512273	CHST6	0.73	6.16	0.53	1.73e-8	Dupuytren's disease;
THYM	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg24874828	chr4:187887005	NA	-0.72	-7.22	-0.6	1.26e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2652822	0.525	rs58789072	chr15:63497553	G/A	cg09251291	chr15:63483946	RAB8B	0.53	4.89	0.45	4.13e-6	Metabolic traits;
THYM	cis	rs9420	1.000	rs543725	chr11:57483039	A/T	cg19752551	chr11:57585705	CTNND1	-0.66	-7.73	-0.62	1.11e-11	Schizophrenia;
THYM	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg21926883	chr2:100939477	LONRF2	-0.61	-5.71	-0.51	1.3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06634786	chr22:41940651	POLR3H	-0.68	-5.18	-0.47	1.22e-6	Vitiligo;
THYM	cis	rs11716531	0.573	rs642570	chr3:27342595	C/G	cg02860705	chr3:27208620	NA	0.65	5.07	0.46	1.94e-6	Diastolic blood pressure;
THYM	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg27572855	chr1:25598939	RHD	0.74	5.76	0.51	1.03e-7	Erythrocyte sedimentation rate;
THYM	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg18512352	chr11:47633146	NA	-0.52	-6.14	-0.53	1.92e-8	Subjective well-being;
THYM	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg24874828	chr4:187887005	NA	-0.75	-7.89	-0.63	5.01e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg03264133	chr6:25882463	NA	-0.8	-5.79	-0.51	8.93e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg08999081	chr20:33150536	PIGU	0.57	4.96	0.45	3.09e-6	Coronary artery disease;
THYM	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26314531	chr2:26401878	FAM59B	-0.78	-5.2	-0.47	1.16e-6	Gut microbiome composition (summer);
THYM	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg23205692	chr1:25664452	TMEM50A	-0.83	-6.37	-0.55	6.66e-9	Erythrocyte sedimentation rate;
THYM	cis	rs11645898	0.872	rs34832584	chr16:72162966	G/T	cg14768367	chr16:72042858	DHODH	-0.77	-5.37	-0.48	5.47e-7	Blood protein levels;
THYM	cis	rs3008870	1.000	rs2815352	chr1:67482104	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.93	7.76	0.62	9.52e-12	Lymphocyte percentage of white cells;
THYM	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg06532163	chr17:45867833	NA	0.65	6.55	0.56	2.91e-9	IgG glycosylation;
THYM	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.3	-0.48	7.34e-7	Monocyte percentage of white cells;
THYM	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg03476357	chr21:30257390	N6AMT1	0.64	4.97	0.45	2.97e-6	Cognitive test performance;
THYM	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg03929089	chr4:120376271	NA	-1.01	-13.68	-0.81	3.47e-24	Height;
THYM	cis	rs1448094	0.511	rs10506920	chr12:86165212	A/T	cg02569458	chr12:86230093	RASSF9	0.69	5.77	0.51	9.84e-8	Major depressive disorder;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg05472062	chr10:93559124	TNKS2	0.98	6.9	0.58	5.7e-10	Depressive symptoms;
THYM	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg13395646	chr4:1353034	KIAA1530	-0.6	-5.7	-0.51	1.31e-7	Longevity;
THYM	cis	rs6430585	0.583	rs3769013	chr2:136556182	C/T	cg23851026	chr2:136556271	LCT	0.79	8.32	0.65	6.29e-13	Corneal structure;
THYM	cis	rs2354432	0.607	rs6593751	chr1:146726023	A/G	cg25205988	chr1:146714368	CHD1L	-1.04	-5.54	-0.49	2.67e-7	Mitochondrial DNA levels;
THYM	cis	rs12950390	0.530	rs16947058	chr17:45825186	A/G	cg06532163	chr17:45867833	NA	-0.53	-5.79	-0.51	9.11e-8	IgG glycosylation;
THYM	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg20887711	chr4:1340912	KIAA1530	0.62	4.73	0.44	7.79e-6	Obesity-related traits;
THYM	cis	rs2070677	1.000	rs1329149	chr10:135349801	T/C	cg20169779	chr10:135381914	SYCE1	0.81	5.79	0.51	8.91e-8	Gout;
THYM	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg13902645	chr11:5959945	NA	-0.54	-4.78	-0.44	6.41e-6	DNA methylation (variation);
THYM	cis	rs7084402	0.967	rs1427199	chr10:60274941	C/T	cg07615347	chr10:60278583	BICC1	-0.53	-4.65	-0.43	1.08e-5	Refractive error;
THYM	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg10505658	chr17:80084571	CCDC57	0.7	7.86	0.63	5.86e-12	Life satisfaction;
THYM	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg10518543	chr12:38710700	ALG10B	-0.56	-4.46	-0.42	2.27e-5	Morning vs. evening chronotype;
THYM	cis	rs11225247	1.000	rs75099131	chr11:102266993	A/G	cg06323957	chr11:102217781	BIRC2	1.09	4.67	0.43	1.01e-5	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02018176	chr4:1364513	KIAA1530	1.0	10.14	0.72	8.23e-17	Longevity;
THYM	cis	rs611744	0.967	rs655707	chr8:109197530	T/C	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg13319975	chr6:146136371	FBXO30	-0.68	-5.91	-0.52	5.44e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs593982	1.000	rs72922786	chr11:65562852	G/C	cg08755490	chr11:65554678	OVOL1	-1.13	-6.1	-0.53	2.25e-8	Atopic dermatitis;
THYM	cis	rs2404602	0.647	rs12904417	chr15:76964152	A/G	cg23625390	chr15:77176239	SCAPER	0.85	5.95	0.52	4.52e-8	Blood metabolite levels;
THYM	cis	rs3087591	1.000	rs7220268	chr17:29451910	T/C	cg24425628	chr17:29625626	OMG;NF1	0.65	5.61	0.5	2e-7	Hip circumference;
THYM	cis	rs965469	0.895	rs6139123	chr20:3396634	C/T	cg25506879	chr20:3388711	C20orf194	-0.84	-5.13	-0.47	1.51e-6	IFN-related cytopenia;
THYM	cis	rs10847980	0.590	rs77970074	chr12:123292186	T/G	cg25930673	chr12:123319894	HIP1R	1.06	4.89	0.45	4.15e-6	Adiponectin levels;
THYM	cis	rs7119	0.717	rs62007348	chr15:77804501	C/T	cg10437265	chr15:77819839	NA	0.76	7.61	0.62	1.98e-11	Type 2 diabetes;
THYM	cis	rs9393777	0.588	rs9467772	chr6:26496578	A/T	cg12826209	chr6:26865740	GUSBL1	1.03	7.13	0.59	1.94e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67311347	0.910	rs13089215	chr3:40495894	T/C	cg24209194	chr3:40518798	ZNF619	-0.64	-5.37	-0.48	5.63e-7	Renal cell carcinoma;
THYM	cis	rs3741151	0.773	rs73542967	chr11:73123512	C/T	cg12959048	chr11:73096162	RELT	-0.53	-5.08	-0.46	1.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg06481639	chr22:41940642	POLR3H	0.84	5.85	0.51	6.94e-8	Vitiligo;
THYM	cis	rs7107174	0.892	rs3018313	chr11:77989644	C/T	cg19901956	chr11:77921274	USP35	-0.68	-5.25	-0.47	9.31e-7	Testicular germ cell tumor;
THYM	cis	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg19847130	chr8:10466454	RP1L1	0.62	5.9	0.52	5.55e-8	Neuroticism;
THYM	cis	rs7078219	0.505	rs10883365	chr10:101287764	C/T	cg04972745	chr10:101287846	NA	-0.51	-4.83	-0.44	5.14e-6	Dental caries;
THYM	cis	rs2806561	0.765	rs643492	chr1:23501354	C/T	cg12483005	chr1:23474871	LUZP1	-0.58	-6.22	-0.54	1.31e-8	Height;
THYM	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4242434	0.646	rs6988593	chr8:22527440	A/G	cg11461670	chr8:22454935	PDLIM2	0.32	5.77	0.51	1.01e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10466239	1.000	rs10466239	chr10:43849827	C/T	cg12352960	chr10:43428578	NA	-0.96	-4.63	-0.43	1.17e-5	Telomere length;
THYM	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg16049864	chr8:95962084	TP53INP1	-0.86	-8.13	-0.64	1.62e-12	Type 2 diabetes;
THYM	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg07414643	chr4:187882934	NA	0.67	5.92	0.52	5.16e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-6.36	-0.55	6.96e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg02782426	chr3:40428986	ENTPD3	0.56	4.95	0.45	3.21e-6	Renal cell carcinoma;
THYM	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7586879	0.964	rs4077680	chr2:25122942	A/G	cg01884057	chr2:25150051	NA	0.65	6.42	0.55	5.27e-9	Body mass index;
THYM	cis	rs1797081	0.967	rs811912	chr10:16859618	G/C	cg23933602	chr10:16859644	RSU1	0.93	10.77	0.74	3.7e-18	Platelet distribution width;
THYM	cis	rs986417	0.505	rs74921601	chr14:61104536	C/T	cg27398547	chr14:60952738	C14orf39	-1.48	-5.24	-0.47	9.51e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs10781543	0.776	rs11145760	chr9:139382594	G/A	cg14115884	chr9:139300582	SDCCAG3	0.72	6.72	0.57	1.35e-9	Monocyte percentage of white cells;
THYM	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	5.83	0.51	7.74e-8	Height;
THYM	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg06028808	chr11:68637592	NA	0.68	7.49	0.61	3.59e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2463822	0.920	rs11828383	chr11:62067818	C/T	cg06239285	chr11:62104954	ASRGL1	-1.43	-7.19	-0.59	1.49e-10	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs72717009	0.825	rs61802846	chr1:161473873	A/C	cg15358701	chr1:161410459	NA	-0.95	-5.06	-0.46	2.08e-6	Rheumatoid arthritis;
THYM	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.26	0.69	6.31e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12478296	0.892	rs60042638	chr2:243038707	G/A	cg06360820	chr2:242988706	NA	-0.87	-5.4	-0.48	4.88e-7	Obesity-related traits;
THYM	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7695732	0.595	rs7697921	chr4:89908661	C/G	cg17769793	chr4:89976368	FAM13A	-0.49	-5.39	-0.48	5.23e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg02725872	chr8:58115012	NA	-0.9	-5.24	-0.47	9.85e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs13102973	0.899	rs11735890	chr4:135902143	A/G	cg14419869	chr4:135874104	NA	0.82	6.86	0.58	7.03e-10	Subjective well-being;
THYM	cis	rs12476592	0.543	rs262539	chr2:63908270	G/A	cg17519650	chr2:63277830	OTX1	0.72	4.73	0.44	7.77e-6	Childhood ear infection;
THYM	cis	rs6424115	0.830	rs1130320	chr1:24200606	A/G	cg15997130	chr1:24165203	NA	0.76	6.39	0.55	6.14e-9	Immature fraction of reticulocytes;
THYM	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.69e-11	Aortic root size;
THYM	cis	rs3135063	0.504	rs78139882	chr4:3287361	C/T	cg16895261	chr4:3391305	RGS12	-0.66	-4.8	-0.44	5.94e-6	Blood protein levels;
THYM	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6964587	0.626	rs12704631	chr7:91523525	T/C	cg17063962	chr7:91808500	NA	-1.01	-9.06	-0.68	1.73e-14	Breast cancer;
THYM	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg24250549	chr1:154909240	PMVK	0.72	5.67	0.5	1.56e-7	Prostate cancer;
THYM	cis	rs10214930	1.000	rs10250333	chr7:27762622	T/C	cg04422003	chr7:28448295	CREB5	-0.62	-4.6	-0.43	1.28e-5	Hypospadias;
THYM	cis	rs5769765	0.671	rs138841	chr22:50181960	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.87	-5.75	-0.51	1.1e-7	Schizophrenia;
THYM	cis	rs4919694	1.000	rs12246689	chr10:104817031	C/T	cg04362960	chr10:104952993	NT5C2	1.14	6.92	0.58	5.36e-10	Arsenic metabolism;
THYM	cis	rs4363385	0.818	rs3795382	chr1:153004853	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs17604090	1.000	rs73297441	chr7:29684363	T/C	cg19413766	chr7:29689036	LOC646762	-0.93	-5.09	-0.46	1.77e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.24	-0.65	9.29e-13	Mean corpuscular volume;
THYM	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg04414720	chr1:150670196	GOLPH3L	-0.64	-4.84	-0.44	5e-6	Tonsillectomy;
THYM	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg04842962	chr6:43655489	MRPS18A	1.41	15.7	0.85	3.85e-28	IgG glycosylation;
THYM	cis	rs17818399	0.708	rs1531133	chr2:46843631	A/G	cg09399716	chr2:46890238	NA	-0.46	-4.6	-0.43	1.28e-5	Height;
THYM	cis	rs807669	0.548	rs885979	chr22:19198375	T/C	cg02655711	chr22:19163373	SLC25A1	0.72	8.14	0.64	1.5e-12	Metabolite levels;
THYM	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg20891558	chr2:74357851	NA	1.16	12.74	0.79	2.82e-22	Gestational age at birth (maternal effect);
THYM	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg23649088	chr2:200775458	C2orf69	-0.74	-4.49	-0.42	2.02e-5	Schizophrenia;
THYM	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg12165864	chr7:66369176	NA	-0.64	-4.97	-0.45	2.97e-6	Aortic root size;
THYM	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg10515332	chr4:99064459	C4orf37	0.58	4.67	0.43	9.88e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9462846	0.887	rs7758576	chr6:42871056	G/A	cg09436375	chr6:42928200	GNMT	-0.37	-4.51	-0.42	1.82e-5	Blood protein levels;
THYM	cis	rs4363385	0.782	rs4845336	chr1:153003853	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg00463982	chr16:1583984	IFT140;TMEM204	-0.61	-5.1	-0.46	1.77e-6	Coronary artery disease;
THYM	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg17366294	chr4:99064904	C4orf37	0.58	7.1	0.59	2.27e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35883536	0.588	rs17403878	chr1:101105310	C/T	cg09408571	chr1:101003634	GPR88	0.4	4.81	0.44	5.73e-6	Monocyte count;
THYM	cis	rs1160297	0.506	rs11888200	chr2:53119838	A/G	cg07782112	chr2:53107842	NA	-0.68	-4.68	-0.43	9.34e-6	Hemostatic factors and hematological phenotypes;
THYM	cis	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg06521331	chr12:34319734	NA	-1.03	-10.3	-0.73	3.74e-17	Morning vs. evening chronotype;
THYM	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg22166914	chr1:53195759	ZYG11B	0.72	6.06	0.53	2.78e-8	Monocyte count;
THYM	cis	rs3820068	0.608	rs7516683	chr1:16020502	A/G	cg05660106	chr1:15850417	CASP9	-0.72	-5.58	-0.5	2.25e-7	Systolic blood pressure;
THYM	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg05283184	chr6:79620031	NA	0.68	6.0	0.52	3.59e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg00383909	chr3:49044727	WDR6	1.07	6.29	0.54	9.72e-9	Cognitive function;
THYM	cis	rs7078219	0.714	rs12414770	chr10:101288238	G/T	cg23904955	chr10:101282759	NA	-0.42	-4.97	-0.45	2.99e-6	Dental caries;
THYM	cis	rs13064411	0.696	rs6766615	chr3:113219342	T/C	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.37	-5.38	-0.48	5.36e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs55728055	0.661	rs55894054	chr22:31976299	T/C	cg01338084	chr22:32026380	PISD	1.39	6.92	0.58	5.23e-10	Age-related hearing impairment;
THYM	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg27129171	chr3:47204927	SETD2	0.78	7.71	0.62	1.24e-11	Colorectal cancer;
THYM	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg00080972	chr5:178986291	RUFY1	0.62	8.7	0.67	9.77e-14	Lung cancer;
THYM	cis	rs7973719	0.865	rs1057225	chr12:7363574	C/G	cg07052231	chr12:7363540	PEX5	0.62	5.2	0.47	1.13e-6	IgG glycosylation;
THYM	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg17757837	chr7:157058334	UBE3C	0.65	5.24	0.47	9.83e-7	Body mass index;
THYM	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg06636001	chr8:8085503	FLJ10661	0.78	6.8	0.57	9.2e-10	Red cell distribution width;
THYM	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg02753203	chr1:228287806	NA	-0.61	-5.15	-0.47	1.43e-6	Diastolic blood pressure;
THYM	cis	rs11886999	0.812	rs7579709	chr2:96881596	A/T	cg18419276	chr2:96971862	SNRNP200	-0.5	-4.77	-0.44	6.69e-6	Cardiac Troponin-T levels;
THYM	cis	rs4523957	0.893	rs9909895	chr17:2161633	G/A	cg16513277	chr17:2031491	SMG6	-0.79	-7.41	-0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1023500	1.000	rs6002554	chr22:42339095	T/C	cg19448990	chr22:41842841	TOB2	-0.75	-4.8	-0.44	5.89e-6	Schizophrenia;
THYM	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg12560992	chr17:57184187	TRIM37	0.95	8.76	0.67	7.44e-14	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg03188948	chr7:1209495	NA	0.69	5.4	0.48	4.94e-7	Longevity;Endometriosis;
THYM	cis	rs2290159	0.800	rs9849807	chr3:12675026	A/G	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg11247378	chr22:39784982	NA	1.03	11.3	0.76	2.83e-19	Intelligence (multi-trait analysis);
THYM	cis	rs338389	0.564	rs338393	chr15:68256995	A/T	cg07562100	chr15:68569975	FEM1B	0.71	5.26	0.47	8.9e-7	Survival in rectal cancer;
THYM	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg12893697	chr11:970389	AP2A2	-0.32	-5.35	-0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs17818399	0.962	rs7565274	chr2:46841861	G/T	cg09399716	chr2:46890238	NA	-0.5	-4.53	-0.42	1.73e-5	Height;
THYM	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.89	4.92	0.45	3.6e-6	Initial pursuit acceleration;
THYM	cis	rs11997175	0.543	rs115681590	chr8:33761157	G/T	ch.8.33884649F	chr8:33765107	NA	0.75	5.36	0.48	5.7e-7	Body mass index;
THYM	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg07362569	chr17:61921086	SMARCD2	-0.74	-6.62	-0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg18538332	chr22:24372958	LOC391322	-0.92	-10.48	-0.73	1.57e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2730245	0.527	rs2709858	chr7:158675266	C/G	cg01219135	chr7:158766336	NA	0.56	4.49	0.42	2.01e-5	Height;
THYM	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs2072510	0.593	rs2660900	chr12:96405077	T/C	cg18817487	chr12:96390143	HAL	0.45	5.47	0.49	3.61e-7	Metabolite levels (small molecules and protein measures);
THYM	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs7582180	0.663	rs4850929	chr2:100990707	A/C	cg08017756	chr2:100939284	LONRF2	-0.72	-7.39	-0.6	5.75e-11	Intelligence (multi-trait analysis);
THYM	cis	rs9905704	0.624	rs34718875	chr17:57072461	G/A	cg12560992	chr17:57184187	TRIM37	0.67	5.33	0.48	6.66e-7	Testicular germ cell tumor;
THYM	trans	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs2425143	0.512	rs11699653	chr20:34622916	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-4.56	-0.42	1.53e-5	Blood protein levels;
THYM	cis	rs17125944	0.686	rs76673112	chr14:53366692	T/C	cg00686598	chr14:53173677	PSMC6	1.16	5.16	0.47	1.37e-6	Alzheimer's disease (late onset);
THYM	cis	rs926938	0.967	rs11587596	chr1:115241857	A/G	cg12756093	chr1:115239321	AMPD1	-0.68	-5.56	-0.5	2.47e-7	Autism;
THYM	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg26384229	chr12:38710491	ALG10B	-0.91	-7.88	-0.63	5.44e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg18131467	chr2:239335373	ASB1	1.1	10.67	0.74	6.26e-18	Multiple system atrophy;
THYM	cis	rs786425	0.585	rs10744161	chr12:124231355	A/G	cg15249119	chr12:124971054	NCOR2	0.55	4.84	0.44	5.11e-6	Pubertal anthropometrics;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg06919312	chr12:64474195	SRGAP1	-0.95	-6.86	-0.58	6.88e-10	Depressive symptoms;
THYM	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg25918947	chr17:41365094	TMEM106A	-0.56	-4.6	-0.43	1.32e-5	Menopause (age at onset);
THYM	cis	rs346785	0.692	rs2279057	chr17:74309425	A/G	cg04798684	chr17:74309056	PRPSAP1	-0.51	-4.51	-0.42	1.88e-5	White matter hyperintensities in ischemic stroke;
THYM	cis	rs9866391	0.571	rs1582874	chr3:141115219	T/C	cg13411656	chr3:141121016	ZBTB38	-0.32	-4.71	-0.44	8.38e-6	Myopia;
THYM	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.53	4.61	0.43	1.27e-5	Blood metabolite levels;
THYM	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg04518342	chr5:131593106	PDLIM4	0.45	5.02	0.46	2.43e-6	Breast cancer;
THYM	cis	rs72627123	0.867	rs59892091	chr14:74417609	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.1	6.43	0.55	5.04e-9	Morning vs. evening chronotype;
THYM	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg22467129	chr15:76604101	ETFA	-0.56	-5.26	-0.47	9.01e-7	Blood metabolite levels;
THYM	cis	rs951188	0.688	rs77804054	chr2:150425945	C/T	cg17961725	chr2:150454027	NA	-0.97	-5.26	-0.47	8.85e-7	Daytime sleep phenotypes;
THYM	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg10360139	chr7:1886902	MAD1L1	-0.85	-7.79	-0.62	8.37e-12	Bipolar disorder and schizophrenia;
THYM	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg10589385	chr1:150898437	SETDB1	0.62	5.08	0.46	1.9e-6	Melanoma;
THYM	cis	rs9403317	1.000	rs9399371	chr6:141825125	C/A	cg15052665	chr6:141804349	NA	0.84	7.18	0.59	1.58e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9902453	0.817	rs1038089	chr17:28178724	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.66	0.43	1.03e-5	Coffee consumption (cups per day);
THYM	trans	rs1147813	0.654	rs993232	chr9:25890597	A/G	cg25149391	chr11:68520448	MTL5	-1.02	-7.04	-0.59	3.03e-10	Morning vs. evening chronotype;
THYM	cis	rs1003719	0.715	rs2156078	chr21:38546473	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg16797656	chr11:68205561	LRP5	0.45	4.66	0.43	1.04e-5	Total body bone mineral density;
THYM	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg07424592	chr7:64974309	NA	1.02	5.29	0.48	7.76e-7	Diabetic kidney disease;
THYM	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg10760299	chr15:45669010	GATM	-0.72	-5.03	-0.46	2.27e-6	Homoarginine levels;
THYM	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11648796	0.765	rs2003832	chr16:769538	G/A	cg10254923	chr16:769848	FAM173A	0.51	5.93	0.52	4.98e-8	Height;
THYM	cis	rs4343996	0.967	rs4722663	chr7:3350567	C/T	cg21248987	chr7:3385318	SDK1	-0.41	-4.95	-0.45	3.17e-6	Motion sickness;
THYM	cis	rs7246657	0.943	rs10420722	chr19:37973774	C/G	cg23950597	chr19:37808831	NA	-0.73	-4.69	-0.43	9.03e-6	Coronary artery calcification;
THYM	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	5.51	0.49	3.02e-7	Hip circumference adjusted for BMI;
THYM	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg06981504	chr1:1234844	ACAP3	0.56	5.09	0.46	1.78e-6	Body mass index;
THYM	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg05890377	chr2:74357713	NA	0.99	8.99	0.68	2.32e-14	Gestational age at birth (maternal effect);
THYM	cis	rs10895275	0.625	rs10895271	chr11:102069745	G/A	cg24447756	chr11:102105824	NA	-0.47	-4.53	-0.42	1.69e-5	Migraine;
THYM	cis	rs8038465	0.789	rs57909886	chr15:73973662	T/C	cg15420318	chr15:73925796	NPTN	0.63	5.11	0.46	1.65e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.58	-4.98	-0.46	2.78e-6	Platelet count;
THYM	cis	rs1003719	0.788	rs2835586	chr21:38461326	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs289828	0.500	rs6708492	chr2:152157973	T/C	cg05960677	chr2:152117363	RBM43	0.69	6.56	0.56	2.86e-9	Blood protein levels;
THYM	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs951188	0.688	rs80219133	chr2:150408460	T/C	cg17961725	chr2:150454027	NA	-0.93	-5.1	-0.46	1.72e-6	Daytime sleep phenotypes;
THYM	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg12373951	chr3:133503437	NA	0.56	6.17	0.53	1.69e-8	Iron status biomarkers;
THYM	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg18301423	chr5:131593218	PDLIM4	0.5	4.7	0.43	8.95e-6	Acylcarnitine levels;
THYM	cis	rs860818	1.000	rs858277	chr7:23252261	G/T	cg05407003	chr7:23246146	NA	1.27	4.72	0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs10426930	0.700	rs10407399	chr19:5009466	A/C	cg25246084	chr19:4971487	KDM4B	0.51	5.3	0.48	7.37e-7	Monocyte percentage of white cells;
THYM	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4509693	1.000	rs4244340	chr10:102499268	G/C	cg24127310	chr10:102502104	NA	1.3	10.12	0.72	9.09e-17	Alzheimer's disease;
THYM	cis	rs10208940	0.614	rs13419614	chr2:68760737	T/C	cg09157127	chr2:69201416	GKN1	0.8	4.5	0.42	1.96e-5	Urate levels in lean individuals;
THYM	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg06028605	chr16:24865363	SLC5A11	0.58	5.69	0.5	1.42e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs6964587	0.626	rs6951795	chr7:91543764	T/C	cg17063962	chr7:91808500	NA	-1.01	-9.06	-0.68	1.73e-14	Breast cancer;
THYM	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	4.79	0.44	6.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4786125	0.555	rs7196838	chr16:6920457	A/G	cg03623568	chr16:6915990	A2BP1	-0.99	-9.71	-0.71	6.74e-16	Heart rate variability traits (SDNN);
THYM	cis	rs2976388	0.935	rs2978980	chr8:143757708	T/G	cg06565975	chr8:143823917	SLURP1	-0.44	-4.94	-0.45	3.37e-6	Urinary tract infection frequency;
THYM	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg06108461	chr20:60628389	TAF4	-1.01	-6.94	-0.58	4.72e-10	Body mass index;
THYM	cis	rs11585357	1.000	rs72646785	chr1:17603472	G/T	cg08277548	chr1:17600880	PADI3	-0.93	-6.22	-0.54	1.3e-8	Hair shape;
THYM	cis	rs67981189	0.529	rs2158996	chr14:71529599	G/A	cg15910301	chr14:71632612	NA	0.56	4.88	0.45	4.23e-6	Schizophrenia;
THYM	cis	rs7570971	0.517	rs10187402	chr2:135771974	C/G	cg07169764	chr2:136633963	MCM6	0.62	4.9	0.45	3.88e-6	Blood metabolite levels;Body mass index;Cholesterol, total;
THYM	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	trans	rs208520	0.690	rs207118	chr6:66788948	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.66	-0.62	1.53e-11	Exhaled nitric oxide output;
THYM	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg13266496	chr6:110720918	DDO	-0.48	-5.23	-0.47	1e-6	Platelet distribution width;
THYM	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg18681998	chr4:17616180	MED28	0.85	7.68	0.62	1.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs7216064	1.000	rs62085993	chr17:65923152	T/C	cg12091567	chr17:66097778	LOC651250	-0.69	-4.51	-0.42	1.86e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs6840360	0.642	rs2724574	chr4:152381800	A/T	cg17479576	chr4:152424074	FAM160A1	0.7	5.32	0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1021993	0.953	rs925077	chr1:209509252	T/C	cg06155620	chr1:209527581	NA	0.57	4.59	0.43	1.37e-5	Gut microbiome composition (winter);
THYM	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.53	-0.61	2.88e-11	Personality dimensions;
THYM	cis	rs4911259	0.552	rs13038017	chr20:31467551	T/C	cg13636640	chr20:31349939	DNMT3B	-0.61	-5.88	-0.52	6.05e-8	Inflammatory bowel disease;
THYM	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg22947322	chr17:47091978	IGF2BP1	-0.61	-6.24	-0.54	1.23e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs986417	0.748	rs12436632	chr14:61034416	T/C	cg27398547	chr14:60952738	C14orf39	1.01	5.77	0.51	1.01e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs1018836	0.663	rs4735190	chr8:91509601	A/G	cg16814680	chr8:91681699	NA	-0.8	-6.87	-0.58	6.76e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg08439880	chr3:133502540	NA	-0.71	-6.05	-0.53	2.86e-8	Iron status biomarkers;
THYM	cis	rs2832077	1.000	rs9983229	chr21:30137674	A/G	cg24692254	chr21:30365293	RNF160	0.83	5.16	0.47	1.38e-6	Cognitive test performance;
THYM	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg01579765	chr21:45077557	HSF2BP	-0.46	-7.25	-0.6	1.12e-10	Mean corpuscular volume;
THYM	cis	rs7107174	0.901	rs2450136	chr11:77925273	T/G	cg19901956	chr11:77921274	USP35	-0.67	-5.34	-0.48	6.37e-7	Testicular germ cell tumor;
THYM	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg18806716	chr10:30721971	MAP3K8	-0.56	-5.58	-0.5	2.24e-7	Inflammatory bowel disease;
THYM	cis	rs2692947	0.550	rs4613327	chr2:96583823	G/A	cg23100626	chr2:96804247	ASTL	0.41	5.15	0.47	1.43e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs6570726	0.791	rs1509214	chr6:145784606	A/C	cg13319975	chr6:146136371	FBXO30	0.66	5.34	0.48	6.33e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs9814567	0.752	rs9836401	chr3:134336897	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.56	-0.61	2.52e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs919433	0.680	rs8539	chr2:198362018	A/G	cg05783139	chr2:198650985	BOLL	0.59	4.61	0.43	1.23e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg08999081	chr20:33150536	PIGU	-0.73	-6.56	-0.56	2.86e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs3126085	0.935	rs4534386	chr1:152251714	A/G	cg10321714	chr1:152280068	FLG	0.67	5.14	0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs7191700	0.578	rs243324	chr16:11354970	A/G	cg00044050	chr16:11439710	C16orf75	0.68	4.91	0.45	3.85e-6	Multiple sclerosis;
THYM	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg17911788	chr17:44343683	NA	0.71	6.76	0.57	1.09e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg26412358	chr1:26503933	CNKSR1	0.36	5.01	0.46	2.48e-6	Height;
THYM	cis	rs7119	0.651	rs12904200	chr15:77845902	C/G	cg10437265	chr15:77819839	NA	0.68	6.14	0.53	1.94e-8	Type 2 diabetes;
THYM	cis	rs9790314	0.645	rs9879687	chr3:160874938	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-5.7	-0.5	1.37e-7	Morning vs. evening chronotype;
THYM	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg23803603	chr1:2058230	PRKCZ	0.6	4.64	0.43	1.1e-5	Height;
THYM	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	5.87	0.52	6.41e-8	Rheumatoid arthritis;
THYM	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.89	8.39	0.65	4.48e-13	Menarche (age at onset);
THYM	cis	rs4243830	0.510	rs7518459	chr1:6596678	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.11	-7.56	-0.61	2.57e-11	Body mass index;
THYM	cis	rs10779751	0.734	rs12569242	chr1:11127511	A/C	cg08854313	chr1:11322531	MTOR	0.86	6.96	0.58	4.46e-10	Body mass index;
THYM	cis	rs2444240	1.000	rs470606	chr11:120028202	T/G	cg03641062	chr11:120099868	OAF	0.52	4.56	0.42	1.51e-5	Corneal curvature;
THYM	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.51	-0.49	3.06e-7	Joint mobility (Beighton score);
THYM	cis	rs11122895	1.000	rs11683033	chr2:112468426	G/C	cg23262488	chr2:112468472	NA	0.67	9.57	0.7	1.36e-15	Allergic sensitization;
THYM	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg08125733	chr17:73851984	WBP2	0.87	5.97	0.52	4.16e-8	Psoriasis;
THYM	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg23422044	chr7:1970798	MAD1L1	-0.76	-5.0	-0.46	2.65e-6	Bipolar disorder;
THYM	cis	rs1957429	0.731	rs1951495	chr14:65336690	T/C	cg23373153	chr14:65346875	NA	0.9	4.82	0.44	5.52e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg26031613	chr14:104095156	KLC1	0.8	5.15	0.47	1.4e-6	Body mass index;
THYM	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg06784218	chr1:46089804	CCDC17	-0.32	-4.51	-0.42	1.86e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs9814567	0.752	rs4306899	chr3:134334513	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.75	7.09	0.59	2.32e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg12179176	chr11:130786555	SNX19	0.73	5.98	0.52	3.82e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs665401	0.899	rs6927262	chr6:117234517	G/A	cg20376953	chr6:117187980	NA	0.63	5.03	0.46	2.27e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs3744061	0.530	rs12450896	chr17:74629867	C/T	cg11469587	chr17:74639849	ST6GALNAC1	0.49	4.63	0.43	1.14e-5	Retinal arteriolar caliber;
THYM	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg02493740	chr2:85810744	VAMP5	-0.63	-4.98	-0.46	2.8e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs61931739	0.892	rs61931711	chr12:34045374	C/T	cg10856724	chr12:34555212	NA	0.63	5.33	0.48	6.57e-7	Morning vs. evening chronotype;
THYM	cis	rs7528419	0.632	rs11102967	chr1:109817245	C/T	cg00908766	chr1:109817496	CELSR2	0.64	5.52	0.49	2.93e-7	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
THYM	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg12935359	chr14:103987150	CKB	-0.53	-6.3	-0.54	9.24e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7246967	0.551	rs7249473	chr19:22906694	T/C	cg05241461	chr19:22816980	ZNF492	0.61	4.75	0.44	7.2e-6	Bronchopulmonary dysplasia;
THYM	cis	rs11650494	0.908	rs77247327	chr17:47411493	T/C	cg08112188	chr17:47440006	ZNF652	1.25	5.41	0.49	4.62e-7	Prostate cancer;
THYM	cis	rs7020830	0.898	rs997318	chr9:37364094	C/T	cg14294708	chr9:37120828	ZCCHC7	1.16	14.09	0.82	5.17e-25	Schizophrenia;
THYM	cis	rs11077998	0.967	rs7502945	chr17:80495039	T/C	cg11779900	chr17:80519722	FOXK2	-0.53	-4.51	-0.42	1.83e-5	Reticulocyte fraction of red cells;
THYM	cis	rs1003719	0.582	rs2835634	chr21:38528270	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-4.72	-0.44	8.18e-6	Eye color traits;
THYM	cis	rs7084402	0.967	rs1658468	chr10:60292664	A/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg24642439	chr20:33292090	TP53INP2	0.68	5.14	0.47	1.45e-6	Coronary artery disease;
THYM	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg10053473	chr17:62856997	LRRC37A3	0.92	7.34	0.6	7.17e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg24692254	chr21:30365293	RNF160	-0.72	-5.09	-0.46	1.83e-6	Dental caries;
THYM	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.65	-4.46	-0.42	2.23e-5	Gut microbiome composition (summer);
THYM	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg19875535	chr5:140030758	IK	-0.63	-5.54	-0.49	2.7e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs9563576	0.735	rs1469873	chr13:58491484	G/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.63	4.68	0.43	9.55e-6	Body mass index;
THYM	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg07679836	chr6:33548423	BAK1	0.49	6.33	0.54	8.22e-9	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
THYM	cis	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg06521331	chr12:34319734	NA	-1.04	-10.31	-0.73	3.52e-17	Morning vs. evening chronotype;
THYM	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg18131467	chr2:239335373	ASB1	1.09	10.65	0.74	6.95e-18	Multiple system atrophy;
THYM	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg25072359	chr17:41440525	NA	0.75	4.69	0.43	9.01e-6	Menopause (age at onset);
THYM	cis	rs7833986	0.501	rs2719261	chr8:56941982	C/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.55	6.55	0.56	2.92e-9	Height;
THYM	cis	rs2251393	1.000	rs2251393	chr17:60778932	A/G	cg05747555	chr17:60778881	MARCH10	-0.62	-4.61	-0.43	1.26e-5	Sudden cardiac arrest;
THYM	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg18681998	chr4:17616180	MED28	0.85	7.68	0.62	1.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg04865290	chr3:52927548	TMEM110	-0.88	-4.55	-0.42	1.59e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs12310956	0.510	rs11052882	chr12:33890017	T/C	cg06521331	chr12:34319734	NA	-0.57	-4.61	-0.43	1.26e-5	Morning vs. evening chronotype;
THYM	cis	rs2970992	0.728	rs1040040	chr2:101321225	A/T	cg01042948	chr2:101319752	NA	0.6	5.92	0.52	5.2e-8	Educational attainment;
THYM	cis	rs7512552	0.809	rs2794685	chr1:150312268	C/T	cg15654264	chr1:150340011	RPRD2	0.45	5.2	0.47	1.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs289828	0.965	rs2278089	chr2:152146672	G/T	cg05960677	chr2:152117363	RBM43	0.58	5.36	0.48	5.69e-7	Blood protein levels;
THYM	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg00686598	chr14:53173677	PSMC6	1.52	7.73	0.62	1.09e-11	Alzheimer's disease (late onset);
THYM	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg08999081	chr20:33150536	PIGU	0.56	4.77	0.44	6.52e-6	Height;
THYM	cis	rs6840360	0.593	rs3805356	chr4:152680701	C/T	cg22705602	chr4:152727874	NA	0.82	11.14	0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg12179176	chr11:130786555	SNX19	0.86	8.13	0.64	1.57e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2075230	0.705	rs1641519	chr17:7550166	C/A	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	-0.3	-4.46	-0.42	2.28e-5	Hormone measurements;
THYM	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg21775007	chr8:11205619	TDH	0.63	4.81	0.44	5.73e-6	Retinal vascular caliber;
THYM	cis	rs9355610	0.892	rs2247314	chr6:167370230	T/C	cg23791538	chr6:167370224	RNASET2	0.84	7.49	0.61	3.58e-11	Graves' disease;
THYM	cis	rs10927875	0.726	rs1763603	chr1:16339809	T/C	cg21385522	chr1:16154831	NA	0.76	5.6	0.5	2.07e-7	Dilated cardiomyopathy;
THYM	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03647317	chr4:187891568	NA	-0.83	-9.1	-0.68	1.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12802200	0.561	rs12792868	chr11:566647	T/A	cg11335335	chr11:637885	DRD4	-0.59	-4.66	-0.43	1.02e-5	Systemic lupus erythematosus;
THYM	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg22189786	chr22:42395067	WBP2NL	0.57	5.17	0.47	1.27e-6	Birth weight;
THYM	cis	rs7943358	0.758	rs10766281	chr11:15728444	A/G	cg11966998	chr11:15692519	NA	-0.44	-4.49	-0.42	2.03e-5	Gut microbiome composition (summer);
THYM	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg03806693	chr22:41940476	POLR3H	-0.76	-5.87	-0.52	6.29e-8	Neuroticism;
THYM	cis	rs3126085	0.935	rs6670717	chr1:152249956	T/C	cg10321714	chr1:152280068	FLG	-0.69	-4.99	-0.46	2.71e-6	Atopic dermatitis;
THYM	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg02038168	chr22:39784481	NA	-0.6	-4.99	-0.46	2.77e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg26924012	chr15:45694286	SPATA5L1	-1.15	-11.49	-0.76	1.16e-19	Homoarginine levels;
THYM	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg06850241	chr22:41845214	NA	0.54	4.77	0.44	6.68e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg12667521	chr19:29218732	NA	0.76	5.59	0.5	2.14e-7	Methadone dose in opioid dependence;
THYM	cis	rs61931739	0.890	rs694706	chr12:34135323	T/C	cg10856724	chr12:34555212	NA	-0.6	-5.28	-0.48	8.14e-7	Morning vs. evening chronotype;
THYM	cis	rs3771570	1.000	rs62186400	chr2:242226700	A/G	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs9788721	0.836	rs7181486	chr15:78741618	C/T	cg18825076	chr15:78729989	IREB2	0.66	6.19	0.54	1.54e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg01579765	chr21:45077557	HSF2BP	0.52	7.58	0.61	2.3e-11	Mean corpuscular volume;
THYM	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg12564285	chr5:131593104	PDLIM4	0.6	7.19	0.59	1.48e-10	Acylcarnitine levels;
THYM	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg05368731	chr17:41323189	NBR1	1.19	10.4	0.73	2.28e-17	Menopause (age at onset);
THYM	cis	rs9970807	0.901	rs55869368	chr1:56986633	C/T	cg11959316	chr1:57001742	PPAP2B	0.8	5.84	0.51	7.12e-8	Myocardial infarction;Coronary artery disease;
THYM	cis	rs4780401	0.703	rs8191295	chr16:11766905	A/G	cg01061890	chr16:11836724	TXNDC11	-0.63	-4.86	-0.45	4.62e-6	Rheumatoid arthritis;
THYM	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg18252515	chr7:66147081	NA	1.37	8.05	0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	trans	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Bladder cancer;
THYM	cis	rs6570726	0.791	rs6570692	chr6:145904401	T/A	cg05347473	chr6:146136440	FBXO30	0.58	4.52	0.42	1.8e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg13695892	chr22:41940480	POLR3H	0.86	6.33	0.54	8.08e-9	Vitiligo;
THYM	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg00898013	chr13:113819073	PROZ	-0.87	-8.78	-0.67	6.82e-14	Platelet distribution width;
THYM	trans	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.18	0.64	1.26e-12	Corneal astigmatism;
THYM	cis	rs786425	0.530	rs10732574	chr12:124219121	A/G	cg15249119	chr12:124971054	NCOR2	0.55	5.09	0.46	1.79e-6	Pubertal anthropometrics;
THYM	cis	rs6754311	0.593	rs1438305	chr2:136502792	C/G	cg20242066	chr2:136595261	LCT	-0.57	-6.93	-0.58	4.9e-10	Mosquito bite size;
THYM	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.05	-5.89	-0.52	5.89e-8	Body mass index;
THYM	cis	rs554111	0.634	rs34740989	chr1:21316782	C/T	cg00373020	chr1:21041521	KIF17	-0.53	-4.47	-0.42	2.14e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg21862992	chr11:68658383	NA	0.23	4.49	0.42	2.02e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg04944784	chr2:26401820	FAM59B	0.76	5.28	0.48	8.27e-7	Gut microbiome composition (summer);
THYM	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs6840360	0.571	rs10026670	chr4:152539212	C/T	cg17479576	chr4:152424074	FAM160A1	-0.78	-5.74	-0.51	1.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	5.57	0.5	2.37e-7	Lung cancer in ever smokers;
THYM	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs8018808	0.935	rs2242619	chr14:77895119	C/T	cg20045696	chr14:77926864	AHSA1	-0.51	-4.6	-0.43	1.29e-5	Myeloid white cell count;
THYM	cis	rs288326	0.561	rs17265824	chr2:183711970	C/G	cg09997497	chr2:183902928	NCKAP1	1.09	5.06	0.46	2.03e-6	Blood protein levels;
THYM	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg26597838	chr10:835615	NA	1.58	12.01	0.78	9.28e-21	Eosinophil percentage of granulocytes;
THYM	cis	rs9583531	0.550	rs7985098	chr13:111386416	G/A	cg24331049	chr13:111365604	ING1	0.69	5.4	0.48	4.91e-7	Coronary artery disease;
THYM	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg00310523	chr12:86230176	RASSF9	0.53	4.6	0.43	1.32e-5	Major depressive disorder;
THYM	cis	rs4951011	0.882	rs12135353	chr1:203755842	G/T	cg24343524	chr1:203763352	ZC3H11A	0.69	6.07	0.53	2.67e-8	Breast cancer;
THYM	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs1113500	0.933	rs11185260	chr1:108635079	A/T	cg06207961	chr1:108661230	NA	-0.64	-5.09	-0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs877282	1.000	rs7100358	chr10:773681	G/A	cg10556349	chr10:835070	NA	-0.69	-4.81	-0.44	5.75e-6	Uric acid levels;
THYM	cis	rs6032067	0.704	rs62205505	chr20:43874856	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.72	-6.57	-0.56	2.73e-9	Blood protein levels;
THYM	cis	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.16	-12.09	-0.78	6.38e-21	Primary sclerosing cholangitis;
THYM	cis	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg20999797	chr1:1681921	NA	0.48	5.17	0.47	1.29e-6	Body mass index;
THYM	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	6.89	0.58	5.96e-10	Electrocardiographic conduction measures;
THYM	cis	rs4750440	0.614	rs7921866	chr10:14030161	C/T	cg27542038	chr10:14027202	FRMD4A	-0.62	-5.16	-0.47	1.34e-6	Adiponectin levels;
THYM	cis	rs7523273	0.564	rs7543097	chr1:207882592	T/G	cg22525895	chr1:207977042	MIR29B2	0.52	4.76	0.44	6.95e-6	Schizophrenia;
THYM	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg00256281	chr22:41985642	PMM1	0.63	4.83	0.44	5.25e-6	Vitiligo;
THYM	cis	rs2721195	0.816	rs4251689	chr8:145741130	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.77	6.23	0.54	1.25e-8	Age at first birth;
THYM	cis	rs672413	0.739	rs500390	chr5:78283656	C/T	cg18828365	chr5:78281819	ARSB	-0.55	-4.98	-0.46	2.78e-6	Blood and toenail selenium levels;Blood protein levels;
THYM	cis	rs912057	0.797	rs1294430	chr6:6744698	A/G	cg13809441	chr6:6737631	NA	0.43	4.86	0.45	4.62e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg26384229	chr12:38710491	ALG10B	0.99	7.94	0.63	3.99e-12	Bladder cancer;
THYM	cis	rs6496667	1.000	rs75444304	chr15:90894246	C/T	cg22089800	chr15:90895588	ZNF774	0.74	5.0	0.46	2.65e-6	Rheumatoid arthritis;
THYM	cis	rs654950	0.934	rs662999	chr1:42001160	A/C	cg06885757	chr1:42089581	HIVEP3	0.54	6.71	0.57	1.38e-9	Airway imaging phenotypes;
THYM	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	10.29	0.73	3.95e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	6.93	0.58	5.11e-10	Smoking behavior;
THYM	cis	rs7772486	0.686	rs2092263	chr6:146029687	G/A	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13326165	0.585	rs61644644	chr3:52307496	T/C	cg08438690	chr3:52279403	PPM1M	-0.88	-5.21	-0.47	1.1e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.89	-0.63	5.1e-12	Chronic sinus infection;
THYM	cis	rs2882877	0.648	rs11694976	chr2:190377894	C/T	cg10752008	chr2:190445175	SLC40A1	0.74	6.23	0.54	1.25e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg02596486	chr22:25115120	PIWIL3	0.41	4.53	0.42	1.73e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg03806693	chr22:41940476	POLR3H	1.31	10.41	0.73	2.19e-17	Vitiligo;
THYM	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg15536230	chr21:44985092	HSF2BP	-0.45	-5.6	-0.5	2.05e-7	Mean corpuscular volume;
THYM	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg08449448	chr8:58056501	NA	0.81	4.65	0.43	1.06e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs9309711	0.883	rs13429373	chr2:3477014	G/A	cg10845886	chr2:3471009	TTC15	-0.59	-4.88	-0.45	4.24e-6	Neurofibrillary tangles;
THYM	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg23583168	chr7:148888333	NA	-1.1	-16.73	-0.86	4.47e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg20887711	chr4:1340912	KIAA1530	-0.56	-4.67	-0.43	9.73e-6	Obesity-related traits;
THYM	cis	rs910187	0.605	rs6122559	chr20:45810617	T/G	cg27589058	chr20:45804311	EYA2	-0.6	-5.26	-0.47	9e-7	Migraine;
THYM	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs9486719	1.000	rs4077932	chr6:96905144	C/T	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg03806693	chr22:41940476	POLR3H	-1.06	-9.46	-0.7	2.36e-15	Vitiligo;
THYM	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg02825527	chr7:2087843	MAD1L1	-0.7	-4.55	-0.42	1.58e-5	Bipolar disorder;
THYM	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg09307838	chr4:120376055	NA	0.6	4.54	0.42	1.63e-5	Corneal astigmatism;
THYM	cis	rs9443189	0.615	rs6453829	chr6:76268509	C/T	cg01950844	chr6:76311363	SENP6	1.1	6.24	0.54	1.21e-8	Prostate cancer;
THYM	cis	rs7071206	0.947	rs1356090	chr10:79395312	T/C	cg07817648	chr10:79422355	NA	-0.94	-7.44	-0.61	4.39e-11	Bone mineral density;
THYM	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-4.87	-0.45	4.47e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs6840360	1.000	rs2007218	chr4:152643972	A/G	cg22705602	chr4:152727874	NA	0.59	6.35	0.55	7.46e-9	Intelligence (multi-trait analysis);
THYM	cis	rs367615	0.918	rs17161895	chr5:108855831	T/G	cg17395555	chr5:108820864	NA	0.53	4.8	0.44	5.95e-6	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg21984481	chr17:79567631	NPLOC4	-0.58	-6.73	-0.57	1.29e-9	Eye color traits;
THYM	cis	rs4731207	0.698	rs10245872	chr7:124535253	A/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.77	6.13	0.53	1.99e-8	Blood protein levels;
THYM	cis	rs6840360	1.000	rs6846114	chr4:152604558	A/G	cg22705602	chr4:152727874	NA	0.61	6.71	0.57	1.39e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7465272	1.000	rs36050651	chr8:143681796	A/G	cg10104451	chr8:143696006	ARC	-0.81	-5.65	-0.5	1.66e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs4889855	0.556	rs61096326	chr17:78543796	G/C	cg16591659	chr17:78472290	NA	0.44	5.03	0.46	2.33e-6	Fractional excretion of uric acid;
THYM	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg23711669	chr6:146136114	FBXO30	0.85	8.17	0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg16680214	chr1:154839983	KCNN3	0.56	7.35	0.6	6.74e-11	Prostate cancer;
THYM	cis	rs4523957	0.928	rs7406247	chr17:2157925	G/A	cg16513277	chr17:2031491	SMG6	0.79	7.41	0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs13102973	0.965	rs13129208	chr4:135858263	A/G	cg14419869	chr4:135874104	NA	0.89	8.76	0.67	7.5e-14	Subjective well-being;
THYM	cis	rs600806	0.751	rs1933182	chr1:109999838	A/C	cg02175308	chr1:109941060	SORT1	-0.55	-4.59	-0.43	1.33e-5	Intelligence (multi-trait analysis);
THYM	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg16230307	chr14:35515116	FAM177A1	0.85	5.53	0.49	2.84e-7	Psoriasis;
THYM	cis	rs7107174	1.000	rs2244508	chr11:77948515	T/A	cg02023728	chr11:77925099	USP35	0.72	6.25	0.54	1.14e-8	Testicular germ cell tumor;
THYM	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg04043695	chr12:129287642	SLC15A4	0.61	5.09	0.46	1.83e-6	Systemic lupus erythematosus;
THYM	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg10515332	chr4:99064459	C4orf37	0.56	4.47	0.42	2.19e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.08	-0.53	2.45e-8	Crohn's disease;
THYM	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.99	8.0	0.63	2.95e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg23428387	chr22:49814324	NA	-0.57	-6.04	-0.53	2.98e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs10851411	0.738	rs60569090	chr15:42746801	T/G	cg04857231	chr15:42782520	NA	-0.48	-4.78	-0.44	6.3e-6	Glucose homeostasis traits;
THYM	trans	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg10856724	chr12:34555212	NA	-0.85	-7.41	-0.61	5.08e-11	Bladder cancer;
THYM	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-4.8	-0.44	5.83e-6	Total cholesterol levels;
THYM	cis	rs6686842	1.000	rs213742	chr1:41621127	A/G	cg03387723	chr1:41708464	SCMH1	0.42	4.96	0.45	3.1e-6	Height;
THYM	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs2290159	0.800	rs73812836	chr3:12655149	T/G	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs600806	0.850	rs10858092	chr1:109943893	A/G	cg16988986	chr1:109941118	SORT1	0.44	4.67	0.43	9.83e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs17174870	0.911	rs4278932	chr2:112761310	C/T	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.94	8.31	0.65	6.68e-13	Colorectal cancer;
THYM	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg01831904	chr17:28903510	LRRC37B2	-1.0	-5.11	-0.46	1.65e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg09263875	chr16:632152	PIGQ	0.58	4.61	0.43	1.26e-5	Height;
THYM	cis	rs7772486	0.754	rs13214277	chr6:146136125	G/T	cg23711669	chr6:146136114	FBXO30	0.98	10.54	0.73	1.18e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg04315214	chr1:2043799	PRKCZ	0.56	4.58	0.43	1.39e-5	Height;
THYM	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4788570	0.615	rs6499526	chr16:71648299	C/T	cg06353428	chr16:71660113	MARVELD3	1.37	9.47	0.7	2.25e-15	Intelligence (multi-trait analysis);
THYM	cis	rs4237845	1.000	rs4237845	chr12:58302436	A/G	cg22764591	chr12:58329936	NA	-0.93	-7.91	-0.63	4.58e-12	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg18876405	chr7:65276391	NA	-0.57	-4.76	-0.44	7e-6	Aortic root size;
THYM	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg19628046	chr18:33552617	C18orf21	0.77	5.47	0.49	3.68e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg16928487	chr17:17741425	SREBF1	0.52	5.23	0.47	1.01e-6	Total body bone mineral density;
THYM	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg21672276	chr3:44754072	ZNF502	-0.48	-4.48	-0.42	2.07e-5	Depressive symptoms;
THYM	cis	rs6674970	1.000	rs4970941	chr1:151068546	A/G	cg11822372	chr1:151115635	SEMA6C	0.72	4.93	0.45	3.53e-6	Childhood ear infection;
THYM	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.49	-0.66	2.78e-13	Mean corpuscular volume;
THYM	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg25237894	chr2:233734115	C2orf82	-0.35	-4.99	-0.46	2.68e-6	Coronary artery disease;
THYM	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg13609457	chr4:120235615	NA	0.59	5.29	0.48	7.68e-7	Corneal astigmatism;
THYM	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11644478	chr21:40555479	PSMG1	-0.54	-4.53	-0.42	1.72e-5	Menarche (age at onset);
THYM	cis	rs9902453	1.000	rs60967688	chr17:28437052	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	5.11	0.46	1.67e-6	Coffee consumption (cups per day);
THYM	cis	rs1983170	1.000	rs483532	chr1:91980447	A/G	cg02896835	chr1:92012615	NA	-0.64	-4.67	-0.43	9.92e-6	Eosinophil percentage of white cells;
THYM	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg15693483	chr7:1102177	C7orf50	0.54	6.26	0.54	1.1e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs9929218	0.501	rs12448999	chr16:68815549	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.93	9.49	0.7	2.01e-15	Colorectal cancer;
THYM	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg16405210	chr4:1374714	KIAA1530	-0.64	-5.21	-0.47	1.09e-6	Longevity;
THYM	cis	rs6429082	0.714	rs184108	chr1:235646160	A/G	cg26050004	chr1:235667680	B3GALNT2	0.76	6.72	0.57	1.36e-9	Adiposity;
THYM	cis	rs4654899	0.865	rs6658526	chr1:21391314	A/G	cg01072550	chr1:21505969	NA	0.73	6.24	0.54	1.19e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs2625529	0.641	rs2035379	chr15:72293202	C/T	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs3760982	0.585	rs68073292	chr19:44291401	T/C	cg11993925	chr19:44307056	LYPD5	0.64	5.0	0.46	2.64e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs887829	0.507	rs10929301	chr2:234663649	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.65	-5.06	-0.46	2.06e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.65	-11.76	-0.77	3.01e-20	Hemostatic factors and hematological phenotypes;
THYM	cis	rs490234	0.812	rs17259739	chr9:128456639	C/T	cg14078157	chr9:128172775	NA	0.66	4.88	0.45	4.29e-6	Mean arterial pressure;
THYM	cis	rs6840360	0.509	rs62327273	chr4:152547594	A/G	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11089937	0.651	rs6001216	chr22:22538145	T/C	cg06866756	chr22:22471216	NA	-0.47	-5.34	-0.48	6.43e-7	Periodontitis (PAL4Q3);
THYM	cis	rs7551222	0.752	rs10900596	chr1:204522457	T/C	cg20240347	chr1:204465584	NA	-0.51	-4.63	-0.43	1.18e-5	Schizophrenia;
THYM	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	6.09	0.53	2.36e-8	Platelet count;
THYM	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg06623918	chr6:96969491	KIAA0776	-1.05	-9.75	-0.71	5.73e-16	Headache;
THYM	cis	rs2046867	0.908	rs11927166	chr3:72795149	C/G	cg25664220	chr3:72788482	NA	-0.86	-6.56	-0.56	2.76e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs947474	0.887	rs10796035	chr10:6396623	G/A	cg25480676	chr10:5710888	NA	0.66	4.47	0.42	2.19e-5	Type 1 diabetes;Rheumatoid arthritis;
THYM	cis	rs2279817	1.000	rs35148872	chr1:18020184	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.84	-5.06	-0.46	2.03e-6	Neuroticism;
THYM	cis	rs10466239	0.892	rs4648316	chr10:43859935	C/T	cg12352960	chr10:43428578	NA	-0.98	-4.61	-0.43	1.23e-5	Telomere length;
THYM	cis	rs933688	0.941	rs11948056	chr5:90680468	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	8.19	0.64	1.22e-12	Smoking behavior;
THYM	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg11327659	chr7:150037044	RARRES2	0.42	5.11	0.46	1.67e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg05872129	chr22:39784769	NA	-1.04	-8.67	-0.66	1.12e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1823778	0.609	rs4891381	chr18:67595449	C/T	cg13164537	chr18:67624071	CD226	-1.27	-4.61	-0.43	1.27e-5	Mean platelet volume;
THYM	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg21100191	chr22:23484243	RTDR1	0.75	6.56	0.56	2.84e-9	Bone mineral density;
THYM	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg25811766	chr13:21894605	NA	0.73	4.89	0.45	4.02e-6	White matter hyperintensity burden;
THYM	cis	rs9595908	1.000	rs9595905	chr13:33183403	G/A	cg12383807	chr13:33924137	NA	-0.54	-4.78	-0.44	6.39e-6	Body mass index;
THYM	trans	rs10162002	0.572	rs117896237	chr13:24023514	C/T	cg17866455	chr15:85173951	SCAND2	0.68	7.2	0.59	1.38e-10	Hypothyroidism;
THYM	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs36051895	0.589	rs10283734	chr9:5217139	A/T	cg02405213	chr9:5042618	JAK2	-0.94	-9.88	-0.71	3.02e-16	Pediatric autoimmune diseases;
THYM	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg07570687	chr10:102243282	WNT8B	0.74	6.47	0.55	4.35e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9486719	1.000	rs12205728	chr6:96891838	T/C	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs4731207	0.596	rs1552119	chr7:124638876	A/T	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs7173743	0.756	rs8035039	chr15:79129823	A/G	cg15571903	chr15:79123663	NA	0.59	6.56	0.56	2.79e-9	Coronary artery disease;
THYM	cis	rs2742417	0.603	rs2742455	chr3:45767116	A/G	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg03526776	chr6:41159608	TREML2	0.5	4.74	0.44	7.49e-6	Alzheimer's disease (late onset);
THYM	cis	rs7681440	0.543	rs2619370	chr4:90736585	C/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.21	-0.47	1.09e-6	Dementia with Lewy bodies;
THYM	cis	rs11779988	0.543	rs415226	chr8:17896138	T/A	cg01800426	chr8:17659068	MTUS1	-0.66	-4.55	-0.42	1.58e-5	Breast cancer;
THYM	cis	rs2346160	0.899	rs206974	chr6:167690300	G/A	cg21686812	chr6:168078911	NA	-0.52	-4.72	-0.44	8.07e-6	Parental extreme longevity (95 years and older);
THYM	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg23161317	chr6:28129485	ZNF389	-0.97	-7.27	-0.6	1.01e-10	Depression;
THYM	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.85	-6.22	-0.54	1.32e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11818084	0.617	rs7921982	chr10:125956773	C/T	cg11660684	chr10:126490277	FAM175B	0.74	4.89	0.45	4.07e-6	Clozapine-induced cytotoxicity;
THYM	cis	rs7578361	0.918	rs1196672	chr2:150335103	A/G	cg17961725	chr2:150454027	NA	0.77	5.71	0.51	1.28e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs2456568	0.548	rs10765647	chr11:93662459	T/C	cg17595323	chr11:93583763	C11orf90	-0.51	-5.46	-0.49	3.83e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs6728642	0.803	rs11891457	chr2:97632449	G/T	cg26665480	chr2:98280029	ACTR1B	-0.8	-4.5	-0.42	1.95e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs1267303	0.675	rs7519040	chr1:46986641	A/G	cg25110126	chr1:46999211	NA	0.64	5.01	0.46	2.51e-6	Monobrow;
THYM	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg17143192	chr8:8559678	CLDN23	-0.94	-7.48	-0.61	3.61e-11	Obesity-related traits;
THYM	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg05754148	chr16:3507555	NAT15	0.72	6.82	0.57	8.39e-10	Tuberculosis;
THYM	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg11245990	chr11:68621969	NA	0.58	7.59	0.61	2.21e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg17366294	chr4:99064904	C4orf37	0.54	6.33	0.54	8.05e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg18477163	chr1:228402036	OBSCN	0.66	6.61	0.56	2.24e-9	Diastolic blood pressure;
THYM	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg20744362	chr22:50050164	C22orf34	0.82	8.02	0.64	2.68e-12	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1801251	0.711	rs778368	chr2:233745333	G/C	cg08000102	chr2:233561755	GIGYF2	-0.55	-4.82	-0.44	5.33e-6	Coronary artery disease;
THYM	cis	rs4363385	0.818	rs451939	chr1:153006877	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs9527	0.615	rs9733635	chr10:104711940	G/A	cg15744005	chr10:104629667	AS3MT	-0.6	-4.58	-0.42	1.43e-5	Arsenic metabolism;
THYM	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	7.86	0.63	6.06e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6430585	0.646	rs12468768	chr2:136494985	C/T	cg23851026	chr2:136556271	LCT	0.63	5.26	0.48	8.72e-7	Corneal structure;
THYM	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg22244940	chr12:132335942	MMP17	0.5	4.84	0.44	4.99e-6	Migraine;
THYM	cis	rs8133932	0.701	rs7276114	chr21:47301187	C/T	cg08707771	chr21:46690014	POFUT2	0.76	4.62	0.43	1.22e-5	Schizophrenia;
THYM	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg19761014	chr17:28927070	LRRC37B2	0.8	4.73	0.44	7.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg05025164	chr4:1340916	KIAA1530	0.86	6.53	0.56	3.3e-9	Longevity;
THYM	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg22508957	chr16:3507546	NAT15	0.7	7.9	0.63	4.94e-12	Tuberculosis;
THYM	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg10047753	chr17:41438598	NA	0.97	7.99	0.63	3.21e-12	Menopause (age at onset);
THYM	cis	rs2898681	0.521	rs115874483	chr4:53728272	G/A	cg00791764	chr4:53727839	RASL11B	0.61	6.76	0.57	1.09e-9	Optic nerve measurement (cup area);
THYM	cis	rs4499344	0.730	rs405858	chr19:33106621	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.84	-7.17	-0.59	1.61e-10	Mean platelet volume;
THYM	cis	rs2970992	0.764	rs2137667	chr2:101332618	C/T	cg01042948	chr2:101319752	NA	0.57	5.74	0.51	1.12e-7	Educational attainment;
THYM	cis	rs600806	0.815	rs4970730	chr1:109979526	T/C	cg23616212	chr1:109941201	SORT1	-0.48	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-4.68	-0.43	9.5e-6	Longevity;
THYM	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	4.8	0.44	5.85e-6	Height;
THYM	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg22105103	chr4:187893119	NA	0.96	10.31	0.73	3.64e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg04362960	chr10:104952993	NT5C2	0.58	4.93	0.45	3.52e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs13256369	0.851	rs13256611	chr8:8564341	G/A	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg24818145	chr4:99064322	C4orf37	0.72	5.72	0.51	1.23e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg26513180	chr16:89883248	FANCA	-0.53	-5.08	-0.46	1.85e-6	Vitiligo;
THYM	cis	rs10493773	0.630	rs3753790	chr1:86174772	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.59	-9.23	-0.69	7.42e-15	Urate levels in overweight individuals;
THYM	cis	rs7942486	0.895	rs4757133	chr11:13268797	G/A	cg13286116	chr11:13302098	ARNTL	-0.72	-8.03	-0.64	2.61e-12	Neuroticism;
THYM	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg17830980	chr10:43048298	ZNF37B	-1.1	-11.0	-0.75	1.23e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg12011299	chr4:100065546	ADH4	-0.85	-8.2	-0.64	1.12e-12	Smoking initiation;
THYM	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg26446133	chr18:72167187	CNDP2	-1.02	-7.49	-0.61	3.5e-11	Refractive error;
THYM	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg06850241	chr22:41845214	NA	0.53	4.56	0.42	1.53e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Body mass index;
THYM	trans	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg07393940	chr7:158741817	NA	-1.17	-9.2	-0.69	8.31e-15	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7178572	0.568	rs12443386	chr15:77491389	C/T	cg22256960	chr15:77711686	NA	1.01	8.22	0.64	1.03e-12	Type 2 diabetes;
THYM	cis	rs7119	0.667	rs1058129	chr15:77905661	A/G	cg27398640	chr15:77910606	LINGO1	0.66	8.46	0.66	3.1400000000000003e-13	Type 2 diabetes;
THYM	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg27490568	chr2:178487706	NA	0.6	5.28	0.48	8.01e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.7	5.66	0.5	1.59e-7	Menarche (age at onset);
THYM	cis	rs6500395	0.832	rs8052733	chr16:48691978	C/T	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7072216	0.763	rs7923729	chr10:100169465	C/T	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs3204270	0.639	rs7216239	chr17:79660187	C/T	cg18367735	chr17:79674897	NA	0.75	4.49	0.42	1.99e-5	Dental caries;
THYM	cis	rs7408868	1.000	rs10416389	chr19:15278674	G/C	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg07211511	chr3:129823064	LOC729375	-1.2	-9.65	-0.7	9.11e-16	Blood pressure (smoking interaction);
THYM	cis	rs7216064	1.000	rs58122682	chr17:65876915	T/C	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs42648	0.869	rs10251227	chr7:89892286	T/G	cg25739043	chr7:89950458	NA	-0.54	-4.62	-0.43	1.19e-5	Homocysteine levels;
THYM	cis	rs11563648	0.573	rs115882589	chr7:126953787	C/T	cg08586737	chr7:127225949	GCC1	-0.33	-4.53	-0.42	1.74e-5	Resting heart rate;
THYM	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.58	4.73	0.44	7.74e-6	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg16586182	chr3:47516702	SCAP	0.66	5.5	0.49	3.19e-7	Colorectal cancer;
THYM	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs911263	0.961	rs1957570	chr14:68729224	A/C	cg18825221	chr14:68749962	RAD51L1	-0.59	-6.32	-0.54	8.43e-9	Primary biliary cholangitis;
THYM	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg18252515	chr7:66147081	NA	-1.57	-8.55	-0.66	2.07e-13	Diabetic kidney disease;
THYM	cis	rs7769051	0.711	rs6569847	chr6:133083187	C/A	cg22852734	chr6:133119734	C6orf192	1.35	8.13	0.64	1.58e-12	Type 2 diabetes nephropathy;
THYM	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs870825	0.616	rs7682505	chr4:185640648	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg21385522	chr1:16154831	NA	-1.31	-14.68	-0.83	3.56e-26	Dilated cardiomyopathy;
THYM	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg24530246	chr3:53118167	NA	-0.82	-4.73	-0.44	7.68e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg02640540	chr1:67518911	SLC35D1	-0.65	-4.78	-0.44	6.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs11711311	0.955	rs2124105	chr3:113406003	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.57	-4.78	-0.44	6.38e-6	IgG glycosylation;
THYM	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08045932	chr20:61659980	NA	-0.96	-10.66	-0.74	6.53e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs921968	0.643	rs832799	chr2:219490111	C/A	cg02176678	chr2:219576539	TTLL4	0.6	5.81	0.51	8.39e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg00647820	chr17:40259828	DHX58	-0.62	-4.65	-0.43	1.06e-5	Fibrinogen levels;
THYM	cis	rs11112613	0.775	rs12305225	chr12:105963266	G/C	cg03607813	chr12:105948248	NA	0.92	7.21	0.59	1.36e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.05	7.36	0.6	6.56e-11	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs1003719	0.708	rs8126491	chr21:38551219	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg14159672	chr1:205819179	PM20D1	0.69	4.76	0.44	7.04e-6	Parkinson's disease;
THYM	cis	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs71636778	0.509	rs11807824	chr1:27270338	A/C	cg16022904	chr1:26870173	RPS6KA1	0.84	4.55	0.42	1.58e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
THYM	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg10760299	chr15:45669010	GATM	0.74	5.59	0.5	2.19e-7	Homoarginine levels;
THYM	cis	rs10499694	0.933	rs12718583	chr7:50582631	T/C	cg18232548	chr7:50535776	DDC	-0.62	-5.1	-0.46	1.75e-6	Body mass index;
THYM	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg11764359	chr7:65958608	NA	-0.85	-7.42	-0.61	5.02e-11	Aortic root size;
THYM	cis	rs17021463	0.902	rs10516950	chr4:95254730	C/T	cg11021082	chr4:95130006	SMARCAD1	0.53	4.47	0.42	2.15e-5	Testicular germ cell tumor;
THYM	cis	rs2692947	0.732	rs56847058	chr2:96406893	C/T	cg22654517	chr2:96458247	NA	0.71	5.34	0.48	6.39e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs10504073	0.669	rs341801	chr8:50037784	A/G	cg00325661	chr8:49890786	NA	0.79	7.02	0.58	3.26e-10	Blood metabolite ratios;
THYM	cis	rs74417235	0.684	rs13186731	chr5:154056002	C/T	cg07371521	chr5:154026371	NA	0.57	5.45	0.49	3.96e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg26168224	chr5:2018326	NA	-0.88	-6.45	-0.55	4.57e-9	Gut microbiome composition (winter);
THYM	cis	rs7084402	0.967	rs1658463	chr10:60298208	C/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.64	-0.5	1.72e-7	Refractive error;
THYM	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg00147160	chr1:26503991	CNKSR1	0.53	7.17	0.59	1.65e-10	Height;
THYM	cis	rs7941600	0.708	rs10840202	chr11:9320346	G/T	cg21110646	chr11:9336536	TMEM41B	1.3	7.38	0.6	6.06e-11	Coronary artery disease;
THYM	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg10018233	chr7:150070692	REPIN1	0.5	7.69	0.62	1.32e-11	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg08645402	chr16:4508243	NA	0.7	6.12	0.53	2.1e-8	Schizophrenia;
THYM	cis	rs6430585	0.591	rs12476135	chr2:136486340	T/C	cg23851026	chr2:136556271	LCT	0.68	5.8	0.51	8.81e-8	Corneal structure;
THYM	cis	rs786425	0.585	rs7398082	chr12:124225073	A/C	cg15249119	chr12:124971054	NCOR2	0.52	4.78	0.44	6.4e-6	Pubertal anthropometrics;
THYM	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg16624210	chr5:671434	TPPP	0.76	5.61	0.5	2.03e-7	Obesity-related traits;
THYM	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg08085267	chr17:45401833	C17orf57	-0.57	-4.99	-0.46	2.71e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
THYM	cis	rs295140	0.507	rs4673814	chr2:201108133	G/A	cg03447810	chr2:200324230	SATB2	-0.59	-4.48	-0.42	2.06e-5	QT interval;
THYM	cis	rs2050392	0.861	rs1042058	chr10:30728101	T/C	cg02070205	chr10:30722105	MAP3K8	-0.53	-4.55	-0.42	1.57e-5	Inflammatory bowel disease;
THYM	cis	rs6831352	0.879	rs7434491	chr4:100069847	G/C	cg12011299	chr4:100065546	ADH4	-0.82	-7.62	-0.62	1.91e-11	Alcohol dependence;
THYM	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.76	6.74	0.57	1.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs677665	0.537	rs72641832	chr1:9336116	C/A	cg03265564	chr1:9748971	PIK3CD	0.26	4.73	0.44	7.77e-6	Eosinophil percentage of white cells;
THYM	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4499344	0.921	rs12973855	chr19:33085395	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.76	-5.45	-0.49	3.97e-7	Mean platelet volume;
THYM	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg00631329	chr6:26305371	NA	-0.65	-7.75	-0.62	1e-11	Educational attainment;
THYM	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg08859206	chr1:53392774	SCP2	0.6	6.72	0.57	1.34e-9	Monocyte count;
THYM	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs34638657	0.732	rs11645372	chr16:82202136	C/T	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.25	-0.47	9.14e-7	Lung adenocarcinoma;
THYM	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.72	0.57	1.37e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.79	-6.78	-0.57	1.01e-9	Lung cancer;
THYM	cis	rs675209	0.638	rs1285874	chr6:7115533	A/T	cg24899545	chr6:7112846	RREB1	-0.51	-4.54	-0.42	1.66e-5	Urate levels;
THYM	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs10501293	0.709	rs10768911	chr11:43028688	G/T	cg03447554	chr11:43094025	NA	0.61	4.51	0.42	1.83e-5	Cognitive performance;
THYM	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg14129053	chr2:1895732	MYT1L	1.13	4.49	0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg09549813	chr16:4587862	C16orf5	-0.59	-6.43	-0.55	5.09e-9	Schizophrenia;
THYM	cis	rs1747683	0.966	rs10737070	chr10:13369846	C/T	cg00142036	chr10:13388442	SEPHS1	-0.29	-5.17	-0.47	1.27e-6	IgG glycosylation;
THYM	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.58	4.95	0.45	3.25e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg09323728	chr8:95962352	TP53INP1	-0.45	-4.67	-0.43	9.99e-6	Type 2 diabetes;
THYM	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg01097406	chr16:89675127	NA	-0.64	-5.34	-0.48	6.43e-7	Vitiligo;
THYM	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg05962950	chr11:130786565	SNX19	0.95	9.03	0.68	2e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg24069376	chr3:38537580	EXOG	-0.66	-6.36	-0.55	7.17e-9	Electrocardiographic conduction measures;
THYM	cis	rs7572733	0.515	rs700675	chr2:198700216	G/A	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	trans	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg07211511	chr3:129823064	LOC729375	-1.22	-9.75	-0.71	5.63e-16	Blood pressure (smoking interaction);
THYM	cis	rs2637266	1.000	rs11001829	chr10:78343387	A/T	cg18941641	chr10:78392320	NA	0.72	6.33	0.54	8.03e-9	Pulmonary function;
THYM	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg26031613	chr14:104095156	KLC1	0.78	5.2	0.47	1.14e-6	Body mass index;
THYM	cis	rs12476592	0.602	rs262533	chr2:63906048	C/G	cg17519650	chr2:63277830	OTX1	-0.72	-4.68	-0.43	9.38e-6	Childhood ear infection;
THYM	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs6032067	1.000	rs6017509	chr20:43830362	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.72	-7.86	-0.63	5.89e-12	Blood protein levels;
THYM	cis	rs7246967	0.551	rs8112442	chr19:22893369	C/T	cg05241461	chr19:22816980	ZNF492	0.6	4.64	0.43	1.11e-5	Bronchopulmonary dysplasia;
THYM	cis	rs2404602	0.735	rs11072598	chr15:76764788	T/C	cg23625390	chr15:77176239	SCAPER	-0.71	-4.87	-0.45	4.37e-6	Blood metabolite levels;
THYM	cis	rs863345	0.604	rs10908654	chr1:158455790	A/T	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg02725872	chr8:58115012	NA	-0.88	-6.21	-0.54	1.38e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs12478296	1.000	rs12478296	chr2:243048760	A/G	cg06360820	chr2:242988706	NA	0.89	5.46	0.49	3.74e-7	Obesity-related traits;
THYM	cis	rs61774743	0.557	rs4359027	chr1:41848296	G/A	cg08462924	chr1:41848221	NA	0.81	9.25	0.69	6.48e-15	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg15704280	chr7:45808275	SEPT13	-0.81	-8.14	-0.64	1.54e-12	Height;
THYM	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg17063962	chr7:91808500	NA	1.14	12.62	0.79	4.97e-22	Breast cancer;
THYM	cis	rs7246657	0.551	rs4806414	chr19:37638788	T/C	cg22634378	chr19:37742834	NA	0.63	4.53	0.42	1.72e-5	Coronary artery calcification;
THYM	cis	rs11574514	1.000	rs13333317	chr16:67872251	A/C	cg04582263	chr16:67973788	LCAT	1.08	5.09	0.46	1.82e-6	Crohn's disease;
THYM	cis	rs4732038	0.510	rs2059329	chr7:134269080	G/C	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs6906287	0.647	rs6925641	chr6:118821894	C/T	cg21191810	chr6:118973309	C6orf204	0.57	5.67	0.5	1.54e-7	Electrocardiographic conduction measures;
THYM	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11890956	chr21:40555474	PSMG1	-0.97	-10.86	-0.74	2.49e-18	Cognitive function;
THYM	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg11673840	chr17:47092156	IGF2BP1	0.62	7.74	0.62	1.07e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs2236918	0.710	rs1776138	chr1:242027075	G/A	cg21919602	chr1:242011447	EXO1	-0.6	-4.46	-0.42	2.29e-5	Menopause (age at onset);
THYM	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs747334	0.811	rs7083495	chr10:92721479	C/T	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg15962314	chr1:44399869	ARTN	0.53	5.39	0.48	5.01e-7	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs4975616	0.807	rs28379291	chr5:1313701	A/G	cg07493874	chr5:1342172	CLPTM1L	0.75	6.56	0.56	2.75e-9	Lung cancer;
THYM	cis	rs12208915	0.848	rs77415956	chr6:79514757	G/A	cg05283184	chr6:79620031	NA	0.74	4.84	0.44	5.06e-6	Left atrial antero-posterior diameter;
THYM	cis	rs11031096	0.655	rs34295904	chr11:4206701	C/A	cg08557956	chr11:4115526	RRM1	-0.55	-4.99	-0.46	2.76e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg00645579	chr11:617140	IRF7;MUPCDH	-0.47	-6.04	-0.53	3.05e-8	Systemic lupus erythematosus;
THYM	cis	rs8170	0.603	rs10259	chr19:17430915	G/A	cg04749549	chr19:17459798	NA	-0.4	-5.05	-0.46	2.09e-6	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
THYM	cis	rs9880211	0.563	rs9881400	chr3:135861666	G/T	cg21827317	chr3:136751795	NA	-0.72	-5.08	-0.46	1.85e-6	Body mass index;Height;
THYM	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg06634786	chr22:41940651	POLR3H	-0.7	-5.38	-0.48	5.4e-7	Vitiligo;
THYM	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.46e-7	Heart rate;
THYM	cis	rs28595532	0.920	rs17259173	chr4:119777232	T/C	cg21605333	chr4:119757512	SEC24D	1.67	6.17	0.53	1.69e-8	Cannabis dependence symptom count;
THYM	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg18758796	chr5:131593413	PDLIM4	0.59	5.32	0.48	6.83e-7	Acylcarnitine levels;
THYM	cis	rs17401966	1.000	rs17396382	chr1:10290268	T/C	cg19773385	chr1:10388646	KIF1B	-0.69	-4.46	-0.42	2.22e-5	Hepatocellular carcinoma;
THYM	cis	rs7172809	0.897	rs1317320	chr15:77830090	G/A	cg22256960	chr15:77711686	NA	-0.69	-4.9	-0.45	3.91e-6	Glucose homeostasis traits;
THYM	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg08213375	chr14:104286397	PPP1R13B	0.45	4.75	0.44	7.26e-6	Reticulocyte count;
THYM	cis	rs7584330	0.554	rs13395743	chr2:238437554	C/T	cg14458575	chr2:238380390	NA	0.81	4.86	0.45	4.63e-6	Prostate cancer;
THYM	cis	rs12681287	0.752	rs13256500	chr8:87247063	G/A	cg27223183	chr8:87520930	FAM82B	-0.6	-4.64	-0.43	1.1e-5	Caudate activity during reward;
THYM	cis	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg24678163	chr13:52769951	THSD1P	0.49	4.58	0.43	1.38e-5	Lewy body disease;
THYM	cis	rs17321999	0.904	rs2089657	chr2:30470178	C/T	cg05247661	chr2:30472410	LBH	0.67	4.91	0.45	3.85e-6	Systemic lupus erythematosus;
THYM	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg24503407	chr1:205819492	PM20D1	0.95	9.42	0.69	2.91e-15	Menarche (age at onset);
THYM	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg03188948	chr7:1209495	NA	0.7	4.87	0.45	4.46e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg23730037	chr7:158596552	ESYT2	0.42	4.51	0.42	1.89e-5	Height;
THYM	cis	rs28595532	0.920	rs114966881	chr4:119761078	C/G	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs34779708	0.931	rs12776390	chr10:35391535	T/G	cg03585969	chr10:35415529	CREM	0.67	4.76	0.44	6.91e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-5.34	-0.48	6.25e-7	Lymphocyte counts;
THYM	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	5.56	0.5	2.43e-7	Eosinophil percentage of white cells;
THYM	cis	rs34779708	0.931	rs10437420	chr10:35335044	A/C	cg03585969	chr10:35415529	CREM	-0.63	-4.66	-0.43	1.01e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg09307838	chr4:120376055	NA	0.68	4.93	0.45	3.43e-6	Corneal astigmatism;
THYM	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg06970220	chr1:156163860	SLC25A44	0.73	5.68	0.5	1.44e-7	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9902453	0.904	rs4598962	chr17:28293948	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.22	0.54	1.3e-8	Coffee consumption (cups per day);
THYM	cis	rs1451375	0.959	rs17133878	chr7:50620927	T/C	cg18232548	chr7:50535776	DDC	0.69	5.28	0.48	8.25e-7	Malaria;
THYM	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg10589385	chr1:150898437	SETDB1	0.64	5.48	0.49	3.48e-7	Tonsillectomy;
THYM	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg02153584	chr22:29168773	CCDC117	0.58	4.56	0.42	1.52e-5	Lymphocyte counts;
THYM	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.71	-5.76	-0.51	1.02e-7	Lung cancer;
THYM	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg13319975	chr6:146136371	FBXO30	0.75	6.26	0.54	1.11e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg08645402	chr16:4508243	NA	0.7	6.19	0.54	1.51e-8	Schizophrenia;
THYM	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg00376283	chr12:123451042	ABCB9	-0.71	-4.75	-0.44	7.32e-6	Neutrophil percentage of white cells;
THYM	cis	rs7953249	0.564	rs1183910	chr12:121420807	G/A	cg02403541	chr12:121454288	C12orf43	0.78	7.02	0.58	3.23e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs4919687	0.550	rs12783444	chr10:104480659	G/A	cg18761893	chr10:103892519	PPRC1	0.61	4.66	0.43	1.02e-5	Colorectal cancer;
THYM	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg09990169	chr2:241835740	C2orf54	-0.35	-5.45	-0.49	3.9e-7	Urinary metabolites;
THYM	cis	rs1387259	0.839	rs7486941	chr12:48578631	C/G	cg21466736	chr12:48725269	NA	0.45	4.54	0.42	1.65e-5	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs11696501	0.739	rs6104252	chr20:44254323	G/A	cg11783356	chr20:44313418	WFDC10B	-0.66	-4.52	-0.42	1.77e-5	Brain structure;
THYM	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1387259	0.723	rs2732488	chr12:48771444	G/A	cg21466736	chr12:48725269	NA	-0.6	-5.43	-0.49	4.29e-7	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs11031096	0.617	rs12288918	chr11:4191466	G/T	cg22027985	chr11:4115532	RRM1	-0.56	-5.25	-0.47	9.12e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg20887711	chr4:1340912	KIAA1530	0.63	5.45	0.49	3.96e-7	Obesity-related traits;
THYM	cis	rs13217797	0.651	rs7743652	chr6:25502076	G/A	cg12474759	chr6:26027625	HIST1H4B	-0.73	-4.71	-0.44	8.37e-6	Schizophrenia;
THYM	cis	rs12142240	0.698	rs1475390	chr1:46816340	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.32e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9790314	0.905	rs7611367	chr3:161003182	A/G	cg03342759	chr3:160939853	NMD3	0.81	7.33	0.6	7.44e-11	Morning vs. evening chronotype;
THYM	cis	rs250677	0.522	rs998304	chr5:148382365	C/A	cg18129178	chr5:148520854	ABLIM3	-0.71	-5.31	-0.48	7.05e-7	Breast cancer;
THYM	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg23622369	chr17:40706682	HSD17B1	-0.76	-7.06	-0.59	2.69e-10	Colorectal or endometrial cancer;
THYM	cis	rs2997447	0.846	rs55912918	chr1:26409801	C/T	cg03844060	chr1:26490628	NA	0.67	4.58	0.43	1.4e-5	QRS complex (12-leadsum);
THYM	cis	rs7107174	1.000	rs4245459	chr11:78065959	T/G	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs2154427	0.655	rs844996	chr21:34041526	C/T	cg21871883	chr21:34145043	C21orf49;C21orf66	-1.04	-5.38	-0.48	5.29e-7	Bilirubin levels;
THYM	cis	rs4455778	0.580	rs7803736	chr7:49125011	A/G	cg26309511	chr7:48887640	NA	0.67	5.88	0.52	6.18e-8	Lung cancer in never smokers;
THYM	cis	rs11723261	0.582	rs114199753	chr4:163520	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.84	5.97	0.52	4.01e-8	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs425535	0.757	rs13117734	chr4:74787503	T/C	cg07868155	chr4:74864709	CXCL5	0.62	4.57	0.42	1.48e-5	Blood protein levels;
THYM	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg25072359	chr17:41440525	NA	0.67	4.72	0.44	7.98e-6	Menopause (age at onset);
THYM	cis	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg23231163	chr10:75533350	FUT11	-0.49	-6.76	-0.57	1.1e-9	Inflammatory bowel disease;
THYM	cis	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg10856724	chr12:34555212	NA	-1.07	-10.09	-0.72	1.09e-16	Morning vs. evening chronotype;
THYM	cis	rs11225247	0.881	rs75976790	chr11:102265076	A/G	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs7523273	0.512	rs2761435	chr1:207918466	C/G	cg22525895	chr1:207977042	MIR29B2	0.72	7.38	0.6	5.98e-11	Schizophrenia;
THYM	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg00271210	chr6:167070053	RPS6KA2	0.72	7.96	0.63	3.73e-12	Crohn's disease;
THYM	cis	rs2273669	0.504	rs78066682	chr6:109464624	A/G	cg17117243	chr6:109341365	SESN1	-0.85	-4.99	-0.46	2.77e-6	Prostate cancer;
THYM	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-6.67	-0.56	1.69e-9	Alzheimer's disease (late onset);
THYM	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg15448220	chr1:150897856	SETDB1	-0.9	-7.66	-0.62	1.56e-11	Melanoma;
THYM	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg24812749	chr6:127587940	RNF146	0.76	5.71	0.51	1.27e-7	Breast cancer;
THYM	cis	rs9914988	0.832	rs34901720	chr17:27179518	A/G	cg20469991	chr17:27169893	C17orf63	-0.83	-5.37	-0.48	5.59e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg11984989	chr7:158649758	WDR60	-1.06	-13.56	-0.81	6.19e-24	Height;
THYM	trans	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs17401966	0.931	rs11585794	chr1:10443867	G/A	cg19773385	chr1:10388646	KIF1B	-0.6	-4.7	-0.43	8.88e-6	Hepatocellular carcinoma;
THYM	cis	rs11605275	1.000	rs76735151	chr11:20026419	G/A	cg14835545	chr11:20032148	NAV2	-1.29	-6.38	-0.55	6.52e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs12765878	0.580	rs11191822	chr10:105599770	T/G	cg04688330	chr10:105451802	SH3PXD2A	0.34	4.48	0.42	2.08e-5	Coronary artery disease;
THYM	cis	rs7677751	0.767	rs6831380	chr4:55076345	G/A	cg17187183	chr4:55093834	PDGFRA	0.67	5.36	0.48	5.82e-7	Corneal astigmatism;
THYM	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.71	9.43	0.7	2.67e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9902453	0.904	rs10853136	chr17:28406018	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-6.08	-0.53	2.47e-8	Coffee consumption (cups per day);
THYM	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08109568	chr15:31115862	NA	-0.76	-6.58	-0.56	2.61e-9	Huntington's disease progression;
THYM	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg23958373	chr8:599963	NA	0.92	4.6	0.43	1.3e-5	IgG glycosylation;
THYM	cis	rs684232	0.666	rs425961	chr17:573714	G/A	cg15660573	chr17:549704	VPS53	-0.87	-8.21	-0.64	1.1e-12	Prostate cancer;
THYM	cis	rs1978968	1.000	rs2099945	chr22:18438642	G/C	cg01550578	chr22:18484421	MICAL3	0.67	5.05	0.46	2.14e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs7107174	0.581	rs11237485	chr11:78126011	G/A	cg02023728	chr11:77925099	USP35	0.54	4.56	0.42	1.55e-5	Testicular germ cell tumor;
THYM	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg11812906	chr14:75593930	NEK9	-0.75	-6.78	-0.57	1.02e-9	Coronary artery disease;
THYM	cis	rs1003719	0.742	rs8129231	chr21:38501034	A/G	cg01329690	chr21:38580129	DSCR9	-0.38	-5.21	-0.47	1.09e-6	Eye color traits;
THYM	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.62	5.26	0.47	8.89e-7	Hemoglobin concentration;
THYM	cis	rs10779751	1.000	rs7549109	chr1:11278813	C/G	cg08854313	chr1:11322531	MTOR	-0.97	-8.91	-0.67	3.49e-14	Body mass index;
THYM	cis	rs11096990	0.855	rs4974986	chr4:39166928	A/G	cg24403649	chr4:39172243	NA	-0.63	-5.3	-0.48	7.61e-7	Cognitive function;
THYM	cis	rs7220711	0.902	rs4793018	chr17:41781069	A/G	cg26893861	chr17:41843967	DUSP3	-0.6	-5.14	-0.47	1.49e-6	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.84	-5.3	-0.48	7.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs728616	0.867	rs61859763	chr10:81671615	A/T	cg18148530	chr10:81370782	SFTPA1	0.74	5.11	0.46	1.65e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg13918804	chr1:2043761	PRKCZ	0.88	9.08	0.68	1.49e-14	Height;
THYM	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg06618935	chr21:46677482	NA	-0.82	-7.54	-0.61	2.8e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg23711669	chr6:146136114	FBXO30	-0.9	-8.32	-0.65	6.26e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg11812906	chr14:75593930	NEK9	-0.8	-7.19	-0.59	1.48e-10	Height;
THYM	cis	rs6860806	0.531	rs270612	chr5:131637338	G/A	cg24060327	chr5:131705240	SLC22A5	-0.78	-6.15	-0.53	1.84e-8	Breast cancer;
THYM	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg25237894	chr2:233734115	C2orf82	-0.34	-4.52	-0.42	1.79e-5	Coronary artery disease;
THYM	cis	rs9527	0.590	rs1541213	chr10:104885330	A/G	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg04842962	chr6:43655489	MRPS18A	-1.28	-9.29	-0.69	5.41e-15	IgG glycosylation;
THYM	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg08901578	chr4:187885870	NA	-0.63	-5.79	-0.51	8.9e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg10360139	chr7:1886902	MAD1L1	-0.62	-5.48	-0.49	3.43e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs9595908	0.965	rs1123462	chr13:33145462	C/T	cg12383807	chr13:33924137	NA	-0.53	-4.59	-0.43	1.36e-5	Body mass index;
THYM	cis	rs6754311	0.509	rs3820794	chr2:136505546	C/T	cg04750100	chr2:136595281	LCT	-0.51	-5.24	-0.47	9.53e-7	Mosquito bite size;
THYM	cis	rs3770752	0.654	rs3770754	chr2:37575381	C/G	cg20091297	chr2:37572423	QPCT	-0.59	-4.54	-0.42	1.62e-5	Schizophrenia;
THYM	cis	rs3126085	0.935	rs12726613	chr1:152185500	C/G	cg10321714	chr1:152280068	FLG	-0.69	-5.03	-0.46	2.27e-6	Atopic dermatitis;
THYM	cis	rs4242434	0.889	rs7817772	chr8:22539316	A/G	cg11461670	chr8:22454935	PDLIM2	0.36	5.94	0.52	4.63e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs17376456	0.597	rs7708175	chr5:93381182	A/G	cg25358565	chr5:93447407	FAM172A	-0.88	-6.25	-0.54	1.18e-8	Diabetic retinopathy;
THYM	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg16486109	chr11:613632	IRF7	0.47	5.59	0.5	2.19e-7	Systemic lupus erythematosus;
THYM	cis	rs9677476	0.731	rs1477470	chr2:232076724	A/C	cg23338755	chr2:231921595	PSMD1	0.68	4.98	0.46	2.81e-6	Food antigen IgG levels;
THYM	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.87e-6	Resting heart rate;
THYM	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg17143192	chr8:8559678	CLDN23	0.91	6.72	0.57	1.33e-9	Obesity-related traits;
THYM	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg14895029	chr7:2775587	GNA12	-0.68	-4.99	-0.46	2.7e-6	Height;
THYM	cis	rs2658782	0.724	rs1563445	chr11:93246042	A/G	cg15737290	chr11:93063684	CCDC67	1.02	7.68	0.62	1.39e-11	Pulmonary function decline;
THYM	cis	rs600806	0.850	rs10858092	chr1:109943893	A/G	cg02175308	chr1:109941060	SORT1	0.61	5.38	0.48	5.35e-7	Intelligence (multi-trait analysis);
THYM	trans	rs75518195	0.543	rs11734078	chr4:64680567	C/T	cg14706739	chr8:21916355	EPB49	0.75	7.37	0.6	6.34e-11	Triptolide cytotoxicity;
THYM	cis	rs7089973	0.584	rs4752255	chr10:116576790	C/T	cg23260525	chr10:116636907	FAM160B1	0.52	5.27	0.48	8.65e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg00810483	chr4:3375144	RGS12	0.32	4.77	0.44	6.67e-6	Serum sulfate level;
THYM	trans	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg25214090	chr10:38739885	LOC399744	-0.94	-7.89	-0.63	5.19e-12	Corneal astigmatism;
THYM	cis	rs12817549	0.754	rs2171124	chr12:94166532	A/C	cg19571390	chr12:94157676	CRADD	0.53	4.47	0.42	2.19e-5	Hip circumference adjusted for BMI;
THYM	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg08645402	chr16:4508243	NA	0.76	6.87	0.58	6.72e-10	Schizophrenia;
THYM	cis	rs2288884	0.806	rs12460587	chr19:52586919	T/G	cg05974498	chr19:52599256	ZNF841	0.36	4.67	0.43	9.88e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs10992471	0.580	rs7852698	chr9:95396409	C/T	cg14631576	chr9:95140430	CENPP	-0.94	-7.64	-0.62	1.75e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg04362960	chr10:104952993	NT5C2	0.65	5.6	0.5	2.04e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg07959070	chr22:50026188	C22orf34	-0.25	-4.69	-0.43	9.18e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg21926883	chr2:100939477	LONRF2	-0.55	-4.99	-0.46	2.74e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4746818	1.000	rs4342912	chr10:70959282	T/C	cg04149295	chr10:70884716	VPS26A	0.79	5.5	0.49	3.13e-7	Left atrial antero-posterior diameter;
THYM	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg12193833	chr17:30244370	NA	-0.63	-4.47	-0.42	2.2e-5	Hip circumference adjusted for BMI;
THYM	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.36	0.48	5.82e-7	Melanoma;
THYM	cis	rs12681287	0.640	rs6992944	chr8:87419308	G/T	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg26418147	chr1:205743515	RAB7L1	-0.55	-4.74	-0.44	7.4e-6	Menarche (age at onset);
THYM	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg11279151	chr3:101281821	RG9MTD1	0.75	5.1	0.46	1.71e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs514406	0.893	rs4584343	chr1:53434539	A/C	cg16325326	chr1:53192061	ZYG11B	-0.81	-7.52	-0.61	3.05e-11	Monocyte count;
THYM	cis	rs7212938	0.509	rs62068170	chr17:38103210	G/A	cg24910161	chr17:38119198	GSDMA	-0.58	-6.82	-0.57	8.35e-10	Asthma and hay fever;
THYM	cis	rs7586879	0.616	rs6545814	chr2:25131316	A/G	cg27107076	chr2:25050844	ADCY3	-0.29	-4.73	-0.44	7.91e-6	Body mass index;
THYM	cis	rs11096990	0.634	rs2381372	chr4:39273091	A/C	cg24403649	chr4:39172243	NA	0.67	5.84	0.51	7.33e-8	Cognitive function;
THYM	cis	rs2806561	0.754	rs750354	chr1:23297406	T/C	cg08872493	chr1:23521417	HTR1D	-0.39	-4.54	-0.42	1.65e-5	Height;
THYM	cis	rs921968	0.613	rs2303566	chr2:219557738	C/T	cg02176678	chr2:219576539	TTLL4	-0.55	-5.46	-0.49	3.79e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs17539620	0.624	rs111484697	chr6:154838903	A/G	cg20019720	chr6:154832845	CNKSR3	0.52	5.35	0.48	6.03e-7	Lipoprotein (a) levels;
THYM	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg03351412	chr1:154909251	PMVK	0.67	4.65	0.43	1.06e-5	Prostate cancer;
THYM	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.68	-4.46	-0.42	2.22e-5	Menarche (age at onset);
THYM	cis	rs448720	0.806	rs4306451	chr15:68157881	A/G	cg24579218	chr15:68104479	NA	-0.69	-6.14	-0.53	1.93e-8	Cognitive performance;
THYM	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg04772025	chr11:68637568	NA	0.66	6.9	0.58	5.88e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1050631	0.564	rs1785925	chr18:33727186	C/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.28	0.48	8.32e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs887829	0.570	rs10175809	chr2:234596865	T/A	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.57	-0.42	1.45e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg27211696	chr2:191398769	TMEM194B	0.85	8.79	0.67	6.5e-14	Pulse pressure;
THYM	cis	rs669446	0.562	rs304303	chr1:44178070	T/G	cg12599982	chr1:44399894	ARTN	0.53	4.76	0.44	6.92e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg21226059	chr5:178986404	RUFY1	0.58	6.05	0.53	2.89e-8	Lung cancer;
THYM	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg26924012	chr15:45694286	SPATA5L1	1.04	9.47	0.7	2.19e-15	Homoarginine levels;
THYM	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.65	5.32	0.48	6.93e-7	Hemoglobin concentration;
THYM	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg12165864	chr7:66369176	NA	-0.63	-4.88	-0.45	4.2e-6	Aortic root size;
THYM	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg18512352	chr11:47633146	NA	-0.56	-7.3	-0.6	8.87e-11	Subjective well-being;
THYM	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.85	0.45	4.76e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg16586182	chr3:47516702	SCAP	0.68	5.7	0.51	1.32e-7	Colorectal cancer;
THYM	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg00376283	chr12:123451042	ABCB9	0.74	5.11	0.46	1.67e-6	Neutrophil percentage of white cells;
THYM	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg00012203	chr2:219082015	ARPC2	0.83	7.44	0.61	4.43e-11	Colorectal cancer;
THYM	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg25072359	chr17:41440525	NA	0.64	4.48	0.42	2.05e-5	Menopause (age at onset);
THYM	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22496380	chr5:211416	CCDC127	-1.28	-7.77	-0.62	9.06e-12	Breast cancer;
THYM	cis	rs9486719	0.857	rs4346856	chr6:96880270	C/T	cg06623918	chr6:96969491	KIAA0776	0.84	5.42	0.49	4.57e-7	Migraine;Coronary artery disease;
THYM	cis	rs11096990	0.613	rs4974995	chr4:39218123	C/T	cg24403649	chr4:39172243	NA	-0.61	-5.25	-0.47	9.41e-7	Cognitive function;
THYM	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg06640241	chr16:89574553	SPG7	0.62	4.7	0.43	8.7e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs7582403	0.807	rs1449958	chr2:148853276	T/C	cg23727674	chr2:148602993	ACVR2A	-0.58	-4.79	-0.44	6.24e-6	Neuroticism;
THYM	cis	rs72772090	0.539	rs111886458	chr5:96125047	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs815815	0.608	rs815808	chr2:47381097	C/T	cg27223769	chr2:47403360	CALM2	0.86	5.49	0.49	3.39e-7	Dialysis-related mortality;
THYM	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg14829155	chr15:31115871	NA	-0.75	-6.3	-0.54	9.11e-9	Huntington's disease progression;
THYM	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg05043794	chr9:111880884	C9orf5	-0.4	-5.83	-0.51	7.54e-8	Menarche (age at onset);
THYM	cis	rs8180040	0.739	rs66539935	chr3:47025327	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-6.68	-0.57	1.59e-9	Colorectal cancer;
THYM	cis	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg14019146	chr3:50243930	SLC38A3	0.83	7.13	0.59	1.92e-10	Intelligence (multi-trait analysis);
THYM	cis	rs17604090	1.000	rs67970052	chr7:29655038	C/T	cg19413766	chr7:29689036	LOC646762	-0.96	-5.2	-0.47	1.15e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs858239	0.636	rs7808488	chr7:23221870	T/C	cg18081818	chr7:23246105	NA	-0.6	-5.43	-0.49	4.39e-7	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg21775007	chr8:11205619	TDH	0.7	6.04	0.53	3.04e-8	Retinal vascular caliber;
THYM	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg26131816	chr17:42072204	PYY	0.53	4.59	0.43	1.35e-5	Menopause (age at onset);
THYM	cis	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.53	-5.4	-0.48	4.82e-7	Crohn's disease;
THYM	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg09307838	chr4:120376055	NA	0.7	5.24	0.47	9.74e-7	Corneal astigmatism;
THYM	cis	rs752010	0.630	rs12134174	chr1:42105942	C/T	cg06885757	chr1:42089581	HIVEP3	0.44	4.99	0.46	2.72e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg23711669	chr6:146136114	FBXO30	0.86	7.92	0.63	4.37e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7103648	1.000	rs12292911	chr11:47449072	C/T	cg20307385	chr11:47447363	PSMC3	0.93	8.66	0.66	1.23e-13	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs7017697	1.000	rs6980875	chr8:19685948	C/T	cg03894339	chr8:19674705	INTS10	-0.55	-4.83	-0.44	5.29e-6	Breast cancer;
THYM	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg14675211	chr2:100938903	LONRF2	0.78	8.49	0.66	2.78e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9527	0.590	rs12355120	chr10:104852166	T/G	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs13082711	0.911	rs997680	chr3:27443638	G/A	cg02860705	chr3:27208620	NA	0.69	4.99	0.46	2.75e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs877282	0.583	rs11253428	chr10:823233	C/T	cg10556349	chr10:835070	NA	-0.83	-5.5	-0.49	3.21e-7	Uric acid levels;
THYM	cis	rs28595532	0.920	rs115878132	chr4:119756239	T/A	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg18132916	chr6:79620363	NA	-0.59	-5.15	-0.47	1.4e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg18681998	chr4:17616180	MED28	0.98	9.9	0.71	2.68e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs1215050	0.527	rs1214998	chr4:99042878	T/G	cg17366294	chr4:99064904	C4orf37	0.43	4.91	0.45	3.74e-6	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs8018808	0.935	rs2364156	chr14:77916746	G/A	cg20045696	chr14:77926864	AHSA1	0.5	4.46	0.42	2.27e-5	Myeloid white cell count;
THYM	cis	rs7695732	0.572	rs2869973	chr4:89904728	T/G	cg17769793	chr4:89976368	FAM13A	-0.49	-5.2	-0.47	1.17e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs3126085	0.867	rs12748016	chr1:152197235	T/C	cg10321714	chr1:152280068	FLG	-0.7	-4.99	-0.46	2.76e-6	Atopic dermatitis;
THYM	cis	rs666930	0.519	rs477992	chr1:120257576	A/G	cg19096424	chr1:120255104	PHGDH	0.85	7.29	0.6	8.97e-11	Breast cancer;
THYM	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg06618935	chr21:46677482	NA	-0.96	-9.3	-0.69	5.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.88	0.63	5.43e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7072216	0.763	rs942803	chr10:100168631	G/T	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg22907277	chr7:1156413	C7orf50	0.58	4.92	0.45	3.56e-6	Longevity;Endometriosis;
THYM	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg08017756	chr2:100939284	LONRF2	-0.72	-7.35	-0.6	6.77e-11	Intelligence (multi-trait analysis);
THYM	cis	rs4595586	0.545	rs12815047	chr12:39380901	A/G	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs747334	0.782	rs2420498	chr10:92704868	C/T	cg07620928	chr10:92689909	NA	0.54	4.84	0.44	5.04e-6	Fibroblast growth factor basic levels;
THYM	cis	rs3096299	0.809	rs2911264	chr16:89499272	A/C	cg06640241	chr16:89574553	SPG7	0.67	5.09	0.46	1.8e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg22535103	chr8:58192502	C8orf71	-0.91	-5.83	-0.51	7.74e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs4866334	1.000	rs74720949	chr5:18503571	T/C	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.84e-7	IgG glycosylation;
THYM	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg00495681	chr13:53174319	NA	0.84	8.73	0.67	8.69e-14	Lewy body disease;
THYM	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs853679	0.599	rs149943	chr6:28002388	G/A	cg12963246	chr6:28129442	ZNF389	0.93	5.06	0.46	2.05e-6	Depression;
THYM	cis	rs1659258	0.655	rs6736170	chr2:88547402	C/T	cg03704645	chr2:88367503	SMYD1	0.83	4.48	0.42	2.07e-5	Visceral fat;
THYM	cis	rs2295499	0.660	rs56215402	chr4:2756912	G/A	cg25585279	chr4:2763026	NA	-0.49	-4.5	-0.42	1.96e-5	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg00271210	chr6:167070053	RPS6KA2	0.7	7.41	0.61	5.11e-11	Crohn's disease;
THYM	cis	rs6496667	1.000	rs7178496	chr15:90896959	C/T	cg22089800	chr15:90895588	ZNF774	0.74	5.0	0.46	2.65e-6	Rheumatoid arthritis;
THYM	cis	rs59698941	0.943	rs12517073	chr5:132240151	T/C	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg08975724	chr8:8085496	FLJ10661	0.6	4.69	0.43	9e-6	Mood instability;
THYM	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg05872129	chr22:39784769	NA	-1.0	-10.66	-0.74	6.49e-18	Intelligence (multi-trait analysis);
THYM	cis	rs7246657	0.943	rs10413602	chr19:37891492	T/C	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg23161317	chr6:28129485	ZNF389	0.84	6.3	0.54	9.31e-9	Depression;
THYM	trans	rs6089829	0.888	rs4809467	chr20:61671688	A/G	cg23505145	chr19:12996616	KLF1	1.03	10.12	0.72	9.21e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7546094	1.000	rs7524494	chr1:113197800	A/G	cg22162597	chr1:113214053	CAPZA1	-0.48	-4.9	-0.45	3.87e-6	Platelet distribution width;
THYM	cis	rs2732480	0.500	rs11168468	chr12:48612465	C/T	cg21466736	chr12:48725269	NA	-0.53	-4.91	-0.45	3.78e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg04287289	chr16:89883240	FANCA	0.62	5.79	0.51	9.18e-8	Vitiligo;
THYM	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg10792982	chr14:105748885	BRF1	0.75	7.8	0.62	7.96e-12	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4523957	0.583	rs2984943	chr17:2030135	T/C	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4919694	1.000	rs11191525	chr10:104793435	G/C	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	cis	rs904251	0.861	rs1757180	chr6:37486145	T/C	cg25019722	chr6:37503610	NA	-0.67	-5.55	-0.49	2.55e-7	Cognitive performance;
THYM	cis	rs9790314	1.000	rs3849524	chr3:161015589	C/T	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg13607699	chr17:42295918	UBTF	-0.91	-9.16	-0.68	1.05e-14	Total body bone mineral density;
THYM	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg24154853	chr7:158122151	PTPRN2	-0.54	-4.82	-0.44	5.51e-6	Calcium levels;
THYM	cis	rs2505998	1.000	rs2435356	chr10:43583150	C/T	cg06632098	chr10:43605906	RET	1.04	8.74	0.67	8.04e-14	Hirschsprung disease;
THYM	cis	rs12754538	0.850	rs17385519	chr1:8527520	C/T	cg06159269	chr1:8767347	RERE	0.22	4.7	0.43	8.75e-6	Subjective well-being;
THYM	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-6.2	-0.54	1.47e-8	Total body bone mineral density;
THYM	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg26384229	chr12:38710491	ALG10B	-0.74	-6.26	-0.54	1.13e-8	Morning vs. evening chronotype;
THYM	cis	rs951188	0.688	rs78256512	chr2:150412918	A/C	cg17961725	chr2:150454027	NA	-1.03	-5.39	-0.48	5.11e-7	Daytime sleep phenotypes;
THYM	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs8067545	0.750	rs28666381	chr17:19984809	C/G	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.64e-6	Schizophrenia;
THYM	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg17063962	chr7:91808500	NA	1.13	12.83	0.8	1.9e-22	Breast cancer;
THYM	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs7957197	0.873	rs7965349	chr12:121471931	C/T	cg13567169	chr12:121410855	C12orf27	0.48	5.41	0.49	4.65e-7	Type 2 diabetes;
THYM	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg18681998	chr4:17616180	MED28	0.91	8.47	0.66	3.08e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2933343	0.700	rs1683777	chr3:128624880	T/G	cg11901034	chr3:128598214	ACAD9	-0.68	-5.57	-0.5	2.4e-7	IgG glycosylation;
THYM	cis	rs2050392	0.517	rs160017	chr10:30772894	A/G	cg13289132	chr10:30722225	MAP3K8	-0.61	-4.98	-0.46	2.81e-6	Inflammatory bowel disease;
THYM	cis	rs10463554	0.963	rs12655592	chr5:102379419	A/G	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg08847533	chr14:75593920	NEK9	-0.96	-10.31	-0.73	3.66e-17	Height;
THYM	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg10047753	chr17:41438598	NA	0.99	8.17	0.64	1.3e-12	Menopause (age at onset);
THYM	cis	rs12367572	0.965	rs11182706	chr12:45223339	T/C	cg03114573	chr12:45410052	DBX2	-0.59	-5.53	-0.49	2.82e-7	Gut microbiome composition (summer);
THYM	cis	rs4072705	0.967	rs10120039	chr9:127406961	A/G	cg13476313	chr9:127244764	NR5A1	0.3	4.58	0.43	1.43e-5	Menarche (age at onset);
THYM	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.65	4.67	0.43	9.93e-6	Renal function-related traits (BUN);
THYM	cis	rs7402982	0.934	rs8028620	chr15:99202875	C/T	cg03437748	chr15:99193247	IGF1R	0.85	7.52	0.61	2.98e-11	Birth weight;
THYM	cis	rs2777491	1.000	rs316605	chr15:41771591	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.09	-12.45	-0.79	1.11e-21	Ulcerative colitis;
THYM	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg00310523	chr12:86230176	RASSF9	0.61	5.31	0.48	7.29e-7	Major depressive disorder;
THYM	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg06558623	chr16:89946397	TCF25	1.15	6.38	0.55	6.37e-9	Skin colour saturation;
THYM	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg06634786	chr22:41940651	POLR3H	0.67	5.36	0.48	5.7e-7	Vitiligo;
THYM	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg22875332	chr1:76189707	ACADM	0.81	7.35	0.6	6.8e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg11494091	chr17:61959527	GH2	1.07	17.57	0.87	1.34e-31	Prudent dietary pattern;
THYM	cis	rs289828	0.542	rs10165284	chr2:152158246	T/C	cg05960677	chr2:152117363	RBM43	0.66	6.17	0.53	1.67e-8	Blood protein levels;
THYM	cis	rs10158481	0.759	rs7547995	chr1:25483136	C/G	cg09264742	chr1:25757510	TMEM57	-0.67	-4.83	-0.44	5.27e-6	Urate levels in obese individuals;
THYM	cis	rs2835345	0.563	rs60727080	chr21:37827174	A/G	cg20643029	chr21:37915044	CLDN14	0.66	5.78	0.51	9.52e-8	Pulmonary function;
THYM	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg02527881	chr3:46936655	PTH1R	0.6	5.51	0.49	3.04e-7	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg11494091	chr17:61959527	GH2	-0.72	-6.81	-0.57	8.85e-10	Height;
THYM	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg04267008	chr7:1944627	MAD1L1	-0.74	-7.02	-0.58	3.26e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg21394778	chr1:3037102	PRDM16	0.46	4.47	0.42	2.12e-5	Height;
THYM	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg20476274	chr7:133979776	SLC35B4	0.67	4.62	0.43	1.22e-5	Mean platelet volume;
THYM	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg00339695	chr16:24857497	SLC5A11	0.69	6.38	0.55	6.46e-9	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg02527881	chr3:46936655	PTH1R	0.65	5.73	0.51	1.2e-7	Colorectal cancer;
THYM	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.73	5.34	0.48	6.26e-7	Height;
THYM	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.13	9.18	0.69	9.2e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4523957	0.651	rs7214741	chr17:2085598	C/T	cg16513277	chr17:2031491	SMG6	-0.95	-8.53	-0.66	2.26e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg01364799	chr7:75623366	TMEM120A	-0.66	-4.67	-0.43	9.93e-6	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs8020441	0.541	rs72681652	chr14:51156155	C/T	cg04730355	chr14:51134070	SAV1	1.0	5.87	0.52	6.49e-8	Cognitive performance;
THYM	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06873352	chr17:61820015	STRADA	0.77	9.62	0.7	1.08e-15	Prudent dietary pattern;
THYM	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg12310025	chr6:25882481	NA	-0.87	-7.09	-0.59	2.38e-10	Intelligence (multi-trait analysis);
THYM	cis	rs11657217	1.000	rs11657217	chr17:77709339	C/G	cg06901238	chr17:77706717	ENPP7	0.64	5.38	0.48	5.24e-7	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
THYM	cis	rs8063160	0.599	rs12921177	chr16:89708037	G/A	cg07984980	chr16:89898383	SPIRE2	1.31	5.21	0.47	1.09e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg10334053	chr1:2078117	PRKCZ	0.45	4.46	0.42	2.25e-5	Height;
THYM	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Body mass index;
THYM	cis	rs6430585	0.583	rs79633114	chr2:136586825	C/T	cg04750100	chr2:136595281	LCT	0.56	5.16	0.47	1.36e-6	Corneal structure;
THYM	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.8	-7.13	-0.59	1.91e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13012494	chr21:47604986	C21orf56	-0.71	-4.64	-0.43	1.13e-5	Testicular germ cell tumor;
THYM	trans	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6087990	0.735	rs1855350	chr20:31387525	C/T	cg13636640	chr20:31349939	DNMT3B	0.9	9.45	0.7	2.46e-15	Ulcerative colitis;
THYM	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.93	-9.65	-0.7	9.29e-16	Menarche (age at onset);
THYM	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg00129232	chr17:37814104	STARD3	-0.71	-4.8	-0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg20283391	chr11:68216788	NA	-0.61	-4.76	-0.44	7e-6	Total body bone mineral density;
THYM	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg25036284	chr2:26402008	FAM59B	-0.82	-5.32	-0.48	6.86e-7	Gut microbiome composition (summer);
THYM	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg05368731	chr17:41323189	NBR1	1.06	6.9	0.58	5.68e-10	Menopause (age at onset);
THYM	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7725337	0.929	rs10040039	chr5:88354597	A/G	cg11280525	chr5:87955695	LOC645323	-0.4	-4.5	-0.42	1.91e-5	Total body bone mineral density;
THYM	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07157834	chr1:205819609	PM20D1	0.88	8.74	0.67	7.98e-14	Menarche (age at onset);
THYM	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg09359103	chr1:154839909	KCNN3	-0.72	-9.45	-0.7	2.44e-15	Prostate cancer;
THYM	trans	rs28595532	0.557	rs12498329	chr4:119311524	C/T	cg26518628	chr1:97050305	NA	-1.1	-8.54	-0.66	2.15e-13	Cannabis dependence symptom count;
THYM	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg00012203	chr2:219082015	ARPC2	0.84	8.14	0.64	1.55e-12	Colorectal cancer;
THYM	cis	rs761746	0.739	rs5753690	chr22:31950005	C/T	cg01338084	chr22:32026380	PISD	0.67	5.78	0.51	9.62e-8	Intelligence;
THYM	cis	rs9674544	0.792	rs8076012	chr17:47101989	G/A	cg07075026	chr17:47091521	IGF2BP1	-0.53	-5.97	-0.52	4.14e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg18876405	chr7:65276391	NA	-0.57	-4.76	-0.44	7e-6	Aortic root size;
THYM	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg21280719	chr6:42927975	GNMT	-0.53	-7.38	-0.6	5.9e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg26384229	chr12:38710491	ALG10B	0.97	7.47	0.61	3.8e-11	Bladder cancer;
THYM	cis	rs9515203	1.000	rs9515203	chr13:111049623	C/T	cg15455643	chr13:111040242	COL4A2	0.57	5.32	0.48	7.03e-7	Coronary artery disease;
THYM	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7072216	0.763	rs7910014	chr10:100172110	C/T	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs7616559	0.629	rs6774654	chr3:156770833	C/T	cg15697575	chr3:156784781	NA	0.43	6.37	0.55	6.84e-9	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.67	5.87	0.52	6.3e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10779751	1.000	rs4845858	chr1:11304720	C/T	cg08854313	chr1:11322531	MTOR	1.03	10.33	0.73	3.19e-17	Body mass index;
THYM	cis	rs2777491	0.872	rs7163649	chr15:41586798	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.12	-12.13	-0.78	5.28e-21	Ulcerative colitis;
THYM	cis	rs6546537	1.000	rs6727435	chr2:69864236	C/A	cg10773587	chr2:69614142	GFPT1	-0.61	-5.31	-0.48	7.23e-7	Serum thyroid-stimulating hormone levels;
THYM	cis	rs8101881	0.535	rs9304839	chr19:33365186	T/C	cg16861209	chr19:33361127	SLC7A9	-0.5	-4.56	-0.42	1.54e-5	Blood metabolite levels;Urinary metabolites;Urinary metabolites (H-NMR features);
THYM	cis	rs4452313	0.547	rs9824172	chr3:16974123	T/G	cg24159436	chr3:16974681	PLCL2	0.33	4.52	0.42	1.78e-5	Rheumatoid arthritis;
THYM	cis	rs10924970	0.967	rs10802617	chr1:235485768	C/T	cg26050004	chr1:235667680	B3GALNT2	0.59	4.48	0.42	2.06e-5	Asthma;
THYM	cis	rs8180040	0.767	rs11920853	chr3:47308183	G/A	cg12976108	chr3:47324180	KIF9;KLHL18	0.5	4.5	0.42	1.92e-5	Colorectal cancer;
THYM	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg08470875	chr2:26401718	FAM59B	0.74	4.59	0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs4642101	0.511	rs9809596	chr3:12840513	C/G	cg11882607	chr3:12858926	CAND2	-0.44	-4.73	-0.44	7.65e-6	QRS complex (12-leadsum);
THYM	cis	rs3825942	0.951	rs74026308	chr15:74223646	G/T	cg23484268	chr15:74220776	LOXL1	0.49	4.63	0.43	1.14e-5	Glaucoma (exfoliation);
THYM	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.46e-7	Heart rate;
THYM	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg08975724	chr8:8085496	FLJ10661	0.77	6.2	0.54	1.42e-8	Mood instability;
THYM	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg07424592	chr7:64974309	NA	1.03	5.4	0.48	4.94e-7	Diabetic kidney disease;
THYM	cis	rs1443512	0.947	rs9804784	chr12:54343472	A/C	cg15261861	chr12:54132255	NA	-0.47	-4.54	-0.42	1.64e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs12540874	0.542	rs3807562	chr7:50566671	G/A	cg18232548	chr7:50535776	DDC	-0.88	-8.38	-0.65	4.66e-13	Systemic sclerosis;
THYM	cis	rs3796352	1.000	rs35163227	chr3:53127876	A/G	cg24530246	chr3:53118167	NA	-0.82	-4.73	-0.44	7.68e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs1497406	0.744	rs12057222	chr1:16508534	A/G	cg03887218	chr1:16534349	ARHGEF19	0.48	4.49	0.42	1.99e-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs986417	1.000	rs12587609	chr14:60928850	C/G	cg27398547	chr14:60952738	C14orf39	1.15	5.91	0.52	5.37e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs2456568	0.503	rs4254038	chr11:93666978	T/C	cg14065697	chr11:93583672	C11orf90	-0.48	-4.62	-0.43	1.19e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg17178900	chr1:205818956	PM20D1	-0.67	-5.58	-0.5	2.29e-7	Prostate-specific antigen levels;
THYM	cis	rs920590	0.642	rs6993525	chr8:19671104	A/G	cg01411142	chr8:19674711	INTS10	-0.59	-4.88	-0.45	4.21e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs259964	1.000	rs259964	chr20:57824309	A/G	cg20910807	chr20:57875384	EDN3	-0.42	-4.54	-0.42	1.62e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	trans	rs75518195	0.500	rs62301924	chr4:64668796	C/T	cg14706739	chr8:21916355	EPB49	0.75	7.37	0.6	6.34e-11	Triptolide cytotoxicity;
THYM	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg12963246	chr6:28129442	ZNF389	0.48	4.7	0.43	8.78e-6	Depression;
THYM	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg12560992	chr17:57184187	TRIM37	-0.92	-8.68	-0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs931127	0.719	rs7949980	chr11:65445950	T/C	cg27068330	chr11:65405492	SIPA1	-0.82	-7.15	-0.59	1.76e-10	Systemic lupus erythematosus;
THYM	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-5.18	-0.47	1.25e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.94	-0.63	4.09e-12	Personality dimensions;
THYM	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg04362960	chr10:104952993	NT5C2	0.6	5.11	0.46	1.66e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7267979	1.000	rs8125868	chr20:25324410	A/G	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg15744005	chr10:104629667	AS3MT	-0.83	-7.75	-0.62	9.94e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg06219351	chr7:158114137	PTPRN2	-0.73	-7.14	-0.59	1.87e-10	Calcium levels;
THYM	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg04990556	chr1:26633338	UBXN11	-0.89	-8.52	-0.66	2.34e-13	Obesity-related traits;
THYM	cis	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg03159660	chr11:2078197	NA	0.62	4.62	0.43	1.22e-5	Calcium levels;
THYM	cis	rs6498114	0.517	rs8052975	chr16:10949263	C/T	cg05349591	chr16:10343871	NA	-0.5	-4.61	-0.43	1.23e-5	Nasopharyngeal carcinoma;
THYM	cis	rs854765	0.624	rs4925116	chr17:17731200	A/G	cg04398451	chr17:18023971	MYO15A	0.74	6.5	0.56	3.65e-9	Total body bone mineral density;
THYM	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-4.78	-0.44	6.47e-6	Mood instability;
THYM	trans	rs2136093	0.600	rs10922861	chr1:90910074	A/G	cg19688584	chr6:167529678	CCR6	0.5	7.06	0.59	2.66e-10	Response to antidepressants;
THYM	cis	rs7192750	0.586	rs62053803	chr16:71989413	G/A	cg06353428	chr16:71660113	MARVELD3	0.69	5.09	0.46	1.77e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11890956	chr21:40555474	PSMG1	0.96	10.57	0.74	9.9e-18	Cognitive function;
THYM	cis	rs4595586	0.545	rs7952765	chr12:39375325	C/G	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg02136620	chr5:178986620	RUFY1	0.6	5.69	0.5	1.43e-7	Lung cancer;
THYM	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg09904177	chr6:26538194	HMGN4	0.64	5.4	0.48	4.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22496380	chr5:211416	CCDC127	-1.28	-7.77	-0.62	9.06e-12	Breast cancer;
THYM	cis	rs2901656	0.691	rs10798005	chr1:172382965	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	-0.54	-5.4	-0.48	4.91e-7	Red cell distribution width;Platelet distribution width;
THYM	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg20486651	chr6:167070296	RPS6KA2	0.46	4.51	0.42	1.82e-5	Crohn's disease;
THYM	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	6.55	0.56	2.95e-9	Obesity-related traits;
THYM	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg05775895	chr3:12838266	CAND2	1.03	10.19	0.72	6.35e-17	QRS complex (12-leadsum);
THYM	cis	rs36051895	0.623	rs10120337	chr9:5243511	G/A	cg02405213	chr9:5042618	JAK2	-0.91	-9.25	-0.69	6.76e-15	Pediatric autoimmune diseases;
THYM	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg22709100	chr7:91322751	NA	-0.6	-4.8	-0.44	5.84e-6	Breast cancer;
THYM	cis	rs9297145	0.761	rs62473015	chr7:98763301	G/A	cg05967295	chr7:98741636	SMURF1	0.86	6.39	0.55	6.04e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs7901056	0.967	rs3006821	chr10:26716353	G/A	cg23318538	chr10:26883079	C10orf50	-0.37	-4.96	-0.45	3.12e-6	Lymphocyte counts;
THYM	cis	rs6998277	0.830	rs12543046	chr8:103603809	A/G	cg10187029	chr8:103597600	NA	-0.53	-4.78	-0.44	6.37e-6	Migraine;
THYM	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg06238570	chr21:40685208	BRWD1	-0.69	-6.08	-0.53	2.47e-8	Menarche (age at onset);
THYM	cis	rs12579753	1.000	rs7956826	chr12:82173365	A/G	cg21231944	chr12:82153410	PPFIA2	-0.69	-5.26	-0.47	8.95e-7	Resting heart rate;
THYM	cis	rs10929159	0.928	rs1349732	chr2:236923716	G/A	cg14895183	chr2:236924282	AGAP1	0.54	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.54	-4.51	-0.42	1.86e-5	Coronary artery disease;
THYM	cis	rs9902453	0.716	rs3098949	chr17:27978694	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.03	0.53	3.1e-8	Coffee consumption (cups per day);
THYM	cis	rs6424115	0.729	rs561733	chr1:24049595	T/G	cg15997130	chr1:24165203	NA	0.66	5.4	0.48	4.82e-7	Immature fraction of reticulocytes;
THYM	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22857025	chr5:266934	NA	-1.52	-9.6	-0.7	1.2e-15	Breast cancer;
THYM	trans	rs4866334	1.000	rs79823740	chr5:18488814	T/C	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs10752881	1.000	rs12028740	chr1:182985581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.79	0.44	6.13e-6	Colorectal cancer;
THYM	cis	rs2075230	0.642	rs1641513	chr17:7554242	T/C	cg27413385	chr17:7515425	FXR2	-0.34	-4.64	-0.43	1.1e-5	Hormone measurements;
THYM	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg06028808	chr11:68637592	NA	0.71	7.61	0.62	1.99e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4731207	0.596	rs7782410	chr7:124571104	A/G	cg05285228	chr7:124571219	POT1	-0.69	-5.25	-0.47	9.35e-7	Cutaneous malignant melanoma;
THYM	cis	rs892961	0.931	rs2411110	chr17:75400143	A/C	cg05865280	chr17:75406074	SEPT9	0.43	4.79	0.44	6.16e-6	Airflow obstruction;
THYM	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg26384229	chr12:38710491	ALG10B	-0.72	-5.79	-0.51	8.96e-8	Morning vs. evening chronotype;
THYM	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg02187348	chr16:89574699	SPG7	0.69	4.95	0.45	3.21e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg00024416	chr22:24240387	NA	-0.62	-6.69	-0.57	1.56e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.58	5.22	0.47	1.05e-6	Lymphocyte counts;
THYM	cis	rs722599	1.000	rs722599	chr14:75327443	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.6	-5.62	-0.5	1.92e-7	IgG glycosylation;
THYM	cis	rs220324	0.738	rs1026400	chr21:43587824	C/T	cg09727148	chr21:43560719	UMODL1	0.67	6.27	0.54	1.04e-8	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs9326248	0.530	rs2513093	chr11:116806687	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.86	4.7	0.43	8.89e-6	Blood protein levels;
THYM	cis	rs995000	0.931	rs12037659	chr1:62923863	C/T	cg06896770	chr1:63153194	DOCK7	1.0	8.17	0.64	1.31e-12	Triglyceride levels;
THYM	trans	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.11	7.98	0.63	3.3e-12	Exhaled nitric oxide output;
THYM	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg23982607	chr1:1823379	GNB1	-0.94	-10.22	-0.72	5.49e-17	Body mass index;
THYM	trans	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg10856724	chr12:34555212	NA	-0.9	-8.53	-0.66	2.28e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs3780378	0.967	rs10815144	chr9:5010192	C/T	cg02405213	chr9:5042618	JAK2	-0.74	-6.8	-0.57	9.43e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19346786	chr7:2764209	NA	-0.71	-6.02	-0.53	3.21e-8	Height;
THYM	cis	rs4727027	0.705	rs10952803	chr7:148890091	T/G	cg23583168	chr7:148888333	NA	-1.12	-17.27	-0.87	4.53e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg05340658	chr4:99064831	C4orf37	0.58	4.72	0.44	8.07e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs6964587	0.758	rs35963176	chr7:91617115	C/T	cg17063962	chr7:91808500	NA	0.96	7.49	0.61	3.6e-11	Breast cancer;
THYM	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Educational attainment;
THYM	cis	rs600806	0.745	rs4246517	chr1:110007636	G/C	cg02175308	chr1:109941060	SORT1	-0.55	-4.59	-0.43	1.33e-5	Intelligence (multi-trait analysis);
THYM	cis	rs946836	0.562	rs10890516	chr1:48422174	T/C	cg18376692	chr1:48452465	NA	0.53	5.49	0.49	3.31e-7	White matter integrity;
THYM	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg00898013	chr13:113819073	PROZ	-0.98	-9.41	-0.69	3.03e-15	Platelet distribution width;
THYM	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22857025	chr5:266934	NA	-1.43	-9.3	-0.69	5.28e-15	Breast cancer;
THYM	cis	rs12039431	0.666	rs177347	chr1:37964322	G/C	cg17933807	chr1:38061675	GNL2	-0.76	-5.45	-0.49	4e-7	Epithelial ovarian cancer;
THYM	cis	rs4509693	0.882	rs7920113	chr10:102493848	A/T	cg24127310	chr10:102502104	NA	1.18	8.78	0.67	6.74e-14	Alzheimer's disease;
THYM	cis	rs11214589	0.747	rs10891537	chr11:113211370	A/C	cg14159747	chr11:113255604	NA	0.29	5.6	0.5	2.03e-7	Neuroticism;
THYM	cis	rs2219968	1.000	rs13281300	chr8:78966585	A/G	cg00738934	chr8:78996279	NA	0.91	9.74	0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9595908	0.581	rs2032507	chr13:33353436	A/T	cg12383807	chr13:33924137	NA	-0.54	-4.62	-0.43	1.22e-5	Body mass index;
THYM	cis	rs2286885	0.965	rs10819167	chr9:129241716	T/A	cg14294646	chr9:129243551	FAM125B	-0.67	-6.41	-0.55	5.49e-9	Intraocular pressure;
THYM	cis	rs2915864	1.000	rs2906069	chr5:141579649	C/T	cg00542992	chr5:141595654	NA	-0.62	-4.65	-0.43	1.06e-5	Facial morphology (factor 20);
THYM	cis	rs4845570	0.834	rs13376155	chr1:151721270	A/G	cg07092448	chr1:151763213	TDRKH	-0.98	-5.27	-0.48	8.55e-7	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	trans	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg01121180	chr19:51302454	C19orf48;SNORD88B	0.79	7.03	0.58	3.18e-10	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7084921	0.578	rs7474935	chr10:101875936	G/C	cg11344164	chr10:101878520	NA	-0.6	-5.44	-0.49	4.08e-7	Bone mineral density;
THYM	cis	rs11771526	0.901	rs62457467	chr7:32301101	T/A	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs2882877	0.621	rs10189190	chr2:190371722	C/T	cg10752008	chr2:190445175	SLC40A1	-0.74	-6.22	-0.54	1.31e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4940575	0.786	rs6567327	chr18:60840750	G/A	cg20947866	chr18:61143580	SERPINB5	0.9	5.34	0.48	6.28e-7	Breast cancer;
THYM	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg16926213	chr1:1841314	NA	0.53	5.49	0.49	3.34e-7	Body mass index;
THYM	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.45	-7.72	-0.62	1.14e-11	Obesity-related traits;
THYM	cis	rs3772130	1.000	rs3732408	chr3:121421179	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.74	4.67	0.43	9.91e-6	Cognitive performance;
THYM	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs67460515	0.563	rs34630898	chr3:160827038	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-4.7	-0.43	8.93e-6	Parkinson's disease;
THYM	cis	rs12496230	0.953	rs1036970	chr3:66850707	A/G	cg17646820	chr3:66848679	NA	0.87	4.74	0.44	7.64e-6	Type 2 diabetes;
THYM	cis	rs28595532	0.920	rs10001115	chr4:119781867	A/C	cg21605333	chr4:119757512	SEC24D	1.56	6.29	0.54	9.68e-9	Cannabis dependence symptom count;
THYM	cis	rs2276498	0.751	rs2299718	chr20:52633683	C/T	cg23682609	chr20:52687365	BCAS1	0.61	5.01	0.46	2.49e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs67311347	0.524	rs11129869	chr3:40259738	G/A	cg13683864	chr3:40499215	RPL14	-0.69	-6.02	-0.53	3.23e-8	Renal cell carcinoma;
THYM	cis	rs7119038	0.865	rs11217046	chr11:118698907	G/A	cg19308663	chr11:118741387	NA	0.58	5.37	0.48	5.48e-7	Sjögren's syndrome;
THYM	cis	rs870825	0.616	rs2696037	chr4:185610940	C/T	cg04058563	chr4:185651563	MLF1IP	-1.06	-8.25	-0.65	8.8e-13	Blood protein levels;
THYM	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg09549813	chr16:4587862	C16orf5	-0.61	-6.88	-0.58	6.45e-10	Schizophrenia;
THYM	cis	rs9796	0.870	rs2412574	chr15:41259707	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.56	-4.62	-0.43	1.19e-5	Menopause (age at onset);
THYM	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.8e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.95	-9.67	-0.7	8.24e-16	Menarche (age at onset);
THYM	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg12564285	chr5:131593104	PDLIM4	0.43	4.95	0.45	3.22e-6	Blood metabolite levels;
THYM	cis	rs28595532	0.920	rs115576008	chr4:119736967	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs7719624	0.692	rs2237065	chr5:135367220	C/T	cg15329133	chr5:135467951	SMAD5;SMAD5OS	-0.61	-5.61	-0.5	1.96e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs12208915	0.709	rs12663824	chr6:79483130	A/C	cg05283184	chr6:79620031	NA	0.79	5.05	0.46	2.14e-6	Left atrial antero-posterior diameter;
THYM	cis	rs3112255	0.935	rs870321	chr2:101296124	A/G	cg01042948	chr2:101319752	NA	0.72	6.28	0.54	1.02e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7586879	0.609	rs7608976	chr2:25075281	G/A	cg15423357	chr2:25149977	NA	0.62	6.45	0.55	4.73e-9	Body mass index;
THYM	cis	rs1823778	0.609	rs4891794	chr18:67611543	G/A	cg12929678	chr18:67624393	CD226	1.3	4.63	0.43	1.14e-5	Mean platelet volume;
THYM	cis	rs6840360	0.533	rs13145446	chr4:152729035	G/A	cg22705602	chr4:152727874	NA	0.76	9.94	0.71	2.21e-16	Intelligence (multi-trait analysis);
THYM	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg18904891	chr8:8559673	CLDN23	0.68	5.08	0.46	1.89e-6	Obesity-related traits;
THYM	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	5.93	0.52	4.8e-8	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg12310025	chr6:25882481	NA	-1.07	-9.31	-0.69	4.84e-15	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg23708337	chr7:1209742	NA	0.73	5.37	0.48	5.5e-7	Longevity;Endometriosis;
THYM	cis	rs13017997	0.808	rs950401	chr2:156837469	A/G	cg03339537	chr2:157184816	NR4A2	-0.35	-4.55	-0.42	1.58e-5	Schizophrenia;
THYM	cis	rs4819852	0.958	rs9606203	chr22:19972118	C/A	cg07821417	chr22:19972146	ARVCF	0.49	5.82	0.51	7.96e-8	Pulse pressure;
THYM	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg23989207	chr17:80870107	TBCD	0.62	5.24	0.47	9.63e-7	Glycated hemoglobin levels;
THYM	trans	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg10856724	chr12:34555212	NA	-0.88	-7.89	-0.63	5.22e-12	Bladder cancer;
THYM	cis	rs17253792	0.545	rs75276278	chr14:56024341	C/T	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.78	0.51	9.35e-8	Obesity-related traits;
THYM	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs4595586	0.505	rs12827467	chr12:39374014	A/G	cg26384229	chr12:38710491	ALG10B	0.69	5.35	0.48	6.11e-7	Morning vs. evening chronotype;
THYM	cis	rs6430585	0.640	rs3816155	chr2:136552526	A/C	cg23851026	chr2:136556271	LCT	-0.77	-7.61	-0.62	2e-11	Corneal structure;
THYM	trans	rs4650994	0.525	rs2493865	chr1:178545016	G/A	cg05059571	chr16:84539110	KIAA1609	0.89	10.47	0.73	1.64e-17	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs611744	0.870	rs640068	chr8:109158002	A/G	cg21045802	chr8:109455806	TTC35	0.61	5.51	0.49	3.01e-7	Dupuytren's disease;
THYM	cis	rs4891159	0.790	rs7241485	chr18:74122325	C/T	cg24786174	chr18:74118243	ZNF516	-0.87	-9.77	-0.71	5.13e-16	Longevity;
THYM	cis	rs8067545	0.641	rs203455	chr17:19821185	A/G	cg20830565	chr17:20408647	MGC102966	-0.56	-5.22	-0.47	1.06e-6	Schizophrenia;
THYM	cis	rs7777754	0.512	rs4470989	chr7:50562698	T/A	cg18232548	chr7:50535776	DDC	-0.87	-7.89	-0.63	5.13e-12	Response to zileuton treatment in asthma (FEV1 change interaction);
THYM	cis	rs10751667	0.621	rs11246375	chr11:999620	T/C	cg20946044	chr11:1010712	AP2A2	-0.54	-4.5	-0.42	1.92e-5	Alzheimer's disease (late onset);
THYM	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg11789530	chr4:8429930	ACOX3	0.7	5.35	0.48	6.07e-7	Response to antineoplastic agents;
THYM	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.95	7.69	0.62	1.33e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs55665837	0.559	rs11023210	chr11:14422762	A/G	cg05501817	chr11:14380813	RRAS2	0.79	6.63	0.56	2e-9	Vitamin D levels;
THYM	cis	rs9972944	0.756	rs6504350	chr17:63764336	G/A	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs11096990	0.892	rs1473364	chr4:39212879	A/G	cg24403649	chr4:39172243	NA	0.62	5.17	0.47	1.31e-6	Cognitive function;
THYM	cis	rs7027203	0.797	rs4744294	chr9:96612114	C/G	cg14598338	chr9:96623480	NA	-0.49	-5.22	-0.47	1.07e-6	DNA methylation (variation);
THYM	cis	rs2281845	1.000	rs2281845	chr1:201081943	C/T	cg22815214	chr1:201083145	CACNA1S	0.77	7.32	0.6	7.97e-11	Permanent tooth development;
THYM	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg03929089	chr4:120376271	NA	0.95	10.29	0.73	3.95e-17	Coronary artery disease;
THYM	cis	rs526231	0.575	rs66730942	chr5:102306779	G/C	cg23492399	chr5:102201601	PAM	-0.61	-4.61	-0.43	1.27e-5	Primary biliary cholangitis;
THYM	cis	rs7246657	0.943	rs10409204	chr19:37917692	G/A	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9896052	0.591	rs7212620	chr17:73461930	A/T	cg00900735	chr17:73316505	GRB2	0.58	4.66	0.43	1.03e-5	Sight-threatening diabetic retinopathy in type 2 diabetes;
THYM	cis	rs9522267	0.737	rs12429582	chr13:112226657	A/G	cg10483660	chr13:112241077	NA	-0.62	-6.72	-0.57	1.33e-9	Hepatitis;
THYM	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg17333051	chr19:2783644	SGTA	0.72	6.18	0.54	1.6e-8	Total cholesterol levels;
THYM	cis	rs1994135	0.715	rs11052742	chr12:33692290	A/C	cg06521331	chr12:34319734	NA	-0.65	-4.68	-0.43	9.49e-6	Resting heart rate;
THYM	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg13010199	chr12:38710504	ALG10B	0.72	5.86	0.52	6.65e-8	Heart rate;
THYM	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg14458575	chr2:238380390	NA	0.9	7.53	0.61	2.94e-11	Prostate cancer;
THYM	cis	rs11792861	0.541	rs838824	chr9:111670707	T/C	cg05043794	chr9:111880884	C9orf5	0.34	4.74	0.44	7.55e-6	Menarche (age at onset);
THYM	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.91	-6.67	-0.56	1.7e-9	Electrocardiographic conduction measures;
THYM	cis	rs36051895	0.589	rs2224571	chr9:5196253	A/C	cg02405213	chr9:5042618	JAK2	-0.92	-9.03	-0.68	2e-14	Pediatric autoimmune diseases;
THYM	cis	rs4363385	0.747	rs6684188	chr1:152974285	A/G	cg13444842	chr1:152974279	SPRR3	-0.57	-4.53	-0.42	1.74e-5	Inflammatory skin disease;
THYM	cis	rs6084875	0.840	rs2065705	chr20:4719407	A/G	cg19614321	chr20:4804581	RASSF2	-0.45	-4.53	-0.42	1.7e-5	Systemic lupus erythematosus;
THYM	cis	rs4638749	1.000	rs12477202	chr2:108867112	G/A	cg23163573	chr2:108905468	SULT1C2	-0.3	-4.47	-0.42	2.16e-5	Blood pressure;
THYM	cis	rs79149102	0.579	rs7173218	chr15:75315328	A/G	cg09165964	chr15:75287851	SCAMP5	-1.1	-6.31	-0.54	8.71e-9	Lung cancer;
THYM	cis	rs57244997	1.000	rs73026573	chr6:162405119	C/T	cg17173639	chr6:162384350	PARK2	-0.97	-5.63	-0.5	1.85e-7	Mosquito bite size;
THYM	cis	rs911263	0.961	rs10131490	chr14:68743307	A/G	cg18825221	chr14:68749962	RAD51L1	-0.61	-6.46	-0.55	4.38e-9	Primary biliary cholangitis;
THYM	cis	rs12310956	0.532	rs1352211	chr12:33983132	G/A	cg10856724	chr12:34555212	NA	-0.75	-6.8	-0.57	9.1e-10	Morning vs. evening chronotype;
THYM	cis	rs28595532	0.841	rs116329146	chr4:119733438	G/A	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg00981070	chr1:2046702	PRKCZ	-0.48	-5.89	-0.52	5.86e-8	Height;
THYM	cis	rs2108622	1.000	rs2108622	chr19:15990431	C/T	cg13772218	chr19:15982569	NA	0.61	5.31	0.48	7.09e-7	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	trans	rs68054310	1	rs68054310	chr12:65033142	AT/A	cg12514734	chr12:3216258	TSPAN9	1.59	7.44	0.61	4.38e-11	Mean platelet volume;
THYM	cis	rs1003719	0.646	rs9985082	chr21:38501021	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-4.75	-0.44	7.3e-6	Eye color traits;
THYM	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs9814567	0.964	rs4539979	chr3:134287597	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-8.41	-0.65	4e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6987853	0.787	rs2923402	chr8:42445400	G/A	cg09913449	chr8:42400586	C8orf40	1.03	10.73	0.74	4.7e-18	Mean corpuscular hemoglobin concentration;
THYM	cis	rs36051895	0.632	rs10974969	chr9:5125336	G/A	cg02405213	chr9:5042618	JAK2	-1.04	-11.53	-0.76	9.18e-20	Pediatric autoimmune diseases;
THYM	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg18876405	chr7:65276391	NA	-0.73	-6.81	-0.57	8.77e-10	Corneal structure;
THYM	cis	rs3818717	0.541	rs55767800	chr17:17674967	T/C	cg04398451	chr17:18023971	MYO15A	0.64	5.32	0.48	6.85e-7	Lymphocyte counts;
THYM	cis	rs916888	0.647	rs199517	chr17:44854587	A/G	cg15921436	chr17:44337874	NA	-0.73	-5.8	-0.51	8.8e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg20295408	chr7:1910781	MAD1L1	-0.68	-5.21	-0.47	1.12e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg04287289	chr16:89883240	FANCA	0.63	5.71	0.51	1.26e-7	Vitiligo;
THYM	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg06221963	chr1:154839813	KCNN3	-0.73	-8.75	-0.67	7.82e-14	Prostate cancer;
THYM	trans	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11890956	chr21:40555474	PSMG1	1.17	13.11	0.8	4.95e-23	Cognitive function;
THYM	cis	rs2282300	0.910	rs528292	chr11:30389710	A/G	cg09906309	chr11:30344399	C11orf46	0.73	5.14	0.47	1.5e-6	Morning vs. evening chronotype;
THYM	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg12310025	chr6:25882481	NA	-0.69	-5.58	-0.5	2.3e-7	Blood metabolite levels;
THYM	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg06713675	chr4:122721982	EXOSC9	-0.86	-9.81	-0.71	4.29e-16	Type 2 diabetes;
THYM	cis	rs9992101	0.517	rs1912833	chr4:77242825	T/A	cg20311846	chr4:77356250	SHROOM3	-0.5	-5.46	-0.49	3.82e-7	Creatinine levels;
THYM	cis	rs524023	0.914	rs526338	chr11:64418900	G/A	cg19131476	chr11:64387923	NRXN2	-0.39	-5.54	-0.49	2.7e-7	Urate levels in obese individuals;
THYM	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs7172809	0.599	rs74026910	chr15:77728444	G/C	cg10437265	chr15:77819839	NA	-0.5	-4.56	-0.42	1.5e-5	Glucose homeostasis traits;
THYM	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs2340727	0.668	rs114341500	chr1:161819499	A/G	cg06514368	chr1:161719587	DUSP12	-0.81	-4.62	-0.43	1.2e-5	White blood cell count;Hematology traits;
THYM	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg10792982	chr14:105748885	BRF1	0.7	7.06	0.59	2.66e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg26695010	chr11:65641043	EFEMP2	0.69	5.17	0.47	1.32e-6	Eosinophil percentage of white cells;
THYM	cis	rs2235573	0.662	rs2018980	chr22:38450620	A/G	cg19171272	chr22:38449367	NA	-0.52	-5.43	-0.49	4.35e-7	Glioblastoma;Glioma;
THYM	cis	rs13082711	0.595	rs6783818	chr3:27361988	C/G	cg02860705	chr3:27208620	NA	0.93	6.95	0.58	4.58e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs904251	0.861	rs1776456	chr6:37484698	C/G	cg25019722	chr6:37503610	NA	-0.65	-5.02	-0.46	2.43e-6	Cognitive performance;
THYM	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg02187348	chr16:89574699	SPG7	0.73	5.66	0.5	1.59e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.82	-4.55	-0.42	1.56e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs981844	1.000	rs2251639	chr4:154656410	T/C	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs12549902	0.966	rs12544241	chr8:41514888	G/A	cg21772509	chr8:41503840	NKX6-3	0.72	6.79	0.57	9.78e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
THYM	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg26384229	chr12:38710491	ALG10B	0.99	7.63	0.62	1.81e-11	Bladder cancer;
THYM	cis	rs9814567	0.896	rs6794258	chr3:134344505	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-8.47	-0.66	3e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7177699	0.557	rs7165075	chr15:79115965	G/A	cg15571903	chr15:79123663	NA	0.57	6.57	0.56	2.71e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs8049634	0.552	rs3826138	chr16:84095451	C/G	cg04832210	chr16:84151246	MBTPS1	0.47	4.78	0.44	6.29e-6	Small cell lung carcinoma;
THYM	cis	rs28647808	0.881	rs7852803	chr9:136245903	A/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.14	-5.2	-0.47	1.15e-6	Blood protein levels;
THYM	cis	rs79149102	0.579	rs73438569	chr15:75354486	T/A	cg09165964	chr15:75287851	SCAMP5	-1.01	-5.72	-0.51	1.25e-7	Lung cancer;
THYM	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg08859206	chr1:53392774	SCP2	-0.5	-5.23	-0.47	1e-6	Monocyte count;
THYM	cis	rs17253792	0.822	rs28481586	chr14:56053863	C/G	cg01858014	chr14:56050164	KTN1	-1.17	-4.89	-0.45	4.1e-6	Putamen volume;
THYM	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg05738196	chr6:26577821	NA	0.95	9.91	0.71	2.53e-16	Intelligence (multi-trait analysis);
THYM	cis	rs9649213	0.593	rs35983874	chr7:97916461	C/T	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs4650994	1.000	rs35810840	chr1:178522642	G/A	cg05059571	chr16:84539110	KIAA1609	-0.75	-8.15	-0.64	1.43e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg12599982	chr1:44399894	ARTN	0.6	4.89	0.45	4.16e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg06713675	chr4:122721982	EXOSC9	-0.89	-10.21	-0.72	5.87e-17	Type 2 diabetes;
THYM	cis	rs3126085	1.000	rs72696952	chr1:152172694	A/T	cg10321714	chr1:152280068	FLG	-0.76	-5.65	-0.5	1.71e-7	Atopic dermatitis;
THYM	cis	rs2916260	0.800	rs75107942	chr6:40384480	G/T	cg08415973	chr6:40346114	TDRG1	0.76	4.64	0.43	1.1e-5	Incident coronary heart disease;
THYM	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.15	-0.59	1.75e-10	Triglycerides;
THYM	cis	rs6500602	0.928	rs3747581	chr16:4462619	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	4.62	0.43	1.22e-5	Schizophrenia;
THYM	cis	rs2295499	0.553	rs17164088	chr4:2675893	A/G	cg14003022	chr4:3043019	NA	0.51	4.48	0.42	2.11e-5	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg19077165	chr18:44547161	KATNAL2	-0.64	-7.95	-0.63	3.85e-12	Personality dimensions;
THYM	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	8.65	0.66	1.24e-13	Platelet count;
THYM	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22496380	chr5:211416	CCDC127	-1.28	-7.77	-0.62	9.06e-12	Breast cancer;
THYM	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg18477163	chr1:228402036	OBSCN	0.63	7.37	0.6	6.18e-11	Diastolic blood pressure;
THYM	cis	rs11948739	0.610	rs4370264	chr5:130192554	T/A	cg08523029	chr5:130500466	HINT1	-0.65	-4.65	-0.43	1.09e-5	Pediatric bone mineral content (hip);
THYM	cis	rs9527	0.662	rs10786714	chr10:104598606	G/C	cg04362960	chr10:104952993	NT5C2	0.64	4.97	0.45	2.97e-6	Arsenic metabolism;
THYM	trans	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.2	-13.75	-0.82	2.52e-24	Exhaled nitric oxide output;
THYM	cis	rs4523957	0.928	rs4790321	chr17:2173499	C/T	cg16513277	chr17:2031491	SMG6	-0.79	-7.14	-0.59	1.86e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs981844	0.601	rs62323856	chr4:154623149	T/C	cg22178613	chr4:154710499	SFRP2	-0.66	-4.45	-0.42	2.33e-5	Response to statins (LDL cholesterol change);
THYM	cis	rs57590327	0.528	rs7642112	chr3:81674927	C/T	cg07356753	chr3:81810745	GBE1	-0.85	-5.98	-0.52	3.99e-8	Extraversion;
THYM	cis	rs28595532	0.920	rs115090549	chr4:119753554	T/C	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg24675056	chr1:15929824	NA	0.72	5.71	0.51	1.26e-7	Systolic blood pressure;
THYM	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg17757837	chr7:157058334	UBE3C	0.65	5.24	0.47	9.83e-7	Body mass index;
THYM	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg03806693	chr22:41940476	POLR3H	-1.04	-7.62	-0.62	1.86e-11	Vitiligo;
THYM	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.69	0.43	9.17e-6	Bipolar disorder;
THYM	cis	rs4666002	0.750	rs13021208	chr2:27901728	C/T	cg27432699	chr2:27873401	GPN1	0.6	4.66	0.43	1.02e-5	Phospholipid levels (plasma);
THYM	cis	rs11186	0.591	rs7420331	chr2:189960329	A/G	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	cis	rs994014	0.847	rs6812825	chr4:82275229	T/C	cg17825130	chr4:82283507	NA	0.46	4.47	0.42	2.16e-5	Height;
THYM	cis	rs40363	0.716	rs9926612	chr16:3540968	A/C	cg01073479	chr16:3509474	NAT15	-0.74	-5.45	-0.49	3.89e-7	Tuberculosis;
THYM	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg22709100	chr7:91322751	NA	0.61	4.73	0.44	7.77e-6	Breast cancer;
THYM	cis	rs34779708	0.931	rs4934724	chr10:35393669	C/T	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6686842	0.965	rs2802548	chr1:41501113	G/T	cg03387723	chr1:41708464	SCMH1	0.44	5.22	0.47	1.04e-6	Height;
THYM	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg13695892	chr22:41940480	POLR3H	-0.98	-7.88	-0.63	5.35e-12	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.9	7.27	0.6	1.02e-10	Multiple sclerosis;
THYM	cis	rs11671005	0.568	rs55987239	chr19:59085045	G/A	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.59	-4.62	-0.43	1.22e-5	Mean platelet volume;
THYM	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg15704280	chr7:45808275	SEPT13	-1.04	-14.05	-0.82	6.23e-25	Height;
THYM	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg11461670	chr8:22454935	PDLIM2	-0.36	-6.07	-0.53	2.65e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs28595532	0.841	rs56388366	chr4:119769242	A/G	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg03388043	chr17:80084554	CCDC57	0.69	5.98	0.52	3.85e-8	Life satisfaction;
THYM	cis	rs1062746	0.557	rs35441225	chr16:87335498	C/A	cg02258303	chr16:87377426	FBXO31	-0.54	-4.62	-0.43	1.22e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs4866334	1.000	rs79543647	chr5:18488484	G/A	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs12540874	0.759	rs12718572	chr7:50573325	C/T	cg00647317	chr7:50633725	DDC	0.36	4.93	0.45	3.52e-6	Systemic sclerosis;
THYM	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg19346786	chr7:2764209	NA	-0.71	-6.01	-0.53	3.36e-8	Height;
THYM	cis	rs865483	0.895	rs853234	chr17:35843050	A/G	cg06716730	chr17:35851459	DUSP14	-0.43	-7.42	-0.61	4.94e-11	Monocyte count;
THYM	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg03161606	chr19:29218774	NA	0.87	7.71	0.62	1.23e-11	Methadone dose in opioid dependence;
THYM	cis	rs149026780	1	rs149026780	chr2:97881612	A/C	cg26665480	chr2:98280029	ACTR1B	-1.04	-4.77	-0.44	6.53e-6	Monocyte chemoattractant protein-3 levels;
THYM	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg06481639	chr22:41940642	POLR3H	-0.62	-4.78	-0.44	6.36e-6	Vitiligo;
THYM	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg22433210	chr17:43662623	NA	1.11	8.45	0.66	3.43e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg18402987	chr7:1209562	NA	0.98	6.61	0.56	2.19e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.3	-0.48	7.66e-7	Bipolar disorder;
THYM	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg26818010	chr10:134567672	INPP5A	-0.72	-5.65	-0.5	1.67e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs10799590	1.000	rs4147293	chr1:224859227	G/A	cg01808320	chr1:224927238	CNIH3	-0.52	-4.65	-0.43	1.08e-5	Opioid dependence;
THYM	cis	rs9653442	0.777	rs6732141	chr2:100743492	G/C	cg07810366	chr2:100720526	AFF3	-0.42	-6.21	-0.54	1.4e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs10489202	0.608	rs10918826	chr1:168075316	C/T	cg24449463	chr1:168025552	DCAF6	-0.79	-7.66	-0.62	1.56e-11	Schizophrenia;
THYM	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.45	0.81	1.03e-23	Height;
THYM	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs9876781	1.000	rs6796491	chr3:48430465	T/G	cg06066452	chr3:48470258	PLXNB1	0.26	4.88	0.45	4.26e-6	Longevity;
THYM	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg16414030	chr3:133502952	NA	0.85	8.38	0.65	4.78e-13	Iron status biomarkers;
THYM	cis	rs6946131	0.509	rs4518612	chr7:54779296	T/C	cg16668896	chr7:54900801	NA	0.42	4.47	0.42	2.16e-5	Systemic lupus erythematosus;
THYM	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg19077165	chr18:44547161	KATNAL2	0.58	7.25	0.6	1.11e-10	Personality dimensions;
THYM	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs1629083	0.967	rs869638	chr11:118100411	C/G	cg25155064	chr11:118100782	MPZL3	-0.61	-5.78	-0.51	9.66e-8	Lung cancer;
THYM	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg12923728	chr3:195709715	SDHAP1	0.72	5.82	0.51	7.98e-8	Pancreatic cancer;
THYM	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.78	-6.4	-0.55	5.77e-9	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs3138083	0.607	rs12376740	chr9:35639595	G/C	cg07116010	chr9:35646325	NA	0.89	8.89	0.67	3.92e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
THYM	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg22655196	chr4:3374909	RGS12	0.64	8.2	0.64	1.16e-12	Serum sulfate level;
THYM	cis	rs7404928	0.651	rs3785392	chr16:23944483	A/G	cg26685404	chr16:23957272	PRKCB	0.68	8.04	0.64	2.51e-12	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs2505998	0.879	rs2435358	chr10:43580215	G/A	cg06632098	chr10:43605906	RET	-1.03	-9.18	-0.69	9.4e-15	Hirschsprung disease;
THYM	cis	rs4690686	0.836	rs10027831	chr4:177256699	T/C	cg17059388	chr4:177262070	NA	0.38	5.49	0.49	3.37e-7	Essential tremor;
THYM	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg13319975	chr6:146136371	FBXO30	-0.65	-5.31	-0.48	7.19e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13012494	chr21:47604986	C21orf56	0.72	4.75	0.44	7.13e-6	Testicular germ cell tumor;
THYM	cis	rs7078219	0.714	rs11190136	chr10:101287681	A/G	cg07044859	chr10:101282883	NA	-0.48	-5.23	-0.47	1.01e-6	Dental caries;
THYM	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg06108461	chr20:60628389	TAF4	-0.82	-7.06	-0.59	2.77e-10	Body mass index;
THYM	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg27494647	chr7:150038898	RARRES2	0.4	4.59	0.43	1.35e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	12.79	0.8	2.27e-22	Height;
THYM	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg02869364	chr7:1081709	C7orf50	-0.6	-4.91	-0.45	3.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg00981070	chr1:2046702	PRKCZ	-0.47	-5.85	-0.51	6.95e-8	Height;
THYM	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg23851026	chr2:136556271	LCT	-0.55	-5.55	-0.49	2.62e-7	Mosquito bite size;
THYM	trans	rs561341	1.000	rs546519	chr17:30297682	T/G	cg20587970	chr11:113659929	NA	-1.26	-9.01	-0.68	2.16e-14	Hip circumference adjusted for BMI;
THYM	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg11764359	chr7:65958608	NA	-0.8	-6.38	-0.55	6.55e-9	Aortic root size;
THYM	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg19016782	chr12:123741754	C12orf65	-0.71	-4.66	-0.43	1.05e-5	Neutrophil percentage of white cells;
THYM	cis	rs1461503	0.966	rs11218910	chr11:122842861	G/A	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs7107174	0.688	rs11237490	chr11:78135229	C/T	cg02023728	chr11:77925099	USP35	0.58	4.88	0.45	4.35e-6	Testicular germ cell tumor;
THYM	cis	rs7246657	0.943	rs10407084	chr19:37907792	T/C	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	7.45	0.61	4.35e-11	Smoking behavior;
THYM	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.75e-6	Reticulocyte count;
THYM	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.1	-0.53	2.29e-8	Crohn's disease;
THYM	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg27490568	chr2:178487706	NA	-0.61	-5.57	-0.5	2.4e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7567389	0.677	rs7556675	chr2:128053747	C/T	cg06038358	chr2:128176007	PROC	-0.43	-4.53	-0.42	1.7e-5	Self-rated health;
THYM	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg17211192	chr8:82754475	SNX16	0.82	7.41	0.61	5.09e-11	Diastolic blood pressure;
THYM	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg19508488	chr2:152266495	RIF1	0.79	6.49	0.55	3.8e-9	Lung cancer;
THYM	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg24112000	chr20:60950667	NA	-0.75	-6.9	-0.58	5.7e-10	Colorectal cancer;
THYM	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg00383909	chr3:49044727	WDR6	1.11	6.7	0.57	1.5e-9	Blood protein levels;
THYM	cis	rs12935418	0.583	rs1469124	chr16:81029654	C/G	cg16651780	chr16:81037892	C16orf61	-0.84	-6.39	-0.55	6.03e-9	Mean corpuscular volume;
THYM	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg08807101	chr21:30365312	RNF160	-0.79	-6.04	-0.53	2.98e-8	Dental caries;
THYM	cis	rs10463554	0.927	rs464720	chr5:102406887	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.13	-0.47	1.56e-6	Parkinson's disease;
THYM	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg22841779	chr14:105766346	BRF1	-0.47	-5.79	-0.51	9.05e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs10493773	0.609	rs6689168	chr1:86174232	G/T	cg17807903	chr1:86174739	ZNHIT6	-0.59	-9.23	-0.69	7.42e-15	Urate levels in overweight individuals;
THYM	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4919694	1.000	rs12241091	chr10:104808997	G/A	cg15744005	chr10:104629667	AS3MT	-0.85	-4.67	-0.43	9.96e-6	Arsenic metabolism;
THYM	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs12935418	0.616	rs55776427	chr16:81005896	T/C	cg16651780	chr16:81037892	C16orf61	0.76	5.4	0.48	4.86e-7	Mean corpuscular volume;
THYM	cis	rs2033711	0.837	rs3764535	chr19:58929052	G/A	cg00825309	chr19:58991885	ZNF446	-0.59	-4.7	-0.43	8.69e-6	Uric acid clearance;
THYM	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs6842789	0.583	rs67119331	chr4:124909121	C/A	cg01723706	chr4:124814442	LOC285419	0.75	4.7	0.43	8.94e-6	Neuroticism;
THYM	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg02725872	chr8:58115012	NA	-0.87	-4.93	-0.45	3.49e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs988913	1.000	rs1503136	chr6:54851965	A/C	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.75e-6	Menarche (age at onset);
THYM	cis	rs17253792	0.822	rs77408754	chr14:56082047	C/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.87	-0.45	4.39e-6	Putamen volume;
THYM	cis	rs4788815	1.000	rs4788815	chr16:71634811	A/T	cg06353428	chr16:71660113	MARVELD3	0.69	4.92	0.45	3.67e-6	Metabolite levels;
THYM	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-5.77	-0.51	9.69e-8	Gut microbiome composition (summer);
THYM	cis	rs8016982	0.593	rs7160569	chr14:81713686	C/T	cg21807262	chr14:81713016	NA	-0.58	-5.65	-0.5	1.66e-7	Schizophrenia;
THYM	cis	rs1455213	0.544	rs2604555	chr4:15168236	C/T	cg12377275	chr4:15005593	CPEB2	0.54	4.49	0.42	2.02e-5	Parental longevity (mother's age at death);
THYM	cis	rs2637266	1.000	rs7896831	chr10:78366649	A/T	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs236907	0.859	rs2232819	chr1:171755182	G/A	cg20598894	chr1:171756153	METTL13	-0.73	-5.28	-0.48	8.25e-7	Mean platelet volume;
THYM	cis	rs11690935	0.550	rs7584187	chr2:172866105	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.58	-4.61	-0.43	1.25e-5	Schizophrenia;
THYM	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7216064	1.000	rs8082512	chr17:65837059	T/C	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs4523957	0.651	rs7223390	chr17:2085653	T/C	cg16513277	chr17:2031491	SMG6	-0.95	-8.69	-0.67	1.05e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs61931739	0.635	rs1405025	chr12:33908491	C/T	cg06521331	chr12:34319734	NA	-0.57	-4.76	-0.44	7e-6	Morning vs. evening chronotype;
THYM	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9362426	1.000	rs173334	chr6:88080223	T/C	cg10393598	chr6:87862264	NA	-0.61	-4.88	-0.45	4.29e-6	Depressive episodes in bipolar disorder;
THYM	cis	rs761746	0.804	rs5749304	chr22:31967775	A/G	cg10537193	chr22:32026975	PISD	0.35	4.67	0.43	1.01e-5	Intelligence;
THYM	cis	rs8108034	0.749	rs251907	chr19:39827086	G/A	cg11865883	chr19:39971137	TIMM50	0.67	4.69	0.43	9.27e-6	Lung adenocarcinoma;
THYM	cis	rs2034650	0.563	rs2412523	chr15:40709686	C/G	cg12699599	chr15:40643142	PHGR1	-0.57	-5.24	-0.47	9.73e-7	Interstitial lung disease;
THYM	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg18252515	chr7:66147081	NA	0.66	5.09	0.46	1.84e-6	Aortic root size;
THYM	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg25427524	chr10:38739819	LOC399744	-0.7	-6.38	-0.55	6.44e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs4732038	0.565	rs6954495	chr7:134279190	C/T	cg06906464	chr7:134288099	NA	-0.48	-4.76	-0.44	7e-6	Longevity;
THYM	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg10661904	chr17:79619235	PDE6G	-0.65	-6.28	-0.54	1.01e-8	Eye color traits;
THYM	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.25	10.58	0.74	9.73e-18	Platelet count;
THYM	cis	rs6500395	1.000	rs12597928	chr16:48714366	G/A	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg06766960	chr11:133703094	NA	-0.59	-5.47	-0.49	3.59e-7	Childhood ear infection;
THYM	cis	rs4833407	0.572	rs2189174	chr4:113283611	G/A	cg25935669	chr4:113448283	NA	-0.6	-5.42	-0.49	4.51e-7	Obesity;
THYM	trans	rs3213961	0.572	rs59479233	chr2:33831770	C/T	cg19997179	chr2:620310	NA	0.55	7.04	0.59	3e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
THYM	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg25214090	chr10:38739885	LOC399744	1.0	8.49	0.66	2.76e-13	Corneal astigmatism;
THYM	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.53	-5.2	-0.47	1.16e-6	Crohn's disease;
THYM	cis	rs7814319	0.901	rs13253635	chr8:97240847	A/G	cg20787634	chr8:97240163	UQCRB	-0.78	-9.45	-0.7	2.49e-15	Lung function (FVC);
THYM	cis	rs2554380	0.657	rs11259916	chr15:84361518	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.5	-4.48	-0.42	2.11e-5	Height;
THYM	cis	rs6924995	0.501	rs2142672	chr6:16197194	G/A	cg11805552	chr6:16175128	NA	0.57	4.85	0.45	4.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg11663144	chr21:46675770	NA	-0.72	-10.13	-0.72	8.56e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg27446573	chr6:127587934	RNF146	1.04	9.87	0.71	3.12e-16	Breast cancer;
THYM	cis	rs4662945	0.762	rs28510974	chr2:130215288	G/A	cg05903289	chr2:130345205	NA	-0.58	-5.66	-0.5	1.6e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs2997447	0.706	rs1414419	chr1:26430501	C/T	cg03844060	chr1:26490628	NA	0.66	4.48	0.42	2.09e-5	QRS complex (12-leadsum);
THYM	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	10.62	0.74	7.85e-18	Chronic sinus infection;
THYM	cis	rs10892173	0.588	rs12363806	chr11:117658211	G/A	cg21640587	chr11:117668038	DSCAML1	1.11	9.66	0.7	8.6e-16	Myopia;
THYM	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg12373951	chr3:133503437	NA	0.66	7.16	0.59	1.68e-10	Iron status biomarkers;
THYM	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg26314531	chr2:26401878	FAM59B	-0.8	-5.34	-0.48	6.43e-7	Gut microbiome composition (summer);
THYM	cis	rs9677476	0.863	rs5018532	chr2:232077075	A/G	cg07929768	chr2:232055508	NA	0.59	6.14	0.53	1.89e-8	Food antigen IgG levels;
THYM	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg11366901	chr6:160182831	ACAT2	1.01	8.95	0.68	2.91e-14	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs78761021	0.720	rs55872800	chr17:9794823	G/A	cg26853458	chr17:9805074	RCVRN	0.53	4.49	0.42	2.01e-5	Type 2 diabetes;
THYM	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg08132940	chr7:1081526	C7orf50	-1.15	-4.47	-0.42	2.2e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7258465	1.000	rs34746918	chr19:18539744	C/T	cg01380346	chr19:18557039	ELL	-0.48	-4.74	-0.44	7.38e-6	Breast cancer;
THYM	cis	rs1669338	0.588	rs6784329	chr3:3200013	C/T	cg16797762	chr3:3221439	CRBN	-1.02	-5.48	-0.49	3.43e-7	White matter integrity;
THYM	cis	rs2290159	0.518	rs9843910	chr3:12591589	G/A	cg23032965	chr3:12705835	RAF1	0.81	4.49	0.42	2e-5	Cholesterol, total;
THYM	cis	rs9527	0.615	rs4919682	chr10:104584330	C/T	cg08772003	chr10:104629869	AS3MT	-0.62	-4.83	-0.44	5.2e-6	Arsenic metabolism;
THYM	cis	rs7818345	0.967	rs11784873	chr8:19281113	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.54	0.42	1.63e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs2806561	0.894	rs628106	chr1:23537685	C/T	cg08872493	chr1:23521417	HTR1D	0.36	4.45	0.42	2.34e-5	Height;
THYM	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg11266682	chr4:10021025	SLC2A9	-0.52	-6.22	-0.54	1.34e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg25767906	chr1:53392781	SCP2	-0.68	-6.52	-0.56	3.45e-9	Monocyte count;
THYM	cis	rs208520	0.706	rs851601	chr6:66893853	G/A	cg07460842	chr6:66804631	NA	-0.91	-6.25	-0.54	1.14e-8	Exhaled nitric oxide output;
THYM	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.8	4.5	0.42	1.9e-5	Alzheimer's disease;
THYM	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg24692254	chr21:30365293	RNF160	-0.96	-8.77	-0.67	6.99e-14	Dental caries;
THYM	cis	rs12765878	1.000	rs11191865	chr10:105672842	G/A	cg11005552	chr10:105648138	OBFC1	0.88	11.55	0.76	8.37e-20	Coronary artery disease;
THYM	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.05	-7.4	-0.6	5.36e-11	Body mass index;
THYM	cis	rs6840360	0.615	rs12647616	chr4:152607662	G/A	cg22705602	chr4:152727874	NA	-0.79	-10.67	-0.74	6.15e-18	Intelligence (multi-trait analysis);
THYM	cis	rs11651000	0.857	rs56172120	chr17:45824904	G/A	cg24803719	chr17:45855879	NA	-0.61	-6.24	-0.54	1.23e-8	IgG glycosylation;
THYM	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg05187965	chr10:45406764	TMEM72	-0.53	-5.3	-0.48	7.36e-7	Mean corpuscular volume;
THYM	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg03605463	chr16:89740564	NA	0.89	6.99	0.58	3.85e-10	Vitiligo;
THYM	cis	rs4849845	0.889	rs6542579	chr2:121014370	C/T	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs11696501	0.591	rs6065854	chr20:44288816	T/C	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	cis	rs10487112	1.000	rs7807342	chr7:90067488	A/C	cg26521402	chr7:89842741	STEAP2	0.51	4.55	0.42	1.6e-5	Perceived unattractiveness to mosquitoes;
THYM	cis	rs728616	0.614	rs12245076	chr10:81713431	G/A	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04871131	chr7:94954202	PON1	-0.61	-5.0	-0.46	2.62e-6	Paraoxonase activity;
THYM	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg04317338	chr11:64019027	PLCB3	0.85	5.81	0.51	8.33e-8	Mean platelet volume;
THYM	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs35110281	0.592	rs10211901	chr21:45122573	G/A	cg01579765	chr21:45077557	HSF2BP	-0.46	-7.4	-0.6	5.36e-11	Mean corpuscular volume;
THYM	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg00071950	chr4:10020882	SLC2A9	0.86	8.81	0.67	5.68e-14	Bone mineral density;
THYM	cis	rs7078219	0.524	rs6584277	chr10:101278055	A/G	cg17888390	chr10:101282816	NA	-0.48	-4.94	-0.45	3.4e-6	Dental caries;
THYM	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg13736514	chr6:26305472	NA	-0.62	-7.42	-0.61	5.02e-11	Educational attainment;
THYM	cis	rs62103177	0.525	rs9949598	chr18:77753037	G/A	cg07235805	chr18:78004237	PARD6G	-0.45	-5.27	-0.48	8.64e-7	Opioid sensitivity;
THYM	cis	rs2797160	0.967	rs926854	chr6:126021780	A/G	cg16306078	chr6:126000798	NA	0.51	5.12	0.47	1.57e-6	Endometrial cancer;
THYM	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg22166914	chr1:53195759	ZYG11B	0.8	8.04	0.64	2.5e-12	Monocyte count;
THYM	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.84	0.51	7.19e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.26	9.1	0.68	1.4e-14	Gut microbiome composition (summer);
THYM	cis	rs4242434	0.927	rs11136092	chr8:22466488	T/G	cg03733263	chr8:22462867	KIAA1967	1.16	11.61	0.77	6.25e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg00898013	chr13:113819073	PROZ	-0.83	-8.33	-0.65	6.02e-13	Platelet distribution width;
THYM	cis	rs853679	1.000	rs1778508	chr6:28229881	C/T	cg23161317	chr6:28129485	ZNF389	-0.83	-5.51	-0.49	3.08e-7	Depression;
THYM	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg12564285	chr5:131593104	PDLIM4	0.43	4.66	0.43	1.04e-5	Breast cancer;
THYM	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	4.6	0.43	1.29e-5	Rheumatoid arthritis;
THYM	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.67	5.22	0.47	1.06e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7809950	0.678	rs7777950	chr7:107004672	T/C	cg23024343	chr7:107201750	COG5	-0.96	-8.04	-0.64	2.42e-12	Coronary artery disease;
THYM	cis	rs642803	0.613	rs565427	chr11:65532825	G/A	cg27068330	chr11:65405492	SIPA1	0.73	5.34	0.48	6.42e-7	Urate levels;
THYM	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg12560992	chr17:57184187	TRIM37	0.93	8.88	0.67	4.06e-14	Intelligence (multi-trait analysis);
THYM	cis	rs12681287	0.640	rs13253296	chr8:87448245	C/T	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.79	6.94	0.58	4.8e-10	Tonsillectomy;
THYM	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg23711669	chr6:146136114	FBXO30	-0.89	-9.21	-0.69	8.12e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.21	0.47	1.1e-6	Electroencephalogram traits;
THYM	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg11301795	chr4:187892539	NA	-1.11	-17.65	-0.88	9.45e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg18681998	chr4:17616180	MED28	0.97	9.8	0.71	4.41e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6840360	0.571	rs4696276	chr4:152532682	G/A	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg04865290	chr3:52927548	TMEM110	-0.96	-4.97	-0.45	2.97e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8180040	0.903	rs7636423	chr3:47309134	C/G	cg02527881	chr3:46936655	PTH1R	-0.66	-6.39	-0.55	6.07e-9	Colorectal cancer;
THYM	cis	rs10463554	0.927	rs39666	chr5:102447127	C/T	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Parkinson's disease;
THYM	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg09436375	chr6:42928200	GNMT	0.44	5.86	0.52	6.75e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2913737	0.563	rs10051756	chr5:175878007	G/A	cg27658698	chr5:175955578	RNF44	0.57	4.51	0.42	1.83e-5	Obesity-related traits;
THYM	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg25072359	chr17:41440525	NA	0.65	4.55	0.42	1.57e-5	Menopause (age at onset);
THYM	cis	rs9527	0.590	rs12355120	chr10:104852166	T/G	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs57994353	0.897	rs3812595	chr9:139369062	C/T	cg14115884	chr9:139300582	SDCCAG3	0.73	5.4	0.48	4.9e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	7.81	0.63	7.54e-12	Monocyte percentage of white cells;
THYM	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg04287289	chr16:89883240	FANCA	-0.49	-4.45	-0.42	2.35e-5	Vitiligo;
THYM	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg07212818	chr11:638076	DRD4	-0.79	-6.69	-0.57	1.57e-9	Systemic lupus erythematosus;
THYM	cis	rs28595532	1.000	rs28600971	chr4:119712728	G/T	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg19318889	chr4:1322082	MAEA	-0.51	-4.48	-0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg00271210	chr6:167070053	RPS6KA2	0.72	7.78	0.62	8.54e-12	Crohn's disease;
THYM	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg04772025	chr11:68637568	NA	0.64	6.69	0.57	1.52e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9581857	0.725	rs9581853	chr13:28016236	T/C	cg22138327	chr13:27999177	GTF3A	0.88	4.91	0.45	3.83e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg26412358	chr1:26503933	CNKSR1	0.34	4.67	0.43	9.73e-6	Height;
THYM	cis	rs3768617	0.510	rs2093985	chr1:183094322	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	trans	rs4650994	0.544	rs6664493	chr1:178494428	C/T	cg05059571	chr16:84539110	KIAA1609	-0.92	-10.65	-0.74	6.65e-18	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs4889855	0.556	rs4506961	chr17:78543182	G/A	cg16591659	chr17:78472290	NA	0.41	4.47	0.42	2.14e-5	Fractional excretion of uric acid;
THYM	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg27286337	chr10:134555280	INPP5A	0.84	5.93	0.52	4.78e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.74	5.24	0.47	9.78e-7	Height;
THYM	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg05731713	chr7:157510257	PTPRN2	0.52	5.0	0.46	2.64e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg13319975	chr6:146136371	FBXO30	-0.69	-5.66	-0.5	1.61e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg02527881	chr3:46936655	PTH1R	0.54	5.21	0.47	1.1e-6	Colorectal cancer;
THYM	cis	rs6988636	1.000	rs10505430	chr8:124191933	A/G	cg23067535	chr8:124195133	FAM83A	1.07	5.8	0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs5769707	0.632	rs6009782	chr22:50010812	C/G	cg07959070	chr22:50026188	C22orf34	-0.29	-4.96	-0.45	3.09e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg18252515	chr7:66147081	NA	-1.6	-8.8	-0.67	6.03e-14	Diabetic kidney disease;
THYM	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg06623918	chr6:96969491	KIAA0776	1.1	9.95	0.71	2.08e-16	Headache;
THYM	cis	rs59698941	0.943	rs55746968	chr5:132298188	T/C	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.68	5.09	0.46	1.79e-6	Tonsillectomy;
THYM	cis	rs2109514	1.000	rs2270189	chr7:116140616	A/G	cg12739419	chr7:116140593	CAV2	-0.48	-4.65	-0.43	1.09e-5	Prevalent atrial fibrillation;
THYM	cis	rs2219968	0.962	rs3884556	chr8:78939959	T/C	cg00738934	chr8:78996279	NA	0.79	8.42	0.65	3.88e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg06850241	chr22:41845214	NA	0.53	4.72	0.44	8.08e-6	Vitiligo;
THYM	cis	rs4242434	0.889	rs4592028	chr8:22449484	T/C	cg03733263	chr8:22462867	KIAA1967	1.17	12.25	0.78	2.96e-21	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs586688	1.000	rs586688	chr1:201630955	G/A	cg12048341	chr1:201712730	NAV1	-0.78	-4.6	-0.43	1.31e-5	Obesity-related traits;
THYM	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg14228332	chr4:119757509	SEC24D	1.36	5.21	0.47	1.12e-6	Cannabis dependence symptom count;
THYM	cis	rs9399401	0.626	rs9373347	chr6:142779885	C/T	cg03128060	chr6:142623767	GPR126	0.62	8.51	0.66	2.47e-13	Chronic obstructive pulmonary disease;
THYM	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg25072359	chr17:41440525	NA	-0.72	-5.26	-0.47	8.95e-7	Menopause (age at onset);
THYM	cis	rs13315871	0.929	rs1554124	chr3:58268968	C/G	cg12435725	chr3:58293450	RPP14	-0.48	-5.4	-0.48	4.99e-7	Cholesterol, total;
THYM	cis	rs6087990	0.735	rs2424922	chr20:31386449	T/C	cg13636640	chr20:31349939	DNMT3B	0.9	9.45	0.7	2.46e-15	Ulcerative colitis;
THYM	cis	rs17102423	0.768	rs34459643	chr14:65579414	A/T	cg11161011	chr14:65562177	MAX	0.67	5.64	0.5	1.76e-7	Obesity-related traits;
THYM	cis	rs7115242	0.699	rs17174502	chr11:116759655	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.89	-4.55	-0.42	1.58e-5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
THYM	cis	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.46	0.42	2.2e-5	Granulocyte percentage of myeloid white cells;
THYM	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg04166595	chr19:18636596	NA	0.62	4.62	0.43	1.19e-5	Breast cancer;
THYM	cis	rs988913	1.000	rs6941796	chr6:54837621	A/T	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.75e-6	Menarche (age at onset);
THYM	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg01528321	chr10:82214614	TSPAN14	0.63	5.29	0.48	7.7300000000000005e-07	Post bronchodilator FEV1;
THYM	cis	rs7772486	0.790	rs6917482	chr6:146243581	C/T	cg13319975	chr6:146136371	FBXO30	0.73	6.11	0.53	2.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4242434	0.889	rs11783129	chr8:22453426	G/A	cg21658235	chr8:22456391	C8orf58	0.56	5.41	0.49	4.62e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg12564285	chr5:131593104	PDLIM4	-0.43	-4.66	-0.43	1.04e-5	Breast cancer;
THYM	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7772486	0.754	rs6915718	chr6:146100676	A/G	cg23711669	chr6:146136114	FBXO30	-0.98	-10.47	-0.73	1.68e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs757081	0.643	rs665311	chr11:17206740	A/T	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.6	-0.43	1.29e-5	Systolic blood pressure;
THYM	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg25554036	chr4:6271136	WFS1	0.5	4.5	0.42	1.96e-5	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs7833986	0.501	rs2719233	chr8:56886156	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.54	5.9	0.52	5.61e-8	Height;
THYM	cis	rs9902453	0.726	rs4795523	chr17:28176314	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	6.21	0.54	1.39e-8	Coffee consumption (cups per day);
THYM	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg04944784	chr2:26401820	FAM59B	0.65	5.0	0.46	2.62e-6	Gut microbiome composition (summer);
THYM	cis	rs2016266	0.855	rs1056692	chr12:53687387	A/G	cg16917193	chr12:54089295	NA	-0.59	-4.53	-0.42	1.69e-5	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg08885076	chr2:99613938	TSGA10	-0.71	-6.69	-0.57	1.51e-9	Chronic sinus infection;
THYM	cis	rs4654899	0.609	rs12128470	chr1:21534055	T/C	cg01072550	chr1:21505969	NA	-0.78	-7.51	-0.61	3.25e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg11335335	chr11:637885	DRD4	-0.69	-6.23	-0.54	1.24e-8	Systemic lupus erythematosus;
THYM	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg05182265	chr7:156933206	UBE3C	-0.69	-9.32	-0.69	4.58e-15	Body mass index;
THYM	cis	rs892961	0.932	rs12453822	chr17:75416792	G/A	cg11351908	chr17:75402473	SEPT9	0.56	5.34	0.48	6.21e-7	Airflow obstruction;
THYM	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.24	-4.55	-0.42	1.58e-5	Obesity-related traits;
THYM	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg20503657	chr10:835505	NA	1.01	5.73	0.51	1.17e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg25358565	chr5:93447407	FAM172A	1.0	7.27	0.6	1.01e-10	Diabetic retinopathy;
THYM	cis	rs6025261	0.562	rs2902978	chr20:55545968	C/G	cg04763273	chr20:55502381	NA	-0.61	-5.24	-0.47	9.86e-7	Verbal memory performance (delayed recall level);
THYM	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg24692254	chr21:30365293	RNF160	-0.99	-8.66	-0.66	1.23e-13	Dental caries;
THYM	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs6531656	0.606	rs337612	chr4:38678642	T/C	cg24279243	chr4:38676559	KLF3	0.87	6.11	0.53	2.2e-8	Lymphocyte counts;
THYM	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg24209194	chr3:40518798	ZNF619	0.67	5.53	0.49	2.85e-7	Renal cell carcinoma;
THYM	cis	rs7584330	0.504	rs11884519	chr2:238425283	T/C	cg08992911	chr2:238395768	MLPH	0.75	5.1	0.46	1.76e-6	Prostate cancer;
THYM	cis	rs13376709	0.636	rs12723537	chr1:243812680	G/A	cg25706552	chr1:244017396	NA	-0.55	-4.72	-0.44	8.24e-6	Schizophrenia;
THYM	cis	rs9796	0.558	rs7166205	chr15:41514733	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.55	-4.52	-0.42	1.75e-5	Menopause (age at onset);
THYM	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.1	-10.9	-0.75	2.01e-18	Primary sclerosing cholangitis;
THYM	cis	rs2734839	0.537	rs6277	chr11:113283459	G/A	cg14159747	chr11:113255604	NA	0.36	8.02	0.64	2.77e-12	Information processing speed;
THYM	cis	rs2235649	0.798	rs78540053	chr16:1853275	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.47	-5.01	-0.46	2.49e-6	Blood metabolite levels;
THYM	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg15744005	chr10:104629667	AS3MT	0.91	9.71	0.71	6.97e-16	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg06766960	chr11:133703094	NA	-0.52	-4.83	-0.44	5.25e-6	Childhood ear infection;
THYM	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg01324343	chr3:183735012	ABCC5	0.9	13.35	0.81	1.59e-23	Anterior chamber depth;
THYM	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg10515332	chr4:99064459	C4orf37	0.72	5.77	0.51	9.88e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2656056	1	rs2656056	chr15:78722519	T/C	cg18825076	chr15:78729989	IREB2	-0.67	-5.14	-0.47	1.5e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs4660531	1.000	rs34883982	chr1:41849873	C/T	cg01193554	chr1:41846683	NA	-0.35	-4.63	-0.43	1.14e-5	Bipolar disorder;
THYM	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg10426581	chr7:100472382	SRRT	1.01	9.56	0.7	1.45e-15	Resting heart rate;
THYM	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg11812906	chr14:75593930	NEK9	-0.8	-7.24	-0.6	1.14e-10	Height;
THYM	trans	rs4650994	0.524	rs2761465	chr1:178579404	G/T	cg05059571	chr16:84539110	KIAA1609	0.94	11.15	0.75	5.8e-19	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg12463550	chr7:65579703	CRCP	-0.57	-4.62	-0.43	1.23e-5	Aortic root size;
THYM	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg01710189	chr8:22454888	PDLIM2	0.55	5.73	0.51	1.17e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg05347473	chr6:146136440	FBXO30	0.59	4.63	0.43	1.16e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg22166914	chr1:53195759	ZYG11B	-0.82	-8.52	-0.66	2.41e-13	Monocyte count;
THYM	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg26714650	chr12:56694279	CS	1.2	6.69	0.57	1.56e-9	Psoriasis vulgaris;
THYM	cis	rs960902	1.000	rs960902	chr2:37731665	G/A	cg25341268	chr2:37734390	NA	0.56	4.61	0.43	1.25e-5	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	trans	rs59551326	0.517	rs73148805	chr21:26580902	C/T	cg17452615	chr12:122019080	KDM2B	-0.8	-6.84	-0.57	7.67e-10	Alcohol dependence;
THYM	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg16294310	chr22:50629110	TRABD	0.65	5.14	0.47	1.45e-6	Obesity-related traits;
THYM	cis	rs6032067	0.777	rs34855539	chr20:43799036	T/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	trans	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg04842962	chr6:43655489	MRPS18A	0.88	7.39	0.6	5.6e-11	IgG glycosylation;
THYM	cis	rs6912958	0.712	rs2787927	chr6:88412786	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-5.7	-0.5	1.37e-7	Monocyte percentage of white cells;
THYM	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.82	-5.96	-0.52	4.21e-8	Total cholesterol levels;
THYM	cis	rs3845702	0.736	rs16867131	chr2:180848651	A/G	cg01881094	chr2:180872142	CWC22	-0.91	-5.5	-0.49	3.16e-7	Schizophrenia;
THYM	cis	rs13006833	0.668	rs2136569	chr2:191167414	C/T	cg21644426	chr2:191273491	MFSD6	-0.62	-4.49	-0.42	2e-5	Urinary metabolites;
THYM	cis	rs11089937	0.616	rs713644	chr22:22535137	A/G	cg06866756	chr22:22471216	NA	-0.43	-4.68	-0.43	9.54e-6	Periodontitis (PAL4Q3);
THYM	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs4638749	1.000	rs1466213	chr2:108856607	G/A	cg25838818	chr2:108905173	SULT1C2	-0.58	-6.02	-0.53	3.26e-8	Blood pressure;
THYM	cis	rs611744	0.563	rs7815105	chr8:109298794	C/T	cg21045802	chr8:109455806	TTC35	0.78	6.58	0.56	2.53e-9	Dupuytren's disease;
THYM	cis	rs35883536	1.000	rs11586051	chr1:101096240	A/T	cg06223162	chr1:101003688	GPR88	-0.6	-4.58	-0.43	1.41e-5	Monocyte count;
THYM	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg18132916	chr6:79620363	NA	-0.6	-5.35	-0.48	6.07e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.735	rs720616	chr7:124452961	A/G	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.08	-0.64	2.06e-12	Mean corpuscular volume;
THYM	cis	rs1372520	0.684	rs2583968	chr4:90745395	C/G	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg25036284	chr2:26402008	FAM59B	0.8	5.36	0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs35883536	0.626	rs34752753	chr1:101045193	T/G	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs1371867	0.875	rs28595052	chr8:101327553	G/A	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg10803722	chr21:46713166	LOC642852	-0.39	-5.07	-0.46	1.97e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7100689	0.556	rs10788541	chr10:82016530	T/G	cg01528321	chr10:82214614	TSPAN14	0.89	7.03	0.59	3.1e-10	Post bronchodilator FEV1;
THYM	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg07212818	chr11:638076	DRD4	-0.77	-5.47	-0.49	3.57e-7	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs763014	0.865	rs2384977	chr16:625388	C/T	cg09263875	chr16:632152	PIGQ	0.71	6.15	0.53	1.85e-8	Height;
THYM	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg13683864	chr3:40499215	RPL14	1.07	12.42	0.79	1.31e-21	Renal cell carcinoma;
THYM	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg12373951	chr3:133503437	NA	0.66	7.21	0.59	1.33e-10	Iron status biomarkers;
THYM	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg15212455	chr7:39170539	POU6F2	0.64	6.01	0.52	3.44e-8	IgG glycosylation;
THYM	cis	rs7119	0.604	rs2271398	chr15:77907784	G/A	cg27398640	chr15:77910606	LINGO1	0.63	8.22	0.64	1.03e-12	Type 2 diabetes;
THYM	cis	rs11614913	0.509	rs12300425	chr12:54395082	G/T	cg05643303	chr12:54402714	HOXC8	-0.56	-5.21	-0.47	1.11e-6	Waist circumference adjusted for body mass index;
THYM	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs8114671	0.562	rs8116657	chr20:33476474	C/G	cg08999081	chr20:33150536	PIGU	0.63	5.21	0.47	1.09e-6	Height;
THYM	cis	rs3213961	0.562	rs60739635	chr2:33831794	T/C	cg26822501	chr2:33171334	LTBP1	-0.65	-4.48	-0.42	2.11e-5	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
THYM	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.67	4.76	0.44	6.93e-6	Aortic root size;
THYM	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs2455799	0.613	rs4684259	chr3:15791279	G/A	cg16303742	chr3:15540471	COLQ	-0.56	-5.73	-0.51	1.18e-7	Mean platelet volume;
THYM	cis	rs904251	0.861	rs1757169	chr6:37487076	G/T	cg25019722	chr6:37503610	NA	-0.65	-5.57	-0.5	2.37e-7	Cognitive performance;
THYM	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.43	0.7	2.73e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg17143192	chr8:8559678	CLDN23	-0.58	-4.71	-0.44	8.34e-6	Mood instability;
THYM	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg12893697	chr11:970389	AP2A2	-0.31	-5.21	-0.47	1.08e-6	Alzheimer's disease (late onset);
THYM	trans	rs6089829	0.888	rs6011559	chr20:61675620	C/T	cg13615516	chr5:77269221	NA	-0.87	-7.56	-0.61	2.55e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11890956	chr21:40555474	PSMG1	1.18	12.69	0.79	3.62e-22	Cognitive function;
THYM	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.33	10.11	0.72	9.63e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg05962950	chr11:130786565	SNX19	0.9	8.8	0.67	6.1e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg22105103	chr4:187893119	NA	-0.88	-9.57	-0.7	1.35e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs73086581	1.000	rs6052217	chr20:3970211	A/G	cg02187196	chr20:3869020	PANK2	0.5	5.62	0.5	1.92e-7	Response to antidepressants in depression;
THYM	cis	rs12681287	0.752	rs4427148	chr8:87250668	G/A	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs35164067	1.000	rs35164067	chr19:10525181	G/A	cg01466491	chr19:10523363	NA	-0.63	-4.91	-0.45	3.8e-6	Inflammatory bowel disease;
THYM	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	5.7	0.5	1.36e-7	Lung cancer in ever smokers;
THYM	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg26597838	chr10:835615	NA	0.72	4.57	0.42	1.48e-5	Eosinophil percentage of granulocytes;
THYM	cis	rs2108225	0.900	rs7805114	chr7:107450033	G/T	cg18560240	chr7:107437656	SLC26A3	0.78	5.57	0.5	2.39e-7	Ulcerative colitis;
THYM	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg13147721	chr7:65941812	NA	-1.0	-6.2	-0.54	1.47e-8	Diabetic kidney disease;
THYM	cis	rs28595532	0.541	rs114463740	chr4:119763329	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg04756594	chr16:24857601	SLC5A11	0.74	5.2	0.47	1.13e-6	Intelligence (multi-trait analysis);
THYM	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg08431931	chr22:42394659	WBP2NL	0.71	4.96	0.45	3.07e-6	Birth weight;
THYM	cis	rs986417	0.818	rs2057135	chr14:61077022	G/A	cg27398547	chr14:60952738	C14orf39	1.04	5.74	0.51	1.14e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs11771526	0.901	rs10244622	chr7:32302960	C/T	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs4919087	1.000	rs61863767	chr10:99084426	C/T	cg19453742	chr10:98862320	SLIT1	-0.6	-4.78	-0.44	6.43e-6	Monocyte count;
THYM	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.95	0.71	2.08e-16	Colorectal cancer;
THYM	cis	rs9868809	0.772	rs9841602	chr3:48713570	A/G	cg00383909	chr3:49044727	WDR6	0.84	4.56	0.42	1.52e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs11771526	0.901	rs17161123	chr7:32305426	G/A	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg10802521	chr3:52805072	NEK4	-0.71	-6.18	-0.54	1.57e-8	Bipolar disorder;
THYM	cis	rs17744026	0.618	rs12286996	chr11:123700896	C/T	cg00079598	chr11:123676903	OR6M1	-0.48	-4.54	-0.42	1.68e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.78	-7.41	-0.61	5.14e-11	Personality dimensions;
THYM	cis	rs12711979	0.765	rs881852	chr2:3821508	A/G	cg17052675	chr2:3827356	NA	-0.45	-4.61	-0.43	1.23e-5	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs6748734	0.625	rs4675871	chr2:241823849	G/A	cg09990169	chr2:241835740	C2orf54	-0.31	-5.04	-0.46	2.18e-6	Urinary metabolites;
THYM	cis	rs67539049	0.842	rs56286613	chr8:11310319	C/T	cg02771117	chr8:11279352	FAM167A;C8orf12	-0.6	-4.49	-0.42	2e-5	Itch intensity from mosquito bite;
THYM	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs3126085	0.877	rs4845742	chr1:152183949	G/A	cg10321714	chr1:152280068	FLG	0.68	4.95	0.45	3.2e-6	Atopic dermatitis;
THYM	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9807989	0.811	rs11689730	chr2:102969984	C/A	cg03938978	chr2:103052716	IL18RAP	0.63	6.46	0.55	4.36e-9	Asthma;
THYM	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg10589385	chr1:150898437	SETDB1	0.62	5.04	0.46	2.2e-6	Melanoma;
THYM	cis	rs2625529	0.824	rs12916694	chr15:72298140	C/T	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg00684032	chr4:1343700	KIAA1530	0.53	4.47	0.42	2.17e-5	Longevity;
THYM	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg11764359	chr7:65958608	NA	-0.74	-6.15	-0.53	1.85e-8	Aortic root size;
THYM	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg20387954	chr3:183756860	HTR3D	0.59	4.82	0.44	5.48e-6	Anterior chamber depth;
THYM	cis	rs1568889	1.000	rs61889046	chr11:28297024	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.55e-6	Bipolar disorder;
THYM	trans	rs75518195	0.566	rs28853639	chr4:64796973	T/C	cg14706739	chr8:21916355	EPB49	0.73	7.25	0.6	1.13e-10	Triptolide cytotoxicity;
THYM	cis	rs8041943	0.583	rs72730838	chr15:79906850	T/C	cg20511832	chr15:78934280	CHRNB4	0.41	4.45	0.42	2.36e-5	Bone mineral density (spine) and age at menarche;
THYM	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg23791538	chr6:167370224	RNASET2	-0.58	-4.54	-0.42	1.67e-5	Crohn's disease;
THYM	cis	rs7523273	1.000	rs7523273	chr1:207977083	A/G	cg22525895	chr1:207977042	MIR29B2	-0.96	-8.31	-0.65	6.69e-13	Schizophrenia;
THYM	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg01741372	chr11:783889	NA	-0.43	-5.36	-0.48	5.83e-7	Breast cancer;
THYM	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg22683308	chr4:1340831	KIAA1530	-0.63	-4.64	-0.43	1.11e-5	Obesity-related traits;
THYM	cis	rs4930103	0.711	rs217710	chr11:2007244	C/T	cg18511798	chr11:2018149	H19;MIR675	-0.59	-6.23	-0.54	1.3e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg22681709	chr2:178499509	PDE11A	-0.61	-5.8	-0.51	8.52e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg06618935	chr21:46677482	NA	-0.92	-8.69	-0.67	1.04e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs6430585	0.528	rs12474975	chr2:136702118	A/T	cg23851026	chr2:136556271	LCT	0.78	6.95	0.58	4.47e-10	Corneal structure;
THYM	cis	rs4654899	0.758	rs4457549	chr1:21487231	A/G	cg01072550	chr1:21505969	NA	0.76	7.39	0.6	5.64e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-7.12	-0.59	2.08e-10	Bone mineral density;
THYM	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.22	0.64	1.03e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs10752881	0.967	rs8179284	chr1:182974707	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs9364687	0.639	rs13202282	chr6:163930243	C/A	cg01639524	chr6:163818125	NA	0.47	4.57	0.42	1.47e-5	Body mass index;
THYM	cis	rs2997447	0.706	rs12062488	chr1:26466253	G/A	cg03844060	chr1:26490628	NA	0.69	4.72	0.44	8.17e-6	QRS complex (12-leadsum);
THYM	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03576123	chr11:487126	PTDSS2	-1.29	-6.4	-0.55	5.87e-9	Body mass index;
THYM	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg21773646	chr17:80085082	CCDC57	-0.37	-5.16	-0.47	1.36e-6	Life satisfaction;
THYM	trans	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg10856724	chr12:34555212	NA	-0.96	-8.66	-0.66	1.22e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9807989	0.507	rs6710034	chr2:103023678	G/A	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg24818145	chr4:99064322	C4orf37	0.76	6.08	0.53	2.55e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.9	5.7	0.51	1.32e-7	Yeast infection;
THYM	cis	rs10857712	0.851	rs56153177	chr10:135216975	G/A	cg19623624	chr10:135278901	LOC619207	-0.59	-4.76	-0.44	6.89e-6	Systemic lupus erythematosus;
THYM	cis	rs73198271	0.813	rs17697237	chr8:8615874	A/C	cg06636001	chr8:8085503	FLJ10661	0.76	5.6	0.5	2.07e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg24818145	chr4:99064322	C4orf37	0.68	5.3	0.48	7.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4664308	0.967	rs56293836	chr2:160910958	T/C	cg03641300	chr2:160917029	PLA2R1	-0.76	-6.83	-0.57	7.92e-10	Idiopathic membranous nephropathy;
THYM	cis	rs2295499	0.754	rs61790220	chr4:2597377	G/C	cg17924901	chr4:3475233	DOK7	-0.21	-4.46	-0.42	2.24e-5	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs2964802	0.505	rs11133627	chr5:10830474	T/G	cg14521931	chr5:10832172	NA	-0.66	-5.49	-0.49	3.31e-7	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs2273669	0.667	rs77936298	chr6:109350616	A/T	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs4690686	0.538	rs6855882	chr4:177261061	T/G	cg17059388	chr4:177262070	NA	0.45	6.01	0.52	3.49e-8	Essential tremor;
THYM	cis	rs72781680	0.716	rs2712068	chr2:23984000	A/G	cg08917208	chr2:24149416	ATAD2B	0.85	4.5	0.42	1.96e-5	Lymphocyte counts;
THYM	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg26818010	chr10:134567672	INPP5A	-0.91	-7.43	-0.61	4.72e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.58	4.73	0.44	7.74e-6	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg27286337	chr10:134555280	INPP5A	0.85	6.07	0.53	2.67e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7187994	0.848	rs12933308	chr16:84770973	A/G	cg07647771	chr16:84786436	USP10	-0.57	-4.73	-0.44	7.95e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg10224037	chr5:178157518	ZNF354A	1.01	7.91	0.63	4.74e-12	Neutrophil percentage of white cells;
THYM	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg19346786	chr7:2764209	NA	-0.72	-6.08	-0.53	2.44e-8	Height;
THYM	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	10.22	0.72	5.61e-17	Chronic sinus infection;
THYM	cis	rs7267979	0.932	rs372678	chr20:25465248	G/A	cg03522245	chr20:25566470	NINL	0.57	4.48	0.42	2.1e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7107174	0.711	rs66583694	chr11:78037773	C/T	cg02023728	chr11:77925099	USP35	0.62	5.99	0.52	3.72e-8	Testicular germ cell tumor;
THYM	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs2154427	0.872	rs80098814	chr21:34133002	C/T	cg21871883	chr21:34145043	C21orf49;C21orf66	1.05	5.15	0.47	1.39e-6	Bilirubin levels;
THYM	cis	rs7119038	0.774	rs11217001	chr11:118607046	G/A	cg19308663	chr11:118741387	NA	0.53	4.87	0.45	4.44e-6	Sjögren's syndrome;
THYM	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg13147721	chr7:65941812	NA	-1.16	-7.64	-0.62	1.7e-11	Diabetic kidney disease;
THYM	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg07424592	chr7:64974309	NA	1.1	5.08	0.46	1.87e-6	Diabetic kidney disease;
THYM	cis	rs3768617	0.510	rs2333621	chr1:183090751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs7267979	0.966	rs2500433	chr20:25296335	A/G	cg08601574	chr20:25228251	PYGB	-0.57	-4.51	-0.42	1.87e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg10515332	chr4:99064459	C4orf37	0.63	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7572733	0.534	rs700667	chr2:198677508	T/C	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-5.51	-0.49	3.1e-7	Prostate cancer;
THYM	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19346786	chr7:2764209	NA	-0.81	-7.38	-0.6	5.93e-11	Height;
THYM	cis	rs3892630	0.612	rs10413282	chr19:33182751	A/G	cg02283691	chr19:33182526	NUDT19	-0.35	-4.46	-0.42	2.22e-5	Red blood cell traits;
THYM	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg06108461	chr20:60628389	TAF4	-1.05	-8.31	-0.65	6.64e-13	Body mass index;
THYM	trans	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg19862616	chr7:65841803	NCRNA00174	1.05	12.28	0.78	2.58e-21	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs763014	0.898	rs4984894	chr16:623103	T/C	cg09263875	chr16:632152	PIGQ	0.71	6.15	0.53	1.85e-8	Height;
THYM	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg26818010	chr10:134567672	INPP5A	-0.91	-7.38	-0.6	5.95e-11	Migraine;
THYM	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg07507251	chr3:52567010	NT5DC2	0.46	5.52	0.49	2.91e-7	Electroencephalogram traits;
THYM	cis	rs2742234	0.541	rs11238481	chr10:43719286	A/G	cg06632098	chr10:43605906	RET	0.8	5.26	0.47	8.98e-7	Hirschsprung disease;
THYM	cis	rs2213920	0.619	rs7870511	chr9:118196904	A/G	cg13918206	chr9:118159781	DEC1	0.86	4.9	0.45	3.86e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs6089829	0.888	rs4809465	chr20:61671156	G/C	cg02380750	chr20:61661411	NA	0.63	6.16	0.53	1.72e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs420259	0.516	rs9927961	chr16:23514525	G/A	cg00143387	chr16:23521605	GGA2	-0.77	-5.51	-0.49	3.12e-7	Bipolar disorder;
THYM	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg20891283	chr12:69753455	YEATS4	0.7	5.98	0.52	3.85e-8	Blood protein levels;
THYM	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg04362960	chr10:104952993	NT5C2	0.58	4.69	0.43	9.04e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1568889	0.838	rs716366	chr11:28121536	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs9807841	0.592	rs6511707	chr19:10767790	C/T	cg17848348	chr19:10766748	ILF3	-0.77	-6.23	-0.54	1.26e-8	Inflammatory skin disease;
THYM	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg20291162	chr17:40259547	DHX58	-0.7	-6.47	-0.55	4.18e-9	Fibrinogen levels;
THYM	cis	rs9515201	0.627	rs11838637	chr13:111029923	G/A	cg06243866	chr13:111019493	COL4A2	-0.96	-11.02	-0.75	1.13e-18	White matter hyperintensity burden;
THYM	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg27286337	chr10:134555280	INPP5A	0.93	6.98	0.58	3.98e-10	Migraine;
THYM	cis	rs11585357	0.895	rs2501795	chr1:17633499	A/G	cg08277548	chr1:17600880	PADI3	-0.81	-5.02	-0.46	2.4e-6	Hair shape;
THYM	cis	rs1451375	1.000	rs6949897	chr7:50621920	C/T	cg18232548	chr7:50535776	DDC	0.73	5.57	0.5	2.35e-7	Malaria;
THYM	cis	rs877282	0.898	rs11253348	chr10:765852	C/T	cg10556349	chr10:835070	NA	-0.79	-5.05	-0.46	2.14e-6	Uric acid levels;
THYM	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg05660106	chr1:15850417	CASP9	0.73	5.92	0.52	5.14e-8	Systolic blood pressure;
THYM	trans	rs10962692	0.608	rs11789875	chr9:16872323	G/A	cg03221025	chr16:88955224	CBFA2T3	0.75	7.2	0.59	1.37e-10	Ovarian cancer in BRCA2 mutation carriers;Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;
THYM	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7187994	0.848	rs8051512	chr16:84781101	C/G	cg07647771	chr16:84786436	USP10	-0.53	-4.91	-0.45	3.81e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs10203711	0.933	rs12692238	chr2:239553940	T/C	cg14580085	chr2:239553406	NA	0.55	4.64	0.43	1.1e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3796352	1.000	rs34121720	chr3:53072167	C/T	cg24530246	chr3:53118167	NA	-0.76	-4.57	-0.42	1.47e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs56077333	1	rs56077333	chr15:78899003	C/A	cg18825076	chr15:78729989	IREB2	-0.58	-5.32	-0.48	6.86e-7	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	4.64	0.43	1.13e-5	Bipolar disorder;
THYM	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg26384229	chr12:38710491	ALG10B	-0.93	-7.78	-0.62	8.73e-12	Morning vs. evening chronotype;
THYM	cis	rs6746082	0.519	rs637519	chr2:25760891	G/A	cg23192403	chr2:25781496	DTNB	-0.44	-5.87	-0.52	6.35e-8	Multiple myeloma;
THYM	cis	rs6732160	0.845	rs6752507	chr2:73385158	C/G	cg24220031	chr2:73402428	NA	-0.79	-8.39	-0.65	4.59e-13	Intelligence (multi-trait analysis);
THYM	cis	rs490234	0.776	rs10115455	chr9:128458850	T/C	cg14078157	chr9:128172775	NA	-0.66	-5.01	-0.46	2.48e-6	Mean arterial pressure;
THYM	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg12219531	chr12:120966889	COQ5	0.8	6.55	0.56	2.9e-9	High light scatter reticulocyte count;
THYM	cis	rs7580658	0.963	rs6732279	chr2:128089540	G/T	cg10021288	chr2:128175891	PROC	-0.81	-6.91	-0.58	5.55e-10	Protein C levels;
THYM	cis	rs2637266	1.000	rs11001835	chr10:78364770	A/G	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs1061377	0.803	rs6857761	chr4:39119973	C/T	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs6665290	0.904	rs3795451	chr1:227181923	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg00990874	chr7:1149470	C7orf50	-0.6	-4.63	-0.43	1.16e-5	Bronchopulmonary dysplasia;
THYM	cis	rs4455778	0.600	rs4255086	chr7:49109798	T/A	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs728616	0.867	rs12415870	chr10:81949470	A/G	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg16926213	chr1:1841314	NA	0.56	5.78	0.51	9.28e-8	Body mass index;
THYM	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg13695892	chr22:41940480	POLR3H	0.93	7.11	0.59	2.14e-10	Vitiligo;
THYM	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg02228675	chr17:40259724	DHX58	-0.66	-5.49	-0.49	3.28e-7	Fibrinogen levels;
THYM	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg06064525	chr11:970664	AP2A2	-0.35	-6.68	-0.57	1.63e-9	Alzheimer's disease (late onset);
THYM	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg20608306	chr11:116969690	SIK3	0.51	5.5	0.49	3.2e-7	Blood protein levels;
THYM	cis	rs6951245	0.542	rs28460147	chr7:1217192	G/A	cg18402987	chr7:1209562	NA	1.21	6.56	0.56	2.8e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2898681	0.739	rs1047959	chr4:53739856	C/G	cg00791764	chr4:53727839	RASL11B	0.47	6.08	0.53	2.5e-8	Optic nerve measurement (cup area);
THYM	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg03433033	chr1:76189801	ACADM	0.77	10.21	0.72	6.01e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2235649	0.588	rs11863172	chr16:1909083	C/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.52	-4.87	-0.45	4.49e-6	Blood metabolite levels;
THYM	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg22907277	chr7:1156413	C7orf50	0.86	5.31	0.48	7.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs665401	0.965	rs630045	chr6:117199790	C/G	cg20376953	chr6:117187980	NA	0.6	4.7	0.43	8.67e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs7894051	1.000	rs11101721	chr10:135190358	C/G	cg20534287	chr10:135191450	PAOX	0.64	5.13	0.47	1.53e-6	Lifespan;
THYM	cis	rs17102423	0.755	rs11158572	chr14:65577411	C/T	cg11161011	chr14:65562177	MAX	-0.85	-6.77	-0.57	1.04e-9	Obesity-related traits;
THYM	cis	rs9814567	1.000	rs9883753	chr3:134247231	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-8.41	-0.65	4e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg15704280	chr7:45808275	SEPT13	-0.77	-6.87	-0.58	6.69e-10	Coronary artery disease;
THYM	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg13319975	chr6:146136371	FBXO30	-0.65	-5.35	-0.48	6.03e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11711311	1.000	rs28394480	chr3:113485143	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.58	-5.13	-0.47	1.55e-6	IgG glycosylation;
THYM	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg24209194	chr3:40518798	ZNF619	-0.64	-5.55	-0.49	2.63e-7	Renal cell carcinoma;
THYM	cis	rs17376456	0.597	rs6869110	chr5:93355531	G/A	cg25358565	chr5:93447407	FAM172A	-0.82	-6.03	-0.53	3.14e-8	Diabetic retinopathy;
THYM	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg20486651	chr6:167070296	RPS6KA2	0.5	4.79	0.44	6.18e-6	Crohn's disease;
THYM	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg18252515	chr7:66147081	NA	0.63	4.54	0.42	1.65e-5	Aortic root size;
THYM	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg21100191	chr22:23484243	RTDR1	0.73	6.54	0.56	3.13e-9	Bone mineral density;
THYM	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-6.2	-0.54	1.47e-8	Total body bone mineral density;
THYM	cis	rs9581943	0.967	rs9579128	chr13:28481938	A/G	cg16302790	chr13:28498334	PDX1	0.52	4.72	0.44	7.98e-6	Pancreatic cancer;
THYM	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg00677455	chr12:58241039	CTDSP2	0.74	5.75	0.51	1.08e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	8.7	0.67	1.01e-13	Monocyte percentage of white cells;
THYM	cis	rs11608355	0.545	rs1073780	chr12:109895143	T/C	cg11367159	chr12:110044531	NA	0.6	4.54	0.42	1.66e-5	Neuroticism;
THYM	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.46	-5.55	-0.49	2.58e-7	Schizophrenia;
THYM	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg17264618	chr3:40429014	ENTPD3	0.53	5.02	0.46	2.41e-6	Renal cell carcinoma;
THYM	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg17279839	chr7:150038598	RARRES2	0.55	5.2	0.47	1.16e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4654899	0.897	rs10916859	chr1:21087956	A/G	cg01072550	chr1:21505969	NA	-0.61	-5.27	-0.48	8.41e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs2273669	0.588	rs75995854	chr6:109325624	C/A	cg17117243	chr6:109341365	SESN1	-0.9	-5.38	-0.48	5.45e-7	Prostate cancer;
THYM	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg21475434	chr5:93447410	FAM172A	-0.86	-5.57	-0.5	2.35e-7	Diabetic retinopathy;
THYM	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg24642844	chr7:1081250	C7orf50	-1.28	-8.22	-0.64	1.06e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1728785	1.000	rs1182968	chr16:68573945	C/T	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs1003719	0.788	rs4817843	chr21:38447040	C/A	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs4638749	0.501	rs1486192	chr2:108751050	A/G	cg25838818	chr2:108905173	SULT1C2	0.52	4.89	0.45	4.13e-6	Blood pressure;
THYM	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg06521331	chr12:34319734	NA	-1.04	-10.13	-0.72	8.85e-17	Morning vs. evening chronotype;
THYM	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg21194808	chr1:2205498	SKI	-0.33	-4.48	-0.42	2.11e-5	Height;
THYM	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg24308560	chr3:49941425	MST1R	0.63	4.78	0.44	6.37e-6	Body mass index;
THYM	cis	rs765787	0.505	rs1648302	chr15:45494238	A/G	cg24006582	chr15:45444508	DUOX1	-0.84	-7.2	-0.59	1.42e-10	Uric acid levels;
THYM	cis	rs977987	0.806	rs34021527	chr16:75474090	A/G	cg03315344	chr16:75512273	CHST6	0.74	5.92	0.52	5.07e-8	Dupuytren's disease;
THYM	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg04317338	chr11:64019027	PLCB3	0.87	6.04	0.53	3.05e-8	Mean platelet volume;
THYM	cis	rs9403317	0.612	rs1338098	chr6:141983983	A/G	cg15052665	chr6:141804349	NA	0.74	5.59	0.5	2.2e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7071206	0.947	rs11002226	chr10:79399656	T/A	cg07817648	chr10:79422355	NA	-0.94	-7.44	-0.61	4.39e-11	Bone mineral density;
THYM	cis	rs6748734	0.625	rs4312490	chr2:241821481	A/G	cg07537917	chr2:241836409	C2orf54	-0.22	-5.06	-0.46	2.08e-6	Urinary metabolites;
THYM	cis	rs57590327	0.555	rs11127740	chr3:81743062	A/C	cg07356753	chr3:81810745	GBE1	-0.88	-6.79	-0.57	9.52e-10	Extraversion;
THYM	cis	rs6032067	0.673	rs991048	chr20:43898227	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	0.65	5.9	0.52	5.65e-8	Blood protein levels;
THYM	cis	rs4790333	1.000	rs2429908	chr17:2268681	T/C	cg02569219	chr17:2266849	SGSM2	0.74	6.55	0.56	3.01e-9	Proinsulin levels;
THYM	cis	rs478304	0.718	rs1151490	chr11:65390485	A/C	cg27068330	chr11:65405492	SIPA1	0.88	8.15	0.64	1.43e-12	Acne (severe);
THYM	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg21737444	chr22:38071591	LGALS1	0.26	4.53	0.42	1.69e-5	Fat distribution (HIV);
THYM	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg26116260	chr4:7069785	GRPEL1	-0.97	-7.15	-0.59	1.79e-10	Monocyte percentage of white cells;
THYM	cis	rs1003719	0.788	rs7277657	chr21:38469523	A/G	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs9896052	0.538	rs4078259	chr17:73488794	C/T	cg22533317	chr17:74079782	EXOC7	0.42	4.62	0.43	1.21e-5	Sight-threatening diabetic retinopathy in type 2 diabetes;
THYM	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg23281280	chr6:28129359	ZNF389	0.61	4.88	0.45	4.21e-6	Depression;
THYM	cis	rs7572733	0.555	rs2342558	chr2:198920142	T/C	cg00792783	chr2:198669748	PLCL1	0.73	4.79	0.44	6.22e-6	Dermatomyositis;
THYM	cis	rs2811415	0.531	rs2116674	chr3:127759664	C/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs11997175	1.000	rs11997175	chr8:33770070	A/G	ch.8.33884649F	chr8:33765107	NA	-0.63	-4.84	-0.44	4.98e-6	Body mass index;
THYM	cis	rs10992471	0.575	rs2147060	chr9:95160477	T/C	cg14631576	chr9:95140430	CENPP	0.7	5.8	0.51	8.62e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg19077165	chr18:44547161	KATNAL2	-0.66	-8.44	-0.65	3.55e-13	Personality dimensions;
THYM	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg05762616	chr10:133787150	BNIP3	-0.69	-4.46	-0.42	2.26e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg03676636	chr4:99064102	C4orf37	0.38	5.41	0.49	4.62e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Body mass index;
THYM	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg02221750	chr19:17393354	ANKLE1	-0.94	-8.56	-0.66	1.92e-13	Systemic lupus erythematosus;
THYM	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03264133	chr6:25882463	NA	-0.73	-5.82	-0.51	7.95e-8	Blood metabolite levels;
THYM	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg21658235	chr8:22456391	C8orf58	0.52	5.15	0.47	1.42e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg26850624	chr5:429559	AHRR	-0.7	-5.6	-0.5	2.07e-7	Cystic fibrosis severity;
THYM	cis	rs950880	0.710	rs56386507	chr2:102971165	C/T	cg03938978	chr2:103052716	IL18RAP	-0.53	-4.57	-0.42	1.46e-5	Serum protein levels (sST2);
THYM	cis	rs7191439	0.728	rs8056374	chr16:88790147	G/T	cg04602696	chr16:88846723	FAM38A	-0.66	-4.87	-0.45	4.44e-6	Plateletcrit;
THYM	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg17366294	chr4:99064904	C4orf37	-0.58	-6.92	-0.58	5.2400000000000005e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6893300	0.506	rs35320050	chr5:179131013	C/T	cg14593053	chr5:179126677	CANX	0.6	4.48	0.42	2.09e-5	Resting heart rate;
THYM	cis	rs1756650	0.571	rs10148595	chr14:87928797	A/G	cg10325478	chr14:88793021	KCNK10	0.61	4.61	0.43	1.28e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
THYM	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg26384229	chr12:38710491	ALG10B	-0.65	-4.96	-0.45	3.14e-6	Heart rate;
THYM	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg21784768	chr11:537496	LRRC56	-1.07	-5.36	-0.48	5.7e-7	Body mass index;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg22549437	chr6:18466223	RNF144B	-0.91	-6.86	-0.58	7.09e-10	Depressive symptoms;
THYM	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs600806	0.815	rs10858097	chr1:109967324	C/A	cg23616212	chr1:109941201	SORT1	-0.5	-4.78	-0.44	6.34e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3892630	0.817	rs12609866	chr19:33184412	C/T	cg02283691	chr19:33182526	NUDT19	-0.41	-4.82	-0.44	5.35e-6	Red blood cell traits;
THYM	cis	rs2455799	0.613	rs2470549	chr3:15737698	T/C	cg16303742	chr3:15540471	COLQ	-0.57	-6.16	-0.53	1.77e-8	Mean platelet volume;
THYM	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg15448220	chr1:150897856	SETDB1	0.85	7.39	0.6	5.73e-11	Melanoma;
THYM	cis	rs4285028	0.948	rs1920309	chr3:121665479	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs1065852	0.526	rs11090066	chr22:42398195	A/G	cg09667013	chr22:42394590	WBP2NL	0.59	5.25	0.47	9.17e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs752010	0.841	rs7519983	chr1:42083369	C/T	cg06885757	chr1:42089581	HIVEP3	0.48	5.24	0.47	9.74e-7	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs7937682	0.793	rs7130440	chr11:111417779	A/G	cg09085632	chr11:111637200	PPP2R1B	0.77	6.25	0.54	1.15e-8	Primary sclerosing cholangitis;
THYM	cis	rs7192750	0.563	rs7184486	chr16:71886530	T/A	cg06353428	chr16:71660113	MARVELD3	0.76	5.53	0.49	2.77e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg05368731	chr17:41323189	NBR1	1.13	10.0	0.72	1.64e-16	Menopause (age at onset);
THYM	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg21014159	chr11:117668035	DSCAML1	0.66	4.79	0.44	6.19e-6	Myopia;
THYM	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg26384229	chr12:38710491	ALG10B	1.0	7.85	0.63	6.12e-12	Bladder cancer;
THYM	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg15704280	chr7:45808275	SEPT13	-1.04	-14.05	-0.82	6.23e-25	Height;
THYM	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg24531977	chr5:56204891	C5orf35	-0.64	-4.97	-0.45	2.92e-6	Coronary artery disease;
THYM	cis	rs1011018	0.628	rs10268753	chr7:139419888	C/T	cg06079564	chr7:139468310	HIPK2	-0.74	-4.88	-0.45	4.32e-6	Systolic blood pressure;
THYM	cis	rs7560272	0.695	rs780394	chr2:73700930	A/G	cg19565262	chr2:73869966	NAT8	0.56	4.75	0.44	7.11e-6	Schizophrenia;
THYM	cis	rs192264	0.768	rs254365	chr16:65983010	G/T	cg02795155	chr16:66785218	DYNC1LI2	0.58	4.58	0.43	1.4e-5	Subjective well-being;
THYM	cis	rs10851411	0.789	rs11638208	chr15:42777190	C/G	cg04308337	chr15:42867303	STARD9	-0.66	-4.98	-0.45	2.85e-6	Glucose homeostasis traits;
THYM	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg12560992	chr17:57184187	TRIM37	0.93	8.88	0.67	4.06e-14	Intelligence (multi-trait analysis);
THYM	cis	rs28785552	0.769	rs11669363	chr19:53232321	C/A	cg22067481	chr19:53234126	ZNF611	-0.96	-10.31	-0.73	3.63e-17	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	8.41	0.65	4.11e-13	Cognitive test performance;
THYM	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg12011299	chr4:100065546	ADH4	0.94	9.78	0.71	4.9e-16	Alcohol dependence;
THYM	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg14092571	chr14:90743983	NA	-0.85	-9.01	-0.68	2.13e-14	Gut microbiota (bacterial taxa);
THYM	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	trans	rs3960554	0.733	rs59170362	chr7:75629267	G/C	cg19862616	chr7:65841803	NCRNA00174	0.96	7.3	0.6	8.89e-11	Eotaxin levels;
THYM	trans	rs8002861	0.664	rs895266	chr13:44461179	T/C	cg17145862	chr1:211918768	LPGAT1	0.88	8.4	0.65	4.26e-13	Leprosy;
THYM	cis	rs7264396	0.580	rs2425181	chr20:34447709	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-4.85	-0.45	4.83e-6	Total cholesterol levels;
THYM	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	5.02	0.46	2.44e-6	Height;
THYM	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg13695892	chr22:41940480	POLR3H	0.85	6.16	0.53	1.72e-8	Vitiligo;
THYM	cis	rs2552220	0.818	rs11781231	chr8:6013345	G/A	cg06481462	chr8:7005678	NA	0.5	5.21	0.47	1.1e-6	Interleukin-8 levels;
THYM	cis	rs8192282	0.739	rs11265627	chr1:154496286	A/C	cg16683920	chr1:154474344	TDRD10;SHE	0.59	5.36	0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg03929089	chr4:120376271	NA	-0.99	-12.83	-0.8	1.9e-22	Height;
THYM	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.61	-0.43	1.27e-5	Mean corpuscular volume;
THYM	cis	rs1003719	0.667	rs2249947	chr21:38433519	C/A	cg01329690	chr21:38580129	DSCR9	-0.38	-4.84	-0.44	5.09e-6	Eye color traits;
THYM	cis	rs2070677	0.935	rs4582924	chr10:135409033	T/G	cg20169779	chr10:135381914	SYCE1	-0.76	-5.95	-0.52	4.55e-8	Gout;
THYM	cis	rs6087771	0.650	rs6060395	chr20:30219823	G/C	cg13852791	chr20:30311386	BCL2L1	0.79	7.21	0.59	1.36e-10	Subcortical brain region volumes;Putamen volume;
THYM	cis	rs2455799	0.613	rs6795100	chr3:15793798	C/T	cg16303742	chr3:15540471	COLQ	-0.56	-5.73	-0.51	1.18e-7	Mean platelet volume;
THYM	cis	rs427394	0.659	rs419128	chr5:6739791	G/A	cg10857441	chr5:6722123	POLS	-0.7	-7.53	-0.61	2.93e-11	Menopause (age at onset);
THYM	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg05335186	chr13:53173507	NA	-0.45	-5.62	-0.5	1.89e-7	Lewy body disease;
THYM	cis	rs2290159	0.800	rs9817675	chr3:12676113	C/T	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs6840360	0.571	rs2407069	chr4:152533201	G/A	cg17479576	chr4:152424074	FAM160A1	-0.78	-5.74	-0.51	1.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4523957	0.553	rs2172593	chr17:2025544	G/C	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9563576	0.778	rs9569800	chr13:58579510	C/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg16049864	chr8:95962084	TP53INP1	-0.75	-6.69	-0.57	1.54e-9	Type 2 diabetes;
THYM	cis	rs7849270	0.879	rs10760587	chr9:131846016	C/G	cg14069949	chr9:131965419	NA	-0.51	-4.45	-0.42	2.32e-5	Blood metabolite ratios;
THYM	cis	rs2688608	0.592	rs11814282	chr10:75490217	T/C	cg23231163	chr10:75533350	FUT11	-0.41	-5.9	-0.52	5.54e-8	Inflammatory bowel disease;
THYM	cis	rs10186029	0.582	rs2371795	chr2:213994789	C/G	cg08319019	chr2:214017104	IKZF2	0.76	5.92	0.52	5.15e-8	Systemic sclerosis;
THYM	cis	rs921968	0.509	rs3856548	chr2:219398164	C/T	cg02176678	chr2:219576539	TTLL4	-0.73	-7.24	-0.6	1.18e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9420	1.000	rs9420	chr11:57510294	A/G	cg19752551	chr11:57585705	CTNND1	0.66	7.73	0.62	1.11e-11	Schizophrenia;
THYM	cis	rs921968	0.565	rs6704575	chr2:219589594	C/T	cg02176678	chr2:219576539	TTLL4	0.45	4.55	0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg26441486	chr22:50317300	CRELD2	0.43	6.27	0.54	1.07e-8	Schizophrenia;
THYM	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg10560079	chr2:191398806	TMEM194B	0.88	7.8	0.63	7.77e-12	Pulse pressure;
THYM	cis	rs1775715	0.870	rs1251407	chr10:32238325	A/G	cg04359828	chr10:32216031	ARHGAP12	0.41	5.19	0.47	1.19e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg23161317	chr6:28129485	ZNF389	0.65	5.2	0.47	1.14e-6	Parkinson's disease;
THYM	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg25427524	chr10:38739819	LOC399744	-0.57	-4.94	-0.45	3.32e-6	Extrinsic epigenetic age acceleration;
THYM	cis	rs55788414	0.725	rs13339033	chr16:81189034	G/A	cg06400318	chr16:81190750	PKD1L2	-0.82	-5.05	-0.46	2.15e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs2625529	0.652	rs8028115	chr15:72339503	C/T	cg16672083	chr15:72433130	SENP8	0.5	4.53	0.42	1.69e-5	Red blood cell count;
THYM	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg15557168	chr22:42548783	NA	-0.59	-4.52	-0.42	1.8e-5	Schizophrenia;
THYM	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg03605463	chr16:89740564	NA	0.58	4.52	0.42	1.76e-5	Hemoglobin concentration;
THYM	cis	rs4589258	0.644	rs55838813	chr11:90410197	C/T	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1150668	0.543	rs2531805	chr6:28412326	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.61	-4.71	-0.44	8.33e-6	Pubertal anthropometrics;
THYM	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.31	4.72	0.44	8.22e-6	Obesity-related traits;
THYM	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg07570687	chr10:102243282	WNT8B	0.74	6.47	0.55	4.35e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg14196790	chr5:131705035	SLC22A5	-0.55	-5.04	-0.46	2.21e-6	Blood metabolite levels;
THYM	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg13944838	chr5:179740914	GFPT2	-0.8	-6.26	-0.54	1.09e-8	Height;
THYM	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg11905131	chr22:24372483	LOC391322	-0.94	-10.28	-0.73	4.07e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6570726	0.764	rs9386125	chr6:145911677	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-4.98	-0.45	2.87e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg10803722	chr21:46713166	LOC642852	-0.41	-5.33	-0.48	6.47e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg00071950	chr4:10020882	SLC2A9	0.86	10.33	0.73	3.3e-17	Bone mineral density;
THYM	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.49	-4.76	-0.44	6.97e-6	Longevity;Endometriosis;
THYM	cis	rs644799	0.511	rs11021302	chr11:95485768	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	5.88	0.52	6.21e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg04447362	chr2:237654635	NA	0.48	4.49	0.42	2.03e-5	Prostate cancer;
THYM	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg08048268	chr3:133502702	NA	-0.66	-5.71	-0.51	1.27e-7	Iron status biomarkers;
THYM	cis	rs2730245	0.527	rs842695	chr7:158662182	G/A	cg24397884	chr7:158709396	WDR60	0.58	5.59	0.5	2.15e-7	Height;
THYM	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg19761014	chr17:28927070	LRRC37B2	-0.73	-4.61	-0.43	1.25e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs4718428	0.924	rs6971897	chr7:66412774	T/A	cg18252515	chr7:66147081	NA	-0.69	-5.1	-0.46	1.72e-6	Corneal structure;
THYM	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg16342193	chr10:102329863	NA	-0.6	-6.32	-0.54	8.57e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2069036	0.903	rs10795342	chr10:16085955	A/G	cg26633223	chr10:15133461	NA	0.7	5.04	0.46	2.2e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs56104184	0.830	rs45589039	chr19:49355385	C/T	cg16594139	chr19:49340574	PLEKHA4;HSD17B14	0.98	4.73	0.44	7.75e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	trans	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs2456568	0.802	rs11020585	chr11:93638493	A/C	cg17595323	chr11:93583763	C11orf90	0.6	6.38	0.55	6.31e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg23708337	chr7:1209742	NA	0.88	4.68	0.43	9.69e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1021993	0.868	rs6685289	chr1:209530669	G/C	cg24997231	chr1:209527535	NA	-0.59	-4.59	-0.43	1.36e-5	Gut microbiome composition (winter);
THYM	cis	rs804280	0.565	rs2645453	chr8:11622001	G/A	cg12395012	chr8:11607386	GATA4	-0.63	-5.7	-0.5	1.33e-7	Myopia (pathological);
THYM	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg16926213	chr1:1841314	NA	0.56	5.87	0.52	6.47e-8	Body mass index;
THYM	cis	rs11608355	0.810	rs12424599	chr12:109866615	A/G	cg11367159	chr12:110044531	NA	0.61	5.15	0.47	1.43e-6	Neuroticism;
THYM	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg17264618	chr3:40429014	ENTPD3	-0.55	-5.44	-0.49	4.17e-7	Renal cell carcinoma;
THYM	cis	rs985746	0.568	rs62303413	chr4:36821908	G/A	cg04301614	chr4:37585993	C4orf19	0.56	4.55	0.42	1.58e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs4790333	0.813	rs2005029	chr17:2255138	G/T	cg02569219	chr17:2266849	SGSM2	-0.72	-6.55	-0.56	2.9e-9	Proinsulin levels;
THYM	cis	rs308447	0.576	rs13145003	chr4:123711260	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.85	6.86	0.58	7.03e-10	Perceived unattractiveness to mosquitoes;
THYM	cis	rs6127978	0.702	rs2426702	chr20:55805426	C/T	cg15851418	chr20:55835831	BMP7	0.68	4.89	0.45	4.12e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg13395646	chr4:1353034	KIAA1530	-0.59	-5.68	-0.5	1.44e-7	Longevity;
THYM	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg06481639	chr22:41940642	POLR3H	0.7	5.12	0.47	1.57e-6	Vitiligo;
THYM	cis	rs9326248	0.530	rs9919599	chr11:116745484	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.93	5.25	0.47	9.19e-7	Blood protein levels;
THYM	cis	rs7705502	1.000	rs6861681	chr5:173362458	G/A	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs7267979	1.000	rs6050565	chr20:25347563	A/C	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg22709100	chr7:91322751	NA	-0.63	-4.89	-0.45	4.05e-6	Breast cancer;
THYM	cis	rs7940866	0.838	rs10736592	chr11:130800572	C/T	cg23692386	chr11:131799662	NTM	0.44	4.55	0.42	1.61e-5	Schizophrenia;
THYM	cis	rs986417	1.000	rs1254302	chr14:60885343	A/C	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg07424592	chr7:64974309	NA	1.08	5.7	0.51	1.32e-7	Diabetic kidney disease;
THYM	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg11245990	chr11:68621969	NA	0.57	7.26	0.6	1.07e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg02734326	chr4:10020555	SLC2A9	0.76	7.25	0.6	1.1e-10	Bone mineral density;
THYM	cis	rs7771547	0.519	rs58153398	chr6:36370394	A/C	cg07856975	chr6:36356162	ETV7	0.65	5.5	0.49	3.13e-7	Platelet distribution width;
THYM	cis	rs7089973	0.872	rs7075888	chr10:116627117	C/T	cg23260525	chr10:116636907	FAM160B1	0.52	4.72	0.44	8.04e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs4891159	0.790	rs689885	chr18:74110563	T/G	cg24786174	chr18:74118243	ZNF516	0.87	9.93	0.71	2.29e-16	Longevity;
THYM	cis	rs6840360	0.571	rs6811676	chr4:152562726	T/C	cg22705602	chr4:152727874	NA	-0.76	-7.92	-0.63	4.35e-12	Intelligence (multi-trait analysis);
THYM	cis	rs11122895	0.791	rs12623828	chr2:112464359	C/T	cg23262488	chr2:112468472	NA	-0.47	-5.33	-0.48	6.64e-7	Allergic sensitization;
THYM	cis	rs858239	0.730	rs858279	chr7:23251005	T/C	cg18081818	chr7:23246105	NA	-0.59	-5.03	-0.46	2.28e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9788721	0.836	rs55983731	chr15:78735269	C/T	cg18825076	chr15:78729989	IREB2	-0.66	-6.19	-0.54	1.54e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg16558253	chr16:72132732	DHX38	-0.58	-5.02	-0.46	2.46e-6	Fibrinogen levels;
THYM	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.05	-0.82	6.23e-25	Height;
THYM	cis	rs6763768	0.606	rs60287116	chr3:53388457	C/T	cg22900224	chr3:52804907	NEK4	0.72	4.64	0.43	1.13e-5	Bacterial meningitis;
THYM	cis	rs9902453	0.904	rs12936302	chr17:28349476	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-6.39	-0.55	6.15e-9	Coffee consumption (cups per day);
THYM	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg19904058	chr10:135279010	LOC619207	-0.55	-5.12	-0.47	1.57e-6	Systemic lupus erythematosus;
THYM	cis	rs12367572	0.796	rs7979141	chr12:45282630	A/T	cg03114573	chr12:45410052	DBX2	-0.52	-4.82	-0.44	5.5e-6	Gut microbiome composition (summer);
THYM	cis	rs6541297	0.715	rs4846840	chr1:230302521	A/C	cg20703242	chr1:230279135	GALNT2	0.73	4.57	0.42	1.48e-5	Coronary artery disease;
THYM	cis	rs7270101	0.749	rs117398381	chr20:3168977	G/A	cg07567308	chr20:3149320	ProSAPiP1	0.64	4.63	0.43	1.15e-5	Chronic hepatitis C infection;
THYM	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg26850624	chr5:429559	AHRR	0.53	4.5	0.42	1.93e-5	Cystic fibrosis severity;
THYM	cis	rs616402	0.527	rs604814	chr1:10567122	G/A	cg20482658	chr1:10539492	PEX14	-0.34	-4.81	-0.44	5.66e-6	Breast size;
THYM	cis	rs9970807	1.000	rs56322312	chr1:56991890	G/T	cg11959316	chr1:57001742	PPAP2B	0.7	5.22	0.47	1.05e-6	Myocardial infarction;Coronary artery disease;
THYM	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Body mass index;
THYM	cis	rs684232	0.666	rs1227028	chr17:573298	G/A	cg15660573	chr17:549704	VPS53	-0.87	-8.2	-0.64	1.14e-12	Prostate cancer;
THYM	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11644478	chr21:40555479	PSMG1	1.08	9.42	0.69	2.93e-15	Cognitive function;
THYM	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg27432699	chr2:27873401	GPN1	0.76	6.79	0.57	9.45e-10	Oral cavity cancer;
THYM	cis	rs7582180	0.663	rs6542930	chr2:100944383	T/A	cg21926883	chr2:100939477	LONRF2	-0.65	-6.15	-0.53	1.82e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6840360	0.692	rs4479686	chr4:152399324	C/T	cg17479576	chr4:152424074	FAM160A1	-0.65	-4.92	-0.45	3.58e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6586111	1.000	rs7915642	chr10:82377861	T/C	cg03086067	chr10:82368399	SH2D4B	-0.53	-6.34	-0.55	7.65e-9	Capecitabine sensitivity;
THYM	cis	rs652260	0.603	rs553205	chr19:7909255	C/T	cg15974673	chr19:7926970	EVI5L	-0.57	-5.4	-0.48	4.88e-7	Menarche (age at onset);
THYM	cis	rs977987	0.806	rs35263058	chr16:75391937	T/C	cg03315344	chr16:75512273	CHST6	0.72	6.11	0.53	2.19e-8	Dupuytren's disease;
THYM	cis	rs7127900	0.904	rs7123418	chr11:2232378	A/C	cg25635251	chr11:2234043	NA	0.74	4.71	0.44	8.43e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs3820068	0.705	rs927206	chr1:15893338	C/T	cg05660106	chr1:15850417	CASP9	1.15	9.97	0.72	1.88e-16	Systolic blood pressure;
THYM	cis	rs2933343	0.679	rs1091938	chr3:128637025	T/C	cg11901034	chr3:128598214	ACAD9	-0.7	-5.44	-0.49	4.15e-7	IgG glycosylation;
THYM	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	7.74	0.62	1.08e-11	Smoking behavior;
THYM	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs12142240	0.698	rs55971480	chr1:46823206	G/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7567389	0.719	rs6733478	chr2:127995989	C/A	cg09760422	chr2:128146352	NA	-0.53	-5.65	-0.5	1.71e-7	Self-rated health;
THYM	cis	rs7777677	0.925	rs6956756	chr7:142369666	A/C	cg21785750	chr7:142428317	NA	0.67	5.88	0.52	6.1e-8	Alcoholic chronic pancreatitis;
THYM	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg07061783	chr6:25882402	NA	-1.03	-9.18	-0.69	9.14e-15	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg22920501	chr2:26401640	FAM59B	-0.8	-6.57	-0.56	2.64e-9	Gut microbiome composition (summer);
THYM	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg25039879	chr17:56429692	SUPT4H1	0.75	4.47	0.42	2.16e-5	Cognitive test performance;
THYM	cis	rs2067615	0.524	rs10467029	chr12:107078448	C/T	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg05973401	chr12:123451056	ABCB9	0.64	4.63	0.43	1.17e-5	Platelet count;
THYM	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg08645402	chr16:4508243	NA	0.61	5.28	0.48	8.07e-7	Schizophrenia;
THYM	cis	rs61931739	1.000	rs11052967	chr12:34020030	T/G	cg06521331	chr12:34319734	NA	0.58	4.57	0.42	1.49e-5	Morning vs. evening chronotype;
THYM	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg24257776	chr3:47051546	LOC100129354	0.41	4.78	0.44	6.38e-6	Colorectal cancer;
THYM	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg13683864	chr3:40499215	RPL14	-1.05	-11.15	-0.75	5.91e-19	Renal cell carcinoma;
THYM	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.25	-5.06	-0.46	2.05e-6	Obesity-related traits;
THYM	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg14004847	chr7:1930337	MAD1L1	-0.65	-5.35	-0.48	6.1e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs6032067	0.777	rs56063128	chr20:43783210	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs72627123	0.867	rs75754154	chr14:74473578	C/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.93	5.3	0.48	7.37e-7	Morning vs. evening chronotype;
THYM	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg05347473	chr6:146136440	FBXO30	0.57	4.59	0.43	1.36e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg22875332	chr1:76189707	ACADM	-0.91	-13.71	-0.81	3.06e-24	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg12165864	chr7:66369176	NA	-0.72	-5.52	-0.49	2.96e-7	Corneal structure;
THYM	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.48	0.49	3.48e-7	Tonsillectomy;
THYM	cis	rs36051895	0.587	rs7019418	chr9:5259847	G/C	cg02405213	chr9:5042618	JAK2	-0.95	-9.83	-0.71	3.76e-16	Pediatric autoimmune diseases;
THYM	cis	rs2018683	0.677	rs12531456	chr7:28970611	A/C	cg27487796	chr7:28973253	NA	-0.26	-4.61	-0.43	1.26e-5	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
THYM	cis	rs55728055	0.661	rs62237843	chr22:32026946	C/G	cg10537193	chr22:32026975	PISD	-0.85	-5.37	-0.48	5.51e-7	Age-related hearing impairment;
THYM	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg05347473	chr6:146136440	FBXO30	0.58	4.51	0.42	1.85e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2067615	0.542	rs4964184	chr12:107070425	A/T	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	cis	rs7927771	0.524	rs7936948	chr11:47704200	T/G	cg18512352	chr11:47633146	NA	0.4	4.47	0.42	2.14e-5	Subjective well-being;
THYM	cis	rs4866334	1.000	rs79823740	chr5:18488814	T/C	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.0	0.63	2.98e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg22307029	chr19:49891270	CCDC155	0.66	6.1	0.53	2.31e-8	Multiple sclerosis;
THYM	cis	rs3733631	1.000	rs11943988	chr4:104654699	A/G	cg24090629	chr4:104641072	TACR3	-0.86	-5.51	-0.49	3.1e-7	Menarche (age at onset);
THYM	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg24642844	chr7:1081250	C7orf50	-1.21	-5.13	-0.47	1.56e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs2637266	1.000	rs2637267	chr10:78331803	A/G	cg18941641	chr10:78392320	NA	0.8	6.91	0.58	5.42e-10	Pulmonary function;
THYM	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg00255919	chr5:131827918	IRF1	-0.45	-5.13	-0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs7192380	0.965	rs4633710	chr16:69632961	A/G	cg09409435	chr16:70099608	PDXDC2	0.62	4.73	0.44	7.92e-6	Sjögren's syndrome;
THYM	cis	rs9527	0.590	rs7894959	chr10:104756182	C/T	cg04362960	chr10:104952993	NT5C2	0.6	4.69	0.43	9.18e-6	Arsenic metabolism;
THYM	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg10018233	chr7:150070692	REPIN1	0.5	7.76	0.62	9.42e-12	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs28595532	0.920	rs114564223	chr4:119729953	A/G	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs8067545	1.000	rs4925066	chr17:19915292	A/G	cg20830565	chr17:20408647	MGC102966	-0.48	-4.46	-0.42	2.23e-5	Schizophrenia;
THYM	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22857025	chr5:266934	NA	-1.61	-10.06	-0.72	1.24e-16	Breast cancer;
THYM	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.71	5.26	0.48	8.78e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6960043	0.905	rs11514706	chr7:15059272	A/C	cg19272540	chr7:15055459	NA	-0.53	-6.34	-0.55	7.81e-9	Type 2 diabetes;
THYM	cis	rs12935418	0.616	rs2549855	chr16:81026852	C/G	cg16651780	chr16:81037892	C16orf61	0.87	7.02	0.58	3.31e-10	Mean corpuscular volume;
THYM	cis	rs758324	0.687	rs156023	chr5:131545168	C/T	cg16205897	chr5:131564050	P4HA2	0.57	4.67	0.43	9.71e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg01483505	chr11:975446	AP2A2	0.58	4.75	0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs61931739	0.679	rs10844831	chr12:34311245	G/T	cg10856724	chr12:34555212	NA	-0.62	-5.55	-0.49	2.62e-7	Morning vs. evening chronotype;
THYM	cis	rs73086581	1.000	rs2326289	chr20:3952300	T/C	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs7809950	0.678	rs62483641	chr7:106901741	T/C	cg23024343	chr7:107201750	COG5	-1.0	-8.43	-0.65	3.79e-13	Coronary artery disease;
THYM	cis	rs4606347	0.872	rs61781317	chr1:66105751	T/C	cg04111102	chr1:66153794	NA	0.6	4.6	0.43	1.31e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2742234	0.590	rs1254962	chr10:43696992	G/A	cg06632098	chr10:43605906	RET	0.79	5.1	0.46	1.73e-6	Hirschsprung disease;
THYM	cis	rs9790314	1.000	rs336567	chr3:161073046	A/G	cg03342759	chr3:160939853	NMD3	-0.75	-6.76	-0.57	1.14e-9	Morning vs. evening chronotype;
THYM	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	trans	rs12764197	0.883	rs17752077	chr10:26431435	A/G	cg00192819	chr18:76486611	NA	1.0	7.09	0.59	2.41e-10	Obesity-related traits;
THYM	cis	rs9462846	0.887	rs6907869	chr6:42850919	G/T	cg09436375	chr6:42928200	GNMT	-0.37	-4.48	-0.42	2.08e-5	Blood protein levels;
THYM	cis	rs9515201	0.781	rs2391825	chr13:111035483	G/A	cg15455643	chr13:111040242	COL4A2	0.55	5.95	0.52	4.41e-8	White matter hyperintensity burden;
THYM	cis	rs4606347	0.789	rs61780870	chr1:66163738	C/G	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.06	7.52	0.61	3.11e-11	Smoking behavior;
THYM	cis	rs12611088	0.600	rs2355994	chr19:44005107	T/C	cg18042043	chr19:44147545	NA	-0.43	-4.93	-0.45	3.49e-6	Plasma amyloid beta peptide concentrations (ABx-42);
THYM	cis	rs7267979	0.932	rs431579	chr20:25470056	T/C	cg03522245	chr20:25566470	NINL	0.57	4.48	0.42	2.1e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6980334	0.679	rs3816829	chr7:137792420	A/G	cg22979093	chr7:137028410	PTN	0.62	4.95	0.45	3.19e-6	Blood metabolite ratios;
THYM	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg18512352	chr11:47633146	NA	-0.5	-6.15	-0.53	1.83e-8	Subjective well-being;
THYM	cis	rs1775715	0.737	rs2808078	chr10:32172552	C/T	cg04359828	chr10:32216031	ARHGAP12	0.39	5.13	0.47	1.52e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs7106204	0.609	rs12791360	chr11:24286239	T/G	ch.11.24196551F	chr11:24239977	NA	0.99	6.28	0.54	1.02e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7666738	0.752	rs35436270	chr4:99088280	G/A	cg18180107	chr4:99064573	C4orf37	0.58	4.47	0.42	2.16e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs10802346	0.545	rs12134404	chr1:246372144	A/G	cg22732515	chr19:44031385	ETHE1	1.06	9.28	0.69	5.61e-15	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg24846680	chr1:228362309	C1orf69	0.51	4.53	0.42	1.74e-5	Diastolic blood pressure;
THYM	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg24692254	chr21:30365293	RNF160	-0.98	-8.78	-0.67	6.83e-14	Dental caries;
THYM	cis	rs2835345	0.596	rs12482138	chr21:37823906	C/T	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs8051149	0.688	rs16943320	chr16:87870379	A/G	cg01412419	chr16:87856264	NA	0.67	5.21	0.47	1.11e-6	Blood metabolite levels;
THYM	cis	rs9534288	0.762	rs9534292	chr13:46611340	T/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs1113500	0.524	rs12145813	chr1:108569904	C/T	cg06207961	chr1:108661230	NA	0.6	4.86	0.45	4.57e-6	Growth-regulated protein alpha levels;
THYM	cis	rs877282	0.838	rs11253408	chr10:796374	T/C	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs3087591	1.000	rs9904169	chr17:29572518	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.68	-5.95	-0.52	4.46e-8	Hip circumference;
THYM	cis	rs6921919	0.583	rs3800328	chr6:28390843	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.59	-4.53	-0.42	1.74e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs59698941	0.943	rs67162224	chr5:132289372	T/C	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.73	5.03	0.46	2.29e-6	Height;
THYM	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.27	6.21	0.54	1.4e-8	Obesity-related traits;
THYM	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.83	-8.82	-0.67	5.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg20587970	chr11:113659929	NA	-1.37	-8.96	-0.68	2.79e-14	Hip circumference adjusted for BMI;
THYM	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg26721908	chr21:47610096	LSS	-0.75	-5.43	-0.49	4.35e-7	Testicular germ cell tumor;
THYM	cis	rs988913	0.662	rs11754240	chr6:54921499	T/G	cg19716238	chr6:54711378	FAM83B	0.47	4.47	0.42	2.13e-5	Menarche (age at onset);
THYM	cis	rs2404602	0.647	rs11632765	chr15:76974261	A/T	cg23625390	chr15:77176239	SCAPER	0.83	5.81	0.51	8.39e-8	Blood metabolite levels;
THYM	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg07414643	chr4:187882934	NA	0.66	5.81	0.51	8.28e-8	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs8002861	0.905	rs12875768	chr13:44428305	C/T	cg17145862	chr1:211918768	LPGAT1	-0.95	-9.27	-0.69	5.89e-15	Leprosy;
THYM	cis	rs11148252	0.583	rs9536048	chr13:52958788	T/C	cg00495681	chr13:53174319	NA	0.77	6.39	0.55	6.2e-9	Lewy body disease;
THYM	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.34	-0.65	5.7e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.62	0.43	1.2e-5	Obesity-related traits;
THYM	cis	rs728616	0.867	rs723193	chr10:81708155	G/T	cg18148530	chr10:81370782	SFTPA1	0.75	5.26	0.47	9.01e-7	Chronic obstructive pulmonary disease-related biomarkers;
THYM	trans	rs2270927	0.834	rs4496693	chr5:75576729	T/C	cg13563193	chr19:33072644	PDCD5	1.6	9.13	0.68	1.21e-14	Mean corpuscular volume;
THYM	cis	rs72627123	0.867	rs73303116	chr14:74483615	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs28595532	0.920	rs115090643	chr4:119729825	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg17554472	chr22:41940697	POLR3H	-0.66	-4.79	-0.44	6.12e-6	Vitiligo;
THYM	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs11225247	1.000	rs57562739	chr11:102306641	G/T	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg05368731	chr17:41323189	NBR1	1.25	11.36	0.76	2.17e-19	Menopause (age at onset);
THYM	cis	rs8048589	0.527	rs9939383	chr16:12176120	C/T	cg02910054	chr16:12241554	SNX29	0.62	4.87	0.45	4.53e-6	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs3791556	0.898	rs3791549	chr2:240109024	A/G	cg03281426	chr2:240109471	HDAC4	-0.58	-5.66	-0.5	1.57e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs6547741	0.935	rs56001553	chr2:27859926	C/T	cg27432699	chr2:27873401	GPN1	-0.74	-6.41	-0.55	5.65e-9	Oral cavity cancer;
THYM	cis	rs4845570	1.000	rs11585294	chr1:151769887	A/C	cg07092448	chr1:151763213	TDRKH	-1.0	-6.13	-0.53	2e-8	Coronary artery disease;
THYM	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg03929089	chr4:120376271	NA	-1.01	-13.68	-0.81	3.47e-24	Height;
THYM	cis	rs539096	0.872	rs573350	chr1:44057950	T/C	cg00143623	chr1:44495758	SLC6A9	0.67	5.18	0.47	1.22e-6	Intelligence (multi-trait analysis);
THYM	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg26384229	chr12:38710491	ALG10B	1.07	10.43	0.73	2.04e-17	Heart rate;
THYM	cis	rs892961	0.867	rs6501955	chr17:75414443	A/G	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs11577318	0.537	rs12030833	chr1:26689220	A/G	cg19677267	chr1:26645161	CD52;UBXN11	0.51	5.7	0.51	1.33e-7	Granulocyte percentage of myeloid white cells;
THYM	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg21644426	chr2:191273491	MFSD6	0.74	6.15	0.53	1.84e-8	Pulse pressure;
THYM	trans	rs28595532	0.844	rs80188901	chr4:119500014	C/T	cg13773247	chr2:42276988	PKDCC	0.89	6.93	0.58	5e-10	Cannabis dependence symptom count;
THYM	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.08	-7.61	-0.62	2e-11	Platelet count;
THYM	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg24399712	chr22:39784796	NA	0.83	9.75	0.71	5.56e-16	IgG glycosylation;
THYM	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg13695892	chr22:41940480	POLR3H	1.01	6.31	0.54	8.83e-9	Vitiligo;
THYM	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg24675658	chr1:53192096	ZYG11B	-0.68	-5.47	-0.49	3.57e-7	Monocyte count;
THYM	cis	rs2806561	1.000	rs1757044	chr1:23515631	T/C	cg08872493	chr1:23521417	HTR1D	0.38	4.87	0.45	4.43e-6	Height;
THYM	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7084402	0.967	rs1593677	chr10:60291642	A/T	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs28374715	0.635	rs112547435	chr15:41648737	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.17	-14.19	-0.82	3.41e-25	Ulcerative colitis;
THYM	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg06808227	chr14:105710500	BRF1	-1.04	-9.07	-0.68	1.64e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4589258	0.933	rs16923789	chr11:90412877	T/G	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg27535305	chr1:53392650	SCP2	0.66	7.27	0.6	9.92e-11	Monocyte count;
THYM	cis	rs2562152	0.706	rs216596	chr16:105320	A/G	cg08336687	chr16:907744	LMF1	-0.8	-4.67	-0.43	9.96e-6	Glioblastoma;
THYM	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs2806561	1.000	rs1757044	chr1:23515631	T/C	cg12483005	chr1:23474871	LUZP1	0.55	5.68	0.5	1.44e-7	Height;
THYM	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg20476274	chr7:133979776	SLC35B4	0.66	4.61	0.43	1.25e-5	Mean platelet volume;
THYM	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg12386194	chr3:101231763	SENP7	0.97	7.83	0.63	6.87e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg26384229	chr12:38710491	ALG10B	0.97	7.89	0.63	5.19e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9913156	0.789	rs56003988	chr17:4600764	G/A	cg19197139	chr17:4613644	ARRB2	0.84	4.97	0.45	2.92e-6	Lymphocyte counts;
THYM	cis	rs6500395	1.000	rs3817029	chr16:48584942	C/T	cg04672837	chr16:48644449	N4BP1	0.46	4.54	0.42	1.66e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg16482183	chr6:26056742	HIST1H1C	0.89	6.11	0.53	2.2e-8	Iron status biomarkers;
THYM	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg10360139	chr7:1886902	MAD1L1	-0.62	-5.48	-0.49	3.43e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs4460079	0.531	rs4422475	chr4:114847398	G/C	cg02060584	chr4:113970739	ANK2	0.59	4.93	0.45	3.48e-6	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg22907277	chr7:1156413	C7orf50	-0.84	-8.34	-0.65	5.62e-13	Longevity;Endometriosis;
THYM	cis	rs754466	0.606	rs10824581	chr10:79599501	A/G	cg17075019	chr10:79541650	NA	-0.7	-5.75	-0.51	1.09e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1691799	0.899	rs1168318	chr12:66745269	A/G	cg16791601	chr12:66731901	HELB	0.75	7.0	0.58	3.54e-10	White blood cell count (basophil);
THYM	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9902453	0.791	rs55655651	chr17:28244286	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.64	0.43	1.11e-5	Coffee consumption (cups per day);
THYM	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg10802521	chr3:52805072	NEK4	-0.8	-7.5	-0.61	3.34e-11	Electroencephalogram traits;
THYM	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg05362011	chr13:21860987	NA	0.57	4.74	0.44	7.52e-6	White matter hyperintensity burden;
THYM	cis	rs7404928	0.707	rs7196543	chr16:23958971	C/T	cg26685404	chr16:23957272	PRKCB	-0.66	-7.96	-0.63	3.59e-12	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs10779751	1.000	rs11121706	chr1:11302065	C/T	cg08854313	chr1:11322531	MTOR	0.97	8.82	0.67	5.44e-14	Body mass index;
THYM	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs11563648	0.535	rs28729203	chr7:127031917	G/T	cg23081781	chr7:127225937	GCC1	-0.37	-5.0	-0.46	2.57e-6	Resting heart rate;
THYM	cis	rs7646881	0.951	rs6441222	chr3:158449767	A/G	cg19483011	chr3:158453295	NA	-0.7	-4.85	-0.45	4.86e-6	Tetralogy of Fallot;
THYM	cis	rs9992101	0.547	rs7674982	chr4:77412997	G/A	cg27417997	chr4:77356416	SHROOM3	-0.37	-4.46	-0.42	2.22e-5	Creatinine levels;
THYM	cis	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg13609457	chr4:120235615	NA	0.53	4.83	0.44	5.22e-6	Corneal astigmatism;
THYM	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg13609457	chr4:120235615	NA	0.64	5.08	0.46	1.86e-6	Corneal astigmatism;
THYM	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02475777	chr4:1388615	CRIPAK	0.72	5.2	0.47	1.13e-6	Longevity;
THYM	cis	rs11677370	0.574	rs10209122	chr2:3871186	C/A	cg17052675	chr2:3827356	NA	-0.7	-6.72	-0.57	1.35e-9	Type 2 diabetes;
THYM	cis	rs4499344	0.604	rs259245	chr19:33145106	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.79	6.03	0.53	3.17e-8	Mean platelet volume;
THYM	cis	rs34779708	0.966	rs34605125	chr10:35411246	A/G	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg26446133	chr18:72167187	CNDP2	-0.99	-7.91	-0.63	4.64e-12	Refractive error;
THYM	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg00684032	chr4:1343700	KIAA1530	0.61	5.33	0.48	6.52e-7	Obesity-related traits;
THYM	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg10518543	chr12:38710700	ALG10B	0.56	4.56	0.42	1.55e-5	Morning vs. evening chronotype;
THYM	cis	rs2554380	0.843	rs1426162	chr15:84386003	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.65	-5.19	-0.47	1.2e-6	Height;
THYM	cis	rs9875589	0.509	rs1386932	chr3:14061369	G/A	cg03204825	chr3:13978759	TPRXL	-0.55	-4.98	-0.46	2.83e-6	Ovarian reserve;
THYM	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.67	-0.5	1.55e-7	Type 2 diabetes;
THYM	cis	rs7043114	0.525	rs10761161	chr9:95262342	C/G	cg14631576	chr9:95140430	CENPP	-0.79	-7.7	-0.62	1.26e-11	Height;
THYM	cis	rs11122272	0.764	rs4486439	chr1:231477470	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-4.53	-0.42	1.69e-5	Hemoglobin concentration;
THYM	cis	rs977102	0.556	rs66509153	chr3:67359361	G/A	cg06096184	chr3:66549732	LRIG1	0.66	4.6	0.43	1.32e-5	Response to amphetamines;
THYM	cis	rs669446	0.562	rs10890273	chr1:44186444	T/A	cg12599982	chr1:44399894	ARTN	0.54	4.88	0.45	4.35e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs907683	0.584	rs12920	chr2:220285666	C/G	cg15015639	chr2:220282977	DES	0.42	5.71	0.51	1.3e-7	Resting heart rate;
THYM	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg07936489	chr17:37558343	FBXL20	0.83	5.69	0.5	1.41e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg02018176	chr4:1364513	KIAA1530	0.55	4.58	0.42	1.44e-5	Obesity-related traits;
THYM	cis	rs1158570	0.814	rs7460225	chr8:131339373	A/G	cg16277922	chr8:131349729	ASAP1	0.64	5.56	0.5	2.46e-7	Platelet count;
THYM	cis	rs7809950	0.678	rs2107317	chr7:106899685	T/C	cg23024343	chr7:107201750	COG5	-1.0	-8.43	-0.65	3.66e-13	Coronary artery disease;
THYM	cis	rs1551570	0.755	rs2290687	chr19:10229521	C/T	cg07753644	chr19:10222175	PPAN-P2RY11;P2RY11	-0.41	-4.49	-0.42	2.01e-5	Narcolepsy;
THYM	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg08975724	chr8:8085496	FLJ10661	0.67	4.87	0.45	4.51e-6	Neuroticism;
THYM	cis	rs2898681	0.614	rs4864680	chr4:53708421	T/G	cg00791764	chr4:53727839	RASL11B	0.42	5.27	0.48	8.41e-7	Optic nerve measurement (cup area);
THYM	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg18681998	chr4:17616180	MED28	0.8	7.06	0.59	2.76e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg02269571	chr22:50332266	NA	-0.74	-4.68	-0.43	9.36e-6	Schizophrenia;
THYM	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg02734326	chr4:10020555	SLC2A9	0.77	7.16	0.59	1.73e-10	Bone mineral density;
THYM	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	6.97	0.58	4.15e-10	Smoking behavior;
THYM	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg18252515	chr7:66147081	NA	0.67	5.24	0.47	9.7e-7	Aortic root size;
THYM	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg01448562	chr3:133502909	NA	0.66	4.87	0.45	4.52e-6	Iron status biomarkers;
THYM	cis	rs12950390	0.512	rs56254413	chr17:45857545	G/T	cg24803719	chr17:45855879	NA	-0.63	-5.21	-0.47	1.08e-6	IgG glycosylation;
THYM	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg14186256	chr22:23484241	RTDR1	0.95	9.14	0.68	1.16e-14	Bone mineral density;
THYM	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg11965913	chr1:205819406	PM20D1	0.63	4.47	0.42	2.17e-5	Parkinson's disease;
THYM	cis	rs9549328	0.577	rs4907571	chr13:113618496	T/C	cg10588471	chr13:113632644	MCF2L	-0.66	-4.62	-0.43	1.22e-5	Systolic blood pressure;
THYM	cis	rs7582180	0.638	rs6734316	chr2:100976210	A/G	cg21926883	chr2:100939477	LONRF2	-0.66	-6.14	-0.53	1.89e-8	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg18876405	chr7:65276391	NA	-0.71	-6.62	-0.56	2.12e-9	Aortic root size;
THYM	cis	rs2273669	0.667	rs12201821	chr6:109340291	C/T	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg14525755	chr12:132671672	NA	0.37	4.61	0.43	1.28e-5	Anti-saccade response;
THYM	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg00666640	chr1:248458726	OR2T12	0.57	4.75	0.44	7.19e-6	Common traits (Other);
THYM	cis	rs59698941	0.882	rs12521723	chr5:132273808	A/T	cg02081065	chr5:132209139	LEAP2	-0.78	-5.3	-0.48	7.5e-7	Apolipoprotein A-IV levels;
THYM	cis	rs72828912	0.665	rs9348630	chr6:24071677	A/G	cg26336265	chr6:25042955	NA	0.73	4.82	0.44	5.35e-6	Squamous cell lung carcinoma;
THYM	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2285947	1.000	rs2285946	chr7:21583329	T/C	cg04471919	chr7:21584483	DNAH11	0.45	4.46	0.42	2.29e-5	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
THYM	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg19418458	chr7:158789849	NA	-0.69	-5.96	-0.52	4.18e-8	Facial morphology (factor 20);
THYM	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg13390004	chr1:15929781	NA	0.63	4.79	0.44	6.2e-6	Systolic blood pressure;
THYM	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg23978390	chr7:1156363	C7orf50	0.69	4.74	0.44	7.43e-6	Longevity;Endometriosis;
THYM	cis	rs73198271	0.773	rs66618176	chr8:8646974	G/C	cg15556689	chr8:8085844	FLJ10661	-0.73	-4.58	-0.43	1.39e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs11031096	0.711	rs11031156	chr11:4179021	C/T	cg08557956	chr11:4115526	RRM1	-0.53	-4.74	-0.44	7.61e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg12524338	chr4:183729343	NA	0.93	6.14	0.53	1.91e-8	Pediatric autoimmune diseases;
THYM	cis	rs4918072	0.876	rs4918069	chr10:105654391	T/G	cg11005552	chr10:105648138	OBFC1	0.75	6.25	0.54	1.15e-8	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7463256	0.965	rs2294123	chr8:23104195	G/T	cg14349055	chr8:23104193	CHMP7	-1.03	-12.64	-0.79	4.59e-22	Attention deficit hyperactivity disorder;
THYM	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg02825527	chr7:2087843	MAD1L1	-0.76	-5.08	-0.46	1.88e-6	Bipolar disorder;
THYM	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.65	0.56	1.88e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8112449	0.822	rs7253185	chr19:10549212	A/G	cg01466491	chr19:10523363	NA	-0.62	-5.9	-0.52	5.56e-8	Multiple sclerosis;Gastritis;
THYM	cis	rs6032067	0.714	rs35665166	chr20:43865006	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.66	-7.59	-0.61	2.22e-11	Blood protein levels;
THYM	trans	rs4650994	0.525	rs4650996	chr1:178517365	A/G	cg05059571	chr16:84539110	KIAA1609	-0.92	-10.85	-0.74	2.56e-18	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs6430585	0.591	rs3098103	chr2:136656094	T/C	cg20242066	chr2:136595261	LCT	0.53	4.95	0.45	3.27e-6	Corneal structure;
THYM	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.91	5.08	0.46	1.85e-6	Initial pursuit acceleration;
THYM	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg11247378	chr22:39784982	NA	-1.08	-13.56	-0.81	6.12e-24	Intelligence (multi-trait analysis);
THYM	cis	rs2075230	0.642	rs1642797	chr17:7543017	C/T	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	-0.31	-4.56	-0.42	1.5e-5	Hormone measurements;
THYM	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg06627557	chr7:32535165	LSM5;AVL9	1.0	10.07	0.72	1.16e-16	Cognitive ability;
THYM	cis	rs7192750	0.539	rs12926300	chr16:71978997	C/T	cg06353428	chr16:71660113	MARVELD3	0.72	5.13	0.47	1.5e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.27	5.57	0.5	2.39e-7	Obesity-related traits;
THYM	cis	rs3091242	0.900	rs35345536	chr1:25766488	A/G	cg20685674	chr1:26233538	STMN1	-0.41	-4.53	-0.42	1.69e-5	Erythrocyte sedimentation rate;
THYM	cis	rs611744	0.816	rs626211	chr8:109189448	A/C	cg21045802	chr8:109455806	TTC35	0.7	6.69	0.57	1.56e-9	Dupuytren's disease;
THYM	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg00149659	chr3:10157352	C3orf10	0.78	4.6	0.43	1.29e-5	Alzheimer's disease;
THYM	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg03609598	chr5:56110824	MAP3K1	0.74	4.78	0.44	6.4e-6	Initial pursuit acceleration;
THYM	cis	rs7246657	0.943	rs35540940	chr19:38008235	G/A	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg17747265	chr1:1875780	NA	-0.8	-8.95	-0.68	2.94e-14	Body mass index;
THYM	cis	rs6812193	0.518	rs28618267	chr4:77191952	G/A	cg20311846	chr4:77356250	SHROOM3	0.52	4.52	0.42	1.81e-5	Parkinson's disease;
THYM	cis	rs710216	0.843	rs1385129	chr1:43408966	G/A	cg16738646	chr1:43409193	SLC2A1	-0.55	-4.92	-0.45	3.62e-6	Red cell distribution width;
THYM	cis	rs3925075	0.966	rs7195945	chr16:31344309	T/C	cg02846316	chr16:31340340	ITGAM	0.58	6.06	0.53	2.7e-8	IgA nephropathy;
THYM	cis	rs4979906	0.920	rs11002239	chr10:79443836	A/C	cg07817648	chr10:79422355	NA	-0.76	-5.61	-0.5	2e-7	Mortality in heart failure;
THYM	cis	rs858239	0.601	rs6461702	chr7:23249273	C/G	cg09755872	chr7:23245557	NA	-0.52	-4.85	-0.45	4.76e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg15704280	chr7:45808275	SEPT13	-0.91	-6.88	-0.58	6.48e-10	Coronary artery disease;
THYM	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg05962950	chr11:130786565	SNX19	0.91	7.76	0.62	9.5e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg23708337	chr7:1209742	NA	0.85	4.58	0.43	1.42e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17253792	0.822	rs11546	chr14:56146357	G/A	cg01858014	chr14:56050164	KTN1	-1.06	-4.54	-0.42	1.66e-5	Putamen volume;
THYM	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	4.78	0.44	6.32e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1079204	1.000	rs6747666	chr2:219188467	C/T	cg05728596	chr2:219128475	GPBAR1	1.14	4.92	0.45	3.6e-6	Smooth-surface caries;
THYM	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.69	-0.62	1.33e-11	Personality dimensions;
THYM	cis	rs28595532	1.000	rs116030177	chr4:119650768	T/C	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg17105886	chr17:28927953	LRRC37B2	1.21	7.24	0.6	1.14e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3780378	0.875	rs10115312	chr9:5003973	G/T	cg02405213	chr9:5042618	JAK2	-0.64	-5.42	-0.49	4.44e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs2637266	0.703	rs2583061	chr10:78558475	G/A	cg18941641	chr10:78392320	NA	0.69	5.52	0.49	2.96e-7	Pulmonary function;
THYM	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg13010199	chr12:38710504	ALG10B	-0.57	-4.99	-0.46	2.74e-6	Heart rate;
THYM	cis	rs892961	0.932	rs3987885	chr17:75414990	A/G	cg11351908	chr17:75402473	SEPT9	0.56	5.4	0.48	4.95e-7	Airflow obstruction;
THYM	cis	rs10744422	1.000	rs7959441	chr12:123363825	C/T	cg25930673	chr12:123319894	HIP1R	-0.84	-4.88	-0.45	4.25e-6	Schizophrenia;
THYM	cis	rs7849270	1.000	rs4713	chr9:131910805	A/T	cg14069949	chr9:131965419	NA	-0.5	-4.52	-0.42	1.8e-5	Blood metabolite ratios;
THYM	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg06521331	chr12:34319734	NA	-0.99	-9.11	-0.68	1.32e-14	Morning vs. evening chronotype;
THYM	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs7980799	0.682	rs1447873	chr12:33615236	A/G	cg06521331	chr12:34319734	NA	0.69	4.93	0.45	3.47e-6	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs2976388	0.967	rs2976393	chr8:143763618	C/G	cg06565975	chr8:143823917	SLURP1	-0.45	-5.23	-0.47	9.95e-7	Urinary tract infection frequency;
THYM	cis	rs550448	0.947	rs77181159	chr7:28172124	G/A	cg26748583	chr7:27497976	NA	-0.89	-4.67	-0.43	9.73e-6	Type 1 diabetes;
THYM	cis	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg09307838	chr4:120376055	NA	0.78	5.88	0.52	5.97e-8	Corneal astigmatism;
THYM	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg07884673	chr3:53033167	SFMBT1	1.27	6.46	0.55	4.47e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs9796	0.866	rs544744	chr15:41366290	G/C	cg21153102	chr15:41252147	NA	0.69	6.18	0.54	1.62e-8	Menopause (age at onset);
THYM	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg21926883	chr2:100939477	LONRF2	-0.6	-5.17	-0.47	1.29e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6701037	0.566	rs729675	chr1:175136946	T/C	cg00958927	chr1:175162553	KIAA0040	0.36	4.92	0.45	3.66e-6	Alcohol dependence;
THYM	cis	rs4363385	0.720	rs1338178	chr1:152981550	A/G	cg13444842	chr1:152974279	SPRR3	-0.59	-4.68	-0.43	9.52e-6	Inflammatory skin disease;
THYM	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg16586182	chr3:47516702	SCAP	-0.67	-5.62	-0.5	1.9e-7	Colorectal cancer;
THYM	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg10523679	chr1:76189770	ACADM	0.94	8.52	0.66	2.42e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9790314	0.586	rs67077657	chr3:161138521	A/G	cg03342759	chr3:160939853	NMD3	-0.88	-7.59	-0.61	2.14e-11	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs4664308	0.618	rs4665139	chr2:160890692	G/T	cg03641300	chr2:160917029	PLA2R1	-0.67	-5.84	-0.51	7.12e-8	Idiopathic membranous nephropathy;
THYM	cis	rs2294693	0.945	rs11756893	chr6:41010058	A/C	cg21128951	chr6:40996213	UNC5CL	0.61	4.58	0.43	1.38e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs11792861	0.555	rs4978767	chr9:111762925	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.8	6.48	0.55	4.15e-9	Menarche (age at onset);
THYM	cis	rs56079296	0.518	rs7722155	chr5:121330638	A/G	cg05256605	chr5:121412184	LOX	-0.61	-4.62	-0.43	1.19e-5	Coronary artery disease;
THYM	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg03859395	chr2:55845619	SMEK2	0.59	5.05	0.46	2.16e-6	Metabolic syndrome;
THYM	cis	rs7197653	0.748	rs8060690	chr16:68340085	G/T	cg09835421	chr16:68378352	PRMT7	-0.75	-4.63	-0.43	1.18e-5	Magnesium levels;
THYM	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg06108461	chr20:60628389	TAF4	-1.06	-9.1	-0.68	1.39e-14	Body mass index;
THYM	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg14895029	chr7:2775587	GNA12	-0.68	-4.95	-0.45	3.24e-6	Height;
THYM	cis	rs12928939	1.000	rs12928939	chr16:71800045	G/A	cg03805757	chr16:71968109	PKD1L3	-0.77	-5.72	-0.51	1.25e-7	Post bronchodilator FEV1;
THYM	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg11845111	chr2:191398756	TMEM194B	0.96	8.41	0.65	4.19e-13	Pulse pressure;
THYM	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg27398817	chr8:82754497	SNX16	-0.83	-6.43	-0.55	5.11e-9	Diastolic blood pressure;
THYM	cis	rs9653442	0.712	rs6749757	chr2:100730111	A/C	cg07810366	chr2:100720526	AFF3	0.34	4.95	0.45	3.27e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs3087591	0.922	rs2905799	chr17:29536901	G/A	cg24425628	chr17:29625626	OMG;NF1	0.61	5.23	0.47	1.02e-6	Hip circumference;
THYM	cis	rs7731657	0.509	rs6595975	chr5:130328051	C/A	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg18252515	chr7:66147081	NA	-0.63	-4.62	-0.43	1.22e-5	Aortic root size;
THYM	cis	rs1011018	0.955	rs12703395	chr7:139427361	A/G	cg06079564	chr7:139468310	HIPK2	-0.73	-5.54	-0.49	2.65e-7	Systolic blood pressure;
THYM	cis	rs7172809	0.599	rs2864840	chr15:77732001	C/T	cg10437265	chr15:77819839	NA	-0.5	-4.56	-0.42	1.5e-5	Glucose homeostasis traits;
THYM	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg22852734	chr6:133119734	C6orf192	1.32	8.71	0.67	9.24e-14	Type 2 diabetes nephropathy;
THYM	cis	rs526231	0.511	rs17154942	chr5:102352718	C/T	cg23492399	chr5:102201601	PAM	0.71	5.32	0.48	6.82e-7	Primary biliary cholangitis;
THYM	cis	rs554111	0.656	rs10799680	chr1:21361181	C/T	cg00373020	chr1:21041521	KIF17	-0.53	-4.46	-0.42	2.26e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg07414643	chr4:187882934	NA	0.58	5.13	0.47	1.54e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg20295408	chr7:1910781	MAD1L1	-0.65	-4.93	-0.45	3.42e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7937890	0.732	rs7946902	chr11:14273308	C/T	cg19336497	chr11:14380999	RRAS2	0.54	5.84	0.51	7.37e-8	Mitochondrial DNA levels;
THYM	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg10150615	chr22:24372951	LOC391322	-1.04	-12.58	-0.79	6.02e-22	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4638749	1.000	rs2198463	chr2:108875093	T/A	cg25838818	chr2:108905173	SULT1C2	-0.6	-6.21	-0.54	1.41e-8	Blood pressure;
THYM	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.77	-6.43	-0.55	5.1e-9	Lung cancer;
THYM	cis	rs981844	0.775	rs17371274	chr4:154738713	A/G	cg09973105	chr4:154681532	RNF175	-0.62	-5.1	-0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs758324	0.732	rs149432	chr5:131441500	C/G	cg16205897	chr5:131564050	P4HA2	0.52	4.6	0.43	1.29e-5	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg27170947	chr2:26402098	FAM59B	0.79	6.27	0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs6684428	0.706	rs10493183	chr1:56333648	T/C	cg11651538	chr1:56320950	NA	-0.66	-5.25	-0.47	9.42e-7	Airflow obstruction;
THYM	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg18758796	chr5:131593413	PDLIM4	0.64	6.37	0.55	6.83e-9	Breast cancer;
THYM	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg23161317	chr6:28129485	ZNF389	0.94	7.03	0.58	3.18e-10	Parkinson's disease;
THYM	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg02820040	chr2:241836501	C2orf54	-0.33	-6.79	-0.57	9.65e-10	Urinary metabolites;
THYM	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.69	6.58	0.56	2.51e-9	Lymphocyte counts;
THYM	cis	rs28595532	0.920	rs116305850	chr4:119779892	A/G	cg14228332	chr4:119757509	SEC24D	1.46	5.36	0.48	5.83e-7	Cannabis dependence symptom count;
THYM	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg10248100	chr7:872053	UNC84A	-0.68	-4.6	-0.43	1.32e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg05340658	chr4:99064831	C4orf37	0.58	4.93	0.45	3.47e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs262150	0.851	rs2657326	chr7:158766262	C/T	cg19418458	chr7:158789849	NA	-0.61	-5.22	-0.47	1.04e-6	Facial morphology (factor 20);
THYM	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.46	5.47	0.49	3.65e-7	Monocyte percentage of white cells;
THYM	cis	rs7246657	0.943	rs4417644	chr19:37852472	A/G	cg22634378	chr19:37742834	NA	0.68	5.67	0.5	1.55e-7	Coronary artery calcification;
THYM	cis	rs34779708	0.966	rs12769484	chr10:35465746	G/A	cg03585969	chr10:35415529	CREM	0.65	4.51	0.42	1.87e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7223966	0.810	rs2665838	chr17:61966465	C/G	cg18032289	chr17:61959525	GH2	-0.5	-4.56	-0.42	1.55e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-5.3	-0.48	7.54e-7	Gut microbiome composition (summer);
THYM	cis	rs17253792	0.732	rs75796044	chr14:56034128	C/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.91	-0.45	3.74e-6	Putamen volume;
THYM	cis	rs2456568	0.709	rs12806128	chr11:93634972	C/T	cg26875233	chr11:93583750	C11orf90	0.49	5.37	0.48	5.63e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2244613	0.882	rs7205790	chr16:55795034	A/G	cg27396498	chr16:55794478	CES4	0.75	4.84	0.45	4.93e-6	Response to dabigatran etexilate treatment;
THYM	cis	rs8078723	0.738	rs4065321	chr17:38143548	C/T	cg17467752	chr17:38218738	THRA	-0.8	-6.7	-0.57	1.46e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs6121246	0.559	rs6119650	chr20:30258480	C/A	cg13852791	chr20:30311386	BCL2L1	1.02	10.02	0.72	1.48e-16	Mean corpuscular hemoglobin;
THYM	cis	rs297325	0.812	rs11024032	chr11:16773500	C/T	cg20214553	chr11:17278779	NA	0.4	4.48	0.42	2.09e-5	Obesity and osteoporosis;
THYM	cis	rs4430311	1.000	rs2953328	chr1:244023680	C/T	cg25706552	chr1:244017396	NA	-0.58	-5.16	-0.47	1.37e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg24375607	chr4:120327624	NA	0.64	5.09	0.46	1.84e-6	Corneal astigmatism;
THYM	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.65	-4.71	-0.44	8.31e-6	Colorectal cancer;
THYM	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.68	-6.13	-0.53	1.95e-8	Total body bone mineral density;
THYM	cis	rs7078219	0.543	rs7095491	chr10:101274058	A/G	cg23904955	chr10:101282759	NA	-0.41	-5.23	-0.47	9.88e-7	Dental caries;
THYM	cis	rs3750965	0.959	rs3376	chr11:68856680	G/A	cg06818126	chr11:68850279	TPCN2	-0.66	-4.47	-0.42	2.14e-5	Hair color;
THYM	cis	rs17443541	0.507	rs1823489	chr2:200463825	C/G	cg03741458	chr2:200468445	NA	-0.8	-6.04	-0.53	3.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg14675211	chr2:100938903	LONRF2	0.76	8.42	0.65	3.99e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg26384229	chr12:38710491	ALG10B	-0.89	-7.77	-0.62	9.19e-12	Morning vs. evening chronotype;
THYM	cis	rs10489202	0.657	rs201541	chr1:167992344	T/A	cg24449463	chr1:168025552	DCAF6	-0.92	-9.44	-0.7	2.67e-15	Schizophrenia;
THYM	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg07690219	chr3:49449608	TCTA;RHOA	0.7	4.71	0.43	8.57e-6	Menarche (age at onset);
THYM	cis	rs4343996	0.626	rs7791898	chr7:3398325	C/T	cg21248987	chr7:3385318	SDK1	-0.41	-5.31	-0.48	7.27e-7	Motion sickness;
THYM	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.85	8.2	0.64	1.16e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg06713675	chr4:122721982	EXOSC9	-0.83	-9.31	-0.69	5.04e-15	Type 2 diabetes;
THYM	cis	rs9534288	0.797	rs7990095	chr13:46587262	G/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg03709012	chr19:19516395	GATAD2A	0.73	5.59	0.5	2.16e-7	Tonsillectomy;
THYM	cis	rs939658	0.805	rs8035606	chr15:79420245	C/T	cg17916960	chr15:79447300	NA	-0.7	-8.14	-0.64	1.53e-12	Refractive error;
THYM	cis	rs11690935	0.655	rs12997093	chr2:172564438	A/G	cg13550731	chr2:172543902	DYNC1I2	0.61	4.82	0.44	5.37e-6	Schizophrenia;
THYM	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg22535103	chr8:58192502	C8orf71	-0.84	-4.73	-0.44	7.94e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9595908	0.900	rs9595890	chr13:33171655	T/C	cg12383807	chr13:33924137	NA	-0.53	-4.74	-0.44	7.41e-6	Body mass index;
THYM	cis	rs3820068	0.580	rs34426856	chr1:16006315	C/T	cg24675056	chr1:15929824	NA	0.69	5.65	0.5	1.66e-7	Systolic blood pressure;
THYM	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg07777115	chr5:623756	CEP72	-0.8	-4.83	-0.44	5.12e-6	Obesity-related traits;
THYM	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-5.32	-0.48	6.76e-7	Heart rate;
THYM	cis	rs9810089	0.843	rs834304	chr3:136111658	G/T	cg12473912	chr3:136751656	NA	0.62	5.05	0.46	2.12e-6	Gestational age at birth (child effect);
THYM	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg22105103	chr4:187893119	NA	-0.89	-9.52	-0.7	1.73e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg23711669	chr6:146136114	FBXO30	0.9	8.8	0.67	6.03e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1933112	1.000	rs1933112	chr1:168521417	A/G	cg00154920	chr1:168513310	XCL2	-0.5	-5.02	-0.46	2.38e-6	Blood protein levels;
THYM	cis	rs9309473	0.607	rs6716776	chr2:73587713	T/C	cg20560298	chr2:73613845	ALMS1	-0.64	-4.48	-0.42	2.1e-5	Metabolite levels;
THYM	cis	rs8017423	0.967	rs4900033	chr14:90701963	C/A	cg04239629	chr14:90701769	NA	-0.62	-4.52	-0.42	1.81e-5	Mortality in heart failure;
THYM	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg26677194	chr12:130822605	PIWIL1	-0.82	-6.47	-0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs9296092	0.538	rs75501442	chr6:33519493	A/G	cg13560919	chr6:33536144	NA	-0.95	-9.43	-0.7	2.72e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg07936489	chr17:37558343	FBXL20	-0.68	-4.78	-0.44	6.4e-6	Asthma;
THYM	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg02463440	chr8:22132932	PIWIL2	-0.55	-4.81	-0.44	5.64e-6	Hypertriglyceridemia;
THYM	cis	rs208520	0.837	rs208467	chr6:66914837	T/C	cg07460842	chr6:66804631	NA	-0.79	-4.96	-0.45	3.05e-6	Exhaled nitric oxide output;
THYM	cis	rs13256369	0.762	rs13278972	chr8:8597180	T/C	cg06636001	chr8:8085503	FLJ10661	0.6	4.48	0.42	2.05e-5	Obesity-related traits;
THYM	trans	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg10856724	chr12:34555212	NA	-0.91	-8.2	-0.64	1.17e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg09033563	chr22:24373618	LOC391322	-0.61	-5.63	-0.5	1.8e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg16928487	chr17:17741425	SREBF1	-0.56	-5.57	-0.5	2.37e-7	Total body bone mineral density;
THYM	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg01699819	chr7:1052092	C7orf50	-0.87	-7.7	-0.62	1.27e-11	Bronchopulmonary dysplasia;
THYM	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.49	-4.62	-0.43	1.21e-5	Crohn's disease;
THYM	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3126085	0.935	rs1353436	chr1:152172658	G/A	cg26020982	chr1:152196106	HRNR	0.37	5.06	0.46	2.05e-6	Atopic dermatitis;
THYM	cis	rs1048238	0.506	rs698890	chr1:16267371	C/G	cg22431228	chr1:16359049	CLCNKA	0.43	4.58	0.43	1.41e-5	Systolic blood pressure;
THYM	cis	rs924712	0.844	rs10948866	chr6:54734123	C/T	cg04690482	chr6:54711388	FAM83B	-0.45	-5.01	-0.46	2.5e-6	Breast cancer;
THYM	cis	rs1971762	0.583	rs10876485	chr12:54087648	C/T	cg16917193	chr12:54089295	NA	-0.93	-9.25	-0.69	6.52e-15	Height;
THYM	cis	rs6754311	0.678	rs309181	chr2:136614813	C/G	cg04750100	chr2:136595281	LCT	-0.56	-6.13	-0.53	1.97e-8	Mosquito bite size;
THYM	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg17211192	chr8:82754475	SNX16	-0.8	-7.08	-0.59	2.52e-10	Diastolic blood pressure;
THYM	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs8050907	0.744	rs74871470	chr16:4584464	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.25	5.11	0.46	1.66e-6	Obesity-related traits;
THYM	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs11723261	0.621	rs6599307	chr4:143777	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.75	5.88	0.52	6.01e-8	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg00495681	chr13:53174319	NA	1.09	13.03	0.8	7.36e-23	Lewy body disease;
THYM	cis	rs10504073	0.584	rs7820270	chr8:49971395	G/T	cg00325661	chr8:49890786	NA	1.04	10.32	0.73	3.47e-17	Blood metabolite ratios;
THYM	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg08807101	chr21:30365312	RNF160	-0.72	-5.52	-0.49	2.99e-7	Dental caries;
THYM	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.89	-6.65	-0.56	1.86e-9	Electrocardiographic conduction measures;
THYM	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	5.31	0.48	7.15e-7	Hip circumference adjusted for BMI;
THYM	cis	rs67981189	0.529	rs8181986	chr14:71582244	G/A	cg15910301	chr14:71632612	NA	0.56	4.88	0.45	4.23e-6	Schizophrenia;
THYM	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg26354017	chr1:205819088	PM20D1	-0.75	-7.05	-0.59	2.82e-10	Menarche (age at onset);
THYM	cis	rs6547741	0.935	rs6547738	chr2:27852637	A/G	cg27432699	chr2:27873401	GPN1	0.7	6.26	0.54	1.12e-8	Oral cavity cancer;
THYM	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg00717180	chr2:96193071	NA	-0.69	-7.33	-0.6	7.62e-11	Coronary artery disease;
THYM	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg12016809	chr21:47604291	C21orf56	0.78	5.38	0.48	5.42e-7	Testicular germ cell tumor;
THYM	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs629535	0.814	rs62513381	chr8:70110991	T/C	cg21567404	chr3:27674614	NA	-1.06	-9.7	-0.71	7.22e-16	Dupuytren's disease;
THYM	cis	rs10779751	1.000	rs2300094	chr1:11266044	C/T	cg08854313	chr1:11322531	MTOR	1.0	9.54	0.7	1.62e-15	Body mass index;
THYM	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg22920501	chr2:26401640	FAM59B	-0.83	-7.3	-0.6	8.69e-11	Gut microbiome composition (summer);
THYM	cis	rs4072705	1.000	rs721862	chr9:127535992	C/T	cg13476313	chr9:127244764	NR5A1	0.32	4.87	0.45	4.41e-6	Menarche (age at onset);
THYM	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg26513180	chr16:89883248	FANCA	0.65	6.69	0.57	1.52e-9	Vitiligo;
THYM	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg04315214	chr1:2043799	PRKCZ	-0.58	-4.54	-0.42	1.67e-5	Height;
THYM	cis	rs1267303	0.682	rs1998545	chr1:46954587	C/T	cg16387850	chr1:46982889	NA	-0.36	-4.63	-0.43	1.18e-5	Monobrow;
THYM	cis	rs4638749	1.000	rs12472278	chr2:108873433	A/T	cg23163573	chr2:108905468	SULT1C2	0.29	4.54	0.42	1.63e-5	Blood pressure;
THYM	cis	rs7394190	0.748	rs79936644	chr10:75545117	C/T	cg07699608	chr10:75541558	CHCHD1	0.91	4.93	0.45	3.49e-6	Incident atrial fibrillation;
THYM	cis	rs2133450	0.526	rs41346444	chr3:7341994	A/G	cg19930620	chr3:7340148	GRM7	-0.5	-5.46	-0.49	3.72e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg11247378	chr22:39784982	NA	-1.02	-11.9	-0.77	1.6e-20	Intelligence (multi-trait analysis);
THYM	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg24675056	chr1:15929824	NA	0.73	5.79	0.51	9.09e-8	Systolic blood pressure;
THYM	trans	rs8002861	0.619	rs1337203	chr13:44423621	T/G	cg17145862	chr1:211918768	LPGAT1	0.85	7.64	0.62	1.69e-11	Leprosy;
THYM	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg25358565	chr5:93447407	FAM172A	1.36	10.94	0.75	1.67e-18	Diabetic retinopathy;
THYM	trans	rs9951602	0.512	rs1903722	chr18:76646539	G/A	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs2806561	0.765	rs623988	chr1:23519477	C/T	cg12483005	chr1:23474871	LUZP1	0.59	6.29	0.54	9.59e-9	Height;
THYM	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg11752832	chr7:134001865	SLC35B4	0.71	4.7	0.43	8.71e-6	Mean platelet volume;
THYM	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg01483505	chr11:975446	AP2A2	-0.58	-4.75	-0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs61931739	0.817	rs188588	chr12:34215277	G/A	cg06521331	chr12:34319734	NA	-0.65	-5.4	-0.48	4.87e-7	Morning vs. evening chronotype;
THYM	cis	rs684232	0.688	rs2657633	chr17:600502	C/T	cg15660573	chr17:549704	VPS53	-0.87	-8.12	-0.64	1.68e-12	Prostate cancer;
THYM	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.43	0.7	2.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3126085	0.877	rs4415568	chr1:152181207	G/A	cg26020982	chr1:152196106	HRNR	0.35	4.57	0.42	1.45e-5	Atopic dermatitis;
THYM	cis	rs4889855	0.530	rs75398920	chr17:78544540	C/T	cg16591659	chr17:78472290	NA	0.44	5.03	0.46	2.33e-6	Fractional excretion of uric acid;
THYM	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg06028808	chr11:68637592	NA	0.64	6.63	0.56	2.06e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg06532163	chr17:45867833	NA	0.64	6.5	0.55	3.66e-9	IgG glycosylation;
THYM	cis	rs2219968	1.000	rs12679679	chr8:78974231	T/C	cg00738934	chr8:78996279	NA	0.91	9.74	0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg05347473	chr6:146136440	FBXO30	0.6	4.86	0.45	4.66e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg06481639	chr22:41940642	POLR3H	-0.79	-5.65	-0.5	1.69e-7	Vitiligo;
THYM	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg15212455	chr7:39170539	POU6F2	0.67	6.02	0.53	3.25e-8	IgG glycosylation;
THYM	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg01191920	chr7:158217561	PTPRN2	-1.06	-12.51	-0.79	8.38e-22	Obesity-related traits;
THYM	cis	rs2336384	0.929	rs56243319	chr1:12048595	C/T	cg24492058	chr1:12203751	TNFRSF8	-0.51	-4.74	-0.44	7.37e-6	Platelet count;
THYM	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg23711669	chr6:146136114	FBXO30	-0.97	-10.49	-0.73	1.45e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg13736514	chr6:26305472	NA	-0.62	-7.39	-0.6	5.58e-11	Educational attainment;
THYM	cis	rs4589258	0.933	rs2511315	chr11:90434761	A/G	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg23978390	chr7:1156363	C7orf50	0.68	5.17	0.47	1.3e-6	Longevity;Endometriosis;
THYM	cis	rs1215050	0.740	rs2695464	chr4:98980929	T/C	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	trans	rs9951602	0.512	rs7234283	chr18:76640552	T/G	cg02800362	chr5:177631904	HNRNPAB	1.11	8.66	0.66	1.21e-13	Obesity-related traits;
THYM	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg09307838	chr4:120376055	NA	0.72	5.48	0.49	3.51e-7	Corneal astigmatism;
THYM	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg18681998	chr4:17616180	MED28	0.85	7.68	0.62	1.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg00106254	chr7:1943704	MAD1L1	-0.5	-4.5	-0.42	1.9e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs10170846	0.924	rs3768973	chr2:223436402	C/T	cg25565276	chr2:223520875	FARSB	0.67	5.5	0.49	3.15e-7	Schizophrenia (inflammation and infection response interaction);
THYM	cis	rs11577318	0.579	rs10794532	chr1:26694260	T/C	cg19677267	chr1:26645161	CD52;UBXN11	0.51	5.7	0.51	1.33e-7	Granulocyte percentage of myeloid white cells;
THYM	cis	rs1005224	0.963	rs12887886	chr14:76167846	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.73	-6.07	-0.53	2.62e-8	Large artery stroke;
THYM	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.36	4.99	0.46	2.7e-6	Obesity-related traits;
THYM	cis	rs7172809	0.599	rs74666689	chr15:77786731	C/T	cg22256960	chr15:77711686	NA	-0.61	-4.47	-0.42	2.18e-5	Glucose homeostasis traits;
THYM	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2219968	0.828	rs13248588	chr8:78880744	A/G	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7113850	0.541	rs4451727	chr11:24216855	G/C	ch.11.24196551F	chr11:24239977	NA	0.85	4.54	0.42	1.67e-5	Bone fracture in osteoporosis;
THYM	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg26384229	chr12:38710491	ALG10B	1.0	7.85	0.63	6.12e-12	Bladder cancer;
THYM	cis	rs28595532	0.920	rs114262028	chr4:119734877	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg09455208	chr3:40491958	NA	0.52	5.54	0.49	2.64e-7	Renal cell carcinoma;
THYM	cis	rs4654899	0.758	rs2320826	chr1:21392096	A/C	cg01072550	chr1:21505969	NA	-0.72	-6.94	-0.58	4.85e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg11494091	chr17:61959527	GH2	-1.09	-17.19	-0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.65	-4.72	-0.44	8.09e-6	Colorectal cancer;
THYM	cis	rs9457247	0.534	rs2345568	chr6:167381804	A/G	cg15592062	chr6:167189543	RPS6KA2	0.53	5.4	0.48	4.92e-7	Crohn's disease;
THYM	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg22431228	chr1:16359049	CLCNKA	0.5	4.46	0.42	2.28e-5	Dilated cardiomyopathy;
THYM	cis	rs12188164	1.000	rs72717412	chr5:429381	C/T	cg14137381	chr5:502291	SLC9A3	-0.62	-4.57	-0.42	1.45e-5	Cystic fibrosis severity;
THYM	cis	rs2456568	0.802	rs1395386	chr11:93639331	A/G	cg17595323	chr11:93583763	C11orf90	0.58	6.09	0.53	2.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	trans	rs9951602	0.512	rs4798995	chr18:76654344	T/G	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg14196790	chr5:131705035	SLC22A5	0.59	5.6	0.5	2.03e-7	Blood metabolite levels;
THYM	cis	rs1747683	0.932	rs1005089	chr10:13387295	G/A	cg11679871	chr10:13388567	SEPHS1	-0.31	-4.6	-0.43	1.3e-5	IgG glycosylation;
THYM	cis	rs888194	0.677	rs10774696	chr12:109875753	C/T	cg10504392	chr12:110044639	NA	0.6	5.49	0.49	3.28e-7	Neuroticism;
THYM	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg13695892	chr22:41940480	POLR3H	0.91	6.69	0.57	1.5e-9	Vitiligo;
THYM	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg02527881	chr3:46936655	PTH1R	-0.65	-6.55	-0.56	2.97e-9	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg07423050	chr13:99094983	FARP1	-0.44	-5.33	-0.48	6.66e-7	Neuroticism;
THYM	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg00256281	chr22:41985642	PMM1	0.62	4.51	0.42	1.85e-5	Vitiligo;
THYM	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg03433033	chr1:76189801	ACADM	-0.51	-5.37	-0.48	5.57e-7	Daytime sleep phenotypes;
THYM	cis	rs10493773	0.894	rs12067749	chr1:86197922	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.48	-5.13	-0.47	1.56e-6	Urate levels in overweight individuals;
THYM	cis	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg16898833	chr6:26189333	HIST1H4D	1.25	5.61	0.5	2e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4595586	0.545	rs12810822	chr12:39391807	T/A	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs12643440	0.503	rs34795372	chr4:17142116	T/C	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg03806693	chr22:41940476	POLR3H	-0.85	-7.46	-0.61	4.04e-11	Neuroticism;
THYM	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg16586182	chr3:47516702	SCAP	-0.6	-5.12	-0.46	1.6e-6	Colorectal cancer;
THYM	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06850241	chr22:41845214	NA	0.59	5.41	0.49	4.76e-7	Vitiligo;
THYM	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs8133932	0.736	rs2839030	chr21:47292007	A/C	cg08707771	chr21:46690014	POFUT2	-0.79	-4.63	-0.43	1.15e-5	Schizophrenia;
THYM	cis	rs11825685	0.887	rs76812821	chr11:134564628	G/A	cg02395454	chr11:134605862	NA	-0.98	-4.88	-0.45	4.22e-6	IgG glycosylation;
THYM	cis	rs4731207	0.596	rs10081375	chr7:124573175	A/G	cg05285228	chr7:124571219	POT1	-0.69	-5.27	-0.48	8.69e-7	Cutaneous malignant melanoma;
THYM	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.09e-8	Systolic blood pressure;
THYM	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg18681998	chr4:17616180	MED28	0.81	6.87	0.58	6.5e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4149423	1.000	rs4149423	chr2:108916044	A/G	cg23163573	chr2:108905468	SULT1C2	-0.42	-4.89	-0.45	4.04e-6	Lobe size;
THYM	cis	rs1823778	0.609	rs8085823	chr18:67646939	C/T	cg20768743	chr18:67624846	CD226	1.23	4.58	0.43	1.42e-5	Mean platelet volume;
THYM	cis	rs2456568	0.802	rs10765639	chr11:93636194	G/A	cg26875233	chr11:93583750	C11orf90	-0.53	-5.53	-0.49	2.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs11096990	0.855	rs6855008	chr4:39173626	A/G	cg24403649	chr4:39172243	NA	-0.66	-5.61	-0.5	1.99e-7	Cognitive function;
THYM	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg06713675	chr4:122721982	EXOSC9	-0.85	-9.54	-0.7	1.57e-15	Type 2 diabetes;
THYM	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg07606381	chr6:8435919	SLC35B3	-0.63	-4.66	-0.43	1.03e-5	Motion sickness;
THYM	cis	rs6598541	0.925	rs11634241	chr15:99259016	C/T	cg13297560	chr15:99320054	IGF1R	-0.44	-4.45	-0.42	2.29e-5	Urate levels;
THYM	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg01528321	chr10:82214614	TSPAN14	-0.63	-5.31	-0.48	7.07e-7	Post bronchodilator FEV1;
THYM	cis	rs34638657	0.872	rs6564982	chr16:82167193	C/T	cg09439754	chr16:82129088	HSD17B2	-0.57	-4.9	-0.45	3.93e-6	Lung adenocarcinoma;
THYM	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	9.66	0.7	8.9e-16	Platelet count;
THYM	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg12011299	chr4:100065546	ADH4	0.87	8.38	0.65	4.76e-13	Smoking initiation;
THYM	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg13175981	chr1:150552382	MCL1	0.81	6.23	0.54	1.25e-8	Tonsillectomy;
THYM	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.01	-9.8	-0.71	4.35e-16	Primary sclerosing cholangitis;
THYM	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg15445000	chr17:37608096	MED1	0.44	5.07	0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-4.61	-0.43	1.26e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg23711669	chr6:146136114	FBXO30	-0.82	-7.62	-0.62	1.89e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11690935	0.959	rs77280952	chr2:172620151	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.8	-5.67	-0.5	1.52e-7	Schizophrenia;
THYM	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg16594139	chr19:49340574	PLEKHA4;HSD17B14	0.92	5.33	0.48	6.65e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs6687430	1.000	rs6687430	chr1:10633245	A/G	cg20482658	chr1:10539492	PEX14	0.38	5.08	0.46	1.86e-6	Hand grip strength;
THYM	cis	rs28595532	0.920	rs114683212	chr4:119760209	A/G	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg04317338	chr11:64019027	PLCB3	0.87	6.04	0.53	3.05e-8	Mean platelet volume;
THYM	cis	rs4654899	0.827	rs12564330	chr1:21207495	A/C	cg01072550	chr1:21505969	NA	0.71	6.51	0.56	3.53e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs7572733	0.534	rs700670	chr2:198687284	T/C	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg24060327	chr5:131705240	SLC22A5	-0.81	-6.71	-0.57	1.4e-9	Breast cancer;
THYM	cis	rs8133932	0.727	rs2150453	chr21:47253215	C/T	cg20357416	chr21:47294739	PCBP3	0.96	6.01	0.52	3.46e-8	Schizophrenia;
THYM	cis	rs7172809	0.599	rs17471480	chr15:77755550	A/G	cg10437265	chr15:77819839	NA	0.52	4.91	0.45	3.71e-6	Glucose homeostasis traits;
THYM	cis	rs6473252	0.584	rs11777950	chr8:81801539	A/G	cg08595989	chr8:81827712	NA	-0.5	-5.45	-0.49	3.9e-7	Breast cancer;
THYM	cis	rs7927592	0.513	rs689075	chr11:68194432	A/C	cg16797656	chr11:68205561	LRP5	0.53	6.16	0.53	1.72e-8	Total body bone mineral density;
THYM	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg20295408	chr7:1910781	MAD1L1	-0.64	-4.97	-0.45	2.91e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs227833	0.559	rs9296445	chr6:44649758	C/T	cg17584530	chr6:45587862	NA	0.71	4.82	0.44	5.44e-6	Monobrow;
THYM	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg02640540	chr1:67518911	SLC35D1	0.58	4.67	0.43	9.97e-6	Lymphocyte percentage of white cells;
THYM	cis	rs10208940	0.614	rs13413327	chr2:68762501	C/T	cg09157127	chr2:69201416	GKN1	0.75	4.47	0.42	2.2e-5	Urate levels in lean individuals;
THYM	trans	rs1445130	0.786	rs16985390	chr2:18837158	C/A	cg24866363	chr5:80050837	MSH3	-0.9	-7.28	-0.6	9.46e-11	Bulimia nervosa;
THYM	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs912057	0.526	rs201061	chr6:6730512	C/T	cg13809441	chr6:6737631	NA	-0.5	-5.83	-0.51	7.54e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs35110281	0.601	rs7278282	chr21:44981958	T/G	cg27168131	chr21:44088823	PDE9A	-0.45	-4.47	-0.42	2.12e-5	Mean corpuscular volume;
THYM	cis	rs9549260	0.755	rs2721045	chr13:41162632	T/A	cg21288729	chr13:41239152	FOXO1	0.73	5.66	0.5	1.62e-7	Red blood cell count;
THYM	cis	rs9796	0.835	rs3100807	chr15:41292206	G/A	cg21153102	chr15:41252147	NA	-0.67	-6.0	-0.52	3.61e-8	Menopause (age at onset);
THYM	cis	rs8016982	0.674	rs1957549	chr14:81706179	G/A	cg01989461	chr14:81687754	GTF2A1	0.88	7.94	0.63	4.02e-12	Schizophrenia;
THYM	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.12	-0.64	1.72e-12	Mean corpuscular volume;
THYM	cis	rs10501293	0.746	rs7952577	chr11:43017703	G/A	cg03447554	chr11:43094025	NA	0.6	4.46	0.42	2.21e-5	Cognitive performance;
THYM	cis	rs7666738	0.570	rs1921415	chr4:99093804	C/T	cg17366294	chr4:99064904	C4orf37	0.48	5.43	0.49	4.3e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2046867	0.818	rs6789061	chr3:72888690	C/T	cg25664220	chr3:72788482	NA	-0.96	-7.85	-0.63	6.21e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7523273	0.606	rs7144	chr1:207967719	A/G	cg22525895	chr1:207977042	MIR29B2	-0.97	-9.93	-0.71	2.37e-16	Schizophrenia;
THYM	cis	rs7626444	0.543	rs843528	chr3:196480335	G/A	cg12930392	chr3:196481615	PAK2	0.4	4.92	0.45	3.58e-6	Monocyte count;
THYM	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.73	-0.44	7.7e-6	Crohn's disease;
THYM	cis	rs11696845	0.626	rs6073537	chr20:43378270	A/G	cg25301532	chr20:43378953	KCNK15	-0.59	-4.7	-0.43	8.89e-6	Obesity-related traits;
THYM	cis	rs7103648	0.669	rs12577383	chr11:47774238	C/T	cg20307385	chr11:47447363	PSMC3	0.82	6.53	0.56	3.26e-9	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg06850241	chr22:41845214	NA	0.54	4.77	0.44	6.68e-6	Vitiligo;
THYM	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.24e-7	Corneal astigmatism;
THYM	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg06728252	chr6:26598149	ABT1	-0.44	-5.24	-0.47	9.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2290159	0.800	rs73132351	chr3:12688284	A/G	cg05467012	chr3:12595696	NA	0.71	4.57	0.42	1.46e-5	Cholesterol, total;
THYM	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22857025	chr5:266934	NA	-1.5	-9.71	-0.71	6.9e-16	Breast cancer;
THYM	cis	rs112591243	0.685	rs117450955	chr21:47990916	T/A	cg26904215	chr21:47823096	PCNT	-0.99	-4.51	-0.42	1.86e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs12935418	0.583	rs2549836	chr16:81023081	T/C	cg16651780	chr16:81037892	C16orf61	-0.85	-6.53	-0.56	3.16e-9	Mean corpuscular volume;
THYM	cis	rs1061377	1.000	rs9999327	chr4:39111731	C/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs860818	1.000	rs858281	chr7:23250567	G/A	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs886716	0.518	rs4722612	chr7:26611969	C/G	cg16880946	chr7:27188465	HOXA6	0.72	4.48	0.42	2.06e-5	Smoking behavior;
THYM	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg00012203	chr2:219082015	ARPC2	-0.67	-5.5	-0.49	3.17e-7	Pyoderma gangrenosum in inflammatory bowel disease;
THYM	cis	rs17030434	0.784	rs11099900	chr4:154669471	C/T	cg14289246	chr4:154710475	SFRP2	-0.75	-5.67	-0.5	1.56e-7	Electrocardiographic conduction measures;
THYM	cis	rs6570726	0.905	rs396492	chr6:145816180	C/G	cg23711669	chr6:146136114	FBXO30	0.77	7.34	0.6	7.09e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg11965913	chr1:205819406	PM20D1	0.89	9.31	0.69	4.85e-15	Menarche (age at onset);
THYM	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg07424592	chr7:64974309	NA	1.02	5.29	0.48	7.76e-7	Diabetic kidney disease;
THYM	cis	rs61931739	0.929	rs7955240	chr12:34066388	G/A	cg10856724	chr12:34555212	NA	0.6	5.36	0.48	5.8e-7	Morning vs. evening chronotype;
THYM	cis	rs7640424	0.620	rs7637244	chr3:107815763	T/A	cg09227934	chr3:107805635	CD47	-0.65	-4.99	-0.46	2.68e-6	Body mass index;
THYM	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg00255919	chr5:131827918	IRF1	-0.45	-4.9	-0.45	3.86e-6	Asthma (sex interaction);
THYM	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg23583168	chr7:148888333	NA	-0.93	-10.14	-0.72	8.24e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6546324	0.540	rs4671811	chr2:67827416	G/A	cg18237512	chr2:67827392	NA	-0.78	-4.63	-0.43	1.16e-5	Endometriosis;
THYM	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg10911889	chr6:126070802	HEY2	0.57	4.6	0.43	1.29e-5	Brugada syndrome;
THYM	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg06850241	chr22:41845214	NA	0.48	4.55	0.42	1.61e-5	Vitiligo;
THYM	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg02725872	chr8:58115012	NA	-1.11	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7851660	0.809	rs3808893	chr9:100663745	C/T	cg13688889	chr9:100608707	NA	-0.79	-5.75	-0.51	1.06e-7	Strep throat;
THYM	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.85	-7.01	-0.58	3.42e-10	Systemic lupus erythematosus;
THYM	cis	rs2404602	0.735	rs2468130	chr15:76796496	T/C	cg23625390	chr15:77176239	SCAPER	-0.61	-4.52	-0.42	1.75e-5	Blood metabolite levels;
THYM	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14159672	chr1:205819179	PM20D1	0.97	10.17	0.72	7.06e-17	Menarche (age at onset);
THYM	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg22166914	chr1:53195759	ZYG11B	-0.91	-10.71	-0.74	5.05e-18	Monocyte count;
THYM	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.66	0.43	1.01e-5	Bipolar disorder;
THYM	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg02696790	chr15:75250997	RPP25	-0.51	-5.37	-0.48	5.63e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg04398451	chr17:18023971	MYO15A	-0.76	-6.96	-0.58	4.39e-10	Total body bone mineral density;
THYM	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg21775007	chr8:11205619	TDH	-0.73	-5.66	-0.5	1.63e-7	Retinal vascular caliber;
THYM	cis	rs6876348	0.598	rs2577539	chr5:128301211	A/G	cg02841155	chr5:128301328	SLC27A6	-0.53	-5.39	-0.48	5.04e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4482178	0.850	rs55768080	chr13:86263394	A/G	cg25308322	chr13:86268291	NA	0.68	4.95	0.45	3.18e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs2273669	0.667	rs113477421	chr6:109310268	C/T	cg17117243	chr6:109341365	SESN1	-0.89	-5.39	-0.48	5.17e-7	Prostate cancer;
THYM	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg00271210	chr6:167070053	RPS6KA2	0.72	7.96	0.63	3.73e-12	Crohn's disease;
THYM	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.89	5.94	0.52	4.6e-8	Gut microbiome composition (summer);
THYM	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg00376283	chr12:123451042	ABCB9	-0.72	-4.88	-0.45	4.24e-6	Neutrophil percentage of white cells;
THYM	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg04518342	chr5:131593106	PDLIM4	0.49	5.45	0.49	3.91e-7	Breast cancer;
THYM	trans	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg10856724	chr12:34555212	NA	-1.01	-9.23	-0.69	7.34e-15	Bladder cancer;
THYM	cis	rs6956675	1.000	rs1967430	chr7:62599308	C/T	cg27518014	chr7:62859535	LOC100287834	0.66	5.05	0.46	2.14e-6	Obesity-related traits;
THYM	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg13390004	chr1:15929781	NA	0.62	4.72	0.44	8.11e-6	Systolic blood pressure;
THYM	cis	rs6430585	0.528	rs309166	chr2:136667487	C/T	cg07169764	chr2:136633963	MCM6	0.95	8.88	0.67	4.06e-14	Corneal structure;
THYM	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg15592062	chr6:167189543	RPS6KA2	-0.49	-5.05	-0.46	2.16e-6	Crohn's disease;
THYM	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg06481639	chr22:41940642	POLR3H	-0.76	-4.94	-0.45	3.29e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs6768930	0.509	rs6787090	chr3:57751032	A/G	cg24033633	chr3:57945695	NA	-0.38	-5.27	-0.48	8.55e-7	Obesity-related traits;
THYM	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg00639195	chr15:79103007	ADAMTS7	-0.74	-5.87	-0.52	6.46e-8	Coronary artery disease or large artery stroke;
THYM	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg17524265	chr8:144659883	NAPRT1	-1.05	-5.88	-0.52	6.16e-8	Attention deficit hyperactivity disorder;
THYM	trans	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg07211511	chr3:129823064	LOC729375	1.26	8.62	0.66	1.46e-13	Blood pressure (smoking interaction);
THYM	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg20295408	chr7:1910781	MAD1L1	-0.63	-5.03	-0.46	2.34e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4654899	0.802	rs3767247	chr1:21227338	T/C	cg01072550	chr1:21505969	NA	-0.69	-6.08	-0.53	2.44e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs7814319	0.700	rs871798	chr8:97257982	T/C	cg20787634	chr8:97240163	UQCRB	-0.73	-7.19	-0.59	1.47e-10	Lung function (FVC);
THYM	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-5.77	-0.51	9.69e-8	Gut microbiome composition (summer);
THYM	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	5.54	0.49	2.68e-7	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs4455778	0.580	rs4437600	chr7:49090274	G/A	cg26309511	chr7:48887640	NA	0.68	5.94	0.52	4.63e-8	Lung cancer in never smokers;
THYM	cis	rs12216545	0.686	rs2373811	chr7:150251651	A/G	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7216064	0.953	rs80135947	chr17:65836001	A/C	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg06808227	chr14:105710500	BRF1	-1.04	-9.07	-0.68	1.64e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11690935	0.959	rs2674484	chr2:172574612	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.88	-6.5	-0.55	3.76e-9	Schizophrenia;
THYM	trans	rs8002861	0.664	rs2184882	chr13:44450346	C/T	cg17145862	chr1:211918768	LPGAT1	0.88	8.09	0.64	1.97e-12	Leprosy;
THYM	cis	rs6598955	0.585	rs6659822	chr1:26626408	C/A	cg19677267	chr1:26645161	CD52;UBXN11	0.49	4.49	0.42	2.04e-5	Obesity-related traits;
THYM	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg06481639	chr22:41940642	POLR3H	0.78	5.35	0.48	6.02e-7	Vitiligo;
THYM	cis	rs7113850	0.541	rs78048500	chr11:24217764	T/G	ch.11.24196551F	chr11:24239977	NA	1.03	5.41	0.49	4.67e-7	Bone fracture in osteoporosis;
THYM	cis	rs7319311	1.000	rs7320755	chr13:111031092	C/G	cg05272587	chr13:111038400	COL4A2	-0.65	-5.18	-0.47	1.23e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg01699819	chr7:1052092	C7orf50	-0.84	-7.66	-0.62	1.59e-11	Bronchopulmonary dysplasia;
THYM	cis	rs67311347	0.544	rs9814779	chr3:40340431	T/C	cg24209194	chr3:40518798	ZNF619	0.55	4.6	0.43	1.29e-5	Renal cell carcinoma;
THYM	cis	rs8067545	0.641	rs175922	chr17:19825579	T/C	cg20830565	chr17:20408647	MGC102966	-0.54	-4.83	-0.44	5.13e-6	Schizophrenia;
THYM	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg13390004	chr1:15929781	NA	0.63	4.79	0.44	6.2e-6	Systolic blood pressure;
THYM	cis	rs28595532	0.920	rs115354352	chr4:119750358	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs868036	0.718	rs4776982	chr15:68114974	C/T	cg24579218	chr15:68104479	NA	0.82	8.25	0.65	8.95e-13	Restless legs syndrome;
THYM	cis	rs2921073	0.604	rs2979140	chr8:8267202	T/A	cg06636001	chr8:8085503	FLJ10661	0.59	4.55	0.42	1.58e-5	Parkinson's disease;
THYM	cis	rs10799590	1.000	rs6686633	chr1:224878572	A/G	cg01808320	chr1:224927238	CNIH3	-0.53	-4.71	-0.44	8.31e-6	Opioid dependence;
THYM	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg19077165	chr18:44547161	KATNAL2	-0.63	-8.06	-0.64	2.21e-12	Personality dimensions;
THYM	cis	rs4851313	0.527	rs10183150	chr2:100939117	A/G	cg21926883	chr2:100939477	LONRF2	-0.65	-6.15	-0.53	1.82e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.64	8.83	0.67	5.25e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.81	-0.63	7.44e-12	Chronic sinus infection;
THYM	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg18252515	chr7:66147081	NA	-0.64	-4.87	-0.45	4.45e-6	Aortic root size;
THYM	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.95	0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03517284	chr6:25882590	NA	-0.82	-6.39	-0.55	6.09e-9	Blood metabolite levels;
THYM	cis	rs11190604	1.000	rs2495732	chr10:102357780	T/C	cg07570687	chr10:102243282	WNT8B	0.72	6.07	0.53	2.64e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11644478	chr21:40555479	PSMG1	-0.77	-6.66	-0.56	1.73e-9	Cognitive function;
THYM	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg14137381	chr5:502291	SLC9A3	-0.58	-4.48	-0.42	2.05e-5	Cystic fibrosis severity;
THYM	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg20203395	chr5:56204925	C5orf35	-0.68	-4.65	-0.43	1.07e-5	Initial pursuit acceleration;
THYM	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg03161606	chr19:29218774	NA	0.85	6.76	0.57	1.12e-9	Methadone dose in opioid dependence;
THYM	cis	rs2070488	0.965	rs2051216	chr3:38562288	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-6.55	-0.56	2.97e-9	Electrocardiographic conduction measures;
THYM	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg27129171	chr3:47204927	SETD2	0.69	6.63	0.56	2.04e-9	Colorectal cancer;
THYM	cis	rs4731207	0.596	rs12539580	chr7:124619404	C/T	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs9595908	0.709	rs9596222	chr13:33341817	A/G	cg12383807	chr13:33924137	NA	-0.53	-4.51	-0.42	1.84e-5	Body mass index;
THYM	cis	rs6687430	0.532	rs12028449	chr1:10617034	A/G	cg20482658	chr1:10539492	PEX14	-0.5	-6.32	-0.54	8.53e-9	Hand grip strength;
THYM	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg02228675	chr17:40259724	DHX58	-0.62	-5.13	-0.47	1.55e-6	Fibrinogen levels;
THYM	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.55	5.02	0.46	2.36e-6	Lymphocyte counts;
THYM	cis	rs10504073	0.647	rs10808744	chr8:49988984	A/G	cg00325661	chr8:49890786	NA	0.93	8.79	0.67	6.32e-14	Blood metabolite ratios;
THYM	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg00012203	chr2:219082015	ARPC2	-0.65	-5.33	-0.48	6.52e-7	Pyoderma gangrenosum in inflammatory bowel disease;
THYM	cis	rs36051895	0.632	rs12337481	chr9:5134599	T/G	cg02405213	chr9:5042618	JAK2	-1.03	-11.39	-0.76	1.84e-19	Pediatric autoimmune diseases;
THYM	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg11663144	chr21:46675770	NA	0.65	8.76	0.67	7.53e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7772486	0.754	rs697053	chr6:145989807	T/C	cg13319975	chr6:146136371	FBXO30	0.63	5.17	0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03517284	chr6:25882590	NA	0.74	5.94	0.52	4.61e-8	Blood metabolite levels;
THYM	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg06026331	chr20:60912101	LAMA5	-0.74	-5.76	-0.51	1.01e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs2552220	0.818	rs11776173	chr8:6006866	T/C	cg06481462	chr8:7005678	NA	0.45	4.76	0.44	6.83e-6	Interleukin-8 levels;
THYM	cis	rs11711311	0.712	rs6795099	chr3:113338782	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.57	-4.92	-0.45	3.7e-6	IgG glycosylation;
THYM	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg27211696	chr2:191398769	TMEM194B	-0.65	-5.18	-0.47	1.26e-6	Diastolic blood pressure;
THYM	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg17366294	chr4:99064904	C4orf37	0.57	6.93	0.58	5.01e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg05347473	chr6:146136440	FBXO30	0.58	4.52	0.42	1.8e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg27211696	chr2:191398769	TMEM194B	-0.6	-4.5	-0.42	1.94e-5	Diastolic blood pressure;
THYM	cis	rs11608355	0.618	rs7958220	chr12:109830980	T/C	cg10504392	chr12:110044639	NA	0.53	4.66	0.43	1.04e-5	Neuroticism;
THYM	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.27	6.26	0.54	1.09e-8	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8051149	0.576	rs731710	chr16:87884547	A/G	cg16773814	chr16:87644704	JPH3	-0.54	-5.39	-0.48	5.09e-7	Blood metabolite levels;
THYM	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs981844	1.000	rs2579917	chr4:154652648	T/G	cg09973105	chr4:154681532	RNF175	-0.59	-4.83	-0.44	5.3e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs8114671	0.935	rs633198	chr20:33778434	T/C	cg08999081	chr20:33150536	PIGU	-0.52	-4.69	-0.43	9.11e-6	Height;
THYM	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg10360139	chr7:1886902	MAD1L1	-0.61	-5.4	-0.48	4.86e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs12496230	0.909	rs13075691	chr3:66857626	T/A	cg23477460	chr3:66848765	NA	0.91	5.89	0.52	5.71e-8	Type 2 diabetes;
THYM	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg00078996	chr12:132293329	NA	-0.58	-5.68	-0.5	1.44e-7	Migraine;
THYM	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs6429082	0.521	rs704711	chr1:235629802	G/A	cg26050004	chr1:235667680	B3GALNT2	0.92	8.67	0.66	1.12e-13	Adiposity;
THYM	cis	rs11969893	0.850	rs3734351	chr6:101307131	C/T	cg12253828	chr6:101329408	ASCC3	1.19	6.88	0.58	6.48e-10	Economic and political preferences (immigration/crime);
THYM	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	5.41	0.49	4.77e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs11249608	0.636	rs6888539	chr5:178449010	T/A	cg01312482	chr5:178451176	ZNF879	-0.68	-5.27	-0.48	8.43e-7	Pubertal anthropometrics;
THYM	cis	rs2806561	0.765	rs668234	chr1:23515467	G/A	cg19743168	chr1:23544995	NA	0.55	5.64	0.5	1.77e-7	Height;
THYM	cis	rs61931739	0.533	rs4270002	chr12:34313126	G/T	cg10856724	chr12:34555212	NA	-0.62	-5.55	-0.49	2.62e-7	Morning vs. evening chronotype;
THYM	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.58	-4.93	-0.45	3.48e-6	Renal function-related traits (BUN);
THYM	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg15921436	chr17:44337874	NA	0.95	6.92	0.58	5.33e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg08847533	chr14:75593920	NEK9	-0.87	-8.79	-0.67	6.26e-14	Coronary artery disease;
THYM	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg03609598	chr5:56110824	MAP3K1	-0.81	-5.41	-0.49	4.67e-7	Initial pursuit acceleration;
THYM	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	4.97	0.45	3.01e-6	Height;
THYM	cis	rs7582180	0.764	rs4851293	chr2:100925106	A/T	cg08017756	chr2:100939284	LONRF2	-0.73	-7.51	-0.61	3.21e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-5.11	-0.46	1.64e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg21926883	chr2:100939477	LONRF2	-0.6	-5.46	-0.49	3.87e-7	Intelligence (multi-trait analysis);
THYM	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg16405210	chr4:1374714	KIAA1530	-1.02	-9.29	-0.69	5.53e-15	Longevity;
THYM	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg20608306	chr11:116969690	SIK3	0.56	6.58	0.56	2.51e-9	Blood protein levels;
THYM	cis	rs9311676	0.656	rs4399910	chr3:58389809	A/G	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.51	-4.79	-0.44	6.24e-6	Lymphocyte counts;
THYM	cis	rs62051538	0.602	rs4503808	chr16:31536542	T/C	cg10091996	chr16:31548640	NA	-0.5	-4.5	-0.42	1.96e-5	Mean corpuscular hemoglobin;
THYM	cis	rs7178572	0.568	rs7176302	chr15:77671216	C/G	cg22256960	chr15:77711686	NA	-1.05	-8.4	-0.65	4.29e-13	Type 2 diabetes;
THYM	cis	rs686320	1.000	rs3132770	chr11:65251317	G/A	cg13044675	chr11:65314161	LTBP3	0.86	4.61	0.43	1.25e-5	Hip circumference adjusted for BMI;
THYM	cis	rs314370	0.951	rs12667888	chr7:100474289	T/C	cg10426581	chr7:100472382	SRRT	1.13	8.97	0.68	2.57e-14	Resting heart rate;
THYM	cis	rs6918586	0.594	rs198842	chr6:26111448	C/T	cg03517284	chr6:25882590	NA	0.71	5.57	0.5	2.4e-7	Schizophrenia;
THYM	cis	rs12530845	1.000	rs56060450	chr7:135331777	C/T	cg23117316	chr7:135346802	PL-5283	-0.66	-5.88	-0.52	6.21e-8	Red blood cell traits;
THYM	cis	rs713587	0.967	rs6752378	chr2:25150116	C/A	cg15423357	chr2:25149977	NA	0.71	8.03	0.64	2.63e-12	Body mass index in non-asthmatics;
THYM	cis	rs4660531	1.000	rs34883982	chr1:41849873	C/T	cg19619003	chr1:41846758	NA	-0.24	-4.57	-0.42	1.49e-5	Bipolar disorder;
THYM	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg05283184	chr6:79620031	NA	0.91	8.88	0.67	4.11e-14	Intelligence (multi-trait analysis);
THYM	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	5.87	0.52	6.23e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4747241	0.705	rs4747246	chr10:74077393	C/T	cg07828833	chr10:74069493	NA	0.53	4.52	0.42	1.75e-5	Heschl's gyrus morphology;
THYM	cis	rs2806561	0.765	rs605367	chr1:23518524	T/C	cg19743168	chr1:23544995	NA	0.55	5.64	0.5	1.77e-7	Height;
THYM	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg04546413	chr19:29218101	NA	1.09	9.39	0.69	3.41e-15	Methadone dose in opioid dependence;
THYM	cis	rs17443541	0.507	rs10196380	chr2:200456655	G/C	cg03741458	chr2:200468445	NA	-0.8	-6.04	-0.53	3.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.63	-4.48	-0.42	2.05e-5	Gut microbiome composition (summer);
THYM	cis	rs919433	0.617	rs10931791	chr2:198573612	A/C	cg05783139	chr2:198650985	BOLL	-0.63	-5.0	-0.46	2.58e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7843479	1.000	rs7821592	chr8:21811530	C/G	cg17168535	chr8:21777572	XPO7	0.67	4.89	0.45	4.05e-6	Mean corpuscular volume;
THYM	cis	rs12930096	1.000	rs55947021	chr16:11678949	C/A	cg00403955	chr16:11680241	LITAF	-0.41	-4.46	-0.42	2.21e-5	QT interval;
THYM	cis	rs61931739	0.635	rs7138254	chr12:33914422	G/T	cg10856724	chr12:34555212	NA	-0.63	-5.9	-0.52	5.54e-8	Morning vs. evening chronotype;
THYM	cis	rs9788682	0.706	rs2568493	chr15:78740233	G/A	cg18825076	chr15:78729989	IREB2	-0.7	-5.36	-0.48	5.71e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs4606347	0.652	rs61780868	chr1:66162762	C/G	cg04111102	chr1:66153794	NA	0.6	4.47	0.42	2.14e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	7.68	0.62	1.38e-11	Platelet count;
THYM	trans	rs75518195	0.504	rs1449177	chr4:64843753	A/G	cg14706739	chr8:21916355	EPB49	0.69	6.85	0.57	7.17e-10	Triptolide cytotoxicity;
THYM	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg24642844	chr7:1081250	C7orf50	-0.73	-5.13	-0.47	1.51e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7107174	0.892	rs4945265	chr11:78027458	G/A	cg19901956	chr11:77921274	USP35	-0.69	-5.3	-0.48	7.42e-7	Testicular germ cell tumor;
THYM	cis	rs2898681	0.521	rs6833350	chr4:53740868	A/G	cg03786743	chr4:53727781	RASL11B	0.57	5.25	0.47	9.41e-7	Optic nerve measurement (cup area);
THYM	cis	rs2361710	0.669	rs12940486	chr17:78118569	T/C	cg09238746	chr17:78121135	EIF4A3	-0.78	-6.43	-0.55	5e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
THYM	cis	rs6768930	0.509	rs266846	chr3:57778634	C/G	cg24033633	chr3:57945695	NA	-0.39	-5.7	-0.5	1.37e-7	Obesity-related traits;
THYM	cis	rs6748734	0.625	rs4312490	chr2:241821481	A/G	cg02820040	chr2:241836501	C2orf54	-0.24	-4.65	-0.43	1.08e-5	Urinary metabolites;
THYM	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg27588902	chr6:42928151	GNMT	0.53	5.04	0.46	2.22e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg03433033	chr1:76189801	ACADM	-0.52	-5.42	-0.49	4.44e-7	Daytime sleep phenotypes;
THYM	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg26769984	chr7:1090371	C7orf50	0.6	4.51	0.42	1.86e-5	Bronchopulmonary dysplasia;
THYM	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.64	-4.6	-0.43	1.32e-5	Body mass index (adult);
THYM	cis	rs669446	0.533	rs3791042	chr1:44219275	T/C	cg15962314	chr1:44399869	ARTN	0.47	5.05	0.46	2.16e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7107770	0.943	rs35408472	chr11:125104632	T/C	cg07747661	chr11:125106135	PKNOX2	-0.84	-5.02	-0.46	2.42e-6	Photic sneeze reflex;
THYM	cis	rs346785	0.551	rs347677	chr17:74274596	C/T	cg09812376	chr17:74270190	QRICH2	-0.8	-12.05	-0.78	7.6e-21	White matter hyperintensities in ischemic stroke;
THYM	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg11764359	chr7:65958608	NA	0.8	6.31	0.54	8.7e-9	Aortic root size;
THYM	cis	rs154659	0.961	rs164739	chr16:89667699	C/G	cg01710450	chr16:89662404	CPNE7	-0.72	-6.15	-0.53	1.79e-8	Tanning;
THYM	cis	rs6480314	0.636	rs61854782	chr10:69991749	T/G	cg27159792	chr10:69524182	NA	0.79	4.72	0.44	8.11e-6	Optic nerve measurement (disc area);
THYM	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg10523679	chr1:76189770	ACADM	-0.55	-4.67	-0.43	9.97e-6	Daytime sleep phenotypes;
THYM	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.27	10.28	0.73	4.18e-17	Platelet count;
THYM	cis	rs34375054	0.752	rs35505608	chr12:125662252	G/T	cg25124228	chr12:125621409	AACS	-0.64	-4.53	-0.42	1.7e-5	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs9563576	0.778	rs9563564	chr13:58546777	A/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg13319975	chr6:146136371	FBXO30	-0.65	-5.24	-0.47	9.55e-7	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9291683	0.655	rs2278121	chr4:10096134	G/A	cg11266682	chr4:10021025	SLC2A9	-0.51	-6.47	-0.55	4.27e-9	Bone mineral density;
THYM	cis	rs1178127	0.722	rs1178132	chr7:18771108	C/G	cg13420273	chr7:18810212	HDAC9	-0.53	-4.82	-0.44	5.38e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs2304206	0.614	rs12104272	chr19:50148052	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	-0.88	-6.74	-0.57	1.24e-9	Vitiligo;
THYM	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg21433313	chr16:3507492	NAT15	0.86	9.14	0.68	1.13e-14	Tuberculosis;
THYM	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg09436375	chr6:42928200	GNMT	-0.4	-5.14	-0.47	1.47e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6032067	0.714	rs6032073	chr20:43881630	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.4	-4.72	-0.44	8.03e-6	Blood protein levels;
THYM	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg24642844	chr7:1081250	C7orf50	-1.05	-5.84	-0.51	7.35e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12935418	0.616	rs9921448	chr16:81009490	A/G	cg16651780	chr16:81037892	C16orf61	0.88	6.52	0.56	3.34e-9	Mean corpuscular volume;
THYM	cis	rs56104184	0.887	rs4801778	chr19:49370609	G/T	cg21252483	chr19:49399788	TULP2	-0.76	-5.34	-0.48	6.46e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg04756594	chr16:24857601	SLC5A11	0.75	5.23	0.47	1.01e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7851660	0.967	rs4743134	chr9:100598568	C/A	cg13688889	chr9:100608707	NA	-0.83	-7.31	-0.6	8.28e-11	Strep throat;
THYM	cis	rs2235573	0.662	rs2076370	chr22:38463968	A/G	cg19171272	chr22:38449367	NA	-0.51	-5.29	-0.48	7.96e-7	Glioblastoma;Glioma;
THYM	cis	rs13202913	0.652	rs9371528	chr6:151832668	G/A	cg03596678	chr6:151814994	C6orf97	-0.69	-4.58	-0.43	1.41e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	5.19	0.47	1.2e-6	Schizophrenia;
THYM	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-4.93	-0.45	3.45e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg00495681	chr13:53174319	NA	-0.74	-6.88	-0.58	6.44e-10	Lewy body disease;
THYM	cis	rs36051895	0.593	rs12340303	chr9:5176147	C/T	cg02405213	chr9:5042618	JAK2	-0.99	-10.66	-0.74	6.38e-18	Pediatric autoimmune diseases;
THYM	cis	rs2976388	1.000	rs2920298	chr8:143763043	A/G	cg06565975	chr8:143823917	SLURP1	-0.45	-5.23	-0.47	9.95e-7	Urinary tract infection frequency;
THYM	trans	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg25517755	chr10:38738941	LOC399744	-0.76	-6.92	-0.58	5.26e-10	Corneal astigmatism;
THYM	cis	rs61931739	0.782	rs451940	chr12:34196005	T/C	cg06521331	chr12:34319734	NA	-0.58	-4.86	-0.45	4.58e-6	Morning vs. evening chronotype;
THYM	cis	rs28595532	0.841	rs115851302	chr4:119776504	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.76	0.51	1.02e-7	Cannabis dependence symptom count;
THYM	cis	rs6570726	0.537	rs1280279	chr6:145884048	G/T	cg13319975	chr6:146136371	FBXO30	-0.72	-5.49	-0.49	3.4e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg08213375	chr14:104286397	PPP1R13B	0.46	4.78	0.44	6.34e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg06565975	chr8:143823917	SLURP1	0.44	4.93	0.45	3.51e-6	Urinary tract infection frequency;
THYM	cis	rs6988636	1.000	rs57322232	chr8:124193532	A/G	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs4819052	0.851	rs2838867	chr21:46713092	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	5.12	0.47	1.59e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs8073060	0.544	rs7211724	chr17:33993414	C/G	cg19694781	chr19:47549865	TMEM160	-1.06	-9.08	-0.68	1.54e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg22920501	chr2:26401640	FAM59B	-0.83	-7.3	-0.6	8.69e-11	Gut microbiome composition (summer);
THYM	cis	rs10887741	0.532	rs791883	chr10:89409287	A/T	cg13926569	chr10:89418898	PAPSS2	-0.63	-5.85	-0.51	7.1e-8	Exercise (leisure time);
THYM	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg00686598	chr14:53173677	PSMC6	1.52	7.73	0.62	1.09e-11	Alzheimer's disease (late onset);
THYM	cis	rs7605378	1.000	rs10194076	chr2:200677663	T/C	cg17644776	chr2:200775616	C2orf69	0.64	4.97	0.45	2.96e-6	Osteoporosis;
THYM	cis	rs2734839	0.964	rs1107162	chr11:113289037	A/G	cg14159747	chr11:113255604	NA	-0.32	-6.41	-0.55	5.61e-9	Information processing speed;
THYM	cis	rs892961	1.000	rs2117924	chr17:75401310	C/T	cg05865280	chr17:75406074	SEPT9	0.5	8.59	0.66	1.73e-13	Airflow obstruction;
THYM	cis	rs6686842	0.798	rs12037263	chr1:41482500	C/G	cg03387723	chr1:41708464	SCMH1	-0.44	-5.01	-0.46	2.46e-6	Height;
THYM	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg15448220	chr1:150897856	SETDB1	0.87	7.04	0.59	2.97e-10	Melanoma;
THYM	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg09549813	chr16:4587862	C16orf5	-0.48	-4.88	-0.45	4.32e-6	Schizophrenia;
THYM	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg05973401	chr12:123451056	ABCB9	0.67	4.54	0.42	1.63e-5	Neutrophil percentage of white cells;
THYM	cis	rs9733	0.650	rs12406712	chr1:150545084	C/A	cg18016565	chr1:150552671	MCL1	-0.57	-4.55	-0.42	1.61e-5	Tonsillectomy;
THYM	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg18252515	chr7:66147081	NA	-1.6	-8.8	-0.67	6.03e-14	Diabetic kidney disease;
THYM	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg06064525	chr11:970664	AP2A2	-0.35	-6.59	-0.56	2.4e-9	Alzheimer's disease (late onset);
THYM	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg26384229	chr12:38710491	ALG10B	0.97	7.89	0.63	5.19e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg08916839	chr5:415575	AHRR	0.92	5.92	0.52	5.12e-8	Fat distribution (HIV);
THYM	trans	rs34156428	1.000	rs35670829	chr11:16494472	C/T	cg02688867	chr12:133019854	NA	0.54	6.89	0.58	6.12e-10	Coronary artery disease;
THYM	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg08773314	chr2:239334832	ASB1	0.64	9.75	0.71	5.79e-16	Multiple system atrophy;
THYM	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3796352	1.000	rs59583591	chr3:53119581	T/C	cg07884673	chr3:53033167	SFMBT1	0.93	4.63	0.43	1.18e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs6665290	0.669	rs12406714	chr1:227177061	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.08	-12.43	-0.79	1.26e-21	Myeloid white cell count;
THYM	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg03433033	chr1:76189801	ACADM	-0.51	-5.32	-0.48	6.86e-7	Daytime sleep phenotypes;
THYM	cis	rs13082711	1.000	rs13082711	chr3:27537909	T/C	cg02860705	chr3:27208620	NA	0.76	4.94	0.45	3.31e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	5.73	0.51	1.18e-7	Blood metabolite levels;
THYM	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs977987	0.806	rs12924920	chr16:75440133	G/A	cg03315344	chr16:75512273	CHST6	0.77	6.31	0.54	8.75e-9	Dupuytren's disease;
THYM	cis	rs986417	0.748	rs1955691	chr14:61004128	G/A	cg27398547	chr14:60952738	C14orf39	1.12	6.0	0.52	3.61e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg11752832	chr7:134001865	SLC35B4	0.62	4.69	0.43	9.25e-6	Mean platelet volume;
THYM	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.17	11.49	0.76	1.16e-19	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6456042	1.000	rs3127420	chr6:166538548	T/C	cg11088901	chr6:166572345	T	-0.52	-4.89	-0.45	4.16e-6	Asthma;
THYM	cis	rs490234	0.841	rs490333	chr9:128354569	T/C	cg14078157	chr9:128172775	NA	0.67	5.36	0.48	5.78e-7	Mean arterial pressure;
THYM	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs4523957	0.757	rs1002135	chr17:2097583	T/G	cg16513277	chr17:2031491	SMG6	-0.83	-8.28	-0.65	7.74e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7943358	0.955	rs12363664	chr11:15694529	G/A	cg11966998	chr11:15692519	NA	-0.5	-4.92	-0.45	3.69e-6	Gut microbiome composition (summer);
THYM	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg05234568	chr11:5960015	NA	-0.63	-5.61	-0.5	2.02e-7	DNA methylation (variation);
THYM	cis	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg14019146	chr3:50243930	SLC38A3	-0.86	-7.39	-0.6	5.62e-11	Intelligence (multi-trait analysis);
THYM	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.7	-5.99	-0.52	3.77e-8	Renal function-related traits (BUN);
THYM	cis	rs1158570	0.835	rs6470816	chr8:131349715	C/T	cg16277922	chr8:131349729	ASAP1	-0.67	-5.98	-0.52	3.91e-8	Platelet count;
THYM	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1957429	0.803	rs10873177	chr14:65318228	G/C	cg23373153	chr14:65346875	NA	0.92	5.01	0.46	2.47e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs2069036	0.903	rs4748244	chr10:16118485	T/A	cg26633223	chr10:15133461	NA	0.68	4.84	0.44	5e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg02891314	chr5:179741120	GFPT2	0.91	7.29	0.6	9.3e-11	Height;
THYM	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg17366294	chr4:99064904	C4orf37	0.51	5.92	0.52	5.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg04731861	chr2:219085781	ARPC2	-0.56	-5.31	-0.48	7.06e-7	Colorectal cancer;
THYM	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.61	-5.1	-0.46	1.77e-6	Coronary artery disease;
THYM	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs12594515	0.506	rs74199860	chr15:45989190	C/T	cg01629716	chr15:45996671	NA	0.49	5.0	0.46	2.61e-6	Waist circumference;Weight;
THYM	cis	rs3755605	0.864	rs6784040	chr3:169770587	C/T	cg18444028	chr3:169782040	GPR160	-0.57	-4.7	-0.43	8.91e-6	Testicular germ cell tumor;
THYM	cis	rs10095849	0.576	rs4376471	chr8:39458399	A/G	cg22755526	chr8:38854673	TM2D2;ADAM9	0.62	4.61	0.43	1.24e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg04287289	chr16:89883240	FANCA	0.62	5.81	0.51	8.26e-8	Vitiligo;
THYM	cis	rs2273669	0.667	rs12198088	chr6:109338433	C/T	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg03609598	chr5:56110824	MAP3K1	-0.85	-5.85	-0.51	6.86e-8	Initial pursuit acceleration;
THYM	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg18904891	chr8:8559673	CLDN23	0.68	5.08	0.46	1.89e-6	Obesity-related traits;
THYM	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg17644776	chr2:200775616	C2orf69	-0.85	-4.51	-0.42	1.84e-5	Schizophrenia;
THYM	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9543976	1.000	rs3818355	chr13:76196867	C/T	cg01531495	chr13:76123901	UCHL3	0.74	5.02	0.46	2.46e-6	Diabetic retinopathy;
THYM	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg09307838	chr4:120376055	NA	0.76	5.41	0.49	4.75e-7	Corneal astigmatism;
THYM	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg06271696	chr7:157225062	NA	-0.75	-6.62	-0.56	2.12e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs4285028	0.948	rs34478505	chr3:121694071	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs28785552	0.776	rs12978372	chr19:53242074	C/T	cg22067481	chr19:53234126	ZNF611	-0.8	-7.7	-0.62	1.26e-11	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs7107174	1.000	rs7101429	chr11:77992967	A/G	cg19901956	chr11:77921274	USP35	-0.73	-5.5	-0.49	3.25e-7	Testicular germ cell tumor;
THYM	cis	rs9876781	1.000	rs6442118	chr3:48440047	G/A	cg06066452	chr3:48470258	PLXNB1	0.26	4.88	0.45	4.26e-6	Longevity;
THYM	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg05043794	chr9:111880884	C9orf5	-0.43	-6.21	-0.54	1.39e-8	Menarche (age at onset);
THYM	cis	rs939574	1.000	rs79013471	chr2:220096122	C/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.28	5.88	0.52	5.96e-8	Platelet distribution width;
THYM	cis	rs13177918	0.578	rs35919198	chr5:149831991	A/T	cg14059543	chr5:149831962	NA	-0.96	-8.07	-0.64	2.12e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7809950	1.000	rs2107713	chr7:107232369	C/T	cg23024343	chr7:107201750	COG5	-0.96	-7.8	-0.62	8e-12	Coronary artery disease;
THYM	cis	rs10484885	0.878	rs55750696	chr6:90552336	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.87	-7.73	-0.62	1.13e-11	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg18252515	chr7:66147081	NA	1.49	9.3	0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg00999904	chr2:3704751	ALLC	-1.12	-8.35	-0.65	5.4e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg12311346	chr5:56204834	C5orf35	0.61	4.73	0.44	7.84e-6	Initial pursuit acceleration;
THYM	trans	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg12386194	chr3:101231763	SENP7	0.67	4.99	0.46	2.75e-6	Colorectal cancer;
THYM	cis	rs6500395	1.000	rs4785535	chr16:48707659	A/G	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs740474	0.569	rs4912761	chr5:140881474	G/T	cg24137543	chr5:140893634	NA	0.39	4.74	0.44	7.38e-6	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs17854409	0.764	rs16983293	chr20:61479056	A/G	cg06598544	chr20:61472147	COL9A3	-1.14	-5.05	-0.46	2.17e-6	Obesity-related traits;
THYM	cis	rs4919687	0.550	rs12761195	chr10:104465374	T/C	cg15744005	chr10:104629667	AS3MT	-0.58	-4.58	-0.43	1.4e-5	Colorectal cancer;
THYM	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg03388043	chr17:80084554	CCDC57	-0.73	-6.17	-0.53	1.69e-8	Life satisfaction;
THYM	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg25427524	chr10:38739819	LOC399744	-0.73	-6.77	-0.57	1.04e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs7084402	0.967	rs1658438	chr10:60326583	A/G	cg09696939	chr10:60272079	BICC1	0.47	5.64	0.5	1.72e-7	Refractive error;
THYM	cis	rs4280164	0.551	rs8008406	chr14:24811159	C/T	cg18846074	chr14:24801073	ADCY4	0.53	4.46	0.42	2.29e-5	Parent of origin effect on language impairment (paternal);
THYM	cis	rs12681287	0.547	rs4961197	chr8:87512436	T/C	cg27223183	chr8:87520930	FAM82B	-0.71	-5.46	-0.49	3.8e-7	Caudate activity during reward;
THYM	trans	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg07393940	chr7:158741817	NA	-1.14	-9.25	-0.69	6.69e-15	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg24812749	chr6:127587940	RNF146	0.98	8.01	0.63	2.86e-12	Breast cancer;
THYM	cis	rs7267979	0.866	rs437635	chr20:25456888	A/G	cg03522245	chr20:25566470	NINL	0.57	4.48	0.42	2.1e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs747334	0.846	rs7897624	chr10:92708801	G/C	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs9479482	1.000	rs9478354	chr6:150334366	G/A	cg25797454	chr6:150327115	RAET1K	0.45	4.73	0.44	7.65e-6	Alopecia areata;
THYM	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg15432903	chr11:17409602	KCNJ11	0.59	6.89	0.58	6.06e-10	Type 2 diabetes;
THYM	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.58	-5.24	-0.47	9.62e-7	Coronary artery disease;
THYM	cis	rs4148087	0.860	rs9980310	chr21:43607858	C/T	cg09727148	chr21:43560719	UMODL1	0.63	5.01	0.46	2.47e-6	Eating disorder in bipolar disorder;
THYM	cis	rs6591182	0.503	rs11227241	chr11:65389890	G/C	cg17480646	chr11:65405466	SIPA1	-0.8	-6.84	-0.57	7.73e-10	Non-alcoholic fatty liver disease histology (lobular);
THYM	cis	rs7598759	0.548	rs6750795	chr2:232378231	T/C	cg19187155	chr2:232395269	NMUR1	0.85	7.64	0.62	1.71e-11	Noise-induced hearing loss;
THYM	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg14829155	chr15:31115871	NA	-0.74	-5.77	-0.51	9.71e-8	Huntington's disease progression;
THYM	cis	rs245880	0.740	rs245889	chr7:29190626	C/T	cg17163760	chr7:29186267	CPVL	-0.59	-4.94	-0.45	3.3e-6	Warfarin maintenance dose;
THYM	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg25072359	chr17:41440525	NA	0.63	4.48	0.42	2.11e-5	Menopause (age at onset);
THYM	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg06028605	chr16:24865363	SLC5A11	0.6	4.67	0.43	9.94e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6429082	0.967	rs1305557	chr1:235627837	C/T	cg26050004	chr1:235667680	B3GALNT2	0.54	4.78	0.44	6.47e-6	Adiposity;
THYM	cis	rs790123	0.842	rs2668339	chr3:122392433	G/C	cg17380795	chr3:122379686	NA	0.53	4.93	0.45	3.54e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2050392	0.630	rs303428	chr10:30739058	C/T	cg25182066	chr10:30743637	MAP3K8	0.55	4.75	0.44	7.18e-6	Inflammatory bowel disease;
THYM	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg19507638	chr5:93509721	C5orf36	-0.67	-4.5	-0.42	1.95e-5	Diabetic retinopathy;
THYM	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	5.78	0.51	9.49e-8	Height;
THYM	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.02	9.72	0.71	6.52e-16	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg11189052	chr15:85197271	WDR73	-0.72	-6.1	-0.53	2.29e-8	P wave terminal force;
THYM	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg05234568	chr11:5960015	NA	-0.6	-4.84	-0.44	4.97e-6	DNA methylation (variation);
THYM	cis	rs7192750	0.586	rs2335712	chr16:71906597	A/G	cg06353428	chr16:71660113	MARVELD3	-0.75	-4.69	-0.43	9.1e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs10924970	0.967	rs7518225	chr1:235394541	A/C	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg04362960	chr10:104952993	NT5C2	0.64	5.58	0.5	2.24e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs490234	0.812	rs4838268	chr9:128280315	G/T	cg14078157	chr9:128172775	NA	-0.67	-5.34	-0.48	6.36e-7	Mean arterial pressure;
THYM	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.84	4.66	0.43	1.04e-5	Initial pursuit acceleration;
THYM	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs79600951	0.516	rs4346201	chr16:56794937	A/G	cg04945457	chr16:56894587	NA	0.73	4.69	0.43	9.18e-6	HDL cholesterol;
THYM	cis	rs2692947	0.770	rs2315421	chr2:96497516	G/C	cg22654517	chr2:96458247	NA	0.65	4.88	0.45	4.29e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs4631830	0.720	rs7090326	chr10:51503375	A/T	cg10326726	chr10:51549505	MSMB	-0.53	-5.25	-0.47	9.14e-7	Prostate-specific antigen levels;
THYM	cis	rs17006441	0.966	rs62253059	chr3:69802443	G/A	cg18496212	chr3:69797108	MITF	0.66	6.94	0.58	4.87e-10	Hemoglobin concentration;
THYM	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg22105103	chr4:187893119	NA	0.89	9.3	0.69	5.11e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg25427524	chr10:38739819	LOC399744	-0.74	-6.75	-0.57	1.17e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs8051431	0.504	rs2335711	chr16:71907559	T/A	cg06353428	chr16:71660113	MARVELD3	0.72	5.11	0.46	1.64e-6	LDL cholesterol levels;
THYM	cis	rs6988636	0.901	rs2602001	chr8:124195974	T/C	cg23067535	chr8:124195133	FAM83A	0.99	5.62	0.5	1.89e-7	Urinary uromodulin levels;
THYM	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg24846343	chr22:24311635	DDTL	-0.38	-4.57	-0.42	1.47e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7084402	0.967	rs1658446	chr10:60314183	A/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg03806693	chr22:41940476	POLR3H	1.04	7.62	0.62	1.86e-11	Vitiligo;
THYM	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.52	4.59	0.43	1.35e-5	Blood metabolite levels;
THYM	cis	rs7119	0.651	rs12902449	chr15:77850926	A/G	cg10437265	chr15:77819839	NA	0.77	7.42	0.61	4.83e-11	Type 2 diabetes;
THYM	cis	rs16866061	1.000	rs2047134	chr2:225347713	A/C	cg12698349	chr2:225449008	CUL3	1.1	9.52	0.7	1.78e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22857025	chr5:266934	NA	-1.41	-9.13	-0.68	1.19e-14	Breast cancer;
THYM	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg25801113	chr15:45476975	SHF	-0.39	-4.5	-0.42	1.91e-5	Uric acid levels;
THYM	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg03452623	chr4:187889614	NA	-1.19	-19.33	-0.89	1.1e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg09307838	chr4:120376055	NA	0.7	5.27	0.48	8.48e-7	Corneal astigmatism;
THYM	cis	rs4718428	0.960	rs6460317	chr7:66390255	A/G	cg18252515	chr7:66147081	NA	-0.69	-5.2	-0.47	1.14e-6	Corneal structure;
THYM	cis	rs7267979	1.000	rs401166	chr20:25446308	C/G	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6032067	0.543	rs7272524	chr20:43908694	A/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.61	-6.91	-0.58	5.52e-10	Blood protein levels;
THYM	cis	rs1551570	0.755	rs11667630	chr19:10229297	A/C	cg16327482	chr19:10226339	EIF3G	-0.41	-5.96	-0.52	4.24e-8	Narcolepsy;
THYM	cis	rs67072384	1.000	rs2886367	chr11:72455034	C/T	cg01380194	chr11:72452482	ARAP1	-0.97	-5.26	-0.47	8.93e-7	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs9563576	0.778	rs36077647	chr13:58612314	C/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs9549260	0.755	rs4943797	chr13:41201633	A/G	cg21288729	chr13:41239152	FOXO1	-0.69	-5.44	-0.49	4.19e-7	Red blood cell count;
THYM	cis	rs72627123	0.737	rs61475846	chr14:74485781	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.86	4.91	0.45	3.77e-6	Morning vs. evening chronotype;
THYM	cis	rs9649213	0.555	rs6968193	chr7:97915902	C/T	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs34638657	0.687	rs2303265	chr16:82203705	A/C	cg09439754	chr16:82129088	HSD17B2	-0.51	-4.99	-0.46	2.72e-6	Lung adenocarcinoma;
THYM	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg12031863	chr16:4587854	C16orf5	-0.46	-4.94	-0.45	3.33e-6	Schizophrenia;
THYM	trans	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg14008862	chr17:28927542	LRRC37B2	0.86	4.61	0.43	1.24e-5	Body mass index;
THYM	cis	rs3820068	0.608	rs10927836	chr1:16034368	G/C	cg13390004	chr1:15929781	NA	0.65	4.81	0.44	5.56e-6	Systolic blood pressure;
THYM	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs9302690	1.000	rs62037100	chr16:57430934	T/G	cg27017172	chr16:57497170	POLR2C	0.82	4.59	0.43	1.36e-5	Blood protein levels;
THYM	cis	rs9302065	0.636	rs2389235	chr13:95955623	G/T	cg26751094	chr13:95954534	ABCC4	-0.47	-5.25	-0.47	9.14e-7	Blood metabolite levels;
THYM	cis	rs595982	0.546	rs10401443	chr19:49402059	C/A	cg19746536	chr19:49375674	PPP1R15A	0.99	9.63	0.7	1.03e-15	Red cell distribution width;
THYM	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg03388043	chr17:80084554	CCDC57	0.66	5.54	0.49	2.66e-7	Life satisfaction;
THYM	cis	rs2282300	0.739	rs1222221	chr11:30342738	A/G	cg06241208	chr11:30344200	C11orf46	-0.79	-5.98	-0.52	3.94e-8	Morning vs. evening chronotype;
THYM	cis	rs854765	0.647	rs854791	chr17:18029857	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.56	4.67	0.43	9.74e-6	Total body bone mineral density;
THYM	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg17202724	chr17:61916730	SMARCD2	-0.45	-4.57	-0.42	1.49e-5	Prudent dietary pattern;
THYM	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg06238570	chr21:40685208	BRWD1	0.9	6.33	0.54	7.95e-9	Cognitive function;
THYM	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg12463550	chr7:65579703	CRCP	-0.57	-4.76	-0.44	7.01e-6	Aortic root size;
THYM	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg24692254	chr21:30365293	RNF160	-0.99	-9.12	-0.68	1.25e-14	Dental caries;
THYM	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg26031613	chr14:104095156	KLC1	0.79	5.22	0.47	1.06e-6	Body mass index;
THYM	cis	rs1950500	0.550	rs7148384	chr14:24828814	C/T	cg01658259	chr14:24837143	NFATC4	0.57	4.52	0.42	1.77e-5	Height;
THYM	cis	rs295140	0.546	rs295119	chr2:201117944	C/T	cg03447810	chr2:200324230	SATB2	0.62	4.59	0.43	1.37e-5	QT interval;
THYM	cis	rs4786125	0.626	rs11077095	chr16:6916451	C/T	cg03623568	chr16:6915990	A2BP1	0.75	5.22	0.47	1.04e-6	Heart rate variability traits (SDNN);
THYM	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg04455712	chr21:45112962	RRP1B	0.52	4.88	0.45	4.19e-6	Mean corpuscular volume;
THYM	cis	rs9814567	0.752	rs4955542	chr3:134328740	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs208520	0.609	rs208436	chr6:66897470	G/A	cg07460842	chr6:66804631	NA	-0.68	-4.51	-0.42	1.87e-5	Exhaled nitric oxide output;
THYM	cis	rs13315871	1.000	rs71311858	chr3:58323793	G/C	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs865483	0.860	rs862490	chr17:35850275	T/C	cg06716730	chr17:35851459	DUSP14	0.45	7.67	0.62	1.52e-11	Monocyte count;
THYM	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg10150615	chr22:24372951	LOC391322	0.8	7.42	0.61	5.03e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7089973	0.668	rs7898347	chr10:116644324	G/A	cg23260525	chr10:116636907	FAM160B1	0.59	6.2	0.54	1.43e-8	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7084402	0.967	rs7097576	chr10:60277055	G/A	cg07615347	chr10:60278583	BICC1	-0.56	-5.15	-0.47	1.39e-6	Refractive error;
THYM	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.94	-0.52	4.76e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4930776	0.897	rs454166	chr12:5764784	G/T	cg02086166	chr12:5775618	ANO2	0.58	5.54	0.49	2.66e-7	Plasma clusterin levels;
THYM	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg00071950	chr4:10020882	SLC2A9	-1.1	-7.56	-0.61	2.54e-11	Bone mineral density;
THYM	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.0	0.63	2.98e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg10523679	chr1:76189770	ACADM	0.9	9.47	0.7	2.2e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.79	-7.25	-0.6	1.13e-10	Personality dimensions;
THYM	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg03433033	chr1:76189801	ACADM	0.66	5.67	0.5	1.56e-7	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4077515	0.901	rs34826348	chr9:139281570	A/C	cg14115884	chr9:139300582	SDCCAG3	0.73	6.9	0.58	5.79e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs13185784	0.667	rs35551113	chr5:179654221	T/C	cg23248424	chr5:179741104	GFPT2	0.74	4.87	0.45	4.37e-6	TRAIL levels;
THYM	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.85	-6.76	-0.57	1.09e-9	Intelligence (multi-trait analysis);
THYM	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg12863693	chr15:85201151	NMB	0.64	5.65	0.5	1.64e-7	Schizophrenia;
THYM	cis	rs10269006	0.727	rs10241912	chr7:94370037	G/C	cg00347863	chr7:94220697	SGCE	0.54	4.68	0.43	9.57e-6	Breast cancer;
THYM	cis	rs1691799	0.528	rs1472314	chr12:66788838	C/G	cg01411026	chr12:66696013	HELB	0.57	4.45	0.42	2.32e-5	White blood cell count (basophil);
THYM	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg24675056	chr1:15929824	NA	0.73	5.79	0.51	9.09e-8	Systolic blood pressure;
THYM	cis	rs1983170	1.000	rs12563578	chr1:91993702	T/C	cg02896835	chr1:92012615	NA	0.63	4.61	0.43	1.24e-5	Eosinophil percentage of white cells;
THYM	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	5.0	0.46	2.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.5	-4.83	-0.44	5.14e-6	Schizophrenia;
THYM	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.8	-6.76	-0.57	1.09e-9	Lymphocyte percentage of white cells;
THYM	cis	rs2658782	1.000	rs2658781	chr11:93166368	C/T	cg15737290	chr11:93063684	CCDC67	-1.03	-7.71	-0.62	1.21e-11	Pulmonary function decline;
THYM	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11890956	chr21:40555474	PSMG1	-0.97	-11.25	-0.76	3.73e-19	Cognitive function;
THYM	cis	rs7677751	0.806	rs67432867	chr4:55104454	A/T	cg17187183	chr4:55093834	PDGFRA	0.71	5.45	0.49	3.99e-7	Corneal astigmatism;
THYM	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg01579765	chr21:45077557	HSF2BP	-0.44	-6.61	-0.56	2.24e-9	Mean corpuscular volume;
THYM	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg22166914	chr1:53195759	ZYG11B	0.94	11.08	0.75	8.2e-19	Monocyte count;
THYM	cis	rs7224314	1.000	rs6504503	chr17:65386690	A/T	cg01507342	chr17:65387096	PITPNC1	-0.93	-10.79	-0.74	3.35e-18	Diisocyanate-induced asthma;
THYM	cis	rs7772486	0.686	rs9376956	chr6:145949844	T/C	cg13319975	chr6:146136371	FBXO30	-0.67	-5.46	-0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7943358	0.758	rs10741683	chr11:15726892	G/A	cg11966998	chr11:15692519	NA	-0.44	-4.49	-0.42	2.03e-5	Gut microbiome composition (summer);
THYM	cis	rs6772849	0.768	rs4521246	chr3:128421166	A/G	cg23732725	chr3:128766093	NA	0.57	4.99	0.46	2.71e-6	Monocyte percentage of white cells;Monocyte count;
THYM	cis	rs2072499	0.833	rs2842870	chr1:156200671	T/C	cg06970220	chr1:156163860	SLC25A44	0.75	6.31	0.54	8.92e-9	Testicular germ cell tumor;
THYM	cis	rs1007190	0.764	rs4793153	chr17:42873792	T/C	cg15406952	chr17:42872593	NA	-0.84	-5.95	-0.52	4.45e-8	DNA methylation (variation);
THYM	cis	rs3768617	0.528	rs3736888	chr1:183084607	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg07936489	chr17:37558343	FBXL20	-0.77	-5.03	-0.46	2.28e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4460079	0.531	rs12498919	chr4:114834055	G/C	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg24209194	chr3:40518798	ZNF619	0.56	4.58	0.43	1.41e-5	Renal cell carcinoma;
THYM	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg01416388	chr22:39784598	NA	-0.91	-9.04	-0.68	1.83e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2997447	0.706	rs55657303	chr1:26421012	A/G	cg03844060	chr1:26490628	NA	0.7	4.82	0.44	5.34e-6	QRS complex (12-leadsum);
THYM	cis	rs684232	0.623	rs117314378	chr17:521672	C/T	cg15660573	chr17:549704	VPS53	-0.95	-9.44	-0.7	2.55e-15	Prostate cancer;
THYM	cis	rs7746082	0.595	rs6908450	chr6:106489708	C/T	cg02270332	chr6:106475062	NA	-0.61	-5.64	-0.5	1.73e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs10506328	0.509	rs3809162	chr12:54674235	A/G	cg16110759	chr12:54330320	NA	-0.55	-4.48	-0.42	2.06e-5	Mean platelet volume;
THYM	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg06627628	chr2:24431161	ITSN2	-0.73	-5.17	-0.47	1.31e-6	Asthma;
THYM	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.77	0.51	1.01e-7	Rheumatoid arthritis;
THYM	cis	rs1018836	0.886	rs10283086	chr8:91616651	G/A	cg16814680	chr8:91681699	NA	-0.99	-9.24	-0.69	7.07e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg18200150	chr17:30822561	MYO1D	-0.63	-5.44	-0.49	4.09e-7	Schizophrenia;
THYM	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg03388043	chr17:80084554	CCDC57	-0.66	-5.66	-0.5	1.61e-7	Life satisfaction;
THYM	cis	rs61931739	1.000	rs12427391	chr12:34022891	A/G	cg10856724	chr12:34555212	NA	0.58	4.99	0.46	2.75e-6	Morning vs. evening chronotype;
THYM	cis	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg16898833	chr6:26189333	HIST1H4D	-1.18	-4.5	-0.42	1.9e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9302065	0.681	rs59108692	chr13:95962424	C/A	cg24476569	chr13:95954382	ABCC4	-0.78	-7.93	-0.63	4.18e-12	Blood metabolite levels;
THYM	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg15744005	chr10:104629667	AS3MT	-0.78	-7.33	-0.6	7.48e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs60695258	0.512	rs2053769	chr4:87908007	T/C	cg10685359	chr4:87814065	C4orf36	0.45	5.79	0.51	9.18e-8	Hematocrit;
THYM	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg04842962	chr6:43655489	MRPS18A	1.41	15.7	0.85	3.85e-28	IgG glycosylation;
THYM	cis	rs662064	0.755	rs6667629	chr1:10524467	T/C	cg20482658	chr1:10539492	PEX14	0.48	5.4	0.48	4.98e-7	Asthma;
THYM	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg23161317	chr6:28129485	ZNF389	0.78	6.42	0.55	5.24e-9	Depression;
THYM	cis	rs666930	1.000	rs666930	chr1:120258970	A/G	cg19096424	chr1:120255104	PHGDH	0.58	4.58	0.43	1.39e-5	Breast cancer;
THYM	cis	rs11605275	1.000	rs76399107	chr11:20029148	C/T	cg14835545	chr11:20032148	NAV2	-1.29	-6.34	-0.55	7.74e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs9563576	0.778	rs34500367	chr13:58686522	A/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.6	4.5	0.42	1.92e-5	Body mass index;
THYM	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg11812906	chr14:75593930	NEK9	-0.81	-7.31	-0.6	8.48e-11	Height;
THYM	cis	rs3750965	0.959	rs4930265	chr11:68855954	A/G	cg01403660	chr11:68851641	TPCN2	0.72	5.75	0.51	1.07e-7	Hair color;
THYM	cis	rs3126085	0.935	rs1390487	chr1:152194601	G/A	cg26020982	chr1:152196106	HRNR	0.38	5.14	0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs4474465	0.920	rs7947852	chr11:78198030	T/C	cg19901956	chr11:77921274	USP35	-0.66	-4.95	-0.45	3.22e-6	Alzheimer's disease (survival time);
THYM	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg21237687	chr17:6899380	ALOX12	0.73	9.27	0.69	6.15e-15	Tonsillectomy;
THYM	cis	rs2034088	0.897	rs12452970	chr17:444517	T/C	cg06217071	chr17:408420	NA	0.8	7.7	0.62	1.3e-11	Hip circumference adjusted for BMI;
THYM	cis	rs9810089	0.814	rs696518	chr3:136120300	A/C	cg12473912	chr3:136751656	NA	0.62	5.32	0.48	6.91e-7	Gestational age at birth (child effect);
THYM	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg18132916	chr6:79620363	NA	-0.6	-5.35	-0.48	6.15e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2806561	0.964	rs1757041	chr1:23506063	G/A	cg08872493	chr1:23521417	HTR1D	0.38	4.88	0.45	4.26e-6	Height;
THYM	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs2625529	0.590	rs7183196	chr15:72544401	A/G	cg16672083	chr15:72433130	SENP8	-0.57	-5.22	-0.47	1.07e-6	Red blood cell count;
THYM	cis	rs3540	0.618	rs2301832	chr15:91040725	A/T	cg22089800	chr15:90895588	ZNF774	-0.68	-5.21	-0.47	1.08e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs28595532	0.920	rs115006522	chr4:119732499	A/G	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs7267979	1.000	rs2500418	chr20:25382268	C/T	cg08601574	chr20:25228251	PYGB	-0.58	-4.67	-0.43	9.97e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs7589342	0.894	rs7557976	chr2:106435061	C/A	cg14210321	chr2:106509881	NCK2	-0.72	-5.12	-0.46	1.62e-6	Addiction;
THYM	cis	rs7580658	0.637	rs4560059	chr2:127972228	T/C	cg10021288	chr2:128175891	PROC	-0.61	-5.55	-0.49	2.59e-7	Protein C levels;
THYM	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg17077180	chr1:38461687	NA	0.41	4.72	0.44	8.13e-6	Coronary artery disease;
THYM	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg13397359	chr6:42928475	GNMT	0.61	5.49	0.49	3.39e-7	Plasma homocysteine levels (post-methionine load test);
THYM	cis	rs7731657	0.509	rs6879819	chr5:130256355	G/T	cg08523029	chr5:130500466	HINT1	0.82	5.67	0.5	1.55e-7	Fasting plasma glucose;
THYM	cis	rs6842047	1.000	rs1511800	chr4:187135556	C/T	cg02012338	chr4:187126139	CYP4V2	1.01	4.77	0.44	6.71e-6	Blood protein levels;
THYM	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg19016782	chr12:123741754	C12orf65	-0.69	-4.5	-0.42	1.94e-5	Neutrophil percentage of white cells;
THYM	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg16325326	chr1:53192061	ZYG11B	-0.73	-6.92	-0.58	5.14e-10	Monocyte count;
THYM	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg15212455	chr7:39170539	POU6F2	0.62	5.55	0.5	2.55e-7	IgG glycosylation;
THYM	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg18252515	chr7:66147081	NA	-0.69	-5.47	-0.49	3.59e-7	Aortic root size;
THYM	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg00786635	chr1:25594202	NA	0.91	7.63	0.62	1.81e-11	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs7267979	1.000	rs6050598	chr20:25397257	C/G	cg08601574	chr20:25228251	PYGB	0.56	4.47	0.42	2.15e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg03188948	chr7:1209495	NA	1.11	6.31	0.54	8.7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg26924012	chr15:45694286	SPATA5L1	1.06	9.17	0.69	9.7e-15	Homoarginine levels;
THYM	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg23803603	chr1:2058230	PRKCZ	0.59	4.56	0.42	1.52e-5	Height;
THYM	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg10803722	chr21:46713166	LOC642852	-0.43	-5.47	-0.49	3.64e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7072216	0.727	rs7913541	chr10:100172479	A/G	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs1003719	0.680	rs2154537	chr21:38502012	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-4.48	-0.42	2.1e-5	Eye color traits;
THYM	cis	rs61990749	0.597	rs11624101	chr14:78138059	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-1.17	-8.04	-0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg26384229	chr12:38710491	ALG10B	1.03	10.33	0.73	3.29e-17	Heart rate;
THYM	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg04362960	chr10:104952993	NT5C2	0.58	4.77	0.44	6.61e-6	Arsenic metabolism;
THYM	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs17125944	0.686	rs912861	chr14:53333290	C/G	cg00686598	chr14:53173677	PSMC6	-0.93	-4.77	-0.44	6.76e-6	Alzheimer's disease (late onset);
THYM	cis	rs1348850	0.574	rs4893834	chr2:178442288	C/T	cg27490568	chr2:178487706	NA	-0.53	-4.62	-0.43	1.2e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2717559	0.522	rs2572918	chr8:143875721	C/A	cg17888033	chr8:143858414	LYNX1	0.48	5.39	0.48	5.08e-7	Urinary tract infection frequency;
THYM	cis	rs7123876	0.830	rs57614870	chr11:72435983	A/G	cg04827223	chr11:72435913	ARAP1	-0.56	-4.51	-0.42	1.88e-5	Body mass index;
THYM	cis	rs7127900	1.000	rs7127900	chr11:2233574	A/G	cg25635251	chr11:2234043	NA	0.74	4.79	0.44	6.19e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs6032067	0.538	rs13042667	chr20:43739664	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.6	-6.1	-0.53	2.24e-8	Blood protein levels;
THYM	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg24678163	chr13:52769951	THSD1P	-0.49	-4.76	-0.44	6.89e-6	Lewy body disease;
THYM	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg13010199	chr12:38710504	ALG10B	-0.62	-4.46	-0.42	2.21e-5	Bladder cancer;
THYM	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg22974920	chr21:40686053	BRWD1	-0.63	-4.97	-0.45	2.98e-6	Cognitive function;
THYM	cis	rs4919044	1.000	rs17108036	chr10:94766779	C/G	cg05127821	chr10:94822908	CYP26C1	-1.04	-4.68	-0.43	9.54e-6	Coronary artery disease;
THYM	cis	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg24375607	chr4:120327624	NA	0.57	4.55	0.42	1.61e-5	Corneal astigmatism;
THYM	cis	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg07460842	chr6:66804631	NA	1.11	8.11	0.64	1.73e-12	Exhaled nitric oxide output;
THYM	cis	rs7818345	0.967	rs12679671	chr8:19270831	G/T	cg11303988	chr8:19266685	CSGALNACT1	0.43	4.74	0.44	7.52e-6	Language performance in older adults (adjusted for episodic memory);
THYM	trans	rs1974653	0.711	rs9605066	chr22:20099654	C/T	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1003719	0.646	rs2032063	chr21:38576657	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-4.53	-0.42	1.72e-5	Eye color traits;
THYM	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg03159660	chr11:2078197	NA	0.62	4.56	0.42	1.53e-5	Calcium levels;
THYM	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.84	0.51	7.19e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg16049864	chr8:95962084	TP53INP1	0.69	6.21	0.54	1.41e-8	Type 2 diabetes;
THYM	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg07532245	chr17:28927093	LRRC37B2	-0.64	-4.71	-0.44	8.38e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9309473	0.500	rs2421668	chr2:73885096	G/A	cg19565262	chr2:73869966	NAT8	0.55	4.6	0.43	1.32e-5	Metabolite levels;
THYM	cis	rs7000551	0.663	rs7827118	chr8:22334669	T/G	cg12081754	chr8:22256438	SLC39A14	0.65	5.59	0.5	2.15e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg16586182	chr3:47516702	SCAP	-0.68	-5.69	-0.5	1.43e-7	Colorectal cancer;
THYM	cis	rs2882877	0.648	rs11677198	chr2:190386579	A/C	cg10752008	chr2:190445175	SLC40A1	-0.7	-5.76	-0.51	1.04e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4523957	0.890	rs216217	chr17:2145090	G/A	cg16513277	chr17:2031491	SMG6	0.8	7.55	0.61	2.58e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs3135063	0.504	rs3129315	chr4:3290600	C/T	cg16895261	chr4:3391305	RGS12	-0.7	-4.82	-0.44	5.5e-6	Blood protein levels;
THYM	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg04267008	chr7:1944627	MAD1L1	-0.69	-6.14	-0.53	1.93e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs11048434	0.736	rs11048195	chr12:9105923	A/G	cg13575925	chr12:9217583	LOC144571	0.52	4.97	0.45	2.96e-6	Sjögren's syndrome;
THYM	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs919433	0.783	rs2565165	chr2:198233575	T/G	cg05783139	chr2:198650985	BOLL	0.56	4.5	0.42	1.96e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9430161	0.579	rs79323519	chr1:11036050	T/C	cg02454025	chr1:11042201	C1orf127	0.95	11.03	0.75	1.06e-18	Ewing sarcoma;
THYM	cis	rs8070624	0.543	rs57728924	chr17:17875342	A/G	cg04398451	chr17:18023971	MYO15A	-0.93	-8.84	-0.67	4.97e-14	Total body bone mineral density;
THYM	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg23649088	chr2:200775458	C2orf69	-0.83	-7.09	-0.59	2.39e-10	Osteoporosis;
THYM	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg15693483	chr7:1102177	C7orf50	0.53	6.19	0.54	1.52e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7828089	0.846	rs11136017	chr8:22238030	T/G	cg12081754	chr8:22256438	SLC39A14	0.61	5.24	0.47	9.64e-7	Verbal declarative memory;
THYM	cis	rs1448094	0.527	rs59445394	chr12:86237843	C/T	cg00310523	chr12:86230176	RASSF9	0.59	5.49	0.49	3.29e-7	Major depressive disorder;
THYM	cis	rs8077889	0.719	rs2079006	chr17:41865745	C/G	cg26893861	chr17:41843967	DUSP3	1.14	12.98	0.8	9.15e-23	Triglycerides;
THYM	cis	rs7193541	0.965	rs4402594	chr16:74701360	C/T	cg01733217	chr16:74700730	RFWD3	0.81	8.15	0.64	1.49e-12	Multiple myeloma;
THYM	cis	rs4863692	0.529	rs61166637	chr4:140771814	C/G	cg15010390	chr4:140216957	NDUFC1	0.63	4.55	0.42	1.59e-5	Educational attainment (years of education);
THYM	cis	rs34638657	0.752	rs2967374	chr16:82209861	A/G	cg09439754	chr16:82129088	HSD17B2	-0.65	-5.57	-0.5	2.4e-7	Lung adenocarcinoma;
THYM	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.58	0.43	1.41e-5	Bipolar disorder;
THYM	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22857025	chr5:266934	NA	-1.59	-10.2	-0.72	6.04e-17	Breast cancer;
THYM	cis	rs10028773	0.700	rs35653026	chr4:120248378	A/G	cg09307838	chr4:120376055	NA	0.67	5.02	0.46	2.37e-6	Educational attainment;
THYM	cis	rs240764	0.697	rs239194	chr6:101131959	G/A	cg21058520	chr6:100914733	NA	-0.59	-5.07	-0.46	2e-6	Neuroticism;
THYM	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg01579765	chr21:45077557	HSF2BP	0.52	8.09	0.64	1.9e-12	Mean corpuscular volume;
THYM	cis	rs757081	0.608	rs214938	chr11:17188516	C/T	cg07093617	chr11:18158918	MRGPRX3	-0.49	-4.61	-0.43	1.23e-5	Systolic blood pressure;
THYM	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg02228675	chr17:40259724	DHX58	-0.62	-5.13	-0.47	1.55e-6	Fibrinogen levels;
THYM	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg03396347	chr1:1875803	NA	0.64	6.25	0.54	1.16e-8	Body mass index;
THYM	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8016982	0.674	rs8004096	chr14:81701082	T/G	cg01989461	chr14:81687754	GTF2A1	0.82	7.69	0.62	1.38e-11	Schizophrenia;
THYM	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg00786635	chr1:25594202	NA	0.9	7.47	0.61	3.83e-11	Erythrocyte sedimentation rate;
THYM	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg23711669	chr6:146136114	FBXO30	0.8	7.12	0.59	2.02e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4917300	0.626	rs28375965	chr8:143103882	A/G	cg25363559	chr8:143086065	NA	-0.56	-5.11	-0.46	1.65e-6	Amyotrophic lateral sclerosis;
THYM	cis	rs4478037	0.822	rs9883177	chr3:33123354	T/C	cg19404215	chr3:33155277	CRTAP	0.96	6.51	0.56	3.58e-9	Major depressive disorder;
THYM	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg03806693	chr22:41940476	POLR3H	-1.03	-8.5	-0.66	2.66e-13	Vitiligo;
THYM	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.64	-0.74	7.23e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs2273669	0.585	rs6900472	chr6:109372120	G/A	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs3825932	0.961	rs2870085	chr15:79234268	T/C	cg25744700	chr15:79237217	CTSH	0.47	4.46	0.42	2.22e-5	Type 1 diabetes;
THYM	cis	rs2573210	0.645	rs1881492	chr2:233406998	A/C	cg22276371	chr2:233390859	CHRND	-0.41	-4.59	-0.43	1.33e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg22709100	chr7:91322751	NA	0.62	4.79	0.44	6.11e-6	Breast cancer;
THYM	cis	rs3755605	0.793	rs6764015	chr3:169782159	A/G	cg18444028	chr3:169782040	GPR160	-0.55	-4.46	-0.42	2.28e-5	Testicular germ cell tumor;
THYM	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.68	4.99	0.46	2.75e-6	Tonsillectomy;
THYM	cis	rs611744	0.647	rs585077	chr8:109245497	C/T	cg21045802	chr8:109455806	TTC35	0.65	5.91	0.52	5.3e-8	Dupuytren's disease;
THYM	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg16325326	chr1:53192061	ZYG11B	0.84	7.99	0.63	3.13e-12	Monocyte count;
THYM	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg26441486	chr22:50317300	CRELD2	0.43	6.61	0.56	2.23e-9	Schizophrenia;
THYM	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg07570687	chr10:102243282	WNT8B	0.84	8.13	0.64	1.59e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs713587	0.719	rs4665736	chr2:25187599	C/T	cg15423357	chr2:25149977	NA	-0.6	-6.27	-0.54	1.05e-8	Body mass index in non-asthmatics;
THYM	trans	rs8073060	0.586	rs72829923	chr17:34045089	T/A	cg19694781	chr19:47549865	TMEM160	1.01	8.58	0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs2273669	0.667	rs12205053	chr6:109338110	T/C	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.79e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.88	5.64	0.5	1.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg17971929	chr21:40555470	PSMG1	0.73	4.75	0.44	7.29e-6	Cognitive function;
THYM	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs6964587	0.610	rs6465338	chr7:91450624	T/C	cg17063962	chr7:91808500	NA	0.97	8.03	0.64	2.56e-12	Breast cancer;
THYM	cis	rs12257961	0.525	rs2883023	chr10:15372931	C/T	cg10616319	chr10:15468812	NA	-0.66	-5.33	-0.48	6.53e-7	Selective IgA deficiency;
THYM	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs4986811	0.929	rs5030180	chr11:32448239	G/A	cg04096767	chr11:32449450	WT1	0.65	4.95	0.45	3.26e-6	Rubella-specific interleukin-6 secretion;
THYM	cis	rs4523957	0.583	rs2760740	chr17:2020989	A/G	cg16513277	chr17:2031491	SMG6	-0.96	-8.72	-0.67	9.17e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg11871910	chr12:69753446	YEATS4	1.06	9.8	0.71	4.32e-16	Blood protein levels;
THYM	cis	rs10411161	0.702	rs75647161	chr19:52398984	T/C	cg25361850	chr19:52391789	ZNF577	0.74	4.96	0.45	3.14e-6	Breast cancer;
THYM	cis	rs12188164	1.000	rs12188678	chr5:428231	T/C	cg26850624	chr5:429559	AHRR	-0.69	-5.39	-0.48	5.09e-7	Cystic fibrosis severity;
THYM	cis	rs7107770	0.943	rs35408472	chr11:125104632	T/C	cg04164023	chr11:125106101	PKNOX2	-0.81	-4.67	-0.43	9.86e-6	Photic sneeze reflex;
THYM	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg23958373	chr8:599963	NA	0.96	4.91	0.45	3.78e-6	IgG glycosylation;
THYM	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.95	6.56	0.56	2.87e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs454510	0.816	rs838987	chr1:120176127	A/G	cg11530693	chr1:120165357	ZNF697	0.72	5.0	0.46	2.58e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
THYM	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg07414643	chr4:187882934	NA	0.67	5.9	0.52	5.58e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg07988820	chr12:82153109	PPFIA2	-0.75	-4.59	-0.43	1.34e-5	Resting heart rate;
THYM	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg25811766	chr13:21894605	NA	-0.77	-4.91	-0.45	3.82e-6	White matter hyperintensity burden;
THYM	cis	rs4660261	0.526	rs2485996	chr1:44354661	C/T	cg12599982	chr1:44399894	ARTN	0.58	4.6	0.43	1.3e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05901451	chr6:126070800	HEY2	-0.93	-9.07	-0.68	1.61e-14	Brugada syndrome;
THYM	cis	rs2180341	0.700	rs4598100	chr6:127565314	G/A	cg27446573	chr6:127587934	RNF146	0.87	6.33	0.54	8e-9	Breast cancer;
THYM	cis	rs662064	0.890	rs1632108	chr1:10561923	C/T	cg20482658	chr1:10539492	PEX14	0.46	5.62	0.5	1.86e-7	Asthma;
THYM	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs11190604	1.000	rs7099913	chr10:102314777	T/C	cg16342193	chr10:102329863	NA	-0.59	-6.12	-0.53	2.06e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6138458	1.000	rs227618	chr20:24909472	T/C	cg26195577	chr20:24973756	C20orf3	1.12	10.51	0.73	1.38e-17	Blood protein levels;
THYM	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg22709100	chr7:91322751	NA	0.62	4.82	0.44	5.36e-6	Breast cancer;
THYM	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg11301795	chr4:187892539	NA	-1.11	-17.65	-0.88	9.45e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs55665837	0.524	rs2882128	chr11:14414634	A/C	cg19336497	chr11:14380999	RRAS2	-0.83	-11.23	-0.76	4.06e-19	Vitamin D levels;
THYM	cis	rs4986811	1.000	rs5030166	chr11:32449799	G/T	cg04096767	chr11:32449450	WT1	0.65	4.76	0.44	7.05e-6	Rubella-specific interleukin-6 secretion;
THYM	cis	rs950880	0.614	rs60038017	chr2:103076001	A/C	cg03938978	chr2:103052716	IL18RAP	-0.53	-4.53	-0.42	1.69e-5	Serum protein levels (sST2);
THYM	cis	rs28795989	0.896	rs7663205	chr4:7889096	C/T	cg12728606	chr4:7903970	AFAP1	0.43	4.59	0.43	1.34e-5	Intraocular pressure;
THYM	cis	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.96	0.45	3.04e-6	Obesity-related traits;
THYM	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.41	-0.65	4.08e-13	Mean corpuscular volume;
THYM	cis	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg21775007	chr8:11205619	TDH	0.75	6.57	0.56	2.67e-9	Retinal vascular caliber;
THYM	cis	rs910187	0.641	rs3818010	chr20:45816562	A/G	cg27589058	chr20:45804311	EYA2	-0.59	-5.04	-0.46	2.21e-6	Migraine;
THYM	cis	rs986417	0.786	rs76632048	chr14:60846934	G/A	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs9644630	0.901	rs13276417	chr8:19350199	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.69	6.58	0.56	2.6e-9	Oropharynx cancer;
THYM	cis	rs6163	0.540	rs11191385	chr10:104513049	G/T	cg05855489	chr10:104503620	C10orf26	0.74	5.79	0.51	9.14e-8	Waist circumference;Hip circumference;
THYM	cis	rs7255045	0.702	rs2293682	chr19:12989560	G/A	cg26870725	chr19:12978805	MAST1	-0.59	-4.5	-0.42	1.89e-5	Mean corpuscular volume;
THYM	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Bladder cancer;
THYM	cis	rs9807841	0.555	rs6511708	chr19:10788813	A/G	cg17848348	chr19:10766748	ILF3	-0.91	-8.29	-0.65	7.5e-13	Inflammatory skin disease;
THYM	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg18477163	chr1:228402036	OBSCN	-0.43	-4.69	-0.43	8.96e-6	Diastolic blood pressure;
THYM	cis	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs6500395	1.000	rs8058362	chr16:48645316	T/C	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg07606381	chr6:8435919	SLC35B3	0.62	4.54	0.42	1.67e-5	Motion sickness;
THYM	cis	rs6500395	0.962	rs9921737	chr16:48589873	G/T	cg04672837	chr16:48644449	N4BP1	0.47	4.46	0.42	2.23e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs4731207	0.596	rs1871770	chr7:124630839	G/T	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs9543976	0.614	rs73223955	chr13:76103211	G/C	cg01531495	chr13:76123901	UCHL3	-0.87	-4.75	-0.44	7.21e-6	Diabetic retinopathy;
THYM	cis	rs924712	0.645	rs148109	chr6:54759226	A/G	cg04690482	chr6:54711388	FAM83B	0.44	5.06	0.46	2.01e-6	Breast cancer;
THYM	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg25703541	chr22:24373054	LOC391322	0.81	8.29	0.65	7.35e-13	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs9303280	0.901	rs2952140	chr17:37928059	C/T	cg24910161	chr17:38119198	GSDMA	-0.47	-4.81	-0.44	5.73e-6	Self-reported allergy;
THYM	cis	rs12142240	0.738	rs10489769	chr1:46806703	A/G	cg00530320	chr1:46809349	NSUN4	0.75	5.28	0.48	8.01e-7	Menopause (age at onset);
THYM	cis	rs761746	0.960	rs14034	chr22:32015406	T/C	cg10537193	chr22:32026975	PISD	-0.35	-4.91	-0.45	3.85e-6	Intelligence;
THYM	cis	rs10463554	0.963	rs257318	chr5:102445470	C/T	cg23492399	chr5:102201601	PAM	-0.69	-5.09	-0.46	1.83e-6	Parkinson's disease;
THYM	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg00801512	chr17:28996047	NA	-0.76	-4.9	-0.45	3.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg11905131	chr22:24372483	LOC391322	-0.96	-10.62	-0.74	7.96e-18	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg03806693	chr22:41940476	POLR3H	0.96	7.63	0.62	1.78e-11	Vitiligo;
THYM	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs4780401	0.755	rs2868981	chr16:11765518	T/C	cg01061890	chr16:11836724	TXNDC11	-0.61	-4.66	-0.43	1.02e-5	Rheumatoid arthritis;
THYM	cis	rs6754311	0.906	rs4954387	chr2:136784344	A/G	cg04750100	chr2:136595281	LCT	0.52	5.14	0.47	1.47e-6	Mosquito bite size;
THYM	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.78	-5.37	-0.48	5.47e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8070740	0.838	rs1050461	chr17:5336210	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.69	5.1	0.46	1.75e-6	Menopause (age at onset);
THYM	cis	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg13789015	chr9:136890014	NCRNA00094	0.84	7.25	0.6	1.09e-10	Platelet distribution width;
THYM	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg10935138	chr17:73851978	WBP2	0.79	4.5	0.42	1.91e-5	Psoriasis;
THYM	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs10779751	0.734	rs1211575	chr1:11118390	G/A	cg08854313	chr1:11322531	MTOR	0.76	6.51	0.56	3.56e-9	Body mass index;
THYM	cis	rs977987	0.778	rs1109341	chr16:75445605	G/A	cg03315344	chr16:75512273	CHST6	0.77	6.3	0.54	9.16e-9	Dupuytren's disease;
THYM	cis	rs7115242	0.800	rs6589597	chr11:116997798	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.87	-4.82	-0.44	5.47e-6	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
THYM	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg14018140	chr10:458528	DIP2C	0.58	6.27	0.54	1.04e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg02478829	chr6:26598070	ABT1	-0.35	-4.54	-0.42	1.63e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg07636037	chr3:49044803	WDR6	0.73	5.06	0.46	2.02e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg18252515	chr7:66147081	NA	-0.66	-4.91	-0.45	3.8e-6	Aortic root size;
THYM	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg09184832	chr6:79620586	NA	-0.58	-4.6	-0.43	1.29e-5	Intelligence (multi-trait analysis);
THYM	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.97	-5.47	-0.49	3.64e-7	Red cell distribution width;
THYM	cis	rs12200560	0.505	rs211171	chr6:97070579	T/G	cg06623918	chr6:96969491	KIAA0776	0.76	5.81	0.51	8.28e-8	Coronary heart disease;
THYM	cis	rs4888262	0.508	rs12598701	chr16:74539904	G/A	cg01733217	chr16:74700730	RFWD3	0.8	8.28	0.65	7.82e-13	Testicular germ cell tumor;
THYM	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg00801512	chr17:28996047	NA	-0.76	-5.0	-0.46	2.65e-6	Body mass index;
THYM	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg08847533	chr14:75593920	NEK9	-0.97	-10.22	-0.72	5.6e-17	Height;
THYM	cis	rs2267137	0.868	rs174770	chr22:29766895	C/T	cg26480862	chr22:28839667	TTC28	0.46	4.54	0.42	1.62e-5	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs8033133	1.000	rs8033133	chr15:25350474	A/G	cg14481604	chr15:25334117	SNORD116-22	-0.67	-4.45	-0.42	2.34e-5	Blood osmolality (transformed sodium);
THYM	cis	rs12496230	1.000	rs12496230	chr3:66829908	A/G	cg04995300	chr3:66848608	NA	1.01	6.42	0.55	5.4e-9	Type 2 diabetes;
THYM	cis	rs2970992	0.728	rs1028043	chr2:101321427	G/A	cg01042948	chr2:101319752	NA	0.6	5.92	0.52	5.2e-8	Educational attainment;
THYM	cis	rs4148689	1.000	rs2237723	chr7:117147547	C/T	cg17204129	chr7:117119601	CFTR	-0.68	-5.4	-0.48	4.88e-7	Gout;
THYM	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.41	6.36	0.55	7.15e-9	Obesity-related traits;
THYM	cis	rs61931739	0.635	rs1852224	chr12:33963080	A/C	cg06521331	chr12:34319734	NA	-0.56	-4.69	-0.43	8.97e-6	Morning vs. evening chronotype;
THYM	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.49	0.42	1.97e-5	Diabetic retinopathy;
THYM	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg06238570	chr21:40685208	BRWD1	0.91	6.57	0.56	2.62e-9	Cognitive function;
THYM	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7103648	0.618	rs11039284	chr11:47564785	A/G	cg20307385	chr11:47447363	PSMC3	0.78	5.43	0.49	4.25e-7	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg20283391	chr11:68216788	NA	-0.6	-4.75	-0.44	7.26e-6	Total body bone mineral density;
THYM	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4718428	0.705	rs4718430	chr7:66432024	G/T	cg18252515	chr7:66147081	NA	-0.8	-5.65	-0.5	1.68e-7	Corneal structure;
THYM	cis	rs35849525	1.000	rs35849525	chr3:50067350	T/C	cg14019146	chr3:50243930	SLC38A3	-0.6	-4.62	-0.43	1.23e-5	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	7.35	0.6	6.78e-11	Platelet count;
THYM	cis	rs2276314	1.000	rs9304154	chr18:33562227	C/T	cg19628046	chr18:33552617	C18orf21	0.79	5.46	0.49	3.74e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7017212	0.610	rs7007046	chr8:10020535	C/T	cg14232358	chr8:10698115	PINX1	0.48	4.64	0.43	1.11e-5	Schizophrenia;
THYM	cis	rs2290159	0.800	rs5746187	chr3:12659419	A/G	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs10256972	0.552	rs6953538	chr7:1196974	A/G	cg04025307	chr7:1156635	C7orf50	0.74	6.42	0.55	5.28e-9	Longevity;Endometriosis;
THYM	cis	rs72627123	0.867	rs1008701	chr14:74327621	A/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg15704280	chr7:45808275	SEPT13	1.02	8.31	0.65	6.7e-13	Height;
THYM	cis	rs757081	0.667	rs17473243	chr11:17266259	G/A	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.6	-0.43	1.29e-5	Systolic blood pressure;
THYM	cis	rs863345	0.565	rs10908671	chr1:158502160	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs7649443	0.959	rs10461050	chr3:196952171	A/C	cg20744464	chr3:196756875	MFI2	0.64	4.65	0.43	1.07e-5	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs11690935	0.959	rs1113389	chr2:172635365	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.79	-5.64	-0.5	1.75e-7	Schizophrenia;
THYM	cis	rs807669	0.525	rs9605955	chr22:19181557	C/T	cg02655711	chr22:19163373	SLC25A1	0.6	6.5	0.56	3.63e-9	Metabolite levels;
THYM	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs6500395	0.926	rs1120275	chr16:48598737	T/G	cg04672837	chr16:48644449	N4BP1	0.48	4.58	0.43	1.39e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs55823223	0.648	rs11867582	chr17:73857306	A/G	cg08125733	chr17:73851984	WBP2	1.24	8.44	0.65	3.58e-13	Psoriasis;
THYM	cis	rs2806561	0.704	rs2868573	chr1:23508253	C/G	cg19743168	chr1:23544995	NA	0.55	5.6	0.5	2.09e-7	Height;
THYM	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg14349672	chr11:133703707	NA	-0.54	-4.77	-0.44	6.63e-6	Childhood ear infection;
THYM	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg16031515	chr1:205743344	RAB7L1	-0.69	-7.2	-0.59	1.4e-10	Menarche (age at onset);
THYM	cis	rs4455778	0.580	rs5004391	chr7:49115629	G/A	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs13185784	0.667	rs4700924	chr5:179645870	A/C	cg23248424	chr5:179741104	GFPT2	-0.7	-4.57	-0.42	1.48e-5	TRAIL levels;
THYM	cis	rs11190604	0.666	rs7084768	chr10:102200497	T/C	cg07570687	chr10:102243282	WNT8B	-0.82	-7.91	-0.63	4.72e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg07424592	chr7:64974309	NA	-0.9	-4.66	-0.43	1.03e-5	Diabetic kidney disease;
THYM	cis	rs8050907	0.744	rs56235717	chr16:4524374	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.3	5.2	0.47	1.16e-6	Obesity-related traits;
THYM	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg24375607	chr4:120327624	NA	0.62	5.0	0.46	2.63e-6	Corneal astigmatism;
THYM	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg20887711	chr4:1340912	KIAA1530	0.57	4.54	0.42	1.68e-5	Obesity-related traits;
THYM	cis	rs3096299	0.838	rs3102384	chr16:89411661	T/G	cg06640241	chr16:89574553	SPG7	0.63	4.67	0.43	1.01e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg10856724	chr12:34555212	NA	-0.92	-9.27	-0.69	6.02e-15	Morning vs. evening chronotype;
THYM	cis	rs4606347	0.932	rs11807752	chr1:66138575	A/G	cg04111102	chr1:66153794	NA	0.57	4.53	0.42	1.73e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs4653767	1.000	rs4653767	chr1:226916078	T/C	cg05262829	chr1:226921576	ITPKB	-0.49	-5.03	-0.46	2.34e-6	Parkinson's disease;
THYM	cis	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg14345882	chr6:26364793	BTN3A2	-0.62	-5.74	-0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs3771570	0.901	rs10190033	chr2:242412358	A/C	cg21155796	chr2:242212141	HDLBP	0.98	5.81	0.51	8.34e-8	Prostate cancer;
THYM	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg15704280	chr7:45808275	SEPT13	1.02	8.31	0.65	6.7e-13	Coronary artery disease;
THYM	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg27572855	chr1:25598939	RHD	0.69	5.34	0.48	6.29e-7	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg10505658	chr17:80084571	CCDC57	-0.74	-8.21	-0.64	1.06e-12	Life satisfaction;
THYM	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.96	-8.0	-0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs7172809	0.897	rs907387	chr15:77828751	T/C	cg22256960	chr15:77711686	NA	-0.67	-4.65	-0.43	1.06e-5	Glucose homeostasis traits;
THYM	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg09359103	chr1:154839909	KCNN3	-0.83	-11.33	-0.76	2.46e-19	Prostate cancer;
THYM	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs6430585	0.646	rs1057031	chr2:136633962	G/A	cg04750100	chr2:136595281	LCT	0.53	5.12	0.46	1.61e-6	Corneal structure;
THYM	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg24675056	chr1:15929824	NA	0.75	5.87	0.52	6.25e-8	Systolic blood pressure;
THYM	cis	rs12121840	0.790	rs12143824	chr1:165547306	G/A	cg19407955	chr1:165599744	MGST3	-0.65	-4.77	-0.44	6.66e-6	Interleukin-1-receptor antagonist levels;
THYM	cis	rs4731207	0.844	rs33935352	chr7:124395310	A/G	cg05285228	chr7:124571219	POT1	0.71	5.63	0.5	1.84e-7	Cutaneous malignant melanoma;
THYM	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs36051895	0.623	rs1555476	chr9:5233054	T/C	cg02405213	chr9:5042618	JAK2	-0.95	-9.21	-0.69	8.17e-15	Pediatric autoimmune diseases;
THYM	cis	rs11096990	0.634	rs10019594	chr4:39288747	C/T	cg24403649	chr4:39172243	NA	-0.64	-5.38	-0.48	5.25e-7	Cognitive function;
THYM	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.3	-0.48	7.34e-7	Monocyte percentage of white cells;
THYM	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg09184832	chr6:79620586	NA	0.64	5.26	0.48	8.83e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2229238	0.911	rs77184252	chr1:154492533	A/G	cg21262032	chr1:154437693	IL6R	-0.6	-5.39	-0.48	5.21e-7	Coronary heart disease;
THYM	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	6.66	0.56	1.74e-9	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2072732	0.861	rs6692292	chr1:2959610	C/T	cg08733933	chr1:2954429	NA	0.57	4.46	0.42	2.25e-5	Plateletcrit;
THYM	cis	rs236352	0.538	rs449840	chr6:36865177	C/T	cg03410223	chr6:36853544	C6orf89	0.69	5.8	0.51	8.51e-8	Heart rate;
THYM	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg07519536	chr6:26501950	BTN1A1	0.56	5.16	0.47	1.36e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg10117171	chr1:25599238	RHD	-0.84	-6.45	-0.55	4.67e-9	Erythrocyte sedimentation rate;
THYM	cis	rs7084402	0.935	rs2393449	chr10:60343030	A/G	cg09696939	chr10:60272079	BICC1	-0.48	-5.67	-0.5	1.56e-7	Refractive error;
THYM	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.86	0.45	4.55e-6	Prudent dietary pattern;
THYM	cis	rs9300255	0.516	rs6488868	chr12:123799974	A/G	cg00376283	chr12:123451042	ABCB9	0.81	5.21	0.47	1.08e-6	Neutrophil percentage of white cells;
THYM	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.3	0.54	9.43e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-5.36	-0.48	5.89e-7	Vitiligo;
THYM	cis	rs6964587	0.692	rs10227225	chr7:91571074	A/G	cg17063962	chr7:91808500	NA	-1.04	-9.32	-0.69	4.62e-15	Breast cancer;
THYM	cis	rs7127900	0.583	rs67186729	chr11:2233549	T/C	cg25635251	chr11:2234043	NA	0.71	5.42	0.49	4.51e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03576123	chr11:487126	PTDSS2	-1.29	-6.4	-0.55	5.87e-9	Body mass index;
THYM	cis	rs13315871	1.000	rs13078787	chr3:58430487	C/T	cg00563845	chr3:58318305	PXK	0.53	4.67	0.43	9.78e-6	Cholesterol, total;
THYM	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg02503808	chr4:7069936	GRPEL1	0.97	8.3	0.65	7e-13	Monocyte percentage of white cells;
THYM	trans	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17712092	chr4:129076599	LARP1B	0.9	7.57	0.61	2.42e-11	Eosinophil percentage of white cells;
THYM	cis	rs9522267	0.535	rs9522301	chr13:112236726	A/T	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs9486719	1.000	rs11153023	chr6:96968525	C/T	cg18709589	chr6:96969512	KIAA0776	-0.73	-4.83	-0.44	5.28e-6	Migraine;Coronary artery disease;
THYM	cis	rs596169	0.764	rs618205	chr1:219122393	T/A	cg19270308	chr1:218458869	RRP15	1.24	4.52	0.42	1.81e-5	Intraocular pressure;
THYM	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg01341218	chr17:43662625	NA	0.86	7.43	0.61	4.66e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	4.63	0.43	1.18e-5	Aortic root size;
THYM	cis	rs818427	0.684	rs42427	chr5:112176325	G/A	cg04614008	chr5:112630677	MCC	-0.64	-4.6	-0.43	1.31e-5	Total body bone mineral density;
THYM	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg03433033	chr1:76189801	ACADM	0.7	6.71	0.57	1.42e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6598955	0.671	rs11247909	chr1:26640135	G/A	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.7	0.43	8.83e-6	Obesity-related traits;
THYM	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	7.02	0.58	3.25e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg26384229	chr12:38710491	ALG10B	-0.72	-5.64	-0.5	1.75e-7	Morning vs. evening chronotype;
THYM	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg15704280	chr7:45808275	SEPT13	-1.04	-14.05	-0.82	6.23e-25	Height;
THYM	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.78	0.51	9.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2836633	0.895	rs61085980	chr21:40032140	C/T	cg12884169	chr21:40033163	ERG	0.7	8.36	0.65	5.29e-13	Coronary artery disease;
THYM	cis	rs3847687	0.546	rs11061295	chr12:131519684	T/C	cg25772418	chr12:131519998	GPR133	-0.35	-4.51	-0.42	1.89e-5	Longevity;
THYM	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg14972814	chr11:95582409	MTMR2	-0.66	-5.57	-0.5	2.34e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg02896835	chr1:92012615	NA	-0.65	-5.74	-0.51	1.15e-7	Breast cancer;
THYM	cis	rs1430128	0.584	rs2888507	chr2:218454986	C/G	cg27640316	chr2:217799104	NA	0.67	4.75	0.44	7.12e-6	Congenital heart disease (inherited effect);
THYM	cis	rs10899021	0.920	rs10899014	chr11:74325109	A/G	cg25880958	chr11:74394337	NA	-0.77	-4.66	-0.43	1.04e-5	Response to metformin (IC50);
THYM	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg02527881	chr3:46936655	PTH1R	-0.66	-6.43	-0.55	5.2e-9	Colorectal cancer;
THYM	cis	rs6539288	0.513	rs7977247	chr12:107259470	T/C	cg15890332	chr12:107067104	RFX4	0.44	4.91	0.45	3.71e-6	Total body bone mineral density;
THYM	cis	rs9790314	1.000	rs464766	chr3:161087592	C/G	cg04691961	chr3:161091175	C3orf57	-0.6	-5.26	-0.47	8.85e-7	Morning vs. evening chronotype;
THYM	cis	rs5985	0.659	rs3024326	chr6:6317942	A/G	cg22185065	chr6:6318785	F13A1	0.78	5.74	0.51	1.15e-7	End-stage coagulation;
THYM	cis	rs921968	0.643	rs1516086	chr2:219431535	C/T	cg02176678	chr2:219576539	TTLL4	0.64	6.08	0.53	2.49e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs983545	0.800	rs7629676	chr3:16966998	C/T	cg24159436	chr3:16974681	PLCL2	0.35	5.36	0.48	5.7e-7	Blood protein levels;
THYM	cis	rs9880211	0.563	rs10512990	chr3:135814627	G/T	cg21827317	chr3:136751795	NA	-0.71	-5.16	-0.47	1.33e-6	Body mass index;Height;
THYM	cis	rs2898681	0.614	rs6839900	chr4:53675334	A/G	cg00791764	chr4:53727839	RASL11B	0.42	5.07	0.46	1.94e-6	Optic nerve measurement (cup area);
THYM	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg17757837	chr7:157058334	UBE3C	0.66	5.29	0.48	7.81e-7	Body mass index;
THYM	cis	rs1299926	0.850	rs1657081	chr16:8870762	C/T	cg08365638	chr16:9212442	C16orf72	-0.96	-4.49	-0.42	1.99e-5	Anger;
THYM	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg05872129	chr22:39784769	NA	1.06	10.68	0.74	6.01e-18	Intelligence (multi-trait analysis);
THYM	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg01097406	chr16:89675127	NA	0.66	5.64	0.5	1.76e-7	Vitiligo;
THYM	trans	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg25214090	chr10:38739885	LOC399744	0.92	7.78	0.62	8.73e-12	Corneal astigmatism;
THYM	cis	rs6882076	0.884	rs7717984	chr5:156369171	A/G	cg06200339	chr5:157079404	SOX30	-0.46	-4.67	-0.43	1e-5	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06873352	chr17:61820015	STRADA	0.8	10.01	0.72	1.54e-16	Prudent dietary pattern;
THYM	cis	rs2688608	0.530	rs71507081	chr10:75493136	G/A	cg23231163	chr10:75533350	FUT11	-0.41	-5.9	-0.52	5.54e-8	Inflammatory bowel disease;
THYM	cis	rs2066819	1.000	rs77853814	chr12:56687572	G/T	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg08017756	chr2:100939284	LONRF2	-0.72	-7.38	-0.6	5.95e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	5.47	0.49	3.58e-7	Personality dimensions;
THYM	cis	rs611744	0.647	rs7015240	chr8:109262204	G/A	cg21045802	chr8:109455806	TTC35	0.65	5.82	0.51	7.78e-8	Dupuytren's disease;
THYM	cis	rs6876348	0.516	rs257999	chr5:128318589	G/A	cg02841155	chr5:128301328	SLC27A6	-0.51	-5.09	-0.46	1.83e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7953508	0.506	rs2053196	chr12:93962959	T/C	cg18151635	chr12:93972918	NA	-0.86	-6.04	-0.53	2.94e-8	Pubertal anthropometrics;
THYM	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg16926213	chr1:1841314	NA	-0.51	-5.29	-0.48	7.88e-7	Body mass index;
THYM	cis	rs2806561	0.765	rs641032	chr1:23513980	C/T	cg08872493	chr1:23521417	HTR1D	-0.36	-4.63	-0.43	1.17e-5	Height;
THYM	cis	rs2712184	0.935	rs2712169	chr2:217671349	G/A	cg05032264	chr2:217675019	NA	-0.57	-4.78	-0.44	6.36e-6	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg00484396	chr16:3507460	NAT15	0.51	4.76	0.44	6.91e-6	Body mass index (adult);
THYM	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs7572733	0.534	rs7604700	chr2:198718630	A/G	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs3947	1.000	rs1736081	chr8:11702840	T/G	cg26752888	chr8:11627280	NEIL2	-0.69	-4.55	-0.42	1.61e-5	Blood protein levels;
THYM	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg07930192	chr7:1003750	NA	0.58	4.8	0.44	5.88e-6	Longevity;Endometriosis;
THYM	cis	rs2552220	0.967	rs13272740	chr8:6007771	C/T	cg06481462	chr8:7005678	NA	0.47	4.77	0.44	6.77e-6	Interleukin-8 levels;
THYM	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs892961	0.867	rs6501955	chr17:75414443	A/G	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs714027	0.534	rs140124	chr22:30143693	G/C	cg27665648	chr22:30112403	NA	0.5	4.45	0.42	2.31e-5	Lymphocyte counts;
THYM	cis	rs4654899	0.758	rs12078457	chr1:21397071	C/T	cg01072550	chr1:21505969	NA	-0.77	-7.49	-0.61	3.45e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg13852791	chr20:30311386	BCL2L1	0.74	5.35	0.48	6.15e-7	Mean corpuscular hemoglobin;
THYM	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.63	-5.4	-0.48	4.81e-7	Height;
THYM	cis	rs6040076	1.000	rs2206815	chr20:10669188	G/T	cg12388309	chr20:9819805	PAK7	-0.55	-4.75	-0.44	7.26e-6	Pulse pressure;Birth weight;
THYM	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg27490568	chr2:178487706	NA	0.64	5.01	0.46	2.47e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7246967	0.673	rs8106215	chr19:22879446	G/A	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06634786	chr22:41940651	POLR3H	-0.84	-6.24	-0.54	1.21e-8	Vitiligo;
THYM	cis	rs2302612	0.528	rs10198860	chr2:102842633	T/A	cg13315345	chr2:102803985	IL1RL2	0.71	4.81	0.44	5.76e-6	Serum protein levels (sST2);
THYM	cis	rs8180040	0.726	rs11130112	chr3:47024495	G/T	cg16586182	chr3:47516702	SCAP	-0.55	-4.7	-0.43	8.89e-6	Colorectal cancer;
THYM	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.76	6.16	0.53	1.77e-8	Blood protein levels;
THYM	trans	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg20587970	chr11:113659929	NA	-1.38	-8.78	-0.67	6.62e-14	Hip circumference adjusted for BMI;
THYM	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg16006841	chr5:176797999	RGS14	0.72	10.48	0.73	1.54e-17	Urinary electrolytes (magnesium/calcium ratio);
THYM	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg27494647	chr7:150038898	RARRES2	0.47	5.43	0.49	4.32e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4940575	0.679	rs17070777	chr18:60833814	A/C	cg20947866	chr18:61143580	SERPINB5	0.88	5.26	0.47	8.96e-7	Breast cancer;
THYM	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.64	-5.53	-0.49	2.78e-7	Systemic lupus erythematosus;
THYM	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1160297	0.643	rs6737483	chr2:53041627	G/A	cg07782112	chr2:53107842	NA	0.67	5.49	0.49	3.35e-7	Hemostatic factors and hematological phenotypes;
THYM	cis	rs9595908	1.000	rs9591143	chr13:33159438	C/T	cg12383807	chr13:33924137	NA	-0.53	-4.71	-0.43	8.6e-6	Body mass index;
THYM	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg22875332	chr1:76189707	ACADM	0.88	11.06	0.75	9.05e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4654899	0.758	rs6690574	chr1:21504279	G/A	cg01072550	chr1:21505969	NA	-0.77	-7.39	-0.6	5.6e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs7220711	0.967	rs2342314	chr17:41786389	T/G	cg26893861	chr17:41843967	DUSP3	0.65	5.63	0.5	1.83e-7	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg26384229	chr12:38710491	ALG10B	1.0	7.56	0.61	2.54e-11	Bladder cancer;
THYM	cis	rs12410462	0.551	rs2814087	chr1:227632334	C/T	cg22525281	chr1:228134933	WNT9A	0.59	4.84	0.44	5.1e-6	Major depressive disorder;
THYM	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg07424592	chr7:64974309	NA	0.99	5.15	0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs9876781	1.000	rs13071337	chr3:48438189	A/G	cg06066452	chr3:48470258	PLXNB1	0.26	4.88	0.45	4.26e-6	Longevity;
THYM	cis	rs986417	0.748	rs4141684	chr14:61069351	C/T	cg27398547	chr14:60952738	C14orf39	0.93	5.06	0.46	2.07e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs1061377	1.000	rs3733278	chr4:39117235	T/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg08885076	chr2:99613938	TSGA10	-0.58	-5.74	-0.51	1.11e-7	Chronic sinus infection;
THYM	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg24531977	chr5:56204891	C5orf35	-0.59	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs7953249	0.618	rs7954039	chr12:121398654	A/C	cg02403541	chr12:121454288	C12orf43	-0.73	-6.78	-0.57	1.03e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs4642101	0.611	rs6442331	chr3:12820636	T/G	cg05775895	chr3:12838266	CAND2	0.84	7.37	0.6	6.32e-11	QRS complex (12-leadsum);
THYM	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs990171	0.955	rs6734736	chr2:103062880	C/T	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.13	-0.47	1.5e-6	Lymphocyte counts;
THYM	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg24060327	chr5:131705240	SLC22A5	0.79	6.49	0.55	3.8e-9	Breast cancer;
THYM	cis	rs9581857	0.615	rs3759435	chr13:27996813	T/G	cg22138327	chr13:27999177	GTF3A	0.88	6.69	0.57	1.52e-9	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg26384229	chr12:38710491	ALG10B	0.97	7.47	0.61	3.8e-11	Bladder cancer;
THYM	cis	rs4455778	0.724	rs10227744	chr7:49007522	A/G	cg26309511	chr7:48887640	NA	-0.53	-4.8	-0.44	5.88e-6	Lung cancer in never smokers;
THYM	cis	rs900145	0.725	rs11022754	chr11:13313243	G/A	cg13286116	chr11:13302098	ARNTL	0.58	4.48	0.42	2.11e-5	Menarche (age at onset);
THYM	cis	rs12579753	1.000	rs11613196	chr12:82173251	A/T	cg21231944	chr12:82153410	PPFIA2	0.69	5.26	0.47	8.95e-7	Resting heart rate;
THYM	cis	rs741677	0.893	rs1978963	chr17:483832	T/C	cg06217071	chr17:408420	NA	0.6	5.53	0.49	2.8e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
THYM	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg12310025	chr6:25882481	NA	-0.69	-5.59	-0.5	2.21e-7	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2749592	0.588	rs2505192	chr10:38395023	G/A	cg25427524	chr10:38739819	LOC399744	-0.72	-6.09	-0.53	2.4e-8	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs684232	0.623	rs365118	chr17:580543	G/A	cg15660573	chr17:549704	VPS53	-0.94	-10.17	-0.72	7.21e-17	Prostate cancer;
THYM	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg27572855	chr1:25598939	RHD	-0.65	-4.93	-0.45	3.43e-6	Erythrocyte sedimentation rate;
THYM	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg21475434	chr5:93447410	FAM172A	0.96	6.1	0.53	2.29e-8	Diabetic retinopathy;
THYM	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg06618935	chr21:46677482	NA	-0.96	-7.85	-0.63	6.34e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg02725872	chr8:58115012	NA	-0.88	-6.24	-0.54	1.24e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs12466960	0.811	rs6547846	chr2:28575961	T/C	cg11535839	chr2:28582676	NA	-0.59	-4.56	-0.42	1.52e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg14583973	chr4:3374767	RGS12	0.68	6.61	0.56	2.24e-9	Serum sulfate level;
THYM	cis	rs11771526	0.901	rs62457468	chr7:32301341	C/T	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs2455799	0.613	rs13078485	chr3:15883236	T/C	cg16303742	chr3:15540471	COLQ	-0.56	-5.87	-0.52	6.41e-8	Mean platelet volume;
THYM	cis	rs12579753	0.917	rs71466033	chr12:82242187	C/T	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.67	-0.43	1.01e-5	Resting heart rate;
THYM	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg15592062	chr6:167189543	RPS6KA2	0.49	4.89	0.45	4.04e-6	Crohn's disease;
THYM	cis	rs250585	0.736	rs30015	chr16:23413774	T/C	cg00143387	chr16:23521605	GGA2	0.75	5.11	0.46	1.67e-6	Egg allergy;
THYM	cis	rs7959663	1	rs7959663	chr12:109884367	G/C	cg10504392	chr12:110044639	NA	0.6	4.67	0.43	9.81e-6	Bipolar disorder lithium response (categorical) or schizophrenia;
THYM	cis	rs7107770	1.000	rs4935915	chr11:125106724	G/C	cg07747661	chr11:125106135	PKNOX2	-0.92	-5.28	-0.48	8.31e-7	Photic sneeze reflex;
THYM	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Body mass index;
THYM	cis	rs3768617	0.510	rs10752903	chr1:183100863	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs2075165	0.901	rs7542798	chr1:156224304	A/G	cg20302342	chr1:156215951	PAQR6	0.48	4.94	0.45	3.37e-6	Tonsillectomy;
THYM	cis	rs55728055	1.000	rs55728055	chr22:32093268	G/C	cg01338084	chr22:32026380	PISD	1.55	6.04	0.53	3.03e-8	Age-related hearing impairment;
THYM	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs4919694	1.000	rs12246689	chr10:104817031	C/T	cg15744005	chr10:104629667	AS3MT	-0.85	-4.67	-0.43	9.96e-6	Arsenic metabolism;
THYM	cis	rs2273669	0.504	rs78885459	chr6:109439138	A/C	cg17117243	chr6:109341365	SESN1	-0.85	-4.99	-0.46	2.77e-6	Prostate cancer;
THYM	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg05556917	chr6:36408633	PXT1	-0.85	-6.98	-0.58	3.89e-10	Depressive symptoms;
THYM	cis	rs7172809	0.561	rs76746801	chr15:77789773	C/T	cg22256960	chr15:77711686	NA	-0.61	-4.47	-0.42	2.18e-5	Glucose homeostasis traits;
THYM	cis	rs12701220	0.590	rs1881124	chr7:1096766	A/C	cg26769984	chr7:1090371	C7orf50	0.84	5.46	0.49	3.75e-7	Bronchopulmonary dysplasia;
THYM	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.64	-4.66	-0.43	1.03e-5	Colorectal cancer;
THYM	cis	rs1957429	0.572	rs3813421	chr14:65347239	G/A	cg23373153	chr14:65346875	NA	1.07	6.45	0.55	4.75e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg06623918	chr6:96969491	KIAA0776	-1.11	-9.86	-0.71	3.24e-16	Headache;
THYM	cis	rs7582180	0.715	rs764828	chr2:100908634	A/C	cg08017756	chr2:100939284	LONRF2	-0.6	-5.5	-0.49	3.19e-7	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg01017244	chr2:74357527	NA	1.1	8.91	0.67	3.51e-14	Gestational age at birth (maternal effect);
THYM	cis	rs920590	0.758	rs7011322	chr8:19661937	C/T	cg01411142	chr8:19674711	INTS10	0.63	4.79	0.44	6.06e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9581857	0.546	rs9581837	chr13:27965764	G/T	cg22138327	chr13:27999177	GTF3A	0.99	5.52	0.49	2.99e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg09549813	chr16:4587862	C16orf5	-0.56	-6.15	-0.53	1.84e-8	Schizophrenia;
THYM	cis	rs2658782	0.789	rs56091149	chr11:93073640	A/C	cg15737290	chr11:93063684	CCDC67	-1.08	-8.9	-0.67	3.65e-14	Pulmonary function decline;
THYM	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22857025	chr5:266934	NA	-1.43	-9.3	-0.69	5.28e-15	Breast cancer;
THYM	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs1003719	0.679	rs2835638	chr21:38534533	T/C	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs7159131	0.775	rs11623436	chr14:37045492	C/T	cg01611862	chr14:36982649	SFTA3	0.5	4.72	0.44	8.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6840360	0.593	rs867800	chr4:152691470	T/C	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg11941060	chr3:133502564	NA	-0.82	-6.94	-0.58	4.88e-10	Iron status biomarkers;
THYM	cis	rs1971762	0.545	rs11170632	chr12:54047935	C/T	cg16917193	chr12:54089295	NA	-0.77	-7.34	-0.6	7.04e-11	Height;
THYM	cis	rs4803468	1.000	rs10422783	chr19:41906436	T/C	cg09537434	chr19:41945824	ATP5SL	-1.09	-10.08	-0.72	1.11e-16	Height;
THYM	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22496380	chr5:211416	CCDC127	1.33	7.99	0.63	3.21e-12	Breast cancer;
THYM	cis	rs2742417	0.624	rs2673068	chr3:45768981	G/A	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg02869364	chr7:1081709	C7orf50	-0.61	-4.96	-0.45	3.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs300703	0.872	rs300752	chr2:209292	A/G	cg21211680	chr2:198530	NA	1.1	5.76	0.51	1.05e-7	Blood protein levels;
THYM	cis	rs12291225	0.585	rs10832242	chr11:14340504	C/T	cg19336497	chr11:14380999	RRAS2	0.92	13.92	0.82	1.13e-24	Sense of smell;
THYM	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg11245990	chr11:68621969	NA	0.57	7.2	0.59	1.41e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7043114	0.525	rs7864630	chr9:95267560	A/C	cg14631576	chr9:95140430	CENPP	-0.79	-7.7	-0.62	1.26e-11	Height;
THYM	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs7100689	0.646	rs1340384	chr10:82088702	T/A	cg01528321	chr10:82214614	TSPAN14	0.84	6.43	0.55	5.15e-9	Post bronchodilator FEV1;
THYM	cis	rs6687430	0.514	rs587916	chr1:10545590	G/A	cg20482658	chr1:10539492	PEX14	-0.49	-6.13	-0.53	2e-8	Hand grip strength;
THYM	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg10193763	chr2:225306901	NA	-0.52	-5.49	-0.49	3.38e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg18305652	chr10:134549665	INPP5A	0.88	8.73	0.67	8.38e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg17173187	chr15:85201210	NMB	-0.42	-4.52	-0.42	1.77e-5	P wave terminal force;
THYM	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg08847533	chr14:75593920	NEK9	-1.01	-11.33	-0.76	2.42e-19	Height;
THYM	cis	rs1003719	0.715	rs2251952	chr21:38559711	T/C	cg01329690	chr21:38580129	DSCR9	-0.34	-4.68	-0.43	9.67e-6	Eye color traits;
THYM	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06481639	chr22:41940642	POLR3H	0.87	5.95	0.52	4.49e-8	Vitiligo;
THYM	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11890956	chr21:40555474	PSMG1	-0.9	-9.45	-0.7	2.51e-15	Cognitive function;
THYM	cis	rs2806561	1.000	rs1571466	chr1:23449183	T/C	cg08872493	chr1:23521417	HTR1D	0.38	4.72	0.44	8.12e-6	Height;
THYM	cis	rs7084402	0.967	rs1649077	chr10:60293906	A/G	cg07615347	chr10:60278583	BICC1	0.56	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs6032067	0.777	rs73907811	chr20:43801395	T/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.93	-0.58	5.03e-10	Blood protein levels;
THYM	cis	rs36051895	0.623	rs10283473	chr9:5244708	C/A	cg02405213	chr9:5042618	JAK2	-0.93	-9.32	-0.69	4.77e-15	Pediatric autoimmune diseases;
THYM	cis	rs12476592	0.543	rs12105140	chr2:63797218	A/G	cg17519650	chr2:63277830	OTX1	-0.7	-4.71	-0.44	8.46e-6	Childhood ear infection;
THYM	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg13010199	chr12:38710504	ALG10B	0.76	6.07	0.53	2.59e-8	Heart rate;
THYM	cis	rs7786877	0.723	rs6969697	chr7:100209604	G/A	cg04499151	chr7:100231278	TFR2	0.63	4.48	0.42	2.07e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.73	-0.44	7.7e-6	Crohn's disease;
THYM	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs2803122	0.807	rs10757035	chr9:19230272	C/G	cg19584733	chr9:19298547	DENND4C	-0.54	-4.72	-0.44	8.2e-6	Pulse pressure;
THYM	cis	rs250677	0.522	rs2217638	chr5:148364355	A/G	cg18129178	chr5:148520854	ABLIM3	0.72	5.4	0.48	4.94e-7	Breast cancer;
THYM	cis	rs4851254	0.660	rs77023845	chr2:100712346	G/A	cg22139774	chr2:100720529	AFF3	-0.41	-4.69	-0.43	9.07e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06634786	chr22:41940651	POLR3H	-0.77	-5.6	-0.5	2.06e-7	Vitiligo;
THYM	cis	rs12149862	1.000	rs7201161	chr16:69468362	T/C	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg01236616	chr12:121019343	POP5	-1.28	-9.82	-0.71	4.03e-16	Type 1 diabetes nephropathy;
THYM	cis	rs800586	0.833	rs800549	chr8:116819874	G/A	cg04656070	chr8:116661063	TRPS1	0.48	4.98	0.45	2.88e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9814567	0.555	rs1498726	chr3:134167300	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.59	5.1	0.46	1.73e-6	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg27398817	chr8:82754497	SNX16	0.84	6.56	0.56	2.79e-9	Diastolic blood pressure;
THYM	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg09537434	chr19:41945824	ATP5SL	0.78	5.99	0.52	3.73e-8	Migraine;Coronary artery disease;
THYM	cis	rs13082711	0.554	rs66854845	chr3:27387008	C/T	cg02860705	chr3:27208620	NA	0.87	6.18	0.54	1.58e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg10792982	chr14:105748885	BRF1	0.76	7.95	0.63	3.92e-12	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4951018	0.526	rs4245718	chr1:205652472	G/A	cg07157834	chr1:205819609	PM20D1	-0.61	-4.87	-0.45	4.38e-6	Prostate-specific antigen levels;
THYM	cis	rs11112613	0.762	rs73184078	chr12:105950017	A/G	cg03607813	chr12:105948248	NA	1.07	9.36	0.69	3.87e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg14798641	chr3:49314920	USP4;C3orf62	-0.69	-4.69	-0.43	9.23e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs7078219	0.686	rs12412391	chr10:101288935	A/G	cg23904955	chr10:101282759	NA	-0.42	-4.97	-0.45	2.99e-6	Dental caries;
THYM	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.02	-0.46	2.42e-6	Blood metabolite levels;
THYM	cis	rs9563576	0.709	rs1326538	chr13:58608018	T/C	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs2933343	0.729	rs789228	chr3:128601050	A/G	cg11901034	chr3:128598214	ACAD9	-0.71	-5.55	-0.49	2.56e-7	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.55	-0.49	2.58e-7	Obesity-related traits;
THYM	cis	rs943437	0.557	rs7749147	chr6:112164313	G/A	cg20596647	chr6:112163498	FYN	0.42	4.46	0.42	2.22e-5	Parkinson's disease;
THYM	cis	rs9828933	0.752	rs73117082	chr3:63947565	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.95	-5.58	-0.5	2.23e-7	Type 2 diabetes;
THYM	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg24642439	chr20:33292090	TP53INP2	0.63	5.01	0.46	2.54e-6	Coronary artery disease;
THYM	cis	rs9522267	0.535	rs9522305	chr13:112237550	A/G	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg24531977	chr5:56204891	C5orf35	0.62	5.08	0.46	1.86e-6	Initial pursuit acceleration;
THYM	cis	rs7572733	0.534	rs700685	chr2:198715972	A/G	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg10360139	chr7:1886902	MAD1L1	-0.61	-5.4	-0.48	4.86e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg14972814	chr11:95582409	MTMR2	-0.73	-6.13	-0.53	1.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg05863683	chr7:1912471	MAD1L1	0.45	4.7	0.43	8.63e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg02527881	chr3:46936655	PTH1R	0.54	5.21	0.47	1.1e-6	Colorectal cancer;
THYM	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Gout;
THYM	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.78	-0.44	6.31e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs11690935	0.877	rs72890834	chr2:172835802	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.82	-5.99	-0.52	3.77e-8	Schizophrenia;
THYM	cis	rs11018874	0.597	rs4393275	chr11:89886397	C/T	cg23743573	chr11:89867420	NAALAD2	0.8	5.4	0.48	4.95e-7	White blood cell types;
THYM	cis	rs10936602	0.527	rs9814802	chr3:169532377	A/G	cg17737146	chr3:169530037	LRRC34	0.52	5.02	0.46	2.44e-6	Renal cell carcinoma;
THYM	cis	rs2976388	0.609	rs2717605	chr8:143801015	T/G	cg06565975	chr8:143823917	SLURP1	0.45	4.97	0.45	2.99e-6	Urinary tract infection frequency;
THYM	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg05283184	chr6:79620031	NA	-0.94	-9.21	-0.69	7.9e-15	Intelligence (multi-trait analysis);
THYM	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21582582	chr3:182698605	DCUN1D1	0.81	7.07	0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg20891558	chr2:74357851	NA	1.15	11.89	0.77	1.62e-20	Gestational age at birth (maternal effect);
THYM	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg12165864	chr7:66369176	NA	0.67	5.26	0.47	8.99e-7	Aortic root size;
THYM	cis	rs4478239	1.000	rs6553053	chr4:188190251	A/G	cg02596645	chr4:187628413	FAT1	-0.79	-4.46	-0.42	2.22e-5	Major depressive disorder;
THYM	cis	rs12950390	0.512	rs11651000	chr17:45835278	G/A	cg24803719	chr17:45855879	NA	-0.63	-5.23	-0.47	1.01e-6	IgG glycosylation;
THYM	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg02734326	chr4:10020555	SLC2A9	-0.76	-6.46	-0.55	4.42e-9	Bone mineral density;
THYM	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg02773041	chr1:40204384	PPIE	0.77	5.99	0.52	3.8e-8	Blood protein levels;
THYM	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg08431931	chr22:42394659	WBP2NL	0.85	5.33	0.48	6.65e-7	Birth weight;
THYM	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.01	-5.45	-0.49	4.03e-7	Body mass index;
THYM	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs9916302	0.706	rs2879259	chr17:37410892	C/G	cg03321784	chr17:37729644	NA	0.55	4.48	0.42	2.08e-5	Glomerular filtration rate (creatinine);
THYM	trans	rs4650994	0.524	rs2811299	chr1:178586377	A/G	cg05059571	chr16:84539110	KIAA1609	0.89	9.74	0.71	5.85e-16	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg14196790	chr5:131705035	SLC22A5	0.52	4.79	0.44	6.07e-6	Breast cancer;Mosquito bite size;
THYM	cis	rs7572733	0.534	rs700683	chr2:198712332	G/A	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs17125944	0.506	rs7160285	chr14:53311400	A/C	cg00686598	chr14:53173677	PSMC6	-1.06	-5.03	-0.46	2.36e-6	Alzheimer's disease (late onset);
THYM	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg26314531	chr2:26401878	FAM59B	-0.72	-4.45	-0.42	2.31e-5	Gut microbiome composition (summer);
THYM	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg26031613	chr14:104095156	KLC1	0.79	5.22	0.47	1.06e-6	Body mass index;
THYM	cis	rs2073300	0.609	rs77673953	chr20:23398794	G/C	cg12062639	chr20:23401060	NAPB	1.1	5.73	0.51	1.16e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06481639	chr22:41940642	POLR3H	-0.85	-5.99	-0.52	3.74e-8	Vitiligo;
THYM	cis	rs7084402	0.902	rs1593670	chr10:60300766	C/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.64	-0.5	1.72e-7	Refractive error;
THYM	cis	rs12946454	0.668	rs4792867	chr17:43249444	C/T	cg00677574	chr17:43221327	ACBD4	0.56	4.77	0.44	6.61e-6	Systolic blood pressure;
THYM	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg10360139	chr7:1886902	MAD1L1	-0.82	-7.31	-0.6	8.13e-11	Bipolar disorder and schizophrenia;
THYM	cis	rs6785206	0.772	rs2811493	chr3:128357299	C/G	cg16766828	chr3:128327626	NA	-0.78	-7.73	-0.62	1.1e-11	Lymphocyte percentage of white cells;
THYM	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg17426766	chr1:2046864	PRKCZ	-0.39	-4.76	-0.44	6.9e-6	Height;
THYM	cis	rs490234	0.588	rs35278449	chr9:128172963	C/G	cg14078157	chr9:128172775	NA	-1.02	-8.86	-0.67	4.54e-14	Mean arterial pressure;
THYM	cis	rs2219968	0.923	rs35703732	chr8:78953269	C/T	cg00738934	chr8:78996279	NA	0.91	9.88	0.71	3.04e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10489202	0.632	rs202265	chr1:167990231	G/C	cg24449463	chr1:168025552	DCAF6	-0.92	-9.44	-0.7	2.67e-15	Schizophrenia;
THYM	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg12573674	chr2:1569213	NA	-1.19	-4.49	-0.42	2.02e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg23989207	chr17:80870107	TBCD	0.59	4.88	0.45	4.27e-6	Glycated hemoglobin levels;
THYM	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg06453172	chr10:134556979	INPP5A	-0.66	-4.77	-0.44	6.78e-6	Migraine;
THYM	cis	rs8050907	0.744	rs1345430	chr16:4527961	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.58	0.43	1.38e-5	Obesity-related traits;
THYM	cis	rs7084402	0.967	rs1649076	chr10:60294061	A/T	cg07615347	chr10:60278583	BICC1	0.56	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg18876405	chr7:65276391	NA	0.61	5.2	0.47	1.13e-6	Aortic root size;
THYM	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.0	0.63	2.98e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg10150615	chr22:24372951	LOC391322	-0.91	-9.11	-0.68	1.32e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7943358	0.758	rs7937707	chr11:15700127	A/T	cg11966998	chr11:15692519	NA	-0.49	-5.13	-0.47	1.54e-6	Gut microbiome composition (summer);
THYM	cis	rs3820068	0.608	rs6668919	chr1:16049893	A/G	cg05660106	chr1:15850417	CASP9	-0.73	-5.82	-0.51	8.01e-8	Systolic blood pressure;
THYM	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg17845761	chr1:175162550	KIAA0040	-0.36	-4.57	-0.42	1.45e-5	Alcohol dependence;
THYM	cis	rs2502731	0.539	rs3003608	chr9:130984430	C/A	cg13642260	chr9:130955380	CIZ1	0.63	4.98	0.45	2.88e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs1499972	0.887	rs73168397	chr3:117657197	C/T	cg07612923	chr3:117604196	NA	1.3	5.07	0.46	1.94e-6	Schizophrenia;
THYM	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg11905131	chr22:24372483	LOC391322	-0.97	-12.83	-0.8	1.87e-22	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7084402	0.967	rs1427200	chr10:60274928	C/T	cg09696939	chr10:60272079	BICC1	0.5	5.75	0.51	1.07e-7	Refractive error;
THYM	cis	rs7631605	0.905	rs11712979	chr3:37195495	C/T	cg21328643	chr3:37258149	NA	-0.48	-4.49	-0.42	2.01e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs12580035	0.568	rs7300241	chr12:1912526	C/T	cg04012082	chr12:1905096	CACNA2D4	-0.37	-4.55	-0.42	1.59e-5	Urate levels in lean individuals;
THYM	cis	rs13315871	1.000	rs71311858	chr3:58323793	G/C	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs17152411	1.000	rs17152381	chr10:126592903	T/G	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs1451375	0.617	rs880029	chr7:50569927	G/C	cg18232548	chr7:50535776	DDC	-0.69	-5.23	-0.47	9.94e-7	Malaria;
THYM	cis	rs793108	0.742	rs867992	chr10:31389313	A/T	cg07137701	chr10:31611868	ZEB1	-0.55	-4.82	-0.44	5.52e-6	Multiple sclerosis;Rheumatoid arthritis;
THYM	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22509189	chr2:225307070	NA	0.92	6.85	0.58	7.16e-10	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs17818399	0.547	rs7607308	chr2:46759104	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.67	4.66	0.43	1.02e-5	Height;
THYM	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg08901578	chr4:187885870	NA	-0.59	-5.46	-0.49	3.83e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10799590	1.000	rs7543218	chr1:224879577	A/C	cg01808320	chr1:224927238	CNIH3	-0.53	-4.71	-0.44	8.31e-6	Opioid dependence;
THYM	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Body mass index;
THYM	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg26038318	chr20:34205095	SPAG4	0.62	4.54	0.42	1.62e-5	Total cholesterol levels;
THYM	cis	rs665401	1.000	rs55915982	chr6:117257582	T/C	cg20376953	chr6:117187980	NA	0.55	4.49	0.42	1.99e-5	Neutrophil percentage of granulocytes;
THYM	cis	rs12121840	0.790	rs56277222	chr1:165536604	T/C	cg19407955	chr1:165599744	MGST3	-0.65	-4.64	-0.43	1.12e-5	Interleukin-1-receptor antagonist levels;
THYM	cis	rs10799590	1.000	rs169888	chr1:224839082	G/A	cg01808320	chr1:224927238	CNIH3	-0.57	-5.16	-0.47	1.35e-6	Opioid dependence;
THYM	cis	rs7267979	0.816	rs6115094	chr20:25210827	A/G	cg08601574	chr20:25228251	PYGB	0.63	4.93	0.45	3.54e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4595586	0.545	rs4623945	chr12:39364572	A/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg11494091	chr17:61959527	GH2	1.07	17.09	0.87	9.87e-31	Prudent dietary pattern;
THYM	cis	rs1728785	1.000	rs6499181	chr16:68593002	A/T	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs2233152	0.572	rs10411008	chr19:41297241	T/C	cg21869046	chr19:41225005	ITPKC	0.41	4.45	0.42	2.29e-5	Kawasaki disease;
THYM	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg22166914	chr1:53195759	ZYG11B	0.8	8.1	0.64	1.82e-12	Monocyte count;
THYM	cis	rs12282928	0.921	rs7108931	chr11:48288626	C/T	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg04282206	chr17:62833786	PLEKHM1P	-0.83	-8.06	-0.64	2.23e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs259282	0.538	rs6510273	chr19:33117884	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.61	4.75	0.44	7.33e-6	Schizophrenia;
THYM	cis	rs7818345	0.874	rs12674938	chr8:19300813	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.44	4.65	0.43	1.08e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs7584330	0.554	rs6736468	chr2:238422228	A/G	cg16989719	chr2:238392110	NA	-0.6	-4.53	-0.42	1.73e-5	Prostate cancer;
THYM	cis	rs6763768	0.606	rs13062474	chr3:53331547	C/T	cg22900224	chr3:52804907	NEK4	0.71	4.57	0.42	1.48e-5	Bacterial meningitis;
THYM	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.2	-9.67	-0.7	8.34e-16	Platelet count;
THYM	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	9.39	0.69	3.37e-15	Chronic sinus infection;
THYM	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg13918804	chr1:2043761	PRKCZ	-0.61	-4.62	-0.43	1.19e-5	Height;
THYM	cis	rs6866344	0.697	rs6873150	chr5:178125704	G/A	cg03877680	chr5:178157825	ZNF354A	0.8	5.35	0.48	5.95e-7	Neutrophil percentage of white cells;
THYM	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg22920501	chr2:26401640	FAM59B	-0.79	-7.07	-0.59	2.63e-10	Gut microbiome composition (summer);
THYM	trans	rs629535	0.814	rs506931	chr8:70068129	T/G	cg21567404	chr3:27674614	NA	1.08	10.14	0.72	8.19e-17	Dupuytren's disease;
THYM	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11645898	0.765	rs112439757	chr16:72168337	C/T	cg14768367	chr16:72042858	DHODH	-0.61	-4.52	-0.42	1.8e-5	Blood protein levels;
THYM	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs4285028	0.699	rs12637968	chr3:121599976	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.82	-5.82	-0.51	7.91e-8	Multiple sclerosis;
THYM	cis	rs6835098	0.692	rs28701033	chr4:174079376	T/A	cg08422745	chr4:174089978	GALNT7	-0.93	-7.38	-0.6	5.97e-11	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs73086581	1.000	rs17215054	chr20:3944779	T/C	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs77372450	0.515	rs2277948	chr5:157098233	T/C	cg15968604	chr5:157098555	C5orf52	-0.59	-4.47	-0.42	2.15e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs12681287	0.647	rs2953510	chr8:87341914	T/C	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs60695258	0.550	rs6531948	chr4:87972968	T/C	cg10685359	chr4:87814065	C4orf36	-0.46	-5.76	-0.51	1.04e-7	Hematocrit;
THYM	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.27	0.69	5.96e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg17105886	chr17:28927953	LRRC37B2	1.32	6.9	0.58	5.89e-10	Body mass index;
THYM	cis	rs7404928	0.651	rs55649386	chr16:23957370	A/T	cg26685404	chr16:23957272	PRKCB	0.68	8.12	0.64	1.7e-12	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs2692947	0.526	rs4907225	chr2:96576670	C/T	cg22654517	chr2:96458247	NA	0.71	5.17	0.47	1.28e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-5.76	-0.51	1.03e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-7.0	-0.58	3.54e-10	Monocyte percentage of white cells;
THYM	cis	rs7465272	1.000	rs7835613	chr8:143682428	C/T	cg01509843	chr8:143695822	ARC	0.73	4.94	0.45	3.34e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg11764359	chr7:65958608	NA	0.66	4.69	0.43	8.98e-6	Aortic root size;
THYM	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg27446573	chr6:127587934	RNF146	0.74	5.98	0.52	3.83e-8	Breast cancer;
THYM	trans	rs8002861	0.875	rs12428432	chr13:44464043	A/G	cg17145862	chr1:211918768	LPGAT1	-0.97	-9.58	-0.7	1.28e-15	Leprosy;
THYM	cis	rs36051895	0.664	rs10974960	chr9:5095842	G/A	cg02405213	chr9:5042618	JAK2	-1.0	-11.3	-0.76	2.84e-19	Pediatric autoimmune diseases;
THYM	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg08999081	chr20:33150536	PIGU	0.79	7.17	0.59	1.62e-10	Coronary artery disease;
THYM	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg12011299	chr4:100065546	ADH4	0.92	9.3	0.69	5.2e-15	Alcohol dependence;
THYM	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg25767906	chr1:53392781	SCP2	0.66	6.2	0.54	1.43e-8	Monocyte count;
THYM	cis	rs4940575	0.679	rs17070779	chr18:60835738	C/T	cg25271770	chr18:61057090	VPS4B	-0.77	-4.61	-0.43	1.24e-5	Breast cancer;
THYM	cis	rs9677476	0.909	rs7562116	chr2:232108246	A/G	cg23338755	chr2:231921595	PSMD1	0.68	4.92	0.45	3.59e-6	Food antigen IgG levels;
THYM	cis	rs9905704	0.914	rs2643117	chr17:56829516	G/A	cg12560992	chr17:57184187	TRIM37	0.66	4.45	0.42	2.35e-5	Testicular germ cell tumor;
THYM	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg10295955	chr4:187884368	NA	1.17	17.37	0.87	3.11e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs28595532	0.920	rs114649974	chr4:119735341	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs735539	0.521	rs513795	chr13:21427448	T/C	cg02792322	chr13:21280448	IL17D	-0.65	-4.68	-0.43	9.45e-6	Dental caries;
THYM	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg03929089	chr4:120376271	NA	-0.94	-10.4	-0.73	2.34e-17	Coronary artery disease;
THYM	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg20891283	chr12:69753455	YEATS4	1.09	12.03	0.78	8.44e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs476633	0.679	rs72737734	chr15:41432899	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.72	-5.57	-0.5	2.35e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg06360820	chr2:242988706	NA	-1.06	-7.65	-0.62	1.66e-11	Obesity-related traits;
THYM	cis	rs1215050	0.740	rs783929	chr4:98972495	T/A	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg22089800	chr15:90895588	ZNF774	0.68	5.25	0.47	9.27e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs10208649	0.908	rs72906714	chr2:54265560	T/C	cg04546899	chr2:54196757	PSME4	0.68	4.73	0.44	7.94e-6	Body mass index;
THYM	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg24578937	chr1:2090814	PRKCZ	-0.6	-6.01	-0.52	3.44e-8	Height;
THYM	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Bladder cancer;
THYM	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg16031515	chr1:205743344	RAB7L1	-0.67	-6.72	-0.57	1.36e-9	Monocyte percentage of white cells;
THYM	cis	rs9876781	0.967	rs9876891	chr3:48481434	G/T	cg06066452	chr3:48470258	PLXNB1	0.27	4.77	0.44	6.64e-6	Longevity;
THYM	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6570726	0.935	rs110289	chr6:145865176	C/G	cg13319975	chr6:146136371	FBXO30	-0.66	-5.62	-0.5	1.89e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1472147	1.000	rs3736609	chr7:128509319	G/A	cg00260937	chr7:128520193	KCP	0.56	5.1	0.46	1.7e-6	Calcium levels;
THYM	cis	rs861020	0.630	rs656566	chr1:210006603	C/T	cg05527609	chr1:210001259	C1orf107	0.85	6.82	0.57	8.53e-10	Orofacial clefts;
THYM	cis	rs654384	0.510	rs597831	chr7:4166769	T/A	cg23474811	chr7:4183807	SDK1	-0.52	-4.58	-0.43	1.43e-5	Positive affect;
THYM	cis	rs34779708	0.966	rs11010129	chr10:35510822	T/C	cg03585969	chr10:35415529	CREM	0.63	4.48	0.42	2.09e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7084402	0.967	rs1658490	chr10:60281616	G/A	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg24675658	chr1:53192096	ZYG11B	-0.8	-7.2	-0.59	1.43e-10	Monocyte count;
THYM	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg00677455	chr12:58241039	CTDSP2	0.75	5.58	0.5	2.27e-7	Multiple sclerosis;
THYM	cis	rs7487075	0.930	rs6582656	chr12:46843416	A/G	cg21428710	chr12:47219797	SLC38A4	0.46	4.63	0.43	1.16e-5	Itch intensity from mosquito bite;
THYM	cis	rs761746	0.960	rs5998042	chr22:31953962	T/C	cg10537193	chr22:32026975	PISD	-0.34	-4.66	-0.43	1.01e-5	Intelligence;
THYM	cis	rs3741151	0.881	rs10898917	chr11:73065979	G/A	cg12959048	chr11:73096162	RELT	-0.43	-4.55	-0.42	1.61e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs831571	0.955	rs35837	chr3:64013249	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	-0.76	-4.52	-0.42	1.8e-5	Type 2 diabetes;
THYM	cis	rs6032067	0.714	rs3761194	chr20:43885935	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.39	-4.59	-0.43	1.33e-5	Blood protein levels;
THYM	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg07636037	chr3:49044803	WDR6	0.97	10.07	0.72	1.15e-16	Parkinson's disease;
THYM	cis	rs7681440	0.583	rs2619366	chr4:90763260	A/G	cg06632027	chr4:90757378	SNCA	-0.66	-5.29	-0.48	7.91e-7	Dementia with Lewy bodies;
THYM	cis	rs7586879	0.598	rs6545806	chr2:25124348	G/A	cg15423357	chr2:25149977	NA	0.7	7.74	0.62	1.03e-11	Body mass index;
THYM	cis	rs7246967	0.673	rs57027767	chr19:22876535	A/G	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg02569458	chr12:86230093	RASSF9	0.58	5.04	0.46	2.22e-6	Major depressive disorder;
THYM	cis	rs7523273	0.565	rs2761422	chr1:207893266	A/T	cg22525895	chr1:207977042	MIR29B2	0.52	4.86	0.45	4.66e-6	Schizophrenia;
THYM	cis	rs6700896	0.900	rs4459081	chr1:66164327	G/C	cg04111102	chr1:66153794	NA	-0.63	-6.28	-0.54	1.02e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg11366901	chr6:160182831	ACAT2	1.01	9.01	0.68	2.12e-14	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs3008870	1.000	rs3008859	chr1:67390999	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.92	7.43	0.61	4.77e-11	Lymphocyte percentage of white cells;
THYM	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.48	-0.42	2.05e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs11771526	0.892	rs62457534	chr7:32357652	G/A	cg27511599	chr7:32358540	NA	0.75	5.02	0.46	2.42e-6	Body mass index;
THYM	cis	rs6901250	0.851	rs168128	chr6:117166865	A/G	cg12892004	chr6:117198278	RFX6	-0.71	-6.97	-0.58	4.22e-10	C-reactive protein levels;
THYM	cis	rs921968	0.643	rs545460	chr2:219392159	A/G	cg02176678	chr2:219576539	TTLL4	0.64	6.08	0.53	2.49e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6424115	1.000	rs4649115	chr1:24155731	A/G	cg15997130	chr1:24165203	NA	-0.78	-6.79	-0.57	9.49e-10	Immature fraction of reticulocytes;
THYM	cis	rs2806561	0.780	rs4655142	chr1:23333728	T/C	cg19743168	chr1:23544995	NA	-0.61	-6.06	-0.53	2.74e-8	Height;
THYM	cis	rs4513633	0.656	rs12054589	chr4:113465971	A/G	cg27432847	chr4:113444372	NA	-0.56	-4.67	-0.43	1e-5	Interleukin-16 levels;
THYM	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg21394778	chr1:3037102	PRDM16	0.46	4.47	0.42	2.12e-5	Height;
THYM	cis	rs12282928	1.000	rs11039675	chr11:48336301	A/G	cg22827986	chr11:48284249	OR4X1	0.53	5.59	0.5	2.21e-7	Migraine - clinic-based;
THYM	cis	rs6596100	0.554	rs12515756	chr5:132238880	T/C	cg02081065	chr5:132209139	LEAP2	-0.85	-5.76	-0.51	1.03e-7	Breast cancer;
THYM	cis	rs1371867	0.875	rs28595052	chr8:101327553	G/A	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs4363385	0.791	rs3120744	chr1:153010330	G/A	cg13444842	chr1:152974279	SPRR3	-0.59	-4.72	-0.44	8.04e-6	Inflammatory skin disease;
THYM	cis	rs7681440	0.606	rs2583970	chr4:90746610	G/A	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs10791111	1	rs10791111	chr11:130856099	T/G	cg12179176	chr11:130786555	SNX19	0.67	5.09	0.46	1.82e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs12701220	0.595	rs12532837	chr7:1122851	T/A	cg01699819	chr7:1052092	C7orf50	-0.72	-5.94	-0.52	4.69e-8	Bronchopulmonary dysplasia;
THYM	cis	rs6763768	0.606	rs1001222	chr3:53352099	G/A	cg16894138	chr3:53270350	TKT	0.71	5.33	0.48	6.47e-7	Bacterial meningitis;
THYM	cis	rs308403	0.509	rs1849431	chr4:123674762	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.95	7.94	0.63	4.09e-12	Blood protein levels;
THYM	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.81	6.04	0.53	3e-8	Cognitive test performance;
THYM	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs990171	0.955	rs6720564	chr2:103079297	T/C	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.13	-0.47	1.56e-6	Lymphocyte counts;
THYM	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg05802129	chr4:122689817	NA	-0.66	-5.34	-0.48	6.4e-7	Type 2 diabetes;
THYM	cis	rs7043114	0.525	rs2274966	chr9:95155563	C/A	cg14631576	chr9:95140430	CENPP	-0.82	-8.2	-0.64	1.12e-12	Height;
THYM	cis	rs2658782	0.951	rs72972357	chr11:93118840	T/C	cg16424440	chr11:93231842	C11orf75	0.7	4.65	0.43	1.06e-5	Pulmonary function decline;
THYM	cis	rs870825	0.616	rs4519838	chr4:185628457	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.69	0.71	7.45e-16	Blood protein levels;
THYM	cis	rs10463554	0.963	rs34829	chr5:102443964	A/T	cg23492399	chr5:102201601	PAM	-0.68	-5.13	-0.47	1.51e-6	Parkinson's disease;
THYM	cis	rs7267979	1.000	rs2027003	chr20:25350498	A/G	cg08601574	chr20:25228251	PYGB	-0.58	-4.71	-0.43	8.54e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6543140	0.964	rs6734203	chr2:103080066	G/C	cg03938978	chr2:103052716	IL18RAP	0.55	5.32	0.48	6.95e-7	Blood protein levels;
THYM	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg11266682	chr4:10021025	SLC2A9	0.73	11.88	0.77	1.74e-20	Bone mineral density;
THYM	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg17264618	chr3:40429014	ENTPD3	0.52	5.13	0.47	1.52e-6	Renal cell carcinoma;
THYM	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg07157834	chr1:205819609	PM20D1	-0.63	-4.95	-0.45	3.18e-6	Menarche (age at onset);
THYM	cis	rs7973719	0.868	rs12825629	chr12:7355583	T/C	cg07052231	chr12:7363540	PEX5	0.61	5.26	0.48	8.71e-7	IgG glycosylation;
THYM	cis	rs2050392	0.799	rs2907	chr10:30728250	A/G	cg02070205	chr10:30722105	MAP3K8	-0.53	-4.55	-0.42	1.57e-5	Inflammatory bowel disease;
THYM	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg00191853	chr8:101177733	SPAG1	0.62	4.93	0.45	3.48e-6	Atrioventricular conduction;
THYM	cis	rs11030122	0.702	rs67300156	chr11:3953949	C/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.59	-0.43	1.36e-5	Mean platelet volume;Platelet distribution width;
THYM	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg23187316	chr7:1099788	C7orf50	0.45	4.98	0.46	2.79e-6	Longevity;Endometriosis;
THYM	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9814567	0.896	rs7653880	chr3:134345788	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-8.47	-0.66	3e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2294693	0.945	rs9381023	chr6:40983281	C/T	cg14418226	chr6:40996092	UNC5CL	-0.67	-5.41	-0.49	4.6e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg21138405	chr5:131827807	IRF1	0.7	5.15	0.47	1.38e-6	Asthma (sex interaction);
THYM	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg06108461	chr20:60628389	TAF4	-1.07	-9.19	-0.69	9.08e-15	Body mass index;
THYM	cis	rs6754311	0.731	rs687670	chr2:136740900	T/C	cg20242066	chr2:136595261	LCT	0.6	7.0	0.58	3.59e-10	Mosquito bite size;
THYM	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg26384229	chr12:38710491	ALG10B	-0.88	-7.17	-0.59	1.6e-10	Morning vs. evening chronotype;
THYM	cis	rs3741151	1.000	rs3741149	chr11:73021084	A/G	cg12959048	chr11:73096162	RELT	0.44	4.58	0.43	1.39e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg15704280	chr7:45808275	SEPT13	-1.02	-13.33	-0.81	1.74e-23	Coronary artery disease;
THYM	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg08132940	chr7:1081526	C7orf50	-0.77	-5.18	-0.47	1.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg10661904	chr17:79619235	PDE6G	-0.65	-6.26	-0.54	1.12e-8	Eye color traits;
THYM	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg24375607	chr4:120327624	NA	-0.59	-4.8	-0.44	5.84e-6	Corneal astigmatism;
THYM	cis	rs244293	0.700	rs12939352	chr17:53007655	T/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.52	-4.49	-0.42	1.99e-5	Menarche (age at onset);
THYM	cis	rs28595532	0.920	rs115372254	chr4:119771735	T/C	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg07414643	chr4:187882934	NA	0.55	4.71	0.43	8.57e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg00495681	chr13:53174319	NA	0.69	7.03	0.58	3.15e-10	Lewy body disease;
THYM	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg05962950	chr11:130786565	SNX19	0.84	7.29	0.6	9.11e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg13607699	chr17:42295918	UBTF	0.6	5.03	0.46	2.33e-6	Total body bone mineral density;
THYM	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg08772003	chr10:104629869	AS3MT	-0.57	-4.9	-0.45	3.89e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs2718058	0.519	rs2598054	chr7:37884640	C/T	cg15028436	chr7:37888078	TXNDC3	0.71	4.66	0.43	1.03e-5	Alzheimer's disease (late onset);
THYM	cis	rs7119	0.717	rs11634174	chr15:77811232	A/T	cg10437265	chr15:77819839	NA	0.77	7.76	0.62	9.39e-12	Type 2 diabetes;
THYM	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	12.13	0.78	5.13e-21	Chronic sinus infection;
THYM	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg19913688	chr11:428466	ANO9	0.86	4.53	0.42	1.69e-5	Body mass index;
THYM	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg08736216	chr1:53307985	ZYG11A	-0.75	-6.62	-0.56	2.12e-9	Monocyte count;
THYM	cis	rs7187994	0.790	rs12922301	chr16:84794870	A/G	cg07647771	chr16:84786436	USP10	-0.55	-5.05	-0.46	2.15e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs4866334	1.000	rs116309900	chr5:18430285	G/T	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs7429990	0.965	rs9811277	chr3:48011638	A/G	cg02219026	chr3:48282209	ZNF589	-0.6	-4.5	-0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs1021993	0.597	rs10494922	chr1:209525430	A/G	cg06155620	chr1:209527581	NA	-0.52	-4.55	-0.42	1.58e-5	Gut microbiome composition (winter);
THYM	cis	rs995000	0.931	rs6678483	chr1:63074442	C/A	cg06896770	chr1:63153194	DOCK7	0.92	7.57	0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs17102423	0.826	rs10873180	chr14:65604361	A/G	cg11161011	chr14:65562177	MAX	0.77	6.58	0.56	2.54e-9	Obesity-related traits;
THYM	cis	rs4523957	0.523	rs2760746	chr17:2034806	G/C	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs454510	0.726	rs838989	chr1:120182906	G/A	cg11530693	chr1:120165357	ZNF697	0.66	4.5	0.42	1.91e-5	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
THYM	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg05890377	chr2:74357713	NA	1.06	9.73	0.71	6.11e-16	Gestational age at birth (maternal effect);
THYM	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg03709012	chr19:19516395	GATAD2A	0.76	6.05	0.53	2.87e-8	Tonsillectomy;
THYM	cis	rs7246657	0.943	rs4801759	chr19:37954985	G/A	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs526231	0.511	rs12109860	chr5:102393112	A/T	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Primary biliary cholangitis;
THYM	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg02478829	chr6:26598070	ABT1	0.33	4.49	0.42	1.97e-5	Intelligence (multi-trait analysis);
THYM	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg04772025	chr11:68637568	NA	0.66	6.99	0.58	3.79e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs208520	0.874	rs208512	chr6:66943869	C/G	cg07460842	chr6:66804631	NA	-0.78	-5.05	-0.46	2.16e-6	Exhaled nitric oxide output;
THYM	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4953076	0.533	rs10173126	chr2:44446492	T/C	cg04920474	chr2:44395004	PPM1B	0.65	5.38	0.48	5.27e-7	Height;
THYM	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg02734326	chr4:10020555	SLC2A9	0.77	6.74	0.57	1.25e-9	Bone mineral density;
THYM	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg02086790	chr16:375327	AXIN1	-0.43	-4.85	-0.45	4.75e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.75e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9384488	0.524	rs9480379	chr6:157020791	A/G	cg08839808	chr6:156983304	NA	-0.73	-4.71	-0.44	8.48e-6	Alzheimer's disease biomarkers;
THYM	cis	rs7830933	0.955	rs13265208	chr8:23583238	C/A	cg04349084	chr8:23602677	NA	0.68	7.07	0.59	2.58e-10	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs6732160	0.741	rs6546806	chr2:73386160	T/C	cg24220031	chr2:73402428	NA	-0.79	-8.39	-0.65	4.59e-13	Intelligence (multi-trait analysis);
THYM	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg08048268	chr3:133502702	NA	-0.64	-5.26	-0.47	8.97e-7	Iron status biomarkers;
THYM	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg11984989	chr7:158649758	WDR60	1.09	12.35	0.78	1.86e-21	Height;
THYM	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.57	4.91	0.45	3.76e-6	Height;
THYM	cis	rs4866334	1.000	rs77695209	chr5:18483369	T/C	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg08305652	chr11:111469057	NA	0.53	4.52	0.42	1.77e-5	Primary sclerosing cholangitis;
THYM	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg27284194	chr4:1044797	NA	0.62	4.73	0.44	7.81e-6	Recombination rate (females);
THYM	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg06191203	chr2:152266755	RIF1	-0.71	-4.85	-0.45	4.87e-6	Lung cancer;
THYM	cis	rs55728055	1.000	rs8142355	chr22:32081681	C/T	cg10537193	chr22:32026975	PISD	-0.89	-5.26	-0.47	8.91e-7	Age-related hearing impairment;
THYM	cis	rs4478037	1.000	rs56733391	chr3:33161434	G/A	cg19404215	chr3:33155277	CRTAP	1.18	8.15	0.64	1.49e-12	Major depressive disorder;
THYM	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-7.53	-0.61	2.9e-11	Lymphocyte percentage of white cells;
THYM	cis	rs4455778	0.692	rs7800120	chr7:49012977	C/T	cg26309511	chr7:48887640	NA	-0.52	-4.71	-0.43	8.57e-6	Lung cancer in never smokers;
THYM	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg01579765	chr21:45077557	HSF2BP	-0.49	-7.97	-0.63	3.43e-12	Mean corpuscular volume;
THYM	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg09455208	chr3:40491958	NA	0.51	5.39	0.48	5.03e-7	Renal cell carcinoma;
THYM	cis	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs7103648	0.742	rs34937994	chr11:47389638	C/T	cg20307385	chr11:47447363	PSMC3	0.83	6.64	0.56	1.95e-9	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs12643440	0.538	rs12641321	chr4:17141393	G/C	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg18230493	chr5:56204884	C5orf35	0.64	4.86	0.45	4.56e-6	Initial pursuit acceleration;
THYM	trans	rs11186	0.524	rs72906338	chr2:189959268	T/C	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg03709012	chr19:19516395	GATAD2A	0.84	7.3	0.6	8.83e-11	Tonsillectomy;
THYM	cis	rs28595532	0.920	rs114333298	chr4:119765305	C/A	cg11846333	chr4:119757529	SEC24D	1.47	5.13	0.47	1.5e-6	Cannabis dependence symptom count;
THYM	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg06108461	chr20:60628389	TAF4	-1.1	-9.46	-0.7	2.37e-15	Body mass index;
THYM	cis	rs2075230	0.588	rs1642802	chr17:7544271	T/C	cg27413385	chr17:7515425	FXR2	-0.36	-5.1	-0.46	1.74e-6	Hormone measurements;
THYM	trans	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs7586879	0.575	rs6712981	chr2:25126230	A/G	cg27107076	chr2:25050844	ADCY3	-0.29	-4.72	-0.44	8.01e-6	Body mass index;
THYM	cis	rs10927875	0.722	rs945425	chr1:16348412	T/C	cg21385522	chr1:16154831	NA	0.79	5.79	0.51	9.09e-8	Dilated cardiomyopathy;
THYM	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg07371521	chr5:154026371	NA	0.57	5.45	0.49	3.96e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs6686842	0.866	rs2802550	chr1:41497628	A/G	cg03387723	chr1:41708464	SCMH1	-0.44	-5.28	-0.48	8.08e-7	Height;
THYM	cis	rs904251	0.772	rs1224127	chr6:37417556	G/A	cg25019722	chr6:37503610	NA	-0.62	-4.62	-0.43	1.2e-5	Cognitive performance;
THYM	cis	rs7512552	0.839	rs11205357	chr1:150267798	T/C	cg15654264	chr1:150340011	RPRD2	-0.45	-5.27	-0.48	8.48e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6754311	0.593	rs313522	chr2:136430866	T/A	cg07169764	chr2:136633963	MCM6	0.7	5.67	0.5	1.55e-7	Mosquito bite size;
THYM	cis	rs6543140	0.865	rs6760275	chr2:103079607	C/T	cg03938978	chr2:103052716	IL18RAP	0.55	5.32	0.48	6.95e-7	Blood protein levels;
THYM	cis	rs6988636	1.000	rs13261021	chr8:124190239	G/A	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.5	-4.48	-0.42	2.06e-5	Pubertal anthropometrics;
THYM	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg11764359	chr7:65958608	NA	0.63	4.92	0.45	3.66e-6	Aortic root size;
THYM	cis	rs3126085	0.935	rs4845423	chr1:152184950	T/G	cg10321714	chr1:152280068	FLG	0.69	5.04	0.46	2.22e-6	Atopic dermatitis;
THYM	cis	rs7917772	0.582	rs4917975	chr10:104358407	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4866334	0.867	rs4866335	chr5:18484034	G/A	cg18608440	chr5:17519013	NA	-1.07	-4.95	-0.45	3.24e-6	IgG glycosylation;
THYM	cis	rs1978968	0.913	rs12158823	chr22:18439420	G/A	cg01550578	chr22:18484421	MICAL3	0.68	5.16	0.47	1.33e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs7772486	0.790	rs9403750	chr6:146167762	G/A	cg23711669	chr6:146136114	FBXO30	0.93	9.15	0.68	1.08e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg25811766	chr13:21894605	NA	0.72	4.89	0.45	4.15e-6	White matter hyperintensity burden;
THYM	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg00647820	chr17:40259828	DHX58	-0.62	-4.65	-0.43	1.06e-5	Fibrinogen levels;
THYM	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg03647317	chr4:187891568	NA	-0.83	-9.17	-0.69	9.91e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg24642439	chr20:33292090	TP53INP2	0.68	5.14	0.47	1.45e-6	Coronary artery disease;
THYM	cis	rs13266463	0.830	rs6983790	chr8:143406575	A/G	cg16886403	chr8:143471632	TSNARE1	0.64	4.85	0.45	4.88e-6	Schizophrenia;
THYM	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg02187348	chr16:89574699	SPG7	0.77	6.38	0.55	6.37e-9	Multiple myeloma (IgH translocation);
THYM	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg12698349	chr2:225449008	CUL3	0.73	5.47	0.49	3.67e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs6980334	0.871	rs3807332	chr7:137760180	A/G	cg18769353	chr7:137028617	PTN	0.57	4.5	0.42	1.9e-5	Blood metabolite ratios;
THYM	cis	rs2997447	0.633	rs11247848	chr1:26357667	G/A	cg19633962	chr1:26362018	EXTL1	-0.76	-5.05	-0.46	2.1e-6	QRS complex (12-leadsum);
THYM	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg11764359	chr7:65958608	NA	-0.74	-6.15	-0.53	1.85e-8	Aortic root size;
THYM	cis	rs55871839	0.708	rs13268621	chr8:59811724	T/G	cg07426533	chr8:59803705	TOX	-0.67	-6.88	-0.58	6.33e-10	Pneumonia;
THYM	cis	rs265548	0.538	rs36688	chr19:17911212	A/C	cg21960279	chr19:17905606	B3GNT3	0.66	6.05	0.53	2.85e-8	Tumor biomarkers;
THYM	cis	rs5758511	0.773	rs1894714	chr22:42349134	T/G	cg08431931	chr22:42394659	WBP2NL	-0.71	-4.46	-0.42	2.25e-5	Birth weight;
THYM	cis	rs4654899	1.000	rs6689819	chr1:21472395	A/T	cg01072550	chr1:21505969	NA	-0.74	-6.69	-0.57	1.54e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs986417	0.901	rs10483726	chr14:61039476	A/G	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs6542838	0.641	rs1581249	chr2:99500630	C/A	cg08885076	chr2:99613938	TSGA10	-0.52	-4.77	-0.44	6.73e-6	Fear of minor pain;
THYM	cis	rs6429082	0.818	rs704714	chr1:235632094	T/C	cg26050004	chr1:235667680	B3GALNT2	0.74	6.18	0.54	1.6e-8	Adiposity;
THYM	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg27168131	chr21:44088823	PDE9A	-0.45	-4.5	-0.42	1.92e-5	Mean corpuscular volume;
THYM	cis	rs748404	0.660	rs690367	chr15:43748304	C/T	cg12861797	chr15:43585817	TGM7	-0.45	-4.62	-0.43	1.19e-5	Lung cancer;
THYM	cis	rs71636778	0.509	rs61457762	chr1:27284157	C/G	cg16022904	chr1:26870173	RPS6KA1	0.84	4.55	0.42	1.58e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
THYM	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4455778	0.580	rs4917034	chr7:49113788	T/C	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg09904177	chr6:26538194	HMGN4	0.62	4.96	0.45	3.06e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7568458	0.870	rs1972297	chr2:85808573	T/C	cg17127132	chr2:85788382	GGCX	0.64	4.9	0.45	3.86e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs11731175	1.000	rs11132590	chr4:189848407	C/T	cg00431894	chr4:189871012	NA	-0.81	-6.15	-0.53	1.83e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs8030485	0.571	rs7182891	chr15:79438697	G/A	cg17916960	chr15:79447300	NA	0.55	5.64	0.5	1.74e-7	Left ventricle wall thickness;
THYM	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	4.67	0.43	1.01e-5	Obesity-related traits;
THYM	cis	rs4788570	0.511	rs4788830	chr16:71732267	A/G	cg06353428	chr16:71660113	MARVELD3	1.29	8.28	0.65	7.7e-13	Intelligence (multi-trait analysis);
THYM	cis	rs268134	0.530	rs17704661	chr2:65585817	G/C	cg03233656	chr2:65214625	SLC1A4	0.63	4.64	0.43	1.1e-5	Educational attainment (years of education);Systemic lupus erythematosus;
THYM	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg16586182	chr3:47516702	SCAP	-0.64	-5.61	-0.5	2.03e-7	Colorectal cancer;
THYM	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	5.59	0.5	2.16e-7	Monocyte percentage of white cells;
THYM	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	4.46	0.42	2.21e-5	Diabetic retinopathy;
THYM	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-9.1	-0.68	1.37e-14	Chronic sinus infection;
THYM	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg09904177	chr6:26538194	HMGN4	0.53	4.5	0.42	1.95e-5	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg22166914	chr1:53195759	ZYG11B	0.92	10.94	0.75	1.67e-18	Monocyte count;
THYM	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg26031613	chr14:104095156	KLC1	-0.7	-4.77	-0.44	6.55e-6	Body mass index;
THYM	cis	rs72781680	0.898	rs56216411	chr2:23934533	G/A	cg08917208	chr2:24149416	ATAD2B	1.1	4.81	0.44	5.71e-6	Lymphocyte counts;
THYM	cis	rs4077515	0.935	rs3812565	chr9:139272502	T/C	cg14115884	chr9:139300582	SDCCAG3	0.71	6.51	0.56	3.46e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs12474201	0.925	rs17822294	chr2:46960004	G/A	cg09399716	chr2:46890238	NA	-0.52	-4.48	-0.42	2.04e-5	Height;
THYM	cis	rs5769765	0.720	rs9628127	chr22:50166092	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	4.9	0.45	3.98e-6	Schizophrenia;
THYM	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	6.49	0.55	3.94e-9	Obesity-related traits;
THYM	cis	rs1451375	0.617	rs11772714	chr7:50542843	G/A	cg18232548	chr7:50535776	DDC	-0.69	-5.35	-0.48	6.08e-7	Malaria;
THYM	cis	rs600806	0.888	rs3879450	chr1:109909149	C/T	cg23032129	chr1:109941072	SORT1	-0.54	-4.55	-0.42	1.58e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1957429	0.614	rs7144637	chr14:65349709	A/G	cg23373153	chr14:65346875	NA	-1.29	-5.55	-0.49	2.56e-7	Pediatric areal bone mineral density (radius);
THYM	cis	rs807669	0.548	rs762522	chr22:19180575	C/T	cg02655711	chr22:19163373	SLC25A1	0.72	8.38	0.65	4.77e-13	Metabolite levels;
THYM	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg02569458	chr12:86230093	RASSF9	0.69	5.77	0.51	9.84e-8	Major depressive disorder;
THYM	cis	rs17401966	1.000	rs12734068	chr1:10376803	G/A	cg19773385	chr1:10388646	KIF1B	-0.63	-4.72	-0.44	8.22e-6	Hepatocellular carcinoma;
THYM	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg03188948	chr7:1209495	NA	0.87	6.6	0.56	2.32e-9	Longevity;Endometriosis;
THYM	cis	rs6121246	0.529	rs41310803	chr20:30452709	A/G	cg09796376	chr20:30640595	HCK	0.79	4.81	0.44	5.64e-6	Mean corpuscular hemoglobin;
THYM	cis	rs7106204	0.514	rs1443044	chr11:24255575	C/G	ch.11.24196551F	chr11:24239977	NA	-1.02	-7.23	-0.6	1.22e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg24531977	chr5:56204891	C5orf35	-1.07	-8.38	-0.65	4.78e-13	Initial pursuit acceleration;
THYM	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg03877680	chr5:178157825	ZNF354A	0.75	5.18	0.47	1.25e-6	Neutrophil percentage of white cells;
THYM	cis	rs1018836	0.631	rs2205157	chr8:91472384	C/T	cg16814680	chr8:91681699	NA	-0.69	-5.58	-0.5	2.3e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg11752832	chr7:134001865	SLC35B4	0.68	4.92	0.45	3.63e-6	Mean platelet volume;
THYM	cis	rs7408868	0.908	rs10416777	chr19:15276923	C/T	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg02782426	chr3:40428986	ENTPD3	-0.51	-4.56	-0.42	1.55e-5	Renal cell carcinoma;
THYM	cis	rs61931739	0.534	rs11052957	chr12:33995354	G/A	cg06521331	chr12:34319734	NA	-0.91	-8.47	-0.66	3.07e-13	Morning vs. evening chronotype;
THYM	cis	rs2282300	0.739	rs1765133	chr11:30339400	C/T	cg06241208	chr11:30344200	C11orf46	-0.78	-5.65	-0.5	1.64e-7	Morning vs. evening chronotype;
THYM	cis	rs3741151	0.773	rs113465107	chr11:73210416	T/G	cg17517138	chr11:73019481	ARHGEF17	0.87	4.65	0.43	1.08e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs17401966	1.000	rs17410793	chr1:10391886	A/G	cg19773385	chr1:10388646	KIF1B	-0.64	-4.77	-0.44	6.6e-6	Hepatocellular carcinoma;
THYM	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg04731861	chr2:219085781	ARPC2	0.54	5.18	0.47	1.26e-6	Colorectal cancer;
THYM	cis	rs7849270	1.000	rs713219	chr9:131900920	T/C	cg14069949	chr9:131965419	NA	0.5	4.52	0.42	1.8e-5	Blood metabolite ratios;
THYM	cis	rs7100689	0.890	rs4934169	chr10:82203663	A/G	cg01528321	chr10:82214614	TSPAN14	1.31	10.32	0.73	3.51e-17	Post bronchodilator FEV1;
THYM	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg15247329	chr7:2764246	NA	-0.68	-5.63	-0.5	1.8e-7	Height;
THYM	cis	rs17739794	0.557	rs7823906	chr8:814710	A/G	cg01971667	chr8:817044	NA	-0.61	-5.56	-0.5	2.42e-7	Clozapine-induced cytotoxicity;
THYM	trans	rs10504229	0.516	rs4361758	chr8:57990401	C/T	cg06642219	chr1:5586147	NA	0.64	6.87	0.58	6.74e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg03709012	chr19:19516395	GATAD2A	0.76	6.05	0.53	2.87e-8	Tonsillectomy;
THYM	cis	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg21775007	chr8:11205619	TDH	0.76	6.72	0.57	1.36e-9	Retinal vascular caliber;
THYM	cis	rs28510890	0.508	rs6496962	chr15:93158222	C/G	cg05775517	chr15:93158989	NA	-0.39	-4.69	-0.43	9.2e-6	Lung cancer in ever smokers;
THYM	cis	rs3862030	0.533	rs715440	chr10:104258095	A/T	cg00122347	chr10:104236741	TMEM180	0.48	7.33	0.6	7.69e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg19077165	chr18:44547161	KATNAL2	0.59	7.29	0.6	9.19e-11	Personality dimensions;
THYM	cis	rs7940866	0.804	rs10894287	chr11:130808483	C/T	cg12179176	chr11:130786555	SNX19	0.62	4.98	0.45	2.85e-6	Schizophrenia;
THYM	cis	rs4285028	0.747	rs3732410	chr3:121415720	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.84	-7.2	-0.59	1.37e-10	Multiple sclerosis;
THYM	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg14820908	chr5:178986412	RUFY1	0.5	4.75	0.44	7.26e-6	Lung cancer;
THYM	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg02869364	chr7:1081709	C7orf50	-0.61	-4.96	-0.45	3.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs742614	0.935	rs6057930	chr20:32477972	C/T	cg06304546	chr20:32448765	NA	-0.71	-5.52	-0.49	2.97e-7	Stearic acid (18:0) levels;
THYM	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg05425664	chr17:57184151	TRIM37	-0.57	-4.63	-0.43	1.16e-5	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.893	rs10888759	chr1:53433274	A/G	cg08859206	chr1:53392774	SCP2	0.65	7.33	0.6	7.72e-11	Monocyte count;
THYM	cis	rs924712	0.844	rs10948866	chr6:54734123	C/T	cg19716238	chr6:54711378	FAM83B	-0.45	-4.55	-0.42	1.57e-5	Breast cancer;
THYM	cis	rs2997447	0.846	rs61775425	chr1:26405634	A/T	cg03844060	chr1:26490628	NA	0.67	4.58	0.43	1.4e-5	QRS complex (12-leadsum);
THYM	cis	rs2236293	0.755	rs10758324	chr9:35799078	C/G	cg12876594	chr9:35791798	NPR2	0.4	4.51	0.42	1.87e-5	Blood protein levels;
THYM	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg23332699	chr15:44069569	ELL3	0.72	4.61	0.43	1.23e-5	Lung cancer in ever smokers;
THYM	cis	rs2050392	0.517	rs302423	chr10:30772513	A/G	cg25182066	chr10:30743637	MAP3K8	-0.54	-4.54	-0.42	1.67e-5	Inflammatory bowel disease;
THYM	cis	rs2637266	0.783	rs11001866	chr10:78486774	C/T	cg18941641	chr10:78392320	NA	0.75	6.06	0.53	2.74e-8	Pulmonary function;
THYM	cis	rs611744	0.870	rs650925	chr8:109196725	T/C	cg21045802	chr8:109455806	TTC35	0.7	6.69	0.57	1.56e-9	Dupuytren's disease;
THYM	cis	rs35883536	0.935	rs1106347	chr1:101149059	A/T	cg06223162	chr1:101003688	GPR88	0.67	5.14	0.47	1.47e-6	Monocyte count;
THYM	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg00640147	chr17:61958756	GH2	-0.43	-4.54	-0.42	1.64e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs55788414	0.932	rs55991107	chr16:81181066	G/A	cg06400318	chr16:81190750	PKD1L2	-0.99	-4.99	-0.46	2.72e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg19077165	chr18:44547161	KATNAL2	-0.6	-7.65	-0.62	1.61e-11	Personality dimensions;
THYM	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg24530246	chr3:53118167	NA	-0.83	-4.74	-0.44	7.62e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs1568889	0.838	rs10835276	chr11:28167147	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg20999797	chr1:1681921	NA	0.51	5.52	0.49	2.92e-7	Body mass index;
THYM	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg18681998	chr4:17616180	MED28	0.98	9.91	0.71	2.55e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg12963246	chr6:28129442	ZNF389	0.64	4.86	0.45	4.62e-6	Parkinson's disease;
THYM	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06634786	chr22:41940651	POLR3H	-0.76	-5.64	-0.5	1.71e-7	Vitiligo;
THYM	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg17173187	chr15:85201210	NMB	0.56	5.48	0.49	3.49e-7	Schizophrenia;
THYM	cis	rs807669	0.934	rs762523	chr22:19180589	A/G	cg02655711	chr22:19163373	SLC25A1	0.97	11.57	0.76	7.63e-20	Metabolite levels;
THYM	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg25036284	chr2:26402008	FAM59B	0.83	4.76	0.44	7.04e-6	Gut microbiome composition (summer);
THYM	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg27125505	chr17:43679177	LOC644172	0.77	6.97	0.58	4.25e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg23187316	chr7:1099788	C7orf50	0.48	5.41	0.49	4.63e-7	Longevity;Endometriosis;
THYM	cis	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg19847130	chr8:10466454	RP1L1	0.52	5.1	0.46	1.73e-6	Neuroticism;
THYM	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg06850241	chr22:41845214	NA	0.54	4.6	0.43	1.33e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.77	-4.48	-0.42	2.1e-5	Alzheimer's disease;
THYM	cis	rs9359856	0.529	rs72915915	chr6:90430593	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg07460842	chr6:66804631	NA	0.92	5.5	0.49	3.15e-7	Exhaled nitric oxide levels;
THYM	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg11502198	chr6:26597334	ABT1	0.65	5.89	0.52	5.74e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7224737	1.000	rs1869365	chr17:40293865	T/C	cg02228675	chr17:40259724	DHX58	-0.67	-5.5	-0.49	3.27e-7	Fibrinogen levels;
THYM	cis	rs11264213	0.901	rs682686	chr1:36443778	T/A	cg27506609	chr1:36549197	TEKT2	0.92	4.83	0.44	5.3e-6	Schizophrenia;
THYM	cis	rs308403	0.568	rs13101575	chr4:123617561	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.66	4.54	0.42	1.65e-5	Blood protein levels;
THYM	cis	rs4363385	0.626	rs6664183	chr1:153064002	A/G	cg06563695	chr1:153756334	NA	-0.58	-4.91	-0.45	3.72e-6	Inflammatory skin disease;
THYM	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg21773646	chr17:80085082	CCDC57	-0.34	-4.97	-0.45	3.01e-6	Life satisfaction;
THYM	cis	rs995000	0.931	rs626787	chr1:62901243	C/G	cg06896770	chr1:63153194	DOCK7	0.86	6.7	0.57	1.49e-9	Triglyceride levels;
THYM	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.44e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6430585	0.702	rs2015532	chr2:136555525	G/T	cg23851026	chr2:136556271	LCT	-0.73	-7.19	-0.59	1.45e-10	Corneal structure;
THYM	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.83	-0.44	5.29e-6	Mean corpuscular volume;
THYM	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg14664628	chr15:75095509	CSK	-0.68	-5.13	-0.47	1.51e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs981844	0.714	rs2405202	chr4:154705132	A/G	cg09973105	chr4:154681532	RNF175	0.55	5.11	0.46	1.67e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs58873874	0.737	rs11744671	chr5:156921231	T/C	cg08916508	chr5:156566250	MED7	-1.34	-5.3	-0.48	7.59e-7	Bipolar disorder (body mass index interaction);
THYM	cis	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs12496230	1.000	rs13100186	chr3:66831642	T/C	cg23477460	chr3:66848765	NA	1.2	7.18	0.59	1.58e-10	Type 2 diabetes;
THYM	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg08133631	chr1:26527909	CATSPER4	-0.61	-5.08	-0.46	1.92e-6	Obesity-related traits;
THYM	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg15733309	chr7:157513707	PTPRN2	0.59	6.55	0.56	3e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg10760299	chr15:45669010	GATM	0.78	6.29	0.54	9.84e-9	Homoarginine levels;
THYM	cis	rs72828912	0.831	rs4574616	chr6:24094037	C/G	cg26336265	chr6:25042955	NA	-0.73	-5.46	-0.49	3.87e-7	Squamous cell lung carcinoma;
THYM	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg05215272	chr17:6899095	ALOX12	-0.65	-8.45	-0.65	3.38e-13	Tonsillectomy;
THYM	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg04267008	chr7:1944627	MAD1L1	-0.62	-5.78	-0.51	9.43e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg18758796	chr5:131593413	PDLIM4	-0.63	-6.49	-0.55	3.95e-9	Acylcarnitine levels;
THYM	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.49	0.42	1.97e-5	Diabetic retinopathy;
THYM	cis	rs9814567	0.806	rs1880375	chr3:134322163	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.09e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs17443541	0.507	rs35916771	chr2:200464855	T/C	cg03741458	chr2:200468445	NA	-0.75	-5.77	-0.51	9.74e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4072705	0.967	rs10818985	chr9:127450571	C/T	cg13476313	chr9:127244764	NR5A1	0.32	4.75	0.44	7.27e-6	Menarche (age at onset);
THYM	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg01304814	chr3:48885189	PRKAR2A	0.89	4.66	0.43	1.03e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg14458575	chr2:238380390	NA	0.96	7.46	0.61	4.11e-11	Prostate cancer;
THYM	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg12408189	chr10:30722286	MAP3K8	-0.56	-4.98	-0.46	2.78e-6	Inflammatory bowel disease;
THYM	cis	rs4664308	0.618	rs17830940	chr2:160891768	T/C	cg03641300	chr2:160917029	PLA2R1	-0.66	-5.79	-0.51	9.16e-8	Idiopathic membranous nephropathy;
THYM	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.21	8.66	0.66	1.18e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs654384	0.798	rs12701426	chr7:4176315	A/G	cg13153353	chr7:4175865	SDK1	-0.55	-5.48	-0.49	3.54e-7	Positive affect;
THYM	cis	rs2916260	0.736	rs6932692	chr6:40389066	G/A	cg08415973	chr6:40346114	TDRG1	0.76	4.77	0.44	6.69e-6	Incident coronary heart disease;
THYM	cis	rs6988636	1.000	rs28600861	chr8:124189063	C/T	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg15962314	chr1:44399869	ARTN	0.53	5.39	0.48	5.01e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg02136620	chr5:178986620	RUFY1	-0.5	-4.86	-0.45	4.64e-6	Lung cancer;
THYM	cis	rs9902453	0.904	rs4077465	chr17:28300144	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.22	0.54	1.3e-8	Coffee consumption (cups per day);
THYM	cis	rs11186	0.556	rs56843866	chr2:189956222	T/C	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.05	6.23	0.54	1.29e-8	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6430585	0.591	rs75223002	chr2:136525309	G/T	cg20242066	chr2:136595261	LCT	0.5	4.7	0.43	8.63e-6	Corneal structure;
THYM	cis	rs9522267	0.643	rs9522279	chr13:112221296	C/T	cg10483660	chr13:112241077	NA	-0.62	-6.34	-0.55	7.71e-9	Hepatitis;
THYM	cis	rs5022636	0.533	rs4971029	chr1:151277259	T/C	cg17724175	chr1:150552817	MCL1	-0.39	-4.46	-0.42	2.28e-5	Gut microbiota (functional units);
THYM	cis	rs757081	0.738	rs1073443	chr11:17350394	C/T	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.54	-0.42	1.68e-5	Systolic blood pressure;
THYM	cis	rs9902453	0.904	rs12952179	chr17:28412687	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.48	-0.55	3.99e-9	Coffee consumption (cups per day);
THYM	cis	rs4891159	0.513	rs35534021	chr18:74130523	G/A	cg24786174	chr18:74118243	ZNF516	0.95	13.93	0.82	1.1e-24	Longevity;
THYM	cis	rs12802200	0.535	rs35391985	chr11:570280	T/C	cg00645579	chr11:617140	IRF7;MUPCDH	-0.4	-4.54	-0.42	1.65e-5	Systemic lupus erythematosus;
THYM	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg15557168	chr22:42548783	NA	-0.59	-4.53	-0.42	1.7e-5	Schizophrenia;
THYM	cis	rs7828089	0.504	rs12676477	chr8:22266425	T/C	cg12081754	chr8:22256438	SLC39A14	0.89	9.11	0.68	1.34e-14	Verbal declarative memory;
THYM	cis	rs1784581	0.802	rs9365355	chr6:162414604	A/G	cg17173639	chr6:162384350	PARK2	0.8	8.01	0.64	2.8e-12	Itch intensity from mosquito bite;
THYM	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1389724	0.648	rs1389718	chr1:111316837	G/A	cg25283465	chr1:111323341	NA	0.58	4.58	0.43	1.4e-5	Schizophrenia;
THYM	cis	rs12410462	0.581	rs111356515	chr1:227537236	C/G	cg23173402	chr1:227635558	NA	0.66	5.25	0.47	9.34e-7	Major depressive disorder;
THYM	cis	rs6980334	0.911	rs10280628	chr7:137767310	C/T	cg11874123	chr7:137028198	PTN	0.68	5.18	0.47	1.26e-6	Blood metabolite ratios;
THYM	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.94	6.06	0.53	2.79e-8	Platelet count;
THYM	cis	rs7104764	1.000	rs6598060	chr11:243987	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	1.18	11.0	0.75	1.22e-18	Menarche (age at onset);
THYM	cis	rs11031096	0.678	rs61899666	chr11:4178711	C/A	cg08557956	chr11:4115526	RRM1	-0.52	-4.68	-0.43	9.36e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs34375054	0.624	rs12832525	chr12:125680366	T/C	cg25124228	chr12:125621409	AACS	-0.65	-4.69	-0.43	9.18e-6	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg00071950	chr4:10020882	SLC2A9	-0.65	-5.77	-0.51	9.74e-8	Bone mineral density;
THYM	cis	rs17152411	1.000	rs17152411	chr10:126649516	A/G	cg07906193	chr10:126599966	NA	0.7	4.74	0.44	7.4e-6	Height;
THYM	cis	rs6430585	0.528	rs499483	chr2:136652524	G/A	cg04750100	chr2:136595281	LCT	0.56	4.93	0.45	3.46e-6	Corneal structure;
THYM	cis	rs6499255	0.951	rs12595869	chr16:69729794	T/G	cg00738113	chr16:70207722	CLEC18C	-0.46	-4.59	-0.43	1.35e-5	IgE levels;
THYM	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7584330	0.554	rs7598559	chr2:238435398	A/G	cg08992911	chr2:238395768	MLPH	-0.89	-5.81	-0.51	8.24e-8	Prostate cancer;
THYM	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg08835221	chr22:38071607	LGALS1	0.38	5.04	0.46	2.21e-6	Fat distribution (HIV);
THYM	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.77	-6.09	-0.53	2.42e-8	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs754466	0.580	rs12357670	chr10:79558180	T/C	cg17075019	chr10:79541650	NA	-0.68	-5.51	-0.49	3.05e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1994135	0.715	rs10844624	chr12:33691010	A/G	cg10856724	chr12:34555212	NA	-0.76	-5.77	-0.51	9.93e-8	Resting heart rate;
THYM	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs7830933	0.955	rs13257987	chr8:23594718	G/C	cg04349084	chr8:23602677	NA	0.58	6.09	0.53	2.42e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs13315871	1.000	rs13063504	chr3:58409854	A/G	cg12435725	chr3:58293450	RPP14	-0.46	-4.93	-0.45	3.54e-6	Cholesterol, total;
THYM	cis	rs747334	0.846	rs10881864	chr10:92706491	G/A	cg07620928	chr10:92689909	NA	0.58	5.14	0.47	1.48e-6	Fibroblast growth factor basic levels;
THYM	cis	rs7189233	0.956	rs62048490	chr16:53456276	T/C	cg02965178	chr16:53538660	AKTIP	-0.61	-4.9	-0.45	3.93e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11771526	0.901	rs34376799	chr7:32316932	T/C	cg27532318	chr7:32358331	NA	0.77	5.06	0.46	2.03e-6	Body mass index;
THYM	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	7.72	0.62	1.17e-11	Platelet count;
THYM	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.98	-0.46	2.82e-6	Diabetic retinopathy;
THYM	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg16486109	chr11:613632	IRF7	0.47	5.59	0.5	2.19e-7	Systemic lupus erythematosus;
THYM	cis	rs4940575	0.679	rs12606418	chr18:60833672	G/T	cg20947866	chr18:61143580	SERPINB5	0.88	5.26	0.47	8.96e-7	Breast cancer;
THYM	cis	rs7578361	0.918	rs1196678	chr2:150342476	C/T	cg17961725	chr2:150454027	NA	0.65	5.03	0.46	2.34e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg23205692	chr1:25664452	TMEM50A	0.84	6.39	0.55	6.15e-9	Erythrocyte sedimentation rate;
THYM	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg09260853	chr1:2094483	PRKCZ	0.46	4.77	0.44	6.66e-6	Height;
THYM	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg02734326	chr4:10020555	SLC2A9	0.76	7.25	0.6	1.13e-10	Bone mineral density;
THYM	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg18252515	chr7:66147081	NA	0.63	4.65	0.43	1.09e-5	Aortic root size;
THYM	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg17366294	chr4:99064904	C4orf37	0.53	5.9	0.52	5.67e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11190604	0.767	rs10748794	chr10:102175918	G/T	cg07570687	chr10:102243282	WNT8B	-0.82	-7.76	-0.62	9.42e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg09085632	chr11:111637200	PPP2R1B	1.21	12.39	0.79	1.54e-21	Primary sclerosing cholangitis;
THYM	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg01579765	chr21:45077557	HSF2BP	0.53	8.58	0.66	1.77e-13	Mean corpuscular volume;
THYM	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg14345882	chr6:26364793	BTN3A2	0.58	5.49	0.49	3.39e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg21475434	chr5:93447410	FAM172A	-0.71	-4.51	-0.42	1.83e-5	Diabetic retinopathy;
THYM	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg08994789	chr17:28903642	LRRC37B2	-1.05	-5.39	-0.48	5.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4792901	0.959	rs12103443	chr17:41631258	A/G	cg21940313	chr17:41620911	ETV4	-0.53	-5.65	-0.5	1.68e-7	Dupuytren's disease;
THYM	cis	rs611744	0.967	rs686251	chr8:109198907	C/A	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs3112255	0.512	rs12623994	chr2:101338073	C/A	cg01042948	chr2:101319752	NA	0.5	4.98	0.46	2.82e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7646881	1.000	rs59217052	chr3:158452456	C/T	cg18349298	chr3:158450550	RARRES1	0.48	4.48	0.42	2.05e-5	Tetralogy of Fallot;
THYM	cis	rs35883536	0.631	rs2783704	chr1:101040652	T/A	cg06223162	chr1:101003688	GPR88	0.83	7.06	0.59	2.67e-10	Monocyte count;
THYM	cis	rs526231	0.543	rs246906	chr5:102566471	A/G	cg23492399	chr5:102201601	PAM	-0.7	-5.28	-0.48	8.19e-7	Primary biliary cholangitis;
THYM	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg06627557	chr7:32535165	LSM5;AVL9	1.03	10.73	0.74	4.6e-18	Cognitive ability;
THYM	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg07606381	chr6:8435919	SLC35B3	-0.58	-4.53	-0.42	1.73e-5	Motion sickness;
THYM	cis	rs10197940	0.578	rs2444264	chr2:152310928	G/T	cg19508488	chr2:152266495	RIF1	-0.74	-5.88	-0.52	6.08e-8	Lung cancer;
THYM	cis	rs9796	0.689	rs13329537	chr15:41449211	C/G	cg21153102	chr15:41252147	NA	-0.6	-4.98	-0.45	2.85e-6	Menopause (age at onset);
THYM	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg02820040	chr2:241836501	C2orf54	-0.33	-6.84	-0.57	7.7e-10	Urinary metabolites;
THYM	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg08847533	chr14:75593920	NEK9	0.98	10.53	0.73	1.23e-17	Height;
THYM	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg04034577	chr2:241836375	C2orf54	-0.45	-7.28	-0.6	9.79e-11	Urinary metabolites;
THYM	cis	rs4974559	0.740	rs11933854	chr4:1315172	G/A	cg02980000	chr4:1222292	CTBP1	0.79	5.09	0.46	1.82e-6	Systolic blood pressure;
THYM	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg18301423	chr5:131593218	PDLIM4	0.48	4.5	0.42	1.95e-5	Breast cancer;
THYM	cis	rs4788570	0.615	rs4788550	chr16:71720523	C/T	cg06353428	chr16:71660113	MARVELD3	1.29	9.01	0.68	2.12e-14	Intelligence (multi-trait analysis);
THYM	cis	rs75059851	0.756	rs7106715	chr11:133838905	A/G	cg14047540	chr11:133829660	NA	1.1	7.34	0.6	7.1e-11	Schizophrenia;
THYM	cis	rs5769707	0.609	rs2071890	chr22:50001291	G/A	cg23428387	chr22:49814324	NA	-0.56	-5.3	-0.48	7.54e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg06112835	chr11:68658793	MRPL21	0.45	6.39	0.55	6.21e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7586879	0.616	rs10203386	chr2:25136866	T/A	cg01884057	chr2:25150051	NA	0.7	7.41	0.61	5.18e-11	Body mass index;
THYM	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg23758822	chr17:41437982	NA	1.19	11.14	0.75	6.31e-19	Menopause (age at onset);
THYM	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg00801512	chr17:28996047	NA	-0.76	-5.02	-0.46	2.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg05962950	chr11:130786565	SNX19	0.92	8.76	0.67	7.45e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1729407	0.625	rs2727789	chr11:116696887	G/T	cg08985259	chr11:116699649	APOC3	-0.61	-5.44	-0.49	4.15e-7	Apolipoprotein A-IV levels;
THYM	cis	rs2235642	0.964	rs9939655	chr16:1577963	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.61	-4.93	-0.45	3.47e-6	Coronary artery disease;
THYM	cis	rs10751667	0.600	rs11246376	chr11:999622	C/T	cg20248691	chr11:532330	HRAS	-0.46	-4.58	-0.43	1.39e-5	Alzheimer's disease (late onset);
THYM	cis	rs2069036	0.909	rs10752040	chr10:16111499	A/C	cg26633223	chr10:15133461	NA	0.66	4.65	0.43	1.08e-5	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs28595532	0.920	rs55794497	chr4:119764664	A/G	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs524023	0.957	rs10792443	chr11:64395252	G/C	cg19131476	chr11:64387923	NRXN2	-0.35	-4.92	-0.45	3.6e-6	Urate levels in obese individuals;
THYM	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg06766960	chr11:133703094	NA	-0.52	-4.83	-0.44	5.25e-6	Childhood ear infection;
THYM	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg26818010	chr10:134567672	INPP5A	-0.82	-6.62	-0.56	2.15e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg10523679	chr1:76189770	ACADM	0.94	8.52	0.66	2.42e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17125944	0.506	rs7151491	chr14:53313711	C/G	cg00686598	chr14:53173677	PSMC6	-1.03	-4.67	-0.43	9.78e-6	Alzheimer's disease (late onset);
THYM	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg05368731	chr17:41323189	NBR1	1.26	11.73	0.77	3.51e-20	Menopause (age at onset);
THYM	cis	rs7131987	0.903	rs11050162	chr12:29420054	T/G	cg09582351	chr12:29534625	ERGIC2	-0.48	-4.54	-0.42	1.66e-5	QT interval;
THYM	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg14779329	chr11:130786720	SNX19	0.56	6.09	0.53	2.34e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs17598306	1.000	rs17656761	chr7:96581553	G/A	cg26766885	chr7:96220185	NA	0.62	5.13	0.47	1.56e-6	Radiation response;
THYM	cis	rs1018836	0.663	rs56784954	chr8:91505094	C/T	cg16814680	chr8:91681699	NA	-0.8	-6.87	-0.58	6.76e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.01	9.83	0.71	3.75e-16	Colorectal cancer;
THYM	cis	rs1978968	0.525	rs4819649	chr22:18396329	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	0.56	5.21	0.47	1.1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs6434928	1	rs6434928	chr2:198304577	G/A	cg00792783	chr2:198669748	PLCL1	0.82	5.67	0.5	1.54e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg00129232	chr17:37814104	STARD3	-0.69	-4.51	-0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg23758822	chr17:41437982	NA	1.22	13.08	0.8	5.68e-23	Menopause (age at onset);
THYM	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg24503407	chr1:205819492	PM20D1	0.97	9.46	0.7	2.35e-15	Menarche (age at onset);
THYM	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg05872129	chr22:39784769	NA	-0.97	-9.48	-0.7	2.15e-15	Intelligence (multi-trait analysis);
THYM	cis	rs4523957	0.620	rs9894215	chr17:2070698	G/A	cg16513277	chr17:2031491	SMG6	-1.04	-9.92	-0.71	2.46e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs883565	0.655	rs7629839	chr3:39115294	G/A	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	5.0	0.46	2.59e-6	Handedness;
THYM	cis	rs3764563	1.000	rs11673070	chr19:15746095	A/G	cg20725493	chr19:15740067	CYP4F8	-1.03	-4.68	-0.43	9.36e-6	Inflammatory biomarkers;
THYM	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs4455778	0.538	rs7795732	chr7:49127493	T/C	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4455778	0.580	rs7808248	chr7:49125067	T/A	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.27	4.52	0.42	1.78e-5	Obesity-related traits;
THYM	cis	rs10847980	0.590	rs12297553	chr12:123283864	C/T	cg25930673	chr12:123319894	HIP1R	1.12	5.07	0.46	1.98e-6	Adiponectin levels;
THYM	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg18806716	chr10:30721971	MAP3K8	0.53	5.37	0.48	5.49e-7	Inflammatory bowel disease;
THYM	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.7	5.33	0.48	6.5e-7	Tonsillectomy;
THYM	cis	rs9826463	0.582	rs73238140	chr3:142046665	T/G	cg20824294	chr3:142316082	PLS1	0.79	5.49	0.49	3.3e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs9534288	0.830	rs1409435	chr13:46631660	G/A	cg15192986	chr13:46630673	CPB2	-0.66	-4.66	-0.43	1.03e-5	Blood protein levels;
THYM	cis	rs10979	1.000	rs9386033	chr6:143888520	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs73206853	0.764	rs28580853	chr12:110826209	C/G	cg24703420	chr12:111373904	NA	0.71	4.52	0.42	1.75e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
THYM	cis	rs7107174	1.000	rs7939646	chr11:78111613	C/T	cg19901956	chr11:77921274	USP35	0.65	5.34	0.48	6.41e-7	Testicular germ cell tumor;
THYM	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg06636001	chr8:8085503	FLJ10661	0.8	7.67	0.62	1.48e-11	Systolic blood pressure;
THYM	trans	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg25214090	chr10:38739885	LOC399744	0.91	7.93	0.63	4.24e-12	Corneal astigmatism;
THYM	cis	rs901683	0.702	rs78034568	chr10:46149580	G/C	cg18240400	chr10:46168597	ANUBL1	0.68	4.67	0.43	9.88e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg02825527	chr7:2087843	MAD1L1	-0.81	-5.11	-0.46	1.64e-6	Neuroticism;
THYM	cis	rs2067615	0.579	rs7964605	chr12:107205413	C/T	cg15890332	chr12:107067104	RFX4	-0.46	-5.29	-0.48	7.8e-7	Heart rate;
THYM	cis	rs28595532	0.920	rs114670456	chr4:119771202	A/G	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs9443189	0.526	rs6902898	chr6:76201856	G/A	cg01950844	chr6:76311363	SENP6	1.12	5.7	0.5	1.37e-7	Prostate cancer;
THYM	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg07636037	chr3:49044803	WDR6	0.97	9.82	0.71	4.1e-16	Parkinson's disease;
THYM	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg01416388	chr22:39784598	NA	-0.91	-9.01	-0.68	2.11e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs2976388	0.647	rs2585136	chr8:143812141	A/G	cg06565975	chr8:143823917	SLURP1	0.46	4.97	0.45	2.94e-6	Urinary tract infection frequency;
THYM	cis	rs6456156	0.774	rs6908364	chr6:167527296	C/T	cg09487078	chr6:167525398	CCR6	-0.44	-4.9	-0.45	3.9e-6	Primary biliary cholangitis;
THYM	cis	rs526231	0.543	rs158244	chr5:102410766	G/C	cg23492399	chr5:102201601	PAM	-0.7	-5.18	-0.47	1.23e-6	Primary biliary cholangitis;
THYM	cis	rs354225	0.544	rs3796018	chr2:54807281	C/T	cg23486701	chr2:54789491	SPTBN1	0.36	4.77	0.44	6.58e-6	Schizophrenia;
THYM	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg04944784	chr2:26401820	FAM59B	0.81	5.1	0.46	1.75e-6	Gut microbiome composition (summer);
THYM	cis	rs6060717	0.653	rs2590962	chr20:34615363	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-5.41	-0.49	4.66e-7	Hip circumference adjusted for BMI;
THYM	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg18252515	chr7:66147081	NA	1.43	8.6	0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs4900538	0.855	rs60215817	chr14:102873886	A/G	cg18135206	chr14:102964638	TECPR2	-0.81	-6.24	-0.54	1.2e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg22974920	chr21:40686053	BRWD1	0.75	5.12	0.46	1.61e-6	Cognitive function;
THYM	cis	rs12594515	1.000	rs7162201	chr15:45992658	A/C	cg01629716	chr15:45996671	NA	0.53	5.27	0.48	8.45e-7	Waist circumference;Weight;
THYM	cis	rs9790314	0.747	rs6789244	chr3:160866230	A/C	cg03342759	chr3:160939853	NMD3	-0.61	-4.61	-0.43	1.26e-5	Morning vs. evening chronotype;
THYM	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-4.68	-0.43	9.61e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6032067	0.641	rs74174932	chr20:43756133	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.67	-5.92	-0.52	5.17e-8	Blood protein levels;
THYM	cis	rs3741151	0.773	rs73544720	chr11:73173496	A/G	cg17517138	chr11:73019481	ARHGEF17	0.93	5.3	0.48	7.62e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs295140	0.681	rs4673912	chr2:201168993	G/T	cg04283868	chr2:201171347	SPATS2L	0.66	4.58	0.43	1.4e-5	QT interval;
THYM	cis	rs6956675	0.874	rs6968344	chr7:62574533	A/G	cg27518014	chr7:62859535	LOC100287834	0.58	4.62	0.43	1.21e-5	Obesity-related traits;
THYM	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg12373951	chr3:133503437	NA	-0.56	-6.18	-0.54	1.62e-8	Iron status biomarkers;
THYM	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	trans	rs9747201	1.000	rs8082212	chr17:80175100	G/C	cg07393940	chr7:158741817	NA	1.1	8.4	0.65	4.38e-13	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg01304814	chr3:48885189	PRKAR2A	0.89	4.66	0.43	1.03e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs11039798	0.588	rs61932767	chr11:48704806	C/T	cg24672777	chr11:48374446	OR4C45	-0.88	-5.49	-0.49	3.39e-7	Axial length;
THYM	cis	rs7246657	0.943	rs4802766	chr19:37981933	T/C	cg23950597	chr19:37808831	NA	-0.75	-4.81	-0.44	5.66e-6	Coronary artery calcification;
THYM	cis	rs4866334	1.000	rs114400023	chr5:18432893	T/C	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs2302612	0.528	rs7560478	chr2:102812526	C/T	cg13315345	chr2:102803985	IL1RL2	-0.68	-4.71	-0.43	8.61e-6	Serum protein levels (sST2);
THYM	cis	rs1348850	0.846	rs4893962	chr2:178421106	A/G	cg27490568	chr2:178487706	NA	0.63	5.74	0.51	1.14e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg27129171	chr3:47204927	SETD2	-0.69	-6.59	-0.56	2.45e-9	Colorectal cancer;
THYM	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg24399712	chr22:39784796	NA	-0.84	-8.53	-0.66	2.28e-13	Intelligence (multi-trait analysis);
THYM	cis	rs36051895	0.695	rs10974922	chr9:5028813	C/T	cg02405213	chr9:5042618	JAK2	-1.06	-11.37	-0.76	2.02e-19	Pediatric autoimmune diseases;
THYM	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.57	0.56	2.67e-9	Total body bone mineral density;
THYM	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22496380	chr5:211416	CCDC127	-1.3	-8.28	-0.65	7.84e-13	Breast cancer;
THYM	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.8	0.82	1.97e-24	Height;
THYM	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg11764359	chr7:65958608	NA	0.63	4.92	0.45	3.66e-6	Aortic root size;
THYM	trans	rs8073060	0.586	rs226087	chr17:34017652	T/C	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg24812749	chr6:127587940	RNF146	0.96	7.77	0.62	9.12e-12	Breast cancer;
THYM	cis	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.58	5.9	0.52	5.68e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg18105134	chr13:113819100	PROZ	-1.16	-10.42	-0.73	2.11e-17	Platelet distribution width;
THYM	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs9467773	0.626	rs6935803	chr6:26350495	A/G	cg14345882	chr6:26364793	BTN3A2	0.36	4.85	0.45	4.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7567389	0.889	rs1504136	chr2:127977118	T/C	cg06038358	chr2:128176007	PROC	-0.45	-4.8	-0.44	5.94e-6	Self-rated health;
THYM	cis	rs4919687	0.577	rs12765459	chr10:104465687	G/C	cg04362960	chr10:104952993	NT5C2	0.65	5.2	0.47	1.16e-6	Colorectal cancer;
THYM	cis	rs17125944	0.686	rs2296495	chr14:53379878	G/A	cg00686598	chr14:53173677	PSMC6	1.15	5.14	0.47	1.45e-6	Alzheimer's disease (late onset);
THYM	cis	rs4243830	0.571	rs60256927	chr1:6614747	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	1.14	7.61	0.62	1.94e-11	Body mass index;
THYM	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg10360139	chr7:1886902	MAD1L1	-0.61	-5.17	-0.47	1.3e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs11122895	0.509	rs10174353	chr2:112447888	C/T	cg23262488	chr2:112468472	NA	0.5	6.37	0.55	6.81e-9	Allergic sensitization;
THYM	trans	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg10856724	chr12:34555212	NA	-1.02	-9.32	-0.69	4.7e-15	Morning vs. evening chronotype;
THYM	cis	rs9581857	0.556	rs1885990	chr13:28040502	C/T	cg22138327	chr13:27999177	GTF3A	0.66	4.72	0.44	8.06e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs240764	0.725	rs239212	chr6:101145178	G/A	cg21058520	chr6:100914733	NA	-0.61	-5.38	-0.48	5.32e-7	Neuroticism;
THYM	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg23682913	chr1:2080710	PRKCZ	-0.61	-5.17	-0.47	1.28e-6	Height;
THYM	cis	rs6430585	0.527	rs57530667	chr2:136444338	A/G	cg23851026	chr2:136556271	LCT	0.67	5.98	0.52	3.89e-8	Corneal structure;
THYM	cis	rs7731657	0.537	rs2189504	chr5:130298900	C/A	cg08523029	chr5:130500466	HINT1	-0.74	-5.01	-0.46	2.49e-6	Fasting plasma glucose;
THYM	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.11e-8	Systolic blood pressure;
THYM	cis	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg21775007	chr8:11205619	TDH	-0.68	-5.27	-0.48	8.47e-7	Retinal vascular caliber;
THYM	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg27532560	chr4:187881888	NA	-0.92	-11.25	-0.76	3.57e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7809950	1.000	rs987391	chr7:107100794	C/G	cg23024343	chr7:107201750	COG5	-0.9	-8.07	-0.64	2.19e-12	Coronary artery disease;
THYM	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg24955955	chr5:415729	AHRR	1.02	5.72	0.51	1.21e-7	Fat distribution (HIV);
THYM	cis	rs4523957	0.855	rs216172	chr17:2126504	G/C	cg16513277	chr17:2031491	SMG6	-0.8	-7.78	-0.62	8.76e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7267979	1.000	rs6037105	chr20:25374199	C/A	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1003719	1.000	rs1003719	chr21:38491095	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.72	5.19	0.47	1.2e-6	Eye color traits;
THYM	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2066819	1.000	rs41363748	chr12:56696056	C/T	cg26714650	chr12:56694279	CS	1.35	7.01	0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs12310956	0.510	rs10844690	chr12:33854752	C/A	cg10856724	chr12:34555212	NA	-0.64	-5.77	-0.51	9.82e-8	Morning vs. evening chronotype;
THYM	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs4866334	1.000	rs116612534	chr5:18506467	C/A	cg24599790	chr5:18972260	NA	-1.15	-4.67	-0.43	9.77e-6	IgG glycosylation;
THYM	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg00376283	chr12:123451042	ABCB9	0.81	6.42	0.55	5.25e-9	Platelet count;
THYM	cis	rs13177918	0.559	rs10447225	chr5:149834454	C/T	cg14059543	chr5:149831962	NA	-0.92	-7.65	-0.62	1.64e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2742540	0.503	rs11042121	chr11:8932640	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.6	5.17	0.47	1.28e-6	Hematocrit;
THYM	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg25358565	chr5:93447407	FAM172A	-1.36	-10.75	-0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs6495122	0.658	rs12909307	chr15:75061929	A/G	cg14664628	chr15:75095509	CSK	-0.8	-6.08	-0.53	2.53e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs2282300	0.653	rs67745574	chr11:30234839	C/T	cg25418670	chr11:30344373	C11orf46	-0.79	-6.85	-0.58	7.18e-10	Morning vs. evening chronotype;
THYM	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.52e-7	Heart rate;
THYM	cis	rs7426056	0.671	rs17449312	chr2:204605343	C/T	cg07930752	chr2:204569955	CD28	0.76	5.6	0.5	2.09e-7	Primary sclerosing cholangitis;
THYM	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06634786	chr22:41940651	POLR3H	0.84	6.24	0.54	1.21e-8	Vitiligo;
THYM	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg00074818	chr8:8560427	CLDN23	0.53	4.76	0.44	6.82e-6	Obesity-related traits;
THYM	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg16594139	chr19:49340574	PLEKHA4;HSD17B14	0.97	5.77	0.51	1.01e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.66e-11	Aortic root size;
THYM	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg07424592	chr7:64974309	NA	0.99	5.15	0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg07460842	chr6:66804631	NA	-1.26	-16.07	-0.86	7.6e-29	Exhaled nitric oxide output;
THYM	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg16928487	chr17:17741425	SREBF1	0.56	5.37	0.48	5.68e-7	Total body bone mineral density;
THYM	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg20744362	chr22:50050164	C22orf34	0.69	6.33	0.54	7.96e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg27284194	chr4:1044797	NA	0.62	4.73	0.44	7.81e-6	Recombination rate (females);
THYM	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9563576	0.709	rs12871811	chr13:58605231	G/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg04944784	chr2:26401820	FAM59B	1.09	8.74	0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs28374715	0.681	rs11629979	chr15:41626579	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.17	-14.19	-0.82	3.41e-25	Ulcerative colitis;
THYM	cis	rs240764	0.817	rs239219	chr6:101116146	C/T	cg21058520	chr6:100914733	NA	-0.57	-5.03	-0.46	2.29e-6	Neuroticism;
THYM	cis	rs36051895	0.632	rs12336875	chr9:5138404	C/A	cg02405213	chr9:5042618	JAK2	-1.04	-11.03	-0.75	1.05e-18	Pediatric autoimmune diseases;
THYM	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg08999081	chr20:33150536	PIGU	0.59	5.03	0.46	2.29e-6	Coronary artery disease;
THYM	cis	rs7078219	0.965	rs11190134	chr10:101282200	C/T	cg07044859	chr10:101282883	NA	-0.49	-5.21	-0.47	1.11e-6	Dental caries;
THYM	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg12310025	chr6:25882481	NA	0.67	5.42	0.49	4.57e-7	Schizophrenia;
THYM	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg05738196	chr6:26577821	NA	-0.66	-5.16	-0.47	1.33e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs741677	0.679	rs11655839	chr17:468945	G/C	cg15660573	chr17:549704	VPS53	0.71	5.92	0.52	5.1e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
THYM	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg01341218	chr17:43662625	NA	-1.07	-9.27	-0.69	5.9e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1190596	0.650	rs1190600	chr14:102591458	A/C	cg08231664	chr14:102516632	DYNC1H1	-0.39	-4.76	-0.44	6.86e-6	Behavioural disinhibition (generation interaction);
THYM	cis	rs901683	1.000	rs12779198	chr10:46013547	G/A	cg18240400	chr10:46168597	ANUBL1	0.8	5.16	0.47	1.38e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2964802	0.505	rs13159419	chr5:10824302	C/A	cg14521931	chr5:10832172	NA	-0.62	-5.12	-0.46	1.63e-6	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg06784218	chr1:46089804	CCDC17	0.3	4.64	0.43	1.1e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg18252515	chr7:66147081	NA	-0.66	-5.0	-0.46	2.65e-6	Aortic root size;
THYM	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.0	8.1	0.64	1.86e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7219021	0.885	rs3848457	chr17:46866026	C/T	cg09029085	chr17:47094198	IGF2BP1	0.34	4.56	0.42	1.52e-5	Schizophrenia or bipolar disorder;
THYM	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg20503657	chr10:835505	NA	1.41	8.88	0.67	4.16e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs10789491	1.000	rs1545206	chr1:47185082	C/G	cg15501359	chr1:47185051	KIAA0494	1.11	7.83	0.63	6.86e-12	Response to hepatitis C treatment;
THYM	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.68	-7.13	-0.59	1.96e-10	Crohn's disease;
THYM	cis	rs11112613	0.775	rs10507194	chr12:105959488	G/A	cg03607813	chr12:105948248	NA	1.01	8.2	0.64	1.13e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	trans	rs9747201	1.000	rs67588022	chr17:80176071	G/A	cg07393940	chr7:158741817	NA	1.1	8.4	0.65	4.38e-13	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs2273669	0.667	rs12216104	chr6:109317635	C/T	cg17117243	chr6:109341365	SESN1	-0.9	-5.38	-0.48	5.45e-7	Prostate cancer;
THYM	cis	rs4638749	0.953	rs4676033	chr2:108869368	G/A	cg25838818	chr2:108905173	SULT1C2	-0.61	-6.18	-0.54	1.6e-8	Blood pressure;
THYM	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg02487422	chr3:49467188	NICN1	0.63	4.82	0.44	5.48e-6	Resting heart rate;
THYM	cis	rs7084402	0.967	rs7091440	chr10:60271372	T/A	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg08859206	chr1:53392774	SCP2	-0.77	-9.43	-0.7	2.75e-15	Monocyte count;
THYM	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs665401	0.965	rs339331	chr6:117210052	A/G	cg20376953	chr6:117187980	NA	0.61	4.87	0.45	4.48e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs9325144	0.624	rs7309400	chr12:39150369	G/C	cg26384229	chr12:38710491	ALG10B	-0.71	-5.57	-0.5	2.4e-7	Morning vs. evening chronotype;
THYM	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg12893697	chr11:970389	AP2A2	-0.31	-5.15	-0.47	1.44e-6	Alzheimer's disease (late onset);
THYM	cis	rs476633	0.708	rs28656781	chr15:41447440	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.69	-5.4	-0.48	4.82e-7	Glomerular filtration rate (creatinine);
THYM	trans	rs1997103	1.000	rs4948012	chr7:55412578	A/C	cg20935933	chr6:143382018	AIG1	0.86	6.91	0.58	5.41e-10	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs7107174	1.000	rs2511157	chr11:77972632	G/A	cg19901956	chr11:77921274	USP35	-0.76	-5.83	-0.51	7.53e-8	Testicular germ cell tumor;
THYM	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg09035930	chr12:129282057	SLC15A4	0.87	12.19	0.78	3.87e-21	Systemic lupus erythematosus;
THYM	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	5.89	0.52	5.84e-8	Rheumatoid arthritis;
THYM	cis	rs2279817	1.000	rs4920619	chr1:18023112	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.77	4.87	0.45	4.5e-6	Neuroticism;
THYM	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.53	4.76	0.44	6.8e-6	Birth weight;
THYM	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs8067545	1.000	rs2108979	chr17:19928566	G/A	cg13482628	chr17:19912719	NA	0.59	4.93	0.45	3.42e-6	Schizophrenia;
THYM	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg17063962	chr7:91808500	NA	-1.17	-13.64	-0.81	4.12e-24	Breast cancer;
THYM	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs59698941	0.943	rs66746130	chr5:132245615	A/G	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9807989	0.507	rs6755905	chr2:103048207	C/A	cg03938978	chr2:103052716	IL18RAP	0.75	9.8	0.71	4.43e-16	Asthma;
THYM	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg22431228	chr1:16359049	CLCNKA	-0.53	-4.83	-0.44	5.16e-6	Dilated cardiomyopathy;
THYM	cis	rs7084402	0.935	rs10763558	chr10:60341934	A/C	cg07615347	chr10:60278583	BICC1	-0.55	-5.03	-0.46	2.31e-6	Refractive error;
THYM	cis	rs1986734	0.619	rs13106227	chr4:77418681	G/A	cg20311846	chr4:77356250	SHROOM3	-0.43	-4.66	-0.43	1.01e-5	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
THYM	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.73	-4.82	-0.44	5.35e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs28595532	0.920	rs115506655	chr4:119757667	A/G	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs28595532	0.841	rs114976553	chr4:119496056	A/G	cg11846333	chr4:119757529	SEC24D	1.37	4.91	0.45	3.85e-6	Cannabis dependence symptom count;
THYM	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg10248100	chr7:872053	UNC84A	0.74	4.99	0.46	2.75e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs516946	0.950	rs508419	chr8:41522991	A/G	cg19441908	chr8:41529140	ANK1	-0.58	-4.55	-0.42	1.56e-5	Type 2 diabetes;
THYM	cis	rs7173743	0.756	rs12903613	chr15:79129076	G/T	cg00540400	chr15:79124168	NA	0.57	5.87	0.52	6.47e-8	Coronary artery disease;
THYM	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg04025307	chr7:1156635	C7orf50	0.82	8.22	0.64	1.04e-12	Longevity;Endometriosis;
THYM	cis	rs9880211	1.000	rs28718456	chr3:136204006	A/G	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs3008870	0.959	rs2815353	chr1:67483372	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.93	7.76	0.62	9.52e-12	Lymphocyte percentage of white cells;
THYM	cis	rs12579753	1.000	rs12580330	chr12:82241280	T/G	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.67	-0.43	1.01e-5	Resting heart rate;
THYM	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg06521331	chr12:34319734	NA	-1.02	-10.14	-0.72	8.47e-17	Morning vs. evening chronotype;
THYM	cis	rs920590	0.684	rs3899017	chr8:19669198	A/T	cg01411142	chr8:19674711	INTS10	0.69	5.21	0.47	1.08e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs34638657	0.872	rs6564982	chr16:82167193	C/T	cg07307142	chr16:82071433	HSD17B2	-1.01	-7.93	-0.63	4.19e-12	Lung adenocarcinoma;
THYM	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.87	-0.82	1.48e-24	Height;
THYM	cis	rs7740797	0.791	rs2351847	chr6:155138810	G/A	cg02865717	chr6:155053990	RBM16	-0.46	-4.64	-0.43	1.11e-5	Colorectal or endometrial cancer;
THYM	cis	rs3791556	0.898	rs3828222	chr2:240109568	A/G	cg03281426	chr2:240109471	HDAC4	-0.58	-5.66	-0.5	1.57e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg15448220	chr1:150897856	SETDB1	0.88	7.08	0.59	2.43e-10	Melanoma;
THYM	cis	rs4731207	0.596	rs7810120	chr7:124644945	A/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg23583168	chr7:148888333	NA	-1.02	-13.89	-0.82	1.32e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs9420	0.961	rs11602109	chr11:57435296	G/A	cg19752551	chr11:57585705	CTNND1	-0.73	-8.02	-0.64	2.79e-12	Schizophrenia;
THYM	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg12310025	chr6:25882481	NA	-0.69	-5.59	-0.5	2.16e-7	Blood metabolite levels;
THYM	cis	rs6674176	0.542	rs803679	chr1:44349405	G/A	cg15962314	chr1:44399869	ARTN	0.52	4.94	0.45	3.31e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg15838173	chr10:75533400	FUT11	-0.51	-5.2	-0.47	1.15e-6	Inflammatory bowel disease;
THYM	cis	rs17744026	0.525	rs79122287	chr11:123709091	C/T	cg00079598	chr11:123676903	OR6M1	-0.5	-4.71	-0.44	8.4e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg03684893	chr10:554711	DIP2C	-0.7	-6.21	-0.54	1.37e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg15448220	chr1:150897856	SETDB1	0.9	7.66	0.62	1.56e-11	Melanoma;
THYM	cis	rs9296092	0.500	rs4376348	chr6:33521097	A/G	cg13560919	chr6:33536144	NA	-0.94	-9.31	-0.69	4.9e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg19610905	chr11:61596333	FADS2	-0.61	-5.16	-0.47	1.36e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
THYM	cis	rs2797160	0.967	rs1777182	chr6:126013614	T/A	cg16306078	chr6:126000798	NA	0.54	5.58	0.5	2.22e-7	Endometrial cancer;
THYM	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg17054759	chr22:49844102	NA	-0.52	-4.59	-0.43	1.35e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs988913	1.000	rs1393772	chr6:54838388	C/T	cg04690482	chr6:54711388	FAM83B	0.46	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	cis	rs6901250	0.632	rs339355	chr6:117196503	A/T	cg12892004	chr6:117198278	RFX6	-0.55	-4.64	-0.43	1.11e-5	C-reactive protein levels;
THYM	cis	rs713587	0.713	rs4665276	chr2:25213333	C/T	cg15423357	chr2:25149977	NA	-0.58	-5.94	-0.52	4.69e-8	Body mass index in non-asthmatics;
THYM	cis	rs9790314	1.000	rs9870059	chr3:161017240	T/C	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg13852791	chr20:30311386	BCL2L1	0.67	4.76	0.44	7.04e-6	Mean corpuscular hemoglobin;
THYM	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.78	0.44	6.31e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs688187	0.843	rs12980275	chr19:39731783	A/G	cg09986680	chr19:39737861	NA	0.34	4.47	0.42	2.13e-5	Mucinous ovarian carcinoma;
THYM	cis	rs78707713	0.560	rs61848398	chr10:71226103	G/A	cg08851181	chr10:71228077	TSPAN15	-0.79	-5.86	-0.52	6.58e-8	Venous thromboembolism;
THYM	cis	rs4940575	0.679	rs60803287	chr18:60830184	A/C	cg20947866	chr18:61143580	SERPINB5	0.95	5.56	0.5	2.42e-7	Breast cancer;
THYM	cis	rs478304	0.619	rs10896028	chr11:65432187	A/T	cg17480646	chr11:65405466	SIPA1	-0.89	-7.82	-0.63	7.05e-12	Acne (severe);
THYM	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg24308560	chr3:49941425	MST1R	0.78	6.78	0.57	1.02e-9	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg25767906	chr1:53392781	SCP2	-0.51	-5.17	-0.47	1.31e-6	Monocyte count;
THYM	cis	rs16866061	0.890	rs72972401	chr2:225404668	T/C	cg12698349	chr2:225449008	CUL3	1.14	10.45	0.73	1.77e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg10224037	chr5:178157518	ZNF354A	0.96	7.71	0.62	1.24e-11	Neutrophil percentage of white cells;
THYM	cis	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg24672777	chr11:48374446	OR4C45	-0.65	-4.54	-0.42	1.67e-5	Coronary artery disease;
THYM	cis	rs7894051	1.000	rs77189950	chr10:135126722	A/T	cg20534287	chr10:135191450	PAOX	0.74	5.11	0.46	1.63e-6	Lifespan;
THYM	cis	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg08133631	chr1:26527909	CATSPER4	-0.57	-4.69	-0.43	9.29e-6	Obesity-related traits;
THYM	trans	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg20587970	chr11:113659929	NA	-1.0	-6.93	-0.58	4.94e-10	Hip circumference adjusted for BMI;
THYM	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg24397884	chr7:158709396	WDR60	-0.44	-5.02	-0.46	2.37e-6	Height;
THYM	cis	rs854765	0.624	rs9891957	chr17:17744439	G/A	cg04398451	chr17:18023971	MYO15A	0.81	7.3	0.6	8.64e-11	Total body bone mineral density;
THYM	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Body mass index;
THYM	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.75	-0.57	1.18e-9	Chronic sinus infection;
THYM	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg21475434	chr5:93447410	FAM172A	0.71	4.51	0.42	1.83e-5	Diabetic retinopathy;
THYM	cis	rs4638749	0.677	rs10454132	chr2:108828111	T/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Urate levels;
THYM	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg06074448	chr4:187884817	NA	1.02	13.66	0.81	3.85e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07167872	chr1:205819463	PM20D1	0.73	6.63	0.56	2.05e-9	Menarche (age at onset);
THYM	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.0	0.63	3.07e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11039798	1.000	rs7928243	chr11:48589192	A/T	cg24672777	chr11:48374446	OR4C45	-1.16	-7.24	-0.6	1.16e-10	Axial length;
THYM	cis	rs6456042	0.893	rs1134482	chr6:166571157	G/A	cg11088901	chr6:166572345	T	-0.54	-5.27	-0.48	8.62e-7	Asthma;
THYM	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.76	-6.38	-0.55	6.46e-9	Systemic lupus erythematosus;
THYM	cis	rs7809950	0.862	rs62482502	chr7:106987810	A/C	cg23024343	chr7:107201750	COG5	-0.89	-7.86	-0.63	5.85e-12	Coronary artery disease;
THYM	cis	rs13082711	0.513	rs7612102	chr3:27372826	A/G	cg02860705	chr3:27208620	NA	-0.79	-5.95	-0.52	4.37e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg02527881	chr3:46936655	PTH1R	0.61	5.63	0.5	1.86e-7	Colorectal cancer;
THYM	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.43	0.7	2.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.89	-0.45	4.06e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-5.1	-0.46	1.75e-6	Gut microbiome composition (summer);
THYM	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg05347473	chr6:146136440	FBXO30	-0.82	-7.36	-0.6	6.62e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.31	4.72	0.44	8.22e-6	Obesity-related traits;
THYM	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg07075026	chr17:47091521	IGF2BP1	0.61	6.53	0.56	3.17e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg17911788	chr17:44343683	NA	0.71	6.76	0.57	1.09e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs10158481	0.759	rs9438889	chr1:25475345	A/G	cg09264742	chr1:25757510	TMEM57	-0.69	-5.03	-0.46	2.36e-6	Urate levels in obese individuals;
THYM	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg14829155	chr15:31115871	NA	-0.75	-6.3	-0.54	9.11e-9	Huntington's disease progression;
THYM	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.37	-0.48	5.64e-7	Total cholesterol levels;
THYM	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg05368731	chr17:41323189	NBR1	1.24	11.23	0.76	4.01e-19	Menopause (age at onset);
THYM	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg27279351	chr12:120934652	DYNLL1	0.92	8.22	0.64	1.04e-12	High light scatter reticulocyte count;
THYM	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.63	4.46	0.42	2.28e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg13114125	chr14:105738426	BRF1	-0.73	-5.75	-0.51	1.1e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.11e-8	Systolic blood pressure;
THYM	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg23708337	chr7:1209742	NA	0.81	4.48	0.42	2.1e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9522267	0.737	rs9515448	chr13:112229526	A/T	cg10483660	chr13:112241077	NA	-0.62	-6.72	-0.57	1.33e-9	Hepatitis;
THYM	cis	rs2213920	0.915	rs980176	chr9:118260408	T/G	cg13918206	chr9:118159781	DEC1	0.83	4.57	0.42	1.47e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs4077515	0.839	rs3812570	chr9:139275204	A/C	cg14115884	chr9:139300582	SDCCAG3	0.76	8.19	0.64	1.21e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs2730245	0.527	rs2788470	chr7:158649801	G/T	cg24397884	chr7:158709396	WDR60	0.55	5.31	0.48	7.06e-7	Height;
THYM	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg14972814	chr11:95582409	MTMR2	-0.55	-4.92	-0.45	3.63e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs10789491	1.000	rs12794	chr1:47141718	T/C	cg15501359	chr1:47185051	KIAA0494	1.16	8.72	0.67	8.86e-14	Response to hepatitis C treatment;
THYM	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg05472934	chr7:22766657	IL6	-0.89	-7.11	-0.59	2.16e-10	Lung cancer;
THYM	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg00645579	chr11:617140	IRF7;MUPCDH	-0.47	-6.04	-0.53	3.05e-8	Systemic lupus erythematosus;
THYM	cis	rs35123781	0.502	rs2336901	chr5:138919078	A/G	cg08720517	chr5:138729919	LOC389333	0.58	4.7	0.43	8.78e-6	Schizophrenia;
THYM	cis	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg19847130	chr8:10466454	RP1L1	-0.49	-4.46	-0.42	2.26e-5	Neuroticism;
THYM	cis	rs4731207	0.506	rs12531282	chr7:124625462	A/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3849570	1.000	rs3849570	chr3:81792112	C/A	cg07356753	chr3:81810745	GBE1	-0.89	-6.75	-0.57	1.17e-9	Waist circumference;Body mass index;
THYM	cis	rs149313	0.560	rs151835	chr5:96070982	A/G	cg24982541	chr5:96078678	CAST	-0.58	-6.53	-0.56	3.29e-9	Blood protein levels;
THYM	cis	rs73086581	0.891	rs11907503	chr20:3887590	C/T	cg02187196	chr20:3869020	PANK2	0.38	4.56	0.42	1.51e-5	Response to antidepressants in depression;
THYM	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg20469991	chr17:27169893	C17orf63	-0.76	-4.78	-0.44	6.27e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs57920188	0.535	rs10915658	chr1:4092921	T/C	cg20703997	chr1:4087676	NA	0.74	5.31	0.48	7.07e-7	Interleukin-17 levels;
THYM	cis	rs7177699	0.557	rs6495335	chr15:79117133	G/T	cg00540400	chr15:79124168	NA	0.64	6.93	0.58	4.98e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs71403859	0.502	rs34015581	chr16:71508229	T/A	cg08717414	chr16:71523259	ZNF19	-1.24	-6.37	-0.55	6.84e-9	Post bronchodilator FEV1;
THYM	cis	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs7582403	0.844	rs6753116	chr2:148852515	C/G	cg23727674	chr2:148602993	ACVR2A	-0.58	-4.79	-0.44	6.24e-6	Neuroticism;
THYM	cis	rs757081	0.667	rs17641418	chr11:17161341	T/C	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.6	-0.43	1.29e-5	Systolic blood pressure;
THYM	cis	rs62229266	0.605	rs2835275	chr21:37460001	C/T	cg08632701	chr21:37451849	NA	-0.7	-7.12	-0.59	2.02e-10	Mitral valve prolapse;
THYM	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.34	-0.48	6.28e-7	Menopause (age at onset);
THYM	cis	rs2717559	0.542	rs2717560	chr8:143881670	G/A	cg17888033	chr8:143858414	LYNX1	-0.45	-4.98	-0.45	2.86e-6	Urinary tract infection frequency;
THYM	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg03929089	chr4:120376271	NA	-1.01	-13.68	-0.81	3.47e-24	Height;
THYM	cis	rs854765	0.583	rs8078138	chr17:17811251	C/T	cg16928487	chr17:17741425	SREBF1	-0.54	-5.21	-0.47	1.08e-6	Total body bone mineral density;
THYM	cis	rs11118844	0.843	rs4601596	chr1:221914458	C/T	cg04222084	chr1:221915650	DUSP10	-1.03	-5.43	-0.49	4.35e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg10792982	chr14:105748885	BRF1	0.69	6.99	0.58	3.84e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22857025	chr5:266934	NA	-1.43	-9.3	-0.69	5.28e-15	Breast cancer;
THYM	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7267979	1.000	rs448396	chr20:25440269	G/A	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg23711669	chr6:146136114	FBXO30	0.83	7.77	0.62	9.16e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs981844	0.666	rs7691303	chr4:154684198	T/C	cg09973105	chr4:154681532	RNF175	0.54	4.98	0.45	2.88e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg11764359	chr7:65958608	NA	-0.86	-7.24	-0.6	1.17e-10	Aortic root size;
THYM	cis	rs6840360	0.533	rs13139327	chr4:152728590	A/C	cg22705602	chr4:152727874	NA	-0.8	-11.37	-0.76	2.06e-19	Intelligence (multi-trait analysis);
THYM	cis	rs9543976	0.623	rs4611344	chr13:76175328	G/A	cg01531495	chr13:76123901	UCHL3	0.66	4.8	0.44	5.85e-6	Diabetic retinopathy;
THYM	cis	rs4718428	1.000	rs4718421	chr7:66350300	C/T	cg18252515	chr7:66147081	NA	-0.67	-4.94	-0.45	3.29e-6	Corneal structure;
THYM	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg16586182	chr3:47516702	SCAP	0.64	5.62	0.5	1.93e-7	Colorectal cancer;
THYM	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg04267008	chr7:1944627	MAD1L1	-0.52	-4.63	-0.43	1.14e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs990171	0.955	rs10197881	chr2:103091715	A/G	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.07	-0.46	1.96e-6	Lymphocyte counts;
THYM	cis	rs7084402	0.967	rs7097576	chr10:60277055	G/A	cg09696939	chr10:60272079	BICC1	0.47	5.47	0.49	3.63e-7	Refractive error;
THYM	cis	rs10819861	0.645	rs3802440	chr9:98859938	G/C	cg14508093	chr9:98862825	NA	-0.24	-4.57	-0.42	1.48e-5	Electrocardiographic traits;
THYM	cis	rs10819861	0.645	rs10819810	chr9:98849911	C/T	cg14508093	chr9:98862825	NA	-0.24	-4.65	-0.43	1.08e-5	Electrocardiographic traits;
THYM	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg12031863	chr16:4587854	C16orf5	-0.44	-4.77	-0.44	6.64e-6	Schizophrenia;
THYM	cis	rs1451375	0.698	rs11238214	chr7:50636018	A/G	cg18232548	chr7:50535776	DDC	0.69	5.35	0.48	6.03e-7	Malaria;
THYM	cis	rs870825	0.616	rs6844146	chr4:185636396	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg05347473	chr6:146136440	FBXO30	0.77	6.53	0.56	3.19e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg26818010	chr10:134567672	INPP5A	-0.79	-6.37	-0.55	6.68e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg06636001	chr8:8085503	FLJ10661	0.61	5.08	0.46	1.84e-6	Neuroticism;
THYM	cis	rs13102973	0.645	rs7692242	chr4:135886041	A/G	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	cis	rs6430585	0.646	rs12468768	chr2:136494985	C/T	cg07169764	chr2:136633963	MCM6	1.19	11.36	0.76	2.09e-19	Corneal structure;
THYM	cis	rs2404602	0.647	rs12914196	chr15:76941361	C/T	cg23625390	chr15:77176239	SCAPER	-0.88	-6.17	-0.54	1.64e-8	Blood metabolite levels;
THYM	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg24818145	chr4:99064322	C4orf37	0.7	5.51	0.49	3.09e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7131987	0.650	rs10843384	chr12:29472409	C/T	cg09582351	chr12:29534625	ERGIC2	-0.59	-5.13	-0.47	1.53e-6	QT interval;
THYM	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg24069376	chr3:38537580	EXOG	0.69	6.79	0.57	9.87e-10	Electrocardiographic conduction measures;
THYM	cis	rs17253792	0.822	rs78988988	chr14:56152404	G/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg23161317	chr6:28129485	ZNF389	0.74	4.9	0.45	3.94e-6	Parkinson's disease;
THYM	cis	rs7809950	0.798	rs2701687	chr7:107304628	C/T	cg23024343	chr7:107201750	COG5	0.59	5.07	0.46	1.94e-6	Coronary artery disease;
THYM	cis	rs12282928	0.694	rs1872023	chr11:48343659	C/A	cg22827986	chr11:48284249	OR4X1	0.53	5.59	0.5	2.21e-7	Migraine - clinic-based;
THYM	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg23187316	chr7:1099788	C7orf50	0.58	4.45	0.42	2.32e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4409675	0.549	rs72872888	chr1:28239809	G/A	cg23691781	chr1:28212827	C1orf38	0.44	4.53	0.42	1.71e-5	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs236907	0.859	rs35930163	chr1:171768184	G/A	cg20598894	chr1:171756153	METTL13	-0.72	-5.34	-0.48	6.21e-7	Mean platelet volume;
THYM	cis	rs2816062	0.813	rs742485	chr1:18900943	A/T	cg18795169	chr1:18902165	NA	-0.97	-11.58	-0.77	7.31e-20	Urate levels in lean individuals;
THYM	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg20387954	chr3:183756860	HTR3D	0.58	4.81	0.44	5.56e-6	Anterior chamber depth;
THYM	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg03517284	chr6:25882590	NA	-0.7	-4.7	-0.43	8.76e-6	Height;
THYM	cis	rs4499344	0.730	rs259285	chr19:33164697	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.56	0.61	2.57e-11	Mean platelet volume;
THYM	cis	rs7119	0.689	rs8040318	chr15:77803660	A/C	cg27398640	chr15:77910606	LINGO1	-0.53	-5.45	-0.49	4e-7	Type 2 diabetes;
THYM	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.11	-10.66	-0.74	6.57e-18	Primary sclerosing cholangitis;
THYM	cis	rs7000551	0.671	rs13274867	chr8:22288198	G/T	cg12081754	chr8:22256438	SLC39A14	1.03	8.87	0.67	4.31e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	trans	rs9929218	0.559	rs55907909	chr16:68805805	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.93	9.71	0.71	6.9e-16	Colorectal cancer;
THYM	cis	rs2976388	0.692	rs2978983	chr8:143765842	A/G	cg13446199	chr8:143762866	PSCA	-0.41	-4.49	-0.42	1.97e-5	Urinary tract infection frequency;
THYM	cis	rs11077998	0.901	rs3794723	chr17:80529495	G/A	cg10255544	chr17:80519551	FOXK2	0.51	4.51	0.42	1.84e-5	Reticulocyte fraction of red cells;
THYM	cis	rs13279522	0.536	rs9298110	chr8:67016106	A/C	cg20171999	chr8:67343066	NA	-0.46	-4.6	-0.43	1.3e-5	Coronary heart disease event reduction (statin therapy interaction);
THYM	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg13319975	chr6:146136371	FBXO30	0.64	5.21	0.47	1.09e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg12310025	chr6:25882481	NA	0.68	5.56	0.5	2.47e-7	Schizophrenia;
THYM	trans	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg10856724	chr12:34555212	NA	-1.02	-9.32	-0.69	4.7e-15	Bladder cancer;
THYM	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg11247378	chr22:39784982	NA	-0.95	-9.31	-0.69	5.03e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg06697600	chr4:7070879	GRPEL1	-0.54	-4.8	-0.44	5.88e-6	Monocyte percentage of white cells;
THYM	trans	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg25214090	chr10:38739885	LOC399744	0.86	7.29	0.6	9.28e-11	Corneal astigmatism;
THYM	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg24060327	chr5:131705240	SLC22A5	-0.74	-5.46	-0.49	3.78e-7	Blood metabolite levels;
THYM	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg05025164	chr4:1340916	KIAA1530	0.83	7.04	0.59	2.99e-10	Longevity;
THYM	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg22535103	chr8:58192502	C8orf71	-0.85	-4.77	-0.44	6.68e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7404928	0.651	rs6497700	chr16:23917377	G/A	cg26685404	chr16:23957272	PRKCB	0.66	7.48	0.61	3.68e-11	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg18758796	chr5:131593413	PDLIM4	0.64	6.37	0.55	6.85e-9	Breast cancer;
THYM	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg02018176	chr4:1364513	KIAA1530	0.57	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.76	0.44	6.93e-6	Diabetic retinopathy;
THYM	cis	rs7192750	0.586	rs6499551	chr16:71943107	T/C	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs13263959	0.582	rs11778217	chr8:142655880	C/T	cg24384331	chr8:142183860	DENND3	0.46	4.47	0.42	2.2e-5	Hair color;
THYM	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg15704280	chr7:45808275	SEPT13	-1.03	-10.46	-0.73	1.69e-17	Height;
THYM	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	8.1	0.64	1.86e-12	Monocyte percentage of white cells;
THYM	cis	rs17001868	0.568	rs2280790	chr22:40745181	T/C	cg07138101	chr22:40742427	ADSL	0.92	5.27	0.48	8.42e-7	Mammographic density (dense area);
THYM	cis	rs988913	1.000	rs1503134	chr6:54836224	G/A	cg04690482	chr6:54711388	FAM83B	0.46	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs25645	0.502	rs7207600	chr17:38091660	G/A	cg24910161	chr17:38119198	GSDMA	-0.55	-5.85	-0.51	7.03e-8	Myeloid white cell count;
THYM	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg00958927	chr1:175162553	KIAA0040	0.33	4.48	0.42	2.06e-5	Alcohol dependence;
THYM	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg16586182	chr3:47516702	SCAP	0.68	5.73	0.51	1.18e-7	Colorectal cancer;
THYM	cis	rs113835537	0.529	rs2305535	chr11:66272237	A/G	cg10315249	chr11:66235081	PELI3	-0.42	-4.45	-0.42	2.34e-5	Airway imaging phenotypes;
THYM	cis	rs919433	0.713	rs6719729	chr2:198480072	G/A	cg00792783	chr2:198669748	PLCL1	0.82	5.73	0.51	1.17e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs950776	0.545	rs28444683	chr15:78984507	C/A	cg21242079	chr15:79101063	ADAMTS7	-0.52	-4.53	-0.42	1.7e-5	Sudden cardiac arrest;
THYM	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg22920501	chr2:26401640	FAM59B	-1.05	-8.59	-0.66	1.72e-13	Gut microbiome composition (summer);
THYM	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg09517075	chr8:22133004	PIWIL2	0.59	5.3	0.48	7.44e-7	Hypertriglyceridemia;
THYM	cis	rs6032067	0.586	rs13044116	chr20:43754444	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.73	-7.71	-0.62	1.23e-11	Blood protein levels;
THYM	cis	rs155076	1.000	rs566364	chr13:21837583	T/C	cg11317459	chr13:21872234	NA	-1.2	-8.92	-0.68	3.4e-14	White matter hyperintensity burden;
THYM	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg13114125	chr14:105738426	BRF1	-0.74	-5.72	-0.51	1.22e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg18252515	chr7:66147081	NA	-0.65	-4.73	-0.44	7.72e-6	Aortic root size;
THYM	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg13939156	chr17:80058883	NA	0.4	5.29	0.48	7.68e-7	Life satisfaction;
THYM	cis	rs977987	0.872	rs4887816	chr16:75319716	T/C	cg03315344	chr16:75512273	CHST6	0.83	6.93	0.58	5e-10	Dupuytren's disease;
THYM	cis	rs7104764	1.000	rs6598063	chr11:243672	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs3092073	0.617	rs56324610	chr20:44564030	G/C	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.49	-5.07	-0.46	1.97e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-5.61	-0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs220324	0.738	rs9325631	chr21:43590845	A/C	cg09727148	chr21:43560719	UMODL1	0.65	6.13	0.53	2.04e-8	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg08772003	chr10:104629869	AS3MT	-0.63	-5.59	-0.5	2.18e-7	Arsenic metabolism;
THYM	cis	rs2213920	0.619	rs2188047	chr9:118256660	G/C	cg13918206	chr9:118159781	DEC1	0.84	4.63	0.43	1.17e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs4727027	0.769	rs2140957	chr7:148758885	A/G	cg23583168	chr7:148888333	NA	-0.98	-12.47	-0.79	1.02e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg18811423	chr2:55921094	PNPT1	0.76	7.1	0.59	2.2e-10	Metabolic syndrome;
THYM	cis	rs17534004	1.000	rs35646895	chr13:31469604	C/T	cg00367615	chr13:31480979	C13orf33	0.66	4.76	0.44	7.05e-6	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs10992471	0.603	rs10761163	chr9:95313287	A/T	cg14631576	chr9:95140430	CENPP	-0.96	-8.92	-0.68	3.33e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.37	6.25	0.54	1.15e-8	Obesity-related traits;
THYM	cis	rs7119	0.700	rs7497168	chr15:77886231	A/C	cg27398640	chr15:77910606	LINGO1	0.73	9.01	0.68	2.15e-14	Type 2 diabetes;
THYM	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4845459	0.967	rs10888503	chr1:152593549	C/T	cg26135325	chr1:152595322	LCE3A	-0.43	-4.74	-0.44	7.51e-6	Psoriasis;
THYM	cis	rs367615	0.506	rs2914684	chr5:108775110	C/T	cg17395555	chr5:108820864	NA	-0.65	-8.37	-0.65	4.86e-13	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs476633	0.691	rs2164996	chr15:41536624	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.65	-5.58	-0.5	2.22e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg08885076	chr2:99613938	TSGA10	-0.66	-6.08	-0.53	2.47e-8	Chronic sinus infection;
THYM	cis	rs986417	1.000	rs2093212	chr14:60843322	G/A	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg07167872	chr1:205819463	PM20D1	-0.62	-4.53	-0.42	1.71e-5	Menarche (age at onset);
THYM	cis	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	9.39	0.69	3.37e-15	Chronic sinus infection;
THYM	cis	rs11096990	0.927	rs6845858	chr4:39238719	T/C	cg24403649	chr4:39172243	NA	-0.69	-5.9	-0.52	5.55e-8	Cognitive function;
THYM	cis	rs690037	0.528	rs568833	chr3:16367836	C/T	cg12172478	chr3:16357591	RFTN1	0.4	4.6	0.43	1.32e-5	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
THYM	cis	rs1371867	0.846	rs1660338	chr8:101242757	C/G	cg00191853	chr8:101177733	SPAG1	-0.5	-4.87	-0.45	4.51e-6	Atrioventricular conduction;
THYM	cis	rs367615	0.704	rs6889301	chr5:108835181	C/T	cg17395555	chr5:108820864	NA	0.74	8.69	0.67	1.04e-13	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg08859206	chr1:53392774	SCP2	-0.66	-7.64	-0.62	1.75e-11	Monocyte count;
THYM	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg06582575	chr6:163149167	PACRG;PARK2	1.08	7.64	0.62	1.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3126085	0.867	rs36033453	chr1:152221226	T/G	cg26020982	chr1:152196106	HRNR	-0.35	-4.53	-0.42	1.69e-5	Atopic dermatitis;
THYM	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7104764	0.917	rs6598068	chr11:243092	A/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg22433210	chr17:43662623	NA	-1.05	-8.08	-0.64	2e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs13315871	1.000	rs13317400	chr3:58408792	T/G	cg12435725	chr3:58293450	RPP14	-0.46	-4.93	-0.45	3.54e-6	Cholesterol, total;
THYM	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg16230307	chr14:35515116	FAM177A1	0.93	5.99	0.52	3.67e-8	Psoriasis;
THYM	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	7.35	0.6	6.78e-11	Platelet count;
THYM	cis	rs4282339	0.868	rs2974432	chr5:168267783	A/G	cg18364770	chr5:168310523	SLIT3	0.4	5.2	0.47	1.17e-6	Height;
THYM	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg18876405	chr7:65276391	NA	-0.56	-4.52	-0.42	1.77e-5	Aortic root size;
THYM	cis	rs7336332	0.569	rs7988412	chr13:28000282	C/T	cg22138327	chr13:27999177	GTF3A	0.68	5.3	0.48	7.34e-7	Weight;
THYM	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg04398451	chr17:18023971	MYO15A	0.82	7.64	0.62	1.72e-11	Total body bone mineral density;
THYM	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.49	-4.83	-0.44	5.32e-6	Schizophrenia;
THYM	cis	rs9677476	0.863	rs12465477	chr2:232073282	G/A	cg07929768	chr2:232055508	NA	0.62	6.17	0.53	1.7e-8	Food antigen IgG levels;
THYM	cis	rs72843506	0.656	rs111249650	chr17:19911830	A/T	cg12065943	chr17:19881925	AKAP10	-0.82	-4.5	-0.42	1.95e-5	Schizophrenia;
THYM	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	7.35	0.6	6.91e-11	Platelet count;
THYM	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg04267008	chr7:1944627	MAD1L1	-0.67	-6.12	-0.53	2.07e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs7769051	0.803	rs59740783	chr6:133231711	G/A	cg07930552	chr6:133119739	C6orf192	0.91	4.77	0.44	6.75e-6	Type 2 diabetes nephropathy;
THYM	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-5.1	-0.46	1.75e-6	Gut microbiome composition (summer);
THYM	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	5.0	0.46	2.6e-6	Height;
THYM	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs995000	0.931	rs10493322	chr1:62905893	C/T	cg06896770	chr1:63153194	DOCK7	1.0	8.17	0.64	1.31e-12	Triglyceride levels;
THYM	cis	rs2276314	0.947	rs3898595	chr18:33565885	T/A	cg19628046	chr18:33552617	C18orf21	0.77	5.47	0.49	3.68e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs4455778	0.580	rs7808387	chr7:49125122	T/C	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs4722585	0.605	rs10268883	chr7:26200417	C/T	cg07876897	chr7:26191696	NFE2L3	0.61	4.84	0.44	4.98e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg22875332	chr1:76189707	ACADM	0.84	9.74	0.71	6.07e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg12310025	chr6:25882481	NA	-0.9	-8.69	-0.67	1.06e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg15693483	chr7:1102177	C7orf50	0.41	5.97	0.52	4.17e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	trans	rs629535	0.773	rs569064	chr8:70065967	A/G	cg21567404	chr3:27674614	NA	1.08	10.14	0.72	8.19e-17	Dupuytren's disease;
THYM	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg20283391	chr11:68216788	NA	0.59	4.47	0.42	2.16e-5	Total body bone mineral density;
THYM	cis	rs939658	0.728	rs12904789	chr15:79412589	G/A	cg17916960	chr15:79447300	NA	-0.6	-6.23	-0.54	1.27e-8	Refractive error;
THYM	cis	rs1421898	0.625	rs10476257	chr5:157944037	C/T	cg06698293	chr5:158690540	UBLCP1	-0.97	-4.6	-0.43	1.28e-5	Inflammatory skin disease;
THYM	cis	rs9309473	0.500	rs1528169	chr2:73669186	T/C	cg19565262	chr2:73869966	NAT8	0.55	4.71	0.43	8.5e-6	Metabolite levels;
THYM	cis	rs57920188	0.535	rs58051771	chr1:4092146	T/C	cg20703997	chr1:4087676	NA	0.76	5.64	0.5	1.74e-7	Interleukin-17 levels;
THYM	cis	rs2712184	0.967	rs1014680	chr2:217672824	A/G	cg05032264	chr2:217675019	NA	0.57	4.89	0.45	4.06e-6	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs11645898	0.511	rs72787023	chr16:72031105	T/C	cg14768367	chr16:72042858	DHODH	-0.78	-6.21	-0.54	1.4e-8	Blood protein levels;
THYM	cis	rs11910985	1.000	rs11910985	chr21:48042766	C/T	cg23283320	chr21:48055893	PRMT2	1.38	6.64	0.56	1.95e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs7177699	0.557	rs4433781	chr15:79121835	A/T	cg00540400	chr15:79124168	NA	-0.64	-6.81	-0.57	8.61e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.57	-5.57	-0.5	2.41e-7	Lymphocyte counts;
THYM	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4792901	0.918	rs79868029	chr17:41622507	A/G	cg21940313	chr17:41620911	ETV4	-0.52	-5.51	-0.49	3.08e-7	Dupuytren's disease;
THYM	cis	rs71636778	0.509	rs6656815	chr1:27292462	G/A	cg09725874	chr1:27480106	SLC9A1	0.46	4.61	0.43	1.25e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
THYM	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg17178900	chr1:205818956	PM20D1	0.64	5.8	0.51	8.83e-8	Menarche (age at onset);
THYM	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.71	5.31	0.48	7.11e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs76878669	0.561	rs905770	chr11:66156765	A/G	cg18002602	chr11:66138449	SLC29A2	0.45	4.62	0.43	1.21e-5	Educational attainment (years of education);
THYM	cis	rs11771526	0.686	rs117514532	chr7:32316615	A/G	cg13207630	chr7:32358064	NA	0.98	5.43	0.49	4.38e-7	Body mass index;
THYM	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg05234568	chr11:5960015	NA	-0.6	-5.17	-0.47	1.28e-6	DNA methylation (variation);
THYM	cis	rs4074961	0.527	rs10908355	chr1:38035286	G/T	cg17933807	chr1:38061675	GNL2	1.09	14.67	0.83	3.78e-26	Axial length;
THYM	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg27446573	chr6:127587934	RNF146	1.01	9.68	0.7	8.06e-16	Breast cancer;
THYM	cis	rs2898681	1.000	rs6833096	chr4:53744275	G/C	cg21521518	chr4:53727714	RASL11B	0.51	5.6	0.5	2.06e-7	Optic nerve measurement (cup area);
THYM	cis	rs7172809	0.573	rs4886864	chr15:77674022	C/T	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.21	8.69	0.67	1.03e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg04866029	chr1:2707161	NA	-0.42	-4.48	-0.42	2.11e-5	Ulcerative colitis;
THYM	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg13319975	chr6:146136371	FBXO30	-0.65	-5.19	-0.47	1.18e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6430585	0.528	rs309166	chr2:136667487	C/T	cg04750100	chr2:136595281	LCT	0.55	5.49	0.49	3.39e-7	Corneal structure;
THYM	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg24209194	chr3:40518798	ZNF619	0.73	6.19	0.54	1.54e-8	Renal cell carcinoma;
THYM	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6669072	0.804	rs1307511	chr1:91312880	T/G	cg08895590	chr1:91227319	NA	0.51	5.72	0.51	1.21e-7	Cognitive function;
THYM	trans	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg10856724	chr12:34555212	NA	-0.94	-8.22	-0.64	1.01e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6754311	0.517	rs1469995	chr2:136542559	G/A	cg04750100	chr2:136595281	LCT	0.53	5.03	0.46	2.3e-6	Mosquito bite size;
THYM	trans	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg10856724	chr12:34555212	NA	-0.95	-8.21	-0.64	1.07e-12	Bladder cancer;
THYM	cis	rs669446	0.528	rs4660743	chr1:44195404	C/T	cg15962314	chr1:44399869	ARTN	0.46	5.1	0.46	1.75e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg19875535	chr5:140030758	IK	-0.6	-4.79	-0.44	6.06e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Bladder cancer;
THYM	cis	rs4808199	0.649	rs12983940	chr19:19516431	G/A	cg03709012	chr19:19516395	GATAD2A	1.15	7.47	0.61	3.83e-11	Nonalcoholic fatty liver disease;
THYM	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg14664628	chr15:75095509	CSK	-0.69	-5.24	-0.47	9.82e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs7809950	0.817	rs2204833	chr7:107283069	T/C	cg23024343	chr7:107201750	COG5	0.95	8.0	0.63	3.07e-12	Coronary artery disease;
THYM	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg24530246	chr3:53118167	NA	-0.82	-4.7	-0.43	8.91e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2637266	0.905	rs2395395	chr10:78360770	A/G	cg18941641	chr10:78392320	NA	0.6	4.79	0.44	6.09e-6	Pulmonary function;
THYM	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg22681709	chr2:178499509	PDE11A	-0.51	-4.47	-0.42	2.18e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs10979	1.000	rs35354710	chr6:143886454	A/G	cg25407410	chr6:143891975	LOC285740	-0.63	-5.46	-0.49	3.76e-7	Hypospadias;
THYM	cis	rs17443541	0.507	rs4234081	chr2:200457562	C/T	cg01795955	chr2:200468626	NA	0.72	5.0	0.46	2.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg06873352	chr17:61820015	STRADA	0.5	4.52	0.42	1.77e-5	Height;
THYM	trans	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.08	8.11	0.64	1.73e-12	Exhaled nitric oxide output;
THYM	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg07936489	chr17:37558343	FBXL20	-0.81	-5.28	-0.48	8.22e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs1448094	0.621	rs10863089	chr12:86279699	C/T	cg02569458	chr12:86230093	RASSF9	0.52	4.73	0.44	7.8e-6	Major depressive disorder;
THYM	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.89	5.72	0.51	1.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs977987	0.806	rs7188231	chr16:75436561	T/C	cg03315344	chr16:75512273	CHST6	0.77	6.43	0.55	5.19e-9	Dupuytren's disease;
THYM	cis	rs7631605	0.967	rs7643836	chr3:37148958	G/A	cg21328643	chr3:37258149	NA	-0.47	-4.6	-0.43	1.3e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs921968	0.565	rs6761437	chr2:219598092	G/A	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1461503	0.932	rs7944492	chr11:122838745	G/T	cg27398637	chr11:122830231	C11orf63	-0.7	-6.7	-0.57	1.48e-9	Menarche (age at onset);
THYM	cis	rs8016982	0.609	rs8009519	chr14:81702503	C/G	cg21807262	chr14:81713016	NA	-0.56	-5.1	-0.46	1.72e-6	Schizophrenia;
THYM	cis	rs4919687	0.550	rs12783444	chr10:104480659	G/A	cg04362960	chr10:104952993	NT5C2	0.61	4.88	0.45	4.22e-6	Colorectal cancer;
THYM	cis	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg06521331	chr12:34319734	NA	-0.98	-8.55	-0.66	2.09e-13	Morning vs. evening chronotype;
THYM	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg14186256	chr22:23484241	RTDR1	0.89	8.34	0.65	5.68e-13	Bone mineral density;
THYM	cis	rs1971762	0.583	rs1527068	chr12:54088688	A/G	cg16917193	chr12:54089295	NA	0.96	9.59	0.7	1.24e-15	Height;
THYM	cis	rs7119	0.635	rs2667764	chr15:77881239	C/T	cg27398640	chr15:77910606	LINGO1	0.7	8.44	0.65	3.49e-13	Type 2 diabetes;
THYM	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg00339695	chr16:24857497	SLC5A11	0.47	4.7	0.43	8.71e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.68	-4.87	-0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs2997447	0.637	rs2000403	chr1:26410161	A/G	cg03844060	chr1:26490628	NA	0.67	4.58	0.43	1.4e-5	QRS complex (12-leadsum);
THYM	cis	rs360798	0.817	rs10208675	chr2:62906722	C/T	cg00752480	chr2:62680940	NA	-0.26	-4.73	-0.44	7.91e-6	Coronary artery disease;
THYM	cis	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg15556689	chr8:8085844	FLJ10661	0.62	4.72	0.44	8.27e-6	Neuroticism;
THYM	cis	rs11249608	0.548	rs2047354	chr5:178455247	T/C	cg01312482	chr5:178451176	ZNF879	-0.76	-6.3	-0.54	9.29e-9	Pubertal anthropometrics;
THYM	cis	rs1829883	0.898	rs2461990	chr5:98793519	G/A	cg08333243	chr5:99726346	NA	-0.55	-4.98	-0.45	2.84e-6	Hemostatic factors and hematological phenotypes;
THYM	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg13866156	chr1:1669148	SLC35E2	-0.71	-7.14	-0.59	1.87e-10	Body mass index;
THYM	cis	rs9915657	0.773	rs9916815	chr17:70105651	A/G	cg09344028	chr17:70110421	NA	0.5	5.05	0.46	2.09e-6	Thyroid hormone levels;
THYM	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06481639	chr22:41940642	POLR3H	-0.75	-5.11	-0.46	1.66e-6	Vitiligo;
THYM	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg06636001	chr8:8085503	FLJ10661	-0.64	-5.4	-0.48	4.86e-7	Joint mobility (Beighton score);
THYM	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg27394845	chr17:28928406	LRRC37B2	1.0	4.88	0.45	4.26e-6	Body mass index;
THYM	cis	rs10992471	0.528	rs7860786	chr9:95245473	C/T	cg14631576	chr9:95140430	CENPP	-0.84	-8.02	-0.64	2.69e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6430585	0.583	rs12472293	chr2:136648077	T/C	cg23851026	chr2:136556271	LCT	0.79	7.62	0.62	1.89e-11	Corneal structure;
THYM	cis	rs3812049	0.737	rs790155	chr5:127498380	C/T	cg05443326	chr5:126853169	PRRC1	-0.66	-4.54	-0.42	1.66e-5	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14893161	chr1:205819251	PM20D1	0.94	10.0	0.72	1.61e-16	Menarche (age at onset);
THYM	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg17644776	chr2:200775616	C2orf69	0.93	7.73	0.62	1.12e-11	Osteoporosis;
THYM	cis	rs7100689	0.646	rs6585967	chr10:82139791	A/G	cg01528321	chr10:82214614	TSPAN14	-0.75	-5.6	-0.5	2.04e-7	Post bronchodilator FEV1;
THYM	cis	rs2034650	0.544	rs11070272	chr15:40725263	A/G	cg12699599	chr15:40643142	PHGR1	-0.57	-4.83	-0.44	5.17e-6	Interstitial lung disease;
THYM	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg23815491	chr16:72088622	HP	-0.84	-7.24	-0.6	1.14e-10	Fibrinogen levels;
THYM	cis	rs17174870	1.000	rs55708724	chr2:112666922	C/A	cg17354880	chr2:112658759	MERTK	-0.59	-4.6	-0.43	1.31e-5	Multiple sclerosis;
THYM	cis	rs919433	0.617	rs700642	chr2:198600730	G/T	cg05783139	chr2:198650985	BOLL	-0.61	-4.96	-0.45	3.13e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs3784262	0.542	rs2899611	chr15:58327347	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.71	-5.38	-0.48	5.31e-7	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
THYM	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg08885076	chr2:99613938	TSGA10	0.62	5.69	0.5	1.41e-7	Chronic sinus infection;
THYM	cis	rs1559088	1.000	rs7260051	chr19:33550111	C/A	cg03563238	chr19:33554763	RHPN2	-0.5	-4.48	-0.42	2.04e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7107174	1.000	rs10899451	chr11:77991222	A/C	cg19901956	chr11:77921274	USP35	-0.74	-5.57	-0.5	2.39e-7	Testicular germ cell tumor;
THYM	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg03188948	chr7:1209495	NA	0.91	5.04	0.46	2.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg11266682	chr4:10021025	SLC2A9	0.73	12.79	0.8	2.25e-22	Bone mineral density;
THYM	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7122539	0.506	rs7944999	chr11:66687863	A/G	cg04006266	chr11:66300458	BBS1	0.43	4.79	0.44	6.21e-6	HIV-1 susceptibility;
THYM	cis	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg12000587	chr17:30186630	C17orf79	-0.4	-4.79	-0.44	6.21e-6	Hip circumference adjusted for BMI;
THYM	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg13695892	chr22:41940480	POLR3H	0.85	6.98	0.58	3.94e-10	Vitiligo;
THYM	cis	rs7264396	0.836	rs6058282	chr20:34212590	T/G	cg26038318	chr20:34205095	SPAG4	0.65	5.34	0.48	6.28e-7	Total cholesterol levels;
THYM	cis	rs2637266	0.935	rs2579728	chr10:78395598	A/G	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg05347473	chr6:146136440	FBXO30	0.58	4.52	0.42	1.8e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs1994135	0.692	rs1816958	chr12:33695066	A/T	cg10856724	chr12:34555212	NA	-0.63	-4.91	-0.45	3.84e-6	Resting heart rate;
THYM	cis	rs921968	0.643	rs613539	chr2:219455967	G/T	cg02176678	chr2:219576539	TTLL4	0.63	6.07	0.53	2.56e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9394152	0.845	rs769051	chr6:33473894	T/G	cg13560919	chr6:33536144	NA	0.73	6.26	0.54	1.09e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs2811415	0.597	rs10934847	chr3:127788955	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs7589728	0.620	rs76687350	chr2:88473832	G/A	cg04511125	chr2:88470314	THNSL2	0.66	4.62	0.43	1.21e-5	Plasma clusterin levels;
THYM	cis	rs26232	0.521	rs3776856	chr5:102358806	T/C	cg23492399	chr5:102201601	PAM	-0.7	-5.21	-0.47	1.08e-6	Rheumatoid arthritis;
THYM	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg07570687	chr10:102243282	WNT8B	0.74	6.47	0.55	4.35e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4924935	1.000	rs11658555	chr17:18817486	C/T	cg26378065	chr17:18585709	ZNF286B	-0.72	-5.3	-0.48	7.42e-7	Pancreatic cancer;
THYM	cis	rs6430585	0.591	rs12477421	chr2:136433740	A/G	cg07169764	chr2:136633963	MCM6	1.16	11.27	0.76	3.33e-19	Corneal structure;
THYM	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg00684032	chr4:1343700	KIAA1530	0.61	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs12681287	0.640	rs6471314	chr8:87400459	G/A	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs7107770	1.000	rs1025812	chr11:125088182	C/G	cg07747661	chr11:125106135	PKNOX2	-0.84	-5.15	-0.47	1.43e-6	Photic sneeze reflex;
THYM	cis	rs17174870	0.955	rs12474039	chr2:112783372	G/A	cg17354880	chr2:112658759	MERTK	-0.6	-4.55	-0.42	1.57e-5	Multiple sclerosis;
THYM	cis	rs6430585	0.527	rs12465544	chr2:136451676	C/T	cg23851026	chr2:136556271	LCT	0.67	5.98	0.52	3.89e-8	Corneal structure;
THYM	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg03859395	chr2:55845619	SMEK2	0.61	5.55	0.49	2.6e-7	Metabolic syndrome;
THYM	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	5.66	0.5	1.62e-7	Schizophrenia;
THYM	cis	rs853679	0.599	rs149990	chr6:27998258	G/A	cg23161317	chr6:28129485	ZNF389	0.98	4.56	0.42	1.53e-5	Depression;
THYM	cis	rs34779708	0.833	rs12777517	chr10:35473927	T/G	cg03585969	chr10:35415529	CREM	0.65	4.51	0.42	1.87e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7586879	0.593	rs11689546	chr2:25130451	A/G	cg15423357	chr2:25149977	NA	0.71	7.63	0.62	1.77e-11	Body mass index;
THYM	cis	rs10992471	0.598	rs10761156	chr9:95171852	C/T	cg14631576	chr9:95140430	CENPP	0.67	5.94	0.52	4.7e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg19507638	chr5:93509721	C5orf36	-0.77	-5.2	-0.47	1.13e-6	Diabetic retinopathy;
THYM	trans	rs877282	1.000	rs11253362	chr10:770979	G/T	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06850241	chr22:41845214	NA	-0.6	-5.27	-0.48	8.47e-7	Vitiligo;
THYM	cis	rs55728055	0.661	rs5753700	chr22:31971258	C/T	cg10537193	chr22:32026975	PISD	-0.87	-5.55	-0.49	2.59e-7	Age-related hearing impairment;
THYM	cis	rs2721195	0.845	rs4244611	chr8:145739924	G/A	cg17328964	chr8:145687451	CYHR1	-0.65	-5.83	-0.51	7.62e-8	Age at first birth;
THYM	cis	rs912057	1.000	rs912057	chr6:6736931	C/T	cg06612196	chr6:6737390	NA	-0.69	-9.84	-0.71	3.67e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs1829883	1.000	rs2461971	chr5:98777650	A/G	cg08333243	chr5:99726346	NA	-0.57	-5.59	-0.5	2.13e-7	Hemostatic factors and hematological phenotypes;
THYM	trans	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg25214090	chr10:38739885	LOC399744	0.97	8.33	0.65	5.98e-13	Corneal astigmatism;
THYM	cis	rs7487075	0.754	rs10880962	chr12:46773444	C/G	cg07601320	chr12:47219841	SLC38A4	0.5	4.72	0.44	8.01e-6	Itch intensity from mosquito bite;
THYM	cis	rs3126085	0.935	rs10788824	chr1:152161694	A/G	cg10321714	chr1:152280068	FLG	0.71	5.04	0.46	2.22e-6	Atopic dermatitis;
THYM	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03264133	chr6:25882463	NA	0.81	6.46	0.55	4.38e-9	Intelligence (multi-trait analysis);
THYM	cis	rs2663905	0.611	rs2663924	chr15:81392903	T/G	cg09888468	chr15:81410853	NA	-0.7	-6.23	-0.54	1.28e-8	QT interval (drug interaction);
THYM	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg23791538	chr6:167370224	RNASET2	-0.78	-6.27	-0.54	1.08e-8	Crohn's disease;
THYM	cis	rs1451375	0.698	rs12669770	chr7:50656334	G/A	cg18232548	chr7:50535776	DDC	0.68	5.28	0.48	8.19e-7	Malaria;
THYM	cis	rs7173743	0.784	rs11072810	chr15:79132206	C/T	cg00540400	chr15:79124168	NA	-0.63	-6.33	-0.54	8.07e-9	Coronary artery disease;
THYM	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg21028142	chr17:79581711	NPLOC4	-0.64	-6.74	-0.57	1.23e-9	Eye color traits;
THYM	cis	rs6754311	0.593	rs4954280	chr2:136420690	C/T	cg04750100	chr2:136595281	LCT	-0.54	-5.74	-0.51	1.11e-7	Mosquito bite size;
THYM	cis	rs11760633	0.607	rs11765833	chr7:1830116	A/C	cg23422044	chr7:1970798	MAD1L1	-0.64	-4.73	-0.44	7.95e-6	Coronary artery disease;
THYM	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg27532560	chr4:187881888	NA	-0.96	-12.62	-0.79	5.09e-22	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs28595532	0.920	rs55901549	chr4:119770172	T/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg17863274	chr19:49399704	TULP2	-1.0	-6.15	-0.53	1.85e-8	Red cell distribution width;
THYM	cis	rs2072510	0.593	rs2247304	chr12:96424665	T/C	cg18817487	chr12:96390143	HAL	0.44	5.37	0.48	5.59e-7	Metabolite levels (small molecules and protein measures);
THYM	cis	rs72627123	0.867	rs77320708	chr14:74478482	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.52	0.56	3.44e-9	Morning vs. evening chronotype;
THYM	cis	rs9880211	1.000	rs9878078	chr3:136237573	C/T	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs9810089	0.814	rs2688600	chr3:136252596	C/A	cg21827317	chr3:136751795	NA	0.59	5.05	0.46	2.11e-6	Gestational age at birth (child effect);
THYM	cis	rs931127	0.617	rs10896027	chr11:65420760	C/G	cg17480646	chr11:65405466	SIPA1	0.63	4.65	0.43	1.09e-5	Systemic lupus erythematosus;
THYM	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.91	8.13	0.64	1.56e-12	Monocyte percentage of white cells;
THYM	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg09877947	chr5:131593287	PDLIM4	0.66	5.37	0.48	5.67e-7	Blood metabolite levels;
THYM	cis	rs273218	0.694	rs274369	chr5:53379987	G/C	ch.5.1024479R	chr5:53302184	ARL15	0.87	7.09	0.59	2.37e-10	Migraine;
THYM	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03517284	chr6:25882590	NA	0.74	5.83	0.51	7.58e-8	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs524023	1.000	rs559946	chr11:64358605	T/C	cg19131476	chr11:64387923	NRXN2	0.35	4.84	0.44	4.98e-6	Urate levels in obese individuals;
THYM	cis	rs2072499	0.966	rs887953	chr1:156191149	T/C	cg24450063	chr1:156163899	SLC25A44	1.13	14.52	0.83	7.42e-26	Testicular germ cell tumor;
THYM	cis	rs921968	0.565	rs7595901	chr2:219606931	A/G	cg02176678	chr2:219576539	TTLL4	-0.47	-4.56	-0.42	1.55e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs3741489	1.000	rs4328251	chr12:133470781	A/G	cg08270023	chr12:132619174	NA	1.01	4.67	0.43	1e-5	Cognitive function;
THYM	cis	rs9560113	1.000	rs9555807	chr13:112179965	C/T	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs4638749	0.677	rs17035849	chr2:108842593	G/T	cg25838818	chr2:108905173	SULT1C2	-0.53	-5.34	-0.48	6.46e-7	Blood pressure;
THYM	cis	rs9902453	0.904	rs6505148	chr17:28289818	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.22	0.54	1.3e-8	Coffee consumption (cups per day);
THYM	cis	rs13102973	0.666	rs11727313	chr4:135884490	A/C	cg14419869	chr4:135874104	NA	0.85	7.05	0.59	2.84e-10	Subjective well-being;
THYM	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.93	-8.04	-0.64	2.47e-12	Menarche (age at onset);
THYM	cis	rs72717009	0.778	rs9427400	chr1:161477204	C/T	cg15358701	chr1:161410459	NA	-0.95	-5.06	-0.46	2.08e-6	Rheumatoid arthritis;
THYM	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.65	0.5	1.68e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg15592062	chr6:167189543	RPS6KA2	-0.58	-5.88	-0.52	6.01e-8	Crohn's disease;
THYM	cis	rs4919694	1.000	rs80327774	chr10:104656671	T/C	cg04362960	chr10:104952993	NT5C2	1.14	7.07	0.59	2.65e-10	Arsenic metabolism;
THYM	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg20607798	chr8:58055168	NA	0.88	4.85	0.45	4.85e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs870825	0.616	rs7658186	chr4:185622509	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.69	0.71	7.45e-16	Blood protein levels;
THYM	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg04025307	chr7:1156635	C7orf50	0.62	5.74	0.51	1.12e-7	Longevity;Endometriosis;
THYM	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg10505658	chr17:80084571	CCDC57	0.74	8.13	0.64	1.59e-12	Life satisfaction;
THYM	cis	rs4363385	0.647	rs4845513	chr1:152998066	T/C	cg13444842	chr1:152974279	SPRR3	-0.58	-4.57	-0.42	1.46e-5	Inflammatory skin disease;
THYM	cis	rs2901656	0.640	rs4916258	chr1:172413526	T/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.61	6.75	0.57	1.16e-9	Red cell distribution width;Platelet distribution width;
THYM	cis	rs4919669	0.546	rs4919644	chr10:104229588	G/A	cg00122347	chr10:104236741	TMEM180	-0.58	-4.8	-0.44	5.83e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
THYM	cis	rs828999	0.619	rs115270243	chr1:108703034	G/A	cg24323958	chr1:108741884	SLC25A24	0.55	5.4	0.48	4.96e-7	Monocyte percentage of white cells;
THYM	cis	rs293526	0.959	rs190889	chr6:83653990	G/A	cg23278060	chr6:83777448	DOPEY1	0.62	4.54	0.42	1.62e-5	Crohn's disease;
THYM	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs4746818	1.000	rs1506770	chr10:70964357	G/A	cg04149295	chr10:70884716	VPS26A	0.78	5.31	0.48	7.18e-7	Left atrial antero-posterior diameter;
THYM	cis	rs6032067	0.929	rs17333555	chr20:43809761	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs6032067	0.714	rs6032057	chr20:43839761	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.64	-7.37	-0.6	6.28e-11	Blood protein levels;
THYM	cis	rs4363385	0.693	rs6690672	chr1:152930564	C/T	cg07796016	chr1:152779584	LCE1C	-0.59	-4.66	-0.43	1.02e-5	Inflammatory skin disease;
THYM	cis	rs4792901	0.959	rs3826413	chr17:41633645	C/G	cg21940313	chr17:41620911	ETV4	0.49	5.11	0.46	1.7e-6	Dupuytren's disease;
THYM	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg27535305	chr1:53392650	SCP2	0.38	4.55	0.42	1.6e-5	Monocyte count;
THYM	cis	rs7567389	0.599	rs6430938	chr2:128162623	A/G	cg06038358	chr2:128176007	PROC	-0.46	-4.98	-0.45	2.84e-6	Self-rated health;
THYM	cis	rs883565	0.655	rs6599000	chr3:39061512	A/G	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	5.0	0.46	2.59e-6	Handedness;
THYM	cis	rs13315871	1.000	rs4075403	chr3:58411445	G/C	cg00563845	chr3:58318305	PXK	0.53	4.67	0.43	9.78e-6	Cholesterol, total;
THYM	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg18252515	chr7:66147081	NA	-1.6	-8.8	-0.67	6.03e-14	Diabetic kidney disease;
THYM	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg13699009	chr12:122356056	WDR66	-0.48	-4.53	-0.42	1.69e-5	Mean corpuscular volume;
THYM	cis	rs3785574	0.650	rs7406102	chr17:62004749	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.52	-4.45	-0.42	2.3e-5	Height;
THYM	cis	rs6032067	0.925	rs13042522	chr20:43829290	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.46	-5.12	-0.46	1.61e-6	Blood protein levels;
THYM	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs61990749	0.544	rs11628888	chr14:78161506	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-1.15	-7.75	-0.62	1.02e-11	Fibroblast growth factor basic levels;
THYM	cis	rs240764	0.621	rs11155636	chr6:101201243	C/T	cg21058520	chr6:100914733	NA	0.6	5.28	0.48	8.25e-7	Neuroticism;
THYM	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg04944784	chr2:26401820	FAM59B	-0.71	-5.48	-0.49	3.46e-7	Gut microbiome composition (summer);
THYM	cis	rs6087990	0.669	rs2424929	chr20:31389518	A/G	cg13636640	chr20:31349939	DNMT3B	0.93	10.23	0.72	5.37e-17	Ulcerative colitis;
THYM	cis	rs3764563	0.877	rs4019751	chr19:15740716	T/G	cg20725493	chr19:15740067	CYP4F8	-1.02	-4.62	-0.43	1.2e-5	Inflammatory biomarkers;
THYM	cis	rs818427	0.927	rs153548	chr5:112237724	A/C	cg26068413	chr5:112256918	REEP5	-0.48	-4.76	-0.44	7.03e-6	Total body bone mineral density;
THYM	cis	rs995000	0.899	rs10889340	chr1:63012071	A/C	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.09	-7.74	-0.62	1.06e-11	Platelet count;
THYM	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg01448562	chr3:133502909	NA	0.82	6.94	0.58	4.74e-10	Iron status biomarkers;
THYM	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg11764359	chr7:65958608	NA	0.75	5.86	0.52	6.54e-8	Aortic root size;
THYM	cis	rs12142240	0.698	rs17357635	chr1:46808668	G/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs12802200	0.561	rs12792868	chr11:566647	T/A	cg03909863	chr11:638404	DRD4	-0.68	-4.8	-0.44	5.78e-6	Systemic lupus erythematosus;
THYM	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg05294307	chr14:35346193	BAZ1A	-0.87	-6.08	-0.53	2.47e-8	Psoriasis;
THYM	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	6.59	0.56	2.43e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg02725872	chr8:58115012	NA	-0.88	-6.3	-0.54	9.14e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7843479	0.601	rs10109521	chr8:21829948	G/A	cg17168535	chr8:21777572	XPO7	0.91	8.56	0.66	1.99e-13	Mean corpuscular volume;
THYM	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs807669	0.548	rs5748028	chr22:19172281	G/A	cg02655711	chr22:19163373	SLC25A1	0.72	8.41	0.65	4.13e-13	Metabolite levels;
THYM	cis	rs1784581	0.802	rs7768986	chr6:162427890	G/C	cg17173639	chr6:162384350	PARK2	0.79	7.74	0.62	1.05e-11	Itch intensity from mosquito bite;
THYM	cis	rs9309711	0.772	rs9309714	chr2:3491830	G/C	cg10845886	chr2:3471009	TTC15	-0.58	-4.68	-0.43	9.58e-6	Neurofibrillary tangles;
THYM	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.77	-6.22	-0.54	1.31e-8	Prostate cancer;
THYM	cis	rs1003719	0.762	rs3787786	chr21:38463436	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg18681998	chr4:17616180	MED28	0.91	8.56	0.66	2e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.76	-4.67	-0.43	9.88e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11722228	0.508	rs3756227	chr4:10087995	C/A	cg02317251	chr4:10116515	WDR1	-0.53	-4.72	-0.44	8.16e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg18252515	chr7:66147081	NA	0.6	4.52	0.42	1.76e-5	Aortic root size;
THYM	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg03929089	chr4:120376271	NA	-1.01	-13.5	-0.81	8.23e-24	Height;
THYM	cis	rs8067545	0.611	rs7216599	chr17:20015600	G/C	cg13482628	chr17:19912719	NA	0.55	4.7	0.43	8.91e-6	Schizophrenia;
THYM	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg26963428	chr7:66367121	NA	-0.59	-4.72	-0.44	8.08e-6	Corneal structure;
THYM	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.89	-4.82	-0.44	5.49e-6	Body mass index;
THYM	cis	rs17006441	0.932	rs9819504	chr3:69880469	A/G	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs919433	0.679	rs6708239	chr2:198525084	A/G	cg00792783	chr2:198669748	PLCL1	0.82	5.44	0.49	4.16e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg09085632	chr11:111637200	PPP2R1B	-0.98	-9.83	-0.71	3.91e-16	Primary sclerosing cholangitis;
THYM	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg11764359	chr7:65958608	NA	-0.82	-6.56	-0.56	2.81e-9	Aortic root size;
THYM	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg23791538	chr6:167370224	RNASET2	-0.61	-4.49	-0.42	1.99e-5	Crohn's disease;
THYM	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg00631329	chr6:26305371	NA	-0.63	-7.46	-0.61	3.99e-11	Educational attainment;
THYM	cis	rs1371867	0.817	rs1660315	chr8:101332956	G/A	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs10929159	0.928	rs6431418	chr2:236919559	C/T	cg20128773	chr2:236923534	AGAP1	0.35	4.6	0.43	1.29e-5	Parkinson's disease;
THYM	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg06002616	chr8:101225028	SPAG1	-0.46	-4.79	-0.44	6.22e-6	Atrioventricular conduction;
THYM	cis	rs1451375	1.000	rs10250513	chr7:50621488	T/G	cg18232548	chr7:50535776	DDC	0.73	5.57	0.5	2.35e-7	Malaria;
THYM	cis	rs6840360	0.615	rs12641438	chr4:152607586	A/G	cg22705602	chr4:152727874	NA	-0.79	-10.67	-0.74	6.15e-18	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg17264618	chr3:40429014	ENTPD3	0.54	5.14	0.47	1.47e-6	Renal cell carcinoma;
THYM	cis	rs7833986	0.501	rs2667978	chr8:56897951	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.57	6.52	0.56	3.36e-9	Height;
THYM	cis	rs929596	0.755	rs3771341	chr2:234673239	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.95	-7.98	-0.63	3.29e-12	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.86	5.71	0.51	1.29e-7	Smoking behavior;
THYM	cis	rs9814567	1.000	rs6772896	chr3:134203347	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.65	-0.62	1.62e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg03609598	chr5:56110824	MAP3K1	0.67	4.7	0.43	8.63e-6	Coronary artery disease;
THYM	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg15445000	chr17:37608096	MED1	-0.44	-5.07	-0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9826463	0.582	rs11714528	chr3:142133218	C/T	cg20824294	chr3:142316082	PLS1	0.76	5.3	0.48	7.53e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg07777115	chr5:623756	CEP72	-0.8	-4.78	-0.44	6.48e-6	Obesity-related traits;
THYM	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg04362960	chr10:104952993	NT5C2	0.58	4.93	0.45	3.55e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs62244186	0.659	rs12489887	chr3:44547124	A/T	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.49	-4.94	-0.45	3.39e-6	Depressive symptoms;
THYM	cis	rs4363385	0.818	rs4845514	chr1:153000820	T/C	cg13444842	chr1:152974279	SPRR3	-0.59	-4.81	-0.44	5.61e-6	Inflammatory skin disease;
THYM	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg11984989	chr7:158649758	WDR60	1.17	15.55	0.85	7.6e-28	Height;
THYM	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg03235661	chr20:60525775	NA	0.57	5.21	0.47	1.11e-6	Obesity-related traits;
THYM	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg10911889	chr6:126070802	HEY2	0.59	4.67	0.43	9.89e-6	Brugada syndrome;
THYM	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg09184832	chr6:79620586	NA	-0.56	-4.46	-0.42	2.24e-5	Intelligence (multi-trait analysis);
THYM	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg14159672	chr1:205819179	PM20D1	0.59	4.68	0.43	9.53e-6	Parkinson's disease;
THYM	cis	rs6032067	0.929	rs2233883	chr20:43835822	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.34	-0.65	5.7e-13	Blood protein levels;
THYM	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.06	-6.18	-0.54	1.56e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12941828	0.793	rs4374217	chr17:6422109	A/G	cg13775913	chr17:7297869	PLSCR3	-0.68	-4.5	-0.42	1.96e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9818758	0.607	rs11713297	chr3:49213030	A/G	cg00383909	chr3:49044727	WDR6	0.79	5.12	0.46	1.6e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg08125733	chr17:73851984	WBP2	-0.79	-5.61	-0.5	1.95e-7	Psoriasis;
THYM	cis	rs17739794	0.557	rs7823711	chr8:814529	A/G	cg01971667	chr8:817044	NA	-0.6	-5.2	-0.47	1.13e-6	Clozapine-induced cytotoxicity;
THYM	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg17143192	chr8:8559678	CLDN23	0.64	4.76	0.44	6.82e-6	Mood instability;
THYM	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22590775	chr19:49891494	CCDC155	0.83	6.78	0.57	1.03e-9	Multiple sclerosis;
THYM	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg13939156	chr17:80058883	NA	0.41	5.37	0.48	5.6e-7	Life satisfaction;
THYM	cis	rs6754311	0.731	rs309164	chr2:136691825	T/C	cg20242066	chr2:136595261	LCT	0.54	6.4	0.55	5.97e-9	Mosquito bite size;
THYM	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg26850624	chr5:429559	AHRR	0.55	4.66	0.43	1.04e-5	Cystic fibrosis severity;
THYM	cis	rs7169223	0.653	rs8029039	chr15:79100871	G/C	cg21242079	chr15:79101063	ADAMTS7	0.61	5.23	0.47	9.86e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg06611532	chr13:114900021	NA	0.64	7.26	0.6	1.05e-10	Schizophrenia;
THYM	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg01416388	chr22:39784598	NA	-0.88	-6.88	-0.58	6.23e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs17604090	0.818	rs73090342	chr7:29687540	T/C	cg19413766	chr7:29689036	LOC646762	-0.94	-5.1	-0.46	1.75e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs2637266	0.783	rs846627	chr10:78539556	A/G	cg18941641	chr10:78392320	NA	0.69	5.52	0.49	2.99e-7	Pulmonary function;
THYM	cis	rs4731207	0.698	rs10085793	chr7:124484166	T/C	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1829883	1.000	rs1829883	chr5:98781103	C/T	cg08333243	chr5:99726346	NA	-0.57	-5.59	-0.5	2.13e-7	Hemostatic factors and hematological phenotypes;
THYM	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.8	-5.44	-0.49	4.14e-7	Body mass index;
THYM	cis	rs3812049	0.784	rs2617617	chr5:127455008	C/T	cg05443326	chr5:126853169	PRRC1	-0.66	-4.57	-0.42	1.48e-5	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg19761014	chr17:28927070	LRRC37B2	0.8	4.73	0.44	7.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11716531	0.510	rs513546	chr3:27348920	A/G	cg02860705	chr3:27208620	NA	0.65	5.07	0.46	1.94e-6	Diastolic blood pressure;
THYM	cis	rs13256369	0.708	rs9644772	chr8:8557685	G/A	cg17143192	chr8:8559678	CLDN23	0.98	7.57	0.61	2.4e-11	Obesity-related traits;
THYM	cis	rs7246657	0.882	rs10412043	chr19:37826626	A/C	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.19e-7	Coronary artery calcification;
THYM	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg14159672	chr1:205819179	PM20D1	-0.76	-7.09	-0.59	2.36e-10	Menarche (age at onset);
THYM	cis	rs611744	0.870	rs634216	chr8:109174803	A/G	cg21045802	chr8:109455806	TTC35	0.67	6.51	0.56	3.49e-9	Dupuytren's disease;
THYM	cis	rs10992471	0.603	rs7865019	chr9:95325631	A/G	cg14631576	chr9:95140430	CENPP	-0.96	-8.92	-0.68	3.33e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7524258	0.867	rs916392	chr1:7271930	T/C	cg07173049	chr1:7289937	CAMTA1	0.79	6.0	0.52	3.59e-8	Tourette's syndrome or obsessive-compulsive disorder;
THYM	trans	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg25214090	chr10:38739885	LOC399744	0.86	7.36	0.6	6.54e-11	Corneal astigmatism;
THYM	cis	rs7567389	0.504	rs13030463	chr2:128188871	G/A	cg06038358	chr2:128176007	PROC	0.41	4.51	0.42	1.84e-5	Self-rated health;
THYM	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs236352	0.515	rs9380610	chr6:36805885	A/C	cg03410223	chr6:36853544	C6orf89	0.61	4.67	0.43	9.88e-6	Heart rate;
THYM	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg13695892	chr22:41940480	POLR3H	0.89	6.37	0.55	6.58e-9	Vitiligo;
THYM	cis	rs526231	0.543	rs62362541	chr5:102322448	G/A	cg23492399	chr5:102201601	PAM	-0.66	-5.15	-0.47	1.4e-6	Primary biliary cholangitis;
THYM	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg10518543	chr12:38710700	ALG10B	-0.56	-4.57	-0.42	1.49e-5	Morning vs. evening chronotype;
THYM	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg00129232	chr17:37814104	STARD3	0.7	4.72	0.44	8.26e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs977987	0.806	rs2865531	chr16:75390316	T/A	cg03315344	chr16:75512273	CHST6	0.75	6.28	0.54	1.02e-8	Dupuytren's disease;
THYM	cis	rs886126	0.950	rs2097658	chr12:111690466	C/T	cg10833066	chr12:111807467	FAM109A	0.48	5.93	0.52	4.87e-8	Coronary heart disease;
THYM	cis	rs7107174	1.000	rs10899486	chr11:78072398	A/G	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs1483890	0.642	rs1010315	chr3:69402165	C/T	cg22125112	chr3:69402811	FRMD4B	0.55	6.74	0.57	1.2e-9	Resting heart rate;
THYM	cis	rs7246657	0.525	rs1667359	chr19:37486172	G/A	cg22634378	chr19:37742834	NA	0.66	4.82	0.44	5.33e-6	Coronary artery calcification;
THYM	cis	rs6763768	0.710	rs13080668	chr3:53443354	C/T	cg16894138	chr3:53270350	TKT	-0.78	-5.74	-0.51	1.11e-7	Bacterial meningitis;
THYM	cis	rs1775715	0.737	rs12256714	chr10:32216262	A/G	cg04359828	chr10:32216031	ARHGAP12	-0.39	-5.1	-0.46	1.73e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs4786125	0.665	rs7201025	chr16:6920592	C/T	cg03623568	chr16:6915990	A2BP1	-1.01	-10.06	-0.72	1.22e-16	Heart rate variability traits (SDNN);
THYM	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg14196790	chr5:131705035	SLC22A5	0.55	5.03	0.46	2.34e-6	Blood metabolite levels;
THYM	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg00484396	chr16:3507460	NAT15	0.45	4.52	0.42	1.81e-5	Body mass index (adult);
THYM	cis	rs7103648	0.897	rs3758675	chr11:47400602	G/A	cg20307385	chr11:47447363	PSMC3	0.86	6.86	0.58	6.91e-10	Diastolic blood pressure;Systolic blood pressure;
THYM	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg11366901	chr6:160182831	ACAT2	1.1	10.38	0.73	2.6e-17	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg00495681	chr13:53174319	NA	1.08	12.84	0.8	1.75e-22	Lewy body disease;
THYM	cis	rs7584330	0.518	rs78358347	chr2:238413566	C/T	cg14458575	chr2:238380390	NA	0.99	5.04	0.46	2.22e-6	Prostate cancer;
THYM	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4718428	0.960	rs6460317	chr7:66390255	A/G	cg12165864	chr7:66369176	NA	-0.7	-5.44	-0.49	4.15e-7	Corneal structure;
THYM	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg23758822	chr17:41437982	NA	1.16	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08109568	chr15:31115862	NA	-0.63	-5.99	-0.52	3.8e-8	Huntington's disease progression;
THYM	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg06112835	chr11:68658793	MRPL21	0.43	6.02	0.53	3.32e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	5.51	0.49	3.1e-7	Schizophrenia;
THYM	cis	rs35883536	0.514	rs4908062	chr1:101013211	T/C	cg09408571	chr1:101003634	GPR88	0.59	6.59	0.56	2.43e-9	Monocyte count;
THYM	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg04520793	chr17:42248056	ASB16	0.32	5.29	0.48	7.7300000000000005e-07	Bone mineral density (hip);Bone mineral density;
THYM	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg11941060	chr3:133502564	NA	-0.73	-6.42	-0.55	5.36e-9	Iron status biomarkers;
THYM	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	trans	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs367615	0.704	rs7704824	chr5:108850278	A/G	cg17395555	chr5:108820864	NA	0.69	8.24	0.65	9.59e-13	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs7072216	0.763	rs6584198	chr10:100169906	G/C	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	trans	rs75518195	0.543	rs62301918	chr4:64666486	C/T	cg14706739	chr8:21916355	EPB49	0.75	7.37	0.6	6.34e-11	Triptolide cytotoxicity;
THYM	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg22968622	chr17:43663579	NA	-1.1	-9.99	-0.72	1.7e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs881952	0.791	rs2577646	chr2:60877171	T/A	cg02592586	chr2:60830257	NA	-0.24	-5.01	-0.46	2.5e-6	Glucose homeostasis traits;
THYM	cis	rs939658	0.805	rs35291410	chr15:79438660	C/T	cg17916960	chr15:79447300	NA	-0.75	-8.88	-0.67	4.14e-14	Refractive error;
THYM	cis	rs887829	0.570	rs10168155	chr2:234596836	C/T	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.57	-0.42	1.45e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs28595532	0.688	rs116580819	chr4:119767362	T/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs4950928	0.823	rs4950929	chr1:203160126	A/C	cg17014757	chr1:203156097	CHI3L1	1.11	6.68	0.57	1.59e-9	YKL-40 levels;
THYM	cis	rs7000551	0.581	rs11136030	chr8:22254235	C/T	cg12081754	chr8:22256438	SLC39A14	1.15	12.01	0.78	9.31e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg15557168	chr22:42548783	NA	0.58	4.68	0.43	9.66e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10791097	0.967	rs6590512	chr11:130717916	A/G	cg05962950	chr11:130786565	SNX19	-0.68	-5.43	-0.49	4.38e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs9443189	0.855	rs2842554	chr6:76455557	C/A	cg01950844	chr6:76311363	SENP6	-0.77	-4.53	-0.42	1.73e-5	Prostate cancer;
THYM	cis	rs4722166	0.630	rs6461667	chr7:22796743	A/G	cg05472934	chr7:22766657	IL6	0.88	7.11	0.59	2.12e-10	Lung cancer;
THYM	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.42	0.49	4.5e-7	Height;
THYM	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.92	0.45	3.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7777677	0.963	rs4726550	chr7:142370764	C/T	cg21785750	chr7:142428317	NA	0.67	5.88	0.52	6.1e-8	Alcoholic chronic pancreatitis;
THYM	cis	rs67981189	0.529	rs2526868	chr14:71390389	C/T	cg15910301	chr14:71632612	NA	-0.56	-4.88	-0.45	4.23e-6	Schizophrenia;
THYM	cis	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg24672777	chr11:48374446	OR4C45	-0.93	-5.95	-0.52	4.55e-8	Axial length;
THYM	cis	rs2976388	0.609	rs2717550	chr8:143787808	T/A	cg06565975	chr8:143823917	SLURP1	0.47	5.22	0.47	1.06e-6	Urinary tract infection frequency;
THYM	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg04414720	chr1:150670196	GOLPH3L	0.62	4.71	0.44	8.35e-6	Tonsillectomy;
THYM	cis	rs3816788	0.774	rs11784816	chr8:21773500	C/T	cg16476235	chr8:21771668	DOK2	-0.51	-4.47	-0.42	2.2e-5	Lung cancer in ever smokers;
THYM	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg10505658	chr17:80084571	CCDC57	0.68	7.45	0.61	4.18e-11	Life satisfaction;
THYM	cis	rs7172809	0.573	rs17470952	chr15:77700916	G/T	cg22256960	chr15:77711686	NA	-0.64	-4.67	-0.43	1e-5	Glucose homeostasis traits;
THYM	cis	rs6694672	1.000	rs1170883	chr1:196951471	C/T	cg13682187	chr1:196946512	CFHR5	-0.81	-4.69	-0.43	9.31e-6	Asthma;
THYM	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg08742575	chr21:47604166	C21orf56	0.64	4.76	0.44	7.04e-6	Testicular germ cell tumor;
THYM	cis	rs7575217	0.784	rs2241872	chr2:101768774	G/C	cg23907051	chr2:101730305	TBC1D8	-0.33	-4.54	-0.42	1.66e-5	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9796	0.870	rs3101436	chr15:41287689	A/G	cg21153102	chr15:41252147	NA	-0.67	-6.0	-0.52	3.61e-8	Menopause (age at onset);
THYM	cis	rs595982	0.546	rs9941490	chr19:49396737	G/A	cg03707168	chr19:49379127	PPP1R15A	0.3	4.47	0.42	2.17e-5	Red cell distribution width;
THYM	cis	rs10992471	0.603	rs7873397	chr9:95205928	G/C	cg14631576	chr9:95140430	CENPP	-0.99	-9.94	-0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7872515	0.536	rs7851249	chr9:94766647	G/T	cg13922115	chr9:95397568	IPPK	0.88	4.51	0.42	1.85e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs56775891	0.527	rs71367545	chr18:77576337	G/A	cg25357022	chr18:77495084	CTDP1	-0.69	-4.53	-0.42	1.72e-5	Schizophrenia;
THYM	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg18904891	chr8:8559673	CLDN23	-0.64	-5.47	-0.49	3.58e-7	Obesity-related traits;
THYM	cis	rs7246657	0.943	rs7259968	chr19:37811854	T/C	cg22634378	chr19:37742834	NA	0.65	5.34	0.48	6.2e-7	Coronary artery calcification;
THYM	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg03684893	chr10:554711	DIP2C	0.73	5.35	0.48	5.95e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.65	-4.88	-0.45	4.2e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs4919694	1.000	rs12242000	chr10:104702413	A/C	cg15744005	chr10:104629667	AS3MT	-0.85	-4.67	-0.43	9.96e-6	Arsenic metabolism;
THYM	cis	rs7584330	0.554	rs62186170	chr2:238425883	C/T	cg08992911	chr2:238395768	MLPH	0.85	5.39	0.48	5.19e-7	Prostate cancer;
THYM	cis	rs56341938	0.904	rs62275515	chr3:168725418	A/G	cg09107232	chr3:169491072	MYNN	0.56	4.81	0.44	5.75e-6	Lung function (FEV1/FVC);
THYM	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.25	4.54	0.42	1.66e-5	Obesity-related traits;
THYM	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.07	6.86	0.58	6.91e-10	Cognitive test performance;
THYM	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	4.46	0.42	2.21e-5	Diabetic retinopathy;
THYM	cis	rs9790314	0.967	rs1382427	chr3:161032576	T/C	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	trans	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg18187862	chr3:45730750	SACM1L	-0.87	-6.84	-0.57	7.56e-10	Primary sclerosing cholangitis;
THYM	cis	rs57590327	0.555	rs6767749	chr3:81725513	G/A	cg07356753	chr3:81810745	GBE1	-0.88	-6.75	-0.57	1.17e-9	Extraversion;
THYM	cis	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg19442545	chr10:75533431	FUT11	-0.51	-5.22	-0.47	1.03e-6	Inflammatory bowel disease;
THYM	cis	rs13064411	0.735	rs7631138	chr3:113231925	A/T	cg18753928	chr3:113234510	CCDC52	-0.97	-9.75	-0.71	5.71e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs728616	0.764	rs75385771	chr10:81692779	T/C	cg05935833	chr10:81318306	SFTPA2	-0.77	-4.66	-0.43	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2742417	0.603	rs2742458	chr3:45767602	C/T	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs2227564	0.574	rs3849969	chr10:75525999	C/T	cg00564723	chr10:75632066	CAMK2G	0.54	4.78	0.44	6.31e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs11771526	0.901	rs10223907	chr7:32297813	G/C	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg24209194	chr3:40518798	ZNF619	0.58	4.78	0.44	6.34e-6	Renal cell carcinoma;
THYM	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg26441486	chr22:50317300	CRELD2	0.43	6.57	0.56	2.71e-9	Schizophrenia;
THYM	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg04520793	chr17:42248056	ASB16	-0.34	-4.78	-0.44	6.45e-6	Total body bone mineral density;
THYM	cis	rs8014204	0.604	rs7156590	chr14:75388183	C/T	cg06637938	chr14:75390232	RPS6KL1	0.59	6.03	0.53	3.19e-8	Caffeine consumption;
THYM	cis	rs72829446	0.530	rs11869864	chr17:7407766	C/A	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.55	-4.71	-0.44	8.34e-6	Platelet count;
THYM	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-4.87	-0.45	4.47e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs1395	0.626	rs72817537	chr2:27497549	G/A	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.21	-0.47	1.12e-6	Blood metabolite levels;
THYM	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg07936489	chr17:37558343	FBXL20	-0.67	-4.9	-0.45	3.86e-6	Asthma;
THYM	cis	rs113835537	0.529	rs11821155	chr11:66246337	C/T	cg24851651	chr11:66362959	CCS	-0.62	-4.48	-0.42	2.09e-5	Airway imaging phenotypes;
THYM	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg01579765	chr21:45077557	HSF2BP	-0.48	-7.81	-0.63	7.62e-12	Mean corpuscular volume;
THYM	cis	rs4499344	0.730	rs35098593	chr19:33103939	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.61	0.62	2.02e-11	Mean platelet volume;
THYM	trans	rs7827290	0.863	rs7014099	chr8:142305766	C/T	cg08449049	chr16:89259820	CDH15	0.66	6.84	0.57	7.61e-10	Bipolar disorder;
THYM	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.55	-0.73	1.12e-17	Primary sclerosing cholangitis;
THYM	cis	rs288326	0.561	rs74564500	chr2:183786420	C/A	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs10186029	0.623	rs10497996	chr2:213997865	T/C	cg08319019	chr2:214017104	IKZF2	0.79	6.19	0.54	1.55e-8	Systemic sclerosis;
THYM	cis	rs761746	0.672	rs5753684	chr22:31939973	A/G	cg10537193	chr22:32026975	PISD	-0.37	-4.78	-0.44	6.45e-6	Intelligence;
THYM	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-11.46	-0.76	1.34e-19	Height;
THYM	cis	rs79387448	0.745	rs1523197	chr2:103163732	A/G	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg06064525	chr11:970664	AP2A2	-0.35	-6.59	-0.56	2.4e-9	Alzheimer's disease (late onset);
THYM	trans	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg26043149	chr18:55253948	FECH	1.21	11.82	0.77	2.36e-20	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg24450063	chr1:156163899	SLC25A44	1.21	15.52	0.85	8.47e-28	Testicular germ cell tumor;
THYM	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg00801512	chr17:28996047	NA	-0.76	-5.02	-0.46	2.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9311676	0.632	rs56398717	chr3:58404355	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs2554380	0.891	rs1155070	chr15:84303084	T/C	cg14598478	chr15:84363061	ADAMTSL3	-0.64	-4.64	-0.43	1.13e-5	Height;
THYM	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg24020549	chr11:64937741	SPDYC	-0.46	-4.46	-0.42	2.23e-5	Eosinophil percentage of white cells;
THYM	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg24375607	chr4:120327624	NA	0.53	4.47	0.42	2.2e-5	Educational attainment;
THYM	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg26131816	chr17:42072204	PYY	0.53	4.6	0.43	1.28e-5	Menopause (age at onset);
THYM	cis	rs7178572	0.568	rs11632941	chr15:77533888	A/G	cg22256960	chr15:77711686	NA	-1.04	-8.57	-0.66	1.83e-13	Type 2 diabetes;
THYM	cis	rs9807989	0.507	rs1420105	chr2:103035119	A/G	cg03938978	chr2:103052716	IL18RAP	0.74	9.64	0.7	9.73e-16	Asthma;
THYM	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07157834	chr1:205819609	PM20D1	-0.88	-9.01	-0.68	2.15e-14	Menarche (age at onset);
THYM	cis	rs2445762	0.642	rs8041933	chr15:51617746	G/A	cg07517944	chr15:51633816	GLDN	0.61	4.82	0.44	5.43e-6	Hormone measurements;
THYM	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg02725872	chr8:58115012	NA	-0.88	-6.24	-0.54	1.24e-8	Developmental language disorder (linguistic errors);
THYM	trans	rs629535	0.590	rs62513427	chr8:70138891	A/T	cg21567404	chr3:27674614	NA	-0.87	-6.84	-0.57	7.52e-10	Dupuytren's disease;
THYM	cis	rs9649213	0.593	rs6970990	chr7:97925382	T/G	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.6e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs453193	0.714	rs3102937	chr2:8447876	A/G	cg12167548	chr2:8464763	NA	0.42	4.54	0.42	1.63e-5	Granulocyte percentage of myeloid white cells;
THYM	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg07389463	chr12:132296394	NA	0.49	4.8	0.44	5.83e-6	Migraine;
THYM	cis	rs35991856	0.597	rs10070734	chr5:87940026	T/C	cg02225085	chr5:87975992	LOC645323	0.59	4.45	0.42	2.35e-5	Neuroticism (multi-trait analysis);
THYM	cis	rs2688608	0.592	rs11000757	chr10:75486815	T/C	cg15838173	chr10:75533400	FUT11	-0.5	-5.09	-0.46	1.82e-6	Inflammatory bowel disease;
THYM	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.98	10.41	0.73	2.25e-17	Intelligence (multi-trait analysis);
THYM	cis	rs8017423	0.967	rs55894943	chr14:90714799	A/G	cg04239629	chr14:90701769	NA	-0.62	-4.56	-0.42	1.55e-5	Mortality in heart failure;
THYM	cis	rs554111	0.613	rs1567128	chr1:21404653	G/A	cg01072550	chr1:21505969	NA	0.58	5.03	0.46	2.27e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg24112000	chr20:60950667	NA	-0.68	-5.62	-0.5	1.92e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs6089584	0.566	rs3787422	chr20:60555346	G/A	cg24733560	chr20:60626293	TAF4	0.61	6.19	0.54	1.52e-8	Body mass index;
THYM	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.64	-4.76	-0.44	7e-6	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg18477163	chr1:228402036	OBSCN	0.57	6.33	0.54	8.11e-9	Diastolic blood pressure;
THYM	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg25703541	chr22:24373054	LOC391322	-0.85	-9.29	-0.69	5.42e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg15556689	chr8:8085844	FLJ10661	0.62	4.87	0.45	4.4e-6	Mood instability;
THYM	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.87e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1461503	0.838	rs7107012	chr11:122829813	G/A	cg27398637	chr11:122830231	C11orf63	-0.67	-5.76	-0.51	1.03e-7	Menarche (age at onset);
THYM	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg17054759	chr22:49844102	NA	-0.53	-5.05	-0.46	2.09e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1371867	0.839	rs1788186	chr8:101335686	T/C	cg00191853	chr8:101177733	SPAG1	-0.51	-5.03	-0.46	2.29e-6	Atrioventricular conduction;
THYM	cis	rs7762018	0.660	rs41265385	chr6:170068086	C/T	cg19338460	chr6:170058176	WDR27	-0.71	-4.78	-0.44	6.38e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.34	5.05	0.46	2.09e-6	Bone mineral density (spine);Bone mineral density;
THYM	trans	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg10856724	chr12:34555212	NA	-0.8	-6.88	-0.58	6.2e-10	Bladder cancer;
THYM	cis	rs9378357	0.614	rs4076221	chr6:3290726	A/G	cg08754725	chr6:3293098	SLC22A23	-0.74	-4.93	-0.45	3.47e-6	Obesity-related traits;
THYM	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg24399712	chr22:39784796	NA	0.79	7.45	0.61	4.3e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs28476539	0.567	rs13102081	chr4:83573226	G/C	cg10249074	chr4:83542146	C4orf11	-0.65	-5.13	-0.47	1.51e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs675209	0.576	rs35257692	chr6:7080823	T/G	cg24899545	chr6:7112846	RREB1	-0.52	-4.87	-0.45	4.45e-6	Urate levels;
THYM	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	5.92	0.52	5.19e-8	Obesity-related traits;
THYM	cis	rs1371867	0.846	rs1660353	chr8:101250907	C/T	cg06636551	chr8:101224915	SPAG1	0.6	5.69	0.5	1.38e-7	Atrioventricular conduction;
THYM	cis	rs747334	0.846	rs7895456	chr10:92720640	A/T	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg24846343	chr22:24311635	DDTL	0.46	5.93	0.52	4.98e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg18252515	chr7:66147081	NA	-0.66	-4.95	-0.45	3.27e-6	Aortic root size;
THYM	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg03929089	chr4:120376271	NA	-1.03	-12.43	-0.79	1.26e-21	Height;
THYM	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs17253792	0.822	rs77315200	chr14:56072643	C/A	cg01858014	chr14:56050164	KTN1	-1.21	-5.09	-0.46	1.83e-6	Putamen volume;
THYM	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	0.43	4.82	0.44	5.45e-6	Insulin-like growth factors;
THYM	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.57	4.81	0.44	5.69e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs9653442	0.609	rs10209110	chr2:100672692	C/T	cg07810366	chr2:100720526	AFF3	-0.43	-6.07	-0.53	2.66e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs7192380	1.000	rs7191292	chr16:69669427	G/A	cg09409435	chr16:70099608	PDXDC2	0.62	4.73	0.44	7.92e-6	Sjögren's syndrome;
THYM	cis	rs12220238	1.000	rs10824128	chr10:76007903	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.86	4.65	0.43	1.08e-5	Soluble interleukin-2 receptor subunit alpha;
THYM	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg10334053	chr1:2078117	PRKCZ	-0.47	-4.71	-0.44	8.47e-6	Height;
THYM	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.54	-0.56	3.07e-9	Personality dimensions;
THYM	cis	rs11112613	0.713	rs11112590	chr12:105951376	C/G	cg03607813	chr12:105948248	NA	-1.0	-8.19	-0.64	1.18e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg17173187	chr15:85201210	NMB	0.56	5.66	0.5	1.6e-7	Schizophrenia;
THYM	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.94	7.19	0.59	1.45e-10	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs1461503	0.512	rs4259833	chr11:122809205	G/A	cg27398637	chr11:122830231	C11orf63	-0.63	-5.73	-0.51	1.2e-7	Menarche (age at onset);
THYM	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg15693483	chr7:1102177	C7orf50	0.54	6.29	0.54	9.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg05855489	chr10:104503620	C10orf26	0.58	4.69	0.43	9.11e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs2130392	0.886	rs3806796	chr4:185652147	G/A	cg04058563	chr4:185651563	MLF1IP	-0.59	-5.68	-0.5	1.45e-7	Kawasaki disease;
THYM	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg00898013	chr13:113819073	PROZ	-0.99	-8.94	-0.68	3.01e-14	Platelet distribution width;
THYM	cis	rs10751667	1.000	rs7396798	chr11:970510	G/T	cg01483505	chr11:975446	AP2A2	0.69	5.59	0.5	2.14e-7	Alzheimer's disease (late onset);
THYM	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg21433313	chr16:3507492	NAT15	0.57	4.75	0.44	7.16e-6	Body mass index (adult);
THYM	cis	rs6842789	0.510	rs6813913	chr4:124886695	T/G	cg01723706	chr4:124814442	LOC285419	0.74	4.65	0.43	1.07e-5	Neuroticism;
THYM	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg18681998	chr4:17616180	MED28	0.82	7.59	0.61	2.16e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2658782	0.547	rs3020065	chr11:93059899	A/G	cg02384510	chr11:93059814	NA	-0.48	-4.6	-0.43	1.28e-5	Pulmonary function decline;
THYM	cis	rs593982	0.920	rs487264	chr11:65481465	A/C	cg08755490	chr11:65554678	OVOL1	1.29	4.66	0.43	1.03e-5	Atopic dermatitis;
THYM	cis	rs12530845	0.887	rs59400686	chr7:135360029	A/G	cg23117316	chr7:135346802	PL-5283	-0.73	-6.24	-0.54	1.19e-8	Red blood cell traits;
THYM	cis	rs3796352	1.000	rs71301804	chr3:53073314	C/A	cg07884673	chr3:53033167	SFMBT1	1.03	5.24	0.47	9.74e-7	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs4499344	0.556	rs259220	chr19:33137629	T/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.93	6.54	0.56	3.01e-9	Mean platelet volume;
THYM	cis	rs17407555	0.657	rs1558488	chr4:10327414	A/G	cg00071950	chr4:10020882	SLC2A9	0.56	5.01	0.46	2.53e-6	Schizophrenia (age at onset);
THYM	cis	rs854765	0.856	rs2955382	chr17:17947710	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.64	-5.43	-0.49	4.27e-7	Total body bone mineral density;
THYM	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg19346786	chr7:2764209	NA	-0.54	-4.58	-0.43	1.42e-5	Height;
THYM	cis	rs7584330	0.554	rs9646713	chr2:238443542	T/C	cg08992911	chr2:238395768	MLPH	0.71	4.69	0.43	9.14e-6	Prostate cancer;
THYM	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.48	0.42	2.07e-5	Motion sickness;
THYM	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg14416269	chr4:6271139	WFS1	0.55	5.69	0.5	1.41e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.05	6.74	0.57	1.23e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs8073060	0.586	rs4795086	chr17:34042190	G/A	cg19694781	chr19:47549865	TMEM160	1.02	8.69	0.67	1.01e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs1267303	0.642	rs114746843	chr1:46999239	C/A	cg25110126	chr1:46999211	NA	0.77	6.12	0.53	2.1e-8	Monobrow;
THYM	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs9902453	0.935	rs7220151	chr17:28334710	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg14675211	chr2:100938903	LONRF2	0.77	8.11	0.64	1.75e-12	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg23958373	chr8:599963	NA	-0.9	-4.75	-0.44	7.27e-6	IgG glycosylation;
THYM	cis	rs11112613	0.713	rs11112589	chr12:105951226	C/G	cg03607813	chr12:105948248	NA	-0.99	-8.15	-0.64	1.47e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-8.1	-0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7553864	0.835	rs719015	chr1:87611710	A/G	cg17420885	chr1:87600446	LOC339524	-0.71	-5.99	-0.52	3.73e-8	Smoking behavior;
THYM	cis	rs10089	1.000	rs59484271	chr5:127503781	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.89	5.0	0.46	2.62e-6	Ileal carcinoids;
THYM	cis	rs1451375	0.617	rs10267323	chr7:50591424	A/G	cg18232548	chr7:50535776	DDC	0.67	5.03	0.46	2.31e-6	Malaria;
THYM	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg15247329	chr7:2764246	NA	-0.67	-5.55	-0.5	2.53e-7	Height;
THYM	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg10047753	chr17:41438598	NA	-0.95	-8.32	-0.65	6.22e-13	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2046867	0.908	rs62251636	chr3:72792650	A/G	cg25664220	chr3:72788482	NA	-0.86	-6.52	-0.56	3.39e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs1557488	0.565	rs4937195	chr11:126706091	C/G	cg03950493	chr11:126582183	KIRREL3	0.4	4.88	0.45	4.31e-6	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	trans	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg10856724	chr12:34555212	NA	-0.87	-7.57	-0.61	2.38e-11	Heart rate;
THYM	cis	rs9972944	0.902	rs9972883	chr17:63771316	C/A	cg07283582	chr17:63770753	CCDC46	0.65	5.25	0.47	9.39e-7	Total body bone mineral density;
THYM	cis	rs61931739	0.635	rs1405024	chr12:33937939	A/T	cg10856724	chr12:34555212	NA	0.63	5.9	0.52	5.54e-8	Morning vs. evening chronotype;
THYM	cis	rs3026101	0.697	rs1806267	chr17:5322106	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.52	4.49	0.42	2.04e-5	Body mass index;
THYM	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.68	-9.74	-0.71	5.95e-16	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg00981070	chr1:2046702	PRKCZ	0.47	5.29	0.48	7.76e-7	Height;
THYM	cis	rs7616559	0.849	rs9838466	chr3:156760176	T/G	cg15697575	chr3:156784781	NA	0.42	5.37	0.48	5.54e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs11209185	0.509	rs9436790	chr1:68447044	G/A	cg22082780	chr1:68452167	NA	0.53	6.09	0.53	2.34e-8	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs2820651	1.000	rs55971690	chr10:1470059	A/G	cg27404824	chr10:1454848	ADARB2	0.92	4.81	0.44	5.74e-6	Migraine with aura;
THYM	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg26384229	chr12:38710491	ALG10B	0.73	5.5	0.49	3.16e-7	Morning vs. evening chronotype;
THYM	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.74	-5.94	-0.52	4.71e-8	Lung cancer;
THYM	cis	rs9303280	0.587	rs35123741	chr17:38092930	A/G	cg24910161	chr17:38119198	GSDMA	-0.55	-6.65	-0.56	1.89e-9	Self-reported allergy;
THYM	cis	rs6557607	1.000	rs2241259	chr8:22868254	C/G	cg04259752	chr8:23262159	LOXL2	0.43	4.55	0.42	1.59e-5	Plasma trimethylamine N-oxide levels;
THYM	cis	rs2836633	0.929	rs4514962	chr21:40041753	C/T	cg12884169	chr21:40033163	ERG	0.7	8.95	0.68	2.88e-14	Coronary artery disease;
THYM	cis	rs1878931	1.000	rs1878931	chr16:3450907	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.96	8.37	0.65	5.04e-13	Body mass index (adult);
THYM	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg05373962	chr22:49881684	NA	-0.66	-6.6	-0.56	2.35e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4925114	0.568	rs9900803	chr17:17650978	C/T	cg04398451	chr17:18023971	MYO15A	0.66	5.36	0.48	5.91e-7	Body mass index;
THYM	cis	rs3126085	0.560	rs11204987	chr1:152342869	G/A	cg10321714	chr1:152280068	FLG	-0.7	-5.19	-0.47	1.19e-6	Atopic dermatitis;
THYM	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg05333889	chr7:157238977	NA	-0.49	-4.66	-0.43	1.03e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs240764	0.782	rs395521	chr6:101054999	C/T	cg21058520	chr6:100914733	NA	-0.57	-5.06	-0.46	2.04e-6	Neuroticism;
THYM	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg09455208	chr3:40491958	NA	0.46	4.67	0.43	9.9e-6	Renal cell carcinoma;
THYM	cis	rs7084402	0.967	rs1649032	chr10:60279701	T/C	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs7809950	1.000	rs2178497	chr7:107278901	T/C	cg23024343	chr7:107201750	COG5	0.93	7.87	0.63	5.64e-12	Coronary artery disease;
THYM	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg22189786	chr22:42395067	WBP2NL	0.57	5.12	0.47	1.59e-6	Birth weight;
THYM	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg24530246	chr3:53118167	NA	-0.77	-4.64	-0.43	1.1e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs1823778	0.609	rs1004623	chr18:67664150	A/T	cg13164537	chr18:67624071	CD226	1.15	4.8	0.44	5.83e-6	Mean platelet volume;
THYM	cis	rs9915657	0.840	rs10512582	chr17:70139393	A/C	cg06234051	chr17:70120541	SOX9	-0.77	-7.38	-0.6	5.87e-11	Thyroid hormone levels;
THYM	cis	rs983545	1.000	rs11928330	chr3:16958367	A/G	cg24159436	chr3:16974681	PLCL2	-0.35	-4.89	-0.45	4.03e-6	Blood protein levels;
THYM	cis	rs7107174	0.901	rs866901	chr11:77926309	C/T	cg02023728	chr11:77925099	USP35	0.7	6.19	0.54	1.5e-8	Testicular germ cell tumor;
THYM	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs11809207	0.522	rs3762459	chr1:26494886	C/G	cg00147160	chr1:26503991	CNKSR1	0.48	5.79	0.51	9e-8	Height;
THYM	cis	rs11651000	0.846	rs41321047	chr17:45813665	G/A	cg03474202	chr17:45855739	NA	-0.76	-4.99	-0.46	2.69e-6	IgG glycosylation;
THYM	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg03806693	chr22:41940476	POLR3H	1.17	10.14	0.72	8.43e-17	Vitiligo;
THYM	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs2281845	0.826	rs4915214	chr1:201076290	T/A	cg17810781	chr1:201082982	CACNA1S	0.55	5.71	0.51	1.29e-7	Permanent tooth development;
THYM	cis	rs12130333	0.517	rs11207993	chr1:63044464	C/T	cg06896770	chr1:63153194	DOCK7	0.97	4.6	0.43	1.3e-5	Triglycerides;
THYM	cis	rs2658782	0.951	rs2608215	chr11:93148817	G/A	cg16424440	chr11:93231842	C11orf75	-0.73	-4.91	-0.45	3.82e-6	Pulmonary function decline;
THYM	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs4343996	0.558	rs11761186	chr7:3412450	A/G	cg21248987	chr7:3385318	SDK1	0.4	4.94	0.45	3.32e-6	Motion sickness;
THYM	cis	rs752010	0.934	rs11210503	chr1:42101134	A/G	cg04490934	chr1:41978749	HIVEP3	-0.56	-4.49	-0.42	2e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg06636001	chr8:8085503	FLJ10661	0.6	4.56	0.42	1.51e-5	Mood instability;
THYM	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg08048268	chr3:133502702	NA	-0.66	-5.65	-0.5	1.64e-7	Iron status biomarkers;
THYM	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3771570	1.000	rs41266959	chr2:242275579	G/A	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs2040771	0.711	rs361639	chr22:19268024	A/G	cg02655711	chr22:19163373	SLC25A1	0.61	6.49	0.55	3.82e-9	Metabolite levels (small molecules and protein measures);
THYM	cis	rs7639513	0.545	rs9874557	chr3:12720967	A/G	cg23032965	chr3:12705835	RAF1	0.92	6.95	0.58	4.64e-10	Itch intensity from mosquito bite;
THYM	cis	rs4731207	0.724	rs6953168	chr7:124506341	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg15556689	chr8:8085844	FLJ10661	0.56	4.46	0.42	2.23e-5	Mood instability;
THYM	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg07424592	chr7:64974309	NA	-0.99	-5.15	-0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg03806693	chr22:41940476	POLR3H	-1.24	-10.72	-0.74	4.88e-18	Vitiligo;
THYM	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg04756594	chr16:24857601	SLC5A11	-0.72	-4.85	-0.45	4.73e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg11764359	chr7:65958608	NA	0.64	5.0	0.46	2.58e-6	Aortic root size;
THYM	cis	rs600806	0.815	rs10858088	chr1:109923586	C/T	cg23616212	chr1:109941201	SORT1	-0.5	-4.65	-0.43	1.06e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6554196	0.525	rs6554194	chr4:55499810	T/G	cg18836493	chr4:55524333	KIT	-0.54	-4.58	-0.43	1.41e-5	Monocyte count;
THYM	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg05335186	chr13:53173507	NA	-0.39	-4.79	-0.44	6.12e-6	Lewy body disease;
THYM	cis	rs28493229	0.786	rs73546894	chr19:41189203	C/T	cg21869046	chr19:41225005	ITPKC	0.59	5.74	0.51	1.15e-7	Kawasaki disease;
THYM	cis	rs988913	0.768	rs2179786	chr6:54753340	G/T	cg18532076	chr6:54711417	FAM83B	0.5	5.07	0.46	1.95e-6	Menarche (age at onset);
THYM	cis	rs7394190	0.748	rs11000772	chr10:75533988	T/G	cg07699608	chr10:75541558	CHCHD1	0.91	4.93	0.45	3.49e-6	Incident atrial fibrillation;
THYM	cis	rs6032067	0.636	rs6104093	chr20:43908297	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.69	-6.3	-0.54	9.04e-9	Blood protein levels;
THYM	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg15448220	chr1:150897856	SETDB1	-0.86	-6.94	-0.58	4.73e-10	Melanoma;
THYM	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg04546413	chr19:29218101	NA	0.85	5.48	0.49	3.44e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg03351412	chr1:154909251	PMVK	0.71	5.6	0.5	2.12e-7	Prostate cancer;
THYM	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg23682913	chr1:2080710	PRKCZ	0.6	4.83	0.44	5.13e-6	Height;
THYM	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg10803722	chr21:46713166	LOC642852	-0.43	-5.74	-0.51	1.13e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg08648136	chr8:956695	NA	0.59	5.11	0.46	1.67e-6	Schizophrenia;
THYM	cis	rs7084921	0.533	rs12765091	chr10:101855231	G/C	cg11344164	chr10:101878520	NA	-0.56	-4.81	-0.44	5.61e-6	Bone mineral density;
THYM	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg21100191	chr22:23484243	RTDR1	0.75	6.66	0.56	1.78e-9	Bone mineral density;
THYM	cis	rs990171	1.000	rs1420106	chr2:103035044	C/T	cg13897122	chr2:103039542	IL18RAP	0.38	4.53	0.42	1.73e-5	Lymphocyte counts;
THYM	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg12560992	chr17:57184187	TRIM37	0.9	8.32	0.65	6.3e-13	Intelligence (multi-trait analysis);
THYM	cis	rs987710	0.568	rs4821790	chr22:22511370	T/C	cg21401457	chr22:22472743	NA	0.92	4.5	0.42	1.91e-5	Iron status biomarkers;Iron deficiency;
THYM	cis	rs1524976	1.000	rs62255278	chr3:65475846	A/T	cg16238336	chr3:65465873	MAGI1	-1.01	-6.33	-0.54	8.04e-9	PR interval;
THYM	cis	rs2273669	0.504	rs76268442	chr6:109493812	A/G	cg17117243	chr6:109341365	SESN1	-0.82	-4.8	-0.44	5.98e-6	Prostate cancer;
THYM	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg01483505	chr11:975446	AP2A2	0.58	4.73	0.44	7.73e-6	Alzheimer's disease (late onset);
THYM	cis	rs6840360	0.574	rs2709844	chr4:152368212	C/T	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg18105134	chr13:113819100	PROZ	1.15	10.31	0.73	3.57e-17	Platelet distribution width;
THYM	cis	rs7011507	0.589	rs72639047	chr8:49415598	G/A	cg08774009	chr8:49309094	NA	-0.6	-4.74	-0.44	7.56e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg10589385	chr1:150898437	SETDB1	0.64	5.32	0.48	7.02e-7	Melanoma;
THYM	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.78	0.44	6.28e-6	Lung cancer in ever smokers;
THYM	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg23803603	chr1:2058230	PRKCZ	0.59	4.56	0.42	1.52e-5	Height;
THYM	cis	rs73787773	0.866	rs60370278	chr5:111484212	T/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.91	-4.83	-0.44	5.23e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs3540	0.553	rs4031431	chr15:90990782	G/T	cg22089800	chr15:90895588	ZNF774	0.7	5.39	0.48	5.08e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs6995541	0.529	rs6988598	chr8:10689678	A/G	cg13457217	chr8:10683266	MIR1322;PINX1	-0.67	-5.02	-0.46	2.39e-6	Triglyceride levels;
THYM	cis	rs10992471	0.598	rs230222	chr9:95265558	C/G	cg14631576	chr9:95140430	CENPP	-0.62	-5.42	-0.49	4.49e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg23803603	chr1:2058230	PRKCZ	-0.58	-4.93	-0.45	3.53e-6	Height;
THYM	cis	rs9677476	0.818	rs13431424	chr2:232060553	G/A	cg07929768	chr2:232055508	NA	0.63	6.35	0.55	7.5e-9	Food antigen IgG levels;
THYM	cis	rs6815814	0.950	rs4540055	chr4:38803255	A/T	cg02016764	chr4:38805732	TLR1	-0.48	-4.83	-0.44	5.26e-6	Breast cancer;
THYM	cis	rs9646944	0.501	rs34946515	chr2:103043320	C/T	cg01241218	chr2:102972058	NA	0.76	4.86	0.45	4.55e-6	Blood protein levels;
THYM	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg22709100	chr7:91322751	NA	0.63	4.86	0.45	4.55e-6	Breast cancer;
THYM	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs2046867	0.628	rs7617996	chr3:72915315	C/T	cg25664220	chr3:72788482	NA	-0.75	-6.81	-0.57	8.6e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg18230493	chr5:56204884	C5orf35	0.81	5.39	0.48	5.07e-7	Initial pursuit acceleration;
THYM	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22857025	chr5:266934	NA	-1.59	-10.2	-0.72	6.04e-17	Breast cancer;
THYM	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg08498830	chr11:832797	CD151	-0.62	-4.56	-0.42	1.53e-5	Mean platelet volume;
THYM	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.83	-7.76	-0.62	9.64e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7107174	1.000	rs58565853	chr11:78036707	C/T	cg02023728	chr11:77925099	USP35	0.62	5.96	0.52	4.19e-8	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11809207	0.953	rs17163666	chr1:26525383	A/G	cg03844060	chr1:26490628	NA	0.62	4.54	0.42	1.65e-5	Height;
THYM	cis	rs4986172	0.539	rs3744760	chr17:43195981	C/T	cg06100756	chr17:43221575	NA	-0.6	-6.11	-0.53	2.22e-8	Height;
THYM	cis	rs4979906	1.000	rs1609790	chr10:79464078	C/T	cg07817648	chr10:79422355	NA	-0.74	-5.21	-0.47	1.11e-6	Mortality in heart failure;
THYM	cis	rs7190997	0.525	rs11150617	chr16:31372290	T/C	cg07842593	chr16:30457166	SEPHS2	0.65	4.53	0.42	1.7e-5	IgA nephropathy;
THYM	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg19875535	chr5:140030758	IK	-0.65	-5.26	-0.48	8.71e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7572733	0.576	rs6734781	chr2:198759973	G/A	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs58688157	0.705	rs936468	chr11:607175	G/A	cg16486109	chr11:613632	IRF7	0.51	5.52	0.49	2.9e-7	Systemic lupus erythematosus;
THYM	cis	rs870825	0.929	rs55880126	chr4:185591237	T/G	cg04058563	chr4:185651563	MLF1IP	1.03	7.36	0.6	6.51e-11	Blood protein levels;
THYM	cis	rs8038465	0.568	rs62004592	chr15:73878019	A/G	cg15420318	chr15:73925796	NPTN	0.62	5.33	0.48	6.52e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7523273	1.000	rs12123251	chr1:207992546	G/A	cg22525895	chr1:207977042	MIR29B2	-0.85	-8.2	-0.64	1.16e-12	Schizophrenia;
THYM	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg05147244	chr20:61493195	TCFL5	-0.86	-5.79	-0.51	8.97e-8	Obesity-related traits;
THYM	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg00684032	chr4:1343700	KIAA1530	0.54	4.67	0.43	9.81e-6	Obesity-related traits;
THYM	cis	rs7264396	0.836	rs6058275	chr20:34186331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.61	-4.78	-0.44	6.51e-6	Total cholesterol levels;
THYM	cis	rs2554380	0.943	rs2585049	chr15:84352873	A/C	cg14598478	chr15:84363061	ADAMTSL3	0.64	4.98	0.45	2.87e-6	Height;
THYM	cis	rs877282	0.853	rs12763400	chr10:763617	C/T	cg10556349	chr10:835070	NA	-0.78	-5.06	-0.46	2.06e-6	Uric acid levels;
THYM	cis	rs1448094	0.512	rs1584368	chr12:86245117	A/C	cg02569458	chr12:86230093	RASSF9	0.61	5.25	0.47	9.41e-7	Major depressive disorder;
THYM	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg18402987	chr7:1209562	NA	1.26	7.81	0.63	7.59e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03576123	chr11:487126	PTDSS2	-1.23	-6.11	-0.53	2.16e-8	Body mass index;
THYM	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg18252515	chr7:66147081	NA	0.59	4.49	0.42	2.03e-5	Aortic root size;
THYM	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg02493798	chr17:6899577	ALOX12	0.61	7.85	0.63	6.28e-12	Tonsillectomy;
THYM	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	5.52	0.49	2.88e-7	Hip circumference adjusted for BMI;
THYM	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg22117172	chr7:91764530	CYP51A1	-0.39	-4.79	-0.44	6.17e-6	Breast cancer;
THYM	cis	rs8067545	1.000	rs28807825	chr17:19942850	G/A	cg08626831	chr17:20841558	NA	-0.47	-4.5	-0.42	1.91e-5	Schizophrenia;
THYM	cis	rs9359856	0.564	rs72913921	chr6:90328692	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.89	-7.95	-0.63	3.88e-12	Bipolar disorder;
THYM	cis	rs8018808	1.000	rs4899652	chr14:77848972	A/G	cg20045696	chr14:77926864	AHSA1	-0.59	-5.39	-0.48	5.16e-7	Myeloid white cell count;
THYM	cis	rs2810114	0.916	rs2810099	chr14:71432421	A/G	cg15910301	chr14:71632612	NA	-0.56	-4.88	-0.45	4.23e-6	Alcohol dependence;
THYM	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	5.73	0.51	1.18e-7	Blood metabolite levels;
THYM	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg15921436	chr17:44337874	NA	-0.91	-6.85	-0.58	7.19e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg22467129	chr15:76604101	ETFA	-0.51	-5.02	-0.46	2.42e-6	Blood metabolite levels;
THYM	cis	rs12291225	0.679	rs11369	chr11:14288096	A/G	cg05501817	chr11:14380813	RRAS2	-0.73	-5.52	-0.49	2.94e-7	Sense of smell;
THYM	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg18252515	chr7:66147081	NA	0.62	4.63	0.43	1.18e-5	Aortic root size;
THYM	cis	rs9826463	0.582	rs73238148	chr3:142061446	G/A	cg20824294	chr3:142316082	PLS1	0.69	4.7	0.43	8.94e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg22709100	chr7:91322751	NA	0.69	5.52	0.49	2.92e-7	Breast cancer;
THYM	cis	rs72712511	0.641	rs4863692	chr4:140764124	G/T	cg15010390	chr4:140216957	NDUFC1	0.62	4.45	0.42	2.33e-5	Intelligence (multi-trait analysis);
THYM	cis	rs42648	0.806	rs6951894	chr7:89893945	A/G	cg25739043	chr7:89950458	NA	-0.58	-4.86	-0.45	4.58e-6	Homocysteine levels;
THYM	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.6	-0.43	1.29e-5	Educational attainment;
THYM	cis	rs9902453	0.808	rs56088359	chr17:28173659	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.61	0.43	1.27e-5	Coffee consumption (cups per day);
THYM	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs1160297	0.539	rs12469781	chr2:53136539	C/T	cg07782112	chr2:53107842	NA	-0.63	-5.13	-0.47	1.5e-6	Hemostatic factors and hematological phenotypes;
THYM	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg26924012	chr15:45694286	SPATA5L1	0.66	4.86	0.45	4.69e-6	Response to fenofibrate (adiponectin levels);
THYM	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg13683864	chr3:40499215	RPL14	-1.05	-11.49	-0.76	1.13e-19	Renal cell carcinoma;
THYM	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs9788721	0.836	rs17483548	chr15:78730313	G/A	cg18825076	chr15:78729989	IREB2	-0.68	-6.14	-0.53	1.88e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg19052272	chr2:3704530	ALLC	-0.67	-5.0	-0.46	2.62e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs1557488	0.565	rs7105625	chr11:126724899	C/A	cg03950493	chr11:126582183	KIRREL3	-0.39	-4.56	-0.42	1.52e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs1061377	1.000	rs4974998	chr4:39110749	C/T	cg24403649	chr4:39172243	NA	0.56	4.56	0.42	1.54e-5	Uric acid levels;
THYM	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg09085632	chr11:111637200	PPP2R1B	0.88	7.44	0.61	4.52e-11	Primary sclerosing cholangitis;
THYM	cis	rs1160297	0.609	rs10208858	chr2:53094982	G/A	cg07782112	chr2:53107842	NA	0.77	6.13	0.53	1.98e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	4.97	0.45	3e-6	Height;
THYM	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg05717871	chr11:638507	DRD4	-0.66	-4.83	-0.44	5.17e-6	Systemic lupus erythematosus;
THYM	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg07389463	chr12:132296394	NA	0.57	5.54	0.49	2.68e-7	Migraine;
THYM	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg13319975	chr6:146136371	FBXO30	-0.65	-5.39	-0.48	5.18e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8133932	0.654	rs425232	chr21:47346525	G/T	cg20357416	chr21:47294739	PCBP3	0.8	4.88	0.45	4.26e-6	Schizophrenia;
THYM	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6089584	0.587	rs3787423	chr20:60555485	G/A	cg24733560	chr20:60626293	TAF4	0.61	6.19	0.54	1.52e-8	Body mass index;
THYM	cis	rs883565	0.792	rs784492	chr3:39175576	A/C	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	4.49	0.42	1.97e-5	Handedness;
THYM	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg27432699	chr2:27873401	GPN1	0.61	5.3	0.48	7.36e-7	Oral cavity cancer;
THYM	cis	rs2404602	0.684	rs11854850	chr15:76844571	C/T	cg23625390	chr15:77176239	SCAPER	-0.84	-6.05	-0.53	2.84e-8	Blood metabolite levels;
THYM	cis	rs4664308	1.000	rs6759924	chr2:160912747	G/A	cg03641300	chr2:160917029	PLA2R1	-0.79	-6.99	-0.58	3.73e-10	Idiopathic membranous nephropathy;
THYM	cis	rs4919694	1.000	rs76892505	chr10:104719290	G/A	cg04362960	chr10:104952993	NT5C2	1.15	7.03	0.59	3.1e-10	Arsenic metabolism;
THYM	cis	rs9522267	0.535	rs7339347	chr13:112237920	C/T	cg10483660	chr13:112241077	NA	-0.6	-6.79	-0.57	9.6e-10	Hepatitis;
THYM	trans	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg10856724	chr12:34555212	NA	-0.94	-8.13	-0.64	1.61e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs6906287	0.647	rs13220480	chr6:118916627	G/A	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs897984	0.645	rs9938550	chr16:30999142	A/G	cg06892815	chr16:30991727	SETD1A	0.51	4.52	0.42	1.79e-5	Dementia with Lewy bodies;
THYM	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg02527881	chr3:46936655	PTH1R	-0.61	-5.74	-0.51	1.15e-7	Colorectal cancer;
THYM	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.85	-6.22	-0.54	1.32e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs7917772	0.560	rs10786697	chr10:104378563	G/T	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs977987	0.778	rs34222958	chr16:75398252	C/T	cg03315344	chr16:75512273	CHST6	0.74	6.13	0.53	2.02e-8	Dupuytren's disease;
THYM	cis	rs7507204	0.572	rs7246730	chr19:3419781	A/G	cg08380311	chr19:3435252	NFIC	-0.81	-7.33	-0.6	7.64e-11	Height;
THYM	cis	rs55788414	0.932	rs12102293	chr16:81181607	T/C	cg06400318	chr16:81190750	PKD1L2	-0.85	-4.56	-0.42	1.53e-5	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg08999081	chr20:33150536	PIGU	0.56	4.66	0.43	1.03e-5	Height;
THYM	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg01191920	chr7:158217561	PTPRN2	-1.07	-12.34	-0.78	1.91e-21	Obesity-related traits;
THYM	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg01831904	chr17:28903510	LRRC37B2	1.03	5.1	0.46	1.7e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg23505145	chr19:12996616	KLF1	-0.96	-9.45	-0.7	2.43e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg27170947	chr2:26402098	FAM59B	-0.79	-6.27	-0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs2702888	0.622	rs2702933	chr8:6760142	A/G	cg03082247	chr8:6756796	NA	-0.59	-4.69	-0.43	9.28e-6	Blood pressure;
THYM	cis	rs1161098	0.716	rs1161179	chr12:67825924	T/A	cg20473420	chr12:67782441	NA	0.86	4.46	0.42	2.26e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg19761014	chr17:28927070	LRRC37B2	0.8	4.73	0.44	7.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs2034088	0.833	rs7214241	chr17:418171	G/T	cg06217071	chr17:408420	NA	0.8	8.45	0.66	3.36e-13	Hip circumference adjusted for BMI;
THYM	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg09469691	chr10:81107165	PPIF	0.73	5.92	0.52	5.04e-8	Height;
THYM	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg17845761	chr1:175162550	KIAA0040	-0.36	-4.57	-0.42	1.45e-5	Alcohol dependence;
THYM	cis	rs9992101	0.547	rs10032549	chr4:77398015	A/G	cg27417997	chr4:77356416	SHROOM3	-0.4	-4.81	-0.44	5.66e-6	Creatinine levels;
THYM	cis	rs3020333	0.755	rs851996	chr6:152016803	C/T	cg22157087	chr6:152012887	ESR1	0.54	6.48	0.55	3.99e-9	Total body bone mineral density;
THYM	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.98	-7.76	-0.62	9.68e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg09354556	chr3:47051341	NA	-0.44	-4.61	-0.43	1.24e-5	Colorectal cancer;
THYM	cis	rs72827839	1.000	rs17624626	chr17:46535805	G/A	cg03177231	chr17:45772386	TBKBP1	0.89	4.58	0.43	1.4e-5	Ease of getting up in the morning;
THYM	cis	rs9490860	1.000	rs9490860	chr6:123989741	G/T	cg15749870	chr6:123317473	CLVS2	-0.6	-4.97	-0.45	2.91e-6	IgG glycosylation;
THYM	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg21926883	chr2:100939477	LONRF2	-0.58	-4.99	-0.46	2.76e-6	Intelligence (multi-trait analysis);
THYM	cis	rs34638657	0.797	rs7203990	chr16:82185320	A/G	cg19807685	chr16:82068980	HSD17B2	-0.62	-4.67	-0.43	9.8200000000000008e-06	Lung adenocarcinoma;
THYM	cis	rs4466137	1.000	rs1154888	chr5:82977410	C/A	cg16102102	chr5:83017553	HAPLN1	-1.04	-8.97	-0.68	2.57e-14	Prostate cancer;
THYM	cis	rs12791968	0.765	rs11038250	chr11:45009114	A/G	cg11846598	chr11:44996168	LOC221122	-0.79	-5.84	-0.51	7.17e-8	Inhibitory control;
THYM	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg24692254	chr21:30365293	RNF160	-0.9	-7.75	-0.62	9.91e-12	Dental caries;
THYM	cis	rs8050907	1.000	rs77214986	chr16:4603722	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.19	4.91	0.45	3.71e-6	Obesity-related traits;
THYM	cis	rs6121246	0.559	rs10439608	chr20:30258814	T/C	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs7772486	0.777	rs1546966	chr6:146386018	G/T	cg13319975	chr6:146136371	FBXO30	-0.64	-5.55	-0.49	2.61e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6032067	0.925	rs35875037	chr20:43859921	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.42	-0.49	4.55e-7	Blood protein levels;
THYM	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.68	6.1	0.53	2.26e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs55871839	0.708	rs10093993	chr8:59811454	T/C	cg07426533	chr8:59803705	TOX	-0.67	-6.88	-0.58	6.33e-10	Pneumonia;
THYM	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg01097406	chr16:89675127	NA	0.6	5.04	0.46	2.23e-6	Vitiligo;
THYM	cis	rs295140	1.000	rs10931899	chr2:201176901	A/G	cg04283868	chr2:201171347	SPATS2L	-0.74	-5.53	-0.49	2.81e-7	QT interval;
THYM	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg11764359	chr7:65958608	NA	0.88	7.53	0.61	2.88e-11	Aortic root size;
THYM	cis	rs6450176	0.904	rs4351101	chr5:53300591	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-6.19	-0.54	1.54e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg14324370	chr2:177042789	NA	-0.69	-5.82	-0.51	7.82e-8	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg14829155	chr15:31115871	NA	-0.58	-5.23	-0.47	1.01e-6	Huntington's disease progression;
THYM	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg22166914	chr1:53195759	ZYG11B	-0.69	-6.96	-0.58	4.39e-10	Monocyte count;
THYM	cis	rs9560113	1.000	rs9560103	chr13:112174253	G/A	cg14154082	chr13:112174009	NA	0.86	8.0	0.63	2.95e-12	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg24253500	chr15:84953950	NA	0.54	4.56	0.42	1.5e-5	Schizophrenia;
THYM	cis	rs7917772	0.582	rs7899004	chr10:104341435	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.76	-6.52	-0.56	3.31e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg07507251	chr3:52567010	NT5DC2	0.44	5.07	0.46	1.94e-6	Bipolar disorder;
THYM	cis	rs12594515	0.967	rs11857628	chr15:45998206	C/T	cg01629716	chr15:45996671	NA	0.51	5.2	0.47	1.14e-6	Waist circumference;Weight;
THYM	cis	rs758324	0.732	rs154730	chr5:131468507	G/A	cg16205897	chr5:131564050	P4HA2	0.52	4.6	0.43	1.29e-5	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs9790314	1.000	rs1478565	chr3:161027464	C/T	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs7131987	0.650	rs7301398	chr12:29455390	G/T	cg09582351	chr12:29534625	ERGIC2	-0.53	-4.68	-0.43	9.37e-6	QT interval;
THYM	cis	rs10992471	0.598	rs7867300	chr9:95183107	A/G	cg14631576	chr9:95140430	CENPP	0.7	5.73	0.51	1.16e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs62435770	1.000	rs4346834	chr6:169530915	C/G	cg07652237	chr6:170125491	PHF10	0.54	4.82	0.44	5.48e-6	Loneliness;
THYM	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg07636037	chr3:49044803	WDR6	1.0	10.57	0.73	1.03e-17	Parkinson's disease;
THYM	cis	rs910187	0.678	rs6124965	chr20:45812957	T/G	cg27589058	chr20:45804311	EYA2	-0.59	-5.07	-0.46	1.95e-6	Migraine;
THYM	cis	rs1747683	0.966	rs7901303	chr10:13378690	T/G	cg25835351	chr10:13388524	SEPHS1	-0.35	-5.73	-0.51	1.17e-7	IgG glycosylation;
THYM	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg04398451	chr17:18023971	MYO15A	-0.78	-7.23	-0.6	1.22e-10	Total body bone mineral density;
THYM	cis	rs7119	0.651	rs17394732	chr15:77835657	A/G	cg10437265	chr15:77819839	NA	-0.79	-8.34	-0.65	5.67e-13	Type 2 diabetes;
THYM	cis	rs11792861	0.530	rs1772047	chr9:111679012	A/G	cg05043794	chr9:111880884	C9orf5	0.34	4.69	0.43	9.18e-6	Menarche (age at onset);
THYM	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg03676636	chr4:99064102	C4orf37	0.5	7.54	0.61	2.74e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11711311	1.000	rs9809850	chr3:113429010	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.62	-5.2	-0.47	1.16e-6	IgG glycosylation;
THYM	cis	rs10789491	1.000	rs7516616	chr1:47186274	A/G	cg15501359	chr1:47185051	KIAA0494	-1.11	-7.83	-0.63	6.86e-12	Response to hepatitis C treatment;
THYM	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.81	0.44	5.64e-6	Bipolar disorder;
THYM	cis	rs12367572	0.965	rs10748405	chr12:45321341	C/G	cg03114573	chr12:45410052	DBX2	-0.55	-5.17	-0.47	1.31e-6	Gut microbiome composition (summer);
THYM	cis	rs303386	0.501	rs4908302	chr1:99583122	A/C	cg03593336	chr1:99471295	LPPR5	0.4	4.49	0.42	2.01e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
THYM	cis	rs7586879	0.789	rs36029941	chr2:25127801	C/T	cg01884057	chr2:25150051	NA	0.53	4.64	0.43	1.13e-5	Body mass index;
THYM	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg01699819	chr7:1052092	C7orf50	-0.84	-7.05	-0.59	2.91e-10	Bronchopulmonary dysplasia;
THYM	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg26818010	chr10:134567672	INPP5A	-0.74	-6.1	-0.53	2.29e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg13402656	chr8:1511478	DLGAP2	-0.76	-7.68	-0.62	1.43e-11	Lung cancer;
THYM	cis	rs67311347	0.544	rs13062243	chr3:40336789	G/A	cg13683864	chr3:40499215	RPL14	-0.79	-7.44	-0.61	4.43e-11	Renal cell carcinoma;
THYM	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg26384229	chr12:38710491	ALG10B	-0.93	-7.72	-0.62	1.16e-11	Bladder cancer;
THYM	cis	rs921968	0.607	rs529474	chr2:219463283	C/T	cg02176678	chr2:219576539	TTLL4	0.63	6.07	0.53	2.56e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs478304	0.637	rs11227255	chr11:65454044	C/T	cg17480646	chr11:65405466	SIPA1	-0.97	-8.99	-0.68	2.44e-14	Acne (severe);
THYM	cis	rs293526	0.917	rs184133	chr6:83671095	G/A	cg23278060	chr6:83777448	DOPEY1	0.63	4.65	0.43	1.07e-5	Crohn's disease;
THYM	cis	rs1669338	0.588	rs4684375	chr3:3170966	T/C	cg16797762	chr3:3221439	CRBN	-0.9	-5.17	-0.47	1.27e-6	White matter integrity;
THYM	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs17407555	0.738	rs3806817	chr4:10118914	C/T	cg00071950	chr4:10020882	SLC2A9	-0.74	-5.16	-0.47	1.37e-6	Schizophrenia (age at onset);
THYM	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg13647721	chr17:30228624	UTP6	0.76	4.98	0.46	2.83e-6	Hip circumference adjusted for BMI;
THYM	cis	rs926938	0.841	rs11588144	chr1:115239355	G/A	cg12756093	chr1:115239321	AMPD1	-0.78	-7.56	-0.61	2.46e-11	Autism;
THYM	cis	rs3540	0.574	rs2256388	chr15:90969335	A/C	cg22089800	chr15:90895588	ZNF774	-0.69	-5.45	-0.49	4.03e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs1003719	0.788	rs9974286	chr21:38456832	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.71	-5.02	-0.46	2.39e-6	Eye color traits;
THYM	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg23758822	chr17:41437982	NA	1.16	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg08742575	chr21:47604166	C21orf56	-0.68	-5.41	-0.49	4.7e-7	Testicular germ cell tumor;
THYM	cis	rs7107770	1.000	rs34457642	chr11:125086200	A/T	cg07747661	chr11:125106135	PKNOX2	-0.87	-5.33	-0.48	6.65e-7	Photic sneeze reflex;
THYM	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg19318889	chr4:1322082	MAEA	0.63	5.46	0.49	3.72e-7	Longevity;
THYM	cis	rs13082711	0.554	rs1494422	chr3:27375190	T/C	cg02860705	chr3:27208620	NA	-0.82	-6.3	-0.54	9.22e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg18301423	chr5:131593218	PDLIM4	-0.53	-5.12	-0.47	1.59e-6	Acylcarnitine levels;
THYM	cis	rs992157	0.798	rs2382818	chr2:219155907	A/T	cg04731861	chr2:219085781	ARPC2	0.55	5.1	0.46	1.71e-6	Colorectal cancer;
THYM	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg23851026	chr2:136556271	LCT	0.5	4.62	0.43	1.18e-5	Mosquito bite size;
THYM	cis	rs7725337	0.930	rs1366142	chr5:88380316	C/T	cg11280525	chr5:87955695	LOC645323	-0.4	-4.52	-0.42	1.78e-5	Total body bone mineral density;
THYM	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9309711	0.961	rs35067331	chr2:3474085	C/T	cg10845886	chr2:3471009	TTC15	-0.57	-4.49	-0.42	1.99e-5	Neurofibrillary tangles;
THYM	cis	rs6754311	0.906	rs4954387	chr2:136784344	A/G	cg20242066	chr2:136595261	LCT	0.56	5.89	0.52	5.77e-8	Mosquito bite size;
THYM	cis	rs57221529	1.000	rs57221529	chr5:586624	A/G	cg16624210	chr5:671434	TPPP	0.68	4.99	0.46	2.71e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg02782426	chr3:40428986	ENTPD3	0.53	4.69	0.43	9.02e-6	Renal cell carcinoma;
THYM	cis	rs4788570	0.697	rs6499540	chr16:71822250	A/C	cg06353428	chr16:71660113	MARVELD3	1.41	8.74	0.67	8.32e-14	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-10.53	-0.73	1.25e-17	Coronary artery disease;
THYM	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	6.64	0.56	1.9e-9	Prudent dietary pattern;
THYM	cis	rs9807989	0.708	rs6543124	chr2:102987459	T/A	cg03938978	chr2:103052716	IL18RAP	0.68	6.98	0.58	4.05e-10	Asthma;
THYM	cis	rs9326248	0.813	rs4938350	chr11:117022276	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.67	4.78	0.44	6.35e-6	Blood protein levels;
THYM	cis	rs7172809	0.599	rs116981387	chr15:77753231	G/A	cg22256960	chr15:77711686	NA	-0.61	-4.47	-0.42	2.18e-5	Glucose homeostasis traits;
THYM	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg22981736	chr15:31284413	MTMR10	-0.56	-4.93	-0.45	3.52e-6	Huntington's disease progression;
THYM	cis	rs12148488	0.763	rs12898551	chr15:75297907	C/G	cg09165964	chr15:75287851	SCAMP5	0.62	4.49	0.42	2.02e-5	Caffeine consumption;
THYM	cis	rs3741151	0.892	rs7930454	chr11:73085034	T/C	cg17517138	chr11:73019481	ARHGEF17	0.95	5.77	0.51	1e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs5769707	0.616	rs6009786	chr22:50015145	A/G	cg17054759	chr22:49844102	NA	-0.53	-4.65	-0.43	1.09e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg08772003	chr10:104629869	AS3MT	-0.55	-4.88	-0.45	4.23e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg02569458	chr12:86230093	RASSF9	0.58	5.02	0.46	2.38e-6	Major depressive disorder;
THYM	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg05481257	chr2:20870211	GDF7	-0.76	-6.44	-0.55	4.93e-9	Abdominal aortic aneurysm;
THYM	cis	rs2777491	1.000	rs2730055	chr15:41735708	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.12	-12.55	-0.79	6.92e-22	Ulcerative colitis;
THYM	cis	rs2976388	1.000	rs2920298	chr8:143763043	A/G	cg13446199	chr8:143762866	PSCA	0.51	6.42	0.55	5.46e-9	Urinary tract infection frequency;
THYM	cis	rs4866334	1.000	rs75393523	chr5:18488595	T/G	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs62070183	0.938	rs75822124	chr17:31037894	C/T	cg02981443	chr17:31254875	TMEM98	-0.54	-4.77	-0.44	6.69e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs9361491	0.608	rs7744731	chr6:79454471	G/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22496380	chr5:211416	CCDC127	-1.33	-7.99	-0.63	3.21e-12	Breast cancer;
THYM	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07157834	chr1:205819609	PM20D1	0.89	8.85	0.67	4.64e-14	Menarche (age at onset);
THYM	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg04990556	chr1:26633338	UBXN11	-0.87	-8.25	-0.65	8.82e-13	Obesity-related traits;
THYM	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg19774624	chr17:42201019	HDAC5	-0.77	-7.16	-0.59	1.73e-10	Total body bone mineral density;
THYM	cis	rs757081	0.667	rs60173525	chr11:17259967	A/G	cg07093617	chr11:18158918	MRGPRX3	-0.49	-4.61	-0.43	1.23e-5	Systolic blood pressure;
THYM	cis	rs208520	0.874	rs208473	chr6:66917265	G/C	cg07460842	chr6:66804631	NA	-0.86	-5.5	-0.49	3.15e-7	Exhaled nitric oxide output;
THYM	cis	rs477692	0.569	rs10764883	chr10:131307817	A/G	cg05714579	chr10:131428358	MGMT	0.58	4.81	0.44	5.56e-6	Response to temozolomide;
THYM	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg14018140	chr10:458528	DIP2C	0.61	7.04	0.59	2.95e-10	Psychosis in Alzheimer's disease;
THYM	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg22307297	chr20:60903441	LAMA5	0.53	4.64	0.43	1.12e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs9549260	0.755	rs9549236	chr13:41147158	C/T	cg21288729	chr13:41239152	FOXO1	-0.71	-5.53	-0.49	2.84e-7	Red blood cell count;
THYM	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg01483505	chr11:975446	AP2A2	0.58	4.73	0.44	7.73e-6	Alzheimer's disease (late onset);
THYM	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg15445000	chr17:37608096	MED1	0.44	5.07	0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs3741151	0.892	rs7102787	chr11:73012614	A/G	cg12959048	chr11:73096162	RELT	-0.42	-4.49	-0.42	1.97e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs6964587	0.655	rs6965864	chr7:91595596	A/G	cg22709100	chr7:91322751	NA	0.63	4.76	0.44	6.78e-6	Breast cancer;
THYM	cis	rs735539	1.000	rs1888001	chr13:21285906	C/G	cg04906043	chr13:21280425	IL17D	-0.69	-4.55	-0.42	1.56e-5	Dental caries;
THYM	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6032067	0.852	rs17424751	chr20:43814622	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs708547	0.836	rs1713997	chr4:57843863	G/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.74	-5.42	-0.49	4.52e-7	Response to bleomycin (chromatid breaks);
THYM	cis	rs6748734	0.625	rs10172404	chr2:241820906	T/C	cg07537917	chr2:241836409	C2orf54	-0.21	-4.62	-0.43	1.22e-5	Urinary metabolites;
THYM	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg11941060	chr3:133502564	NA	-0.73	-6.25	-0.54	1.18e-8	Iron status biomarkers;
THYM	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg06636001	chr8:8085503	FLJ10661	0.71	6.43	0.55	5.14e-9	Mood instability;
THYM	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg07936489	chr17:37558343	FBXL20	0.85	5.64	0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs597539	0.503	rs7131462	chr11:68610143	G/A	cg21862992	chr11:68658383	NA	-0.25	-4.58	-0.43	1.42e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs17152411	0.895	rs66531168	chr10:126586908	T/A	cg07906193	chr10:126599966	NA	0.68	4.65	0.43	1.08e-5	Height;
THYM	cis	rs11997175	0.756	rs4739435	chr8:33818818	A/G	ch.8.33884649F	chr8:33765107	NA	0.74	5.87	0.52	6.33e-8	Body mass index;
THYM	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg03929089	chr4:120376271	NA	-0.97	-10.61	-0.74	8.11e-18	Coronary artery disease;
THYM	cis	rs7769051	0.522	rs6934190	chr6:133116664	G/A	cg22852734	chr6:133119734	C6orf192	1.45	6.1	0.53	2.32e-8	Type 2 diabetes nephropathy;
THYM	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	5.44	0.49	4.18e-7	Obesity-related traits;
THYM	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs4979906	1.000	rs4325263	chr10:79444236	A/G	cg07817648	chr10:79422355	NA	-0.76	-5.61	-0.5	2e-7	Mortality in heart failure;
THYM	cis	rs9560113	0.959	rs4771756	chr13:112176083	T/G	cg14154082	chr13:112174009	NA	0.86	8.0	0.63	2.95e-12	Menarche (age at onset);
THYM	cis	rs1904096	0.506	rs4693378	chr4:95168552	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.2	-0.47	1.14e-6	Type 2 diabetes;
THYM	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg08968635	chr6:28129556	ZNF389	0.59	4.57	0.42	1.46e-5	Parkinson's disease;
THYM	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg14972814	chr11:95582409	MTMR2	0.65	5.21	0.47	1.11e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg06521331	chr12:34319734	NA	-1.04	-10.16	-0.72	7.37e-17	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3126085	0.877	rs868304	chr1:152178568	G/A	cg26020982	chr1:152196106	HRNR	0.35	4.57	0.42	1.45e-5	Atopic dermatitis;
THYM	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg09260853	chr1:2094483	PRKCZ	-0.44	-4.6	-0.43	1.31e-5	Height;
THYM	cis	rs4363385	0.818	rs2152994	chr1:152991060	C/T	cg13444842	chr1:152974279	SPRR3	0.57	4.76	0.44	6.94e-6	Inflammatory skin disease;
THYM	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg24209194	chr3:40518798	ZNF619	-0.67	-5.53	-0.49	2.85e-7	Renal cell carcinoma;
THYM	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.05	-10.37	-0.73	2.72e-17	Primary sclerosing cholangitis;
THYM	cis	rs17253792	0.822	rs10483645	chr14:56103766	G/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs2280630	1.000	rs2280630	chr3:39195964	C/T	cg15678707	chr3:39149194	GORASP1;TTC21A	0.56	4.63	0.43	1.14e-5	Verbal declarative memory;
THYM	cis	rs13006833	0.694	rs291444	chr2:191176223	T/C	cg11845111	chr2:191398756	TMEM194B	0.65	4.65	0.43	1.09e-5	Urinary metabolites;
THYM	cis	rs636291	0.517	rs673254	chr1:10550352	C/T	cg20482658	chr1:10539492	PEX14	-0.33	-4.79	-0.44	6.08e-6	Prostate cancer;
THYM	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg17784876	chr1:39464086	AKIRIN1	-0.93	-6.96	-0.58	4.41e-10	Depressive symptoms;
THYM	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg04772025	chr11:68637568	NA	0.59	5.98	0.52	3.92e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	trans	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg25214090	chr10:38739885	LOC399744	-0.96	-8.37	-0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs7084402	0.565	rs11006188	chr10:60333471	G/C	cg09696939	chr10:60272079	BICC1	-0.49	-5.7	-0.5	1.35e-7	Refractive error;
THYM	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg06728252	chr6:26598149	ABT1	-0.43	-5.11	-0.46	1.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11771526	0.901	rs10282699	chr7:32297967	C/T	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs600806	0.850	rs6537757	chr1:109936682	G/A	cg23616212	chr1:109941201	SORT1	-0.49	-4.66	-0.43	1.01e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3820068	0.608	rs12092485	chr1:16048038	A/G	cg24675056	chr1:15929824	NA	0.77	6.17	0.53	1.67e-8	Systolic blood pressure;
THYM	cis	rs586688	1.000	rs571723	chr1:201642628	C/G	cg07139329	chr1:201708558	NAV1	0.54	4.73	0.44	7.84e-6	Obesity-related traits;
THYM	cis	rs2637266	0.935	rs2583058	chr10:78396018	T/A	cg18941641	chr10:78392320	NA	0.81	6.88	0.58	6.3e-10	Pulmonary function;
THYM	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs711830	1.000	rs2249131	chr2:177032095	C/T	cg26754761	chr2:177040938	NA	-0.55	-4.56	-0.42	1.52e-5	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg24692254	chr21:30365293	RNF160	0.63	4.46	0.42	2.27e-5	Selective IgA deficiency;
THYM	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg20486651	chr6:167070296	RPS6KA2	-0.49	-4.72	-0.44	8.15e-6	Crohn's disease;
THYM	cis	rs1729951	0.546	rs835632	chr3:136676525	A/T	cg12473912	chr3:136751656	NA	0.61	5.03	0.46	2.31e-6	Neuroticism;
THYM	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs2574704	0.532	rs2616551	chr3:11667123	A/G	cg07643000	chr3:11666825	VGLL4	-0.54	-5.31	-0.48	7.26e-7	Body mass index;
THYM	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg12386194	chr3:101231763	SENP7	0.68	5.06	0.46	2.09e-6	Colorectal cancer;
THYM	cis	rs6543140	0.964	rs6543136	chr2:103065547	G/A	cg03938978	chr2:103052716	IL18RAP	0.58	5.84	0.51	7.16e-8	Blood protein levels;
THYM	cis	rs10479542	0.766	rs9286047	chr5:178969147	C/A	cg09060608	chr5:178986726	RUFY1	-0.49	-4.71	-0.44	8.41e-6	Lung cancer;
THYM	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg06221963	chr1:154839813	KCNN3	-0.84	-9.35	-0.69	4.03e-15	Prostate cancer;
THYM	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg27068330	chr11:65405492	SIPA1	-0.93	-8.76	-0.67	7.52e-14	Non-alcoholic fatty liver disease histology (lobular);
THYM	cis	rs9814567	0.752	rs13075117	chr3:134329535	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	7.38	0.6	5.86e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.76	-4.99	-0.46	2.73e-6	Body mass index;
THYM	cis	rs7953508	0.711	rs11611927	chr12:93977591	A/G	cg13201927	chr12:93977447	NA	0.65	4.6	0.43	1.28e-5	Pubertal anthropometrics;
THYM	cis	rs1461503	0.966	rs10892937	chr11:122841904	T/C	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs951188	0.688	rs75332979	chr2:150450814	A/C	cg17961725	chr2:150454027	NA	-1.02	-5.39	-0.48	5.12e-7	Daytime sleep phenotypes;
THYM	cis	rs9314614	0.789	rs4840640	chr8:6712688	A/G	cg27319216	chr8:6693540	XKR5	-0.55	-5.77	-0.51	9.97e-8	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs7107174	1.000	rs7127187	chr11:77995188	G/A	cg19901956	chr11:77921274	USP35	-0.73	-5.52	-0.49	2.97e-7	Testicular germ cell tumor;
THYM	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06481639	chr22:41940642	POLR3H	0.85	5.83	0.51	7.73e-8	Vitiligo;
THYM	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	7.35	0.6	6.91e-11	Platelet count;
THYM	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg18032289	chr17:61959525	GH2	-0.51	-4.56	-0.42	1.52e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg18252515	chr7:66147081	NA	-0.71	-5.67	-0.5	1.56e-7	Aortic root size;
THYM	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-4.76	-0.44	6.82e-6	Gut microbiome composition (summer);
THYM	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.77	-8.54	-0.66	2.15e-13	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs2970992	0.764	rs3112257	chr2:101326877	G/T	cg01042948	chr2:101319752	NA	0.57	5.61	0.5	2.02e-7	Educational attainment;
THYM	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg14675211	chr2:100938903	LONRF2	0.75	7.93	0.63	4.32e-12	Intelligence (multi-trait analysis);
THYM	cis	rs2354432	0.607	rs2297752	chr1:146765454	C/G	cg25205988	chr1:146714368	CHD1L	-1.1	-6.28	-0.54	1e-8	Mitochondrial DNA levels;
THYM	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.61	-5.95	-0.52	4.41e-8	Prudent dietary pattern;
THYM	cis	rs7523273	0.606	rs2796266	chr1:207922945	C/T	cg22525895	chr1:207977042	MIR29B2	-0.94	-10.57	-0.74	1e-17	Schizophrenia;
THYM	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg11993925	chr19:44307056	LYPD5	0.71	5.53	0.49	2.75e-7	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg13695892	chr22:41940480	POLR3H	0.87	6.35	0.55	7.28e-9	Vitiligo;
THYM	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22857025	chr5:266934	NA	-1.43	-9.2	-0.69	8.43e-15	Breast cancer;
THYM	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Body mass index;
THYM	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg13695892	chr22:41940480	POLR3H	-1.05	-8.51	-0.66	2.45e-13	Vitiligo;
THYM	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg27446573	chr6:127587934	RNF146	1.02	9.5	0.7	1.93e-15	Breast cancer;
THYM	cis	rs8102476	0.846	rs11083450	chr19:38754239	T/C	cg08052629	chr19:38746615	PPP1R14A	-0.48	-6.02	-0.53	3.24e-8	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9563576	0.778	rs2182503	chr13:58599568	C/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.62	4.49	0.42	2.01e-5	Body mass index;
THYM	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg06092702	chr1:163392909	NA	-0.63	-5.62	-0.5	1.91e-7	Motion sickness;
THYM	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.68	0.5	1.45e-7	Height;
THYM	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg10523679	chr1:76189770	ACADM	-0.86	-6.95	-0.58	4.49e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7829975	0.632	rs68168815	chr8:8556865	G/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-5.04	-0.46	2.22e-6	Mood instability;
THYM	cis	rs6665290	0.835	rs7549586	chr1:227214566	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.11	-14.38	-0.83	1.43e-25	Myeloid white cell count;
THYM	cis	rs981844	0.857	rs62325139	chr4:154712213	C/T	cg09973105	chr4:154681532	RNF175	-0.67	-5.58	-0.5	2.25e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs6815814	0.861	rs73142654	chr4:38785697	T/A	cg06935464	chr4:38784597	TLR10	0.71	5.22	0.47	1.06e-6	Breast cancer;
THYM	cis	rs9611565	0.506	rs2024567	chr22:41699206	G/C	cg06481639	chr22:41940642	POLR3H	-0.62	-4.78	-0.44	6.36e-6	Vitiligo;
THYM	cis	rs61990749	0.597	rs7142390	chr14:78232880	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	1.2	7.64	0.62	1.71e-11	Fibroblast growth factor basic levels;
THYM	cis	rs41005	1.000	rs41008	chr2:8108588	G/T	cg03155496	chr2:8117019	LOC339788	0.94	9.12	0.68	1.28e-14	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs7481584	0.624	rs377765	chr11:3046298	C/T	cg03159660	chr11:2078197	NA	0.63	4.76	0.44	7e-6	Calcium levels;
THYM	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg10057126	chr4:77819792	ANKRD56	0.74	6.36	0.55	6.96e-9	Emphysema distribution in smoking;
THYM	cis	rs12496230	1.000	rs17782285	chr3:66833592	A/G	cg23477460	chr3:66848765	NA	1.16	7.16	0.59	1.71e-10	Type 2 diabetes;
THYM	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg27572855	chr1:25598939	RHD	-0.67	-5.26	-0.48	8.74e-7	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs9527	0.668	rs7092815	chr10:104736345	G/T	cg15744005	chr10:104629667	AS3MT	-0.61	-4.55	-0.42	1.61e-5	Arsenic metabolism;
THYM	cis	rs1278352	0.737	rs1278365	chr10:127776530	C/T	cg08295661	chr10:127769903	ADAM12	-0.52	-5.21	-0.47	1.11e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg02527881	chr3:46936655	PTH1R	0.57	5.4	0.48	4.99e-7	Colorectal cancer;
THYM	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg03160526	chr17:80928410	B3GNTL1	-0.49	-4.89	-0.45	4.16e-6	Glycated hemoglobin levels;
THYM	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg00024416	chr22:24240387	NA	-0.68	-7.33	-0.6	7.49e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2070677	0.542	rs7086127	chr10:135393731	T/C	cg20169779	chr10:135381914	SYCE1	-0.78	-6.01	-0.52	3.43e-8	Gout;
THYM	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg08975724	chr8:8085496	FLJ10661	0.73	5.92	0.52	5.1e-8	Mood instability;
THYM	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg17366294	chr4:99064904	C4orf37	0.56	6.57	0.56	2.62e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7582180	0.903	rs13032368	chr2:100896112	C/T	cg14675211	chr2:100938903	LONRF2	0.64	5.43	0.49	4.28e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg06850241	chr22:41845214	NA	0.53	4.56	0.42	1.54e-5	Vitiligo;
THYM	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg11461670	chr8:22454935	PDLIM2	-0.33	-5.26	-0.48	8.71e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg17063962	chr7:91808500	NA	1.13	12.56	0.79	6.81e-22	Breast cancer;
THYM	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg20887711	chr4:1340912	KIAA1530	0.98	9.48	0.7	2.13e-15	Longevity;
THYM	cis	rs10028773	0.700	rs35653026	chr4:120248378	A/G	cg13609457	chr4:120235615	NA	0.55	5.13	0.47	1.5e-6	Educational attainment;
THYM	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.88	0.63	5.43e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg10248100	chr7:872053	UNC84A	0.74	4.99	0.46	2.75e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs6743226	0.811	rs10933537	chr2:242154930	C/G	cg23350296	chr2:242663858	ING5	0.46	4.49	0.42	1.99e-5	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs5760092	0.717	rs5760101	chr22:24248712	T/C	cg25703541	chr22:24373054	LOC391322	-0.71	-5.71	-0.51	1.31e-7	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg24209194	chr3:40518798	ZNF619	-0.54	-4.54	-0.42	1.67e-5	Renal cell carcinoma;
THYM	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg07755735	chr2:20870362	GDF7	-0.8	-6.6	-0.56	2.37e-9	Abdominal aortic aneurysm;
THYM	cis	rs684232	0.602	rs2160955	chr17:560604	T/C	cg15660573	chr17:549704	VPS53	-0.99	-11.0	-0.75	1.22e-18	Prostate cancer;
THYM	cis	rs155076	0.666	rs4638420	chr13:21872348	A/G	cg14456004	chr13:21872349	NA	1.25	11.49	0.76	1.13e-19	White matter hyperintensity burden;
THYM	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg16744531	chr19:17905626	B3GNT3	0.59	6.11	0.53	2.19e-8	Tumor biomarkers;
THYM	cis	rs6430585	0.583	rs3754689	chr2:136590746	C/T	cg20242066	chr2:136595261	LCT	0.54	5.9	0.52	5.7e-8	Corneal structure;
THYM	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg08305652	chr11:111469057	NA	0.52	4.47	0.42	2.2e-5	Primary sclerosing cholangitis;
THYM	cis	rs2458413	0.935	rs2514667	chr8:105358590	C/T	cg04554929	chr8:105342491	NA	0.37	5.13	0.47	1.55e-6	Paget's disease;
THYM	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.84	-5.66	-0.5	1.57e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs728616	0.867	rs76239460	chr10:81723227	C/T	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06850241	chr22:41845214	NA	0.59	5.41	0.49	4.76e-7	Vitiligo;
THYM	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg12386194	chr3:101231763	SENP7	0.97	7.83	0.63	6.87e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg05457628	chr5:178986728	RUFY1	0.64	6.05	0.53	2.83e-8	Lung cancer;
THYM	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg24733560	chr20:60626293	TAF4	0.6	6.35	0.55	7.51e-9	Body mass index;
THYM	cis	rs7651736	1.000	rs7651736	chr3:136760598	A/G	cg21827317	chr3:136751795	NA	0.59	5.8	0.51	8.51e-8	Neuroticism;
THYM	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg04181038	chr4:183730758	NA	1.01	8.48	0.66	2.96e-13	Pediatric autoimmune diseases;
THYM	cis	rs9896052	0.580	rs7406977	chr17:73460417	T/G	cg27112972	chr17:74378252	NA	0.56	4.45	0.42	2.35e-5	Sight-threatening diabetic retinopathy in type 2 diabetes;
THYM	cis	rs10492096	1.000	rs12422771	chr12:6580273	G/T	cg13857086	chr12:6580257	VAMP1	0.9	5.49	0.49	3.34e-7	Hip geometry;
THYM	cis	rs34172651	0.917	rs12599643	chr16:24832693	C/T	cg06028605	chr16:24865363	SLC5A11	0.57	5.66	0.5	1.58e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7772486	0.686	rs10872579	chr6:145966012	C/G	cg13319975	chr6:146136371	FBXO30	-0.67	-5.48	-0.49	3.42e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg12310025	chr6:25882481	NA	-0.69	-5.47	-0.49	3.69e-7	Blood metabolite levels;
THYM	cis	rs293526	0.959	rs293499	chr6:83631920	T/G	cg23278060	chr6:83777448	DOPEY1	0.61	4.49	0.42	2.02e-5	Crohn's disease;
THYM	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg12963246	chr6:28129442	ZNF389	0.64	5.93	0.52	4.86e-8	Depression;
THYM	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg10515332	chr4:99064459	C4orf37	0.71	5.67	0.5	1.51e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17739794	0.517	rs6982473	chr8:773986	G/T	cg01971667	chr8:817044	NA	-0.87	-7.33	-0.6	7.41e-11	Clozapine-induced cytotoxicity;
THYM	cis	rs4642101	0.561	rs7638333	chr3:12806142	T/C	cg11882607	chr3:12858926	CAND2	-0.46	-5.24	-0.47	9.7e-7	QRS complex (12-leadsum);
THYM	cis	rs12765878	0.967	rs11598018	chr10:105661315	C/A	cg11005552	chr10:105648138	OBFC1	0.87	11.39	0.76	1.84e-19	Coronary artery disease;
THYM	cis	rs10411161	0.702	rs7251689	chr19:52389117	A/T	cg25361850	chr19:52391789	ZNF577	0.74	5.18	0.47	1.22e-6	Breast cancer;
THYM	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4243830	1.000	rs41278016	chr1:6584045	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	1.11	6.12	0.53	2.06e-8	Body mass index;
THYM	cis	rs2012796	1.000	rs7153469	chr14:81820979	T/G	cg02996355	chr14:81879375	NA	0.67	4.69	0.43	9.03e-6	Night sleep phenotypes;
THYM	trans	rs1974653	0.672	rs9606240	chr22:20071423	A/G	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs2282930	0.512	rs2237457	chr7:50726144	A/G	cg08586669	chr7:50727761	GRB10	-0.32	-4.77	-0.44	6.66e-6	Bone mineral density;
THYM	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg14798641	chr3:49314920	USP4;C3orf62	-0.65	-4.57	-0.42	1.47e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg03433033	chr1:76189801	ACADM	0.77	10.21	0.72	6.01e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9303280	0.901	rs12936231	chr17:38029120	C/G	cg24910161	chr17:38119198	GSDMA	0.46	4.7	0.43	8.72e-6	Self-reported allergy;
THYM	cis	rs6499129	1.000	rs55877766	chr16:67473389	G/A	cg03615565	chr16:67572595	FAM65A	0.47	4.6	0.43	1.32e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg08994789	chr17:28903642	LRRC37B2	-1.05	-5.39	-0.48	5.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg18105134	chr13:113819100	PROZ	-1.15	-10.31	-0.73	3.57e-17	Platelet distribution width;
THYM	cis	rs7909074	0.798	rs10900126	chr10:45386322	G/T	cg05187965	chr10:45406764	TMEM72	-0.55	-5.34	-0.48	6.44e-7	Mean corpuscular volume;
THYM	cis	rs72827839	0.802	rs16953382	chr17:46252906	C/T	cg23391107	chr17:45924227	SP6	0.83	5.6	0.5	2.08e-7	Ease of getting up in the morning;
THYM	cis	rs7582180	0.577	rs6542942	chr2:100985378	G/T	cg14675211	chr2:100938903	LONRF2	0.66	6.28	0.54	1.01e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9787249	0.874	rs7520588	chr1:40214525	T/A	cg19912559	chr1:40204330	PPIE	0.64	4.92	0.45	3.61e-6	Blood protein levels;
THYM	cis	rs1569175	0.522	rs10221945	chr2:200875847	T/C	cg23649088	chr2:200775458	C2orf69	-0.71	-5.03	-0.46	2.34e-6	Response to treatment for acute lymphoblastic leukemia;
THYM	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-5.92	-0.52	5.01e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs651907	0.712	rs796410	chr3:101610189	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	5.33	0.48	6.58e-7	Colorectal cancer;
THYM	cis	rs40363	0.868	rs37772	chr16:3512843	A/G	cg01073479	chr16:3509474	NAT15	0.51	4.74	0.44	7.36e-6	Tuberculosis;
THYM	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg25566285	chr7:158114605	PTPRN2	0.92	11.63	0.77	5.69e-20	Calcium levels;
THYM	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg06481639	chr22:41940642	POLR3H	-0.76	-4.94	-0.45	3.29e-6	Vitiligo;
THYM	trans	rs11774066	0.950	rs13258810	chr8:99455851	G/A	cg09678939	chr6:149806081	ZC3H12D	-0.57	-7.53	-0.61	2.85e-11	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg06219351	chr7:158114137	PTPRN2	-0.77	-7.95	-0.63	3.79e-12	Calcium levels;
THYM	cis	rs9549260	0.755	rs9532579	chr13:41243458	T/C	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs1144700	0.628	rs1144698	chr6:16743334	A/G	cg15250073	chr6:16769480	NA	-0.31	-4.49	-0.42	2.01e-5	Neutrophil count;White blood cell count;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
THYM	cis	rs11792861	0.591	rs7027874	chr9:111717112	A/G	cg05043794	chr9:111880884	C9orf5	-0.35	-4.83	-0.44	5.31e-6	Menarche (age at onset);
THYM	cis	rs67311347	0.668	rs73071710	chr3:40288587	A/G	cg17264618	chr3:40429014	ENTPD3	0.49	4.87	0.45	4.49e-6	Renal cell carcinoma;
THYM	cis	rs828999	0.715	rs6663170	chr1:108695540	T/C	cg24323958	chr1:108741884	SLC25A24	0.54	5.33	0.48	6.59e-7	Monocyte percentage of white cells;
THYM	cis	rs12410462	0.681	rs4131980	chr1:227572123	A/G	cg23173402	chr1:227635558	NA	0.71	5.61	0.5	1.96e-7	Major depressive disorder;
THYM	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg00383909	chr3:49044727	WDR6	1.12	6.62	0.56	2.13e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs6032067	0.759	rs2206889	chr20:43886487	C/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.56	-5.33	-0.48	6.58e-7	Blood protein levels;
THYM	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg08901578	chr4:187885870	NA	-0.63	-5.75	-0.51	1.09e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.16	-0.47	1.36e-6	Total cholesterol levels;
THYM	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Bladder cancer;
THYM	cis	rs686320	1.000	rs72643572	chr11:65250967	A/G	cg13044675	chr11:65314161	LTBP3	0.91	4.63	0.43	1.16e-5	Hip circumference adjusted for BMI;
THYM	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg03517284	chr6:25882590	NA	-1.05	-10.17	-0.72	7e-17	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg25918947	chr17:41365094	TMEM106A	0.56	4.62	0.43	1.22e-5	Menopause (age at onset);
THYM	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg16524733	chr11:117070046	TAGLN	0.41	4.54	0.42	1.64e-5	Blood protein levels;
THYM	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg23711669	chr6:146136114	FBXO30	0.96	9.87	0.71	3.12e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9420	0.528	rs11229075	chr11:57391023	A/C	cg19752551	chr11:57585705	CTNND1	-0.6	-5.01	-0.46	2.56e-6	Schizophrenia;
THYM	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg06074448	chr4:187884817	NA	-1.0	-13.81	-0.82	1.9e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3126085	0.515	rs6668764	chr1:152349078	C/T	cg10321714	chr1:152280068	FLG	0.61	4.45	0.42	2.34e-5	Atopic dermatitis;
THYM	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg04731861	chr2:219085781	ARPC2	0.54	5.05	0.46	2.11e-6	Colorectal cancer;
THYM	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg02915803	chr1:1606292	LOC728661;CDK11B	0.6	4.96	0.45	3.03e-6	Body mass index;
THYM	cis	rs616402	0.527	rs11121581	chr1:10577740	A/G	cg20482658	chr1:10539492	PEX14	-0.37	-5.82	-0.51	7.94e-8	Breast size;
THYM	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs7635838	0.617	rs2606731	chr3:11291615	A/C	cg00170343	chr3:11313890	ATG7	0.63	4.86	0.45	4.61e-6	HDL cholesterol;
THYM	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg03762994	chr17:6899332	ALOX12	-0.75	-9.68	-0.7	7.9e-16	Tonsillectomy;
THYM	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg27129171	chr3:47204927	SETD2	0.7	6.76	0.57	1.13e-9	Colorectal cancer;
THYM	cis	rs6032067	0.777	rs35434469	chr20:43778544	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.72	-6.69	-0.57	1.51e-9	Blood protein levels;
THYM	cis	rs7833986	1.000	rs66796428	chr8:57094797	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	4.98	0.45	2.84e-6	Height;
THYM	cis	rs10924970	0.870	rs7531130	chr1:235440556	C/G	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs3924048	0.574	rs12062307	chr1:12611852	C/T	cg00291366	chr1:12616550	NA	0.4	6.33	0.54	7.89e-9	Optic cup area;
THYM	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg02869364	chr7:1081709	C7orf50	-0.4	-4.55	-0.42	1.58e-5	Longevity;Endometriosis;
THYM	cis	rs7851660	0.809	rs7031386	chr9:100665669	G/T	cg13688889	chr9:100608707	NA	-0.79	-5.75	-0.51	1.06e-7	Strep throat;
THYM	cis	rs9326248	0.559	rs10892064	chr11:116896553	G/C	cg20608306	chr11:116969690	SIK3	0.62	7.41	0.61	5.21e-11	Blood protein levels;
THYM	cis	rs12602172	1	rs12602172	chr17:38163567	G/A	cg17467752	chr17:38218738	THRA	0.86	7.09	0.59	2.4e-10	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
THYM	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.94	0.75	1.62e-18	Diabetic retinopathy;
THYM	cis	rs7177699	0.534	rs4387568	chr15:79109514	C/G	cg00540400	chr15:79124168	NA	-0.67	-7.16	-0.59	1.68e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6815814	0.904	rs73236628	chr4:38825443	C/T	cg02016764	chr4:38805732	TLR1	-0.52	-5.13	-0.47	1.52e-6	Breast cancer;
THYM	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg09060608	chr5:178986726	RUFY1	0.58	6.26	0.54	1.09e-8	Lung cancer;
THYM	cis	rs11608355	1.000	rs11066591	chr12:109880523	G/A	cg11367159	chr12:110044531	NA	0.63	5.98	0.52	3.95e-8	Neuroticism;
THYM	cis	rs6430585	0.528	rs56064699	chr2:136595706	G/A	cg20242066	chr2:136595261	LCT	0.52	4.81	0.44	5.67e-6	Corneal structure;
THYM	cis	rs595982	0.527	rs35023389	chr19:49377873	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.92	-4.97	-0.45	3e-6	Red cell distribution width;
THYM	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg13683864	chr3:40499215	RPL14	-1.05	-11.46	-0.76	1.29e-19	Renal cell carcinoma;
THYM	cis	rs6987853	0.563	rs7004796	chr8:42450170	T/G	cg09913449	chr8:42400586	C8orf40	0.61	5.21	0.47	1.08e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg09323728	chr8:95962352	TP53INP1	-0.47	-4.66	-0.43	1.02e-5	Type 2 diabetes;
THYM	trans	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg10840412	chr1:235813424	GNG4	0.89	6.88	0.58	6.46e-10	Bipolar disorder;
THYM	cis	rs9393692	0.620	rs9358916	chr6:26283185	G/A	cg00631329	chr6:26305371	NA	-0.46	-4.71	-0.44	8.43e-6	Educational attainment;
THYM	cis	rs4790333	0.845	rs7210932	chr17:2272024	A/G	cg02569219	chr17:2266849	SGSM2	-0.66	-5.77	-0.51	9.69e-8	Proinsulin levels;
THYM	cis	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.98	0.45	2.85e-6	Obesity-related traits;
THYM	cis	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg06521331	chr12:34319734	NA	-1.04	-10.16	-0.72	7.37e-17	Morning vs. evening chronotype;
THYM	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg06656553	chr16:89960601	TCF25	-0.98	-4.53	-0.42	1.74e-5	Skin colour saturation;
THYM	cis	rs6032067	0.929	rs6017512	chr20:43835038	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.34	-0.65	5.7e-13	Blood protein levels;
THYM	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg03388043	chr17:80084554	CCDC57	0.73	6.06	0.53	2.75e-8	Life satisfaction;
THYM	cis	rs9914988	0.943	rs34693224	chr17:27079555	C/T	cg20469991	chr17:27169893	C17orf63	-0.78	-4.64	-0.43	1.11e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-8.52	-0.66	2.33e-13	Schizophrenia;
THYM	cis	rs3820068	0.608	rs10927840	chr1:16045250	A/G	cg13390004	chr1:15929781	NA	0.63	4.59	0.43	1.34e-5	Systolic blood pressure;
THYM	cis	rs524281	0.692	rs10896076	chr11:65840668	A/G	cg00563793	chr11:65837595	PACS1	0.72	4.59	0.43	1.38e-5	Electroencephalogram traits;
THYM	cis	rs7793919	0.726	rs10232008	chr7:4783206	T/G	cg09789173	chr7:4769017	FOXK1	0.81	7.92	0.63	4.44e-12	Mosquito bite size;
THYM	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.77	7.13	0.59	1.95e-10	Personality dimensions;
THYM	cis	rs7771547	0.573	rs566742	chr6:36395668	C/T	cg07856975	chr6:36356162	ETV7	0.53	4.89	0.45	4.06e-6	Platelet distribution width;
THYM	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	6.3	0.54	9.17e-9	Platelet count;
THYM	cis	rs1943345	0.731	rs498292	chr11:82903283	C/T	cg07047830	chr11:82868014	PCF11	0.74	6.79	0.57	9.74e-10	Obesity-related traits;
THYM	cis	rs2810114	0.760	rs2810105	chr14:71424651	T/A	cg15910301	chr14:71632612	NA	-0.56	-4.88	-0.45	4.23e-6	Alcohol dependence;
THYM	cis	rs17174870	0.955	rs6710733	chr2:112773500	A/G	cg17354880	chr2:112658759	MERTK	-0.6	-4.73	-0.44	7.84e-6	Multiple sclerosis;
THYM	cis	rs7582180	0.700	rs11685293	chr2:100976502	A/C	cg08017756	chr2:100939284	LONRF2	-0.72	-7.42	-0.61	4.95e-11	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.67	6.21	0.54	1.37e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9297145	0.916	rs4236540	chr7:98769025	A/C	cg05967295	chr7:98741636	SMURF1	0.97	9.11	0.68	1.3e-14	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg05887092	chr17:76393375	PGS1	0.41	4.67	0.43	9.98e-6	HDL cholesterol levels;
THYM	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.06	9.19	0.69	8.69e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg09904177	chr6:26538194	HMGN4	0.54	4.57	0.42	1.47e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.636	rs6032094	chr20:43912637	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.65	-6.06	-0.53	2.76e-8	Blood protein levels;
THYM	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg12011299	chr4:100065546	ADH4	0.85	8.12	0.64	1.67e-12	Alcohol dependence;
THYM	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg07532245	chr17:28927093	LRRC37B2	0.64	4.66	0.43	1.04e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7586879	0.616	rs13410999	chr2:25097939	T/C	cg15423357	chr2:25149977	NA	0.66	7.01	0.58	3.49e-10	Body mass index;
THYM	cis	rs7219021	0.705	rs999475	chr17:46988044	C/T	cg09029085	chr17:47094198	IGF2BP1	0.33	4.48	0.42	2.04e-5	Schizophrenia or bipolar disorder;
THYM	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg11764359	chr7:65958608	NA	0.7	4.89	0.45	4.09e-6	Aortic root size;
THYM	cis	rs6087990	0.735	rs2424920	chr20:31385452	T/C	cg13636640	chr20:31349939	DNMT3B	0.89	9.06	0.68	1.66e-14	Ulcerative colitis;
THYM	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg12419862	chr22:24373484	LOC391322	-0.73	-6.82	-0.57	8.4e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg02070205	chr10:30722105	MAP3K8	-0.7	-6.11	-0.53	2.17e-8	Inflammatory bowel disease;
THYM	cis	rs897984	0.762	rs2305880	chr16:30999462	T/C	cg06892815	chr16:30991727	SETD1A	0.51	4.52	0.42	1.79e-5	Dementia with Lewy bodies;
THYM	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg17366294	chr4:99064904	C4orf37	0.49	5.34	0.48	6.25e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9649213	0.593	rs35941058	chr7:97918159	T/C	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9914544	0.545	rs4924940	chr17:18800092	T/C	cg26378065	chr17:18585709	ZNF286B	0.58	4.65	0.43	1.05e-5	Educational attainment (years of education);
THYM	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg10803722	chr21:46713166	LOC642852	-0.4	-5.22	-0.47	1.06e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg14018140	chr10:458528	DIP2C	-0.61	-7.19	-0.59	1.49e-10	Psychosis in Alzheimer's disease;
THYM	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg02551604	chr5:131831745	NA	-0.78	-6.25	-0.54	1.15e-8	Asthma (sex interaction);
THYM	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg06558623	chr16:89946397	TCF25	1.48	7.81	0.63	7.43e-12	Skin colour saturation;
THYM	cis	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg16306078	chr6:126000798	NA	0.53	5.02	0.46	2.38e-6	Endometrial cancer;
THYM	cis	rs7818345	0.540	rs4623445	chr8:19347184	A/G	cg01280390	chr8:19363452	CSGALNACT1	0.54	4.69	0.43	9.24e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs7312774	0.618	rs4964518	chr12:107466217	C/T	cg16260113	chr12:107380972	MTERFD3	0.88	4.75	0.44	7.11e-6	Severe influenza A (H1N1) infection;
THYM	cis	rs2070488	0.861	rs1858740	chr3:38438372	T/C	cg24069376	chr3:38537580	EXOG	0.64	6.6	0.56	2.36e-9	Electrocardiographic conduction measures;
THYM	cis	rs9633835	0.715	rs11022766	chr11:13348249	T/G	cg13286116	chr11:13302098	ARNTL	0.63	6.49	0.55	3.92e-9	Body mass index;
THYM	cis	rs3741151	1.000	rs76764824	chr11:73073580	C/T	cg12959048	chr11:73096162	RELT	-0.53	-5.13	-0.47	1.52e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs877282	0.853	rs10904545	chr10:757100	G/A	cg10556349	chr10:835070	NA	-0.8	-5.27	-0.48	8.58e-7	Uric acid levels;
THYM	cis	rs8067545	0.750	rs62067555	chr17:20001502	T/C	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.61e-6	Schizophrenia;
THYM	cis	rs860554	0.529	rs861272	chr1:201269122	A/C	cg01022117	chr1:201258280	PKP1	0.74	4.84	0.44	4.97e-6	Panic disorder;
THYM	cis	rs73198271	0.740	rs11781430	chr8:8651733	G/C	cg15556689	chr8:8085844	FLJ10661	-0.75	-4.95	-0.45	3.2e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs2018683	0.707	rs4722875	chr7:28969632	A/G	cg27487796	chr7:28973253	NA	-0.27	-4.69	-0.43	9.24e-6	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
THYM	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.23	9.82	0.71	4.08e-16	Platelet count;
THYM	cis	rs2066819	0.792	rs1274496	chr12:56625693	C/A	cg26714650	chr12:56694279	CS	1.29	6.58	0.56	2.53e-9	Psoriasis vulgaris;
THYM	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg01324343	chr3:183735012	ABCC5	0.88	13.13	0.8	4.58e-23	Anterior chamber depth;
THYM	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg21784768	chr11:537496	LRRC56	-1.09	-5.41	-0.49	4.65e-7	Body mass index;
THYM	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg00383909	chr3:49044727	WDR6	1.12	6.62	0.56	2.13e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	cis	rs1018836	0.651	rs2339175	chr8:91565805	A/T	cg16814680	chr8:91681699	NA	-0.79	-6.6	-0.56	2.36e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg11764359	chr7:65958608	NA	-0.82	-6.65	-0.56	1.85e-9	Aortic root size;
THYM	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg04602696	chr16:88846723	FAM38A	-0.64	-4.91	-0.45	3.71e-6	Plateletcrit;
THYM	cis	rs10779751	0.770	rs12097293	chr1:11197467	A/G	cg08854313	chr1:11322531	MTOR	-0.72	-5.44	-0.49	4.1e-7	Body mass index;
THYM	cis	rs8102476	0.846	rs11083450	chr19:38754239	T/C	cg05778847	chr19:38746538	PPP1R14A	-0.49	-5.57	-0.5	2.32e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs500891	0.525	rs12524968	chr6:84076466	C/G	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg00786635	chr1:25594202	NA	-0.96	-8.13	-0.64	1.61e-12	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs11771526	0.901	rs10264625	chr7:32304205	T/C	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg13866156	chr1:1669148	SLC35E2	-0.71	-7.14	-0.59	1.87e-10	Body mass index;
THYM	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg27279351	chr12:120934652	DYNLL1	0.96	8.2	0.64	1.14e-12	High light scatter reticulocyte count;
THYM	cis	rs4646404	0.509	rs4646356	chr17:17471175	A/G	cg11245205	chr17:17398264	RASD1	0.4	4.63	0.43	1.17e-5	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
THYM	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg16586182	chr3:47516702	SCAP	-0.67	-5.62	-0.5	1.9e-7	Colorectal cancer;
THYM	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg16624210	chr5:671434	TPPP	0.73	4.95	0.45	3.21e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg00129232	chr17:37814104	STARD3	0.69	4.45	0.42	2.32e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg02475777	chr4:1388615	CRIPAK	0.65	4.66	0.43	1.02e-5	Longevity;
THYM	cis	rs3733631	1.000	rs17034046	chr4:104659604	C/T	cg24090629	chr4:104641072	TACR3	-0.86	-5.51	-0.49	3.1e-7	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.92	-8.98	-0.68	2.53e-14	Height;
THYM	cis	rs7582180	0.676	rs6542940	chr2:100982144	A/T	cg14675211	chr2:100938903	LONRF2	0.61	5.81	0.51	8.36e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6754311	0.731	rs309160	chr2:136685228	C/T	cg20242066	chr2:136595261	LCT	0.61	7.05	0.59	2.89e-10	Mosquito bite size;
THYM	cis	rs35934224	0.783	rs34462686	chr22:19859917	A/G	cg11182965	chr22:19864308	TXNRD2	-0.71	-5.85	-0.51	7.1e-8	Glaucoma (primary open-angle);
THYM	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg22974920	chr21:40686053	BRWD1	-0.59	-4.59	-0.43	1.34e-5	Cognitive function;
THYM	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg10803722	chr21:46713166	LOC642852	-0.5	-6.28	-0.54	1.02e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg18681998	chr4:17616180	MED28	0.98	9.91	0.71	2.55e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9486719	1.000	rs10872018	chr6:97026429	G/A	cg18709589	chr6:96969512	KIAA0776	-0.68	-4.7	-0.43	8.62e-6	Migraine;Coronary artery disease;
THYM	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg11247378	chr22:39784982	NA	0.96	9.59	0.7	1.26e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs6867032	1.000	rs4975796	chr5:2015520	A/T	cg26168224	chr5:2018326	NA	-1.21	-14.72	-0.83	3.03e-26	Gut microbiome composition (winter);
THYM	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.73	-6.64	-0.56	1.9e-9	Personality dimensions;
THYM	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg18230493	chr5:56204884	C5orf35	-0.89	-6.53	-0.56	3.25e-9	Initial pursuit acceleration;
THYM	cis	rs9403317	0.700	rs11757988	chr6:141886696	C/T	cg15052665	chr6:141804349	NA	0.78	5.95	0.52	4.55e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg15247329	chr7:2764246	NA	-0.68	-5.59	-0.5	2.19e-7	Height;
THYM	cis	rs10979	1.000	rs11155300	chr6:143894576	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs2997447	0.761	rs17257113	chr1:26449595	G/A	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs1642645	0.831	rs12042133	chr1:42499365	A/C	cg22816091	chr1:42611670	NA	-0.61	-5.49	-0.49	3.38e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg15445000	chr17:37608096	MED1	0.41	4.72	0.44	8.17e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs59112743	0.510	rs9464795	chr6:15530164	G/A	cg10111214	chr6:14815676	NA	0.74	5.04	0.46	2.26e-6	Multiple keratinocyte cancers;
THYM	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg22875332	chr1:76189707	ACADM	0.88	11.22	0.75	4.31e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs262150	0.672	rs2730230	chr7:158788529	A/G	cg19418458	chr7:158789849	NA	-0.58	-5.1	-0.46	1.74e-6	Facial morphology (factor 20);
THYM	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg11245990	chr11:68621969	NA	0.55	7.14	0.59	1.89e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7809950	0.599	rs2237658	chr7:106837866	T/G	cg23024343	chr7:107201750	COG5	-0.86	-7.35	-0.6	7.03e-11	Coronary artery disease;
THYM	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg08773314	chr2:239334832	ASB1	0.65	9.86	0.71	3.36e-16	Multiple system atrophy;
THYM	cis	rs6459804	0.787	rs78566714	chr7:157508951	G/A	cg11757124	chr7:157526947	PTPRN2	-0.66	-5.21	-0.47	1.11e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6768930	0.509	rs6445929	chr3:57815602	T/G	cg07735586	chr3:57945651	NA	-0.33	-5.04	-0.46	2.18e-6	Obesity-related traits;
THYM	cis	rs9910055	0.550	rs376816	chr17:42156471	A/C	cg19774624	chr17:42201019	HDAC5	0.59	4.6	0.43	1.3e-5	Total body bone mineral density;
THYM	cis	rs7769051	0.708	rs9483514	chr6:133228716	G/A	cg07930552	chr6:133119739	C6orf192	0.88	5.14	0.47	1.47e-6	Type 2 diabetes nephropathy;
THYM	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.83	-6.4	-0.55	5.87e-9	IgG glycosylation;
THYM	cis	rs11126435	0.641	rs6709863	chr2:74746080	C/T	cg04255230	chr2:74727010	LBX2	0.52	4.64	0.43	1.1e-5	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs644148	0.902	rs12982159	chr19:44964300	C/T	cg15540054	chr19:45004280	ZNF180	-0.56	-4.48	-0.42	2.11e-5	Personality dimensions;
THYM	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg11663144	chr21:46675770	NA	-0.7	-8.38	-0.65	4.67e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10979	1.000	rs1416207	chr6:143889275	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg26354017	chr1:205819088	PM20D1	0.68	6.38	0.55	6.43e-9	Menarche (age at onset);
THYM	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg04362960	chr10:104952993	NT5C2	0.57	4.67	0.43	9.99e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg12826209	chr6:26865740	GUSBL1	0.98	5.09	0.46	1.83e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg06521331	chr12:34319734	NA	-1.04	-10.13	-0.72	8.85e-17	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	trans	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg20966754	chr17:47091339	IGF2BP1	-0.57	-7.22	-0.6	1.3e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs2070677	0.935	rs11812637	chr10:135413418	A/G	cg20169779	chr10:135381914	SYCE1	-0.75	-5.76	-0.51	1.03e-7	Gout;
THYM	cis	rs2625529	0.701	rs2306490	chr15:72227837	A/G	cg16672083	chr15:72433130	SENP8	-0.56	-5.03	-0.46	2.35e-6	Red blood cell count;
THYM	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs4654899	0.758	rs3820326	chr1:21277141	G/A	cg01072550	chr1:21505969	NA	-0.75	-7.21	-0.59	1.34e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	17.14	0.87	8.02e-31	Chronic sinus infection;
THYM	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg24642439	chr20:33292090	TP53INP2	0.67	5.24	0.47	9.85e-7	Coronary artery disease;
THYM	cis	rs2273669	0.915	rs6928200	chr6:109294164	A/C	cg17117243	chr6:109341365	SESN1	-0.76	-4.55	-0.42	1.6e-5	Prostate cancer;
THYM	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg26597838	chr10:835615	NA	1.23	8.86	0.67	4.56e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs10752881	1.000	rs10911191	chr1:182984524	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg05157140	chr7:1272545	UNCX	0.46	4.5	0.42	1.96e-5	Subjective well-being;
THYM	cis	rs80319144	1.000	rs77276698	chr2:159250229	G/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg06873352	chr17:61820015	STRADA	-0.77	-9.67	-0.7	8.42e-16	Prudent dietary pattern;
THYM	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs2806561	0.765	rs1738468	chr1:23510850	T/G	cg19743168	chr1:23544995	NA	0.55	5.6	0.5	2.09e-7	Height;
THYM	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg06618935	chr21:46677482	NA	-0.99	-9.28	-0.69	5.6e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg05962950	chr11:130786565	SNX19	0.8	7.0	0.58	3.62e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg09307838	chr4:120376055	NA	0.68	5.08	0.46	1.89e-6	Corneal astigmatism;
THYM	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg12311346	chr5:56204834	C5orf35	-0.83	-6.19	-0.54	1.52e-8	Initial pursuit acceleration;
THYM	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06873352	chr17:61820015	STRADA	0.8	9.86	0.71	3.29e-16	Prudent dietary pattern;
THYM	cis	rs11030122	0.645	rs11493482	chr11:4034772	A/G	cg18678763	chr11:4115507	RRM1	-0.45	-5.78	-0.51	9.37e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg09260853	chr1:2094483	PRKCZ	-0.43	-4.49	-0.42	2.03e-5	Height;
THYM	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-5.63	-0.5	1.84e-7	Chronic sinus infection;
THYM	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg24874828	chr4:187887005	NA	-0.72	-7.15	-0.59	1.75e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg27286337	chr10:134555280	INPP5A	0.84	5.93	0.52	4.78e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg22907277	chr7:1156413	C7orf50	0.87	7.59	0.61	2.16e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg05340658	chr4:99064831	C4orf37	0.54	4.51	0.42	1.83e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2046867	0.818	rs62249879	chr3:72917171	A/G	cg25664220	chr3:72788482	NA	-0.96	-7.86	-0.63	6.06e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7799006	0.755	rs2256545	chr7:2291943	G/A	cg08027265	chr7:2291960	NA	-0.45	-5.47	-0.49	3.64e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs17433780	0.612	rs7911	chr1:89518120	A/G	cg09516651	chr1:89888402	LOC400759	0.88	7.52	0.61	3.06e-11	Carotid intima media thickness;
THYM	cis	rs9875589	0.509	rs1488379	chr3:14014719	A/G	cg03204825	chr3:13978759	TPRXL	-0.51	-4.46	-0.42	2.26e-5	Ovarian reserve;
THYM	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg24920358	chr1:40204285	PPIE	-0.6	-5.57	-0.5	2.39e-7	Blood protein levels;
THYM	cis	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg08133631	chr1:26527909	CATSPER4	-0.57	-4.69	-0.43	9.29e-6	Obesity-related traits;
THYM	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6032067	0.632	rs35632684	chr20:43802889	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.93	-0.58	5.03e-10	Blood protein levels;
THYM	cis	rs2985684	0.894	rs2354439	chr14:50019417	G/C	cg02151108	chr14:50098012	C14orf104	-0.75	-6.31	-0.54	8.87e-9	Carotid intima media thickness;
THYM	cis	rs6032067	0.516	rs1883829	chr20:43891253	G/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.58	-6.61	-0.56	2.2e-9	Blood protein levels;
THYM	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg18305652	chr10:134549665	INPP5A	0.81	6.63	0.56	1.99e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs17539620	0.624	rs871069	chr6:154837578	A/C	cg20019720	chr6:154832845	CNKSR3	0.47	4.79	0.44	6.17e-6	Lipoprotein (a) levels;
THYM	cis	rs2732480	0.577	rs1489108	chr12:48738781	G/A	cg21466736	chr12:48725269	NA	-0.6	-5.35	-0.48	6.07e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg09085632	chr11:111637200	PPP2R1B	1.14	11.75	0.77	3.18e-20	Primary sclerosing cholangitis;
THYM	cis	rs11249608	0.548	rs6894076	chr5:178449813	T/C	cg01312482	chr5:178451176	ZNF879	-0.75	-6.21	-0.54	1.37e-8	Pubertal anthropometrics;
THYM	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	trans	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg07211511	chr3:129823064	LOC729375	-1.22	-9.75	-0.71	5.63e-16	Blood pressure (smoking interaction);
THYM	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg12311346	chr5:56204834	C5orf35	0.99	7.77	0.62	9.17e-12	Initial pursuit acceleration;
THYM	cis	rs6500395	0.926	rs2883643	chr16:48693018	C/G	cg04672837	chr16:48644449	N4BP1	0.49	4.76	0.44	7.03e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg21926883	chr2:100939477	LONRF2	-0.65	-5.96	-0.52	4.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs988913	1.000	rs6926997	chr6:54817326	C/G	cg18532076	chr6:54711417	FAM83B	0.49	4.84	0.44	5.09e-6	Menarche (age at onset);
THYM	cis	rs7072216	0.763	rs3814140	chr10:100170762	C/T	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs59698941	0.882	rs66537260	chr5:132309237	C/T	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs4792901	0.918	rs2271959	chr17:41622740	G/T	cg21940313	chr17:41620911	ETV4	-0.52	-5.51	-0.49	3.08e-7	Dupuytren's disease;
THYM	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	7.38	0.6	6.08e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.37	6.53	0.56	3.25e-9	Obesity-related traits;
THYM	cis	rs526231	0.543	rs257310	chr5:102418853	C/T	cg23492399	chr5:102201601	PAM	-0.7	-5.18	-0.47	1.23e-6	Primary biliary cholangitis;
THYM	cis	rs28595532	0.920	rs115860482	chr4:119759546	A/G	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.5	-0.49	3.18e-7	Obesity-related traits;
THYM	cis	rs12936587	0.535	rs6502615	chr17:17612023	C/T	cg04398451	chr17:18023971	MYO15A	0.6	4.93	0.45	3.5e-6	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
THYM	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg01264106	chr22:38071602	LGALS1	0.4	5.0	0.46	2.61e-6	Fat distribution (HIV);
THYM	cis	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg00495681	chr13:53174319	NA	0.63	5.78	0.51	9.65e-8	Lewy body disease;
THYM	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.96	-8.0	-0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.26	-10.46	-0.73	1.73e-17	Platelet count;
THYM	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.34	-0.65	5.7e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg24503407	chr1:205819492	PM20D1	-0.7	-5.93	-0.52	4.92e-8	Menarche (age at onset);
THYM	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg11871910	chr12:69753446	YEATS4	0.66	4.84	0.44	5.01e-6	Response to diuretic therapy;
THYM	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg02820040	chr2:241836501	C2orf54	-0.32	-6.68	-0.57	1.62e-9	Urinary metabolites;
THYM	cis	rs17321999	1.000	rs13386455	chr2:30480865	A/G	cg05247661	chr2:30472410	LBH	0.62	4.47	0.42	2.16e-5	Systemic lupus erythematosus;
THYM	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg02524346	chr8:600233	NA	0.94	4.97	0.45	2.94e-6	IgG glycosylation;
THYM	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg15448220	chr1:150897856	SETDB1	0.9	7.56	0.61	2.52e-11	Melanoma;
THYM	cis	rs8013055	0.796	rs4075105	chr14:106000231	C/T	cg23356831	chr14:105996513	TMEM121	0.6	6.24	0.54	1.19e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs7731657	0.537	rs1018948	chr5:130290958	C/A	cg08523029	chr5:130500466	HINT1	-0.79	-5.38	-0.48	5.39e-7	Fasting plasma glucose;
THYM	cis	rs4866334	1.000	rs76306109	chr5:18481141	A/C	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs988913	0.706	rs4715489	chr6:54732965	C/T	cg18532076	chr6:54711417	FAM83B	0.52	4.89	0.45	4.13e-6	Menarche (age at onset);
THYM	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg10018233	chr7:150070692	REPIN1	0.4	5.66	0.5	1.63e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7781557	1.000	rs10487281	chr7:102477581	G/C	cg06322601	chr7:102330635	NA	0.65	4.73	0.44	7.87e-6	Colorectal adenoma (advanced);
THYM	cis	rs40363	0.645	rs40447	chr16:3514841	G/A	cg01073479	chr16:3509474	NAT15	0.56	5.47	0.49	3.61e-7	Tuberculosis;
THYM	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs11166927	0.967	rs7834010	chr8:140791732	A/C	cg16909799	chr8:140841666	TRAPPC9	0.59	5.04	0.46	2.26e-6	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg23711669	chr6:146136114	FBXO30	0.9	9.23	0.69	7.15e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs16976116	0.951	rs3809540	chr15:55489412	A/C	cg11288833	chr15:55489084	RSL24D1	0.69	4.49	0.42	2e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg07747251	chr5:1868357	NA	0.68	5.86	0.52	6.67e-8	Cardiovascular disease risk factors;
THYM	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg24209194	chr3:40518798	ZNF619	0.67	5.53	0.49	2.85e-7	Renal cell carcinoma;
THYM	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg24308560	chr3:49941425	MST1R	0.6	4.47	0.42	2.15e-5	Body mass index;
THYM	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.85	8.97	0.68	2.63e-14	Menarche (age at onset);
THYM	cis	rs1728785	0.901	rs1728797	chr16:68570989	A/T	cg02972257	chr16:68554789	NA	-0.74	-4.54	-0.42	1.63e-5	Ulcerative colitis;
THYM	cis	rs138918	1.000	rs138918	chr22:43559451	G/A	cg02233750	chr22:43539658	MCAT	0.59	5.08	0.46	1.9e-6	Monocyte count;
THYM	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg17366294	chr4:99064904	C4orf37	0.57	6.81	0.57	8.63e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg27170947	chr2:26402098	FAM59B	-0.85	-6.64	-0.56	1.96e-9	Gut microbiome composition (summer);
THYM	cis	rs9527	0.668	rs7092815	chr10:104736345	G/T	cg04362960	chr10:104952993	NT5C2	0.63	4.76	0.44	6.9e-6	Arsenic metabolism;
THYM	cis	rs4243830	0.850	rs4908910	chr1:6599362	T/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.06	-6.24	-0.54	1.21e-8	Body mass index;
THYM	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg23730037	chr7:158596552	ESYT2	-0.49	-5.08	-0.46	1.9e-6	Height;
THYM	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg00786635	chr1:25594202	NA	0.92	7.28	0.6	9.42e-11	Erythrocyte sedimentation rate;
THYM	cis	rs10791097	0.765	rs7943757	chr11:130716157	C/T	cg12179176	chr11:130786555	SNX19	0.79	6.62	0.56	2.16e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs778371	0.788	rs4973569	chr2:233767037	A/G	cg08000102	chr2:233561755	GIGYF2	-0.73	-5.77	-0.51	1e-7	Schizophrenia;
THYM	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03264133	chr6:25882463	NA	-0.87	-7.32	-0.6	8.06e-11	Intelligence (multi-trait analysis);
THYM	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg18305652	chr10:134549665	INPP5A	0.75	5.9	0.52	5.46e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7926906	1.000	rs4304731	chr11:90523785	C/A	cg26138821	chr11:89956704	CHORDC1	-0.52	-4.74	-0.44	7.54e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1003719	0.788	rs2835605	chr21:38490734	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs7809950	0.768	rs2701678	chr7:107283711	A/G	cg23024343	chr7:107201750	COG5	0.75	6.24	0.54	1.19e-8	Coronary artery disease;
THYM	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	5.47	0.49	3.58e-7	Personality dimensions;
THYM	cis	rs863345	0.565	rs10908668	chr1:158501933	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.6e-6	Pneumococcal bacteremia;
THYM	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6754311	0.551	rs6739713	chr2:136488978	A/G	cg04750100	chr2:136595281	LCT	0.55	4.85	0.45	4.9100000000000004e-06	Mosquito bite size;
THYM	cis	rs1322639	1.000	rs1322639	chr6:169587103	G/A	cg03254818	chr6:169586852	NA	-0.78	-5.74	-0.51	1.15e-7	Pulse pressure;
THYM	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg03929089	chr4:120376271	NA	-1.02	-12.97	-0.8	9.51e-23	Height;
THYM	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs2730245	0.527	rs1188974	chr7:158665748	C/T	cg11984989	chr7:158649758	WDR60	1.03	8.36	0.65	5.29e-13	Height;
THYM	trans	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	trans	rs10162002	0.515	rs9580630	chr13:24027634	A/C	cg10504632	chr7:40591610	C7orf10	-0.69	-6.86	-0.58	6.82e-10	Hypothyroidism;
THYM	cis	rs11969893	0.850	rs9404058	chr6:101323078	T/C	cg12253828	chr6:101329408	ASCC3	1.19	6.88	0.58	6.48e-10	Economic and political preferences (immigration/crime);
THYM	cis	rs7078219	0.743	rs11190133	chr10:101278725	C/T	cg07044859	chr10:101282883	NA	-0.46	-4.94	-0.45	3.34e-6	Dental caries;
THYM	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg12407791	chr17:73824354	UNC13D	-0.45	-5.18	-0.47	1.22e-6	White matter hyperintensity burden;
THYM	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg20887711	chr4:1340912	KIAA1530	0.57	4.54	0.42	1.65e-5	Obesity-related traits;
THYM	cis	rs2229238	0.780	rs61698846	chr1:154504854	C/T	cg21262032	chr1:154437693	IL6R	-0.63	-5.65	-0.5	1.68e-7	Coronary heart disease;
THYM	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg20283391	chr11:68216788	NA	-0.74	-5.43	-0.49	4.25e-7	Total body bone mineral density;
THYM	cis	rs13102973	0.538	rs13140134	chr4:135912595	C/T	cg14419869	chr4:135874104	NA	0.69	5.54	0.49	2.65e-7	Subjective well-being;
THYM	cis	rs28595532	0.920	rs116366070	chr4:119764180	A/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs3008870	1.000	rs2755244	chr1:67484470	C/T	cg02640540	chr1:67518911	SLC35D1	-0.65	-4.83	-0.44	5.32e-6	Lymphocyte percentage of white cells;
THYM	cis	rs7833986	1.000	rs4263734	chr8:57099931	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	4.78	0.44	6.48e-6	Height;
THYM	cis	rs11048434	0.761	rs12827988	chr12:9130287	A/G	cg13575925	chr12:9217583	LOC144571	0.53	5.0	0.46	2.59e-6	Sjögren's syndrome;
THYM	cis	rs870825	0.616	rs7680779	chr4:185652830	G/C	cg04058563	chr4:185651563	MLF1IP	-1.06	-9.32	-0.69	4.75e-15	Blood protein levels;
THYM	cis	rs7336332	0.598	rs74563672	chr13:28010660	A/G	cg22138327	chr13:27999177	GTF3A	0.62	4.62	0.43	1.21e-5	Weight;
THYM	cis	rs1395	0.778	rs2580761	chr2:27426362	G/A	cg23587288	chr2:27483067	SLC30A3	-0.61	-5.33	-0.48	6.52e-7	Blood metabolite levels;
THYM	cis	rs7975161	0.579	rs7962423	chr12:104710910	G/A	cg25273343	chr12:104657179	TXNRD1	-0.74	-4.51	-0.42	1.83e-5	Toenail selenium levels;
THYM	cis	rs6993813	0.678	rs7824837	chr8:120008736	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.57	4.54	0.42	1.65e-5	Bone mineral density (hip);
THYM	cis	rs1357245	0.631	rs7648065	chr3:27097222	C/T	cg03895047	chr3:27114861	NA	0.49	4.58	0.43	1.42e-5	Breast cancer;
THYM	trans	rs480407	0.667	rs58988844	chr2:161752127	T/G	cg06548410	chr19:1997657	BTBD2	0.74	7.0	0.58	3.58e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs9788682	0.748	rs2456020	chr15:78868398	C/T	cg18825076	chr15:78729989	IREB2	0.58	4.69	0.43	9.13e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg05855489	chr10:104503620	C10orf26	-0.61	-4.84	-0.44	4.99e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg08017756	chr2:100939284	LONRF2	-0.75	-7.8	-0.62	7.89e-12	Intelligence (multi-trait analysis);
THYM	trans	rs4262150	0.842	rs55992747	chr5:152253548	C/T	cg08281791	chr5:76607845	PDE8B	0.93	6.87	0.58	6.5e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs12216545	0.765	rs2373813	chr7:150251937	G/A	cg08960815	chr7:150264767	GIMAP4	-0.87	-7.96	-0.63	3.61e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10751667	0.961	rs7943115	chr11:973885	T/C	cg01483505	chr11:975446	AP2A2	0.69	5.59	0.5	2.14e-7	Alzheimer's disease (late onset);
THYM	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9933309	0.839	rs9932423	chr16:88846849	C/A	cg04602696	chr16:88846723	FAM38A	0.49	4.71	0.44	8.32e-6	Glycated hemoglobin levels;
THYM	cis	rs863345	0.584	rs6427438	chr1:158454730	C/T	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg17509989	chr5:176798049	RGS14	0.65	5.63	0.5	1.81e-7	Urate levels in lean individuals;
THYM	cis	rs883565	0.568	rs4381879	chr3:39028460	G/C	cg15678707	chr3:39149194	GORASP1;TTC21A	0.65	4.91	0.45	3.76e-6	Handedness;
THYM	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg11247378	chr22:39784982	NA	-1.02	-13.44	-0.81	1.05e-23	Intelligence (multi-trait analysis);
THYM	cis	rs6842047	0.706	rs4862666	chr4:187136307	A/G	cg09526685	chr4:187126073	CYP4V2	1.14	5.71	0.51	1.26e-7	Blood protein levels;
THYM	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg13609457	chr4:120235615	NA	0.61	5.47	0.49	3.57e-7	Corneal astigmatism;
THYM	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg08999081	chr20:33150536	PIGU	-0.58	-5.18	-0.47	1.25e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9393777	0.588	rs6456728	chr6:26477779	G/A	cg12826209	chr6:26865740	GUSBL1	1.01	6.9	0.58	5.73e-10	Intelligence (multi-trait analysis);
THYM	cis	rs11039798	0.614	rs2174703	chr11:48788242	G/A	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	trans	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.38e-13	Corneal astigmatism;
THYM	cis	rs728616	0.764	rs56122289	chr10:81746027	G/A	cg05935833	chr10:81318306	SFTPA2	-0.79	-4.86	-0.45	4.55e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg06784218	chr1:46089804	CCDC17	-0.33	-4.94	-0.45	3.31e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs987710	0.568	rs738885	chr22:22517026	T/C	cg21401457	chr22:22472743	NA	0.92	4.5	0.42	1.91e-5	Iron status biomarkers;Iron deficiency;
THYM	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.64	-4.68	-0.43	9.69e-6	Colorectal cancer;
THYM	cis	rs3087591	0.919	rs7406870	chr17:29590617	G/A	cg24425628	chr17:29625626	OMG;NF1	0.66	4.97	0.45	2.9e-6	Hip circumference;
THYM	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg15704280	chr7:45808275	SEPT13	-1.02	-13.15	-0.8	4.15e-23	Height;
THYM	cis	rs75059851	1.000	rs73036064	chr11:133829442	G/A	cg14047540	chr11:133829660	NA	-1.16	-8.05	-0.64	2.36e-12	Schizophrenia;
THYM	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg12310025	chr6:25882481	NA	-0.66	-4.58	-0.43	1.4e-5	Height;
THYM	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg06640241	chr16:89574553	SPG7	0.84	5.82	0.51	7.9e-8	Multiple myeloma (IgH translocation);
THYM	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2273669	0.667	rs79285264	chr6:109318279	G/T	cg17117243	chr6:109341365	SESN1	-0.92	-5.21	-0.47	1.09e-6	Prostate cancer;
THYM	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg15556689	chr8:8085844	FLJ10661	-0.61	-5.1	-0.46	1.75e-6	Mood instability;
THYM	cis	rs10979	1.000	rs9376756	chr6:143886125	C/T	cg25407410	chr6:143891975	LOC285740	-0.7	-5.29	-0.48	7.92e-7	Hypospadias;
THYM	cis	rs35934224	0.769	rs17745314	chr22:19857342	G/A	cg11182965	chr22:19864308	TXNRD2	-0.79	-4.93	-0.45	3.51e-6	Glaucoma (primary open-angle);
THYM	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Body mass index;
THYM	trans	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg10856724	chr12:34555212	NA	-0.94	-8.13	-0.64	1.61e-12	Bladder cancer;
THYM	cis	rs6047844	0.569	rs6113534	chr20:22117778	C/G	cg16502866	chr20:23015624	SSTR4	-0.54	-4.6	-0.43	1.29e-5	Male-pattern baldness;
THYM	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-4.63	-0.43	1.15e-5	Alzheimer's disease;
THYM	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg09367891	chr1:107599246	PRMT6	-0.69	-4.79	-0.44	6.24e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg27432699	chr2:27873401	GPN1	0.76	6.97	0.58	4.25e-10	Oral cavity cancer;
THYM	cis	rs3008870	1.000	rs2182143	chr1:67378936	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.95	7.79	0.62	8.27e-12	Lymphocyte percentage of white cells;
THYM	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg13319975	chr6:146136371	FBXO30	-0.65	-5.34	-0.48	6.42e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.73	-6.27	-0.54	1.05e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg15838173	chr10:75533400	FUT11	-0.6	-5.89	-0.52	5.93e-8	Inflammatory bowel disease;
THYM	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg14675211	chr2:100938903	LONRF2	0.76	8.42	0.65	3.99e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg09184832	chr6:79620586	NA	-0.56	-4.46	-0.42	2.24e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9296092	0.538	rs76589475	chr6:33519517	G/C	cg13560919	chr6:33536144	NA	-0.95	-9.43	-0.7	2.72e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg03690763	chr11:133734501	NA	0.6	4.73	0.44	7.72e-6	Childhood ear infection;
THYM	cis	rs2692947	0.832	rs2438972	chr2:96690873	T/C	cg23100626	chr2:96804247	ASTL	0.36	4.83	0.44	5.17e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14893161	chr1:205819251	PM20D1	0.89	8.97	0.68	2.62e-14	Menarche (age at onset);
THYM	cis	rs4482178	0.511	rs5000203	chr13:86299627	A/T	cg25308322	chr13:86268291	NA	0.73	4.83	0.44	5.31e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs2067615	0.579	rs4385986	chr12:107133775	C/T	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs8067545	0.616	rs203477	chr17:19831819	A/C	cg20830565	chr17:20408647	MGC102966	-0.54	-4.95	-0.45	3.16e-6	Schizophrenia;
THYM	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg12165864	chr7:66369176	NA	-0.81	-6.12	-0.53	2.11e-8	Corneal structure;
THYM	cis	rs6539288	0.933	rs759604	chr12:107307296	T/G	cg26297688	chr12:107349093	C12orf23	-0.47	-4.89	-0.45	4.15e-6	Total body bone mineral density;
THYM	cis	rs478304	0.651	rs4930319	chr11:65555458	G/C	cg27068330	chr11:65405492	SIPA1	-0.97	-8.91	-0.67	3.48e-14	Acne (severe);
THYM	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg01528321	chr10:82214614	TSPAN14	0.63	5.31	0.48	7.07e-7	Post bronchodilator FEV1;
THYM	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg11663144	chr21:46675770	NA	-0.69	-8.13	-0.64	1.58e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg04025307	chr7:1156635	C7orf50	0.68	5.96	0.52	4.27e-8	Longevity;Endometriosis;
THYM	cis	rs4919687	0.550	rs12783444	chr10:104480659	G/A	cg05855489	chr10:104503620	C10orf26	0.69	5.49	0.49	3.32e-7	Colorectal cancer;
THYM	cis	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg09307838	chr4:120376055	NA	-0.74	-5.8	-0.51	8.52e-8	Corneal astigmatism;
THYM	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg24818145	chr4:99064322	C4orf37	0.94	5.81	0.51	8.31e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs877282	0.945	rs11253390	chr10:788678	A/G	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg00684032	chr4:1343700	KIAA1530	0.55	4.76	0.44	7.03e-6	Obesity-related traits;
THYM	cis	rs2404602	0.698	rs12909656	chr15:76664378	A/T	cg23482746	chr15:76478102	C15orf27	0.45	4.57	0.42	1.44e-5	Blood metabolite levels;
THYM	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg24250549	chr1:154909240	PMVK	0.65	5.28	0.48	8.28e-7	Prostate cancer;
THYM	cis	rs7828089	0.934	rs12544427	chr8:22263115	C/T	cg13512537	chr8:22265999	SLC39A14	0.63	5.26	0.47	9e-7	Verbal declarative memory;
THYM	cis	rs9527	0.590	rs7906754	chr10:104782557	T/C	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs9902453	0.817	rs2628170	chr17:28056612	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.74	-5.54	-0.49	2.65e-7	Coffee consumption (cups per day);
THYM	cis	rs4601821	0.895	rs2155464	chr11:113242448	T/C	cg14159747	chr11:113255604	NA	0.26	4.77	0.44	6.72e-6	Alcoholic chronic pancreatitis;
THYM	cis	rs7178572	0.568	rs11854193	chr15:77458136	C/A	cg22256960	chr15:77711686	NA	-1.01	-7.9	-0.63	4.83e-12	Type 2 diabetes;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg04607442	chr13:21872219	NA	-1.28	-7.18	-0.59	1.52e-10	Pulmonary function decline;
THYM	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg05368731	chr17:41323189	NBR1	1.25	11.37	0.76	2.01e-19	Menopause (age at onset);
THYM	cis	rs6722750	0.901	rs7567728	chr2:64411932	A/C	cg22352474	chr2:64371530	PELI1	-0.66	-4.99	-0.46	2.67e-6	Neuroticism;
THYM	cis	rs7849270	1.000	rs3118632	chr9:131901284	G/A	cg14069949	chr9:131965419	NA	-0.5	-4.52	-0.42	1.8e-5	Blood metabolite ratios;
THYM	cis	rs28595532	0.920	rs114414928	chr4:119728188	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg00012203	chr2:219082015	ARPC2	-0.6	-4.83	-0.44	5.19e-6	Colorectal cancer;
THYM	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg26038318	chr20:34205095	SPAG4	0.65	5.25	0.47	9.22e-7	Total cholesterol levels;
THYM	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg09354556	chr3:47051341	NA	0.46	4.72	0.44	8.03e-6	Colorectal cancer;
THYM	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg26418147	chr1:205743515	RAB7L1	-0.6	-4.93	-0.45	3.43e-6	Menarche (age at onset);
THYM	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg17054759	chr22:49844102	NA	-0.52	-4.93	-0.45	3.54e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg12560992	chr17:57184187	TRIM37	0.93	8.88	0.67	4.06e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7757969	0.500	rs9387042	chr6:112155670	T/G	cg08601457	chr6:112115117	FYN	0.4	4.87	0.45	4.51e-6	Schizophrenia;
THYM	cis	rs4866334	1.000	rs76790673	chr5:18502463	G/C	cg24599790	chr5:18972260	NA	-1.15	-4.67	-0.43	9.77e-6	IgG glycosylation;
THYM	cis	rs7626444	0.625	rs9877495	chr3:196483280	G/A	cg12930392	chr3:196481615	PAK2	0.4	4.97	0.45	2.97e-6	Monocyte count;
THYM	cis	rs4595586	0.545	rs925827	chr12:39364307	C/T	cg26384229	chr12:38710491	ALG10B	0.71	5.56	0.5	2.42e-7	Morning vs. evening chronotype;
THYM	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg05738196	chr6:26577821	NA	0.83	8.34	0.65	5.8e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2071518	0.951	rs2071526	chr8:120426597	G/A	cg05020510	chr8:120428057	NOV	0.45	4.74	0.44	7.41e-6	Pulse pressure;Blood pressure;
THYM	cis	rs2361718	0.592	rs7209921	chr17:78085214	A/G	cg09238746	chr17:78121135	EIF4A3	-0.91	-6.71	-0.57	1.41e-9	Yeast infection;
THYM	cis	rs2692947	0.637	rs1168967	chr2:96826016	A/G	cg23100626	chr2:96804247	ASTL	0.36	4.97	0.45	3.01e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs6087990	0.735	rs2424921	chr20:31385814	C/T	cg13636640	chr20:31349939	DNMT3B	0.88	9.08	0.68	1.49e-14	Ulcerative colitis;
THYM	cis	rs7586879	0.598	rs6724772	chr2:25128730	T/C	cg27107076	chr2:25050844	ADCY3	-0.29	-4.73	-0.44	7.91e-6	Body mass index;
THYM	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg09307838	chr4:120376055	NA	0.72	5.06	0.46	2.02e-6	Corneal astigmatism;
THYM	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg08779649	chr13:50194554	NA	0.58	5.03	0.46	2.31e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs2294693	0.730	rs4714410	chr6:40941052	G/T	cg14418226	chr6:40996092	UNC5CL	0.68	5.37	0.48	5.69e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg15997130	chr1:24165203	NA	0.78	6.95	0.58	4.61e-10	Immature fraction of reticulocytes;
THYM	cis	rs4478037	0.558	rs73826343	chr3:33067676	C/A	cg19404215	chr3:33155277	CRTAP	1.2	5.7	0.5	1.36e-7	Major depressive disorder;
THYM	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg09703963	chr11:616879	IRF7;MUPCDH	-0.76	-6.38	-0.55	6.46e-9	Systemic lupus erythematosus;
THYM	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg17294928	chr15:75287854	SCAMP5	-1.02	-9.12	-0.68	1.26e-14	Blood trace element (Zn levels);
THYM	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg12963246	chr6:28129442	ZNF389	0.77	6.4	0.55	5.74e-9	Parkinson's disease;
THYM	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg02725872	chr8:58115012	NA	-1.11	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs3791406	1.000	rs3791405	chr2:240030284	G/A	cg05758467	chr2:240035894	HDAC4	-0.44	-4.51	-0.42	1.84e-5	Skin aging (microtopography measurement);
THYM	cis	rs2219968	0.828	rs1871788	chr8:78945481	T/C	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg11461670	chr8:22454935	PDLIM2	-0.36	-6.56	-0.56	2.82e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg19318889	chr4:1322082	MAEA	0.7	6.07	0.53	2.65e-8	Longevity;
THYM	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg12310025	chr6:25882481	NA	0.71	5.93	0.52	4.82e-8	Blood metabolite levels;
THYM	cis	rs4642101	0.561	rs9831765	chr3:12805934	A/T	cg05775895	chr3:12838266	CAND2	0.75	6.02	0.53	3.26e-8	QRS complex (12-leadsum);
THYM	cis	rs2011503	1.000	rs1557723	chr19:19443033	A/G	cg02887458	chr19:19495540	GATAD2A	0.42	5.0	0.46	2.58e-6	Bipolar disorder;
THYM	cis	rs1981331	0.609	rs117296583	chr21:48053238	C/T	cg17243659	chr21:48055224	PRMT2	1.28	5.63	0.5	1.8e-7	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg23131131	chr22:24373011	LOC391322	-0.8	-5.87	-0.52	6.3e-8	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg17366294	chr4:99064904	C4orf37	0.58	6.87	0.58	6.55e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	8.22	0.64	1.02e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2050392	0.861	rs303448	chr10:30727084	G/T	cg02070205	chr10:30722105	MAP3K8	-0.53	-4.55	-0.42	1.57e-5	Inflammatory bowel disease;
THYM	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg20891283	chr12:69753455	YEATS4	0.75	6.43	0.55	5e-9	Blood protein levels;
THYM	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg05373962	chr22:49881684	NA	-0.59	-6.2	-0.54	1.48e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs10089	0.953	rs758180	chr5:127354423	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.94	6.29	0.54	9.62e-9	Ileal carcinoids;
THYM	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg23260525	chr10:116636907	FAM160B1	0.53	5.33	0.48	6.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs6430585	0.528	rs309159	chr2:136684940	C/T	cg07169764	chr2:136633963	MCM6	0.94	8.34	0.65	5.72e-13	Corneal structure;
THYM	cis	rs9560113	1.000	rs61967684	chr13:112178026	G/C	cg10483660	chr13:112241077	NA	0.54	4.88	0.45	4.33e-6	Menarche (age at onset);
THYM	cis	rs7084402	0.967	rs1649059	chr10:60312599	T/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.49	-0.49	3.34e-7	Refractive error;
THYM	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg26963428	chr7:66367121	NA	0.59	4.69	0.43	9e-6	Corneal structure;
THYM	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06634786	chr22:41940651	POLR3H	0.78	6.01	0.53	3.36e-8	Vitiligo;
THYM	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg06191203	chr2:152266755	RIF1	-0.73	-5.0	-0.46	2.62e-6	Lung cancer;
THYM	cis	rs6450176	0.909	rs80213371	chr5:53300874	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-6.2	-0.54	1.45e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs4606347	0.789	rs61780880	chr1:66166869	C/T	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7107174	1.000	rs901104	chr11:77930499	C/T	cg19901956	chr11:77921274	USP35	-0.81	-6.18	-0.54	1.56e-8	Testicular germ cell tumor;
THYM	cis	rs611744	0.647	rs2594357	chr8:109255989	A/G	cg21045802	chr8:109455806	TTC35	0.64	5.66	0.5	1.57e-7	Dupuytren's disease;
THYM	cis	rs2456568	0.564	rs4608039	chr11:93624799	C/G	cg17347335	chr11:93583973	C11orf90	0.58	6.11	0.53	2.16e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg18446336	chr7:2847575	GNA12	-0.46	-4.87	-0.45	4.41e-6	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs977987	0.843	rs11860231	chr16:75385159	A/G	cg03315344	chr16:75512273	CHST6	0.72	5.9	0.52	5.66e-8	Dupuytren's disease;
THYM	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg00074818	chr8:8560427	CLDN23	0.55	5.38	0.48	5.32e-7	Obesity-related traits;
THYM	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg16680214	chr1:154839983	KCNN3	-0.54	-6.65	-0.56	1.85e-9	Prostate cancer;
THYM	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg10515332	chr4:99064459	C4orf37	0.61	4.92	0.45	3.58e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg03605463	chr16:89740564	NA	-0.62	-5.03	-0.46	2.29e-6	Hemoglobin concentration;
THYM	cis	rs8067545	0.611	rs2703781	chr17:20144714	A/G	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg13175981	chr1:150552382	MCL1	0.72	5.19	0.47	1.2e-6	Tonsillectomy;
THYM	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg03690763	chr11:133734501	NA	-0.6	-4.67	-0.43	9.83e-6	Childhood ear infection;
THYM	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	7.32	0.6	7.82e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg23758822	chr17:41437982	NA	1.27	14.18	0.82	3.54e-25	Menopause (age at onset);
THYM	cis	rs6686842	1.000	rs6600365	chr1:41556253	C/T	cg03387723	chr1:41708464	SCMH1	0.44	5.22	0.47	1.04e-6	Height;
THYM	cis	rs9359856	0.510	rs4053618	chr6:90459454	G/A	cg13799429	chr6:90582589	CASP8AP2	0.85	8.18	0.64	1.27e-12	Bipolar disorder;
THYM	cis	rs6531656	0.663	rs337620	chr4:38623174	G/C	cg24279243	chr4:38676559	KLF3	0.81	6.99	0.58	3.82e-10	Lymphocyte counts;
THYM	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg02869364	chr7:1081709	C7orf50	-0.61	-4.96	-0.45	3.08e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg14675211	chr2:100938903	LONRF2	0.76	8.42	0.65	3.99e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9527	0.590	rs34104646	chr10:104896078	T/A	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg22875332	chr1:76189707	ACADM	-0.54	-5.07	-0.46	1.96e-6	Daytime sleep phenotypes;
THYM	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg18032289	chr17:61959525	GH2	-0.49	-4.7	-0.43	8.9e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs7312774	0.618	rs4964501	chr12:107330079	C/T	cg16260113	chr12:107380972	MTERFD3	-1.38	-6.87	-0.58	6.6e-10	Severe influenza A (H1N1) infection;
THYM	cis	rs728616	0.867	rs41298231	chr10:81682461	C/T	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4660531	1.000	rs4660532	chr1:41840197	C/T	cg08462924	chr1:41848221	NA	0.65	6.05	0.53	2.91e-8	Bipolar disorder;
THYM	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg11494091	chr17:61959527	GH2	1.03	15.35	0.84	1.84e-27	Prudent dietary pattern;
THYM	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg00256281	chr22:41985642	PMM1	0.63	4.86	0.45	4.67e-6	Vitiligo;
THYM	cis	rs921968	0.565	rs12694439	chr2:219590871	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg02725872	chr8:58115012	NA	-1.09	-6.87	-0.58	6.64e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg06618935	chr21:46677482	NA	-0.95	-9.03	-0.68	1.91e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12791968	1.000	rs11038237	chr11:45001880	C/T	cg11846598	chr11:44996168	LOC221122	-0.93	-8.0	-0.63	3.08e-12	Inhibitory control;
THYM	cis	rs2734839	0.964	rs12364051	chr11:113305314	A/G	cg14159747	chr11:113255604	NA	0.31	6.08	0.53	2.52e-8	Information processing speed;
THYM	cis	rs4642101	0.824	rs3889515	chr3:12844112	G/C	cg05775895	chr3:12838266	CAND2	0.94	8.62	0.66	1.49e-13	QRS complex (12-leadsum);
THYM	cis	rs34734847	1.000	rs55730005	chr12:121157536	C/A	cg10600917	chr12:121163489	ACADS	0.57	5.15	0.47	1.41e-6	Mean corpuscular volume;
THYM	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg18230493	chr5:56204884	C5orf35	0.88	6.22	0.54	1.35e-8	Initial pursuit acceleration;
THYM	cis	rs7940866	0.801	rs10894288	chr11:130808679	T/C	cg12179176	chr11:130786555	SNX19	0.64	4.94	0.45	3.39e-6	Schizophrenia;
THYM	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg24530246	chr3:53118167	NA	-0.77	-4.64	-0.43	1.1e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg10589385	chr1:150898437	SETDB1	0.65	5.45	0.49	4.01e-7	Melanoma;
THYM	cis	rs9790314	1.000	rs7653361	chr3:160992291	C/T	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs1298062	0.535	rs2463240	chr19:50941905	A/G	cg10687087	chr19:50962411	MYBPC2	0.55	4.69	0.43	9.14e-6	Age of smoking initiation;
THYM	cis	rs4731207	0.533	rs1481326	chr7:124625984	G/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs1021993	1.000	rs1507341	chr1:209472850	C/T	cg06155620	chr1:209527581	NA	0.58	4.67	0.43	9.97e-6	Gut microbiome composition (winter);
THYM	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg25036284	chr2:26402008	FAM59B	-0.78	-5.22	-0.47	1.06e-6	Gut microbiome composition (summer);
THYM	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg21773646	chr17:80085082	CCDC57	0.32	4.58	0.43	1.43e-5	Life satisfaction;
THYM	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg27572855	chr1:25598939	RHD	0.69	5.34	0.48	6.29e-7	Erythrocyte sedimentation rate;
THYM	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	4.82	0.44	5.49e-6	Total body bone mineral density;
THYM	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg12386194	chr3:101231763	SENP7	0.69	5.15	0.47	1.41e-6	Colorectal cancer;
THYM	cis	rs2463822	0.669	rs72919496	chr11:62052730	T/C	cg06239285	chr11:62104954	ASRGL1	-1.27	-5.97	-0.52	4.09e-8	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg16482183	chr6:26056742	HIST1H1C	0.97	6.7	0.57	1.45e-9	Iron status biomarkers;
THYM	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg03161606	chr19:29218774	NA	0.87	7.3	0.6	8.75e-11	Methadone dose in opioid dependence;
THYM	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	18.27	0.88	7.47e-33	Chronic sinus infection;
THYM	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	4.57	0.42	1.48e-5	Schizophrenia;
THYM	cis	rs7872515	0.536	rs73510406	chr9:94786781	C/T	cg13922115	chr9:95397568	IPPK	0.92	4.62	0.43	1.19e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs11645898	0.810	rs72787046	chr16:72079342	A/G	cg03805757	chr16:71968109	PKD1L3	-0.73	-5.31	-0.48	7.32e-7	Blood protein levels;
THYM	cis	rs6967414	0.786	rs3757482	chr7:6748927	A/G	cg09896999	chr7:6746977	ZNF12	-0.63	-4.85	-0.45	4.76e-6	Hematocrit;Hemoglobin concentration;
THYM	cis	rs478304	0.654	rs10896034	chr11:65460783	T/A	cg27068330	chr11:65405492	SIPA1	-1.03	-10.31	-0.73	3.55e-17	Acne (severe);
THYM	cis	rs9915657	0.870	rs1042678	chr17:70122108	G/A	cg06234051	chr17:70120541	SOX9	-0.77	-7.36	-0.6	6.5500000000000006e-11	Thyroid hormone levels;
THYM	cis	rs728616	0.867	rs4387301	chr10:81736399	C/T	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.85	-5.32	-0.48	6.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4733781	0.527	rs11774659	chr8:131190336	C/T	cg16277922	chr8:131349729	ASAP1	0.57	4.73	0.44	7.72e-6	Tuberculosis;
THYM	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg10911889	chr6:126070802	HEY2	0.59	4.72	0.44	8.23e-6	Brugada syndrome;
THYM	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03576123	chr11:487126	PTDSS2	-1.29	-6.68	-0.57	1.6e-9	Body mass index;
THYM	cis	rs4940575	0.786	rs4940574	chr18:60837844	G/C	cg24349668	chr18:61441546	SERPINB7	0.76	4.66	0.43	1.01e-5	Breast cancer;
THYM	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg17757837	chr7:157058334	UBE3C	0.65	5.25	0.47	9.38e-7	Body mass index;
THYM	cis	rs11190604	0.767	rs74869390	chr10:102189385	A/G	cg07570687	chr10:102243282	WNT8B	0.81	7.78	0.62	8.93e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg05985134	chr18:33552581	C18orf21	0.68	4.77	0.44	6.59e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs611744	0.550	rs57045491	chr8:109279120	A/C	cg21045802	chr8:109455806	TTC35	0.69	6.21	0.54	1.42e-8	Dupuytren's disease;
THYM	cis	rs11771526	0.786	rs28670858	chr7:32293126	G/A	cg27532318	chr7:32358331	NA	0.73	4.87	0.45	4.39e-6	Body mass index;
THYM	cis	rs965469	0.895	rs6037592	chr20:3392950	T/G	cg25506879	chr20:3388711	C20orf194	-0.84	-5.13	-0.47	1.51e-6	IFN-related cytopenia;
THYM	cis	rs4523957	0.890	rs432200	chr17:2191960	A/G	cg16513277	chr17:2031491	SMG6	0.8	7.45	0.61	4.29e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9324022	0.860	rs72698720	chr14:101178715	C/G	cg18089426	chr14:101175970	NA	0.75	5.12	0.46	1.61e-6	Plateletcrit;
THYM	cis	rs977987	0.806	rs4888391	chr16:75400746	C/T	cg03315344	chr16:75512273	CHST6	0.69	5.55	0.49	2.56e-7	Dupuytren's disease;
THYM	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.73	0.44	7.82e-6	Alzheimer's disease (late onset);
THYM	cis	rs533123	0.877	rs482692	chr1:29154255	T/C	cg08366446	chr1:29138936	OPRD1	1.11	5.63	0.5	1.84e-7	Schizophrenia;
THYM	cis	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg06521331	chr12:34319734	NA	-0.73	-5.66	-0.5	1.59e-7	Morning vs. evening chronotype;
THYM	cis	rs995000	0.839	rs1168010	chr1:62943979	G/A	cg06896770	chr1:63153194	DOCK7	-0.91	-7.58	-0.61	2.33e-11	Triglyceride levels;
THYM	cis	rs6987853	0.933	rs2356610	chr8:42446238	T/G	cg09913449	chr8:42400586	C8orf40	0.85	7.88	0.63	5.43e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs71403859	0.502	rs35981926	chr16:71500755	A/T	cg08717414	chr16:71523259	ZNF19	-1.45	-7.43	-0.61	4.75e-11	Post bronchodilator FEV1;
THYM	cis	rs8192282	0.691	rs4845640	chr1:154497802	C/T	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs6570726	0.935	rs409121	chr6:145839793	G/A	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs828999	0.654	rs10785836	chr1:108697180	C/G	cg24323958	chr1:108741884	SLC25A24	0.54	5.32	0.48	6.79e-7	Monocyte percentage of white cells;
THYM	cis	rs17450784	0.752	rs78334147	chr5:109017236	C/T	cg17395555	chr5:108820864	NA	0.58	4.62	0.43	1.21e-5	Exploratory eye movement dysfunction in schizophrenia (responsive search score);Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
THYM	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg24397884	chr7:158709396	WDR60	-0.47	-5.35	-0.48	6.19e-7	Height;
THYM	cis	rs1775715	0.707	rs2065443	chr10:32164236	C/G	cg04359828	chr10:32216031	ARHGAP12	0.41	5.09	0.46	1.78e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs9807989	0.507	rs2110659	chr2:103043867	G/A	cg03938978	chr2:103052716	IL18RAP	0.75	9.8	0.71	4.43e-16	Asthma;
THYM	cis	rs55665837	0.559	rs11023209	chr11:14422600	T/C	cg19336497	chr11:14380999	RRAS2	-0.84	-11.43	-0.76	1.49e-19	Vitamin D levels;
THYM	cis	rs6988636	1.000	rs28537152	chr8:124189071	T/C	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs10870270	0.957	rs10870307	chr10:133780610	T/C	cg00744431	chr10:134226547	PWWP2B	-0.6	-4.63	-0.43	1.16e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg00684032	chr4:1343700	KIAA1530	0.78	6.75	0.57	1.16e-9	Obesity-related traits;
THYM	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg21361702	chr7:150065534	REPIN1	0.68	4.98	0.46	2.8e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs12348691	0.503	rs3021523	chr9:100616583	T/C	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Alopecia areata;
THYM	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	7.06	0.59	2.77e-10	Smoking behavior;
THYM	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs4891159	0.548	rs10782013	chr18:74128348	C/T	cg24786174	chr18:74118243	ZNF516	0.97	14.43	0.83	1.15e-25	Longevity;
THYM	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg11189052	chr15:85197271	WDR73	-0.64	-4.99	-0.46	2.76e-6	P wave terminal force;
THYM	cis	rs765787	0.530	rs11634794	chr15:45534492	A/C	cg24006582	chr15:45444508	DUOX1	-0.84	-7.2	-0.59	1.39e-10	Uric acid levels;
THYM	cis	rs11186	0.504	rs72906305	chr2:189955346	T/C	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs72828912	0.731	rs9366559	chr6:24078056	C/T	cg26336265	chr6:25042955	NA	-0.87	-5.53	-0.49	2.85e-7	Squamous cell lung carcinoma;
THYM	cis	rs2235642	0.525	rs8048290	chr16:1562026	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.59	-5.69	-0.5	1.41e-7	Coronary artery disease;
THYM	cis	rs6918586	0.565	rs13196986	chr6:26090452	T/C	cg03517284	chr6:25882590	NA	-0.74	-4.91	-0.45	3.72e-6	Schizophrenia;
THYM	cis	rs2046867	0.862	rs2322611	chr3:72830087	T/G	cg25664220	chr3:72788482	NA	-0.85	-6.63	-0.56	2.01e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11644478	chr21:40555479	PSMG1	-0.57	-4.63	-0.43	1.17e-5	Menarche (age at onset);
THYM	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg19747945	chr6:42946146	PEX6	0.34	4.83	0.44	5.25e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	trans	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg25517755	chr10:38738941	LOC399744	-0.8	-7.86	-0.63	6e-12	Corneal astigmatism;
THYM	cis	rs9290065	0.519	rs6441345	chr3:160696867	C/T	cg03342759	chr3:160939853	NMD3	-0.59	-4.56	-0.42	1.52e-5	Kawasaki disease;
THYM	cis	rs6867032	0.695	rs3902820	chr5:2000330	T/A	cg26168224	chr5:2018326	NA	-1.15	-11.43	-0.76	1.53e-19	Gut microbiome composition (winter);
THYM	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg04944784	chr2:26401820	FAM59B	-1.05	-8.18	-0.64	1.23e-12	Gut microbiome composition (summer);
THYM	cis	rs9807989	0.507	rs2310300	chr2:103049074	A/G	cg03938978	chr2:103052716	IL18RAP	0.75	9.8	0.71	4.43e-16	Asthma;
THYM	cis	rs9807989	0.839	rs10192157	chr2:102968356	C/T	cg03938978	chr2:103052716	IL18RAP	0.63	6.56	0.56	2.81e-9	Asthma;
THYM	cis	rs4665630	0.764	rs4665629	chr2:23894482	A/T	cg08081869	chr2:24582653	ITSN2	0.77	4.51	0.42	1.86e-5	Hypertension;
THYM	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg17911788	chr17:44343683	NA	0.54	5.33	0.48	6.72e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9810089	0.814	rs73226190	chr3:136213310	T/C	cg12473912	chr3:136751656	NA	0.59	4.84	0.44	5.09e-6	Gestational age at birth (child effect);
THYM	cis	rs4731207	0.698	rs7801140	chr7:124505761	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.09	-0.46	1.83e-6	Cutaneous malignant melanoma;
THYM	cis	rs6980334	0.817	rs3805361	chr7:137794519	C/T	cg06915773	chr7:137028165	PTN	0.58	4.74	0.44	7.59e-6	Blood metabolite ratios;
THYM	cis	rs524023	0.874	rs506338	chr11:64440920	T/C	cg19131476	chr11:64387923	NRXN2	-0.39	-5.54	-0.49	2.7e-7	Urate levels in obese individuals;
THYM	cis	rs7267979	0.966	rs2151144	chr20:25414924	G/C	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs13418717	1.000	rs7572403	chr2:127662420	G/A	cg25501666	chr2:127640322	NA	1.36	6.36	0.55	7e-9	Heart failure;
THYM	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg15741354	chr8:8146129	NA	-0.29	-5.0	-0.46	2.61e-6	Joint mobility (Beighton score);
THYM	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg00981070	chr1:2046702	PRKCZ	0.47	5.21	0.47	1.1e-6	Height;
THYM	cis	rs6700896	0.931	rs2211651	chr1:66156021	G/T	cg04111102	chr1:66153794	NA	0.55	5.29	0.48	7.87e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg11663144	chr21:46675770	NA	-0.64	-8.56	-0.66	2.01e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3741151	1.000	rs7941454	chr11:73085336	C/T	cg17517138	chr11:73019481	ARHGEF17	1.0	6.02	0.53	3.26e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg08999081	chr20:33150536	PIGU	-0.57	-4.95	-0.45	3.25e-6	Height;
THYM	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg13695892	chr22:41940480	POLR3H	0.89	7.16	0.59	1.69e-10	Vitiligo;
THYM	cis	rs11771526	0.748	rs11765652	chr7:32336444	A/G	cg13207630	chr7:32358064	NA	0.71	4.73	0.44	7.9e-6	Body mass index;
THYM	cis	rs6430585	0.528	rs614193	chr2:136653925	A/T	cg04750100	chr2:136595281	LCT	0.55	5.52	0.49	2.99e-7	Corneal structure;
THYM	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg27279351	chr12:120934652	DYNLL1	0.95	8.62	0.66	1.44e-13	High light scatter reticulocyte count;
THYM	trans	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.09	-13.24	-0.81	2.77e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2130392	0.886	rs6845294	chr4:185653826	G/A	cg04058563	chr4:185651563	MLF1IP	-0.53	-4.69	-0.43	9.16e-6	Kawasaki disease;
THYM	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg09165964	chr15:75287851	SCAMP5	-1.08	-10.79	-0.74	3.35e-18	Blood trace element (Zn levels);
THYM	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs9291683	0.679	rs2278122	chr4:10096241	T/A	cg02734326	chr4:10020555	SLC2A9	-0.58	-5.2	-0.47	1.16e-6	Bone mineral density;
THYM	cis	rs7191439	0.522	rs8060640	chr16:88744430	G/C	cg27087555	chr16:88793112	FAM38A	-1.26	-5.83	-0.51	7.44e-8	Plateletcrit;
THYM	cis	rs7804356	0.871	rs6461962	chr7:26746304	A/T	cg24979288	chr7:27242424	NA	0.62	4.46	0.42	2.26e-5	Type 1 diabetes;
THYM	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg02353165	chr6:42928485	GNMT	0.78	6.87	0.58	6.52e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.5	-4.93	-0.45	3.5e-6	Crohn's disease;
THYM	cis	rs11608355	0.618	rs4486687	chr12:109790741	T/A	cg10504392	chr12:110044639	NA	0.52	4.71	0.43	8.59e-6	Neuroticism;
THYM	cis	rs11696501	0.688	rs6065861	chr20:44311056	A/G	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg18132916	chr6:79620363	NA	-0.6	-5.44	-0.49	4.1e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg12031863	chr16:4587854	C16orf5	-0.46	-4.96	-0.45	3.09e-6	Schizophrenia;
THYM	cis	rs728616	0.867	rs61860420	chr10:81739379	G/A	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	4.55	0.42	1.61e-5	Bipolar disorder;
THYM	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1729951	0.575	rs1682333	chr3:136688618	G/A	cg21827317	chr3:136751795	NA	0.74	6.6	0.56	2.29e-9	Neuroticism;
THYM	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg18681998	chr4:17616180	MED28	0.99	10.21	0.72	5.85e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs1878931	0.520	rs2015640	chr16:3465018	G/C	cg05754148	chr16:3507555	NAT15	0.62	5.28	0.48	8.2e-7	Body mass index (adult);
THYM	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg09035930	chr12:129282057	SLC15A4	0.86	12.0	0.78	9.76e-21	Systemic lupus erythematosus;
THYM	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg13918804	chr1:2043761	PRKCZ	-0.63	-4.78	-0.44	6.48e-6	Height;
THYM	cis	rs11096990	0.855	rs2566179	chr4:39158033	C/G	cg24403649	chr4:39172243	NA	-0.6	-5.09	-0.46	1.77e-6	Cognitive function;
THYM	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg00129232	chr17:37814104	STARD3	-0.71	-4.8	-0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg24874828	chr4:187887005	NA	-0.72	-7.22	-0.6	1.26e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12681963	0.702	rs11777119	chr8:29932284	C/T	cg10113081	chr8:30601548	UBXN8	0.81	4.45	0.42	2.34e-5	Migraine;
THYM	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.68	5.08	0.46	1.89e-6	Tonsillectomy;
THYM	cis	rs6828523	0.698	rs77278383	chr4:175852929	G/T	cg14561282	chr4:175839468	ADAM29	0.61	4.51	0.42	1.83e-5	Breast cancer;
THYM	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg16325326	chr1:53192061	ZYG11B	-0.95	-10.63	-0.74	7.38e-18	Monocyte count;
THYM	cis	rs6918586	0.658	rs198809	chr6:26128766	G/A	cg03517284	chr6:25882590	NA	0.71	5.64	0.5	1.75e-7	Schizophrenia;
THYM	cis	rs8170	0.603	rs8110408	chr19:17440542	C/G	cg04749549	chr19:17459798	NA	-0.43	-5.26	-0.47	8.95e-7	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
THYM	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg10518543	chr12:38710700	ALG10B	-0.59	-4.7	-0.43	8.88e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg25767906	chr1:53392781	SCP2	-0.59	-5.73	-0.51	1.17e-7	Monocyte count;
THYM	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg09549813	chr16:4587862	C16orf5	-0.58	-6.51	-0.56	3.57e-9	Schizophrenia;
THYM	cis	rs2658782	0.654	rs2605622	chr11:93248242	A/G	cg15737290	chr11:93063684	CCDC67	0.98	7.25	0.6	1.1e-10	Pulmonary function decline;
THYM	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg13390004	chr1:15929781	NA	0.62	4.72	0.44	8.11e-6	Systolic blood pressure;
THYM	cis	rs4481887	0.927	rs4517383	chr1:248426484	C/T	cg00666640	chr1:248458726	OR2T12	0.52	4.53	0.42	1.7e-5	Common traits (Other);
THYM	cis	rs10504073	0.584	rs62507178	chr8:49938572	A/C	cg00325661	chr8:49890786	NA	1.09	11.06	0.75	9.14e-19	Blood metabolite ratios;
THYM	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg10803722	chr21:46713166	LOC642852	-0.5	-6.28	-0.54	1.02e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-1.18	-9.5	-0.7	1.93e-15	Cognitive test performance;
THYM	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg02725872	chr8:58115012	NA	-1.1	-8.24	-0.65	9.17e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs728616	0.867	rs61860412	chr10:81728486	G/A	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	7.77	0.62	9.07e-12	Smoking behavior;
THYM	cis	rs1003719	0.737	rs9974374	chr21:38479885	A/G	cg01329690	chr21:38580129	DSCR9	0.42	5.74	0.51	1.13e-7	Eye color traits;
THYM	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg18904891	chr8:8559673	CLDN23	0.72	5.47	0.49	3.66e-7	Obesity-related traits;
THYM	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg19746536	chr19:49375674	PPP1R15A	0.81	4.6	0.43	1.33e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10095849	0.608	rs4734001	chr8:39441186	T/A	cg22755526	chr8:38854673	TM2D2;ADAM9	-0.64	-4.74	-0.44	7.57e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg27534772	chr1:16042836	PLEKHM2	-0.52	-5.43	-0.49	4.34e-7	Systolic blood pressure;
THYM	trans	rs3960554	0.673	rs57358338	chr7:75732923	T/C	cg19862616	chr7:65841803	NCRNA00174	0.97	7.23	0.6	1.21e-10	Eotaxin levels;
THYM	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg13395646	chr4:1353034	KIAA1530	-0.58	-5.4	-0.48	4.91e-7	Longevity;
THYM	cis	rs9399401	0.890	rs3817929	chr6:142751062	G/C	cg04461802	chr6:142623433	GPR126	0.48	4.8	0.44	5.86e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg20887711	chr4:1340912	KIAA1530	-0.94	-8.45	-0.66	3.37e-13	Longevity;
THYM	cis	rs11850957	0.502	rs77757127	chr14:25442259	G/A	cg26846476	chr14:24838993	NFATC4	0.9	4.79	0.44	6.2e-6	Subcutaneous adipose tissue;
THYM	cis	rs9649213	0.586	rs55648546	chr7:97960800	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.67	-5.67	-0.5	1.53e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6835098	0.924	rs13138282	chr4:174120906	C/T	cg08422745	chr4:174089978	GALNT7	0.98	7.53	0.61	2.86e-11	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs12594515	1.000	rs8032361	chr15:45988553	T/C	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs9796	0.621	rs1659227	chr15:41472398	G/A	cg18705301	chr15:41695430	NDUFAF1	0.58	4.75	0.44	7.08e-6	Menopause (age at onset);
THYM	cis	rs7605378	1.000	rs769958	chr2:200695901	G/A	cg17644776	chr2:200775616	C2orf69	0.64	4.92	0.45	3.6e-6	Osteoporosis;
THYM	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg07570687	chr10:102243282	WNT8B	0.74	6.5	0.56	3.63e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg11812906	chr14:75593930	NEK9	0.83	7.48	0.61	3.63e-11	Height;
THYM	cis	rs9393777	0.668	rs16897515	chr6:27278020	A/C	cg22548220	chr6:27277996	POM121L2	-0.83	-5.21	-0.47	1.11e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg24846343	chr22:24311635	DDTL	-0.45	-5.91	-0.52	5.39e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs763014	0.931	rs59476302	chr16:629006	C/T	cg09263875	chr16:632152	PIGQ	0.73	6.29	0.54	9.69e-9	Height;
THYM	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	cis	rs1395	0.744	rs4665962	chr2:27515105	A/G	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.3	-0.48	7.55e-7	Blood metabolite levels;
THYM	cis	rs728616	0.614	rs59169164	chr10:81711915	T/C	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs8042849	1	rs8042849	chr15:78817929	C/T	cg18825076	chr15:78729989	IREB2	0.55	5.19	0.47	1.17e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Parental lifespan;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg14768367	chr16:72042858	DHODH	0.67	5.27	0.48	8.41e-7	Fibrinogen levels;
THYM	cis	rs4721295	0.502	rs2058430	chr7:2206110	A/G	cg10360139	chr7:1886902	MAD1L1	-0.62	-4.72	-0.44	8.1e-6	Schizophrenia, schizoaffective disorder or bipolar disorder;
THYM	cis	rs1178127	0.682	rs727851	chr7:18786817	G/T	cg13420273	chr7:18810212	HDAC9	0.54	4.63	0.43	1.16e-5	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs59698941	0.882	rs56353702	chr5:132248575	A/G	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs6732160	0.809	rs6728959	chr2:73383327	C/T	cg24220031	chr2:73402428	NA	-0.79	-8.39	-0.65	4.59e-13	Intelligence (multi-trait analysis);
THYM	cis	rs1483890	0.605	rs6549209	chr3:69413028	A/C	cg22125112	chr3:69402811	FRMD4B	0.41	5.18	0.47	1.23e-6	Resting heart rate;
THYM	cis	rs6543140	0.927	rs917999	chr2:103067869	G/A	cg03938978	chr2:103052716	IL18RAP	0.58	5.84	0.51	7.16e-8	Blood protein levels;
THYM	cis	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10929159	0.928	rs6761121	chr2:236922541	T/C	cg14895183	chr2:236924282	AGAP1	0.54	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs7809950	0.954	rs2520241	chr7:107135443	A/G	cg23024343	chr7:107201750	COG5	-0.93	-8.3	-0.65	7.11e-13	Coronary artery disease;
THYM	cis	rs7106204	0.590	rs28864378	chr11:24206582	C/A	ch.11.24196551F	chr11:24239977	NA	0.84	6.01	0.52	3.46e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs800586	0.788	rs800542	chr8:116731444	C/T	cg04656070	chr8:116661063	TRPS1	0.48	4.49	0.42	2.01e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg07570687	chr10:102243282	WNT8B	0.75	6.92	0.58	5.2e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg15838173	chr10:75533400	FUT11	-0.55	-5.4	-0.48	4.87e-7	Inflammatory bowel disease;
THYM	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg20203395	chr5:56204925	C5orf35	-0.67	-4.58	-0.42	1.44e-5	Initial pursuit acceleration;
THYM	cis	rs4072980	0.545	rs7519947	chr1:38447725	T/C	cg18451016	chr1:38461880	NA	-0.38	-4.62	-0.43	1.21e-5	Coronary artery disease;
THYM	cis	rs10832963	0.961	rs10832954	chr11:18643559	G/A	cg09201001	chr11:18656081	SPTY2D1	1.07	9.63	0.7	1.04e-15	Breast cancer;
THYM	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg17173187	chr15:85201210	NMB	0.55	5.34	0.48	6.21e-7	Schizophrenia;
THYM	cis	rs747334	0.811	rs1334580	chr10:92720862	C/T	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs11030122	0.673	rs10835508	chr11:4045360	A/T	cg18678763	chr11:4115507	RRM1	-0.45	-6.02	-0.53	3.26e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg17105886	chr17:28927953	LRRC37B2	1.25	6.76	0.57	1.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7264396	0.733	rs6060515	chr20:34211779	A/G	cg26038318	chr20:34205095	SPAG4	0.64	5.28	0.48	8.13e-7	Total cholesterol levels;
THYM	cis	rs11723261	0.564	rs60994255	chr4:77446	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.94	5.99	0.52	3.68e-8	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.79e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs4766646	0.640	rs4766640	chr12:110300147	C/T	cg10794374	chr12:110278745	NA	0.22	4.97	0.45	3.01e-6	Metabolite levels (MHPG);
THYM	cis	rs7100689	0.577	rs1340385	chr10:82058851	G/A	cg01528321	chr10:82214614	TSPAN14	0.97	7.32	0.6	7.9e-11	Post bronchodilator FEV1;
THYM	cis	rs6669072	1.000	rs10922924	chr1:91252863	A/G	cg08895590	chr1:91227319	NA	0.52	5.92	0.52	5.18e-8	Cognitive function;
THYM	cis	rs9560113	0.959	rs4773385	chr13:112178452	C/T	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg00640147	chr17:61958756	GH2	-0.44	-4.82	-0.44	5.49e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7771547	0.607	rs614028	chr6:36484252	G/A	cg07856975	chr6:36356162	ETV7	0.52	5.01	0.46	2.48e-6	Platelet distribution width;
THYM	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.76	-5.87	-0.52	6.27e-8	Eosinophil percentage of white cells;
THYM	cis	rs7810240	0.967	rs2373695	chr7:150083090	C/T	cg17279839	chr7:150038598	RARRES2	-0.5	-4.78	-0.44	6.39e-6	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
THYM	cis	rs2836950	0.501	rs1474490	chr21:40716136	C/A	cg06238570	chr21:40685208	BRWD1	-0.72	-6.01	-0.53	3.36e-8	Menarche (age at onset);
THYM	cis	rs7614311	0.681	rs55917937	chr3:63894829	A/C	cg22134162	chr3:63841271	THOC7	-0.4	-4.92	-0.45	3.6e-6	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg06481639	chr22:41940642	POLR3H	-0.69	-5.15	-0.47	1.42e-6	Vitiligo;
THYM	cis	rs4285028	0.948	rs34696871	chr3:121671880	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-5.08	-0.46	1.87e-6	Multiple sclerosis;
THYM	cis	rs2066819	1.000	rs871130	chr12:56648777	A/G	cg26714650	chr12:56694279	CS	1.19	6.0	0.52	3.63e-8	Psoriasis vulgaris;
THYM	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg06481639	chr22:41940642	POLR3H	0.74	5.39	0.48	5.01e-7	Vitiligo;
THYM	cis	rs4262150	0.883	rs72802890	chr5:152255145	G/T	cg06854687	chr5:151642065	NA	0.64	4.46	0.42	2.27e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs2282300	0.667	rs10734405	chr11:30273750	T/C	cg25418670	chr11:30344373	C11orf46	0.82	6.97	0.58	4.25e-10	Morning vs. evening chronotype;
THYM	cis	rs9500256	0.967	rs4928431	chr6:58306258	A/G	cg16251399	chr6:58287822	GUSBL2	-0.69	-5.8	-0.51	8.8e-8	Eosinophilic esophagitis (pediatric);
THYM	cis	rs501916	0.634	rs61333299	chr15:48066806	G/A	cg20869673	chr15:48010124	SEMA6D	0.63	4.49	0.42	1.99e-5	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg23161317	chr6:28129485	ZNF389	1.0	7.99	0.63	3.23e-12	Depression;
THYM	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.68	-5.06	-0.46	2.08e-6	Colorectal cancer;
THYM	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg25817165	chr18:72167213	CNDP2	-0.99	-7.58	-0.61	2.27e-11	Refractive error;
THYM	cis	rs34734847	1.000	rs55730005	chr12:121157536	C/A	cg21892295	chr12:121157589	UNC119B	-0.66	-7.5	-0.61	3.43e-11	Mean corpuscular volume;
THYM	cis	rs7646501	0.734	rs954734	chr3:24055654	A/C	cg21910673	chr3:24143257	LOC152024	0.5	4.53	0.42	1.72e-5	Cognitive ability;Intelligence;
THYM	cis	rs4474465	1.000	rs7925034	chr11:78193242	A/G	cg19901956	chr11:77921274	USP35	-0.62	-4.62	-0.43	1.19e-5	Alzheimer's disease (survival time);
THYM	cis	rs7119	0.717	rs11634174	chr15:77811232	A/T	cg27398640	chr15:77910606	LINGO1	-0.57	-5.76	-0.51	1.03e-7	Type 2 diabetes;
THYM	cis	rs11771526	0.901	rs10271047	chr7:32289660	A/C	cg13207630	chr7:32358064	NA	-0.72	-4.82	-0.44	5.44e-6	Body mass index;
THYM	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg26384229	chr12:38710491	ALG10B	-0.79	-7.73	-0.62	1.09e-11	Heart rate;
THYM	cis	rs2731664	0.756	rs335433	chr5:176867207	T/C	cg14098951	chr5:176875120	PRR7	0.56	4.99	0.46	2.69e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg04025307	chr7:1156635	C7orf50	0.77	6.5	0.55	3.68e-9	Longevity;Endometriosis;
THYM	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg15448220	chr1:150897856	SETDB1	0.86	7.21	0.59	1.33e-10	Tonsillectomy;
THYM	cis	rs7872515	0.536	rs10992201	chr9:94780754	C/A	cg13922115	chr9:95397568	IPPK	0.88	4.46	0.42	2.25e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg15445000	chr17:37608096	MED1	-0.44	-5.19	-0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs61990749	0.544	rs7151211	chr14:78151901	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-1.17	-8.04	-0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs950880	0.677	rs17027087	chr2:103015918	C/T	cg03938978	chr2:103052716	IL18RAP	-0.52	-4.64	-0.43	1.13e-5	Serum protein levels (sST2);
THYM	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg22907277	chr7:1156413	C7orf50	0.82	4.98	0.46	2.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg11764359	chr7:65958608	NA	0.62	4.73	0.44	7.94e-6	Aortic root size;
THYM	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg11327659	chr7:150037044	RARRES2	0.47	5.32	0.48	6.94e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7072216	0.763	rs942803	chr10:100168631	G/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg22535103	chr8:58192502	C8orf71	-0.96	-5.47	-0.49	3.7e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg00495681	chr13:53174319	NA	0.82	8.39	0.65	4.5e-13	Lewy body disease;
THYM	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.06	7.46	0.61	4.05e-11	Platelet count;
THYM	cis	rs11039798	0.920	rs11039940	chr11:48716316	C/T	cg24672777	chr11:48374446	OR4C45	-1.12	-6.73	-0.57	1.28e-9	Axial length;
THYM	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12893428	chr3:195717962	SDHAP1	0.51	4.57	0.42	1.49e-5	Pancreatic cancer;
THYM	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg12373951	chr3:133503437	NA	0.66	7.16	0.59	1.73e-10	Iron status biomarkers;
THYM	cis	rs13315871	0.790	rs13066409	chr3:58428444	A/G	cg12435725	chr3:58293450	RPP14	-0.46	-4.93	-0.45	3.54e-6	Cholesterol, total;
THYM	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg08470875	chr2:26401718	FAM59B	-0.74	-4.59	-0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs12039431	0.746	rs61776184	chr1:38008523	C/T	cg17933807	chr1:38061675	GNL2	-0.77	-5.62	-0.5	1.88e-7	Epithelial ovarian cancer;
THYM	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg17644776	chr2:200775616	C2orf69	0.77	5.4	0.48	5.01e-7	Schizophrenia;
THYM	cis	rs2299587	0.623	rs12718384	chr8:17781112	T/C	cg01800426	chr8:17659068	MTUS1	-0.59	-4.75	-0.44	7.18e-6	Economic and political preferences;
THYM	cis	rs7580658	0.926	rs4662725	chr2:128141320	G/A	cg10021288	chr2:128175891	PROC	-0.83	-7.11	-0.59	2.19e-10	Protein C levels;
THYM	cis	rs6840360	0.870	rs7680604	chr4:152469917	C/T	cg17479576	chr4:152424074	FAM160A1	-0.59	-4.52	-0.42	1.77e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2806561	1.000	rs2806558	chr1:23503456	T/C	cg08872493	chr1:23521417	HTR1D	0.39	5.11	0.46	1.64e-6	Height;
THYM	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	4.98	0.46	2.79e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs887829	0.641	rs10179094	chr2:234597825	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.81	-6.59	-0.56	2.39e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs28374715	0.532	rs7168431	chr15:41672384	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.21	-13.52	-0.81	7.22e-24	Ulcerative colitis;
THYM	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7592578	0.508	rs55919641	chr2:191265414	G/A	cg11845111	chr2:191398756	TMEM194B	-0.85	-6.37	-0.55	6.74e-9	Diastolic blood pressure;
THYM	cis	rs7809950	1.000	rs2237676	chr7:107198079	C/A	cg23024343	chr7:107201750	COG5	-0.94	-8.66	-0.66	1.21e-13	Coronary artery disease;
THYM	cis	rs2637266	1.000	rs2395389	chr10:78357701	C/T	cg18941641	chr10:78392320	NA	0.81	7.03	0.58	3.17e-10	Pulmonary function;
THYM	cis	rs8101881	0.576	rs7254042	chr19:33362148	A/G	cg05467458	chr19:33361032	SLC7A9	-0.57	-5.18	-0.47	1.25e-6	Blood metabolite levels;Urinary metabolites;Urinary metabolites (H-NMR features);
THYM	cis	rs3126085	0.877	rs3126045	chr1:152256794	A/G	cg10321714	chr1:152280068	FLG	0.62	4.66	0.43	1.01e-5	Atopic dermatitis;
THYM	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg24397884	chr7:158709396	WDR60	0.46	5.0	0.46	2.63e-6	Height;
THYM	cis	rs7582180	0.627	rs4407265	chr2:101005846	C/G	cg14675211	chr2:100938903	LONRF2	0.6	5.82	0.51	7.81e-8	Intelligence (multi-trait analysis);
THYM	cis	rs10431058	0.896	rs10890742	chr11:107474795	A/G	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.72	5.34	0.48	6.35e-7	Common traits (Other);
THYM	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg27129171	chr3:47204927	SETD2	0.73	7.17	0.59	1.64e-10	Colorectal cancer;
THYM	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06481639	chr22:41940642	POLR3H	0.81	5.59	0.5	2.2e-7	Vitiligo;
THYM	cis	rs500891	0.525	rs12215595	chr6:84055783	A/G	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs12935418	0.552	rs2549838	chr16:81023210	C/T	cg16651780	chr16:81037892	C16orf61	-0.85	-6.53	-0.56	3.16e-9	Mean corpuscular volume;
THYM	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.67	4.84	0.45	4.92e-6	Renal function-related traits (BUN);
THYM	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg11189052	chr15:85197271	WDR73	0.7	5.6	0.5	2.1e-7	P wave terminal force;
THYM	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs28595532	0.841	rs114123875	chr4:119733408	A/G	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs981844	1.000	rs2606328	chr4:154653864	C/T	cg09973105	chr4:154681532	RNF175	-0.59	-4.89	-0.45	4.1e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs7804356	0.871	rs117217399	chr7:26805212	T/C	cg24979288	chr7:27242424	NA	-0.63	-4.54	-0.42	1.66e-5	Type 1 diabetes;
THYM	cis	rs28595532	0.920	rs56291421	chr4:119732294	G/A	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	trans	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg17830980	chr10:43048298	ZNF37B	-0.82	-6.99	-0.58	3.81e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs1580019	0.883	rs6945294	chr7:32472099	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.84	7.5	0.61	3.34e-11	Cognitive ability;
THYM	cis	rs7772486	0.686	rs9376961	chr6:146048737	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-5.03	-0.46	2.33e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13232179	1.000	rs9655607	chr7:151114229	G/A	cg05714773	chr7:150493706	TMEM176B	0.71	5.16	0.47	1.35e-6	Coronary heart disease;
THYM	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg06618935	chr21:46677482	NA	-0.97	-9.14	-0.68	1.12e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7119	0.717	rs12916515	chr15:77818518	G/T	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg21427119	chr20:30132790	HM13	-0.67	-4.62	-0.43	1.19e-5	Mean corpuscular hemoglobin;
THYM	cis	rs1448094	0.510	rs11117016	chr12:86141602	T/C	cg00310523	chr12:86230176	RASSF9	-0.57	-4.98	-0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg09549813	chr16:4587862	C16orf5	-0.58	-5.98	-0.52	3.87e-8	Schizophrenia;
THYM	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-4.65	-0.43	1.07e-5	Gut microbiome composition (summer);
THYM	cis	rs11031096	0.678	rs11031184	chr11:4186192	C/T	cg08557956	chr11:4115526	RRM1	-0.53	-5.06	-0.46	2.05e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7119	0.604	rs2682924	chr15:77863720	C/T	cg10437265	chr15:77819839	NA	0.62	6.21	0.54	1.37e-8	Type 2 diabetes;
THYM	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg07212818	chr11:638076	DRD4	-0.79	-6.17	-0.53	1.66e-8	Systemic lupus erythematosus;
THYM	cis	rs7553864	0.966	rs11161937	chr1:87614510	A/G	cg17420885	chr1:87600446	LOC339524	-0.72	-6.03	-0.53	3.18e-8	Smoking behavior;
THYM	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11890956	chr21:40555474	PSMG1	1.17	12.69	0.79	3.56e-22	Cognitive function;
THYM	cis	rs1797885	0.738	rs2655261	chr3:12562637	C/A	cg05467012	chr3:12595696	NA	0.55	4.61	0.43	1.28e-5	Immature fraction of reticulocytes;
THYM	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	5.57	0.5	2.37e-7	Lung cancer in ever smokers;
THYM	cis	rs6539288	0.901	rs7974499	chr12:107341385	T/C	cg26297688	chr12:107349093	C12orf23	-0.47	-4.94	-0.45	3.36e-6	Total body bone mineral density;
THYM	cis	rs7917772	0.582	rs7075269	chr10:104365724	C/T	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs10779751	0.770	rs11121696	chr1:11238063	A/G	cg08854313	chr1:11322531	MTOR	-0.7	-5.37	-0.48	5.67e-7	Body mass index;
THYM	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	7.45	0.61	4.17e-11	Platelet count;
THYM	trans	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs2717559	0.542	rs2585156	chr8:143879795	G/A	cg17888033	chr8:143858414	LYNX1	-0.44	-4.9	-0.45	3.94e-6	Urinary tract infection frequency;
THYM	cis	rs17253792	0.822	rs9972180	chr14:56073732	G/T	cg01858014	chr14:56050164	KTN1	-1.22	-5.13	-0.47	1.52e-6	Putamen volume;
THYM	cis	rs7264396	0.790	rs3787166	chr20:34229072	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-5.62	-0.5	1.92e-7	Total cholesterol levels;
THYM	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1883415	0.727	rs7775073	chr6:24499551	A/G	cg00346970	chr6:24499591	ALDH5A1	0.4	5.14	0.47	1.48e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2732480	0.577	rs2732486	chr12:48737834	G/A	cg21466736	chr12:48725269	NA	-0.6	-5.36	-0.48	5.86e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg06784218	chr1:46089804	CCDC17	-0.32	-4.82	-0.44	5.41e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg18538332	chr22:24372958	LOC391322	-1.09	-14.7	-0.83	3.24e-26	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg00071950	chr4:10020882	SLC2A9	0.67	6.66	0.56	1.79e-9	Bone mineral density;
THYM	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg03690763	chr11:133734501	NA	-0.61	-4.77	-0.44	6.59e-6	Childhood ear infection;
THYM	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg24209194	chr3:40518798	ZNF619	0.57	4.52	0.42	1.77e-5	Renal cell carcinoma;
THYM	cis	rs72829446	0.932	rs72827565	chr17:7469607	G/A	cg07091842	chr17:7155530	C17orf81;DULLARD	-0.98	-4.46	-0.42	2.29e-5	Androgen levels;
THYM	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg13607699	chr17:42295918	UBTF	-0.68	-5.59	-0.5	2.14e-7	Total body bone mineral density;
THYM	cis	rs7103648	0.864	rs10769264	chr11:47423340	C/T	cg20307385	chr11:47447363	PSMC3	0.93	8.66	0.66	1.23e-13	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	5.28	0.48	8.21e-7	Hip circumference adjusted for BMI;
THYM	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-7.94	-0.63	4.1e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9479482	0.686	rs1194970	chr6:150374468	G/A	cg25797454	chr6:150327115	RAET1K	0.48	4.76	0.44	6.98e-6	Alopecia areata;
THYM	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs4845875	0.626	rs12734761	chr1:11834182	G/A	cg24844545	chr1:11908347	NPPA	0.45	4.62	0.43	1.19e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs1061377	0.965	rs3733275	chr4:39122697	C/T	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs7722022	0.504	rs750167	chr5:172902130	A/G	cg18512156	chr5:172661970	NKX2-5	-0.54	-4.5	-0.42	1.9e-5	Adiponectin levels;
THYM	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13126279	chr21:47581558	C21orf56	-0.61	-4.5	-0.42	1.93e-5	Testicular germ cell tumor;
THYM	cis	rs7833986	1.000	rs36088882	chr8:57092914	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	4.98	0.45	2.84e-6	Height;
THYM	cis	rs28595532	0.920	rs116105567	chr4:119746204	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs4986811	0.568	rs1799933	chr11:32449486	C/T	cg13301003	chr11:32449254	WT1	0.69	4.59	0.43	1.34e-5	Rubella-specific interleukin-6 secretion;
THYM	cis	rs921968	0.541	rs496674	chr2:219432569	G/A	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg27490568	chr2:178487706	NA	0.54	4.68	0.43	9.42e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2354432	1.000	rs10900325	chr1:146692174	C/T	cg25205988	chr1:146714368	CHD1L	-1.06	-6.98	-0.58	3.91e-10	Mitochondrial DNA levels;
THYM	cis	rs6840360	0.615	rs72728173	chr4:152469373	C/T	cg17479576	chr4:152424074	FAM160A1	-0.85	-6.4	-0.55	5.9e-9	Intelligence (multi-trait analysis);
THYM	cis	rs870825	0.929	rs72689255	chr4:185590141	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	7.66	0.62	1.59e-11	Blood protein levels;
THYM	cis	rs524281	0.692	rs2254388	chr11:65837599	C/T	cg00563793	chr11:65837595	PACS1	-0.68	-5.19	-0.47	1.19e-6	Electroencephalogram traits;
THYM	cis	rs526231	0.543	rs32849	chr5:102470043	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.49e-6	Primary biliary cholangitis;
THYM	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg16325326	chr1:53192061	ZYG11B	1.0	11.58	0.77	7.2e-20	Monocyte count;
THYM	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg17294928	chr15:75287854	SCAMP5	-0.94	-7.94	-0.63	4.01e-12	Blood trace element (Zn levels);
THYM	cis	rs10504073	0.647	rs10504072	chr8:49993083	G/A	cg00325661	chr8:49890786	NA	0.93	8.79	0.67	6.32e-14	Blood metabolite ratios;
THYM	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs9814567	1.000	rs9854299	chr3:134206728	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.33	-0.65	5.98e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg23791538	chr6:167370224	RNASET2	0.73	5.67	0.5	1.53e-7	Crohn's disease;
THYM	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg06108461	chr20:60628389	TAF4	-1.01	-6.94	-0.58	4.72e-10	Body mass index;
THYM	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg23161317	chr6:28129485	ZNF389	0.87	6.22	0.54	1.31e-8	Depression;
THYM	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg27490568	chr2:178487706	NA	0.59	5.91	0.52	5.43e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2302777	0.507	rs9889711	chr17:38108292	A/T	cg24910161	chr17:38119198	GSDMA	-0.58	-6.31	-0.54	8.93e-9	Multiple myeloma (hyperdiploidy);
THYM	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg27102117	chr16:15229624	NA	0.58	4.45	0.42	2.29e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
THYM	cis	rs6598541	1.000	rs12908437	chr15:99287375	T/C	cg13297560	chr15:99320054	IGF1R	0.44	4.51	0.42	1.86e-5	Urate levels;
THYM	cis	rs8031584	1.000	rs890159	chr15:31291634	G/A	cg08704250	chr15:31115839	NA	-0.55	-6.13	-0.53	2.04e-8	Huntington's disease progression;
THYM	cis	rs2932538	0.885	rs7516421	chr1:113089696	T/C	cg22162597	chr1:113214053	CAPZA1	0.63	5.07	0.46	1.94e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg15592062	chr6:167189543	RPS6KA2	0.49	4.93	0.45	3.47e-6	Crohn's disease;
THYM	cis	rs7973719	0.833	rs3825405	chr12:7360143	G/T	cg07052231	chr12:7363540	PEX5	0.61	5.26	0.48	8.71e-7	IgG glycosylation;
THYM	cis	rs7843479	0.965	rs3816786	chr8:21860425	A/T	cg17168535	chr8:21777572	XPO7	0.62	4.67	0.43	9.86e-6	Mean corpuscular volume;
THYM	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg05347473	chr6:146136440	FBXO30	0.8	7.14	0.59	1.83e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs66731853	0.769	rs477679	chr1:20894618	A/G	cg04087271	chr1:20915334	CDA	0.83	6.04	0.53	2.99e-8	Mean corpuscular volume;
THYM	cis	rs7107174	1.000	rs10899453	chr11:77997482	A/C	cg02023728	chr11:77925099	USP35	0.68	6.05	0.53	2.9e-8	Testicular germ cell tumor;
THYM	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg10911889	chr6:126070802	HEY2	0.57	4.54	0.42	1.63e-5	Brugada syndrome;
THYM	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg10047753	chr17:41438598	NA	1.18	11.26	0.76	3.4e-19	Menopause (age at onset);
THYM	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs28795989	0.896	rs7441569	chr4:7887548	A/G	cg12728606	chr4:7903970	AFAP1	0.44	4.64	0.43	1.09e-5	Intraocular pressure;
THYM	cis	rs193541	0.509	rs10054392	chr5:122228566	C/G	cg19808643	chr5:122110361	SNX2	-0.63	-5.28	-0.48	8.32e-7	Glucose homeostasis traits;
THYM	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg06481639	chr22:41940642	POLR3H	-0.74	-4.85	-0.45	4.81e-6	Vitiligo;
THYM	cis	rs34779708	0.966	rs35777088	chr10:35409048	T/C	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	trans	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg17105886	chr17:28927953	LRRC37B2	1.16	6.57	0.56	2.67e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg00277334	chr10:82204260	NA	-0.53	-5.41	-0.49	4.75e-7	Post bronchodilator FEV1;
THYM	cis	rs9527	0.535	rs4917999	chr10:104963051	C/G	cg04362960	chr10:104952993	NT5C2	-0.63	-4.59	-0.43	1.35e-5	Arsenic metabolism;
THYM	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.1	12.7	0.79	3.51e-22	Intelligence (multi-trait analysis);
THYM	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg22709100	chr7:91322751	NA	0.6	4.7	0.43	8.94e-6	Breast cancer;
THYM	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg06766960	chr11:133703094	NA	-0.62	-5.61	-0.5	2e-7	Childhood ear infection;
THYM	cis	rs10979	1.000	rs9376760	chr6:143886969	C/T	cg25407410	chr6:143891975	LOC285740	-0.64	-5.49	-0.49	3.38e-7	Hypospadias;
THYM	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	trans	rs9951602	0.512	rs4799247	chr18:76653449	G/A	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs3087591	0.960	rs2953012	chr17:29496486	A/G	cg24425628	chr17:29625626	OMG;NF1	0.66	5.79	0.51	9.11e-8	Hip circumference;
THYM	cis	rs757110	0.745	rs2074311	chr11:17421860	A/G	cg15432903	chr11:17409602	KCNJ11	0.56	6.37	0.55	6.73e-9	Type 2 diabetes;
THYM	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.66	8.96	0.68	2.76e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs476633	0.708	rs11857484	chr15:41441734	G/T	cg21153102	chr15:41252147	NA	0.59	4.61	0.43	1.26e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs2294693	0.853	rs9296350	chr6:40977623	G/A	cg14769373	chr6:40998127	UNC5CL	-0.57	-4.61	-0.43	1.28e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg10802521	chr3:52805072	NEK4	-0.71	-6.18	-0.54	1.57e-8	Bipolar disorder;
THYM	cis	rs7089973	0.872	rs7909657	chr10:116629096	C/G	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.14	-0.47	1.5e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs2276314	0.857	rs62101394	chr18:33592299	C/T	cg19628046	chr18:33552617	C18orf21	0.74	5.43	0.49	4.29e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7580658	0.891	rs3768866	chr2:128045415	G/A	cg10021288	chr2:128175891	PROC	-0.78	-6.82	-0.57	8.26e-10	Protein C levels;
THYM	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.71	5.44	0.49	4.19e-7	Height;
THYM	cis	rs1538970	0.816	rs34673142	chr1:45985561	G/A	cg05343316	chr1:45956843	TESK2	0.8	4.98	0.46	2.82e-6	Platelet count;
THYM	cis	rs1847202	0.517	rs13062803	chr3:72951840	T/A	cg25664220	chr3:72788482	NA	-0.67	-5.01	-0.46	2.48e-6	Motion sickness;
THYM	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg16405210	chr4:1374714	KIAA1530	-1.11	-10.71	-0.74	5.14e-18	Longevity;
THYM	cis	rs6032067	0.929	rs17424578	chr20:43806321	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs11225247	1.000	rs1058606	chr11:102267098	A/T	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg27446573	chr6:127587934	RNF146	0.74	6.53	0.56	3.27e-9	Breast cancer;
THYM	cis	rs4474465	0.850	rs10899528	chr11:78207686	T/C	cg19901956	chr11:77921274	USP35	0.67	4.94	0.45	3.29e-6	Alzheimer's disease (survival time);
THYM	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg09021430	chr5:549028	NA	-0.72	-5.32	-0.48	6.89e-7	Ulcerative colitis;
THYM	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg14019146	chr3:50243930	SLC38A3	-0.58	-4.89	-0.45	4.06e-6	Body mass index;
THYM	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg17509989	chr5:176798049	RGS14	0.64	5.87	0.52	6.43e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg09085632	chr11:111637200	PPP2R1B	1.19	12.69	0.79	3.69e-22	Primary sclerosing cholangitis;
THYM	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.75	-5.87	-0.52	6.25e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg21862992	chr11:68658383	NA	0.24	4.52	0.42	1.78e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11105298	0.891	rs10858854	chr12:89835728	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.82	-5.06	-0.46	2.06e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	5.78	0.51	9.52e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg24818145	chr4:99064322	C4orf37	0.66	5.05	0.46	2.11e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs950880	0.645	rs4851006	chr2:103024738	T/A	cg03938978	chr2:103052716	IL18RAP	-0.53	-4.62	-0.43	1.2e-5	Serum protein levels (sST2);
THYM	cis	rs9500256	0.903	rs726783	chr6:58332861	A/C	cg16251399	chr6:58287822	GUSBL2	0.72	6.0	0.52	3.54e-8	Eosinophilic esophagitis (pediatric);
THYM	cis	rs2495707	0.624	rs10883518	chr10:102416555	C/A	cg07099331	chr10:102419617	NA	-0.46	-5.11	-0.46	1.65e-6	Body mass index;
THYM	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg06074448	chr4:187884817	NA	-1.02	-13.05	-0.8	6.55e-23	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs883115	0.748	rs10799588	chr1:224819109	A/G	cg01808320	chr1:224927238	CNIH3	-0.58	-4.81	-0.44	5.76e-6	Cancer;
THYM	cis	rs6988636	1.000	rs58189203	chr8:124184739	G/T	cg22384356	chr8:124195192	FAM83A	-0.86	-5.15	-0.47	1.41e-6	Urinary uromodulin levels;
THYM	cis	rs289828	0.868	rs10169816	chr2:152139271	C/T	cg05960677	chr2:152117363	RBM43	0.61	6.05	0.53	2.89e-8	Blood protein levels;
THYM	cis	rs7072216	0.763	rs2274245	chr10:100175082	C/T	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg21775007	chr8:11205619	TDH	-0.73	-6.0	-0.52	3.51e-8	Retinal vascular caliber;
THYM	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs7267979	1.000	rs2482930	chr20:25334115	G/C	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.74	5.89	0.52	5.86e-8	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs7043114	0.525	rs7850432	chr9:95130510	G/A	cg14631576	chr9:95140430	CENPP	-0.86	-9.03	-0.68	1.97e-14	Height;
THYM	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.43	1.27e-5	Breast cancer;
THYM	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.17	0.64	1.34e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7572733	0.515	rs6752458	chr2:198835106	G/T	cg00792783	chr2:198669748	PLCL1	0.82	5.75	0.51	1.08e-7	Dermatomyositis;
THYM	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg18132916	chr6:79620363	NA	-0.54	-4.78	-0.44	6.44e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6430585	0.528	rs6430594	chr2:136719173	C/T	cg20242066	chr2:136595261	LCT	-0.5	-4.86	-0.45	4.68e-6	Corneal structure;
THYM	cis	rs17253792	0.822	rs112739186	chr14:56065167	A/T	cg01858014	chr14:56050164	KTN1	-1.24	-5.01	-0.46	2.56e-6	Putamen volume;
THYM	cis	rs4077515	0.874	rs35670379	chr9:139270606	T/C	cg14115884	chr9:139300582	SDCCAG3	0.76	8.2	0.64	1.15e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg05043794	chr9:111880884	C9orf5	-0.43	-6.35	-0.55	7.29e-9	Menarche (age at onset);
THYM	cis	rs714027	1.000	rs9614090	chr22:30269907	T/A	cg11564601	chr22:30592435	NA	0.3	5.38	0.48	5.35e-7	Lymphocyte counts;
THYM	cis	rs11645898	0.748	rs72791112	chr16:72204069	T/A	cg14768367	chr16:72042858	DHODH	-0.67	-4.85	-0.45	4.88e-6	Blood protein levels;
THYM	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg05025164	chr4:1340916	KIAA1530	0.9	7.1	0.59	2.23e-10	Longevity;
THYM	cis	rs4273100	0.646	rs4924987	chr17:19247075	G/A	cg25447019	chr17:19030144	GRAPL	0.79	6.24	0.54	1.2e-8	Schizophrenia;
THYM	cis	rs10779751	0.690	rs2791659	chr1:11126569	C/A	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg03476357	chr21:30257390	N6AMT1	-0.61	-4.72	-0.44	8.17e-6	Dental caries;
THYM	cis	rs4332037	0.539	rs4719416	chr7:2106608	G/A	cg06789500	chr7:2109450	MAD1L1	-0.69	-4.9	-0.45	3.86e-6	Bipolar disorder;
THYM	cis	rs13064411	0.518	rs6769604	chr3:113185064	A/G	cg18753928	chr3:113234510	CCDC52	-0.78	-7.16	-0.59	1.68e-10	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs9457247	0.515	rs1951459	chr6:167402536	G/A	cg23791538	chr6:167370224	RNASET2	0.83	7.32	0.6	7.9e-11	Crohn's disease;
THYM	cis	rs7149242	0.697	rs12881760	chr14:101176335	G/C	cg18089426	chr14:101175970	NA	-0.57	-5.43	-0.49	4.23e-7	Platelet count;
THYM	cis	rs10924970	0.967	rs1933246	chr1:235391446	T/C	cg26050004	chr1:235667680	B3GALNT2	0.6	4.5	0.42	1.92e-5	Asthma;
THYM	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03517284	chr6:25882590	NA	-1.19	-12.3	-0.78	2.31e-21	Uric acid levels;
THYM	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg22907277	chr7:1156413	C7orf50	0.92	8.57	0.66	1.89e-13	Longevity;Endometriosis;
THYM	cis	rs10779751	1.000	rs4845982	chr1:11271576	T/C	cg08854313	chr1:11322531	MTOR	0.89	7.6	0.62	2.03e-11	Body mass index;
THYM	cis	rs1278352	0.660	rs1278344	chr10:127771424	A/G	cg08295661	chr10:127769903	ADAM12	-0.53	-5.35	-0.48	6.07e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs2299587	0.573	rs6986123	chr8:17888073	G/A	cg01800426	chr8:17659068	MTUS1	-0.56	-4.51	-0.42	1.83e-5	Economic and political preferences;
THYM	cis	rs240764	0.746	rs240153	chr6:101067135	A/C	cg21058520	chr6:100914733	NA	-0.57	-5.02	-0.46	2.39e-6	Neuroticism;
THYM	cis	rs273218	1.000	rs274366	chr5:53374636	C/G	ch.5.1024479R	chr5:53302184	ARL15	0.93	7.97	0.63	3.55e-12	Migraine;
THYM	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg25817165	chr18:72167213	CNDP2	-0.98	-10.2	-0.72	6.18e-17	Refractive error;
THYM	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg03476357	chr21:30257390	N6AMT1	-0.59	-4.6	-0.43	1.31e-5	Dental caries;
THYM	cis	rs11731175	1.000	rs11731095	chr4:189861010	G/C	cg00431894	chr4:189871012	NA	-0.8	-6.01	-0.53	3.35e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.86	-5.67	-0.5	1.56e-7	Body mass index;
THYM	cis	rs747334	0.846	rs1418815	chr10:92726054	G/C	cg07620928	chr10:92689909	NA	0.57	5.04	0.46	2.25e-6	Fibroblast growth factor basic levels;
THYM	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg15536230	chr21:44985092	HSF2BP	-0.41	-4.81	-0.44	5.64e-6	Mean corpuscular volume;
THYM	cis	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg07460842	chr6:66804631	NA	-1.22	-15.37	-0.84	1.64e-27	Exhaled nitric oxide output;
THYM	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11711311	0.668	rs11718061	chr3:113341826	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.53	4.47	0.42	2.15e-5	IgG glycosylation;
THYM	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.57	-4.73	-0.44	7.79e-6	Hip circumference adjusted for BMI;
THYM	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Electroencephalogram traits;
THYM	cis	rs7216064	1.000	rs4791299	chr17:65930937	A/G	cg12091567	chr17:66097778	LOC651250	-0.73	-5.18	-0.47	1.25e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs2806561	0.929	rs641452	chr1:23538386	A/G	cg08872493	chr1:23521417	HTR1D	0.37	4.61	0.43	1.26e-5	Height;
THYM	cis	rs1062746	0.528	rs891092	chr16:87338226	G/A	cg02258303	chr16:87377426	FBXO31	-0.63	-5.28	-0.48	8.23e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg26850624	chr5:429559	AHRR	-0.72	-5.68	-0.5	1.45e-7	Cystic fibrosis severity;
THYM	trans	rs4596713	0.508	rs4745656	chr9:71782556	A/G	cg16512924	chr15:28394682	HERC2	0.8	6.84	0.57	7.64e-10	Headache;
THYM	cis	rs4481887	1.000	rs10888351	chr1:248451608	G/A	cg13385794	chr1:248469461	NA	0.69	4.71	0.43	8.6e-6	Common traits (Other);
THYM	cis	rs981844	0.712	rs3925717	chr4:154750917	C/G	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg00631329	chr6:26305371	NA	-0.61	-7.35	-0.6	6.96e-11	Educational attainment;
THYM	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg02569458	chr12:86230093	RASSF9	0.62	5.34	0.48	6.31e-7	Major depressive disorder;
THYM	cis	rs10504073	0.647	rs12549138	chr8:50007203	C/T	cg00325661	chr8:49890786	NA	0.93	8.63	0.66	1.37e-13	Blood metabolite ratios;
THYM	cis	rs12310956	0.510	rs6488178	chr12:33885251	C/G	cg10856724	chr12:34555212	NA	-0.65	-5.89	-0.52	5.95e-8	Morning vs. evening chronotype;
THYM	cis	rs17598306	0.873	rs2894085	chr7:96584407	G/C	cg13449377	chr7:96631089	DLX6AS	0.76	4.78	0.44	6.38e-6	Radiation response;
THYM	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.58	-5.59	-0.5	2.13e-7	Caffeine consumption;
THYM	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11890956	chr21:40555474	PSMG1	-0.9	-9.57	-0.7	1.4e-15	Cognitive function;
THYM	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg09549813	chr16:4587862	C16orf5	-0.59	-6.65	-0.56	1.84e-9	Schizophrenia;
THYM	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg17264618	chr3:40429014	ENTPD3	-0.53	-5.15	-0.47	1.38e-6	Renal cell carcinoma;
THYM	trans	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.18	0.64	1.26e-12	Corneal astigmatism;
THYM	cis	rs7512552	0.966	rs10788873	chr1:150250534	T/A	cg15654264	chr1:150340011	RPRD2	-0.51	-6.04	-0.53	3.05e-8	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2898681	0.739	rs1047959	chr4:53739856	C/G	cg00338735	chr4:53728038	RASL11B	0.53	4.66	0.43	1.01e-5	Optic nerve measurement (cup area);
THYM	cis	rs17608059	0.679	rs9898056	chr17:13951966	C/G	cg11395062	chr17:14139857	CDRT15	0.64	5.85	0.51	7.1e-8	Temperament;
THYM	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs6531656	0.632	rs337629	chr4:38635358	A/G	cg24279243	chr4:38676559	KLF3	0.81	6.99	0.58	3.82e-10	Lymphocyte counts;
THYM	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg09307838	chr4:120376055	NA	-0.69	-5.17	-0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs921968	0.528	rs35695178	chr2:219589164	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg00376283	chr12:123451042	ABCB9	0.68	5.22	0.47	1.04e-6	Neutrophil percentage of white cells;
THYM	cis	rs6732160	0.691	rs11886257	chr2:73416873	C/T	cg24220031	chr2:73402428	NA	-0.78	-9.27	-0.69	6.15e-15	Intelligence (multi-trait analysis);
THYM	cis	rs3741151	0.773	rs79994237	chr11:73147974	T/C	cg17517138	chr11:73019481	ARHGEF17	0.94	5.48	0.49	3.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs1050631	0.592	rs1785903	chr18:33711642	G/C	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.6	4.69	0.43	9.09e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg00271210	chr6:167070053	RPS6KA2	0.72	7.93	0.63	4.27e-12	Crohn's disease;
THYM	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg05802129	chr4:122689817	NA	-0.59	-4.65	-0.43	1.08e-5	Type 2 diabetes;
THYM	cis	rs17209837	0.607	rs2270187	chr7:87080698	T/C	cg04996195	chr7:87105398	ABCB4	0.63	4.79	0.44	6.03e-6	Gallbladder cancer;
THYM	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg07606381	chr6:8435919	SLC35B3	-0.6	-4.47	-0.42	2.12e-5	Motion sickness;
THYM	cis	rs3112255	0.901	rs2942890	chr2:101293283	A/G	cg01042948	chr2:101319752	NA	0.7	5.96	0.52	4.3e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2235649	0.833	rs9925460	chr16:1849943	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.44	-0.49	4.11e-7	Blood metabolite levels;
THYM	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg04518342	chr5:131593106	PDLIM4	0.47	5.19	0.47	1.2e-6	Blood metabolite levels;
THYM	cis	rs8077889	1.000	rs17742905	chr17:41891143	C/A	cg26893861	chr17:41843967	DUSP3	1.09	10.05	0.72	1.3e-16	Triglycerides;
THYM	cis	rs7429990	0.965	rs4858810	chr3:48043737	G/A	cg02219026	chr3:48282209	ZNF589	0.64	4.71	0.44	8.47e-6	Educational attainment (years of education);
THYM	cis	rs6754311	0.906	rs4954387	chr2:136784344	A/G	cg07169764	chr2:136633963	MCM6	0.72	5.75	0.51	1.09e-7	Mosquito bite size;
THYM	trans	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Bladder cancer;
THYM	cis	rs2921036	0.545	rs4840975	chr8:8363258	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-4.5	-0.42	1.95e-5	Neuroticism;
THYM	cis	rs4936894	0.500	rs12807551	chr11:124129518	A/G	cg23571170	chr11:124180298	OR8D1	-0.51	-4.52	-0.42	1.8e-5	Aging (time to death);
THYM	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg04398451	chr17:18023971	MYO15A	0.95	10.77	0.74	3.86e-18	Total body bone mineral density;
THYM	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg20290983	chr6:43655470	MRPS18A	1.4	15.53	0.85	8.27e-28	IgG glycosylation;
THYM	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg08772003	chr10:104629869	AS3MT	0.68	6.5	0.55	3.7e-9	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs11031096	0.502	rs1442726	chr11:4094748	G/C	cg18678763	chr11:4115507	RRM1	-0.43	-5.59	-0.5	2.14e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg12963246	chr6:28129442	ZNF389	0.77	6.4	0.55	5.74e-9	Parkinson's disease;
THYM	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg13010199	chr12:38710504	ALG10B	-0.57	-4.99	-0.46	2.74e-6	Heart rate;
THYM	cis	rs12701220	0.503	rs12531999	chr7:1181601	T/A	cg00990874	chr7:1149470	C7orf50	-0.6	-4.51	-0.42	1.89e-5	Bronchopulmonary dysplasia;
THYM	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg00814883	chr7:100076585	TSC22D4	-1.0	-6.8	-0.57	9.22e-10	Platelet count;
THYM	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg13395646	chr4:1353034	KIAA1530	-0.58	-5.47	-0.49	3.57e-7	Obesity-related traits;
THYM	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	7.22	0.6	1.3e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs4731207	0.596	rs922711	chr7:124604304	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg13447684	chr7:1895903	MAD1L1	-0.5	-4.54	-0.42	1.66e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg04234412	chr22:24373322	LOC391322	-0.91	-8.84	-0.67	4.95e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11048434	0.761	rs12824380	chr12:9132017	A/G	cg26114124	chr12:9217669	LOC144571	0.46	4.57	0.42	1.44e-5	Sjögren's syndrome;
THYM	cis	rs9527	0.615	rs36045108	chr10:104697929	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-5.01	-0.46	2.51e-6	Arsenic metabolism;
THYM	cis	rs2637266	0.935	rs2252661	chr10:78404793	A/G	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs10752881	0.839	rs2093983	chr1:183094210	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Colorectal cancer;
THYM	cis	rs10463554	0.963	rs26524	chr5:102456304	A/G	cg23492399	chr5:102201601	PAM	-0.7	-5.11	-0.46	1.69e-6	Parkinson's disease;
THYM	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg05660106	chr1:15850417	CASP9	0.71	5.75	0.51	1.07e-7	Systolic blood pressure;
THYM	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg11764359	chr7:65958608	NA	0.64	5.08	0.46	1.88e-6	Aortic root size;
THYM	cis	rs7106204	0.748	rs12293729	chr11:24224679	A/G	ch.11.24196551F	chr11:24239977	NA	1.04	7.55	0.61	2.59e-11	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg13319975	chr6:146136371	FBXO30	-0.61	-4.96	-0.45	3.05e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2235573	0.657	rs5756890	chr22:38445400	C/A	cg19171272	chr22:38449367	NA	-0.51	-5.38	-0.48	5.38e-7	Glioblastoma;Glioma;
THYM	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg19346786	chr7:2764209	NA	-0.58	-4.98	-0.45	2.88e-6	Height;
THYM	cis	rs11997175	0.646	rs7386741	chr8:33769709	A/G	ch.8.33884649F	chr8:33765107	NA	0.79	5.45	0.49	4e-7	Body mass index;
THYM	cis	rs12594515	0.967	rs12595138	chr15:45986108	G/C	cg01629716	chr15:45996671	NA	0.54	5.52	0.49	2.91e-7	Waist circumference;Weight;
THYM	cis	rs2282032	0.527	rs57011283	chr14:90767165	G/T	cg14092571	chr14:90743983	NA	0.64	6.32	0.54	8.28e-9	Longevity;
THYM	cis	rs11622475	0.580	rs36026329	chr14:104351661	T/A	cg12183467	chr14:104352244	NA	-0.64	-5.46	-0.49	3.74e-7	Bipolar disorder;
THYM	cis	rs986417	1.000	rs6573318	chr14:61087985	A/G	cg27398547	chr14:60952738	C14orf39	1.26	6.1	0.53	2.29e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.59	-7.6	-0.62	2.04e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg15744005	chr10:104629667	AS3MT	-0.83	-7.67	-0.62	1.47e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs600231	0.708	rs1784100	chr11:65249227	T/C	cg17120908	chr11:65337727	SSSCA1	-0.62	-4.77	-0.44	6.53e-6	Bone mineral density;
THYM	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs9902453	0.817	rs4794861	chr17:28183174	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.75	5.26	0.47	9.07e-7	Coffee consumption (cups per day);
THYM	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg14004847	chr7:1930337	MAD1L1	-0.61	-4.75	-0.44	7.24e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs35883536	0.935	rs3904674	chr1:101138932	C/T	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg11327659	chr7:150037044	RARRES2	-0.36	-4.57	-0.42	1.48e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs11948739	0.501	rs3981332	chr5:130372203	A/T	cg08523029	chr5:130500466	HINT1	-0.85	-5.98	-0.52	3.88e-8	Pediatric bone mineral content (hip);
THYM	cis	rs600550	0.588	rs7103808	chr11:60078176	A/G	cg05040360	chr11:60102449	MS4A6E	-0.49	-4.55	-0.42	1.58e-5	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg11812906	chr14:75593930	NEK9	-0.81	-7.31	-0.6	8.48e-11	Height;
THYM	cis	rs9479482	0.686	rs9397137	chr6:150382002	G/A	cg25797454	chr6:150327115	RAET1K	0.48	4.77	0.44	6.66e-6	Alopecia areata;
THYM	cis	rs1003719	0.788	rs2835579	chr21:38457965	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.71	5.03	0.46	2.32e-6	Eye color traits;
THYM	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg25072359	chr17:41440525	NA	0.7	4.84	0.44	5e-6	Menopause (age at onset);
THYM	cis	rs11031096	0.503	rs67065286	chr11:4105273	A/C	cg18678763	chr11:4115507	RRM1	-0.43	-5.52	-0.49	2.97e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg02070205	chr10:30722105	MAP3K8	-0.67	-6.09	-0.53	2.44e-8	Inflammatory bowel disease;
THYM	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4731207	0.535	rs1351471	chr7:124672015	A/T	cg05285228	chr7:124571219	POT1	-0.65	-5.0	-0.46	2.64e-6	Cutaneous malignant melanoma;
THYM	cis	rs9810089	0.814	rs834305	chr3:136119354	C/T	cg12473912	chr3:136751656	NA	0.62	5.29	0.48	7.77e-7	Gestational age at birth (child effect);
THYM	cis	rs2139634	0.965	rs11130093	chr3:46540612	A/T	cg02332537	chr3:46540019	RTP3	-0.51	-5.31	-0.48	7.11e-7	Cerebrospinal fluid biomarker levels;
THYM	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg22764044	chr5:178986830	RUFY1	0.49	4.96	0.45	3.1e-6	Lung cancer;
THYM	cis	rs6550435	0.527	rs6769400	chr3:36958995	C/T	cg21328643	chr3:37258149	NA	-0.49	-4.82	-0.44	5.52e-6	Schizophrenia;Bipolar disorder;
THYM	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg15838173	chr10:75533400	FUT11	-0.55	-5.4	-0.48	4.87e-7	Inflammatory bowel disease;
THYM	cis	rs7264396	1.000	rs224409	chr20:34124920	A/T	cg26038318	chr20:34205095	SPAG4	0.57	4.51	0.42	1.86e-5	Total cholesterol levels;
THYM	cis	rs7211079	0.912	rs4889831	chr17:78114653	C/T	cg09238746	chr17:78121135	EIF4A3	-0.74	-4.64	-0.43	1.1e-5	Myocardial infarction;
THYM	cis	rs6665290	0.904	rs2297416	chr1:227172935	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.15	-15.98	-0.85	1.12e-28	Myeloid white cell count;
THYM	cis	rs1348850	0.837	rs12619074	chr2:178472336	G/A	cg27490568	chr2:178487706	NA	0.61	5.4	0.48	4.89e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg08847533	chr14:75593920	NEK9	-0.98	-10.48	-0.73	1.56e-17	Height;
THYM	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg02725872	chr8:58115012	NA	-1.1	-6.73	-0.57	1.29e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs11648796	0.765	rs3829492	chr16:781633	G/A	cg16899442	chr16:776458	CCDC78;HAGHL	0.45	4.65	0.43	1.09e-5	Height;
THYM	cis	rs6496667	0.779	rs8032687	chr15:90945186	C/T	cg22089800	chr15:90895588	ZNF774	0.76	4.9	0.45	4.01e-6	Rheumatoid arthritis;
THYM	cis	rs12410462	0.681	rs6681096	chr1:227609720	G/A	cg23173402	chr1:227635558	NA	0.67	4.75	0.44	7.32e-6	Major depressive disorder;
THYM	cis	rs7586879	0.662	rs2384059	chr2:25100338	C/T	cg15423357	chr2:25149977	NA	0.68	7.39	0.6	5.58e-11	Body mass index;
THYM	cis	rs9563576	0.709	rs2321151	chr13:58521542	C/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.65	4.82	0.44	5.54e-6	Body mass index;
THYM	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg06850241	chr22:41845214	NA	0.54	4.6	0.43	1.33e-5	Vitiligo;
THYM	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12310956	0.532	rs10844720	chr12:33987859	G/T	cg06521331	chr12:34319734	NA	-0.92	-8.57	-0.66	1.89e-13	Morning vs. evening chronotype;
THYM	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg17863274	chr19:49399704	TULP2	-1.01	-6.47	-0.55	4.29e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg05368731	chr17:41323189	NBR1	1.28	11.44	0.76	1.46e-19	Menopause (age at onset);
THYM	cis	rs7131987	0.617	rs3764953	chr12:29502236	T/C	cg09582351	chr12:29534625	ERGIC2	-0.59	-5.14	-0.47	1.49e-6	QT interval;
THYM	cis	rs9527	0.590	rs1926037	chr10:104878010	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06850241	chr22:41845214	NA	0.59	5.16	0.47	1.37e-6	Vitiligo;
THYM	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12667521	chr19:29218732	NA	0.89	8.17	0.64	1.34e-12	Methadone dose in opioid dependence;
THYM	cis	rs8020441	0.541	rs59857560	chr14:51158851	G/A	cg04730355	chr14:51134070	SAV1	1.01	6.03	0.53	3.14e-8	Cognitive performance;
THYM	cis	rs11997175	0.624	rs7819074	chr8:33682472	C/T	ch.8.33884649F	chr8:33765107	NA	0.66	5.03	0.46	2.33e-6	Body mass index;
THYM	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs66887589	0.720	rs11724758	chr4:120239878	G/A	cg13609457	chr4:120235615	NA	0.52	5.23	0.47	1.02e-6	Diastolic blood pressure;
THYM	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg15691649	chr6:25882328	NA	-0.65	-5.01	-0.46	2.48e-6	Blood metabolite levels;
THYM	cis	rs7131987	0.801	rs6487804	chr12:29454934	G/A	cg09582351	chr12:29534625	ERGIC2	-0.52	-4.95	-0.45	3.25e-6	QT interval;
THYM	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	7.98	0.63	3.34e-12	Platelet count;
THYM	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg16928487	chr17:17741425	SREBF1	0.51	5.14	0.47	1.46e-6	Strep throat;
THYM	cis	rs9326248	0.520	rs2735183	chr11:117015195	C/T	cg20608306	chr11:116969690	SIK3	0.53	6.84	0.57	7.5e-10	Blood protein levels;
THYM	cis	rs9807989	0.811	rs4485584	chr2:102970750	T/C	cg03938978	chr2:103052716	IL18RAP	0.63	6.46	0.55	4.36e-9	Asthma;
THYM	cis	rs2075230	0.705	rs1641536	chr17:7545984	T/C	cg27413385	chr17:7515425	FXR2	-0.35	-5.06	-0.46	2.06e-6	Hormone measurements;
THYM	trans	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg20587970	chr11:113659929	NA	-1.26	-9.01	-0.68	2.16e-14	Hip circumference adjusted for BMI;
THYM	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.58	0.43	1.41e-5	Bipolar disorder;
THYM	cis	rs3126085	0.935	rs10888471	chr1:152200849	G/T	cg26020982	chr1:152196106	HRNR	-0.38	-5.1	-0.46	1.74e-6	Atopic dermatitis;
THYM	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg27494647	chr7:150038898	RARRES2	0.48	5.97	0.52	4.16e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3008870	0.920	rs975452	chr1:67480190	A/T	cg02640540	chr1:67518911	SLC35D1	0.65	4.83	0.44	5.32e-6	Lymphocyte percentage of white cells;
THYM	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.7	0.71	7.32e-16	Colorectal cancer;
THYM	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg25072359	chr17:41440525	NA	0.7	4.91	0.45	3.75e-6	Menopause (age at onset);
THYM	cis	rs9653442	1.000	rs11676922	chr2:100806940	T/A	cg07810366	chr2:100720526	AFF3	-0.39	-5.48	-0.49	3.52e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs7542375	0.655	rs11590376	chr1:221086484	G/A	cg16008148	chr1:221062819	NA	0.57	5.9	0.52	5.45e-8	Obesity-related traits;
THYM	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg09549813	chr16:4587862	C16orf5	-0.59	-6.12	-0.53	2.04e-8	Schizophrenia;
THYM	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.69e-11	Aortic root size;
THYM	cis	rs9880211	1.000	rs6768743	chr3:136205007	C/T	cg21827317	chr3:136751795	NA	0.67	4.5	0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs2898681	1.000	rs2411281	chr4:53757057	G/A	cg00791764	chr4:53727839	RASL11B	0.48	5.77	0.51	1e-7	Optic nerve measurement (cup area);
THYM	cis	rs9902453	0.845	rs3102558	chr17:28023142	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.85	0.45	4.84e-6	Coffee consumption (cups per day);
THYM	cis	rs1215050	0.740	rs783941	chr4:99008235	T/C	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs13082711	0.911	rs7644466	chr3:27515271	C/G	cg02860705	chr3:27208620	NA	0.72	5.15	0.47	1.39e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs3126085	0.935	rs10888471	chr1:152200849	G/T	cg10321714	chr1:152280068	FLG	-0.67	-4.81	-0.44	5.71e-6	Atopic dermatitis;
THYM	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2730245	0.527	rs2527187	chr7:158716912	T/C	cg11984989	chr7:158649758	WDR60	-1.02	-8.64	-0.66	1.3e-13	Height;
THYM	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg00376283	chr12:123451042	ABCB9	0.68	5.22	0.47	1.04e-6	Neutrophil percentage of white cells;
THYM	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg27432699	chr2:27873401	GPN1	0.76	6.79	0.57	9.45e-10	Oral cavity cancer;
THYM	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Body mass index;
THYM	cis	rs782590	0.967	rs17278044	chr2:55748217	G/C	cg18811423	chr2:55921094	PNPT1	0.74	7.05	0.59	2.83e-10	Metabolic syndrome;
THYM	cis	rs11997175	0.624	rs4733175	chr8:33679744	T/A	ch.8.33884649F	chr8:33765107	NA	0.66	5.0	0.46	2.57e-6	Body mass index;
THYM	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg26384229	chr12:38710491	ALG10B	-0.72	-5.68	-0.5	1.5e-7	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg20608306	chr11:116969690	SIK3	0.53	5.78	0.51	9.3e-8	Blood protein levels;
THYM	cis	rs9462846	0.853	rs7765132	chr6:42872829	G/A	cg09436375	chr6:42928200	GNMT	-0.37	-4.51	-0.42	1.82e-5	Blood protein levels;
THYM	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.79	-6.58	-0.56	2.59e-9	Intelligence (multi-trait analysis);
THYM	cis	rs11264213	0.901	rs10796876	chr1:36424985	A/G	cg27506609	chr1:36549197	TEKT2	0.92	4.83	0.44	5.3e-6	Schizophrenia;
THYM	cis	rs7107174	1.000	rs10899470	chr11:78020052	C/T	cg02023728	chr11:77925099	USP35	0.65	5.83	0.51	7.52e-8	Testicular germ cell tumor;
THYM	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs4731207	0.698	rs10236403	chr7:124539542	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs34779708	0.931	rs17591135	chr10:35465190	T/A	cg03585969	chr10:35415529	CREM	0.65	4.51	0.42	1.87e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs61931739	1.000	rs12305700	chr12:34036332	T/C	cg06521331	chr12:34319734	NA	0.61	4.76	0.44	6.95e-6	Morning vs. evening chronotype;
THYM	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg08999081	chr20:33150536	PIGU	0.63	5.12	0.46	1.61e-6	Coronary artery disease;
THYM	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg16325326	chr1:53192061	ZYG11B	-0.79	-6.42	-0.55	5.39e-9	Monocyte count;
THYM	cis	rs6665290	0.904	rs11586604	chr1:227183865	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.13	-15.82	-0.85	2.26e-28	Myeloid white cell count;
THYM	cis	rs2692947	0.526	rs58719199	chr2:96578247	G/A	cg23100626	chr2:96804247	ASTL	0.41	5.16	0.47	1.34e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs9359856	0.510	rs6454775	chr6:90465000	A/T	cg13799429	chr6:90582589	CASP8AP2	0.85	8.18	0.64	1.27e-12	Bipolar disorder;
THYM	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg25811766	chr13:21894605	NA	0.8	5.02	0.46	2.42e-6	White matter hyperintensity burden;
THYM	cis	rs9611565	1.000	rs9611565	chr22:41767486	T/C	cg00256281	chr22:41985642	PMM1	0.56	4.7	0.43	8.64e-6	Vitiligo;
THYM	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg08132940	chr7:1081526	C7orf50	-1.16	-6.66	-0.56	1.78e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2075230	0.588	rs1641537	chr17:7545721	T/C	cg10509001	chr17:7553872	ATP1B2	-0.56	-4.52	-0.42	1.79e-5	Hormone measurements;
THYM	cis	rs9826463	0.582	rs55687115	chr3:142148372	G/A	cg20824294	chr3:142316082	PLS1	0.76	5.3	0.48	7.53e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs2505998	0.796	rs2505537	chr10:43592158	T/C	cg06632098	chr10:43605906	RET	-1.1	-10.64	-0.74	7.21e-18	Hirschsprung disease;
THYM	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg00071950	chr4:10020882	SLC2A9	0.7	7.29	0.6	9.04e-11	Bone mineral density;
THYM	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.5	0.42	1.93e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg19016782	chr12:123741754	C12orf65	-0.69	-4.47	-0.42	2.18e-5	Neutrophil percentage of white cells;
THYM	cis	rs757081	0.637	rs586785	chr11:17208714	T/C	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.55	-0.42	1.59e-5	Systolic blood pressure;
THYM	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg23791538	chr6:167370224	RNASET2	-0.59	-4.55	-0.42	1.6e-5	Crohn's disease;
THYM	cis	rs3750965	0.920	rs10896420	chr11:68863047	G/A	cg01403660	chr11:68851641	TPCN2	0.73	5.79	0.51	9.21e-8	Hair color;
THYM	cis	rs6674970	1.000	rs6656450	chr1:151089602	A/T	cg11822372	chr1:151115635	SEMA6C	0.72	4.93	0.45	3.53e-6	Childhood ear infection;
THYM	cis	rs4072705	0.615	rs4838189	chr9:127248926	C/A	cg13476313	chr9:127244764	NR5A1	0.39	5.88	0.52	6.05e-8	Menarche (age at onset);
THYM	cis	rs61931739	0.963	rs1817759	chr12:34101521	G/A	cg10856724	chr12:34555212	NA	0.61	4.98	0.46	2.8e-6	Morning vs. evening chronotype;
THYM	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs8049634	0.552	rs999781	chr16:84095254	C/G	cg04832210	chr16:84151246	MBTPS1	-0.48	-4.85	-0.45	4.82e-6	Small cell lung carcinoma;
THYM	cis	rs17407555	0.710	rs7696388	chr4:10272933	T/A	cg00071950	chr4:10020882	SLC2A9	0.51	4.83	0.44	5.23e-6	Schizophrenia (age at onset);
THYM	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg03388043	chr17:80084554	CCDC57	0.69	5.87	0.52	6.36e-8	Life satisfaction;
THYM	cis	rs9311676	0.609	rs1126551	chr3:58416535	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs7640424	0.929	rs17828045	chr3:107821546	A/C	cg09227934	chr3:107805635	CD47	-0.55	-4.77	-0.44	6.61e-6	Body mass index;
THYM	cis	rs11563648	0.517	rs4731353	chr7:127006237	C/T	cg23081781	chr7:127225937	GCC1	-0.34	-4.57	-0.42	1.45e-5	Resting heart rate;
THYM	cis	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg10856724	chr12:34555212	NA	-0.88	-8.25	-0.65	8.84e-13	Morning vs. evening chronotype;
THYM	cis	rs9649213	0.593	rs7803372	chr7:97992257	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1864400	0.690	rs7098237	chr10:43740513	T/A	cg06632098	chr10:43605906	RET	0.74	4.97	0.45	2.95e-6	Hirschsprung disease;
THYM	cis	rs8060598	1.000	rs34552113	chr16:50789250	G/C	cg05261686	chr16:50743296	NOD2	0.35	4.51	0.42	1.87e-5	Leprosy;
THYM	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.25	5.43	0.49	4.35e-7	Obesity-related traits;
THYM	cis	rs7224314	1.000	rs8075952	chr17:65381358	C/T	cg01507342	chr17:65387096	PITPNC1	-0.95	-10.71	-0.74	5.15e-18	Diisocyanate-induced asthma;
THYM	cis	rs6918586	0.658	rs198809	chr6:26128766	G/A	cg12310025	chr6:25882481	NA	0.68	5.56	0.5	2.47e-7	Schizophrenia;
THYM	cis	rs9875589	0.509	rs2731337	chr3:14091440	G/C	cg03204825	chr3:13978759	TPRXL	-0.51	-4.46	-0.42	2.26e-5	Ovarian reserve;
THYM	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg00129232	chr17:37814104	STARD3	-0.87	-7.03	-0.59	3.07e-10	Asthma;
THYM	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg08885076	chr2:99613938	TSGA10	-0.46	-4.63	-0.43	1.16e-5	Bipolar disorder;
THYM	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.82	-7.5	-0.61	3.29e-11	Schizophrenia;
THYM	cis	rs9992101	0.645	rs907446	chr4:77254804	C/T	cg20311846	chr4:77356250	SHROOM3	-0.54	-5.96	-0.52	4.32e-8	Creatinine levels;
THYM	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg25817165	chr18:72167213	CNDP2	-0.97	-10.17	-0.72	7.3e-17	Refractive error;
THYM	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg16586182	chr3:47516702	SCAP	-0.65	-5.62	-0.5	1.94e-7	Colorectal cancer;
THYM	cis	rs3008870	0.727	rs2755270	chr1:67474503	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.79	6.84	0.57	7.8e-10	Lymphocyte percentage of white cells;
THYM	cis	rs8133932	0.906	rs71324444	chr21:47198301	G/A	cg20357416	chr21:47294739	PCBP3	0.77	4.56	0.42	1.54e-5	Schizophrenia;
THYM	cis	rs7267979	1.000	rs12428	chr20:25433821	G/T	cg08601574	chr20:25228251	PYGB	-0.57	-4.65	-0.43	1.09e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg21237687	chr17:6899380	ALOX12	-0.77	-8.99	-0.68	2.42e-14	Tonsillectomy;
THYM	cis	rs8050907	0.744	rs8062952	chr16:4573229	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.13	4.76	0.44	6.97e-6	Obesity-related traits;
THYM	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg04546413	chr19:29218101	NA	1.01	7.34	0.6	7.07e-11	Methadone dose in opioid dependence;
THYM	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg13246856	chr1:44399776	ARTN	-0.51	-4.95	-0.45	3.16e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs77320796	1.000	rs61781289	chr1:40391255	C/T	cg05657805	chr1:40942785	ZNF642	0.78	4.63	0.43	1.18e-5	Platelet count;
THYM	cis	rs11048434	0.761	rs10842660	chr12:9138897	G/A	cg14913610	chr12:9142341	KLRG1	-0.29	-4.48	-0.42	2.11e-5	Sjögren's syndrome;
THYM	cis	rs1003719	0.762	rs2835590	chr21:38463406	A/G	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg17830980	chr10:43048298	ZNF37B	1.04	10.37	0.73	2.74e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.61	0.56	2.25e-9	Prudent dietary pattern;
THYM	cis	rs7926906	0.967	rs2213086	chr11:90528578	A/T	cg26138821	chr11:89956704	CHORDC1	-0.53	-4.89	-0.45	4.17e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7104764	0.957	rs58692051	chr11:207410	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	-1.11	-9.7	-0.71	7.11e-16	Menarche (age at onset);
THYM	cis	rs11948739	0.610	rs1363696	chr5:130378070	C/T	cg08523029	chr5:130500466	HINT1	0.77	5.33	0.48	6.72e-7	Pediatric bone mineral content (hip);
THYM	cis	rs12540874	0.728	rs3807563	chr7:50566390	C/T	cg18232548	chr7:50535776	DDC	-0.85	-6.97	-0.58	4.11e-10	Systemic sclerosis;
THYM	trans	rs12516208	0.579	rs10900710	chr5:115328625	G/A	cg27552493	chr12:62652662	NA	0.83	6.92	0.58	5.2e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
THYM	cis	rs853679	1.000	rs853694	chr6:28279100	A/T	cg23161317	chr6:28129485	ZNF389	0.73	4.75	0.44	7.33e-6	Depression;
THYM	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg18252515	chr7:66147081	NA	-0.73	-5.59	-0.5	2.21e-7	Aortic root size;
THYM	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.65	5.62	0.5	1.88e-7	Personality dimensions;
THYM	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	4.53	0.42	1.71e-5	Height;
THYM	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs800586	0.628	rs2737252	chr8:116663898	G/A	cg04656070	chr8:116661063	TRPS1	-0.56	-5.72	-0.51	1.21e-7	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2228479	0.850	rs3819569	chr16:89826336	G/C	cg06558623	chr16:89946397	TCF25	1.54	6.04	0.53	2.93e-8	Skin colour saturation;
THYM	cis	rs354225	0.544	rs10182538	chr2:54808251	T/A	cg23486701	chr2:54789491	SPTBN1	0.36	4.96	0.45	3.11e-6	Schizophrenia;
THYM	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg21724239	chr8:58056113	NA	0.78	5.37	0.48	5.53e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs9828933	0.577	rs832194	chr3:63857071	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	0.89	5.55	0.49	2.58e-7	Type 2 diabetes;
THYM	cis	rs3750965	0.920	rs11828017	chr11:68818617	A/G	cg01403660	chr11:68851641	TPCN2	0.66	5.47	0.49	3.69e-7	Hair color;
THYM	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg15691649	chr6:25882328	NA	-0.7	-5.47	-0.49	3.69e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2742234	0.518	rs2505514	chr10:43633248	A/G	cg06632098	chr10:43605906	RET	-0.77	-4.96	-0.45	3.09e-6	Hirschsprung disease;
THYM	cis	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg06521331	chr12:34319734	NA	-0.95	-9.14	-0.68	1.14e-14	Morning vs. evening chronotype;
THYM	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg17830980	chr10:43048298	ZNF37B	-1.01	-10.1	-0.72	1.02e-16	Extrinsic epigenetic age acceleration;
THYM	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs10857712	0.687	rs11101742	chr10:135224372	C/G	cg19899694	chr10:135237140	SPRN	0.57	4.78	0.44	6.42e-6	Systemic lupus erythematosus;
THYM	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	5.49	0.49	3.27e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs34375054	0.738	rs10773145	chr12:125625603	C/T	cg25124228	chr12:125621409	AACS	0.76	6.37	0.55	6.71e-9	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg24209194	chr3:40518798	ZNF619	-0.73	-6.19	-0.54	1.54e-8	Renal cell carcinoma;
THYM	cis	rs9649213	0.586	rs11768599	chr7:97974555	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.68	-5.75	-0.51	1.08e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg00376283	chr12:123451042	ABCB9	0.68	5.24	0.47	9.49e-7	Neutrophil percentage of white cells;
THYM	trans	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.47	0.49	3.63e-7	Bipolar disorder;
THYM	cis	rs7639513	0.767	rs7617041	chr3:12709167	A/G	cg23032965	chr3:12705835	RAF1	0.99	7.86	0.63	5.93e-12	Itch intensity from mosquito bite;
THYM	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs4851254	0.660	rs56037757	chr2:100690130	A/G	cg22139774	chr2:100720529	AFF3	-0.41	-4.69	-0.43	9.07e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg17173187	chr15:85201210	NMB	0.56	5.57	0.5	2.38e-7	Schizophrenia;
THYM	trans	rs4749080	0.573	rs2887177	chr10:26451645	T/G	cg00192819	chr18:76486611	NA	0.99	6.98	0.58	3.89e-10	Obesity-related traits;
THYM	cis	rs73416724	1.000	rs4714675	chr6:43287893	T/C	cg26312998	chr6:43337775	ZNF318	-0.99	-4.89	-0.45	4.17e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.66	-4.46	-0.42	2.25e-5	Body mass index (adult);
THYM	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg06600287	chr1:53387719	ECHDC2	-0.34	-5.37	-0.48	5.55e-7	Monocyte count;
THYM	cis	rs6754311	0.597	rs2278544	chr2:136546110	A/G	cg23851026	chr2:136556271	LCT	-0.56	-5.73	-0.51	1.2e-7	Mosquito bite size;
THYM	cis	rs34779708	0.931	rs4934702	chr10:35323074	T/C	cg03585969	chr10:35415529	CREM	0.64	4.5	0.42	1.93e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs1692120	0.545	rs11230768	chr11:61430471	G/A	cg19838087	chr11:61442541	NA	0.56	5.87	0.52	6.39e-8	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
THYM	trans	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17712092	chr4:129076599	LARP1B	-0.86	-7.26	-0.6	1.07e-10	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs6768930	0.509	rs2061573	chr3:57763642	G/A	cg07735586	chr3:57945651	NA	-0.33	-4.9	-0.45	3.9e-6	Obesity-related traits;
THYM	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg06636001	chr8:8085503	FLJ10661	0.63	5.23	0.47	9.96e-7	Mood instability;
THYM	cis	rs72792324	1.000	rs12386471	chr5:140737531	C/T	cg21929183	chr5:140807225	PCDHGA4;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB8P;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	-0.89	-4.6	-0.43	1.31e-5	Mean platelet volume;
THYM	cis	rs883565	0.771	rs1053530	chr3:39138082	A/G	cg15678707	chr3:39149194	GORASP1;TTC21A	-0.77	-5.52	-0.49	2.95e-7	Handedness;
THYM	cis	rs17449243	0.938	rs12125335	chr1:21385436	T/C	cg01072550	chr1:21505969	NA	-0.86	-5.45	-0.49	3.9e-7	Subjective well-being;
THYM	cis	rs1385374	0.858	rs12298615	chr12:129286756	G/A	cg04043695	chr12:129287642	SLC15A4	-0.79	-4.74	-0.44	7.61e-6	Systemic lupus erythematosus;
THYM	cis	rs55823223	0.503	rs55699990	chr17:73859186	A/G	cg08125733	chr17:73851984	WBP2	0.85	5.58	0.5	2.24e-7	Psoriasis;
THYM	cis	rs12310956	0.532	rs6488186	chr12:33974122	G/A	cg10856724	chr12:34555212	NA	-0.75	-6.8	-0.57	9.1e-10	Morning vs. evening chronotype;
THYM	cis	rs9296092	0.560	rs9469506	chr6:33527897	A/G	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg18230493	chr5:56204884	C5orf35	-0.64	-5.01	-0.46	2.53e-6	Type 2 diabetes;
THYM	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg14349672	chr11:133703707	NA	-0.54	-4.74	-0.44	7.5e-6	Childhood ear infection;
THYM	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.57	-4.88	-0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs7584330	0.554	rs10190935	chr2:238435482	G/A	cg14458575	chr2:238380390	NA	0.81	4.86	0.45	4.63e-6	Prostate cancer;
THYM	cis	rs11039571	0.544	rs7947811	chr11:48167738	C/T	cg24672777	chr11:48374446	OR4C45	0.8	4.68	0.43	9.48e-6	D-dimer levels;
THYM	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs11048434	0.636	rs11614970	chr12:9060053	G/A	cg13575925	chr12:9217583	LOC144571	0.52	4.79	0.44	6.06e-6	Sjögren's syndrome;
THYM	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg08885076	chr2:99613938	TSGA10	0.52	5.02	0.46	2.4e-6	Chronic sinus infection;
THYM	cis	rs758324	0.732	rs128738	chr5:131540875	G/T	cg16205897	chr5:131564050	P4HA2	0.59	4.83	0.44	5.13e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs1451375	0.698	rs1839740	chr7:50646280	C/T	cg18232548	chr7:50535776	DDC	0.69	5.35	0.48	6.03e-7	Malaria;
THYM	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11644478	chr21:40555479	PSMG1	1.11	9.99	0.72	1.76e-16	Cognitive function;
THYM	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg00922110	chr4:57842668	C4orf14	-0.43	-4.45	-0.42	2.36e-5	Response to bleomycin (chromatid breaks);
THYM	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg12564285	chr5:131593104	PDLIM4	0.54	5.73	0.51	1.2e-7	Blood metabolite levels;
THYM	cis	rs9796	0.689	rs28497404	chr15:41449510	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.6	-4.76	-0.44	6.79e-6	Menopause (age at onset);
THYM	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg05738196	chr6:26577821	NA	0.84	8.48	0.66	2.87e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2552220	1.000	rs13259089	chr8:6009927	A/T	cg06481462	chr8:7005678	NA	0.51	5.21	0.47	1.08e-6	Interleukin-8 levels;
THYM	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.62e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg06634786	chr22:41940651	POLR3H	-0.59	-5.02	-0.46	2.41e-6	Vitiligo;
THYM	cis	rs61931739	0.817	rs7963318	chr12:34244929	C/G	cg10856724	chr12:34555212	NA	0.62	5.76	0.51	1.04e-7	Morning vs. evening chronotype;
THYM	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.69	-0.62	1.33e-11	Personality dimensions;
THYM	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	5.49	0.49	3.4e-7	Platelet count;
THYM	cis	rs6430585	0.583	rs1435577	chr2:136624947	C/G	cg07169764	chr2:136633963	MCM6	1.24	13.85	0.82	1.58e-24	Corneal structure;
THYM	cis	rs2898681	0.614	rs62338810	chr4:53678507	G/A	cg00791764	chr4:53727839	RASL11B	0.41	4.66	0.43	1.01e-5	Optic nerve measurement (cup area);
THYM	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg24257776	chr3:47051546	LOC100129354	0.41	4.81	0.44	5.71e-6	Colorectal cancer;
THYM	cis	rs2903698	0.585	rs28851837	chr4:76342566	C/T	cg03209871	chr4:76438412	RCHY1;THAP6	0.43	5.05	0.46	2.17e-6	Prion diseases;
THYM	cis	rs7968440	1.000	rs7977690	chr12:51130414	A/G	cg20014596	chr12:50898483	DIP2B	0.54	4.46	0.42	2.29e-5	Fibrinogen;
THYM	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.42	0.49	4.44e-7	Height;
THYM	cis	rs4654899	0.865	rs6693020	chr1:21378057	A/G	cg01072550	chr1:21505969	NA	-0.71	-6.16	-0.53	1.76e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs6032067	0.777	rs34233258	chr20:43788265	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg13607699	chr17:42295918	UBTF	0.71	5.77	0.51	9.78e-8	Total body bone mineral density;
THYM	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg13531842	chr10:38383804	ZNF37A	-0.55	-4.56	-0.42	1.54e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-5.16	-0.47	1.34e-6	Hemoglobin concentration;
THYM	cis	rs9403317	0.700	rs62433114	chr6:141925480	T/C	cg15052665	chr6:141804349	NA	0.76	5.75	0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4808199	0.895	rs12981405	chr19:19651577	C/T	cg03709012	chr19:19516395	GATAD2A	1.12	6.66	0.56	1.79e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs7172809	0.573	rs55994208	chr15:77525296	C/T	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.25	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs7760949	0.852	rs9464423	chr6:13931851	A/G	cg11053062	chr6:13924544	RNF182	-0.46	-4.45	-0.42	2.34e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs35883536	1.000	rs11583008	chr1:101085094	A/G	cg06223162	chr1:101003688	GPR88	0.61	4.49	0.42	1.98e-5	Monocyte count;
THYM	cis	rs3892630	0.824	rs35700505	chr19:33325006	C/T	cg22928329	chr19:33183273	NUDT19	-0.78	-5.83	-0.51	7.6e-8	Red blood cell traits;
THYM	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg08772003	chr10:104629869	AS3MT	0.68	6.42	0.55	5.42e-9	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg18538332	chr22:24372958	LOC391322	0.92	11.38	0.76	1.9e-19	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.11	-0.64	1.76e-12	Mean corpuscular volume;
THYM	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg05368731	chr17:41323189	NBR1	-1.19	-10.51	-0.73	1.38e-17	Menopause (age at onset);
THYM	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg00074818	chr8:8560427	CLDN23	0.53	4.76	0.44	6.82e-6	Obesity-related traits;
THYM	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	6.07	0.53	2.66e-8	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg24818145	chr4:99064322	C4orf37	0.75	5.96	0.52	4.35e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	4.99	0.46	2.72e-6	Hip circumference adjusted for BMI;
THYM	cis	rs36051895	0.664	rs1034072	chr9:5088903	T/A	cg02405213	chr9:5042618	JAK2	-1.01	-10.98	-0.75	1.34e-18	Pediatric autoimmune diseases;
THYM	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10992471	0.598	rs331380	chr9:95256519	C/T	cg14631576	chr9:95140430	CENPP	0.62	5.42	0.49	4.49e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7115242	0.925	rs7925256	chr11:117045335	T/C	cg01368799	chr11:117014884	PAFAH1B2	1.17	5.28	0.48	8.09e-7	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
THYM	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs7560272	0.723	rs780391	chr2:73703904	C/T	cg19565262	chr2:73869966	NAT8	0.64	5.17	0.47	1.3e-6	Schizophrenia;
THYM	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg24675056	chr1:15929824	NA	0.73	5.89	0.52	5.95e-8	Systolic blood pressure;
THYM	cis	rs6565180	1.000	rs8049108	chr16:30376486	A/G	cg17640201	chr16:30407289	ZNF48	-0.86	-7.81	-0.63	7.7e-12	Tonsillectomy;
THYM	cis	rs10911251	0.546	rs2147578	chr1:183107699	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.66	0.43	1.03e-5	Colorectal cancer;
THYM	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg26384229	chr12:38710491	ALG10B	0.97	7.43	0.61	4.72e-11	Morning vs. evening chronotype;
THYM	cis	rs1933112	0.900	rs7519937	chr1:168504641	A/C	cg17186328	chr1:168545835	XCL1	-0.56	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg01483505	chr11:975446	AP2A2	0.57	4.63	0.43	1.17e-5	Alzheimer's disease (late onset);
THYM	cis	rs6500395	0.963	rs2041921	chr16:48714002	T/C	cg04672837	chr16:48644449	N4BP1	-0.52	-5.05	-0.46	2.16e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg10523679	chr1:76189770	ACADM	0.9	7.35	0.6	7.04e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs2456568	0.548	rs4402256	chr11:93660803	T/C	cg26875233	chr11:93583750	C11orf90	-0.51	-5.65	-0.5	1.7e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7688540	0.771	rs7686546	chr4:240614	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.72	4.88	0.45	4.35e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg06611532	chr13:114900021	NA	0.59	6.54	0.56	3.15e-9	Schizophrenia;
THYM	cis	rs2075230	0.588	rs1641537	chr17:7545721	T/C	cg27413385	chr17:7515425	FXR2	-0.35	-5.06	-0.46	2.06e-6	Hormone measurements;
THYM	cis	rs3126085	0.560	rs6587668	chr1:152333958	A/G	cg10321714	chr1:152280068	FLG	-0.69	-4.84	-0.44	5.1e-6	Atopic dermatitis;
THYM	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg05283184	chr6:79620031	NA	-0.92	-9.08	-0.68	1.52e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7725337	1.000	rs4916669	chr5:88393124	A/G	cg11280525	chr5:87955695	LOC645323	0.39	4.47	0.42	2.15e-5	Total body bone mineral density;
THYM	cis	rs2139634	1.000	rs10514713	chr3:46543617	G/T	cg02332537	chr3:46540019	RTP3	0.47	5.0	0.46	2.57e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs12367572	1.000	rs7295923	chr12:45269284	C/T	cg03114573	chr12:45410052	DBX2	-0.53	-4.92	-0.45	3.69e-6	Gut microbiome composition (summer);
THYM	cis	rs28595532	0.920	rs115681185	chr4:119757700	G/A	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg13395646	chr4:1353034	KIAA1530	-0.72	-6.51	-0.56	3.46e-9	Obesity-related traits;
THYM	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-11.39	-0.76	1.85e-19	Coronary artery disease;
THYM	cis	rs7584330	0.554	rs4420668	chr2:238444793	G/A	cg14458575	chr2:238380390	NA	0.74	4.59	0.43	1.34e-5	Prostate cancer;
THYM	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg24803719	chr17:45855879	NA	-0.6	-6.33	-0.54	7.96e-9	IgG glycosylation;
THYM	cis	rs11166927	0.935	rs12541565	chr8:140794689	C/A	cg16909799	chr8:140841666	TRAPPC9	0.62	5.32	0.48	6.95e-7	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12928939	0.517	rs12445641	chr16:71967783	C/T	cg03805757	chr16:71968109	PKD1L3	-1.09	-11.04	-0.75	1.02e-18	Post bronchodilator FEV1;
THYM	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.28	6.37	0.55	6.77e-9	Obesity-related traits;
THYM	cis	rs10799590	1.000	rs4653402	chr1:224874300	A/T	cg01808320	chr1:224927238	CNIH3	0.54	4.82	0.44	5.39e-6	Opioid dependence;
THYM	cis	rs9583531	0.527	rs12875067	chr13:111365104	A/G	cg24331049	chr13:111365604	ING1	0.72	6.04	0.53	2.96e-8	Coronary artery disease;
THYM	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg23326234	chr5:490647	SLC9A3	0.62	4.78	0.44	6.44e-6	Cystic fibrosis severity;
THYM	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg12863693	chr15:85201151	NMB	0.65	5.9	0.52	5.46e-8	Schizophrenia;
THYM	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg25072359	chr17:41440525	NA	0.65	4.56	0.42	1.5e-5	Menopause (age at onset);
THYM	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg27572855	chr1:25598939	RHD	0.61	4.98	0.45	2.84e-6	Erythrocyte sedimentation rate;
THYM	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg05025164	chr4:1340916	KIAA1530	-0.8	-6.2	-0.54	1.43e-8	Longevity;
THYM	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg12310025	chr6:25882481	NA	0.68	5.56	0.5	2.47e-7	Schizophrenia;
THYM	cis	rs367615	0.660	rs10477972	chr5:108831951	C/A	cg17395555	chr5:108820864	NA	0.74	8.76	0.67	7.24e-14	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs3849570	1.000	rs3772883	chr3:81802802	C/T	cg07356753	chr3:81810745	GBE1	-0.76	-5.56	-0.5	2.45e-7	Waist circumference;Body mass index;
THYM	cis	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg13443165	chr9:33130375	B4GALT1	-0.87	-7.99	-0.63	3.23e-12	IgG glycosylation;
THYM	cis	rs1499972	0.887	rs1499970	chr3:117692767	G/A	cg07612923	chr3:117604196	NA	-1.42	-5.49	-0.49	3.4e-7	Schizophrenia;
THYM	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg00012203	chr2:219082015	ARPC2	-0.65	-5.33	-0.48	6.58e-7	Colorectal cancer;
THYM	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs11785693	0.862	rs11781233	chr8:4993653	C/G	cg26367366	chr8:4980734	NA	-1.21	-6.11	-0.53	2.2e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs9790314	0.905	rs1154701	chr3:161008025	T/A	cg03342759	chr3:160939853	NMD3	-0.81	-7.28	-0.6	9.51e-11	Morning vs. evening chronotype;
THYM	cis	rs6701037	0.681	rs34370567	chr1:175131340	C/T	cg00958927	chr1:175162553	KIAA0040	-0.33	-4.48	-0.42	2.06e-5	Alcohol dependence;
THYM	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	4.59	0.43	1.35e-5	Aortic root size;
THYM	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg07884673	chr3:53033167	SFMBT1	1.17	5.88	0.52	6.13e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7580658	0.724	rs6712551	chr2:127998485	G/A	cg09152259	chr2:128156114	NA	-0.41	-5.29	-0.48	7.7e-7	Protein C levels;
THYM	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	9.78	0.71	4.77e-16	Platelet count;
THYM	cis	rs921968	0.541	rs488767	chr2:219466860	G/T	cg02176678	chr2:219576539	TTLL4	0.68	6.83	0.57	8.06e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4474465	0.790	rs10793325	chr11:78252575	T/C	cg19901956	chr11:77921274	USP35	0.57	4.49	0.42	1.97e-5	Alzheimer's disease (survival time);
THYM	cis	rs863345	0.564	rs11265014	chr1:158503221	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs8141529	0.753	rs5752813	chr22:29226570	T/G	cg02153584	chr22:29168773	CCDC117	0.58	4.56	0.42	1.52e-5	Lymphocyte counts;
THYM	cis	rs8180040	0.903	rs11130124	chr3:47292183	T/C	cg02527881	chr3:46936655	PTH1R	-0.63	-6.19	-0.54	1.52e-8	Colorectal cancer;
THYM	cis	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg21775007	chr8:11205619	TDH	0.62	4.73	0.44	7.9e-6	Retinal vascular caliber;
THYM	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg24642439	chr20:33292090	TP53INP2	0.62	4.87	0.45	4.38e-6	Coronary artery disease;
THYM	cis	rs4242434	0.854	rs11782130	chr8:22452357	G/T	cg14690197	chr8:22456421	C8orf58	0.48	4.64	0.43	1.11e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6500395	1.000	rs6500397	chr16:48642235	T/C	cg04672837	chr16:48644449	N4BP1	0.49	4.62	0.43	1.22e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs11651000	0.625	rs4794063	chr17:45804494	C/T	cg24803719	chr17:45855879	NA	-0.6	-6.29	-0.54	9.67e-9	IgG glycosylation;
THYM	cis	rs500891	0.525	rs9800770	chr6:84070313	C/T	cg08257003	chr6:84140564	ME1	0.58	4.66	0.43	1.01e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg15556689	chr8:8085844	FLJ10661	0.62	4.99	0.46	2.74e-6	Mood instability;
THYM	cis	rs1395	0.710	rs58965570	chr2:27481460	C/T	cg23587288	chr2:27483067	SLC30A3	-0.64	-5.72	-0.51	1.26e-7	Blood metabolite levels;
THYM	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg22166914	chr1:53195759	ZYG11B	0.7	6.84	0.57	7.82e-10	Monocyte count;
THYM	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.22	-0.47	1.06e-6	Chronic sinus infection;
THYM	cis	rs6876348	0.516	rs257904	chr5:128316255	C/T	cg25555059	chr5:128301488	SLC27A6	-0.45	-4.62	-0.43	1.21e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	4.68	0.43	9.45e-6	Aortic root size;
THYM	trans	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg10856724	chr12:34555212	NA	-0.9	-8.08	-0.64	2.05e-12	Bladder cancer;
THYM	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg16325326	chr1:53192061	ZYG11B	0.94	9.94	0.71	2.22e-16	Monocyte count;
THYM	cis	rs36051895	0.530	rs4142064	chr9:5221818	C/T	cg02405213	chr9:5042618	JAK2	-0.8	-7.78	-0.62	8.91e-12	Pediatric autoimmune diseases;
THYM	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg06981504	chr1:1234844	ACAP3	-0.49	-4.73	-0.44	7.94e-6	Body mass index;
THYM	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg06766960	chr11:133703094	NA	0.62	5.98	0.52	3.96e-8	Childhood ear infection;
THYM	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg24006582	chr15:45444508	DUOX1	-0.83	-7.16	-0.59	1.7e-10	Uric acid levels;
THYM	cis	rs870825	0.655	rs72703561	chr4:185630890	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs17125944	0.686	rs7149638	chr14:53346931	T/C	cg00686598	chr14:53173677	PSMC6	-1.08	-4.83	-0.44	5.23e-6	Alzheimer's disease (late onset);
THYM	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2806561	0.765	rs643492	chr1:23501354	C/T	cg19743168	chr1:23544995	NA	-0.54	-5.62	-0.5	1.91e-7	Height;
THYM	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08704250	chr15:31115839	NA	-0.47	-5.7	-0.5	1.36e-7	Huntington's disease progression;
THYM	cis	rs860818	1.000	rs1637223	chr7:23228669	A/C	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs289828	0.519	rs4665168	chr2:152152130	A/C	cg05960677	chr2:152117363	RBM43	0.75	7.26	0.6	1.05e-10	Blood protein levels;
THYM	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	7.18	0.59	1.57e-10	Electrocardiographic conduction measures;
THYM	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg06481639	chr22:41940642	POLR3H	0.72	4.68	0.43	9.65e-6	Vitiligo;
THYM	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg06917634	chr15:78832804	PSMA4	0.96	8.76	0.67	7.4e-14	Sudden cardiac arrest;
THYM	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg06618935	chr21:46677482	NA	-0.96	-7.93	-0.63	4.3e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4889855	0.556	rs4890040	chr17:78518408	G/A	cg16591659	chr17:78472290	NA	0.41	4.82	0.44	5.53e-6	Fractional excretion of uric acid;
THYM	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg15704280	chr7:45808275	SEPT13	0.99	7.95	0.63	3.79e-12	Coronary artery disease;
THYM	cis	rs7590720	0.819	rs6435931	chr2:216892754	C/G	cg25588852	chr2:216877276	MREG	-0.59	-5.2	-0.47	1.12e-6	Alcohol dependence;
THYM	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.94	0.75	1.67e-18	Diabetic retinopathy;
THYM	cis	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.61	6.51	0.56	3.61e-9	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg00684032	chr4:1343700	KIAA1530	-0.66	-5.62	-0.5	1.9e-7	Obesity-related traits;
THYM	cis	rs35110281	0.607	rs11701518	chr21:44987079	C/T	cg15536230	chr21:44985092	HSF2BP	-0.41	-4.98	-0.45	2.9e-6	Mean corpuscular volume;
THYM	cis	rs4409675	0.576	rs6660899	chr1:28214281	G/C	cg23691781	chr1:28212827	C1orf38	0.44	4.48	0.42	2.08e-5	Corneal astigmatism;
THYM	cis	rs9420	0.528	rs34052104	chr11:57384519	A/C	cg19752551	chr11:57585705	CTNND1	-0.6	-5.01	-0.46	2.56e-6	Schizophrenia;
THYM	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs13253111	1.000	rs13253111	chr8:28061974	C/T	cg26534493	chr8:28060551	NA	0.58	4.46	0.42	2.29e-5	Childhood body mass index;
THYM	cis	rs9361491	0.610	rs4706731	chr6:79468298	C/T	cg04547799	chr6:79944526	HMGN3	-0.64	-4.47	-0.42	2.13e-5	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs115853212	chr4:119765354	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs4919044	0.808	rs1750741	chr10:94804530	G/T	cg05127821	chr10:94822908	CYP26C1	-1.23	-6.66	-0.56	1.76e-9	Coronary artery disease;
THYM	cis	rs7322722	0.648	rs9574026	chr13:77858395	A/G	cg04565255	chr13:77565759	CLN5	0.48	5.14	0.47	1.49e-6	Preeclampsia;
THYM	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg18709589	chr6:96969512	KIAA0776	-0.55	-4.52	-0.42	1.75e-5	Headache;
THYM	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg06481639	chr22:41940642	POLR3H	-0.75	-5.22	-0.47	1.06e-6	Vitiligo;
THYM	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg08859206	chr1:53392774	SCP2	0.81	8.47	0.66	3e-13	Monocyte count;
THYM	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg02725872	chr8:58115012	NA	-1.09	-8.15	-0.64	1.43e-12	Developmental language disorder (linguistic errors);
THYM	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg03909863	chr11:638404	DRD4	-0.76	-6.04	-0.53	2.95e-8	Systemic lupus erythematosus;
THYM	cis	rs7084921	0.608	rs1853700	chr10:101862694	T/C	cg11344164	chr10:101878520	NA	-0.55	-4.72	-0.44	8.27e-6	Bone mineral density;
THYM	cis	rs35264875	0.851	rs7933746	chr11:68867722	A/G	cg21670003	chr11:68867965	NA	0.64	4.47	0.42	2.14e-5	Blond vs. brown hair color;
THYM	cis	rs11096990	0.964	rs7678689	chr4:39262760	G/A	cg24403649	chr4:39172243	NA	-0.7	-5.87	-0.52	6.45e-8	Cognitive function;
THYM	cis	rs11792861	0.926	rs17628095	chr9:111889172	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.62	-4.95	-0.45	3.16e-6	Menarche (age at onset);
THYM	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg09307838	chr4:120376055	NA	0.74	5.29	0.48	7.72e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg07917127	chr4:99064746	C4orf37	0.59	4.5	0.42	1.93e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg06108461	chr20:60628389	TAF4	-1.03	-8.14	-0.64	1.49e-12	Body mass index;
THYM	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg17294928	chr15:75287854	SCAMP5	0.67	4.59	0.43	1.37e-5	Blood trace element (Zn levels);
THYM	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg21231944	chr12:82153410	PPFIA2	-0.61	-4.45	-0.42	2.33e-5	Resting heart rate;
THYM	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg10862848	chr6:42927986	GNMT	-0.51	-6.67	-0.56	1.66e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs10463554	0.927	rs257317	chr5:102422585	T/C	cg23492399	chr5:102201601	PAM	-0.69	-5.13	-0.47	1.5e-6	Parkinson's disease;
THYM	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-5.57	-0.5	2.41e-7	Chronic sinus infection;
THYM	cis	rs7429990	0.965	rs13075795	chr3:48024629	A/T	cg02219026	chr3:48282209	ZNF589	0.6	4.5	0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6032067	0.777	rs13037651	chr20:43782230	C/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs4589258	0.933	rs1792613	chr11:90429589	C/A	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg18252515	chr7:66147081	NA	-1.41	-8.25	-0.65	8.89e-13	Diabetic kidney disease;
THYM	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12667521	chr19:29218732	NA	0.89	8.17	0.64	1.34e-12	Methadone dose in opioid dependence;
THYM	cis	rs10896135	0.554	rs3741364	chr11:66451178	C/T	cg24851651	chr11:66362959	CCS	0.79	5.29	0.48	7.93e-7	Bipolar disorder;
THYM	cis	rs2302729	0.929	rs10744567	chr12:2780816	A/G	cg19945202	chr12:2788847	CACNA1C	-0.94	-6.09	-0.53	2.41e-8	Sleep quality;
THYM	cis	rs8067545	0.611	rs2526482	chr17:20119133	C/T	cg20830565	chr17:20408647	MGC102966	0.49	4.48	0.42	2.05e-5	Schizophrenia;
THYM	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.61	-5.07	-0.46	2e-6	Renal function-related traits (BUN);
THYM	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg10862848	chr6:42927986	GNMT	-0.54	-7.36	-0.6	6.51e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.84	-5.69	-0.5	1.43e-7	Yeast infection;
THYM	cis	rs9914988	0.943	rs66588554	chr17:27141110	A/G	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs60695258	0.550	rs340636	chr4:87930760	T/G	cg10685359	chr4:87814065	C4orf36	0.44	5.68	0.5	1.5e-7	Hematocrit;
THYM	cis	rs12541335	0.615	rs4872464	chr8:22153381	G/A	cg26039829	chr8:22132926	PIWIL2	0.7	6.19	0.54	1.55e-8	Hypertriglyceridemia;
THYM	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg00744431	chr10:134226547	PWWP2B	-0.6	-4.73	-0.44	7.73e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg12408189	chr10:30722286	MAP3K8	-0.55	-4.67	-0.43	1.01e-5	Inflammatory bowel disease;
THYM	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg17178900	chr1:205818956	PM20D1	-0.66	-5.06	-0.46	2.04e-6	Menarche (age at onset);
THYM	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg24818145	chr4:99064322	C4orf37	0.64	4.8	0.44	5.87e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg06481639	chr22:41940642	POLR3H	-0.76	-5.47	-0.49	3.67e-7	Vitiligo;
THYM	cis	rs1160297	0.539	rs7559124	chr2:53134517	C/G	cg07782112	chr2:53107842	NA	-0.64	-5.15	-0.47	1.42e-6	Hemostatic factors and hematological phenotypes;
THYM	cis	rs11696845	0.626	rs1111032	chr20:43378770	A/G	cg25301532	chr20:43378953	KCNK15	0.61	5.05	0.46	2.17e-6	Obesity-related traits;
THYM	cis	rs1003719	0.646	rs2835671	chr21:38581125	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.5	-0.42	1.95e-5	Eye color traits;
THYM	cis	rs1483890	0.851	rs6762186	chr3:69402923	T/G	cg22125112	chr3:69402811	FRMD4B	0.47	6.02	0.53	3.28e-8	Resting heart rate;
THYM	cis	rs13082711	0.954	rs67282221	chr3:27552752	T/A	cg02860705	chr3:27208620	NA	0.76	5.0	0.46	2.57e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs2404602	0.684	rs1603860	chr15:76849591	A/T	cg23625390	chr15:77176239	SCAPER	-0.9	-6.37	-0.55	6.74e-9	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg07061783	chr6:25882402	NA	-0.6	-4.6	-0.43	1.31e-5	Height;
THYM	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2806561	0.606	rs218341	chr1:23294153	G/C	cg19743168	chr1:23544995	NA	0.5	4.69	0.43	9.12e-6	Height;
THYM	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg22709100	chr7:91322751	NA	-0.59	-4.77	-0.44	6.76e-6	Breast cancer;
THYM	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg10295955	chr4:187884368	NA	-1.16	-16.24	-0.86	3.64e-29	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg08885076	chr2:99613938	TSGA10	0.59	5.23	0.47	1.01e-6	Chronic sinus infection;
THYM	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg16325326	chr1:53192061	ZYG11B	-0.82	-8.46	-0.66	3.1400000000000003e-13	Monocyte count;
THYM	cis	rs4460079	0.531	rs9917901	chr4:114838274	C/T	cg02060584	chr4:113970739	ANK2	-0.58	-4.81	-0.44	5.55e-6	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs3820068	0.577	rs9728986	chr1:16040603	G/A	cg24675056	chr1:15929824	NA	0.78	6.16	0.53	1.73e-8	Systolic blood pressure;
THYM	cis	rs36093924	0.586	rs6002561	chr22:42359204	A/G	cg10296410	chr22:42095368	MEI1	0.43	4.5	0.42	1.93e-5	Intelligence;
THYM	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs73086581	1.000	rs6107393	chr20:3987738	C/T	cg02187196	chr20:3869020	PANK2	0.48	5.43	0.49	4.4e-7	Response to antidepressants in depression;
THYM	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg05872129	chr22:39784769	NA	-1.04	-10.98	-0.75	1.35e-18	Intelligence (multi-trait analysis);
THYM	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg07541023	chr7:19748670	TWISTNB	1.11	7.49	0.61	3.56e-11	Night sleep phenotypes;
THYM	cis	rs6867032	0.839	rs4314451	chr5:2001859	T/C	cg26168224	chr5:2018326	NA	-1.06	-10.47	-0.73	1.64e-17	Gut microbiome composition (winter);
THYM	trans	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs7084402	0.967	rs1649074	chr10:60295342	T/G	cg07615347	chr10:60278583	BICC1	0.54	4.91	0.45	3.7e-6	Refractive error;
THYM	cis	rs782590	0.620	rs4322879	chr2:55797033	G/T	cg18811423	chr2:55921094	PNPT1	-0.55	-4.98	-0.46	2.83e-6	Metabolic syndrome;
THYM	cis	rs888194	0.677	rs10850139	chr12:109875934	A/C	cg11367159	chr12:110044531	NA	0.53	4.82	0.44	5.39e-6	Neuroticism;
THYM	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg05973401	chr12:123451056	ABCB9	0.64	4.63	0.43	1.17e-5	Platelet count;
THYM	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs6988636	0.818	rs73339658	chr8:124173007	A/G	cg23067535	chr8:124195133	FAM83A	-1.07	-5.32	-0.48	6.91e-7	Urinary uromodulin levels;
THYM	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	5.1	0.46	1.73e-6	Total body bone mineral density;
THYM	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.91	-5.08	-0.46	1.88e-6	Initial pursuit acceleration;
THYM	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg01570182	chr17:44337453	NA	-0.62	-6.48	-0.55	4.01e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg15536230	chr21:44985092	HSF2BP	-0.39	-4.7	-0.43	8.69e-6	Mean corpuscular volume;
THYM	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg03676636	chr4:99064102	C4orf37	0.42	6.09	0.53	2.33e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4363385	0.693	rs490553	chr1:153033277	A/G	cg13444842	chr1:152974279	SPRR3	-0.62	-5.07	-0.46	1.96e-6	Inflammatory skin disease;
THYM	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs4595586	0.545	rs4254106	chr12:39389342	G/A	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.75	6.93	0.58	4.96e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg00376283	chr12:123451042	ABCB9	0.73	4.97	0.45	2.96e-6	Neutrophil percentage of white cells;
THYM	cis	rs478304	0.903	rs546202	chr11:65510024	C/T	cg27068330	chr11:65405492	SIPA1	-0.82	-7.91	-0.63	4.72e-12	Acne (severe);
THYM	cis	rs6897795	0.680	rs10074768	chr5:177610700	A/G	cg25087499	chr5:177592761	NA	0.55	4.82	0.44	5.37e-6	Plateletcrit;
THYM	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg11211951	chr8:145729740	GPT	0.62	6.38	0.55	6.28e-9	Age at first birth;
THYM	cis	rs950880	0.710	rs17027006	chr2:102965332	C/G	cg03938978	chr2:103052716	IL18RAP	0.52	4.58	0.43	1.42e-5	Serum protein levels (sST2);
THYM	cis	rs7149242	0.796	rs12588718	chr14:101149605	G/C	cg18089426	chr14:101175970	NA	-0.56	-5.16	-0.47	1.37e-6	Platelet count;
THYM	cis	rs4363385	0.510	rs61811902	chr1:153053464	A/G	cg13444842	chr1:152974279	SPRR3	-0.64	-4.99	-0.46	2.7e-6	Inflammatory skin disease;
THYM	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg06636551	chr8:101224915	SPAG1	-0.67	-6.52	-0.56	3.36e-9	Atrioventricular conduction;
THYM	cis	rs12936587	0.601	rs8068296	chr17:17554563	A/C	cg04398451	chr17:18023971	MYO15A	0.56	4.56	0.42	1.51e-5	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
THYM	cis	rs11690935	0.571	rs13020884	chr2:172901699	T/G	cg13550731	chr2:172543902	DYNC1I2	0.73	5.94	0.52	4.76e-8	Schizophrenia;
THYM	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs2637266	0.783	rs2395436	chr10:78488513	G/T	cg18941641	chr10:78392320	NA	0.75	6.01	0.53	3.35e-8	Pulmonary function;
THYM	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg07905836	chr2:113190072	RGPD8;RGPD5	0.89	5.62	0.5	1.9e-7	Yeast infection;
THYM	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg24375607	chr4:120327624	NA	0.61	5.25	0.47	9.41e-7	Corneal astigmatism;
THYM	cis	rs7113850	0.541	rs80243979	chr11:24231811	A/C	ch.11.24196551F	chr11:24239977	NA	0.92	4.92	0.45	3.58e-6	Bone fracture in osteoporosis;
THYM	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg22841779	chr14:105766346	BRF1	-0.46	-5.71	-0.51	1.27e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg23018236	chr17:30244563	NA	-0.6	-4.45	-0.42	2.3e-5	Hip circumference adjusted for BMI;
THYM	cis	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.61	-6.2	-0.54	1.45e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	8.7	0.67	9.84e-14	Chronic sinus infection;
THYM	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	5.84	0.51	7.4e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.7	5.56	0.5	2.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg22166914	chr1:53195759	ZYG11B	0.91	10.7	0.74	5.4e-18	Monocyte count;
THYM	cis	rs733592	1.000	rs733592	chr12:48429776	C/T	cg21466736	chr12:48725269	NA	0.49	5.36	0.48	5.84e-7	Plateletcrit;
THYM	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg00129232	chr17:37814104	STARD3	0.7	4.79	0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg14456004	chr13:21872349	NA	1.25	11.07	0.75	8.58e-19	White matter hyperintensity burden;
THYM	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg07424592	chr7:64974309	NA	1.08	5.73	0.51	1.2e-7	Diabetic kidney disease;
THYM	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg23161317	chr6:28129485	ZNF389	0.81	6.74	0.57	1.2e-9	Depression;
THYM	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg17178900	chr1:205818956	PM20D1	0.71	5.93	0.52	4.93e-8	Menarche (age at onset);
THYM	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg18230493	chr5:56204884	C5orf35	-0.89	-6.62	-0.56	2.09e-9	Initial pursuit acceleration;
THYM	cis	rs2637266	0.967	rs12246436	chr10:78352914	C/T	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg10518543	chr12:38710700	ALG10B	-0.57	-4.47	-0.42	2.16e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg13609457	chr4:120235615	NA	0.58	5.33	0.48	6.55e-7	Corneal astigmatism;
THYM	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg18230493	chr5:56204884	C5orf35	0.65	4.89	0.45	4.11e-6	Initial pursuit acceleration;
THYM	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg07936489	chr17:37558343	FBXL20	-0.71	-5.25	-0.47	9.23e-7	Asthma;
THYM	cis	rs259282	0.605	rs35728696	chr19:33108096	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.57	4.73	0.44	7.88e-6	Schizophrenia;
THYM	cis	rs2898681	0.614	rs6839900	chr4:53675334	A/G	cg00338735	chr4:53728038	RASL11B	0.55	4.81	0.44	5.59e-6	Optic nerve measurement (cup area);
THYM	cis	rs2273669	0.588	rs12205061	chr6:109338161	T/C	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	cis	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg10856724	chr12:34555212	NA	-0.91	-9.26	-0.69	6.21e-15	Morning vs. evening chronotype;
THYM	cis	rs9290065	0.519	rs10513560	chr3:160710798	C/T	cg03342759	chr3:160939853	NMD3	-0.59	-4.59	-0.43	1.37e-5	Kawasaki disease;
THYM	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg23602478	chr1:26503979	CNKSR1	0.36	4.97	0.45	2.96e-6	Height;
THYM	cis	rs11190604	1.000	rs6584383	chr10:102303065	C/G	cg07570687	chr10:102243282	WNT8B	0.75	6.74	0.57	1.21e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2806561	0.780	rs12751560	chr1:23407081	C/A	cg12483005	chr1:23474871	LUZP1	-0.51	-4.6	-0.43	1.3e-5	Height;
THYM	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.5	-4.93	-0.45	3.5e-6	Crohn's disease;
THYM	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.57	-7.32	-0.6	7.81e-11	Monocyte percentage of white cells;
THYM	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg07636037	chr3:49044803	WDR6	0.78	4.81	0.44	5.67e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg02734326	chr4:10020555	SLC2A9	-0.6	-4.7	-0.43	8.84e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4792901	0.802	rs76971300	chr17:41580588	A/G	cg21940313	chr17:41620911	ETV4	-0.54	-5.17	-0.47	1.32e-6	Dupuytren's disease;
THYM	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18252515	chr7:66147081	NA	-0.66	-5.05	-0.46	2.16e-6	Aortic root size;
THYM	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03517284	chr6:25882590	NA	-0.78	-6.24	-0.54	1.22e-8	Blood metabolite levels;
THYM	trans	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg25214090	chr10:38739885	LOC399744	0.93	7.84	0.63	6.64e-12	Corneal astigmatism;
THYM	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs4242434	0.857	rs11777808	chr8:22462755	A/C	cg21658235	chr8:22456391	C8orf58	0.5	5.02	0.46	2.4e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7917772	0.582	rs729024	chr10:104341975	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg22105103	chr4:187893119	NA	0.89	9.3	0.69	5.11e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs137603	0.644	rs137636	chr22:39722477	C/A	cg24268161	chr22:39747459	SYNGR1	0.64	5.29	0.48	7.67e-7	Primary biliary cholangitis;
THYM	cis	rs892961	0.932	rs7216155	chr17:75405155	C/G	cg05865280	chr17:75406074	SEPT9	0.5	8.56	0.66	1.99e-13	Airflow obstruction;
THYM	cis	rs9866391	0.607	rs4683605	chr3:141094769	C/A	cg13411656	chr3:141121016	ZBTB38	-0.35	-5.25	-0.47	9.16e-7	Myopia;
THYM	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg05347473	chr6:146136440	FBXO30	0.82	7.36	0.6	6.62e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2241210	0.550	rs7486178	chr12:109980266	G/A	cg13986417	chr12:110012484	MVK;MMAB	-0.61	-5.47	-0.49	3.66e-7	HDL cholesterol levels;
THYM	cis	rs11186	0.556	rs72906322	chr2:189957803	T/G	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.69	-5.03	-0.46	2.32e-6	Longevity;Endometriosis;
THYM	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg24112000	chr20:60950667	NA	0.61	5.05	0.46	2.11e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.67	5.9	0.52	5.62e-8	Lung disease severity in cystic fibrosis;
THYM	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg13289132	chr10:30722225	MAP3K8	-0.57	-4.82	-0.44	5.38e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.45	0.49	3.91e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs240764	0.817	rs2036052	chr6:101154909	G/A	cg21058520	chr6:100914733	NA	0.58	5.22	0.47	1.04e-6	Neuroticism;
THYM	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg25817165	chr18:72167213	CNDP2	-0.92	-8.15	-0.64	1.48e-12	Refractive error;
THYM	cis	rs6939532	0.517	rs733528	chr6:26374903	A/G	cg14345882	chr6:26364793	BTN3A2	0.4	5.13	0.47	1.51e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg24375607	chr4:120327624	NA	0.58	4.8	0.44	5.82e-6	Corneal astigmatism;
THYM	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg01966878	chr4:90757139	SNCA	-0.59	-4.71	-0.44	8.43e-6	Neuroticism;
THYM	cis	rs13040088	1.000	rs10854167	chr20:61533039	G/C	cg23096297	chr20:61557774	DIDO1	1.07	7.41	0.61	5.15e-11	Menopause (age at onset);
THYM	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	6.38	0.55	6.45e-9	Smoking behavior;
THYM	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg04756594	chr16:24857601	SLC5A11	0.74	5.13	0.47	1.55e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9430161	0.579	rs7542164	chr1:11040223	G/A	cg02454025	chr1:11042201	C1orf127	0.85	9.91	0.71	2.54e-16	Ewing sarcoma;
THYM	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg05368731	chr17:41323189	NBR1	1.25	11.33	0.76	2.42e-19	Menopause (age at onset);
THYM	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg27414909	chr4:1201492	LOC100130872;LOC100130872-SPON2	0.61	4.51	0.42	1.84e-5	Longevity;
THYM	cis	rs1034435	0.755	rs5767172	chr22:48892314	A/C	cg05992904	chr22:48892994	FAM19A5	-0.81	-9.07	-0.68	1.58e-14	Late-onset Alzheimer's disease;
THYM	cis	rs7188873	1	rs7188873	chr16:24727064	A/G	cg06028605	chr16:24865363	SLC5A11	-0.49	-4.6	-0.43	1.33e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3733631	0.696	rs7672658	chr4:104631530	G/A	cg24090629	chr4:104641072	TACR3	-0.83	-5.06	-0.46	2.06e-6	Menarche (age at onset);
THYM	cis	rs7681440	0.560	rs67876224	chr4:90808918	T/C	cg06632027	chr4:90757378	SNCA	-0.63	-4.83	-0.44	5.26e-6	Dementia with Lewy bodies;
THYM	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg26384229	chr12:38710491	ALG10B	1.05	10.57	0.74	9.98e-18	Heart rate;
THYM	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg13902645	chr11:5959945	NA	-0.57	-4.97	-0.45	2.98e-6	DNA methylation (variation);
THYM	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.38	-8.79	-0.67	6.39e-14	Hemostatic factors and hematological phenotypes;
THYM	cis	rs6992820	0.902	rs13274826	chr8:56764794	G/T	cg06880721	chr8:56792545	LYN	-0.61	-5.33	-0.48	6.66e-7	Mean platelet volume;
THYM	cis	rs12681287	0.511	rs4129535	chr8:87524094	G/T	cg27223183	chr8:87520930	FAM82B	-0.74	-5.72	-0.51	1.21e-7	Caudate activity during reward;
THYM	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg13147721	chr7:65941812	NA	-1.1	-7.08	-0.59	2.45e-10	Diabetic kidney disease;
THYM	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.09	0.64	1.96e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17321999	1.000	rs17009304	chr2:30479283	A/T	cg05247661	chr2:30472410	LBH	0.64	4.6	0.43	1.29e-5	Systemic lupus erythematosus;
THYM	cis	rs4072705	1.000	rs4838196	chr9:127357678	C/T	cg13476313	chr9:127244764	NR5A1	0.32	4.84	0.44	5.02e-6	Menarche (age at onset);
THYM	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg26441486	chr22:50317300	CRELD2	0.37	5.55	0.49	2.57e-7	Schizophrenia;
THYM	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.14	0.47	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.54	-5.17	-0.47	1.31e-6	Lymphocyte counts;
THYM	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg11845111	chr2:191398756	TMEM194B	-0.96	-7.22	-0.6	1.26e-10	Diastolic blood pressure;
THYM	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg22974920	chr21:40686053	BRWD1	-0.57	-4.48	-0.42	2.04e-5	Cognitive function;
THYM	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03264133	chr6:25882463	NA	-0.91	-7.71	-0.62	1.2e-11	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.35	-0.55	7.4e-9	Total body bone mineral density;
THYM	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg18252515	chr7:66147081	NA	0.72	5.57	0.5	2.33e-7	Cotinine glucuronidation;
THYM	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg14196790	chr5:131705035	SLC22A5	0.53	4.77	0.44	6.72e-6	Blood metabolite levels;
THYM	cis	rs55728055	0.661	rs7288051	chr22:32013816	C/T	cg10537193	chr22:32026975	PISD	-0.85	-5.39	-0.48	5.13e-7	Age-related hearing impairment;
THYM	cis	rs12946454	0.668	rs4792867	chr17:43249444	C/T	cg06100756	chr17:43221575	NA	0.54	5.23	0.47	1.01e-6	Systolic blood pressure;
THYM	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg23803603	chr1:2058230	PRKCZ	-0.59	-5.39	-0.48	5.2e-7	Height;
THYM	trans	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg01121180	chr19:51302454	C19orf48;SNORD88B	0.79	7.04	0.59	2.98e-10	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6450176	0.951	rs5013866	chr5:53300947	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.14	-0.53	1.94e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs6500395	0.962	rs1115759	chr16:48599530	A/G	cg04672837	chr16:48644449	N4BP1	0.47	4.48	0.42	2.08e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs34638657	0.732	rs12597171	chr16:82200119	A/G	cg09894383	chr16:82067445	HSD17B2	0.48	5.39	0.48	5.09e-7	Lung adenocarcinoma;
THYM	cis	rs4731207	0.596	rs12533918	chr7:124647263	C/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs747334	0.682	rs7917623	chr10:92701390	C/G	cg07620928	chr10:92689909	NA	0.52	4.51	0.42	1.86e-5	Fibroblast growth factor basic levels;
THYM	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.41	-4.65	-0.43	1.07e-5	Cognitive function;
THYM	cis	rs1345301	1.000	rs13405355	chr2:102878206	C/T	cg03938978	chr2:103052716	IL18RAP	-0.62	-6.09	-0.53	2.36e-8	Waist circumference;
THYM	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg03709012	chr19:19516395	GATAD2A	-0.74	-5.8	-0.51	8.48e-8	Tonsillectomy;
THYM	cis	rs4580814	0.869	rs4535497	chr5:1107428	G/T	cg14596589	chr5:1107148	SLC12A7	0.35	4.87	0.45	4.36e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.38	0.55	6.27e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6700896	0.931	rs11208717	chr1:66158994	T/C	cg04111102	chr1:66153794	NA	0.52	4.94	0.45	3.32e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	trans	rs4650994	1.000	rs17276527	chr1:178520680	G/A	cg05059571	chr16:84539110	KIAA1609	-0.75	-8.03	-0.64	2.57e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs988913	0.813	rs2143798	chr6:54753054	A/T	cg04690482	chr6:54711388	FAM83B	0.54	6.6	0.56	2.3e-9	Menarche (age at onset);
THYM	cis	rs11157436	0.918	rs12437004	chr14:22617415	G/T	cg26433554	chr14:23315189	MMP14	0.44	4.61	0.43	1.24e-5	Neurocognitive impairment in HIV-1 infection (continuous);
THYM	cis	rs4936891	0.577	rs12225469	chr11:123902719	G/A	cg22125253	chr11:123886957	OR10G4	-0.61	-4.9	-0.45	3.91e-6	Male fertility;
THYM	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06873352	chr17:61820015	STRADA	0.56	5.63	0.5	1.84e-7	Height;
THYM	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11018874	0.597	rs4268468	chr11:89886284	C/T	cg05041596	chr11:89867385	NAALAD2	0.74	4.85	0.45	4.85e-6	White blood cell types;
THYM	cis	rs909685	0.590	rs3747177	chr22:39746168	C/A	cg24268161	chr22:39747459	SYNGR1	-0.66	-5.42	-0.49	4.53e-7	Rheumatoid arthritis;
THYM	cis	rs2742234	0.541	rs2742235	chr10:43616325	A/G	cg06632098	chr10:43605906	RET	-0.78	-4.97	-0.45	2.99e-6	Hirschsprung disease;
THYM	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg09184832	chr6:79620586	NA	-0.56	-4.46	-0.42	2.24e-5	Intelligence (multi-trait analysis);
THYM	cis	rs8133932	0.564	rs452797	chr21:47348455	C/G	cg20357416	chr21:47294739	PCBP3	0.8	4.88	0.45	4.26e-6	Schizophrenia;
THYM	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.05	-5.39	-0.48	5.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs28595532	0.920	rs115154263	chr4:119765307	G/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs7084402	0.934	rs1579394	chr10:60294625	T/A	cg07615347	chr10:60278583	BICC1	0.56	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs36207871	1	rs36207871	chr12:56684496	TAGGAA/T	cg26714650	chr12:56694279	CS	1.26	7.39	0.6	5.59e-11	Inflammatory skin disease;
THYM	cis	rs4930103	0.904	rs4929984	chr11:2024683	A/C	cg06197492	chr11:2016605	H19	-0.64	-5.64	-0.5	1.76e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs600806	0.850	rs10858095	chr1:109962642	G/C	cg16988986	chr1:109941118	SORT1	-0.44	-4.67	-0.43	9.83e-6	Intelligence (multi-trait analysis);
THYM	cis	rs17401966	0.931	rs34225619	chr1:10371987	C/T	cg19773385	chr1:10388646	KIF1B	-0.62	-4.54	-0.42	1.67e-5	Hepatocellular carcinoma;
THYM	cis	rs4077515	0.934	rs3829111	chr9:139269483	G/A	cg14115884	chr9:139300582	SDCCAG3	0.72	6.78	0.57	9.97e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4940575	0.786	rs6567326	chr18:60840608	G/T	cg20947866	chr18:61143580	SERPINB5	0.9	5.34	0.48	6.28e-7	Breast cancer;
THYM	cis	rs3825932	0.961	rs28655102	chr15:79232700	C/T	cg25744700	chr15:79237217	CTSH	0.47	4.46	0.42	2.22e-5	Type 1 diabetes;
THYM	cis	rs13315871	1.000	rs13060489	chr3:58339287	G/A	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs79480871	0.667	rs3731628	chr2:24929851	A/T	cg26312337	chr2:25170414	DNAJC27	0.64	5.35	0.48	6e-7	Diffuse large B cell lymphoma;
THYM	cis	rs9314614	0.789	rs2951862	chr8:6711304	C/G	cg27319216	chr8:6693540	XKR5	-0.59	-6.05	-0.53	2.89e-8	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg01570182	chr17:44337453	NA	0.91	9.94	0.71	2.22e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg08975724	chr8:8085496	FLJ10661	0.63	4.94	0.45	3.28e-6	Mood instability;
THYM	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.77	7.14	0.59	1.82e-10	Personality dimensions;
THYM	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg02734326	chr4:10020555	SLC2A9	0.77	7.16	0.59	1.73e-10	Bone mineral density;
THYM	cis	rs2108225	0.837	rs6466186	chr7:107446966	G/C	cg18560240	chr7:107437656	SLC26A3	-0.77	-5.46	-0.49	3.82e-7	Ulcerative colitis;
THYM	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg25838465	chr1:92012736	NA	0.67	4.85	0.45	4.9e-6	Eosinophil percentage of white cells;
THYM	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg24675056	chr1:15929824	NA	0.74	6.01	0.53	3.37e-8	Systolic blood pressure;
THYM	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg27494647	chr7:150038898	RARRES2	0.47	5.41	0.49	4.77e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7909791	0.678	rs10883932	chr10:105623956	T/A	cg24587175	chr10:105670608	OBFC1	0.7	6.63	0.56	2.03e-9	White matter hyperintensity burden;
THYM	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg19862616	chr7:65841803	NCRNA00174	1.09	12.48	0.79	9.87e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs11785693	0.862	rs17435835	chr8:5000713	C/T	cg26367366	chr8:4980734	NA	-1.19	-6.2	-0.54	1.44e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs11577318	0.579	rs11247934	chr1:26695758	A/T	cg16664472	chr1:26644822	UBXN11;CD52	0.33	4.69	0.43	9e-6	Granulocyte percentage of myeloid white cells;
THYM	cis	rs12594515	0.935	rs8042519	chr15:45996341	G/C	cg01629716	chr15:45996671	NA	0.53	5.27	0.48	8.45e-7	Waist circumference;Weight;
THYM	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg04025307	chr7:1156635	C7orf50	0.76	4.73	0.44	7.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg03690763	chr11:133734501	NA	0.62	5.12	0.46	1.6e-6	Childhood ear infection;
THYM	cis	rs7112925	0.738	rs12803688	chr11:66833265	G/A	cg24851651	chr11:66362959	CCS	-0.62	-5.03	-0.46	2.27e-6	Height;
THYM	cis	rs11168351	0.750	rs11168366	chr12:48421773	T/C	cg21466736	chr12:48725269	NA	0.48	4.54	0.42	1.65e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg18252515	chr7:66147081	NA	-1.37	-8.05	-0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs1322639	0.614	rs6925188	chr6:169563337	T/C	cg04662567	chr6:169592167	NA	-0.79	-6.17	-0.53	1.69e-8	Pulse pressure;
THYM	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg06028605	chr16:24865363	SLC5A11	-0.56	-5.26	-0.47	8.84e-7	Intelligence (multi-trait analysis);
THYM	cis	rs478304	0.651	rs4930319	chr11:65555458	G/C	cg17480646	chr11:65405466	SIPA1	-0.96	-8.75	-0.67	7.82e-14	Acne (severe);
THYM	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg26039829	chr8:22132926	PIWIL2	0.65	5.7	0.5	1.37e-7	Hypertriglyceridemia;
THYM	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg07606381	chr6:8435919	SLC35B3	0.64	4.8	0.44	5.92e-6	Motion sickness;
THYM	cis	rs16866061	0.855	rs11687736	chr2:225405122	A/T	cg22455342	chr2:225449267	CUL3	0.67	4.84	0.44	4.98e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg03676636	chr4:99064102	C4orf37	-0.44	-6.64	-0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9929218	0.581	rs12185157	chr16:68784587	G/A	cg01251360	chr16:68772225	CDH1	-0.3	-4.55	-0.42	1.59e-5	Colorectal cancer;
THYM	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg11812906	chr14:75593930	NEK9	-0.87	-8.3	-0.65	7.13e-13	Height;
THYM	cis	rs9674544	0.792	rs8076012	chr17:47101989	G/A	cg20966754	chr17:47091339	IGF2BP1	-0.55	-7.38	-0.6	6.02e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs2219968	0.525	rs1352212	chr8:78877841	T/C	cg00738934	chr8:78996279	NA	0.61	4.93	0.45	3.5e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7078219	0.543	rs7096296	chr10:101277816	A/G	cg17888390	chr10:101282816	NA	0.45	4.7	0.43	8.65e-6	Dental caries;
THYM	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg05294307	chr14:35346193	BAZ1A	-0.82	-5.39	-0.48	5.09e-7	Psoriasis;
THYM	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg13683864	chr3:40499215	RPL14	-0.88	-8.62	-0.66	1.5e-13	Renal cell carcinoma;
THYM	cis	rs1870805	0.580	rs4736126	chr8:140991284	C/T	cg15997020	chr8:140990656	TRAPPC9	-0.83	-6.89	-0.58	5.99e-10	Obesity-related traits;
THYM	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg18477163	chr1:228402036	OBSCN	0.61	6.64	0.56	1.92e-9	Diastolic blood pressure;
THYM	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg08999081	chr20:33150536	PIGU	0.57	4.79	0.44	6.02e-6	Coronary artery disease;
THYM	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg05313129	chr8:58192883	C8orf71	-0.85	-4.97	-0.45	2.97e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg06481639	chr22:41940642	POLR3H	-0.74	-5.55	-0.49	2.6e-7	Vitiligo;
THYM	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg07061783	chr6:25882402	NA	-0.86	-7.58	-0.61	2.3e-11	Intelligence (multi-trait analysis);
THYM	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg04398451	chr17:18023971	MYO15A	-0.67	-5.57	-0.5	2.37e-7	Total body bone mineral density;
THYM	cis	rs1642645	0.831	rs4660212	chr1:42496399	C/T	cg06092502	chr1:42611687	NA	-0.64	-4.88	-0.45	4.26e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg25036284	chr2:26402008	FAM59B	0.8	5.36	0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs476633	0.708	rs3986303	chr15:41443179	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.7	-5.46	-0.49	3.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg11266682	chr4:10021025	SLC2A9	0.68	9.72	0.71	6.47e-16	Bone mineral density;
THYM	cis	rs9902453	0.967	rs4533341	chr17:28495672	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	4.6	0.43	1.33e-5	Coffee consumption (cups per day);
THYM	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg17830980	chr10:43048298	ZNF37B	-1.09	-10.96	-0.75	1.49e-18	Extrinsic epigenetic age acceleration;
THYM	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg03929089	chr4:120376271	NA	-0.98	-10.16	-0.72	7.65e-17	Height;
THYM	cis	rs4727027	0.704	rs2888600	chr7:148908562	C/T	cg23583168	chr7:148888333	NA	-1.07	-15.64	-0.85	5e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs142483589	1	rs142483589	chr9:139320323	CCG/C	cg14115884	chr9:139300582	SDCCAG3	0.71	4.75	0.44	7.34e-6	White blood cell count;
THYM	cis	rs7679	0.947	rs6065908	chr20:44569930	C/T	cg09053081	chr20:44746392	CD40	0.82	4.55	0.42	1.6e-5	Triglycerides;HDL cholesterol;Gut microbiota (functional units);
THYM	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.55	-0.73	1.12e-17	Primary sclerosing cholangitis;
THYM	cis	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg07460842	chr6:66804631	NA	-0.9	-6.58	-0.56	2.6e-9	Exhaled nitric oxide output;
THYM	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg23711669	chr6:146136114	FBXO30	1.0	10.85	0.74	2.58e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg20007245	chr22:24372913	LOC391322	-0.74	-7.09	-0.59	2.4e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs654950	0.774	rs941972	chr1:42040740	T/C	cg06885757	chr1:42089581	HIVEP3	-0.53	-6.83	-0.57	8.19e-10	Airway imaging phenotypes;
THYM	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg18230493	chr5:56204884	C5orf35	0.79	5.09	0.46	1.82e-6	Initial pursuit acceleration;
THYM	cis	rs4273100	0.688	rs1533034	chr17:19153175	G/C	cg25447019	chr17:19030144	GRAPL	-0.79	-6.16	-0.53	1.74e-8	Schizophrenia;
THYM	cis	rs7178375	0.843	rs3794596	chr15:31223026	C/G	cg24163575	chr15:30261379	NA	0.62	4.56	0.42	1.54e-5	Hypertriglyceridemia;
THYM	cis	rs1564271	0.553	rs2489583	chr10:26987698	A/G	cg24343755	chr10:26987087	PDSS1	-0.63	-4.57	-0.42	1.47e-5	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
THYM	cis	rs12478296	0.901	rs9653611	chr2:243006956	C/G	cg18898632	chr2:242989856	NA	-0.65	-4.47	-0.42	2.18e-5	Obesity-related traits;
THYM	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg06917634	chr15:78832804	PSMA4	-0.91	-7.9	-0.63	4.85e-12	Sudden cardiac arrest;
THYM	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg14004847	chr7:1930337	MAD1L1	0.7	5.67	0.5	1.56e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs16866061	1.000	rs10933068	chr2:225418360	G/A	cg22455342	chr2:225449267	CUL3	0.67	4.84	0.44	4.98e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs2229238	0.911	rs73020234	chr1:154482767	C/A	cg21262032	chr1:154437693	IL6R	-0.6	-5.3	-0.48	7.51e-7	Coronary heart disease;
THYM	cis	rs4888262	0.716	rs6564157	chr16:74710254	T/C	cg01733217	chr16:74700730	RFWD3	1.03	11.66	0.77	5.08e-20	Testicular germ cell tumor;
THYM	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg11245990	chr11:68621969	NA	0.54	6.82	0.57	8.33e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4690686	0.509	rs11730559	chr4:177259257	A/T	cg17059388	chr4:177262070	NA	0.45	6.01	0.52	3.49e-8	Essential tremor;
THYM	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.81	-6.93	-0.58	4.99e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7267979	1.000	rs2387880	chr20:25377787	T/C	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs8044868	0.586	rs7201643	chr16:72100780	C/A	cg16558253	chr16:72132732	DHX38	-0.55	-4.58	-0.43	1.41e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs9314614	0.714	rs2980949	chr8:6713250	C/G	cg27319216	chr8:6693540	XKR5	-0.56	-5.69	-0.5	1.42e-7	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs9807989	0.524	rs6543126	chr2:103027104	G/A	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs9807841	0.858	rs734535	chr19:10847298	G/T	cg17848348	chr19:10766748	ILF3	-0.62	-5.01	-0.46	2.51e-6	Inflammatory skin disease;
THYM	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg16989719	chr2:238392110	NA	-0.6	-5.82	-0.51	8.08e-8	Prostate cancer;
THYM	cis	rs12410462	1.000	rs75198003	chr1:227623853	C/A	cg23173402	chr1:227635558	NA	0.68	6.15	0.53	1.79e-8	Major depressive disorder;
THYM	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg18105134	chr13:113819100	PROZ	1.02	9.35	0.69	4.08e-15	Platelet distribution width;
THYM	cis	rs6430585	0.584	rs4954276	chr2:136402117	A/G	cg07169764	chr2:136633963	MCM6	0.73	5.98	0.52	3.83e-8	Corneal structure;
THYM	cis	rs8050907	0.744	rs7194436	chr16:4539832	G/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.58	0.43	1.38e-5	Obesity-related traits;
THYM	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg25703541	chr22:24373054	LOC391322	-0.9	-10.28	-0.73	4.16e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg12667521	chr19:29218732	NA	0.54	4.46	0.42	2.25e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	trans	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg01121180	chr19:51302454	C19orf48;SNORD88B	0.79	7.03	0.58	3.18e-10	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10504073	0.584	rs7823690	chr8:49943831	G/A	cg00325661	chr8:49890786	NA	1.06	10.84	0.74	2.75e-18	Blood metabolite ratios;
THYM	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.26	0.47	9.05e-7	Height;
THYM	cis	rs10847980	0.590	rs75217947	chr12:123346177	G/C	cg25930673	chr12:123319894	HIP1R	1.19	5.19	0.47	1.21e-6	Adiponectin levels;
THYM	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23221052	chr5:179740743	GFPT2	-0.85	-6.84	-0.57	7.77e-10	Height;
THYM	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg03188948	chr7:1209495	NA	0.88	5.58	0.5	2.29e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg12205435	chr5:138714322	SLC23A1	-0.66	-5.24	-0.47	9.62e-7	Esophageal squamous cell carcinoma;
THYM	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg21984481	chr17:79567631	NPLOC4	-0.6	-6.66	-0.56	1.74e-9	Eye color traits;
THYM	cis	rs2012796	0.785	rs61986599	chr14:81860917	G/A	cg02996355	chr14:81879375	NA	0.84	6.47	0.55	4.29e-9	Night sleep phenotypes;
THYM	cis	rs2637266	0.935	rs12259550	chr10:78352843	A/G	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg13699009	chr12:122356056	WDR66	0.55	5.79	0.51	9.03e-8	Mean corpuscular volume;
THYM	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg06558623	chr16:89946397	TCF25	1.48	7.49	0.61	3.57e-11	Skin colour saturation;
THYM	cis	rs2811415	0.627	rs1984451	chr3:127768462	C/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs7000551	0.736	rs10107873	chr8:22356971	A/G	cg12081754	chr8:22256438	SLC39A14	0.64	5.85	0.51	6.94e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.96	-0.63	3.62e-12	Personality dimensions;
THYM	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg00908189	chr16:619842	PIGQ	1.06	9.15	0.68	1.07e-14	Height;
THYM	cis	rs2075230	0.705	rs1642795	chr17:7542591	C/T	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	-0.31	-4.56	-0.42	1.5e-5	Hormone measurements;
THYM	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg01097406	chr16:89675127	NA	-0.55	-4.69	-0.43	8.99e-6	Vitiligo;
THYM	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03264133	chr6:25882463	NA	-0.76	-5.83	-0.51	7.72e-8	Blood metabolite levels;
THYM	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg12963246	chr6:28129442	ZNF389	0.51	4.56	0.42	1.52e-5	Parkinson's disease;
THYM	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg12165864	chr7:66369176	NA	-0.65	-5.08	-0.46	1.89e-6	Aortic root size;
THYM	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg20503657	chr10:835505	NA	1.17	8.3	0.65	7.12e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs7107174	0.892	rs10793310	chr11:78099014	T/G	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs55702914	1.000	rs56234206	chr2:198215995	T/A	cg00792783	chr2:198669748	PLCL1	0.64	4.83	0.44	5.26e-6	Major depression and alcohol dependence;
THYM	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg26384229	chr12:38710491	ALG10B	1.05	10.44	0.73	1.86e-17	Heart rate;
THYM	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg25566285	chr7:158114605	PTPRN2	0.88	10.16	0.72	7.65e-17	Calcium levels;
THYM	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg02820040	chr2:241836501	C2orf54	-0.33	-6.84	-0.57	7.7e-10	Urinary metabolites;
THYM	cis	rs4731207	0.844	rs34204767	chr7:124401764	C/T	cg05285228	chr7:124571219	POT1	0.71	5.65	0.5	1.64e-7	Cutaneous malignant melanoma;
THYM	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg22875332	chr1:76189707	ACADM	0.88	9.61	0.7	1.12e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg18252515	chr7:66147081	NA	-0.66	-4.96	-0.45	3.08e-6	Aortic root size;
THYM	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.86	5.48	0.49	3.47e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg16586182	chr3:47516702	SCAP	-0.6	-5.15	-0.47	1.39e-6	Colorectal cancer;
THYM	trans	rs3960554	0.741	rs28446604	chr7:75662518	C/T	cg19862616	chr7:65841803	NCRNA00174	0.95	7.29	0.6	9.36e-11	Eotaxin levels;
THYM	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg18252515	chr7:66147081	NA	-1.45	-8.82	-0.67	5.41e-14	Diabetic kidney disease;
THYM	cis	rs4474465	0.920	rs9804428	chr11:78158948	G/A	cg19901956	chr11:77921274	USP35	-0.62	-4.63	-0.43	1.15e-5	Alzheimer's disease (survival time);
THYM	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg00484396	chr16:3507460	NAT15	0.66	6.44	0.55	4.97e-9	Tuberculosis;
THYM	cis	rs8064299	0.967	rs878905	chr17:72769411	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.65	5.68	0.5	1.45e-7	Monocyte count;
THYM	cis	rs951188	0.688	rs78439062	chr2:150408140	T/A	cg17961725	chr2:150454027	NA	-1.03	-5.39	-0.48	5.11e-7	Daytime sleep phenotypes;
THYM	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11890956	chr21:40555474	PSMG1	1.08	10.56	0.73	1.05e-17	Cognitive function;
THYM	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.7	5.63	0.5	1.85e-7	Menarche (age at onset);
THYM	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs10487112	1.000	rs13222596	chr7:90050168	G/A	cg26521402	chr7:89842741	STEAP2	0.51	4.67	0.43	1.01e-5	Perceived unattractiveness to mosquitoes;
THYM	cis	rs887829	0.667	rs7577677	chr2:234590616	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.81	-6.58	-0.56	2.52e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs9581857	0.579	rs76657892	chr13:27997604	A/G	cg22138327	chr13:27999177	GTF3A	1.04	6.13	0.53	1.97e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg20887711	chr4:1340912	KIAA1530	-0.58	-4.64	-0.43	1.13e-5	Obesity-related traits;
THYM	cis	rs6076065	0.723	rs4815199	chr20:23347169	G/A	cg11657817	chr20:23433608	CST11	0.31	4.57	0.42	1.48e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs3772130	0.962	rs11719093	chr3:121487686	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.77	4.8	0.44	5.85e-6	Cognitive performance;
THYM	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.21	0.47	1.1e-6	Electroencephalogram traits;
THYM	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg07532245	chr17:28927093	LRRC37B2	0.71	4.48	0.42	2.04e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs863345	0.604	rs923664	chr1:158507691	A/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg15448220	chr1:150897856	SETDB1	0.92	7.75	0.62	1.01e-11	Melanoma;
THYM	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg07157834	chr1:205819609	PM20D1	0.85	8.15	0.64	1.44e-12	Monocyte percentage of white cells;
THYM	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs988913	0.706	rs7761336	chr6:54734602	A/T	cg19716238	chr6:54711378	FAM83B	0.53	5.47	0.49	3.67e-7	Menarche (age at onset);
THYM	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg06968155	chr5:131705112	SLC22A5	0.59	4.72	0.44	8.07e-6	Blood metabolite levels;
THYM	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg14784868	chr12:69753453	YEATS4	1.13	10.92	0.75	1.82e-18	Blood protein levels;
THYM	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg20891283	chr12:69753455	YEATS4	-0.65	-4.77	-0.44	6.62e-6	Response to diuretic therapy;
THYM	cis	rs728616	0.867	rs61860400	chr10:81723427	T/C	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7771547	0.642	rs628213	chr6:36508646	T/C	cg07856975	chr6:36356162	ETV7	0.52	5.01	0.46	2.48e-6	Platelet distribution width;
THYM	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg25036284	chr2:26402008	FAM59B	-0.76	-5.02	-0.46	2.44e-6	Gut microbiome composition (summer);
THYM	cis	rs7294478	0.839	rs6487849	chr12:7263699	A/G	cg01074767	chr12:7262137	C1RL;LOC283314	-0.54	-4.51	-0.42	1.84e-5	Neuritic plaque;
THYM	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg11494091	chr17:61959527	GH2	1.07	16.2	0.86	4.34e-29	Prudent dietary pattern;
THYM	cis	rs6430585	1.000	rs6430585	chr2:136506927	A/C	cg23851026	chr2:136556271	LCT	-0.63	-5.85	-0.51	6.93e-8	Corneal structure;
THYM	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg20295408	chr7:1910781	MAD1L1	-0.65	-5.2	-0.47	1.16e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg15782153	chr7:917662	C7orf20	0.63	7.14	0.59	1.82e-10	Perceived unattractiveness to mosquitoes;
THYM	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg26314531	chr2:26401878	FAM59B	0.78	5.13	0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs73086581	1.000	rs73086540	chr20:3950850	T/C	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg26384229	chr12:38710491	ALG10B	0.61	4.67	0.43	9.91e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg12615879	chr12:58013172	SLC26A10	0.63	5.8	0.51	8.6e-8	Multiple sclerosis;
THYM	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.1	-7.57	-0.61	2.45e-11	Schizophrenia;
THYM	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs9796	0.561	rs7173086	chr15:41509288	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.55	-4.57	-0.42	1.49e-5	Menopause (age at onset);
THYM	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg05890377	chr2:74357713	NA	1.08	9.83	0.71	3.73e-16	Gestational age at birth (maternal effect);
THYM	cis	rs6785206	0.803	rs6774512	chr3:128415868	C/T	cg16766828	chr3:128327626	NA	-0.77	-7.55	-0.61	2.68e-11	Lymphocyte percentage of white cells;
THYM	cis	rs988913	1.000	rs9382408	chr6:54836984	A/G	cg18532076	chr6:54711417	FAM83B	0.49	4.71	0.44	8.33e-6	Menarche (age at onset);
THYM	cis	rs3204270	0.673	rs62077190	chr17:79676109	C/A	cg13117272	chr17:79681052	SLC25A10	-0.78	-4.86	-0.45	4.69e-6	Dental caries;
THYM	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs8067545	0.611	rs7222984	chr17:20019694	A/C	cg13482628	chr17:19912719	NA	0.56	4.62	0.43	1.22e-5	Schizophrenia;
THYM	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg23173402	chr1:227635558	NA	0.82	6.44	0.55	4.95e-9	Major depressive disorder;
THYM	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-6.02	-0.53	3.27e-8	Prostate cancer;
THYM	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg17830980	chr10:43048298	ZNF37B	-1.09	-10.96	-0.75	1.49e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs4242434	0.854	rs3735893	chr8:22452704	A/G	cg14690197	chr8:22456421	C8orf58	0.48	4.63	0.43	1.16e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.89	0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs2282300	0.956	rs1717779	chr11:30376698	A/T	cg06241208	chr11:30344200	C11orf46	-0.8	-5.64	-0.5	1.73e-7	Morning vs. evening chronotype;
THYM	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.64	8.42	0.65	3.88e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg22875332	chr1:76189707	ACADM	-0.54	-5.15	-0.47	1.39e-6	Daytime sleep phenotypes;
THYM	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.65	0.5	1.69e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg13683864	chr3:40499215	RPL14	-1.04	-11.27	-0.76	3.35e-19	Renal cell carcinoma;
THYM	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg13695892	chr22:41940480	POLR3H	-1.05	-8.58	-0.66	1.76e-13	Vitiligo;
THYM	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg01570182	chr17:44337453	NA	0.91	9.94	0.71	2.22e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs28408315	0.958	rs1036377	chr15:79197129	G/A	cg00540400	chr15:79124168	NA	0.64	5.1	0.46	1.73e-6	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;
THYM	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.99	6.27	0.54	1.06e-8	Gut microbiome composition (summer);
THYM	cis	rs7216064	0.589	rs8072723	chr17:66056970	T/A	cg12091567	chr17:66097778	LOC651250	0.94	7.63	0.62	1.84e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs427394	0.664	rs274696	chr5:6732213	A/C	cg10857441	chr5:6722123	POLS	-0.69	-8.08	-0.64	2.05e-12	Menopause (age at onset);
THYM	cis	rs7104764	0.879	rs6421986	chr11:221659	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.1	9.77	0.71	5.16e-16	Menarche (age at onset);
THYM	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-4.5	-0.42	1.93e-5	Cognitive function;
THYM	cis	rs7582180	1.000	rs4851286	chr2:100915629	T/C	cg14675211	chr2:100938903	LONRF2	0.59	4.53	0.42	1.75e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg04025307	chr7:1156635	C7orf50	0.69	6.8	0.57	9.42e-10	Longevity;Endometriosis;
THYM	cis	rs892961	0.932	rs55661113	chr17:75408386	A/C	cg11351908	chr17:75402473	SEPT9	0.59	5.74	0.51	1.11e-7	Airflow obstruction;
THYM	cis	rs497273	0.534	rs9431	chr12:121202664	A/C	cg02403541	chr12:121454288	C12orf43	0.53	4.53	0.42	1.73e-5	Systemic lupus erythematosus;
THYM	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11905131	chr22:24372483	LOC391322	0.88	9.2	0.69	8.31e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11648796	0.717	rs10682	chr16:767430	C/G	cg10254923	chr16:769848	FAM173A	0.52	6.26	0.54	1.12e-8	Height;
THYM	cis	rs9309473	0.607	rs2421488	chr2:73590625	C/T	cg20560298	chr2:73613845	ALMS1	-0.64	-4.48	-0.42	2.1e-5	Metabolite levels;
THYM	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs12643440	0.538	rs2041444	chr4:17138005	A/C	cg22650099	chr4:17144496	NA	-0.64	-4.54	-0.42	1.64e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg11812906	chr14:75593930	NEK9	-0.87	-8.2	-0.64	1.16e-12	Height;
THYM	cis	rs17604090	0.938	rs28664977	chr7:29685369	C/T	cg19413766	chr7:29689036	LOC646762	-0.93	-5.09	-0.46	1.77e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs5769707	0.604	rs1018814	chr22:50036900	T/C	cg05373962	chr22:49881684	NA	-0.67	-6.31	-0.54	8.78e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1629083	0.935	rs2368238	chr11:118091761	T/G	cg25155064	chr11:118100782	MPZL3	-0.57	-5.04	-0.46	2.21e-6	Lung cancer;
THYM	cis	rs6665290	0.669	rs3795445	chr1:227180947	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.08	-12.43	-0.79	1.26e-21	Myeloid white cell count;
THYM	cis	rs818427	0.684	rs866006	chr5:112176559	T/G	cg04614008	chr5:112630677	MCC	-0.64	-4.6	-0.43	1.31e-5	Total body bone mineral density;
THYM	cis	rs2237457	0.543	rs2529386	chr7:50701957	C/T	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.48e-6	Schizophrenia (treatment resistant);
THYM	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg17279839	chr7:150038598	RARRES2	0.55	5.21	0.47	1.1e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg02353165	chr6:42928485	GNMT	0.84	7.53	0.61	2.96e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06850241	chr22:41845214	NA	-0.6	-5.36	-0.48	5.9e-7	Vitiligo;
THYM	cis	rs892961	0.965	rs312856	chr17:75401598	A/G	cg05865280	chr17:75406074	SEPT9	0.47	7.97	0.63	3.46e-12	Airflow obstruction;
THYM	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg21657705	chr17:61574500	ACE	0.43	4.68	0.43	9.67e-6	Prudent dietary pattern;
THYM	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg03060546	chr3:49711283	APEH	0.74	6.04	0.53	2.97e-8	Resting heart rate;
THYM	cis	rs10463554	0.927	rs56361326	chr5:102389888	T/C	cg23492399	chr5:102201601	PAM	-0.69	-5.09	-0.46	1.83e-6	Parkinson's disease;
THYM	cis	rs6754311	0.593	rs313518	chr2:136439090	C/T	cg04750100	chr2:136595281	LCT	0.56	5.89	0.52	5.87e-8	Mosquito bite size;
THYM	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12667521	chr19:29218732	NA	0.89	8.11	0.64	1.8e-12	Methadone dose in opioid dependence;
THYM	cis	rs1018836	0.739	rs4734247	chr8:91569144	A/G	cg16814680	chr8:91681699	NA	-0.78	-6.38	-0.55	6.35e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg08305652	chr11:111469057	NA	0.52	4.47	0.42	2.2e-5	Primary sclerosing cholangitis;
THYM	cis	rs4808199	0.895	rs6511036	chr19:19582651	A/G	cg03709012	chr19:19516395	GATAD2A	1.19	7.25	0.6	1.12e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg08885076	chr2:99613938	TSGA10	0.57	5.28	0.48	8.05e-7	Chronic sinus infection;
THYM	cis	rs9810089	0.708	rs711977	chr3:136227387	G/A	cg21827317	chr3:136751795	NA	0.59	5.03	0.46	2.33e-6	Gestational age at birth (child effect);
THYM	cis	rs6840360	0.554	rs62329088	chr4:152471289	C/T	cg22705602	chr4:152727874	NA	-0.71	-7.94	-0.63	4.03e-12	Intelligence (multi-trait analysis);
THYM	cis	rs907683	0.635	rs11691617	chr2:220295167	C/T	cg15015639	chr2:220282977	DES	0.43	5.91	0.52	5.29e-8	Resting heart rate;
THYM	cis	rs2806561	0.894	rs629107	chr1:23537971	C/T	cg08872493	chr1:23521417	HTR1D	0.37	4.61	0.43	1.26e-5	Height;
THYM	cis	rs10992471	0.630	rs10992322	chr9:95159196	A/G	cg14631576	chr9:95140430	CENPP	-0.82	-8.2	-0.64	1.12e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs713587	0.713	rs12618252	chr2:25207950	G/A	cg01884057	chr2:25150051	NA	-0.56	-5.49	-0.49	3.37e-7	Body mass index in non-asthmatics;
THYM	cis	rs55728055	0.661	rs58365021	chr22:32060838	G/C	cg01338084	chr22:32026380	PISD	1.4	5.58	0.5	2.23e-7	Age-related hearing impairment;
THYM	cis	rs8067545	0.611	rs2703795	chr17:20077141	C/A	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.14e-5	Schizophrenia;
THYM	cis	rs4638749	0.677	rs6755598	chr2:108827674	G/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg01819863	chr10:32635814	EPC1	1.04	6.64	0.56	1.9e-9	Sexual dysfunction (female);
THYM	cis	rs2029213	0.523	rs2035450	chr3:53269317	C/T	cg16894138	chr3:53270350	TKT	0.83	7.87	0.63	5.52e-12	Heart rate;
THYM	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg17911788	chr17:44343683	NA	0.59	5.86	0.52	6.74e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg07460842	chr6:66804631	NA	1.1	8.21	0.64	1.08e-12	Exhaled nitric oxide output;
THYM	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg00852783	chr1:26633632	UBXN11	0.86	8.81	0.67	5.74e-14	Obesity-related traits;
THYM	cis	rs34912216	0.580	rs13232652	chr7:4131427	G/C	cg03141780	chr7:4150753	SDK1	0.65	4.89	0.45	4.1e-6	Motion sickness;
THYM	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg12564285	chr5:131593104	PDLIM4	0.6	7.19	0.59	1.48e-10	Acylcarnitine levels;
THYM	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg10802521	chr3:52805072	NEK4	-0.71	-5.96	-0.52	4.22e-8	Bipolar disorder;
THYM	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg03684893	chr10:554711	DIP2C	0.63	5.47	0.49	3.61e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	10.29	0.73	4e-17	Chronic sinus infection;
THYM	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs2742234	0.590	rs2435338	chr10:43642115	A/G	cg06632098	chr10:43605906	RET	-0.77	-4.96	-0.45	3.09e-6	Hirschsprung disease;
THYM	cis	rs6565180	0.851	rs3574	chr16:30411382	C/G	cg17640201	chr16:30407289	ZNF48	0.93	8.59	0.66	1.72e-13	Tonsillectomy;
THYM	cis	rs72829446	0.932	rs72827584	chr17:7487573	C/T	cg07091842	chr17:7155530	C17orf81;DULLARD	-1.04	-4.62	-0.43	1.22e-5	Androgen levels;
THYM	cis	rs12310956	0.515	rs1405031	chr12:33958931	A/C	cg06521331	chr12:34319734	NA	-0.88	-8.25	-0.65	9.01e-13	Morning vs. evening chronotype;
THYM	cis	rs6906287	0.647	rs6938226	chr6:118852561	C/A	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs593982	1.000	rs470360	chr11:65500530	T/C	cg08755490	chr11:65554678	OVOL1	1.36	8.73	0.67	8.51e-14	Atopic dermatitis;
THYM	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg13319975	chr6:146136371	FBXO30	-0.69	-5.76	-0.51	1.02e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg02527881	chr3:46936655	PTH1R	0.62	6.09	0.53	2.34e-8	Colorectal cancer;
THYM	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg01710189	chr8:22454888	PDLIM2	-0.55	-5.88	-0.52	6.08e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6693295	0.536	rs59080925	chr1:246221360	C/G	cg11798871	chr1:246315928	SMYD3	-0.78	-4.71	-0.43	8.52e-6	Migraine - clinic-based;Migraine with aura;
THYM	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg10360139	chr7:1886902	MAD1L1	-0.59	-5.22	-0.47	1.04e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs11651000	0.895	rs79065115	chr17:45855929	C/G	cg03474202	chr17:45855739	NA	-0.71	-4.81	-0.44	5.73e-6	IgG glycosylation;
THYM	cis	rs4919687	0.550	rs12775883	chr10:104485301	G/A	cg18761893	chr10:103892519	PPRC1	0.61	4.47	0.42	2.15e-5	Colorectal cancer;
THYM	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-5.29	-0.48	7.68e-7	Hemoglobin concentration;
THYM	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.67	-0.81	3.71e-24	Height;
THYM	cis	rs1023500	1.000	rs7293091	chr22:42341308	A/G	cg19448990	chr22:41842841	TOB2	-0.76	-4.89	-0.45	4.06e-6	Schizophrenia;
THYM	cis	rs10203711	1.000	rs907107	chr2:239565780	T/C	cg14580085	chr2:239553406	NA	0.68	6.17	0.53	1.65e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6138458	1.000	rs227630	chr20:24913584	A/G	cg26195577	chr20:24973756	C20orf3	1.11	10.52	0.73	1.29e-17	Blood protein levels;
THYM	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.69	5.65	0.5	1.67e-7	Blood metabolite levels;
THYM	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg10589385	chr1:150898437	SETDB1	0.57	4.55	0.42	1.56e-5	Melanoma;
THYM	cis	rs941408	1.000	rs1076448	chr19:2792343	G/A	cg06609049	chr19:2785107	THOP1	0.78	6.48	0.55	3.97e-9	Total cholesterol levels;
THYM	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg10803722	chr21:46713166	LOC642852	0.38	5.0	0.46	2.58e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs786425	0.530	rs10734908	chr12:124219036	C/A	cg15249119	chr12:124971054	NCOR2	0.53	4.98	0.46	2.8e-6	Pubertal anthropometrics;
THYM	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9902453	0.845	rs3115101	chr17:28041627	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.85	0.45	4.84e-6	Coffee consumption (cups per day);
THYM	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg21433313	chr16:3507492	NAT15	-0.51	-4.53	-0.42	1.7e-5	Body mass index (adult);
THYM	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.33	10.0	0.72	1.62e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg08645402	chr16:4508243	NA	0.68	5.43	0.49	4.34e-7	Schizophrenia;
THYM	cis	rs988913	0.958	rs1503140	chr6:54810766	A/G	cg18532076	chr6:54711417	FAM83B	0.51	5.02	0.46	2.38e-6	Menarche (age at onset);
THYM	cis	rs6754311	0.773	rs4988226	chr2:136610598	A/G	cg20242066	chr2:136595261	LCT	-0.6	-7.14	-0.59	1.83e-10	Mosquito bite size;
THYM	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.7	-5.63	-0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg27398817	chr8:82754497	SNX16	-0.71	-6.05	-0.53	2.89e-8	Diastolic blood pressure;
THYM	cis	rs2299587	0.689	rs6586670	chr8:17772332	A/G	cg01800426	chr8:17659068	MTUS1	-0.57	-4.51	-0.42	1.87e-5	Economic and political preferences;
THYM	cis	rs870825	0.548	rs12513029	chr4:185665118	G/A	cg04058563	chr4:185651563	MLF1IP	0.92	7.16	0.59	1.66e-10	Blood protein levels;
THYM	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg04111992	chr7:158790115	NA	-0.57	-4.89	-0.45	4.17e-6	Facial morphology (factor 20);
THYM	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg02569458	chr12:86230093	RASSF9	-0.55	-4.78	-0.44	6.5e-6	Major depressive disorder;
THYM	cis	rs28595532	0.920	rs115242199	chr4:119728652	A/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs6669072	0.728	rs1188927	chr1:91315786	T/A	cg08895590	chr1:91227319	NA	0.53	5.63	0.5	1.86e-7	Cognitive function;
THYM	cis	rs4460079	0.531	rs4364328	chr4:114865091	C/T	cg02060584	chr4:113970739	ANK2	-0.54	-4.47	-0.42	2.15e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs11690935	0.959	rs13419987	chr2:172623914	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.84	-6.16	-0.53	1.77e-8	Schizophrenia;
THYM	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg24209194	chr3:40518798	ZNF619	0.57	4.61	0.43	1.28e-5	Renal cell carcinoma;
THYM	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.99	-0.75	1.26e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg00256281	chr22:41985642	PMM1	-0.58	-4.63	-0.43	1.17e-5	Vitiligo;
THYM	cis	rs13401104	0.680	rs72620813	chr2:237146225	C/T	cg19324714	chr2:237145437	ASB18	0.63	4.68	0.43	9.6e-6	Educational attainment;
THYM	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg22590775	chr19:49891494	CCDC155	0.63	4.8	0.44	5.89e-6	Multiple sclerosis;
THYM	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg04731861	chr2:219085781	ARPC2	-0.5	-4.5	-0.42	1.93e-5	Colorectal cancer;
THYM	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs12681287	0.752	rs10085920	chr8:87252666	C/T	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs7635838	0.650	rs1375206	chr3:11339117	C/G	cg00170343	chr3:11313890	ATG7	0.57	4.56	0.42	1.51e-5	HDL cholesterol;
THYM	cis	rs11039216	1	rs11039216	chr11:47406592	C/T	cg20307385	chr11:47447363	PSMC3	0.71	5.84	0.51	7.15e-8	Neuroticism;
THYM	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	6.66	0.56	1.74e-9	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4242434	0.854	rs13258100	chr8:22451116	A/T	cg21658235	chr8:22456391	C8orf58	0.59	5.42	0.49	4.48e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.54e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg04750100	chr2:136595281	LCT	0.57	6.2	0.54	1.44e-8	Mosquito bite size;
THYM	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	4.5	0.42	1.92e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs4731207	0.596	rs900047	chr7:124673373	A/G	cg05285228	chr7:124571219	POT1	0.63	4.74	0.44	7.37e-6	Cutaneous malignant melanoma;
THYM	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg10802521	chr3:52805072	NEK4	-0.73	-6.21	-0.54	1.42e-8	Bipolar disorder;
THYM	cis	rs10208940	0.614	rs10208566	chr2:68836020	A/C	cg09157127	chr2:69201416	GKN1	0.95	4.9	0.45	3.96e-6	Urate levels in lean individuals;
THYM	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-5.16	-0.47	1.34e-6	Hemoglobin concentration;
THYM	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg02569458	chr12:86230093	RASSF9	0.65	5.55	0.49	2.6e-7	Major depressive disorder;
THYM	cis	rs2976388	0.647	rs2585136	chr8:143812141	A/G	cg13446199	chr8:143762866	PSCA	-0.46	-5.08	-0.46	1.89e-6	Urinary tract infection frequency;
THYM	cis	rs4343996	0.566	rs6967278	chr7:3396185	A/G	cg21248987	chr7:3385318	SDK1	-0.4	-5.14	-0.47	1.44e-6	Motion sickness;
THYM	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg00757033	chr12:89920650	WDR51B	0.77	11.72	0.77	3.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg06636001	chr8:8085503	FLJ10661	0.76	6.85	0.57	7.46e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs6547741	0.775	rs11692692	chr2:27861707	G/A	cg27432699	chr2:27873401	GPN1	-0.87	-7.83	-0.63	6.71e-12	Oral cavity cancer;
THYM	cis	rs10911251	0.546	rs2027085	chr1:183108611	G/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.59	-4.66	-0.43	1.02e-5	Colorectal cancer;
THYM	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg11526020	chr17:80870163	TBCD	0.47	4.67	0.43	1.01e-5	Glycated hemoglobin levels;
THYM	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg03476357	chr21:30257390	N6AMT1	0.6	4.57	0.42	1.44e-5	Dental caries;
THYM	trans	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.21	14.16	0.82	3.81e-25	Exhaled nitric oxide output;
THYM	cis	rs56079296	1.000	rs3792802	chr5:121403659	G/A	cg05256605	chr5:121412184	LOX	0.58	4.51	0.42	1.88e-5	Coronary artery disease;
THYM	cis	rs524023	0.914	rs4930556	chr11:64377726	G/C	cg19131476	chr11:64387923	NRXN2	-0.39	-5.58	-0.5	2.27e-7	Urate levels in obese individuals;
THYM	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg15693483	chr7:1102177	C7orf50	0.51	5.87	0.52	6.35e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg02269571	chr22:50332266	NA	-0.79	-5.71	-0.51	1.3e-7	Schizophrenia;
THYM	cis	rs13102973	0.617	rs11734991	chr4:135885411	T/G	cg14419869	chr4:135874104	NA	0.89	8.28	0.65	7.61e-13	Subjective well-being;
THYM	cis	rs1045902	0.967	rs10207625	chr2:73464808	T/C	cg24220031	chr2:73402428	NA	-0.81	-9.65	-0.7	9.42e-16	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg18681998	chr4:17616180	MED28	1.01	10.48	0.73	1.53e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4940575	0.679	rs2199937	chr18:60827789	C/T	cg20947866	chr18:61143580	SERPINB5	0.88	5.04	0.46	2.23e-6	Breast cancer;
THYM	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06850241	chr22:41845214	NA	-0.47	-4.6	-0.43	1.31e-5	Vitiligo;
THYM	cis	rs58521262	0.652	rs4024169	chr19:22901663	A/G	cg07749055	chr19:23076870	NA	-0.73	-5.7	-0.5	1.34e-7	Testicular germ cell tumor;
THYM	cis	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg21775007	chr8:11205619	TDH	-0.73	-5.68	-0.5	1.49e-7	Retinal vascular caliber;
THYM	trans	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03264133	chr6:25882463	NA	-0.84	-7.12	-0.59	2.08e-10	Intelligence (multi-trait analysis);
THYM	cis	rs1483890	0.642	rs1843050	chr3:69403918	C/T	cg22125112	chr3:69402811	FRMD4B	-0.54	-6.72	-0.57	1.31e-9	Resting heart rate;
THYM	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg05340658	chr4:99064831	C4orf37	-0.53	-4.51	-0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6596100	0.500	rs67904956	chr5:132274044	A/G	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Breast cancer;
THYM	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg17211192	chr8:82754475	SNX16	-0.85	-6.85	-0.57	7.41e-10	Diastolic blood pressure;
THYM	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg04717802	chr22:42394638	WBP2NL	0.74	4.66	0.43	1.02e-5	Birth weight;
THYM	cis	rs7968440	1.000	rs2251603	chr12:51049653	A/G	cg20014596	chr12:50898483	DIP2B	-0.56	-4.55	-0.42	1.57e-5	Fibrinogen;
THYM	cis	rs1670533	0.818	rs643484	chr4:1085826	A/G	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg16325326	chr1:53192061	ZYG11B	0.92	9.73	0.71	6.18e-16	Monocyte count;
THYM	cis	rs9905704	0.801	rs302847	chr17:56687481	C/T	cg12560992	chr17:57184187	TRIM37	0.65	4.51	0.42	1.89e-5	Testicular germ cell tumor;
THYM	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg25036284	chr2:26402008	FAM59B	-0.74	-4.87	-0.45	4.39e-6	Gut microbiome composition (summer);
THYM	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs7084402	0.967	rs1593678	chr10:60291548	A/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg18512352	chr11:47633146	NA	-0.38	-4.52	-0.42	1.76e-5	HDL cholesterol;
THYM	cis	rs11148252	0.538	rs2408611	chr13:52709742	C/T	cg05335186	chr13:53173507	NA	-0.37	-4.79	-0.44	6.11e-6	Lewy body disease;
THYM	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.62	5.61	0.5	2.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3768617	0.565	rs2027080	chr1:183074415	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg06074448	chr4:187884817	NA	-1.02	-13.05	-0.8	6.55e-23	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg15693483	chr7:1102177	C7orf50	0.54	6.37	0.55	6.72e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg23982607	chr1:1823379	GNB1	-0.94	-10.26	-0.72	4.61e-17	Body mass index;
THYM	cis	rs17321999	1.000	rs111597890	chr2:30492116	G/A	cg05247661	chr2:30472410	LBH	0.71	4.75	0.44	7.32e-6	Systemic lupus erythematosus;
THYM	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg04111992	chr7:158790115	NA	-0.55	-4.49	-0.42	2.03e-5	Facial morphology (factor 20);
THYM	cis	rs7843479	0.965	rs11135763	chr8:21813962	A/G	cg17168535	chr8:21777572	XPO7	0.73	5.25	0.47	9.34e-7	Mean corpuscular volume;
THYM	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.79	5.06	0.46	2.03e-6	Schizophrenia;
THYM	cis	rs5769765	0.671	rs138841	chr22:50181960	C/A	cg26441486	chr22:50317300	CRELD2	0.38	5.52	0.49	3e-7	Schizophrenia;
THYM	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg01017244	chr2:74357527	NA	1.08	9.57	0.7	1.37e-15	Gestational age at birth (maternal effect);
THYM	cis	rs6546324	0.625	rs1430789	chr2:67866370	T/C	cg18237512	chr2:67827392	NA	-0.79	-4.66	-0.43	1.03e-5	Endometriosis;
THYM	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg27398817	chr8:82754497	SNX16	-0.8	-6.37	-0.55	6.59e-9	Diastolic blood pressure;
THYM	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.65	0.5	1.64e-7	Tonsillectomy;
THYM	cis	rs236907	0.812	rs55732843	chr1:171796962	A/G	cg20598894	chr1:171756153	METTL13	-0.69	-4.66	-0.43	1.03e-5	Mean platelet volume;
THYM	cis	rs2806561	0.929	rs856508	chr1:23532995	A/C	cg12483005	chr1:23474871	LUZP1	0.57	5.65	0.5	1.68e-7	Height;
THYM	cis	rs861020	1.000	rs595918	chr1:209966843	A/G	cg05527609	chr1:210001259	C1orf107	1.0	7.89	0.63	5.05e-12	Orofacial clefts;
THYM	cis	rs10493773	0.775	rs2069208	chr1:86117583	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.48	-6.24	-0.54	1.19e-8	Urate levels in overweight individuals;
THYM	cis	rs3126085	0.935	rs12027807	chr1:152253726	C/G	cg10321714	chr1:152280068	FLG	0.67	5.14	0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg02187348	chr16:89574699	SPG7	0.66	5.14	0.47	1.45e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs2504916	0.739	rs2504956	chr6:160760215	C/T	cg19643109	chr6:160697625	NA	-0.65	-4.83	-0.44	5.32e-6	Response to hepatitis C treatment;
THYM	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg23281280	chr6:28129359	ZNF389	0.61	4.88	0.45	4.21e-6	Parkinson's disease;
THYM	cis	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg06521331	chr12:34319734	NA	-0.73	-5.66	-0.5	1.59e-7	Morning vs. evening chronotype;
THYM	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg14416269	chr4:6271139	WFS1	0.54	5.62	0.5	1.93e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs4523957	0.614	rs7212964	chr17:2059319	C/T	cg16513277	chr17:2031491	SMG6	-0.94	-8.42	-0.65	3.95e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg15604051	chr3:44754201	ZNF502	-0.58	-4.97	-0.45	2.97e-6	Depressive symptoms;
THYM	cis	rs6032067	0.641	rs13042991	chr20:43767178	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.64	-5.8	-0.51	8.81e-8	Blood protein levels;
THYM	cis	rs4262150	0.883	rs72804775	chr5:152303195	C/T	cg06854687	chr5:151642065	NA	0.68	4.82	0.44	5.35e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.47	0.49	3.63e-7	Bipolar disorder;
THYM	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	6.97	0.58	4.12e-10	Platelet count;
THYM	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg20007245	chr22:24372913	LOC391322	-0.65	-4.52	-0.42	1.81e-5	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs8048589	1.000	rs12599090	chr16:12187341	C/G	cg01990910	chr16:12207648	SNX29	-0.44	-4.71	-0.44	8.46e-6	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs11031096	0.754	rs4910886	chr11:4143721	G/T	cg18678763	chr11:4115507	RRM1	-0.38	-5.17	-0.47	1.27e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9326248	0.581	rs4938331	chr11:116930682	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.66	5.27	0.48	8.49e-7	Blood protein levels;
THYM	cis	rs11563648	0.535	rs28729203	chr7:127031917	G/T	cg08586737	chr7:127225949	GCC1	-0.33	-4.57	-0.42	1.47e-5	Resting heart rate;
THYM	cis	rs4242434	0.927	rs35952885	chr8:22491622	T/G	cg01710189	chr8:22454888	PDLIM2	-0.52	-4.79	-0.44	6.21e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7772486	0.875	rs7766463	chr6:146364453	A/G	cg23711669	chr6:146136114	FBXO30	0.93	9.69	0.7	7.64e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7336332	0.598	rs45622135	chr13:28011594	T/C	cg22138327	chr13:27999177	GTF3A	0.62	4.62	0.43	1.21e-5	Weight;
THYM	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg10589385	chr1:150898437	SETDB1	0.66	5.58	0.5	2.27e-7	Melanoma;
THYM	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2067615	0.560	rs10431462	chr12:107106546	G/A	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs11997175	0.583	rs7460295	chr8:33812288	C/T	ch.8.33884649F	chr8:33765107	NA	0.75	5.39	0.48	5.09e-7	Body mass index;
THYM	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg11764359	chr7:65958608	NA	0.82	6.56	0.56	2.81e-9	Aortic root size;
THYM	cis	rs7584330	0.740	rs2292885	chr2:238443407	G/C	cg14458575	chr2:238380390	NA	0.63	4.98	0.46	2.83e-6	Prostate cancer;
THYM	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	8.04	0.64	2.54e-12	Chronic sinus infection;
THYM	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1580019	0.961	rs1580021	chr7:32497702	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.59	0.56	2.42e-9	Cognitive ability;
THYM	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg26116260	chr4:7069785	GRPEL1	1.12	11.02	0.75	1.14e-18	Monocyte percentage of white cells;
THYM	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg17971929	chr21:40555470	PSMG1	0.72	4.61	0.43	1.24e-5	Cognitive function;
THYM	cis	rs10457678	0.564	rs6570281	chr6:139105519	A/G	cg05131254	chr6:138188363	TNFAIP3	0.63	4.45	0.42	2.33e-5	Colorectal or endometrial cancer;
THYM	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg23332699	chr15:44069569	ELL3	0.73	4.71	0.43	8.55e-6	Lung cancer in ever smokers;
THYM	cis	rs6032067	0.636	rs6032092	chr20:43911886	A/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.6	-5.56	-0.5	2.43e-7	Blood protein levels;
THYM	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg09549813	chr16:4587862	C16orf5	0.48	4.94	0.45	3.37e-6	Schizophrenia;
THYM	cis	rs3849570	1.000	rs11711331	chr3:81819040	A/G	cg07356753	chr3:81810745	GBE1	0.91	7.45	0.61	4.23e-11	Waist circumference;Body mass index;
THYM	cis	rs7119038	0.774	rs73005426	chr11:118681083	A/G	cg19308663	chr11:118741387	NA	0.45	4.93	0.45	3.45e-6	Sjögren's syndrome;
THYM	cis	rs4786125	0.665	rs8060329	chr16:6908864	G/A	cg03623568	chr16:6915990	A2BP1	-1.04	-10.49	-0.73	1.46e-17	Heart rate variability traits (SDNN);
THYM	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs7666738	0.785	rs11097614	chr4:99092175	G/C	cg03676636	chr4:99064102	C4orf37	0.47	6.3	0.54	9.09e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg13010199	chr12:38710504	ALG10B	-0.62	-4.56	-0.42	1.53e-5	Morning vs. evening chronotype;
THYM	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg07061783	chr6:25882402	NA	-0.8	-6.41	-0.55	5.69e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg10360139	chr7:1886902	MAD1L1	0.62	5.34	0.48	6.28e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs926938	0.584	rs869990	chr1:115379614	A/G	cg12756093	chr1:115239321	AMPD1	-0.6	-4.91	-0.45	3.72e-6	Autism;
THYM	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg23711669	chr6:146136114	FBXO30	-0.97	-10.42	-0.73	2.06e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10851411	0.908	rs10454039	chr15:42832534	C/T	cg04308337	chr15:42867303	STARD9	-0.64	-4.86	-0.45	4.54e-6	Glucose homeostasis traits;
THYM	cis	rs4819852	0.958	rs2238792	chr22:19983213	C/T	cg07821417	chr22:19972146	ARVCF	0.49	5.82	0.51	7.84e-8	Pulse pressure;
THYM	cis	rs3015497	0.753	rs4643225	chr14:51122205	G/C	cg04730355	chr14:51134070	SAV1	-0.53	-4.7	-0.43	8.68e-6	Mean platelet volume;
THYM	cis	rs9486719	1.000	rs2472895	chr6:96870387	A/T	cg18709589	chr6:96969512	KIAA0776	0.69	4.51	0.42	1.83e-5	Migraine;Coronary artery disease;
THYM	cis	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg10856724	chr12:34555212	NA	-0.91	-9.08	-0.68	1.57e-14	Morning vs. evening chronotype;
THYM	cis	rs17641971	0.684	rs11990854	chr8:49992048	T/C	cg00325661	chr8:49890786	NA	0.6	4.79	0.44	6.24e-6	Blood metabolite levels;
THYM	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	7.41	0.61	5.1e-11	Platelet count;
THYM	cis	rs7582180	0.677	rs11694723	chr2:100878122	C/T	cg14675211	chr2:100938903	LONRF2	0.66	6.16	0.53	1.72e-8	Intelligence (multi-trait analysis);
THYM	cis	rs3020333	0.875	rs2941741	chr6:152008982	G/A	cg22157087	chr6:152012887	ESR1	0.49	5.27	0.48	8.46e-7	Total body bone mineral density;
THYM	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg03060546	chr3:49711283	APEH	0.75	6.08	0.53	2.55e-8	Resting heart rate;
THYM	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs7107174	1.000	rs2512532	chr11:77968641	T/C	cg02023728	chr11:77925099	USP35	0.64	5.65	0.5	1.69e-7	Testicular germ cell tumor;
THYM	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg17063962	chr7:91808500	NA	-1.12	-12.68	-0.79	3.85e-22	Breast cancer;
THYM	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg21926883	chr2:100939477	LONRF2	-0.68	-6.44	-0.55	4.95e-9	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg02602264	chr7:1026310	CYP2W1	-0.45	-4.58	-0.43	1.42e-5	Longevity;Endometriosis;
THYM	cis	rs9915657	0.743	rs9894720	chr17:70097607	C/T	cg09344028	chr17:70110421	NA	0.48	4.86	0.45	4.68e-6	Thyroid hormone levels;
THYM	cis	rs11190604	0.607	rs12220970	chr10:102175269	G/A	cg07570687	chr10:102243282	WNT8B	0.81	7.57	0.61	2.4e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg22764591	chr12:58329936	NA	-0.69	-5.23	-0.47	9.95e-7	Multiple sclerosis;
THYM	cis	rs10779751	0.960	rs12739368	chr1:11288247	T/C	cg08854313	chr1:11322531	MTOR	0.92	7.76	0.62	9.52e-12	Body mass index;
THYM	cis	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg07235805	chr18:78004237	PARD6G	-0.43	-4.93	-0.45	3.51e-6	Opioid sensitivity;
THYM	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.53	-4.86	-0.45	4.59e-6	Lymphocyte counts;
THYM	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg24846680	chr1:228362309	C1orf69	0.52	4.72	0.44	8.06e-6	Diastolic blood pressure;
THYM	cis	rs1371867	0.875	rs1788173	chr8:101330939	A/G	cg06636551	chr8:101224915	SPAG1	0.63	6.33	0.54	8.05e-9	Atrioventricular conduction;
THYM	cis	rs2674946	0.644	rs8077659	chr17:13042271	G/A	cg12799781	chr17:12569110	MYOCD	-0.56	-5.22	-0.47	1.05e-6	Squamous cell lung carcinoma;
THYM	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.3	-0.48	7.34e-7	Monocyte percentage of white cells;
THYM	cis	rs6812193	0.508	rs7676094	chr4:77412894	C/T	cg27417997	chr4:77356416	SHROOM3	-0.37	-4.46	-0.42	2.22e-5	Parkinson's disease;
THYM	cis	rs55728055	0.661	rs7285893	chr22:32010042	A/G	cg01338084	chr22:32026380	PISD	1.45	6.78	0.57	1.03e-9	Age-related hearing impairment;
THYM	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg03433033	chr1:76189801	ACADM	0.72	8.14	0.64	1.53e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg17372223	chr3:52568218	NT5DC2	0.36	5.49	0.49	3.41e-7	Bipolar disorder;
THYM	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg22947322	chr17:47091978	IGF2BP1	-0.64	-6.74	-0.57	1.2e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs2898681	0.567	rs77657787	chr4:53729981	G/A	cg21521518	chr4:53727714	RASL11B	0.63	5.48	0.49	3.5e-7	Optic nerve measurement (cup area);
THYM	cis	rs883565	0.655	rs6599002	chr3:39076073	T/C	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	5.0	0.46	2.59e-6	Handedness;
THYM	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg27129171	chr3:47204927	SETD2	-0.71	-6.56	-0.56	2.82e-9	Colorectal cancer;
THYM	cis	rs73086581	0.741	rs17212649	chr20:3853093	A/G	cg02187196	chr20:3869020	PANK2	0.48	5.01	0.46	2.48e-6	Response to antidepressants in depression;
THYM	cis	rs921968	0.643	rs2178019	chr2:219316303	G/A	cg02176678	chr2:219576539	TTLL4	0.65	6.27	0.54	1.05e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg02773041	chr1:40204384	PPIE	0.77	5.83	0.51	7.67e-8	Blood protein levels;
THYM	cis	rs17253792	0.822	rs112308750	chr14:56080073	G/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg00278517	chr6:167070616	RPS6KA2	-0.35	-4.57	-0.42	1.49e-5	Crohn's disease;
THYM	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg13695892	chr22:41940480	POLR3H	-1.04	-8.51	-0.66	2.47e-13	Vitiligo;
THYM	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg08835221	chr22:38071607	LGALS1	0.35	4.88	0.45	4.34e-6	Fat distribution (HIV);
THYM	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9992101	0.547	rs4318673	chr4:77412338	A/T	cg27417997	chr4:77356416	SHROOM3	-0.37	-4.46	-0.42	2.22e-5	Creatinine levels;
THYM	cis	rs35110281	0.601	rs7278282	chr21:44981958	T/G	cg15536230	chr21:44985092	HSF2BP	-0.41	-5.02	-0.46	2.43e-6	Mean corpuscular volume;
THYM	cis	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg16188243	chr19:2783719	SGTA	0.68	4.69	0.43	9.04e-6	Total cholesterol levels;
THYM	cis	rs28595532	0.920	rs115214765	chr4:119728167	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs2279817	0.863	rs871088	chr1:18017558	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.71	4.46	0.42	2.28e-5	Neuroticism;
THYM	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg04025307	chr7:1156635	C7orf50	0.77	6.65	0.56	1.86e-9	Longevity;Endometriosis;
THYM	cis	rs9560113	0.806	rs9560112	chr13:112183320	A/G	cg10483660	chr13:112241077	NA	0.53	4.77	0.44	6.66e-6	Menarche (age at onset);
THYM	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg14829155	chr15:31115871	NA	-0.74	-6.03	-0.53	3.19e-8	Huntington's disease progression;
THYM	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg18681998	chr4:17616180	MED28	0.95	8.92	0.67	3.41e-14	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg02187348	chr16:89574699	SPG7	0.69	5.27	0.48	8.52e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs1692120	0.897	rs1692122	chr11:61430988	A/C	cg19838087	chr11:61442541	NA	0.61	6.76	0.57	1.12e-9	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
THYM	cis	rs3540	0.576	rs12907587	chr15:91045851	G/C	cg22089800	chr15:90895588	ZNF774	-0.69	-5.32	-0.48	6.9e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.99	-0.75	1.26e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg00256281	chr22:41985642	PMM1	-0.56	-4.72	-0.44	8.11e-6	Vitiligo;
THYM	cis	rs9287719	0.781	rs6732671	chr2:10759149	T/G	cg03983476	chr2:10830698	NOL10	-0.58	-5.35	-0.48	6.15e-7	Prostate cancer;
THYM	cis	rs7592578	0.640	rs56127319	chr2:191296429	G/A	cg21644426	chr2:191273491	MFSD6	-0.74	-5.1	-0.46	1.73e-6	Diastolic blood pressure;
THYM	cis	rs1550582	1.000	rs1550582	chr8:135542084	A/G	cg17885191	chr8:135476712	NA	-0.77	-4.91	-0.45	3.83e-6	Educational attainment;
THYM	cis	rs654128	0.640	rs945080	chr6:117225343	G/A	cg12892004	chr6:117198278	RFX6	-0.72	-5.66	-0.5	1.61e-7	Telomere length;
THYM	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg12826209	chr6:26865740	GUSBL1	1.04	6.68	0.57	1.63e-9	Intelligence (multi-trait analysis);
THYM	cis	rs985746	0.527	rs12501297	chr4:36796325	T/C	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs1062746	0.558	rs889608	chr16:87337543	A/G	cg02258303	chr16:87377426	FBXO31	-0.63	-5.28	-0.48	8.23e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs537626	1.000	rs537626	chr11:69307695	C/G	cg08353955	chr11:69289746	NA	1.01	5.54	0.49	2.75e-7	Breast cancer (early onset);
THYM	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg08017756	chr2:100939284	LONRF2	0.72	7.49	0.61	3.51e-11	Intelligence (multi-trait analysis);
THYM	cis	rs10979	1.000	rs9496673	chr6:143885393	C/G	cg25407410	chr6:143891975	LOC285740	-0.63	-5.41	-0.49	4.6e-7	Hypospadias;
THYM	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg18758796	chr5:131593413	PDLIM4	0.5	4.8	0.44	5.79e-6	Breast cancer;
THYM	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg01819863	chr10:32635814	EPC1	1.04	6.64	0.56	1.9e-9	Sexual dysfunction (female);
THYM	cis	rs5758511	0.680	rs5758699	chr22:42688034	C/G	cg22189786	chr22:42395067	WBP2NL	0.5	4.5	0.42	1.92e-5	Birth weight;
THYM	cis	rs859767	0.540	rs13424016	chr2:135406395	A/G	cg12500956	chr2:135428796	TMEM163	-0.56	-4.83	-0.44	5.2e-6	Neuroticism;
THYM	cis	rs4986811	1.000	rs4986811	chr11:32451093	T/G	cg13301003	chr11:32449254	WT1	0.67	5.08	0.46	1.88e-6	Rubella-specific interleukin-6 secretion;
THYM	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg25767906	chr1:53392781	SCP2	-0.52	-5.15	-0.47	1.41e-6	Monocyte count;
THYM	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg01191920	chr7:158217561	PTPRN2	-1.04	-12.31	-0.78	2.18e-21	Obesity-related traits;
THYM	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg16928487	chr17:17741425	SREBF1	-0.55	-5.47	-0.49	3.62e-7	Total body bone mineral density;
THYM	cis	rs13326165	0.585	rs11717028	chr3:52354061	A/G	cg08438690	chr3:52279403	PPM1M	-0.78	-4.62	-0.43	1.19e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.96	-6.76	-0.57	1.12e-9	Schizophrenia;
THYM	cis	rs4940575	0.679	rs7230053	chr18:60836185	T/A	cg25271770	chr18:61057090	VPS4B	0.77	4.61	0.43	1.24e-5	Breast cancer;
THYM	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg06784218	chr1:46089804	CCDC17	-0.3	-4.64	-0.43	1.1e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs34638657	0.732	rs2911425	chr16:82203026	T/C	cg09439754	chr16:82129088	HSD17B2	-0.53	-5.14	-0.47	1.5e-6	Lung adenocarcinoma;
THYM	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg05662444	chr5:154026397	NA	0.55	4.83	0.44	5.29e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.88	-7.78	-0.62	8.71e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7942486	0.895	rs11825504	chr11:13269921	A/T	cg13286116	chr11:13302098	ARNTL	-0.72	-8.03	-0.64	2.61e-12	Neuroticism;
THYM	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg11335335	chr11:637885	DRD4	-0.69	-6.23	-0.54	1.24e-8	Systemic lupus erythematosus;
THYM	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg10047753	chr17:41438598	NA	1.18	11.26	0.76	3.4e-19	Menopause (age at onset);
THYM	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg13447684	chr7:1895903	MAD1L1	0.54	4.54	0.42	1.62e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs2730245	0.527	rs2709858	chr7:158675266	C/G	cg24397884	chr7:158709396	WDR60	0.55	5.36	0.48	5.79e-7	Height;
THYM	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs2933343	0.649	rs789216	chr3:128594503	A/C	cg11901034	chr3:128598214	ACAD9	-0.7	-5.68	-0.5	1.47e-7	IgG glycosylation;
THYM	cis	rs4654899	0.758	rs9426652	chr1:21458151	G/A	cg01072550	chr1:21505969	NA	-0.76	-7.43	-0.61	4.71e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs61931739	0.817	rs2636084	chr12:34130210	G/A	cg10856724	chr12:34555212	NA	-0.6	-5.27	-0.48	8.62e-7	Morning vs. evening chronotype;
THYM	cis	rs526231	0.543	rs17154913	chr5:102328490	C/G	cg23492399	chr5:102201601	PAM	-0.65	-5.1	-0.46	1.73e-6	Primary biliary cholangitis;
THYM	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg05738196	chr6:26577821	NA	-0.66	-5.16	-0.47	1.33e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg01528321	chr10:82214614	TSPAN14	0.66	5.16	0.47	1.35e-6	Post bronchodilator FEV1;
THYM	cis	rs17597773	0.638	rs10495152	chr1:220990355	C/A	cg16008148	chr1:221062819	NA	0.41	4.54	0.42	1.62e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg05368731	chr17:41323189	NBR1	1.23	11.16	0.75	5.64e-19	Menopause (age at onset);
THYM	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg03159660	chr11:2078197	NA	-0.62	-4.53	-0.42	1.69e-5	Longevity;
THYM	cis	rs61931739	0.517	rs11052980	chr12:34036036	T/C	cg06521331	chr12:34319734	NA	-0.93	-8.67	-0.66	1.15e-13	Morning vs. evening chronotype;
THYM	cis	rs62158800	0.568	rs2083401	chr2:108370337	G/A	cg10013287	chr2:108537568	NA	1.12	5.41	0.49	4.61e-7	Facial morphology (factor 22);
THYM	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Body mass index;
THYM	cis	rs4654899	0.727	rs11805169	chr1:21156862	A/T	cg01072550	chr1:21505969	NA	0.61	5.16	0.47	1.34e-6	Superior frontal gyrus grey matter volume;
THYM	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg17345569	chr6:42928274	GNMT	-0.45	-4.46	-0.42	2.22e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.59	5.34	0.48	6.35e-7	Schizophrenia;
THYM	cis	rs2354432	0.607	rs894471	chr1:146687913	A/G	cg25205988	chr1:146714368	CHD1L	-1.02	-4.57	-0.42	1.48e-5	Mitochondrial DNA levels;
THYM	cis	rs9900062	1.000	rs11871616	chr17:62737602	C/T	cg11885555	chr17:61910219	SMARCD2	0.7	4.52	0.42	1.81e-5	QT interval;
THYM	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.33	0.48	6.64e-7	Height;
THYM	cis	rs1797885	0.564	rs959088	chr3:12582138	G/C	cg05467012	chr3:12595696	NA	0.54	4.5	0.42	1.92e-5	Immature fraction of reticulocytes;
THYM	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	15.13	0.84	4.91e-27	Chronic sinus infection;
THYM	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg03476357	chr21:30257390	N6AMT1	0.62	4.72	0.44	8.12e-6	Cognitive test performance;
THYM	cis	rs2963155	0.518	rs865482	chr5:142640317	C/A	cg17617527	chr5:142782415	NR3C1	1.16	6.19	0.54	1.49e-8	Breast cancer;
THYM	cis	rs3126085	0.935	rs1858480	chr1:152301735	A/G	cg10321714	chr1:152280068	FLG	-0.66	-4.87	-0.45	4.53e-6	Atopic dermatitis;
THYM	trans	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.18	0.64	1.26e-12	Corneal astigmatism;
THYM	cis	rs7567389	0.812	rs6710496	chr2:127976374	A/C	cg06038358	chr2:128176007	PROC	-0.45	-4.8	-0.44	5.94e-6	Self-rated health;
THYM	cis	rs13082711	0.911	rs77685358	chr3:27519158	C/T	cg02860705	chr3:27208620	NA	0.72	5.06	0.46	2.01e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs554111	0.656	rs964466	chr1:21375163	T/G	cg01072550	chr1:21505969	NA	0.57	4.88	0.45	4.2e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs11771526	0.686	rs62457463	chr7:32289856	C/T	cg13207630	chr7:32358064	NA	0.84	5.28	0.48	8.15e-7	Body mass index;
THYM	cis	rs2235649	0.789	rs9939680	chr16:1852720	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs6570726	0.791	rs401561	chr6:145835917	G/T	cg23711669	chr6:146136114	FBXO30	0.95	9.55	0.7	1.52e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2710642	0.815	rs6545971	chr2:63074986	A/T	cg17519650	chr2:63277830	OTX1	0.71	5.01	0.46	2.56e-6	LDL cholesterol levels;LDL cholesterol;
THYM	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg01475377	chr6:109611718	NA	-0.56	-4.69	-0.43	9.21e-6	Reticulocyte fraction of red cells;
THYM	cis	rs17102423	0.623	rs12100752	chr14:65611546	G/C	cg11161011	chr14:65562177	MAX	-0.57	-4.61	-0.43	1.27e-5	Obesity-related traits;
THYM	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg20999797	chr1:1681921	NA	0.49	5.41	0.48	4.8e-7	Body mass index;
THYM	cis	rs17407555	0.779	rs6851524	chr4:10155041	C/A	cg11266682	chr4:10021025	SLC2A9	-0.6	-5.79	-0.51	8.88e-8	Schizophrenia (age at onset);
THYM	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	5.14	0.47	1.45e-6	Schizophrenia;
THYM	cis	rs2562456	0.561	rs12610883	chr19:21750059	A/G	cg21751540	chr19:21541537	ZNF738	-0.71	-4.97	-0.45	2.9e-6	Pain;
THYM	cis	rs868036	1.000	rs884202	chr15:68054388	G/A	cg24579218	chr15:68104479	NA	0.65	6.18	0.54	1.6e-8	Restless legs syndrome;
THYM	cis	rs1775715	0.707	rs2799019	chr10:32142850	C/T	cg04359828	chr10:32216031	ARHGAP12	0.41	5.12	0.46	1.62e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs919433	0.647	rs13404366	chr2:198522632	A/G	cg05783139	chr2:198650985	BOLL	0.63	4.71	0.43	8.5e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg26398791	chr1:38455867	SF3A3	-0.63	-5.18	-0.47	1.26e-6	Coronary artery disease;
THYM	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg06784218	chr1:46089804	CCDC17	-0.34	-5.03	-0.46	2.28e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg22508957	chr16:3507546	NAT15	0.48	4.92	0.45	3.56e-6	Body mass index (adult);
THYM	cis	rs9826463	0.582	rs73238150	chr3:142062457	C/A	cg20824294	chr3:142316082	PLS1	0.79	5.44	0.49	4.19e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs7851660	0.967	rs7851552	chr9:100610652	C/A	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg05340658	chr4:99064831	C4orf37	0.54	4.52	0.42	1.76e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.14	-0.64	1.54e-12	Mean corpuscular volume;
THYM	cis	rs7833986	0.534	rs72653928	chr8:56907735	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	6.4	0.55	5.76e-9	Height;
THYM	cis	rs3733631	0.947	rs1351623	chr4:104587977	C/T	cg24090629	chr4:104641072	TACR3	-0.89	-5.68	-0.5	1.46e-7	Menarche (age at onset);
THYM	cis	rs7729356	0.761	rs13179507	chr5:107480397	T/C	cg12405754	chr5:107005487	EFNA5	-0.53	-4.51	-0.42	1.82e-5	Educational attainment;
THYM	cis	rs977987	0.806	rs2903033	chr16:75389606	T/A	cg03315344	chr16:75512273	CHST6	0.74	6.05	0.53	2.9e-8	Dupuytren's disease;
THYM	cis	rs10917477	0.655	rs2745212	chr1:19899350	G/A	cg09356672	chr1:19665131	NA	0.46	4.45	0.42	2.35e-5	Thyroid function;
THYM	cis	rs7729447	0.776	rs1458053	chr5:32690413	G/A	cg16267343	chr5:32710456	NPR3	0.77	7.05	0.59	2.9e-10	Blood pressure;
THYM	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs79349575	0.783	rs318090	chr17:46991752	G/A	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.62	0.66	1.45e-13	Cognitive test performance;
THYM	cis	rs2932538	0.885	rs6693880	chr1:113110261	A/G	cg22162597	chr1:113214053	CAPZA1	0.65	5.32	0.48	6.9e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs7894051	1.000	rs7894051	chr10:135184421	C/G	cg06270799	chr10:135191613	PAOX	-0.77	-4.5	-0.42	1.94e-5	Lifespan;
THYM	cis	rs2227564	0.620	rs3911887	chr10:75548026	A/G	cg23231163	chr10:75533350	FUT11	-0.37	-4.65	-0.43	1.08e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	10.29	0.73	4e-17	Chronic sinus infection;
THYM	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg23428387	chr22:49814324	NA	-0.55	-5.64	-0.5	1.78e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs912057	0.965	rs1294409	chr6:6738355	A/G	cg06612196	chr6:6737390	NA	-0.7	-10.05	-0.72	1.31e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg17830980	chr10:43048298	ZNF37B	-1.01	-10.1	-0.72	1.02e-16	Extrinsic epigenetic age acceleration;
THYM	cis	rs12142240	0.667	rs41293287	chr1:46808852	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-5.56	-0.5	2.45e-7	Mood instability;
THYM	cis	rs950881	0.932	rs72823619	chr2:102924615	C/T	cg20060108	chr2:102954350	IL1RL1	0.81	4.47	0.42	2.14e-5	Allergy;
THYM	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.81	-0.63	7.44e-12	Chronic sinus infection;
THYM	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg27394845	chr17:28928406	LRRC37B2	1.03	4.98	0.45	2.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.8	-7.94	-0.63	4.1e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs62103177	0.568	rs2365388	chr18:77973702	G/T	cg07235805	chr18:78004237	PARD6G	0.48	5.48	0.49	3.47e-7	Opioid sensitivity;
THYM	cis	rs13394619	0.935	rs12468019	chr2:11725049	T/C	cg07314298	chr2:11723111	GREB1	-0.62	-6.09	-0.53	2.36e-8	Endometriosis;
THYM	cis	rs497273	0.512	rs504403	chr12:121133037	C/G	cg13914990	chr12:121174878	ACADS	-0.45	-4.53	-0.42	1.7e-5	Systemic lupus erythematosus;
THYM	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08704250	chr15:31115839	NA	-0.53	-6.18	-0.54	1.61e-8	Huntington's disease progression;
THYM	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg16486109	chr11:613632	IRF7	0.5	5.54	0.49	2.7e-7	Systemic lupus erythematosus;
THYM	trans	rs11165623	0.792	rs2104236	chr1:96908690	C/T	cg10631902	chr5:14652156	NA	-0.65	-7.36	-0.6	6.59e-11	Hip circumference;Waist circumference;
THYM	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.7	-5.82	-0.51	7.84e-8	Lung cancer;
THYM	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg08270630	chr22:50330655	NA	-0.83	-4.75	-0.44	7.33e-6	Schizophrenia;
THYM	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-4.68	-0.43	9.5e-6	Longevity;
THYM	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg16049864	chr8:95962084	TP53INP1	-0.68	-6.05	-0.53	2.91e-8	Type 2 diabetes;
THYM	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.02	-0.46	2.44e-6	Hemoglobin concentration;
THYM	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg09307838	chr4:120376055	NA	0.68	5.08	0.46	1.86e-6	Corneal astigmatism;
THYM	cis	rs11771526	0.786	rs28670858	chr7:32293126	G/A	cg13207630	chr7:32358064	NA	0.78	5.0	0.46	2.64e-6	Body mass index;
THYM	cis	rs7772486	0.875	rs2224120	chr6:146343280	A/C	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg06618935	chr21:46677482	NA	-0.94	-8.05	-0.64	2.4e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2251260	0.891	rs2246695	chr14:62008065	C/T	cg13564459	chr14:62004353	PRKCH	0.46	5.52	0.49	2.97e-7	Yeast infection;
THYM	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.77	-5.05	-0.46	2.13e-6	Mean platelet volume;
THYM	cis	rs988913	1.000	rs9382403	chr6:54825687	A/C	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.74e-6	Menarche (age at onset);
THYM	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg07936489	chr17:37558343	FBXL20	0.78	5.0	0.46	2.67e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg24530246	chr3:53118167	NA	-0.85	-4.82	-0.44	5.52e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7586879	0.639	rs7567997	chr2:25096952	A/G	cg15423357	chr2:25149977	NA	0.66	7.05	0.59	2.91e-10	Body mass index;
THYM	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg08772003	chr10:104629869	AS3MT	-0.57	-4.92	-0.45	3.56e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg15448220	chr1:150897856	SETDB1	0.87	7.38	0.6	6.09e-11	Melanoma;
THYM	cis	rs2294693	0.786	rs12055704	chr6:40988504	C/T	cg21128951	chr6:40996213	UNC5CL	0.63	4.72	0.44	8.19e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs28595532	0.920	rs115500312	chr4:119752551	G/A	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs9807989	0.839	rs6749114	chr2:102967587	A/C	cg03938978	chr2:103052716	IL18RAP	0.63	6.56	0.56	2.81e-9	Asthma;
THYM	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.76	-0.51	1.03e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs892961	0.932	rs11657725	chr17:75405501	G/C	cg05865280	chr17:75406074	SEPT9	0.5	8.56	0.66	1.99e-13	Airflow obstruction;
THYM	cis	rs1065852	0.526	rs9611711	chr22:42410695	G/A	cg22189786	chr22:42395067	WBP2NL	0.54	5.55	0.49	2.6e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg24375607	chr4:120327624	NA	0.53	4.47	0.42	2.2e-5	Corneal astigmatism;
THYM	cis	rs3096299	0.967	rs2965937	chr16:89488779	A/T	cg06640241	chr16:89574553	SPG7	0.71	5.43	0.49	4.32e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg22875332	chr1:76189707	ACADM	0.8	7.18	0.59	1.58e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6840360	1.000	rs7663045	chr4:152676350	T/C	cg22705602	chr4:152727874	NA	-0.58	-6.26	-0.54	1.1e-8	Intelligence (multi-trait analysis);
THYM	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg06028808	chr11:68637592	NA	-0.63	-6.68	-0.57	1.64e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg17178900	chr1:205818956	PM20D1	-0.66	-5.06	-0.46	2.04e-6	Menarche (age at onset);
THYM	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg08213375	chr14:104286397	PPP1R13B	0.54	6.52	0.56	3.32e-9	Schizophrenia;
THYM	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs72781680	1.000	rs72781679	chr2:24237712	G/A	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg00645579	chr11:617140	IRF7;MUPCDH	-0.52	-6.46	-0.55	4.44e-9	Systemic lupus erythematosus;
THYM	cis	rs7429990	0.965	rs7430879	chr3:48038714	C/T	cg02219026	chr3:48282209	ZNF589	0.6	4.5	0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg07636037	chr3:49044803	WDR6	0.78	4.81	0.44	5.67e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg07061783	chr6:25882402	NA	-0.93	-8.76	-0.67	7.23e-14	Intelligence (multi-trait analysis);
THYM	cis	rs13232179	1.000	rs1860463	chr7:151119332	C/T	cg01177956	chr7:150756509	SLC4A2;CDK5	-0.79	-4.66	-0.43	1.03e-5	Coronary heart disease;
THYM	cis	rs7078219	0.714	rs10883368	chr10:101289998	A/G	cg07044859	chr10:101282883	NA	-0.5	-5.47	-0.49	3.66e-7	Dental caries;
THYM	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg03684893	chr10:554711	DIP2C	-0.71	-6.02	-0.53	3.33e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg24399712	chr22:39784796	NA	-0.92	-10.94	-0.75	1.67e-18	Intelligence (multi-trait analysis);
THYM	cis	rs1395	0.922	rs11608	chr2:27435374	G/A	cg23587288	chr2:27483067	SLC30A3	0.57	5.09	0.46	1.8e-6	Blood metabolite levels;
THYM	cis	rs7631605	0.905	rs11711968	chr3:37224967	C/G	cg21328643	chr3:37258149	NA	-0.48	-4.54	-0.42	1.67e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs2049953	1.000	rs6569975	chr6:135141277	A/C	cg16772717	chr6:134958611	NA	0.64	4.93	0.45	3.5e-6	Non-alcoholic fatty liver disease histology (AST);
THYM	cis	rs6733011	0.578	rs1581250	chr2:99500750	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.69	-0.43	9.32e-6	Bipolar disorder;
THYM	cis	rs4986172	0.726	rs12946454	chr17:43208121	A/T	cg06100756	chr17:43221575	NA	0.71	7.19	0.59	1.5e-10	Height;
THYM	cis	rs7980799	0.716	rs1351683	chr12:33598563	G/A	cg06521331	chr12:34319734	NA	0.66	4.54	0.42	1.65e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg06850241	chr22:41845214	NA	-0.57	-5.05	-0.46	2.12e-6	Vitiligo;
THYM	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	5.03	0.46	2.33e-6	Smoking behavior;
THYM	cis	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs10899021	0.920	rs11236174	chr11:74334201	G/A	cg25880958	chr11:74394337	NA	-0.77	-4.66	-0.43	1.04e-5	Response to metformin (IC50);
THYM	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg13010199	chr12:38710504	ALG10B	0.73	5.82	0.51	7.99e-8	Heart rate;
THYM	cis	rs7312774	0.618	rs4964195	chr12:107392778	T/C	cg16260113	chr12:107380972	MTERFD3	0.93	4.89	0.45	4.16e-6	Severe influenza A (H1N1) infection;
THYM	cis	rs8078723	0.677	rs8073254	chr17:38149350	C/G	cg17467752	chr17:38218738	THRA	-0.75	-5.97	-0.52	4.05e-8	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg12560992	chr17:57184187	TRIM37	0.69	4.94	0.45	3.4e-6	Cognitive test performance;
THYM	trans	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.96	-8.0	-0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg18252515	chr7:66147081	NA	-0.65	-4.84	-0.44	4.98e-6	Aortic root size;
THYM	cis	rs4363385	0.510	rs7543689	chr1:153046803	A/T	cg13444842	chr1:152974279	SPRR3	-0.6	-4.74	-0.44	7.54e-6	Inflammatory skin disease;
THYM	cis	rs10992471	0.580	rs10992393	chr9:95420983	A/G	cg14631576	chr9:95140430	CENPP	-0.91	-7.1	-0.59	2.26e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg22907277	chr7:1156413	C7orf50	0.87	7.59	0.61	2.16e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9467711	0.651	rs17587226	chr6:25962304	C/T	cg12826209	chr6:26865740	GUSBL1	1.08	4.52	0.42	1.77e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs58722170	0.659	rs12023270	chr1:38086578	A/G	cg17933807	chr1:38061675	GNL2	0.9	6.91	0.58	5.62e-10	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs295140	0.507	rs13019821	chr2:201106815	C/G	cg03447810	chr2:200324230	SATB2	-0.66	-5.09	-0.46	1.81e-6	QT interval;
THYM	cis	rs11048434	0.736	rs12823100	chr12:9108908	C/A	cg13575925	chr12:9217583	LOC144571	0.52	4.97	0.45	2.96e-6	Sjögren's syndrome;
THYM	cis	rs55637147	0.703	rs3741090	chr11:57118467	A/C	cg15971518	chr11:57159174	PRG2	-0.62	-4.79	-0.44	6.21e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	trans	rs8002861	0.935	rs1373903	chr13:44475514	G/T	cg17145862	chr1:211918768	LPGAT1	0.99	11.51	0.76	1.04e-19	Leprosy;
THYM	cis	rs17253792	0.822	rs7145064	chr14:56088860	C/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg14018140	chr10:458528	DIP2C	0.63	6.11	0.53	2.17e-8	Psychosis in Alzheimer's disease;
THYM	trans	rs1997103	1.000	rs2009441	chr7:55405989	A/G	cg20935933	chr6:143382018	AIG1	0.85	6.93	0.58	4.91e-10	QRS interval (sulfonylurea treatment interaction);
THYM	trans	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs2734839	0.964	rs1116313	chr11:113296107	A/G	cg14159747	chr11:113255604	NA	0.32	6.33	0.54	8.07e-9	Information processing speed;
THYM	cis	rs1005224	0.864	rs11625011	chr14:76144828	G/A	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.71	-5.8	-0.51	8.86e-8	Large artery stroke;
THYM	cis	rs9929218	0.551	rs3785134	chr16:68728938	C/T	cg01251360	chr16:68772225	CDH1	-0.29	-4.45	-0.42	2.36e-5	Colorectal cancer;
THYM	cis	rs4786125	0.581	rs7193000	chr16:6918270	G/C	cg03623568	chr16:6915990	A2BP1	-1.0	-10.07	-0.72	1.18e-16	Heart rate variability traits (SDNN);
THYM	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg05368731	chr17:41323189	NBR1	1.26	11.24	0.76	3.79e-19	Menopause (age at onset);
THYM	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	8.87	0.67	4.33e-14	Chronic sinus infection;
THYM	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg02136620	chr5:178986620	RUFY1	0.56	5.66	0.5	1.58e-7	Lung cancer;
THYM	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs7119	0.604	rs2682927	chr15:77859168	C/T	cg27398640	chr15:77910606	LINGO1	0.62	7.11	0.59	2.18e-10	Type 2 diabetes;
THYM	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg06618935	chr21:46677482	NA	0.98	9.67	0.7	8.28e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs986417	0.901	rs12883305	chr14:61006690	A/G	cg27398547	chr14:60952738	C14orf39	1.07	6.35	0.55	7.27e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs12681287	0.547	rs9297921	chr8:87542286	C/T	cg27223183	chr8:87520930	FAM82B	0.71	5.56	0.5	2.44e-7	Caudate activity during reward;
THYM	cis	rs1050631	0.657	rs1789551	chr18:33716092	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.28	0.48	8.32e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs2069036	0.953	rs11253753	chr10:16090058	A/G	cg26633223	chr10:15133461	NA	0.67	4.7	0.43	8.93e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs4792901	1.000	rs4792901	chr17:41660081	C/A	cg21940313	chr17:41620911	ETV4	0.5	5.42	0.49	4.55e-7	Dupuytren's disease;
THYM	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.56	-5.13	-0.47	1.51e-6	Type 2 diabetes;
THYM	cis	rs7107174	1.000	rs11601590	chr11:78073288	T/G	cg02023728	chr11:77925099	USP35	0.62	6.0	0.52	3.51e-8	Testicular germ cell tumor;
THYM	cis	rs11696501	0.694	rs1487325	chr20:44258989	A/G	cg11783356	chr20:44313418	WFDC10B	0.68	4.57	0.42	1.48e-5	Brain structure;
THYM	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg09455208	chr3:40491958	NA	-0.43	-4.57	-0.42	1.48e-5	Renal cell carcinoma;
THYM	cis	rs2658782	0.654	rs2605620	chr11:93247646	C/T	cg15737290	chr11:93063684	CCDC67	0.89	6.83	0.57	7.91e-10	Pulmonary function decline;
THYM	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs36051895	0.632	rs1360063	chr9:5167649	A/G	cg02405213	chr9:5042618	JAK2	-0.98	-9.59	-0.7	1.25e-15	Pediatric autoimmune diseases;
THYM	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg07362569	chr17:61921086	SMARCD2	0.68	6.13	0.53	1.99e-8	Prudent dietary pattern;
THYM	cis	rs7000551	0.653	rs4872504	chr8:22326717	A/G	cg12081754	chr8:22256438	SLC39A14	0.65	5.56	0.5	2.52e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg03806693	chr22:41940476	POLR3H	1.23	10.66	0.74	6.4e-18	Vitiligo;
THYM	cis	rs2710642	0.564	rs6752597	chr2:62823444	T/C	cg17519650	chr2:63277830	OTX1	0.62	4.54	0.42	1.67e-5	LDL cholesterol levels;LDL cholesterol;
THYM	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg13395646	chr4:1353034	KIAA1530	-0.61	-5.56	-0.5	2.42e-7	Obesity-related traits;
THYM	cis	rs983545	0.800	rs7629676	chr3:16966998	C/T	cg19448816	chr3:16974217	PLCL2	0.53	4.66	0.43	1.05e-5	Blood protein levels;
THYM	cis	rs7262634	0.892	rs73302063	chr20:45832579	G/T	cg18599129	chr20:45867857	ZMYND8	0.84	4.91	0.45	3.71e-6	Response to protease inhibitor treatment in hepatitis c (bilirubin toxicity);
THYM	cis	rs1003719	0.788	rs3787783	chr21:38462959	T/A	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	trans	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg01710189	chr8:22454888	PDLIM2	-0.56	-5.91	-0.52	5.23e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4243830	0.522	rs10157142	chr1:6618785	A/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.98	-6.24	-0.54	1.23e-8	Body mass index;
THYM	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.09	-0.64	1.9e-12	Mean corpuscular volume;
THYM	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg27394845	chr17:28928406	LRRC37B2	-0.98	-4.83	-0.44	5.31e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs9790314	0.934	rs461638	chr3:161103166	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-6.46	-0.55	4.46e-9	Morning vs. evening chronotype;
THYM	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg00129232	chr17:37814104	STARD3	-0.67	-4.54	-0.42	1.63e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg20608306	chr11:116969690	SIK3	-0.55	-5.92	-0.52	5.15e-8	Blood protein levels;
THYM	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	trans	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	trans	rs8073060	0.586	rs4796104	chr17:34046832	T/C	cg19694781	chr19:47549865	TMEM160	1.01	8.58	0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs11585357	0.895	rs877552	chr1:17631236	C/T	cg08277548	chr1:17600880	PADI3	-0.82	-4.95	-0.45	3.23e-6	Hair shape;
THYM	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg10760299	chr15:45669010	GATM	-0.74	-5.59	-0.5	2.19e-7	Homoarginine levels;
THYM	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg19507638	chr5:93509721	C5orf36	-0.68	-4.57	-0.42	1.49e-5	Diabetic retinopathy;
THYM	cis	rs988913	0.957	rs1393774	chr6:54838449	G/C	cg19716238	chr6:54711378	FAM83B	0.5	4.91	0.45	3.76e-6	Menarche (age at onset);
THYM	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg18252515	chr7:66147081	NA	-0.66	-4.91	-0.45	3.8e-6	Aortic root size;
THYM	cis	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg12826209	chr6:26865740	GUSBL1	0.88	4.84	0.44	5.04e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg04317338	chr11:64019027	PLCB3	0.85	5.81	0.51	8.33e-8	Mean platelet volume;
THYM	cis	rs939658	0.935	rs954292	chr15:79449237	C/T	cg17916960	chr15:79447300	NA	0.75	8.81	0.67	5.71e-14	Refractive error;
THYM	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs7586879	0.681	rs6723803	chr2:25120713	G/C	cg01884057	chr2:25150051	NA	0.71	7.7	0.62	1.31e-11	Body mass index;
THYM	cis	rs17174870	0.725	rs28377357	chr2:112769721	G/A	cg17354880	chr2:112658759	MERTK	-0.55	-4.6	-0.43	1.28e-5	Multiple sclerosis;
THYM	cis	rs17604090	0.878	rs4457221	chr7:29701774	C/T	cg19413766	chr7:29689036	LOC646762	-1.04	-5.82	-0.51	7.9e-8	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs13185784	0.667	rs6882940	chr5:179648989	A/G	cg23248424	chr5:179741104	GFPT2	-0.72	-4.68	-0.43	9.58e-6	TRAIL levels;
THYM	cis	rs13315871	0.929	rs7643185	chr3:58311158	A/C	cg12435725	chr3:58293450	RPP14	0.51	5.83	0.51	7.69e-8	Cholesterol, total;
THYM	cis	rs990171	0.695	rs759382	chr2:103094213	G/T	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.67	-0.43	1.01e-5	Lymphocyte counts;
THYM	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg02038168	chr22:39784481	NA	-0.72	-5.31	-0.48	7.08e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs2637266	0.902	rs2583056	chr10:78399498	A/G	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs981844	0.922	rs75543972	chr4:154664792	G/C	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs9790314	1.000	rs62279921	chr3:161065441	T/C	cg03342759	chr3:160939853	NMD3	-0.7	-5.9	-0.52	5.48e-8	Morning vs. evening chronotype;
THYM	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg22920501	chr2:26401640	FAM59B	-1.04	-9.12	-0.68	1.26e-14	Gut microbiome composition (summer);
THYM	cis	rs6430585	0.640	rs6716070	chr2:136544651	G/T	cg23851026	chr2:136556271	LCT	-0.76	-7.4	-0.6	5.52e-11	Corneal structure;
THYM	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg25767906	chr1:53392781	SCP2	0.72	6.48	0.55	4.15e-9	Monocyte count;
THYM	cis	rs921968	0.591	rs3731877	chr2:219602499	G/C	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9486715	0.838	rs9386473	chr6:96873341	C/A	cg06623918	chr6:96969491	KIAA0776	1.08	8.95	0.68	2.9e-14	Headache;
THYM	cis	rs4589258	0.933	rs7113248	chr11:90416949	A/C	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs59698941	0.943	rs57045911	chr5:132272311	T/C	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs7575217	0.740	rs12468712	chr2:101746066	A/T	cg23907051	chr2:101730305	TBC1D8	-0.41	-5.42	-0.49	4.44e-7	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs300703	0.542	rs189762	chr2:180079	A/T	cg21211680	chr2:198530	NA	-0.88	-5.75	-0.51	1.06e-7	Blood protein levels;
THYM	cis	rs6980334	1.000	rs7787591	chr7:137778203	C/T	cg11874123	chr7:137028198	PTN	0.67	5.24	0.47	9.68e-7	Blood metabolite ratios;
THYM	cis	rs9906944	0.707	rs9912906	chr17:47104432	A/T	cg11673840	chr17:47092156	IGF2BP1	-0.54	-5.48	-0.49	3.55e-7	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg07636037	chr3:49044803	WDR6	0.91	8.11	0.64	1.74e-12	Parkinson's disease;
THYM	cis	rs13064411	0.696	rs6799610	chr3:113248748	A/C	cg10517650	chr3:113235015	CCDC52	0.61	5.35	0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11756438	0.658	rs6937176	chr6:119007308	A/G	cg01113488	chr6:119027122	NA	0.56	4.5	0.42	1.92e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19346786	chr7:2764209	NA	-0.82	-7.72	-0.62	1.18e-11	Height;
THYM	cis	rs6743226	0.811	rs12471975	chr2:242154849	C/T	cg23350296	chr2:242663858	ING5	-0.47	-4.62	-0.43	1.18e-5	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs6987853	0.787	rs10958722	chr8:42425487	T/C	cg09913449	chr8:42400586	C8orf40	1.06	11.6	0.77	6.75e-20	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg05768032	chr16:30646687	NA	0.49	4.85	0.45	4.82e-6	Multiple myeloma;
THYM	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg05738196	chr6:26577821	NA	0.62	4.75	0.44	7.34e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11190604	0.767	rs10883484	chr10:102174803	G/C	cg07570687	chr10:102243282	WNT8B	0.82	7.71	0.62	1.25e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.58	4.97	0.45	2.98e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.28	10.82	0.74	2.95e-18	Platelet count;
THYM	cis	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg09307838	chr4:120376055	NA	-0.75	-5.91	-0.52	5.25e-8	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg17366294	chr4:99064904	C4orf37	0.47	5.13	0.47	1.52e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6570726	0.967	rs1396648	chr6:145785248	C/A	cg13319975	chr6:146136371	FBXO30	0.67	5.68	0.5	1.45e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg10560079	chr2:191398806	TMEM194B	-0.95	-7.69	-0.62	1.34e-11	Diastolic blood pressure;
THYM	cis	rs9790314	1.000	rs4597724	chr3:160963110	A/G	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg16928487	chr17:17741425	SREBF1	0.54	5.29	0.48	7.67e-7	Total body bone mineral density;
THYM	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg08439880	chr3:133502540	NA	-0.69	-5.73	-0.51	1.19e-7	Iron status biomarkers;
THYM	cis	rs8070128	0.568	rs3935505	chr17:17882020	T/G	cg04398451	chr17:18023971	MYO15A	-0.81	-7.21	-0.59	1.35e-10	Total body bone mineral density;
THYM	cis	rs9902453	0.709	rs6505162	chr17:28444183	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	5.06	0.46	2.09e-6	Coffee consumption (cups per day);
THYM	trans	rs4866334	1.000	rs75485994	chr5:18488330	A/G	cg08675002	chr5:90437527	GPR98	-1.47	-7.13	-0.59	1.98e-10	IgG glycosylation;
THYM	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg23758822	chr17:41437982	NA	1.17	11.09	0.75	7.75e-19	Menopause (age at onset);
THYM	trans	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg10856724	chr12:34555212	NA	-1.02	-9.32	-0.69	4.7e-15	Morning vs. evening chronotype;
THYM	cis	rs1971762	0.527	rs1247957	chr12:53961493	G/T	cg16917193	chr12:54089295	NA	-0.73	-6.55	-0.56	2.99e-9	Height;
THYM	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.75	7.26	0.6	1.06e-10	Lymphocyte counts;
THYM	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg06108461	chr20:60628389	TAF4	-0.79	-6.2	-0.54	1.44e-8	Body mass index;
THYM	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg18681998	chr4:17616180	MED28	1.02	9.76	0.71	5.5e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6665290	0.935	rs6670924	chr1:227196048	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs11225247	1.000	rs12275185	chr11:102272277	G/T	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg03209412	chr4:183728196	NA	0.69	6.42	0.55	5.3300000000000004e-09	Pediatric autoimmune diseases;
THYM	cis	rs13256369	0.802	rs13281933	chr8:8562665	C/A	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg07936489	chr17:37558343	FBXL20	0.85	5.64	0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03264133	chr6:25882463	NA	0.67	5.43	0.49	4.38e-7	Blood metabolite levels;
THYM	cis	rs6032067	0.929	rs13039083	chr20:43878838	T/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.47	-5.2	-0.47	1.15e-6	Blood protein levels;
THYM	cis	rs432925	0.529	rs9925945	chr16:393564	A/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.31	4.78	0.44	6.26e-6	Morning vs. evening chronotype;
THYM	cis	rs6835098	1.000	rs4695826	chr4:174089426	T/G	cg08422745	chr4:174089978	GALNT7	-1.0	-8.48	-0.66	2.83e-13	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs1580019	1.000	rs1580019	chr7:32493169	A/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.78	-7.27	-0.6	9.9e-11	Cognitive ability;
THYM	cis	rs2290159	0.800	rs11709504	chr3:12674199	T/C	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs72829446	0.932	rs62059823	chr17:7476493	G/C	cg07091842	chr17:7155530	C17orf81;DULLARD	-1.03	-4.58	-0.43	1.4e-5	Androgen levels;
THYM	cis	rs6964587	0.692	rs6970629	chr7:91846599	T/C	cg22709100	chr7:91322751	NA	0.67	5.07	0.46	1.97e-6	Breast cancer;
THYM	cis	rs3892630	0.878	rs2903759	chr19:33195947	A/G	cg22928329	chr19:33183273	NUDT19	-0.79	-6.0	-0.52	3.5e-8	Red blood cell traits;
THYM	cis	rs888194	0.677	rs7973253	chr12:109878115	A/G	cg11367159	chr12:110044531	NA	0.56	5.14	0.47	1.45e-6	Neuroticism;
THYM	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg22920501	chr2:26401640	FAM59B	-1.04	-9.12	-0.68	1.26e-14	Gut microbiome composition (summer);
THYM	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg24812749	chr6:127587940	RNF146	0.92	7.35	0.6	6.98e-11	Breast cancer;
THYM	trans	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg19862616	chr7:65841803	NCRNA00174	1.13	13.24	0.81	2.74e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg18681998	chr4:17616180	MED28	0.94	8.64	0.66	1.36e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg16928487	chr17:17741425	SREBF1	-0.56	-5.44	-0.49	4.09e-7	Total body bone mineral density;
THYM	cis	rs7216064	1.000	rs2046323	chr17:65849927	T/G	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2637266	0.775	rs2579744	chr10:78311824	A/G	cg18941641	chr10:78392320	NA	0.7	5.56	0.5	2.44e-7	Pulmonary function;
THYM	cis	rs4481887	1.000	rs4244174	chr1:248467956	A/G	cg13385794	chr1:248469461	NA	0.65	4.66	0.43	1.04e-5	Common traits (Other);
THYM	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg16586182	chr3:47516702	SCAP	0.62	5.33	0.48	6.61e-7	Colorectal cancer;
THYM	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs7326068	0.610	rs9552265	chr13:21311695	C/T	cg02792322	chr13:21280448	IL17D	-0.64	-4.47	-0.42	2.16e-5	Schizophrenia, bipolar disorder and depression (combined);
THYM	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg17063962	chr7:91808500	NA	-1.08	-11.41	-0.76	1.71e-19	Breast cancer;
THYM	cis	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs5758511	0.773	rs62241023	chr22:42385429	G/A	cg11601000	chr22:42348013	LOC339674	-0.57	-4.97	-0.45	2.99e-6	Birth weight;
THYM	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg27532560	chr4:187881888	NA	-0.96	-11.4	-0.76	1.72e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg05294307	chr14:35346193	BAZ1A	-0.93	-6.68	-0.57	1.64e-9	Psoriasis;
THYM	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg12373951	chr3:133503437	NA	0.65	7.02	0.58	3.27e-10	Iron status biomarkers;
THYM	cis	rs1878931	0.507	rs11648783	chr16:3406626	A/G	cg21433313	chr16:3507492	NAT15	-0.54	-4.73	-0.44	7.71e-6	Body mass index (adult);
THYM	cis	rs4474465	0.850	rs4579956	chr11:78232445	G/C	cg19901956	chr11:77921274	USP35	0.7	5.2	0.47	1.16e-6	Alzheimer's disease (survival time);
THYM	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg05896524	chr21:47604654	C21orf56	-0.72	-4.96	-0.45	3.08e-6	Testicular germ cell tumor;
THYM	cis	rs9814567	0.806	rs11927539	chr3:134319448	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.09e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg20295408	chr7:1910781	MAD1L1	-0.68	-5.59	-0.5	2.17e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg27129171	chr3:47204927	SETD2	-0.69	-6.63	-0.56	2.03e-9	Colorectal cancer;
THYM	cis	rs490234	0.718	rs2133386	chr9:128173838	C/A	cg14078157	chr9:128172775	NA	-0.85	-6.77	-0.57	1.05e-9	Mean arterial pressure;
THYM	cis	rs4732038	0.546	rs59085389	chr7:134279285	A/G	cg06906464	chr7:134288099	NA	-0.48	-4.76	-0.44	7e-6	Longevity;
THYM	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg08772003	chr10:104629869	AS3MT	-0.62	-5.45	-0.49	3.88e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2803122	0.774	rs10757034	chr9:19227803	A/C	cg19584733	chr9:19298547	DENND4C	-0.54	-4.67	-0.43	9.76e-6	Pulse pressure;
THYM	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg08999081	chr20:33150536	PIGU	-0.79	-7.05	-0.59	2.79e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs3845702	0.736	rs115569960	chr2:180848214	C/T	cg01881094	chr2:180872142	CWC22	0.89	5.34	0.48	6.22e-7	Schizophrenia;
THYM	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg27446573	chr6:127587934	RNF146	0.72	5.79	0.51	9.22e-8	Breast cancer;
THYM	cis	rs2398893	1.000	rs2398893	chr9:96758342	A/G	cg14459158	chr9:96720562	NA	0.49	4.52	0.42	1.78e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4792901	0.765	rs28874115	chr17:41538254	A/C	cg21940313	chr17:41620911	ETV4	-0.53	-4.94	-0.45	3.29e-6	Dupuytren's disease;
THYM	cis	rs10089	1.000	rs62373701	chr5:127416294	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	7.21	0.59	1.32e-10	Ileal carcinoids;
THYM	cis	rs611744	0.901	rs599357	chr8:109194160	T/C	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs10887741	0.690	rs7908056	chr10:89444650	G/A	cg13926569	chr10:89418898	PAPSS2	0.61	6.54	0.56	3.06e-9	Exercise (leisure time);
THYM	cis	rs6924995	0.501	rs7760370	chr6:16193281	G/A	cg11805552	chr6:16175128	NA	0.58	4.8	0.44	5.89e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs11039798	0.925	rs7929225	chr11:48931739	G/C	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg23583168	chr7:148888333	NA	-1.05	-15.12	-0.84	4.95e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs113835537	0.529	rs3816492	chr11:66297363	C/T	cg24851651	chr11:66362959	CCS	0.74	5.07	0.46	1.94e-6	Airway imaging phenotypes;
THYM	cis	rs2811415	0.597	rs9809497	chr3:127782514	T/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg03188948	chr7:1209495	NA	1.04	6.09	0.53	2.41e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11048434	0.673	rs2159961	chr12:9061456	G/T	cg13575925	chr12:9217583	LOC144571	0.53	4.82	0.44	5.35e-6	Sjögren's syndrome;
THYM	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg06481639	chr22:41940642	POLR3H	-0.8	-5.6	-0.5	2.11e-7	Vitiligo;
THYM	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg25072359	chr17:41440525	NA	0.72	5.26	0.47	8.95e-7	Menopause (age at onset);
THYM	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg00684032	chr4:1343700	KIAA1530	0.8	6.88	0.58	6.2e-10	Obesity-related traits;
THYM	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg18032289	chr17:61959525	GH2	-0.49	-4.7	-0.43	8.9e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg22875332	chr1:76189707	ACADM	0.72	5.7	0.5	1.35e-7	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7901181	0.673	rs17135529	chr10:3673600	C/G	cg14302214	chr10:3805273	NA	0.81	4.78	0.44	6.48e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6570726	0.935	rs368848	chr6:145855281	A/T	cg13319975	chr6:146136371	FBXO30	-0.66	-5.63	-0.5	1.85e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg26818010	chr10:134567672	INPP5A	-0.72	-5.65	-0.5	1.67e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg24209194	chr3:40518798	ZNF619	-0.56	-4.46	-0.42	2.26e-5	Renal cell carcinoma;
THYM	cis	rs3126085	0.560	rs12403031	chr1:152343394	T/C	cg10321714	chr1:152280068	FLG	-0.69	-4.84	-0.44	5.1e-6	Atopic dermatitis;
THYM	cis	rs733592	0.894	rs886589	chr12:48477197	C/T	cg21466736	chr12:48725269	NA	0.48	5.29	0.48	7.82e-7	Plateletcrit;
THYM	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03517284	chr6:25882590	NA	-0.82	-6.35	-0.55	7.33e-9	Blood metabolite levels;
THYM	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg24846680	chr1:228362309	C1orf69	0.51	4.53	0.42	1.72e-5	Diastolic blood pressure;
THYM	cis	rs7246967	0.608	rs2569728	chr19:23014004	C/T	cg05241461	chr19:22816980	ZNF492	0.54	4.53	0.42	1.74e-5	Bronchopulmonary dysplasia;
THYM	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg00310523	chr12:86230176	RASSF9	-0.55	-4.87	-0.45	4.51e-6	Major depressive disorder;
THYM	cis	rs950880	0.710	rs4140785	chr2:103088517	A/C	cg03938978	chr2:103052716	IL18RAP	-0.56	-4.77	-0.44	6.57e-6	Serum protein levels (sST2);
THYM	cis	rs35110281	0.607	rs8131020	chr21:44981063	C/A	cg27168131	chr21:44088823	PDE9A	-0.48	-4.77	-0.44	6.71e-6	Mean corpuscular volume;
THYM	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3008870	0.755	rs2755243	chr1:67482783	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.79	6.84	0.57	7.8e-10	Lymphocyte percentage of white cells;
THYM	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg04842962	chr6:43655489	MRPS18A	0.98	8.35	0.65	5.51e-13	IgG glycosylation;
THYM	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06634786	chr22:41940651	POLR3H	0.73	5.77	0.51	9.81e-8	Vitiligo;
THYM	cis	rs67072384	0.818	rs1872127	chr11:72465085	G/A	cg01380194	chr11:72452482	ARAP1	-0.81	-4.57	-0.42	1.49e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg14895029	chr7:2775587	GNA12	-0.67	-4.89	-0.45	4.14e-6	Height;
THYM	cis	rs611744	0.573	rs1457210	chr8:109261562	A/G	cg21045802	chr8:109455806	TTC35	-0.67	-6.19	-0.54	1.52e-8	Dupuytren's disease;
THYM	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg23803603	chr1:2058230	PRKCZ	0.6	4.69	0.43	9.29e-6	Height;
THYM	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs4363385	0.818	rs4845512	chr1:152995241	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.76	-0.44	6.94e-6	Inflammatory skin disease;
THYM	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg04865290	chr3:52927548	TMEM110	-0.88	-4.55	-0.42	1.59e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs55728055	0.661	rs16989519	chr22:31725416	C/T	cg10537193	chr22:32026975	PISD	-0.91	-5.25	-0.47	9.24e-7	Age-related hearing impairment;
THYM	cis	rs6032067	0.704	rs35009666	chr20:43786020	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs4474465	0.790	rs7932315	chr11:78214878	G/A	cg19901956	chr11:77921274	USP35	0.63	4.67	0.43	9.79e-6	Alzheimer's disease (survival time);
THYM	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg02734326	chr4:10020555	SLC2A9	-0.56	-4.63	-0.43	1.17e-5	Bone mineral density;
THYM	cis	rs748404	0.631	rs4296223	chr15:43645246	T/C	cg12861797	chr15:43585817	TGM7	0.44	4.67	0.43	9.79e-6	Lung cancer;
THYM	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg20295408	chr7:1910781	MAD1L1	-0.58	-4.63	-0.43	1.14e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs4466137	0.953	rs1420654	chr5:82975793	G/A	cg16102102	chr5:83017553	HAPLN1	-1.04	-8.97	-0.68	2.57e-14	Prostate cancer;
THYM	cis	rs12216545	0.669	rs1879871	chr7:150300393	A/G	cg08960815	chr7:150264767	GIMAP4	-0.83	-7.51	-0.61	3.22e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs2811415	0.597	rs9849210	chr3:127779633	G/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg11327659	chr7:150037044	RARRES2	0.37	4.61	0.43	1.25e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2658782	1.000	rs2658782	chr11:93166731	T/G	cg15737290	chr11:93063684	CCDC67	1.05	7.97	0.63	3.42e-12	Pulmonary function decline;
THYM	cis	rs12611088	0.571	rs7252955	chr19:44021766	A/T	cg18042043	chr19:44147545	NA	-0.42	-4.94	-0.45	3.3e-6	Plasma amyloid beta peptide concentrations (ABx-42);
THYM	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg03609598	chr5:56110824	MAP3K1	0.72	4.57	0.42	1.48e-5	Initial pursuit acceleration;
THYM	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11577318	0.579	rs11548246	chr1:26697166	G/A	cg16664472	chr1:26644822	UBXN11;CD52	0.34	4.91	0.45	3.79e-6	Granulocyte percentage of myeloid white cells;
THYM	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg27490568	chr2:178487706	NA	0.59	5.91	0.52	5.43e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg02734326	chr4:10020555	SLC2A9	0.63	5.28	0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6427356	0.513	rs12038802	chr1:157141337	A/G	cg27547283	chr1:156698502	C1orf66;ISG20L2	-0.58	-4.49	-0.42	2.02e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg12923728	chr3:195709715	SDHAP1	-0.78	-6.42	-0.55	5.43e-9	Pancreatic cancer;
THYM	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4974559	0.790	rs28712208	chr4:1316695	A/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.44	-4.96	-0.45	3.05e-6	Systolic blood pressure;
THYM	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs6831352	0.879	rs4699717	chr4:100066137	C/T	cg12011299	chr4:100065546	ADH4	-0.82	-7.62	-0.62	1.91e-11	Alcohol dependence;
THYM	cis	rs72827839	0.603	rs72833466	chr17:45948952	C/A	cg23391107	chr17:45924227	SP6	0.72	5.38	0.48	5.3e-7	Ease of getting up in the morning;
THYM	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.67	4.69	0.43	9.25e-6	Aortic root size;
THYM	cis	rs7772486	0.720	rs4896844	chr6:146075224	T/C	cg23711669	chr6:146136114	FBXO30	-0.97	-10.49	-0.73	1.45e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg06600287	chr1:53387719	ECHDC2	-0.34	-5.4	-0.48	4.88e-7	Monocyte count;
THYM	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.43	0.7	2.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.85	-0.51	7.09e-8	Bipolar disorder and schizophrenia;
THYM	trans	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg25214090	chr10:38739885	LOC399744	0.83	7.11	0.59	2.14e-10	Corneal astigmatism;
THYM	cis	rs3096299	0.583	rs2965949	chr16:89520452	A/G	cg02187348	chr16:89574699	SPG7	0.71	4.6	0.43	1.31e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs2463822	0.844	rs7104149	chr11:62171627	A/G	cg06239285	chr11:62104954	ASRGL1	-1.4	-6.65	-0.56	1.86e-9	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs1784581	0.588	rs9458428	chr6:162424579	A/G	cg17173639	chr6:162384350	PARK2	-0.81	-7.48	-0.61	3.75e-11	Itch intensity from mosquito bite;
THYM	cis	rs9527	0.615	rs4919682	chr10:104584330	C/T	cg05855489	chr10:104503620	C10orf26	0.63	4.49	0.42	2.04e-5	Arsenic metabolism;
THYM	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs59698941	0.943	rs67437142	chr5:132306722	T/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs4866334	1.000	rs78178098	chr5:18487497	T/C	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg06784218	chr1:46089804	CCDC17	-0.32	-4.82	-0.44	5.41e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs4242434	0.672	rs2404654	chr8:22484949	T/C	cg11461670	chr8:22454935	PDLIM2	-0.33	-6.26	-0.54	1.09e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4631830	0.832	rs2337711	chr10:51504604	C/T	cg10326726	chr10:51549505	MSMB	0.54	5.33	0.48	6.65e-7	Prostate-specific antigen levels;
THYM	cis	rs870825	0.616	rs1401358	chr4:185640057	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs4730276	0.640	rs8721	chr7:107559722	A/T	cg23293999	chr7:106826042	HBP1	-0.61	-5.07	-0.46	1.95e-6	Ulcerative colitis;
THYM	cis	rs6918586	0.658	rs198840	chr6:26112164	T/G	cg07061783	chr6:25882402	NA	0.58	4.57	0.42	1.46e-5	Schizophrenia;
THYM	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg24450063	chr1:156163899	SLC25A44	1.15	14.75	0.83	2.59e-26	Testicular germ cell tumor;
THYM	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg13393036	chr8:95962371	TP53INP1	-0.47	-4.9	-0.45	3.95e-6	Type 2 diabetes;
THYM	cis	rs9560113	0.573	rs1888304	chr13:112242454	A/G	cg15979348	chr13:112237479	NA	0.55	5.15	0.47	1.39e-6	Menarche (age at onset);
THYM	cis	rs7582180	0.817	rs1437967	chr2:100929072	C/G	cg14675211	chr2:100938903	LONRF2	0.67	6.48	0.55	4.1e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1979654	0.543	rs16940985	chr16:86403723	C/G	cg26992566	chr16:85814166	COX4NB	0.51	4.54	0.42	1.67e-5	Barrett's esophagus  or Esophageal adenocarcinoma;
THYM	cis	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg02825527	chr7:2087843	MAD1L1	-0.7	-4.55	-0.42	1.58e-5	Bipolar disorder;
THYM	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg27284194	chr4:1044797	NA	0.62	4.73	0.44	7.81e-6	Recombination rate (females);
THYM	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg05932139	chr16:680872	WFIKKN1	-0.59	-4.84	-0.44	5.07e-6	Height;
THYM	cis	rs793571	0.544	rs12912699	chr15:58917021	T/C	cg05156742	chr15:59063176	FAM63B	0.62	5.19	0.47	1.2e-6	Schizophrenia;
THYM	cis	rs7582180	0.676	rs1437969	chr2:100983482	A/C	cg21926883	chr2:100939477	LONRF2	-0.66	-6.14	-0.53	1.89e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs892961	0.932	rs7224442	chr17:75413439	A/G	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs6430585	0.697	rs1050115	chr2:136511817	A/G	cg07169764	chr2:136633963	MCM6	1.22	13.28	0.81	2.23e-23	Corneal structure;
THYM	cis	rs13082711	0.871	rs13061912	chr3:27495586	A/G	cg02860705	chr3:27208620	NA	0.72	5.22	0.47	1.03e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.48	4.52	0.42	1.76e-5	Birth weight;
THYM	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg05962950	chr11:130786565	SNX19	0.84	7.44	0.61	4.56e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg12179176	chr11:130786555	SNX19	-0.95	-9.75	-0.71	5.56e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg03929089	chr4:120376271	NA	0.96	10.53	0.73	1.2e-17	Coronary artery disease;
THYM	cis	rs8067545	0.641	rs203457	chr17:19818338	A/C	cg20830565	chr17:20408647	MGC102966	0.51	4.64	0.43	1.11e-5	Schizophrenia;
THYM	cis	rs860818	1.000	rs1637224	chr7:23228400	A/G	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs761746	0.960	rs5753733	chr22:32027922	A/G	cg10537193	chr22:32026975	PISD	-0.35	-4.82	-0.44	5.42e-6	Intelligence;
THYM	cis	rs6665290	0.839	rs6699400	chr1:227190497	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	trans	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7567389	0.719	rs1504135	chr2:128003251	C/T	cg06038358	chr2:128176007	PROC	-0.47	-4.45	-0.42	2.33e-5	Self-rated health;
THYM	cis	rs1650123	0.645	rs703616	chr12:104020232	T/C	cg23227824	chr12:103980017	STAB2	0.47	4.75	0.44	7.11e-6	IgG glycosylation;
THYM	cis	rs7584330	0.554	rs7570873	chr2:238435054	G/A	cg14458575	chr2:238380390	NA	0.81	4.86	0.45	4.63e-6	Prostate cancer;
THYM	cis	rs2085601	0.542	rs2670626	chr4:89967292	C/T	cg17769793	chr4:89976368	FAM13A	-0.59	-6.86	-0.58	6.96e-10	Hair greying;
THYM	cis	rs6960043	0.652	rs6461149	chr7:15044103	C/T	cg19272540	chr7:15055459	NA	0.49	5.18	0.47	1.26e-6	Type 2 diabetes;
THYM	cis	rs7917772	0.582	rs10786683	chr10:104320476	G/A	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs11031096	0.782	rs4910888	chr11:4152915	G/A	cg18678763	chr11:4115507	RRM1	-0.43	-5.81	-0.51	8.3e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg03264133	chr6:25882463	NA	-0.66	-4.49	-0.42	2.01e-5	Height;
THYM	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg00495681	chr13:53174319	NA	0.87	8.71	0.67	9.4e-14	Lewy body disease;
THYM	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg07636037	chr3:49044803	WDR6	0.81	5.96	0.52	4.31e-8	Menarche (age at onset);
THYM	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22496380	chr5:211416	CCDC127	-1.31	-8.26	-0.65	8.38e-13	Breast cancer;
THYM	cis	rs6754311	0.773	rs4988183	chr2:136622046	T/C	cg07169764	chr2:136633963	MCM6	0.7	5.73	0.51	1.2e-7	Mosquito bite size;
THYM	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs9828933	0.626	rs73119018	chr3:63975328	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.97	-5.66	-0.5	1.58e-7	Type 2 diabetes;
THYM	cis	rs786425	0.530	rs9788204	chr12:124207209	C/T	cg15249119	chr12:124971054	NCOR2	0.51	4.68	0.43	9.53e-6	Pubertal anthropometrics;
THYM	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg15242686	chr22:24348715	GSTTP1	0.55	5.39	0.48	5.13e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11169225	0.906	rs3782319	chr12:50345079	G/A	cg23855989	chr12:50355821	AQP5	0.68	6.2	0.54	1.44e-8	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg11764359	chr7:65958608	NA	0.82	6.56	0.56	2.81e-9	Aortic root size;
THYM	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Electroencephalogram traits;
THYM	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.67	5.56	0.5	2.48e-7	Blood metabolite levels;
THYM	cis	rs490234	0.902	rs12351538	chr9:128281503	A/G	cg14078157	chr9:128172775	NA	-0.62	-4.97	-0.45	2.94e-6	Mean arterial pressure;
THYM	cis	rs7830933	0.866	rs6991688	chr8:23582909	T/G	cg04349084	chr8:23602677	NA	0.63	6.61	0.56	2.23e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs7084921	0.552	rs11598495	chr10:101889417	T/C	cg11344164	chr10:101878520	NA	-0.59	-5.15	-0.47	1.4e-6	Bone mineral density;
THYM	cis	rs4478037	1.000	rs4074418	chr3:33161165	G/T	cg19404215	chr3:33155277	CRTAP	1.18	8.15	0.64	1.49e-12	Major depressive disorder;
THYM	cis	rs6598955	0.502	rs6683157	chr1:26545865	G/A	cg04990556	chr1:26633338	UBXN11	0.96	6.06	0.53	2.7e-8	Obesity-related traits;
THYM	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.76	-0.44	6.97e-6	Mean corpuscular volume;
THYM	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.52e-7	Heart rate;
THYM	cis	rs12310956	0.532	rs11052920	chr12:33955891	T/G	cg10856724	chr12:34555212	NA	-0.72	-6.65	-0.56	1.82e-9	Morning vs. evening chronotype;
THYM	cis	rs35883536	1.000	rs6663612	chr1:101085835	A/G	cg06223162	chr1:101003688	GPR88	0.63	4.62	0.43	1.22e-5	Monocyte count;
THYM	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg16928487	chr17:17741425	SREBF1	-0.48	-4.49	-0.42	2.01e-5	Total body bone mineral density;
THYM	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg23711669	chr6:146136114	FBXO30	0.93	9.7	0.71	7.07e-16	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.97	-7.62	-0.62	1.88e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs17006441	0.932	rs9854710	chr3:69864325	G/A	cg18496212	chr3:69797108	MITF	0.66	6.61	0.56	2.28e-9	Hemoglobin concentration;
THYM	cis	rs2235649	0.663	rs6600168	chr16:1848927	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.61	-5.31	-0.48	7.12e-7	Blood metabolite levels;
THYM	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg20387954	chr3:183756860	HTR3D	0.56	4.64	0.43	1.11e-5	Anterior chamber depth;
THYM	cis	rs420259	0.516	rs9933261	chr16:23515952	G/A	cg00143387	chr16:23521605	GGA2	-0.74	-5.31	-0.48	7.21e-7	Bipolar disorder;
THYM	cis	rs2235649	0.798	rs9932983	chr16:1848184	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.57	-4.91	-0.45	3.81e-6	Blood metabolite levels;
THYM	cis	rs11247915	0.583	rs66569416	chr1:26659737	C/G	cg00852783	chr1:26633632	UBXN11	0.73	6.07	0.53	2.63e-8	Obesity-related traits;
THYM	cis	rs870825	0.655	rs28555435	chr4:185647300	C/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs2742417	0.603	rs2742374	chr3:45784082	T/C	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs9788721	0.836	rs17483686	chr15:78733390	A/T	cg18825076	chr15:78729989	IREB2	-0.66	-6.19	-0.54	1.54e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg04944784	chr2:26401820	FAM59B	-1.06	-7.83	-0.63	6.7e-12	Gut microbiome composition (summer);
THYM	cis	rs7943358	0.955	rs10832499	chr11:15686365	T/A	cg11966998	chr11:15692519	NA	-0.47	-4.71	-0.44	8.28e-6	Gut microbiome composition (summer);
THYM	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg07507251	chr3:52567010	NT5DC2	0.42	4.88	0.45	4.27e-6	Electroencephalogram traits;
THYM	cis	rs59698941	0.943	rs67160603	chr5:132285618	G/C	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg15448220	chr1:150897856	SETDB1	0.88	7.18	0.59	1.51e-10	Melanoma;
THYM	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg17747265	chr1:1875780	NA	-0.8	-9.28	-0.69	5.67e-15	Body mass index;
THYM	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg22535103	chr8:58192502	C8orf71	-1.05	-6.6	-0.56	2.38e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg23010205	chr3:189546664	TP63;MIR944	-0.67	-4.47	-0.42	2.2e-5	Lung adenocarcinoma;
THYM	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg00757033	chr12:89920650	WDR51B	0.73	11.3	0.76	2.83e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs863345	0.625	rs12119672	chr1:158500285	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg23711669	chr6:146136114	FBXO30	0.93	9.55	0.7	1.53e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg06789500	chr7:2109450	MAD1L1	-0.65	-4.46	-0.42	2.24e-5	Bipolar disorder;
THYM	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg08132940	chr7:1081526	C7orf50	-1.03	-6.42	-0.55	5.3e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs56309584	0.560	rs79224651	chr17:8076667	T/G	cg08322244	chr17:8066669	VAMP2	-0.55	-5.21	-0.47	1.09e-6	Initial pursuit acceleration;
THYM	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg18451016	chr1:38461880	NA	0.43	5.26	0.47	8.97e-7	Coronary artery disease;
THYM	cis	rs992157	0.932	rs1870125	chr2:219187901	C/T	cg00012203	chr2:219082015	ARPC2	0.64	5.58	0.5	2.28e-7	Colorectal cancer;
THYM	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg00898013	chr13:113819073	PROZ	-0.89	-9.29	-0.69	5.34e-15	Platelet distribution width;
THYM	cis	rs10799590	1.000	rs713098	chr1:224832627	A/T	cg01808320	chr1:224927238	CNIH3	-0.57	-5.01	-0.46	2.54e-6	Opioid dependence;
THYM	cis	rs308403	0.600	rs309366	chr4:123661408	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.69	4.71	0.44	8.35e-6	Blood protein levels;
THYM	cis	rs4654899	0.571	rs6692677	chr1:21251717	C/T	cg01072550	chr1:21505969	NA	-0.71	-6.87	-0.58	6.56e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs6988636	0.818	rs10111810	chr8:124169565	G/A	cg23067535	chr8:124195133	FAM83A	-1.04	-5.22	-0.47	1.05e-6	Urinary uromodulin levels;
THYM	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg24324837	chr19:49891574	CCDC155	0.52	4.75	0.44	7.07e-6	Multiple sclerosis;
THYM	cis	rs42648	0.693	rs3747800	chr7:89899488	G/T	cg25739043	chr7:89950458	NA	-0.53	-4.49	-0.42	2.01e-5	Homocysteine levels;
THYM	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	6.44	0.55	4.96e-9	Platelet count;
THYM	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg21773646	chr17:80085082	CCDC57	0.32	4.5	0.42	1.93e-5	Life satisfaction;
THYM	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg12863693	chr15:85201151	NMB	0.62	5.42	0.49	4.5e-7	Schizophrenia;
THYM	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg14004847	chr7:1930337	MAD1L1	-0.66	-4.87	-0.45	4.5e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg23018236	chr17:30244563	NA	-0.6	-4.45	-0.42	2.3e-5	Hip circumference adjusted for BMI;
THYM	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg25358565	chr5:93447407	FAM172A	-1.36	-10.86	-0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs7851660	0.809	rs35324451	chr9:100660136	A/T	cg13688889	chr9:100608707	NA	-0.74	-5.27	-0.48	8.35e-7	Strep throat;
THYM	cis	rs686320	1.000	rs1787666	chr11:65249089	A/C	cg20588859	chr11:65321429	LTBP3	0.83	4.91	0.45	3.76e-6	Hip circumference adjusted for BMI;
THYM	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	7.0	0.58	3.69e-10	Platelet count;
THYM	cis	rs2710642	0.779	rs360807	chr2:62926859	C/T	cg17519650	chr2:63277830	OTX1	-0.74	-4.87	-0.45	4.43e-6	LDL cholesterol levels;LDL cholesterol;
THYM	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg18402987	chr7:1209562	NA	0.6	4.56	0.42	1.51e-5	Longevity;Endometriosis;
THYM	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.41	0.6	5.28e-11	Obesity-related traits;
THYM	cis	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg10856724	chr12:34555212	NA	-0.78	-6.99	-0.58	3.83e-10	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg10802521	chr3:52805072	NEK4	-0.63	-5.3	-0.48	7.54e-7	Electroencephalogram traits;
THYM	cis	rs747334	0.653	rs10881858	chr10:92701586	T/C	cg07620928	chr10:92689909	NA	0.52	4.51	0.42	1.86e-5	Fibroblast growth factor basic levels;
THYM	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg27034606	chr17:28928453	LRRC37B2	-0.7	-4.52	-0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7084402	0.935	rs10763553	chr10:60274049	C/A	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs12817211	0.524	rs7967979	chr12:50520676	G/A	cg06168149	chr12:50497778	GPD1	0.31	4.69	0.43	9.04e-6	Colorectal or endometrial cancer;
THYM	cis	rs728616	0.614	rs61858841	chr10:81714176	C/T	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs892961	1.000	rs1075457	chr17:75400737	A/G	cg11351908	chr17:75402473	SEPT9	-0.56	-5.7	-0.51	1.32e-7	Airflow obstruction;
THYM	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	18.27	0.88	7.47e-33	Chronic sinus infection;
THYM	cis	rs113835537	0.529	rs57691879	chr11:66236604	C/T	cg24851651	chr11:66362959	CCS	0.63	4.49	0.42	2.01e-5	Airway imaging phenotypes;
THYM	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg23803603	chr1:2058230	PRKCZ	0.64	5.53	0.49	2.77e-7	Height;
THYM	cis	rs7917772	0.582	rs7091252	chr10:104328859	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs12291225	0.679	rs11023178	chr11:14310282	G/A	cg19336497	chr11:14380999	RRAS2	-0.82	-9.66	-0.7	8.92e-16	Sense of smell;
THYM	cis	rs9810089	0.706	rs521746	chr3:136103920	C/T	cg12473912	chr3:136751656	NA	-0.59	-4.97	-0.45	2.93e-6	Gestational age at birth (child effect);
THYM	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg12373951	chr3:133503437	NA	-0.57	-6.12	-0.53	2.07e-8	Iron status biomarkers;
THYM	cis	rs9457247	0.534	rs9347170	chr6:167405187	C/T	cg15592062	chr6:167189543	RPS6KA2	0.52	5.32	0.48	6.84e-7	Crohn's disease;
THYM	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg02753203	chr1:228287806	NA	-0.61	-5.27	-0.48	8.54e-7	Diastolic blood pressure;
THYM	cis	rs2637266	0.783	rs4980006	chr10:78477993	G/C	cg18941641	chr10:78392320	NA	0.74	6.0	0.52	3.53e-8	Pulmonary function;
THYM	cis	rs870825	0.929	rs72689254	chr4:185589941	C/T	cg04058563	chr4:185651563	MLF1IP	0.96	6.66	0.56	1.78e-9	Blood protein levels;
THYM	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg20242066	chr2:136595261	LCT	-0.54	-6.85	-0.57	7.31e-10	Mosquito bite size;
THYM	cis	rs36051895	0.659	rs12343867	chr9:5074189	T/C	cg02405213	chr9:5042618	JAK2	-1.04	-11.49	-0.76	1.15e-19	Pediatric autoimmune diseases;
THYM	cis	rs5769765	0.542	rs5770725	chr22:50256309	C/T	cg08270630	chr22:50330655	NA	0.72	4.68	0.43	9.6e-6	Schizophrenia;
THYM	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg15556689	chr8:8085844	FLJ10661	0.62	5.08	0.46	1.86e-6	Mood instability;
THYM	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.85	-6.75	-0.57	1.14e-9	Lung cancer in ever smokers;
THYM	cis	rs10752881	1.000	rs4233193	chr1:182970865	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.86	0.45	4.61e-6	Colorectal cancer;
THYM	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg10295955	chr4:187884368	NA	-1.22	-17.54	-0.87	1.51e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs861020	0.606	rs629224	chr1:210005071	C/T	cg05527609	chr1:210001259	C1orf107	0.88	7.15	0.59	1.75e-10	Orofacial clefts;
THYM	cis	rs7178572	1.000	rs2055901	chr15:77759295	G/A	cg22256960	chr15:77711686	NA	-0.94	-7.93	-0.63	4.23e-12	Type 2 diabetes;
THYM	cis	rs1775715	0.707	rs2808088	chr10:32146150	A/G	cg04359828	chr10:32216031	ARHGAP12	0.41	5.12	0.46	1.62e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs7818345	1.000	rs4618712	chr8:19302621	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.44	4.65	0.43	1.08e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.27	-5.73	-0.51	1.2e-7	Obesity-related traits;
THYM	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.76	-6.58	-0.56	2.51e-9	Personality dimensions;
THYM	cis	rs478304	0.651	rs11604451	chr11:65551710	C/T	cg27068330	chr11:65405492	SIPA1	-0.96	-9.31	-0.69	4.93e-15	Acne (severe);
THYM	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg00071950	chr4:10020882	SLC2A9	0.79	8.24	0.65	9.19e-13	Bone mineral density;
THYM	cis	rs1011018	0.955	rs4726525	chr7:139468472	T/C	cg06079564	chr7:139468310	HIPK2	-0.75	-5.88	-0.52	6.14e-8	Systolic blood pressure;
THYM	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03264133	chr6:25882463	NA	0.72	5.71	0.51	1.29e-7	Blood metabolite levels;
THYM	cis	rs12291225	0.679	rs34238445	chr11:14315915	C/T	cg05501817	chr11:14380813	RRAS2	-0.75	-5.76	-0.51	1.02e-7	Sense of smell;
THYM	cis	rs17597773	0.527	rs2484698	chr1:221086065	A/T	cg16008148	chr1:221062819	NA	-0.37	-5.4	-0.48	4.9e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs950394	1.000	rs62152281	chr2:104980678	T/C	cg20302975	chr2:105468274	NA	-0.78	-4.78	-0.44	6.45e-6	Schizophrenia;
THYM	cis	rs1461503	0.534	rs4293127	chr11:122804263	G/C	cg27398637	chr11:122830231	C11orf63	-0.54	-4.73	-0.44	7.73e-6	Menarche (age at onset);
THYM	cis	rs7020830	0.825	rs10973248	chr9:37197768	C/T	cg14294708	chr9:37120828	ZCCHC7	1.27	16.36	0.86	2.19e-29	Schizophrenia;
THYM	cis	rs1499972	0.938	rs2925312	chr3:117720473	C/T	cg07612923	chr3:117604196	NA	-1.5	-5.16	-0.47	1.38e-6	Schizophrenia;
THYM	cis	rs909002	0.800	rs7529064	chr1:32105192	C/A	cg13919466	chr1:32135498	COL16A1	-0.49	-4.88	-0.45	4.24e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg23711669	chr6:146136114	FBXO30	0.91	9.55	0.7	1.49e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg17105886	chr17:28927953	LRRC37B2	1.29	6.93	0.58	5.09e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg24399712	chr22:39784796	NA	-0.87	-10.11	-0.72	9.8e-17	Intelligence (multi-trait analysis);
THYM	cis	rs7107174	0.892	rs1017907	chr11:77959124	A/T	cg19901956	chr11:77921274	USP35	-0.81	-6.12	-0.53	2.12e-8	Testicular germ cell tumor;
THYM	cis	rs289828	0.538	rs9287955	chr2:152153925	C/G	cg05960677	chr2:152117363	RBM43	0.71	6.61	0.56	2.24e-9	Blood protein levels;
THYM	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg12311346	chr5:56204834	C5orf35	-0.99	-7.9	-0.63	4.92e-12	Initial pursuit acceleration;
THYM	cis	rs9796	0.576	rs13329511	chr15:41299121	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.67	-5.75	-0.51	1.08e-7	Menopause (age at onset);
THYM	cis	rs240764	0.711	rs240148	chr6:101076767	C/T	cg21058520	chr6:100914733	NA	-0.57	-5.02	-0.46	2.39e-6	Neuroticism;
THYM	cis	rs2731664	0.756	rs2545796	chr5:176864269	T/C	cg14098951	chr5:176875120	PRR7	0.54	4.9	0.45	3.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg04731861	chr2:219085781	ARPC2	0.54	5.05	0.46	2.11e-6	Colorectal cancer;
THYM	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg26441486	chr22:50317300	CRELD2	0.42	7.41	0.61	5.09e-11	Schizophrenia;
THYM	cis	rs2637266	0.875	rs12783253	chr10:78378108	A/G	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg14019146	chr3:50243930	SLC38A3	-0.61	-5.3	-0.48	7.4e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg18128536	chr17:47092178	IGF2BP1	-0.61	-9.55	-0.7	1.49e-15	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs6565180	0.962	rs35480350	chr16:30366039	G/A	cg17640201	chr16:30407289	ZNF48	-0.87	-7.44	-0.61	4.46e-11	Tonsillectomy;
THYM	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg09904177	chr6:26538194	HMGN4	0.53	4.47	0.42	2.16e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7639513	0.767	rs3806661	chr3:12705855	A/G	cg23032965	chr3:12705835	RAF1	0.98	7.85	0.63	6.27e-12	Itch intensity from mosquito bite;
THYM	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg24531977	chr5:56204891	C5orf35	0.9	6.55	0.56	2.91e-9	Initial pursuit acceleration;
THYM	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg07936489	chr17:37558343	FBXL20	0.84	5.76	0.51	1.03e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-5.66	-0.5	1.58e-7	Morning vs. evening chronotype;
THYM	cis	rs6840360	0.642	rs2709834	chr4:152375424	T/G	cg17479576	chr4:152424074	FAM160A1	-0.68	-5.17	-0.47	1.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg03433033	chr1:76189801	ACADM	0.79	11.21	0.75	4.52e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg09260853	chr1:2094483	PRKCZ	-0.43	-4.55	-0.42	1.58e-5	Height;
THYM	cis	rs12310956	0.510	rs7965329	chr12:33868199	C/A	cg06521331	chr12:34319734	NA	-0.57	-4.6	-0.43	1.33e-5	Morning vs. evening chronotype;
THYM	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07167872	chr1:205819463	PM20D1	0.97	9.74	0.71	5.94e-16	Menarche (age at onset);
THYM	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs2692947	0.644	rs1168970	chr2:96816606	C/T	cg23100626	chr2:96804247	ASTL	0.38	4.74	0.44	7.37e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg08807101	chr21:30365312	RNF160	-0.67	-4.87	-0.45	4.5e-6	Dental caries;
THYM	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg16624210	chr5:671434	TPPP	-0.64	-6.62	-0.56	2.15e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg17063962	chr7:91808500	NA	1.13	12.47	0.79	1.03e-21	Breast cancer;
THYM	cis	rs1957429	0.614	rs73279833	chr14:65352523	A/G	cg23373153	chr14:65346875	NA	-1.29	-5.55	-0.49	2.56e-7	Pediatric areal bone mineral density (radius);
THYM	cis	rs863345	0.584	rs6672789	chr1:158497139	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.15	6.86	0.58	7.08e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4455778	0.580	rs56191832	chr7:49128223	C/A	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs8141797	0.685	rs732811	chr22:24587818	T/C	cg07048516	chr22:24105087	C22orf15	-0.72	-4.5	-0.42	1.92e-5	Amyotrophic lateral sclerosis;Coronary artery disease;
THYM	cis	rs6748734	0.625	rs4563218	chr2:241820035	G/A	cg15164180	chr2:241846931	NA	-0.35	-4.75	-0.44	7.32e-6	Urinary metabolites;
THYM	cis	rs9972944	0.702	rs987931	chr17:63765911	T/G	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	trans	rs7918405	0.724	rs12778643	chr10:114459083	T/C	cg24847366	chr12:125034283	NA	0.83	7.57	0.61	2.41e-11	QRS duration;
THYM	cis	rs36051895	0.623	rs57707737	chr9:5062844	A/T	cg02405213	chr9:5042618	JAK2	-1.02	-11.35	-0.76	2.29e-19	Pediatric autoimmune diseases;
THYM	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg03433033	chr1:76189801	ACADM	0.77	10.18	0.72	6.87e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg08132940	chr7:1081526	C7orf50	-1.26	-7.56	-0.61	2.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg08772003	chr10:104629869	AS3MT	-0.56	-4.97	-0.45	3e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs921665	0.831	rs3792156	chr2:3196859	C/T	cg16434511	chr2:3151078	NA	1.13	6.04	0.53	2.97e-8	World class endurance athleticism;
THYM	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg18681998	chr4:17616180	MED28	-0.79	-6.79	-0.57	9.51e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs593982	0.920	rs521678	chr11:65485727	T/G	cg08755490	chr11:65554678	OVOL1	1.29	4.66	0.43	1.03e-5	Atopic dermatitis;
THYM	cis	rs7512552	0.803	rs9435997	chr1:150289496	G/A	cg15654264	chr1:150340011	RPRD2	-0.44	-5.19	-0.47	1.21e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg03690763	chr11:133734501	NA	-0.62	-4.97	-0.45	3.01e-6	Childhood ear infection;
THYM	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg06766960	chr11:133703094	NA	-0.61	-5.42	-0.49	4.41e-7	Childhood ear infection;
THYM	cis	rs208520	0.690	rs176289	chr6:66766522	C/T	cg07460842	chr6:66804631	NA	-1.11	-8.11	-0.64	1.73e-12	Exhaled nitric oxide output;
THYM	cis	rs447921	0.861	rs4789297	chr17:74447351	G/T	cg17201438	chr17:74438067	UBE2O	0.77	5.46	0.49	3.74e-7	Mitochondrial DNA levels;
THYM	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	4.55	0.42	1.61e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	4.92	0.45	3.68e-6	Menarche (age at onset);
THYM	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2229238	0.868	rs73018293	chr1:154465577	C/T	cg21262032	chr1:154437693	IL6R	-0.55	-4.81	-0.44	5.6e-6	Coronary heart disease;
THYM	cis	rs5771069	0.931	rs137856	chr22:50444484	A/G	cg27467552	chr22:50353597	PIM3	-0.46	-4.87	-0.45	4.45e-6	Ulcerative colitis;
THYM	cis	rs6723226	0.881	rs10181198	chr2:32686582	A/G	cg02381751	chr2:32503542	YIPF4	0.64	5.33	0.48	6.65e-7	Intelligence (multi-trait analysis);
THYM	cis	rs929596	0.564	rs2741038	chr2:234563998	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.67	-4.54	-0.42	1.63e-5	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg18811423	chr2:55921094	PNPT1	0.69	6.42	0.55	5.24e-9	Metabolic syndrome;
THYM	cis	rs8192482	1	rs8192482	chr15:78886198	C/T	cg18825076	chr15:78729989	IREB2	-0.54	-4.81	-0.44	5.71e-6	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs61931739	0.533	rs7970871	chr12:33917301	G/A	cg06521331	chr12:34319734	NA	-0.57	-4.76	-0.44	7e-6	Morning vs. evening chronotype;
THYM	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg11317459	chr13:21872234	NA	-1.23	-9.84	-0.71	3.7e-16	White matter hyperintensity burden;
THYM	cis	rs12122100	0.651	rs12728300	chr1:146542184	T/C	cg03526459	chr1:146549940	NA	-0.66	-4.49	-0.42	1.97e-5	HIV-1 control;
THYM	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs2806561	0.734	rs10799788	chr1:23356864	G/A	cg19743168	chr1:23544995	NA	0.48	4.69	0.43	9.07e-6	Height;
THYM	cis	rs7572733	0.534	rs1435568	chr2:198762879	T/C	cg00792783	chr2:198669748	PLCL1	0.84	5.97	0.52	4.15e-8	Dermatomyositis;
THYM	cis	rs10779751	1.000	rs742824	chr1:11274022	G/A	cg08854313	chr1:11322531	MTOR	1.01	9.78	0.71	4.97e-16	Body mass index;
THYM	cis	rs1670533	0.585	rs6827206	chr4:1065071	A/T	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.75	-4.88	-0.45	4.29e-6	Mean platelet volume;
THYM	cis	rs1389724	0.648	rs12030728	chr1:111316083	G/A	cg25283465	chr1:111323341	NA	0.58	4.58	0.43	1.4e-5	Schizophrenia;
THYM	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg26513180	chr16:89883248	FANCA	-0.55	-5.28	-0.48	8.21e-7	Vitiligo;
THYM	cis	rs1747683	0.966	rs2275128	chr10:13378445	A/G	cg00142036	chr10:13388442	SEPHS1	-0.29	-5.17	-0.47	1.32e-6	IgG glycosylation;
THYM	cis	rs2811415	0.597	rs10934840	chr3:127746083	G/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs11651000	0.947	rs11657376	chr17:45835984	A/T	cg24803719	chr17:45855879	NA	-0.63	-5.23	-0.47	1.01e-6	IgG glycosylation;
THYM	cis	rs10504073	0.669	rs341802	chr8:50039313	C/T	cg00325661	chr8:49890786	NA	0.79	7.02	0.58	3.26e-10	Blood metabolite ratios;
THYM	cis	rs3733631	0.557	rs17034068	chr4:104681287	A/G	cg24090629	chr4:104641072	TACR3	-0.95	-5.28	-0.48	8.08e-7	Menarche (age at onset);
THYM	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.7	-5.63	-0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg03433033	chr1:76189801	ACADM	0.78	10.85	0.74	2.55e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10752881	1.000	rs8179283	chr1:182974602	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.66	-0.43	1.03e-5	Prostate cancer;
THYM	cis	rs4273100	0.688	rs12939947	chr17:19204531	A/T	cg25447019	chr17:19030144	GRAPL	-0.79	-6.24	-0.54	1.2e-8	Schizophrenia;
THYM	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg13609457	chr4:120235615	NA	0.51	4.76	0.44	6.87e-6	Corneal astigmatism;
THYM	cis	rs13315871	0.929	rs11715290	chr3:58298413	C/T	cg00563845	chr3:58318305	PXK	0.59	5.03	0.46	2.29e-6	Cholesterol, total;
THYM	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.14	0.47	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs740474	0.707	rs251019	chr5:140899784	G/C	cg24137543	chr5:140893634	NA	0.6	7.55	0.61	2.59e-11	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs1003719	0.788	rs59637309	chr21:38475398	G/A	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg26384229	chr12:38710491	ALG10B	0.7	5.46	0.49	3.75e-7	Morning vs. evening chronotype;
THYM	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.23e-16	Bone mineral density;
THYM	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22968622	chr17:43663579	NA	-0.82	-6.99	-0.58	3.76e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg11461670	chr8:22454935	PDLIM2	-0.35	-6.16	-0.53	1.73e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs4481887	0.861	rs4497248	chr1:248450525	T/C	cg00666640	chr1:248458726	OR2T12	0.54	4.56	0.42	1.54e-5	Common traits (Other);
THYM	cis	rs3741151	0.686	rs1002127	chr11:73103835	G/C	cg12959048	chr11:73096162	RELT	-0.48	-4.94	-0.45	3.29e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg23803603	chr1:2058230	PRKCZ	-0.57	-5.12	-0.47	1.58e-6	Height;
THYM	cis	rs9467773	0.587	rs12214031	chr6:26376628	T/C	cg14345882	chr6:26364793	BTN3A2	0.34	4.53	0.42	1.72e-5	Intelligence (multi-trait analysis);
THYM	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs9527	0.567	rs6584539	chr10:104879402	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg18032289	chr17:61959525	GH2	-0.51	-4.94	-0.45	3.29e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs36051895	0.664	rs11788834	chr9:5092466	G/A	cg02405213	chr9:5042618	JAK2	-1.0	-10.94	-0.75	1.67e-18	Pediatric autoimmune diseases;
THYM	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg16586182	chr3:47516702	SCAP	-0.62	-5.32	-0.48	6.98e-7	Colorectal cancer;
THYM	cis	rs7772486	0.558	rs62435775	chr6:146136415	G/C	cg23711669	chr6:146136114	FBXO30	0.84	7.74	0.62	1.07e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6956675	0.915	rs10232119	chr7:62638227	C/T	cg08930214	chr7:62859557	LOC100287834	0.67	4.98	0.45	2.85e-6	Obesity-related traits;
THYM	cis	rs55788414	0.932	rs35326835	chr16:81190413	T/C	cg06400318	chr16:81190750	PKD1L2	-1.05	-5.74	-0.51	1.14e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs7586879	0.616	rs6722587	chr2:25132192	C/A	cg15423357	chr2:25149977	NA	0.7	7.76	0.62	9.56e-12	Body mass index;
THYM	cis	rs6906287	0.552	rs7740645	chr6:118929208	T/A	cg21191810	chr6:118973309	C6orf204	0.58	5.8	0.51	8.72e-8	Electrocardiographic conduction measures;
THYM	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-4.47	-0.42	2.17e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs919433	0.662	rs2043018	chr2:198236958	G/A	cg00792783	chr2:198669748	PLCL1	0.78	5.6	0.5	2.12e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9399401	0.633	rs262118	chr6:142843054	C/A	cg03128060	chr6:142623767	GPR126	0.57	6.74	0.57	1.21e-9	Chronic obstructive pulmonary disease;
THYM	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg08498830	chr11:832797	CD151	-0.62	-4.53	-0.42	1.73e-5	Mean platelet volume;
THYM	cis	rs3026101	0.578	rs11209	chr17:5289580	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.54	-4.64	-0.43	1.12e-5	Body mass index;
THYM	cis	rs73198271	0.722	rs488566	chr8:8639575	A/G	cg15556689	chr8:8085844	FLJ10661	-0.71	-4.54	-0.42	1.64e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg24812749	chr6:127587940	RNF146	0.96	7.77	0.62	9.12e-12	Breast cancer;
THYM	cis	rs59698941	0.943	rs4705980	chr5:132286084	T/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg18904891	chr8:8559673	CLDN23	-0.62	-5.35	-0.48	6.13e-7	Neuroticism;
THYM	cis	rs6980334	0.817	rs1038626	chr7:137797477	A/T	cg22979093	chr7:137028410	PTN	0.65	5.2	0.47	1.16e-6	Blood metabolite ratios;
THYM	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg12165864	chr7:66369176	NA	0.68	5.21	0.47	1.09e-6	Cotinine glucuronidation;
THYM	cis	rs7173743	0.525	rs7166501	chr15:79133739	C/T	cg15571903	chr15:79123663	NA	0.48	4.86	0.45	4.54e-6	Coronary artery disease;
THYM	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.46	0.61	4.08e-11	Obesity-related traits;
THYM	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg02734326	chr4:10020555	SLC2A9	0.78	6.67	0.56	1.68e-9	Bone mineral density;
THYM	cis	rs12257961	0.640	rs10796276	chr10:15351938	G/T	cg10616319	chr10:15468812	NA	0.63	4.9	0.45	3.98e-6	Selective IgA deficiency;
THYM	cis	rs4606347	0.789	rs61780875	chr1:66164928	C/A	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9430161	0.579	rs6696575	chr1:11037136	G/A	cg02454025	chr1:11042201	C1orf127	0.85	9.91	0.71	2.54e-16	Ewing sarcoma;
THYM	cis	rs365132	0.967	rs11740768	chr5:176339499	G/A	cg17809377	chr5:176326619	HK3	-0.3	-4.55	-0.42	1.59e-5	Menarche and menopause (age at onset);Menopause (age at onset);
THYM	cis	rs1215050	0.740	rs783938	chr4:99010336	A/T	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs501916	0.634	rs531596	chr15:48058214	C/T	cg20869673	chr15:48010124	SEMA6D	0.64	4.63	0.43	1.14e-5	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg10911889	chr6:126070802	HEY2	-0.59	-4.73	-0.44	7.89e-6	Brugada syndrome;
THYM	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.09e-8	Systolic blood pressure;
THYM	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg04944784	chr2:26401820	FAM59B	0.76	5.28	0.48	8.27e-7	Gut microbiome composition (summer);
THYM	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.15	8.41	0.65	4.11e-13	Cognitive test performance;
THYM	cis	rs941408	1.000	rs2741990	chr19:2796644	C/T	cg06609049	chr19:2785107	THOP1	0.7	5.7	0.5	1.37e-7	Total cholesterol levels;
THYM	cis	rs1322639	0.614	rs6940913	chr6:169563666	G/A	cg04662567	chr6:169592167	NA	-0.79	-6.17	-0.53	1.69e-8	Pulse pressure;
THYM	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg09877947	chr5:131593287	PDLIM4	0.66	5.37	0.48	5.67e-7	Blood metabolite levels;
THYM	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg05962950	chr11:130786565	SNX19	0.92	8.76	0.67	7.45e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	trans	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg21582582	chr3:182698605	DCUN1D1	0.8	6.9	0.58	5.88e-10	Intelligence (multi-trait analysis);
THYM	cis	rs1981331	0.609	rs73907584	chr21:48079678	A/G	cg23283320	chr21:48055893	PRMT2	1.4	7.76	0.62	9.83e-12	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs9677476	0.818	rs16827879	chr2:232092301	C/T	cg23338755	chr2:231921595	PSMD1	0.66	4.9	0.45	3.98e-6	Food antigen IgG levels;
THYM	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.93	-6.09	-0.53	2.41e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.55	-8.69	-0.67	1.05e-13	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	5.53	0.49	2.78e-7	Height;
THYM	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.56	4.88	0.45	4.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg09904177	chr6:26538194	HMGN4	-0.6	-4.96	-0.45	3.13e-6	Intelligence (multi-trait analysis);
THYM	cis	rs354225	0.544	rs10169975	chr2:54808159	C/T	cg23486701	chr2:54789491	SPTBN1	0.36	4.96	0.45	3.11e-6	Schizophrenia;
THYM	cis	rs4722166	0.695	rs7793125	chr7:22809160	A/G	cg05472934	chr7:22766657	IL6	0.69	6.1	0.53	2.25e-8	Lung cancer;
THYM	cis	rs6546324	0.625	rs1023693	chr2:67868732	T/C	cg18237512	chr2:67827392	NA	-0.77	-4.57	-0.42	1.47e-5	Endometriosis;
THYM	cis	rs36051895	0.589	rs7848312	chr9:5237442	T/C	cg02405213	chr9:5042618	JAK2	-0.93	-9.39	-0.69	3.26e-15	Pediatric autoimmune diseases;
THYM	cis	rs4242434	0.927	rs2272718	chr8:22457388	G/A	cg21658235	chr8:22456391	C8orf58	0.59	5.4	0.48	5e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg19506201	chr17:79936561	ASPSCR1	-0.52	-4.77	-0.44	6.7e-6	Glycated hemoglobin levels;
THYM	cis	rs10752881	0.967	rs4652758	chr1:182975100	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs11671005	0.610	rs3816329	chr19:59058693	G/A	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.62	-5.07	-0.46	1.95e-6	Mean platelet volume;
THYM	cis	rs6450176	0.638	rs3822497	chr5:53299693	C/G	ch.5.1024479R	chr5:53302184	ARL15	-1.23	-10.23	-0.72	5.24e-17	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs7312774	0.618	rs7979117	chr12:107345883	C/T	cg16260113	chr12:107380972	MTERFD3	1.3	6.73	0.57	1.28e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs7614311	0.689	rs73120898	chr3:63828780	G/A	cg22134162	chr3:63841271	THOC7	-0.63	-7.68	-0.62	1.42e-11	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg14196790	chr5:131705035	SLC22A5	-0.47	-4.74	-0.44	7.45e-6	Breast cancer;
THYM	cis	rs4523957	0.788	rs7217687	chr17:2098272	G/C	cg16513277	chr17:2031491	SMG6	-0.83	-8.1	-0.64	1.83e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg04267008	chr7:1944627	MAD1L1	-0.65	-5.87	-0.52	6.49e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg09021430	chr5:549028	NA	-0.72	-5.35	-0.48	6.11e-7	Lung disease severity in cystic fibrosis;
THYM	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg15741354	chr8:8146129	NA	-0.31	-5.24	-0.47	9.49e-7	Joint mobility (Beighton score);
THYM	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg01119278	chr6:110721349	DDO	-0.63	-7.5	-0.61	3.28e-11	Platelet distribution width;
THYM	cis	rs7688540	0.771	rs1986557	chr4:283118	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.65	4.93	0.45	3.47e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs67981189	0.896	rs8012728	chr14:71447948	T/C	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg19761014	chr17:28927070	LRRC37B2	0.8	4.73	0.44	7.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3126085	0.867	rs11204948	chr1:152218473	A/G	cg10321714	chr1:152280068	FLG	0.7	5.07	0.46	1.95e-6	Atopic dermatitis;
THYM	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.18	8.62	0.66	1.44e-13	Cognitive test performance;
THYM	trans	rs75518195	0.543	rs62301951	chr4:64678474	C/T	cg14706739	chr8:21916355	EPB49	0.75	7.37	0.6	6.34e-11	Triptolide cytotoxicity;
THYM	cis	rs174601	0.582	rs108499	chr11:61547237	C/T	cg19610905	chr11:61596333	FADS2	-0.6	-4.86	-0.45	4.57e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
THYM	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg18876405	chr7:65276391	NA	0.61	5.42	0.49	4.6e-7	Aortic root size;
THYM	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg06634786	chr22:41940651	POLR3H	0.62	4.81	0.44	5.64e-6	Vitiligo;
THYM	cis	rs7107174	1.000	rs7119933	chr11:78049750	A/C	cg19901956	chr11:77921274	USP35	-0.63	-5.2	-0.47	1.17e-6	Testicular germ cell tumor;
THYM	cis	rs34638657	0.833	rs4889479	chr16:82201474	T/C	cg09894383	chr16:82067445	HSD17B2	-0.47	-5.24	-0.47	9.72e-7	Lung adenocarcinoma;
THYM	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg10802521	chr3:52805072	NEK4	-0.76	-7.08	-0.59	2.49e-10	Bipolar disorder;
THYM	cis	rs1669338	0.510	rs3804788	chr3:3169466	C/A	cg16797762	chr3:3221439	CRBN	-0.92	-5.06	-0.46	2.04e-6	White matter integrity;
THYM	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg26384229	chr12:38710491	ALG10B	0.95	7.4	0.6	5.52e-11	Bladder cancer;
THYM	cis	rs600806	0.813	rs4970760	chr1:109985439	A/G	cg02175308	chr1:109941060	SORT1	-0.56	-4.88	-0.45	4.33e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9399401	0.667	rs1329707	chr6:142724439	T/C	cg04461802	chr6:142623433	GPR126	0.74	7.37	0.6	6.15e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	4.78	0.44	6.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg13443165	chr9:33130375	B4GALT1	-0.87	-7.97	-0.63	3.46e-12	IgG glycosylation;
THYM	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg20503657	chr10:835505	NA	0.84	5.16	0.47	1.35e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs3741151	0.686	rs11544310	chr11:73107592	A/G	cg12959048	chr11:73096162	RELT	-0.46	-4.84	-0.45	4.94e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7100689	0.646	rs2039757	chr10:82078868	C/A	cg01528321	chr10:82214614	TSPAN14	0.84	6.43	0.55	5.15e-9	Post bronchodilator FEV1;
THYM	cis	rs2991971	1.000	rs2991971	chr1:46012748	C/G	cg15605315	chr1:45957053	TESK2	0.65	5.12	0.46	1.6e-6	High light scatter reticulocyte count;
THYM	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg27129171	chr3:47204927	SETD2	0.71	6.66	0.56	1.81e-9	Colorectal cancer;
THYM	cis	rs11645898	0.935	rs28419077	chr16:72196776	A/G	cg14768367	chr16:72042858	DHODH	-0.69	-5.08	-0.46	1.87e-6	Blood protein levels;
THYM	cis	rs2625529	0.617	rs6494973	chr15:72145728	A/T	cg16672083	chr15:72433130	SENP8	0.51	4.5	0.42	1.91e-5	Red blood cell count;
THYM	cis	rs28595532	0.844	rs115202072	chr4:119732458	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg12011299	chr4:100065546	ADH4	0.94	9.97	0.72	1.91e-16	Alcohol dependence;
THYM	cis	rs7843479	0.601	rs4872209	chr8:21848832	A/T	cg17168535	chr8:21777572	XPO7	0.86	7.65	0.62	1.6e-11	Mean corpuscular volume;
THYM	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg07884673	chr3:53033167	SFMBT1	1.17	5.9	0.52	5.49e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg06718696	chr17:78121285	EIF4A3	1.02	7.38	0.6	5.95e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
THYM	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg20887711	chr4:1340912	KIAA1530	-0.62	-4.9	-0.45	3.91e-6	Obesity-related traits;
THYM	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg27129171	chr3:47204927	SETD2	0.71	6.76	0.57	1.1e-9	Colorectal cancer;
THYM	cis	rs4242434	0.672	rs3758041	chr8:22486987	A/G	cg03733263	chr8:22462867	KIAA1967	1.0	11.13	0.75	6.58e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg04034577	chr2:241836375	C2orf54	0.42	6.58	0.56	2.6e-9	Urinary metabolites;
THYM	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg22920501	chr2:26401640	FAM59B	1.07	9.54	0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs1499972	0.941	rs55979908	chr3:117598306	A/C	cg07612923	chr3:117604196	NA	1.3	5.57	0.5	2.35e-7	Schizophrenia;
THYM	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg00129232	chr17:37814104	STARD3	-0.77	-5.27	-0.48	8.58e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs1003719	0.737	rs9974374	chr21:38479885	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.67	4.61	0.43	1.25e-5	Eye color traits;
THYM	cis	rs71403859	0.803	rs17282500	chr16:71633653	C/A	cg08717414	chr16:71523259	ZNF19	-1.11	-5.85	-0.51	6.82e-8	Post bronchodilator FEV1;
THYM	cis	rs7208859	0.673	rs9889755	chr17:29234505	A/G	cg19761014	chr17:28927070	LRRC37B2	-0.74	-4.86	-0.45	4.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1499972	0.941	rs62264779	chr3:117654731	G/T	cg07612923	chr3:117604196	NA	1.31	5.1	0.46	1.73e-6	Schizophrenia;
THYM	cis	rs2625529	0.590	rs713048	chr15:72543084	G/A	cg16672083	chr15:72433130	SENP8	-0.57	-5.24	-0.47	9.69e-7	Red blood cell count;
THYM	cis	rs116095464	1.000	rs10475185	chr5:306981	C/T	cg22857025	chr5:266934	NA	-1.59	-5.22	-0.47	1.06e-6	Breast cancer;
THYM	cis	rs2108622	0.958	rs79400241	chr19:15984402	C/G	cg13772218	chr19:15982569	NA	0.61	5.48	0.49	3.52e-7	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg11845111	chr2:191398756	TMEM194B	-0.98	-6.9	-0.58	5.68e-10	Diastolic blood pressure;
THYM	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg11764359	chr7:65958608	NA	-0.83	-6.96	-0.58	4.35e-10	Aortic root size;
THYM	cis	rs9563576	0.778	rs9569788	chr13:58550688	A/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs7089973	0.872	rs35622181	chr10:116631976	C/T	cg23260525	chr10:116636907	FAM160B1	0.52	4.66	0.43	1.02e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg00686598	chr14:53173677	PSMC6	1.52	7.73	0.62	1.09e-11	Alzheimer's disease (late onset);
THYM	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.4	6.56	0.56	2.8e-9	Obesity-related traits;
THYM	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg23602478	chr1:26503979	CNKSR1	-0.36	-4.97	-0.45	2.96e-6	Height;
THYM	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg06108461	chr20:60628389	TAF4	-1.04	-8.31	-0.65	6.66e-13	Body mass index;
THYM	cis	rs9810089	1.000	rs9810089	chr3:135807609	G/T	cg21827317	chr3:136751795	NA	-0.56	-4.8	-0.44	5.89e-6	Gestational age at birth (child effect);
THYM	cis	rs665401	0.965	rs339340	chr6:117215114	T/C	cg20376953	chr6:117187980	NA	0.6	4.82	0.44	5.5e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg16418258	chr15:42840397	LRRC57;HAUS2	-0.56	-4.5	-0.42	1.95e-5	Lung cancer;
THYM	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg17264618	chr3:40429014	ENTPD3	0.51	5.06	0.46	2.03e-6	Renal cell carcinoma;
THYM	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg06481639	chr22:41940642	POLR3H	0.84	5.85	0.51	6.94e-8	Vitiligo;
THYM	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.7	0.71	7.32e-16	Colorectal cancer;
THYM	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg24874828	chr4:187887005	NA	-0.71	-7.13	-0.59	1.93e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7914606	0.516	rs1984156	chr10:85218018	G/A	cg01558777	chr10:85933798	C10orf99	-1.09	-4.7	-0.43	8.68e-6	Trans fatty acid levels;
THYM	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg02734326	chr4:10020555	SLC2A9	-0.59	-4.56	-0.42	1.55e-5	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2294693	0.945	rs9349175	chr6:40982401	T/C	cg14418226	chr6:40996092	UNC5CL	0.67	5.41	0.49	4.6e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs17016200	0.513	rs73846442	chr3:78360853	T/C	cg24512093	chr3:78698151	ROBO1	0.92	5.18	0.47	1.25e-6	Facial emotion recognition;
THYM	cis	rs3125734	0.633	rs1873685	chr10:64032126	C/T	cg09941381	chr10:64027924	RTKN2	-0.58	-4.77	-0.44	6.73e-6	Rheumatoid arthritis;
THYM	cis	rs367615	0.679	rs11241021	chr5:108812090	T/G	cg17395555	chr5:108820864	NA	0.74	9.32	0.69	4.68e-15	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs6084875	0.840	rs1999664	chr20:4721148	C/T	cg19614321	chr20:4804581	RASSF2	0.45	4.56	0.42	1.52e-5	Systemic lupus erythematosus;
THYM	cis	rs6032067	0.777	rs979641	chr20:43786336	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg04546413	chr19:29218101	NA	1.07	8.46	0.66	3.27e-13	Methadone dose in opioid dependence;
THYM	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg02475777	chr4:1388615	CRIPAK	0.73	5.23	0.47	1e-6	Longevity;
THYM	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg14159672	chr1:205819179	PM20D1	-0.72	-5.65	-0.5	1.66e-7	Menarche (age at onset);
THYM	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg00256281	chr22:41985642	PMM1	0.66	5.11	0.46	1.64e-6	Vitiligo;
THYM	cis	rs6719884	0.965	rs6545700	chr2:59026387	A/G	cg09452692	chr2:58468460	FANCL	-0.58	-4.46	-0.42	2.22e-5	Myasthenia gravis;
THYM	cis	rs728616	0.867	rs75447386	chr10:81739647	G/A	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg12568756	chr2:218717561	TNS1	0.52	4.54	0.42	1.68e-5	Thyroid cancer;
THYM	cis	rs6952809	0.590	rs1468337	chr7:2432211	C/T	cg13581527	chr7:1708566	NA	-0.77	-5.44	-0.49	4.11e-7	Multiple sclerosis;
THYM	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Bladder cancer;
THYM	cis	rs2067615	0.579	rs6539283	chr12:107222989	C/T	cg15890332	chr12:107067104	RFX4	0.48	5.63	0.5	1.81e-7	Heart rate;
THYM	cis	rs7246657	1.000	rs8110011	chr19:37745813	G/T	cg22634378	chr19:37742834	NA	0.64	5.31	0.48	7.33e-7	Coronary artery calcification;
THYM	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	6.15	0.53	1.86e-8	Schizophrenia;
THYM	cis	rs42648	0.738	rs10248104	chr7:89895262	C/T	cg25739043	chr7:89950458	NA	-0.54	-4.47	-0.42	2.16e-5	Homocysteine levels;
THYM	cis	rs72901758	0.700	rs56245572	chr17:76248064	G/C	cg25512537	chr17:76250053	NA	0.41	5.87	0.52	6.45e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
THYM	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg19875535	chr5:140030758	IK	-0.61	-5.34	-0.48	6.3e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg20999797	chr1:1681921	NA	0.49	5.41	0.49	4.78e-7	Body mass index;
THYM	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg20486651	chr6:167070296	RPS6KA2	0.5	4.79	0.44	6.18e-6	Crohn's disease;
THYM	trans	rs2136093	0.600	rs12137490	chr1:90910544	C/T	cg19688584	chr6:167529678	CCR6	0.5	7.06	0.59	2.66e-10	Response to antidepressants;
THYM	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg14186256	chr22:23484241	RTDR1	0.97	9.46	0.7	2.38e-15	Bone mineral density;
THYM	cis	rs7172809	0.599	rs116981387	chr15:77753231	G/A	cg10437265	chr15:77819839	NA	-0.5	-4.57	-0.42	1.47e-5	Glucose homeostasis traits;
THYM	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs1451375	0.572	rs4948205	chr7:50557774	G/A	cg18232548	chr7:50535776	DDC	-0.68	-5.19	-0.47	1.21e-6	Malaria;
THYM	cis	rs7944735	0.545	rs4752805	chr11:48018355	A/G	cg25800328	chr11:47736132	AGBL2	0.41	4.54	0.42	1.66e-5	Intraocular pressure;
THYM	cis	rs6701037	0.681	rs1894709	chr1:175132371	G/T	cg00958927	chr1:175162553	KIAA0040	-0.33	-4.48	-0.42	2.06e-5	Alcohol dependence;
THYM	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg17105886	chr17:28927953	LRRC37B2	1.31	6.9	0.58	5.83e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2463822	0.844	rs2513737	chr11:62119495	G/C	cg06239285	chr11:62104954	ASRGL1	1.44	7.7	0.62	1.3e-11	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg14675211	chr2:100938903	LONRF2	0.77	8.32	0.65	6.49e-13	Intelligence (multi-trait analysis);
THYM	cis	rs11118844	0.696	rs11118860	chr1:221953558	A/G	cg04222084	chr1:221915650	DUSP10	0.96	4.76	0.44	6.94e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs7940866	0.903	rs11222421	chr11:130872351	A/T	cg23692386	chr11:131799662	NTM	0.47	5.0	0.46	2.63e-6	Schizophrenia;
THYM	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg04654363	chr8:8581213	NA	-0.46	-4.54	-0.42	1.63e-5	Obesity-related traits;
THYM	cis	rs6543140	0.964	rs10200081	chr2:103091556	T/C	cg03938978	chr2:103052716	IL18RAP	0.62	6.09	0.53	2.33e-8	Blood protein levels;
THYM	cis	rs13082711	0.640	rs35903173	chr3:27287751	T/C	cg02860705	chr3:27208620	NA	1.13	8.6	0.66	1.63e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg09307838	chr4:120376055	NA	0.7	4.78	0.44	6.5e-6	Corneal astigmatism;
THYM	cis	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg00495681	chr13:53174319	NA	0.63	5.75	0.51	1.07e-7	Lewy body disease;
THYM	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg00750074	chr16:89608354	SPG7	-0.48	-4.48	-0.42	2.08e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg27129171	chr3:47204927	SETD2	-0.81	-7.78	-0.62	8.79e-12	Colorectal cancer;
THYM	cis	rs11096990	0.634	rs4975002	chr4:39288353	T/G	cg24403649	chr4:39172243	NA	-0.65	-5.47	-0.49	3.68e-7	Cognitive function;
THYM	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg18357526	chr6:26021779	HIST1H4A	0.77	6.38	0.55	6.56e-9	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.698	rs6466954	chr7:124515346	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg17366294	chr4:99064904	C4orf37	0.55	6.58	0.56	2.51e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg16680214	chr1:154839983	KCNN3	-0.45	-5.03	-0.46	2.32e-6	Prostate cancer;
THYM	cis	rs611744	0.934	rs1668178	chr8:109191700	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg19825600	chr2:3704501	ALLC	-0.69	-5.8	-0.51	8.78e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs1957429	0.901	rs3813423	chr14:65347475	C/A	cg23373153	chr14:65346875	NA	1.07	6.45	0.55	4.75e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg12893697	chr11:970389	AP2A2	-0.31	-5.21	-0.47	1.08e-6	Alzheimer's disease (late onset);
THYM	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg24006582	chr15:45444508	DUOX1	0.77	5.95	0.52	4.47e-8	Uric acid levels;
THYM	cis	rs977987	0.586	rs12920883	chr16:75432681	T/C	cg03315344	chr16:75512273	CHST6	0.73	6.14	0.53	1.88e-8	Dupuytren's disease;
THYM	cis	rs4631830	0.720	rs11599333	chr10:51499655	A/C	cg10326726	chr10:51549505	MSMB	0.53	5.15	0.47	1.38e-6	Prostate-specific antigen levels;
THYM	cis	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.73	0.44	7.82e-6	Obesity-related traits;
THYM	cis	rs2834081	0.536	rs11702285	chr21:34474294	G/A	cg00274965	chr21:34405681	NA	0.56	6.06	0.53	2.73e-8	Sum eosinophil basophil counts;
THYM	cis	rs1448094	0.512	rs6539925	chr12:86244358	A/G	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs988913	0.837	rs9475109	chr6:54861913	T/C	cg19716238	chr6:54711378	FAM83B	0.47	4.53	0.42	1.71e-5	Menarche (age at onset);
THYM	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg02475777	chr4:1388615	CRIPAK	0.64	5.04	0.46	2.19e-6	Longevity;
THYM	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg00419117	chr1:228361641	C1orf69	0.48	4.49	0.42	2.01e-5	Diastolic blood pressure;
THYM	cis	rs4732038	0.510	rs61022470	chr7:134275558	C/G	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg13615516	chr5:77269221	NA	0.88	8.57	0.66	1.87e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs10463554	0.927	rs158253	chr5:102405206	G/A	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs7100689	0.580	rs7083519	chr10:82207524	C/G	cg00277334	chr10:82204260	NA	-0.66	-6.63	-0.56	2.06e-9	Post bronchodilator FEV1;
THYM	cis	rs9790314	0.601	rs1450519	chr3:161094930	A/G	cg04691961	chr3:161091175	C3orf57	-0.55	-4.59	-0.43	1.35e-5	Morning vs. evening chronotype;
THYM	cis	rs59698941	0.882	rs6871970	chr5:132189594	G/A	cg02081065	chr5:132209139	LEAP2	-0.79	-5.26	-0.47	8.96e-7	Apolipoprotein A-IV levels;
THYM	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg16928487	chr17:17741425	SREBF1	0.52	5.06	0.46	2.02e-6	Total body bone mineral density;
THYM	cis	rs6980334	0.817	rs11982192	chr7:137795842	G/T	cg11874123	chr7:137028198	PTN	0.67	5.17	0.47	1.29e-6	Blood metabolite ratios;
THYM	cis	rs4343996	0.521	rs12667184	chr7:3413793	A/G	cg21248987	chr7:3385318	SDK1	0.4	4.91	0.45	3.72e-6	Motion sickness;
THYM	cis	rs711830	0.965	rs2857532	chr2:177033283	A/G	cg26754761	chr2:177040938	NA	-0.55	-4.56	-0.42	1.52e-5	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs8062405	0.723	rs35175818	chr16:28608746	A/C	cg04193835	chr16:28379378	NA	-0.5	-4.76	-0.44	7e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs988913	0.957	rs960835	chr6:54823422	A/G	cg18532076	chr6:54711417	FAM83B	0.52	4.95	0.45	3.25e-6	Menarche (age at onset);
THYM	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs988913	1.000	rs9382402	chr6:54809493	C/T	cg04690482	chr6:54711388	FAM83B	0.48	5.36	0.48	5.77e-7	Menarche (age at onset);
THYM	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg16558253	chr16:72132732	DHX38	-0.57	-4.87	-0.45	4.42e-6	Fibrinogen levels;
THYM	cis	rs7586879	0.828	rs1077641	chr2:25123665	G/A	cg01884057	chr2:25150051	NA	0.52	4.59	0.43	1.35e-5	Body mass index;
THYM	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg08885076	chr2:99613938	TSGA10	0.53	5.14	0.47	1.46e-6	Chronic sinus infection;
THYM	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg18755752	chr8:142205143	DENND3	-0.8	-8.07	-0.64	2.18e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg19077165	chr18:44547161	KATNAL2	0.58	7.25	0.6	1.11e-10	Personality dimensions;
THYM	cis	rs12579753	0.917	rs10862360	chr12:82187411	A/G	cg21231944	chr12:82153410	PPFIA2	-0.68	-5.12	-0.46	1.6e-6	Resting heart rate;
THYM	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs662064	0.925	rs597438	chr1:10554505	A/G	cg20482658	chr1:10539492	PEX14	-0.49	-6.13	-0.53	2e-8	Asthma;
THYM	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg17845761	chr1:175162550	KIAA0040	0.38	4.81	0.44	5.73e-6	Diastolic blood pressure;
THYM	cis	rs7107174	0.901	rs2511159	chr11:77974193	G/T	cg19901956	chr11:77921274	USP35	0.68	5.34	0.48	6.23e-7	Testicular germ cell tumor;
THYM	cis	rs750460	0.932	rs1550436	chr15:74221157	C/T	cg01349856	chr15:74220517	LOXL1	-0.61	-4.51	-0.42	1.83e-5	Height;
THYM	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg16989719	chr2:238392110	NA	-0.58	-5.47	-0.49	3.7e-7	Prostate cancer;
THYM	cis	rs28595532	0.920	rs116514715	chr4:119756280	G/T	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg00012203	chr2:219082015	ARPC2	-0.69	-5.87	-0.52	6.36e-8	Colorectal cancer;
THYM	cis	rs10463554	0.853	rs246907	chr5:102566278	A/T	cg23492399	chr5:102201601	PAM	-0.68	-5.16	-0.47	1.36e-6	Parkinson's disease;
THYM	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg26597838	chr10:835615	NA	1.52	11.37	0.76	2.05e-19	Eosinophil percentage of granulocytes;
THYM	cis	rs7119	0.651	rs8041520	chr15:77839169	C/T	cg27398640	chr15:77910606	LINGO1	-0.62	-6.46	-0.55	4.52e-9	Type 2 diabetes;
THYM	cis	rs478304	0.934	rs474483	chr11:65520060	T/G	cg17480646	chr11:65405466	SIPA1	0.7	6.27	0.54	1.07e-8	Acne (severe);
THYM	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6918586	1.000	rs6918586	chr6:26097384	T/C	cg15691649	chr6:25882328	NA	-0.61	-4.65	-0.43	1.07e-5	Schizophrenia;
THYM	cis	rs7851660	0.839	rs10113884	chr9:100624622	C/T	cg13688889	chr9:100608707	NA	-0.77	-5.31	-0.48	7.25e-7	Strep throat;
THYM	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06850241	chr22:41845214	NA	-0.58	-5.19	-0.47	1.18e-6	Vitiligo;
THYM	cis	rs56104184	0.775	rs3760785	chr19:49403178	G/T	cg21252483	chr19:49399788	TULP2	-0.84	-6.49	-0.55	3.88e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs765787	0.530	rs12442533	chr15:45529631	G/C	cg25801113	chr15:45476975	SHF	-0.39	-4.57	-0.42	1.48e-5	Uric acid levels;
THYM	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg02187348	chr16:89574699	SPG7	0.74	4.89	0.45	4.05e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs9563576	0.778	rs11148424	chr13:58651813	G/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.63	4.68	0.43	9.64e-6	Body mass index;
THYM	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg03676636	chr4:99064102	C4orf37	0.5	7.65	0.62	1.6e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg04476341	chr5:669733	TPPP	0.48	4.83	0.44	5.21e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg06481639	chr22:41940642	POLR3H	0.74	4.85	0.45	4.81e-6	Vitiligo;
THYM	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs4790312	0.765	rs3760230	chr17:1994071	C/G	cg15816464	chr17:2026533	SMG6	0.36	4.87	0.45	4.4e-6	Left atrial antero-posterior diameter;
THYM	cis	rs9311676	0.656	rs6799077	chr3:58404096	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.88	0.63	5.43e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7104764	0.507	rs7121085	chr11:258523	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	0.91	5.87	0.52	6.26e-8	Menarche (age at onset);
THYM	cis	rs6988636	1.000	rs60827294	chr8:124187842	T/C	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg10661904	chr17:79619235	PDE6G	0.54	4.79	0.44	6.25e-6	Eye color traits;
THYM	cis	rs6768930	0.509	rs7649133	chr3:57771722	A/G	cg07735586	chr3:57945651	NA	-0.32	-4.93	-0.45	3.51e-6	Obesity-related traits;
THYM	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs58804349	0.685	rs9422448	chr10:43288816	A/G	cg08461752	chr10:43522343	NA	-0.9	-4.62	-0.43	1.18e-5	Pediatric bone mineral content (radius);
THYM	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg17366294	chr4:99064904	C4orf37	0.56	6.69	0.57	1.53e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg06238570	chr21:40685208	BRWD1	-0.69	-5.77	-0.51	9.86e-8	Menarche (age at onset);
THYM	cis	rs9677476	0.863	rs10181630	chr2:232091757	C/T	cg27665808	chr2:232055229	NA	0.54	4.52	0.42	1.76e-5	Food antigen IgG levels;
THYM	cis	rs7100689	0.622	rs1340379	chr10:82121455	G/A	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg24375607	chr4:120327624	NA	0.53	4.47	0.42	2.2e-5	Corneal astigmatism;
THYM	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.2e-16	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg04731861	chr2:219085781	ARPC2	-0.57	-5.36	-0.48	5.72e-7	Colorectal cancer;
THYM	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.08	-0.53	2.48e-8	Total body bone mineral density;
THYM	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg02527881	chr3:46936655	PTH1R	-0.86	-8.53	-0.66	2.23e-13	Birth weight;
THYM	cis	rs929354	1.000	rs929354	chr7:157045557	C/T	cg17757837	chr7:157058334	UBE3C	-0.79	-6.82	-0.57	8.2e-10	Body mass index;
THYM	cis	rs1003719	0.788	rs2835589	chr21:38463342	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs9443189	0.570	rs9341532	chr6:76403674	A/G	cg01950844	chr6:76311363	SENP6	1.05	6.66	0.56	1.73e-9	Prostate cancer;
THYM	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg25208724	chr1:156163844	SLC25A44	1.05	8.4	0.65	4.31e-13	Testicular germ cell tumor;
THYM	cis	rs870825	0.932	rs28594349	chr4:185574415	G/A	cg04058563	chr4:185651563	MLF1IP	0.94	6.42	0.55	5.44e-9	Blood protein levels;
THYM	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg00757033	chr12:89920650	WDR51B	0.77	11.72	0.77	3.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg09085632	chr11:111637200	PPP2R1B	1.16	11.93	0.77	1.35e-20	Primary sclerosing cholangitis;
THYM	cis	rs6456156	0.846	rs10946211	chr6:167515489	G/A	cg09487078	chr6:167525398	CCR6	-0.46	-5.07	-0.46	1.98e-6	Primary biliary cholangitis;
THYM	cis	rs9926296	0.687	rs397891	chr16:89753031	G/C	cg26513180	chr16:89883248	FANCA	-0.52	-4.58	-0.42	1.43e-5	Vitiligo;
THYM	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg15744005	chr10:104629667	AS3MT	-0.76	-7.03	-0.58	3.13e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg24818145	chr4:99064322	C4orf37	0.7	5.51	0.49	3.09e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11723261	0.582	rs6814287	chr4:122323	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.85	5.95	0.52	4.45e-8	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg07599136	chr5:415885	AHRR	1.05	6.03	0.53	3.18e-8	Fat distribution (HIV);
THYM	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg09238746	chr17:78121135	EIF4A3	-1.17	-10.29	-0.73	3.9e-17	Yeast infection;
THYM	cis	rs7107174	1.000	rs2450122	chr11:77930345	T/C	cg02023728	chr11:77925099	USP35	0.71	6.44	0.55	4.97e-9	Testicular germ cell tumor;
THYM	cis	rs3791406	0.963	rs3791408	chr2:240030591	C/T	cg11903188	chr2:239195602	PER2	-0.43	-4.59	-0.43	1.37e-5	Skin aging (microtopography measurement);
THYM	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg23791538	chr6:167370224	RNASET2	0.72	5.66	0.5	1.58e-7	Crohn's disease;
THYM	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg12311346	chr5:56204834	C5orf35	0.97	7.56	0.61	2.49e-11	Initial pursuit acceleration;
THYM	cis	rs2737265	0.723	rs2205380	chr8:116659776	G/A	cg04656070	chr8:116661063	TRPS1	-0.56	-6.48	-0.55	4.03e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;
THYM	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg01017244	chr2:74357527	NA	1.1	9.68	0.7	8.07e-16	Gestational age at birth (maternal effect);
THYM	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg01416388	chr22:39784598	NA	-0.92	-9.0	-0.68	2.32e-14	Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg10334053	chr1:2078117	PRKCZ	-0.47	-4.71	-0.44	8.47e-6	Height;
THYM	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg21970626	chr13:21893289	NA	-0.68	-6.1	-0.53	2.33e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg03929089	chr4:120376271	NA	1.02	8.18	0.64	1.26e-12	Coronary artery disease;
THYM	cis	rs9807989	0.839	rs7603730	chr2:102974371	A/C	cg03938978	chr2:103052716	IL18RAP	0.63	6.55	0.56	2.99e-9	Asthma;
THYM	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg06481639	chr22:41940642	POLR3H	0.8	5.56	0.5	2.48e-7	Vitiligo;
THYM	cis	rs2219968	0.639	rs11776284	chr8:78958808	A/C	cg00738934	chr8:78996279	NA	0.72	5.76	0.51	1.04e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03760483	chr17:6899297	ALOX12	-0.69	-9.44	-0.7	2.64e-15	Tonsillectomy;
THYM	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.84e-8	Systolic blood pressure;
THYM	cis	rs35264875	1.000	rs72919415	chr11:68827082	G/A	cg01993067	chr11:68851601	TPCN2	1.0	4.68	0.43	9.62e-6	Blond vs. brown hair color;
THYM	cis	rs7582180	0.613	rs12988464	chr2:100946285	A/G	cg14675211	chr2:100938903	LONRF2	0.62	5.99	0.52	3.73e-8	Intelligence (multi-trait analysis);
THYM	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.95	8.11	0.64	1.77e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Urate levels;
THYM	cis	rs7586879	1.000	rs11683212	chr2:25120196	T/C	cg15423357	chr2:25149977	NA	0.56	5.49	0.49	3.41e-7	Body mass index;
THYM	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg04267008	chr7:1944627	MAD1L1	-0.72	-6.7	-0.57	1.43e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.77	5.92	0.52	5.07e-8	Height;
THYM	cis	rs2913737	0.502	rs2913904	chr5:175935729	C/T	cg27658698	chr5:175955578	RNF44	0.59	4.63	0.43	1.15e-5	Obesity-related traits;
THYM	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg11871910	chr12:69753446	YEATS4	0.75	6.09	0.53	2.39e-8	Blood protein levels;
THYM	cis	rs11771526	0.901	rs13438711	chr7:32297310	G/A	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg15133208	chr4:90757351	SNCA	-0.59	-4.85	-0.45	4.81e-6	Neuroticism;
THYM	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.59	-4.49	-0.42	1.98e-5	Breast cancer;
THYM	cis	rs4072705	0.614	rs1570581	chr9:127234059	A/G	cg13476313	chr9:127244764	NR5A1	0.33	4.65	0.43	1.09e-5	Menarche (age at onset);
THYM	cis	rs9549260	0.664	rs9532575	chr13:41225361	G/C	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs36051895	0.554	rs10975027	chr9:5248827	G/A	cg02405213	chr9:5042618	JAK2	-0.93	-9.34	-0.69	4.28e-15	Pediatric autoimmune diseases;
THYM	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg00376283	chr12:123451042	ABCB9	0.92	7.65	0.62	1.62e-11	Platelet count;
THYM	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.79e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs11085466	1.000	rs4399664	chr19:21778026	C/T	cg23004160	chr19:21646329	NA	-0.63	-4.61	-0.43	1.24e-5	Colorectal or endometrial cancer;
THYM	cis	rs10193935	0.901	rs17029411	chr2:42479149	G/A	cg27598129	chr2:42591480	NA	-0.73	-4.64	-0.43	1.11e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2455799	0.574	rs2470534	chr3:15701054	C/G	cg16303742	chr3:15540471	COLQ	0.56	5.62	0.5	1.92e-7	Mean platelet volume;
THYM	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg11663144	chr21:46675770	NA	-0.69	-8.05	-0.64	2.41e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs28493229	0.708	rs4803352	chr19:41159193	C/T	cg21869046	chr19:41225005	ITPKC	-0.5	-4.59	-0.43	1.36e-5	Kawasaki disease;
THYM	cis	rs7567851	0.590	rs4499456	chr2:178971266	C/G	cg17320194	chr2:178042734	NA	-0.87	-4.48	-0.42	2.06e-5	Height;
THYM	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg15693483	chr7:1102177	C7orf50	0.41	5.82	0.51	7.95e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.68	-4.87	-0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg06656553	chr16:89960601	TCF25	-0.92	-4.45	-0.42	2.34e-5	Skin colour saturation;
THYM	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg24069376	chr3:38537580	EXOG	-0.65	-6.4	-0.55	5.87e-9	Electrocardiographic conduction measures;
THYM	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.62	5.16	0.47	1.34e-6	Blood metabolite levels;
THYM	cis	rs10089	1.000	rs4836368	chr5:127486330	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs11048434	0.736	rs933462	chr12:9103665	T/G	cg13575925	chr12:9217583	LOC144571	0.53	4.94	0.45	3.31e-6	Sjögren's syndrome;
THYM	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg15921436	chr17:44337874	NA	0.91	6.52	0.56	3.43e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs847577	0.715	rs12665986	chr7:97719676	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.61	-4.67	-0.43	9.79e-6	Breast cancer;
THYM	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg27129171	chr3:47204927	SETD2	-0.69	-6.62	-0.56	2.18e-9	Colorectal cancer;
THYM	cis	rs10929159	0.928	rs10200358	chr2:236935791	A/G	cg20128773	chr2:236923534	AGAP1	0.35	4.55	0.42	1.56e-5	Parkinson's disease;
THYM	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg04518342	chr5:131593106	PDLIM4	0.49	5.12	0.47	1.6e-6	Blood metabolite levels;
THYM	cis	rs10992471	0.528	rs10992347	chr9:95220633	C/A	cg14631576	chr9:95140430	CENPP	-0.84	-7.97	-0.63	3.47e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg24818145	chr4:99064322	C4orf37	-0.75	-6.03	-0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg07570687	chr10:102243282	WNT8B	0.76	6.67	0.56	1.72e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12667521	chr19:29218732	NA	0.89	7.64	0.62	1.69e-11	Methadone dose in opioid dependence;
THYM	cis	rs7084402	0.967	rs1820542	chr10:60315643	T/C	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.85e-6	Life satisfaction;
THYM	cis	rs6084875	0.840	rs6052833	chr20:4731142	C/G	cg19614321	chr20:4804581	RASSF2	0.44	4.48	0.42	2.09e-5	Systemic lupus erythematosus;
THYM	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg27121462	chr16:89883253	FANCA	0.57	4.64	0.43	1.12e-5	Vitiligo;
THYM	cis	rs4242434	0.889	rs7817772	chr8:22539316	A/G	cg03733263	chr8:22462867	KIAA1967	-1.2	-12.99	-0.8	8.79e-23	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs67072384	0.892	rs11235578	chr11:72452970	G/T	cg01380194	chr11:72452482	ARAP1	-0.97	-5.26	-0.47	8.93e-7	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs11096990	0.855	rs2566181	chr4:39159607	C/T	cg24403649	chr4:39172243	NA	-0.6	-5.09	-0.46	1.77e-6	Cognitive function;
THYM	cis	rs2219968	0.962	rs7817567	chr8:78937473	A/T	cg00738934	chr8:78996279	NA	0.79	8.42	0.65	3.88e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs2070433	0.539	rs2070432	chr21:47957332	G/A	cg12379764	chr21:47803548	PCNT	0.65	4.78	0.44	6.28e-6	Lymphocyte counts;
THYM	cis	rs994014	0.691	rs7698086	chr4:82271775	G/A	cg17825130	chr4:82283507	NA	0.51	4.64	0.43	1.11e-5	Height;
THYM	cis	rs4654899	0.897	rs10916856	chr1:21082074	A/C	cg01072550	chr1:21505969	NA	-0.63	-5.51	-0.49	3.12e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs939658	0.805	rs35484723	chr15:79441032	A/G	cg17916960	chr15:79447300	NA	-0.73	-8.47	-0.66	2.98e-13	Refractive error;
THYM	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg11301795	chr4:187892539	NA	-1.12	-16.92	-0.87	2.01e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg24531977	chr5:56204891	C5orf35	-0.75	-6.43	-0.55	5.13e-9	Type 2 diabetes;
THYM	cis	rs7122539	0.646	rs682842	chr11:66568943	A/G	cg24851651	chr11:66362959	CCS	-0.67	-5.83	-0.51	7.6e-8	HIV-1 susceptibility;
THYM	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg20295408	chr7:1910781	MAD1L1	-0.63	-4.73	-0.44	7.7e-6	Schizophrenia;
THYM	cis	rs986417	0.901	rs2351171	chr14:61000322	T/C	cg27398547	chr14:60952738	C14orf39	1.0	4.92	0.45	3.59e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs17193922	0.876	rs55813797	chr16:53551310	A/G	cg04059762	chr16:53544020	NA	-0.56	-4.89	-0.45	4.07e-6	Hip circumference adjusted for BMI;
THYM	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.45	-5.39	-0.48	5.1e-7	Longevity;Endometriosis;
THYM	trans	rs916888	0.779	rs199526	chr17:44847707	C/G	cg22433210	chr17:43662623	NA	-0.93	-7.48	-0.61	3.73e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg20887711	chr4:1340912	KIAA1530	0.97	8.91	0.67	3.52e-14	Longevity;
THYM	cis	rs1538970	0.816	rs10789464	chr1:45959102	C/T	cg05343316	chr1:45956843	TESK2	0.85	5.45	0.49	3.93e-7	Platelet count;
THYM	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg11812906	chr14:75593930	NEK9	-0.82	-7.38	-0.6	5.85e-11	Height;
THYM	cis	rs747334	0.543	rs2016612	chr10:92763068	C/T	cg07620928	chr10:92689909	NA	0.55	4.56	0.42	1.53e-5	Fibroblast growth factor basic levels;
THYM	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs9522267	0.535	rs11069897	chr13:112231319	A/G	cg10483660	chr13:112241077	NA	-0.58	-6.7	-0.57	1.49e-9	Hepatitis;
THYM	cis	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg11879182	chr18:77439856	CTDP1	0.81	7.86	0.63	5.87e-12	Monocyte count;
THYM	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.74	8.1	0.64	1.83e-12	Eosinophil percentage of white cells;
THYM	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg23422044	chr7:1970798	MAD1L1	0.77	5.39	0.48	5.19e-7	Bipolar disorder;
THYM	cis	rs919433	0.783	rs805497	chr2:198222548	A/T	cg00792783	chr2:198669748	PLCL1	0.72	4.93	0.45	3.53e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg21231944	chr12:82153410	PPFIA2	-0.64	-4.76	-0.44	7.01e-6	Resting heart rate;
THYM	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs924712	0.646	rs171224	chr6:54807006	T/G	cg04690482	chr6:54711388	FAM83B	0.45	5.39	0.48	5.07e-7	Breast cancer;
THYM	cis	rs7590720	1.000	rs6435930	chr2:216885852	A/G	cg25588852	chr2:216877276	MREG	-0.56	-4.74	-0.44	7.47e-6	Alcohol dependence;
THYM	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs860818	1.000	rs858253	chr7:23217720	C/T	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs611744	0.805	rs378515	chr8:109104905	T/G	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.05e-6	Dupuytren's disease;
THYM	cis	rs13108904	0.521	rs11247998	chr4:1363602	T/C	cg02018176	chr4:1364513	KIAA1530	0.61	4.94	0.45	3.29e-6	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1215050	0.765	rs783947	chr4:99012943	T/C	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10895275	0.961	rs17097547	chr11:102094889	C/T	cg24447756	chr11:102105824	NA	0.53	4.62	0.43	1.22e-5	Migraine;
THYM	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg24733560	chr20:60626293	TAF4	0.63	6.78	0.57	9.91e-10	Body mass index;
THYM	cis	rs2072499	0.966	rs2853646	chr1:156189626	C/T	cg24450063	chr1:156163899	SLC25A44	1.18	13.84	0.82	1.7e-24	Testicular germ cell tumor;
THYM	cis	rs2637266	0.756	rs846607	chr10:78561254	A/T	cg18941641	chr10:78392320	NA	0.72	5.7	0.51	1.32e-7	Pulmonary function;
THYM	cis	rs10979	0.964	rs12526234	chr6:143898680	A/T	cg25407410	chr6:143891975	LOC285740	-0.62	-4.88	-0.45	4.22e-6	Hypospadias;
THYM	cis	rs895636	0.519	rs4953155	chr2:45189496	A/T	cg19772092	chr2:45177632	NA	-0.42	-4.5	-0.42	1.96e-5	Metabolite levels;Fasting plasma glucose;
THYM	cis	rs2439831	0.681	rs1837959	chr15:43698679	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.68	4.7	0.43	8.71e-6	Lung cancer in ever smokers;
THYM	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg24375607	chr4:120327624	NA	-0.64	-5.08	-0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs17739794	0.557	rs35185084	chr8:808721	C/G	cg01971667	chr8:817044	NA	0.61	5.46	0.49	3.83e-7	Clozapine-induced cytotoxicity;
THYM	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg24642844	chr7:1081250	C7orf50	-1.29	-8.31	-0.65	6.62e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6510489	1.000	rs17638216	chr19:35978458	G/A	cg19537317	chr19:36337105	NPHS1	-0.55	-4.47	-0.42	2.13e-5	Bipolar disorder;
THYM	cis	rs3825932	0.961	rs11638844	chr15:79231518	A/G	cg25744700	chr15:79237217	CTSH	0.55	5.17	0.47	1.32e-6	Type 1 diabetes;
THYM	cis	rs7426056	0.525	rs4673263	chr2:204622019	C/T	cg13651908	chr2:204570033	CD28	-0.58	-4.87	-0.45	4.52e-6	Primary sclerosing cholangitis;
THYM	cis	rs227425	0.507	rs61305	chr14:70460031	G/A	cg12046056	chr14:71067695	MED6	0.56	4.58	0.43	1.43e-5	Bone mineral density;
THYM	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.27	10.28	0.73	4.18e-17	Platelet count;
THYM	cis	rs3096299	0.809	rs2911264	chr16:89499272	A/C	cg02187348	chr16:89574699	SPG7	0.73	5.71	0.51	1.26e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs7725337	1.000	rs12660032	chr5:88390545	C/A	cg11280525	chr5:87955695	LOC645323	-0.39	-4.47	-0.42	2.15e-5	Total body bone mineral density;
THYM	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg01264106	chr22:38071602	LGALS1	0.36	4.55	0.42	1.56e-5	Fat distribution (HIV);
THYM	cis	rs2371030	1.000	rs2111713	chr2:211576458	G/A	cg18417063	chr2:211583084	NA	-0.53	-4.57	-0.42	1.48e-5	Non-small cell lung cancer;
THYM	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg15997130	chr1:24165203	NA	0.77	6.87	0.58	6.61e-10	Immature fraction of reticulocytes;
THYM	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg23205692	chr1:25664452	TMEM50A	0.88	7.1	0.59	2.26e-10	Erythrocyte sedimentation rate;
THYM	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-4.45	-0.42	2.35e-5	Body mass index;
THYM	cis	rs7757969	1.000	rs9384810	chr6:112149373	A/G	cg08601457	chr6:112115117	FYN	0.4	4.55	0.42	1.58e-5	Schizophrenia;
THYM	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg26924012	chr15:45694286	SPATA5L1	1.1	10.42	0.73	2.09e-17	Homoarginine levels;
THYM	cis	rs988913	0.706	rs9475130	chr6:54925466	C/T	cg19716238	chr6:54711378	FAM83B	0.47	4.47	0.42	2.13e-5	Menarche (age at onset);
THYM	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg11984989	chr7:158649758	WDR60	-1.03	-11.88	-0.77	1.7e-20	Height;
THYM	cis	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs10752881	0.935	rs3935221	chr1:182969010	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.67	0.43	9.78e-6	Colorectal cancer;
THYM	cis	rs8135828	0.770	rs5763301	chr22:29929627	G/A	cg16189954	chr22:29138267	HSCB;CHEK2	0.77	4.7	0.43	8.66e-6	Lipid traits;
THYM	trans	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.1	7.92	0.63	4.4e-12	Exhaled nitric oxide output;
THYM	cis	rs9435341	0.896	rs1730851	chr1:107596443	A/G	cg00944433	chr1:107599041	PRMT6	0.41	5.04	0.46	2.23e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs4803468	1.000	rs284651	chr19:41928336	T/C	cg09537434	chr19:41945824	ATP5SL	-1.04	-8.98	-0.68	2.48e-14	Height;
THYM	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg15536230	chr21:44985092	HSF2BP	0.4	4.75	0.44	7.21e-6	Mean corpuscular volume;
THYM	cis	rs12282928	1.000	rs2128677	chr11:48319974	G/A	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg04546413	chr19:29218101	NA	1.13	9.17	0.69	9.75e-15	Methadone dose in opioid dependence;
THYM	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.02	6.98	0.58	4.02e-10	Smoking behavior;
THYM	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-4.48	-0.42	2.06e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7043114	0.525	rs7853859	chr9:95151377	A/G	cg14631576	chr9:95140430	CENPP	-0.86	-9.03	-0.68	1.97e-14	Height;
THYM	cis	rs2070488	0.965	rs1984312	chr3:38538466	G/T	cg24069376	chr3:38537580	EXOG	-0.63	-6.35	-0.55	7.46e-9	Electrocardiographic conduction measures;
THYM	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg24112000	chr20:60950667	NA	-0.74	-6.9	-0.58	5.68e-10	Colorectal cancer;
THYM	cis	rs7267979	0.966	rs6037097	chr20:25347221	C/T	cg08601574	chr20:25228251	PYGB	0.57	4.65	0.43	1.09e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg18132916	chr6:79620363	NA	-0.6	-5.35	-0.48	6.07e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg00898013	chr13:113819073	PROZ	-1.0	-9.89	-0.71	2.79e-16	Platelet distribution width;
THYM	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg27490568	chr2:178487706	NA	0.67	5.56	0.5	2.42e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4891159	0.756	rs3892540	chr18:74118058	C/T	cg24786174	chr18:74118243	ZNF516	-0.86	-9.51	-0.7	1.85e-15	Longevity;
THYM	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg24257776	chr3:47051546	LOC100129354	0.41	4.69	0.43	9.15e-6	Colorectal cancer;
THYM	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg10589385	chr1:150898437	SETDB1	0.59	4.75	0.44	7.21e-6	Melanoma;
THYM	cis	rs62070183	0.938	rs75393526	chr17:31035018	A/G	cg02981443	chr17:31254875	TMEM98	-0.54	-4.77	-0.44	6.69e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs87938	0.830	rs34695788	chr3:41166131	A/G	cg02247160	chr3:41243829	CTNNB1	-0.34	-4.59	-0.43	1.37e-5	Bone mineral density (hip);
THYM	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg06636001	chr8:8085503	FLJ10661	0.7	5.72	0.51	1.22e-7	Neuroticism;
THYM	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg27532560	chr4:187881888	NA	-0.96	-12.62	-0.79	5.09e-22	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg02269571	chr22:50332266	NA	-0.67	-4.57	-0.42	1.47e-5	Schizophrenia;
THYM	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg18876405	chr7:65276391	NA	0.55	4.6	0.43	1.29e-5	Aortic root size;
THYM	cis	rs28595532	0.920	rs17323034	chr4:119606518	G/A	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs12137294	0.761	rs1172150	chr1:205221861	A/G	cg17889831	chr1:205181581	DSTYK	-0.41	-5.09	-0.46	1.82e-6	Red cell distribution width;
THYM	cis	rs9457247	0.534	rs12055488	chr6:167379570	A/G	cg00271210	chr6:167070053	RPS6KA2	0.46	4.55	0.42	1.6e-5	Crohn's disease;
THYM	trans	rs8073060	0.586	rs225256	chr17:33955756	C/T	cg19694781	chr19:47549865	TMEM160	-0.95	-7.8	-0.62	7.8e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg06221963	chr1:154839813	KCNN3	-0.78	-9.71	-0.71	7.02e-16	Prostate cancer;
THYM	cis	rs6558530	0.730	rs7341635	chr8:1721643	G/A	cg09410841	chr8:1729607	CLN8	0.81	6.04	0.53	2.93e-8	Systolic blood pressure;
THYM	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11644478	chr21:40555479	PSMG1	0.8	6.91	0.58	5.38e-10	Cognitive function;
THYM	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	0.52	4.47	0.42	2.14e-5	Renal function-related traits (BUN);
THYM	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg18876405	chr7:65276391	NA	-0.76	-7.25	-0.6	1.09e-10	Calcium levels;
THYM	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs921968	0.565	rs4674330	chr2:219595710	T/C	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg06808227	chr14:105710500	BRF1	-1.01	-8.64	-0.66	1.31e-13	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2862064	0.745	rs4704733	chr5:156480104	T/G	cg12943317	chr5:156479607	HAVCR1	-0.76	-4.63	-0.43	1.16e-5	Platelet count;
THYM	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.76	-6.39	-0.55	6.09e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9560113	0.960	rs9560101	chr13:112173798	G/A	cg10483660	chr13:112241077	NA	0.53	4.76	0.44	6.81e-6	Menarche (age at onset);
THYM	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg26149184	chr10:133730230	NA	0.75	4.84	0.44	4.96e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs6032067	0.714	rs6513969	chr20:43878475	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.36	-0.48	5.9e-7	Blood protein levels;
THYM	cis	rs9875589	0.509	rs2733548	chr3:14094478	C/T	cg03204825	chr3:13978759	TPRXL	-0.51	-4.46	-0.42	2.26e-5	Ovarian reserve;
THYM	trans	rs877282	0.700	rs816311	chr10:796490	C/A	cg22713356	chr15:30763199	NA	1.18	9.79	0.71	4.66e-16	Uric acid levels;
THYM	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg10803722	chr21:46713166	LOC642852	-0.5	-6.19	-0.54	1.5e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7523273	0.606	rs2488252	chr1:207938228	C/T	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	cis	rs7412746	0.611	rs2228099	chr1:150808889	C/G	cg10589385	chr1:150898437	SETDB1	0.59	5.05	0.46	2.14e-6	Melanoma;
THYM	cis	rs67072384	1.000	rs7128364	chr11:72451941	A/C	cg01380194	chr11:72452482	ARAP1	-0.97	-5.26	-0.47	8.93e-7	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg05368731	chr17:41323189	NBR1	-1.25	-11.63	-0.77	5.89e-20	Menopause (age at onset);
THYM	trans	rs877282	0.898	rs36064821	chr10:760952	C/T	cg22713356	chr15:30763199	NA	1.37	10.06	0.72	1.21e-16	Uric acid levels;
THYM	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg18131467	chr2:239335373	ASB1	1.1	10.54	0.73	1.16e-17	Multiple system atrophy;
THYM	cis	rs28595532	0.920	rs115706007	chr4:119733638	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs9563576	0.778	rs12870875	chr13:58636569	T/C	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.63	4.68	0.43	9.64e-6	Body mass index;
THYM	cis	rs7909074	0.933	rs879073	chr10:45399882	C/G	cg05187965	chr10:45406764	TMEM72	-0.49	-4.62	-0.43	1.19e-5	Mean corpuscular volume;
THYM	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg00071950	chr4:10020882	SLC2A9	-0.67	-5.98	-0.52	3.97e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs28595532	0.920	rs115259971	chr4:119762654	T/C	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg09877947	chr5:131593287	PDLIM4	0.66	5.5	0.49	3.21e-7	Blood metabolite levels;
THYM	cis	rs6952809	0.516	rs6952959	chr7:2440722	C/T	cg23289794	chr7:2394357	EIF3B	-0.76	-4.72	-0.44	8.17e-6	Multiple sclerosis;
THYM	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg02380750	chr20:61661411	NA	0.61	6.16	0.53	1.78e-8	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg20290983	chr6:43655470	MRPS18A	1.28	12.7	0.79	3.43e-22	IgG glycosylation;
THYM	cis	rs17209837	0.607	rs2071645	chr7:87105276	G/C	cg04996195	chr7:87105398	ABCB4	0.67	4.86	0.45	4.55e-6	Gallbladder cancer;
THYM	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg06521331	chr12:34319734	NA	-0.95	-9.14	-0.68	1.14e-14	Morning vs. evening chronotype;
THYM	cis	rs2637266	1.000	rs7101318	chr10:78379780	T/C	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg27490568	chr2:178487706	NA	0.66	6.09	0.53	2.4e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs506338	0.517	rs516117	chr11:64433444	T/C	cg19395706	chr11:64412079	NRXN2	0.34	4.51	0.42	1.86e-5	Body mass index;Urate levels;
THYM	cis	rs11792861	0.619	rs2289480	chr9:111705501	A/C	cg05043794	chr9:111880884	C9orf5	-0.34	-4.77	-0.44	6.55e-6	Menarche (age at onset);
THYM	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg21926883	chr2:100939477	LONRF2	-0.65	-5.96	-0.52	4.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs924712	0.677	rs239792	chr6:54802044	C/T	cg04690482	chr6:54711388	FAM83B	0.45	5.39	0.48	5.07e-7	Breast cancer;
THYM	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg23711669	chr6:146136114	FBXO30	0.96	10.32	0.73	3.35e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2282930	0.512	rs17133918	chr7:50712272	C/T	cg08586669	chr7:50727761	GRB10	0.33	4.89	0.45	4.18e-6	Bone mineral density;
THYM	cis	rs6942756	1.000	rs2141075	chr7:128877305	C/T	cg02491457	chr7:128862824	NA	0.44	4.53	0.42	1.69e-5	White matter hyperintensity burden;
THYM	cis	rs12446552	0.661	rs72781032	chr16:11699401	A/C	cg09662852	chr16:11707685	NA	-0.65	-6.22	-0.54	1.35e-8	Colorectal or endometrial cancer;
THYM	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg08901578	chr4:187885870	NA	-0.64	-6.03	-0.53	3.1e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7567389	0.534	rs72845982	chr2:128098570	G/A	cg09760422	chr2:128146352	NA	0.4	4.79	0.44	6.04e-6	Self-rated health;
THYM	cis	rs4731207	0.596	rs7810654	chr7:124645089	G/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg13319975	chr6:146136371	FBXO30	-0.67	-5.35	-0.48	6.13e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg22875332	chr1:76189707	ACADM	0.88	11.63	0.77	5.83e-20	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg06108461	chr20:60628389	TAF4	-1.03	-8.14	-0.64	1.49e-12	Body mass index;
THYM	cis	rs2456568	0.802	rs10765638	chr11:93636171	A/T	cg17347335	chr11:93583973	C11orf90	-0.48	-4.58	-0.43	1.39e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.63	5.4	0.48	4.92e-7	Hemoglobin concentration;
THYM	cis	rs490647	0.948	rs1886913	chr1:37230656	C/T	cg09088576	chr1:36947785	CSF3R	-0.46	-4.52	-0.42	1.8e-5	Neuroticism;
THYM	cis	rs10789491	0.951	rs35050319	chr1:47103886	C/A	cg15501359	chr1:47185051	KIAA0494	-1.08	-7.67	-0.62	1.48e-11	Response to hepatitis C treatment;
THYM	cis	rs12585310	1.000	rs12585310	chr13:27528347	C/T	cg11275620	chr13:28194854	POLR1D;LNX2	-0.63	-4.48	-0.42	2.09e-5	Inflammatory bowel disease;
THYM	cis	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg08133631	chr1:26527909	CATSPER4	-0.61	-5.08	-0.46	1.92e-6	Obesity-related traits;
THYM	cis	rs7252981	0.632	rs739461	chr19:19715794	T/C	cg13523818	chr19:19371900	HAPLN4	-0.58	-4.56	-0.42	1.54e-5	Perceived unattractiveness to mosquitoes;
THYM	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg17173187	chr15:85201210	NMB	0.56	5.57	0.5	2.38e-7	Schizophrenia;
THYM	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg17366294	chr4:99064904	C4orf37	0.54	6.31	0.54	8.73e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg13390004	chr1:15929781	NA	0.64	4.85	0.45	4.88e-6	Systolic blood pressure;
THYM	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg13695892	chr22:41940480	POLR3H	0.99	7.48	0.61	3.75e-11	Vitiligo;
THYM	cis	rs41264869	0.600	rs73083129	chr1:205186206	T/C	cg17889831	chr1:205181581	DSTYK	0.41	4.65	0.43	1.05e-5	Blood protein levels;
THYM	cis	rs2133450	0.712	rs9990258	chr3:7366452	C/T	cg19930620	chr3:7340148	GRM7	-0.48	-4.49	-0.42	1.98e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs72827839	0.790	rs116944299	chr17:46267765	C/A	cg23391107	chr17:45924227	SP6	0.83	5.59	0.5	2.18e-7	Ease of getting up in the morning;
THYM	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg20007245	chr22:24372913	LOC391322	0.82	6.88	0.58	6.42e-10	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg26038318	chr20:34205095	SPAG4	0.65	5.25	0.47	9.22e-7	Total cholesterol levels;
THYM	cis	rs9522267	0.535	rs914031	chr13:112240176	C/A	cg10483660	chr13:112241077	NA	-0.6	-6.79	-0.57	9.74e-10	Hepatitis;
THYM	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg01579765	chr21:45077557	HSF2BP	-0.47	-7.43	-0.61	4.78e-11	Mean corpuscular volume;
THYM	cis	rs9810089	0.843	rs11717954	chr3:136112109	A/G	cg12473912	chr3:136751656	NA	0.62	5.05	0.46	2.12e-6	Gestational age at birth (child effect);
THYM	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7940866	0.838	rs12790299	chr11:130803634	A/G	cg23692386	chr11:131799662	NTM	0.44	4.48	0.42	2.07e-5	Schizophrenia;
THYM	cis	rs6032067	0.759	rs2206889	chr20:43886487	C/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.58	-6.45	-0.55	4.75e-9	Blood protein levels;
THYM	cis	rs9361491	0.608	rs2321770	chr6:79445408	T/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs34638657	0.732	rs62045962	chr16:82200604	T/C	cg09439754	chr16:82129088	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.45	0.49	3.92e-7	Electroencephalogram traits;
THYM	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg06481639	chr22:41940642	POLR3H	-0.82	-5.68	-0.5	1.49e-7	Vitiligo;
THYM	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg10253484	chr15:75165896	SCAMP2	-0.62	-4.54	-0.42	1.64e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg10047753	chr17:41438598	NA	0.97	6.37	0.55	6.79e-9	Menopause (age at onset);
THYM	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg13695892	chr22:41940480	POLR3H	0.89	6.26	0.54	1.1e-8	Cannabis dependence symptom count;
THYM	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg24874828	chr4:187887005	NA	-0.72	-7.22	-0.6	1.26e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4474465	0.850	rs10899551	chr11:78256998	A/C	cg19901956	chr11:77921274	USP35	-0.61	-4.64	-0.43	1.1e-5	Alzheimer's disease (survival time);
THYM	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	4.69	0.43	9e-6	Menarche (age at onset);
THYM	cis	rs1670533	1.000	rs34956924	chr4:1047270	T/C	cg27284194	chr4:1044797	NA	0.65	4.99	0.46	2.72e-6	Recombination rate (females);
THYM	cis	rs8070740	0.898	rs4239056	chr17:5324406	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.72	6.03	0.53	3.15e-8	Menopause (age at onset);
THYM	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg03396347	chr1:1875803	NA	-0.68	-6.68	-0.57	1.62e-9	Body mass index;
THYM	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	4.68	0.43	9.7e-6	Height;
THYM	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg13010199	chr12:38710504	ALG10B	-0.59	-4.72	-0.44	8.19e-6	Morning vs. evening chronotype;
THYM	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg23161317	chr6:28129485	ZNF389	0.85	6.33	0.54	8.19e-9	Depression;
THYM	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg12419862	chr22:24373484	LOC391322	-0.61	-4.74	-0.44	7.48e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7192750	0.586	rs4788571	chr16:71920823	G/A	cg06353428	chr16:71660113	MARVELD3	0.76	5.6	0.5	2.04e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg23711669	chr6:146136114	FBXO30	0.91	8.87	0.67	4.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg08213375	chr14:104286397	PPP1R13B	0.52	6.25	0.54	1.18e-8	Schizophrenia;
THYM	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg21385522	chr1:16154831	NA	-0.91	-6.8	-0.57	9.03e-10	Dilated cardiomyopathy;
THYM	cis	rs735539	0.521	rs2818992	chr13:21398087	G/A	cg02792322	chr13:21280448	IL17D	-0.65	-4.63	-0.43	1.16e-5	Dental caries;
THYM	cis	rs863345	0.625	rs10489833	chr1:158490451	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs9633835	0.524	rs11022726	chr11:13273305	G/A	cg13286116	chr11:13302098	ARNTL	-0.75	-8.31	-0.65	6.72e-13	Body mass index;
THYM	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs9970807	1.000	rs9970807	chr1:56965664	C/T	cg11959316	chr1:57001742	PPAP2B	0.69	5.23	0.47	1.01e-6	Myocardial infarction;Coronary artery disease;
THYM	cis	rs11648796	0.717	rs10682	chr16:767430	C/G	cg09263875	chr16:632152	PIGQ	0.66	5.39	0.48	5.04e-7	Height;
THYM	cis	rs6748734	0.625	rs4675792	chr2:241819526	A/G	cg09990169	chr2:241835740	C2orf54	0.31	4.96	0.45	3.08e-6	Urinary metabolites;
THYM	cis	rs2073300	1.000	rs2236021	chr20:23432528	A/G	cg12062639	chr20:23401060	NAPB	1.17	6.02	0.53	3.29e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7828089	0.646	rs10094778	chr8:22285490	A/G	cg12081754	chr8:22256438	SLC39A14	0.82	7.22	0.6	1.3e-10	Verbal declarative memory;
THYM	cis	rs3820068	0.608	rs12740492	chr1:16048951	A/T	cg24675056	chr1:15929824	NA	0.77	6.08	0.53	2.44e-8	Systolic blood pressure;
THYM	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg24642844	chr7:1081250	C7orf50	-1.28	-8.22	-0.64	1.06e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3924048	0.574	rs61776783	chr1:12612657	T/C	cg00291366	chr1:12616550	NA	0.4	6.33	0.54	7.89e-9	Optic cup area;
THYM	cis	rs6496667	0.558	rs10459677	chr15:91042399	A/C	cg00425431	chr15:90792223	TTLL13	-0.4	-4.61	-0.43	1.25e-5	Rheumatoid arthritis;
THYM	cis	rs1971762	0.542	rs12303370	chr12:54091807	A/C	cg16917193	chr12:54089295	NA	0.9	8.7	0.67	9.77e-14	Height;
THYM	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	5.49	0.49	3.4e-7	Platelet count;
THYM	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7173743	0.756	rs6495337	chr15:79125689	C/G	cg00540400	chr15:79124168	NA	-0.62	-6.61	-0.56	2.2e-9	Coronary artery disease;
THYM	cis	rs7107174	0.901	rs7941639	chr11:78116959	A/G	cg19901956	chr11:77921274	USP35	0.64	5.14	0.47	1.48e-6	Testicular germ cell tumor;
THYM	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg11871910	chr12:69753446	YEATS4	0.62	4.79	0.44	6.25e-6	Response to diuretic therapy;
THYM	cis	rs346785	0.580	rs347676	chr17:74274998	G/A	cg09812376	chr17:74270190	QRICH2	-0.8	-12.05	-0.78	7.6e-21	White matter hyperintensities in ischemic stroke;
THYM	cis	rs36051895	0.530	rs2093447	chr9:5230374	G/T	cg02405213	chr9:5042618	JAK2	-0.82	-7.34	-0.6	7.31e-11	Pediatric autoimmune diseases;
THYM	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg26818010	chr10:134567672	INPP5A	-0.78	-6.32	-0.54	8.39e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs951188	0.688	rs79604623	chr2:150401041	C/T	cg17961725	chr2:150454027	NA	-1.03	-5.39	-0.48	5.11e-7	Daytime sleep phenotypes;
THYM	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg15962314	chr1:44399869	ARTN	0.54	5.43	0.49	4.32e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs2836633	0.929	rs58120977	chr21:40037346	C/T	cg12884169	chr21:40033163	ERG	0.71	9.05	0.68	1.8e-14	Coronary artery disease;
THYM	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg09549813	chr16:4587862	C16orf5	-0.56	-6.15	-0.53	1.84e-8	Schizophrenia;
THYM	cis	rs10463554	1.000	rs11949145	chr5:102330256	G/T	cg23492399	chr5:102201601	PAM	-0.64	-5.09	-0.46	1.8e-6	Parkinson's disease;
THYM	cis	rs3768617	0.528	rs10737241	chr1:183098208	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.76	0.44	7e-6	Fuchs's corneal dystrophy;
THYM	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg08999081	chr20:33150536	PIGU	0.57	4.9	0.45	3.95e-6	Height;
THYM	cis	rs2067615	0.542	rs4346064	chr12:107081599	C/A	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	cis	rs4523957	0.890	rs11078024	chr17:2189324	T/C	cg16513277	chr17:2031491	SMG6	0.79	7.41	0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs13424612	0.839	rs13848	chr2:240946766	A/G	cg01812947	chr2:240904978	NDUFA10	0.58	4.9	0.45	3.96e-6	Odorant perception (isobutyraldehyde);
THYM	cis	rs6977660	0.652	rs58559474	chr7:19751569	C/T	cg05791153	chr7:19748676	TWISTNB	1.27	7.31	0.6	8.2e-11	Thyroid stimulating hormone;
THYM	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg06481639	chr22:41940642	POLR3H	-0.61	-4.89	-0.45	4.15e-6	Neuroticism;
THYM	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-5.32	-0.48	6.76e-7	Heart rate;
THYM	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	5.09	0.46	1.82e-6	Obesity-related traits;
THYM	cis	rs2249625	0.545	rs60835713	chr6:72880349	T/C	cg27608224	chr6:72922399	RIMS1	-0.58	-4.9	-0.45	3.94e-6	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
THYM	cis	rs4820539	0.966	rs5751590	chr22:23486830	A/C	cg21100191	chr22:23484243	RTDR1	0.75	6.4	0.55	5.81e-9	Bone mineral density;
THYM	cis	rs12310956	0.532	rs10844715	chr12:33968444	A/G	cg10856724	chr12:34555212	NA	-0.72	-6.65	-0.56	1.82e-9	Morning vs. evening chronotype;
THYM	cis	rs9527	0.590	rs7898770	chr10:104756636	A/G	cg04362960	chr10:104952993	NT5C2	-0.61	-4.67	-0.43	9.92e-6	Arsenic metabolism;
THYM	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg12379764	chr21:47803548	PCNT	-0.69	-4.61	-0.43	1.24e-5	Testicular germ cell tumor;
THYM	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs2734839	0.929	rs11608185	chr11:113294976	T/C	cg14159747	chr11:113255604	NA	0.32	6.33	0.54	8.07e-9	Information processing speed;
THYM	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg00256281	chr22:41985642	PMM1	0.62	4.67	0.43	9.91e-6	Vitiligo;
THYM	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg14018140	chr10:458528	DIP2C	-0.51	-5.27	-0.48	8.35e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs10186029	0.582	rs1441165	chr2:214009831	A/G	cg08319019	chr2:214017104	IKZF2	0.76	5.83	0.51	7.74e-8	Systemic sclerosis;
THYM	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg02527881	chr3:46936655	PTH1R	-0.63	-6.29	-0.54	9.52e-9	Colorectal cancer;
THYM	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg13683864	chr3:40499215	RPL14	-1.06	-12.31	-0.78	2.17e-21	Renal cell carcinoma;
THYM	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	5.56	0.5	2.42e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7172809	0.643	rs16968930	chr15:77843434	T/A	cg22256960	chr15:77711686	NA	-0.69	-5.08	-0.46	1.89e-6	Glucose homeostasis traits;
THYM	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg15448220	chr1:150897856	SETDB1	0.9	7.66	0.62	1.56e-11	Melanoma;
THYM	cis	rs13256369	1.000	rs7843488	chr8:8576217	C/T	cg18904891	chr8:8559673	CLDN23	0.66	4.72	0.44	8.16e-6	Obesity-related traits;
THYM	trans	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg21644426	chr2:191273491	MFSD6	-0.65	-4.54	-0.42	1.62e-5	Diastolic blood pressure;
THYM	cis	rs686320	1.000	rs72643572	chr11:65250967	A/G	cg21144158	chr11:65211084	MIR612	0.75	5.24	0.47	9.51e-7	Hip circumference adjusted for BMI;
THYM	cis	rs9677476	1.000	rs13415839	chr2:232126534	C/T	cg07929768	chr2:232055508	NA	0.49	5.15	0.47	1.39e-6	Food antigen IgG levels;
THYM	cis	rs9814567	0.679	rs1880379	chr3:134330612	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9816226	0.591	rs10513801	chr3:185822353	T/G	cg00760338	chr3:185826511	ETV5	-0.84	-4.53	-0.42	1.74e-5	Obesity;Body mass index;
THYM	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg13289132	chr10:30722225	MAP3K8	-0.56	-4.47	-0.42	2.18e-5	Itch intensity from mosquito bite;
THYM	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg14675211	chr2:100938903	LONRF2	0.72	7.72	0.62	1.18e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7508	0.535	rs13261745	chr8:17787005	A/G	cg18067069	chr8:17937731	ASAH1	-0.63	-4.74	-0.44	7.44e-6	Atrial fibrillation;
THYM	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03264133	chr6:25882463	NA	-0.69	-5.26	-0.48	8.71e-7	Blood metabolite levels;
THYM	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg12408189	chr10:30722286	MAP3K8	-0.58	-4.91	-0.45	3.83e-6	Inflammatory bowel disease;
THYM	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg18876405	chr7:65276391	NA	-0.71	-6.53	-0.56	3.15e-9	Aortic root size;
THYM	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg07936489	chr17:37558343	FBXL20	0.87	5.78	0.51	9.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.06	-0.46	2.03e-6	Body mass index;
THYM	cis	rs7113850	0.541	rs76344090	chr11:24223375	C/G	ch.11.24196551F	chr11:24239977	NA	1.03	5.41	0.49	4.67e-7	Bone fracture in osteoporosis;
THYM	cis	rs17604090	0.823	rs28415620	chr7:29701104	T/C	cg19413766	chr7:29689036	LOC646762	-1.04	-5.82	-0.51	7.9e-8	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg10505658	chr17:80084571	CCDC57	0.7	8.05	0.64	2.35e-12	Life satisfaction;
THYM	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg17063962	chr7:91808500	NA	-1.12	-12.68	-0.79	3.85e-22	Breast cancer;
THYM	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg22974920	chr21:40686053	BRWD1	-0.63	-4.97	-0.45	2.98e-6	Cognitive function;
THYM	cis	rs901683	1.000	rs34539215	chr10:46087378	C/A	cg18240400	chr10:46168597	ANUBL1	0.73	4.73	0.44	7.89e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg21475434	chr5:93447410	FAM172A	0.95	6.03	0.53	3.16e-8	Diabetic retinopathy;
THYM	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg00256281	chr22:41985642	PMM1	0.63	4.85	0.45	4.76e-6	Vitiligo;
THYM	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg17105886	chr17:28927953	LRRC37B2	1.26	7.59	0.61	2.23e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7772486	0.875	rs1330939	chr6:146308518	T/A	cg23711669	chr6:146136114	FBXO30	0.89	8.8	0.67	5.96e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2273669	0.915	rs4992383	chr6:109292816	C/A	cg17117243	chr6:109341365	SESN1	-0.75	-4.55	-0.42	1.6e-5	Prostate cancer;
THYM	cis	rs2229238	0.774	rs4240872	chr1:154436195	A/G	cg21262032	chr1:154437693	IL6R	-0.68	-6.72	-0.57	1.32e-9	Coronary heart disease;
THYM	cis	rs73198271	0.773	rs66618176	chr8:8646974	G/C	cg06636001	chr8:8085503	FLJ10661	-0.76	-5.06	-0.46	2.01e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs9527	0.615	rs7096452	chr10:104736563	G/A	cg04362960	chr10:104952993	NT5C2	0.63	4.76	0.44	6.9e-6	Arsenic metabolism;
THYM	cis	rs4389656	0.857	rs416847	chr5:6739567	A/G	cg10857441	chr5:6722123	POLS	-0.45	-4.55	-0.42	1.57e-5	Coronary artery disease;
THYM	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg13393036	chr8:95962371	TP53INP1	-0.44	-4.52	-0.42	1.81e-5	Type 2 diabetes;
THYM	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg18876405	chr7:65276391	NA	0.61	5.2	0.47	1.13e-6	Aortic root size;
THYM	cis	rs929596	0.793	rs2602376	chr2:234582051	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.82	-5.71	-0.51	1.31e-7	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs3755605	0.864	rs6788950	chr3:169767021	T/C	cg18444028	chr3:169782040	GPR160	0.56	4.53	0.42	1.71e-5	Testicular germ cell tumor;
THYM	trans	rs8073060	0.614	rs225275	chr17:33972567	G/C	cg19694781	chr19:47549865	TMEM160	-0.95	-7.96	-0.63	3.6e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs9902453	0.765	rs1531553	chr17:28066752	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg19847130	chr8:10466454	RP1L1	0.52	4.74	0.44	7.57e-6	Neuroticism;
THYM	cis	rs1865721	0.771	rs62092763	chr18:73128623	T/G	cg26385618	chr18:73139727	C18orf62	-0.69	-5.19	-0.47	1.18e-6	Intelligence;
THYM	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg03684893	chr10:554711	DIP2C	-0.7	-5.81	-0.51	8.18e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg12893697	chr11:970389	AP2A2	-0.32	-5.39	-0.48	5.18e-7	Alzheimer's disease (late onset);
THYM	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg24818145	chr4:99064322	C4orf37	0.74	5.97	0.52	4.09e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.85	-0.51	7.09e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs3862260	0.509	rs7552885	chr1:120164966	C/T	cg11530693	chr1:120165357	ZNF697	1.08	12.42	0.79	1.33e-21	Systemic lupus erythematosus;
THYM	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.27	6.27	0.54	1.04e-8	Obesity-related traits;
THYM	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg17366294	chr4:99064904	C4orf37	0.54	6.01	0.53	3.37e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs6918586	0.615	rs198824	chr6:26122783	T/C	cg12310025	chr6:25882481	NA	0.68	5.51	0.49	3.1e-7	Schizophrenia;
THYM	cis	rs4280164	0.551	rs2295300	chr14:24805117	C/T	cg18846074	chr14:24801073	ADCY4	-0.59	-4.79	-0.44	6.07e-6	Parent of origin effect on language impairment (paternal);
THYM	cis	rs7592578	0.771	rs10432434	chr2:191387079	T/G	cg21644426	chr2:191273491	MFSD6	-0.64	-4.51	-0.42	1.88e-5	Diastolic blood pressure;
THYM	cis	rs1568889	1.000	rs66702115	chr11:28181703	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.55e-6	Bipolar disorder;
THYM	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg16586182	chr3:47516702	SCAP	-0.64	-5.67	-0.5	1.53e-7	Colorectal cancer;
THYM	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg04518342	chr5:131593106	PDLIM4	0.52	6.04	0.53	2.96e-8	Acylcarnitine levels;
THYM	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg21775007	chr8:11205619	TDH	-0.67	-5.47	-0.49	3.56e-7	Retinal vascular caliber;
THYM	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg27170947	chr2:26402098	FAM59B	0.79	6.27	0.54	1.05e-8	Mean corpuscular hemoglobin;
THYM	cis	rs11209185	0.509	rs12130147	chr1:68446944	G/A	cg22082780	chr1:68452167	NA	0.53	6.09	0.53	2.34e-8	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2074409	0.509	rs853205	chr17:35824396	C/T	cg06716730	chr17:35851459	DUSP14	0.29	4.5	0.42	1.9e-5	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1018836	0.628	rs6471085	chr8:91463783	G/A	cg16814680	chr8:91681699	NA	-0.68	-5.26	-0.47	8.84e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.67	5.46	0.49	3.75e-7	Blood protein levels;
THYM	cis	rs2069036	0.817	rs2185634	chr10:16098883	T/G	cg26633223	chr10:15133461	NA	0.66	4.65	0.43	1.08e-5	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs28595532	0.920	rs114796605	chr4:119744472	C/A	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs2816062	0.735	rs2816045	chr1:18892999	A/G	cg18795169	chr1:18902165	NA	-0.99	-12.21	-0.78	3.62e-21	Urate levels in lean individuals;
THYM	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.72	-0.44	7.99e-6	Resting heart rate;
THYM	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.09	-0.46	1.83e-6	Life satisfaction;
THYM	cis	rs6946131	0.509	rs2330770	chr7:54809200	C/T	cg16668896	chr7:54900801	NA	0.46	4.65	0.43	1.07e-5	Systemic lupus erythematosus;
THYM	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.48	-0.55	4e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg22852734	chr6:133119734	C6orf192	1.32	8.71	0.67	9.24e-14	Type 2 diabetes nephropathy;
THYM	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg10523679	chr1:76189770	ACADM	-0.55	-4.49	-0.42	1.97e-5	Daytime sleep phenotypes;
THYM	cis	rs9915657	0.773	rs9896360	chr17:70099469	C/G	cg09344028	chr17:70110421	NA	0.51	5.42	0.49	4.53e-7	Thyroid hormone levels;
THYM	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg18402987	chr7:1209562	NA	0.84	5.23	0.47	1.01e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7580658	0.724	rs6712213	chr2:127998230	G/A	cg09152259	chr2:128156114	NA	-0.39	-5.0	-0.46	2.63e-6	Protein C levels;
THYM	cis	rs6138458	0.816	rs2151463	chr20:24911819	A/C	cg26195577	chr20:24973756	C20orf3	1.11	10.52	0.73	1.29e-17	Blood protein levels;
THYM	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	trans	rs8002861	0.967	rs9533689	chr13:44480413	A/C	cg17145862	chr1:211918768	LPGAT1	0.99	11.5	0.76	1.07e-19	Leprosy;
THYM	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg07936489	chr17:37558343	FBXL20	0.79	5.7	0.5	1.37e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg06558623	chr16:89946397	TCF25	1.48	7.81	0.63	7.43e-12	Skin colour saturation;
THYM	cis	rs3008870	1.000	rs1118393	chr1:67366668	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.93	7.13	0.59	1.96e-10	Lymphocyte percentage of white cells;
THYM	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-4.56	-0.42	1.51e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg19318889	chr4:1322082	MAEA	-0.58	-5.01	-0.46	2.53e-6	Longevity;
THYM	cis	rs6510489	0.921	rs7253910	chr19:35981868	G/A	cg15078284	chr19:36004994	DMKN	0.42	4.86	0.45	4.67e-6	Bipolar disorder;
THYM	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg05472934	chr7:22766657	IL6	0.73	5.54	0.49	2.66e-7	Lung cancer;
THYM	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.77	-0.44	6.61e-6	Eye color traits;
THYM	cis	rs9810089	0.843	rs681783	chr3:136035303	C/T	cg12473912	chr3:136751656	NA	0.6	4.87	0.45	4.42e-6	Gestational age at birth (child effect);
THYM	cis	rs6840360	0.607	rs6815320	chr4:152432500	T/C	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg27170947	chr2:26402098	FAM59B	-0.8	-6.37	-0.55	6.74e-9	Gut microbiome composition (summer);
THYM	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.01	9.45	0.7	2.5e-15	Colorectal cancer;
THYM	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg13390004	chr1:15929781	NA	0.62	4.72	0.44	8.11e-6	Systolic blood pressure;
THYM	cis	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg21775007	chr8:11205619	TDH	0.65	5.29	0.48	7.91e-7	Retinal vascular caliber;
THYM	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.92	-9.02	-0.68	2.01e-14	Lung cancer;
THYM	cis	rs6918586	1.000	rs198806	chr6:26133616	A/G	cg12310025	chr6:25882481	NA	0.67	5.34	0.48	6.46e-7	Schizophrenia;
THYM	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-4.85	-0.45	4.79e-6	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	9.67	0.7	8.34e-16	Platelet count;
THYM	cis	rs319204	1.000	rs2082405	chr5:146258596	C/T	cg13983063	chr5:146258615	PPP2R2B	0.45	4.49	0.42	2e-5	Schizophrenia;
THYM	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs10927875	0.864	rs12135073	chr1:16167799	C/T	cg21385522	chr1:16154831	NA	1.27	10.37	0.73	2.73e-17	Dilated cardiomyopathy;
THYM	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg15704280	chr7:45808275	SEPT13	-1.06	-15.16	-0.84	4.28e-27	Height;
THYM	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg21926883	chr2:100939477	LONRF2	-0.65	-5.96	-0.52	4.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg20503657	chr10:835505	NA	1.22	7.64	0.62	1.69e-11	Eosinophil percentage of granulocytes;
THYM	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg08773314	chr2:239334832	ASB1	0.64	9.75	0.71	5.79e-16	Multiple system atrophy;
THYM	cis	rs600806	0.813	rs4970759	chr1:109982213	C/A	cg23616212	chr1:109941201	SORT1	-0.48	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.82	-4.8	-0.44	5.9e-6	Lung function (FEV1/FVC);
THYM	cis	rs332034	0.546	rs10099757	chr8:8695242	C/A	cg06636001	chr8:8085503	FLJ10661	-0.8	-4.52	-0.42	1.76e-5	Conduct disorder (maternal expressed emotions interaction);
THYM	cis	rs2219968	0.962	rs7828745	chr8:78947372	G/A	cg00738934	chr8:78996279	NA	0.85	9.44	0.7	2.56e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg19508488	chr2:152266495	RIF1	0.77	5.94	0.52	4.72e-8	Lung cancer;
THYM	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.89	-8.2	-0.64	1.13e-12	Monocyte percentage of white cells;
THYM	cis	rs2811415	0.597	rs13079887	chr3:127745248	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg16680214	chr1:154839983	KCNN3	-0.39	-4.63	-0.43	1.15e-5	Prostate cancer;
THYM	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg16680214	chr1:154839983	KCNN3	-0.39	-4.63	-0.43	1.15e-5	Prostate cancer;
THYM	cis	rs9972944	0.756	rs9894010	chr17:63760156	T/G	cg07283582	chr17:63770753	CCDC46	-0.64	-4.91	-0.45	3.77e-6	Total body bone mineral density;
THYM	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg25319279	chr11:5960081	NA	-0.61	-5.22	-0.47	1.06e-6	DNA methylation (variation);
THYM	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg08999081	chr20:33150536	PIGU	0.77	6.95	0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs995000	0.895	rs1472257	chr1:63042126	A/G	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs3125734	0.633	rs3765002	chr10:64006124	G/T	cg09941381	chr10:64027924	RTKN2	-0.56	-4.55	-0.42	1.56e-5	Rheumatoid arthritis;
THYM	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg03676636	chr4:99064102	C4orf37	0.38	5.2	0.47	1.13e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2637266	1.000	rs2637264	chr10:78322794	A/C	cg18941641	chr10:78392320	NA	0.8	6.9	0.58	5.69e-10	Pulmonary function;
THYM	cis	rs11190604	0.767	rs77769532	chr10:102193646	T/C	cg16342193	chr10:102329863	NA	-0.5	-5.17	-0.47	1.29e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4713118	0.662	rs9468276	chr6:28027688	A/C	cg12963246	chr6:28129442	ZNF389	0.77	6.4	0.55	5.74e-9	Parkinson's disease;
THYM	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg24209194	chr3:40518798	ZNF619	0.56	4.6	0.43	1.32e-5	Renal cell carcinoma;
THYM	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.42	-0.49	4.5e-7	Total cholesterol levels;
THYM	cis	rs10186029	0.680	rs10179508	chr2:213978526	C/T	cg08319019	chr2:214017104	IKZF2	-0.81	-6.59	-0.56	2.49e-9	Systemic sclerosis;
THYM	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg02725872	chr8:58115012	NA	-1.09	-8.15	-0.64	1.43e-12	Developmental language disorder (linguistic errors);
THYM	cis	rs7084402	0.967	rs1649062	chr10:60309326	G/A	cg07615347	chr10:60278583	BICC1	0.56	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs990171	0.955	rs2058658	chr2:103054803	T/C	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.17	-0.47	1.27e-6	Lymphocyte counts;
THYM	cis	rs977987	0.806	rs7188604	chr16:75451170	T/G	cg03315344	chr16:75512273	CHST6	0.76	6.16	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg14784868	chr12:69753453	YEATS4	-1.13	-12.24	-0.78	3.08e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2404602	0.698	rs12909656	chr15:76664378	A/T	cg23625390	chr15:77176239	SCAPER	-0.65	-4.7	-0.43	8.68e-6	Blood metabolite levels;
THYM	cis	rs892961	0.932	rs7208671	chr17:75413129	T/C	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs1421898	0.582	rs62384973	chr5:157935302	C/T	cg06698293	chr5:158690540	UBLCP1	-0.97	-4.6	-0.43	1.28e-5	Inflammatory skin disease;
THYM	cis	rs791590	0.887	rs11591302	chr10:6051741	A/G	cg17191567	chr10:6178319	NA	0.7	4.55	0.42	1.58e-5	Soluble interleukin-2 receptor subunit alpha;
THYM	cis	rs1729951	0.546	rs12054408	chr3:136677645	T/C	cg21827317	chr3:136751795	NA	0.75	6.64	0.56	1.92e-9	Neuroticism;
THYM	cis	rs9826463	0.582	rs11720762	chr3:142140511	T/G	cg20824294	chr3:142316082	PLS1	0.76	5.3	0.48	7.53e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	6.96	0.58	4.45e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs477692	0.544	rs7923750	chr10:131446895	G/C	cg05714579	chr10:131428358	MGMT	-0.94	-9.46	-0.7	2.39e-15	Response to temozolomide;
THYM	cis	rs57545798	0.963	rs8042860	chr15:100640042	A/G	cg20941820	chr15:100882334	ADAMTS17	0.56	4.72	0.44	7.96e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	trans	rs629535	0.679	rs62511660	chr8:70157089	G/A	cg21567404	chr3:27674614	NA	-0.88	-7.0	-0.58	3.66e-10	Dupuytren's disease;
THYM	cis	rs12594515	1.000	rs8025258	chr15:45987554	C/A	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.41	-5.2	-0.47	1.15e-6	Monocyte percentage of white cells;
THYM	cis	rs950394	1.000	rs56230702	chr2:104990227	G/A	cg20302975	chr2:105468274	NA	-0.78	-4.58	-0.43	1.4e-5	Schizophrenia;
THYM	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg10560079	chr2:191398806	TMEM194B	-0.84	-5.7	-0.5	1.34e-7	Diastolic blood pressure;
THYM	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05901451	chr6:126070800	HEY2	-0.97	-9.68	-0.7	7.99e-16	Brugada syndrome;
THYM	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg18876405	chr7:65276391	NA	0.57	4.75	0.44	7.2e-6	Aortic root size;
THYM	cis	rs761746	0.739	rs5753690	chr22:31950005	C/T	cg10537193	chr22:32026975	PISD	-0.37	-4.75	-0.44	7.09e-6	Intelligence;
THYM	cis	rs7119038	0.818	rs10892294	chr11:118667357	C/G	cg19308663	chr11:118741387	NA	-0.53	-5.69	-0.5	1.39e-7	Sjögren's syndrome;
THYM	cis	rs7666738	0.785	rs11944120	chr4:99079932	A/C	cg17366294	chr4:99064904	C4orf37	0.56	5.68	0.5	1.5e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs17407555	0.955	rs56332418	chr4:10249535	C/A	cg11266682	chr4:10021025	SLC2A9	-0.52	-4.88	-0.45	4.31e-6	Schizophrenia (age at onset);
THYM	cis	rs7843479	0.930	rs4871903	chr8:21827833	C/T	cg17168535	chr8:21777572	XPO7	-0.62	-4.79	-0.44	6.05e-6	Mean corpuscular volume;
THYM	cis	rs7429990	0.930	rs13075457	chr3:48054553	A/G	cg02219026	chr3:48282209	ZNF589	0.6	4.52	0.42	1.75e-5	Educational attainment (years of education);
THYM	cis	rs11771526	0.792	rs17161105	chr7:32299187	T/C	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs17125944	0.686	rs78623109	chr14:53383077	G/T	cg00686598	chr14:53173677	PSMC6	1.09	4.9	0.45	3.95e-6	Alzheimer's disease (late onset);
THYM	cis	rs4589258	0.504	rs4753022	chr11:90388429	A/G	cg26138821	chr11:89956704	CHORDC1	0.62	4.45	0.42	2.36e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6463094	0.713	rs2108364	chr7:42259870	T/C	cg00560277	chr7:42267269	GLI3	-0.57	-4.51	-0.42	1.85e-5	Gut microbiome composition (summer);
THYM	cis	rs17253792	0.822	rs28754619	chr14:56088394	G/A	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs710865	0.723	rs710870	chr1:19549759	G/A	cg13387374	chr1:19411106	UBR4	0.63	5.16	0.47	1.34e-6	Brain structure;
THYM	cis	rs6840360	0.593	rs10022023	chr4:152560731	A/G	cg22705602	chr4:152727874	NA	-0.77	-8.58	-0.66	1.81e-13	Intelligence (multi-trait analysis);
THYM	cis	rs17174870	0.955	rs11884641	chr2:112767406	C/T	cg17354880	chr2:112658759	MERTK	0.56	4.45	0.42	2.31e-5	Multiple sclerosis;
THYM	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg21644426	chr2:191273491	MFSD6	-0.74	-5.2	-0.47	1.13e-6	Diastolic blood pressure;
THYM	cis	rs7567389	0.719	rs6738690	chr2:127992725	T/C	cg09760422	chr2:128146352	NA	-0.52	-5.6	-0.5	2.08e-7	Self-rated health;
THYM	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.89	-7.71	-0.62	1.24e-11	Menarche (age at onset);
THYM	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg24209194	chr3:40518798	ZNF619	0.61	4.79	0.44	6.14e-6	Renal cell carcinoma;
THYM	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg23978390	chr7:1156363	C7orf50	0.61	4.66	0.43	1.02e-5	Longevity;Endometriosis;
THYM	cis	rs2273669	0.667	rs77002235	chr6:109321497	G/A	cg17117243	chr6:109341365	SESN1	-0.9	-5.38	-0.48	5.45e-7	Prostate cancer;
THYM	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs11264213	0.901	rs581459	chr1:36375110	C/T	cg27506609	chr1:36549197	TEKT2	0.84	4.48	0.42	2.07e-5	Schizophrenia;
THYM	trans	rs4749080	0.573	rs10508712	chr10:26416212	G/A	cg00192819	chr18:76486611	NA	1.0	7.09	0.59	2.41e-10	Obesity-related traits;
THYM	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg07362569	chr17:61921086	SMARCD2	-0.74	-6.58	-0.56	2.6e-9	Prudent dietary pattern;
THYM	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs790123	0.692	rs796892	chr3:122385402	C/T	cg15604389	chr3:122379662	NA	-0.59	-4.86	-0.45	4.62e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs1371867	0.810	rs1692004	chr8:101247320	T/C	cg06636551	chr8:101224915	SPAG1	0.65	5.99	0.52	3.8e-8	Atrioventricular conduction;
THYM	cis	rs4363385	0.530	rs11205181	chr1:153045728	C/T	cg13444842	chr1:152974279	SPRR3	-0.6	-4.66	-0.43	1.03e-5	Inflammatory skin disease;
THYM	cis	rs10781543	0.748	rs68002978	chr9:139325641	C/T	cg14115884	chr9:139300582	SDCCAG3	0.57	4.49	0.42	2.04e-5	Monocyte percentage of white cells;
THYM	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg00376283	chr12:123451042	ABCB9	0.7	4.57	0.42	1.44e-5	Neutrophil percentage of white cells;
THYM	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg23188684	chr11:67383651	NA	-0.59	-4.49	-0.42	2.01e-5	Mean corpuscular volume;
THYM	cis	rs4363385	0.626	rs10888531	chr1:153063406	T/C	cg06563695	chr1:153756334	NA	-0.62	-5.12	-0.46	1.61e-6	Inflammatory skin disease;
THYM	cis	rs28374715	0.681	rs59000092	chr15:41626148	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.17	-14.19	-0.82	3.41e-25	Ulcerative colitis;
THYM	cis	rs7917772	0.582	rs10786695	chr10:104368756	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4986172	0.655	rs1044977	chr17:43227214	T/C	cg24180402	chr17:43221464	ACBD4	0.61	5.02	0.46	2.39e-6	Height;
THYM	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg09323728	chr8:95962352	TP53INP1	-0.45	-4.48	-0.42	2.11e-5	Type 2 diabetes;
THYM	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg22974920	chr21:40686053	BRWD1	0.74	5.03	0.46	2.36e-6	Cognitive function;
THYM	cis	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg06521331	chr12:34319734	NA	-1.04	-10.13	-0.72	8.85e-17	Morning vs. evening chronotype;
THYM	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05901451	chr6:126070800	HEY2	-0.69	-5.78	-0.51	9.39e-8	Brugada syndrome;
THYM	cis	rs7851660	0.839	rs7027221	chr9:100662379	T/C	cg13688889	chr9:100608707	NA	-0.79	-5.71	-0.51	1.28e-7	Strep throat;
THYM	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs10743315	0.778	rs1586843	chr12:19354550	T/C	cg02471346	chr12:19282374	PLEKHA5	-0.81	-5.34	-0.48	6.38e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg04398451	chr17:18023971	MYO15A	-0.83	-8.34	-0.65	5.8e-13	Total body bone mineral density;
THYM	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg27068330	chr11:65405492	SIPA1	-0.66	-4.47	-0.42	2.17e-5	Breast cancer;
THYM	trans	rs629535	0.514	rs55653755	chr8:70154383	A/C	cg21567404	chr3:27674614	NA	-0.88	-7.0	-0.58	3.66e-10	Dupuytren's disease;
THYM	cis	rs4790333	0.967	rs2002863	chr17:2269769	C/T	cg02569219	chr17:2266849	SGSM2	0.71	6.3	0.54	9.19e-9	Proinsulin levels;
THYM	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg02782426	chr3:40428986	ENTPD3	0.53	4.63	0.43	1.15e-5	Renal cell carcinoma;
THYM	cis	rs10484885	0.878	rs17506550	chr6:90508896	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.89	-8.13	-0.64	1.6e-12	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs6815814	0.950	rs55903115	chr4:38786474	C/A	cg02016764	chr4:38805732	TLR1	-0.55	-5.29	-0.48	7.82e-7	Breast cancer;
THYM	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.73	7.09	0.59	2.35e-10	Lymphocyte counts;
THYM	cis	rs4924935	0.798	rs1737940	chr17:18845320	T/G	cg26378065	chr17:18585709	ZNF286B	0.73	5.91	0.52	5.42e-8	Pancreatic cancer;
THYM	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg19678392	chr7:94953810	PON1	0.72	5.55	0.49	2.6e-7	Paraoxonase activity;
THYM	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	5.56	0.5	2.42e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12754538	0.777	rs12040568	chr1:8727944	G/T	cg06159269	chr1:8767347	RERE	0.22	4.56	0.42	1.53e-5	Subjective well-being;
THYM	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg06766960	chr11:133703094	NA	-0.67	-6.41	-0.55	5.5e-9	Childhood ear infection;
THYM	cis	rs9534288	0.797	rs7995256	chr13:46579414	A/T	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg23711669	chr6:146136114	FBXO30	-0.96	-10.01	-0.72	1.54e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg22709100	chr7:91322751	NA	0.6	4.62	0.43	1.23e-5	Breast cancer;
THYM	cis	rs17407555	0.821	rs17198197	chr4:10139157	A/G	cg00071950	chr4:10020882	SLC2A9	0.73	5.96	0.52	4.34e-8	Schizophrenia (age at onset);
THYM	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg17105886	chr17:28927953	LRRC37B2	1.32	6.56	0.56	2.79e-9	Body mass index;
THYM	cis	rs36051895	0.695	rs10124627	chr9:5025746	T/G	cg02405213	chr9:5042618	JAK2	-1.03	-10.37	-0.73	2.67e-17	Pediatric autoimmune diseases;
THYM	cis	rs7582180	0.627	rs4851312	chr2:101011241	G/A	cg21926883	chr2:100939477	LONRF2	-0.67	-6.27	-0.54	1.04e-8	Intelligence (multi-trait analysis);
THYM	cis	rs684232	0.602	rs10521107	chr17:511156	G/A	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.4	-4.8	-0.44	6e-6	Prostate cancer;
THYM	cis	rs11690935	0.788	rs6715929	chr2:172877507	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.68	-4.87	-0.45	4.47e-6	Schizophrenia;
THYM	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg20891283	chr12:69753455	YEATS4	1.06	10.14	0.72	8.47e-17	Blood protein levels;
THYM	cis	rs7127900	0.583	rs11043142	chr11:2234042	A/G	cg25635251	chr11:2234043	NA	0.71	5.42	0.49	4.51e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	trans	rs10802346	0.545	rs6662672	chr1:246387611	A/C	cg22732515	chr19:44031385	ETHE1	1.05	8.69	0.67	1.02e-13	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.55	-0.73	1.12e-17	Primary sclerosing cholangitis;
THYM	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg14582100	chr15:45693742	SPATA5L1	0.62	4.99	0.46	2.71e-6	Homoarginine levels;
THYM	cis	rs6500395	1.000	rs11859909	chr16:48668441	T/C	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg02640540	chr1:67518911	SLC35D1	0.65	4.83	0.44	5.32e-6	Lymphocyte percentage of white cells;
THYM	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg14008862	chr17:28927542	LRRC37B2	0.85	4.6	0.43	1.33e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7633857	0.512	rs7611005	chr3:160698549	A/T	cg03342759	chr3:160939853	NMD3	-0.67	-5.25	-0.47	9.11e-7	Educational attainment (years of education);
THYM	cis	rs901683	0.702	rs74940001	chr10:46144294	G/A	cg18240400	chr10:46168597	ANUBL1	0.68	4.67	0.43	9.88e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg18512352	chr11:47633146	NA	0.51	6.11	0.53	2.21e-8	Subjective well-being;
THYM	cis	rs994014	0.655	rs56075827	chr4:82272037	T/A	cg17825130	chr4:82283507	NA	0.51	4.64	0.43	1.11e-5	Height;
THYM	cis	rs644799	0.582	rs1727149	chr11:95497171	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.71	-6.45	-0.55	4.67e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7582180	0.715	rs7571306	chr2:100906084	G/C	cg14675211	chr2:100938903	LONRF2	0.69	6.3	0.54	9.2e-9	Intelligence (multi-trait analysis);
THYM	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg08048268	chr3:133502702	NA	-0.66	-5.71	-0.51	1.27e-7	Iron status biomarkers;
THYM	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg06808227	chr14:105710500	BRF1	-1.01	-8.64	-0.66	1.31e-13	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11771526	0.579	rs117934886	chr7:32380547	G/T	cg13207630	chr7:32358064	NA	1.02	5.03	0.46	2.31e-6	Body mass index;
THYM	cis	rs2898681	0.561	rs6855240	chr4:53740787	G/A	cg03786743	chr4:53727781	RASL11B	0.55	4.91	0.45	3.79e-6	Optic nerve measurement (cup area);
THYM	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	6.05	0.53	2.89e-8	Obesity-related traits;
THYM	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg17366294	chr4:99064904	C4orf37	0.56	6.57	0.56	2.62e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2625529	0.818	rs2246225	chr15:72115230	C/T	cg16672083	chr15:72433130	SENP8	0.54	4.57	0.42	1.46e-5	Red blood cell count;
THYM	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.1	-0.72	9.93e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg12310025	chr6:25882481	NA	-0.66	-4.59	-0.43	1.36e-5	Height;
THYM	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.81	7.97	0.63	3.44e-12	Lymphocyte counts;
THYM	cis	rs4389656	0.826	rs192443	chr5:6733664	G/T	cg10857441	chr5:6722123	POLS	-0.44	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs72627123	0.867	rs73303113	chr14:74481068	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs12142240	0.698	rs56358525	chr1:46849520	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg13395646	chr4:1353034	KIAA1530	0.59	5.31	0.48	7.33e-7	Obesity-related traits;
THYM	cis	rs2658782	1.000	rs2658778	chr11:93148948	C/G	cg16424440	chr11:93231842	C11orf75	-0.74	-4.69	-0.43	9.19e-6	Pulmonary function decline;
THYM	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.09e-8	Systolic blood pressure;
THYM	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4845875	0.602	rs4846043	chr1:11839966	G/A	cg25341925	chr1:11908058	NPPA	0.42	4.49	0.42	1.99e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg26441486	chr22:50317300	CRELD2	0.47	6.61	0.56	2.26e-9	Schizophrenia;
THYM	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg12011299	chr4:100065546	ADH4	0.94	9.78	0.71	4.9e-16	Alcohol dependence;
THYM	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28595532	0.920	rs55671478	chr4:119753811	A/G	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg24209194	chr3:40518798	ZNF619	0.66	5.3	0.48	7.62e-7	Renal cell carcinoma;
THYM	cis	rs17381785	0.545	rs1494947	chr4:14969983	T/G	cg12377275	chr4:15005593	CPEB2	0.92	7.91	0.63	4.68e-12	Urate levels in overweight individuals;
THYM	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg27286337	chr10:134555280	INPP5A	0.84	5.93	0.52	4.78e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs637571	0.607	rs589253	chr11:65693080	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	6.34	0.55	7.83e-9	Eosinophil percentage of white cells;
THYM	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg06219351	chr7:158114137	PTPRN2	-0.8	-7.16	-0.59	1.7e-10	Response to amphetamines;
THYM	cis	rs8050907	0.661	rs17137056	chr16:4524685	G/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.58	0.43	1.38e-5	Obesity-related traits;
THYM	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg15445000	chr17:37608096	MED1	-0.42	-5.08	-0.46	1.91e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg15247329	chr7:2764246	NA	-0.73	-6.33	-0.54	8.03e-9	Height;
THYM	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg09904177	chr6:26538194	HMGN4	-0.53	-4.57	-0.42	1.47e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7267979	1.000	rs4815424	chr20:25390284	T/C	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs13102973	0.932	rs11099305	chr4:135895569	C/G	cg14419869	chr4:135874104	NA	0.89	8.63	0.66	1.39e-13	Subjective well-being;
THYM	cis	rs1209950	0.966	rs1209948	chr21:40170078	C/T	cg01359822	chr21:40176597	ETS2	0.66	5.29	0.48	7.89e-7	Non-small cell lung cancer (survival);
THYM	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs1401999	0.714	rs1000002	chr3:183635768	A/G	cg01324343	chr3:183735012	ABCC5	-0.62	-8.05	-0.64	2.41e-12	Anterior chamber depth;
THYM	cis	rs17401966	0.931	rs12130563	chr1:10428452	G/A	cg19773385	chr1:10388646	KIF1B	-0.6	-4.7	-0.43	8.88e-6	Hepatocellular carcinoma;
THYM	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg21475434	chr5:93447410	FAM172A	0.96	6.1	0.53	2.29e-8	Diabetic retinopathy;
THYM	cis	rs7851660	0.839	rs2417575	chr9:100628642	G/A	cg13688889	chr9:100608707	NA	-0.79	-5.92	-0.52	5.07e-8	Strep throat;
THYM	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6570726	0.689	rs411785	chr6:145888398	G/A	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg22907277	chr7:1156413	C7orf50	0.83	5.1	0.46	1.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs36051895	0.623	rs7035456	chr9:5261440	G/A	cg02405213	chr9:5042618	JAK2	-0.97	-9.59	-0.7	1.24e-15	Pediatric autoimmune diseases;
THYM	cis	rs3771317	0.887	rs16832798	chr2:191534372	T/C	cg17118478	chr2:191543902	NAB1	-0.59	-4.5	-0.42	1.9e-5	Primary biliary cholangitis;
THYM	cis	rs2039659	0.752	rs1764954	chr13:86253251	G/A	cg25308322	chr13:86268291	NA	0.66	5.51	0.49	3.11e-7	Blood osmolality (transformed sodium);
THYM	cis	rs7084402	0.967	rs1658440	chr10:60323933	T/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg24675658	chr1:53192096	ZYG11B	-0.77	-6.93	-0.58	5.04e-10	Monocyte count;
THYM	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg06636001	chr8:8085503	FLJ10661	0.65	5.59	0.5	2.14e-7	Mood instability;
THYM	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	18.96	0.89	4.77e-34	Chronic sinus infection;
THYM	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9527	0.545	rs10883847	chr10:104958284	C/T	cg04362960	chr10:104952993	NT5C2	0.62	4.74	0.44	7.52e-6	Arsenic metabolism;
THYM	cis	rs2282300	0.739	rs35883696	chr11:30246407	A/C	cg06241208	chr11:30344200	C11orf46	-0.77	-5.59	-0.5	2.15e-7	Morning vs. evening chronotype;
THYM	cis	rs892961	0.932	rs7207891	chr17:75413922	G/C	cg05865280	chr17:75406074	SEPT9	0.48	8.22	0.64	1.06e-12	Airflow obstruction;
THYM	cis	rs308447	0.516	rs13142203	chr4:123679002	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.71	4.79	0.44	6.24e-6	Perceived unattractiveness to mosquitoes;
THYM	cis	rs67460515	0.892	rs6780536	chr3:161058726	T/C	cg03342759	chr3:160939853	NMD3	-0.89	-7.82	-0.63	7.06e-12	Parkinson's disease;
THYM	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14159672	chr1:205819179	PM20D1	-0.78	-7.16	-0.59	1.68e-10	Monocyte percentage of white cells;
THYM	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg01699819	chr7:1052092	C7orf50	-0.51	-4.53	-0.42	1.71e-5	Longevity;Endometriosis;
THYM	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06634786	chr22:41940651	POLR3H	0.82	6.05	0.53	2.85e-8	Vitiligo;
THYM	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg17366294	chr4:99064904	C4orf37	0.47	5.42	0.49	4.42e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs9747201	0.963	rs9747989	chr17:80176092	A/G	cg07393940	chr7:158741817	NA	1.06	8.18	0.64	1.28e-12	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.83	0.82	1.75e-24	Height;
THYM	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06850241	chr22:41845214	NA	-0.6	-5.27	-0.48	8.47e-7	Vitiligo;
THYM	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg26441486	chr22:50317300	CRELD2	0.43	6.57	0.56	2.71e-9	Schizophrenia;
THYM	cis	rs41311933	1.000	rs41311897	chr9:123745816	T/C	cg13567360	chr9:123745713	C5	-1.01	-5.32	-0.48	6.81e-7	Coronary artery disease;
THYM	cis	rs4462272	0.628	rs6584351	chr10:101970997	A/G	cg20925178	chr10:102027628	CWF19L1	0.58	4.54	0.42	1.67e-5	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs1994135	0.669	rs11052746	chr12:33697473	A/C	cg06521331	chr12:34319734	NA	0.66	4.94	0.45	3.29e-6	Resting heart rate;
THYM	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.63	4.61	0.43	1.26e-5	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs7953249	0.656	rs6489786	chr12:121397875	A/G	cg02403541	chr12:121454288	C12orf43	-0.71	-6.38	-0.55	6.44e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs11651000	0.817	rs11657479	chr17:45822901	T/C	cg06532163	chr17:45867833	NA	0.5	4.55	0.42	1.59e-5	IgG glycosylation;
THYM	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg00383909	chr3:49044727	WDR6	1.12	6.66	0.56	1.75e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs7729356	0.761	rs10464048	chr5:107485907	A/G	cg12405754	chr5:107005487	EFNA5	-0.53	-4.69	-0.43	9.3e-6	Educational attainment;
THYM	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg20587970	chr11:113659929	NA	-1.37	-8.96	-0.68	2.79e-14	Hip circumference adjusted for BMI;
THYM	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.81	-6.96	-0.58	4.43e-10	Lung cancer in ever smokers;
THYM	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg04731861	chr2:219085781	ARPC2	-0.56	-5.31	-0.48	7.06e-7	Colorectal cancer;
THYM	cis	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg23557926	chr1:196620963	CFH	0.72	5.24	0.47	9.84e-7	Depressive symptoms;
THYM	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg22467129	chr15:76604101	ETFA	-0.57	-5.41	-0.49	4.76e-7	Blood metabolite levels;
THYM	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs6558530	0.965	rs4372027	chr8:1707958	T/C	cg09410841	chr8:1729607	CLN8	0.75	5.54	0.49	2.74e-7	Systolic blood pressure;
THYM	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg06640241	chr16:89574553	SPG7	0.82	5.47	0.49	3.61e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs778371	0.723	rs12105766	chr2:233617647	A/G	cg08000102	chr2:233561755	GIGYF2	0.89	8.03	0.64	2.55e-12	Schizophrenia;
THYM	cis	rs11771526	0.901	rs7357161	chr7:32302475	A/C	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs7119	0.717	rs11639293	chr15:77810845	T/C	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs2073300	1.000	rs74273799	chr20:23444492	T/C	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs8048589	0.615	rs34598762	chr16:12234958	A/G	cg01990910	chr16:12207648	SNX29	-0.5	-5.68	-0.5	1.46e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg14983838	chr19:29218262	NA	0.96	7.49	0.61	3.57e-11	Methadone dose in opioid dependence;
THYM	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg23035555	chr19:3500370	DOHH	-0.8	-4.65	-0.43	1.09e-5	Total cholesterol levels;
THYM	cis	rs9527	0.830	rs3740392	chr10:104636855	T/C	cg15744005	chr10:104629667	AS3MT	-0.67	-4.96	-0.45	3.03e-6	Arsenic metabolism;
THYM	cis	rs921968	0.565	rs3731876	chr2:219602819	G/A	cg02176678	chr2:219576539	TTLL4	-0.48	-4.73	-0.44	7.94e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7177699	0.534	rs7403708	chr15:79123885	T/C	cg15571903	chr15:79123663	NA	-0.57	-6.35	-0.55	7.46e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	trans	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-12.71	-0.79	3.25e-22	Exhaled nitric oxide output;
THYM	cis	rs4951018	0.526	rs4245718	chr1:205652472	G/A	cg14893161	chr1:205819251	PM20D1	-0.56	-4.47	-0.42	2.14e-5	Prostate-specific antigen levels;
THYM	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg11812906	chr14:75593930	NEK9	0.81	7.19	0.59	1.49e-10	Height;
THYM	cis	rs2279817	1.000	rs2279817	chr1:18021858	T/C	cg21791023	chr1:18019539	ARHGEF10L	-0.8	-4.54	-0.42	1.63e-5	Neuroticism;
THYM	cis	rs240764	0.853	rs1875400	chr6:101020968	T/C	cg21058520	chr6:100914733	NA	0.57	5.02	0.46	2.36e-6	Neuroticism;
THYM	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg22907277	chr7:1156413	C7orf50	0.75	6.24	0.54	1.22e-8	Longevity;Endometriosis;
THYM	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg06558623	chr16:89946397	TCF25	1.39	6.62	0.56	2.11e-9	Skin colour saturation;
THYM	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg06028808	chr11:68637592	NA	0.69	7.13	0.59	1.96e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg14129053	chr2:1895732	MYT1L	1.13	4.49	0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs7731657	0.510	rs2569257	chr5:130245468	A/G	cg08523029	chr5:130500466	HINT1	-0.77	-5.3	-0.48	7.38e-7	Fasting plasma glucose;
THYM	cis	rs981844	0.796	rs17030437	chr4:154704225	A/C	cg09973105	chr4:154681532	RNF175	0.7	6.32	0.54	8.49e-9	Response to statins (LDL cholesterol change);
THYM	cis	rs6429082	0.782	rs704705	chr1:235612320	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.67	-5.06	-0.46	2.05e-6	Adiposity;
THYM	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg14196790	chr5:131705035	SLC22A5	0.55	5.04	0.46	2.21e-6	Blood metabolite levels;
THYM	trans	rs3960554	0.808	rs112962015	chr7:75659303	C/T	cg19862616	chr7:65841803	NCRNA00174	0.95	7.29	0.6	9.36e-11	Eotaxin levels;
THYM	cis	rs7084402	0.934	rs1658428	chr10:60330917	T/C	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg08859206	chr1:53392774	SCP2	0.46	4.81	0.44	5.75e-6	Monocyte count;
THYM	cis	rs8103278	0.864	rs2070737	chr19:46282890	A/T	cg14061069	chr19:46274453	DMPK	-0.57	-5.64	-0.5	1.77e-7	Coronary artery disease;
THYM	cis	rs60843830	0.661	rs11674325	chr2:105517	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.57	4.63	0.43	1.18e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs10779751	1.000	rs4845859	chr1:11304873	A/G	cg08854313	chr1:11322531	MTOR	0.94	8.23	0.65	9.67e-13	Body mass index;
THYM	cis	rs4466137	0.909	rs4466136	chr5:82985576	T/G	cg16102102	chr5:83017553	HAPLN1	-1.06	-9.76	-0.71	5.38e-16	Prostate cancer;
THYM	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg14829155	chr15:31115871	NA	-0.58	-5.13	-0.47	1.51e-6	Huntington's disease progression;
THYM	cis	rs7640424	0.819	rs162070	chr3:107835448	G/A	cg09227934	chr3:107805635	CD47	0.54	4.57	0.42	1.45e-5	Body mass index;
THYM	cis	rs9880211	1.000	rs17364492	chr3:136204437	G/T	cg21827317	chr3:136751795	NA	0.67	4.5	0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg20387954	chr3:183756860	HTR3D	0.54	5.21	0.47	1.09e-6	Anterior chamber depth;
THYM	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg18641463	chr7:2144579	MAD1L1	-0.65	-4.84	-0.44	5.01e-6	Height;
THYM	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg24308560	chr3:49941425	MST1R	-0.75	-6.42	-0.55	5.45e-9	Intelligence (multi-trait analysis);
THYM	cis	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg07460842	chr6:66804631	NA	1.11	8.15	0.64	1.42e-12	Exhaled nitric oxide output;
THYM	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg08847533	chr14:75593920	NEK9	-0.95	-9.92	-0.71	2.4e-16	Height;
THYM	cis	rs6754311	0.552	rs1030765	chr2:136553188	A/T	cg20242066	chr2:136595261	LCT	-0.58	-7.39	-0.6	5.78e-11	Mosquito bite size;
THYM	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg14196790	chr5:131705035	SLC22A5	-0.55	-5.04	-0.46	2.21e-6	Blood metabolite levels;
THYM	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg06221963	chr1:154839813	KCNN3	0.54	5.54	0.49	2.65e-7	Prostate cancer;
THYM	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs9875589	0.509	rs11128679	chr3:14075245	C/T	cg03204825	chr3:13978759	TPRXL	-0.54	-4.67	-0.43	1.01e-5	Ovarian reserve;
THYM	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7208859	0.614	rs216477	chr17:28866744	A/C	cg17105886	chr17:28927953	LRRC37B2	-1.05	-5.51	-0.49	3.04e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg04267008	chr7:1944627	MAD1L1	-0.68	-6.17	-0.54	1.64e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs7586879	0.575	rs6721750	chr2:25128719	A/G	cg15423357	chr2:25149977	NA	0.7	7.76	0.62	9.56e-12	Body mass index;
THYM	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg20607798	chr8:58055168	NA	-0.84	-4.75	-0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7100689	0.560	rs10887891	chr10:82207717	A/C	cg01528321	chr10:82214614	TSPAN14	0.72	5.67	0.5	1.56e-7	Post bronchodilator FEV1;
THYM	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg15536230	chr21:44985092	HSF2BP	-0.39	-4.7	-0.43	8.69e-6	Mean corpuscular volume;
THYM	cis	rs6995541	0.505	rs7010680	chr8:10702103	A/G	cg13457217	chr8:10683266	MIR1322;PINX1	-0.63	-4.61	-0.43	1.23e-5	Triglyceride levels;
THYM	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg03929089	chr4:120376271	NA	-1.05	-9.92	-0.71	2.44e-16	Height;
THYM	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs747334	0.846	rs7897141	chr10:92708621	C/T	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs3917265	0.602	rs997049	chr2:102782433	T/A	cg13315345	chr2:102803985	IL1RL2	0.54	5.32	0.48	6.81e-7	Atopic dermatitis;
THYM	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg17143192	chr8:8559678	CLDN23	0.89	6.45	0.55	4.55e-9	Obesity-related traits;
THYM	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg18305652	chr10:134549665	INPP5A	0.89	8.52	0.66	2.39e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs763014	0.714	rs3743901	chr16:632699	C/G	cg07343612	chr16:622815	PIGQ	-1.1	-11.43	-0.76	1.55e-19	Height;
THYM	cis	rs2574704	0.810	rs11708985	chr3:11651896	G/C	cg07643000	chr3:11666825	VGLL4	0.42	5.04	0.46	2.23e-6	Body mass index;
THYM	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg24578937	chr1:2090814	PRKCZ	0.81	8.54	0.66	2.22e-13	Height;
THYM	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg04772025	chr11:68637568	NA	0.65	6.95	0.58	4.61e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9796	0.689	rs692195	chr15:41444894	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.62	-4.92	-0.45	3.61e-6	Menopause (age at onset);
THYM	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg02734326	chr4:10020555	SLC2A9	-0.56	-4.63	-0.43	1.17e-5	Bone mineral density;
THYM	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg21427119	chr20:30132790	HM13	-0.96	-7.02	-0.58	3.34e-10	Mean corpuscular hemoglobin;
THYM	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	6.08	0.53	2.48e-8	Obesity-related traits;
THYM	cis	rs864643	0.773	rs115422734	chr3:39595927	T/C	cg20142358	chr3:39093977	WDR48	-0.69	-4.79	-0.44	6.04e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs10089	1.000	rs9968597	chr5:127455383	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.02	7.11	0.59	2.11e-10	Ileal carcinoids;
THYM	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg23933602	chr10:16859644	RSU1	0.87	9.12	0.68	1.28e-14	Platelet distribution width;
THYM	cis	rs11087123	0.500	rs439381	chr20:15120037	G/C	cg09937190	chr20:15177509	MACROD2	-0.46	-5.05	-0.46	2.15e-6	Eating disorders;
THYM	cis	rs11785693	0.862	rs17351027	chr8:4987098	A/G	cg26367366	chr8:4980734	NA	-0.98	-5.32	-0.48	6.92e-7	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg15592062	chr6:167189543	RPS6KA2	0.51	5.0	0.46	2.58e-6	Crohn's disease;
THYM	cis	rs6960043	1.000	rs6962498	chr7:15050305	C/G	cg19272540	chr7:15055459	NA	-0.53	-6.25	-0.54	1.15e-8	Type 2 diabetes;
THYM	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg23711669	chr6:146136114	FBXO30	-0.87	-8.4	-0.65	4.38e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1878931	0.580	rs7194596	chr16:3404408	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.96	8.86	0.67	4.43e-14	Body mass index (adult);
THYM	cis	rs9311676	0.632	rs7643057	chr3:58374015	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs6980334	1.000	rs13243992	chr7:137784790	C/T	cg18769353	chr7:137028617	PTN	0.63	5.06	0.46	2.01e-6	Blood metabolite ratios;
THYM	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg13319975	chr6:146136371	FBXO30	-0.66	-5.62	-0.5	1.89e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.46e-7	Heart rate;
THYM	cis	rs2806561	0.765	rs1738468	chr1:23510850	T/G	cg12483005	chr1:23474871	LUZP1	0.59	6.31	0.54	9.03e-9	Height;
THYM	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg00814883	chr7:100076585	TSC22D4	-0.95	-6.39	-0.55	6.08e-9	Platelet count;
THYM	cis	rs7980799	0.682	rs10437795	chr12:33635336	C/G	cg10856724	chr12:34555212	NA	0.62	4.58	0.42	1.43e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs7412746	0.611	rs16827671	chr1:150738759	T/C	cg15448220	chr1:150897856	SETDB1	0.88	7.31	0.6	8.31e-11	Melanoma;
THYM	cis	rs289828	0.538	rs4665170	chr2:152152457	A/G	cg05960677	chr2:152117363	RBM43	0.72	6.75	0.57	1.17e-9	Blood protein levels;
THYM	cis	rs9790314	0.905	rs6441370	chr3:160993754	C/T	cg03342759	chr3:160939853	NMD3	-0.8	-7.08	-0.59	2.52e-10	Morning vs. evening chronotype;
THYM	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg18252515	chr7:66147081	NA	-1.61	-8.73	-0.67	8.74e-14	Diabetic kidney disease;
THYM	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg09034736	chr1:150693464	HORMAD1	0.51	4.49	0.42	1.98e-5	Tonsillectomy;
THYM	cis	rs2073300	1.000	rs6106655	chr20:23441982	C/G	cg12062639	chr20:23401060	NAPB	1.32	6.06	0.53	2.7e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg24308560	chr3:49941425	MST1R	-0.73	-6.26	-0.54	1.12e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg13609457	chr4:120235615	NA	-0.6	-5.37	-0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg17211192	chr8:82754475	SNX16	-0.9	-7.34	-0.6	7.07e-11	Diastolic blood pressure;
THYM	cis	rs9807841	0.517	rs10404348	chr19:10840201	A/G	cg16900796	chr19:10755136	SLC44A2	0.29	4.69	0.43	9.06e-6	Inflammatory skin disease;
THYM	cis	rs56775891	1.000	rs34945223	chr18:77575871	A/G	cg26740109	chr18:77585428	NA	-0.68	-4.77	-0.44	6.61e-6	Schizophrenia;
THYM	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg15693483	chr7:1102177	C7orf50	0.4	5.76	0.51	1.04e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2282300	0.739	rs1222208	chr11:30361377	A/C	cg06241208	chr11:30344200	C11orf46	-0.81	-5.93	-0.52	4.8e-8	Morning vs. evening chronotype;
THYM	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg00686598	chr14:53173677	PSMC6	1.39	7.01	0.58	3.52e-10	Alzheimer's disease (late onset);
THYM	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg19761014	chr17:28927070	LRRC37B2	0.83	4.65	0.43	1.06e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7771547	0.519	rs6928287	chr6:36375438	G/A	cg07856975	chr6:36356162	ETV7	0.65	5.5	0.49	3.13e-7	Platelet distribution width;
THYM	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg12011299	chr4:100065546	ADH4	-0.89	-8.5	-0.66	2.63e-13	Alcohol dependence;
THYM	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg22981736	chr15:31284413	MTMR10	-0.56	-4.54	-0.42	1.66e-5	Huntington's disease progression;
THYM	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg14019146	chr3:50243930	SLC38A3	-0.61	-5.19	-0.47	1.19e-6	Intelligence (multi-trait analysis);
THYM	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg18252515	chr7:66147081	NA	-0.66	-4.85	-0.45	4.8e-6	Aortic root size;
THYM	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg11845111	chr2:191398756	TMEM194B	1.0	7.65	0.62	1.66e-11	Diastolic blood pressure;
THYM	cis	rs2286885	1.000	rs10819171	chr9:129253074	G/A	cg14294646	chr9:129243551	FAM125B	-0.57	-5.32	-0.48	6.84e-7	Intraocular pressure;
THYM	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg11871910	chr12:69753446	YEATS4	1.01	9.83	0.71	3.8e-16	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6835098	0.962	rs4377567	chr4:174083590	C/G	cg08422745	chr4:174089978	GALNT7	1.01	8.75	0.67	7.78e-14	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs858239	0.537	rs6942981	chr7:23231548	C/T	cg09755872	chr7:23245557	NA	-0.52	-4.85	-0.45	4.76e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs3204270	0.639	rs62080213	chr17:79642531	C/T	cg18367735	chr17:79674897	NA	0.8	4.9	0.45	3.92e-6	Dental caries;
THYM	cis	rs2976388	0.967	rs2976393	chr8:143763618	C/G	cg13446199	chr8:143762866	PSCA	0.51	6.42	0.55	5.46e-9	Urinary tract infection frequency;
THYM	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg18252515	chr7:66147081	NA	1.37	8.05	0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs4482178	0.850	rs11617680	chr13:86265518	G/T	cg25308322	chr13:86268291	NA	0.96	5.45	0.49	3.9e-7	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg18512352	chr11:47633146	NA	-0.53	-6.43	-0.55	5.09e-9	Subjective well-being;
THYM	cis	rs7586879	0.575	rs6721750	chr2:25128719	A/G	cg01884057	chr2:25150051	NA	0.73	7.92	0.63	4.47e-12	Body mass index;
THYM	trans	rs11186	0.556	rs56380683	chr2:189964891	A/G	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Body mass index;
THYM	cis	rs1018836	0.884	rs9643307	chr8:91625257	A/C	cg16814680	chr8:91681699	NA	-0.85	-7.17	-0.59	1.59e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg22709100	chr7:91322751	NA	0.71	5.51	0.49	3.09e-7	Breast cancer;
THYM	cis	rs12754538	0.777	rs6675857	chr1:8652154	A/G	cg06159269	chr1:8767347	RERE	0.22	4.58	0.43	1.39e-5	Subjective well-being;
THYM	cis	rs11249608	0.548	rs7704565	chr5:178473923	G/C	cg01312482	chr5:178451176	ZNF879	-0.75	-5.91	-0.52	5.39e-8	Pubertal anthropometrics;
THYM	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg09904177	chr6:26538194	HMGN4	0.64	5.4	0.48	4.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs240764	0.658	rs846803	chr6:101272801	C/T	cg21058520	chr6:100914733	NA	0.61	5.45	0.49	4.02e-7	Neuroticism;
THYM	cis	rs478304	0.651	rs11532071	chr11:65500198	C/A	cg17480646	chr11:65405466	SIPA1	-0.94	-8.85	-0.67	4.72e-14	Acne (severe);
THYM	cis	rs9457247	0.663	rs7749278	chr6:167435325	C/T	cg00271210	chr6:167070053	RPS6KA2	0.54	5.46	0.49	3.82e-7	Crohn's disease;
THYM	cis	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg12000587	chr17:30186630	C17orf79	-0.42	-6.37	-0.55	6.84e-9	Hip circumference adjusted for BMI;
THYM	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg00129232	chr17:37814104	STARD3	0.76	5.25	0.47	9.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg08975724	chr8:8085496	FLJ10661	0.66	5.36	0.48	5.92e-7	Neuroticism;
THYM	cis	rs800586	0.526	rs2737251	chr8:116662108	C/T	cg04656070	chr8:116661063	TRPS1	-0.59	-6.81	-0.57	8.62e-10	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg03806693	chr22:41940476	POLR3H	0.98	8.0	0.63	3.08e-12	Vitiligo;
THYM	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg09260853	chr1:2094483	PRKCZ	-0.5	-4.95	-0.45	3.22e-6	Height;
THYM	cis	rs13064411	0.735	rs9875025	chr3:113147552	T/C	cg18753928	chr3:113234510	CCDC52	-0.86	-7.83	-0.63	6.7e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs7107174	1.000	rs4945267	chr11:78037933	G/A	cg02023728	chr11:77925099	USP35	0.61	5.81	0.51	8.17e-8	Testicular germ cell tumor;
THYM	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg26597838	chr10:835615	NA	1.23	8.88	0.67	4.1e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg16624210	chr5:671434	TPPP	0.76	5.61	0.5	2.03e-7	Obesity-related traits;
THYM	cis	rs295140	1.000	rs55677233	chr2:201168695	T/C	cg04283868	chr2:201171347	SPATS2L	0.74	5.53	0.49	2.81e-7	QT interval;
THYM	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs34638657	0.732	rs11866711	chr16:82201038	A/C	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.25	-0.47	9.14e-7	Lung adenocarcinoma;
THYM	cis	rs1160297	0.609	rs17504530	chr2:53092800	C/G	cg07782112	chr2:53107842	NA	0.72	5.76	0.51	1.02e-7	Hemostatic factors and hematological phenotypes;
THYM	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg14004847	chr7:1930337	MAD1L1	-0.62	-4.84	-0.44	5.04e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs10489202	0.683	rs202253	chr1:167986465	T/G	cg24449463	chr1:168025552	DCAF6	-0.85	-8.32	-0.65	6.35e-13	Schizophrenia;
THYM	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg18876405	chr7:65276391	NA	0.63	5.53	0.49	2.83e-7	Aortic root size;
THYM	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg16031515	chr1:205743344	RAB7L1	-0.72	-7.65	-0.62	1.65e-11	Menarche (age at onset);
THYM	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.67	5.22	0.47	1.06e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2075230	0.642	rs1642811	chr17:7549151	A/C	cg27413385	chr17:7515425	FXR2	-0.36	-5.31	-0.48	7.3e-7	Hormone measurements;
THYM	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg12310025	chr6:25882481	NA	0.69	5.58	0.5	2.3e-7	Blood metabolite levels;
THYM	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg06453172	chr10:134556979	INPP5A	-0.66	-4.77	-0.44	6.78e-6	Migraine;
THYM	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg09021430	chr5:549028	NA	-0.64	-4.84	-0.44	4.98e-6	Obesity-related traits;
THYM	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg20891283	chr12:69753455	YEATS4	0.85	7.17	0.59	1.61e-10	Blood protein levels;
THYM	cis	rs1005224	0.819	rs10147492	chr14:76155309	T/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.71	-5.83	-0.51	7.54e-8	Large artery stroke;
THYM	cis	rs728616	0.867	rs61860400	chr10:81723427	T/C	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7584330	0.740	rs11891348	chr2:238440449	T/G	cg08992911	chr2:238395768	MLPH	0.67	4.66	0.43	1.03e-5	Prostate cancer;
THYM	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg05926586	chr15:74592786	CCDC33	0.56	5.43	0.49	4.31e-7	Airflow obstruction;
THYM	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	4.78	0.44	6.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2976388	0.609	rs2572907	chr8:143801938	G/A	cg13446199	chr8:143762866	PSCA	-0.41	-4.54	-0.42	1.67e-5	Urinary tract infection frequency;
THYM	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg03806693	chr22:41940476	POLR3H	-0.77	-5.81	-0.51	8.2e-8	Neuroticism;
THYM	cis	rs7191439	0.626	rs8059794	chr16:88787388	C/T	cg02389323	chr16:88786976	FAM38A	0.94	5.76	0.51	1.02e-7	Plateletcrit;
THYM	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg09307838	chr4:120376055	NA	0.62	4.73	0.44	7.88e-6	Corneal astigmatism;
THYM	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg27170947	chr2:26402098	FAM59B	0.79	6.27	0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.09e-8	Systolic blood pressure;
THYM	cis	rs7567389	0.719	rs4150499	chr2:128028792	T/C	cg06038358	chr2:128176007	PROC	-0.43	-4.53	-0.42	1.7e-5	Self-rated health;
THYM	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg22655196	chr4:3374909	RGS12	0.63	7.77	0.62	9.02e-12	Serum sulfate level;
THYM	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg18032289	chr17:61959525	GH2	-0.49	-4.76	-0.44	7e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs3741151	0.773	rs73542952	chr11:73108556	A/G	cg17517138	chr11:73019481	ARHGEF17	0.94	5.48	0.49	3.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7404928	0.651	rs12446563	chr16:23939947	C/T	cg26685404	chr16:23957272	PRKCB	0.68	8.04	0.64	2.51e-12	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg05043794	chr9:111880884	C9orf5	-0.43	-6.33	-0.54	8.02e-9	Menarche (age at onset);
THYM	cis	rs9364687	0.639	rs9364692	chr6:163956329	G/A	cg01639524	chr6:163818125	NA	0.49	4.86	0.45	4.57e-6	Body mass index;
THYM	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.12	8.84	0.67	5.07e-14	Cognitive test performance;
THYM	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg02734326	chr4:10020555	SLC2A9	-0.62	-5.04	-0.46	2.21e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs3892630	0.500	rs6510301	chr19:33359791	A/T	cg22928329	chr19:33183273	NUDT19	-0.76	-5.0	-0.46	2.64e-6	Red blood cell traits;
THYM	trans	rs28595532	0.920	rs116668854	chr4:119707642	A/G	cg13773247	chr2:42276988	PKDCC	0.89	6.93	0.58	4.92e-10	Cannabis dependence symptom count;
THYM	cis	rs2562456	0.917	rs2562468	chr19:21714850	G/A	cg21751540	chr19:21541537	ZNF738	0.67	4.66	0.43	1.04e-5	Pain;
THYM	cis	rs9914544	0.933	rs11871889	chr17:18771425	T/C	cg26378065	chr17:18585709	ZNF286B	0.6	4.83	0.44	5.3e-6	Educational attainment (years of education);
THYM	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg05738196	chr6:26577821	NA	0.84	8.3	0.65	6.92e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs12257961	0.549	rs1949435	chr10:15373670	G/T	cg10616319	chr10:15468812	NA	-0.66	-5.35	-0.48	6.08e-7	Selective IgA deficiency;
THYM	cis	rs36051895	0.632	rs12343038	chr9:5178579	A/G	cg02405213	chr9:5042618	JAK2	0.99	11.0	0.75	1.26e-18	Pediatric autoimmune diseases;
THYM	cis	rs35883536	0.647	rs10875315	chr1:101044062	G/A	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg19693284	chr19:2783607	SGTA	0.86	6.36	0.55	6.97e-9	Total cholesterol levels;
THYM	cis	rs4243830	1.000	rs11809957	chr1:6584420	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	1.09	6.24	0.54	1.23e-8	Body mass index;
THYM	cis	rs295140	0.805	rs11890234	chr2:201206706	C/T	cg04283868	chr2:201171347	SPATS2L	0.64	5.36	0.48	5.92e-7	QT interval;
THYM	cis	rs11771526	0.551	rs1008652	chr7:32254403	A/G	cg13207630	chr7:32358064	NA	-0.75	-5.18	-0.47	1.23e-6	Body mass index;
THYM	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1079204	1.000	rs2292549	chr2:219128506	C/T	cg05728596	chr2:219128475	GPBAR1	-1.38	-6.94	-0.58	4.82e-10	Smooth-surface caries;
THYM	cis	rs7100689	0.577	rs9421464	chr10:82043426	C/T	cg09936400	chr10:82049201	MAT1A	0.41	4.52	0.42	1.8e-5	Post bronchodilator FEV1;
THYM	cis	rs922692	0.744	rs4886592	chr15:79082547	T/C	cg22753661	chr15:79092743	ADAMTS7	0.65	4.98	0.45	2.86e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	trans	rs10802346	0.545	rs4607841	chr1:246373295	T/C	cg22732515	chr19:44031385	ETHE1	1.06	8.92	0.68	3.37e-14	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs7731657	0.537	rs6595968	chr5:130284843	G/C	cg08523029	chr5:130500466	HINT1	0.76	5.21	0.47	1.11e-6	Fasting plasma glucose;
THYM	cis	rs7246967	0.673	rs12974988	chr19:22925965	G/T	cg05241461	chr19:22816980	ZNF492	0.59	4.61	0.43	1.26e-5	Bronchopulmonary dysplasia;
THYM	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg03159660	chr11:2078197	NA	-0.64	-4.95	-0.45	3.22e-6	Longevity;
THYM	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg04362960	chr10:104952993	NT5C2	0.57	4.68	0.43	9.61e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6570726	0.935	rs12663211	chr6:145818427	G/A	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3020264	0.525	rs2911991	chr8:6494655	A/G	cg19662554	chr8:6663633	NA	0.44	4.56	0.42	1.53e-5	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);
THYM	cis	rs7100689	0.753	rs2185426	chr10:82120887	G/A	cg01528321	chr10:82214614	TSPAN14	0.97	7.39	0.6	5.79e-11	Post bronchodilator FEV1;
THYM	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.26	-0.47	8.87e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg10856724	chr12:34555212	NA	-0.95	-8.27	-0.65	7.91e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg16989719	chr2:238392110	NA	-0.6	-5.82	-0.51	8.08e-8	Prostate cancer;
THYM	cis	rs7119	0.651	rs8025968	chr15:77839616	C/T	cg10437265	chr15:77819839	NA	0.8	8.02	0.64	2.77e-12	Type 2 diabetes;
THYM	cis	rs6032067	0.641	rs17423416	chr20:43758144	G/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.39	-0.48	5.13e-7	Blood protein levels;
THYM	cis	rs9479482	1.000	rs11754987	chr6:150351204	G/A	cg25797454	chr6:150327115	RAET1K	0.43	4.47	0.42	2.18e-5	Alopecia areata;
THYM	cis	rs921665	0.831	rs11688404	chr2:3188755	C/T	cg16434511	chr2:3151078	NA	-0.79	-5.31	-0.48	7.18e-7	World class endurance athleticism;
THYM	cis	rs7582180	0.790	rs13020451	chr2:100927131	T/G	cg08017756	chr2:100939284	LONRF2	-0.73	-7.51	-0.61	3.21e-11	Intelligence (multi-trait analysis);
THYM	cis	rs11671005	0.735	rs56292587	chr19:58919066	A/T	cg18639983	chr19:58920768	ZNF584	0.59	5.0	0.46	2.63e-6	Mean platelet volume;
THYM	cis	rs800586	0.956	rs1089117	chr8:116805292	T/C	cg04656070	chr8:116661063	TRPS1	0.49	4.7	0.43	8.9e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg12560992	chr17:57184187	TRIM37	0.93	8.64	0.66	1.32e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2637266	0.685	rs2395427	chr10:78462535	G/A	cg18941641	chr10:78392320	NA	0.83	6.79	0.57	9.69e-10	Pulmonary function;
THYM	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg15212455	chr7:39170539	POU6F2	0.64	6.01	0.52	3.44e-8	IgG glycosylation;
THYM	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg20203395	chr5:56204925	C5orf35	-0.67	-4.49	-0.42	1.98e-5	Initial pursuit acceleration;
THYM	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg03526776	chr6:41159608	TREML2	-0.5	-4.56	-0.42	1.51e-5	Alzheimer's disease (late onset);
THYM	cis	rs34375054	0.553	rs12580221	chr12:125621066	T/C	cg25124228	chr12:125621409	AACS	-0.72	-5.71	-0.51	1.27e-7	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs9311676	0.656	rs6800514	chr3:58358717	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs988913	0.957	rs1393774	chr6:54838449	G/C	cg18532076	chr6:54711417	FAM83B	0.52	4.95	0.45	3.25e-6	Menarche (age at onset);
THYM	cis	rs4786125	0.587	rs9938245	chr16:6926744	T/G	cg03623568	chr16:6915990	A2BP1	-1.0	-9.73	-0.71	6.14e-16	Heart rate variability traits (SDNN);
THYM	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg06074448	chr4:187884817	NA	-1.02	-12.88	-0.8	1.45e-22	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28374715	0.532	rs28477406	chr15:41642036	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.21	-13.52	-0.81	7.22e-24	Ulcerative colitis;
THYM	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs12530845	1.000	rs60179239	chr7:135333028	A/G	cg23117316	chr7:135346802	PL-5283	-0.66	-5.88	-0.52	6.21e-8	Red blood cell traits;
THYM	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg03929089	chr4:120376271	NA	-1.03	-12.19	-0.78	3.85e-21	Height;
THYM	cis	rs1335587	0.582	rs3916910	chr13:102108308	A/G	cg13538571	chr13:102108074	ITGBL1	-0.55	-4.5	-0.42	1.91e-5	Obesity-related traits;
THYM	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg10518543	chr12:38710700	ALG10B	-0.57	-4.47	-0.42	2.16e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg24130564	chr14:104152367	KLC1	-0.62	-5.48	-0.49	3.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs56364904	chr4:119742504	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs10911251	0.528	rs4652777	chr1:183091992	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Colorectal cancer;
THYM	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg18132916	chr6:79620363	NA	-0.6	-5.35	-0.48	6.15e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.16	-0.75	5.56e-19	Primary sclerosing cholangitis;
THYM	cis	rs7216064	1.000	rs9897982	chr17:65879592	G/T	cg12091567	chr17:66097778	LOC651250	-0.72	-5.0	-0.46	2.59e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg05738196	chr6:26577821	NA	0.95	9.38	0.69	3.53e-15	Intelligence (multi-trait analysis);
THYM	cis	rs10791323	0.571	rs4937839	chr11:133734177	T/C	cg14349672	chr11:133703707	NA	-0.52	-4.77	-0.44	6.6e-6	Childhood ear infection;
THYM	cis	rs3741151	1.000	rs60924672	chr11:73098724	A/C	cg12959048	chr11:73096162	RELT	-0.53	-5.05	-0.46	2.11e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg12893697	chr11:970389	AP2A2	-0.32	-5.35	-0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs7809950	0.678	rs2395868	chr7:106897500	C/T	cg23024343	chr7:107201750	COG5	0.99	8.39	0.65	4.58e-13	Coronary artery disease;
THYM	cis	rs887829	0.569	rs3806597	chr2:234637569	C/T	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	0.56	4.62	0.43	1.21e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs7968679	1	rs7968679	chr12:9313304	A/G	cg20380214	chr12:9217688	LOC144571	-0.61	-5.78	-0.51	9.33e-8	Myopia;
THYM	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg21784768	chr11:537496	LRRC56	-1.16	-5.78	-0.51	9.66e-8	Body mass index;
THYM	cis	rs9549260	0.755	rs17061450	chr13:41183716	G/A	cg21288729	chr13:41239152	FOXO1	0.66	5.41	0.48	4.8e-7	Red blood cell count;
THYM	cis	rs11997175	0.624	rs4593494	chr8:33692621	C/T	ch.8.33884649F	chr8:33765107	NA	0.73	5.06	0.46	2.01e-6	Body mass index;
THYM	cis	rs7193541	0.695	rs7199490	chr16:74716026	G/A	cg01733217	chr16:74700730	RFWD3	0.7	6.25	0.54	1.17e-8	Multiple myeloma;
THYM	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06634786	chr22:41940651	POLR3H	-0.79	-5.92	-0.52	5e-8	Vitiligo;
THYM	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg13609457	chr4:120235615	NA	-0.62	-5.74	-0.51	1.13e-7	Corneal astigmatism;
THYM	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg23989207	chr17:80870107	TBCD	0.61	5.0	0.46	2.61e-6	Glycated hemoglobin levels;
THYM	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg10018233	chr7:150070692	REPIN1	0.5	7.76	0.62	9.42e-12	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs977987	0.735	rs11149831	chr16:75451461	G/A	cg07303275	chr16:75499416	TMEM170A	0.58	4.54	0.42	1.63e-5	Dupuytren's disease;
THYM	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg19077165	chr18:44547161	KATNAL2	0.56	6.81	0.57	8.89e-10	Personality dimensions;
THYM	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg01264106	chr22:38071602	LGALS1	0.39	4.64	0.43	1.1e-5	Fat distribution (HIV);
THYM	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs600806	0.778	rs2043059	chr1:109991009	C/A	cg02175308	chr1:109941060	SORT1	-0.55	-4.59	-0.43	1.33e-5	Intelligence (multi-trait analysis);
THYM	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4499344	0.730	rs2545357	chr19:33104610	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.61	0.62	2.02e-11	Mean platelet volume;
THYM	cis	rs593982	1.000	rs1941746	chr11:65502413	A/G	cg08755490	chr11:65554678	OVOL1	1.36	8.73	0.67	8.51e-14	Atopic dermatitis;
THYM	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06873352	chr17:61820015	STRADA	0.8	9.88	0.71	2.94e-16	Prudent dietary pattern;
THYM	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg26818010	chr10:134567672	INPP5A	-0.71	-5.62	-0.5	1.87e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg12564285	chr5:131593104	PDLIM4	0.44	4.79	0.44	6.25e-6	Breast cancer;
THYM	cis	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg06521331	chr12:34319734	NA	-0.86	-6.19	-0.54	1.54e-8	Morning vs. evening chronotype;
THYM	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg08772003	chr10:104629869	AS3MT	-0.62	-5.45	-0.49	3.88e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs28595532	0.920	rs115673173	chr4:119755321	C/T	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg13010199	chr12:38710504	ALG10B	0.65	4.65	0.43	1.06e-5	Morning vs. evening chronotype;
THYM	cis	rs6964587	0.610	rs6942852	chr7:91437883	A/C	cg22709100	chr7:91322751	NA	0.63	4.57	0.42	1.44e-5	Breast cancer;
THYM	cis	rs3771570	1.000	rs55634485	chr2:242268994	T/C	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs10782582	0.593	rs74968421	chr1:76233496	T/C	cg03433033	chr1:76189801	ACADM	-0.5	-4.93	-0.45	3.51e-6	Daytime sleep phenotypes;
THYM	cis	rs7084402	1.000	rs6481402	chr10:60268977	T/C	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg25072359	chr17:41440525	NA	0.7	4.92	0.45	3.6e-6	Menopause (age at onset);
THYM	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs2915864	0.904	rs2906071	chr5:141579204	A/G	cg00542992	chr5:141595654	NA	0.62	4.65	0.43	1.06e-5	Facial morphology (factor 20);
THYM	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg00981070	chr1:2046702	PRKCZ	0.48	5.33	0.48	6.68e-7	Height;
THYM	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg20290983	chr6:43655470	MRPS18A	1.44	16.17	0.86	4.93e-29	IgG glycosylation;
THYM	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg18132916	chr6:79620363	NA	-0.59	-5.3	-0.48	7.54e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03264133	chr6:25882463	NA	0.7	5.51	0.49	3.06e-7	Blood metabolite levels;
THYM	cis	rs1298062	0.756	rs2463241	chr19:50996961	C/T	cg11430371	chr19:50961752	MYBPC2	-0.45	-4.51	-0.42	1.85e-5	Age of smoking initiation;
THYM	cis	rs7804356	0.822	rs73061894	chr7:26802085	T/C	cg24979288	chr7:27242424	NA	-0.63	-4.54	-0.42	1.66e-5	Type 1 diabetes;
THYM	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	5.02	0.46	2.44e-6	Height;
THYM	cis	rs988913	0.768	rs9370337	chr6:54750488	C/T	cg19716238	chr6:54711378	FAM83B	0.48	5.24	0.47	9.83e-7	Menarche (age at onset);
THYM	cis	rs7757969	0.500	rs10440852	chr6:112157020	G/C	cg08601457	chr6:112115117	FYN	0.4	4.88	0.45	4.29e-6	Schizophrenia;
THYM	cis	rs9393777	0.588	rs3799380	chr6:26467182	C/T	cg12826209	chr6:26865740	GUSBL1	-1.0	-6.87	-0.58	6.74e-10	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg24257776	chr3:47051546	LOC100129354	0.41	4.78	0.44	6.38e-6	Colorectal cancer;
THYM	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg23803603	chr1:2058230	PRKCZ	0.59	4.56	0.42	1.52e-5	Height;
THYM	cis	rs28374715	0.532	rs28535540	chr15:41659277	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.78	-0.83	2.3e-26	Ulcerative colitis;
THYM	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg02380750	chr20:61661411	NA	0.61	6.16	0.53	1.78e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11122272	0.766	rs2790872	chr1:231540543	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-5.32	-0.48	6.84e-7	Hemoglobin concentration;
THYM	cis	rs919433	0.857	rs36071109	chr2:198183191	C/A	cg00792783	chr2:198669748	PLCL1	-0.66	-4.63	-0.43	1.16e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs763014	0.898	rs35666389	chr16:629458	A/G	cg09263875	chr16:632152	PIGQ	0.73	6.24	0.54	1.22e-8	Height;
THYM	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg06481639	chr22:41940642	POLR3H	-0.64	-4.94	-0.45	3.29e-6	Neuroticism;
THYM	cis	rs4285028	0.747	rs7648343	chr3:121426195	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.78	-5.48	-0.49	3.46e-7	Multiple sclerosis;
THYM	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg26384229	chr12:38710491	ALG10B	0.91	7.46	0.61	4.14e-11	Bladder cancer;
THYM	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg22709100	chr7:91322751	NA	0.62	4.79	0.44	6.11e-6	Breast cancer;
THYM	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6127978	0.702	rs78553081	chr20:55829370	C/T	cg15851418	chr20:55835831	BMP7	0.66	4.64	0.43	1.12e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	trans	rs1974653	0.672	rs9606251	chr22:20092777	C/A	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs8030485	1.000	rs8030485	chr15:79408932	C/T	cg17916960	chr15:79447300	NA	-0.48	-4.95	-0.45	3.26e-6	Left ventricle wall thickness;
THYM	cis	rs2276498	0.751	rs67082409	chr20:52645954	C/T	cg23682609	chr20:52687365	BCAS1	0.56	4.57	0.42	1.45e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs1050631	0.564	rs948416	chr18:33715673	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.32	0.48	6.94e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03647317	chr4:187891568	NA	-0.84	-9.05	-0.68	1.74e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8058578	1.000	rs56656810	chr16:30788759	C/A	cg05768032	chr16:30646687	NA	0.57	5.78	0.51	9.53e-8	Multiple myeloma;
THYM	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg11166453	chr1:247681781	NA	0.59	4.77	0.44	6.54e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs55665837	1.000	rs10832278	chr11:14496619	G/A	cg19336497	chr11:14380999	RRAS2	-0.64	-7.04	-0.59	3e-10	Vitamin D levels;
THYM	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg12573674	chr2:1569213	NA	-1.34	-5.12	-0.46	1.6e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg06028605	chr16:24865363	SLC5A11	0.56	5.26	0.47	8.84e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9810089	0.814	rs1279424	chr3:136007333	A/G	cg21827317	chr3:136751795	NA	0.54	4.47	0.42	2.18e-5	Gestational age at birth (child effect);
THYM	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg20007245	chr22:24372913	LOC391322	-0.7	-6.29	-0.54	9.52e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.61	-4.71	-0.44	8.43e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg01819863	chr10:32635814	EPC1	1.12	6.59	0.56	2.46e-9	Sexual dysfunction (female);
THYM	cis	rs9359856	0.529	rs1328017	chr6:90297603	T/C	cg13799429	chr6:90582589	CASP8AP2	0.88	7.7	0.62	1.28e-11	Bipolar disorder;
THYM	cis	rs612683	0.524	rs11166456	chr1:100925633	C/T	cg06223162	chr1:101003688	GPR88	0.83	7.99	0.63	3.1e-12	Breast cancer;
THYM	cis	rs7731657	0.537	rs11744408	chr5:130360784	T/C	cg08523029	chr5:130500466	HINT1	0.72	4.91	0.45	3.85e-6	Fasting plasma glucose;
THYM	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg11189052	chr15:85197271	WDR73	-0.58	-4.45	-0.42	2.36e-5	P wave terminal force;
THYM	cis	rs1975974	0.574	rs17052370	chr17:21736353	A/G	cg18423549	chr17:21743878	NA	0.65	5.26	0.48	8.81e-7	Psoriasis;
THYM	cis	rs11563648	0.553	rs9791825	chr7:127018596	G/A	cg23081781	chr7:127225937	GCC1	-0.34	-4.64	-0.43	1.14e-5	Resting heart rate;
THYM	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9825379	0.643	rs10513137	chr3:141143430	A/G	cg13411656	chr3:141121016	ZBTB38	0.49	4.54	0.42	1.62e-5	Height;
THYM	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Bladder cancer;
THYM	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs11085466	1.000	rs4399664	chr19:21778026	C/T	cg23026602	chr19:21646605	NA	-0.64	-4.75	-0.44	7.1e-6	Colorectal or endometrial cancer;
THYM	cis	rs9430161	0.579	rs77578010	chr1:11035758	G/A	cg02454025	chr1:11042201	C1orf127	0.95	11.03	0.75	1.06e-18	Ewing sarcoma;
THYM	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.78	5.09	0.46	1.82e-6	Smoking behavior;
THYM	cis	rs7084402	0.967	rs1658458	chr10:60301382	T/C	cg07615347	chr10:60278583	BICC1	0.57	5.36	0.48	5.86e-7	Refractive error;
THYM	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs55871839	0.708	rs4738733	chr8:59813760	T/C	cg07426533	chr8:59803705	TOX	-0.67	-6.88	-0.58	6.33e-10	Pneumonia;
THYM	cis	rs17604090	0.646	rs75322793	chr7:29683176	G/A	cg19413766	chr7:29689036	LOC646762	-0.94	-5.1	-0.46	1.75e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.875	rs6930975	chr6:146387111	C/T	cg23711669	chr6:146136114	FBXO30	0.9	8.82	0.67	5.37e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9906944	0.707	rs8068981	chr17:47122525	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.49	-4.47	-0.42	2.15e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg06026331	chr20:60912101	LAMA5	-0.76	-5.85	-0.51	7.06e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg13390004	chr1:15929781	NA	0.61	4.63	0.43	1.15e-5	Systolic blood pressure;
THYM	cis	rs240764	0.853	rs12374612	chr6:100955752	C/T	cg21058520	chr6:100914733	NA	0.54	4.69	0.43	9.32e-6	Neuroticism;
THYM	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs1994135	0.654	rs1447872	chr12:33718343	C/A	cg10856724	chr12:34555212	NA	-0.74	-5.54	-0.49	2.74e-7	Resting heart rate;
THYM	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg11327659	chr7:150037044	RARRES2	0.45	5.34	0.48	6.32e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs526231	0.575	rs12652973	chr5:102306322	G/A	cg23492399	chr5:102201601	PAM	-0.61	-4.61	-0.43	1.27e-5	Primary biliary cholangitis;
THYM	cis	rs7781977	0.644	rs10269380	chr7:50354512	G/A	cg01139861	chr7:50343298	IKZF1	0.62	5.89	0.52	5.7e-8	IgG glycosylation;
THYM	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg06697600	chr4:7070879	GRPEL1	-0.55	-4.91	-0.45	3.84e-6	Monocyte percentage of white cells;
THYM	cis	rs193541	0.565	rs6865599	chr5:122339787	T/C	cg19808643	chr5:122110361	SNX2	-0.64	-5.39	-0.48	5.15e-7	Glucose homeostasis traits;
THYM	cis	rs870825	0.655	rs67798981	chr4:185619567	A/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg12935359	chr14:103987150	CKB	0.51	6.07	0.53	2.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg05335186	chr13:53173507	NA	-0.4	-5.03	-0.46	2.36e-6	Lewy body disease;
THYM	cis	rs1403694	0.515	rs822362	chr3:186453065	A/C	cg12454167	chr3:186435060	KNG1	0.46	6.12	0.53	2.04e-8	Blood protein levels;
THYM	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg12011299	chr4:100065546	ADH4	0.75	7.3	0.6	8.58e-11	Alcohol dependence;
THYM	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg04317338	chr11:64019027	PLCB3	0.88	6.04	0.53	2.99e-8	Mean platelet volume;
THYM	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg26384229	chr12:38710491	ALG10B	1.02	8.22	0.64	1.05e-12	Bladder cancer;
THYM	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	5.11	0.46	1.7e-6	Motion sickness;
THYM	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg24692254	chr21:30365293	RNF160	1.06	9.92	0.71	2.49e-16	Dental caries;
THYM	cis	rs7772486	0.738	rs75288066	chr6:146319386	C/A	cg13319975	chr6:146136371	FBXO30	-0.64	-5.05	-0.46	2.14e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7216064	0.954	rs8079291	chr17:65887622	A/G	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg02018176	chr4:1364513	KIAA1530	-0.8	-7.57	-0.61	2.41e-11	Obesity-related traits;
THYM	cis	rs9560113	0.959	rs9560108	chr13:112180303	A/C	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs2069036	0.729	rs10795345	chr10:16117310	T/C	cg26633223	chr10:15133461	NA	0.61	4.55	0.42	1.61e-5	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs57994353	0.793	rs35531907	chr9:139327143	C/T	cg14115884	chr9:139300582	SDCCAG3	0.7	4.58	0.43	1.43e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs868036	0.718	rs3784710	chr15:68072458	T/C	cg24579218	chr15:68104479	NA	-0.8	-8.57	-0.66	1.84e-13	Restless legs syndrome;
THYM	cis	rs2637266	1.000	rs2395385	chr10:78341125	G/A	cg18941641	chr10:78392320	NA	0.72	6.33	0.54	8.03e-9	Pulmonary function;
THYM	cis	rs642803	1.000	rs642803	chr11:65560620	C/T	cg17480646	chr11:65405466	SIPA1	0.63	4.65	0.43	1.07e-5	Urate levels;
THYM	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg21475434	chr5:93447410	FAM172A	0.92	5.31	0.48	7.14e-7	Diabetic retinopathy;
THYM	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.54	-0.56	3.07e-9	Personality dimensions;
THYM	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.91	-5.98	-0.52	3.94e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg05335186	chr13:53173507	NA	0.45	5.62	0.5	1.89e-7	Lewy body disease;
THYM	cis	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg05373962	chr22:49881684	NA	-0.64	-6.22	-0.54	1.31e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4891159	0.790	rs72973773	chr18:74115176	T/C	cg24786174	chr18:74118243	ZNF516	-0.87	-9.75	-0.71	5.54e-16	Longevity;
THYM	cis	rs7107174	0.792	rs12291726	chr11:78088210	A/G	cg02023728	chr11:77925099	USP35	0.59	5.64	0.5	1.76e-7	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg24209194	chr3:40518798	ZNF619	-0.74	-6.33	-0.54	7.99e-9	Renal cell carcinoma;
THYM	cis	rs6570726	0.935	rs385134	chr6:145851005	C/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.75	-0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6032067	0.571	rs6017536	chr20:43907369	G/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.65	-5.91	-0.52	5.32e-8	Blood protein levels;
THYM	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg00024416	chr22:24240387	NA	-0.68	-6.98	-0.58	3.99e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg11764359	chr7:65958608	NA	-0.82	-6.65	-0.56	1.85e-9	Aortic root size;
THYM	cis	rs994533	0.855	rs11678088	chr2:218286099	C/T	cg15335768	chr2:218268053	DIRC3	0.34	4.46	0.42	2.25e-5	Height;
THYM	cis	rs921968	0.643	rs2278530	chr2:219501133	G/A	cg02176678	chr2:219576539	TTLL4	0.59	5.62	0.5	1.91e-7	Mean corpuscular hemoglobin concentration;
THYM	trans	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg25214090	chr10:38739885	LOC399744	-0.78	-7.01	-0.58	3.52e-10	Corneal astigmatism;
THYM	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11644478	chr21:40555479	PSMG1	1.02	8.35	0.65	5.48e-13	Cognitive function;
THYM	cis	rs17125944	0.505	rs76219229	chr14:53178346	G/A	cg00686598	chr14:53173677	PSMC6	1.43	7.14	0.59	1.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg11764359	chr7:65958608	NA	0.78	6.09	0.53	2.42e-8	Aortic root size;
THYM	cis	rs11651000	0.857	rs16947078	chr17:45825500	A/G	cg24803719	chr17:45855879	NA	-0.6	-6.03	-0.53	3.18e-8	IgG glycosylation;
THYM	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg03806693	chr22:41940476	POLR3H	-0.77	-5.95	-0.52	4.56e-8	Neuroticism;
THYM	cis	rs988913	0.957	rs6459035	chr6:54757520	A/G	cg19716238	chr6:54711378	FAM83B	0.5	5.04	0.46	2.22e-6	Menarche (age at onset);
THYM	cis	rs57590327	0.555	rs3821551	chr3:81710179	A/T	cg07356753	chr3:81810745	GBE1	-0.83	-5.87	-0.52	6.26e-8	Extraversion;
THYM	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.74	-6.7	-0.57	1.47e-9	Personality dimensions;
THYM	cis	rs4824093	0.610	rs73443923	chr22:50285348	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-4.63	-0.43	1.16e-5	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs17401966	1.000	rs12734551	chr1:10391536	A/C	cg19773385	chr1:10388646	KIF1B	-0.64	-4.77	-0.44	6.6e-6	Hepatocellular carcinoma;
THYM	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg11764359	chr7:65958608	NA	-0.65	-5.05	-0.46	2.15e-6	Aortic root size;
THYM	cis	rs78761021	0.720	rs7221637	chr17:9797209	C/T	cg26853458	chr17:9805074	RCVRN	0.53	4.46	0.42	2.24e-5	Type 2 diabetes;
THYM	cis	rs9470366	0.637	rs4151702	chr6:36645988	G/C	cg11920449	chr6:36645608	CDKN1A	-0.78	-5.53	-0.49	2.81e-7	QRS duration;
THYM	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg06481639	chr22:41940642	POLR3H	0.72	4.68	0.43	9.65e-6	Cannabis dependence symptom count;
THYM	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg19677267	chr1:26645161	CD52;UBXN11	-0.45	-5.89	-0.52	5.87e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg20283391	chr11:68216788	NA	-0.69	-5.14	-0.47	1.49e-6	Total body bone mineral density;
THYM	cis	rs11096990	0.929	rs55976583	chr4:39224491	A/G	cg24403649	chr4:39172243	NA	-0.65	-5.59	-0.5	2.13e-7	Cognitive function;
THYM	cis	rs4273100	0.646	rs1472932	chr17:19220666	C/T	cg25447019	chr17:19030144	GRAPL	0.79	6.24	0.54	1.2e-8	Schizophrenia;
THYM	cis	rs10501293	0.746	rs4755184	chr11:43009790	T/C	cg03447554	chr11:43094025	NA	0.6	4.46	0.42	2.21e-5	Cognitive performance;
THYM	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs5769707	0.681	rs4622843	chr22:50036916	T/G	cg05373962	chr22:49881684	NA	-0.61	-5.68	-0.5	1.5e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4731207	0.535	rs1552120	chr7:124639238	A/G	cg05285228	chr7:124571219	POT1	-0.71	-5.45	-0.49	3.91e-7	Cutaneous malignant melanoma;
THYM	cis	rs6424115	0.830	rs2501425	chr1:24199339	A/C	cg15997130	chr1:24165203	NA	0.74	6.34	0.55	7.54e-9	Immature fraction of reticulocytes;
THYM	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2377058	1.000	rs2377058	chr16:89734831	A/G	cg03605463	chr16:89740564	NA	-0.61	-4.5	-0.42	1.92e-5	Hip circumference adjusted for BMI;
THYM	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg21644426	chr2:191273491	MFSD6	-0.75	-6.15	-0.53	1.85e-8	Pulse pressure;
THYM	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-5.66	-0.5	1.58e-7	Morning vs. evening chronotype;
THYM	cis	rs11186	0.556	rs7424845	chr2:189967466	G/A	cg11041835	chr2:189156425	GULP1	0.8	4.58	0.43	1.41e-5	Parkinson's disease;
THYM	cis	rs790123	0.842	rs2650958	chr3:122396187	A/T	cg17380795	chr3:122379686	NA	0.55	4.95	0.45	3.22e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs2295359	1.000	rs11465753	chr1:67631423	T/C	cg11235152	chr1:67600687	NA	0.57	4.46	0.42	2.21e-5	Psoriasis;
THYM	cis	rs6558530	0.932	rs6558531	chr8:1707566	A/G	cg09410841	chr8:1729607	CLN8	0.67	4.91	0.45	3.85e-6	Systolic blood pressure;
THYM	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg13395646	chr4:1353034	KIAA1530	0.57	5.48	0.49	3.55e-7	Obesity-related traits;
THYM	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg16512390	chr1:228756714	NA	-0.62	-4.92	-0.45	3.66e-6	Chronic lymphocytic leukemia;
THYM	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1021993	0.597	rs1014817	chr1:209523664	G/C	cg24997231	chr1:209527535	NA	-0.59	-5.35	-0.48	6.01e-7	Gut microbiome composition (winter);
THYM	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg14295534	chr9:134004811	NUP214	-0.98	-7.27	-0.6	9.98e-11	Subcortical brain region volumes;
THYM	cis	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.96	0.45	3.04e-6	Obesity-related traits;
THYM	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg26038318	chr20:34205095	SPAG4	0.63	5.16	0.47	1.36e-6	Total cholesterol levels;
THYM	cis	rs2066819	1.000	rs2066819	chr12:56750204	C/T	cg26714650	chr12:56694279	CS	-1.38	-6.84	-0.57	7.68e-10	Psoriasis vulgaris;
THYM	cis	rs7794273	0.821	rs2520343	chr7:18843808	C/A	cg13420273	chr7:18810212	HDAC9	0.6	4.96	0.45	3.1e-6	Night sleep phenotypes;
THYM	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg08999081	chr20:33150536	PIGU	0.57	4.78	0.44	6.41e-6	Coronary artery disease;
THYM	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.97	8.85	0.67	4.71e-14	Body mass index (adult);
THYM	cis	rs1994135	0.647	rs67243558	chr12:33695383	T/C	cg06521331	chr12:34319734	NA	-0.72	-4.99	-0.46	2.68e-6	Resting heart rate;
THYM	cis	rs4654899	1.000	rs72865329	chr1:21517567	G/A	cg01072550	chr1:21505969	NA	-0.71	-6.39	-0.55	6.24e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs12681288	0.550	rs76893867	chr8:962618	G/C	cg08648136	chr8:956695	NA	0.57	5.05	0.46	2.14e-6	Schizophrenia;
THYM	cis	rs131777	0.545	rs140514	chr22:51018579	A/G	cg00983520	chr22:51017067	CPT1B;CHKB-CPT1B	0.33	4.7	0.43	8.72e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg02734326	chr4:10020555	SLC2A9	0.76	7.25	0.6	1.13e-10	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-6.2	-0.54	1.43e-8	Total body bone mineral density;
THYM	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg08968635	chr6:28129556	ZNF389	0.68	5.52	0.49	2.96e-7	Depression;
THYM	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7267979	1.000	rs6083809	chr20:25329309	A/G	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg02503808	chr4:7069936	GRPEL1	-0.84	-5.72	-0.51	1.21e-7	Monocyte percentage of white cells;
THYM	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg03929089	chr4:120376271	NA	-1.01	-13.71	-0.82	3.1e-24	Height;
THYM	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs4940575	0.679	rs17070777	chr18:60833814	A/C	cg08454546	chr15:59731340	FAM81A	1.02	6.91	0.58	5.4e-10	Breast cancer;
THYM	cis	rs1978968	1.000	rs11705221	chr22:18443287	T/C	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs2075230	0.642	rs1613071	chr17:7551229	A/G	cg27413385	chr17:7515425	FXR2	-0.36	-5.31	-0.48	7.3e-7	Hormone measurements;
THYM	cis	rs4919694	0.611	rs77328741	chr10:105066314	T/C	cg04362960	chr10:104952993	NT5C2	0.8	4.49	0.42	2e-5	Arsenic metabolism;
THYM	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2835345	0.630	rs73204236	chr21:37819219	C/T	cg20643029	chr21:37915044	CLDN14	0.59	4.64	0.43	1.12e-5	Pulmonary function;
THYM	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg02725872	chr8:58115012	NA	-1.15	-7.43	-0.61	4.64e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs7560272	0.723	rs4852927	chr2:73641557	C/T	cg19565262	chr2:73869966	NAT8	0.64	5.07	0.46	1.96e-6	Schizophrenia;
THYM	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg08847533	chr14:75593920	NEK9	-0.95	-9.92	-0.71	2.4e-16	Height;
THYM	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.03	10.05	0.72	1.3e-16	Colorectal cancer;
THYM	cis	rs752010	0.756	rs6600380	chr1:42054814	C/T	cg06885757	chr1:42089581	HIVEP3	-0.46	-5.5	-0.49	3.22e-7	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg01751800	chr4:77820391	ANKRD56	0.54	4.53	0.42	1.74e-5	Emphysema distribution in smoking;
THYM	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs4919044	0.599	rs17378057	chr10:94703333	A/G	cg05127821	chr10:94822908	CYP26C1	-1.13	-6.8	-0.57	9.28e-10	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13102973	0.932	rs4130841	chr4:135869673	T/C	cg14419869	chr4:135874104	NA	-0.82	-7.99	-0.63	3.12e-12	Subjective well-being;
THYM	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs11711311	1.000	rs7622403	chr3:113472434	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.63	5.63	0.5	1.83e-7	IgG glycosylation;
THYM	cis	rs2029213	0.523	rs4687715	chr3:53269904	G/A	cg16894138	chr3:53270350	TKT	0.79	7.44	0.61	4.37e-11	Heart rate;
THYM	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg21427119	chr20:30132790	HM13	-0.71	-4.72	-0.44	8.04e-6	Mean corpuscular hemoglobin;
THYM	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.33	9.84	0.71	3.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2836633	0.929	rs2836610	chr21:40044502	C/T	cg12884169	chr21:40033163	ERG	0.7	8.63	0.66	1.38e-13	Coronary artery disease;
THYM	cis	rs13102973	0.640	rs11099303	chr4:135887709	C/A	cg14419869	chr4:135874104	NA	-0.78	-6.5	-0.56	3.64e-9	Subjective well-being;
THYM	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg12031863	chr16:4587854	C16orf5	-0.45	-4.93	-0.45	3.42e-6	Schizophrenia;
THYM	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg14634687	chr17:47094252	IGF2BP1	0.31	4.82	0.44	5.38e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7312774	0.748	rs12308071	chr12:107314539	T/A	cg16260113	chr12:107380972	MTERFD3	0.99	5.71	0.51	1.27e-7	Severe influenza A (H1N1) infection;
THYM	cis	rs1912528	0.752	rs769665	chr4:140867638	G/A	cg11128457	chr4:140864437	MAML3	0.5	5.36	0.48	5.72e-7	Educational attainment (years of education);
THYM	cis	rs4242434	0.672	rs10113779	chr8:22485934	G/C	cg01710189	chr8:22454888	PDLIM2	-0.46	-4.51	-0.42	1.88e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs4595586	0.545	rs7308161	chr12:39363459	A/G	cg26384229	chr12:38710491	ALG10B	0.7	5.39	0.48	5.22e-7	Morning vs. evening chronotype;
THYM	cis	rs9486719	1.000	rs12193732	chr6:96942609	G/A	cg18709589	chr6:96969512	KIAA0776	-0.73	-4.83	-0.44	5.28e-6	Migraine;Coronary artery disease;
THYM	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg18252515	chr7:66147081	NA	-1.55	-8.42	-0.65	3.94e-13	Diabetic kidney disease;
THYM	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg27494647	chr7:150038898	RARRES2	0.44	5.51	0.49	3.09e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs12466960	0.935	rs11901535	chr2:28581826	G/A	cg11535839	chr2:28582676	NA	0.6	4.78	0.44	6.35e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-4.93	-0.45	3.42e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-4.74	-0.44	7.42e-6	Joint mobility (Beighton score);
THYM	cis	rs713587	0.563	rs1529897	chr2:25086827	T/G	cg15423357	chr2:25149977	NA	0.6	5.75	0.51	1.07e-7	Body mass index in non-asthmatics;
THYM	cis	rs6429082	0.818	rs704722	chr1:235669988	G/A	cg26050004	chr1:235667680	B3GALNT2	0.74	5.91	0.52	5.24e-8	Adiposity;
THYM	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg24209194	chr3:40518798	ZNF619	0.67	5.5	0.49	3.17e-7	Renal cell carcinoma;
THYM	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs68190844	1	rs68190844	chr17:4568953	CTA/C	cg19197139	chr17:4613644	ARRB2	-0.84	-5.2	-0.47	1.16e-6	Eosinophil percentage of white cells;
THYM	cis	rs9543976	0.623	rs6562914	chr13:76167537	C/A	cg01531495	chr13:76123901	UCHL3	0.59	4.48	0.42	2.06e-5	Diabetic retinopathy;
THYM	cis	rs6430585	0.536	rs3213892	chr2:136552517	G/A	cg04750100	chr2:136595281	LCT	0.5	4.73	0.44	7.82e-6	Corneal structure;
THYM	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs367615	0.552	rs10042721	chr5:108713970	C/T	cg17395555	chr5:108820864	NA	-0.51	-5.97	-0.52	4.11e-8	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg11235152	chr1:67600687	NA	0.61	5.04	0.46	2.24e-6	Psoriasis;
THYM	cis	rs2354432	0.607	rs57078845	chr1:146722222	G/A	cg25205988	chr1:146714368	CHD1L	-1.07	-5.61	-0.5	2.01e-7	Mitochondrial DNA levels;
THYM	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg12311346	chr5:56204834	C5orf35	0.83	6.09	0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1160297	0.585	rs12713228	chr2:53090032	T/C	cg07782112	chr2:53107842	NA	0.77	6.31	0.54	8.76e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.55	-5.45	-0.49	3.95e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.84	6.93	0.58	5.01e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12137294	0.669	rs1768585	chr1:205239121	C/G	cg17889831	chr1:205181581	DSTYK	-0.4	-4.87	-0.45	4.5e-6	Red cell distribution width;
THYM	cis	rs288326	0.561	rs77535302	chr2:183870045	T/A	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs859767	0.812	rs842355	chr2:135344881	G/C	cg12500956	chr2:135428796	TMEM163	0.54	5.24	0.47	9.82e-7	Neuroticism;
THYM	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg12981288	chr8:11183844	MTMR9	-0.48	-4.59	-0.43	1.35e-5	Retinal vascular caliber;
THYM	cis	rs34638657	0.732	rs12597010	chr16:82199971	G/A	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.25	-0.47	9.14e-7	Lung adenocarcinoma;
THYM	cis	rs55883249	0.957	rs62119393	chr2:9718247	C/T	cg23886495	chr2:9695866	ADAM17	0.84	5.26	0.48	8.74e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs7944735	0.567	rs7946766	chr11:48004369	C/T	cg24672777	chr11:48374446	OR4C45	-0.88	-4.72	-0.44	8.14e-6	Intraocular pressure;
THYM	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg03351412	chr1:154909251	PMVK	-0.71	-5.17	-0.47	1.31e-6	Prostate cancer;
THYM	cis	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg13443165	chr9:33130375	B4GALT1	-0.86	-7.96	-0.63	3.71e-12	IgG glycosylation;
THYM	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.79	-0.44	6.04e-6	Mean corpuscular volume;
THYM	cis	rs4911259	0.513	rs6057665	chr20:31463460	A/G	cg13636640	chr20:31349939	DNMT3B	-0.63	-6.18	-0.54	1.61e-8	Inflammatory bowel disease;
THYM	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg17063962	chr7:91808500	NA	1.14	12.22	0.78	3.42e-21	Breast cancer;
THYM	cis	rs4638749	0.501	rs6715622	chr2:108759372	A/C	cg25838818	chr2:108905173	SULT1C2	-0.5	-4.6	-0.43	1.33e-5	Blood pressure;
THYM	cis	rs2732480	0.500	rs1552550	chr12:48643351	C/A	cg21466736	chr12:48725269	NA	-0.53	-4.93	-0.45	3.44e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg04944784	chr2:26401820	FAM59B	-1.06	-8.49	-0.66	2.77e-13	Gut microbiome composition (summer);
THYM	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg20295408	chr7:1910781	MAD1L1	-0.59	-4.63	-0.43	1.15e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs880496	0.625	rs12145463	chr1:224824529	G/T	cg01808320	chr1:224927238	CNIH3	-0.62	-4.64	-0.43	1.13e-5	Cancer;
THYM	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-5.64	-0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg23422044	chr7:1970798	MAD1L1	-0.79	-5.15	-0.47	1.42e-6	Bipolar disorder;
THYM	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg12165864	chr7:66369176	NA	-0.67	-5.26	-0.47	8.99e-7	Aortic root size;
THYM	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg18252515	chr7:66147081	NA	0.63	4.74	0.44	7.37e-6	Aortic root size;
THYM	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs9682041	0.866	rs6444926	chr3:170133235	T/C	cg11886554	chr3:170076028	SKIL	1.51	5.95	0.52	4.42e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	trans	rs8073060	0.586	rs8077826	chr17:34001139	G/A	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs1003719	0.680	rs2835670	chr21:38581114	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.5	-0.42	1.95e-5	Eye color traits;
THYM	cis	rs7107174	1.000	rs10899478	chr11:78052238	C/T	cg19901956	chr11:77921274	USP35	-0.65	-5.38	-0.48	5.38e-7	Testicular germ cell tumor;
THYM	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg05932139	chr16:680872	WFIKKN1	-0.6	-4.81	-0.44	5.76e-6	Height;
THYM	cis	rs7681440	0.566	rs356187	chr4:90692468	A/G	cg06632027	chr4:90757378	SNCA	0.59	4.61	0.43	1.27e-5	Dementia with Lewy bodies;
THYM	cis	rs2455799	0.613	rs3856830	chr3:15806520	A/C	cg16303742	chr3:15540471	COLQ	-0.56	-5.72	-0.51	1.26e-7	Mean platelet volume;
THYM	cis	rs12519773	1.000	rs4470752	chr5:92460541	C/T	cg18783429	chr5:92414398	NA	0.48	4.54	0.42	1.64e-5	Migraine;
THYM	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg18252515	chr7:66147081	NA	1.48	8.83	0.67	5.15e-14	Diabetic kidney disease;
THYM	cis	rs9913711	1.000	rs9913711	chr17:70098161	C/G	cg06234051	chr17:70120541	SOX9	-0.66	-5.49	-0.49	3.38e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4930776	1.000	rs4930743	chr12:5766807	G/T	cg02086166	chr12:5775618	ANO2	-0.58	-5.71	-0.51	1.3e-7	Plasma clusterin levels;
THYM	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs921968	0.643	rs4674324	chr2:219523433	T/G	cg01872077	chr2:219646372	CYP27A1	0.58	4.49	0.42	2e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs35883536	1.000	rs3904672	chr1:101136651	C/T	cg06223162	chr1:101003688	GPR88	0.68	5.16	0.47	1.36e-6	Monocyte count;
THYM	cis	rs4523957	0.890	rs62069332	chr17:2112720	A/G	cg16513277	chr17:2031491	SMG6	-0.79	-7.76	-0.62	9.62e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	7.29	0.6	9.22e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.29	0.6	9.09e-11	Bladder cancer;
THYM	cis	rs7944004	1.000	rs7944004	chr11:2311152	G/T	cg02056751	chr11:2320647	C11orf21	0.27	5.04	0.46	2.2e-6	Chronic lymphocytic leukemia;
THYM	cis	rs2658782	0.547	rs3020054	chr11:93055556	C/T	cg15737290	chr11:93063684	CCDC67	1.14	11.15	0.75	5.98e-19	Pulmonary function decline;
THYM	cis	rs7760949	0.852	rs9475800	chr6:13932230	A/G	cg11053062	chr6:13924544	RNF182	-0.47	-4.54	-0.42	1.62e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7216064	0.953	rs9890629	chr17:65871559	G/A	cg12091567	chr17:66097778	LOC651250	-0.7	-4.67	-0.43	9.79e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs1448094	0.511	rs4462416	chr12:86150966	T/C	cg02569458	chr12:86230093	RASSF9	-0.62	-5.24	-0.47	9.68e-7	Major depressive disorder;
THYM	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg03929089	chr4:120376271	NA	-0.94	-10.4	-0.73	2.34e-17	Coronary artery disease;
THYM	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg24818145	chr4:99064322	C4orf37	0.87	7.23	0.6	1.19e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg11663144	chr21:46675770	NA	-0.7	-9.8	-0.71	4.38e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs9929218	0.551	rs3785133	chr16:68728611	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.06	12.89	0.8	1.44e-22	Colorectal cancer;
THYM	cis	rs7089973	0.932	rs17794346	chr10:116643095	C/T	cg23260525	chr10:116636907	FAM160B1	-0.57	-5.14	-0.47	1.49e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7119	0.717	rs35284122	chr15:77804568	G/T	cg27398640	chr15:77910606	LINGO1	-0.52	-5.21	-0.47	1.12e-6	Type 2 diabetes;
THYM	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg15704280	chr7:45808275	SEPT13	1.0	11.4	0.76	1.77e-19	Coronary artery disease;
THYM	cis	rs3819817	0.575	rs2043606	chr12:96354777	A/C	cg26410635	chr12:96350720	AMDHD1	0.53	5.02	0.46	2.38e-6	Vitamin D levels;
THYM	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg11301795	chr4:187892539	NA	-1.12	-16.65	-0.86	6.34e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg16928487	chr17:17741425	SREBF1	-0.48	-4.48	-0.42	2.09e-5	Total body bone mineral density;
THYM	cis	rs758324	0.732	rs1983246	chr5:131525881	T/C	cg16205897	chr5:131564050	P4HA2	0.61	5.11	0.46	1.64e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs17407555	0.606	rs59871456	chr4:10014441	G/A	cg13000635	chr4:9523653	NA	0.67	4.56	0.42	1.52e-5	Schizophrenia (age at onset);
THYM	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7426056	0.789	rs4675365	chr2:204605455	A/T	cg13651908	chr2:204570033	CD28	-0.52	-4.53	-0.42	1.73e-5	Primary sclerosing cholangitis;
THYM	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.27	10.84	0.74	2.66e-18	Platelet count;
THYM	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	0.4	4.48	0.42	2.1e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs10208940	0.614	rs35985687	chr2:68723017	G/A	cg09157127	chr2:69201416	GKN1	0.85	4.76	0.44	6.92e-6	Urate levels in lean individuals;
THYM	cis	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs7659604	0.643	rs6839054	chr4:122663628	C/T	cg06713675	chr4:122721982	EXOSC9	-0.54	-4.79	-0.44	6.18e-6	Type 2 diabetes;
THYM	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	6.11	0.53	2.14e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg22307297	chr20:60903441	LAMA5	0.53	4.57	0.42	1.45e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs747334	0.811	rs6583741	chr10:92721142	G/A	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs3741798	1.000	rs61922023	chr12:12485555	G/A	cg08615371	chr12:12503544	MANSC1	0.88	4.89	0.45	4.17e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9534288	0.659	rs2031634	chr13:46661129	G/C	cg15192986	chr13:46630673	CPB2	-0.72	-5.07	-0.46	1.93e-6	Blood protein levels;
THYM	cis	rs10892173	0.566	rs111578166	chr11:117666714	G/T	cg21640587	chr11:117668038	DSCAML1	1.05	9.34	0.69	4.24e-15	Myopia;
THYM	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg06873352	chr17:61820015	STRADA	-0.59	-6.75	-0.57	1.18e-9	Prudent dietary pattern;
THYM	cis	rs2811415	0.561	rs9857061	chr3:127763226	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs2637266	0.756	rs2583063	chr10:78558048	T/C	cg18941641	chr10:78392320	NA	0.72	5.7	0.51	1.32e-7	Pulmonary function;
THYM	cis	rs7666738	0.606	rs3846446	chr4:99099768	C/A	cg10515332	chr4:99064459	C4orf37	0.57	4.54	0.42	1.62e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1994135	0.654	rs1384591	chr12:33734170	T/C	cg06521331	chr12:34319734	NA	-0.67	-4.65	-0.43	1.06e-5	Resting heart rate;
THYM	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg18904891	chr8:8559673	CLDN23	0.68	5.08	0.46	1.89e-6	Obesity-related traits;
THYM	cis	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg13443165	chr9:33130375	B4GALT1	-0.86	-7.96	-0.63	3.71e-12	IgG glycosylation;
THYM	cis	rs9633835	0.594	rs61882109	chr11:13288885	A/C	cg13286116	chr11:13302098	ARNTL	-0.75	-8.79	-0.67	6.29e-14	Body mass index;
THYM	cis	rs72843506	0.656	rs77090106	chr17:19948145	G/A	cg12065943	chr17:19881925	AKAP10	-0.82	-4.5	-0.42	1.95e-5	Schizophrenia;
THYM	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg21028142	chr17:79581711	NPLOC4	0.52	5.13	0.47	1.52e-6	Eye color traits;
THYM	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg20295408	chr7:1910781	MAD1L1	-0.65	-5.21	-0.47	1.12e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg09307838	chr4:120376055	NA	0.66	4.99	0.46	2.76e-6	Corneal astigmatism;
THYM	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13418717	0.793	rs4663054	chr2:127639995	C/T	cg25501666	chr2:127640322	NA	-1.4	-7.5	-0.61	3.29e-11	Heart failure;
THYM	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.7	-5.29	-0.48	7.77e-7	Eosinophil percentage of white cells;
THYM	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg08885076	chr2:99613938	TSGA10	-0.61	-5.79	-0.51	9.26e-8	Chronic sinus infection;
THYM	cis	rs886126	0.585	rs7295764	chr12:111693198	G/A	cg10833066	chr12:111807467	FAM109A	0.44	5.25	0.47	9.44e-7	Coronary heart disease;
THYM	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg09904177	chr6:26538194	HMGN4	0.65	5.1	0.46	1.74e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg25817165	chr18:72167213	CNDP2	-0.99	-7.58	-0.61	2.27e-11	Refractive error;
THYM	cis	rs12282928	0.837	rs7125962	chr11:48245266	G/A	cg22827986	chr11:48284249	OR4X1	-0.51	-5.43	-0.49	4.28e-7	Migraine - clinic-based;
THYM	cis	rs10992471	0.528	rs10820975	chr9:95211922	T/G	cg14631576	chr9:95140430	CENPP	-0.84	-8.02	-0.64	2.69e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg13880726	chr7:1868755	MAD1L1	-0.72	-4.8	-0.44	5.78e-6	Bipolar disorder;
THYM	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg13397359	chr6:42928475	GNMT	0.69	6.42	0.55	5.32e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg11494091	chr17:61959527	GH2	-1.05	-21.47	-0.91	3.23e-38	Prudent dietary pattern;
THYM	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg27129171	chr3:47204927	SETD2	0.71	6.76	0.57	1.1e-9	Colorectal cancer;
THYM	cis	rs7429990	0.965	rs7651237	chr3:48105528	A/G	cg02219026	chr3:48282209	ZNF589	0.69	4.7	0.43	8.77e-6	Educational attainment (years of education);
THYM	cis	rs9486719	0.901	rs13206547	chr6:97006942	T/C	cg18709589	chr6:96969512	KIAA0776	-0.68	-4.71	-0.44	8.44e-6	Migraine;Coronary artery disease;
THYM	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg06627557	chr7:32535165	LSM5;AVL9	0.97	9.37	0.69	3.62e-15	Cognitive ability;
THYM	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg10661904	chr17:79619235	PDE6G	-0.65	-6.24	-0.54	1.19e-8	Eye color traits;
THYM	cis	rs8078723	1.000	rs56922390	chr17:38157021	C/G	cg17467752	chr17:38218738	THRA	0.87	7.22	0.59	1.3e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg26924012	chr15:45694286	SPATA5L1	0.62	4.51	0.42	1.84e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs554111	0.613	rs6699704	chr1:21241432	G/C	cg01072550	chr1:21505969	NA	0.59	5.17	0.47	1.3e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg04944784	chr2:26401820	FAM59B	-1.08	-8.57	-0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs6980334	0.817	rs10228366	chr7:137794905	T/A	cg22979093	chr7:137028410	PTN	0.62	4.95	0.45	3.19e-6	Blood metabolite ratios;
THYM	cis	rs2235573	0.625	rs713991	chr22:38426043	A/G	cg19171272	chr22:38449367	NA	-0.53	-5.54	-0.49	2.67e-7	Glioblastoma;Glioma;
THYM	cis	rs17030434	0.871	rs78151744	chr4:154730266	C/T	cg14289246	chr4:154710475	SFRP2	-0.67	-4.98	-0.45	2.86e-6	Electrocardiographic conduction measures;
THYM	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg22709100	chr7:91322751	NA	-0.59	-4.77	-0.44	6.76e-6	Breast cancer;
THYM	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg23205692	chr1:25664452	TMEM50A	-0.82	-6.11	-0.53	2.2e-8	Erythrocyte sedimentation rate;
THYM	cis	rs6840360	1.000	rs4571	chr4:152592191	T/C	cg22705602	chr4:152727874	NA	-0.61	-6.43	-0.55	5.2e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg09904177	chr6:26538194	HMGN4	0.53	4.5	0.42	1.95e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg05707623	chr12:122985044	ZCCHC8	0.75	5.1	0.46	1.7e-6	Body mass index;
THYM	cis	rs919433	0.889	rs10931782	chr2:198211579	G/A	cg00792783	chr2:198669748	PLCL1	-0.68	-4.85	-0.45	4.84e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg10053473	chr17:62856997	LRRC37A3	0.92	7.34	0.6	7.17e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7089973	0.872	rs7918253	chr10:116614501	T/C	cg23260525	chr10:116636907	FAM160B1	0.51	4.57	0.42	1.49e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg17063962	chr7:91808500	NA	-1.1	-12.47	-0.79	1.01e-21	Breast cancer;
THYM	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg21475434	chr5:93447410	FAM172A	-0.65	-4.47	-0.42	2.16e-5	Diabetic retinopathy;
THYM	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg26597838	chr10:835615	NA	1.33	8.87	0.67	4.23e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs7312774	0.618	rs35435903	chr12:107346572	G/C	cg16260113	chr12:107380972	MTERFD3	1.3	6.63	0.56	2.04e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg08859206	chr1:53392774	SCP2	-0.75	-9.07	-0.68	1.59e-14	Monocyte count;
THYM	cis	rs7084402	0.967	rs1658419	chr10:60332812	A/C	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs5771069	0.787	rs5771192	chr22:50441985	A/C	cg27467552	chr22:50353597	PIM3	-0.46	-4.87	-0.45	4.5e-6	Ulcerative colitis;
THYM	cis	rs9814567	0.752	rs6779326	chr3:134330027	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg03159660	chr11:2078197	NA	0.62	4.62	0.43	1.22e-5	Calcium levels;
THYM	cis	rs4654899	0.714	rs12133972	chr1:21091338	A/T	cg01072550	chr1:21505969	NA	-0.64	-5.53	-0.49	2.79e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg10518543	chr12:38710700	ALG10B	-0.57	-4.54	-0.42	1.67e-5	Morning vs. evening chronotype;
THYM	cis	rs11711311	0.747	rs9882193	chr3:113349451	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.54	4.61	0.43	1.28e-5	IgG glycosylation;
THYM	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg12826209	chr6:26865740	GUSBL1	1.03	6.64	0.56	1.94e-9	Intelligence (multi-trait analysis);
THYM	cis	rs13279522	0.536	rs4262310	chr8:67000607	T/G	cg20171999	chr8:67343066	NA	-0.48	-4.81	-0.44	5.73e-6	Coronary heart disease event reduction (statin therapy interaction);
THYM	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg15247329	chr7:2764246	NA	-0.73	-6.14	-0.53	1.89e-8	Height;
THYM	trans	rs4866334	1.000	rs76533277	chr5:18488162	G/A	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	trans	rs877282	0.838	rs11253374	chr10:774961	C/T	cg22713356	chr15:30763199	NA	1.36	11.55	0.76	8.64e-20	Uric acid levels;
THYM	cis	rs7572263	0.724	rs6705133	chr2:209054422	G/A	cg23998903	chr2:209048830	C2orf80	-0.46	-4.78	-0.44	6.38e-6	Glioma;Non-glioblastoma glioma;
THYM	cis	rs7100689	0.577	rs2342813	chr10:82046302	T/G	cg09936400	chr10:82049201	MAT1A	0.46	5.0	0.46	2.61e-6	Post bronchodilator FEV1;
THYM	cis	rs35934224	0.710	rs73381841	chr22:19850598	A/G	cg11182965	chr22:19864308	TXNRD2	-0.76	-4.67	-0.43	9.79e-6	Glaucoma (primary open-angle);
THYM	cis	rs72781680	1.000	rs72798411	chr2:24184343	A/G	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs9906944	0.742	rs4073893	chr17:47118523	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.49	-4.47	-0.42	2.15e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg02887458	chr19:19495540	GATAD2A	-0.42	-4.86	-0.45	4.69e-6	Bipolar disorder;
THYM	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg15744005	chr10:104629667	AS3MT	-0.86	-8.33	-0.65	6.01e-13	Arsenic metabolism;
THYM	cis	rs2933343	0.700	rs876754	chr3:128627753	T/C	cg11901034	chr3:128598214	ACAD9	-0.68	-5.57	-0.5	2.4e-7	IgG glycosylation;
THYM	cis	rs7719624	0.811	rs17689879	chr5:135393138	C/T	cg15329133	chr5:135467951	SMAD5;SMAD5OS	-0.58	-5.21	-0.47	1.11e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs2050392	1.000	rs2489864	chr10:30693744	C/G	cg02070205	chr10:30722105	MAP3K8	-0.5	-4.45	-0.42	2.31e-5	Inflammatory bowel disease;
THYM	trans	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg18187862	chr3:45730750	SACM1L	-0.88	-7.2	-0.59	1.4e-10	Primary sclerosing cholangitis;
THYM	cis	rs9527	0.590	rs11191572	chr10:104893137	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs7264396	0.676	rs6058380	chr20:34552900	T/G	cg26038318	chr20:34205095	SPAG4	0.59	4.81	0.44	5.6e-6	Total cholesterol levels;
THYM	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg15704280	chr7:45808275	SEPT13	-1.04	-14.07	-0.82	5.85e-25	Height;
THYM	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg22920501	chr2:26401640	FAM59B	0.79	5.34	0.48	6.4e-7	Gut microbiome composition (summer);
THYM	cis	rs12530845	1.000	rs6979391	chr7:135328873	C/T	cg23117316	chr7:135346802	PL-5283	-0.66	-5.88	-0.52	6.21e-8	Red blood cell traits;
THYM	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg05368731	chr17:41323189	NBR1	1.25	11.17	0.75	5.29e-19	Menopause (age at onset);
THYM	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg13010199	chr12:38710504	ALG10B	-0.72	-5.92	-0.52	5.01e-8	Heart rate;
THYM	cis	rs9435341	0.965	rs55909997	chr1:107581039	G/A	cg00944433	chr1:107599041	PRMT6	-0.41	-5.03	-0.46	2.27e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg03517284	chr6:25882590	NA	-0.68	-4.52	-0.42	1.76e-5	Height;
THYM	cis	rs4242434	0.889	rs11783129	chr8:22453426	G/A	cg14690197	chr8:22456421	C8orf58	0.51	4.82	0.44	5.54e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg17063962	chr7:91808500	NA	1.14	11.01	0.75	1.16e-18	Breast cancer;
THYM	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg26384229	chr12:38710491	ALG10B	0.95	7.72	0.62	1.17e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2552220	0.616	rs10503358	chr8:6016142	C/T	cg07710907	chr8:6688074	XKR5	-0.5	-4.47	-0.42	2.2e-5	Interleukin-8 levels;
THYM	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs981844	0.712	rs4538465	chr4:154746763	T/C	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	trans	rs4650994	1.000	rs17276513	chr1:178520604	A/T	cg05059571	chr16:84539110	KIAA1609	0.77	8.29	0.65	7.26e-13	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs73206853	0.614	rs116919748	chr12:110851422	C/T	cg24010859	chr12:110868153	NA	0.63	4.51	0.42	1.88e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
THYM	cis	rs981844	0.740	rs6841173	chr4:154682563	A/G	cg09973105	chr4:154681532	RNF175	0.53	4.8	0.44	5.83e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg13114125	chr14:105738426	BRF1	-0.75	-5.82	-0.51	7.93e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg03433033	chr1:76189801	ACADM	0.77	10.21	0.72	6.01e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs11997175	0.603	rs4291230	chr8:33674570	A/C	ch.8.33884649F	chr8:33765107	NA	-0.69	-4.59	-0.43	1.33e-5	Body mass index;
THYM	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg08847533	chr14:75593920	NEK9	-1.01	-11.33	-0.76	2.42e-19	Height;
THYM	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg27170947	chr2:26402098	FAM59B	0.8	6.37	0.55	6.74e-9	Gut microbiome composition (summer);
THYM	cis	rs36051895	0.632	rs7871515	chr9:5175288	A/G	cg02405213	chr9:5042618	JAK2	0.99	10.66	0.74	6.38e-18	Pediatric autoimmune diseases;
THYM	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg12179176	chr11:130786555	SNX19	0.87	8.18	0.64	1.27e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.41	6.33	0.54	8.15e-9	Obesity-related traits;
THYM	cis	rs728616	0.614	rs10887244	chr10:81717108	G/C	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9443645	0.507	rs9343814	chr6:79473073	C/G	cg04547799	chr6:79944526	HMGN3	-0.68	-5.08	-0.46	1.92e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.14	8.06	0.64	2.2e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg06028808	chr11:68637592	NA	0.7	7.59	0.61	2.22e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg18252515	chr7:66147081	NA	-1.39	-8.16	-0.64	1.37e-12	Diabetic kidney disease;
THYM	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg03476357	chr21:30257390	N6AMT1	-0.61	-4.73	-0.44	7.84e-6	Dental caries;
THYM	cis	rs11577318	0.853	rs7541333	chr1:26622889	C/T	cg19677267	chr1:26645161	CD52;UBXN11	-0.45	-5.91	-0.52	5.42e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs988913	1.000	rs960834	chr6:54823431	C/T	cg04690482	chr6:54711388	FAM83B	0.51	5.55	0.49	2.61e-7	Menarche (age at onset);
THYM	cis	rs2882877	0.648	rs11691332	chr2:190388444	A/C	cg10752008	chr2:190445175	SLC40A1	0.71	5.91	0.52	5.32e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7177699	0.557	rs55870734	chr15:79117917	A/T	cg00540400	chr15:79124168	NA	-0.64	-6.81	-0.57	8.61e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	trans	rs8002861	0.664	rs4941474	chr13:44450289	C/T	cg17145862	chr1:211918768	LPGAT1	0.88	8.09	0.64	1.97e-12	Leprosy;
THYM	cis	rs11645898	0.872	rs72787070	chr16:72151101	T/C	cg14768367	chr16:72042858	DHODH	-0.73	-5.18	-0.47	1.23e-6	Blood protein levels;
THYM	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg12893697	chr11:970389	AP2A2	-0.32	-5.35	-0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs17030434	0.784	rs10032475	chr4:154674748	C/T	cg14289246	chr4:154710475	SFRP2	-0.66	-5.46	-0.49	3.86e-7	Electrocardiographic conduction measures;
THYM	cis	rs9916302	0.706	rs649180	chr17:37464959	A/C	cg07936489	chr17:37558343	FBXL20	0.86	5.49	0.49	3.4e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg06981504	chr1:1234844	ACAP3	0.54	4.94	0.45	3.32e-6	Body mass index;
THYM	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg18252515	chr7:66147081	NA	-0.72	-5.6	-0.5	2.03e-7	Aortic root size;
THYM	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg03690763	chr11:133734501	NA	-0.62	-5.12	-0.46	1.6e-6	Childhood ear infection;
THYM	cis	rs7772486	0.701	rs2244308	chr6:146213706	C/T	cg13319975	chr6:146136371	FBXO30	-0.76	-6.48	-0.55	4.09e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7246657	0.525	rs10410594	chr19:37477758	C/T	cg22634378	chr19:37742834	NA	0.66	4.83	0.44	5.32e-6	Coronary artery calcification;
THYM	cis	rs4243830	0.737	rs56036909	chr1:6608503	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.15	7.49	0.61	3.53e-11	Body mass index;
THYM	cis	rs2639990	0.744	rs640261	chr18:72905808	C/T	cg11568697	chr18:72916393	ZADH2	1.17	5.37	0.48	5.6e-7	Vascular endothelial growth factor levels;
THYM	cis	rs10979	1.000	rs9376763	chr6:143887386	C/T	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg12908607	chr1:44402522	ARTN	0.64	5.37	0.48	5.65e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs7084402	0.967	rs1365741	chr10:60277489	C/T	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg10018233	chr7:150070692	REPIN1	0.38	5.42	0.49	4.46e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4523957	0.583	rs2984942	chr17:2030155	A/G	cg16513277	chr17:2031491	SMG6	-1.03	-10.01	-0.72	1.6e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs728616	0.867	rs4633405	chr10:81927446	G/T	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs17001868	0.568	rs9611315	chr22:40736900	A/T	cg07138101	chr22:40742427	ADSL	0.94	5.71	0.51	1.3e-7	Mammographic density (dense area);
THYM	cis	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg09307838	chr4:120376055	NA	0.68	4.92	0.45	3.57e-6	Corneal astigmatism;
THYM	cis	rs6427356	0.513	rs946578	chr1:157146677	C/G	cg27547283	chr1:156698502	C1orf66;ISG20L2	-0.58	-4.49	-0.42	2.02e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs887829	0.569	rs4294999	chr2:234635467	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.73	-5.98	-0.52	3.99e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg24846343	chr22:24311635	DDTL	0.38	4.6	0.43	1.33e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg23758822	chr17:41437982	NA	1.14	10.17	0.72	7.25e-17	Menopause (age at onset);
THYM	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg10950924	chr17:47092072	IGF2BP1	-0.58	-7.29	-0.6	8.95e-11	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg11812906	chr14:75593930	NEK9	0.87	8.3	0.65	7.13e-13	Height;
THYM	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg23711669	chr6:146136114	FBXO30	0.89	9.19	0.69	8.71e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1978968	0.956	rs12159837	chr22:18447491	G/A	cg01550578	chr22:18484421	MICAL3	0.68	5.16	0.47	1.37e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg23711669	chr6:146136114	FBXO30	0.91	8.94	0.68	3.02e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg02753203	chr1:228287806	NA	0.89	8.68	0.67	1.1e-13	Diastolic blood pressure;
THYM	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg22907277	chr7:1156413	C7orf50	0.78	4.49	0.42	2.01e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7740797	0.875	rs9322480	chr6:155128332	G/C	cg02865717	chr6:155053990	RBM16	-0.47	-4.8	-0.44	5.84e-6	Colorectal or endometrial cancer;
THYM	trans	rs9951602	0.512	rs12454617	chr18:76656007	C/T	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs4243830	0.737	rs4908926	chr1:6617041	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.04	-7.03	-0.59	3.11e-10	Body mass index;
THYM	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg00376283	chr12:123451042	ABCB9	0.7	4.72	0.44	8.27e-6	Neutrophil percentage of white cells;
THYM	cis	rs11030122	0.673	rs10767767	chr11:4003678	C/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.74	-0.44	7.59e-6	Mean platelet volume;Platelet distribution width;
THYM	cis	rs3741151	0.773	rs58564192	chr11:73228904	G/A	cg17517138	chr11:73019481	ARHGEF17	0.9	4.73	0.44	7.74e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7113850	0.541	rs7933381	chr11:24237534	T/C	ch.11.24196551F	chr11:24239977	NA	0.87	4.66	0.43	1.04e-5	Bone fracture in osteoporosis;
THYM	cis	rs7851660	0.967	rs13288000	chr9:100608980	A/G	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs4499344	0.730	rs10413061	chr19:33103278	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.61	0.62	2.02e-11	Mean platelet volume;
THYM	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg06026331	chr20:60912101	LAMA5	0.74	5.76	0.51	1.01e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs2319125	0.683	rs1373074	chr17:64046278	A/G	cg04446870	chr17:64440273	PRKCA	0.5	4.48	0.42	2.12e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg23711669	chr6:146136114	FBXO30	0.93	9.39	0.69	3.29e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3008870	0.755	rs2755242	chr1:67479598	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.79	6.84	0.57	7.8e-10	Lymphocyte percentage of white cells;
THYM	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg02725872	chr8:58115012	NA	-1.12	-7.66	-0.62	1.56e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs2072499	0.932	rs2540183	chr1:156164885	C/G	cg24450063	chr1:156163899	SLC25A44	1.18	14.53	0.83	7.19e-26	Testicular germ cell tumor;
THYM	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg09323728	chr8:95962352	TP53INP1	-0.45	-4.67	-0.43	9.99e-6	Type 2 diabetes;
THYM	cis	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.33e-5	Retinal vascular caliber;
THYM	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg27170947	chr2:26402098	FAM59B	-0.84	-6.46	-0.55	4.42e-9	Gut microbiome composition (summer);
THYM	cis	rs4343996	0.727	rs4722696	chr7:3374580	C/G	cg21248987	chr7:3385318	SDK1	-0.37	-4.47	-0.42	2.14e-5	Motion sickness;
THYM	cis	rs7836436	0.818	rs7818635	chr8:121028061	C/T	cg05020510	chr8:120428057	NOV	1.02	5.63	0.5	1.85e-7	HIV-1 viral setpoint;
THYM	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg01483505	chr11:975446	AP2A2	0.57	4.63	0.43	1.16e-5	Alzheimer's disease (late onset);
THYM	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.11	0.75	7.24e-19	Metabolite levels (small molecules and protein measures);
THYM	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg27432699	chr2:27873401	GPN1	0.76	6.79	0.57	9.45e-10	Oral cavity cancer;
THYM	cis	rs1371867	0.875	rs1788168	chr8:101324960	G/T	cg00191853	chr8:101177733	SPAG1	-0.51	-5.03	-0.46	2.29e-6	Atrioventricular conduction;
THYM	cis	rs12935418	0.616	rs2549859	chr16:81027003	A/G	cg16651780	chr16:81037892	C16orf61	-0.81	-6.17	-0.53	1.69e-8	Mean corpuscular volume;
THYM	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg17211192	chr8:82754475	SNX16	-0.85	-6.85	-0.57	7.41e-10	Diastolic blood pressure;
THYM	cis	rs17125944	0.556	rs11625479	chr14:53354172	A/C	cg00686598	chr14:53173677	PSMC6	-1.01	-4.55	-0.42	1.56e-5	Alzheimer's disease (late onset);
THYM	cis	rs800586	0.796	rs800519	chr8:116806029	A/G	cg04656070	chr8:116661063	TRPS1	0.48	4.95	0.45	3.24e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg06656553	chr16:89960601	TCF25	-0.8	-4.74	-0.44	7.37e-6	Skin colour saturation;
THYM	cis	rs9905704	0.846	rs304267	chr17:56799380	A/G	cg12560992	chr17:57184187	TRIM37	0.64	4.46	0.42	2.28e-5	Testicular germ cell tumor;
THYM	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.52	-5.32	-0.48	6.9e-7	Schizophrenia;
THYM	cis	rs6840360	0.615	rs2120098	chr4:152457180	T/A	cg22705602	chr4:152727874	NA	-0.68	-6.96	-0.58	4.33e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6025261	0.529	rs11699056	chr20:55546323	A/C	cg04763273	chr20:55502381	NA	0.58	4.91	0.45	3.85e-6	Verbal memory performance (delayed recall level);
THYM	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs17744026	0.525	rs17683143	chr11:123714050	T/C	cg00079598	chr11:123676903	OR6M1	-0.5	-4.63	-0.43	1.17e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs7084402	0.967	rs6481404	chr10:60286071	C/G	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg19418458	chr7:158789849	NA	-0.7	-6.08	-0.53	2.54e-8	Facial morphology (factor 20);
THYM	cis	rs75920871	0.528	rs7941428	chr11:116903384	C/G	cg20608306	chr11:116969690	SIK3	-0.54	-6.01	-0.52	3.45e-8	Subjective well-being;
THYM	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg27535305	chr1:53392650	SCP2	-0.58	-6.53	-0.56	3.23e-9	Monocyte count;
THYM	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg13683864	chr3:40499215	RPL14	-1.02	-10.45	-0.73	1.79e-17	Renal cell carcinoma;
THYM	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg06221963	chr1:154839813	KCNN3	-0.77	-9.84	-0.71	3.56e-16	Prostate cancer;
THYM	cis	rs7546094	1.000	rs2932532	chr1:113234456	G/A	cg22162597	chr1:113214053	CAPZA1	-0.47	-4.75	-0.44	7.09e-6	Platelet distribution width;
THYM	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg08999081	chr20:33150536	PIGU	-0.61	-5.13	-0.47	1.51e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11644478	chr21:40555479	PSMG1	1.07	9.23	0.69	7.24e-15	Cognitive function;
THYM	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg17911788	chr17:44343683	NA	0.59	5.86	0.52	6.55e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs3741151	0.656	rs11544311	chr11:73106237	A/C	cg17517138	chr11:73019481	ARHGEF17	0.93	5.39	0.48	5.23e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7246657	0.943	rs10424574	chr19:37838393	A/G	cg22634378	chr19:37742834	NA	0.68	5.67	0.5	1.55e-7	Coronary artery calcification;
THYM	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.75	5.97	0.52	4.1e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6450176	0.638	rs1542167	chr5:53305742	T/G	ch.5.1024479R	chr5:53302184	ARL15	-1.24	-10.28	-0.73	4.11e-17	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs35883536	0.587	rs2809799	chr1:101036516	A/G	cg09408571	chr1:101003634	GPR88	0.5	5.5	0.49	3.16e-7	Monocyte count;
THYM	cis	rs2797160	0.935	rs6940748	chr6:125994080	C/T	cg16306078	chr6:126000798	NA	-0.54	-5.61	-0.5	2.02e-7	Endometrial cancer;
THYM	cis	rs2075230	0.642	rs1641528	chr17:7548320	A/G	cg27413385	chr17:7515425	FXR2	-0.36	-4.96	-0.45	3.04e-6	Hormone measurements;
THYM	cis	rs2292884	0.505	rs11889660	chr2:238438395	C/T	cg14458575	chr2:238380390	NA	1.0	5.68	0.5	1.47e-7	Prostate cancer;
THYM	cis	rs7426056	0.530	rs7426281	chr2:204577559	A/G	cg13651908	chr2:204570033	CD28	-0.7	-5.33	-0.48	6.55e-7	Primary sclerosing cholangitis;
THYM	cis	rs9644630	0.696	rs7828025	chr8:19314693	A/G	cg06562184	chr8:19319451	CSGALNACT1	0.61	5.52	0.49	2.88e-7	Oropharynx cancer;
THYM	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg13319975	chr6:146136371	FBXO30	0.72	6.09	0.53	2.43e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg06656553	chr16:89960601	TCF25	-0.93	-5.27	-0.48	8.6e-7	Skin colour saturation;
THYM	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.51	5.06	0.46	2.07e-6	Schizophrenia;
THYM	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.64	-0.74	7.23e-18	Extrinsic epigenetic age acceleration;
THYM	trans	rs9929218	0.539	rs1125557	chr16:68809599	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.94	9.79	0.71	4.69e-16	Colorectal cancer;
THYM	cis	rs7631605	0.905	rs11716414	chr3:37258835	G/A	cg21328643	chr3:37258149	NA	-0.58	-5.57	-0.5	2.39e-7	Cerebrospinal P-tau181p levels;
THYM	cis	rs11641184	0.528	rs9932684	chr16:11707291	C/T	cg09662852	chr16:11707685	NA	-0.44	-5.0	-0.46	2.61e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs428668	0.681	rs428064	chr5:150696498	G/A	cg11125805	chr5:150678162	SLC36A3	0.47	5.01	0.46	2.54e-6	Skin aging (microtopography measurement);
THYM	cis	rs11190604	0.832	rs2489041	chr10:102333635	G/C	cg07570687	chr10:102243282	WNT8B	0.79	6.11	0.53	2.14e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg14895029	chr7:2775587	GNA12	-0.68	-4.95	-0.45	3.24e-6	Height;
THYM	cis	rs4891159	0.790	rs8098821	chr18:74140345	T/C	cg24786174	chr18:74118243	ZNF516	-0.86	-9.62	-0.7	1.09e-15	Longevity;
THYM	cis	rs3126085	0.735	rs35061954	chr1:152240583	G/T	cg10321714	chr1:152280068	FLG	0.68	5.18	0.47	1.27e-6	Atopic dermatitis;
THYM	cis	rs448720	0.811	rs4776382	chr15:68179651	C/T	cg23793686	chr15:68133972	NA	-0.56	-5.09	-0.46	1.83e-6	Cognitive performance;
THYM	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg06636001	chr8:8085503	FLJ10661	0.63	5.2	0.47	1.14e-6	Parkinson's disease;
THYM	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg11327659	chr7:150037044	RARRES2	0.43	5.27	0.48	8.39e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg03733263	chr8:22462867	KIAA1967	1.16	14.28	0.83	2.24e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.56	4.55	0.42	1.56e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg14018140	chr10:458528	DIP2C	0.58	6.27	0.54	1.04e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs2688608	0.592	rs11000759	chr10:75493726	G/A	cg15838173	chr10:75533400	FUT11	-0.54	-5.36	-0.48	5.84e-7	Inflammatory bowel disease;
THYM	cis	rs4690686	0.538	rs11730551	chr4:177259182	A/G	cg17059388	chr4:177262070	NA	0.45	6.01	0.52	3.49e-8	Essential tremor;
THYM	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs7106204	0.609	rs16912359	chr11:24290818	C/T	ch.11.24196551F	chr11:24239977	NA	0.94	5.87	0.52	6.47e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs2495707	0.532	rs2495709	chr10:102416833	C/T	cg00272971	chr10:102419564	NA	-0.54	-5.77	-0.51	1.01e-7	Body mass index;
THYM	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-5.96	-0.52	4.22e-8	Bipolar disorder;
THYM	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg01191920	chr7:158217561	PTPRN2	-1.06	-12.51	-0.79	8.38e-22	Obesity-related traits;
THYM	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg20587970	chr11:113659929	NA	-1.37	-8.96	-0.68	2.79e-14	Hip circumference adjusted for BMI;
THYM	cis	rs4563143	0.675	rs56407818	chr19:29279379	G/A	cg14983838	chr19:29218262	NA	1.09	8.97	0.68	2.58e-14	Methadone dose in opioid dependence;
THYM	cis	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg03684893	chr10:554711	DIP2C	0.79	6.59	0.56	2.45e-9	Psychosis in Alzheimer's disease;
THYM	cis	rs4363385	0.747	rs4314835	chr1:152984901	C/T	cg13444842	chr1:152974279	SPRR3	-0.58	-4.71	-0.44	8.32e-6	Inflammatory skin disease;
THYM	cis	rs26232	0.551	rs26431	chr5:102365794	G/C	cg23492399	chr5:102201601	PAM	0.65	4.69	0.43	8.99e-6	Rheumatoid arthritis;
THYM	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg14458575	chr2:238380390	NA	0.85	7.02	0.58	3.27e-10	Prostate cancer;
THYM	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.42	4.5	0.42	1.89e-5	Hemoglobin concentration;
THYM	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg15704280	chr7:45808275	SEPT13	-1.05	-9.64	-0.7	9.5e-16	Height;
THYM	cis	rs17407555	0.657	rs16895675	chr4:10272055	A/G	cg00071950	chr4:10020882	SLC2A9	0.53	5.02	0.46	2.43e-6	Schizophrenia (age at onset);
THYM	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg13683864	chr3:40499215	RPL14	0.86	8.64	0.66	1.34e-13	Renal cell carcinoma;
THYM	cis	rs1829883	0.898	rs2688941	chr5:98769659	A/G	cg08333243	chr5:99726346	NA	0.54	5.02	0.46	2.45e-6	Hemostatic factors and hematological phenotypes;
THYM	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg09640425	chr7:158790006	NA	-0.59	-4.88	-0.45	4.22e-6	Facial morphology (factor 20);
THYM	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg24375607	chr4:120327624	NA	0.67	5.3	0.48	7.57e-7	Corneal astigmatism;
THYM	cis	rs300703	0.515	rs300693	chr2:181748	C/A	cg21211680	chr2:198530	NA	-0.86	-5.61	-0.5	1.95e-7	Blood protein levels;
THYM	cis	rs72627123	0.867	rs79250763	chr14:74491121	G/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.14	6.41	0.55	5.69e-9	Morning vs. evening chronotype;
THYM	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg13944838	chr5:179740914	GFPT2	0.86	6.69	0.57	1.55e-9	Height;
THYM	cis	rs8030485	0.571	rs1402760	chr15:79439159	G/A	cg17916960	chr15:79447300	NA	0.55	5.64	0.5	1.74e-7	Left ventricle wall thickness;
THYM	cis	rs919433	0.783	rs805497	chr2:198222548	A/T	cg05783139	chr2:198650985	BOLL	0.58	4.57	0.42	1.44e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs427394	0.802	rs274694	chr5:6734079	A/G	cg10857441	chr5:6722123	POLS	-0.72	-8.87	-0.67	4.28e-14	Menopause (age at onset);
THYM	cis	rs6665290	0.669	rs6426558	chr1:227175367	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.07	-12.1	-0.78	5.96e-21	Myeloid white cell count;
THYM	cis	rs11690935	0.959	rs6722757	chr2:172591963	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.85	-6.26	-0.54	1.09e-8	Schizophrenia;
THYM	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg27631724	chr1:11040367	C1orf127	0.64	5.61	0.5	1.98e-7	Ewing sarcoma;
THYM	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs6723226	0.721	rs10172510	chr2:32620888	A/G	cg02381751	chr2:32503542	YIPF4	0.59	4.95	0.45	3.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs427394	0.664	rs274722	chr5:6718668	C/T	cg10857441	chr5:6722123	POLS	-0.69	-8.08	-0.64	2.05e-12	Menopause (age at onset);
THYM	cis	rs236907	0.859	rs10913684	chr1:171758758	A/G	cg20598894	chr1:171756153	METTL13	-0.74	-5.59	-0.5	2.16e-7	Mean platelet volume;
THYM	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs600806	0.850	rs11102981	chr1:109967323	G/C	cg02175308	chr1:109941060	SORT1	-0.61	-5.38	-0.48	5.35e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7528684	0.872	rs7522061	chr1:157668390	A/G	cg17134153	chr1:157670328	FCRL3	-0.52	-4.72	-0.44	7.97e-6	Insulinoma-associated antigen 2 autoantibody levels in type 1 diabetes;
THYM	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg05234568	chr11:5960015	NA	-0.64	-5.68	-0.5	1.48e-7	DNA methylation (variation);
THYM	cis	rs1978968	0.869	rs5992931	chr22:18455914	G/A	cg01550578	chr22:18484421	MICAL3	0.6	4.62	0.43	1.23e-5	Presence of antiphospholipid antibodies;
THYM	cis	rs6541297	0.941	rs2144299	chr1:230280366	A/G	cg05784532	chr1:230284198	GALNT2	0.79	4.72	0.44	8.12e-6	Coronary artery disease;
THYM	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg07936489	chr17:37558343	FBXL20	0.85	5.64	0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg07131210	chr7:1025825	CYP2W1	-0.85	-4.72	-0.44	8.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs478304	0.718	rs1144789	chr11:65389631	A/G	cg27068330	chr11:65405492	SIPA1	0.87	7.96	0.63	3.6e-12	Acne (severe);
THYM	cis	rs4731207	0.698	rs4731214	chr7:124442905	A/G	cg05285228	chr7:124571219	POT1	0.66	5.22	0.47	1.06e-6	Cutaneous malignant melanoma;
THYM	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg02269571	chr22:50332266	NA	-0.71	-4.5	-0.42	1.94e-5	Schizophrenia;
THYM	cis	rs57994353	0.796	rs3923776	chr9:139331221	G/C	cg14115884	chr9:139300582	SDCCAG3	0.66	4.6	0.43	1.32e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg22764044	chr5:178986830	RUFY1	0.51	5.25	0.47	9.45e-7	Lung cancer;
THYM	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg08773314	chr2:239334832	ASB1	-0.65	-10.04	-0.72	1.38e-16	Multiple system atrophy;
THYM	cis	rs9486719	0.857	rs3798293	chr6:97033370	A/G	cg18709589	chr6:96969512	KIAA0776	-0.64	-4.58	-0.43	1.41e-5	Migraine;Coronary artery disease;
THYM	cis	rs4654899	0.758	rs6698462	chr1:21341293	G/C	cg01072550	chr1:21505969	NA	-0.76	-7.43	-0.61	4.71e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs10504073	0.584	rs10957356	chr8:49980634	G/A	cg00325661	chr8:49890786	NA	1.06	10.54	0.73	1.17e-17	Blood metabolite ratios;
THYM	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg16325326	chr1:53192061	ZYG11B	-0.73	-7.1	-0.59	2.23e-10	Monocyte count;
THYM	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg08847533	chr14:75593920	NEK9	-0.96	-10.29	-0.73	4.02e-17	Height;
THYM	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg22907277	chr7:1156413	C7orf50	0.77	4.48	0.42	2.09e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9302690	1.000	rs16957051	chr16:57468408	C/T	cg27017172	chr16:57497170	POLR2C	-0.82	-4.88	-0.45	4.29e-6	Blood protein levels;
THYM	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.49	4.62	0.43	1.22e-5	Birth weight;
THYM	cis	rs7799006	0.657	rs10447540	chr7:2301484	A/G	cg08027265	chr7:2291960	NA	-0.44	-5.33	-0.48	6.67e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7511006	1.000	rs7364173	chr22:50681029	C/T	cg16294310	chr22:50629110	TRABD	-0.6	-4.55	-0.42	1.56e-5	Obesity-related traits;
THYM	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg03188948	chr7:1209495	NA	0.99	5.67	0.5	1.51e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3820068	0.705	rs4646110	chr1:15817318	A/T	cg05660106	chr1:15850417	CASP9	1.15	10.57	0.74	9.96e-18	Systolic blood pressure;
THYM	cis	rs1055129	0.682	rs7217432	chr17:73834604	A/G	cg12407791	chr17:73824354	UNC13D	-0.43	-4.93	-0.45	3.5e-6	White matter hyperintensity burden;
THYM	cis	rs7267979	0.903	rs6115101	chr20:25229564	C/A	cg08601574	chr20:25228251	PYGB	0.59	4.68	0.43	9.42e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4911259	0.552	rs11700082	chr20:31460244	A/G	cg13636640	chr20:31349939	DNMT3B	-0.61	-5.9	-0.52	5.6e-8	Inflammatory bowel disease;
THYM	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg12963246	chr6:28129442	ZNF389	0.87	7.7	0.62	1.29e-11	Depression;
THYM	cis	rs1467026	0.563	rs58674721	chr3:12811233	G/A	cg11882607	chr3:12858926	CAND2	-0.5	-5.57	-0.5	2.39e-7	P wave duration;
THYM	cis	rs1050846	0.564	rs1050863	chr16:87440895	C/T	cg00512563	chr16:87398040	FBXO31	-0.53	-7.0	-0.58	3.6e-10	Neuroticism;
THYM	cis	rs4478037	1.000	rs4076086	chr3:33161898	C/T	cg19404215	chr3:33155277	CRTAP	1.11	7.21	0.59	1.33e-10	Major depressive disorder;
THYM	cis	rs42648	0.755	rs1557650	chr7:89971556	A/C	cg25739043	chr7:89950458	NA	-0.51	-4.45	-0.42	2.31e-5	Homocysteine levels;
THYM	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg27129171	chr3:47204927	SETD2	0.69	6.63	0.56	2.04e-9	Colorectal cancer;
THYM	cis	rs6430585	0.528	rs586964	chr2:136652491	G/A	cg07169764	chr2:136633963	MCM6	1.06	8.93	0.68	3.17e-14	Corneal structure;
THYM	cis	rs17604090	0.793	rs66956566	chr7:29688702	A/G	cg19413766	chr7:29689036	LOC646762	-0.91	-5.02	-0.46	2.37e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs1975974	0.511	rs112710683	chr17:21741695	C/A	cg18423549	chr17:21743878	NA	-0.66	-5.38	-0.48	5.28e-7	Psoriasis;
THYM	cis	rs7833986	0.501	rs2976012	chr8:56974343	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.4	0.6	5.43e-11	Height;
THYM	cis	rs12681287	0.605	rs2953509	chr8:87343194	C/T	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.2e-16	Bone mineral density;
THYM	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg05973401	chr12:123451056	ABCB9	0.7	4.53	0.42	1.73e-5	Neutrophil percentage of white cells;
THYM	cis	rs35110281	0.601	rs7278282	chr21:44981958	T/G	cg01579765	chr21:45077557	HSF2BP	-0.47	-7.44	-0.61	4.41e-11	Mean corpuscular volume;
THYM	cis	rs422249	0.547	rs102275	chr11:61557803	T/C	cg19610905	chr11:61596333	FADS2	-0.6	-5.13	-0.47	1.51e-6	Trans fatty acid levels;
THYM	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.75e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4595586	0.545	rs7973338	chr12:39380704	T/C	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs13418717	1.000	rs10167924	chr2:127658694	G/A	cg25501666	chr2:127640322	NA	1.61	6.45	0.55	4.76e-9	Heart failure;
THYM	cis	rs12318506	0.623	rs12313311	chr12:75768327	A/T	cg04728562	chr12:75699417	CAPS2	-1.62	-5.72	-0.51	1.24e-7	Coronary artery calcification;
THYM	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg02931644	chr1:25747376	RHCE	0.57	4.52	0.42	1.77e-5	Erythrocyte sedimentation rate;
THYM	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg16797656	chr11:68205561	LRP5	0.46	4.96	0.45	3.09e-6	Total body bone mineral density;
THYM	cis	rs2456568	0.771	rs2102333	chr11:93634749	G/A	cg17595323	chr11:93583763	C11orf90	-0.58	-6.09	-0.53	2.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs763014	0.833	rs3743904	chr16:632767	A/G	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg22764044	chr5:178986830	RUFY1	0.54	5.53	0.49	2.78e-7	Lung cancer;
THYM	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg22920501	chr2:26401640	FAM59B	-0.71	-6.34	-0.55	7.66e-9	Gut microbiome composition (summer);
THYM	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg02734326	chr4:10020555	SLC2A9	-0.64	-5.9	-0.52	5.59e-8	Bone mineral density;
THYM	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg18758796	chr5:131593413	PDLIM4	0.53	4.8	0.44	5.98e-6	Acylcarnitine levels;
THYM	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.72	-4.74	-0.44	7.54e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg14458575	chr2:238380390	NA	1.0	7.86	0.63	5.79e-12	Prostate cancer;
THYM	cis	rs9486719	1.000	rs11152968	chr6:96908653	A/G	cg18709589	chr6:96969512	KIAA0776	0.7	4.72	0.44	8.07e-6	Migraine;Coronary artery disease;
THYM	cis	rs3087591	1.000	rs9902893	chr17:29625638	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.69	-6.04	-0.53	2.94e-8	Hip circumference;
THYM	trans	rs877282	0.945	rs71491303	chr10:772884	G/T	cg22713356	chr15:30763199	NA	1.26	10.12	0.72	9.24e-17	Uric acid levels;
THYM	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg10515332	chr4:99064459	C4orf37	0.67	5.33	0.48	6.48e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs240764	0.579	rs240151	chr6:101067720	A/T	cg21058520	chr6:100914733	NA	-0.58	-4.89	-0.45	4.16e-6	Neuroticism;
THYM	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs1061377	1.000	rs11096982	chr4:39134867	G/C	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg27446573	chr6:127587934	RNF146	0.98	9.21	0.69	8.26e-15	Breast cancer;
THYM	cis	rs892961	0.932	rs67415822	chr17:75412678	A/G	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs6980334	1.000	rs7795946	chr7:137785091	A/G	cg06915773	chr7:137028165	PTN	0.58	4.79	0.44	6.22e-6	Blood metabolite ratios;
THYM	cis	rs295137	0.836	rs10804097	chr2:201104924	A/T	cg03447810	chr2:200324230	SATB2	0.65	5.03	0.46	2.3e-6	Asthma (bronchodilator response);
THYM	cis	rs314370	1.000	rs12705089	chr7:100465355	C/T	cg08558340	chr7:100472263	SRRT	0.61	4.98	0.46	2.82e-6	Resting heart rate;
THYM	cis	rs10895275	0.886	rs2187525	chr11:102049716	C/T	cg24447756	chr11:102105824	NA	-0.51	-4.59	-0.43	1.34e-5	Migraine;
THYM	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs72627123	0.867	rs75773875	chr14:74498053	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg03647317	chr4:187891568	NA	-0.78	-8.33	-0.65	6.18e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11645898	0.683	rs72787038	chr16:72066102	A/C	cg14768367	chr16:72042858	DHODH	-0.65	-4.87	-0.45	4.5e-6	Blood protein levels;
THYM	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-1.0	-9.39	-0.69	3.32e-15	Colorectal cancer;
THYM	cis	rs8028313	0.529	rs380803	chr15:68161273	T/C	cg24579218	chr15:68104479	NA	0.7	6.42	0.55	5.38e-9	Obesity;
THYM	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg04842962	chr6:43655489	MRPS18A	-1.25	-7.29	-0.6	9.11e-11	IgG glycosylation;
THYM	cis	rs2997447	0.846	rs61775428	chr1:26409126	G/C	cg03844060	chr1:26490628	NA	0.67	4.58	0.43	1.4e-5	QRS complex (12-leadsum);
THYM	cis	rs478304	0.627	rs11227254	chr11:65454000	A/G	cg17480646	chr11:65405466	SIPA1	-0.97	-8.99	-0.68	2.44e-14	Acne (severe);
THYM	cis	rs6430585	0.583	rs12472293	chr2:136648077	T/C	cg20242066	chr2:136595261	LCT	0.5	4.72	0.44	8.01e-6	Corneal structure;
THYM	cis	rs6918586	0.658	rs13161	chr6:26114702	C/T	cg03264133	chr6:25882463	NA	0.64	4.94	0.45	3.34e-6	Schizophrenia;
THYM	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg06728252	chr6:26598149	ABT1	-0.43	-5.08	-0.46	1.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg25036284	chr2:26402008	FAM59B	-0.78	-5.19	-0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg14298792	chr15:30685198	CHRFAM7A	0.78	5.67	0.5	1.55e-7	Huntington's disease progression;
THYM	cis	rs76878669	0.561	rs12416747	chr11:66135614	A/G	cg18002602	chr11:66138449	SLC29A2	0.49	4.98	0.45	2.86e-6	Educational attainment (years of education);
THYM	cis	rs7429990	0.965	rs7427418	chr3:48022707	T/C	cg02219026	chr3:48282209	ZNF589	0.6	4.5	0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs7000551	0.671	rs7837700	chr8:22289093	T/C	cg12081754	chr8:22256438	SLC39A14	1.03	8.83	0.67	5.27e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg16989719	chr2:238392110	NA	-0.65	-5.95	-0.52	4.44e-8	Prostate cancer;
THYM	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg11502198	chr6:26597334	ABT1	0.65	5.82	0.51	7.88e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/A	cg13327734	chr17:4634568	MED11	-0.98	-5.0	-0.46	2.59e-6	Type 2 diabetes;
THYM	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.41	0.6	5.28e-11	Obesity-related traits;
THYM	cis	rs3771570	1.000	rs7557535	chr2:242206555	T/C	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs1692120	0.545	rs7930946	chr11:61407838	C/A	cg19838087	chr11:61442541	NA	0.52	5.91	0.52	5.42e-8	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
THYM	cis	rs2742417	0.603	rs1962800	chr3:45779943	C/T	cg04837898	chr3:45731254	SACM1L	-0.82	-5.49	-0.49	3.32e-7	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg13114125	chr14:105738426	BRF1	-0.76	-6.05	-0.53	2.84e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9326248	0.581	rs7121898	chr11:116796846	A/T	cg01368799	chr11:117014884	PAFAH1B2	0.67	5.37	0.48	5.46e-7	Blood protein levels;
THYM	cis	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg06521331	chr12:34319734	NA	0.76	5.88	0.52	6.13e-8	Morning vs. evening chronotype;
THYM	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg06238570	chr21:40685208	BRWD1	0.96	8.95	0.68	2.83e-14	Cognitive function;
THYM	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg24060327	chr5:131705240	SLC22A5	-0.66	-4.84	-0.44	4.98e-6	Blood metabolite levels;
THYM	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3126085	1.000	rs12567463	chr1:152180128	T/A	cg10321714	chr1:152280068	FLG	-0.69	-4.93	-0.45	3.52e-6	Atopic dermatitis;
THYM	cis	rs2219968	0.504	rs7007379	chr8:78907855	T/A	cg00738934	chr8:78996279	NA	0.62	5.03	0.46	2.36e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2281845	0.859	rs4915217	chr1:201077470	T/A	cg22815214	chr1:201083145	CACNA1S	0.72	6.82	0.57	8.32e-10	Permanent tooth development;
THYM	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg02038168	chr22:39784481	NA	-0.71	-5.19	-0.47	1.17e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	trans	rs6089829	0.888	rs4809467	chr20:61671688	A/G	cg13615516	chr5:77269221	NA	0.83	7.27	0.6	9.91e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7567851	0.623	rs334070	chr2:179008396	T/G	cg17320194	chr2:178042734	NA	-0.89	-4.78	-0.44	6.32e-6	Height;
THYM	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg08000102	chr2:233561755	GIGYF2	-0.68	-6.11	-0.53	2.16e-8	Coronary artery disease;
THYM	cis	rs6867032	1.000	rs4254943	chr5:2009878	C/T	cg26168224	chr5:2018326	NA	1.21	13.81	0.82	1.96e-24	Gut microbiome composition (winter);
THYM	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4654899	1.000	rs6659152	chr1:21355841	C/G	cg01072550	chr1:21505969	NA	-0.72	-6.54	-0.56	3.04e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs314370	0.951	rs6706	chr7:100471044	C/T	cg10426581	chr7:100472382	SRRT	1.13	8.97	0.68	2.57e-14	Resting heart rate;
THYM	cis	rs72781680	0.752	rs56152044	chr2:23927680	A/G	cg08917208	chr2:24149416	ATAD2B	1.14	5.03	0.46	2.32e-6	Lymphocyte counts;
THYM	cis	rs7634476	1	rs7634476	chr3:136398387	A/G	cg21827317	chr3:136751795	NA	-0.57	-4.87	-0.45	4.42e-6	Neuroticism;
THYM	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.09	0.64	1.96e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6980334	0.551	rs2035647	chr7:137799569	A/G	cg06915773	chr7:137028165	PTN	0.62	4.95	0.45	3.26e-6	Blood metabolite ratios;
THYM	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg12311346	chr5:56204834	C5orf35	-0.97	-7.33	-0.6	7.71e-11	Initial pursuit acceleration;
THYM	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg21280719	chr6:42927975	GNMT	-0.53	-7.38	-0.6	5.9e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs28595532	0.920	rs114963870	chr4:119758099	T/C	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg23281280	chr6:28129359	ZNF389	0.61	4.94	0.45	3.3e-6	Depression;
THYM	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs4787491	0.679	rs12933575	chr16:30022564	A/G	cg06015834	chr16:30021696	DOC2A	-0.5	-4.46	-0.42	2.27e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg18876405	chr7:65276391	NA	0.59	4.92	0.45	3.67e-6	Aortic root size;
THYM	cis	rs7940866	0.874	rs1433979	chr11:130871617	G/A	cg23692386	chr11:131799662	NTM	0.43	4.69	0.43	9.27e-6	Schizophrenia;
THYM	cis	rs7584330	0.554	rs880931	chr2:238396741	G/A	cg14458575	chr2:238380390	NA	0.88	4.54	0.42	1.68e-5	Prostate cancer;
THYM	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg02527881	chr3:46936655	PTH1R	-0.69	-7.11	-0.59	2.11e-10	Colorectal cancer;
THYM	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.76	0.44	7.04e-6	Bipolar disorder;
THYM	cis	rs11711311	1.000	rs9865435	chr3:113450046	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.27	-0.48	8.41e-7	IgG glycosylation;
THYM	cis	rs950880	0.710	rs2080289	chr2:102995020	G/A	cg03938978	chr2:103052716	IL18RAP	-0.5	-4.46	-0.42	2.24e-5	Serum protein levels (sST2);
THYM	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg06108461	chr20:60628389	TAF4	-1.1	-9.46	-0.7	2.37e-15	Body mass index;
THYM	cis	rs7590720	0.788	rs4674050	chr2:216907322	G/T	cg12620499	chr2:216877984	MREG	0.84	6.24	0.54	1.21e-8	Alcohol dependence;
THYM	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.24	-5.14	-0.47	1.45e-6	Obesity-related traits;
THYM	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2041895	0.509	rs7970139	chr12:107312430	T/C	cg13944111	chr12:107296891	NA	0.63	5.02	0.46	2.42e-6	Glaucoma (low intraocular pressure);
THYM	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg20007245	chr22:24372913	LOC391322	-0.75	-7.0	-0.58	3.57e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs2237457	0.525	rs2529427	chr7:50704994	A/G	cg08586669	chr7:50727761	GRB10	0.31	5.17	0.47	1.29e-6	Schizophrenia (treatment resistant);
THYM	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg16778714	chr17:28903809	LRRC37B2	-0.68	-4.58	-0.43	1.42e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	5.92	0.52	5.15e-8	Total body bone mineral density;
THYM	cis	rs4631830	0.900	rs4630241	chr10:51532751	G/A	cg16070123	chr10:51489643	NA	-0.53	-4.79	-0.44	6.07e-6	Prostate-specific antigen levels;
THYM	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg06108461	chr20:60628389	TAF4	-0.85	-7.2	-0.59	1.41e-10	Body mass index;
THYM	cis	rs7107174	1.000	rs2511177	chr11:77922960	C/T	cg19901956	chr11:77921274	USP35	-0.69	-5.53	-0.49	2.84e-7	Testicular germ cell tumor;
THYM	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.99	12.2	0.78	3.73e-21	Chronic sinus infection;
THYM	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg22920501	chr2:26401640	FAM59B	-1.05	-8.59	-0.66	1.72e-13	Gut microbiome composition (summer);
THYM	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg06917634	chr15:78832804	PSMA4	-0.96	-8.89	-0.67	3.96e-14	Sudden cardiac arrest;
THYM	trans	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg25517755	chr10:38738941	LOC399744	-0.8	-7.87	-0.63	5.58e-12	Educational attainment;
THYM	cis	rs34638657	0.518	rs4889467	chr16:82169385	C/T	cg07307142	chr16:82071433	HSD17B2	-0.84	-6.7	-0.57	1.5e-9	Lung adenocarcinoma;
THYM	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg14159672	chr1:205819179	PM20D1	-0.73	-5.77	-0.51	9.83e-8	Menarche (age at onset);
THYM	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.88	5.74	0.51	1.15e-7	Smoking behavior;
THYM	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg27490568	chr2:178487706	NA	0.61	5.53	0.49	2.76e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg26354017	chr1:205819088	PM20D1	0.98	10.26	0.72	4.68e-17	Menarche (age at onset);
THYM	cis	rs67311347	0.544	rs9821440	chr3:40342347	T/C	cg24209194	chr3:40518798	ZNF619	0.55	4.6	0.43	1.3e-5	Renal cell carcinoma;
THYM	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.05	-0.82	6.23e-25	Height;
THYM	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg11266682	chr4:10021025	SLC2A9	0.73	12.02	0.78	8.71e-21	Bone mineral density;
THYM	cis	rs2219968	0.961	rs1121551	chr8:78958512	A/G	cg00738934	chr8:78996279	NA	0.84	8.81	0.67	5.75e-14	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs11722228	0.522	rs2241468	chr4:10113905	G/A	cg26043149	chr18:55253948	FECH	1.16	10.82	0.74	2.98e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs11089937	0.616	rs1076851	chr22:22531828	A/G	cg06866756	chr22:22471216	NA	-0.43	-4.66	-0.43	1.02e-5	Periodontitis (PAL4Q3);
THYM	cis	rs6918586	0.658	rs198843	chr6:26110314	A/T	cg12310025	chr6:25882481	NA	0.68	5.49	0.49	3.36e-7	Schizophrenia;
THYM	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-4.93	-0.45	3.51e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10924970	0.967	rs1933251	chr1:235451172	G/T	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs478304	0.903	rs495961	chr11:65540886	C/T	cg27068330	chr11:65405492	SIPA1	0.82	7.91	0.63	4.72e-12	Acne (severe);
THYM	cis	rs4631830	0.869	rs4131357	chr10:51537292	C/A	cg10326726	chr10:51549505	MSMB	-0.62	-6.27	-0.54	1.07e-8	Prostate-specific antigen levels;
THYM	cis	rs112427907	1	rs112427907	chr3:47995270	G/A	cg09665691	chr3:47563885	NA	1.53	5.32	0.48	6.94e-7	Stem cell growth factor beta levels;
THYM	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg25918947	chr17:41365094	TMEM106A	-0.63	-5.18	-0.47	1.25e-6	Menopause (age at onset);
THYM	cis	rs72627123	0.737	rs61475846	chr14:74485781	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.52	0.56	3.44e-9	Morning vs. evening chronotype;
THYM	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg27535305	chr1:53392650	SCP2	-0.45	-5.06	-0.46	2.02e-6	Monocyte count;
THYM	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg16325326	chr1:53192061	ZYG11B	0.95	10.53	0.73	1.24e-17	Monocyte count;
THYM	cis	rs8038465	0.662	rs57771618	chr15:73967578	T/C	cg15420318	chr15:73925796	NPTN	0.56	4.77	0.44	6.71e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21659725	chr3:3221576	CRBN	-0.9	-10.07	-0.72	1.19e-16	Intelligence (multi-trait analysis);
THYM	cis	rs977987	0.843	rs4887820	chr16:75397287	C/T	cg03315344	chr16:75512273	CHST6	0.74	6.13	0.53	2.02e-8	Dupuytren's disease;
THYM	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg18132916	chr6:79620363	NA	-0.6	-4.99	-0.46	2.72e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg00495681	chr13:53174319	NA	-0.69	-7.03	-0.58	3.15e-10	Lewy body disease;
THYM	cis	rs16866061	0.517	rs7594223	chr2:225472985	T/C	cg10193763	chr2:225306901	NA	-0.43	-4.63	-0.43	1.17e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs6429082	0.818	rs210037	chr1:235649501	A/G	cg26050004	chr1:235667680	B3GALNT2	0.74	6.18	0.54	1.6e-8	Adiposity;
THYM	cis	rs11249608	0.636	rs6888567	chr5:178449074	C/T	cg21905437	chr5:178450457	ZNF879	-0.59	-4.6	-0.43	1.28e-5	Pubertal anthropometrics;
THYM	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Body mass index;
THYM	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg15604051	chr3:44754201	ZNF502	-0.6	-5.36	-0.48	5.94e-7	Depressive symptoms;
THYM	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg17173187	chr15:85201210	NMB	0.57	5.65	0.5	1.67e-7	Schizophrenia;
THYM	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg21926883	chr2:100939477	LONRF2	-0.6	-5.49	-0.49	3.35e-7	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg11764359	chr7:65958608	NA	0.68	4.87	0.45	4.51e-6	Aortic root size;
THYM	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg18132916	chr6:79620363	NA	0.55	4.84	0.44	4.99e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg08968635	chr6:28129556	ZNF389	0.71	5.58	0.5	2.28e-7	Parkinson's disease;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg26339992	chr1:28241106	RPA2	-1.38	-7.1	-0.59	2.2e-10	Pulmonary function decline;
THYM	cis	rs9677476	0.863	rs62197323	chr2:232063714	A/G	cg07929768	chr2:232055508	NA	0.61	6.17	0.53	1.65e-8	Food antigen IgG levels;
THYM	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg14004847	chr7:1930337	MAD1L1	-0.67	-4.96	-0.45	3.08e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg25767906	chr1:53392781	SCP2	-0.52	-5.29	-0.48	7.7300000000000005e-07	Monocyte count;
THYM	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg27588902	chr6:42928151	GNMT	-0.57	-5.69	-0.5	1.38e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg01368799	chr11:117014884	PAFAH1B2	0.82	6.59	0.56	2.46e-9	Blood protein levels;
THYM	cis	rs2133450	0.712	rs17697952	chr3:7368066	T/C	cg19930620	chr3:7340148	GRM7	-0.48	-4.49	-0.42	2.01e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg02403541	chr12:121454288	C12orf43	0.8	7.33	0.6	7.47e-11	N-glycan levels;
THYM	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg10505658	chr17:80084571	CCDC57	-0.74	-8.13	-0.64	1.59e-12	Life satisfaction;
THYM	cis	rs11030122	0.702	rs7102215	chr11:3943970	C/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.59	-0.5	2.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.3	-0.48	7.57e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg10370574	chr19:1840461	REXO1	1.01	9.41	0.69	3.03e-15	Bipolar disorder;
THYM	cis	rs854765	0.718	rs7224815	chr17:17845800	A/T	cg16928487	chr17:17741425	SREBF1	-0.59	-5.54	-0.49	2.66e-7	Total body bone mineral density;
THYM	cis	rs13064411	0.696	rs9869318	chr3:113146271	T/C	cg10517650	chr3:113235015	CCDC52	-0.6	-5.06	-0.46	2.06e-6	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs4481887	0.962	rs12037921	chr1:248454167	T/G	cg00666640	chr1:248458726	OR2T12	0.56	4.61	0.43	1.26e-5	Common traits (Other);
THYM	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-5.09	-0.46	1.8e-6	Joint mobility (Beighton score);
THYM	cis	rs7814319	0.933	rs7002575	chr8:97242124	G/A	cg20787634	chr8:97240163	UQCRB	-0.78	-9.51	-0.7	1.84e-15	Lung function (FVC);
THYM	cis	rs12549902	0.966	rs6990613	chr8:41515130	A/G	cg21772509	chr8:41503840	NKX6-3	0.72	6.79	0.57	9.78e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
THYM	cis	rs96067	0.805	rs7522400	chr1:36613380	A/G	cg24686825	chr1:36642396	MAP7D1	-0.67	-4.53	-0.42	1.73e-5	Corneal structure;
THYM	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg05855489	chr10:104503620	C10orf26	0.66	5.32	0.48	7.01e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs10887741	0.966	rs2762528	chr10:89420789	A/G	cg13926569	chr10:89418898	PAPSS2	-0.61	-6.58	-0.56	2.53e-9	Exercise (leisure time);
THYM	cis	rs2439831	0.681	rs884704	chr15:43691150	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.68	4.7	0.43	8.71e-6	Lung cancer in ever smokers;
THYM	cis	rs9361491	0.608	rs9350775	chr6:79463785	A/G	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1061377	1.000	rs7681116	chr4:39134635	C/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs992157	0.932	rs1473901	chr2:219188838	C/T	cg00012203	chr2:219082015	ARPC2	0.64	5.58	0.5	2.28e-7	Colorectal cancer;
THYM	cis	rs9807989	0.524	rs4851576	chr2:103028895	C/T	cg03938978	chr2:103052716	IL18RAP	0.74	9.76	0.71	5.45e-16	Asthma;
THYM	cis	rs7078219	0.543	rs4919342	chr10:101282553	G/C	cg04972745	chr10:101287846	NA	-0.53	-4.86	-0.45	4.55e-6	Dental caries;
THYM	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9361491	0.608	rs9359343	chr6:79456731	G/A	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10089	1.000	rs4835943	chr5:127457569	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs751984	0.706	rs3802951	chr11:61273700	T/C	cg10537699	chr11:60897371	NA	1.07	4.45	0.42	2.3e-5	Diastolic blood pressure;Systolic blood pressure;Mean arterial pressure;
THYM	cis	rs7705042	0.826	rs6883827	chr5:141504991	A/G	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs10493773	0.775	rs12564080	chr1:86196586	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.49	-6.19	-0.54	1.5e-8	Urate levels in overweight individuals;
THYM	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.43	1.27e-5	Breast cancer;
THYM	cis	rs2742417	0.603	rs6807438	chr3:45778623	G/A	cg04837898	chr3:45731254	SACM1L	-0.74	-5.11	-0.46	1.67e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.36e-7	Corneal astigmatism;
THYM	cis	rs6761276	0.649	rs3811057	chr2:113831188	C/A	cg12858261	chr2:113808755	IL1F8	0.54	4.47	0.42	2.16e-5	Protein quantitative trait loci;
THYM	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg19346786	chr7:2764209	NA	0.73	6.25	0.54	1.18e-8	Height;
THYM	cis	rs911119	1.000	rs34374560	chr20:23609462	C/T	cg16589663	chr20:23618590	CST3	0.77	4.71	0.44	8.31e-6	Chronic kidney disease;
THYM	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.83	0.44	5.26e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg24253500	chr15:84953950	NA	0.54	4.62	0.43	1.23e-5	Schizophrenia;
THYM	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg27394845	chr17:28928406	LRRC37B2	0.98	4.82	0.44	5.45e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg06766960	chr11:133703094	NA	-0.59	-5.47	-0.49	3.59e-7	Childhood ear infection;
THYM	cis	rs1797081	1.000	rs812426	chr10:16857133	C/G	cg23933602	chr10:16859644	RSU1	0.91	9.98	0.72	1.82e-16	Platelet distribution width;
THYM	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg08017756	chr2:100939284	LONRF2	-0.73	-7.54	-0.61	2.77e-11	Intelligence (multi-trait analysis);
THYM	cis	rs9515201	0.740	rs9555695	chr13:111033125	C/T	cg26053697	chr13:111039873	COL4A2	0.54	4.58	0.43	1.39e-5	White matter hyperintensity burden;
THYM	cis	rs1788820	0.917	rs1788825	chr18:21109250	T/C	cg14672496	chr18:21087552	C18orf8	0.76	6.02	0.53	3.21e-8	Body mass index;
THYM	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg24578937	chr1:2090814	PRKCZ	-0.57	-5.81	-0.51	8.15e-8	Height;
THYM	cis	rs11648796	0.717	rs10682	chr16:767430	C/G	cg20104307	chr16:778658	HAGHL	0.32	4.52	0.42	1.76e-5	Height;
THYM	cis	rs1878931	0.543	rs17612463	chr16:3420479	G/C	cg21433313	chr16:3507492	NAT15	-0.59	-4.99	-0.46	2.75e-6	Body mass index (adult);
THYM	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg05738196	chr6:26577821	NA	0.86	8.72	0.67	9.13e-14	Intelligence (multi-trait analysis);
THYM	cis	rs55702914	0.935	rs67735550	chr2:198229453	G/A	cg00792783	chr2:198669748	PLCL1	0.7	5.09	0.46	1.8e-6	Major depression and alcohol dependence;
THYM	cis	rs7688540	0.771	rs11724417	chr4:223352	A/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.72	4.88	0.45	4.35e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs684232	0.623	rs417171	chr17:576941	A/G	cg15660573	chr17:549704	VPS53	-0.87	-8.21	-0.64	1.1e-12	Prostate cancer;
THYM	cis	rs6546324	0.625	rs2861640	chr2:67794589	G/C	cg18237512	chr2:67827392	NA	-0.8	-4.75	-0.44	7.3e-6	Endometriosis;
THYM	cis	rs9826463	0.582	rs7642634	chr3:142110818	T/C	cg20824294	chr3:142316082	PLS1	0.77	5.31	0.48	7.08e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg00376283	chr12:123451042	ABCB9	0.73	5.58	0.5	2.25e-7	Neutrophil percentage of white cells;
THYM	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg02953382	chr22:24373134	LOC391322	-0.73	-6.69	-0.57	1.53e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg18252515	chr7:66147081	NA	0.63	4.7	0.43	8.9e-6	Aortic root size;
THYM	cis	rs7246657	0.943	rs9304566	chr19:37845504	T/C	cg22634378	chr19:37742834	NA	0.68	5.67	0.5	1.55e-7	Coronary artery calcification;
THYM	cis	rs11096990	0.634	rs6531702	chr4:39275394	C/T	cg24403649	chr4:39172243	NA	0.68	5.98	0.52	3.91e-8	Cognitive function;
THYM	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg17796960	chr10:135278976	LOC619207	-0.57	-4.79	-0.44	6.25e-6	Systemic lupus erythematosus;
THYM	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg05768032	chr16:30646687	NA	0.55	5.56	0.5	2.46e-7	Multiple myeloma;
THYM	cis	rs12594515	0.967	rs11856523	chr15:45989495	C/T	cg01629716	chr15:45996671	NA	0.51	5.15	0.47	1.38e-6	Waist circumference;Weight;
THYM	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg27284194	chr4:1044797	NA	0.62	4.73	0.44	7.81e-6	Recombination rate (females);
THYM	cis	rs7582403	0.844	rs1234402	chr2:148829652	C/T	cg23727674	chr2:148602993	ACVR2A	-0.59	-4.9	-0.45	3.88e-6	Neuroticism;
THYM	cis	rs7177699	0.525	rs7166770	chr15:79113568	A/G	cg00540400	chr15:79124168	NA	0.64	6.9	0.58	5.65e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7043114	0.507	rs2007837	chr9:95189767	A/T	cg14631576	chr9:95140430	CENPP	-0.81	-8.04	-0.64	2.45e-12	Height;
THYM	cis	rs8180040	0.800	rs56250009	chr3:47279497	G/C	cg16586182	chr3:47516702	SCAP	0.69	6.0	0.52	3.63e-8	Colorectal cancer;
THYM	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg14779329	chr11:130786720	SNX19	0.56	6.12	0.53	2.08e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs2242663	0.529	rs1785640	chr11:66223158	C/T	cg22973812	chr11:65786500	CATSPER1	-0.56	-4.82	-0.44	5.46e-6	Bipolar disorder;
THYM	cis	rs2237457	0.900	rs2237465	chr7:50731802	T/C	cg08586669	chr7:50727761	GRB10	0.32	4.8	0.44	5.97e-6	Schizophrenia (treatment resistant);
THYM	cis	rs7572733	0.534	rs10931794	chr2:198776140	C/T	cg00792783	chr2:198669748	PLCL1	-0.84	-5.97	-0.52	4.15e-8	Dermatomyositis;
THYM	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs9788721	0.806	rs951985	chr15:78720923	T/G	cg18825076	chr15:78729989	IREB2	-0.71	-6.17	-0.54	1.63e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs1021993	0.868	rs6661759	chr1:209530799	C/G	cg24997231	chr1:209527535	NA	-0.59	-4.68	-0.43	9.43e-6	Gut microbiome composition (winter);
THYM	cis	rs8133932	0.701	rs2839035	chr21:47308281	A/G	cg20357416	chr21:47294739	PCBP3	-0.91	-5.91	-0.52	5.39e-8	Schizophrenia;
THYM	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.96	-6.82	-0.57	8.39e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg23422044	chr7:1970798	MAD1L1	-0.79	-5.21	-0.47	1.09e-6	Bipolar disorder;
THYM	cis	rs1003719	0.715	rs7280251	chr21:38567911	T/C	cg01329690	chr21:38580129	DSCR9	-0.36	-5.0	-0.46	2.67e-6	Eye color traits;
THYM	cis	rs4824093	0.610	rs7410534	chr22:50289925	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.05	-4.79	-0.44	6.23e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg23428387	chr22:49814324	NA	-0.57	-5.37	-0.48	5.56e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2108225	1.000	rs2108225	chr7:107453103	G/A	cg18560240	chr7:107437656	SLC26A3	-0.81	-5.93	-0.52	4.92e-8	Ulcerative colitis;
THYM	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.69	-4.5	-0.42	1.95e-5	Menarche (age at onset);
THYM	cis	rs73787773	0.594	rs25788	chr5:111466355	T/C	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.83	-4.68	-0.43	9.66e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg06981504	chr1:1234844	ACAP3	0.54	4.94	0.45	3.29e-6	Body mass index;
THYM	cis	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs34638657	0.656	rs1134847	chr16:82203742	C/T	cg09894383	chr16:82067445	HSD17B2	0.45	5.01	0.46	2.47e-6	Lung adenocarcinoma;
THYM	cis	rs4919694	1.000	rs11191473	chr10:104710710	C/G	cg04362960	chr10:104952993	NT5C2	1.14	6.92	0.58	5.36e-10	Arsenic metabolism;
THYM	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.64	-0.74	7.23e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg19774624	chr17:42201019	HDAC5	0.68	5.66	0.5	1.63e-7	Total body bone mineral density;
THYM	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs6032067	0.586	rs62208373	chr20:43764426	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.64	-5.8	-0.51	8.81e-8	Blood protein levels;
THYM	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-4.96	-0.45	3.03e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9807841	0.545	rs4804514	chr19:10764203	G/T	cg17848348	chr19:10766748	ILF3	-0.75	-6.08	-0.53	2.53e-8	Inflammatory skin disease;
THYM	cis	rs995000	0.931	rs2366636	chr1:63056670	G/A	cg06896770	chr1:63153194	DOCK7	0.92	7.57	0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs1403694	0.515	rs710448	chr3:186452885	A/G	cg12454167	chr3:186435060	KNG1	0.46	6.08	0.53	2.55e-8	Blood protein levels;
THYM	cis	rs6988636	1.000	rs6983795	chr8:124185296	T/C	cg26140120	chr8:124219575	FAM83A	0.87	4.81	0.44	5.77e-6	Urinary uromodulin levels;
THYM	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg03806693	chr22:41940476	POLR3H	-0.88	-6.54	-0.56	3.13e-9	Neuroticism;
THYM	cis	rs6163	0.588	rs11191392	chr10:104526951	C/A	cg05855489	chr10:104503620	C10orf26	0.8	7.62	0.62	1.87e-11	Waist circumference;Hip circumference;
THYM	cis	rs78579285	0.545	rs113907912	chr16:88793872	T/C	cg04002220	chr16:89598305	SPG7	0.68	4.83	0.44	5.27e-6	Joint mobility (Beighton score);
THYM	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg11812906	chr14:75593930	NEK9	0.89	8.2	0.64	1.11e-12	Height;
THYM	cis	rs757110	0.902	rs2074310	chr11:17421886	T/C	cg15432903	chr11:17409602	KCNJ11	0.67	7.72	0.62	1.19e-11	Type 2 diabetes;
THYM	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg13147721	chr7:65941812	NA	0.96	5.84	0.51	7.26e-8	Diabetic kidney disease;
THYM	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg14582100	chr15:45693742	SPATA5L1	0.61	5.06	0.46	2.03e-6	Homoarginine levels;
THYM	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg01191920	chr7:158217561	PTPRN2	1.06	12.51	0.79	8.38e-22	Obesity-related traits;
THYM	cis	rs2408955	0.501	rs8716	chr12:48539482	T/G	cg21466736	chr12:48725269	NA	-0.46	-4.65	-0.43	1.05e-5	Glycated hemoglobin levels;
THYM	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs34912216	0.580	rs13223305	chr7:4131578	T/C	cg03141780	chr7:4150753	SDK1	0.68	5.17	0.47	1.29e-6	Motion sickness;
THYM	cis	rs7843479	0.601	rs7220	chr8:21863290	G/A	cg17168535	chr8:21777572	XPO7	0.84	7.46	0.61	4.13e-11	Mean corpuscular volume;
THYM	cis	rs9359856	0.564	rs3818133	chr6:90374456	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.91	-8.21	-0.64	1.08e-12	Bipolar disorder;
THYM	cis	rs921968	0.619	rs1554623	chr2:219606177	C/T	cg02176678	chr2:219576539	TTLL4	-0.47	-4.56	-0.42	1.55e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1669338	0.588	rs73005226	chr3:3195369	A/G	cg16797762	chr3:3221439	CRBN	-0.97	-5.43	-0.49	4.36e-7	White matter integrity;
THYM	cis	rs9807841	0.592	rs10407349	chr19:10758453	G/A	cg17848348	chr19:10766748	ILF3	-0.61	-5.07	-0.46	1.97e-6	Inflammatory skin disease;
THYM	cis	rs4769475	1.000	rs4769474	chr13:26731453	A/G	cg13319468	chr13:27597730	NA	-0.6	-4.62	-0.43	1.2e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03647317	chr4:187891568	NA	-0.83	-9.1	-0.68	1.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg03433033	chr1:76189801	ACADM	-0.52	-5.42	-0.49	4.44e-7	Daytime sleep phenotypes;
THYM	cis	rs926938	0.520	rs2007231	chr1:115266306	C/T	cg12756093	chr1:115239321	AMPD1	-0.55	-4.52	-0.42	1.77e-5	Autism;
THYM	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg27129171	chr3:47204927	SETD2	0.77	7.65	0.62	1.67e-11	Colorectal cancer;
THYM	cis	rs1322639	0.614	rs6925201	chr6:169563357	C/T	cg04662567	chr6:169592167	NA	0.87	5.52	0.49	2.97e-7	Pulse pressure;
THYM	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg24324837	chr19:49891574	CCDC155	0.52	4.79	0.44	6.25e-6	Multiple sclerosis;
THYM	cis	rs2806561	1.000	rs2473851	chr1:23489869	A/G	cg12483005	chr1:23474871	LUZP1	0.55	5.68	0.5	1.46e-7	Height;
THYM	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6748734	0.625	rs4675871	chr2:241823849	G/A	cg07537917	chr2:241836409	C2orf54	-0.21	-4.89	-0.45	4.05e-6	Urinary metabolites;
THYM	cis	rs9876781	1.000	rs9826195	chr3:48433635	A/C	cg06066452	chr3:48470258	PLXNB1	0.26	4.88	0.45	4.26e-6	Longevity;
THYM	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13732083	chr21:47605072	C21orf56	0.76	4.98	0.45	2.88e-6	Testicular germ cell tumor;
THYM	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg05335186	chr13:53173507	NA	-0.58	-6.91	-0.58	5.39e-10	Lewy body disease;
THYM	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg04607235	chr12:12878440	APOLD1	-0.93	-5.53	-0.49	2.79e-7	Systemic lupus erythematosus;
THYM	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg00071950	chr4:10020882	SLC2A9	0.56	4.98	0.45	2.86e-6	Bone mineral density;
THYM	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg27534772	chr1:16042836	PLEKHM2	0.53	5.9	0.52	5.65e-8	Systolic blood pressure;
THYM	cis	rs4363385	0.818	rs407448	chr1:153007504	C/T	cg13444842	chr1:152974279	SPRR3	-0.59	-4.81	-0.44	5.61e-6	Inflammatory skin disease;
THYM	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg04455712	chr21:45112962	RRP1B	0.54	5.04	0.46	2.22e-6	Mean corpuscular volume;
THYM	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg06728252	chr6:26598149	ABT1	-0.43	-5.08	-0.46	1.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg00631329	chr6:26305371	NA	-0.6	-7.22	-0.6	1.27e-10	Educational attainment;
THYM	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg21926883	chr2:100939477	LONRF2	-0.6	-5.39	-0.48	5.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6570726	0.791	rs408443	chr6:145874643	T/C	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17826219	0.568	rs59858012	chr17:29078582	C/T	cg17105886	chr17:28927953	LRRC37B2	1.27	5.81	0.51	8.24e-8	Body mass index;
THYM	cis	rs9788682	0.747	rs938682	chr15:78896547	A/G	cg18825076	chr15:78729989	IREB2	0.57	4.83	0.44	5.26e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs9486715	0.929	rs2025044	chr6:97067028	A/G	cg06623918	chr6:96969491	KIAA0776	-1.06	-10.36	-0.73	2.88e-17	Headache;
THYM	cis	rs4589258	0.933	rs2508414	chr11:90428572	C/T	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg00256281	chr22:41985642	PMM1	0.51	4.58	0.43	1.42e-5	Vitiligo;
THYM	trans	rs4650994	0.935	rs2811290	chr1:178572978	C/T	cg05059571	chr16:84539110	KIAA1609	0.74	7.38	0.6	5.88e-11	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg12560992	chr17:57184187	TRIM37	-0.77	-6.6	-0.56	2.3e-9	Intelligence (multi-trait analysis);
THYM	cis	rs600806	0.850	rs10858091	chr1:109935578	T/C	cg02175308	chr1:109941060	SORT1	-0.6	-5.3	-0.48	7.58e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7649443	0.959	rs10461048	chr3:196953291	T/A	cg20744464	chr3:196756875	MFI2	0.63	4.64	0.43	1.12e-5	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs12549902	0.800	rs7825337	chr8:41507237	C/T	cg21772509	chr8:41503840	NKX6-3	0.64	5.48	0.49	3.55e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
THYM	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg10589385	chr1:150898437	SETDB1	0.66	5.58	0.5	2.27e-7	Tonsillectomy;
THYM	cis	rs892961	1.000	rs892961	chr17:75400100	A/T	cg05865280	chr17:75406074	SEPT9	0.56	4.53	0.42	1.7e-5	Airflow obstruction;
THYM	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg08564027	chr20:61660810	NA	0.93	9.57	0.7	1.39e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg14008862	chr17:28927542	LRRC37B2	0.92	4.53	0.42	1.72e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11948739	0.648	rs13184567	chr5:130250524	C/G	cg08523029	chr5:130500466	HINT1	-0.86	-5.83	-0.51	7.62e-8	Pediatric bone mineral content (hip);
THYM	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg10518543	chr12:38710700	ALG10B	-0.56	-4.46	-0.42	2.22e-5	Morning vs. evening chronotype;
THYM	cis	rs1008375	0.931	rs4479701	chr4:17571496	G/A	cg18681998	chr4:17616180	MED28	0.86	7.7	0.62	1.31e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg10150615	chr22:24372951	LOC391322	-0.9	-9.64	-0.7	9.64e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.89	-10.77	-0.74	3.77e-18	Chronic sinus infection;
THYM	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg24060327	chr5:131705240	SLC22A5	0.81	6.65	0.56	1.82e-9	Breast cancer;
THYM	cis	rs67981189	0.519	rs2526879	chr14:71377218	T/C	cg15910301	chr14:71632612	NA	-0.56	-4.88	-0.45	4.23e-6	Schizophrenia;
THYM	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	4.56	0.42	1.54e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	trans	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg25517755	chr10:38738941	LOC399744	-0.8	-7.87	-0.63	5.58e-12	Corneal astigmatism;
THYM	cis	rs9431487	0.760	rs2803888	chr1:219004615	C/A	cg13962170	chr1:218691051	NA	0.55	4.81	0.44	5.63e-6	Gut microbiome composition (summer);
THYM	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg05025164	chr4:1340916	KIAA1530	0.96	7.72	0.62	1.19e-11	Longevity;
THYM	cis	rs4148883	0.651	rs4147547	chr4:100127311	G/T	cg12011299	chr4:100065546	ADH4	0.68	5.86	0.51	6.77e-8	Alcohol dependence;
THYM	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg13609457	chr4:120235615	NA	-0.59	-5.25	-0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	5.56	0.5	2.5e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs6732160	0.624	rs10865397	chr2:73358292	C/T	cg24220031	chr2:73402428	NA	-0.5	-4.92	-0.45	3.6e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4499344	0.633	rs259282	chr19:33163043	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.91	7.55	0.61	2.63e-11	Mean platelet volume;
THYM	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg24812749	chr6:127587940	RNF146	0.95	7.54	0.61	2.83e-11	Breast cancer;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg08072980	chr7:50450320	IKZF1	1.39	7.77	0.62	9.15e-12	Pulmonary function decline;
THYM	cis	rs2188554	0.740	rs213933	chr7:117211054	A/G	cg21212505	chr7:117228958	CFTR	-0.61	-4.73	-0.44	7.65e-6	Esophageal adenocarcinoma;
THYM	cis	rs9549260	0.755	rs1413482	chr13:41218451	C/T	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg11812906	chr14:75593930	NEK9	-0.82	-7.38	-0.6	5.94e-11	Height;
THYM	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg08885076	chr2:99613938	TSGA10	-0.57	-5.63	-0.5	1.81e-7	Chronic sinus infection;
THYM	cis	rs501916	0.634	rs1561483	chr15:48069488	A/C	cg20869673	chr15:48010124	SEMA6D	0.63	4.49	0.42	1.99e-5	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs9810089	0.903	rs7432375	chr3:136288405	G/A	cg21827317	chr3:136751795	NA	0.57	4.87	0.45	4.42e-6	Gestational age at birth (child effect);
THYM	cis	rs4148883	0.651	rs10020052	chr4:100086331	C/G	cg12011299	chr4:100065546	ADH4	0.66	5.65	0.5	1.65e-7	Alcohol dependence;
THYM	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg04176532	chr22:50317003	CRELD2	0.43	4.6	0.43	1.33e-5	Schizophrenia;
THYM	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg01380346	chr19:18557039	ELL	-0.47	-4.69	-0.43	8.97e-6	Breast cancer;
THYM	cis	rs61931739	0.578	rs1384597	chr12:33604164	A/T	cg06521331	chr12:34319734	NA	0.62	4.55	0.42	1.59e-5	Morning vs. evening chronotype;
THYM	cis	rs10887741	0.646	rs7903568	chr10:89433931	T/A	cg13926569	chr10:89418898	PAPSS2	0.63	7.28	0.6	9.67e-11	Exercise (leisure time);
THYM	cis	rs7599312	0.534	rs7596285	chr2:213406961	G/A	cg20637307	chr2:213403960	ERBB4	1.0	10.5	0.73	1.43e-17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg17554472	chr22:41940697	POLR3H	0.75	5.12	0.46	1.61e-6	Vitiligo;
THYM	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.81	-6.72	-0.57	1.34e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg05283184	chr6:79620031	NA	-0.87	-8.26	-0.65	8.34e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg22709100	chr7:91322751	NA	0.63	4.86	0.45	4.55e-6	Breast cancer;
THYM	cis	rs2554380	0.891	rs2244838	chr15:84298598	C/T	cg14598478	chr15:84363061	ADAMTSL3	-0.62	-4.87	-0.45	4.46e-6	Height;
THYM	cis	rs9916302	0.561	rs12453198	chr17:37741879	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-5.35	-0.48	6.16e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg00339695	chr16:24857497	SLC5A11	0.48	4.79	0.44	6.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9378357	0.850	rs9392473	chr6:3291236	C/T	cg08754725	chr6:3293098	SLC22A23	-0.94	-4.97	-0.45	2.91e-6	Obesity-related traits;
THYM	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg08772003	chr10:104629869	AS3MT	-0.57	-4.95	-0.45	3.23e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7072216	0.727	rs3750603	chr10:100175536	A/T	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg14456004	chr13:21872349	NA	-1.25	-10.05	-0.72	1.28e-16	White matter hyperintensity burden;
THYM	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg06634786	chr22:41940651	POLR3H	-0.63	-5.39	-0.48	5.14e-7	Vitiligo;
THYM	cis	rs12149862	1.000	rs28878014	chr16:69472141	C/G	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs5769765	0.658	rs2157536	chr22:50190180	G/A	cg26441486	chr22:50317300	CRELD2	0.38	5.7	0.5	1.34e-7	Schizophrenia;
THYM	cis	rs4919694	1.000	rs12266291	chr10:104806884	G/A	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	cis	rs7172809	0.599	rs11856084	chr15:77750410	T/G	cg22256960	chr15:77711686	NA	-0.61	-4.47	-0.42	2.18e-5	Glucose homeostasis traits;
THYM	cis	rs2637266	1.000	rs12774835	chr10:78352226	C/G	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg10661904	chr17:79619235	PDE6G	-0.66	-6.09	-0.53	2.38e-8	Eye color traits;
THYM	cis	rs72627123	0.867	rs78742875	chr14:74457214	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	4.87	0.45	4.38e-6	Morning vs. evening chronotype;
THYM	cis	rs941408	1.000	rs941407	chr19:2812153	A/G	cg17333051	chr19:2783644	SGTA	0.55	4.9	0.45	3.97e-6	Total cholesterol levels;
THYM	cis	rs9807841	0.670	rs2010492	chr19:10803395	A/G	cg17848348	chr19:10766748	ILF3	-0.87	-7.74	-0.62	1.06e-11	Inflammatory skin disease;
THYM	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg23205692	chr1:25664452	TMEM50A	-0.83	-6.24	-0.54	1.22e-8	Erythrocyte sedimentation rate;
THYM	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg04944784	chr2:26401820	FAM59B	-1.05	-8.18	-0.64	1.23e-12	Gut microbiome composition (summer);
THYM	cis	rs7635838	0.617	rs2122031	chr3:11314143	G/A	cg00170343	chr3:11313890	ATG7	0.66	4.92	0.45	3.63e-6	HDL cholesterol;
THYM	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg08883853	chr7:1026168	CYP2W1	-0.45	-4.99	-0.46	2.68e-6	Longevity;Endometriosis;
THYM	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg02353165	chr6:42928485	GNMT	0.78	6.87	0.58	6.52e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg11266682	chr4:10021025	SLC2A9	0.74	12.07	0.78	6.94e-21	Bone mineral density;
THYM	cis	rs7200543	1.000	rs14347	chr16:15133889	T/G	cg01933576	chr16:15083564	PDXDC1	-0.99	-8.04	-0.64	2.48e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	trans	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	5.98	0.52	3.96e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.62	0.56	2.09e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2276314	1.000	rs9956938	chr18:33567061	A/G	cg19628046	chr18:33552617	C18orf21	0.79	5.46	0.49	3.74e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs67385638	1.000	rs67385638	chr11:5290370	C/G	cg12559170	chr11:5275217	HBG2	0.81	7.31	0.6	8.21e-11	Hemoglobin levels;
THYM	trans	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg27129171	chr3:47204927	SETD2	-0.77	-7.4	-0.6	5.32e-11	Colorectal cancer;
THYM	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg06600287	chr1:53387719	ECHDC2	-0.31	-5.11	-0.46	1.68e-6	Monocyte count;
THYM	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.5	0.42	1.93e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11039798	1.000	rs7125559	chr11:48984207	C/G	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg10047753	chr17:41438598	NA	0.97	7.74	0.62	1.06e-11	Menopause (age at onset);
THYM	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg06917634	chr15:78832804	PSMA4	0.94	8.55	0.66	2.02e-13	Sudden cardiac arrest;
THYM	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg06600287	chr1:53387719	ECHDC2	-0.29	-4.69	-0.43	9.17e-6	Monocyte count;
THYM	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg13319975	chr6:146136371	FBXO30	0.66	5.42	0.49	4.59e-7	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs8073060	0.586	rs4796101	chr17:33998593	C/T	cg19694781	chr19:47549865	TMEM160	-1.02	-8.69	-0.67	1.01e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg19507638	chr5:93509721	C5orf36	-0.65	-4.54	-0.42	1.63e-5	Diabetic retinopathy;
THYM	cis	rs138055607	1	rs138055607	chr10:75450901	C/G	cg02286717	chr10:75415704	SYNPO2L	-0.81	-5.11	-0.46	1.63e-6	Initial pursuit acceleration;
THYM	cis	rs2806561	0.704	rs664301	chr1:23522522	C/T	cg12483005	chr1:23474871	LUZP1	0.58	5.84	0.51	7.3900000000000007e-08	Height;
THYM	cis	rs4986172	0.655	rs1044977	chr17:43227214	T/C	cg27395066	chr17:43221220	ACBD4	0.62	5.03	0.46	2.28e-6	Height;
THYM	trans	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg13615516	chr5:77269221	NA	0.86	7.64	0.62	1.71e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs34599045	0.522	rs78073526	chr1:152901982	G/C	cg07796016	chr1:152779584	LCE1C	-1.14	-4.45	-0.42	2.33e-5	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	5.66	0.5	1.57e-7	Bipolar disorder;
THYM	cis	rs12935418	1.000	rs2602431	chr16:81070697	A/G	cg16651780	chr16:81037892	C16orf61	-0.91	-4.89	-0.45	4.05e-6	Mean corpuscular volume;
THYM	cis	rs61931739	0.817	rs866515	chr12:34215479	A/G	cg06521331	chr12:34319734	NA	-0.63	-5.33	-0.48	6.72e-7	Morning vs. evening chronotype;
THYM	cis	rs7078219	0.505	rs11190140	chr10:101291593	T/C	cg23904955	chr10:101282759	NA	-0.35	-4.5	-0.42	1.92e-5	Dental caries;
THYM	cis	rs11031096	0.711	rs4910891	chr11:4153408	A/G	cg18678763	chr11:4115507	RRM1	-0.47	-6.57	-0.56	2.7e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07157834	chr1:205819609	PM20D1	1.0	10.2	0.72	6.05e-17	Menarche (age at onset);
THYM	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg11871910	chr12:69753446	YEATS4	1.06	9.77	0.71	5.12e-16	Blood protein levels;
THYM	cis	rs7975161	0.640	rs4477504	chr12:104710465	T/C	cg25273343	chr12:104657179	TXNRD1	-0.69	-4.7	-0.43	8.65e-6	Toenail selenium levels;
THYM	cis	rs9972944	0.902	rs12939558	chr17:63772152	A/G	cg07283582	chr17:63770753	CCDC46	0.64	4.96	0.45	3.11e-6	Total body bone mineral density;
THYM	cis	rs1003719	0.708	rs2000417	chr21:38502868	C/T	cg01329690	chr21:38580129	DSCR9	-0.38	-5.21	-0.47	1.09e-6	Eye color traits;
THYM	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg12935359	chr14:103987150	CKB	-0.67	-6.52	-0.56	3.38e-9	Body mass index;
THYM	cis	rs2066819	1.000	rs2695782	chr12:56722830	C/T	cg26714650	chr12:56694279	CS	1.47	8.21	0.64	1.06e-12	Psoriasis vulgaris;
THYM	cis	rs8050907	0.744	rs28680621	chr16:4518994	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.3	5.2	0.47	1.16e-6	Obesity-related traits;
THYM	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg15557168	chr22:42548783	NA	-0.58	-4.68	-0.43	9.66e-6	Schizophrenia;
THYM	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg11245990	chr11:68621969	NA	0.57	7.46	0.61	4.06e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg00898013	chr13:113819073	PROZ	-0.89	-9.29	-0.69	5.34e-15	Platelet distribution width;
THYM	cis	rs6429082	0.818	rs696248	chr1:235668511	C/A	cg26050004	chr1:235667680	B3GALNT2	0.73	6.1	0.53	2.32e-8	Adiposity;
THYM	trans	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg10856724	chr12:34555212	NA	-0.87	-7.41	-0.61	5.14e-11	Drug-induced liver injury (flucloxacillin);
THYM	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg04842962	chr6:43655489	MRPS18A	1.4	15.42	0.85	1.3e-27	IgG glycosylation;
THYM	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg19507638	chr5:93509721	C5orf36	-0.7	-4.71	-0.44	8.43e-6	Diabetic retinopathy;
THYM	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg08270630	chr22:50330655	NA	-0.83	-4.52	-0.42	1.8e-5	Mean platelet volume;
THYM	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	4.9	0.45	3.98e-6	Hip circumference adjusted for BMI;
THYM	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg08132940	chr7:1081526	C7orf50	-1.08	-6.99	-0.58	3.8e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs72627123	0.867	rs75754154	chr14:74473578	C/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.1	6.16	0.53	1.76e-8	Morning vs. evening chronotype;
THYM	trans	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17712092	chr4:129076599	LARP1B	0.89	7.34	0.6	7.33e-11	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs2085601	0.519	rs1708679	chr4:89976963	T/C	cg17769793	chr4:89976368	FAM13A	-0.59	-6.62	-0.56	2.17e-9	Hair greying;
THYM	cis	rs36051895	0.632	rs10118789	chr9:5141178	G/A	cg02405213	chr9:5042618	JAK2	-1.03	-10.73	-0.74	4.67e-18	Pediatric autoimmune diseases;
THYM	cis	rs4072705	0.615	rs7851737	chr9:127247931	G/A	cg13476313	chr9:127244764	NR5A1	-0.39	-5.96	-0.52	4.23e-8	Menarche (age at onset);
THYM	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03452623	chr4:187889614	NA	1.17	20.04	0.9	6.92e-36	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.83	-7.04	-0.59	2.94e-10	Systemic lupus erythematosus;
THYM	cis	rs9560113	1.000	rs914026	chr13:112182029	G/A	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs7264396	0.676	rs6058383	chr20:34556005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-4.8	-0.44	6.01e-6	Total cholesterol levels;
THYM	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg02887458	chr19:19495540	GATAD2A	0.42	5.0	0.46	2.58e-6	Bipolar disorder;
THYM	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs35883536	1.000	rs964906	chr1:101087479	G/A	cg06223162	chr1:101003688	GPR88	0.61	4.49	0.42	1.98e-5	Monocyte count;
THYM	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs919433	0.617	rs4850809	chr2:198583403	C/T	cg00792783	chr2:198669748	PLCL1	-0.77	-5.4	-0.48	4.91e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg02782426	chr3:40428986	ENTPD3	-0.51	-4.56	-0.42	1.55e-5	Renal cell carcinoma;
THYM	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.0	8.1	0.64	1.86e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7542375	0.683	rs10495156	chr1:221106024	T/C	cg16008148	chr1:221062819	NA	0.46	4.82	0.44	5.46e-6	Obesity-related traits;
THYM	cis	rs2841233	0.558	rs10145270	chr14:105349891	G/A	cg16576083	chr14:105354267	KIAA0284	0.59	5.5	0.49	3.23e-7	IgG glycosylation;
THYM	cis	rs7107174	0.892	rs11237450	chr11:78023356	C/A	cg19901956	chr11:77921274	USP35	-0.68	-5.17	-0.47	1.29e-6	Testicular germ cell tumor;
THYM	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg25918947	chr17:41365094	TMEM106A	-0.69	-5.84	-0.51	7.34e-8	Menopause (age at onset);
THYM	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg24250549	chr1:154909240	PMVK	-0.79	-6.37	-0.55	6.62e-9	Prostate cancer;
THYM	cis	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs7267979	0.966	rs4813557	chr20:25292545	C/T	cg08601574	chr20:25228251	PYGB	-0.57	-4.61	-0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg26119090	chr2:26468346	HADHA;HADHB	1.25	9.0	0.68	2.26e-14	Gut microbiome composition (summer);
THYM	cis	rs6087771	0.651	rs6060775	chr20:30286191	A/G	cg13852791	chr20:30311386	BCL2L1	0.6	5.63	0.5	1.85e-7	Subcortical brain region volumes;Putamen volume;
THYM	cis	rs7586879	0.559	rs13387729	chr2:25076126	A/G	cg01884057	chr2:25150051	NA	0.65	6.53	0.56	3.2e-9	Body mass index;
THYM	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	4.86	0.45	4.67e-6	Hip circumference adjusted for BMI;
THYM	cis	rs3126085	0.515	rs10788836	chr1:152350135	A/T	cg10321714	chr1:152280068	FLG	-0.64	-4.62	-0.43	1.22e-5	Atopic dermatitis;
THYM	cis	rs526231	0.543	rs62362544	chr5:102334247	C/T	cg23492399	chr5:102201601	PAM	-0.64	-4.99	-0.46	2.68e-6	Primary biliary cholangitis;
THYM	cis	rs8016982	0.633	rs8019108	chr14:81716781	A/T	cg21807262	chr14:81713016	NA	-0.58	-5.69	-0.5	1.42e-7	Schizophrenia;
THYM	cis	rs9479482	1.000	rs9479405	chr6:150338065	G/A	cg25797454	chr6:150327115	RAET1K	0.46	5.03	0.46	2.33e-6	Alopecia areata;
THYM	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg18252515	chr7:66147081	NA	-1.37	-8.05	-0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs12579753	1.000	rs7300900	chr12:82166821	G/T	cg07988820	chr12:82153109	PPFIA2	-0.81	-5.25	-0.47	9.1e-7	Resting heart rate;
THYM	cis	rs7572733	0.534	rs4850815	chr2:198786167	G/T	cg05783139	chr2:198650985	BOLL	-0.62	-4.91	-0.45	3.8e-6	Dermatomyositis;
THYM	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	5.49	0.49	3.4e-7	Platelet count;
THYM	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg20503657	chr10:835505	NA	1.1	7.6	0.61	2.12e-11	Eosinophil percentage of granulocytes;
THYM	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg11984989	chr7:158649758	WDR60	1.02	13.27	0.81	2.39e-23	Height;
THYM	cis	rs16866061	1.000	rs10933068	chr2:225418360	G/A	cg12698349	chr2:225449008	CUL3	1.14	10.45	0.73	1.77e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.29e-7	Corneal astigmatism;
THYM	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg13397359	chr6:42928475	GNMT	0.65	5.67	0.5	1.55e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg06221963	chr1:154839813	KCNN3	-0.73	-8.77	-0.67	7.12e-14	Prostate cancer;
THYM	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs7909074	0.966	rs4268464	chr10:45401081	T/A	cg04218760	chr10:45406644	TMEM72	-0.63	-5.46	-0.49	3.84e-7	Mean corpuscular volume;
THYM	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg18758796	chr5:131593413	PDLIM4	0.53	4.8	0.44	5.98e-6	Acylcarnitine levels;
THYM	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs128738	0.500	rs6875603	chr5:131565390	A/C	cg22598563	chr5:131563921	P4HA2	0.56	4.89	0.45	4.11e-6	Giant cell arteritis;
THYM	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg01745370	chr2:109065127	GCC2	0.6	4.84	0.44	4.97e-6	Mean platelet volume;
THYM	cis	rs9905704	0.846	rs302851	chr17:56685424	G/A	cg12560992	chr17:57184187	TRIM37	0.66	4.94	0.45	3.37e-6	Testicular germ cell tumor;
THYM	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs208520	0.802	rs208496	chr6:66930786	G/C	cg07460842	chr6:66804631	NA	-0.85	-5.46	-0.49	3.87e-7	Exhaled nitric oxide output;
THYM	cis	rs2730245	0.527	rs842693	chr7:158660491	C/T	cg24397884	chr7:158709396	WDR60	0.58	5.59	0.5	2.15e-7	Height;
THYM	cis	rs17401966	0.838	rs12132134	chr1:10378428	A/G	cg19773385	chr1:10388646	KIF1B	-0.59	-4.82	-0.44	5.39e-6	Hepatocellular carcinoma;
THYM	cis	rs11148252	0.716	rs1887360	chr13:52779166	A/G	cg05335186	chr13:53173507	NA	-0.48	-5.42	-0.49	4.49e-7	Lewy body disease;
THYM	cis	rs9880211	0.948	rs9857966	chr3:136279390	A/G	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg21775007	chr8:11205619	TDH	0.7	6.11	0.53	2.17e-8	Retinal vascular caliber;
THYM	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg14768367	chr16:72042858	DHODH	0.65	5.08	0.46	1.89e-6	Fibrinogen levels;
THYM	cis	rs12288023	1.000	rs12288023	chr11:67421341	A/G	cg18416981	chr11:67820569	CHKA	0.87	4.64	0.43	1.12e-5	Serum metabolite levels;
THYM	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg03806693	chr22:41940476	POLR3H	-1.25	-10.88	-0.74	2.22e-18	Vitiligo;
THYM	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg03709012	chr19:19516395	GATAD2A	-0.76	-5.89	-0.52	5.81e-8	Tonsillectomy;
THYM	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg09222892	chr1:25734099	RHCE	0.63	4.95	0.45	3.16e-6	Erythrocyte sedimentation rate;
THYM	cis	rs3857067	0.806	rs12505596	chr4:95109600	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs7246967	0.673	rs12979264	chr19:22865134	G/A	cg05241461	chr19:22816980	ZNF492	0.59	4.51	0.42	1.89e-5	Bronchopulmonary dysplasia;
THYM	cis	rs854765	0.647	rs854817	chr17:18021882	T/C	cg04398451	chr17:18023971	MYO15A	-0.98	-10.42	-0.73	2.1e-17	Total body bone mineral density;
THYM	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg11266682	chr4:10021025	SLC2A9	0.74	10.8	0.74	3.21e-18	Bone mineral density;
THYM	cis	rs1865721	0.804	rs3745084	chr18:73142510	T/G	cg26385618	chr18:73139727	C18orf62	-0.63	-4.56	-0.42	1.5e-5	Intelligence;
THYM	cis	rs9296092	0.517	rs7743445	chr6:33470600	G/T	cg13560919	chr6:33536144	NA	-0.84	-6.92	-0.58	5.15e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	trans	rs2136093	0.600	rs12126859	chr1:90907842	G/T	cg19688584	chr6:167529678	CCR6	0.48	6.96	0.58	4.3e-10	Response to antidepressants;
THYM	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.76	0.44	6.99e-6	Aortic root size;
THYM	cis	rs4919694	1.000	rs12242000	chr10:104702413	A/C	cg04362960	chr10:104952993	NT5C2	1.14	6.92	0.58	5.36e-10	Arsenic metabolism;
THYM	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs919433	0.679	rs13000656	chr2:198522126	T/C	cg00792783	chr2:198669748	PLCL1	-0.86	-5.65	-0.5	1.67e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6840360	0.638	rs2406974	chr4:152601841	G/A	cg22705602	chr4:152727874	NA	-0.8	-10.41	-0.73	2.22e-17	Intelligence (multi-trait analysis);
THYM	cis	rs986417	1.000	rs12895784	chr14:60980116	G/T	cg27398547	chr14:60952738	C14orf39	1.26	6.46	0.55	4.37e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg17366294	chr4:99064904	C4orf37	0.57	6.82	0.57	8.42e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7107174	0.892	rs1007837	chr11:77941076	A/G	cg19901956	chr11:77921274	USP35	-0.68	-5.37	-0.48	5.54e-7	Testicular germ cell tumor;
THYM	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6960043	0.748	rs10228561	chr7:15063961	C/T	cg19272540	chr7:15055459	NA	-0.45	-4.96	-0.45	3.09e-6	Type 2 diabetes;
THYM	cis	rs2069036	1.000	rs2069036	chr10:16116747	C/T	cg26633223	chr10:15133461	NA	-0.71	-5.24	-0.47	9.57e-7	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs9359856	0.564	rs56084221	chr6:90365349	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.91	-8.21	-0.64	1.08e-12	Bipolar disorder;
THYM	cis	rs346785	1.000	rs346785	chr17:74283769	C/T	cg09812376	chr17:74270190	QRICH2	0.6	7.02	0.58	3.32e-10	White matter hyperintensities in ischemic stroke;
THYM	cis	rs2806561	0.765	rs668234	chr1:23515467	G/A	cg12483005	chr1:23474871	LUZP1	0.59	6.29	0.54	9.59e-9	Height;
THYM	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.03	0.46	2.29e-6	Obesity-related traits;
THYM	cis	rs9479482	0.967	rs61730071	chr6:150342232	G/A	cg25797454	chr6:150327115	RAET1K	0.45	4.78	0.44	6.29e-6	Alopecia areata;
THYM	cis	rs11997175	0.624	rs4733460	chr8:33675169	T/C	ch.8.33884649F	chr8:33765107	NA	0.67	5.04	0.46	2.18e-6	Body mass index;
THYM	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7394190	0.748	rs2242254	chr10:75585307	G/A	cg07699608	chr10:75541558	CHCHD1	0.87	4.75	0.44	7.17e-6	Incident atrial fibrillation;
THYM	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg06112835	chr11:68658793	MRPL21	0.44	6.39	0.55	6.23e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06850241	chr22:41845214	NA	-0.62	-5.45	-0.49	3.93e-7	Vitiligo;
THYM	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg00786635	chr1:25594202	NA	0.9	7.06	0.59	2.74e-10	Erythrocyte sedimentation rate;
THYM	trans	rs7615952	0.512	rs34085484	chr3:125544186	T/C	cg07211511	chr3:129823064	LOC729375	-0.92	-7.28	-0.6	9.56e-11	Blood pressure (smoking interaction);
THYM	cis	rs997295	0.592	rs7162320	chr15:67766038	C/G	cg24579218	chr15:68104479	NA	0.54	4.71	0.44	8.39e-6	Motion sickness;
THYM	trans	rs7952251	0.812	rs6589301	chr11:112424565	G/A	cg14154186	chr1:204970430	NFASC	-0.73	-7.54	-0.61	2.79e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg06981504	chr1:1234844	ACAP3	0.53	4.86	0.45	4.67e-6	Body mass index;
THYM	cis	rs6541297	0.702	rs4846904	chr1:230279410	G/A	cg20703242	chr1:230279135	GALNT2	0.92	6.26	0.54	1.13e-8	Coronary artery disease;
THYM	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-5.02	-0.46	2.39e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03576123	chr11:487126	PTDSS2	-1.24	-6.13	-0.53	1.97e-8	Body mass index;
THYM	cis	rs7267979	1.000	rs4815404	chr20:25301845	T/G	cg08601574	chr20:25228251	PYGB	-0.57	-4.59	-0.43	1.35e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg24450063	chr1:156163899	SLC25A44	1.16	9.68	0.7	8.04e-16	Testicular germ cell tumor;
THYM	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg03676636	chr4:99064102	C4orf37	0.33	4.47	0.42	2.16e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7731657	0.537	rs4705917	chr5:130206326	A/G	cg08523029	chr5:130500466	HINT1	-0.75	-5.17	-0.47	1.3e-6	Fasting plasma glucose;
THYM	cis	rs7106204	0.534	rs113519220	chr11:24251432	T/C	ch.11.24196551F	chr11:24239977	NA	0.96	4.95	0.45	3.18e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg26850624	chr5:429559	AHRR	-0.72	-5.68	-0.5	1.45e-7	Cystic fibrosis severity;
THYM	cis	rs3774830	0.846	rs168987	chr4:5434857	A/C	cg26943120	chr4:5472116	STK32B	-0.54	-4.9	-0.45	3.96e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Body mass index;
THYM	cis	rs7586879	0.681	rs6756609	chr2:25121125	C/A	cg15423357	chr2:25149977	NA	0.68	7.53	0.61	2.9e-11	Body mass index;
THYM	cis	rs1178127	0.759	rs11764116	chr7:18800413	G/T	cg13420273	chr7:18810212	HDAC9	0.54	4.5	0.42	1.92e-5	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs13082711	0.834	rs2840088	chr3:27428371	G/A	cg02860705	chr3:27208620	NA	0.67	4.72	0.44	8.23e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-7.13	-0.59	2e-10	Coronary artery disease;
THYM	cis	rs9443189	0.570	rs659807	chr6:76293435	C/A	cg01950844	chr6:76311363	SENP6	1.1	6.88	0.58	6.48e-10	Prostate cancer;
THYM	cis	rs4731207	0.596	rs3900363	chr7:124667961	C/A	cg05285228	chr7:124571219	POT1	-0.6	-4.52	-0.42	1.81e-5	Cutaneous malignant melanoma;
THYM	cis	rs10095849	0.576	rs10099250	chr8:39444134	T/G	cg01911981	chr8:39380341	ADAM3A	-0.58	-5.0	-0.46	2.57e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7809950	0.953	rs2520267	chr7:107187497	T/C	cg23024343	chr7:107201750	COG5	-0.93	-8.53	-0.66	2.33e-13	Coronary artery disease;
THYM	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg24578937	chr1:2090814	PRKCZ	-0.57	-5.88	-0.52	6e-8	Height;
THYM	cis	rs17006441	0.932	rs1529585	chr3:69870595	A/G	cg18496212	chr3:69797108	MITF	0.65	6.36	0.55	7.15e-9	Hemoglobin concentration;
THYM	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg09021430	chr5:549028	NA	-0.69	-4.57	-0.42	1.44e-5	Lung disease severity in cystic fibrosis;
THYM	cis	rs7616559	0.962	rs1905208	chr3:156752487	G/A	cg15697575	chr3:156784781	NA	0.4	4.98	0.46	2.79e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg06115741	chr20:33292138	TP53INP2	0.7	4.67	0.43	9.98e-6	Coronary artery disease;
THYM	cis	rs4606347	0.789	rs77837631	chr1:66163438	A/G	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs7772486	0.875	rs2814874	chr6:146305895	C/T	cg23711669	chr6:146136114	FBXO30	0.96	10.29	0.73	3.99e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg14675211	chr2:100938903	LONRF2	-0.77	-8.32	-0.65	6.49e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6531656	0.796	rs337608	chr4:38660249	G/A	cg24279243	chr4:38676559	KLF3	0.81	5.49	0.49	3.3e-7	Lymphocyte counts;
THYM	cis	rs870825	0.860	rs72703519	chr4:185602707	G/A	cg04058563	chr4:185651563	MLF1IP	1.0	7.42	0.61	4.93e-11	Blood protein levels;
THYM	cis	rs240110	0.539	rs6919745	chr6:101338978	T/C	cg21058520	chr6:100914733	NA	-0.57	-4.92	-0.45	3.69e-6	Neuroticism;
THYM	cis	rs6466832	0.537	rs73220293	chr7:122352475	C/T	cg22586324	chr7:123296098	LMOD2	-0.93	-5.05	-0.46	2.12e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7582180	0.627	rs2099611	chr2:101021090	A/G	cg08017756	chr2:100939284	LONRF2	-0.71	-7.21	-0.59	1.33e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg00852783	chr1:26633632	UBXN11	0.86	8.81	0.67	5.74e-14	Obesity-related traits;
THYM	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg01416388	chr22:39784598	NA	-0.87	-8.13	-0.64	1.59e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs8030485	0.756	rs1521624	chr15:79412399	C/A	cg17916960	chr15:79447300	NA	0.57	6.05	0.53	2.79e-8	Left ventricle wall thickness;
THYM	cis	rs6500602	0.826	rs9932461	chr16:4454170	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.54	6.0	0.52	3.52e-8	Schizophrenia;
THYM	cis	rs4733781	0.901	rs4733777	chr8:131271562	C/T	cg16277922	chr8:131349729	ASAP1	0.71	5.27	0.48	8.6e-7	Tuberculosis;
THYM	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.74	-7.03	-0.59	3.08e-10	Personality dimensions;
THYM	cis	rs1371867	0.846	rs1660345	chr8:101322762	C/A	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs4072705	0.615	rs7869829	chr9:127247177	G/A	cg13476313	chr9:127244764	NR5A1	-0.39	-5.98	-0.52	3.9e-8	Menarche (age at onset);
THYM	cis	rs9921192	0.934	rs233948	chr16:4327174	C/T	cg00021532	chr16:4324280	TFAP4	0.84	7.63	0.62	1.82e-11	Prostate-specific antigen levels;
THYM	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg00801512	chr17:28996047	NA	-0.79	-5.11	-0.46	1.63e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg08270630	chr22:50330655	NA	-0.94	-4.8	-0.44	5.98e-6	Schizophrenia;
THYM	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.9	7.83	0.63	6.8e-12	Multiple sclerosis;
THYM	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05901451	chr6:126070800	HEY2	-0.98	-10.01	-0.72	1.54e-16	Brugada syndrome;
THYM	cis	rs7267979	1.000	rs1077889	chr20:25267893	A/G	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2732480	0.500	rs2732461	chr12:48692802	C/A	cg21466736	chr12:48725269	NA	-0.54	-5.02	-0.46	2.44e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs941408	1.000	rs2741990	chr19:2796644	C/T	cg17333051	chr19:2783644	SGTA	0.55	4.86	0.45	4.58e-6	Total cholesterol levels;
THYM	cis	rs4866334	1.000	rs79036917	chr5:18441030	A/C	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs36051895	0.659	rs10121491	chr9:5046935	T/C	cg02405213	chr9:5042618	JAK2	-1.04	-10.76	-0.74	3.89e-18	Pediatric autoimmune diseases;
THYM	cis	rs3135718	1.000	rs2860197	chr10:123351302	G/A	cg15049101	chr10:123353889	FGFR2	-0.6	-5.2	-0.47	1.13e-6	Estrogen receptor status in breast cancer;
THYM	cis	rs651907	0.613	rs1707618	chr3:101631207	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	5.21	0.47	1.1e-6	Colorectal cancer;
THYM	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs1003719	0.788	rs2040341	chr21:38489753	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs1538970	0.816	rs9727262	chr1:45998579	T/G	cg05343316	chr1:45956843	TESK2	0.83	5.28	0.48	8.03e-7	Platelet count;
THYM	cis	rs714027	0.585	rs73162764	chr22:30358745	G/A	cg27665648	chr22:30112403	NA	0.51	4.65	0.43	1.05e-5	Lymphocyte counts;
THYM	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg13736514	chr6:26305472	NA	-0.65	-6.59	-0.56	2.5e-9	Mosquito bite size;
THYM	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg26354017	chr1:205819088	PM20D1	0.97	10.31	0.73	3.67e-17	Menarche (age at onset);
THYM	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg20607798	chr8:58055168	NA	-0.84	-4.75	-0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2463822	1.000	rs2513052	chr11:62108248	C/G	cg06239285	chr11:62104954	ASRGL1	1.44	7.7	0.62	1.3e-11	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7107174	0.901	rs2450140	chr11:77924388	T/C	cg02023728	chr11:77925099	USP35	0.66	6.14	0.53	1.94e-8	Testicular germ cell tumor;
THYM	cis	rs7192750	0.562	rs9889011	chr16:71987816	T/A	cg06353428	chr16:71660113	MARVELD3	0.72	5.4	0.48	4.87e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.09	-0.53	2.34e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs4886920	0.894	rs6495252	chr15:78117685	C/T	cg10461261	chr15:78109450	NA	0.51	5.06	0.46	2.07e-6	Neuroticism;
THYM	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg15448220	chr1:150897856	SETDB1	0.9	7.66	0.62	1.56e-11	Melanoma;
THYM	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg09307838	chr4:120376055	NA	0.71	5.3	0.48	7.51e-7	Educational attainment;
THYM	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-5.26	-0.47	9.05e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.77	0.62	9.17e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.27	5.57	0.5	2.39e-7	Obesity-related traits;
THYM	cis	rs3780378	0.935	rs1028912	chr9:5050369	G/C	cg02405213	chr9:5042618	JAK2	-0.78	-7.34	-0.6	7.17e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg20887711	chr4:1340912	KIAA1530	0.68	6.07	0.53	2.64e-8	Longevity;
THYM	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs7011507	0.700	rs55864946	chr8:49340518	C/T	cg08774009	chr8:49309094	NA	-0.62	-4.83	-0.44	5.19e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg04182591	chr4:9445586	DEFB131	-1.3	-5.68	-0.5	1.46e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs10927875	0.619	rs7546589	chr1:16129530	A/G	cg21385522	chr1:16154831	NA	-0.78	-6.45	-0.55	4.71e-9	Dilated cardiomyopathy;
THYM	cis	rs11731175	1.000	rs62341061	chr4:189860396	C/G	cg00431894	chr4:189871012	NA	-0.86	-6.17	-0.54	1.63e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1629083	0.935	rs2051480	chr11:118094513	A/G	cg25155064	chr11:118100782	MPZL3	-0.57	-5.04	-0.46	2.21e-6	Lung cancer;
THYM	cis	rs34779708	0.931	rs12240347	chr10:35359475	A/G	cg03585969	chr10:35415529	CREM	0.63	4.66	0.43	1.01e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg00376283	chr12:123451042	ABCB9	0.93	7.86	0.63	6.06e-12	Platelet count;
THYM	cis	rs5167	0.743	rs57204168	chr19:45496776	A/G	cg09555818	chr19:45449301	APOC2	0.47	4.96	0.45	3.09e-6	Blood protein levels;
THYM	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg06219351	chr7:158114137	PTPRN2	0.69	6.87	0.58	6.7e-10	Calcium levels;
THYM	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg20295408	chr7:1910781	MAD1L1	-0.68	-5.18	-0.47	1.23e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2295359	0.892	rs4655687	chr1:67649946	C/T	cg11235152	chr1:67600687	NA	0.69	5.69	0.5	1.37e-7	Psoriasis;
THYM	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg22166914	chr1:53195759	ZYG11B	0.81	8.11	0.64	1.74e-12	Monocyte count;
THYM	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg12560992	chr17:57184187	TRIM37	0.93	8.88	0.67	4.06e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2692947	0.599	rs7561198	chr2:96774981	C/G	cg23100626	chr2:96804247	ASTL	-0.37	-4.46	-0.42	2.22e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs4262150	0.883	rs72804778	chr5:152309607	G/A	cg06854687	chr5:151642065	NA	0.66	4.7	0.43	8.85e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9633835	0.642	rs10766077	chr11:13349781	G/A	cg13286116	chr11:13302098	ARNTL	0.61	6.34	0.55	7.81e-9	Body mass index;
THYM	cis	rs6430585	0.697	rs1050115	chr2:136511817	A/G	cg04750100	chr2:136595281	LCT	0.53	4.86	0.45	4.59e-6	Corneal structure;
THYM	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg16586182	chr3:47516702	SCAP	-0.63	-5.52	-0.49	2.96e-7	Colorectal cancer;
THYM	cis	rs863345	0.604	rs11265007	chr1:158498522	C/T	cg12129480	chr1:158549410	OR10X1	0.48	4.72	0.44	8.22e-6	Pneumococcal bacteremia;
THYM	trans	rs629535	0.748	rs689410	chr8:70037558	G/A	cg21567404	chr3:27674614	NA	1.12	10.86	0.74	2.44e-18	Dupuytren's disease;
THYM	cis	rs7113850	0.541	rs7944769	chr11:24224823	G/C	ch.11.24196551F	chr11:24239977	NA	0.92	4.89	0.45	4.04e-6	Bone fracture in osteoporosis;
THYM	cis	rs1499972	0.941	rs62264816	chr3:117666232	C/G	cg07612923	chr3:117604196	NA	1.42	5.49	0.49	3.4e-7	Schizophrenia;
THYM	cis	rs4523957	0.552	rs923862	chr17:2031382	A/C	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg04320152	chr17:18167836	SMCR7	0.56	4.47	0.42	2.13e-5	Total body bone mineral density;
THYM	cis	rs7567389	0.600	rs11691088	chr2:128131853	A/G	cg09760422	chr2:128146352	NA	0.4	4.78	0.44	6.27e-6	Self-rated health;
THYM	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg05457628	chr5:178986728	RUFY1	-0.63	-6.56	-0.56	2.82e-9	Lung cancer;
THYM	cis	rs6593803	0.622	rs11586154	chr1:147165238	T/C	cg06627043	chr1:147838662	NA	0.53	4.91	0.45	3.8e-6	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
THYM	cis	rs765787	0.530	rs12904331	chr15:45518293	C/T	cg25801113	chr15:45476975	SHF	-0.38	-4.53	-0.42	1.68e-5	Uric acid levels;
THYM	cis	rs62158800	0.568	rs78259088	chr2:108361571	T/A	cg10013287	chr2:108537568	NA	1.2	5.61	0.5	1.97e-7	Facial morphology (factor 22);
THYM	cis	rs4638749	0.677	rs13389470	chr2:108806301	C/G	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs9633835	0.524	rs55957464	chr11:13277443	A/G	cg13286116	chr11:13302098	ARNTL	-0.72	-8.03	-0.64	2.61e-12	Body mass index;
THYM	cis	rs7781977	0.723	rs11765436	chr7:50344077	T/A	cg14216940	chr7:50343131	IKZF1	0.54	4.59	0.43	1.35e-5	IgG glycosylation;
THYM	trans	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg25214090	chr10:38739885	LOC399744	0.91	7.65	0.62	1.67e-11	Corneal astigmatism;
THYM	cis	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg07460842	chr6:66804631	NA	0.92	5.5	0.49	3.15e-7	Exhaled nitric oxide levels;
THYM	cis	rs9359856	0.564	rs10484885	chr6:90395016	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg23711669	chr6:146136114	FBXO30	0.96	10.29	0.73	3.99e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg14983838	chr19:29218262	NA	1.09	9.77	0.71	5e-16	Methadone dose in opioid dependence;
THYM	cis	rs13064411	0.696	rs7622740	chr3:113206771	G/A	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.82	6.83	0.57	8.15e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6138458	0.961	rs227625	chr20:24911618	T/C	cg26195577	chr20:24973756	C20orf3	1.11	10.52	0.73	1.29e-17	Blood protein levels;
THYM	cis	rs2235649	0.789	rs4567715	chr16:1849363	G/C	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs6733011	0.530	rs7608889	chr2:99481350	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-4.64	-0.43	1.11e-5	Bipolar disorder;
THYM	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9914544	0.545	rs12937933	chr17:18770283	C/G	cg26378065	chr17:18585709	ZNF286B	0.59	4.5	0.42	1.9e-5	Educational attainment (years of education);
THYM	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg02931644	chr1:25747376	RHCE	0.57	4.59	0.43	1.37e-5	Erythrocyte sedimentation rate;
THYM	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs586688	0.929	rs587180	chr1:201631088	G/A	cg12048341	chr1:201712730	NAV1	-0.78	-4.6	-0.43	1.31e-5	Obesity-related traits;
THYM	cis	rs868036	1.000	rs1026733	chr15:68095122	G/A	cg24579218	chr15:68104479	NA	-0.65	-6.51	-0.56	3.59e-9	Restless legs syndrome;
THYM	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg13683864	chr3:40499215	RPL14	-1.05	-11.59	-0.77	7e-20	Renal cell carcinoma;
THYM	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.37	0.55	6.72e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg27129171	chr3:47204927	SETD2	-0.81	-7.78	-0.62	8.79e-12	Colorectal cancer;
THYM	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg02569458	chr12:86230093	RASSF9	-0.61	-5.12	-0.47	1.57e-6	Major depressive disorder;
THYM	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs7772486	0.686	rs9390349	chr6:146054430	T/G	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7833986	0.501	rs72653962	chr8:56997505	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	6.82	0.57	8.29e-10	Height;
THYM	trans	rs10504229	0.516	rs4060631	chr8:57990757	G/A	cg06642219	chr1:5586147	NA	0.64	6.87	0.58	6.74e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs2282300	0.739	rs1222219	chr11:30344345	G/C	cg25418670	chr11:30344373	C11orf46	-0.82	-6.98	-0.58	3.93e-10	Morning vs. evening chronotype;
THYM	trans	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11096990	0.891	rs61691409	chr4:39245421	T/A	cg24403649	chr4:39172243	NA	-0.67	-5.68	-0.5	1.5e-7	Cognitive function;
THYM	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg07424592	chr7:64974309	NA	-1.04	-5.27	-0.48	8.52e-7	Diabetic kidney disease;
THYM	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.14	-0.64	1.51e-12	Personality dimensions;
THYM	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg07747251	chr5:1868357	NA	0.68	5.86	0.52	6.67e-8	Cardiovascular disease risk factors;
THYM	cis	rs1021993	0.818	rs906349	chr1:209528128	G/T	cg24997231	chr1:209527535	NA	-0.56	-4.61	-0.43	1.24e-5	Gut microbiome composition (winter);
THYM	cis	rs4474465	0.790	rs10751293	chr11:78250956	A/T	cg19901956	chr11:77921274	USP35	0.61	4.6	0.43	1.3e-5	Alzheimer's disease (survival time);
THYM	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg14582100	chr15:45693742	SPATA5L1	0.59	4.91	0.45	3.79e-6	Homoarginine levels;
THYM	cis	rs2085601	0.542	rs9307062	chr4:89949228	T/G	cg17769793	chr4:89976368	FAM13A	-0.53	-5.83	-0.51	7.75e-8	Hair greying;
THYM	cis	rs6480314	0.636	rs61854788	chr10:70001737	T/A	cg27159792	chr10:69524182	NA	0.81	4.89	0.45	4.06e-6	Optic nerve measurement (disc area);
THYM	cis	rs6448317	0.954	rs11946846	chr4:24922703	G/A	cg22968281	chr4:24586266	DHX15	0.66	4.53	0.42	1.69e-5	Heschl's gyrus morphology;
THYM	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg01579765	chr21:45077557	HSF2BP	-0.5	-7.58	-0.61	2.34e-11	Mean corpuscular volume;
THYM	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg15445000	chr17:37608096	MED1	-0.44	-5.22	-0.47	1.07e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg14416269	chr4:6271139	WFS1	0.46	4.64	0.43	1.13e-5	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs6032067	0.759	rs3761193	chr20:43885827	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.39	-4.45	-0.42	2.29e-5	Blood protein levels;
THYM	cis	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg10518543	chr12:38710700	ALG10B	-0.57	-4.47	-0.42	2.16e-5	Bladder cancer;
THYM	cis	rs2938670	1	rs2938670	chr15:78740688	T/G	cg18825076	chr15:78729989	IREB2	-0.66	-6.33	-0.54	8.02e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs2663905	0.605	rs2683235	chr15:81398791	A/G	cg27419860	chr15:81426477	C15orf26	-0.72	-4.81	-0.44	5.63e-6	QT interval (drug interaction);
THYM	cis	rs9325144	0.505	rs6582691	chr12:38806894	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-5.61	-0.5	1.98e-7	Morning vs. evening chronotype;
THYM	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs7178572	0.568	rs11630689	chr15:77520094	C/T	cg22256960	chr15:77711686	NA	-1.04	-8.57	-0.66	1.83e-13	Type 2 diabetes;
THYM	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg00717180	chr2:96193071	NA	-0.7	-7.27	-0.6	9.91e-11	HDL cholesterol;
THYM	cis	rs790123	1.000	rs790113	chr3:122383276	T/A	cg17380795	chr3:122379686	NA	0.57	5.3	0.48	7.36e-7	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs4866334	1.000	rs77574409	chr5:18485477	G/T	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg09021430	chr5:549028	NA	0.61	5.8	0.51	8.66e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs11585357	0.689	rs2977293	chr1:17599444	C/T	cg08277548	chr1:17600880	PADI3	-0.6	-4.46	-0.42	2.28e-5	Hair shape;
THYM	cis	rs1907989	0.521	rs12650814	chr4:4808784	G/T	cg01956386	chr4:5056767	STK32B	-0.41	-4.65	-0.43	1.06e-5	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs57927100	0.800	rs3760143	chr17:75316497	C/T	cg18271897	chr17:75316784	SEPT9	0.79	8.06	0.64	2.29e-12	Systolic blood pressure;
THYM	cis	rs7246657	0.882	rs13345148	chr19:37819631	A/G	cg22634378	chr19:37742834	NA	0.62	5.12	0.47	1.57e-6	Coronary artery calcification;
THYM	cis	rs6964587	0.626	rs6979235	chr7:91511776	T/C	cg22709100	chr7:91322751	NA	-0.64	-4.72	-0.44	8e-6	Breast cancer;
THYM	cis	rs7830933	0.955	rs1550280	chr8:23601830	C/T	cg04349084	chr8:23602677	NA	0.65	7.36	0.6	6.49e-11	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg15536230	chr21:44985092	HSF2BP	0.42	5.04	0.46	2.26e-6	Mean corpuscular volume;
THYM	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg24910161	chr17:38119198	GSDMA	0.48	4.76	0.44	6.81e-6	Self-reported allergy;
THYM	cis	rs67311347	0.544	rs9868700	chr3:40345408	G/A	cg24209194	chr3:40518798	ZNF619	0.55	4.6	0.43	1.3e-5	Renal cell carcinoma;
THYM	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg04398451	chr17:18023971	MYO15A	0.96	10.54	0.73	1.17e-17	Total body bone mineral density;
THYM	cis	rs28595532	0.920	rs10025640	chr4:119787451	G/A	cg11846333	chr4:119757529	SEC24D	1.38	5.03	0.46	2.27e-6	Cannabis dependence symptom count;
THYM	cis	rs2562456	0.876	rs11085468	chr19:21751889	C/T	cg21751540	chr19:21541537	ZNF738	-0.69	-5.0	-0.46	2.58e-6	Pain;
THYM	cis	rs7639513	0.590	rs3729931	chr3:12626516	A/G	cg23032965	chr3:12705835	RAF1	-0.88	-6.78	-0.57	1.01e-9	Itch intensity from mosquito bite;
THYM	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg21028142	chr17:79581711	NPLOC4	0.65	6.66	0.56	1.75e-9	Eye color traits;
THYM	cis	rs6598955	0.671	rs12090258	chr1:26644698	C/T	cg08133631	chr1:26527909	CATSPER4	-0.63	-5.22	-0.47	1.05e-6	Obesity-related traits;
THYM	cis	rs700651	0.685	rs976180	chr2:198880443	C/T	cg00792783	chr2:198669748	PLCL1	-0.82	-5.63	-0.5	1.79e-7	Intracranial aneurysm;
THYM	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg13266496	chr6:110720918	DDO	-0.46	-5.05	-0.46	2.16e-6	Platelet distribution width;
THYM	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17253792	0.822	rs75016910	chr14:56050466	C/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs988913	0.957	rs9475100	chr6:54840233	C/T	cg19716238	chr6:54711378	FAM83B	0.5	4.91	0.45	3.76e-6	Menarche (age at onset);
THYM	cis	rs887829	0.569	rs871514	chr2:234628529	T/C	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.6	-0.43	1.3e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg00744431	chr10:134226547	PWWP2B	-0.6	-4.74	-0.44	7.41e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg08431931	chr22:42394659	WBP2NL	0.7	4.97	0.45	2.96e-6	Birth weight;
THYM	cis	rs713587	1.000	rs713587	chr2:25158281	C/T	cg01884057	chr2:25150051	NA	0.66	6.99	0.58	3.84e-10	Body mass index in non-asthmatics;
THYM	cis	rs4638749	1.000	rs1466213	chr2:108856607	G/A	cg06795125	chr2:108905320	SULT1C2	-0.4	-5.34	-0.48	6.42e-7	Blood pressure;
THYM	cis	rs7809950	1.000	rs2395883	chr7:107089670	T/C	cg23024343	chr7:107201750	COG5	-0.9	-8.07	-0.64	2.19e-12	Coronary artery disease;
THYM	cis	rs7260598	0.642	rs67799720	chr19:24164149	C/T	cg15526094	chr19:24182596	NA	-0.68	-4.87	-0.45	4.48e-6	Response to taxane treatment (placlitaxel);
THYM	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.55	-0.73	1.09e-17	Primary sclerosing cholangitis;
THYM	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs3741151	0.773	rs73542990	chr11:73134398	C/T	cg12959048	chr11:73096162	RELT	-0.53	-5.08	-0.46	1.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs3960554	0.808	rs78478514	chr7:75655896	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-4.59	-0.43	1.34e-5	Eotaxin levels;
THYM	cis	rs9972944	0.702	rs987930	chr17:63765862	C/T	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg24112000	chr20:60950667	NA	-0.62	-5.06	-0.46	2.07e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.15e-13	Diabetic kidney disease;
THYM	cis	rs6732160	0.574	rs12465780	chr2:73472012	A/G	cg24220031	chr2:73402428	NA	0.8	9.64	0.7	9.8e-16	Intelligence (multi-trait analysis);
THYM	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg22875332	chr1:76189707	ACADM	-0.55	-5.2	-0.47	1.13e-6	Daytime sleep phenotypes;
THYM	cis	rs12580035	0.524	rs3741973	chr12:1914321	T/C	cg25356715	chr12:1904796	CACNA2D4	0.47	4.76	0.44	6.83e-6	Urate levels in lean individuals;
THYM	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg22920501	chr2:26401640	FAM59B	-0.82	-7.38	-0.6	5.95e-11	Gut microbiome composition (summer);
THYM	trans	rs2274089	0.649	rs77244967	chr6:25536591	A/C	cg12244275	chr2:70355397	NA	1.28	6.93	0.58	4.98e-10	Iron status biomarkers;
THYM	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg21773646	chr17:80085082	CCDC57	-0.34	-4.91	-0.45	3.76e-6	Life satisfaction;
THYM	cis	rs3772130	0.962	rs9812137	chr3:121539103	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg00814883	chr7:100076585	TSC22D4	-1.0	-6.85	-0.57	7.35e-10	Platelet count;
THYM	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg22431228	chr1:16359049	CLCNKA	-0.53	-5.13	-0.47	1.51e-6	Dilated cardiomyopathy;
THYM	cis	rs2235649	0.746	rs113666107	chr16:1848642	C/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs4363385	0.782	rs10788857	chr1:153024941	T/G	cg13444842	chr1:152974279	SPRR3	-0.63	-5.12	-0.46	1.61e-6	Inflammatory skin disease;
THYM	cis	rs7267979	0.966	rs2261698	chr20:25259910	A/G	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs526231	0.511	rs3910557	chr5:102350471	T/A	cg23492399	chr5:102201601	PAM	-0.7	-5.21	-0.47	1.08e-6	Primary biliary cholangitis;
THYM	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg22105103	chr4:187893119	NA	0.92	10.09	0.72	1.04e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg15445000	chr17:37608096	MED1	-0.43	-4.75	-0.44	7.15e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg14458575	chr2:238380390	NA	0.9	7.53	0.61	2.94e-11	Prostate cancer;
THYM	cis	rs9902453	0.704	rs2617874	chr17:28085172	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	5.07	0.46	1.92e-6	Coffee consumption (cups per day);
THYM	cis	rs13177918	0.677	rs13161099	chr5:149822362	G/A	cg14059543	chr5:149831962	NA	-1.0	-7.6	-0.61	2.11e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-5.43	-0.49	4.23e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9902453	0.967	rs55748380	chr17:28469782	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	4.6	0.43	1.33e-5	Coffee consumption (cups per day);
THYM	cis	rs988913	0.957	rs4712081	chr6:54756529	A/G	cg18532076	chr6:54711417	FAM83B	-0.52	-4.8	-0.44	5.86e-6	Menarche (age at onset);
THYM	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg03806693	chr22:41940476	POLR3H	1.24	10.81	0.74	3.08e-18	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg25036284	chr2:26402008	FAM59B	-0.82	-5.32	-0.48	6.86e-7	Gut microbiome composition (summer);
THYM	cis	rs28595532	0.920	rs56302493	chr4:119772382	A/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs2070488	0.965	rs6599206	chr3:38545349	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.91	-6.67	-0.56	1.7e-9	Electrocardiographic conduction measures;
THYM	cis	rs7631605	0.967	rs9874437	chr3:37266678	C/T	cg21328643	chr3:37258149	NA	-0.48	-4.48	-0.42	2.07e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs9486719	1.000	rs2142653	chr6:96871520	C/A	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	6.47	0.55	4.21e-9	Schizophrenia;
THYM	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg03405983	chr8:143858548	LYNX1	-0.53	-5.69	-0.5	1.4e-7	Urinary tract infection frequency;
THYM	cis	rs854765	0.693	rs9915776	chr17:17749056	A/G	cg04398451	chr17:18023971	MYO15A	0.8	7.38	0.6	5.95e-11	Total body bone mineral density;
THYM	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg13319975	chr6:146136371	FBXO30	-0.69	-5.67	-0.5	1.51e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg11317459	chr13:21872234	NA	1.19	9.7	0.71	7.22e-16	White matter hyperintensity burden;
THYM	cis	rs9527	0.567	rs11191573	chr10:104896816	T/C	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4845570	1.000	rs3790514	chr1:151744168	T/C	cg18019451	chr1:151746047	TDRKH	-0.73	-4.49	-0.42	1.98e-5	Coronary artery disease;
THYM	cis	rs6430585	0.528	rs16832417	chr2:136744678	C/T	cg20242066	chr2:136595261	LCT	0.56	5.2	0.47	1.14e-6	Corneal structure;
THYM	cis	rs73086581	1.000	rs73086581	chr20:3977325	T/C	cg02187196	chr20:3869020	PANK2	0.5	5.66	0.5	1.61e-7	Response to antidepressants in depression;
THYM	cis	rs5758511	0.680	rs5758681	chr22:42645091	A/G	cg08431931	chr22:42394659	WBP2NL	0.63	4.7	0.43	8.83e-6	Birth weight;
THYM	cis	rs7572733	0.534	rs700672	chr2:198691455	G/A	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg26597838	chr10:835615	NA	1.23	8.88	0.67	4.1e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg02228675	chr17:40259724	DHX58	-0.62	-5.13	-0.47	1.55e-6	Fibrinogen levels;
THYM	cis	rs3204270	0.639	rs62080213	chr17:79642531	C/T	cg13117272	chr17:79681052	SLC25A10	-0.72	-4.48	-0.42	2.05e-5	Dental caries;
THYM	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg20891283	chr12:69753455	YEATS4	1.09	11.99	0.78	1.02e-20	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6665290	0.669	rs3738725	chr1:227174210	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.08	-12.43	-0.79	1.26e-21	Myeloid white cell count;
THYM	cis	rs4845875	0.530	rs4846048	chr1:11846252	A/G	cg24844545	chr1:11908347	NPPA	-0.56	-4.75	-0.44	7.33e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs7731657	0.537	rs10062336	chr5:130193668	T/A	cg08523029	chr5:130500466	HINT1	-0.74	-5.19	-0.47	1.2e-6	Fasting plasma glucose;
THYM	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg22535103	chr8:58192502	C8orf71	-0.96	-5.47	-0.49	3.7e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs55702914	0.904	rs73050839	chr2:198231218	T/G	cg00792783	chr2:198669748	PLCL1	0.66	4.73	0.44	7.88e-6	Major depression and alcohol dependence;
THYM	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg26441486	chr22:50317300	CRELD2	0.43	6.66	0.56	1.76e-9	Schizophrenia;
THYM	cis	rs3791556	0.898	rs3828222	chr2:240109568	A/G	cg27074582	chr2:240114406	HDAC4	-0.54	-4.86	-0.45	4.7e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg11461670	chr8:22454935	PDLIM2	-0.36	-5.82	-0.51	8e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs790123	0.842	rs2650957	chr3:122396097	C/G	cg15604389	chr3:122379662	NA	0.52	4.71	0.44	8.38e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs35110281	0.567	rs4819219	chr21:44984864	T/C	cg15536230	chr21:44985092	HSF2BP	-0.45	-5.63	-0.5	1.86e-7	Mean corpuscular volume;
THYM	cis	rs12282928	1.000	rs10838850	chr11:48285856	C/T	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1021993	1.000	rs2174775	chr1:209484767	T/C	cg06155620	chr1:209527581	NA	0.58	4.67	0.43	9.97e-6	Gut microbiome composition (winter);
THYM	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg20295408	chr7:1910781	MAD1L1	-0.65	-4.87	-0.45	4.47e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg07343612	chr16:622815	PIGQ	-1.08	-11.34	-0.76	2.36e-19	Height;
THYM	cis	rs7818345	0.935	rs6991212	chr8:19276522	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.65	0.43	1.07e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs9644630	0.930	rs6586839	chr8:19365543	A/T	cg01280390	chr8:19363452	CSGALNACT1	-0.81	-8.75	-0.67	7.56e-14	Oropharynx cancer;
THYM	cis	rs268134	0.530	rs13011574	chr2:65582052	T/C	cg03233656	chr2:65214625	SLC1A4	0.63	4.55	0.42	1.61e-5	Educational attainment (years of education);Systemic lupus erythematosus;
THYM	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.95	0.68	2.83e-14	Chronic sinus infection;
THYM	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-6.98	-0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg05768032	chr16:30646687	NA	0.52	5.48	0.49	3.5e-7	Multiple myeloma;
THYM	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg07061783	chr6:25882402	NA	-0.76	-6.09	-0.53	2.37e-8	Intelligence (multi-trait analysis);
THYM	cis	rs13315871	0.929	rs13075746	chr3:58293867	G/A	cg00563845	chr3:58318305	PXK	0.59	5.03	0.46	2.29e-6	Cholesterol, total;
THYM	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg02734326	chr4:10020555	SLC2A9	-0.59	-4.77	-0.44	6.72e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg13695892	chr22:41940480	POLR3H	-0.72	-6.71	-0.57	1.39e-9	Vitiligo;
THYM	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg16797656	chr11:68205561	LRP5	0.45	4.78	0.44	6.46e-6	Total body bone mineral density;
THYM	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg06808227	chr14:105710500	BRF1	-1.04	-9.02	-0.68	2.02e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7772486	0.817	rs9322047	chr6:146400394	G/A	cg23711669	chr6:146136114	FBXO30	0.95	10.14	0.72	8.37e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs5769707	0.521	rs739244	chr22:50060158	A/G	cg20744362	chr22:50050164	C22orf34	0.61	5.41	0.49	4.63e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg21433313	chr16:3507492	NAT15	-0.58	-4.91	-0.45	3.71e-6	Body mass index (adult);
THYM	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg18904891	chr8:8559673	CLDN23	0.67	5.52	0.49	2.92e-7	Mood instability;
THYM	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg07636037	chr3:49044803	WDR6	0.97	10.07	0.72	1.15e-16	Parkinson's disease;
THYM	cis	rs988913	0.678	rs4407708	chr6:54978059	A/C	cg18532076	chr6:54711417	FAM83B	0.49	4.62	0.43	1.18e-5	Menarche (age at onset);
THYM	cis	rs74925218	1	rs74925218	chr15:78796732	C/T	cg18825076	chr15:78729989	IREB2	0.7	5.4	0.48	4.91e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg05084668	chr3:125655381	ALG1L	-0.71	-4.61	-0.43	1.23e-5	Blood pressure (smoking interaction);
THYM	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg10057126	chr4:77819792	ANKRD56	0.72	6.14	0.53	1.93e-8	Emphysema distribution in smoking;
THYM	cis	rs9486715	1.000	rs6905737	chr6:97066659	A/T	cg06623918	chr6:96969491	KIAA0776	-1.05	-10.59	-0.74	9.01e-18	Headache;
THYM	cis	rs79149102	0.579	rs7163390	chr15:75280426	T/C	cg09165964	chr15:75287851	SCAMP5	-1.08	-5.99	-0.52	3.79e-8	Lung cancer;
THYM	cis	rs2933343	0.729	rs789230	chr3:128602558	G/A	cg11901034	chr3:128598214	ACAD9	-0.71	-5.55	-0.49	2.56e-7	IgG glycosylation;
THYM	cis	rs990171	0.802	rs1558650	chr2:103060024	T/A	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.08	-0.46	1.87e-6	Lymphocyte counts;
THYM	cis	rs7677751	0.848	rs7673625	chr4:55088586	C/T	cg17187183	chr4:55093834	PDGFRA	0.7	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs7575217	0.767	rs6543018	chr2:101730288	A/G	cg23907051	chr2:101730305	TBC1D8	0.42	5.77	0.51	1e-7	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	5.95	0.52	4.51e-8	Total body bone mineral density;
THYM	cis	rs6743226	0.870	rs4675966	chr2:242244342	T/C	cg10021735	chr2:242295487	FARP2	0.63	4.49	0.42	1.98e-5	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg08645402	chr16:4508243	NA	0.77	7.09	0.59	2.4e-10	Schizophrenia;
THYM	cis	rs904251	0.861	rs1757169	chr6:37487076	G/T	cg01843034	chr6:37503916	NA	-0.71	-5.61	-0.5	1.98e-7	Cognitive performance;
THYM	cis	rs250677	0.522	rs10045726	chr5:148352990	C/T	cg18129178	chr5:148520854	ABLIM3	0.68	5.01	0.46	2.54e-6	Breast cancer;
THYM	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg25817165	chr18:72167213	CNDP2	-0.98	-8.01	-0.63	2.9e-12	Refractive error;
THYM	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg07061783	chr6:25882402	NA	-0.6	-4.6	-0.43	1.31e-5	Height;
THYM	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	9.37	0.69	3.62e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1697139	0.604	rs874550	chr5:66530945	C/T	cg11553311	chr5:66541588	NA	-0.69	-7.24	-0.6	1.16e-10	Breast cancer;
THYM	cis	rs35934224	0.783	rs9754418	chr22:19854733	A/G	cg11182965	chr22:19864308	TXNRD2	-0.68	-5.74	-0.51	1.11e-7	Glaucoma (primary open-angle);
THYM	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg10862848	chr6:42927986	GNMT	-0.51	-6.51	-0.56	3.5e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg06728252	chr6:26598149	ABT1	-0.43	-5.08	-0.46	1.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-1.04	-5.06	-0.46	2.04e-6	Alzheimer's disease;
THYM	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.71	-5.98	-0.52	3.95e-8	Lymphocyte counts;
THYM	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg20290983	chr6:43655470	MRPS18A	1.18	7.85	0.63	6.13e-12	IgG glycosylation;
THYM	cis	rs13064411	0.696	rs1386336	chr3:113144153	C/T	cg10517650	chr3:113235015	CCDC52	-0.6	-5.06	-0.46	2.06e-6	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs6531656	0.848	rs1056583	chr4:38664715	A/C	cg24279243	chr4:38676559	KLF3	0.81	5.49	0.49	3.3e-7	Lymphocyte counts;
THYM	cis	rs9905704	0.874	rs304265	chr17:56749298	C/T	cg12560992	chr17:57184187	TRIM37	0.67	4.68	0.43	9.59e-6	Testicular germ cell tumor;
THYM	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg10589385	chr1:150898437	SETDB1	0.64	5.24	0.47	9.73e-7	Melanoma;
THYM	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg14972814	chr11:95582409	MTMR2	-0.58	-5.2	-0.47	1.14e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs62070183	0.938	rs62068432	chr17:31066497	A/G	cg23177095	chr17:30873196	MYO1D	0.66	5.14	0.47	1.48e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs7909791	0.606	rs3814219	chr10:105647095	A/G	cg24587175	chr10:105670608	OBFC1	-0.76	-7.41	-0.61	5.2e-11	White matter hyperintensity burden;
THYM	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg06138931	chr13:21896616	NA	0.59	5.08	0.46	1.89e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs6032067	1.000	rs13038434	chr20:43888106	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.62	-6.2	-0.54	1.47e-8	Blood protein levels;
THYM	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg11247378	chr22:39784982	NA	-0.97	-10.29	-0.73	4.06e-17	Intelligence (multi-trait analysis);
THYM	cis	rs7100689	0.784	rs7081903	chr10:82162509	T/C	cg01528321	chr10:82214614	TSPAN14	1.08	8.58	0.66	1.76e-13	Post bronchodilator FEV1;
THYM	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg18252515	chr7:66147081	NA	0.64	4.9	0.45	3.89e-6	Aortic root size;
THYM	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.79e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs7312774	0.881	rs7309260	chr12:107313254	T/A	cg16260113	chr12:107380972	MTERFD3	0.97	5.63	0.5	1.84e-7	Severe influenza A (H1N1) infection;
THYM	cis	rs1403694	0.966	rs1656908	chr3:186437342	T/C	cg12454167	chr3:186435060	KNG1	0.45	5.95	0.52	4.46e-8	Blood protein levels;
THYM	cis	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg17333051	chr19:2783644	SGTA	0.56	5.18	0.47	1.22e-6	Total cholesterol levels;
THYM	trans	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg26043149	chr18:55253948	FECH	1.21	11.52	0.76	9.63e-20	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg00071950	chr4:10020882	SLC2A9	0.87	10.34	0.73	3.16e-17	Bone mineral density;
THYM	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-5.85	-0.51	7.06e-8	Total body bone mineral density;
THYM	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs7106204	0.514	rs7935857	chr11:24252420	C/T	ch.11.24196551F	chr11:24239977	NA	1.02	7.07	0.59	2.58e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs4919044	0.808	rs2478238	chr10:94805531	A/G	cg05127821	chr10:94822908	CYP26C1	-1.23	-6.66	-0.56	1.76e-9	Coronary artery disease;
THYM	cis	rs6547741	1.000	rs10205364	chr2:27794233	C/T	cg27432699	chr2:27873401	GPN1	0.68	5.97	0.52	4.14e-8	Oral cavity cancer;
THYM	cis	rs12039431	0.589	rs61776186	chr1:38011993	G/C	cg17933807	chr1:38061675	GNL2	-0.8	-5.98	-0.52	3.83e-8	Epithelial ovarian cancer;
THYM	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg18252515	chr7:66147081	NA	-0.63	-4.68	-0.43	9.63e-6	Aortic root size;
THYM	cis	rs920590	0.684	rs59565447	chr8:19668430	A/T	cg01411142	chr8:19674711	INTS10	0.68	5.37	0.48	5.48e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg08305652	chr11:111469057	NA	0.53	4.51	0.42	1.88e-5	Primary sclerosing cholangitis;
THYM	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.54	-4.51	-0.42	1.86e-5	Coronary artery disease;
THYM	cis	rs9906944	0.707	rs729003	chr17:47117775	C/T	cg11673840	chr17:47092156	IGF2BP1	-0.54	-5.48	-0.49	3.55e-7	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs2625529	0.775	rs4777484	chr15:72376543	T/C	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs986417	1.000	rs958504	chr14:60949740	G/A	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs1957429	0.731	rs28370916	chr14:65346094	A/G	cg23373153	chr14:65346875	NA	1.09	6.45	0.55	4.57e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg26038318	chr20:34205095	SPAG4	0.65	5.26	0.48	8.7e-7	Total cholesterol levels;
THYM	cis	rs2286885	1.000	rs10733677	chr9:129242209	A/G	cg14319473	chr9:129242481	FAM125B	0.64	4.74	0.44	7.38e-6	Intraocular pressure;
THYM	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg02825527	chr7:2087843	MAD1L1	-0.75	-4.96	-0.45	3.1e-6	Bipolar disorder;
THYM	cis	rs12681287	0.640	rs6471309	chr8:87387760	C/T	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg14983838	chr19:29218262	NA	0.98	7.32	0.6	7.87e-11	Methadone dose in opioid dependence;
THYM	cis	rs13215566	1.000	rs35124757	chr6:89918215	A/T	cg08400210	chr6:89908154	GABRR1	0.87	4.77	0.44	6.53e-6	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg06634786	chr22:41940651	POLR3H	0.71	5.22	0.47	1.07e-6	Vitiligo;
THYM	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs7584099	0.516	rs7577025	chr2:148747439	A/G	cg23727674	chr2:148602993	ACVR2A	0.54	4.73	0.44	7.88e-6	Response to statin therapy;
THYM	cis	rs36051895	0.632	rs11791281	chr9:5172540	G/A	cg02405213	chr9:5042618	JAK2	-1.0	-10.58	-0.74	9.7e-18	Pediatric autoimmune diseases;
THYM	cis	rs2898681	0.618	rs7677726	chr4:53739262	A/G	cg21521518	chr4:53727714	RASL11B	-0.62	-5.61	-0.5	1.97e-7	Optic nerve measurement (cup area);
THYM	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg06766960	chr11:133703094	NA	-0.6	-5.5	-0.49	3.24e-7	Childhood ear infection;
THYM	cis	rs1451375	1.000	rs10247443	chr7:50620586	G/A	cg18232548	chr7:50535776	DDC	0.73	5.66	0.5	1.57e-7	Malaria;
THYM	cis	rs71403859	0.570	rs77809998	chr16:71430687	C/T	cg08717414	chr16:71523259	ZNF19	-1.13	-4.58	-0.43	1.41e-5	Post bronchodilator FEV1;
THYM	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg04034577	chr2:241836375	C2orf54	-0.43	-7.58	-0.61	2.31e-11	Urinary metabolites;
THYM	cis	rs669446	0.591	rs574736	chr1:44106266	C/T	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7940866	0.801	rs2113928	chr11:130835975	A/G	cg12179176	chr11:130786555	SNX19	0.66	5.03	0.46	2.27e-6	Schizophrenia;
THYM	cis	rs7814319	0.700	rs11995989	chr8:97264456	C/G	cg20787634	chr8:97240163	UQCRB	-0.74	-7.04	-0.59	3.03e-10	Lung function (FVC);
THYM	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs7614311	0.636	rs73117041	chr3:63896266	A/T	cg22134162	chr3:63841271	THOC7	-0.58	-7.03	-0.59	3.13e-10	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs9290065	0.519	rs6441346	chr3:160709229	C/T	cg03342759	chr3:160939853	NMD3	-0.59	-4.56	-0.42	1.52e-5	Kawasaki disease;
THYM	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg25918947	chr17:41365094	TMEM106A	-0.57	-4.79	-0.44	6.13e-6	Menopause (age at onset);
THYM	cis	rs9325144	0.560	rs10876005	chr12:39126149	C/G	cg26384229	chr12:38710491	ALG10B	-0.83	-7.3	-0.6	8.71e-11	Morning vs. evening chronotype;
THYM	cis	rs67311347	0.544	rs9814779	chr3:40340431	T/C	cg13683864	chr3:40499215	RPL14	-0.79	-7.44	-0.61	4.43e-11	Renal cell carcinoma;
THYM	cis	rs8133932	0.654	rs382303	chr21:47349284	G/A	cg20357416	chr21:47294739	PCBP3	0.8	4.88	0.45	4.26e-6	Schizophrenia;
THYM	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.99	8.04	0.64	2.52e-12	Schizophrenia;
THYM	cis	rs6570726	0.846	rs446031	chr6:145885592	C/T	cg13319975	chr6:146136371	FBXO30	-0.67	-5.44	-0.49	4.21e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13102973	0.965	rs13131455	chr4:135883112	A/C	cg14419869	chr4:135874104	NA	-0.89	-8.63	-0.66	1.39e-13	Subjective well-being;
THYM	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg09333631	chr3:44802604	KIF15;KIAA1143	0.45	4.73	0.44	7.87e-6	Depressive symptoms;
THYM	cis	rs6840360	0.571	rs62327270	chr4:152533618	C/T	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6121246	0.559	rs6060933	chr20:30351903	C/T	cg13852791	chr20:30311386	BCL2L1	1.02	10.02	0.72	1.48e-16	Mean corpuscular hemoglobin;
THYM	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs80319144	0.953	rs78536365	chr2:159174724	C/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.6	4.64	0.43	1.12e-5	Restless legs syndrome;
THYM	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.9	-6.67	-0.56	1.72e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9658691	0.607	rs12411452	chr10:90780607	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.88	-5.87	-0.52	6.48e-8	Mosquito bite size;
THYM	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs10779751	1.000	rs12730522	chr1:11284091	G/A	cg08854313	chr1:11322531	MTOR	1.01	9.78	0.71	4.97e-16	Body mass index;
THYM	cis	rs6032067	0.641	rs34811768	chr20:43765800	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.64	-5.8	-0.51	8.81e-8	Blood protein levels;
THYM	cis	rs7426056	0.671	rs3116487	chr2:204586037	C/G	cg07930752	chr2:204569955	CD28	-0.65	-4.53	-0.42	1.71e-5	Primary sclerosing cholangitis;
THYM	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg19507638	chr5:93509721	C5orf36	-0.7	-4.71	-0.44	8.43e-6	Diabetic retinopathy;
THYM	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg24846343	chr22:24311635	DDTL	-0.44	-5.53	-0.49	2.77e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7089973	0.624	rs61867965	chr10:116574794	A/T	cg23260525	chr10:116636907	FAM160B1	0.53	5.32	0.48	6.94e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7187994	0.848	rs12933228	chr16:84770691	G/A	cg07647771	chr16:84786436	USP10	-0.57	-4.73	-0.44	7.95e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg11764359	chr7:65958608	NA	0.78	6.31	0.54	8.88e-9	Aortic root size;
THYM	cis	rs61931739	0.927	rs1906135	chr12:34038103	C/A	cg10856724	chr12:34555212	NA	0.63	5.33	0.48	6.57e-7	Morning vs. evening chronotype;
THYM	cis	rs1847202	0.592	rs13073005	chr3:72951007	C/T	cg25664220	chr3:72788482	NA	-0.67	-5.01	-0.46	2.48e-6	Motion sickness;
THYM	cis	rs4731207	0.698	rs9886177	chr7:124513450	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7216064	0.953	rs4791046	chr17:65851973	G/A	cg12091567	chr17:66097778	LOC651250	-0.73	-5.06	-0.46	2.01e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Urate levels;
THYM	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03452623	chr4:187889614	NA	-1.19	-19.53	-0.89	4.93e-35	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	10.73	0.74	4.66e-18	Chronic sinus infection;
THYM	cis	rs72717009	0.825	rs11810143	chr1:161480649	A/G	cg15358701	chr1:161410459	NA	-0.92	-4.83	-0.44	5.17e-6	Rheumatoid arthritis;
THYM	cis	rs9560113	0.573	rs9560133	chr13:112240013	C/A	cg14154082	chr13:112174009	NA	0.5	4.47	0.42	2.14e-5	Menarche (age at onset);
THYM	cis	rs1267303	0.675	rs1745370	chr1:46982863	C/G	cg25110126	chr1:46999211	NA	-0.71	-5.28	-0.48	8.29e-7	Monobrow;
THYM	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg19904058	chr10:135279010	LOC619207	-0.5	-4.7	-0.43	8.9e-6	Systemic lupus erythematosus;
THYM	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg09367891	chr1:107599246	PRMT6	-0.69	-4.9	-0.45	3.88e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg12908607	chr1:44402522	ARTN	-0.52	-4.67	-0.43	9.88e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs11209185	0.509	rs12142271	chr1:68446837	A/G	cg22082780	chr1:68452167	NA	0.53	6.09	0.53	2.34e-8	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs2034088	0.897	rs11652657	chr17:439124	A/G	cg13332499	chr17:408570	NA	0.55	4.65	0.43	1.07e-5	Hip circumference adjusted for BMI;
THYM	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg08999081	chr20:33150536	PIGU	-0.59	-5.22	-0.47	1.03e-6	Height;
THYM	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg24642439	chr20:33292090	TP53INP2	0.7	5.46	0.49	3.77e-7	Coronary artery disease;
THYM	cis	rs72781680	0.898	rs12612492	chr2:24093756	C/T	cg08917208	chr2:24149416	ATAD2B	1.11	4.97	0.45	2.9e-6	Lymphocyte counts;
THYM	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg17211192	chr8:82754475	SNX16	-0.79	-6.97	-0.58	4.24e-10	Diastolic blood pressure;
THYM	cis	rs7178572	0.524	rs2175941	chr15:77584498	T/C	cg22256960	chr15:77711686	NA	-1.03	-8.45	-0.66	3.3e-13	Type 2 diabetes;
THYM	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg02187348	chr16:89574699	SPG7	-0.79	-6.92	-0.58	5.2e-10	Multiple myeloma (IgH translocation);
THYM	cis	rs7216064	1.000	rs12600941	chr17:65918807	A/G	cg12091567	chr17:66097778	LOC651250	-0.69	-4.51	-0.42	1.86e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs2898681	0.874	rs6852148	chr4:53750002	T/C	cg00338735	chr4:53728038	RASL11B	0.53	4.53	0.42	1.73e-5	Optic nerve measurement (cup area);
THYM	cis	rs4523957	0.583	rs923864	chr17:2031507	C/T	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs12971120	0.838	rs3794950	chr18:72182965	G/A	cg25817165	chr18:72167213	CNDP2	-0.98	-7.33	-0.6	7.62e-11	Refractive error;
THYM	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg20999797	chr1:1681921	NA	0.51	5.52	0.49	2.92e-7	Body mass index;
THYM	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg25208724	chr1:156163844	SLC25A44	1.17	13.26	0.81	2.43e-23	Testicular germ cell tumor;
THYM	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	5.59	0.5	2.16e-7	Monocyte percentage of white cells;
THYM	cis	rs977987	0.836	rs7198873	chr16:75474754	G/A	cg03315344	chr16:75512273	CHST6	0.74	5.92	0.52	5.07e-8	Dupuytren's disease;
THYM	cis	rs7107174	1.000	rs10899454	chr11:77997513	T/C	cg19901956	chr11:77921274	USP35	-0.73	-5.52	-0.49	2.88e-7	Testicular germ cell tumor;
THYM	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg18758796	chr5:131593413	PDLIM4	-0.49	-4.64	-0.43	1.13e-5	Breast cancer;
THYM	cis	rs67072384	0.818	rs2291291	chr11:72466897	T/C	cg01380194	chr11:72452482	ARAP1	-0.81	-4.57	-0.42	1.49e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg15704280	chr7:45808275	SEPT13	1.01	7.86	0.63	5.81e-12	Coronary artery disease;
THYM	cis	rs1045902	0.574	rs1053329	chr2:73461483	C/A	cg24220031	chr2:73402428	NA	-0.62	-5.22	-0.47	1.05e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.844	rs12673697	chr7:124395006	G/C	cg05285228	chr7:124571219	POT1	0.71	5.63	0.5	1.84e-7	Cutaneous malignant melanoma;
THYM	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg23018236	chr17:30244563	NA	-0.6	-4.45	-0.42	2.3e-5	Hip circumference adjusted for BMI;
THYM	cis	rs2985684	0.948	rs4900925	chr14:50012325	A/G	cg02151108	chr14:50098012	C14orf104	0.73	5.99	0.52	3.71e-8	Carotid intima media thickness;
THYM	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg20503657	chr10:835505	NA	1.37	9.33	0.69	4.52e-15	Eosinophil percentage of granulocytes;
THYM	cis	rs72829446	0.530	rs59665520	chr17:7383136	C/A	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg03709012	chr19:19516395	GATAD2A	0.76	6.05	0.53	2.89e-8	Tonsillectomy;
THYM	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.82	6.23	0.54	1.24e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs11910985	0.546	rs9977877	chr21:48080493	G/A	cg17243659	chr21:48055224	PRMT2	0.86	4.57	0.42	1.46e-5	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs10743315	0.778	rs9805106	chr12:19372357	A/G	cg02471346	chr12:19282374	PLEKHA5	-0.8	-4.98	-0.46	2.82e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02018176	chr4:1364513	KIAA1530	-0.91	-8.33	-0.65	6.14e-13	Longevity;
THYM	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg06481639	chr22:41940642	POLR3H	0.7	5.12	0.47	1.57e-6	Vitiligo;
THYM	cis	rs12532214	0.697	rs4324842	chr7:3171664	T/C	cg19214707	chr7:3157722	NA	-0.87	-5.39	-0.48	5.09e-7	Itch intensity from mosquito bite;
THYM	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs12956009	0.583	rs11662486	chr18:44868325	C/T	cg19077165	chr18:44547161	KATNAL2	-0.49	-4.57	-0.42	1.49e-5	Educational attainment (years of education);
THYM	cis	rs9810089	0.934	rs66691851	chr3:136154828	C/T	cg12473912	chr3:136751656	NA	0.62	5.22	0.47	1.05e-6	Gestational age at birth (child effect);
THYM	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg11812906	chr14:75593930	NEK9	0.89	8.2	0.64	1.11e-12	Height;
THYM	cis	rs9443645	0.589	rs6938951	chr6:79477620	A/C	cg04547799	chr6:79944526	HMGN3	-0.68	-5.08	-0.46	1.92e-6	Intelligence (multi-trait analysis);
THYM	cis	rs889398	0.802	rs12919094	chr16:69843357	A/G	cg09409435	chr16:70099608	PDXDC2	-0.59	-4.47	-0.42	2.13e-5	Body mass index;
THYM	cis	rs7072216	0.650	rs10883089	chr10:100163120	A/C	cg03852570	chr10:100175106	PYROXD2	0.36	4.58	0.43	1.39e-5	Metabolite levels;
THYM	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg26967526	chr14:35346199	BAZ1A	-0.72	-5.33	-0.48	6.65e-7	Psoriasis;
THYM	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs56979318	1	rs56979318	chr17:80522718	A/T	cg10255544	chr17:80519551	FOXK2	0.5	4.45	0.42	2.3e-5	Reticulocyte count;
THYM	cis	rs6499129	0.571	rs12051249	chr16:67241427	A/G	cg26912222	chr16:68000829	SLC12A4	0.73	4.81	0.44	5.71e-6	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs422249	0.547	rs174536	chr11:61551927	A/C	cg19610905	chr11:61596333	FADS2	-0.6	-5.03	-0.46	2.31e-6	Trans fatty acid levels;
THYM	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg15388900	chr16:88312269	NA	-0.6	-4.52	-0.42	1.77e-5	Social autistic-like traits;
THYM	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg24209194	chr3:40518798	ZNF619	0.6	5.06	0.46	2.05e-6	Renal cell carcinoma;
THYM	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg03647317	chr4:187891568	NA	-0.84	-9.05	-0.68	1.74e-14	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg07393940	chr7:158741817	NA	-1.14	-9.25	-0.69	6.69e-15	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg21609526	chr1:3105151	PRDM16	0.61	5.09	0.46	1.81e-6	Migraine;
THYM	cis	rs61931739	0.635	rs10743836	chr12:33961680	C/T	cg06521331	chr12:34319734	NA	-0.56	-4.69	-0.43	8.97e-6	Morning vs. evening chronotype;
THYM	cis	rs7772486	0.875	rs9399572	chr6:146362945	T/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.74	-5.52	-0.49	2.88e-7	Systemic lupus erythematosus;
THYM	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-4.54	-0.42	1.62e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs9549367	0.588	rs9549360	chr13:113893032	C/G	cg00898013	chr13:113819073	PROZ	-0.78	-5.69	-0.5	1.42e-7	Platelet distribution width;
THYM	cis	rs13064411	0.696	rs6768979	chr3:113204149	G/A	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.64	-5.34	-0.48	6.3e-7	Monocyte percentage of white cells;
THYM	cis	rs8114671	0.967	rs2093058	chr20:33791281	C/T	cg08999081	chr20:33150536	PIGU	-0.53	-4.77	-0.44	6.63e-6	Height;
THYM	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg08008072	chr16:1524255	CLCN7	0.54	6.68	0.57	1.58e-9	Bone mineral density;
THYM	cis	rs514406	0.928	rs1672917	chr1:53291550	A/G	cg08736216	chr1:53307985	ZYG11A	-0.62	-5.7	-0.5	1.37e-7	Monocyte count;
THYM	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs2239547	0.563	rs2581820	chr3:53020544	A/G	cg11645453	chr3:52864694	ITIH4	-0.29	-4.74	-0.44	7.63e-6	Schizophrenia;
THYM	cis	rs295137	0.836	rs1217429	chr2:201094151	G/T	cg23649088	chr2:200775458	C2orf69	0.62	5.41	0.49	4.7e-7	Asthma (bronchodilator response);
THYM	cis	rs750134	0.901	rs78866567	chr12:109180115	G/T	cg07887608	chr12:109221600	SSH1	0.87	4.87	0.45	4.37e-6	Low high density lipoprotein cholesterol levels;
THYM	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg26384229	chr12:38710491	ALG10B	1.01	7.83	0.63	6.96e-12	Heart rate;
THYM	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg23583168	chr7:148888333	NA	-1.02	-13.7	-0.81	3.17e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg02187348	chr16:89574699	SPG7	0.8	6.67	0.56	1.7e-9	Multiple myeloma (IgH translocation);
THYM	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs1372520	0.564	rs2737011	chr4:90746219	T/C	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs11048434	0.518	rs1805669	chr12:9180251	T/C	cg26114124	chr12:9217669	LOC144571	0.52	4.54	0.42	1.66e-5	Sjögren's syndrome;
THYM	cis	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs2976388	0.967	rs2976395	chr8:143763750	G/A	cg06565975	chr8:143823917	SLURP1	-0.45	-5.23	-0.47	9.95e-7	Urinary tract infection frequency;
THYM	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg04756594	chr16:24857601	SLC5A11	-0.77	-5.35	-0.48	6.1e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg17063962	chr7:91808500	NA	1.16	13.12	0.8	4.77e-23	Breast cancer;
THYM	cis	rs6089829	0.888	rs6011559	chr20:61675620	C/T	cg08564027	chr20:61660810	NA	-1.0	-10.6	-0.74	8.76e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4242434	0.819	rs1059592	chr8:22477778	G/A	cg11461670	chr8:22454935	PDLIM2	-0.32	-6.07	-0.53	2.63e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2237898	0.585	rs35678303	chr11:2878958	G/A	cg12614029	chr11:2160564	INS-IGF2;IGF2AS;IGF2	-1.21	-4.5	-0.42	1.89e-5	Mosquito bite size;
THYM	cis	rs11190604	0.767	rs4559620	chr10:102199935	C/T	cg07570687	chr10:102243282	WNT8B	0.8	7.69	0.62	1.37e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg08132940	chr7:1081526	C7orf50	-0.77	-5.19	-0.47	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs12928939	0.815	rs61753635	chr16:71660404	G/A	cg02602352	chr16:70688171	IL34	0.42	4.53	0.42	1.69e-5	Post bronchodilator FEV1;
THYM	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-6.33	-0.54	8.23e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs4654899	0.931	rs4654726	chr1:21203898	A/C	cg01072550	chr1:21505969	NA	0.71	6.48	0.55	4.12e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs747334	0.846	rs1122870	chr10:92716729	C/T	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg26418147	chr1:205743515	RAB7L1	-0.57	-4.98	-0.46	2.82e-6	Menarche (age at onset);
THYM	cis	rs4343996	0.565	rs13246563	chr7:3438243	C/G	cg21248987	chr7:3385318	SDK1	0.4	5.29	0.48	7.97e-7	Motion sickness;
THYM	cis	rs11039798	1.000	rs115429994	chr11:48761183	C/G	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs7177699	0.526	rs7182529	chr15:79123631	T/C	cg00540400	chr15:79124168	NA	0.65	7.03	0.58	3.16e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs28829049	0.597	rs2313509	chr1:19437860	C/T	cg13387374	chr1:19411106	UBR4	0.67	4.96	0.45	3.08e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs67311347	0.544	rs6599088	chr3:40329288	T/C	cg13683864	chr3:40499215	RPL14	-0.76	-7.1	-0.59	2.3e-10	Renal cell carcinoma;
THYM	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.74	4.52	0.42	1.79e-5	Diabetic retinopathy;
THYM	cis	rs9581857	0.546	rs9579082	chr13:27965763	C/T	cg22138327	chr13:27999177	GTF3A	0.99	5.52	0.49	2.99e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.96	-0.45	3.07e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06481639	chr22:41940642	POLR3H	-0.79	-5.46	-0.49	3.87e-7	Vitiligo;
THYM	cis	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg10856724	chr12:34555212	NA	-0.92	-9.14	-0.68	1.12e-14	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg08994789	chr17:28903642	LRRC37B2	-1.03	-4.96	-0.45	3.05e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg05368731	chr17:41323189	NBR1	-1.11	-10.16	-0.72	7.45e-17	Menopause (age at onset);
THYM	cis	rs8141529	0.778	rs9625566	chr22:29162506	G/A	cg02153584	chr22:29168773	CCDC117	0.72	5.5	0.49	3.13e-7	Lymphocyte counts;
THYM	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg25036284	chr2:26402008	FAM59B	-0.8	-5.36	-0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs7213347	0.799	rs216195	chr17:2203167	T/G	cg19216660	chr17:2268602	SGSM2	-0.5	-4.62	-0.43	1.21e-5	Total body bone mineral density;
THYM	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.36	5.15	0.47	1.38e-6	Obesity-related traits;
THYM	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs910187	0.641	rs3818011	chr20:45816566	A/G	cg27589058	chr20:45804311	EYA2	-0.59	-5.04	-0.46	2.21e-6	Migraine;
THYM	cis	rs10927875	0.541	rs1739843	chr1:16343254	T/C	cg21385522	chr1:16154831	NA	0.65	4.65	0.43	1.08e-5	Dilated cardiomyopathy;
THYM	cis	rs1981331	1.000	rs75843712	chr21:47976115	A/G	cg23283320	chr21:48055893	PRMT2	1.15	5.47	0.49	3.71e-7	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs45430	0.635	rs398800	chr21:42742212	A/C	cg06102954	chr21:42741788	MX2	-0.66	-4.5	-0.42	1.94e-5	Melanoma;
THYM	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg27494647	chr7:150038898	RARRES2	0.46	5.81	0.51	8.13e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs611744	0.967	rs475865	chr8:109235858	G/C	cg21045802	chr8:109455806	TTC35	0.6	5.31	0.48	7.15e-7	Dupuytren's disease;
THYM	cis	rs17767294	0.708	rs77450054	chr6:28083949	G/A	cg08851530	chr6:28072375	NA	1.15	4.46	0.42	2.28e-5	Parkinson's disease;
THYM	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg00944433	chr1:107599041	PRMT6	0.4	5.17	0.47	1.28e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs4660531	0.890	rs61229336	chr1:41834935	C/T	cg08462924	chr1:41848221	NA	0.64	5.98	0.52	3.86e-8	Bipolar disorder;
THYM	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg15744005	chr10:104629667	AS3MT	-0.82	-7.79	-0.62	8.37e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9462846	1.000	rs2894484	chr6:42851497	A/G	cg10862848	chr6:42927986	GNMT	-0.45	-4.68	-0.43	9.33e-6	Blood protein levels;
THYM	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg00717180	chr2:96193071	NA	-0.7	-7.27	-0.6	1.01e-10	HDL cholesterol;
THYM	cis	rs921968	0.643	rs563268	chr2:219372912	T/G	cg02176678	chr2:219576539	TTLL4	0.64	6.08	0.53	2.49e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs600806	0.778	rs2039694	chr1:109991700	A/G	cg02175308	chr1:109941060	SORT1	-0.55	-4.59	-0.43	1.33e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg15448220	chr1:150897856	SETDB1	0.89	7.59	0.61	2.17e-11	Melanoma;
THYM	cis	rs28785552	0.769	rs7253672	chr19:53243212	G/C	cg10871876	chr19:53194124	ZNF83	0.81	6.86	0.58	6.83e-10	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs9329289	0.510	rs28579610	chr10:2546080	C/A	cg07014206	chr10:2547000	NA	-0.59	-5.32	-0.48	6.89e-7	Age-related hearing impairment;
THYM	cis	rs6539288	0.500	rs11113116	chr12:107195929	C/A	cg15890332	chr12:107067104	RFX4	0.48	5.63	0.5	1.81e-7	Total body bone mineral density;
THYM	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-7.24	-0.6	1.15e-10	Schizophrenia;
THYM	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-4.73	-0.44	7.71e-6	Mood instability;
THYM	cis	rs3017493	0.786	rs78344725	chr11:70687830	G/A	cg03578926	chr11:70508032	SHANK2	0.88	4.93	0.45	3.52e-6	Renal transplant outcome;
THYM	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg18402987	chr7:1209562	NA	0.6	4.61	0.43	1.25e-5	Longevity;Endometriosis;
THYM	cis	rs8067545	1.000	rs8067545	chr17:19912710	T/C	cg20830565	chr17:20408647	MGC102966	-0.5	-4.67	-0.43	9.85e-6	Schizophrenia;
THYM	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.68	6.04	0.53	2.94e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-4.49	-0.42	1.99e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs13064411	0.518	rs1552433	chr3:113225730	C/A	cg18753928	chr3:113234510	CCDC52	-0.78	-7.16	-0.59	1.68e-10	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	5.8	0.51	8.76e-8	Monocyte percentage of white cells;
THYM	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.95	6.45	0.55	4.57e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6988636	1.000	rs59601467	chr8:124193488	C/T	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs4343996	0.566	rs6971287	chr7:3396180	T/G	cg21248987	chr7:3385318	SDK1	-0.4	-5.14	-0.47	1.44e-6	Motion sickness;
THYM	cis	rs4595586	0.545	rs7970307	chr12:39380760	A/C	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2624839	0.704	rs2624838	chr3:50205642	C/G	cg14019146	chr3:50243930	SLC38A3	-0.69	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.56	-0.42	1.51e-5	Prostate cancer;
THYM	cis	rs5769765	0.720	rs9628127	chr22:50166092	A/G	cg26441486	chr22:50317300	CRELD2	0.37	5.15	0.47	1.39e-6	Schizophrenia;
THYM	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Educational attainment;
THYM	cis	rs8192282	0.646	rs4288587	chr1:154492357	A/T	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg00757033	chr12:89920650	WDR51B	0.77	11.72	0.77	3.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.42	-4.5	-0.42	1.91e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
THYM	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg19418458	chr7:158789849	NA	-0.67	-6.55	-0.56	3e-9	Facial morphology (factor 20);
THYM	cis	rs4242434	0.927	rs57594397	chr8:22475657	T/C	cg11461670	chr8:22454935	PDLIM2	-0.39	-6.48	-0.55	4.02e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg25554036	chr4:6271136	WFS1	0.56	5.29	0.48	7.94e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.77	-5.02	-0.46	2.45e-6	Mean platelet volume;
THYM	cis	rs4242434	0.819	rs1871902	chr8:22470710	G/A	cg01710189	chr8:22454888	PDLIM2	-0.5	-5.31	-0.48	7.08e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg00814883	chr7:100076585	TSC22D4	-1.0	-6.8	-0.57	9.22e-10	Platelet count;
THYM	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg18230493	chr5:56204884	C5orf35	0.91	6.71	0.57	1.43e-9	Initial pursuit acceleration;
THYM	trans	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg07211511	chr3:129823064	LOC729375	1.22	9.05	0.68	1.8e-14	Blood pressure (smoking interaction);
THYM	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg01616529	chr11:638424	DRD4	-0.74	-5.71	-0.51	1.27e-7	Systemic lupus erythematosus;
THYM	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22509189	chr2:225307070	NA	-0.88	-7.52	-0.61	3.1e-11	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg08305652	chr11:111469057	NA	0.52	4.47	0.42	2.2e-5	Primary sclerosing cholangitis;
THYM	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg26384229	chr12:38710491	ALG10B	0.96	7.37	0.6	6.13e-11	Morning vs. evening chronotype;
THYM	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg02980000	chr4:1222292	CTBP1	-0.69	-4.67	-0.43	9.87e-6	Systolic blood pressure;
THYM	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.12	8.58	0.66	1.79e-13	Cognitive test performance;
THYM	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9359856	0.564	rs72915933	chr6:90441464	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs9828933	0.752	rs28675788	chr3:63942188	C/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.94	-5.49	-0.49	3.33e-7	Type 2 diabetes;
THYM	cis	rs335206	1.000	rs335206	chr5:122504566	T/C	cg16368670	chr5:122501738	PRDM6	-0.56	-4.55	-0.42	1.56e-5	QRS duration;
THYM	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg00810483	chr4:3375144	RGS12	0.32	4.93	0.45	3.55e-6	Serum sulfate level;
THYM	cis	rs6570726	0.526	rs72994723	chr6:145722948	G/A	cg23711669	chr6:146136114	FBXO30	-0.61	-4.83	-0.44	5.16e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs354225	0.584	rs10188545	chr2:54831875	A/G	cg23486701	chr2:54789491	SPTBN1	0.39	5.1	0.46	1.72e-6	Schizophrenia;
THYM	cis	rs9467711	0.790	rs35942569	chr6:26339131	A/G	cg16898833	chr6:26189333	HIST1H4D	1.25	5.64	0.5	1.74e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7584330	0.554	rs77180399	chr2:238442951	G/A	cg14458575	chr2:238380390	NA	1.03	5.54	0.49	2.71e-7	Prostate cancer;
THYM	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg23851026	chr2:136556271	LCT	-0.56	-6.05	-0.53	2.91e-8	Mosquito bite size;
THYM	cis	rs2625529	0.627	rs1037680	chr15:72514319	T/C	cg16672083	chr15:72433130	SENP8	-0.52	-4.65	-0.43	1.06e-5	Red blood cell count;
THYM	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg10150615	chr22:24372951	LOC391322	-0.76	-7.11	-0.59	2.17e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs990171	1.000	rs11123931	chr2:103085660	A/G	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.1	-0.46	1.74e-6	Lymphocyte counts;
THYM	cis	rs2862064	0.932	rs1553319	chr5:156479001	T/A	cg12943317	chr5:156479607	HAVCR1	-0.84	-5.23	-0.47	9.88e-7	Platelet count;
THYM	cis	rs6598541	0.890	rs907808	chr15:99280254	A/G	cg13297560	chr15:99320054	IGF1R	-0.51	-4.7	-0.43	8.65e-6	Urate levels;
THYM	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg14779329	chr11:130786720	SNX19	-0.48	-5.08	-0.46	1.85e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1642645	0.597	rs1011281	chr1:42570834	G/A	cg22816091	chr1:42611670	NA	-0.56	-4.5	-0.42	1.89e-5	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs2154427	0.872	rs78882615	chr21:34100648	G/T	cg21871883	chr21:34145043	C21orf49;C21orf66	1.01	5.23	0.47	9.88e-7	Bilirubin levels;
THYM	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	trans	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg10856724	chr12:34555212	NA	-0.89	-8.58	-0.66	1.77e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2652822	0.525	rs17828874	chr15:63516266	C/G	cg09251291	chr15:63483946	RAB8B	-0.53	-4.89	-0.45	4.04e-6	Metabolic traits;
THYM	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg23187316	chr7:1099788	C7orf50	0.59	4.49	0.42	2.01e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg16325326	chr1:53192061	ZYG11B	0.84	8.29	0.65	7.48e-13	Monocyte count;
THYM	cis	rs7084402	0.967	rs1658452	chr10:60311114	A/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs1448094	0.512	rs7309500	chr12:86249647	C/T	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11711311	1.000	rs12497716	chr3:113453258	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.59	-5.19	-0.47	1.2e-6	IgG glycosylation;
THYM	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg03388043	chr17:80084554	CCDC57	0.68	5.64	0.5	1.74e-7	Life satisfaction;
THYM	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg01579765	chr21:45077557	HSF2BP	-0.5	-7.6	-0.61	2.09e-11	Mean corpuscular volume;
THYM	cis	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg21775007	chr8:11205619	TDH	-0.68	-5.26	-0.47	8.84e-7	Retinal vascular caliber;
THYM	cis	rs9563576	0.778	rs7988244	chr13:58686760	T/C	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.6	4.5	0.42	1.92e-5	Body mass index;
THYM	cis	rs4474465	0.831	rs10899510	chr11:78170841	G/A	cg19901956	chr11:77921274	USP35	-0.6	-4.55	-0.42	1.56e-5	Alzheimer's disease (survival time);
THYM	cis	rs4262150	0.883	rs17488630	chr5:152244165	C/T	cg06854687	chr5:151642065	NA	0.66	4.59	0.43	1.36e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	5.72	0.51	1.23e-7	Platelet count;
THYM	cis	rs2273669	0.667	rs12214121	chr6:109322554	A/G	cg17117243	chr6:109341365	SESN1	0.89	5.4	0.48	4.9e-7	Prostate cancer;
THYM	cis	rs7688540	0.771	rs61792116	chr4:301077	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.72	4.78	0.44	6.39e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg08873628	chr1:175162347	KIAA0040	0.51	4.59	0.43	1.34e-5	Alcohol dependence;
THYM	cis	rs1642645	0.831	rs1327711	chr1:42495949	A/G	cg06092502	chr1:42611687	NA	0.59	4.59	0.43	1.35e-5	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg07690219	chr3:49449608	TCTA;RHOA	0.7	4.71	0.43	8.57e-6	Menarche (age at onset);
THYM	cis	rs3820068	0.608	rs7514858	chr1:16035246	G/A	cg27534772	chr1:16042836	PLEKHM2	0.51	5.25	0.47	9.14e-7	Systolic blood pressure;
THYM	cis	rs863345	0.604	rs11264999	chr1:158488860	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs9420	0.961	rs11601320	chr11:57642617	T/C	cg19752551	chr11:57585705	CTNND1	-0.72	-7.34	-0.6	7.26e-11	Schizophrenia;
THYM	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2562152	0.515	rs2562176	chr16:146487	G/C	cg02949481	chr16:131562	MPG	1.21	7.66	0.62	1.58e-11	Glioblastoma;
THYM	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg03474202	chr17:45855739	NA	-0.74	-6.5	-0.55	3.7e-9	IgG glycosylation;
THYM	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg04398451	chr17:18023971	MYO15A	-0.84	-7.61	-0.62	1.97e-11	Total body bone mineral density;
THYM	cis	rs6570726	0.791	rs435671	chr6:145881215	A/G	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg14820908	chr5:178986412	RUFY1	0.64	6.95	0.58	4.6e-10	Lung cancer;
THYM	cis	rs6840360	0.615	rs6836249	chr4:152465829	T/G	cg22705602	chr4:152727874	NA	-0.71	-7.43	-0.61	4.71e-11	Intelligence (multi-trait analysis);
THYM	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12667521	chr19:29218732	NA	0.89	8.17	0.64	1.34e-12	Methadone dose in opioid dependence;
THYM	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-1.07	-9.37	-0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs960902	0.620	rs11693033	chr2:37737206	C/T	cg25341268	chr2:37734390	NA	-0.65	-5.28	-0.48	8.08e-7	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs10170846	0.800	rs10194743	chr2:223518151	A/G	cg25565276	chr2:223520875	FARSB	0.6	4.72	0.44	8.21e-6	Schizophrenia (inflammation and infection response interaction);
THYM	cis	rs9527	0.590	rs2066322	chr10:104909339	T/G	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs4919044	1.000	rs17108050	chr10:94772223	A/G	cg05127821	chr10:94822908	CYP26C1	-1.18	-5.88	-0.52	6.18e-8	Coronary artery disease;
THYM	cis	rs72699765	0.655	rs12593463	chr15:25859669	A/G	cg01432432	chr15:25199028	SNRPN;SNURF	-1.09	-4.55	-0.42	1.58e-5	Obstructive sleep apnea trait (average respiratory event duration);
THYM	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg08859206	chr1:53392774	SCP2	-0.65	-7.37	-0.6	6.31e-11	Monocyte count;
THYM	cis	rs11585357	0.709	rs735281	chr1:17616194	T/C	cg08277548	chr1:17600880	PADI3	0.89	5.32	0.48	6.92e-7	Hair shape;
THYM	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg03161606	chr19:29218774	NA	0.65	4.58	0.43	1.39e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.76	-6.18	-0.54	1.57e-8	Prostate cancer;
THYM	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-4.75	-0.44	7.13e-6	Type 2 diabetes;
THYM	cis	rs35883536	0.609	rs1855631	chr1:101040010	C/T	cg09408571	chr1:101003634	GPR88	-0.48	-5.18	-0.47	1.24e-6	Monocyte count;
THYM	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.43e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6840360	1.000	rs3749561	chr4:152610117	C/T	cg22705602	chr4:152727874	NA	0.6	6.47	0.55	4.28e-9	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs116231457	chr4:119762396	A/C	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs981844	0.961	rs17299034	chr4:154671396	A/G	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs7173743	0.784	rs11072811	chr15:79132330	G/T	cg00540400	chr15:79124168	NA	-0.59	-6.02	-0.53	3.25e-8	Coronary artery disease;
THYM	cis	rs600806	0.850	rs10858091	chr1:109935578	T/C	cg23032129	chr1:109941072	SORT1	-0.59	-5.03	-0.46	2.31e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg05025164	chr4:1340916	KIAA1530	0.94	7.64	0.62	1.7e-11	Longevity;
THYM	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg14008862	chr17:28927542	LRRC37B2	0.94	5.08	0.46	1.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4409675	0.597	rs1467464	chr1:28211650	T/C	cg23691781	chr1:28212827	C1orf38	0.44	4.47	0.42	2.16e-5	Corneal astigmatism;
THYM	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg03806693	chr22:41940476	POLR3H	1.11	8.99	0.68	2.33e-14	Vitiligo;
THYM	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg06728252	chr6:26598149	ABT1	0.43	5.08	0.46	1.84e-6	Intelligence (multi-trait analysis);
THYM	trans	rs1349882	0.557	rs10166401	chr2:52946506	T/C	cg09203490	chr14:60098107	RTN1	0.7	6.95	0.58	4.6e-10	Asymmetrical dimethylarginine levels;
THYM	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg05738196	chr6:26577821	NA	0.83	7.86	0.63	6e-12	Intelligence (multi-trait analysis);
THYM	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1784581	0.588	rs1789988	chr6:162408472	C/T	cg17173639	chr6:162384350	PARK2	-0.81	-7.68	-0.62	1.42e-11	Itch intensity from mosquito bite;
THYM	cis	rs7705502	0.962	rs72810995	chr5:173331851	A/G	cg18693985	chr5:173351052	CPEB4	-0.78	-5.64	-0.5	1.71e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg00647820	chr17:40259828	DHX58	-0.6	-4.53	-0.42	1.72e-5	Fibrinogen levels;
THYM	cis	rs10799590	1.000	rs1436169	chr1:224878881	T/C	cg01808320	chr1:224927238	CNIH3	0.51	4.53	0.42	1.68e-5	Opioid dependence;
THYM	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs57920188	0.568	rs12137595	chr1:4094068	C/T	cg20703997	chr1:4087676	NA	0.86	5.28	0.48	8.16e-7	Interleukin-17 levels;
THYM	cis	rs9527	0.615	rs7073295	chr10:104672233	A/G	cg04362960	chr10:104952993	NT5C2	0.6	4.62	0.43	1.2e-5	Arsenic metabolism;
THYM	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg18876405	chr7:65276391	NA	-0.61	-5.19	-0.47	1.21e-6	Cotinine glucuronidation;
THYM	cis	rs6665290	0.669	rs3795446	chr1:227180981	C/T	cg10327440	chr1:227177885	CDC42BPA	1.08	12.43	0.79	1.26e-21	Myeloid white cell count;
THYM	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg24803719	chr17:45855879	NA	-0.6	-6.31	-0.54	8.89e-9	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12681287	0.547	rs71502658	chr8:87478785	T/A	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg01119278	chr6:110721349	DDO	0.62	7.25	0.6	1.1e-10	Platelet distribution width;
THYM	cis	rs4731207	0.698	rs4379394	chr7:124519627	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03264133	chr6:25882463	NA	-0.69	-5.32	-0.48	7.03e-7	Blood metabolite levels;
THYM	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.77	5.96	0.52	4.19e-8	Electrocardiographic conduction measures;
THYM	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg04282206	chr17:62833786	PLEKHM1P	-0.83	-8.06	-0.64	2.23e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs548181	0.611	rs1293672	chr11:125461034	A/G	cg03464685	chr11:125439445	EI24	1.54	8.69	0.67	1.06e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg11366901	chr6:160182831	ACAT2	1.01	8.95	0.68	2.91e-14	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg11494091	chr17:61959527	GH2	1.07	17.57	0.87	1.34e-31	Prudent dietary pattern;
THYM	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs500891	0.525	rs6454322	chr6:84057542	A/G	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg22189786	chr22:42395067	WBP2NL	0.57	4.86	0.45	4.65e-6	Birth weight;
THYM	cis	rs7192750	0.586	rs12444521	chr16:71941698	A/T	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg23815491	chr16:72088622	HP	0.69	5.3	0.48	7.58e-7	Fibrinogen levels;
THYM	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	7.63	0.62	1.83e-11	Platelet count;
THYM	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg24803719	chr17:45855879	NA	-0.6	-6.33	-0.54	7.96e-9	IgG glycosylation;
THYM	cis	rs34779708	0.931	rs4934709	chr10:35339324	A/C	cg03585969	chr10:35415529	CREM	-0.64	-4.5	-0.42	1.93e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs1847202	0.963	rs34317383	chr3:72946652	A/C	cg25664220	chr3:72788482	NA	-0.62	-4.75	-0.44	7.34e-6	Motion sickness;
THYM	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg04944784	chr2:26401820	FAM59B	-0.59	-4.5	-0.42	1.93e-5	Gut microbiome composition (summer);
THYM	cis	rs877282	0.838	rs34778553	chr10:796865	T/C	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs995000	0.931	rs1168015	chr1:62996046	C/G	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs4343996	0.967	rs7785994	chr7:3351810	T/C	cg21248987	chr7:3385318	SDK1	-0.42	-5.14	-0.47	1.48e-6	Motion sickness;
THYM	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg01579765	chr21:45077557	HSF2BP	-0.54	-8.77	-0.67	7.18e-14	Mean corpuscular volume;
THYM	cis	rs7695732	0.595	rs9307054	chr4:89899483	G/A	cg17769793	chr4:89976368	FAM13A	-0.49	-5.2	-0.47	1.17e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs3820068	0.532	rs74057713	chr1:15944620	G/C	cg27534772	chr1:16042836	PLEKHM2	0.55	6.09	0.53	2.38e-8	Systolic blood pressure;
THYM	cis	rs977987	0.806	rs8056236	chr16:75448273	C/T	cg03315344	chr16:75512273	CHST6	0.76	6.16	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg00898013	chr13:113819073	PROZ	-0.87	-8.78	-0.67	6.82e-14	Platelet distribution width;
THYM	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg16928487	chr17:17741425	SREBF1	-0.56	-5.57	-0.5	2.37e-7	Total body bone mineral density;
THYM	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg08017756	chr2:100939284	LONRF2	-0.69	-7.09	-0.59	2.35e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg06219351	chr7:158114137	PTPRN2	-0.77	-8.01	-0.63	2.9e-12	Calcium levels;
THYM	cis	rs11690935	0.885	rs6752812	chr2:172851502	C/A	cg13550731	chr2:172543902	DYNC1I2	-0.71	-5.0	-0.46	2.63e-6	Schizophrenia;
THYM	cis	rs4731207	0.596	rs6954614	chr7:124629794	G/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs76935404	0.736	rs57274441	chr19:41431422	T/G	cg19493303	chr19:41414353	NA	0.56	4.96	0.45	3.04e-6	nicotine metabolite ratio in current smokers;
THYM	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg22920501	chr2:26401640	FAM59B	-1.02	-9.27	-0.69	6.06e-15	Gut microbiome composition (summer);
THYM	cis	rs67981189	0.896	rs17108967	chr14:71542168	T/C	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs800586	0.595	rs2721961	chr8:116657911	T/G	cg04656070	chr8:116661063	TRPS1	-0.49	-5.32	-0.48	6.87e-7	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs786425	0.530	rs7295552	chr12:124223844	A/G	cg15249119	chr12:124971054	NCOR2	0.55	5.09	0.46	1.79e-6	Pubertal anthropometrics;
THYM	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg10852096	chr15:79043040	NA	-0.62	-4.72	-0.44	8.1e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg19077165	chr18:44547161	KATNAL2	-0.68	-8.66	-0.66	1.18e-13	Personality dimensions;
THYM	cis	rs10256972	0.694	rs7784701	chr7:1003041	A/G	cg02602264	chr7:1026310	CYP2W1	-0.54	-5.13	-0.47	1.52e-6	Longevity;Endometriosis;
THYM	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.8e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs10832963	1.000	rs11024739	chr11:18645843	A/C	cg20219074	chr11:18656078	SPTY2D1	-0.79	-6.42	-0.55	5.25e-9	Breast cancer;
THYM	cis	rs995000	0.509	rs11207978	chr1:62980512	T/C	cg06896770	chr1:63153194	DOCK7	0.92	4.63	0.43	1.16e-5	Triglyceride levels;
THYM	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06634786	chr22:41940651	POLR3H	-0.81	-6.28	-0.54	1.03e-8	Vitiligo;
THYM	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg24308560	chr3:49941425	MST1R	-0.79	-7.04	-0.59	2.96e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7017697	1.000	rs2410612	chr8:19681647	A/G	cg03894339	chr8:19674705	INTS10	0.55	4.77	0.44	6.73e-6	Breast cancer;
THYM	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs9549260	0.564	rs4943812	chr13:41335816	T/C	cg21288729	chr13:41239152	FOXO1	0.7	5.27	0.48	8.56e-7	Red blood cell count;
THYM	cis	rs858239	0.539	rs4377861	chr7:23185969	C/T	cg09755872	chr7:23245557	NA	-0.5	-4.71	-0.43	8.55e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs273218	1.000	rs168861	chr5:53377310	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.9	7.52	0.61	3.06e-11	Migraine;
THYM	cis	rs12579753	0.871	rs1922540	chr12:82197496	A/G	cg21231944	chr12:82153410	PPFIA2	-0.65	-4.87	-0.45	4.42e-6	Resting heart rate;
THYM	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg05973401	chr12:123451056	ABCB9	0.67	4.54	0.42	1.63e-5	Neutrophil percentage of white cells;
THYM	cis	rs2276314	1.000	rs4799832	chr18:33559646	T/C	cg19628046	chr18:33552617	C18orf21	0.77	5.47	0.49	3.68e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	13.59	0.81	5.3e-24	Chronic sinus infection;
THYM	cis	rs12935418	0.583	rs2911150	chr16:81028799	C/T	cg16651780	chr16:81037892	C16orf61	0.86	6.69	0.57	1.54e-9	Mean corpuscular volume;
THYM	cis	rs7828089	0.561	rs13266541	chr8:22266135	G/A	cg13512537	chr8:22265999	SLC39A14	-0.65	-5.29	-0.48	7.74e-7	Verbal declarative memory;
THYM	cis	rs7246657	0.943	rs10405064	chr19:37861861	C/T	cg23950597	chr19:37808831	NA	-0.73	-4.7	-0.43	8.94e-6	Coronary artery calcification;
THYM	cis	rs6918586	0.616	rs198836	chr6:26113616	T/A	cg07061783	chr6:25882402	NA	0.58	4.58	0.43	1.42e-5	Schizophrenia;
THYM	cis	rs863345	0.604	rs6663277	chr1:158495001	A/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg00271210	chr6:167070053	RPS6KA2	0.48	4.65	0.43	1.08e-5	Crohn's disease;
THYM	cis	rs6500395	1.000	rs9937610	chr16:48671274	C/G	cg04672837	chr16:48644449	N4BP1	0.55	5.86	0.52	6.57e-8	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg19774624	chr17:42201019	HDAC5	0.69	5.89	0.52	5.78e-8	Total body bone mineral density;
THYM	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.61	5.43	0.49	4.25e-7	Personality dimensions;
THYM	cis	rs3768617	0.510	rs2027078	chr1:183073478	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs9826463	0.757	rs113288103	chr3:142175321	C/T	cg20824294	chr3:142316082	PLS1	0.62	4.52	0.42	1.8e-5	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg18511798	chr11:2018149	H19;MIR675	-0.51	-4.98	-0.45	2.84e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs2109514	0.902	rs7810505	chr7:116111078	G/T	cg12739419	chr7:116140593	CAV2	-0.48	-4.92	-0.45	3.58e-6	Prevalent atrial fibrillation;
THYM	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg05872129	chr22:39784769	NA	-0.77	-6.73	-0.57	1.3e-9	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg04944784	chr2:26401820	FAM59B	0.76	5.28	0.48	8.27e-7	Gut microbiome composition (summer);
THYM	cis	rs2336384	0.613	rs873458	chr1:12046089	A/G	cg24492058	chr1:12203751	TNFRSF8	0.63	5.69	0.5	1.42e-7	Platelet count;
THYM	cis	rs12579753	0.957	rs35001833	chr12:82188510	C/G	cg21231944	chr12:82153410	PPFIA2	-0.66	-4.93	-0.45	3.5e-6	Resting heart rate;
THYM	cis	rs2109514	0.902	rs926197	chr7:116118330	A/C	cg12739419	chr7:116140593	CAV2	0.48	4.92	0.45	3.67e-6	Prevalent atrial fibrillation;
THYM	cis	rs7980799	0.711	rs12319055	chr12:33626509	C/T	cg06521331	chr12:34319734	NA	0.69	4.93	0.45	3.47e-6	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.17	0.47	1.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg18305652	chr10:134549665	INPP5A	0.87	8.04	0.64	2.48e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs2820651	0.614	rs12245649	chr10:1487676	C/T	cg13720710	chr10:1452970	ADARB2	0.7	4.58	0.43	1.43e-5	Migraine with aura;
THYM	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12540874	0.698	rs3807566	chr7:50564204	G/T	cg18232548	chr7:50535776	DDC	-0.79	-6.88	-0.58	6.41e-10	Systemic sclerosis;
THYM	cis	rs2637266	0.935	rs2579774	chr10:78402253	T/C	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs6987853	0.623	rs10109400	chr8:42455353	T/C	cg09913449	chr8:42400586	C8orf40	0.95	9.53	0.7	1.64e-15	Mean corpuscular hemoglobin concentration;
THYM	cis	rs28595532	1.000	rs114039398	chr4:119631627	T/C	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs3087591	0.881	rs2905804	chr17:29519995	T/C	cg24425628	chr17:29625626	OMG;NF1	0.68	5.44	0.49	4.14e-7	Hip circumference;
THYM	cis	rs4523957	0.651	rs9906968	chr17:2077493	G/C	cg16513277	chr17:2031491	SMG6	-0.95	-8.69	-0.67	1.05e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs73787773	0.629	rs27981	chr5:111465851	G/A	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.97	-5.27	-0.48	8.35e-7	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg00576331	chr11:65640516	EFEMP2	0.68	4.58	0.43	1.42e-5	Crohn's disease;
THYM	cis	rs2806561	0.765	rs623988	chr1:23519477	C/T	cg19743168	chr1:23544995	NA	0.55	5.64	0.5	1.77e-7	Height;
THYM	cis	rs761746	0.739	rs5998054	chr22:31994406	C/A	cg10537193	chr22:32026975	PISD	-0.36	-4.92	-0.45	3.57e-6	Intelligence;
THYM	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg06611532	chr13:114900021	NA	0.63	6.91	0.58	5.62e-10	Schizophrenia;
THYM	cis	rs1003719	0.628	rs2835635	chr21:38528866	A/G	cg01329690	chr21:38580129	DSCR9	-0.4	-5.36	-0.48	5.81e-7	Eye color traits;
THYM	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg15445000	chr17:37608096	MED1	0.44	5.1	0.46	1.73e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs34779708	0.966	rs11592567	chr10:35409369	C/T	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg17054759	chr22:49844102	NA	-0.52	-4.78	-0.44	6.31e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs8070740	0.740	rs980408	chr17:5338990	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.72	5.7	0.5	1.34e-7	Menopause (age at onset);
THYM	cis	rs11252926	0.673	rs816620	chr10:645916	A/G	cg14018140	chr10:458528	DIP2C	0.5	5.11	0.46	1.66e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs7833986	0.534	rs2458083	chr8:56898785	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	6.63	0.56	2.06e-9	Height;
THYM	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg18357526	chr6:26021779	HIST1H4A	0.86	7.62	0.62	1.85e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg23711669	chr6:146136114	FBXO30	0.93	9.69	0.7	7.64e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg05660106	chr1:15850417	CASP9	0.76	6.27	0.54	1.06e-8	Systolic blood pressure;
THYM	cis	rs7809950	0.678	rs2237665	chr7:106906998	T/C	cg23024343	chr7:107201750	COG5	-1.0	-8.43	-0.65	3.79e-13	Coronary artery disease;
THYM	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg08885076	chr2:99613938	TSGA10	0.51	4.89	0.45	4.12e-6	Chronic sinus infection;
THYM	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg12560992	chr17:57184187	TRIM37	-0.92	-8.69	-0.67	1.04e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg07936489	chr17:37558343	FBXL20	-0.74	-4.75	-0.44	7.26e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs1971762	1.000	rs10876481	chr12:54066743	T/C	cg16917193	chr12:54089295	NA	0.57	4.45	0.42	2.33e-5	Height;
THYM	cis	rs7119	0.636	rs11635606	chr15:77819591	A/G	cg10437265	chr15:77819839	NA	0.7	6.4	0.55	5.91e-9	Type 2 diabetes;
THYM	trans	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.11	8.17	0.64	1.3e-12	Exhaled nitric oxide output;
THYM	cis	rs765787	0.530	rs12909987	chr15:45512207	C/T	cg24006582	chr15:45444508	DUOX1	-0.77	-6.12	-0.53	2.12e-8	Uric acid levels;
THYM	cis	rs7220711	0.648	rs4793016	chr17:41777286	A/T	cg26893861	chr17:41843967	DUSP3	0.62	5.37	0.48	5.67e-7	Bone mineral density (spine);Bone mineral density (hip);
THYM	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs6930083	0.737	rs13196885	chr6:36632688	C/T	cg24425727	chr6:36645648	CDKN1A	0.74	6.77	0.57	1.08e-9	Coronary artery disease;
THYM	cis	rs870825	0.698	rs66462315	chr4:185623917	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg14196790	chr5:131705035	SLC22A5	0.51	4.78	0.44	6.26e-6	Breast cancer;Mosquito bite size;
THYM	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-4.48	-0.42	2.06e-5	Monocyte percentage of white cells;
THYM	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg17426766	chr1:2046864	PRKCZ	-0.44	-5.23	-0.47	1.02e-6	Height;
THYM	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.08	8.96	0.68	2.75e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22133161	chr19:49891603	CCDC155	0.84	5.69	0.5	1.42e-7	Multiple sclerosis;
THYM	cis	rs728616	0.867	rs56000427	chr10:81986946	A/G	cg27452691	chr10:81370291	SFTPA1	0.83	4.59	0.43	1.38e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg23583168	chr7:148888333	NA	-1.02	-14.09	-0.82	5.29e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06481639	chr22:41940642	POLR3H	0.65	4.77	0.44	6.53e-6	Vitiligo;
THYM	cis	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs938554	0.571	rs4144	chr4:10016322	T/C	cg26689780	chr4:10079554	WDR1	-0.42	-4.57	-0.42	1.49e-5	Blood metabolite levels;
THYM	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs2836633	0.859	rs8132069	chr21:40032611	T/C	cg05519781	chr21:40033154	ERG	0.73	6.7	0.57	1.49e-9	Coronary artery disease;
THYM	cis	rs10895275	0.886	rs1893498	chr11:102055452	A/T	cg24447756	chr11:102105824	NA	-0.51	-4.54	-0.42	1.64e-5	Migraine;
THYM	cis	rs11711311	1.000	rs2603793	chr3:113496418	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.62	-5.52	-0.49	2.89e-7	IgG glycosylation;
THYM	cis	rs8048589	0.948	rs11648228	chr16:12181702	G/T	cg02910054	chr16:12241554	SNX29	0.67	5.68	0.5	1.46e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs3772130	0.583	rs4296627	chr3:121567684	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.86	7.17	0.59	1.63e-10	Cognitive performance;
THYM	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.65	0.56	1.88e-9	Schizophrenia;
THYM	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.4	-0.55	5.94e-9	Personality dimensions;
THYM	cis	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg08883853	chr7:1026168	CYP2W1	-0.45	-5.18	-0.47	1.24e-6	Longevity;Endometriosis;
THYM	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg02187348	chr16:89574699	SPG7	0.76	6.13	0.53	2.01e-8	Multiple myeloma (IgH translocation);
THYM	cis	rs1018836	0.595	rs2223010	chr8:91480068	A/G	cg16814680	chr8:91681699	NA	-0.76	-6.29	-0.54	9.76e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs59197085	0.892	rs3734972	chr7:128470838	C/T	cg23102659	chr7:128001356	PRRT4	-1.0	-4.57	-0.42	1.44e-5	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
THYM	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg01831904	chr17:28903510	LRRC37B2	-1.13	-5.5	-0.49	3.13e-7	Body mass index;
THYM	cis	rs13082711	0.554	rs7635958	chr3:27385616	A/C	cg02860705	chr3:27208620	NA	0.87	6.13	0.53	1.96e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs2361701	0.929	rs1467979	chr17:78060743	A/G	cg09238746	chr17:78121135	EIF4A3	0.74	4.53	0.42	1.73e-5	IgG glycosylation;
THYM	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg07636037	chr3:49044803	WDR6	0.81	5.82	0.51	7.99e-8	Menarche (age at onset);
THYM	cis	rs7760949	0.852	rs9475800	chr6:13932230	A/G	cg27413430	chr6:13925136	RNF182	0.51	4.52	0.42	1.77e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg03684893	chr10:554711	DIP2C	0.77	6.46	0.55	4.53e-9	Psychosis in Alzheimer's disease;
THYM	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg06636001	chr8:8085503	FLJ10661	0.55	4.51	0.42	1.82e-5	Mean corpuscular volume;
THYM	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs4363385	0.693	rs821755	chr1:153036245	G/C	cg13444842	chr1:152974279	SPRR3	-0.61	-5.1	-0.46	1.71e-6	Inflammatory skin disease;
THYM	cis	rs2797160	0.967	rs1739358	chr6:126019736	G/A	cg16306078	chr6:126000798	NA	0.52	5.19	0.47	1.19e-6	Endometrial cancer;
THYM	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg02018176	chr4:1364513	KIAA1530	0.74	7.0	0.58	3.59e-10	Longevity;
THYM	cis	rs75059851	1.000	rs3802924	chr11:133827733	A/C	cg14047540	chr11:133829660	NA	-1.16	-7.94	-0.63	4.02e-12	Schizophrenia;
THYM	cis	rs4148689	0.904	rs2402204	chr7:117146393	T/C	cg17204129	chr7:117119601	CFTR	-0.63	-4.92	-0.45	3.69e-6	Gout;
THYM	cis	rs2115630	0.967	rs8027779	chr15:85255385	T/C	cg11189052	chr15:85197271	WDR73	-0.63	-4.8	-0.44	5.99e-6	P wave terminal force;
THYM	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg05368731	chr17:41323189	NBR1	1.25	11.64	0.77	5.42e-20	Menopause (age at onset);
THYM	cis	rs7267979	0.932	rs449370	chr20:25451180	A/G	cg08601574	chr20:25228251	PYGB	-0.56	-4.47	-0.42	2.15e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg01874867	chr7:94954059	PON1	-0.69	-5.51	-0.49	3.04e-7	Paraoxonase activity;
THYM	cis	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg09307838	chr4:120376055	NA	0.78	5.89	0.52	5.7e-8	Corneal astigmatism;
THYM	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05901451	chr6:126070800	HEY2	0.98	10.02	0.72	1.48e-16	Brugada syndrome;
THYM	cis	rs10832963	0.625	rs4757673	chr11:18612468	A/T	cg20219074	chr11:18656078	SPTY2D1	0.63	4.52	0.42	1.81e-5	Breast cancer;
THYM	cis	rs9733	0.566	rs878471	chr1:150547747	G/A	cg18016565	chr1:150552671	MCL1	-0.58	-4.78	-0.44	6.41e-6	Tonsillectomy;
THYM	cis	rs55728055	0.661	rs16989682	chr22:31900224	A/G	cg10537193	chr22:32026975	PISD	0.9	5.14	0.47	1.46e-6	Age-related hearing impairment;
THYM	cis	rs4285028	0.715	rs71329249	chr3:121711346	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.69	-4.7	-0.43	8.9e-6	Multiple sclerosis;
THYM	cis	rs7843479	0.965	rs733543	chr8:21835465	A/G	cg17168535	chr8:21777572	XPO7	0.7	5.29	0.48	7.87e-7	Mean corpuscular volume;
THYM	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg06766960	chr11:133703094	NA	-0.52	-4.83	-0.44	5.25e-6	Childhood ear infection;
THYM	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg15691649	chr6:25882328	NA	0.67	5.14	0.47	1.47e-6	Blood metabolite levels;
THYM	cis	rs7178572	0.568	rs7166927	chr15:77673459	A/G	cg22256960	chr15:77711686	NA	1.05	8.4	0.65	4.29e-13	Type 2 diabetes;
THYM	cis	rs4343996	0.967	rs6958390	chr7:3353005	T/C	cg21248987	chr7:3385318	SDK1	-0.4	-4.87	-0.45	4.53e-6	Motion sickness;
THYM	cis	rs10466239	0.803	rs10899793	chr10:43860202	C/T	cg12352960	chr10:43428578	NA	-0.98	-4.61	-0.43	1.23e-5	Telomere length;
THYM	cis	rs11726022	0.889	rs34846424	chr4:188166018	T/G	cg09690449	chr4:187998952	NA	-0.51	-5.15	-0.47	1.41e-6	Systolic blood pressure (cigarette smoking interaction);
THYM	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21659725	chr3:3221576	CRBN	0.88	9.81	0.71	4.18e-16	Intelligence (multi-trait analysis);
THYM	cis	rs319204	0.918	rs2963080	chr5:146261089	C/T	cg13983063	chr5:146258615	PPP2R2B	0.45	4.45	0.42	2.34e-5	Schizophrenia;
THYM	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg21658235	chr8:22456391	C8orf58	0.52	5.15	0.47	1.42e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2976388	0.609	rs2717601	chr8:143807924	T/C	cg06565975	chr8:143823917	SLURP1	0.5	5.62	0.5	1.9e-7	Urinary tract infection frequency;
THYM	cis	rs28595532	0.841	rs116329146	chr4:119733438	G/A	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs4845459	0.967	rs9633406	chr1:152591446	C/G	cg27206522	chr1:152595629	LCE3A	-0.52	-4.56	-0.42	1.5e-5	Psoriasis;
THYM	cis	rs863345	0.604	rs11265021	chr1:158511810	A/T	cg12129480	chr1:158549410	OR10X1	0.49	4.78	0.44	6.5e-6	Pneumococcal bacteremia;
THYM	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg25427524	chr10:38739819	LOC399744	-0.52	-4.72	-0.44	8.18e-6	Extrinsic epigenetic age acceleration;
THYM	cis	rs6674176	0.542	rs803679	chr1:44349405	G/A	cg13246856	chr1:44399776	ARTN	0.46	4.51	0.42	1.82e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg17294928	chr15:75287854	SCAMP5	-0.67	-4.59	-0.43	1.37e-5	Blood trace element (Zn levels);
THYM	cis	rs4243830	0.737	rs11581831	chr1:6609958	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.09	-7.38	-0.6	5.96e-11	Body mass index;
THYM	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg26597838	chr10:835615	NA	1.27	9.37	0.69	3.74e-15	Eosinophil percentage of granulocytes;
THYM	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg06713675	chr4:122721982	EXOSC9	-0.86	-9.77	-0.71	5.25e-16	Type 2 diabetes;
THYM	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.75	0.57	1.16e-9	Total body bone mineral density;
THYM	cis	rs7586879	0.616	rs6545813	chr2:25131287	C/T	cg01884057	chr2:25150051	NA	0.73	7.92	0.63	4.47e-12	Body mass index;
THYM	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.52	-6.42	-0.55	5.41e-9	Bone mineral density;
THYM	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg02527881	chr3:46936655	PTH1R	-0.69	-6.99	-0.58	3.83e-10	Colorectal cancer;
THYM	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg24733560	chr20:60626293	TAF4	0.51	4.58	0.43	1.41e-5	Body mass index;
THYM	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2075230	0.705	rs1641520	chr17:7550157	T/A	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.63	-0.43	1.16e-5	Hormone measurements;
THYM	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg07870213	chr5:140052090	DND1	0.71	8.17	0.64	1.32e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg09537434	chr19:41945824	ATP5SL	-1.09	-10.28	-0.73	4.16e-17	Height;
THYM	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg23758822	chr17:41437982	NA	1.21	11.71	0.77	3.86e-20	Menopause (age at onset);
THYM	cis	rs2562456	0.876	rs62110202	chr19:21754601	C/T	cg08562672	chr19:21860753	NA	-0.58	-4.55	-0.42	1.61e-5	Pain;
THYM	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	7.53	0.61	2.85e-11	Platelet count;
THYM	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg12292205	chr6:26970375	C6orf41	0.57	4.78	0.44	6.44e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg06481639	chr22:41940642	POLR3H	0.7	5.21	0.47	1.1e-6	Vitiligo;
THYM	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg04756594	chr16:24857601	SLC5A11	0.74	5.2	0.47	1.13e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9560113	0.580	rs9560116	chr13:112193731	G/A	cg15979348	chr13:112237479	NA	0.53	4.65	0.43	1.08e-5	Menarche (age at onset);
THYM	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg07936489	chr17:37558343	FBXL20	-0.73	-5.03	-0.46	2.32e-6	Asthma;
THYM	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs870825	0.616	rs28490461	chr4:185651638	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg21028142	chr17:79581711	NPLOC4	-0.52	-5.13	-0.47	1.52e-6	Eye color traits;
THYM	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-5.83	-0.51	7.7e-8	Total cholesterol levels;
THYM	cis	rs11997175	0.646	rs55898196	chr8:33765862	A/G	ch.8.33884649F	chr8:33765107	NA	0.72	5.61	0.5	2.02e-7	Body mass index;
THYM	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg20290983	chr6:43655470	MRPS18A	1.43	15.77	0.85	2.83e-28	IgG glycosylation;
THYM	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg01191920	chr7:158217561	PTPRN2	-0.89	-8.64	-0.66	1.36e-13	Obesity-related traits;
THYM	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg03806693	chr22:41940476	POLR3H	1.1	8.83	0.67	5.2e-14	Vitiligo;
THYM	cis	rs34779708	0.966	rs4934540	chr10:35474699	T/C	cg03585969	chr10:35415529	CREM	0.64	4.66	0.43	1.03e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg02640540	chr1:67518911	SLC35D1	0.64	4.68	0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs3857067	0.806	rs72665627	chr4:95111824	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg15448220	chr1:150897856	SETDB1	0.9	7.49	0.61	3.57e-11	Melanoma;
THYM	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg23649088	chr2:200775458	C2orf69	-0.75	-5.7	-0.5	1.35e-7	Osteoporosis;
THYM	cis	rs4820539	1.000	rs885965	chr22:23461425	A/G	cg21100191	chr22:23484243	RTDR1	0.74	6.36	0.55	7.18e-9	Bone mineral density;
THYM	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg07362569	chr17:61921086	SMARCD2	0.69	6.16	0.53	1.78e-8	Prudent dietary pattern;
THYM	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg17143192	chr8:8559678	CLDN23	0.7	5.33	0.48	6.51e-7	Neuroticism;
THYM	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg02915803	chr1:1606292	LOC728661;CDK11B	0.62	5.25	0.47	9.23e-7	Body mass index;
THYM	trans	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.11	8.15	0.64	1.44e-12	Exhaled nitric oxide output;
THYM	cis	rs9527	0.615	rs9733635	chr10:104711940	G/A	cg04362960	chr10:104952993	NT5C2	0.6	4.62	0.43	1.2e-5	Arsenic metabolism;
THYM	cis	rs6430585	0.941	rs7589832	chr2:136504101	A/C	cg20242066	chr2:136595261	LCT	0.55	5.64	0.5	1.73e-7	Corneal structure;
THYM	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg24257776	chr3:47051546	LOC100129354	0.41	4.8	0.44	5.81e-6	Colorectal cancer;
THYM	cis	rs3750965	0.920	rs4930644	chr11:68819097	C/T	cg01403660	chr11:68851641	TPCN2	0.67	4.94	0.45	3.33e-6	Hair color;
THYM	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg25801113	chr15:45476975	SHF	-0.39	-4.52	-0.42	1.79e-5	Uric acid levels;
THYM	cis	rs600806	0.888	rs10745352	chr1:109871787	T/C	cg23032129	chr1:109941072	SORT1	-0.57	-4.84	-0.44	5.11e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7584330	0.697	rs7574337	chr2:238439503	A/G	cg14458575	chr2:238380390	NA	0.62	4.94	0.45	3.39e-6	Prostate cancer;
THYM	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18252515	chr7:66147081	NA	0.65	4.81	0.44	5.74e-6	Aortic root size;
THYM	cis	rs758324	0.732	rs247285	chr5:131465688	C/T	cg16205897	chr5:131564050	P4HA2	0.58	4.96	0.45	3.03e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg24818145	chr4:99064322	C4orf37	0.69	5.38	0.48	5.43e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2721195	0.845	rs4244611	chr8:145739924	G/A	cg11211951	chr8:145729740	GPT	0.6	6.08	0.53	2.47e-8	Age at first birth;
THYM	cis	rs28595532	0.920	rs116023344	chr4:119760263	A/G	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11771526	0.792	rs28394389	chr7:32298509	C/T	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg15736062	chr7:158136485	PTPRN2	-0.63	-5.03	-0.46	2.34e-6	Response to amphetamines;
THYM	cis	rs7264396	0.563	rs61191623	chr20:34219987	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.58	-0.43	1.38e-5	Total cholesterol levels;
THYM	cis	rs12472274	0.648	rs67102443	chr2:239084602	A/G	cg17459225	chr2:239074497	NA	0.65	4.47	0.42	2.17e-5	Phospholipid levels (plasma);
THYM	cis	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg05901451	chr6:126070800	HEY2	0.61	5.08	0.46	1.87e-6	Endometrial cancer;
THYM	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.0	9.43	0.7	2.72e-15	Colorectal cancer;
THYM	cis	rs2282300	0.739	rs10835648	chr11:30320506	A/G	cg06241208	chr11:30344200	C11orf46	0.79	5.98	0.52	3.94e-8	Morning vs. evening chronotype;
THYM	cis	rs3087591	0.960	rs2905787	chr17:29482381	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	5.47	0.49	3.62e-7	Hip circumference;
THYM	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg01579765	chr21:45077557	HSF2BP	-0.5	-7.81	-0.63	7.46e-12	Mean corpuscular volume;
THYM	cis	rs11599315	0.757	rs11250392	chr10:1342543	T/C	cg01270228	chr10:1369114	ADARB2	0.72	6.34	0.55	7.83e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs7705042	0.826	rs13184323	chr5:141494719	T/G	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg16486109	chr11:613632	IRF7	0.52	5.33	0.48	6.51e-7	Systemic lupus erythematosus;
THYM	cis	rs12681287	0.546	rs12546802	chr8:87499335	T/A	cg27223183	chr8:87520930	FAM82B	-0.71	-5.09	-0.46	1.82e-6	Caudate activity during reward;
THYM	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg06618935	chr21:46677482	NA	-0.98	-9.5	-0.7	1.95e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10767942	0.582	rs76286407	chr11:32461059	C/A	cg13301003	chr11:32449254	WT1	-0.74	-4.48	-0.42	2.07e-5	Attention deficit hyperactivity disorder;
THYM	cis	rs931127	0.666	rs7932857	chr11:65457493	A/C	cg17480646	chr11:65405466	SIPA1	-0.81	-7.19	-0.59	1.5e-10	Systemic lupus erythematosus;
THYM	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg07362569	chr17:61921086	SMARCD2	0.73	6.6	0.56	2.3e-9	Prudent dietary pattern;
THYM	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg00631329	chr6:26305371	NA	-0.57	-6.87	-0.58	6.65e-10	Educational attainment;
THYM	cis	rs4589258	1.000	rs2213088	chr11:90480517	C/T	cg26138821	chr11:89956704	CHORDC1	-0.69	-5.52	-0.49	3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6087990	0.842	rs6119279	chr20:31330612	A/G	cg13636640	chr20:31349939	DNMT3B	0.89	9.37	0.69	3.66e-15	Ulcerative colitis;
THYM	cis	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg07460842	chr6:66804631	NA	-0.61	-4.94	-0.45	3.28e-6	Blood trace element (Cu levels);
THYM	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.43	7.88	0.63	5.28e-12	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs7020830	0.823	rs13285624	chr9:37129496	T/G	cg14294708	chr9:37120828	ZCCHC7	1.3	15.57	0.85	6.87e-28	Schizophrenia;
THYM	cis	rs4919694	0.572	rs72846714	chr10:104878454	G/A	cg04362960	chr10:104952993	NT5C2	0.97	6.41	0.55	5.51e-9	Arsenic metabolism;
THYM	cis	rs6831352	0.819	rs896992	chr4:100002372	C/T	cg12011299	chr4:100065546	ADH4	0.84	8.05	0.64	2.41e-12	Alcohol dependence;
THYM	cis	rs1957429	0.614	rs76809238	chr14:65380579	C/T	cg23373153	chr14:65346875	NA	-1.25	-5.03	-0.46	2.29e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	4.69	0.43	8.99e-6	Height;
THYM	cis	rs10162002	0.935	rs9578603	chr13:24040733	C/G	cg00158254	chr13:24040743	NA	0.69	4.8	0.44	5.81e-6	Hypothyroidism;
THYM	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs9677476	0.863	rs12478335	chr2:232064967	C/A	cg23338755	chr2:231921595	PSMD1	0.69	5.02	0.46	2.43e-6	Food antigen IgG levels;
THYM	cis	rs2404602	0.684	rs12591622	chr15:76930655	A/T	cg23625390	chr15:77176239	SCAPER	-0.93	-6.29	-0.54	9.68e-9	Blood metabolite levels;
THYM	cis	rs747334	0.811	rs1334582	chr10:92720690	C/T	cg07620928	chr10:92689909	NA	0.58	5.14	0.47	1.48e-6	Fibroblast growth factor basic levels;
THYM	cis	rs737337	0.623	rs3826815	chr19:11332505	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.66	4.7	0.43	8.89e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg18681998	chr4:17616180	MED28	-0.82	-6.64	-0.56	1.91e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg10856724	chr12:34555212	NA	-0.85	-7.6	-0.61	2.1e-11	Morning vs. evening chronotype;
THYM	cis	rs9420	0.809	rs11600169	chr11:57464945	T/A	cg19752551	chr11:57585705	CTNND1	-0.66	-6.83	-0.57	7.99e-10	Schizophrenia;
THYM	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg24308560	chr3:49941425	MST1R	0.79	6.93	0.58	5.04e-10	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg08885076	chr2:99613938	TSGA10	0.52	5.02	0.46	2.4e-6	Chronic sinus infection;
THYM	cis	rs478304	0.934	rs1193692	chr11:65504069	A/C	cg17480646	chr11:65405466	SIPA1	0.7	6.08	0.53	2.48e-8	Acne (severe);
THYM	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg03476357	chr21:30257390	N6AMT1	-0.6	-4.56	-0.42	1.53e-5	Dental caries;
THYM	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.78	-5.26	-0.47	8.86e-7	Body mass index;
THYM	cis	rs7843479	1.000	rs7843479	chr8:21820813	G/T	cg17168535	chr8:21777572	XPO7	0.74	5.01	0.46	2.47e-6	Mean corpuscular volume;
THYM	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg03188948	chr7:1209495	NA	1.04	6.03	0.53	3.13e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.87e-6	Resting heart rate;
THYM	cis	rs10486003	1.000	rs7801319	chr7:97255523	C/G	cg19056687	chr7:97922028	BAIAP2L1;BRI3	1.09	5.16	0.47	1.36e-6	Response to platinum-based agents;
THYM	cis	rs13326165	0.585	rs6793317	chr3:52298986	C/T	cg08438690	chr3:52279403	PPM1M	0.72	4.52	0.42	1.77e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs2997447	0.846	rs61775431	chr1:26411275	T/G	cg03844060	chr1:26490628	NA	0.67	4.61	0.43	1.26e-5	QRS complex (12-leadsum);
THYM	cis	rs1797885	0.604	rs299628	chr3:12577395	G/C	cg05467012	chr3:12595696	NA	0.55	4.65	0.43	1.06e-5	Immature fraction of reticulocytes;
THYM	cis	rs6598955	0.543	rs12122527	chr1:26549748	C/T	cg04990556	chr1:26633338	UBXN11	0.96	6.06	0.53	2.7e-8	Obesity-related traits;
THYM	cis	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg12863693	chr15:85201151	NMB	0.62	5.57	0.5	2.41e-7	Schizophrenia;
THYM	cis	rs67072384	0.748	rs6592484	chr11:72464470	C/T	cg01380194	chr11:72452482	ARAP1	-0.81	-4.57	-0.42	1.49e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6032067	0.636	rs6032094	chr20:43912637	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.43	-4.76	-0.44	7e-6	Blood protein levels;
THYM	cis	rs113835537	0.529	rs11227515	chr11:66287383	C/T	cg24851651	chr11:66362959	CCS	0.67	4.68	0.43	9.67e-6	Airway imaging phenotypes;
THYM	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.78	0.51	9.58e-8	Hip circumference adjusted for BMI;
THYM	cis	rs11651000	0.947	rs11657376	chr17:45835984	A/T	cg06532163	chr17:45867833	NA	0.58	4.49	0.42	2e-5	IgG glycosylation;
THYM	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg24253500	chr15:84953950	NA	0.55	4.63	0.43	1.16e-5	Schizophrenia;
THYM	cis	rs6032067	0.929	rs55726011	chr20:43855229	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.49	-0.49	3.31e-7	Blood protein levels;
THYM	cis	rs928736	0.599	rs1000005	chr21:34433051	C/G	cg04836472	chr21:34405997	NA	0.47	5.38	0.48	5.4e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs2066819	1.000	rs1274493	chr12:56682371	C/T	cg26714650	chr12:56694279	CS	1.26	7.39	0.6	5.59e-11	Psoriasis vulgaris;
THYM	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg12599982	chr1:44399894	ARTN	0.56	4.66	0.43	1.02e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2073300	0.609	rs6137945	chr20:23406136	C/T	cg12062639	chr20:23401060	NAPB	1.1	5.73	0.51	1.16e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7524258	0.903	rs4908608	chr1:7292772	T/C	cg07173049	chr1:7289937	CAMTA1	0.82	6.34	0.55	7.82e-9	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg10645314	chr2:3704589	ALLC	0.79	5.82	0.51	7.97e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs9583531	0.600	rs9555724	chr13:111354110	C/T	cg24331049	chr13:111365604	ING1	-0.74	-6.16	-0.53	1.77e-8	Coronary artery disease;
THYM	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs10949662	1.000	rs11765189	chr7:157535977	A/G	cg11757124	chr7:157526947	PTPRN2	-1.0	-8.67	-0.66	1.12e-13	Intelligence (multi-trait analysis);
THYM	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg14298792	chr15:30685198	CHRFAM7A	0.81	5.63	0.5	1.81e-7	Huntington's disease progression;
THYM	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg16989719	chr2:238392110	NA	-0.67	-5.39	-0.48	5.07e-7	Prostate cancer;
THYM	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg10360139	chr7:1886902	MAD1L1	-0.62	-5.45	-0.49	3.96e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs899997	1.000	rs8030335	chr15:79034124	G/A	cg04896959	chr15:78267971	NA	0.91	7.28	0.6	9.49e-11	Coronary artery disease or large artery stroke;
THYM	cis	rs3126085	0.735	rs4845752	chr1:152226576	C/A	cg10321714	chr1:152280068	FLG	0.65	4.64	0.43	1.1e-5	Atopic dermatitis;
THYM	cis	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg13443165	chr9:33130375	B4GALT1	-0.74	-5.44	-0.49	4.08e-7	IgG glycosylation;
THYM	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	4.79	0.44	6.04e-6	Menarche (age at onset);
THYM	cis	rs4499344	0.556	rs259217	chr19:33138368	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.93	6.54	0.56	3.01e-9	Mean platelet volume;
THYM	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg15592062	chr6:167189543	RPS6KA2	-0.47	-4.59	-0.43	1.34e-5	Crohn's disease;
THYM	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg08901578	chr4:187885870	NA	0.68	6.86	0.58	6.97e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9902453	0.933	rs8080343	chr17:28456758	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	4.9	0.45	3.93e-6	Coffee consumption (cups per day);
THYM	cis	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg24308560	chr3:49941425	MST1R	0.64	5.54	0.49	2.73e-7	Body mass index;
THYM	cis	rs941408	1.000	rs1736181	chr19:2797703	C/T	cg19693284	chr19:2783607	SGTA	0.68	5.25	0.47	9.18e-7	Total cholesterol levels;
THYM	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg22764591	chr12:58329936	NA	0.84	5.9	0.52	5.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg14829155	chr15:31115871	NA	-0.51	-4.82	-0.44	5.4e-6	Huntington's disease progression;
THYM	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg05283184	chr6:79620031	NA	-0.94	-9.25	-0.69	6.49e-15	Intelligence (multi-trait analysis);
THYM	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg12011299	chr4:100065546	ADH4	0.66	5.76	0.51	1.03e-7	Alcohol dependence;
THYM	cis	rs4499344	0.730	rs380320	chr19:33105904	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.8	6.6	0.56	2.29e-9	Mean platelet volume;
THYM	cis	rs1691799	0.899	rs1177555	chr12:66727568	A/G	cg16791601	chr12:66731901	HELB	-0.76	-7.33	-0.6	7.6e-11	White blood cell count (basophil);
THYM	cis	rs12410462	0.681	rs76191945	chr1:227673919	A/G	cg23173402	chr1:227635558	NA	0.83	6.46	0.55	4.53e-9	Major depressive disorder;
THYM	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg18105134	chr13:113819100	PROZ	1.04	7.14	0.59	1.86e-10	Platelet distribution width;
THYM	cis	rs13102973	0.931	rs4608864	chr4:135883488	G/A	cg14419869	chr4:135874104	NA	0.91	8.81	0.67	5.67e-14	Subjective well-being;
THYM	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg05738196	chr6:26577821	NA	0.94	9.47	0.7	2.2e-15	Intelligence (multi-trait analysis);
THYM	cis	rs11651000	0.625	rs11079786	chr17:45805916	A/G	cg24803719	chr17:45855879	NA	0.54	5.55	0.49	2.63e-7	IgG glycosylation;
THYM	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg23187316	chr7:1099788	C7orf50	0.58	4.45	0.42	2.32e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	7.32	0.6	7.96e-11	Platelet count;
THYM	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg08736216	chr1:53307985	ZYG11A	-0.59	-5.5	-0.49	3.22e-7	Monocyte count;
THYM	cis	rs815815	0.608	rs815809	chr2:47380203	T/C	cg27223769	chr2:47403360	CALM2	-0.8	-5.12	-0.46	1.61e-6	Dialysis-related mortality;
THYM	cis	rs2832077	0.506	rs2832088	chr21:30158620	G/A	cg24692254	chr21:30365293	RNF160	-0.88	-6.37	-0.55	6.78e-9	Cognitive test performance;
THYM	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg24874828	chr4:187887005	NA	-0.5	-4.69	-0.43	9.28e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.61	5.3	0.48	7.56e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10851411	0.789	rs1900920	chr15:42768198	C/T	cg04308337	chr15:42867303	STARD9	-0.59	-4.47	-0.42	2.2e-5	Glucose homeostasis traits;
THYM	cis	rs921968	0.541	rs3731867	chr2:219472734	G/A	cg02176678	chr2:219576539	TTLL4	-0.72	-7.15	-0.59	1.75e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs72627509	0.638	rs7658601	chr4:57781347	C/T	cg26694713	chr4:57773883	REST	0.77	4.68	0.43	9.34e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs4631830	0.863	rs2611507	chr10:51518673	T/C	cg16070123	chr10:51489643	NA	-0.48	-4.51	-0.42	1.86e-5	Prostate-specific antigen levels;
THYM	cis	rs10029851	0.627	rs6821411	chr4:109539508	G/A	cg21648245	chr4:109541405	LOC285456;RPL34	-0.64	-5.01	-0.46	2.47e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs72627123	0.656	rs76479281	chr14:74564609	C/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.29	7.08	0.59	2.46e-10	Morning vs. evening chronotype;
THYM	cis	rs8064299	0.967	rs878907	chr17:72769694	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.66	5.58	0.5	2.27e-7	Monocyte count;
THYM	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.61	-0.43	1.27e-5	Type 2 diabetes;
THYM	trans	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg26043149	chr18:55253948	FECH	1.16	10.82	0.74	2.98e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	5.12	0.46	1.62e-6	Menarche (age at onset);
THYM	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg13866156	chr1:1669148	SLC35E2	-0.72	-7.31	-0.6	8.41e-11	Body mass index;
THYM	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg24803719	chr17:45855879	NA	-0.61	-6.41	-0.55	5.61e-9	IgG glycosylation;
THYM	cis	rs9443645	0.527	rs10943596	chr6:79575292	C/T	cg05283184	chr6:79620031	NA	-0.6	-4.64	-0.43	1.1e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.509	rs6977699	chr7:124617109	A/G	cg05285228	chr7:124571219	POT1	-0.7	-5.27	-0.48	8.57e-7	Cutaneous malignant melanoma;
THYM	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg18230493	chr5:56204884	C5orf35	0.65	4.89	0.45	4.11e-6	Initial pursuit acceleration;
THYM	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg27284194	chr4:1044797	NA	0.61	4.6	0.43	1.29e-5	Recombination rate (females);
THYM	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg12311346	chr5:56204834	C5orf35	-0.81	-5.9	-0.52	5.54e-8	Initial pursuit acceleration;
THYM	trans	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg20587970	chr11:113659929	NA	-1.26	-9.15	-0.68	1.09e-14	Hip circumference adjusted for BMI;
THYM	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg21784768	chr11:537496	LRRC56	-1.09	-5.41	-0.49	4.65e-7	Body mass index;
THYM	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg18681998	chr4:17616180	MED28	0.99	10.18	0.72	6.74e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg02725872	chr8:58115012	NA	-1.12	-7.26	-0.6	1.08e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs17407555	0.647	rs55811736	chr4:10014221	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-5.87	-0.52	6.48e-8	Schizophrenia (age at onset);
THYM	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs55702914	0.628	rs17730989	chr2:198362524	C/T	cg00792783	chr2:198669748	PLCL1	0.63	4.64	0.43	1.11e-5	Major depression and alcohol dependence;
THYM	trans	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg04842962	chr6:43655489	MRPS18A	1.29	9.25	0.69	6.52e-15	IgG glycosylation;
THYM	cis	rs4455778	0.580	rs9942682	chr7:49077999	G/C	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg06713675	chr4:122721982	EXOSC9	-0.51	-4.7	-0.43	8.75e-6	Type 2 diabetes;
THYM	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg08994789	chr17:28903642	LRRC37B2	-1.16	-5.63	-0.5	1.85e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg06009448	chr7:1102226	C7orf50	0.44	4.46	0.42	2.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg09307838	chr4:120376055	NA	0.67	5.06	0.46	2.04e-6	Corneal astigmatism;
THYM	cis	rs1357245	0.631	rs7617491	chr3:27097059	T/C	cg03895047	chr3:27114861	NA	0.49	4.58	0.43	1.42e-5	Breast cancer;
THYM	cis	rs754466	0.606	rs7084705	chr10:79596675	A/G	cg17075019	chr10:79541650	NA	-0.68	-5.82	-0.51	7.99e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12594515	1.000	rs12911309	chr15:45985719	G/C	cg01629716	chr15:45996671	NA	0.54	5.52	0.49	2.91e-7	Waist circumference;Weight;
THYM	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.7	-5.63	-0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.74	7.33	0.6	7.54e-11	Lymphocyte counts;
THYM	cis	rs57920188	0.584	rs12128330	chr1:4092926	G/A	cg20703997	chr1:4087676	NA	0.85	5.76	0.51	1.04e-7	Interleukin-17 levels;
THYM	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg12463550	chr7:65579703	CRCP	-0.55	-4.5	-0.42	1.95e-5	Aortic root size;
THYM	cis	rs2637266	0.596	rs2637247	chr10:78273160	A/C	cg18941641	chr10:78392320	NA	0.6	4.65	0.43	1.07e-5	Pulmonary function;
THYM	cis	rs854765	0.624	rs11652144	chr17:17733934	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-5.45	-0.49	3.94e-7	Total body bone mineral density;
THYM	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs7100689	0.646	rs10466235	chr10:82149655	C/T	cg01528321	chr10:82214614	TSPAN14	-0.84	-6.85	-0.57	7.39e-10	Post bronchodilator FEV1;
THYM	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2073300	1.000	rs6114135	chr20:23456746	C/A	cg12062639	chr20:23401060	NAPB	1.03	5.0	0.46	2.57e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7814319	0.840	rs10504961	chr8:97240129	C/T	cg20787634	chr8:97240163	UQCRB	-0.78	-9.51	-0.7	1.84e-15	Lung function (FVC);
THYM	cis	rs7107174	1.000	rs11237438	chr11:77998488	T/C	cg02023728	chr11:77925099	USP35	0.67	5.88	0.52	6.07e-8	Testicular germ cell tumor;
THYM	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg14004847	chr7:1930337	MAD1L1	-0.62	-4.46	-0.42	2.27e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg07511668	chr11:68622177	NA	0.46	4.68	0.43	9.59e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg18876405	chr7:65276391	NA	-0.55	-4.63	-0.43	1.16e-5	Aortic root size;
THYM	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg25358565	chr5:93447407	FAM172A	-0.93	-6.97	-0.58	4.2e-10	Diabetic retinopathy;
THYM	trans	rs8002861	0.935	rs9533678	chr13:44463409	C/T	cg17145862	chr1:211918768	LPGAT1	1.03	11.49	0.76	1.13e-19	Leprosy;
THYM	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.57	4.57	0.42	1.47e-5	Platelet count;
THYM	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg18681998	chr4:17616180	MED28	0.86	7.7	0.62	1.31e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg14829155	chr15:31115871	NA	-0.55	-5.04	-0.46	2.26e-6	Huntington's disease progression;
THYM	cis	rs8016982	0.617	rs2241621	chr14:81737076	G/T	cg01989461	chr14:81687754	GTF2A1	-0.69	-5.94	-0.52	4.77e-8	Schizophrenia;
THYM	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg11327659	chr7:150037044	RARRES2	0.43	5.02	0.46	2.42e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7567389	0.504	rs5937	chr2:128184770	T/C	cg09760422	chr2:128146352	NA	0.38	4.55	0.42	1.6e-5	Self-rated health;
THYM	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.64	-4.64	-0.43	1.12e-5	Colorectal cancer;
THYM	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg09260853	chr1:2094483	PRKCZ	-0.41	-4.46	-0.42	2.2e-5	Height;
THYM	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg18876405	chr7:65276391	NA	-0.55	-4.73	-0.44	7.84e-6	Aortic root size;
THYM	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11890956	chr21:40555474	PSMG1	1.17	12.99	0.8	8.73e-23	Cognitive function;
THYM	cis	rs6089584	0.587	rs3787423	chr20:60555485	G/A	cg22316451	chr20:60645197	NA	-0.46	-4.45	-0.42	2.29e-5	Body mass index;
THYM	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-4.93	-0.45	3.45e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs654950	1.000	rs654950	chr1:41987868	G/C	cg06885757	chr1:42089581	HIVEP3	-0.58	-7.74	-0.62	1.05e-11	Airway imaging phenotypes;
THYM	cis	rs12893597	0.898	rs12885469	chr14:76809245	C/G	cg20290672	chr14:76816747	NA	-0.58	-4.8	-0.44	5.85e-6	Maximal oxygen uptake response;
THYM	cis	rs886774	0.526	rs67178545	chr7:107508147	T/C	cg23293999	chr7:106826042	HBP1	-0.58	-4.59	-0.43	1.35e-5	Ulcerative colitis;
THYM	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg09034736	chr1:150693464	HORMAD1	0.54	4.76	0.44	6.81e-6	Blood protein levels;
THYM	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg16342193	chr10:102329863	NA	-0.58	-5.99	-0.52	3.78e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg21775007	chr8:11205619	TDH	-0.73	-5.68	-0.5	1.49e-7	Retinal vascular caliber;
THYM	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs4660306	1.000	rs7534467	chr1:45988691	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.43	-0.49	4.37e-7	Homocysteine levels;
THYM	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg15445000	chr17:37608096	MED1	-0.44	-5.22	-0.47	1.05e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.63	-4.94	-0.45	3.4e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg27087555	chr16:88793112	FAM38A	-1.51	-9.92	-0.71	2.42e-16	Plateletcrit;
THYM	cis	rs2806561	0.734	rs2143156	chr1:23374629	T/G	cg12483005	chr1:23474871	LUZP1	0.54	5.49	0.49	3.4e-7	Height;
THYM	cis	rs4343996	0.581	rs7790869	chr7:3455370	C/T	cg21248987	chr7:3385318	SDK1	0.39	4.76	0.44	6.89e-6	Motion sickness;
THYM	cis	rs61931739	0.635	rs1486883	chr12:33908740	C/T	cg10856724	chr12:34555212	NA	-0.63	-5.9	-0.52	5.54e-8	Morning vs. evening chronotype;
THYM	cis	rs7572733	0.534	rs1401095	chr2:198779867	C/T	cg05783139	chr2:198650985	BOLL	-0.62	-4.89	-0.45	4.15e-6	Dermatomyositis;
THYM	cis	rs34638657	1.000	rs34638657	chr16:82153538	A/C	cg07307142	chr16:82071433	HSD17B2	0.92	7.02	0.58	3.31e-10	Lung adenocarcinoma;
THYM	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg00012203	chr2:219082015	ARPC2	-0.69	-5.87	-0.52	6.36e-8	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg11812906	chr14:75593930	NEK9	-0.87	-8.3	-0.65	7.13e-13	Height;
THYM	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg02070205	chr10:30722105	MAP3K8	-0.54	-4.53	-0.42	1.71e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg27129171	chr3:47204927	SETD2	0.69	5.58	0.5	2.3e-7	Birth weight;
THYM	cis	rs977987	0.806	rs4888390	chr16:75400320	G/A	cg03315344	chr16:75512273	CHST6	0.69	5.55	0.49	2.56e-7	Dupuytren's disease;
THYM	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg13175981	chr1:150552382	MCL1	0.78	5.82	0.51	7.88e-8	Tonsillectomy;
THYM	cis	rs9420	0.961	rs7949841	chr11:57524700	G/C	cg19752551	chr11:57585705	CTNND1	-0.73	-7.98	-0.63	3.28e-12	Schizophrenia;
THYM	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg04944784	chr2:26401820	FAM59B	-1.05	-8.18	-0.64	1.23e-12	Gut microbiome composition (summer);
THYM	cis	rs28595532	0.920	rs114751999	chr4:119759651	G/A	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.1	12.46	0.79	1.09e-21	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg17264618	chr3:40429014	ENTPD3	0.47	4.54	0.42	1.62e-5	Renal cell carcinoma;
THYM	cis	rs859767	0.704	rs6750788	chr2:135362981	A/G	cg12500956	chr2:135428796	TMEM163	-0.49	-4.98	-0.46	2.8e-6	Neuroticism;
THYM	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.72	-0.44	7.98e-6	Fear of minor pain;
THYM	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg12893428	chr3:195717962	SDHAP1	0.52	4.65	0.43	1.09e-5	Pancreatic cancer;
THYM	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	4.52	0.42	1.76e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11792861	0.564	rs3816237	chr9:111718348	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.83	7.1	0.59	2.3e-10	Menarche (age at onset);
THYM	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.63	4.46	0.42	2.28e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.43	-4.5	-0.42	1.89e-5	Hemoglobin concentration;
THYM	cis	rs662064	0.962	rs648324	chr1:10556447	G/T	cg20482658	chr1:10539492	PEX14	-0.49	-6.03	-0.53	3.11e-8	Asthma;
THYM	cis	rs7909074	0.691	rs11239274	chr10:45393219	A/C	cg04218760	chr10:45406644	TMEM72	0.59	5.18	0.47	1.26e-6	Mean corpuscular volume;
THYM	cis	rs6480314	0.636	rs34888891	chr10:70002108	A/G	cg27159792	chr10:69524182	NA	0.81	4.89	0.45	4.06e-6	Optic nerve measurement (disc area);
THYM	cis	rs10979	1.000	rs9390107	chr6:143892721	A/T	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg03060546	chr3:49711283	APEH	0.74	6.04	0.53	2.97e-8	Resting heart rate;
THYM	cis	rs11690935	1.000	rs6433311	chr2:172549248	A/G	cg13550731	chr2:172543902	DYNC1I2	0.88	6.48	0.55	4.02e-9	Schizophrenia;
THYM	cis	rs651907	0.588	rs1707613	chr3:101637189	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	5.39	0.48	5.08e-7	Colorectal cancer;
THYM	cis	rs137603	0.901	rs137612	chr22:39698010	A/G	cg24268161	chr22:39747459	SYNGR1	0.57	5.08	0.46	1.87e-6	Primary biliary cholangitis;
THYM	cis	rs4713118	0.699	rs200969	chr6:27859453	T/C	cg12963246	chr6:28129442	ZNF389	0.48	4.6	0.43	1.28e-5	Parkinson's disease;
THYM	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1669338	0.588	rs62228620	chr3:3184913	C/T	cg16797762	chr3:3221439	CRBN	-0.97	-5.15	-0.47	1.41e-6	White matter integrity;
THYM	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg20295408	chr7:1910781	MAD1L1	-0.62	-4.76	-0.44	6.9e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs760805	1.000	rs10903115	chr1:25261696	A/G	cg22509179	chr1:25234806	RUNX3	-0.74	-6.93	-0.58	5.06e-10	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2692947	0.832	rs2438978	chr2:96679740	G/C	cg23100626	chr2:96804247	ASTL	0.42	5.36	0.48	5.73e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg13918804	chr1:2043761	PRKCZ	0.82	7.43	0.61	4.76e-11	Height;
THYM	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg11266682	chr4:10021025	SLC2A9	-0.69	-10.15	-0.72	7.87e-17	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg26924012	chr15:45694286	SPATA5L1	1.13	11.02	0.75	1.11e-18	Homoarginine levels;
THYM	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.76	6.19	0.54	1.55e-8	Schizophrenia;
THYM	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.69	-4.7	-0.43	8.9e-6	Cardiac Troponin-T levels;
THYM	cis	rs2070488	1.000	rs36006749	chr3:38443312	T/C	cg24069376	chr3:38537580	EXOG	0.64	6.35	0.55	7.32e-9	Electrocardiographic conduction measures;
THYM	cis	rs7940866	0.845	rs1433976	chr11:130875123	C/T	cg23692386	chr11:131799662	NTM	-0.42	-4.51	-0.42	1.82e-5	Schizophrenia;
THYM	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg02569458	chr12:86230093	RASSF9	0.69	5.77	0.51	9.84e-8	Major depressive disorder;
THYM	cis	rs8005962	0.785	rs11624615	chr14:96047421	T/G	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.6	4.48	0.42	2.09e-5	Tuberculosis;
THYM	cis	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg09754243	chr16:73083863	ZFHX3	0.62	5.14	0.47	1.48e-6	Energy expenditure (24h);
THYM	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs71403859	0.730	rs17355804	chr16:71717214	A/G	cg08717414	chr16:71523259	ZNF19	-0.92	-5.16	-0.47	1.32e-6	Post bronchodilator FEV1;
THYM	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs7781977	0.723	rs11765436	chr7:50344077	T/A	cg01139861	chr7:50343298	IKZF1	0.69	6.46	0.55	4.36e-9	IgG glycosylation;
THYM	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg21427119	chr20:30132790	HM13	-0.96	-7.02	-0.58	3.34e-10	Mean corpuscular hemoglobin;
THYM	cis	rs3768617	0.510	rs6424888	chr1:183085696	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.55	-4.48	-0.42	2.08e-5	Fuchs's corneal dystrophy;
THYM	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg10852096	chr15:79043040	NA	-0.64	-4.47	-0.42	2.16e-5	Coronary artery disease or large artery stroke;
THYM	cis	rs17005891	0.517	rs11725437	chr4:83541391	T/A	cg10249074	chr4:83542146	C4orf11	-0.59	-4.97	-0.45	2.96e-6	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg04731861	chr2:219085781	ARPC2	-0.48	-4.56	-0.42	1.52e-5	Colorectal cancer;
THYM	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7592578	0.508	rs55919641	chr2:191265414	G/A	cg21644426	chr2:191273491	MFSD6	-0.64	-4.52	-0.42	1.8e-5	Diastolic blood pressure;
THYM	cis	rs6686842	0.896	rs11209725	chr1:41694017	G/T	cg03387723	chr1:41708464	SCMH1	-0.43	-5.05	-0.46	2.14e-6	Height;
THYM	cis	rs9303280	0.617	rs4795406	chr17:38100134	G/C	cg24910161	chr17:38119198	GSDMA	-0.55	-6.54	-0.56	3.1e-9	Self-reported allergy;
THYM	cis	rs10784496	1.000	rs10748026	chr12:66158206	A/G	cg23788418	chr12:65904983	NA	-0.52	-4.52	-0.42	1.78e-5	Cerebrospinal fluid AB1-42 levels;
THYM	cis	rs7264396	0.943	rs6060448	chr20:34112192	C/G	cg26038318	chr20:34205095	SPAG4	-0.54	-4.49	-0.42	2.03e-5	Total cholesterol levels;
THYM	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4803480	0.543	rs7257282	chr19:42042947	T/C	cg24901063	chr19:41732221	AXL	0.7	4.46	0.42	2.23e-5	Schizophrenia;
THYM	cis	rs988913	0.678	rs9357840	chr6:54966582	A/C	cg18532076	chr6:54711417	FAM83B	0.48	4.77	0.44	6.56e-6	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7084402	0.935	rs12263522	chr10:60343527	C/A	cg09696939	chr10:60272079	BICC1	-0.48	-5.67	-0.5	1.56e-7	Refractive error;
THYM	cis	rs10463554	0.963	rs34826	chr5:102441748	T/C	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Parkinson's disease;
THYM	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg19774624	chr17:42201019	HDAC5	-0.78	-6.84	-0.57	7.79e-10	Total body bone mineral density;
THYM	cis	rs4849845	0.925	rs4849844	chr2:121013056	T/C	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs2072499	0.833	rs2251847	chr1:156204047	G/A	cg25208724	chr1:156163844	SLC25A44	0.97	9.79	0.71	4.58e-16	Testicular germ cell tumor;
THYM	cis	rs7089973	0.872	rs7094072	chr10:116627160	T/G	cg23260525	chr10:116636907	FAM160B1	0.52	4.72	0.44	8.04e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9902453	0.689	rs56788338	chr17:28186557	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	5.39	0.48	5.13e-7	Coffee consumption (cups per day);
THYM	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg15592062	chr6:167189543	RPS6KA2	0.58	5.8	0.51	8.65e-8	Crohn's disease;
THYM	cis	rs994014	0.727	rs725826	chr4:82277656	C/G	cg17825130	chr4:82283507	NA	-0.5	-4.48	-0.42	2.07e-5	Height;
THYM	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg18252515	chr7:66147081	NA	0.72	5.66	0.5	1.59e-7	Aortic root size;
THYM	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10851411	0.779	rs7169615	chr15:42754518	A/G	cg04308337	chr15:42867303	STARD9	0.63	4.46	0.42	2.23e-5	Glucose homeostasis traits;
THYM	cis	rs17708984	0.585	rs56123108	chr19:16190906	A/G	cg13618979	chr19:16186840	TPM4	0.36	4.78	0.44	6.39e-6	Platelet count;Platelet distribution width;
THYM	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg02569458	chr12:86230093	RASSF9	-0.62	-5.24	-0.47	9.68e-7	Major depressive disorder;
THYM	cis	rs1981331	1.000	rs1981331	chr21:47995443	A/C	cg17243659	chr21:48055224	PRMT2	0.99	4.65	0.43	1.09e-5	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.12	7.12	0.59	2.01e-10	Cognitive test performance;
THYM	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg06634786	chr22:41940651	POLR3H	0.54	4.64	0.43	1.11e-5	Vitiligo;
THYM	cis	rs10186029	0.676	rs10932464	chr2:213968315	T/A	cg08319019	chr2:214017104	IKZF2	0.9	7.44	0.61	4.49e-11	Systemic sclerosis;
THYM	cis	rs4242434	0.819	rs1871902	chr8:22470710	G/A	cg03733263	chr8:22462867	KIAA1967	1.0	10.9	0.75	1.96e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs11574514	1.000	rs73591936	chr16:67761825	G/A	cg04582263	chr16:67973788	LCAT	0.94	4.45	0.42	2.31e-5	Crohn's disease;
THYM	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08109568	chr15:31115862	NA	-0.62	-5.94	-0.52	4.67e-8	Huntington's disease progression;
THYM	cis	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg07460842	chr6:66804631	NA	0.92	5.5	0.49	3.15e-7	Exhaled nitric oxide levels;
THYM	cis	rs11711311	1.000	rs9851731	chr3:113502651	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.61	5.47	0.49	3.61e-7	IgG glycosylation;
THYM	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg01416388	chr22:39784598	NA	-0.91	-8.26	-0.65	8.64e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4919694	0.901	rs113541728	chr10:104716771	A/T	cg15744005	chr10:104629667	AS3MT	-0.85	-4.67	-0.43	9.96e-6	Arsenic metabolism;
THYM	cis	rs9309473	0.583	rs6705203	chr2:73574600	T/C	cg20560298	chr2:73613845	ALMS1	-0.65	-4.65	-0.43	1.06e-5	Metabolite levels;
THYM	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg10802521	chr3:52805072	NEK4	-0.63	-5.33	-0.48	6.63e-7	Electroencephalogram traits;
THYM	cis	rs11792861	0.591	rs11791855	chr9:111684139	C/T	cg04062823	chr9:111881713	C9orf5	0.63	4.86	0.45	4.67e-6	Menarche (age at onset);
THYM	cis	rs7818345	0.637	rs13280711	chr8:19353600	T/A	cg11303988	chr8:19266685	CSGALNACT1	0.46	4.61	0.43	1.26e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg18512352	chr11:47633146	NA	-0.54	-7.07	-0.59	2.54e-10	Subjective well-being;
THYM	cis	rs12579753	1.000	rs17748942	chr12:82170478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.78	-4.97	-0.45	2.92e-6	Resting heart rate;
THYM	cis	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg09307838	chr4:120376055	NA	0.73	5.51	0.49	3.11e-7	Corneal astigmatism;
THYM	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg03806693	chr22:41940476	POLR3H	1.25	10.88	0.74	2.22e-18	Vitiligo;
THYM	cis	rs9902453	1.000	rs12600993	chr17:28291222	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.81	0.44	5.74e-6	Coffee consumption (cups per day);
THYM	cis	rs10791323	0.628	rs4937838	chr11:133733406	T/C	cg06766960	chr11:133703094	NA	-0.57	-5.38	-0.48	5.43e-7	Childhood ear infection;
THYM	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg03159660	chr11:2078197	NA	0.66	4.9	0.45	3.94e-6	Calcium levels;
THYM	cis	rs686320	0.588	rs11602839	chr11:65177439	G/A	cg19332572	chr11:65321591	LTBP3	1.07	5.25	0.47	9.32e-7	Hip circumference adjusted for BMI;
THYM	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg22974920	chr21:40686053	BRWD1	-0.63	-4.97	-0.45	2.98e-6	Cognitive function;
THYM	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg13918804	chr1:2043761	PRKCZ	-0.61	-4.51	-0.42	1.86e-5	Height;
THYM	cis	rs7512552	0.839	rs3820544	chr1:150457876	A/T	cg15654264	chr1:150340011	RPRD2	0.45	5.19	0.47	1.18e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs4285028	0.747	rs12634032	chr3:121524575	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.92	-6.85	-0.57	7.3e-10	Multiple sclerosis;
THYM	cis	rs3917265	0.616	rs917994	chr2:102837414	G/A	cg13315345	chr2:102803985	IL1RL2	0.67	7.92	0.63	4.38e-12	Atopic dermatitis;
THYM	cis	rs6011002	0.938	rs117314802	chr20:62301849	A/G	cg08432509	chr20:62317768	RTEL1	0.68	4.46	0.42	2.23e-5	Dental caries;
THYM	cis	rs4845875	0.530	rs6667720	chr1:11831615	A/G	cg24844545	chr1:11908347	NPPA	-0.59	-4.9	-0.45	3.94e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs12519773	0.555	rs2009416	chr5:92415111	C/T	cg18783429	chr5:92414398	NA	0.49	4.54	0.42	1.63e-5	Migraine;
THYM	cis	rs6500395	1.000	rs7196823	chr16:48616278	G/A	cg04672837	chr16:48644449	N4BP1	0.51	4.98	0.45	2.85e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2302612	0.528	rs12468673	chr2:102841042	C/G	cg13315345	chr2:102803985	IL1RL2	0.72	4.85	0.45	4.8e-6	Serum protein levels (sST2);
THYM	cis	rs17033621	0.560	rs1013014	chr2:107623697	G/T	cg25305879	chr2:106814630	NA	-0.3	-4.49	-0.42	1.99e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9563576	0.778	rs34723208	chr13:58677379	T/C	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.6	4.5	0.42	1.9e-5	Body mass index;
THYM	cis	rs6840360	1.000	rs6818667	chr4:152598698	T/C	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg07424592	chr7:64974309	NA	1.15	5.47	0.49	3.58e-7	Diabetic kidney disease;
THYM	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg14768367	chr16:72042858	DHODH	0.65	4.98	0.46	2.83e-6	Fibrinogen levels;
THYM	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs36051895	0.632	rs10758674	chr9:5163645	G/A	cg02405213	chr9:5042618	JAK2	-1.02	-10.57	-0.74	1.02e-17	Pediatric autoimmune diseases;
THYM	cis	rs3820068	0.705	rs72643694	chr1:15860185	C/T	cg05660106	chr1:15850417	CASP9	1.11	9.62	0.7	1.09e-15	Systolic blood pressure;
THYM	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg24209194	chr3:40518798	ZNF619	0.55	4.48	0.42	2.1e-5	Renal cell carcinoma;
THYM	cis	rs6956675	0.534	rs1879840	chr7:62653307	C/T	cg27056864	chr7:62859493	LOC100287834	-0.55	-5.02	-0.46	2.42e-6	Obesity-related traits;
THYM	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg26516362	chr5:178986906	RUFY1	0.39	4.53	0.42	1.71e-5	Lung cancer;
THYM	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg23187316	chr7:1099788	C7orf50	0.59	4.49	0.42	2.01e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg12165864	chr7:66369176	NA	0.65	5.05	0.46	2.12e-6	Aortic root size;
THYM	cis	rs28374715	0.662	rs522063	chr15:41476209	A/G	cg18705301	chr15:41695430	NDUFAF1	1.03	8.67	0.66	1.17e-13	Ulcerative colitis;
THYM	cis	rs7247513	1.000	rs8104385	chr19:12700284	G/A	cg01871581	chr19:12707946	ZNF490	-0.88	-9.08	-0.68	1.54e-14	Bipolar disorder;
THYM	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg11764359	chr7:65958608	NA	0.89	7.48	0.61	3.63e-11	Aortic root size;
THYM	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.5	-4.67	-0.43	1e-5	Lymphocyte counts;
THYM	cis	rs6032067	0.777	rs34085254	chr20:43786170	T/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.62	-0.5	1.89e-7	Blood protein levels;
THYM	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg12011299	chr4:100065546	ADH4	0.86	8.3	0.65	7.14e-13	Smoking initiation;
THYM	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg05283184	chr6:79620031	NA	-0.94	-9.25	-0.69	6.67e-15	Intelligence (multi-trait analysis);
THYM	cis	rs9814567	0.896	rs13089566	chr3:134349710	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	7.64	0.62	1.72e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg16898833	chr6:26189333	HIST1H4D	1.3	4.47	0.42	2.14e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6495367	0.872	rs6495366	chr15:79373677	C/T	cg17916960	chr15:79447300	NA	0.6	6.32	0.54	8.56e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg03733263	chr8:22462867	KIAA1967	1.15	13.54	0.81	6.65e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs8180040	0.726	rs11130112	chr3:47024495	G/T	cg02527881	chr3:46936655	PTH1R	-0.64	-6.61	-0.56	2.22e-9	Colorectal cancer;
THYM	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg07930552	chr6:133119739	C6orf192	0.95	5.65	0.5	1.69e-7	Type 2 diabetes nephropathy;
THYM	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg02896835	chr1:92012615	NA	-0.65	-5.74	-0.51	1.15e-7	Breast cancer;
THYM	cis	rs3771570	1.000	rs62193207	chr2:242318501	G/C	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg24549020	chr5:56110836	MAP3K1	0.69	4.52	0.42	1.8e-5	Initial pursuit acceleration;
THYM	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.61	-0.43	1.24e-5	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs56079296	1.000	rs3792801	chr5:121403410	A/G	cg05256605	chr5:121412184	LOX	-0.58	-4.51	-0.42	1.88e-5	Coronary artery disease;
THYM	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg11965913	chr1:205819406	PM20D1	0.52	4.49	0.42	2.04e-5	Parkinson's disease;
THYM	cis	rs910187	0.605	rs6018317	chr20:45803236	A/G	cg27589058	chr20:45804311	EYA2	-0.68	-6.04	-0.53	3.03e-8	Migraine;
THYM	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.22	0.64	1.03e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22496380	chr5:211416	CCDC127	-1.39	-8.13	-0.64	1.62e-12	Breast cancer;
THYM	trans	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg23505145	chr19:12996616	KLF1	1.01	10.01	0.72	1.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1448094	0.549	rs7297996	chr12:86235899	C/T	cg00310523	chr12:86230176	RASSF9	0.59	5.41	0.49	4.71e-7	Major depressive disorder;
THYM	cis	rs7191700	0.601	rs243329	chr16:11352313	A/T	cg00044050	chr16:11439710	C16orf75	0.71	5.22	0.47	1.04e-6	Multiple sclerosis;
THYM	cis	rs1568889	1.000	rs12796293	chr11:28177723	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.74	-4.86	-0.45	4.55e-6	Bipolar disorder;
THYM	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg03609598	chr5:56110824	MAP3K1	0.75	4.48	0.42	2.09e-5	Initial pursuit acceleration;
THYM	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg07362569	chr17:61921086	SMARCD2	0.69	6.16	0.53	1.78e-8	Prudent dietary pattern;
THYM	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg24692254	chr21:30365293	RNF160	0.65	4.63	0.43	1.18e-5	Selective IgA deficiency;
THYM	cis	rs7586879	0.828	rs11675013	chr2:25107208	G/A	cg01884057	chr2:25150051	NA	0.52	4.65	0.43	1.09e-5	Body mass index;
THYM	cis	rs9399401	0.667	rs17071756	chr6:142715195	C/T	cg03128060	chr6:142623767	GPR126	-0.68	-9.28	-0.69	5.63e-15	Chronic obstructive pulmonary disease;
THYM	cis	rs3126085	0.935	rs3126048	chr1:152260165	T/C	cg10321714	chr1:152280068	FLG	-0.67	-5.14	-0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs7267979	0.873	rs6115093	chr20:25210730	C/T	cg03522245	chr20:25566470	NINL	0.62	4.47	0.42	2.16e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs10892173	0.545	rs115865940	chr11:117666711	C/T	cg07621104	chr11:117668040	DSCAML1	0.77	5.98	0.52	3.82e-8	Myopia;
THYM	cis	rs7408868	0.831	rs7245850	chr19:15274585	A/C	cg14696996	chr19:15285081	NOTCH3	0.99	5.63	0.5	1.81e-7	Pulse pressure;
THYM	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg04455712	chr21:45112962	RRP1B	0.57	5.5	0.49	3.14e-7	Mean corpuscular volume;
THYM	cis	rs4930776	0.933	rs4313660	chr12:5766165	T/C	cg02086166	chr12:5775618	ANO2	-0.58	-5.71	-0.51	1.3e-7	Plasma clusterin levels;
THYM	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg06981504	chr1:1234844	ACAP3	-0.48	-4.5	-0.42	1.91e-5	Body mass index;
THYM	cis	rs8016982	0.674	rs2288499	chr14:81660997	C/T	cg21807262	chr14:81713016	NA	-0.57	-5.28	-0.48	8.05e-7	Schizophrenia;
THYM	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.06	-5.25	-0.47	9.31e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7152530	0.571	rs7155953	chr14:98636535	T/C	cg05180522	chr14:98101740	NA	-0.59	-4.7	-0.43	8.79e-6	Staphylococcus aureus infection;
THYM	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27286337	chr10:134555280	INPP5A	0.84	5.93	0.52	4.78e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs6964587	0.626	rs2106745	chr7:91506635	C/T	cg22709100	chr7:91322751	NA	-0.64	-4.72	-0.44	8.02e-6	Breast cancer;
THYM	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg08439880	chr3:133502540	NA	-0.73	-6.46	-0.55	4.44e-9	Iron status biomarkers;
THYM	cis	rs12580035	0.568	rs7315298	chr12:1912880	C/T	cg04012082	chr12:1905096	CACNA2D4	0.4	4.79	0.44	6.04e-6	Urate levels in lean individuals;
THYM	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg12165864	chr7:66369176	NA	-0.64	-4.98	-0.46	2.82e-6	Aortic root size;
THYM	cis	rs17641971	0.662	rs10435575	chr8:49996107	C/T	cg00325661	chr8:49890786	NA	0.6	4.79	0.44	6.24e-6	Blood metabolite levels;
THYM	cis	rs10484885	0.878	rs72921955	chr6:90588789	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.87	-7.73	-0.62	1.13e-11	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg22852734	chr6:133119734	C6orf192	1.21	7.33	0.6	7.58e-11	Type 2 diabetes nephropathy;
THYM	cis	rs10089	1.000	rs4835945	chr5:127526481	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	5.46	0.49	3.81e-7	Ileal carcinoids;
THYM	cis	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg02825527	chr7:2087843	MAD1L1	-0.81	-4.9	-0.45	3.97e-6	Neuroticism;
THYM	cis	rs11731175	0.961	rs62342328	chr4:189849203	C/T	cg00431894	chr4:189871012	NA	-0.88	-6.75	-0.57	1.15e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs17767294	0.708	rs78094982	chr6:27968350	G/A	cg08851530	chr6:28072375	NA	1.39	5.71	0.51	1.31e-7	Parkinson's disease;
THYM	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg13695892	chr22:41940480	POLR3H	0.91	6.69	0.57	1.5e-9	Vitiligo;
THYM	cis	rs877282	0.898	rs12356744	chr10:757477	G/C	cg10556349	chr10:835070	NA	-0.77	-4.95	-0.45	3.24e-6	Uric acid levels;
THYM	cis	rs4842666	0.915	rs111478946	chr12:90058842	G/A	cg00757033	chr12:89920650	WDR51B	0.46	4.53	0.42	1.71e-5	Blood pressure;
THYM	trans	rs877282	0.945	rs35342920	chr10:790484	T/C	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg07636037	chr3:49044803	WDR6	0.93	9.72	0.71	6.62e-16	Parkinson's disease;
THYM	cis	rs6427499	0.740	rs7551141	chr1:159892780	A/G	cg15641364	chr1:159892206	TAGLN2	0.39	4.51	0.42	1.83e-5	Platelet distribution width;
THYM	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg09060608	chr5:178986726	RUFY1	0.58	5.9	0.52	5.61e-8	Lung cancer;
THYM	cis	rs11096990	0.577	rs6830736	chr4:39283087	A/G	cg24403649	chr4:39172243	NA	-0.64	-5.54	-0.49	2.67e-7	Cognitive function;
THYM	cis	rs2637266	1.000	rs12251862	chr10:78367929	A/G	cg18941641	chr10:78392320	NA	0.77	6.49	0.55	3.9e-9	Pulmonary function;
THYM	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs12478296	0.681	rs6598999	chr2:242994405	C/A	cg06360820	chr2:242988706	NA	-0.96	-6.76	-0.57	1.09e-9	Obesity-related traits;
THYM	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11890956	chr21:40555474	PSMG1	1.08	10.56	0.73	1.05e-17	Cognitive function;
THYM	cis	rs7107174	0.901	rs2512522	chr11:77925855	G/C	cg02023728	chr11:77925099	USP35	0.68	6.29	0.54	9.53e-9	Testicular germ cell tumor;
THYM	cis	rs2075230	0.642	rs1641535	chr17:7546133	T/C	cg10509001	chr17:7553872	ATP1B2	-0.56	-4.52	-0.42	1.79e-5	Hormone measurements;
THYM	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg21252483	chr19:49399788	TULP2	-0.96	-7.25	-0.6	1.09e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7192750	0.586	rs7204708	chr16:71986946	C/T	cg06353428	chr16:71660113	MARVELD3	-0.68	-5.01	-0.46	2.5e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs73110464	0.591	rs11829997	chr12:53315659	A/G	cg17405586	chr12:53074257	KRT1	1.09	4.54	0.42	1.67e-5	Cancer (pleiotropy);
THYM	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg23815491	chr16:72088622	HP	0.81	6.46	0.55	4.54e-9	Fibrinogen levels;
THYM	cis	rs877282	0.891	rs11253406	chr10:796297	G/A	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11890956	chr21:40555474	PSMG1	-0.66	-6.38	-0.55	6.51e-9	Menarche (age at onset);
THYM	cis	rs4363385	0.693	rs368076	chr1:153046514	A/C	cg13444842	chr1:152974279	SPRR3	-0.61	-5.02	-0.46	2.44e-6	Inflammatory skin disease;
THYM	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg12419862	chr22:24373484	LOC391322	-0.91	-10.39	-0.73	2.39e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.09	-0.53	2.34e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7818345	0.595	rs12155539	chr8:19316086	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.52	4.52	0.42	1.77e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg25208724	chr1:156163844	SLC25A44	1.1	8.39	0.65	4.57e-13	Testicular germ cell tumor;
THYM	cis	rs4722585	0.533	rs2237335	chr7:26200213	A/G	cg07876897	chr7:26191696	NFE2L3	0.56	4.47	0.42	2.16e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs1198430	1.000	rs1198431	chr1:23755716	C/T	cg27447006	chr1:23763279	ASAP3	-0.86	-4.52	-0.42	1.79e-5	Total cholesterol levels;
THYM	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg06092702	chr1:163392909	NA	0.62	5.65	0.5	1.69e-7	Motion sickness;
THYM	cis	rs1467026	0.584	rs9865381	chr3:12801685	C/T	cg11882607	chr3:12858926	CAND2	-0.49	-5.61	-0.5	2e-7	P wave duration;
THYM	cis	rs9467711	0.651	rs13197334	chr6:26122648	G/C	cg01386294	chr6:25732093	NA	0.9	4.88	0.45	4.34e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg03161606	chr19:29218774	NA	0.84	7.27	0.6	1.01e-10	Methadone dose in opioid dependence;
THYM	cis	rs7319075	0.830	rs9533533	chr13:44152148	A/C	cg07493307	chr13:44854706	NA	0.54	4.52	0.42	1.77e-5	Photic sneeze reflex;
THYM	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg05973401	chr12:123451056	ABCB9	0.65	4.82	0.44	5.35e-6	Platelet count;
THYM	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg08048268	chr3:133502702	NA	0.61	4.9	0.45	3.95e-6	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg15691649	chr6:25882328	NA	-0.77	-5.9	-0.52	5.46e-8	Uric acid levels;
THYM	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg00129232	chr17:37814104	STARD3	0.69	4.45	0.42	2.32e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.88	0.58	6.2e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9788721	0.836	rs17484524	chr15:78772676	A/G	cg18825076	chr15:78729989	IREB2	-0.67	-6.17	-0.54	1.63e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs7618501	1.000	rs2247036	chr3:49882349	C/T	cg24308560	chr3:49941425	MST1R	-0.57	-4.52	-0.42	1.79e-5	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4242434	0.927	rs10099846	chr8:22534178	C/T	cg11461670	chr8:22454935	PDLIM2	0.37	6.02	0.53	3.27e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs870825	0.616	rs7682677	chr4:185640717	C/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs593982	0.843	rs552312	chr11:65477349	C/T	cg08755490	chr11:65554678	OVOL1	1.29	4.66	0.43	1.03e-5	Atopic dermatitis;
THYM	cis	rs7084921	0.608	rs12775433	chr10:101834092	C/T	cg11344164	chr10:101878520	NA	-0.56	-4.81	-0.44	5.61e-6	Bone mineral density;
THYM	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg04663057	chr3:46933782	PTH1R	0.53	5.07	0.46	1.99e-6	Birth weight;
THYM	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg15536230	chr21:44985092	HSF2BP	-0.46	-5.66	-0.5	1.63e-7	Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg18128536	chr17:47092178	IGF2BP1	-0.53	-8.16	-0.64	1.4e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.16	-0.75	5.56e-19	Primary sclerosing cholangitis;
THYM	cis	rs6840360	0.571	rs11729136	chr4:152529227	C/A	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7084402	1.000	rs11006169	chr10:60269326	T/A	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg18758796	chr5:131593413	PDLIM4	-0.48	-4.45	-0.42	2.34e-5	Blood metabolite levels;
THYM	cis	rs9314614	0.872	rs2738060	chr8:6709933	G/C	cg27319216	chr8:6693540	XKR5	-0.6	-6.22	-0.54	1.31e-8	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs28374715	0.617	rs28626792	chr15:41562218	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.94	-8.33	-0.65	5.91e-13	Ulcerative colitis;
THYM	cis	rs11764590	0.671	rs12669370	chr7:2081914	G/A	cg21110456	chr7:2059412	MAD1L1	-0.47	-4.66	-0.43	1.03e-5	Neuroticism;
THYM	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs2730245	0.527	rs1188971	chr7:158664463	G/T	cg01219135	chr7:158766336	NA	0.56	4.49	0.42	2.01e-5	Height;
THYM	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg13319975	chr6:146136371	FBXO30	-0.69	-5.67	-0.5	1.51e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs56161922	1.000	rs17045979	chr1:207842704	T/C	cg09557387	chr1:207818395	CR1L	1.14	5.13	0.47	1.52e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg13010199	chr12:38710504	ALG10B	-0.65	-5.03	-0.46	2.27e-6	Morning vs. evening chronotype;
THYM	cis	rs7578361	0.918	rs10204886	chr2:150369240	A/G	cg17961725	chr2:150454027	NA	0.74	5.41	0.48	4.79e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9814567	0.712	rs9838889	chr3:134332311	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg08213375	chr14:104286397	PPP1R13B	0.54	6.47	0.55	4.26e-9	Schizophrenia;
THYM	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg20283391	chr11:68216788	NA	-0.59	-4.71	-0.44	8.32e-6	Total body bone mineral density;
THYM	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg24257776	chr3:47051546	LOC100129354	0.41	4.73	0.44	7.73e-6	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.48	-0.55	4.1e-9	Personality dimensions;
THYM	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.47	-4.48	-0.42	2.1e-5	Crohn's disease;
THYM	cis	rs672413	0.739	rs500390	chr5:78283656	C/T	cg11541897	chr5:78281793	ARSB	-0.52	-4.76	-0.44	6.83e-6	Blood and toenail selenium levels;Blood protein levels;
THYM	cis	rs7107770	1.000	rs34457642	chr11:125086200	A/T	cg04164023	chr11:125106101	PKNOX2	-0.87	-5.22	-0.47	1.04e-6	Photic sneeze reflex;
THYM	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs9914988	0.832	rs11650788	chr17:27174523	T/A	cg20469991	chr17:27169893	C17orf63	-0.82	-5.18	-0.47	1.23e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg09904177	chr6:26538194	HMGN4	-0.64	-5.41	-0.49	4.78e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4430311	0.723	rs7552659	chr1:243983723	T/C	cg25706552	chr1:244017396	NA	-0.57	-4.86	-0.45	4.67e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg18477163	chr1:228402036	OBSCN	-0.46	-5.0	-0.46	2.64e-6	Diastolic blood pressure;
THYM	cis	rs11731175	1.000	rs11726703	chr4:189851833	G/A	cg00431894	chr4:189871012	NA	-0.81	-6.19	-0.54	1.52e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1975974	0.511	rs17052375	chr17:21743877	G/A	cg18423549	chr17:21743878	NA	-0.66	-5.38	-0.48	5.28e-7	Psoriasis;
THYM	cis	rs7107174	1.000	rs10793300	chr11:78019582	T/A	cg19901956	chr11:77921274	USP35	-0.74	-5.57	-0.5	2.39e-7	Testicular germ cell tumor;
THYM	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-4.74	-0.44	7.42e-6	Joint mobility (Beighton score);
THYM	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	6.61	0.56	2.26e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs7843479	1.000	rs11775444	chr8:21813018	A/G	cg17168535	chr8:21777572	XPO7	0.72	5.25	0.47	9.39e-7	Mean corpuscular volume;
THYM	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg12564285	chr5:131593104	PDLIM4	0.44	4.57	0.42	1.46e-5	Blood metabolite levels;
THYM	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs28595532	0.841	rs114970257	chr4:119756937	G/A	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg06238570	chr21:40685208	BRWD1	0.91	6.77	0.57	1.08e-9	Cognitive function;
THYM	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg06582575	chr6:163149167	PACRG;PARK2	1.12	7.7	0.62	1.28e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg13443165	chr9:33130375	B4GALT1	-0.87	-7.99	-0.63	3.23e-12	IgG glycosylation;
THYM	cis	rs2932538	0.922	rs6537745	chr1:113154080	T/C	cg22162597	chr1:113214053	CAPZA1	0.63	5.21	0.47	1.08e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs12984174	1.000	rs403439	chr19:18142075	A/G	cg21649277	chr19:18117794	ARRDC2	-0.89	-5.25	-0.47	9.19e-7	Pulmonary function in asthmatics;
THYM	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg22875332	chr1:76189707	ACADM	0.89	12.06	0.78	7.38e-21	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg11301795	chr4:187892539	NA	-1.12	-16.74	-0.86	4.36e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg13319975	chr6:146136371	FBXO30	-0.69	-5.7	-0.5	1.37e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg04750100	chr2:136595281	LCT	0.54	6.43	0.55	5.16e-9	Mosquito bite size;
THYM	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg18105134	chr13:113819100	PROZ	-1.13	-10.33	-0.73	3.22e-17	Platelet distribution width;
THYM	cis	rs7917772	0.560	rs35095897	chr10:104377759	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-5.66	-0.5	1.57e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg18850127	chr7:39170497	POU6F2	0.6	5.66	0.5	1.57e-7	IgG glycosylation;
THYM	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg19628046	chr18:33552617	C18orf21	-0.78	-5.53	-0.49	2.78e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs911119	1.000	rs6114206	chr20:23611789	A/G	cg16589663	chr20:23618590	CST3	0.77	4.71	0.44	8.31e-6	Chronic kidney disease;
THYM	cis	rs8114671	0.562	rs6120746	chr20:33448496	A/G	cg08999081	chr20:33150536	PIGU	0.63	5.25	0.47	9.29e-7	Height;
THYM	cis	rs34375054	0.623	rs2297478	chr12:125591844	C/T	cg25124228	chr12:125621409	AACS	-0.78	-6.04	-0.53	3.02e-8	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.61	4.66	0.43	1.05e-5	Tonsillectomy;
THYM	cis	rs886126	0.853	rs4766558	chr12:111664061	T/G	cg10833066	chr12:111807467	FAM109A	0.44	5.46	0.49	3.84e-7	Coronary heart disease;
THYM	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg03388043	chr17:80084554	CCDC57	-0.71	-5.85	-0.51	6.98e-8	Life satisfaction;
THYM	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg27121462	chr16:89883253	FANCA	0.57	4.54	0.42	1.65e-5	Vitiligo;
THYM	cis	rs763014	0.500	rs11865749	chr16:717971	C/G	cg01252526	chr16:711033	WDR90	-0.65	-6.1	-0.53	2.29e-8	Height;
THYM	cis	rs10503871	0.545	rs10955031	chr8:30475926	A/G	cg12158488	chr8:31336998	NA	-0.4	-4.69	-0.43	9.29e-6	Metabolite levels  (X-11787);
THYM	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg00074818	chr8:8560427	CLDN23	0.58	5.4	0.48	4.91e-7	Obesity-related traits;
THYM	cis	rs7584330	0.518	rs11888077	chr2:238424763	G/A	cg14458575	chr2:238380390	NA	1.01	5.25	0.47	9.18e-7	Prostate cancer;
THYM	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg05335186	chr13:53173507	NA	-0.52	-7.57	-0.61	2.42e-11	Lewy body disease;
THYM	cis	rs17407555	0.697	rs73212840	chr4:10087458	C/T	cg00071950	chr4:10020882	SLC2A9	-0.73	-5.39	-0.48	5.09e-7	Schizophrenia (age at onset);
THYM	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg19077165	chr18:44547161	KATNAL2	-0.59	-7.3	-0.6	8.69e-11	Personality dimensions;
THYM	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg05731713	chr7:157510257	PTPRN2	0.54	5.33	0.48	6.68e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs478304	0.934	rs669742	chr11:65501291	C/T	cg27068330	chr11:65405492	SIPA1	0.82	7.91	0.63	4.72e-12	Acne (severe);
THYM	cis	rs12549902	0.933	rs17659428	chr8:41513809	T/C	cg21772509	chr8:41503840	NKX6-3	0.72	6.79	0.57	9.78e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
THYM	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg05802129	chr4:122689817	NA	-0.57	-4.47	-0.42	2.17e-5	Type 2 diabetes;
THYM	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg07936489	chr17:37558343	FBXL20	-0.85	-5.64	-0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	cis	rs478304	0.654	rs6591185	chr11:65455742	A/G	cg17480646	chr11:65405466	SIPA1	-0.97	-8.99	-0.68	2.44e-14	Acne (severe);
THYM	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.33	0.48	6.55e-7	Height;
THYM	cis	rs2276314	1.000	rs4799834	chr18:33566243	T/C	cg19628046	chr18:33552617	C18orf21	0.77	5.47	0.49	3.68e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs2133450	0.526	rs17047063	chr3:7343584	G/A	cg19930620	chr3:7340148	GRM7	-0.5	-5.46	-0.49	3.72e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs4919694	0.572	rs12262258	chr10:104900272	G/A	cg04362960	chr10:104952993	NT5C2	0.97	6.41	0.55	5.51e-9	Arsenic metabolism;
THYM	cis	rs9790314	1.000	rs163328	chr3:161073599	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-6.57	-0.56	2.67e-9	Morning vs. evening chronotype;
THYM	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg05738196	chr6:26577821	NA	-0.86	-8.72	-0.67	9.08e-14	Intelligence (multi-trait analysis);
THYM	cis	rs6840360	0.571	rs11726892	chr4:152555106	A/G	cg22705602	chr4:152727874	NA	-0.8	-8.47	-0.66	3e-13	Intelligence (multi-trait analysis);
THYM	cis	rs11608355	1.000	rs10850134	chr12:109861454	G/C	cg11367159	chr12:110044531	NA	0.66	6.29	0.54	9.83e-9	Neuroticism;
THYM	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg10505658	chr17:80084571	CCDC57	-0.69	-7.95	-0.63	3.85e-12	Life satisfaction;
THYM	cis	rs6032067	0.641	rs6032006	chr20:43755053	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.7	-7.59	-0.61	2.14e-11	Blood protein levels;
THYM	cis	rs80319144	0.904	rs79671796	chr2:159168143	C/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.6	4.64	0.43	1.12e-5	Restless legs syndrome;
THYM	cis	rs8016982	0.698	rs12590764	chr14:81704417	G/A	cg01989461	chr14:81687754	GTF2A1	0.82	7.69	0.62	1.32e-11	Schizophrenia;
THYM	cis	rs4363385	0.747	rs3753454	chr1:152973776	T/C	cg13444842	chr1:152974279	SPRR3	-0.6	-4.79	-0.44	6.2e-6	Inflammatory skin disease;
THYM	cis	rs7267979	1.000	rs422424	chr20:25445446	G/C	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.07	7.53	0.61	2.93e-11	Smoking behavior;
THYM	cis	rs9486719	0.947	rs2472893	chr6:96870048	G/C	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.07	-10.85	-0.74	2.51e-18	Primary sclerosing cholangitis;
THYM	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg24531977	chr5:56204891	C5orf35	-1.01	-8.29	-0.65	7.47e-13	Initial pursuit acceleration;
THYM	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg00277334	chr10:82204260	NA	-0.53	-5.41	-0.49	4.75e-7	Post bronchodilator FEV1;
THYM	cis	rs3820068	0.705	rs4645992	chr1:15849742	G/T	cg05660106	chr1:15850417	CASP9	1.09	8.94	0.68	3.01e-14	Systolic blood pressure;
THYM	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg13918804	chr1:2043761	PRKCZ	0.76	7.44	0.61	4.5e-11	Height;
THYM	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg11317459	chr13:21872234	NA	-1.22	-9.38	-0.69	3.53e-15	White matter hyperintensity burden;
THYM	cis	rs7772486	0.875	rs1331644	chr6:146398660	T/C	cg23711669	chr6:146136114	FBXO30	0.93	9.69	0.7	7.78e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7917772	0.510	rs2001389	chr10:104375258	G/A	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg26597838	chr10:835615	NA	1.1	6.33	0.54	8e-9	Eosinophil percentage of granulocytes;
THYM	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs9790314	1.000	rs7653233	chr3:160992033	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-7.0	-0.58	3.68e-10	Morning vs. evening chronotype;
THYM	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg18806716	chr10:30721971	MAP3K8	-0.49	-4.51	-0.42	1.85e-5	Itch intensity from mosquito bite;
THYM	cis	rs55728055	0.661	rs62237764	chr22:31947393	T/G	cg10537193	chr22:32026975	PISD	-0.92	-5.68	-0.5	1.45e-7	Age-related hearing impairment;
THYM	cis	rs9926296	0.687	rs397891	chr16:89753031	G/C	cg01097406	chr16:89675127	NA	0.85	7.89	0.63	5.12e-12	Vitiligo;
THYM	cis	rs9467711	0.651	rs34197618	chr6:26083519	T/C	cg16898833	chr6:26189333	HIST1H4D	1.33	4.61	0.43	1.24e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11771526	0.686	rs62457501	chr7:32329946	A/G	cg13207630	chr7:32358064	NA	0.82	5.06	0.46	2.06e-6	Body mass index;
THYM	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.07	-6.19	-0.54	1.52e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3892630	0.757	rs8109823	chr19:33183316	A/G	cg22928329	chr19:33183273	NUDT19	-0.78	-5.91	-0.52	5.31e-8	Red blood cell traits;
THYM	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.03	6.98	0.58	3.88e-10	Platelet count;
THYM	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs34853779	1	rs34853779	chr4:144240024	CT/C	cg01601573	chr4:144256835	GAB1	0.41	5.13	0.47	1.56e-6	Breast cancer;
THYM	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg03929089	chr4:120376271	NA	-0.94	-10.56	-0.73	1.03e-17	Height;
THYM	cis	rs3026101	0.624	rs17635627	chr17:5296059	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	5.23	0.47	9.95e-7	Body mass index;
THYM	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.93	-6.05	-0.53	2.84e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg11494091	chr17:61959527	GH2	0.7	6.56	0.56	2.79e-9	Height;
THYM	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg11494091	chr17:61959527	GH2	1.07	16.52	0.86	1.13e-29	Prudent dietary pattern;
THYM	cis	rs778371	0.676	rs13024330	chr2:233715487	A/G	cg08000102	chr2:233561755	GIGYF2	0.82	7.28	0.6	9.82e-11	Schizophrenia;
THYM	cis	rs11577318	0.853	rs11247913	chr1:26648551	G/C	cg00852783	chr1:26633632	UBXN11	0.71	5.85	0.51	7.08e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs6570726	0.791	rs9376953	chr6:145912226	G/T	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg26022315	chr17:47021804	SNF8	0.49	4.55	0.42	1.6e-5	Type 2 diabetes;
THYM	cis	rs8067545	0.611	rs2526486	chr17:20101626	T/G	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg02734326	chr4:10020555	SLC2A9	0.74	6.66	0.56	1.73e-9	Bone mineral density;
THYM	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg26967526	chr14:35346199	BAZ1A	-0.76	-4.97	-0.45	2.96e-6	Psoriasis;
THYM	cis	rs28595532	0.920	rs56042726	chr4:119751777	T/A	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg10802521	chr3:52805072	NEK4	0.74	6.63	0.56	2.03e-9	Bipolar disorder;
THYM	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg27129171	chr3:47204927	SETD2	-0.69	-6.56	-0.56	2.84e-9	Colorectal cancer;
THYM	cis	rs6570726	0.935	rs400968	chr6:145819718	A/G	cg23711669	chr6:146136114	FBXO30	0.82	7.84	0.63	6.69e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	7.48	0.61	3.78e-11	Smoking behavior;
THYM	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg03060546	chr3:49711283	APEH	0.74	6.04	0.53	2.97e-8	Resting heart rate;
THYM	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg24060327	chr5:131705240	SLC22A5	-0.84	-6.76	-0.57	1.13e-9	Breast cancer;
THYM	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	8.7	0.67	9.84e-14	Chronic sinus infection;
THYM	cis	rs35362007	0.530	rs17835086	chr14:96012465	A/G	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.93	4.54	0.42	1.63e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs4849845	0.889	rs6542576	chr2:121013781	G/A	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs6032067	0.777	rs56063128	chr20:43783210	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs6032067	0.714	rs2071651	chr20:43853153	T/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.64	-7.41	-0.61	5.15e-11	Blood protein levels;
THYM	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg00825309	chr19:58991885	ZNF446	-0.59	-4.45	-0.42	2.31e-5	Uric acid clearance;
THYM	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2637266	0.905	rs10824428	chr10:78346041	G/A	cg18941641	chr10:78392320	NA	0.69	5.55	0.49	2.57e-7	Pulmonary function;
THYM	cis	rs4888262	0.564	rs8050850	chr16:74582597	C/A	cg01733217	chr16:74700730	RFWD3	0.8	8.28	0.65	7.82e-13	Testicular germ cell tumor;
THYM	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06634786	chr22:41940651	POLR3H	0.79	6.02	0.53	3.27e-8	Vitiligo;
THYM	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg27129171	chr3:47204927	SETD2	-0.8	-7.64	-0.62	1.69e-11	Colorectal cancer;
THYM	cis	rs7726839	0.555	rs7720419	chr5:589343	A/T	cg16624210	chr5:671434	TPPP	0.62	5.95	0.52	4.4e-8	Obesity-related traits;
THYM	cis	rs7590720	1.000	rs4674048	chr2:216900023	G/A	cg12620499	chr2:216877984	MREG	0.83	5.71	0.51	1.29e-7	Alcohol dependence;
THYM	cis	rs9926296	0.568	rs417323	chr16:89746277	T/G	cg03605463	chr16:89740564	NA	0.84	6.53	0.56	3.26e-9	Vitiligo;
THYM	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg26384229	chr12:38710491	ALG10B	-0.79	-7.74	-0.62	1.08e-11	Heart rate;
THYM	cis	rs5769707	0.777	rs739243	chr22:50057211	C/T	cg17054759	chr22:49844102	NA	-0.51	-5.23	-0.47	1.01e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg09307838	chr4:120376055	NA	0.7	5.27	0.48	8.48e-7	Corneal astigmatism;
THYM	cis	rs11937061	0.514	rs35601542	chr4:78137122	C/A	cg01930676	chr4:78783082	MRPL1	-0.56	-4.5	-0.42	1.93e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs732765	0.648	rs8019391	chr14:75409682	T/C	cg15890469	chr14:75408846	PGF	0.7	4.93	0.45	3.48e-6	Non-small cell lung cancer;
THYM	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg17689763	chr4:710664	PCGF3	-1.12	-10.08	-0.72	1.11e-16	White blood cell count;
THYM	cis	rs6700896	0.931	rs4420065	chr1:66161461	T/C	cg04111102	chr1:66153794	NA	-0.52	-5.06	-0.46	2.05e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs6424115	0.830	rs1105	chr1:24200800	T/C	cg15997130	chr1:24165203	NA	0.76	6.39	0.55	6.14e-9	Immature fraction of reticulocytes;
THYM	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg06784218	chr1:46089804	CCDC17	0.29	4.48	0.42	2.04e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg22079354	chr11:130786696	SNX19	-0.51	-4.53	-0.42	1.7e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg26818010	chr10:134567672	INPP5A	0.75	5.83	0.51	7.69e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs17006441	0.932	rs6549251	chr3:69845508	A/T	cg18496212	chr3:69797108	MITF	0.68	6.86	0.58	6.83e-10	Hemoglobin concentration;
THYM	cis	rs7769051	0.711	rs7738071	chr6:133085116	G/A	cg07930552	chr6:133119739	C6orf192	0.97	5.12	0.47	1.59e-6	Type 2 diabetes nephropathy;
THYM	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg05043794	chr9:111880884	C9orf5	-0.37	-5.18	-0.47	1.22e-6	Menarche (age at onset);
THYM	cis	rs951188	0.744	rs72992987	chr2:150345018	A/G	cg17961725	chr2:150454027	NA	-0.94	-4.79	-0.44	6.22e-6	Daytime sleep phenotypes;
THYM	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg14829155	chr15:31115871	NA	-0.55	-5.11	-0.46	1.67e-6	Huntington's disease progression;
THYM	cis	rs3126085	0.935	rs6587666	chr1:152296863	C/T	cg10321714	chr1:152280068	FLG	-0.65	-4.49	-0.42	2.04e-5	Atopic dermatitis;
THYM	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg13699009	chr12:122356056	WDR66	0.48	4.56	0.42	1.51e-5	Mean corpuscular volume;
THYM	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.05	-5.39	-0.48	5.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg08564027	chr20:61660810	NA	0.93	9.57	0.7	1.39e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg05472934	chr7:22766657	IL6	0.87	8.07	0.64	2.11e-12	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
THYM	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg06636001	chr8:8085503	FLJ10661	0.72	6.66	0.56	1.76e-9	Joint mobility (Beighton score);
THYM	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg08999081	chr20:33150536	PIGU	-0.78	-6.84	-0.57	7.47e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs3796352	0.881	rs34238610	chr3:53026480	A/T	cg24530246	chr3:53118167	NA	-0.84	-4.74	-0.44	7.56e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs10089	0.953	rs6879970	chr5:127387178	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.97	6.65	0.56	1.82e-9	Ileal carcinoids;
THYM	cis	rs9361491	0.657	rs9341750	chr6:79477484	C/T	cg04547799	chr6:79944526	HMGN3	-0.66	-4.57	-0.42	1.44e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg05347473	chr6:146136440	FBXO30	-0.58	-4.49	-0.42	2e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9826463	0.702	rs73228757	chr3:142320081	A/G	cg20824294	chr3:142316082	PLS1	0.63	4.55	0.42	1.62e-5	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg16928487	chr17:17741425	SREBF1	-0.56	-5.57	-0.5	2.37e-7	Total body bone mineral density;
THYM	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg08807101	chr21:30365312	RNF160	-0.92	-7.54	-0.61	2.83e-11	Dental caries;
THYM	cis	rs4900538	0.821	rs2009575	chr14:102820787	C/T	cg18135206	chr14:102964638	TECPR2	-0.84	-6.0	-0.52	3.64e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg25358565	chr5:93447407	FAM172A	-1.38	-11.32	-0.76	2.6e-19	Diabetic retinopathy;
THYM	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21659725	chr3:3221576	CRBN	0.89	9.76	0.71	5.32e-16	Intelligence (multi-trait analysis);
THYM	cis	rs7940866	0.874	rs10791113	chr11:130873165	A/G	cg05962950	chr11:130786565	SNX19	0.63	4.89	0.45	4.05e-6	Schizophrenia;
THYM	cis	rs950880	0.593	rs887971	chr2:103041167	T/C	cg03938978	chr2:103052716	IL18RAP	-0.56	-5.06	-0.46	2.02e-6	Serum protein levels (sST2);
THYM	cis	rs708547	0.647	rs1718839	chr4:57827206	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.55	-4.69	-0.43	9.21e-6	Response to bleomycin (chromatid breaks);
THYM	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg10150615	chr22:24372951	LOC391322	0.9	7.45	0.61	4.34e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg26384229	chr12:38710491	ALG10B	0.73	5.35	0.48	6.04e-7	Morning vs. evening chronotype;
THYM	trans	rs5417	0.780	rs222849	chr17:7185861	T/C	cg15655154	chr3:113604241	GRAMD1C	-1.03	-8.76	-0.67	7.3e-14	Diastolic blood pressure;
THYM	cis	rs921968	0.643	rs523396	chr2:219338789	T/G	cg02176678	chr2:219576539	TTLL4	0.68	6.71	0.57	1.42e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.85	-5.77	-0.51	9.99e-8	Yeast infection;
THYM	cis	rs1829883	0.898	rs2963577	chr5:98785343	C/T	cg08333243	chr5:99726346	NA	0.55	5.05	0.46	2.15e-6	Hemostatic factors and hematological phenotypes;
THYM	trans	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg07393940	chr7:158741817	NA	1.1	8.37	0.65	4.87e-13	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg25036284	chr2:26402008	FAM59B	-0.81	-4.62	-0.43	1.23e-5	Gut microbiome composition (summer);
THYM	cis	rs8060598	0.745	rs34133110	chr16:50743919	C/T	cg05261686	chr16:50743296	NOD2	0.4	4.88	0.45	4.3e-6	Leprosy;
THYM	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.58	0.56	2.61e-9	Total body bone mineral density;
THYM	trans	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg19862616	chr7:65841803	NCRNA00174	1.12	13.73	0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs986417	1.000	rs1254332	chr14:60916587	T/C	cg27398547	chr14:60952738	C14orf39	-1.08	-5.91	-0.52	5.32e-8	Gut microbiota (bacterial taxa);
THYM	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg20290983	chr6:43655470	MRPS18A	1.44	15.94	0.85	1.35e-28	IgG glycosylation;
THYM	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg14004847	chr7:1930337	MAD1L1	-0.68	-5.13	-0.47	1.56e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12188164	0.965	rs11742144	chr5:422178	G/A	cg26850624	chr5:429559	AHRR	-0.7	-5.5	-0.49	3.15e-7	Cystic fibrosis severity;
THYM	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg24257776	chr3:47051546	LOC100129354	0.41	4.73	0.44	7.73e-6	Colorectal cancer;
THYM	cis	rs11651000	0.895	rs79065115	chr17:45855929	C/G	cg24803719	chr17:45855879	NA	-0.62	-5.11	-0.46	1.65e-6	IgG glycosylation;
THYM	cis	rs9790314	0.586	rs35713426	chr3:161131271	A/G	cg03342759	chr3:160939853	NMD3	-0.84	-7.74	-0.62	1.07e-11	Morning vs. evening chronotype;
THYM	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-1.18	-9.38	-0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs877282	1.000	rs11253366	chr10:773386	C/T	cg22713356	chr15:30763199	NA	1.26	10.12	0.72	9.24e-17	Uric acid levels;
THYM	cis	rs240764	0.725	rs11155477	chr6:100935505	T/A	cg21058520	chr6:100914733	NA	0.55	4.92	0.45	3.63e-6	Neuroticism;
THYM	cis	rs28595532	0.920	rs114963870	chr4:119758099	T/C	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg06808227	chr14:105710500	BRF1	-1.02	-8.8	-0.67	6.06e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg04034577	chr2:241836375	C2orf54	-0.49	-8.8	-0.67	6.02e-14	Urinary metabolites;
THYM	cis	rs6430585	0.527	rs62168830	chr2:136443900	A/T	cg07169764	chr2:136633963	MCM6	1.03	9.12	0.68	1.26e-14	Corneal structure;
THYM	cis	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg01364799	chr7:75623366	TMEM120A	0.64	4.67	0.43	1e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.79	0.51	8.89e-8	Obesity-related traits;
THYM	cis	rs2237457	0.543	rs2262464	chr7:50702628	C/A	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.48e-6	Schizophrenia (treatment resistant);
THYM	cis	rs213032	1.000	rs213027	chr1:21651660	G/T	cg18221576	chr1:22213934	HSPG2	0.5	4.53	0.42	1.72e-5	Obesity-related traits;
THYM	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg13010199	chr12:38710504	ALG10B	0.63	4.67	0.43	9.8e-6	Morning vs. evening chronotype;
THYM	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg01324343	chr3:183735012	ABCC5	-0.9	-13.62	-0.81	4.71e-24	Anterior chamber depth;
THYM	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg17054759	chr22:49844102	NA	-0.52	-5.01	-0.46	2.51e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9900062	1.000	rs2521879	chr17:62742678	A/G	cg11885555	chr17:61910219	SMARCD2	0.91	4.72	0.44	7.96e-6	QT interval;
THYM	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg04362960	chr10:104952993	NT5C2	0.63	4.47	0.42	2.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg01097406	chr16:89675127	NA	-0.53	-4.76	-0.44	6.95e-6	Hemoglobin concentration;
THYM	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.94	6.08	0.53	2.45e-8	Platelet count;
THYM	cis	rs7572733	0.534	rs1435568	chr2:198762879	T/C	cg05783139	chr2:198650985	BOLL	0.62	4.89	0.45	4.15e-6	Dermatomyositis;
THYM	cis	rs62070183	0.938	rs75393526	chr17:31035018	A/G	cg23177095	chr17:30873196	MYO1D	0.64	4.92	0.45	3.61e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg08999081	chr20:33150536	PIGU	-0.59	-5.12	-0.46	1.61e-6	Coronary artery disease;
THYM	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg08470875	chr2:26401718	FAM59B	-0.77	-4.6	-0.43	1.29e-5	Gut microbiome composition (summer);
THYM	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg11941060	chr3:133502564	NA	-0.73	-6.23	-0.54	1.24e-8	Iron status biomarkers;
THYM	cis	rs9486719	0.857	rs2971609	chr6:97039665	A/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-5.55	-0.49	2.61e-7	Migraine;Coronary artery disease;
THYM	cis	rs7909074	1.000	rs1408814	chr10:45399088	A/G	cg04218760	chr10:45406644	TMEM72	-0.64	-5.65	-0.5	1.71e-7	Mean corpuscular volume;
THYM	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg06238570	chr21:40685208	BRWD1	0.96	8.95	0.68	2.83e-14	Cognitive function;
THYM	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs2811415	0.597	rs13059751	chr3:127782662	T/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs7107174	1.000	rs10899486	chr11:78072398	A/G	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg14583973	chr4:3374767	RGS12	-0.66	-6.45	-0.55	4.56e-9	Serum sulfate level;
THYM	cis	rs7072216	0.727	rs7913541	chr10:100172479	A/G	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg16414030	chr3:133502952	NA	-0.84	-8.39	-0.65	4.55e-13	Iron status biomarkers;
THYM	cis	rs13064411	0.696	rs9836396	chr3:113184282	T/C	cg18753928	chr3:113234510	CCDC52	-0.9	-8.68	-0.66	1.1e-13	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg09307838	chr4:120376055	NA	0.62	4.54	0.42	1.62e-5	Corneal astigmatism;
THYM	cis	rs7727544	0.582	rs3828675	chr5:131546868	G/A	cg16205897	chr5:131564050	P4HA2	-0.45	-4.55	-0.42	1.56e-5	Blood metabolite levels;
THYM	cis	rs9595908	0.900	rs9591137	chr13:33152482	T/C	cg12383807	chr13:33924137	NA	-0.55	-4.94	-0.45	3.37e-6	Body mass index;
THYM	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg11375102	chr16:1583810	IFT140;TMEM204	-0.61	-5.17	-0.47	1.3e-6	Coronary artery disease;
THYM	cis	rs2067615	0.524	rs7309351	chr12:107077432	C/T	cg15890332	chr12:107067104	RFX4	-0.46	-5.34	-0.48	6.31e-7	Heart rate;
THYM	cis	rs17407555	0.821	rs80278615	chr4:10143666	G/A	cg11266682	chr4:10021025	SLC2A9	-0.6	-5.79	-0.51	8.88e-8	Schizophrenia (age at onset);
THYM	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg08847533	chr14:75593920	NEK9	0.96	10.45	0.73	1.83e-17	Height;
THYM	cis	rs941408	1.000	rs1076448	chr19:2792343	G/A	cg17333051	chr19:2783644	SGTA	0.58	5.08	0.46	1.89e-6	Total cholesterol levels;
THYM	cis	rs7236492	0.627	rs76032846	chr18:77198322	G/A	cg15644404	chr18:77186268	NFATC1	-1.03	-4.73	-0.44	7.66e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4720575	1.000	rs6463383	chr7:47091686	A/G	cg00036614	chr7:47093842	NA	0.58	5.05	0.46	2.12e-6	Angiotensin-converting enzyme inhibitor intolerance;
THYM	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg12310025	chr6:25882481	NA	-0.73	-6.01	-0.52	3.41e-8	Blood metabolite levels;
THYM	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg09467607	chr2:36825704	FEZ2	0.4	4.92	0.45	3.61e-6	Height;
THYM	cis	rs9581857	0.579	rs9581838	chr13:27966127	G/A	cg22138327	chr13:27999177	GTF3A	0.99	5.52	0.49	2.99e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs2069837	0.636	rs7801503	chr7:22806753	T/G	cg21239317	chr7:23640510	CCDC126	-0.72	-4.46	-0.42	2.24e-5	Longevity;
THYM	cis	rs2307394	1.000	rs12998729	chr2:148617292	G/A	cg02093647	chr2:148602395	ACVR2A	-0.63	-4.49	-0.42	2.01e-5	Urate levels;
THYM	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.99	-0.75	1.26e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs941873	0.805	rs876678	chr10:81111036	G/T	cg09469691	chr10:81107165	PPIF	0.71	5.6	0.5	2.05e-7	Height;
THYM	cis	rs11225247	1.000	rs75093003	chr11:102321675	T/C	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs11096990	0.634	rs6815855	chr4:39296546	C/A	cg24403649	chr4:39172243	NA	-0.64	-5.48	-0.49	3.43e-7	Cognitive function;
THYM	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.77	7.13	0.59	1.95e-10	Personality dimensions;
THYM	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg22709100	chr7:91322751	NA	-0.6	-4.78	-0.44	6.36e-6	Breast cancer;
THYM	cis	rs17006441	0.932	rs34818992	chr3:69861779	A/C	cg18496212	chr3:69797108	MITF	0.65	6.36	0.55	7.15e-9	Hemoglobin concentration;
THYM	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg16586182	chr3:47516702	SCAP	0.65	5.39	0.48	5.18e-7	Colorectal cancer;
THYM	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.19	-0.64	1.21e-12	Mean corpuscular volume;
THYM	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7247513	0.964	rs2042946	chr19:12705354	A/G	cg01871581	chr19:12707946	ZNF490	-0.85	-8.92	-0.68	3.4e-14	Bipolar disorder;
THYM	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg18758796	chr5:131593413	PDLIM4	0.58	5.14	0.47	1.46e-6	Acylcarnitine levels;
THYM	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg04756594	chr16:24857601	SLC5A11	-0.75	-4.88	-0.45	4.19e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg06634786	chr22:41940651	POLR3H	0.68	5.0	0.46	2.65e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs757110	0.705	rs10832778	chr11:17394073	C/G	cg15432903	chr11:17409602	KCNJ11	0.58	6.28	0.54	1.01e-8	Type 2 diabetes;
THYM	cis	rs6840360	0.967	rs7684350	chr4:152672882	T/G	cg22705602	chr4:152727874	NA	-0.58	-6.26	-0.54	1.1e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg09085632	chr11:111637200	PPP2R1B	1.12	11.24	0.76	3.87e-19	Primary sclerosing cholangitis;
THYM	cis	rs57994353	0.865	rs34376913	chr9:139378914	T/C	cg14115884	chr9:139300582	SDCCAG3	0.73	5.4	0.48	4.9e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs1348850	0.526	rs2141157	chr2:178374112	C/T	cg27490568	chr2:178487706	NA	0.68	5.53	0.49	2.77e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg02527881	chr3:46936655	PTH1R	-0.68	-6.97	-0.58	4.19e-10	Colorectal cancer;
THYM	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.71	-5.63	-0.5	1.8e-7	Tonsillectomy;
THYM	cis	rs912057	0.671	rs1294427	chr6:6744546	T/G	cg06612196	chr6:6737390	NA	0.71	11.57	0.76	7.5599999999999994e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs763014	0.898	rs62030902	chr16:638264	C/G	cg00908189	chr16:619842	PIGQ	1.16	11.18	0.75	5.05e-19	Height;
THYM	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg05425664	chr17:57184151	TRIM37	-0.56	-4.48	-0.42	2.06e-5	Intelligence (multi-trait analysis);
THYM	cis	rs921968	0.608	rs495855	chr2:219357858	A/G	cg02176678	chr2:219576539	TTLL4	0.65	5.98	0.52	3.94e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg13736514	chr6:26305472	NA	-0.66	-6.64	-0.56	1.91e-9	Educational attainment;
THYM	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs8038465	0.638	rs56262972	chr15:73946745	G/A	cg15420318	chr15:73925796	NPTN	0.63	5.49	0.49	3.29e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12410462	0.901	rs2814090	chr1:227658444	C/G	cg23173402	chr1:227635558	NA	-0.56	-5.26	-0.47	8.96e-7	Major depressive disorder;
THYM	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg02527881	chr3:46936655	PTH1R	-0.53	-5.1	-0.46	1.77e-6	Colorectal cancer;
THYM	cis	rs939658	0.776	rs35904425	chr15:79444567	G/A	cg17916960	chr15:79447300	NA	-0.75	-8.88	-0.67	4.18e-14	Refractive error;
THYM	cis	rs10276303	0.519	rs6947525	chr7:3396065	C/A	cg21248987	chr7:3385318	SDK1	-0.4	-4.97	-0.45	3e-6	Dupuytren's disease;
THYM	cis	rs2458413	0.543	rs2514658	chr8:105337871	G/A	cg04554929	chr8:105342491	NA	-0.49	-7.61	-0.62	2e-11	Paget's disease;
THYM	cis	rs28785552	0.589	rs11669056	chr19:53244443	G/A	cg10871876	chr19:53194124	ZNF83	0.71	5.98	0.52	3.91e-8	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg06521331	chr12:34319734	NA	-0.73	-5.69	-0.5	1.38e-7	Morning vs. evening chronotype;
THYM	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg11335335	chr11:637885	DRD4	-0.66	-4.9	-0.45	3.93e-6	Systemic lupus erythematosus;
THYM	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Body mass index;
THYM	cis	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg05368731	chr17:41323189	NBR1	1.22	11.32	0.76	2.56e-19	Menopause (age at onset);
THYM	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg08859206	chr1:53392774	SCP2	0.7	7.41	0.61	5.19e-11	Monocyte count;
THYM	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg21773646	chr17:80085082	CCDC57	0.35	4.77	0.44	6.54e-6	Life satisfaction;
THYM	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg04317338	chr11:64019027	PLCB3	0.85	5.81	0.51	8.33e-8	Mean platelet volume;
THYM	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg18538332	chr22:24372958	LOC391322	-1.07	-14.81	-0.84	2.03e-26	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg13695892	chr22:41940480	POLR3H	-0.75	-6.56	-0.56	2.8e-9	Vitiligo;
THYM	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	trans	rs916888	0.647	rs199524	chr17:44848438	G/T	cg01341218	chr17:43662625	NA	-0.8	-6.85	-0.57	7.15e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs28476539	0.640	rs7691733	chr4:83554220	C/T	cg10249074	chr4:83542146	C4orf11	0.66	5.26	0.47	9.03e-7	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs7666738	0.819	rs13139560	chr4:99081188	C/T	cg17366294	chr4:99064904	C4orf37	0.55	5.53	0.49	2.87e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2276498	0.574	rs6097749	chr20:52672536	A/T	cg23682609	chr20:52687365	BCAS1	0.55	4.45	0.42	2.36e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg21361702	chr7:150065534	REPIN1	0.66	4.67	0.43	9.84e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs526231	0.543	rs34767	chr5:102489511	A/C	cg23492399	chr5:102201601	PAM	-0.68	-5.08	-0.46	1.89e-6	Primary biliary cholangitis;
THYM	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg27446573	chr6:127587934	RNF146	-1.03	-9.94	-0.71	2.25e-16	Breast cancer;
THYM	cis	rs7757969	1.000	rs6919306	chr6:112119619	C/T	cg08601457	chr6:112115117	FYN	0.42	4.79	0.44	6.23e-6	Schizophrenia;
THYM	cis	rs28647808	1.000	rs56677055	chr9:136227019	G/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.11	-4.86	-0.45	4.64e-6	Blood protein levels;
THYM	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg03806693	chr22:41940476	POLR3H	-1.22	-10.85	-0.74	2.58e-18	Vitiligo;
THYM	cis	rs2075230	0.705	rs1641539	chr17:7545578	T/C	cg27413385	chr17:7515425	FXR2	-0.35	-5.06	-0.46	2.06e-6	Hormone measurements;
THYM	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg17757837	chr7:157058334	UBE3C	0.79	6.84	0.57	7.63e-10	Body mass index;
THYM	cis	rs9788721	0.775	rs12914385	chr15:78898723	C/T	cg18825076	chr15:78729989	IREB2	-0.51	-4.59	-0.43	1.33e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg18252515	chr7:66147081	NA	1.37	8.05	0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg19761014	chr17:28927070	LRRC37B2	0.8	4.73	0.44	7.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9581857	0.579	rs77187836	chr13:27998646	C/A	cg22138327	chr13:27999177	GTF3A	1.04	6.08	0.53	2.45e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg06873352	chr17:61820015	STRADA	-0.59	-6.66	-0.56	1.75e-9	Prudent dietary pattern;
THYM	cis	rs919433	0.647	rs1979239	chr2:198498316	T/G	cg05783139	chr2:198650985	BOLL	0.67	5.05	0.46	2.12e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs28374715	0.681	rs28712264	chr15:41588797	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.21	-13.52	-0.81	7.22e-24	Ulcerative colitis;
THYM	cis	rs7849270	0.837	rs4642748	chr9:131854947	T/C	cg14069949	chr9:131965419	NA	0.5	4.46	0.42	2.28e-5	Blood metabolite ratios;
THYM	cis	rs2658782	0.826	rs2925355	chr11:93090887	T/C	cg15737290	chr11:93063684	CCDC67	0.99	8.2	0.64	1.16e-12	Pulmonary function decline;
THYM	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg04546413	chr19:29218101	NA	0.93	6.72	0.57	1.35e-9	Methadone dose in opioid dependence;
THYM	cis	rs78366141	0.649	rs112818517	chr4:89653103	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	1.24	5.15	0.47	1.43e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg06521331	chr12:34319734	NA	-1.0	-8.89	-0.67	3.97e-14	Morning vs. evening chronotype;
THYM	cis	rs35660623	0.718	rs71516595	chr8:10628520	C/G	cg12395012	chr8:11607386	GATA4	0.96	4.66	0.43	1.05e-5	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg07424592	chr7:64974309	NA	0.99	5.15	0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs17019602	0.748	rs17019474	chr1:108128558	T/C	cg02990361	chr1:107599529	PRMT6	0.84	5.0	0.46	2.58e-6	IgA nephropathy;
THYM	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg27532560	chr4:187881888	NA	-0.96	-11.4	-0.76	1.72e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg17264618	chr3:40429014	ENTPD3	0.48	4.54	0.42	1.67e-5	Renal cell carcinoma;
THYM	cis	rs988913	0.957	rs12525787	chr6:54789072	C/T	cg04690482	chr6:54711388	FAM83B	0.51	5.38	0.48	5.24e-7	Menarche (age at onset);
THYM	cis	rs7580658	0.724	rs71414745	chr2:127992588	A/G	cg09152259	chr2:128156114	NA	-0.39	-5.18	-0.47	1.25e-6	Protein C levels;
THYM	trans	rs58106596	0.660	rs62197212	chr2:232562727	G/A	cg01370599	chr3:116745421	NA	1.11	8.18	0.64	1.24e-12	White blood cell count;Lymphocyte counts;
THYM	cis	rs3796352	1.000	rs13091844	chr3:53010271	C/T	cg07884673	chr3:53033167	SFMBT1	1.19	6.0	0.52	3.59e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs1969821	1	rs1969821	chr10:89415148	G/A	cg13926569	chr10:89418898	PAPSS2	-0.66	-6.13	-0.53	1.97e-8	Magnesium levels;
THYM	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg00024416	chr22:24240387	NA	-0.82	-7.41	-0.61	5.15e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs11577318	0.853	rs12743998	chr1:26629882	G/A	cg19677267	chr1:26645161	CD52;UBXN11	-0.46	-5.87	-0.52	6.35e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg22431228	chr1:16359049	CLCNKA	0.53	4.66	0.43	1.03e-5	Dilated cardiomyopathy;
THYM	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg00300879	chr1:26503847	CNKSR1	0.43	5.74	0.51	1.15e-7	Height;
THYM	cis	rs6430585	0.527	rs76380759	chr2:136438517	G/A	cg07169764	chr2:136633963	MCM6	1.03	9.12	0.68	1.26e-14	Corneal structure;
THYM	cis	rs6032067	0.636	rs6032093	chr20:43912167	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.69	-7.36	-0.6	6.44e-11	Blood protein levels;
THYM	cis	rs1957429	0.901	rs1467570	chr14:65347858	A/G	cg23373153	chr14:65346875	NA	1.07	6.45	0.55	4.75e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs7771547	0.519	rs12190911	chr6:36378487	C/T	cg07856975	chr6:36356162	ETV7	-0.58	-4.75	-0.44	7.26e-6	Platelet distribution width;
THYM	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg14972814	chr11:95582409	MTMR2	-0.76	-7.0	-0.58	3.56e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg14972814	chr11:95582409	MTMR2	-0.61	-5.66	-0.5	1.58e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg15921436	chr17:44337874	NA	-0.8	-6.51	-0.56	3.51e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg26384229	chr12:38710491	ALG10B	0.97	7.47	0.61	3.87e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9403317	0.577	rs1338099	chr6:142014678	A/T	cg15052665	chr6:141804349	NA	0.74	5.38	0.48	5.31e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs798766	0.830	rs8389	chr4:1746844	A/T	cg05874882	chr4:1763078	NA	-0.63	-4.53	-0.42	1.72e-5	Bladder cancer;Urinary bladder cancer;
THYM	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg10802521	chr3:52805072	NEK4	-0.73	-6.21	-0.54	1.42e-8	Bipolar disorder;
THYM	cis	rs4891159	0.548	rs11150952	chr18:74128188	T/C	cg24786174	chr18:74118243	ZNF516	0.97	14.43	0.83	1.15e-25	Longevity;
THYM	cis	rs765787	0.530	rs12903149	chr15:45539076	G/A	cg24006582	chr15:45444508	DUOX1	0.81	6.55	0.56	2.99e-9	Uric acid levels;
THYM	cis	rs6456042	1.000	rs3099355	chr6:166534826	T/C	cg11088901	chr6:166572345	T	-0.51	-4.82	-0.44	5.5e-6	Asthma;
THYM	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg06112835	chr11:68658793	MRPL21	0.44	6.26	0.54	1.11e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg20503657	chr10:835505	NA	0.96	5.68	0.5	1.47e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg15242686	chr22:24348715	GSTTP1	0.55	4.91	0.45	3.74e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.96	-0.45	3.07e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10208649	0.808	rs11886366	chr2:54224263	A/G	cg04546899	chr2:54196757	PSME4	0.67	4.66	0.43	1.05e-5	Body mass index;
THYM	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11890956	chr21:40555474	PSMG1	1.15	12.23	0.78	3.25e-21	Cognitive function;
THYM	cis	rs490234	0.934	rs7865246	chr9:128269511	T/C	cg14078157	chr9:128172775	NA	-0.61	-4.84	-0.45	4.95e-6	Mean arterial pressure;
THYM	cis	rs4950928	0.823	rs10920579	chr1:203158972	A/G	cg14085262	chr1:203155938	CHI3L1	-0.78	-5.34	-0.48	6.31e-7	YKL-40 levels;
THYM	cis	rs9311676	0.632	rs11130631	chr3:58366128	G/C	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs4866334	1.000	rs74776941	chr5:18489387	T/G	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs67460515	0.892	rs1382429	chr3:161015153	T/C	cg03342759	chr3:160939853	NMD3	-0.91	-7.79	-0.62	8.5e-12	Parkinson's disease;
THYM	cis	rs6032067	0.516	rs6104085	chr20:43901302	A/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.61	-6.91	-0.58	5.45e-10	Blood protein levels;
THYM	cis	rs6906287	0.647	rs11153767	chr6:118960519	C/T	cg21191810	chr6:118973309	C6orf204	0.58	5.8	0.51	8.72e-8	Electrocardiographic conduction measures;
THYM	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg15247329	chr7:2764246	NA	-0.72	-6.06	-0.53	2.79e-8	Height;
THYM	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg10523679	chr1:76189770	ACADM	-0.83	-6.65	-0.56	1.82e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7426056	0.530	rs10515943	chr2:204582679	T/C	cg13651908	chr2:204570033	CD28	-0.7	-5.33	-0.48	6.55e-7	Primary sclerosing cholangitis;
THYM	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.76	-6.69	-0.57	1.52e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg20360395	chr12:132671235	NA	0.31	4.54	0.42	1.62e-5	Anti-saccade response;
THYM	cis	rs611744	0.608	rs667742	chr8:109254003	T/C	cg21045802	chr8:109455806	TTC35	0.65	5.91	0.52	5.3e-8	Dupuytren's disease;
THYM	cis	rs500891	0.525	rs1170485	chr6:84038677	G/T	cg08257003	chr6:84140564	ME1	0.57	4.6	0.43	1.3e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg22431228	chr1:16359049	CLCNKA	-0.53	-5.13	-0.47	1.51e-6	Dilated cardiomyopathy;
THYM	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg03388025	chr16:89894329	SPIRE2	0.53	4.61	0.43	1.23e-5	Vitiligo;
THYM	cis	rs2069837	0.636	rs62449520	chr7:22787385	C/T	cg21239317	chr7:23640510	CCDC126	-0.78	-4.65	-0.43	1.07e-5	Longevity;
THYM	cis	rs113835537	0.597	rs57288351	chr11:66307489	C/T	cg24851651	chr11:66362959	CCS	0.7	4.69	0.43	9.3e-6	Airway imaging phenotypes;
THYM	cis	rs28595532	0.844	rs80188901	chr4:119500014	C/T	cg14228332	chr4:119757509	SEC24D	1.35	4.49	0.42	1.98e-5	Cannabis dependence symptom count;
THYM	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg05802129	chr4:122689817	NA	-0.65	-5.26	-0.47	8.85e-7	Type 2 diabetes;
THYM	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg07138768	chr7:917805	C7orf20	0.24	4.52	0.42	1.79e-5	Perceived unattractiveness to mosquitoes;
THYM	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6840360	0.593	rs10222925	chr4:152690215	A/G	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs3810291	0.859	rs9304665	chr19:47602577	A/T	cg12068280	chr19:46804528	HIF3A	-0.45	-4.93	-0.45	3.48e-6	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);BMI in smokers;Hip circumference;Body mass index;Body mass index in physically active individuals;
THYM	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg04398451	chr17:18023971	MYO15A	0.78	7.04	0.59	3e-10	Total body bone mineral density;
THYM	cis	rs6430585	0.528	rs16832205	chr2:136684632	G/A	cg04750100	chr2:136595281	LCT	0.56	4.96	0.45	3.03e-6	Corneal structure;
THYM	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-6.98	-0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	cis	rs733592	0.560	rs2158515	chr12:48507668	T/C	cg21466736	chr12:48725269	NA	0.42	4.5	0.42	1.91e-5	Plateletcrit;
THYM	cis	rs17253792	0.822	rs74720318	chr14:56099828	G/T	cg01858014	chr14:56050164	KTN1	-1.06	-4.54	-0.42	1.66e-5	Putamen volume;
THYM	cis	rs899997	0.906	rs1809415	chr15:79028201	C/T	cg00639195	chr15:79103007	ADAMTS7	0.79	4.93	0.45	3.44e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg24399712	chr22:39784796	NA	-0.71	-6.84	-0.57	7.81e-10	Intelligence (multi-trait analysis);
THYM	cis	rs11048434	0.761	rs10842662	chr12:9139344	G/A	cg14913610	chr12:9142341	KLRG1	-0.29	-4.45	-0.42	2.33e-5	Sjögren's syndrome;
THYM	cis	rs10753787	1.000	rs10753787	chr1:169549775	T/C	cg23244997	chr1:169763992	C1orf156;C1orf112	0.56	4.74	0.44	7.39e-6	Vertical cup-disc ratio;
THYM	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.62	5.61	0.5	2.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7192380	0.893	rs1469908	chr16:69764412	C/T	cg09409435	chr16:70099608	PDXDC2	-0.61	-4.63	-0.43	1.17e-5	Sjögren's syndrome;
THYM	cis	rs1483890	0.517	rs2314990	chr3:69364176	T/C	cg22125112	chr3:69402811	FRMD4B	0.42	5.26	0.47	8.91e-7	Resting heart rate;
THYM	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg21231944	chr12:82153410	PPFIA2	0.61	4.53	0.42	1.71e-5	Resting heart rate;
THYM	cis	rs2115536	0.935	rs11854390	chr15:80224817	C/T	cg00225070	chr15:80189496	MTHFS	0.58	4.75	0.44	7.34e-6	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs10779751	1.000	rs6679878	chr1:11306882	A/G	cg08854313	chr1:11322531	MTOR	0.94	8.23	0.65	9.67e-13	Body mass index;
THYM	cis	rs7107174	1.000	rs901103	chr11:77931346	C/T	cg02023728	chr11:77925099	USP35	0.75	6.63	0.56	2.04e-9	Testicular germ cell tumor;
THYM	cis	rs2295499	0.559	rs12509910	chr4:2731109	G/C	cg14003022	chr4:3043019	NA	0.52	4.59	0.43	1.35e-5	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg22709100	chr7:91322751	NA	0.61	4.86	0.45	4.66e-6	Breast cancer;
THYM	cis	rs478304	0.593	rs4645927	chr11:65482827	C/T	cg27068330	chr11:65405492	SIPA1	-0.99	-9.96	-0.71	2.02e-16	Acne (severe);
THYM	cis	rs2976388	0.507	rs13259549	chr8:143838519	T/C	cg17252645	chr8:143867129	LY6D	0.55	5.49	0.49	3.27e-7	Urinary tract infection frequency;
THYM	cis	rs62158800	0.568	rs62161312	chr2:108346567	C/T	cg09155462	chr2:109189131	NA	1.25	4.98	0.46	2.79e-6	Facial morphology (factor 22);
THYM	cis	rs447921	0.861	rs4789301	chr17:74454212	A/C	cg17201438	chr17:74438067	UBE2O	-0.76	-5.44	-0.49	4.18e-7	Mitochondrial DNA levels;
THYM	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg08999081	chr20:33150536	PIGU	0.8	7.37	0.6	6.23e-11	Coronary artery disease;
THYM	cis	rs67981189	0.593	rs2240341	chr14:71373580	T/C	cg15910301	chr14:71632612	NA	-0.53	-4.63	-0.43	1.14e-5	Schizophrenia;
THYM	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg17063962	chr7:91808500	NA	1.14	12.22	0.78	3.42e-21	Breast cancer;
THYM	cis	rs7107174	1.000	rs2510054	chr11:77959659	A/G	cg02023728	chr11:77925099	USP35	-0.71	-6.27	-0.54	1.04e-8	Testicular germ cell tumor;
THYM	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg02640540	chr1:67518911	SLC35D1	0.64	4.68	0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs10979	0.782	rs9390108	chr6:143892722	A/T	cg25407410	chr6:143891975	LOC285740	-0.59	-4.86	-0.45	4.67e-6	Hypospadias;
THYM	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg23682913	chr1:2080710	PRKCZ	-0.59	-5.46	-0.49	3.84e-7	Height;
THYM	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg21252483	chr19:49399788	TULP2	-0.96	-7.25	-0.6	1.09e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs10979	1.000	rs9285500	chr6:143897614	G/C	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs112184198	0.704	rs4917911	chr10:102559421	G/A	cg03679755	chr10:101875035	NA	0.81	4.84	0.44	5.02e-6	Systolic blood pressure;
THYM	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs7072216	0.763	rs10748729	chr10:100171371	G/C	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg14675211	chr2:100938903	LONRF2	0.77	8.32	0.65	6.49e-13	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg10047753	chr17:41438598	NA	1.07	9.29	0.69	5.32e-15	Menopause (age at onset);
THYM	cis	rs7312774	0.529	rs12314792	chr12:107333672	T/C	cg16260113	chr12:107380972	MTERFD3	1.34	6.39	0.55	6.14e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs9611519	0.857	rs4820434	chr22:41637119	G/T	cg06634786	chr22:41940651	POLR3H	-0.58	-4.63	-0.43	1.14e-5	Neuroticism;
THYM	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg00495681	chr13:53174319	NA	0.73	7.22	0.6	1.25e-10	Lewy body disease;
THYM	cis	rs2046867	0.908	rs62251654	chr3:72816488	C/T	cg25664220	chr3:72788482	NA	-0.84	-6.29	-0.54	9.66e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs3820068	0.705	rs4646085	chr1:15825411	A/T	cg05660106	chr1:15850417	CASP9	1.13	10.0	0.72	1.65e-16	Systolic blood pressure;
THYM	cis	rs4866334	1.000	rs75534671	chr5:18487744	G/A	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg01350728	chr13:21893604	NA	-0.59	-4.45	-0.42	2.36e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4646404	0.544	rs4646358	chr17:17470708	A/G	cg11245205	chr17:17398264	RASD1	-0.41	-4.8	-0.44	5.96e-6	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
THYM	cis	rs40363	1.000	rs37773	chr16:3512834	G/A	cg05754148	chr16:3507555	NAT15	0.89	8.54	0.66	2.13e-13	Tuberculosis;
THYM	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg06532163	chr17:45867833	NA	0.66	6.75	0.57	1.17e-9	IgG glycosylation;
THYM	cis	rs6032067	0.641	rs34622539	chr20:43756548	A/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.41	-0.49	4.61e-7	Blood protein levels;
THYM	cis	rs7107174	0.892	rs2511167	chr11:77964698	C/T	cg02023728	chr11:77925099	USP35	0.68	6.03	0.53	3.06e-8	Testicular germ cell tumor;
THYM	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03264133	chr6:25882463	NA	-0.76	-5.81	-0.51	8.12e-8	Blood metabolite levels;
THYM	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1448094	0.511	rs61930581	chr12:86157241	G/A	cg02569458	chr12:86230093	RASSF9	0.62	5.13	0.47	1.56e-6	Major depressive disorder;
THYM	cis	rs4074961	0.505	rs4653306	chr1:38065390	C/T	cg17933807	chr1:38061675	GNL2	1.11	15.99	0.85	1.07e-28	Axial length;
THYM	cis	rs73198271	0.641	rs34473848	chr8:8649837	C/T	cg15556689	chr8:8085844	FLJ10661	-0.74	-4.91	-0.45	3.75e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	trans	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg11764359	chr7:65958608	NA	-0.85	-7.43	-0.61	4.73e-11	Aortic root size;
THYM	cis	rs7000551	0.671	rs4872495	chr8:22289126	A/G	cg12081754	chr8:22256438	SLC39A14	1.02	8.84	0.67	5.06e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg22764044	chr5:178986830	RUFY1	-0.49	-4.96	-0.45	3.1e-6	Lung cancer;
THYM	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg27446573	chr6:127587934	RNF146	0.74	6.53	0.56	3.27e-9	Breast cancer;
THYM	cis	rs192264	0.614	rs7186304	chr16:65987084	C/T	cg02795155	chr16:66785218	DYNC1LI2	0.6	5.0	0.46	2.63e-6	Subjective well-being;
THYM	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg05738196	chr6:26577821	NA	-0.84	-8.48	-0.66	2.87e-13	Intelligence (multi-trait analysis);
THYM	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg06221963	chr1:154839813	KCNN3	-0.87	-10.88	-0.74	2.16e-18	Prostate cancer;
THYM	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg22089800	chr15:90895588	ZNF774	-0.68	-5.26	-0.47	9e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg16797656	chr11:68205561	LRP5	0.52	6.03	0.53	3.17e-8	Total body bone mineral density;
THYM	cis	rs2139634	0.965	rs1402151	chr3:46527930	T/C	cg02332537	chr3:46540019	RTP3	0.45	4.61	0.43	1.26e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg06600287	chr1:53387719	ECHDC2	-0.34	-5.4	-0.48	4.89e-7	Monocyte count;
THYM	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg21854759	chr1:92012499	NA	-0.7	-5.67	-0.5	1.5e-7	Breast cancer;
THYM	cis	rs3892630	0.878	rs8112955	chr19:33191192	C/T	cg02283691	chr19:33182526	NUDT19	-0.4	-4.75	-0.44	7.23e-6	Red blood cell traits;
THYM	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg13918804	chr1:2043761	PRKCZ	-0.63	-4.77	-0.44	6.78e-6	Height;
THYM	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg27129171	chr3:47204927	SETD2	0.67	6.43	0.55	5.04e-9	Colorectal cancer;
THYM	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	5.78	0.51	9.49e-8	Height;
THYM	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.21	-0.47	1.11e-6	Hemoglobin concentration;
THYM	cis	rs739401	0.619	rs10766481	chr11:2961512	G/C	cg03159660	chr11:2078197	NA	-0.67	-4.88	-0.45	4.29e-6	Longevity;
THYM	cis	rs12257961	0.579	rs10737095	chr10:15382547	C/G	cg10616319	chr10:15468812	NA	-0.64	-5.43	-0.49	4.3e-7	Selective IgA deficiency;
THYM	cis	rs8180040	0.800	rs2088135	chr3:47280018	T/C	cg12976108	chr3:47324180	KIF9;KLHL18	0.5	4.5	0.42	1.92e-5	Colorectal cancer;
THYM	cis	rs36051895	0.632	rs10815167	chr9:5150058	A/G	cg02405213	chr9:5042618	JAK2	-1.04	-10.96	-0.75	1.47e-18	Pediatric autoimmune diseases;
THYM	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.69	-5.86	-0.52	6.64e-8	Renal function-related traits (BUN);
THYM	cis	rs35934224	0.783	rs7287073	chr22:19864335	G/A	cg11182965	chr22:19864308	TXNRD2	-0.94	-7.2	-0.59	1.37e-10	Glaucoma (primary open-angle);
THYM	cis	rs863345	0.604	rs1342945	chr1:158512912	C/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg18806716	chr10:30721971	MAP3K8	-0.53	-5.37	-0.48	5.59e-7	Inflammatory bowel disease;
THYM	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg06028605	chr16:24865363	SLC5A11	-0.67	-5.04	-0.46	2.24e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg03060546	chr3:49711283	APEH	-0.67	-5.08	-0.46	1.85e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs877282	0.945	rs10904556	chr10:789429	A/G	cg10556349	chr10:835070	NA	-0.78	-5.38	-0.48	5.34e-7	Uric acid levels;
THYM	cis	rs12310956	0.510	rs4931743	chr12:33867588	T/C	cg10856724	chr12:34555212	NA	-0.64	-5.78	-0.51	9.56e-8	Morning vs. evening chronotype;
THYM	cis	rs1609391	0.543	rs9859810	chr3:136629986	A/G	cg15507776	chr3:136538369	TMEM22	0.64	4.9	0.45	4.02e-6	Neuroticism;
THYM	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg11764359	chr7:65958608	NA	-0.81	-6.42	-0.55	5.45e-9	Aortic root size;
THYM	cis	rs1650123	1.000	rs1650123	chr12:104034319	C/T	cg23227824	chr12:103980017	STAB2	0.47	4.97	0.45	2.91e-6	IgG glycosylation;
THYM	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg15445000	chr17:37608096	MED1	0.44	5.07	0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg12419862	chr22:24373484	LOC391322	-0.71	-6.53	-0.56	3.24e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1775715	0.707	rs1541262	chr10:32179771	A/G	cg04359828	chr10:32216031	ARHGAP12	0.41	5.12	0.46	1.62e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg13319975	chr6:146136371	FBXO30	-0.7	-5.88	-0.52	6.22e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-4.85	-0.45	4.76e-6	Hemoglobin concentration;
THYM	cis	rs11785693	0.862	rs11780705	chr8:4988221	G/A	cg26367366	chr8:4980734	NA	1.21	5.9	0.52	5.46e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs7607369	0.679	rs6751527	chr2:219630965	C/G	cg02176678	chr2:219576539	TTLL4	0.66	5.81	0.51	8.36e-8	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs4631830	0.540	rs2843562	chr10:51496796	A/G	cg16070123	chr10:51489643	NA	0.64	6.31	0.54	8.8e-9	Prostate-specific antigen levels;
THYM	cis	rs919433	0.680	rs699319	chr2:198281776	C/A	cg00792783	chr2:198669748	PLCL1	0.82	5.67	0.5	1.54e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6032067	0.929	rs45461302	chr20:43805274	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.56	-0.5	2.44e-7	Blood protein levels;
THYM	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs34638657	0.872	rs2967352	chr16:82196676	T/C	cg19807685	chr16:82068980	HSD17B2	-0.66	-5.14	-0.47	1.47e-6	Lung adenocarcinoma;
THYM	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg11764359	chr7:65958608	NA	-0.76	-6.07	-0.53	2.59e-8	Aortic root size;
THYM	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg00898013	chr13:113819073	PROZ	-1.02	-10.0	-0.72	1.62e-16	Platelet distribution width;
THYM	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg14664628	chr15:75095509	CSK	-0.66	-5.19	-0.47	1.17e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.2	-0.47	1.14e-6	Recombination measurement;
THYM	cis	rs67460515	0.563	rs6794882	chr3:160851849	G/A	cg03342759	chr3:160939853	NMD3	-0.62	-4.68	-0.43	9.42e-6	Parkinson's disease;
THYM	cis	rs4638749	0.677	rs12329189	chr2:108812855	T/C	cg25838818	chr2:108905173	SULT1C2	-0.56	-5.59	-0.5	2.19e-7	Blood pressure;
THYM	cis	rs16912285	0.685	rs16912402	chr11:24313135	C/G	ch.11.24196551F	chr11:24239977	NA	1.0	6.18	0.54	1.6e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7432375	1.000	rs10935186	chr3:136346206	T/C	cg21827317	chr3:136751795	NA	0.57	4.89	0.45	4.1e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg10047753	chr17:41438598	NA	1.19	11.33	0.76	2.52e-19	Menopause (age at onset);
THYM	cis	rs11574514	1.000	rs78033175	chr16:67931431	G/A	cg09738193	chr16:67926317	PSKH1	-0.91	-4.66	-0.43	1.01e-5	Crohn's disease;
THYM	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg06532163	chr17:45867833	NA	0.65	6.58	0.56	2.6e-9	IgG glycosylation;
THYM	trans	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg19774624	chr17:42201019	HDAC5	-0.78	-6.84	-0.57	7.79e-10	Total body bone mineral density;
THYM	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg02012338	chr4:187126139	CYP4V2	0.97	4.59	0.43	1.36e-5	Blood protein levels;
THYM	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg07747251	chr5:1868357	NA	0.68	5.86	0.52	6.67e-8	Cardiovascular disease risk factors;
THYM	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg07648498	chr16:89883185	FANCA	0.64	4.72	0.44	7.96e-6	Vitiligo;
THYM	cis	rs1784581	0.651	rs1784590	chr6:162389462	C/A	cg17173639	chr6:162384350	PARK2	-0.83	-7.3	-0.6	8.62e-11	Itch intensity from mosquito bite;
THYM	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg22496339	chr2:162101262	NA	0.94	9.01	0.68	2.19e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs1267303	0.537	rs59935547	chr1:47001423	A/G	cg25110126	chr1:46999211	NA	0.69	5.39	0.48	5.13e-7	Monobrow;
THYM	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg07570687	chr10:102243282	WNT8B	0.76	6.83	0.57	8.09e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7084402	0.967	rs1649049	chr10:60324095	G/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs7584330	0.554	rs6705908	chr2:238433965	A/G	cg05099493	chr2:239009232	ESPNL	-0.61	-4.84	-0.44	5.01e-6	Prostate cancer;
THYM	cis	rs72792324	0.744	rs57735633	chr5:140741761	A/G	cg21929183	chr5:140807225	PCDHGA4;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB8P;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	-0.89	-4.6	-0.43	1.31e-5	Mean platelet volume;
THYM	cis	rs950881	0.932	rs13431828	chr2:102954653	C/T	cg20060108	chr2:102954350	IL1RL1	0.85	4.68	0.43	9.48e-6	Allergy;
THYM	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs2645424	0.671	rs2294138	chr8:11705139	C/T	cg09232555	chr8:11619866	NA	0.42	4.47	0.42	2.16e-5	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
THYM	cis	rs1448094	0.512	rs6539926	chr12:86244460	G/A	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg08994789	chr17:28903642	LRRC37B2	0.98	4.81	0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11121246	0.518	rs6684644	chr1:8910578	G/C	cg06972019	chr1:8937448	ENO1	0.7	5.6	0.5	2.04e-7	Plateletcrit;
THYM	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg05347473	chr6:146136440	FBXO30	0.58	4.73	0.44	7.91e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.52e-7	Heart rate;
THYM	cis	rs886126	1.000	rs10082818	chr12:111663177	C/G	cg10833066	chr12:111807467	FAM109A	0.44	5.46	0.49	3.84e-7	Coronary heart disease;
THYM	cis	rs4731207	0.596	rs1531716	chr7:124638538	A/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg00684032	chr4:1343700	KIAA1530	0.63	5.48	0.49	3.56e-7	Obesity-related traits;
THYM	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg11366901	chr6:160182831	ACAT2	1.07	9.53	0.7	1.68e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg16423285	chr20:60520624	NA	-0.64	-4.48	-0.42	2.08e-5	Body mass index;
THYM	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg04315214	chr1:2043799	PRKCZ	0.65	5.29	0.48	7.9e-7	Height;
THYM	cis	rs11886999	0.723	rs62153018	chr2:96876455	T/C	cg18419276	chr2:96971862	SNRNP200	-0.5	-4.77	-0.44	6.69e-6	Cardiac Troponin-T levels;
THYM	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg24060327	chr5:131705240	SLC22A5	-0.8	-6.52	-0.56	3.35e-9	Acylcarnitine levels;
THYM	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg25072359	chr17:41440525	NA	0.68	4.71	0.44	8.33e-6	Menopause (age at onset);
THYM	cis	rs4268898	0.610	rs34216622	chr2:24463445	G/C	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg21773646	chr17:80085082	CCDC57	-0.34	-4.91	-0.45	3.76e-6	Life satisfaction;
THYM	cis	rs988913	1.000	rs9382404	chr6:54835218	C/G	cg04690482	chr6:54711388	FAM83B	0.46	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	cis	rs11186	0.556	rs72904492	chr2:189951973	T/C	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs1670533	0.872	rs10017931	chr4:1060747	G/A	cg27284194	chr4:1044797	NA	0.63	4.85	0.45	4.74e-6	Recombination rate (females);
THYM	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg24209194	chr3:40518798	ZNF619	-0.73	-6.31	-0.54	8.87e-9	Renal cell carcinoma;
THYM	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.36	0.48	5.75e-7	Height;
THYM	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg17143192	chr8:8559678	CLDN23	-0.64	-4.88	-0.45	4.22e-6	Mood instability;
THYM	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg17063962	chr7:91808500	NA	-1.12	-12.68	-0.79	3.85e-22	Breast cancer;
THYM	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg23982607	chr1:1823379	GNB1	-0.94	-10.26	-0.72	4.61e-17	Body mass index;
THYM	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg08508325	chr11:3079039	CARS	-0.54	-6.74	-0.57	1.22e-9	Longevity;
THYM	cis	rs7927771	0.524	rs7107922	chr11:47669289	C/A	cg20307385	chr11:47447363	PSMC3	0.6	4.55	0.42	1.58e-5	Subjective well-being;
THYM	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg05182265	chr7:156933206	UBE3C	-0.69	-9.34	-0.69	4.32e-15	Body mass index;
THYM	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.63	-4.48	-0.42	2.05e-5	Gut microbiome composition (summer);
THYM	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.53	0.56	3.27e-9	Total body bone mineral density;
THYM	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg11247378	chr22:39784982	NA	0.93	8.69	0.67	1.05e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg04155289	chr7:94953770	PON1	-0.61	-5.6	-0.5	2.06e-7	Paraoxonase activity;
THYM	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg21784768	chr11:537496	LRRC56	-1.13	-5.64	-0.5	1.74e-7	Body mass index;
THYM	cis	rs300703	0.542	rs300691	chr2:180171	C/A	cg21211680	chr2:198530	NA	-0.91	-6.24	-0.54	1.23e-8	Blood protein levels;
THYM	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg12408189	chr10:30722286	MAP3K8	0.53	4.73	0.44	7.65e-6	Inflammatory bowel disease;
THYM	cis	rs11671007	1	rs11671007	chr19:2893405	A/G	cg22793129	chr19:2085297	MOBKL2A	-0.96	-4.57	-0.42	1.49e-5	Daytime sleep phenotypes;
THYM	cis	rs7224296	0.709	rs199518	chr17:44854580	A/C	cg01570182	chr17:44337453	NA	-0.66	-7.17	-0.59	1.62e-10	Intelligence (multi-trait analysis);
THYM	cis	rs72627123	1.000	rs59363432	chr14:74397545	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs2882877	0.620	rs62184660	chr2:190383525	C/T	cg10752008	chr2:190445175	SLC40A1	0.71	5.91	0.52	5.32e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs3126085	0.560	rs3120667	chr1:152318161	A/G	cg10321714	chr1:152280068	FLG	-0.75	-5.29	-0.48	7.81e-7	Atopic dermatitis;
THYM	trans	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg10856724	chr12:34555212	NA	-0.95	-8.39	-0.65	4.46e-13	Bladder cancer;
THYM	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg05872129	chr22:39784769	NA	-1.0	-8.32	-0.65	6.32e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs67460515	0.563	rs9876142	chr3:160780968	A/G	cg03342759	chr3:160939853	NMD3	0.63	4.61	0.43	1.26e-5	Parkinson's disease;
THYM	cis	rs7771547	0.519	rs6923337	chr6:36369260	C/T	cg07856975	chr6:36356162	ETV7	0.65	5.5	0.49	3.13e-7	Platelet distribution width;
THYM	cis	rs4481887	0.676	rs6691314	chr1:248548020	G/A	cg00666640	chr1:248458726	OR2T12	0.54	4.63	0.43	1.17e-5	Common traits (Other);
THYM	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg18402987	chr7:1209562	NA	1.02	6.01	0.53	3.37e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs76878669	0.515	rs947978	chr11:66108660	C/T	cg18002602	chr11:66138449	SLC29A2	0.5	5.0	0.46	2.62e-6	Educational attainment (years of education);
THYM	cis	rs9359856	0.564	rs34732313	chr6:90368380	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.91	-8.21	-0.64	1.08e-12	Bipolar disorder;
THYM	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4919694	1.000	rs75219158	chr10:104747594	C/T	cg04362960	chr10:104952993	NT5C2	1.14	6.92	0.58	5.38e-10	Arsenic metabolism;
THYM	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs7267979	1.000	rs6083804	chr20:25317060	A/G	cg08601574	chr20:25228251	PYGB	-0.57	-4.59	-0.43	1.35e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9443189	0.530	rs614065	chr6:76315633	G/A	cg01950844	chr6:76311363	SENP6	1.05	6.55	0.56	2.95e-9	Prostate cancer;
THYM	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg27446573	chr6:127587934	RNF146	1.03	9.76	0.71	5.36e-16	Breast cancer;
THYM	cis	rs11696501	0.793	rs4812909	chr20:44167244	G/A	cg11783356	chr20:44313418	WFDC10B	-0.67	-4.47	-0.42	2.17e-5	Brain structure;
THYM	cis	rs6700896	0.897	rs2375805	chr1:66156567	C/T	cg04111102	chr1:66153794	NA	0.55	5.29	0.48	7.87e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs10927875	0.632	rs1122068	chr1:16127480	G/C	cg21385522	chr1:16154831	NA	-1.32	-13.48	-0.81	9e-24	Dilated cardiomyopathy;
THYM	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg10523679	chr1:76189770	ACADM	0.89	8.55	0.66	2.05e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg22105103	chr4:187893119	NA	-0.89	-9.4	-0.69	3.23e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs854765	0.624	rs11652144	chr17:17733934	C/T	cg04398451	chr17:18023971	MYO15A	0.87	7.92	0.63	4.37e-12	Total body bone mineral density;
THYM	cis	rs11087123	0.500	rs1743471	chr20:15120323	C/T	cg09937190	chr20:15177509	MACROD2	0.45	4.92	0.45	3.68e-6	Eating disorders;
THYM	cis	rs1322639	0.614	rs9294967	chr6:169565406	C/T	cg04662567	chr6:169592167	NA	0.77	5.45	0.49	4.04e-7	Pulse pressure;
THYM	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg13319975	chr6:146136371	FBXO30	0.7	5.77	0.51	1.01e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7772486	0.754	rs9373476	chr6:146139741	C/G	cg23711669	chr6:146136114	FBXO30	0.9	9.26	0.69	6.45e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs427394	0.772	rs274689	chr5:6736215	G/C	cg10857441	chr5:6722123	POLS	-0.73	-8.88	-0.67	4.02e-14	Menopause (age at onset);
THYM	cis	rs10779751	0.734	rs7533211	chr1:11132965	G/C	cg08854313	chr1:11322531	MTOR	0.85	7.33	0.6	7.43e-11	Body mass index;
THYM	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs9515201	0.627	rs952359	chr13:111026734	G/A	cg06243866	chr13:111019493	COL4A2	-0.95	-10.75	-0.74	4.19e-18	White matter hyperintensity burden;
THYM	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg03709012	chr19:19516395	GATAD2A	-0.74	-5.8	-0.51	8.48e-8	Tonsillectomy;
THYM	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg20295408	chr7:1910781	MAD1L1	-0.58	-4.63	-0.43	1.14e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs5771069	0.933	rs137848	chr22:50440296	A/G	cg27467552	chr22:50353597	PIM3	-0.47	-5.05	-0.46	2.1e-6	Ulcerative colitis;
THYM	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06873352	chr17:61820015	STRADA	0.55	5.53	0.49	2.79e-7	Height;
THYM	cis	rs9420	0.961	rs12146541	chr11:57508678	G/C	cg19752551	chr11:57585705	CTNND1	-0.73	-8.02	-0.64	2.79e-12	Schizophrenia;
THYM	cis	rs9560113	1.000	rs4771757	chr13:112176379	G/T	cg14154082	chr13:112174009	NA	0.86	8.0	0.63	2.95e-12	Menarche (age at onset);
THYM	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg26354017	chr1:205819088	PM20D1	1.08	11.69	0.77	4.25e-20	Menarche (age at onset);
THYM	cis	rs4720575	1.000	rs4720575	chr7:47086805	A/G	cg00036614	chr7:47093842	NA	-0.6	-5.28	-0.48	8.3e-7	Angiotensin-converting enzyme inhibitor intolerance;
THYM	cis	rs208520	0.754	rs851594	chr6:66876695	A/G	cg07460842	chr6:66804631	NA	-0.91	-6.41	-0.55	5.65e-9	Exhaled nitric oxide output;
THYM	cis	rs3781426	0.920	rs4962421	chr10:126724927	G/A	cg04494136	chr10:126703576	CTBP2	-0.39	-5.18	-0.47	1.26e-6	Height;
THYM	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs4523957	0.533	rs216216	chr17:2145046	A/G	cg16513277	chr17:2031491	SMG6	0.68	5.35	0.48	6.08e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11997175	0.740	rs6991071	chr8:33814103	G/A	ch.8.33884649F	chr8:33765107	NA	0.74	5.87	0.52	6.33e-8	Body mass index;
THYM	trans	rs877282	0.853	rs11596346	chr10:756673	A/T	cg22713356	chr15:30763199	NA	1.27	9.37	0.69	3.62e-15	Uric acid levels;
THYM	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg04398451	chr17:18023971	MYO15A	-0.9	-9.5	-0.7	1.95e-15	Total body bone mineral density;
THYM	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg16325326	chr1:53192061	ZYG11B	0.8	7.44	0.61	4.39e-11	Monocyte count;
THYM	cis	rs600806	0.821	rs10127790	chr1:109891133	C/T	cg23032129	chr1:109941072	SORT1	-0.57	-4.83	-0.44	5.22e-6	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg10856724	chr12:34555212	NA	-0.76	-7.04	-0.59	2.99e-10	Morning vs. evening chronotype;
THYM	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs9291683	0.655	rs2278121	chr4:10096134	G/A	cg00071950	chr4:10020882	SLC2A9	-0.63	-6.09	-0.53	2.41e-8	Bone mineral density;
THYM	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg06028605	chr16:24865363	SLC5A11	0.63	5.03	0.46	2.3e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4363385	0.818	rs409986	chr1:153014741	A/C	cg13444842	chr1:152974279	SPRR3	0.61	5.08	0.46	1.86e-6	Inflammatory skin disease;
THYM	cis	rs11112613	0.713	rs55646142	chr12:105949557	G/A	cg03607813	chr12:105948248	NA	1.07	9.36	0.69	3.87e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs2075230	0.850	rs9908405	chr17:7467461	A/C	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	0.31	4.48	0.42	2.07e-5	Hormone measurements;
THYM	cis	rs4803468	0.967	rs13345590	chr19:41886455	T/G	cg09537434	chr19:41945824	ATP5SL	-1.08	-9.69	-0.7	7.75e-16	Height;
THYM	cis	rs1878931	0.582	rs40633	chr16:3425325	A/G	cg21433313	chr16:3507492	NAT15	0.58	4.78	0.44	6.41e-6	Body mass index (adult);
THYM	cis	rs72949976	0.864	rs62186566	chr2:214024421	G/A	cg08319019	chr2:214017104	IKZF2	-0.73	-5.56	-0.5	2.47e-7	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs4660306	1.000	rs11211132	chr1:45990516	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.4	-0.48	4.87e-7	Homocysteine levels;
THYM	cis	rs3857067	0.772	rs4692999	chr4:95107644	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg14008862	chr17:28927542	LRRC37B2	0.94	5.08	0.46	1.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8135828	0.770	rs7609	chr22:29951650	A/T	cg16189954	chr22:29138267	HSCB;CHEK2	-0.73	-4.74	-0.44	7.4e-6	Lipid traits;
THYM	cis	rs28595532	0.920	rs115464801	chr4:119730673	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs7814319	0.966	rs10112328	chr8:97254372	C/T	cg20787634	chr8:97240163	UQCRB	0.77	8.76	0.67	7.41e-14	Lung function (FVC);
THYM	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg26818010	chr10:134567672	INPP5A	-0.79	-6.34	-0.55	7.68e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs3087591	1.000	rs12939853	chr17:29455021	G/A	cg24425628	chr17:29625626	OMG;NF1	0.64	5.45	0.49	3.96e-7	Hip circumference;
THYM	cis	rs9309473	0.519	rs2421586	chr2:73899719	C/T	cg19565262	chr2:73869966	NAT8	0.54	4.58	0.43	1.43e-5	Metabolite levels;
THYM	cis	rs9326248	0.861	rs1871757	chr11:117030581	A/T	cg01368799	chr11:117014884	PAFAH1B2	0.67	4.78	0.44	6.27e-6	Blood protein levels;
THYM	cis	rs3112255	0.846	rs13423120	chr2:101281354	A/C	cg01042948	chr2:101319752	NA	-0.7	-5.9	-0.52	5.55e-8	Intelligence (multi-trait analysis);
THYM	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg12893697	chr11:970389	AP2A2	-0.31	-5.21	-0.47	1.08e-6	Alzheimer's disease (late onset);
THYM	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg13695892	chr22:41940480	POLR3H	-0.85	-6.94	-0.58	4.74e-10	Vitiligo;
THYM	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg10523679	chr1:76189770	ACADM	0.92	10.35	0.73	2.94e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	cg01483505	chr11:975446	AP2A2	0.64	5.05	0.46	2.17e-6	Alzheimer's disease (late onset);
THYM	cis	rs2282300	0.739	rs1222210	chr11:30362125	A/G	cg09906309	chr11:30344399	C11orf46	0.72	5.11	0.46	1.66e-6	Morning vs. evening chronotype;
THYM	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.77	4.72	0.44	7.99e-6	Diabetic retinopathy;
THYM	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs2219968	0.701	rs2200015	chr8:78990829	T/C	cg00738934	chr8:78996279	NA	0.87	8.41	0.65	4.01e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2235649	0.833	rs2011088	chr16:1850091	T/C	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg22709100	chr7:91322751	NA	-0.6	-4.68	-0.43	9.41e-6	Breast cancer;
THYM	cis	rs7833986	0.501	rs2668007	chr8:56944111	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.54	6.51	0.56	3.51e-9	Height;
THYM	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg12386194	chr3:101231763	SENP7	0.95	7.47	0.61	3.85e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg10518543	chr12:38710700	ALG10B	-0.59	-4.67	-0.43	9.89e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg20848291	chr7:100343083	ZAN	-0.61	-4.48	-0.42	2.04e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg10523679	chr1:76189770	ACADM	0.9	9.47	0.7	2.2e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg04520793	chr17:42248056	ASB16	-0.35	-4.98	-0.45	2.85e-6	Total body bone mineral density;
THYM	cis	rs10911232	0.507	rs6660111	chr1:183014289	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs2235642	0.507	rs9934455	chr16:1579483	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.57	-5.81	-0.51	8.13e-8	Coronary artery disease;
THYM	cis	rs17253792	0.822	rs77197405	chr14:56159662	T/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg27572855	chr1:25598939	RHD	0.67	5.09	0.46	1.84e-6	Erythrocyte sedimentation rate;
THYM	cis	rs939658	0.776	rs4778925	chr15:79443791	C/T	cg17916960	chr15:79447300	NA	-0.75	-8.73	-0.67	8.52e-14	Refractive error;
THYM	cis	rs8049040	0.564	rs310335	chr16:71573918	T/A	cg08717414	chr16:71523259	ZNF19	-0.79	-4.92	-0.45	3.61e-6	Blood protein levels;
THYM	cis	rs921665	0.831	rs2368672	chr2:3188893	A/C	cg16434511	chr2:3151078	NA	-0.84	-5.24	-0.47	9.7e-7	World class endurance athleticism;
THYM	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg00024416	chr22:24240387	NA	-0.67	-7.02	-0.58	3.23e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10479542	0.766	rs2411380	chr5:178973780	T/C	cg05457628	chr5:178986728	RUFY1	-0.55	-5.0	-0.46	2.62e-6	Lung cancer;
THYM	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg02478829	chr6:26598070	ABT1	-0.33	-4.49	-0.42	1.97e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg18758796	chr5:131593413	PDLIM4	-0.5	-4.72	-0.44	8.15e-6	Breast cancer;
THYM	cis	rs901683	0.850	rs78990676	chr10:46101725	C/T	cg18240400	chr10:46168597	ANUBL1	0.67	5.22	0.47	1.04e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg04234412	chr22:24373322	LOC391322	0.96	8.01	0.63	2.89e-12	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22857025	chr5:266934	NA	-1.43	-9.3	-0.69	5.28e-15	Breast cancer;
THYM	cis	rs11696501	0.688	rs6130897	chr20:44330004	C/T	cg11783356	chr20:44313418	WFDC10B	-0.69	-4.73	-0.44	7.72e-6	Brain structure;
THYM	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg14820908	chr5:178986412	RUFY1	-0.63	-7.26	-0.6	1.06e-10	Lung cancer;
THYM	cis	rs921968	0.643	rs4674320	chr2:219510768	A/G	cg02176678	chr2:219576539	TTLL4	0.6	5.84	0.51	7.3e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11696501	0.739	rs6017637	chr20:44264190	G/A	cg11783356	chr20:44313418	WFDC10B	-0.69	-4.76	-0.44	6.98e-6	Brain structure;
THYM	cis	rs1348850	0.645	rs13431091	chr2:178434615	A/G	cg27490568	chr2:178487706	NA	0.58	4.88	0.45	4.25e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs554111	0.613	rs1567128	chr1:21404653	G/A	cg00373020	chr1:21041521	KIF17	-0.54	-4.64	-0.43	1.12e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.76	0.44	7.03e-6	Obesity-related traits;
THYM	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg26149184	chr10:133730230	NA	0.78	4.72	0.44	8.15e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs1692580	0.870	rs262680	chr1:2167149	C/T	cg21194808	chr1:2205498	SKI	0.31	4.64	0.43	1.11e-5	Coronary artery disease;
THYM	cis	rs2448490	0.642	rs507859	chr11:65471982	G/A	cg17480646	chr11:65405466	SIPA1	0.74	5.88	0.52	6.1e-8	Platelet count;
THYM	cis	rs73198271	0.740	rs10113326	chr8:8647630	A/T	cg06636001	chr8:8085503	FLJ10661	-0.76	-5.06	-0.46	2.01e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7546094	1.000	rs12126277	chr1:113106369	A/G	cg22162597	chr1:113214053	CAPZA1	0.45	4.62	0.43	1.21e-5	Platelet distribution width;
THYM	cis	rs17030434	0.822	rs28367474	chr4:154718642	A/G	cg14289246	chr4:154710475	SFRP2	-0.67	-5.2	-0.47	1.15e-6	Electrocardiographic conduction measures;
THYM	cis	rs7953249	0.618	rs2650000	chr12:121388962	G/T	cg02403541	chr12:121454288	C12orf43	0.72	6.65	0.56	1.83e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg16558253	chr16:72132732	DHX38	-0.59	-5.05	-0.46	2.17e-6	Fibrinogen levels;
THYM	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg24812749	chr6:127587940	RNF146	0.97	7.72	0.62	1.14e-11	Breast cancer;
THYM	cis	rs12310956	0.532	rs7306007	chr12:33975209	C/G	cg06521331	chr12:34319734	NA	-0.92	-8.57	-0.66	1.89e-13	Morning vs. evening chronotype;
THYM	cis	rs977987	0.836	rs7199062	chr16:75474827	G/A	cg03315344	chr16:75512273	CHST6	0.73	5.98	0.52	3.87e-8	Dupuytren's disease;
THYM	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg00645579	chr11:617140	IRF7;MUPCDH	-0.47	-6.04	-0.53	3.05e-8	Systemic lupus erythematosus;
THYM	cis	rs752010	0.619	rs6703992	chr1:42115888	G/A	cg06885757	chr1:42089581	HIVEP3	0.69	9.55	0.7	1.55e-15	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs12935418	0.672	rs9938541	chr16:81045228	T/G	cg16651780	chr16:81037892	C16orf61	0.87	6.38	0.55	6.35e-9	Mean corpuscular volume;
THYM	cis	rs1620921	0.967	rs783159	chr6:161185325	C/T	cg17993073	chr6:160527228	IGF2R	0.56	4.49	0.42	2e-5	Lipoprotein (a) - cholesterol levels;
THYM	cis	rs2108225	0.837	rs7810937	chr7:107447500	A/G	cg18560240	chr7:107437656	SLC26A3	-0.91	-6.69	-0.57	1.57e-9	Ulcerative colitis;
THYM	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg12379764	chr21:47803548	PCNT	-0.78	-5.76	-0.51	1.05e-7	Testicular germ cell tumor;
THYM	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg27068330	chr11:65405492	SIPA1	-0.94	-9.11	-0.68	1.29e-14	Non-alcoholic fatty liver disease histology (lobular);
THYM	cis	rs28595532	0.920	rs116246794	chr4:119732491	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.81	-6.29	-0.54	9.55e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs8112449	1.000	rs8112449	chr19:10520064	C/T	cg01466491	chr19:10523363	NA	-0.7	-6.98	-0.58	4.01e-10	Multiple sclerosis;Gastritis;
THYM	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg10661904	chr17:79619235	PDE6G	-0.54	-4.79	-0.44	6.25e-6	Eye color traits;
THYM	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg26031613	chr14:104095156	KLC1	-0.68	-4.59	-0.43	1.37e-5	Body mass index;
THYM	cis	rs800586	0.868	rs800566	chr8:116709834	A/G	cg04656070	chr8:116661063	TRPS1	0.51	4.76	0.44	6.9e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg18512352	chr11:47633146	NA	-0.38	-4.52	-0.42	1.76e-5	HDL cholesterol;
THYM	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg05962950	chr11:130786565	SNX19	0.96	9.68	0.7	7.81e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	trans	rs877282	0.755	rs1769242	chr10:787896	T/C	cg22713356	chr15:30763199	NA	1.18	9.79	0.71	4.66e-16	Uric acid levels;
THYM	cis	rs7264396	0.563	rs17092980	chr20:34289005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.76	-0.44	6.84e-6	Total cholesterol levels;
THYM	cis	rs265548	0.510	rs28415068	chr19:17910582	T/A	cg21960279	chr19:17905606	B3GNT3	0.56	5.25	0.47	9.07e-7	Tumor biomarkers;
THYM	cis	rs2273669	0.504	rs74448917	chr6:109463989	G/A	cg17117243	chr6:109341365	SESN1	-0.85	-4.99	-0.46	2.77e-6	Prostate cancer;
THYM	cis	rs6032067	1.000	rs6032066	chr20:43857700	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.73	-7.62	-0.62	1.9e-11	Blood protein levels;
THYM	cis	rs7729447	0.776	rs7738037	chr5:32696549	C/T	cg16267343	chr5:32710456	NPR3	0.8	7.27	0.6	1.01e-10	Blood pressure;
THYM	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11644478	chr21:40555479	PSMG1	-0.79	-6.94	-0.58	4.72e-10	Cognitive function;
THYM	cis	rs4481887	0.927	rs7534188	chr1:248434303	C/T	cg13385794	chr1:248469461	NA	-0.73	-4.55	-0.42	1.59e-5	Common traits (Other);
THYM	cis	rs2115536	1.000	rs11072871	chr15:80197931	T/C	cg00225070	chr15:80189496	MTHFS	0.59	5.12	0.47	1.6e-6	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03264133	chr6:25882463	NA	0.77	6.07	0.53	2.59e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg26384229	chr12:38710491	ALG10B	0.97	7.35	0.6	7e-11	Bladder cancer;
THYM	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg00024416	chr22:24240387	NA	-0.68	-7.08	-0.59	2.47e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs240764	0.817	rs240115	chr6:101053069	T/C	cg21058520	chr6:100914733	NA	-0.57	-5.02	-0.46	2.4e-6	Neuroticism;
THYM	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg12935359	chr14:103987150	CKB	-0.65	-6.4	-0.55	5.78e-9	Body mass index;
THYM	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03452623	chr4:187889614	NA	-1.16	-18.39	-0.88	4.68e-33	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg09307838	chr4:120376055	NA	0.68	4.93	0.45	3.43e-6	Corneal astigmatism;
THYM	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg16188243	chr19:2783719	SGTA	0.68	4.71	0.44	8.34e-6	Total cholesterol levels;
THYM	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg01570182	chr17:44337453	NA	-0.84	-9.31	-0.69	5.04e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.41	-6.4	-0.55	5.78e-9	Obesity-related traits;
THYM	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg16586182	chr3:47516702	SCAP	-0.63	-5.52	-0.49	2.96e-7	Colorectal cancer;
THYM	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs10857712	0.521	rs10857714	chr10:135235370	C/A	cg19899694	chr10:135237140	SPRN	0.61	5.22	0.47	1.05e-6	Systemic lupus erythematosus;
THYM	cis	rs1278769	0.735	rs9577395	chr13:113534984	C/G	cg17842918	chr13:113540400	ATP11A	-0.43	-4.46	-0.42	2.27e-5	Interstitial lung disease;
THYM	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg11764359	chr7:65958608	NA	-0.82	-6.44	-0.55	4.81e-9	Aortic root size;
THYM	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg13695892	chr22:41940480	POLR3H	-0.81	-6.07	-0.53	2.63e-8	Vitiligo;
THYM	cis	rs8067545	0.611	rs8066143	chr17:20048355	A/C	cg13482628	chr17:19912719	NA	0.55	4.68	0.43	9.41e-6	Schizophrenia;
THYM	cis	rs863345	0.604	rs7555174	chr1:158487426	A/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs4938534	0.559	rs1944919	chr11:111259876	A/C	cg01212326	chr11:111250286	POU2AF1	0.51	5.0	0.46	2.62e-6	Primary biliary cholangitis;
THYM	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10089	1.000	rs4836367	chr5:127482592	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.02	7.11	0.59	2.11e-10	Ileal carcinoids;
THYM	cis	rs1691799	0.899	rs1168310	chr12:66726355	A/G	cg16791601	chr12:66731901	HELB	0.77	7.29	0.6	8.98e-11	White blood cell count (basophil);
THYM	cis	rs2075230	0.705	rs1642795	chr17:7542591	C/T	cg10509001	chr17:7553872	ATP1B2	-0.58	-4.71	-0.44	8.48e-6	Hormone measurements;
THYM	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg08885076	chr2:99613938	TSGA10	-0.53	-5.13	-0.47	1.51e-6	Chronic sinus infection;
THYM	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg27087555	chr16:88793112	FAM38A	-1.19	-6.67	-0.56	1.69e-9	Plateletcrit;
THYM	cis	rs1046896	0.607	rs12449739	chr17:80683420	G/A	cg02711726	chr17:80685570	FN3KRP	-0.62	-4.62	-0.43	1.19e-5	Glycated hemoglobin levels;
THYM	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2806561	1.000	rs2806563	chr1:23506625	C/T	cg08872493	chr1:23521417	HTR1D	-0.37	-4.46	-0.42	2.24e-5	Height;
THYM	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg13319975	chr6:146136371	FBXO30	0.75	6.26	0.54	1.11e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg00801512	chr17:28996047	NA	0.79	5.19	0.47	1.2e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg17063962	chr7:91808500	NA	-1.17	-13.64	-0.81	4.12e-24	Breast cancer;
THYM	cis	rs6546537	1.000	rs17036866	chr2:69857711	T/C	cg10773587	chr2:69614142	GFPT1	-0.61	-5.36	-0.48	5.77e-7	Serum thyroid-stimulating hormone levels;
THYM	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.09	-7.74	-0.62	1.06e-11	Platelet count;
THYM	cis	rs11771526	1.000	rs117890465	chr7:32351009	A/C	cg27532318	chr7:32358331	NA	0.87	5.49	0.49	3.33e-7	Body mass index;
THYM	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg22968622	chr17:43663579	NA	-1.1	-9.99	-0.72	1.7e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7432375	0.610	rs60574021	chr3:136520281	C/G	cg21827317	chr3:136751795	NA	0.54	4.64	0.43	1.13e-5	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs4788570	0.686	rs9937511	chr16:71815913	C/T	cg06353428	chr16:71660113	MARVELD3	1.41	8.74	0.67	8.32e-14	Intelligence (multi-trait analysis);
THYM	cis	rs6121246	0.609	rs2376998	chr20:30340663	T/C	cg13852791	chr20:30311386	BCL2L1	0.87	8.17	0.64	1.31e-12	Mean corpuscular hemoglobin;
THYM	cis	rs1729951	0.575	rs747843	chr3:136703130	G/C	cg21827317	chr3:136751795	NA	0.75	6.71	0.57	1.41e-9	Neuroticism;
THYM	trans	rs208520	0.690	rs207096	chr6:66797287	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.66	-0.62	1.53e-11	Exhaled nitric oxide output;
THYM	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg04518342	chr5:131593106	PDLIM4	0.45	5.02	0.46	2.43e-6	Breast cancer;
THYM	cis	rs2016266	0.750	rs10876432	chr12:53731891	G/A	cg26875137	chr12:53738046	NA	0.82	6.28	0.54	1.03e-8	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs17152411	1.000	rs61873277	chr10:126619331	C/A	cg07906193	chr10:126599966	NA	0.69	4.71	0.44	8.45e-6	Height;
THYM	cis	rs2976388	0.669	rs2585135	chr8:143814193	A/G	cg06565975	chr8:143823917	SLURP1	-0.43	-4.71	-0.44	8.35e-6	Urinary tract infection frequency;
THYM	cis	rs4280164	0.551	rs3212260	chr14:24804088	A/T	cg22990158	chr14:24802150	ADCY4	0.59	5.03	0.46	2.29e-6	Parent of origin effect on language impairment (paternal);
THYM	cis	rs994014	0.804	rs2034632	chr4:82225114	C/T	cg17825130	chr4:82283507	NA	0.5	4.45	0.42	2.3e-5	Height;
THYM	cis	rs35660623	1.000	rs13280573	chr8:10668578	C/G	cg12395012	chr8:11607386	GATA4	1.01	5.38	0.48	5.24e-7	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs3892630	0.588	rs2287881	chr19:33333155	A/G	cg22928329	chr19:33183273	NUDT19	0.69	5.48	0.49	3.45e-7	Red blood cell traits;
THYM	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg15448220	chr1:150897856	SETDB1	0.84	6.98	0.58	3.9e-10	Melanoma;
THYM	cis	rs9470366	0.883	rs7756236	chr6:36627053	A/G	cg24425727	chr6:36645648	CDKN1A	-0.59	-4.77	-0.44	6.55e-6	QRS duration;
THYM	cis	rs10788264	0.504	rs7898942	chr10:124024608	G/T	cg09507567	chr10:124027408	NA	-0.54	-5.59	-0.5	2.16e-7	Total body bone mineral density;
THYM	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	trans	rs8073060	0.586	rs7214742	chr17:33981969	C/A	cg19694781	chr19:47549865	TMEM160	-1.02	-8.69	-0.67	1.01e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs1008375	0.646	rs4235387	chr4:17569327	T/G	cg16339924	chr4:17578868	LAP3	0.69	4.59	0.43	1.35e-5	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7683537	0.692	rs56368159	chr4:185654827	T/G	cg27112742	chr4:185696749	ACSL1	-0.94	-4.89	-0.45	4.04e-6	Systemic lupus erythematosus;
THYM	cis	rs2046867	0.661	rs9861834	chr3:72909272	C/T	cg25664220	chr3:72788482	NA	-0.74	-6.68	-0.57	1.58e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg21475434	chr5:93447410	FAM172A	0.96	6.1	0.53	2.29e-8	Diabetic retinopathy;
THYM	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs3087591	0.810	rs2269856	chr17:29482701	C/T	cg24425628	chr17:29625626	OMG;NF1	0.68	5.44	0.49	4.14e-7	Hip circumference;
THYM	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg24531977	chr5:56204891	C5orf35	0.72	5.77	0.51	9.7e-8	Initial pursuit acceleration;
THYM	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs2370759	0.891	rs11592754	chr10:32619572	A/C	cg01819863	chr10:32635814	EPC1	0.98	4.94	0.45	3.33e-6	Sexual dysfunction (female);
THYM	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg19770292	chr5:1868693	NA	0.49	4.57	0.42	1.48e-5	Cardiovascular disease risk factors;
THYM	cis	rs9972944	0.756	rs11870607	chr17:63773122	A/G	cg07283582	chr17:63770753	CCDC46	0.68	5.54	0.49	2.69e-7	Total body bone mineral density;
THYM	cis	rs988913	1.000	rs7765236	chr6:54835567	G/A	cg18532076	chr6:54711417	FAM83B	0.5	4.91	0.45	3.78e-6	Menarche (age at onset);
THYM	cis	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg21775007	chr8:11205619	TDH	0.74	6.67	0.57	1.65e-9	Retinal vascular caliber;
THYM	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg13918804	chr1:2043761	PRKCZ	-0.61	-4.62	-0.43	1.19e-5	Height;
THYM	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26314531	chr2:26401878	FAM59B	-0.76	-4.99	-0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs7084921	0.578	rs12765808	chr10:101872687	A/C	cg11344164	chr10:101878520	NA	-0.55	-4.69	-0.43	9.12e-6	Bone mineral density;
THYM	cis	rs6430585	0.583	rs1435577	chr2:136624947	C/G	cg23851026	chr2:136556271	LCT	0.79	7.51	0.61	3.2e-11	Corneal structure;
THYM	cis	rs3796619	0.961	rs11732520	chr4:1074009	C/T	cg27284194	chr4:1044797	NA	0.54	4.92	0.45	3.69e-6	Recombination rate (males);
THYM	cis	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg26384229	chr12:38710491	ALG10B	0.95	7.73	0.62	1.11e-11	Bladder cancer;
THYM	cis	rs10992471	0.639	rs10821008	chr9:95487497	C/T	cg14631576	chr9:95140430	CENPP	-0.95	-8.6	-0.66	1.58e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs728616	0.867	rs4520539	chr10:81740529	C/G	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg12165864	chr7:66369176	NA	-0.63	-5.01	-0.46	2.51e-6	Aortic root size;
THYM	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg26384229	chr12:38710491	ALG10B	0.74	5.62	0.5	1.91e-7	Morning vs. evening chronotype;
THYM	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg00495681	chr13:53174319	NA	1.03	10.28	0.73	4.23e-17	Lewy body disease;
THYM	cis	rs2267137	0.903	rs2283850	chr22:29772391	G/C	cg26480862	chr22:28839667	TTC28	0.46	4.54	0.42	1.62e-5	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs9549260	0.522	rs4245401	chr13:41277736	G/T	cg21288729	chr13:41239152	FOXO1	0.66	4.95	0.45	3.27e-6	Red blood cell count;
THYM	cis	rs1699337	0.740	rs709157	chr3:12462024	G/A	cg05467012	chr3:12595696	NA	0.55	4.49	0.42	1.99e-5	Cholesterol, total;
THYM	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.81	-6.29	-0.54	9.55e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.05e-6	Crohn's disease;
THYM	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.76	-5.27	-0.48	8.34e-7	Gut microbiome composition (summer);
THYM	cis	rs28595532	0.920	rs56027489	chr4:119780882	A/G	cg14228332	chr4:119757509	SEC24D	1.46	5.36	0.48	5.83e-7	Cannabis dependence symptom count;
THYM	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.58	0.5	2.25e-7	Tonsillectomy;
THYM	cis	rs9807989	0.811	rs4485585	chr2:102970759	T/C	cg03938978	chr2:103052716	IL18RAP	0.63	6.46	0.55	4.36e-9	Asthma;
THYM	cis	rs9329289	0.510	rs2029604	chr10:2554700	T/C	cg07014206	chr10:2547000	NA	-0.57	-5.24	-0.47	9.47e-7	Age-related hearing impairment;
THYM	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg12310025	chr6:25882481	NA	0.71	6.02	0.53	3.27e-8	Blood metabolite levels;
THYM	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.55	4.45	0.42	2.37e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg02527881	chr3:46936655	PTH1R	-0.69	-7.14	-0.59	1.9e-10	Colorectal cancer;
THYM	cis	rs600806	0.815	rs4970754	chr1:109969721	A/G	cg23032129	chr1:109941072	SORT1	-0.57	-4.82	-0.44	5.54e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg00666640	chr1:248458726	OR2T12	0.57	4.75	0.44	7.19e-6	Common traits (Other);
THYM	cis	rs3862030	0.720	rs7081467	chr10:104231662	G/C	cg00122347	chr10:104236741	TMEM180	0.46	6.63	0.56	2.04e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	trans	rs1974653	0.672	rs1558495	chr22:20071652	T/G	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs7100689	0.542	rs10887869	chr10:82194689	A/G	cg00277334	chr10:82204260	NA	-0.54	-5.52	-0.49	2.88e-7	Post bronchodilator FEV1;
THYM	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg12560992	chr17:57184187	TRIM37	-0.92	-8.68	-0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs933688	1.000	rs12188467	chr5:90765632	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.78	4.97	0.45	2.93e-6	Smoking behavior;
THYM	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg02527881	chr3:46936655	PTH1R	-0.6	-5.96	-0.52	4.25e-8	Colorectal cancer;
THYM	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg24818145	chr4:99064322	C4orf37	0.87	7.23	0.6	1.19e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg04025307	chr7:1156635	C7orf50	0.78	6.67	0.56	1.66e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg10360139	chr7:1886902	MAD1L1	-0.58	-5.11	-0.46	1.63e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6539288	0.630	rs10778520	chr12:107364873	A/G	cg26297688	chr12:107349093	C12orf23	0.44	4.9	0.45	4e-6	Total body bone mineral density;
THYM	cis	rs10822136	0.756	rs10822133	chr10:64865872	G/A	cg09254098	chr10:65029020	JMJD1C	0.72	4.48	0.42	2.11e-5	IgG glycosylation;
THYM	cis	rs28595532	0.841	rs10019311	chr4:119785458	G/A	cg11846333	chr4:119757529	SEC24D	1.38	5.03	0.46	2.27e-6	Cannabis dependence symptom count;
THYM	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs4363385	0.747	rs1338180	chr1:152981404	A/G	cg13444842	chr1:152974279	SPRR3	-0.59	-4.68	-0.43	9.52e-6	Inflammatory skin disease;
THYM	cis	rs79149102	0.579	rs78664321	chr15:75339575	G/A	cg17294928	chr15:75287854	SCAMP5	-1.07	-5.23	-0.47	9.89e-7	Lung cancer;
THYM	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg27068330	chr11:65405492	SIPA1	-1.03	-10.58	-0.74	9.72e-18	Acne (severe);
THYM	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg19077165	chr18:44547161	KATNAL2	-0.66	-8.44	-0.65	3.55e-13	Personality dimensions;
THYM	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg06766960	chr11:133703094	NA	-0.62	-5.49	-0.49	3.3e-7	Childhood ear infection;
THYM	cis	rs6450176	1.000	rs3776716	chr5:53298923	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.14	-0.53	1.94e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11890956	chr21:40555474	PSMG1	1.17	12.99	0.8	8.73e-23	Cognitive function;
THYM	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg23791538	chr6:167370224	RNASET2	-0.58	-4.48	-0.42	2.07e-5	Crohn's disease;
THYM	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg06873352	chr17:61820015	STRADA	-0.58	-5.53	-0.49	2.83e-7	Height;
THYM	trans	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg06618935	chr21:46677482	NA	-0.98	-9.5	-0.7	1.95e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs8078723	0.802	rs9303283	chr17:38192633	A/G	cg17467752	chr17:38218738	THRA	0.95	7.57	0.61	2.45e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	trans	rs8002861	0.840	rs7989353	chr13:44438957	T/C	cg17145862	chr1:211918768	LPGAT1	0.93	9.72	0.71	6.69e-16	Leprosy;
THYM	cis	rs758324	0.732	rs156045	chr5:131492616	G/A	cg16205897	chr5:131564050	P4HA2	0.52	4.6	0.43	1.29e-5	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs34779708	0.931	rs6481935	chr10:35342959	C/T	cg03585969	chr10:35415529	CREM	0.63	4.66	0.43	1.01e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6032067	0.929	rs55726011	chr20:43855229	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.72	-6.57	-0.56	2.7e-9	Blood protein levels;
THYM	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg06009448	chr7:1102226	C7orf50	0.53	5.59	0.5	2.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08109568	chr15:31115862	NA	0.76	6.82	0.57	8.54e-10	Huntington's disease progression;
THYM	cis	rs323167	0.608	rs321970	chr7:78312157	C/T	cg20996682	chr7:79084048	MAGI2	-0.59	-4.5	-0.42	1.9e-5	Schizophrenia;
THYM	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg12573674	chr2:1569213	NA	-1.22	-4.82	-0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg24675658	chr1:53192096	ZYG11B	-0.73	-6.36	-0.55	6.96e-9	Monocyte count;
THYM	cis	rs7247513	0.964	rs4804200	chr19:12710752	C/G	cg01871581	chr19:12707946	ZNF490	-0.87	-9.36	-0.69	3.84e-15	Bipolar disorder;
THYM	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg19774624	chr17:42201019	HDAC5	-0.67	-5.44	-0.49	4.13e-7	Total body bone mineral density;
THYM	cis	rs12802200	0.561	rs12792868	chr11:566647	T/A	cg16486109	chr11:613632	IRF7	0.5	5.48	0.49	3.44e-7	Systemic lupus erythematosus;
THYM	cis	rs13064411	0.518	rs9852703	chr3:113189368	C/T	cg18753928	chr3:113234510	CCDC52	0.78	7.16	0.59	1.68e-10	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs791888	0.929	rs2755431	chr10:89415104	C/T	cg13926569	chr10:89418898	PAPSS2	-0.73	-8.08	-0.64	2.07e-12	Magnesium levels;
THYM	cis	rs2455799	0.634	rs1345160	chr3:15862026	C/T	cg16303742	chr3:15540471	COLQ	-0.54	-5.78	-0.51	9.67e-8	Mean platelet volume;
THYM	cis	rs910316	0.904	rs7156089	chr14:75645527	A/G	cg08847533	chr14:75593920	NEK9	-1.01	-11.06	-0.75	9.12e-19	Height;
THYM	cis	rs10887741	0.865	rs2762527	chr10:89418167	T/G	cg13926569	chr10:89418898	PAPSS2	-0.67	-7.07	-0.59	2.61e-10	Exercise (leisure time);
THYM	cis	rs7695732	0.595	rs2178584	chr4:89891198	C/T	cg17769793	chr4:89976368	FAM13A	0.47	4.99	0.46	2.74e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs1122608	0.580	rs12610374	chr19:11080921	C/T	cg17326582	chr19:11976514	ZNF439	0.59	4.55	0.42	1.56e-5	Coronary artery disease or ischemic stroke;Coronary artery disease;Coronary artery disease or large artery stroke;Coronary heart disease;Myocardial infarction (early onset);
THYM	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg11764359	chr7:65958608	NA	0.8	6.58	0.56	2.51e-9	Aortic root size;
THYM	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg15556689	chr8:8085844	FLJ10661	0.63	4.76	0.44	6.96e-6	Mood instability;
THYM	cis	rs995000	1.000	rs995000	chr1:63107526	C/T	cg06896770	chr1:63153194	DOCK7	1.0	8.13	0.64	1.61e-12	Triglyceride levels;
THYM	cis	rs17321999	1.000	rs10171305	chr2:30481343	A/T	cg05247661	chr2:30472410	LBH	0.67	4.46	0.42	2.25e-5	Systemic lupus erythematosus;
THYM	cis	rs6750795	0.569	rs1797387	chr2:232414692	A/G	cg19187155	chr2:232395269	NMUR1	0.92	9.07	0.68	1.61e-14	Height;
THYM	cis	rs782590	0.935	rs6739513	chr2:55749902	G/A	cg18811423	chr2:55921094	PNPT1	0.74	7.05	0.59	2.83e-10	Metabolic syndrome;
THYM	cis	rs7224737	1.000	rs12603330	chr17:40290589	T/A	cg00647820	chr17:40259828	DHX58	-0.6	-4.53	-0.42	1.72e-5	Fibrinogen levels;
THYM	cis	rs7107770	1.000	rs12787799	chr11:125094342	T/C	cg04164023	chr11:125106101	PKNOX2	-0.8	-4.65	-0.43	1.05e-5	Photic sneeze reflex;
THYM	cis	rs986417	1.000	rs1116853	chr14:60917476	A/G	cg27398547	chr14:60952738	C14orf39	1.19	6.12	0.53	2.05e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs9419702	0.568	rs7920966	chr10:133555185	G/T	cg20568497	chr10:133558893	NA	0.48	4.76	0.44	6.88e-6	Survival in rectal cancer;
THYM	cis	rs2625529	0.761	rs8028532	chr15:72348054	G/A	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg24642844	chr7:1081250	C7orf50	-1.26	-8.22	-0.64	1.03e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs470093	0.866	rs80637	chr22:44242067	C/T	cg09142166	chr22:44276013	PNPLA5	-0.6	-5.77	-0.51	9.87e-8	Staphylococcus aureus infection;
THYM	cis	rs9906944	0.898	rs9909861	chr17:47079416	C/A	cg09029085	chr17:47094198	IGF2BP1	0.43	5.73	0.51	1.16e-7	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs9443189	0.855	rs1321161	chr6:76454182	G/A	cg01950844	chr6:76311363	SENP6	-0.79	-4.59	-0.43	1.33e-5	Prostate cancer;
THYM	cis	rs9560113	1.000	rs9560110	chr13:112181233	C/T	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs10911232	0.507	rs10911230	chr1:183051118	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.5	5.41	0.49	4.61e-7	Mean corpuscular volume;
THYM	cis	rs700651	0.856	rs9288280	chr2:198744324	A/G	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Intracranial aneurysm;
THYM	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg24675658	chr1:53192096	ZYG11B	-0.66	-5.23	-0.47	1.01e-6	Monocyte count;
THYM	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg20387954	chr3:183756860	HTR3D	0.55	4.53	0.42	1.74e-5	Anterior chamber depth;
THYM	cis	rs4499344	0.921	rs2277927	chr19:33088366	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	5.45	0.49	3.97e-7	Mean platelet volume;
THYM	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg26418147	chr1:205743515	RAB7L1	-0.56	-4.94	-0.45	3.38e-6	Menarche (age at onset);
THYM	cis	rs4638749	0.501	rs4322804	chr2:108744939	G/T	cg25838818	chr2:108905173	SULT1C2	-0.52	-4.89	-0.45	4.13e-6	Blood pressure;
THYM	cis	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs7584330	0.554	rs77648388	chr2:238431832	G/C	cg14458575	chr2:238380390	NA	1.02	5.32	0.48	6.82e-7	Prostate cancer;
THYM	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg06623918	chr6:96969491	KIAA0776	-1.03	-10.03	-0.72	1.41e-16	Headache;
THYM	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg17143192	chr8:8559678	CLDN23	0.91	6.72	0.57	1.33e-9	Obesity-related traits;
THYM	cis	rs3126085	0.935	rs7550106	chr1:152197202	C/T	cg26020982	chr1:152196106	HRNR	-0.38	-5.03	-0.46	2.32e-6	Atopic dermatitis;
THYM	cis	rs4363385	0.818	rs4845335	chr1:152993955	G/A	cg13444842	chr1:152974279	SPRR3	-0.61	-5.11	-0.46	1.68e-6	Inflammatory skin disease;
THYM	cis	rs7481584	0.624	rs1077335	chr11:3030524	A/G	cg03159660	chr11:2078197	NA	0.65	4.96	0.45	3.08e-6	Calcium levels;
THYM	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-4.99	-0.46	2.73e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4792901	0.802	rs55956367	chr17:41582284	A/G	cg21940313	chr17:41620911	ETV4	-0.53	-5.03	-0.46	2.28e-6	Dupuytren's disease;
THYM	cis	rs3126085	0.877	rs7535536	chr1:152193544	A/G	cg26020982	chr1:152196106	HRNR	0.38	5.14	0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs7119	0.717	rs12904348	chr15:77815738	G/C	cg10437265	chr15:77819839	NA	0.77	7.76	0.62	9.39e-12	Type 2 diabetes;
THYM	cis	rs7107174	1.000	rs10899460	chr11:78010080	A/G	cg19901956	chr11:77921274	USP35	-0.69	-5.3	-0.48	7.42e-7	Testicular germ cell tumor;
THYM	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06481639	chr22:41940642	POLR3H	0.65	4.77	0.44	6.53e-6	Cannabis dependence symptom count;
THYM	cis	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg24678163	chr13:52769951	THSD1P	0.49	4.58	0.43	1.38e-5	Lewy body disease;
THYM	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.64	-4.59	-0.43	1.35e-5	Aortic root size;
THYM	cis	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg10856724	chr12:34555212	NA	-0.76	-7.04	-0.59	2.99e-10	Morning vs. evening chronotype;
THYM	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4900538	0.855	rs1190537	chr14:102887816	C/T	cg18135206	chr14:102964638	TECPR2	-0.81	-6.24	-0.54	1.2e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg18477163	chr1:228402036	OBSCN	-0.48	-5.32	-0.48	6.77e-7	Diastolic blood pressure;
THYM	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.01	8.98	0.68	2.49e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg07212818	chr11:638076	DRD4	-0.79	-6.69	-0.57	1.57e-9	Systemic lupus erythematosus;
THYM	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22496380	chr5:211416	CCDC127	-1.28	-8.11	-0.64	1.75e-12	Breast cancer;
THYM	cis	rs7119	0.635	rs938090	chr15:77879975	A/G	cg27398640	chr15:77910606	LINGO1	0.7	8.44	0.65	3.49e-13	Type 2 diabetes;
THYM	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.28	0.54	1.02e-8	Total body bone mineral density;
THYM	cis	rs6732160	0.691	rs2007191	chr2:73421463	T/G	cg24220031	chr2:73402428	NA	-0.78	-9.27	-0.69	6.15e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg18681998	chr4:17616180	MED28	-0.88	-7.39	-0.6	5.81e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg10803722	chr21:46713166	LOC642852	-0.5	-6.28	-0.54	1.02e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7084402	1.000	rs1427202	chr10:60267917	A/T	cg07615347	chr10:60278583	BICC1	-0.56	-5.14	-0.47	1.5e-6	Refractive error;
THYM	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg06191203	chr2:152266755	RIF1	-0.73	-5.0	-0.46	2.62e-6	Lung cancer;
THYM	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg00271210	chr6:167070053	RPS6KA2	-0.49	-4.79	-0.44	6.22e-6	Crohn's disease;
THYM	cis	rs7586879	0.687	rs11892869	chr2:25096692	A/T	cg01884057	chr2:25150051	NA	0.7	7.27	0.6	1.01e-10	Body mass index;
THYM	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg03929089	chr4:120376271	NA	-1.01	-13.71	-0.82	3.1e-24	Height;
THYM	cis	rs5769765	0.671	rs138841	chr22:50181960	C/A	cg02269571	chr22:50332266	NA	-0.67	-4.57	-0.42	1.47e-5	Schizophrenia;
THYM	cis	rs2040771	0.804	rs1340958	chr22:19253332	A/G	cg02655711	chr22:19163373	SLC25A1	-0.57	-6.08	-0.53	2.5e-8	Metabolite levels (small molecules and protein measures);
THYM	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg12165864	chr7:66369176	NA	-0.65	-5.08	-0.46	1.89e-6	Aortic root size;
THYM	cis	rs4866334	1.000	rs76258230	chr5:18433807	G/C	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg17264618	chr3:40429014	ENTPD3	0.53	4.99	0.46	2.69e-6	Renal cell carcinoma;
THYM	cis	rs611744	1.000	rs611744	chr8:109228008	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.15	0.47	1.38e-6	Dupuytren's disease;
THYM	cis	rs4523957	0.855	rs7217226	chr17:2136065	A/C	cg16513277	chr17:2031491	SMG6	-0.82	-8.2	-0.64	1.15e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs338389	0.586	rs338387	chr15:68260982	A/G	cg07562100	chr15:68569975	FEM1B	-0.7	-5.24	-0.47	9.57e-7	Survival in rectal cancer;
THYM	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg13319975	chr6:146136371	FBXO30	-0.62	-4.98	-0.46	2.81e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13064411	0.542	rs4396864	chr3:113212562	C/T	cg18753928	chr3:113234510	CCDC52	-0.84	-7.97	-0.63	3.49e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg09990169	chr2:241835740	C2orf54	-0.37	-6.27	-0.54	1.08e-8	Urinary metabolites;
THYM	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg06784218	chr1:46089804	CCDC17	-0.32	-4.82	-0.44	5.41e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs9527	0.590	rs10883839	chr10:104920341	A/G	cg04362960	chr10:104952993	NT5C2	0.62	4.74	0.44	7.64e-6	Arsenic metabolism;
THYM	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs13315871	0.615	rs7625655	chr3:58337723	C/T	cg12435725	chr3:58293450	RPP14	0.37	4.81	0.44	5.67e-6	Cholesterol, total;
THYM	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg26677194	chr12:130822605	PIWIL1	0.86	7.08	0.59	2.53e-10	Menopause (age at onset);
THYM	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg06112835	chr11:68658793	MRPL21	0.44	6.2	0.54	1.43e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7634476	1	rs7634476	chr3:136398387	A/G	cg12473912	chr3:136751656	NA	-0.62	-5.22	-0.47	1.05e-6	Neuroticism;
THYM	cis	rs921665	0.831	rs2242084	chr2:3196040	A/G	cg16434511	chr2:3151078	NA	-0.87	-5.46	-0.49	3.8e-7	World class endurance athleticism;
THYM	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg00024416	chr22:24240387	NA	-0.69	-7.38	-0.6	6.02e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg11764359	chr7:65958608	NA	-0.69	-4.75	-0.44	7.23e-6	Aortic root size;
THYM	cis	rs3741151	1.000	rs111882289	chr11:73053714	T/C	cg17517138	chr11:73019481	ARHGEF17	0.99	5.88	0.52	5.97e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7584330	0.638	rs13429533	chr2:238448712	A/G	cg16989719	chr2:238392110	NA	-0.47	-4.64	-0.43	1.1e-5	Prostate cancer;
THYM	cis	rs910187	0.678	rs1046667	chr20:45817255	A/C	cg27589058	chr20:45804311	EYA2	-0.58	-4.97	-0.45	2.96e-6	Migraine;
THYM	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg09184832	chr6:79620586	NA	0.57	4.57	0.42	1.48e-5	Intelligence (multi-trait analysis);
THYM	cis	rs13082711	0.906	rs34775440	chr3:27447333	G/T	cg02860705	chr3:27208620	NA	0.72	5.14	0.47	1.46e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs7226229	1.000	rs7211094	chr17:20923750	C/T	cg21263980	chr17:20946333	USP22	-0.65	-4.88	-0.45	4.33e-6	Blood trace element (Se levels);
THYM	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.27	0.54	1.07e-8	Platelet count;
THYM	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs3741489	1.000	rs12229449	chr12:133477628	A/G	cg03157182	chr12:132655797	NA	-0.55	-4.48	-0.42	2.09e-5	Cognitive function;
THYM	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.57	0.42	1.48e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs865483	0.895	rs853192	chr17:35821931	C/G	cg06716730	chr17:35851459	DUSP14	0.42	7.13	0.59	1.93e-10	Monocyte count;
THYM	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs9914544	0.545	rs3826380	chr17:18793225	A/G	cg26378065	chr17:18585709	ZNF286B	0.58	4.65	0.43	1.05e-5	Educational attainment (years of education);
THYM	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg12935359	chr14:103987150	CKB	0.51	6.07	0.53	2.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg17863274	chr19:49399704	TULP2	-1.01	-6.47	-0.55	4.29e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2274459	0.778	rs2296737	chr6:33656416	G/A	cg06253072	chr6:33679850	C6orf125	0.47	4.7	0.43	8.63e-6	Obesity (extreme);
THYM	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg12311346	chr5:56204834	C5orf35	0.58	4.51	0.42	1.87e-5	Initial pursuit acceleration;
THYM	cis	rs4722166	0.695	rs7808122	chr7:22798080	A/G	cg26061582	chr7:22766209	IL6	0.57	4.51	0.42	1.83e-5	Lung cancer;
THYM	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-10.93	-0.75	1.77e-18	Coronary artery disease;
THYM	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg10515332	chr4:99064459	C4orf37	0.63	5.09	0.46	1.78e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg03806693	chr22:41940476	POLR3H	-1.02	-8.36	-0.65	5.25e-13	Vitiligo;
THYM	cis	rs988913	1.000	rs6929930	chr6:54812710	G/A	cg18532076	chr6:54711417	FAM83B	0.51	5.02	0.46	2.38e-6	Menarche (age at onset);
THYM	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.25	5.48	0.49	3.54e-7	Obesity-related traits;
THYM	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg10792982	chr14:105748885	BRF1	0.67	6.69	0.57	1.5e-9	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11112613	0.713	rs17037317	chr12:105952058	T/C	cg03607813	chr12:105948248	NA	0.97	8.02	0.64	2.67e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs7769051	0.521	rs9321367	chr6:133084359	G/T	cg22852734	chr6:133119734	C6orf192	1.05	4.6	0.43	1.3e-5	Type 2 diabetes nephropathy;
THYM	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg27489772	chr12:121021490	NA	-0.66	-4.46	-0.42	2.29e-5	Type 1 diabetes nephropathy;
THYM	cis	rs3008870	1.000	rs2755246	chr1:67488984	A/G	cg02640540	chr1:67518911	SLC35D1	0.62	4.53	0.42	1.7e-5	Lymphocyte percentage of white cells;
THYM	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg04607235	chr12:12878440	APOLD1	-1.05	-10.0	-0.72	1.66e-16	Lymphocyte counts;
THYM	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg23649088	chr2:200775458	C2orf69	-0.75	-4.67	-0.43	9.85e-6	Schizophrenia;
THYM	cis	rs4638749	0.677	rs10185270	chr2:108838692	A/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg12564285	chr5:131593104	PDLIM4	0.43	4.76	0.44	6.88e-6	Breast cancer;
THYM	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg22709100	chr7:91322751	NA	0.6	4.69	0.43	9.3e-6	Breast cancer;
THYM	cis	rs8067545	0.611	rs1992561	chr17:20219119	G/A	cg13482628	chr17:19912719	NA	-0.56	-4.6	-0.43	1.32e-5	Schizophrenia;
THYM	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg02070205	chr10:30722105	MAP3K8	0.62	5.02	0.46	2.4e-6	Inflammatory bowel disease;
THYM	cis	rs10516089	0.504	rs254874	chr5:171138689	T/C	cg17535961	chr5:171094783	NA	-0.41	-4.47	-0.42	2.18e-5	Venous thromboembolism (SNP x SNP interaction);
THYM	cis	rs7119	0.717	rs12902912	chr15:77809170	A/G	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs2403083	0.697	rs2403084	chr8:86111482	C/T	cg13721134	chr8:86350390	CA3	0.49	4.79	0.44	6.21e-6	Plasma amyloid beta peptide concentrations (ABx-40);
THYM	cis	rs7264396	0.563	rs2425100	chr20:34310115	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.77	-0.44	6.57e-6	Total cholesterol levels;
THYM	cis	rs6539288	0.933	rs4964498	chr12:107306723	T/A	cg26297688	chr12:107349093	C12orf23	-0.47	-4.89	-0.45	4.15e-6	Total body bone mineral density;
THYM	cis	rs9972944	0.756	rs4594282	chr17:63762930	G/A	cg07283582	chr17:63770753	CCDC46	-0.65	-4.99	-0.46	2.68e-6	Total body bone mineral density;
THYM	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg01831904	chr17:28903510	LRRC37B2	-1.02	-5.06	-0.46	2.05e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4638749	0.677	rs10454132	chr2:108828111	T/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg11335335	chr11:637885	DRD4	-0.63	-5.11	-0.46	1.64e-6	Systemic lupus erythematosus;
THYM	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg14835575	chr10:16859367	RSU1	0.6	4.63	0.43	1.18e-5	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
THYM	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg09260853	chr1:2094483	PRKCZ	-0.5	-5.1	-0.46	1.75e-6	Height;
THYM	cis	rs4435363	1.000	rs8105727	chr19:47066644	C/T	cg10017888	chr19:47105860	CALM3	0.69	4.91	0.45	3.74e-6	Immature fraction of reticulocytes;P wave terminal force;
THYM	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg23035555	chr19:3500370	DOHH	0.79	4.57	0.42	1.44e-5	Total cholesterol levels;
THYM	cis	rs921968	0.541	rs514356	chr2:219375018	C/T	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs57994353	0.667	rs34985258	chr9:139327154	C/T	cg14115884	chr9:139300582	SDCCAG3	0.7	4.58	0.43	1.43e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs5417	0.761	rs6503010	chr17:7180435	C/T	cg25256661	chr17:7137939	DVL2	-1.05	-8.2	-0.64	1.12e-12	Diastolic blood pressure;
THYM	cis	rs2836974	0.583	rs8132993	chr21:40716410	T/C	cg11644478	chr21:40555479	PSMG1	0.65	4.76	0.44	7.05e-6	Cognitive function;
THYM	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg13683864	chr3:40499215	RPL14	-1.05	-11.46	-0.76	1.29e-19	Renal cell carcinoma;
THYM	cis	rs35264875	1.000	rs6591370	chr11:68843003	G/A	cg01993067	chr11:68851601	TPCN2	1.0	4.68	0.43	9.62e-6	Blond vs. brown hair color;
THYM	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg20295408	chr7:1910781	MAD1L1	-0.63	-4.73	-0.44	7.7e-6	Schizophrenia;
THYM	cis	rs7084402	0.967	rs1649069	chr10:60303695	A/G	cg07615347	chr10:60278583	BICC1	-0.57	-5.36	-0.48	5.86e-7	Refractive error;
THYM	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg16325326	chr1:53192061	ZYG11B	-0.77	-5.72	-0.51	1.21e-7	Monocyte count;
THYM	cis	rs6918586	1.000	rs198806	chr6:26133616	A/G	cg03264133	chr6:25882463	NA	0.63	4.81	0.44	5.63e-6	Schizophrenia;
THYM	cis	rs12562037	0.673	rs16851653	chr1:15779113	A/G	cg05660106	chr1:15850417	CASP9	-0.81	-4.58	-0.43	1.39e-5	Alcoholic chronic pancreatitis;
THYM	cis	rs4523957	0.620	rs898749	chr17:2085185	G/A	cg16513277	chr17:2031491	SMG6	-0.95	-8.69	-0.67	1.05e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-5.4	-0.48	4.89e-7	Chronic sinus infection;
THYM	cis	rs920590	0.627	rs28585593	chr8:19646084	A/C	cg01411142	chr8:19674711	INTS10	0.64	5.06	0.46	2.05e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs2249694	0.620	rs2070673	chr10:135340567	A/T	cg20169779	chr10:135381914	SYCE1	0.65	4.84	0.44	5.11e-6	Obesity-related traits;
THYM	cis	rs7769051	0.522	rs7775241	chr6:133109022	T/C	cg22852734	chr6:133119734	C6orf192	1.47	6.85	0.57	7.36e-10	Type 2 diabetes nephropathy;
THYM	cis	rs950880	0.710	rs2287034	chr2:103010588	A/C	cg03938978	chr2:103052716	IL18RAP	0.52	4.57	0.42	1.49e-5	Serum protein levels (sST2);
THYM	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.98	-9.81	-0.71	4.28e-16	Primary sclerosing cholangitis;
THYM	cis	rs7178572	0.568	rs3743478	chr15:77400388	T/C	cg22256960	chr15:77711686	NA	-0.95	-7.7	-0.62	1.31e-11	Type 2 diabetes;
THYM	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.13	-5.5	-0.49	3.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs36051895	0.632	rs10815164	chr9:5131312	T/A	cg02405213	chr9:5042618	JAK2	-1.02	-11.18	-0.75	5.05e-19	Pediatric autoimmune diseases;
THYM	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg21475434	chr5:93447410	FAM172A	0.96	6.1	0.53	2.29e-8	Diabetic retinopathy;
THYM	cis	rs611744	0.529	rs13282825	chr8:109263237	T/C	cg21045802	chr8:109455806	TTC35	0.63	5.66	0.5	1.62e-7	Dupuytren's disease;
THYM	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg27446573	chr6:127587934	RNF146	1.03	9.76	0.71	5.36e-16	Breast cancer;
THYM	cis	rs10916082	1	rs10916082	chr1:227252626	A/G	cg24860534	chr1:227506868	CDC42BPA	0.45	5.79	0.51	8.99e-8	Diastolic blood pressure;
THYM	cis	rs28595532	0.920	rs114037572	chr4:119735609	T/G	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs7584330	0.554	rs10178682	chr2:238433818	T/G	cg14458575	chr2:238380390	NA	0.82	4.89	0.45	4.16e-6	Prostate cancer;
THYM	cis	rs2456568	0.805	rs55649862	chr11:93682888	G/T	cg26875233	chr11:93583750	C11orf90	-0.5	-4.88	-0.45	4.28e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs9880211	1.000	rs28750366	chr3:136361055	T/C	cg21827317	chr3:136751795	NA	-0.69	-4.63	-0.43	1.14e-5	Body mass index;Height;
THYM	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg09467607	chr2:36825704	FEZ2	0.39	4.88	0.45	4.29e-6	Height;
THYM	cis	rs7927771	0.524	rs11039329	chr11:47684908	A/G	cg20307385	chr11:47447363	PSMC3	0.6	4.69	0.43	9.07e-6	Subjective well-being;
THYM	cis	rs763014	0.865	rs8675	chr16:633843	A/G	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs6543140	0.964	rs6761350	chr2:103030776	A/G	cg03938978	chr2:103052716	IL18RAP	0.61	6.13	0.53	1.96e-8	Blood protein levels;
THYM	cis	rs2806561	1.000	rs2473851	chr1:23489869	A/G	cg19743168	chr1:23544995	NA	0.62	6.64	0.56	1.93e-9	Height;
THYM	cis	rs9326248	0.509	rs533556	chr11:116741572	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.64	5.11	0.46	1.66e-6	Blood protein levels;
THYM	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg15549821	chr19:49342101	PLEKHA4	-1.21	-6.43	-0.55	5.11e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs26232	0.521	rs67019105	chr5:102374163	T/A	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Rheumatoid arthritis;
THYM	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg22709100	chr7:91322751	NA	-0.59	-4.77	-0.44	6.76e-6	Breast cancer;
THYM	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg23711669	chr6:146136114	FBXO30	0.9	9.23	0.69	7.15e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1160297	0.576	rs1451458	chr2:53088905	G/C	cg07782112	chr2:53107842	NA	0.77	6.31	0.54	8.76e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg12963246	chr6:28129442	ZNF389	0.72	6.2	0.54	1.44e-8	Depression;
THYM	cis	rs116095464	1.000	rs7736	chr5:314935	T/C	cg22857025	chr5:266934	NA	-1.41	-5.27	-0.48	8.69e-7	Breast cancer;
THYM	cis	rs7772486	0.632	rs9386128	chr6:146049053	G/A	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg26384229	chr12:38710491	ALG10B	1.0	7.61	0.62	1.97e-11	Bladder cancer;
THYM	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg00495681	chr13:53174319	NA	0.69	6.88	0.58	6.34e-10	Lewy body disease;
THYM	cis	rs6840360	0.530	rs12645029	chr4:152650032	T/C	cg22705602	chr4:152727874	NA	-0.86	-8.88	-0.67	3.99e-14	Intelligence (multi-trait analysis);
THYM	cis	rs6539288	0.899	rs2053206	chr12:107306179	A/G	cg26297688	chr12:107349093	C12orf23	-0.47	-4.89	-0.45	4.15e-6	Total body bone mineral density;
THYM	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg03676636	chr4:99064102	C4orf37	0.46	6.91	0.58	5.62e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs752010	0.806	rs4641303	chr1:42091310	A/G	cg06885757	chr1:42089581	HIVEP3	0.55	6.52	0.56	3.4e-9	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg26384229	chr12:38710491	ALG10B	1.02	8.22	0.64	1.05e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7927771	0.524	rs2869024	chr11:47674101	G/A	cg20307385	chr11:47447363	PSMC3	-0.59	-4.52	-0.42	1.75e-5	Subjective well-being;
THYM	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg23352942	chr3:46931381	PTH1R	-0.59	-5.29	-0.48	7.96e-7	Birth weight;
THYM	cis	rs11096990	0.929	rs56037933	chr4:39227273	A/G	cg24403649	chr4:39172243	NA	-0.65	-5.59	-0.5	2.13e-7	Cognitive function;
THYM	cis	rs6840360	1.000	rs1105536	chr4:152605027	C/T	cg22705602	chr4:152727874	NA	-0.59	-6.33	-0.54	8.23e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10924970	0.967	rs12731177	chr1:235463173	T/G	cg26050004	chr1:235667680	B3GALNT2	0.6	4.5	0.42	1.95e-5	Asthma;
THYM	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg18904891	chr8:8559673	CLDN23	0.62	5.14	0.47	1.47e-6	Mood instability;
THYM	cis	rs11696501	0.895	rs6130855	chr20:44148515	T/C	cg11783356	chr20:44313418	WFDC10B	-0.69	-4.64	-0.43	1.1e-5	Brain structure;
THYM	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg00814883	chr7:100076585	TSC22D4	-1.05	-6.68	-0.57	1.57e-9	Platelet count;
THYM	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg24503407	chr1:205819492	PM20D1	0.91	8.34	0.65	5.81e-13	Menarche (age at onset);
THYM	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2898681	0.614	rs10016904	chr4:53694296	C/A	cg00791764	chr4:53727839	RASL11B	0.43	5.42	0.49	4.42e-7	Optic nerve measurement (cup area);
THYM	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg09034736	chr1:150693464	HORMAD1	0.53	4.85	0.45	4.83e-6	Tonsillectomy;
THYM	cis	rs9616064	0.506	rs11705341	chr22:47066294	T/C	cg05621596	chr22:47072043	GRAMD4	-0.54	-4.58	-0.42	1.43e-5	Urate levels in obese individuals;
THYM	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7084402	0.967	rs10763551	chr10:60273898	G/A	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs35264875	0.808	rs2305498	chr11:68866914	G/A	cg01993067	chr11:68851601	TPCN2	0.74	4.62	0.43	1.21e-5	Blond vs. brown hair color;
THYM	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2288884	0.767	rs3450	chr19:52552999	T/C	cg05974498	chr19:52599256	ZNF841	0.36	4.52	0.42	1.78e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg01483505	chr11:975446	AP2A2	0.58	4.73	0.44	7.82e-6	Alzheimer's disease (late onset);
THYM	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg18876405	chr7:65276391	NA	-0.58	-4.99	-0.46	2.78e-6	Aortic root size;
THYM	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.06	0.68	1.73e-14	Chronic sinus infection;
THYM	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg27532560	chr4:187881888	NA	-0.96	-11.4	-0.76	1.72e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2067615	0.599	rs1579808	chr12:107239947	A/G	cg15890332	chr12:107067104	RFX4	-0.46	-5.49	-0.49	3.36e-7	Heart rate;
THYM	cis	rs9486719	1.000	rs2472888	chr6:96865501	T/C	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.94	7.1	0.59	2.21e-10	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg21028142	chr17:79581711	NPLOC4	0.62	6.13	0.53	1.96e-8	Eye color traits;
THYM	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.7	5.63	0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs2455799	0.613	rs2470548	chr3:15737689	G/A	cg16303742	chr3:15540471	COLQ	-0.55	-5.89	-0.52	5.95e-8	Mean platelet volume;
THYM	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs665401	0.965	rs654971	chr6:117220055	C/A	cg20376953	chr6:117187980	NA	0.6	4.82	0.44	5.5e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs4242434	0.672	rs6993302	chr8:22527457	T/C	cg03733263	chr8:22462867	KIAA1967	-0.97	-9.87	-0.71	3.09e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6866344	0.568	rs10516147	chr5:178094484	A/G	cg10224037	chr5:178157518	ZNF354A	0.79	5.08	0.46	1.9e-6	Neutrophil percentage of white cells;
THYM	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg22709100	chr7:91322751	NA	0.63	4.95	0.45	3.18e-6	Breast cancer;
THYM	cis	rs4901869	0.966	rs9972206	chr14:59336095	A/G	cg02291164	chr14:59296302	NA	0.8	7.85	0.63	6.35e-12	Panic disorder;
THYM	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg03060546	chr3:49711283	APEH	-0.68	-5.24	-0.47	9.81e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg04282206	chr17:62833786	PLEKHM1P	0.82	7.23	0.6	1.21e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7639513	0.767	rs9878151	chr3:12703714	G/C	cg23032965	chr3:12705835	RAF1	0.98	7.85	0.63	6.27e-12	Itch intensity from mosquito bite;
THYM	cis	rs800586	0.833	rs2694047	chr8:116750548	A/G	cg04656070	chr8:116661063	TRPS1	0.45	4.47	0.42	2.17e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg08773314	chr2:239334832	ASB1	0.64	9.92	0.71	2.51e-16	Multiple system atrophy;
THYM	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg06219351	chr7:158114137	PTPRN2	-0.8	-7.12	-0.59	2.04e-10	Response to amphetamines;
THYM	cis	rs6840360	0.571	rs7674244	chr4:152488302	T/C	cg17479576	chr4:152424074	FAM160A1	-0.8	-5.92	-0.52	5.02e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	trans	rs59551326	0.517	rs2829645	chr21:26590600	A/G	cg17452615	chr12:122019080	KDM2B	-0.8	-6.84	-0.57	7.67e-10	Alcohol dependence;
THYM	cis	rs3741151	0.773	rs57673166	chr11:73232557	T/A	cg17517138	chr11:73019481	ARHGEF17	0.9	4.73	0.44	7.74e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2282300	0.739	rs1222221	chr11:30342738	A/G	cg22891988	chr11:30607959	MPPED2	-0.69	-4.58	-0.43	1.41e-5	Morning vs. evening chronotype;
THYM	cis	rs9359856	0.673	rs1179897	chr6:90318624	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.77	-7.08	-0.59	2.53e-10	Bipolar disorder;
THYM	cis	rs59698941	0.943	rs73271090	chr5:132313550	G/A	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg11301795	chr4:187892539	NA	-1.09	-16.54	-0.86	1.01e-29	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg24006582	chr15:45444508	DUOX1	0.83	7.16	0.59	1.66e-10	Uric acid levels;
THYM	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.36	0.48	5.75e-7	Height;
THYM	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg25072359	chr17:41440525	NA	0.66	4.67	0.43	9.85e-6	Menopause (age at onset);
THYM	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	trans	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg01121180	chr19:51302454	C19orf48;SNORD88B	0.79	6.84	0.57	7.7e-10	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg22105103	chr4:187893119	NA	0.95	10.14	0.72	8.41e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10924970	0.967	rs4659721	chr1:235426917	C/T	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs9807841	0.544	rs10407692	chr19:10770783	A/G	cg16900796	chr19:10755136	SLC44A2	0.4	6.3	0.54	9.4e-9	Inflammatory skin disease;
THYM	cis	rs7187994	0.515	rs7199123	chr16:84776178	A/T	cg06246199	chr16:85458415	NA	-0.42	-4.48	-0.42	2.06e-5	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs7216064	1.000	rs73352808	chr17:65875157	G/A	cg12091567	chr17:66097778	LOC651250	-0.69	-4.65	-0.43	1.05e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11890956	chr21:40555474	PSMG1	-0.67	-6.25	-0.54	1.17e-8	Menarche (age at onset);
THYM	cis	rs198426	0.506	rs11230766	chr11:61426582	A/T	cg19838087	chr11:61442541	NA	-0.59	-6.79	-0.57	9.45e-10	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
THYM	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.99	-0.75	1.26e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg15536230	chr21:44985092	HSF2BP	-0.42	-5.04	-0.46	2.26e-6	Mean corpuscular volume;
THYM	cis	rs4363385	0.720	rs1970328	chr1:152975829	A/G	cg13444842	chr1:152974279	SPRR3	-0.57	-4.53	-0.42	1.74e-5	Inflammatory skin disease;
THYM	cis	rs4262150	0.883	rs12153328	chr5:152247221	T/C	cg06854687	chr5:151642065	NA	0.66	4.59	0.43	1.36e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs3772130	0.583	rs9819530	chr3:121387784	T/G	cg20356878	chr3:121714668	ILDR1	0.62	4.84	0.44	4.96e-6	Cognitive performance;
THYM	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4499344	0.556	rs438268	chr19:33109904	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.79	5.71	0.51	1.31e-7	Mean platelet volume;
THYM	cis	rs8077889	0.956	rs4792910	chr17:41840229	T/C	cg26893861	chr17:41843967	DUSP3	1.07	9.87	0.71	3.12e-16	Triglycerides;
THYM	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg06634786	chr22:41940651	POLR3H	-0.7	-5.35	-0.48	6.16e-7	Vitiligo;
THYM	cis	rs2963155	0.518	rs2963151	chr5:142734151	T/C	cg17617527	chr5:142782415	NR3C1	1.1	5.9	0.52	5.61e-8	Breast cancer;
THYM	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg19875535	chr5:140030758	IK	0.58	4.46	0.42	2.21e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs9430161	0.579	rs77578010	chr1:11035758	G/A	cg27631724	chr1:11040367	C1orf127	0.63	5.35	0.48	6.13e-7	Ewing sarcoma;
THYM	cis	rs9633740	1.000	rs7097656	chr10:82250831	T/C	cg01528321	chr10:82214614	TSPAN14	0.94	4.5	0.42	1.9e-5	Post bronchodilator FEV1;
THYM	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg14983838	chr19:29218262	NA	1.09	9.77	0.71	5e-16	Methadone dose in opioid dependence;
THYM	cis	rs1048238	0.506	rs848195	chr1:16286522	A/G	cg21385522	chr1:16154831	NA	-0.67	-5.57	-0.5	2.38e-7	Systolic blood pressure;
THYM	cis	rs9733	0.596	rs2867304	chr1:150630995	G/A	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs2303759	0.666	rs66967196	chr19:49808894	G/A	cg24324837	chr19:49891574	CCDC155	0.52	4.75	0.44	7.07e-6	Multiple sclerosis;
THYM	cis	rs240764	0.853	rs2001102	chr6:100978351	C/T	cg21058520	chr6:100914733	NA	0.57	5.03	0.46	2.35e-6	Neuroticism;
THYM	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg07777115	chr5:623756	CEP72	-0.79	-4.7	-0.43	8.8e-6	Obesity-related traits;
THYM	trans	rs877282	0.945	rs11253388	chr10:787852	A/G	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs2147904	0.934	rs783625	chr1:42365548	C/T	cg16685388	chr1:42384056	HIVEP3	0.56	4.65	0.43	1.05e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
THYM	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg13695892	chr22:41940480	POLR3H	-0.98	-7.92	-0.63	4.36e-12	Vitiligo;
THYM	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg00640147	chr17:61958756	GH2	-0.43	-4.54	-0.42	1.64e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg23187316	chr7:1099788	C7orf50	0.48	5.21	0.47	1.07e-6	Longevity;Endometriosis;
THYM	cis	rs68170813	0.559	rs77641084	chr7:106970522	G/A	cg00661777	chr7:106511741	PIK3CG	-0.68	-4.71	-0.44	8.28e-6	Coronary artery disease;
THYM	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg11843606	chr2:227700838	RHBDD1	-1.05	-6.92	-0.58	5.34e-10	Coronary artery disease;
THYM	cis	rs916888	0.558	rs199521	chr17:44853456	G/C	cg01570182	chr17:44337453	NA	-0.68	-7.33	-0.6	7.48e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	7.7	0.62	1.28e-11	Lung cancer in ever smokers;
THYM	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs7590720	1.000	rs6435930	chr2:216885852	A/G	cg12620499	chr2:216877984	MREG	0.89	6.31	0.54	8.76e-9	Alcohol dependence;
THYM	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.62	4.6	0.43	1.3e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg10803722	chr21:46713166	LOC642852	0.51	5.79	0.51	9.19e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10782582	0.593	rs12130832	chr1:76234294	T/C	cg03433033	chr1:76189801	ACADM	-0.5	-4.93	-0.45	3.51e-6	Daytime sleep phenotypes;
THYM	cis	rs2976388	1.000	rs2717562	chr8:143776668	T/C	cg06565975	chr8:143823917	SLURP1	-0.46	-5.49	-0.49	3.3e-7	Urinary tract infection frequency;
THYM	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg06481639	chr22:41940642	POLR3H	0.84	5.85	0.51	6.94e-8	Vitiligo;
THYM	cis	rs4474465	1.000	rs7943673	chr11:78172986	A/G	cg19901956	chr11:77921274	USP35	-0.6	-4.55	-0.42	1.56e-5	Alzheimer's disease (survival time);
THYM	cis	rs6430585	0.528	rs2278682	chr2:136743143	G/C	cg04750100	chr2:136595281	LCT	0.56	5.51	0.49	3.01e-7	Corneal structure;
THYM	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg20744362	chr22:50050164	C22orf34	0.79	7.19	0.59	1.5e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs7255436	0.894	rs10413136	chr19:8452879	T/C	cg10174797	chr19:8464628	RAB11B	0.43	5.19	0.47	1.18e-6	HDL cholesterol;
THYM	cis	rs16866061	1.000	rs72974222	chr2:225424143	C/T	cg22455342	chr2:225449267	CUL3	0.67	4.84	0.44	4.98e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	7.35	0.6	6.79e-11	Platelet count;
THYM	cis	rs2448490	0.642	rs507859	chr11:65471982	G/A	cg27068330	chr11:65405492	SIPA1	0.77	6.16	0.53	1.76e-8	Platelet count;
THYM	cis	rs713587	0.563	rs7591460	chr2:25103967	A/C	cg15423357	chr2:25149977	NA	0.62	6.14	0.53	1.91e-8	Body mass index in non-asthmatics;
THYM	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg23803603	chr1:2058230	PRKCZ	0.62	5.67	0.5	1.55e-7	Height;
THYM	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14893161	chr1:205819251	PM20D1	0.93	9.81	0.71	4.29e-16	Menarche (age at onset);
THYM	cis	rs10992471	0.729	rs1022844	chr9:95553464	A/T	cg14631576	chr9:95140430	CENPP	-0.85	-7.31	-0.6	8.31e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs9515201	0.859	rs9521735	chr13:111037328	G/C	cg05272587	chr13:111038400	COL4A2	-0.74	-6.15	-0.53	1.8e-8	White matter hyperintensity burden;
THYM	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg16342193	chr10:102329863	NA	-0.6	-6.25	-0.54	1.16e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs4474465	0.541	rs11237527	chr11:78219664	C/A	cg19901956	chr11:77921274	USP35	0.66	4.84	0.44	4.99e-6	Alzheimer's disease (survival time);
THYM	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs877282	1.000	rs11253361	chr10:770387	T/C	cg22713356	chr15:30763199	NA	1.27	10.11	0.72	9.46e-17	Uric acid levels;
THYM	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg24812749	chr6:127587940	RNF146	0.9	6.51	0.56	3.48e-9	Breast cancer;
THYM	cis	rs9831754	1.000	rs112170848	chr3:78359996	G/A	cg06138941	chr3:78371609	NA	-0.66	-4.47	-0.42	2.14e-5	Calcium levels;
THYM	cis	rs7084921	0.640	rs12773244	chr10:101865344	G/A	cg11344164	chr10:101878520	NA	-0.58	-4.98	-0.45	2.86e-6	Bone mineral density;
THYM	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg13736514	chr6:26305472	NA	-0.66	-6.8	-0.57	9.14e-10	Educational attainment;
THYM	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg27535305	chr1:53392650	SCP2	0.42	4.82	0.44	5.53e-6	Monocyte count;
THYM	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg21926883	chr2:100939477	LONRF2	-0.61	-5.71	-0.51	1.3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9644630	1.000	rs4921657	chr8:19370867	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.76	8.04	0.64	2.5e-12	Oropharynx cancer;
THYM	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4262150	0.883	rs17489682	chr5:152312444	T/G	cg06854687	chr5:151642065	NA	0.66	4.7	0.43	8.85e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg08885076	chr2:99613938	TSGA10	-0.66	-6.08	-0.53	2.47e-8	Chronic sinus infection;
THYM	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.76	4.9	0.45	3.98e-6	Smoking behavior;
THYM	cis	rs4731207	0.596	rs723444	chr7:124659224	G/A	cg05285228	chr7:124571219	POT1	-0.67	-5.2	-0.47	1.16e-6	Cutaneous malignant melanoma;
THYM	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.33	9.91	0.71	2.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.84	-5.77	-0.51	1e-7	Body mass index;
THYM	cis	rs9381107	0.660	rs9470548	chr6:9422242	A/G	cg27283345	chr6:10416531	TFAP2A	-0.47	-4.6	-0.43	1.3e-5	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs1457451	0.688	rs7589055	chr2:65862734	G/A	cg16240816	chr2:65861662	NA	0.69	8.5	0.66	2.57e-13	Iron status biomarkers;
THYM	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg17264618	chr3:40429014	ENTPD3	-0.53	-5.26	-0.47	9.05e-7	Renal cell carcinoma;
THYM	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg15536230	chr21:44985092	HSF2BP	-0.46	-5.69	-0.5	1.38e-7	Mean corpuscular volume;
THYM	cis	rs735396	0.731	rs1182933	chr12:121454622	C/T	cg02403541	chr12:121454288	C12orf43	0.77	6.64	0.56	1.91e-9	N-glycan levels;
THYM	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg03388043	chr17:80084554	CCDC57	-0.73	-6.17	-0.53	1.69e-8	Life satisfaction;
THYM	cis	rs12530845	0.623	rs73721681	chr7:135361917	A/G	cg23117316	chr7:135346802	PL-5283	-0.83	-6.31	-0.54	8.67e-9	Red blood cell traits;
THYM	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg04731861	chr2:219085781	ARPC2	-0.54	-5.22	-0.47	1.03e-6	Colorectal cancer;
THYM	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg05368731	chr17:41323189	NBR1	1.25	11.51	0.76	1.04e-19	Menopause (age at onset);
THYM	cis	rs7829975	0.632	rs68168815	chr8:8556865	G/C	cg15556689	chr8:8085844	FLJ10661	-0.57	-4.83	-0.44	5.27e-6	Mood instability;
THYM	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg22764044	chr5:178986830	RUFY1	-0.51	-5.4	-0.48	4.99e-7	Lung cancer;
THYM	cis	rs12594515	1.000	rs12906442	chr15:45985254	C/A	cg01629716	chr15:45996671	NA	0.54	5.52	0.49	2.91e-7	Waist circumference;Weight;
THYM	cis	rs59112743	0.510	rs9296977	chr6:15525492	T/C	cg10111214	chr6:14815676	NA	0.78	5.07	0.46	1.98e-6	Multiple keratinocyte cancers;
THYM	cis	rs12142240	0.698	rs6690075	chr1:46819848	G/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs8064299	0.597	rs2166703	chr17:72781812	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.88	8.63	0.66	1.37e-13	Monocyte count;
THYM	cis	rs16912285	0.688	rs12279442	chr11:24317174	C/G	ch.11.24196551F	chr11:24239977	NA	0.99	6.99	0.58	3.82e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg27286337	chr10:134555280	INPP5A	0.84	5.93	0.52	4.78e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	6.27	0.54	1.04e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10162002	0.872	rs3764067	chr13:24042897	T/C	cg00158254	chr13:24040743	NA	0.7	4.8	0.44	5.86e-6	Hypothyroidism;
THYM	cis	rs941408	0.515	rs1736193	chr19:2785273	G/C	cg16188243	chr19:2783719	SGTA	0.67	4.63	0.43	1.15e-5	Total cholesterol levels;
THYM	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg10803722	chr21:46713166	LOC642852	-0.42	-5.39	-0.48	5.04e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs854765	0.718	rs12943500	chr17:17790588	C/T	cg04398451	chr17:18023971	MYO15A	0.79	6.54	0.56	3.11e-9	Total body bone mineral density;
THYM	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27286337	chr10:134555280	INPP5A	-0.82	-5.75	-0.51	1.07e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg15556689	chr8:8085844	FLJ10661	0.81	7.49	0.61	3.51e-11	Neuroticism;
THYM	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg26612409	chr5:160335	PLEKHG4B	0.67	4.52	0.42	1.81e-5	Cystic fibrosis severity;
THYM	cis	rs10208649	1.000	rs2112120	chr2:54252094	G/C	cg04546899	chr2:54196757	PSME4	0.68	4.73	0.44	7.94e-6	Body mass index;
THYM	cis	rs10929159	0.928	rs2317305	chr2:236922151	G/A	cg20128773	chr2:236923534	AGAP1	0.35	4.66	0.43	1.01e-5	Parkinson's disease;
THYM	cis	rs6009824	0.836	rs6009821	chr22:50085697	C/T	cg27029450	chr22:50098074	NA	0.83	5.4	0.48	4.96e-7	Natriuretic peptide levels;
THYM	cis	rs10466239	0.892	rs10899791	chr10:43860054	G/A	cg12352960	chr10:43428578	NA	-0.98	-4.61	-0.43	1.23e-5	Telomere length;
THYM	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg11266682	chr4:10021025	SLC2A9	0.73	12.79	0.8	2.29e-22	Bone mineral density;
THYM	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6047844	0.750	rs6137527	chr20:22043921	C/T	cg16502866	chr20:23015624	SSTR4	-0.58	-4.46	-0.42	2.24e-5	Male-pattern baldness;
THYM	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg07220782	chr6:26987966	LOC100270746;C6orf41	0.49	4.52	0.42	1.8e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6669072	0.835	rs12046172	chr1:91325323	T/G	cg08895590	chr1:91227319	NA	-0.52	-5.79	-0.51	8.87e-8	Cognitive function;
THYM	cis	rs7772486	0.658	rs9403737	chr6:145962193	G/T	cg23711669	chr6:146136114	FBXO30	0.96	10.03	0.72	1.41e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11166927	0.524	rs7814631	chr8:140811743	T/C	cg16909799	chr8:140841666	TRAPPC9	0.57	4.63	0.43	1.14e-5	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg02398342	chr17:80708632	TBCD;FN3K	0.7	5.14	0.47	1.47e-6	Glycated hemoglobin levels;
THYM	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg06640241	chr16:89574553	SPG7	0.86	7.51	0.61	3.2e-11	Multiple myeloma (IgH translocation);
THYM	cis	rs1829883	0.898	rs1879360	chr5:98775330	G/A	cg08333243	chr5:99726346	NA	-0.55	-5.05	-0.46	2.15e-6	Hemostatic factors and hematological phenotypes;
THYM	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg05717871	chr11:638507	DRD4	-0.69	-6.03	-0.53	3.1e-8	Systemic lupus erythematosus;
THYM	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.84	4.66	0.43	1.04e-5	Initial pursuit acceleration;
THYM	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg02018176	chr4:1364513	KIAA1530	0.76	7.42	0.61	4.83e-11	Longevity;
THYM	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.69	6.58	0.56	2.51e-9	Lymphocyte counts;
THYM	cis	rs10425738	0.830	rs7249124	chr19:41437619	T/C	cg17435250	chr19:41386441	CYP2A7	-0.63	-4.52	-0.42	1.79e-5	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
THYM	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg24596788	chr1:163392923	NA	0.77	7.15	0.59	1.78e-10	Motion sickness;
THYM	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg04287289	chr16:89883240	FANCA	0.58	5.31	0.48	7.31e-7	Vitiligo;
THYM	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs1065852	0.503	rs9620006	chr22:42399547	T/A	cg08431931	chr22:42394659	WBP2NL	0.74	6.08	0.53	2.48e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs6138458	0.585	rs1007881	chr20:25014385	A/G	cg26195577	chr20:24973756	C20orf3	0.75	6.01	0.53	3.36e-8	Blood protein levels;
THYM	cis	rs7084402	0.935	rs1632584	chr10:60282078	T/C	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs9796	0.866	rs2176998	chr15:41420807	A/G	cg21153102	chr15:41252147	NA	0.72	6.66	0.56	1.76e-9	Menopause (age at onset);
THYM	cis	rs208520	0.690	rs866452	chr6:66849936	A/T	cg07460842	chr6:66804631	NA	-0.9	-6.53	-0.56	3.15e-9	Exhaled nitric oxide output;
THYM	cis	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg10856724	chr12:34555212	NA	-0.81	-8.07	-0.64	2.17e-12	Morning vs. evening chronotype;
THYM	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg10360139	chr7:1886902	MAD1L1	-0.58	-4.61	-0.43	1.23e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs8049040	0.586	rs13333985	chr16:71550853	T/C	cg08717414	chr16:71523259	ZNF19	-0.87	-5.29	-0.48	7.89e-7	Blood protein levels;
THYM	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19346786	chr7:2764209	NA	-0.71	-6.02	-0.53	3.29e-8	Height;
THYM	cis	rs12472274	0.817	rs12621791	chr2:239104061	G/A	cg17459225	chr2:239074497	NA	0.78	5.63	0.5	1.83e-7	Phospholipid levels (plasma);
THYM	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	6.88	0.58	6.35e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7567851	0.623	rs334072	chr2:179008705	G/C	cg17320194	chr2:178042734	NA	-0.89	-4.78	-0.44	6.32e-6	Height;
THYM	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg18252515	chr7:66147081	NA	-0.67	-5.09	-0.46	1.82e-6	Aortic root size;
THYM	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg19747945	chr6:42946146	PEX6	-0.34	-5.12	-0.46	1.61e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg20290983	chr6:43655470	MRPS18A	1.44	16.02	0.85	9.41e-29	IgG glycosylation;
THYM	cis	rs7901181	0.673	rs60602074	chr10:3676597	C/T	cg14302214	chr10:3805273	NA	-0.84	-4.88	-0.45	4.32e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg15445000	chr17:37608096	MED1	0.44	5.1	0.46	1.73e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7762018	0.607	rs75999653	chr6:170066927	A/G	cg19338460	chr6:170058176	WDR27	-1.04	-6.21	-0.54	1.42e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs208520	0.690	rs207118	chr6:66788948	T/A	cg07460842	chr6:66804631	NA	-1.06	-7.89	-0.63	5.14e-12	Exhaled nitric oxide output;
THYM	cis	rs4911259	0.552	rs11697394	chr20:31460076	G/A	cg13636640	chr20:31349939	DNMT3B	-0.61	-5.9	-0.52	5.6e-8	Inflammatory bowel disease;
THYM	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg21280719	chr6:42927975	GNMT	-0.53	-7.15	-0.59	1.75e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg25427524	chr10:38739819	LOC399744	0.66	6.36	0.55	6.98e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg21775007	chr8:11205619	TDH	0.73	6.63	0.56	2.04e-9	Retinal vascular caliber;
THYM	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg05872129	chr22:39784769	NA	-0.89	-7.68	-0.62	1.42e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs13102973	0.965	rs13108037	chr4:135885643	A/G	cg14419869	chr4:135874104	NA	-0.89	-8.63	-0.66	1.39e-13	Subjective well-being;
THYM	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg13695892	chr22:41940480	POLR3H	-0.63	-4.85	-0.45	4.81e-6	Neuroticism;
THYM	cis	rs10504073	0.584	rs56134839	chr8:49918899	C/T	cg00325661	chr8:49890786	NA	1.04	10.53	0.73	1.2e-17	Blood metabolite ratios;
THYM	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7078219	0.897	rs10883360	chr10:101281158	C/G	cg23904955	chr10:101282759	NA	-0.44	-5.07	-0.46	1.93e-6	Dental caries;
THYM	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs2637266	0.783	rs846583	chr10:78495658	T/A	cg18941641	chr10:78392320	NA	0.65	5.36	0.48	5.76e-7	Pulmonary function;
THYM	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg21427119	chr20:30132790	HM13	-0.96	-7.02	-0.58	3.34e-10	Mean corpuscular hemoglobin;
THYM	cis	rs16912285	0.688	rs12801367	chr11:24321827	G/A	ch.11.24196551F	chr11:24239977	NA	1.01	7.15	0.59	1.75e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs478304	0.654	rs10896032	chr11:65459419	C/A	cg27068330	chr11:65405492	SIPA1	-1.03	-10.31	-0.73	3.55e-17	Acne (severe);
THYM	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg22920501	chr2:26401640	FAM59B	1.07	9.54	0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-5.89	-0.52	5.81e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg04756594	chr16:24857601	SLC5A11	0.79	5.61	0.5	2e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs61931739	0.749	rs11053093	chr12:34231095	A/G	cg10856724	chr12:34555212	NA	-0.6	-5.51	-0.49	3e-7	Morning vs. evening chronotype;
THYM	cis	rs4653767	1.000	rs10495249	chr1:226919119	A/G	cg05262829	chr1:226921576	ITPKB	-0.48	-4.93	-0.45	3.45e-6	Parkinson's disease;
THYM	cis	rs3126085	0.667	rs12747821	chr1:152240424	G/A	cg26020982	chr1:152196106	HRNR	0.34	4.63	0.43	1.14e-5	Atopic dermatitis;
THYM	cis	rs4642101	1.000	rs4642101	chr3:12842223	T/G	cg05775895	chr3:12838266	CAND2	0.75	6.02	0.53	3.29e-8	QRS complex (12-leadsum);
THYM	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg22907277	chr7:1156413	C7orf50	0.87	7.58	0.61	2.31e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6539288	0.933	rs1037011	chr12:107302778	T/C	cg26297688	chr12:107349093	C12orf23	-0.47	-4.91	-0.45	3.79e-6	Total body bone mineral density;
THYM	cis	rs500891	0.525	rs1170339	chr6:84031251	T/C	cg08257003	chr6:84140564	ME1	0.56	4.47	0.42	2.19e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs7131987	0.903	rs2194519	chr12:29423583	C/T	cg09582351	chr12:29534625	ERGIC2	0.48	4.69	0.43	9.31e-6	QT interval;
THYM	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4523957	0.583	rs2641437	chr17:2019158	G/A	cg16513277	chr17:2031491	SMG6	-0.95	-8.83	-0.67	5.21e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9522267	0.535	rs12583489	chr13:112233455	G/A	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs1943345	0.519	rs11233504	chr11:82886525	A/G	cg07047830	chr11:82868014	PCF11	0.68	5.93	0.52	4.97e-8	Obesity-related traits;
THYM	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg11632617	chr15:75315747	PPCDC	-0.54	-4.58	-0.42	1.43e-5	Blood trace element (Zn levels);
THYM	cis	rs28595532	0.920	rs116094766	chr4:119729291	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg18811423	chr2:55921094	PNPT1	0.79	7.61	0.62	1.97e-11	Metabolic syndrome;
THYM	cis	rs9790314	0.695	rs7637086	chr3:160836822	T/C	cg03342759	chr3:160939853	NMD3	-0.6	-4.47	-0.42	2.18e-5	Morning vs. evening chronotype;
THYM	cis	rs10779751	0.959	rs2092642	chr1:11317320	C/T	cg08854313	chr1:11322531	MTOR	1.04	10.45	0.73	1.85e-17	Body mass index;
THYM	trans	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg07393940	chr7:158741817	NA	-1.14	-9.25	-0.69	6.69e-15	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg17426766	chr1:2046864	PRKCZ	0.4	4.78	0.44	6.41e-6	Height;
THYM	cis	rs7107174	1.000	rs2373009	chr11:77945815	T/A	cg02023728	chr11:77925099	USP35	0.73	6.33	0.54	7.9e-9	Testicular germ cell tumor;
THYM	cis	rs909002	0.800	rs1056526	chr1:32084904	C/T	cg13919466	chr1:32135498	COL16A1	-0.5	-5.13	-0.47	1.51e-6	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg01097406	chr16:89675127	NA	-0.55	-4.56	-0.42	1.52e-5	Vitiligo;
THYM	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg18402987	chr7:1209562	NA	0.81	5.12	0.46	1.6e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg25358565	chr5:93447407	FAM172A	1.35	10.38	0.73	2.61e-17	Diabetic retinopathy;
THYM	cis	rs728616	0.867	rs1923534	chr10:81710485	A/G	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.8	0.57	9.03e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.07	-10.85	-0.74	2.51e-18	Primary sclerosing cholangitis;
THYM	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg14024328	chr4:719362	PCGF3	-0.7	-4.6	-0.43	1.29e-5	White blood cell count;
THYM	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs35883536	1.000	rs2297715	chr1:101092594	A/G	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs2282930	0.512	rs737292	chr7:50718654	A/C	cg08586669	chr7:50727761	GRB10	-0.32	-4.8	-0.44	5.99e-6	Bone mineral density;
THYM	cis	rs1448094	0.511	rs61930582	chr12:86157387	T/C	cg00310523	chr12:86230176	RASSF9	0.53	4.6	0.43	1.32e-5	Major depressive disorder;
THYM	cis	rs4631830	0.540	rs2843562	chr10:51496796	A/G	cg10326726	chr10:51549505	MSMB	0.59	6.07	0.53	2.59e-8	Prostate-specific antigen levels;
THYM	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg08859206	chr1:53392774	SCP2	-0.5	-5.23	-0.47	1e-6	Monocyte count;
THYM	cis	rs3825942	1.000	rs6495085	chr15:74221313	G/C	cg23484268	chr15:74220776	LOXL1	0.5	4.81	0.44	5.74e-6	Glaucoma (exfoliation);
THYM	cis	rs4660306	0.961	rs7546268	chr1:45965340	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.43	-0.49	4.37e-7	Homocysteine levels;
THYM	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg23803603	chr1:2058230	PRKCZ	-0.57	-4.6	-0.43	1.31e-5	Height;
THYM	cis	rs10256972	0.552	rs6953538	chr7:1196974	A/G	cg22907277	chr7:1156413	C7orf50	0.81	6.95	0.58	4.67e-10	Longevity;Endometriosis;
THYM	cis	rs7584330	0.518	rs11888077	chr2:238424763	G/A	cg08992911	chr2:238395768	MLPH	1.16	6.81	0.57	8.75e-10	Prostate cancer;
THYM	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.68	-5.0	-0.46	2.64e-6	Colorectal cancer;
THYM	cis	rs1808579	0.904	rs1652343	chr18:21131929	T/C	cg14672496	chr18:21087552	C18orf8	0.52	4.8	0.44	5.85e-6	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
THYM	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg06558623	chr16:89946397	TCF25	1.15	6.38	0.55	6.37e-9	Skin colour saturation;
THYM	cis	rs1150668	0.799	rs2142730	chr6:28266149	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.66	-5.0	-0.46	2.59e-6	Pubertal anthropometrics;
THYM	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg10515332	chr4:99064459	C4orf37	0.67	5.33	0.48	6.48e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs72829446	0.556	rs10048219	chr17:7403792	C/T	cg02795151	chr17:7402630	POLR2A	0.55	5.6	0.5	2.12e-7	Androgen levels;
THYM	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg08994789	chr17:28903642	LRRC37B2	-1.05	-5.39	-0.48	5.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7404928	0.651	rs7202347	chr16:23951106	A/G	cg26685404	chr16:23957272	PRKCB	0.68	8.11	0.64	1.8e-12	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs6918586	1.000	rs198811	chr6:26128446	A/G	cg03517284	chr6:25882590	NA	-0.62	-4.6	-0.43	1.32e-5	Schizophrenia;
THYM	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg07930192	chr7:1003750	NA	0.58	4.8	0.44	5.88e-6	Longevity;Endometriosis;
THYM	cis	rs3925075	1.000	rs55742763	chr16:31340368	G/A	cg02846316	chr16:31340340	ITGAM	0.58	6.01	0.52	3.4e-8	IgA nephropathy;
THYM	cis	rs6964587	0.692	rs10236483	chr7:91797296	A/C	cg17063962	chr7:91808500	NA	0.98	8.49	0.66	2.78e-13	Breast cancer;
THYM	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg20203395	chr5:56204925	C5orf35	-0.66	-4.62	-0.43	1.22e-5	Initial pursuit acceleration;
THYM	cis	rs11089937	0.521	rs6001221	chr22:22539566	C/G	cg21401457	chr22:22472743	NA	0.58	4.88	0.45	4.28e-6	Periodontitis (PAL4Q3);
THYM	cis	rs55692411	0.517	rs13095697	chr3:50136463	G/A	cg14019146	chr3:50243930	SLC38A3	-0.61	-4.75	-0.44	7.08e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.14	0.47	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs754466	0.606	rs11002308	chr10:79594796	A/T	cg17075019	chr10:79541650	NA	-0.71	-5.92	-0.52	5.19e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12681287	0.609	rs13279850	chr8:87477800	C/T	cg27223183	chr8:87520930	FAM82B	-0.66	-4.94	-0.45	3.29e-6	Caudate activity during reward;
THYM	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.43	5.34	0.48	6.44e-7	Monocyte percentage of white cells;
THYM	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg22852734	chr6:133119734	C6orf192	1.28	8.61	0.66	1.55e-13	Type 2 diabetes nephropathy;
THYM	cis	rs611744	0.967	rs636399	chr8:109235569	G/A	cg21045802	chr8:109455806	TTC35	0.59	5.25	0.47	9.08e-7	Dupuytren's disease;
THYM	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	5.14	0.47	1.45e-6	Total body bone mineral density;
THYM	cis	rs72828912	0.731	rs9379634	chr6:24061896	A/G	cg26336265	chr6:25042955	NA	-0.86	-5.43	-0.49	4.31e-7	Squamous cell lung carcinoma;
THYM	cis	rs981844	0.890	rs55850399	chr4:154684906	C/T	cg09973105	chr4:154681532	RNF175	-0.66	-5.44	-0.49	4.11e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg09469691	chr10:81107165	PPIF	0.69	5.7	0.51	1.32e-7	Height;
THYM	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg04944784	chr2:26401820	FAM59B	-0.75	-5.49	-0.49	3.33e-7	Gut microbiome composition (summer);
THYM	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg00684032	chr4:1343700	KIAA1530	0.8	7.13	0.59	1.91e-10	Obesity-related traits;
THYM	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg10862848	chr6:42927986	GNMT	-0.51	-6.67	-0.56	1.66e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg14820908	chr5:178986412	RUFY1	-0.67	-7.49	-0.61	3.58e-11	Lung cancer;
THYM	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg21926883	chr2:100939477	LONRF2	-0.61	-5.71	-0.51	1.3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg06636001	chr8:8085503	FLJ10661	0.75	7.02	0.58	3.27e-10	Neuroticism;
THYM	cis	rs6032067	0.636	rs7272597	chr20:43908869	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.43	-4.76	-0.44	7e-6	Blood protein levels;
THYM	cis	rs1050631	0.592	rs1539823	chr18:33736261	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.32	0.48	6.94e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg10523679	chr1:76189770	ACADM	-0.83	-6.65	-0.56	1.82e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg16325326	chr1:53192061	ZYG11B	-0.73	-7.1	-0.59	2.23e-10	Monocyte count;
THYM	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7592578	0.679	rs62181019	chr2:191325414	A/G	cg11845111	chr2:191398756	TMEM194B	-0.96	-7.22	-0.6	1.26e-10	Diastolic blood pressure;
THYM	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg06221963	chr1:154839813	KCNN3	-0.89	-12.33	-0.78	2.04e-21	Prostate cancer;
THYM	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg07167872	chr1:205819463	PM20D1	0.56	4.57	0.42	1.46e-5	Parkinson's disease;
THYM	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs875971	1.000	rs2220626	chr7:65546062	C/T	cg11764359	chr7:65958608	NA	-0.82	-6.65	-0.56	1.85e-9	Aortic root size;
THYM	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg17063962	chr7:91808500	NA	1.11	11.51	0.76	1.05e-19	Breast cancer;
THYM	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg06766960	chr11:133703094	NA	-0.5	-4.74	-0.44	7.52e-6	Childhood ear infection;
THYM	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.58	0.5	2.25e-7	Tonsillectomy;
THYM	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg05283184	chr6:79620031	NA	0.88	8.41	0.65	4.04e-13	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.58	5.03	0.46	2.3e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9807989	0.524	rs7594402	chr2:103021267	A/T	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs6840360	0.642	rs4696092	chr4:152412603	T/C	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg22841779	chr14:105766346	BRF1	-0.48	-5.94	-0.52	4.72e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs8077889	0.956	rs4793026	chr17:41850508	A/G	cg26893861	chr17:41843967	DUSP3	1.04	9.19	0.69	9.09e-15	Triglycerides;
THYM	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg23815491	chr16:72088622	HP	0.77	6.1	0.53	2.28e-8	Fibrinogen levels;
THYM	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg21926883	chr2:100939477	LONRF2	-0.67	-6.31	-0.54	8.8e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg21280719	chr6:42927975	GNMT	-0.52	-7.09	-0.59	2.35e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg24692254	chr21:30365293	RNF160	-0.69	-4.7	-0.43	8.85e-6	Cognitive test performance;
THYM	cis	rs11696501	0.688	rs6124726	chr20:44307866	T/A	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.99	7.87	0.63	5.54e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg26769984	chr7:1090371	C7orf50	0.82	5.3	0.48	7.56e-7	Bronchopulmonary dysplasia;
THYM	cis	rs36051895	0.589	rs16922772	chr9:5194521	C/A	cg02405213	chr9:5042618	JAK2	-0.88	-8.73	-0.67	8.56e-14	Pediatric autoimmune diseases;
THYM	cis	rs9633835	0.584	rs72867447	chr11:13301875	C/G	cg13286116	chr11:13302098	ARNTL	-0.8	-9.59	-0.7	1.23e-15	Body mass index;
THYM	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.58	5.92	0.52	4.99e-8	Eosinophil percentage of white cells;
THYM	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.27	10.84	0.74	2.66e-18	Platelet count;
THYM	cis	rs6429082	0.818	rs291383	chr1:235643100	G/A	cg26050004	chr1:235667680	B3GALNT2	0.76	6.72	0.57	1.36e-9	Adiposity;
THYM	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14240646	chr10:27532245	ACBD5	-0.82	-4.7	-0.43	8.74e-6	Breast cancer;
THYM	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg22907277	chr7:1156413	C7orf50	0.81	4.98	0.45	2.9e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6429082	0.715	rs2153204	chr1:235580382	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.63	-5.31	-0.48	7.25e-7	Adiposity;
THYM	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.83	-6.89	-0.58	6.14e-10	Menarche (age at onset);
THYM	cis	rs1981331	0.609	rs76937225	chr21:48069682	C/T	cg17243659	chr21:48055224	PRMT2	1.36	6.3	0.54	9.09e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs17401966	0.800	rs12122029	chr1:10339822	G/A	cg19773385	chr1:10388646	KIF1B	-0.57	-4.49	-0.42	2.04e-5	Hepatocellular carcinoma;
THYM	cis	rs6665290	0.935	rs6659424	chr1:227197875	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs6840360	0.571	rs11729136	chr4:152529227	C/A	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7833986	0.501	rs2976044	chr8:56986737	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	6.73	0.57	1.25e-9	Height;
THYM	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.17	0.47	1.31e-6	Electroencephalogram traits;
THYM	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg13395646	chr4:1353034	KIAA1530	-0.58	-5.54	-0.49	2.71e-7	Obesity-related traits;
THYM	cis	rs2336384	0.858	rs74976972	chr1:12068546	C/T	cg24492058	chr1:12203751	TNFRSF8	-0.53	-4.65	-0.43	1.06e-5	Platelet count;
THYM	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg04287289	chr16:89883240	FANCA	0.65	5.87	0.52	6.49e-8	Vitiligo;
THYM	cis	rs9543976	0.557	rs6562916	chr13:76171222	A/G	cg01531495	chr13:76123901	UCHL3	0.66	4.8	0.44	5.85e-6	Diabetic retinopathy;
THYM	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs790123	0.553	rs1106346	chr3:122354037	A/G	cg15604389	chr3:122379662	NA	0.59	5.25	0.47	9.27e-7	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg02725872	chr8:58115012	NA	-1.09	-8.15	-0.64	1.43e-12	Developmental language disorder (linguistic errors);
THYM	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg27170947	chr2:26402098	FAM59B	-0.61	-5.04	-0.46	2.25e-6	Gut microbiome composition (summer);
THYM	cis	rs1050631	0.592	rs1785927	chr18:33726447	C/G	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.58	4.56	0.42	1.54e-5	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs4363385	0.818	rs426360	chr1:153014710	C/T	cg13444842	chr1:152974279	SPRR3	-0.59	-4.81	-0.44	5.72e-6	Inflammatory skin disease;
THYM	cis	rs11627756	0.846	rs12887440	chr14:103083899	G/A	cg27124170	chr14:102829869	TECPR2;CINP	-0.65	-4.47	-0.42	2.15e-5	Mean platelet volume;
THYM	cis	rs4803468	1.000	rs284658	chr19:41929988	G/A	cg09537434	chr19:41945824	ATP5SL	-1.1	-10.47	-0.73	1.66e-17	Height;
THYM	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg09455208	chr3:40491958	NA	0.46	4.57	0.42	1.48e-5	Renal cell carcinoma;
THYM	cis	rs4363385	0.510	rs11488175	chr1:153039778	A/G	cg13444842	chr1:152974279	SPRR3	0.62	5.01	0.46	2.48e-6	Inflammatory skin disease;
THYM	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg06028808	chr11:68637592	NA	0.71	7.73	0.62	1.13e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11771526	0.901	rs62457469	chr7:32303052	T/C	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg10150615	chr22:24372951	LOC391322	-1.01	-11.54	-0.76	9.13e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7246967	0.673	rs12985495	chr19:22930378	A/G	cg05241461	chr19:22816980	ZNF492	0.59	4.61	0.43	1.26e-5	Bronchopulmonary dysplasia;
THYM	cis	rs3820068	0.608	rs58140482	chr1:16043979	A/G	cg13390004	chr1:15929781	NA	0.65	4.81	0.44	5.56e-6	Systolic blood pressure;
THYM	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg19507638	chr5:93509721	C5orf36	-0.67	-4.48	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Body mass index;
THYM	cis	rs59698941	0.943	rs73259116	chr5:132218461	A/G	cg02081065	chr5:132209139	LEAP2	-0.85	-5.74	-0.51	1.14e-7	Apolipoprotein A-IV levels;
THYM	cis	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg10856724	chr12:34555212	NA	-0.78	-6.99	-0.58	3.83e-10	Morning vs. evening chronotype;
THYM	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	6.51	0.56	3.5e-9	Total body bone mineral density;
THYM	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg12031863	chr16:4587854	C16orf5	-0.43	-4.48	-0.42	2.08e-5	Schizophrenia;
THYM	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs752010	0.811	rs10749836	chr1:42086860	G/C	cg13396354	chr1:41153348	NA	-0.47	-4.65	-0.43	1.08e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg09184832	chr6:79620586	NA	-0.58	-4.83	-0.44	5.2e-6	Intelligence (multi-trait analysis);
THYM	cis	rs28785552	1.000	rs28785552	chr19:53234161	G/A	cg10871876	chr19:53194124	ZNF83	0.81	6.93	0.58	5.12e-10	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10256972	0.552	rs6953538	chr7:1196974	A/G	cg03188948	chr7:1209495	NA	0.88	6.81	0.57	8.99e-10	Longevity;Endometriosis;
THYM	cis	rs1348850	0.645	rs4893963	chr2:178430747	A/G	cg27490568	chr2:178487706	NA	-0.54	-4.86	-0.45	4.64e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs11096990	0.892	rs28639548	chr4:39187150	G/C	cg24403649	chr4:39172243	NA	-0.65	-5.47	-0.49	3.69e-7	Cognitive function;
THYM	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg01819863	chr10:32635814	EPC1	1.04	6.59	0.56	2.43e-9	Sexual dysfunction (female);
THYM	cis	rs1003719	0.641	rs13046844	chr21:38517603	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-4.72	-0.44	8.18e-6	Eye color traits;
THYM	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg19904058	chr10:135279010	LOC619207	-0.57	-5.32	-0.48	7.02e-7	Systemic lupus erythematosus;
THYM	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg23758822	chr17:41437982	NA	1.19	11.23	0.76	3.96e-19	Menopause (age at onset);
THYM	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg13609457	chr4:120235615	NA	0.53	4.89	0.45	4.12e-6	Corneal astigmatism;
THYM	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg06636551	chr8:101224915	SPAG1	0.75	5.9	0.52	5.52e-8	Atrioventricular conduction;
THYM	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg21605333	chr4:119757512	SEC24D	1.54	6.13	0.53	1.97e-8	Cannabis dependence symptom count;
THYM	cis	rs11696501	0.739	rs4812938	chr20:44249919	T/A	cg11783356	chr20:44313418	WFDC10B	-0.66	-4.52	-0.42	1.77e-5	Brain structure;
THYM	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg16624210	chr5:671434	TPPP	0.7	5.14	0.47	1.45e-6	Obesity-related traits;
THYM	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg22467129	chr15:76604101	ETFA	-0.56	-5.26	-0.47	9.01e-7	Blood metabolite levels;
THYM	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs2046867	0.862	rs11922180	chr3:72836119	A/G	cg25664220	chr3:72788482	NA	0.9	7.18	0.59	1.54e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg01386294	chr6:25732093	NA	0.89	4.51	0.42	1.84e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg20283391	chr11:68216788	NA	-0.69	-5.14	-0.47	1.49e-6	Total body bone mineral density;
THYM	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg07959070	chr22:50026188	C22orf34	-0.25	-4.69	-0.43	9.18e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6759518	0.793	rs7437	chr2:27439751	G/T	cg25309888	chr2:27988724	NA	1.06	4.5	0.42	1.91e-5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
THYM	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.77	-0.44	6.76e-6	Mean corpuscular volume;
THYM	cis	rs6964587	0.605	rs6956022	chr7:91553199	A/G	cg17063962	chr7:91808500	NA	-1.02	-9.26	-0.69	6.44e-15	Breast cancer;
THYM	trans	rs2521263	0.606	rs2651827	chr11:2306833	C/T	cg00500498	chr6:169653935	THBS2	-1.04	-7.02	-0.58	3.27e-10	Obesity-related traits;
THYM	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg17252645	chr8:143867129	LY6D	-0.85	-10.51	-0.73	1.35e-17	Urinary tract infection frequency;
THYM	cis	rs11096990	0.927	rs56009503	chr4:39244262	C/T	cg24403649	chr4:39172243	NA	-0.67	-5.68	-0.5	1.5e-7	Cognitive function;
THYM	cis	rs5821446	1	rs5821446	chr17:65962538	A/AT	cg12091567	chr17:66097778	LOC651250	0.71	4.93	0.45	3.51e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg04944784	chr2:26401820	FAM59B	-1.08	-8.57	-0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs6448317	0.954	rs13116026	chr4:24922242	T/A	cg22968281	chr4:24586266	DHX15	0.66	4.53	0.42	1.69e-5	Heschl's gyrus morphology;
THYM	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.78	-4.88	-0.45	4.27e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs983545	0.800	rs1837698	chr3:16959075	C/A	cg24159436	chr3:16974681	PLCL2	0.33	5.03	0.46	2.32e-6	Blood protein levels;
THYM	cis	rs2282300	0.739	rs6484478	chr11:30306440	A/G	cg06241208	chr11:30344200	C11orf46	0.78	5.65	0.5	1.67e-7	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg06634786	chr22:41940651	POLR3H	-0.77	-5.73	-0.51	1.16e-7	Vitiligo;
THYM	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg09877947	chr5:131593287	PDLIM4	0.7	6.33	0.54	7.92e-9	Acylcarnitine levels;
THYM	cis	rs1167827	0.680	rs1167800	chr7:75176196	G/A	cg15428835	chr7:75027521	TRIM73;TRIM74	-0.76	-6.38	-0.55	6.32e-9	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg06636001	chr8:8085503	FLJ10661	0.76	6.85	0.57	7.41e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg11812906	chr14:75593930	NEK9	-0.89	-8.02	-0.64	2.74e-12	Height;
THYM	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs28595532	0.920	rs116697254	chr4:119733603	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs9733	0.596	rs2175615	chr1:150624101	A/G	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg11764359	chr7:65958608	NA	-0.69	-4.67	-0.43	9.75e-6	Aortic root size;
THYM	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg16928487	chr17:17741425	SREBF1	0.56	5.36	0.48	5.91e-7	Total body bone mineral density;
THYM	cis	rs9522267	0.535	rs9515453	chr13:112234612	T/C	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg19774624	chr17:42201019	HDAC5	0.78	7.24	0.6	1.15e-10	Total body bone mineral density;
THYM	cis	rs7772486	0.790	rs9390365	chr6:146235626	A/G	cg23711669	chr6:146136114	FBXO30	-0.96	-9.96	-0.71	2.04e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs741677	0.663	rs441438	chr17:491006	C/T	cg15660573	chr17:549704	VPS53	0.71	5.56	0.5	2.52e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
THYM	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.83	5.25	0.47	9.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.34	-0.48	6.28e-7	Menopause (age at onset);
THYM	cis	rs1403694	0.695	rs11927941	chr3:186433046	A/G	cg12454167	chr3:186435060	KNG1	0.5	6.72	0.57	1.35e-9	Blood protein levels;
THYM	cis	rs2984613	1	rs2984613	chr1:156197380	C/T	cg06970220	chr1:156163860	SLC25A44	0.7	5.73	0.51	1.19e-7	Intracerebral hemorrhage;White matter hyperintensity burden;
THYM	cis	rs425277	0.583	rs3128334	chr1:2038662	G/A	cg23682913	chr1:2080710	PRKCZ	-0.6	-5.33	-0.48	6.54e-7	Height;
THYM	cis	rs11671005	0.735	rs11668814	chr19:58946833	T/C	cg18639983	chr19:58920768	ZNF584	0.59	4.82	0.44	5.48e-6	Mean platelet volume;
THYM	cis	rs6988636	1.000	rs13260318	chr8:124190165	C/G	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs6960043	0.875	rs10249299	chr7:15054391	C/T	cg19272540	chr7:15055459	NA	0.51	5.35	0.48	6e-7	Type 2 diabetes;
THYM	cis	rs4481887	1.000	rs10888352	chr1:248451965	G/A	cg00666640	chr1:248458726	OR2T12	0.56	4.53	0.42	1.69e-5	Common traits (Other);
THYM	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs10979	0.894	rs6924940	chr6:143906183	C/T	cg25407410	chr6:143891975	LOC285740	-0.62	-4.94	-0.45	3.32e-6	Hypospadias;
THYM	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg26131816	chr17:42072204	PYY	0.53	4.6	0.43	1.28e-5	Menopause (age at onset);
THYM	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg18876405	chr7:65276391	NA	-0.71	-6.62	-0.56	2.12e-9	Aortic root size;
THYM	cis	rs2073300	1.000	rs6132620	chr20:23436654	A/G	cg12062639	chr20:23401060	NAPB	0.99	4.9	0.45	3.87e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6500602	0.778	rs7184899	chr16:4472087	T/A	cg08645402	chr16:4508243	NA	0.61	5.22	0.47	1.05e-6	Schizophrenia;
THYM	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg22496339	chr2:162101262	NA	-0.66	-5.79	-0.51	8.92e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg09034736	chr1:150693464	HORMAD1	0.51	4.49	0.42	1.98e-5	Tonsillectomy;
THYM	cis	rs6430585	0.528	rs309161	chr2:136688749	A/G	cg04750100	chr2:136595281	LCT	-0.56	-5.51	-0.49	3.01e-7	Corneal structure;
THYM	cis	rs6669072	0.809	rs1188933	chr1:91305125	A/C	cg08895590	chr1:91227319	NA	0.5	5.46	0.49	3.72e-7	Cognitive function;
THYM	cis	rs4888262	0.526	rs6564145	chr16:74621129	G/A	cg01733217	chr16:74700730	RFWD3	0.82	8.54	0.66	2.2e-13	Testicular germ cell tumor;
THYM	cis	rs4808199	0.895	rs10403731	chr19:19469296	G/A	cg03709012	chr19:19516395	GATAD2A	1.07	6.07	0.53	2.58e-8	Nonalcoholic fatty liver disease;
THYM	cis	rs4713118	0.662	rs9393881	chr6:28023751	C/G	cg23161317	chr6:28129485	ZNF389	0.99	7.12	0.59	2.01e-10	Parkinson's disease;
THYM	cis	rs4660306	0.961	rs4660867	chr1:45986484	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.43	-0.49	4.37e-7	Homocysteine levels;
THYM	cis	rs2404602	0.735	rs4886495	chr15:76738959	C/T	cg23625390	chr15:77176239	SCAPER	0.69	5.07	0.46	1.93e-6	Blood metabolite levels;
THYM	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg09260853	chr1:2094483	PRKCZ	-0.44	-4.56	-0.42	1.5e-5	Height;
THYM	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.64	-0.74	7.23e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs2237457	0.543	rs2262465	chr7:50702665	G/C	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.48e-6	Schizophrenia (treatment resistant);
THYM	cis	rs6956675	0.831	rs10268923	chr7:62652624	C/G	cg27518014	chr7:62859535	LOC100287834	0.59	4.8	0.44	5.95e-6	Obesity-related traits;
THYM	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg22875332	chr1:76189707	ACADM	-0.55	-5.23	-0.47	9.9e-7	Daytime sleep phenotypes;
THYM	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg10792982	chr14:105748885	BRF1	0.76	7.95	0.63	3.92e-12	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg20486651	chr6:167070296	RPS6KA2	0.5	4.73	0.44	7.7e-6	Crohn's disease;
THYM	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg26384229	chr12:38710491	ALG10B	1.07	10.43	0.73	2.04e-17	Heart rate;
THYM	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg21475434	chr5:93447410	FAM172A	-0.91	-5.43	-0.49	4.3e-7	Diabetic retinopathy;
THYM	cis	rs3106136	0.546	rs183993	chr4:95130025	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.1	-0.46	1.7e-6	Capecitabine sensitivity;
THYM	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs4808199	0.948	rs757001	chr19:19448808	G/A	cg03709012	chr19:19516395	GATAD2A	1.1	6.32	0.54	8.6e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs4474465	0.850	rs4945289	chr11:78245334	G/T	cg19901956	chr11:77921274	USP35	0.61	4.6	0.43	1.3e-5	Alzheimer's disease (survival time);
THYM	cis	rs17006441	0.932	rs6795463	chr3:69846108	A/C	cg18496212	chr3:69797108	MITF	-0.66	-6.5	-0.55	3.66e-9	Hemoglobin concentration;
THYM	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.43	0.61	4.69e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9972944	0.756	rs8072765	chr17:63763508	T/C	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs7828089	0.624	rs7001171	chr8:22270040	T/G	cg13512537	chr8:22265999	SLC39A14	-0.74	-5.94	-0.52	4.64e-8	Verbal declarative memory;
THYM	cis	rs7810240	0.762	rs10282108	chr7:150082610	A/G	cg17279839	chr7:150038598	RARRES2	-0.48	-4.52	-0.42	1.81e-5	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
THYM	cis	rs3741151	0.773	rs17244596	chr11:73179236	A/G	cg17517138	chr11:73019481	ARHGEF17	0.94	5.48	0.49	3.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2070677	0.935	rs4350328	chr10:135414948	G/A	cg20169779	chr10:135381914	SYCE1	-0.74	-5.57	-0.5	2.34e-7	Gout;
THYM	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg19052272	chr2:3704530	ALLC	-0.68	-5.08	-0.46	1.92e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs6901250	0.819	rs9374623	chr6:117127312	C/A	cg12892004	chr6:117198278	RFX6	0.71	6.96	0.58	4.39e-10	C-reactive protein levels;
THYM	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg10047753	chr17:41438598	NA	1.18	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.69	5.35	0.48	5.98e-7	Tonsillectomy;
THYM	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10479542	0.766	rs2411380	chr5:178973780	T/C	cg09060608	chr5:178986726	RUFY1	-0.49	-4.72	-0.44	7.99e-6	Lung cancer;
THYM	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg00677455	chr12:58241039	CTDSP2	0.72	4.87	0.45	4.51e-6	Multiple sclerosis;
THYM	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg11266682	chr4:10021025	SLC2A9	0.75	12.66	0.79	4.08e-22	Bone mineral density;
THYM	cis	rs6496667	1.000	rs7178663	chr15:90897058	C/T	cg22089800	chr15:90895588	ZNF774	0.84	4.96	0.45	3.04e-6	Rheumatoid arthritis;
THYM	cis	rs4499344	0.633	rs259239	chr19:33141090	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.96	8.04	0.64	2.53e-12	Mean platelet volume;
THYM	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg17105886	chr17:28927953	LRRC37B2	1.32	6.56	0.56	2.79e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg06850241	chr22:41845214	NA	-0.49	-4.75	-0.44	7.2e-6	Vitiligo;
THYM	cis	rs7731657	0.537	rs6595978	chr5:130335009	G/A	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs7260598	0.642	rs10407805	chr19:24165705	C/T	cg15526094	chr19:24182596	NA	-0.66	-4.72	-0.44	8.18e-6	Response to taxane treatment (placlitaxel);
THYM	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs969413	0.624	rs7213540	chr17:79255912	C/T	cg06324037	chr17:79279053	C17orf55	0.45	4.45	0.42	2.31e-5	Frontotemporal dementia;
THYM	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-4.73	-0.44	7.69e-6	Alzheimer's disease;
THYM	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg06481639	chr22:41940642	POLR3H	0.73	4.68	0.43	9.66e-6	Vitiligo;
THYM	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg11301795	chr4:187892539	NA	1.11	18.94	0.89	5.16e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg19761014	chr17:28927070	LRRC37B2	0.76	4.73	0.44	7.7e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs61931739	0.578	rs12426748	chr12:33596654	G/T	cg06521331	chr12:34319734	NA	0.61	4.54	0.42	1.65e-5	Morning vs. evening chronotype;
THYM	cis	rs611744	0.934	rs1989388	chr8:109220269	A/T	cg21045802	chr8:109455806	TTC35	0.71	5.57	0.5	2.41e-7	Dupuytren's disease;
THYM	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg07936489	chr17:37558343	FBXL20	-0.83	-5.84	-0.51	7.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs7586879	0.719	rs7565468	chr2:25130092	C/T	cg01884057	chr2:25150051	NA	0.52	4.64	0.43	1.12e-5	Body mass index;
THYM	cis	rs4149423	1.000	rs4149423	chr2:108916044	A/G	cg13968390	chr2:108904812	SULT1C2	-0.78	-5.16	-0.47	1.33e-6	Lobe size;
THYM	cis	rs7546094	0.935	rs10776757	chr1:113121673	G/C	cg25616829	chr1:112535356	NA	0.57	4.72	0.44	8.11e-6	Platelet distribution width;
THYM	cis	rs13070279	0.708	rs2322143	chr3:71825873	C/A	cg19388776	chr3:71835112	PROK2	-0.73	-4.69	-0.43	9.25e-6	Monocyte count;
THYM	cis	rs17174870	0.725	rs3811632	chr2:112754828	G/T	cg17354880	chr2:112658759	MERTK	-0.55	-4.6	-0.43	1.28e-5	Multiple sclerosis;
THYM	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg27534772	chr1:16042836	PLEKHM2	0.54	5.92	0.52	5.1e-8	Systolic blood pressure;
THYM	cis	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg12981288	chr8:11183844	MTMR9	0.46	4.56	0.42	1.52e-5	Retinal vascular caliber;
THYM	trans	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg23958373	chr8:599963	NA	-1.01	-4.56	-0.42	1.51e-5	IgG glycosylation;
THYM	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg24308560	chr3:49941425	MST1R	0.8	6.84	0.57	7.6e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6988636	1.000	rs6988636	chr8:124185970	A/G	cg23067535	chr8:124195133	FAM83A	-1.1	-5.77	-0.51	9.8e-8	Urinary uromodulin levels;
THYM	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.68	5.08	0.46	1.89e-6	Tonsillectomy;
THYM	cis	rs11677370	0.574	rs11686118	chr2:3854938	C/T	cg17052675	chr2:3827356	NA	-0.7	-6.51	-0.56	3.54e-9	Type 2 diabetes;
THYM	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.91	8.14	0.64	1.49e-12	Monocyte percentage of white cells;
THYM	cis	rs4919669	0.668	rs11191359	chr10:104401486	A/T	cg24934431	chr10:104597864	CYP17A1	0.59	4.93	0.45	3.51e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
THYM	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg06481639	chr22:41940642	POLR3H	0.8	5.61	0.5	2e-7	Vitiligo;
THYM	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg08213375	chr14:104286397	PPP1R13B	-0.51	-5.54	-0.49	2.73e-7	Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs854765	0.624	rs9899634	chr17:17727943	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.59	-5.12	-0.47	1.59e-6	Total body bone mineral density;
THYM	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg06713675	chr4:122721982	EXOSC9	-0.89	-10.5	-0.73	1.43e-17	Type 2 diabetes;
THYM	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.81	6.44	0.55	4.85e-9	Lung cancer in ever smokers;
THYM	cis	rs1448094	0.621	rs7133309	chr12:86284078	T/C	cg02569458	chr12:86230093	RASSF9	0.52	4.71	0.44	8.37e-6	Major depressive disorder;
THYM	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg03060546	chr3:49711283	APEH	-0.74	-6.21	-0.54	1.42e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs28512361	0.502	rs134859	chr22:46066043	G/C	cg00273220	chr22:46667083	TTC38	0.82	4.85	0.45	4.89e-6	Breast cancer;
THYM	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg03351412	chr1:154909251	PMVK	0.73	5.58	0.5	2.3e-7	Prostate cancer;
THYM	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg22496339	chr2:162101262	NA	0.94	9.01	0.68	2.19e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs2806561	0.704	rs636940	chr1:23522967	A/T	cg19743168	chr1:23544995	NA	0.62	6.31	0.54	8.74e-9	Height;
THYM	cis	rs67311347	0.544	rs2278930	chr3:40351092	C/T	cg13683864	chr3:40499215	RPL14	-0.7	-6.3	-0.54	9.16e-9	Renal cell carcinoma;
THYM	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	8.1	0.64	1.86e-12	Monocyte percentage of white cells;
THYM	cis	rs4460079	0.507	rs4834363	chr4:114837676	C/T	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs912057	0.833	rs1294424	chr6:6744135	G/A	cg13809441	chr6:6737631	NA	0.43	4.86	0.45	4.62e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs9790314	1.000	rs7647327	chr3:161016421	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-6.29	-0.54	9.45e-9	Morning vs. evening chronotype;
THYM	cis	rs6121246	0.567	rs7266471	chr20:30220599	T/A	cg21427119	chr20:30132790	HM13	-0.96	-6.95	-0.58	4.65e-10	Mean corpuscular hemoglobin;
THYM	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg20891283	chr12:69753455	YEATS4	0.73	6.09	0.53	2.39e-8	Blood protein levels;
THYM	cis	rs9394152	0.845	rs9380367	chr6:33474975	G/A	cg13560919	chr6:33536144	NA	0.73	6.26	0.54	1.09e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs10193935	0.901	rs62142596	chr2:42529339	C/T	cg27598129	chr2:42591480	NA	-0.71	-4.56	-0.42	1.5e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11651000	0.761	rs11657388	chr17:45820707	C/G	cg24803719	chr17:45855879	NA	-0.54	-5.58	-0.5	2.29e-7	IgG glycosylation;
THYM	cis	rs295137	0.836	rs1217456	chr2:201092279	C/T	cg22973789	chr2:200321011	SATB2	0.59	4.48	0.42	2.09e-5	Asthma (bronchodilator response);
THYM	cis	rs7926906	0.840	rs7926034	chr11:90514796	A/G	cg26138821	chr11:89956704	CHORDC1	-0.59	-5.44	-0.49	4.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg08125733	chr17:73851984	WBP2	1.35	6.66	0.56	1.81e-9	Psoriasis;
THYM	cis	rs2050392	0.517	rs160018	chr10:30772703	T/C	cg02070205	chr10:30722105	MAP3K8	-0.62	-5.01	-0.46	2.51e-6	Inflammatory bowel disease;
THYM	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg26384229	chr12:38710491	ALG10B	-0.89	-9.06	-0.68	1.67e-14	Heart rate;
THYM	cis	rs2273669	0.667	rs7765732	chr6:109347057	A/C	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs6032067	0.929	rs17424668	chr20:43809647	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	0.74	8.23	0.64	1e-12	Blood protein levels;
THYM	cis	rs9928842	0.823	rs8061356	chr16:75294232	G/A	cg09066997	chr16:75300724	BCAR1	0.71	4.51	0.42	1.88e-5	Alcoholic chronic pancreatitis;
THYM	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg17063962	chr7:91808500	NA	1.1	12.12	0.78	5.59e-21	Breast cancer;
THYM	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg04398451	chr17:18023971	MYO15A	-0.76	-6.96	-0.58	4.39e-10	Total body bone mineral density;
THYM	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg06009448	chr7:1102226	C7orf50	0.53	5.55	0.49	2.6e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3760982	0.585	rs11083724	chr19:44298988	A/G	cg11993925	chr19:44307056	LYPD5	0.64	5.02	0.46	2.4e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11039798	0.778	rs7944523	chr11:48911019	G/A	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs2267708	0.506	rs1842616	chr7:124582172	G/C	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Chronic lymphocytic leukemia;
THYM	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4285028	0.948	rs7615571	chr3:121665950	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs9560113	1.000	rs9555807	chr13:112179965	C/T	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs7267979	1.000	rs11100	chr20:25281184	G/C	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1003719	0.715	rs9980353	chr21:38558812	T/G	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg00383909	chr3:49044727	WDR6	1.12	6.61	0.56	2.27e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg23791538	chr6:167370224	RNASET2	-0.72	-5.66	-0.5	1.58e-7	Crohn's disease;
THYM	cis	rs11089937	0.616	rs5750675	chr22:22533623	C/G	cg06866756	chr22:22471216	NA	-0.43	-4.71	-0.44	8.45e-6	Periodontitis (PAL4Q3);
THYM	cis	rs7264396	0.676	rs58372200	chr20:34555445	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-4.8	-0.44	6.01e-6	Total cholesterol levels;
THYM	cis	rs2554380	0.843	rs1365198	chr15:84398903	T/G	cg14598478	chr15:84363061	ADAMTSL3	-0.65	-5.23	-0.47	1.02e-6	Height;
THYM	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg10792982	chr14:105748885	BRF1	0.69	6.99	0.58	3.84e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg18252515	chr7:66147081	NA	-0.69	-5.5	-0.49	3.21e-7	Aortic root size;
THYM	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	6.46	0.55	4.49e-9	Obesity-related traits;
THYM	cis	rs4666002	0.956	rs34502053	chr2:27854524	G/A	cg27432699	chr2:27873401	GPN1	0.61	4.63	0.43	1.15e-5	Phospholipid levels (plasma);
THYM	cis	rs2932538	0.961	rs3795820	chr1:113163042	C/A	cg22162597	chr1:113214053	CAPZA1	-0.63	-4.96	-0.45	3.13e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs7582180	0.817	rs1437967	chr2:100929072	C/G	cg08017756	chr2:100939284	LONRF2	-0.76	-7.81	-0.63	7.52e-12	Intelligence (multi-trait analysis);
THYM	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.93	5.98	0.52	3.95e-8	Smoking behavior;
THYM	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg18032289	chr17:61959525	GH2	-0.5	-4.55	-0.42	1.58e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.48	-0.42	2.05e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg14690197	chr8:22456421	C8orf58	0.5	4.5	0.42	1.94e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6427356	0.513	rs10908535	chr1:157148022	A/G	cg27547283	chr1:156698502	C1orf66;ISG20L2	-0.58	-4.49	-0.42	2.02e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs611744	0.870	rs416611	chr8:109124593	T/C	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.06e-6	Dupuytren's disease;
THYM	cis	rs7359257	0.935	rs56108040	chr15:67707833	G/C	cg24579218	chr15:68104479	NA	0.53	4.64	0.43	1.12e-5	Menarche (age at onset);
THYM	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs9361491	0.614	rs9361437	chr6:79479335	T/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.88e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg11266682	chr4:10021025	SLC2A9	-0.62	-7.75	-0.62	1e-11	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs921968	0.612	rs832810	chr2:219322430	T/C	cg02176678	chr2:219576539	TTLL4	0.65	6.27	0.54	1.05e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10832963	0.924	rs10832950	chr11:18635815	A/G	cg09201001	chr11:18656081	SPTY2D1	1.07	9.63	0.7	1.04e-15	Breast cancer;
THYM	cis	rs8192282	0.739	rs4845641	chr1:154497930	C/G	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg03909863	chr11:638404	DRD4	-0.86	-5.99	-0.52	3.66e-8	Systemic lupus erythematosus;
THYM	cis	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg06521331	chr12:34319734	NA	-1.04	-10.13	-0.72	8.85e-17	Morning vs. evening chronotype;
THYM	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.31	7.61	0.62	2e-11	Gut microbiome composition (summer);
THYM	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg01236616	chr12:121019343	POP5	1.29	9.92	0.71	2.51e-16	Type 1 diabetes nephropathy;
THYM	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg21775007	chr8:11205619	TDH	-0.68	-5.26	-0.47	8.84e-7	Retinal vascular caliber;
THYM	cis	rs67311347	0.524	rs11129869	chr3:40259738	G/A	cg09455208	chr3:40491958	NA	0.43	4.54	0.42	1.65e-5	Renal cell carcinoma;
THYM	cis	rs6840360	1.000	rs6833368	chr4:152603177	C/T	cg22705602	chr4:152727874	NA	0.63	6.81	0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7681440	0.583	rs2583989	chr4:90769422	A/G	cg06632027	chr4:90757378	SNCA	-0.66	-5.29	-0.48	7.91e-7	Dementia with Lewy bodies;
THYM	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11089937	0.616	rs7291684	chr22:22538224	A/G	cg06866756	chr22:22471216	NA	-0.46	-5.09	-0.46	1.79e-6	Periodontitis (PAL4Q3);
THYM	cis	rs9359856	0.564	rs72913975	chr6:90387116	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg09354556	chr3:47051341	NA	0.46	4.74	0.44	7.63e-6	Colorectal cancer;
THYM	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg10018233	chr7:150070692	REPIN1	0.47	6.85	0.58	7.26e-10	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6840360	0.571	rs2406976	chr4:152541056	G/C	cg22705602	chr4:152727874	NA	-0.78	-8.73	-0.67	8.56e-14	Intelligence (multi-trait analysis);
THYM	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg11502198	chr6:26597334	ABT1	0.64	5.68	0.5	1.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg12564285	chr5:131593104	PDLIM4	0.53	5.95	0.52	4.4e-8	Breast cancer;
THYM	cis	rs35100037	0.803	rs13169520	chr5:128649489	A/T	cg05211662	chr5:128795605	ADAMTS19	-0.85	-4.46	-0.42	2.22e-5	Ankle injury;
THYM	cis	rs35123781	0.502	rs355157	chr5:138993415	T/C	cg08720517	chr5:138729919	LOC389333	0.57	4.69	0.43	9.29e-6	Schizophrenia;
THYM	cis	rs4595586	0.545	rs7980848	chr12:39375166	G/C	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg17366294	chr4:99064904	C4orf37	0.53	5.9	0.52	5.67e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg01299579	chr2:10830716	NOL10	0.48	4.52	0.42	1.78e-5	Prostate cancer;
THYM	cis	rs9880211	0.613	rs12695644	chr3:135844938	C/T	cg21827317	chr3:136751795	NA	-0.72	-5.21	-0.47	1.11e-6	Body mass index;Height;
THYM	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg03909863	chr11:638404	DRD4	-0.78	-5.75	-0.51	1.07e-7	Systemic lupus erythematosus;
THYM	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg02569458	chr12:86230093	RASSF9	0.68	5.69	0.5	1.38e-7	Major depressive disorder;
THYM	cis	rs8014204	0.935	rs3742786	chr14:75373011	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.58	-5.59	-0.5	2.13e-7	Caffeine consumption;
THYM	cis	rs13323323	0.842	rs56377787	chr3:44293513	A/G	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.54	-4.85	-0.45	4.81e-6	IgG glycosylation;
THYM	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22857025	chr5:266934	NA	-1.61	-10.34	-0.73	3.11e-17	Breast cancer;
THYM	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.67	-4.49	-0.42	1.98e-5	Menarche (age at onset);
THYM	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.96	8.0	0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg24308560	chr3:49941425	MST1R	0.59	4.46	0.42	2.29e-5	Body mass index;
THYM	cis	rs7312774	0.618	rs61061573	chr12:107372758	T/C	cg16260113	chr12:107380972	MTERFD3	1.45	7.15	0.59	1.79e-10	Severe influenza A (H1N1) infection;
THYM	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs17443541	0.507	rs4675712	chr2:200460112	A/C	cg03741458	chr2:200468445	NA	-0.75	-5.77	-0.51	9.74e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7757969	1.000	rs2182643	chr6:112121096	G/A	cg08601457	chr6:112115117	FYN	0.42	4.88	0.45	4.22e-6	Schizophrenia;
THYM	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg14456004	chr13:21872349	NA	-1.25	-10.18	-0.72	6.85e-17	White matter hyperintensity burden;
THYM	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg01966878	chr4:90757139	SNCA	-0.62	-4.95	-0.45	3.15e-6	Neuroticism;
THYM	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg20887711	chr4:1340912	KIAA1530	-0.7	-5.99	-0.52	3.75e-8	Obesity-related traits;
THYM	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg24399712	chr22:39784796	NA	-0.93	-10.87	-0.74	2.34e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs600806	0.850	rs4120621	chr1:109949008	A/G	cg02175308	chr1:109941060	SORT1	-0.56	-4.99	-0.46	2.76e-6	Intelligence (multi-trait analysis);
THYM	cis	rs761746	0.739	rs5998054	chr22:31994406	C/A	cg01338084	chr22:32026380	PISD	0.53	4.63	0.43	1.15e-5	Intelligence;
THYM	cis	rs6586111	1.000	rs4933462	chr10:82372612	A/G	cg03086067	chr10:82368399	SH2D4B	-0.51	-6.5	-0.56	3.64e-9	Capecitabine sensitivity;
THYM	cis	rs7575217	1.000	rs7575217	chr2:101776932	A/G	cg23907051	chr2:101730305	TBC1D8	-0.35	-4.53	-0.42	1.71e-5	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs9457247	0.534	rs933243	chr6:167403873	A/C	cg23791538	chr6:167370224	RNASET2	-0.86	-7.69	-0.62	1.32e-11	Crohn's disease;
THYM	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg10505658	chr17:80084571	CCDC57	0.68	7.72	0.62	1.16e-11	Life satisfaction;
THYM	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg05425664	chr17:57184151	TRIM37	-0.61	-4.93	-0.45	3.42e-6	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs114213539	chr4:119758794	G/C	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg19645103	chr12:69753606	YEATS4	-0.58	-4.81	-0.44	5.71e-6	Response to diuretic therapy;
THYM	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg04025307	chr7:1156635	C7orf50	0.78	6.67	0.56	1.68e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg06850241	chr22:41845214	NA	0.53	4.56	0.42	1.54e-5	Cannabis dependence symptom count;
THYM	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs1335645	0.570	rs6703407	chr1:111622807	G/A	cg00321911	chr1:111669324	DRAM2	-1.41	-7.11	-0.59	2.13e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.55	4.49	0.42	2e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7688540	0.771	rs61792114	chr4:289139	A/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.65	4.82	0.44	5.41e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs1784581	1.000	rs1618170	chr6:162400337	C/T	cg17173639	chr6:162384350	PARK2	-0.94	-8.8	-0.67	6.05e-14	Itch intensity from mosquito bite;
THYM	cis	rs7584330	0.554	rs7571100	chr2:238435305	G/T	cg14458575	chr2:238380390	NA	0.81	4.86	0.45	4.63e-6	Prostate cancer;
THYM	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs9796	0.576	rs13329511	chr15:41299121	T/C	cg21153102	chr15:41252147	NA	0.6	5.24	0.47	9.53e-7	Menopause (age at onset);
THYM	cis	rs28830936	0.510	rs7175346	chr15:42100674	G/A	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.46	-4.45	-0.42	2.36e-5	Diastolic blood pressure;
THYM	cis	rs7264396	0.676	rs6060727	chr20:34556000	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-4.8	-0.44	6.01e-6	Total cholesterol levels;
THYM	cis	rs7740797	0.818	rs9375	chr6:155155039	C/T	cg02865717	chr6:155053990	RBM16	0.46	4.64	0.43	1.11e-5	Colorectal or endometrial cancer;
THYM	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg03476357	chr21:30257390	N6AMT1	0.59	4.6	0.43	1.31e-5	Dental caries;
THYM	cis	rs4509693	0.598	rs79350316	chr10:102493835	C/T	cg24127310	chr10:102502104	NA	-1.26	-4.99	-0.46	2.75e-6	Alzheimer's disease;
THYM	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg07424592	chr7:64974309	NA	1.03	5.4	0.48	4.94e-7	Diabetic kidney disease;
THYM	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11644478	chr21:40555479	PSMG1	0.81	7.03	0.59	3.12e-10	Cognitive function;
THYM	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg01831904	chr17:28903510	LRRC37B2	-1.02	-5.06	-0.46	2.05e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6738485	0.531	rs72819612	chr2:106846316	T/C	cg16099169	chr2:106886729	NA	-0.82	-4.8	-0.44	5.97e-6	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
THYM	cis	rs7695732	0.595	rs10009019	chr4:89901824	A/G	cg17769793	chr4:89976368	FAM13A	-0.49	-5.2	-0.47	1.17e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs2219968	0.770	rs12545292	chr8:78886841	A/T	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg03605463	chr16:89740564	NA	0.88	6.76	0.57	1.13e-9	Vitiligo;
THYM	cis	rs12519773	0.550	rs4242242	chr5:92519387	G/A	cg18783429	chr5:92414398	NA	0.53	5.37	0.48	5.63e-7	Migraine;
THYM	cis	rs6500395	0.890	rs3843724	chr16:48618573	C/G	cg04672837	chr16:48644449	N4BP1	0.48	4.64	0.43	1.13e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg23442198	chr4:187126114	CYP4V2	0.96	4.51	0.42	1.87e-5	Blood protein levels;
THYM	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs4499344	0.577	rs259289	chr19:33164927	G/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.88	7.61	0.62	2.03e-11	Mean platelet volume;
THYM	cis	rs17102423	0.594	rs1256417	chr14:65563678	C/T	cg11161011	chr14:65562177	MAX	-0.69	-5.58	-0.5	2.31e-7	Obesity-related traits;
THYM	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg02493740	chr2:85810744	VAMP5	-0.61	-4.87	-0.45	4.36e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs9522267	0.737	rs9522285	chr13:112230701	C/T	cg10483660	chr13:112241077	NA	-0.62	-6.49	-0.55	3.94e-9	Hepatitis;
THYM	cis	rs7169223	0.653	rs2904228	chr15:79086099	G/A	cg21242079	chr15:79101063	ADAMTS7	-0.59	-5.37	-0.48	5.51e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.74	0.67	8.17e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7107770	1.000	rs4935916	chr11:125106898	G/A	cg07747661	chr11:125106135	PKNOX2	-0.91	-5.2	-0.47	1.16e-6	Photic sneeze reflex;
THYM	cis	rs60695258	0.529	rs340630	chr4:87958395	G/A	cg10685359	chr4:87814065	C4orf36	0.45	5.81	0.51	8.24e-8	Hematocrit;
THYM	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg11166453	chr1:247681781	NA	0.69	5.38	0.48	5.45e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06873352	chr17:61820015	STRADA	-0.79	-9.87	-0.71	3.15e-16	Prudent dietary pattern;
THYM	cis	rs10095849	0.680	rs13248954	chr8:39454677	G/T	cg22755526	chr8:38854673	TM2D2;ADAM9	0.66	4.48	0.42	2.04e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg10856724	chr12:34555212	NA	-1.05	-10.53	-0.73	1.23e-17	Morning vs. evening chronotype;
THYM	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg02018176	chr4:1364513	KIAA1530	0.56	4.52	0.42	1.8e-5	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg12373951	chr3:133503437	NA	-0.56	-6.18	-0.54	1.62e-8	Iron status biomarkers;
THYM	cis	rs7828089	0.542	rs7332050	chr8:22265294	G/T	cg12081754	chr8:22256438	SLC39A14	0.87	8.62	0.66	1.5e-13	Verbal declarative memory;
THYM	cis	rs9674544	0.792	rs8076012	chr17:47101989	G/A	cg22947322	chr17:47091978	IGF2BP1	-0.6	-6.47	-0.55	4.21e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs7586879	0.639	rs13407913	chr2:25097644	A/G	cg27107076	chr2:25050844	ADCY3	-0.29	-4.62	-0.43	1.2e-5	Body mass index;
THYM	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg12310025	chr6:25882481	NA	-0.73	-5.72	-0.51	1.22e-7	Blood metabolite levels;
THYM	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg09323728	chr8:95962352	TP53INP1	-0.47	-4.66	-0.43	1.01e-5	Type 2 diabetes;
THYM	cis	rs12956009	0.518	rs71352652	chr18:44869536	A/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-4.93	-0.45	3.51e-6	Educational attainment (years of education);
THYM	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg10802521	chr3:52805072	NEK4	-0.74	-6.34	-0.55	7.65e-9	Bipolar disorder;
THYM	cis	rs6754311	0.593	rs313528	chr2:136445869	G/A	cg20242066	chr2:136595261	LCT	0.55	6.04	0.53	3.05e-8	Mosquito bite size;
THYM	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg07936489	chr17:37558343	FBXL20	0.79	5.7	0.5	1.37e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg22974920	chr21:40686053	BRWD1	0.61	4.75	0.44	7.29e-6	Cognitive function;
THYM	cis	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs10203711	1.000	rs907099	chr2:239559769	G/C	cg14580085	chr2:239553406	NA	0.71	6.63	0.56	2.01e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs859767	0.741	rs11898084	chr2:135428054	T/C	cg12500956	chr2:135428796	TMEM163	-0.51	-5.31	-0.48	7.1e-7	Neuroticism;
THYM	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg02380750	chr20:61661411	NA	-0.6	-6.15	-0.53	1.79e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg00852783	chr1:26633632	UBXN11	0.83	8.39	0.65	4.45e-13	Obesity-related traits;
THYM	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg12863693	chr15:85201151	NMB	0.53	4.73	0.44	7.81e-6	Schizophrenia;
THYM	cis	rs3892630	0.824	rs35654350	chr19:33223766	T/C	cg22980127	chr19:33182716	NUDT19	1.14	9.23	0.69	7.47e-15	Red blood cell traits;
THYM	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26314531	chr2:26401878	FAM59B	0.78	5.13	0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9653442	1.000	rs6712515	chr2:100806514	T/C	cg07810366	chr2:100720526	AFF3	-0.36	-5.04	-0.46	2.26e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.835	rs6780013	chr3:47452118	G/A	cg27129171	chr3:47204927	SETD2	-0.68	-6.09	-0.53	2.35e-8	Colorectal cancer;
THYM	cis	rs911263	0.961	rs8008961	chr14:68752643	A/G	cg18825221	chr14:68749962	RAD51L1	0.6	6.25	0.54	1.15e-8	Primary biliary cholangitis;
THYM	cis	rs7178572	1.000	rs8024485	chr15:77718368	C/A	cg22256960	chr15:77711686	NA	-0.94	-7.93	-0.63	4.23e-12	Type 2 diabetes;
THYM	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg06219351	chr7:158114137	PTPRN2	-0.79	-8.18	-0.64	1.27e-12	Calcium levels;
THYM	cis	rs61931739	0.853	rs7133716	chr12:34041847	G/C	cg06521331	chr12:34319734	NA	0.61	4.76	0.44	6.95e-6	Morning vs. evening chronotype;
THYM	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg17143192	chr8:8559678	CLDN23	0.59	4.61	0.43	1.26e-5	Mood instability;
THYM	cis	rs28595532	0.844	rs115202072	chr4:119732458	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs11651000	0.894	rs11650354	chr17:45822092	A/G	cg03474202	chr17:45855739	NA	0.75	5.24	0.47	9.83e-7	IgG glycosylation;
THYM	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.14	-0.64	1.51e-12	Personality dimensions;
THYM	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.24	0.47	9.61e-7	Height;
THYM	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg18105134	chr13:113819100	PROZ	0.96	9.14	0.68	1.16e-14	Platelet distribution width;
THYM	cis	rs7909074	1.000	rs4948927	chr10:45397071	G/A	cg04218760	chr10:45406644	TMEM72	-0.67	-6.01	-0.52	3.42e-8	Mean corpuscular volume;
THYM	trans	rs12760731	0.565	rs12034657	chr1:178099354	A/C	cg06907405	chr16:48400475	SIAH1	1.21	7.03	0.58	3.16e-10	Obesity-related traits;
THYM	cis	rs12282928	0.959	rs960640	chr11:48290320	A/G	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs7943358	0.910	rs10832500	chr11:15687596	G/A	cg11966998	chr11:15692519	NA	-0.46	-4.53	-0.42	1.72e-5	Gut microbiome composition (summer);
THYM	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg15704280	chr7:45808275	SEPT13	-1.06	-15.41	-0.85	1.38e-27	Height;
THYM	cis	rs4866334	1.000	rs6866535	chr5:18431650	G/A	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs533581	0.866	rs871756	chr16:88969076	G/C	cg15388900	chr16:88312269	NA	-0.62	-4.79	-0.44	6.1e-6	Social autistic-like traits;
THYM	cis	rs56079296	0.929	rs11241627	chr5:121273302	C/T	cg01191064	chr5:121408893	LOX	-0.67	-4.47	-0.42	2.18e-5	Coronary artery disease;
THYM	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg10523679	chr1:76189770	ACADM	-0.55	-4.67	-0.43	9.97e-6	Daytime sleep phenotypes;
THYM	cis	rs4919687	0.550	rs10437480	chr10:104453024	C/G	cg18761893	chr10:103892519	PPRC1	0.61	4.66	0.43	1.05e-5	Colorectal cancer;
THYM	cis	rs6964587	0.610	rs6950682	chr7:91464218	G/T	cg17063962	chr7:91808500	NA	0.99	8.28	0.65	7.62e-13	Breast cancer;
THYM	cis	rs36051895	0.594	rs10115464	chr9:5144268	C/T	cg02405213	chr9:5042618	JAK2	-1.02	-10.43	-0.73	2.01e-17	Pediatric autoimmune diseases;
THYM	cis	rs8041943	0.550	rs4779122	chr15:79891509	C/T	cg20511832	chr15:78934280	CHRNB4	0.44	4.52	0.42	1.8e-5	Bone mineral density (spine) and age at menarche;
THYM	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg10862848	chr6:42927986	GNMT	-0.55	-7.21	-0.59	1.36e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg03647317	chr4:187891568	NA	-0.83	-8.92	-0.67	3.42e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs57920188	0.640	rs4478781	chr1:4086827	C/T	cg20703997	chr1:4087676	NA	1.07	7.08	0.59	2.49e-10	Interleukin-17 levels;
THYM	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg18305652	chr10:134549665	INPP5A	-0.78	-7.59	-0.61	2.23e-11	Migraine;
THYM	cis	rs55665837	1.000	rs10047457	chr11:14439459	T/A	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg00024416	chr22:24240387	NA	-0.68	-6.98	-0.58	3.99e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg21110456	chr7:2059412	MAD1L1	-0.46	-4.92	-0.45	3.61e-6	Neuroticism;
THYM	cis	rs1059312	0.932	rs7960920	chr12:129283149	T/C	cg09035930	chr12:129282057	SLC15A4	0.83	11.19	0.75	4.95e-19	Systemic lupus erythematosus;
THYM	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs7264396	0.836	rs4911183	chr20:34181553	G/A	cg26038318	chr20:34205095	SPAG4	-0.55	-4.57	-0.42	1.46e-5	Total cholesterol levels;
THYM	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.28	6.03	0.53	3.11e-8	Obesity-related traits;
THYM	cis	rs679087	1.000	rs302321	chr12:29928388	A/C	cg14258853	chr12:29935411	TMTC1	0.67	6.14	0.53	1.9e-8	Schizophrenia;
THYM	cis	rs11563648	0.553	rs9791822	chr7:127018589	C/T	cg23081781	chr7:127225937	GCC1	-0.34	-4.64	-0.43	1.14e-5	Resting heart rate;
THYM	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg06481639	chr22:41940642	POLR3H	0.82	5.68	0.5	1.49e-7	Vitiligo;
THYM	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg10792982	chr14:105748885	BRF1	0.75	7.8	0.62	7.96e-12	Mean platelet volume;Platelet distribution width;
THYM	cis	rs10752881	1.000	rs4454510	chr1:182982303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.65	-5.2	-0.47	1.16e-6	Colorectal cancer;
THYM	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg10018233	chr7:150070692	REPIN1	0.4	5.58	0.5	2.24e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg13319975	chr6:146136371	FBXO30	0.7	5.8	0.51	8.55e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg16586182	chr3:47516702	SCAP	0.61	5.29	0.48	7.83e-7	Colorectal cancer;
THYM	cis	rs4919044	0.808	rs835277	chr10:94809677	T/C	cg05127821	chr10:94822908	CYP26C1	-1.23	-6.66	-0.56	1.76e-9	Coronary artery disease;
THYM	cis	rs28595532	0.844	rs115573749	chr4:119756848	T/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs7580658	0.895	rs4662722	chr2:128102569	T/C	cg10021288	chr2:128175891	PROC	-0.74	-6.4	-0.55	5.94e-9	Protein C levels;
THYM	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg07341220	chr16:1583899	IFT140;TMEM204	0.59	5.2	0.47	1.16e-6	Coronary artery disease;
THYM	cis	rs7084402	0.935	rs10740732	chr10:60352888	G/A	cg07615347	chr10:60278583	BICC1	0.53	4.97	0.45	2.99e-6	Refractive error;
THYM	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.62	-0.5	1.93e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg03264133	chr6:25882463	NA	0.65	5.09	0.46	1.83e-6	Schizophrenia;
THYM	cis	rs17401966	0.838	rs4846212	chr1:10370312	T/C	cg19773385	chr1:10388646	KIF1B	-0.57	-4.47	-0.42	2.15e-5	Hepatocellular carcinoma;
THYM	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg02725872	chr8:58115012	NA	1.08	7.38	0.6	5.92e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg26384229	chr12:38710491	ALG10B	0.99	7.63	0.62	1.81e-11	Bladder cancer;
THYM	cis	rs68170813	0.559	rs12535258	chr7:106971050	T/C	cg00661777	chr7:106511741	PIK3CG	-0.68	-4.71	-0.44	8.28e-6	Coronary artery disease;
THYM	cis	rs988913	0.768	rs9396003	chr6:54741853	A/G	cg15217784	chr6:54722227	FAM83B	-0.52	-4.6	-0.43	1.28e-5	Menarche (age at onset);
THYM	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10463554	0.963	rs34774	chr5:102450820	G/T	cg23492399	chr5:102201601	PAM	-0.69	-5.07	-0.46	1.92e-6	Parkinson's disease;
THYM	cis	rs6500395	1.000	rs8059905	chr16:48629934	C/T	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg14664628	chr15:75095509	CSK	-0.68	-5.35	-0.48	6.07e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs9326248	0.539	rs10892065	chr11:116897024	T/C	cg20608306	chr11:116969690	SIK3	0.62	7.41	0.61	5.21e-11	Blood protein levels;
THYM	cis	rs1642645	0.872	rs7550500	chr1:42505522	T/C	cg22816091	chr1:42611670	NA	0.6	5.39	0.48	5.19e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs2227564	0.620	rs12783161	chr10:75572201	G/C	cg00564723	chr10:75632066	CAMK2G	-0.5	-4.48	-0.42	2.1e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs250677	0.522	rs1432798	chr5:148383345	C/G	cg18129178	chr5:148520854	ABLIM3	-0.64	-5.04	-0.46	2.22e-6	Breast cancer;
THYM	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg27170947	chr2:26402098	FAM59B	-0.8	-6.3	-0.54	9.35e-9	Gut microbiome composition (summer);
THYM	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg22709100	chr7:91322751	NA	-0.61	-4.85	-0.45	4.9e-6	Breast cancer;
THYM	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg11752832	chr7:134001865	SLC35B4	0.68	4.92	0.45	3.63e-6	Mean platelet volume;
THYM	cis	rs6121246	0.512	rs6060938	chr20:30363645	T/C	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs78062588	1.000	rs61300392	chr1:154575685	A/T	cg03138446	chr1:153746880	SLC27A3	1.19	4.64	0.43	1.1e-5	Lung cancer;
THYM	cis	rs1448094	0.512	rs11117061	chr12:86250916	G/A	cg00310523	chr12:86230176	RASSF9	0.58	5.32	0.48	6.98e-7	Major depressive disorder;
THYM	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.75	-6.23	-0.54	1.27e-8	Lung cancer;
THYM	cis	rs28595532	0.920	rs115154263	chr4:119765307	G/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg04842962	chr6:43655489	MRPS18A	0.88	7.39	0.6	5.6e-11	IgG glycosylation;
THYM	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg06009448	chr7:1102226	C7orf50	0.53	5.55	0.49	2.6e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs4866334	0.867	rs78373067	chr5:18463912	A/G	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg24692254	chr21:30365293	RNF160	-0.71	-5.14	-0.47	1.48e-6	Cognitive test performance;
THYM	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs8067545	1.000	rs9891739	chr17:19942177	C/T	cg13482628	chr17:19912719	NA	0.58	4.98	0.46	2.82e-6	Schizophrenia;
THYM	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg04043695	chr12:129287642	SLC15A4	0.57	4.48	0.42	2.06e-5	Systemic lupus erythematosus;
THYM	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.88	8.58	0.66	1.75e-13	Menarche (age at onset);
THYM	cis	rs9810089	0.843	rs696081	chr3:136047189	C/T	cg12473912	chr3:136751656	NA	-0.61	-4.91	-0.45	3.85e-6	Gestational age at birth (child effect);
THYM	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg21361702	chr7:150065534	REPIN1	0.69	5.76	0.51	1.06e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg04455712	chr21:45112962	RRP1B	0.57	5.54	0.49	2.69e-7	Mean corpuscular volume;
THYM	cis	rs4400599	1.000	rs4845364	chr1:154141908	A/G	cg05139571	chr1:154127138	NUP210L	0.58	4.95	0.45	3.26e-6	Platelet distribution width;
THYM	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg22974920	chr21:40686053	BRWD1	0.74	5.02	0.46	2.45e-6	Cognitive function;
THYM	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg02725872	chr8:58115012	NA	-1.11	-6.84	-0.57	7.55e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg26924012	chr15:45694286	SPATA5L1	0.66	4.86	0.45	4.65e-6	Response to fenofibrate (adiponectin levels);
THYM	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg03476357	chr21:30257390	N6AMT1	-0.61	-4.59	-0.43	1.38e-5	Dental caries;
THYM	cis	rs7607369	0.648	rs17470271	chr2:219651995	A/T	cg02176678	chr2:219576539	TTLL4	0.59	5.48	0.49	3.54e-7	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs909002	0.819	rs2292989	chr1:32135773	A/G	cg13919466	chr1:32135498	COL16A1	0.52	4.64	0.43	1.13e-5	Intelligence (multi-trait analysis);
THYM	cis	rs919433	0.648	rs3097384	chr2:198278834	T/A	cg05783139	chr2:198650985	BOLL	0.63	4.93	0.45	3.48e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2692947	0.644	rs1168974	chr2:96814928	G/A	cg23100626	chr2:96804247	ASTL	0.38	4.52	0.42	1.78e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs10857712	0.851	rs56153177	chr10:135216975	G/A	cg17796960	chr10:135278976	LOC619207	-0.59	-5.06	-0.46	2.07e-6	Systemic lupus erythematosus;
THYM	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg00640147	chr17:61958756	GH2	-0.44	-4.82	-0.44	5.49e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs1003719	0.788	rs7277657	chr21:38469523	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs7084402	0.902	rs1649044	chr10:60327298	A/C	cg07615347	chr10:60278583	BICC1	0.56	5.17	0.47	1.27e-6	Refractive error;
THYM	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg10193763	chr2:225306901	NA	0.5	4.63	0.43	1.15e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs735539	0.521	rs1810717	chr13:21412235	A/G	cg02792322	chr13:21280448	IL17D	-0.66	-4.78	-0.44	6.37e-6	Dental caries;
THYM	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7027203	0.828	rs10821229	chr9:96595136	A/C	cg14598338	chr9:96623480	NA	-0.51	-5.65	-0.5	1.69e-7	DNA methylation (variation);
THYM	cis	rs2294693	0.891	rs9369256	chr6:40998344	G/C	cg21128951	chr6:40996213	UNC5CL	0.58	4.61	0.43	1.25e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	4.97	0.45	3e-6	Height;
THYM	cis	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg07988820	chr12:82153109	PPFIA2	-0.83	-5.29	-0.48	7.71e-7	Resting heart rate;
THYM	cis	rs892961	0.899	rs3650	chr17:75415835	T/C	cg05865280	chr17:75406074	SEPT9	0.48	8.22	0.64	1.06e-12	Airflow obstruction;
THYM	cis	rs61931739	0.534	rs1608912	chr12:34008574	C/T	cg10856724	chr12:34555212	NA	-0.76	-6.75	-0.57	1.15e-9	Morning vs. evening chronotype;
THYM	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg11861562	chr11:117069780	TAGLN	-0.33	-4.76	-0.44	6.88e-6	Blood protein levels;
THYM	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg15997130	chr1:24165203	NA	-0.77	-6.87	-0.58	6.61e-10	Immature fraction of reticulocytes;
THYM	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg17401067	chr22:41840292	TOB2	-0.5	-4.73	-0.44	7.81e-6	Vitiligo;
THYM	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg26597838	chr10:835615	NA	1.21	8.65	0.66	1.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg05373962	chr22:49881684	NA	-0.65	-6.14	-0.53	1.94e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg06558623	chr16:89946397	TCF25	1.51	8.29	0.65	7.35e-13	Skin colour saturation;
THYM	cis	rs6502050	0.723	rs66871014	chr17:80181874	G/A	cg21773646	chr17:80085082	CCDC57	-0.37	-5.08	-0.46	1.9e-6	Life satisfaction;
THYM	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg04234412	chr22:24373322	LOC391322	-1.09	-14.2	-0.82	3.27e-25	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg13609457	chr4:120235615	NA	0.63	5.02	0.46	2.42e-6	Corneal astigmatism;
THYM	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg14196790	chr5:131705035	SLC22A5	-0.54	-4.94	-0.45	3.38e-6	Blood metabolite levels;
THYM	cis	rs9430161	0.579	rs10864486	chr1:11040979	A/G	cg27631724	chr1:11040367	C1orf127	0.68	6.42	0.55	5.25e-9	Ewing sarcoma;
THYM	cis	rs4918072	0.834	rs7923008	chr10:105711383	A/G	cg11005552	chr10:105648138	OBFC1	0.57	4.61	0.43	1.26e-5	Coronary artery disease;
THYM	cis	rs2251260	0.685	rs2246609	chr14:62007872	G/A	cg13564459	chr14:62004353	PRKCH	0.45	5.55	0.49	2.63e-7	Yeast infection;
THYM	cis	rs4660306	0.633	rs1771549	chr1:45896779	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.64	4.65	0.43	1.07e-5	Homocysteine levels;
THYM	cis	rs7119	0.635	rs2667764	chr15:77881239	C/T	cg10437265	chr15:77819839	NA	-0.61	-5.83	-0.51	7.54e-8	Type 2 diabetes;
THYM	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg01324343	chr3:183735012	ABCC5	0.89	13.33	0.81	1.82e-23	Anterior chamber depth;
THYM	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg17264618	chr3:40429014	ENTPD3	0.51	5.06	0.46	2.03e-6	Renal cell carcinoma;
THYM	cis	rs950881	0.601	rs3771164	chr2:102991786	A/T	cg01241218	chr2:102972058	NA	0.82	5.33	0.48	6.7e-7	Allergy;
THYM	cis	rs9378357	0.850	rs6910086	chr6:3287118	T/C	cg08754725	chr6:3293098	SLC22A23	0.96	4.53	0.42	1.7e-5	Obesity-related traits;
THYM	cis	rs9790314	0.750	rs6765270	chr3:160899974	A/G	cg04691961	chr3:161091175	C3orf57	-0.61	-4.96	-0.45	3.05e-6	Morning vs. evening chronotype;
THYM	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg11301795	chr4:187892539	NA	-1.12	-16.69	-0.86	5.4e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12257961	0.521	rs10796281	chr10:15375605	T/G	cg10616319	chr10:15468812	NA	-0.66	-5.33	-0.48	6.53e-7	Selective IgA deficiency;
THYM	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg16586182	chr3:47516702	SCAP	-0.6	-5.11	-0.46	1.63e-6	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg05340658	chr4:99064831	C4orf37	0.54	4.55	0.42	1.58e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6935502	1	rs6935502	chr6:54653540	C/G	cg18532076	chr6:54711417	FAM83B	-0.5	-4.54	-0.42	1.67e-5	Subjective well-being;
THYM	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg02734326	chr4:10020555	SLC2A9	0.66	5.62	0.5	1.93e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg05738196	chr6:26577821	NA	0.95	9.89	0.71	2.78e-16	Intelligence (multi-trait analysis);
THYM	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg03060546	chr3:49711283	APEH	-0.72	-5.78	-0.51	9.62e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs1699337	0.538	rs66615477	chr3:12298314	G/T	cg05467012	chr3:12595696	NA	0.51	4.58	0.43	1.38e-5	Cholesterol, total;
THYM	cis	rs7267979	0.966	rs2145126	chr20:25263648	G/A	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9649465	1.000	rs55633050	chr7:123388474	A/G	cg15443791	chr7:124364398	NA	0.57	4.7	0.43	8.8e-6	Migraine;
THYM	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.72	5.3	0.48	7.65e-7	Glycated hemoglobin levels;
THYM	cis	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg21775007	chr8:11205619	TDH	-0.59	-4.61	-0.43	1.24e-5	Monocyte count;
THYM	cis	rs986417	0.901	rs10139995	chr14:60947177	G/T	cg27398547	chr14:60952738	C14orf39	1.14	5.33	0.48	6.64e-7	Gut microbiota (bacterial taxa);
THYM	trans	rs877282	0.682	rs2265092	chr10:780293	C/T	cg22713356	chr15:30763199	NA	-1.04	-8.8	-0.67	6.08e-14	Uric acid levels;
THYM	cis	rs289828	0.538	rs13420739	chr2:152151694	G/A	cg05960677	chr2:152117363	RBM43	0.72	6.74	0.57	1.23e-9	Blood protein levels;
THYM	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg10950924	chr17:47092072	IGF2BP1	-0.6	-7.5	-0.61	3.33e-11	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs34638657	0.789	rs2967363	chr16:82204132	C/G	cg09894383	chr16:82067445	HSD17B2	-0.44	-4.72	-0.44	7.99e-6	Lung adenocarcinoma;
THYM	cis	rs6840360	1.000	rs10019048	chr4:152603615	A/G	cg22705602	chr4:152727874	NA	-0.62	-6.67	-0.56	1.69e-9	Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg23803603	chr1:2058230	PRKCZ	-0.67	-5.73	-0.51	1.18e-7	Height;
THYM	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg18132916	chr6:79620363	NA	-0.58	-5.27	-0.48	8.5e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs35934224	0.710	rs73381834	chr22:19849953	T/A	cg11182965	chr22:19864308	TXNRD2	-0.76	-4.67	-0.43	9.79e-6	Glaucoma (primary open-angle);
THYM	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	13.4	0.81	1.29e-23	Chronic sinus infection;
THYM	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.28	6.03	0.53	3.11e-8	Obesity-related traits;
THYM	cis	rs9563576	0.542	rs7997797	chr13:58311555	C/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.63	4.89	0.45	4.04e-6	Body mass index;
THYM	cis	rs57920188	0.535	rs4295856	chr1:4094842	C/T	cg20703997	chr1:4087676	NA	0.74	5.31	0.48	7.07e-7	Interleukin-17 levels;
THYM	cis	rs3849570	1.000	rs13088000	chr3:81839404	T/C	cg07356753	chr3:81810745	GBE1	-0.89	-6.98	-0.58	3.93e-10	Waist circumference;Body mass index;
THYM	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg08835221	chr22:38071607	LGALS1	0.38	5.04	0.46	2.21e-6	Fat distribution (HIV);
THYM	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28595532	0.920	rs116559327	chr4:119754526	T/G	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg21773646	chr17:80085082	CCDC57	0.31	4.49	0.42	2.02e-5	Life satisfaction;
THYM	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg03806693	chr22:41940476	POLR3H	-1.23	-10.89	-0.75	2.09e-18	Vitiligo;
THYM	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg01570182	chr17:44337453	NA	0.88	9.33	0.69	4.51e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.63	-8.15	-0.64	1.44e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg20203395	chr5:56204925	C5orf35	-0.67	-4.58	-0.42	1.44e-5	Initial pursuit acceleration;
THYM	cis	rs57590327	0.504	rs11712243	chr3:81840674	T/G	cg07356753	chr3:81810745	GBE1	-0.87	-6.56	-0.56	2.8e-9	Extraversion;
THYM	cis	rs637571	0.510	rs3892696	chr11:65582341	G/C	cg22664400	chr11:66445111	RBM4B	0.57	4.49	0.42	2.03e-5	Eosinophil percentage of white cells;
THYM	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg19748678	chr4:122722346	EXOSC9	0.7	4.85	0.45	4.79e-6	Type 2 diabetes;
THYM	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg05738196	chr6:26577821	NA	0.83	8.21	0.64	1.09e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg11871910	chr12:69753446	YEATS4	1.0	8.91	0.67	3.51e-14	Blood protein levels;
THYM	cis	rs72781680	0.821	rs72790304	chr2:24108557	G/A	cg08917208	chr2:24149416	ATAD2B	0.92	4.78	0.44	6.4e-6	Lymphocyte counts;
THYM	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs4144027	1.000	rs4144027	chr14:104357638	T/C	cg08213375	chr14:104286397	PPP1R13B	0.45	4.78	0.44	6.44e-6	Blood metabolite levels;
THYM	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg00487526	chr15:90818384	NA	-0.58	-4.46	-0.42	2.24e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs476633	0.691	rs6492997	chr15:41541171	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.66	-5.46	-0.49	3.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.63	4.51	0.42	1.82e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg05182265	chr7:156933206	UBE3C	-0.69	-9.32	-0.69	4.58e-15	Body mass index;
THYM	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg03929089	chr4:120376271	NA	-0.8	-8.0	-0.63	2.94e-12	Height;
THYM	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-6.71	-0.57	1.4e-9	Total body bone mineral density;
THYM	cis	rs778371	0.659	rs2289911	chr2:233704252	A/G	cg08000102	chr2:233561755	GIGYF2	-0.81	-7.2	-0.59	1.41e-10	Schizophrenia;
THYM	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg08916839	chr5:415575	AHRR	1.14	7.05	0.59	2.87e-10	Fat distribution (HIV);
THYM	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg01751800	chr4:77820391	ANKRD56	0.55	4.59	0.43	1.36e-5	Emphysema distribution in smoking;
THYM	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.49	4.71	0.43	8.55e-6	Lymphocyte counts;
THYM	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg03929089	chr4:120376271	NA	-0.94	-10.4	-0.73	2.34e-17	Coronary artery disease;
THYM	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.36	0.48	5.75e-7	Height;
THYM	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03517284	chr6:25882590	NA	-1.17	-11.71	-0.77	3.87e-20	Intelligence (multi-trait analysis);
THYM	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.71	5.32	0.48	7.02e-7	Height;
THYM	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-4.79	-0.44	6.22e-6	Atrioventricular conduction;
THYM	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg23161317	chr6:28129485	ZNF389	0.72	4.79	0.44	6.09e-6	Parkinson's disease;
THYM	cis	rs9486719	0.895	rs3734239	chr6:96996244	A/G	cg18709589	chr6:96969512	KIAA0776	-0.68	-4.71	-0.44	8.44e-6	Migraine;Coronary artery disease;
THYM	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.44	5.46	0.49	3.77e-7	Monocyte percentage of white cells;
THYM	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs7011507	0.700	rs76497882	chr8:49317150	T/C	cg08774009	chr8:49309094	NA	-0.65	-5.1	-0.46	1.75e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs56309584	0.560	rs56346215	chr17:8076917	A/C	cg08322244	chr17:8066669	VAMP2	-0.55	-5.11	-0.46	1.69e-6	Initial pursuit acceleration;
THYM	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg27168131	chr21:44088823	PDE9A	-0.46	-4.53	-0.42	1.74e-5	Mean corpuscular volume;
THYM	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg24209194	chr3:40518798	ZNF619	0.67	5.5	0.49	3.2e-7	Renal cell carcinoma;
THYM	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg12292205	chr6:26970375	C6orf41	-0.62	-5.11	-0.46	1.63e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg22841779	chr14:105766346	BRF1	-0.46	-5.67	-0.5	1.53e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs554111	0.634	rs4654875	chr1:21165176	A/G	cg01072550	chr1:21505969	NA	0.54	4.79	0.44	6.24e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs6835098	0.924	rs1991727	chr4:174163169	A/G	cg08422745	chr4:174089978	GALNT7	-1.05	-9.63	-0.7	1.02e-15	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs354225	0.584	rs11898033	chr2:54821518	G/A	cg23486701	chr2:54789491	SPTBN1	0.35	4.68	0.43	9.65e-6	Schizophrenia;
THYM	cis	rs17030434	1.000	rs75083896	chr4:154719082	A/G	cg14289246	chr4:154710475	SFRP2	-0.76	-5.24	-0.47	9.79e-7	Electrocardiographic conduction measures;
THYM	cis	rs11031096	0.678	rs4606468	chr11:4183643	G/T	cg08557956	chr11:4115526	RRM1	-0.53	-4.79	-0.44	6.2e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.69	-4.62	-0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs41278232	1.000	rs7260907	chr20:62663136	A/C	cg03065311	chr20:62601662	ZNF512B	0.71	5.37	0.48	5.5e-7	Tonsillectomy;
THYM	cis	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg24672777	chr11:48374446	OR4C45	0.66	4.59	0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs9378357	0.614	rs4959230	chr6:3289983	T/C	cg10513992	chr6:3293720	SLC22A23	-0.68	-4.52	-0.42	1.78e-5	Obesity-related traits;
THYM	cis	rs2276314	0.802	rs4799838	chr18:33597530	T/C	cg05985134	chr18:33552581	C18orf21	0.69	4.88	0.45	4.22e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs1808579	0.904	rs1652344	chr18:21128857	T/C	cg14672496	chr18:21087552	C18orf8	0.53	4.86	0.45	4.63e-6	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
THYM	cis	rs6450176	0.909	rs6898870	chr5:53293107	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-6.61	-0.56	2.22e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs7192750	0.538	rs11075911	chr16:71988505	T/C	cg06353428	chr16:71660113	MARVELD3	0.72	5.4	0.48	4.87e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs6939532	0.522	rs9379870	chr6:26374410	A/G	cg14345882	chr6:26364793	BTN3A2	0.4	5.16	0.47	1.35e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg10523679	chr1:76189770	ACADM	0.91	9.7	0.71	7.37e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs3845702	0.736	rs259810	chr2:180787821	T/C	cg01881094	chr2:180872142	CWC22	-0.91	-5.4	-0.48	5.01e-7	Schizophrenia;
THYM	trans	rs877282	0.947	rs7475589	chr10:767479	C/G	cg22713356	chr15:30763199	NA	1.41	11.51	0.76	1.04e-19	Uric acid levels;
THYM	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg25182066	chr10:30743637	MAP3K8	-0.57	-4.88	-0.45	4.28e-6	Inflammatory bowel disease;
THYM	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg10803722	chr21:46713166	LOC642852	-0.39	-5.07	-0.46	1.97e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4654899	1.000	rs6684976	chr1:21367501	G/A	cg01072550	chr1:21505969	NA	-0.75	-6.82	-0.57	8.26e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.55	-5.42	-0.49	4.55e-7	Crohn's disease;
THYM	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg05872129	chr22:39784769	NA	1.05	11.76	0.77	3.15e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs1669338	0.588	rs3864049	chr3:3186719	T/G	cg16797762	chr3:3221439	CRBN	-0.97	-5.43	-0.49	4.36e-7	White matter integrity;
THYM	cis	rs2108225	0.837	rs6959729	chr7:107446180	A/C	cg18560240	chr7:107437656	SLC26A3	-0.89	-6.57	-0.56	2.67e-9	Ulcerative colitis;
THYM	cis	rs6547741	1.000	rs1080060	chr2:27768808	T/A	cg27432699	chr2:27873401	GPN1	0.68	5.97	0.52	4.17e-8	Oral cavity cancer;
THYM	cis	rs2294693	0.579	rs10947939	chr6:40947618	C/G	cg21128951	chr6:40996213	UNC5CL	0.61	4.52	0.42	1.76e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs988913	1.000	rs4715492	chr6:54835178	C/T	cg04690482	chr6:54711388	FAM83B	0.46	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	cis	rs1003719	0.788	rs7275582	chr21:38451130	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.7	4.95	0.45	3.22e-6	Eye color traits;
THYM	cis	rs524023	0.914	rs80841	chr11:64437490	T/C	cg19131476	chr11:64387923	NRXN2	-0.39	-5.54	-0.49	2.7e-7	Urate levels in obese individuals;
THYM	cis	rs55728055	0.661	rs62237814	chr22:31992574	G/C	cg01338084	chr22:32026380	PISD	1.39	6.92	0.58	5.23e-10	Age-related hearing impairment;
THYM	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg18758796	chr5:131593413	PDLIM4	-0.5	-4.72	-0.44	8.15e-6	Breast cancer;
THYM	cis	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg18512352	chr11:47633146	NA	-0.38	-4.52	-0.42	1.75e-5	HDL cholesterol;
THYM	cis	rs3733606	0.503	rs11731274	chr4:6891455	T/G	cg05012661	chr4:6891264	NA	0.6	4.54	0.42	1.62e-5	Platelet count;
THYM	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg11984989	chr7:158649758	WDR60	1.1	12.75	0.79	2.74e-22	Height;
THYM	cis	rs12908161	0.853	rs12912342	chr15:85248216	T/C	cg17173187	chr15:85201210	NMB	0.5	4.7	0.43	8.85e-6	Schizophrenia;
THYM	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg11663144	chr21:46675770	NA	-0.71	-9.92	-0.71	2.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7584330	0.554	rs6744807	chr2:238424684	A/G	cg14458575	chr2:238380390	NA	0.79	4.62	0.43	1.22e-5	Prostate cancer;
THYM	cis	rs793571	0.568	rs6494029	chr15:58923206	T/C	cg05156742	chr15:59063176	FAM63B	0.65	5.26	0.47	8.87e-7	Schizophrenia;
THYM	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1003719	0.715	rs2051398	chr21:38550258	C/T	cg01329690	chr21:38580129	DSCR9	0.36	5.06	0.46	2.03e-6	Eye color traits;
THYM	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg16405210	chr4:1374714	KIAA1530	0.87	7.71	0.62	1.25e-11	Obesity-related traits;
THYM	cis	rs11634944	0.865	rs2554443	chr15:25261833	A/G	cg10601234	chr15:25523666	NA	-0.5	-4.64	-0.43	1.09e-5	Interleukin-8 levels;
THYM	trans	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.92	-0.58	5.35e-10	Corneal astigmatism;
THYM	cis	rs113835537	0.559	rs11227498	chr11:66269714	A/G	cg24851651	chr11:66362959	CCS	0.7	4.92	0.45	3.61e-6	Airway imaging phenotypes;
THYM	cis	rs8038465	0.615	rs6495076	chr15:73982965	G/A	cg15420318	chr15:73925796	NPTN	0.6	5.23	0.47	1.03e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg12310025	chr6:25882481	NA	-0.69	-5.59	-0.5	2.16e-7	Blood metabolite levels;
THYM	cis	rs4595586	0.545	rs7294600	chr12:39373416	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg24692254	chr21:30365293	RNF160	-0.99	-9.06	-0.68	1.67e-14	Dental caries;
THYM	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs9431487	0.710	rs618413	chr1:219016018	T/C	cg13962170	chr1:218691051	NA	-0.54	-4.76	-0.44	6.8e-6	Gut microbiome composition (summer);
THYM	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg26408565	chr15:76604113	ETFA	-0.52	-4.47	-0.42	2.16e-5	Blood metabolite levels;
THYM	cis	rs7172809	0.573	rs1015813	chr15:77533274	C/T	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs7107174	1.000	rs1942352	chr11:77970563	T/G	cg19901956	chr11:77921274	USP35	-0.72	-5.54	-0.49	2.71e-7	Testicular germ cell tumor;
THYM	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22857025	chr5:266934	NA	-1.43	-9.3	-0.69	5.28e-15	Breast cancer;
THYM	cis	rs6942756	1.000	rs67820265	chr7:128887925	A/G	cg02491457	chr7:128862824	NA	-0.44	-4.53	-0.42	1.69e-5	White matter hyperintensity burden;
THYM	cis	rs35883536	0.565	rs2809813	chr1:101032003	A/C	cg06223162	chr1:101003688	GPR88	0.85	7.33	0.6	7.63e-11	Monocyte count;
THYM	cis	rs78456975	0.600	rs72776256	chr2:1529595	C/A	cg12573674	chr2:1569213	NA	-1.25	-4.59	-0.43	1.37e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs4481887	0.927	rs7521689	chr1:248435831	G/T	cg00666640	chr1:248458726	OR2T12	0.56	4.76	0.44	6.8e-6	Common traits (Other);
THYM	cis	rs910316	0.575	rs12889133	chr14:75465089	C/T	cg08847533	chr14:75593920	NEK9	0.87	7.86	0.63	5.85e-12	Height;
THYM	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg08772003	chr10:104629869	AS3MT	-0.64	-5.68	-0.5	1.45e-7	Arsenic metabolism;
THYM	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg16325326	chr1:53192061	ZYG11B	0.93	10.11	0.72	9.54e-17	Monocyte count;
THYM	cis	rs665401	0.965	rs339327	chr6:117207682	A/G	cg20376953	chr6:117187980	NA	0.6	4.82	0.44	5.5e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs662064	0.963	rs10864459	chr1:10563609	C/T	cg20482658	chr1:10539492	PEX14	0.48	6.38	0.55	6.56e-9	Asthma;
THYM	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	5.38	0.48	5.45e-7	Schizophrenia;
THYM	cis	rs2073300	0.536	rs6137947	chr20:23414630	C/A	cg12062639	chr20:23401060	NAPB	1.1	5.73	0.51	1.16e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs1018836	0.770	rs13266461	chr8:91652817	T/C	cg16814680	chr8:91681699	NA	-0.95	-9.42	-0.69	2.89e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg03929089	chr4:120376271	NA	-1.0	-12.64	-0.79	4.61e-22	Height;
THYM	cis	rs7264396	0.563	rs2425122	chr20:34328848	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Total cholesterol levels;
THYM	cis	rs988913	0.736	rs4588693	chr6:54878219	A/G	cg04690482	chr6:54711388	FAM83B	0.45	4.7	0.43	8.66e-6	Menarche (age at onset);
THYM	cis	rs55966801	0.740	rs72878036	chr11:217171	C/T	cg20268054	chr11:393029	PKP3	0.52	4.72	0.44	8.26e-6	Plateletcrit;
THYM	cis	rs662064	0.962	rs2506901	chr1:10563492	A/G	cg20482658	chr1:10539492	PEX14	0.5	6.28	0.54	1.02e-8	Asthma;
THYM	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg04990556	chr1:26633338	UBXN11	1.0	8.02	0.64	2.67e-12	Obesity-related traits;
THYM	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg27211696	chr2:191398769	TMEM194B	-0.81	-8.03	-0.64	2.6e-12	Pulse pressure;
THYM	cis	rs3741151	0.764	rs79892955	chr11:73096280	G/T	cg17517138	chr11:73019481	ARHGEF17	0.99	5.79	0.51	9.03e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7614311	0.681	rs6801346	chr3:63947128	A/G	cg22134162	chr3:63841271	THOC7	0.52	6.05	0.53	2.81e-8	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg24209194	chr3:40518798	ZNF619	0.54	4.46	0.42	2.23e-5	Renal cell carcinoma;
THYM	cis	rs10752881	1.000	rs6701400	chr1:182977197	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg16006841	chr5:176797999	RGS14	0.5	5.97	0.52	4.02e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg09469691	chr10:81107165	PPIF	0.69	5.7	0.51	1.32e-7	Height;
THYM	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg20283391	chr11:68216788	NA	0.58	4.47	0.42	2.16e-5	Total body bone mineral density;
THYM	cis	rs9563576	0.778	rs9563565	chr13:58551342	T/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.63	4.63	0.43	1.18e-5	Body mass index;
THYM	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.84	-5.3	-0.48	7.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg18230493	chr5:56204884	C5orf35	-0.91	-6.78	-0.57	9.99e-10	Initial pursuit acceleration;
THYM	cis	rs7246657	0.943	rs7258692	chr19:37818829	C/A	cg22634378	chr19:37742834	NA	0.68	5.67	0.5	1.55e-7	Coronary artery calcification;
THYM	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg18132916	chr6:79620363	NA	-0.6	-5.66	-0.5	1.6e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3768617	0.510	rs10797851	chr1:183098001	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs13102973	0.864	rs7697346	chr4:135899283	G/A	cg14419869	chr4:135874104	NA	0.82	6.86	0.58	7.03e-10	Subjective well-being;
THYM	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs308447	0.516	rs6815982	chr4:123677472	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	-0.68	-4.45	-0.42	2.29e-5	Perceived unattractiveness to mosquitoes;
THYM	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg15997130	chr1:24165203	NA	-0.71	-6.11	-0.53	2.22e-8	Immature fraction of reticulocytes;
THYM	cis	rs988913	0.813	rs4712082	chr6:54771019	G/A	cg19716238	chr6:54711378	FAM83B	0.54	5.59	0.5	2.16e-7	Menarche (age at onset);
THYM	cis	rs9928842	0.823	rs2870472	chr16:75278841	C/G	cg09066997	chr16:75300724	BCAR1	0.69	4.47	0.42	2.19e-5	Alcoholic chronic pancreatitis;
THYM	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg00012203	chr2:219082015	ARPC2	0.89	8.63	0.66	1.37e-13	Colorectal cancer;
THYM	cis	rs13082711	0.522	rs11927257	chr3:27334294	C/T	cg02860705	chr3:27208620	NA	0.66	5.29	0.48	7.89e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg06970220	chr1:156163860	SLC25A44	0.74	5.67	0.5	1.53e-7	Testicular germ cell tumor;
THYM	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg06640241	chr16:89574553	SPG7	0.89	8.43	0.65	3.69e-13	Multiple myeloma (IgH translocation);
THYM	cis	rs988913	0.813	rs2143798	chr6:54753054	A/T	cg19716238	chr6:54711378	FAM83B	0.51	5.64	0.5	1.76e-7	Menarche (age at onset);
THYM	cis	rs2075230	0.705	rs1619016	chr17:7550553	C/T	cg27413385	chr17:7515425	FXR2	-0.36	-5.31	-0.48	7.3e-7	Hormone measurements;
THYM	cis	rs1385374	0.698	rs2170988	chr12:129290876	A/C	cg04043695	chr12:129287642	SLC15A4	-0.8	-4.83	-0.44	5.3e-6	Systemic lupus erythematosus;
THYM	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg01341218	chr17:43662625	NA	-1.07	-9.27	-0.69	5.9e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6087990	0.735	rs1040555	chr20:31380201	A/T	cg13636640	chr20:31349939	DNMT3B	-0.9	-9.6	-0.7	1.2e-15	Ulcerative colitis;
THYM	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg11141652	chr22:24348549	GSTTP1	0.62	6.25	0.54	1.17e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3892630	1.000	rs3892630	chr19:33181484	A/G	cg22980127	chr19:33182716	NUDT19	-1.11	-9.17	-0.69	9.75e-15	Red blood cell traits;
THYM	cis	rs11690935	0.959	rs35391289	chr2:172634983	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.84	-6.16	-0.53	1.77e-8	Schizophrenia;
THYM	cis	rs3741151	0.773	rs6592526	chr11:73208911	C/T	cg17517138	chr11:73019481	ARHGEF17	0.87	4.65	0.43	1.08e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg00074818	chr8:8560427	CLDN23	-0.59	-5.49	-0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg09307838	chr4:120376055	NA	0.78	5.89	0.52	5.7e-8	Corneal astigmatism;
THYM	cis	rs7869969	0.527	rs10992726	chr9:96173044	G/T	cg13460858	chr9:96720652	NA	-0.55	-4.56	-0.42	1.51e-5	Childhood body mass index;
THYM	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.68	-5.06	-0.46	2.08e-6	Colorectal cancer;
THYM	cis	rs1079204	0.793	rs10206448	chr2:219188443	T/G	cg05728596	chr2:219128475	GPBAR1	1.14	4.92	0.45	3.6e-6	Smooth-surface caries;
THYM	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg13695892	chr22:41940480	POLR3H	0.85	6.16	0.53	1.72e-8	Vitiligo;
THYM	cis	rs7731657	0.537	rs987024	chr5:130337029	T/G	cg08523029	chr5:130500466	HINT1	-0.81	-5.6	-0.5	2.04e-7	Fasting plasma glucose;
THYM	cis	rs13256369	0.950	rs1522839	chr8:8580453	C/T	cg17143192	chr8:8559678	CLDN23	0.9	6.48	0.55	4.12e-9	Obesity-related traits;
THYM	cis	rs6748734	0.625	rs4312490	chr2:241821481	A/G	cg04034577	chr2:241836375	C2orf54	-0.29	-4.51	-0.42	1.86e-5	Urinary metabolites;
THYM	cis	rs13232179	1.000	rs34311452	chr7:151113143	T/C	cg05714773	chr7:150493706	TMEM176B	0.67	4.68	0.43	9.33e-6	Coronary heart disease;
THYM	cis	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg24692254	chr21:30365293	RNF160	0.73	5.36	0.48	5.83e-7	Cognitive test performance;
THYM	cis	rs13082711	0.911	rs57317249	chr3:27515854	A/C	cg02860705	chr3:27208620	NA	0.72	5.15	0.47	1.39e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg00376283	chr12:123451042	ABCB9	0.71	4.76	0.44	6.85e-6	Neutrophil percentage of white cells;
THYM	cis	rs870825	0.655	rs28451943	chr4:185645572	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg24733560	chr20:60626293	TAF4	0.51	4.58	0.43	1.41e-5	Body mass index;
THYM	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg02696790	chr15:75250997	RPP25	-0.51	-5.4	-0.48	4.95e-7	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs13221852	0.659	rs1554502	chr7:3418411	C/T	cg21248987	chr7:3385318	SDK1	0.4	4.94	0.45	3.32e-6	Acute graft versus host disease in bone marrow transplantation (donor effect);
THYM	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg02869364	chr7:1081709	C7orf50	-0.45	-5.12	-0.46	1.61e-6	Longevity;Endometriosis;
THYM	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg26384229	chr12:38710491	ALG10B	1.02	8.46	0.66	3.1400000000000003e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs921968	0.541	rs485975	chr2:219374250	C/T	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4332037	0.539	rs4719416	chr7:2106608	G/A	cg23422044	chr7:1970798	MAD1L1	-0.76	-5.13	-0.47	1.54e-6	Bipolar disorder;
THYM	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg07930552	chr6:133119739	C6orf192	0.96	5.32	0.48	6.9e-7	Type 2 diabetes nephropathy;
THYM	cis	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg21775007	chr8:11205619	TDH	0.75	6.69	0.57	1.56e-9	Retinal vascular caliber;
THYM	cis	rs10911232	0.524	rs10911229	chr1:183050368	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs6032067	0.777	rs80323300	chr20:43785287	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg07690219	chr3:49449608	TCTA;RHOA	0.73	4.79	0.44	6.06e-6	Menarche (age at onset);
THYM	cis	rs4072705	0.614	rs7020027	chr9:127241414	G/A	cg01786973	chr9:127249749	NR5A1	-0.42	-5.41	-0.49	4.65e-7	Menarche (age at onset);
THYM	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs9650657	0.615	rs6601534	chr8:10691993	A/G	cg12981288	chr8:11183844	MTMR9	-0.51	-4.74	-0.44	7.51e-6	Neuroticism;
THYM	trans	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg10856724	chr12:34555212	NA	-1.01	-9.23	-0.69	7.34e-15	Morning vs. evening chronotype;
THYM	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg10360139	chr7:1886902	MAD1L1	-0.58	-4.63	-0.43	1.15e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	5.0	0.46	2.59e-6	Hip circumference adjusted for BMI;
THYM	cis	rs6430585	0.528	rs75524146	chr2:136725459	C/T	cg20242066	chr2:136595261	LCT	0.56	5.2	0.47	1.14e-6	Corneal structure;
THYM	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg04520793	chr17:42248056	ASB16	-0.35	-4.98	-0.45	2.85e-6	Total body bone mineral density;
THYM	cis	rs1061377	0.760	rs7678457	chr4:39137661	A/T	cg24403649	chr4:39172243	NA	0.59	4.78	0.44	6.29e-6	Uric acid levels;
THYM	cis	rs2066819	1.000	rs116849218	chr12:56683975	C/T	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs1075232	0.677	rs72714666	chr15:31492226	T/C	cg01030201	chr15:31746330	NA	-1.34	-4.45	-0.42	2.35e-5	Survival in colorectal cancer (non-distant metastatic);
THYM	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	10.3	0.73	3.73e-17	Chronic sinus infection;
THYM	cis	rs9902453	0.935	rs9905950	chr17:28431198	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.85	6.74	0.57	1.24e-9	Coffee consumption (cups per day);
THYM	cis	rs12928939	0.769	rs34680964	chr16:71658594	G/A	cg02602352	chr16:70688171	IL34	0.42	4.53	0.42	1.69e-5	Post bronchodilator FEV1;
THYM	cis	rs13232179	1.000	rs7797900	chr7:151117495	C/T	cg05714773	chr7:150493706	TMEM176B	0.66	4.86	0.45	4.69e-6	Coronary heart disease;
THYM	cis	rs36051895	0.695	rs12347727	chr9:5000811	A/G	cg02405213	chr9:5042618	JAK2	-1.04	-10.5	-0.73	1.38e-17	Pediatric autoimmune diseases;
THYM	cis	rs10911232	0.507	rs4652772	chr1:183023696	C/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.57	-4.54	-0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs4273100	0.607	rs1043809	chr17:19239432	C/T	cg25447019	chr17:19030144	GRAPL	0.79	6.24	0.54	1.2e-8	Schizophrenia;
THYM	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg21110456	chr7:2059412	MAD1L1	-0.46	-4.88	-0.45	4.27e-6	Neuroticism;
THYM	cis	rs941408	1.000	rs1736182	chr19:2798686	T/G	cg06609049	chr19:2785107	THOP1	0.69	5.71	0.51	1.29e-7	Total cholesterol levels;
THYM	cis	rs3741151	0.656	rs10501411	chr11:73292085	A/C	cg17517138	chr11:73019481	ARHGEF17	0.9	4.71	0.43	8.56e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg00810483	chr4:3375144	RGS12	0.32	4.83	0.44	5.29e-6	Serum sulfate level;
THYM	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg08305652	chr11:111469057	NA	0.53	4.58	0.43	1.41e-5	Primary sclerosing cholangitis;
THYM	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg02725872	chr8:58115012	NA	-1.09	-8.15	-0.64	1.43e-12	Developmental language disorder (linguistic errors);
THYM	cis	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg23422044	chr7:1970798	MAD1L1	0.86	5.98	0.52	3.83e-8	Bipolar disorder;
THYM	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg11266682	chr4:10021025	SLC2A9	0.66	9.49	0.7	2.03e-15	Bone mineral density;
THYM	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg10802521	chr3:52805072	NEK4	-0.8	-7.53	-0.61	2.92e-11	Bipolar disorder;
THYM	cis	rs73198271	0.722	rs488566	chr8:8639575	A/G	cg06636001	chr8:8085503	FLJ10661	-0.82	-5.75	-0.51	1.08e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.37	-4.57	-0.42	1.46e-5	Longevity;Endometriosis;
THYM	cis	rs4909189	0.957	rs71547528	chr7:158135431	T/C	cg25566285	chr7:158114605	PTPRN2	0.78	7.07	0.59	2.55e-10	Response to amphetamines;
THYM	cis	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg13609457	chr4:120235615	NA	0.58	5.33	0.48	6.48e-7	Corneal astigmatism;
THYM	cis	rs3741151	0.773	rs73543000	chr11:73151774	T/C	cg17517138	chr11:73019481	ARHGEF17	0.94	5.48	0.49	3.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs919433	0.680	rs788021	chr2:198293691	T/C	cg00792783	chr2:198669748	PLCL1	0.82	5.67	0.5	1.54e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4866334	1.000	rs79107423	chr5:18501522	A/G	cg02002538	chr5:17811409	NA	-1.1	-4.55	-0.42	1.61e-5	IgG glycosylation;
THYM	cis	rs11723261	0.621	rs3829	chr4:134851	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.86	5.68	0.5	1.48e-7	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg00071950	chr4:10020882	SLC2A9	0.66	5.93	0.52	4.8e-8	Bone mineral density;
THYM	cis	rs9814567	1.000	rs9841212	chr3:134191938	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-8.35	-0.65	5.59e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Gout;
THYM	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs56036086	0.762	rs11913090	chr22:50645219	G/A	cg16473166	chr22:50639996	SELO	0.76	4.81	0.44	5.76e-6	Platelet count;Plateletcrit;
THYM	cis	rs2455799	0.573	rs2455831	chr3:15751583	T/A	cg16303742	chr3:15540471	COLQ	-0.56	-5.95	-0.52	4.42e-8	Mean platelet volume;
THYM	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.77	-0.51	9.82e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg27129171	chr3:47204927	SETD2	-0.71	-6.75	-0.57	1.16e-9	Colorectal cancer;
THYM	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11644478	chr21:40555479	PSMG1	-0.56	-4.69	-0.43	9.07e-6	Menarche (age at onset);
THYM	cis	rs7580658	0.864	rs4150454	chr2:128038544	T/C	cg10021288	chr2:128175891	PROC	-0.72	-6.36	-0.55	7.09e-9	Protein C levels;
THYM	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg20887711	chr4:1340912	KIAA1530	0.69	6.28	0.54	1.02e-8	Longevity;
THYM	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg06028605	chr16:24865363	SLC5A11	0.63	5.18	0.47	1.26e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg13319975	chr6:146136371	FBXO30	-0.69	-5.6	-0.5	2.04e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	5.56	0.5	2.42e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.71	9.43	0.7	2.67e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg24530246	chr3:53118167	NA	-0.84	-4.74	-0.44	7.56e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg24450063	chr1:156163899	SLC25A44	1.18	9.94	0.71	2.2e-16	Testicular germ cell tumor;
THYM	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4595586	0.525	rs3914597	chr12:39388693	G/A	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.05e-5	Morning vs. evening chronotype;
THYM	cis	rs17443541	0.507	rs6721266	chr2:200469388	C/T	cg01795955	chr2:200468626	NA	-0.66	-4.59	-0.43	1.38e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03576123	chr11:487126	PTDSS2	-1.29	-6.4	-0.55	5.87e-9	Body mass index;
THYM	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4343996	0.901	rs1112428	chr7:3352512	T/C	cg21248987	chr7:3385318	SDK1	-0.37	-4.49	-0.42	1.98e-5	Motion sickness;
THYM	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.91	0.45	3.71e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs977987	0.806	rs1549306	chr16:75415341	A/G	cg03315344	chr16:75512273	CHST6	0.68	5.62	0.5	1.88e-7	Dupuytren's disease;
THYM	cis	rs7824557	0.564	rs7828263	chr8:11231886	A/G	cg21775007	chr8:11205619	TDH	-0.65	-5.16	-0.47	1.37e-6	Retinal vascular caliber;
THYM	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg23205692	chr1:25664452	TMEM50A	0.85	6.56	0.56	2.79e-9	Plateletcrit;Mean corpuscular volume;
THYM	trans	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg18240062	chr17:79603768	NPLOC4	0.73	6.55	0.56	2.9e-9	Eye color traits;
THYM	cis	rs988913	1.000	rs9475106	chr6:54851455	G/T	cg04690482	chr6:54711388	FAM83B	0.49	5.28	0.48	8.01e-7	Menarche (age at onset);
THYM	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg14972814	chr11:95582409	MTMR2	-0.72	-5.89	-0.52	5.93e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	5.84	0.51	7.3e-8	Lung cancer in ever smokers;
THYM	cis	rs7614311	0.681	rs6809100	chr3:63901180	A/G	cg22134162	chr3:63841271	THOC7	-0.58	-7.03	-0.59	3.13e-10	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg02869364	chr7:1081709	C7orf50	-0.61	-5.5	-0.49	3.23e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg09549813	chr16:4587862	C16orf5	0.59	6.9	0.58	5.78e-10	Schizophrenia;
THYM	cis	rs7626444	0.627	rs5021326	chr3:196477628	A/T	cg12930392	chr3:196481615	PAK2	0.4	4.92	0.45	3.58e-6	Monocyte count;
THYM	cis	rs6906287	0.531	rs56344535	chr6:119011263	T/C	cg01113488	chr6:119027122	NA	0.63	5.14	0.47	1.45e-6	Electrocardiographic conduction measures;
THYM	cis	rs6596100	0.500	rs67685368	chr5:132292946	T/G	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Breast cancer;
THYM	cis	rs273218	0.951	rs428213	chr5:53382790	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.93	-8.07	-0.64	2.17e-12	Migraine;
THYM	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11644478	chr21:40555479	PSMG1	-0.79	-6.78	-0.57	1e-9	Cognitive function;
THYM	cis	rs4523957	0.559	rs170040	chr17:2165714	C/T	cg16513277	chr17:2031491	SMG6	0.65	5.15	0.47	1.41e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg27129171	chr3:47204927	SETD2	0.77	7.52	0.61	3.08e-11	Colorectal cancer;
THYM	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg03909863	chr11:638404	DRD4	-0.86	-5.99	-0.52	3.66e-8	Systemic lupus erythematosus;
THYM	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg09263875	chr16:632152	PIGQ	0.68	5.63	0.5	1.85e-7	Height;
THYM	cis	rs4746818	0.688	rs951718	chr10:70928044	A/G	cg04149295	chr10:70884716	VPS26A	0.78	5.31	0.48	7.18e-7	Left atrial antero-posterior diameter;
THYM	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.68	-5.28	-0.48	8.12e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6430585	0.536	rs3213892	chr2:136552517	G/A	cg23851026	chr2:136556271	LCT	0.74	7.29	0.6	9.19e-11	Corneal structure;
THYM	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22496380	chr5:211416	CCDC127	-1.25	-7.51	-0.61	3.27e-11	Breast cancer;
THYM	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg11663144	chr21:46675770	NA	-0.72	-10.48	-0.73	1.54e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9522267	0.535	rs9522304	chr13:112237316	C/T	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	trans	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs4363385	0.747	rs3806219	chr1:152972522	C/T	cg13444842	chr1:152974279	SPRR3	0.57	4.53	0.42	1.71e-5	Inflammatory skin disease;
THYM	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.55	-5.04	-0.46	2.2e-6	Type 2 diabetes;
THYM	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg12310025	chr6:25882481	NA	-0.7	-5.47	-0.49	3.7e-7	Blood metabolite levels;
THYM	cis	rs800586	0.912	rs702773	chr8:116806658	C/A	cg04656070	chr8:116661063	TRPS1	0.46	4.71	0.43	8.51e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg03388043	chr17:80084554	CCDC57	0.71	6.05	0.53	2.83e-8	Life satisfaction;
THYM	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg04267008	chr7:1944627	MAD1L1	-0.55	-4.81	-0.44	5.64e-6	Bipolar disorder and schizophrenia;
THYM	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-8.31	-0.65	6.7e-13	Coronary artery disease;
THYM	cis	rs3892630	0.588	rs2287881	chr19:33333155	A/G	cg22980127	chr19:33182716	NUDT19	-1.13	-10.36	-0.73	2.85e-17	Red blood cell traits;
THYM	trans	rs629535	0.814	rs62513371	chr8:70077779	T/A	cg21567404	chr3:27674614	NA	-1.09	-10.28	-0.73	4.24e-17	Dupuytren's disease;
THYM	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg12963246	chr6:28129442	ZNF389	0.77	6.4	0.55	5.74e-9	Parkinson's disease;
THYM	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg11245990	chr11:68621969	NA	0.52	6.56	0.56	2.75e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs131805	1.000	rs3091397	chr22:50957520	C/T	cg25309564	chr22:51001381	C22orf41	0.73	5.16	0.47	1.33e-6	Granulocyte percentage of myeloid white cells;
THYM	cis	rs8067545	0.611	rs12603372	chr17:20181566	C/T	cg20830565	chr17:20408647	MGC102966	-0.48	-4.46	-0.42	2.28e-5	Schizophrenia;
THYM	cis	rs11264213	0.591	rs619666	chr1:36488956	C/T	cg27506609	chr1:36549197	TEKT2	-0.95	-5.02	-0.46	2.4e-6	Schizophrenia;
THYM	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	6.31	0.54	8.85e-9	Platelet count;
THYM	cis	rs6032067	0.925	rs62208424	chr20:43813341	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs7267979	1.000	rs6115168	chr20:25372891	C/A	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2398893	1.000	rs10993017	chr9:96760384	C/T	cg14459158	chr9:96720562	NA	-0.49	-4.6	-0.43	1.31e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs13315871	0.929	rs9842917	chr3:58244800	C/T	cg12435725	chr3:58293450	RPP14	-0.53	-5.7	-0.5	1.34e-7	Cholesterol, total;
THYM	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg10193763	chr2:225306901	NA	0.52	5.48	0.49	3.41e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg04944784	chr2:26401820	FAM59B	0.71	4.59	0.43	1.36e-5	Gut microbiome composition (summer);
THYM	cis	rs7523273	0.597	rs4844620	chr1:207980901	C/T	cg22525895	chr1:207977042	MIR29B2	-0.74	-4.85	-0.45	4.73e-6	Schizophrenia;
THYM	cis	rs11711311	1.000	rs12632983	chr3:113481913	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.61	-5.45	-0.49	4.02e-7	IgG glycosylation;
THYM	cis	rs7465272	1.000	rs7465272	chr8:143691838	A/T	cg10104451	chr8:143696006	ARC	-0.82	-5.66	-0.5	1.59e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7688540	0.511	rs76125013	chr4:195282	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.91	5.56	0.5	2.45e-7	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg11663144	chr21:46675770	NA	-0.74	-10.09	-0.72	1.05e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6539288	0.641	rs12318060	chr12:107340612	T/C	cg26297688	chr12:107349093	C12orf23	-0.5	-6.02	-0.53	3.22e-8	Total body bone mineral density;
THYM	cis	rs2997447	0.761	rs61776576	chr1:26429898	G/A	cg03844060	chr1:26490628	NA	0.7	4.81	0.44	5.61e-6	QRS complex (12-leadsum);
THYM	cis	rs9326248	0.530	rs11216316	chr11:117081500	A/C	cg01368799	chr11:117014884	PAFAH1B2	-0.91	-5.15	-0.47	1.38e-6	Blood protein levels;
THYM	cis	rs11574514	1.000	rs11574514	chr16:67971380	C/T	cg09738193	chr16:67926317	PSKH1	-0.92	-4.53	-0.42	1.69e-5	Crohn's disease;
THYM	cis	rs6987853	0.563	rs2974302	chr8:42443119	C/G	cg09913449	chr8:42400586	C8orf40	0.71	6.39	0.55	6.22e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs113835537	0.735	rs519380	chr11:66409409	G/A	cg24851651	chr11:66362959	CCS	0.67	4.71	0.44	8.45e-6	Airway imaging phenotypes;
THYM	cis	rs17001868	0.568	rs9611318	chr22:40739414	C/G	cg07138101	chr22:40742427	ADSL	0.94	5.71	0.51	1.3e-7	Mammographic density (dense area);
THYM	cis	rs2408955	0.521	rs11168437	chr12:48566156	C/T	cg21466736	chr12:48725269	NA	-0.51	-4.98	-0.46	2.83e-6	Glycated hemoglobin levels;
THYM	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg12219531	chr12:120966889	COQ5	0.85	6.6	0.56	2.33e-9	High light scatter reticulocyte count;
THYM	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg10802521	chr3:52805072	NEK4	-0.68	-5.79	-0.51	9.01e-8	Bipolar disorder;
THYM	cis	rs870825	0.655	rs10033035	chr4:185630880	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	trans	rs480407	0.857	rs270959	chr2:161714863	G/T	cg06548410	chr19:1997657	BTBD2	-0.72	-7.14	-0.59	1.82e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs2288073	0.562	rs112892911	chr2:24590800	G/A	cg06627628	chr2:24431161	ITSN2	-0.73	-5.17	-0.47	1.31e-6	Venous thromboembolism (SNP x SNP interaction);
THYM	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg26818010	chr10:134567672	INPP5A	-0.92	-7.52	-0.61	3.1e-11	Migraine;
THYM	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg02869364	chr7:1081709	C7orf50	-0.45	-5.14	-0.47	1.46e-6	Longevity;Endometriosis;
THYM	cis	rs2074585	0.560	rs12903058	chr15:91061121	G/T	cg22089800	chr15:90895588	ZNF774	-0.68	-4.99	-0.46	2.7e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
THYM	cis	rs800586	0.956	rs800518	chr8:116801780	C/T	cg04656070	chr8:116661063	TRPS1	0.51	4.86	0.45	4.59e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg22841779	chr14:105766346	BRF1	-0.48	-6.05	-0.53	2.81e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7511006	0.893	rs2038049	chr22:50654888	G/C	cg11077631	chr22:50617003	PANX2	-0.53	-5.94	-0.52	4.66e-8	Obesity-related traits;
THYM	cis	rs11989744	1.000	rs11989744	chr8:23567463	A/G	cg04349084	chr8:23602677	NA	-0.45	-4.75	-0.44	7.23e-6	Waist-hip ratio;
THYM	cis	rs7100689	0.577	rs9285726	chr10:82035150	A/T	cg01528321	chr10:82214614	TSPAN14	0.95	7.36	0.6	6.54e-11	Post bronchodilator FEV1;
THYM	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg10661904	chr17:79619235	PDE6G	-0.65	-6.24	-0.54	1.19e-8	Eye color traits;
THYM	cis	rs7078219	0.505	rs6584281	chr10:101286480	A/G	cg23904955	chr10:101282759	NA	-0.37	-4.71	-0.43	8.5e-6	Dental caries;
THYM	cis	rs11634944	0.508	rs10451029	chr15:25237343	C/T	cg14481604	chr15:25334117	SNORD116-22	-0.64	-4.95	-0.45	3.22e-6	Interleukin-8 levels;
THYM	cis	rs28374715	0.578	rs8036026	chr15:41630499	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.78	-0.83	2.3e-26	Ulcerative colitis;
THYM	cis	rs3126085	0.877	rs12065368	chr1:152253497	C/T	cg10321714	chr1:152280068	FLG	0.64	4.81	0.44	5.57e-6	Atopic dermatitis;
THYM	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs4363385	0.818	rs1415969	chr1:153006448	G/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg05973401	chr12:123451056	ABCB9	0.68	4.55	0.42	1.58e-5	Neutrophil percentage of white cells;
THYM	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.77	0.51	1.01e-7	Rheumatoid arthritis;
THYM	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg24675658	chr1:53192096	ZYG11B	0.57	4.67	0.43	9.78e-6	Monocyte count;
THYM	cis	rs899997	1.000	rs8030090	chr15:79034260	A/G	cg00639195	chr15:79103007	ADAMTS7	-0.79	-5.55	-0.49	2.62e-7	Coronary artery disease or large artery stroke;
THYM	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg15448220	chr1:150897856	SETDB1	0.9	7.66	0.62	1.56e-11	Melanoma;
THYM	cis	rs4285028	0.747	rs58367397	chr3:121451700	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.85	-7.37	-0.6	6.22e-11	Multiple sclerosis;
THYM	cis	rs6496667	1.000	rs1452408	chr15:90891117	A/C	cg22089800	chr15:90895588	ZNF774	0.74	5.0	0.46	2.65e-6	Rheumatoid arthritis;
THYM	cis	rs1113500	0.524	rs11185270	chr1:108654362	G/A	cg06207961	chr1:108661230	NA	0.63	4.93	0.45	3.44e-6	Growth-regulated protein alpha levels;
THYM	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg19016782	chr12:123741754	C12orf65	-0.7	-4.59	-0.43	1.35e-5	Neutrophil percentage of white cells;
THYM	cis	rs684232	0.623	rs417171	chr17:576941	A/G	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.38	-4.47	-0.42	2.18e-5	Prostate cancer;
THYM	cis	rs17122693	1.000	rs17122683	chr14:51080422	G/A	cg04730355	chr14:51134070	SAV1	0.99	5.4	0.48	4.94e-7	Cognitive performance;
THYM	cis	rs17253792	0.822	rs10137364	chr14:56059987	G/A	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.8	-8.45	-0.65	3.38e-13	Lymphocyte counts;
THYM	cis	rs3791406	1.000	rs3791412	chr2:240031088	A/G	cg20627572	chr2:239991813	HDAC4	-0.46	-4.49	-0.42	2.04e-5	Skin aging (microtopography measurement);
THYM	cis	rs739496	0.542	rs12423926	chr12:111781055	C/T	cg10833066	chr12:111807467	FAM109A	-0.54	-6.33	-0.54	8.12e-9	Platelet count;
THYM	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg07884673	chr3:53033167	SFMBT1	1.19	6.0	0.52	3.59e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs9948	1.000	rs72811629	chr2:97519901	T/G	cg01990225	chr2:97406019	LMAN2L	-0.97	-4.83	-0.44	5.28e-6	Erectile dysfunction and prostate cancer treatment;
THYM	trans	rs682457	0.524	rs72962904	chr11:87943861	A/G	cg25852200	chr11:1328419	TOLLIP	0.95	7.51	0.61	3.17e-11	Post-traumatic stress disorder;
THYM	cis	rs17641971	0.708	rs10957317	chr8:49888870	C/T	cg00325661	chr8:49890786	NA	-0.67	-5.25	-0.47	9.09e-7	Blood metabolite levels;
THYM	cis	rs7084921	0.552	rs12780023	chr10:101874829	C/T	cg11344164	chr10:101878520	NA	-0.53	-4.99	-0.46	2.77e-6	Bone mineral density;
THYM	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg14004847	chr7:1930337	MAD1L1	-0.68	-5.34	-0.48	6.29e-7	Schizophrenia;
THYM	cis	rs7319311	0.589	rs952358	chr13:111026738	T/A	cg06243866	chr13:111019493	COL4A2	0.69	4.51	0.42	1.86e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs10929159	0.928	rs7598567	chr2:236920673	A/G	cg14895183	chr2:236924282	AGAP1	0.52	4.51	0.42	1.88e-5	Parkinson's disease;
THYM	cis	rs4979906	1.000	rs68092325	chr10:79446719	T/A	cg07817648	chr10:79422355	NA	-0.77	-5.61	-0.5	1.98e-7	Mortality in heart failure;
THYM	cis	rs6831352	0.879	rs56222233	chr4:100069627	T/G	cg12011299	chr4:100065546	ADH4	-0.82	-7.62	-0.62	1.91e-11	Alcohol dependence;
THYM	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11644478	chr21:40555479	PSMG1	-0.76	-6.49	-0.55	3.85e-9	Cognitive function;
THYM	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg10150615	chr22:24372951	LOC391322	-1.01	-11.97	-0.78	1.11e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11018874	0.597	rs10765243	chr11:89855118	C/G	cg23743573	chr11:89867420	NAALAD2	0.77	4.76	0.44	6.87e-6	White blood cell types;
THYM	cis	rs12134245	0.874	rs35115044	chr1:92021650	A/G	cg25838465	chr1:92012736	NA	-0.57	-5.1	-0.46	1.7e-6	Breast cancer;
THYM	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg18252515	chr7:66147081	NA	-0.62	-4.55	-0.42	1.59e-5	Aortic root size;
THYM	cis	rs713587	0.935	rs11676272	chr2:25141538	A/G	cg15423357	chr2:25149977	NA	0.69	7.66	0.62	1.56e-11	Body mass index in non-asthmatics;
THYM	cis	rs10492096	0.947	rs61918020	chr12:6605514	C/T	cg13857086	chr12:6580257	VAMP1	0.87	5.27	0.48	8.47e-7	Hip geometry;
THYM	cis	rs665401	0.965	rs339301	chr6:117224303	A/G	cg20376953	chr6:117187980	NA	0.6	4.82	0.44	5.5e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs3924048	0.574	rs11588028	chr1:12612385	T/C	cg00291366	chr1:12616550	NA	0.4	6.33	0.54	7.89e-9	Optic cup area;
THYM	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.71	6.78	0.57	1.03e-9	Lymphocyte counts;
THYM	cis	rs758324	0.645	rs247317	chr5:131442305	C/T	cg16205897	chr5:131564050	P4HA2	0.53	4.63	0.43	1.18e-5	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs7267979	1.000	rs6076345	chr20:25381895	T/G	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg03405983	chr8:143858548	LYNX1	-0.55	-5.9	-0.52	5.66e-8	Urinary tract infection frequency;
THYM	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	5.09	0.46	1.8e-6	Menarche (age at onset);
THYM	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg00677455	chr12:58241039	CTDSP2	0.65	4.63	0.43	1.17e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2599510	0.744	rs2254106	chr2:32768797	G/A	cg02381751	chr2:32503542	YIPF4	0.58	4.69	0.43	9.05e-6	Interleukin-18 levels;
THYM	cis	rs1922291	0.546	rs12476585	chr2:102841145	G/C	cg13315345	chr2:102803985	IL1RL2	0.63	7.15	0.59	1.77e-10	Blood protein levels;
THYM	cis	rs72627123	0.867	rs8020310	chr14:74494437	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.52	0.56	3.44e-9	Morning vs. evening chronotype;
THYM	cis	rs6968419	0.537	rs12673240	chr7:115739565	C/T	cg24623608	chr7:116503366	CAPZA2	0.61	4.55	0.42	1.59e-5	Intraocular pressure;
THYM	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg09021430	chr5:549028	NA	-0.73	-5.44	-0.49	4.18e-7	Obesity-related traits;
THYM	cis	rs9361491	0.657	rs2321773	chr6:79476243	G/A	cg04547799	chr6:79944526	HMGN3	-0.66	-4.57	-0.42	1.44e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg06221963	chr1:154839813	KCNN3	-0.73	-8.62	-0.66	1.5e-13	Prostate cancer;
THYM	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg15445000	chr17:37608096	MED1	-0.44	-5.07	-0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4595586	0.545	rs12826080	chr12:39387772	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.05e-5	Morning vs. evening chronotype;
THYM	cis	rs9868873	0.748	rs9856455	chr3:122704281	T/C	cg07898018	chr3:122399831	PARP14	-0.99	-4.91	-0.45	3.74e-6	Esophageal cancer;
THYM	cis	rs2562456	0.837	rs62110205	chr19:21760071	A/G	cg00806126	chr19:22604979	ZNF98	-0.72	-4.56	-0.42	1.52e-5	Pain;
THYM	cis	rs7192750	0.586	rs3794692	chr16:71961339	T/C	cg06353428	chr16:71660113	MARVELD3	0.72	5.12	0.46	1.62e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs7507204	0.723	rs12979645	chr19:3414688	A/T	cg08380311	chr19:3435252	NFIC	0.92	7.44	0.61	4.44e-11	Height;
THYM	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg12963246	chr6:28129442	ZNF389	0.83	7.46	0.61	3.97e-11	Depression;
THYM	cis	rs10781543	0.839	rs6560632	chr9:139371786	A/C	cg14115884	chr9:139300582	SDCCAG3	0.71	6.66	0.56	1.76e-9	Monocyte percentage of white cells;
THYM	cis	rs4886920	0.672	rs8040443	chr15:78130915	C/G	cg10461261	chr15:78109450	NA	0.47	4.64	0.43	1.13e-5	Neuroticism;
THYM	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg08736216	chr1:53307985	ZYG11A	-0.56	-5.21	-0.47	1.08e-6	Monocyte count;
THYM	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4953911	0.893	rs2166736	chr2:135054058	A/G	cg18482303	chr2:135041380	MGAT5	0.29	5.04	0.46	2.25e-6	Multiple sclerosis (severity);
THYM	cis	rs3812049	0.737	rs790155	chr5:127498380	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.41	0.48	4.8e-7	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs6121246	0.559	rs6058468	chr20:30406448	C/A	cg13852791	chr20:30311386	BCL2L1	1.03	10.0	0.72	1.65e-16	Mean corpuscular hemoglobin;
THYM	cis	rs4730276	0.674	rs2237685	chr7:107574784	A/G	cg23293999	chr7:106826042	HBP1	0.6	4.86	0.45	4.65e-6	Ulcerative colitis;
THYM	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg24818145	chr4:99064322	C4orf37	0.64	4.85	0.45	4.77e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs500891	0.525	rs1170346	chr6:84021751	C/T	cg21688264	chr6:84418724	SNAP91	0.79	5.09	0.46	1.83e-6	Platelet-derived growth factor BB levels;
THYM	cis	rs4638749	0.677	rs115510885	chr2:108824365	C/T	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg07061783	chr6:25882402	NA	0.62	4.5	0.42	1.92e-5	Blood metabolite levels;
THYM	cis	rs13082711	0.522	rs640065	chr3:27363937	A/T	cg02860705	chr3:27208620	NA	0.71	4.79	0.44	6.18e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs8018808	0.935	rs4899655	chr14:77898077	G/A	cg20045696	chr14:77926864	AHSA1	0.51	4.6	0.43	1.29e-5	Myeloid white cell count;
THYM	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg13390004	chr1:15929781	NA	0.61	4.63	0.43	1.15e-5	Systolic blood pressure;
THYM	cis	rs7226229	0.950	rs2291037	chr17:20924523	C/T	cg21263980	chr17:20946333	USP22	0.66	5.0	0.46	2.61e-6	Blood trace element (Se levels);
THYM	cis	rs2970992	0.764	rs4850949	chr2:101324382	A/T	cg01042948	chr2:101319752	NA	-0.64	-6.5	-0.55	3.74e-9	Educational attainment;
THYM	cis	rs11792861	0.591	rs11791855	chr9:111684139	C/T	cg05043794	chr9:111880884	C9orf5	-0.35	-4.73	-0.44	7.83e-6	Menarche (age at onset);
THYM	cis	rs6840360	0.571	rs62327268	chr4:152522326	T/A	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs259282	0.605	rs60968670	chr19:33108982	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.57	4.73	0.44	7.87e-6	Schizophrenia;
THYM	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.59	0.66	1.68e-13	Colorectal cancer;
THYM	cis	rs17401966	0.931	rs34225619	chr1:10371987	C/T	cg20482658	chr1:10539492	PEX14	0.39	4.71	0.44	8.47e-6	Hepatocellular carcinoma;
THYM	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg16558253	chr16:72132732	DHX38	-0.58	-5.02	-0.46	2.46e-6	Fibrinogen levels;
THYM	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg11062466	chr8:58055876	NA	0.92	4.62	0.43	1.19e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs2455799	0.613	rs13060772	chr3:15896795	C/T	cg16303742	chr3:15540471	COLQ	-0.57	-5.81	-0.51	8.21e-8	Mean platelet volume;
THYM	cis	rs1045902	0.967	rs1469530	chr2:73464948	C/T	cg24220031	chr2:73402428	NA	-0.81	-9.65	-0.7	9.42e-16	Intelligence (multi-trait analysis);
THYM	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg14972814	chr11:95582409	MTMR2	-0.7	-5.54	-0.49	2.75e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg15110403	chr19:17392923	ANKLE1	-0.57	-4.94	-0.45	3.36e-6	Systemic lupus erythematosus;
THYM	cis	rs34375054	0.660	rs35941060	chr12:125594245	G/A	cg25124228	chr12:125621409	AACS	-0.78	-6.04	-0.53	3.02e-8	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs7255436	0.965	rs4044435	chr19:8448177	T/C	cg10174797	chr19:8464628	RAB11B	0.41	4.88	0.45	4.31e-6	HDL cholesterol;
THYM	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg21028142	chr17:79581711	NPLOC4	-0.52	-5.13	-0.47	1.52e-6	Eye color traits;
THYM	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg12373951	chr3:133503437	NA	0.48	4.72	0.44	7.96e-6	Iron status biomarkers;
THYM	cis	rs6138458	0.626	rs6138473	chr20:25012155	A/G	cg26195577	chr20:24973756	C20orf3	-0.8	-6.49	-0.55	3.84e-9	Blood protein levels;
THYM	cis	rs12282928	0.885	rs4472898	chr11:48260983	T/A	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.28	6.38	0.55	6.45e-9	Obesity-related traits;
THYM	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs6089829	0.888	rs4809268	chr20:61675249	C/G	cg08564027	chr20:61660810	NA	0.96	10.46	0.73	1.7e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg23711669	chr6:146136114	FBXO30	-0.98	-10.47	-0.73	1.68e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg09307838	chr4:120376055	NA	-0.64	-4.7	-0.43	8.72e-6	Corneal astigmatism;
THYM	cis	rs2991971	1.000	rs2991972	chr1:46013208	C/T	cg15605315	chr1:45957053	TESK2	0.65	5.12	0.46	1.6e-6	High light scatter reticulocyte count;
THYM	cis	rs89107	0.576	rs17825652	chr6:118788986	G/A	cg21191810	chr6:118973309	C6orf204	0.5	5.04	0.46	2.25e-6	Cardiac structure and function;
THYM	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg23018236	chr17:30244563	NA	-0.6	-4.45	-0.42	2.3e-5	Hip circumference adjusted for BMI;
THYM	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg08975724	chr8:8085496	FLJ10661	0.74	6.05	0.53	2.88e-8	Mood instability;
THYM	cis	rs12347191	0.500	rs973473	chr9:100620730	T/G	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Orofacial clefts;
THYM	cis	rs9443645	0.507	rs1876389	chr6:79481932	A/T	cg05283184	chr6:79620031	NA	-0.63	-4.95	-0.45	3.21e-6	Intelligence (multi-trait analysis);
THYM	cis	rs863345	0.604	rs12078065	chr1:158465063	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs9807989	0.801	rs4851566	chr2:102972799	G/C	cg03938978	chr2:103052716	IL18RAP	0.63	6.46	0.55	4.36e-9	Asthma;
THYM	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg04455712	chr21:45112962	RRP1B	0.58	5.33	0.48	6.69e-7	Mean corpuscular volume;
THYM	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg05890377	chr2:74357713	NA	1.11	10.68	0.74	5.99e-18	Gestational age at birth (maternal effect);
THYM	cis	rs2069036	0.951	rs2027458	chr10:16094926	G/A	cg26633223	chr10:15133461	NA	0.68	4.76	0.44	6.94e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	trans	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg06437703	chr8:37914619	EIF4EBP1	-0.69	-7.01	-0.58	3.39e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs921968	0.541	rs41461846	chr2:219313354	A/G	cg02176678	chr2:219576539	TTLL4	-0.77	-7.63	-0.62	1.81e-11	Mean corpuscular hemoglobin concentration;
THYM	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg18252515	chr7:66147081	NA	-0.66	-5.01	-0.46	2.55e-6	Aortic root size;
THYM	cis	rs7481584	0.624	rs511990	chr11:3052936	A/G	cg03159660	chr11:2078197	NA	0.62	4.6	0.43	1.3e-5	Calcium levels;
THYM	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg12564285	chr5:131593104	PDLIM4	0.44	4.57	0.42	1.46e-5	Blood metabolite levels;
THYM	cis	rs55665837	1.000	rs11023223	chr11:14457112	A/G	cg19336497	chr11:14380999	RRAS2	-0.64	-7.04	-0.59	3e-10	Vitamin D levels;
THYM	cis	rs2742234	0.590	rs2115817	chr10:43686552	C/T	cg06632098	chr10:43605906	RET	-0.79	-5.1	-0.46	1.73e-6	Hirschsprung disease;
THYM	cis	rs1981331	1.000	rs1981331	chr21:47995443	A/C	cg23283320	chr21:48055893	PRMT2	1.24	6.23	0.54	1.27e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg17863274	chr19:49399704	TULP2	-1.01	-6.47	-0.55	4.29e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	4.95	0.45	3.22e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs79387448	0.745	rs72993720	chr2:103121269	A/T	cg09003973	chr2:102972529	NA	0.76	4.68	0.43	9.37e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.87	0.45	4.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs4737010	0.501	rs7000282	chr8:41647493	A/C	cg08923054	chr8:41654455	ANK1	0.79	4.74	0.44	7.49e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
THYM	cis	rs1550582	0.917	rs7831961	chr8:135507060	C/G	cg09855544	chr8:135498122	ZFAT	-0.7	-5.18	-0.47	1.23e-6	Educational attainment;
THYM	cis	rs9914988	0.565	rs34039488	chr17:27320232	G/A	cg26182037	chr17:27055700	NEK8	0.84	4.53	0.42	1.72e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg08999081	chr20:33150536	PIGU	-0.56	-4.74	-0.44	7.37e-6	Height;
THYM	cis	rs920590	0.527	rs79929516	chr8:19650050	G/C	cg03894339	chr8:19674705	INTS10	0.9	7.3	0.6	8.7e-11	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1050631	0.592	rs1785927	chr18:33726447	C/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.32	0.48	6.94e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs11585357	0.843	rs72646796	chr1:17612503	T/C	cg08277548	chr1:17600880	PADI3	-0.9	-5.43	-0.49	4.38e-7	Hair shape;
THYM	cis	rs17767294	0.708	rs76223516	chr6:27939475	C/T	cg08851530	chr6:28072375	NA	1.39	5.71	0.51	1.31e-7	Parkinson's disease;
THYM	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg06074448	chr4:187884817	NA	-1.01	-13.54	-0.81	6.7e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs747334	0.811	rs11596841	chr10:92715663	A/G	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-5.77	-0.51	9.89e-8	Total cholesterol levels;
THYM	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9549260	0.816	rs7334318	chr13:41217410	C/G	cg21288729	chr13:41239152	FOXO1	0.73	5.82	0.51	7.84e-8	Red blood cell count;
THYM	cis	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22857025	chr5:266934	NA	-1.52	-9.95	-0.71	2.14e-16	Breast cancer;
THYM	cis	rs5769765	0.658	rs2157536	chr22:50190180	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-5.73	-0.51	1.19e-7	Schizophrenia;
THYM	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg08859206	chr1:53392774	SCP2	-0.61	-6.77	-0.57	1.05e-9	Monocyte count;
THYM	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs61931739	0.817	rs2636084	chr12:34130210	G/A	cg06521331	chr12:34319734	NA	-0.6	-4.84	-0.44	4.98e-6	Morning vs. evening chronotype;
THYM	cis	rs11031096	0.727	rs2268168	chr11:4142069	C/T	cg18678763	chr11:4115507	RRM1	-0.47	-6.57	-0.56	2.7e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4595586	0.545	rs12827823	chr12:39392144	G/T	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs11361923	1	rs11361923	chr14:77862679	GC/G	cg20045696	chr14:77926864	AHSA1	-0.56	-4.94	-0.45	3.41e-6	Sum basophil neutrophil counts;White blood cell count;Granulocyte count;
THYM	cis	rs28595532	0.920	rs56303276	chr4:119723514	C/T	cg21605333	chr4:119757512	SEC24D	1.66	6.08	0.53	2.49e-8	Cannabis dependence symptom count;
THYM	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg03388043	chr17:80084554	CCDC57	-0.71	-5.83	-0.51	7.47e-8	Life satisfaction;
THYM	cis	rs2273669	0.504	rs78123955	chr6:109434847	T/C	cg17117243	chr6:109341365	SESN1	-0.85	-4.99	-0.46	2.77e-6	Prostate cancer;
THYM	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg14349672	chr11:133703707	NA	-0.54	-4.74	-0.44	7.5e-6	Childhood ear infection;
THYM	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg26116260	chr4:7069785	GRPEL1	1.12	11.02	0.75	1.14e-18	Monocyte percentage of white cells;
THYM	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg11752832	chr7:134001865	SLC35B4	0.74	5.65	0.5	1.69e-7	Mean platelet volume;
THYM	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.33	9.84	0.71	3.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg16558253	chr16:72132732	DHX38	-0.54	-4.57	-0.42	1.47e-5	Fibrinogen levels;
THYM	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg22508957	chr16:3507546	NAT15	-0.41	-4.53	-0.42	1.71e-5	Body mass index (adult);
THYM	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg19761014	chr17:28927070	LRRC37B2	0.74	4.53	0.42	1.73e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11890956	chr21:40555474	PSMG1	-0.66	-6.44	-0.55	4.92e-9	Menarche (age at onset);
THYM	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg10792982	chr14:105748885	BRF1	0.7	7.06	0.59	2.74e-10	Mean platelet volume;Platelet distribution width;
THYM	trans	rs11098499	0.821	rs56155624	chr4:120291026	C/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.99	-0.58	3.7e-10	Corneal astigmatism;
THYM	cis	rs13086611	1	rs13086611	chr3:49385417	A/T	cg03060546	chr3:49711283	APEH	-0.67	-5.19	-0.47	1.2e-6	Educational attainment;
THYM	cis	rs6840360	0.550	rs7675818	chr4:152690777	C/G	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.714	rs6017527	chr20:43886291	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.38	-4.48	-0.42	2.07e-5	Blood protein levels;
THYM	trans	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg23505145	chr19:12996616	KLF1	1.01	10.01	0.72	1.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9311676	0.609	rs55646457	chr3:58415263	T/A	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs7219021	0.705	rs11079842	chr17:47002762	G/A	cg09029085	chr17:47094198	IGF2BP1	0.33	4.48	0.42	2.04e-5	Schizophrenia or bipolar disorder;
THYM	cis	rs1451375	0.583	rs3779078	chr7:50610918	C/T	cg18232548	chr7:50535776	DDC	0.67	5.0	0.46	2.63e-6	Malaria;
THYM	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg02891314	chr5:179741120	GFPT2	-0.89	-7.19	-0.59	1.48e-10	Height;
THYM	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg07930192	chr7:1003750	NA	0.58	4.8	0.44	5.88e-6	Longevity;Endometriosis;
THYM	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg24257776	chr3:47051546	LOC100129354	0.42	4.75	0.44	7.25e-6	Colorectal cancer;
THYM	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg17796960	chr10:135278976	LOC619207	-0.55	-4.6	-0.43	1.33e-5	Systemic lupus erythematosus;
THYM	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg22166914	chr1:53195759	ZYG11B	0.72	6.07	0.53	2.67e-8	Monocyte count;
THYM	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg15693483	chr7:1102177	C7orf50	0.41	5.93	0.52	4.81e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4731207	0.596	rs2402757	chr7:124611713	A/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.7	5.56	0.5	2.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs7192750	0.586	rs8054111	chr16:71990651	A/G	cg06353428	chr16:71660113	MARVELD3	0.74	5.57	0.5	2.35e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.98	0.45	2.85e-6	Obesity-related traits;
THYM	cis	rs861020	0.959	rs658860	chr1:209990549	C/T	cg05527609	chr1:210001259	C1orf107	1.04	7.82	0.63	7.16e-12	Orofacial clefts;
THYM	cis	rs36051895	0.632	rs12344116	chr9:5142216	G/A	cg02405213	chr9:5042618	JAK2	-1.02	-10.51	-0.73	1.37e-17	Pediatric autoimmune diseases;
THYM	cis	rs2637266	0.935	rs2583057	chr10:78396019	C/T	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs1847505	0.609	rs1514541	chr13:61586096	C/T	cg25164009	chr13:61490935	NA	0.76	4.84	0.44	5.09e-6	Polychlorinated biphenyl levels;
THYM	cis	rs922692	1.000	rs922692	chr15:78984214	C/A	cg15571903	chr15:79123663	NA	-0.56	-5.05	-0.46	2.09e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg03388025	chr16:89894329	SPIRE2	0.53	4.49	0.42	1.97e-5	Vitiligo;
THYM	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg13319975	chr6:146136371	FBXO30	-0.71	-5.72	-0.51	1.24e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4606347	0.932	rs61781318	chr1:66105805	A/G	cg04111102	chr1:66153794	NA	0.59	4.54	0.42	1.67e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg16405210	chr4:1374714	KIAA1530	-0.61	-4.63	-0.43	1.15e-5	Obesity-related traits;
THYM	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg00484396	chr16:3507460	NAT15	-0.66	-8.16	-0.64	1.36e-12	Tuberculosis;
THYM	cis	rs611744	0.647	rs13280487	chr8:109270263	G/C	cg21045802	chr8:109455806	TTC35	0.62	5.4	0.48	4.9e-7	Dupuytren's disease;
THYM	cis	rs990171	1.000	rs1861246	chr2:102966783	T/C	cg13897122	chr2:103039542	IL18RAP	-0.42	-4.92	-0.45	3.56e-6	Lymphocyte counts;
THYM	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg12165864	chr7:66369176	NA	-0.67	-5.26	-0.47	8.99e-7	Aortic root size;
THYM	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.57	4.48	0.42	2.12e-5	Chronic sinus infection;
THYM	cis	rs4654899	0.644	rs6669077	chr1:21290520	A/C	cg01072550	chr1:21505969	NA	-0.75	-7.21	-0.59	1.34e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs9677476	0.863	rs57199832	chr2:232069083	T/G	cg20307347	chr2:231734563	ITM2C	-0.55	-4.74	-0.44	7.36e-6	Food antigen IgG levels;
THYM	cis	rs9303401	0.573	rs67378767	chr17:57194237	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.11	8.69	0.67	1.03e-13	Cognitive test performance;
THYM	cis	rs6032067	0.777	rs34343273	chr20:43795293	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg13319975	chr6:146136371	FBXO30	-0.66	-5.57	-0.5	2.33e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs87938	0.830	rs6599143	chr3:41165616	A/G	cg02247160	chr3:41243829	CTNNB1	-0.34	-4.56	-0.42	1.5e-5	Bone mineral density (hip);
THYM	cis	rs78579285	0.545	rs113385327	chr16:88785242	A/C	cg04002220	chr16:89598305	SPG7	0.65	4.73	0.44	7.78e-6	Joint mobility (Beighton score);
THYM	cis	rs12142240	0.698	rs10158572	chr1:46822440	G/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7901056	0.967	rs2992332	chr10:26724317	A/G	cg23318538	chr10:26883079	C10orf50	-0.34	-4.46	-0.42	2.21e-5	Lymphocyte counts;
THYM	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg24375607	chr4:120327624	NA	0.68	5.5	0.49	3.15e-7	Corneal astigmatism;
THYM	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg24803719	chr17:45855879	NA	-0.6	-6.3	-0.54	9.35e-9	IgG glycosylation;
THYM	cis	rs6930083	0.713	rs1321309	chr6:36638636	G/A	cg08179530	chr6:36648295	CDKN1A	-0.8	-5.96	-0.52	4.31e-8	Coronary artery disease;
THYM	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg00944433	chr1:107599041	PRMT6	0.41	5.16	0.47	1.34e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs9326248	0.861	rs4938343	chr11:117003528	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.66	4.66	0.43	1.05e-5	Blood protein levels;
THYM	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.67e-7	Corneal astigmatism;
THYM	cis	rs56161922	1.000	rs56235509	chr1:207839769	C/G	cg09557387	chr1:207818395	CR1L	1.14	5.13	0.47	1.52e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs10501293	0.675	rs720292	chr11:43036224	T/C	cg03447554	chr11:43094025	NA	0.61	4.51	0.42	1.83e-5	Cognitive performance;
THYM	cis	rs1775715	0.811	rs1775741	chr10:32267284	C/T	cg04359828	chr10:32216031	ARHGAP12	-0.38	-4.83	-0.44	5.18e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs4482178	0.850	rs1764957	chr13:86261426	A/T	cg25308322	chr13:86268291	NA	0.7	5.06	0.46	2.03e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg24209194	chr3:40518798	ZNF619	0.68	5.69	0.5	1.43e-7	Renal cell carcinoma;
THYM	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg11663144	chr21:46675770	NA	-0.71	-9.85	-0.71	3.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4845875	0.514	rs198392	chr1:11879162	G/A	cg24844545	chr1:11908347	NPPA	-0.49	-4.78	-0.44	6.47e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.57	4.65	0.43	1.06e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs4606347	0.789	rs61780864	chr1:66162581	C/T	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg23583168	chr7:148888333	NA	-1.0	-13.12	-0.8	4.81e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs778371	0.522	rs6704768	chr2:233592501	C/T	cg08000102	chr2:233561755	GIGYF2	0.75	6.84	0.57	7.81e-10	Schizophrenia;
THYM	cis	rs427394	0.802	rs274698	chr5:6730957	T/G	cg10857441	chr5:6722123	POLS	-0.72	-8.87	-0.67	4.28e-14	Menopause (age at onset);
THYM	cis	rs600806	0.854	rs11142	chr1:109897103	A/G	cg16988986	chr1:109941118	SORT1	-0.42	-4.49	-0.42	1.99e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1061377	1.000	rs2890659	chr4:39127021	T/C	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.04	-0.46	2.24e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	5.45	0.49	4.03e-7	Obesity-related traits;
THYM	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg08975724	chr8:8085496	FLJ10661	-0.72	-5.85	-0.51	7.07e-8	Mood instability;
THYM	cis	rs4889855	1.000	rs4889855	chr17:78513280	G/A	cg14352416	chr17:78021565	CCDC40	-0.66	-4.6	-0.43	1.28e-5	Fractional excretion of uric acid;
THYM	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg03676636	chr4:99064102	C4orf37	0.39	5.55	0.49	2.57e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs943437	0.511	rs9400505	chr6:112110528	T/C	cg08601457	chr6:112115117	FYN	0.42	4.84	0.44	4.98e-6	Parkinson's disease;
THYM	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg22166914	chr1:53195759	ZYG11B	-0.96	-11.92	-0.77	1.4e-20	Monocyte count;
THYM	cis	rs10819861	0.645	rs4743535	chr9:98857953	C/T	cg14508093	chr9:98862825	NA	-0.24	-4.71	-0.44	8.41e-6	Electrocardiographic traits;
THYM	cis	rs4345220	0.546	rs12511338	chr4:41644585	T/G	cg15232654	chr4:41643107	LIMCH1	0.41	4.52	0.42	1.8e-5	Migraine with aura;
THYM	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg10523679	chr1:76189770	ACADM	0.79	5.79	0.51	9.26e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.73	5.66	0.5	1.6e-7	Tonsillectomy;
THYM	cis	rs67311347	0.521	rs2887963	chr3:40243466	C/T	cg13683864	chr3:40499215	RPL14	0.58	4.8	0.44	5.9e-6	Renal cell carcinoma;
THYM	trans	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs3849570	1.000	rs6548773	chr3:81840222	C/T	cg07356753	chr3:81810745	GBE1	0.91	7.45	0.61	4.23e-11	Waist circumference;Body mass index;
THYM	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg02454025	chr1:11042201	C1orf127	0.91	10.49	0.73	1.51e-17	Ewing sarcoma;
THYM	cis	rs59698941	0.943	rs66628697	chr5:132252561	C/T	cg02081065	chr5:132209139	LEAP2	-0.72	-4.72	-0.44	8.09e-6	Apolipoprotein A-IV levels;
THYM	cis	rs6977660	0.598	rs72591445	chr7:19773035	G/A	cg05791153	chr7:19748676	TWISTNB	0.9	4.91	0.45	3.78e-6	Thyroid stimulating hormone;
THYM	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg13695892	chr22:41940480	POLR3H	-0.99	-7.51	-0.61	3.24e-11	Vitiligo;
THYM	cis	rs10463554	0.892	rs158246	chr5:102408849	A/G	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs10899021	0.920	rs7122710	chr11:74323175	C/T	cg25880958	chr11:74394337	NA	-0.77	-4.66	-0.43	1.04e-5	Response to metformin (IC50);
THYM	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-5.19	-0.47	1.19e-6	Morning vs. evening chronotype;
THYM	cis	rs7772486	0.790	rs2253768	chr6:146199922	A/G	cg23711669	chr6:146136114	FBXO30	0.91	9.28	0.69	5.59e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7224314	1.000	rs8072471	chr17:65367062	C/T	cg01507342	chr17:65387096	PITPNC1	-0.9	-9.03	-0.68	1.99e-14	Diisocyanate-induced asthma;
THYM	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs2404602	0.622	rs4886506	chr15:77207277	G/T	cg23625390	chr15:77176239	SCAPER	0.87	5.98	0.52	3.86e-8	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg20503657	chr10:835505	NA	1.15	8.11	0.64	1.78e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs3770081	0.590	rs6736342	chr2:86615493	A/G	cg03318654	chr2:87034200	CD8A	0.84	4.52	0.42	1.77e-5	Facial emotion recognition (sad faces);
THYM	cis	rs2276314	0.857	rs62101402	chr18:33629435	A/G	cg05985134	chr18:33552581	C18orf21	0.66	4.84	0.44	5.02e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs1003719	0.788	rs2835584	chr21:38460338	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.67	4.81	0.44	5.64e-6	Eye color traits;
THYM	cis	rs654950	0.875	rs34227270	chr1:41998967	C/T	cg06885757	chr1:42089581	HIVEP3	0.43	4.95	0.45	3.19e-6	Airway imaging phenotypes;
THYM	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg06028605	chr16:24865363	SLC5A11	0.64	5.14	0.47	1.48e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	4.54	0.42	1.67e-5	Alzheimer's disease;
THYM	cis	rs6598955	0.671	rs12090258	chr1:26644698	C/T	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.7	0.43	8.83e-6	Obesity-related traits;
THYM	cis	rs950880	0.710	rs17027071	chr2:103012674	C/T	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.83	-0.44	5.17e-6	Serum protein levels (sST2);
THYM	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.88	-6.6	-0.56	2.29e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	9.08	0.68	1.5e-14	Platelet count;
THYM	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg05738196	chr6:26577821	NA	0.83	8.34	0.65	5.8e-13	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	1.000	rs114778020	chr4:119662584	C/A	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2976388	0.590	rs4736322	chr8:143822208	T/C	cg06565975	chr8:143823917	SLURP1	-0.62	-7.47	-0.61	3.85e-11	Urinary tract infection frequency;
THYM	cis	rs67460515	0.926	rs13062740	chr3:161024208	G/A	cg03342759	chr3:160939853	NMD3	-0.91	-7.79	-0.62	8.5e-12	Parkinson's disease;
THYM	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.56	-5.0	-0.46	2.56e-6	Type 2 diabetes;
THYM	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg01191920	chr7:158217561	PTPRN2	-0.91	-9.49	-0.7	2e-15	Obesity-related traits;
THYM	cis	rs12200782	0.505	rs7765920	chr6:26514771	C/T	cg12826209	chr6:26865740	GUSBL1	0.67	4.59	0.43	1.38e-5	Small cell lung carcinoma;
THYM	cis	rs6032067	0.777	rs35476703	chr20:43802875	C/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.52	-5.89	-0.52	5.76e-8	Blood protein levels;
THYM	cis	rs931127	0.719	rs2170082	chr11:65454795	A/G	cg17480646	chr11:65405466	SIPA1	-0.73	-6.38	-0.55	6.56e-9	Systemic lupus erythematosus;
THYM	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.57	-0.42	1.45e-5	Prostate cancer;
THYM	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.97	-5.43	-0.49	4.36e-7	Red cell distribution width;
THYM	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg05855489	chr10:104503620	C10orf26	-0.75	-6.57	-0.56	2.69e-9	Waist circumference;Hip circumference;
THYM	cis	rs1003719	0.762	rs11701556	chr21:38455153	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.71	5.03	0.46	2.32e-6	Eye color traits;
THYM	cis	rs8070740	0.898	rs4493114	chr17:5324207	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.72	6.06	0.53	2.72e-8	Menopause (age at onset);
THYM	cis	rs2070488	0.965	rs2126534	chr3:38445165	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	6.66	0.56	1.76e-9	Electrocardiographic conduction measures;
THYM	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg15704280	chr7:45808275	SEPT13	-0.98	-11.44	-0.76	1.43e-19	Coronary artery disease;
THYM	cis	rs728616	1.000	rs12414891	chr10:81690385	G/C	cg05935833	chr10:81318306	SFTPA2	-0.77	-4.66	-0.43	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg08999081	chr20:33150536	PIGU	-0.78	-7.16	-0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg08355456	chr11:67383691	NA	-0.66	-4.58	-0.43	1.41e-5	Mean corpuscular volume;
THYM	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg05890377	chr2:74357713	NA	-1.06	-8.6	-0.66	1.58e-13	Gestational age at birth (maternal effect);
THYM	cis	rs868036	0.957	rs9920662	chr15:68104297	G/A	cg24579218	chr15:68104479	NA	-0.65	-6.51	-0.56	3.59e-9	Restless legs syndrome;
THYM	cis	rs4730268	0.861	rs4730264	chr7:107438561	C/T	cg18560240	chr7:107437656	SLC26A3	-0.91	-4.97	-0.45	2.92e-6	IgG glycosylation;
THYM	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.7	5.63	0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs600806	0.889	rs585545	chr1:109841662	A/T	cg02175308	chr1:109941060	SORT1	-0.55	-4.68	-0.43	9.67e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg09085632	chr11:111637200	PPP2R1B	1.19	12.69	0.79	3.69e-22	Primary sclerosing cholangitis;
THYM	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs77140172	0.677	rs28435799	chr4:89617931	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	1.39	5.71	0.51	1.3e-7	Post bronchodilator FEV1;
THYM	trans	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg25517755	chr10:38738941	LOC399744	0.76	6.94	0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs34375054	0.687	rs35540170	chr12:125669122	C/G	cg25124228	chr12:125621409	AACS	-0.68	-4.85	-0.45	4.81e-6	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.54	0.42	1.66e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg18252515	chr7:66147081	NA	-1.52	-7.58	-0.61	2.26e-11	Diabetic kidney disease;
THYM	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs752010	0.714	rs7515948	chr1:42079046	T/G	cg06885757	chr1:42089581	HIVEP3	0.61	7.94	0.63	3.95e-12	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs907683	0.584	rs1058284	chr2:220286142	G/A	cg15015639	chr2:220282977	DES	-0.42	-5.71	-0.51	1.3e-7	Resting heart rate;
THYM	cis	rs10781543	0.839	rs4379550	chr9:139376426	C/T	cg14115884	chr9:139300582	SDCCAG3	-0.73	-7.03	-0.59	3.08e-10	Monocyte percentage of white cells;
THYM	cis	rs7267979	1.000	rs2482928	chr20:25331530	A/G	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs10463554	0.889	rs34775	chr5:102451276	C/T	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Parkinson's disease;
THYM	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg23711669	chr6:146136114	FBXO30	0.95	9.55	0.7	1.52e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4733781	0.871	rs12549794	chr8:131214247	T/C	cg16277922	chr8:131349729	ASAP1	0.75	5.61	0.5	2.01e-7	Tuberculosis;
THYM	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.98	-7.76	-0.62	9.68e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg02269571	chr22:50332266	NA	-0.7	-4.87	-0.45	4.41e-6	Schizophrenia;
THYM	cis	rs4273100	0.646	rs2296981	chr17:19213335	C/G	cg25447019	chr17:19030144	GRAPL	0.75	5.87	0.52	6.25e-8	Schizophrenia;
THYM	cis	rs2074585	0.679	rs2601195	chr15:90938232	G/A	cg22089800	chr15:90895588	ZNF774	0.7	5.52	0.49	2.99e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
THYM	cis	rs2354432	0.556	rs11239965	chr1:146753907	C/A	cg25205988	chr1:146714368	CHD1L	-1.07	-5.61	-0.5	2.01e-7	Mitochondrial DNA levels;
THYM	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs11840576	0.643	rs149577	chr13:110318648	G/A	cg15975806	chr13:110319607	NA	-0.74	-5.93	-0.52	4.9e-8	Paclitaxel disposition in epithelial ovarian cancer;
THYM	cis	rs6842047	0.563	rs10025990	chr4:187146258	T/C	cg09526685	chr4:187126073	CYP4V2	1.26	5.93	0.52	4.89e-8	Blood protein levels;
THYM	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg11812906	chr14:75593930	NEK9	-0.87	-8.2	-0.64	1.16e-12	Height;
THYM	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg03929089	chr4:120376271	NA	1.03	8.74	0.67	8.32e-14	Coronary artery disease;
THYM	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg26513180	chr16:89883248	FANCA	0.49	4.57	0.42	1.49e-5	Vitiligo;
THYM	cis	rs7584330	0.554	rs75918156	chr2:238426287	G/A	cg08992911	chr2:238395768	MLPH	0.85	5.39	0.48	5.19e-7	Prostate cancer;
THYM	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11644478	chr21:40555479	PSMG1	0.95	7.1	0.59	2.31e-10	Cognitive function;
THYM	cis	rs73086581	1.000	rs3746665	chr20:3910406	C/T	cg02187196	chr20:3869020	PANK2	-0.47	-5.26	-0.47	9.03e-7	Response to antidepressants in depression;
THYM	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg12560992	chr17:57184187	TRIM37	0.7	5.55	0.49	2.59e-7	Testicular germ cell tumor;
THYM	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg13683864	chr3:40499215	RPL14	-0.88	-8.62	-0.66	1.5e-13	Renal cell carcinoma;
THYM	cis	rs4866334	1.000	rs75393523	chr5:18488595	T/G	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg05896524	chr21:47604654	C21orf56	0.72	4.9	0.45	3.96e-6	Testicular germ cell tumor;
THYM	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-4.48	-0.42	2.06e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs12791968	0.917	rs11038239	chr11:45002012	A/G	cg11846598	chr11:44996168	LOC221122	-0.94	-8.04	-0.64	2.5e-12	Inhibitory control;
THYM	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08109568	chr15:31115862	NA	0.76	6.62	0.56	2.14e-9	Huntington's disease progression;
THYM	cis	rs10425738	0.830	rs3844443	chr19:41431935	C/T	cg17435250	chr19:41386441	CYP2A7	0.63	4.52	0.42	1.79e-5	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
THYM	cis	rs55883249	1.000	rs60319753	chr2:9767944	A/G	cg23886495	chr2:9695866	ADAM17	0.86	5.48	0.49	3.47e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs4631830	0.900	rs7075009	chr10:51544143	T/G	cg10326726	chr10:51549505	MSMB	-0.6	-5.87	-0.52	6.26e-8	Prostate-specific antigen levels;
THYM	cis	rs9302635	0.513	rs8061282	chr16:72155938	C/T	cg23815491	chr16:72088622	HP	0.7	5.32	0.48	6.83e-7	Blood protein levels;
THYM	cis	rs7772486	0.875	rs9390372	chr6:146363638	G/C	cg23711669	chr6:146136114	FBXO30	0.93	9.69	0.7	7.64e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-6.65	-0.56	1.84e-9	Chronic sinus infection;
THYM	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.72	-4.65	-0.43	1.07e-5	Lymphocyte percentage of white cells;
THYM	cis	rs3020333	0.875	rs2982573	chr6:152010534	A/G	cg22157087	chr6:152012887	ESR1	0.45	4.87	0.45	4.53e-6	Total body bone mineral density;
THYM	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12946454	0.621	rs11651809	chr17:43255681	C/G	cg06100756	chr17:43221575	NA	0.54	5.25	0.47	9.12e-7	Systolic blood pressure;
THYM	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.97	-0.45	2.98e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4262150	0.774	rs12188960	chr5:152214214	C/G	cg06854687	chr5:151642065	NA	0.69	4.74	0.44	7.54e-6	Bipolar disorder and schizophrenia;
THYM	trans	rs1973993	0.691	rs553785	chr1:96895325	G/A	cg10631902	chr5:14652156	NA	0.76	9.45	0.7	2.51e-15	Weight;
THYM	cis	rs4474465	0.850	rs10899549	chr11:78255389	T/C	cg19901956	chr11:77921274	USP35	0.61	4.64	0.43	1.1e-5	Alzheimer's disease (survival time);
THYM	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg12560992	chr17:57184187	TRIM37	0.93	8.61	0.66	1.5700000000000001e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6952809	0.561	rs1548598	chr7:2438912	T/C	cg23289794	chr7:2394357	EIF3B	-0.75	-4.62	-0.43	1.21e-5	Multiple sclerosis;
THYM	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg27394845	chr17:28928406	LRRC37B2	0.91	4.58	0.42	1.44e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7616559	0.849	rs1351654	chr3:156764651	A/G	cg15697575	chr3:156784781	NA	0.42	5.37	0.48	5.54e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg12386194	chr3:101231763	SENP7	0.69	5.16	0.47	1.34e-6	Colorectal cancer;
THYM	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.39	0.6	5.63e-11	Obesity-related traits;
THYM	cis	rs9902453	0.765	rs2729448	chr17:28091953	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs35883536	0.587	rs2809812	chr1:101032087	G/T	cg09408571	chr1:101003634	GPR88	0.5	5.55	0.49	2.61e-7	Monocyte count;
THYM	cis	rs17253792	0.822	rs28831725	chr14:56087569	C/T	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg09184832	chr6:79620586	NA	-0.58	-4.53	-0.42	1.68e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg12310025	chr6:25882481	NA	-0.69	-5.47	-0.49	3.69e-7	Blood metabolite levels;
THYM	cis	rs11605275	1.000	rs16937344	chr11:20024139	A/G	cg14835545	chr11:20032148	NAV2	-1.38	-6.36	-0.55	6.98e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.68	5.09	0.46	1.79e-6	Tonsillectomy;
THYM	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg06636001	chr8:8085503	FLJ10661	0.75	6.68	0.57	1.58e-9	Joint mobility (Beighton score);
THYM	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.87	0.45	4.53e-6	Bipolar disorder;
THYM	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7084402	0.967	rs7087528	chr10:60301294	A/T	cg07615347	chr10:60278583	BICC1	-0.57	-5.36	-0.48	5.86e-7	Refractive error;
THYM	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg12756686	chr19:29218302	NA	0.71	4.76	0.44	6.8e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg26384229	chr12:38710491	ALG10B	-0.68	-5.26	-0.48	8.72e-7	Morning vs. evening chronotype;
THYM	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.64	-0.5	1.72e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs10895275	0.961	rs2282652	chr11:102097315	C/T	cg24447756	chr11:102105824	NA	-0.54	-4.74	-0.44	7.37e-6	Migraine;
THYM	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg13147721	chr7:65941812	NA	-1.1	-7.08	-0.59	2.51e-10	Diabetic kidney disease;
THYM	cis	rs13006833	0.739	rs172366	chr2:191191233	G/T	cg21644426	chr2:191273491	MFSD6	0.62	4.49	0.42	1.99e-5	Urinary metabolites;
THYM	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.09e-8	Systolic blood pressure;
THYM	cis	rs977987	0.806	rs11643410	chr16:75428306	C/T	cg03315344	chr16:75512273	CHST6	0.73	6.16	0.53	1.73e-8	Dupuytren's disease;
THYM	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg22968622	chr17:43663579	NA	-1.1	-9.99	-0.72	1.7e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2039659	0.679	rs2245400	chr13:86259361	A/G	cg25308322	chr13:86268291	NA	0.64	5.58	0.5	2.23e-7	Blood osmolality (transformed sodium);
THYM	cis	rs7091068	0.615	rs11187609	chr10:95467031	A/C	cg20715218	chr10:95462985	C10orf4	0.71	4.65	0.43	1.05e-5	Urinary tract infection frequency;
THYM	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg05283184	chr6:79620031	NA	-0.91	-8.67	-0.66	1.16e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg00129232	chr17:37814104	STARD3	-0.89	-6.95	-0.58	4.57e-10	Asthma;
THYM	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg20283391	chr11:68216788	NA	-0.59	-4.47	-0.42	2.16e-5	Total body bone mineral density;
THYM	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs2747539	0.623	rs1040552	chr20:32449329	A/G	cg06304546	chr20:32448765	NA	-0.68	-4.66	-0.43	1.03e-5	Dysphagia;
THYM	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg16624210	chr5:671434	TPPP	0.74	6.34	0.54	7.87e-9	Obesity-related traits;
THYM	cis	rs1113500	0.573	rs10748507	chr1:108631521	G/A	cg06207961	chr1:108661230	NA	0.66	4.74	0.44	7.63e-6	Growth-regulated protein alpha levels;
THYM	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg27490568	chr2:178487706	NA	0.61	5.7	0.5	1.34e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	trans	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg10856724	chr12:34555212	NA	-0.96	-8.52	-0.66	2.36e-13	Bladder cancer;
THYM	cis	rs4523957	0.928	rs11657644	chr17:2175210	C/G	cg16513277	chr17:2031491	SMG6	-0.78	-7.38	-0.6	6.02e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9420907	1.000	rs9420907	chr10:105676465	A/C	cg11005552	chr10:105648138	OBFC1	-0.59	-4.61	-0.43	1.23e-5	Telomere length;
THYM	cis	rs10992471	0.756	rs11792342	chr9:95143668	G/A	cg14631576	chr9:95140430	CENPP	-0.95	-10.73	-0.74	4.66e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg18404041	chr3:52824283	ITIH1	0.45	4.55	0.42	1.62e-5	Bipolar disorder;
THYM	cis	rs4788570	0.625	rs4788813	chr16:71625572	T/C	cg06353428	chr16:71660113	MARVELD3	1.43	7.67	0.62	1.47e-11	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.58	5.48	0.49	3.45e-7	Schizophrenia;
THYM	cis	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg21775007	chr8:11205619	TDH	-0.68	-5.27	-0.48	8.47e-7	Retinal vascular caliber;
THYM	cis	rs12474201	0.928	rs17822019	chr2:46934505	T/C	cg09399716	chr2:46890238	NA	-0.5	-4.47	-0.42	2.2e-5	Height;
THYM	cis	rs7578361	0.918	rs12476540	chr2:150369756	C/T	cg17961725	chr2:150454027	NA	0.78	5.97	0.52	4.06e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1499972	0.941	rs62263122	chr3:117630669	T/C	cg07612923	chr3:117604196	NA	1.19	5.0	0.46	2.66e-6	Schizophrenia;
THYM	cis	rs595982	0.527	rs35087747	chr19:49377918	G/T	cg17863274	chr19:49399704	TULP2	-0.94	-5.52	-0.49	2.88e-7	Red cell distribution width;
THYM	cis	rs35883536	0.528	rs1577512	chr1:101030832	G/A	cg06223162	chr1:101003688	GPR88	0.86	7.07	0.59	2.63e-10	Monocyte count;
THYM	cis	rs921665	0.831	rs7596478	chr2:3176358	A/G	cg16434511	chr2:3151078	NA	-0.84	-5.24	-0.47	9.7e-7	World class endurance athleticism;
THYM	cis	rs7110373	1	rs7110373	chr11:122813224	C/T	cg27398637	chr11:122830231	C11orf63	-0.59	-5.19	-0.47	1.21e-6	Age at voice drop;
THYM	cis	rs12935418	0.887	rs2873310	chr16:81072145	A/C	cg16651780	chr16:81037892	C16orf61	-0.88	-4.48	-0.42	2.04e-5	Mean corpuscular volume;
THYM	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg07424592	chr7:64974309	NA	-1.04	-5.27	-0.48	8.52e-7	Diabetic kidney disease;
THYM	trans	rs11722228	0.521	rs56403947	chr4:10112529	T/G	cg26043149	chr18:55253948	FECH	1.16	10.82	0.74	2.98e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg18512352	chr11:47633146	NA	-0.51	-5.88	-0.52	5.99e-8	Subjective well-being;
THYM	cis	rs9649213	0.593	rs13307593	chr7:97986146	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg08305652	chr11:111469057	NA	0.53	4.58	0.43	1.41e-5	Primary sclerosing cholangitis;
THYM	cis	rs7084402	1.000	rs7073504	chr10:60271987	C/T	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs7705042	0.865	rs11739961	chr5:141508488	A/C	cg07392085	chr5:141489673	NDFIP1	0.54	4.46	0.42	2.27e-5	Asthma;
THYM	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg08125733	chr17:73851984	WBP2	0.85	5.96	0.52	4.23e-8	Psoriasis;
THYM	cis	rs9807989	0.811	rs11688573	chr2:102969971	C/A	cg03938978	chr2:103052716	IL18RAP	0.63	6.46	0.55	4.36e-9	Asthma;
THYM	cis	rs4790312	0.935	rs3865240	chr17:1991460	A/G	cg15816464	chr17:2026533	SMG6	0.39	4.73	0.44	7.69e-6	Left atrial antero-posterior diameter;
THYM	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg17063962	chr7:91808500	NA	1.15	11.98	0.78	1.08e-20	Breast cancer;
THYM	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg13390004	chr1:15929781	NA	0.63	4.8	0.44	5.87e-6	Systolic blood pressure;
THYM	cis	rs1065852	0.526	rs2097562	chr22:42389500	T/C	cg08431931	chr22:42394659	WBP2NL	0.74	6.08	0.53	2.48e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs6011002	0.572	rs6011067	chr20:62364376	G/C	cg06363034	chr20:62225388	GMEB2	-0.41	-4.57	-0.42	1.49e-5	Dental caries;
THYM	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg20486651	chr6:167070296	RPS6KA2	-0.49	-4.7	-0.43	8.94e-6	Crohn's disease;
THYM	cis	rs11096990	0.855	rs2043102	chr4:39152912	T/C	cg24403649	chr4:39172243	NA	-0.6	-5.09	-0.46	1.77e-6	Cognitive function;
THYM	cis	rs2219968	1.000	rs1073445	chr8:78959745	T/C	cg00738934	chr8:78996279	NA	0.91	9.77	0.71	5.03e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs9527	0.662	rs4919686	chr10:104592249	A/C	cg15744005	chr10:104629667	AS3MT	-0.7	-5.45	-0.49	4.04e-7	Arsenic metabolism;
THYM	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg00310523	chr12:86230176	RASSF9	0.53	4.84	0.44	5.02e-6	Major depressive disorder;
THYM	cis	rs1800871	0.862	rs1518110	chr1:206944861	A/C	cg12587213	chr1:206589868	SRGAP2	0.48	4.48	0.42	2.08e-5	Gut microbiota (functional units);Behcet's disease;
THYM	cis	rs7172809	0.574	rs74026913	chr15:77733083	A/G	cg10437265	chr15:77819839	NA	-0.5	-4.56	-0.42	1.5e-5	Glucose homeostasis traits;
THYM	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg22709100	chr7:91322751	NA	0.63	4.86	0.45	4.55e-6	Breast cancer;
THYM	cis	rs9563576	0.778	rs35298938	chr13:58630011	C/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg10589385	chr1:150898437	SETDB1	0.62	5.08	0.46	1.9e-6	Melanoma;
THYM	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg11266682	chr4:10021025	SLC2A9	0.48	5.78	0.51	9.65e-8	Bone mineral density;
THYM	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg16325326	chr1:53192061	ZYG11B	0.92	9.83	0.71	3.77e-16	Monocyte count;
THYM	cis	rs4642101	0.590	rs6799544	chr3:12812979	T/C	cg11882607	chr3:12858926	CAND2	-0.42	-4.68	-0.43	9.69e-6	QRS complex (12-leadsum);
THYM	cis	rs448720	0.811	rs1996120	chr15:68181534	G/A	cg23793686	chr15:68133972	NA	-0.52	-4.83	-0.44	5.14e-6	Cognitive performance;
THYM	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs3120667	0.789	rs11204993	chr1:152356333	C/T	cg10321714	chr1:152280068	FLG	-0.69	-4.84	-0.44	5.1e-6	Eating disorders;
THYM	cis	rs11031096	0.535	rs10767886	chr11:4218391	T/C	cg08557956	chr11:4115526	RRM1	-0.56	-4.64	-0.43	1.13e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg24675658	chr1:53192096	ZYG11B	0.78	7.02	0.58	3.33e-10	Monocyte count;
THYM	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg26597838	chr10:835615	NA	1.52	11.37	0.76	2.05e-19	Eosinophil percentage of granulocytes;
THYM	cis	rs8067545	0.641	rs4925060	chr17:19863258	C/G	cg20830565	chr17:20408647	MGC102966	-0.54	-4.95	-0.45	3.16e-6	Schizophrenia;
THYM	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg26031613	chr14:104095156	KLC1	1.23	12.6	0.79	5.44e-22	Body mass index;
THYM	cis	rs4595586	0.545	rs12812750	chr12:39363258	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg03806693	chr22:41940476	POLR3H	-1.08	-8.77	-0.67	7.1e-14	Vitiligo;
THYM	cis	rs96067	0.805	rs4652902	chr1:36612955	C/A	cg24686825	chr1:36642396	MAP7D1	-0.68	-4.71	-0.44	8.32e-6	Corneal structure;
THYM	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg10803722	chr21:46713166	LOC642852	-0.41	-4.98	-0.45	2.89e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1866758	1.000	rs538599	chr1:42323486	C/G	cg19619028	chr1:42327967	HIVEP3	-0.5	-4.57	-0.42	1.45e-5	Intraocular pressure;
THYM	cis	rs669446	0.591	rs617521	chr1:44114199	G/T	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.65	-4.72	-0.44	8.09e-6	Colorectal cancer;
THYM	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg00376283	chr12:123451042	ABCB9	0.72	4.94	0.45	3.36e-6	Neutrophil percentage of white cells;
THYM	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs57920188	0.658	rs7548273	chr1:4078945	G/C	cg20703997	chr1:4087676	NA	0.9	6.28	0.54	9.95e-9	Interleukin-17 levels;
THYM	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.54	-0.56	3.08e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6032067	0.527	rs35828065	chr20:43732374	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.54	-5.12	-0.47	1.58e-6	Blood protein levels;
THYM	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg26384229	chr12:38710491	ALG10B	1.01	8.04	0.64	2.5e-12	Bladder cancer;
THYM	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg16680214	chr1:154839983	KCNN3	-0.5	-6.22	-0.54	1.32e-8	Prostate cancer;
THYM	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg26314531	chr2:26401878	FAM59B	0.78	5.13	0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg02527881	chr3:46936655	PTH1R	0.6	5.51	0.49	3.04e-7	Colorectal cancer;
THYM	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg01616529	chr11:638424	DRD4	-0.79	-6.22	-0.54	1.33e-8	Systemic lupus erythematosus;
THYM	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg07884673	chr3:53033167	SFMBT1	1.27	6.46	0.55	4.47e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg18252515	chr7:66147081	NA	0.62	4.55	0.42	1.59e-5	Aortic root size;
THYM	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.25	0.47	9.11e-7	Melanoma;
THYM	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg23758822	chr17:41437982	NA	1.22	13.08	0.8	5.68e-23	Menopause (age at onset);
THYM	cis	rs6840360	0.642	rs7676493	chr4:152426765	C/T	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs612683	0.824	rs17454919	chr1:100830370	A/G	cg09408571	chr1:101003634	GPR88	0.43	4.65	0.43	1.06e-5	Breast cancer;
THYM	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg06481639	chr22:41940642	POLR3H	-0.77	-5.37	-0.48	5.67e-7	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs8133932	0.598	rs753092	chr21:47293521	C/A	cg20357416	chr21:47294739	PCBP3	-0.85	-5.24	-0.47	9.77e-7	Schizophrenia;
THYM	cis	rs2458413	0.563	rs2458422	chr8:105332817	C/T	cg04554929	chr8:105342491	NA	-0.5	-8.01	-0.63	2.85e-12	Paget's disease;
THYM	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg25251562	chr2:3704773	ALLC	-0.83	-5.59	-0.5	2.16e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg05347473	chr6:146136440	FBXO30	0.58	4.53	0.42	1.7e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4731207	0.596	rs1525618	chr7:124654706	G/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-6.2	-0.54	1.46e-8	Chronic sinus infection;
THYM	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs7027203	0.828	rs4744287	chr9:96585567	A/G	cg14598338	chr9:96623480	NA	0.49	5.31	0.48	7.13e-7	DNA methylation (variation);
THYM	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg03929089	chr4:120376271	NA	-1.01	-13.68	-0.81	3.47e-24	Height;
THYM	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg26384229	chr12:38710491	ALG10B	0.7	5.31	0.48	7.06e-7	Heart rate;
THYM	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg08901578	chr4:187885870	NA	-0.64	-6.03	-0.53	3.1e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.88	-7.81	-0.63	7.51e-12	Monocyte percentage of white cells;
THYM	cis	rs7818345	1.000	rs4409408	chr8:19311538	T/G	cg11303988	chr8:19266685	CSGALNACT1	0.44	4.45	0.42	2.31e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg00074818	chr8:8560427	CLDN23	-0.45	-4.69	-0.43	9.03e-6	Mood instability;
THYM	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg15536230	chr21:44985092	HSF2BP	-0.42	-5.18	-0.47	1.26e-6	Mean corpuscular volume;
THYM	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.82	6.54	0.56	3.07e-9	Blood protein levels;
THYM	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs11992162	0.636	rs4841646	chr8:11798707	C/G	cg21775007	chr8:11205619	TDH	0.61	4.82	0.44	5.41e-6	Monocyte count;
THYM	cis	rs7546094	1.000	rs3013440	chr1:113195789	G/A	cg22162597	chr1:113214053	CAPZA1	-0.48	-4.9	-0.45	3.87e-6	Platelet distribution width;
THYM	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg16586182	chr3:47516702	SCAP	0.63	5.58	0.5	2.26e-7	Colorectal cancer;
THYM	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg18681998	chr4:17616180	MED28	0.81	6.85	0.58	7.23e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg04850017	chr11:63683019	RCOR2	0.84	10.44	0.73	1.91e-17	Pulse pressure;
THYM	cis	rs9644630	0.745	rs7816777	chr8:19371767	T/C	cg01280390	chr8:19363452	CSGALNACT1	0.77	7.02	0.58	3.22e-10	Oropharynx cancer;
THYM	cis	rs2244613	0.832	rs7187684	chr16:55794951	C/T	cg27396498	chr16:55794478	CES4	-0.78	-5.51	-0.49	3.07e-7	Response to dabigatran etexilate treatment;
THYM	cis	rs1499972	0.941	rs62263119	chr3:117630175	T/G	cg07612923	chr3:117604196	NA	1.19	5.0	0.46	2.66e-6	Schizophrenia;
THYM	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.43e-7	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17712092	chr4:129076599	LARP1B	0.89	7.3	0.6	8.81e-11	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg27129171	chr3:47204927	SETD2	-0.82	-7.96	-0.63	3.62e-12	Colorectal cancer;
THYM	cis	rs289828	0.868	rs6747782	chr2:152138115	A/G	cg05960677	chr2:152117363	RBM43	0.61	6.05	0.53	2.89e-8	Blood protein levels;
THYM	cis	rs4786125	0.665	rs1565634	chr16:6919370	T/C	cg03623568	chr16:6915990	A2BP1	-1.02	-10.42	-0.73	2.1e-17	Heart rate variability traits (SDNN);
THYM	trans	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg10856724	chr12:34555212	NA	-0.82	-7.45	-0.61	4.33e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg11663144	chr21:46675770	NA	0.72	10.04	0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3008870	1.000	rs2815357	chr1:67491854	T/C	cg02640540	chr1:67518911	SLC35D1	0.64	4.73	0.44	7.69e-6	Lymphocyte percentage of white cells;
THYM	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg03060546	chr3:49711283	APEH	0.74	6.04	0.53	2.97e-8	Resting heart rate;
THYM	cis	rs514406	0.526	rs835608	chr1:53169758	T/A	cg22166914	chr1:53195759	ZYG11B	-0.8	-7.79	-0.62	8.3e-12	Monocyte count;
THYM	cis	rs782590	0.643	rs13009906	chr2:55739434	A/G	cg03859395	chr2:55845619	SMEK2	-0.5	-4.71	-0.44	8.32e-6	Metabolic syndrome;
THYM	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg05313129	chr8:58192883	C8orf71	-0.85	-4.97	-0.45	2.93e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7107174	0.681	rs3102742	chr11:77949334	G/T	cg19901956	chr11:77921274	USP35	-0.83	-6.25	-0.54	1.17e-8	Testicular germ cell tumor;
THYM	cis	rs10779751	0.734	rs2748877	chr1:11129437	T/C	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs6032067	0.852	rs17424613	chr20:43806441	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs80319144	1.000	rs78219577	chr2:159207367	C/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.59	4.67	0.43	1e-5	Restless legs syndrome;
THYM	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs539096	0.872	rs2004899	chr1:44045465	A/G	cg00143623	chr1:44495758	SLC6A9	0.67	5.18	0.47	1.22e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11577318	0.853	rs17645	chr1:26646730	A/G	cg00852783	chr1:26633632	UBXN11	0.69	5.68	0.5	1.44e-7	Granulocyte percentage of myeloid white cells;
THYM	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg22841779	chr14:105766346	BRF1	-0.49	-6.09	-0.53	2.42e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.27	-0.65	8.15e-13	Mean corpuscular volume;
THYM	trans	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg10856724	chr12:34555212	NA	-0.91	-8.46	-0.66	3.15e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2806561	0.765	rs4333826	chr1:23517514	C/T	cg19743168	chr1:23544995	NA	0.55	5.64	0.5	1.77e-7	Height;
THYM	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg10802521	chr3:52805072	NEK4	-0.68	-5.79	-0.51	8.87e-8	Bipolar disorder;
THYM	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg00256281	chr22:41985642	PMM1	0.62	4.78	0.44	6.4e-6	Vitiligo;
THYM	cis	rs34311866	0.808	rs11728344	chr4:963755	T/C	cg11017086	chr4:979022	SLC26A1	0.71	4.65	0.43	1.08e-5	Parkinson's disease;
THYM	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg18352616	chr4:3374830	RGS12	0.72	7.92	0.63	4.53e-12	Serum sulfate level;
THYM	trans	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg18305652	chr10:134549665	INPP5A	-0.78	-7.73	-0.62	1.1e-11	Migraine;
THYM	cis	rs28595532	0.920	rs116091383	chr4:119635518	A/G	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg22709100	chr7:91322751	NA	0.62	4.82	0.44	5.36e-6	Breast cancer;
THYM	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg08439880	chr3:133502540	NA	-0.71	-6.05	-0.53	2.86e-8	Iron status biomarkers;
THYM	cis	rs4638749	0.677	rs13414687	chr2:108806245	A/G	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg01256987	chr12:42539512	GXYLT1	-0.68	-4.87	-0.45	4.42e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
THYM	cis	rs8067545	0.611	rs9902032	chr17:20015178	G/C	cg13482628	chr17:19912719	NA	0.54	4.64	0.43	1.11e-5	Schizophrenia;
THYM	cis	rs988913	1.000	rs9382402	chr6:54809493	C/T	cg18532076	chr6:54711417	FAM83B	0.51	5.02	0.46	2.38e-6	Menarche (age at onset);
THYM	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg19677267	chr1:26645161	CD52;UBXN11	-0.45	-5.83	-0.51	7.66e-8	Granulocyte percentage of myeloid white cells;
THYM	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.64	-0.74	7.23e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs11039798	0.588	rs12278284	chr11:48612063	G/C	cg24672777	chr11:48374446	OR4C45	-0.93	-6.01	-0.52	3.39e-8	Axial length;
THYM	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg13319975	chr6:146136371	FBXO30	-0.64	-5.19	-0.47	1.18e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg09307838	chr4:120376055	NA	0.78	5.64	0.5	1.76e-7	Corneal astigmatism;
THYM	cis	rs2717559	0.541	rs12549240	chr8:143881380	C/T	cg17252645	chr8:143867129	LY6D	-0.62	-6.06	-0.53	2.78e-8	Urinary tract infection frequency;
THYM	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs6980334	0.767	rs10274304	chr7:137790882	G/A	cg22979093	chr7:137028410	PTN	0.6	4.77	0.44	6.71e-6	Blood metabolite ratios;
THYM	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg00495681	chr13:53174319	NA	0.77	6.97	0.58	4.24e-10	Lewy body disease;
THYM	cis	rs11009175	0.725	rs10827173	chr10:33328779	T/A	cg00146027	chr10:33299147	NA	-0.73	-4.88	-0.45	4.29e-6	Depression (quantitative trait);
THYM	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg07424592	chr7:64974309	NA	1.07	5.56	0.5	2.48e-7	Diabetic kidney disease;
THYM	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg26924012	chr15:45694286	SPATA5L1	0.99	7.91	0.63	4.75e-12	Homoarginine levels;
THYM	cis	rs7589728	0.563	rs2292868	chr2:88475047	A/G	cg04511125	chr2:88470314	THNSL2	-0.66	-4.62	-0.43	1.21e-5	Plasma clusterin levels;
THYM	cis	rs4842666	0.915	rs73437338	chr12:90054619	T/C	cg00757033	chr12:89920650	WDR51B	0.56	4.97	0.45	3.01e-6	Blood pressure;
THYM	cis	rs13102973	0.932	rs13149380	chr4:135866539	A/C	cg14419869	chr4:135874104	NA	0.88	8.62	0.66	1.45e-13	Subjective well-being;
THYM	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	6.57	0.56	2.64e-9	Total body bone mineral density;
THYM	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg13695892	chr22:41940480	POLR3H	-0.77	-6.64	-0.56	1.92e-9	Vitiligo;
THYM	cis	rs1448094	0.512	rs7313035	chr12:86250100	C/G	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-4.95	-0.45	3.24e-6	Hemoglobin concentration;
THYM	cis	rs2836633	0.895	rs61085980	chr21:40032140	C/T	cg05519781	chr21:40033154	ERG	0.73	6.7	0.57	1.49e-9	Coronary artery disease;
THYM	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg19729930	chr2:74357872	NA	1.26	12.75	0.79	2.74e-22	Gestational age at birth (maternal effect);
THYM	cis	rs4930776	0.932	rs450725	chr12:5761140	A/G	cg02086166	chr12:5775618	ANO2	0.61	6.07	0.53	2.57e-8	Plasma clusterin levels;
THYM	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg02018176	chr4:1364513	KIAA1530	0.56	4.57	0.42	1.46e-5	Obesity-related traits;
THYM	cis	rs17767294	0.708	rs61744109	chr6:28075519	C/T	cg08851530	chr6:28072375	NA	1.15	4.46	0.42	2.28e-5	Parkinson's disease;
THYM	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.13	7.52	0.61	3e-11	Cognitive test performance;
THYM	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg11673840	chr17:47092156	IGF2BP1	-0.59	-7.55	-0.61	2.61e-11	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	8.23	0.65	9.9e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6539288	0.803	rs10778517	chr12:107341664	G/T	cg26297688	chr12:107349093	C12orf23	0.51	5.75	0.51	1.06e-7	Total body bone mineral density;
THYM	cis	rs7084402	0.967	rs1649037	chr10:60331135	C/T	cg09696939	chr10:60272079	BICC1	-0.46	-5.42	-0.49	4.53e-7	Refractive error;
THYM	cis	rs9902453	0.868	rs9896012	chr17:28470091	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	6.58	0.56	2.55e-9	Coffee consumption (cups per day);
THYM	cis	rs28595532	0.920	rs56331118	chr4:119767054	G/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs3540	0.597	rs4932346	chr15:91048991	T/C	cg22089800	chr15:90895588	ZNF774	-0.69	-5.3	-0.48	7.54e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg12386194	chr3:101231763	SENP7	0.67	4.99	0.46	2.75e-6	Colorectal cancer;
THYM	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	5.63	0.5	1.82e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs42648	0.869	rs1015402	chr7:89913269	C/T	cg25739043	chr7:89950458	NA	-0.53	-4.53	-0.42	1.72e-5	Homocysteine levels;
THYM	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg11984989	chr7:158649758	WDR60	-1.04	-13.55	-0.81	6.29e-24	Height;
THYM	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.71	5.31	0.48	7.11e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.53e-12	Life satisfaction;
THYM	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg22535103	chr8:58192502	C8orf71	-0.93	-6.13	-0.53	1.98e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2625529	0.878	rs71395051	chr15:72239789	C/T	cg16672083	chr15:72433130	SENP8	-0.56	-5.03	-0.46	2.35e-6	Red blood cell count;
THYM	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg25554036	chr4:6271136	WFS1	0.56	5.29	0.48	7.94e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs9311676	0.656	rs66793022	chr3:58391565	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg16342193	chr10:102329863	NA	-0.52	-5.31	-0.48	7.18e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg02569458	chr12:86230093	RASSF9	0.69	5.77	0.51	9.84e-8	Major depressive disorder;
THYM	cis	rs10927875	0.632	rs4481843	chr1:16128205	G/A	cg21385522	chr1:16154831	NA	-1.32	-13.48	-0.81	9e-24	Dilated cardiomyopathy;
THYM	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg11812906	chr14:75593930	NEK9	-0.81	-7.31	-0.6	8.48e-11	Height;
THYM	cis	rs34779708	0.900	rs73262807	chr10:35496386	C/T	cg03585969	chr10:35415529	CREM	0.63	4.48	0.42	2.09e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs630041	0.901	rs2315332	chr1:20387748	A/C	cg15555335	chr1:20208763	OTUD3	0.83	4.63	0.43	1.15e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
THYM	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs4731207	0.536	rs7792731	chr7:124653436	G/T	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg09354556	chr3:47051341	NA	0.44	4.57	0.42	1.46e-5	Colorectal cancer;
THYM	cis	rs1061377	1.000	rs3733276	chr4:39116911	T/C	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	trans	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg19862616	chr7:65841803	NCRNA00174	1.11	13.16	0.8	3.94e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2070433	0.539	rs721131	chr21:47957767	T/C	cg12379764	chr21:47803548	PCNT	0.6	4.5	0.42	1.94e-5	Lymphocyte counts;
THYM	cis	rs763014	0.500	rs11865749	chr16:717971	C/G	cg02852791	chr16:710674	WDR90	-0.64	-6.52	-0.56	3.43e-9	Height;
THYM	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg12564285	chr5:131593104	PDLIM4	0.44	4.57	0.42	1.46e-5	Blood metabolite levels;
THYM	cis	rs12410462	0.901	rs1120000	chr1:227659615	T/C	cg23173402	chr1:227635558	NA	0.59	5.43	0.49	4.23e-7	Major depressive disorder;
THYM	cis	rs11711311	0.826	rs13077644	chr3:113467777	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.25	-0.47	9.35e-7	IgG glycosylation;
THYM	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg02753203	chr1:228287806	NA	0.76	6.53	0.56	3.21e-9	Diastolic blood pressure;
THYM	trans	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg10856724	chr12:34555212	NA	-0.94	-8.13	-0.64	1.61e-12	Bladder cancer;
THYM	cis	rs7264396	0.676	rs1341603	chr20:34556216	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-4.8	-0.44	6.01e-6	Total cholesterol levels;
THYM	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.88	0.63	5.43e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg06636001	chr8:8085503	FLJ10661	0.72	6.22	0.54	1.36e-8	Mood instability;
THYM	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg17480646	chr11:65405466	SIPA1	-0.94	-8.85	-0.67	4.72e-14	Acne (severe);
THYM	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg04455712	chr21:45112962	RRP1B	0.49	4.48	0.42	2.07e-5	Mean corpuscular volume;
THYM	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg15693483	chr7:1102177	C7orf50	0.46	5.79	0.51	9.24e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs28374715	0.662	rs72737786	chr15:41500361	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.02	-8.4	-0.65	4.27e-13	Ulcerative colitis;
THYM	cis	rs9906944	0.657	rs4643373	chr17:47123423	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.55	-5.43	-0.49	4.36e-7	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs1483890	0.632	rs111868405	chr3:69412154	A/T	cg22125112	chr3:69402811	FRMD4B	0.55	6.93	0.58	4.98e-10	Resting heart rate;
THYM	cis	rs9420	0.961	rs12807250	chr11:57600285	C/T	cg19752551	chr11:57585705	CTNND1	-0.73	-8.07	-0.64	2.15e-12	Schizophrenia;
THYM	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06873352	chr17:61820015	STRADA	0.56	5.66	0.5	1.63e-7	Height;
THYM	cis	rs11190604	1.000	rs10509744	chr10:102271579	C/T	cg07570687	chr10:102243282	WNT8B	0.77	7.17	0.59	1.63e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs12973672	0.680	rs564117	chr19:35718938	C/T	cg17925829	chr19:36399328	TYROBP	0.55	4.64	0.43	1.13e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg08885076	chr2:99613938	TSGA10	-0.78	-6.9	-0.58	5.75e-10	Chronic sinus infection;
THYM	cis	rs4940575	0.679	rs7228914	chr18:60833226	A/G	cg20947866	chr18:61143580	SERPINB5	0.83	5.18	0.47	1.27e-6	Breast cancer;
THYM	cis	rs10832963	1.000	rs7943121	chr11:18656062	G/C	cg20219074	chr11:18656078	SPTY2D1	0.79	6.46	0.55	4.47e-9	Breast cancer;
THYM	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg06481639	chr22:41940642	POLR3H	0.7	4.51	0.42	1.88e-5	Vitiligo;
THYM	cis	rs7187994	0.790	rs16974508	chr16:84781075	G/A	cg07647771	chr16:84786436	USP10	-0.55	-5.06	-0.46	2.03e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs9768139	0.634	rs11762383	chr7:158113889	C/T	cg24154853	chr7:158122151	PTPRN2	0.55	4.94	0.45	3.35e-6	Calcium levels;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg16588007	chr3:123300842	PTPLB	-0.88	-6.93	-0.58	4.99e-10	Depressive symptoms;
THYM	cis	rs11997175	0.646	rs61693382	chr8:33697255	A/C	ch.8.33884649F	chr8:33765107	NA	0.63	4.76	0.44	6.85e-6	Body mass index;
THYM	cis	rs12643440	0.538	rs2041442	chr4:17137895	C/T	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs6430585	0.583	rs3754689	chr2:136590746	C/T	cg23851026	chr2:136556271	LCT	0.67	6.9	0.58	5.67e-10	Corneal structure;
THYM	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg06784218	chr1:46089804	CCDC17	-0.29	-4.54	-0.42	1.65e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.83	0.44	5.29e-6	Obesity-related traits;
THYM	cis	rs10191773	0.589	rs11676628	chr2:112953355	A/G	cg07905836	chr2:113190072	RGPD8;RGPD5	-0.84	-4.77	-0.44	6.54e-6	Yeast infection;
THYM	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.53	6.13	0.53	1.99e-8	Insulin-like growth factors;
THYM	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.1	8.39	0.65	4.46e-13	Cognitive test performance;
THYM	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg04990556	chr1:26633338	UBXN11	-0.89	-8.53	-0.66	2.26e-13	Obesity-related traits;
THYM	cis	rs12476592	0.543	rs2604615	chr2:63898428	T/C	cg17519650	chr2:63277830	OTX1	-0.69	-4.69	-0.43	9.3e-6	Childhood ear infection;
THYM	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs5769707	0.521	rs739244	chr22:50060158	A/G	cg05373962	chr22:49881684	NA	-0.66	-6.78	-0.57	1.01e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg23602478	chr1:26503979	CNKSR1	0.34	4.65	0.43	1.06e-5	Height;
THYM	cis	rs2213920	0.516	rs71505546	chr9:118158372	G/A	cg13918206	chr9:118159781	DEC1	-1.03	-6.0	-0.52	3.51e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs4866334	1.000	rs77699507	chr5:18481057	A/G	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs7586879	0.616	rs6545814	chr2:25131316	A/G	cg15423357	chr2:25149977	NA	0.7	7.76	0.62	9.56e-12	Body mass index;
THYM	cis	rs9443645	0.507	rs9343814	chr6:79473073	C/G	cg05283184	chr6:79620031	NA	-0.61	-4.89	-0.45	4.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg18252515	chr7:66147081	NA	1.45	8.88	0.67	4.01e-14	Diabetic kidney disease;
THYM	cis	rs2997447	0.601	rs61776580	chr1:26432719	C/T	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg05660106	chr1:15850417	CASP9	0.76	6.27	0.54	1.06e-8	Systolic blood pressure;
THYM	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11249608	0.548	rs7709054	chr5:178462757	C/T	cg01312482	chr5:178451176	ZNF879	-0.76	-6.3	-0.54	9.29e-9	Pubertal anthropometrics;
THYM	cis	rs7119038	0.818	rs6421571	chr11:118743772	T/C	cg19308663	chr11:118741387	NA	-0.59	-5.68	-0.5	1.47e-7	Sjögren's syndrome;
THYM	cis	rs61931739	0.534	rs11052957	chr12:33995354	G/A	cg10856724	chr12:34555212	NA	-0.72	-6.49	-0.55	3.94e-9	Morning vs. evening chronotype;
THYM	cis	rs4273100	0.831	rs59571799	chr17:19178892	C/A	cg18093559	chr17:18951025	GRAP	-0.75	-4.7	-0.43	8.62e-6	Schizophrenia;
THYM	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg12311346	chr5:56204834	C5orf35	0.72	5.52	0.49	2.91e-7	Coronary artery disease;
THYM	cis	rs9807841	0.670	rs3843750	chr19:10748073	C/G	cg16900796	chr19:10755136	SLC44A2	0.33	5.02	0.46	2.39e-6	Inflammatory skin disease;
THYM	cis	rs7107174	1.000	rs11601196	chr11:78043431	A/C	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs6748734	0.625	rs10172404	chr2:241820906	T/C	cg15164180	chr2:241846931	NA	-0.34	-4.63	-0.43	1.14e-5	Urinary metabolites;
THYM	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg10193763	chr2:225306901	NA	-0.52	-5.48	-0.49	3.41e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg12963246	chr6:28129442	ZNF389	0.72	6.2	0.54	1.44e-8	Parkinson's disease;
THYM	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.6	5.61	0.5	1.96e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6924995	0.501	rs2142673	chr6:16197144	G/A	cg11805552	chr6:16175128	NA	0.52	4.5	0.42	1.9e-5	Response to statins (LDL cholesterol change);
THYM	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg02782426	chr3:40428986	ENTPD3	0.57	5.06	0.46	2.05e-6	Renal cell carcinoma;
THYM	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg07507251	chr3:52567010	NT5DC2	0.42	4.96	0.45	3.09e-6	Bipolar disorder;
THYM	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg21984481	chr17:79567631	NPLOC4	0.46	4.86	0.45	4.62e-6	Eye color traits;
THYM	cis	rs11190604	0.767	rs11190509	chr10:102156208	G/A	cg07570687	chr10:102243282	WNT8B	0.81	7.62	0.62	1.87e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs501916	0.796	rs55961203	chr15:48050518	G/T	cg20869673	chr15:48010124	SEMA6D	0.71	5.36	0.48	5.76e-7	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs8016982	0.963	rs2099108	chr14:81675420	C/G	cg01989461	chr14:81687754	GTF2A1	0.61	4.46	0.42	2.25e-5	Schizophrenia;
THYM	cis	rs2066819	1.000	rs17118409	chr12:56630764	G/A	cg26714650	chr12:56694279	CS	-1.27	-6.32	-0.54	8.6e-9	Psoriasis vulgaris;
THYM	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.33	10.0	0.72	1.62e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7688540	0.771	rs10027325	chr4:282608	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.65	4.93	0.45	3.47e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs728616	0.614	rs2146192	chr10:81715738	T/C	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4595586	0.545	rs12826080	chr12:39387772	A/G	cg26384229	chr12:38710491	ALG10B	0.69	5.19	0.47	1.18e-6	Morning vs. evening chronotype;
THYM	cis	rs950881	0.932	rs72823632	chr2:102931534	C/T	cg20060108	chr2:102954350	IL1RL1	0.87	4.77	0.44	6.56e-6	Allergy;
THYM	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg11812906	chr14:75593930	NEK9	-0.87	-8.22	-0.64	1.04e-12	Height;
THYM	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg22875332	chr1:76189707	ACADM	-0.55	-5.1	-0.46	1.7e-6	Daytime sleep phenotypes;
THYM	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg10802521	chr3:52805072	NEK4	-0.73	-6.35	-0.55	7.48e-9	Bipolar disorder;
THYM	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg15448220	chr1:150897856	SETDB1	-0.88	-7.27	-0.6	1.02e-10	Tonsillectomy;
THYM	cis	rs5769765	0.542	rs1033666	chr22:50252783	T/C	cg08270630	chr22:50330655	NA	0.72	4.68	0.43	9.6e-6	Schizophrenia;
THYM	cis	rs7553864	0.614	rs10493796	chr1:87614175	A/G	cg17420885	chr1:87600446	LOC339524	0.87	7.2	0.59	1.38e-10	Smoking behavior;
THYM	cis	rs747334	0.811	rs1001845	chr10:92717452	C/T	cg07620928	chr10:92689909	NA	0.57	5.13	0.47	1.54e-6	Fibroblast growth factor basic levels;
THYM	cis	rs2046867	0.818	rs62249860	chr3:72866073	T/G	cg25664220	chr3:72788482	NA	-0.95	-7.97	-0.63	3.52e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7572263	0.959	rs6725512	chr2:209050418	A/G	cg23998903	chr2:209048830	C2orf80	-0.42	-5.64	-0.5	1.78e-7	Glioma;Non-glioblastoma glioma;
THYM	cis	rs1775715	0.870	rs1775735	chr10:32255846	A/G	cg04359828	chr10:32216031	ARHGAP12	0.41	5.21	0.47	1.11e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs5743289	0.547	rs5743266	chr16:50731096	C/T	cg05261686	chr16:50743296	NOD2	-0.39	-4.64	-0.43	1.1e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs346785	0.610	rs347674	chr17:74278548	C/G	cg04798684	chr17:74309056	PRPSAP1	-0.5	-4.45	-0.42	2.34e-5	White matter hyperintensities in ischemic stroke;
THYM	cis	rs7909791	0.743	rs12776760	chr10:105627575	C/A	cg24587175	chr10:105670608	OBFC1	0.7	6.63	0.56	2.05e-9	White matter hyperintensity burden;
THYM	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg11335335	chr11:637885	DRD4	-0.69	-6.23	-0.54	1.24e-8	Systemic lupus erythematosus;
THYM	cis	rs11264213	0.901	rs665521	chr1:36445837	T/C	cg27506609	chr1:36549197	TEKT2	0.92	4.83	0.44	5.3e-6	Schizophrenia;
THYM	cis	rs8038465	0.874	rs12591553	chr15:73993755	G/A	cg15420318	chr15:73925796	NPTN	0.59	4.72	0.44	8.26e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg21798802	chr22:38057573	PDXP	0.47	5.34	0.48	6.29e-7	Fat distribution (HIV);
THYM	cis	rs7267979	0.899	rs2104734	chr20:25526668	A/G	cg03522245	chr20:25566470	NINL	0.59	4.5	0.42	1.93e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6866344	0.570	rs59259518	chr5:178142628	C/T	cg10224037	chr5:178157518	ZNF354A	1.03	8.33	0.65	5.98e-13	Neutrophil percentage of white cells;
THYM	cis	rs75059851	1.000	rs73036065	chr11:133830067	G/T	cg14047540	chr11:133829660	NA	-1.2	-8.46	-0.66	3.23e-13	Schizophrenia;
THYM	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg05754148	chr16:3507555	NAT15	-0.54	-4.65	-0.43	1.05e-5	Body mass index (adult);
THYM	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.95	7.49	0.61	3.46e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3902354	1	rs3902354	chr1:109819296	C/A	cg00908766	chr1:109817496	CELSR2	0.64	5.65	0.5	1.68e-7	Cholesterol, total;
THYM	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg05043794	chr9:111880884	C9orf5	-0.35	-4.93	-0.45	3.42e-6	Menarche (age at onset);
THYM	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg07570687	chr10:102243282	WNT8B	-0.75	-6.59	-0.56	2.4e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs3204270	0.500	rs62077175	chr17:79649568	G/T	cg18367735	chr17:79674897	NA	0.8	4.77	0.44	6.61e-6	Dental caries;
THYM	cis	rs2219968	0.961	rs12056471	chr8:78962821	T/C	cg00738934	chr8:78996279	NA	0.91	9.75	0.71	5.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02463440	chr8:22132932	PIWIL2	0.59	5.07	0.46	1.94e-6	Hypertriglyceridemia;
THYM	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg17366294	chr4:99064904	C4orf37	0.54	6.05	0.53	2.81e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg06808227	chr14:105710500	BRF1	-1.03	-8.98	-0.68	2.5e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs59698941	0.943	rs67462411	chr5:132220031	C/T	cg02081065	chr5:132209139	LEAP2	-0.85	-5.74	-0.51	1.14e-7	Apolipoprotein A-IV levels;
THYM	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg13395646	chr4:1353034	KIAA1530	-0.56	-5.35	-0.48	6.09e-7	Obesity-related traits;
THYM	cis	rs3008870	1.000	rs975451	chr1:67480060	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.93	7.76	0.62	9.52e-12	Lymphocyte percentage of white cells;
THYM	cis	rs9807989	0.507	rs2160201	chr2:103033961	T/C	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg18230493	chr5:56204884	C5orf35	-0.91	-6.9	-0.58	5.71e-10	Initial pursuit acceleration;
THYM	cis	rs1065852	0.526	rs9623490	chr22:42398266	G/C	cg22189786	chr22:42395067	WBP2NL	0.54	5.55	0.49	2.6e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs7894051	1.000	rs11101721	chr10:135190358	C/G	cg12428399	chr10:135191333	PAOX	1.04	5.35	0.48	6.08e-7	Lifespan;
THYM	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg06623918	chr6:96969491	KIAA0776	1.11	10.16	0.72	7.43e-17	Headache;
THYM	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg14829155	chr15:31115871	NA	-0.57	-5.01	-0.46	2.51e-6	Huntington's disease progression;
THYM	cis	rs7246657	0.525	rs10405238	chr19:37488055	T/G	cg22634378	chr19:37742834	NA	0.66	4.83	0.44	5.32e-6	Coronary artery calcification;
THYM	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg07424592	chr7:64974309	NA	-1.03	-5.38	-0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs420259	0.516	rs152455	chr16:23583073	G/A	cg00143387	chr16:23521605	GGA2	0.75	5.39	0.48	5.1e-7	Bipolar disorder;
THYM	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.79	-5.62	-0.5	1.94e-7	Body mass index;
THYM	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg22841779	chr14:105766346	BRF1	-0.47	-5.81	-0.51	8.18e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg08508325	chr11:3079039	CARS	-0.54	-6.67	-0.56	1.69e-9	Longevity;
THYM	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs67311347	0.544	rs35112505	chr3:40337075	A/G	cg13683864	chr3:40499215	RPL14	-0.79	-7.44	-0.61	4.43e-11	Renal cell carcinoma;
THYM	cis	rs4523957	0.548	rs11869619	chr17:2066150	G/C	cg16513277	chr17:2031491	SMG6	-1.03	-9.33	-0.69	4.41e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4242434	0.889	rs4592028	chr8:22449484	T/C	cg21658235	chr8:22456391	C8orf58	0.54	4.99	0.46	2.72e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6565180	1.000	rs12930787	chr16:30381303	C/G	cg17640201	chr16:30407289	ZNF48	-0.92	-8.17	-0.64	1.32e-12	Tonsillectomy;
THYM	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg18512352	chr11:47633146	NA	-0.52	-6.14	-0.53	1.92e-8	Subjective well-being;
THYM	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg10248100	chr7:872053	UNC84A	0.74	4.99	0.46	2.75e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg10803722	chr21:46713166	LOC642852	-0.43	-5.74	-0.51	1.13e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	8.82	0.67	5.59e-14	Chronic sinus infection;
THYM	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28595532	0.920	rs55726697	chr4:119742863	G/A	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.98	7.87	0.63	5.71e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg23173402	chr1:227635558	NA	-0.75	-5.97	-0.52	4.16e-8	Major depressive disorder;
THYM	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-4.91	-0.45	3.79e-6	Gut microbiome composition (summer);
THYM	cis	rs72772090	0.539	rs11747896	chr5:96113397	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.72	4.5	0.42	1.89e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs10158481	0.759	rs6681089	chr1:25487868	C/T	cg09264742	chr1:25757510	TMEM57	-0.63	-4.5	-0.42	1.89e-5	Urate levels in obese individuals;
THYM	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg12311346	chr5:56204834	C5orf35	-0.82	-6.04	-0.53	3.01e-8	Initial pursuit acceleration;
THYM	cis	rs6430585	0.528	rs16832440	chr2:136754183	G/A	cg04750100	chr2:136595281	LCT	0.57	5.03	0.46	2.31e-6	Corneal structure;
THYM	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg03709012	chr19:19516395	GATAD2A	-0.82	-6.79	-0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs586688	0.625	rs601757	chr1:201657508	A/G	cg14168733	chr1:201708718	NAV1	-0.58	-5.38	-0.48	5.32e-7	Obesity-related traits;
THYM	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08704250	chr15:31115839	NA	-0.54	-6.18	-0.54	1.59e-8	Huntington's disease progression;
THYM	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg25767906	chr1:53392781	SCP2	-0.53	-5.26	-0.47	9.05e-7	Monocyte count;
THYM	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.19	-0.47	1.18e-6	Monocyte percentage of white cells;
THYM	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg16586182	chr3:47516702	SCAP	-0.6	-5.11	-0.46	1.63e-6	Colorectal cancer;
THYM	trans	rs9951602	0.541	rs7243702	chr18:76645637	G/A	cg02800362	chr5:177631904	HNRNPAB	1.12	8.77	0.67	6.87e-14	Obesity-related traits;
THYM	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.93	-6.07	-0.53	2.58e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg20503657	chr10:835505	NA	1.37	9.33	0.69	4.52e-15	Eosinophil percentage of granulocytes;
THYM	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg23791538	chr6:167370224	RNASET2	-0.78	-6.28	-0.54	1.02e-8	Crohn's disease;
THYM	cis	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg16068833	chr1:26644515	UBXN11;CD52	0.28	4.86	0.45	4.68e-6	Obesity-related traits;
THYM	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.85	-5.77	-0.51	1.01e-7	Platelet count;
THYM	cis	rs61931739	0.817	rs1687002	chr12:34170263	T/C	cg10856724	chr12:34555212	NA	-0.62	-5.59	-0.5	2.2e-7	Morning vs. evening chronotype;
THYM	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg26384229	chr12:38710491	ALG10B	-0.89	-9.06	-0.68	1.67e-14	Heart rate;
THYM	cis	rs2997447	0.846	rs76713804	chr1:26392437	G/A	cg03844060	chr1:26490628	NA	0.68	4.67	0.43	1e-5	QRS complex (12-leadsum);
THYM	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg11663144	chr21:46675770	NA	-0.76	-10.98	-0.75	1.34e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4731207	0.565	rs1552118	chr7:124628858	C/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs2295499	0.553	rs10937922	chr4:2682663	C/T	cg14003022	chr4:3043019	NA	0.51	4.55	0.42	1.56e-5	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs2281845	0.859	rs1325312	chr1:201079021	A/G	cg17810781	chr1:201082982	CACNA1S	0.64	6.86	0.58	6.97e-10	Permanent tooth development;
THYM	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg15536230	chr21:44985092	HSF2BP	-0.42	-5.18	-0.47	1.24e-6	Mean corpuscular volume;
THYM	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg03060546	chr3:49711283	APEH	0.75	6.08	0.53	2.55e-8	Resting heart rate;
THYM	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs2219968	0.651	rs6981003	chr8:78904535	T/C	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs72781680	0.898	rs56179550	chr2:23934867	C/T	cg08917208	chr2:24149416	ATAD2B	1.1	4.81	0.44	5.71e-6	Lymphocyte counts;
THYM	cis	rs611744	0.967	rs591792	chr8:109200446	T/C	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg05962950	chr11:130786565	SNX19	0.95	9.03	0.68	2e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs77236434	0.571	rs1729140	chr8:13179191	T/A	cg06835018	chr8:12272982	NA	0.75	4.86	0.45	4.68e-6	Familial hepatitis B virus-related hepatocellular carcinoma;
THYM	cis	rs4731207	0.698	rs2158677	chr7:124443966	T/C	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs12049351	0.725	rs1328219	chr1:229596260	A/G	cg11742688	chr1:229674241	ABCB10	-0.57	-4.66	-0.43	1.02e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs17401966	1.000	rs12755094	chr1:10305711	T/C	cg20482658	chr1:10539492	PEX14	0.37	4.5	0.42	1.91e-5	Hepatocellular carcinoma;
THYM	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.63	8.72	0.67	8.99e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg26924012	chr15:45694286	SPATA5L1	0.65	4.75	0.44	7.21e-6	Response to fenofibrate (adiponectin levels);
THYM	cis	rs12466960	0.846	rs2089628	chr2:28572854	G/C	cg11535839	chr2:28582676	NA	0.59	4.69	0.43	9.04e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17539620	0.624	rs111868524	chr6:154839960	G/C	cg20019720	chr6:154832845	CNKSR3	0.49	4.85	0.45	4.81e-6	Lipoprotein (a) levels;
THYM	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs2811415	0.597	rs9810599	chr3:127749086	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs3087591	0.919	rs2018624	chr17:29560777	T/G	cg24425628	chr17:29625626	OMG;NF1	-0.63	-5.35	-0.48	6.02e-7	Hip circumference;
THYM	cis	rs8070740	0.838	rs35491297	chr17:5327481	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.71	5.6	0.5	2.03e-7	Menopause (age at onset);
THYM	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg03605463	chr16:89740564	NA	-0.78	-6.25	-0.54	1.14e-8	Vitiligo;
THYM	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.32e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6840360	0.642	rs2724568	chr4:152352223	C/G	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg09307838	chr4:120376055	NA	0.79	5.77	0.51	9.81e-8	Corneal astigmatism;
THYM	cis	rs7084402	0.967	rs1649046	chr10:60326109	T/C	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg12310025	chr6:25882481	NA	-0.94	-9.05	-0.68	1.81e-14	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-6.49	-0.55	3.93e-9	Chronic sinus infection;
THYM	cis	rs7586879	0.828	rs9631062	chr2:25110084	C/T	cg01884057	chr2:25150051	NA	0.52	4.64	0.43	1.1e-5	Body mass index;
THYM	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg05187965	chr10:45406764	TMEM72	0.56	5.5	0.49	3.16e-7	Mean corpuscular volume;
THYM	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg12935359	chr14:103987150	CKB	-0.48	-4.63	-0.43	1.15e-5	Body mass index;
THYM	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-7.42	-0.61	4.94e-11	Chronic sinus infection;
THYM	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg07570687	chr10:102243282	WNT8B	0.75	6.59	0.56	2.4e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg27170947	chr2:26402098	FAM59B	-0.79	-6.27	-0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs71403859	0.730	rs17356206	chr16:71736359	G/C	cg08717414	chr16:71523259	ZNF19	-0.89	-4.98	-0.45	2.88e-6	Post bronchodilator FEV1;
THYM	cis	rs6499255	0.904	rs10852458	chr16:69672410	G/A	cg00738113	chr16:70207722	CLEC18C	-0.45	-4.57	-0.42	1.49e-5	IgE levels;
THYM	cis	rs8030485	0.501	rs13379776	chr15:79394577	G/T	cg17916960	chr15:79447300	NA	0.52	5.13	0.47	1.51e-6	Left ventricle wall thickness;
THYM	cis	rs11771526	0.686	rs28399034	chr7:32272898	A/G	cg13207630	chr7:32358064	NA	0.74	4.98	0.46	2.8e-6	Body mass index;
THYM	cis	rs12620999	1.000	rs4558538	chr2:238055975	C/T	cg23555395	chr2:238036564	NA	-0.57	-4.54	-0.42	1.68e-5	Systemic lupus erythematosus;
THYM	trans	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7119	0.604	rs2667783	chr15:77862529	G/A	cg10437265	chr15:77819839	NA	-0.72	-7.52	-0.61	3.06e-11	Type 2 diabetes;
THYM	cis	rs28595532	0.841	rs116582665	chr4:119487248	G/C	cg14228332	chr4:119757509	SEC24D	1.38	4.99	0.46	2.77e-6	Cannabis dependence symptom count;
THYM	cis	rs2806561	1.000	rs2806558	chr1:23503456	T/C	cg12483005	chr1:23474871	LUZP1	0.55	5.79	0.51	9e-8	Height;
THYM	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg12560992	chr17:57184187	TRIM37	-0.92	-8.68	-0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs4731207	0.596	rs12535807	chr7:124591433	A/T	cg05285228	chr7:124571219	POT1	-0.69	-5.25	-0.47	9.35e-7	Cutaneous malignant melanoma;
THYM	cis	rs11997175	0.646	rs6468196	chr8:33734183	T/C	ch.8.33884649F	chr8:33765107	NA	0.74	5.12	0.46	1.6e-6	Body mass index;
THYM	cis	rs9326248	0.509	rs533556	chr11:116741572	A/C	cg20608306	chr11:116969690	SIK3	0.56	6.6	0.56	2.37e-9	Blood protein levels;
THYM	cis	rs6570726	0.935	rs399169	chr6:145836353	C/A	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg16405210	chr4:1374714	KIAA1530	-1.05	-9.76	-0.71	5.26e-16	Longevity;
THYM	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg04772025	chr11:68637568	NA	0.63	6.58	0.56	2.59e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	trans	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg25214090	chr10:38739885	LOC399744	0.9	7.87	0.63	5.61e-12	Corneal astigmatism;
THYM	cis	rs73086581	1.000	rs6052220	chr20:3970594	C/T	cg02187196	chr20:3869020	PANK2	0.48	5.42	0.49	4.59e-7	Response to antidepressants in depression;
THYM	cis	rs13064411	0.696	rs7613546	chr3:113228019	G/A	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs12681287	0.927	rs2976177	chr8:87332332	A/T	cg00550725	chr8:87521180	FAM82B	0.57	4.58	0.42	1.44e-5	Caudate activity during reward;
THYM	cis	rs12291225	0.545	rs11023187	chr11:14345559	T/G	cg05501817	chr11:14380813	RRAS2	-0.8	-6.63	-0.56	2.05e-9	Sense of smell;
THYM	cis	rs1336149	0.935	rs945508	chr1:156907081	T/C	cg04298847	chr1:156447084	MEF2D	-0.35	-4.59	-0.43	1.36e-5	Chin dimples;
THYM	cis	rs41278232	1.000	rs73153149	chr20:62656325	G/A	cg03065311	chr20:62601662	ZNF512B	0.73	5.63	0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs9892942	1	rs9892942	chr17:27178761	C/T	cg20469991	chr17:27169893	C17orf63	-0.79	-5.1	-0.46	1.76e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7177026	0.500	rs7176681	chr15:79927544	C/T	cg20511832	chr15:78934280	CHRNB4	0.44	5.03	0.46	2.27e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs61931739	0.569	rs1872746	chr12:33985843	T/C	cg10856724	chr12:34555212	NA	-0.65	-6.2	-0.54	1.47e-8	Morning vs. evening chronotype;
THYM	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg20242066	chr2:136595261	LCT	0.6	7.1	0.59	2.23e-10	Mosquito bite size;
THYM	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg23428387	chr22:49814324	NA	-0.5	-4.62	-0.43	1.21e-5	Monocyte count;Monocyte percentage of white cells;
THYM	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg03929089	chr4:120376271	NA	-1.01	-13.68	-0.81	3.47e-24	Height;
THYM	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg13695892	chr22:41940480	POLR3H	-1.05	-8.67	-0.66	1.14e-13	Vitiligo;
THYM	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg01341218	chr17:43662625	NA	-0.82	-7.11	-0.59	2.12e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg26818010	chr10:134567672	INPP5A	-0.93	-7.52	-0.61	3.02e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg24818145	chr4:99064322	C4orf37	0.9	7.36	0.6	6.5e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1692580	1.000	rs1692580	chr1:2157948	T/C	cg21194808	chr1:2205498	SKI	0.32	4.81	0.44	5.74e-6	Coronary artery disease;
THYM	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg06028808	chr11:68637592	NA	0.64	6.63	0.56	2.06e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg24308560	chr3:49941425	MST1R	0.79	6.8	0.57	9.31e-10	Intelligence (multi-trait analysis);
THYM	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg27068330	chr11:65405492	SIPA1	1.03	10.31	0.73	3.55e-17	Acne (severe);
THYM	cis	rs981844	1.000	rs72731672	chr4:154664925	G/T	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs3126085	0.515	rs12760712	chr1:152355550	G/A	cg10321714	chr1:152280068	FLG	-0.62	-4.48	-0.42	2.11e-5	Atopic dermatitis;
THYM	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg20744362	chr22:50050164	C22orf34	0.81	7.22	0.6	1.25e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg09263875	chr16:632152	PIGQ	0.67	5.33	0.48	6.59e-7	Height;
THYM	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg11494091	chr17:61959527	GH2	-0.95	-13.5	-0.81	7.92e-24	Prudent dietary pattern;
THYM	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg08901578	chr4:187885870	NA	-0.64	-6.03	-0.53	3.1e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6430585	0.697	rs115944351	chr2:136515458	G/A	cg07169764	chr2:136633963	MCM6	1.22	13.28	0.81	2.23e-23	Corneal structure;
THYM	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg22681709	chr2:178499509	PDE11A	-0.54	-5.16	-0.47	1.37e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	5.72	0.51	1.23e-7	Monocyte percentage of white cells;
THYM	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.44	-5.27	-0.48	8.41e-7	Longevity;Endometriosis;
THYM	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7246657	1.000	rs8110011	chr19:37745813	G/T	cg23950597	chr19:37808831	NA	-0.72	-4.62	-0.43	1.22e-5	Coronary artery calcification;
THYM	cis	rs10845606	0.874	rs11055009	chr12:12817965	T/G	cg04607235	chr12:12878440	APOLD1	-0.75	-4.57	-0.42	1.48e-5	Systemic lupus erythematosus;
THYM	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg20744362	chr22:50050164	C22orf34	0.79	6.9	0.58	5.9e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-4.68	-0.43	9.55e-6	Educational attainment;
THYM	cis	rs858239	0.539	rs6975852	chr7:23186654	T/C	cg09755872	chr7:23245557	NA	-0.49	-4.71	-0.44	8.28e-6	Cerebrospinal fluid biomarker levels;
THYM	trans	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg10856724	chr12:34555212	NA	-0.91	-8.12	-0.64	1.64e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg06221963	chr1:154839813	KCNN3	-0.77	-9.84	-0.71	3.56e-16	Prostate cancer;
THYM	cis	rs1018836	0.786	rs7016220	chr8:91606848	A/G	cg16814680	chr8:91681699	NA	-0.93	-7.89	-0.63	5.06e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg09060608	chr5:178986726	RUFY1	0.58	5.74	0.51	1.14e-7	Lung cancer;
THYM	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	trans	rs9951602	0.512	rs4799248	chr18:76653459	G/A	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg01570182	chr17:44337453	NA	0.88	9.33	0.69	4.51e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg22875332	chr1:76189707	ACADM	0.88	11.22	0.75	4.31e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg06784218	chr1:46089804	CCDC17	0.31	4.93	0.45	3.45e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg11335335	chr11:637885	DRD4	-0.56	-4.45	-0.42	2.33e-5	Systemic lupus erythematosus;
THYM	cis	rs35110281	0.607	rs8131020	chr21:44981063	C/A	cg15536230	chr21:44985092	HSF2BP	-0.41	-4.98	-0.45	2.9e-6	Mean corpuscular volume;
THYM	cis	rs10504073	0.584	rs11776843	chr8:49928449	C/T	cg00325661	chr8:49890786	NA	1.04	10.9	0.75	2.02e-18	Blood metabolite ratios;
THYM	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg06623918	chr6:96969491	KIAA0776	0.81	5.27	0.48	8.45e-7	Migraine;Coronary artery disease;
THYM	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg02527881	chr3:46936655	PTH1R	0.66	6.77	0.57	1.04e-9	Colorectal cancer;
THYM	cis	rs10791097	0.702	rs11222346	chr11:130715343	T/C	cg12179176	chr11:130786555	SNX19	-0.75	-6.17	-0.54	1.64e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg02640540	chr1:67518911	SLC35D1	-0.65	-4.78	-0.44	6.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs4907240	0.961	rs6759099	chr2:97267260	G/C	cg18419276	chr2:96971862	SNRNP200	-0.4	-4.73	-0.44	7.72e-6	Event-related brain oscillations;
THYM	cis	rs2075230	0.705	rs2543555	chr17:7548785	A/C	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.74	-0.44	7.55e-6	Hormone measurements;
THYM	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg23930681	chr7:2205249	MAD1L1	-0.62	-4.51	-0.42	1.87e-5	Schizophrenia, schizoaffective disorder or bipolar disorder;
THYM	cis	rs7267979	0.932	rs1541061	chr20:25521057	G/A	cg03522245	chr20:25566470	NINL	0.59	4.5	0.42	1.93e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs73195822	0.542	rs73206863	chr12:110808631	G/A	cg24010859	chr12:110868153	NA	0.67	4.76	0.44	6.79e-6	Itch intensity from mosquito bite;
THYM	trans	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs2898681	0.519	rs6848200	chr4:53730181	A/G	cg21521518	chr4:53727714	RASL11B	0.49	4.51	0.42	1.82e-5	Optic nerve measurement (cup area);
THYM	cis	rs7119	0.717	rs12904584	chr15:77815991	C/T	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs7192750	0.586	rs11075908	chr16:71928850	C/T	cg06353428	chr16:71660113	MARVELD3	-0.78	-5.74	-0.51	1.12e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs28595532	0.920	rs114207133	chr4:119755140	T/C	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	trans	rs1147813	0.654	rs993232	chr9:25890597	A/G	cg12013342	chr6:130182967	C6orf191	-0.97	-6.92	-0.58	5.33e-10	Morning vs. evening chronotype;
THYM	cis	rs6087990	0.899	rs6058893	chr20:31392777	C/T	cg13636640	chr20:31349939	DNMT3B	0.94	10.59	0.74	9.26e-18	Ulcerative colitis;
THYM	cis	rs611744	0.506	rs4735054	chr8:109261780	A/C	cg21045802	chr8:109455806	TTC35	-0.76	-7.54	-0.61	2.72e-11	Dupuytren's disease;
THYM	cis	rs636291	0.517	rs11121579	chr1:10541824	G/C	cg20482658	chr1:10539492	PEX14	-0.33	-4.89	-0.45	4.18e-6	Prostate cancer;
THYM	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg18850127	chr7:39170497	POU6F2	0.6	5.66	0.5	1.57e-7	IgG glycosylation;
THYM	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg11905131	chr22:24372483	LOC391322	-0.73	-6.98	-0.58	4.05e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg19077165	chr18:44547161	KATNAL2	-0.67	-8.66	-0.66	1.19e-13	Personality dimensions;
THYM	cis	rs863345	0.604	rs2054993	chr1:158505968	T/G	cg12129480	chr1:158549410	OR10X1	-0.49	-4.83	-0.44	5.3e-6	Pneumococcal bacteremia;
THYM	cis	rs11997175	0.603	rs7464072	chr8:33776973	G/A	ch.8.33884649F	chr8:33765107	NA	0.68	5.26	0.47	8.9e-7	Body mass index;
THYM	cis	rs977987	0.843	rs6564260	chr16:75447426	A/G	cg03315344	chr16:75512273	CHST6	0.76	6.16	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg10856724	chr12:34555212	NA	-0.79	-7.37	-0.6	6.29e-11	Morning vs. evening chronotype;
THYM	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg09455208	chr3:40491958	NA	0.49	5.1	0.46	1.75e-6	Renal cell carcinoma;
THYM	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.34	-0.65	5.7e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs997295	0.684	rs4776970	chr15:68080886	A/T	cg24579218	chr15:68104479	NA	-0.5	-4.53	-0.42	1.73e-5	Motion sickness;
THYM	cis	rs4731207	0.536	rs1904971	chr7:124669695	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.09	-0.46	1.78e-6	Cutaneous malignant melanoma;
THYM	cis	rs332507	0.558	rs62265576	chr3:124349126	G/A	cg04915618	chr3:124304960	KALRN	-0.67	-5.32	-0.48	6.86e-7	Plateletcrit;
THYM	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg24531977	chr5:56204891	C5orf35	0.73	6.37	0.55	6.57e-9	Type 2 diabetes;
THYM	cis	rs4363385	0.747	rs2339496	chr1:152970719	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.53	-0.42	1.71e-5	Inflammatory skin disease;
THYM	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.68	9.17	0.69	1e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs11190604	0.767	rs11190534	chr10:102190930	G/A	cg16342193	chr10:102329863	NA	-0.5	-5.17	-0.47	1.29e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11577318	0.537	rs12030833	chr1:26689220	A/G	cg16664472	chr1:26644822	UBXN11;CD52	0.33	4.69	0.43	9e-6	Granulocyte percentage of myeloid white cells;
THYM	cis	rs9522267	0.535	rs7323829	chr13:112232308	C/G	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4589258	0.933	rs4564292	chr11:90506250	T/G	cg26138821	chr11:89956704	CHORDC1	-0.7	-5.64	-0.5	1.74e-7	Intelligence (multi-trait analysis);
THYM	cis	rs73735248	0.850	rs16901621	chr6:21813153	A/G	cg17770034	chr6:22249139	NA	-0.78	-4.58	-0.43	1.38e-5	Plateletcrit;
THYM	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-6.06	-0.53	2.7e-8	Myopia (pathological);
THYM	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg25319279	chr11:5960081	NA	-0.64	-5.61	-0.5	2.02e-7	DNA methylation (variation);
THYM	cis	rs12549902	0.932	rs6981607	chr8:41508168	A/C	cg21772509	chr8:41503840	NKX6-3	0.72	6.66	0.56	1.75e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
THYM	cis	rs8112449	0.930	rs8112675	chr19:10538719	C/T	cg01466491	chr19:10523363	NA	-0.67	-6.11	-0.53	2.17e-8	Multiple sclerosis;Gastritis;
THYM	cis	rs3733631	0.557	rs2189223	chr4:104695124	T/C	cg24090629	chr4:104641072	TACR3	-0.87	-4.61	-0.43	1.26e-5	Menarche (age at onset);
THYM	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg27490568	chr2:178487706	NA	0.61	5.6	0.5	2.12e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1461503	0.512	rs4293126	chr11:122804133	A/G	cg27398637	chr11:122830231	C11orf63	0.56	5.0	0.46	2.62e-6	Menarche (age at onset);
THYM	cis	rs2404602	0.647	rs11072616	chr15:76985269	T/C	cg23625390	chr15:77176239	SCAPER	-0.82	-5.85	-0.51	6.95e-8	Blood metabolite levels;
THYM	cis	rs599083	0.530	rs576118	chr11:68177708	C/T	cg16797656	chr11:68205561	LRP5	-0.47	-5.15	-0.47	1.43e-6	Bone mineral density (spine);
THYM	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg03609598	chr5:56110824	MAP3K1	-0.89	-6.07	-0.53	2.63e-8	Type 2 diabetes;
THYM	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg13395646	chr4:1353034	KIAA1530	-0.56	-4.89	-0.45	4.03e-6	Longevity;
THYM	cis	rs259964	1.000	rs259963	chr20:57824901	A/C	cg09005679	chr20:57875326	EDN3	-0.43	-5.08	-0.46	1.85e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg13390004	chr1:15929781	NA	0.63	4.79	0.44	6.2e-6	Systolic blood pressure;
THYM	cis	rs1784581	0.706	rs9346895	chr6:162431168	T/C	cg17173639	chr6:162384350	PARK2	0.79	7.93	0.63	4.31e-12	Itch intensity from mosquito bite;
THYM	cis	rs9486719	1.000	rs2499816	chr6:96878206	C/T	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg14768367	chr16:72042858	DHODH	0.62	4.72	0.44	8.24e-6	Fibrinogen levels;
THYM	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg20290983	chr6:43655470	MRPS18A	1.44	15.94	0.85	1.35e-28	IgG glycosylation;
THYM	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg21433313	chr16:3507492	NAT15	-0.68	-6.42	-0.55	5.36e-9	Tuberculosis;
THYM	cis	rs13064411	0.696	rs3732803	chr3:113211957	T/C	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs6754311	0.593	rs313522	chr2:136430866	T/A	cg04750100	chr2:136595281	LCT	0.56	5.89	0.52	5.87e-8	Mosquito bite size;
THYM	cis	rs2637266	0.568	rs1907329	chr10:78248191	G/A	cg18941641	chr10:78392320	NA	0.6	4.55	0.42	1.57e-5	Pulmonary function;
THYM	cis	rs1557488	0.565	rs1946059	chr11:126685222	C/T	cg03950493	chr11:126582183	KIRREL3	-0.38	-4.53	-0.42	1.75e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs9880211	0.613	rs28519617	chr3:135874930	T/G	cg21827317	chr3:136751795	NA	-0.71	-5.16	-0.47	1.33e-6	Body mass index;Height;
THYM	cis	rs11771526	0.901	rs10252755	chr7:32304676	G/A	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs7851660	0.874	rs7868534	chr9:100632606	G/A	cg13688889	chr9:100608707	NA	-0.79	-5.92	-0.52	5.07e-8	Strep throat;
THYM	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg12963246	chr6:28129442	ZNF389	0.81	6.75	0.57	1.19e-9	Parkinson's disease;
THYM	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg26818010	chr10:134567672	INPP5A	-0.91	-7.12	-0.59	2.1e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs12579753	0.917	rs10862361	chr12:82197946	T/C	cg21231944	chr12:82153410	PPFIA2	-0.66	-5.01	-0.46	2.51e-6	Resting heart rate;
THYM	cis	rs4919687	0.550	rs4264100	chr10:104454113	C/G	cg05855489	chr10:104503620	C10orf26	0.64	5.01	0.46	2.56e-6	Colorectal cancer;
THYM	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg23281280	chr6:28129359	ZNF389	0.61	4.88	0.45	4.21e-6	Depression;
THYM	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg20203395	chr5:56204925	C5orf35	-0.65	-4.53	-0.42	1.68e-5	Initial pursuit acceleration;
THYM	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg06917634	chr15:78832804	PSMA4	-0.94	-8.42	-0.65	3.92e-13	Sudden cardiac arrest;
THYM	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg01528321	chr10:82214614	TSPAN14	0.63	4.87	0.45	4.5e-6	Post bronchodilator FEV1;
THYM	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg07167872	chr1:205819463	PM20D1	0.95	9.12	0.68	1.27e-14	Menarche (age at onset);
THYM	cis	rs10929159	0.964	rs876739	chr2:236943672	C/T	cg20128773	chr2:236923534	AGAP1	0.37	4.8	0.44	5.94e-6	Parkinson's disease;
THYM	cis	rs9649213	0.614	rs3801258	chr7:97988428	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.68	-5.75	-0.51	1.08e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg08000102	chr2:233561755	GIGYF2	0.68	5.98	0.52	3.96e-8	Coronary artery disease;
THYM	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg26384229	chr12:38710491	ALG10B	0.63	4.79	0.44	6.02e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9875589	0.509	rs9836573	chr3:14065239	G/A	cg03204825	chr3:13978759	TPRXL	-0.51	-4.46	-0.42	2.26e-5	Ovarian reserve;
THYM	cis	rs2562456	0.917	rs6511256	chr19:21693315	G/T	cg21751540	chr19:21541537	ZNF738	0.7	4.89	0.45	4.11e-6	Pain;
THYM	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.93	-8.51	-0.66	2.48e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6840360	0.642	rs2724577	chr4:152354905	C/G	cg17479576	chr4:152424074	FAM160A1	-0.67	-4.53	-0.42	1.73e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1448094	0.556	rs2061686	chr12:86170951	C/T	cg00310523	chr12:86230176	RASSF9	-0.53	-4.89	-0.45	4.11e-6	Major depressive disorder;
THYM	cis	rs6598955	0.670	rs12733645	chr1:26540356	G/T	cg04990556	chr1:26633338	UBXN11	-0.87	-7.92	-0.63	4.4e-12	Obesity-related traits;
THYM	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg20295408	chr7:1910781	MAD1L1	0.61	4.96	0.45	3.14e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg10856724	chr12:34555212	NA	0.91	8.78	0.67	6.77e-14	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7247513	0.866	rs2861405	chr19:12722332	A/C	cg01871581	chr19:12707946	ZNF490	-0.91	-9.57	-0.7	1.35e-15	Bipolar disorder;
THYM	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	4.93	0.45	3.51e-6	Motion sickness;
THYM	cis	rs13315871	0.929	rs7634153	chr3:58237501	G/A	cg12435725	chr3:58293450	RPP14	-0.53	-5.68	-0.5	1.47e-7	Cholesterol, total;
THYM	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg03060546	chr3:49711283	APEH	-0.7	-5.83	-0.51	7.58e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs4731207	0.596	rs2402762	chr7:124599846	A/G	cg05285228	chr7:124571219	POT1	-0.69	-5.25	-0.47	9.35e-7	Cutaneous malignant melanoma;
THYM	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg06600287	chr1:53387719	ECHDC2	-0.31	-5.11	-0.46	1.68e-6	Monocyte count;
THYM	cis	rs7809950	1.000	rs10251808	chr7:107120453	G/A	cg23024343	chr7:107201750	COG5	-0.93	-8.29	-0.65	7.51e-13	Coronary artery disease;
THYM	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg06074448	chr4:187884817	NA	-1.02	-13.56	-0.81	6e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg08885076	chr2:99613938	TSGA10	0.52	5.04	0.46	2.24e-6	Chronic sinus infection;
THYM	cis	rs9814567	1.000	rs9289476	chr3:134237103	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-8.41	-0.65	4e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs8016982	0.593	rs7160569	chr14:81713686	C/T	cg01989461	chr14:81687754	GTF2A1	0.81	7.33	0.6	7.68e-11	Schizophrenia;
THYM	cis	rs2625529	0.761	rs11853268	chr15:72238973	T/C	cg16672083	chr15:72433130	SENP8	-0.55	-4.89	-0.45	4.1e-6	Red blood cell count;
THYM	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg02640540	chr1:67518911	SLC35D1	0.65	4.78	0.44	6.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs6665290	0.904	rs3795449	chr1:227181838	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg11812906	chr14:75593930	NEK9	0.87	8.16	0.64	1.38e-12	Height;
THYM	cis	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg09307838	chr4:120376055	NA	-0.61	-4.54	-0.42	1.66e-5	Corneal astigmatism;
THYM	cis	rs7646881	1.000	rs59313096	chr3:158452242	G/C	cg19483011	chr3:158453295	NA	-0.77	-5.54	-0.49	2.65e-7	Tetralogy of Fallot;
THYM	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.49	0.49	3.33e-7	Platelet count;
THYM	cis	rs1018836	0.663	rs2205152	chr8:91483618	C/T	cg16814680	chr8:91681699	NA	0.8	6.6	0.56	2.3e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.56	-5.13	-0.47	1.51e-6	Type 2 diabetes;
THYM	cis	rs2439831	0.681	rs1837960	chr15:43698602	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.68	4.7	0.43	8.71e-6	Lung cancer in ever smokers;
THYM	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg22535103	chr8:58192502	C8orf71	-0.93	-4.56	-0.42	1.52e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg26031613	chr14:104095156	KLC1	-0.57	-4.87	-0.45	4.52e-6	Schizophrenia;
THYM	cis	rs2075165	0.901	rs10908492	chr1:156224795	C/T	cg20302342	chr1:156215951	PAQR6	0.46	4.61	0.43	1.24e-5	Tonsillectomy;
THYM	cis	rs240764	0.781	rs12212736	chr6:101151410	C/T	cg21058520	chr6:100914733	NA	0.58	5.22	0.47	1.04e-6	Neuroticism;
THYM	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg14972814	chr11:95582409	MTMR2	-0.76	-7.01	-0.58	3.38e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2256039	1.000	rs2245879	chr9:86789653	A/C	cg14555996	chr9:86785905	NA	-0.29	-4.57	-0.42	1.47e-5	Multiple system atrophy;
THYM	cis	rs12496230	0.953	rs12494775	chr3:66874105	A/G	cg23477460	chr3:66848765	NA	-1.26	-8.27	-0.65	8.26e-13	Type 2 diabetes;
THYM	cis	rs6956675	0.831	rs10268923	chr7:62652624	C/G	cg08930214	chr7:62859557	LOC100287834	0.61	4.78	0.44	6.47e-6	Obesity-related traits;
THYM	cis	rs877282	0.842	rs7092986	chr10:756373	G/A	cg10556349	chr10:835070	NA	-0.69	-4.49	-0.42	2.03e-5	Uric acid levels;
THYM	cis	rs7119	0.717	rs12910975	chr15:77817487	C/T	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg07507251	chr3:52567010	NT5DC2	0.41	4.89	0.45	4.17e-6	Cognitive function;
THYM	cis	rs2717559	0.522	rs2572922	chr8:143871652	G/A	cg17888033	chr8:143858414	LYNX1	0.46	5.26	0.47	9.03e-7	Urinary tract infection frequency;
THYM	cis	rs4731207	0.564	rs1471569	chr7:124650721	A/G	cg05285228	chr7:124571219	POT1	-0.71	-5.47	-0.49	3.59e-7	Cutaneous malignant melanoma;
THYM	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg09074113	chr2:20870087	GDF7	-0.76	-6.94	-0.58	4.88e-10	Abdominal aortic aneurysm;
THYM	cis	rs1483890	0.723	rs900670	chr3:69406781	G/A	cg22125112	chr3:69402811	FRMD4B	0.57	7.19	0.59	1.44e-10	Resting heart rate;
THYM	cis	rs6960043	0.818	rs10950546	chr7:15050391	C/T	cg19272540	chr7:15055459	NA	0.45	4.55	0.42	1.56e-5	Type 2 diabetes;
THYM	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg04455712	chr21:45112962	RRP1B	0.51	4.72	0.44	8.23e-6	Mean corpuscular volume;
THYM	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.9	-0.45	4.01e-6	Monocyte count;
THYM	cis	rs919433	0.679	rs7600862	chr2:198534514	C/T	cg05783139	chr2:198650985	BOLL	0.66	4.98	0.46	2.78e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg12165864	chr7:66369176	NA	0.67	5.26	0.47	8.99e-7	Aortic root size;
THYM	cis	rs757110	0.770	rs2051772	chr11:17389850	G/A	cg15432903	chr11:17409602	KCNJ11	0.58	6.28	0.54	1.01e-8	Type 2 diabetes;
THYM	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg17054759	chr22:49844102	NA	-0.52	-4.55	-0.42	1.6e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7781557	0.702	rs4377880	chr7:102473163	A/G	cg06322601	chr7:102330635	NA	0.81	5.42	0.49	4.56e-7	Colorectal adenoma (advanced);
THYM	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	trans	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs6840360	1.000	rs7439465	chr4:152594814	C/T	cg22705602	chr4:152727874	NA	0.61	6.54	0.56	3.02e-9	Intelligence (multi-trait analysis);
THYM	cis	rs17102423	0.964	rs8015330	chr14:65602183	C/T	cg11161011	chr14:65562177	MAX	-0.74	-6.52	-0.56	3.43e-9	Obesity-related traits;
THYM	cis	rs524281	0.773	rs2298468	chr11:66042962	G/A	cg00563793	chr11:65837595	PACS1	0.81	4.87	0.45	4.42e-6	Electroencephalogram traits;
THYM	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg08999081	chr20:33150536	PIGU	-0.56	-4.83	-0.44	5.18e-6	Height;
THYM	cis	rs12220238	1.000	rs10824129	chr10:76008855	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.86	4.65	0.43	1.08e-5	Soluble interleukin-2 receptor subunit alpha;
THYM	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg10589385	chr1:150898437	SETDB1	0.63	5.2	0.47	1.14e-6	Melanoma;
THYM	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-8.1	-0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs36051895	0.559	rs72701680	chr9:5207294	A/T	cg02405213	chr9:5042618	JAK2	-0.87	-8.5	-0.66	2.64e-13	Pediatric autoimmune diseases;
THYM	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	5.15	0.47	1.39e-6	Schizophrenia;
THYM	cis	rs684232	0.602	rs379998	chr17:556884	A/G	cg15660573	chr17:549704	VPS53	-0.99	-11.0	-0.75	1.22e-18	Prostate cancer;
THYM	trans	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs6570726	0.935	rs425717	chr6:145838620	A/T	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.21	-0.47	1.09e-6	Mood instability;
THYM	cis	rs147144681	1	rs147144681	chr15:78900908	C/T	cg04882995	chr15:78912658	CHRNA3	0.54	4.55	0.42	1.61e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs9595908	0.965	rs9595795	chr13:33122795	T/C	cg12383807	chr13:33924137	NA	-0.53	-4.59	-0.43	1.36e-5	Body mass index;
THYM	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	trans	rs8002861	0.664	rs9567292	chr13:44444816	A/G	cg17145862	chr1:211918768	LPGAT1	0.88	8.09	0.64	1.97e-12	Leprosy;
THYM	cis	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg17333051	chr19:2783644	SGTA	0.57	5.32	0.48	6.94e-7	Total cholesterol levels;
THYM	cis	rs17125944	0.615	rs7145392	chr14:53321016	G/A	cg00686598	chr14:53173677	PSMC6	-1.1	-4.97	-0.45	3e-6	Alzheimer's disease (late onset);
THYM	cis	rs600806	0.815	rs4970754	chr1:109969721	A/G	cg02175308	chr1:109941060	SORT1	-0.59	-5.15	-0.47	1.38e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg04156016	chr5:1868137	NA	0.5	4.63	0.43	1.17e-5	Cardiovascular disease risk factors;
THYM	cis	rs2976388	0.647	rs2082801	chr8:143786461	A/G	cg13446199	chr8:143762866	PSCA	-0.41	-4.53	-0.42	1.7e-5	Urinary tract infection frequency;
THYM	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg08885076	chr2:99613938	TSGA10	0.57	5.28	0.48	8.05e-7	Chronic sinus infection;
THYM	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg22709100	chr7:91322751	NA	0.62	4.76	0.44	7.01e-6	Breast cancer;
THYM	cis	rs981844	0.712	rs1037652	chr4:154746565	C/T	cg09973105	chr4:154681532	RNF175	-0.52	-4.98	-0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg24846680	chr1:228362309	C1orf69	0.52	4.74	0.44	7.61e-6	Diastolic blood pressure;
THYM	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg18402987	chr7:1209562	NA	1.03	6.06	0.53	2.77e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7942486	0.895	rs34588274	chr11:13269946	C/T	cg13286116	chr11:13302098	ARNTL	-0.72	-8.03	-0.64	2.61e-12	Neuroticism;
THYM	cis	rs6987853	0.933	rs2974340	chr8:42397731	T/C	cg09913449	chr8:42400586	C8orf40	0.88	8.02	0.64	2.8e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg24209194	chr3:40518798	ZNF619	0.58	4.78	0.44	6.34e-6	Renal cell carcinoma;
THYM	cis	rs1003719	0.751	rs2835585	chr21:38460488	T/A	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs2012796	0.956	rs7147254	chr14:81820503	G/A	cg02996355	chr14:81879375	NA	0.67	4.69	0.43	9.03e-6	Night sleep phenotypes;
THYM	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg21475434	chr5:93447410	FAM172A	0.95	6.03	0.53	3.16e-8	Diabetic retinopathy;
THYM	cis	rs822354	1.000	rs822354	chr3:186480206	A/G	cg23249140	chr3:186560453	ADIPOQ	-0.5	-4.85	-0.45	4.77e-6	Adiponectin levels;
THYM	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg04398451	chr17:18023971	MYO15A	-0.92	-9.26	-0.69	6.4e-15	Total body bone mineral density;
THYM	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg03806693	chr22:41940476	POLR3H	1.17	10.14	0.72	8.43e-17	Vitiligo;
THYM	cis	rs3780378	0.935	rs2230724	chr9:5081780	G/A	cg02405213	chr9:5042618	JAK2	-0.71	-6.64	-0.56	1.92e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg20503657	chr10:835505	NA	1.37	9.33	0.69	4.52e-15	Eosinophil percentage of granulocytes;
THYM	cis	rs79349575	0.745	rs170319	chr17:46991531	T/C	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs10492096	0.947	rs10774435	chr12:6616120	G/T	cg13857086	chr12:6580257	VAMP1	0.73	4.58	0.43	1.41e-5	Hip geometry;
THYM	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg16342193	chr10:102329863	NA	-0.5	-5.13	-0.47	1.54e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs728616	0.867	rs61860412	chr10:81728486	G/A	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs612683	0.524	rs584350	chr1:100908324	A/G	cg06223162	chr1:101003688	GPR88	0.73	6.23	0.54	1.25e-8	Breast cancer;
THYM	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg22467129	chr15:76604101	ETFA	-0.56	-5.16	-0.47	1.37e-6	Blood metabolite levels;
THYM	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	13.34	0.81	1.71e-23	Height;
THYM	cis	rs11048434	0.636	rs12815310	chr12:9059934	A/G	cg13575925	chr12:9217583	LOC144571	0.52	4.79	0.44	6.06e-6	Sjögren's syndrome;
THYM	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg18876405	chr7:65276391	NA	0.58	4.8	0.44	6.01e-6	Aortic root size;
THYM	cis	rs8050907	1.000	rs75117781	chr16:4654204	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.34	5.32	0.48	7e-7	Obesity-related traits;
THYM	cis	rs17030434	0.953	rs10014299	chr4:154700858	A/G	cg14289246	chr4:154710475	SFRP2	-0.76	-5.24	-0.47	9.79e-7	Electrocardiographic conduction measures;
THYM	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs860818	1.000	rs858249	chr7:23220639	C/T	cg05407003	chr7:23246146	NA	1.27	4.72	0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03407747	chr17:6899364	ALOX12	0.77	9.81	0.71	4.17e-16	Tonsillectomy;
THYM	cis	rs7777677	0.888	rs9655574	chr7:142370244	G/C	cg21785750	chr7:142428317	NA	0.67	5.88	0.52	6.1e-8	Alcoholic chronic pancreatitis;
THYM	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.66	5.79	0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs12643440	0.538	rs62296722	chr4:17140970	T/G	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs12935418	0.583	rs7206625	chr16:80964433	G/A	cg16651780	chr16:81037892	C16orf61	0.82	5.2	0.47	1.13e-6	Mean corpuscular volume;
THYM	cis	rs6032067	0.561	rs2741502	chr20:43936265	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.53	-5.32	-0.48	7.02e-7	Blood protein levels;
THYM	cis	rs11746309	0.775	rs6859162	chr5:149484429	A/T	cg17820459	chr5:150400531	GPX3	0.58	4.53	0.42	1.73e-5	Blood protein levels;
THYM	cis	rs28595532	0.920	rs17324821	chr4:119770716	A/G	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs71636778	0.509	rs17162339	chr1:27252823	A/C	cg16022904	chr1:26870173	RPS6KA1	-0.84	-4.55	-0.42	1.58e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
THYM	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.6	5.5	0.49	3.26e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg22166914	chr1:53195759	ZYG11B	-0.78	-8.26	-0.65	8.53e-13	Monocyte count;
THYM	cis	rs4499344	0.730	rs7250272	chr19:33100338	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.61	0.62	2.02e-11	Mean platelet volume;
THYM	cis	rs4944092	0.960	rs10400322	chr11:75910913	C/T	cg04588336	chr11:75916460	WNT11	0.63	6.59	0.56	2.42e-9	PR interval;
THYM	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg16325326	chr1:53192061	ZYG11B	0.73	6.24	0.54	1.24e-8	Monocyte count;
THYM	cis	rs4733781	0.814	rs34656350	chr8:131270076	G/C	cg16277922	chr8:131349729	ASAP1	0.65	4.57	0.42	1.46e-5	Tuberculosis;
THYM	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg11812906	chr14:75593930	NEK9	0.87	8.3	0.65	7.13e-13	Height;
THYM	cis	rs7677751	0.806	rs4864859	chr4:55090015	A/G	cg17187183	chr4:55093834	PDGFRA	0.72	5.56	0.5	2.49e-7	Corneal astigmatism;
THYM	cis	rs7107174	1.000	rs1485483	chr11:77930138	T/C	cg02023728	chr11:77925099	USP35	0.69	5.95	0.52	4.46e-8	Testicular germ cell tumor;
THYM	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg16230307	chr14:35515116	FAM177A1	0.94	6.05	0.53	2.9e-8	Psoriasis;
THYM	cis	rs12579753	0.956	rs35278765	chr12:82173126	T/C	cg07988820	chr12:82153109	PPFIA2	-0.79	-5.02	-0.46	2.38e-6	Resting heart rate;
THYM	cis	rs9790314	0.723	rs1026572	chr3:160887654	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-4.73	-0.44	7.66e-6	Morning vs. evening chronotype;
THYM	cis	rs6163	0.508	rs12776506	chr10:104532828	A/G	cg15744005	chr10:104629667	AS3MT	-0.65	-5.06	-0.46	2e-6	Waist circumference;Hip circumference;
THYM	cis	rs17401966	0.838	rs10492971	chr1:10342975	G/A	cg19773385	chr1:10388646	KIF1B	-0.57	-4.49	-0.42	2.04e-5	Hepatocellular carcinoma;
THYM	cis	rs10186029	0.539	rs4672676	chr2:214001948	C/T	cg08319019	chr2:214017104	IKZF2	0.78	6.14	0.53	1.95e-8	Systemic sclerosis;
THYM	cis	rs7731657	0.537	rs6887982	chr5:130275716	C/G	cg08523029	chr5:130500466	HINT1	0.85	6.0	0.52	3.55e-8	Fasting plasma glucose;
THYM	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs4523957	0.579	rs4790883	chr17:2087605	T/C	cg16513277	chr17:2031491	SMG6	-0.97	-8.83	-0.67	5.35e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs72828912	0.731	rs9348627	chr6:24065658	T/G	cg26336265	chr6:25042955	NA	-0.87	-5.5	-0.49	3.26e-7	Squamous cell lung carcinoma;
THYM	cis	rs870825	0.616	rs28649620	chr4:185648997	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs665401	0.692	rs339318	chr6:117187910	C/T	cg20376953	chr6:117187980	NA	0.59	4.76	0.44	6.79e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs16866061	1.000	rs16866061	chr2:225439844	A/G	cg12698349	chr2:225449008	CUL3	1.14	10.35	0.73	2.9e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs9943465	0.688	rs359056	chr10:132103656	A/G	cg02700606	chr10:131763134	EBF3	0.73	4.75	0.44	7.24e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs1843834	0.858	rs12105685	chr2:225513164	A/G	cg22509189	chr2:225307070	NA	-0.66	-4.63	-0.43	1.15e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg00290607	chr11:67383545	NA	-0.76	-5.21	-0.47	1.11e-6	Mean corpuscular volume;
THYM	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg07570687	chr10:102243282	WNT8B	0.76	6.76	0.57	1.13e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg17264618	chr3:40429014	ENTPD3	0.53	5.02	0.46	2.41e-6	Renal cell carcinoma;
THYM	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg13319975	chr6:146136371	FBXO30	-0.67	-5.64	-0.5	1.78e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4849845	0.889	rs10203096	chr2:121033490	T/A	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg23958373	chr8:599963	NA	0.96	5.02	0.46	2.4e-6	IgG glycosylation;
THYM	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg13695892	chr22:41940480	POLR3H	-1.06	-8.17	-0.64	1.29e-12	Vitiligo;
THYM	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.87	9.74	0.71	6.05e-16	Prudent dietary pattern;
THYM	cis	rs41005	0.967	rs17433703	chr2:8115300	A/G	cg03155496	chr2:8117019	LOC339788	0.96	9.3	0.69	5.16e-15	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs7212938	0.509	rs3893044	chr17:38103016	C/T	cg24910161	chr17:38119198	GSDMA	0.52	6.04	0.53	2.97e-8	Asthma and hay fever;
THYM	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg06623918	chr6:96969491	KIAA0776	1.09	9.89	0.71	2.89e-16	Headache;
THYM	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.27	6.2	0.54	1.47e-8	Obesity-related traits;
THYM	cis	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg09307838	chr4:120376055	NA	0.73	5.51	0.49	3.11e-7	Corneal astigmatism;
THYM	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg05368731	chr17:41323189	NBR1	1.2	10.98	0.75	1.36e-18	Menopause (age at onset);
THYM	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26314531	chr2:26401878	FAM59B	-0.79	-5.3	-0.48	7.64e-7	Gut microbiome composition (summer);
THYM	cis	rs332507	0.830	rs10804562	chr3:124377196	C/T	cg14688451	chr3:124303035	KALRN	0.58	4.56	0.42	1.52e-5	Plateletcrit;
THYM	cis	rs1061377	1.000	rs35437629	chr4:39133332	C/G	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	cis	rs7968440	0.931	rs2251024	chr12:51103633	C/T	cg20014596	chr12:50898483	DIP2B	0.54	4.46	0.42	2.29e-5	Fibrinogen;
THYM	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg16558253	chr16:72132732	DHX38	-0.56	-4.87	-0.45	4.39e-6	Fibrinogen levels;
THYM	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg18904891	chr8:8559673	CLDN23	-0.66	-4.9	-0.45	3.99e-6	Obesity-related traits;
THYM	cis	rs6500395	1.000	rs1420704	chr16:48716902	C/T	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs6424115	0.830	rs12744386	chr1:24168019	C/T	cg15997130	chr1:24165203	NA	-0.7	-5.72	-0.51	1.21e-7	Immature fraction of reticulocytes;
THYM	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg23711669	chr6:146136114	FBXO30	0.85	8.24	0.65	9.39e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg03733263	chr8:22462867	KIAA1967	1.15	13.54	0.81	6.65e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7106204	0.609	rs11825384	chr11:24285137	G/T	ch.11.24196551F	chr11:24239977	NA	0.96	5.93	0.52	4.81e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4845570	0.834	rs13376155	chr1:151721270	A/G	cg18019451	chr1:151746047	TDRKH	-0.9	-5.04	-0.46	2.19e-6	Coronary artery disease;
THYM	trans	rs11186	0.556	rs72904492	chr2:189951973	T/C	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs4919694	1.000	rs4917382	chr10:104838510	G/A	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg02187348	chr16:89574699	SPG7	0.78	6.6	0.56	2.3e-9	Multiple myeloma (IgH translocation);
THYM	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg19875535	chr5:140030758	IK	-0.63	-5.69	-0.5	1.43e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs828999	0.653	rs6666316	chr1:108696160	T/G	cg24323958	chr1:108741884	SLC25A24	0.54	5.33	0.48	6.7e-7	Monocyte percentage of white cells;
THYM	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	4.78	0.44	6.33e-6	Menarche (age at onset);
THYM	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs35660623	1.000	rs17152492	chr8:10667934	A/G	cg12395012	chr8:11607386	GATA4	1.04	5.79	0.51	8.95e-8	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg23758822	chr17:41437982	NA	1.16	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs9915657	0.811	rs35126550	chr17:70118699	G/A	cg09344028	chr17:70110421	NA	0.47	4.69	0.43	9.15e-6	Thyroid hormone levels;
THYM	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.64	-4.59	-0.43	1.35e-5	Aortic root size;
THYM	cis	rs2404602	0.598	rs11855999	chr15:76627333	A/C	cg23482746	chr15:76478102	C15orf27	0.45	4.53	0.42	1.7e-5	Blood metabolite levels;
THYM	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07157834	chr1:205819609	PM20D1	0.89	9.0	0.68	2.28e-14	Menarche (age at onset);
THYM	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg22166914	chr1:53195759	ZYG11B	-0.68	-6.72	-0.57	1.31e-9	Monocyte count;
THYM	cis	rs9638182	0.725	rs80189144	chr7:72939939	T/C	cg22888238	chr7:73256761	WBSCR27	-1.04	-4.55	-0.42	1.59e-5	Triglycerides;
THYM	cis	rs859767	1.000	rs859767	chr2:135341200	A/G	cg12500956	chr2:135428796	TMEM163	0.56	5.35	0.48	6.01e-7	Neuroticism;
THYM	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg11494091	chr17:61959527	GH2	0.69	6.16	0.53	1.73e-8	Height;
THYM	cis	rs10779751	0.770	rs2486922	chr1:11124885	T/C	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs9649213	0.593	rs13232181	chr7:97935671	C/G	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3741151	0.881	rs73542929	chr11:73094539	G/T	cg12959048	chr11:73096162	RELT	-0.54	-5.2	-0.47	1.13e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.63	4.74	0.44	7.5e-6	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.62	0.43	1.2e-5	Obesity-related traits;
THYM	cis	rs988913	0.958	rs9475078	chr6:54809589	T/A	cg19716238	chr6:54711378	FAM83B	0.49	5.04	0.46	2.25e-6	Menarche (age at onset);
THYM	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg11247378	chr22:39784982	NA	-1.02	-9.68	-0.7	7.98e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg07424592	chr7:64974309	NA	1.05	4.76	0.44	6.92e-6	Diabetic kidney disease;
THYM	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.75	-6.16	-0.53	1.74e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	5.57	0.5	2.39e-7	Monocyte percentage of white cells;
THYM	cis	rs1372520	0.684	rs2737030	chr4:90710099	C/T	cg01966878	chr4:90757139	SNCA	-0.61	-4.71	-0.43	8.61e-6	Neuroticism;
THYM	cis	rs7100689	0.646	rs12253992	chr10:82158710	G/A	cg09936400	chr10:82049201	MAT1A	0.42	4.63	0.43	1.14e-5	Post bronchodilator FEV1;
THYM	cis	rs9543976	0.623	rs9318361	chr13:76177080	A/G	cg01531495	chr13:76123901	UCHL3	0.66	4.8	0.44	5.85e-6	Diabetic retinopathy;
THYM	cis	rs981844	1.000	rs17371021	chr4:154664295	A/G	cg09973105	chr4:154681532	RNF175	0.68	5.7	0.5	1.33e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs9902453	0.791	rs2628166	chr17:28113123	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-5.02	-0.46	2.43e-6	Coffee consumption (cups per day);
THYM	cis	rs12681287	0.640	rs12678720	chr8:87457929	T/G	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg06108461	chr20:60628389	TAF4	-1.06	-9.1	-0.68	1.39e-14	Body mass index;
THYM	trans	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs2932538	0.922	rs6668533	chr1:113064468	C/T	cg22162597	chr1:113214053	CAPZA1	0.55	4.49	0.42	2.02e-5	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs34112283	0.592	rs3795872	chr2:144245287	G/A	cg17056048	chr2:144271431	ARHGAP15	0.67	6.47	0.55	4.29e-9	Neuroticism;
THYM	cis	rs1957429	0.808	rs6573581	chr14:65331955	G/A	cg23373153	chr14:65346875	NA	0.95	5.17	0.47	1.28e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.59	-0.43	1.36e-5	Resting heart rate;
THYM	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg07424592	chr7:64974309	NA	1.12	5.24	0.47	9.64e-7	Diabetic kidney disease;
THYM	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg26384229	chr12:38710491	ALG10B	0.95	7.64	0.62	1.72e-11	Bladder cancer;
THYM	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg08968635	chr6:28129556	ZNF389	0.72	5.69	0.5	1.4e-7	Parkinson's disease;
THYM	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg10047753	chr17:41438598	NA	1.18	11.26	0.76	3.4e-19	Menopause (age at onset);
THYM	cis	rs7103648	0.932	rs7104036	chr11:47462140	A/G	cg20307385	chr11:47447363	PSMC3	0.94	8.67	0.66	1.15e-13	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	0.51	4.57	0.42	1.47e-5	Renal function-related traits (BUN);
THYM	cis	rs17253792	0.545	rs12893610	chr14:56016347	C/T	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs7264396	0.676	rs6060727	chr20:34556000	G/A	cg26038318	chr20:34205095	SPAG4	0.59	4.81	0.44	5.6e-6	Total cholesterol levels;
THYM	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg26384229	chr12:38710491	ALG10B	-0.7	-5.46	-0.49	3.87e-7	Morning vs. evening chronotype;
THYM	cis	rs1345301	1.000	rs12475055	chr2:102878891	G/T	cg03938978	chr2:103052716	IL18RAP	0.62	6.09	0.53	2.36e-8	Waist circumference;
THYM	cis	rs800586	0.522	rs2049870	chr8:116661516	C/T	cg04656070	chr8:116661063	TRPS1	-0.54	-6.14	-0.53	1.94e-8	Response to tocilizumab in rheumatoid arthritis;
THYM	trans	rs4866334	1.000	rs6866535	chr5:18431650	G/A	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs863345	0.604	rs11264997	chr1:158485482	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs13177918	0.581	rs2748244	chr5:149816050	A/T	cg14059543	chr5:149831962	NA	-0.86	-7.64	-0.62	1.68e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg24920358	chr1:40204285	PPIE	0.6	5.59	0.5	2.19e-7	Blood protein levels;
THYM	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.64	-0.62	1.74e-11	Personality dimensions;
THYM	cis	rs7100689	0.646	rs4468295	chr10:82119276	C/G	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs2554380	0.760	rs1946367	chr15:84425263	G/T	cg14598478	chr15:84363061	ADAMTSL3	-0.59	-4.89	-0.45	4.13e-6	Height;
THYM	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg06636001	chr8:8085503	FLJ10661	-0.76	-6.87	-0.58	6.7e-10	Neuroticism;
THYM	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg27588902	chr6:42928151	GNMT	-0.56	-5.54	-0.49	2.65e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.67	6.21	0.54	1.37e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs13082711	0.522	rs7651661	chr3:27362773	G/C	cg02860705	chr3:27208620	NA	0.62	4.79	0.44	6.17e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs995000	0.965	rs7520810	chr1:63095711	C/T	cg06896770	chr1:63153194	DOCK7	0.89	7.31	0.6	8.2e-11	Triglyceride levels;
THYM	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.47	4.49	0.42	2.01e-5	Schizophrenia;
THYM	cis	rs8050907	1.000	rs7201176	chr16:4626881	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.27	5.12	0.46	1.6e-6	Obesity-related traits;
THYM	cis	rs7793919	0.652	rs10228886	chr7:4783224	C/T	cg09789173	chr7:4769017	FOXK1	-0.81	-8.34	-0.65	5.79e-13	Mosquito bite size;
THYM	cis	rs28830936	0.528	rs11630242	chr15:42124643	T/C	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.46	-4.52	-0.42	1.79e-5	Diastolic blood pressure;
THYM	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg12564285	chr5:131593104	PDLIM4	0.5	5.65	0.5	1.69e-7	Breast cancer;
THYM	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg20999797	chr1:1681921	NA	0.51	5.59	0.5	2.15e-7	Body mass index;
THYM	cis	rs332034	0.507	rs4840366	chr8:8689966	G/C	cg06636001	chr8:8085503	FLJ10661	0.73	4.58	0.43	1.41e-5	Conduct disorder (maternal expressed emotions interaction);
THYM	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg13609457	chr4:120235615	NA	0.5	4.77	0.44	6.72e-6	Corneal astigmatism;
THYM	cis	rs4435363	1.000	rs4435363	chr19:47072395	A/G	cg10017888	chr19:47105860	CALM3	0.72	5.0	0.46	2.64e-6	Immature fraction of reticulocytes;P wave terminal force;
THYM	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25427524	chr10:38739819	LOC399744	-0.73	-6.77	-0.57	1.04e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg18252515	chr7:66147081	NA	-0.66	-5.01	-0.46	2.55e-6	Aortic root size;
THYM	cis	rs11948739	0.610	rs2419754	chr5:130252688	T/C	cg08523029	chr5:130500466	HINT1	0.77	5.3	0.48	7.38e-7	Pediatric bone mineral content (hip);
THYM	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.22	9.08	0.68	1.54e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7860634	0.872	rs7847312	chr9:139089718	A/C	cg04455058	chr9:139085579	NA	0.65	6.08	0.53	2.54e-8	Thyroid hormone levels;
THYM	cis	rs9810089	0.814	rs10804640	chr3:136165695	G/A	cg12473912	chr3:136751656	NA	0.62	5.27	0.48	8.44e-7	Gestational age at birth (child effect);
THYM	cis	rs3126085	0.877	rs10888472	chr1:152206896	C/G	cg10321714	chr1:152280068	FLG	-0.67	-4.85	-0.45	4.72e-6	Atopic dermatitis;
THYM	cis	rs2286885	1.000	rs2277159	chr9:129243383	C/T	cg14294646	chr9:129243551	FAM125B	-0.67	-6.38	-0.55	6.32e-9	Intraocular pressure;
THYM	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg02527881	chr3:46936655	PTH1R	-0.86	-8.53	-0.66	2.23e-13	Birth weight;
THYM	cis	rs3771570	1.000	rs4675811	chr2:242402062	A/T	cg21155796	chr2:242212141	HDLBP	1.07	6.22	0.54	1.33e-8	Prostate cancer;
THYM	cis	rs9560113	1.000	rs914026	chr13:112182029	G/A	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs7695732	0.551	rs9307056	chr4:89900717	T/C	cg17769793	chr4:89976368	FAM13A	-0.47	-4.94	-0.45	3.39e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6496667	0.865	rs7162697	chr15:90889337	A/C	cg22089800	chr15:90895588	ZNF774	0.74	4.47	0.42	2.14e-5	Rheumatoid arthritis;
THYM	cis	rs11716531	0.574	rs13075192	chr3:27279235	C/T	cg02860705	chr3:27208620	NA	0.77	5.99	0.52	3.81e-8	Diastolic blood pressure;
THYM	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg13609457	chr4:120235615	NA	0.59	5.22	0.47	1.03e-6	Corneal astigmatism;
THYM	cis	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg12981288	chr8:11183844	MTMR9	0.45	4.52	0.42	1.8e-5	Retinal vascular caliber;
THYM	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg16405210	chr4:1374714	KIAA1530	-1.1	-10.6	-0.74	8.64e-18	Longevity;
THYM	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg00684032	chr4:1343700	KIAA1530	-0.61	-5.45	-0.49	4.01e-7	Obesity-related traits;
THYM	cis	rs1650123	0.932	rs703624	chr12:104035804	A/G	cg23227824	chr12:103980017	STAB2	-0.47	-4.97	-0.45	2.91e-6	IgG glycosylation;
THYM	cis	rs12310956	0.532	rs11052954	chr12:33993512	C/G	cg10856724	chr12:34555212	NA	-0.76	-6.58	-0.56	2.6e-9	Morning vs. evening chronotype;
THYM	cis	rs13418717	0.793	rs58039373	chr2:127667254	C/T	cg25501666	chr2:127640322	NA	1.36	6.65	0.56	1.89e-9	Heart failure;
THYM	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7113850	0.541	rs114370606	chr11:24232247	C/T	ch.11.24196551F	chr11:24239977	NA	0.92	4.92	0.45	3.58e-6	Bone fracture in osteoporosis;
THYM	cis	rs3126085	0.866	rs3126067	chr1:152276889	A/G	cg10321714	chr1:152280068	FLG	-0.7	-5.43	-0.49	4.36e-7	Atopic dermatitis;
THYM	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg24531977	chr5:56204891	C5orf35	0.72	5.83	0.51	7.64e-8	Initial pursuit acceleration;
THYM	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg11279151	chr3:101281821	RG9MTD1	-0.87	-6.47	-0.55	4.16e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9326248	0.581	rs10892072	chr11:116960313	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.65	5.14	0.47	1.46e-6	Blood protein levels;
THYM	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg02753203	chr1:228287806	NA	-0.61	-5.28	-0.48	8.19e-7	Diastolic blood pressure;
THYM	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs7926906	1.000	rs1540170	chr11:90529456	A/G	cg26138821	chr11:89956704	CHORDC1	-0.57	-5.27	-0.48	8.36e-7	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2273669	0.667	rs11153156	chr6:109365911	C/T	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg08772003	chr10:104629869	AS3MT	-0.66	-6.07	-0.53	2.61e-8	Arsenic metabolism;
THYM	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg24060327	chr5:131705240	SLC22A5	-0.83	-6.92	-0.58	5.2e-10	Acylcarnitine levels;
THYM	cis	rs2769264	0.505	rs11801791	chr1:151387508	C/T	cg18801370	chr1:151430492	POGZ	0.65	4.7	0.43	8.63e-6	Blood trace element (Cu levels);
THYM	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg11764359	chr7:65958608	NA	0.86	7.24	0.6	1.17e-10	Aortic root size;
THYM	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg03161606	chr19:29218774	NA	0.87	7.71	0.62	1.23e-11	Methadone dose in opioid dependence;
THYM	cis	rs911119	1.000	rs3827142	chr20:23617007	G/A	cg16589663	chr20:23618590	CST3	0.78	4.79	0.44	6.1e-6	Chronic kidney disease;
THYM	cis	rs919433	0.713	rs10178946	chr2:198463090	G/T	cg00792783	chr2:198669748	PLCL1	0.77	5.31	0.48	7.16e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg09359103	chr1:154839909	KCNN3	0.79	10.37	0.73	2.74e-17	Prostate cancer;
THYM	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg00071950	chr4:10020882	SLC2A9	0.79	7.4	0.6	5.29e-11	Bone mineral density;
THYM	cis	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg24672777	chr11:48374446	OR4C45	0.73	4.6	0.43	1.28e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg24690094	chr11:67383802	NA	-0.69	-4.56	-0.42	1.51e-5	Mean corpuscular volume;
THYM	cis	rs7772486	0.686	rs702314	chr6:146003510	G/A	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7226229	0.847	rs4985941	chr17:20862133	A/G	cg21263980	chr17:20946333	USP22	0.72	4.73	0.44	7.88e-6	Blood trace element (Se levels);
THYM	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg04842962	chr6:43655489	MRPS18A	1.41	15.7	0.85	3.85e-28	IgG glycosylation;
THYM	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg22709100	chr7:91322751	NA	0.68	5.07	0.46	1.97e-6	Breast cancer;
THYM	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.55	-0.73	1.12e-17	Primary sclerosing cholangitis;
THYM	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg19346786	chr7:2764209	NA	-0.73	-6.22	-0.54	1.34e-8	Height;
THYM	cis	rs12188164	1.000	rs12188164	chr5:428236	C/A	cg26850624	chr5:429559	AHRR	-0.69	-5.39	-0.48	5.09e-7	Cystic fibrosis severity;
THYM	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg19904058	chr10:135279010	LOC619207	-0.57	-5.38	-0.48	5.35e-7	Systemic lupus erythematosus;
THYM	cis	rs1003719	0.708	rs2000417	chr21:38502868	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-4.75	-0.44	7.3e-6	Eye color traits;
THYM	cis	rs2219968	1.000	rs13266678	chr8:78958272	T/C	cg00738934	chr8:78996279	NA	0.88	9.31	0.69	4.91e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg00012203	chr2:219082015	ARPC2	0.54	4.72	0.44	8.08e-6	Colorectal cancer;
THYM	cis	rs55728055	0.661	rs73160611	chr22:31803487	A/G	cg01338084	chr22:32026380	PISD	1.35	4.93	0.45	3.5e-6	Age-related hearing impairment;
THYM	cis	rs478304	0.903	rs12293022	chr11:65531698	C/T	cg17480646	chr11:65405466	SIPA1	0.7	6.13	0.53	2e-8	Acne (severe);
THYM	cis	rs11039798	0.858	rs7121333	chr11:48332138	C/T	cg24672777	chr11:48374446	OR4C45	-1.17	-7.15	-0.59	1.78e-10	Axial length;
THYM	cis	rs600550	0.528	rs7109174	chr11:59844803	C/T	cg02771260	chr11:59836817	MS4A3	0.73	5.51	0.49	3.11e-7	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs995000	0.868	rs1168017	chr1:63002551	A/G	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs11089937	0.616	rs12484482	chr22:22534548	C/T	cg06866756	chr22:22471216	NA	-0.43	-4.71	-0.44	8.4e-6	Periodontitis (PAL4Q3);
THYM	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg22655196	chr4:3374909	RGS12	0.61	7.41	0.61	5.15e-11	Serum sulfate level;
THYM	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs7107174	0.901	rs2511162	chr11:77927101	A/G	cg02023728	chr11:77925099	USP35	0.68	6.32	0.54	8.26e-9	Testicular germ cell tumor;
THYM	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg17644776	chr2:200775616	C2orf69	-0.78	-4.58	-0.43	1.43e-5	Schizophrenia;
THYM	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg09060608	chr5:178986726	RUFY1	0.58	6.21	0.54	1.37e-8	Lung cancer;
THYM	trans	rs877282	0.755	rs11253399	chr10:790030	T/A	cg22713356	chr15:30763199	NA	1.18	9.79	0.71	4.66e-16	Uric acid levels;
THYM	cis	rs16865717	1.000	rs16865717	chr2:7032618	T/C	cg20486407	chr2:7037101	RSAD2	-1.19	-10.39	-0.73	2.45e-17	Venous thromboembolism (SNP x SNP interaction);
THYM	cis	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg23161317	chr6:28129485	ZNF389	1.05	6.18	0.54	1.58e-8	Depression;
THYM	cis	rs1912528	0.783	rs9997448	chr4:140870515	C/T	cg11128457	chr4:140864437	MAML3	0.46	4.84	0.44	4.96e-6	Educational attainment (years of education);
THYM	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg15247329	chr7:2764246	NA	-0.69	-5.68	-0.5	1.46e-7	Height;
THYM	cis	rs2637266	1.000	rs7476937	chr10:78357692	A/T	cg18941641	chr10:78392320	NA	0.85	7.44	0.61	4.53e-11	Pulmonary function;
THYM	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg11645453	chr3:52864694	ITIH4	0.3	4.69	0.43	8.99e-6	Schizophrenia;
THYM	cis	rs12208915	0.848	rs9343834	chr6:79517671	G/A	cg05283184	chr6:79620031	NA	0.74	4.81	0.44	5.67e-6	Left atrial antero-posterior diameter;
THYM	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg18758796	chr5:131593413	PDLIM4	0.49	4.54	0.42	1.62e-5	Breast cancer;
THYM	cis	rs2289328	0.943	rs12905240	chr15:40672145	C/T	cg13931752	chr15:40660718	DISP2	0.59	4.48	0.42	2.11e-5	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
THYM	cis	rs40363	0.645	rs37774	chr16:3512695	T/C	cg22508957	chr16:3507546	NAT15	0.69	9.35	0.69	4.05e-15	Tuberculosis;
THYM	cis	rs936229	1.000	rs4886615	chr15:75131661	A/G	cg14664628	chr15:75095509	CSK	-1.03	-8.07	-0.64	2.12e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs1915146	1.000	rs1915146	chr10:126846214	A/G	cg23000734	chr10:126850823	CTBP2	0.86	10.99	0.75	1.28e-18	Menarche (age at onset);
THYM	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg01579765	chr21:45077557	HSF2BP	-0.49	-7.89	-0.63	5.01e-12	Mean corpuscular volume;
THYM	cis	rs1003719	0.788	rs2835588	chr21:38462716	A/G	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs12496230	1.000	rs34508066	chr3:66837509	G/T	cg23477460	chr3:66848765	NA	1.18	7.37	0.6	6.39e-11	Type 2 diabetes;
THYM	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg23583168	chr7:148888333	NA	-1.06	-14.1	-0.82	4.94e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6598955	0.671	rs11247910	chr1:26645666	G/A	cg20415053	chr1:26527928	CATSPER4	-0.58	-4.71	-0.43	8.58e-6	Obesity-related traits;
THYM	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg02725872	chr8:58115012	NA	-1.09	-6.87	-0.58	6.64e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg22105103	chr4:187893119	NA	-0.89	-9.35	-0.69	4.03e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2133450	0.526	rs56174360	chr3:7349316	T/C	cg19930620	chr3:7340148	GRM7	-0.52	-5.62	-0.5	1.86e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg12386194	chr3:101231763	SENP7	0.92	7.36	0.6	6.68e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8067545	0.611	rs11653869	chr17:20197586	T/G	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg00801512	chr17:28996047	NA	-0.75	-4.83	-0.44	5.19e-6	Body mass index;
THYM	cis	rs4285028	0.747	rs9817818	chr3:121466826	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.85	-7.37	-0.6	6.22e-11	Multiple sclerosis;
THYM	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg24060327	chr5:131705240	SLC22A5	-0.76	-5.68	-0.5	1.46e-7	Blood metabolite levels;
THYM	cis	rs3204270	0.639	rs79193599	chr17:79651490	C/A	cg18367735	chr17:79674897	NA	0.8	4.77	0.44	6.61e-6	Dental caries;
THYM	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg04520793	chr17:42248056	ASB16	-0.33	-4.56	-0.42	1.54e-5	Total body bone mineral density;
THYM	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg14349672	chr11:133703707	NA	-0.52	-4.59	-0.43	1.37e-5	Childhood ear infection;
THYM	cis	rs11031096	0.678	rs4606468	chr11:4183643	G/T	cg22027985	chr11:4115532	RRM1	-0.53	-4.89	-0.45	4.11e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7584330	0.740	rs13418586	chr2:238445593	A/G	cg14458575	chr2:238380390	NA	0.63	5.01	0.46	2.48e-6	Prostate cancer;
THYM	cis	rs736408	0.812	rs2239699	chr3:52827915	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-5.77	-0.51	9.75e-8	Bipolar disorder;
THYM	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg24803719	chr17:45855879	NA	-0.6	-6.31	-0.54	8.89e-9	IgG glycosylation;
THYM	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg08558340	chr7:100472263	SRRT	0.52	4.85	0.45	4.9100000000000004e-06	Resting heart rate;
THYM	cis	rs2131877	0.871	rs59361541	chr3:194869939	T/C	cg21937377	chr3:194868750	C3orf21	0.39	4.53	0.42	1.69e-5	Non-small cell lung cancer;
THYM	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg10047753	chr17:41438598	NA	1.21	11.66	0.77	5.04e-20	Menopause (age at onset);
THYM	cis	rs4788570	0.697	rs9930015	chr16:71801092	C/G	cg06353428	chr16:71660113	MARVELD3	1.34	8.25	0.65	9.04e-13	Intelligence (multi-trait analysis);
THYM	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg00999904	chr2:3704751	ALLC	-0.71	-4.85	-0.45	4.75e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg19774624	chr17:42201019	HDAC5	-0.77	-7.16	-0.59	1.73e-10	Total body bone mineral density;
THYM	cis	rs7119	0.635	rs2667767	chr15:77876031	T/C	cg10437265	chr15:77819839	NA	-0.68	-6.57	-0.56	2.66e-9	Type 2 diabetes;
THYM	cis	rs9296092	0.538	rs62407566	chr6:33535786	C/T	cg13560919	chr6:33536144	NA	-0.93	-8.29	-0.65	7.19e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg03806693	chr22:41940476	POLR3H	1.07	8.04	0.64	2.49e-12	Vitiligo;
THYM	cis	rs6754311	0.773	rs309130	chr2:136631031	C/A	cg23851026	chr2:136556271	LCT	-0.5	-4.76	-0.44	6.97e-6	Mosquito bite size;
THYM	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg26116260	chr4:7069785	GRPEL1	1.09	10.85	0.74	2.51e-18	Monocyte percentage of white cells;
THYM	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg15605315	chr1:45957053	TESK2	0.79	6.68	0.57	1.61e-9	High light scatter reticulocyte count;
THYM	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9527	0.545	rs35756290	chr10:104585572	G/A	cg15744005	chr10:104629667	AS3MT	-0.69	-5.46	-0.49	3.79e-7	Arsenic metabolism;
THYM	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg18758796	chr5:131593413	PDLIM4	0.51	4.83	0.44	5.32e-6	Breast cancer;
THYM	cis	rs55871839	0.533	rs7813733	chr8:59852429	C/T	cg07426533	chr8:59803705	TOX	0.64	5.27	0.48	8.68e-7	Pneumonia;
THYM	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.03	10.05	0.72	1.3e-16	Colorectal cancer;
THYM	cis	rs470093	0.932	rs138087	chr22:44244621	A/G	cg09142166	chr22:44276013	PNPLA5	-0.6	-5.77	-0.51	9.87e-8	Staphylococcus aureus infection;
THYM	cis	rs6032067	0.929	rs2664581	chr20:43804522	A/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.56	-0.5	2.46e-7	Blood protein levels;
THYM	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.96	4.84	0.44	4.97e-6	Initial pursuit acceleration;
THYM	trans	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg10856724	chr12:34555212	NA	-0.96	-8.66	-0.66	1.22e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26314531	chr2:26401878	FAM59B	-0.76	-4.99	-0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg18402987	chr7:1209562	NA	0.73	5.27	0.48	8.58e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2235649	0.663	rs113908028	chr16:1848915	G/C	cg03034668	chr16:1723424	CRAMP1L	-0.61	-5.31	-0.48	7.12e-7	Blood metabolite levels;
THYM	cis	rs6840360	0.967	rs6841204	chr4:152598603	C/T	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg18032289	chr17:61959525	GH2	-0.49	-4.7	-0.43	8.9e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs7010267	0.935	rs6415470	chr8:119955111	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.6	4.87	0.45	4.36e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg18402987	chr7:1209562	NA	0.72	5.21	0.47	1.1e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7833986	0.534	rs2667980	chr8:56896541	A/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.6	6.63	0.56	2.06e-9	Height;
THYM	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg23422044	chr7:1970798	MAD1L1	-0.79	-5.34	-0.48	6.39e-7	Bipolar disorder;
THYM	cis	rs35100037	0.730	rs10056165	chr5:128661339	G/A	cg05211662	chr5:128795605	ADAMTS19	-0.81	-4.45	-0.42	2.32e-5	Ankle injury;
THYM	cis	rs3126085	0.877	rs6662450	chr1:152191709	C/G	cg10321714	chr1:152280068	FLG	0.69	5.04	0.46	2.22e-6	Atopic dermatitis;
THYM	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs2811415	0.627	rs1549873	chr3:127769599	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs6089584	0.566	rs12373885	chr20:60556393	A/C	cg24733560	chr20:60626293	TAF4	0.61	6.19	0.54	1.52e-8	Body mass index;
THYM	trans	rs1973993	0.967	rs11165643	chr1:96924097	C/T	cg10631902	chr5:14652156	NA	0.63	6.91	0.58	5.62e-10	Weight;
THYM	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg13695892	chr22:41940480	POLR3H	0.99	7.48	0.61	3.75e-11	Vitiligo;
THYM	cis	rs12367572	0.620	rs2544102	chr12:45420127	A/G	cg03114573	chr12:45410052	DBX2	-0.61	-5.93	-0.52	4.94e-8	Gut microbiome composition (summer);
THYM	cis	rs3772130	0.962	rs11721291	chr3:121563285	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.75	4.64	0.43	1.1e-5	Cognitive performance;
THYM	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg03676636	chr4:99064102	C4orf37	0.43	6.32	0.54	8.55e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6542838	0.673	rs1949424	chr2:99468341	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.51	4.47	0.42	2.19e-5	Fear of minor pain;
THYM	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg18221576	chr1:22213934	HSPG2	-0.55	-4.67	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg26384229	chr12:38710491	ALG10B	1.03	10.33	0.73	3.29e-17	Heart rate;
THYM	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg03474202	chr17:45855739	NA	-0.74	-6.44	-0.55	4.93e-9	IgG glycosylation;
THYM	cis	rs981844	0.712	rs1456397	chr4:154744554	C/G	cg09973105	chr4:154681532	RNF175	-0.52	-4.98	-0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.58	0.43	1.41e-5	Bipolar disorder;
THYM	cis	rs11048434	0.687	rs12814670	chr12:9060025	C/T	cg13575925	chr12:9217583	LOC144571	0.52	4.79	0.44	6.06e-6	Sjögren's syndrome;
THYM	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg04025307	chr7:1156635	C7orf50	0.76	4.73	0.44	7.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17407555	0.697	rs73212840	chr4:10087458	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-5.39	-0.48	5.08e-7	Schizophrenia (age at onset);
THYM	cis	rs4660261	0.526	rs2485996	chr1:44354661	C/T	cg15962314	chr1:44399869	ARTN	0.54	5.24	0.47	9.63e-7	Intelligence (multi-trait analysis);
THYM	cis	rs261532	0.953	rs446588	chr5:138987756	G/C	cg08720517	chr5:138729919	LOC389333	0.58	4.86	0.45	4.6e-6	Immune reponse to smallpox (secreted IFN-alpha);
THYM	cis	rs870825	0.616	rs7680639	chr4:185652915	C/T	cg04058563	chr4:185651563	MLF1IP	-1.06	-9.32	-0.69	4.75e-15	Blood protein levels;
THYM	cis	rs786425	0.585	rs10744160	chr12:124225542	A/G	cg15249119	chr12:124971054	NCOR2	0.51	4.68	0.43	9.66e-6	Pubertal anthropometrics;
THYM	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg18132916	chr6:79620363	NA	-0.58	-5.09	-0.46	1.79e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7681440	0.583	rs2736993	chr4:90772851	A/C	cg06632027	chr4:90757378	SNCA	-0.66	-5.29	-0.48	7.91e-7	Dementia with Lewy bodies;
THYM	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg03060546	chr3:49711283	APEH	-0.67	-5.08	-0.46	1.85e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg04750100	chr2:136595281	LCT	-0.54	-6.51	-0.56	3.59e-9	Mosquito bite size;
THYM	cis	rs7580658	0.613	rs12478656	chr2:128196520	G/T	cg10021288	chr2:128175891	PROC	-0.65	-5.65	-0.5	1.66e-7	Protein C levels;
THYM	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg23711669	chr6:146136114	FBXO30	-0.83	-7.95	-0.63	3.78e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg05283184	chr6:79620031	NA	-0.94	-8.82	-0.67	5.62e-14	Intelligence (multi-trait analysis);
THYM	cis	rs6582630	0.599	rs12824838	chr12:38373584	G/T	cg10518543	chr12:38710700	ALG10B	-0.59	-4.76	-0.44	6.86e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs11048434	0.736	rs12424026	chr12:9110993	T/C	cg04155231	chr12:9217510	LOC144571	0.47	4.47	0.42	2.14e-5	Sjögren's syndrome;
THYM	cis	rs4690686	0.500	rs4690429	chr4:177263983	G/A	cg17059388	chr4:177262070	NA	0.48	6.73	0.57	1.29e-9	Essential tremor;
THYM	cis	rs7296418	0.518	rs28825193	chr12:123878262	T/C	cg00376283	chr12:123451042	ABCB9	0.8	6.45	0.55	4.56e-9	Platelet count;
THYM	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg10150615	chr22:24372951	LOC391322	-0.89	-6.91	-0.58	5.43e-10	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs6988636	0.792	rs62521807	chr8:124163621	T/C	cg23067535	chr8:124195133	FAM83A	-0.99	-4.82	-0.44	5.52e-6	Urinary uromodulin levels;
THYM	cis	rs9527	0.615	rs3897401	chr10:104696379	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-5.01	-0.46	2.51e-6	Arsenic metabolism;
THYM	cis	rs8070740	0.786	rs12761	chr17:5326145	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.72	6.03	0.53	3.15e-8	Menopause (age at onset);
THYM	cis	rs12519773	0.502	rs67862943	chr5:92529268	G/A	cg18783429	chr5:92414398	NA	0.53	5.39	0.48	5.18e-7	Migraine;
THYM	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg11764359	chr7:65958608	NA	0.7	4.89	0.45	4.09e-6	Aortic root size;
THYM	cis	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg20415053	chr1:26527928	CATSPER4	-0.58	-4.71	-0.43	8.58e-6	Obesity-related traits;
THYM	cis	rs61931739	0.929	rs1825358	chr12:34011895	C/T	cg10856724	chr12:34555212	NA	0.59	5.13	0.47	1.56e-6	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg00814883	chr7:100076585	TSC22D4	-0.95	-6.36	-0.55	6.93e-9	Platelet count;
THYM	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg04234412	chr22:24373322	LOC391322	1.08	14.2	0.82	3.15e-25	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11141652	chr22:24348549	GSTTP1	-0.6	-5.82	-0.51	7.93e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs55728055	0.661	rs62237764	chr22:31947393	T/G	cg01338084	chr22:32026380	PISD	1.47	5.89	0.52	5.9e-8	Age-related hearing impairment;
THYM	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477602	0.938	rs6752522	chr2:203290013	C/G	cg10634136	chr2:202901470	FZD7	-0.69	-4.5	-0.42	1.9e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg19748678	chr4:122722346	EXOSC9	0.71	4.98	0.45	2.9e-6	Type 2 diabetes;
THYM	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	4.5	0.42	1.92e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.03	9.77	0.71	5.25e-16	Colorectal cancer;
THYM	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg02725872	chr8:58115012	NA	-0.9	-5.24	-0.47	9.85e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg00666640	chr1:248458726	OR2T12	0.55	4.67	0.43	9.91e-6	Common traits (Other);
THYM	cis	rs7408868	1.000	rs10422818	chr19:15285272	A/G	cg14696996	chr19:15285081	NOTCH3	0.94	5.48	0.49	3.49e-7	Pulse pressure;
THYM	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs9914988	0.943	rs7211502	chr17:27163295	C/A	cg20469991	chr17:27169893	C17orf63	-0.76	-4.78	-0.44	6.27e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs35883536	0.506	rs2809814	chr1:101031829	C/T	cg06223162	chr1:101003688	GPR88	0.85	7.33	0.6	7.63e-11	Monocyte count;
THYM	cis	rs7119	0.717	rs11629652	chr15:77779951	C/A	cg10437265	chr15:77819839	NA	0.56	4.99	0.46	2.78e-6	Type 2 diabetes;
THYM	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg00376283	chr12:123451042	ABCB9	0.67	5.17	0.47	1.31e-6	Neutrophil percentage of white cells;
THYM	cis	rs2075230	0.705	rs11078702	chr17:7543508	T/G	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.73	-0.44	7.7e-6	Hormone measurements;
THYM	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs7940866	0.903	rs10750457	chr11:130850277	T/C	cg23692386	chr11:131799662	NTM	0.43	4.7	0.43	8.9e-6	Schizophrenia;
THYM	cis	rs11096990	0.634	rs11096988	chr4:39265701	G/A	cg24403649	chr4:39172243	NA	0.67	5.84	0.51	7.33e-8	Cognitive function;
THYM	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	6.49	0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg19346786	chr7:2764209	NA	-0.72	-6.08	-0.53	2.55e-8	Height;
THYM	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg25918947	chr17:41365094	TMEM106A	0.64	5.41	0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg22753661	chr15:79092743	ADAMTS7	0.74	4.74	0.44	7.35e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg08017756	chr2:100939284	LONRF2	-0.75	-7.8	-0.62	7.89e-12	Intelligence (multi-trait analysis);
THYM	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg11764359	chr7:65958608	NA	0.76	5.99	0.52	3.74e-8	Aortic root size;
THYM	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg00129232	chr17:37814104	STARD3	-0.9	-7.76	-0.62	9.6e-12	Asthma;
THYM	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg13736514	chr6:26305472	NA	-0.62	-7.42	-0.61	5.02e-11	Educational attainment;
THYM	cis	rs995000	0.899	rs1305521	chr1:62949034	A/G	cg06896770	chr1:63153194	DOCK7	-0.92	-7.56	-0.61	2.53e-11	Triglyceride levels;
THYM	cis	rs79149102	0.579	rs76518150	chr15:75292721	C/G	cg17294928	chr15:75287854	SCAMP5	-1.06	-5.68	-0.5	1.49e-7	Lung cancer;
THYM	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg24818145	chr4:99064322	C4orf37	0.72	5.66	0.5	1.62e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg21475434	chr5:93447410	FAM172A	0.96	6.11	0.53	2.23e-8	Diabetic retinopathy;
THYM	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22433210	chr17:43662623	NA	-1.05	-8.08	-0.64	2e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6867032	0.958	rs4975798	chr5:2015580	G/A	cg26168224	chr5:2018326	NA	1.29	15.53	0.85	8.25e-28	Gut microbiome composition (winter);
THYM	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.79	-6.7	-0.57	1.46e-9	Lung cancer;
THYM	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg18132916	chr6:79620363	NA	-0.59	-5.31	-0.48	7.31e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg11861562	chr11:117069780	TAGLN	-0.32	-4.67	-0.43	9.96e-6	Blood protein levels;
THYM	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs10743315	0.557	rs1552750	chr12:19356505	A/T	cg02471346	chr12:19282374	PLEKHA5	1.09	4.55	0.42	1.58e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs3026101	0.624	rs1065483	chr17:5284770	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.58	5.23	0.47	1.01e-6	Body mass index;
THYM	cis	rs6032067	0.777	rs62208386	chr20:43790872	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.56	4.65	0.43	1.07e-5	Lung disease severity in cystic fibrosis;
THYM	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg16031515	chr1:205743344	RAB7L1	-0.71	-7.47	-0.61	3.85e-11	Menarche (age at onset);
THYM	cis	rs17102423	0.594	rs2781374	chr14:65568563	C/T	cg11161011	chr14:65562177	MAX	-0.7	-5.66	-0.5	1.59e-7	Obesity-related traits;
THYM	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg24838063	chr12:130822603	PIWIL1	-0.91	-7.18	-0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg01191920	chr7:158217561	PTPRN2	-1.06	-12.51	-0.79	8.38e-22	Obesity-related traits;
THYM	cis	rs4664308	0.840	rs17218566	chr2:161054748	C/T	cg03641300	chr2:160917029	PLA2R1	-0.75	-6.67	-0.56	1.73e-9	Idiopathic membranous nephropathy;
THYM	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg18876405	chr7:65276391	NA	0.7	6.14	0.53	1.87e-8	Aortic root size;
THYM	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg01528321	chr10:82214614	TSPAN14	0.96	7.48	0.61	3.7e-11	Post bronchodilator FEV1;
THYM	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg06618935	chr21:46677482	NA	0.99	8.38	0.65	4.78e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg09359103	chr1:154839909	KCNN3	-0.69	-8.43	-0.65	3.66e-13	Prostate cancer;
THYM	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.61	-0.43	1.27e-5	Type 2 diabetes;
THYM	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg17294928	chr15:75287854	SCAMP5	-0.99	-9.14	-0.68	1.15e-14	Blood trace element (Zn levels);
THYM	cis	rs6430585	0.527	rs2254780	chr2:136435526	C/T	cg07169764	chr2:136633963	MCM6	0.93	8.4	0.65	4.37e-13	Corneal structure;
THYM	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg06784218	chr1:46089804	CCDC17	-0.29	-4.6	-0.43	1.33e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-5.16	-0.47	1.34e-6	Hemoglobin concentration;
THYM	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg01097406	chr16:89675127	NA	0.87	7.77	0.62	9.17e-12	Vitiligo;
THYM	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg06981504	chr1:1234844	ACAP3	0.53	4.82	0.44	5.41e-6	Body mass index;
THYM	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10462794	0.789	rs7719895	chr5:4490338	C/T	cg27071312	chr5:5422796	KIAA0947	0.87	4.62	0.43	1.19e-5	DNA methylation (variation);
THYM	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg16342193	chr10:102329863	NA	-0.51	-5.11	-0.46	1.67e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg24154853	chr7:158122151	PTPRN2	0.55	4.82	0.44	5.35e-6	Calcium levels;
THYM	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg16342193	chr10:102329863	NA	-0.5	-4.86	-0.45	4.66e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs34638657	0.827	rs2303262	chr16:82203758	C/T	cg07307142	chr16:82071433	HSD17B2	-0.91	-6.56	-0.56	2.86e-9	Lung adenocarcinoma;
THYM	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg11764359	chr7:65958608	NA	0.63	4.92	0.45	3.66e-6	Aortic root size;
THYM	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	6.38	0.55	6.45e-9	Smoking behavior;
THYM	cis	rs11096990	0.634	rs17754	chr4:39289308	G/C	cg24403649	chr4:39172243	NA	0.66	5.65	0.5	1.67e-7	Cognitive function;
THYM	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg25811766	chr13:21894605	NA	-0.78	-5.02	-0.46	2.38e-6	White matter hyperintensity burden;
THYM	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg11245990	chr11:68621969	NA	-0.58	-7.58	-0.61	2.33e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs892961	0.806	rs35489990	chr17:75412312	T/C	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs12765878	1.000	rs11191849	chr10:105650880	T/A	cg11005552	chr10:105648138	OBFC1	0.87	11.39	0.76	1.84e-19	Coronary artery disease;
THYM	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg08859206	chr1:53392774	SCP2	-0.6	-6.87	-0.58	6.76e-10	Monocyte count;
THYM	cis	rs4746818	1.000	rs4284308	chr10:70884861	C/T	cg11621586	chr10:70884670	VPS26A	1.24	10.73	0.74	4.63e-18	Left atrial antero-posterior diameter;
THYM	cis	rs7646881	0.812	rs113166116	chr3:158460256	C/T	cg18349298	chr3:158450550	RARRES1	0.54	4.6	0.43	1.29e-5	Tetralogy of Fallot;
THYM	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg07936489	chr17:37558343	FBXL20	-0.64	-4.73	-0.44	7.85e-6	Asthma;
THYM	cis	rs7216064	1.000	rs7208663	chr17:65885171	T/C	cg12091567	chr17:66097778	LOC651250	-0.73	-4.94	-0.45	3.37e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg03929089	chr4:120376271	NA	-1.02	-12.97	-0.8	9.51e-23	Height;
THYM	cis	rs7677751	0.767	rs7676985	chr4:55064573	G/A	cg17187183	chr4:55093834	PDGFRA	0.63	4.85	0.45	4.86e-6	Corneal astigmatism;
THYM	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg11845111	chr2:191398756	TMEM194B	-0.96	-7.22	-0.6	1.26e-10	Diastolic blood pressure;
THYM	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg10760299	chr15:45669010	GATM	0.75	5.67	0.5	1.52e-7	Homoarginine levels;
THYM	cis	rs7953249	0.807	rs7970695	chr12:121423376	G/A	cg02403541	chr12:121454288	C12orf43	-0.57	-4.54	-0.42	1.66e-5	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs2835345	0.531	rs2409816	chr21:37825961	T/C	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs3126085	0.935	rs10888475	chr1:152226012	C/T	cg10321714	chr1:152280068	FLG	0.65	4.77	0.44	6.63e-6	Atopic dermatitis;
THYM	cis	rs1670533	0.818	rs6835141	chr4:1070140	G/T	cg27284194	chr4:1044797	NA	0.62	4.73	0.44	7.81e-6	Recombination rate (females);
THYM	cis	rs28595532	1.000	rs115004746	chr4:119642137	C/T	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.8	-5.59	-0.5	2.21e-7	Huntington's disease progression;
THYM	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg03188948	chr7:1209495	NA	0.9	5.02	0.46	2.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg10645314	chr2:3704589	ALLC	0.77	5.7	0.5	1.36e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs11031096	0.621	rs12282967	chr11:4191477	A/T	cg22027985	chr11:4115532	RRM1	-0.56	-5.25	-0.47	9.12e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4638749	0.677	rs1563111	chr2:108845717	A/G	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10186029	0.509	rs10194726	chr2:213936876	G/A	cg08319019	chr2:214017104	IKZF2	-0.69	-5.46	-0.49	3.88e-7	Systemic sclerosis;
THYM	cis	rs2455799	0.613	rs7614204	chr3:15792748	A/G	cg16303742	chr3:15540471	COLQ	-0.56	-5.73	-0.51	1.18e-7	Mean platelet volume;
THYM	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg06481639	chr22:41940642	POLR3H	-0.72	-5.25	-0.47	9.4e-7	Neuroticism;
THYM	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg07424592	chr7:64974309	NA	1.04	5.31	0.48	7.18e-7	Diabetic kidney disease;
THYM	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg12893697	chr11:970389	AP2A2	-0.32	-5.35	-0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs6860806	0.661	rs1588263	chr5:131577158	T/C	cg24060327	chr5:131705240	SLC22A5	-0.69	-5.27	-0.48	8.64e-7	Breast cancer;
THYM	cis	rs6700896	0.931	rs4655582	chr1:66153363	C/G	cg04111102	chr1:66153794	NA	0.59	5.83	0.51	7.66e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2340727	0.866	rs7529274	chr1:161948127	A/G	cg06514368	chr1:161719587	DUSP12	-0.83	-4.6	-0.43	1.29e-5	White blood cell count;Hematology traits;
THYM	cis	rs7089973	0.872	rs7072356	chr10:116634651	T/C	cg23260525	chr10:116636907	FAM160B1	0.52	4.66	0.43	1.02e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs4808199	0.901	rs11669516	chr19:19532682	G/A	cg03709012	chr19:19516395	GATAD2A	1.17	7.57	0.61	2.43e-11	Nonalcoholic fatty liver disease;
THYM	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.7	5.3	0.48	7.39e-7	Tonsillectomy;
THYM	cis	rs4509693	0.891	rs10748797	chr10:102502173	A/C	cg15234845	chr10:102496500	NA	0.67	4.71	0.44	8.29e-6	Alzheimer's disease;
THYM	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg21385522	chr1:16154831	NA	0.78	5.97	0.52	4e-8	Dilated cardiomyopathy;
THYM	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg12310025	chr6:25882481	NA	-0.69	-5.47	-0.49	3.69e-7	Blood metabolite levels;
THYM	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.22	0.64	1.03e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.38	-0.55	6.47e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg09354556	chr3:47051341	NA	0.44	4.57	0.42	1.46e-5	Colorectal cancer;
THYM	trans	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg26384229	chr12:38710491	ALG10B	0.87	7.04	0.59	2.94e-10	Morning vs. evening chronotype;
THYM	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg22920501	chr2:26401640	FAM59B	0.79	7.09	0.59	2.38e-10	Gut microbiome composition (summer);
THYM	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg18538332	chr22:24372958	LOC391322	1.04	12.81	0.8	2.09e-22	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4363385	0.818	rs2879487	chr1:152985360	C/A	cg13444842	chr1:152974279	SPRR3	-0.59	-4.84	-0.44	5.05e-6	Inflammatory skin disease;
THYM	cis	rs500891	0.547	rs1170480	chr6:84036345	A/G	cg21688264	chr6:84418724	SNAP91	0.74	4.51	0.42	1.87e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg26818010	chr10:134567672	INPP5A	-0.91	-7.38	-0.6	5.95e-11	Migraine;
THYM	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg08000102	chr2:233561755	GIGYF2	0.68	6.04	0.53	2.97e-8	Coronary artery disease;
THYM	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg23583168	chr7:148888333	NA	-1.03	-13.7	-0.81	3.25e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs3862030	0.694	rs1984795	chr10:104226830	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.66	-5.41	-0.49	4.72e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs924712	0.677	rs239813	chr6:54813423	A/G	cg04690482	chr6:54711388	FAM83B	0.43	5.22	0.47	1.05e-6	Breast cancer;
THYM	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg08847533	chr14:75593920	NEK9	-1.01	-11.33	-0.76	2.42e-19	Height;
THYM	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs7809950	1.000	rs4727680	chr7:107087407	T/G	cg23024343	chr7:107201750	COG5	-0.9	-8.07	-0.64	2.19e-12	Coronary artery disease;
THYM	cis	rs9876781	1.000	rs1563736	chr3:48436794	G/A	cg06066452	chr3:48470258	PLXNB1	0.26	4.88	0.45	4.26e-6	Longevity;
THYM	cis	rs7772486	0.558	rs702316	chr6:146004677	C/A	cg13319975	chr6:146136371	FBXO30	0.73	5.47	0.49	3.64e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7106204	0.514	rs7118022	chr11:24253352	C/T	ch.11.24196551F	chr11:24239977	NA	1.02	7.07	0.59	2.58e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs12893597	1.000	rs35788287	chr14:76814313	A/G	cg20290672	chr14:76816747	NA	-0.68	-5.16	-0.47	1.35e-6	Maximal oxygen uptake response;
THYM	cis	rs13064411	0.696	rs9839921	chr3:113199093	G/C	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	trans	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg11890956	chr21:40555474	PSMG1	-0.63	-5.79	-0.51	9.1e-8	Menarche (age at onset);
THYM	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	5.02	0.46	2.38e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg00129232	chr17:37814104	STARD3	-0.84	-5.96	-0.52	4.35e-8	Asthma;
THYM	cis	rs7762018	0.769	rs4716339	chr6:170063210	C/T	cg19338460	chr6:170058176	WDR27	-0.71	-4.87	-0.45	4.51e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg17509989	chr5:176798049	RGS14	0.66	6.02	0.53	3.24e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.04	-0.46	2.24e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.84	-6.12	-0.53	2.12e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4654899	1.000	rs6669102	chr1:21355543	A/G	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.26e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs4746818	0.793	rs2008553	chr10:70860475	C/G	cg04149295	chr10:70884716	VPS26A	0.68	4.47	0.42	2.17e-5	Left atrial antero-posterior diameter;
THYM	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg06808227	chr14:105710500	BRF1	-1.08	-9.65	-0.7	9.45e-16	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9527	0.590	rs7917650	chr10:104937100	G/C	cg04362960	chr10:104952993	NT5C2	0.6	4.6	0.43	1.32e-5	Arsenic metabolism;
THYM	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg02463440	chr8:22132932	PIWIL2	0.59	5.02	0.46	2.4e-6	Hypertriglyceridemia;
THYM	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg05283184	chr6:79620031	NA	-0.91	-8.88	-0.67	4.11e-14	Intelligence (multi-trait analysis);
THYM	cis	rs868036	0.718	rs16951275	chr15:68077168	T/C	cg24579218	chr15:68104479	NA	-0.82	-9.12	-0.68	1.26e-14	Restless legs syndrome;
THYM	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg18404041	chr3:52824283	ITIH1	-0.53	-5.23	-0.47	9.96e-7	Bipolar disorder;
THYM	cis	rs8103278	1.000	rs1548029	chr19:46309203	A/C	cg14061069	chr19:46274453	DMPK	-0.58	-5.78	-0.51	9.57e-8	Coronary artery disease;
THYM	cis	rs6032067	0.852	rs6032053	chr20:43829935	G/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg24846343	chr22:24311635	DDTL	0.44	5.32	0.48	6.75e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3849570	0.925	rs13091492	chr3:81891476	A/G	cg07356753	chr3:81810745	GBE1	-0.81	-6.28	-0.54	9.92e-9	Waist circumference;Body mass index;
THYM	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg17211192	chr8:82754475	SNX16	0.9	7.34	0.6	7.07e-11	Diastolic blood pressure;
THYM	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg09354556	chr3:47051341	NA	0.46	4.74	0.44	7.63e-6	Colorectal cancer;
THYM	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg23758822	chr17:41437982	NA	1.15	11.04	0.75	1.01e-18	Menopause (age at onset);
THYM	cis	rs289828	0.538	rs115072570	chr2:152153501	G/A	cg05960677	chr2:152117363	RBM43	0.71	6.86	0.58	6.88e-10	Blood protein levels;
THYM	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg26384229	chr12:38710491	ALG10B	0.94	7.62	0.62	1.86e-11	Morning vs. evening chronotype;
THYM	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg03929089	chr4:120376271	NA	-0.96	-7.52	-0.61	3.03e-11	Coronary artery disease;
THYM	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg08564027	chr20:61660810	NA	0.92	9.78	0.71	4.93e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs57590327	0.503	rs7426937	chr3:81881360	T/C	cg07356753	chr3:81810745	GBE1	-0.79	-5.82	-0.51	7.89e-8	Extraversion;
THYM	cis	rs911555	0.692	rs7145753	chr14:103866100	G/A	cg12935359	chr14:103987150	CKB	0.53	6.24	0.54	1.22e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4363385	0.791	rs4041401	chr1:152985629	A/G	cg13444842	chr1:152974279	SPRR3	-0.57	-4.76	-0.44	6.94e-6	Inflammatory skin disease;
THYM	cis	rs11225247	0.649	rs12283885	chr11:102257902	G/T	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg18876405	chr7:65276391	NA	0.61	5.2	0.47	1.13e-6	Aortic root size;
THYM	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg20283391	chr11:68216788	NA	-0.64	-4.58	-0.43	1.41e-5	Total body bone mineral density;
THYM	cis	rs40363	1.000	rs37771	chr16:3512866	G/T	cg00484396	chr16:3507460	NAT15	0.66	6.2	0.54	1.47e-8	Tuberculosis;
THYM	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-1.02	-9.91	-0.71	2.58e-16	Colorectal cancer;
THYM	cis	rs78761021	0.720	rs874306	chr17:9797994	G/A	cg26853458	chr17:9805074	RCVRN	0.53	4.46	0.42	2.24e-5	Type 2 diabetes;
THYM	cis	rs5417	0.780	rs222849	chr17:7185861	T/C	cg15298719	chr17:7165255	CLDN7	-0.36	-5.0	-0.46	2.56e-6	Diastolic blood pressure;
THYM	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg22841779	chr14:105766346	BRF1	-0.46	-5.67	-0.5	1.53e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg00256281	chr22:41985642	PMM1	0.62	4.67	0.43	9.91e-6	Vitiligo;
THYM	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg19746536	chr19:49375674	PPP1R15A	0.81	4.47	0.42	2.12e-5	Red cell distribution width;
THYM	cis	rs72627123	0.867	rs73301479	chr14:74467757	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg05234568	chr11:5960015	NA	0.67	6.16	0.53	1.77e-8	DNA methylation (variation);
THYM	cis	rs3806843	1.000	rs10050455	chr5:140204650	A/G	cg19875535	chr5:140030758	IK	0.61	4.81	0.44	5.71e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg07212818	chr11:638076	DRD4	-0.77	-5.92	-0.52	5.09e-8	Systemic lupus erythematosus;
THYM	cis	rs3741151	0.773	rs7110369	chr11:73160946	C/A	cg12959048	chr11:73096162	RELT	-0.53	-5.08	-0.46	1.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs4845570	1.000	rs4845570	chr1:151759104	C/T	cg18019451	chr1:151746047	TDRKH	0.73	4.52	0.42	1.75e-5	Coronary artery disease;
THYM	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg16928487	chr17:17741425	SREBF1	-0.56	-5.57	-0.5	2.37e-7	Total body bone mineral density;
THYM	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg24812749	chr6:127587940	RNF146	0.98	7.94	0.63	4.04e-12	Breast cancer;
THYM	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg10802521	chr3:52805072	NEK4	-0.71	-6.18	-0.54	1.57e-8	Bipolar disorder;
THYM	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg18681998	chr4:17616180	MED28	-0.77	-6.55	-0.56	2.88e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg05890377	chr2:74357713	NA	1.07	8.7	0.67	9.96e-14	Gestational age at birth (maternal effect);
THYM	cis	rs6768930	0.509	rs7620169	chr3:57893050	A/G	cg07735586	chr3:57945651	NA	-0.3	-4.48	-0.42	2.05e-5	Obesity-related traits;
THYM	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg18132916	chr6:79620363	NA	-0.59	-5.3	-0.48	7.54e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg11062466	chr8:58055876	NA	0.92	4.62	0.43	1.19e-5	Developmental language disorder (linguistic errors);
THYM	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg03929089	chr4:120376271	NA	-1.01	-13.5	-0.81	8.17e-24	Height;
THYM	cis	rs2495707	0.647	rs1541266	chr10:102421292	C/T	cg07919443	chr10:102419409	NA	-0.65	-5.73	-0.51	1.18e-7	Body mass index;
THYM	cis	rs2354432	0.607	rs6694347	chr1:146751140	T/C	cg25205988	chr1:146714368	CHD1L	-1.08	-5.63	-0.5	1.86e-7	Mitochondrial DNA levels;
THYM	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg07404485	chr7:94953653	PON1	0.87	7.58	0.61	2.32e-11	Paraoxonase activity;
THYM	cis	rs11078597	0.731	rs12944946	chr17:1649486	C/G	cg18436246	chr17:1640651	WDR81	0.64	4.63	0.43	1.14e-5	Serum albumin level;
THYM	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg18904891	chr8:8559673	CLDN23	0.59	4.85	0.45	4.79e-6	Mood instability;
THYM	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg16006841	chr5:176797999	RGS14	-0.5	-5.97	-0.52	4.02e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg18681998	chr4:17616180	MED28	0.88	8.13	0.64	1.64e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	4.78	0.44	6.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg21775007	chr8:11205619	TDH	-0.6	-4.64	-0.43	1.14e-5	Monocyte count;
THYM	cis	rs1971762	0.527	rs7972401	chr12:53940046	T/C	cg16917193	chr12:54089295	NA	0.7	6.18	0.54	1.57e-8	Height;
THYM	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs7394190	0.748	rs11000766	chr10:75512952	C/T	cg07699608	chr10:75541558	CHCHD1	0.91	4.9	0.45	3.9e-6	Incident atrial fibrillation;
THYM	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs2235649	0.753	rs7200472	chr16:1849669	T/C	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg16558253	chr16:72132732	DHX38	-0.58	-5.02	-0.46	2.46e-6	Fibrinogen levels;
THYM	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg22431228	chr1:16359049	CLCNKA	-0.57	-5.48	-0.49	3.44e-7	Systolic blood pressure;
THYM	cis	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg23422044	chr7:1970798	MAD1L1	-0.77	-4.68	-0.43	9.51e-6	Neuroticism;
THYM	cis	rs17006441	0.932	rs35879809	chr3:69876984	C/A	cg18496212	chr3:69797108	MITF	0.65	6.36	0.55	7.15e-9	Hemoglobin concentration;
THYM	cis	rs2742417	0.624	rs2673029	chr3:45758867	A/G	cg04837898	chr3:45731254	SACM1L	-0.73	-5.13	-0.47	1.56e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs7107174	0.792	rs10899488	chr11:78088754	A/G	cg19901956	chr11:77921274	USP35	-0.66	-5.28	-0.48	8.09e-7	Testicular germ cell tumor;
THYM	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg21854759	chr1:92012499	NA	-0.7	-5.66	-0.5	1.57e-7	Breast cancer;
THYM	cis	rs1550582	0.662	rs6981748	chr8:135501309	A/C	cg17885191	chr8:135476712	NA	-1.11	-9.16	-0.68	1.05e-14	Educational attainment;
THYM	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg09469691	chr10:81107165	PPIF	0.67	5.38	0.48	5.25e-7	Height;
THYM	cis	rs13315871	1.000	rs28626602	chr3:58409786	G/C	cg00563845	chr3:58318305	PXK	0.53	4.67	0.43	9.78e-6	Cholesterol, total;
THYM	cis	rs600806	0.821	rs1030522	chr1:109900707	C/G	cg16988986	chr1:109941118	SORT1	-0.43	-4.6	-0.43	1.32e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2625529	0.824	rs2306488	chr15:72292115	A/G	cg16672083	chr15:72433130	SENP8	-0.51	-4.54	-0.42	1.67e-5	Red blood cell count;
THYM	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg05425664	chr17:57184151	TRIM37	0.61	4.97	0.45	2.98e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	4.47	0.42	2.13e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4792901	0.802	rs9908559	chr17:41603161	T/C	cg21940313	chr17:41620911	ETV4	-0.53	-5.03	-0.46	2.28e-6	Dupuytren's disease;
THYM	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg22105103	chr4:187893119	NA	0.87	8.83	0.67	5.17e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg26384229	chr12:38710491	ALG10B	0.72	5.52	0.49	2.97e-7	Morning vs. evening chronotype;
THYM	cis	rs28595532	0.920	rs114670456	chr4:119771202	A/G	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs7084402	0.935	rs4141671	chr10:60338753	T/C	cg07615347	chr10:60278583	BICC1	-0.57	-5.27	-0.48	8.59e-7	Refractive error;
THYM	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg18825531	chr11:62321136	NA	-0.46	-5.32	-0.48	6.94e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs2836974	0.583	rs741795	chr21:40718440	T/C	cg11890956	chr21:40555474	PSMG1	0.66	5.18	0.47	1.23e-6	Cognitive function;
THYM	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg24818145	chr4:99064322	C4orf37	0.77	6.16	0.53	1.77e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6584283	0.846	rs11190135	chr10:101286848	A/G	cg04972745	chr10:101287846	NA	-0.5	-4.65	-0.43	1.08e-5	Ulcerative colitis;
THYM	cis	rs977102	0.556	rs12497778	chr3:67380570	G/C	cg06096184	chr3:66549732	LRIG1	0.66	4.6	0.43	1.32e-5	Response to amphetamines;
THYM	cis	rs6840360	0.582	rs6535796	chr4:152304728	G/A	cg17479576	chr4:152424074	FAM160A1	-0.74	-5.5	-0.49	3.17e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7192750	0.562	rs8063403	chr16:71931032	C/T	cg06353428	chr16:71660113	MARVELD3	0.76	5.6	0.5	2.04e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs2195525	0.572	rs948415	chr11:119217455	C/T	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.44	4.92	0.45	3.56e-6	Urate levels;
THYM	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg10117171	chr1:25599238	RHD	0.67	4.79	0.44	6.2e-6	Erythrocyte sedimentation rate;
THYM	cis	rs7246657	0.943	rs6508732	chr19:38000468	C/T	cg22634378	chr19:37742834	NA	0.58	4.84	0.44	5.03e-6	Coronary artery calcification;
THYM	cis	rs888405	0.588	rs222336	chr3:64232104	A/C	cg23047271	chr3:64210991	PRICKLE2	-0.67	-4.66	-0.43	1.01e-5	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
THYM	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg02725872	chr8:58115012	NA	-0.88	-6.55	-0.56	3e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs7100689	0.580	rs10736366	chr10:82207921	C/T	cg00277334	chr10:82204260	NA	-0.66	-6.63	-0.56	2.06e-9	Post bronchodilator FEV1;
THYM	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg20891283	chr12:69753455	YEATS4	1.06	10.08	0.72	1.1e-16	Blood protein levels;
THYM	cis	rs9906944	0.641	rs11655587	chr17:47140794	C/T	cg09029085	chr17:47094198	IGF2BP1	0.46	6.95	0.58	4.57e-10	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs2070488	0.804	rs7372452	chr3:38444298	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.57	4.45	0.42	2.31e-5	Electrocardiographic conduction measures;
THYM	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.69	-4.7	-0.43	8.9e-6	Cardiac Troponin-T levels;
THYM	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg01073479	chr16:3509474	NAT15	0.63	5.26	0.48	8.71e-7	Tuberculosis;
THYM	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg12407791	chr17:73824354	UNC13D	0.44	5.06	0.46	2.06e-6	White matter hyperintensity burden;
THYM	cis	rs7809615	0.901	rs13243267	chr7:99053314	C/G	cg12290671	chr7:99195819	NA	0.99	4.87	0.45	4.51e-6	Blood metabolite ratios;
THYM	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg12756686	chr19:29218302	NA	0.71	4.51	0.42	1.83e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs7172809	0.897	rs16968893	chr15:77825082	A/G	cg22256960	chr15:77711686	NA	-0.67	-4.61	-0.43	1.27e-5	Glucose homeostasis traits;
THYM	cis	rs6032067	0.641	rs34622539	chr20:43756548	A/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.73	-7.71	-0.62	1.23e-11	Blood protein levels;
THYM	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg18252515	chr7:66147081	NA	-1.48	-8.83	-0.67	5.23e-14	Diabetic kidney disease;
THYM	cis	rs9470366	0.527	rs733590	chr6:36645203	A/G	cg11920449	chr6:36645608	CDKN1A	-0.69	-5.74	-0.51	1.15e-7	QRS duration;
THYM	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9549260	0.709	rs4943795	chr13:41173433	C/T	cg21288729	chr13:41239152	FOXO1	-0.71	-5.58	-0.5	2.23e-7	Red blood cell count;
THYM	cis	rs6429082	0.623	rs7547849	chr1:235564254	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.74	-5.43	-0.49	4.26e-7	Adiposity;
THYM	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg03517284	chr6:25882590	NA	-1.23	-13.29	-0.81	2.11e-23	Urate levels;
THYM	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg27490568	chr2:178487706	NA	0.55	5.17	0.47	1.29e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1371867	0.875	rs1788178	chr8:101332518	A/C	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg24578937	chr1:2090814	PRKCZ	-0.56	-5.65	-0.5	1.67e-7	Height;
THYM	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs1165472	0.755	rs12566150	chr1:56160904	C/G	cg11523071	chr1:56160889	NA	-0.44	-4.46	-0.42	2.23e-5	Paclitaxel-induced neuropathy;
THYM	cis	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg12000587	chr17:30186630	C17orf79	0.5	7.14	0.59	1.84e-10	Hip circumference adjusted for BMI;
THYM	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs7584330	0.704	rs72620820	chr2:238358844	G/A	cg16989719	chr2:238392110	NA	-0.66	-5.12	-0.46	1.62e-6	Prostate cancer;
THYM	cis	rs2502731	0.583	rs3003579	chr9:130995751	C/G	cg13642260	chr9:130955380	CIZ1	0.67	5.21	0.47	1.11e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg08773314	chr2:239334832	ASB1	0.64	9.76	0.71	5.36e-16	Multiple system atrophy;
THYM	cis	rs2456568	0.900	rs2511373	chr11:93671414	T/C	cg26875233	chr11:93583750	C11orf90	-0.5	-4.88	-0.45	4.2e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs733592	0.524	rs10875741	chr12:48492922	A/C	cg21466736	chr12:48725269	NA	0.45	4.85	0.45	4.83e-6	Plateletcrit;
THYM	cis	rs7084402	0.935	rs10763556	chr10:60341398	A/G	cg27040468	chr10:60456715	BICC1	0.54	4.49	0.42	1.98e-5	Refractive error;
THYM	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg03467027	chr4:99064603	C4orf37	0.59	4.5	0.42	1.92e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.01	7.9	0.63	4.97e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg27129171	chr3:47204927	SETD2	-0.69	-6.59	-0.56	2.45e-9	Colorectal cancer;
THYM	cis	rs34638657	0.872	rs6420437	chr16:82187181	T/C	cg09439754	chr16:82129088	HSD17B2	-0.6	-5.24	-0.47	9.81e-7	Lung adenocarcinoma;
THYM	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg25358565	chr5:93447407	FAM172A	1.34	10.76	0.74	4.03e-18	Diabetic retinopathy;
THYM	cis	rs11688816	0.569	rs7591708	chr2:63022050	T/C	cg17519650	chr2:63277830	OTX1	-0.61	-4.93	-0.45	3.53e-6	Body mass index;
THYM	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	5.88	0.52	6.2e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg27534772	chr1:16042836	PLEKHM2	0.56	6.31	0.54	8.77e-9	Systolic blood pressure;
THYM	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg02527881	chr3:46936655	PTH1R	0.54	5.21	0.47	1.1e-6	Colorectal cancer;
THYM	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg17757837	chr7:157058334	UBE3C	-0.79	-6.82	-0.57	8.2e-10	Body mass index;
THYM	cis	rs6570726	0.791	rs370112	chr6:145859853	T/G	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.76	-0.44	6.98e-6	Crohn's disease;
THYM	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	4.92	0.45	3.68e-6	Prudent dietary pattern;
THYM	cis	rs10979	1.000	rs13198159	chr6:143891953	C/T	cg25407410	chr6:143891975	LOC285740	-0.59	-4.83	-0.44	5.18e-6	Hypospadias;
THYM	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg18904891	chr8:8559673	CLDN23	0.58	4.51	0.42	1.85e-5	Obesity-related traits;
THYM	cis	rs7558911	0.801	rs13006529	chr2:202082459	T/A	cg12105450	chr2:202048100	CASP10	0.53	4.52	0.42	1.77e-5	Chronic lymphocytic leukemia;
THYM	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	trans	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2456568	0.564	rs4608039	chr11:93624799	C/G	cg26875233	chr11:93583750	C11orf90	0.51	5.45	0.49	3.92e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs10979	1.000	rs9403504	chr6:143885430	G/A	cg25407410	chr6:143891975	LOC285740	-0.63	-5.41	-0.49	4.6e-7	Hypospadias;
THYM	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg08000102	chr2:233561755	GIGYF2	-0.54	-4.87	-0.45	4.52e-6	Coronary artery disease;
THYM	cis	rs752010	0.806	rs4641303	chr1:42091310	A/G	cg22486000	chr1:42919398	ZMYND12	-0.43	-4.83	-0.44	5.16e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs4242434	0.689	rs4872006	chr8:22536502	T/C	cg03733263	chr8:22462867	KIAA1967	-1.03	-10.38	-0.73	2.6e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs4568518	0.530	rs6461368	chr7:18063072	G/C	cg00911873	chr7:18067463	PRPS1L1	-0.57	-4.62	-0.43	1.23e-5	Measles;
THYM	cis	rs10492096	0.947	rs10849483	chr12:6635374	G/A	cg13857086	chr12:6580257	VAMP1	0.87	5.27	0.48	8.47e-7	Hip geometry;
THYM	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.53	0.42	1.7e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2334880	0.678	rs6499520	chr16:71458100	C/T	cg06353428	chr16:71660113	MARVELD3	-0.85	-4.61	-0.43	1.26e-5	Malaria;
THYM	cis	rs9633835	0.594	rs7942486	chr11:13288698	G/T	cg13286116	chr11:13302098	ARNTL	-0.72	-8.65	-0.66	1.24e-13	Body mass index;
THYM	cis	rs11771526	0.901	rs17161124	chr7:32307324	A/T	cg13207630	chr7:32358064	NA	-0.81	-5.16	-0.47	1.38e-6	Body mass index;
THYM	cis	rs763014	0.931	rs11648728	chr16:635525	C/T	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs902774	0.554	rs4503623	chr12:53353759	T/C	cg14581129	chr12:53358946	NA	-0.85	-6.28	-0.54	1.01e-8	Prostate cancer;
THYM	cis	rs17174870	0.955	rs55972521	chr2:112680519	A/G	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs9902453	0.935	rs9911794	chr17:28349466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	4.47	0.42	2.13e-5	Alzheimer's disease;
THYM	cis	rs2041895	0.509	rs1035236	chr12:107310797	C/T	cg26297688	chr12:107349093	C12orf23	-0.49	-4.81	-0.44	5.66e-6	Glaucoma (low intraocular pressure);
THYM	cis	rs985746	0.614	rs6832908	chr4:36788069	T/C	cg04301614	chr4:37585993	C4orf19	0.55	4.47	0.42	2.16e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg10803722	chr21:46713166	LOC642852	-0.41	-5.51	-0.49	3.07e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg19862616	chr7:65841803	NCRNA00174	1.08	12.96	0.8	1.02e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2637266	0.967	rs7900230	chr10:78366879	A/G	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg27286337	chr10:134555280	INPP5A	1.1	11.73	0.77	3.59e-20	Migraine;
THYM	cis	rs7267979	1.000	rs6050590	chr20:25384994	G/A	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg06221963	chr1:154839813	KCNN3	-0.88	-11.68	-0.77	4.46e-20	Prostate cancer;
THYM	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg05294307	chr14:35346193	BAZ1A	-0.91	-7.47	-0.61	3.85e-11	Psoriasis;
THYM	trans	rs17083844	0.655	rs76952305	chr18:68883150	A/G	cg17102648	chr1:61401827	NA	0.88	6.86	0.58	6.91e-10	Systemic lupus erythematosus;
THYM	cis	rs2075184	1	rs2075184	chr2:103080592	T/C	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.1	-0.46	1.74e-6	Pediatric autoimmune diseases;
THYM	cis	rs1278352	0.767	rs1278353	chr10:127773838	G/A	cg08295661	chr10:127769903	ADAM12	-0.55	-5.64	-0.5	1.71e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg22166914	chr1:53195759	ZYG11B	-0.69	-6.96	-0.58	4.39e-10	Monocyte count;
THYM	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg15744005	chr10:104629667	AS3MT	-0.83	-7.68	-0.62	1.44e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2625529	0.824	rs12439900	chr15:72373640	A/G	cg16672083	chr15:72433130	SENP8	-0.55	-4.92	-0.45	3.61e-6	Red blood cell count;
THYM	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.74	-0.44	7.64e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2294693	0.945	rs9369255	chr6:40989503	T/C	cg14418226	chr6:40996092	UNC5CL	0.69	5.65	0.5	1.7e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs763014	0.898	rs8060921	chr16:635988	C/A	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs9902453	0.935	rs4310926	chr17:28433275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.77	5.74	0.51	1.13e-7	Coffee consumption (cups per day);
THYM	cis	rs72627123	0.867	rs17093520	chr14:74346295	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs12291225	0.639	rs61883858	chr11:14294708	C/T	cg19336497	chr11:14380999	RRAS2	-0.82	-9.53	-0.7	1.67e-15	Sense of smell;
THYM	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg23982607	chr1:1823379	GNB1	-0.91	-9.76	-0.71	5.29e-16	Body mass index;
THYM	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg00495681	chr13:53174319	NA	0.71	7.05	0.59	2.91e-10	Lewy body disease;
THYM	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg11494091	chr17:61959527	GH2	-1.09	-17.3	-0.87	4.08e-31	Prudent dietary pattern;
THYM	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	7.64	0.62	1.71e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4148689	1.000	rs1896887	chr7:117200481	C/G	cg17204129	chr7:117119601	CFTR	-0.57	-4.47	-0.42	2.2e-5	Gout;
THYM	cis	rs2997447	0.802	rs61776621	chr1:26459058	C/G	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs35883536	0.513	rs4907910	chr1:101013277	T/A	cg09408571	chr1:101003634	GPR88	0.59	6.59	0.56	2.43e-9	Monocyte count;
THYM	cis	rs7072216	0.763	rs6584198	chr10:100169906	G/C	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs10889850	0.704	rs1612509	chr1:70197907	A/G	cg01711146	chr1:70671364	SFRS11;LRRC40	0.77	4.49	0.42	1.98e-5	Body mass index;
THYM	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg23281280	chr6:28129359	ZNF389	0.65	5.02	0.46	2.45e-6	Parkinson's disease;
THYM	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg03690763	chr11:133734501	NA	-0.6	-4.93	-0.45	3.51e-6	Childhood ear infection;
THYM	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg15557168	chr22:42548783	NA	0.58	4.68	0.43	9.66e-6	Schizophrenia;
THYM	cis	rs757081	0.667	rs17560341	chr11:17107163	C/T	cg15432903	chr11:17409602	KCNJ11	-0.49	-4.58	-0.43	1.43e-5	Systolic blood pressure;
THYM	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg03060546	chr3:49711283	APEH	-0.67	-5.08	-0.46	1.85e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs1018836	0.608	rs6986165	chr8:91477062	C/G	cg16814680	chr8:91681699	NA	-0.75	-6.21	-0.54	1.42e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg19770292	chr5:1868693	NA	0.51	4.77	0.44	6.62e-6	Cardiovascular disease risk factors;
THYM	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg01341218	chr17:43662625	NA	1.1	9.4	0.69	3.24e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs3008870	1.000	rs2985811	chr1:67377722	G/T	cg02640540	chr1:67518911	SLC35D1	0.64	4.6	0.43	1.33e-5	Lymphocyte percentage of white cells;
THYM	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.78	-7.17	-0.59	1.61e-10	Personality dimensions;
THYM	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03264133	chr6:25882463	NA	0.72	5.72	0.51	1.25e-7	Blood metabolite levels;
THYM	cis	rs713587	0.719	rs58048722	chr2:25187825	C/T	cg01884057	chr2:25150051	NA	-0.56	-5.49	-0.49	3.31e-7	Body mass index in non-asthmatics;
THYM	cis	rs7027203	0.797	rs57882762	chr9:96580825	T/G	cg14598338	chr9:96623480	NA	-0.5	-5.55	-0.49	2.59e-7	DNA methylation (variation);
THYM	cis	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg13443165	chr9:33130375	B4GALT1	-0.73	-5.15	-0.47	1.38e-6	IgG glycosylation;
THYM	cis	rs1499972	0.941	rs55958116	chr3:117672772	C/T	cg07612923	chr3:117604196	NA	1.42	5.49	0.49	3.4e-7	Schizophrenia;
THYM	cis	rs6733011	0.578	rs4851171	chr2:99510817	A/G	cg08885076	chr2:99613938	TSGA10	-0.46	-4.5	-0.42	1.96e-5	Bipolar disorder;
THYM	cis	rs6964587	0.620	rs7808587	chr7:91620096	G/A	cg22709100	chr7:91322751	NA	0.63	4.76	0.44	6.93e-6	Breast cancer;
THYM	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs7705502	1.000	rs72812840	chr5:173374655	A/G	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg10360139	chr7:1886902	MAD1L1	-0.59	-4.75	-0.44	7.29e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg22535103	chr8:58192502	C8orf71	-0.93	-5.25	-0.47	9.15e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs10193935	0.901	rs10169971	chr2:42602189	G/A	cg27598129	chr2:42591480	NA	-0.74	-4.58	-0.43	1.4e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4843185	0.667	rs4143865	chr16:85716612	T/A	cg26571870	chr16:85723150	GINS2	-0.4	-4.68	-0.43	9.61e-6	Platelet distribution width;
THYM	cis	rs4499344	0.693	rs382416	chr19:33107938	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.81	-5.96	-0.52	4.29e-8	Mean platelet volume;
THYM	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	8.57	0.66	1.88e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs921665	0.505	rs11127384	chr2:3203977	C/T	cg16434511	chr2:3151078	NA	-1.05	-5.23	-0.47	1.01e-6	World class endurance athleticism;
THYM	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs4845459	0.967	rs4845446	chr1:152590750	C/T	cg26135325	chr1:152595322	LCE3A	0.45	5.21	0.47	1.09e-6	Psoriasis;
THYM	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg09359103	chr1:154839909	KCNN3	-0.81	-10.6	-0.74	8.67e-18	Prostate cancer;
THYM	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg17554472	chr22:41940697	POLR3H	0.64	4.54	0.42	1.65e-5	Vitiligo;
THYM	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg14458575	chr2:238380390	NA	1.01	8.02	0.64	2.71e-12	Prostate cancer;
THYM	cis	rs9595908	0.785	rs4120131	chr13:33277086	A/G	cg12383807	chr13:33924137	NA	0.52	4.61	0.43	1.26e-5	Body mass index;
THYM	cis	rs2991971	0.782	rs10789463	chr1:45927848	C/A	cg15605315	chr1:45957053	TESK2	-0.66	-5.32	-0.48	6.98e-7	High light scatter reticulocyte count;
THYM	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg08645402	chr16:4508243	NA	0.69	5.13	0.47	1.55e-6	Schizophrenia;
THYM	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg01238044	chr22:24384105	GSTT1	0.5	4.6	0.43	1.32e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.84	-6.04	-0.53	2.99e-8	Multiple sclerosis;
THYM	trans	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg19862616	chr7:65841803	NCRNA00174	-1.12	-13.73	-0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg25036284	chr2:26402008	FAM59B	-0.76	-5.02	-0.46	2.44e-6	Gut microbiome composition (summer);
THYM	cis	rs11711311	0.955	rs9866806	chr3:113379865	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.58	4.84	0.44	5.07e-6	IgG glycosylation;
THYM	cis	rs7909791	0.632	rs3752949	chr10:105670503	A/G	cg24587175	chr10:105670608	OBFC1	0.76	7.41	0.61	5.2e-11	White matter hyperintensity burden;
THYM	cis	rs7084402	0.967	rs1346302	chr10:60267137	G/A	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg09359103	chr1:154839909	KCNN3	0.83	11.98	0.78	1.06e-20	Prostate cancer;
THYM	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg24874828	chr4:187887005	NA	-0.75	-7.65	-0.62	1.65e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg22852734	chr6:133119734	C6orf192	1.32	8.71	0.67	9.24e-14	Type 2 diabetes nephropathy;
THYM	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.84	-5.28	-0.48	8.06e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12458462	0.892	rs35928863	chr18:77438956	A/G	cg11879182	chr18:77439856	CTDP1	0.81	7.86	0.63	5.87e-12	Monocyte count;
THYM	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg24692254	chr21:30365293	RNF160	-0.85	-7.06	-0.59	2.74e-10	Dental caries;
THYM	cis	rs13064411	0.542	rs2087130	chr3:113226983	T/A	cg18753928	chr3:113234510	CCDC52	-0.84	-7.87	-0.63	5.58e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs11648796	0.959	rs9928077	chr16:784765	C/T	cg02852791	chr16:710674	WDR90	-0.61	-5.18	-0.47	1.23e-6	Height;
THYM	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg18904891	chr8:8559673	CLDN23	0.65	4.9	0.45	3.88e-6	Obesity-related traits;
THYM	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg14675211	chr2:100938903	LONRF2	0.71	6.91	0.58	5.47e-10	Intelligence (multi-trait analysis);
THYM	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg05182265	chr7:156933206	UBE3C	0.7	9.62	0.7	1.06e-15	Body mass index;
THYM	cis	rs478304	0.934	rs603645	chr11:65533000	A/C	cg17480646	chr11:65405466	SIPA1	0.7	6.13	0.53	2e-8	Acne (severe);
THYM	cis	rs7107174	0.792	rs10751287	chr11:78072476	T/C	cg19901956	chr11:77921274	USP35	-0.65	-5.34	-0.48	6.25e-7	Testicular germ cell tumor;
THYM	trans	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs6669072	0.565	rs7554094	chr1:91283104	A/T	cg08895590	chr1:91227319	NA	-0.39	-4.45	-0.42	2.32e-5	Cognitive function;
THYM	cis	rs11118844	0.739	rs12070192	chr1:221945870	A/T	cg04222084	chr1:221915650	DUSP10	-1.02	-5.31	-0.48	7.05e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg12311346	chr5:56204834	C5orf35	-0.97	-7.04	-0.59	2.95e-10	Initial pursuit acceleration;
THYM	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg24112000	chr20:60950667	NA	-0.61	-4.95	-0.45	3.23e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg12667521	chr19:29218732	NA	0.72	5.33	0.48	6.47e-7	Methadone dose in opioid dependence;
THYM	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg15448220	chr1:150897856	SETDB1	0.92	7.66	0.62	1.56e-11	Melanoma;
THYM	cis	rs886774	0.526	rs6964893	chr7:107499725	G/T	cg23293999	chr7:106826042	HBP1	-0.59	-4.59	-0.43	1.36e-5	Ulcerative colitis;
THYM	cis	rs4746818	1.000	rs7916991	chr10:70895373	C/A	cg11621586	chr10:70884670	VPS26A	1.2	7.86	0.63	5.83e-12	Left atrial antero-posterior diameter;
THYM	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg24812749	chr6:127587940	RNF146	0.79	5.99	0.52	3.76e-8	Breast cancer;
THYM	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg18131467	chr2:239335373	ASB1	1.08	10.28	0.73	4.19e-17	Multiple system atrophy;
THYM	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg24209194	chr3:40518798	ZNF619	0.65	5.27	0.48	8.46e-7	Renal cell carcinoma;
THYM	cis	rs9287719	0.625	rs7567304	chr2:10790029	T/C	cg02196655	chr2:10830764	NOL10	0.52	5.06	0.46	2.05e-6	Prostate cancer;
THYM	cis	rs6918586	1.000	rs6918586	chr6:26097384	T/C	cg03264133	chr6:25882463	NA	-0.62	-4.66	-0.43	1.03e-5	Schizophrenia;
THYM	cis	rs12216545	0.765	rs2204130	chr7:150251436	C/T	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg22764044	chr5:178986830	RUFY1	-0.51	-5.25	-0.47	9.45e-7	Lung cancer;
THYM	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg06558623	chr16:89946397	TCF25	1.42	6.85	0.58	7.17e-10	Skin colour saturation;
THYM	cis	rs11077998	0.967	rs4789796	chr17:80521135	T/C	cg11779900	chr17:80519722	FOXK2	-0.54	-4.67	-0.43	1e-5	Reticulocyte fraction of red cells;
THYM	cis	rs6570726	0.935	rs414222	chr6:145850482	C/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.75	-0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2066819	1.000	rs2306693	chr12:56680531	T/C	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs3820068	0.637	rs4646080	chr1:15826627	A/T	cg05660106	chr1:15850417	CASP9	1.13	10.23	0.72	5.39e-17	Systolic blood pressure;
THYM	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.66	0.56	1.78e-9	Total body bone mineral density;
THYM	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg04842962	chr6:43655489	MRPS18A	-1.38	-14.83	-0.84	1.8e-26	IgG glycosylation;
THYM	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg17054759	chr22:49844102	NA	-0.52	-4.77	-0.44	6.52e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs8018808	0.935	rs6574372	chr14:77906295	T/G	cg20045696	chr14:77926864	AHSA1	0.5	4.46	0.42	2.27e-5	Myeloid white cell count;
THYM	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg17863274	chr19:49399704	TULP2	-1.02	-6.56	-0.56	2.8e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg16535667	chr11:65410126	SIPA1	-0.76	-4.47	-0.42	2.19e-5	Blood pressure (age interaction);
THYM	cis	rs9902453	0.691	rs140701	chr17:28538532	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	4.71	0.43	8.49e-6	Coffee consumption (cups per day);
THYM	cis	rs17407555	0.779	rs57757169	chr4:10115703	G/A	cg00071950	chr4:10020882	SLC2A9	-0.67	-5.53	-0.49	2.83e-7	Schizophrenia (age at onset);
THYM	cis	rs4919044	0.756	rs835257	chr10:94779801	T/A	cg05127821	chr10:94822908	CYP26C1	-1.31	-6.9	-0.58	5.75e-10	Coronary artery disease;
THYM	cis	rs6032067	0.929	rs35869085	chr20:43805134	G/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs4866334	0.557	rs116250256	chr5:18457657	A/T	cg04591469	chr5:17810299	NA	-1.12	-4.54	-0.42	1.65e-5	IgG glycosylation;
THYM	cis	rs7927771	0.524	rs7933184	chr11:47682402	C/T	cg18512352	chr11:47633146	NA	0.41	4.55	0.42	1.61e-5	Subjective well-being;
THYM	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.94	6.12	0.53	2.08e-8	Smoking behavior;
THYM	cis	rs977987	0.778	rs62059846	chr16:75430809	T/A	cg03315344	chr16:75512273	CHST6	0.73	6.16	0.53	1.73e-8	Dupuytren's disease;
THYM	trans	rs1318772	0.867	rs13171389	chr5:112907818	C/T	cg09357140	chr16:332745	ARHGDIG;PDIA2	1.16	7.12	0.59	2.09e-10	F-cell distribution;
THYM	cis	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg21775007	chr8:11205619	TDH	-0.7	-5.78	-0.51	9.67e-8	Retinal vascular caliber;
THYM	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2282300	0.739	rs12577729	chr11:30257377	C/T	cg09906309	chr11:30344399	C11orf46	-0.72	-5.34	-0.48	6.24e-7	Morning vs. evening chronotype;
THYM	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg11764359	chr7:65958608	NA	0.85	7.26	0.6	1.06e-10	Aortic root size;
THYM	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg24642439	chr20:33292090	TP53INP2	0.68	5.14	0.47	1.45e-6	Coronary artery disease;
THYM	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs9527	0.615	rs11191401	chr10:104573403	A/G	cg15744005	chr10:104629667	AS3MT	-0.77	-6.4	-0.55	5.92e-9	Arsenic metabolism;
THYM	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg09877947	chr5:131593287	PDLIM4	0.7	6.33	0.54	7.92e-9	Acylcarnitine levels;
THYM	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg15448220	chr1:150897856	SETDB1	0.89	7.59	0.61	2.17e-11	Melanoma;
THYM	cis	rs7943203	0.568	rs61913891	chr11:108335075	A/G	cg04873221	chr11:107992290	ACAT1	-0.72	-4.71	-0.43	8.56e-6	Red blood cell count;Mean corpuscular volume;
THYM	cis	rs4654899	0.897	rs6670897	chr1:21066376	T/C	cg01072550	chr1:21505969	NA	-0.6	-5.26	-0.47	8.9e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7894407	0.760	rs4917386	chr10:105007528	C/T	cg15744005	chr10:104629667	AS3MT	0.56	4.46	0.42	2.24e-5	White matter hyperintensity burden;
THYM	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg08885076	chr2:99613938	TSGA10	-0.63	-5.68	-0.5	1.47e-7	Chronic sinus infection;
THYM	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg22907277	chr7:1156413	C7orf50	0.83	5.1	0.46	1.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg13147721	chr7:65941812	NA	0.76	4.93	0.45	3.42e-6	Gout;
THYM	cis	rs11225247	0.764	rs11225237	chr11:102250527	A/G	cg06323957	chr11:102217781	BIRC2	1.08	4.83	0.44	5.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs332034	0.591	rs9650614	chr8:8693386	G/A	cg06636001	chr8:8085503	FLJ10661	-0.76	-4.51	-0.42	1.85e-5	Conduct disorder (maternal expressed emotions interaction);
THYM	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg12419862	chr22:24373484	LOC391322	0.76	7.23	0.6	1.19e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7119038	0.629	rs11216993	chr11:118603495	T/A	cg19308663	chr11:118741387	NA	0.49	4.55	0.42	1.6e-5	Sjögren's syndrome;
THYM	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg16405210	chr4:1374714	KIAA1530	1.11	10.82	0.74	2.96e-18	Longevity;
THYM	cis	rs2073300	1.000	rs2207988	chr20:23446000	C/A	cg12062639	chr20:23401060	NAPB	1.32	6.15	0.53	1.81e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs1451375	0.583	rs7776816	chr7:50583534	G/A	cg18232548	chr7:50535776	DDC	0.67	5.03	0.46	2.31e-6	Malaria;
THYM	cis	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg18127003	chr8:11614472	GATA4	-0.5	-4.67	-0.43	9.84e-6	Morning vs. evening chronotype;
THYM	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.49	-4.98	-0.45	2.88e-6	Crohn's disease;
THYM	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg00801512	chr17:28996047	NA	-0.76	-5.08	-0.46	1.91e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg11266682	chr4:10021025	SLC2A9	0.74	12.07	0.78	6.92e-21	Bone mineral density;
THYM	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg14004847	chr7:1930337	MAD1L1	-0.66	-5.4	-0.48	5e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg08859206	chr1:53392774	SCP2	-0.66	-7.55	-0.61	2.7e-11	Monocyte count;
THYM	cis	rs13255292	0.599	rs60696357	chr8:129083773	T/A	cg03076047	chr8:128748337	MYC	-0.58	-4.56	-0.42	1.5e-5	Diffuse large B cell lymphoma;
THYM	cis	rs9646944	0.501	rs13030675	chr2:103091618	C/A	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	cis	rs35883536	0.609	rs12747197	chr1:101036831	A/C	cg09408571	chr1:101003634	GPR88	-0.49	-5.3	-0.48	7.62e-7	Monocyte count;
THYM	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg06784218	chr1:46089804	CCDC17	-0.3	-4.61	-0.43	1.28e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg27034606	chr17:28928453	LRRC37B2	0.8	5.13	0.47	1.52e-6	Body mass index;
THYM	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg14972814	chr11:95582409	MTMR2	-0.71	-6.61	-0.56	2.19e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1981331	0.609	rs117296583	chr21:48053238	C/T	cg23283320	chr21:48055893	PRMT2	1.55	7.5	0.61	3.39e-11	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs7843479	0.898	rs4311656	chr8:21802276	T/G	cg17168535	chr8:21777572	XPO7	0.72	5.08	0.46	1.91e-6	Mean corpuscular volume;
THYM	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg07424592	chr7:64974309	NA	1.13	5.51	0.49	3.04e-7	Diabetic kidney disease;
THYM	cis	rs11792861	0.589	rs75742991	chr9:111929624	C/G	cg05043794	chr9:111880884	C9orf5	-0.4	-5.93	-0.52	4.88e-8	Menarche (age at onset);
THYM	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs854765	0.547	rs4365348	chr17:17912548	C/T	cg04398451	chr17:18023971	MYO15A	-0.95	-9.84	-0.71	3.63e-16	Total body bone mineral density;
THYM	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg11266682	chr4:10021025	SLC2A9	0.68	9.72	0.71	6.47e-16	Bone mineral density;
THYM	cis	rs17127169	1.000	rs78969683	chr1:65411289	T/C	cg12075498	chr1:65428216	JAK1	-0.42	-5.21	-0.47	1.09e-6	Sitting height ratio;
THYM	cis	rs514406	0.928	rs1672917	chr1:53291550	A/G	cg08859206	chr1:53392774	SCP2	-0.6	-6.58	-0.56	2.6e-9	Monocyte count;
THYM	cis	rs7100689	0.646	rs4601708	chr10:82119583	G/T	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs8106542	0.865	rs8105546	chr19:10741202	G/A	cg17848348	chr19:10766748	ILF3	-0.8	-6.62	-0.56	2.13e-9	Platelet distribution width;
THYM	trans	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg25214090	chr10:38739885	LOC399744	0.94	8.07	0.64	2.11e-12	Corneal astigmatism;
THYM	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg13607699	chr17:42295918	UBTF	0.93	9.6	0.7	1.19e-15	Total body bone mineral density;
THYM	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg11764359	chr7:65958608	NA	0.69	4.78	0.44	6.35e-6	Aortic root size;
THYM	cis	rs611744	0.967	rs641721	chr8:109230140	G/A	cg21045802	chr8:109455806	TTC35	0.59	5.25	0.47	9.08e-7	Dupuytren's disease;
THYM	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6450176	0.909	rs3776720	chr5:53296158	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.84	-6.38	-0.55	6.53e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs3741151	0.773	rs7110369	chr11:73160946	C/A	cg17517138	chr11:73019481	ARHGEF17	0.94	5.48	0.49	3.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs1113500	0.541	rs6692571	chr1:108576684	G/A	cg06207961	chr1:108661230	NA	0.63	4.59	0.43	1.35e-5	Growth-regulated protein alpha levels;
THYM	cis	rs6032067	0.641	rs35882692	chr20:43763968	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.73	-7.71	-0.62	1.23e-11	Blood protein levels;
THYM	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.19	0.64	1.21e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg18512352	chr11:47633146	NA	0.5	5.89	0.52	5.85e-8	Subjective well-being;
THYM	cis	rs28595532	0.920	rs115317002	chr4:119722809	T/C	cg11846333	chr4:119757529	SEC24D	1.36	5.13	0.47	1.5e-6	Cannabis dependence symptom count;
THYM	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19346786	chr7:2764209	NA	-0.8	-7.25	-0.6	1.09e-10	Height;
THYM	cis	rs6906287	0.647	rs2356183	chr6:118770264	A/G	cg21191810	chr6:118973309	C6orf204	0.55	5.54	0.49	2.68e-7	Electrocardiographic conduction measures;
THYM	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	5.21	0.47	1.11e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.62	5.67	0.5	1.54e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs11249608	0.548	rs7733072	chr5:178456007	A/G	cg01312482	chr5:178451176	ZNF879	-0.76	-6.3	-0.54	9.29e-9	Pubertal anthropometrics;
THYM	cis	rs11096990	0.634	rs7666632	chr4:39240188	C/T	cg24403649	chr4:39172243	NA	0.67	5.87	0.52	6.24e-8	Cognitive function;
THYM	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg04731861	chr2:219085781	ARPC2	0.56	5.39	0.48	5.21e-7	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs2219968	1.000	rs13255746	chr8:78954214	A/T	cg00738934	chr8:78996279	NA	0.91	9.88	0.71	3.04e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg04455712	chr21:45112962	RRP1B	0.51	4.58	0.43	1.4e-5	Mean corpuscular volume;
THYM	cis	rs56079296	0.929	rs10045728	chr5:121277101	A/G	cg05256605	chr5:121412184	LOX	-0.61	-4.69	-0.43	9.18e-6	Coronary artery disease;
THYM	cis	rs2281845	0.826	rs4915215	chr1:201077212	C/T	cg17810781	chr1:201082982	CACNA1S	-0.57	-5.77	-0.51	9.97e-8	Permanent tooth development;
THYM	cis	rs17152411	1.000	rs1807099	chr10:126593774	C/T	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs7216064	1.000	rs7221651	chr17:65832390	A/G	cg12091567	chr17:66097778	LOC651250	0.71	4.76	0.44	6.86e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs9486719	0.690	rs2092094	chr6:96844123	G/C	cg18709589	chr6:96969512	KIAA0776	0.75	4.49	0.42	2.02e-5	Migraine;Coronary artery disease;
THYM	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg16325326	chr1:53192061	ZYG11B	0.92	9.77	0.71	5.06e-16	Monocyte count;
THYM	cis	rs2066819	1.000	rs773664	chr12:56702176	C/T	cg26714650	chr12:56694279	CS	1.26	7.39	0.6	5.59e-11	Psoriasis vulgaris;
THYM	cis	rs2976388	0.967	rs2978981	chr8:143759137	C/T	cg06565975	chr8:143823917	SLURP1	-0.44	-4.94	-0.45	3.37e-6	Urinary tract infection frequency;
THYM	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg21984481	chr17:79567631	NPLOC4	-0.47	-4.95	-0.45	3.22e-6	Eye color traits;
THYM	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg08835221	chr22:38071607	LGALS1	0.37	4.95	0.45	3.22e-6	Fat distribution (HIV);
THYM	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.61	4.6	0.43	1.29e-5	Renal function-related traits (BUN);
THYM	cis	rs9403317	0.537	rs8180666	chr6:142026555	A/C	cg15052665	chr6:141804349	NA	-0.73	-5.34	-0.48	6.39e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4363385	0.747	rs1415959	chr1:152973690	C/T	cg13444842	chr1:152974279	SPRR3	0.57	4.53	0.42	1.71e-5	Inflammatory skin disease;
THYM	trans	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg20587970	chr11:113659929	NA	-1.25	-9.01	-0.68	2.13e-14	Hip circumference adjusted for BMI;
THYM	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg18105134	chr13:113819100	PROZ	1.02	9.35	0.69	4.08e-15	Platelet distribution width;
THYM	cis	rs4866334	1.000	rs77574409	chr5:18485477	G/T	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs2688608	0.725	rs2675666	chr10:75682651	G/T	cg02947784	chr10:75434997	AGAP5	0.49	4.61	0.43	1.26e-5	Inflammatory bowel disease;
THYM	cis	rs1461503	0.903	rs7124683	chr11:122834036	A/G	cg27398637	chr11:122830231	C11orf63	0.61	5.32	0.48	7e-7	Menarche (age at onset);
THYM	cis	rs10489202	1.000	rs12407660	chr1:167954363	C/T	cg24449463	chr1:168025552	DCAF6	-0.83	-6.51	-0.56	3.58e-9	Schizophrenia;
THYM	cis	rs367615	0.918	rs10054960	chr5:108866448	C/A	cg17395555	chr5:108820864	NA	0.53	4.8	0.44	5.95e-6	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs17127169	1.000	rs17127169	chr1:65412137	A/C	cg12075498	chr1:65428216	JAK1	-0.42	-5.21	-0.47	1.09e-6	Sitting height ratio;
THYM	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg03388043	chr17:80084554	CCDC57	0.71	6.11	0.53	2.15e-8	Life satisfaction;
THYM	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2737265	0.723	rs2737247	chr8:116660365	A/G	cg04656070	chr8:116661063	TRPS1	-0.55	-6.41	-0.55	5.59e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;
THYM	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg09990169	chr2:241835740	C2orf54	-0.38	-6.01	-0.52	3.48e-8	Urinary metabolites;
THYM	cis	rs4731207	0.596	rs1026837	chr7:124673079	C/T	cg05285228	chr7:124571219	POT1	-0.61	-4.58	-0.43	1.39e-5	Cutaneous malignant melanoma;
THYM	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg26384229	chr12:38710491	ALG10B	-0.9	-7.35	-0.6	6.77e-11	Morning vs. evening chronotype;
THYM	cis	rs2903698	0.565	rs6835573	chr4:76436429	A/G	cg03209871	chr4:76438412	RCHY1;THAP6	0.4	4.58	0.43	1.39e-5	Prion diseases;
THYM	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg12292205	chr6:26970375	C6orf41	0.61	4.84	0.44	5.01e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11696845	0.776	rs6073538	chr20:43379264	A/C	cg25301532	chr20:43378953	KCNK15	0.64	5.12	0.47	1.6e-6	Obesity-related traits;
THYM	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg07690219	chr3:49449608	TCTA;RHOA	0.72	4.83	0.44	5.31e-6	Menarche (age at onset);
THYM	cis	rs526231	0.543	rs26523	chr5:102456254	C/T	cg23492399	chr5:102201601	PAM	-0.7	-5.23	-0.47	9.9e-7	Primary biliary cholangitis;
THYM	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg27423445	chr12:12879764	APOLD1	-0.4	-4.74	-0.44	7.46e-6	Birth weight;
THYM	cis	rs7584330	0.554	rs13390883	chr2:238432619	A/T	cg14458575	chr2:238380390	NA	0.8	4.67	0.43	9.97e-6	Prostate cancer;
THYM	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg18538332	chr22:24372958	LOC391322	-0.86	-9.3	-0.69	5.13e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg27490568	chr2:178487706	NA	0.63	6.05	0.53	2.91e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4732038	0.565	rs12665934	chr7:134281053	A/C	cg06906464	chr7:134288099	NA	0.46	4.61	0.43	1.26e-5	Longevity;
THYM	cis	rs6762477	0.748	rs11714286	chr3:50185508	G/A	cg24308560	chr3:49941425	MST1R	0.59	4.69	0.43	9.11e-6	Menarche (age at onset);
THYM	cis	rs459571	0.920	rs460154	chr9:136909309	C/T	cg13789015	chr9:136890014	NCRNA00094	0.75	6.37	0.55	6.62e-9	Platelet distribution width;
THYM	cis	rs2066819	1.000	rs2695789	chr12:56694261	C/A	cg26714650	chr12:56694279	CS	1.26	7.39	0.6	5.59e-11	Psoriasis vulgaris;
THYM	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg00786635	chr1:25594202	NA	0.96	7.71	0.62	1.2e-11	Erythrocyte sedimentation rate;
THYM	cis	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg09307838	chr4:120376055	NA	0.66	4.93	0.45	3.49e-6	Corneal astigmatism;
THYM	cis	rs4731207	0.698	rs2040926	chr7:124457295	C/G	cg05285228	chr7:124571219	POT1	-0.69	-5.48	-0.49	3.54e-7	Cutaneous malignant melanoma;
THYM	cis	rs11122895	1.000	rs34217241	chr2:112465639	G/A	cg23262488	chr2:112468472	NA	0.67	9.57	0.7	1.36e-15	Allergic sensitization;
THYM	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	7.12	0.59	2.09e-10	Cognitive test performance;
THYM	trans	rs8073060	0.544	rs225252	chr17:33952401	G/A	cg19694781	chr19:47549865	TMEM160	-0.95	-7.8	-0.62	7.8e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg24733560	chr20:60626293	TAF4	0.52	4.69	0.43	9.24e-6	Body mass index;
THYM	cis	rs10504906	0.643	rs9297896	chr8:92419241	T/C	cg09373786	chr8:93156639	NA	1.28	4.51	0.42	1.88e-5	Fat distribution (HIV);
THYM	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg05347473	chr6:146136440	FBXO30	0.57	4.54	0.42	1.66e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg11366901	chr6:160182831	ACAT2	1.08	9.54	0.7	1.56e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.45	0.49	3.92e-7	Electroencephalogram traits;
THYM	cis	rs7027203	0.759	rs10761282	chr9:96586175	G/A	cg13679303	chr9:96623674	NA	-0.46	-4.6	-0.43	1.32e-5	DNA methylation (variation);
THYM	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg06634786	chr22:41940651	POLR3H	-0.66	-4.8	-0.44	5.78e-6	Vitiligo;
THYM	cis	rs2455799	0.573	rs2455833	chr3:15752830	T/C	cg16303742	chr3:15540471	COLQ	-0.58	-6.1	-0.53	2.29e-8	Mean platelet volume;
THYM	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg27490568	chr2:178487706	NA	0.56	4.89	0.45	4.1e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4792901	0.759	rs75491854	chr17:41574650	T/C	cg21940313	chr17:41620911	ETV4	-0.54	-5.17	-0.47	1.32e-6	Dupuytren's disease;
THYM	cis	rs7584330	0.695	rs7570882	chr2:238435086	G/A	cg16989719	chr2:238392110	NA	-0.49	-4.88	-0.45	4.35e-6	Prostate cancer;
THYM	cis	rs7103648	0.966	rs896817	chr11:47394305	A/G	cg20307385	chr11:47447363	PSMC3	-0.96	-8.72	-0.67	9.14e-14	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs926938	0.618	rs1286555	chr1:115361896	C/T	cg12756093	chr1:115239321	AMPD1	-0.59	-4.79	-0.44	6.1e-6	Autism;
THYM	cis	rs3017493	1.000	rs3017493	chr11:70665521	A/G	cg14537332	chr11:70508113	SHANK2	0.84	5.17	0.47	1.28e-6	Renal transplant outcome;
THYM	cis	rs7528419	0.895	rs1277930	chr1:109822143	G/A	cg00908766	chr1:109817496	CELSR2	0.77	6.26	0.54	1.09e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
THYM	cis	rs2439831	0.681	rs2278858	chr15:43632755	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	8.06	0.64	2.23e-12	Lung cancer in ever smokers;
THYM	cis	rs9807989	0.507	rs11465721	chr2:103063240	T/G	cg03938978	chr2:103052716	IL18RAP	0.75	9.44	0.7	2.63e-15	Asthma;
THYM	cis	rs7953508	0.636	rs10859535	chr12:93979892	A/G	cg13201927	chr12:93977447	NA	0.71	4.96	0.45	3.12e-6	Pubertal anthropometrics;
THYM	cis	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg05084668	chr3:125655381	ALG1L	-0.72	-4.78	-0.44	6.44e-6	Blood pressure (smoking interaction);
THYM	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg23583168	chr7:148888333	NA	-1.02	-13.92	-0.82	1.16e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg15744005	chr10:104629667	AS3MT	-0.79	-7.24	-0.6	1.14e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs4638749	0.677	rs6713634	chr2:108827907	T/G	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs62070183	0.882	rs17183600	chr17:31175079	T/C	cg23177095	chr17:30873196	MYO1D	0.63	4.86	0.45	4.63e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs2898681	0.770	rs62336795	chr4:53737772	G/A	cg21521518	chr4:53727714	RASL11B	0.43	4.79	0.44	6.09e-6	Optic nerve measurement (cup area);
THYM	cis	rs61990749	0.597	rs6574391	chr14:78208121	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.04	0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs11025559	0.812	rs10833338	chr11:20514709	A/G	cg19653624	chr11:20408972	PRMT3	-0.75	-5.17	-0.47	1.27e-6	Pursuit maintenance gain;
THYM	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg26384229	chr12:38710491	ALG10B	0.73	5.4	0.48	5.01e-7	Morning vs. evening chronotype;
THYM	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg08645402	chr16:4508243	NA	0.77	7.09	0.59	2.4e-10	Schizophrenia;
THYM	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg01699819	chr7:1052092	C7orf50	-0.78	-6.97	-0.58	4.06e-10	Bronchopulmonary dysplasia;
THYM	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs2742234	0.541	rs11238479	chr10:43717423	C/T	cg06632098	chr10:43605906	RET	0.8	5.26	0.47	8.98e-7	Hirschsprung disease;
THYM	cis	rs6473252	0.546	rs7834840	chr8:81822519	T/C	cg08595989	chr8:81827712	NA	-0.53	-5.69	-0.5	1.43e-7	Breast cancer;
THYM	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.02	8.91	0.67	3.55e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs2811415	0.597	rs9813812	chr3:127791936	G/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg16586182	chr3:47516702	SCAP	0.67	5.61	0.5	1.99e-7	Colorectal cancer;
THYM	cis	rs951188	0.793	rs58652945	chr2:150348692	A/T	cg17961725	chr2:150454027	NA	-0.77	-4.74	-0.44	7.64e-6	Daytime sleep phenotypes;
THYM	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg22920501	chr2:26401640	FAM59B	-1.05	-9.27	-0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs7917772	0.539	rs12572775	chr10:104285594	A/T	cg00122347	chr10:104236741	TMEM180	0.46	6.77	0.57	1.06e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10779751	0.770	rs6701524	chr1:11198502	A/G	cg08854313	chr1:11322531	MTOR	-0.74	-5.94	-0.52	4.61e-8	Body mass index;
THYM	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg14582100	chr15:45693742	SPATA5L1	0.6	4.73	0.44	7.83e-6	Homoarginine levels;
THYM	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.58	4.95	0.45	3.25e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg12560992	chr17:57184187	TRIM37	0.73	5.99	0.52	3.72e-8	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs7173743	0.525	rs7166723	chr15:79133848	C/T	cg15571903	chr15:79123663	NA	0.48	4.8	0.44	5.83e-6	Coronary artery disease;
THYM	cis	rs4907240	0.961	rs11682934	chr2:97237153	C/T	cg01950434	chr2:97203154	ARID5A	-0.55	-4.62	-0.43	1.21e-5	Event-related brain oscillations;
THYM	cis	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg02317251	chr4:10116515	WDR1	-0.56	-4.95	-0.45	3.23e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg18105134	chr13:113819100	PROZ	-0.98	-9.0	-0.68	2.28e-14	Platelet distribution width;
THYM	cis	rs6430585	0.583	rs3769008	chr2:136586183	C/T	cg23851026	chr2:136556271	LCT	0.77	7.67	0.62	1.48e-11	Corneal structure;
THYM	cis	rs7113850	0.512	rs11027747	chr11:24197995	A/G	ch.11.24196551F	chr11:24239977	NA	-0.81	-4.64	-0.43	1.11e-5	Bone fracture in osteoporosis;
THYM	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg04248312	chr19:17393744	ANKLE1	0.98	13.19	0.8	3.47e-23	Systemic lupus erythematosus;
THYM	cis	rs1003719	0.788	rs2835593	chr21:38465873	G/C	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs7553864	0.966	rs1886635	chr1:87614950	G/A	cg17420885	chr1:87600446	LOC339524	-0.71	-6.08	-0.53	2.55e-8	Smoking behavior;
THYM	cis	rs4074961	0.509	rs4653300	chr1:38024054	A/G	cg17933807	chr1:38061675	GNL2	1.12	14.77	0.83	2.45e-26	Axial length;
THYM	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg18357526	chr6:26021779	HIST1H4A	0.77	6.26	0.54	1.09e-8	Intelligence (multi-trait analysis);
THYM	cis	rs3087591	0.960	rs2905878	chr17:29511199	T/C	cg24425628	chr17:29625626	OMG;NF1	0.65	5.69	0.5	1.38e-7	Hip circumference;
THYM	cis	rs67072384	1.000	rs12294368	chr11:72451239	G/A	cg01380194	chr11:72452482	ARAP1	-0.97	-5.26	-0.47	8.93e-7	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	trans	rs4650994	1.000	rs12138561	chr1:178518784	G/T	cg05059571	chr16:84539110	KIAA1609	-0.75	-8.02	-0.64	2.68e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg07606381	chr6:8435919	SLC35B3	0.61	4.51	0.42	1.86e-5	Motion sickness;
THYM	cis	rs9796	0.689	rs692153	chr15:41452681	C/T	cg21153102	chr15:41252147	NA	0.6	4.97	0.45	2.97e-6	Menopause (age at onset);
THYM	cis	rs863345	0.535	rs12068285	chr1:158499632	G/A	cg12129480	chr1:158549410	OR10X1	-0.54	-5.21	-0.47	1.12e-6	Pneumococcal bacteremia;
THYM	cis	rs72828912	0.731	rs9358747	chr6:24069549	A/T	cg19882886	chr6:25043046	NA	-0.86	-4.47	-0.42	2.14e-5	Squamous cell lung carcinoma;
THYM	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg10802521	chr3:52805072	NEK4	-0.75	-6.97	-0.58	4.08e-10	Bipolar disorder;
THYM	trans	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg20587970	chr11:113659929	NA	-1.26	-9.15	-0.68	1.09e-14	Hip circumference adjusted for BMI;
THYM	cis	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg12963246	chr6:28129442	ZNF389	0.71	5.16	0.47	1.34e-6	Depression;
THYM	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg05294307	chr14:35346193	BAZ1A	-0.82	-5.51	-0.49	3.06e-7	Psoriasis;
THYM	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg24803719	chr17:45855879	NA	-0.6	-6.33	-0.54	7.96e-9	IgG glycosylation;
THYM	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg18477163	chr1:228402036	OBSCN	0.59	6.61	0.56	2.25e-9	Diastolic blood pressure;
THYM	cis	rs11652874	0.655	rs1490931	chr17:31979334	C/T	cg07860833	chr17:31537624	ACCN1	0.87	4.64	0.43	1.11e-5	Severe gingival inflammation;
THYM	cis	rs2811415	0.531	rs9850146	chr3:127744122	G/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs1150668	0.699	rs1531681	chr6:28226878	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.74	-6.12	-0.53	2.12e-8	Pubertal anthropometrics;
THYM	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg11494091	chr17:61959527	GH2	0.69	6.32	0.54	8.45e-9	Height;
THYM	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg23161317	chr6:28129485	ZNF389	0.87	6.22	0.54	1.31e-8	Depression;
THYM	cis	rs5758511	0.689	rs45441993	chr22:42471738	C/A	cg22189786	chr22:42395067	WBP2NL	0.66	4.52	0.42	1.8e-5	Birth weight;
THYM	cis	rs228769	1.000	rs12937692	chr17:42256430	G/A	cg13607699	chr17:42295918	UBTF	0.58	4.66	0.43	1.01e-5	Bone mineral density (hip);Bone mineral density (spine);
THYM	cis	rs2976388	1.000	rs1045531	chr8:143763547	C/A	cg13446199	chr8:143762866	PSCA	0.51	6.42	0.55	5.46e-9	Urinary tract infection frequency;
THYM	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg02753203	chr1:228287806	NA	-0.61	-5.28	-0.48	8.19e-7	Diastolic blood pressure;
THYM	cis	rs709400	0.526	rs11622473	chr14:103979762	G/A	cg12935359	chr14:103987150	CKB	-0.61	-5.46	-0.49	3.8e-7	Body mass index;
THYM	cis	rs4654899	1.000	rs6681064	chr1:21339644	A/G	cg01072550	chr1:21505969	NA	-0.74	-6.82	-0.57	8.58e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg17264618	chr3:40429014	ENTPD3	0.49	4.69	0.43	9.06e-6	Renal cell carcinoma;
THYM	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg24642844	chr7:1081250	C7orf50	-1.11	-6.31	-0.54	8.63e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11644478	chr21:40555479	PSMG1	-0.56	-4.69	-0.43	9.07e-6	Menarche (age at onset);
THYM	cis	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg24818145	chr4:99064322	C4orf37	0.67	5.2	0.47	1.13e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4788570	0.566	rs1804984	chr16:71481520	T/A	cg06353428	chr16:71660113	MARVELD3	-1.01	-5.04	-0.46	2.2e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6980334	0.679	rs1872930	chr7:137801444	C/T	cg06915773	chr7:137028165	PTN	0.61	4.76	0.44	6.93e-6	Blood metabolite ratios;
THYM	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg16205897	chr5:131564050	P4HA2	-0.5	-4.52	-0.42	1.77e-5	Blood metabolite levels;
THYM	cis	rs4919687	0.550	rs12259058	chr10:104484799	A/G	cg05855489	chr10:104503620	C10orf26	0.74	5.73	0.51	1.18e-7	Colorectal cancer;
THYM	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs2273669	0.665	rs55885457	chr6:109403325	T/C	cg17117243	chr6:109341365	SESN1	-0.86	-5.26	-0.47	9.04e-7	Prostate cancer;
THYM	trans	rs1997103	1.000	rs9649781	chr7:55411809	A/G	cg20935933	chr6:143382018	AIG1	0.86	6.91	0.58	5.51e-10	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs288326	0.561	rs80231765	chr2:183745777	C/T	cg09997497	chr2:183902928	NCKAP1	1.11	5.07	0.46	1.94e-6	Blood protein levels;
THYM	cis	rs4072705	0.586	rs7855247	chr9:127246644	T/C	cg01786973	chr9:127249749	NR5A1	-0.4	-5.24	-0.47	9.69e-7	Menarche (age at onset);
THYM	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg22089800	chr15:90895588	ZNF774	0.68	5.26	0.47	9e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs11070747	1.000	rs11070747	chr15:50376439	C/G	cg19960114	chr15:50296100	ATP8B4	0.5	5.0	0.46	2.59e-6	Verbal declarative memory;
THYM	cis	rs2066819	1.000	rs744051	chr12:56667298	C/T	cg26714650	chr12:56694279	CS	1.35	7.01	0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs921665	0.831	rs3887811	chr2:3182777	A/G	cg16434511	chr2:3151078	NA	-0.85	-5.29	-0.48	7.76e-7	World class endurance athleticism;
THYM	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg23743428	chr13:21893420	NA	-0.64	-5.73	-0.51	1.16e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs9768139	0.935	rs62480865	chr7:158122307	A/C	cg06219351	chr7:158114137	PTPRN2	0.69	6.86	0.58	6.93e-10	Calcium levels;
THYM	cis	rs3741151	1.000	rs7122825	chr11:73061324	C/T	cg17517138	chr11:73019481	ARHGEF17	0.99	5.88	0.52	5.97e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs11118844	0.744	rs11118857	chr1:221952209	C/T	cg04222084	chr1:221915650	DUSP10	-0.95	-4.72	-0.44	8.03e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg00495681	chr13:53174319	NA	0.73	7.21	0.59	1.34e-10	Lewy body disease;
THYM	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg08999081	chr20:33150536	PIGU	0.8	7.37	0.6	6.23e-11	Coronary artery disease;
THYM	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	7.96	0.63	3.74e-12	Monocyte percentage of white cells;
THYM	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.58	0.56	2.61e-9	Total body bone mineral density;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg27196691	chr11:105947405	KBTBD3;AASDHPPT	1.33	7.14	0.59	1.88e-10	Pulmonary function decline;
THYM	cis	rs9527	0.545	rs7894588	chr10:104756030	A/T	cg04362960	chr10:104952993	NT5C2	0.6	4.52	0.42	1.77e-5	Arsenic metabolism;
THYM	cis	rs72627123	1.000	rs58204112	chr14:74359417	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs7953249	0.514	rs1169312	chr12:121441461	G/T	cg02403541	chr12:121454288	C12orf43	0.59	4.78	0.44	6.47e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs56079296	0.929	rs73795205	chr5:121352305	A/G	cg05256605	chr5:121412184	LOX	0.59	4.47	0.42	2.18e-5	Coronary artery disease;
THYM	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg04518342	chr5:131593106	PDLIM4	-0.43	-4.5	-0.42	1.91e-5	Blood metabolite levels;
THYM	cis	rs11690935	0.885	rs6750058	chr2:172786909	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.71	-5.03	-0.46	2.27e-6	Schizophrenia;
THYM	cis	rs4889855	0.530	rs72856551	chr17:78552267	G/T	cg16591659	chr17:78472290	NA	0.45	5.14	0.47	1.46e-6	Fractional excretion of uric acid;
THYM	cis	rs35883536	0.528	rs1855800	chr1:101030641	G/A	cg09408571	chr1:101003634	GPR88	0.55	5.85	0.51	6.87e-8	Monocyte count;
THYM	cis	rs9653442	0.675	rs2871326	chr2:100662010	T/C	cg07810366	chr2:100720526	AFF3	-0.42	-6.07	-0.53	2.57e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg27170947	chr2:26402098	FAM59B	-0.84	-6.46	-0.55	4.42e-9	Gut microbiome composition (summer);
THYM	cis	rs55871839	0.708	rs4738731	chr8:59809840	C/G	cg07426533	chr8:59803705	TOX	-0.67	-6.88	-0.58	6.33e-10	Pneumonia;
THYM	cis	rs684232	0.666	rs2254134	chr17:628664	A/G	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.41	-4.84	-0.44	5.1e-6	Prostate cancer;
THYM	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg08994789	chr17:28903642	LRRC37B2	-1.06	-5.25	-0.47	9.31e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg12560992	chr17:57184187	TRIM37	0.93	8.88	0.67	4.06e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2882877	0.648	rs13007486	chr2:190397484	G/A	cg10752008	chr2:190445175	SLC40A1	0.72	6.14	0.53	1.9e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg27170947	chr2:26402098	FAM59B	-0.8	-6.46	-0.55	4.47e-9	Gut microbiome composition (summer);
THYM	cis	rs2806561	0.754	rs10917344	chr1:23342193	C/G	cg19743168	chr1:23544995	NA	-0.61	-6.1	-0.53	2.32e-8	Height;
THYM	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg00012203	chr2:219082015	ARPC2	0.87	8.52	0.66	2.38e-13	Colorectal cancer;
THYM	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2282300	0.956	rs1222212	chr11:30374643	C/T	cg09906309	chr11:30344399	C11orf46	-0.73	-5.14	-0.47	1.5e-6	Morning vs. evening chronotype;
THYM	cis	rs28595532	0.920	rs55726697	chr4:119742863	G/A	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	trans	rs4650994	0.507	rs12405456	chr1:178512331	T/G	cg05059571	chr16:84539110	KIAA1609	-0.88	-10.25	-0.72	4.73e-17	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg06002616	chr8:101225028	SPAG1	-0.46	-4.79	-0.44	6.22e-6	Atrioventricular conduction;
THYM	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg14196790	chr5:131705035	SLC22A5	-0.56	-5.02	-0.46	2.41e-6	Blood metabolite levels;
THYM	cis	rs2991971	0.933	rs666720	chr1:46020795	T/C	cg15605315	chr1:45957053	TESK2	0.65	5.13	0.47	1.52e-6	High light scatter reticulocyte count;
THYM	cis	rs9796	0.870	rs2925346	chr15:41315695	G/A	cg18705301	chr15:41695430	NDUFAF1	0.59	4.83	0.44	5.25e-6	Menopause (age at onset);
THYM	cis	rs7107174	1.000	rs2511158	chr11:77973980	C/T	cg19901956	chr11:77921274	USP35	-0.76	-5.83	-0.51	7.53e-8	Testicular germ cell tumor;
THYM	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg04362960	chr10:104952993	NT5C2	0.58	4.75	0.44	7.17e-6	Arsenic metabolism;
THYM	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7107174	0.681	rs881337	chr11:78128335	G/C	cg19901956	chr11:77921274	USP35	-0.71	-5.35	-0.48	6.07e-7	Testicular germ cell tumor;
THYM	cis	rs2241584	0.967	rs11748814	chr5:175939898	G/C	cg27658698	chr5:175955578	RNF44	-0.52	-6.25	-0.54	1.18e-8	Menopause (age at onset);
THYM	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	trans	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg05926928	chr17:57297772	GDPD1	1.25	9.97	0.72	1.88e-16	Opioid sensitivity;
THYM	cis	rs6121246	0.559	rs6060599	chr20:30257754	T/G	cg13852791	chr20:30311386	BCL2L1	1.02	10.02	0.72	1.48e-16	Mean corpuscular hemoglobin;
THYM	cis	rs17608059	0.710	rs8080167	chr17:13949828	G/A	cg27005118	chr17:13972210	COX10	-0.44	-4.5	-0.42	1.95e-5	Temperament;
THYM	cis	rs28647808	1.000	rs7857017	chr9:136271101	A/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.96	-0.45	3.06e-6	Blood protein levels;
THYM	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg10518543	chr12:38710700	ALG10B	-0.57	-4.49	-0.42	2.04e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs34779708	0.966	rs17591781	chr10:35498538	G/A	cg03585969	chr10:35415529	CREM	0.63	4.48	0.42	2.09e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	4.59	0.43	1.35e-5	Rheumatoid arthritis;
THYM	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.13	-5.48	-0.49	3.56e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.43	-0.49	4.24e-7	Mean corpuscular volume;
THYM	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg08645402	chr16:4508243	NA	0.71	6.28	0.54	9.98e-9	Schizophrenia;
THYM	cis	rs761746	0.960	rs4820983	chr22:31929654	C/T	cg10537193	chr22:32026975	PISD	0.37	4.98	0.45	2.89e-6	Intelligence;
THYM	cis	rs3784262	0.757	rs74655564	chr15:58325512	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.57	-4.45	-0.42	2.33e-5	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
THYM	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg25427524	chr10:38739819	LOC399744	-0.7	-6.38	-0.55	6.44e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg13531842	chr10:38383804	ZNF37A	-0.55	-4.56	-0.42	1.52e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg06481639	chr22:41940642	POLR3H	0.84	5.85	0.51	6.94e-8	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs1062746	0.711	rs8056833	chr16:87378388	G/C	cg27119004	chr16:87376851	FBXO31	0.49	5.08	0.46	1.89e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.55	-7.31	-0.6	8.48e-11	Monocyte percentage of white cells;
THYM	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11905131	chr22:24372483	LOC391322	-0.9	-10.61	-0.74	8.47e-18	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs8063160	0.688	rs12924124	chr16:89791126	C/T	cg07984980	chr16:89898383	SPIRE2	1.6	6.42	0.55	5.28e-9	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	6.88	0.58	6.35e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs10186029	0.676	rs10804213	chr2:213964399	G/A	cg08319019	chr2:214017104	IKZF2	0.9	7.44	0.61	4.49e-11	Systemic sclerosis;
THYM	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg22875332	chr1:76189707	ACADM	-0.73	-6.28	-0.54	1.03e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4595586	0.525	rs7313120	chr12:39388027	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.05e-5	Morning vs. evening chronotype;
THYM	cis	rs2859741	1.000	rs2859741	chr1:37509352	C/T	cg09363841	chr1:37513479	NA	-0.74	-6.92	-0.58	5.2e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs12509991	0.531	rs11723414	chr4:127042613	G/C	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs870825	0.518	rs12512933	chr4:185665055	C/T	cg27112742	chr4:185696749	ACSL1	-0.99	-5.29	-0.48	7.68e-7	Blood protein levels;
THYM	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg18151425	chr2:69093574	BMP10	-0.96	-6.93	-0.58	5.06e-10	Subcortical brain region volumes;
THYM	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg26031613	chr14:104095156	KLC1	1.21	12.73	0.79	3.03e-22	Body mass index;
THYM	cis	rs568617	1.000	rs687672	chr11:65649984	T/C	cg00576331	chr11:65640516	EFEMP2	0.67	4.51	0.42	1.87e-5	Crohn's disease;
THYM	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg13395646	chr4:1353034	KIAA1530	-0.51	-4.67	-0.43	1.01e-5	Longevity;
THYM	cis	rs10186029	0.676	rs10187830	chr2:213964796	C/G	cg08319019	chr2:214017104	IKZF2	0.9	7.44	0.61	4.49e-11	Systemic sclerosis;
THYM	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg09877947	chr5:131593287	PDLIM4	0.58	4.82	0.44	5.38e-6	Blood metabolite levels;
THYM	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg24130564	chr14:104152367	KLC1	0.61	5.28	0.48	8.13e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg17211192	chr8:82754475	SNX16	-0.9	-7.34	-0.6	7.07e-11	Diastolic blood pressure;
THYM	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg25801113	chr15:45476975	SHF	-0.39	-4.57	-0.42	1.48e-5	Uric acid levels;
THYM	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg06640241	chr16:89574553	SPG7	-0.9	-8.41	-0.65	4.13e-13	Multiple myeloma (IgH translocation);
THYM	cis	rs11031096	0.621	rs12282967	chr11:4191477	A/T	cg08557956	chr11:4115526	RRM1	-0.59	-5.44	-0.49	4.19e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.75	-0.67	7.74e-14	Mean corpuscular volume;
THYM	cis	rs7917772	0.604	rs10883756	chr10:104400112	T/C	cg00122347	chr10:104236741	TMEM180	0.4	5.08	0.46	1.89e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	trans	rs75518195	0.521	rs10013982	chr4:64666216	C/T	cg14706739	chr8:21916355	EPB49	0.76	7.56	0.61	2.58e-11	Triptolide cytotoxicity;
THYM	trans	rs10962692	0.530	rs62541926	chr9:16877423	T/C	cg03221025	chr16:88955224	CBFA2T3	0.74	7.08	0.59	2.43e-10	Ovarian cancer in BRCA2 mutation carriers;Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;
THYM	cis	rs7705042	0.793	rs7705547	chr5:141514027	A/G	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs11850957	0.502	rs17109406	chr14:25450433	C/T	cg26846476	chr14:24838993	NFATC4	0.88	4.55	0.42	1.61e-5	Subcutaneous adipose tissue;
THYM	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.53	-5.95	-0.52	4.4e-8	Schizophrenia;
THYM	cis	rs4944092	0.793	rs94111	chr11:75915139	A/G	cg04588336	chr11:75916460	WNT11	-0.68	-7.07	-0.59	2.6e-10	PR interval;
THYM	cis	rs7524258	0.900	rs2412151	chr1:7303216	G/C	cg07173049	chr1:7289937	CAMTA1	0.7	5.7	0.51	1.32e-7	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs7106204	0.514	rs2099890	chr11:24255948	C/T	ch.11.24196551F	chr11:24239977	NA	1.0	6.88	0.58	6.32e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs259964	1.000	rs259963	chr20:57824901	A/C	cg16205854	chr20:57875318	EDN3	-0.4	-4.46	-0.42	2.28e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	trans	rs8073060	0.586	rs225298	chr17:33923946	T/G	cg19694781	chr19:47549865	TMEM160	-1.05	-9.1	-0.68	1.42e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs9790314	1.000	rs336543	chr3:161061080	C/T	cg04691961	chr3:161091175	C3orf57	0.6	5.01	0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs977987	0.872	rs4888422	chr16:75470576	A/G	cg03315344	chr16:75512273	CHST6	0.71	5.8	0.51	8.53e-8	Dupuytren's disease;
THYM	cis	rs2108622	0.727	rs62107764	chr19:15982658	A/G	cg13772218	chr19:15982569	NA	0.5	4.48	0.42	2.06e-5	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg22875332	chr1:76189707	ACADM	-0.53	-4.83	-0.44	5.2e-6	Daytime sleep phenotypes;
THYM	cis	rs7833986	1.000	rs34516759	chr8:57097138	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	4.78	0.44	6.48e-6	Height;
THYM	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg27535305	chr1:53392650	SCP2	-0.41	-4.77	-0.44	6.58e-6	Monocyte count;
THYM	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg12863693	chr15:85201151	NMB	0.62	5.39	0.48	5.18e-7	Schizophrenia;
THYM	cis	rs7178572	0.568	rs12916731	chr15:77507021	C/T	cg22256960	chr15:77711686	NA	-1.04	-8.57	-0.66	1.83e-13	Type 2 diabetes;
THYM	cis	rs12681287	0.640	rs8635	chr8:87479810	C/T	cg27223183	chr8:87520930	FAM82B	-0.69	-5.24	-0.47	9.65e-7	Caudate activity during reward;
THYM	cis	rs55665837	1.000	rs10832254	chr11:14434698	A/G	cg19336497	chr11:14380999	RRAS2	-0.64	-6.95	-0.58	4.63e-10	Vitamin D levels;
THYM	cis	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg12000587	chr17:30186630	C17orf79	0.43	4.67	0.43	1.01e-5	Hip circumference adjusted for BMI;
THYM	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg10803722	chr21:46713166	LOC642852	-0.42	-5.58	-0.5	2.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3849570	0.925	rs9841087	chr3:81907949	A/G	cg07356753	chr3:81810745	GBE1	-0.8	-5.94	-0.52	4.58e-8	Waist circumference;Body mass index;
THYM	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg07884673	chr3:53033167	SFMBT1	1.17	5.88	0.52	6.13e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs28595532	0.764	rs55704595	chr4:119780607	G/A	cg11846333	chr4:119757529	SEC24D	1.36	4.83	0.44	5.31e-6	Cannabis dependence symptom count;
THYM	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg09060608	chr5:178986726	RUFY1	0.5	5.34	0.48	6.29e-7	Lung cancer;
THYM	cis	rs62229266	0.626	rs7280896	chr21:37460906	G/A	cg08632701	chr21:37451849	NA	-0.7	-6.92	-0.58	5.34e-10	Mitral valve prolapse;
THYM	cis	rs58950470	0.521	rs7950197	chr11:65446126	T/C	cg27068330	chr11:65405492	SIPA1	-0.76	-6.35	-0.55	7.32e-9	Schizophrenia;
THYM	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg08508325	chr11:3079039	CARS	-0.49	-6.34	-0.55	7.54e-9	Longevity;
THYM	trans	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	3.97e-12	Bladder cancer;
THYM	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg03605463	chr16:89740564	NA	0.9	7.02	0.58	3.25e-10	Vitiligo;
THYM	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg06618935	chr21:46677482	NA	-0.96	-9.3	-0.69	5.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9914544	0.689	rs11078421	chr17:18804385	A/G	cg26378065	chr17:18585709	ZNF286B	0.54	4.51	0.42	1.89e-5	Educational attainment (years of education);
THYM	trans	rs9951602	0.541	rs56882694	chr18:76647010	C/T	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg13789015	chr9:136890014	NCRNA00094	0.76	6.38	0.55	6.47e-9	Platelet distribution width;
THYM	cis	rs4575098	0.681	rs6779	chr1:161141432	C/G	cg24329783	chr1:161160887	ADAMTS4	-0.61	-5.37	-0.48	5.65e-7	Monocyte percentage of white cells;
THYM	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg07636037	chr3:49044803	WDR6	0.91	7.97	0.63	3.42e-12	Menarche (age at onset);
THYM	cis	rs7107174	1.000	rs4945270	chr11:78068216	A/G	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs3741151	0.881	rs12099129	chr11:73091318	T/G	cg17517138	chr11:73019481	ARHGEF17	1.0	5.82	0.51	7.84e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs72781680	0.699	rs72796125	chr2:23919169	C/T	cg08917208	chr2:24149416	ATAD2B	1.19	5.46	0.49	3.73e-7	Lymphocyte counts;
THYM	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg17554472	chr22:41940697	POLR3H	-0.69	-4.6	-0.43	1.32e-5	Vitiligo;
THYM	cis	rs9515201	0.627	rs9521730	chr13:111031180	C/T	cg05272587	chr13:111038400	COL4A2	-0.53	-4.5	-0.42	1.96e-5	White matter hyperintensity burden;
THYM	cis	rs2777491	0.957	rs7163788	chr15:41704789	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.13	-12.95	-0.8	1.06e-22	Ulcerative colitis;
THYM	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs73198271	0.740	rs1039911	chr8:8648206	G/A	cg15556689	chr8:8085844	FLJ10661	-0.74	-4.83	-0.44	5.24e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg26605046	chr4:2439731	NA	-0.5	-4.73	-0.44	7.8e-6	Cognitive function;
THYM	cis	rs4638749	0.501	rs2101357	chr2:108748974	G/A	cg25838818	chr2:108905173	SULT1C2	-0.52	-4.89	-0.45	4.13e-6	Blood pressure;
THYM	cis	rs11048434	0.698	rs1805784	chr12:9065172	G/T	cg13575925	chr12:9217583	LOC144571	0.53	4.82	0.44	5.35e-6	Sjögren's syndrome;
THYM	cis	rs4662945	0.525	rs28625431	chr2:130303333	A/G	cg05903289	chr2:130345205	NA	-0.55	-5.1	-0.46	1.72e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs4907240	0.731	rs11900310	chr2:97141830	C/G	cg18419276	chr2:96971862	SNRNP200	0.41	4.99	0.46	2.69e-6	Event-related brain oscillations;
THYM	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg05707623	chr12:122985044	ZCCHC8	0.71	4.74	0.44	7.5e-6	Body mass index;
THYM	cis	rs7584330	0.554	rs116656801	chr2:238431257	A/G	cg14458575	chr2:238380390	NA	0.8	4.67	0.43	9.97e-6	Prostate cancer;
THYM	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg06713675	chr4:122721982	EXOSC9	-0.53	-4.9	-0.45	3.93e-6	Type 2 diabetes;
THYM	cis	rs10927875	0.541	rs1739840	chr1:16342237	A/G	cg21385522	chr1:16154831	NA	0.65	4.65	0.43	1.08e-5	Dilated cardiomyopathy;
THYM	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1403694	0.966	rs1656910	chr3:186438993	A/C	cg12454167	chr3:186435060	KNG1	0.43	5.82	0.51	8.09e-8	Blood protein levels;
THYM	cis	rs7264396	0.512	rs2425072	chr20:34293686	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.76	-0.44	6.84e-6	Total cholesterol levels;
THYM	cis	rs6840360	0.571	rs12647566	chr4:152482525	C/T	cg17479576	chr4:152424074	FAM160A1	-0.8	-5.92	-0.52	5.02e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4589258	0.788	rs4303201	chr11:90462564	A/G	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.93	-0.45	3.53e-6	Intelligence (multi-trait analysis);
THYM	trans	rs75518195	0.590	rs62302818	chr4:64733880	C/T	cg14706739	chr8:21916355	EPB49	0.76	7.43	0.61	4.59e-11	Triptolide cytotoxicity;
THYM	cis	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg19847130	chr8:10466454	RP1L1	0.56	5.35	0.48	6.05e-7	Neuroticism;
THYM	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg22920501	chr2:26401640	FAM59B	-0.73	-4.78	-0.44	6.45e-6	Gut microbiome composition (summer);
THYM	cis	rs2189609	0.521	rs2526066	chr16:74037837	A/C	ch.16.1684049R	chr16:74565916	GLG1	-0.73	-5.36	-0.48	5.88e-7	Energy expenditure (24h);
THYM	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg14895029	chr7:2775587	GNA12	-0.64	-4.58	-0.43	1.4e-5	Height;
THYM	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg06640241	chr16:89574553	SPG7	0.87	8.13	0.64	1.59e-12	Multiple myeloma (IgH translocation);
THYM	cis	rs6844506	0.565	rs1087300	chr4:185226003	T/C	cg12654155	chr4:185238627	NA	-0.56	-4.5	-0.42	1.89e-5	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
THYM	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg12386194	chr3:101231763	SENP7	0.67	4.99	0.46	2.75e-6	Colorectal cancer;
THYM	cis	rs665401	0.681	rs9481676	chr6:117176258	G/A	cg20376953	chr6:117187980	NA	0.6	4.79	0.44	6.2e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs1915146	1.000	rs1915146	chr10:126846214	A/G	cg05090351	chr10:126851162	NA	0.76	8.91	0.67	3.46e-14	Menarche (age at onset);
THYM	cis	rs3008870	0.755	rs2755251	chr1:67496425	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.76	6.2	0.54	1.48e-8	Lymphocyte percentage of white cells;
THYM	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg11494091	chr17:61959527	GH2	0.71	6.57	0.56	2.64e-9	Height;
THYM	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg18512352	chr11:47633146	NA	-0.53	-6.56	-0.56	2.75e-9	Neuroticism;
THYM	cis	rs7849270	0.879	rs10739741	chr9:131855160	G/C	cg14069949	chr9:131965419	NA	0.5	4.46	0.42	2.28e-5	Blood metabolite ratios;
THYM	cis	rs2688608	0.672	rs2227576	chr10:75678276	T/G	cg02947784	chr10:75434997	AGAP5	0.52	4.83	0.44	5.12e-6	Inflammatory bowel disease;
THYM	cis	rs7107174	0.892	rs11601195	chr11:78073501	A/G	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.62	0.43	1.23e-5	Obesity-related traits;
THYM	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg21984481	chr17:79567631	NPLOC4	0.46	4.86	0.45	4.62e-6	Eye color traits;
THYM	cis	rs7953249	0.618	rs2650000	chr12:121388962	G/T	cg14101638	chr12:121416612	HNF1A	0.49	5.35	0.48	5.99e-7	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7107174	1.000	rs72931690	chr11:78073192	G/A	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.78	-5.5	-0.49	3.16e-7	Body mass index;
THYM	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.44	5.41	0.49	4.78e-7	Monocyte percentage of white cells;
THYM	cis	rs3126085	1.000	rs3126097	chr1:152311026	G/A	cg26020982	chr1:152196106	HRNR	-0.39	-5.35	-0.48	6.19e-7	Atopic dermatitis;
THYM	cis	rs2708977	0.899	rs12992413	chr2:97277489	A/G	cg01950434	chr2:97203154	ARID5A	0.57	5.2	0.47	1.16e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs13126513	0.708	rs2172138	chr4:100489785	G/C	cg05468953	chr4:100565104	NA	0.64	5.88	0.52	6.06e-8	Metabolite levels (MHPG);
THYM	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-5.39	-0.48	5.22e-7	Hemoglobin concentration;
THYM	cis	rs9549260	0.755	rs12585277	chr13:41224813	C/T	cg21288729	chr13:41239152	FOXO1	0.73	5.82	0.51	7.84e-8	Red blood cell count;
THYM	cis	rs11122895	0.967	rs11683921	chr2:112471633	T/G	cg23262488	chr2:112468472	NA	0.67	9.57	0.7	1.36e-15	Allergic sensitization;
THYM	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg20283391	chr11:68216788	NA	-0.64	-4.58	-0.43	1.41e-5	Total body bone mineral density;
THYM	cis	rs2070677	0.935	rs4384343	chr10:135422545	G/C	cg20169779	chr10:135381914	SYCE1	-0.77	-5.98	-0.52	3.93e-8	Gout;
THYM	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg18876405	chr7:65276391	NA	0.61	5.3	0.48	7.49e-7	Aortic root size;
THYM	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.93	-8.04	-0.64	2.47e-12	Menarche (age at onset);
THYM	cis	rs7727544	0.581	rs10075801	chr5:131677642	A/G	cg14196790	chr5:131705035	SLC22A5	0.56	5.26	0.47	9.05e-7	Blood metabolite levels;
THYM	cis	rs7582180	0.638	rs6734316	chr2:100976210	A/G	cg08017756	chr2:100939284	LONRF2	-0.72	-7.42	-0.61	4.95e-11	Intelligence (multi-trait analysis);
THYM	cis	rs11771526	0.901	rs17161137	chr7:32323799	G/T	cg13207630	chr7:32358064	NA	0.84	5.28	0.48	8.15e-7	Body mass index;
THYM	cis	rs2016266	0.859	rs11170507	chr12:53740682	C/A	cg26875137	chr12:53738046	NA	-0.78	-5.78	-0.51	9.62e-8	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs7786808	0.588	rs4909078	chr7:158183835	C/G	cg15440763	chr7:158190612	PTPRN2	0.48	4.58	0.43	1.4e-5	Obesity-related traits;
THYM	cis	rs72712511	0.571	rs3796630	chr4:140763005	A/G	cg15010390	chr4:140216957	NDUFC1	0.62	4.67	0.43	9.92e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2963155	0.518	rs9324918	chr5:142767160	T/C	cg17617527	chr5:142782415	NR3C1	1.11	5.94	0.52	4.58e-8	Breast cancer;
THYM	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg08392591	chr16:89556376	ANKRD11	0.56	4.7	0.43	8.72e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs1448094	0.511	rs10863079	chr12:86152700	T/A	cg00310523	chr12:86230176	RASSF9	-0.57	-4.83	-0.44	5.15e-6	Major depressive disorder;
THYM	cis	rs28595532	0.920	rs115242199	chr4:119728652	A/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs42648	0.837	rs10262472	chr7:89900383	T/C	cg25739043	chr7:89950458	NA	-0.52	-4.46	-0.42	2.21e-5	Homocysteine levels;
THYM	cis	rs804280	0.662	rs7826055	chr8:11611723	G/C	cg12395012	chr8:11607386	GATA4	0.62	5.26	0.48	8.77e-7	Myopia (pathological);
THYM	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg21226059	chr5:178986404	RUFY1	0.49	5.2	0.47	1.14e-6	Lung cancer;
THYM	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg12560992	chr17:57184187	TRIM37	0.91	8.51	0.66	2.54e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9457247	0.668	rs2236313	chr6:167360389	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.48	-5.12	-0.47	1.57e-6	Crohn's disease;
THYM	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg23205692	chr1:25664452	TMEM50A	0.86	6.69	0.57	1.57e-9	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg04455712	chr21:45112962	RRP1B	0.48	4.46	0.42	2.24e-5	Mean corpuscular volume;
THYM	cis	rs6840360	0.571	rs72730104	chr4:152543857	A/G	cg17479576	chr4:152424074	FAM160A1	-0.8	-5.65	-0.5	1.68e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7851660	0.967	rs7860598	chr9:100600702	G/A	cg13688889	chr9:100608707	NA	-0.83	-7.31	-0.6	8.28e-11	Strep throat;
THYM	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg18681998	chr4:17616180	MED28	0.81	6.87	0.58	6.5e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg16414030	chr3:133502952	NA	0.6	4.76	0.44	6.96e-6	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg03983476	chr2:10830698	NOL10	0.55	4.96	0.45	3.13e-6	Prostate cancer;
THYM	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg24209194	chr3:40518798	ZNF619	0.67	5.53	0.49	2.85e-7	Renal cell carcinoma;
THYM	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg18032289	chr17:61959525	GH2	-0.46	-4.45	-0.42	2.3e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	trans	rs877282	0.945	rs11253391	chr10:788752	G/A	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs3820068	0.603	rs2236215	chr1:15892415	A/C	cg05660106	chr1:15850417	CASP9	1.0	7.74	0.62	1.05e-11	Systolic blood pressure;
THYM	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03264133	chr6:25882463	NA	-0.7	-5.51	-0.49	3.02e-7	Blood metabolite levels;
THYM	cis	rs13102973	0.720	rs13129730	chr4:135888329	G/A	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	cis	rs6866344	0.569	rs56027952	chr5:178150181	C/A	cg10224037	chr5:178157518	ZNF354A	0.99	8.07	0.64	2.1e-12	Neutrophil percentage of white cells;
THYM	cis	rs16858210	0.520	rs12633858	chr3:183549395	C/T	cg03417191	chr3:183542750	MAP6D1	-0.87	-4.54	-0.42	1.66e-5	Menopause (age at onset);
THYM	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg24818145	chr4:99064322	C4orf37	0.87	7.23	0.6	1.19e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12142240	0.698	rs72886911	chr1:46814352	G/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg06850241	chr22:41845214	NA	0.54	4.85	0.45	4.87e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs35883536	0.647	rs10875312	chr1:101042320	G/C	cg06223162	chr1:101003688	GPR88	-0.8	-6.89	-0.58	6.01e-10	Monocyte count;
THYM	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.16	-0.75	5.56e-19	Primary sclerosing cholangitis;
THYM	cis	rs4455778	0.538	rs7779474	chr7:49107537	A/G	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg02725872	chr8:58115012	NA	-0.82	-5.47	-0.49	3.66e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg16405210	chr4:1374714	KIAA1530	-0.65	-5.28	-0.48	8.16e-7	Longevity;
THYM	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg21385522	chr1:16154831	NA	0.65	4.65	0.43	1.08e-5	Dilated cardiomyopathy;
THYM	cis	rs6424115	0.793	rs2502998	chr1:24198327	T/A	cg15997130	chr1:24165203	NA	0.74	6.35	0.55	7.22e-9	Immature fraction of reticulocytes;
THYM	cis	rs7940866	0.834	rs10894298	chr11:130840571	C/A	cg12179176	chr11:130786555	SNX19	0.62	4.8	0.44	5.99e-6	Schizophrenia;
THYM	cis	rs2932538	0.961	rs2932534	chr1:113200797	A/G	cg22162597	chr1:113214053	CAPZA1	0.65	5.32	0.48	6.9e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs367615	0.506	rs1428932	chr5:108792479	A/G	cg17395555	chr5:108820864	NA	-0.72	-9.3	-0.69	5.2e-15	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs11252926	0.545	rs1551508	chr10:555469	A/G	cg14018140	chr10:458528	DIP2C	-0.51	-5.25	-0.47	9.1e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg08807101	chr21:30365312	RNF160	-0.81	-6.14	-0.53	1.93e-8	Dental caries;
THYM	cis	rs2456568	0.548	rs7105031	chr11:93661207	C/T	cg17595323	chr11:93583763	C11orf90	-0.52	-5.52	-0.49	2.98e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs12410462	0.681	rs74813874	chr1:227611588	C/T	cg23173402	chr1:227635558	NA	0.88	4.9	0.45	4e-6	Major depressive disorder;
THYM	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg15691649	chr6:25882328	NA	-0.83	-6.1	-0.53	2.28e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1788820	0.917	rs1624695	chr18:21142992	A/T	cg14672496	chr18:21087552	C18orf8	0.79	6.29	0.54	9.67e-9	Body mass index;
THYM	cis	rs7809950	1.000	rs2520264	chr7:107179344	T/C	cg23024343	chr7:107201750	COG5	-0.93	-8.53	-0.66	2.33e-13	Coronary artery disease;
THYM	cis	rs6500395	1.000	rs1486412	chr16:48651750	A/T	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9303280	0.776	rs9891174	chr17:38031802	T/A	cg24910161	chr17:38119198	GSDMA	0.47	4.93	0.45	3.55e-6	Self-reported allergy;
THYM	cis	rs11608355	0.545	rs12819142	chr12:109896316	G/T	cg11367159	chr12:110044531	NA	0.6	4.54	0.42	1.66e-5	Neuroticism;
THYM	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg00129232	chr17:37814104	STARD3	-0.89	-7.05	-0.59	2.86e-10	Asthma;
THYM	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg09165964	chr15:75287851	SCAMP5	0.6	4.59	0.43	1.38e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs6456042	1.000	rs3127412	chr6:166535561	A/G	cg11088901	chr6:166572345	T	0.51	4.82	0.44	5.5e-6	Asthma;
THYM	cis	rs865483	0.895	rs6607275	chr17:35833208	T/C	cg06716730	chr17:35851459	DUSP14	0.43	7.3	0.6	8.71e-11	Monocyte count;
THYM	cis	rs4455778	0.724	rs993872	chr7:48993694	T/G	cg26309511	chr7:48887640	NA	-0.55	-5.08	-0.46	1.92e-6	Lung cancer in never smokers;
THYM	cis	rs7152530	0.571	rs7154993	chr14:98636696	C/T	cg05180522	chr14:98101740	NA	-0.61	-4.74	-0.44	7.57e-6	Staphylococcus aureus infection;
THYM	cis	rs7224737	0.957	rs6503687	chr17:40295397	G/A	cg20291162	chr17:40259547	DHX58	-0.69	-6.44	-0.55	4.96e-9	Fibrinogen levels;
THYM	cis	rs2901656	0.677	rs10752957	chr1:172408271	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.58	6.12	0.53	2.04e-8	Red cell distribution width;Platelet distribution width;
THYM	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg13319975	chr6:146136371	FBXO30	-0.64	-5.25	-0.47	9.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.46	-4.85	-0.45	4.9e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg15247329	chr7:2764246	NA	-0.7	-5.74	-0.51	1.13e-7	Height;
THYM	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg08859206	chr1:53392774	SCP2	-0.8	-9.26	-0.69	6.22e-15	Monocyte count;
THYM	cis	rs8067545	0.611	rs1859407	chr17:20078137	T/C	cg13482628	chr17:19912719	NA	-0.56	-4.63	-0.43	1.17e-5	Schizophrenia;
THYM	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg00814883	chr7:100076585	TSC22D4	-1.0	-6.85	-0.57	7.35e-10	Platelet count;
THYM	cis	rs36051895	0.632	rs12001334	chr9:5152604	C/A	cg02405213	chr9:5042618	JAK2	-1.03	-10.82	-0.74	3.01e-18	Pediatric autoimmune diseases;
THYM	cis	rs2070488	0.965	rs2051216	chr3:38562288	C/T	cg24069376	chr3:38537580	EXOG	-0.65	-6.4	-0.55	5.87e-9	Electrocardiographic conduction measures;
THYM	trans	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17712092	chr4:129076599	LARP1B	0.9	7.57	0.61	2.42e-11	Eosinophil percentage of white cells;
THYM	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg00310523	chr12:86230176	RASSF9	0.53	4.84	0.44	5.02e-6	Major depressive disorder;
THYM	cis	rs4731207	0.536	rs2127967	chr7:124605672	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg17294928	chr15:75287854	SCAMP5	-1.02	-8.79	-0.67	6.45e-14	Blood trace element (Zn levels);
THYM	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg25918947	chr17:41365094	TMEM106A	-0.59	-4.92	-0.45	3.66e-6	Menopause (age at onset);
THYM	cis	rs13185784	0.703	rs62406991	chr5:179658323	A/G	cg23248424	chr5:179741104	GFPT2	0.72	4.76	0.44	6.87e-6	TRAIL levels;
THYM	cis	rs12893597	0.659	rs748379	chr14:76855363	C/G	cg20290672	chr14:76816747	NA	-0.55	-4.59	-0.43	1.36e-5	Maximal oxygen uptake response;
THYM	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg11965913	chr1:205819406	PM20D1	0.7	6.86	0.58	6.97e-10	Menarche (age at onset);
THYM	cis	rs300703	0.515	rs424292	chr2:191931	C/T	cg21211680	chr2:198530	NA	-0.9	-5.83	-0.51	7.5e-8	Blood protein levels;
THYM	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2806561	0.734	rs2143156	chr1:23374629	T/G	cg19743168	chr1:23544995	NA	0.48	4.69	0.43	9.07e-6	Height;
THYM	cis	rs9875589	0.509	rs2731336	chr3:14091908	G/A	cg03204825	chr3:13978759	TPRXL	-0.51	-4.46	-0.42	2.26e-5	Ovarian reserve;
THYM	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg17644776	chr2:200775616	C2orf69	0.77	5.4	0.48	5.01e-7	Schizophrenia;
THYM	cis	rs11690935	0.959	rs76324055	chr2:172620150	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.8	-5.67	-0.5	1.52e-7	Schizophrenia;
THYM	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg20503657	chr10:835505	NA	0.81	4.97	0.45	2.98e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs665401	1.000	rs6907088	chr6:117258674	T/C	cg20376953	chr6:117187980	NA	0.55	4.49	0.42	1.99e-5	Neutrophil percentage of granulocytes;
THYM	cis	rs911555	0.723	rs12436956	chr14:103852607	G/T	cg12935359	chr14:103987150	CKB	0.48	5.25	0.47	9.39e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg07493874	chr5:1342172	CLPTM1L	0.93	9.13	0.68	1.19e-14	Lung cancer;
THYM	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg00814883	chr7:100076585	TSC22D4	-1.0	-6.8	-0.57	9.22e-10	Platelet count;
THYM	cis	rs2985684	0.748	rs2985686	chr14:50100683	C/G	cg02151108	chr14:50098012	C14orf104	-0.67	-5.5	-0.49	3.22e-7	Carotid intima media thickness;
THYM	cis	rs3772130	0.962	rs9878086	chr3:121488353	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.72	4.54	0.42	1.65e-5	Cognitive performance;
THYM	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg10523679	chr1:76189770	ACADM	-0.57	-4.89	-0.45	4.12e-6	Daytime sleep phenotypes;
THYM	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg00071950	chr4:10020882	SLC2A9	-0.64	-5.51	-0.49	3.06e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9807841	0.617	rs2360944	chr19:10769974	T/C	cg17848348	chr19:10766748	ILF3	-0.87	-7.74	-0.62	1.06e-11	Inflammatory skin disease;
THYM	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg03188948	chr7:1209495	NA	0.61	4.72	0.44	8.09e-6	Longevity;Endometriosis;
THYM	cis	rs4919687	0.550	rs11191372	chr10:104462187	T/C	cg04362960	chr10:104952993	NT5C2	0.61	4.89	0.45	4.08e-6	Colorectal cancer;
THYM	cis	rs933688	1.000	rs1541674	chr5:90660447	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	6.71	0.57	1.42e-9	Smoking behavior;
THYM	cis	rs11850957	0.502	rs17109397	chr14:25447817	C/A	cg26846476	chr14:24838993	NFATC4	0.93	4.77	0.44	6.66e-6	Subcutaneous adipose tissue;
THYM	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg18032289	chr17:61959525	GH2	-0.5	-4.84	-0.44	5.07e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs28476539	0.567	rs57642298	chr4:83562170	G/A	cg10249074	chr4:83542146	C4orf11	-0.64	-5.0	-0.46	2.58e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs7851660	0.809	rs7036589	chr9:100657720	A/T	cg13688889	chr9:100608707	NA	0.78	5.67	0.5	1.53e-7	Strep throat;
THYM	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg25358565	chr5:93447407	FAM172A	1.32	11.28	0.76	3.22e-19	Diabetic retinopathy;
THYM	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg17757837	chr7:157058334	UBE3C	0.66	5.32	0.48	6.85e-7	Body mass index;
THYM	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs8013055	0.846	rs7160747	chr14:105983740	A/G	cg23356831	chr14:105996513	TMEM121	0.61	6.21	0.54	1.42e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs4866334	1.000	rs77552202	chr5:18489043	A/T	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs2652822	0.507	rs7176597	chr15:63494482	G/A	cg09251291	chr15:63483946	RAB8B	0.55	4.84	0.44	5.08e-6	Metabolic traits;
THYM	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs7614311	0.639	rs111234932	chr3:63842449	C/T	cg22134162	chr3:63841271	THOC7	-0.64	-7.42	-0.61	4.94e-11	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg18252515	chr7:66147081	NA	-1.48	-8.83	-0.67	5.23e-14	Diabetic kidney disease;
THYM	cis	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg05335186	chr13:53173507	NA	0.44	5.25	0.47	9.15e-7	Lewy body disease;
THYM	cis	rs12579753	0.879	rs11115010	chr12:82165895	G/T	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.72	-0.44	7.99e-6	Resting heart rate;
THYM	cis	rs7104764	1.000	rs6598066	chr11:243185	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.69	0.74	5.65e-18	Menarche (age at onset);
THYM	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg06026331	chr20:60912101	LAMA5	0.78	6.12	0.53	2.13e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs4460079	0.507	rs10007297	chr4:114840655	T/A	cg02060584	chr4:113970739	ANK2	0.58	4.81	0.44	5.55e-6	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg08000102	chr2:233561755	GIGYF2	-0.69	-6.09	-0.53	2.35e-8	Coronary artery disease;
THYM	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.32	9.94	0.71	2.24e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.8	-8.87	-0.67	4.36e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.83	0.82	1.75e-24	Height;
THYM	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg20007245	chr22:24372913	LOC391322	-0.69	-6.11	-0.53	2.16e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs208520	0.661	rs207111	chr6:66792513	C/T	cg07460842	chr6:66804631	NA	-1.06	-7.89	-0.63	5.14e-12	Exhaled nitric oxide output;
THYM	cis	rs89107	0.688	rs283091	chr6:118588684	A/G	cg21191810	chr6:118973309	C6orf204	-0.49	-4.46	-0.42	2.28e-5	Cardiac structure and function;
THYM	cis	rs4866334	1.000	rs75485994	chr5:18488330	A/G	cg18608440	chr5:17519013	NA	1.17	5.43	0.49	4.25e-7	IgG glycosylation;
THYM	cis	rs2637266	0.685	rs7098713	chr10:78452828	C/T	cg18941641	chr10:78392320	NA	0.73	5.86	0.52	6.64e-8	Pulmonary function;
THYM	cis	rs28595532	0.764	rs56071514	chr4:119761833	T/C	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg10224037	chr5:178157518	ZNF354A	0.95	7.64	0.62	1.74e-11	Neutrophil percentage of white cells;
THYM	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.55	0.42	1.57e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11760633	0.526	rs7800019	chr7:1824028	C/T	cg27050990	chr7:2629313	IQCE	0.67	4.75	0.44	7.33e-6	Coronary artery disease;
THYM	cis	rs10751667	1.000	rs12798036	chr11:947585	T/C	cg01483505	chr11:975446	AP2A2	0.69	5.57	0.5	2.41e-7	Alzheimer's disease (late onset);
THYM	cis	rs8077889	0.719	rs4793033	chr17:41879627	C/T	cg26893861	chr17:41843967	DUSP3	1.14	12.24	0.78	3.12e-21	Triglycerides;
THYM	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg15693483	chr7:1102177	C7orf50	0.44	4.66	0.43	1.01e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg26924012	chr15:45694286	SPATA5L1	0.65	4.75	0.44	7.21e-6	Response to fenofibrate (adiponectin levels);
THYM	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-5.89	-0.52	5.93e-8	Total cholesterol levels;
THYM	cis	rs7255045	0.582	rs4804209	chr19:12985955	G/C	cg26870725	chr19:12978805	MAST1	-0.63	-4.87	-0.45	4.37e-6	Mean corpuscular volume;
THYM	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg18512352	chr11:47633146	NA	0.5	6.02	0.53	3.3e-8	Subjective well-being;
THYM	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg25427524	chr10:38739819	LOC399744	-0.7	-6.38	-0.55	6.44e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg02353165	chr6:42928485	GNMT	0.82	7.18	0.59	1.53e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9972944	0.691	rs7225471	chr17:63777913	T/C	cg07283582	chr17:63770753	CCDC46	0.68	5.54	0.49	2.69e-7	Total body bone mineral density;
THYM	cis	rs9677476	0.644	rs12470661	chr2:232060050	A/G	cg07929768	chr2:232055508	NA	0.64	6.4	0.55	5.83e-9	Food antigen IgG levels;
THYM	cis	rs977987	0.741	rs10514393	chr16:75344476	C/T	cg03315344	chr16:75512273	CHST6	0.83	6.82	0.57	8.49e-10	Dupuytren's disease;
THYM	cis	rs5769707	0.632	rs6009782	chr22:50010812	C/G	cg17054759	chr22:49844102	NA	-0.53	-4.61	-0.43	1.25e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg22974920	chr21:40686053	BRWD1	-0.61	-4.81	-0.44	5.69e-6	Cognitive function;
THYM	cis	rs6510489	1.000	rs76711718	chr19:35989226	G/A	cg15078284	chr19:36004994	DMKN	0.44	5.19	0.47	1.2e-6	Bipolar disorder;
THYM	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg20999797	chr1:1681921	NA	0.51	5.52	0.49	2.94e-7	Body mass index;
THYM	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg27494647	chr7:150038898	RARRES2	0.45	5.47	0.49	3.7e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4907240	0.961	rs12469420	chr2:97243305	A/G	cg18419276	chr2:96971862	SNRNP200	0.38	4.55	0.42	1.57e-5	Event-related brain oscillations;
THYM	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg03676636	chr4:99064102	C4orf37	-0.4	-5.65	-0.5	1.65e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7191700	0.836	rs12708722	chr16:11428905	T/A	cg00044050	chr16:11439710	C16orf75	0.7	4.81	0.44	5.71e-6	Multiple sclerosis;
THYM	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg27286337	chr10:134555280	INPP5A	0.89	6.88	0.58	6.33e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs2913737	0.530	rs2162777	chr5:175929102	C/T	cg27658698	chr5:175955578	RNF44	0.59	4.66	0.43	1.03e-5	Obesity-related traits;
THYM	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg23711669	chr6:146136114	FBXO30	0.93	9.51	0.7	1.83e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4719841	0.662	rs4574742	chr7:25995063	A/G	cg10085138	chr7:25991722	NA	-0.54	-4.64	-0.43	1.11e-5	Triglyceride levels;
THYM	cis	rs12579753	0.956	rs7959951	chr12:82231132	T/C	cg21231944	chr12:82153410	PPFIA2	-0.65	-4.83	-0.44	5.17e-6	Resting heart rate;
THYM	cis	rs6032067	0.777	rs62208416	chr20:43803226	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.93	-0.58	5.03e-10	Blood protein levels;
THYM	cis	rs61990749	0.597	rs759808	chr14:78250845	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.0	0.63	3.03e-12	Fibroblast growth factor basic levels;
THYM	cis	rs61931739	1.000	rs12427391	chr12:34022891	A/G	cg06521331	chr12:34319734	NA	0.58	4.57	0.42	1.49e-5	Morning vs. evening chronotype;
THYM	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs3812049	0.826	rs2409110	chr5:127433047	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.42	0.49	4.45e-7	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg03161606	chr19:29218774	NA	0.87	7.71	0.62	1.23e-11	Methadone dose in opioid dependence;
THYM	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs2219968	0.828	rs10102662	chr8:78906075	C/T	cg00738934	chr8:78996279	NA	0.82	8.49	0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg26441486	chr22:50317300	CRELD2	0.38	5.89	0.52	5.91e-8	Schizophrenia;
THYM	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs6754311	0.773	rs309130	chr2:136631031	C/A	cg07169764	chr2:136633963	MCM6	-0.71	-6.05	-0.53	2.81e-8	Mosquito bite size;
THYM	cis	rs673253	0.571	rs61768370	chr1:44111963	A/T	cg09903430	chr1:44172605	ST3GAL3	-0.5	-4.54	-0.42	1.65e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2040771	0.745	rs362148	chr22:19262852	T/C	cg02655711	chr22:19163373	SLC25A1	0.6	6.43	0.55	5.03e-9	Metabolite levels (small molecules and protein measures);
THYM	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg20608306	chr11:116969690	SIK3	0.55	6.48	0.55	4.05e-9	Blood protein levels;
THYM	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg06064525	chr11:970664	AP2A2	0.34	6.58	0.56	2.57e-9	Alzheimer's disease (late onset);
THYM	cis	rs10461617	0.541	rs7715822	chr5:56043600	G/T	cg24531977	chr5:56204891	C5orf35	-0.83	-4.51	-0.42	1.83e-5	Type 2 diabetes;
THYM	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg15038512	chr6:170123185	PHF10	0.57	5.21	0.47	1.08e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs1957429	0.522	rs73279816	chr14:65348375	G/A	cg23373153	chr14:65346875	NA	-1.29	-5.55	-0.49	2.56e-7	Pediatric areal bone mineral density (radius);
THYM	cis	rs2071518	1.000	rs7839760	chr8:120421534	T/C	cg15718811	chr8:120427810	NOV	0.48	4.45	0.42	2.31e-5	Pulse pressure;Blood pressure;
THYM	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg06850241	chr22:41845214	NA	-0.54	-4.68	-0.43	9.37e-6	Vitiligo;
THYM	cis	rs514406	0.928	rs1672917	chr1:53291550	A/G	cg27535305	chr1:53392650	SCP2	-0.42	-4.82	-0.44	5.54e-6	Monocyte count;
THYM	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg03188948	chr7:1209495	NA	0.91	5.04	0.46	2.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7809950	0.678	rs2237659	chr7:106847492	G/T	cg23024343	chr7:107201750	COG5	1.03	7.58	0.61	2.33e-11	Coronary artery disease;
THYM	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg23131131	chr22:24373011	LOC391322	-0.86	-8.56	-0.66	1.94e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4595586	0.545	rs1156707	chr12:39372451	G/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs7586879	0.638	rs10203482	chr2:25136916	T/C	cg15423357	chr2:25149977	NA	0.7	7.73	0.62	1.09e-11	Body mass index;
THYM	cis	rs986417	1.000	rs8021347	chr14:60952773	G/C	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs17152411	0.895	rs7079416	chr10:126587312	C/G	cg07906193	chr10:126599966	NA	0.68	4.65	0.43	1.08e-5	Height;
THYM	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg18252515	chr7:66147081	NA	0.64	4.69	0.43	9.21e-6	Aortic root size;
THYM	cis	rs454510	0.857	rs838990	chr1:120193252	A/G	cg16322792	chr1:120165303	ZNF697	0.58	5.01	0.46	2.55e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
THYM	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg11663144	chr21:46675770	NA	-0.68	-8.3	-0.65	6.95e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg11327659	chr7:150037044	RARRES2	0.47	5.32	0.48	6.94e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11644478	chr21:40555479	PSMG1	-0.82	-7.29	-0.6	9.29e-11	Cognitive function;
THYM	cis	rs13006833	0.668	rs291449	chr2:191177467	A/G	cg27211696	chr2:191398769	TMEM194B	-0.56	-4.47	-0.42	2.19e-5	Urinary metabolites;
THYM	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.54e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg09354556	chr3:47051341	NA	0.45	4.63	0.43	1.14e-5	Colorectal cancer;
THYM	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg13395646	chr4:1353034	KIAA1530	-0.56	-5.12	-0.47	1.56e-6	Longevity;
THYM	cis	rs2034088	0.965	rs28537324	chr17:443527	A/G	cg06217071	chr17:408420	NA	0.8	7.7	0.62	1.3e-11	Hip circumference adjusted for BMI;
THYM	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg14835575	chr10:16859367	RSU1	0.65	4.53	0.42	1.69e-5	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
THYM	cis	rs4589258	0.933	rs1783790	chr11:90439007	C/G	cg26138821	chr11:89956704	CHORDC1	0.7	5.9	0.52	5.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	4.54	0.42	1.66e-5	Hip circumference adjusted for BMI;
THYM	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.58	0.43	1.41e-5	Bipolar disorder;
THYM	cis	rs10779751	0.960	rs1883964	chr1:11294942	T/A	cg08854313	chr1:11322531	MTOR	0.94	8.23	0.65	9.67e-13	Body mass index;
THYM	cis	rs66887589	0.967	rs6844263	chr4:120433807	A/G	cg13609457	chr4:120235615	NA	0.47	4.93	0.45	3.5e-6	Diastolic blood pressure;
THYM	cis	rs3750965	0.959	rs4930265	chr11:68855954	A/G	cg06818126	chr11:68850279	TPCN2	-0.66	-4.47	-0.42	2.14e-5	Hair color;
THYM	cis	rs9875589	0.509	rs9867041	chr3:14014615	T/C	cg03204825	chr3:13978759	TPRXL	-0.54	-4.67	-0.43	1.01e-5	Ovarian reserve;
THYM	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg05182265	chr7:156933206	UBE3C	-0.69	-9.32	-0.69	4.58e-15	Body mass index;
THYM	cis	rs742614	0.533	rs6059498	chr20:32447282	T/C	cg06304546	chr20:32448765	NA	-1.0	-10.8	-0.74	3.31e-18	Stearic acid (18:0) levels;
THYM	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg24846343	chr22:24311635	DDTL	0.45	5.65	0.5	1.67e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4363385	0.747	rs4845506	chr1:152968407	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.51	-0.42	1.88e-5	Inflammatory skin disease;
THYM	cis	rs4937076	0.510	rs13424	chr11:125826953	A/C	cg09127759	chr11:125811660	NA	-0.4	-4.54	-0.42	1.63e-5	Primary tooth development (time to first tooth eruption);
THYM	cis	rs6906287	0.647	rs12194555	chr6:118819212	C/A	cg21191810	chr6:118973309	C6orf204	0.53	5.24	0.47	9.58e-7	Electrocardiographic conduction measures;
THYM	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-4.55	-0.42	1.56e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg11335335	chr11:637885	DRD4	-0.66	-4.9	-0.45	3.93e-6	Systemic lupus erythematosus;
THYM	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg17063962	chr7:91808500	NA	1.08	11.35	0.76	2.25e-19	Breast cancer;
THYM	cis	rs6032067	0.516	rs57047308	chr20:43899974	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.59	-5.8	-0.51	8.81e-8	Blood protein levels;
THYM	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg00898013	chr13:113819073	PROZ	0.95	9.56	0.7	1.45e-15	Platelet distribution width;
THYM	cis	rs72627123	0.867	rs75730360	chr14:74409035	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-5.62	-0.5	1.9e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg22166914	chr1:53195759	ZYG11B	0.8	8.08	0.64	2.09e-12	Monocyte count;
THYM	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs4851266	0.865	rs11695996	chr2:100854336	C/T	cg08017756	chr2:100939284	LONRF2	-0.56	-4.45	-0.42	2.31e-5	Educational attainment;
THYM	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg08772003	chr10:104629869	AS3MT	-0.59	-5.36	-0.48	5.83e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	trans	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7760949	0.889	rs9475795	chr6:13931270	A/C	cg11053062	chr6:13924544	RNF182	-0.48	-4.62	-0.43	1.21e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.18	8.91	0.67	3.51e-14	Cognitive test performance;
THYM	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.64	-0.74	7.23e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs981844	0.714	rs2405204	chr4:154705248	A/G	cg09973105	chr4:154681532	RNF175	0.55	5.11	0.46	1.67e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs3741151	0.773	rs73544716	chr11:73170061	C/T	cg12959048	chr11:73096162	RELT	-0.53	-5.08	-0.46	1.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs977987	0.806	rs7202596	chr16:75491072	G/T	cg03315344	chr16:75512273	CHST6	0.73	5.99	0.52	3.73e-8	Dupuytren's disease;
THYM	cis	rs10203711	0.966	rs10167210	chr2:239601726	A/C	cg14580085	chr2:239553406	NA	-0.63	-5.73	-0.51	1.18e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	9.78	0.71	4.77e-16	Platelet count;
THYM	cis	rs9790314	1.000	rs1600209	chr3:161038217	A/T	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs2668423	0.922	rs3826942	chr19:1360575	A/G	cg02639931	chr19:1387894	NDUFS7	0.49	5.45	0.49	3.98e-7	Nonalcoholic fatty liver disease;
THYM	cis	rs6987853	0.563	rs2974301	chr8:42442238	A/G	cg09913449	chr8:42400586	C8orf40	0.68	5.9	0.52	5.66e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4662945	0.688	rs62174140	chr2:130202893	C/T	cg05903289	chr2:130345205	NA	-0.59	-5.69	-0.5	1.38e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs9902453	0.967	rs4994355	chr17:28386284	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-4.79	-0.44	6.09e-6	Coffee consumption (cups per day);
THYM	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.6	8.4	0.65	4.21e-13	Monocyte percentage of white cells;
THYM	cis	rs2219968	0.926	rs13258410	chr8:78924203	T/C	cg00738934	chr8:78996279	NA	0.8	8.66	0.66	1.18e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9486719	1.000	rs2472887	chr6:96865437	A/G	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs6500395	1.000	rs9930365	chr16:48682154	A/C	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9906944	0.707	rs3816272	chr17:47120467	A/G	cg09029085	chr17:47094198	IGF2BP1	0.47	6.53	0.56	3.17e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs17253792	0.822	rs76472022	chr14:56053660	C/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs6032067	0.586	rs62208373	chr20:43764426	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.7	-7.59	-0.61	2.14e-11	Blood protein levels;
THYM	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg07936489	chr17:37558343	FBXL20	-0.79	-5.7	-0.5	1.37e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2273669	0.667	rs7767882	chr6:109334971	C/A	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg14582100	chr15:45693742	SPATA5L1	0.58	4.62	0.43	1.21e-5	Homoarginine levels;
THYM	cis	rs1568889	1.000	rs35343234	chr11:28034379	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.46	0.42	2.26e-5	Bipolar disorder;
THYM	cis	rs6060717	0.654	rs6058347	chr20:34483781	A/G	cg26038318	chr20:34205095	SPAG4	0.64	5.07	0.46	1.94e-6	Hip circumference adjusted for BMI;
THYM	cis	rs9649213	0.574	rs7790229	chr7:97919338	G/A	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs988913	1.000	rs9396007	chr6:54807622	T/A	cg18532076	chr6:54711417	FAM83B	0.52	4.79	0.44	6.22e-6	Menarche (age at onset);
THYM	cis	rs2371447	1	rs2371447	chr3:41171177	T/G	cg02247160	chr3:41243829	CTNNB1	-0.36	-4.85	-0.45	4.78e-6	Total body bone mineral density (age over 60);
THYM	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.96	8.0	0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	15.57	0.85	6.94e-28	Chronic sinus infection;
THYM	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg15556689	chr8:8085844	FLJ10661	0.65	4.85	0.45	4.81e-6	Neuroticism;
THYM	cis	rs2282300	0.739	rs67670125	chr11:30214914	C/T	cg06241208	chr11:30344200	C11orf46	-0.77	-5.69	-0.5	1.38e-7	Morning vs. evening chronotype;
THYM	cis	rs72827839	0.681	rs76811231	chr17:46476403	C/A	cg23391107	chr17:45924227	SP6	0.87	5.61	0.5	2.02e-7	Ease of getting up in the morning;
THYM	cis	rs4589258	0.933	rs7102324	chr11:90396116	T/C	cg26834418	chr11:89957033	CHORDC1	0.49	4.45	0.42	2.31e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg13866156	chr1:1669148	SLC35E2	-0.74	-7.52	-0.61	3.02e-11	Body mass index;
THYM	trans	rs4650994	0.544	rs4652301	chr1:178499799	T/C	cg05059571	chr16:84539110	KIAA1609	-0.95	-11.25	-0.76	3.55e-19	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs3892630	0.878	rs6510277	chr19:33183669	C/A	cg02283691	chr19:33182526	NUDT19	-0.41	-4.82	-0.44	5.35e-6	Red blood cell traits;
THYM	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg09359103	chr1:154839909	KCNN3	-0.73	-9.25	-0.69	6.79e-15	Prostate cancer;
THYM	cis	rs6089829	0.888	rs4809268	chr20:61675249	C/G	cg03213289	chr20:61660250	NA	0.98	10.68	0.74	5.81e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10788264	0.518	rs1028632	chr10:124044657	C/G	cg09507567	chr10:124027408	NA	0.47	4.83	0.44	5.13e-6	Total body bone mineral density;
THYM	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg04317338	chr11:64019027	PLCB3	0.86	5.95	0.52	4.48e-8	Mean platelet volume;
THYM	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	13.4	0.81	1.29e-23	Chronic sinus infection;
THYM	cis	rs9674544	0.556	rs1390154	chr17:47071483	A/G	cg20966754	chr17:47091339	IGF2BP1	-0.44	-5.36	-0.48	5.87e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs6541297	1.000	rs4846909	chr1:230285372	G/A	cg20703242	chr1:230279135	GALNT2	0.95	6.29	0.54	9.66e-9	Coronary artery disease;
THYM	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg02269571	chr22:50332266	NA	-0.79	-5.71	-0.51	1.3e-7	Schizophrenia;
THYM	cis	rs7968440	0.715	rs7957659	chr12:50638810	T/C	cg20014596	chr12:50898483	DIP2B	-0.51	-4.71	-0.44	8.41e-6	Fibrinogen;
THYM	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg00639195	chr15:79103007	ADAMTS7	0.84	6.03	0.53	3.13e-8	Coronary artery disease or large artery stroke;
THYM	cis	rs71636778	0.509	rs35962879	chr1:27283456	T/C	cg16022904	chr1:26870173	RPS6KA1	0.84	4.55	0.42	1.58e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
THYM	cis	rs919433	0.679	rs6741314	chr2:198526088	G/A	cg00792783	chr2:198669748	PLCL1	0.82	5.44	0.49	4.16e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg16680214	chr1:154839983	KCNN3	-0.39	-4.63	-0.43	1.15e-5	Prostate cancer;
THYM	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg18811423	chr2:55921094	PNPT1	0.72	6.92	0.58	5.22e-10	Metabolic syndrome;
THYM	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg03128534	chr1:43423976	SLC2A1	0.73	6.9	0.58	5.66e-10	Red cell distribution width;
THYM	cis	rs5995756	0.627	rs1008677	chr22:40009336	C/T	cg21377881	chr22:40064566	CACNA1I	-0.55	-4.72	-0.44	8.03e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg20283391	chr11:68216788	NA	-0.74	-5.43	-0.49	4.25e-7	Total body bone mineral density;
THYM	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Body mass index;
THYM	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg06112835	chr11:68658793	MRPL21	0.44	6.26	0.54	1.11e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs13064411	0.696	rs2129434	chr3:113138763	A/C	cg10517650	chr3:113235015	CCDC52	-0.6	-5.06	-0.46	2.06e-6	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs1385374	0.858	rs11059933	chr12:129303593	T/C	cg04043695	chr12:129287642	SLC15A4	-0.8	-4.83	-0.44	5.3e-6	Systemic lupus erythematosus;
THYM	cis	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg18252515	chr7:66147081	NA	-1.52	-8.02	-0.64	2.72e-12	Gout;
THYM	cis	rs4523957	0.553	rs2641440	chr17:2027182	G/C	cg16513277	chr17:2031491	SMG6	-1.02	-9.92	-0.71	2.49e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9359856	0.510	rs78649003	chr6:90454644	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.85	-8.18	-0.64	1.27e-12	Bipolar disorder;
THYM	cis	rs2408955	0.561	rs9971924	chr12:48479832	C/G	cg21466736	chr12:48725269	NA	0.51	5.11	0.46	1.69e-6	Glycated hemoglobin levels;
THYM	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg15448220	chr1:150897856	SETDB1	0.9	7.47	0.61	3.94e-11	Melanoma;
THYM	cis	rs3733631	0.557	rs10488857	chr4:104679531	A/G	cg24090629	chr4:104641072	TACR3	-0.88	-5.19	-0.47	1.19e-6	Menarche (age at onset);
THYM	cis	rs8133932	0.654	rs10854475	chr21:47332749	A/G	cg20357416	chr21:47294739	PCBP3	-0.81	-4.93	-0.45	3.54e-6	Schizophrenia;
THYM	cis	rs2688608	0.592	rs7076585	chr10:75503692	T/C	cg23231163	chr10:75533350	FUT11	-0.44	-6.22	-0.54	1.34e-8	Inflammatory bowel disease;
THYM	cis	rs1371867	0.846	rs1616833	chr8:101271821	C/T	cg06636551	chr8:101224915	SPAG1	0.63	6.33	0.54	8.05e-9	Atrioventricular conduction;
THYM	cis	rs7107174	1.000	rs10899495	chr11:78123293	C/T	cg19901956	chr11:77921274	USP35	-0.68	-5.47	-0.49	3.6e-7	Testicular germ cell tumor;
THYM	cis	rs17253792	0.732	rs79014965	chr14:56117551	T/G	cg01858014	chr14:56050164	KTN1	-1.2	-4.88	-0.45	4.19e-6	Putamen volume;
THYM	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg21984481	chr17:79567631	NPLOC4	0.61	6.89	0.58	6.13e-10	Eye color traits;
THYM	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.59	4.47	0.42	2.19e-5	Aortic root size;
THYM	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.9	5.49	0.49	3.33e-7	Platelet count;
THYM	cis	rs12530845	1.000	rs77068811	chr7:135334571	A/G	cg23117316	chr7:135346802	PL-5283	-0.66	-5.88	-0.52	6.21e-8	Red blood cell traits;
THYM	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg06636001	chr8:8085503	FLJ10661	-0.65	-5.38	-0.48	5.45e-7	Mood instability;
THYM	cis	rs141518190	1	rs141518190	chr15:78900647	A/G	cg18825076	chr15:78729989	IREB2	-0.55	-5.04	-0.46	2.26e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs2932538	0.922	rs12739994	chr1:113131159	T/C	cg22162597	chr1:113214053	CAPZA1	0.61	4.81	0.44	5.73e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs3087591	0.919	rs2940180	chr17:29409347	G/T	cg24425628	chr17:29625626	OMG;NF1	0.66	5.74	0.51	1.11e-7	Hip circumference;
THYM	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.27	5.56	0.5	2.45e-7	Obesity-related traits;
THYM	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg08807101	chr21:30365312	RNF160	-0.91	-7.64	-0.62	1.7e-11	Dental caries;
THYM	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg02773041	chr1:40204384	PPIE	0.77	5.92	0.52	5.08e-8	Blood protein levels;
THYM	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.1	-0.53	2.29e-8	Crohn's disease;
THYM	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg06634786	chr22:41940651	POLR3H	0.68	4.97	0.45	3.01e-6	Vitiligo;
THYM	cis	rs2915864	1.000	rs2906066	chr5:141580277	A/G	cg00542992	chr5:141595654	NA	0.62	4.65	0.43	1.06e-5	Facial morphology (factor 20);
THYM	cis	rs868036	0.918	rs4776967	chr15:68033922	T/C	cg24579218	chr15:68104479	NA	-0.69	-6.76	-0.57	1.11e-9	Restless legs syndrome;
THYM	cis	rs988913	0.957	rs4712081	chr6:54756529	A/G	cg19716238	chr6:54711378	FAM83B	-0.52	-5.21	-0.47	1.1e-6	Menarche (age at onset);
THYM	cis	rs2073300	1.000	rs6132623	chr20:23442324	T/A	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs72827839	0.779	rs16955073	chr17:46381746	T/C	cg23391107	chr17:45924227	SP6	0.86	5.55	0.5	2.54e-7	Ease of getting up in the morning;
THYM	cis	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.43	-4.71	-0.44	8.43e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs422249	0.512	rs1535	chr11:61597972	A/G	cg19610905	chr11:61596333	FADS2	-0.62	-5.19	-0.47	1.2e-6	Trans fatty acid levels;
THYM	cis	rs89107	0.576	rs114951787	chr6:118839081	C/G	cg21191810	chr6:118973309	C6orf204	0.51	5.11	0.46	1.67e-6	Cardiac structure and function;
THYM	cis	rs699	0.583	rs2493150	chr1:230868427	C/T	cg24474852	chr1:230850050	AGT	0.43	4.45	0.42	2.36e-5	Coronary artery disease;
THYM	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06634786	chr22:41940651	POLR3H	0.78	6.01	0.53	3.36e-8	Vitiligo;
THYM	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg21100191	chr22:23484243	RTDR1	0.73	6.54	0.56	3.07e-9	Bone mineral density;
THYM	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg27121462	chr16:89883253	FANCA	0.58	4.51	0.42	1.84e-5	Vitiligo;
THYM	cis	rs2286885	1.000	rs10733679	chr9:129242416	C/T	cg14319473	chr9:129242481	FAM125B	0.66	5.01	0.46	2.52e-6	Intraocular pressure;
THYM	cis	rs17739794	0.967	rs3860880	chr8:809497	G/T	cg01971667	chr8:817044	NA	0.57	4.99	0.46	2.78e-6	Clozapine-induced cytotoxicity;
THYM	trans	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg07393940	chr7:158741817	NA	-1.14	-9.25	-0.69	6.69e-15	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg02004499	chr7:4244250	SDK1	0.66	5.6	0.5	2.06e-7	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
THYM	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs4919669	0.546	rs2902544	chr10:104261359	C/T	cg00122347	chr10:104236741	TMEM180	-0.56	-4.46	-0.42	2.24e-5	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
THYM	cis	rs8067545	0.611	rs7219615	chr17:20132558	T/A	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs13418717	0.793	rs13403026	chr2:127618436	A/G	cg25501666	chr2:127640322	NA	-1.4	-5.59	-0.5	2.21e-7	Heart failure;
THYM	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg13447684	chr7:1895903	MAD1L1	0.55	4.66	0.43	1.01e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg20891283	chr12:69753455	YEATS4	1.04	9.67	0.7	8.35e-16	Blood protein levels;
THYM	cis	rs986417	0.818	rs10151839	chr14:60980688	T/G	cg27398547	chr14:60952738	C14orf39	1.14	5.33	0.48	6.64e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg15693483	chr7:1102177	C7orf50	0.52	6.03	0.53	3.13e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg05457628	chr5:178986728	RUFY1	0.63	6.68	0.57	1.59e-9	Lung cancer;
THYM	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg24154853	chr7:158122151	PTPRN2	0.55	4.88	0.45	4.32e-6	Calcium levels;
THYM	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.63	-5.43	-0.49	4.26e-7	Coronary artery disease;
THYM	cis	rs11186	0.556	rs72906316	chr2:189956761	T/C	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs62103177	0.564	rs55867755	chr18:77723434	C/T	cg07235805	chr18:78004237	PARD6G	0.45	4.96	0.45	3.02e-6	Opioid sensitivity;
THYM	cis	rs35264875	0.851	rs72930621	chr11:68866745	C/T	cg01993067	chr11:68851601	TPCN2	0.94	4.92	0.45	3.67e-6	Blond vs. brown hair color;
THYM	cis	rs10779751	1.000	rs11121710	chr1:11313244	T/C	cg08854313	chr1:11322531	MTOR	0.95	8.04	0.64	2.44e-12	Body mass index;
THYM	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg19746536	chr19:49375674	PPP1R15A	0.81	4.6	0.43	1.33e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs1018836	0.669	rs6471243	chr8:91656967	C/T	cg16814680	chr8:91681699	NA	1.11	14.25	0.83	2.58e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg05973401	chr12:123451056	ABCB9	0.65	4.72	0.44	8.08e-6	Platelet count;
THYM	cis	rs13380717	0.732	rs9933616	chr16:86903194	A/G	cg05661093	chr16:86825505	NA	-0.56	-5.19	-0.47	1.21e-6	Sepsis in extremely premature infants;
THYM	cis	rs11190604	0.767	rs77838250	chr10:102180090	T/G	cg07570687	chr10:102243282	WNT8B	0.81	7.79	0.62	8.34e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs10463554	0.963	rs34382	chr5:102396225	G/C	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg04756594	chr16:24857601	SLC5A11	0.76	5.51	0.49	3e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs10905065	1.000	rs7913067	chr10:5787305	C/T	cg11519256	chr10:5708881	ASB13	0.49	4.85	0.45	4.79e-6	Menopause (age at onset);
THYM	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.48	-0.73	1.54e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg03060546	chr3:49711283	APEH	-0.67	-5.08	-0.46	1.85e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs6032067	0.929	rs2868238	chr20:43826993	C/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg23711669	chr6:146136114	FBXO30	0.9	8.92	0.68	3.32e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12540874	0.931	rs9791817	chr7:50661187	C/G	cg18232548	chr7:50535776	DDC	-0.64	-5.19	-0.47	1.17e-6	Systemic sclerosis;
THYM	cis	rs924712	0.816	rs6918402	chr6:54732919	G/A	cg04690482	chr6:54711388	FAM83B	-0.45	-4.97	-0.45	3.02e-6	Breast cancer;
THYM	trans	rs1974653	0.672	rs9606244	chr22:20082881	C/T	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs791888	0.767	rs2255684	chr10:89419971	C/T	cg13926569	chr10:89418898	PAPSS2	-0.71	-8.38	-0.65	4.64e-13	Magnesium levels;
THYM	cis	rs7512552	0.839	rs12042229	chr1:150447398	A/G	cg15654264	chr1:150340011	RPRD2	0.44	5.02	0.46	2.37e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.73	0.67	8.5e-14	Colorectal cancer;
THYM	cis	rs6032067	0.866	rs6104054	chr20:43822771	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.61	-5.88	-0.52	5.97e-8	Blood protein levels;
THYM	cis	rs635808	0.561	rs491700	chr6:167171838	A/G	cg17732216	chr6:167178280	RPS6KA2	-0.62	-4.97	-0.45	2.95e-6	Dental caries;
THYM	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg08000102	chr2:233561755	GIGYF2	0.68	6.14	0.53	1.86e-8	Coronary artery disease;
THYM	cis	rs6032067	0.777	rs2868235	chr20:43794069	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.69	-0.43	8.98e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.69	0.5	1.43e-7	Height;
THYM	cis	rs9790314	0.690	rs6799130	chr3:160847801	C/G	cg03342759	chr3:160939853	NMD3	-0.6	-4.47	-0.42	2.18e-5	Morning vs. evening chronotype;
THYM	cis	rs61990749	0.511	rs2052444	chr14:78312918	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.87	5.4	0.48	5.01e-7	Fibroblast growth factor basic levels;
THYM	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg11941060	chr3:133502564	NA	-0.72	-6.02	-0.53	3.24e-8	Iron status biomarkers;
THYM	cis	rs6500395	1.000	rs34844432	chr16:48682418	C/T	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.64	-5.53	-0.49	2.78e-7	Systemic lupus erythematosus;
THYM	cis	rs2016266	0.859	rs7953656	chr12:53738433	G/T	cg26875137	chr12:53738046	NA	0.87	6.91	0.58	5.41e-10	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs7262634	1.000	rs6018346	chr20:45841979	C/G	cg18599129	chr20:45867857	ZMYND8	-0.71	-4.48	-0.42	2.09e-5	Response to protease inhibitor treatment in hepatitis c (bilirubin toxicity);
THYM	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg10047753	chr17:41438598	NA	1.16	10.76	0.74	3.96e-18	Menopause (age at onset);
THYM	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg03405983	chr8:143858548	LYNX1	-0.53	-5.64	-0.5	1.71e-7	Urinary tract infection frequency;
THYM	cis	rs6918586	1.000	rs198811	chr6:26128446	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.68	5.56	0.5	2.42e-7	Schizophrenia;
THYM	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg11461670	chr8:22454935	PDLIM2	-0.33	-6.19	-0.54	1.5e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg16325326	chr1:53192061	ZYG11B	-0.83	-8.3	-0.65	7.07e-13	Monocyte count;
THYM	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg13852791	chr20:30311386	BCL2L1	0.74	5.35	0.48	6.15e-7	Mean corpuscular hemoglobin;
THYM	cis	rs6964587	0.626	rs9008	chr7:91502407	C/G	cg17063962	chr7:91808500	NA	-1.0	-8.65	-0.66	1.28e-13	Breast cancer;
THYM	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg15556689	chr8:8085844	FLJ10661	0.59	4.74	0.44	7.48e-6	Neuroticism;
THYM	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg09307838	chr4:120376055	NA	0.62	4.73	0.44	7.88e-6	Corneal astigmatism;
THYM	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg22841779	chr14:105766346	BRF1	-0.51	-6.58	-0.56	2.6e-9	Mean platelet volume;Platelet distribution width;
THYM	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.76	6.71	0.57	1.37e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs34779708	0.966	rs12769575	chr10:35435927	A/T	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs6032067	0.673	rs4522674	chr20:43893276	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.66	-5.86	-0.52	6.74e-8	Blood protein levels;
THYM	cis	rs9876781	1.000	rs9883759	chr3:48463618	T/A	cg06066452	chr3:48470258	PLXNB1	0.27	4.77	0.44	6.64e-6	Longevity;
THYM	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg13607699	chr17:42295918	UBTF	-0.63	-5.23	-0.47	9.96e-7	Total body bone mineral density;
THYM	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg27129171	chr3:47204927	SETD2	0.8	7.67	0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs7953508	0.711	rs3825199	chr12:93976954	A/G	cg18151635	chr12:93972918	NA	-0.71	-5.07	-0.46	1.99e-6	Pubertal anthropometrics;
THYM	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg04267008	chr7:1944627	MAD1L1	-0.53	-4.71	-0.44	8.28e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6665290	0.669	rs3768419	chr1:227173477	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.08	-12.43	-0.79	1.26e-21	Myeloid white cell count;
THYM	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg25036284	chr2:26402008	FAM59B	0.8	5.36	0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs2072510	0.593	rs2540497	chr12:96404275	A/T	cg18817487	chr12:96390143	HAL	0.45	5.47	0.49	3.61e-7	Metabolite levels (small molecules and protein measures);
THYM	cis	rs10752881	0.935	rs10911197	chr1:182995399	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Colorectal cancer;
THYM	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18252515	chr7:66147081	NA	0.66	5.08	0.46	1.91e-6	Aortic root size;
THYM	cis	rs10463554	0.963	rs11242483	chr5:102323766	C/T	cg23492399	chr5:102201601	PAM	-0.65	-5.08	-0.46	1.91e-6	Parkinson's disease;
THYM	cis	rs425535	0.941	rs440676	chr4:74857970	C/A	cg07868155	chr4:74864709	CXCL5	0.61	5.11	0.46	1.68e-6	Blood protein levels;
THYM	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg03929089	chr4:120376271	NA	-0.83	-8.52	-0.66	2.37e-13	Height;
THYM	cis	rs2251260	0.685	rs2246700	chr14:62008147	T/A	cg13564459	chr14:62004353	PRKCH	0.43	5.52	0.49	2.88e-7	Yeast infection;
THYM	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg26818010	chr10:134567672	INPP5A	-0.87	-7.31	-0.6	8.22e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg24672777	chr11:48374446	OR4C45	0.73	4.53	0.42	1.75e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9311676	0.656	rs11712213	chr3:58384995	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg04043695	chr12:129287642	SLC15A4	0.6	4.66	0.43	1.03e-5	Systemic lupus erythematosus;
THYM	cis	rs12446552	0.661	rs72781049	chr16:11707633	C/T	cg09662852	chr16:11707685	NA	-0.67	-6.06	-0.53	2.68e-8	Colorectal or endometrial cancer;
THYM	cis	rs12682352	0.605	rs60707155	chr8:8724415	C/T	cg06636001	chr8:8085503	FLJ10661	0.6	5.19	0.47	1.21e-6	Neuroticism;
THYM	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	5.55	0.49	2.55e-7	Monocyte percentage of white cells;
THYM	trans	rs11175492	1.000	rs7296498	chr12:65038015	C/G	cg12514734	chr12:3216258	TSPAN9	1.52	7.19	0.59	1.45e-10	Platelet count;
THYM	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg13319975	chr6:146136371	FBXO30	-0.72	-6.02	-0.53	3.32e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12681287	0.604	rs6471316	chr8:87403587	G/C	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg13607699	chr17:42295918	UBTF	0.6	5.03	0.46	2.33e-6	Total body bone mineral density;
THYM	cis	rs870825	0.616	rs6552801	chr4:185620623	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs34526934	0.566	rs34028621	chr2:177042779	C/T	cg14324370	chr2:177042789	NA	-0.7	-6.14	-0.53	1.95e-8	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs17152411	0.895	rs7080475	chr10:126585767	A/G	cg07906193	chr10:126599966	NA	0.68	4.65	0.43	1.08e-5	Height;
THYM	cis	rs6563842	0.563	rs4941991	chr13:41335719	T/C	cg21288729	chr13:41239152	FOXO1	0.63	4.75	0.44	7.33e-6	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
THYM	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg09021430	chr5:549028	NA	-0.6	-5.66	-0.5	1.63e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.3	6.14	0.53	1.9e-8	Obesity-related traits;
THYM	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg13010199	chr12:38710504	ALG10B	0.65	4.68	0.43	9.67e-6	Morning vs. evening chronotype;
THYM	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg18402987	chr7:1209562	NA	1.25	7.8	0.62	8.07e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17122693	1.000	rs17122693	chr14:51084235	C/T	cg04730355	chr14:51134070	SAV1	-0.97	-5.42	-0.49	4.46e-7	Cognitive performance;
THYM	cis	rs7833986	1.000	rs34952804	chr8:57097399	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	4.78	0.44	6.48e-6	Height;
THYM	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg03186999	chr17:7165420	CLDN7	0.49	5.18	0.47	1.24e-6	Diastolic blood pressure;
THYM	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg24324837	chr19:49891574	CCDC155	0.5	4.99	0.46	2.72e-6	Multiple sclerosis;
THYM	cis	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.33e-5	Retinal vascular caliber;
THYM	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg04111992	chr7:158790115	NA	0.57	4.69	0.43	9.24e-6	Facial morphology (factor 20);
THYM	cis	rs7192750	0.586	rs12444829	chr16:71959727	A/G	cg06353428	chr16:71660113	MARVELD3	0.78	5.71	0.51	1.3e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs72792324	0.655	rs10051438	chr5:140757325	A/T	cg00808170	chr5:140807787	PCDHGA4;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB8P;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	-0.78	-4.61	-0.43	1.27e-5	Mean platelet volume;
THYM	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-5.1	-0.46	1.74e-6	Lymphocyte counts;
THYM	cis	rs7666738	0.606	rs3846447	chr4:99099907	G/A	cg17366294	chr4:99064904	C4orf37	0.5	5.74	0.51	1.15e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg10862848	chr6:42927986	GNMT	-0.52	-7.06	-0.59	2.68e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs548181	0.736	rs497344	chr11:125470524	T/C	cg03464685	chr11:125439445	EI24	1.24	7.56	0.61	2.49e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg14416269	chr4:6271139	WFS1	-0.47	-4.71	-0.43	8.55e-6	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs9549260	0.755	rs7317254	chr13:41217849	A/G	cg21288729	chr13:41239152	FOXO1	0.73	5.82	0.51	7.84e-8	Red blood cell count;
THYM	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg23482746	chr15:76478102	C15orf27	-0.38	-4.55	-0.42	1.61e-5	Blood metabolite levels;
THYM	cis	rs4866334	1.000	rs114114986	chr5:18428605	C/A	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg10518543	chr12:38710700	ALG10B	-0.57	-4.57	-0.42	1.47e-5	Morning vs. evening chronotype;
THYM	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg19770292	chr5:1868693	NA	0.54	4.97	0.45	2.95e-6	Cardiovascular disease risk factors;
THYM	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg20503657	chr10:835505	NA	0.92	5.02	0.46	2.4e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg18681998	chr4:17616180	MED28	1.04	10.1	0.72	1.01e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs1150668	0.796	rs728122	chr6:28399124	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.67	-5.35	-0.48	5.95e-7	Pubertal anthropometrics;
THYM	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.76	6.74	0.57	1.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs977987	0.705	rs4888377	chr16:75325686	C/G	cg03315344	chr16:75512273	CHST6	0.79	6.39	0.55	6.24e-9	Dupuytren's disease;
THYM	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg05962950	chr11:130786565	SNX19	0.83	7.14	0.59	1.86e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg13010199	chr12:38710504	ALG10B	-0.58	-4.53	-0.42	1.72e-5	Morning vs. evening chronotype;
THYM	cis	rs7104764	1.000	rs1128322	chr11:244197	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	-1.16	-10.92	-0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs7639513	0.545	rs12714874	chr3:12719928	C/T	cg23032965	chr3:12705835	RAF1	0.9	6.76	0.57	1.09e-9	Itch intensity from mosquito bite;
THYM	cis	rs7568458	0.870	rs1009	chr2:85808737	A/G	cg17127132	chr2:85788382	GGCX	0.6	4.53	0.42	1.73e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs9527	0.615	rs10883811	chr10:104727279	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.68	-4.74	-0.44	7.59e-6	Arsenic metabolism;
THYM	cis	rs786425	0.530	rs2333839	chr12:124216852	T/C	cg15249119	chr12:124971054	NCOR2	0.54	5.0	0.46	2.64e-6	Pubertal anthropometrics;
THYM	cis	rs7084921	0.552	rs1324693	chr10:101890617	A/G	cg11344164	chr10:101878520	NA	-0.59	-5.15	-0.47	1.4e-6	Bone mineral density;
THYM	cis	rs2798269	0.604	rs2488803	chr13:22159277	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.61	-4.55	-0.42	1.6e-5	PR segment;
THYM	cis	rs514406	0.893	rs6588446	chr1:53425260	G/A	cg25767906	chr1:53392781	SCP2	0.57	5.69	0.5	1.41e-7	Monocyte count;
THYM	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg12011299	chr4:100065546	ADH4	0.75	7.3	0.6	8.58e-11	Alcohol dependence;
THYM	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg15212455	chr7:39170539	POU6F2	0.64	6.01	0.52	3.44e-8	IgG glycosylation;
THYM	cis	rs8038465	0.638	rs12591473	chr15:73967485	A/T	cg15420318	chr15:73925796	NPTN	0.6	5.19	0.47	1.17e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4766566	0.651	rs933306	chr12:111737985	A/T	cg10833066	chr12:111807467	FAM109A	0.6	8.12	0.64	1.67e-12	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
THYM	cis	rs9359856	0.564	rs72915903	chr6:90420190	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg07424592	chr7:64974309	NA	1.04	5.27	0.48	8.52e-7	Diabetic kidney disease;
THYM	cis	rs2229238	0.911	rs73023349	chr1:154513440	T/C	cg21262032	chr1:154437693	IL6R	-0.64	-5.79	-0.51	8.9e-8	Coronary heart disease;
THYM	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg18811423	chr2:55921094	PNPT1	0.63	5.74	0.51	1.14e-7	Metabolic syndrome;
THYM	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg03806693	chr22:41940476	POLR3H	-0.84	-6.41	-0.55	5.51e-9	Neuroticism;
THYM	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg00825309	chr19:58991885	ZNF446	-0.6	-4.69	-0.43	9.02e-6	Uric acid clearance;
THYM	cis	rs2408955	0.521	rs10875753	chr12:48557141	C/T	cg21466736	chr12:48725269	NA	-0.49	-4.9	-0.45	3.87e-6	Glycated hemoglobin levels;
THYM	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26314531	chr2:26401878	FAM59B	0.78	5.13	0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14893161	chr1:205819251	PM20D1	0.91	9.59	0.7	1.26e-15	Menarche (age at onset);
THYM	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11644478	chr21:40555479	PSMG1	-0.82	-7.39	-0.6	5.7e-11	Cognitive function;
THYM	cis	rs55871839	0.708	rs1448541	chr8:59812938	G/A	cg07426533	chr8:59803705	TOX	-0.67	-6.88	-0.58	6.33e-10	Pneumonia;
THYM	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs4731207	0.698	rs10233306	chr7:124498417	G/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.48	-4.9	-0.45	3.92e-6	Primary biliary cholangitis;
THYM	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg06027949	chr8:82754900	SNX16	-0.64	-5.17	-0.47	1.29e-6	Diastolic blood pressure;
THYM	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.55	-4.71	-0.44	8.34e-6	Platelet count;
THYM	cis	rs3892630	0.878	rs11878394	chr19:33205844	G/C	cg22928329	chr19:33183273	NUDT19	-0.78	-5.9	-0.52	5.55e-8	Red blood cell traits;
THYM	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg08772003	chr10:104629869	AS3MT	-0.57	-4.95	-0.45	3.23e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs752010	0.695	rs10789408	chr1:42106579	T/C	cg06885757	chr1:42089581	HIVEP3	0.48	5.84	0.51	7.38e-8	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs236907	0.859	rs10489252	chr1:171748145	A/T	cg20598894	chr1:171756153	METTL13	-0.74	-5.52	-0.49	2.9e-7	Mean platelet volume;
THYM	cis	rs7412746	0.597	rs868751	chr1:150669414	T/G	cg15448220	chr1:150897856	SETDB1	0.88	7.27	0.6	1.02e-10	Melanoma;
THYM	cis	rs11078597	0.671	rs1045806	chr17:1641806	G/A	cg18436246	chr17:1640651	WDR81	0.65	4.6	0.43	1.29e-5	Serum albumin level;
THYM	cis	rs72627123	0.867	rs73303135	chr14:74495090	C/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.52	0.56	3.44e-9	Morning vs. evening chronotype;
THYM	cis	rs7267979	0.932	rs367666	chr20:25449818	T/C	cg08601574	chr20:25228251	PYGB	0.57	4.64	0.43	1.1e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs11711311	1.000	rs2566963	chr3:113531849	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.63	5.45	0.49	3.91e-7	IgG glycosylation;
THYM	cis	rs3126085	1.000	rs3126092	chr1:152307955	T/A	cg26020982	chr1:152196106	HRNR	-0.36	-4.95	-0.45	3.19e-6	Atopic dermatitis;
THYM	trans	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs2456568	0.564	rs6483270	chr11:93624380	C/T	cg17595323	chr11:93583763	C11orf90	-0.57	-6.15	-0.53	1.81e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg01699819	chr7:1052092	C7orf50	-0.86	-7.87	-0.63	5.55e-12	Bronchopulmonary dysplasia;
THYM	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg20891283	chr12:69753455	YEATS4	-0.71	-5.52	-0.49	2.9e-7	Response to diuretic therapy;
THYM	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg25036284	chr2:26402008	FAM59B	0.8	5.36	0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs9527	0.622	rs12779263	chr10:104886533	G/T	cg15744005	chr10:104629667	AS3MT	-0.64	-4.66	-0.43	1.02e-5	Arsenic metabolism;
THYM	cis	rs2625529	0.761	rs972028	chr15:72173092	C/T	cg16672083	chr15:72433130	SENP8	-0.53	-4.85	-0.45	4.82e-6	Red blood cell count;
THYM	cis	rs240764	0.817	rs239242	chr6:101092776	C/T	cg21058520	chr6:100914733	NA	-0.57	-5.06	-0.46	2.04e-6	Neuroticism;
THYM	cis	rs58235267	0.591	rs2162014	chr2:63345507	C/A	cg17519650	chr2:63277830	OTX1	0.61	4.89	0.45	4.08e-6	Prostate-specific antigen levels (conditioned on lead SNPs);
THYM	trans	rs6089829	0.888	rs4809268	chr20:61675249	C/G	cg13615516	chr5:77269221	NA	0.83	7.35	0.6	6.87e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg18404041	chr3:52824283	ITIH1	-0.57	-5.74	-0.51	1.13e-7	Bipolar disorder;
THYM	cis	rs6700896	0.931	rs1938492	chr1:66117829	A/C	cg04111102	chr1:66153794	NA	0.55	5.22	0.47	1.06e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs1499972	0.938	rs817509	chr3:117750861	A/G	cg07612923	chr3:117604196	NA	-1.5	-5.16	-0.47	1.38e-6	Schizophrenia;
THYM	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.08	7.64	0.62	1.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7586879	0.658	rs7563204	chr2:25125075	T/G	cg01884057	chr2:25150051	NA	0.73	7.9	0.63	4.81e-12	Body mass index;
THYM	cis	rs7264396	0.561	rs6142470	chr20:34570579	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-4.48	-0.42	2.06e-5	Total cholesterol levels;
THYM	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg10150615	chr22:24372951	LOC391322	1.04	12.58	0.79	6.02e-22	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.58	0.43	1.41e-5	Bipolar disorder;
THYM	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.95	0.71	2.08e-16	Colorectal cancer;
THYM	cis	rs34526934	0.566	rs35563571	chr2:177044459	T/G	cg26754761	chr2:177040938	NA	-0.73	-6.35	-0.55	7.32e-9	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs72717009	0.825	rs9427398	chr1:161476205	A/G	cg15358701	chr1:161410459	NA	-0.95	-5.06	-0.46	2.08e-6	Rheumatoid arthritis;
THYM	cis	rs9403317	0.573	rs6937394	chr6:142020750	G/A	cg15052665	chr6:141804349	NA	-0.75	-5.5	-0.49	3.23e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg02915803	chr1:1606292	LOC728661;CDK11B	0.6	5.13	0.47	1.54e-6	Body mass index;
THYM	cis	rs941408	1.000	rs1640266	chr19:2787832	T/G	cg06609049	chr19:2785107	THOP1	0.78	6.55	0.56	2.94e-9	Total cholesterol levels;
THYM	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg10018233	chr7:150070692	REPIN1	0.38	5.36	0.48	5.72e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2046867	0.818	rs17010133	chr3:72827987	T/C	cg25664220	chr3:72788482	NA	-0.87	-6.57	-0.56	2.66e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs295140	0.506	rs4673855	chr2:201136143	A/G	cg17644776	chr2:200775616	C2orf69	-0.62	-4.89	-0.45	4.06e-6	QT interval;
THYM	cis	rs7599312	0.534	rs10207878	chr2:213409337	A/G	cg16329650	chr2:213403929	ERBB4	1.04	12.32	0.78	2.07e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12931792	0.712	rs4787495	chr16:30165725	C/T	cg17640201	chr16:30407289	ZNF48	-0.61	-5.08	-0.46	1.87e-6	Tonsillectomy;
THYM	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg13699009	chr12:122356056	WDR66	0.46	4.53	0.42	1.71e-5	Mean corpuscular volume;
THYM	cis	rs3892630	0.878	rs1559177	chr19:33210646	A/G	cg22980127	chr19:33182716	NUDT19	1.15	9.47	0.7	2.23e-15	Red blood cell traits;
THYM	cis	rs2108622	0.727	rs9305069	chr19:15983386	A/G	cg13772218	chr19:15982569	NA	0.5	4.48	0.42	2.06e-5	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs7729447	0.813	rs10941022	chr5:32691416	C/T	cg16267343	chr5:32710456	NPR3	0.78	7.15	0.59	1.78e-10	Blood pressure;
THYM	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg27494647	chr7:150038898	RARRES2	0.44	5.34	0.48	6.25e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	4.53	0.42	1.71e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs2290159	0.752	rs3773352	chr3:12651982	G/C	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg14196676	chr1:1911069	KIAA1751	-1.15	-14.21	-0.82	3.05e-25	Severe influenza A (H1N1) infection;
THYM	cis	rs7119	0.689	rs8040318	chr15:77803660	A/C	cg10437265	chr15:77819839	NA	0.75	7.8	0.62	8.02e-12	Type 2 diabetes;
THYM	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs2302612	0.528	rs2302620	chr2:102842467	C/T	cg13315345	chr2:102803985	IL1RL2	-0.72	-4.88	-0.45	4.28e-6	Serum protein levels (sST2);
THYM	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg13683864	chr3:40499215	RPL14	-0.75	-6.78	-0.57	1.03e-9	Renal cell carcinoma;
THYM	cis	rs4595586	0.545	rs61939641	chr12:39378001	T/C	cg26384229	chr12:38710491	ALG10B	0.69	5.35	0.48	6.11e-7	Morning vs. evening chronotype;
THYM	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg18681998	chr4:17616180	MED28	0.81	6.87	0.58	6.5e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4455778	0.580	rs6583508	chr7:49122331	C/A	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs7851660	0.870	rs55960649	chr9:100598695	C/A	cg13688889	chr9:100608707	NA	-0.83	-7.31	-0.6	8.28e-11	Strep throat;
THYM	cis	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6733011	0.628	rs981602	chr2:99464275	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-4.58	-0.42	1.43e-5	Bipolar disorder;
THYM	cis	rs1021993	0.868	rs906350	chr1:209528108	T/C	cg24997231	chr1:209527535	NA	-0.56	-4.61	-0.43	1.24e-5	Gut microbiome composition (winter);
THYM	cis	rs763014	0.833	rs3743902	chr16:632728	T/C	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg18758796	chr5:131593413	PDLIM4	-0.58	-5.28	-0.48	8.11e-7	Acylcarnitine levels;
THYM	cis	rs7333764	0.744	rs3737043	chr13:34185201	C/G	cg16285566	chr13:33682212	STARD13	-1.18	-4.51	-0.42	1.85e-5	CTACK levels;
THYM	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg22974920	chr21:40686053	BRWD1	-0.62	-4.95	-0.45	3.22e-6	Cognitive function;
THYM	cis	rs11214589	0.665	rs4370966	chr11:113231691	G/A	cg14159747	chr11:113255604	NA	0.31	6.03	0.53	3.09e-8	Neuroticism;
THYM	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg09549813	chr16:4587862	C16orf5	-0.6	-6.68	-0.57	1.63e-9	Schizophrenia;
THYM	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg23131131	chr22:24373011	LOC391322	-0.81	-7.18	-0.59	1.56e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg12564285	chr5:131593104	PDLIM4	0.43	4.76	0.44	6.88e-6	Breast cancer;
THYM	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg10360139	chr7:1886902	MAD1L1	-0.83	-7.35	-0.6	7.02e-11	Bipolar disorder and schizophrenia;
THYM	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg13390004	chr1:15929781	NA	0.61	4.63	0.43	1.15e-5	Systolic blood pressure;
THYM	cis	rs6032067	0.929	rs13043296	chr20:43805688	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs4731207	0.596	rs10954051	chr7:124579236	T/C	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	trans	rs1879637	0.517	rs73988941	chr2:212882867	A/G	cg18109231	chr19:6110877	RFX2	-1.22	-7.35	-0.6	6.91e-11	Personality dimensions;
THYM	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg24060327	chr5:131705240	SLC22A5	-0.68	-5.18	-0.47	1.26e-6	Breast cancer;
THYM	cis	rs988913	1.000	rs6929930	chr6:54812710	G/A	cg19716238	chr6:54711378	FAM83B	0.49	5.07	0.46	1.99e-6	Menarche (age at onset);
THYM	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg17911788	chr17:44343683	NA	-0.59	-4.89	-0.45	4.11e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs5769707	0.706	rs763128	chr22:50018045	G/A	cg07959070	chr22:50026188	C22orf34	-0.28	-4.73	-0.44	7.76e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1691799	0.867	rs1183274	chr12:66732057	C/G	cg16791601	chr12:66731901	HELB	-0.76	-7.23	-0.6	1.21e-10	White blood cell count (basophil);
THYM	cis	rs6032067	0.852	rs17333180	chr20:43803708	C/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.52	-5.89	-0.52	5.76e-8	Blood protein levels;
THYM	cis	rs4242434	0.819	rs6558167	chr8:22473850	T/C	cg01710189	chr8:22454888	PDLIM2	-0.45	-4.93	-0.45	3.51e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg20887711	chr4:1340912	KIAA1530	0.69	6.25	0.54	1.16e-8	Longevity;
THYM	cis	rs10504073	0.669	rs11779189	chr8:50030592	C/G	cg00325661	chr8:49890786	NA	-0.78	-7.03	-0.59	3.11e-10	Blood metabolite ratios;
THYM	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg16006841	chr5:176797999	RGS14	-0.52	-5.85	-0.51	6.93e-8	Urate levels in lean individuals;
THYM	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	7.02	0.58	3.25e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7247513	0.964	rs12104149	chr19:12721088	A/G	cg01871581	chr19:12707946	ZNF490	-0.92	-10.63	-0.74	7.51e-18	Bipolar disorder;
THYM	cis	rs593982	0.764	rs55796623	chr11:65411714	G/A	cg08755490	chr11:65554678	OVOL1	-1.15	-4.54	-0.42	1.67e-5	Atopic dermatitis;
THYM	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg14159672	chr1:205819179	PM20D1	-0.81	-7.76	-0.62	9.84e-12	Menarche (age at onset);
THYM	cis	rs1691799	0.867	rs961049	chr12:66762591	A/C	cg16791601	chr12:66731901	HELB	0.63	5.36	0.48	5.76e-7	White blood cell count (basophil);
THYM	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg18132916	chr6:79620363	NA	-0.58	-5.27	-0.48	8.5e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg14349672	chr11:133703707	NA	0.54	4.79	0.44	6.17e-6	Childhood ear infection;
THYM	cis	rs62045849	0.557	rs6500533	chr16:89190065	G/A	cg06035645	chr16:89190857	ACSF3	-0.88	-5.57	-0.5	2.39e-7	Red blood cell count;
THYM	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg06028808	chr11:68637592	NA	0.68	7.24	0.6	1.18e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg06850241	chr22:41845214	NA	-0.49	-4.71	-0.44	8.38e-6	Vitiligo;
THYM	trans	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs2806561	0.808	rs2235546	chr1:23409538	A/G	cg12483005	chr1:23474871	LUZP1	0.51	4.69	0.43	9.25e-6	Height;
THYM	cis	rs611744	0.608	rs1448152	chr8:109278249	C/T	cg21045802	chr8:109455806	TTC35	0.68	6.04	0.53	3.03e-8	Dupuytren's disease;
THYM	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg08772003	chr10:104629869	AS3MT	-0.57	-4.92	-0.45	3.56e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg08999081	chr20:33150536	PIGU	0.78	7.16	0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs11723261	0.582	rs4582104	chr4:136942	A/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.73	5.69	0.5	1.41e-7	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg22681709	chr2:178499509	PDE11A	-0.57	-5.42	-0.49	4.6e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg03709012	chr19:19516395	GATAD2A	-0.74	-5.8	-0.51	8.48e-8	Tonsillectomy;
THYM	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg15445000	chr17:37608096	MED1	-0.44	-5.19	-0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs1158570	0.778	rs7817803	chr8:131319822	A/C	cg16277922	chr8:131349729	ASAP1	0.64	5.56	0.5	2.46e-7	Platelet count;
THYM	cis	rs2408955	0.522	rs3997	chr12:48481587	T/C	cg21466736	chr12:48725269	NA	0.49	4.85	0.45	4.92e-6	Glycated hemoglobin levels;
THYM	cis	rs9948	1.000	rs13419073	chr2:97507554	G/C	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.83	-0.44	5.18e-6	Erectile dysfunction and prostate cancer treatment;
THYM	cis	rs4925114	0.568	rs4925109	chr17:17661802	A/G	cg04398451	chr17:18023971	MYO15A	0.66	5.31	0.48	7.24e-7	Body mass index;
THYM	cis	rs7119038	0.818	rs2155433	chr11:118612921	G/A	cg19308663	chr11:118741387	NA	0.44	4.61	0.43	1.25e-5	Sjögren's syndrome;
THYM	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg04320152	chr17:18167836	SMCR7	0.59	4.67	0.43	9.92e-6	Total body bone mineral density;
THYM	cis	rs911555	0.755	rs10148970	chr14:103892000	G/A	cg12935359	chr14:103987150	CKB	-0.51	-6.07	-0.53	2.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg24874828	chr4:187887005	NA	-0.72	-7.11	-0.59	2.16e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs67460515	0.563	rs68166680	chr3:160829735	T/A	cg03342759	chr3:160939853	NMD3	-0.63	-4.7	-0.43	8.93e-6	Parkinson's disease;
THYM	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg16850897	chr7:100343110	ZAN	-0.71	-5.37	-0.48	5.67e-7	Other erythrocyte phenotypes;
THYM	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg09354556	chr3:47051341	NA	0.46	4.71	0.44	8.28e-6	Colorectal cancer;
THYM	cis	rs12039431	0.788	rs58284750	chr1:38042926	C/A	cg17933807	chr1:38061675	GNL2	-0.82	-6.03	-0.53	3.07e-8	Epithelial ovarian cancer;
THYM	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg01483505	chr11:975446	AP2A2	-0.57	-4.63	-0.43	1.16e-5	Alzheimer's disease (late onset);
THYM	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.17	11.49	0.76	1.16e-19	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs16912285	0.748	rs12786638	chr11:24346006	A/G	ch.11.24196551F	chr11:24239977	NA	0.89	6.14	0.53	1.88e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs782590	0.608	rs10207590	chr2:55921782	G/C	cg03859395	chr2:55845619	SMEK2	-0.51	-4.61	-0.43	1.27e-5	Metabolic syndrome;
THYM	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg20295408	chr7:1910781	MAD1L1	0.63	4.64	0.43	1.1e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs8078723	0.510	rs3087852	chr17:38137364	G/A	cg17467752	chr17:38218738	THRA	-0.71	-5.24	-0.47	9.77e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs7731657	0.537	rs6867710	chr5:130201260	A/C	cg08523029	chr5:130500466	HINT1	-0.74	-5.19	-0.47	1.2e-6	Fasting plasma glucose;
THYM	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg00271210	chr6:167070053	RPS6KA2	0.72	7.96	0.63	3.73e-12	Crohn's disease;
THYM	cis	rs9486719	1.000	rs11153067	chr6:97039421	A/T	cg18709589	chr6:96969512	KIAA0776	0.67	4.64	0.43	1.1e-5	Migraine;Coronary artery disease;
THYM	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg17143192	chr8:8559678	CLDN23	-0.63	-4.79	-0.44	6.13e-6	Mood instability;
THYM	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg12560992	chr17:57184187	TRIM37	0.9	8.37	0.65	4.89e-13	Intelligence (multi-trait analysis);
THYM	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg26038318	chr20:34205095	SPAG4	0.59	4.65	0.43	1.08e-5	Total cholesterol levels;
THYM	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg03690763	chr11:133734501	NA	-0.61	-4.73	-0.44	7.77e-6	Childhood ear infection;
THYM	cis	rs2067615	0.542	rs10861654	chr12:107122896	A/G	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs7681440	0.606	rs2736999	chr4:90754111	C/T	cg06632027	chr4:90757378	SNCA	0.67	5.31	0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs3741798	1.000	rs73277486	chr12:12494761	T/C	cg08615371	chr12:12503544	MANSC1	0.88	4.98	0.46	2.79e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9296092	0.522	rs62405955	chr6:33527176	T/C	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs1729951	0.546	rs835632	chr3:136676525	A/T	cg21827317	chr3:136751795	NA	0.69	6.09	0.53	2.36e-8	Neuroticism;
THYM	cis	rs34375054	0.752	rs12582867	chr12:125659798	A/C	cg25124228	chr12:125621409	AACS	-0.68	-4.98	-0.45	2.89e-6	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg21475434	chr5:93447410	FAM172A	-0.96	-6.1	-0.53	2.29e-8	Diabetic retinopathy;
THYM	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg02915803	chr1:1606292	LOC728661;CDK11B	-0.68	-6.45	-0.55	4.61e-9	Body mass index;
THYM	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg11663144	chr21:46675770	NA	0.71	9.92	0.71	2.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs17253792	0.822	rs17683656	chr14:56053361	C/T	cg01858014	chr14:56050164	KTN1	1.23	5.16	0.47	1.36e-6	Putamen volume;
THYM	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.29	4.48	0.42	2.08e-5	Obesity-related traits;
THYM	cis	rs16937	0.618	rs6659069	chr1:205182031	A/G	cg17889831	chr1:205181581	DSTYK	-0.36	-4.48	-0.42	2.11e-5	Schizophrenia;
THYM	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg13939156	chr17:80058883	NA	0.4	5.29	0.48	7.68e-7	Life satisfaction;
THYM	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg07936489	chr17:37558343	FBXL20	0.83	5.84	0.51	7.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg14004847	chr7:1930337	MAD1L1	-0.67	-4.96	-0.45	3.08e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	5.59	0.5	2.16e-7	Monocyte percentage of white cells;
THYM	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg20242066	chr2:136595261	LCT	0.6	7.1	0.59	2.23e-10	Mosquito bite size;
THYM	cis	rs17253792	0.545	rs12886406	chr14:56027605	G/A	cg01858014	chr14:56050164	KTN1	-1.16	-4.92	-0.45	3.69e-6	Putamen volume;
THYM	cis	rs295140	1.000	rs11888462	chr2:201160499	G/T	cg04283868	chr2:201171347	SPATS2L	0.73	5.46	0.49	3.82e-7	QT interval;
THYM	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg08213375	chr14:104286397	PPP1R13B	0.45	4.75	0.44	7.26e-6	Reticulocyte count;
THYM	cis	rs7760949	0.889	rs9396264	chr6:13930342	T/A	cg27413430	chr6:13925136	RNF182	0.53	4.74	0.44	7.6e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6570726	0.935	rs906774	chr6:145813770	T/C	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2504916	0.739	rs2450971	chr6:160758578	G/A	cg19643109	chr6:160697625	NA	-0.66	-4.86	-0.45	4.54e-6	Response to hepatitis C treatment;
THYM	cis	rs8050907	0.661	rs13334411	chr16:4602686	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.2	4.92	0.45	3.64e-6	Obesity-related traits;
THYM	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.16	-0.47	1.36e-6	Total cholesterol levels;
THYM	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg13609457	chr4:120235615	NA	0.51	4.76	0.44	6.87e-6	Corneal astigmatism;
THYM	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg07870213	chr5:140052090	DND1	-0.69	-8.1	-0.64	1.86e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs981844	0.712	rs4302444	chr4:154745663	A/G	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4474465	0.920	rs10793321	chr11:78237566	A/G	cg19901956	chr11:77921274	USP35	0.7	5.2	0.47	1.16e-6	Alzheimer's disease (survival time);
THYM	cis	rs57244997	0.582	rs73030432	chr6:162439864	G/A	cg17173639	chr6:162384350	PARK2	-0.74	-4.9	-0.45	3.87e-6	Mosquito bite size;
THYM	cis	rs7786808	0.552	rs4909207	chr7:158187136	G/A	cg01191920	chr7:158217561	PTPRN2	-0.93	-9.5	-0.7	1.93e-15	Obesity-related traits;
THYM	cis	rs901683	1.000	rs9422442	chr10:46048078	C/A	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs72772090	0.539	rs10515250	chr5:96150193	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.84	-5.01	-0.46	2.48e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7043114	0.525	rs7045409	chr9:95201540	A/T	cg14631576	chr9:95140430	CENPP	-0.82	-8.18	-0.64	1.27e-12	Height;
THYM	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg04944784	chr2:26401820	FAM59B	1.04	6.46	0.55	4.4e-9	Gut microbiome composition (summer);
THYM	cis	rs76662990	0.610	rs6453070	chr5:73944217	C/T	cg13275603	chr5:73927487	ENC1	-0.77	-4.63	-0.43	1.17e-5	Residual cognition;
THYM	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg09184832	chr6:79620586	NA	-0.56	-4.46	-0.42	2.24e-5	Intelligence (multi-trait analysis);
THYM	cis	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.56	-0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2522056	0.808	rs17771891	chr5:131744202	A/G	cg24060327	chr5:131705240	SLC22A5	-0.76	-4.54	-0.42	1.64e-5	Lymphocyte counts;Fibrinogen;
THYM	cis	rs1747683	0.966	rs10737070	chr10:13369846	C/T	cg11679871	chr10:13388567	SEPHS1	-0.31	-4.6	-0.43	1.3e-5	IgG glycosylation;
THYM	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg06532163	chr17:45867833	NA	0.65	6.55	0.56	2.91e-9	IgG glycosylation;
THYM	cis	rs2273669	0.504	rs61743581	chr6:109480562	T/C	cg17117243	chr6:109341365	SESN1	-0.82	-4.8	-0.44	5.98e-6	Prostate cancer;
THYM	cis	rs10744422	1.000	rs1587856	chr12:123342229	A/G	cg25930673	chr12:123319894	HIP1R	-0.84	-4.72	-0.44	8.03e-6	Schizophrenia;
THYM	cis	rs9796	0.621	rs58109657	chr15:41471750	A/G	cg18705301	chr15:41695430	NDUFAF1	0.57	4.75	0.44	7.07e-6	Menopause (age at onset);
THYM	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg02825527	chr7:2087843	MAD1L1	-0.76	-5.08	-0.46	1.88e-6	Bipolar disorder;
THYM	cis	rs11563648	0.553	rs1057454	chr7:127032599	A/C	cg23081781	chr7:127225937	GCC1	-0.34	-4.65	-0.43	1.07e-5	Resting heart rate;
THYM	cis	rs8044868	0.586	rs7200854	chr16:72083318	G/A	cg06353428	chr16:71660113	MARVELD3	0.6	4.56	0.42	1.54e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.47	-0.55	4.33e-9	Bone mineral density;
THYM	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg10852096	chr15:79043040	NA	-0.64	-4.47	-0.42	2.16e-5	Coronary artery disease or large artery stroke;
THYM	cis	rs8018808	1.000	rs2193595	chr14:77845121	A/G	cg20045696	chr14:77926864	AHSA1	-0.53	-4.74	-0.44	7.5e-6	Myeloid white cell count;
THYM	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg07884673	chr3:53033167	SFMBT1	1.27	6.43	0.55	5.06e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs17407555	0.821	rs73222526	chr4:10203917	G/A	cg00071950	chr4:10020882	SLC2A9	-0.59	-4.45	-0.42	2.35e-5	Schizophrenia (age at onset);
THYM	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg18352616	chr4:3374830	RGS12	0.76	8.49	0.66	2.72e-13	Serum sulfate level;
THYM	cis	rs919433	0.783	rs787979	chr2:198242868	A/T	cg00792783	chr2:198669748	PLCL1	0.76	5.53	0.49	2.79e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs514406	0.825	rs12089511	chr1:53436427	A/T	cg08859206	chr1:53392774	SCP2	0.65	7.33	0.6	7.72e-11	Monocyte count;
THYM	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9807989	0.507	rs1420096	chr2:103010912	C/T	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg24531977	chr5:56204891	C5orf35	1.02	8.34	0.65	5.72e-13	Initial pursuit acceleration;
THYM	cis	rs2455799	0.573	rs2255248	chr3:15754849	A/G	cg16303742	chr3:15540471	COLQ	0.52	5.69	0.5	1.39e-7	Mean platelet volume;
THYM	trans	rs9747201	1.000	rs4506966	chr17:80175421	T/C	cg07393940	chr7:158741817	NA	1.1	8.4	0.65	4.38e-13	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.59	4.58	0.43	1.4e-5	Height;
THYM	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg05234568	chr11:5960015	NA	-0.59	-4.75	-0.44	7.28e-6	DNA methylation (variation);
THYM	cis	rs711830	1.000	rs2857540	chr2:177026698	G/T	cg13092806	chr2:177043255	NA	0.64	4.87	0.45	4.36e-6	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs1003719	0.788	rs2835586	chr21:38461326	G/A	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-5.41	-0.49	4.61e-7	Vitiligo;
THYM	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.87e-6	Resting heart rate;
THYM	cis	rs6480314	0.636	rs61854797	chr10:70005611	T/C	cg27159792	chr10:69524182	NA	0.81	4.89	0.45	4.06e-6	Optic nerve measurement (disc area);
THYM	cis	rs9677476	0.909	rs13408391	chr2:232124127	G/T	cg07929768	chr2:232055508	NA	0.62	6.15	0.53	1.8e-8	Food antigen IgG levels;
THYM	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg06634786	chr22:41940651	POLR3H	0.73	5.33	0.48	6.69e-7	Vitiligo;
THYM	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg00981070	chr1:2046702	PRKCZ	0.47	5.21	0.47	1.1e-6	Height;
THYM	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg18352616	chr4:3374830	RGS12	-0.72	-8.0	-0.63	3.02e-12	Serum sulfate level;
THYM	cis	rs1129187	0.748	rs9471968	chr6:42905235	A/G	cg27588902	chr6:42928151	GNMT	-0.6	-6.1	-0.53	2.24e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.95	7.71	0.62	1.25e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9807841	0.643	rs3843751	chr19:10748121	C/T	cg16900796	chr19:10755136	SLC44A2	0.34	5.15	0.47	1.41e-6	Inflammatory skin disease;
THYM	cis	rs8060598	0.745	rs1861759	chr16:50745583	A/C	cg05261686	chr16:50743296	NOD2	0.38	4.62	0.43	1.21e-5	Leprosy;
THYM	cis	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg23035555	chr19:3500370	DOHH	-0.79	-4.47	-0.42	2.14e-5	Total cholesterol levels;
THYM	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg06640241	chr16:89574553	SPG7	0.6	4.61	0.43	1.25e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs75908454	1.000	rs117534547	chr6:169891608	G/A	cg19338460	chr6:170058176	WDR27	-1.02	-4.64	-0.43	1.11e-5	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg25436886	chr3:127056972	NA	-0.78	-5.98	-0.52	3.88e-8	Interleukin-10 levels;Interleukin-13 levels;
THYM	trans	rs480407	0.759	rs35415665	chr2:161759265	C/T	cg06548410	chr19:1997657	BTBD2	0.73	6.89	0.58	6.14e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs6815814	0.898	rs2174284	chr4:38859339	C/T	cg06935464	chr4:38784597	TLR10	0.76	4.7	0.43	8.87e-6	Breast cancer;
THYM	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg10792982	chr14:105748885	BRF1	0.72	7.5	0.61	3.35e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg20291162	chr17:40259547	DHX58	-0.7	-6.47	-0.55	4.18e-9	Fibrinogen levels;
THYM	cis	rs1322639	1.000	rs9689079	chr6:169587148	A/G	cg03254818	chr6:169586852	NA	-0.76	-5.51	-0.49	3.03e-7	Pulse pressure;
THYM	cis	rs4733781	0.563	rs6985563	chr8:131332344	C/T	cg16277922	chr8:131349729	ASAP1	0.57	4.75	0.44	7.09e-6	Tuberculosis;
THYM	cis	rs12935418	0.560	rs12325013	chr16:80961574	G/C	cg16651780	chr16:81037892	C16orf61	0.78	4.99	0.46	2.7e-6	Mean corpuscular volume;
THYM	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg03388043	chr17:80084554	CCDC57	-0.73	-6.03	-0.53	3.06e-8	Life satisfaction;
THYM	cis	rs6732160	0.691	rs10197935	chr2:73412362	A/T	cg24220031	chr2:73402428	NA	-0.79	-9.26	-0.69	6.32e-15	Intelligence (multi-trait analysis);
THYM	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	5.63	0.5	1.82e-7	Schizophrenia;
THYM	cis	rs870825	0.929	rs72689258	chr4:185590550	G/C	cg04058563	chr4:185651563	MLF1IP	0.96	6.73	0.57	1.26e-9	Blood protein levels;
THYM	cis	rs113835537	0.529	rs11227500	chr11:66273233	T/C	cg24851651	chr11:66362959	CCS	0.7	4.82	0.44	5.46e-6	Airway imaging phenotypes;
THYM	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06634786	chr22:41940651	POLR3H	0.78	6.01	0.53	3.36e-8	Vitiligo;
THYM	cis	rs7246657	1.000	rs34544865	chr19:37801242	G/C	cg22634378	chr19:37742834	NA	0.64	5.16	0.47	1.35e-6	Coronary artery calcification;
THYM	cis	rs6665290	0.904	rs9727512	chr1:227185375	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.13	-15.82	-0.85	2.26e-28	Myeloid white cell count;
THYM	cis	rs3768617	0.528	rs6672093	chr1:183079853	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.67	6.16	0.53	1.73e-8	Personality dimensions;
THYM	cis	rs7100689	0.646	rs1815650	chr10:82157464	C/T	cg01528321	chr10:82214614	TSPAN14	0.94	7.9	0.63	4.9e-12	Post bronchodilator FEV1;
THYM	cis	rs6500395	0.962	rs1477135	chr16:48726823	C/T	cg04672837	chr16:48644449	N4BP1	0.49	4.76	0.44	7.03e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9814567	1.000	rs1357762	chr3:134264859	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-8.41	-0.65	4e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9818758	0.607	rs12185979	chr3:49651970	C/G	cg00383909	chr3:49044727	WDR6	1.12	5.62	0.5	1.94e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg07167872	chr1:205819463	PM20D1	-0.64	-4.68	-0.43	9.68e-6	Menarche (age at onset);
THYM	cis	rs2133450	0.508	rs7653020	chr3:7335201	G/A	cg19930620	chr3:7340148	GRM7	-0.56	-5.83	-0.51	7.65e-8	Early response to risperidone in schizophrenia;
THYM	trans	rs11186	0.556	rs72906336	chr2:189959092	C/A	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs2702888	0.503	rs2741714	chr8:6759967	C/A	cg26795848	chr8:6756730	NA	-0.65	-5.95	-0.52	4.55e-8	Blood pressure;
THYM	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg08067268	chr2:26466485	HADHB;HADHA	-0.68	-4.89	-0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs2658782	0.724	rs2605627	chr11:93259515	A/G	cg15737290	chr11:93063684	CCDC67	1.02	7.57	0.61	2.4e-11	Pulmonary function decline;
THYM	cis	rs240764	0.817	rs239206	chr6:101137332	T/G	cg21058520	chr6:100914733	NA	-0.57	-5.21	-0.47	1.1e-6	Neuroticism;
THYM	cis	rs7940866	0.678	rs61909201	chr11:130839547	C/T	cg12179176	chr11:130786555	SNX19	0.66	5.31	0.48	7.18e-7	Schizophrenia;
THYM	cis	rs17443541	0.507	rs6709301	chr2:200466505	G/A	cg03741458	chr2:200468445	NA	-0.8	-6.04	-0.53	3.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg18252515	chr7:66147081	NA	-1.65	-9.03	-0.68	1.94e-14	Diabetic kidney disease;
THYM	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs7823896	0.929	rs73311386	chr8:110149694	G/T	cg18044723	chr8:109261011	EIF3E	-0.89	-4.68	-0.43	9.42e-6	Myopia (pathological);
THYM	cis	rs28785552	0.897	rs10424736	chr19:53239176	G/A	cg22067481	chr19:53234126	ZNF611	-1.01	-10.68	-0.74	5.86e-18	Response to paliperidone in schizophrenia (PANSS score);
THYM	trans	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg18187862	chr3:45730750	SACM1L	-0.89	-7.26	-0.6	1.08e-10	Primary sclerosing cholangitis;
THYM	cis	rs2282300	0.739	rs10742237	chr11:30310659	C/T	cg09906309	chr11:30344399	C11orf46	0.73	5.38	0.48	5.3e-7	Morning vs. evening chronotype;
THYM	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg03160526	chr17:80928410	B3GNTL1	0.49	4.52	0.42	1.81e-5	Glycated hemoglobin levels;
THYM	cis	rs6987853	0.814	rs2923447	chr8:42439848	G/T	cg09913449	chr8:42400586	C8orf40	1.04	11.18	0.75	5.21e-19	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg12310025	chr6:25882481	NA	0.69	5.44	0.49	4.15e-7	Blood metabolite levels;
THYM	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg13609457	chr4:120235615	NA	0.61	5.47	0.49	3.63e-7	Corneal astigmatism;
THYM	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg25319279	chr11:5960081	NA	-0.64	-5.64	-0.5	1.77e-7	DNA methylation (variation);
THYM	cis	rs6732160	0.593	rs2288630	chr2:73457552	C/T	cg24220031	chr2:73402428	NA	-0.8	-9.34	-0.69	4.32e-15	Intelligence (multi-trait analysis);
THYM	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg24531977	chr5:56204891	C5orf35	-0.93	-7.44	-0.61	4.48e-11	Initial pursuit acceleration;
THYM	cis	rs7191700	0.583	rs243314	chr16:11385104	G/C	cg00044050	chr16:11439710	C16orf75	0.88	7.12	0.59	2.01e-10	Multiple sclerosis;
THYM	cis	rs4595586	0.545	rs3914595	chr12:39388530	G/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.05e-5	Morning vs. evening chronotype;
THYM	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg25036284	chr2:26402008	FAM59B	-0.74	-4.87	-0.45	4.39e-6	Gut microbiome composition (summer);
THYM	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs10779751	0.734	rs1130683	chr1:11132217	G/A	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg13010199	chr12:38710504	ALG10B	0.73	5.82	0.51	7.99e-8	Heart rate;
THYM	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg06634786	chr22:41940651	POLR3H	-0.73	-5.36	-0.48	5.89e-7	Vitiligo;
THYM	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	5.63	0.5	1.79e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs524281	0.773	rs2236652	chr11:66002681	G/A	cg00563793	chr11:65837595	PACS1	0.79	4.71	0.43	8.53e-6	Electroencephalogram traits;
THYM	cis	rs490234	0.702	rs10986788	chr9:128303942	G/C	cg14078157	chr9:128172775	NA	-0.77	-6.1	-0.53	2.27e-8	Mean arterial pressure;
THYM	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg24399712	chr22:39784796	NA	-0.9	-9.28	-0.69	5.68e-15	Intelligence (multi-trait analysis);
THYM	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6032067	0.526	rs2743347	chr20:43920493	T/C	cg24575067	chr20:44746902	CD40	-0.72	-5.23	-0.47	1.02e-6	Blood protein levels;
THYM	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs4144027	0.818	rs881057	chr14:104354258	T/G	cg08213375	chr14:104286397	PPP1R13B	-0.45	-4.69	-0.43	9.2e-6	Blood metabolite levels;
THYM	cis	rs55871839	0.684	rs13271523	chr8:59806664	T/C	cg07426533	chr8:59803705	TOX	-0.64	-6.3	-0.54	9.2e-9	Pneumonia;
THYM	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg04772025	chr11:68637568	NA	0.61	6.33	0.54	8.18e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg04362960	chr10:104952993	NT5C2	-0.63	-5.48	-0.49	3.49e-7	Waist circumference;Hip circumference;
THYM	cis	rs4642101	0.669	rs1467026	chr3:12830775	G/A	cg05775895	chr3:12838266	CAND2	0.89	7.69	0.62	1.32e-11	QRS complex (12-leadsum);
THYM	cis	rs9457247	0.508	rs6902119	chr6:167505791	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.48	-4.61	-0.43	1.24e-5	Crohn's disease;
THYM	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg23758822	chr17:41437982	NA	1.06	7.46	0.61	4.13e-11	Menopause (age at onset);
THYM	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg11663144	chr21:46675770	NA	-0.71	-8.52	-0.66	2.34e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4722166	0.695	rs7808122	chr7:22798080	A/G	cg05472934	chr7:22766657	IL6	0.7	6.18	0.54	1.56e-8	Lung cancer;
THYM	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.88	0.63	5.43e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs6456156	0.774	rs2022001	chr6:167529509	C/T	cg09487078	chr6:167525398	CCR6	-0.44	-4.92	-0.45	3.63e-6	Primary biliary cholangitis;
THYM	cis	rs10887741	0.646	rs10218939	chr10:89436853	A/G	cg13926569	chr10:89418898	PAPSS2	0.63	7.28	0.6	9.67e-11	Exercise (leisure time);
THYM	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.92	-7.98	-0.63	3.29e-12	Menarche (age at onset);
THYM	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg00339695	chr16:24857497	SLC5A11	-0.68	-6.18	-0.54	1.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4919687	0.514	rs12573077	chr10:104434630	C/A	cg18761893	chr10:103892519	PPRC1	0.6	4.45	0.42	2.3e-5	Colorectal cancer;
THYM	cis	rs4666002	0.636	rs2272406	chr2:27892023	A/T	cg27432699	chr2:27873401	GPN1	0.6	4.59	0.43	1.37e-5	Phospholipid levels (plasma);
THYM	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg23260525	chr10:116636907	FAM160B1	0.5	5.12	0.47	1.58e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg02887458	chr19:19495540	GATAD2A	-0.45	-4.89	-0.45	4.05e-6	Bipolar disorder;
THYM	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg17845761	chr1:175162550	KIAA0040	0.38	4.86	0.45	4.62e-6	Alcohol dependence;
THYM	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg06028808	chr11:68637592	NA	0.68	7.49	0.61	3.59e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs35123781	0.502	rs2455154	chr5:138913058	A/G	cg08720517	chr5:138729919	LOC389333	0.58	4.67	0.43	9.81e-6	Schizophrenia;
THYM	cis	rs9560113	1.000	rs9560105	chr13:112175363	A/T	cg14154082	chr13:112174009	NA	-0.86	-8.0	-0.63	2.95e-12	Menarche (age at onset);
THYM	cis	rs1007190	0.881	rs9900293	chr17:42936003	G/C	cg15406952	chr17:42872593	NA	0.8	5.57	0.5	2.34e-7	DNA methylation (variation);
THYM	cis	rs7084402	0.935	rs1649068	chr10:60304864	A/C	cg09696939	chr10:60272079	BICC1	-0.46	-5.37	-0.48	5.51e-7	Refractive error;
THYM	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg01710189	chr8:22454888	PDLIM2	-0.55	-5.72	-0.51	1.21e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg03467027	chr4:99064603	C4orf37	0.59	4.5	0.42	1.92e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10463554	0.889	rs246908	chr5:102564177	G/A	cg23492399	chr5:102201601	PAM	-0.68	-5.12	-0.46	1.61e-6	Parkinson's disease;
THYM	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg07061783	chr6:25882402	NA	0.57	4.48	0.42	2.07e-5	Schizophrenia;
THYM	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6876348	0.928	rs6864732	chr5:128118028	G/T	cg25555059	chr5:128301488	SLC27A6	-0.46	-4.95	-0.45	3.19e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11997175	0.583	rs7829680	chr8:33794207	C/T	ch.8.33884649F	chr8:33765107	NA	-0.67	-4.95	-0.45	3.2e-6	Body mass index;
THYM	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg25427524	chr10:38739819	LOC399744	0.67	6.06	0.53	2.72e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6539288	0.899	rs759603	chr12:107307391	G/T	cg26297688	chr12:107349093	C12orf23	-0.47	-4.89	-0.45	4.15e-6	Total body bone mineral density;
THYM	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg13609457	chr4:120235615	NA	0.53	4.87	0.45	4.45e-6	Educational attainment;
THYM	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg21475434	chr5:93447410	FAM172A	0.83	5.31	0.48	7.13e-7	Diabetic retinopathy;
THYM	cis	rs2070433	0.752	rs11700468	chr21:47776391	C/T	cg12379764	chr21:47803548	PCNT	0.84	5.03	0.46	2.35e-6	Lymphocyte counts;
THYM	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg06238570	chr21:40685208	BRWD1	-0.72	-6.28	-0.54	9.9e-9	Menarche (age at onset);
THYM	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg11266682	chr4:10021025	SLC2A9	0.7	10.92	0.75	1.79e-18	Bone mineral density;
THYM	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg12826209	chr6:26865740	GUSBL1	0.94	5.02	0.46	2.37e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1466045	0.841	rs2166567	chr11:3157534	C/T	cg14568032	chr11:3122963	OSBPL5	0.55	4.55	0.42	1.58e-5	Cisplatin-induced ototoxicity;
THYM	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg24530246	chr3:53118167	NA	-0.77	-4.64	-0.43	1.1e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.61	-4.76	-0.44	6.98e-6	Systemic lupus erythematosus;
THYM	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg23281280	chr6:28129359	ZNF389	0.64	5.1	0.46	1.74e-6	Depression;
THYM	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg27034606	chr17:28928453	LRRC37B2	0.79	4.89	0.45	4.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg01416388	chr22:39784598	NA	-0.87	-7.91	-0.63	4.66e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4930103	0.602	rs170101	chr11:2008936	C/T	cg06197492	chr11:2016605	H19	0.59	5.09	0.46	1.81e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs34638657	0.626	rs2967377	chr16:82213239	T/G	cg07307142	chr16:82071433	HSD17B2	-0.58	-4.72	-0.44	8.22e-6	Lung adenocarcinoma;
THYM	cis	rs10504073	0.647	rs10957357	chr8:49988587	C/A	cg00325661	chr8:49890786	NA	0.93	8.79	0.67	6.32e-14	Blood metabolite ratios;
THYM	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg21784768	chr11:537496	LRRC56	-1.09	-4.91	-0.45	3.76e-6	Body mass index;
THYM	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg11764359	chr7:65958608	NA	0.64	5.0	0.46	2.58e-6	Aortic root size;
THYM	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-4.92	-0.45	3.68e-6	Hemoglobin concentration;
THYM	cis	rs12701220	0.689	rs12530960	chr7:1095471	G/A	cg26769984	chr7:1090371	C7orf50	0.84	5.46	0.49	3.75e-7	Bronchopulmonary dysplasia;
THYM	cis	rs11048434	0.761	rs2110192	chr12:9136351	A/T	cg04155231	chr12:9217510	LOC144571	0.5	4.95	0.45	3.27e-6	Sjögren's syndrome;
THYM	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg15536230	chr21:44985092	HSF2BP	-0.41	-4.99	-0.46	2.72e-6	Mean corpuscular volume;
THYM	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg12923728	chr3:195709715	SDHAP1	-0.78	-6.38	-0.55	6.41e-9	Pancreatic cancer;
THYM	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg10803722	chr21:46713166	LOC642852	-0.42	-5.58	-0.5	2.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-7.08	-0.59	2.42e-10	Chronic sinus infection;
THYM	cis	rs6906287	0.573	rs11153732	chr6:118704967	C/T	cg21191810	chr6:118973309	C6orf204	0.47	4.59	0.43	1.35e-5	Electrocardiographic conduction measures;
THYM	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg07636037	chr3:49044803	WDR6	0.88	9.06	0.68	1.72e-14	Parkinson's disease;
THYM	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg21433313	chr16:3507492	NAT15	-0.72	-5.35	-0.48	6.13e-7	Tuberculosis;
THYM	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg10589385	chr1:150898437	SETDB1	0.6	4.94	0.45	3.3e-6	Tonsillectomy;
THYM	cis	rs711830	0.931	rs6755766	chr2:177043205	T/C	cg26754761	chr2:177040938	NA	-0.55	-4.83	-0.44	5.24e-6	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs6496667	0.865	rs12592226	chr15:90926190	C/T	cg22089800	chr15:90895588	ZNF774	0.79	4.75	0.44	7.21e-6	Rheumatoid arthritis;
THYM	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.64	5.12	0.47	1.59e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg14004847	chr7:1930337	MAD1L1	-0.65	-5.29	-0.48	7.86e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs3741151	0.656	rs112699563	chr11:73015243	C/T	cg12959048	chr11:73096162	RELT	-0.42	-4.45	-0.42	2.3e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs6840360	0.550	rs6535806	chr4:152483906	G/A	cg17479576	chr4:152424074	FAM160A1	-0.8	-5.92	-0.52	5.02e-8	Intelligence (multi-trait analysis);
THYM	cis	rs62229266	0.605	rs11701331	chr21:37458392	T/C	cg12218747	chr21:37451666	NA	-0.69	-6.81	-0.57	8.95e-10	Mitral valve prolapse;
THYM	cis	rs9914988	0.673	rs12325788	chr17:27080049	G/A	cg20469991	chr17:27169893	C17orf63	-0.88	-5.54	-0.49	2.72e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs9902453	0.791	rs6505141	chr17:27998187	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	6.2	0.54	1.45e-8	Coffee consumption (cups per day);
THYM	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg08736216	chr1:53307985	ZYG11A	-0.62	-5.49	-0.49	3.31e-7	Monocyte count;
THYM	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg14004847	chr7:1930337	MAD1L1	-0.63	-4.68	-0.43	9.69e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4242434	0.672	rs900267	chr8:22485258	T/C	cg21658235	chr8:22456391	C8orf58	0.45	4.57	0.42	1.48e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs5753037	0.803	rs131263	chr22:30133045	C/T	cg27665648	chr22:30112403	NA	0.5	4.56	0.42	1.51e-5	Type 1 diabetes;
THYM	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg11366901	chr6:160182831	ACAT2	1.04	8.69	0.67	1.03e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs12216545	0.737	rs7788962	chr7:150227227	G/A	cg00323915	chr7:150264987	GIMAP4	-0.49	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs832540	0.898	rs170732	chr5:56251777	C/T	cg24531977	chr5:56204891	C5orf35	-0.64	-4.56	-0.42	1.55e-5	Coronary artery disease;
THYM	cis	rs939658	0.728	rs11637459	chr15:79413554	A/G	cg17916960	chr15:79447300	NA	-0.62	-6.46	-0.55	4.37e-9	Refractive error;
THYM	cis	rs3096299	0.838	rs3096319	chr16:89402634	C/G	cg06640241	chr16:89574553	SPG7	0.62	4.59	0.43	1.36e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg13147721	chr7:65941812	NA	-0.96	-6.01	-0.52	3.45e-8	Diabetic kidney disease;
THYM	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg04398451	chr17:18023971	MYO15A	0.95	10.61	0.74	8.23e-18	Schizophrenia;
THYM	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.56	-6.89	-0.58	6.11e-10	Schizophrenia;
THYM	cis	rs524281	0.638	rs4261293	chr11:65805135	T/C	cg14541915	chr11:65894463	PACS1	-0.89	-4.49	-0.42	1.99e-5	Electroencephalogram traits;
THYM	cis	rs2213920	0.523	rs7857923	chr9:118176789	A/G	cg13918206	chr9:118159781	DEC1	0.86	4.9	0.45	3.86e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs4803468	1.000	rs2241708	chr19:41912270	C/T	cg09537434	chr19:41945824	ATP5SL	-1.16	-11.61	-0.77	6.5e-20	Height;
THYM	cis	rs4886920	0.862	rs4486846	chr15:78138936	C/T	cg10461261	chr15:78109450	NA	-0.47	-4.5	-0.42	1.91e-5	Neuroticism;
THYM	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Body mass index;
THYM	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg23131131	chr22:24373011	LOC391322	-0.91	-9.19	-0.69	8.85e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4664308	0.840	rs1870102	chr2:161070582	A/G	cg03641300	chr2:160917029	PLA2R1	-0.72	-6.32	-0.54	8.5e-9	Idiopathic membranous nephropathy;
THYM	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.83	-7.18	-0.59	1.56e-10	Chronic sinus infection;
THYM	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.75	5.9	0.52	5.58e-8	Total cholesterol levels;
THYM	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg22947322	chr17:47091978	IGF2BP1	-0.58	-6.32	-0.54	8.4e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs1371867	0.846	rs1660349	chr8:101319326	G/A	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs4478037	0.558	rs72854770	chr3:33066743	C/G	cg19404215	chr3:33155277	CRTAP	1.19	5.78	0.51	9.27e-8	Major depressive disorder;
THYM	cis	rs7818345	0.624	rs12682196	chr8:19332963	A/C	cg01280390	chr8:19363452	CSGALNACT1	-0.68	-6.18	-0.54	1.59e-8	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs9467711	0.538	rs13214169	chr6:25890656	A/G	cg12826209	chr6:26865740	GUSBL1	0.92	4.45	0.42	2.36e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs425277	0.583	rs3128334	chr1:2038662	G/A	cg13918804	chr1:2043761	PRKCZ	0.69	6.02	0.53	3.32e-8	Height;
THYM	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg06917634	chr15:78832804	PSMA4	-0.64	-4.48	-0.42	2.08e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs1062746	0.502	rs76128303	chr16:87339236	T/C	cg02258303	chr16:87377426	FBXO31	-0.61	-4.82	-0.44	5.53e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs28476539	0.567	rs6822801	chr4:83576829	G/A	cg10249074	chr4:83542146	C4orf11	-0.65	-5.13	-0.47	1.51e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg25566285	chr7:158114605	PTPRN2	0.78	7.03	0.58	3.19e-10	Response to amphetamines;
THYM	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg06028605	chr16:24865363	SLC5A11	0.56	5.26	0.47	8.84e-7	Intelligence (multi-trait analysis);
THYM	cis	rs941408	1.000	rs1076448	chr19:2792343	G/A	cg19693284	chr19:2783607	SGTA	0.72	5.44	0.49	4.08e-7	Total cholesterol levels;
THYM	cis	rs7546094	0.967	rs1032312	chr1:113112746	G/A	cg22162597	chr1:113214053	CAPZA1	0.45	4.62	0.43	1.21e-5	Platelet distribution width;
THYM	cis	rs4889855	0.505	rs4890057	chr17:78591679	A/G	cg16591659	chr17:78472290	NA	-0.4	-5.08	-0.46	1.9e-6	Fractional excretion of uric acid;
THYM	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11644478	chr21:40555479	PSMG1	-0.54	-4.53	-0.42	1.72e-5	Menarche (age at onset);
THYM	cis	rs28498503	1.000	rs7238348	chr18:76660408	C/T	cg24134504	chr18:76639479	NA	0.71	4.79	0.44	6.21e-6	Attention function in attention deficit hyperactive disorder;
THYM	cis	rs288326	0.561	rs80099669	chr2:183776981	G/T	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg06640241	chr16:89574553	SPG7	0.88	8.43	0.65	3.67e-13	Multiple myeloma (IgH translocation);
THYM	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06481639	chr22:41940642	POLR3H	-0.86	-5.91	-0.52	5.28e-8	Vitiligo;
THYM	cis	rs7586879	0.521	rs1865689	chr2:25108197	C/T	cg01884057	chr2:25150051	NA	-0.62	-5.99	-0.52	3.8e-8	Body mass index;
THYM	cis	rs13326165	0.585	rs73088773	chr3:52286585	G/A	cg08438690	chr3:52279403	PPM1M	-0.82	-4.74	-0.44	7.45e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg12516959	chr21:47718080	NA	-0.43	-5.21	-0.47	1.09e-6	Testicular germ cell tumor;
THYM	cis	rs1003719	0.680	rs2835619	chr21:38505380	C/T	cg01329690	chr21:38580129	DSCR9	-0.38	-5.21	-0.47	1.09e-6	Eye color traits;
THYM	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Body mass index;
THYM	cis	rs2637266	0.905	rs2130796	chr10:78329712	C/G	cg18941641	chr10:78392320	NA	0.69	5.5	0.49	3.16e-7	Pulmonary function;
THYM	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg18811423	chr2:55921094	PNPT1	0.68	5.81	0.51	8.25e-8	Metabolic syndrome;
THYM	cis	rs7901056	0.935	rs1889693	chr10:26718745	A/G	cg23318538	chr10:26883079	C10orf50	-0.37	-4.96	-0.45	3.12e-6	Lymphocyte counts;
THYM	cis	rs4595586	0.525	rs4441057	chr12:39420620	T/A	cg13010199	chr12:38710504	ALG10B	0.65	4.5	0.42	1.96e-5	Morning vs. evening chronotype;
THYM	cis	rs6754311	0.638	rs1011361	chr2:136553639	G/A	cg20242066	chr2:136595261	LCT	-0.57	-7.01	-0.58	3.39e-10	Mosquito bite size;
THYM	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs116095464	1.000	rs6555159	chr5:311562	G/A	cg22857025	chr5:266934	NA	-1.41	-5.27	-0.48	8.69e-7	Breast cancer;
THYM	cis	rs75920871	0.528	rs7484045	chr11:116946890	C/T	cg20608306	chr11:116969690	SIK3	-0.52	-5.78	-0.51	9.38e-8	Subjective well-being;
THYM	cis	rs6840360	0.667	rs2709829	chr4:152355390	C/T	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs17608059	0.679	rs9898056	chr17:13951966	C/G	cg27005118	chr17:13972210	COX10	-0.44	-4.5	-0.42	1.95e-5	Temperament;
THYM	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02018176	chr4:1364513	KIAA1530	-0.96	-9.59	-0.7	1.22e-15	Longevity;
THYM	cis	rs12496230	1.000	rs3899502	chr3:66856411	A/G	cg17646820	chr3:66848679	NA	-0.9	-6.01	-0.53	3.35e-8	Type 2 diabetes;
THYM	cis	rs887829	0.570	rs4261716	chr2:234593117	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.79	-6.64	-0.56	1.94e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg17426766	chr1:2046864	PRKCZ	-0.39	-4.61	-0.43	1.23e-5	Height;
THYM	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg26384229	chr12:38710491	ALG10B	0.98	7.51	0.61	3.24e-11	Morning vs. evening chronotype;
THYM	cis	rs28374715	0.532	rs3204853	chr15:41689166	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.21	-13.52	-0.81	7.22e-24	Ulcerative colitis;
THYM	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.42	0.49	4.44e-7	Height;
THYM	cis	rs901683	1.000	rs35902429	chr10:46024335	T/C	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs2976388	1.000	rs1045547	chr8:143763757	T/G	cg06565975	chr8:143823917	SLURP1	-0.45	-5.23	-0.47	9.95e-7	Urinary tract infection frequency;
THYM	cis	rs728616	0.867	rs12412257	chr10:81729603	C/T	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6665290	0.904	rs6684821	chr1:227190233	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.13	-15.82	-0.85	2.26e-28	Myeloid white cell count;
THYM	cis	rs3733585	0.577	rs28558552	chr4:9964913	G/A	cg02734326	chr4:10020555	SLC2A9	-0.65	-4.91	-0.45	3.72e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4631830	0.737	rs7071471	chr10:51503335	C/T	cg10326726	chr10:51549505	MSMB	0.53	5.33	0.48	6.53e-7	Prostate-specific antigen levels;
THYM	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg02478829	chr6:26598070	ABT1	-0.33	-4.49	-0.42	1.97e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.59	-7.39	-0.6	5.73e-11	Longevity;Endometriosis;
THYM	cis	rs2898681	0.770	rs10032190	chr4:53734940	C/A	cg00338735	chr4:53728038	RASL11B	0.52	4.78	0.44	6.4e-6	Optic nerve measurement (cup area);
THYM	cis	rs17270561	0.541	rs2009610	chr6:25967068	C/T	cg16482183	chr6:26056742	HIST1H1C	0.97	5.74	0.51	1.15e-7	Iron status biomarkers;
THYM	cis	rs986417	0.901	rs1061108	chr14:60978071	C/G	cg27398547	chr14:60952738	C14orf39	1.25	6.45	0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg11166453	chr1:247681781	NA	-0.64	-5.0	-0.46	2.61e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.69e-11	Aortic root size;
THYM	cis	rs34779708	0.931	rs10466072	chr10:35402756	C/T	cg03585969	chr10:35415529	CREM	0.67	5.01	0.46	2.51e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg26384229	chr12:38710491	ALG10B	1.02	8.24	0.65	9.34e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7975161	0.624	rs11111943	chr12:104632418	T/C	cg25273343	chr12:104657179	TXNRD1	-0.77	-4.57	-0.42	1.48e-5	Toenail selenium levels;
THYM	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg17775962	chr7:1200435	ZFAND2A	0.45	5.29	0.48	7.9e-7	Longevity;Endometriosis;
THYM	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg05802129	chr4:122689817	NA	-0.59	-4.63	-0.43	1.15e-5	Type 2 diabetes;
THYM	cis	rs9902453	1.000	rs7223786	chr17:28332107	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg24818145	chr4:99064322	C4orf37	0.71	5.75	0.51	1.09e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg10505658	chr17:80084571	CCDC57	0.62	4.73	0.44	7.82e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg13607699	chr17:42295918	UBTF	0.61	5.05	0.46	2.12e-6	Total body bone mineral density;
THYM	cis	rs28595532	0.841	rs115209862	chr4:119742225	G/A	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg14004847	chr7:1930337	MAD1L1	-0.64	-5.11	-0.46	1.67e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg03388043	chr17:80084554	CCDC57	-0.71	-5.9	-0.52	5.47e-8	Life satisfaction;
THYM	cis	rs2932538	0.961	rs4839257	chr1:113219388	A/T	cg22162597	chr1:113214053	CAPZA1	-0.63	-5.07	-0.46	1.94e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg08508325	chr11:3079039	CARS	-0.48	-6.16	-0.53	1.74e-8	Longevity;
THYM	cis	rs9443645	0.561	rs9341751	chr6:79479836	T/C	cg05283184	chr6:79620031	NA	-0.63	-4.95	-0.45	3.21e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.78	-6.34	-0.55	7.76e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg03433033	chr1:76189801	ACADM	0.77	10.21	0.72	6.01e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg00339695	chr16:24857497	SLC5A11	0.68	6.43	0.55	5.15e-9	Intelligence (multi-trait analysis);
THYM	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.09	-0.64	1.98e-12	Personality dimensions;
THYM	cis	rs6901250	0.788	rs591794	chr6:117089018	G/A	cg12892004	chr6:117198278	RFX6	0.71	6.89	0.58	6.07e-10	C-reactive protein levels;
THYM	cis	rs4919669	0.668	rs10883757	chr10:104400133	C/T	cg24934431	chr10:104597864	CYP17A1	0.53	4.55	0.42	1.58e-5	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
THYM	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg13010199	chr12:38710504	ALG10B	0.74	5.91	0.52	5.32e-8	Heart rate;
THYM	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg11871910	chr12:69753446	YEATS4	1.06	9.74	0.71	6.07e-16	Blood protein levels;
THYM	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.77	4.99	0.46	2.67e-6	Diabetic retinopathy;
THYM	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.94	10.54	0.73	1.14e-17	Prudent dietary pattern;
THYM	cis	rs62158800	0.568	rs78259088	chr2:108361571	T/A	cg09155462	chr2:109189131	NA	1.25	4.98	0.46	2.79e-6	Facial morphology (factor 22);
THYM	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg18709589	chr6:96969512	KIAA0776	-0.53	-4.48	-0.42	2.09e-5	Headache;
THYM	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.67	-4.87	-0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg11266682	chr4:10021025	SLC2A9	0.54	6.55	0.56	2.92e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1003719	0.688	rs2000416	chr21:38540089	T/A	cg01329690	chr21:38580129	DSCR9	-0.36	-5.01	-0.46	2.54e-6	Eye color traits;
THYM	cis	rs7772486	0.790	rs2247206	chr6:146216184	C/T	cg13319975	chr6:146136371	FBXO30	-0.76	-6.48	-0.55	4.09e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg06238570	chr21:40685208	BRWD1	-0.97	-9.29	-0.69	5.57e-15	Cognitive function;
THYM	cis	rs9913156	0.670	rs4470203	chr17:4567798	G/A	cg19197139	chr17:4613644	ARRB2	-0.77	-4.7	-0.43	8.71e-6	Lymphocyte counts;
THYM	cis	rs4631830	0.863	rs2611508	chr10:51518047	T/A	cg10326726	chr10:51549505	MSMB	-0.53	-5.27	-0.48	8.41e-7	Prostate-specific antigen levels;
THYM	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg04043695	chr12:129287642	SLC15A4	-0.6	-4.83	-0.44	5.27e-6	Systemic lupus erythematosus;
THYM	cis	rs55871839	0.708	rs10112089	chr8:59813429	C/T	cg07426533	chr8:59803705	TOX	-0.67	-6.88	-0.58	6.33e-10	Pneumonia;
THYM	cis	rs28595532	0.920	rs115994609	chr4:119777273	G/A	cg14228332	chr4:119757509	SEC24D	1.59	5.76	0.51	1.02e-7	Cannabis dependence symptom count;
THYM	cis	rs12579753	1.000	rs12830268	chr12:82233627	A/C	cg07988820	chr12:82153109	PPFIA2	-0.73	-4.53	-0.42	1.71e-5	Resting heart rate;
THYM	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg08885076	chr2:99613938	TSGA10	-0.48	-4.95	-0.45	3.25e-6	Fear of minor pain;
THYM	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg17173187	chr15:85201210	NMB	0.54	5.39	0.48	5.09e-7	Schizophrenia;
THYM	cis	rs995000	0.899	rs1748201	chr1:63045506	A/C	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs289828	0.868	rs3771888	chr2:152138789	A/G	cg05960677	chr2:152117363	RBM43	0.62	5.95	0.52	4.49e-8	Blood protein levels;
THYM	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg03806693	chr22:41940476	POLR3H	-1.22	-10.52	-0.73	1.3e-17	Vitiligo;
THYM	cis	rs7719624	1.000	rs1989972	chr5:135377802	A/C	cg15329133	chr5:135467951	SMAD5;SMAD5OS	0.55	4.76	0.44	6.96e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg05294307	chr14:35346193	BAZ1A	0.8	5.37	0.48	5.58e-7	Psoriasis;
THYM	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg18252515	chr7:66147081	NA	-1.42	-8.45	-0.66	3.31e-13	Diabetic kidney disease;
THYM	cis	rs7312774	0.618	rs4964513	chr12:107375758	T/C	cg16260113	chr12:107380972	MTERFD3	1.45	7.15	0.59	1.79e-10	Severe influenza A (H1N1) infection;
THYM	cis	rs9902453	1.000	rs9912741	chr17:28359511	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs75059851	0.756	rs11223650	chr11:133840647	A/G	cg14047540	chr11:133829660	NA	-1.1	-7.34	-0.6	7.1e-11	Schizophrenia;
THYM	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg20295408	chr7:1910781	MAD1L1	-0.66	-5.02	-0.46	2.45e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg27170947	chr2:26402098	FAM59B	-0.8	-6.37	-0.55	6.74e-9	Gut microbiome composition (summer);
THYM	cis	rs600806	0.821	rs3879447	chr1:109891403	C/T	cg02175308	chr1:109941060	SORT1	-0.59	-5.13	-0.47	1.51e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7677751	0.767	rs890205	chr4:55063373	C/A	cg17187183	chr4:55093834	PDGFRA	0.66	5.08	0.46	1.91e-6	Corneal astigmatism;
THYM	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs72827839	1.000	rs72827830	chr17:46397502	T/C	cg23391107	chr17:45924227	SP6	0.76	4.58	0.43	1.39e-5	Ease of getting up in the morning;
THYM	cis	rs4780355	0.776	rs9936459	chr16:11437779	C/T	cg00044050	chr16:11439710	C16orf75	-0.86	-6.01	-0.52	3.38e-8	Crohn's disease and psoriasis;
THYM	trans	rs877282	0.891	rs34383514	chr10:800181	T/C	cg22713356	chr15:30763199	NA	1.38	10.62	0.74	7.91e-18	Uric acid levels;
THYM	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26314531	chr2:26401878	FAM59B	-0.78	-5.13	-0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.58	-0.43	1.39e-5	Fear of minor pain;
THYM	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg08859206	chr1:53392774	SCP2	0.51	5.7	0.51	1.32e-7	Monocyte count;
THYM	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg13147721	chr7:65941812	NA	-1.1	-7.08	-0.59	2.45e-10	Diabetic kidney disease;
THYM	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg00631329	chr6:26305371	NA	-0.61	-7.35	-0.6	6.77e-11	Educational attainment;
THYM	cis	rs2219968	0.525	rs4570145	chr8:78876673	A/T	cg00738934	chr8:78996279	NA	0.61	4.93	0.45	3.5e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11989744	0.957	rs61099147	chr8:23573953	A/G	cg04349084	chr8:23602677	NA	0.5	5.21	0.47	1.09e-6	Waist-hip ratio;
THYM	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg08999081	chr20:33150536	PIGU	0.63	5.29	0.48	7.68e-7	Coronary artery disease;
THYM	cis	rs6754311	0.593	rs7608045	chr2:136413359	T/C	cg07169764	chr2:136633963	MCM6	0.7	5.67	0.5	1.55e-7	Mosquito bite size;
THYM	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg18252515	chr7:66147081	NA	-0.87	-6.7	-0.57	1.47e-9	Corneal structure;
THYM	cis	rs800586	0.500	rs2721957	chr8:116654887	G/A	cg04656070	chr8:116661063	TRPS1	-0.55	-6.57	-0.56	2.67e-9	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg25767906	chr1:53392781	SCP2	0.53	5.2	0.47	1.13e-6	Monocyte count;
THYM	cis	rs920590	0.684	rs59259846	chr8:19669468	C/G	cg01411142	chr8:19674711	INTS10	0.7	5.4	0.48	4.95e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs3780378	0.875	rs2031906	chr9:5087495	C/T	cg02405213	chr9:5042618	JAK2	-0.69	-6.46	-0.55	4.4e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	trans	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg25214090	chr10:38739885	LOC399744	0.92	7.7	0.62	1.26e-11	Corneal astigmatism;
THYM	cis	rs514406	0.893	rs6588446	chr1:53425260	G/A	cg22166914	chr1:53195759	ZYG11B	-0.78	-7.68	-0.62	1.38e-11	Monocyte count;
THYM	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg03929089	chr4:120376271	NA	-1.0	-7.14	-0.59	1.82e-10	Coronary artery disease;
THYM	cis	rs7586879	0.559	rs13387729	chr2:25076126	A/G	cg27107076	chr2:25050844	ADCY3	-0.31	-4.9	-0.45	3.91e-6	Body mass index;
THYM	cis	rs6674970	1.000	rs61819219	chr1:151084375	C/G	cg11822372	chr1:151115635	SEMA6C	0.72	4.93	0.45	3.53e-6	Childhood ear infection;
THYM	cis	rs4851266	0.898	rs12994592	chr2:100857984	T/C	cg14675211	chr2:100938903	LONRF2	0.67	5.59	0.5	2.15e-7	Educational attainment;
THYM	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg09904177	chr6:26538194	HMGN4	0.54	4.57	0.42	1.47e-5	Intelligence (multi-trait analysis);
THYM	cis	rs651907	0.817	rs654102	chr3:101608155	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.61	5.33	0.48	6.65e-7	Colorectal cancer;
THYM	cis	rs9906944	0.707	rs9899931	chr17:47108282	G/A	cg11673840	chr17:47092156	IGF2BP1	-0.54	-5.48	-0.49	3.55e-7	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg05084668	chr3:125655381	ALG1L	-0.74	-4.68	-0.43	9.36e-6	Blood pressure (smoking interaction);
THYM	cis	rs4986172	0.840	rs8067974	chr17:43232566	A/G	cg00677574	chr17:43221327	ACBD4	0.51	4.76	0.44	7.05e-6	Height;
THYM	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	4.89	0.45	4.04e-6	Prudent dietary pattern;
THYM	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg25072359	chr17:41440525	NA	0.64	4.48	0.42	2.05e-5	Menopause (age at onset);
THYM	cis	rs9486719	0.857	rs4265039	chr6:96878929	T/C	cg06623918	chr6:96969491	KIAA0776	0.84	5.42	0.49	4.57e-7	Migraine;Coronary artery disease;
THYM	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg13695892	chr22:41940480	POLR3H	0.83	6.73	0.57	1.26e-9	Vitiligo;
THYM	cis	rs17209837	0.646	rs4148818	chr7:87083738	T/C	cg04996195	chr7:87105398	ABCB4	0.63	4.79	0.44	6.03e-6	Gallbladder cancer;
THYM	cis	rs4919694	1.000	rs112809537	chr10:104670346	C/T	cg15744005	chr10:104629667	AS3MT	-0.85	-4.67	-0.43	9.96e-6	Arsenic metabolism;
THYM	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg14349672	chr11:133703707	NA	-0.5	-4.52	-0.42	1.76e-5	Childhood ear infection;
THYM	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg00012203	chr2:219082015	ARPC2	0.69	5.83	0.51	7.48e-8	Pyoderma gangrenosum in inflammatory bowel disease;
THYM	cis	rs7508	0.511	rs438818	chr8:17899561	A/G	cg01800426	chr8:17659068	MTUS1	-0.69	-4.87	-0.45	4.36e-6	Atrial fibrillation;
THYM	cis	rs2898681	0.618	rs116241740	chr4:53733523	A/G	cg00791764	chr4:53727839	RASL11B	0.65	6.4	0.55	5.74e-9	Optic nerve measurement (cup area);
THYM	cis	rs2456568	0.741	rs10831137	chr11:93636912	C/T	cg26875233	chr11:93583750	C11orf90	-0.53	-5.53	-0.49	2.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs3916	0.911	rs3999408	chr12:121167387	C/T	cg21892295	chr12:121157589	UNC119B	-0.5	-4.89	-0.45	4.08e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs57994353	0.897	rs11999532	chr9:139371405	G/C	cg14115884	chr9:139300582	SDCCAG3	0.68	4.7	0.43	8.9e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.68	-5.18	-0.47	1.24e-6	Lung cancer in ever smokers;
THYM	cis	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg00495681	chr13:53174319	NA	0.77	6.95	0.58	4.59e-10	Lewy body disease;
THYM	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.59	-11.2	-0.75	4.73e-19	Hemostatic factors and hematological phenotypes;
THYM	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg17294928	chr15:75287854	SCAMP5	-0.99	-9.18	-0.69	9.28e-15	Blood trace element (Zn levels);
THYM	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.13	9.25	0.69	6.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg26116260	chr4:7069785	GRPEL1	1.01	7.68	0.62	1.4e-11	Monocyte percentage of white cells;
THYM	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	13.94	0.82	1.08e-24	Height;
THYM	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg05791153	chr7:19748676	TWISTNB	-1.19	-6.73	-0.57	1.29e-9	Thyroid stimulating hormone;
THYM	cis	rs28595532	0.920	rs114683212	chr4:119760209	A/G	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs763014	0.898	rs4984894	chr16:623103	T/C	cg07343612	chr16:622815	PIGQ	-1.05	-10.74	-0.74	4.28e-18	Height;
THYM	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.79	0.51	9.18e-8	Rheumatoid arthritis;
THYM	cis	rs4072705	0.900	rs1931189	chr9:127560653	C/T	cg13476313	chr9:127244764	NR5A1	0.33	5.12	0.46	1.6e-6	Menarche (age at onset);
THYM	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg08132940	chr7:1081526	C7orf50	-1.16	-6.65	-0.56	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs6866614	0.605	rs5029422	chr5:131390614	G/C	cg00255919	chr5:131827918	IRF1	-0.43	-4.64	-0.43	1.11e-5	Perceived unattractiveness to mosquitoes;
THYM	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg11764359	chr7:65958608	NA	0.82	6.56	0.56	2.81e-9	Aortic root size;
THYM	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg18681998	chr4:17616180	MED28	0.88	8.09	0.64	1.94e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs8017423	0.967	rs11628812	chr14:90713720	G/T	cg04239629	chr14:90701769	NA	0.62	4.52	0.42	1.81e-5	Mortality in heart failure;
THYM	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22455342	chr2:225449267	CUL3	-0.94	-8.63	-0.66	1.36e-13	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs9790314	1.000	rs336577	chr3:161066294	C/T	cg03342759	chr3:160939853	NMD3	-0.75	-6.73	-0.57	1.28e-9	Morning vs. evening chronotype;
THYM	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg14675211	chr2:100938903	LONRF2	0.76	8.01	0.64	2.81e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7260598	0.642	rs67908565	chr19:24181381	G/A	cg15526094	chr19:24182596	NA	-0.66	-4.62	-0.43	1.18e-5	Response to taxane treatment (placlitaxel);
THYM	cis	rs2354432	0.607	rs55918563	chr1:146718973	G/C	cg25205988	chr1:146714368	CHD1L	-1.04	-5.54	-0.49	2.67e-7	Mitochondrial DNA levels;
THYM	cis	rs2075230	0.850	rs9908405	chr17:7467461	A/C	cg16696476	chr17:8191344	RANGRF;SLC25A35	0.29	4.54	0.42	1.66e-5	Hormone measurements;
THYM	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg15164180	chr2:241846931	NA	-0.33	-4.48	-0.42	2.06e-5	Urinary metabolites;
THYM	cis	rs6992820	0.967	rs13263466	chr8:56648474	T/C	cg06880721	chr8:56792545	LYN	-0.6	-4.68	-0.43	9.44e-6	Mean platelet volume;
THYM	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Body mass index;
THYM	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg15247329	chr7:2764246	NA	-0.7	-5.91	-0.52	5.43e-8	Height;
THYM	cis	rs9314614	0.789	rs2977795	chr8:6709805	G/A	cg27319216	chr8:6693540	XKR5	-0.6	-6.08	-0.53	2.48e-8	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg02493798	chr17:6899577	ALOX12	0.62	8.0	0.63	2.98e-12	Tonsillectomy;
THYM	cis	rs11585357	0.947	rs11585119	chr1:17605792	C/A	cg08277548	chr1:17600880	PADI3	-0.93	-6.22	-0.54	1.3e-8	Hair shape;
THYM	cis	rs8067545	0.586	rs2526463	chr17:20078297	G/A	cg13482628	chr17:19912719	NA	-0.56	-4.63	-0.43	1.17e-5	Schizophrenia;
THYM	cis	rs8067354	0.645	rs56236317	chr17:57822125	C/T	cg20151207	chr17:57696971	CLTC	-0.7	-4.67	-0.43	9.76e-6	Hemoglobin concentration;
THYM	cis	rs1050631	0.592	rs1010955	chr18:33710610	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.28	0.48	8.32e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs7000551	0.751	rs2443494	chr8:22372262	C/G	cg12081754	chr8:22256438	SLC39A14	0.63	5.71	0.51	1.27e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs3820068	0.608	rs10927836	chr1:16034368	G/C	cg24675056	chr1:15929824	NA	0.78	6.16	0.53	1.73e-8	Systolic blood pressure;
THYM	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs4589258	0.898	rs12575063	chr11:90418766	T/C	cg26138821	chr11:89956704	CHORDC1	0.75	6.36	0.55	6.94e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6782029	0.583	rs11128564	chr3:11679509	C/T	cg07643000	chr3:11666825	VGLL4	0.46	4.84	0.44	4.98e-6	Anorexia nervosa;
THYM	trans	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg06636001	chr8:8085503	FLJ10661	0.76	6.84	0.57	7.63e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs9790314	0.936	rs7629987	chr3:161002023	A/C	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg15744005	chr10:104629667	AS3MT	-0.83	-7.74	-0.62	1.08e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg10802521	chr3:52805072	NEK4	-0.8	-7.53	-0.61	2.92e-11	Bipolar disorder;
THYM	cis	rs7408868	0.908	rs62113793	chr19:15277336	G/A	cg14696996	chr19:15285081	NOTCH3	0.96	5.19	0.47	1.21e-6	Pulse pressure;
THYM	cis	rs36051895	0.623	rs10975031	chr9:5253153	G/T	cg02405213	chr9:5042618	JAK2	-0.93	-9.64	-0.7	9.49e-16	Pediatric autoimmune diseases;
THYM	cis	rs6163	0.588	rs10786706	chr10:104500659	C/T	cg08772003	chr10:104629869	AS3MT	-0.51	-4.53	-0.42	1.69e-5	Waist circumference;Hip circumference;
THYM	cis	rs2274459	1.000	rs2274459	chr6:33762242	G/A	cg06253072	chr6:33679850	C6orf125	0.52	4.67	0.43	1e-5	Obesity (extreme);
THYM	cis	rs35150201	0.529	rs7806221	chr7:135318779	T/C	cg23117316	chr7:135346802	PL-5283	-0.61	-6.49	-0.55	3.79e-9	Plateletcrit;Mean corpuscular hemoglobin;Mean platelet volume;
THYM	cis	rs12643440	0.538	rs6818238	chr4:17140193	C/T	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg01386294	chr6:25732093	NA	0.89	4.51	0.42	1.84e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11574514	0.744	rs117539386	chr16:67916047	C/G	cg09738193	chr16:67926317	PSKH1	-0.91	-4.66	-0.43	1.01e-5	Crohn's disease;
THYM	cis	rs9807841	0.670	rs10405617	chr19:10752968	C/T	cg16900796	chr19:10755136	SLC44A2	-0.32	-4.87	-0.45	4.5e-6	Inflammatory skin disease;
THYM	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg14664628	chr15:75095509	CSK	-0.88	-7.14	-0.59	1.85e-10	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg12179176	chr11:130786555	SNX19	0.8	6.83	0.57	8.02e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs924712	0.677	rs2816812	chr6:54749496	C/T	cg04690482	chr6:54711388	FAM83B	0.44	5.09	0.46	1.79e-6	Breast cancer;
THYM	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs10781543	0.845	rs10781542	chr9:139327439	A/G	cg14115884	chr9:139300582	SDCCAG3	0.69	6.28	0.54	1.02e-8	Monocyte percentage of white cells;
THYM	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg10224037	chr5:178157518	ZNF354A	0.98	7.61	0.62	1.99e-11	Neutrophil percentage of white cells;
THYM	cis	rs12935418	0.616	rs8045512	chr16:80986307	A/G	cg16651780	chr16:81037892	C16orf61	0.91	5.33	0.48	6.72e-7	Mean corpuscular volume;
THYM	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg12560992	chr17:57184187	TRIM37	0.78	6.62	0.56	2.08e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9905759	0.622	rs4338847	chr17:7929777	A/C	cg14438174	chr17:7137923	DVL2	0.57	4.49	0.42	2.01e-5	Childhood ear infection;
THYM	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg18876405	chr7:65276391	NA	0.54	4.86	0.45	4.66e-6	Calcium levels;
THYM	cis	rs10484885	0.824	rs72919982	chr6:90532600	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.87	-7.73	-0.62	1.13e-11	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs989128	0.600	rs9913430	chr17:48628470	A/T	cg16068336	chr17:48637367	CACNA1G	-0.59	-4.54	-0.42	1.65e-5	Type 2 diabetes;
THYM	cis	rs7823896	0.929	rs73311400	chr8:110151487	C/T	cg18044723	chr8:109261011	EIF3E	-0.89	-4.68	-0.43	9.42e-6	Myopia (pathological);
THYM	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg17328964	chr8:145687451	CYHR1	0.73	6.59	0.56	2.42e-9	Age at first birth;
THYM	cis	rs2692947	0.740	rs60452119	chr2:96420050	T/C	cg22654517	chr2:96458247	NA	0.59	4.65	0.43	1.05e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs4660306	0.961	rs945179	chr1:45992460	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.65	5.25	0.47	9.39e-7	Homocysteine levels;
THYM	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	5.63	0.5	1.82e-7	Schizophrenia;
THYM	cis	rs2213920	0.516	rs2188042	chr9:118159740	C/T	cg13918206	chr9:118159781	DEC1	-1.03	-6.33	-0.54	7.94e-9	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg04267008	chr7:1944627	MAD1L1	-0.62	-5.46	-0.49	3.81e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs4589258	0.966	rs10765386	chr11:90485981	T/C	cg26138821	chr11:89956704	CHORDC1	-0.68	-5.64	-0.5	1.73e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6815814	0.898	rs6848423	chr4:38887933	C/T	cg06935464	chr4:38784597	TLR10	0.72	5.03	0.46	2.35e-6	Breast cancer;
THYM	cis	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg24375607	chr4:120327624	NA	0.59	4.68	0.43	9.43e-6	Corneal astigmatism;
THYM	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg13695892	chr22:41940480	POLR3H	-0.97	-7.51	-0.61	3.25e-11	Vitiligo;
THYM	cis	rs7523273	0.606	rs1970530	chr1:207924066	G/A	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	cis	rs11048434	0.626	rs1805736	chr12:9084931	A/G	cg13575925	chr12:9217583	LOC144571	-0.5	-4.75	-0.44	7.34e-6	Sjögren's syndrome;
THYM	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg11905131	chr22:24372483	LOC391322	-0.96	-12.11	-0.78	5.74e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10089	0.953	rs1985268	chr5:127375931	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.97	6.65	0.56	1.82e-9	Ileal carcinoids;
THYM	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	7.92	0.63	4.42e-12	Smoking behavior;
THYM	cis	rs12216545	0.765	rs6962518	chr7:150245938	G/C	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs78773383	0.505	rs6823497	chr4:39385821	C/A	cg16714752	chr4:39368184	RFC1	-0.53	-5.06	-0.46	2.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10504073	0.647	rs12546839	chr8:50009020	C/T	cg00325661	chr8:49890786	NA	0.93	8.63	0.66	1.37e-13	Blood metabolite ratios;
THYM	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg14972814	chr11:95582409	MTMR2	-0.61	-5.15	-0.47	1.42e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg24678163	chr13:52769951	THSD1P	0.49	4.58	0.43	1.38e-5	Lewy body disease;
THYM	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13082711	0.522	rs864241	chr3:27332674	T/C	cg02860705	chr3:27208620	NA	0.65	5.09	0.46	1.79e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs2408955	0.522	rs973398	chr12:48491048	A/G	cg21466736	chr12:48725269	NA	0.49	4.85	0.45	4.81e-6	Glycated hemoglobin levels;
THYM	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg18230493	chr5:56204884	C5orf35	0.64	5.14	0.47	1.44e-6	Type 2 diabetes;
THYM	cis	rs931127	0.532	rs4930304	chr11:65463447	T/G	cg27068330	chr11:65405492	SIPA1	0.74	6.0	0.52	3.56e-8	Systemic lupus erythematosus;
THYM	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs10089	1.000	rs10064357	chr5:127417272	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.02	7.11	0.59	2.11e-10	Ileal carcinoids;
THYM	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg06917634	chr15:78832804	PSMA4	-0.91	-7.9	-0.63	4.85e-12	Sudden cardiac arrest;
THYM	cis	rs13185784	0.703	rs1127580	chr5:179661528	C/T	cg23248424	chr5:179741104	GFPT2	0.69	4.81	0.44	5.62e-6	TRAIL levels;
THYM	cis	rs3892630	0.588	rs1976501	chr19:33208155	C/T	cg22980127	chr19:33182716	NUDT19	1.13	10.13	0.72	8.77e-17	Red blood cell traits;
THYM	cis	rs8030485	0.571	rs7174337	chr15:79441373	C/A	cg17916960	chr15:79447300	NA	0.54	5.4	0.48	5e-7	Left ventricle wall thickness;
THYM	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.71	5.41	0.49	4.78e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg26384229	chr12:38710491	ALG10B	1.05	10.43	0.73	1.96e-17	Heart rate;
THYM	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg05872129	chr22:39784769	NA	-1.04	-10.98	-0.75	1.35e-18	Intelligence (multi-trait analysis);
THYM	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg20203395	chr5:56204925	C5orf35	-0.67	-4.58	-0.42	1.44e-5	Initial pursuit acceleration;
THYM	cis	rs11096990	0.613	rs6829660	chr4:39282563	A/C	cg24403649	chr4:39172243	NA	0.67	5.84	0.51	7.33e-8	Cognitive function;
THYM	cis	rs7829975	0.628	rs1109618	chr8:8571364	A/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-4.95	-0.45	3.26e-6	Mood instability;
THYM	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg23018236	chr17:30244563	NA	-0.6	-4.45	-0.42	2.3e-5	Hip circumference adjusted for BMI;
THYM	cis	rs42648	0.935	rs42635	chr7:89966198	T/A	cg25739043	chr7:89950458	NA	-0.55	-4.64	-0.43	1.12e-5	Homocysteine levels;
THYM	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-10.16	-0.72	7.64e-17	Primary sclerosing cholangitis;
THYM	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg18357526	chr6:26021779	HIST1H4A	0.75	5.87	0.52	6.31e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7178572	0.633	rs4886875	chr15:77838419	C/T	cg22256960	chr15:77711686	NA	0.77	5.95	0.52	4.54e-8	Type 2 diabetes;
THYM	trans	rs4745216	0.748	rs9792653	chr9:75786053	C/T	cg16489975	chr1:154733435	KCNN3	-1.17	-6.97	-0.58	4.16e-10	Blood protein levels;
THYM	cis	rs7584330	0.554	rs7558685	chr2:238434943	A/G	cg08992911	chr2:238395768	MLPH	0.89	5.81	0.51	8.24e-8	Prostate cancer;
THYM	trans	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg18335740	chr13:41363409	SLC25A15	0.82	8.34	0.65	5.65e-13	Lewy body disease;
THYM	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg22535103	chr8:58192502	C8orf71	-0.93	-4.66	-0.43	1.02e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg24060327	chr5:131705240	SLC22A5	-0.63	-4.73	-0.44	7.82e-6	Blood metabolite levels;
THYM	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg05802129	chr4:122689817	NA	-0.64	-5.24	-0.47	9.82e-7	Type 2 diabetes;
THYM	cis	rs11969893	0.737	rs1358758	chr6:101411891	T/C	cg12253828	chr6:101329408	ASCC3	0.84	4.69	0.43	9.18e-6	Economic and political preferences (immigration/crime);
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg04113056	chr14:64010798	PPP2R5E	0.91	6.99	0.58	3.82e-10	Energy expenditure (24h);
THYM	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg11752832	chr7:134001865	SLC35B4	-0.68	-4.63	-0.43	1.14e-5	Mean platelet volume;
THYM	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.66	5.8	0.51	8.62e-8	Hemoglobin concentration;
THYM	cis	rs3947	1.000	rs1736083	chr8:11703497	G/T	cg26752888	chr8:11627280	NEIL2	-0.7	-4.57	-0.42	1.49e-5	Blood protein levels;
THYM	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs2721195	0.845	rs4244611	chr8:145739924	G/A	cg26752003	chr8:145688521	CYHR1	-0.77	-6.43	-0.55	5.05e-9	Age at first birth;
THYM	cis	rs807669	0.505	rs28651174	chr22:19236489	C/T	cg02655711	chr22:19163373	SLC25A1	0.57	6.08	0.53	2.5e-8	Metabolite levels;
THYM	cis	rs1829883	1.000	rs2461989	chr5:98793999	T/A	cg08333243	chr5:99726346	NA	-0.57	-5.55	-0.49	2.57e-7	Hemostatic factors and hematological phenotypes;
THYM	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13012494	chr21:47604986	C21orf56	0.66	4.55	0.42	1.59e-5	Testicular germ cell tumor;
THYM	cis	rs4930776	0.897	rs371607	chr12:5762402	C/T	cg02086166	chr12:5775618	ANO2	0.61	5.91	0.52	5.26e-8	Plasma clusterin levels;
THYM	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11644478	chr21:40555479	PSMG1	1.02	8.35	0.65	5.48e-13	Cognitive function;
THYM	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg05738196	chr6:26577821	NA	-0.66	-5.16	-0.47	1.33e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs67981189	0.574	rs2526884	chr14:71367967	G/A	cg15910301	chr14:71632612	NA	-0.53	-4.62	-0.43	1.18e-5	Schizophrenia;
THYM	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg16405210	chr4:1374714	KIAA1530	0.84	7.53	0.61	2.85e-11	Obesity-related traits;
THYM	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs1691799	0.867	rs1168344	chr12:66758213	G/A	cg16791601	chr12:66731901	HELB	-0.72	-6.82	-0.57	8.35e-10	White blood cell count (basophil);
THYM	cis	rs10504073	0.669	rs341809	chr8:50042557	C/T	cg00325661	chr8:49890786	NA	0.79	6.96	0.58	4.43e-10	Blood metabolite ratios;
THYM	cis	rs2147904	0.704	rs783628	chr1:42361102	G/A	cg16685388	chr1:42384056	HIVEP3	0.58	4.91	0.45	3.81e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
THYM	cis	rs8030485	0.730	rs57488047	chr15:79403002	T/C	cg17916960	chr15:79447300	NA	0.55	5.8	0.51	8.64e-8	Left ventricle wall thickness;
THYM	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg18252515	chr7:66147081	NA	0.7	5.48	0.49	3.47e-7	Aortic root size;
THYM	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg25072359	chr17:41440525	NA	0.65	4.54	0.42	1.64e-5	Menopause (age at onset);
THYM	cis	rs7260598	0.642	rs10423626	chr19:24161031	A/T	cg15526094	chr19:24182596	NA	-0.66	-4.72	-0.44	8.28e-6	Response to taxane treatment (placlitaxel);
THYM	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	5.02	0.46	2.38e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg25517755	chr10:38738941	LOC399744	-0.76	-7.6	-0.61	2.06e-11	Corneal astigmatism;
THYM	cis	rs3796352	0.527	rs11714793	chr3:52924930	A/G	cg04865290	chr3:52927548	TMEM110	-0.85	-5.5	-0.49	3.18e-7	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs7072216	0.727	rs6584199	chr10:100169983	A/G	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs600550	0.588	rs61900468	chr11:60079555	C/T	cg05040360	chr11:60102449	MS4A6E	-0.49	-4.55	-0.42	1.58e-5	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.32e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs10743315	0.778	rs7399032	chr12:19371546	T/C	cg02471346	chr12:19282374	PLEKHA5	-0.79	-5.09	-0.46	1.8e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs6510489	1.000	rs10421540	chr19:35971227	T/C	cg15078284	chr19:36004994	DMKN	0.44	5.24	0.47	9.6e-7	Bipolar disorder;
THYM	cis	rs7000551	0.689	rs6993341	chr8:22310933	T/C	cg12081754	chr8:22256438	SLC39A14	0.63	5.32	0.48	6.79e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg19748678	chr4:122722346	EXOSC9	0.73	5.15	0.47	1.42e-6	Type 2 diabetes;
THYM	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg10505658	chr17:80084571	CCDC57	0.7	8.07	0.64	2.18e-12	Life satisfaction;
THYM	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg17911788	chr17:44343683	NA	-0.6	-6.01	-0.52	3.4e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs35883536	1.000	rs1577504	chr1:101123913	A/T	cg06223162	chr1:101003688	GPR88	0.66	4.9	0.45	3.94e-6	Monocyte count;
THYM	cis	rs11225247	0.772	rs11501343	chr11:102227214	A/C	cg06323957	chr11:102217781	BIRC2	1.02	4.74	0.44	7.52e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs6920965	0.509	rs654213	chr6:126149127	C/T	cg05901451	chr6:126070800	HEY2	0.59	4.94	0.45	3.39e-6	High light scatter reticulocyte count;
THYM	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg00757033	chr12:89920650	WDR51B	0.75	10.23	0.72	5.28e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs1524976	0.698	rs9864728	chr3:65486793	A/C	cg16238336	chr3:65465873	MAGI1	1.05	6.05	0.53	2.81e-8	PR interval;
THYM	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg25554036	chr4:6271136	WFS1	0.56	5.29	0.48	7.94e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs7020830	0.830	rs308499	chr9:37348059	C/G	cg14294708	chr9:37120828	ZCCHC7	1.14	13.46	0.81	9.93e-24	Schizophrenia;
THYM	cis	rs6964587	0.597	rs975707	chr7:91874527	C/G	cg03714773	chr7:91764589	CYP51A1	0.44	4.99	0.46	2.68e-6	Breast cancer;
THYM	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg18811423	chr2:55921094	PNPT1	0.72	6.56	0.56	2.79e-9	Metabolic syndrome;
THYM	cis	rs4595586	0.545	rs969469	chr12:39366775	A/C	cg26384229	chr12:38710491	ALG10B	0.7	5.32	0.48	6.96e-7	Morning vs. evening chronotype;
THYM	cis	rs58722170	0.659	rs72659423	chr1:38083472	C/T	cg17933807	chr1:38061675	GNL2	-0.9	-6.91	-0.58	5.62e-10	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs7100689	0.646	rs7903701	chr10:82129268	T/C	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs4363385	0.818	rs558363	chr1:153010431	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs7567389	0.719	rs6744237	chr2:128004045	C/G	cg06038358	chr2:128176007	PROC	-0.47	-4.45	-0.42	2.33e-5	Self-rated health;
THYM	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.97	-5.47	-0.49	3.64e-7	Red cell distribution width;
THYM	cis	rs2845885	0.744	rs56271783	chr11:64004723	G/C	cg15432711	chr11:63952213	STIP1	0.65	4.68	0.43	9.51e-6	Body mass index;
THYM	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg06191203	chr2:152266755	RIF1	-0.65	-4.7	-0.43	8.67e-6	Lung cancer;
THYM	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg22974920	chr21:40686053	BRWD1	-0.62	-4.95	-0.45	3.22e-6	Cognitive function;
THYM	cis	rs6495367	1.000	rs13380104	chr15:79378821	C/T	cg17916960	chr15:79447300	NA	0.55	6.01	0.52	3.45e-8	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg05896524	chr21:47604654	C21orf56	-0.74	-5.2	-0.47	1.16e-6	Testicular germ cell tumor;
THYM	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs901683	0.867	rs71496625	chr10:46086649	C/T	cg18240400	chr10:46168597	ANUBL1	0.73	4.73	0.44	7.89e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs4731207	0.596	rs922712	chr7:124607050	C/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs7705502	1.000	rs56184817	chr5:173367586	T/C	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg16325326	chr1:53192061	ZYG11B	-0.93	-10.1	-0.72	9.86e-17	Monocyte count;
THYM	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg07022442	chr13:21864356	NA	-0.73	-4.93	-0.45	3.5e-6	White matter hyperintensity burden;
THYM	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg01341218	chr17:43662625	NA	1.15	9.87	0.71	3.19e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	trans	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg10856724	chr12:34555212	NA	-0.91	-8.12	-0.64	1.64e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs854765	0.624	rs9891957	chr17:17744439	G/A	cg16928487	chr17:17741425	SREBF1	0.53	4.97	0.45	3.01e-6	Total body bone mineral density;
THYM	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg09455208	chr3:40491958	NA	0.48	5.12	0.46	1.61e-6	Renal cell carcinoma;
THYM	cis	rs6519955	1.000	rs7511036	chr22:46438873	C/G	cg05468064	chr22:46423449	NA	0.43	5.48	0.49	3.49e-7	Dupuytren's disease;
THYM	cis	rs960902	0.764	rs7582204	chr2:37729801	G/T	cg25341268	chr2:37734390	NA	-0.57	-4.61	-0.43	1.24e-5	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.91	0.71	2.58e-16	Colorectal cancer;
THYM	cis	rs490234	0.841	rs2790035	chr9:128439923	C/T	cg14078157	chr9:128172775	NA	0.62	4.9	0.45	4.01e-6	Mean arterial pressure;
THYM	cis	rs1512268	0.526	rs73216756	chr8:23494194	C/T	cg20272884	chr8:23712762	STC1	-0.47	-4.69	-0.43	9.09e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11650494	0.831	rs73324348	chr17:47455752	G/A	cg08112188	chr17:47440006	ZNF652	1.01	4.53	0.42	1.69e-5	Prostate cancer;
THYM	cis	rs7512552	0.525	rs2298161	chr1:150237624	A/G	cg15654264	chr1:150340011	RPRD2	0.41	4.86	0.45	4.63e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2280018	0.609	rs2941253	chr16:15173746	G/A	cg27102117	chr16:15229624	NA	0.63	4.86	0.45	4.56e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
THYM	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg06481639	chr22:41940642	POLR3H	-0.71	-5.13	-0.47	1.51e-6	Neuroticism;
THYM	cis	rs6980334	0.911	rs10954602	chr7:137774930	A/G	cg22979093	chr7:137028410	PTN	0.57	4.52	0.42	1.77e-5	Blood metabolite ratios;
THYM	trans	rs10962692	0.608	rs62541879	chr9:16861508	A/G	cg03221025	chr16:88955224	CBFA2T3	0.75	7.2	0.59	1.37e-10	Ovarian cancer in BRCA2 mutation carriers;Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;
THYM	cis	rs892961	1.000	rs2164449	chr17:75401190	G/A	cg11351908	chr17:75402473	SEPT9	0.56	5.6	0.5	2.08e-7	Airflow obstruction;
THYM	cis	rs73735248	0.852	rs2208881	chr6:21819416	T/A	cg17770034	chr6:22249139	NA	-0.74	-4.51	-0.42	1.88e-5	Plateletcrit;
THYM	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg18252515	chr7:66147081	NA	-0.63	-4.69	-0.43	8.99e-6	Aortic root size;
THYM	cis	rs7078219	0.524	rs6584277	chr10:101278055	A/G	cg04972745	chr10:101287846	NA	-0.52	-4.8	-0.44	5.92e-6	Dental caries;
THYM	cis	rs4750440	0.642	rs7921741	chr10:14030776	G/A	cg27542038	chr10:14027202	FRMD4A	-0.5	-4.45	-0.42	2.36e-5	Adiponectin levels;
THYM	cis	rs7580658	0.637	rs3902960	chr2:127988242	G/C	cg09152259	chr2:128156114	NA	-0.37	-4.77	-0.44	6.68e-6	Protein C levels;
THYM	cis	rs6502050	0.769	rs66670693	chr17:80181799	G/A	cg21773646	chr17:80085082	CCDC57	-0.37	-5.31	-0.48	7.27e-7	Life satisfaction;
THYM	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.73	0.57	1.29e-9	Tonsillectomy;
THYM	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.77	-5.49	-0.49	3.37e-7	Response to bleomycin (chromatid breaks);
THYM	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1018836	0.631	rs2205158	chr8:91472515	C/T	cg16814680	chr8:91681699	NA	-0.69	-5.58	-0.5	2.3e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg27068330	chr11:65405492	SIPA1	0.84	8.34	0.65	5.78e-13	Acne (severe);
THYM	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg11812906	chr14:75593930	NEK9	-0.87	-8.2	-0.64	1.16e-12	Height;
THYM	cis	rs7043114	0.525	rs8067	chr9:95218829	G/T	cg14631576	chr9:95140430	CENPP	-0.82	-8.14	-0.64	1.56e-12	Height;
THYM	cis	rs7220711	1.000	rs9896582	chr17:41787209	G/C	cg26893861	chr17:41843967	DUSP3	0.65	5.63	0.5	1.83e-7	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg19862616	chr7:65841803	NCRNA00174	1.11	13.28	0.81	2.28e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg04414720	chr1:150670196	GOLPH3L	0.6	4.62	0.43	1.19e-5	Tonsillectomy;
THYM	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg12863693	chr15:85201151	NMB	0.54	4.67	0.43	9.93e-6	Schizophrenia;
THYM	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs912057	0.671	rs1294434	chr6:6745377	G/A	cg13809441	chr6:6737631	NA	0.44	5.44	0.49	4.13e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs79387448	0.638	rs78123896	chr2:103075417	T/C	cg09003973	chr2:102972529	NA	1.24	7.3	0.6	8.69e-11	Gut microbiota (bacterial taxa);
THYM	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	trans	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg25214090	chr10:38739885	LOC399744	0.85	7.16	0.59	1.7e-10	Corneal astigmatism;
THYM	cis	rs7084402	0.967	rs1649091	chr10:60289440	T/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs7115242	0.669	rs1241658	chr11:116819617	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.86	4.7	0.43	8.89e-6	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
THYM	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg27532560	chr4:187881888	NA	-0.96	-11.4	-0.76	1.72e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg00012203	chr2:219082015	ARPC2	-0.64	-5.28	-0.48	8.18e-7	Colorectal cancer;
THYM	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.22e-7	Corneal astigmatism;
THYM	cis	rs36051895	0.623	rs10975023	chr9:5239549	A/G	cg02405213	chr9:5042618	JAK2	0.89	8.99	0.68	2.33e-14	Pediatric autoimmune diseases;
THYM	cis	rs67981189	0.865	rs2810071	chr14:71387648	A/G	cg15910301	chr14:71632612	NA	-0.51	-4.68	-0.43	9.44e-6	Schizophrenia;
THYM	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg13147721	chr7:65941812	NA	0.73	4.58	0.43	1.42e-5	Diabetic kidney disease;
THYM	cis	rs2970992	0.764	rs13024200	chr2:101329338	T/G	cg01042948	chr2:101319752	NA	0.6	5.89	0.52	5.76e-8	Educational attainment;
THYM	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg13114125	chr14:105738426	BRF1	-0.72	-5.6	-0.5	2.07e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1823778	0.609	rs1369290	chr18:67691520	A/C	cg13164537	chr18:67624071	CD226	1.15	4.8	0.44	5.83e-6	Mean platelet volume;
THYM	trans	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg10856724	chr12:34555212	NA	-0.94	-8.13	-0.64	1.61e-12	Bladder cancer;
THYM	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg18876405	chr7:65276391	NA	-0.57	-4.76	-0.44	7e-6	Aortic root size;
THYM	cis	rs12611088	0.571	rs2305375	chr19:44013260	C/T	cg18042043	chr19:44147545	NA	-0.4	-4.72	-0.44	8.13e-6	Plasma amyloid beta peptide concentrations (ABx-42);
THYM	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg20290983	chr6:43655470	MRPS18A	1.44	16.17	0.86	4.93e-29	IgG glycosylation;
THYM	cis	rs17666538	0.818	rs62486207	chr8:588932	G/T	cg00450029	chr8:599525	NA	-0.93	-4.53	-0.42	1.72e-5	IgG glycosylation;
THYM	cis	rs988913	1.000	rs988913	chr6:54756308	C/T	cg18532076	chr6:54711417	FAM83B	0.5	4.83	0.44	5.14e-6	Menarche (age at onset);
THYM	cis	rs7113850	0.541	rs4536215	chr11:24245374	C/A	ch.11.24196551F	chr11:24239977	NA	1.01	5.31	0.48	7.32e-7	Bone fracture in osteoporosis;
THYM	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg24812749	chr6:127587940	RNF146	0.99	8.06	0.64	2.3e-12	Breast cancer;
THYM	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg25838465	chr1:92012736	NA	-0.9	-8.35	-0.65	5.39e-13	Breast cancer;
THYM	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg23583168	chr7:148888333	NA	-1.03	-13.7	-0.81	3.25e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.36	5.21	0.47	1.1e-6	Obesity-related traits;
THYM	cis	rs2228479	0.619	rs78001663	chr16:89896331	C/A	cg06558623	chr16:89946397	TCF25	1.22	5.31	0.48	7.11e-7	Skin colour saturation;
THYM	cis	rs6840360	0.550	rs7683134	chr4:152503362	A/C	cg22705602	chr4:152727874	NA	-0.77	-8.05	-0.64	2.4e-12	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg18252515	chr7:66147081	NA	-0.62	-4.55	-0.42	1.59e-5	Aortic root size;
THYM	cis	rs672413	0.620	rs663646	chr5:78285778	G/A	cg18828365	chr5:78281819	ARSB	-0.55	-5.03	-0.46	2.35e-6	Blood and toenail selenium levels;Blood protein levels;
THYM	cis	rs79387448	0.745	rs75644281	chr2:103151316	A/T	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg16680214	chr1:154839983	KCNN3	0.55	6.93	0.58	5.06e-10	Prostate cancer;
THYM	cis	rs67460515	0.567	rs34691229	chr3:160876897	G/T	cg03342759	chr3:160939853	NMD3	-0.65	-4.86	-0.45	4.71e-6	Parkinson's disease;
THYM	cis	rs7177699	0.557	rs62011002	chr15:79120578	C/T	cg00540400	chr15:79124168	NA	0.63	6.89	0.58	6.04e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.62	-7.16	-0.59	1.69e-10	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg20887711	chr4:1340912	KIAA1530	0.57	4.58	0.43	1.42e-5	Obesity-related traits;
THYM	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg22875332	chr1:76189707	ACADM	0.85	10.92	0.75	1.83e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2637266	0.783	rs2395434	chr10:78476161	T/C	cg18941641	chr10:78392320	NA	0.71	5.95	0.52	4.42e-8	Pulmonary function;
THYM	cis	rs763014	0.898	rs4984669	chr16:624713	C/T	cg00908189	chr16:619842	PIGQ	1.02	9.27	0.69	6.03e-15	Height;
THYM	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2455799	0.533	rs924754	chr3:15756215	A/T	cg16303742	chr3:15540471	COLQ	-0.54	-5.87	-0.52	6.25e-8	Mean platelet volume;
THYM	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg06219351	chr7:158114137	PTPRN2	-0.77	-8.01	-0.63	2.9e-12	Calcium levels;
THYM	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs7772486	0.790	rs6926076	chr6:146232804	C/T	cg23711669	chr6:146136114	FBXO30	-0.93	-9.39	-0.69	3.39e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9486719	0.857	rs1157316	chr6:96869710	G/A	cg06623918	chr6:96969491	KIAA0776	0.77	4.67	0.43	9.75e-6	Migraine;Coronary artery disease;
THYM	cis	rs925255	0.901	rs906805	chr2:28604879	A/G	cg01273330	chr2:28605224	NA	-0.89	-9.34	-0.69	4.26e-15	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7592578	0.508	rs10931451	chr2:191270888	G/A	cg10560079	chr2:191398806	TMEM194B	-0.77	-5.88	-0.52	6.05e-8	Diastolic blood pressure;
THYM	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg27170947	chr2:26402098	FAM59B	-0.8	-6.37	-0.55	6.74e-9	Gut microbiome composition (summer);
THYM	trans	rs8073060	0.586	rs225291	chr17:33927126	A/G	cg19694781	chr19:47549865	TMEM160	-0.84	-7.32	-0.6	7.85e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7762018	0.607	rs75521584	chr6:170051595	T/C	cg19338460	chr6:170058176	WDR27	-0.99	-5.79	-0.51	9.19e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs3741151	1.000	rs61037777	chr11:73046663	A/G	cg12959048	chr11:73096162	RELT	-0.46	-4.81	-0.44	5.69e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg11764359	chr7:65958608	NA	0.78	6.29	0.54	9.72e-9	Aortic root size;
THYM	trans	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg25214090	chr10:38739885	LOC399744	0.94	7.98	0.63	3.31e-12	Corneal astigmatism;
THYM	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg20242066	chr2:136595261	LCT	0.6	6.99	0.58	3.7e-10	Mosquito bite size;
THYM	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	5.72	0.51	1.25e-7	Blood metabolite levels;
THYM	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.84	-7.36	-0.6	6.43e-11	Platelet distribution width;
THYM	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.63	-5.42	-0.49	4.54e-7	Bipolar disorder;
THYM	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg23851026	chr2:136556271	LCT	0.58	5.95	0.52	4.37e-8	Mosquito bite size;
THYM	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg24578937	chr1:2090814	PRKCZ	0.78	7.9	0.63	5e-12	Height;
THYM	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg23711669	chr6:146136114	FBXO30	-0.87	-8.4	-0.65	4.2e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs863345	0.604	rs6670343	chr1:158497258	A/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg21028142	chr17:79581711	NPLOC4	-0.64	-6.74	-0.57	1.23e-9	Eye color traits;
THYM	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg02038168	chr22:39784481	NA	0.69	5.36	0.48	5.85e-7	Intelligence (multi-trait analysis);
THYM	cis	rs12216545	0.765	rs7801447	chr7:150227281	C/T	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg10047753	chr17:41438598	NA	0.91	5.91	0.52	5.4e-8	Menopause (age at onset);
THYM	cis	rs4654899	0.802	rs17449966	chr1:21203996	A/G	cg01072550	chr1:21505969	NA	-0.69	-5.99	-0.52	3.78e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg00786635	chr1:25594202	NA	-0.92	-7.19	-0.59	1.46e-10	Erythrocyte sedimentation rate;
THYM	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg20891283	chr12:69753455	YEATS4	1.09	12.05	0.78	7.75e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7084402	0.935	rs1593675	chr10:60291694	G/A	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs6138458	0.961	rs11700073	chr20:24975215	C/G	cg26195577	chr20:24973756	C20orf3	1.09	10.72	0.74	4.84e-18	Blood protein levels;
THYM	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	5.78	0.51	9.49e-8	Height;
THYM	cis	rs7084402	0.967	rs1649058	chr10:60317087	G/A	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs34638657	0.833	rs7200628	chr16:82200747	C/T	cg19807685	chr16:82068980	HSD17B2	-0.59	-5.08	-0.46	1.91e-6	Lung adenocarcinoma;
THYM	cis	rs2242116	0.592	rs6442039	chr3:46960797	C/G	cg27129171	chr3:47204927	SETD2	0.75	5.41	0.49	4.75e-7	Birth weight;
THYM	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg02524346	chr8:600233	NA	1.01	5.05	0.46	2.12e-6	IgG glycosylation;
THYM	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg13266496	chr6:110720918	DDO	0.47	5.03	0.46	2.35e-6	Platelet distribution width;
THYM	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs600806	0.815	rs3768495	chr1:109935325	C/T	cg02175308	chr1:109941060	SORT1	-0.6	-5.3	-0.48	7.58e-7	Intelligence (multi-trait analysis);
THYM	trans	rs877282	0.898	rs11253348	chr10:765852	C/T	cg22713356	chr15:30763199	NA	1.36	9.83	0.71	3.89e-16	Uric acid levels;
THYM	cis	rs7084402	0.967	rs1658486	chr10:60288081	A/T	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg22535103	chr8:58192502	C8orf71	-0.88	-4.93	-0.45	3.51e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.83	0.82	1.75e-24	Height;
THYM	cis	rs11252926	0.510	rs4881371	chr10:554514	G/A	cg14018140	chr10:458528	DIP2C	-0.51	-5.25	-0.47	9.1e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs4924935	0.781	rs2472694	chr17:18848498	A/G	cg26378065	chr17:18585709	ZNF286B	0.76	4.75	0.44	7.11e-6	Pancreatic cancer;
THYM	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs250677	0.522	rs10050928	chr5:148353463	C/A	cg18129178	chr5:148520854	ABLIM3	0.68	5.01	0.46	2.54e-6	Breast cancer;
THYM	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.57	-0.5	2.4e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9826463	0.582	rs6769123	chr3:142107897	A/G	cg20824294	chr3:142316082	PLS1	0.77	5.31	0.48	7.08e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs7000551	0.680	rs28546543	chr8:22314872	A/C	cg12081754	chr8:22256438	SLC39A14	0.6	5.25	0.47	9.31e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs3126085	0.597	rs12047544	chr1:152169922	C/T	cg10321714	chr1:152280068	FLG	0.65	4.72	0.44	8.02e-6	Atopic dermatitis;
THYM	cis	rs9359856	0.517	rs11962350	chr6:90592406	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.87	-7.73	-0.62	1.13e-11	Bipolar disorder;
THYM	cis	rs4654899	0.758	rs12137408	chr1:21282945	A/G	cg01072550	chr1:21505969	NA	-0.77	-7.5	-0.61	3.31e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs7511006	0.895	rs5771270	chr22:50682865	G/A	cg11077631	chr22:50617003	PANX2	-0.49	-5.37	-0.48	5.6e-7	Obesity-related traits;
THYM	cis	rs1421898	0.625	rs62384987	chr5:157961867	A/T	cg06698293	chr5:158690540	UBLCP1	-0.97	-4.6	-0.43	1.28e-5	Inflammatory skin disease;
THYM	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg24675658	chr1:53192096	ZYG11B	-0.57	-4.54	-0.42	1.62e-5	Monocyte count;
THYM	cis	rs17407555	0.954	rs714815	chr4:10181206	C/T	cg11266682	chr4:10021025	SLC2A9	-0.52	-4.75	-0.44	7.25e-6	Schizophrenia (age at onset);
THYM	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg18681998	chr4:17616180	MED28	0.8	7.21	0.59	1.32e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs1580019	0.885	rs3801331	chr7:32497039	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.83	-7.5	-0.61	3.43e-11	Cognitive ability;
THYM	cis	rs2229238	0.911	rs4390168	chr1:154509096	A/G	cg21262032	chr1:154437693	IL6R	-0.63	-5.65	-0.5	1.68e-7	Coronary heart disease;
THYM	trans	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg19862616	chr7:65841803	NCRNA00174	1.12	13.77	0.82	2.35e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7756236	0.521	rs9394368	chr6:36630525	C/G	cg24425727	chr6:36645648	CDKN1A	0.7	6.66	0.56	1.79e-9	QRS duration;
THYM	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.77	5.84	0.51	7.3900000000000007e-08	IgG glycosylation;
THYM	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg04944784	chr2:26401820	FAM59B	1.06	6.72	0.57	1.34e-9	Gut microbiome composition (summer);
THYM	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg08859206	chr1:53392774	SCP2	0.51	5.48	0.49	3.47e-7	Monocyte count;
THYM	cis	rs8180040	0.726	rs2305638	chr3:47046842	G/C	cg27129171	chr3:47204927	SETD2	0.83	7.69	0.62	1.34e-11	Colorectal cancer;
THYM	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg13390004	chr1:15929781	NA	0.63	4.79	0.44	6.2e-6	Systolic blood pressure;
THYM	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	-1.02	-5.11	-0.46	1.67e-6	Initial pursuit acceleration;
THYM	cis	rs2274459	1.000	rs12660955	chr6:33760320	C/G	cg06253072	chr6:33679850	C6orf125	0.52	4.65	0.43	1.07e-5	Obesity (extreme);
THYM	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06634786	chr22:41940651	POLR3H	0.64	5.0	0.46	2.61e-6	Vitiligo;
THYM	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg05872129	chr22:39784769	NA	-1.06	-11.41	-0.76	1.68e-19	Intelligence (multi-trait analysis);
THYM	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.73	6.0	0.52	3.5e-8	Schizophrenia;
THYM	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg26818010	chr10:134567672	INPP5A	-0.93	-7.47	-0.61	3.83e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs988913	0.706	rs13192291	chr6:54964746	T/C	cg18532076	chr6:54711417	FAM83B	0.49	4.62	0.43	1.18e-5	Menarche (age at onset);
THYM	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg26354017	chr1:205819088	PM20D1	0.96	10.28	0.73	4.12e-17	Menarche (age at onset);
THYM	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	4.5	0.42	1.91e-5	Obesity-related traits;
THYM	cis	rs728616	0.867	rs723191	chr10:81707920	A/G	cg18148530	chr10:81370782	SFTPA1	0.75	5.26	0.47	9.01e-7	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4363385	0.747	rs1577964	chr1:152961784	C/A	cg13444842	chr1:152974279	SPRR3	-0.59	-4.55	-0.42	1.6e-5	Inflammatory skin disease;
THYM	cis	rs11112613	0.938	rs2374513	chr12:106007300	C/T	cg03607813	chr12:105948248	NA	0.93	5.87	0.52	6.36e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs877282	0.583	rs11253429	chr10:823234	A/C	cg10556349	chr10:835070	NA	-0.83	-5.5	-0.49	3.21e-7	Uric acid levels;
THYM	cis	rs2806561	0.514	rs7519093	chr1:23541078	A/T	cg19743168	chr1:23544995	NA	-0.93	-8.28	-0.65	7.87e-13	Height;
THYM	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.64	-4.59	-0.43	1.35e-5	Aortic root size;
THYM	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	6.03	0.53	3.12e-8	Obesity-related traits;
THYM	cis	rs2712184	0.935	rs2541387	chr2:217666174	A/C	cg05032264	chr2:217675019	NA	-0.56	-4.79	-0.44	6.17e-6	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg25036284	chr2:26402008	FAM59B	-0.8	-5.36	-0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs4731207	0.503	rs1481325	chr7:124625753	C/T	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs986417	0.818	rs8005621	chr14:61106699	G/A	cg27398547	chr14:60952738	C14orf39	0.94	5.21	0.47	1.07e-6	Gut microbiota (bacterial taxa);
THYM	trans	rs629535	0.547	rs62513420	chr8:70122597	G/A	cg21567404	chr3:27674614	NA	-0.89	-7.13	-0.59	1.95e-10	Dupuytren's disease;
THYM	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg00717180	chr2:96193071	NA	-0.69	-7.28	-0.6	9.56e-11	Coronary artery disease;
THYM	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg02725872	chr8:58115012	NA	-0.86	-6.07	-0.53	2.67e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7909074	0.831	rs2065466	chr10:45384047	T/C	cg05187965	chr10:45406764	TMEM72	-0.48	-4.55	-0.42	1.58e-5	Mean corpuscular volume;
THYM	cis	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg13443165	chr9:33130375	B4GALT1	-0.7	-4.68	-0.43	9.38e-6	IgG glycosylation;
THYM	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg04282206	chr17:62833786	PLEKHM1P	-0.83	-8.06	-0.64	2.23e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9902453	0.765	rs2127001	chr17:28098219	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs10992471	0.580	rs7847534	chr9:95282653	C/T	cg14631576	chr9:95140430	CENPP	-0.96	-9.19	-0.69	9.02e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs9534288	0.797	rs2094246	chr13:46602163	C/T	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs28595532	1.000	rs114778020	chr4:119662584	C/A	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg27170947	chr2:26402098	FAM59B	-0.61	-5.04	-0.46	2.25e-6	Gut microbiome composition (summer);
THYM	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg18477163	chr1:228402036	OBSCN	-0.46	-5.01	-0.46	2.54e-6	Diastolic blood pressure;
THYM	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-5.91	-0.52	5.44e-8	Bone mineral density;
THYM	cis	rs9826463	0.527	rs73238169	chr3:142099367	G/A	cg20824294	chr3:142316082	PLS1	0.8	5.46	0.49	3.74e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg04455712	chr21:45112962	RRP1B	0.51	4.72	0.44	8.23e-6	Mean corpuscular volume;
THYM	cis	rs1003719	0.751	rs56268364	chr21:38542765	C/T	cg01329690	chr21:38580129	DSCR9	-0.36	-5.09	-0.46	1.81e-6	Eye color traits;
THYM	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs55728055	0.661	rs62237843	chr22:32026946	C/G	cg01338084	chr22:32026380	PISD	1.51	6.43	0.55	5.06e-9	Age-related hearing impairment;
THYM	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg12573674	chr2:1569213	NA	-1.45	-7.31	-0.6	8.47e-11	Placebo response in major depressive disorder (% change in symptom score);
THYM	trans	rs8073060	0.586	rs225292	chr17:33926383	G/A	cg19694781	chr19:47549865	TMEM160	-0.81	-6.99	-0.58	3.82e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs1797885	0.564	rs2454435	chr3:12586240	T/C	cg05467012	chr3:12595696	NA	0.54	4.5	0.42	1.96e-5	Immature fraction of reticulocytes;
THYM	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg25817165	chr18:72167213	CNDP2	-0.91	-8.14	-0.64	1.55e-12	Refractive error;
THYM	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg22117172	chr7:91764530	CYP51A1	-0.35	-4.47	-0.42	2.12e-5	Breast cancer;
THYM	cis	rs7106204	0.688	rs4462347	chr11:24218865	G/A	ch.11.24196551F	chr11:24239977	NA	0.86	4.57	0.42	1.46e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg10523679	chr1:76189770	ACADM	0.92	10.35	0.73	2.94e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6696239	0.794	rs6664307	chr1:227918562	C/T	cg02736395	chr1:227748424	NA	-0.62	-4.89	-0.45	4.08e-6	Height;
THYM	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg21926883	chr2:100939477	LONRF2	-0.61	-5.56	-0.5	2.42e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6754311	0.773	rs309137	chr2:136765951	A/G	cg23851026	chr2:136556271	LCT	0.51	4.72	0.44	8.1e-6	Mosquito bite size;
THYM	trans	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg23505145	chr19:12996616	KLF1	1.01	9.96	0.71	1.99e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs17006441	0.932	rs1544978	chr3:69900137	A/G	cg18496212	chr3:69797108	MITF	0.68	6.85	0.57	7.35e-10	Hemoglobin concentration;
THYM	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg10047753	chr17:41438598	NA	1.18	11.26	0.76	3.4e-19	Menopause (age at onset);
THYM	cis	rs17443541	0.507	rs7572945	chr2:200470934	T/C	cg01795955	chr2:200468626	NA	-0.66	-4.59	-0.43	1.38e-5	Intelligence (multi-trait analysis);
THYM	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg11812906	chr14:75593930	NEK9	0.89	8.2	0.64	1.11e-12	Height;
THYM	cis	rs611744	0.967	rs681099	chr8:109218892	T/C	cg21045802	chr8:109455806	TTC35	0.59	5.25	0.47	9.08e-7	Dupuytren's disease;
THYM	cis	rs6163	0.588	rs12763284	chr10:104508202	C/T	cg08772003	chr10:104629869	AS3MT	0.51	4.57	0.42	1.44e-5	Waist circumference;Hip circumference;
THYM	cis	rs8077889	0.917	rs72836553	chr17:41909851	A/G	cg26893861	chr17:41843967	DUSP3	1.11	10.19	0.72	6.43e-17	Triglycerides;
THYM	cis	rs7027203	0.828	rs10761287	chr9:96609150	A/G	cg14598338	chr9:96623480	NA	-0.49	-5.22	-0.47	1.07e-6	DNA methylation (variation);
THYM	cis	rs6543140	0.890	rs61122764	chr2:102999520	A/G	cg03938978	chr2:103052716	IL18RAP	0.61	6.13	0.53	1.99e-8	Blood protein levels;
THYM	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg27535305	chr1:53392650	SCP2	-0.57	-6.37	-0.55	6.87e-9	Monocyte count;
THYM	cis	rs2404602	0.684	rs965818	chr15:76866785	T/C	cg23625390	chr15:77176239	SCAPER	-0.88	-6.38	-0.55	6.3e-9	Blood metabolite levels;
THYM	cis	rs7605378	1.000	rs2346662	chr2:200679158	C/T	cg17644776	chr2:200775616	C2orf69	0.64	4.93	0.45	3.52e-6	Osteoporosis;
THYM	cis	rs2637266	1.000	rs12260379	chr10:78365036	C/T	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	trans	rs480407	0.857	rs270958	chr2:161715638	G/A	cg06548410	chr19:1997657	BTBD2	0.73	7.17	0.59	1.64e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg13010199	chr12:38710504	ALG10B	0.69	5.5	0.49	3.16e-7	Heart rate;
THYM	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg24450063	chr1:156163899	SLC25A44	1.18	9.94	0.71	2.2e-16	Testicular germ cell tumor;
THYM	cis	rs642803	0.933	rs644740	chr11:65561468	C/T	cg27068330	chr11:65405492	SIPA1	0.73	5.65	0.5	1.68e-7	Urate levels;
THYM	cis	rs9902453	0.904	rs7219456	chr17:28374112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.22	-0.54	1.3e-8	Coffee consumption (cups per day);
THYM	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg06618935	chr21:46677482	NA	-0.99	-9.28	-0.69	5.6e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs793108	0.742	rs2793109	chr10:31379846	T/A	cg07137701	chr10:31611868	ZEB1	-0.56	-5.06	-0.46	2.01e-6	Multiple sclerosis;Rheumatoid arthritis;
THYM	cis	rs6840360	0.615	rs72728171	chr4:152469372	C/A	cg17479576	chr4:152424074	FAM160A1	-0.85	-6.4	-0.55	5.9e-9	Intelligence (multi-trait analysis);
THYM	cis	rs11048434	0.723	rs2080117	chr12:9138341	C/T	cg14913610	chr12:9142341	KLRG1	-0.29	-4.48	-0.42	2.11e-5	Sjögren's syndrome;
THYM	cis	rs9311676	0.632	rs11130637	chr3:58405573	C/G	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs61990749	0.597	rs176946	chr14:78178439	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.04	0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs28595532	0.920	rs56104443	chr4:119752052	G/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg07936489	chr17:37558343	FBXL20	0.78	5.31	0.48	7.28e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg00383909	chr3:49044727	WDR6	1.13	6.67	0.56	1.72e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2637266	0.783	rs58247832	chr10:78471383	C/A	cg18941641	chr10:78392320	NA	0.77	6.17	0.54	1.64e-8	Pulmonary function;
THYM	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg02734326	chr4:10020555	SLC2A9	0.76	6.89	0.58	6.16e-10	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg18105134	chr13:113819100	PROZ	-1.16	-10.42	-0.73	2.11e-17	Platelet distribution width;
THYM	cis	rs1957429	0.808	rs1570296	chr14:65332294	T/A	cg23373153	chr14:65346875	NA	0.95	5.17	0.47	1.28e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs72772090	0.539	rs10515248	chr5:96112005	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-4.67	-0.43	9.81e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs34638657	0.732	rs7206093	chr16:82201884	G/A	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.11	-0.64	1.73e-12	Lung adenocarcinoma;
THYM	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg04362960	chr10:104952993	NT5C2	0.59	4.9	0.45	3.87e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs10911251	0.546	rs1547715	chr1:183113952	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.66	0.43	1.02e-5	Colorectal cancer;
THYM	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg13531842	chr10:38383804	ZNF37A	-0.54	-4.58	-0.42	1.44e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg09260853	chr1:2094483	PRKCZ	0.51	4.82	0.44	5.42e-6	Height;
THYM	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg08999081	chr20:33150536	PIGU	0.59	5.28	0.48	8.16e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.83	-7.65	-0.62	1.67e-11	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg21657705	chr17:61574500	ACE	-0.43	-4.65	-0.43	1.06e-5	Prudent dietary pattern;
THYM	cis	rs736801	0.729	rs1050152	chr5:131676320	C/T	cg14196790	chr5:131705035	SLC22A5	0.51	4.6	0.43	1.29e-5	Breast cancer;Mosquito bite size;
THYM	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg19774624	chr17:42201019	HDAC5	-0.85	-8.23	-0.65	9.73e-13	Total body bone mineral density;
THYM	cis	rs2859741	0.967	rs507460	chr1:37493206	C/G	cg09363841	chr1:37513479	NA	0.67	6.22	0.54	1.33e-8	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs362272	0.524	rs6819202	chr4:3368264	G/A	cg22655196	chr4:3374909	RGS12	0.61	7.55	0.61	2.64e-11	Serum sulfate level;
THYM	cis	rs7107770	0.825	rs4935911	chr11:125084742	G/A	cg04164023	chr11:125106101	PKNOX2	-0.85	-5.14	-0.47	1.45e-6	Photic sneeze reflex;
THYM	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.4	6.13	0.53	2.02e-8	Obesity-related traits;
THYM	cis	rs67072384	0.818	rs12287481	chr11:72472336	A/C	cg01380194	chr11:72452482	ARAP1	0.78	4.59	0.43	1.34e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs6723108	0.738	rs10928512	chr2:135451302	A/C	cg12500956	chr2:135428796	TMEM163	0.55	4.98	0.46	2.83e-6	Type 2 diabetes;
THYM	cis	rs2124969	0.548	rs62175388	chr2:161019664	G/A	cg03641300	chr2:160917029	PLA2R1	-0.65	-4.58	-0.43	1.38e-5	Waist circumference adjusted for body mass index;
THYM	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg13390004	chr1:15929781	NA	0.62	4.75	0.44	7.16e-6	Systolic blood pressure;
THYM	cis	rs9807841	0.670	rs8102380	chr19:10801185	G/A	cg17848348	chr19:10766748	ILF3	-0.85	-7.48	-0.61	3.69e-11	Inflammatory skin disease;
THYM	cis	rs5771242	0.776	rs6010198	chr22:50610628	A/G	cg16473166	chr22:50639996	SELO	-0.79	-5.65	-0.5	1.71e-7	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
THYM	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg03351412	chr1:154909251	PMVK	0.67	4.65	0.43	1.07e-5	Prostate cancer;
THYM	cis	rs3825932	0.922	rs10400902	chr15:79231616	A/G	cg25744700	chr15:79237217	CTSH	0.54	5.09	0.46	1.78e-6	Type 1 diabetes;
THYM	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.65	-5.29	-0.48	7.84e-7	Coronary artery disease;
THYM	cis	rs988913	0.706	rs10948870	chr6:54745098	G/A	cg18532076	chr6:54711417	FAM83B	0.51	4.78	0.44	6.31e-6	Menarche (age at onset);
THYM	cis	rs1550582	0.662	rs4909628	chr8:135502380	A/T	cg17885191	chr8:135476712	NA	-1.08	-8.8	-0.67	5.98e-14	Educational attainment;
THYM	cis	rs6032067	0.929	rs2267864	chr20:43805279	C/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.69	-7.9	-0.63	4.92e-12	Blood protein levels;
THYM	cis	rs9467711	0.651	rs13210041	chr6:26037601	G/A	cg16898833	chr6:26189333	HIST1H4D	1.33	4.61	0.43	1.24e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg05962950	chr11:130786565	SNX19	0.92	8.76	0.67	7.45e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6669072	1.000	rs3904677	chr1:91252126	C/T	cg08895590	chr1:91227319	NA	-0.52	-5.89	-0.52	5.71e-8	Cognitive function;
THYM	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg03859395	chr2:55845619	SMEK2	0.55	4.95	0.45	3.23e-6	Metabolic syndrome;
THYM	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg06784218	chr1:46089804	CCDC17	-0.3	-4.64	-0.43	1.1e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg17173187	chr15:85201210	NMB	0.56	5.66	0.5	1.6e-7	Schizophrenia;
THYM	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg23281280	chr6:28129359	ZNF389	-0.69	-5.22	-0.47	1.06e-6	Depression;
THYM	cis	rs9554348	0.541	rs61966874	chr13:96934961	G/A	cg25169784	chr13:96706045	UGGT2	0.85	4.67	0.43	1e-5	Schizophrenia;
THYM	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg03929089	chr4:120376271	NA	-0.84	-8.56	-0.66	1.97e-13	Height;
THYM	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg08779649	chr13:50194554	NA	-0.6	-5.28	-0.48	8.21e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs9527	0.615	rs36045108	chr10:104697929	G/A	cg04362960	chr10:104952993	NT5C2	0.6	4.62	0.43	1.2e-5	Arsenic metabolism;
THYM	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg21798802	chr22:38057573	PDXP	0.45	5.13	0.47	1.54e-6	Fat distribution (HIV);
THYM	cis	rs3947	0.951	rs1692819	chr8:11705448	G/A	cg26752888	chr8:11627280	NEIL2	-0.73	-4.76	-0.44	6.8e-6	Blood protein levels;
THYM	cis	rs4866334	1.000	rs116499870	chr5:18479009	G/A	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg23260525	chr10:116636907	FAM160B1	-0.53	-5.33	-0.48	6.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs11118346	0.640	rs10779361	chr1:219742744	C/T	cg07908999	chr1:219785142	NA	-0.4	-4.48	-0.42	2.11e-5	Height;
THYM	cis	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg05084668	chr3:125655381	ALG1L	-0.93	-4.8	-0.44	5.97e-6	Blood pressure (smoking interaction);
THYM	cis	rs758324	0.680	rs392149	chr5:131450542	T/G	cg16205897	chr5:131564050	P4HA2	0.61	5.04	0.46	2.2e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs58722170	0.659	rs61776209	chr1:38090323	C/T	cg17933807	chr1:38061675	GNL2	-0.9	-6.91	-0.58	5.62e-10	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs28595532	0.920	rs116514715	chr4:119756280	G/T	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs2663905	0.706	rs7162859	chr15:81360038	C/T	cg26546864	chr15:81426434	C15orf26	0.83	5.16	0.47	1.34e-6	QT interval (drug interaction);
THYM	cis	rs7119	0.651	rs12902948	chr15:77849254	T/C	cg27398640	chr15:77910606	LINGO1	-0.58	-5.73	-0.51	1.19e-7	Type 2 diabetes;
THYM	cis	rs9866391	0.607	rs13068733	chr3:141118028	A/G	cg13411656	chr3:141121016	ZBTB38	-0.35	-5.23	-0.47	9.9e-7	Myopia;
THYM	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg07492924	chr16:433825	LOC100134368	0.47	5.03	0.46	2.3e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg21926883	chr2:100939477	LONRF2	-0.66	-6.17	-0.54	1.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1371867	0.875	rs1788178	chr8:101332518	A/C	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg17366294	chr4:99064904	C4orf37	0.53	5.9	0.52	5.67e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg09436375	chr6:42928200	GNMT	-0.44	-5.86	-0.52	6.75e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs28595532	0.920	rs56364904	chr4:119742504	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs3126085	0.935	rs1496051	chr1:152164923	G/A	cg10321714	chr1:152280068	FLG	0.65	4.72	0.44	8.02e-6	Atopic dermatitis;
THYM	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.53	-4.86	-0.45	4.57e-6	Lymphocyte counts;
THYM	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg15448220	chr1:150897856	SETDB1	-0.87	-7.15	-0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2290159	0.706	rs11923427	chr3:12663835	C/G	cg23032965	chr3:12705835	RAF1	0.87	5.17	0.47	1.28e-6	Cholesterol, total;
THYM	cis	rs13102973	0.899	rs10212820	chr4:135899842	G/T	cg14419869	chr4:135874104	NA	-0.78	-6.5	-0.55	3.76e-9	Subjective well-being;
THYM	cis	rs4730276	0.608	rs35765154	chr7:107552741	G/A	cg23293999	chr7:106826042	HBP1	-0.57	-4.56	-0.42	1.53e-5	Ulcerative colitis;
THYM	cis	rs7639513	0.520	rs4684111	chr3:12729485	T/G	cg23032965	chr3:12705835	RAF1	0.9	6.69	0.57	1.57e-9	Itch intensity from mosquito bite;
THYM	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.21	-0.64	1.07e-12	Mean corpuscular volume;
THYM	cis	rs8067545	1.000	rs1860302	chr17:19914399	T/A	cg08626831	chr17:20841558	NA	-0.48	-4.5	-0.42	1.94e-5	Schizophrenia;
THYM	cis	rs7000551	0.663	rs11778844	chr8:22335170	C/T	cg12081754	chr8:22256438	SLC39A14	0.65	5.59	0.5	2.15e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs478304	0.718	rs1144789	chr11:65389631	A/G	cg17480646	chr11:65405466	SIPA1	0.76	6.37	0.55	6.69e-9	Acne (severe);
THYM	cis	rs7917772	0.582	rs7907760	chr10:104345197	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg24308560	chr3:49941425	MST1R	0.79	6.8	0.57	9.31e-10	Intelligence (multi-trait analysis);
THYM	cis	rs4849845	0.889	rs3933619	chr2:121035007	C/G	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg11366901	chr6:160182831	ACAT2	-1.02	-9.16	-0.68	1.05e-14	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.37	-4.46	-0.42	2.22e-5	Monocyte percentage of white cells;
THYM	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg17211192	chr8:82754475	SNX16	-0.85	-6.85	-0.57	7.41e-10	Diastolic blood pressure;
THYM	cis	rs4478037	0.558	rs59482503	chr3:33077163	G/A	cg19404215	chr3:33155277	CRTAP	1.16	5.96	0.52	4.27e-8	Major depressive disorder;
THYM	cis	rs9858542	0.543	rs2230929	chr3:49343175	G/A	cg00383909	chr3:49044727	WDR6	0.76	5.0	0.46	2.62e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg07747251	chr5:1868357	NA	0.67	5.7	0.51	1.32e-7	Cardiovascular disease risk factors;
THYM	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs877282	1.000	rs11253366	chr10:773386	C/T	cg10556349	chr10:835070	NA	-0.69	-4.81	-0.44	5.75e-6	Uric acid levels;
THYM	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	7.8	0.62	7.92e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11650494	0.908	rs75904857	chr17:47370449	T/G	cg08112188	chr17:47440006	ZNF652	1.25	5.41	0.49	4.62e-7	Prostate cancer;
THYM	cis	rs9543976	1.000	rs7989568	chr13:76155564	T/C	cg01531495	chr13:76123901	UCHL3	0.78	5.26	0.48	8.8e-7	Diabetic retinopathy;
THYM	cis	rs62229266	0.647	rs59397717	chr21:37451725	C/T	cg08632701	chr21:37451849	NA	-0.7	-7.02	-0.58	3.35e-10	Mitral valve prolapse;
THYM	cis	rs55637147	0.579	rs72923914	chr11:57129851	A/G	cg15971518	chr11:57159174	PRG2	-0.62	-5.12	-0.47	1.59e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg10515332	chr4:99064459	C4orf37	0.57	4.54	0.42	1.63e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7107770	0.941	rs61912980	chr11:125106293	T/C	cg07747661	chr11:125106135	PKNOX2	-0.92	-5.19	-0.47	1.17e-6	Photic sneeze reflex;
THYM	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg15445000	chr17:37608096	MED1	-0.44	-5.22	-0.47	1.05e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2072732	0.861	rs77840846	chr1:2968983	G/C	cg08733933	chr1:2954429	NA	-0.64	-4.55	-0.42	1.61e-5	Plateletcrit;
THYM	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg26384229	chr12:38710491	ALG10B	-0.89	-9.06	-0.68	1.67e-14	Heart rate;
THYM	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	6.88	0.58	6.35e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg11871910	chr12:69753446	YEATS4	1.06	9.8	0.71	4.32e-16	Blood protein levels;
THYM	cis	rs597583	0.715	rs1940040	chr11:117393294	G/C	cg27161313	chr11:117392002	DSCAML1	-0.59	-4.48	-0.42	2.1e-5	Putamen volume;
THYM	cis	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg02258972	chr17:37360836	RPL19	1.02	6.99	0.58	3.7e-10	Depressive symptoms;
THYM	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg13607699	chr17:42295918	UBTF	0.62	4.83	0.44	5.31e-6	Total body bone mineral density;
THYM	cis	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg21775007	chr8:11205619	TDH	-0.71	-5.84	-0.51	7.31e-8	Retinal vascular caliber;
THYM	cis	rs4888262	0.545	rs7193959	chr16:74664969	T/A	cg01733217	chr16:74700730	RFWD3	0.87	9.07	0.68	1.59e-14	Testicular germ cell tumor;
THYM	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	4.6	0.43	1.29e-5	Rheumatoid arthritis;
THYM	cis	rs13102973	0.931	rs6822196	chr4:135855582	T/A	cg14419869	chr4:135874104	NA	0.89	8.76	0.67	7.5e-14	Subjective well-being;
THYM	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg02953382	chr22:24373134	LOC391322	-0.76	-7.54	-0.61	2.79e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4732038	0.510	rs10255114	chr7:134269158	C/A	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs7772486	0.654	rs9376958	chr6:146023040	C/T	cg23711669	chr6:146136114	FBXO30	-0.88	-8.41	-0.65	4.15e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg25358565	chr5:93447407	FAM172A	1.37	10.94	0.75	1.67e-18	Diabetic retinopathy;
THYM	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg10360139	chr7:1886902	MAD1L1	-0.59	-4.52	-0.42	1.77e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg25036284	chr2:26402008	FAM59B	-0.79	-5.46	-0.49	3.73e-7	Gut microbiome composition (summer);
THYM	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.75	-0.67	7.74e-14	Mean corpuscular volume;
THYM	cis	rs2816062	1.000	rs2816062	chr1:18903902	G/A	cg18795169	chr1:18902165	NA	-0.86	-9.67	-0.7	8.51e-16	Urate levels in lean individuals;
THYM	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg02734326	chr4:10020555	SLC2A9	-0.71	-6.2	-0.54	1.44e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs835154	0.845	rs835155	chr5:14875868	A/G	cg11792786	chr5:14870083	ANKH	0.49	5.46	0.49	3.72e-7	Blood metabolite levels;
THYM	cis	rs2070677	0.935	rs11101880	chr10:135412888	T/C	cg20169779	chr10:135381914	SYCE1	-0.79	-6.0	-0.52	3.64e-8	Gout;
THYM	cis	rs2456568	0.803	rs10831138	chr11:93640468	T/C	cg17347335	chr11:93583973	C11orf90	-0.48	-4.63	-0.43	1.18e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg13257436	chr8:145726034	PPP1R16A	0.58	4.48	0.42	2.08e-5	Age at first birth;
THYM	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs289828	0.507	rs4665150	chr2:152134149	A/G	cg05960677	chr2:152117363	RBM43	-0.76	-8.27	-0.65	7.98e-13	Blood protein levels;
THYM	cis	rs17152411	1.000	rs61873263	chr10:126589202	G/A	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg20891283	chr12:69753455	YEATS4	1.09	12.03	0.78	8.44e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs295140	0.507	rs1369842	chr2:201108987	C/A	cg23649088	chr2:200775458	C2orf69	-0.63	-5.59	-0.5	2.16e-7	QT interval;
THYM	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg11812906	chr14:75593930	NEK9	0.81	7.22	0.6	1.3e-10	Height;
THYM	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg01570182	chr17:44337453	NA	-0.63	-6.68	-0.57	1.61e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.67	8.64	0.66	1.35e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs6032067	0.714	rs6104069	chr20:43852243	C/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.47	-0.49	3.71e-7	Blood protein levels;
THYM	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg03433033	chr1:76189801	ACADM	-0.76	-9.82	-0.71	3.96e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg18230493	chr5:56204884	C5orf35	-0.87	-6.41	-0.55	5.5e-9	Initial pursuit acceleration;
THYM	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg22907277	chr7:1156413	C7orf50	0.7	6.07	0.53	2.67e-8	Longevity;Endometriosis;
THYM	cis	rs4654899	0.743	rs17409373	chr1:21188871	C/A	cg01072550	chr1:21505969	NA	-0.71	-6.39	-0.55	6.25e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18252515	chr7:66147081	NA	0.66	4.96	0.45	3.11e-6	Aortic root size;
THYM	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs7610301	1.000	rs4683249	chr3:46643141	A/G	cg22951056	chr3:46887651	NA	-0.75	-4.88	-0.45	4.23e-6	Blood protein levels;
THYM	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg00083206	chr6:110721305	DDO	-0.58	-6.96	-0.58	4.26e-10	Platelet distribution width;
THYM	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs10463554	0.963	rs26254	chr5:102556859	A/G	cg23492399	chr5:102201601	PAM	-0.69	-5.21	-0.47	1.1e-6	Parkinson's disease;
THYM	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg05340658	chr4:99064831	C4orf37	0.55	4.64	0.43	1.11e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg16342193	chr10:102329863	NA	-0.53	-5.45	-0.49	4.01e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg20387954	chr3:183756860	HTR3D	-0.81	-7.36	-0.6	6.42e-11	Anterior chamber depth;
THYM	cis	rs889398	0.802	rs12598642	chr16:69848772	A/G	cg09409435	chr16:70099608	PDXDC2	-0.59	-4.6	-0.43	1.32e-5	Body mass index;
THYM	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs360798	0.553	rs11682530	chr2:63073194	C/T	cg17519650	chr2:63277830	OTX1	-0.69	-4.9	-0.45	3.86e-6	Coronary artery disease;
THYM	cis	rs9560113	1.000	rs9560107	chr13:112180146	G/A	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg06636001	chr8:8085503	FLJ10661	0.58	4.62	0.43	1.19e-5	Mood instability;
THYM	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	4.79	0.44	6.04e-6	Menarche (age at onset);
THYM	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg01570182	chr17:44337453	NA	0.63	6.62	0.56	2.1e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4731207	0.596	rs7795605	chr7:124578447	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs6686842	0.932	rs1008505	chr1:41560235	C/T	cg03387723	chr1:41708464	SCMH1	0.44	5.22	0.47	1.06e-6	Height;
THYM	cis	rs6032067	0.714	rs4359712	chr20:43884861	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.39	-4.67	-0.43	9.78e-6	Blood protein levels;
THYM	cis	rs55728055	0.661	rs62239172	chr22:32047941	G/A	cg01338084	chr22:32026380	PISD	1.43	6.67	0.56	1.68e-9	Age-related hearing impairment;
THYM	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg06728252	chr6:26598149	ABT1	-0.45	-4.93	-0.45	3.51e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg15448220	chr1:150897856	SETDB1	0.88	7.27	0.6	1.02e-10	Tonsillectomy;
THYM	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24549020	chr5:56110836	MAP3K1	0.69	4.52	0.42	1.8e-5	Initial pursuit acceleration;
THYM	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg12560992	chr17:57184187	TRIM37	0.91	8.17	0.64	1.29e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4285028	0.898	rs73855476	chr3:121633412	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.83	-5.75	-0.51	1.07e-7	Multiple sclerosis;
THYM	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.43	-5.35	-0.48	6.04e-7	Longevity;Endometriosis;
THYM	cis	rs1011018	0.628	rs73158611	chr7:139425430	G/C	cg06079564	chr7:139468310	HIPK2	-0.72	-4.73	-0.44	7.73e-6	Systolic blood pressure;
THYM	cis	rs9287719	0.781	rs12472807	chr2:10781605	G/A	cg02196655	chr2:10830764	NOL10	-0.44	-4.59	-0.43	1.38e-5	Prostate cancer;
THYM	cis	rs516243	0.703	rs284313	chr1:10736434	A/G	cg02903756	chr1:10750680	CASZ1	-0.61	-5.11	-0.46	1.65e-6	Migraine - clinic-based;
THYM	cis	rs4750440	0.523	rs4565800	chr10:14032326	G/C	cg27542038	chr10:14027202	FRMD4A	-0.59	-5.05	-0.46	2.17e-6	Adiponectin levels;
THYM	cis	rs34638657	0.789	rs2967363	chr16:82204132	C/G	cg07307142	chr16:82071433	HSD17B2	-0.85	-6.84	-0.57	7.54e-10	Lung adenocarcinoma;
THYM	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg10295955	chr4:187884368	NA	1.1	11.67	0.77	4.84e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs17433780	0.808	rs12125301	chr1:89508501	G/A	cg09516651	chr1:89888402	LOC400759	0.97	8.07	0.64	2.12e-12	Carotid intima media thickness;
THYM	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs4853012	1.000	rs4853012	chr2:74361290	G/A	cg01017244	chr2:74357527	NA	1.19	9.24	0.69	6.83e-15	Gestational age at birth (maternal effect);
THYM	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.73	0.67	8.5e-14	Colorectal cancer;
THYM	cis	rs76662990	0.610	rs10474421	chr5:73943257	C/T	cg13275603	chr5:73927487	ENC1	0.77	4.65	0.43	1.08e-5	Residual cognition;
THYM	cis	rs7255045	0.913	rs10419408	chr19:12942750	C/T	cg26870725	chr19:12978805	MAST1	0.65	4.79	0.44	6.02e-6	Mean corpuscular volume;
THYM	cis	rs11948739	0.573	rs12332505	chr5:130337348	T/G	cg08523029	chr5:130500466	HINT1	-0.81	-5.6	-0.5	2.04e-7	Pediatric bone mineral content (hip);
THYM	cis	rs9915657	0.966	rs8071725	chr17:70128726	C/T	cg09344028	chr17:70110421	NA	0.44	4.45	0.42	2.35e-5	Thyroid hormone levels;
THYM	cis	rs9902453	0.874	rs7220004	chr17:28369548	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.22	-0.54	1.3e-8	Coffee consumption (cups per day);
THYM	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg16414030	chr3:133502952	NA	-0.69	-5.53	-0.49	2.82e-7	Iron status biomarkers;
THYM	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg22920501	chr2:26401640	FAM59B	0.79	7.07	0.59	2.63e-10	Gut microbiome composition (summer);
THYM	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg11905131	chr22:24372483	LOC391322	-0.88	-10.22	-0.72	5.47e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg22981736	chr15:31284413	MTMR10	-0.57	-4.77	-0.44	6.64e-6	Huntington's disease progression;
THYM	cis	rs2273669	0.588	rs6568555	chr6:109331777	A/G	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	cis	rs4474465	1.000	rs7934678	chr11:78192968	G/A	cg19901956	chr11:77921274	USP35	-0.64	-4.72	-0.44	7.96e-6	Alzheimer's disease (survival time);
THYM	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg19746536	chr19:49375674	PPP1R15A	-0.79	-4.46	-0.42	2.28e-5	Red cell distribution width;
THYM	cis	rs7567389	0.600	rs3732209	chr2:128079806	A/G	cg06038358	chr2:128176007	PROC	0.47	5.31	0.48	7.16e-7	Self-rated health;
THYM	cis	rs2976388	0.609	rs2585140	chr8:143806896	A/G	cg06565975	chr8:143823917	SLURP1	0.5	5.62	0.5	1.9e-7	Urinary tract infection frequency;
THYM	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.11e-8	Systolic blood pressure;
THYM	cis	rs4363385	0.626	rs12062847	chr1:153062994	A/G	cg07796016	chr1:152779584	LCE1C	-0.53	-4.6	-0.43	1.31e-5	Inflammatory skin disease;
THYM	cis	rs59197085	0.636	rs2307037	chr7:128449405	G/A	cg00734629	chr7:128471146	FLNC	0.76	4.51	0.42	1.89e-5	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
THYM	cis	rs4481887	0.676	rs28684663	chr1:248548325	T/C	cg00666640	chr1:248458726	OR2T12	0.53	4.62	0.43	1.2e-5	Common traits (Other);
THYM	cis	rs2562456	0.550	rs4809143	chr19:21772728	C/A	cg21751540	chr19:21541537	ZNF738	-0.68	-4.51	-0.42	1.87e-5	Pain;
THYM	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22496380	chr5:211416	CCDC127	-1.41	-8.22	-0.64	1.05e-12	Breast cancer;
THYM	cis	rs600806	0.850	rs1465607	chr1:109958035	T/C	cg02175308	chr1:109941060	SORT1	-0.57	-5.08	-0.46	1.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6543140	0.964	rs4851010	chr2:103056127	A/T	cg03938978	chr2:103052716	IL18RAP	-0.6	-5.95	-0.52	4.55e-8	Blood protein levels;
THYM	cis	rs9810089	0.872	rs527888	chr3:136031358	G/C	cg12473912	chr3:136751656	NA	0.61	4.97	0.45	3e-6	Gestational age at birth (child effect);
THYM	cis	rs7568458	0.811	rs1446668	chr2:85764960	G/T	cg17127132	chr2:85788382	GGCX	0.59	4.76	0.44	6.87e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg24578937	chr1:2090814	PRKCZ	0.81	8.42	0.65	3.97e-13	Height;
THYM	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg05962950	chr11:130786565	SNX19	0.92	8.74	0.67	8.09e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4666002	0.789	rs6727215	chr2:27934731	G/A	cg27432699	chr2:27873401	GPN1	0.62	4.73	0.44	7.77e-6	Phospholipid levels (plasma);
THYM	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg00645579	chr11:617140	IRF7;MUPCDH	-0.47	-6.04	-0.53	3.05e-8	Systemic lupus erythematosus;
THYM	cis	rs921968	0.519	rs62191659	chr2:219630510	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs10779751	0.770	rs10864490	chr1:11236410	A/C	cg08854313	chr1:11322531	MTOR	0.79	6.3	0.54	9.1e-9	Body mass index;
THYM	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg21280719	chr6:42927975	GNMT	-0.54	-7.4	-0.6	5.43e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg03433033	chr1:76189801	ACADM	0.71	6.46	0.55	4.53e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	trans	rs11098499	0.690	rs7674713	chr4:120322257	T/C	cg25214090	chr10:38739885	LOC399744	0.92	8.08	0.64	2.07e-12	Corneal astigmatism;
THYM	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.87	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg07212818	chr11:638076	DRD4	-0.77	-5.92	-0.52	5.09e-8	Systemic lupus erythematosus;
THYM	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.48	-0.55	4.1e-9	Personality dimensions;
THYM	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg20608306	chr11:116969690	SIK3	0.52	5.49	0.49	3.32e-7	Blood protein levels;
THYM	cis	rs859767	0.779	rs6430528	chr2:135395348	A/G	cg12500956	chr2:135428796	TMEM163	-0.51	-5.09	-0.46	1.79e-6	Neuroticism;
THYM	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg27534772	chr1:16042836	PLEKHM2	0.53	5.9	0.52	5.65e-8	Systolic blood pressure;
THYM	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg13683864	chr3:40499215	RPL14	-0.76	-7.0	-0.58	3.61e-10	Renal cell carcinoma;
THYM	cis	rs929354	1.000	rs1182381	chr7:157043473	G/A	cg17757837	chr7:157058334	UBE3C	-0.79	-6.83	-0.57	7.88e-10	Body mass index;
THYM	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg20887711	chr4:1340912	KIAA1530	-0.95	-9.13	-0.68	1.17e-14	Longevity;
THYM	cis	rs6840360	0.904	rs6825241	chr4:152543783	C/A	cg22705602	chr4:152727874	NA	-0.49	-4.97	-0.45	2.93e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg22907277	chr7:1156413	C7orf50	0.8	4.85	0.45	4.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg17279839	chr7:150038598	RARRES2	0.55	5.2	0.47	1.16e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs1395	1.000	rs1275538	chr2:27441397	C/T	cg23587288	chr2:27483067	SLC30A3	-0.57	-4.98	-0.45	2.9e-6	Blood metabolite levels;
THYM	cis	rs2712184	0.868	rs1548946	chr2:217665368	C/T	cg05032264	chr2:217675019	NA	-0.56	-4.79	-0.44	6.17e-6	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11644478	chr21:40555479	PSMG1	-0.58	-4.76	-0.44	6.94e-6	Menarche (age at onset);
THYM	cis	rs12935418	0.616	rs8047785	chr16:80969352	T/C	cg16651780	chr16:81037892	C16orf61	0.88	5.56	0.5	2.45e-7	Mean corpuscular volume;
THYM	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg22875332	chr1:76189707	ACADM	-0.54	-5.07	-0.46	1.96e-6	Daytime sleep phenotypes;
THYM	cis	rs2806561	0.894	rs1738475	chr1:23536891	C/G	cg12483005	chr1:23474871	LUZP1	0.52	5.23	0.47	1.01e-6	Height;
THYM	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg01874867	chr7:94954059	PON1	0.83	6.74	0.57	1.19e-9	Paraoxonase activity;
THYM	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg15247329	chr7:2764246	NA	-0.74	-6.47	-0.55	4.2e-9	Height;
THYM	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg10047753	chr17:41438598	NA	1.19	11.63	0.77	5.87e-20	Menopause (age at onset);
THYM	cis	rs988913	0.957	rs9475068	chr6:54791581	A/G	cg18532076	chr6:54711417	FAM83B	0.52	4.79	0.44	6.11e-6	Menarche (age at onset);
THYM	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg25817165	chr18:72167213	CNDP2	-1.0	-7.72	-0.62	1.18e-11	Refractive error;
THYM	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.78	6.88	0.58	6.23e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg11166453	chr1:247681781	NA	0.68	5.26	0.47	8.98e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg18252515	chr7:66147081	NA	0.63	4.7	0.43	8.9e-6	Aortic root size;
THYM	cis	rs3126085	0.935	rs4595369	chr1:152248193	G/A	cg10321714	chr1:152280068	FLG	0.67	5.14	0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.21	0.47	1.1e-6	Electroencephalogram traits;
THYM	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg18252515	chr7:66147081	NA	1.43	8.54	0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.18	8.91	0.67	3.47e-14	Cognitive test performance;
THYM	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg24818145	chr4:99064322	C4orf37	0.64	4.8	0.44	5.87e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7828089	0.819	rs7846557	chr8:22243654	T/C	cg12081754	chr8:22256438	SLC39A14	0.63	5.51	0.49	3.08e-7	Verbal declarative memory;
THYM	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg26924012	chr15:45694286	SPATA5L1	1.16	11.22	0.75	4.31e-19	Homoarginine levels;
THYM	cis	rs2072510	0.643	rs2367755	chr12:96393082	T/C	cg18817487	chr12:96390143	HAL	0.4	5.3	0.48	7.43e-7	Metabolite levels (small molecules and protein measures);
THYM	cis	rs858239	0.665	rs858305	chr7:23242830	C/G	cg18081818	chr7:23246105	NA	0.57	5.25	0.47	9.24e-7	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg23711669	chr6:146136114	FBXO30	0.95	9.55	0.7	1.52e-15	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs208520	0.690	rs207091	chr6:66799847	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.66	-0.62	1.53e-11	Exhaled nitric oxide output;
THYM	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg10295955	chr4:187884368	NA	-1.19	-16.63	-0.86	6.9e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg14349672	chr11:133703707	NA	-0.54	-4.74	-0.44	7.5e-6	Childhood ear infection;
THYM	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs289828	0.538	rs289922	chr2:152091039	G/T	cg05960677	chr2:152117363	RBM43	-0.71	-7.56	-0.61	2.46e-11	Blood protein levels;
THYM	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg10150615	chr22:24372951	LOC391322	-0.85	-6.36	-0.55	7.04e-9	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7523273	0.606	rs2724388	chr1:207933577	T/G	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg00717180	chr2:96193071	NA	-0.72	-7.45	-0.61	4.21e-11	Coronary artery disease;
THYM	cis	rs5769707	0.632	rs135871	chr22:50008969	A/G	cg23428387	chr22:49814324	NA	-0.57	-5.4	-0.48	4.99e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg18758796	chr5:131593413	PDLIM4	-0.5	-4.83	-0.44	5.16e-6	Breast cancer;
THYM	cis	rs7107174	0.892	rs12281104	chr11:78046940	T/C	cg19901956	chr11:77921274	USP35	-0.65	-5.37	-0.48	5.66e-7	Testicular germ cell tumor;
THYM	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg10802521	chr3:52805072	NEK4	-0.73	-6.35	-0.55	7.48e-9	Bipolar disorder;
THYM	cis	rs931127	0.692	rs7934517	chr11:65445673	C/T	cg27068330	chr11:65405492	SIPA1	-0.79	-7.05	-0.59	2.85e-10	Systemic lupus erythematosus;
THYM	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.66	4.85	0.45	4.9e-6	Lung cancer in ever smokers;
THYM	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg08968635	chr6:28129556	ZNF389	0.66	5.19	0.47	1.21e-6	Depression;
THYM	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22590775	chr19:49891494	CCDC155	0.61	4.71	0.43	8.55e-6	Multiple sclerosis;
THYM	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg03806693	chr22:41940476	POLR3H	-1.04	-7.62	-0.62	1.86e-11	Vitiligo;
THYM	cis	rs3126085	0.935	rs56013982	chr1:152176503	C/T	cg10321714	chr1:152280068	FLG	-0.76	-5.65	-0.5	1.71e-7	Atopic dermatitis;
THYM	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg10802521	chr3:52805072	NEK4	-0.8	-7.5	-0.61	3.34e-11	Electroencephalogram traits;
THYM	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg18512352	chr11:47633146	NA	0.5	6.42	0.55	5.46e-9	Subjective well-being;
THYM	cis	rs2898681	0.739	rs1047959	chr4:53739856	C/G	cg00812761	chr4:53799391	SCFD2	-0.54	-4.81	-0.44	5.72e-6	Optic nerve measurement (cup area);
THYM	cis	rs17854409	0.881	rs68066790	chr20:61487150	T/A	cg05147244	chr20:61493195	TCFL5	1.04	6.36	0.55	6.94e-9	Obesity-related traits;
THYM	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs76935404	0.811	rs28417358	chr19:41428105	G/A	cg19493303	chr19:41414353	NA	0.57	5.06	0.46	2.03e-6	nicotine metabolite ratio in current smokers;
THYM	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.15	-0.47	1.4e-6	Total cholesterol levels;
THYM	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg22875332	chr1:76189707	ACADM	0.87	10.81	0.74	3.09e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg15693483	chr7:1102177	C7orf50	0.5	5.65	0.5	1.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6500395	1.000	rs28577888	chr16:48673281	T/G	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs4455778	0.580	rs6583501	chr7:49077636	A/T	cg26309511	chr7:48887640	NA	0.68	5.94	0.52	4.63e-8	Lung cancer in never smokers;
THYM	cis	rs4266144	0.563	rs61124401	chr3:156840919	A/G	cg14969094	chr3:156848003	NA	-0.48	-4.62	-0.43	1.22e-5	Coronary artery disease;
THYM	cis	rs11644362	0.631	rs74245921	chr16:12967545	A/G	cg06890432	chr16:12997467	SHISA9	-0.53	-4.94	-0.45	3.32e-6	Positive affect;Subjective well-being;
THYM	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg23803603	chr1:2058230	PRKCZ	-0.62	-4.85	-0.45	4.8e-6	Height;
THYM	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs2933343	0.700	rs2249514	chr3:128643812	C/T	cg11901034	chr3:128598214	ACAD9	-0.69	-5.57	-0.5	2.32e-7	IgG glycosylation;
THYM	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg07936489	chr17:37558343	FBXL20	-0.71	-5.25	-0.47	9.23e-7	Asthma;
THYM	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg15704280	chr7:45808275	SEPT13	-0.94	-7.11	-0.59	2.19e-10	Coronary artery disease;
THYM	cis	rs1629083	0.902	rs11216827	chr11:118110202	A/T	cg25155064	chr11:118100782	MPZL3	-0.57	-5.04	-0.46	2.25e-6	Lung cancer;
THYM	cis	rs1568889	0.838	rs7121937	chr11:28359858	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.14	0.59	1.87e-10	Bipolar disorder;
THYM	cis	rs7631605	0.875	rs4678935	chr3:37119835	A/C	cg21328643	chr3:37258149	NA	-0.49	-4.7	-0.43	8.95e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg00376283	chr12:123451042	ABCB9	0.69	5.25	0.47	9.12e-7	Height;Educational attainment;Head circumference (infant);
THYM	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg14018140	chr10:458528	DIP2C	-0.61	-7.2	-0.59	1.39e-10	Psychosis in Alzheimer's disease;
THYM	cis	rs9325144	0.560	rs10876005	chr12:39126149	C/G	cg13010199	chr12:38710504	ALG10B	-0.58	-4.56	-0.42	1.52e-5	Morning vs. evening chronotype;
THYM	cis	rs2040771	0.872	rs12485084	chr22:19162326	A/G	cg02655711	chr22:19163373	SLC25A1	0.6	6.42	0.55	5.3300000000000004e-09	Metabolite levels (small molecules and protein measures);
THYM	cis	rs10865397	0.506	rs60764301	chr2:73384850	G/A	cg24220031	chr2:73402428	NA	-0.75	-6.87	-0.58	6.79e-10	Intelligence (multi-trait analysis);
THYM	cis	rs8048589	0.604	rs11642033	chr16:12207990	A/G	cg01990910	chr16:12207648	SNX29	-0.55	-5.81	-0.51	8.24e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs6430585	0.583	rs59213715	chr2:136646582	A/C	cg07169764	chr2:136633963	MCM6	1.19	11.2	0.75	4.62e-19	Corneal structure;
THYM	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg00339695	chr16:24857497	SLC5A11	-0.48	-4.79	-0.44	6.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11644478	chr21:40555479	PSMG1	1.05	8.94	0.68	3.02e-14	Cognitive function;
THYM	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg00684032	chr4:1343700	KIAA1530	0.7	5.74	0.51	1.11e-7	Obesity-related traits;
THYM	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs9595908	0.965	rs7984903	chr13:33126139	G/A	cg12383807	chr13:33924137	NA	-0.54	-4.72	-0.44	8.02e-6	Body mass index;
THYM	cis	rs4950928	0.823	rs10920579	chr1:203158972	A/G	cg17014757	chr1:203156097	CHI3L1	-1.14	-6.89	-0.58	6e-10	YKL-40 levels;
THYM	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.41	0.61	5.04e-11	Obesity-related traits;
THYM	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg04865290	chr3:52927548	TMEM110	-0.89	-4.61	-0.43	1.27e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg04455712	chr21:45112962	RRP1B	0.5	4.71	0.44	8.37e-6	Mean corpuscular volume;
THYM	cis	rs7260598	0.642	rs4313914	chr19:24176996	A/G	cg15526094	chr19:24182596	NA	-0.81	-5.08	-0.46	1.91e-6	Response to taxane treatment (placlitaxel);
THYM	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.62	-5.6	-0.5	2.08e-7	Hip circumference adjusted for BMI;
THYM	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg08916839	chr5:415575	AHRR	1.14	6.87	0.58	6.77e-10	Fat distribution (HIV);
THYM	cis	rs7828089	0.875	rs6998575	chr8:22254499	C/T	cg12081754	chr8:22256438	SLC39A14	0.66	5.84	0.51	7.29e-8	Verbal declarative memory;
THYM	cis	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg05335186	chr13:53173507	NA	-0.46	-6.2	-0.54	1.43e-8	Lewy body disease;
THYM	cis	rs4343996	1.000	rs6959702	chr7:3356286	G/C	cg21248987	chr7:3385318	SDK1	-0.38	-4.61	-0.43	1.26e-5	Motion sickness;
THYM	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	4.56	0.42	1.55e-5	Multiple sclerosis;
THYM	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs752010	1.000	rs6664724	chr1:42093821	G/A	cg06885757	chr1:42089581	HIVEP3	0.41	4.67	0.43	9.9e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg11266682	chr4:10021025	SLC2A9	0.73	12.79	0.8	2.29e-22	Bone mineral density;
THYM	cis	rs960902	0.561	rs4517954	chr2:37734421	G/A	cg25341268	chr2:37734390	NA	-0.69	-6.28	-0.54	9.9e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs72627123	1.000	rs72627123	chr14:74368331	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg12310025	chr6:25882481	NA	-0.68	-5.3	-0.48	7.65e-7	Height;
THYM	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-5.04	-0.46	2.23e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6815814	0.808	rs7673348	chr4:38845198	G/A	cg02016764	chr4:38805732	TLR1	-0.52	-5.52	-0.49	2.99e-7	Breast cancer;
THYM	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg22974920	chr21:40686053	BRWD1	0.74	5.03	0.46	2.28e-6	Cognitive function;
THYM	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg06713675	chr4:122721982	EXOSC9	-0.86	-9.81	-0.71	4.29e-16	Type 2 diabetes;
THYM	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.24	-4.56	-0.42	1.52e-5	Obesity-related traits;
THYM	cis	rs2637266	0.935	rs1866890	chr10:78397073	C/T	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg13010199	chr12:38710504	ALG10B	-0.55	-4.6	-0.43	1.29e-5	Morning vs. evening chronotype;
THYM	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg23428387	chr22:49814324	NA	-0.5	-4.87	-0.45	4.42e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7011507	0.594	rs55656120	chr8:49345257	C/T	cg08774009	chr8:49309094	NA	-0.6	-4.71	-0.44	8.47e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg04731861	chr2:219085781	ARPC2	0.5	4.75	0.44	7.25e-6	Colorectal cancer;
THYM	cis	rs6570726	0.818	rs437978	chr6:145809134	A/G	cg13319975	chr6:146136371	FBXO30	-0.72	-6.1	-0.53	2.28e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12714314	0.914	rs1991773	chr2:1957476	A/G	cg05313794	chr2:1845466	MYT1L	0.49	4.46	0.42	2.21e-5	Type 2 diabetes (age of onset);
THYM	cis	rs12310956	0.510	rs6488178	chr12:33885251	C/G	cg06521331	chr12:34319734	NA	-0.57	-4.58	-0.43	1.42e-5	Morning vs. evening chronotype;
THYM	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg24642844	chr7:1081250	C7orf50	-1.29	-8.3	-0.65	7.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg07636037	chr3:49044803	WDR6	0.92	7.92	0.63	4.36e-12	Menarche (age at onset);
THYM	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg11301795	chr4:187892539	NA	-1.11	-17.65	-0.88	9.45e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9733	0.596	rs17606613	chr1:150683015	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs6921919	0.583	rs16894108	chr6:28401790	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.59	-4.53	-0.42	1.74e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.03	0.46	2.29e-6	Obesity-related traits;
THYM	cis	rs7216064	0.684	rs7406031	chr17:66021753	C/T	cg12091567	chr17:66097778	LOC651250	0.97	7.82	0.63	7.11e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs4731207	0.596	rs7802007	chr7:124638034	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs3924048	0.574	rs12096486	chr1:12616911	T/C	cg00291366	chr1:12616550	NA	0.38	5.85	0.51	7.04e-8	Optic cup area;
THYM	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs946836	0.537	rs6684538	chr1:48380390	G/A	cg18376692	chr1:48452465	NA	-0.5	-4.97	-0.45	2.94e-6	White matter integrity;
THYM	cis	rs7952251	0.528	rs11602446	chr11:112422841	C/T	cg25091705	chr11:111752853	C11orf1	0.83	4.7	0.43	8.94e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs597539	0.545	rs3794027	chr11:68697336	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	6.99	0.58	3.73e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg01616529	chr11:638424	DRD4	-0.76	-5.38	-0.48	5.42e-7	Systemic lupus erythematosus;
THYM	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.76	5.8	0.51	8.8e-8	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs13315871	0.929	rs1045115	chr3:58305199	C/T	cg00563845	chr3:58318305	PXK	0.59	5.02	0.46	2.37e-6	Cholesterol, total;
THYM	cis	rs912057	0.671	rs1294417	chr6:6741932	T/C	cg13809441	chr6:6737631	NA	0.47	5.59	0.5	2.21e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs3008870	1.000	rs975451	chr1:67480060	T/C	cg02640540	chr1:67518911	SLC35D1	0.65	4.83	0.44	5.32e-6	Lymphocyte percentage of white cells;
THYM	cis	rs67072384	1.000	rs12292781	chr11:72448385	A/C	cg01380194	chr11:72452482	ARAP1	-0.97	-5.26	-0.47	8.93e-7	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs2806561	0.695	rs66592286	chr1:23333649	G/C	cg12483005	chr1:23474871	LUZP1	0.53	5.42	0.49	4.43e-7	Height;
THYM	cis	rs2237457	0.543	rs2429073	chr7:50703110	T/C	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.48e-6	Schizophrenia (treatment resistant);
THYM	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg07936489	chr17:37558343	FBXL20	-0.82	-5.65	-0.5	1.7e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs977987	0.815	rs11646677	chr16:75408981	T/C	cg03315344	chr16:75512273	CHST6	0.72	6.21	0.54	1.38e-8	Dupuytren's disease;
THYM	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.09	-7.74	-0.62	1.06e-11	Platelet count;
THYM	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg13866156	chr1:1669148	SLC35E2	0.71	7.66	0.62	1.53e-11	Body mass index;
THYM	cis	rs3796352	1.000	rs11720191	chr3:53013839	T/C	cg07884673	chr3:53033167	SFMBT1	1.19	6.0	0.52	3.59e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg16031515	chr1:205743344	RAB7L1	-0.75	-8.06	-0.64	2.28e-12	Menarche (age at onset);
THYM	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg06618935	chr21:46677482	NA	-0.96	-9.38	-0.69	3.52e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg26384229	chr12:38710491	ALG10B	0.92	7.34	0.6	7.32e-11	Bladder cancer;
THYM	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.57	-4.88	-0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs2637266	0.783	rs7898786	chr10:78481338	T/C	cg18941641	chr10:78392320	NA	0.71	5.69	0.5	1.42e-7	Pulmonary function;
THYM	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg06558623	chr16:89946397	TCF25	0.87	4.57	0.42	1.48e-5	Skin colour saturation;
THYM	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.77	-6.56	-0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs9677476	0.863	rs7601741	chr2:232062351	C/T	cg07929768	chr2:232055508	NA	0.6	6.0	0.52	3.65e-8	Food antigen IgG levels;
THYM	cis	rs61931739	0.736	rs7314457	chr12:34454301	G/A	cg10856724	chr12:34555212	NA	-0.72	-6.2	-0.54	1.48e-8	Morning vs. evening chronotype;
THYM	cis	rs10493773	0.775	rs11161662	chr1:86185040	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.49	-6.19	-0.54	1.5e-8	Urate levels in overweight individuals;
THYM	cis	rs11096990	0.928	rs2008681	chr4:39268016	A/G	cg24403649	chr4:39172243	NA	-0.68	-5.77	-0.51	9.87e-8	Cognitive function;
THYM	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg17480646	chr11:65405466	SIPA1	-0.94	-8.68	-0.67	1.07e-13	Acne (severe);
THYM	cis	rs73416724	1.000	rs17209407	chr6:43358362	A/G	cg26312998	chr6:43337775	ZNF318	1.05	4.98	0.45	2.87e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs28595532	0.920	rs114938162	chr4:119756407	T/G	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs4792901	0.802	rs28608935	chr17:41609470	G/A	cg21940313	chr17:41620911	ETV4	-0.5	-4.59	-0.43	1.37e-5	Dupuytren's disease;
THYM	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg17366294	chr4:99064904	C4orf37	0.58	7.05	0.59	2.83e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10927875	0.541	rs1739841	chr1:16342727	A/G	cg22431228	chr1:16359049	CLCNKA	-0.49	-4.61	-0.43	1.27e-5	Dilated cardiomyopathy;
THYM	cis	rs1566080	0.702	rs13271156	chr8:142565478	C/T	cg16717864	chr8:143254645	NA	-0.51	-4.45	-0.42	2.35e-5	Obesity-related traits;
THYM	cis	rs28785552	0.589	rs7257371	chr19:53243910	A/G	cg22067481	chr19:53234126	ZNF611	-0.82	-7.87	-0.63	5.58e-12	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg24846680	chr1:228362309	C1orf69	0.52	4.74	0.44	7.61e-6	Diastolic blood pressure;
THYM	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg26398791	chr1:38455867	SF3A3	-0.63	-5.18	-0.47	1.26e-6	Coronary artery disease;
THYM	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs919433	0.680	rs2605039	chr2:198362851	C/A	cg00792783	chr2:198669748	PLCL1	0.83	5.74	0.51	1.14e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs61990749	0.597	rs1477260	chr14:78256818	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	1.18	8.07	0.64	2.13e-12	Fibroblast growth factor basic levels;
THYM	cis	rs259282	0.538	rs12151311	chr19:33112707	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.61	4.66	0.43	1.04e-5	Schizophrenia;
THYM	cis	rs9788682	0.747	rs2938674	chr15:78757913	C/A	cg18825076	chr15:78729989	IREB2	0.71	5.63	0.5	1.85e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg02931644	chr1:25747376	RHCE	0.58	4.46	0.42	2.28e-5	Erythrocyte sedimentation rate;
THYM	cis	rs62070183	0.766	rs62070232	chr17:31230093	A/C	cg23177095	chr17:30873196	MYO1D	0.63	4.85	0.45	4.76e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.25	5.41	0.49	4.78e-7	Obesity-related traits;
THYM	cis	rs1267303	0.710	rs1535739	chr1:46957719	A/C	cg16387850	chr1:46982889	NA	0.38	4.82	0.44	5.54e-6	Monobrow;
THYM	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.61	4.78	0.44	6.48e-6	Renal function-related traits (BUN);
THYM	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg00080972	chr5:178986291	RUFY1	0.61	8.47	0.66	3.01e-13	Lung cancer;
THYM	trans	rs4773860	0.717	rs2892716	chr13:95899643	A/G	cg07598561	chr15:41218984	NA	0.65	6.98	0.58	3.96e-10	Plateletcrit;
THYM	cis	rs1971762	0.583	rs3852561	chr12:54085842	C/T	cg16917193	chr12:54089295	NA	0.96	9.59	0.7	1.24e-15	Height;
THYM	cis	rs1421898	0.625	rs17623812	chr5:157943321	A/G	cg06698293	chr5:158690540	UBLCP1	-0.97	-4.6	-0.43	1.28e-5	Inflammatory skin disease;
THYM	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg18402987	chr7:1209562	NA	0.65	5.13	0.47	1.55e-6	Longevity;Endometriosis;
THYM	cis	rs16857609	1.000	rs57481445	chr2:218296374	A/G	cg15335768	chr2:218268053	DIRC3	-0.36	-5.19	-0.47	1.17e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	trans	rs629535	0.773	rs630235	chr8:70033529	T/G	cg21567404	chr3:27674614	NA	1.12	10.86	0.74	2.44e-18	Dupuytren's disease;
THYM	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.54	-0.49	2.74e-7	Menopause (age at onset);
THYM	cis	rs790123	0.553	rs1106346	chr3:122354037	A/G	cg17380795	chr3:122379686	NA	0.6	5.31	0.48	7.21e-7	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs9303401	0.646	rs9303403	chr17:57219300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.65	-4.87	-0.45	4.39e-6	Cognitive test performance;
THYM	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg00810483	chr4:3375144	RGS12	0.32	4.69	0.43	9.16e-6	Serum sulfate level;
THYM	cis	rs2997447	0.655	rs12094933	chr1:26374779	T/C	cg19633962	chr1:26362018	EXTL1	-0.75	-5.18	-0.47	1.25e-6	QRS complex (12-leadsum);
THYM	cis	rs675209	0.552	rs6925389	chr6:7112819	A/G	cg24899545	chr6:7112846	RREB1	-0.45	-4.58	-0.43	1.39e-5	Urate levels;
THYM	cis	rs7599312	1.000	rs7599312	chr2:213413231	C/T	cg16329650	chr2:213403929	ERBB4	0.88	6.28	0.54	1.01e-8	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg26924012	chr15:45694286	SPATA5L1	0.62	4.51	0.42	1.84e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs763014	0.833	rs3743902	chr16:632728	T/C	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.95	0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg08645402	chr16:4508243	NA	0.61	4.97	0.45	2.91e-6	Schizophrenia;
THYM	cis	rs6084875	0.840	rs6052822	chr20:4726510	T/G	cg19614321	chr20:4804581	RASSF2	0.44	4.46	0.42	2.22e-5	Systemic lupus erythematosus;
THYM	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg23422044	chr7:1970798	MAD1L1	-0.81	-5.38	-0.48	5.42e-7	Bipolar disorder;
THYM	cis	rs4285028	0.699	rs12629742	chr3:121614895	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.81	-5.7	-0.5	1.36e-7	Multiple sclerosis;
THYM	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg24692254	chr21:30365293	RNF160	1.01	9.91	0.71	2.52e-16	Dental caries;
THYM	cis	rs1372520	0.745	rs2736994	chr4:90784528	A/G	cg01966878	chr4:90757139	SNCA	-0.71	-5.7	-0.51	1.32e-7	Neuroticism;
THYM	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg21644426	chr2:191273491	MFSD6	-0.74	-5.2	-0.47	1.13e-6	Diastolic blood pressure;
THYM	cis	rs965469	0.843	rs6139122	chr20:3395871	T/G	cg25506879	chr20:3388711	C20orf194	-0.87	-5.25	-0.47	9.31e-7	IFN-related cytopenia;
THYM	cis	rs7560272	0.723	rs12995433	chr2:73641326	C/T	cg19565262	chr2:73869966	NAT8	0.64	5.07	0.46	1.96e-6	Schizophrenia;
THYM	cis	rs870825	0.616	rs28450662	chr4:185638900	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs3772130	0.962	rs9822949	chr3:121541239	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs6598955	0.671	rs10159433	chr1:26618370	A/G	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.62	0.43	1.2e-5	Obesity-related traits;
THYM	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg25918947	chr17:41365094	TMEM106A	-0.69	-5.84	-0.51	7.34e-8	Menopause (age at onset);
THYM	cis	rs1843834	0.858	rs2047136	chr2:225511361	A/T	cg22509189	chr2:225307070	NA	-0.64	-4.56	-0.42	1.53e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg21773646	chr17:80085082	CCDC57	-0.35	-4.95	-0.45	3.2e-6	Life satisfaction;
THYM	cis	rs10911232	0.507	rs10797819	chr1:183006911	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs6121246	0.559	rs6121243	chr20:30415094	C/G	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg13319975	chr6:146136371	FBXO30	-0.72	-6.02	-0.53	3.33e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9905704	0.874	rs2643126	chr17:56737765	A/G	cg12560992	chr17:57184187	TRIM37	0.69	4.79	0.44	6.04e-6	Testicular germ cell tumor;
THYM	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg07570687	chr10:102243282	WNT8B	0.84	8.04	0.64	2.45e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4790333	0.605	rs2447087	chr17:2253793	G/A	cg02569219	chr17:2266849	SGSM2	0.65	5.41	0.49	4.76e-7	Proinsulin levels;
THYM	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg22841779	chr14:105766346	BRF1	-0.49	-6.27	-0.54	1.04e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs12579753	1.000	rs66646148	chr12:82248520	T/G	cg21231944	chr12:82153410	PPFIA2	-0.6	-4.65	-0.43	1.07e-5	Resting heart rate;
THYM	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs7819412	0.512	rs1435282	chr8:11251705	G/A	cg21775007	chr8:11205619	TDH	-0.67	-5.29	-0.48	7.8e-7	Triglycerides;
THYM	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs9326248	0.861	rs7120449	chr11:117042899	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.67	4.78	0.44	6.27e-6	Blood protein levels;
THYM	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs7769051	0.522	rs7775241	chr6:133109022	T/C	cg07930552	chr6:133119739	C6orf192	1.21	5.29	0.48	7.84e-7	Type 2 diabetes nephropathy;
THYM	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg18252515	chr7:66147081	NA	-1.57	-8.55	-0.66	2.07e-13	Diabetic kidney disease;
THYM	cis	rs2236521	0.659	rs73144993	chr20:60893458	A/G	cg09594475	chr20:60884601	LAMA5	0.32	4.61	0.43	1.25e-5	Pelvic organ prolapse;
THYM	cis	rs600806	0.813	rs6664236	chr1:109986672	C/A	cg23616212	chr1:109941201	SORT1	-0.48	-4.47	-0.42	2.17e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03517284	chr6:25882590	NA	-0.76	-5.98	-0.52	3.87e-8	Blood metabolite levels;
THYM	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg07061783	chr6:25882402	NA	0.58	4.51	0.42	1.88e-5	Height;
THYM	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg23958373	chr8:599963	NA	0.9	4.54	0.42	1.63e-5	IgG glycosylation;
THYM	cis	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg13609457	chr4:120235615	NA	-0.53	-4.97	-0.45	2.97e-6	Corneal astigmatism;
THYM	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg12016809	chr21:47604291	C21orf56	-0.63	-4.55	-0.42	1.6e-5	Testicular germ cell tumor;
THYM	cis	rs7980799	0.649	rs10772088	chr12:33663849	A/T	cg06521331	chr12:34319734	NA	0.67	4.64	0.43	1.11e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg21784768	chr11:537496	LRRC56	-1.37	-6.17	-0.53	1.7e-8	Body mass index;
THYM	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg18252515	chr7:66147081	NA	0.63	4.74	0.44	7.37e-6	Aortic root size;
THYM	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg24818145	chr4:99064322	C4orf37	0.69	5.37	0.48	5.48e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4242434	0.927	rs2272718	chr8:22457388	G/A	cg03733263	chr8:22462867	KIAA1967	1.2	11.86	0.77	1.94e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1061377	0.585	rs1367296	chr4:39068515	C/T	cg24403649	chr4:39172243	NA	0.57	4.59	0.43	1.35e-5	Uric acid levels;
THYM	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.59	4.45	0.42	2.3e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs1512268	0.526	rs56014938	chr8:23519135	T/A	cg20272884	chr8:23712762	STC1	-0.45	-4.53	-0.42	1.69e-5	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7258465	1.000	rs8107367	chr19:18564705	A/G	cg01380346	chr19:18557039	ELL	-0.47	-4.69	-0.43	8.97e-6	Breast cancer;
THYM	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg03388043	chr17:80084554	CCDC57	-0.63	-5.29	-0.48	7.76e-7	Life satisfaction;
THYM	cis	rs36051895	0.632	rs12684720	chr9:5150800	T/C	cg02405213	chr9:5042618	JAK2	-1.04	-10.96	-0.75	1.47e-18	Pediatric autoimmune diseases;
THYM	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg16414030	chr3:133502952	NA	-0.84	-8.28	-0.65	7.65e-13	Iron status biomarkers;
THYM	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg12564285	chr5:131593104	PDLIM4	-0.43	-4.66	-0.43	1.04e-5	Breast cancer;
THYM	cis	rs6429082	0.508	rs4233473	chr1:235488052	C/G	cg26050004	chr1:235667680	B3GALNT2	0.58	4.51	0.42	1.88e-5	Adiposity;
THYM	cis	rs6840360	1.000	rs3749562	chr4:152596540	T/C	cg22705602	chr4:152727874	NA	-0.61	-6.54	-0.56	3.02e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1021993	0.868	rs906350	chr1:209528108	T/C	cg06155620	chr1:209527581	NA	-0.63	-5.34	-0.48	6.36e-7	Gut microbiome composition (winter);
THYM	cis	rs1915146	0.904	rs28414241	chr10:126851739	A/T	cg05090351	chr10:126851162	NA	0.75	8.86	0.67	4.61e-14	Menarche (age at onset);
THYM	cis	rs6918586	0.616	rs1056314	chr6:26114653	G/A	cg12310025	chr6:25882481	NA	-0.68	-5.49	-0.49	3.3e-7	Schizophrenia;
THYM	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg11335335	chr11:637885	DRD4	-0.69	-6.23	-0.54	1.24e-8	Systemic lupus erythematosus;
THYM	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg10911889	chr6:126070802	HEY2	-0.59	-4.82	-0.44	5.46e-6	Brugada syndrome;
THYM	cis	rs4732038	0.526	rs12672016	chr7:134273321	T/C	cg06906464	chr7:134288099	NA	-0.52	-5.31	-0.48	7.3e-7	Longevity;
THYM	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg02782426	chr3:40428986	ENTPD3	0.56	5.02	0.46	2.37e-6	Renal cell carcinoma;
THYM	cis	rs35883536	0.551	rs6666607	chr1:101032368	A/G	cg09408571	chr1:101003634	GPR88	-0.53	-5.71	-0.51	1.28e-7	Monocyte count;
THYM	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg14983838	chr19:29218262	NA	1.13	9.44	0.7	2.55e-15	Methadone dose in opioid dependence;
THYM	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg16586182	chr3:47516702	SCAP	-0.67	-5.62	-0.5	1.9e-7	Colorectal cancer;
THYM	cis	rs921968	0.509	rs7571743	chr2:219352572	C/T	cg02176678	chr2:219576539	TTLL4	0.73	7.09	0.59	2.4e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs6546324	0.625	rs2861686	chr2:67838051	A/T	cg18237512	chr2:67827392	NA	-0.78	-4.63	-0.43	1.16e-5	Endometriosis;
THYM	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg08859206	chr1:53392774	SCP2	-0.51	-5.32	-0.48	7.04e-7	Monocyte count;
THYM	cis	rs61931739	0.782	rs1197569	chr12:34186733	A/T	cg06521331	chr12:34319734	NA	-0.58	-4.86	-0.45	4.58e-6	Morning vs. evening chronotype;
THYM	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	8.9	0.67	3.71e-14	Cognitive test performance;
THYM	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg18402987	chr7:1209562	NA	1.04	6.2	0.54	1.45e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg27129171	chr3:47204927	SETD2	0.75	7.25	0.6	1.09e-10	Colorectal cancer;
THYM	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg25072359	chr17:41440525	NA	0.72	5.31	0.48	7.04e-7	Menopause (age at onset);
THYM	cis	rs4731207	0.596	rs13233978	chr7:124587620	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs977987	0.778	rs11149825	chr16:75434878	C/T	cg03315344	chr16:75512273	CHST6	0.77	6.31	0.54	8.75e-9	Dupuytren's disease;
THYM	cis	rs28829049	0.731	rs7537573	chr1:19373605	C/T	cg13387374	chr1:19411106	UBR4	0.65	5.43	0.49	4.41e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-4.73	-0.44	7.8e-6	Chronic sinus infection;
THYM	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg06728252	chr6:26598149	ABT1	-0.43	-5.11	-0.46	1.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg11764359	chr7:65958608	NA	0.69	4.78	0.44	6.27e-6	Aortic root size;
THYM	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.76	6.74	0.57	1.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2075230	0.705	rs1641536	chr17:7545984	T/C	cg10509001	chr17:7553872	ATP1B2	-0.56	-4.52	-0.42	1.79e-5	Hormone measurements;
THYM	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.41	7.18	0.59	1.55e-10	Obesity-related traits;
THYM	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg24399712	chr22:39784796	NA	0.92	10.98	0.75	1.36e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22307029	chr19:49891270	CCDC155	0.59	4.61	0.43	1.25e-5	Multiple sclerosis;
THYM	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg10802521	chr3:52805072	NEK4	-0.71	-6.18	-0.54	1.57e-8	Bipolar disorder;
THYM	cis	rs4888262	0.526	rs8056718	chr16:74612030	G/C	cg01733217	chr16:74700730	RFWD3	0.83	8.61	0.66	1.55e-13	Testicular germ cell tumor;
THYM	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg26384229	chr12:38710491	ALG10B	0.95	7.55	0.61	2.7e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg01448562	chr3:133502909	NA	-0.83	-6.92	-0.58	5.15e-10	Iron status biomarkers;
THYM	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg03433033	chr1:76189801	ACADM	0.79	11.21	0.75	4.52e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.69	-4.59	-0.43	1.35e-5	Menarche (age at onset);
THYM	cis	rs7772486	0.790	rs9497427	chr6:146238302	T/A	cg13319975	chr6:146136371	FBXO30	0.75	6.27	0.54	1.07e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8067545	0.516	rs4925086	chr17:20013459	A/T	cg13482628	chr17:19912719	NA	0.55	4.7	0.43	8.64e-6	Schizophrenia;
THYM	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	6.13	0.53	1.95e-8	Total body bone mineral density;
THYM	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg06028808	chr11:68637592	NA	0.68	7.24	0.6	1.18e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6500395	1.000	rs2354579	chr16:48601521	T/C	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2035647	0.537	rs3857868	chr7:137797764	T/A	cg18769353	chr7:137028617	PTN	0.59	4.46	0.42	2.22e-5	Blood metabolite levels;
THYM	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg02640540	chr1:67518911	SLC35D1	0.59	4.64	0.43	1.09e-5	Lymphocyte percentage of white cells;
THYM	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg13319975	chr6:146136371	FBXO30	-0.67	-5.64	-0.5	1.77e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.69	-4.62	-0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg02478829	chr6:26598070	ABT1	-0.33	-4.49	-0.42	1.97e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg23187316	chr7:1099788	C7orf50	0.58	4.45	0.42	2.32e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg01416388	chr22:39784598	NA	-0.88	-7.96	-0.63	3.57e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10871290	0.650	rs3760055	chr16:74490529	G/A	cg01733217	chr16:74700730	RFWD3	0.62	4.98	0.46	2.8e-6	Breast cancer;
THYM	cis	rs6754311	0.593	rs313523	chr2:136432103	G/A	cg20242066	chr2:136595261	LCT	0.55	6.04	0.53	3.05e-8	Mosquito bite size;
THYM	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-5.22	-0.47	1.04e-6	Hemoglobin concentration;
THYM	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg20290983	chr6:43655470	MRPS18A	1.44	16.17	0.86	4.93e-29	IgG glycosylation;
THYM	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9311676	0.656	rs9881869	chr3:58333255	G/A	cg26110898	chr3:58419937	PDHB	-0.44	-4.58	-0.43	1.41e-5	Systemic lupus erythematosus;
THYM	cis	rs2282300	0.739	rs10835647	chr11:30313268	A/G	cg06241208	chr11:30344200	C11orf46	-0.82	-6.01	-0.52	3.38e-8	Morning vs. evening chronotype;
THYM	cis	rs10498870	0.534	rs2502560	chr6:70595373	G/T	cg03001484	chr6:70507230	LMBRD1	-0.28	-4.68	-0.43	9.62e-6	Subjective well-being (multi-trait analysis);
THYM	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	cis	rs7804356	0.871	rs2189019	chr7:26798581	C/T	cg24979288	chr7:27242424	NA	0.63	4.54	0.42	1.66e-5	Type 1 diabetes;
THYM	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg26441486	chr22:50317300	CRELD2	0.45	7.6	0.62	2.04e-11	Schizophrenia;
THYM	cis	rs7809950	1.000	rs10267907	chr7:107184466	C/T	cg23024343	chr7:107201750	COG5	-0.94	-8.59	-0.66	1.7e-13	Coronary artery disease;
THYM	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Bladder cancer;
THYM	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg23281280	chr6:28129359	ZNF389	0.67	5.17	0.47	1.31e-6	Parkinson's disease;
THYM	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg23711669	chr6:146136114	FBXO30	0.96	10.29	0.73	3.99e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1048238	0.506	rs12039892	chr1:16167974	A/G	cg21385522	chr1:16154831	NA	0.68	5.6	0.5	2.12e-7	Systolic blood pressure;
THYM	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg19875535	chr5:140030758	IK	-0.63	-5.69	-0.5	1.43e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7107174	0.892	rs12281104	chr11:78046940	T/C	cg02023728	chr11:77925099	USP35	0.62	6.0	0.52	3.51e-8	Testicular germ cell tumor;
THYM	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	6.66	0.56	1.74e-9	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg04063615	chr12:132293388	NA	-0.6	-6.29	-0.54	9.78e-9	Migraine;
THYM	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg08017756	chr2:100939284	LONRF2	-0.74	-7.65	-0.62	1.65e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7843479	0.601	rs10866827	chr8:21801141	G/A	cg17168535	chr8:21777572	XPO7	0.94	8.69	0.67	1.06e-13	Mean corpuscular volume;
THYM	cis	rs13215566	0.929	rs35007480	chr6:89924201	A/G	cg08400210	chr6:89908154	GABRR1	0.92	5.05	0.46	2.13e-6	Spherical equivalent (joint analysis main effects and education interaction);
THYM	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21659725	chr3:3221576	CRBN	0.88	9.8	0.71	4.47e-16	Intelligence (multi-trait analysis);
THYM	cis	rs7027203	0.828	rs7037960	chr9:96584028	G/A	cg13679303	chr9:96623674	NA	-0.47	-4.74	-0.44	7.5e-6	DNA methylation (variation);
THYM	cis	rs2461751	0.527	rs80274443	chr2:176492091	G/A	cg00495775	chr2:176972041	HOXD11	0.82	4.46	0.42	2.26e-5	Electrocardiographic conduction measures;
THYM	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.82	7.51	0.61	3.23e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg02953382	chr22:24373134	LOC391322	-0.93	-10.38	-0.73	2.56e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg10523679	chr1:76189770	ACADM	0.91	9.7	0.71	7.37e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg10802521	chr3:52805072	NEK4	-0.7	-5.93	-0.52	4.97e-8	Bipolar disorder;
THYM	cis	rs72627123	0.867	rs73303113	chr14:74481068	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg12219531	chr12:120966889	COQ5	-0.84	-6.97	-0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.83	7.04	0.59	2.94e-10	Systemic lupus erythematosus;
THYM	cis	rs7980799	0.682	rs10437795	chr12:33635336	C/G	cg06521331	chr12:34319734	NA	0.7	4.93	0.45	3.53e-6	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs8014204	0.804	rs35769520	chr14:75255115	G/A	cg06637938	chr14:75390232	RPS6KL1	0.56	5.49	0.49	3.27e-7	Caffeine consumption;
THYM	cis	rs2882877	0.735	rs994227	chr2:190432467	T/C	cg10752008	chr2:190445175	SLC40A1	0.67	5.35	0.48	6.06e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg17063962	chr7:91808500	NA	1.1	12.12	0.78	5.59e-21	Breast cancer;
THYM	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg13683864	chr3:40499215	RPL14	-0.87	-8.43	-0.65	3.64e-13	Renal cell carcinoma;
THYM	cis	rs7084402	0.967	rs1649062	chr10:60309326	G/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.65e-7	Refractive error;
THYM	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs2742234	0.541	rs7073849	chr10:43740474	G/C	cg06632098	chr10:43605906	RET	0.74	4.97	0.45	2.95e-6	Hirschsprung disease;
THYM	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11890956	chr21:40555474	PSMG1	0.95	10.43	0.73	2.02e-17	Cognitive function;
THYM	cis	rs7432375	0.580	rs4678442	chr3:136532971	A/G	cg21827317	chr3:136751795	NA	0.54	4.64	0.43	1.13e-5	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg18681998	chr4:17616180	MED28	0.91	8.58	0.66	1.75e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.88	9.61	0.7	1.12e-15	Prudent dietary pattern;
THYM	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg18681998	chr4:17616180	MED28	0.96	8.93	0.68	3.19e-14	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg08257088	chr16:3726052	TRAP1	-0.66	-4.94	-0.45	3.32e-6	Tuberculosis;
THYM	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.16	0.47	1.37e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg06028808	chr11:68637592	NA	0.67	7.14	0.59	1.87e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7830933	0.780	rs11986562	chr8:23609098	T/C	cg04349084	chr8:23602677	NA	0.59	6.37	0.55	6.65e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg27490568	chr2:178487706	NA	0.61	5.46	0.49	3.84e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs10504073	0.584	rs62507182	chr8:49942500	C/A	cg00325661	chr8:49890786	NA	1.08	10.81	0.74	3.14e-18	Blood metabolite ratios;
THYM	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg05552183	chr6:42928497	GNMT	0.68	5.51	0.49	3.08e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg17863274	chr19:49399704	TULP2	-1.01	-6.26	-0.54	1.12e-8	Red cell distribution width;
THYM	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.06	-0.75	9.31e-19	Primary sclerosing cholangitis;
THYM	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg13695892	chr22:41940480	POLR3H	0.86	6.43	0.55	5.06e-9	Vitiligo;
THYM	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg13114125	chr14:105738426	BRF1	-0.7	-5.36	-0.48	5.73e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg07362569	chr17:61921086	SMARCD2	0.72	6.4	0.55	5.96e-9	Prudent dietary pattern;
THYM	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg02753203	chr1:228287806	NA	0.74	6.44	0.55	4.87e-9	Diastolic blood pressure;
THYM	cis	rs2273669	0.915	rs7753554	chr6:109292133	G/C	cg17117243	chr6:109341365	SESN1	-0.77	-4.68	-0.43	9.63e-6	Prostate cancer;
THYM	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg17554472	chr22:41940697	POLR3H	-0.7	-4.52	-0.42	1.8e-5	Vitiligo;
THYM	cis	rs477692	0.569	rs1711670	chr10:131281115	A/G	cg05714579	chr10:131428358	MGMT	0.61	4.94	0.45	3.37e-6	Response to temozolomide;
THYM	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.72	0.51	1.2e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.26	-9.1	-0.68	1.4e-14	Gut microbiome composition (summer);
THYM	cis	rs2456568	0.835	rs1518578	chr11:93656854	G/T	cg26875233	chr11:93583750	C11orf90	-0.5	-4.89	-0.45	4.04e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs10791097	0.739	rs735094	chr11:130725109	G/C	cg12179176	chr11:130786555	SNX19	0.71	5.86	0.52	6.77e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg12292205	chr6:26970375	C6orf41	-0.64	-5.19	-0.47	1.19e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6840360	1.000	rs6838966	chr4:152603475	C/T	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs11048434	0.666	rs12371786	chr12:9090086	G/A	cg13575925	chr12:9217583	LOC144571	0.53	4.94	0.45	3.31e-6	Sjögren's syndrome;
THYM	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs4866334	1.000	rs76259459	chr5:18456963	A/T	cg08675002	chr5:90437527	GPR98	-1.55	-7.42	-0.61	4.85e-11	IgG glycosylation;
THYM	cis	rs4664308	0.691	rs1877196	chr2:160915150	G/T	cg03641300	chr2:160917029	PLA2R1	-0.76	-6.79	-0.57	9.83e-10	Idiopathic membranous nephropathy;
THYM	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg08807101	chr21:30365312	RNF160	0.93	7.48	0.61	3.68e-11	Dental caries;
THYM	cis	rs362272	0.525	rs910568	chr4:3307373	A/G	cg14583973	chr4:3374767	RGS12	0.67	6.54	0.56	3.12e-9	Serum sulfate level;
THYM	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.5	0.73	1.4e-17	Prudent dietary pattern;
THYM	cis	rs28595532	0.764	rs115298416	chr4:119565383	C/T	cg14228332	chr4:119757509	SEC24D	1.35	4.49	0.42	1.98e-5	Cannabis dependence symptom count;
THYM	cis	rs6443245	1.000	rs6443245	chr3:9636660	C/T	cg19099050	chr3:9594382	LHFPL4	0.52	4.74	0.44	7.6e-6	Daytime sleep phenotypes;
THYM	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.29	4.46	0.42	2.27e-5	Obesity-related traits;
THYM	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Body mass index;
THYM	cis	rs11641184	0.528	rs13335254	chr16:11706848	C/T	cg09662852	chr16:11707685	NA	-0.44	-4.94	-0.45	3.31e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg06917634	chr15:78832804	PSMA4	0.88	7.74	0.62	1.04e-11	Sudden cardiac arrest;
THYM	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs981844	1.000	rs55722886	chr4:154668335	A/G	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg12310025	chr6:25882481	NA	0.68	5.56	0.5	2.47e-7	Schizophrenia;
THYM	cis	rs877282	0.853	rs7092652	chr10:756109	G/A	cg10556349	chr10:835070	NA	-0.69	-4.49	-0.42	2.03e-5	Uric acid levels;
THYM	cis	rs7119	0.604	rs2682924	chr15:77863720	C/T	cg27398640	chr15:77910606	LINGO1	-0.59	-6.76	-0.57	1.11e-9	Type 2 diabetes;
THYM	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg11965913	chr1:205819406	PM20D1	-0.79	-7.82	-0.63	7.29e-12	Monocyte percentage of white cells;
THYM	cis	rs1691799	0.867	rs1027399	chr12:66760942	G/A	cg16791601	chr12:66731901	HELB	-0.73	-6.97	-0.58	4.16e-10	White blood cell count (basophil);
THYM	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg04455712	chr21:45112962	RRP1B	0.54	5.04	0.46	2.22e-6	Mean corpuscular volume;
THYM	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg10589385	chr1:150898437	SETDB1	0.65	5.45	0.49	4.01e-7	Melanoma;
THYM	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg24399712	chr22:39784796	NA	0.79	7.09	0.59	2.39e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.84	0.71	3.66e-16	Prudent dietary pattern;
THYM	cis	rs2273669	0.667	rs12210444	chr6:109305743	T/C	cg17117243	chr6:109341365	SESN1	-0.84	-4.94	-0.45	3.41e-6	Prostate cancer;
THYM	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs192264	0.680	rs365789	chr16:65971881	T/C	cg02795155	chr16:66785218	DYNC1LI2	0.61	4.9	0.45	3.96e-6	Subjective well-being;
THYM	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	7.14	0.59	1.88e-10	Platelet count;
THYM	cis	rs7833986	0.501	rs2667999	chr8:56950474	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.4	0.6	5.43e-11	Height;
THYM	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs490234	0.841	rs521119	chr9:128314394	T/C	cg14078157	chr9:128172775	NA	0.67	5.28	0.48	8.02e-7	Mean arterial pressure;
THYM	cis	rs1023500	1.000	rs9620001	chr22:42330229	T/C	cg25094927	chr22:41682102	RANGAP1	-0.72	-4.74	-0.44	7.35e-6	Schizophrenia;
THYM	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1395	0.925	rs1659696	chr2:27407831	G/A	cg23587288	chr2:27483067	SLC30A3	0.58	5.12	0.46	1.62e-6	Blood metabolite levels;
THYM	cis	rs8018808	1.000	rs35881785	chr14:77873571	C/T	cg20045696	chr14:77926864	AHSA1	0.53	4.73	0.44	7.86e-6	Myeloid white cell count;
THYM	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg14349672	chr11:133703707	NA	-0.52	-4.77	-0.44	6.62e-6	Childhood ear infection;
THYM	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg23161317	chr6:28129485	ZNF389	0.67	5.33	0.48	6.55e-7	Parkinson's disease;
THYM	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg04750100	chr2:136595281	LCT	0.49	5.41	0.49	4.69e-7	Mosquito bite size;
THYM	cis	rs4589258	0.737	rs35972962	chr11:90456315	T/C	cg26138821	chr11:89956704	CHORDC1	-0.58	-4.8	-0.44	6.01e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg02475777	chr4:1388615	CRIPAK	0.58	4.47	0.42	2.14e-5	Longevity;
THYM	cis	rs3126085	1.000	rs1858482	chr1:152306921	A/G	cg26020982	chr1:152196106	HRNR	0.36	4.95	0.45	3.19e-6	Atopic dermatitis;
THYM	cis	rs12310956	0.532	rs11052951	chr12:33986181	T/A	cg10856724	chr12:34555212	NA	-0.71	-6.55	-0.56	2.92e-9	Morning vs. evening chronotype;
THYM	cis	rs2354432	0.607	rs11239980	chr1:146782698	G/A	cg25205988	chr1:146714368	CHD1L	-1.0	-5.33	-0.48	6.54e-7	Mitochondrial DNA levels;
THYM	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg23750338	chr8:142222470	SLC45A4	-0.5	-4.64	-0.43	1.13e-5	Immature fraction of reticulocytes;
THYM	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg03806693	chr22:41940476	POLR3H	-1.16	-9.9	-0.71	2.75e-16	Vitiligo;
THYM	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg12310025	chr6:25882481	NA	0.77	6.25	0.54	1.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2625529	0.823	rs11072332	chr15:72108307	G/T	cg16672083	chr15:72433130	SENP8	-0.59	-4.93	-0.45	3.43e-6	Red blood cell count;
THYM	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg07936489	chr17:37558343	FBXL20	-0.82	-5.61	-0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg09307838	chr4:120376055	NA	0.78	5.64	0.5	1.76e-7	Corneal astigmatism;
THYM	cis	rs662064	0.962	rs620405	chr1:10554794	T/C	cg20482658	chr1:10539492	PEX14	-0.47	-6.06	-0.53	2.71e-8	Asthma;
THYM	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg20891283	chr12:69753455	YEATS4	-0.63	-5.32	-0.48	7.01e-7	Blood protein levels;
THYM	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg17143192	chr8:8559678	CLDN23	0.91	6.74	0.57	1.2e-9	Obesity-related traits;
THYM	cis	rs3110496	0.751	rs3115096	chr17:27907486	A/G	cg04498198	chr17:27899966	TP53I13	-0.56	-6.11	-0.53	2.15e-8	Height;
THYM	cis	rs6539288	0.899	rs6539292	chr12:107313713	C/T	cg26297688	chr12:107349093	C12orf23	-0.47	-4.89	-0.45	4.15e-6	Total body bone mineral density;
THYM	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg02734326	chr4:10020555	SLC2A9	0.76	7.25	0.6	1.1e-10	Bone mineral density;
THYM	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg13010199	chr12:38710504	ALG10B	0.71	5.77	0.51	9.75e-8	Heart rate;
THYM	cis	rs7704138	0.639	rs4865978	chr5:55016092	A/G	cg18456523	chr5:54516805	NA	-0.58	-4.59	-0.43	1.34e-5	Height;
THYM	cis	rs2836974	0.800	rs12482857	chr21:40514861	T/C	cg11644478	chr21:40555479	PSMG1	1.08	9.12	0.68	1.27e-14	Cognitive function;
THYM	cis	rs2219968	0.683	rs13261986	chr8:78906904	C/T	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03264133	chr6:25882463	NA	-1.07	-9.26	-0.69	6.18e-15	Intelligence (multi-trait analysis);
THYM	cis	rs10089	1.000	rs6595806	chr5:127499764	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs10927875	0.541	rs1763601	chr1:16340460	G/T	cg22431228	chr1:16359049	CLCNKA	-0.53	-5.13	-0.47	1.51e-6	Dilated cardiomyopathy;
THYM	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg11247378	chr22:39784982	NA	-1.07	-14.35	-0.83	1.63e-25	Intelligence (multi-trait analysis);
THYM	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg01304814	chr3:48885189	PRKAR2A	0.99	5.2	0.47	1.13e-6	Cognitive function;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg09499248	chr16:103531	POLR3K;SNRNP25	1.26	6.93	0.58	4.95e-10	Pulmonary function decline;
THYM	cis	rs7809615	0.792	rs45618033	chr7:99046617	G/A	cg12290671	chr7:99195819	NA	-0.99	-4.83	-0.44	5.27e-6	Blood metabolite ratios;
THYM	cis	rs56161922	1.000	rs4562622	chr1:207876577	A/C	cg09557387	chr1:207818395	CR1L	-1.25	-5.55	-0.5	2.53e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg13944838	chr5:179740914	GFPT2	-0.86	-6.69	-0.57	1.55e-9	Height;
THYM	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg08000102	chr2:233561755	GIGYF2	-0.55	-4.87	-0.45	4.42e-6	Coronary artery disease;
THYM	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg16342193	chr10:102329863	NA	-0.5	-5.13	-0.47	1.54e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4638749	0.677	rs4676187	chr2:108842936	T/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs6500395	0.926	rs1039342	chr16:48577498	G/A	cg04672837	chr16:48644449	N4BP1	0.49	4.74	0.44	7.38e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs10411161	0.721	rs10401778	chr19:52384315	C/T	cg25361850	chr19:52391789	ZNF577	0.71	4.99	0.46	2.69e-6	Breast cancer;
THYM	cis	rs11645898	1.000	rs72791115	chr16:72207315	T/C	cg03805757	chr16:71968109	PKD1L3	-0.66	-4.94	-0.45	3.34e-6	Blood protein levels;
THYM	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg17063962	chr7:91808500	NA	1.15	11.85	0.77	1.98e-20	Breast cancer;
THYM	cis	rs17744026	0.618	rs76807617	chr11:123702983	T/C	cg00079598	chr11:123676903	OR6M1	-0.48	-4.54	-0.42	1.68e-5	IgE levels in asthmatics (D.p. specific);
THYM	trans	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs1003719	0.788	rs1543749	chr21:38446621	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg18357526	chr6:26021779	HIST1H4A	0.75	6.65	0.56	1.89e-9	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.41	0.61	5.04e-11	Obesity-related traits;
THYM	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg26022315	chr17:47021804	SNF8	0.51	4.87	0.45	4.44e-6	Type 2 diabetes;
THYM	cis	rs6430585	0.583	rs79633114	chr2:136586825	C/T	cg07169764	chr2:136633963	MCM6	1.23	13.52	0.81	7.29e-24	Corneal structure;
THYM	cis	rs55940034	0.523	rs2149067	chr13:111062324	G/A	cg06243866	chr13:111019493	COL4A2	-0.58	-4.95	-0.45	3.26e-6	Myocardial infarction;
THYM	cis	rs883565	0.655	rs1608728	chr3:39089560	C/T	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	5.0	0.46	2.59e-6	Handedness;
THYM	cis	rs994014	0.847	rs6824784	chr4:82275412	A/G	cg17825130	chr4:82283507	NA	0.46	4.47	0.42	2.16e-5	Height;
THYM	cis	rs7220711	0.677	rs9908642	chr17:41776859	G/C	cg26893861	chr17:41843967	DUSP3	0.58	4.91	0.45	3.74e-6	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs7011507	0.594	rs72639024	chr8:49343578	C/T	cg08774009	chr8:49309094	NA	-0.6	-4.71	-0.44	8.47e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs4242434	0.854	rs11782130	chr8:22452357	G/T	cg11461670	chr8:22454935	PDLIM2	-0.38	-6.79	-0.57	9.56e-10	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs8070740	0.786	rs34856659	chr17:5327572	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.71	5.6	0.5	2.03e-7	Menopause (age at onset);
THYM	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg00495681	chr13:53174319	NA	1.05	10.63	0.74	7.44e-18	Lewy body disease;
THYM	cis	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs55665837	1.000	rs7121171	chr11:14446420	A/G	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs6163	0.727	rs284862	chr10:104572081	C/T	cg08772003	chr10:104629869	AS3MT	0.66	6.15	0.53	1.79e-8	Waist circumference;Hip circumference;
THYM	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg10560079	chr2:191398806	TMEM194B	-0.95	-7.86	-0.63	5.88e-12	Diastolic blood pressure;
THYM	cis	rs8103278	1.000	rs7256192	chr19:46338492	G/A	cg14061069	chr19:46274453	DMPK	-0.54	-5.16	-0.47	1.38e-6	Coronary artery disease;
THYM	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg12963246	chr6:28129442	ZNF389	0.72	6.2	0.54	1.44e-8	Depression;
THYM	cis	rs3218192	1.000	rs3218192	chr1:23841370	G/T	cg06033387	chr1:23751582	TCEA3	-0.5	-4.5	-0.42	1.93e-5	Sum eosinophil basophil counts;
THYM	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg05802129	chr4:122689817	NA	-0.57	-4.45	-0.42	2.31e-5	Type 2 diabetes;
THYM	cis	rs478304	0.651	rs11537193	chr11:65500003	A/C	cg27068330	chr11:65405492	SIPA1	-0.95	-8.8	-0.67	6.03e-14	Acne (severe);
THYM	cis	rs240764	0.645	rs454747	chr6:101055566	T/C	cg21058520	chr6:100914733	NA	-0.58	-4.91	-0.45	3.81e-6	Neuroticism;
THYM	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg26149184	chr10:133730230	NA	0.78	4.74	0.44	7.39e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg19761014	chr17:28927070	LRRC37B2	0.89	4.93	0.45	3.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2777491	1.000	rs316610	chr15:41752852	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.09	-12.45	-0.79	1.11e-21	Ulcerative colitis;
THYM	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg10057126	chr4:77819792	ANKRD56	0.72	6.14	0.53	1.93e-8	Emphysema distribution in smoking;
THYM	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg00376283	chr12:123451042	ABCB9	0.91	7.59	0.61	2.14e-11	Platelet count;
THYM	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.67	-5.24	-0.47	9.47e-7	Diastolic blood pressure;
THYM	cis	rs7107174	1.000	rs4128206	chr11:78015952	A/C	cg02023728	chr11:77925099	USP35	0.71	6.35	0.55	7.45e-9	Testicular germ cell tumor;
THYM	cis	rs300703	0.719	rs400040	chr2:199422	G/T	cg21211680	chr2:198530	NA	1.15	6.94	0.58	4.7e-10	Blood protein levels;
THYM	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.71e-7	Alzheimer's disease (late onset);
THYM	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.6	-0.56	2.37e-9	Chronic sinus infection;
THYM	cis	rs2637266	1.000	rs2894339	chr10:78354104	G/A	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs7580658	0.637	rs4662710	chr2:127976817	C/G	cg10021288	chr2:128175891	PROC	-0.61	-5.48	-0.49	3.52e-7	Protein C levels;
THYM	cis	rs57590327	0.503	rs13080520	chr3:81850742	T/C	cg07356753	chr3:81810745	GBE1	-0.68	-4.66	-0.43	1.04e-5	Extraversion;
THYM	cis	rs6815814	0.950	rs73236632	chr4:38836071	G/A	cg02016764	chr4:38805732	TLR1	-0.51	-5.08	-0.46	1.85e-6	Breast cancer;
THYM	cis	rs6866344	0.598	rs34703961	chr5:178147874	A/G	cg03877680	chr5:178157825	ZNF354A	0.75	5.13	0.47	1.52e-6	Neutrophil percentage of white cells;
THYM	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg07884673	chr3:53033167	SFMBT1	1.17	5.9	0.52	5.49e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg17480646	chr11:65405466	SIPA1	-0.94	-8.85	-0.67	4.72e-14	Acne (severe);
THYM	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.03	8.87	0.67	4.38e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs17443541	0.507	rs6711524	chr2:200462940	T/C	cg03741458	chr2:200468445	NA	-0.8	-6.04	-0.53	3.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg24846680	chr1:228362309	C1orf69	0.51	4.53	0.42	1.72e-5	Diastolic blood pressure;
THYM	cis	rs7681440	0.560	rs2583986	chr4:90757947	T/A	cg06632027	chr4:90757378	SNCA	-0.71	-5.59	-0.5	2.13e-7	Dementia with Lewy bodies;
THYM	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg20999797	chr1:1681921	NA	0.43	4.76	0.44	6.82e-6	Body mass index;
THYM	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg02887458	chr19:19495540	GATAD2A	0.47	5.3	0.48	7.47e-7	Bipolar disorder;
THYM	cis	rs4789939	1.000	rs4789939	chr17:76881703	T/C	cg08012219	chr17:76913036	TIMP2	-0.78	-5.4	-0.48	4.89e-7	Dupuytren's disease;
THYM	cis	rs9560113	1.000	rs9560106	chr13:112179605	A/G	cg14154082	chr13:112174009	NA	0.85	7.78	0.62	8.66e-12	Menarche (age at onset);
THYM	cis	rs6946131	0.614	rs7787290	chr7:54788838	C/G	cg16668896	chr7:54900801	NA	0.45	4.78	0.44	6.45e-6	Systemic lupus erythematosus;
THYM	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	5.42	0.49	4.47e-7	Schizophrenia;
THYM	cis	rs6496667	0.557	rs2601203	chr15:90958129	T/G	cg00425431	chr15:90792223	TTLL13	0.44	5.14	0.47	1.45e-6	Rheumatoid arthritis;
THYM	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs344364	0.577	rs2745194	chr16:1854038	C/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	0.4	4.45	0.42	2.33e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs11078597	0.731	rs12937244	chr17:1646317	T/C	cg18436246	chr17:1640651	WDR81	0.64	4.63	0.43	1.14e-5	Serum albumin level;
THYM	cis	rs7833790	0.724	rs6473299	chr8:82676936	A/G	cg17211192	chr8:82754475	SNX16	-0.84	-6.47	-0.55	4.23e-9	Diastolic blood pressure;
THYM	cis	rs4769475	1.000	rs7332725	chr13:26732262	G/C	cg13319468	chr13:27597730	NA	-0.58	-4.48	-0.42	2.09e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs6840360	0.967	rs17027798	chr4:152597540	A/G	cg22705602	chr4:152727874	NA	-0.61	-6.54	-0.56	3.02e-9	Intelligence (multi-trait analysis);
THYM	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg16342193	chr10:102329863	NA	-0.54	-5.37	-0.48	5.67e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs612683	0.759	rs12722868	chr1:100956478	A/G	cg09408571	chr1:101003634	GPR88	0.42	4.46	0.42	2.21e-5	Breast cancer;
THYM	cis	rs58873874	0.737	rs11466784	chr5:156921651	G/A	cg08916508	chr5:156566250	MED7	-1.34	-5.28	-0.48	8.28e-7	Bipolar disorder (body mass index interaction);
THYM	cis	rs892961	0.932	rs312853	chr17:75406045	T/G	cg05865280	chr17:75406074	SEPT9	0.5	8.67	0.66	1.13e-13	Airflow obstruction;
THYM	cis	rs7011507	0.700	rs55927958	chr8:49335274	C/T	cg08774009	chr8:49309094	NA	-0.62	-4.83	-0.44	5.19e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs4911259	0.552	rs6057663	chr20:31463071	G/T	cg13636640	chr20:31349939	DNMT3B	-0.63	-6.18	-0.54	1.61e-8	Inflammatory bowel disease;
THYM	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg07636037	chr3:49044803	WDR6	0.97	10.07	0.72	1.15e-16	Parkinson's disease;
THYM	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg04287289	chr16:89883240	FANCA	-0.55	-4.84	-0.44	4.99e-6	Vitiligo;
THYM	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg18876405	chr7:65276391	NA	-0.61	-5.32	-0.48	6.95e-7	Aortic root size;
THYM	cis	rs7646881	0.812	rs9864589	chr3:158430706	A/G	cg18349298	chr3:158450550	RARRES1	0.52	4.48	0.42	2.07e-5	Tetralogy of Fallot;
THYM	cis	rs9311676	0.632	rs62258126	chr3:58396114	T/C	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs9486719	1.000	rs13202675	chr6:97028427	C/T	cg18709589	chr6:96969512	KIAA0776	-0.68	-4.7	-0.43	8.62e-6	Migraine;Coronary artery disease;
THYM	cis	rs3820068	0.544	rs7551750	chr1:16035008	T/C	cg13390004	chr1:15929781	NA	0.65	4.81	0.44	5.56e-6	Systolic blood pressure;
THYM	cis	rs68170813	0.559	rs7809508	chr7:107004119	T/C	cg00661777	chr7:106511741	PIK3CG	-0.66	-4.61	-0.43	1.25e-5	Coronary artery disease;
THYM	cis	rs9649213	0.593	rs6465682	chr7:98016417	C/A	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs990171	1.000	rs6727306	chr2:102981644	A/C	cg13897122	chr2:103039542	IL18RAP	-0.4	-4.76	-0.44	6.87e-6	Lymphocyte counts;
THYM	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg13319975	chr6:146136371	FBXO30	-0.69	-5.43	-0.49	4.3e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03264133	chr6:25882463	NA	-0.84	-7.12	-0.59	2.08e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2625529	0.824	rs4445848	chr15:72354598	C/T	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06850241	chr22:41845214	NA	-0.56	-4.84	-0.44	5.08e-6	Vitiligo;
THYM	cis	rs6674970	0.933	rs12134957	chr1:151045419	A/G	cg11822372	chr1:151115635	SEMA6C	0.72	4.93	0.45	3.53e-6	Childhood ear infection;
THYM	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg14186256	chr22:23484241	RTDR1	0.94	9.08	0.68	1.53e-14	Bone mineral density;
THYM	cis	rs10887741	0.532	rs1408378	chr10:89413960	G/A	cg13926569	chr10:89418898	PAPSS2	-0.62	-5.89	-0.52	5.75e-8	Exercise (leisure time);
THYM	cis	rs240764	0.614	rs12210312	chr6:101170849	A/G	cg21058520	chr6:100914733	NA	0.61	5.13	0.47	1.55e-6	Neuroticism;
THYM	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.15	-14.79	-0.83	2.2e-26	Chronic sinus infection;
THYM	cis	rs11039798	0.844	rs7126949	chr11:48972166	A/G	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs35883536	0.647	rs10875313	chr1:101043057	T/C	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs863345	0.548	rs1032352	chr1:158493154	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg24531977	chr5:56204891	C5orf35	1.02	8.34	0.65	5.72e-13	Initial pursuit acceleration;
THYM	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg24818145	chr4:99064322	C4orf37	0.87	7.23	0.6	1.19e-10	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.95	0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg01751800	chr4:77820391	ANKRD56	0.56	4.63	0.43	1.15e-5	Emphysema distribution in smoking;
THYM	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg06112835	chr11:68658793	MRPL21	0.44	6.39	0.55	6.23e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7267979	1.000	rs6037086	chr20:25306338	A/G	cg08601574	chr20:25228251	PYGB	-0.57	-4.49	-0.42	2.02e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2070677	0.877	rs8192777	chr10:135350871	G/T	cg20169779	chr10:135381914	SYCE1	0.81	5.79	0.51	8.91e-8	Gout;
THYM	trans	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs7729447	0.566	rs3792765	chr5:32713836	A/G	cg16267343	chr5:32710456	NPR3	0.8	6.97	0.58	4.09e-10	Blood pressure;
THYM	cis	rs921968	0.648	rs538483	chr2:219458656	T/C	cg02176678	chr2:219576539	TTLL4	0.67	6.66	0.56	1.78e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg02175503	chr12:58329896	NA	0.83	5.66	0.5	1.58e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg07936489	chr17:37558343	FBXL20	0.82	5.69	0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7043114	0.525	rs10820969	chr9:95106678	G/C	cg14631576	chr9:95140430	CENPP	-0.86	-9.03	-0.68	1.97e-14	Height;
THYM	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg07341220	chr16:1583899	IFT140;TMEM204	-0.65	-5.36	-0.48	5.85e-7	Coronary artery disease;
THYM	cis	rs854765	0.583	rs7207395	chr17:17819335	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.34	0.55	7.83e-9	Total body bone mineral density;
THYM	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.78	6.31	0.54	8.8e-9	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7359257	1.000	rs7359257	chr15:67702907	A/C	cg24579218	chr15:68104479	NA	0.54	4.66	0.43	1.04e-5	Menarche (age at onset);
THYM	cis	rs2625529	0.627	rs12898585	chr15:72473928	T/C	cg16672083	chr15:72433130	SENP8	-0.59	-5.35	-0.48	6.11e-7	Red blood cell count;
THYM	cis	rs9790314	0.934	rs9290074	chr3:160997823	T/C	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs4930776	0.897	rs377088	chr12:5762847	A/G	cg02086166	chr12:5775618	ANO2	0.61	6.07	0.53	2.57e-8	Plasma clusterin levels;
THYM	cis	rs865483	0.929	rs853195	chr17:35848255	G/T	cg06716730	chr17:35851459	DUSP14	0.44	7.45	0.61	4.2e-11	Monocyte count;
THYM	cis	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg18512352	chr11:47633146	NA	-0.38	-4.52	-0.42	1.75e-5	HDL cholesterol;
THYM	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg22875332	chr1:76189707	ACADM	-0.73	-6.85	-0.57	7.37e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg06481639	chr22:41940642	POLR3H	-0.82	-5.68	-0.5	1.49e-7	Vitiligo;
THYM	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-6.58	-0.56	2.57e-9	Total body bone mineral density;
THYM	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg20966754	chr17:47091339	IGF2BP1	0.57	7.18	0.59	1.57e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg10360139	chr7:1886902	MAD1L1	-0.57	-4.53	-0.42	1.69e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs7200543	1.000	rs16966952	chr16:15135943	C/T	cg01933576	chr16:15083564	PDXDC1	-0.99	-8.04	-0.64	2.48e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg05872129	chr22:39784769	NA	-1.03	-11.26	-0.76	3.53e-19	Intelligence (multi-trait analysis);
THYM	cis	rs289828	0.811	rs10182245	chr2:152139493	A/G	cg05960677	chr2:152117363	RBM43	0.61	6.05	0.53	2.89e-8	Blood protein levels;
THYM	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs986417	0.748	rs4400969	chr14:61013298	A/C	cg27398547	chr14:60952738	C14orf39	1.0	5.05	0.46	2.14e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs2730245	0.527	rs2730237	chr7:158706166	A/G	cg11984989	chr7:158649758	WDR60	1.01	8.5	0.66	2.65e-13	Height;
THYM	cis	rs1003719	0.680	rs2257091	chr21:38522618	G/T	cg01329690	chr21:38580129	DSCR9	-0.41	-5.68	-0.5	1.45e-7	Eye color traits;
THYM	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	8.87	0.67	4.33e-14	Chronic sinus infection;
THYM	cis	rs7814319	0.933	rs13261747	chr8:97238769	A/G	cg20787634	chr8:97240163	UQCRB	-0.8	-9.82	-0.71	4.05e-16	Lung function (FVC);
THYM	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg13902645	chr11:5959945	NA	-0.54	-4.78	-0.44	6.41e-6	DNA methylation (variation);
THYM	cis	rs1747683	0.966	rs3802583	chr10:13380084	A/G	cg25835351	chr10:13388524	SEPHS1	-0.34	-5.66	-0.5	1.57e-7	IgG glycosylation;
THYM	cis	rs6430585	0.583	rs3754689	chr2:136590746	C/T	cg04750100	chr2:136595281	LCT	0.56	5.89	0.52	5.86e-8	Corneal structure;
THYM	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs596169	0.655	rs28438493	chr1:219173488	T/A	cg19270308	chr1:218458869	RRP15	-1.24	-4.52	-0.42	1.81e-5	Intraocular pressure;
THYM	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg04362960	chr10:104952993	NT5C2	0.59	4.81	0.44	5.73e-6	Arsenic metabolism;
THYM	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg15997130	chr1:24165203	NA	-0.72	-5.53	-0.49	2.82e-7	Immature fraction of reticulocytes;
THYM	cis	rs9921192	1.000	rs251734	chr16:4321441	A/G	cg00021532	chr16:4324280	TFAP4	0.91	8.2	0.64	1.15e-12	Prostate-specific antigen levels;
THYM	cis	rs11096990	0.656	rs3796513	chr4:39291082	G/A	cg24403649	chr4:39172243	NA	-0.64	-5.48	-0.49	3.43e-7	Cognitive function;
THYM	cis	rs7851660	0.874	rs10122541	chr9:100628268	G/A	cg13688889	chr9:100608707	NA	-0.79	-5.92	-0.52	5.07e-8	Strep throat;
THYM	cis	rs7794273	0.755	rs2588621	chr7:18842091	A/T	cg13420273	chr7:18810212	HDAC9	0.57	4.51	0.42	1.83e-5	Night sleep phenotypes;
THYM	cis	rs8100891	0.665	rs7259259	chr19:32819841	G/C	cg16662424	chr19:32837316	ZNF507	-0.44	-4.68	-0.43	9.39e-6	Neuroticism;
THYM	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Body mass index;
THYM	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg18128536	chr17:47092178	IGF2BP1	-0.44	-4.91	-0.45	3.84e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg25517755	chr10:38738941	LOC399744	-0.77	-7.17	-0.59	1.66e-10	Corneal astigmatism;
THYM	trans	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs10463554	0.927	rs468844	chr5:102423576	A/G	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg04546413	chr19:29218101	NA	1.05	8.38	0.65	4.72e-13	Methadone dose in opioid dependence;
THYM	cis	rs11711311	0.955	rs10934241	chr3:113394705	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.55	-4.57	-0.42	1.48e-5	IgG glycosylation;
THYM	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg07131210	chr7:1025825	CYP2W1	-0.84	-4.62	-0.43	1.21e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs887829	0.570	rs10171367	chr2:234597667	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-6.51	-0.56	3.47e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs11166927	0.870	rs11166930	chr8:140824621	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.53	-4.89	-0.45	4.09e-6	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs354225	0.544	rs12713268	chr2:54808845	C/G	cg23486701	chr2:54789491	SPTBN1	-0.37	-4.88	-0.45	4.28e-6	Schizophrenia;
THYM	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12756686	chr19:29218302	NA	1.0	8.27	0.65	8.26e-13	Methadone dose in opioid dependence;
THYM	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg12165864	chr7:66369176	NA	-0.81	-6.03	-0.53	3.07e-8	Corneal structure;
THYM	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg11812906	chr14:75593930	NEK9	0.82	7.6	0.61	2.11e-11	Height;
THYM	trans	rs11186	0.556	rs72906363	chr2:189962922	A/G	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	cis	rs6499129	1.000	rs12935253	chr16:67466430	T/C	cg03615565	chr16:67572595	FAM65A	0.48	4.62	0.43	1.23e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs804280	1.000	rs804281	chr8:11611865	A/G	cg23916205	chr8:11614368	GATA4	-0.49	-4.51	-0.42	1.83e-5	Myopia (pathological);
THYM	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-4.66	-0.43	1.03e-5	Mood instability;
THYM	cis	rs10847980	0.590	rs78462864	chr12:123365867	C/T	cg25930673	chr12:123319894	HIP1R	1.12	5.11	0.46	1.64e-6	Adiponectin levels;
THYM	cis	rs6674176	0.569	rs11210935	chr1:44369444	G/A	cg15962314	chr1:44399869	ARTN	0.5	4.53	0.42	1.68e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg15744005	chr10:104629667	AS3MT	-0.78	-7.33	-0.6	7.48e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7000551	0.606	rs11780055	chr8:22268929	T/A	cg12081754	chr8:22256438	SLC39A14	1.18	12.05	0.78	7.68e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs78761021	0.755	rs75458334	chr17:9795535	C/T	cg26853458	chr17:9805074	RCVRN	0.53	4.46	0.42	2.24e-5	Type 2 diabetes;
THYM	cis	rs2456568	0.741	rs10831137	chr11:93636912	C/T	cg17347335	chr11:93583973	C11orf90	-0.48	-4.58	-0.43	1.39e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg12599982	chr1:44399894	ARTN	0.58	4.7	0.43	8.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4478037	0.558	rs56106158	chr3:33081833	A/G	cg19404215	chr3:33155277	CRTAP	0.94	4.97	0.45	2.9e-6	Major depressive disorder;
THYM	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg03806693	chr22:41940476	POLR3H	-1.04	-7.64	-0.62	1.75e-11	Vitiligo;
THYM	cis	rs11153147	0.649	rs11153145	chr6:109300799	C/T	cg17117243	chr6:109341365	SESN1	-0.86	-4.9	-0.45	3.88e-6	Mean corpuscular volume;
THYM	cis	rs4851266	0.765	rs11123821	chr2:100871189	A/C	cg14675211	chr2:100938903	LONRF2	0.67	5.56	0.5	2.43e-7	Educational attainment;
THYM	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg17211192	chr8:82754475	SNX16	-0.8	-7.08	-0.59	2.52e-10	Diastolic blood pressure;
THYM	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.87	5.86	0.52	6.54e-8	Smoking behavior;
THYM	cis	rs3768617	0.510	rs4651142	chr1:183097386	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.91	0.45	3.8e-6	Fuchs's corneal dystrophy;
THYM	cis	rs4803468	1.000	rs166925	chr19:41926098	T/C	cg09537434	chr19:41945824	ATP5SL	-1.05	-9.33	-0.69	4.53e-15	Height;
THYM	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg05754148	chr16:3507555	NAT15	-0.71	-6.75	-0.57	1.18e-9	Tuberculosis;
THYM	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.07	7.53	0.61	2.93e-11	Smoking behavior;
THYM	cis	rs2806561	0.695	rs67238799	chr1:23335012	G/A	cg19743168	chr1:23544995	NA	0.49	4.82	0.44	5.44e-6	Height;
THYM	cis	rs13082711	1.000	rs35944308	chr3:27536356	G/A	cg02860705	chr3:27208620	NA	0.76	4.94	0.45	3.31e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs2688608	0.623	rs2633317	chr10:75690268	A/G	cg02947784	chr10:75434997	AGAP5	0.52	4.83	0.44	5.12e-6	Inflammatory bowel disease;
THYM	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg17747265	chr1:1875780	NA	-0.79	-9.12	-0.68	1.23e-14	Body mass index;
THYM	cis	rs6032067	0.759	rs6032043	chr20:43817897	A/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-6.1	-0.53	2.33e-8	Blood protein levels;
THYM	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg00080972	chr5:178986291	RUFY1	-0.65	-8.99	-0.68	2.41e-14	Lung cancer;
THYM	cis	rs17401966	1.000	rs6700866	chr1:10306038	A/G	cg20482658	chr1:10539492	PEX14	0.37	4.5	0.42	1.91e-5	Hepatocellular carcinoma;
THYM	cis	rs457717	0.767	rs10045033	chr5:75923945	A/T	cg00415993	chr5:75919188	F2RL2;IQGAP2	-0.32	-4.63	-0.43	1.14e-5	Hearing impairment;
THYM	cis	rs10492096	0.945	rs2041386	chr12:6562538	C/T	cg13857086	chr12:6580257	VAMP1	0.89	5.4	0.48	5.01e-7	Hip geometry;
THYM	cis	rs12282928	0.959	rs7120768	chr11:48264835	T/A	cg22827986	chr11:48284249	OR4X1	0.51	5.43	0.49	4.28e-7	Migraine - clinic-based;
THYM	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg25072359	chr17:41440525	NA	0.72	5.31	0.48	7.04e-7	Menopause (age at onset);
THYM	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14240646	chr10:27532245	ACBD5	-0.78	-4.74	-0.44	7.52e-6	Breast cancer;
THYM	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.74	-8.05	-0.64	2.4e-12	Prudent dietary pattern;
THYM	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg03859395	chr2:55845619	SMEK2	0.6	5.52	0.49	2.95e-7	Metabolic syndrome;
THYM	cis	rs9359856	0.957	rs9342201	chr6:90310356	G/T	cg13799429	chr6:90582589	CASP8AP2	0.47	4.54	0.42	1.66e-5	Bipolar disorder;
THYM	cis	rs17598306	0.935	rs17598132	chr7:96579339	C/T	cg23184042	chr7:96615519	DLX6AS	0.61	4.76	0.44	6.82e-6	Radiation response;
THYM	cis	rs2282300	0.739	rs16920406	chr11:30216158	A/C	cg25418670	chr11:30344373	C11orf46	-0.8	-6.95	-0.58	4.48e-10	Morning vs. evening chronotype;
THYM	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg13736514	chr6:26305472	NA	-0.63	-7.76	-0.62	9.51e-12	Educational attainment;
THYM	cis	rs887829	0.570	rs7563561	chr2:234598991	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.79	-6.86	-0.58	7.08e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs791888	0.760	rs10788561	chr10:89423245	A/G	cg10377144	chr10:89419177	PAPSS2	0.42	7.08	0.59	2.44e-10	Magnesium levels;
THYM	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg24818145	chr4:99064322	C4orf37	-0.76	-6.08	-0.53	2.55e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg07022442	chr13:21864356	NA	0.7	4.71	0.43	8.6e-6	White matter hyperintensity burden;
THYM	cis	rs6701037	0.782	rs12760073	chr1:175139295	G/T	cg17845761	chr1:175162550	KIAA0040	-0.36	-4.57	-0.42	1.45e-5	Alcohol dependence;
THYM	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg26963428	chr7:66367121	NA	-0.59	-4.69	-0.43	9.05e-6	Corneal structure;
THYM	cis	rs7209460	0.556	rs2316513	chr17:1988377	A/T	cg20777128	chr17:1945076	DPH1;OVCA2	-0.48	-4.63	-0.43	1.17e-5	Coronary artery disease;Total body bone mineral density;
THYM	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg16797656	chr11:68205561	LRP5	0.42	4.6	0.43	1.3e-5	Total body bone mineral density;
THYM	cis	rs3741151	1.000	rs74346863	chr11:73054772	C/T	cg12959048	chr11:73096162	RELT	-0.52	-4.96	-0.45	3.04e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs4638749	0.677	rs7568919	chr2:108832376	C/A	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg24450063	chr1:156163899	SLC25A44	1.21	15.52	0.85	8.47e-28	Testicular germ cell tumor;
THYM	cis	rs863345	0.604	rs10797020	chr1:158490324	A/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs6032067	0.925	rs13042522	chr20:43829290	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.68	-7.15	-0.59	1.74e-10	Blood protein levels;
THYM	cis	rs490234	0.702	rs12553311	chr9:128398996	T/C	cg14078157	chr9:128172775	NA	-0.77	-5.97	-0.52	4.01e-8	Mean arterial pressure;
THYM	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg12386194	chr3:101231763	SENP7	0.69	5.13	0.47	1.52e-6	Colorectal cancer;
THYM	cis	rs17006441	0.932	rs9823839	chr3:69880602	A/G	cg18496212	chr3:69797108	MITF	0.69	6.9	0.58	5.82e-10	Hemoglobin concentration;
THYM	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg08885076	chr2:99613938	TSGA10	0.63	5.66	0.5	1.57e-7	Chronic sinus infection;
THYM	cis	rs7599312	0.534	rs7355673	chr2:213404389	T/C	cg20637307	chr2:213403960	ERBB4	1.04	11.16	0.75	5.66e-19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9549328	0.731	rs2873371	chr13:113616242	C/T	cg17524180	chr13:113633600	MCF2L	-0.52	-4.6	-0.43	1.3e-5	Systolic blood pressure;
THYM	cis	rs72627123	0.867	rs73303129	chr14:74489244	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.86	4.91	0.45	3.77e-6	Morning vs. evening chronotype;
THYM	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.48	-0.55	4.06e-9	Personality dimensions;
THYM	cis	rs57920188	0.537	rs72852529	chr1:4076373	A/G	cg20703997	chr1:4087676	NA	1.07	7.68	0.62	1.42e-11	Interleukin-17 levels;
THYM	cis	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg01364799	chr7:75623366	TMEM120A	0.63	4.56	0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7631605	0.905	rs4678943	chr3:37197355	T/C	cg21328643	chr3:37258149	NA	-0.52	-5.0	-0.46	2.65e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs7084402	0.967	rs1658436	chr10:60326910	G/A	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs6669072	1.000	rs3856225	chr1:91242473	G/A	cg08895590	chr1:91227319	NA	-0.54	-6.35	-0.55	7.48e-9	Cognitive function;
THYM	cis	rs7927771	0.839	rs59360790	chr11:47669175	T/C	cg18512352	chr11:47633146	NA	-0.44	-4.97	-0.45	2.91e-6	Subjective well-being;
THYM	cis	rs12701220	0.590	rs1881124	chr7:1096766	A/C	cg01699819	chr7:1052092	C7orf50	-0.83	-6.96	-0.58	4.26e-10	Bronchopulmonary dysplasia;
THYM	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.63	5.29	0.48	7.94e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Body mass index;
THYM	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2154427	0.935	rs2833953	chr21:34162319	G/C	cg21871883	chr21:34145043	C21orf49;C21orf66	0.96	4.63	0.43	1.18e-5	Bilirubin levels;
THYM	cis	rs6570726	0.791	rs401331	chr6:145831408	A/G	cg13319975	chr6:146136371	FBXO30	-0.68	-5.44	-0.49	4.16e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs804280	0.525	rs804287	chr8:11618311	C/T	cg12395012	chr8:11607386	GATA4	-0.64	-5.26	-0.47	9.01e-7	Myopia (pathological);
THYM	trans	rs11109072	1.000	rs7963407	chr12:97907325	T/C	cg17633015	chr7:2020501	MAD1L1	1.0	7.4	0.6	5.45e-11	Obesity (early onset extreme);
THYM	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg16325326	chr1:53192061	ZYG11B	0.96	10.87	0.74	2.35e-18	Monocyte count;
THYM	cis	rs338389	0.586	rs338402	chr15:68253951	C/T	cg07562100	chr15:68569975	FEM1B	0.71	5.26	0.47	8.9e-7	Survival in rectal cancer;
THYM	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg24112000	chr20:60950667	NA	-0.82	-7.21	-0.59	1.3100000000000001e-10	Colorectal cancer;
THYM	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.87	0.45	4.53e-6	Bipolar disorder;
THYM	cis	rs11089937	0.616	rs5995616	chr22:22541057	A/G	cg06866756	chr22:22471216	NA	0.46	5.06	0.46	2.07e-6	Periodontitis (PAL4Q3);
THYM	cis	rs2554380	0.943	rs11636516	chr15:84361773	A/T	cg14598478	chr15:84363061	ADAMTSL3	-0.65	-5.09	-0.46	1.83e-6	Height;
THYM	cis	rs28374715	0.662	rs111522288	chr15:41480169	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.02	-8.4	-0.65	4.27e-13	Ulcerative colitis;
THYM	cis	rs1747683	0.702	rs2254252	chr10:13363822	C/T	cg25835351	chr10:13388524	SEPHS1	0.34	6.11	0.53	2.21e-8	IgG glycosylation;
THYM	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg15557168	chr22:42548783	NA	-0.58	-4.5	-0.42	1.96e-5	Schizophrenia;
THYM	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg10515332	chr4:99064459	C4orf37	0.57	4.56	0.42	1.54e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg18252515	chr7:66147081	NA	-0.66	-5.01	-0.46	2.55e-6	Aortic root size;
THYM	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg00339695	chr16:24857497	SLC5A11	0.68	6.43	0.55	5.15e-9	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg04320152	chr17:18167836	SMCR7	0.6	4.71	0.44	8.34e-6	Total body bone mineral density;
THYM	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg18538332	chr22:24372958	LOC391322	-1.05	-13.67	-0.81	3.63e-24	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12449964	0.524	rs897457	chr17:17572987	A/T	cg04398451	chr17:18023971	MYO15A	0.57	4.59	0.43	1.38e-5	Coronary artery disease or ischemic stroke;
THYM	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg00631329	chr6:26305371	NA	-0.63	-7.46	-0.61	3.99e-11	Educational attainment;
THYM	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg03452623	chr4:187889614	NA	-1.16	-21.23	-0.91	7.79e-38	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2273669	0.667	rs12153822	chr6:109315115	T/C	cg17117243	chr6:109341365	SESN1	-0.9	-5.38	-0.48	5.45e-7	Prostate cancer;
THYM	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg02915803	chr1:1606292	LOC728661;CDK11B	0.64	5.37	0.48	5.49e-7	Body mass index;
THYM	cis	rs17102423	0.594	rs1998688	chr14:65562306	C/G	cg11161011	chr14:65562177	MAX	0.69	5.58	0.5	2.31e-7	Obesity-related traits;
THYM	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg23758822	chr17:41437982	NA	1.16	11.05	0.75	9.86e-19	Menopause (age at onset);
THYM	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11225247	0.764	rs79028911	chr11:102262449	T/C	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg11752832	chr7:134001865	SLC35B4	0.72	5.43	0.49	4.28e-7	Mean platelet volume;
THYM	cis	rs6988636	1.000	rs60827294	chr8:124187842	T/C	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs448720	0.806	rs47713	chr15:68173855	C/T	cg24579218	chr15:68104479	NA	0.66	5.95	0.52	4.5e-8	Cognitive performance;
THYM	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.54	4.65	0.43	1.09e-5	Total body bone mineral density;
THYM	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs828999	0.688	rs1340532	chr1:108715011	A/G	cg24323958	chr1:108741884	SLC25A24	0.57	5.61	0.5	1.97e-7	Monocyte percentage of white cells;
THYM	cis	rs7216064	0.906	rs7223643	chr17:65830282	A/G	cg12091567	chr17:66097778	LOC651250	-0.71	-4.69	-0.43	9.11e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	7.64	0.62	1.71e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	trans	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg19862616	chr7:65841803	NCRNA00174	1.06	11.85	0.77	2e-20	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg04944784	chr2:26401820	FAM59B	-1.05	-8.18	-0.64	1.23e-12	Gut microbiome composition (summer);
THYM	trans	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg18335740	chr13:41363409	SLC25A15	0.7	7.5	0.61	3.31e-11	Lewy body disease;
THYM	cis	rs2997447	0.761	rs17184891	chr1:26447557	A/T	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs9832461	0.793	rs941316	chr3:39768979	C/T	cg09883745	chr3:40086528	MYRIP	0.68	4.59	0.43	1.38e-5	Brain structure (temporal lobe volume);
THYM	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg25072359	chr17:41440525	NA	0.72	5.37	0.48	5.5e-7	Menopause (age at onset);
THYM	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg17554472	chr22:41940697	POLR3H	0.72	4.49	0.42	2e-5	Vitiligo;
THYM	cis	rs113835537	0.529	rs12099041	chr11:66232773	C/T	cg24851651	chr11:66362959	CCS	0.63	4.49	0.42	2.01e-5	Airway imaging phenotypes;
THYM	cis	rs11711311	1.000	rs7622515	chr3:113472538	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.61	-5.46	-0.49	3.86e-7	IgG glycosylation;
THYM	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg07959070	chr22:50026188	C22orf34	-0.28	-4.95	-0.45	3.17e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7247513	0.897	rs12972944	chr19:12713808	G/A	cg01871581	chr19:12707946	ZNF490	-0.86	-9.19	-0.69	8.84e-15	Bipolar disorder;
THYM	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg00074818	chr8:8560427	CLDN23	-0.59	-5.47	-0.49	3.61e-7	Obesity-related traits;
THYM	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg13447684	chr7:1895903	MAD1L1	0.59	4.99	0.46	2.78e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg04455712	chr21:45112962	RRP1B	0.5	4.5	0.42	1.93e-5	Mean corpuscular volume;
THYM	cis	rs12310956	0.532	rs1525903	chr12:33964163	T/C	cg10856724	chr12:34555212	NA	-0.75	-6.8	-0.57	9.1e-10	Morning vs. evening chronotype;
THYM	cis	rs988913	1.000	rs1393772	chr6:54838388	C/T	cg18532076	chr6:54711417	FAM83B	0.5	4.91	0.45	3.78e-6	Menarche (age at onset);
THYM	cis	rs7551222	0.789	rs2290855	chr1:204515863	C/T	cg20240347	chr1:204465584	NA	-0.51	-4.54	-0.42	1.64e-5	Schizophrenia;
THYM	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg14690197	chr8:22456421	C8orf58	0.46	4.56	0.42	1.5e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	5.72	0.51	1.23e-7	Platelet count;
THYM	cis	rs7312774	0.609	rs2374656	chr12:107380411	A/C	cg16260113	chr12:107380972	MTERFD3	1.43	6.15	0.53	1.82e-8	Severe influenza A (H1N1) infection;
THYM	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-13.33	-0.81	1.74e-23	Coronary artery disease;
THYM	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg27446573	chr6:127587934	RNF146	0.7	6.13	0.53	1.99e-8	Breast cancer;
THYM	cis	rs939658	0.805	rs2010524	chr15:79435825	G/T	cg17916960	chr15:79447300	NA	-0.75	-8.77	-0.67	6.86e-14	Refractive error;
THYM	cis	rs6570726	0.902	rs4895678	chr6:145935510	C/T	cg23711669	chr6:146136114	FBXO30	0.77	7.17	0.59	1.63e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg13683864	chr3:40499215	RPL14	1.04	11.33	0.76	2.41e-19	Renal cell carcinoma;
THYM	cis	rs2439831	1.000	rs550239	chr15:43720197	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg11764359	chr7:65958608	NA	0.85	7.32	0.6	8.03e-11	Aortic root size;
THYM	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg11764359	chr7:65958608	NA	-0.82	-6.6	-0.56	2.29e-9	Aortic root size;
THYM	cis	rs3741151	0.773	rs17310361	chr11:73233724	T/C	cg12959048	chr11:73096162	RELT	-0.51	-4.51	-0.42	1.87e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.22e-16	Bone mineral density;
THYM	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg27211696	chr2:191398769	TMEM194B	-0.61	-4.53	-0.42	1.72e-5	Diastolic blood pressure;
THYM	cis	rs11121246	0.518	rs6673587	chr1:8910705	A/T	cg06972019	chr1:8937448	ENO1	-0.67	-5.29	-0.48	7.87e-7	Plateletcrit;
THYM	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs9479482	0.967	rs11752529	chr6:150347971	C/T	cg25797454	chr6:150327115	RAET1K	0.43	4.46	0.42	2.21e-5	Alopecia areata;
THYM	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22968622	chr17:43663579	NA	0.82	7.02	0.58	3.23e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12210905	0.925	rs858986	chr6:27178523	C/A	cg22548220	chr6:27277996	POM121L2	-0.8	-4.6	-0.43	1.3e-5	Hip circumference adjusted for BMI;
THYM	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9290065	0.538	rs6809206	chr3:160755708	G/A	cg03342759	chr3:160939853	NMD3	-0.58	-4.48	-0.42	2.06e-5	Kawasaki disease;
THYM	cis	rs2274459	1.000	rs36122085	chr6:33765255	T/C	cg06253072	chr6:33679850	C6orf125	0.52	4.7	0.43	8.72e-6	Obesity (extreme);
THYM	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.81	-6.93	-0.58	4.91e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2659067	1.000	rs2659067	chr19:51485622	A/G	cg06258834	chr19:51487136	KLK7	-0.91	-4.88	-0.45	4.21e-6	Blood protein levels;
THYM	cis	rs8050907	0.590	rs17878588	chr16:4556450	A/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.13	4.76	0.44	6.97e-6	Obesity-related traits;
THYM	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg02640540	chr1:67518911	SLC35D1	-0.64	-4.68	-0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs6840360	0.571	rs875668	chr4:152525661	C/T	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11651000	0.625	rs58067360	chr17:45819587	G/C	cg06532163	chr17:45867833	NA	0.54	5.34	0.48	6.3e-7	IgG glycosylation;
THYM	cis	rs8041943	0.550	rs72730818	chr15:79889758	C/T	cg20511832	chr15:78934280	CHRNB4	0.46	4.54	0.42	1.68e-5	Bone mineral density (spine) and age at menarche;
THYM	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg18681998	chr4:17616180	MED28	-0.76	-6.53	-0.56	3.15e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7589342	0.839	rs12995333	chr2:106436366	A/C	cg14210321	chr2:106509881	NCK2	0.69	4.86	0.45	4.58e-6	Addiction;
THYM	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg10760299	chr15:45669010	GATM	0.83	6.25	0.54	1.19e-8	Homoarginine levels;
THYM	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg09021430	chr5:549028	NA	-0.6	-5.64	-0.5	1.71e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs7193541	0.965	rs7184423	chr16:74709737	C/A	cg01733217	chr16:74700730	RFWD3	0.83	8.1	0.64	1.82e-12	Multiple myeloma;
THYM	cis	rs9420	0.961	rs7938083	chr11:57493622	C/A	cg19752551	chr11:57585705	CTNND1	-0.74	-8.03	-0.64	2.65e-12	Schizophrenia;
THYM	cis	rs823143	0.549	rs1094647	chr1:205655378	G/A	cg07157834	chr1:205819609	PM20D1	0.85	8.15	0.64	1.44e-12	Monocyte percentage of white cells;
THYM	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg04602696	chr16:88846723	FAM38A	-0.69	-5.28	-0.48	8.06e-7	Plateletcrit;
THYM	cis	rs4474465	1.000	rs2063726	chr11:78183533	T/C	cg19901956	chr11:77921274	USP35	-0.61	-4.63	-0.43	1.18e-5	Alzheimer's disease (survival time);
THYM	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.17	-8.75	-0.67	7.68e-14	Platelet count;
THYM	cis	rs6988636	1.000	rs4377946	chr8:124185887	T/C	cg22384356	chr8:124195192	FAM83A	-0.86	-5.15	-0.47	1.41e-6	Urinary uromodulin levels;
THYM	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	7.25	0.6	1.12e-10	Platelet count;
THYM	cis	rs7178572	0.633	rs12900004	chr15:77844904	A/G	cg22256960	chr15:77711686	NA	-0.74	-5.67	-0.5	1.55e-7	Type 2 diabetes;
THYM	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg11266682	chr4:10021025	SLC2A9	0.73	12.79	0.8	2.29e-22	Bone mineral density;
THYM	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11890956	chr21:40555474	PSMG1	-0.66	-6.44	-0.55	4.92e-9	Menarche (age at onset);
THYM	cis	rs728616	0.867	rs3088308	chr10:81697868	A/T	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	trans	rs8002861	0.664	rs1808097	chr13:44424766	A/G	cg17145862	chr1:211918768	LPGAT1	0.85	7.64	0.62	1.69e-11	Leprosy;
THYM	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg19761014	chr17:28927070	LRRC37B2	0.8	4.73	0.44	7.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg13390004	chr1:15929781	NA	0.63	4.79	0.44	6.2e-6	Systolic blood pressure;
THYM	cis	rs17407555	0.683	rs7676442	chr4:10272591	C/T	cg00071950	chr4:10020882	SLC2A9	0.52	4.95	0.45	3.17e-6	Schizophrenia (age at onset);
THYM	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg03929089	chr4:120376271	NA	-1.03	-12.19	-0.78	3.85e-21	Height;
THYM	cis	rs59698941	0.882	rs12514947	chr5:132311567	G/T	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs11096990	0.855	rs2711934	chr4:39157874	C/T	cg24403649	chr4:39172243	NA	-0.64	-5.4	-0.48	4.98e-7	Cognitive function;
THYM	cis	rs7918232	0.943	rs4747584	chr10:27373333	G/A	cg14240646	chr10:27532245	ACBD5	-0.74	-4.52	-0.42	1.78e-5	Breast cancer;
THYM	cis	rs3126085	0.877	rs4415568	chr1:152181207	G/A	cg10321714	chr1:152280068	FLG	0.68	4.95	0.45	3.2e-6	Atopic dermatitis;
THYM	cis	rs4363385	0.782	rs394859	chr1:153025704	T/C	cg13444842	chr1:152974279	SPRR3	-0.63	-5.12	-0.47	1.58e-6	Inflammatory skin disease;
THYM	trans	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg25214090	chr10:38739885	LOC399744	0.93	7.92	0.63	4.43e-12	Corneal astigmatism;
THYM	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg17063962	chr7:91808500	NA	1.16	13.14	0.8	4.39e-23	Breast cancer;
THYM	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.76	-5.06	-0.46	2.05e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	-0.68	-5.66	-0.5	1.63e-7	Lymphocyte counts;
THYM	cis	rs4665630	0.764	rs2098769	chr2:23891540	C/T	cg08081869	chr2:24582653	ITSN2	0.78	4.57	0.42	1.44e-5	Hypertension;
THYM	cis	rs2046867	0.908	rs62251650	chr3:72809823	T/C	cg25664220	chr3:72788482	NA	-0.86	-6.56	-0.56	2.76e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.77	-7.02	-0.58	3.34e-10	Personality dimensions;
THYM	cis	rs4731207	0.623	rs1600744	chr7:124585960	T/C	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs11030122	0.702	rs995498	chr11:3967791	A/G	cg18678763	chr11:4115507	RRM1	-0.44	-5.73	-0.51	1.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6032067	0.850	rs4566421	chr20:43783761	G/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.65	-6.42	-0.55	5.45e-9	Blood protein levels;
THYM	cis	rs4969178	0.600	rs2376583	chr17:76402105	A/T	cg05887092	chr17:76393375	PGS1	0.41	4.59	0.43	1.37e-5	HDL cholesterol levels;
THYM	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9486719	0.948	rs6920913	chr6:96874297	A/G	cg18709589	chr6:96969512	KIAA0776	0.77	5.09	0.46	1.82e-6	Migraine;Coronary artery disease;
THYM	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.63	-0.62	1.76e-11	Personality dimensions;
THYM	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg11812906	chr14:75593930	NEK9	-0.84	-7.72	-0.62	1.17e-11	Height;
THYM	cis	rs4975616	0.710	rs27996	chr5:1345474	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.73	-6.58	-0.56	2.61e-9	Lung cancer;
THYM	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg13397359	chr6:42928475	GNMT	0.55	4.67	0.43	9.78e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg14895029	chr7:2775587	GNA12	-0.68	-4.93	-0.45	3.55e-6	Height;
THYM	cis	rs17122693	0.748	rs72681630	chr14:51141250	A/G	cg04730355	chr14:51134070	SAV1	0.96	6.08	0.53	2.46e-8	Cognitive performance;
THYM	trans	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs9796	0.870	rs2927061	chr15:41302219	A/G	cg21153102	chr15:41252147	NA	0.68	6.13	0.53	2.01e-8	Menopause (age at onset);
THYM	cis	rs8063160	0.666	rs12918773	chr16:89741403	G/A	cg07984980	chr16:89898383	SPIRE2	1.31	5.27	0.48	8.34e-7	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg19729930	chr2:74357872	NA	1.24	10.68	0.74	5.94e-18	Gestational age at birth (maternal effect);
THYM	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs3781426	0.960	rs2018366	chr10:126697609	T/C	cg04494136	chr10:126703576	CTBP2	-0.42	-5.56	-0.5	2.51e-7	Height;
THYM	cis	rs36051895	0.632	rs7047795	chr9:5181467	C/T	cg02405213	chr9:5042618	JAK2	-0.98	-10.8	-0.74	3.25e-18	Pediatric autoimmune diseases;
THYM	cis	rs11756438	0.683	rs57237379	chr6:119018319	G/A	cg01113488	chr6:119027122	NA	0.56	4.5	0.42	1.92e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs1371867	0.810	rs2860518	chr8:101238120	G/T	cg00191853	chr8:101177733	SPAG1	0.5	4.78	0.44	6.49e-6	Atrioventricular conduction;
THYM	cis	rs10992471	0.603	rs12342019	chr9:95192508	C/T	cg14631576	chr9:95140430	CENPP	-0.99	-9.94	-0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs28595532	0.764	rs115916994	chr4:119688758	A/G	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg12826209	chr6:26865740	GUSBL1	0.84	6.07	0.53	2.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs35883536	0.647	rs10875313	chr1:101043057	T/C	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs6960043	0.764	rs7798124	chr7:15055616	A/G	cg19272540	chr7:15055459	NA	-0.55	-6.21	-0.54	1.37e-8	Type 2 diabetes;
THYM	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg11871910	chr12:69753446	YEATS4	0.64	5.26	0.47	9.03e-7	Response to diuretic therapy;
THYM	cis	rs13070279	0.655	rs4677042	chr3:71781701	C/G	cg19388776	chr3:71835112	PROK2	0.88	5.11	0.46	1.67e-6	Monocyte count;
THYM	cis	rs4363385	0.719	rs12748969	chr1:152932654	T/C	cg07796016	chr1:152779584	LCE1C	-0.58	-4.76	-0.44	6.79e-6	Inflammatory skin disease;
THYM	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg01341218	chr17:43662625	NA	1.13	9.52	0.7	1.72e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7149242	0.662	rs4905998	chr14:101181781	A/G	cg18089426	chr14:101175970	NA	-0.56	-5.48	-0.49	3.56e-7	Platelet count;
THYM	cis	rs11077998	0.903	rs8064554	chr17:80501093	A/G	cg10255544	chr17:80519551	FOXK2	0.5	4.47	0.42	2.14e-5	Reticulocyte fraction of red cells;
THYM	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg17063962	chr7:91808500	NA	-1.13	-12.74	-0.79	2.8e-22	Breast cancer;
THYM	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11039798	1.000	rs7104642	chr11:48588534	C/T	cg24672777	chr11:48374446	OR4C45	-1.16	-7.24	-0.6	1.16e-10	Axial length;
THYM	cis	rs240764	0.604	rs9404016	chr6:101177728	G/A	cg21058520	chr6:100914733	NA	-0.58	-5.05	-0.46	2.11e-6	Neuroticism;
THYM	cis	rs2236521	0.659	rs72487383	chr20:60889313	A/C	cg06026331	chr20:60912101	LAMA5	0.81	6.26	0.54	1.12e-8	Pelvic organ prolapse;
THYM	cis	rs28647808	1.000	rs6597629	chr9:136270841	A/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg10505658	chr17:80084571	CCDC57	0.7	8.07	0.64	2.18e-12	Life satisfaction;
THYM	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg18538332	chr22:24372958	LOC391322	0.87	8.75	0.67	7.67e-14	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs11118844	0.793	rs10863654	chr1:221946787	G/A	cg04222084	chr1:221915650	DUSP10	-1.05	-5.27	-0.48	8.64e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg11266682	chr4:10021025	SLC2A9	-0.62	-7.75	-0.62	1e-11	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.0	0.46	2.58e-6	Bipolar disorder;
THYM	cis	rs262150	0.536	rs73167296	chr7:158783129	C/T	cg19418458	chr7:158789849	NA	0.65	4.79	0.44	6.22e-6	Facial morphology (factor 20);
THYM	cis	rs950776	1.000	rs950776	chr15:78926018	A/G	cg06917634	chr15:78832804	PSMA4	0.8	5.59	0.5	2.15e-7	Sudden cardiac arrest;
THYM	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg06481639	chr22:41940642	POLR3H	0.74	5.39	0.48	5.01e-7	Vitiligo;
THYM	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg00814883	chr7:100076585	TSC22D4	-0.96	-6.41	-0.55	5.64e-9	Platelet count;
THYM	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs17152411	1.000	rs7914110	chr10:126599886	C/G	cg07906193	chr10:126599966	NA	0.69	4.71	0.44	8.45e-6	Height;
THYM	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg11245990	chr11:68621969	NA	0.57	7.46	0.61	4.06e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.76	-5.07	-0.46	1.95e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs57920188	0.584	rs12062024	chr1:4089259	A/T	cg20703997	chr1:4087676	NA	-0.85	-5.76	-0.51	1.04e-7	Interleukin-17 levels;
THYM	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg11764359	chr7:65958608	NA	-0.85	-7.43	-0.61	4.73e-11	Aortic root size;
THYM	cis	rs9677476	0.863	rs58067379	chr2:232088295	A/T	cg07929768	chr2:232055508	NA	0.59	6.14	0.53	1.9e-8	Food antigen IgG levels;
THYM	cis	rs7119	0.643	rs12904384	chr15:77410878	T/G	cg10437265	chr15:77819839	NA	0.58	5.52	0.49	2.98e-7	Type 2 diabetes;
THYM	cis	rs9359856	0.564	rs11961752	chr6:90481896	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg14004847	chr7:1930337	MAD1L1	-0.66	-4.87	-0.45	4.5e-6	Schizophrenia;
THYM	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg22709100	chr7:91322751	NA	0.71	5.58	0.5	2.22e-7	Breast cancer;
THYM	cis	rs10744422	0.925	rs3825143	chr12:123352179	C/T	cg25930673	chr12:123319894	HIP1R	-0.9	-5.14	-0.47	1.47e-6	Schizophrenia;
THYM	cis	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg10856724	chr12:34555212	NA	-0.88	-8.25	-0.65	8.84e-13	Morning vs. evening chronotype;
THYM	cis	rs34779708	0.931	rs67261877	chr10:35386340	T/A	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs28595532	0.925	rs10000445	chr4:119485311	C/T	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.21e-7	Cannabis dependence symptom count;
THYM	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs2334880	0.678	rs7186112	chr16:71840073	A/T	cg06353428	chr16:71660113	MARVELD3	1.41	8.74	0.67	8.32e-14	Malaria;
THYM	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.7	-5.63	-0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.69e-11	Aortic root size;
THYM	cis	rs4455778	0.580	rs6952050	chr7:49116354	A/C	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg22433210	chr17:43662623	NA	1.12	8.59	0.66	1.69e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11771526	0.892	rs11764802	chr7:32372978	C/T	cg13207630	chr7:32358064	NA	1.06	6.2	0.54	1.44e-8	Body mass index;
THYM	cis	rs7104764	0.957	rs1128321	chr11:244171	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs12216545	0.765	rs4607525	chr7:150229350	A/T	cg08960815	chr7:150264767	GIMAP4	-0.89	-8.27	-0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	5.02	0.46	2.39e-6	Menarche (age at onset);
THYM	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	5.11	0.46	1.7e-6	Motion sickness;
THYM	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg09455208	chr3:40491958	NA	-0.47	-4.83	-0.44	5.3e-6	Renal cell carcinoma;
THYM	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg15164180	chr2:241846931	NA	-0.33	-4.55	-0.42	1.6e-5	Urinary metabolites;
THYM	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	6.27	0.54	1.04e-8	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg02734326	chr4:10020555	SLC2A9	0.78	6.67	0.56	1.68e-9	Bone mineral density;
THYM	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg05855489	chr10:104503620	C10orf26	0.56	4.49	0.42	1.99e-5	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs965469	0.603	rs6115892	chr20:3411569	C/T	cg25506879	chr20:3388711	C20orf194	-0.63	-4.83	-0.44	5.29e-6	IFN-related cytopenia;
THYM	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.58	-5.52	-0.49	2.94e-7	Lymphocyte counts;
THYM	cis	rs8067545	0.750	rs6587215	chr17:19980779	G/T	cg13482628	chr17:19912719	NA	0.56	4.6	0.43	1.3e-5	Schizophrenia;
THYM	cis	rs7725337	0.894	rs6880872	chr5:88333916	C/T	cg11280525	chr5:87955695	LOC645323	-0.41	-4.54	-0.42	1.66e-5	Total body bone mineral density;
THYM	cis	rs11157436	0.918	rs1983522	chr14:22618541	G/A	cg26433554	chr14:23315189	MMP14	0.44	4.61	0.43	1.24e-5	Neurocognitive impairment in HIV-1 infection (continuous);
THYM	cis	rs354225	0.544	rs10208219	chr2:54806047	G/A	cg23486701	chr2:54789491	SPTBN1	0.36	4.69	0.43	9.11e-6	Schizophrenia;
THYM	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.61	-0.43	1.24e-5	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs3768617	0.510	rs10797849	chr1:183088988	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.61	4.98	0.46	2.84e-6	Fuchs's corneal dystrophy;
THYM	cis	rs7607369	0.580	rs17573731	chr2:219652153	T/C	cg02176678	chr2:219576539	TTLL4	-0.59	-5.48	-0.49	3.54e-7	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs2806561	0.765	rs2806557	chr1:23503372	T/A	cg12483005	chr1:23474871	LUZP1	0.58	6.22	0.54	1.31e-8	Height;
THYM	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg17366294	chr4:99064904	C4orf37	0.55	6.73	0.57	1.26e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3126085	0.877	rs4456098	chr1:152176034	C/T	cg26020982	chr1:152196106	HRNR	0.36	4.7	0.43	8.63e-6	Atopic dermatitis;
THYM	cis	rs2439831	0.867	rs2251844	chr15:43836478	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	6.36	0.55	6.96e-9	Lung cancer in ever smokers;
THYM	cis	rs7809950	0.635	rs62483629	chr7:106866178	T/C	cg23024343	chr7:107201750	COG5	-1.0	-8.43	-0.65	3.79e-13	Coronary artery disease;
THYM	cis	rs6089584	0.566	rs3787422	chr20:60555346	G/A	cg06108461	chr20:60628389	TAF4	-0.79	-6.32	-0.54	8.42e-9	Body mass index;
THYM	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.66	0.43	1.01e-5	Bipolar disorder;
THYM	cis	rs6674970	0.933	rs11204772	chr1:151056305	C/T	cg11822372	chr1:151115635	SEMA6C	0.72	4.93	0.45	3.53e-6	Childhood ear infection;
THYM	cis	rs11249608	0.636	rs62393070	chr5:178447943	A/G	cg21905437	chr5:178450457	ZNF879	0.62	4.61	0.43	1.24e-5	Pubertal anthropometrics;
THYM	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg08772003	chr10:104629869	AS3MT	-0.6	-5.54	-0.49	2.68e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg23649088	chr2:200775458	C2orf69	-0.75	-5.16	-0.47	1.36e-6	Schizophrenia;
THYM	cis	rs960902	0.738	rs6746868	chr2:37729551	T/C	cg25341268	chr2:37734390	NA	-0.58	-4.73	-0.44	7.67e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	trans	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs10216189	1.000	rs7799970	chr7:5527714	G/C	cg08928675	chr7:5528044	FBXL18	0.47	4.62	0.43	1.18e-5	Relative hand skill in reading disability;
THYM	cis	rs749052	0.831	rs3100624	chr2:232938583	C/T	cg22331108	chr2:232478452	NA	0.97	4.57	0.42	1.45e-5	Height;
THYM	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg17718321	chr1:152188247	HRNR	-0.51	-4.85	-0.45	4.73e-6	Inflammatory skin disease;
THYM	cis	rs1642645	0.831	rs6600396	chr1:42489534	G/A	cg22816091	chr1:42611670	NA	0.62	5.52	0.49	2.99e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg07157834	chr1:205819609	PM20D1	-0.55	-4.5	-0.42	1.94e-5	Prostate-specific antigen levels;
THYM	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	6.13	0.53	1.95e-8	Total body bone mineral density;
THYM	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs11771526	0.686	rs77847042	chr7:32277207	A/G	cg27532318	chr7:32358331	NA	0.76	5.44	0.49	4.16e-7	Body mass index;
THYM	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.77	-0.51	9.87e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1580019	0.961	rs1868776	chr7:32494435	G/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.74	-6.51	-0.56	3.62e-9	Cognitive ability;
THYM	cis	rs12594515	0.967	rs11854477	chr15:45998345	A/C	cg01629716	chr15:45996671	NA	0.51	5.2	0.47	1.14e-6	Waist circumference;Weight;
THYM	cis	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs7582180	0.663	rs1114595	chr2:100960072	T/A	cg21926883	chr2:100939477	LONRF2	-0.62	-5.86	-0.52	6.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs3916	1.000	rs3916	chr12:121177272	G/C	cg10600917	chr12:121163489	ACADS	0.59	4.98	0.45	2.84e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs7177699	0.550	rs7182103	chr15:79123946	G/T	cg00540400	chr15:79124168	NA	0.65	7.03	0.58	3.16e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs892961	1.000	rs11653743	chr17:75401923	C/A	cg11351908	chr17:75402473	SEPT9	0.59	5.74	0.51	1.11e-7	Airflow obstruction;
THYM	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg08645402	chr16:4508243	NA	-0.76	-6.91	-0.58	5.6e-10	Schizophrenia;
THYM	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg10505658	chr17:80084571	CCDC57	0.73	8.11	0.64	1.75e-12	Life satisfaction;
THYM	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg27171569	chr16:83987465	OSGIN1	-0.56	-5.14	-0.47	1.49e-6	Pursuit maintenance gain;
THYM	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg16414030	chr3:133502952	NA	-0.64	-5.35	-0.48	6.08e-7	Iron status biomarkers;
THYM	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12586317	0.553	rs78124218	chr14:35570606	G/A	cg05294307	chr14:35346193	BAZ1A	-0.82	-5.51	-0.49	3.06e-7	Psoriasis;
THYM	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.01	0.58	3.39e-10	Prudent dietary pattern;
THYM	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg16586182	chr3:47516702	SCAP	0.68	5.66	0.5	1.58e-7	Colorectal cancer;
THYM	cis	rs7834588	0.544	rs13277301	chr8:63816442	C/T	cg12194929	chr8:63776755	NKAIN3	-0.53	-4.47	-0.42	2.2e-5	Response to Vitamin E supplementation;
THYM	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg17554472	chr22:41940697	POLR3H	-0.66	-4.6	-0.43	1.31e-5	Vitiligo;
THYM	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg18477163	chr1:228402036	OBSCN	-0.5	-5.52	-0.49	2.99e-7	Diastolic blood pressure;
THYM	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg08968635	chr6:28129556	ZNF389	-0.64	-4.57	-0.42	1.47e-5	Parkinson's disease;
THYM	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.77	0.51	1.01e-7	Rheumatoid arthritis;
THYM	cis	rs6430585	0.528	rs309161	chr2:136688749	A/G	cg23851026	chr2:136556271	LCT	-0.69	-6.68	-0.57	1.64e-9	Corneal structure;
THYM	cis	rs775227	0.574	rs13067967	chr3:113265215	C/G	cg18753928	chr3:113234510	CCDC52	-0.77	-5.44	-0.49	4.13e-7	Dental caries;
THYM	cis	rs7084402	1.000	rs36097682	chr10:60269738	G/A	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs9677476	0.648	rs7565313	chr2:232054514	A/G	cg23338755	chr2:231921595	PSMD1	0.75	5.64	0.5	1.72e-7	Food antigen IgG levels;
THYM	cis	rs860554	0.640	rs2300293	chr1:201264902	C/T	cg01022117	chr1:201258280	PKP1	-0.65	-6.46	-0.55	4.44e-9	Panic disorder;
THYM	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg07835181	chr16:1525278	CLCN7	-0.77	-7.52	-0.61	3.03e-11	Bone mineral density;
THYM	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg11871910	chr12:69753446	YEATS4	0.75	6.08	0.53	2.54e-8	Blood protein levels;
THYM	cis	rs67969689	0.515	rs1658243	chr2:19486169	A/G	cg16234068	chr2:18544572	NA	0.55	4.49	0.42	1.97e-5	Myringotomy;
THYM	cis	rs56775891	1.000	rs56775891	chr18:77575613	C/T	cg26740109	chr18:77585428	NA	-0.81	-5.73	-0.51	1.2e-7	Schizophrenia;
THYM	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	4.76	0.44	7.01e-6	Schizophrenia;
THYM	cis	rs733592	1.000	rs1859440	chr12:48427329	T/C	cg21466736	chr12:48725269	NA	0.49	5.51	0.49	3.13e-7	Plateletcrit;
THYM	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.97	-4.64	-0.43	1.13e-5	Alzheimer's disease;
THYM	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg04842962	chr6:43655489	MRPS18A	1.41	15.71	0.85	3.75e-28	IgG glycosylation;
THYM	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg13683864	chr3:40499215	RPL14	0.93	9.24	0.69	7.06e-15	Renal cell carcinoma;
THYM	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg24818145	chr4:99064322	C4orf37	-0.75	-6.03	-0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10992471	0.627	rs10820980	chr9:95253342	C/T	cg14631576	chr9:95140430	CENPP	-0.99	-9.94	-0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg15448220	chr1:150897856	SETDB1	0.85	7.1	0.59	2.25e-10	Tonsillectomy;
THYM	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.55	4.49	0.42	2e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg23803603	chr1:2058230	PRKCZ	-0.57	-5.03	-0.46	2.33e-6	Height;
THYM	cis	rs754466	0.706	rs7099526	chr10:79657705	C/G	cg17075019	chr10:79541650	NA	-0.58	-4.66	-0.43	1.02e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	5.71	0.51	1.3e-7	Platelet count;
THYM	cis	rs9486719	0.948	rs2472906	chr6:96875318	G/T	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs2585417	0.742	rs6127138	chr20:52828384	A/G	cg14415559	chr20:52836060	PFDN4	-0.5	-4.59	-0.43	1.34e-5	Obesity-related traits;
THYM	cis	rs6121246	0.583	rs28815498	chr20:30351560	T/C	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs13040088	0.518	rs2427452	chr20:61577275	T/C	cg23096297	chr20:61557774	DIDO1	-0.82	-6.29	-0.54	9.48e-9	Menopause (age at onset);
THYM	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg04518342	chr5:131593106	PDLIM4	0.45	5.04	0.46	2.22e-6	Breast cancer;
THYM	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg22968622	chr17:43663579	NA	1.14	10.29	0.73	4.02e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs10504073	0.647	rs10435612	chr8:49993696	A/T	cg00325661	chr8:49890786	NA	0.93	8.79	0.67	6.32e-14	Blood metabolite ratios;
THYM	cis	rs6942756	0.955	rs55638303	chr7:128885770	C/T	cg08635249	chr7:127983877	RBM28	0.68	4.47	0.42	2.16e-5	White matter hyperintensity burden;
THYM	cis	rs6430585	0.583	rs76097170	chr2:136593498	C/T	cg23851026	chr2:136556271	LCT	0.7	6.93	0.58	5.03e-10	Corneal structure;
THYM	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg22709100	chr7:91322751	NA	0.6	4.69	0.43	9.3e-6	Breast cancer;
THYM	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs2562152	0.744	rs1045001	chr16:107275	G/T	cg02949481	chr16:131562	MPG	-0.83	-5.21	-0.47	1.11e-6	Glioblastoma;
THYM	cis	rs9443645	0.527	rs12527806	chr6:79507667	A/T	cg05283184	chr6:79620031	NA	-0.61	-4.77	-0.44	6.62e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg24846343	chr22:24311635	DDTL	0.47	6.16	0.53	1.77e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9549260	0.592	rs9315783	chr13:41289164	T/C	cg21288729	chr13:41239152	FOXO1	0.63	4.63	0.43	1.15e-5	Red blood cell count;
THYM	cis	rs10484885	0.887	rs17707738	chr6:90602735	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.8	-6.83	-0.57	8.08e-10	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg17796960	chr10:135278976	LOC619207	-0.58	-4.9	-0.45	4e-6	Systemic lupus erythematosus;
THYM	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg12599982	chr1:44399894	ARTN	0.56	4.66	0.43	1.02e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs1395	0.710	rs2083363	chr2:27475318	G/C	cg23587288	chr2:27483067	SLC30A3	-0.69	-6.19	-0.54	1.53e-8	Blood metabolite levels;
THYM	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs4343996	0.747	rs13237637	chr7:3503207	G/C	cg21248987	chr7:3385318	SDK1	0.39	4.79	0.44	6.13e-6	Motion sickness;
THYM	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg14004847	chr7:1930337	MAD1L1	-0.64	-5.12	-0.46	1.62e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg22117172	chr7:91764530	CYP51A1	0.4	4.79	0.44	6.21e-6	Breast cancer;
THYM	cis	rs17253792	0.822	rs75115817	chr14:56069537	G/A	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg24818145	chr4:99064322	C4orf37	0.8	6.45	0.55	4.71e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7582180	0.614	rs9973737	chr2:100942296	T/C	cg14675211	chr2:100938903	LONRF2	0.62	5.99	0.52	3.73e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg07570687	chr10:102243282	WNT8B	0.84	8.04	0.64	2.45e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs9644630	0.870	rs4244453	chr8:19359711	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.77	8.45	0.66	3.38e-13	Oropharynx cancer;
THYM	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.31	8.7	0.67	9.92e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.68	-5.28	-0.48	8.12e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs477692	0.692	rs12265758	chr10:131445144	A/G	cg05714579	chr10:131428358	MGMT	-0.83	-7.01	-0.58	3.51e-10	Response to temozolomide;
THYM	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg00786635	chr1:25594202	NA	0.92	7.28	0.6	9.7e-11	Erythrocyte sedimentation rate;
THYM	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg17757837	chr7:157058334	UBE3C	0.64	5.09	0.46	1.79e-6	Body mass index;
THYM	cis	rs9512730	0.527	rs11619722	chr13:27998600	T/C	cg04070771	chr13:27998621	GTF3A	0.79	5.56	0.5	2.52e-7	Schizophrenia;
THYM	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4919694	0.536	rs12414777	chr10:104697781	C/T	cg04362960	chr10:104952993	NT5C2	0.72	5.33	0.48	6.7e-7	Arsenic metabolism;
THYM	cis	rs34375054	0.660	rs12305181	chr12:125594156	C/A	cg25124228	chr12:125621409	AACS	-0.78	-6.04	-0.53	3.02e-8	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg13683864	chr3:40499215	RPL14	-0.85	-7.88	-0.63	5.41e-12	Renal cell carcinoma;
THYM	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg09033563	chr22:24373618	LOC391322	0.63	4.98	0.45	2.9e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7809950	0.798	rs10281535	chr7:107229618	T/G	cg23024343	chr7:107201750	COG5	0.9	8.13	0.64	1.58e-12	Coronary artery disease;
THYM	cis	rs17253792	0.822	rs10137340	chr14:56050989	A/G	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs12039431	0.746	rs41267303	chr1:38002068	C/T	cg17933807	chr1:38061675	GNL2	-0.76	-5.38	-0.48	5.25e-7	Epithelial ovarian cancer;
THYM	cis	rs6987853	0.966	rs2974359	chr8:42434194	T/C	cg09913449	chr8:42400586	C8orf40	0.87	8.22	0.64	1.02e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6430585	0.583	rs7581814	chr2:136641593	C/G	cg07169764	chr2:136633963	MCM6	-1.25	-14.39	-0.83	1.36e-25	Corneal structure;
THYM	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg10047753	chr17:41438598	NA	-0.97	-7.99	-0.63	3.21e-12	Menopause (age at onset);
THYM	cis	rs7580658	0.613	rs12463538	chr2:128196854	G/T	cg10021288	chr2:128175891	PROC	-0.65	-5.65	-0.5	1.66e-7	Protein C levels;
THYM	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg00645579	chr11:617140	IRF7;MUPCDH	-0.46	-5.85	-0.51	6.85e-8	Systemic lupus erythematosus;
THYM	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	6.52	0.56	3.31e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg13609457	chr4:120235615	NA	0.5	4.76	0.44	6.95e-6	Educational attainment;
THYM	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.8	8.17	0.64	1.33e-12	Lymphocyte counts;
THYM	cis	rs7537052	0.564	rs6669395	chr1:36653717	A/G	cg24686825	chr1:36642396	MAP7D1	-0.76	-7.01	-0.58	3.4e-10	Schizophrenia;
THYM	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg04518342	chr5:131593106	PDLIM4	0.51	5.6	0.5	2.11e-7	Breast cancer;
THYM	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg04320152	chr17:18167836	SMCR7	-0.57	-4.63	-0.43	1.18e-5	Total body bone mineral density;
THYM	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg20587970	chr11:113659929	NA	-1.37	-8.99	-0.68	2.41e-14	Hip circumference adjusted for BMI;
THYM	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg08859206	chr1:53392774	SCP2	0.51	5.47	0.49	3.67e-7	Monocyte count;
THYM	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg23711669	chr6:146136114	FBXO30	-0.93	-9.69	-0.7	7.64e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2120019	0.567	rs72625793	chr15:75207083	A/G	cg09165964	chr15:75287851	SCAMP5	-0.67	-4.45	-0.42	2.33e-5	Blood trace element (Zn levels);
THYM	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg15921436	chr17:44337874	NA	0.94	6.79	0.57	9.84e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06481639	chr22:41940642	POLR3H	-0.75	-5.11	-0.46	1.66e-6	Vitiligo;
THYM	cis	rs990171	0.955	rs10165460	chr2:103085631	C/T	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.1	-0.46	1.74e-6	Lymphocyte counts;
THYM	cis	rs3087591	0.960	rs12945157	chr17:29603631	G/A	cg24425628	chr17:29625626	OMG;NF1	0.63	5.33	0.48	6.51e-7	Hip circumference;
THYM	cis	rs1691799	0.899	rs903589	chr12:66745835	C/T	cg16791601	chr12:66731901	HELB	-0.76	-7.14	-0.59	1.86e-10	White blood cell count (basophil);
THYM	cis	rs6032067	0.714	rs6032073	chr20:43881630	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.59	-5.71	-0.51	1.29e-7	Blood protein levels;
THYM	cis	rs7000551	0.675	rs2469758	chr8:22363032	C/T	cg12081754	chr8:22256438	SLC39A14	0.63	5.77	0.51	9.97e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg18252515	chr7:66147081	NA	1.49	9.3	0.69	5.16e-15	Gout;
THYM	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22857025	chr5:266934	NA	1.5	9.71	0.71	6.9e-16	Breast cancer;
THYM	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs6840360	0.593	rs28602726	chr4:152499788	T/C	cg17479576	chr4:152424074	FAM160A1	-0.8	-5.92	-0.52	5.02e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg07570687	chr10:102243282	WNT8B	0.75	6.59	0.56	2.4e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs3780378	0.967	rs7043371	chr9:5040203	T/A	cg02405213	chr9:5042618	JAK2	-0.75	-6.9	-0.58	5.87e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs4481887	0.927	rs4916121	chr1:248432003	C/T	cg00666640	chr1:248458726	OR2T12	0.57	4.78	0.44	6.46e-6	Common traits (Other);
THYM	cis	rs9563576	0.778	rs7988221	chr13:58623602	G/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg18512352	chr11:47633146	NA	-0.49	-5.93	-0.52	4.9e-8	Subjective well-being;
THYM	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-5.9	-0.52	5.58e-8	Total cholesterol levels;
THYM	cis	rs17001868	0.568	rs2075764	chr22:40758581	C/T	cg07138101	chr22:40742427	ADSL	0.91	5.19	0.47	1.2e-6	Mammographic density (dense area);
THYM	cis	rs11650494	0.908	rs79768864	chr17:47446968	C/A	cg08112188	chr17:47440006	ZNF652	1.24	5.37	0.48	5.59e-7	Prostate cancer;
THYM	cis	rs34779708	0.931	rs12242882	chr10:35347860	G/C	cg03585969	chr10:35415529	CREM	0.63	4.66	0.43	1.01e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg18477163	chr1:228402036	OBSCN	-0.47	-5.21	-0.47	1.11e-6	Diastolic blood pressure;
THYM	cis	rs7172809	0.561	rs28712147	chr15:77844661	C/G	cg22256960	chr15:77711686	NA	-0.71	-5.37	-0.48	5.6e-7	Glucose homeostasis traits;
THYM	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg17105886	chr17:28927953	LRRC37B2	1.21	7.24	0.6	1.14e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9297145	0.585	rs10953281	chr7:98772131	C/T	cg05967295	chr7:98741636	SMURF1	-0.72	-5.86	-0.52	6.66e-8	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg18477163	chr1:228402036	OBSCN	0.57	6.22	0.54	1.36e-8	Diastolic blood pressure;
THYM	cis	rs9913711	0.826	rs9911723	chr17:70107882	A/G	cg06234051	chr17:70120541	SOX9	-0.63	-4.81	-0.44	5.61e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12042938	0.507	rs2570408	chr1:231732934	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.57	-0.5	2.4e-7	Neuranatomic and neurocognitive phenotypes;
THYM	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs61931739	0.817	rs1705754	chr12:34145569	A/G	cg10856724	chr12:34555212	NA	-0.65	-5.88	-0.52	6.08e-8	Morning vs. evening chronotype;
THYM	cis	rs16912285	0.688	rs7124856	chr11:24324926	C/T	ch.11.24196551F	chr11:24239977	NA	1.0	7.03	0.58	3.18e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg06238570	chr21:40685208	BRWD1	0.72	6.28	0.54	9.9e-9	Menarche (age at onset);
THYM	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg04315214	chr1:2043799	PRKCZ	0.55	4.58	0.43	1.41e-5	Height;
THYM	cis	rs9807841	0.592	rs7250071	chr19:10765819	A/G	cg17848348	chr19:10766748	ILF3	0.71	5.66	0.5	1.59e-7	Inflammatory skin disease;
THYM	cis	rs1062753	0.731	rs11914200	chr22:42378070	G/A	cg08431931	chr22:42394659	WBP2NL	0.63	4.8	0.44	5.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs11031096	0.782	rs10835684	chr11:4168308	G/T	cg18678763	chr11:4115507	RRM1	-0.38	-4.94	-0.45	3.37e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs454510	0.826	rs347903	chr1:120192431	C/T	cg11530693	chr1:120165357	ZNF697	0.65	4.86	0.45	4.57e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
THYM	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg10117171	chr1:25599238	RHD	-0.67	-4.82	-0.44	5.52e-6	Erythrocyte sedimentation rate;
THYM	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg04944784	chr2:26401820	FAM59B	-0.83	-6.37	-0.55	6.83e-9	Gut microbiome composition (summer);
THYM	cis	rs11785693	0.862	rs13281354	chr8:4987756	G/T	cg26367366	chr8:4980734	NA	1.21	6.11	0.53	2.2e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg04518342	chr5:131593106	PDLIM4	-0.55	-6.51	-0.56	3.51e-9	Acylcarnitine levels;
THYM	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg00290607	chr11:67383545	NA	-0.71	-4.9	-0.45	3.88e-6	Mean corpuscular volume;
THYM	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg22753661	chr15:79092743	ADAMTS7	0.74	4.74	0.44	7.35e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg11812906	chr14:75593930	NEK9	-0.79	-7.31	-0.6	8.22e-11	Height;
THYM	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.65	5.17	0.47	1.3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9933309	0.839	rs9932423	chr16:88846849	C/A	cg00153919	chr16:88859944	NA	-0.63	-5.54	-0.49	2.69e-7	Glycated hemoglobin levels;
THYM	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	5.58	0.5	2.28e-7	Obesity-related traits;
THYM	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg12011299	chr4:100065546	ADH4	0.75	7.3	0.6	8.58e-11	Alcohol dependence;
THYM	cis	rs9810089	0.814	rs2688600	chr3:136252596	C/A	cg12473912	chr3:136751656	NA	0.62	5.27	0.48	8.44e-7	Gestational age at birth (child effect);
THYM	cis	rs9314614	0.901	rs2978902	chr8:6690173	C/G	cg16580759	chr8:6693379	XKR5	0.47	4.91	0.45	3.82e-6	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs17511627	0.755	rs7988938	chr13:26743342	C/T	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg18230493	chr5:56204884	C5orf35	0.8	5.37	0.48	5.63e-7	Initial pursuit acceleration;
THYM	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg08213375	chr14:104286397	PPP1R13B	0.42	4.5	0.42	1.9e-5	Reticulocyte count;
THYM	cis	rs7582180	0.614	rs9973737	chr2:100942296	T/C	cg08017756	chr2:100939284	LONRF2	-0.74	-7.68	-0.62	1.41e-11	Intelligence (multi-trait analysis);
THYM	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg08885076	chr2:99613938	TSGA10	-0.47	-4.71	-0.43	8.61e-6	Fear of minor pain;
THYM	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg25358565	chr5:93447407	FAM172A	1.31	11.12	0.75	6.98e-19	Diabetic retinopathy;
THYM	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs4930776	0.593	rs412316	chr12:5757189	T/C	cg02086166	chr12:5775618	ANO2	0.59	4.94	0.45	3.37e-6	Plasma clusterin levels;
THYM	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.08	7.64	0.62	1.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7255045	0.742	rs6511842	chr19:12955178	C/T	cg26870725	chr19:12978805	MAST1	-0.63	-4.9	-0.45	3.96e-6	Mean corpuscular volume;
THYM	cis	rs3892630	0.824	rs7247264	chr19:33239846	T/G	cg22980127	chr19:33182716	NUDT19	1.14	9.23	0.69	7.47e-15	Red blood cell traits;
THYM	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg26597838	chr10:835615	NA	0.86	4.92	0.45	3.62e-6	Eosinophil percentage of granulocytes;
THYM	trans	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17712092	chr4:129076599	LARP1B	0.91	7.62	0.62	1.87e-11	Eosinophil percentage of white cells;
THYM	cis	rs6840360	0.642	rs6843639	chr4:152416015	C/T	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg17366294	chr4:99064904	C4orf37	0.53	5.9	0.52	5.67e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.81	-4.97	-0.45	2.91e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg21658235	chr8:22456391	C8orf58	0.53	4.98	0.46	2.79e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg20283391	chr11:68216788	NA	-0.68	-5.11	-0.46	1.69e-6	Total body bone mineral density;
THYM	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg26031613	chr14:104095156	KLC1	0.75	5.11	0.46	1.63e-6	Body mass index;
THYM	cis	rs13006833	0.668	rs291462	chr2:191181678	T/C	cg11845111	chr2:191398756	TMEM194B	0.65	4.51	0.42	1.88e-5	Urinary metabolites;
THYM	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg12179176	chr11:130786555	SNX19	0.89	8.25	0.65	8.93e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	10.62	0.74	7.85e-18	Chronic sinus infection;
THYM	cis	rs6430585	0.528	rs309159	chr2:136684940	C/T	cg20242066	chr2:136595261	LCT	0.57	5.94	0.52	4.74e-8	Corneal structure;
THYM	cis	rs10924970	0.967	rs12741262	chr1:235406849	T/C	cg26050004	chr1:235667680	B3GALNT2	0.6	4.5	0.42	1.92e-5	Asthma;
THYM	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg08132940	chr7:1081526	C7orf50	-0.77	-5.19	-0.47	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs919433	0.680	rs787983	chr2:198345797	C/T	cg05783139	chr2:198650985	BOLL	0.6	4.59	0.43	1.37e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg18252515	chr7:66147081	NA	-1.48	-8.83	-0.67	5.15e-14	Diabetic kidney disease;
THYM	cis	rs2235642	0.507	rs2235643	chr16:1585115	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.62	6.53	0.56	3.2e-9	Coronary artery disease;
THYM	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg00786635	chr1:25594202	NA	0.99	8.22	0.64	1.04e-12	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs7000551	0.505	rs73227818	chr8:22243325	T/C	cg12081754	chr8:22256438	SLC39A14	1.15	11.29	0.76	2.96e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg27414909	chr4:1201492	LOC100130872;LOC100130872-SPON2	0.6	4.55	0.42	1.58e-5	Longevity;
THYM	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs6584283	0.875	rs10748783	chr10:101285872	C/A	cg04972745	chr10:101287846	NA	-0.5	-4.65	-0.43	1.09e-5	Ulcerative colitis;
THYM	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg09640425	chr7:158790006	NA	-0.56	-4.6	-0.43	1.33e-5	Facial morphology (factor 20);
THYM	cis	rs2282300	0.739	rs34234618	chr11:30241701	T/C	cg09906309	chr11:30344399	C11orf46	-0.72	-5.34	-0.48	6.24e-7	Morning vs. evening chronotype;
THYM	cis	rs6547741	1.000	rs4665381	chr2:27757150	A/C	cg27432699	chr2:27873401	GPN1	0.68	5.98	0.52	3.96e-8	Oral cavity cancer;
THYM	cis	rs17443541	0.507	rs768637	chr2:200474888	A/C	cg01795955	chr2:200468626	NA	-0.66	-4.45	-0.42	2.35e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg03433033	chr1:76189801	ACADM	0.71	6.82	0.57	8.21e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.7	5.63	0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs6840360	0.571	rs11939356	chr4:152505234	G/C	cg17479576	chr4:152424074	FAM160A1	-0.85	-6.08	-0.53	2.49e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	5.53	0.49	2.87e-7	Monocyte percentage of white cells;
THYM	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg05234568	chr11:5960015	NA	-0.61	-4.91	-0.45	3.74e-6	DNA methylation (variation);
THYM	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02018176	chr4:1364513	KIAA1530	1.0	10.28	0.73	4.2e-17	Longevity;
THYM	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.11e-8	Systolic blood pressure;
THYM	cis	rs2273669	0.667	rs2003315	chr6:109367169	C/T	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs6768930	0.509	rs9819294	chr3:57720901	G/C	cg07735586	chr3:57945651	NA	-0.33	-5.05	-0.46	2.13e-6	Obesity-related traits;
THYM	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg00999904	chr2:3704751	ALLC	0.7	5.04	0.46	2.23e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs6754311	0.593	rs313528	chr2:136445869	G/A	cg07169764	chr2:136633963	MCM6	0.7	5.67	0.5	1.55e-7	Mosquito bite size;
THYM	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg11764359	chr7:65958608	NA	-0.65	-4.97	-0.45	2.95e-6	Aortic root size;
THYM	cis	rs12702595	0.875	rs2108783	chr7:7266867	A/C	cg24410064	chr7:7222050	C1GALT1	0.6	4.64	0.43	1.1e-5	Serum dimethylarginine levels (asymmetric/symetric ratio);Symmetrical dimethylarginine levels;
THYM	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg22875332	chr1:76189707	ACADM	-0.73	-6.49	-0.55	3.89e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg20486651	chr6:167070296	RPS6KA2	0.5	4.68	0.43	9.42e-6	Crohn's disease;
THYM	cis	rs71403859	0.730	rs12447672	chr16:71715131	G/A	cg08717414	chr16:71523259	ZNF19	-0.92	-5.16	-0.47	1.32e-6	Post bronchodilator FEV1;
THYM	cis	rs651907	0.588	rs1378838	chr3:101634543	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	5.39	0.48	5.08e-7	Colorectal cancer;
THYM	cis	rs4824093	0.610	rs7410773	chr22:50313727	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.03	-4.99	-0.46	2.68e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs28595532	0.541	rs114463740	chr4:119763329	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-4.8	-0.44	5.84e-6	Total cholesterol levels;
THYM	cis	rs10484885	0.824	rs72921954	chr6:90586656	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.87	-7.73	-0.62	1.13e-11	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs7894051	1.000	rs7894051	chr10:135184421	C/G	cg07511014	chr10:135191624	PAOX	-0.77	-5.21	-0.47	1.1e-6	Lifespan;
THYM	cis	rs673253	0.556	rs9787076	chr1:44141149	A/C	cg24466421	chr1:44070974	PTPRF	-0.56	-4.76	-0.44	6.96e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10752881	1.000	rs10737235	chr1:182971816	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.62	5.03	0.46	2.29e-6	Colorectal cancer;
THYM	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.75	-5.87	-0.52	6.4e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.68	6.04	0.53	2.94e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg17054759	chr22:49844102	NA	-0.53	-4.68	-0.43	9.5e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs96067	0.711	rs11263861	chr1:36628033	G/A	cg24686825	chr1:36642396	MAP7D1	-0.68	-5.66	-0.5	1.6e-7	Corneal structure;
THYM	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg17063962	chr7:91808500	NA	1.13	12.22	0.78	3.38e-21	Breast cancer;
THYM	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg18357526	chr6:26021779	HIST1H4A	0.8	6.91	0.58	5.55e-10	Intelligence (multi-trait analysis);
THYM	cis	rs13256369	0.755	rs11776987	chr8:8559401	C/G	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg24250549	chr1:154909240	PMVK	0.68	5.08	0.46	1.92e-6	Prostate cancer;
THYM	cis	rs2637266	0.765	rs2395391	chr10:78359932	G/A	cg18941641	chr10:78392320	NA	0.7	5.55	0.49	2.57e-7	Pulmonary function;
THYM	cis	rs12681287	0.640	rs13261901	chr8:87478717	G/C	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.44e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg11211951	chr8:145729740	GPT	-0.54	-5.04	-0.46	2.22e-6	Age at first birth;
THYM	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06481639	chr22:41940642	POLR3H	-0.76	-5.66	-0.5	1.61e-7	Vitiligo;
THYM	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.93	5.98	0.52	3.95e-8	Smoking behavior;
THYM	cis	rs6840360	0.606	rs10028035	chr4:152347825	T/G	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.3	-0.48	7.43e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3126085	0.877	rs1552992	chr1:152171625	C/G	cg26020982	chr1:152196106	HRNR	0.37	5.06	0.46	2.05e-6	Atopic dermatitis;
THYM	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11644478	chr21:40555479	PSMG1	0.64	4.66	0.43	1.04e-5	Cognitive function;
THYM	cis	rs7944584	0.563	rs61895112	chr11:47560433	T/C	cg20307385	chr11:47447363	PSMC3	0.78	5.43	0.49	4.25e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
THYM	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs4143844	0.867	rs2303405	chr15:62253791	C/T	cg01254644	chr15:62937909	MGC15885	-0.86	-4.55	-0.42	1.59e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg18681998	chr4:17616180	MED28	0.79	7.15	0.59	1.77e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg05872129	chr22:39784769	NA	-0.99	-9.59	-0.7	1.25e-15	Intelligence (multi-trait analysis);
THYM	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg07424592	chr7:64974309	NA	1.12	5.24	0.47	9.64e-7	Diabetic kidney disease;
THYM	cis	rs8048589	0.615	rs34598762	chr16:12234958	A/G	cg02910054	chr16:12241554	SNX29	0.83	7.08	0.59	2.47e-10	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs28647808	1.000	rs28540113	chr9:136273463	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg17294928	chr15:75287854	SCAMP5	-0.99	-9.14	-0.68	1.15e-14	Blood trace element (Zn levels);
THYM	cis	rs7107174	1.000	rs2510032	chr11:77968631	G/C	cg02023728	chr11:77925099	USP35	0.65	5.79	0.51	9.23e-8	Testicular germ cell tumor;
THYM	trans	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg25214090	chr10:38739885	LOC399744	0.98	8.29	0.65	7.22e-13	Corneal astigmatism;
THYM	cis	rs3820068	0.603	rs7516453	chr1:15972558	C/G	cg13390004	chr1:15929781	NA	0.7	5.05	0.46	2.17e-6	Systolic blood pressure;
THYM	cis	rs986417	0.901	rs11158292	chr14:61043183	G/T	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs7818345	0.935	rs6990217	chr8:19276661	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.65	0.43	1.07e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg12963246	chr6:28129442	ZNF389	0.83	7.05	0.59	2.89e-10	Parkinson's disease;
THYM	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg02478829	chr6:26598070	ABT1	-0.33	-4.49	-0.42	1.97e-5	Intelligence (multi-trait analysis);
THYM	cis	rs8013055	0.846	rs12893999	chr14:105970842	C/G	cg23356831	chr14:105996513	TMEM121	0.57	6.17	0.53	1.69e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg03859395	chr2:55845619	SMEK2	-0.5	-4.64	-0.43	1.13e-5	Metabolic syndrome;
THYM	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-4.52	-0.42	1.76e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs9527	0.590	rs11191547	chr10:104843148	C/T	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg04362960	chr10:104952993	NT5C2	0.59	4.96	0.45	3.02e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg26418147	chr1:205743515	RAB7L1	-0.52	-4.51	-0.42	1.88e-5	Menarche (age at onset);
THYM	cis	rs10791097	0.967	rs1944142	chr11:130717440	C/T	cg14779329	chr11:130786720	SNX19	0.54	5.7	0.5	1.34e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg10560079	chr2:191398806	TMEM194B	0.9	8.45	0.65	3.42e-13	Pulse pressure;
THYM	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11890956	chr21:40555474	PSMG1	1.14	12.12	0.78	5.55e-21	Cognitive function;
THYM	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6977955	1.000	rs2893312	chr7:28170403	C/T	cg04959634	chr7:27219224	HOXA10	-0.61	-4.46	-0.42	2.23e-5	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs4589258	0.933	rs34226552	chr11:90409355	G/A	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg22907277	chr7:1156413	C7orf50	0.63	5.61	0.5	2.02e-7	Longevity;Endometriosis;
THYM	cis	rs13424612	0.839	rs4461287	chr2:240906574	C/T	cg01812947	chr2:240904978	NDUFA10	0.56	4.59	0.43	1.35e-5	Odorant perception (isobutyraldehyde);
THYM	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg04476341	chr5:669733	TPPP	0.48	4.86	0.45	4.54e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs7542375	0.683	rs61819203	chr1:221090010	A/G	cg16008148	chr1:221062819	NA	0.54	5.51	0.49	3.02e-7	Obesity-related traits;
THYM	trans	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg19862616	chr7:65841803	NCRNA00174	1.06	11.85	0.77	2e-20	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9788682	0.747	rs12910984	chr15:78891627	G/A	cg18825076	chr15:78729989	IREB2	-0.6	-4.95	-0.45	3.25e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs7851660	0.548	rs1156850	chr9:100573164	G/A	cg13688889	chr9:100608707	NA	-0.97	-8.58	-0.66	1.81e-13	Strep throat;
THYM	cis	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg05084668	chr3:125655381	ALG1L	-0.71	-4.61	-0.43	1.23e-5	Blood pressure (smoking interaction);
THYM	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg22105103	chr4:187893119	NA	0.95	10.29	0.73	3.97e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg27532560	chr4:187881888	NA	-0.95	-11.61	-0.77	6.5e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	4.92	0.45	3.68e-6	Schizophrenia;
THYM	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg24642439	chr20:33292090	TP53INP2	0.63	4.95	0.45	3.19e-6	Coronary artery disease;
THYM	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg27535305	chr1:53392650	SCP2	0.4	4.77	0.44	6.65e-6	Monocyte count;
THYM	trans	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg10856724	chr12:34555212	NA	-0.87	-7.75	-0.62	9.89e-12	Bladder cancer;
THYM	cis	rs728616	0.867	rs7080405	chr10:81901943	G/C	cg18148530	chr10:81370782	SFTPA1	0.7	4.53	0.42	1.7e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9633835	0.585	rs34796300	chr11:13315205	T/C	cg13286116	chr11:13302098	ARNTL	-0.79	-8.78	-0.67	6.8e-14	Body mass index;
THYM	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.02	0.46	2.4e-6	Prudent dietary pattern;
THYM	cis	rs11039798	0.660	rs717897	chr11:48375604	A/G	cg24672777	chr11:48374446	OR4C45	0.93	6.0	0.52	3.56e-8	Axial length;
THYM	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	4.86	0.45	4.63e-6	Hip circumference adjusted for BMI;
THYM	cis	rs7769051	1.000	rs9493438	chr6:133098349	T/C	cg07930552	chr6:133119739	C6orf192	1.02	5.81	0.51	8.43e-8	Type 2 diabetes nephropathy;
THYM	cis	rs12681288	0.550	rs4637864	chr8:959761	C/T	cg08648136	chr8:956695	NA	0.56	5.0	0.46	2.63e-6	Schizophrenia;
THYM	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg17178900	chr1:205818956	PM20D1	-0.76	-6.86	-0.58	7.03e-10	Monocyte percentage of white cells;
THYM	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg16342193	chr10:102329863	NA	-0.6	-6.24	-0.54	1.22e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg06481639	chr22:41940642	POLR3H	-0.72	-5.25	-0.47	9.4e-7	Neuroticism;
THYM	cis	rs7009516	0.669	rs13251418	chr8:24246832	A/T	cg01759110	chr8:24241694	ADAMDEC1	-0.54	-4.85	-0.45	4.81e-6	Hair greying;
THYM	cis	rs714031	0.934	rs5757764	chr22:40067818	C/T	cg21377881	chr22:40064566	CACNA1I	-0.59	-5.32	-0.48	6.98e-7	Schizophrenia;
THYM	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9906944	0.707	rs4794020	chr17:47111399	C/T	cg09029085	chr17:47094198	IGF2BP1	0.47	6.53	0.56	3.17e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg23958373	chr8:599963	NA	0.88	4.53	0.42	1.73e-5	IgG glycosylation;
THYM	cis	rs11048434	0.761	rs12827988	chr12:9130287	A/G	cg26114124	chr12:9217669	LOC144571	0.46	4.51	0.42	1.85e-5	Sjögren's syndrome;
THYM	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg14004847	chr7:1930337	MAD1L1	-0.62	-4.46	-0.42	2.27e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs7107174	1.000	rs10899469	chr11:78018313	T/C	cg19901956	chr11:77921274	USP35	-0.74	-5.57	-0.5	2.39e-7	Testicular germ cell tumor;
THYM	cis	rs12935418	0.616	rs9937731	chr16:81012303	C/A	cg16651780	chr16:81037892	C16orf61	0.86	6.35	0.55	7.49e-9	Mean corpuscular volume;
THYM	cis	rs7432375	0.901	rs900818	chr3:136471815	C/T	cg12473912	chr3:136751656	NA	-0.62	-5.24	-0.47	9.64e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg07936489	chr17:37558343	FBXL20	0.87	5.78	0.51	9.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs7078219	0.505	rs10883362	chr10:101286984	C/T	cg23904955	chr10:101282759	NA	-0.36	-4.53	-0.42	1.73e-5	Dental caries;
THYM	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg11752832	chr7:134001865	SLC35B4	0.67	4.98	0.45	2.9e-6	Mean platelet volume;
THYM	cis	rs12282928	0.876	rs7942250	chr11:48243481	G/A	cg22827986	chr11:48284249	OR4X1	-0.51	-5.43	-0.49	4.28e-7	Migraine - clinic-based;
THYM	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs4474465	1.000	rs10899513	chr11:78172353	T/C	cg02023728	chr11:77925099	USP35	0.52	4.54	0.42	1.67e-5	Alzheimer's disease (survival time);
THYM	cis	rs6060717	0.610	rs1891151	chr20:34612726	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-4.68	-0.43	9.42e-6	Hip circumference adjusted for BMI;
THYM	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg11494091	chr17:61959527	GH2	1.1	16.28	0.86	3.05e-29	Prudent dietary pattern;
THYM	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-5.33	-0.48	6.7e-7	Hemoglobin concentration;
THYM	cis	rs6980334	0.817	rs11982192	chr7:137795842	G/T	cg06915773	chr7:137028165	PTN	0.58	4.74	0.44	7.59e-6	Blood metabolite ratios;
THYM	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	8.81	0.67	5.81e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg27398817	chr8:82754497	SNX16	0.71	6.05	0.53	2.89e-8	Diastolic blood pressure;
THYM	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg06609049	chr19:2785107	THOP1	1.21	12.96	0.8	9.99e-23	Total cholesterol levels;
THYM	cis	rs6988636	1.000	rs13261021	chr8:124190239	G/A	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs36051895	0.632	rs2149552	chr9:5132838	A/G	cg02405213	chr9:5042618	JAK2	-1.04	-11.85	-0.77	1.96e-20	Pediatric autoimmune diseases;
THYM	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs4792901	0.918	rs12103666	chr17:41636310	G/A	cg21940313	chr17:41620911	ETV4	-0.48	-5.27	-0.48	8.38e-7	Dupuytren's disease;
THYM	cis	rs9326248	0.559	rs482371	chr11:116752163	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.67	5.3	0.48	7.39e-7	Blood protein levels;
THYM	cis	rs17433780	0.964	rs12121223	chr1:89481583	C/T	cg09516651	chr1:89888402	LOC400759	0.88	6.84	0.57	7.69e-10	Carotid intima media thickness;
THYM	trans	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg25214090	chr10:38739885	LOC399744	0.87	7.52	0.61	2.99e-11	Corneal astigmatism;
THYM	cis	rs72781680	1.000	rs72798408	chr2:24181845	G/C	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs807029	0.577	rs750866	chr10:102761458	A/G	cg14905631	chr10:102746534	C10orf2;MRPL43	0.37	4.96	0.45	3.08e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06850241	chr22:41845214	NA	0.49	4.62	0.43	1.21e-5	Cannabis dependence symptom count;
THYM	cis	rs4355801	0.558	rs3103970	chr8:119859758	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.57	4.52	0.42	1.78e-5	Bone mineral density;
THYM	cis	rs6430585	0.528	rs78274583	chr2:136734569	C/T	cg20242066	chr2:136595261	LCT	0.56	5.2	0.47	1.14e-6	Corneal structure;
THYM	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs870825	0.860	rs2696052	chr4:185604356	G/A	cg04058563	chr4:185651563	MLF1IP	-0.8	-6.09	-0.53	2.4e-8	Blood protein levels;
THYM	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg10515332	chr4:99064459	C4orf37	0.6	4.74	0.44	7.59e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4836694	0.574	rs67899211	chr9:132935614	G/A	cg13414629	chr9:132935646	FREQ	0.75	5.24	0.47	9.58e-7	Alzheimer's disease (cognitive decline);
THYM	cis	rs7582180	0.715	rs7571306	chr2:100906084	G/C	cg08017756	chr2:100939284	LONRF2	-0.64	-5.58	-0.5	2.23e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3947	0.950	rs1692811	chr8:11703048	C/G	cg26752888	chr8:11627280	NEIL2	-0.7	-4.52	-0.42	1.77e-5	Blood protein levels;
THYM	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg20999797	chr1:1681921	NA	0.49	5.4	0.48	4.89e-7	Body mass index;
THYM	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg09436375	chr6:42928200	GNMT	-0.4	-5.14	-0.47	1.47e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs11250464	0.833	rs11250466	chr10:1409378	C/T	cg08668359	chr10:1443807	ADARB2	0.64	5.67	0.5	1.55e-7	Radiation response;
THYM	cis	rs12579753	0.869	rs17692407	chr12:82171369	G/C	cg07988820	chr12:82153109	PPFIA2	-0.78	-4.97	-0.45	2.92e-6	Resting heart rate;
THYM	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg22467129	chr15:76604101	ETFA	0.52	5.41	0.49	4.74e-7	Blood metabolite levels;
THYM	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg06623918	chr6:96969491	KIAA0776	1.11	10.57	0.74	9.82e-18	Headache;
THYM	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg09060608	chr5:178986726	RUFY1	0.58	6.26	0.54	1.09e-8	Lung cancer;
THYM	cis	rs6960043	0.738	rs10266209	chr7:15058691	C/T	cg19272540	chr7:15055459	NA	-0.57	-6.29	-0.54	9.47e-9	Type 2 diabetes;
THYM	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.34	0.48	6.29e-7	Height;
THYM	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.76	0.44	7.04e-6	Bipolar disorder;
THYM	cis	rs11048434	0.723	rs12820395	chr12:9137096	T/G	cg13575925	chr12:9217583	LOC144571	0.55	5.48	0.49	3.45e-7	Sjögren's syndrome;
THYM	trans	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg10856724	chr12:34555212	NA	0.83	7.46	0.61	4.03e-11	Morning vs. evening chronotype;
THYM	cis	rs2742234	0.590	rs2503863	chr10:43667398	G/A	cg06632098	chr10:43605906	RET	-0.79	-5.1	-0.46	1.73e-6	Hirschsprung disease;
THYM	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg02070205	chr10:30722105	MAP3K8	-0.52	-4.45	-0.42	2.29e-5	Itch intensity from mosquito bite;
THYM	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg05872129	chr22:39784769	NA	-1.0	-10.66	-0.74	6.49e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.76	-0.44	7.03e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs8070740	0.898	rs11078562	chr17:5326857	A/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.7	5.88	0.52	6.09e-8	Menopause (age at onset);
THYM	cis	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2070488	0.965	rs6796845	chr3:38567771	C/A	cg24069376	chr3:38537580	EXOG	-0.65	-6.4	-0.55	5.87e-9	Electrocardiographic conduction measures;
THYM	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg03161606	chr19:29218774	NA	0.77	6.42	0.55	5.32e-9	Methadone dose in opioid dependence;
THYM	cis	rs1160297	0.609	rs10164868	chr2:53095923	G/T	cg07782112	chr2:53107842	NA	0.79	6.37	0.55	6.61e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	8.23	0.65	9.9e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs3809566	0.637	rs8026047	chr15:63323347	C/G	cg12160578	chr15:63334699	TPM1	0.62	4.63	0.43	1.15e-5	Platelet count;
THYM	cis	rs2273669	0.667	rs12202145	chr6:109357829	A/G	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs17739167	0.569	rs11638621	chr15:42228226	C/T	cg20935245	chr15:42234343	EHD4	0.41	4.85	0.45	4.78e-6	Monocyte count;
THYM	cis	rs9867325	1.000	rs9867325	chr3:136618909	G/C	cg21827317	chr3:136751795	NA	-0.76	-5.12	-0.47	1.57e-6	Body mass index;
THYM	cis	rs354225	0.544	rs11892443	chr2:54805776	A/G	cg23486701	chr2:54789491	SPTBN1	0.36	4.69	0.43	9.11e-6	Schizophrenia;
THYM	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.32	9.94	0.71	2.24e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6570726	0.935	rs367643	chr6:145859602	A/C	cg13319975	chr6:146136371	FBXO30	-0.67	-5.64	-0.5	1.78e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs36051895	0.594	rs7029244	chr9:5180961	A/C	cg02405213	chr9:5042618	JAK2	-1.01	-11.19	-0.75	4.95e-19	Pediatric autoimmune diseases;
THYM	trans	rs208520	0.690	rs207077	chr6:66769855	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-7.98	-0.63	3.3e-12	Exhaled nitric oxide output;
THYM	trans	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-4.84	-0.44	5e-6	Total body bone mineral density;
THYM	cis	rs12824058	0.831	rs7979497	chr12:130804706	C/T	cg26677194	chr12:130822605	PIWIL1	0.8	6.12	0.53	2.13e-8	Menopause (age at onset);
THYM	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg23482746	chr15:76478102	C15orf27	-0.38	-4.55	-0.42	1.61e-5	Blood metabolite levels;
THYM	cis	rs2282300	0.739	rs1933343	chr11:30310992	T/C	cg06241208	chr11:30344200	C11orf46	0.78	5.65	0.5	1.67e-7	Morning vs. evening chronotype;
THYM	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg18252515	chr7:66147081	NA	0.62	4.55	0.42	1.59e-5	Aortic root size;
THYM	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg05347473	chr6:146136440	FBXO30	-0.58	-4.53	-0.42	1.71e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg26384229	chr12:38710491	ALG10B	0.89	6.76	0.57	1.13e-9	Bladder cancer;
THYM	cis	rs1079204	1.000	rs73088143	chr2:219188428	C/A	cg05728596	chr2:219128475	GPBAR1	1.14	4.92	0.45	3.6e-6	Smooth-surface caries;
THYM	cis	rs7580658	0.676	rs4662717	chr2:128013504	C/T	cg09152259	chr2:128156114	NA	-0.34	-4.61	-0.43	1.26e-5	Protein C levels;
THYM	cis	rs10231759	0.617	rs2080054	chr7:150515674	T/C	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.64	4.93	0.45	3.53e-6	Height;
THYM	cis	rs6901250	0.851	rs339307	chr6:117177340	A/G	cg12892004	chr6:117198278	RFX6	-0.7	-6.78	-0.57	9.91e-10	C-reactive protein levels;
THYM	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11563648	0.511	rs1419405	chr7:127057758	G/A	cg23081781	chr7:127225937	GCC1	-0.33	-4.52	-0.42	1.78e-5	Resting heart rate;
THYM	cis	rs2963155	0.518	rs72801029	chr5:142625806	T/C	cg17617527	chr5:142782415	NR3C1	1.28	5.29	0.48	7.96e-7	Breast cancer;
THYM	cis	rs4242434	0.672	rs900267	chr8:22485258	T/C	cg03733263	chr8:22462867	KIAA1967	1.0	11.13	0.75	6.58e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg04447362	chr2:237654635	NA	0.48	4.49	0.42	2.03e-5	Prostate cancer;
THYM	cis	rs4654899	0.743	rs61778528	chr1:21059837	C/T	cg01072550	chr1:21505969	NA	-0.58	-4.82	-0.44	5.34e-6	Superior frontal gyrus grey matter volume;
THYM	cis	rs11641184	0.528	rs9932278	chr16:11707567	G/A	cg09662852	chr16:11707685	NA	-0.44	-4.92	-0.45	3.63e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg18230493	chr5:56204884	C5orf35	-0.89	-6.62	-0.56	2.09e-9	Initial pursuit acceleration;
THYM	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg03161606	chr19:29218774	NA	0.87	7.71	0.62	1.23e-11	Methadone dose in opioid dependence;
THYM	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg04865290	chr3:52927548	TMEM110	-0.88	-4.55	-0.42	1.59e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs58950470	0.927	rs1193851	chr11:65386206	C/G	cg27068330	chr11:65405492	SIPA1	0.62	4.74	0.44	7.54e-6	Schizophrenia;
THYM	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg04647918	chr11:67383862	NA	-0.65	-5.55	-0.49	2.61e-7	Mean corpuscular volume;
THYM	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg24503407	chr1:205819492	PM20D1	0.92	8.61	0.66	1.53e-13	Menarche (age at onset);
THYM	cis	rs7940866	0.845	rs2324314	chr11:130834589	A/C	cg05962950	chr11:130786565	SNX19	0.63	4.89	0.45	4.11e-6	Schizophrenia;
THYM	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg06238570	chr21:40685208	BRWD1	-0.96	-9.14	-0.68	1.13e-14	Cognitive function;
THYM	cis	rs2811415	0.597	rs9827421	chr3:127775499	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg08885076	chr2:99613938	TSGA10	0.56	5.03	0.46	2.31e-6	Chronic sinus infection;
THYM	cis	rs9902453	0.765	rs8079209	chr17:28186773	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	5.39	0.48	5.13e-7	Coffee consumption (cups per day);
THYM	cis	rs11677370	0.574	rs10190477	chr2:3862738	A/G	cg07307994	chr2:3828216	NA	0.7	4.66	0.43	1.03e-5	Type 2 diabetes;
THYM	cis	rs709400	0.663	rs72710714	chr14:103981849	T/G	cg12935359	chr14:103987150	CKB	-0.61	-5.59	-0.5	2.19e-7	Body mass index;
THYM	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg10792982	chr14:105748885	BRF1	0.73	7.44	0.61	4.37e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg00757033	chr12:89920650	WDR51B	0.77	11.72	0.77	3.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg07414643	chr4:187882934	NA	0.59	5.07	0.46	1.96e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7258015	0.865	rs7250656	chr19:10448566	A/G	cg01466491	chr19:10523363	NA	0.65	5.14	0.47	1.47e-6	Systemic lupus erythematosus or rheumatoid arthritis;
THYM	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg23711669	chr6:146136114	FBXO30	0.91	8.94	0.68	3.02e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4845459	0.967	rs4845452	chr1:152591647	A/G	cg27206522	chr1:152595629	LCE3A	-0.52	-4.56	-0.42	1.5e-5	Psoriasis;
THYM	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg09549813	chr16:4587862	C16orf5	-0.61	-6.88	-0.58	6.48e-10	Schizophrenia;
THYM	cis	rs8038465	0.615	rs11634399	chr15:73949210	A/G	cg15420318	chr15:73925796	NPTN	0.62	5.46	0.49	3.74e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg24006582	chr15:45444508	DUOX1	0.77	6.04	0.53	3.05e-8	Uric acid levels;
THYM	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg02018176	chr4:1364513	KIAA1530	0.73	6.96	0.58	4.45e-10	Longevity;
THYM	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	4.79	0.44	6.04e-6	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs12216545	0.737	rs1522598	chr7:150239836	G/A	cg00323915	chr7:150264987	GIMAP4	-0.49	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05901451	chr6:126070800	HEY2	-0.68	-5.92	-0.52	5.07e-8	Brugada syndrome;
THYM	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	5.28	0.48	8.21e-7	Hip circumference adjusted for BMI;
THYM	cis	rs3768617	0.510	rs10752895	chr1:183068505	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.76	0.44	6.83e-6	Fuchs's corneal dystrophy;
THYM	cis	rs6429082	0.818	rs291381	chr1:235641924	A/G	cg26050004	chr1:235667680	B3GALNT2	0.76	6.72	0.57	1.36e-9	Adiposity;
THYM	cis	rs11711311	1.000	rs10934243	chr3:113430239	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.59	-5.23	-0.47	1.01e-6	IgG glycosylation;
THYM	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	6.51	0.56	3.5e-9	Total body bone mineral density;
THYM	cis	rs12472274	0.941	rs2880131	chr2:239089151	A/C	cg17459225	chr2:239074497	NA	0.76	5.58	0.5	2.27e-7	Phospholipid levels (plasma);
THYM	cis	rs17005891	0.618	rs34156523	chr4:83548191	A/G	cg10249074	chr4:83542146	C4orf11	-0.59	-5.0	-0.46	2.58e-6	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs11574514	1.000	rs117436074	chr16:67752282	A/G	cg09738193	chr16:67926317	PSKH1	-0.92	-4.53	-0.42	1.69e-5	Crohn's disease;
THYM	cis	rs2953805	1	rs2953805	chr8:8914757	T/C	cg15741354	chr8:8146129	NA	-0.32	-5.15	-0.47	1.4e-6	Neuroticism;Morning vs. evening chronotype;
THYM	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs977987	0.902	rs34539062	chr16:75493279	C/A	cg03315344	chr16:75512273	CHST6	0.72	5.68	0.5	1.46e-7	Dupuytren's disease;
THYM	cis	rs2279817	0.863	rs11203439	chr1:18026328	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.77	4.77	0.44	6.58e-6	Neuroticism;
THYM	cis	rs427394	0.743	rs274716	chr5:6722289	T/C	cg10857441	chr5:6722123	POLS	-0.73	-8.95	-0.68	2.89e-14	Menopause (age at onset);
THYM	cis	rs7179456	0.544	rs2555357	chr15:59087115	A/G	cg05156742	chr15:59063176	FAM63B	0.58	4.94	0.45	3.32e-6	Asperger disorder;
THYM	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07157834	chr1:205819609	PM20D1	0.9	8.98	0.68	2.53e-14	Menarche (age at onset);
THYM	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg15242686	chr22:24348715	GSTTP1	0.67	7.26	0.6	1.06e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg12560992	chr17:57184187	TRIM37	-0.9	-8.19	-0.64	1.2e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4918072	0.637	rs61861137	chr10:105613383	A/G	cg11005552	chr10:105648138	OBFC1	0.62	4.81	0.44	5.65e-6	Coronary artery disease;
THYM	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg10018233	chr7:150070692	REPIN1	0.49	7.65	0.62	1.66e-11	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg15592062	chr6:167189543	RPS6KA2	-0.48	-4.71	-0.44	8.34e-6	Crohn's disease;
THYM	cis	rs57994353	1.000	rs57994353	chr9:139356987	T/C	cg14115884	chr9:139300582	SDCCAG3	0.67	5.16	0.47	1.38e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs6732160	0.932	rs13417029	chr2:73380423	T/G	cg24220031	chr2:73402428	NA	-0.65	-6.38	-0.55	6.44e-9	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg18252515	chr7:66147081	NA	-0.69	-5.39	-0.48	5.11e-7	Aortic root size;
THYM	trans	rs8073060	0.586	rs72829927	chr17:34049992	A/G	cg19694781	chr19:47549865	TMEM160	1.01	8.58	0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs6430585	0.528	rs309161	chr2:136688749	A/G	cg07169764	chr2:136633963	MCM6	-0.95	-8.49	-0.66	2.72e-13	Corneal structure;
THYM	cis	rs2456568	0.741	rs9633811	chr11:93628327	A/G	cg17595323	chr11:93583763	C11orf90	0.59	6.36	0.55	7e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg05335186	chr13:53173507	NA	0.49	6.23	0.54	1.28e-8	Lewy body disease;
THYM	cis	rs12368653	0.584	rs7295422	chr12:58099736	G/A	cg12615879	chr12:58013172	SLC26A10	0.54	5.36	0.48	5.75e-7	Multiple sclerosis;
THYM	cis	rs7894051	0.614	rs11101707	chr10:135175844	T/C	cg02114346	chr10:135191542	PAOX	-0.87	-4.63	-0.43	1.18e-5	Lifespan;
THYM	cis	rs4986811	1.000	rs5030172	chr11:32449274	G/C	cg04096767	chr11:32449450	WT1	0.62	4.7	0.43	8.82e-6	Rubella-specific interleukin-6 secretion;
THYM	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg21280719	chr6:42927975	GNMT	-0.53	-7.38	-0.6	5.9e-11	Plasma homocysteine levels (post-methionine load test);
THYM	cis	rs10823500	0.674	rs7089860	chr10:71992848	C/G	cg25502086	chr10:71892093	AIFM2	-0.57	-5.02	-0.46	2.38e-6	Blood protein levels;
THYM	cis	rs7917772	0.604	rs11191358	chr10:104399250	C/T	cg00122347	chr10:104236741	TMEM180	0.41	5.46	0.49	3.82e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7666738	0.752	rs35436270	chr4:99088280	G/A	cg17366294	chr4:99064904	C4orf37	0.53	5.49	0.49	3.32e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11190604	0.725	rs9420796	chr10:102323092	G/C	cg07570687	chr10:102243282	WNT8B	0.73	6.55	0.56	2.96e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05901451	chr6:126070800	HEY2	-0.7	-5.81	-0.51	8.18e-8	Brugada syndrome;
THYM	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg22681709	chr2:178499509	PDE11A	-0.57	-5.4	-0.48	4.83e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg27446573	chr6:127587934	RNF146	1.04	9.87	0.71	3.12e-16	Breast cancer;
THYM	cis	rs28785552	0.554	rs11084183	chr19:53213517	T/C	cg10871876	chr19:53194124	ZNF83	0.72	5.59	0.5	2.21e-7	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs909002	0.800	rs3753614	chr1:32081785	G/A	cg13919466	chr1:32135498	COL16A1	-0.49	-4.91	-0.45	3.73e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg17063962	chr7:91808500	NA	1.1	11.9	0.77	1.56e-20	Breast cancer;
THYM	cis	rs3741151	0.892	rs7930454	chr11:73085034	T/C	cg12959048	chr11:73096162	RELT	-0.47	-4.64	-0.43	1.12e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9563576	0.778	rs12585096	chr13:58605261	C/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	-0.64	-4.65	-0.43	1.09e-5	Body mass index;
THYM	cis	rs7177699	0.557	rs7176187	chr15:79121373	A/G	cg00540400	chr15:79124168	NA	0.62	6.72	0.57	1.36e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs1788820	0.871	rs1623003	chr18:21165163	C/T	cg14672496	chr18:21087552	C18orf8	0.78	6.05	0.53	2.82e-8	Body mass index;
THYM	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.6	0.5	2.04e-7	Lung cancer in ever smokers;
THYM	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg00487526	chr15:90818384	NA	0.58	4.46	0.42	2.24e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs17006441	0.932	rs34165775	chr3:69868530	C/T	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.58	-0.43	1.42e-5	Morning vs. evening chronotype;
THYM	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg06600287	chr1:53387719	ECHDC2	-0.31	-5.11	-0.46	1.68e-6	Monocyte count;
THYM	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg04025307	chr7:1156635	C7orf50	0.79	6.63	0.56	2.05e-9	Longevity;Endometriosis;
THYM	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg00271210	chr6:167070053	RPS6KA2	-0.55	-5.33	-0.48	6.65e-7	Crohn's disease;
THYM	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg05973401	chr12:123451056	ABCB9	0.67	4.49	0.42	2.02e-5	Neutrophil percentage of white cells;
THYM	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg10589385	chr1:150898437	SETDB1	0.62	5.08	0.46	1.9e-6	Melanoma;
THYM	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.74	-6.98	-0.58	4.05e-10	Personality dimensions;
THYM	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.64	-0.74	7.23e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	5.78	0.51	9.58e-8	Lung cancer in ever smokers;
THYM	cis	rs870825	0.616	rs28666955	chr4:185631338	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs977987	0.742	rs12928898	chr16:75462081	G/A	cg03315344	chr16:75512273	CHST6	0.76	6.17	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs4285214	0.715	rs10079692	chr5:124025450	A/G	cg15082166	chr5:124005151	ZNF608	-0.57	-4.59	-0.43	1.33e-5	Survival in pancreatic cancer;
THYM	cis	rs9796	0.558	rs7166905	chr15:41514876	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.55	-4.52	-0.42	1.75e-5	Menopause (age at onset);
THYM	cis	rs990171	1.000	rs2272129	chr2:103040249	C/T	cg13897122	chr2:103039542	IL18RAP	-0.39	-4.72	-0.44	7.96e-6	Lymphocyte counts;
THYM	cis	rs500891	0.525	rs12529407	chr6:84062581	C/T	cg08257003	chr6:84140564	ME1	-0.57	-4.53	-0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs12216545	0.765	rs6464078	chr7:150248396	C/T	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs3960554	0.808	rs3779419	chr7:75695081	G/A	cg17325771	chr7:75508891	RHBDD2	-0.4	-4.57	-0.42	1.44e-5	Eotaxin levels;
THYM	cis	rs7927771	0.524	rs10742817	chr11:47689343	A/G	cg18512352	chr11:47633146	NA	-0.38	-4.49	-0.42	2.01e-5	Subjective well-being;
THYM	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs600806	0.850	rs7518013	chr1:109944078	C/T	cg02175308	chr1:109941060	SORT1	0.57	5.08	0.46	1.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg06238570	chr21:40685208	BRWD1	-0.96	-9.14	-0.68	1.13e-14	Cognitive function;
THYM	cis	rs1729951	0.575	rs835641	chr3:136703474	G/T	cg21827317	chr3:136751795	NA	0.75	6.71	0.57	1.41e-9	Neuroticism;
THYM	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg06970220	chr1:156163860	SLC25A44	0.69	5.42	0.49	4.41e-7	Testicular germ cell tumor;
THYM	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-7.08	-0.59	2.42e-10	Chronic sinus infection;
THYM	cis	rs2073300	0.609	rs56094936	chr20:23401586	G/A	cg12062639	chr20:23401060	NAPB	1.1	5.73	0.51	1.16e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs17127169	1.000	rs61786112	chr1:65421169	A/G	cg12075498	chr1:65428216	JAK1	-0.42	-5.17	-0.47	1.32e-6	Sitting height ratio;
THYM	cis	rs2273669	0.915	rs2145766	chr6:109296261	G/C	cg17117243	chr6:109341365	SESN1	-0.77	-4.68	-0.43	9.63e-6	Prostate cancer;
THYM	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6424115	0.830	rs2501423	chr1:24199026	A/C	cg15997130	chr1:24165203	NA	0.74	6.34	0.55	7.54e-9	Immature fraction of reticulocytes;
THYM	cis	rs6430585	0.527	rs1900306	chr2:136416533	G/A	cg07169764	chr2:136633963	MCM6	1.16	11.27	0.76	3.33e-19	Corneal structure;
THYM	cis	rs4664308	0.967	rs7563607	chr2:160910215	C/G	cg03641300	chr2:160917029	PLA2R1	-0.76	-6.83	-0.57	7.92e-10	Idiopathic membranous nephropathy;
THYM	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg08470875	chr2:26401718	FAM59B	-0.75	-4.69	-0.43	8.96e-6	Gut microbiome composition (summer);
THYM	cis	rs791888	0.728	rs2255682	chr10:89419873	C/G	cg17916473	chr10:89419373	PAPSS2	-0.43	-4.46	-0.42	2.27e-5	Magnesium levels;
THYM	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg07570687	chr10:102243282	WNT8B	0.74	6.43	0.55	5.18e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2046867	0.818	rs17010215	chr3:72886965	A/G	cg25664220	chr3:72788482	NA	-0.96	-7.85	-0.63	6.21e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs10982256	0.782	rs10982244	chr9:117250278	A/G	cg15903421	chr9:117267460	DFNB31	-0.55	-5.35	-0.48	6.03e-7	Bipolar disorder;
THYM	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg10802521	chr3:52805072	NEK4	-0.63	-5.33	-0.48	6.63e-7	Electroencephalogram traits;
THYM	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg24818145	chr4:99064322	C4orf37	0.82	6.88	0.58	6.2e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2268241	0.938	rs11088251	chr21:34770810	A/C	cg14850771	chr21:34775459	IFNGR2	0.99	7.09	0.59	2.35e-10	Obesity-related traits;
THYM	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg27535305	chr1:53392650	SCP2	-0.54	-6.32	-0.54	8.36e-9	Monocyte count;
THYM	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg24375607	chr4:120327624	NA	0.69	5.53	0.49	2.83e-7	Corneal astigmatism;
THYM	cis	rs3862030	0.694	rs41306870	chr10:104229785	C/T	cg00122347	chr10:104236741	TMEM180	0.48	7.03	0.59	3.09e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs6430585	0.583	rs79633114	chr2:136586825	C/T	cg23851026	chr2:136556271	LCT	0.81	7.79	0.62	8.52e-12	Corneal structure;
THYM	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.33	9.84	0.71	3.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11031096	0.678	rs12223062	chr11:4180178	G/T	cg22027985	chr11:4115532	RRM1	-0.5	-4.6	-0.43	1.3e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs924712	0.522	rs1910356	chr6:54706143	T/C	cg19716238	chr6:54711378	FAM83B	-0.47	-4.45	-0.42	2.36e-5	Breast cancer;
THYM	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg07959070	chr22:50026188	C22orf34	-0.28	-4.98	-0.46	2.82e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6565180	0.888	rs12921440	chr16:30408765	C/T	cg17640201	chr16:30407289	ZNF48	0.92	8.59	0.66	1.71e-13	Tonsillectomy;
THYM	cis	rs12282928	1.000	rs10769344	chr11:48333823	G/A	cg22827986	chr11:48284249	OR4X1	0.53	5.59	0.5	2.21e-7	Migraine - clinic-based;
THYM	cis	rs931812	0.535	rs3100053	chr8:101944559	T/A	cg04962480	chr8:101962118	YWHAZ	-0.38	-5.93	-0.52	4.88e-8	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3820068	0.705	rs7533125	chr1:15883744	T/C	cg05660106	chr1:15850417	CASP9	1.16	9.85	0.71	3.54e-16	Systolic blood pressure;
THYM	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.77	-5.1	-0.46	1.7e-6	Body mass index;
THYM	cis	rs13102973	0.965	rs11099302	chr4:135880751	G/T	cg14419869	chr4:135874104	NA	0.91	8.81	0.67	5.67e-14	Subjective well-being;
THYM	cis	rs807029	0.577	rs11190786	chr10:102757442	A/G	cg14905631	chr10:102746534	C10orf2;MRPL43	0.37	4.96	0.45	3.08e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg08859206	chr1:53392774	SCP2	0.47	4.84	0.44	5.09e-6	Monocyte count;
THYM	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05901451	chr6:126070800	HEY2	-0.95	-9.33	-0.69	4.41e-15	Brugada syndrome;
THYM	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg06618935	chr21:46677482	NA	-0.98	-9.5	-0.7	1.95e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs36051895	0.664	rs3780370	chr9:5095167	A/C	cg02405213	chr9:5042618	JAK2	-1.0	-10.96	-0.75	1.46e-18	Pediatric autoimmune diseases;
THYM	cis	rs7429990	0.901	rs7433678	chr3:48037078	G/A	cg02219026	chr3:48282209	ZNF589	0.6	4.5	0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs11252926	0.673	rs816620	chr10:645916	A/G	cg03684893	chr10:554711	DIP2C	0.6	4.73	0.44	7.77e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs4786125	0.920	rs6500852	chr16:6896649	A/G	cg03623568	chr16:6915990	A2BP1	-0.79	-6.25	-0.54	1.17e-8	Heart rate variability traits (SDNN);
THYM	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg07131210	chr7:1025825	CYP2W1	-0.85	-4.72	-0.44	8.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs889398	0.835	rs62050037	chr16:69784670	T/C	cg09409435	chr16:70099608	PDXDC2	-0.6	-4.55	-0.42	1.57e-5	Body mass index;
THYM	cis	rs665401	0.692	rs339359	chr6:117160693	G/A	cg20376953	chr6:117187980	NA	0.61	4.89	0.45	4.05e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs7072216	0.763	rs10883092	chr10:100167276	A/C	cg03852570	chr10:100175106	PYROXD2	0.37	4.92	0.45	3.63e-6	Metabolite levels;
THYM	cis	rs240764	0.658	rs11155637	chr6:101203592	A/G	cg21058520	chr6:100914733	NA	0.6	5.28	0.48	8.25e-7	Neuroticism;
THYM	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg26597838	chr10:835615	NA	1.23	8.92	0.68	3.4e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs6543140	0.964	rs11886793	chr2:103072220	T/G	cg03938978	chr2:103052716	IL18RAP	0.58	5.84	0.51	7.16e-8	Blood protein levels;
THYM	cis	rs6570726	0.791	rs387376	chr6:145822565	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.44	-0.49	4.16e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg01181863	chr3:195395398	SDHAP2	-0.63	-4.89	-0.45	4.09e-6	Pancreatic cancer;
THYM	cis	rs34779708	0.931	rs11596502	chr10:35387187	A/C	cg03585969	chr10:35415529	CREM	0.7	4.75	0.44	7.34e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs2302612	0.514	rs7572853	chr2:102853783	G/A	cg13315345	chr2:102803985	IL1RL2	0.64	4.95	0.45	3.26e-6	Serum protein levels (sST2);
THYM	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg06481639	chr22:41940642	POLR3H	-0.64	-5.05	-0.46	2.1e-6	Neuroticism;
THYM	cis	rs4478037	0.822	rs77355992	chr3:33107518	T/C	cg19404215	chr3:33155277	CRTAP	1.05	6.53	0.56	3.2e-9	Major depressive disorder;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg22701143	chr6:14712347	NA	-0.85	-7.14	-0.59	1.85e-10	Depressive symptoms;
THYM	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07167872	chr1:205819463	PM20D1	0.97	9.53	0.7	1.65e-15	Menarche (age at onset);
THYM	cis	rs113835537	0.529	rs75683511	chr11:66275026	A/G	cg10315249	chr11:66235081	PELI3	0.42	4.53	0.42	1.69e-5	Airway imaging phenotypes;
THYM	cis	rs1185460	0.565	rs584115	chr11:118938880	A/G	cg13248115	chr11:119294414	THY1	0.47	4.53	0.42	1.73e-5	Coronary artery disease;
THYM	cis	rs7226229	0.750	rs60329988	chr17:20912781	C/A	cg21263980	chr17:20946333	USP22	0.67	5.02	0.46	2.38e-6	Blood trace element (Se levels);
THYM	cis	rs2888875	0.547	rs67193054	chr2:43840813	C/G	cg22033476	chr2:43532275	THADA	-0.39	-4.46	-0.42	2.25e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg00786635	chr1:25594202	NA	0.89	7.09	0.59	2.37e-10	Erythrocyte sedimentation rate;
THYM	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg01570182	chr17:44337453	NA	0.91	9.94	0.71	2.22e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7119	0.635	rs2682910	chr15:77880114	C/A	cg27398640	chr15:77910606	LINGO1	0.7	8.44	0.65	3.49e-13	Type 2 diabetes;
THYM	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg10852096	chr15:79043040	NA	-0.66	-5.07	-0.46	1.96e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg17063962	chr7:91808500	NA	-0.99	-7.31	-0.6	8.21e-11	Breast cancer;
THYM	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg27446573	chr6:127587934	RNF146	0.87	6.74	0.57	1.22e-9	Breast cancer;
THYM	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg24503407	chr1:205819492	PM20D1	0.94	9.0	0.68	2.24e-14	Menarche (age at onset);
THYM	cis	rs7635838	0.617	rs184700	chr3:11293061	A/G	cg00170343	chr3:11313890	ATG7	0.6	4.48	0.42	2.12e-5	HDL cholesterol;
THYM	cis	rs12460587	0.587	rs10415150	chr19:52604625	C/G	cg05974498	chr19:52599256	ZNF841	0.32	5.28	0.48	8.24e-7	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs501344	0.836	rs509608	chr8:103113668	A/T	cg15842116	chr8:103136774	NCALD	0.56	4.69	0.43	9.11e-6	LDL peak particle diameter (total fat intake interaction);
THYM	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	6.99	0.58	3.78e-10	Prudent dietary pattern;
THYM	cis	rs7512552	0.839	rs1103115	chr1:150332304	G/A	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs8141529	0.778	rs7287806	chr22:29213011	G/A	cg02153584	chr22:29168773	CCDC117	0.58	4.56	0.42	1.52e-5	Lymphocyte counts;
THYM	cis	rs17253792	0.822	rs77182097	chr14:56136695	G/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs4242434	0.819	rs720745	chr8:22471147	G/T	cg21658235	chr8:22456391	C8orf58	0.44	4.54	0.42	1.65e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6060717	0.698	rs8123175	chr20:34609872	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-5.25	-0.47	9.38e-7	Hip circumference adjusted for BMI;
THYM	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg06713675	chr4:122721982	EXOSC9	-0.67	-6.69	-0.57	1.56e-9	Type 2 diabetes;
THYM	cis	rs76662990	1.000	rs9293628	chr5:73796519	C/A	cg01264639	chr5:73839484	NA	1.42	5.8	0.51	8.57e-8	Residual cognition;
THYM	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs13315871	1.000	rs11713214	chr3:58445991	C/T	cg00563845	chr3:58318305	PXK	0.53	4.67	0.43	9.78e-6	Cholesterol, total;
THYM	cis	rs2916260	0.733	rs78583869	chr6:40390938	A/G	cg17190781	chr6:40387783	LRFN2	-1.09	-5.14	-0.47	1.45e-6	Incident coronary heart disease;
THYM	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs2976388	1.000	rs2920282	chr8:143757763	T/C	cg13446199	chr8:143762866	PSCA	0.5	5.96	0.52	4.36e-8	Urinary tract infection frequency;
THYM	cis	rs2976388	0.506	rs2572902	chr8:143791387	A/G	cg06565975	chr8:143823917	SLURP1	0.47	5.22	0.47	1.06e-6	Urinary tract infection frequency;
THYM	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg05457628	chr5:178986728	RUFY1	-0.65	-6.62	-0.56	2.15e-9	Lung cancer;
THYM	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.59	4.45	0.42	2.35e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg02527881	chr3:46936655	PTH1R	-0.83	-8.29	-0.65	7.33e-13	Birth weight;
THYM	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9393692	0.620	rs9358916	chr6:26283185	G/A	cg13736514	chr6:26305472	NA	-0.48	-5.01	-0.46	2.49e-6	Educational attainment;
THYM	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg17211192	chr8:82754475	SNX16	-0.82	-7.41	-0.61	5.09e-11	Diastolic blood pressure;
THYM	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10489202	1.000	rs12404574	chr1:167961235	C/T	cg24449463	chr1:168025552	DCAF6	0.72	6.23	0.54	1.25e-8	Schizophrenia;
THYM	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg01616529	chr11:638424	DRD4	-0.79	-5.78	-0.51	9.38e-8	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs485842	1.000	rs484953	chr11:96018862	A/C	cg23866687	chr11:96026956	MAML2	0.44	6.19	0.54	1.53e-8	Corneal astigmatism;
THYM	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg06656553	chr16:89960601	TCF25	-0.92	-4.45	-0.42	2.34e-5	Skin colour saturation;
THYM	cis	rs7512552	0.839	rs4581308	chr1:150276872	A/G	cg15654264	chr1:150340011	RPRD2	-0.44	-5.19	-0.47	1.21e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs2859741	0.967	rs592520	chr1:37513503	G/C	cg09363841	chr1:37513479	NA	-0.88	-9.64	-0.7	9.7e-16	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs2554380	0.843	rs2562779	chr15:84390975	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.65	-5.23	-0.47	1.02e-6	Height;
THYM	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.96	-7.26	-0.6	1.03e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs34375054	0.738	rs3751181	chr12:125626535	A/G	cg25124228	chr12:125621409	AACS	-0.75	-6.25	-0.54	1.16e-8	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs67311347	0.544	rs13062243	chr3:40336789	G/A	cg24209194	chr3:40518798	ZNF619	0.55	4.6	0.43	1.29e-5	Renal cell carcinoma;
THYM	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg18402987	chr7:1209562	NA	1.02	6.45	0.55	4.67e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg09367891	chr1:107599246	PRMT6	-0.69	-4.88	-0.45	4.2e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg16558253	chr16:72132732	DHX38	-0.56	-5.08	-0.46	1.9e-6	Fibrinogen levels;
THYM	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg11141652	chr22:24348549	GSTTP1	0.58	5.52	0.49	2.91e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1018836	0.632	rs1028255	chr8:91485578	A/T	cg16814680	chr8:91681699	NA	-0.78	-6.61	-0.56	2.26e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs36051895	0.559	rs7868706	chr9:5210936	T/G	cg02405213	chr9:5042618	JAK2	-0.89	-8.66	-0.66	1.18e-13	Pediatric autoimmune diseases;
THYM	cis	rs67072384	0.792	rs7936968	chr11:72479681	T/C	cg01380194	chr11:72452482	ARAP1	-0.98	-5.15	-0.47	1.4e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs11696501	0.694	rs7266372	chr20:44266635	T/C	cg11783356	chr20:44313418	WFDC10B	-0.66	-4.54	-0.42	1.66e-5	Brain structure;
THYM	cis	rs3892630	0.588	rs8106748	chr19:33282797	G/A	cg22980127	chr19:33182716	NUDT19	1.13	10.38	0.73	2.61e-17	Red blood cell traits;
THYM	cis	rs189798	0.738	rs330908	chr8:8995166	A/G	cg18904891	chr8:8559673	CLDN23	0.57	4.49	0.42	1.96e-5	Myopia (pathological);
THYM	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.17e-16	Bone mineral density;
THYM	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg18402987	chr7:1209562	NA	0.73	5.27	0.48	8.58e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11771526	0.786	rs11768955	chr7:32378706	T/C	cg13207630	chr7:32358064	NA	0.96	5.27	0.48	8.67e-7	Body mass index;
THYM	cis	rs17443541	0.507	rs4675702	chr2:200453139	C/G	cg03741458	chr2:200468445	NA	-0.76	-5.6	-0.5	2.09e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4654899	0.802	rs7519685	chr1:21192623	G/A	cg01072550	chr1:21505969	NA	-0.71	-6.39	-0.55	6.25e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg23758822	chr17:41437982	NA	1.17	11.09	0.75	7.75e-19	Menopause (age at onset);
THYM	cis	rs4280164	0.551	rs3181251	chr14:24805824	C/T	cg22990158	chr14:24802150	ADCY4	0.6	5.05	0.46	2.16e-6	Parent of origin effect on language impairment (paternal);
THYM	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.6	4.56	0.42	1.5e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg02018176	chr4:1364513	KIAA1530	-0.58	-4.62	-0.43	1.19e-5	Obesity-related traits;
THYM	cis	rs58530613	0.892	rs78659475	chr4:124736640	A/C	cg11268546	chr4:124983615	NA	0.7	4.45	0.42	2.36e-5	Platelet count;
THYM	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg18252515	chr7:66147081	NA	1.48	8.83	0.67	5.15e-14	Diabetic kidney disease;
THYM	cis	rs4243830	0.850	rs1010584	chr1:6579843	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.78	-4.47	-0.42	2.15e-5	Body mass index;
THYM	trans	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg10856724	chr12:34555212	NA	-0.95	-8.21	-0.64	1.07e-12	Bladder cancer;
THYM	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.59	-0.5	2.15e-7	Menopause (age at onset);
THYM	cis	rs800586	0.500	rs2737239	chr8:116656949	A/G	cg04656070	chr8:116661063	TRPS1	-0.56	-6.66	-0.56	1.75e-9	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.78	-7.17	-0.59	1.61e-10	Personality dimensions;
THYM	cis	rs7705502	1.000	rs1564823	chr5:173383194	G/T	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs735396	0.965	rs2257962	chr12:121445808	T/C	cg02403541	chr12:121454288	C12orf43	0.61	4.94	0.45	3.37e-6	N-glycan levels;
THYM	cis	rs6728642	0.572	rs7574488	chr2:97599618	T/C	cg26665480	chr2:98280029	ACTR1B	-0.75	-5.01	-0.46	2.55e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs944002	1.000	rs10131298	chr14:103568614	T/A	cg16996574	chr14:103691482	NA	0.48	4.49	0.42	2.01e-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;
THYM	cis	rs66569888	0.710	rs67005606	chr2:106876277	T/C	cg16099169	chr2:106886729	NA	-0.6	-4.65	-0.43	1.08e-5	Facial morphology (factor 23);
THYM	cis	rs11264213	0.901	rs645123	chr1:36458075	T/C	cg27506609	chr1:36549197	TEKT2	1.13	4.46	0.42	2.23e-5	Schizophrenia;
THYM	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg03517284	chr6:25882590	NA	-0.68	-4.52	-0.42	1.76e-5	Height;
THYM	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg00495681	chr13:53174319	NA	0.92	9.74	0.71	5.81e-16	Lewy body disease;
THYM	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg14779329	chr11:130786720	SNX19	0.52	5.67	0.5	1.54e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7927771	0.524	rs12785949	chr11:47729770	C/T	cg20307385	chr11:47447363	PSMC3	0.6	4.49	0.42	2.02e-5	Subjective well-being;
THYM	cis	rs12367572	0.620	rs1857924	chr12:45344212	T/G	cg03114573	chr12:45410052	DBX2	-0.54	-4.95	-0.45	3.18e-6	Gut microbiome composition (summer);
THYM	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg00254258	chr1:3105189	PRDM16	-0.65	-5.57	-0.5	2.32e-7	Migraine;
THYM	cis	rs2688608	0.901	rs2664282	chr10:75620757	T/C	cg19442545	chr10:75533431	FUT11	-0.43	-4.56	-0.42	1.54e-5	Inflammatory bowel disease;
THYM	cis	rs34421088	0.564	rs6983129	chr8:11591136	A/C	cg12395012	chr8:11607386	GATA4	-0.57	-4.93	-0.45	3.54e-6	Neuroticism;
THYM	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.83	6.89	0.58	5.96e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg17294928	chr15:75287854	SCAMP5	-1.01	-9.1	-0.68	1.4e-14	Blood trace element (Zn levels);
THYM	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg02493740	chr2:85810744	VAMP5	-0.61	-4.75	-0.44	7.22e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs35264875	0.846	rs72930625	chr11:68867120	T/A	cg23845249	chr11:68861649	NA	0.62	7.41	0.61	5.1e-11	Blond vs. brown hair color;
THYM	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.43	1.27e-5	Breast cancer;
THYM	cis	rs8180040	0.800	rs6768221	chr3:47296899	C/G	cg12976108	chr3:47324180	KIF9;KLHL18	0.5	4.5	0.42	1.92e-5	Colorectal cancer;
THYM	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg00944433	chr1:107599041	PRMT6	-0.42	-5.42	-0.49	4.52e-7	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg08772003	chr10:104629869	AS3MT	-0.57	-4.92	-0.45	3.69e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg15556689	chr8:8085844	FLJ10661	-0.64	-4.92	-0.45	3.65e-6	Mood instability;
THYM	cis	rs8078723	1.000	rs4795418	chr17:38164851	T/C	cg17467752	chr17:38218738	THRA	0.86	7.09	0.59	2.4e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs6988636	0.818	rs59428574	chr8:124166061	G/A	cg23067535	chr8:124195133	FAM83A	-1.03	-4.98	-0.46	2.82e-6	Urinary uromodulin levels;
THYM	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22857025	chr5:266934	NA	-1.38	-9.05	-0.68	1.76e-14	Breast cancer;
THYM	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg12560992	chr17:57184187	TRIM37	0.9	8.24	0.65	9.52e-13	Intelligence (multi-trait analysis);
THYM	cis	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg06360820	chr2:242988706	NA	-1.08	-6.69	-0.57	1.56e-9	Obesity-related traits;
THYM	cis	rs722599	0.501	rs7158047	chr14:75388803	G/A	cg08847533	chr14:75593920	NEK9	0.61	5.3	0.48	7.61e-7	IgG glycosylation;
THYM	cis	rs7020830	0.867	rs1339553	chr9:37266123	C/G	cg14294708	chr9:37120828	ZCCHC7	1.28	16.76	0.86	4.05e-30	Schizophrenia;
THYM	cis	rs4731207	0.596	rs10258873	chr7:124650489	G/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs35881094	1.000	rs1030035	chr2:58878085	G/A	cg09452692	chr2:58468460	FANCL	0.58	4.56	0.42	1.53e-5	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs868036	0.645	rs4776987	chr15:68123915	A/T	cg24579218	chr15:68104479	NA	0.79	7.95	0.63	3.83e-12	Restless legs syndrome;
THYM	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg02734326	chr4:10020555	SLC2A9	0.7	6.25	0.54	1.14e-8	Bone mineral density;
THYM	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.48	-0.42	2.05e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg11245990	chr11:68621969	NA	0.51	6.45	0.55	4.76e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg26384229	chr12:38710491	ALG10B	-0.69	-5.22	-0.47	1.04e-6	Morning vs. evening chronotype;
THYM	cis	rs7192750	0.562	rs9888748	chr16:71987851	G/A	cg06353428	chr16:71660113	MARVELD3	0.72	5.4	0.48	4.87e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs4819852	0.958	rs1034564	chr22:19984013	A/G	cg07821417	chr22:19972146	ARVCF	-0.47	-5.69	-0.5	1.4e-7	Pulse pressure;
THYM	cis	rs7264396	0.887	rs6120954	chr20:34059536	A/G	cg26038318	chr20:34205095	SPAG4	0.53	4.45	0.42	2.33e-5	Total cholesterol levels;
THYM	cis	rs8030485	0.728	rs13379886	chr15:79394894	A/G	cg17916960	chr15:79447300	NA	-0.57	-5.96	-0.52	4.29e-8	Left ventricle wall thickness;
THYM	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg25588787	chr5:154027256	NA	0.9	4.6	0.43	1.32e-5	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs17407555	0.738	rs56143194	chr4:10067535	C/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-5.82	-0.51	7.86e-8	Schizophrenia (age at onset);
THYM	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg15556689	chr8:8085844	FLJ10661	0.71	5.71	0.51	1.26e-7	Red cell distribution width;
THYM	cis	rs6570726	0.846	rs426874	chr6:145880630	A/C	cg13319975	chr6:146136371	FBXO30	-0.66	-5.46	-0.49	3.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12282928	0.959	rs1158897	chr11:48273340	T/C	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg10802521	chr3:52805072	NEK4	-0.67	-5.56	-0.5	2.52e-7	Bipolar disorder;
THYM	cis	rs36051895	0.589	rs62543574	chr9:5204090	A/T	cg02405213	chr9:5042618	JAK2	-0.9	-9.02	-0.68	2.02e-14	Pediatric autoimmune diseases;
THYM	cis	rs6500602	0.964	rs62039173	chr16:4463846	G/A	cg09549813	chr16:4587862	C16orf5	-0.49	-5.18	-0.47	1.24e-6	Schizophrenia;
THYM	cis	rs57994353	0.897	rs67220311	chr9:139376668	T/C	cg14115884	chr9:139300582	SDCCAG3	0.73	5.4	0.48	4.9e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs58688157	0.705	rs936468	chr11:607175	G/A	cg11335335	chr11:637885	DRD4	-0.6	-4.62	-0.43	1.19e-5	Systemic lupus erythematosus;
THYM	cis	rs1065852	0.526	rs9611711	chr22:42410695	G/A	cg08431931	chr22:42394659	WBP2NL	0.74	6.08	0.53	2.48e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs10927875	0.722	rs1763605	chr1:16338925	T/G	cg21385522	chr1:16154831	NA	0.76	5.61	0.5	2e-7	Dilated cardiomyopathy;
THYM	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg04398451	chr17:18023971	MYO15A	0.75	6.59	0.56	2.47e-9	Total body bone mineral density;
THYM	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg13609457	chr4:120235615	NA	0.54	5.06	0.46	2.01e-6	Corneal astigmatism;
THYM	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg21427119	chr20:30132790	HM13	-0.71	-4.72	-0.44	8.04e-6	Mean corpuscular hemoglobin;
THYM	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg02820040	chr2:241836501	C2orf54	-0.33	-6.37	-0.55	6.78e-9	Urinary metabolites;
THYM	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.88	7.81	0.63	7.51e-12	Monocyte percentage of white cells;
THYM	cis	rs62435770	1.000	rs62434684	chr6:169509381	A/G	cg07652237	chr6:170125491	PHF10	0.55	4.91	0.45	3.84e-6	Loneliness;
THYM	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg14972814	chr11:95582409	MTMR2	-0.65	-5.3	-0.48	7.37e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.26	-10.46	-0.73	1.73e-17	Platelet count;
THYM	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg16325326	chr1:53192061	ZYG11B	-0.98	-11.37	-0.76	2.04e-19	Monocyte count;
THYM	cis	rs28595532	0.920	rs114611353	chr4:119736607	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs259282	0.583	rs12981373	chr19:33108189	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.63	5.26	0.47	9.06e-7	Schizophrenia;
THYM	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg02734326	chr4:10020555	SLC2A9	0.61	4.98	0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg14137381	chr5:502291	SLC9A3	-0.61	-4.52	-0.42	1.76e-5	Cystic fibrosis severity;
THYM	cis	rs1061377	1.000	rs1036036	chr4:39112724	G/A	cg24403649	chr4:39172243	NA	0.59	4.78	0.44	6.29e-6	Uric acid levels;
THYM	cis	rs2932538	0.922	rs999923	chr1:113110548	T/C	cg22162597	chr1:113214053	CAPZA1	0.65	5.32	0.48	6.9e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs515186	1	rs515186	chr6:36397492	T/G	cg07856975	chr6:36356162	ETV7	0.52	4.72	0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.55	0.56	2.92e-9	Total body bone mineral density;
THYM	cis	rs2997447	0.637	rs3008413	chr1:26407063	G/A	cg03844060	chr1:26490628	NA	0.67	4.56	0.42	1.52e-5	QRS complex (12-leadsum);
THYM	cis	rs2072499	0.932	rs2736613	chr1:156196016	T/C	cg24450063	chr1:156163899	SLC25A44	1.14	13.78	0.82	2.16e-24	Testicular germ cell tumor;
THYM	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.95	7.71	0.62	1.25e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7894051	1.000	rs77189950	chr10:135126722	A/T	cg06270799	chr10:135191613	PAOX	0.79	4.53	0.42	1.71e-5	Lifespan;
THYM	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.2	8.02	0.64	2.74e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17453880	0.852	rs6882013	chr5:152049652	T/C	cg12297329	chr5:152029980	NA	-0.59	-4.48	-0.42	2.06e-5	Subjective well-being;
THYM	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-4.9	-0.45	3.91e-6	Mood instability;
THYM	cis	rs1642645	0.757	rs6600394	chr1:42472453	T/C	cg22816091	chr1:42611670	NA	0.61	5.38	0.48	5.4e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg19913688	chr11:428466	ANO9	-0.88	-4.6	-0.43	1.3e-5	Body mass index;
THYM	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg04287289	chr16:89883240	FANCA	-0.5	-4.47	-0.42	2.16e-5	Vitiligo;
THYM	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-7.84	-0.63	6.55e-12	Lymphocyte percentage of white cells;
THYM	cis	rs73198271	0.855	rs57301822	chr8:8608642	C/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-4.87	-0.45	4.44e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg00012203	chr2:219082015	ARPC2	-0.67	-5.5	-0.49	3.17e-7	Pyoderma gangrenosum in inflammatory bowel disease;
THYM	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg15448220	chr1:150897856	SETDB1	0.9	7.66	0.62	1.56e-11	Melanoma;
THYM	cis	rs9486719	0.895	rs34051754	chr6:97007754	A/T	cg18709589	chr6:96969512	KIAA0776	-0.68	-4.71	-0.44	8.44e-6	Migraine;Coronary artery disease;
THYM	cis	rs7264396	0.563	rs2425090	chr20:34304783	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.69	-0.43	9.19e-6	Total cholesterol levels;
THYM	cis	rs3812831	0.599	rs428637	chr13:114927139	T/G	cg06611532	chr13:114900021	NA	0.62	6.98	0.58	3.95e-10	Schizophrenia;
THYM	cis	rs17407555	0.657	rs12505222	chr4:10271136	G/T	cg00071950	chr4:10020882	SLC2A9	0.59	5.53	0.49	2.81e-7	Schizophrenia (age at onset);
THYM	cis	rs17102423	0.723	rs8181939	chr14:65555758	G/A	cg11161011	chr14:65562177	MAX	-0.83	-6.62	-0.56	2.13e-9	Obesity-related traits;
THYM	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs4076764	0.801	rs4571944	chr1:163367975	T/C	cg24596788	chr1:163392923	NA	-0.73	-6.2	-0.54	1.47e-8	Motion sickness;
THYM	cis	rs7100689	0.646	rs9804236	chr10:82135100	T/C	cg01528321	chr10:82214614	TSPAN14	0.79	6.01	0.52	3.47e-8	Post bronchodilator FEV1;
THYM	cis	rs6032067	0.929	rs62208428	chr20:43827578	A/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs9905704	0.836	rs302875	chr17:56767874	A/G	cg12560992	chr17:57184187	TRIM37	-0.69	-4.85	-0.45	4.9100000000000004e-06	Testicular germ cell tumor;
THYM	cis	rs10479542	0.533	rs10464056	chr5:178972705	G/T	cg22764044	chr5:178986830	RUFY1	0.56	4.67	0.43	1e-5	Lung cancer;
THYM	cis	rs13102973	0.835	rs4280795	chr4:135857246	T/A	cg14419869	chr4:135874104	NA	0.89	8.49	0.66	2.83e-13	Subjective well-being;
THYM	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs995000	0.965	rs10789118	chr1:63094692	A/G	cg06896770	chr1:63153194	DOCK7	0.99	8.07	0.64	2.19e-12	Triglyceride levels;
THYM	cis	rs7894051	1.000	rs10776675	chr10:135183094	C/A	cg20534287	chr10:135191450	PAOX	-0.76	-5.92	-0.52	4.99e-8	Lifespan;
THYM	cis	rs12291225	0.877	rs2303974	chr11:14264979	G/T	cg19336497	chr11:14380999	RRAS2	-0.64	-6.07	-0.53	2.57e-8	Sense of smell;
THYM	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg26116260	chr4:7069785	GRPEL1	1.09	10.63	0.74	7.51e-18	Monocyte percentage of white cells;
THYM	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg07424592	chr7:64974309	NA	-1.04	-4.78	-0.44	6.31e-6	Diabetic kidney disease;
THYM	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg23758822	chr17:41437982	NA	1.1	7.85	0.63	6.3e-12	Menopause (age at onset);
THYM	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg11764359	chr7:65958608	NA	0.83	6.85	0.57	7.44e-10	Aortic root size;
THYM	cis	rs4077515	0.839	rs1132005	chr9:139296927	T/C	cg14115884	chr9:139300582	SDCCAG3	0.76	8.17	0.64	1.29e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-6.98	-0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	cis	rs7567389	0.677	rs10850	chr2:128063945	T/C	cg09760422	chr2:128146352	NA	-0.4	-4.52	-0.42	1.8e-5	Self-rated health;
THYM	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg13531842	chr10:38383804	ZNF37A	-0.54	-4.53	-0.42	1.75e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg15605315	chr1:45957053	TESK2	0.78	6.5	0.55	3.7e-9	High light scatter reticulocyte count;
THYM	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.56	-5.06	-0.46	2e-6	Type 2 diabetes;
THYM	cis	rs3087591	1.000	rs7220483	chr17:29577248	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.68	-5.95	-0.52	4.46e-8	Hip circumference;
THYM	cis	rs4788570	0.566	rs16973112	chr16:71501274	T/C	cg06353428	chr16:71660113	MARVELD3	-1.04	-5.01	-0.46	2.5e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg12501888	chr15:85177176	SCAND2	-0.59	-4.63	-0.43	1.15e-5	P wave terminal force;
THYM	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg19761014	chr17:28927070	LRRC37B2	0.78	4.99	0.46	2.76e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs3772130	0.962	rs9848027	chr3:121551227	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg01710189	chr8:22454888	PDLIM2	0.54	5.31	0.48	7.12e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs539096	0.872	rs663618	chr1:44043105	T/C	cg08936794	chr1:43833873	ELOVL1	0.63	4.47	0.42	2.15e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg13607699	chr17:42295918	UBTF	0.59	4.86	0.45	4.58e-6	Total body bone mineral density;
THYM	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg13319975	chr6:146136371	FBXO30	0.7	5.77	0.51	1.01e-7	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg25214090	chr10:38739885	LOC399744	0.83	7.11	0.59	2.14e-10	Corneal astigmatism;
THYM	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg02640540	chr1:67518911	SLC35D1	-0.6	-4.73	-0.44	7.79e-6	Lymphocyte percentage of white cells;
THYM	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg08968635	chr6:28129556	ZNF389	0.69	4.89	0.45	4.16e-6	Depression;
THYM	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg06713675	chr4:122721982	EXOSC9	-0.86	-9.77	-0.71	5.25e-16	Type 2 diabetes;
THYM	cis	rs6763768	0.606	rs2029213	chr3:53378245	C/T	cg16894138	chr3:53270350	TKT	0.71	5.38	0.48	5.32e-7	Bacterial meningitis;
THYM	cis	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg13443165	chr9:33130375	B4GALT1	-0.87	-7.99	-0.63	3.23e-12	IgG glycosylation;
THYM	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg18105134	chr13:113819100	PROZ	-0.99	-9.17	-0.69	9.65e-15	Platelet distribution width;
THYM	cis	rs9658691	0.607	rs9658786	chr10:90776349	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.85	5.72	0.51	1.25e-7	Mosquito bite size;
THYM	cis	rs6956675	0.534	rs1806453	chr7:62641533	A/G	cg27056864	chr7:62859493	LOC100287834	-0.52	-4.71	-0.44	8.28e-6	Obesity-related traits;
THYM	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg15242686	chr22:24348715	GSTTP1	-0.68	-5.6	-0.5	2.09e-7	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs1018836	0.668	rs9297857	chr8:91480964	A/C	cg16814680	chr8:91681699	NA	-0.75	-6.23	-0.54	1.26e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4950928	0.823	rs2153101	chr1:203168474	A/T	cg14085262	chr1:203155938	CHI3L1	-0.74	-5.39	-0.48	5.18e-7	YKL-40 levels;
THYM	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg18252515	chr7:66147081	NA	-0.72	-5.6	-0.5	2.03e-7	Aortic root size;
THYM	cis	rs7043114	0.525	rs7869742	chr9:95256174	A/G	cg14631576	chr9:95140430	CENPP	-0.82	-8.18	-0.64	1.27e-12	Height;
THYM	cis	rs17473412	1.000	rs17473412	chr5:122697431	C/T	cg18093572	chr5:122598329	NA	0.55	4.69	0.43	9.08e-6	Total body bone mineral density;
THYM	cis	rs3126085	1.000	rs3120662	chr1:152302865	G/T	cg10321714	chr1:152280068	FLG	-0.72	-5.44	-0.49	4.14e-7	Atopic dermatitis;
THYM	cis	rs55788414	0.932	rs7185658	chr16:81189336	A/G	cg06400318	chr16:81190750	PKD1L2	-0.89	-4.92	-0.45	3.57e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs4664308	0.935	rs4520993	chr2:160937673	G/A	cg03641300	chr2:160917029	PLA2R1	-0.78	-6.97	-0.58	4.25e-10	Idiopathic membranous nephropathy;
THYM	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg06873352	chr17:61820015	STRADA	0.75	8.77	0.67	7.17e-14	Prudent dietary pattern;
THYM	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg22907277	chr7:1156413	C7orf50	0.83	7.12	0.59	2.04e-10	Longevity;Endometriosis;
THYM	cis	rs12936587	0.536	rs8075153	chr17:17622666	C/T	cg04398451	chr17:18023971	MYO15A	0.58	4.84	0.45	4.95e-6	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
THYM	cis	rs7944735	0.517	rs12274550	chr11:48196752	C/A	cg24672777	chr11:48374446	OR4C45	-1.08	-6.32	-0.54	8.31e-9	Intraocular pressure;
THYM	cis	rs7264396	0.635	rs6058382	chr20:34553948	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-4.8	-0.44	6.01e-6	Total cholesterol levels;
THYM	cis	rs7584330	0.554	rs7559057	chr2:238435306	A/T	cg14458575	chr2:238380390	NA	0.81	4.86	0.45	4.63e-6	Prostate cancer;
THYM	cis	rs11096990	0.574	rs34070258	chr4:39189752	T/C	cg24403649	chr4:39172243	NA	0.6	5.16	0.47	1.35e-6	Cognitive function;
THYM	cis	rs447921	0.768	rs34546420	chr17:74459602	C/A	cg17201438	chr17:74438067	UBE2O	0.78	5.84	0.51	7.22e-8	Mitochondrial DNA levels;
THYM	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	5.12	0.47	1.59e-6	Smoking behavior;
THYM	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11644478	chr21:40555479	PSMG1	-1.09	-9.31	-0.69	5.05e-15	Cognitive function;
THYM	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg23422044	chr7:1970798	MAD1L1	-0.79	-5.24	-0.47	9.83e-7	Bipolar disorder;
THYM	cis	rs10089	1.000	rs3792866	chr5:127479900	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.97	5.8	0.51	8.7e-8	Ileal carcinoids;
THYM	cis	rs12282928	0.879	rs713324	chr11:48285064	T/C	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg02527881	chr3:46936655	PTH1R	0.61	5.7	0.51	1.33e-7	Colorectal cancer;
THYM	trans	rs7952251	0.812	rs7111561	chr11:112424128	A/G	cg14154186	chr1:204970430	NFASC	-0.71	-7.14	-0.59	1.86e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg27211696	chr2:191398769	TMEM194B	-0.6	-4.5	-0.42	1.94e-5	Diastolic blood pressure;
THYM	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg01528321	chr10:82214614	TSPAN14	0.66	5.16	0.47	1.35e-6	Post bronchodilator FEV1;
THYM	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg15704280	chr7:45808275	SEPT13	-0.98	-11.52	-0.76	9.66e-20	Coronary artery disease;
THYM	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg25237894	chr2:233734115	C2orf82	-0.35	-4.96	-0.45	3.12e-6	Coronary artery disease;
THYM	cis	rs7537052	0.646	rs1748399	chr1:36655652	C/T	cg24686825	chr1:36642396	MAP7D1	-0.91	-9.14	-0.68	1.14e-14	Schizophrenia;
THYM	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg13695892	chr22:41940480	POLR3H	-0.99	-7.38	-0.6	5.86e-11	Vitiligo;
THYM	cis	rs739496	0.592	rs695871	chr12:112037000	G/C	cg10833066	chr12:111807467	FAM109A	-0.43	-4.62	-0.43	1.22e-5	Platelet count;
THYM	cis	rs7731657	0.537	rs2419937	chr5:130316874	C/G	cg08523029	chr5:130500466	HINT1	-0.84	-6.14	-0.53	1.87e-8	Fasting plasma glucose;
THYM	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.76	0.44	6.99e-6	Aortic root size;
THYM	cis	rs4280164	0.551	rs1109152	chr14:24799024	G/C	cg22990158	chr14:24802150	ADCY4	0.6	5.11	0.46	1.68e-6	Parent of origin effect on language impairment (paternal);
THYM	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg04317338	chr11:64019027	PLCB3	0.86	5.95	0.52	4.48e-8	Mean platelet volume;
THYM	cis	rs6424115	0.618	rs10917420	chr1:24062987	C/T	cg15997130	chr1:24165203	NA	0.64	5.31	0.48	7.06e-7	Immature fraction of reticulocytes;
THYM	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs514406	0.893	rs10888759	chr1:53433274	A/G	cg22166914	chr1:53195759	ZYG11B	-0.77	-7.61	-0.62	1.98e-11	Monocyte count;
THYM	cis	rs10979	0.964	rs9496683	chr6:143898845	G/A	cg25407410	chr6:143891975	LOC285740	-0.59	-4.81	-0.44	5.6e-6	Hypospadias;
THYM	cis	rs17125944	0.505	rs3783447	chr14:53191647	G/A	cg00686598	chr14:53173677	PSMC6	1.38	6.88	0.58	6.42e-10	Alzheimer's disease (late onset);
THYM	cis	rs11696501	0.739	rs6073820	chr20:44249272	T/A	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.57	-0.42	1.46e-5	Brain structure;
THYM	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs5769707	0.777	rs739243	chr22:50057211	C/T	cg20744362	chr22:50050164	C22orf34	0.72	7.37	0.6	6.21e-11	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg18758796	chr5:131593413	PDLIM4	0.5	4.72	0.44	8.15e-6	Breast cancer;
THYM	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg18252515	chr7:66147081	NA	0.66	4.87	0.45	4.38e-6	Aortic root size;
THYM	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg22974920	chr21:40686053	BRWD1	-0.64	-5.1	-0.46	1.74e-6	Cognitive function;
THYM	cis	rs2463822	1.000	rs1406384	chr11:62083530	A/G	cg06239285	chr11:62104954	ASRGL1	-1.41	-7.85	-0.63	6.12e-12	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7000551	0.715	rs2461477	chr8:22378314	A/G	cg12081754	chr8:22256438	SLC39A14	0.64	5.83	0.51	7.7e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs3126085	0.935	rs1496049	chr1:152161949	C/T	cg26020982	chr1:152196106	HRNR	-0.35	-4.49	-0.42	1.96e-5	Atopic dermatitis;
THYM	cis	rs2404602	0.735	rs4886805	chr15:76739384	A/G	cg23482746	chr15:76478102	C15orf27	-0.5	-4.96	-0.45	3.04e-6	Blood metabolite levels;
THYM	cis	rs2625529	0.824	rs12593134	chr15:72303007	G/C	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs9290065	0.519	rs9857743	chr3:160677732	G/A	cg03342759	chr3:160939853	NMD3	-0.57	-4.51	-0.42	1.86e-5	Kawasaki disease;
THYM	cis	rs7084402	0.967	rs1658422	chr10:60331758	G/T	cg07615347	chr10:60278583	BICC1	0.53	4.98	0.45	2.85e-6	Refractive error;
THYM	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg27129171	chr3:47204927	SETD2	0.77	7.66	0.62	1.57e-11	Colorectal cancer;
THYM	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg00310523	chr12:86230176	RASSF9	-0.57	-4.83	-0.44	5.15e-6	Major depressive disorder;
THYM	cis	rs4769475	1.000	rs6491113	chr13:26729658	A/G	cg13319468	chr13:27597730	NA	-0.6	-4.65	-0.43	1.06e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.94	7.84	0.63	6.55e-12	Lymphocyte percentage of white cells;
THYM	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19346786	chr7:2764209	NA	-0.56	-4.8	-0.44	5.87e-6	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg04218760	chr10:45406644	TMEM72	-0.67	-6.0	-0.52	3.63e-8	Mean corpuscular volume;
THYM	cis	rs7824557	0.564	rs7828263	chr8:11231886	A/G	cg12981288	chr8:11183844	MTMR9	-0.46	-4.66	-0.43	1.02e-5	Retinal vascular caliber;
THYM	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg15693483	chr7:1102177	C7orf50	0.54	6.26	0.54	1.1e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.55	4.68	0.43	9.44e-6	Blood metabolite levels;
THYM	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg13395646	chr4:1353034	KIAA1530	-0.59	-5.53	-0.49	2.75e-7	Obesity-related traits;
THYM	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.59	-4.49	-0.42	1.98e-5	Breast cancer;
THYM	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs10186029	0.676	rs35922168	chr2:213949018	T/C	cg08319019	chr2:214017104	IKZF2	0.89	7.36	0.6	6.58e-11	Systemic sclerosis;
THYM	cis	rs2273669	0.667	rs2145765	chr6:109296362	C/G	cg17117243	chr6:109341365	SESN1	-0.86	-4.9	-0.45	3.88e-6	Prostate cancer;
THYM	cis	rs4535497	0.525	rs4975639	chr5:1108250	A/G	cg01551729	chr5:1099476	SLC12A7	0.77	6.69	0.57	1.52e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7107174	1.000	rs4945261	chr11:77990260	A/G	cg02023728	chr11:77925099	USP35	-0.65	-5.83	-0.51	7.52e-8	Testicular germ cell tumor;
THYM	cis	rs9906944	0.707	rs4794019	chr17:47107290	G/T	cg18128536	chr17:47092178	IGF2BP1	-0.43	-4.71	-0.44	8.43e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7428	0.527	rs1061782	chr2:85546615	A/G	cg24342717	chr2:85555507	TGOLN2	0.74	6.34	0.55	7.78e-9	Ear protrusion;
THYM	cis	rs476633	0.708	rs11857484	chr15:41441734	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.7	-5.46	-0.49	3.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2229238	0.868	rs72999419	chr1:154514092	T/C	cg21262032	chr1:154437693	IL6R	-0.64	-5.79	-0.51	8.9e-8	Coronary heart disease;
THYM	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.89	0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg19748678	chr4:122722346	EXOSC9	0.71	4.93	0.45	3.44e-6	Type 2 diabetes;
THYM	cis	rs7727544	0.606	rs72795121	chr5:131638324	T/A	cg24060327	chr5:131705240	SLC22A5	-0.64	-4.81	-0.44	5.73e-6	Blood metabolite levels;
THYM	cis	rs7226229	1.000	rs11204330	chr17:20925846	T/C	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs7772486	0.875	rs1960885	chr6:146325930	G/T	cg23711669	chr6:146136114	FBXO30	0.9	8.92	0.68	3.32e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1403694	0.695	rs5029969	chr3:186434405	G/T	cg12454167	chr3:186435060	KNG1	0.51	7.04	0.59	2.94e-10	Blood protein levels;
THYM	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11771526	0.901	rs17161137	chr7:32323799	G/T	cg27532318	chr7:32358331	NA	0.77	5.06	0.46	2.03e-6	Body mass index;
THYM	cis	rs2278491	0.557	rs4876680	chr8:117777914	C/G	cg23513447	chr8:117778558	UTP23	-0.74	-5.27	-0.48	8.41e-7	Body mass index;
THYM	cis	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg07460842	chr6:66804631	NA	0.94	5.94	0.52	4.75e-8	Exhaled nitric oxide levels;
THYM	cis	rs17604090	1.000	rs114892953	chr7:29676298	G/A	cg19413766	chr7:29689036	LOC646762	-0.94	-5.1	-0.46	1.75e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs6723226	0.772	rs2366894	chr2:32713706	A/T	cg02381751	chr2:32503542	YIPF4	0.61	5.44	0.49	4.15e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6500395	0.962	rs9922356	chr16:48640025	C/T	cg04672837	chr16:48644449	N4BP1	0.48	4.59	0.43	1.35e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18252515	chr7:66147081	NA	-0.66	-5.04	-0.46	2.24e-6	Aortic root size;
THYM	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg00256281	chr22:41985642	PMM1	-0.57	-4.69	-0.43	9.08e-6	Cannabis dependence symptom count;
THYM	cis	rs17818399	0.716	rs62134741	chr2:46782189	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.73	4.88	0.45	4.29e-6	Height;
THYM	cis	rs7216064	0.684	rs8182243	chr17:66018505	T/C	cg12091567	chr17:66097778	LOC651250	0.99	8.2	0.64	1.12e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs4733781	0.901	rs62524650	chr8:131173179	G/C	cg16277922	chr8:131349729	ASAP1	0.74	5.53	0.49	2.83e-7	Tuberculosis;
THYM	cis	rs13315871	1.000	rs9844128	chr3:58391127	C/T	cg12435725	chr3:58293450	RPP14	-0.47	-4.66	-0.43	1.05e-5	Cholesterol, total;
THYM	cis	rs6032067	0.777	rs116517830	chr20:43784872	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg11245990	chr11:68621969	NA	0.57	7.46	0.61	4.06e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs7917772	0.545	rs10786681	chr10:104317357	G/T	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	trans	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg23161317	chr6:28129485	ZNF389	-1.02	-7.95	-0.63	3.81e-12	Depression;
THYM	cis	rs3087591	1.000	rs4795577	chr17:29456879	T/G	cg24425628	chr17:29625626	OMG;NF1	0.65	5.52	0.49	2.96e-7	Hip circumference;
THYM	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Body mass index;
THYM	cis	rs6496932	0.563	rs2344083	chr15:85897432	T/C	cg19183879	chr15:85880815	NA	-0.57	-6.4	-0.55	5.87e-9	Central corneal thickness;Corneal structure;
THYM	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs3804749	0.966	rs3792366	chr3:122839876	G/A	cg26084141	chr3:122786895	PDIA5	0.45	4.53	0.42	1.73e-5	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs240764	0.578	rs1414734	chr6:101201823	T/C	cg21058520	chr6:100914733	NA	-0.58	-5.04	-0.46	2.21e-6	Neuroticism;
THYM	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg22875332	chr1:76189707	ACADM	0.88	11.22	0.75	4.31e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg08885076	chr2:99613938	TSGA10	-0.45	-4.53	-0.42	1.7e-5	Fear of minor pain;
THYM	cis	rs35264875	0.851	rs72930611	chr11:68863659	G/T	cg23845249	chr11:68861649	NA	0.55	6.45	0.55	4.67e-9	Blond vs. brown hair color;
THYM	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg00078996	chr12:132293329	NA	0.6	6.09	0.53	2.33e-8	Migraine;
THYM	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg04654363	chr8:8581213	NA	-0.48	-4.62	-0.43	1.22e-5	Obesity-related traits;
THYM	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg00300879	chr1:26503847	CNKSR1	0.43	5.74	0.51	1.15e-7	Height;
THYM	cis	rs7264396	0.887	rs8116304	chr20:34054409	C/T	cg26038318	chr20:34205095	SPAG4	0.53	4.47	0.42	2.15e-5	Total cholesterol levels;
THYM	cis	rs11696845	0.666	rs6073533	chr20:43361082	G/T	cg09357268	chr20:43379437	KCNK15	-0.45	-4.67	-0.43	9.84e-6	Obesity-related traits;
THYM	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg08017756	chr2:100939284	LONRF2	-0.73	-7.71	-0.62	1.25e-11	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.27	6.19	0.54	1.5e-8	Obesity-related traits;
THYM	cis	rs7828089	0.582	rs7825938	chr8:22266866	G/A	cg12081754	chr8:22256438	SLC39A14	0.89	9.11	0.68	1.34e-14	Verbal declarative memory;
THYM	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg13147721	chr7:65941812	NA	-0.73	-4.56	-0.42	1.52e-5	Diabetic kidney disease;
THYM	trans	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg10856724	chr12:34555212	NA	-0.88	-8.1	-0.64	1.84e-12	Bladder cancer;
THYM	cis	rs2282300	0.739	rs35229181	chr11:30241698	A/G	cg06241208	chr11:30344200	C11orf46	-0.77	-5.59	-0.5	2.15e-7	Morning vs. evening chronotype;
THYM	cis	rs741677	0.702	rs9893847	chr17:489043	C/G	cg15660573	chr17:549704	VPS53	-0.71	-5.44	-0.49	4.15e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
THYM	cis	rs665401	0.692	rs339356	chr6:117197378	T/A	cg20376953	chr6:117187980	NA	0.59	4.76	0.44	6.79e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg08901578	chr4:187885870	NA	-0.64	-6.03	-0.53	3.1e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7107174	1.000	rs57738705	chr11:77994489	A/G	cg19901956	chr11:77921274	USP35	-0.72	-5.45	-0.49	4.02e-7	Testicular germ cell tumor;
THYM	cis	rs4523957	0.583	rs2760744	chr17:2017029	T/C	cg16513277	chr17:2031491	SMG6	-0.98	-8.95	-0.68	2.89e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6946131	0.509	rs12672900	chr7:54774744	C/T	cg16668896	chr7:54900801	NA	0.44	4.52	0.42	1.76e-5	Systemic lupus erythematosus;
THYM	cis	rs490234	0.586	rs3122934	chr9:128154100	C/G	cg14078157	chr9:128172775	NA	0.8	6.64	0.56	1.96e-9	Mean arterial pressure;
THYM	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	5.0	0.46	2.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg27534772	chr1:16042836	PLEKHM2	0.56	6.31	0.54	8.77e-9	Systolic blood pressure;
THYM	cis	rs2404602	0.735	rs1607017	chr15:76726465	G/T	cg23625390	chr15:77176239	SCAPER	-0.65	-4.55	-0.42	1.6e-5	Blood metabolite levels;
THYM	cis	rs11030122	0.702	rs10767702	chr11:3934132	T/C	cg18678763	chr11:4115507	RRM1	-0.44	-5.59	-0.5	2.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs8133932	0.701	rs9637207	chr21:47283359	A/G	cg20357416	chr21:47294739	PCBP3	-0.84	-5.2	-0.47	1.12e-6	Schizophrenia;
THYM	cis	rs1448094	0.511	rs10779207	chr12:86152913	A/G	cg02569458	chr12:86230093	RASSF9	-0.65	-5.33	-0.48	6.59e-7	Major depressive disorder;
THYM	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg09667013	chr22:42394590	WBP2NL	0.72	5.04	0.46	2.18e-6	Birth weight;
THYM	cis	rs12612325	1.000	rs12612325	chr2:119632252	G/A	cg03693553	chr2:120130028	DBI	0.57	4.47	0.42	2.13e-5	Total body bone mineral density;
THYM	cis	rs600806	0.821	rs4970840	chr1:109873367	A/G	cg02175308	chr1:109941060	SORT1	-0.54	-4.71	-0.43	8.55e-6	Intelligence (multi-trait analysis);
THYM	cis	rs888194	0.587	rs6606711	chr12:109849297	A/G	cg11367159	chr12:110044531	NA	0.55	4.83	0.44	5.24e-6	Neuroticism;
THYM	cis	rs735396	1.000	rs2259852	chr12:121434833	G/A	cg02403541	chr12:121454288	C12orf43	0.59	4.74	0.44	7.63e-6	N-glycan levels;
THYM	cis	rs7084402	0.967	rs1303970	chr10:60298477	G/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.64	-0.5	1.72e-7	Refractive error;
THYM	cis	rs2074038	1.000	rs2074038	chr11:44087989	G/T	cg00452199	chr11:44088257	ACCS	-0.87	-5.04	-0.46	2.22e-6	IgA nephropathy;
THYM	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg11845111	chr2:191398756	TMEM194B	-0.98	-6.96	-0.58	4.34e-10	Diastolic blood pressure;
THYM	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs909002	0.962	rs1474181	chr1:32136610	C/G	cg13919466	chr1:32135498	COL16A1	-0.53	-5.35	-0.48	6.09e-7	Intelligence (multi-trait analysis);
THYM	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.58	-10.88	-0.74	2.23e-18	Hemostatic factors and hematological phenotypes;
THYM	cis	rs2625529	0.730	rs2929527	chr15:72282270	T/G	cg16672083	chr15:72433130	SENP8	0.5	4.5	0.42	1.92e-5	Red blood cell count;
THYM	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg15556689	chr8:8085844	FLJ10661	0.62	5.09	0.46	1.83e-6	Mood instability;
THYM	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg05738196	chr6:26577821	NA	0.83	8.34	0.65	5.8e-13	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs9534288	0.843	rs4362286	chr13:46566514	G/A	cg15192986	chr13:46630673	CPB2	-0.6	-4.52	-0.42	1.8e-5	Blood protein levels;
THYM	cis	rs7512552	0.966	rs2274127	chr1:150252984	T/G	cg15654264	chr1:150340011	RPRD2	-0.51	-5.96	-0.52	4.23e-8	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg21427119	chr20:30132790	HM13	-0.96	-7.02	-0.58	3.34e-10	Mean corpuscular hemoglobin;
THYM	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg06766960	chr11:133703094	NA	-0.55	-5.4	-0.48	4.84e-7	Childhood ear infection;
THYM	cis	rs10463554	0.892	rs257307	chr5:102417509	A/G	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs11650494	0.908	rs73324323	chr17:47420054	G/T	cg08112188	chr17:47440006	ZNF652	1.05	4.51	0.42	1.83e-5	Prostate cancer;
THYM	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs7107770	1.000	rs4935912	chr11:125090279	T/G	cg04164023	chr11:125106101	PKNOX2	-0.82	-4.54	-0.42	1.67e-5	Photic sneeze reflex;
THYM	cis	rs6547741	0.935	rs4665384	chr2:27848397	A/G	cg27432699	chr2:27873401	GPN1	0.72	6.3	0.54	9.14e-9	Oral cavity cancer;
THYM	cis	rs12122100	0.651	rs12126527	chr1:146551259	C/G	cg03526459	chr1:146549940	NA	-0.66	-4.49	-0.42	1.97e-5	HIV-1 control;
THYM	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.8	6.84	0.57	7.61e-10	Monocyte percentage of white cells;
THYM	cis	rs4916588	0.635	rs7638251	chr3:196676599	T/C	cg01228739	chr3:197427591	KIAA0226	0.71	4.47	0.42	2.14e-5	Night sleep phenotypes;
THYM	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	cis	rs192264	0.680	rs1094972	chr16:65970486	C/T	cg02795155	chr16:66785218	DYNC1LI2	-0.59	-4.76	-0.44	6.81e-6	Subjective well-being;
THYM	cis	rs4731207	0.844	rs2402749	chr7:124389723	A/T	cg05285228	chr7:124571219	POT1	0.75	5.96	0.52	4.22e-8	Cutaneous malignant melanoma;
THYM	cis	rs7917772	0.560	rs7912339	chr10:104373758	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1729407	0.786	rs5100	chr11:116692694	G/A	cg08985259	chr11:116699649	APOC3	-0.63	-5.47	-0.49	3.65e-7	Apolipoprotein A-IV levels;
THYM	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	6.03	0.53	3.12e-8	Obesity-related traits;
THYM	cis	rs2282300	0.739	rs1933343	chr11:30310992	T/C	cg09906309	chr11:30344399	C11orf46	0.73	5.38	0.48	5.3e-7	Morning vs. evening chronotype;
THYM	cis	rs155076	1.000	rs566364	chr13:21837583	T/C	cg14456004	chr13:21872349	NA	-1.22	-9.62	-0.7	1.06e-15	White matter hyperintensity burden;
THYM	cis	rs8133932	0.768	rs73907803	chr21:47044516	C/T	cg20357416	chr21:47294739	PCBP3	0.77	4.8	0.44	5.79e-6	Schizophrenia;
THYM	cis	rs7524258	0.867	rs35399313	chr1:7277293	T/C	cg07173049	chr1:7289937	CAMTA1	0.64	5.2	0.47	1.17e-6	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs259282	0.707	rs1103851	chr19:33146414	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.77	5.66	0.5	1.59e-7	Schizophrenia;
THYM	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13732083	chr21:47605072	C21orf56	-0.68	-4.82	-0.44	5.46e-6	Testicular germ cell tumor;
THYM	cis	rs9296092	0.560	rs7765263	chr6:33525559	A/G	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs879620	1.000	rs879620	chr16:4015729	A/G	cg27081103	chr16:3241159	NA	0.6	4.5	0.42	1.95e-5	Hip circumference;Body mass index;
THYM	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg21475434	chr5:93447410	FAM172A	-0.97	-6.09	-0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg03060546	chr3:49711283	APEH	-0.66	-5.1	-0.46	1.71e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.3	0.48	7.63e-7	Height;
THYM	trans	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg07211511	chr3:129823064	LOC729375	1.18	7.61	0.62	2.02e-11	Blood pressure (smoking interaction);
THYM	cis	rs6503525	0.701	rs28618095	chr17:38109075	T/C	cg24910161	chr17:38119198	GSDMA	-0.59	-6.36	-0.55	7.18e-9	Asthma;
THYM	cis	rs1371867	0.875	rs1125706	chr8:101326739	T/A	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.86	5.45	0.49	3.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.27	6.33	0.54	8.13e-9	Obesity-related traits;
THYM	cis	rs7107174	0.892	rs1893449	chr11:77968977	G/C	cg02023728	chr11:77925099	USP35	0.69	6.19	0.54	1.55e-8	Testicular germ cell tumor;
THYM	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg13443165	chr9:33130375	B4GALT1	-0.86	-7.96	-0.63	3.71e-12	IgG glycosylation;
THYM	cis	rs6840360	0.606	rs2709814	chr4:152360870	T/C	cg17479576	chr4:152424074	FAM160A1	-0.74	-5.67	-0.5	1.53e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2455799	0.613	rs62241264	chr3:15943471	T/C	cg16303742	chr3:15540471	COLQ	-0.56	-5.6	-0.5	2.11e-7	Mean platelet volume;
THYM	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg09455208	chr3:40491958	NA	-0.44	-4.59	-0.43	1.37e-5	Renal cell carcinoma;
THYM	cis	rs9595908	0.900	rs9595850	chr13:33153910	A/G	cg12383807	chr13:33924137	NA	-0.56	-4.92	-0.45	3.69e-6	Body mass index;
THYM	cis	rs2898681	0.528	rs73814883	chr4:53728054	G/C	cg21521518	chr4:53727714	RASL11B	0.66	5.82	0.51	8.04e-8	Optic nerve measurement (cup area);
THYM	cis	rs1331623	0.955	rs1331622	chr9:122198568	A/G	cg25935911	chr9:122132261	DBC1	-0.54	-4.91	-0.45	3.8e-6	Height;
THYM	cis	rs9515201	0.818	rs9521733	chr13:111034542	C/T	cg06243866	chr13:111019493	COL4A2	0.95	9.85	0.71	3.51e-16	White matter hyperintensity burden;
THYM	cis	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg09307838	chr4:120376055	NA	0.71	5.41	0.49	4.61e-7	Corneal astigmatism;
THYM	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.85	-5.11	-0.46	1.69e-6	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs10191773	0.535	rs12477879	chr2:112969865	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.91	5.71	0.51	1.3e-7	Yeast infection;
THYM	cis	rs4951018	0.526	rs4245718	chr1:205652472	G/A	cg26354017	chr1:205819088	PM20D1	-0.61	-4.81	-0.44	5.71e-6	Prostate-specific antigen levels;
THYM	cis	rs7084402	0.967	rs1658424	chr10:60331588	G/A	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg26384229	chr12:38710491	ALG10B	0.96	7.27	0.6	9.84e-11	Morning vs. evening chronotype;
THYM	cis	rs2625529	0.775	rs4777489	chr15:72430434	C/T	cg16672083	chr15:72433130	SENP8	0.54	4.82	0.44	5.55e-6	Red blood cell count;
THYM	cis	rs12765878	0.580	rs10786772	chr10:105610326	A/G	cg04688330	chr10:105451802	SH3PXD2A	-0.35	-4.45	-0.42	2.31e-5	Coronary artery disease;
THYM	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.77	8.58	0.66	1.8e-13	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs7178572	0.568	rs28584877	chr15:77599003	C/A	cg22256960	chr15:77711686	NA	1.01	8.22	0.64	1.05e-12	Type 2 diabetes;
THYM	cis	rs28595532	0.920	rs114938162	chr4:119756407	T/G	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg22841779	chr14:105766346	BRF1	-0.49	-6.27	-0.54	1.04e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6669072	0.669	rs814545	chr1:91240551	C/G	cg08895590	chr1:91227319	NA	-0.65	-8.25	-0.65	9.1e-13	Cognitive function;
THYM	cis	rs11089937	0.523	rs4821832	chr22:22542888	T/C	cg06866756	chr22:22471216	NA	-0.46	-5.27	-0.48	8.65e-7	Periodontitis (PAL4Q3);
THYM	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2282300	0.739	rs7925340	chr11:30280408	A/C	cg09906309	chr11:30344399	C11orf46	0.73	5.38	0.48	5.3e-7	Morning vs. evening chronotype;
THYM	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg08439880	chr3:133502540	NA	0.67	5.31	0.48	7.29e-7	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs1003719	0.715	rs6517405	chr21:38560334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs7582180	0.739	rs11123824	chr2:100924029	G/A	cg08017756	chr2:100939284	LONRF2	-0.73	-7.51	-0.61	3.21e-11	Intelligence (multi-trait analysis);
THYM	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg09469691	chr10:81107165	PPIF	0.72	5.92	0.52	5.13e-8	Height;
THYM	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg26384229	chr12:38710491	ALG10B	0.99	7.62	0.62	1.85e-11	Bladder cancer;
THYM	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs986417	1.000	rs1033733	chr14:60932438	G/T	cg27398547	chr14:60952738	C14orf39	1.24	6.16	0.53	1.77e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg01238044	chr22:24384105	GSTT1	0.62	4.81	0.44	5.55e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg07648498	chr16:89883185	FANCA	0.61	4.49	0.42	1.99e-5	Vitiligo;
THYM	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2239785	0.959	rs136163	chr22:36657628	T/G	cg15716373	chr22:36655542	APOL1	-0.39	-4.7	-0.43	8.69e-6	Glomerulosclerosis;
THYM	cis	rs981844	1.000	rs2251997	chr4:154654067	A/G	cg09973105	chr4:154681532	RNF175	0.59	4.89	0.45	4.1e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs1568889	0.838	rs11030220	chr11:28145769	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs6032067	0.527	rs6104012	chr20:43734571	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.58	-6.12	-0.53	2.05e-8	Blood protein levels;
THYM	cis	rs7107174	1.000	rs114142124	chr11:78047537	T/C	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs881952	0.791	rs842759	chr2:60878203	A/T	cg02592586	chr2:60830257	NA	0.24	5.01	0.46	2.5e-6	Glucose homeostasis traits;
THYM	cis	rs4363385	0.720	rs6665527	chr1:152967009	C/A	cg13444842	chr1:152974279	SPRR3	-0.6	-4.62	-0.43	1.22e-5	Inflammatory skin disease;
THYM	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03647317	chr4:187891568	NA	-0.84	-9.05	-0.68	1.74e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg17911788	chr17:44343683	NA	0.75	6.85	0.57	7.37e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg24733560	chr20:60626293	TAF4	0.51	4.58	0.43	1.41e-5	Body mass index;
THYM	cis	rs2658782	1.000	rs2658779	chr11:93163137	G/T	cg15737290	chr11:93063684	CCDC67	-1.05	-7.97	-0.63	3.42e-12	Pulmonary function decline;
THYM	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg04520793	chr17:42248056	ASB16	-0.34	-4.78	-0.44	6.45e-6	Total body bone mineral density;
THYM	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-7.9	-0.63	4.93e-12	Chronic sinus infection;
THYM	cis	rs7560272	0.695	rs10190002	chr2:73794054	C/T	cg19565262	chr2:73869966	NAT8	-0.62	-5.14	-0.47	1.49e-6	Schizophrenia;
THYM	cis	rs36051895	0.623	rs72703608	chr9:5258127	A/G	cg02405213	chr9:5042618	JAK2	-0.95	-9.21	-0.69	8.17e-15	Pediatric autoimmune diseases;
THYM	cis	rs28595532	0.764	rs55913633	chr4:119747444	C/A	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs2933343	0.630	rs75824035	chr3:128652985	T/C	cg11901034	chr3:128598214	ACAD9	-0.7	-5.44	-0.49	4.15e-7	IgG glycosylation;
THYM	cis	rs765787	0.530	rs2899379	chr15:45534799	C/T	cg24006582	chr15:45444508	DUOX1	0.81	6.55	0.56	2.99e-9	Uric acid levels;
THYM	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg16558253	chr16:72132732	DHX38	-0.56	-4.73	-0.44	7.95e-6	Fibrinogen levels;
THYM	cis	rs12765878	0.967	rs34887477	chr10:105643436	C/T	cg11005552	chr10:105648138	OBFC1	0.85	11.02	0.75	1.12e-18	Coronary artery disease;
THYM	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg09044154	chr16:88155775	NA	-0.64	-4.47	-0.42	2.13e-5	Menopause (age at onset);
THYM	cis	rs9972944	0.756	rs6504357	chr17:63770621	C/T	cg07283582	chr17:63770753	CCDC46	-0.67	-5.24	-0.47	9.77e-7	Total body bone mineral density;
THYM	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg11245990	chr11:68621969	NA	0.58	7.58	0.61	2.33e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg10018233	chr7:150070692	REPIN1	0.5	7.69	0.62	1.32e-11	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6840360	0.593	rs1877186	chr4:152692418	C/G	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg04546413	chr19:29218101	NA	1.13	9.17	0.69	9.75e-15	Methadone dose in opioid dependence;
THYM	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg21475434	chr5:93447410	FAM172A	0.95	6.03	0.53	3.16e-8	Diabetic retinopathy;
THYM	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg17971929	chr21:40555470	PSMG1	0.7	4.57	0.42	1.46e-5	Cognitive function;
THYM	cis	rs72627123	0.867	rs80083802	chr14:74456996	C/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.14	6.41	0.55	5.69e-9	Morning vs. evening chronotype;
THYM	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.58	-5.88	-0.52	6.01e-8	Crohn's disease;
THYM	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	trans	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg25214090	chr10:38739885	LOC399744	0.83	7.11	0.59	2.14e-10	Corneal astigmatism;
THYM	cis	rs858239	0.896	rs1637192	chr7:23260514	G/A	cg05407003	chr7:23246146	NA	-0.58	-4.82	-0.44	5.36e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg06970220	chr1:156163860	SLC25A44	0.72	5.46	0.49	3.86e-7	Testicular germ cell tumor;
THYM	trans	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	3.97e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg03474202	chr17:45855739	NA	0.74	6.44	0.55	4.93e-9	IgG glycosylation;
THYM	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.21	8.51	0.66	2.47e-13	Cognitive test performance;
THYM	cis	rs6722750	1.000	rs4671552	chr2:64393955	A/G	cg22352474	chr2:64371530	PELI1	0.65	5.01	0.46	2.46e-6	Neuroticism;
THYM	cis	rs295140	0.605	rs159320	chr2:201187775	A/G	cg14106933	chr2:201194453	SPATS2L	-0.42	-4.49	-0.42	2e-5	QT interval;
THYM	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg03806693	chr22:41940476	POLR3H	1.08	10.03	0.72	1.42e-16	Vitiligo;
THYM	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg13175981	chr1:150552382	MCL1	0.74	5.52	0.49	2.97e-7	Tonsillectomy;
THYM	cis	rs11121246	0.565	rs914994	chr1:8917212	G/T	cg06972019	chr1:8937448	ENO1	0.67	5.46	0.49	3.78e-7	Plateletcrit;
THYM	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.85	0.74	2.52e-18	Chronic sinus infection;
THYM	cis	rs7084402	0.967	rs6481404	chr10:60286071	C/G	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18402987	chr7:1209562	NA	0.73	5.4	0.48	4.85e-7	Longevity;Endometriosis;
THYM	cis	rs2806561	0.894	rs598438	chr1:23531563	C/T	cg12483005	chr1:23474871	LUZP1	0.52	5.23	0.47	1.01e-6	Height;
THYM	cis	rs11792861	0.926	rs17628095	chr9:111889172	A/G	cg05043794	chr9:111880884	C9orf5	0.41	6.29	0.54	9.63e-9	Menarche (age at onset);
THYM	cis	rs10929159	0.928	rs7557693	chr2:236920713	G/A	cg14895183	chr2:236924282	AGAP1	0.52	4.51	0.42	1.88e-5	Parkinson's disease;
THYM	cis	rs669446	0.561	rs641365	chr1:44083507	A/G	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs9677476	0.863	rs5018532	chr2:232077075	A/G	cg23338755	chr2:231921595	PSMD1	0.66	5.09	0.46	1.81e-6	Food antigen IgG levels;
THYM	cis	rs477692	0.669	rs12265939	chr10:131445398	A/G	cg05714579	chr10:131428358	MGMT	-0.83	-7.01	-0.58	3.51e-10	Response to temozolomide;
THYM	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg24675658	chr1:53192096	ZYG11B	0.74	6.65	0.56	1.82e-9	Monocyte count;
THYM	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg17143192	chr8:8559678	CLDN23	-0.97	-7.44	-0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg10803722	chr21:46713166	LOC642852	-0.41	-5.11	-0.46	1.69e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg23708337	chr7:1209742	NA	0.89	5.02	0.46	2.41e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg08125733	chr17:73851984	WBP2	0.8	5.7	0.5	1.35e-7	Psoriasis;
THYM	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg26384229	chr12:38710491	ALG10B	1.05	10.43	0.73	1.96e-17	Heart rate;
THYM	cis	rs2237457	0.543	rs2237443	chr7:50699937	A/T	cg08586669	chr7:50727761	GRB10	-0.28	-4.59	-0.43	1.36e-5	Schizophrenia (treatment resistant);
THYM	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg13147721	chr7:65941812	NA	0.73	4.58	0.43	1.42e-5	Diabetic kidney disease;
THYM	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg23682913	chr1:2080710	PRKCZ	-0.59	-5.28	-0.48	8.17e-7	Height;
THYM	cis	rs8013055	0.898	rs8004007	chr14:105971435	G/C	cg23356831	chr14:105996513	TMEM121	0.57	6.17	0.53	1.69e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs9399401	0.921	rs4637667	chr6:142794021	C/A	cg03128060	chr6:142623767	GPR126	0.36	4.51	0.42	1.83e-5	Chronic obstructive pulmonary disease;
THYM	cis	rs2777491	0.872	rs11267024	chr15:41576241	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.06	-9.79	-0.71	4.61e-16	Ulcerative colitis;
THYM	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg12310025	chr6:25882481	NA	0.78	6.29	0.54	9.76e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6956675	0.957	rs10236165	chr7:62596446	T/A	cg08930214	chr7:62859557	LOC100287834	0.65	4.79	0.44	6.1e-6	Obesity-related traits;
THYM	cis	rs28595532	0.920	rs56212415	chr4:119737731	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs7578361	0.959	rs10932470	chr2:150432690	T/A	cg17961725	chr2:150454027	NA	0.75	6.19	0.54	1.54e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg09877947	chr5:131593287	PDLIM4	-0.6	-5.1	-0.46	1.71e-6	Breast cancer;
THYM	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs2290159	0.706	rs7643321	chr3:12663233	A/G	cg05467012	chr3:12595696	NA	0.9	5.74	0.51	1.12e-7	Cholesterol, total;
THYM	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17253792	0.822	rs77415412	chr14:56154146	A/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs6964587	0.692	rs10236483	chr7:91797296	A/C	cg22709100	chr7:91322751	NA	0.67	5.07	0.46	1.97e-6	Breast cancer;
THYM	cis	rs858239	0.508	rs7805071	chr7:23190212	C/T	cg09755872	chr7:23245557	NA	-0.5	-4.71	-0.43	8.55e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs12310956	0.515	rs115836245	chr12:33951369	T/C	cg10856724	chr12:34555212	NA	-0.72	-6.65	-0.56	1.82e-9	Morning vs. evening chronotype;
THYM	cis	rs10193935	0.901	rs7605782	chr2:42502332	C/T	cg27598129	chr2:42591480	NA	-0.74	-4.45	-0.42	2.37e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg04990556	chr1:26633338	UBXN11	-0.87	-8.25	-0.65	8.82e-13	Obesity-related traits;
THYM	cis	rs9527	0.590	rs1475642	chr10:104546183	C/T	cg04362960	chr10:104952993	NT5C2	-0.6	-4.75	-0.44	7.21e-6	Arsenic metabolism;
THYM	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg13695892	chr22:41940480	POLR3H	-0.92	-7.98	-0.63	3.32e-12	Vitiligo;
THYM	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg01448562	chr3:133502909	NA	-0.94	-7.93	-0.63	4.17e-12	Iron status biomarkers;
THYM	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.76	6.74	0.57	1.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg04772025	chr11:68637568	NA	0.55	5.76	0.51	1.05e-7	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.39	6.97	0.58	4.15e-10	Obesity-related traits;
THYM	cis	rs17102423	0.755	rs35769504	chr14:65576857	G/A	cg11161011	chr14:65562177	MAX	-0.85	-6.77	-0.57	1.04e-9	Obesity-related traits;
THYM	cis	rs524023	0.914	rs11606370	chr11:64378452	C/A	cg19131476	chr11:64387923	NRXN2	-0.39	-5.54	-0.49	2.7e-7	Urate levels in obese individuals;
THYM	cis	rs804280	0.638	rs36038176	chr8:11609995	C/T	cg23916205	chr8:11614368	GATA4	0.58	4.54	0.42	1.66e-5	Myopia (pathological);
THYM	cis	rs728616	0.867	rs12414096	chr10:81713629	A/G	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg03760483	chr17:6899297	ALOX12	0.67	8.78	0.67	6.77e-14	Tonsillectomy;
THYM	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg06634786	chr22:41940651	POLR3H	-0.7	-4.92	-0.45	3.59e-6	Vitiligo;
THYM	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg11494091	chr17:61959527	GH2	-1.02	-18.48	-0.88	3.25e-33	Prudent dietary pattern;
THYM	cis	rs673253	0.638	rs552638	chr1:44043392	G/A	cg24466421	chr1:44070974	PTPRF	-0.55	-4.83	-0.44	5.29e-6	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg11764359	chr7:65958608	NA	-0.77	-6.31	-0.54	8.95e-9	Aortic root size;
THYM	cis	rs2835345	0.528	rs73204243	chr21:37824074	A/G	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs7917772	0.636	rs2253709	chr10:104542745	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	6.29	0.54	9.56e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs9359856	0.564	rs17584290	chr6:90467114	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.9	-7.81	-0.63	7.61e-12	Bipolar disorder;
THYM	cis	rs1994135	0.617	rs1384590	chr12:33734271	C/T	cg10856724	chr12:34555212	NA	-0.72	-5.57	-0.5	2.4e-7	Resting heart rate;
THYM	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg08045932	chr20:61659980	NA	0.94	10.68	0.74	5.76e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg25767906	chr1:53392781	SCP2	-0.49	-4.74	-0.44	7.63e-6	Monocyte count;
THYM	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.01	10.61	0.74	8.47e-18	Intelligence (multi-trait analysis);
THYM	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg15782153	chr7:917662	C7orf20	0.46	4.86	0.45	4.54e-6	Perceived unattractiveness to mosquitoes;
THYM	cis	rs17407555	0.738	rs73212870	chr4:10111798	C/G	cg00071950	chr4:10020882	SLC2A9	-0.69	-5.6	-0.5	2.08e-7	Schizophrenia (age at onset);
THYM	cis	rs11031096	0.655	rs34295904	chr11:4206701	C/A	cg22027985	chr11:4115532	RRM1	-0.53	-4.91	-0.45	3.77e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs10791097	0.765	rs7943757	chr11:130716157	C/T	cg05962950	chr11:130786565	SNX19	0.77	6.2	0.54	1.48e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7084402	0.935	rs1658492	chr10:60281267	C/T	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg18230493	chr5:56204884	C5orf35	-0.92	-6.99	-0.58	3.72e-10	Initial pursuit acceleration;
THYM	cis	rs761746	0.739	rs5753691	chr22:31952045	A/G	cg01338084	chr22:32026380	PISD	0.6	4.73	0.44	7.7e-6	Intelligence;
THYM	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg02887458	chr19:19495540	GATAD2A	-0.44	-5.19	-0.47	1.17e-6	Bipolar disorder;
THYM	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg03676636	chr4:99064102	C4orf37	0.5	7.59	0.61	2.14e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg03060546	chr3:49711283	APEH	-0.67	-5.08	-0.46	1.85e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs9361491	0.608	rs4706722	chr6:79462697	T/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg05717871	chr11:638507	DRD4	-0.64	-5.11	-0.46	1.69e-6	Systemic lupus erythematosus;
THYM	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs7020830	0.931	rs7027473	chr9:37132462	A/G	cg14294708	chr9:37120828	ZCCHC7	1.33	17.97	0.88	2.58e-32	Schizophrenia;
THYM	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg23482746	chr15:76478102	C15orf27	-0.38	-4.55	-0.42	1.61e-5	Blood metabolite levels;
THYM	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg11141652	chr22:24348549	GSTTP1	0.62	6.35	0.55	7.25e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs4638749	0.677	rs10203004	chr2:108826535	G/T	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs4746818	1.000	rs7071904	chr10:70903005	C/T	cg04149295	chr10:70884716	VPS26A	0.78	5.27	0.48	8.48e-7	Left atrial antero-posterior diameter;
THYM	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4731207	0.698	rs2107936	chr7:124449041	A/T	cg05285228	chr7:124571219	POT1	0.66	5.24	0.47	9.66e-7	Cutaneous malignant melanoma;
THYM	cis	rs1062746	0.738	rs2303764	chr16:87377455	C/G	cg02258303	chr16:87377426	FBXO31	0.62	5.7	0.5	1.36e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.35	-5.0	-0.46	2.58e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg24803719	chr17:45855879	NA	-0.6	-6.33	-0.54	7.96e-9	IgG glycosylation;
THYM	cis	rs9810089	0.527	rs838199	chr3:135950090	T/C	cg21827317	chr3:136751795	NA	0.64	5.97	0.52	4.08e-8	Gestational age at birth (child effect);
THYM	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg24375607	chr4:120327624	NA	0.68	5.4	0.48	4.92e-7	Corneal astigmatism;
THYM	cis	rs2046867	0.818	rs67355490	chr3:72830935	T/C	cg25664220	chr3:72788482	NA	-0.92	-7.27	-0.6	1.01e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg11301795	chr4:187892539	NA	-1.12	-16.92	-0.87	2.01e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg13852791	chr20:30311386	BCL2L1	0.83	6.43	0.55	5.21e-9	Mean corpuscular hemoglobin;
THYM	cis	rs17818399	0.547	rs13020299	chr2:46758717	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.64	-4.45	-0.42	2.3e-5	Height;
THYM	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	9.4	0.69	3.1e-15	Chronic sinus infection;
THYM	cis	rs9352866	0.967	rs13209851	chr6:81515796	A/G	cg08356243	chr6:80645827	ELOVL4	-0.45	-4.46	-0.42	2.23e-5	Antibody level in response to infection;
THYM	cis	rs1971762	0.583	rs11170648	chr12:54089660	C/T	cg16917193	chr12:54089295	NA	0.96	9.59	0.7	1.24e-15	Height;
THYM	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg00677455	chr12:58241039	CTDSP2	-0.7	-4.59	-0.43	1.37e-5	Multiple sclerosis;
THYM	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg13609457	chr4:120235615	NA	0.51	4.8	0.44	5.83e-6	Corneal astigmatism;
THYM	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg14416269	chr4:6271139	WFS1	0.54	5.33	0.48	6.64e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs2046867	0.628	rs1393584	chr3:72917193	G/T	cg25664220	chr3:72788482	NA	-0.77	-6.92	-0.58	5.18e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg03929089	chr4:120376271	NA	-1.04	-14.13	-0.82	4.42e-25	Height;
THYM	cis	rs7512552	0.803	rs11205385	chr1:150476516	G/A	cg15654264	chr1:150340011	RPRD2	0.45	5.2	0.47	1.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs11008222	0.902	rs12768910	chr10:31041992	G/A	cg00941203	chr10:31016591	NA	-0.34	-4.73	-0.44	7.88e-6	Congenital left-sided heart lesions (maternal effect);
THYM	cis	rs2933343	0.649	rs789214	chr3:128594995	A/G	cg11901034	chr3:128598214	ACAD9	-0.7	-5.68	-0.5	1.47e-7	IgG glycosylation;
THYM	cis	rs748404	0.660	rs2444251	chr15:43788595	A/G	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8067545	0.586	rs3850779	chr17:20171872	C/T	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs2985684	1.000	rs1952012	chr14:50098896	T/A	cg02151108	chr14:50098012	C14orf104	-0.67	-5.33	-0.48	6.48e-7	Carotid intima media thickness;
THYM	cis	rs526231	0.511	rs17155009	chr5:102374144	C/T	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Primary biliary cholangitis;
THYM	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg13695892	chr22:41940480	POLR3H	-1.04	-8.38	-0.65	4.84e-13	Vitiligo;
THYM	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg01097406	chr16:89675127	NA	0.85	7.68	0.62	1.44e-11	Vitiligo;
THYM	cis	rs250677	0.522	rs11954893	chr5:148392362	A/G	cg18129178	chr5:148520854	ABLIM3	-0.71	-5.31	-0.48	7.05e-7	Breast cancer;
THYM	cis	rs7084402	0.565	rs11006187	chr10:60333383	A/G	cg09696939	chr10:60272079	BICC1	0.49	5.7	0.5	1.35e-7	Refractive error;
THYM	cis	rs4363385	0.818	rs572821	chr1:153008276	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	6.31	0.54	8.98e-9	Smoking behavior;
THYM	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg10862848	chr6:42927986	GNMT	-0.51	-6.83	-0.57	8.14e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1322639	0.614	rs9455889	chr6:169566087	A/T	cg04662567	chr6:169592167	NA	-0.71	-5.51	-0.49	3.09e-7	Pulse pressure;
THYM	cis	rs9543976	0.623	rs3783028	chr13:76165282	T/C	cg01531495	chr13:76123901	UCHL3	0.66	4.8	0.44	5.85e-6	Diabetic retinopathy;
THYM	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg07690219	chr3:49449608	TCTA;RHOA	0.7	4.71	0.43	8.57e-6	Menarche (age at onset);
THYM	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg10523679	chr1:76189770	ACADM	-0.56	-4.78	-0.44	6.31e-6	Daytime sleep phenotypes;
THYM	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.44	-0.49	4.16e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg19507638	chr5:93509721	C5orf36	-0.69	-4.54	-0.42	1.62e-5	Diabetic retinopathy;
THYM	cis	rs9611519	0.929	rs926914	chr22:41418154	C/T	cg03806693	chr22:41940476	POLR3H	-0.77	-5.95	-0.52	4.56e-8	Neuroticism;
THYM	cis	rs2458413	0.564	rs2669452	chr8:105370385	C/A	cg21295575	chr8:105352067	TM7SF4	-0.35	-5.3	-0.48	7.58e-7	Paget's disease;
THYM	cis	rs4803468	0.934	rs11880674	chr19:41889423	A/T	cg09537434	chr19:41945824	ATP5SL	-1.13	-10.6	-0.74	8.86e-18	Height;
THYM	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg12165864	chr7:66369176	NA	-0.81	-6.09	-0.53	2.36e-8	Corneal structure;
THYM	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg06238570	chr21:40685208	BRWD1	-0.73	-6.28	-0.54	1.01e-8	Menarche (age at onset);
THYM	trans	rs10802346	0.514	rs4443861	chr1:246372574	G/T	cg22732515	chr19:44031385	ETHE1	1.07	9.43	0.7	2.68e-15	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg17178900	chr1:205818956	PM20D1	0.92	8.98	0.68	2.55e-14	Menarche (age at onset);
THYM	cis	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg10856724	chr12:34555212	NA	-0.92	-9.1	-0.68	1.41e-14	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.88	0.58	6.24e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg24060327	chr5:131705240	SLC22A5	-0.74	-5.46	-0.49	3.74e-7	Blood metabolite levels;
THYM	cis	rs13064411	0.735	rs6778800	chr3:113149236	A/G	cg18753928	chr3:113234510	CCDC52	-0.83	-7.29	-0.6	9.08e-11	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg07636037	chr3:49044803	WDR6	-0.83	-7.33	-0.6	7.59e-11	Menarche (age at onset);
THYM	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg22683308	chr4:1340831	KIAA1530	-0.62	-4.61	-0.43	1.25e-5	Longevity;
THYM	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg19610905	chr11:61596333	FADS2	0.57	4.71	0.44	8.45e-6	Trans fatty acid levels;
THYM	cis	rs11696501	0.793	rs1883520	chr20:44130777	T/C	cg11783356	chr20:44313418	WFDC10B	-0.69	-4.61	-0.43	1.24e-5	Brain structure;
THYM	cis	rs9486719	1.000	rs12191653	chr6:96903898	T/C	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg03684893	chr10:554711	DIP2C	-0.69	-6.1	-0.53	2.24e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs700651	0.789	rs6715070	chr2:198898265	A/G	cg00792783	chr2:198669748	PLCL1	-0.83	-5.9	-0.52	5.65e-8	Intracranial aneurysm;
THYM	cis	rs4891159	0.790	rs1787448	chr18:74113179	T/C	cg24786174	chr18:74118243	ZNF516	0.87	9.75	0.71	5.54e-16	Longevity;
THYM	cis	rs2276314	0.802	rs58906216	chr18:33630297	T/C	cg19628046	chr18:33552617	C18orf21	0.75	5.33	0.48	6.55e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg06028605	chr16:24865363	SLC5A11	0.55	5.15	0.47	1.41e-6	Intelligence (multi-trait analysis);
THYM	cis	rs912057	0.671	rs1294428	chr6:6744623	A/G	cg13809441	chr6:6737631	NA	0.44	5.32	0.48	6.97e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs1007190	0.881	rs3816275	chr17:42957327	G/A	cg15406952	chr17:42872593	NA	0.8	5.57	0.5	2.34e-7	DNA methylation (variation);
THYM	cis	rs7683537	0.501	rs2171838	chr4:185667404	A/G	cg04058563	chr4:185651563	MLF1IP	-0.84	-6.0	-0.52	3.63e-8	Systemic lupus erythematosus;
THYM	cis	rs960902	0.747	rs115003310	chr2:37719263	A/C	cg25341268	chr2:37734390	NA	0.56	4.72	0.44	8.06e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs7084402	0.967	rs7897298	chr10:60274606	T/C	cg09696939	chr10:60272079	BICC1	0.47	5.53	0.49	2.84e-7	Refractive error;
THYM	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg02353165	chr6:42928485	GNMT	0.87	8.22	0.64	1.02e-12	Plasma homocysteine levels (post-methionine load test);
THYM	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg27572855	chr1:25598939	RHD	0.65	5.11	0.46	1.64e-6	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs6510489	1.000	rs62111717	chr19:35978567	T/C	cg15078284	chr19:36004994	DMKN	0.42	4.91	0.45	3.77e-6	Bipolar disorder;
THYM	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg04896959	chr15:78267971	NA	0.93	7.69	0.62	1.38e-11	Coronary artery disease or large artery stroke;
THYM	cis	rs3862260	0.509	rs12076924	chr1:120165826	C/T	cg16322792	chr1:120165303	ZNF697	0.92	11.5	0.76	1.09e-19	Systemic lupus erythematosus;
THYM	cis	rs2072499	0.865	rs2758603	chr1:156198994	T/C	cg24450063	chr1:156163899	SLC25A44	1.0	11.18	0.75	5.17e-19	Testicular germ cell tumor;
THYM	cis	rs669446	0.828	rs656131	chr1:44129099	C/T	cg12599982	chr1:44399894	ARTN	-0.52	-4.7	-0.43	8.75e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs11078597	0.731	rs34962442	chr17:1640529	C/T	cg18436246	chr17:1640651	WDR81	0.64	4.63	0.43	1.14e-5	Serum albumin level;
THYM	cis	rs72712511	0.644	rs2271391	chr4:140787695	C/T	cg15010390	chr4:140216957	NDUFC1	0.64	4.54	0.42	1.64e-5	Intelligence (multi-trait analysis);
THYM	cis	rs13315871	0.929	rs35376204	chr3:58325563	T/C	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs6840360	0.934	rs6817058	chr4:152603865	T/C	cg22705602	chr4:152727874	NA	-0.63	-6.72	-0.57	1.37e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg06636001	chr8:8085503	FLJ10661	0.64	5.48	0.49	3.49e-7	Mood instability;
THYM	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9341808	0.527	rs2505946	chr6:80810683	A/G	cg08355045	chr6:80787529	NA	0.55	4.96	0.45	3.06e-6	Sitting height ratio;
THYM	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	7.8	0.62	7.81e-12	Platelet count;
THYM	cis	rs76878669	0.561	rs10896112	chr11:66116836	G/C	cg18002602	chr11:66138449	SLC29A2	-0.48	-4.72	-0.44	8.12e-6	Educational attainment (years of education);
THYM	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg05234568	chr11:5960015	NA	-0.56	-4.48	-0.42	2.1e-5	DNA methylation (variation);
THYM	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs11249608	0.744	rs4701025	chr5:178444474	G/A	cg01312482	chr5:178451176	ZNF879	0.6	4.85	0.45	4.78e-6	Pubertal anthropometrics;
THYM	cis	rs11608355	0.846	rs4766598	chr12:109853306	A/G	cg11367159	chr12:110044531	NA	0.59	5.06	0.46	2.04e-6	Neuroticism;
THYM	cis	rs7772486	0.754	rs6922507	chr6:146250155	A/T	cg23711669	chr6:146136114	FBXO30	-0.96	-10.01	-0.72	1.54e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs7582180	1.000	rs4851287	chr2:100915772	A/G	cg14675211	chr2:100938903	LONRF2	0.6	4.61	0.43	1.26e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg05347473	chr6:146136440	FBXO30	0.57	4.52	0.42	1.78e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg18681998	chr4:17616180	MED28	0.79	6.77	0.57	1.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7851660	0.967	rs3758248	chr9:100614601	G/A	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs7584330	0.554	rs13390883	chr2:238432619	A/T	cg08992911	chr2:238395768	MLPH	0.9	5.8	0.51	8.78e-8	Prostate cancer;
THYM	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg11752832	chr7:134001865	SLC35B4	0.76	5.72	0.51	1.24e-7	Mean platelet volume;
THYM	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg00981070	chr1:2046702	PRKCZ	0.49	5.49	0.49	3.34e-7	Height;
THYM	cis	rs6956675	0.915	rs7787116	chr7:62654060	G/A	cg08930214	chr7:62859557	LOC100287834	0.61	4.78	0.44	6.47e-6	Obesity-related traits;
THYM	cis	rs57221529	0.655	rs72704791	chr5:547896	A/G	cg16624210	chr5:671434	TPPP	0.67	4.61	0.43	1.25e-5	Lung disease severity in cystic fibrosis;
THYM	cis	rs601999	1	rs601999	chr17:40698158	T/C	cg07777703	chr17:40811829	TUBG2	-0.67	-4.88	-0.45	4.22e-6	Parkinson's disease;
THYM	cis	rs800586	0.956	rs800517	chr8:116801489	G/A	cg04656070	chr8:116661063	TRPS1	0.49	4.7	0.43	8.9e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs3126085	0.877	rs4456098	chr1:152176034	C/T	cg10321714	chr1:152280068	FLG	0.69	5.08	0.46	1.88e-6	Atopic dermatitis;
THYM	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg06558623	chr16:89946397	TCF25	1.45	7.27	0.6	9.84e-11	Skin colour saturation;
THYM	cis	rs17854409	0.881	rs1046784	chr20:61472808	G/C	cg06598544	chr20:61472147	COL9A3	-1.09	-7.18	-0.59	1.51e-10	Obesity-related traits;
THYM	cis	rs2797685	0.898	rs3753503	chr1:7841971	G/A	cg06712362	chr1:7811235	CAMTA1	0.77	5.57	0.5	2.35e-7	Crohn's disease;
THYM	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.89	0.52	5.93e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg01097406	chr16:89675127	NA	-0.6	-5.04	-0.46	2.23e-6	Vitiligo;
THYM	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg08885076	chr2:99613938	TSGA10	0.52	5.04	0.46	2.24e-6	Chronic sinus infection;
THYM	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.6	-0.5	2.11e-7	Menopause (age at onset);
THYM	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg04455712	chr21:45112962	RRP1B	0.6	5.97	0.52	4.06e-8	Mean corpuscular volume;
THYM	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg04398451	chr17:18023971	MYO15A	-0.8	-7.37	-0.6	6.29e-11	Total body bone mineral density;
THYM	cis	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg02825527	chr7:2087843	MAD1L1	-0.7	-4.55	-0.42	1.58e-5	Bipolar disorder;
THYM	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg19748678	chr4:122722346	EXOSC9	0.77	5.55	0.49	2.55e-7	Type 2 diabetes;
THYM	cis	rs2439831	0.867	rs3213991	chr15:43670280	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg05802129	chr4:122689817	NA	-0.57	-4.51	-0.42	1.88e-5	Type 2 diabetes;
THYM	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg12310025	chr6:25882481	NA	0.56	4.54	0.42	1.68e-5	Blood metabolite levels;
THYM	cis	rs289828	0.859	rs34949325	chr2:152088755	G/A	cg05960677	chr2:152117363	RBM43	-0.63	-6.02	-0.53	3.21e-8	Blood protein levels;
THYM	cis	rs5758511	0.637	rs5751244	chr22:42617411	T/C	cg08431931	chr22:42394659	WBP2NL	0.64	4.7	0.43	8.87e-6	Birth weight;
THYM	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-6.77	-0.57	1.04e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs7772486	0.686	rs6933161	chr6:146081369	G/A	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4819852	1.000	rs2073743	chr22:19989612	C/G	cg07821417	chr22:19972146	ARVCF	0.43	4.71	0.44	8.44e-6	Pulse pressure;
THYM	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7575217	0.767	rs796056	chr2:101735276	A/C	cg23907051	chr2:101730305	TBC1D8	-0.42	-5.66	-0.5	1.61e-7	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs2066819	1.000	rs2695788	chr12:56697110	G/A	cg26714650	chr12:56694279	CS	1.2	7.01	0.58	3.36e-10	Psoriasis vulgaris;
THYM	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2439831	0.867	rs2243434	chr15:43689867	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs11249608	0.511	rs58827878	chr5:178481936	C/G	cg01312482	chr5:178451176	ZNF879	-0.71	-5.39	-0.48	5.21e-7	Pubertal anthropometrics;
THYM	cis	rs946836	0.562	rs982157	chr1:48382362	C/T	cg18376692	chr1:48452465	NA	-0.5	-4.97	-0.45	2.94e-6	White matter integrity;
THYM	cis	rs1986734	0.555	rs12512288	chr4:77416817	C/G	cg20311846	chr4:77356250	SHROOM3	-0.43	-4.66	-0.43	1.01e-5	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
THYM	cis	rs11785693	0.862	rs73183618	chr8:4988340	T/C	cg26367366	chr8:4980734	NA	0.94	4.74	0.44	7.42e-6	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs995000	0.931	rs1781195	chr1:62988972	T/C	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs9796	0.870	rs2412572	chr15:41264426	G/C	cg21153102	chr15:41252147	NA	-0.68	-6.32	-0.54	8.44e-9	Menopause (age at onset);
THYM	cis	rs9814567	0.929	rs9815297	chr3:134215052	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-8.41	-0.65	4e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2455799	0.552	rs2470519	chr3:15762847	G/A	cg16303742	chr3:15540471	COLQ	-0.56	-5.98	-0.52	3.83e-8	Mean platelet volume;
THYM	cis	rs1113500	0.548	rs7541433	chr1:108645641	G/A	cg06207961	chr1:108661230	NA	0.63	4.93	0.45	3.44e-6	Growth-regulated protein alpha levels;
THYM	cis	rs6876348	0.564	rs2577427	chr5:128311818	C/T	cg25555059	chr5:128301488	SLC27A6	-0.51	-5.86	-0.52	6.67e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg03983476	chr2:10830698	NOL10	-0.61	-5.52	-0.49	2.94e-7	Prostate cancer;
THYM	cis	rs6598541	0.925	rs61168554	chr15:99286980	A/G	cg13297560	chr15:99320054	IGF1R	-0.47	-4.74	-0.44	7.5e-6	Urate levels;
THYM	cis	rs11640436	0.565	rs1594051	chr16:77307040	G/A	cg06128999	chr16:77247126	NA	-0.39	-5.01	-0.46	2.48e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9902453	0.542	rs3809789	chr17:27955761	A/G	cg12000131	chr17:27941776	ANKRD13B;CORO6	-0.6	-4.56	-0.42	1.5e-5	Coffee consumption (cups per day);
THYM	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg10360139	chr7:1886902	MAD1L1	-0.61	-5.17	-0.47	1.3e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12627970	0.565	rs2072872	chr22:39713128	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.6	4.59	0.43	1.33e-5	Inflammatory bowel disease;
THYM	cis	rs7107174	1.000	rs72931639	chr11:78036703	C/T	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg24375607	chr4:120327624	NA	0.59	4.75	0.44	7.3e-6	Corneal astigmatism;
THYM	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg27588902	chr6:42928151	GNMT	-0.58	-5.86	-0.52	6.72e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.14	-8.83	-0.67	5.34e-14	Schizophrenia;
THYM	cis	rs6430585	0.527	rs62168830	chr2:136443900	A/T	cg23851026	chr2:136556271	LCT	0.67	5.98	0.52	3.89e-8	Corneal structure;
THYM	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg24675056	chr1:15929824	NA	-0.75	-6.09	-0.53	2.36e-8	Systolic blood pressure;
THYM	cis	rs4731207	0.596	rs3903521	chr7:124668184	A/G	cg05285228	chr7:124571219	POT1	-0.6	-4.52	-0.42	1.81e-5	Cutaneous malignant melanoma;
THYM	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg09455208	chr3:40491958	NA	-0.46	-4.86	-0.45	4.68e-6	Renal cell carcinoma;
THYM	cis	rs7172809	0.599	rs75323552	chr15:77421943	A/T	cg22256960	chr15:77711686	NA	-0.64	-4.76	-0.44	6.9e-6	Glucose homeostasis traits;
THYM	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs425277	1.000	rs196128	chr1:2078444	T/G	cg23803603	chr1:2058230	PRKCZ	0.59	4.56	0.42	1.52e-5	Height;
THYM	trans	rs34156428	1.000	rs12787119	chr11:16505932	G/A	cg02688867	chr12:133019854	NA	0.54	6.89	0.58	6.12e-10	Coronary artery disease;
THYM	cis	rs9677476	0.863	rs2006780	chr2:232066704	T/G	cg27665808	chr2:232055229	NA	0.55	4.53	0.42	1.72e-5	Food antigen IgG levels;
THYM	cis	rs2985684	0.789	rs7161649	chr14:50064028	A/G	cg02151108	chr14:50098012	C14orf104	-0.72	-5.57	-0.5	2.39e-7	Carotid intima media thickness;
THYM	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg11245990	chr11:68621969	NA	0.55	7.18	0.59	1.55e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg16049864	chr8:95962084	TP53INP1	-0.74	-6.65	-0.56	1.88e-9	Type 2 diabetes;
THYM	cis	rs8050907	0.661	rs28535861	chr16:4620608	G/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.34	5.32	0.48	7e-7	Obesity-related traits;
THYM	cis	rs7187994	0.848	rs16974532	chr16:84783310	G/A	cg07647771	chr16:84786436	USP10	-0.53	-4.91	-0.45	3.81e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs11696501	0.843	rs6130846	chr20:44115129	A/G	cg11783356	chr20:44313418	WFDC10B	-0.76	-4.74	-0.44	7.55e-6	Brain structure;
THYM	cis	rs17030434	0.871	rs74380369	chr4:154730273	C/T	cg14289246	chr4:154710475	SFRP2	-0.67	-4.98	-0.45	2.86e-6	Electrocardiographic conduction measures;
THYM	cis	rs2903698	0.565	rs9307834	chr4:76453850	A/C	cg03209871	chr4:76438412	RCHY1;THAP6	0.38	4.48	0.42	2.05e-5	Prion diseases;
THYM	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.56	4.61	0.43	1.24e-5	Lung disease severity in cystic fibrosis;
THYM	cis	rs2674946	0.644	rs2069138	chr17:13040819	A/C	cg12799781	chr17:12569110	MYOCD	-0.56	-5.22	-0.47	1.05e-6	Squamous cell lung carcinoma;
THYM	cis	rs1697139	0.583	rs11739603	chr5:66540687	C/T	cg11553311	chr5:66541588	NA	0.71	7.38	0.6	5.98e-11	Breast cancer;
THYM	cis	rs600806	0.850	rs3931560	chr1:109966718	A/C	cg23616212	chr1:109941201	SORT1	-0.51	-4.75	-0.44	7.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg04025307	chr7:1156635	C7orf50	0.72	4.46	0.42	2.27e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1823778	0.609	rs8085823	chr18:67646939	C/T	cg26848442	chr18:67624264	CD226	1.38	4.93	0.45	3.52e-6	Mean platelet volume;
THYM	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg21773646	chr17:80085082	CCDC57	-0.34	-4.91	-0.45	3.76e-6	Life satisfaction;
THYM	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg20295408	chr7:1910781	MAD1L1	-0.74	-6.14	-0.53	1.91e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg08975724	chr8:8085496	FLJ10661	0.6	4.77	0.44	6.75e-6	Mood instability;
THYM	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs4731207	0.698	rs7778956	chr7:124527733	C/T	cg05285228	chr7:124571219	POT1	-0.67	-5.35	-0.48	5.99e-7	Cutaneous malignant melanoma;
THYM	cis	rs3008870	1.000	rs2065001	chr1:67486509	C/G	cg02640540	chr1:67518911	SLC35D1	0.64	4.78	0.44	6.32e-6	Lymphocyte percentage of white cells;
THYM	cis	rs61990749	0.544	rs176962	chr14:78185510	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.04	0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27286337	chr10:134555280	INPP5A	0.86	6.52	0.56	3.39e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs56161922	1.000	rs74184055	chr1:207852226	G/A	cg09557387	chr1:207818395	CR1L	1.14	5.13	0.47	1.52e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	cis	rs9420	0.961	rs2847308	chr11:57498232	C/T	cg19752551	chr11:57585705	CTNND1	0.66	7.73	0.62	1.11e-11	Schizophrenia;
THYM	cis	rs3741151	0.773	rs7951072	chr11:73221721	G/A	cg17517138	chr11:73019481	ARHGEF17	0.89	4.73	0.44	7.86e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs6032067	0.714	rs6032073	chr20:43881630	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.61	-6.81	-0.57	8.9e-10	Blood protein levels;
THYM	cis	rs7072216	0.727	rs10748728	chr10:100171198	C/T	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs4589258	0.966	rs4451691	chr11:90473356	A/C	cg26138821	chr11:89956704	CHORDC1	-0.69	-5.52	-0.49	3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3960554	0.673	rs112680895	chr7:75623520	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-4.8	-0.44	5.8e-6	Eotaxin levels;
THYM	cis	rs11048434	0.736	rs11048190	chr12:9104939	C/T	cg13575925	chr12:9217583	LOC144571	0.52	4.97	0.45	2.96e-6	Sjögren's syndrome;
THYM	cis	rs10493773	0.862	rs12075929	chr1:86248138	A/C	cg17807903	chr1:86174739	ZNHIT6	0.47	5.18	0.47	1.22e-6	Urate levels in overweight individuals;
THYM	cis	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg10856724	chr12:34555212	NA	-0.91	-9.08	-0.68	1.57e-14	Morning vs. evening chronotype;
THYM	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg18825531	chr11:62321136	NA	-0.45	-5.11	-0.46	1.63e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs11671005	0.693	rs11668821	chr19:58955813	G/A	cg18639983	chr19:58920768	ZNF584	0.57	4.59	0.43	1.33e-5	Mean platelet volume;
THYM	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs7192750	0.586	rs9934812	chr16:71981652	T/G	cg06353428	chr16:71660113	MARVELD3	0.77	5.72	0.51	1.21e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg14675211	chr2:100938903	LONRF2	0.74	7.8	0.62	7.88e-12	Intelligence (multi-trait analysis);
THYM	cis	rs56309584	0.596	rs11649742	chr17:8176415	C/T	cg08322244	chr17:8066669	VAMP2	-0.55	-4.87	-0.45	4.39e-6	Initial pursuit acceleration;
THYM	cis	rs4460079	0.531	rs4410591	chr4:114839803	T/C	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	6.77	0.57	1.08e-9	Lung cancer in ever smokers;
THYM	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg26408565	chr15:76604113	ETFA	-0.55	-4.85	-0.45	4.73e-6	Blood metabolite levels;
THYM	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg02018176	chr4:1364513	KIAA1530	0.95	8.86	0.67	4.46e-14	Longevity;
THYM	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11209185	0.527	rs11209186	chr1:68434340	A/G	cg22082780	chr1:68452167	NA	-0.53	-6.09	-0.53	2.34e-8	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.19	8.83	0.67	5.32e-14	Cognitive test performance;
THYM	cis	rs9560113	0.509	rs4771758	chr13:112201573	C/G	cg15979348	chr13:112237479	NA	0.55	4.93	0.45	3.46e-6	Menarche (age at onset);
THYM	cis	rs11645898	0.935	rs28419077	chr16:72196776	A/G	cg03805757	chr16:71968109	PKD1L3	-0.65	-4.91	-0.45	3.83e-6	Blood protein levels;
THYM	cis	rs1847202	0.826	rs11922892	chr3:72952186	T/G	cg25664220	chr3:72788482	NA	-0.65	-4.83	-0.44	5.21e-6	Motion sickness;
THYM	cis	rs7177699	0.526	rs7166764	chr15:79123509	T/G	cg15571903	chr15:79123663	NA	0.58	6.51	0.56	3.52e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg27034606	chr17:28928453	LRRC37B2	0.7	4.72	0.44	8.26e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg03806693	chr22:41940476	POLR3H	1.25	10.88	0.74	2.22e-18	Vitiligo;
THYM	cis	rs2120243	0.539	rs6441127	chr3:157095507	T/C	cg24825693	chr3:157122686	VEPH1	-0.48	-4.48	-0.42	2.09e-5	Hepatocellular carcinoma in hepatitis B infection;
THYM	cis	rs9329289	0.510	rs10903785	chr10:2550063	C/T	cg15501526	chr10:2543763	NA	0.51	4.64	0.43	1.09e-5	Age-related hearing impairment;
THYM	cis	rs854765	0.583	rs4534911	chr17:17852330	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	6.5	0.55	3.73e-9	Total body bone mineral density;
THYM	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-4.49	-0.42	1.98e-5	Monocyte percentage of white cells;
THYM	cis	rs9527	0.567	rs6584539	chr10:104879402	G/C	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs9527	0.662	rs743575	chr10:104594906	T/G	cg15744005	chr10:104629667	AS3MT	-0.68	-5.36	-0.48	5.86e-7	Arsenic metabolism;
THYM	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg03609598	chr5:56110824	MAP3K1	0.72	4.57	0.42	1.48e-5	Initial pursuit acceleration;
THYM	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg15782153	chr7:917662	C7orf20	-0.46	-4.86	-0.45	4.56e-6	Perceived unattractiveness to mosquitoes;
THYM	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg18681998	chr4:17616180	MED28	-0.89	-7.49	-0.61	3.44e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2456568	0.503	rs4254038	chr11:93666978	T/C	cg17595323	chr11:93583763	C11orf90	-0.52	-5.62	-0.5	1.94e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg01831904	chr17:28903510	LRRC37B2	-1.0	-4.84	-0.44	5.12e-6	Body mass index;
THYM	cis	rs6032067	0.516	rs1883829	chr20:43891253	G/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.57	-5.69	-0.5	1.41e-7	Blood protein levels;
THYM	cis	rs2742234	0.541	rs10793427	chr10:43747443	G/A	cg06632098	chr10:43605906	RET	0.74	4.86	0.45	4.54e-6	Hirschsprung disease;
THYM	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11890956	chr21:40555474	PSMG1	-0.63	-5.77	-0.51	9.89e-8	Menarche (age at onset);
THYM	cis	rs7084402	0.967	rs1649045	chr10:60327047	T/C	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs12121840	0.736	rs12135169	chr1:165582849	G/C	cg19407955	chr1:165599744	MGST3	-0.65	-4.59	-0.43	1.36e-5	Interleukin-1-receptor antagonist levels;
THYM	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg14008862	chr17:28927542	LRRC37B2	0.92	4.79	0.44	6.05e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs61931739	0.513	rs1486889	chr12:33901229	A/G	cg10856724	chr12:34555212	NA	-0.67	-5.95	-0.52	4.46e-8	Morning vs. evening chronotype;
THYM	cis	rs7474896	0.583	rs10827818	chr10:38000856	T/C	cg07661167	chr10:37990439	NA	-0.67	-4.54	-0.42	1.62e-5	Obesity (extreme);
THYM	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg03806693	chr22:41940476	POLR3H	1.07	9.94	0.71	2.25e-16	Vitiligo;
THYM	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg06600287	chr1:53387719	ECHDC2	-0.34	-5.4	-0.48	4.88e-7	Monocyte count;
THYM	cis	rs2458413	0.543	rs2514658	chr8:105337871	G/A	cg21295575	chr8:105352067	TM7SF4	0.32	4.7	0.43	8.69e-6	Paget's disease;
THYM	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg18512352	chr11:47633146	NA	-0.54	-7.07	-0.59	2.54e-10	Subjective well-being;
THYM	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.18	8.58	0.66	1.74e-13	Cognitive test performance;
THYM	cis	rs1018836	0.923	rs1476427	chr8:91552791	A/G	cg16814680	chr8:91681699	NA	0.78	6.73	0.57	1.27e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs7100689	0.622	rs1340373	chr10:82129250	G/A	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs4654899	0.758	rs7521711	chr1:21400218	A/G	cg01072550	chr1:21505969	NA	-0.77	-7.49	-0.61	3.45e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg13319975	chr6:146136371	FBXO30	0.66	5.2	0.47	1.13e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4474465	1.000	rs10751290	chr11:78192707	G/A	cg19901956	chr11:77921274	USP35	-0.63	-4.74	-0.44	7.64e-6	Alzheimer's disease (survival time);
THYM	cis	rs2991971	1.000	rs2993262	chr1:46013733	G/C	cg15605315	chr1:45957053	TESK2	0.65	5.12	0.46	1.6e-6	High light scatter reticulocyte count;
THYM	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.48	-4.87	-0.45	4.51e-6	Crohn's disease;
THYM	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg02825527	chr7:2087843	MAD1L1	-0.75	-4.92	-0.45	3.62e-6	Neuroticism;
THYM	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs920590	0.758	rs35280191	chr8:19665214	A/C	cg01411142	chr8:19674711	INTS10	0.64	4.85	0.45	4.81e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs72901758	0.768	rs1567237	chr17:76246294	A/G	cg25512537	chr17:76250053	NA	-0.4	-5.67	-0.5	1.52e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
THYM	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.81	-8.07	-0.64	2.12e-12	Chronic sinus infection;
THYM	cis	rs12444261	0.961	rs56213816	chr16:11744697	G/A	cg09662852	chr16:11707685	NA	-0.49	-4.55	-0.42	1.59e-5	QT interval;
THYM	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg04117972	chr1:227635322	NA	0.81	4.63	0.43	1.17e-5	Major depressive disorder;
THYM	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6754311	0.593	rs313523	chr2:136432103	G/A	cg23851026	chr2:136556271	LCT	0.59	5.62	0.5	1.91e-7	Mosquito bite size;
THYM	cis	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg10856724	chr12:34555212	NA	-0.79	-7.69	-0.62	1.34e-11	Morning vs. evening chronotype;
THYM	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg08048268	chr3:133502702	NA	-0.65	-5.5	-0.49	3.15e-7	Iron status biomarkers;
THYM	cis	rs4654899	1.000	rs6697555	chr1:21287938	C/T	cg01072550	chr1:21505969	NA	-0.73	-6.62	-0.56	2.1e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg00078996	chr12:132293329	NA	-0.6	-6.11	-0.53	2.16e-8	Migraine;
THYM	cis	rs863345	0.604	rs1342947	chr1:158459714	G/A	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg18105134	chr13:113819100	PROZ	-0.99	-9.17	-0.69	9.97e-15	Platelet distribution width;
THYM	cis	rs6906287	0.625	rs9489355	chr6:118685314	A/G	cg21191810	chr6:118973309	C6orf204	0.63	6.14	0.53	1.95e-8	Electrocardiographic conduction measures;
THYM	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.96	8.0	0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs346785	0.692	rs8072944	chr17:74291733	T/G	cg09812376	chr17:74270190	QRICH2	-0.49	-4.9	-0.45	3.92e-6	White matter hyperintensities in ischemic stroke;
THYM	cis	rs34734847	1.000	rs3752531	chr12:121157851	A/G	cg10600917	chr12:121163489	ACADS	0.57	5.15	0.47	1.41e-6	Mean corpuscular volume;
THYM	cis	rs7610301	0.505	rs35597886	chr3:46642782	T/C	cg22951056	chr3:46887651	NA	-0.77	-5.06	-0.46	2.06e-6	Blood protein levels;
THYM	cis	rs9790314	0.905	rs7633186	chr3:161003124	A/G	cg03342759	chr3:160939853	NMD3	-0.81	-7.28	-0.6	9.51e-11	Morning vs. evening chronotype;
THYM	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg19770292	chr5:1868693	NA	0.54	4.94	0.45	3.35e-6	Cardiovascular disease risk factors;
THYM	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg07061783	chr6:25882402	NA	-0.89	-8.79	-0.67	6.51e-14	Intelligence (multi-trait analysis);
THYM	cis	rs539096	0.872	rs10890255	chr1:44031493	A/G	cg00143623	chr1:44495758	SLC6A9	0.75	6.24	0.54	1.22e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7246657	1.000	rs35398388	chr19:37740358	A/G	cg23950597	chr19:37808831	NA	-0.72	-4.62	-0.43	1.22e-5	Coronary artery calcification;
THYM	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg24069376	chr3:38537580	EXOG	-0.67	-6.5	-0.55	3.7e-9	Electrocardiographic conduction measures;
THYM	cis	rs12200560	0.524	rs1413525	chr6:97073096	C/T	cg06623918	chr6:96969491	KIAA0776	0.68	4.89	0.45	4.16e-6	Coronary heart disease;
THYM	cis	rs9905704	0.831	rs12949598	chr17:56707245	C/T	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.74e-6	Testicular germ cell tumor;
THYM	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg21252483	chr19:49399788	TULP2	-0.96	-7.25	-0.6	1.09e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.75e-6	Aortic root size;
THYM	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg12981288	chr8:11183844	MTMR9	-0.49	-4.8	-0.44	5.86e-6	Retinal vascular caliber;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg18224988	chr10:21787079	C10orf114	-0.97	-7.15	-0.59	1.8e-10	Depressive symptoms;
THYM	cis	rs9549260	0.709	rs12585870	chr13:41199487	A/C	cg21288729	chr13:41239152	FOXO1	0.72	5.55	0.49	2.61e-7	Red blood cell count;
THYM	cis	rs4974559	0.740	rs11933854	chr4:1315172	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.42	-4.85	-0.45	4.74e-6	Systolic blood pressure;
THYM	cis	rs7267979	1.000	rs6138572	chr20:25435934	G/C	cg08601574	chr20:25228251	PYGB	0.57	4.55	0.42	1.6e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4891159	0.790	rs7234653	chr18:74111988	C/T	cg24786174	chr18:74118243	ZNF516	-0.87	-10.02	-0.72	1.48e-16	Longevity;
THYM	cis	rs7428	0.527	rs7608892	chr2:85542718	G/A	cg24342717	chr2:85555507	TGOLN2	-0.74	-6.34	-0.55	7.78e-9	Ear protrusion;
THYM	cis	rs2625529	0.668	rs8192431	chr15:72492352	G/A	cg16672083	chr15:72433130	SENP8	-0.53	-4.76	-0.44	6.97e-6	Red blood cell count;
THYM	cis	rs3917265	0.582	rs2110726	chr2:102794282	G/A	cg13315345	chr2:102803985	IL1RL2	0.52	4.8	0.44	5.82e-6	Atopic dermatitis;
THYM	cis	rs11605275	0.892	rs16937352	chr11:20032010	G/C	cg14835545	chr11:20032148	NAV2	-1.38	-7.35	-0.6	7e-11	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg24692254	chr21:30365293	RNF160	0.84	5.97	0.52	4.1e-8	Cognitive test performance;
THYM	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg10150615	chr22:24372951	LOC391322	-0.84	-9.06	-0.68	1.69e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7943358	0.911	rs1385163	chr11:15689490	G/C	cg11966998	chr11:15692519	NA	-0.49	-5.15	-0.47	1.42e-6	Gut microbiome composition (summer);
THYM	cis	rs8050907	0.744	rs1362625	chr16:4526310	G/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.58	0.43	1.38e-5	Obesity-related traits;
THYM	cis	rs3755605	0.864	rs6784109	chr3:169770645	T/C	cg18444028	chr3:169782040	GPR160	0.56	4.62	0.43	1.19e-5	Testicular germ cell tumor;
THYM	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg01304814	chr3:48885189	PRKAR2A	0.89	4.66	0.43	1.03e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs988913	0.813	rs7741915	chr6:54755871	C/T	cg04690482	chr6:54711388	FAM83B	0.53	6.56	0.56	2.83e-9	Menarche (age at onset);
THYM	cis	rs7980799	0.654	rs10844618	chr12:33625010	A/G	cg10856724	chr12:34555212	NA	0.6	4.5	0.42	1.93e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs7610301	1.000	rs4683251	chr3:46643387	C/T	cg10242476	chr3:46619364	LRRC2;TDGF1	0.46	4.54	0.42	1.65e-5	Blood protein levels;
THYM	cis	rs7428	0.962	rs3637	chr2:85549874	A/G	cg24342717	chr2:85555507	TGOLN2	-0.57	-4.8	-0.44	5.92e-6	Ear protrusion;
THYM	cis	rs877282	0.842	rs35117541	chr10:764683	C/T	cg10556349	chr10:835070	NA	-0.78	-5.06	-0.46	2.06e-6	Uric acid levels;
THYM	cis	rs4343996	0.727	rs12537113	chr7:3370274	C/G	cg21248987	chr7:3385318	SDK1	-0.38	-4.59	-0.43	1.35e-5	Motion sickness;
THYM	cis	rs2235649	0.833	rs9925460	chr16:1849943	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.97	-0.45	3.01e-6	Blood metabolite levels;
THYM	cis	rs12579753	1.000	rs12830268	chr12:82233627	A/C	cg21231944	chr12:82153410	PPFIA2	-0.65	-4.83	-0.44	5.17e-6	Resting heart rate;
THYM	cis	rs7818345	0.935	rs7016592	chr8:19277735	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.65	0.43	1.07e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg02018176	chr4:1364513	KIAA1530	0.6	4.69	0.43	9.18e-6	Obesity-related traits;
THYM	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg17279839	chr7:150038598	RARRES2	0.57	5.41	0.49	4.68e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs12318506	0.826	rs11180453	chr12:75694006	T/C	cg04728562	chr12:75699417	CAPS2	-1.36	-5.43	-0.49	4.37e-7	Coronary artery calcification;
THYM	cis	rs4148689	1.000	rs12538252	chr7:117160988	A/G	cg17204129	chr7:117119601	CFTR	-0.64	-4.95	-0.45	3.18e-6	Gout;
THYM	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08109568	chr15:31115862	NA	-0.63	-5.99	-0.52	3.8e-8	Huntington's disease progression;
THYM	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg10792982	chr14:105748885	BRF1	0.72	7.5	0.61	3.35e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3845702	0.736	rs9288045	chr2:180814194	G/A	cg01881094	chr2:180872142	CWC22	-0.85	-5.0	-0.46	2.64e-6	Schizophrenia;
THYM	cis	rs8070624	0.543	rs11870660	chr17:17877096	C/T	cg04398451	chr17:18023971	MYO15A	-0.93	-8.84	-0.67	4.97e-14	Total body bone mineral density;
THYM	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg08975724	chr8:8085496	FLJ10661	0.71	5.71	0.51	1.31e-7	Mood instability;
THYM	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg06238570	chr21:40685208	BRWD1	-0.72	-6.28	-0.54	9.9e-9	Menarche (age at onset);
THYM	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.61	5.3	0.48	7.56e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4266144	0.562	rs56357317	chr3:156835174	T/A	cg14969094	chr3:156848003	NA	-0.47	-4.5	-0.42	1.93e-5	Coronary artery disease;
THYM	cis	rs9287719	0.810	rs7601748	chr2:10785446	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-4.59	-0.43	1.37e-5	Prostate cancer;
THYM	cis	rs13256369	0.802	rs11781257	chr8:8559663	A/T	cg00074818	chr8:8560427	CLDN23	0.59	5.5	0.49	3.26e-7	Obesity-related traits;
THYM	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg12219531	chr12:120966889	COQ5	0.83	6.78	0.57	1.02e-9	High light scatter reticulocyte count;
THYM	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-5.73	-0.51	1.18e-7	Chronic sinus infection;
THYM	cis	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.33e-5	Retinal vascular caliber;
THYM	cis	rs35110281	0.501	rs162381	chr21:44920915	A/G	cg01579765	chr21:45077557	HSF2BP	0.41	5.38	0.48	5.29e-7	Mean corpuscular volume;
THYM	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg27129171	chr3:47204927	SETD2	0.79	7.89	0.63	5.02e-12	Colorectal cancer;
THYM	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg03351412	chr1:154909251	PMVK	0.73	5.58	0.5	2.3e-7	Prostate cancer;
THYM	cis	rs4478037	1.000	rs4074415	chr3:33161745	A/G	cg19404215	chr3:33155277	CRTAP	1.14	7.96	0.63	3.58e-12	Major depressive disorder;
THYM	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg04398451	chr17:18023971	MYO15A	0.95	9.9	0.71	2.77e-16	Total body bone mineral density;
THYM	cis	rs2282300	0.739	rs6484478	chr11:30306440	A/G	cg09906309	chr11:30344399	C11orf46	0.73	5.38	0.48	5.3e-7	Morning vs. evening chronotype;
THYM	cis	rs10463554	0.927	rs34831	chr5:102444089	C/T	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Parkinson's disease;
THYM	cis	rs9807841	0.538	rs892086	chr19:10837677	C/T	cg16900796	chr19:10755136	SLC44A2	0.27	4.62	0.43	1.22e-5	Inflammatory skin disease;
THYM	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg10862848	chr6:42927986	GNMT	-0.51	-6.72	-0.57	1.36e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.44	-0.65	3.55e-13	Mean corpuscular volume;
THYM	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs7635838	0.617	rs346071	chr3:11305584	A/T	cg00170343	chr3:11313890	ATG7	-0.66	-5.19	-0.47	1.19e-6	HDL cholesterol;
THYM	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2251260	0.629	rs1088672	chr14:62004299	G/T	cg13564459	chr14:62004353	PRKCH	0.48	5.05	0.46	2.17e-6	Yeast infection;
THYM	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg12419862	chr22:24373484	LOC391322	0.85	9.8	0.71	4.34e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs595982	0.527	rs55670257	chr19:49382654	G/A	cg21252483	chr19:49399788	TULP2	-0.77	-5.11	-0.46	1.69e-6	Red cell distribution width;
THYM	cis	rs11811982	0.793	rs76569448	chr1:227406767	A/G	cg09853570	chr1:228403422	OBSCN	1.21	4.67	0.43	9.81e-6	Optic disc area;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg08938727	chr3:134074767	AMOTL2	-0.87	-7.03	-0.58	3.07e-10	Depressive symptoms;
THYM	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg26769984	chr7:1090371	C7orf50	0.81	5.42	0.49	4.45e-7	Bronchopulmonary dysplasia;
THYM	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs3819817	0.575	rs7487846	chr12:96355674	T/C	cg26410635	chr12:96350720	AMDHD1	0.53	5.02	0.46	2.38e-6	Vitamin D levels;
THYM	cis	rs3804749	0.966	rs920900	chr3:122845671	C/G	cg26084141	chr3:122786895	PDIA5	-0.45	-4.53	-0.42	1.73e-5	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs2734839	0.964	rs7131440	chr11:113299910	A/G	cg14159747	chr11:113255604	NA	-0.31	-6.33	-0.54	8.14e-9	Information processing speed;
THYM	cis	rs12291225	0.585	rs10832242	chr11:14340504	C/T	cg05501817	chr11:14380813	RRAS2	0.79	6.42	0.55	5.37e-9	Sense of smell;
THYM	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg05660106	chr1:15850417	CASP9	0.74	5.87	0.52	6.36e-8	Systolic blood pressure;
THYM	cis	rs2066819	1.000	rs11171806	chr12:56733531	A/G	cg26714650	chr12:56694279	CS	1.35	7.01	0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs4930103	0.591	rs11042048	chr11:1986240	C/G	cg18511798	chr11:2018149	H19;MIR675	-0.56	-5.72	-0.51	1.24e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg00981070	chr1:2046702	PRKCZ	-0.43	-5.41	-0.49	4.65e-7	Height;
THYM	cis	rs11209185	0.509	rs2419044	chr1:68421087	C/T	cg22082780	chr1:68452167	NA	0.54	5.38	0.48	5.35e-7	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs55728055	0.661	rs62237849	chr22:32029807	T/C	cg10537193	chr22:32026975	PISD	-0.81	-5.25	-0.47	9.23e-7	Age-related hearing impairment;
THYM	cis	rs3847687	0.565	rs11061293	chr12:131519579	A/G	cg25772418	chr12:131519998	GPR133	-0.35	-4.58	-0.43	1.4e-5	Longevity;
THYM	cis	rs877282	0.842	rs12357963	chr10:757562	C/T	cg10556349	chr10:835070	NA	-0.77	-4.95	-0.45	3.24e-6	Uric acid levels;
THYM	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg27490568	chr2:178487706	NA	0.62	6.0	0.52	3.56e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg00484396	chr16:3507460	NAT15	0.71	9.1	0.68	1.41e-14	Tuberculosis;
THYM	cis	rs11711311	1.000	rs2603789	chr3:113470479	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.61	-5.44	-0.49	4.15e-7	IgG glycosylation;
THYM	cis	rs960902	0.713	rs7557408	chr2:37742301	C/T	cg25341268	chr2:37734390	NA	-0.68	-6.01	-0.53	3.35e-8	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg18252515	chr7:66147081	NA	0.66	5.11	0.46	1.68e-6	Aortic root size;
THYM	cis	rs6754311	0.551	rs10928545	chr2:136501840	A/G	cg23851026	chr2:136556271	LCT	-0.53	-5.25	-0.47	9.31e-7	Mosquito bite size;
THYM	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg04111992	chr7:158790115	NA	-0.59	-4.83	-0.44	5.29e-6	Facial morphology (factor 20);
THYM	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg06481639	chr22:41940642	POLR3H	0.7	4.98	0.45	2.89e-6	Vitiligo;
THYM	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs13315871	0.860	rs17059098	chr3:58255739	G/A	cg12435725	chr3:58293450	RPP14	-0.55	-5.81	-0.51	8.25e-8	Cholesterol, total;
THYM	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg18876405	chr7:65276391	NA	0.68	6.23	0.54	1.29e-8	Aortic root size;
THYM	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.41	-4.79	-0.44	6.15e-6	Longevity;Endometriosis;
THYM	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.58	5.22	0.47	1.05e-6	Lymphocyte counts;
THYM	cis	rs7107174	0.892	rs2510038	chr11:77966034	C/T	cg02023728	chr11:77925099	USP35	0.68	6.11	0.53	2.16e-8	Testicular germ cell tumor;
THYM	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg08807101	chr21:30365312	RNF160	0.94	7.64	0.62	1.69e-11	Dental caries;
THYM	cis	rs7572733	0.534	rs7557203	chr2:198795650	A/G	cg00792783	chr2:198669748	PLCL1	0.84	5.95	0.52	4.51e-8	Dermatomyositis;
THYM	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg07835181	chr16:1525278	CLCN7	0.74	7.18	0.59	1.56e-10	Bone mineral density;
THYM	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg06582575	chr6:163149167	PACRG;PARK2	1.15	6.86	0.58	7.08e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3820068	0.822	rs2901964	chr1:15792426	C/G	cg05660106	chr1:15850417	CASP9	1.07	8.27	0.65	8.28e-13	Systolic blood pressure;
THYM	trans	rs4866334	1.000	rs116612534	chr5:18506467	C/A	cg08675002	chr5:90437527	GPR98	-1.55	-7.42	-0.61	4.86e-11	IgG glycosylation;
THYM	cis	rs4589258	0.933	rs1783805	chr11:90430375	T/G	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg18876405	chr7:65276391	NA	-0.56	-4.65	-0.43	1.09e-5	Aortic root size;
THYM	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg23422044	chr7:1970798	MAD1L1	-0.75	-4.56	-0.42	1.54e-5	Neuroticism;
THYM	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg16928487	chr17:17741425	SREBF1	0.5	4.75	0.44	7.16e-6	Total body bone mineral density;
THYM	cis	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg10856724	chr12:34555212	NA	-0.88	-8.21	-0.64	1.08e-12	Morning vs. evening chronotype;
THYM	cis	rs16912285	0.535	rs6484040	chr11:24309809	C/A	ch.11.24196551F	chr11:24239977	NA	1.0	7.24	0.6	1.15e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs17401966	1.000	rs11578788	chr1:10422958	A/G	cg20482658	chr1:10539492	PEX14	0.39	4.72	0.44	8.05e-6	Hepatocellular carcinoma;
THYM	cis	rs67981189	0.896	rs4048474	chr14:71527699	A/G	cg15910301	chr14:71632612	NA	0.5	4.64	0.43	1.11e-5	Schizophrenia;
THYM	cis	rs73787773	0.867	rs17651424	chr5:111488600	T/C	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.91	-4.83	-0.44	5.23e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs362296	0.550	rs3135064	chr4:3285389	T/C	cg18352616	chr4:3374830	RGS12	0.5	4.98	0.46	2.79e-6	Parental longevity (mother's age at death);
THYM	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg17509989	chr5:176798049	RGS14	0.69	6.41	0.55	5.47e-9	Hemoglobin concentration;Hematocrit;
THYM	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg07424592	chr7:64974309	NA	1.03	5.26	0.47	8.88e-7	Diabetic kidney disease;
THYM	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-4.93	-0.45	3.45e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7894051	0.764	rs1049951	chr10:135184126	G/A	cg07511014	chr10:135191624	PAOX	-0.71	-5.0	-0.46	2.62e-6	Lifespan;
THYM	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg20887711	chr4:1340912	KIAA1530	-0.71	-6.11	-0.53	2.14e-8	Obesity-related traits;
THYM	cis	rs6754311	0.731	rs309160	chr2:136685228	C/T	cg07169764	chr2:136633963	MCM6	0.69	5.68	0.5	1.44e-7	Mosquito bite size;
THYM	cis	rs11186	0.591	rs72906354	chr2:189961771	C/T	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg08645402	chr16:4508243	NA	0.7	6.12	0.53	2.1e-8	Schizophrenia;
THYM	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7107174	0.901	rs2450139	chr11:77924544	G/A	cg02023728	chr11:77925099	USP35	0.68	6.18	0.54	1.59e-8	Testicular germ cell tumor;
THYM	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs539096	0.540	rs3011217	chr1:44303266	C/T	cg15962314	chr1:44399869	ARTN	-0.54	-5.78	-0.51	9.62e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs13082711	0.555	rs73038733	chr3:27263537	C/G	cg02860705	chr3:27208620	NA	0.94	7.6	0.61	2.08e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs4918072	0.798	rs2067831	chr10:105643223	G/C	cg11005552	chr10:105648138	OBFC1	0.71	6.02	0.53	3.26e-8	Coronary artery disease;
THYM	cis	rs1050631	0.657	rs1789551	chr18:33716092	G/A	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.6	4.69	0.43	9.09e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg11812906	chr14:75593930	NEK9	-0.76	-6.86	-0.58	7.09e-10	Height;
THYM	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg13609457	chr4:120235615	NA	0.5	4.77	0.44	6.72e-6	Corneal astigmatism;
THYM	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg24642844	chr7:1081250	C7orf50	-0.73	-5.1	-0.46	1.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs10186029	0.680	rs10179425	chr2:213978441	T/C	cg08319019	chr2:214017104	IKZF2	0.81	6.59	0.56	2.49e-9	Systemic sclerosis;
THYM	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs7267979	0.966	rs6050532	chr20:25308793	A/T	cg08601574	chr20:25228251	PYGB	-0.57	-4.59	-0.43	1.35e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7769051	0.522	rs7769354	chr6:133146865	G/T	cg22852734	chr6:133119734	C6orf192	1.35	4.73	0.44	7.88e-6	Type 2 diabetes nephropathy;
THYM	cis	rs7616559	0.887	rs6441107	chr3:156709207	G/A	cg15697575	chr3:156784781	NA	0.39	4.63	0.43	1.14e-5	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs12257961	0.548	rs10796282	chr10:15380825	C/T	cg10616319	chr10:15468812	NA	-0.59	-4.92	-0.45	3.56e-6	Selective IgA deficiency;
THYM	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs3540	0.597	rs10152221	chr15:91047664	A/G	cg22089800	chr15:90895588	ZNF774	-0.69	-5.31	-0.48	7.26e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg04267008	chr7:1944627	MAD1L1	-0.66	-5.45	-0.49	3.97e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg05182265	chr7:156933206	UBE3C	-0.69	-9.34	-0.69	4.32e-15	Body mass index;
THYM	cis	rs4363385	0.765	rs1094409	chr1:153021040	T/A	cg13444842	chr1:152974279	SPRR3	-0.63	-5.12	-0.47	1.58e-6	Inflammatory skin disease;
THYM	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg13147721	chr7:65941812	NA	-1.1	-7.08	-0.59	2.45e-10	Diabetic kidney disease;
THYM	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg00686598	chr14:53173677	PSMC6	1.39	7.01	0.58	3.52e-10	Alzheimer's disease (late onset);
THYM	cis	rs1003719	0.788	rs59637309	chr21:38475398	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg27129171	chr3:47204927	SETD2	-0.72	-6.87	-0.58	6.72e-10	Colorectal cancer;
THYM	cis	rs4792901	0.959	rs3765174	chr17:41623670	C/T	cg21940313	chr17:41620911	ETV4	-0.52	-5.51	-0.49	3.08e-7	Dupuytren's disease;
THYM	cis	rs11770686	0.513	rs2705825	chr7:75301209	T/C	cg07211516	chr7:75296079	HIP1	-0.55	-4.47	-0.42	2.12e-5	Essential tremor;
THYM	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg07936489	chr17:37558343	FBXL20	0.87	5.59	0.5	2.15e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg07362569	chr17:61921086	SMARCD2	-0.74	-6.62	-0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs6720763	0.891	rs73017939	chr2:168004354	G/A	cg10633051	chr2:168042982	XIRP2	-0.68	-4.69	-0.43	9.2e-6	Atopic dermatitis;
THYM	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg13736514	chr6:26305472	NA	-0.62	-7.42	-0.61	5.02e-11	Educational attainment;
THYM	cis	rs4523957	0.855	rs11078883	chr17:2138828	C/G	cg16513277	chr17:2031491	SMG6	-0.7	-6.43	-0.55	5.1e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg01191920	chr7:158217561	PTPRN2	0.84	8.06	0.64	2.25e-12	Obesity-related traits;
THYM	cis	rs665401	0.652	rs7756165	chr6:117144925	A/G	cg20376953	chr6:117187980	NA	-0.61	-4.77	-0.44	6.56e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg13395646	chr4:1353034	KIAA1530	-0.55	-4.58	-0.43	1.42e-5	Longevity;
THYM	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg13319975	chr6:146136371	FBXO30	0.63	5.03	0.46	2.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12701220	0.762	rs10247470	chr7:1092512	C/G	cg26769984	chr7:1090371	C7orf50	0.71	4.88	0.45	4.22e-6	Bronchopulmonary dysplasia;
THYM	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs28647808	1.000	rs4962142	chr9:136274883	A/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs3924048	0.547	rs12410652	chr1:12611231	T/G	cg00291366	chr1:12616550	NA	0.38	5.83	0.51	7.74e-8	Optic cup area;
THYM	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg22166914	chr1:53195759	ZYG11B	-0.69	-6.96	-0.58	4.39e-10	Monocyte count;
THYM	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.8	6.76	0.57	1.09e-9	Lymphocyte percentage of white cells;
THYM	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg17252645	chr8:143867129	LY6D	-0.85	-10.81	-0.74	3.04e-18	Urinary tract infection frequency;
THYM	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.68	0.43	9.35e-6	Tonsillectomy;
THYM	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg05754148	chr16:3507555	NAT15	-0.72	-6.82	-0.57	8.39e-10	Tuberculosis;
THYM	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22496380	chr5:211416	CCDC127	-1.39	-8.13	-0.64	1.62e-12	Breast cancer;
THYM	cis	rs526231	0.511	rs2288389	chr5:102353808	C/G	cg23492399	chr5:102201601	PAM	-0.7	-5.21	-0.47	1.08e-6	Primary biliary cholangitis;
THYM	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11890956	chr21:40555474	PSMG1	-0.92	-10.2	-0.72	6.08e-17	Cognitive function;
THYM	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg03396347	chr1:1875803	NA	-0.67	-6.86	-0.58	6.84e-10	Body mass index;
THYM	cis	rs41311933	1.000	rs41311911	chr9:123743921	C/T	cg13567360	chr9:123745713	C5	-0.94	-5.41	-0.49	4.69e-7	Coronary artery disease;
THYM	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg24910161	chr17:38119198	GSDMA	0.5	5.09	0.46	1.82e-6	Self-reported allergy;
THYM	cis	rs2637266	0.905	rs1907313	chr10:78338072	A/G	cg18941641	chr10:78392320	NA	0.7	5.56	0.5	2.49e-7	Pulmonary function;
THYM	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg18811423	chr2:55921094	PNPT1	0.69	6.41	0.55	5.6e-9	Metabolic syndrome;
THYM	cis	rs2717559	0.683	rs2717611	chr8:143879927	C/T	cg17252645	chr8:143867129	LY6D	-0.68	-7.73	-0.62	1.13e-11	Urinary tract infection frequency;
THYM	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg07690219	chr3:49449608	TCTA;RHOA	0.7	4.71	0.43	8.57e-6	Menarche (age at onset);
THYM	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg08439880	chr3:133502540	NA	-0.73	-6.09	-0.53	2.36e-8	Iron status biomarkers;
THYM	cis	rs4845459	1.000	rs6702463	chr1:152598711	A/T	cg26135325	chr1:152595322	LCE3A	-0.4	-4.53	-0.42	1.72e-5	Psoriasis;
THYM	cis	rs6032067	0.641	rs6017495	chr20:43756955	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.47	-5.31	-0.48	7.26e-7	Blood protein levels;
THYM	cis	rs79149102	0.579	rs6495137	chr15:75295541	G/A	cg17294928	chr15:75287854	SCAMP5	-1.06	-5.68	-0.5	1.49e-7	Lung cancer;
THYM	cis	rs36051895	0.632	rs62541945	chr9:5161571	T/C	cg02405213	chr9:5042618	JAK2	-1.09	-10.97	-0.75	1.41e-18	Pediatric autoimmune diseases;
THYM	cis	rs4788570	0.655	rs2133773	chr16:71812296	A/G	cg06353428	chr16:71660113	MARVELD3	1.42	8.29	0.65	7.34e-13	Intelligence (multi-trait analysis);
THYM	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs2294693	0.531	rs10947940	chr6:40948496	C/T	cg14418226	chr6:40996092	UNC5CL	0.72	5.42	0.49	4.49e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs9677476	1.000	rs12470450	chr2:232113888	T/A	cg07929768	chr2:232055508	NA	0.5	5.16	0.47	1.37e-6	Food antigen IgG levels;
THYM	cis	rs13326165	0.709	rs352143	chr3:52264907	A/G	cg08438690	chr3:52279403	PPM1M	-0.6	-4.47	-0.42	2.12e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs295140	1.000	rs7559005	chr2:201161371	C/T	cg04283868	chr2:201171347	SPATS2L	0.75	5.71	0.51	1.31e-7	QT interval;
THYM	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg05283184	chr6:79620031	NA	-0.9	-8.99	-0.68	2.38e-14	Intelligence (multi-trait analysis);
THYM	cis	rs933688	1.000	rs12188467	chr5:90765632	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	6.06	0.53	2.72e-8	Smoking behavior;
THYM	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg00599163	chr2:162100495	NA	0.83	7.68	0.62	1.41e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs11910985	0.546	rs9978916	chr21:48080492	A/C	cg17243659	chr21:48055224	PRMT2	0.86	4.57	0.42	1.46e-5	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg25208724	chr1:156163844	SLC25A44	1.17	13.26	0.81	2.43e-23	Testicular germ cell tumor;
THYM	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs7000551	0.606	rs3802199	chr8:22267385	A/G	cg12081754	chr8:22256438	SLC39A14	1.15	11.77	0.77	2.99e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.6	5.61	0.5	1.96e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4750440	0.614	rs4750446	chr10:14030319	T/G	cg27542038	chr10:14027202	FRMD4A	-0.62	-5.23	-0.47	9.88e-7	Adiponectin levels;
THYM	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg24675658	chr1:53192096	ZYG11B	0.88	6.66	0.56	1.8e-9	Monocyte count;
THYM	cis	rs11087114	0.666	rs1028542	chr20:14782742	C/T	cg04470754	chr20:14904432	MACROD2	0.72	4.62	0.43	1.22e-5	Common carotid intima-media thickness in HIV infection;
THYM	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05901451	chr6:126070800	HEY2	-0.67	-5.74	-0.51	1.11e-7	Brugada syndrome;
THYM	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg14061069	chr19:46274453	DMPK	0.89	13.75	0.82	2.55e-24	Coronary artery disease;
THYM	cis	rs77372450	0.551	rs61663448	chr5:157077191	T/C	cg00312553	chr5:157098553	C5orf52	-0.65	-4.63	-0.43	1.16e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs6430585	0.583	rs7561565	chr2:136640787	A/C	cg20242066	chr2:136595261	LCT	0.51	5.02	0.46	2.43e-6	Corneal structure;
THYM	cis	rs4654899	0.802	rs6426648	chr1:21179527	A/G	cg01072550	chr1:21505969	NA	-0.7	-6.32	-0.54	8.56e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg17294928	chr15:75287854	SCAMP5	-0.81	-4.47	-0.42	2.14e-5	Blood trace element (Zn levels);
THYM	cis	rs7119038	0.818	rs10892288	chr11:118644694	A/G	cg19308663	chr11:118741387	NA	0.58	5.47	0.49	3.57e-7	Sjögren's syndrome;
THYM	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg20573242	chr4:122745356	CCNA2	0.63	4.6	0.43	1.32e-5	Type 2 diabetes;
THYM	cis	rs4907240	0.731	rs2118836	chr2:97162972	A/G	cg18419276	chr2:96971862	SNRNP200	-0.38	-4.5	-0.42	1.91e-5	Event-related brain oscillations;
THYM	cis	rs9581943	0.967	rs7985481	chr13:28466090	A/C	cg16302790	chr13:28498334	PDX1	0.52	4.6	0.43	1.33e-5	Pancreatic cancer;
THYM	cis	rs13082711	1.000	rs73050029	chr3:27514760	C/A	cg02860705	chr3:27208620	NA	0.83	5.61	0.5	2e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg06108461	chr20:60628389	TAF4	-1.04	-8.24	-0.65	9.18e-13	Body mass index;
THYM	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg10803722	chr21:46713166	LOC642852	-0.44	-5.8	-0.51	8.54e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs13082711	0.522	rs480238	chr3:27347577	A/T	cg02860705	chr3:27208620	NA	0.65	5.07	0.46	1.94e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg24154853	chr7:158122151	PTPRN2	0.55	4.82	0.44	5.35e-6	Calcium levels;
THYM	cis	rs9902453	0.904	rs7225686	chr17:28356744	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.22	-0.54	1.3e-8	Coffee consumption (cups per day);
THYM	cis	rs4713118	0.662	rs9468271	chr6:28024570	A/G	cg23281280	chr6:28129359	ZNF389	0.61	4.74	0.44	7.58e-6	Parkinson's disease;
THYM	cis	rs611744	0.647	rs11774904	chr8:109273435	G/A	cg21045802	chr8:109455806	TTC35	0.62	5.38	0.48	5.43e-7	Dupuytren's disease;
THYM	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.47	-0.42	2.16e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4589258	0.698	rs1792617	chr11:90449164	A/G	cg26138821	chr11:89956704	CHORDC1	0.58	4.72	0.44	8.17e-6	Intelligence (multi-trait analysis);
THYM	cis	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg07460842	chr6:66804631	NA	-0.94	-6.74	-0.57	1.2e-9	Exhaled nitric oxide output;
THYM	trans	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs1483890	0.723	rs13061189	chr3:69411453	T/C	cg22125112	chr3:69402811	FRMD4B	0.54	6.85	0.58	7.21e-10	Resting heart rate;
THYM	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg22683308	chr4:1340831	KIAA1530	-0.59	-4.62	-0.43	1.2e-5	Longevity;
THYM	cis	rs9880211	1.000	rs28811905	chr3:136252052	T/C	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-7.23	-0.6	1.2e-10	Schizophrenia;
THYM	cis	rs6831352	0.729	rs4699718	chr4:100067791	G/A	cg12011299	chr4:100065546	ADH4	-0.82	-7.62	-0.62	1.91e-11	Alcohol dependence;
THYM	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg08048268	chr3:133502702	NA	0.62	4.88	0.45	4.27e-6	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs6456156	0.742	rs6456157	chr6:167527818	C/A	cg09487078	chr6:167525398	CCR6	-0.44	-4.92	-0.45	3.63e-6	Primary biliary cholangitis;
THYM	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg03467027	chr4:99064603	C4orf37	0.59	4.53	0.42	1.69e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8050907	0.744	rs11861315	chr16:4518783	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.22	4.58	0.43	1.43e-5	Obesity-related traits;
THYM	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg21862992	chr11:68658383	NA	-0.24	-4.55	-0.42	1.6e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg00576331	chr11:65640516	EFEMP2	-0.68	-4.58	-0.43	1.42e-5	Crohn's disease;
THYM	cis	rs2797685	0.898	rs2071987	chr1:7834026	G/A	cg06712362	chr1:7811235	CAMTA1	0.74	5.58	0.5	2.28e-7	Crohn's disease;
THYM	cis	rs7586879	0.639	rs2033653	chr2:25103446	C/T	cg01884057	chr2:25150051	NA	-0.68	-7.19	-0.59	1.47e-10	Body mass index;
THYM	cis	rs67460515	0.892	rs34896809	chr3:161059804	C/T	cg03342759	chr3:160939853	NMD3	-0.91	-7.85	-0.63	6.27e-12	Parkinson's disease;
THYM	cis	rs11574514	1.000	rs59376497	chr16:67681170	C/T	cg04582263	chr16:67973788	LCAT	0.97	4.56	0.42	1.54e-5	Crohn's disease;
THYM	cis	rs7705502	1.000	rs1484803	chr5:173349840	A/G	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg22166914	chr1:53195759	ZYG11B	-0.72	-6.13	-0.53	2.02e-8	Monocyte count;
THYM	cis	rs7107174	1.000	rs11237468	chr11:78072833	A/G	cg02023728	chr11:77925099	USP35	0.62	6.0	0.52	3.51e-8	Testicular germ cell tumor;
THYM	cis	rs791590	0.941	rs12722559	chr10:6070273	C/A	cg17191567	chr10:6178319	NA	0.73	4.73	0.44	7.79e-6	Soluble interleukin-2 receptor subunit alpha;
THYM	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg13114125	chr14:105738426	BRF1	-0.72	-5.55	-0.49	2.61e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2712184	0.846	rs7598172	chr2:217677999	G/T	cg05032264	chr2:217675019	NA	-0.57	-5.06	-0.46	2.08e-6	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs757081	0.667	rs12577418	chr11:17101554	C/G	cg15432903	chr11:17409602	KCNJ11	-0.49	-4.58	-0.43	1.42e-5	Systolic blood pressure;
THYM	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg08645402	chr16:4508243	NA	0.61	5.32	0.48	6.81e-7	Schizophrenia;
THYM	cis	rs1559088	1.000	rs28840147	chr19:33561976	A/G	cg03563238	chr19:33554763	RHPN2	-0.5	-4.52	-0.42	1.8e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs3826795	0.569	rs7254961	chr19:46795884	C/T	cg15229275	chr19:46800054	HIF3A	0.92	5.54	0.49	2.69e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg07570687	chr10:102243282	WNT8B	0.84	8.13	0.64	1.59e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1345301	1.000	rs13431601	chr2:102873713	G/A	cg03938978	chr2:103052716	IL18RAP	-0.62	-6.09	-0.53	2.36e-8	Waist circumference;
THYM	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg02038168	chr22:39784481	NA	-0.63	-5.19	-0.47	1.17e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.71	5.79	0.51	8.91e-8	Menarche (age at onset);
THYM	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg16624210	chr5:671434	TPPP	0.77	5.67	0.5	1.54e-7	Obesity-related traits;
THYM	cis	rs6032067	0.777	rs17332620	chr20:43777506	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.52	-5.89	-0.52	5.76e-8	Blood protein levels;
THYM	cis	rs10193935	0.901	rs10179237	chr2:42515501	C/T	cg27598129	chr2:42591480	NA	-0.71	-4.56	-0.42	1.5e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg02953382	chr22:24373134	LOC391322	-0.66	-5.73	-0.51	1.16e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1048238	0.548	rs848217	chr1:16272250	A/G	cg22431228	chr1:16359049	CLCNKA	0.45	4.54	0.42	1.67e-5	Systolic blood pressure;
THYM	cis	rs3849570	1.000	rs3772882	chr3:81808602	C/A	cg07356753	chr3:81810745	GBE1	-0.79	-5.83	-0.51	7.51e-8	Waist circumference;Body mass index;
THYM	cis	rs7107174	1.000	rs2450128	chr11:77940075	G/A	cg02023728	chr11:77925099	USP35	0.67	6.46	0.55	4.39e-9	Testicular germ cell tumor;
THYM	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg24503407	chr1:205819492	PM20D1	0.93	8.85	0.67	4.8e-14	Menarche (age at onset);
THYM	cis	rs4631830	0.863	rs3123078	chr10:51524971	A/G	cg10326726	chr10:51549505	MSMB	0.59	5.86	0.52	6.68e-8	Prostate-specific antigen levels;
THYM	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs490234	0.756	rs925473	chr9:128228026	A/G	cg14078157	chr9:128172775	NA	-0.69	-5.54	-0.49	2.71e-7	Mean arterial pressure;
THYM	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg12310025	chr6:25882481	NA	0.78	6.29	0.54	9.76e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg24818145	chr4:99064322	C4orf37	0.67	5.2	0.47	1.13e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs611744	0.967	rs702802	chr8:109218238	G/A	cg21045802	chr8:109455806	TTC35	0.59	5.31	0.48	7.16e-7	Dupuytren's disease;
THYM	cis	rs12802200	0.535	rs12290412	chr11:569230	T/C	cg00645579	chr11:617140	IRF7;MUPCDH	-0.4	-4.54	-0.42	1.65e-5	Systemic lupus erythematosus;
THYM	cis	rs1978968	1.000	rs7291169	chr22:18449038	A/G	cg01550578	chr22:18484421	MICAL3	0.69	5.21	0.47	1.1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs11645898	0.935	rs72787091	chr16:72190184	C/T	cg14768367	chr16:72042858	DHODH	-0.75	-5.44	-0.49	4.18e-7	Blood protein levels;
THYM	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg00080972	chr5:178986291	RUFY1	0.58	7.3	0.6	8.89e-11	Lung cancer;
THYM	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.92	5.02	0.46	2.41e-6	Initial pursuit acceleration;
THYM	cis	rs920590	0.879	rs67391684	chr8:19654642	A/T	cg01411142	chr8:19674711	INTS10	0.6	4.53	0.42	1.71e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11890956	chr21:40555474	PSMG1	-0.93	-10.04	-0.72	1.34e-16	Cognitive function;
THYM	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg07936489	chr17:37558343	FBXL20	0.83	5.84	0.51	7.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs854765	0.624	rs4925119	chr17:17742904	A/G	cg16928487	chr17:17741425	SREBF1	0.51	4.75	0.44	7.18e-6	Total body bone mineral density;
THYM	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg14517863	chr17:44321492	NA	0.43	4.81	0.44	5.57e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2294693	0.945	rs9369253	chr6:40986538	A/G	cg14769373	chr6:40998127	UNC5CL	-0.6	-4.47	-0.42	2.19e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg21361702	chr7:150065534	REPIN1	0.68	4.98	0.46	2.8e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg20291162	chr17:40259547	DHX58	-0.7	-6.47	-0.55	4.18e-9	Fibrinogen levels;
THYM	cis	rs9430161	0.598	rs34350247	chr1:11034460	A/G	cg27631724	chr1:11040367	C1orf127	0.64	5.64	0.5	1.72e-7	Ewing sarcoma;
THYM	cis	rs6570726	1.000	rs450076	chr6:145847655	G/T	cg23711669	chr6:146136114	FBXO30	0.81	7.61	0.62	2.01e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9649213	0.593	rs6967457	chr7:97912221	T/G	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2688608	0.901	rs2675671	chr10:75632760	C/T	cg15838173	chr10:75533400	FUT11	-0.45	-4.78	-0.44	6.48e-6	Inflammatory bowel disease;
THYM	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg27535305	chr1:53392650	SCP2	-0.41	-4.71	-0.44	8.48e-6	Monocyte count;
THYM	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs7264396	0.836	rs6058276	chr20:34187728	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.57	-4.5	-0.42	1.89e-5	Total cholesterol levels;
THYM	cis	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg07460842	chr6:66804631	NA	1.11	8.12	0.64	1.7e-12	Exhaled nitric oxide output;
THYM	cis	rs113835537	0.529	rs2276406	chr11:66283257	C/T	cg24851651	chr11:66362959	CCS	0.7	4.89	0.45	4.04e-6	Airway imaging phenotypes;
THYM	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-7.24	-0.6	1.15e-10	Schizophrenia;
THYM	cis	rs1994135	0.715	rs10844625	chr12:33693006	C/T	cg10856724	chr12:34555212	NA	-0.63	-4.95	-0.45	3.23e-6	Resting heart rate;
THYM	trans	rs2136093	0.600	rs12128841	chr1:90909557	G/T	cg19688584	chr6:167529678	CCR6	0.5	7.06	0.59	2.66e-10	Response to antidepressants;
THYM	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg01699819	chr7:1052092	C7orf50	-0.87	-7.92	-0.63	4.5e-12	Bronchopulmonary dysplasia;
THYM	cis	rs4072705	0.646	rs7037254	chr9:127245412	C/T	cg01786973	chr9:127249749	NR5A1	-0.4	-5.21	-0.47	1.09e-6	Menarche (age at onset);
THYM	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg27494647	chr7:150038898	RARRES2	0.39	4.51	0.42	1.84e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg17105886	chr17:28927953	LRRC37B2	1.32	6.56	0.56	2.79e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg03929089	chr4:120376271	NA	-0.76	-7.08	-0.59	2.51e-10	Coronary artery disease;
THYM	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.57	-4.49	-0.42	1.99e-5	Chronic sinus infection;
THYM	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg05368731	chr17:41323189	NBR1	1.26	11.54	0.76	9.06e-20	Menopause (age at onset);
THYM	cis	rs7106204	1.000	rs4244512	chr11:24217355	A/G	ch.11.24196551F	chr11:24239977	NA	-0.96	-6.08	-0.53	2.49e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs2732480	0.500	rs11168464	chr12:48602115	C/T	cg21466736	chr12:48725269	NA	-0.54	-4.88	-0.45	4.33e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs8192282	0.739	rs4845636	chr1:154486370	A/G	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg02527881	chr3:46936655	PTH1R	0.62	5.83	0.51	7.48e-8	Colorectal cancer;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg26034313	chr11:117110208	RNF214	-0.92	-7.17	-0.59	1.59e-10	Depressive symptoms;
THYM	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg12756686	chr19:29218302	NA	0.82	6.13	0.53	1.96e-8	Methadone dose in opioid dependence;
THYM	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg18681998	chr4:17616180	MED28	0.79	6.77	0.57	1.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.61	4.46	0.42	2.23e-5	Glycated hemoglobin levels;
THYM	cis	rs8078723	0.705	rs8065443	chr17:38208940	A/G	cg17467752	chr17:38218738	THRA	-1.0	-7.72	-0.62	1.15e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg11494091	chr17:61959527	GH2	0.69	6.42	0.55	5.32e-9	Height;
THYM	cis	rs7975161	0.506	rs7953434	chr12:104622101	T/G	cg25273343	chr12:104657179	TXNRD1	-0.78	-5.35	-0.48	6.15e-7	Toenail selenium levels;
THYM	cis	rs9290065	0.519	rs1530636	chr3:160697442	A/G	cg03342759	chr3:160939853	NMD3	0.59	4.56	0.42	1.52e-5	Kawasaki disease;
THYM	cis	rs8068544	0.818	rs7209012	chr17:40161323	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.47	-7.45	-0.61	4.22e-11	Reticulocyte fraction of red cells;Reticulocyte count;
THYM	cis	rs7084402	0.967	rs1649074	chr10:60295342	T/G	cg09696939	chr10:60272079	BICC1	-0.46	-5.38	-0.48	5.23e-7	Refractive error;
THYM	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg23131131	chr22:24373011	LOC391322	-0.82	-7.79	-0.62	8.46e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	5.98	0.52	3.86e-8	Schizophrenia;
THYM	cis	rs13064411	0.696	rs1486897	chr3:113215818	G/A	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg08885076	chr2:99613938	TSGA10	0.7	6.51	0.56	3.59e-9	Chronic sinus infection;
THYM	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg08772003	chr10:104629869	AS3MT	-0.63	-5.62	-0.5	1.87e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.34	-0.48	6.24e-7	Monocyte percentage of white cells;
THYM	trans	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg06636001	chr8:8085503	FLJ10661	0.78	6.99	0.58	3.83e-10	Neuroticism;
THYM	cis	rs4455778	0.580	rs4917197	chr7:49075894	C/T	cg26309511	chr7:48887640	NA	0.69	6.04	0.53	3e-8	Lung cancer in never smokers;
THYM	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg19875535	chr5:140030758	IK	-0.58	-4.92	-0.45	3.6e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7786808	0.653	rs4909213	chr7:158202404	G/A	cg01191920	chr7:158217561	PTPRN2	-0.94	-9.67	-0.7	8.56e-16	Obesity-related traits;
THYM	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	trans	rs1920324	0.622	rs6797582	chr3:103886680	C/T	cg01901466	chr14:93388880	CHGA	0.65	6.91	0.58	5.4e-10	Colorectal cancer;
THYM	cis	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg24692254	chr21:30365293	RNF160	-0.8	-4.48	-0.42	2.07e-5	Cognitive test performance;
THYM	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg16928487	chr17:17741425	SREBF1	0.54	5.39	0.48	5.09e-7	Total body bone mineral density;
THYM	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg06808227	chr14:105710500	BRF1	-1.05	-9.15	-0.68	1.1e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg22920501	chr2:26401640	FAM59B	-0.77	-5.44	-0.49	4.17e-7	Gut microbiome composition (summer);
THYM	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs7084402	0.967	rs7098326	chr10:60276906	C/T	cg07615347	chr10:60278583	BICC1	-0.56	-5.21	-0.47	1.07e-6	Refractive error;
THYM	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg05657792	chr17:6899758	ALOX12	0.51	5.22	0.47	1.03e-6	Tonsillectomy;
THYM	cis	rs988913	0.768	rs1115159	chr6:54753541	T/C	cg19716238	chr6:54711378	FAM83B	0.48	5.29	0.48	7.86e-7	Menarche (age at onset);
THYM	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg02527881	chr3:46936655	PTH1R	-0.66	-6.44	-0.55	4.76e-9	Colorectal cancer;
THYM	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg06558623	chr16:89946397	TCF25	1.01	5.18	0.47	1.25e-6	Skin colour saturation;
THYM	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg02389323	chr16:88786976	FAM38A	0.92	5.27	0.48	8.47e-7	Plateletcrit;
THYM	cis	rs4455778	0.580	rs10215945	chr7:49096423	G/A	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg13319975	chr6:146136371	FBXO30	-0.66	-5.48	-0.49	3.43e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1322639	0.614	rs9689800	chr6:169572945	T/A	cg04662567	chr6:169592167	NA	0.57	5.18	0.47	1.26e-6	Pulse pressure;
THYM	cis	rs55637147	0.671	rs2276038	chr11:57137424	C/T	cg15971518	chr11:57159174	PRG2	-0.66	-5.02	-0.46	2.43e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg00383909	chr3:49044727	WDR6	1.19	7.36	0.6	6.4e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs6430585	0.528	rs75753154	chr2:136665711	T/C	cg07169764	chr2:136633963	MCM6	1.24	14.04	0.82	6.77e-25	Corneal structure;
THYM	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg27394845	chr17:28928406	LRRC37B2	0.98	4.82	0.44	5.45e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2625529	0.824	rs16956328	chr15:72143855	A/T	cg16672083	chr15:72433130	SENP8	-0.53	-4.69	-0.43	9.15e-6	Red blood cell count;
THYM	cis	rs6450176	0.564	rs381024	chr5:53326234	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.94	-8.32	-0.65	6.26e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg24253500	chr15:84953950	NA	0.55	4.63	0.43	1.17e-5	Schizophrenia;
THYM	cis	rs6060717	0.610	rs6058393	chr20:34608664	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-5.06	-0.46	2.05e-6	Hip circumference adjusted for BMI;
THYM	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg07424592	chr7:64974309	NA	1.1	5.08	0.46	1.87e-6	Diabetic kidney disease;
THYM	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg25072359	chr17:41440525	NA	0.77	5.74	0.51	1.15e-7	Menopause (age at onset);
THYM	cis	rs2039659	0.719	rs4911018	chr13:86274736	T/C	cg25308322	chr13:86268291	NA	0.67	6.04	0.53	2.93e-8	Blood osmolality (transformed sodium);
THYM	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg13147721	chr7:65941812	NA	-1.0	-6.2	-0.54	1.47e-8	Diabetic kidney disease;
THYM	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.64	-5.51	-0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs28595532	0.920	rs115485705	chr4:119733286	G/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs10752881	1.000	rs10737237	chr1:182989269	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Colorectal cancer;
THYM	cis	rs988913	1.000	rs988913	chr6:54756308	C/T	cg15217784	chr6:54722227	FAM83B	-0.5	-4.49	-0.42	1.99e-5	Menarche (age at onset);
THYM	cis	rs11577318	0.579	rs11247936	chr1:26698884	A/G	cg16664472	chr1:26644822	UBXN11;CD52	0.33	4.69	0.43	9e-6	Granulocyte percentage of myeloid white cells;
THYM	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg22709100	chr7:91322751	NA	0.61	4.83	0.44	5.26e-6	Breast cancer;
THYM	cis	rs12148477	0.623	rs12595284	chr15:51655762	C/G	cg25905881	chr15:51634250	GLDN	0.55	4.47	0.42	2.12e-5	Follicule stimulating hormone;
THYM	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg06481639	chr22:41940642	POLR3H	-0.84	-5.93	-0.52	4.87e-8	Vitiligo;
THYM	cis	rs4499344	0.730	rs434020	chr19:33104070	C/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.61	0.62	2.02e-11	Mean platelet volume;
THYM	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg05754148	chr16:3507555	NAT15	-0.87	-6.93	-0.58	4.92e-10	Tuberculosis;
THYM	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg12908607	chr1:44402522	ARTN	-0.54	-4.64	-0.43	1.1e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.12	8.84	0.67	5.07e-14	Cognitive test performance;
THYM	cis	rs13006833	0.765	rs291431	chr2:191199530	G/A	cg11845111	chr2:191398756	TMEM194B	0.67	4.76	0.44	6.85e-6	Urinary metabolites;
THYM	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	4.54	0.42	1.66e-5	Hip circumference adjusted for BMI;
THYM	cis	rs4604732	0.578	rs12040725	chr1:247644697	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.69	4.54	0.42	1.64e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs61931739	0.926	rs13377754	chr12:34051765	T/C	cg06521331	chr12:34319734	NA	0.6	4.61	0.43	1.27e-5	Morning vs. evening chronotype;
THYM	cis	rs6496667	1.000	rs6496665	chr15:90891615	G/A	cg22089800	chr15:90895588	ZNF774	0.74	5.0	0.46	2.65e-6	Rheumatoid arthritis;
THYM	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg00677455	chr12:58241039	CTDSP2	0.77	6.11	0.53	2.16e-8	Intelligence (multi-trait analysis);
THYM	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg09323728	chr8:95962352	TP53INP1	-0.44	-4.45	-0.42	2.33e-5	Type 2 diabetes;
THYM	cis	rs75920871	0.588	rs688456	chr11:116722551	G/T	cg04087571	chr11:116723030	SIK3	-0.32	-4.77	-0.44	6.61e-6	Subjective well-being;
THYM	cis	rs2354432	0.607	rs4950310	chr1:146659964	A/G	cg25205988	chr1:146714368	CHD1L	1.26	5.61	0.5	2e-7	Mitochondrial DNA levels;
THYM	cis	rs7084402	0.967	rs7099881	chr10:60316211	A/G	cg09696939	chr10:60272079	BICC1	0.48	5.64	0.5	1.76e-7	Refractive error;
THYM	cis	rs6565180	0.962	rs11642676	chr16:30371655	C/G	cg17640201	chr16:30407289	ZNF48	-0.87	-7.42	-0.61	4.83e-11	Tonsillectomy;
THYM	cis	rs4430311	0.964	rs2953331	chr1:244024268	A/G	cg25706552	chr1:244017396	NA	-0.6	-5.39	-0.48	5.21e-7	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3540	0.597	rs7498113	chr15:91051192	C/G	cg22089800	chr15:90895588	ZNF774	-0.68	-5.14	-0.47	1.48e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg07414643	chr4:187882934	NA	0.66	5.79	0.51	9.15e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg10661904	chr17:79619235	PDE6G	-0.53	-4.66	-0.43	1.03e-5	Eye color traits;
THYM	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg02527881	chr3:46936655	PTH1R	0.57	5.18	0.47	1.24e-6	Colorectal cancer;
THYM	cis	rs3540	0.554	rs34650360	chr15:91059017	T/C	cg22089800	chr15:90895588	ZNF774	-0.7	-5.23	-0.47	1.02e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs9595908	1.000	rs9595908	chr13:33184288	T/C	cg12383807	chr13:33924137	NA	-0.5	-4.51	-0.42	1.85e-5	Body mass index;
THYM	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg27170947	chr2:26402098	FAM59B	-0.78	-6.09	-0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs2075230	0.850	rs6503039	chr17:7470060	A/G	cg27413385	chr17:7515425	FXR2	0.32	4.47	0.42	2.17e-5	Hormone measurements;
THYM	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg23758822	chr17:41437982	NA	1.16	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs7833986	0.501	rs2953911	chr8:56948009	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.4	0.6	5.43e-11	Height;
THYM	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg11764359	chr7:65958608	NA	-0.83	-6.6	-0.56	2.37e-9	Aortic root size;
THYM	cis	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg21775007	chr8:11205619	TDH	-0.68	-5.06	-0.46	2.06e-6	Retinal vascular caliber;
THYM	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg06028808	chr11:68637592	NA	0.67	7.26	0.6	1.07e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs754466	1.000	rs12220328	chr10:79681482	G/C	cg17075019	chr10:79541650	NA	-0.61	-4.65	-0.43	1.08e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11771526	0.901	rs7357136	chr7:32302338	G/T	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs9309473	0.632	rs11885217	chr2:73553208	A/G	cg20560298	chr2:73613845	ALMS1	-0.65	-4.69	-0.43	9.13e-6	Metabolite levels;
THYM	cis	rs236907	0.812	rs35400839	chr1:171743312	G/A	cg20598894	chr1:171756153	METTL13	-0.71	-5.25	-0.47	9.39e-7	Mean platelet volume;
THYM	cis	rs7089973	0.872	rs35622181	chr10:116631976	C/T	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.05	-0.46	2.15e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7481584	0.624	rs12417389	chr11:3035304	G/C	cg03159660	chr11:2078197	NA	0.65	4.86	0.45	4.54e-6	Calcium levels;
THYM	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg18876405	chr7:65276391	NA	-0.57	-4.78	-0.44	6.26e-6	Aortic root size;
THYM	cis	rs10463554	0.927	rs257314	chr5:102421095	T/C	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg18876405	chr7:65276391	NA	0.57	4.73	0.44	7.67e-6	Aortic root size;
THYM	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.59	-8.27	-0.65	7.92e-13	Monocyte percentage of white cells;
THYM	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg03929089	chr4:120376271	NA	-1.01	-13.68	-0.81	3.47e-24	Height;
THYM	cis	rs9790314	0.747	rs1599378	chr3:160874511	A/C	cg04691961	chr3:161091175	C3orf57	-0.61	-4.96	-0.45	3.03e-6	Morning vs. evening chronotype;
THYM	cis	rs6906287	0.647	rs12214483	chr6:118780146	G/C	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs7119	0.717	rs10519167	chr15:77723027	G/T	cg10437265	chr15:77819839	NA	0.56	4.99	0.46	2.78e-6	Type 2 diabetes;
THYM	cis	rs533581	0.866	rs871756	chr16:88969076	G/C	cg06763375	chr16:89025547	CBFA2T3	-0.54	-4.6	-0.43	1.31e-5	Social autistic-like traits;
THYM	trans	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	Neuroticism;
THYM	cis	rs2976388	1.000	rs2572910	chr8:143770135	C/G	cg06565975	chr8:143823917	SLURP1	-0.46	-5.49	-0.49	3.3e-7	Urinary tract infection frequency;
THYM	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg24642844	chr7:1081250	C7orf50	-1.17	-7.15	-0.59	1.75e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg05425664	chr17:57184151	TRIM37	-0.56	-4.48	-0.42	2.06e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10916814	0.513	rs1253805	chr1:20885618	G/A	cg04087271	chr1:20915334	CDA	-0.63	-5.23	-0.47	1.02e-6	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg06766960	chr11:133703094	NA	-0.61	-5.52	-0.49	2.94e-7	Childhood ear infection;
THYM	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg14798641	chr3:49314920	USP4;C3orf62	-0.65	-4.57	-0.42	1.47e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs6480314	0.573	rs12573244	chr10:70001245	G/A	cg27159792	chr10:69524182	NA	0.81	4.89	0.45	4.06e-6	Optic nerve measurement (disc area);
THYM	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg04476341	chr5:669733	TPPP	-0.51	-5.11	-0.46	1.66e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs12579753	0.917	rs12366599	chr12:82212112	C/T	cg21231944	chr12:82153410	PPFIA2	-0.71	-5.53	-0.49	2.82e-7	Resting heart rate;
THYM	cis	rs7772486	0.840	rs854144	chr6:146360880	G/T	cg13319975	chr6:146136371	FBXO30	0.64	5.53	0.49	2.83e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg20295408	chr7:1910781	MAD1L1	-0.62	-4.45	-0.42	2.36e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs7246657	0.943	rs10422967	chr19:37850137	T/C	cg22634378	chr19:37742834	NA	0.68	5.67	0.5	1.55e-7	Coronary artery calcification;
THYM	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg08132940	chr7:1081526	C7orf50	-0.77	-5.19	-0.47	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2692947	0.832	rs2692954	chr2:96683378	T/G	cg22654517	chr2:96458247	NA	0.68	4.99	0.46	2.76e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg11494091	chr17:61959527	GH2	0.7	6.46	0.55	4.55e-9	Height;
THYM	cis	rs11779988	0.545	rs438873	chr8:17786516	G/A	cg01800426	chr8:17659068	MTUS1	-0.76	-5.32	-0.48	6.94e-7	Breast cancer;
THYM	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg27490568	chr2:178487706	NA	0.54	4.68	0.43	9.42e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg06640241	chr16:89574553	SPG7	-0.66	-4.76	-0.44	7.05e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs6980334	0.911	rs2120846	chr7:137773291	T/G	cg11874123	chr7:137028198	PTN	0.66	5.12	0.46	1.62e-6	Blood metabolite ratios;
THYM	trans	rs10802346	0.514	rs5024440	chr1:246372608	G/C	cg13514129	chr1:39547527	MACF1	1.03	10.76	0.74	3.93e-18	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4285028	0.747	rs9852845	chr3:121390618	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.84	-7.2	-0.59	1.37e-10	Multiple sclerosis;
THYM	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg27532560	chr4:187881888	NA	-0.96	-11.3	-0.76	2.88e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7107174	0.688	rs869202	chr11:78127914	A/G	cg02023728	chr11:77925099	USP35	0.54	4.53	0.42	1.69e-5	Testicular germ cell tumor;
THYM	cis	rs6840360	0.615	rs1561916	chr4:152479234	C/T	cg17479576	chr4:152424074	FAM160A1	-0.85	-6.4	-0.55	5.9e-9	Intelligence (multi-trait analysis);
THYM	cis	rs3812831	0.654	rs9314900	chr13:114937618	A/C	cg06611532	chr13:114900021	NA	0.58	6.37	0.55	6.86e-9	Schizophrenia;
THYM	cis	rs11785693	0.862	rs11782343	chr8:5001642	C/G	cg26367366	chr8:4980734	NA	1.09	5.09	0.46	1.81e-6	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs1385374	0.858	rs3765107	chr12:129278310	A/G	cg04043695	chr12:129287642	SLC15A4	-0.81	-4.89	-0.45	4.04e-6	Systemic lupus erythematosus;
THYM	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7757969	1.000	rs1022649	chr6:112119981	A/G	cg08601457	chr6:112115117	FYN	0.42	4.79	0.44	6.23e-6	Schizophrenia;
THYM	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg02269571	chr22:50332266	NA	-1.27	-6.97	-0.58	4.2e-10	Acne (severe);
THYM	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg12011299	chr4:100065546	ADH4	-0.85	-8.12	-0.64	1.67e-12	Alcohol dependence;
THYM	cis	rs807029	0.758	rs807027	chr10:102764607	T/A	cg14905631	chr10:102746534	C10orf2;MRPL43	0.33	4.49	0.42	2.03e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7465272	1.000	rs35868630	chr8:143685933	G/A	cg10104451	chr8:143696006	ARC	-0.78	-5.42	-0.49	4.45e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs13315871	1.000	rs9864325	chr3:58336846	A/C	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg03354898	chr7:1950403	MAD1L1	-0.45	-4.45	-0.42	2.36e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs6060717	0.654	rs6060686	chr20:34512606	C/G	cg26038318	chr20:34205095	SPAG4	0.64	4.95	0.45	3.18e-6	Hip circumference adjusted for BMI;
THYM	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg09549813	chr16:4587862	C16orf5	-0.59	-6.37	-0.55	6.82e-9	Schizophrenia;
THYM	cis	rs2276314	0.857	rs62101376	chr18:33582955	T/C	cg19628046	chr18:33552617	C18orf21	0.74	5.22	0.47	1.05e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs4642101	0.793	rs6799179	chr3:12829095	A/C	cg05775895	chr3:12838266	CAND2	0.81	6.98	0.58	3.99e-10	QRS complex (12-leadsum);
THYM	cis	rs4646404	0.509	rs4646352	chr17:17473853	C/T	cg11245205	chr17:17398264	RASD1	-0.41	-4.65	-0.43	1.06e-5	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
THYM	cis	rs7089973	0.872	rs7918253	chr10:116614501	T/C	cg08188268	chr10:116634841	FAM160B1	-0.3	-4.93	-0.45	3.54e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs2997447	0.633	rs6665062	chr1:26362001	C/T	cg19633962	chr1:26362018	EXTL1	-0.76	-4.73	-0.44	7.94e-6	QRS complex (12-leadsum);
THYM	cis	rs4919044	0.736	rs56087738	chr10:94767057	T/A	cg05127821	chr10:94822908	CYP26C1	-1.04	-4.68	-0.43	9.54e-6	Coronary artery disease;
THYM	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg13319975	chr6:146136371	FBXO30	-0.67	-5.49	-0.49	3.29e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6121246	0.559	rs6060857	chr20:30300222	A/G	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.22	0.64	1.03e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9574309	0.776	rs9544885	chr13:79388708	A/C	cg20271865	chr13:80233183	NA	0.37	4.66	0.43	1.05e-5	IgG glycosylation;
THYM	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg13609457	chr4:120235615	NA	0.66	5.61	0.5	2.03e-7	Corneal astigmatism;
THYM	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg18850127	chr7:39170497	POU6F2	0.6	5.66	0.5	1.57e-7	IgG glycosylation;
THYM	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg10802521	chr3:52805072	NEK4	-0.71	-5.96	-0.52	4.22e-8	Bipolar disorder;
THYM	cis	rs2552220	0.818	rs11774508	chr8:6013050	C/T	cg06481462	chr8:7005678	NA	0.47	4.97	0.45	3.02e-6	Interleukin-8 levels;
THYM	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg00677455	chr12:58241039	CTDSP2	0.66	4.45	0.42	2.32e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9880211	0.800	rs34324561	chr3:136101242	T/G	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs34602589	0.535	rs7346579	chr20:43844722	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.37	-0.48	5.67e-7	Parental longevity (mother's age at death);
THYM	cis	rs10089	1.000	rs11957052	chr5:127524055	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	5.46	0.49	3.81e-7	Ileal carcinoids;
THYM	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg06917634	chr15:78832804	PSMA4	0.96	8.76	0.67	7.4e-14	Sudden cardiac arrest;
THYM	cis	rs4731207	0.596	rs7789392	chr7:124611076	T/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg07061783	chr6:25882402	NA	0.57	4.48	0.42	2.07e-5	Schizophrenia;
THYM	cis	rs7582180	0.676	rs1437969	chr2:100983482	A/C	cg08017756	chr2:100939284	LONRF2	-0.72	-7.42	-0.61	4.95e-11	Intelligence (multi-trait analysis);
THYM	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg03161606	chr19:29218774	NA	0.69	4.69	0.43	9.13e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg09260853	chr1:2094483	PRKCZ	0.47	4.67	0.43	9.79e-6	Height;
THYM	cis	rs11671005	0.656	rs11671092	chr19:59009109	T/C	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.66	-4.9	-0.45	3.98e-6	Mean platelet volume;
THYM	cis	rs6138458	0.828	rs6132785	chr20:24993414	T/C	cg26195577	chr20:24973756	C20orf3	0.96	9.1	0.68	1.41e-14	Blood protein levels;
THYM	cis	rs4148689	1.000	rs35388491	chr7:117156923	T/G	cg17204129	chr7:117119601	CFTR	-0.67	-5.27	-0.48	8.55e-7	Gout;
THYM	cis	rs921968	0.541	rs6717433	chr2:219375711	G/C	cg02176678	chr2:219576539	TTLL4	-0.73	-7.24	-0.6	1.18e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4363385	0.693	rs440598	chr1:153044733	T/C	cg13444842	chr1:152974279	SPRR3	-0.61	-5.01	-0.46	2.46e-6	Inflammatory skin disease;
THYM	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.71	5.46	0.49	3.74e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs916888	0.647	rs199520	chr17:44853872	G/A	cg17911788	chr17:44343683	NA	0.49	4.72	0.44	8e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg23205692	chr1:25664452	TMEM50A	0.83	6.58	0.56	2.53e-9	Erythrocyte sedimentation rate;
THYM	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg00376283	chr12:123451042	ABCB9	0.79	6.23	0.54	1.28e-8	Platelet count;
THYM	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg08859206	chr1:53392774	SCP2	-0.61	-6.77	-0.57	1.05e-9	Monocyte count;
THYM	cis	rs1696756	0.638	rs1290396	chr17:77830767	C/T	cg00646381	chr17:77835854	NA	0.47	5.37	0.48	5.53e-7	Glucocorticoid-induced osteonecrosis (age 10 years and older);
THYM	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg23428387	chr22:49814324	NA	-0.53	-4.98	-0.45	2.88e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs34421088	0.678	rs35726503	chr8:11591916	A/T	cg12395012	chr8:11607386	GATA4	0.57	4.97	0.45	3.01e-6	Neuroticism;
THYM	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg06481639	chr22:41940642	POLR3H	-0.84	-5.85	-0.51	6.94e-8	Vitiligo;
THYM	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg06917634	chr15:78832804	PSMA4	0.96	8.76	0.67	7.4e-14	Sudden cardiac arrest;
THYM	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg01069141	chr11:67398826	TBX10;NUDT8	0.49	5.34	0.48	6.25e-7	Mean corpuscular volume;
THYM	cis	rs11039798	0.588	rs10160381	chr11:48599491	A/G	cg24672777	chr11:48374446	OR4C45	-0.93	-6.01	-0.52	3.39e-8	Axial length;
THYM	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs921665	0.831	rs11690724	chr2:3188333	T/G	cg16434511	chr2:3151078	NA	-0.84	-5.24	-0.47	9.7e-7	World class endurance athleticism;
THYM	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.46	-0.49	3.77e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3087591	0.922	rs2952994	chr17:29422861	A/T	cg24425628	chr17:29625626	OMG;NF1	0.72	6.1	0.53	2.26e-8	Hip circumference;
THYM	cis	rs9549260	0.753	rs9532562	chr13:41153585	A/G	cg21288729	chr13:41239152	FOXO1	0.68	4.81	0.44	5.77e-6	Red blood cell count;
THYM	cis	rs883565	0.655	rs6599275	chr3:39050758	C/A	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	5.0	0.46	2.59e-6	Handedness;
THYM	cis	rs3772130	0.545	rs7340674	chr3:121574215	T/C	cg20356878	chr3:121714668	ILDR1	0.73	6.49	0.55	3.8e-9	Cognitive performance;
THYM	cis	rs1728785	1.000	rs1728785	chr16:68591230	G/T	cg02972257	chr16:68554789	NA	0.77	4.9	0.45	3.98e-6	Ulcerative colitis;
THYM	cis	rs6754311	0.597	rs2082729	chr2:136550109	C/T	cg23851026	chr2:136556271	LCT	-0.57	-5.98	-0.52	3.84e-8	Mosquito bite size;
THYM	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg06453172	chr10:134556979	INPP5A	-0.67	-4.84	-0.44	5.1e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg04267008	chr7:1944627	MAD1L1	-0.61	-4.94	-0.45	3.29e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg27129171	chr3:47204927	SETD2	-0.78	-7.49	-0.61	3.57e-11	Colorectal cancer;
THYM	cis	rs9807841	0.670	rs2738042	chr19:10790143	C/G	cg17848348	chr19:10766748	ILF3	-0.87	-7.74	-0.62	1.06e-11	Inflammatory skin disease;
THYM	cis	rs4731207	0.596	rs1031956	chr7:124627183	G/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs490234	0.841	rs10114882	chr9:128303425	T/C	cg14078157	chr9:128172775	NA	-0.63	-4.88	-0.45	4.3e-6	Mean arterial pressure;
THYM	cis	rs652260	1.000	rs590394	chr19:7902505	C/T	cg15974673	chr19:7926970	EVI5L	-0.55	-5.08	-0.46	1.88e-6	Menarche (age at onset);
THYM	trans	rs10487112	0.625	rs714498	chr7:90167839	A/T	cg20714059	chr3:170214166	SLC7A14	-0.69	-7.05	-0.59	2.92e-10	Perceived unattractiveness to mosquitoes;
THYM	cis	rs89107	0.576	rs12661338	chr6:118794690	C/A	cg21191810	chr6:118973309	C6orf204	0.5	5.02	0.46	2.46e-6	Cardiac structure and function;
THYM	cis	rs7523273	0.565	rs2761420	chr1:207889368	G/T	cg22525895	chr1:207977042	MIR29B2	-0.54	-5.12	-0.46	1.62e-6	Schizophrenia;
THYM	cis	rs7524258	0.901	rs11120884	chr1:7305361	C/A	cg07173049	chr1:7289937	CAMTA1	0.7	5.7	0.51	1.32e-7	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs6032067	0.929	rs35880287	chr20:43821001	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.73	-8.04	-0.64	2.47e-12	Blood protein levels;
THYM	cis	rs2945412	0.669	rs17778144	chr17:25849803	C/T	cg07487925	chr17:25620950	WSB1	-0.65	-4.68	-0.43	9.56e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg13147721	chr7:65941812	NA	0.73	4.58	0.43	1.42e-5	Diabetic kidney disease;
THYM	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg15744005	chr10:104629667	AS3MT	-0.8	-7.57	-0.61	2.4e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg06481639	chr22:41940642	POLR3H	0.76	5.25	0.47	9.34e-7	Vitiligo;
THYM	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	4.96	0.45	3.09e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg13699009	chr12:122356056	WDR66	0.53	5.66	0.5	1.63e-7	Mean corpuscular volume;
THYM	cis	rs6032067	0.636	rs7272597	chr20:43908869	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.65	-6.06	-0.53	2.76e-8	Blood protein levels;
THYM	cis	rs17443541	0.507	rs4675699	chr2:200451389	A/C	cg03741458	chr2:200468445	NA	-0.8	-5.86	-0.52	6.75e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg18105134	chr13:113819100	PROZ	-0.98	-9.11	-0.68	1.32e-14	Platelet distribution width;
THYM	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg11245990	chr11:68621969	NA	0.57	7.46	0.61	4.06e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6087990	0.865	rs6058859	chr20:31335157	A/G	cg13636640	chr20:31349939	DNMT3B	0.9	8.97	0.68	2.62e-14	Ulcerative colitis;
THYM	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	5.57	0.5	2.41e-7	Obesity-related traits;
THYM	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.1	-0.53	2.24e-8	Crohn's disease;
THYM	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg25036284	chr2:26402008	FAM59B	-0.74	-4.87	-0.45	4.39e-6	Gut microbiome composition (summer);
THYM	cis	rs1048238	0.506	rs848195	chr1:16286522	A/G	cg22431228	chr1:16359049	CLCNKA	0.43	4.62	0.43	1.21e-5	Systolic blood pressure;
THYM	cis	rs2463822	1.000	rs2513076	chr11:62103711	A/G	cg06239285	chr11:62104954	ASRGL1	1.44	7.77	0.62	9.14e-12	Chronic obstructive pulmonary disease-related biomarkers;
THYM	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg03929089	chr4:120376271	NA	-0.95	-11.06	-0.75	9.07e-19	Coronary artery disease;
THYM	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg24060327	chr5:131705240	SLC22A5	-0.76	-5.73	-0.51	1.16e-7	Blood metabolite levels;
THYM	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg07936489	chr17:37558343	FBXL20	0.82	5.61	0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg08975724	chr8:8085496	FLJ10661	0.73	5.76	0.51	1.05e-7	Mood instability;
THYM	cis	rs7027203	0.521	rs9299412	chr9:96523268	G/T	cg14598338	chr9:96623480	NA	-0.4	-4.45	-0.42	2.35e-5	DNA methylation (variation);
THYM	cis	rs7909074	0.966	rs4948645	chr10:45391481	A/G	cg04218760	chr10:45406644	TMEM72	-0.59	-5.24	-0.47	9.81e-7	Mean corpuscular volume;
THYM	cis	rs6430585	0.941	rs60963894	chr2:136539670	T/G	cg04750100	chr2:136595281	LCT	0.53	5.13	0.47	1.55e-6	Corneal structure;
THYM	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg07075026	chr17:47091521	IGF2BP1	-0.56	-5.99	-0.52	3.79e-8	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs2933343	0.729	rs789231	chr3:128602847	A/G	cg11901034	chr3:128598214	ACAD9	-0.71	-5.55	-0.49	2.56e-7	IgG glycosylation;
THYM	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs8077889	0.703	rs231532	chr17:41945769	C/T	cg26893861	chr17:41843967	DUSP3	-0.67	-5.04	-0.46	2.25e-6	Triglycerides;
THYM	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.11	8.06	0.64	2.21e-12	Cognitive test performance;
THYM	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg07061783	chr6:25882402	NA	0.56	4.54	0.42	1.65e-5	Blood metabolite levels;
THYM	trans	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg07393940	chr7:158741817	NA	-1.14	-9.25	-0.69	6.69e-15	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs889398	0.967	rs244415	chr16:69666683	C/T	cg09409435	chr16:70099608	PDXDC2	-0.63	-4.92	-0.45	3.64e-6	Body mass index;
THYM	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs9359856	0.623	rs1179907	chr6:90324849	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.77	-7.5	-0.61	3.36e-11	Bipolar disorder;
THYM	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06873352	chr17:61820015	STRADA	0.56	5.42	0.49	4.45e-7	Height;
THYM	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg16586182	chr3:47516702	SCAP	0.67	5.62	0.5	1.9e-7	Colorectal cancer;
THYM	cis	rs78707713	0.560	rs2394563	chr10:71238618	G/A	cg08851181	chr10:71228077	TSPAN15	-0.8	-5.95	-0.52	4.46e-8	Venous thromboembolism;
THYM	cis	rs6763768	0.668	rs312475	chr3:53513354	A/G	cg05923681	chr3:52580707	PBRM1	0.67	4.45	0.42	2.33e-5	Bacterial meningitis;
THYM	cis	rs2658782	0.593	rs2243410	chr11:93255519	T/G	cg15737290	chr11:93063684	CCDC67	0.97	7.14	0.59	1.87e-10	Pulmonary function decline;
THYM	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg26874164	chr19:58962979	ZNF324B	0.64	4.7	0.43	8.64e-6	Mean platelet volume;
THYM	cis	rs59112743	0.510	rs2743549	chr6:15583189	T/C	cg10111214	chr6:14815676	NA	0.74	4.84	0.44	5.08e-6	Multiple keratinocyte cancers;
THYM	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg12963246	chr6:28129442	ZNF389	-0.81	-7.09	-0.59	2.34e-10	Depression;
THYM	cis	rs2041895	0.509	rs10861676	chr12:107311235	G/A	cg13944111	chr12:107296891	NA	0.63	5.02	0.46	2.42e-6	Glaucoma (low intraocular pressure);
THYM	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.66	5.23	0.47	9.9e-7	Tonsillectomy;
THYM	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg18252515	chr7:66147081	NA	0.63	4.68	0.43	9.36e-6	Aortic root size;
THYM	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.8e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2976388	1.000	rs2920283	chr8:143757037	T/C	cg13446199	chr8:143762866	PSCA	0.49	5.95	0.52	4.41e-8	Urinary tract infection frequency;
THYM	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.16	-0.75	5.56e-19	Primary sclerosing cholangitis;
THYM	cis	rs293526	0.959	rs2783166	chr6:83645883	A/G	cg23278060	chr6:83777448	DOPEY1	0.62	4.65	0.43	1.07e-5	Crohn's disease;
THYM	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg16989719	chr2:238392110	NA	-0.61	-6.03	-0.53	3.18e-8	Prostate cancer;
THYM	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs9649213	0.614	rs10953254	chr7:97914305	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.7	-5.52	-0.49	2.96e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg02018176	chr4:1364513	KIAA1530	0.98	9.59	0.7	1.26e-15	Longevity;
THYM	cis	rs611744	0.806	rs2440387	chr8:109067078	A/G	cg21045802	chr8:109455806	TTC35	0.64	5.63	0.5	1.83e-7	Dupuytren's disease;
THYM	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg23815491	chr16:72088622	HP	0.84	6.94	0.58	4.78e-10	Fibrinogen levels;
THYM	cis	rs11809207	0.574	rs2783633	chr1:26505265	A/G	cg23602478	chr1:26503979	CNKSR1	0.36	4.97	0.45	2.96e-6	Height;
THYM	cis	rs909002	0.849	rs6663012	chr1:32091779	T/G	cg13919466	chr1:32135498	COL16A1	-0.49	-4.73	-0.44	7.75e-6	Intelligence (multi-trait analysis);
THYM	cis	rs60695258	0.517	rs867196	chr4:87971600	G/C	cg10685359	chr4:87814065	C4orf36	-0.46	-5.76	-0.51	1.04e-7	Hematocrit;
THYM	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.38	0.48	5.3e-7	Tonsillectomy;
THYM	cis	rs912057	0.671	rs1294428	chr6:6744623	A/G	cg06612196	chr6:6737390	NA	0.71	11.9	0.77	1.57e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs1371867	0.875	rs28595052	chr8:101327553	G/A	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs863345	0.604	rs7549581	chr1:158489704	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs6665290	0.901	rs61834005	chr1:227202789	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.05	-0.85	8.4e-29	Myeloid white cell count;
THYM	cis	rs4911259	0.552	rs13037833	chr20:31459562	C/T	cg13636640	chr20:31349939	DNMT3B	-0.61	-5.9	-0.52	5.6e-8	Inflammatory bowel disease;
THYM	cis	rs2012796	0.661	rs59969857	chr14:81841579	A/G	cg02996355	chr14:81879375	NA	0.83	6.38	0.55	6.55e-9	Night sleep phenotypes;
THYM	cis	rs1371867	0.875	rs1660320	chr8:101337579	A/C	cg00191853	chr8:101177733	SPAG1	-0.51	-5.08	-0.46	1.85e-6	Atrioventricular conduction;
THYM	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg09877947	chr5:131593287	PDLIM4	0.7	6.33	0.54	7.92e-9	Acylcarnitine levels;
THYM	cis	rs7584330	0.518	rs13420503	chr2:238437623	G/A	cg08992911	chr2:238395768	MLPH	0.89	5.81	0.51	8.24e-8	Prostate cancer;
THYM	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg03709012	chr19:19516395	GATAD2A	0.74	5.71	0.51	1.31e-7	Tonsillectomy;
THYM	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg09034736	chr1:150693464	HORMAD1	0.51	4.49	0.42	1.98e-5	Tonsillectomy;
THYM	cis	rs9972944	0.783	rs9972942	chr17:63771007	A/G	cg07283582	chr17:63770753	CCDC46	0.67	5.14	0.47	1.47e-6	Total body bone mineral density;
THYM	cis	rs9807841	0.500	rs1368459	chr19:10835338	C/G	cg16900796	chr19:10755136	SLC44A2	0.28	4.51	0.42	1.83e-5	Inflammatory skin disease;
THYM	cis	rs765787	0.530	rs12592055	chr15:45514477	C/T	cg24006582	chr15:45444508	DUOX1	0.81	6.32	0.54	8.51e-9	Uric acid levels;
THYM	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg15557168	chr22:42548783	NA	-0.59	-4.52	-0.42	1.8e-5	Schizophrenia;
THYM	cis	rs477895	0.713	rs7944061	chr11:63956839	A/T	cg04317338	chr11:64019027	PLCB3	0.88	6.16	0.53	1.76e-8	Mean platelet volume;
THYM	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg10360139	chr7:1886902	MAD1L1	-0.61	-5.4	-0.48	4.86e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg00271210	chr6:167070053	RPS6KA2	0.69	7.42	0.61	4.85e-11	Crohn's disease;
THYM	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg15448220	chr1:150897856	SETDB1	-0.87	-7.15	-0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg06532163	chr17:45867833	NA	0.65	6.58	0.56	2.6e-9	IgG glycosylation;
THYM	cis	rs371025208	1	rs371025208	chr20:43928602	TGGGTGTGTGTGTGTAGGG/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.61	-6.14	-0.53	1.94e-8	Parental longevity (mother's age at death);
THYM	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg18252515	chr7:66147081	NA	1.48	8.83	0.67	5.15e-14	Diabetic kidney disease;
THYM	cis	rs12530845	1.000	rs4291212	chr7:135335465	C/T	cg23117316	chr7:135346802	PL-5283	-0.66	-5.88	-0.52	6.21e-8	Red blood cell traits;
THYM	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg18477163	chr1:228402036	OBSCN	-0.46	-4.88	-0.45	4.25e-6	Diastolic blood pressure;
THYM	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs4654899	0.802	rs12123910	chr1:21233316	C/T	cg01072550	chr1:21505969	NA	-0.69	-6.04	-0.53	3.04e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs17511627	0.808	rs9512139	chr13:26743606	C/A	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs76878669	0.561	rs4930177	chr11:66120784	T/C	cg18002602	chr11:66138449	SLC29A2	0.49	4.98	0.45	2.86e-6	Educational attainment (years of education);
THYM	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg17054759	chr22:49844102	NA	-0.5	-5.14	-0.47	1.44e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg07884673	chr3:53033167	SFMBT1	1.13	5.83	0.51	7.45e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs11696501	0.688	rs6073842	chr20:44293841	G/C	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg09307838	chr4:120376055	NA	0.6	4.54	0.42	1.63e-5	Corneal astigmatism;
THYM	cis	rs4919687	0.550	rs12784517	chr10:104464970	T/C	cg04362960	chr10:104952993	NT5C2	0.61	4.89	0.45	4.08e-6	Colorectal cancer;
THYM	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs4650994	0.544	rs4132058	chr1:178505557	A/C	cg05059571	chr16:84539110	KIAA1609	-0.86	-9.99	-0.72	1.74e-16	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg23711669	chr6:146136114	FBXO30	0.88	8.52	0.66	2.41e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs919433	0.680	rs1563340	chr2:198414713	A/T	cg05783139	chr2:198650985	BOLL	0.64	4.93	0.45	3.54e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs3771570	0.792	rs4675970	chr2:242200406	G/A	cg21155796	chr2:242212141	HDLBP	1.09	6.4	0.55	5.95e-9	Prostate cancer;
THYM	cis	rs6032067	0.641	rs74174934	chr20:43761331	T/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.73	-7.71	-0.62	1.23e-11	Blood protein levels;
THYM	cis	rs28595532	1.000	rs114682099	chr4:119702004	C/T	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.78	-5.8	-0.51	8.48e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2080501	0.571	rs1861657	chr16:49675807	G/T	cg05126388	chr16:49670144	ZNF423	0.85	11.04	0.75	9.91e-19	IgG glycosylation;
THYM	cis	rs7100689	0.577	rs10749560	chr10:82092801	G/T	cg01528321	chr10:82214614	TSPAN14	0.84	6.43	0.55	5.15e-9	Post bronchodilator FEV1;
THYM	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg12908607	chr1:44402522	ARTN	-0.56	-4.88	-0.45	4.26e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg13319975	chr6:146136371	FBXO30	-0.72	-6.02	-0.53	3.33e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8063160	0.688	rs12924124	chr16:89791126	C/T	cg27050730	chr16:88968896	CBFA2T3	0.96	4.45	0.42	2.33e-5	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg24642844	chr7:1081250	C7orf50	-1.18	-7.63	-0.62	1.76e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2637266	1.000	rs2395384	chr10:78335329	G/A	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg24250549	chr1:154909240	PMVK	0.75	6.45	0.55	4.66e-9	Prostate cancer;
THYM	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg18230493	chr5:56204884	C5orf35	0.59	4.58	0.43	1.39e-5	Initial pursuit acceleration;
THYM	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg22105103	chr4:187893119	NA	-0.93	-9.27	-0.69	5.88e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8180040	0.800	rs62248905	chr3:47274082	A/G	cg12976108	chr3:47324180	KIF9;KLHL18	0.5	4.5	0.42	1.92e-5	Colorectal cancer;
THYM	cis	rs11690935	0.589	rs62183782	chr2:172865009	T/A	cg13550731	chr2:172543902	DYNC1I2	0.59	4.63	0.43	1.15e-5	Schizophrenia;
THYM	cis	rs1957429	0.808	rs1467573	chr14:65347583	T/C	cg23373153	chr14:65346875	NA	1.07	6.45	0.55	4.75e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs6121246	0.559	rs6060932	chr20:30350545	A/G	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs7586879	0.639	rs6749170	chr2:25110962	A/G	cg01884057	chr2:25150051	NA	0.72	7.81	0.63	7.61e-12	Body mass index;
THYM	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg03433033	chr1:76189801	ACADM	0.79	11.21	0.75	4.52e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs17739794	0.517	rs6982473	chr8:773986	G/T	cg07178994	chr8:816998	NA	-0.77	-7.3	-0.6	8.77e-11	Clozapine-induced cytotoxicity;
THYM	cis	rs7607369	0.648	rs7559629	chr2:219657013	A/T	cg02176678	chr2:219576539	TTLL4	-0.6	-5.51	-0.49	3.11e-7	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19346786	chr7:2764209	NA	-0.78	-6.96	-0.58	4.45e-10	Height;
THYM	cis	rs9527	0.567	rs11191573	chr10:104896816	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs2658782	0.951	rs72972357	chr11:93118840	T/C	cg15737290	chr11:93063684	CCDC67	-0.98	-7.67	-0.62	1.51e-11	Pulmonary function decline;
THYM	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg04414720	chr1:150670196	GOLPH3L	0.62	4.58	0.43	1.41e-5	Tonsillectomy;
THYM	cis	rs55728055	0.661	rs55673702	chr22:32035518	G/A	cg01338084	chr22:32026380	PISD	1.32	6.78	0.57	1e-9	Age-related hearing impairment;
THYM	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-15.39	-0.84	1.51e-27	Height;
THYM	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg13395646	chr4:1353034	KIAA1530	-0.71	-6.45	-0.55	4.71e-9	Obesity-related traits;
THYM	cis	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg14019146	chr3:50243930	SLC38A3	-0.65	-5.52	-0.49	2.94e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs986417	0.551	rs4901991	chr14:61065025	T/C	cg27398547	chr14:60952738	C14orf39	1.3	6.11	0.53	2.15e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs12701220	0.842	rs10236293	chr7:1032637	G/A	cg00990874	chr7:1149470	C7orf50	-0.67	-4.78	-0.44	6.5e-6	Bronchopulmonary dysplasia;
THYM	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg16230307	chr14:35515116	FAM177A1	0.83	5.31	0.48	7.33e-7	Psoriasis;
THYM	cis	rs977987	0.645	rs34904236	chr16:75498253	G/T	cg03315344	chr16:75512273	CHST6	0.68	5.58	0.5	2.31e-7	Dupuytren's disease;
THYM	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs1697139	0.583	rs6895853	chr5:66541427	T/C	cg11553311	chr5:66541588	NA	0.72	7.71	0.62	1.21e-11	Breast cancer;
THYM	cis	rs4589258	0.966	rs1783803	chr11:90452370	T/A	cg26138821	chr11:89956704	CHORDC1	-0.69	-5.55	-0.49	2.57e-7	Intelligence (multi-trait analysis);
THYM	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg07870213	chr5:140052090	DND1	-0.69	-8.1	-0.64	1.86e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs994014	0.847	rs11732408	chr4:82273827	A/T	cg17825130	chr4:82283507	NA	0.46	4.47	0.42	2.16e-5	Height;
THYM	cis	rs728616	0.702	rs78734698	chr10:81756449	G/A	cg27452691	chr10:81370291	SFTPA1	0.84	4.54	0.42	1.68e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg13385794	chr1:248469461	NA	0.67	4.61	0.43	1.24e-5	Common traits (Other);
THYM	cis	rs7267979	0.816	rs6115094	chr20:25210827	A/G	cg03522245	chr20:25566470	NINL	0.66	4.98	0.45	2.89e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg15445000	chr17:37608096	MED1	-0.42	-5.07	-0.46	1.93e-6	Glomerular filtration rate (creatinine);
THYM	trans	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg06112835	chr11:68658793	MRPL21	0.45	6.44	0.55	4.77e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg12179176	chr11:130786555	SNX19	0.82	7.66	0.62	1.59e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4919687	0.550	rs10437480	chr10:104453024	C/G	cg05855489	chr10:104503620	C10orf26	0.64	5.01	0.46	2.56e-6	Colorectal cancer;
THYM	cis	rs6138458	1.000	rs227629	chr20:24913551	G/T	cg06937882	chr20:24974362	C20orf3	-0.47	-4.54	-0.42	1.66e-5	Blood protein levels;
THYM	cis	rs4979906	1.000	rs11002244	chr10:79446207	T/C	cg07817648	chr10:79422355	NA	-0.76	-5.58	-0.5	2.26e-7	Mortality in heart failure;
THYM	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg08968635	chr6:28129556	ZNF389	0.57	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg07936489	chr17:37558343	FBXL20	0.79	5.7	0.5	1.37e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs4631830	0.832	rs1585378	chr10:51523213	A/T	cg10326726	chr10:51549505	MSMB	-0.6	-6.03	-0.53	3.13e-8	Prostate-specific antigen levels;
THYM	cis	rs6500395	0.962	rs9972682	chr16:48686644	T/G	cg04672837	chr16:48644449	N4BP1	0.48	4.65	0.43	1.06e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7953249	0.656	rs2178463	chr12:121389721	A/G	cg02403541	chr12:121454288	C12orf43	-0.72	-6.68	-0.57	1.63e-9	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs4732038	0.510	rs12673257	chr7:134278732	C/A	cg06906464	chr7:134288099	NA	-0.56	-5.49	-0.49	3.31e-7	Longevity;
THYM	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg26384229	chr12:38710491	ALG10B	-0.72	-6.0	-0.52	3.63e-8	Morning vs. evening chronotype;
THYM	cis	rs4268898	0.571	rs1986478	chr2:24468545	G/A	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	trans	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg05926928	chr17:57297772	GDPD1	1.26	10.02	0.72	1.5e-16	Opioid sensitivity;
THYM	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg14019146	chr3:50243930	SLC38A3	0.83	7.13	0.59	1.92e-10	Intelligence (multi-trait analysis);
THYM	cis	rs1629083	0.967	rs1104542	chr11:118129340	C/T	cg25155064	chr11:118100782	MPZL3	-0.57	-5.03	-0.46	2.33e-6	Lung cancer;
THYM	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg16329650	chr2:213403929	ERBB4	0.99	11.32	0.76	2.57e-19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg00852783	chr1:26633632	UBXN11	0.86	8.81	0.67	5.74e-14	Obesity-related traits;
THYM	cis	rs11048434	0.698	rs7300767	chr12:9123477	T/G	cg13575925	chr12:9217583	LOC144571	0.51	4.86	0.45	4.61e-6	Sjögren's syndrome;
THYM	cis	rs12540874	0.663	rs1451371	chr7:50553051	T/C	cg18232548	chr7:50535776	DDC	-0.9	-8.59	-0.66	1.73e-13	Systemic sclerosis;
THYM	cis	rs9290065	0.519	rs6763532	chr3:160701816	G/A	cg03342759	chr3:160939853	NMD3	-0.59	-4.56	-0.42	1.52e-5	Kawasaki disease;
THYM	cis	rs4970988	0.640	rs7524734	chr1:150655686	C/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Urate levels;
THYM	cis	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg24375607	chr4:120327624	NA	0.64	5.09	0.46	1.82e-6	Corneal astigmatism;
THYM	cis	rs2072732	0.768	rs12045368	chr1:2960192	A/G	cg08733933	chr1:2954429	NA	-0.65	-4.67	-0.43	9.8e-6	Plateletcrit;
THYM	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg03213289	chr20:61660250	NA	0.82	7.01	0.58	3.43e-10	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs16857609	0.564	rs12624106	chr2:218290445	A/G	cg15335768	chr2:218268053	DIRC3	-0.52	-7.45	-0.61	4.22e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	cis	rs7178572	0.633	rs907369	chr15:77843560	A/G	cg22256960	chr15:77711686	NA	-0.77	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg21784768	chr11:537496	LRRC56	-1.16	-5.78	-0.51	9.66e-8	Body mass index;
THYM	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg00631329	chr6:26305371	NA	-0.44	-4.9	-0.45	3.94e-6	Educational attainment;
THYM	cis	rs7943203	0.568	rs170548	chr11:108234836	A/C	cg04873221	chr11:107992290	ACAT1	-0.7	-4.65	-0.43	1.08e-5	Red blood cell count;Mean corpuscular volume;
THYM	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg00071950	chr4:10020882	SLC2A9	-0.66	-5.9	-0.52	5.59e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg22920501	chr2:26401640	FAM59B	-1.05	-9.24	-0.69	6.92e-15	Gut microbiome composition (summer);
THYM	cis	rs2334880	0.836	rs9939458	chr16:71667131	T/G	cg06353428	chr16:71660113	MARVELD3	1.36	9.32	0.69	4.74e-15	Malaria;
THYM	cis	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg06521331	chr12:34319734	NA	-0.96	-8.88	-0.67	4.06e-14	Morning vs. evening chronotype;
THYM	cis	rs11249608	0.590	rs36051170	chr5:178447971	T/C	cg01312482	chr5:178451176	ZNF879	-0.65	-5.0	-0.46	2.67e-6	Pubertal anthropometrics;
THYM	cis	rs7089973	0.836	rs1966384	chr10:116627910	G/T	cg23260525	chr10:116636907	FAM160B1	0.53	4.73	0.44	7.73e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs2898681	0.519	rs6554057	chr4:53730147	A/T	cg21521518	chr4:53727714	RASL11B	0.49	4.51	0.42	1.82e-5	Optic nerve measurement (cup area);
THYM	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg19626725	chr5:178986131	RUFY1	-0.31	-4.94	-0.45	3.36e-6	Lung cancer;
THYM	cis	rs11031096	0.678	rs11031219	chr11:4197578	G/A	cg08557956	chr11:4115526	RRM1	-0.59	-5.44	-0.49	4.19e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs736801	0.729	rs1050152	chr5:131676320	C/T	cg18758796	chr5:131593413	PDLIM4	0.51	4.6	0.43	1.32e-5	Breast cancer;Mosquito bite size;
THYM	cis	rs6598955	0.671	rs12090258	chr1:26644698	C/T	cg20415053	chr1:26527928	CATSPER4	-0.58	-4.71	-0.43	8.58e-6	Obesity-related traits;
THYM	cis	rs427394	0.802	rs274692	chr5:6734625	C/T	cg10857441	chr5:6722123	POLS	-0.72	-8.87	-0.67	4.28e-14	Menopause (age at onset);
THYM	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.85	-7.01	-0.58	3.42e-10	Systemic lupus erythematosus;
THYM	cis	rs11651000	0.894	rs72831632	chr17:45805177	C/T	cg24803719	chr17:45855879	NA	-0.66	-5.44	-0.49	4.06e-7	IgG glycosylation;
THYM	cis	rs8106542	0.906	rs8110055	chr19:10739143	A/C	cg17848348	chr19:10766748	ILF3	-0.82	-6.86	-0.58	6.85e-10	Platelet distribution width;
THYM	cis	rs6586163	0.509	rs2031610	chr10:90754487	T/C	cg03111039	chr10:90751583	FAS;ACTA2	0.55	5.27	0.48	8.52e-7	Chronic lymphocytic leukemia;
THYM	cis	rs10095849	0.576	rs10090933	chr8:39441745	T/C	cg22755526	chr8:38854673	TM2D2;ADAM9	-0.64	-4.74	-0.44	7.57e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg19346786	chr7:2764209	NA	0.71	6.01	0.53	3.36e-8	Height;
THYM	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	5.92	0.52	5.12e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.31	4.72	0.44	8.22e-6	Obesity-related traits;
THYM	cis	rs7617773	0.780	rs77044321	chr3:48349314	C/T	cg02219026	chr3:48282209	ZNF589	-0.64	-4.54	-0.42	1.62e-5	Coronary artery disease;
THYM	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg26384229	chr12:38710491	ALG10B	0.99	7.62	0.62	1.85e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7586879	0.828	rs1865688	chr2:25108245	C/G	cg01884057	chr2:25150051	NA	0.52	4.64	0.43	1.1e-5	Body mass index;
THYM	cis	rs73198271	0.740	rs10100066	chr8:8650393	T/G	cg15556689	chr8:8085844	FLJ10661	-0.74	-4.91	-0.45	3.75e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4788570	0.538	rs16973286	chr16:71552257	C/A	cg06353428	chr16:71660113	MARVELD3	-1.02	-5.08	-0.46	1.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs115446044	chr4:119754635	T/C	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs12257961	0.646	rs10752363	chr10:15349264	C/T	cg10616319	chr10:15468812	NA	-0.64	-5.19	-0.47	1.18e-6	Selective IgA deficiency;
THYM	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg20119798	chr7:94954144	PON1	0.56	4.85	0.45	4.78e-6	Paraoxonase activity;
THYM	cis	rs11225247	1.000	rs75493121	chr11:102269132	T/C	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg22974920	chr21:40686053	BRWD1	-0.63	-4.97	-0.45	2.98e-6	Cognitive function;
THYM	cis	rs7772486	0.754	rs4566902	chr6:146244128	A/G	cg13319975	chr6:146136371	FBXO30	0.73	6.11	0.53	2.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg15838173	chr10:75533400	FUT11	-0.5	-5.09	-0.46	1.82e-6	Inflammatory bowel disease;
THYM	cis	rs55728055	0.661	rs61561528	chr22:31983071	A/G	cg01338084	chr22:32026380	PISD	1.36	5.56	0.5	2.44e-7	Age-related hearing impairment;
THYM	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg18876405	chr7:65276391	NA	0.54	4.86	0.45	4.66e-6	Calcium levels;
THYM	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs1050631	0.564	rs589213	chr18:33743610	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.64	4.95	0.45	3.23e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs951188	0.688	rs4600614	chr2:150454000	C/T	cg17961725	chr2:150454027	NA	-1.02	-5.39	-0.48	5.12e-7	Daytime sleep phenotypes;
THYM	cis	rs289828	0.579	rs6713190	chr2:152159459	T/C	cg05960677	chr2:152117363	RBM43	0.69	6.43	0.55	5.12e-9	Blood protein levels;
THYM	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg22764044	chr5:178986830	RUFY1	0.62	6.18	0.54	1.58e-8	Lung cancer;
THYM	cis	rs995000	0.899	rs1168099	chr1:63122859	C/A	cg06896770	chr1:63153194	DOCK7	-0.92	-7.54	-0.61	2.71e-11	Triglyceride levels;
THYM	cis	rs7177699	0.557	rs4073322	chr15:79122541	G/C	cg00540400	chr15:79124168	NA	0.64	6.96	0.58	4.33e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9324022	0.929	rs17099617	chr14:101170488	A/G	cg18089426	chr14:101175970	NA	0.78	5.26	0.48	8.77e-7	Plateletcrit;
THYM	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs2273669	0.504	rs58362207	chr6:109492837	T/C	cg17117243	chr6:109341365	SESN1	-0.82	-4.8	-0.44	5.98e-6	Prostate cancer;
THYM	cis	rs4731207	0.662	rs7782031	chr7:124505784	C/A	cg05285228	chr7:124571219	POT1	-0.66	-5.09	-0.46	1.83e-6	Cutaneous malignant melanoma;
THYM	cis	rs2552220	0.818	rs11778742	chr8:6013075	T/G	cg06481462	chr8:7005678	NA	0.47	4.97	0.45	3.02e-6	Interleukin-8 levels;
THYM	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg03433033	chr1:76189801	ACADM	0.77	9.42	0.69	2.92e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs11690935	0.959	rs1474074	chr2:172659852	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.78	-5.51	-0.49	3.01e-7	Schizophrenia;
THYM	cis	rs1728785	1.000	rs4783657	chr16:68586322	G/T	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs7681440	0.583	rs2737023	chr4:90739505	T/C	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs12911832	0.727	rs2604454	chr15:59098732	C/A	cg05156742	chr15:59063176	FAM63B	0.54	4.71	0.43	8.61e-6	Schizophrenia;
THYM	cis	rs4455778	0.579	rs4563839	chr7:49076344	T/A	cg26309511	chr7:48887640	NA	0.68	5.91	0.52	5.44e-8	Lung cancer in never smokers;
THYM	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg02734326	chr4:10020555	SLC2A9	0.61	4.98	0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg27129171	chr3:47204927	SETD2	0.8	7.91	0.63	4.58e-12	Colorectal cancer;
THYM	cis	rs854765	0.693	rs8079418	chr17:17924060	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	5.62	0.5	1.9e-7	Total body bone mineral density;
THYM	cis	rs3087591	0.919	rs2953004	chr17:29502723	C/T	cg24425628	chr17:29625626	OMG;NF1	0.69	5.47	0.49	3.62e-7	Hip circumference;
THYM	cis	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg24672777	chr11:48374446	OR4C45	-0.93	-5.95	-0.52	4.55e-8	Axial length;
THYM	cis	rs7264396	0.563	rs6058322	chr20:34367277	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.74	4.55	0.42	1.56e-5	Total cholesterol levels;
THYM	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg05043794	chr9:111880884	C9orf5	0.43	6.21	0.54	1.39e-8	Menarche (age at onset);
THYM	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg13609457	chr4:120235615	NA	0.53	4.93	0.45	3.5e-6	Corneal astigmatism;
THYM	cis	rs7572733	0.534	rs700685	chr2:198715972	A/G	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs4919044	0.808	rs860669	chr10:94796031	T/C	cg05127821	chr10:94822908	CYP26C1	-1.23	-6.66	-0.56	1.76e-9	Coronary artery disease;
THYM	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg27170947	chr2:26402098	FAM59B	-0.83	-6.78	-0.57	9.95e-10	Gut microbiome composition (summer);
THYM	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg14004847	chr7:1930337	MAD1L1	0.65	4.72	0.44	8.17e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4642101	0.597	rs12638595	chr3:12819281	T/C	cg05775895	chr3:12838266	CAND2	1.07	10.78	0.74	3.56e-18	QRS complex (12-leadsum);
THYM	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg18252515	chr7:66147081	NA	-1.61	-8.73	-0.67	8.74e-14	Diabetic kidney disease;
THYM	cis	rs995000	0.899	rs1184865	chr1:62973795	A/G	cg06896770	chr1:63153194	DOCK7	-0.91	-6.69	-0.57	1.55e-9	Triglyceride levels;
THYM	cis	rs28595532	0.920	rs10018977	chr4:119785229	C/T	cg11846333	chr4:119757529	SEC24D	1.38	5.03	0.46	2.27e-6	Cannabis dependence symptom count;
THYM	cis	rs454510	0.816	rs347904	chr1:120177620	C/T	cg11530693	chr1:120165357	ZNF697	0.71	4.95	0.45	3.22e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
THYM	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg24692254	chr21:30365293	RNF160	0.99	9.36	0.69	3.83e-15	Dental caries;
THYM	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg03264133	chr6:25882463	NA	-0.66	-4.49	-0.42	2.01e-5	Height;
THYM	cis	rs6495122	0.662	rs11632414	chr15:75061916	A/G	cg14664628	chr15:75095509	CSK	-0.8	-6.08	-0.53	2.53e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs887829	0.570	rs6753320	chr2:234595615	G/T	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	0.56	4.59	0.43	1.36e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.11	8.07	0.64	2.15e-12	Cognitive test performance;
THYM	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg03806693	chr22:41940476	POLR3H	-1.2	-10.58	-0.74	9.44e-18	Vitiligo;
THYM	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg22467129	chr15:76604101	ETFA	0.53	5.17	0.47	1.27e-6	Blood metabolite levels;
THYM	cis	rs7560272	0.682	rs2421546	chr2:73641077	A/C	cg19565262	chr2:73869966	NAT8	0.55	4.65	0.43	1.05e-5	Schizophrenia;
THYM	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs10484885	0.878	rs111664889	chr6:90566427	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.87	-7.73	-0.62	1.13e-11	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg17644776	chr2:200775616	C2orf69	0.9	7.45	0.61	4.33e-11	Osteoporosis;
THYM	cis	rs3767633	0.925	rs4657103	chr1:161740483	G/T	cg27495845	chr1:161693088	FCRLB	-0.52	-4.71	-0.44	8.42e-6	IgG glycosylation;
THYM	cis	rs7172809	0.573	rs11854182	chr15:77448977	T/C	cg22256960	chr15:77711686	NA	-0.64	-4.76	-0.44	6.83e-6	Glucose homeostasis traits;
THYM	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg07169764	chr2:136633963	MCM6	-0.67	-5.92	-0.52	5.11e-8	Mosquito bite size;
THYM	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg15052019	chr19:19431593	KIAA0892;SF4	-0.67	-5.38	-0.48	5.31e-7	Tonsillectomy;
THYM	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg26384229	chr12:38710491	ALG10B	0.94	8.07	0.64	2.1e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9649465	1.000	rs11770041	chr7:123365788	C/T	cg15443791	chr7:124364398	NA	0.6	4.97	0.45	3.01e-6	Migraine;
THYM	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg26597838	chr10:835615	NA	1.23	8.88	0.67	4.1e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs9875589	0.509	rs4047237	chr3:14012861	T/C	cg03204825	chr3:13978759	TPRXL	-0.51	-4.46	-0.42	2.26e-5	Ovarian reserve;
THYM	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.82	-4.55	-0.42	1.56e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg11502198	chr6:26597334	ABT1	0.65	5.82	0.51	7.88e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg11871910	chr12:69753446	YEATS4	1.01	9.87	0.71	3.09e-16	Cerebrospinal fluid biomarker levels;
THYM	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg05887092	chr17:76393375	PGS1	0.42	4.82	0.44	5.41e-6	HDL cholesterol;
THYM	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg21252483	chr19:49399788	TULP2	-0.96	-7.25	-0.6	1.09e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs804280	0.525	rs809204	chr8:11619163	A/G	cg12395012	chr8:11607386	GATA4	-0.64	-5.26	-0.47	9.01e-7	Myopia (pathological);
THYM	cis	rs896854	0.517	rs896851	chr8:95950251	T/C	cg16049864	chr8:95962084	TP53INP1	-0.79	-5.67	-0.5	1.52e-7	Type 2 diabetes;
THYM	cis	rs1971762	0.583	rs12810378	chr12:54091838	G/T	cg16917193	chr12:54089295	NA	0.91	8.8	0.67	6.07e-14	Height;
THYM	cis	rs6429082	0.749	rs3819974	chr1:235601958	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.67	-5.51	-0.49	3.04e-7	Adiposity;
THYM	cis	rs4919087	0.926	rs2861875	chr10:98990139	C/G	cg19453742	chr10:98862320	SLIT1	0.64	4.69	0.43	9.01e-6	Monocyte count;
THYM	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg20891558	chr2:74357851	NA	1.17	12.06	0.78	7.44e-21	Gestational age at birth (maternal effect);
THYM	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg02734326	chr4:10020555	SLC2A9	0.76	6.47	0.55	4.18e-9	Bone mineral density;
THYM	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.71	-4.92	-0.45	3.67e-6	Body mass index;
THYM	cis	rs4389656	0.857	rs274713	chr5:6723560	A/C	cg10857441	chr5:6722123	POLS	-0.45	-4.67	-0.43	1.01e-5	Coronary artery disease;
THYM	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg20966754	chr17:47091339	IGF2BP1	-0.54	-7.28	-0.6	9.49e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg16558253	chr16:72132732	DHX38	-0.64	-5.7	-0.51	1.32e-7	Fibrinogen levels;
THYM	cis	rs11190604	0.767	rs11190533	chr10:102190792	T/C	cg16342193	chr10:102329863	NA	-0.5	-5.17	-0.47	1.29e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg25319279	chr11:5960081	NA	-0.64	-5.64	-0.5	1.77e-7	DNA methylation (variation);
THYM	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg27398817	chr8:82754497	SNX16	-0.8	-6.37	-0.55	6.59e-9	Diastolic blood pressure;
THYM	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg12863693	chr15:85201151	NMB	0.65	5.67	0.5	1.56e-7	Schizophrenia;
THYM	cis	rs13315871	0.929	rs13322156	chr3:58287620	C/T	cg12435725	chr3:58293450	RPP14	-0.53	-5.57	-0.5	2.32e-7	Cholesterol, total;
THYM	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg25072359	chr17:41440525	NA	0.67	4.71	0.43	8.56e-6	Menopause (age at onset);
THYM	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-1.03	-10.71	-0.74	5.03e-18	Cognitive ability;
THYM	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg17554472	chr22:41940697	POLR3H	-0.63	-4.49	-0.42	1.99e-5	Vitiligo;
THYM	cis	rs11635868	0.702	rs351230	chr15:74482997	C/T	cg12001592	chr15:75316240	PPCDC	0.76	4.56	0.42	1.51e-5	Inhibitory control;
THYM	cis	rs6686842	1.000	rs6686842	chr1:41530871	C/T	cg03387723	chr1:41708464	SCMH1	-0.44	-5.28	-0.48	8.08e-7	Height;
THYM	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg09263875	chr16:632152	PIGQ	0.67	5.33	0.48	6.59e-7	Height;
THYM	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg10518543	chr12:38710700	ALG10B	-0.56	-4.51	-0.42	1.83e-5	Morning vs. evening chronotype;
THYM	cis	rs4662945	0.714	rs17578014	chr2:130191969	T/A	cg05903289	chr2:130345205	NA	-0.59	-5.67	-0.5	1.53e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg06784218	chr1:46089804	CCDC17	0.3	4.9	0.45	3.93e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7843479	0.601	rs1031882	chr8:21788934	T/G	cg17168535	chr8:21777572	XPO7	0.95	8.86	0.67	4.4e-14	Mean corpuscular volume;
THYM	cis	rs728616	0.867	rs723191	chr10:81707920	A/G	cg05935833	chr10:81318306	SFTPA2	-0.75	-4.98	-0.45	2.85e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg08807101	chr21:30365312	RNF160	-0.78	-5.36	-0.48	5.78e-7	Dental caries;
THYM	cis	rs6723226	0.572	rs176404	chr2:32638846	T/C	cg02381751	chr2:32503542	YIPF4	-0.58	-5.03	-0.46	2.34e-6	Intelligence (multi-trait analysis);
THYM	cis	rs526231	0.543	rs34785	chr5:102458103	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.49e-6	Primary biliary cholangitis;
THYM	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg08430604	chr3:44902960	MIR564;TMEM42	0.53	5.08	0.46	1.87e-6	Depressive symptoms;
THYM	cis	rs892961	0.806	rs312910	chr17:75413961	A/C	cg11351908	chr17:75402473	SEPT9	0.61	6.19	0.54	1.52e-8	Airflow obstruction;
THYM	cis	rs9810089	0.934	rs66691851	chr3:136154828	C/T	cg21827317	chr3:136751795	NA	0.57	4.87	0.45	4.42e-6	Gestational age at birth (child effect);
THYM	cis	rs7246967	0.673	rs16999580	chr19:22923487	C/T	cg05241461	chr19:22816980	ZNF492	0.59	4.61	0.43	1.26e-5	Bronchopulmonary dysplasia;
THYM	cis	rs17001868	0.568	rs9611325	chr22:40782490	G/A	cg07138101	chr22:40742427	ADSL	0.92	5.48	0.49	3.43e-7	Mammographic density (dense area);
THYM	cis	rs4363385	0.818	rs10788854	chr1:153002320	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg08999081	chr20:33150536	PIGU	-0.78	-7.16	-0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs262150	0.501	rs1017034	chr7:158820460	A/G	cg19418458	chr7:158789849	NA	-0.62	-5.83	-0.51	7.67e-8	Facial morphology (factor 20);
THYM	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs1823778	0.609	rs7244421	chr18:67685007	C/T	cg12929678	chr18:67624393	CD226	1.28	4.87	0.45	4.4e-6	Mean platelet volume;
THYM	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-5.55	-0.49	2.59e-7	Monocyte percentage of white cells;
THYM	cis	rs9534288	0.699	rs1409433	chr13:46655501	T/C	cg15192986	chr13:46630673	CPB2	-0.65	-4.57	-0.42	1.44e-5	Blood protein levels;
THYM	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg19645103	chr12:69753606	YEATS4	-0.56	-4.49	-0.42	1.97e-5	Response to diuretic therapy;
THYM	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	5.25	0.47	9.15e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2456568	0.803	rs10765642	chr11:93640355	C/T	cg26875233	chr11:93583750	C11orf90	0.54	5.78	0.51	9.51e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg06808227	chr14:105710500	BRF1	-0.99	-8.33	-0.65	6.16e-13	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6960043	0.738	rs4721400	chr7:15059906	G/A	cg19272540	chr7:15055459	NA	0.57	6.2	0.54	1.47e-8	Type 2 diabetes;
THYM	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs17598306	0.873	rs2189774	chr7:96605287	A/G	cg13449377	chr7:96631089	DLX6AS	0.76	4.78	0.44	6.38e-6	Radiation response;
THYM	cis	rs9457247	0.534	rs9355610	chr6:167383075	G/A	cg00271210	chr6:167070053	RPS6KA2	0.46	4.55	0.42	1.6e-5	Crohn's disease;
THYM	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg05182265	chr7:156933206	UBE3C	0.63	7.88	0.63	5.39e-12	Body mass index;
THYM	cis	rs2070677	1.000	rs743534	chr10:135349226	G/T	cg20169779	chr10:135381914	SYCE1	0.81	5.79	0.51	8.91e-8	Gout;
THYM	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg00071950	chr4:10020882	SLC2A9	0.71	6.46	0.55	4.52e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6754311	0.593	rs11679508	chr2:136474098	A/T	cg20242066	chr2:136595261	LCT	-0.54	-5.9	-0.52	5.63e-8	Mosquito bite size;
THYM	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.08	7.54	0.61	2.77e-11	Smoking behavior;
THYM	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs765787	0.530	rs12905246	chr15:45500841	C/T	cg25801113	chr15:45476975	SHF	-0.38	-4.52	-0.42	1.81e-5	Uric acid levels;
THYM	cis	rs829880	0.570	rs4488248	chr12:98853688	G/C	cg25150519	chr12:98850993	NA	0.7	6.24	0.54	1.24e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg08779649	chr13:50194554	NA	0.59	5.12	0.47	1.6e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg21361702	chr7:150065534	REPIN1	0.69	4.92	0.45	3.65e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs478304	0.593	rs7120713	chr11:65483374	G/C	cg17480646	chr11:65405466	SIPA1	-0.9	-8.19	-0.64	1.22e-12	Acne (severe);
THYM	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg10661904	chr17:79619235	PDE6G	-0.57	-5.3	-0.48	7.61e-7	Eye color traits;
THYM	cis	rs1387259	0.899	rs7307566	chr12:48604682	A/G	cg21466736	chr12:48725269	NA	-0.54	-4.88	-0.45	4.33e-6	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs1003719	0.762	rs3787787	chr21:38463452	T/C	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs9581943	0.967	rs8000004	chr13:28477590	A/G	cg16302790	chr13:28498334	PDX1	0.52	4.73	0.44	7.69e-6	Pancreatic cancer;
THYM	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs754466	0.606	rs11002310	chr10:79596030	A/C	cg17075019	chr10:79541650	NA	-0.72	-6.17	-0.53	1.65e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9399401	0.922	rs9496369	chr6:142724918	C/T	cg04461802	chr6:142623433	GPR126	0.44	4.51	0.42	1.86e-5	Chronic obstructive pulmonary disease;
THYM	cis	rs4732038	0.510	rs12669728	chr7:134272965	G/A	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs13064411	0.518	rs1471884	chr3:113212041	G/A	cg18753928	chr3:113234510	CCDC52	-0.78	-7.16	-0.59	1.68e-10	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg11279151	chr3:101281821	RG9MTD1	-0.85	-6.22	-0.54	1.32e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12216545	0.711	rs2090955	chr7:150235486	A/G	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg00684032	chr4:1343700	KIAA1530	0.54	4.67	0.43	9.81e-6	Obesity-related traits;
THYM	cis	rs4788570	0.585	rs7499576	chr16:71789553	T/G	cg06353428	chr16:71660113	MARVELD3	1.43	8.68	0.67	1.09e-13	Intelligence (multi-trait analysis);
THYM	cis	rs901683	1.000	rs17157898	chr10:46037209	C/G	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs61931739	0.817	rs304313	chr12:34216898	C/T	cg10856724	chr12:34555212	NA	-0.6	-5.51	-0.49	3e-7	Morning vs. evening chronotype;
THYM	cis	rs2811415	0.597	rs11714256	chr3:127804368	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	trans	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg18335740	chr13:41363409	SLC25A15	0.73	7.51	0.61	3.14e-11	Lewy body disease;
THYM	cis	rs8050907	0.661	rs17137056	chr16:4524685	G/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.3	5.2	0.47	1.16e-6	Obesity-related traits;
THYM	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg06558623	chr16:89946397	TCF25	1.48	7.81	0.63	7.43e-12	Skin colour saturation;
THYM	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg04317338	chr11:64019027	PLCB3	0.88	5.88	0.52	6.04e-8	Mean platelet volume;
THYM	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg10802521	chr3:52805072	NEK4	-0.68	-5.79	-0.51	9.01e-8	Bipolar disorder;
THYM	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg18681998	chr4:17616180	MED28	0.99	10.27	0.73	4.28e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4481887	0.708	rs6696691	chr1:248539720	T/C	cg00666640	chr1:248458726	OR2T12	0.55	4.71	0.44	8.41e-6	Common traits (Other);
THYM	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg23161317	chr6:28129485	ZNF389	0.66	5.26	0.47	8.9e-7	Parkinson's disease;
THYM	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg21280719	chr6:42927975	GNMT	-0.53	-7.28	-0.6	9.53e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg05890377	chr2:74357713	NA	1.07	9.01	0.68	2.11e-14	Gestational age at birth (maternal effect);
THYM	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14159672	chr1:205819179	PM20D1	1.0	10.79	0.74	3.47e-18	Menarche (age at onset);
THYM	cis	rs4148689	0.904	rs6466613	chr7:117136858	T/G	cg17204129	chr7:117119601	CFTR	-0.58	-4.65	-0.43	1.08e-5	Gout;
THYM	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg11812906	chr14:75593930	NEK9	-0.82	-7.6	-0.61	2.11e-11	Height;
THYM	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg08772003	chr10:104629869	AS3MT	-0.57	-4.95	-0.45	3.23e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs514406	0.698	rs11206055	chr1:53436632	A/T	cg24675658	chr1:53192096	ZYG11B	0.67	5.26	0.47	8.84e-7	Monocyte count;
THYM	cis	rs7404928	0.557	rs12932420	chr16:23939438	C/T	cg26685404	chr16:23957272	PRKCB	-0.58	-6.53	-0.56	3.16e-9	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Body mass index;
THYM	cis	rs7319311	0.965	rs9583488	chr13:111031352	G/A	cg05272587	chr13:111038400	COL4A2	0.63	5.05	0.46	2.14e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg13852791	chr20:30311386	BCL2L1	-0.88	-7.22	-0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	5.09	0.46	1.8e-6	Menarche (age at onset);
THYM	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg15164180	chr2:241846931	NA	-0.35	-4.73	-0.44	7.74e-6	Urinary metabolites;
THYM	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.99	-6.88	-0.58	6.31e-10	Schizophrenia;
THYM	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg26384229	chr12:38710491	ALG10B	0.71	5.52	0.49	2.92e-7	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6480314	0.831	rs10740287	chr10:69973890	G/A	cg27159792	chr10:69524182	NA	-0.74	-4.7	-0.43	8.91e-6	Optic nerve measurement (disc area);
THYM	cis	rs596169	0.655	rs1764871	chr1:219182808	A/C	cg19270308	chr1:218458869	RRP15	-1.24	-4.52	-0.42	1.81e-5	Intraocular pressure;
THYM	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg02187348	chr16:89574699	SPG7	0.71	5.43	0.49	4.31e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs2976388	1.000	rs2920283	chr8:143757037	T/C	cg06565975	chr8:143823917	SLURP1	-0.42	-4.76	-0.44	6.92e-6	Urinary tract infection frequency;
THYM	cis	rs7084402	0.902	rs3001715	chr10:60285509	A/G	cg09696939	chr10:60272079	BICC1	-0.46	-5.25	-0.47	9.38e-7	Refractive error;
THYM	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg00383909	chr3:49044727	WDR6	1.12	6.61	0.56	2.27e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg16188243	chr19:2783719	SGTA	0.68	4.8	0.44	5.82e-6	Total cholesterol levels;
THYM	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg06221963	chr1:154839813	KCNN3	-0.8	-8.92	-0.67	3.43e-14	Prostate cancer;
THYM	cis	rs28795989	0.795	rs2385910	chr4:7903151	G/C	cg00251875	chr4:7801337	AFAP1	0.59	4.75	0.44	7.24e-6	Intraocular pressure;
THYM	cis	rs10504073	0.647	rs7817571	chr8:50003218	T/C	cg00325661	chr8:49890786	NA	0.88	7.93	0.63	4.22e-12	Blood metabolite ratios;
THYM	cis	rs11031096	0.727	rs7932702	chr11:4124372	C/T	cg18678763	chr11:4115507	RRM1	-0.47	-6.57	-0.56	2.7e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs921968	0.541	rs4674314	chr2:219423520	A/G	cg02176678	chr2:219576539	TTLL4	-0.73	-7.24	-0.6	1.18e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.74	7.42	0.61	4.94e-11	Lymphocyte counts;
THYM	cis	rs761746	0.960	rs5998035	chr22:31939612	G/A	cg10537193	chr22:32026975	PISD	-0.36	-4.8	-0.44	5.91e-6	Intelligence;
THYM	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7726839	0.578	rs112516582	chr5:584319	G/A	cg16624210	chr5:671434	TPPP	0.62	5.95	0.52	4.4e-8	Obesity-related traits;
THYM	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	5.74	0.51	1.11e-7	Hip circumference adjusted for BMI;
THYM	cis	rs728616	0.717	rs116884206	chr10:81990546	A/G	cg18148530	chr10:81370782	SFTPA1	0.75	4.87	0.45	4.4e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg00814883	chr7:100076585	TSC22D4	-0.95	-6.39	-0.55	6.08e-9	Platelet count;
THYM	cis	rs524023	0.957	rs538737	chr11:64355772	C/G	cg19131476	chr11:64387923	NRXN2	0.32	4.59	0.43	1.34e-5	Urate levels in obese individuals;
THYM	cis	rs7580658	0.637	rs12463909	chr2:127971738	C/G	cg10021288	chr2:128175891	PROC	0.61	5.65	0.5	1.68e-7	Protein C levels;
THYM	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg02269571	chr22:50332266	NA	-0.71	-4.91	-0.45	3.78e-6	Schizophrenia;
THYM	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg13319975	chr6:146136371	FBXO30	-0.69	-5.7	-0.5	1.37e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg27534772	chr1:16042836	PLEKHM2	0.56	6.31	0.54	8.77e-9	Systolic blood pressure;
THYM	cis	rs7106204	0.668	rs7951530	chr11:24246904	T/C	ch.11.24196551F	chr11:24239977	NA	0.91	6.36	0.55	6.98e-9	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs7172809	0.573	rs11854466	chr15:77584733	T/C	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.74	6.14	0.53	1.87e-8	Tonsillectomy;
THYM	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.06	-0.53	2.71e-8	Life satisfaction;
THYM	cis	rs2997447	0.601	rs61776577	chr1:26431931	T/C	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg12373951	chr3:133503437	NA	0.5	4.79	0.44	6.23e-6	Iron status biomarkers;
THYM	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg26597838	chr10:835615	NA	1.23	8.86	0.67	4.56e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs2213920	0.679	rs4979523	chr9:118177550	G/A	cg13918206	chr9:118159781	DEC1	0.86	4.9	0.45	3.86e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs7669967	0.576	rs13121931	chr4:156070886	C/T	cg17641028	chr4:156585641	NA	0.57	5.16	0.47	1.34e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.61	-0.43	1.27e-5	Type 2 diabetes;
THYM	cis	rs7246657	0.525	rs1667357	chr19:37484352	T/C	cg22634378	chr19:37742834	NA	0.66	4.82	0.44	5.33e-6	Coronary artery calcification;
THYM	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.44	-7.58	-0.61	2.34e-11	Obesity-related traits;
THYM	cis	rs10095849	0.576	rs10107204	chr8:39468899	T/A	cg22755526	chr8:38854673	TM2D2;ADAM9	-0.62	-4.61	-0.43	1.24e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg06238570	chr21:40685208	BRWD1	-0.72	-6.28	-0.54	9.9e-9	Menarche (age at onset);
THYM	cis	rs4638749	0.677	rs13022268	chr2:108837320	A/G	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-11.02	-0.75	1.13e-18	Coronary artery disease;
THYM	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg05335186	chr13:53173507	NA	-0.46	-5.61	-0.5	2.03e-7	Lewy body disease;
THYM	cis	rs1344694	0.566	rs4672790	chr2:216892446	C/T	cg12620499	chr2:216877984	MREG	0.64	4.65	0.43	1.08e-5	Alcohol dependence;
THYM	cis	rs4595586	0.545	rs12820138	chr12:39357049	A/G	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.58	-4.99	-0.46	2.67e-6	Prudent dietary pattern;
THYM	cis	rs10089	1.000	rs10463838	chr5:127518305	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	5.46	0.49	3.81e-7	Ileal carcinoids;
THYM	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg08807101	chr21:30365312	RNF160	-0.81	-6.14	-0.53	1.93e-8	Dental caries;
THYM	cis	rs600806	0.713	rs11102984	chr1:109997373	T/C	cg02175308	chr1:109941060	SORT1	-0.55	-4.59	-0.43	1.33e-5	Intelligence (multi-trait analysis);
THYM	cis	rs59698941	0.943	rs67952459	chr5:132297902	C/T	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs36051895	0.632	rs10217652	chr9:5119939	A/G	cg02405213	chr9:5042618	JAK2	-1.05	-11.83	-0.77	2.21e-20	Pediatric autoimmune diseases;
THYM	trans	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg25214090	chr10:38739885	LOC399744	0.91	7.54	0.61	2.8e-11	Corneal astigmatism;
THYM	cis	rs877282	0.520	rs12360072	chr10:813082	C/T	cg20199549	chr10:820835	NA	0.54	4.75	0.44	7.12e-6	Uric acid levels;
THYM	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.79	-4.65	-0.43	1.08e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs425277	1.000	rs262672	chr1:2080813	G/T	cg23803603	chr1:2058230	PRKCZ	0.59	4.56	0.42	1.52e-5	Height;
THYM	cis	rs10818894	1.000	rs10818894	chr9:126695770	A/G	cg16191174	chr9:126692580	DENND1A	-0.74	-4.55	-0.42	1.6e-5	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
THYM	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg12560992	chr17:57184187	TRIM37	0.94	8.84	0.67	5.01e-14	Intelligence (multi-trait analysis);
THYM	cis	rs40363	1.000	rs1635393	chr16:3520493	C/T	cg21433313	chr16:3507492	NAT15	0.78	6.7	0.57	1.43e-9	Tuberculosis;
THYM	cis	rs985746	0.614	rs28633796	chr4:36786349	C/A	cg04301614	chr4:37585993	C4orf19	0.55	4.47	0.42	2.16e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg22166914	chr1:53195759	ZYG11B	0.81	8.73	0.67	8.72e-14	Monocyte count;
THYM	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg00376283	chr12:123451042	ABCB9	0.7	4.72	0.44	8.27e-6	Neutrophil percentage of white cells;
THYM	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg07936489	chr17:37558343	FBXL20	-0.67	-4.82	-0.44	5.53e-6	Asthma;
THYM	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg15556689	chr8:8085844	FLJ10661	0.62	5.09	0.46	1.83e-6	Mood instability;
THYM	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg20887711	chr4:1340912	KIAA1530	0.97	8.8	0.67	6.18e-14	Longevity;
THYM	cis	rs2404602	0.591	rs11635162	chr15:76951105	C/T	cg23625390	chr15:77176239	SCAPER	-0.85	-5.19	-0.47	1.19e-6	Blood metabolite levels;
THYM	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	trans	rs8073060	0.586	rs3859284	chr17:34012792	C/T	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs11621135	0.567	rs10145569	chr14:71653170	T/A	cg18506020	chr14:71758942	NA	-0.47	-4.5	-0.42	1.9e-5	Hair greying;
THYM	cis	rs6838801	0.964	rs4859701	chr4:77564469	T/G	cg01477861	chr4:77609841	SHROOM3	-0.45	-4.52	-0.42	1.79e-5	Cleft lip with or without cleft palate;
THYM	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg23482746	chr15:76478102	C15orf27	-0.38	-4.55	-0.42	1.61e-5	Blood metabolite levels;
THYM	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.6	-0.5	2.08e-7	Type 2 diabetes;
THYM	cis	rs3772130	1.000	rs11721318	chr3:121429485	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.74	4.67	0.43	9.91e-6	Cognitive performance;
THYM	cis	rs6032067	0.602	rs2741523	chr20:43920446	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.59	-5.42	-0.49	4.5e-7	Blood protein levels;
THYM	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg17063962	chr7:91808500	NA	1.15	12.12	0.78	5.47e-21	Breast cancer;
THYM	cis	rs3087591	0.960	rs2940184	chr17:29423119	T/C	cg24425628	chr17:29625626	OMG;NF1	0.65	5.59	0.5	2.16e-7	Hip circumference;
THYM	cis	rs10779751	0.734	rs2791653	chr1:11129848	A/G	cg08854313	chr1:11322531	MTOR	0.81	6.19	0.54	1.52e-8	Body mass index;
THYM	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg00684032	chr4:1343700	KIAA1530	0.55	4.72	0.44	8.07e-6	Obesity-related traits;
THYM	cis	rs880496	0.789	rs6669231	chr1:224798726	C/T	cg01808320	chr1:224927238	CNIH3	-0.66	-5.3	-0.48	7.51e-7	Cancer;
THYM	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg17366294	chr4:99064904	C4orf37	0.59	6.78	0.57	1e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10911232	0.507	rs10752888	chr1:182993751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg08807101	chr21:30365312	RNF160	-0.82	-6.55	-0.56	3.01e-9	Dental caries;
THYM	cis	rs1163251	0.837	rs839612	chr1:120247176	T/C	cg19096424	chr1:120255104	PHGDH	0.71	5.24	0.47	9.57e-7	Blood metabolite levels;
THYM	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs3741151	1.000	rs75912489	chr11:73073846	G/A	cg12959048	chr11:73096162	RELT	-0.53	-5.13	-0.47	1.52e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs11608355	0.597	rs10850070	chr12:109793882	A/G	cg11367159	chr12:110044531	NA	0.53	4.93	0.45	3.46e-6	Neuroticism;
THYM	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg02478829	chr6:26598070	ABT1	-0.34	-4.6	-0.43	1.28e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.92	6.07	0.53	2.66e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4072705	0.615	rs7851737	chr9:127247931	G/A	cg01786973	chr9:127249749	NR5A1	-0.4	-5.24	-0.47	9.69e-7	Menarche (age at onset);
THYM	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.66	-5.38	-0.48	5.38e-7	Blood metabolite levels;
THYM	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.61	-0.43	1.27e-5	Type 2 diabetes;
THYM	cis	rs10781543	0.845	rs10781540	chr9:139321836	G/A	cg14115884	chr9:139300582	SDCCAG3	0.66	5.8	0.51	8.72e-8	Monocyte percentage of white cells;
THYM	cis	rs7000551	0.725	rs2469757	chr8:22360938	C/T	cg12081754	chr8:22256438	SLC39A14	0.62	5.69	0.5	1.43e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg13854012	chr2:162103682	NA	-0.65	-5.39	-0.48	5.19e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs13040088	0.580	rs11905041	chr20:61563408	C/T	cg23096297	chr20:61557774	DIDO1	0.81	6.22	0.54	1.31e-8	Menopause (age at onset);
THYM	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg22920501	chr2:26401640	FAM59B	-0.7	-5.98	-0.52	3.96e-8	Gut microbiome composition (summer);
THYM	trans	rs28595532	0.764	rs115298416	chr4:119565383	C/T	cg13773247	chr2:42276988	PKDCC	0.89	6.93	0.58	5e-10	Cannabis dependence symptom count;
THYM	cis	rs4731207	0.596	rs9969187	chr7:124661472	T/C	cg05285228	chr7:124571219	POT1	-0.62	-4.74	-0.44	7.4e-6	Cutaneous malignant melanoma;
THYM	cis	rs4891159	1.000	rs4891159	chr18:74101941	A/G	cg24786174	chr18:74118243	ZNF516	0.73	7.45	0.61	4.19e-11	Longevity;
THYM	cis	rs2806561	0.765	rs1738470	chr1:23511911	G/A	cg12483005	chr1:23474871	LUZP1	0.59	6.3	0.54	9.23e-9	Height;
THYM	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7769051	0.522	rs6569852	chr6:133108333	C/A	cg22852734	chr6:133119734	C6orf192	1.45	6.1	0.53	2.32e-8	Type 2 diabetes nephropathy;
THYM	cis	rs6430585	0.583	rs4988201	chr2:136618507	A/G	cg04750100	chr2:136595281	LCT	0.57	5.29	0.48	7.86e-7	Corneal structure;
THYM	cis	rs4974559	0.790	rs10012582	chr4:1324481	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.45	-4.92	-0.45	3.67e-6	Systolic blood pressure;
THYM	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg14517863	chr17:44321492	NA	-0.44	-5.0	-0.46	2.59e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg01191920	chr7:158217561	PTPRN2	0.9	8.64	0.66	1.32e-13	Obesity-related traits;
THYM	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg00684032	chr4:1343700	KIAA1530	0.8	7.13	0.59	1.91e-10	Obesity-related traits;
THYM	cis	rs9902453	0.765	rs2729447	chr17:28099002	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs8112449	0.719	rs7249459	chr19:10537092	C/T	cg01466491	chr19:10523363	NA	-0.65	-5.79	-0.51	9.19e-8	Multiple sclerosis;Gastritis;
THYM	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs900145	0.773	rs4757141	chr11:13307095	A/G	cg13286116	chr11:13302098	ARNTL	0.59	4.56	0.42	1.54e-5	Menarche (age at onset);
THYM	cis	rs36051895	0.659	rs1576271	chr9:5039652	A/C	cg02405213	chr9:5042618	JAK2	-1.06	-11.46	-0.76	1.34e-19	Pediatric autoimmune diseases;
THYM	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg27535305	chr1:53392650	SCP2	0.38	4.55	0.42	1.6e-5	Monocyte count;
THYM	cis	rs10791323	0.571	rs4937839	chr11:133734177	T/C	cg06766960	chr11:133703094	NA	-0.59	-5.53	-0.49	2.78e-7	Childhood ear infection;
THYM	cis	rs17828380	0.777	rs2291881	chr15:63597639	A/G	cg12013685	chr15:63243220	NA	0.75	4.47	0.42	2.2e-5	Social communication problems;
THYM	cis	rs2836950	0.772	rs62222988	chr21:40569508	T/C	cg11890956	chr21:40555474	PSMG1	-0.62	-4.75	-0.44	7.34e-6	Menarche (age at onset);
THYM	cis	rs2505998	1.000	rs1864410	chr10:43575625	T/G	cg06632098	chr10:43605906	RET	-1.06	-9.44	-0.7	2.63e-15	Hirschsprung disease;
THYM	cis	rs36051895	0.559	rs6476949	chr9:5208048	G/A	cg02405213	chr9:5042618	JAK2	-0.91	-9.4	-0.69	3.24e-15	Pediatric autoimmune diseases;
THYM	cis	rs2456568	0.802	rs1395387	chr11:93639307	A/T	cg26875233	chr11:93583750	C11orf90	-0.53	-5.67	-0.5	1.57e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg03929089	chr4:120376271	NA	-0.94	-10.56	-0.73	1.03e-17	Height;
THYM	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2066819	0.818	rs773652	chr12:56674766	G/A	cg26714650	chr12:56694279	CS	1.26	7.39	0.6	5.59e-11	Psoriasis vulgaris;
THYM	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg25251562	chr2:3704773	ALLC	-0.83	-5.59	-0.5	2.16e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg24399712	chr22:39784796	NA	-0.84	-8.53	-0.66	2.28e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg19442545	chr10:75533431	FUT11	0.57	6.16	0.53	1.74e-8	Inflammatory bowel disease;
THYM	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg04944784	chr2:26401820	FAM59B	1.09	8.74	0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg00129232	chr17:37814104	STARD3	0.75	5.4	0.48	4.93e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2858942	0.527	rs7198029	chr16:249464	C/T	cg17291625	chr16:236080	NA	-0.59	-4.99	-0.46	2.75e-6	Mean corpuscular hemoglobin;
THYM	cis	rs12367572	1.000	rs7304472	chr12:45262324	A/G	cg03114573	chr12:45410052	DBX2	-0.54	-5.08	-0.46	1.86e-6	Gut microbiome composition (summer);
THYM	cis	rs7953508	0.711	rs3825199	chr12:93976954	A/G	cg13201927	chr12:93977447	NA	0.65	4.6	0.43	1.28e-5	Pubertal anthropometrics;
THYM	cis	rs2290159	0.800	rs3773345	chr3:12642945	G/C	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs9361491	0.608	rs4706725	chr6:79466391	A/G	cg04547799	chr6:79944526	HMGN3	-0.64	-4.47	-0.42	2.13e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg15693483	chr7:1102177	C7orf50	0.54	6.29	0.54	9.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs72828912	0.831	rs10806983	chr6:24094895	A/C	cg26336265	chr6:25042955	NA	-0.67	-5.21	-0.47	1.11e-6	Squamous cell lung carcinoma;
THYM	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg18252515	chr7:66147081	NA	-0.66	-5.01	-0.46	2.55e-6	Aortic root size;
THYM	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg12310025	chr6:25882481	NA	-0.65	-5.12	-0.46	1.62e-6	Height;
THYM	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg06108461	chr20:60628389	TAF4	-1.07	-9.19	-0.69	9.08e-15	Body mass index;
THYM	cis	rs2108225	0.934	rs2301988	chr7:107443833	A/G	cg18560240	chr7:107437656	SLC26A3	0.73	5.01	0.46	2.51e-6	Ulcerative colitis;
THYM	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg02353165	chr6:42928485	GNMT	0.75	5.44	0.49	4.13e-7	Blood protein levels;
THYM	cis	rs1784581	0.674	rs1789989	chr6:162408138	C/T	cg17173639	chr6:162384350	PARK2	0.81	7.45	0.61	4.29e-11	Itch intensity from mosquito bite;
THYM	cis	rs155076	1.000	rs2783107	chr13:21837532	C/A	cg14456004	chr13:21872349	NA	-1.22	-9.62	-0.7	1.06e-15	White matter hyperintensity burden;
THYM	cis	rs11190604	0.747	rs11190516	chr10:102173525	G/A	cg07570687	chr10:102243282	WNT8B	0.81	7.68	0.62	1.44e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11039798	0.920	rs11039848	chr11:48598243	C/T	cg24672777	chr11:48374446	OR4C45	-1.08	-5.95	-0.52	4.42e-8	Axial length;
THYM	cis	rs1670533	1.000	rs10084890	chr4:1053934	C/G	cg27284194	chr4:1044797	NA	-0.61	-4.6	-0.43	1.29e-5	Recombination rate (females);
THYM	cis	rs61931739	0.817	rs10743842	chr12:34306859	C/T	cg10856724	chr12:34555212	NA	-0.6	-5.42	-0.49	4.57e-7	Morning vs. evening chronotype;
THYM	cis	rs919433	0.619	rs699318	chr2:198281743	T/C	cg05783139	chr2:198650985	BOLL	0.63	4.93	0.45	3.48e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg14972814	chr11:95582409	MTMR2	-0.68	-5.43	-0.49	4.38e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2637266	0.935	rs7900900	chr10:78367383	A/T	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs11645898	0.748	rs72787056	chr16:72099694	C/T	cg14768367	chr16:72042858	DHODH	-0.81	-5.89	-0.52	5.95e-8	Blood protein levels;
THYM	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs17253792	0.545	rs34446601	chr14:56010586	A/G	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg24818145	chr4:99064322	C4orf37	0.74	5.29	0.48	7.93e-7	Colonoscopy-negative controls vs population controls;
THYM	trans	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	Neuroticism;
THYM	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg05294307	chr14:35346193	BAZ1A	-0.82	-5.36	-0.48	5.9e-7	Psoriasis;
THYM	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.65	-4.49	-0.42	2.04e-5	Gut microbiome composition (summer);
THYM	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-5.74	-0.51	1.12e-7	Systemic lupus erythematosus;
THYM	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg09469691	chr10:81107165	PPIF	0.66	4.79	0.44	6.2e-6	Height;
THYM	cis	rs17539620	0.624	rs62432743	chr6:154836214	T/G	cg20019720	chr6:154832845	CNKSR3	0.47	4.79	0.44	6.17e-6	Lipoprotein (a) levels;
THYM	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg00484396	chr16:3507460	NAT15	-0.47	-4.56	-0.42	1.55e-5	Body mass index (adult);
THYM	cis	rs2456568	0.867	rs2462750	chr11:93668590	C/T	cg17595323	chr11:93583763	C11orf90	-0.54	-5.23	-0.47	1.02e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs9457247	1.000	rs416131	chr6:167406544	A/C	cg20486651	chr6:167070296	RPS6KA2	0.5	4.79	0.44	6.18e-6	Crohn's disease;
THYM	cis	rs941408	0.963	rs1640268	chr19:2791469	T/C	cg19693284	chr19:2783607	SGTA	0.72	5.44	0.49	4.08e-7	Total cholesterol levels;
THYM	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg15164180	chr2:241846931	NA	-0.38	-4.98	-0.45	2.87e-6	Urinary metabolites;
THYM	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs2734839	0.964	rs1800498	chr11:113291588	G/A	cg14159747	chr11:113255604	NA	0.32	6.41	0.55	5.69e-9	Information processing speed;
THYM	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg08885076	chr2:99613938	TSGA10	-0.63	-6.05	-0.53	2.86e-8	Chronic sinus infection;
THYM	cis	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg07460842	chr6:66804631	NA	-0.97	-6.96	-0.58	4.44e-10	Exhaled nitric oxide output;
THYM	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg01483505	chr11:975446	AP2A2	0.58	4.73	0.44	7.73e-6	Alzheimer's disease (late onset);
THYM	trans	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg05926928	chr17:57297772	GDPD1	1.26	10.02	0.72	1.5e-16	Opioid sensitivity;
THYM	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg26850624	chr5:429559	AHRR	-0.72	-5.68	-0.5	1.45e-7	Cystic fibrosis severity;
THYM	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg18252515	chr7:66147081	NA	0.7	5.46	0.49	3.77e-7	Aortic root size;
THYM	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg06481639	chr22:41940642	POLR3H	0.82	5.68	0.5	1.49e-7	Vitiligo;
THYM	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3015497	0.789	rs8003372	chr14:51102351	G/A	cg04730355	chr14:51134070	SAV1	-0.54	-4.76	-0.44	6.85e-6	Mean platelet volume;
THYM	cis	rs710865	0.527	rs2275403	chr1:19557713	C/G	cg22333259	chr1:19394757	NA	-0.64	-6.44	-0.55	4.83e-9	Brain structure;
THYM	cis	rs12188164	0.582	rs72700694	chr5:483267	T/C	cg03281154	chr5:1086625	SLC12A7	0.62	5.16	0.47	1.34e-6	Cystic fibrosis severity;
THYM	cis	rs9394152	0.817	rs4428487	chr6:33468394	G/A	cg13560919	chr6:33536144	NA	0.72	6.21	0.54	1.37e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs2463822	0.925	rs1881535	chr11:62121623	C/T	cg06239285	chr11:62104954	ASRGL1	1.44	7.7	0.62	1.3e-11	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7560272	0.669	rs7598660	chr2:73740425	C/T	cg19565262	chr2:73869966	NAT8	-0.55	-4.81	-0.44	5.7e-6	Schizophrenia;
THYM	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg10589385	chr1:150898437	SETDB1	0.62	5.03	0.46	2.31e-6	Melanoma;
THYM	cis	rs11690935	0.959	rs66835971	chr2:172677459	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.81	-5.84	-0.51	7.21e-8	Schizophrenia;
THYM	cis	rs17433780	0.897	rs12120863	chr1:89501522	T/C	cg09516651	chr1:89888402	LOC400759	0.94	7.55	0.61	2.65e-11	Carotid intima media thickness;
THYM	cis	rs59698941	0.943	rs57550938	chr5:132248104	G/A	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs3845702	0.736	rs6722147	chr2:180829704	G/A	cg01881094	chr2:180872142	CWC22	-0.89	-5.34	-0.48	6.22e-7	Schizophrenia;
THYM	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg27286337	chr10:134555280	INPP5A	0.96	8.32	0.65	6.42e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7084921	0.526	rs11594323	chr10:101880479	G/A	cg11344164	chr10:101878520	NA	-0.58	-5.59	-0.5	2.14e-7	Bone mineral density;
THYM	cis	rs9612	1.000	rs7246677	chr19:44248625	G/A	cg08581076	chr19:44259116	C19orf61	0.68	4.56	0.42	1.5e-5	Exhaled nitric oxide output;
THYM	cis	rs3924048	0.559	rs4075303	chr1:12626593	C/G	cg00291366	chr1:12616550	NA	0.34	5.07	0.46	1.93e-6	Optic cup area;
THYM	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg23711669	chr6:146136114	FBXO30	0.82	7.92	0.63	4.54e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6987853	0.933	rs2974352	chr8:42408483	C/T	cg09913449	chr8:42400586	C8orf40	0.95	8.95	0.68	2.86e-14	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg09238746	chr17:78121135	EIF4A3	1.11	10.77	0.74	3.72e-18	Yeast infection;
THYM	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg24531977	chr5:56204891	C5orf35	-0.66	-5.11	-0.46	1.64e-6	Coronary artery disease;
THYM	cis	rs8078723	0.510	rs3859189	chr17:38137033	A/G	cg17467752	chr17:38218738	THRA	-0.71	-5.24	-0.47	9.77e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs1436955	0.637	rs7163194	chr15:62382775	A/G	cg10760209	chr15:62986915	TLN2	0.64	4.5	0.42	1.93e-5	Type 2 diabetes;
THYM	cis	rs9876781	1.000	rs7630741	chr3:48419723	G/T	cg06066452	chr3:48470258	PLXNB1	0.28	5.14	0.47	1.49e-6	Longevity;
THYM	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg05025164	chr4:1340916	KIAA1530	-0.7	-5.4	-0.48	4.85e-7	Obesity-related traits;
THYM	cis	rs6032067	0.852	rs6032064	chr20:43854827	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.72	-6.57	-0.56	2.7e-9	Blood protein levels;
THYM	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Body mass index;
THYM	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg26384229	chr12:38710491	ALG10B	0.73	5.4	0.48	5.01e-7	Morning vs. evening chronotype;
THYM	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.85	-7.05	-0.59	2.87e-10	Systemic lupus erythematosus;
THYM	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg05872129	chr22:39784769	NA	-1.09	-12.07	-0.78	6.85e-21	Intelligence (multi-trait analysis);
THYM	cis	rs870825	0.616	rs4263438	chr4:185624238	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg01416388	chr22:39784598	NA	-0.92	-8.25	-0.65	8.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9527	0.590	rs3781282	chr10:104852419	C/T	cg04362960	chr10:104952993	NT5C2	-0.64	-4.99	-0.46	2.68e-6	Arsenic metabolism;
THYM	cis	rs4919694	0.808	rs80020194	chr10:105035954	A/G	cg04362960	chr10:104952993	NT5C2	0.92	5.42	0.49	4.53e-7	Arsenic metabolism;
THYM	cis	rs7809950	0.530	rs34021916	chr7:106817901	A/G	cg23024343	chr7:107201750	COG5	-0.86	-7.0	-0.58	3.53e-10	Coronary artery disease;
THYM	cis	rs7777754	0.512	rs7785224	chr7:50562361	T/C	cg18232548	chr7:50535776	DDC	-0.92	-8.25	-0.65	8.89e-13	Response to zileuton treatment in asthma (FEV1 change interaction);
THYM	cis	rs11711311	0.869	rs12493635	chr3:113373019	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-4.94	-0.45	3.3e-6	IgG glycosylation;
THYM	cis	rs986417	1.000	rs7160408	chr14:60977471	A/G	cg27398547	chr14:60952738	C14orf39	1.13	5.43	0.49	4.26e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs270601	0.817	rs460089	chr5:131629772	C/G	cg24060327	chr5:131705240	SLC22A5	-0.81	-6.14	-0.53	1.89e-8	Acylcarnitine levels;
THYM	cis	rs7127900	1.000	rs6579001	chr11:2232056	A/G	cg25635251	chr11:2234043	NA	0.74	4.71	0.44	8.43e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs2273669	0.667	rs117941557	chr6:109298135	G/A	cg17117243	chr6:109341365	SESN1	-0.86	-4.9	-0.45	3.88e-6	Prostate cancer;
THYM	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg24675658	chr1:53192096	ZYG11B	0.69	5.84	0.51	7.41e-8	Monocyte count;
THYM	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg18252515	chr7:66147081	NA	-0.88	-6.71	-0.57	1.4e-9	Corneal structure;
THYM	cis	rs7572733	0.534	rs1435570	chr2:198731371	T/C	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg24060327	chr5:131705240	SLC22A5	-0.8	-6.52	-0.56	3.35e-9	Breast cancer;
THYM	cis	rs7512552	0.839	rs12045304	chr1:150399818	G/A	cg15654264	chr1:150340011	RPRD2	0.45	5.19	0.47	1.21e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg00376283	chr12:123451042	ABCB9	0.73	5.03	0.46	2.29e-6	Neutrophil percentage of white cells;
THYM	cis	rs4662750	0.798	rs777435	chr2:128369896	A/G	cg01966334	chr2:128378434	MYO7B	0.69	6.2	0.54	1.43e-8	Renal cell carcinoma;
THYM	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs8028313	0.630	rs28418298	chr15:67935745	C/T	cg26545918	chr15:68124484	LBXCOR1	0.53	4.75	0.44	7.26e-6	Obesity;
THYM	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg24450063	chr1:156163899	SLC25A44	1.17	9.81	0.71	4.12e-16	Testicular germ cell tumor;
THYM	cis	rs9902453	0.902	rs4075014	chr17:28305674	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.81	0.44	5.74e-6	Coffee consumption (cups per day);
THYM	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg25382214	chr1:3105252	PRDM16	-0.55	-4.71	-0.44	8.37e-6	Migraine;
THYM	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	5.57	0.5	2.37e-7	Lung cancer in ever smokers;
THYM	cis	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg12981288	chr8:11183844	MTMR9	0.43	4.47	0.42	2.12e-5	Retinal vascular caliber;
THYM	cis	rs9972944	0.691	rs10083837	chr17:63775311	C/G	cg07283582	chr17:63770753	CCDC46	0.68	5.54	0.49	2.69e-7	Total body bone mineral density;
THYM	cis	rs8180040	0.903	rs2276853	chr3:47282303	G/A	cg16586182	chr3:47516702	SCAP	-0.64	-5.55	-0.49	2.6e-7	Colorectal cancer;
THYM	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.34	0.55	7.83e-9	Total body bone mineral density;
THYM	cis	rs1007190	0.764	rs758020	chr17:42872579	C/A	cg15406952	chr17:42872593	NA	-0.84	-5.95	-0.52	4.45e-8	DNA methylation (variation);
THYM	trans	rs1973993	0.691	rs1989141	chr1:96898520	C/T	cg10631902	chr5:14652156	NA	0.76	9.45	0.7	2.51e-15	Weight;
THYM	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg12031863	chr16:4587854	C16orf5	-0.46	-4.89	-0.45	4.03e-6	Schizophrenia;
THYM	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg10803722	chr21:46713166	LOC642852	0.42	5.4	0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg09359103	chr1:154839909	KCNN3	-0.72	-9.45	-0.7	2.44e-15	Prostate cancer;
THYM	cis	rs11696501	0.738	rs6104294	chr20:44326850	T/C	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg08975724	chr8:8085496	FLJ10661	0.63	5.0	0.46	2.58e-6	Neuroticism;
THYM	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg11317459	chr13:21872234	NA	-1.2	-9.08	-0.68	1.49e-14	White matter hyperintensity burden;
THYM	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.68	-4.46	-0.42	2.22e-5	Menarche (age at onset);
THYM	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	5.75	0.51	1.08e-7	Blood metabolite levels;
THYM	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.59	-7.32	-0.6	7.84e-11	Longevity;Endometriosis;
THYM	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg09904177	chr6:26538194	HMGN4	0.61	4.93	0.45	3.55e-6	Intelligence (multi-trait analysis);
THYM	cis	rs425277	1.000	rs421992	chr1:2077260	C/T	cg24578937	chr1:2090814	PRKCZ	0.81	8.51	0.66	2.51e-13	Height;
THYM	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg15448220	chr1:150897856	SETDB1	0.86	7.21	0.59	1.33e-10	Tonsillectomy;
THYM	trans	rs480407	0.818	rs270967	chr2:161689277	G/A	cg06548410	chr19:1997657	BTBD2	0.71	6.92	0.58	5.23e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg04398451	chr17:18023971	MYO15A	-0.8	-7.33	-0.6	7.5e-11	Total body bone mineral density;
THYM	cis	rs2997447	0.846	rs3008429	chr1:26390833	A/G	cg03844060	chr1:26490628	NA	0.66	4.5	0.42	1.96e-5	QRS complex (12-leadsum);
THYM	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg26031613	chr14:104095156	KLC1	1.21	12.87	0.8	1.52e-22	Body mass index;
THYM	cis	rs11148252	0.683	rs9536006	chr13:52887707	T/G	cg00495681	chr13:53174319	NA	0.72	6.48	0.55	3.97e-9	Lewy body disease;
THYM	cis	rs612683	0.735	rs10493923	chr1:100930254	A/G	cg06223162	chr1:101003688	GPR88	-0.72	-6.3	-0.54	9.14e-9	Breast cancer;
THYM	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3780378	0.967	rs7023146	chr9:5040163	G/A	cg02405213	chr9:5042618	JAK2	-0.78	-7.34	-0.6	7.17e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs7212938	0.570	rs8071050	chr17:38106599	A/G	cg24910161	chr17:38119198	GSDMA	-0.45	-5.21	-0.47	1.11e-6	Asthma and hay fever;
THYM	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	4.98	0.46	2.8e-6	Eosinophil percentage of white cells;
THYM	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg13319975	chr6:146136371	FBXO30	0.65	5.31	0.48	7.34e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg13395646	chr4:1353034	KIAA1530	0.59	5.69	0.5	1.42e-7	Obesity-related traits;
THYM	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg00852783	chr1:26633632	UBXN11	0.86	8.94	0.68	3.08e-14	Obesity-related traits;
THYM	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg07690219	chr3:49449608	TCTA;RHOA	0.69	4.62	0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg08859206	chr1:53392774	SCP2	-0.47	-4.87	-0.45	4.46e-6	Monocyte count;
THYM	cis	rs9534288	0.659	rs7996394	chr13:46653503	A/C	cg15192986	chr13:46630673	CPB2	-0.65	-4.57	-0.42	1.44e-5	Blood protein levels;
THYM	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg10523679	chr1:76189770	ACADM	0.91	9.7	0.71	7.37e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg03264133	chr6:25882463	NA	0.74	5.71	0.51	1.3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs977987	0.806	rs12917651	chr16:75466696	G/T	cg03315344	chr16:75512273	CHST6	0.73	5.88	0.52	6.15e-8	Dupuytren's disease;
THYM	cis	rs7107174	0.892	rs11237463	chr11:78060464	A/G	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs6430585	0.583	rs3769001	chr2:136626078	A/G	cg20242066	chr2:136595261	LCT	0.51	4.87	0.45	4.44e-6	Corneal structure;
THYM	cis	rs11773103	0.500	rs1636913	chr7:86952076	C/T	cg25477497	chr7:87228808	ABCB1	-0.45	-4.77	-0.44	6.53e-6	Bipolar disorder or major depressive disorder (combined);
THYM	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg23260525	chr10:116636907	FAM160B1	0.53	5.33	0.48	6.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Body mass index;
THYM	cis	rs8077889	0.956	rs116979403	chr17:41849105	G/A	cg26893861	chr17:41843967	DUSP3	1.09	9.9	0.71	2.65e-16	Triglycerides;
THYM	cis	rs9807841	0.617	rs2229383	chr19:10794630	G/T	cg16900796	chr19:10755136	SLC44A2	0.4	6.31	0.54	8.69e-9	Inflammatory skin disease;
THYM	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	4.78	0.44	6.33e-6	Alzheimer's disease (late onset);
THYM	cis	rs10851411	0.688	rs16973265	chr15:42752542	C/T	cg04857231	chr15:42782520	NA	-0.5	-4.71	-0.43	8.57e-6	Glucose homeostasis traits;
THYM	cis	rs7809950	0.817	rs2701679	chr7:107283908	A/G	cg23024343	chr7:107201750	COG5	0.75	6.24	0.54	1.19e-8	Coronary artery disease;
THYM	cis	rs997295	0.592	rs2899724	chr15:67760808	C/T	cg24579218	chr15:68104479	NA	0.55	4.73	0.44	7.79e-6	Motion sickness;
THYM	cis	rs10203711	0.933	rs4994754	chr2:239567218	A/G	cg14580085	chr2:239553406	NA	0.68	6.18	0.54	1.6e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11756438	0.683	rs60497831	chr6:119009327	G/A	cg01113488	chr6:119027122	NA	0.56	4.5	0.42	1.92e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs859767	0.709	rs1516990	chr2:135369630	C/G	cg12500956	chr2:135428796	TMEM163	-0.49	-4.95	-0.45	3.22e-6	Neuroticism;
THYM	cis	rs11190604	0.725	rs9420796	chr10:102323092	G/C	cg16342193	chr10:102329863	NA	-0.57	-6.03	-0.53	3.13e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg05347473	chr6:146136440	FBXO30	0.58	4.52	0.42	1.8e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg19875535	chr5:140030758	IK	-0.67	-5.76	-0.51	1.05e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg17211192	chr8:82754475	SNX16	-0.82	-7.41	-0.61	5.09e-11	Diastolic blood pressure;
THYM	cis	rs921968	0.643	rs10187066	chr2:219514759	A/G	cg01872077	chr2:219646372	CYP27A1	0.58	4.49	0.42	2e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg09085632	chr11:111637200	PPP2R1B	1.15	11.77	0.77	2.94e-20	Primary sclerosing cholangitis;
THYM	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs988913	1.000	rs6902422	chr6:54811210	C/T	cg18532076	chr6:54711417	FAM83B	-0.53	-5.2	-0.47	1.12e-6	Menarche (age at onset);
THYM	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg03909863	chr11:638404	DRD4	-0.76	-6.04	-0.53	2.95e-8	Systemic lupus erythematosus;
THYM	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs28595532	0.764	rs56309519	chr4:119754158	C/T	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs10227331	1.000	rs10227331	chr7:157294938	A/T	cg04156418	chr7:157293606	NA	0.82	7.39	0.6	5.65e-11	Inattentive symptoms;
THYM	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg22968622	chr17:43663579	NA	1.15	10.2	0.72	6.29e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg04772025	chr11:68637568	NA	0.62	6.61	0.56	2.21e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg17294928	chr15:75287854	SCAMP5	-1.01	-9.1	-0.68	1.4e-14	Blood trace element (Zn levels);
THYM	cis	rs35160687	0.862	rs17737955	chr2:86508014	C/T	cg10973622	chr2:86423274	IMMT	0.52	4.54	0.42	1.64e-5	Night sleep phenotypes;
THYM	cis	rs2806561	1.000	rs654585	chr1:23514714	T/C	cg19743168	chr1:23544995	NA	0.6	6.04	0.53	2.93e-8	Height;
THYM	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg13683864	chr3:40499215	RPL14	-0.76	-6.83	-0.57	8.03e-10	Renal cell carcinoma;
THYM	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg03806693	chr22:41940476	POLR3H	1.08	8.25	0.65	8.91e-13	Vitiligo;
THYM	cis	rs2268241	0.938	rs9978166	chr21:34770516	A/G	cg14850771	chr21:34775459	IFNGR2	1.0	7.12	0.59	2.09e-10	Obesity-related traits;
THYM	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg00278517	chr6:167070616	RPS6KA2	-0.34	-4.68	-0.43	9.42e-6	Crohn's disease;
THYM	cis	rs6980334	0.906	rs10264658	chr7:137779000	T/C	cg26979473	chr7:137028389	PTN	0.61	4.5	0.42	1.92e-5	Blood metabolite ratios;
THYM	cis	rs11723261	0.546	rs57839456	chr4:148289	C/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.81	5.57	0.5	2.37e-7	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg18876405	chr7:65276391	NA	0.67	5.93	0.52	4.91e-8	Aortic root size;
THYM	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg13866156	chr1:1669148	SLC35E2	-0.71	-7.14	-0.59	1.86e-10	Body mass index;
THYM	cis	rs12780046	0.656	rs10786510	chr10:100899295	C/T	cg20566587	chr10:101492029	COX15;CUTC	-0.75	-4.51	-0.42	1.85e-5	Non-glioblastoma glioma;
THYM	cis	rs9443189	0.703	rs2748950	chr6:76442985	A/G	cg01950844	chr6:76311363	SENP6	-0.77	-4.53	-0.42	1.73e-5	Prostate cancer;
THYM	cis	rs2921073	0.510	rs2976944	chr8:8270914	T/C	cg06636001	chr8:8085503	FLJ10661	0.57	4.57	0.42	1.49e-5	Parkinson's disease;
THYM	cis	rs3820068	0.822	rs3753326	chr1:15790974	A/G	cg05660106	chr1:15850417	CASP9	1.09	8.31	0.65	6.71e-13	Systolic blood pressure;
THYM	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg00684032	chr4:1343700	KIAA1530	0.62	5.57	0.5	2.37e-7	Obesity-related traits;
THYM	cis	rs7917772	0.582	rs10786689	chr10:104356359	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7078219	1.000	rs61872688	chr10:101273546	G/A	cg07044859	chr10:101282883	NA	-0.47	-5.14	-0.47	1.45e-6	Dental caries;
THYM	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg27572855	chr1:25598939	RHD	0.61	4.67	0.43	9.87e-6	Erythrocyte sedimentation rate;
THYM	cis	rs9902453	0.619	rs1038088	chr17:28074563	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.8	-0.57	9.09e-10	Coffee consumption (cups per day);
THYM	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg22079354	chr11:130786696	SNX19	0.49	4.48	0.42	2.05e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10739663	0.520	rs13294786	chr9:128156961	A/G	cg14078157	chr9:128172775	NA	-0.9	-8.15	-0.64	1.45e-12	Resting heart rate;
THYM	cis	rs1559088	0.600	rs7255229	chr19:33562807	A/G	cg03563238	chr19:33554763	RHPN2	-0.55	-4.69	-0.43	8.98e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg11764359	chr7:65958608	NA	0.64	4.96	0.45	3.13e-6	Aortic root size;
THYM	cis	rs4343996	0.902	rs4722693	chr7:3374312	C/T	cg21248987	chr7:3385318	SDK1	-0.41	-4.84	-0.44	4.95e-6	Motion sickness;
THYM	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg26516362	chr5:178986906	RUFY1	0.37	4.63	0.43	1.17e-5	Lung cancer;
THYM	cis	rs6424115	0.867	rs4649119	chr1:24171543	C/G	cg15997130	chr1:24165203	NA	-0.7	-5.72	-0.51	1.21e-7	Immature fraction of reticulocytes;
THYM	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg08109568	chr15:31115862	NA	-0.55	-5.52	-0.49	2.92e-7	Huntington's disease progression;
THYM	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3771570	0.901	rs62190407	chr2:242405772	G/A	cg21155796	chr2:242212141	HDLBP	1.02	6.18	0.54	1.6e-8	Prostate cancer;
THYM	cis	rs6500395	0.928	rs12934788	chr16:48706343	C/A	cg04672837	chr16:48644449	N4BP1	-0.48	-4.72	-0.44	8.24e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7688540	0.771	rs11723261	chr4:282499	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.68	4.82	0.44	5.43e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs6720763	0.891	rs58616240	chr2:168029842	C/G	cg10633051	chr2:168042982	XIRP2	-0.69	-4.75	-0.44	7.08e-6	Atopic dermatitis;
THYM	cis	rs9906944	0.707	rs4794020	chr17:47111399	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.49	-4.47	-0.42	2.15e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs4924935	1.000	rs4924935	chr17:18753870	C/T	cg26378065	chr17:18585709	ZNF286B	0.67	5.33	0.48	6.55e-7	Pancreatic cancer;
THYM	cis	rs854765	0.663	rs9915248	chr17:17747514	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.66	-5.76	-0.51	1.04e-7	Total body bone mineral density;
THYM	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg17063962	chr7:91808500	NA	1.15	12.77	0.79	2.49e-22	Breast cancer;
THYM	cis	rs35934224	0.783	rs7290770	chr22:19861161	C/T	cg11182965	chr22:19864308	TXNRD2	-0.94	-7.32	-0.6	7.94e-11	Glaucoma (primary open-angle);
THYM	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg18252515	chr7:66147081	NA	-0.88	-6.74	-0.57	1.22e-9	Corneal structure;
THYM	cis	rs6960043	0.782	rs10228456	chr7:15063926	C/T	cg19272540	chr7:15055459	NA	-0.41	-4.56	-0.42	1.55e-5	Type 2 diabetes;
THYM	cis	rs11096990	0.656	rs6531710	chr4:39302278	C/T	cg24403649	chr4:39172243	NA	-0.63	-5.42	-0.49	4.58e-7	Cognitive function;
THYM	cis	rs6882076	1.000	rs4704727	chr5:156380067	T/G	cg12943317	chr5:156479607	HAVCR1	-0.72	-5.81	-0.51	8.25e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs6840360	0.837	rs4696294	chr4:152713089	C/A	cg22705602	chr4:152727874	NA	0.57	6.19	0.54	1.54e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg03433033	chr1:76189801	ACADM	0.77	10.09	0.72	1.07e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4962416	0.785	rs7077275	chr10:126697210	T/C	cg04494136	chr10:126703576	CTBP2	-0.34	-4.65	-0.43	1.09e-5	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs9361491	0.608	rs9352616	chr6:79441503	C/T	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6828523	0.698	rs56004315	chr4:175859382	C/T	cg14561282	chr4:175839468	ADAM29	0.62	4.53	0.42	1.7e-5	Breast cancer;
THYM	cis	rs1728785	0.786	rs1728770	chr16:68564124	G/C	cg02972257	chr16:68554789	NA	-0.76	-4.76	-0.44	6.82e-6	Ulcerative colitis;
THYM	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs2219968	0.525	rs6473068	chr8:78873010	A/G	cg00738934	chr8:78996279	NA	0.6	4.94	0.45	3.35e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4919044	0.599	rs10882131	chr10:94711319	C/T	cg05127821	chr10:94822908	CYP26C1	-1.06	-6.33	-0.54	8.17e-9	Coronary artery disease;
THYM	cis	rs7616559	0.962	rs9818427	chr3:156726832	T/A	cg15697575	chr3:156784781	NA	0.4	5.03	0.46	2.35e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs8114671	0.967	rs4911472	chr20:33775377	T/A	cg08999081	chr20:33150536	PIGU	0.53	4.77	0.44	6.63e-6	Height;
THYM	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg05313129	chr8:58192883	C8orf71	-0.87	-5.08	-0.46	1.84e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs3096299	0.738	rs9929606	chr16:89527537	C/T	cg02187348	chr16:89574699	SPG7	0.82	6.61	0.56	2.25e-9	Multiple myeloma (IgH translocation);
THYM	trans	rs34156428	1.000	rs67445592	chr11:16505584	G/T	cg02688867	chr12:133019854	NA	0.54	6.89	0.58	6.12e-10	Coronary artery disease;
THYM	cis	rs2439831	0.867	rs2242068	chr15:43699304	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	7.09	0.59	2.39e-10	Lung cancer in ever smokers;
THYM	cis	rs1385374	0.858	rs11059928	chr12:129296103	A/T	cg04043695	chr12:129287642	SLC15A4	-0.81	-4.85	-0.45	4.79e-6	Systemic lupus erythematosus;
THYM	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12257961	0.608	rs7072713	chr10:15339742	C/T	cg10616319	chr10:15468812	NA	-0.59	-4.79	-0.44	6.05e-6	Selective IgA deficiency;
THYM	cis	rs853679	1.000	rs10456362	chr6:28221816	A/G	cg17849569	chr6:28058911	ZSCAN12L1	-0.74	-4.48	-0.42	2.05e-5	Depression;
THYM	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg06636001	chr8:8085503	FLJ10661	0.68	6.5	0.55	3.77e-9	Systolic blood pressure;
THYM	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg24874828	chr4:187887005	NA	-0.75	-7.9	-0.63	4.98e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg11764359	chr7:65958608	NA	0.69	4.67	0.43	9.75e-6	Aortic root size;
THYM	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg19507638	chr5:93509721	C5orf36	-0.65	-4.54	-0.42	1.63e-5	Diabetic retinopathy;
THYM	cis	rs1050631	0.592	rs1789547	chr18:33725705	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.32	0.48	6.94e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs3947	1.000	rs3947	chr8:11702375	G/A	cg26752888	chr8:11627280	NEIL2	-0.69	-4.55	-0.42	1.61e-5	Blood protein levels;
THYM	cis	rs10979	0.931	rs9403509	chr6:143888691	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg04865290	chr3:52927548	TMEM110	-0.88	-4.55	-0.42	1.59e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg16586182	chr3:47516702	SCAP	-0.64	-5.61	-0.5	2.03e-7	Colorectal cancer;
THYM	cis	rs11628318	0.515	rs1951630	chr14:103076807	A/T	cg27124170	chr14:102829869	TECPR2;CINP	-0.65	-4.47	-0.42	2.15e-5	Platelet count;
THYM	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg18876405	chr7:65276391	NA	-0.6	-5.13	-0.47	1.52e-6	Aortic root size;
THYM	cis	rs17102423	0.652	rs4902361	chr14:65548470	G/T	cg11161011	chr14:65562177	MAX	-0.69	-5.51	-0.49	3.02e-7	Obesity-related traits;
THYM	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7100689	0.622	rs10736344	chr10:82133955	T/C	cg01528321	chr10:82214614	TSPAN14	0.79	6.01	0.52	3.47e-8	Post bronchodilator FEV1;
THYM	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.72	-5.83	-0.51	7.65e-8	Systemic lupus erythematosus;
THYM	cis	rs6988636	1.000	rs58177772	chr8:124188067	T/C	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs4638749	0.677	rs6757761	chr2:108834842	T/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs1050631	0.592	rs1789546	chr18:33725874	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.6	4.84	0.44	5.05e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg01831904	chr17:28903510	LRRC37B2	-1.0	-5.11	-0.46	1.65e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg25427524	chr10:38739819	LOC399744	-0.69	-6.47	-0.55	4.31e-9	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg10661904	chr17:79619235	PDE6G	-0.59	-5.65	-0.5	1.69e-7	Eye color traits;
THYM	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg09990169	chr2:241835740	C2orf54	0.37	6.15	0.53	1.8e-8	Urinary metabolites;
THYM	cis	rs7246657	0.941	rs10418729	chr19:37737065	A/C	cg23950597	chr19:37808831	NA	-0.74	-4.72	-0.44	7.99e-6	Coronary artery calcification;
THYM	cis	rs2505998	0.787	rs28502801	chr10:43584039	A/T	cg06632098	chr10:43605906	RET	-1.08	-10.26	-0.73	4.6e-17	Hirschsprung disease;
THYM	cis	rs11696501	0.688	rs4812955	chr20:44324638	G/C	cg11783356	chr20:44313418	WFDC10B	-0.71	-4.79	-0.44	6.07e-6	Brain structure;
THYM	cis	rs28595532	0.841	rs55823625	chr4:119780600	T/A	cg21605333	chr4:119757512	SEC24D	1.61	6.06	0.53	2.69e-8	Cannabis dependence symptom count;
THYM	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg18446336	chr7:2847575	GNA12	-0.43	-4.47	-0.42	2.16e-5	Height;
THYM	cis	rs986417	0.901	rs11627533	chr14:61037801	C/T	cg27398547	chr14:60952738	C14orf39	1.25	6.45	0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg27490568	chr2:178487706	NA	0.59	5.66	0.5	1.59e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg10792982	chr14:105748885	BRF1	0.67	6.69	0.57	1.5e-9	Mean platelet volume;Platelet distribution width;
THYM	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg05393297	chr12:53359155	NA	-0.57	-6.54	-0.56	3.13e-9	Prostate cancer;
THYM	cis	rs988913	0.793	rs995851	chr6:54735594	G/A	cg18532076	chr6:54711417	FAM83B	0.53	4.81	0.44	5.66e-6	Menarche (age at onset);
THYM	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg25358565	chr5:93447407	FAM172A	0.96	6.78	0.57	1.01e-9	Diabetic retinopathy;
THYM	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg16624210	chr5:671434	TPPP	-0.76	-5.61	-0.5	2.03e-7	Obesity-related traits;
THYM	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg12165864	chr7:66369176	NA	-0.81	-6.09	-0.53	2.36e-8	Corneal structure;
THYM	cis	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg09307838	chr4:120376055	NA	0.7	5.27	0.48	8.48e-7	Corneal astigmatism;
THYM	cis	rs346785	0.692	rs2279056	chr17:74309474	C/T	cg10318678	chr17:74308979	PRPSAP1	0.5	4.6	0.43	1.32e-5	White matter hyperintensities in ischemic stroke;
THYM	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg06784218	chr1:46089804	CCDC17	-0.34	-5.03	-0.46	2.28e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7523273	0.586	rs2796264	chr1:207919968	A/G	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg10018233	chr7:150070692	REPIN1	0.37	5.3	0.48	7.38e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg04944784	chr2:26401820	FAM59B	-1.05	-8.18	-0.64	1.23e-12	Gut microbiome composition (summer);
THYM	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg11266682	chr4:10021025	SLC2A9	0.73	12.79	0.8	2.29e-22	Bone mineral density;
THYM	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.73	-5.88	-0.52	6.11e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg06634786	chr22:41940651	POLR3H	-0.58	-4.83	-0.44	5.22e-6	Neuroticism;
THYM	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg18811423	chr2:55921094	PNPT1	0.68	5.81	0.51	8.25e-8	Metabolic syndrome;
THYM	cis	rs360798	0.512	rs2710640	chr2:63144305	A/G	cg17519650	chr2:63277830	OTX1	0.69	4.82	0.44	5.38e-6	Coronary artery disease;
THYM	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg16325326	chr1:53192061	ZYG11B	0.69	5.67	0.5	1.56e-7	Monocyte count;
THYM	cis	rs4523957	0.890	rs216218	chr17:2145329	A/G	cg16513277	chr17:2031491	SMG6	0.8	7.55	0.61	2.58e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1061377	0.965	rs7669376	chr4:39118337	T/C	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg02725872	chr8:58115012	NA	-1.16	-7.63	-0.62	1.8e-11	Developmental language disorder (linguistic errors);
THYM	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs9403317	1.000	rs9403317	chr6:141859282	A/G	cg15052665	chr6:141804349	NA	0.83	7.58	0.61	2.27e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7173743	0.756	rs8035039	chr15:79129823	A/G	cg00540400	chr15:79124168	NA	0.59	6.04	0.53	2.97e-8	Coronary artery disease;
THYM	cis	rs7246967	0.673	rs7247191	chr19:22899585	C/T	cg05241461	chr19:22816980	ZNF492	0.6	4.66	0.43	1.05e-5	Bronchopulmonary dysplasia;
THYM	cis	rs11924390	0.749	rs822364	chr3:186452716	A/G	cg12454167	chr3:186435060	KNG1	0.46	6.08	0.53	2.55e-8	Adiponectin levels;
THYM	cis	rs4970988	0.607	rs7548516	chr1:150980281	C/T	cg15448220	chr1:150897856	SETDB1	-0.68	-4.46	-0.42	2.23e-5	Urate levels;
THYM	cis	rs13403149	1.000	rs13403149	chr2:2843308	G/A	cg12915819	chr2:3453113	TTC15	-0.5	-4.48	-0.42	2.07e-5	Smoking initiation;
THYM	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02475777	chr4:1388615	CRIPAK	-0.66	-4.81	-0.44	5.58e-6	Longevity;
THYM	cis	rs3771570	0.901	rs3815262	chr2:242352582	A/T	cg21155796	chr2:242212141	HDLBP	1.09	6.4	0.55	5.95e-9	Prostate cancer;
THYM	cis	rs4589258	0.933	rs1792601	chr11:90440531	G/T	cg26138821	chr11:89956704	CHORDC1	0.7	5.9	0.52	5.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs34638657	0.833	rs4889479	chr16:82201474	T/C	cg09439754	chr16:82129088	HSD17B2	-0.57	-5.6	-0.5	2.06e-7	Lung adenocarcinoma;
THYM	cis	rs11696501	0.688	rs6104291	chr20:44323368	C/G	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg19875535	chr5:140030758	IK	-0.59	-5.11	-0.46	1.63e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs3772130	0.926	rs13072767	chr3:121504098	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs1267303	0.642	rs1267301	chr1:46992853	C/G	cg25110126	chr1:46999211	NA	-0.78	-6.01	-0.53	3.35e-8	Monobrow;
THYM	cis	rs4788570	0.584	rs979790	chr16:71665985	A/T	cg06353428	chr16:71660113	MARVELD3	-1.31	-8.93	-0.68	3.12e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg19901468	chr14:105411992	AHNAK2	-0.82	-6.74	-0.57	1.24e-9	Rheumatoid arthritis;
THYM	cis	rs9807989	0.765	rs6751967	chr2:102967413	T/C	cg03938978	chr2:103052716	IL18RAP	0.61	6.04	0.53	3.04e-8	Asthma;
THYM	cis	rs13102973	0.932	rs28801464	chr4:135876630	A/G	cg14419869	chr4:135874104	NA	-0.82	-7.97	-0.63	3.53e-12	Subjective well-being;
THYM	cis	rs888194	0.677	rs7973253	chr12:109878115	A/G	cg10504392	chr12:110044639	NA	0.64	5.96	0.52	4.31e-8	Neuroticism;
THYM	cis	rs2133450	0.508	rs17047073	chr3:7349612	A/G	cg19930620	chr3:7340148	GRM7	-0.52	-5.62	-0.5	1.86e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg10856724	chr12:34555212	NA	-0.8	-7.05	-0.59	2.88e-10	Morning vs. evening chronotype;
THYM	cis	rs933688	0.818	rs10052492	chr5:90759930	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.05	7.75	0.62	1.03e-11	Smoking behavior;
THYM	cis	rs4363385	0.818	rs1048296	chr1:153012240	A/C	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs11948739	0.610	rs6873276	chr5:130225030	A/G	cg08523029	chr5:130500466	HINT1	-0.81	-5.75	-0.51	1.08e-7	Pediatric bone mineral content (hip);
THYM	cis	rs10857712	0.687	rs11101742	chr10:135224372	C/G	cg00491522	chr10:135256596	NA	0.61	5.04	0.46	2.21e-6	Systemic lupus erythematosus;
THYM	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	4.83	0.44	5.15e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.78	4.62	0.43	1.22e-5	Lung function (FEV1/FVC);
THYM	cis	rs2295499	0.610	rs17164090	chr4:2676016	G/C	cg14003022	chr4:3043019	NA	0.51	4.48	0.42	2.11e-5	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg08305652	chr11:111469057	NA	-0.53	-4.46	-0.42	2.23e-5	Primary sclerosing cholangitis;
THYM	cis	rs7089973	0.872	rs17092497	chr10:116612628	G/A	cg08188268	chr10:116634841	FAM160B1	-0.31	-4.99	-0.46	2.7e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs11825685	0.887	rs78806216	chr11:134568320	C/T	cg02395454	chr11:134605862	NA	-0.98	-4.88	-0.45	4.22e-6	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1801251	0.964	rs12472839	chr2:233559615	A/G	cg08000102	chr2:233561755	GIGYF2	0.72	6.64	0.56	1.89e-9	Coronary artery disease;
THYM	cis	rs9359856	0.662	rs1179904	chr6:90322573	A/G	cg13799429	chr6:90582589	CASP8AP2	0.8	7.65	0.62	1.65e-11	Bipolar disorder;
THYM	cis	rs6964587	0.610	rs4729008	chr7:91457054	G/T	cg17063962	chr7:91808500	NA	0.98	8.04	0.64	2.49e-12	Breast cancer;
THYM	cis	rs981844	0.725	rs872453	chr4:154727131	T/C	cg09973105	chr4:154681532	RNF175	-0.67	-6.2	-0.54	1.44e-8	Response to statins (LDL cholesterol change);
THYM	cis	rs72627123	0.867	rs73301475	chr14:74462868	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs711830	1.000	rs6433571	chr2:177039578	G/T	cg26754761	chr2:177040938	NA	-0.58	-5.03	-0.46	2.27e-6	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg13683864	chr3:40499215	RPL14	-1.07	-11.9	-0.77	1.58e-20	Renal cell carcinoma;
THYM	cis	rs9646944	0.501	rs10172116	chr2:103087573	C/T	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg07570687	chr10:102243282	WNT8B	0.75	6.81	0.57	8.62e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs12444261	0.961	rs4510029	chr16:11738037	C/A	cg09662852	chr16:11707685	NA	-0.49	-4.62	-0.43	1.23e-5	QT interval;
THYM	cis	rs67981189	0.788	rs2526860	chr14:71411878	T/C	cg15910301	chr14:71632612	NA	-0.5	-4.52	-0.42	1.77e-5	Schizophrenia;
THYM	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg27572855	chr1:25598939	RHD	-0.65	-4.93	-0.45	3.43e-6	Erythrocyte sedimentation rate;
THYM	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6138458	1.000	rs227616	chr20:24908811	T/C	cg26195577	chr20:24973756	C20orf3	1.12	10.51	0.73	1.38e-17	Blood protein levels;
THYM	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15506890	chr2:3487001	NA	-0.54	-4.55	-0.42	1.55e-5	Neurofibrillary tangles;
THYM	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg24692254	chr21:30365293	RNF160	0.64	4.6	0.43	1.31e-5	Selective IgA deficiency;
THYM	cis	rs459571	1.000	rs456207	chr9:136911140	G/A	cg13789015	chr9:136890014	NCRNA00094	0.78	6.65	0.56	1.88e-9	Platelet distribution width;
THYM	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg25767906	chr1:53392781	SCP2	-0.68	-6.42	-0.55	5.45e-9	Monocyte count;
THYM	cis	rs2663905	0.560	rs1879454	chr15:81377717	C/A	cg09888468	chr15:81410853	NA	-0.7	-5.44	-0.49	4.12e-7	QT interval (drug interaction);
THYM	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg11764359	chr7:65958608	NA	-0.82	-6.45	-0.55	4.58e-9	Aortic root size;
THYM	cis	rs8048589	0.559	rs35542345	chr16:12210618	T/C	cg02910054	chr16:12241554	SNX29	0.8	6.12	0.53	2.08e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs6466832	0.568	rs17144752	chr7:122359692	A/G	cg22684968	chr7:121784356	AASS	0.83	4.48	0.42	2.06e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4719841	0.662	rs4574742	chr7:25995063	A/G	cg24254488	chr7:25991654	NA	-0.52	-4.68	-0.43	9.35e-6	Triglyceride levels;
THYM	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg03806693	chr22:41940476	POLR3H	-1.19	-10.1	-0.72	1.03e-16	Vitiligo;
THYM	cis	rs10095849	0.608	rs72641297	chr8:39472233	C/T	cg22755526	chr8:38854673	TM2D2;ADAM9	-0.62	-4.61	-0.43	1.24e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4986172	0.726	rs12051846	chr17:43226887	A/G	cg27395066	chr17:43221220	ACBD4	0.62	5.03	0.46	2.28e-6	Height;
THYM	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.24	-4.55	-0.42	1.58e-5	Obesity-related traits;
THYM	cis	rs12815613	0.621	rs11065360	chr12:121386532	A/G	cg02403541	chr12:121454288	C12orf43	-0.69	-5.12	-0.47	1.58e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
THYM	cis	rs11563648	0.573	rs7804307	chr7:126946000	G/A	cg23081781	chr7:127225937	GCC1	-0.34	-4.69	-0.43	9.14e-6	Resting heart rate;
THYM	cis	rs7107174	1.000	rs2510046	chr11:77988817	T/C	cg19901956	chr11:77921274	USP35	-0.69	-5.3	-0.48	7.42e-7	Testicular germ cell tumor;
THYM	cis	rs28595532	0.841	rs114175487	chr4:119733580	C/G	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs73198271	0.740	rs10110711	chr8:8650456	C/T	cg15556689	chr8:8085844	FLJ10661	-0.74	-4.91	-0.45	3.75e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs10089	0.953	rs72794400	chr5:127516028	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.93	6.03	0.53	3.15e-8	Ileal carcinoids;
THYM	cis	rs7551222	0.752	rs4252677	chr1:204495253	G/A	cg20240347	chr1:204465584	NA	-0.51	-4.54	-0.42	1.64e-5	Schizophrenia;
THYM	cis	rs17209837	0.646	rs10452935	chr7:87094247	A/T	cg04996195	chr7:87105398	ABCB4	0.62	4.78	0.44	6.49e-6	Gallbladder cancer;
THYM	cis	rs7572733	0.555	rs7561950	chr2:198754244	C/T	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs1729951	0.575	rs1654923	chr3:136692620	A/T	cg12473912	chr3:136751656	NA	0.63	5.13	0.47	1.55e-6	Neuroticism;
THYM	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg19746536	chr19:49375674	PPP1R15A	0.79	4.46	0.42	2.28e-5	Red cell distribution width;
THYM	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg19748678	chr4:122722346	EXOSC9	0.71	4.98	0.45	2.9e-6	Type 2 diabetes;
THYM	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg23711669	chr6:146136114	FBXO30	-0.88	-8.54	-0.66	2.18e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7264396	0.887	rs58458373	chr20:34045611	T/A	cg26038318	chr20:34205095	SPAG4	0.53	4.47	0.42	2.15e-5	Total cholesterol levels;
THYM	cis	rs2050392	0.965	rs2265370	chr10:30690581	C/T	cg02070205	chr10:30722105	MAP3K8	-0.53	-4.69	-0.43	9.07e-6	Inflammatory bowel disease;
THYM	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg22920501	chr2:26401640	FAM59B	-1.05	-9.27	-0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs4654899	0.796	rs61779135	chr1:21532625	G/A	cg01072550	chr1:21505969	NA	-0.75	-6.75	-0.57	1.19e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Body mass index;
THYM	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg22431228	chr1:16359049	CLCNKA	-0.52	-4.99	-0.46	2.71e-6	Dilated cardiomyopathy;
THYM	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg23583168	chr7:148888333	NA	-1.02	-13.19	-0.8	3.43e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg09436375	chr6:42928200	GNMT	-0.45	-5.88	-0.52	6.11e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7616559	0.789	rs4680336	chr3:156770688	T/A	cg15697575	chr3:156784781	NA	0.44	5.73	0.51	1.18e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg03806693	chr22:41940476	POLR3H	1.08	8.77	0.67	7.1e-14	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4919044	0.808	rs835256	chr10:94779550	C/T	cg05127821	chr10:94822908	CYP26C1	-1.31	-6.9	-0.58	5.75e-10	Coronary artery disease;
THYM	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs2806561	0.765	rs679591	chr1:23499916	T/C	cg19743168	chr1:23544995	NA	0.57	5.85	0.51	6.96e-8	Height;
THYM	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg27535305	chr1:53392650	SCP2	0.38	4.55	0.42	1.6e-5	Monocyte count;
THYM	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg12031863	chr16:4587854	C16orf5	-0.42	-4.47	-0.42	2.15e-5	Schizophrenia;
THYM	cis	rs800586	0.522	rs2049874	chr8:116664938	G/A	cg04656070	chr8:116661063	TRPS1	-0.55	-6.57	-0.56	2.66e-9	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs300890	0.689	rs7697838	chr4:144247348	T/C	cg01601573	chr4:144256835	GAB1	0.37	4.53	0.42	1.7e-5	Nasopharyngeal carcinoma;
THYM	cis	rs8013055	0.796	rs4075104	chr14:106000214	C/A	cg04429589	chr14:105992532	TMEM121	-0.53	-5.66	-0.5	1.58e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg18252515	chr7:66147081	NA	-0.66	-5.01	-0.46	2.55e-6	Aortic root size;
THYM	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg00981070	chr1:2046702	PRKCZ	0.47	5.21	0.47	1.1e-6	Height;
THYM	cis	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs6032067	0.683	rs6032029	chr20:43786064	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-6.26	-0.54	1.12e-8	Blood protein levels;
THYM	cis	rs966423	0.550	rs2568176	chr2:218303958	G/A	cg15335768	chr2:218268053	DIRC3	-0.33	-4.68	-0.43	9.59e-6	Thyroid cancer;
THYM	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg00376283	chr12:123451042	ABCB9	-0.78	-6.19	-0.54	1.55e-8	Platelet count;
THYM	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg12310025	chr6:25882481	NA	0.66	5.46	0.49	3.84e-7	Blood metabolite levels;
THYM	cis	rs10819861	0.679	rs7854100	chr9:98864599	T/G	cg14508093	chr9:98862825	NA	-0.24	-4.47	-0.42	2.13e-5	Electrocardiographic traits;
THYM	cis	rs10979	1.000	rs10979	chr6:143890039	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg05717871	chr11:638507	DRD4	-0.69	-6.03	-0.53	3.1e-8	Systemic lupus erythematosus;
THYM	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg13736514	chr6:26305472	NA	-0.61	-7.45	-0.61	4.16e-11	Educational attainment;
THYM	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs10799590	0.897	rs873594	chr1:224881546	C/G	cg01808320	chr1:224927238	CNIH3	0.51	4.55	0.42	1.59e-5	Opioid dependence;
THYM	cis	rs868036	0.681	rs28670272	chr15:68109907	C/T	cg24579218	chr15:68104479	NA	0.82	8.76	0.67	7.24e-14	Restless legs syndrome;
THYM	cis	rs7917772	0.582	rs12411442	chr10:104349531	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg03909863	chr11:638404	DRD4	-0.78	-5.75	-0.51	1.07e-7	Systemic lupus erythematosus;
THYM	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg12311346	chr5:56204834	C5orf35	-0.7	-5.3	-0.48	7.6e-7	Coronary artery disease;
THYM	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs2637266	1.000	rs12251543	chr10:78345465	G/A	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs899997	1.000	rs12907207	chr15:79031290	G/A	cg04896959	chr15:78267971	NA	0.89	7.17	0.59	1.64e-10	Coronary artery disease or large artery stroke;
THYM	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg04520793	chr17:42248056	ASB16	0.33	4.56	0.42	1.54e-5	Total body bone mineral density;
THYM	cis	rs728616	0.614	rs57966752	chr10:81728313	G/A	cg27452691	chr10:81370291	SFTPA1	0.59	4.6	0.43	1.33e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg10505658	chr17:80084571	CCDC57	0.62	4.49	0.42	1.99e-5	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6838801	0.892	rs10029193	chr4:77576894	G/A	cg01477861	chr4:77609841	SHROOM3	0.47	4.7	0.43	8.9e-6	Cleft lip with or without cleft palate;
THYM	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.61	7.95	0.63	3.85e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6733011	0.628	rs4850888	chr2:99456946	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.46	-0.42	2.26e-5	Bipolar disorder;
THYM	cis	rs12950390	0.512	rs11655306	chr17:45858744	C/T	cg24803719	chr17:45855879	NA	-0.63	-5.21	-0.47	1.08e-6	IgG glycosylation;
THYM	cis	rs870825	0.616	rs10013562	chr4:185610486	A/G	cg04058563	chr4:185651563	MLF1IP	1.08	9.64	0.7	9.89e-16	Blood protein levels;
THYM	cis	rs12935418	0.583	rs2549848	chr16:81024298	G/C	cg16651780	chr16:81037892	C16orf61	-0.86	-6.73	-0.57	1.3e-9	Mean corpuscular volume;
THYM	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg24675658	chr1:53192096	ZYG11B	0.55	4.66	0.43	1.04e-5	Monocyte count;
THYM	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg11905131	chr22:24372483	LOC391322	0.96	10.62	0.74	7.96e-18	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg01364799	chr7:75623366	TMEM120A	0.63	4.56	0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6901004	0.570	rs783084	chr6:111477887	T/C	cg15721981	chr6:111408429	SLC16A10	0.92	6.12	0.53	2.06e-8	Blood metabolite levels;
THYM	cis	rs7772486	0.558	rs7753273	chr6:146066039	C/T	cg23711669	chr6:146136114	FBXO30	-0.84	-7.83	-0.63	6.82e-12	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs9929218	0.551	rs4783663	chr16:68720271	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.15	16.62	0.86	7.12e-30	Colorectal cancer;
THYM	cis	rs2997447	0.846	rs61775417	chr1:26393347	C/G	cg03844060	chr1:26490628	NA	0.66	4.5	0.42	1.96e-5	QRS complex (12-leadsum);
THYM	cis	rs4845875	0.600	rs6699881	chr1:11836628	T/C	cg06193043	chr1:11908199	NPPA	0.58	4.95	0.45	3.18e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs72712511	0.505	rs795989	chr4:140729346	A/G	cg15010390	chr4:140216957	NDUFC1	0.73	6.23	0.54	1.27e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg12863693	chr15:85201151	NMB	0.63	5.49	0.49	3.38e-7	Schizophrenia;
THYM	cis	rs2073300	1.000	rs6048833	chr20:23462185	G/A	cg12062639	chr20:23401060	NAPB	0.96	4.84	0.45	4.95e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	trans	rs8002861	0.870	rs4942255	chr13:44451844	A/T	cg17145862	chr1:211918768	LPGAT1	-0.86	-8.68	-0.67	1.07e-13	Leprosy;
THYM	cis	rs9633835	0.524	rs4757134	chr11:13272902	C/T	cg13286116	chr11:13302098	ARNTL	-0.72	-8.03	-0.64	2.61e-12	Body mass index;
THYM	cis	rs7255436	0.931	rs7249520	chr19:8446056	G/A	cg10174797	chr19:8464628	RAB11B	0.42	4.97	0.45	2.99e-6	HDL cholesterol;
THYM	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg27534772	chr1:16042836	PLEKHM2	0.56	6.21	0.54	1.4e-8	Systolic blood pressure;
THYM	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03517284	chr6:25882590	NA	-0.72	-5.78	-0.51	9.51e-8	Blood metabolite levels;
THYM	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg07936489	chr17:37558343	FBXL20	-0.71	-5.25	-0.47	9.23e-7	Asthma;
THYM	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg04731861	chr2:219085781	ARPC2	0.53	4.9	0.45	4.01e-6	Colorectal cancer;
THYM	cis	rs17470137	1.000	rs17469907	chr5:122528420	A/G	cg04547002	chr5:122551801	NA	0.65	4.62	0.43	1.22e-5	Aortic root size;
THYM	cis	rs7017697	0.642	rs3927029	chr8:19681933	G/A	cg03894339	chr8:19674705	INTS10	-0.61	-4.83	-0.44	5.3e-6	Breast cancer;
THYM	cis	rs3126085	0.935	rs12409762	chr1:152175398	G/A	cg26020982	chr1:152196106	HRNR	-0.35	-4.62	-0.43	1.22e-5	Atopic dermatitis;
THYM	cis	rs9527	0.590	rs10786738	chr10:104869451	C/T	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs9644630	0.965	rs10105097	chr8:19364883	A/C	cg01280390	chr8:19363452	CSGALNACT1	-0.83	-9.12	-0.68	1.27e-14	Oropharynx cancer;
THYM	cis	rs2919009	0.607	rs12265028	chr10:122719074	G/A	cg26518861	chr10:122708898	NA	-0.63	-4.9	-0.45	3.97e-6	Obesity-related traits;
THYM	cis	rs2506889	0.553	rs11580264	chr1:10605796	C/A	cg20482658	chr1:10539492	PEX14	-0.38	-5.96	-0.52	4.36e-8	Breast cancer;
THYM	cis	rs734999	0.588	rs78506337	chr1:2537095	G/A	cg04866029	chr1:2707161	NA	0.43	4.53	0.42	1.73e-5	Ulcerative colitis;
THYM	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg26031613	chr14:104095156	KLC1	0.79	5.33	0.48	6.61e-7	Body mass index;
THYM	cis	rs6032067	0.777	rs2868234	chr20:43794026	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs854765	0.551	rs6502626	chr17:17849450	C/T	cg04398451	chr17:18023971	MYO15A	-0.79	-7.17	-0.59	1.63e-10	Total body bone mineral density;
THYM	cis	rs939658	0.683	rs8038464	chr15:79463036	A/T	cg17916960	chr15:79447300	NA	-0.71	-8.21	-0.64	1.1e-12	Refractive error;
THYM	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg01416388	chr22:39784598	NA	-0.77	-4.63	-0.43	1.17e-5	IgG glycosylation;
THYM	cis	rs1729951	0.575	rs1654904	chr3:136681149	T/C	cg12473912	chr3:136751656	NA	0.63	5.13	0.47	1.55e-6	Neuroticism;
THYM	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg05234568	chr11:5960015	NA	-0.58	-4.7	-0.43	8.93e-6	DNA methylation (variation);
THYM	trans	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg19862616	chr7:65841803	NCRNA00174	-1.12	-13.73	-0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7809950	0.593	rs62482503	chr7:106987988	A/G	cg23024343	chr7:107201750	COG5	-1.0	-8.47	-0.66	3.05e-13	Coronary artery disease;
THYM	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg27446573	chr6:127587934	RNF146	0.87	6.74	0.57	1.22e-9	Breast cancer;
THYM	cis	rs921968	0.643	rs535830	chr2:219372233	C/G	cg02176678	chr2:219576539	TTLL4	0.64	6.08	0.53	2.49e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg05368731	chr17:41323189	NBR1	1.25	11.25	0.76	3.57e-19	Menopause (age at onset);
THYM	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg13395646	chr4:1353034	KIAA1530	-0.61	-6.13	-0.53	2.03e-8	Longevity;
THYM	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Body mass index;
THYM	cis	rs2282300	0.739	rs7926465	chr11:30333016	C/T	cg09906309	chr11:30344399	C11orf46	0.73	5.37	0.48	5.47e-7	Morning vs. evening chronotype;
THYM	cis	rs988913	0.957	rs9475068	chr6:54791581	A/G	cg04690482	chr6:54711388	FAM83B	0.5	5.29	0.48	7.88e-7	Menarche (age at onset);
THYM	cis	rs13315871	0.929	rs17354606	chr3:58237289	T/C	cg00563845	chr3:58318305	PXK	0.59	4.88	0.45	4.23e-6	Cholesterol, total;
THYM	cis	rs7786808	0.579	rs12669482	chr7:158188813	G/A	cg15440763	chr7:158190612	PTPRN2	0.49	4.61	0.43	1.24e-5	Obesity-related traits;
THYM	trans	rs637571	0.584	rs659824	chr11:65636509	A/G	cg17712092	chr4:129076599	LARP1B	-0.92	-7.8	-0.62	7.9e-12	Eosinophil percentage of white cells;
THYM	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg23260525	chr10:116636907	FAM160B1	0.49	5.01	0.46	2.49e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg11752832	chr7:134001865	SLC35B4	0.72	4.89	0.45	4.16e-6	Mean platelet volume;
THYM	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg08017756	chr2:100939284	LONRF2	-0.75	-7.78	-0.62	8.81e-12	Intelligence (multi-trait analysis);
THYM	cis	rs3916	0.910	rs7306541	chr12:121130046	A/G	cg21892295	chr12:121157589	UNC119B	-0.52	-5.17	-0.47	1.31e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs1691799	0.867	rs1168342	chr12:66758734	A/T	cg16791601	chr12:66731901	HELB	-0.72	-6.82	-0.57	8.35e-10	White blood cell count (basophil);
THYM	cis	rs9470366	0.509	rs4714001	chr6:36638175	G/A	cg08179530	chr6:36648295	CDKN1A	-0.62	-4.54	-0.42	1.64e-5	QRS duration;
THYM	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.48	-4.8	-0.44	5.86e-6	Crohn's disease;
THYM	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs17253792	0.822	rs17747083	chr14:56110594	T/C	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-11.39	-0.76	1.85e-19	Coronary artery disease;
THYM	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg13736514	chr6:26305472	NA	-0.58	-6.5	-0.55	3.75e-9	Educational attainment;
THYM	cis	rs7836436	0.818	rs2001252	chr8:121035672	G/A	cg05020510	chr8:120428057	NOV	1.02	5.63	0.5	1.85e-7	HIV-1 viral setpoint;
THYM	cis	rs6952809	0.532	rs7803015	chr7:2432143	G/A	cg13581527	chr7:1708566	NA	-0.76	-5.36	-0.48	5.7e-7	Multiple sclerosis;
THYM	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg18477163	chr1:228402036	OBSCN	-0.46	-5.01	-0.46	2.54e-6	Diastolic blood pressure;
THYM	cis	rs12208915	0.848	rs7757382	chr6:79502277	C/G	cg05283184	chr6:79620031	NA	0.79	5.28	0.48	8.01e-7	Left atrial antero-posterior diameter;
THYM	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg22431228	chr1:16359049	CLCNKA	0.5	5.07	0.46	1.96e-6	Dilated cardiomyopathy;
THYM	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.89	-5.94	-0.52	4.64e-8	Gut microbiome composition (summer);
THYM	cis	rs1747683	0.932	rs2027167	chr10:13372390	T/C	cg00142036	chr10:13388442	SEPHS1	-0.29	-5.18	-0.47	1.24e-6	IgG glycosylation;
THYM	cis	rs7572733	0.534	rs1983359	chr2:198805098	C/T	cg00792783	chr2:198669748	PLCL1	0.82	5.75	0.51	1.08e-7	Dermatomyositis;
THYM	cis	rs9549260	0.755	rs1923249	chr13:41143881	C/A	cg21288729	chr13:41239152	FOXO1	0.73	5.6	0.5	2.11e-7	Red blood cell count;
THYM	cis	rs6840360	0.642	rs11099815	chr4:152343888	G/T	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.3	-0.48	7.43e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg10523679	chr1:76189770	ACADM	-0.83	-6.65	-0.56	1.82e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg18758796	chr5:131593413	PDLIM4	0.63	6.48	0.55	4.03e-9	Acylcarnitine levels;
THYM	cis	rs7191439	0.858	rs4390574	chr16:88776297	T/C	cg27087555	chr16:88793112	FAM38A	-1.2	-7.27	-0.6	1.03e-10	Plateletcrit;
THYM	cis	rs7255045	0.742	rs2305796	chr19:12954141	C/T	cg26870725	chr19:12978805	MAST1	-0.62	-4.61	-0.43	1.27e-5	Mean corpuscular volume;
THYM	cis	rs7607369	0.718	rs6727147	chr2:219639024	G/A	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs5758511	0.680	rs5758699	chr22:42688034	C/G	cg08431931	chr22:42394659	WBP2NL	0.69	4.95	0.45	3.24e-6	Birth weight;
THYM	cis	rs9992101	0.612	rs56049812	chr4:77227676	A/C	cg20311846	chr4:77356250	SHROOM3	-0.54	-5.96	-0.52	4.32e-8	Creatinine levels;
THYM	cis	rs1150668	0.830	rs2023493	chr6:28400162	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.62	-4.93	-0.45	3.51e-6	Pubertal anthropometrics;
THYM	cis	rs2219968	0.887	rs1947897	chr8:78946874	G/C	cg00738934	chr8:78996279	NA	0.76	7.35	0.6	6.88e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs600806	0.850	rs1880670	chr1:109941133	C/T	cg23032129	chr1:109941072	SORT1	-0.59	-5.03	-0.46	2.31e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg05962950	chr11:130786565	SNX19	0.7	5.57	0.5	2.41e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9457247	0.534	rs4710154	chr6:167394634	A/T	cg23791538	chr6:167370224	RNASET2	0.83	7.32	0.6	7.9e-11	Crohn's disease;
THYM	cis	rs10752881	0.967	rs4652757	chr1:182974750	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs7106204	0.748	rs28552633	chr11:24207518	A/C	ch.11.24196551F	chr11:24239977	NA	0.95	6.84	0.57	7.8e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs56775891	1.000	rs6650631	chr18:77566535	G/C	cg13263691	chr18:77568018	NA	0.64	4.86	0.45	4.69e-6	Schizophrenia;
THYM	cis	rs13102973	0.720	rs7668824	chr4:135884707	A/T	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs80319144	1.000	rs112505400	chr2:159217187	C/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.58	4.66	0.43	1.05e-5	Restless legs syndrome;
THYM	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg02524346	chr8:600233	NA	1.0	4.61	0.43	1.24e-5	IgG glycosylation;
THYM	cis	rs4986172	0.690	rs11657325	chr17:43242694	C/T	cg10701640	chr17:43249399	NA	0.64	4.71	0.43	8.53e-6	Height;
THYM	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22496380	chr5:211416	CCDC127	-1.29	-7.89	-0.63	5.17e-12	Breast cancer;
THYM	cis	rs7084402	0.967	rs2170779	chr10:60277249	G/A	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg07131210	chr7:1025825	CYP2W1	-0.84	-4.55	-0.42	1.57e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7651039	0.641	rs2455916	chr3:15667383	C/T	cg16303742	chr3:15540471	COLQ	0.71	7.02	0.58	3.27e-10	Coronary heart disease;
THYM	cis	rs9906944	1.000	rs9906944	chr17:47091420	C/T	cg22947322	chr17:47091978	IGF2BP1	-0.55	-4.7	-0.43	8.67e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03452623	chr4:187889614	NA	-1.19	-19.33	-0.89	1.1e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg11530693	chr1:120165357	ZNF697	1.08	12.42	0.79	1.33e-21	Systemic lupus erythematosus;
THYM	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-4.96	-0.45	3.03e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg03605463	chr16:89740564	NA	-0.62	-4.54	-0.42	1.62e-5	Vitiligo;
THYM	cis	rs728616	0.867	rs12414521	chr10:81949534	G/C	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg08975724	chr8:8085496	FLJ10661	-0.63	-4.73	-0.44	7.66e-6	Mood instability;
THYM	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.01	7.9	0.63	4.97e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg19913688	chr11:428466	ANO9	-0.87	-4.61	-0.43	1.24e-5	Body mass index;
THYM	cis	rs4731207	0.671	rs4397336	chr7:124503196	C/T	cg05285228	chr7:124571219	POT1	0.72	5.15	0.47	1.4e-6	Cutaneous malignant melanoma;
THYM	cis	rs8067545	0.750	rs4925081	chr17:19991993	A/G	cg13482628	chr17:19912719	NA	-0.54	-4.52	-0.42	1.77e-5	Schizophrenia;
THYM	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg02734326	chr4:10020555	SLC2A9	-0.62	-5.17	-0.47	1.31e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg12935359	chr14:103987150	CKB	-0.64	-6.43	-0.55	5.14e-9	Body mass index;
THYM	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs4866334	0.867	rs78519816	chr5:18463568	G/A	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg13695892	chr22:41940480	POLR3H	-0.94	-7.28	-0.6	9.46e-11	Vitiligo;
THYM	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg00256281	chr22:41985642	PMM1	-0.56	-4.47	-0.42	2.2e-5	Vitiligo;
THYM	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	8.57	0.66	1.88e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg21433313	chr16:3507492	NAT15	-0.72	-5.35	-0.48	6.13e-7	Tuberculosis;
THYM	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg06634786	chr22:41940651	POLR3H	0.68	5.0	0.46	2.65e-6	Vitiligo;
THYM	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg25767906	chr1:53392781	SCP2	-0.53	-5.2	-0.47	1.13e-6	Monocyte count;
THYM	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.32	-9.95	-0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.47	0.49	3.63e-7	Bipolar disorder;
THYM	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg17366294	chr4:99064904	C4orf37	0.59	6.78	0.57	1e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs11785693	0.862	rs6990234	chr8:4996812	A/G	cg26367366	chr8:4980734	NA	1.21	5.9	0.52	5.46e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs3771570	1.000	rs62193204	chr2:242315443	A/G	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs6430585	0.941	rs7589832	chr2:136504101	A/C	cg07169764	chr2:136633963	MCM6	0.94	8.32	0.65	6.19e-13	Corneal structure;
THYM	cis	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg10760299	chr15:45669010	GATM	0.66	4.89	0.45	4.04e-6	Homoarginine levels;
THYM	cis	rs367615	0.879	rs4351197	chr5:108866667	A/G	cg17395555	chr5:108820864	NA	0.53	4.8	0.44	5.95e-6	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs34638657	0.518	rs7196560	chr16:82168162	A/T	cg09439754	chr16:82129088	HSD17B2	-0.49	-4.58	-0.43	1.39e-5	Lung adenocarcinoma;
THYM	trans	rs10802346	0.524	rs10802356	chr1:246385857	T/C	cg22732515	chr19:44031385	ETHE1	1.02	8.5	0.66	2.63e-13	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg27170947	chr2:26402098	FAM59B	-0.61	-5.04	-0.46	2.25e-6	Gut microbiome composition (summer);
THYM	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg18132916	chr6:79620363	NA	-0.59	-5.31	-0.48	7.31e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg17366294	chr4:99064904	C4orf37	0.54	6.4	0.55	5.74e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2219968	0.639	rs6986948	chr8:78907570	G/A	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg08975724	chr8:8085496	FLJ10661	0.66	5.45	0.49	3.96e-7	Mood instability;
THYM	cis	rs8060598	0.600	rs4990643	chr16:50759269	T/A	cg05261686	chr16:50743296	NOD2	0.37	4.56	0.42	1.52e-5	Leprosy;
THYM	cis	rs2273669	0.667	rs12208578	chr6:109369745	T/C	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg01073479	chr16:3509474	NAT15	0.63	5.24	0.47	9.82e-7	Tuberculosis;
THYM	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs59698941	0.943	rs17691584	chr5:132284251	A/C	cg02081065	chr5:132209139	LEAP2	-0.73	-4.79	-0.44	6.17e-6	Apolipoprotein A-IV levels;
THYM	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg03605463	chr16:89740564	NA	0.82	6.38	0.55	6.56e-9	Vitiligo;
THYM	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg01017244	chr2:74357527	NA	1.08	9.47	0.7	2.22e-15	Gestational age at birth (maternal effect);
THYM	cis	rs34311866	0.752	rs11725653	chr4:963397	C/T	cg11017086	chr4:979022	SLC26A1	0.71	4.65	0.43	1.08e-5	Parkinson's disease;
THYM	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg08742575	chr21:47604166	C21orf56	-0.68	-5.41	-0.49	4.7e-7	Testicular germ cell tumor;
THYM	cis	rs736408	0.581	rs3617	chr3:52833805	C/A	cg10802521	chr3:52805072	NEK4	-0.55	-4.74	-0.44	7.52e-6	Bipolar disorder;
THYM	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg11663144	chr21:46675770	NA	-0.69	-8.11	-0.64	1.79e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs75064307	0.798	rs2290601	chr3:108112760	C/T	cg03329597	chr3:108125523	MYH15	0.66	4.75	0.44	7.15e-6	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg15704280	chr7:45808275	SEPT13	-1.07	-15.24	-0.84	2.93e-27	Height;
THYM	cis	rs9443645	0.509	rs12176511	chr6:79565721	G/A	cg18132916	chr6:79620363	NA	0.5	4.57	0.42	1.44e-5	Intelligence (multi-trait analysis);
THYM	cis	rs760805	1.000	rs3845302	chr1:25259884	C/G	cg22509179	chr1:25234806	RUNX3	-0.7	-6.45	-0.55	4.71e-9	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7264396	0.616	rs6060744	chr20:34581555	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-4.71	-0.43	8.54e-6	Total cholesterol levels;
THYM	cis	rs12142240	0.698	rs7515284	chr1:46809419	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7631605	0.905	rs1558527	chr3:37115658	C/T	cg21328643	chr3:37258149	NA	0.49	4.69	0.43	9.17e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs919433	0.617	rs700646	chr2:198608511	C/T	cg00792783	chr2:198669748	PLCL1	0.77	5.13	0.47	1.53e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs17641971	0.684	rs12680366	chr8:49930674	T/C	cg00325661	chr8:49890786	NA	0.64	4.74	0.44	7.51e-6	Blood metabolite levels;
THYM	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg12379764	chr21:47803548	PCNT	0.91	8.23	0.64	1e-12	Testicular germ cell tumor;
THYM	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06873352	chr17:61820015	STRADA	0.56	5.58	0.5	2.22e-7	Height;
THYM	cis	rs67981189	0.858	rs35631530	chr14:71508029	G/C	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg12963246	chr6:28129442	ZNF389	0.72	6.2	0.54	1.44e-8	Depression;
THYM	cis	rs9296092	0.538	rs7761268	chr6:33519300	C/T	cg13560919	chr6:33536144	NA	-0.95	-9.43	-0.7	2.72e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs7851660	0.967	rs1443435	chr9:100617583	T/C	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-1.08	-13.5	-0.81	8.08e-24	Height;
THYM	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6032067	0.640	rs13043809	chr20:43753220	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.73	-7.61	-0.62	1.99e-11	Blood protein levels;
THYM	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7512552	0.803	rs7513205	chr1:150472781	A/G	cg15654264	chr1:150340011	RPRD2	0.45	5.2	0.47	1.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg08736216	chr1:53307985	ZYG11A	-0.59	-5.37	-0.48	5.57e-7	Monocyte count;
THYM	cis	rs9527	0.641	rs34130454	chr10:104903638	A/G	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg03929089	chr4:120376271	NA	-0.93	-8.72	-0.67	9.16e-14	Coronary artery disease;
THYM	cis	rs2282300	0.739	rs1222221	chr11:30342738	A/G	cg25418670	chr11:30344373	C11orf46	-0.79	-6.99	-0.58	3.74e-10	Morning vs. evening chronotype;
THYM	cis	rs919433	0.926	rs787996	chr2:198216805	A/G	cg00792783	chr2:198669748	PLCL1	0.72	5.27	0.48	8.59e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4891159	0.790	rs660029	chr18:74149668	A/G	cg24786174	chr18:74118243	ZNF516	0.94	12.85	0.8	1.66e-22	Longevity;
THYM	cis	rs8067354	0.645	rs2645467	chr17:57854783	C/T	cg20151207	chr17:57696971	CLTC	-0.69	-4.7	-0.43	8.87e-6	Hemoglobin concentration;
THYM	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg09033563	chr22:24373618	LOC391322	0.65	5.58	0.5	2.27e-7	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg23281280	chr6:28129359	ZNF389	0.65	4.9	0.45	4.01e-6	Parkinson's disease;
THYM	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg22709100	chr7:91322751	NA	-0.62	-4.96	-0.45	3.05e-6	Breast cancer;
THYM	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg02153584	chr22:29168773	CCDC117	0.59	4.57	0.42	1.46e-5	Lymphocyte counts;
THYM	cis	rs3768617	0.510	rs20557	chr1:183093875	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs2130392	1.000	rs2130392	chr4:185639169	A/G	cg04058563	chr4:185651563	MLF1IP	0.59	5.64	0.5	1.78e-7	Kawasaki disease;
THYM	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg21433313	chr16:3507492	NAT15	0.51	4.53	0.42	1.7e-5	Body mass index (adult);
THYM	cis	rs6598955	0.543	rs6699798	chr1:26556442	G/T	cg04990556	chr1:26633338	UBXN11	0.96	6.06	0.53	2.7e-8	Obesity-related traits;
THYM	cis	rs12121840	0.790	rs6657863	chr1:165546671	G/A	cg19407955	chr1:165599744	MGST3	-0.63	-4.76	-0.44	7.02e-6	Interleukin-1-receptor antagonist levels;
THYM	cis	rs7107174	1.000	rs10899458	chr11:78007451	A/T	cg02023728	chr11:77925099	USP35	0.65	5.83	0.51	7.52e-8	Testicular germ cell tumor;
THYM	cis	rs995000	0.826	rs12023489	chr1:62923858	G/A	cg06896770	chr1:63153194	DOCK7	0.93	7.76	0.62	9.83e-12	Triglyceride levels;
THYM	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg24257776	chr3:47051546	LOC100129354	0.41	4.73	0.44	7.73e-6	Colorectal cancer;
THYM	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg26818010	chr10:134567672	INPP5A	-0.93	-7.48	-0.61	3.71e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs4803468	0.967	rs2304243	chr19:41942708	C/G	cg09537434	chr19:41945824	ATP5SL	1.09	10.16	0.72	7.58e-17	Height;
THYM	cis	rs600806	0.888	rs6695482	chr1:109870859	C/G	cg02175308	chr1:109941060	SORT1	-0.57	-4.96	-0.45	3.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1451375	0.698	rs56233242	chr7:50634053	C/A	cg18232548	chr7:50535776	DDC	0.69	5.34	0.48	6.47e-7	Malaria;
THYM	cis	rs1050631	0.592	rs1785921	chr18:33737196	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.32	0.48	6.94e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg06917634	chr15:78832804	PSMA4	-0.82	-7.3	-0.6	8.93e-11	Sudden cardiac arrest;
THYM	cis	rs728616	0.867	rs12414096	chr10:81713629	A/G	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9361491	0.657	rs9361426	chr6:79457550	G/T	cg04547799	chr6:79944526	HMGN3	-0.66	-4.58	-0.43	1.41e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg07532245	chr17:28927093	LRRC37B2	0.71	4.48	0.42	2.04e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2562456	0.917	rs2650793	chr19:21676115	C/G	cg21751540	chr19:21541537	ZNF738	0.69	5.03	0.46	2.28e-6	Pain;
THYM	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg17279839	chr7:150038598	RARRES2	0.55	5.34	0.48	6.26e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs3017493	0.685	rs78711146	chr11:70671687	G/A	cg19942459	chr11:70508110	SHANK2	1.26	7.4	0.6	5.29e-11	Renal transplant outcome;
THYM	cis	rs13315871	0.929	rs7628038	chr3:58313813	T/C	cg00563845	chr3:58318305	PXK	0.6	5.3	0.48	7.63e-7	Cholesterol, total;
THYM	cis	rs4889855	0.556	rs9897453	chr17:78634300	C/T	cg16591659	chr17:78472290	NA	-0.37	-4.45	-0.42	2.32e-5	Fractional excretion of uric acid;
THYM	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg15921436	chr17:44337874	NA	-0.78	-6.3	-0.54	9.05e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs427394	0.582	rs274665	chr5:6707981	C/T	cg10857441	chr5:6722123	POLS	-0.7	-7.46	-0.61	3.98e-11	Menopause (age at onset);
THYM	cis	rs6754311	0.513	rs1438304	chr2:136503157	A/G	cg07169764	chr2:136633963	MCM6	-0.67	-5.92	-0.52	5.11e-8	Mosquito bite size;
THYM	cis	rs1003719	0.667	rs13050226	chr21:38457708	C/T	cg01329690	chr21:38580129	DSCR9	0.36	4.77	0.44	6.72e-6	Eye color traits;
THYM	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg12573674	chr2:1569213	NA	-1.38	-9.08	-0.68	1.52e-14	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs6696239	0.840	rs12097239	chr1:227912474	G/A	cg02736395	chr1:227748424	NA	-0.64	-5.23	-0.47	1e-6	Height;
THYM	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg05872129	chr22:39784769	NA	0.91	7.91	0.63	4.65e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs4474465	0.915	rs10899512	chr11:78171338	G/A	cg19901956	chr11:77921274	USP35	-0.6	-4.46	-0.42	2.25e-5	Alzheimer's disease (survival time);
THYM	trans	rs1973993	0.691	rs4000303	chr1:96913765	A/G	cg10631902	chr5:14652156	NA	0.76	9.49	0.7	1.99e-15	Weight;
THYM	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg11764359	chr7:65958608	NA	0.83	7.0	0.58	3.54e-10	Aortic root size;
THYM	cis	rs2276314	0.857	rs28379448	chr18:33604364	C/A	cg19628046	chr18:33552617	C18orf21	0.75	5.33	0.48	6.55e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg18512352	chr11:47633146	NA	-0.53	-6.44	-0.55	4.99e-9	Subjective well-being;
THYM	cis	rs9733	0.621	rs932054	chr1:150539867	C/G	cg13175981	chr1:150552382	MCL1	0.74	5.28	0.48	8.19e-7	Tonsillectomy;
THYM	cis	rs4845875	0.600	rs4846039	chr1:11836868	A/G	cg14194983	chr1:11908298	NPPA	0.54	4.97	0.45	2.93e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg01819863	chr10:32635814	EPC1	1.04	6.64	0.56	1.9e-9	Sexual dysfunction (female);
THYM	cis	rs10191773	0.535	rs56187472	chr2:113111668	G/A	cg07905836	chr2:113190072	RGPD8;RGPD5	0.84	5.12	0.46	1.6e-6	Yeast infection;
THYM	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs36051895	0.632	rs57698263	chr9:5143262	G/A	cg02405213	chr9:5042618	JAK2	-1.02	-10.51	-0.73	1.37e-17	Pediatric autoimmune diseases;
THYM	trans	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs8078723	0.738	rs3816472	chr17:38142677	A/C	cg17467752	chr17:38218738	THRA	-0.8	-6.7	-0.57	1.46e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg19346786	chr7:2764209	NA	-0.53	-4.48	-0.42	2.08e-5	Height;
THYM	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg16586182	chr3:47516702	SCAP	-0.67	-5.62	-0.5	1.9e-7	Colorectal cancer;
THYM	cis	rs990171	1.000	rs6543134	chr2:103050458	T/G	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.17	-0.47	1.27e-6	Lymphocyte counts;
THYM	cis	rs61931739	1.000	rs12305700	chr12:34036332	T/C	cg10856724	chr12:34555212	NA	0.63	5.33	0.48	6.57e-7	Morning vs. evening chronotype;
THYM	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg13683864	chr3:40499215	RPL14	0.92	9.18	0.69	9.41e-15	Renal cell carcinoma;
THYM	cis	rs4072705	0.646	rs4838187	chr9:127242076	G/C	cg01786973	chr9:127249749	NR5A1	0.42	5.41	0.49	4.65e-7	Menarche (age at onset);
THYM	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8016982	0.634	rs1035948	chr14:81682392	C/T	cg21807262	chr14:81713016	NA	-0.58	-5.38	-0.48	5.23e-7	Schizophrenia;
THYM	cis	rs13177918	0.626	rs3819332	chr5:149828750	G/C	cg14059543	chr5:149831962	NA	-0.94	-8.1	-0.64	1.86e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs34912216	0.587	rs28721959	chr7:4122625	T/C	cg03141780	chr7:4150753	SDK1	0.7	5.05	0.46	2.14e-6	Motion sickness;
THYM	cis	rs6840360	0.571	rs1822346	chr4:152525303	G/C	cg22705602	chr4:152727874	NA	-0.78	-8.73	-0.67	8.56e-14	Intelligence (multi-trait analysis);
THYM	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg03351412	chr1:154909251	PMVK	0.66	4.51	0.42	1.87e-5	Prostate cancer;
THYM	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.7	5.5	0.49	3.18e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg27129171	chr3:47204927	SETD2	0.7	6.7	0.57	1.44e-9	Colorectal cancer;
THYM	cis	rs9938149	0.706	rs58657775	chr16:88323829	A/G	cg05067156	chr16:88591451	ZFPM1	0.44	4.58	0.43	1.39e-5	Corneal structure;Central corneal thickness;
THYM	cis	rs34638657	0.833	rs4889479	chr16:82201474	T/C	cg19807685	chr16:82068980	HSD17B2	-0.59	-5.08	-0.46	1.91e-6	Lung adenocarcinoma;
THYM	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs944002	0.857	rs77071436	chr14:103568981	A/C	cg16996574	chr14:103691482	NA	0.52	4.8	0.44	5.92e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;
THYM	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs12681287	0.640	rs12544463	chr8:87481114	A/G	cg27223183	chr8:87520930	FAM82B	-0.69	-5.24	-0.47	9.46e-7	Caudate activity during reward;
THYM	cis	rs4523957	0.928	rs216209	chr17:2195130	A/G	cg16513277	chr17:2031491	SMG6	0.79	7.3	0.6	8.63e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs735539	1.000	rs1888001	chr13:21285906	C/G	cg02792322	chr13:21280448	IL17D	-0.62	-4.68	-0.43	9.38e-6	Dental caries;
THYM	cis	rs7833986	0.534	rs17813240	chr8:56925791	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	6.4	0.55	5.76e-9	Height;
THYM	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6840360	0.642	rs2724578	chr4:152367304	A/G	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs8067545	0.717	rs9907788	chr17:20008903	T/C	cg13482628	chr17:19912719	NA	0.57	4.86	0.45	4.57e-6	Schizophrenia;
THYM	cis	rs6964587	0.692	rs2158138	chr7:91700879	A/G	cg22709100	chr7:91322751	NA	0.61	4.62	0.43	1.22e-5	Breast cancer;
THYM	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.65	-7.87	-0.63	5.74e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs11249608	0.548	rs6875473	chr5:178451387	C/A	cg01312482	chr5:178451176	ZNF879	-0.76	-6.36	-0.55	7.14e-9	Pubertal anthropometrics;
THYM	cis	rs6840360	0.571	rs62327272	chr4:152545090	A/C	cg17479576	chr4:152424074	FAM160A1	-0.8	-5.65	-0.5	1.68e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7580658	0.724	rs6712446	chr2:127998399	G/T	cg10021288	chr2:128175891	PROC	-0.67	-5.93	-0.52	4.89e-8	Protein C levels;
THYM	cis	rs9399401	0.601	rs262130	chr6:142853486	C/T	cg03128060	chr6:142623767	GPR126	0.57	6.95	0.58	4.47e-10	Chronic obstructive pulmonary disease;
THYM	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg03188948	chr7:1209495	NA	0.91	7.1	0.59	2.21e-10	Longevity;Endometriosis;
THYM	cis	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg02317251	chr4:10116515	WDR1	-0.56	-4.95	-0.45	3.23e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs8020441	0.541	rs67026579	chr14:51155207	A/G	cg04730355	chr14:51134070	SAV1	1.03	6.05	0.53	2.87e-8	Cognitive performance;
THYM	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg00277334	chr10:82204260	NA	-0.83	-10.18	-0.72	6.99e-17	Post bronchodilator FEV1;
THYM	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7646881	1.000	rs59918529	chr3:158452705	T/C	cg18349298	chr3:158450550	RARRES1	0.51	4.95	0.45	3.15e-6	Tetralogy of Fallot;
THYM	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.81e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg08859206	chr1:53392774	SCP2	-0.65	-7.37	-0.6	6.31e-11	Monocyte count;
THYM	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg05660106	chr1:15850417	CASP9	0.73	6.14	0.53	1.88e-8	Systolic blood pressure;
THYM	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs6578985	0.520	rs7924316	chr11:2173447	G/T	cg16346422	chr11:2920819	SLC22A18;SLC22A18AS	0.44	4.6	0.43	1.29e-5	Femoral neck bone geometry and menarche (age at onset);
THYM	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg05043794	chr9:111880884	C9orf5	-0.43	-6.35	-0.55	7.29e-9	Menarche (age at onset);
THYM	cis	rs9361491	0.608	rs9350772	chr6:79456569	C/A	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.83	-5.84	-0.51	7.19e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs11771526	0.901	rs10264511	chr7:32304170	T/C	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.7	6.89	0.58	5.97e-10	Chronic sinus infection;
THYM	cis	rs11969893	0.850	rs12664068	chr6:101362098	G/T	cg12253828	chr6:101329408	ASCC3	1.17	6.75	0.57	1.16e-9	Economic and political preferences (immigration/crime);
THYM	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg06481639	chr22:41940642	POLR3H	0.72	4.68	0.43	9.65e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs12458462	1.000	rs12458462	chr18:77472436	C/A	cg11879182	chr18:77439856	CTDP1	0.79	7.29	0.6	9.11e-11	Monocyte count;
THYM	cis	rs600550	0.528	rs17154527	chr11:59828070	A/G	cg02771260	chr11:59836817	MS4A3	0.67	4.88	0.45	4.28e-6	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg17366294	chr4:99064904	C4orf37	0.54	6.4	0.55	5.74e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs200367988	1	rs200367988	chr10:122674849	G/A	cg14149699	chr10:122610679	WDR11	-0.63	-5.57	-0.5	2.41e-7	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;
THYM	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg09021430	chr5:549028	NA	-0.72	-5.39	-0.48	5.07e-7	Obesity-related traits;
THYM	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	7.0	0.58	3.69e-10	Platelet count;
THYM	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.82	7.43	0.61	4.64e-11	Chronic sinus infection;
THYM	cis	rs7582180	0.614	rs4340543	chr2:101005511	G/A	cg08017756	chr2:100939284	LONRF2	-0.74	-7.6	-0.62	2.03e-11	Intelligence (multi-trait analysis);
THYM	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.55	5.8	0.51	8.79e-8	Mean corpuscular volume;
THYM	cis	rs9650657	0.644	rs6601535	chr8:10695652	G/C	cg12981288	chr8:11183844	MTMR9	-0.5	-4.71	-0.44	8.34e-6	Neuroticism;
THYM	cis	rs4589258	0.788	rs7929571	chr11:90461220	A/T	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.72	-0.44	7.95e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs9677476	0.818	rs7598728	chr2:232086055	C/T	cg23338755	chr2:231921595	PSMD1	0.7	5.26	0.47	9.01e-7	Food antigen IgG levels;
THYM	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg22681709	chr2:178499509	PDE11A	-0.52	-5.05	-0.46	2.16e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg00376283	chr12:123451042	ABCB9	0.72	4.94	0.45	3.36e-6	Neutrophil percentage of white cells;
THYM	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg18477163	chr1:228402036	OBSCN	0.65	6.53	0.56	3.17e-9	Diastolic blood pressure;
THYM	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg18904891	chr8:8559673	CLDN23	0.68	5.08	0.46	1.89e-6	Obesity-related traits;
THYM	cis	rs7107174	1.000	rs4134379	chr11:77992588	A/G	cg02023728	chr11:77925099	USP35	0.71	6.46	0.55	4.43e-9	Testicular germ cell tumor;
THYM	cis	rs4866334	1.000	rs76371744	chr5:18441614	T/G	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Lung disease severity in cystic fibrosis;
THYM	cis	rs6815814	0.950	rs11722813	chr4:38810769	C/T	cg02016764	chr4:38805732	TLR1	-0.52	-4.8	-0.44	5.97e-6	Breast cancer;
THYM	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs910187	0.605	rs3787239	chr20:45802729	T/C	cg27589058	chr20:45804311	EYA2	-0.71	-6.23	-0.54	1.24e-8	Migraine;
THYM	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg01579765	chr21:45077557	HSF2BP	0.49	8.03	0.64	2.57e-12	Mean corpuscular volume;
THYM	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg06558623	chr16:89946397	TCF25	1.33	5.65	0.5	1.64e-7	Skin colour saturation;
THYM	cis	rs7216064	1.000	rs12451511	chr17:65874861	T/G	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg17063962	chr7:91808500	NA	1.08	11.78	0.77	2.79e-20	Breast cancer;
THYM	cis	rs1691799	0.899	rs1168295	chr12:66734151	G/C	cg16791601	chr12:66731901	HELB	-0.76	-7.23	-0.6	1.21e-10	White blood cell count (basophil);
THYM	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg24308560	chr3:49941425	MST1R	0.8	6.84	0.57	7.6e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9527	0.662	rs4919687	chr10:104595248	G/A	cg15744005	chr10:104629667	AS3MT	-0.68	-5.36	-0.48	5.86e-7	Arsenic metabolism;
THYM	cis	rs7113850	0.541	rs75347910	chr11:24213815	G/A	ch.11.24196551F	chr11:24239977	NA	0.89	4.57	0.42	1.48e-5	Bone fracture in osteoporosis;
THYM	cis	rs427394	0.632	rs169285	chr5:6736587	G/C	cg10857441	chr5:6722123	POLS	-0.7	-7.53	-0.61	2.93e-11	Menopause (age at onset);
THYM	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.42	-0.49	4.57e-7	Bipolar disorder;
THYM	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg27170947	chr2:26402098	FAM59B	0.64	5.19	0.47	1.17e-6	Gut microbiome composition (summer);
THYM	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg04317338	chr11:64019027	PLCB3	0.85	5.81	0.51	8.33e-8	Mean platelet volume;
THYM	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg25918947	chr17:41365094	TMEM106A	-0.69	-5.84	-0.51	7.34e-8	Menopause (age at onset);
THYM	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg01017244	chr2:74357527	NA	1.08	9.57	0.7	1.37e-15	Gestational age at birth (maternal effect);
THYM	trans	rs11165623	0.765	rs11807955	chr1:96891623	C/T	cg10631902	chr5:14652156	NA	-0.64	-7.29	-0.6	9.18e-11	Hip circumference;Waist circumference;
THYM	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg20387954	chr3:183756860	HTR3D	0.58	4.74	0.44	7.61e-6	Anterior chamber depth;
THYM	cis	rs10504073	0.626	rs6472220	chr8:50008477	C/A	cg00325661	chr8:49890786	NA	0.87	7.79	0.62	8.16e-12	Blood metabolite ratios;
THYM	cis	rs9902453	1.000	rs4239227	chr17:28389103	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg05738196	chr6:26577821	NA	0.83	8.34	0.65	5.8e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9649213	0.614	rs9640655	chr7:98017099	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.68	-5.75	-0.51	1.08e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg06238570	chr21:40685208	BRWD1	-0.69	-5.71	-0.51	1.31e-7	Menarche (age at onset);
THYM	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg15448220	chr1:150897856	SETDB1	0.89	7.44	0.61	4.54e-11	Melanoma;
THYM	cis	rs7000551	0.700	rs2461480	chr8:22381839	C/T	cg12081754	chr8:22256438	SLC39A14	0.66	6.11	0.53	2.19e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9826463	1.000	rs9813377	chr3:142321717	C/T	cg20824294	chr3:142316082	PLS1	0.72	4.99	0.46	2.71e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs9814567	1.000	rs9876658	chr3:134179453	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	8.33	0.65	6.06e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs977987	0.843	rs17696749	chr16:75403062	C/G	cg03315344	chr16:75512273	CHST6	0.67	5.56	0.5	2.44e-7	Dupuytren's disease;
THYM	cis	rs4919044	0.808	rs12416051	chr10:94788835	C/T	cg05127821	chr10:94822908	CYP26C1	-1.32	-7.18	-0.59	1.51e-10	Coronary artery disease;
THYM	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg22496339	chr2:162101262	NA	0.94	9.01	0.68	2.19e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg26441486	chr22:50317300	CRELD2	0.44	7.57	0.61	2.37e-11	Schizophrenia;
THYM	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg12863693	chr15:85201151	NMB	0.63	5.46	0.49	3.78e-7	Schizophrenia;
THYM	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg15704280	chr7:45808275	SEPT13	-1.0	-11.25	-0.76	3.63e-19	Coronary artery disease;
THYM	cis	rs17776563	0.768	rs1470108	chr15:89153744	G/T	cg01779732	chr15:90015521	RHCG	0.46	4.47	0.42	2.2e-5	Thyroid hormone levels;
THYM	cis	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg07988820	chr12:82153109	PPFIA2	-0.85	-5.59	-0.5	2.16e-7	Resting heart rate;
THYM	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg11764359	chr7:65958608	NA	0.85	7.17	0.59	1.65e-10	Aortic root size;
THYM	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg10295955	chr4:187884368	NA	-1.17	-17.37	-0.87	3.11e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7107174	1.000	rs4492844	chr11:78026516	A/G	cg19901956	chr11:77921274	USP35	-0.69	-5.29	-0.48	7.93e-7	Testicular germ cell tumor;
THYM	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.58	4.73	0.44	7.87e-6	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg23711669	chr6:146136114	FBXO30	0.85	7.99	0.63	3.12e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6754311	0.773	rs309130	chr2:136631031	C/A	cg20242066	chr2:136595261	LCT	-0.6	-7.1	-0.59	2.23e-10	Mosquito bite size;
THYM	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.49	-4.68	-0.43	9.64e-6	Crohn's disease;
THYM	cis	rs920590	0.796	rs10788700	chr8:19635098	T/C	cg01411142	chr8:19674711	INTS10	0.72	5.55	0.5	2.53e-7	Acute lymphoblastic leukemia (childhood);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg06109238	chr13:99017232	FARP1	-0.91	-6.86	-0.58	6.91e-10	Depressive symptoms;
THYM	cis	rs10911251	0.546	rs20560	chr1:183105534	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.75	0.44	7.29e-6	Colorectal cancer;
THYM	cis	rs3126085	0.935	rs10888470	chr1:152200472	T/C	cg26020982	chr1:152196106	HRNR	0.34	4.52	0.42	1.76e-5	Atopic dermatitis;
THYM	cis	rs2820651	1.000	rs2820656	chr10:1466607	G/A	cg02445968	chr10:1449028	ADARB2	-1.22	-6.14	-0.53	1.93e-8	Migraine with aura;
THYM	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg26384229	chr12:38710491	ALG10B	0.9	7.73	0.62	1.12e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2933343	0.621	rs789242	chr3:128585707	T/C	cg11901034	chr3:128598214	ACAD9	-0.7	-5.68	-0.5	1.47e-7	IgG glycosylation;
THYM	cis	rs2730245	0.527	rs1188974	chr7:158665748	C/T	cg24397884	chr7:158709396	WDR60	0.58	5.59	0.5	2.15e-7	Height;
THYM	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg01570182	chr17:44337453	NA	-0.84	-9.31	-0.69	5.04e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	9.55	0.7	1.49e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7614311	0.636	rs66490742	chr3:63913653	G/A	cg22134162	chr3:63841271	THOC7	-0.55	-6.24	-0.54	1.23e-8	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs2811415	0.597	rs2053014	chr3:127760006	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	trans	rs9951602	0.512	rs12607612	chr18:76651799	G/A	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg05294307	chr14:35346193	BAZ1A	-0.89	-7.29	-0.6	9.28e-11	Psoriasis;
THYM	cis	rs10227331	0.692	rs34036749	chr7:157298870	T/C	cg04156418	chr7:157293606	NA	0.79	7.48	0.61	3.62e-11	Inattentive symptoms;
THYM	cis	rs6733011	0.604	rs12712035	chr2:99461298	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.56	-0.42	1.54e-5	Bipolar disorder;
THYM	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg16797656	chr11:68205561	LRP5	0.44	4.56	0.42	1.52e-5	Total body bone mineral density;
THYM	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg08772003	chr10:104629869	AS3MT	-0.61	-5.55	-0.49	2.58e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs12519773	0.501	rs4321736	chr5:92533363	C/T	cg18783429	chr5:92414398	NA	0.5	4.91	0.45	3.72e-6	Migraine;
THYM	cis	rs9913156	0.748	rs72835635	chr17:4563127	A/G	cg19197139	chr17:4613644	ARRB2	0.78	4.92	0.45	3.63e-6	Lymphocyte counts;
THYM	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14442939	chr10:27389572	ANKRD26	0.94	4.65	0.43	1.07e-5	Breast cancer;
THYM	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg06636551	chr8:101224915	SPAG1	0.64	5.67	0.5	1.52e-7	Atrioventricular conduction;
THYM	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.54	-5.17	-0.47	1.31e-6	Lymphocyte counts;
THYM	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg03605463	chr16:89740564	NA	0.88	6.76	0.57	1.13e-9	Vitiligo;
THYM	cis	rs4343996	0.902	rs4349886	chr7:3370038	C/T	cg21248987	chr7:3385318	SDK1	-0.41	-4.97	-0.45	3.02e-6	Motion sickness;
THYM	cis	rs1729951	0.575	rs75976	chr3:136700455	G/A	cg12473912	chr3:136751656	NA	0.6	5.04	0.46	2.2e-6	Neuroticism;
THYM	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg04287289	chr16:89883240	FANCA	0.63	5.79	0.51	9.19e-8	Vitiligo;
THYM	cis	rs4144027	0.967	rs72712857	chr14:104362673	T/C	cg08213375	chr14:104286397	PPP1R13B	0.45	4.69	0.43	9.3e-6	Blood metabolite levels;
THYM	trans	rs637571	0.726	rs526631	chr11:65681965	T/G	cg17712092	chr4:129076599	LARP1B	-1.03	-10.38	-0.73	2.49e-17	Eosinophil percentage of white cells;
THYM	cis	rs10979	0.965	rs9376758	chr6:143886878	G/A	cg25407410	chr6:143891975	LOC285740	-0.62	-5.3	-0.48	7.39e-7	Hypospadias;
THYM	cis	rs6430585	0.528	rs309151	chr2:136661150	C/T	cg04750100	chr2:136595281	LCT	0.54	4.87	0.45	4.39e-6	Corneal structure;
THYM	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg23260525	chr10:116636907	FAM160B1	0.52	5.19	0.47	1.19e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs10208940	0.614	rs34050760	chr2:68758025	G/A	cg09157127	chr2:69201416	GKN1	0.89	4.71	0.43	8.61e-6	Urate levels in lean individuals;
THYM	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.56	4.53	0.42	1.7e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	trans	rs10802346	0.545	rs4478780	chr1:246372241	T/C	cg13514129	chr1:39547527	MACF1	1.03	10.85	0.74	2.56e-18	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg11327659	chr7:150037044	RARRES2	0.42	5.0	0.46	2.59e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	6.72	0.57	1.31e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs10095849	0.576	rs10107204	chr8:39468899	T/A	cg01911981	chr8:39380341	ADAM3A	-0.59	-5.05	-0.46	2.13e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4845875	0.563	rs11121829	chr1:11834765	A/G	cg24844545	chr1:11908347	NPPA	0.58	4.89	0.45	4.17e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs12122100	0.651	rs12743228	chr1:146548275	G/A	cg03526459	chr1:146549940	NA	-0.66	-4.49	-0.42	1.97e-5	HIV-1 control;
THYM	cis	rs3768617	0.565	rs2022392	chr1:183104863	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.85	0.45	4.73e-6	Fuchs's corneal dystrophy;
THYM	cis	rs17006441	0.966	rs6777363	chr3:69843971	A/C	cg18496212	chr3:69797108	MITF	0.67	6.67	0.56	1.69e-9	Hemoglobin concentration;
THYM	cis	rs921968	0.565	rs13412324	chr2:219620521	T/C	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs873946	0.689	rs2803993	chr10:134550606	T/C	cg18305652	chr10:134549665	INPP5A	0.87	8.6	0.66	1.58e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs611744	0.934	rs682954	chr8:109210559	C/T	cg21045802	chr8:109455806	TTC35	0.6	5.37	0.48	5.65e-7	Dupuytren's disease;
THYM	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.29e-7	Corneal astigmatism;
THYM	cis	rs4242434	0.819	rs751680	chr8:22475627	G/A	cg11461670	chr8:22454935	PDLIM2	-0.32	-6.0	-0.52	3.64e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs3781426	1.000	rs4962723	chr10:126705111	C/T	cg04494136	chr10:126703576	CTBP2	-0.34	-4.52	-0.42	1.81e-5	Height;
THYM	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg27170947	chr2:26402098	FAM59B	-0.78	-6.09	-0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs4523957	0.614	rs7208638	chr17:2061334	G/C	cg16513277	chr17:2031491	SMG6	-0.94	-8.42	-0.65	3.95e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs782590	0.934	rs17369191	chr2:55757885	T/C	cg18811423	chr2:55921094	PNPT1	0.74	7.05	0.59	2.83e-10	Metabolic syndrome;
THYM	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg05662444	chr5:154026397	NA	0.55	4.83	0.44	5.29e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.76	-0.44	6.98e-6	Crohn's disease;
THYM	cis	rs73086581	0.786	rs6037705	chr20:3952830	G/C	cg02187196	chr20:3869020	PANK2	0.5	5.62	0.5	1.92e-7	Response to antidepressants in depression;
THYM	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg02640540	chr1:67518911	SLC35D1	-0.64	-4.68	-0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs35264875	1.000	rs72919432	chr11:68829954	C/T	cg23845249	chr11:68861649	NA	0.54	5.48	0.49	3.53e-7	Blond vs. brown hair color;
THYM	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs7705502	1.000	rs55924019	chr5:173375257	A/G	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs13082711	0.911	rs7650165	chr3:27462440	C/T	cg02860705	chr3:27208620	NA	0.69	4.99	0.46	2.75e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs2046867	0.908	rs68142603	chr3:72790220	A/C	cg25664220	chr3:72788482	NA	-0.83	-6.25	-0.54	1.18e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs728616	0.717	rs116884206	chr10:81990546	A/G	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.87	-0.45	4.49e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.54	-5.17	-0.47	1.31e-6	Lymphocyte counts;
THYM	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	8.7	0.67	9.84e-14	Chronic sinus infection;
THYM	cis	rs7580658	0.963	rs9789510	chr2:128137012	G/A	cg10021288	chr2:128175891	PROC	-0.83	-7.11	-0.59	2.19e-10	Protein C levels;
THYM	cis	rs7578199	0.576	rs9679726	chr2:242442847	C/G	cg21155796	chr2:242212141	HDLBP	0.65	4.99	0.46	2.77e-6	Chronic lymphocytic leukemia;
THYM	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.77	-7.42	-0.61	4.98e-11	Personality dimensions;
THYM	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs889398	0.741	rs2362642	chr16:69931458	G/A	cg09409435	chr16:70099608	PDXDC2	0.7	5.44	0.49	4.11e-7	Body mass index;
THYM	cis	rs75920871	0.528	rs7930264	chr11:116870766	G/A	cg20608306	chr11:116969690	SIK3	-0.54	-6.03	-0.53	3.11e-8	Subjective well-being;
THYM	trans	rs34156428	1.000	rs12787015	chr11:16498063	T/C	cg02688867	chr12:133019854	NA	0.54	6.89	0.58	6.12e-10	Coronary artery disease;
THYM	cis	rs425277	0.917	rs78609670	chr1:2045886	G/T	cg23682913	chr1:2080710	PRKCZ	0.59	4.55	0.42	1.6e-5	Height;
THYM	cis	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg01364799	chr7:75623366	TMEM120A	0.63	4.56	0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2050392	0.630	rs303427	chr10:30739780	G/A	cg13289132	chr10:30722225	MAP3K8	-0.59	-4.71	-0.44	8.35e-6	Inflammatory bowel disease;
THYM	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg23711669	chr6:146136114	FBXO30	0.96	9.87	0.71	3.12e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg19747945	chr6:42946146	PEX6	-0.33	-4.82	-0.44	5.43e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2242116	0.833	rs6442038	chr3:46960742	A/G	cg02527881	chr3:46936655	PTH1R	-0.85	-8.4	-0.65	4.32e-13	Birth weight;
THYM	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg00129232	chr17:37814104	STARD3	0.69	4.45	0.42	2.32e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.79	-5.07	-0.46	1.95e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7607369	0.714	rs55900247	chr2:219618708	T/C	cg02176678	chr2:219576539	TTLL4	-0.65	-6.28	-0.54	9.93e-9	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs8114671	0.562	rs6088635	chr20:33466501	A/G	cg08999081	chr20:33150536	PIGU	0.63	5.21	0.47	1.09e-6	Height;
THYM	cis	rs2066819	1.000	rs2371454	chr12:56647243	A/G	cg26714650	chr12:56694279	CS	1.27	6.32	0.54	8.6e-9	Psoriasis vulgaris;
THYM	cis	rs16917546	0.935	rs12766391	chr10:64441204	C/T	cg03961010	chr10:64397487	ZNF365	-0.66	-5.47	-0.49	3.59e-7	Basal cell carcinoma;
THYM	cis	rs9972944	0.729	rs10083870	chr17:63773272	C/T	cg07283582	chr17:63770753	CCDC46	0.71	5.78	0.51	9.27e-8	Total body bone mineral density;
THYM	cis	rs7772486	0.790	rs2247666	chr6:146220409	C/A	cg13319975	chr6:146136371	FBXO30	-0.7	-5.77	-0.51	1.01e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6032067	0.929	rs2868238	chr20:43826993	C/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg00639195	chr15:79103007	ADAMTS7	-0.79	-6.15	-0.53	1.81e-8	Coronary artery disease or large artery stroke;
THYM	cis	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs8048589	0.604	rs2175020	chr16:12219190	C/T	cg02910054	chr16:12241554	SNX29	0.83	6.79	0.57	9.57e-10	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs62158800	0.568	rs72826922	chr2:108370643	C/T	cg09155462	chr2:109189131	NA	1.11	4.51	0.42	1.86e-5	Facial morphology (factor 22);
THYM	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg09877947	chr5:131593287	PDLIM4	-0.6	-4.96	-0.45	3.05e-6	Blood metabolite levels;
THYM	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg26384229	chr12:38710491	ALG10B	0.99	7.35	0.6	6.8e-11	Bladder cancer;
THYM	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg24675056	chr1:15929824	NA	0.73	5.79	0.51	9.09e-8	Systolic blood pressure;
THYM	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg00071950	chr4:10020882	SLC2A9	0.85	9.64	0.7	9.78e-16	Bone mineral density;
THYM	cis	rs7639513	0.767	rs7648488	chr3:12708946	T/C	cg23032965	chr3:12705835	RAF1	0.99	7.86	0.63	5.93e-12	Itch intensity from mosquito bite;
THYM	cis	rs7100689	0.577	rs9421464	chr10:82043426	C/T	cg01528321	chr10:82214614	TSPAN14	0.84	6.48	0.55	4.08e-9	Post bronchodilator FEV1;
THYM	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs72827839	1.000	rs17696392	chr17:46427160	A/T	cg23391107	chr17:45924227	SP6	-0.76	-4.58	-0.43	1.39e-5	Ease of getting up in the morning;
THYM	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg15744005	chr10:104629667	AS3MT	-0.83	-7.75	-0.62	9.94e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1914816	0.653	rs480672	chr15:76781930	T/C	cg26291519	chr15:76640005	NA	0.73	4.45	0.42	2.36e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs1395	0.571	rs114507490	chr2:27527246	T/A	cg23587288	chr2:27483067	SLC30A3	-0.58	-4.74	-0.44	7.48e-6	Blood metabolite levels;
THYM	cis	rs2290159	0.752	rs3773349	chr3:12649732	T/C	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg04476341	chr5:669733	TPPP	0.61	4.52	0.42	1.8e-5	Obesity-related traits;
THYM	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg06112835	chr11:68658793	MRPL21	0.44	6.41	0.55	5.69e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs35883536	0.967	rs1984134	chr1:101109307	A/G	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs7616559	0.512	rs35354535	chr3:156732380	T/A	cg15697575	chr3:156784781	NA	0.36	5.11	0.46	1.64e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg08885076	chr2:99613938	TSGA10	0.56	5.32	0.48	6.99e-7	Chronic sinus infection;
THYM	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg04398451	chr17:18023971	MYO15A	0.97	10.82	0.74	3.02e-18	Total body bone mineral density;
THYM	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg13395646	chr4:1353034	KIAA1530	0.57	5.4	0.48	4.91e-7	Obesity-related traits;
THYM	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.91	0.71	2.58e-16	Colorectal cancer;
THYM	cis	rs4589258	0.933	rs1783789	chr11:90437993	A/G	cg26138821	chr11:89956704	CHORDC1	0.7	5.9	0.52	5.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg11965913	chr1:205819406	PM20D1	0.98	11.2	0.75	4.68e-19	Menarche (age at onset);
THYM	cis	rs2354432	0.607	rs4950385	chr1:146656292	A/G	cg25205988	chr1:146714368	CHD1L	1.1	4.92	0.45	3.66e-6	Mitochondrial DNA levels;
THYM	cis	rs9653442	0.648	rs6733895	chr2:100666082	C/G	cg22139774	chr2:100720529	AFF3	-0.33	-5.08	-0.46	1.92e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg16325326	chr1:53192061	ZYG11B	0.84	8.51	0.66	2.56e-13	Monocyte count;
THYM	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11644478	chr21:40555479	PSMG1	-0.8	-6.91	-0.58	5.38e-10	Cognitive function;
THYM	cis	rs73086581	0.947	rs67356712	chr20:3892886	A/G	cg02187196	chr20:3869020	PANK2	0.41	4.77	0.44	6.7e-6	Response to antidepressants in depression;
THYM	cis	rs12257961	0.549	rs1955342	chr10:15377871	A/G	cg10616319	chr10:15468812	NA	-0.66	-5.33	-0.48	6.53e-7	Selective IgA deficiency;
THYM	cis	rs9486719	1.000	rs12214469	chr6:97019471	G/T	cg18709589	chr6:96969512	KIAA0776	-0.68	-4.7	-0.43	8.62e-6	Migraine;Coronary artery disease;
THYM	cis	rs9522267	0.535	rs7329118	chr13:112232693	C/T	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg17264618	chr3:40429014	ENTPD3	0.52	4.86	0.45	4.57e-6	Renal cell carcinoma;
THYM	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.8	-6.8	-0.57	9.2e-10	Menarche (age at onset);
THYM	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.49	0.49	3.33e-7	Platelet count;
THYM	cis	rs2016266	0.826	rs61928079	chr12:53741468	T/C	cg26875137	chr12:53738046	NA	-0.78	-5.78	-0.51	9.62e-8	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg14433983	chr11:636460	DRD4	-0.63	-4.55	-0.42	1.6e-5	Systemic lupus erythematosus;
THYM	cis	rs763014	0.865	rs2071979	chr16:624114	A/G	cg09263875	chr16:632152	PIGQ	0.71	6.15	0.53	1.85e-8	Height;
THYM	cis	rs7404928	0.678	rs8054675	chr16:23932707	T/C	cg26685404	chr16:23957272	PRKCB	0.61	7.0	0.58	3.53e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg07570687	chr10:102243282	WNT8B	0.84	8.04	0.64	2.45e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4654899	0.606	rs651085	chr1:21097783	A/G	cg01072550	chr1:21505969	NA	0.62	5.66	0.5	1.62e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg21252483	chr19:49399788	TULP2	-0.92	-5.72	-0.51	1.24e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.37e-7	Diabetic kidney disease;
THYM	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-5.57	-0.5	2.41e-7	Chronic sinus infection;
THYM	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg09307838	chr4:120376055	NA	0.77	5.56	0.5	2.5e-7	Corneal astigmatism;
THYM	cis	rs9826463	0.582	rs73238145	chr3:142060559	G/A	cg20824294	chr3:142316082	PLS1	0.76	5.28	0.48	8.31e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs6430585	0.528	rs6750549	chr2:136707480	A/G	cg20242066	chr2:136595261	LCT	0.5	4.86	0.45	4.68e-6	Corneal structure;
THYM	trans	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg10856724	chr12:34555212	NA	-0.87	-7.75	-0.62	9.89e-12	Morning vs. evening chronotype;
THYM	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg21984481	chr17:79567631	NPLOC4	-0.47	-4.97	-0.45	2.98e-6	Eye color traits;
THYM	cis	rs6748734	0.625	rs7355583	chr2:241821707	T/C	cg09990169	chr2:241835740	C2orf54	-0.31	-5.15	-0.47	1.43e-6	Urinary metabolites;
THYM	cis	rs1267303	0.675	rs1267313	chr1:46986322	G/T	cg16387850	chr1:46982889	NA	0.44	5.6	0.5	2.05e-7	Monobrow;
THYM	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg15448220	chr1:150897856	SETDB1	0.85	6.76	0.57	1.1e-9	Melanoma;
THYM	cis	rs7089973	0.624	rs61867965	chr10:116574794	A/T	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.45	-0.42	2.35e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg11764359	chr7:65958608	NA	-0.81	-6.42	-0.55	5.45e-9	Aortic root size;
THYM	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg09703963	chr11:616879	IRF7;MUPCDH	-0.64	-5.53	-0.49	2.78e-7	Systemic lupus erythematosus;
THYM	cis	rs2256039	1.000	rs2256039	chr9:86799429	C/A	cg14555996	chr9:86785905	NA	-0.3	-4.64	-0.43	1.11e-5	Multiple system atrophy;
THYM	cis	rs2806561	0.780	rs12135629	chr1:23338899	A/G	cg19743168	chr1:23544995	NA	-0.61	-6.06	-0.53	2.74e-8	Height;
THYM	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.48	-0.42	2.05e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg24060327	chr5:131705240	SLC22A5	-0.82	-6.73	-0.57	1.29e-9	Breast cancer;
THYM	cis	rs3825942	1.000	rs1550437	chr15:74221298	A/G	cg23484268	chr15:74220776	LOXL1	-0.44	-4.68	-0.43	9.36e-6	Glaucoma (exfoliation);
THYM	cis	rs35883536	0.588	rs955337	chr1:101108834	A/T	cg09408571	chr1:101003634	GPR88	0.43	5.16	0.47	1.34e-6	Monocyte count;
THYM	cis	rs12704876	0.509	rs1608741	chr7:96354206	G/A	cg03808172	chr7:96339361	SHFM1	0.73	5.18	0.47	1.22e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs611744	0.967	rs2212704	chr8:109198415	C/T	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs9403317	0.585	rs9399377	chr6:141961784	T/C	cg15052665	chr6:141804349	NA	0.76	5.72	0.51	1.21e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs904251	0.523	rs914348	chr6:37484729	G/A	cg25019722	chr6:37503610	NA	-0.62	-5.12	-0.46	1.61e-6	Cognitive performance;
THYM	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.56	-5.13	-0.47	1.51e-6	Type 2 diabetes;
THYM	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg23682913	chr1:2080710	PRKCZ	-0.58	-5.41	-0.49	4.64e-7	Height;
THYM	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs11148252	0.633	rs9535888	chr13:52733206	C/G	cg05335186	chr13:53173507	NA	-0.47	-5.7	-0.51	1.32e-7	Lewy body disease;
THYM	cis	rs3733631	1.000	rs4141203	chr4:104638435	A/G	cg24090629	chr4:104641072	TACR3	-0.86	-5.51	-0.49	3.1e-7	Menarche (age at onset);
THYM	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg22117172	chr7:91764530	CYP51A1	-0.37	-4.61	-0.43	1.27e-5	Breast cancer;
THYM	cis	rs2235649	0.833	rs9939766	chr16:1852808	C/A	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg09904177	chr6:26538194	HMGN4	0.6	4.63	0.43	1.16e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2455799	0.634	rs6771390	chr3:15906637	C/G	cg16303742	chr3:15540471	COLQ	-0.57	-5.76	-0.51	1.04e-7	Mean platelet volume;
THYM	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg25072359	chr17:41440525	NA	0.64	4.46	0.42	2.28e-5	Menopause (age at onset);
THYM	cis	rs778371	0.748	rs2675953	chr2:233749565	G/C	cg08000102	chr2:233561755	GIGYF2	-0.84	-6.89	-0.58	6.07e-10	Schizophrenia;
THYM	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg04414720	chr1:150670196	GOLPH3L	0.62	4.71	0.44	8.35e-6	Tonsillectomy;
THYM	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg09455208	chr3:40491958	NA	0.46	4.92	0.45	3.65e-6	Renal cell carcinoma;
THYM	cis	rs12478296	0.591	rs12468297	chr2:242996474	A/G	cg06360820	chr2:242988706	NA	-0.71	-5.17	-0.47	1.3e-6	Obesity-related traits;
THYM	cis	rs1395	0.634	rs62130713	chr2:27525661	A/G	cg23587288	chr2:27483067	SLC30A3	-0.61	-4.97	-0.45	2.96e-6	Blood metabolite levels;
THYM	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg03474202	chr17:45855739	NA	0.74	6.44	0.55	4.93e-9	IgG glycosylation;
THYM	cis	rs11096990	0.855	rs2566184	chr4:39164320	T/C	cg24403649	chr4:39172243	NA	-0.64	-5.39	-0.48	5.2e-7	Cognitive function;
THYM	cis	rs926938	0.618	rs904292	chr1:115358421	C/T	cg12756093	chr1:115239321	AMPD1	0.6	4.93	0.45	3.54e-6	Autism;
THYM	cis	rs9393692	0.620	rs9358927	chr6:26330492	T/G	cg13736514	chr6:26305472	NA	-0.46	-4.7	-0.43	8.63e-6	Educational attainment;
THYM	cis	rs10779751	1.000	rs7526649	chr1:11278163	C/T	cg08854313	chr1:11322531	MTOR	0.88	7.52	0.61	3.09e-11	Body mass index;
THYM	cis	rs5015933	0.801	rs2416961	chr9:128140357	C/T	cg14078157	chr9:128172775	NA	-0.55	-4.61	-0.43	1.27e-5	Body mass index;
THYM	cis	rs3791556	0.661	rs3791539	chr2:240102327	C/T	cg03281426	chr2:240109471	HDAC4	0.46	4.71	0.44	8.47e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg08736216	chr1:53307985	ZYG11A	-0.62	-5.55	-0.5	2.53e-7	Monocyte count;
THYM	cis	rs1691799	0.867	rs1495497	chr12:66770020	A/T	cg16791601	chr12:66731901	HELB	-0.68	-5.88	-0.52	6.15e-8	White blood cell count (basophil);
THYM	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg21385522	chr1:16154831	NA	-0.91	-6.8	-0.57	9.03e-10	Dilated cardiomyopathy;
THYM	cis	rs2195525	0.598	rs10892352	chr11:119218553	T/C	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.43	4.69	0.43	9.19e-6	Urate levels;
THYM	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg08975724	chr8:8085496	FLJ10661	0.6	4.76	0.44	7e-6	Mood instability;
THYM	cis	rs12765878	0.557	rs2984133	chr10:105670848	T/A	cg04688330	chr10:105451802	SH3PXD2A	0.38	4.83	0.44	5.13e-6	Coronary artery disease;
THYM	cis	rs2302612	0.528	rs12474373	chr2:102839457	G/A	cg13315345	chr2:102803985	IL1RL2	0.68	4.58	0.43	1.4e-5	Serum protein levels (sST2);
THYM	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22590775	chr19:49891494	CCDC155	0.81	6.85	0.58	7.16e-10	Multiple sclerosis;
THYM	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02475777	chr4:1388615	CRIPAK	0.7	5.06	0.46	2.05e-6	Longevity;
THYM	cis	rs4836694	0.574	rs4837476	chr9:132937533	T/C	cg05251000	chr9:132935664	FREQ	0.8	5.36	0.48	5.73e-7	Alzheimer's disease (cognitive decline);
THYM	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg18758796	chr5:131593413	PDLIM4	0.6	5.9	0.52	5.68e-8	Acylcarnitine levels;
THYM	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.64	-8.65	-0.66	1.29e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg06219351	chr7:158114137	PTPRN2	-0.74	-7.14	-0.59	1.86e-10	Calcium levels;
THYM	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg18252515	chr7:66147081	NA	0.72	5.64	0.5	1.73e-7	Aortic root size;
THYM	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg04842962	chr6:43655489	MRPS18A	1.4	15.42	0.85	1.3e-27	IgG glycosylation;
THYM	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.24	-4.68	-0.43	9.56e-6	Obesity-related traits;
THYM	trans	rs629535	0.862	rs2178955	chr8:70045303	C/T	cg21567404	chr3:27674614	NA	1.12	10.86	0.74	2.44e-18	Dupuytren's disease;
THYM	cis	rs911119	1.000	rs13039536	chr20:23612305	A/G	cg16589663	chr20:23618590	CST3	0.78	4.77	0.44	6.71e-6	Chronic kidney disease;
THYM	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg08901578	chr4:187885870	NA	-0.53	-4.95	-0.45	3.18e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg17178900	chr1:205818956	PM20D1	-0.69	-6.29	-0.54	9.55e-9	Monocyte percentage of white cells;
THYM	cis	rs9314614	0.789	rs4840643	chr8:6712784	T/A	cg27319216	chr8:6693540	XKR5	-0.56	-5.87	-0.52	6.33e-8	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg19418458	chr7:158789849	NA	-0.65	-5.82	-0.51	7.93e-8	Facial morphology (factor 20);
THYM	cis	rs2637266	0.627	rs1992396	chr10:78482228	T/C	cg18941641	chr10:78392320	NA	0.73	5.72	0.51	1.23e-7	Pulmonary function;
THYM	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg00757033	chr12:89920650	WDR51B	0.76	10.12	0.72	9.09e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs8133932	0.608	rs373267	chr21:47343320	G/T	cg20357416	chr21:47294739	PCBP3	0.8	4.88	0.45	4.26e-6	Schizophrenia;
THYM	cis	rs2219968	0.676	rs1586415	chr8:78840220	A/C	cg00738934	chr8:78996279	NA	-0.7	-6.22	-0.54	1.35e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4523957	0.786	rs216213	chr17:2134225	G/A	cg16513277	chr17:2031491	SMG6	0.83	8.22	0.64	1.04e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4687717	0.689	rs2306569	chr3:53274602	C/T	cg16894138	chr3:53270350	TKT	-0.91	-7.26	-0.6	1.05e-10	Blood metabolite levels;Blood metabolite ratios;
THYM	cis	rs6720763	0.945	rs11893404	chr2:168020995	G/A	cg10633051	chr2:168042982	XIRP2	-0.69	-4.73	-0.44	7.73e-6	Atopic dermatitis;
THYM	cis	rs6960043	0.818	rs10228796	chr7:15064190	C/G	cg19272540	chr7:15055459	NA	-0.42	-4.71	-0.44	8.42e-6	Type 2 diabetes;
THYM	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg22166914	chr1:53195759	ZYG11B	0.91	10.7	0.74	5.4e-18	Monocyte count;
THYM	cis	rs360798	0.512	rs4671050	chr2:62988169	G/T	cg17519650	chr2:63277830	OTX1	-0.69	-4.57	-0.42	1.48e-5	Coronary artery disease;
THYM	cis	rs9470366	0.545	rs6930083	chr6:36634156	A/G	cg24425727	chr6:36645648	CDKN1A	0.73	6.75	0.57	1.19e-9	QRS duration;
THYM	cis	rs2011503	0.941	rs4808934	chr19:19370917	C/T	cg02887458	chr19:19495540	GATAD2A	-0.43	-5.21	-0.47	1.1e-6	Bipolar disorder;
THYM	cis	rs1843834	0.755	rs10197382	chr2:225574650	T/C	cg10193763	chr2:225306901	NA	-0.42	-4.49	-0.42	2.03e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg18681998	chr4:17616180	MED28	0.79	6.77	0.57	1.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4372836	0.543	rs11686412	chr2:28992405	A/G	cg09522027	chr2:28974177	PPP1CB	-0.62	-4.79	-0.44	6.18e-6	Body mass index;
THYM	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg15556689	chr8:8085844	FLJ10661	-0.65	-5.72	-0.51	1.25e-7	Mood instability;
THYM	cis	rs62103177	0.564	rs3930043	chr18:77723832	G/A	cg02751453	chr18:77725136	HSBP1L1	-0.64	-5.34	-0.48	6.2e-7	Opioid sensitivity;
THYM	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg18876405	chr7:65276391	NA	-0.57	-4.86	-0.45	4.62e-6	Aortic root size;
THYM	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg03859395	chr2:55845619	SMEK2	0.64	5.71	0.51	1.29e-7	Metabolic syndrome;
THYM	cis	rs4662945	0.714	rs10205941	chr2:130191184	A/G	cg05903289	chr2:130345205	NA	-0.53	-5.16	-0.47	1.36e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs4845459	0.967	rs75567512	chr1:152587933	C/A	cg26135325	chr1:152595322	LCE3A	-0.45	-5.21	-0.47	1.09e-6	Psoriasis;
THYM	cis	rs9554348	0.541	rs59805867	chr13:96953789	A/G	cg25169784	chr13:96706045	UGGT2	0.85	4.66	0.43	1.03e-5	Schizophrenia;
THYM	cis	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg23231163	chr10:75533350	FUT11	-0.49	-6.76	-0.57	1.1e-9	Inflammatory bowel disease;
THYM	cis	rs1075265	0.633	rs7591431	chr2:54222165	C/A	cg04546899	chr2:54196757	PSME4	0.48	5.43	0.49	4.31e-7	Morning vs. evening chronotype;Chronotype;
THYM	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg02734326	chr4:10020555	SLC2A9	-0.58	-4.71	-0.44	8.42e-6	Bone mineral density;
THYM	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg02527881	chr3:46936655	PTH1R	-0.67	-7.11	-0.59	2.16e-10	Colorectal cancer;
THYM	cis	rs2219968	0.525	rs7834051	chr8:78872337	T/C	cg00738934	chr8:78996279	NA	0.6	4.94	0.45	3.35e-6	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs877282	0.891	rs12357999	chr10:796468	A/C	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	5.1	0.46	1.74e-6	Schizophrenia;
THYM	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg06115741	chr20:33292138	TP53INP2	0.71	4.9	0.45	3.9e-6	Coronary artery disease;
THYM	cis	rs951188	0.688	rs1196679	chr2:150343163	G/A	cg17961725	chr2:150454027	NA	0.94	4.78	0.44	6.41e-6	Daytime sleep phenotypes;
THYM	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs9810089	0.527	rs590198	chr3:135953729	G/A	cg21827317	chr3:136751795	NA	0.64	5.99	0.52	3.69e-8	Gestational age at birth (child effect);
THYM	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg07636037	chr3:49044803	WDR6	0.97	10.07	0.72	1.15e-16	Parkinson's disease;
THYM	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg22166914	chr1:53195759	ZYG11B	0.8	8.04	0.64	2.5e-12	Monocyte count;
THYM	cis	rs7010267	0.935	rs7463176	chr8:119957625	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.6	4.87	0.45	4.36e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs6430585	0.528	rs586964	chr2:136652491	G/A	cg23851026	chr2:136556271	LCT	0.84	7.9	0.63	4.84e-12	Corneal structure;
THYM	cis	rs10743315	0.557	rs74669613	chr12:19313696	T/C	cg02471346	chr12:19282374	PLEKHA5	1.17	4.86	0.45	4.65e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg24818145	chr4:99064322	C4orf37	-0.74	-5.72	-0.51	1.23e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs921968	0.565	rs7573999	chr2:219601392	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs921665	0.831	rs6751452	chr2:3183930	T/G	cg16434511	chr2:3151078	NA	-0.85	-5.48	-0.49	3.49e-7	World class endurance athleticism;
THYM	cis	rs926938	0.584	rs6689326	chr1:115369112	T/A	cg12756093	chr1:115239321	AMPD1	-0.6	-4.91	-0.45	3.72e-6	Autism;
THYM	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg06600287	chr1:53387719	ECHDC2	-0.31	-5.11	-0.46	1.68e-6	Monocyte count;
THYM	cis	rs6840360	0.571	rs4696274	chr4:152528478	C/A	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2273669	0.504	rs11970018	chr6:109492740	G/A	cg17117243	chr6:109341365	SESN1	-0.82	-4.8	-0.44	5.98e-6	Prostate cancer;
THYM	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg27211696	chr2:191398769	TMEM194B	-0.62	-4.72	-0.44	8.15e-6	Diastolic blood pressure;
THYM	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg15693483	chr7:1102177	C7orf50	0.48	5.63	0.5	1.86e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg18301423	chr5:131593218	PDLIM4	0.5	4.7	0.43	8.95e-6	Acylcarnitine levels;
THYM	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg14196790	chr5:131705035	SLC22A5	0.51	4.83	0.44	5.28e-6	Breast cancer;Mosquito bite size;
THYM	cis	rs7833986	0.501	rs17814658	chr8:56989130	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	6.82	0.57	8.29e-10	Height;
THYM	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg01579765	chr21:45077557	HSF2BP	-0.47	-7.52	-0.61	3.11e-11	Mean corpuscular volume;
THYM	cis	rs13102973	0.666	rs2042650	chr4:135897082	T/C	cg14419869	chr4:135874104	NA	-0.8	-6.58	-0.56	2.54e-9	Subjective well-being;
THYM	cis	rs9677476	0.689	rs6761645	chr2:232055153	T/A	cg20307347	chr2:231734563	ITM2C	-0.53	-4.47	-0.42	2.16e-5	Food antigen IgG levels;
THYM	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg22907277	chr7:1156413	C7orf50	0.63	5.56	0.5	2.47e-7	Longevity;Endometriosis;
THYM	cis	rs939658	0.805	rs2177056	chr15:79441489	T/C	cg17916960	chr15:79447300	NA	-0.73	-8.58	-0.66	1.81e-13	Refractive error;
THYM	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17102423	0.755	rs7143495	chr14:65546361	C/T	cg11161011	chr14:65562177	MAX	0.86	7.2	0.59	1.41e-10	Obesity-related traits;
THYM	cis	rs921968	0.565	rs3770220	chr2:219619550	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8064299	0.597	rs4789098	chr17:72781292	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.88	8.77	0.67	6.87e-14	Monocyte count;
THYM	cis	rs7681440	0.606	rs2583969	chr4:90746133	T/C	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs8038465	0.592	rs58443257	chr15:73930707	A/T	cg15420318	chr15:73925796	NPTN	0.58	4.72	0.44	8.11e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.21	0.47	1.1e-6	Platelet count;
THYM	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg16068833	chr1:26644515	UBXN11;CD52	0.26	4.5	0.42	1.9e-5	Obesity-related traits;
THYM	cis	rs4262150	0.883	rs72802874	chr5:152240163	C/T	cg06854687	chr5:151642065	NA	0.64	4.46	0.42	2.27e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs7546094	0.875	rs1110043	chr1:113236421	G/A	cg25616829	chr1:112535356	NA	-0.56	-4.53	-0.42	1.69e-5	Platelet distribution width;
THYM	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg26039829	chr8:22132926	PIWIL2	0.67	5.85	0.51	7.03e-8	Hypertriglyceridemia;
THYM	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1691799	0.899	rs1168308	chr12:66742183	A/G	cg16791601	chr12:66731901	HELB	-0.76	-7.23	-0.6	1.21e-10	White blood cell count (basophil);
THYM	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg06634786	chr22:41940651	POLR3H	0.71	5.04	0.46	2.19e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4836694	0.574	rs3780712	chr9:132943082	A/G	cg05251000	chr9:132935664	FREQ	0.77	5.2	0.47	1.16e-6	Alzheimer's disease (cognitive decline);
THYM	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg07424592	chr7:64974309	NA	1.03	5.26	0.47	8.88e-7	Diabetic kidney disease;
THYM	cis	rs9867325	0.778	rs9877089	chr3:136656593	C/T	cg21827317	chr3:136751795	NA	-0.69	-4.47	-0.42	2.14e-5	Body mass index;
THYM	cis	rs300703	0.935	rs417829	chr2:206851	A/G	cg21211680	chr2:198530	NA	0.93	5.14	0.47	1.45e-6	Blood protein levels;
THYM	cis	rs2075230	0.588	rs1641530	chr17:7548052	T/C	cg10509001	chr17:7553872	ATP1B2	-0.56	-4.46	-0.42	2.22e-5	Hormone measurements;
THYM	cis	rs9902453	0.845	rs2617875	chr17:28090024	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	4.61	0.43	1.24e-5	Coffee consumption (cups per day);
THYM	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg25072359	chr17:41440525	NA	0.66	4.67	0.43	9.85e-6	Menopause (age at onset);
THYM	cis	rs1568889	1.000	rs34140872	chr11:28335872	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.74	0.44	7.51e-6	Bipolar disorder;
THYM	cis	rs1335645	0.570	rs6662965	chr1:111642226	C/A	cg00321911	chr1:111669324	DRAM2	-1.2	-6.73	-0.57	1.3e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7247513	0.964	rs1007352	chr19:12722545	G/C	cg01871581	chr19:12707946	ZNF490	-0.92	-9.9	-0.71	2.67e-16	Bipolar disorder;
THYM	cis	rs11085466	1.000	rs75079001	chr19:21757375	A/G	cg23026602	chr19:21646605	NA	-0.66	-4.84	-0.45	4.94e-6	Colorectal or endometrial cancer;
THYM	cis	rs12188164	1.000	rs72717412	chr5:429381	C/T	cg26850624	chr5:429559	AHRR	-0.69	-5.39	-0.48	5.09e-7	Cystic fibrosis severity;
THYM	cis	rs7771547	0.605	rs659726	chr6:36467791	C/G	cg07856975	chr6:36356162	ETV7	0.52	5.01	0.46	2.48e-6	Platelet distribution width;
THYM	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg15445000	chr17:37608096	MED1	0.42	4.91	0.45	3.85e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.65e-6	Aortic root size;
THYM	cis	rs9302690	1.000	rs4151118	chr16:57451334	G/A	cg27017172	chr16:57497170	POLR2C	0.82	4.88	0.45	4.29e-6	Blood protein levels;
THYM	cis	rs2732480	0.500	rs2932093	chr12:48648271	G/T	cg21466736	chr12:48725269	NA	-0.55	-5.02	-0.46	2.43e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg18876405	chr7:65276391	NA	0.56	4.79	0.44	6.25e-6	Aortic root size;
THYM	cis	rs3204270	0.810	rs62077191	chr17:79678063	A/G	cg13117272	chr17:79681052	SLC25A10	-0.78	-4.81	-0.44	5.69e-6	Dental caries;
THYM	cis	rs490234	0.902	rs7038668	chr9:128239920	T/C	cg14078157	chr9:128172775	NA	-0.6	-4.72	-0.44	8.08e-6	Mean arterial pressure;
THYM	cis	rs10256972	0.694	rs7784701	chr7:1003041	A/G	cg07930192	chr7:1003750	NA	0.87	7.62	0.62	1.89e-11	Longevity;Endometriosis;
THYM	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg13319975	chr6:146136371	FBXO30	-0.66	-5.54	-0.49	2.67e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9633835	0.524	rs4757136	chr11:13281327	T/A	cg13286116	chr11:13302098	ARNTL	-0.72	-8.01	-0.63	2.85e-12	Body mass index;
THYM	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg06558623	chr16:89946397	TCF25	1.34	5.65	0.5	1.67e-7	Skin colour saturation;
THYM	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg21138405	chr5:131827807	IRF1	-0.84	-9.6	-0.7	1.21e-15	Asthma (sex interaction);
THYM	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg08847533	chr14:75593920	NEK9	1.01	11.32	0.76	2.63e-19	Height;
THYM	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg14675211	chr2:100938903	LONRF2	0.74	7.77	0.62	9.09e-12	Intelligence (multi-trait analysis);
THYM	cis	rs6686842	0.965	rs10157966	chr1:41722576	G/T	cg03387723	chr1:41708464	SCMH1	0.42	4.99	0.46	2.78e-6	Height;
THYM	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg27170947	chr2:26402098	FAM59B	0.79	6.27	0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg09877947	chr5:131593287	PDLIM4	0.58	4.76	0.44	6.94e-6	Blood metabolite levels;
THYM	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg24441899	chr7:4244372	SDK1	0.48	4.48	0.42	2.11e-5	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
THYM	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs919433	0.927	rs6759834	chr2:198204860	C/T	cg00792783	chr2:198669748	PLCL1	-0.7	-4.78	-0.44	6.3e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs892961	0.899	rs7222532	chr17:75413302	G/C	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs58847541	0.584	rs16898590	chr8:124587044	C/T	cg25406735	chr8:124553149	FBXO32	0.88	4.58	0.43	1.41e-5	Breast cancer;
THYM	cis	rs3820068	0.608	rs10927840	chr1:16045250	A/G	cg05660106	chr1:15850417	CASP9	0.72	5.56	0.5	2.5e-7	Systolic blood pressure;
THYM	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg20503657	chr10:835505	NA	1.1	7.6	0.61	2.12e-11	Eosinophil percentage of granulocytes;
THYM	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.47	0.49	3.65e-7	Obesity-related traits;
THYM	cis	rs6835098	0.828	rs28612521	chr4:174085294	G/A	cg08422745	chr4:174089978	GALNT7	-1.0	-8.54	-0.66	2.21e-13	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	trans	rs6537837	0.793	rs12023963	chr1:110084827	A/G	cg07321467	chr4:81960704	BMP3	-0.91	-7.07	-0.59	2.6e-10	Major depressive disorder;
THYM	cis	rs6815814	0.861	rs1135430	chr4:38789361	T/C	cg06935464	chr4:38784597	TLR10	0.71	5.2	0.47	1.15e-6	Breast cancer;
THYM	cis	rs25645	0.502	rs8065126	chr17:38099035	C/T	cg24910161	chr17:38119198	GSDMA	0.56	6.0	0.52	3.57e-8	Myeloid white cell count;
THYM	cis	rs1451375	0.572	rs745042	chr7:50544138	A/G	cg18232548	chr7:50535776	DDC	-0.67	-5.07	-0.46	1.94e-6	Malaria;
THYM	cis	rs988913	1.000	rs2221334	chr6:54834541	A/C	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.75e-6	Menarche (age at onset);
THYM	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg12573674	chr2:1569213	NA	-1.35	-8.81	-0.67	5.84e-14	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs4383453	0.539	rs16834218	chr3:123097988	T/C	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs227425	0.544	rs7142362	chr14:70416718	G/T	cg12046056	chr14:71067695	MED6	0.54	5.04	0.46	2.23e-6	Bone mineral density;
THYM	cis	rs17511627	0.808	rs9507677	chr13:26743556	C/A	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs17030434	0.954	rs6847810	chr4:154752789	C/T	cg14289246	chr4:154710475	SFRP2	-0.79	-5.38	-0.48	5.25e-7	Electrocardiographic conduction measures;
THYM	cis	rs13006833	0.668	rs2582746	chr2:191163784	T/C	cg21644426	chr2:191273491	MFSD6	0.64	4.46	0.42	2.25e-5	Urinary metabolites;
THYM	cis	rs3768617	0.510	rs2296288	chr1:183072590	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.56	4.54	0.42	1.62e-5	Fuchs's corneal dystrophy;
THYM	cis	rs11030122	0.673	rs11030660	chr11:4043268	T/C	cg18678763	chr11:4115507	RRM1	-0.45	-6.0	-0.52	3.61e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg12935359	chr14:103987150	CKB	-0.62	-6.48	-0.55	3.97e-9	Body mass index;
THYM	cis	rs11096990	0.819	rs1367297	chr4:39161234	A/C	cg24403649	chr4:39172243	NA	-0.6	-5.09	-0.46	1.77e-6	Cognitive function;
THYM	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs5769765	0.874	rs11703411	chr22:50258751	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.97	6.62	0.56	2.14e-9	Schizophrenia;
THYM	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-6.68	-0.57	1.63e-9	Alzheimer's disease (late onset);
THYM	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg18402987	chr7:1209562	NA	0.72	5.21	0.47	1.1e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs28595532	0.920	rs10004184	chr4:119486801	G/T	cg11846333	chr4:119757529	SEC24D	1.37	4.91	0.45	3.85e-6	Cannabis dependence symptom count;
THYM	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.88	-0.58	6.43e-10	Eye color traits;
THYM	cis	rs944002	1.000	rs2297066	chr14:103566835	C/G	cg16996574	chr14:103691482	NA	0.51	4.71	0.44	8.42e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;
THYM	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg02070205	chr10:30722105	MAP3K8	-0.59	-4.79	-0.44	6.07e-6	Inflammatory bowel disease;
THYM	cis	rs9914544	0.583	rs35783872	chr17:18748820	A/C	cg26378065	chr17:18585709	ZNF286B	0.59	4.56	0.42	1.52e-5	Educational attainment (years of education);
THYM	cis	rs6500395	0.775	rs7191225	chr16:48662675	C/G	cg04672837	chr16:48644449	N4BP1	0.47	4.62	0.43	1.18e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs6429082	0.749	rs291362	chr1:235686690	T/A	cg26050004	chr1:235667680	B3GALNT2	0.78	6.83	0.57	8.01e-10	Adiposity;
THYM	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg13902645	chr11:5959945	NA	-0.55	-4.82	-0.44	5.5e-6	DNA methylation (variation);
THYM	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg08132940	chr7:1081526	C7orf50	-1.26	-7.56	-0.61	2.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg00645579	chr11:617140	IRF7;MUPCDH	-0.41	-4.77	-0.44	6.56e-6	Systemic lupus erythematosus;
THYM	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs6669072	0.565	rs34898539	chr1:91283679	G/A	cg08895590	chr1:91227319	NA	-0.39	-4.45	-0.42	2.32e-5	Cognitive function;
THYM	cis	rs11771526	0.901	rs28709683	chr7:32301989	A/G	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg09549813	chr16:4587862	C16orf5	-0.6	-6.89	-0.58	5.94e-10	Schizophrenia;
THYM	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg00640147	chr17:61958756	GH2	-0.44	-4.67	-0.43	9.9e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	trans	rs4596713	0.538	rs4744829	chr9:71748416	G/C	cg16512924	chr15:28394682	HERC2	0.83	7.29	0.6	9.03e-11	Headache;
THYM	cis	rs7020830	0.898	rs13289199	chr9:37278064	A/T	cg14294708	chr9:37120828	ZCCHC7	1.19	14.78	0.83	2.32e-26	Schizophrenia;
THYM	cis	rs6430585	0.583	rs3769001	chr2:136626078	A/G	cg23851026	chr2:136556271	LCT	0.79	7.51	0.61	3.2e-11	Corneal structure;
THYM	cis	rs2806561	0.606	rs10917335	chr1:23294136	A/G	cg12483005	chr1:23474871	LUZP1	0.5	4.79	0.44	6.24e-6	Height;
THYM	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg06640241	chr16:89574553	SPG7	0.91	8.53	0.66	2.29e-13	Multiple myeloma (IgH translocation);
THYM	cis	rs9902453	0.900	rs12451122	chr17:28486376	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.83	0.44	5.26e-6	Coffee consumption (cups per day);
THYM	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg06532163	chr17:45867833	NA	0.65	6.58	0.56	2.6e-9	IgG glycosylation;
THYM	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg02931644	chr1:25747376	RHCE	0.61	4.95	0.45	3.24e-6	Erythrocyte sedimentation rate;
THYM	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs2133450	0.780	rs2030154	chr3:7361512	T/A	cg19930620	chr3:7340148	GRM7	-0.49	-4.66	-0.43	1.02e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-5.69	-0.5	1.41e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg00898013	chr13:113819073	PROZ	0.9	8.68	0.67	1.08e-13	Platelet distribution width;
THYM	cis	rs4845570	0.920	rs10788809	chr1:151760792	A/G	cg18019451	chr1:151746047	TDRKH	0.77	4.69	0.43	9.29e-6	Coronary artery disease;
THYM	cis	rs12950390	0.512	rs11651000	chr17:45835278	G/A	cg03474202	chr17:45855739	NA	-0.72	-4.87	-0.45	4.42e-6	IgG glycosylation;
THYM	cis	rs9902453	0.765	rs3115087	chr17:28030267	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	5.13	0.47	1.5e-6	Coffee consumption (cups per day);
THYM	cis	rs6542838	0.641	rs10192266	chr2:99521837	A/C	cg08885076	chr2:99613938	TSGA10	-0.48	-4.64	-0.43	1.11e-5	Fear of minor pain;
THYM	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg22166914	chr1:53195759	ZYG11B	0.78	7.69	0.62	1.37e-11	Monocyte count;
THYM	cis	rs3755605	0.864	rs2241296	chr3:169775249	T/A	cg18444028	chr3:169782040	GPR160	0.56	4.63	0.43	1.15e-5	Testicular germ cell tumor;
THYM	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg18252515	chr7:66147081	NA	0.69	5.32	0.48	6.93e-7	Aortic root size;
THYM	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg11663144	chr21:46675770	NA	-0.71	-9.54	-0.7	1.6e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg14196790	chr5:131705035	SLC22A5	0.55	5.05	0.46	2.15e-6	High light scatter reticulocyte percentage of red cells;
THYM	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03647317	chr4:187891568	NA	0.83	9.1	0.68	1.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg00990874	chr7:1149470	C7orf50	-0.61	-4.82	-0.44	5.35e-6	Bronchopulmonary dysplasia;
THYM	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02475777	chr4:1388615	CRIPAK	0.71	5.18	0.47	1.27e-6	Longevity;
THYM	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg10047753	chr17:41438598	NA	1.12	10.51	0.73	1.36e-17	Menopause (age at onset);
THYM	cis	rs13064411	0.866	rs35278902	chr3:113239021	A/G	cg18753928	chr3:113234510	CCDC52	-0.82	-5.69	-0.5	1.41e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg03806693	chr22:41940476	POLR3H	-0.8	-6.48	-0.55	4.06e-9	Neuroticism;
THYM	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.96	-8.81	-0.67	5.78e-14	Colorectal cancer;
THYM	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg09549813	chr16:4587862	C16orf5	-0.59	-6.65	-0.56	1.84e-9	Schizophrenia;
THYM	cis	rs17125944	0.556	rs1952088	chr14:53319832	A/C	cg00686598	chr14:53173677	PSMC6	-1.03	-4.67	-0.43	9.78e-6	Alzheimer's disease (late onset);
THYM	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.54	0.42	1.68e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8180040	0.800	rs7632501	chr3:47268306	T/C	cg12976108	chr3:47324180	KIF9;KLHL18	0.5	4.46	0.42	2.25e-5	Colorectal cancer;
THYM	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg17054759	chr22:49844102	NA	-0.53	-5.17	-0.47	1.32e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2811415	0.597	rs9819833	chr3:127793408	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs4065321	0.609	rs8075668	chr17:38137623	C/T	cg17467752	chr17:38218738	THRA	-0.71	-5.24	-0.47	9.77e-7	White blood cell count (basophil);White blood cell count;
THYM	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg18758796	chr5:131593413	PDLIM4	-0.5	-4.73	-0.44	7.8e-6	Breast cancer;
THYM	cis	rs7172118	1	rs7172118	chr15:78862453	C/A	cg18825076	chr15:78729989	IREB2	-0.54	-4.77	-0.44	6.53e-6	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06850241	chr22:41845214	NA	0.49	4.66	0.43	1.03e-5	Vitiligo;
THYM	cis	rs75139539	0.661	rs72883868	chr1:43959126	T/C	cg21148737	chr1:44707057	ERI3	1.22	4.5	0.42	1.91e-5	Plateletcrit;
THYM	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg06623918	chr6:96969491	KIAA0776	1.09	9.82	0.71	3.91e-16	Headache;
THYM	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs1021993	0.868	rs6674309	chr1:209530828	A/G	cg24997231	chr1:209527535	NA	-0.59	-4.68	-0.43	9.43e-6	Gut microbiome composition (winter);
THYM	cis	rs1421898	0.625	rs13356363	chr5:157938087	A/G	cg06698293	chr5:158690540	UBLCP1	0.97	4.6	0.43	1.28e-5	Inflammatory skin disease;
THYM	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.54e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9677476	0.863	rs60953838	chr2:232065864	G/C	cg23338755	chr2:231921595	PSMD1	0.7	5.3	0.48	7.54e-7	Food antigen IgG levels;
THYM	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg16524936	chr4:1340807	KIAA1530	-0.62	-4.94	-0.45	3.3e-6	Longevity;
THYM	cis	rs7000551	0.642	rs2449328	chr8:22375043	A/G	cg12081754	chr8:22256438	SLC39A14	0.63	5.71	0.51	1.27e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs117297873	0.826	rs117838191	chr14:91968387	C/A	cg00021325	chr14:91294412	NA	0.88	5.07	0.46	1.95e-6	Daytime sleep phenotypes;
THYM	cis	rs12310956	0.527	rs1608910	chr12:33895414	T/C	cg10856724	chr12:34555212	NA	-0.67	-5.88	-0.52	6.01e-8	Morning vs. evening chronotype;
THYM	cis	rs58688157	0.705	rs936468	chr11:607175	G/A	cg05717871	chr11:638507	DRD4	-0.63	-4.78	-0.44	6.33e-6	Systemic lupus erythematosus;
THYM	cis	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg01191920	chr7:158217561	PTPRN2	-0.99	-10.9	-0.75	2.03e-18	Obesity-related traits;
THYM	cis	rs600806	0.888	rs3853501	chr1:109864374	G/A	cg23032129	chr1:109941072	SORT1	-0.57	-4.84	-0.44	5.11e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3820068	0.580	rs36100011	chr1:16046920	C/T	cg27534772	chr1:16042836	PLEKHM2	0.47	4.84	0.44	5.12e-6	Systolic blood pressure;
THYM	cis	rs7631605	0.905	rs4678940	chr3:37187513	G/A	cg21328643	chr3:37258149	NA	-0.5	-4.87	-0.45	4.38e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg25256661	chr17:7137939	DVL2	-0.9	-6.6	-0.56	2.31e-9	Diastolic blood pressure;
THYM	cis	rs7264396	0.528	rs3787174	chr20:34487921	G/A	cg26038318	chr20:34205095	SPAG4	0.64	5.07	0.46	1.94e-6	Total cholesterol levels;
THYM	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg14784868	chr12:69753453	YEATS4	1.12	10.87	0.74	2.32e-18	Blood protein levels;
THYM	cis	rs2455799	0.634	rs62243671	chr3:15921098	C/T	cg16303742	chr3:15540471	COLQ	-0.56	-5.57	-0.5	2.34e-7	Mean platelet volume;
THYM	cis	rs6424115	0.830	rs6663474	chr1:24199642	G/A	cg15997130	chr1:24165203	NA	0.74	6.34	0.55	7.54e-9	Immature fraction of reticulocytes;
THYM	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg20007245	chr22:24372913	LOC391322	0.71	6.11	0.53	2.22e-8	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06873352	chr17:61820015	STRADA	0.77	9.62	0.7	1.08e-15	Prudent dietary pattern;
THYM	cis	rs7429990	0.932	rs9862913	chr3:48016172	T/C	cg02219026	chr3:48282209	ZNF589	-0.6	-4.5	-0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg12379764	chr21:47803548	PCNT	-0.83	-5.37	-0.48	5.52e-7	Testicular germ cell tumor;
THYM	cis	rs12579753	1.000	rs34031374	chr12:82235615	G/C	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.67	-0.43	1.01e-5	Resting heart rate;
THYM	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg11812906	chr14:75593930	NEK9	-0.85	-7.64	-0.62	1.7e-11	Height;
THYM	cis	rs459571	1.000	rs459571	chr9:136912626	C/T	cg13789015	chr9:136890014	NCRNA00094	0.84	6.97	0.58	4.25e-10	Platelet distribution width;
THYM	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.61	8.39	0.65	4.53e-13	Monocyte percentage of white cells;
THYM	cis	rs748404	0.660	rs2467742	chr15:43750237	C/A	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs10979	1.000	rs9496671	chr6:143884742	G/A	cg25407410	chr6:143891975	LOC285740	-0.62	-5.0	-0.46	2.59e-6	Hypospadias;
THYM	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg26886231	chr17:78936889	RPTOR	0.53	4.72	0.44	8.16e-6	Eye color traits;
THYM	cis	rs11048434	0.736	rs56130437	chr12:9093001	G/A	cg13575925	chr12:9217583	LOC144571	0.5	4.77	0.44	6.55e-6	Sjögren's syndrome;
THYM	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg00852783	chr1:26633632	UBXN11	0.7	5.79	0.51	9e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs7267979	1.000	rs2500448	chr20:25404027	A/C	cg08601574	chr20:25228251	PYGB	-0.58	-4.67	-0.43	9.97e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1642645	0.831	rs7535305	chr1:42489602	C/A	cg06092502	chr1:42611687	NA	0.61	4.74	0.44	7.58e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.32	-9.88	-0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs9788682	0.668	rs2036529	chr15:78726272	A/T	cg18825076	chr15:78729989	IREB2	-0.66	-5.06	-0.46	2.04e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg03188948	chr7:1209495	NA	0.9	5.0	0.46	2.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.53	-4.97	-0.45	3e-6	Lymphocyte counts;
THYM	cis	rs4243830	1.000	rs34757678	chr1:6583270	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	1.11	6.34	0.55	7.69e-9	Body mass index;
THYM	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Educational attainment;
THYM	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg20295408	chr7:1910781	MAD1L1	-0.62	-4.51	-0.42	1.87e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg12667521	chr19:29218732	NA	0.86	7.18	0.59	1.56e-10	Methadone dose in opioid dependence;
THYM	cis	rs593982	1.000	rs593982	chr11:65513107	T/C	cg08755490	chr11:65554678	OVOL1	1.36	8.73	0.67	8.51e-14	Atopic dermatitis;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg22410743	chr15:67574897	IQCH	-0.96	-7.11	-0.59	2.18e-10	Depressive symptoms;
THYM	cis	rs10779751	0.922	rs11121708	chr1:11307253	G/C	cg08854313	chr1:11322531	MTOR	0.94	8.23	0.65	9.67e-13	Body mass index;
THYM	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19346786	chr7:2764209	NA	-0.74	-6.36	-0.55	6.89e-9	Height;
THYM	cis	rs459482	1.000	rs461981	chr21:42794081	T/C	cg16817229	chr21:42798199	MX1	0.59	4.65	0.43	1.05e-5	IgG glycosylation;
THYM	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.78	-0.44	6.31e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22857025	chr5:266934	NA	-1.4	-8.88	-0.67	4.04e-14	Breast cancer;
THYM	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg06108461	chr20:60628389	TAF4	-1.04	-8.24	-0.65	9.18e-13	Body mass index;
THYM	cis	rs7582180	0.817	rs2309820	chr2:100899676	T/C	cg14675211	chr2:100938903	LONRF2	0.65	5.52	0.49	2.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs875971	1.000	rs2420820	chr7:66091907	T/C	cg11764359	chr7:65958608	NA	-0.86	-7.24	-0.6	1.17e-10	Aortic root size;
THYM	cis	rs4499344	0.730	rs2868150	chr19:33098875	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.61	0.62	1.96e-11	Mean platelet volume;
THYM	cis	rs28595532	0.920	rs116428408	chr4:119758514	G/C	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	4.96	0.45	3.08e-6	Hip circumference adjusted for BMI;
THYM	cis	rs9913156	0.748	rs55986729	chr17:4560499	G/T	cg19197139	chr17:4613644	ARRB2	0.78	4.92	0.45	3.63e-6	Lymphocyte counts;
THYM	cis	rs859767	0.812	rs842357	chr2:135345059	G/A	cg12500956	chr2:135428796	TMEM163	0.54	5.46	0.49	3.78e-7	Neuroticism;
THYM	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9905704	0.624	rs11652761	chr17:56986095	C/T	cg12560992	chr17:57184187	TRIM37	0.7	5.55	0.49	2.59e-7	Testicular germ cell tumor;
THYM	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg18538332	chr22:24372958	LOC391322	-1.05	-15.75	-0.85	3.08e-28	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs921968	0.544	rs58827325	chr2:219415166	A/T	cg02176678	chr2:219576539	TTLL4	0.73	7.2	0.59	1.4e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11608355	1.000	rs11066591	chr12:109880523	G/A	cg10504392	chr12:110044639	NA	0.66	6.22	0.54	1.35e-8	Neuroticism;
THYM	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg13395646	chr4:1353034	KIAA1530	-0.59	-5.12	-0.47	1.59e-6	Obesity-related traits;
THYM	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7107174	1.000	rs2512541	chr11:77981747	A/T	cg02023728	chr11:77925099	USP35	0.65	5.95	0.52	4.47e-8	Testicular germ cell tumor;
THYM	cis	rs7481584	0.624	rs516443	chr11:3047294	A/G	cg03159660	chr11:2078197	NA	0.62	4.62	0.43	1.22e-5	Calcium levels;
THYM	cis	rs79149102	0.579	rs6495138	chr15:75304692	A/G	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	cis	rs960902	0.689	rs888101	chr2:37732062	A/T	cg25341268	chr2:37734390	NA	-0.59	-4.84	-0.44	5.12e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg22117172	chr7:91764530	CYP51A1	0.39	4.79	0.44	6.17e-6	Breast cancer;
THYM	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg26031613	chr14:104095156	KLC1	0.79	5.22	0.47	1.06e-6	Body mass index;
THYM	cis	rs7809950	1.000	rs10234355	chr7:107086517	T/G	cg23024343	chr7:107201750	COG5	-0.9	-8.07	-0.64	2.19e-12	Coronary artery disease;
THYM	cis	rs1003719	0.715	rs9981715	chr21:38499610	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-4.75	-0.44	7.3e-6	Eye color traits;
THYM	cis	rs8070740	1.000	rs8066928	chr17:5328155	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.67	5.26	0.47	8.92e-7	Menopause (age at onset);
THYM	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg18681998	chr4:17616180	MED28	0.81	6.87	0.58	6.5e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6584283	0.846	rs10883370	chr10:101291472	T/C	cg23904955	chr10:101282759	NA	-0.35	-4.5	-0.42	1.92e-5	Ulcerative colitis;
THYM	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg25036284	chr2:26402008	FAM59B	0.8	5.36	0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg13147721	chr7:65941812	NA	-0.73	-4.58	-0.43	1.42e-5	Diabetic kidney disease;
THYM	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg00071950	chr4:10020882	SLC2A9	0.86	10.33	0.73	3.3e-17	Bone mineral density;
THYM	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg05283184	chr6:79620031	NA	-0.94	-9.21	-0.69	7.9e-15	Intelligence (multi-trait analysis);
THYM	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg15445000	chr17:37608096	MED1	0.44	5.22	0.47	1.05e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg07424592	chr7:64974309	NA	0.99	5.15	0.47	1.42e-6	Diabetic kidney disease;
THYM	trans	rs4596713	0.507	rs10115134	chr9:71800562	T/C	cg16512924	chr15:28394682	HERC2	0.87	7.25	0.6	1.12e-10	Headache;
THYM	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg23161317	chr6:28129485	ZNF389	0.72	4.79	0.44	6.09e-6	Parkinson's disease;
THYM	cis	rs2625529	0.824	rs4131630	chr15:72355398	C/T	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.77	5.19	0.47	1.21e-6	Gut microbiome composition (summer);
THYM	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-5.02	-0.46	2.43e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8078723	1.000	rs3826331	chr17:38150492	T/C	cg17467752	chr17:38218738	THRA	-0.87	-7.22	-0.59	1.3e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs669446	0.528	rs7538463	chr1:44196416	T/A	cg15962314	chr1:44399869	ARTN	0.47	5.18	0.47	1.22e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7169223	0.653	rs8042170	chr15:79096599	G/A	cg21242079	chr15:79101063	ADAMTS7	0.52	4.77	0.44	6.59e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs4720575	1.000	rs917108	chr7:47088047	A/G	cg00036614	chr7:47093842	NA	-0.59	-5.24	-0.47	9.71e-7	Angiotensin-converting enzyme inhibitor intolerance;
THYM	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg08999081	chr20:33150536	PIGU	-0.57	-4.95	-0.45	3.25e-6	Height;
THYM	trans	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg10856724	chr12:34555212	NA	-1.02	-9.32	-0.69	4.7e-15	Morning vs. evening chronotype;
THYM	cis	rs7769051	0.522	rs56908272	chr6:133102165	G/C	cg22852734	chr6:133119734	C6orf192	1.44	5.87	0.52	6.36e-8	Type 2 diabetes nephropathy;
THYM	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg27490568	chr2:178487706	NA	-0.59	-4.73	-0.44	7.83e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs804280	0.662	rs11784764	chr8:11610874	C/T	cg12395012	chr8:11607386	GATA4	0.57	4.59	0.43	1.33e-5	Myopia (pathological);
THYM	cis	rs6456156	0.526	rs1854853	chr6:167533062	A/G	cg09487078	chr6:167525398	CCR6	-0.37	-4.78	-0.44	6.27e-6	Primary biliary cholangitis;
THYM	cis	rs3796352	0.892	rs35076015	chr3:53026366	C/T	cg24530246	chr3:53118167	NA	-0.84	-4.74	-0.44	7.56e-6	Immune reponse to smallpox (secreted IL-2);
THYM	trans	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg25214090	chr10:38739885	LOC399744	-0.96	-8.24	-0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs2637266	0.627	rs2013238	chr10:78476272	A/C	cg18941641	chr10:78392320	NA	0.73	5.72	0.51	1.23e-7	Pulmonary function;
THYM	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg24209194	chr3:40518798	ZNF619	-0.74	-6.41	-0.55	5.6e-9	Renal cell carcinoma;
THYM	cis	rs12282928	0.959	rs1503168	chr11:48272696	A/G	cg22827986	chr11:48284249	OR4X1	-0.49	-5.13	-0.47	1.52e-6	Migraine - clinic-based;
THYM	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg18811423	chr2:55921094	PNPT1	-0.62	-5.9	-0.52	5.58e-8	Metabolic syndrome;
THYM	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg03709012	chr19:19516395	GATAD2A	0.84	7.3	0.6	8.83e-11	Tonsillectomy;
THYM	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg02725872	chr8:58115012	NA	-1.12	-7.66	-0.62	1.56e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg18876405	chr7:65276391	NA	-0.61	-5.2	-0.47	1.13e-6	Aortic root size;
THYM	cis	rs4803480	0.872	rs10420470	chr19:42073433	A/G	cg09848080	chr19:41642064	NA	0.63	4.49	0.42	1.97e-5	Schizophrenia;
THYM	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg15693483	chr7:1102177	C7orf50	0.51	5.85	0.51	6.94e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4907240	0.961	rs60959055	chr2:97313450	C/G	cg18419276	chr2:96971862	SNRNP200	-0.4	-4.67	-0.43	9.99e-6	Event-related brain oscillations;
THYM	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg25817165	chr18:72167213	CNDP2	-0.99	-7.58	-0.61	2.27e-11	Refractive error;
THYM	cis	rs2294693	0.945	rs2073015	chr6:41008747	A/G	cg14418226	chr6:40996092	UNC5CL	0.75	6.13	0.53	1.97e-8	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs4601821	1.000	rs877138	chr11:113256508	A/G	cg14159747	chr11:113255604	NA	-0.26	-5.02	-0.46	2.4e-6	Alcoholic chronic pancreatitis;
THYM	cis	rs6032067	0.777	rs17423897	chr20:43780307	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.41	-0.65	4.05e-13	Blood protein levels;
THYM	cis	rs886774	0.526	rs4727690	chr7:107502671	G/A	cg23293999	chr7:106826042	HBP1	-0.6	-4.81	-0.44	5.65e-6	Ulcerative colitis;
THYM	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg02734326	chr4:10020555	SLC2A9	0.76	6.89	0.58	6.16e-10	Bone mineral density;
THYM	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg27284194	chr4:1044797	NA	0.61	4.6	0.43	1.29e-5	Recombination rate (females);
THYM	cis	rs1018836	0.923	rs2187982	chr8:91556317	G/T	cg16814680	chr8:91681699	NA	-0.87	-8.03	-0.64	2.54e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg19794706	chr14:75643232	TMED10	-1.02	-6.93	-0.58	4.99e-10	Depressive symptoms;
THYM	cis	rs600806	0.888	rs4970749	chr1:109873573	G/A	cg02175308	chr1:109941060	SORT1	-0.57	-4.96	-0.45	3.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7843479	0.965	rs733544	chr8:21835628	A/G	cg17168535	chr8:21777572	XPO7	0.7	5.29	0.48	7.87e-7	Mean corpuscular volume;
THYM	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs7943358	0.678	rs2170911	chr11:15678575	G/A	cg11966998	chr11:15692519	NA	-0.46	-4.73	-0.44	7.71e-6	Gut microbiome composition (summer);
THYM	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.79	7.66	0.62	1.56e-11	Chronic sinus infection;
THYM	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs593982	0.920	rs563427	chr11:65484569	A/G	cg08755490	chr11:65554678	OVOL1	1.29	4.66	0.43	1.03e-5	Atopic dermatitis;
THYM	cis	rs9807841	0.670	rs8099926	chr19:10778647	A/G	cg17848348	chr19:10766748	ILF3	-0.85	-7.48	-0.61	3.69e-11	Inflammatory skin disease;
THYM	cis	rs2455799	0.613	rs13096622	chr3:15837656	A/G	cg16303742	chr3:15540471	COLQ	-0.56	-5.88	-0.52	6.13e-8	Mean platelet volume;
THYM	cis	rs35883536	0.967	rs3904673	chr1:101137162	A/C	cg06223162	chr1:101003688	GPR88	0.63	4.79	0.44	6.24e-6	Monocyte count;
THYM	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg14004847	chr7:1930337	MAD1L1	-0.62	-4.86	-0.45	4.7e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs1865063	1.000	rs1865063	chr19:11341029	C/T	cg21487509	chr19:11347464	LOC55908;DOCK6	0.71	4.54	0.42	1.63e-5	HDL cholesterol levels;
THYM	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg09307838	chr4:120376055	NA	-0.74	-5.24	-0.47	9.62e-7	Corneal astigmatism;
THYM	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg02527881	chr3:46936655	PTH1R	-0.61	-5.7	-0.51	1.33e-7	Colorectal cancer;
THYM	trans	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11608355	1.000	rs7958625	chr12:109869218	A/T	cg10504392	chr12:110044639	NA	0.67	6.21	0.54	1.41e-8	Neuroticism;
THYM	cis	rs4908768	0.657	rs10492963	chr1:8810341	A/G	cg06972019	chr1:8937448	ENO1	0.56	4.67	0.43	9.78e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
THYM	cis	rs7729447	0.804	rs116090595	chr5:32698148	T/G	cg16267343	chr5:32710456	NPR3	0.8	7.27	0.6	1.01e-10	Blood pressure;
THYM	cis	rs2046867	0.818	rs6808341	chr3:72914847	A/G	cg25664220	chr3:72788482	NA	-0.87	-7.65	-0.62	1.64e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs11645898	0.630	rs72791135	chr16:72259718	G/C	cg14768367	chr16:72042858	DHODH	-0.7	-4.65	-0.43	1.05e-5	Blood protein levels;
THYM	cis	rs3741151	0.773	rs73542938	chr11:73103012	G/C	cg12959048	chr11:73096162	RELT	-0.54	-5.2	-0.47	1.13e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	trans	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7584099	0.516	rs1872198	chr2:148750509	T/C	cg23727674	chr2:148602993	ACVR2A	0.54	4.73	0.44	7.88e-6	Response to statin therapy;
THYM	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06873352	chr17:61820015	STRADA	0.8	10.1	0.72	1e-16	Prudent dietary pattern;
THYM	cis	rs7584330	0.518	rs7561919	chr2:238435241	A/G	cg08992911	chr2:238395768	MLPH	1.11	6.57	0.56	2.65e-9	Prostate cancer;
THYM	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg11301795	chr4:187892539	NA	-1.12	-16.92	-0.87	2.01e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4266144	0.632	rs56268334	chr3:156848024	C/T	cg14969094	chr3:156848003	NA	-0.52	-4.65	-0.43	1.07e-5	Coronary artery disease;
THYM	cis	rs981844	0.775	rs62323976	chr4:154739032	A/G	cg09973105	chr4:154681532	RNF175	-0.62	-5.1	-0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg18904891	chr8:8559673	CLDN23	0.66	4.9	0.45	3.99e-6	Obesity-related traits;
THYM	cis	rs1062746	0.777	rs34400756	chr16:87372078	A/G	cg27365499	chr16:87376795	FBXO31	0.58	6.02	0.53	3.23e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs11214589	0.651	rs12360992	chr11:113262900	A/C	cg14159747	chr11:113255604	NA	0.36	7.61	0.62	1.95e-11	Neuroticism;
THYM	cis	rs3892630	0.878	rs66788054	chr19:33190146	G/T	cg22928329	chr19:33183273	NUDT19	-0.77	-5.81	-0.51	8.39e-8	Red blood cell traits;
THYM	cis	rs4888262	0.526	rs4887772	chr16:74537591	C/T	cg01733217	chr16:74700730	RFWD3	0.8	8.24	0.65	9.33e-13	Testicular germ cell tumor;
THYM	cis	rs747782	0.527	rs12289516	chr11:48234680	G/A	cg24672777	chr11:48374446	OR4C45	-1.14	-6.78	-0.57	1e-9	Intraocular pressure;
THYM	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg03188948	chr7:1209495	NA	1.13	6.46	0.55	4.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg13683864	chr3:40499215	RPL14	-1.03	-11.14	-0.75	6.18e-19	Renal cell carcinoma;
THYM	cis	rs67460515	0.563	rs13071892	chr3:160817877	A/C	cg12349858	chr3:160822545	B3GALNT1	0.58	4.67	0.43	9.98e-6	Parkinson's disease;
THYM	cis	rs36051895	0.554	rs11789744	chr9:5134213	G/A	cg02405213	chr9:5042618	JAK2	-1.05	-10.94	-0.75	1.69e-18	Pediatric autoimmune diseases;
THYM	cis	rs7107174	1.000	rs11237462	chr11:78058812	C/A	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg01528321	chr10:82214614	TSPAN14	0.65	5.06	0.46	2.01e-6	Post bronchodilator FEV1;
THYM	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg19508488	chr2:152266495	RIF1	0.82	6.77	0.57	1.05e-9	Lung cancer;
THYM	cis	rs1568889	0.838	rs10458896	chr11:28057957	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	6.81	0.57	8.87e-10	Bipolar disorder;
THYM	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.54	5.34	0.48	6.2e-7	Schizophrenia;
THYM	cis	rs28476539	0.640	rs35614535	chr4:83555526	G/C	cg10249074	chr4:83542146	C4orf11	-0.62	-4.96	-0.45	3.12e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg17294928	chr15:75287854	SCAMP5	0.62	4.54	0.42	1.68e-5	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs12310956	0.510	rs1565026	chr12:33887499	A/G	cg06521331	chr12:34319734	NA	-0.56	-4.51	-0.42	1.83e-5	Morning vs. evening chronotype;
THYM	cis	rs11122895	1.000	rs11122896	chr2:112470214	G/C	cg23262488	chr2:112468472	NA	0.67	9.57	0.7	1.36e-15	Allergic sensitization;
THYM	cis	rs4731207	0.698	rs10228376	chr7:124493743	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs6032067	0.526	rs2743347	chr20:43920493	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.59	-5.42	-0.49	4.5e-7	Blood protein levels;
THYM	cis	rs750460	0.966	rs11638944	chr15:74234082	C/G	cg01349856	chr15:74220517	LOXL1	-0.62	-4.56	-0.42	1.51e-5	Height;
THYM	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3206736	0.548	rs328895	chr7:35016387	G/C	cg13068698	chr7:35078082	DPY19L1	0.47	4.54	0.42	1.66e-5	Diastolic blood pressure;
THYM	cis	rs2237898	0.585	rs34495402	chr11:2876631	C/A	cg12614029	chr11:2160564	INS-IGF2;IGF2AS;IGF2	-1.21	-4.48	-0.42	2.05e-5	Mosquito bite size;
THYM	trans	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg09458595	chr6:14467611	NA	-0.75	-6.93	-0.58	5.09e-10	Lung adenocarcinoma;
THYM	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.64	4.6	0.43	1.32e-5	Body mass index (adult);
THYM	cis	rs11190604	0.806	rs76835764	chr10:102193612	C/T	cg16342193	chr10:102329863	NA	-0.5	-5.17	-0.47	1.29e-6	Palmitoleic acid (16:1n-7) levels;
THYM	trans	rs8073060	0.504	rs225271	chr17:33969836	C/T	cg19694781	chr19:47549865	TMEM160	-0.95	-7.96	-0.63	3.6e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg03433033	chr1:76189801	ACADM	-0.77	-9.42	-0.69	2.92e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9435341	0.930	rs12408634	chr1:107579540	G/A	cg09367891	chr1:107599246	PRMT6	0.7	4.7	0.43	8.81e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs2658782	0.738	rs2605628	chr11:93261560	C/A	cg15737290	chr11:93063684	CCDC67	1.01	7.31	0.6	8.17e-11	Pulmonary function decline;
THYM	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7777677	0.889	rs6975391	chr7:142369835	C/T	cg21785750	chr7:142428317	NA	0.67	5.88	0.52	6.1e-8	Alcoholic chronic pancreatitis;
THYM	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12912251	0.947	rs12899449	chr15:38995491	A/G	cg08274633	chr15:38988533	C15orf53	-0.23	-4.52	-0.42	1.76e-5	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
THYM	cis	rs1878931	0.559	rs2106863	chr16:3391330	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.71	5.06	0.46	2.06e-6	Body mass index (adult);
THYM	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg23711669	chr6:146136114	FBXO30	0.85	7.9	0.63	4.99e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg15592062	chr6:167189543	RPS6KA2	-0.48	-4.86	-0.45	4.64e-6	Crohn's disease;
THYM	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg09323728	chr8:95962352	TP53INP1	-0.48	-4.93	-0.45	3.53e-6	Type 2 diabetes;
THYM	cis	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg11879182	chr18:77439856	CTDP1	0.8	7.5	0.61	3.42e-11	Monocyte count;
THYM	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.22e-16	Bone mineral density;
THYM	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg19628046	chr18:33552617	C18orf21	0.77	5.47	0.49	3.68e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg08645402	chr16:4508243	NA	0.69	6.07	0.53	2.63e-8	Schizophrenia;
THYM	cis	rs13082711	0.522	rs569960	chr3:27329540	C/T	cg02860705	chr3:27208620	NA	0.65	5.09	0.46	1.79e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs2404602	0.647	rs12910820	chr15:77022825	T/C	cg23625390	chr15:77176239	SCAPER	-0.85	-5.95	-0.52	4.43e-8	Blood metabolite levels;
THYM	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg27087555	chr16:88793112	FAM38A	1.22	7.56	0.61	2.57e-11	Plateletcrit;
THYM	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-4.79	-0.44	6.04e-6	Total cholesterol levels;
THYM	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg06558623	chr16:89946397	TCF25	1.48	7.81	0.63	7.43e-12	Skin colour saturation;
THYM	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg17173187	chr15:85201210	NMB	0.56	5.75	0.51	1.09e-7	Schizophrenia;
THYM	trans	rs877282	0.947	rs4133015	chr10:774131	T/C	cg22713356	chr15:30763199	NA	1.25	9.95	0.71	2.11e-16	Uric acid levels;
THYM	cis	rs314370	0.951	rs6706	chr7:100471044	C/T	cg08558340	chr7:100472263	SRRT	0.61	4.99	0.46	2.75e-6	Resting heart rate;
THYM	cis	rs863345	0.527	rs10797019	chr1:158490221	A/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg22166914	chr1:53195759	ZYG11B	-0.69	-6.96	-0.58	4.39e-10	Monocyte count;
THYM	cis	rs1483890	0.723	rs6549207	chr3:69412018	T/G	cg22125112	chr3:69402811	FRMD4B	0.54	6.85	0.58	7.21e-10	Resting heart rate;
THYM	cis	rs10936602	0.527	rs6793160	chr3:169535266	A/C	cg17737146	chr3:169530037	LRRC34	-0.48	-4.5	-0.42	1.93e-5	Renal cell carcinoma;
THYM	cis	rs3862030	0.839	rs2281880	chr10:104269217	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.68	-5.74	-0.51	1.15e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.57	-0.42	1.45e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg20219074	chr11:18656078	SPTY2D1	0.79	6.46	0.55	4.47e-9	Breast cancer;
THYM	cis	rs11690935	0.632	rs12991740	chr2:172885996	C/T	cg13550731	chr2:172543902	DYNC1I2	0.68	5.68	0.5	1.47e-7	Schizophrenia;
THYM	cis	rs6163	0.540	rs11191385	chr10:104513049	G/T	cg04362960	chr10:104952993	NT5C2	0.68	5.45	0.49	4.01e-7	Waist circumference;Hip circumference;
THYM	cis	rs4072705	0.562	rs7855918	chr9:127239939	T/C	cg01786973	chr9:127249749	NR5A1	0.42	5.14	0.47	1.46e-6	Menarche (age at onset);
THYM	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg02734326	chr4:10020555	SLC2A9	-0.7	-6.06	-0.53	2.68e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9677476	0.774	rs1973016	chr2:232117513	C/G	cg23338755	chr2:231921595	PSMD1	0.69	4.92	0.45	3.67e-6	Food antigen IgG levels;
THYM	cis	rs7584330	0.518	rs79618460	chr2:238419959	T/C	cg14458575	chr2:238380390	NA	0.89	4.55	0.42	1.59e-5	Prostate cancer;
THYM	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs240764	0.687	rs1336245	chr6:101197640	A/T	cg21058520	chr6:100914733	NA	0.56	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.61e-20	Menopause (age at onset);
THYM	cis	rs9913156	0.789	rs72824951	chr17:4588500	G/C	cg19197139	chr17:4613644	ARRB2	0.84	4.97	0.45	2.92e-6	Lymphocyte counts;
THYM	cis	rs11048434	0.518	rs34651717	chr12:9177750	C/A	cg26114124	chr12:9217669	LOC144571	0.52	4.57	0.42	1.49e-5	Sjögren's syndrome;
THYM	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-4.8	-0.44	5.91e-6	Schizophrenia;
THYM	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg19774624	chr17:42201019	HDAC5	0.68	6.26	0.54	1.12e-8	Total body bone mineral density;
THYM	trans	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg10856724	chr12:34555212	NA	-0.86	-7.5	-0.61	3.34e-11	Heart rate;
THYM	cis	rs8077889	0.917	rs4793038	chr17:41916761	A/T	cg26893861	chr17:41843967	DUSP3	1.06	10.14	0.72	8.24e-17	Triglycerides;
THYM	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg06481639	chr22:41940642	POLR3H	-0.83	-6.19	-0.54	1.55e-8	Vitiligo;
THYM	trans	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg15693483	chr7:1102177	C7orf50	0.47	5.04	0.46	2.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9649465	1.000	rs10215473	chr7:123380681	C/G	cg15443791	chr7:124364398	NA	0.58	4.81	0.44	5.62e-6	Migraine;
THYM	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg06634786	chr22:41940651	POLR3H	-0.7	-4.92	-0.45	3.59e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs10193935	0.901	rs2374405	chr2:42479874	A/C	cg27598129	chr2:42591480	NA	-0.74	-4.45	-0.42	2.37e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10949834	0.504	rs13238778	chr7:73567709	G/A	cg07137043	chr7:73588983	EIF4H	-0.76	-4.8	-0.44	6e-6	Verbal memory performance (residualized delayed recall change);
THYM	cis	rs11608355	0.672	rs9943689	chr12:109890339	G/A	cg11367159	chr12:110044531	NA	0.66	5.67	0.5	1.53e-7	Neuroticism;
THYM	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg04362960	chr10:104952993	NT5C2	0.6	5.11	0.46	1.66e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs7809950	0.953	rs2253271	chr7:107201252	G/C	cg23024343	chr7:107201750	COG5	-0.94	-8.66	-0.66	1.21e-13	Coronary artery disease;
THYM	cis	rs11651000	0.894	rs66490177	chr17:45817723	T/C	cg03474202	chr17:45855739	NA	-0.76	-4.99	-0.46	2.69e-6	IgG glycosylation;
THYM	cis	rs13315871	0.929	rs73835170	chr3:58318448	A/G	cg00563845	chr3:58318305	PXK	0.58	4.99	0.46	2.73e-6	Cholesterol, total;
THYM	cis	rs9992101	0.547	rs10029860	chr4:77411101	C/A	cg20311846	chr4:77356250	SHROOM3	-0.45	-4.72	-0.44	8.12e-6	Creatinine levels;
THYM	cis	rs13064411	0.696	rs6768648	chr3:113234141	C/G	cg18753928	chr3:113234510	CCDC52	-0.97	-9.75	-0.71	5.71e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs4842666	0.915	rs11105368	chr12:90074441	G/C	cg00757033	chr12:89920650	WDR51B	0.46	4.58	0.43	1.42e-5	Blood pressure;
THYM	cis	rs9905704	0.647	rs3809723	chr17:57061978	T/G	cg12560992	chr17:57184187	TRIM37	0.71	5.54	0.49	2.66e-7	Testicular germ cell tumor;
THYM	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.97	-0.45	2.98e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7072216	0.763	rs7909822	chr10:100172035	A/C	cg03852570	chr10:100175106	PYROXD2	0.38	5.03	0.46	2.35e-6	Metabolite levels;
THYM	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg11266682	chr4:10021025	SLC2A9	-0.59	-7.57	-0.61	2.41e-11	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs28595532	0.920	rs115006522	chr4:119732499	A/G	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs3820068	0.580	rs12082523	chr1:16005792	A/G	cg13390004	chr1:15929781	NA	-0.64	-4.8	-0.44	5.83e-6	Systolic blood pressure;
THYM	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg27034606	chr17:28928453	LRRC37B2	0.82	5.26	0.48	8.74e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg06784218	chr1:46089804	CCDC17	-0.33	-4.89	-0.45	4.06e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.53	0.49	2.84e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs854765	0.663	rs9915248	chr17:17747514	C/T	cg04398451	chr17:18023971	MYO15A	0.82	7.57	0.61	2.42e-11	Total body bone mineral density;
THYM	cis	rs7586879	0.639	rs7567997	chr2:25096952	A/G	cg27107076	chr2:25050844	ADCY3	-0.29	-4.64	-0.43	1.12e-5	Body mass index;
THYM	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg23851026	chr2:136556271	LCT	0.5	4.76	0.44	6.97e-6	Mosquito bite size;
THYM	cis	rs3849570	0.925	rs6799080	chr3:81905591	G/A	cg07356753	chr3:81810745	GBE1	-0.8	-5.94	-0.52	4.58e-8	Waist circumference;Body mass index;
THYM	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg22920501	chr2:26401640	FAM59B	-1.07	-9.54	-0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs2506889	0.553	rs17035189	chr1:10597024	A/G	cg20482658	chr1:10539492	PEX14	-0.37	-5.94	-0.52	4.75e-8	Breast cancer;
THYM	cis	rs1113500	0.862	rs3853494	chr1:108637334	G/A	cg06207961	chr1:108661230	NA	0.64	5.09	0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs8008758	0.517	rs1772024	chr14:101695220	A/C	cg26224664	chr14:101693935	NA	0.78	8.56	0.66	1.98e-13	Body mass index (alcohol intake interaction);
THYM	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08704250	chr15:31115839	NA	-0.69	-7.64	-0.62	1.7e-11	Huntington's disease progression;
THYM	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.87	-7.12	-0.59	2.09e-10	Cognitive test performance;
THYM	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.61	-4.63	-0.43	1.17e-5	Monocyte percentage of white cells;
THYM	cis	rs4273100	0.688	rs4924980	chr17:19204863	T/C	cg25447019	chr17:19030144	GRAPL	0.79	6.24	0.54	1.2e-8	Schizophrenia;
THYM	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg24692254	chr21:30365293	RNF160	-0.99	-9.12	-0.68	1.25e-14	Dental caries;
THYM	cis	rs981844	0.617	rs4077965	chr4:154710520	G/C	cg09973105	chr4:154681532	RNF175	-0.71	-6.46	-0.55	4.42e-9	Response to statins (LDL cholesterol change);
THYM	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg24692254	chr21:30365293	RNF160	0.66	4.81	0.44	5.71e-6	Selective IgA deficiency;
THYM	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.76	0.44	6.93e-6	Diabetic retinopathy;
THYM	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg18758796	chr5:131593413	PDLIM4	0.5	4.79	0.44	6.07e-6	Acylcarnitine levels;
THYM	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg01966878	chr4:90757139	SNCA	-0.61	-4.71	-0.44	8.38e-6	Neuroticism;
THYM	cis	rs922692	0.715	rs2277546	chr15:79083376	C/A	cg15571903	chr15:79123663	NA	-0.49	-4.59	-0.43	1.37e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14159672	chr1:205819179	PM20D1	1.13	12.55	0.79	6.88e-22	Menarche (age at onset);
THYM	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg12386194	chr3:101231763	SENP7	-0.69	-5.21	-0.47	1.1e-6	Colorectal cancer;
THYM	cis	rs1401999	0.546	rs59679804	chr3:183633094	G/A	cg01324343	chr3:183735012	ABCC5	0.56	6.75	0.57	1.18e-9	Anterior chamber depth;
THYM	cis	rs10847980	0.590	rs12319654	chr12:123327160	C/T	cg25930673	chr12:123319894	HIP1R	1.15	5.3	0.48	7.53e-7	Adiponectin levels;
THYM	cis	rs10503871	0.584	rs7831616	chr8:30449536	A/G	cg12158488	chr8:31336998	NA	0.41	4.51	0.42	1.87e-5	Metabolite levels  (X-11787);
THYM	cis	rs10904908	0.733	rs359298	chr10:17334176	C/T	cg01003015	chr10:17271136	VIM	0.56	4.62	0.43	1.23e-5	Total cholesterol levels;Cholesterol, total;
THYM	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.88	0.63	5.43e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg15592062	chr6:167189543	RPS6KA2	0.59	6.1	0.53	2.29e-8	Crohn's disease;
THYM	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs3741151	0.773	rs73542976	chr11:73127471	A/G	cg17517138	chr11:73019481	ARHGEF17	0.94	5.48	0.49	3.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs616402	0.564	rs602601	chr1:10567058	C/T	cg20482658	chr1:10539492	PEX14	-0.34	-4.82	-0.44	5.48e-6	Breast size;
THYM	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg04282206	chr17:62833786	PLEKHM1P	0.82	7.53	0.61	2.9100000000000002e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4790333	0.531	rs2447107	chr17:2257864	A/G	cg02569219	chr17:2266849	SGSM2	0.7	5.87	0.52	6.33e-8	Proinsulin levels;
THYM	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg04398451	chr17:18023971	MYO15A	-0.95	-9.84	-0.71	3.63e-16	Total body bone mineral density;
THYM	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg15536230	chr21:44985092	HSF2BP	-0.43	-5.37	-0.48	5.47e-7	Mean corpuscular volume;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg24163360	chr6:25931557	SLC17A2	-0.88	-6.92	-0.58	5.15e-10	Depressive symptoms;
THYM	cis	rs7216064	1.000	rs1976054	chr17:65833224	T/G	cg12091567	chr17:66097778	LOC651250	-0.71	-4.76	-0.44	6.86e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs870825	0.872	rs12506750	chr4:185571123	C/T	cg04058563	chr4:185651563	MLF1IP	0.99	6.78	0.57	9.89e-10	Blood protein levels;
THYM	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg17173187	chr15:85201210	NMB	-0.42	-4.55	-0.42	1.56e-5	P wave terminal force;
THYM	cis	rs4737010	0.530	rs4026	chr8:41645710	C/T	cg08923054	chr8:41654455	ANK1	0.85	5.06	0.46	2.04e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
THYM	cis	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg02782426	chr3:40428986	ENTPD3	-0.51	-4.56	-0.42	1.55e-5	Renal cell carcinoma;
THYM	cis	rs35883536	0.647	rs10875317	chr1:101045438	G/T	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs4642101	0.765	rs9872103	chr3:12827452	G/T	cg05775895	chr3:12838266	CAND2	0.79	7.06	0.59	2.66e-10	QRS complex (12-leadsum);
THYM	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg15744005	chr10:104629667	AS3MT	-0.85	-8.44	-0.65	3.62e-13	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06481639	chr22:41940642	POLR3H	0.79	5.41	0.49	4.76e-7	Vitiligo;
THYM	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	5.42	0.49	4.47e-7	Schizophrenia;
THYM	cis	rs240764	0.746	rs240156	chr6:101063149	C/G	cg21058520	chr6:100914733	NA	-0.57	-5.02	-0.46	2.39e-6	Neuroticism;
THYM	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.91	-4.86	-0.45	4.55e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13315871	0.929	rs9818581	chr3:58293101	A/G	cg12435725	chr3:58293450	RPP14	-0.53	-5.57	-0.5	2.32e-7	Cholesterol, total;
THYM	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg07061783	chr6:25882402	NA	0.57	4.47	0.42	2.14e-5	Schizophrenia;
THYM	cis	rs17030434	1.000	rs17030434	chr4:154703596	A/G	cg14289246	chr4:154710475	SFRP2	-0.76	-5.24	-0.47	9.79e-7	Electrocardiographic conduction measures;
THYM	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg04398451	chr17:18023971	MYO15A	-0.79	-7.19	-0.59	1.45e-10	Total body bone mineral density;
THYM	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg12560992	chr17:57184187	TRIM37	0.88	7.82	0.63	7.3e-12	Intelligence (multi-trait analysis);
THYM	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs7267979	1.000	rs398036	chr20:25439850	C/T	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.63	4.46	0.42	2.25e-5	Aortic root size;
THYM	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2108622	0.727	rs8101038	chr19:15982864	C/T	cg13772218	chr19:15982569	NA	0.5	4.48	0.42	2.06e-5	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs12791968	1.000	rs10838397	chr11:45009133	A/G	cg11846598	chr11:44996168	LOC221122	0.9	7.67	0.62	1.51e-11	Inhibitory control;
THYM	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg26384229	chr12:38710491	ALG10B	-0.75	-6.0	-0.52	3.55e-8	Morning vs. evening chronotype;
THYM	cis	rs55788414	0.505	rs7190543	chr16:81189320	T/C	cg06400318	chr16:81190750	PKD1L2	-0.92	-6.7	-0.57	1.46e-9	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs7809950	0.724	rs1858888	chr7:107046062	T/A	cg23024343	chr7:107201750	COG5	-0.97	-7.67	-0.62	1.5e-11	Coronary artery disease;
THYM	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg12524338	chr4:183729343	NA	0.91	5.86	0.52	6.52e-8	Pediatric autoimmune diseases;
THYM	trans	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs6424115	0.679	rs2267961	chr1:24071048	A/G	cg15997130	chr1:24165203	NA	-0.75	-5.52	-0.49	2.99e-7	Immature fraction of reticulocytes;
THYM	cis	rs6500602	1.000	rs11648292	chr16:4462897	C/A	cg09549813	chr16:4587862	C16orf5	-0.46	-4.79	-0.44	6.02e-6	Schizophrenia;
THYM	cis	rs2319125	0.683	rs7212467	chr17:64050156	T/C	cg04446870	chr17:64440273	PRKCA	0.5	4.48	0.42	2.12e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs11039798	1.000	rs6485856	chr11:48556298	G/C	cg24672777	chr11:48374446	OR4C45	-1.14	-6.95	-0.58	4.55e-10	Axial length;
THYM	cis	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg07988820	chr12:82153109	PPFIA2	-0.83	-5.29	-0.48	7.71e-7	Resting heart rate;
THYM	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg02353165	chr6:42928485	GNMT	1.02	11.21	0.75	4.51e-19	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg06027949	chr8:82754900	SNX16	-0.62	-5.06	-0.46	2.01e-6	Diastolic blood pressure;
THYM	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg26314531	chr2:26401878	FAM59B	-0.76	-5.02	-0.46	2.37e-6	Gut microbiome composition (summer);
THYM	cis	rs8038465	0.592	rs1542580	chr15:73935834	C/G	cg15420318	chr15:73925796	NPTN	0.61	5.25	0.47	9.1e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg13319975	chr6:146136371	FBXO30	-0.67	-5.46	-0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2430307	0.556	rs3930019	chr7:76541610	C/T	cg15770687	chr7:76625569	PMS2L11	0.87	5.94	0.52	4.63e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs8013055	0.846	rs35590487	chr14:105989599	C/T	cg04429589	chr14:105992532	TMEM121	-0.52	-5.39	-0.48	5.17e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs59698941	0.882	rs4705977	chr5:132245114	C/A	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs10510102	1.000	rs7923678	chr10:123592061	G/A	cg24202772	chr10:124402857	DMBT1	-0.62	-4.54	-0.42	1.66e-5	Breast cancer;
THYM	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg25319279	chr11:5960081	NA	-0.57	-4.45	-0.42	2.32e-5	DNA methylation (variation);
THYM	cis	rs9788721	0.934	rs55676755	chr15:78898932	C/G	cg18825076	chr15:78729989	IREB2	-0.57	-5.05	-0.46	2.14e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs72627123	0.867	rs117818304	chr14:74474396	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.16	6.54	0.56	3.13e-9	Morning vs. evening chronotype;
THYM	cis	rs4654899	0.772	rs10916892	chr1:21201325	A/G	cg01072550	chr1:21505969	NA	-0.67	-5.09	-0.46	1.78e-6	Superior frontal gyrus grey matter volume;
THYM	cis	rs28785552	0.554	rs8112079	chr19:53216544	T/A	cg22067481	chr19:53234126	ZNF611	-0.96	-9.2	-0.69	8.29e-15	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.56	0.42	1.54e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12291225	0.679	rs4757245	chr11:14297872	A/C	cg19336497	chr11:14380999	RRAS2	-0.82	-9.53	-0.7	1.67e-15	Sense of smell;
THYM	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg00530320	chr1:46809349	NSUN4	-0.73	-5.06	-0.46	2.02e-6	Menopause (age at onset);
THYM	cis	rs2288884	0.537	rs4145658	chr19:52588718	C/T	cg05974498	chr19:52599256	ZNF841	0.31	4.51	0.42	1.86e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs17152411	0.947	rs61873270	chr10:126595923	C/A	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg16586182	chr3:47516702	SCAP	0.69	5.74	0.51	1.11e-7	Colorectal cancer;
THYM	cis	rs910187	0.678	rs3818009	chr20:45816514	C/T	cg27589058	chr20:45804311	EYA2	-0.56	-4.94	-0.45	3.3e-6	Migraine;
THYM	cis	rs6456156	0.742	rs3093026	chr6:167532690	A/G	cg09487078	chr6:167525398	CCR6	0.42	4.85	0.45	4.81e-6	Primary biliary cholangitis;
THYM	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-5.24	-0.47	9.67e-7	Hemoglobin concentration;
THYM	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs62158800	0.568	rs78259088	chr2:108361571	T/A	cg27431625	chr2:107679531	NA	1.04	4.9	0.45	3.87e-6	Facial morphology (factor 22);
THYM	cis	rs988913	0.915	rs9475107	chr6:54853342	G/A	cg18532076	chr6:54711417	FAM83B	0.52	4.95	0.45	3.25e-6	Menarche (age at onset);
THYM	cis	rs4866334	1.000	rs74368495	chr5:18483062	T/C	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs946836	0.562	rs12119021	chr1:48385998	C/T	cg18376692	chr1:48452465	NA	-0.54	-4.85	-0.45	4.75e-6	White matter integrity;
THYM	cis	rs828999	0.715	rs11185295	chr1:108711074	A/C	cg24323958	chr1:108741884	SLC25A24	0.57	5.61	0.5	1.97e-7	Monocyte percentage of white cells;
THYM	cis	rs4642101	0.793	rs6763619	chr3:12822147	T/G	cg05775895	chr3:12838266	CAND2	0.76	6.79	0.57	9.61e-10	QRS complex (12-leadsum);
THYM	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg06623918	chr6:96969491	KIAA0776	-1.04	-7.83	-0.63	6.99e-12	Headache;
THYM	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	4.83	0.44	5.26e-6	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs714027	0.545	rs41161	chr22:30407652	T/C	cg27665648	chr22:30112403	NA	-0.52	-4.68	-0.43	9.61e-6	Lymphocyte counts;
THYM	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg06634786	chr22:41940651	POLR3H	-0.6	-4.6	-0.43	1.32e-5	Vitiligo;
THYM	cis	rs17253792	0.822	rs8007065	chr14:56081272	A/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg00012203	chr2:219082015	ARPC2	-0.65	-5.32	-0.48	6.78e-7	Colorectal cancer;
THYM	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg02734326	chr4:10020555	SLC2A9	-0.6	-4.7	-0.43	8.84e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg12165864	chr7:66369176	NA	-0.64	-4.97	-0.45	2.97e-6	Aortic root size;
THYM	cis	rs9880211	1.000	rs9823373	chr3:136167027	T/C	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	trans	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs9486719	0.552	rs9399923	chr6:96850379	G/A	cg06623918	chr6:96969491	KIAA0776	0.79	4.75	0.44	7.22e-6	Migraine;Coronary artery disease;
THYM	cis	rs4919087	0.810	rs10786321	chr10:99026112	T/C	cg19453742	chr10:98862320	SLIT1	-0.63	-4.82	-0.44	5.34e-6	Monocyte count;
THYM	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg13319975	chr6:146136371	FBXO30	-0.72	-6.1	-0.53	2.24e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12534701	1.000	rs12534701	chr7:154680910	A/C	cg24255201	chr7:154684926	DPP6	-0.71	-5.38	-0.48	5.37e-7	Colorectal cancer (diet interaction);
THYM	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg22166914	chr1:53195759	ZYG11B	-0.69	-5.33	-0.48	6.5e-7	Monocyte count;
THYM	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg13683864	chr3:40499215	RPL14	-1.05	-11.49	-0.76	1.13e-19	Renal cell carcinoma;
THYM	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg27129171	chr3:47204927	SETD2	0.74	7.4	0.6	5.4e-11	Colorectal cancer;
THYM	cis	rs1372520	0.745	rs2736994	chr4:90784528	A/G	cg15133208	chr4:90757351	SNCA	-0.59	-4.71	-0.43	8.52e-6	Neuroticism;
THYM	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg00645579	chr11:617140	IRF7;MUPCDH	-0.47	-6.04	-0.53	3.05e-8	Systemic lupus erythematosus;
THYM	cis	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg12963246	chr6:28129442	ZNF389	0.95	6.67	0.56	1.72e-9	Depression;
THYM	cis	rs2219968	0.651	rs12679467	chr8:78900393	A/G	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg00278517	chr6:167070616	RPS6KA2	-0.33	-4.54	-0.42	1.68e-5	Crohn's disease;
THYM	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg06728252	chr6:26598149	ABT1	-0.43	-4.72	-0.44	8.14e-6	Intelligence (multi-trait analysis);
THYM	trans	rs8073060	0.544	rs225274	chr17:33971221	C/T	cg19694781	chr19:47549865	TMEM160	0.95	7.96	0.63	3.6e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs11249608	0.548	rs17078991	chr5:178459426	A/C	cg01312482	chr5:178451176	ZNF879	-0.76	-6.3	-0.54	9.29e-9	Pubertal anthropometrics;
THYM	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg03576123	chr11:487126	PTDSS2	-1.26	-6.18	-0.54	1.59e-8	Body mass index;
THYM	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg13147721	chr7:65941812	NA	-0.94	-5.74	-0.51	1.12e-7	Diabetic kidney disease;
THYM	cis	rs1003719	0.715	rs2835644	chr21:38545610	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-4.96	-0.45	3.14e-6	Heart rate;
THYM	cis	rs17102423	0.755	rs8009714	chr14:65573446	G/T	cg11161011	chr14:65562177	MAX	-0.85	-6.77	-0.57	1.04e-9	Obesity-related traits;
THYM	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg00376283	chr12:123451042	ABCB9	0.74	5.11	0.46	1.67e-6	Neutrophil percentage of white cells;
THYM	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.05	-0.82	6.23e-25	Height;
THYM	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg26441486	chr22:50317300	CRELD2	-0.42	-6.45	-0.55	4.58e-9	Schizophrenia;
THYM	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg06611532	chr13:114900021	NA	0.64	7.17	0.59	1.61e-10	Schizophrenia;
THYM	cis	rs2945412	0.695	rs8075695	chr17:25867693	A/G	cg07487925	chr17:25620950	WSB1	0.64	4.6	0.43	1.31e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs2976388	0.647	rs2585138	chr8:143808951	C/T	cg06565975	chr8:143823917	SLURP1	0.5	5.62	0.5	1.9e-7	Urinary tract infection frequency;
THYM	cis	rs7666738	0.785	rs11944120	chr4:99079932	A/C	cg18180107	chr4:99064573	C4orf37	0.62	4.7	0.43	8.78e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4523957	0.560	rs1994884	chr17:2084008	G/A	cg16513277	chr17:2031491	SMG6	-0.95	-8.69	-0.67	1.05e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2976388	1.000	rs2572910	chr8:143770135	C/G	cg13446199	chr8:143762866	PSCA	0.5	6.27	0.54	1.06e-8	Urinary tract infection frequency;
THYM	cis	rs10946292	0.706	rs3013253	chr6:170432164	A/G	cg17692702	chr6:169717942	NA	0.57	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg00129232	chr17:37814104	STARD3	-0.67	-4.5	-0.42	1.96e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs9359856	0.564	rs76069351	chr6:90425043	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs11025559	0.812	rs11025583	chr11:20513260	C/T	cg19653624	chr11:20408972	PRMT3	0.71	4.94	0.45	3.31e-6	Pursuit maintenance gain;
THYM	cis	rs6570726	0.935	rs419854	chr6:145844085	A/C	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg08017756	chr2:100939284	LONRF2	-0.69	-7.09	-0.59	2.35e-10	Intelligence (multi-trait analysis);
THYM	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg04865290	chr3:52927548	TMEM110	-0.96	-5.03	-0.46	2.34e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.41	0.49	4.79e-7	Height;
THYM	cis	rs7814319	1.000	rs7814319	chr8:97263418	C/T	cg20787634	chr8:97240163	UQCRB	-0.76	-8.47	-0.66	3.03e-13	Lung function (FVC);
THYM	cis	rs9807841	0.544	rs10417412	chr19:10766798	A/C	cg17848348	chr19:10766748	ILF3	-0.87	-7.74	-0.62	1.06e-11	Inflammatory skin disease;
THYM	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs10203711	1.000	rs6713610	chr2:239566874	C/A	cg14580085	chr2:239553406	NA	0.68	6.18	0.54	1.6e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg00576331	chr11:65640516	EFEMP2	-0.68	-4.58	-0.43	1.42e-5	Crohn's disease;
THYM	cis	rs1747683	0.966	rs2275128	chr10:13378445	A/G	cg25835351	chr10:13388524	SEPHS1	-0.34	-5.66	-0.5	1.57e-7	IgG glycosylation;
THYM	cis	rs1371867	0.846	rs1660347	chr8:101314980	G/A	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs7220711	1.000	rs12602349	chr17:41792236	T/C	cg26893861	chr17:41843967	DUSP3	0.67	5.79	0.51	8.98e-8	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg06634786	chr22:41940651	POLR3H	-0.61	-4.98	-0.46	2.84e-6	Neuroticism;
THYM	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg01416388	chr22:39784598	NA	-0.89	-8.75	-0.67	7.72e-14	Intelligence (multi-trait analysis);
THYM	cis	rs4638749	1.000	rs12472278	chr2:108873433	A/T	cg25838818	chr2:108905173	SULT1C2	0.61	6.5	0.56	3.62e-9	Blood pressure;
THYM	cis	rs1065852	0.526	rs9623490	chr22:42398266	G/C	cg09667013	chr22:42394590	WBP2NL	0.54	4.8	0.44	5.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs13418717	1.000	rs79581146	chr2:127644428	C/T	cg25501666	chr2:127640322	NA	1.68	7.27	0.6	9.85e-11	Heart failure;
THYM	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg06558623	chr16:89946397	TCF25	1.16	5.01	0.46	2.5e-6	Skin colour saturation;
THYM	cis	rs13177918	1.000	rs13161334	chr5:149822673	A/G	cg14059543	chr5:149831962	NA	-0.87	-5.53	-0.49	2.78e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2730245	0.615	rs2527207	chr7:158743078	A/G	cg24397884	chr7:158709396	WDR60	-0.61	-5.79	-0.51	9.21e-8	Height;
THYM	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg16230307	chr14:35515116	FAM177A1	0.92	5.88	0.52	5.99e-8	Psoriasis;
THYM	cis	rs2463822	0.925	rs2513075	chr11:62102408	C/T	cg06239285	chr11:62104954	ASRGL1	1.44	7.77	0.62	9.14e-12	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg08736216	chr1:53307985	ZYG11A	-0.65	-5.73	-0.51	1.19e-7	Monocyte count;
THYM	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg05657792	chr17:6899758	ALOX12	-0.57	-5.61	-0.5	1.96e-7	Tonsillectomy;
THYM	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs7818345	0.637	rs3923920	chr8:19359184	A/G	cg01280390	chr8:19363452	CSGALNACT1	-0.67	-6.06	-0.53	2.74e-8	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs6964587	0.692	rs2374550	chr7:91820987	A/G	cg22709100	chr7:91322751	NA	0.67	5.07	0.46	1.97e-6	Breast cancer;
THYM	cis	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg06521331	chr12:34319734	NA	-1.04	-10.13	-0.72	8.85e-17	Morning vs. evening chronotype;
THYM	cis	rs57920188	0.535	rs4295855	chr1:4094993	C/T	cg20703997	chr1:4087676	NA	0.95	6.23	0.54	1.25e-8	Interleukin-17 levels;
THYM	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg27170947	chr2:26402098	FAM59B	-0.78	-6.09	-0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs3804749	0.966	rs9823527	chr3:122842611	G/A	cg26084141	chr3:122786895	PDIA5	0.45	4.53	0.42	1.73e-5	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-6.9	-0.58	5.67e-10	Chronic sinus infection;
THYM	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg20295408	chr7:1910781	MAD1L1	-0.63	-4.54	-0.42	1.67e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg22907277	chr7:1156413	C7orf50	0.71	6.57	0.56	2.73e-9	Longevity;Endometriosis;
THYM	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg10803722	chr21:46713166	LOC642852	-0.38	-4.75	-0.44	7.19e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6430585	0.702	rs3213890	chr2:136552188	G/A	cg04750100	chr2:136595281	LCT	0.5	4.73	0.44	7.82e-6	Corneal structure;
THYM	cis	rs9810089	0.934	rs1153877	chr3:136004925	C/T	cg12473912	chr3:136751656	NA	0.61	5.13	0.47	1.5e-6	Gestational age at birth (child effect);
THYM	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg22664400	chr11:66445111	RBM4B	0.66	4.47	0.42	2.14e-5	Crohn's disease;
THYM	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg08431931	chr22:42394659	WBP2NL	0.69	4.88	0.45	4.33e-6	Birth weight;
THYM	cis	rs13064411	0.696	rs869343	chr3:113226705	C/T	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs738322	0.839	rs9607517	chr22:38596100	G/A	cg25457927	chr22:38595422	NA	0.52	5.35	0.48	6.06e-7	Cutaneous nevi;
THYM	cis	rs7586673	0.866	rs7579662	chr2:161915810	G/A	cg22496339	chr2:162101262	NA	0.59	4.61	0.43	1.27e-5	Intelligence (multi-trait analysis);
THYM	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs990171	0.874	rs6419573	chr2:103027103	T/C	cg13897122	chr2:103039542	IL18RAP	-0.39	-4.72	-0.44	7.96e-6	Lymphocyte counts;
THYM	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg11764359	chr7:65958608	NA	-0.82	-6.6	-0.56	2.29e-9	Aortic root size;
THYM	cis	rs7226229	0.898	rs4985952	chr17:20894957	T/C	cg21263980	chr17:20946333	USP22	0.72	5.05	0.46	2.16e-6	Blood trace element (Se levels);
THYM	cis	rs6496667	0.533	rs2074584	chr15:91009381	C/T	cg00425431	chr15:90792223	TTLL13	0.39	4.55	0.42	1.61e-5	Rheumatoid arthritis;
THYM	cis	rs13326165	0.585	rs746239	chr3:52404111	G/A	cg08438690	chr3:52279403	PPM1M	-0.84	-4.6	-0.43	1.32e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs6430585	0.583	rs2839740	chr2:136648883	G/T	cg20242066	chr2:136595261	LCT	0.56	5.16	0.47	1.38e-6	Corneal structure;
THYM	cis	rs818427	0.684	rs351771	chr5:112164561	G/A	cg04614008	chr5:112630677	MCC	-0.64	-4.6	-0.43	1.31e-5	Total body bone mineral density;
THYM	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg24531977	chr5:56204891	C5orf35	-0.89	-5.16	-0.47	1.34e-6	Type 2 diabetes;
THYM	cis	rs969413	0.624	rs7213540	chr17:79255912	C/T	cg14413466	chr17:79170920	AZI1	-0.64	-5.81	-0.51	8.47e-8	Frontotemporal dementia;
THYM	cis	rs4285028	0.747	rs77790376	chr3:121492211	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.9	-6.66	-0.56	1.8e-9	Multiple sclerosis;
THYM	cis	rs6921919	0.583	rs28360638	chr6:28362329	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.5	-0.42	1.89e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.22	-0.47	1.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg17366294	chr4:99064904	C4orf37	0.58	7.03	0.58	3.2e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1021993	1.000	rs1395747	chr1:209488564	C/T	cg06155620	chr1:209527581	NA	-0.56	-4.68	-0.43	9.48e-6	Gut microbiome composition (winter);
THYM	cis	rs2273669	0.504	rs79564261	chr6:109495333	C/A	cg17117243	chr6:109341365	SESN1	-0.82	-4.8	-0.44	5.98e-6	Prostate cancer;
THYM	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg27494647	chr7:150038898	RARRES2	0.41	4.59	0.43	1.34e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs7639513	0.767	rs6784168	chr3:12702847	T/G	cg23032965	chr3:12705835	RAF1	0.98	7.85	0.63	6.27e-12	Itch intensity from mosquito bite;
THYM	cis	rs6430585	0.528	rs309152	chr2:136657252	C/T	cg04750100	chr2:136595281	LCT	-0.5	-4.99	-0.46	2.75e-6	Corneal structure;
THYM	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs5015933	0.736	rs10125995	chr9:128145942	C/T	cg13590414	chr9:128173245	NA	-0.52	-5.11	-0.46	1.65e-6	Body mass index;
THYM	cis	rs4455778	0.580	rs34230450	chr7:49118157	T/C	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs11771526	0.901	rs10252755	chr7:32304676	G/A	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs7408868	1.000	rs7408868	chr19:15285679	G/C	cg14696996	chr19:15285081	NOTCH3	0.94	5.66	0.5	1.63e-7	Pulse pressure;
THYM	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs782590	0.643	rs13009906	chr2:55739434	A/G	cg18811423	chr2:55921094	PNPT1	-0.54	-5.05	-0.46	2.12e-6	Metabolic syndrome;
THYM	cis	rs7084402	0.870	rs4948525	chr10:60361270	G/A	cg27040468	chr10:60456715	BICC1	-0.57	-4.82	-0.44	5.41e-6	Refractive error;
THYM	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs9549260	0.755	rs3900833	chr13:41188292	A/G	cg21288729	chr13:41239152	FOXO1	0.66	5.41	0.48	4.8e-7	Red blood cell count;
THYM	cis	rs713587	0.713	rs1982200	chr2:25205427	C/T	cg15423357	chr2:25149977	NA	-0.58	-5.94	-0.52	4.62e-8	Body mass index in non-asthmatics;
THYM	cis	rs10186029	0.680	rs11689451	chr2:213937840	C/T	cg08319019	chr2:214017104	IKZF2	0.83	6.86	0.58	6.99e-10	Systemic sclerosis;
THYM	trans	rs1920324	0.622	rs9288778	chr3:103898520	G/A	cg01901466	chr14:93388880	CHGA	0.65	6.91	0.58	5.4e-10	Colorectal cancer;
THYM	cis	rs6980334	0.551	rs2035647	chr7:137799569	A/G	cg22979093	chr7:137028410	PTN	0.64	5.01	0.46	2.51e-6	Blood metabolite ratios;
THYM	cis	rs3768617	0.510	rs1547712	chr1:183088013	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg20966754	chr17:47091339	IGF2BP1	-0.57	-7.19	-0.59	1.45e-10	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7119	0.651	rs12917431	chr15:77850184	C/G	cg10437265	chr15:77819839	NA	0.75	7.25	0.6	1.08e-10	Type 2 diabetes;
THYM	cis	rs61990749	0.597	rs1008988	chr14:78260795	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	1.18	8.07	0.64	2.13e-12	Fibroblast growth factor basic levels;
THYM	cis	rs739496	0.542	rs7316698	chr12:111790511	C/T	cg10833066	chr12:111807467	FAM109A	0.52	5.92	0.52	5e-8	Platelet count;
THYM	cis	rs593982	1.000	rs74638829	chr11:65495571	C/T	cg08755490	chr11:65554678	OVOL1	-1.44	-7.91	-0.63	4.57e-12	Atopic dermatitis;
THYM	cis	rs988913	0.706	rs6908568	chr6:54881564	C/G	cg19716238	chr6:54711378	FAM83B	0.47	4.49	0.42	2.03e-5	Menarche (age at onset);
THYM	cis	rs1535500	0.935	rs34247110	chr6:39282371	G/A	cg00012638	chr6:39280541	KCNK17	0.61	8.08	0.64	2.06e-12	Type 2 diabetes;
THYM	cis	rs4266144	0.558	rs4680339	chr3:156835419	G/T	cg16248515	chr3:156840234	NA	0.51	4.75	0.44	7.27e-6	Coronary artery disease;
THYM	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg20887711	chr4:1340912	KIAA1530	-0.56	-4.68	-0.43	9.53e-6	Obesity-related traits;
THYM	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg10802521	chr3:52805072	NEK4	-0.71	-5.96	-0.52	4.22e-8	Bipolar disorder;
THYM	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg24675056	chr1:15929824	NA	0.73	5.89	0.52	5.95e-8	Systolic blood pressure;
THYM	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg15921436	chr17:44337874	NA	-0.91	-6.85	-0.58	7.19e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg23978390	chr7:1156363	C7orf50	0.68	5.17	0.47	1.3e-6	Longevity;Endometriosis;
THYM	cis	rs2073300	0.609	rs3736755	chr20:23377642	C/T	cg12062639	chr20:23401060	NAPB	1.1	5.73	0.51	1.16e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs800586	0.796	rs2736231	chr8:116723397	C/T	cg04656070	chr8:116661063	TRPS1	0.47	5.04	0.46	2.26e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7849270	1.000	rs3124510	chr9:131899690	C/T	cg14069949	chr9:131965419	NA	-0.5	-4.52	-0.42	1.8e-5	Blood metabolite ratios;
THYM	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg07537917	chr2:241836409	C2orf54	0.24	5.01	0.46	2.48e-6	Urinary metabolites;
THYM	cis	rs12530845	0.623	rs73721677	chr7:135354238	C/A	cg23117316	chr7:135346802	PL-5283	-0.83	-6.31	-0.54	8.67e-9	Red blood cell traits;
THYM	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Body mass index;
THYM	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg06636001	chr8:8085503	FLJ10661	0.64	5.3	0.48	7.47e-7	Mood instability;
THYM	cis	rs7172809	0.573	rs75180243	chr15:77649707	G/A	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg00310523	chr12:86230176	RASSF9	-0.57	-5.07	-0.46	1.98e-6	Major depressive disorder;
THYM	cis	rs9325144	0.723	rs11169518	chr12:39177237	C/A	cg26384229	chr12:38710491	ALG10B	-0.6	-4.59	-0.43	1.38e-5	Morning vs. evening chronotype;
THYM	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg03188948	chr7:1209495	NA	0.64	5.02	0.46	2.42e-6	Longevity;Endometriosis;
THYM	cis	rs56104184	0.830	rs17206679	chr19:49342237	C/G	cg26267310	chr19:49340593	PLEKHA4;HSD17B14	0.94	4.94	0.45	3.28e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs10197940	0.648	rs7587301	chr2:152347600	A/G	cg19508488	chr2:152266495	RIF1	0.72	5.6	0.5	2.04e-7	Lung cancer;
THYM	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs36051895	0.553	rs16922773	chr9:5197436	T/G	cg02405213	chr9:5042618	JAK2	-0.9	-8.43	-0.65	3.66e-13	Pediatric autoimmune diseases;
THYM	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.85	-6.22	-0.54	1.32e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg20503657	chr10:835505	NA	0.91	4.99	0.46	2.75e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.49	-0.42	2.04e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6754311	0.731	rs218174	chr2:136658345	C/T	cg20242066	chr2:136595261	LCT	-0.61	-7.05	-0.59	2.87e-10	Mosquito bite size;
THYM	cis	rs747334	1.000	rs2118824	chr10:92738106	A/G	cg07620928	chr10:92689909	NA	0.55	4.52	0.42	1.79e-5	Fibroblast growth factor basic levels;
THYM	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg26967526	chr14:35346199	BAZ1A	-0.72	-5.33	-0.48	6.65e-7	Psoriasis;
THYM	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.57	4.47	0.42	2.15e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7100689	0.577	rs10788545	chr10:82034675	A/G	cg01528321	chr10:82214614	TSPAN14	0.95	7.36	0.6	6.54e-11	Post bronchodilator FEV1;
THYM	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg10047753	chr17:41438598	NA	1.21	10.99	0.75	1.31e-18	Menopause (age at onset);
THYM	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg06238570	chr21:40685208	BRWD1	0.91	4.93	0.45	3.53e-6	Cognitive function;
THYM	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg04944784	chr2:26401820	FAM59B	1.09	8.74	0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs6430585	0.528	rs309123	chr2:136761175	C/G	cg20242066	chr2:136595261	LCT	0.52	5.66	0.5	1.63e-7	Corneal structure;
THYM	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-5.52	-0.49	2.95e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	trans	rs8073060	0.544	rs8071584	chr17:33999435	G/A	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg05043794	chr9:111880884	C9orf5	-0.36	-5.01	-0.46	2.48e-6	Menarche (age at onset);
THYM	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06850241	chr22:41845214	NA	-0.6	-5.37	-0.48	5.63e-7	Vitiligo;
THYM	cis	rs4474465	0.850	rs10751294	chr11:78253303	T/A	cg19901956	chr11:77921274	USP35	0.57	4.49	0.42	1.97e-5	Alzheimer's disease (survival time);
THYM	cis	rs4631830	0.863	rs2843546	chr10:51518688	A/C	cg10326726	chr10:51549505	MSMB	-0.61	-6.23	-0.54	1.25e-8	Prostate-specific antigen levels;
THYM	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs2282300	0.739	rs1222208	chr11:30361377	A/C	cg25418670	chr11:30344373	C11orf46	-0.83	-7.18	-0.59	1.55e-10	Morning vs. evening chronotype;
THYM	cis	rs10782582	0.593	rs11801414	chr1:76124517	G/A	cg03433033	chr1:76189801	ACADM	-0.51	-5.31	-0.48	7.2e-7	Daytime sleep phenotypes;
THYM	cis	rs1018836	0.828	rs7816023	chr8:91567398	T/C	cg16814680	chr8:91681699	NA	-0.9	-7.92	-0.63	4.36e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg22166914	chr1:53195759	ZYG11B	0.87	9.75	0.71	5.62e-16	Monocyte count;
THYM	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg06074448	chr4:187884817	NA	-1.01	-13.54	-0.81	6.7e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs288326	0.561	rs75466155	chr2:183706804	T/G	cg09997497	chr2:183902928	NCKAP1	1.06	4.79	0.44	6.12e-6	Blood protein levels;
THYM	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	5.08	0.46	1.86e-6	Obesity-related traits;
THYM	cis	rs2108622	0.727	rs76984410	chr19:15982700	C/T	cg13772218	chr19:15982569	NA	0.5	4.48	0.42	2.06e-5	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg11764359	chr7:65958608	NA	0.75	5.86	0.52	6.54e-8	Aortic root size;
THYM	cis	rs4460079	0.531	rs4834365	chr4:114845958	C/T	cg02060584	chr4:113970739	ANK2	0.59	4.93	0.45	3.48e-6	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg24531977	chr5:56204891	C5orf35	-0.93	-7.44	-0.61	4.48e-11	Initial pursuit acceleration;
THYM	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg21784768	chr11:537496	LRRC56	-1.14	-5.72	-0.51	1.21e-7	Body mass index;
THYM	cis	rs500891	0.525	rs1144177	chr6:84029793	A/G	cg21688264	chr6:84418724	SNAP91	0.74	4.51	0.42	1.87e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs6500395	0.775	rs4471681	chr16:48665946	C/T	cg04672837	chr16:48644449	N4BP1	0.47	4.62	0.43	1.18e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg21028142	chr17:79581711	NPLOC4	0.51	5.01	0.46	2.47e-6	Eye color traits;
THYM	cis	rs2072732	0.861	rs12409277	chr1:2957600	A/G	cg08733933	chr1:2954429	NA	-0.59	-4.46	-0.42	2.26e-5	Plateletcrit;
THYM	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg07061783	chr6:25882402	NA	-0.81	-6.5	-0.55	3.66e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.519	rs7529194	chr1:150622620	A/T	cg15448220	chr1:150897856	SETDB1	0.79	5.8	0.51	8.8e-8	Tonsillectomy;
THYM	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg03188948	chr7:1209495	NA	0.9	5.02	0.46	2.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	9.4	0.69	3.1e-15	Chronic sinus infection;
THYM	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg21433313	chr16:3507492	NAT15	0.85	10.09	0.72	1.08e-16	Tuberculosis;
THYM	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg10792982	chr14:105748885	BRF1	0.72	7.5	0.61	3.35e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs11633958	1	rs11633958	chr15:78862064	C/T	cg18825076	chr15:78729989	IREB2	-0.55	-4.93	-0.45	3.54e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs11247915	0.622	rs4072445	chr1:26664219	T/C	cg00852783	chr1:26633632	UBXN11	0.74	6.08	0.53	2.52e-8	Obesity-related traits;
THYM	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg13695892	chr22:41940480	POLR3H	0.93	7.09	0.59	2.34e-10	Vitiligo;
THYM	cis	rs8103278	1.000	rs36091860	chr19:46312880	G/A	cg14061069	chr19:46274453	DMPK	-0.58	-5.78	-0.51	9.61e-8	Coronary artery disease;
THYM	cis	rs8050907	0.744	rs75930956	chr16:4564326	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.13	4.76	0.44	6.97e-6	Obesity-related traits;
THYM	cis	rs9910055	0.593	rs58392387	chr17:42297889	A/G	cg13607699	chr17:42295918	UBTF	0.9	8.72	0.67	8.8e-14	Total body bone mineral density;
THYM	cis	rs2072499	0.966	rs887953	chr1:156191149	T/C	cg25208724	chr1:156163844	SLC25A44	1.11	12.9	0.8	1.35e-22	Testicular germ cell tumor;
THYM	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg16928487	chr17:17741425	SREBF1	-0.55	-5.47	-0.49	3.62e-7	Total body bone mineral density;
THYM	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.51	-0.66	2.53e-13	Monocyte count;
THYM	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg18904891	chr8:8559673	CLDN23	0.61	4.84	0.44	5.08e-6	Neuroticism;
THYM	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg04398451	chr17:18023971	MYO15A	0.9	9.5	0.7	1.95e-15	Total body bone mineral density;
THYM	cis	rs9633835	0.524	rs9783306	chr11:13276923	C/A	cg13286116	chr11:13302098	ARNTL	-0.72	-8.03	-0.64	2.61e-12	Body mass index;
THYM	cis	rs939658	0.683	rs8041222	chr15:79465549	A/G	cg17916960	chr15:79447300	NA	-0.69	-8.08	-0.64	2e-12	Refractive error;
THYM	cis	rs986417	1.000	rs1254255	chr14:60831342	G/A	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs9649213	0.727	rs12113294	chr7:97910637	C/G	cg09267113	chr7:98030324	BAIAP2L1	0.53	4.63	0.43	1.14e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg06481639	chr22:41940642	POLR3H	-0.74	-5.23	-0.47	9.99e-7	Neuroticism;
THYM	cis	rs10927875	0.619	rs7537101	chr1:16150384	T/C	cg21385522	chr1:16154831	NA	-0.77	-6.63	-0.56	2.01e-9	Dilated cardiomyopathy;
THYM	cis	rs2046867	0.818	rs6792109	chr3:72867091	C/T	cg25664220	chr3:72788482	NA	-0.93	-7.63	-0.62	1.81e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.61e-20	Menopause (age at onset);
THYM	cis	rs7246657	0.823	rs4802236	chr19:37919246	A/G	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg18252515	chr7:66147081	NA	0.63	4.75	0.44	7.08e-6	Aortic root size;
THYM	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.76	-0.44	6.97e-6	Mean corpuscular volume;
THYM	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg13695892	chr22:41940480	POLR3H	-0.94	-7.28	-0.6	9.46e-11	Vitiligo;
THYM	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg02753203	chr1:228287806	NA	0.97	8.35	0.65	5.57e-13	Diastolic blood pressure;
THYM	cis	rs2282300	0.739	rs7925340	chr11:30280408	A/C	cg25418670	chr11:30344373	C11orf46	0.82	6.97	0.58	4.25e-10	Morning vs. evening chronotype;
THYM	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg16989719	chr2:238392110	NA	-0.65	-5.93	-0.52	4.98e-8	Prostate cancer;
THYM	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11644478	chr21:40555479	PSMG1	1.0	7.96	0.63	3.72e-12	Cognitive function;
THYM	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg24818145	chr4:99064322	C4orf37	0.9	7.36	0.6	6.5e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg17775962	chr7:1200435	ZFAND2A	0.42	4.9	0.45	3.96e-6	Longevity;Endometriosis;
THYM	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs9403317	0.552	rs62430857	chr6:141893360	A/T	cg15052665	chr6:141804349	NA	0.76	5.75	0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2777491	0.915	rs8032838	chr15:41605632	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.14	-12.89	-0.8	1.38e-22	Ulcerative colitis;
THYM	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg00129232	chr17:37814104	STARD3	-0.64	-4.46	-0.42	2.27e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg00129232	chr17:37814104	STARD3	0.73	4.98	0.45	2.87e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs6089829	0.851	rs10854168	chr20:61669550	A/G	cg02380750	chr20:61661411	NA	0.63	6.18	0.54	1.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg11941060	chr3:133502564	NA	0.83	7.11	0.59	2.11e-10	Iron status biomarkers;
THYM	cis	rs34638657	0.702	rs67612167	chr16:82199598	A/G	cg07307142	chr16:82071433	HSD17B2	-0.87	-7.97	-0.63	3.55e-12	Lung adenocarcinoma;
THYM	trans	rs877282	0.853	rs12779017	chr10:763619	T/C	cg22713356	chr15:30763199	NA	1.36	10.13	0.72	8.77e-17	Uric acid levels;
THYM	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg02569458	chr12:86230093	RASSF9	-0.65	-5.33	-0.48	6.59e-7	Major depressive disorder;
THYM	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.82	8.28	0.65	7.61e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg08645402	chr16:4508243	NA	0.77	6.96	0.58	4.31e-10	Schizophrenia;
THYM	cis	rs11997175	0.646	rs4733180	chr8:33700520	C/T	ch.8.33884649F	chr8:33765107	NA	0.63	4.76	0.44	6.85e-6	Body mass index;
THYM	cis	rs4481887	0.800	rs4278391	chr1:248450495	C/T	cg00666640	chr1:248458726	OR2T12	0.54	4.52	0.42	1.79e-5	Common traits (Other);
THYM	cis	rs4523957	0.786	rs28524880	chr17:2125444	C/A	cg16513277	chr17:2031491	SMG6	-0.8	-7.63	-0.62	1.8e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6570726	0.846	rs453834	chr6:145886261	T/C	cg13319975	chr6:146136371	FBXO30	-0.67	-5.44	-0.49	4.21e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10929159	0.928	rs4442947	chr2:236931642	G/C	cg20128773	chr2:236923534	AGAP1	0.36	4.75	0.44	7.16e-6	Parkinson's disease;
THYM	cis	rs9534288	0.830	rs2404963	chr13:46632836	C/T	cg15192986	chr13:46630673	CPB2	-0.66	-4.66	-0.43	1.03e-5	Blood protein levels;
THYM	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg01264106	chr22:38071602	LGALS1	0.38	4.64	0.43	1.13e-5	Fat distribution (HIV);
THYM	cis	rs665401	1.000	rs1761881	chr6:117258344	G/A	cg20376953	chr6:117187980	NA	0.55	4.49	0.42	1.99e-5	Neutrophil percentage of granulocytes;
THYM	cis	rs17401966	1.000	rs1049887	chr1:10460485	T/C	cg19773385	chr1:10388646	KIF1B	-0.64	-4.72	-0.44	7.96e-6	Hepatocellular carcinoma;
THYM	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs244293	0.760	rs8069447	chr17:53008873	A/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.52	-4.49	-0.42	1.98e-5	Menarche (age at onset);
THYM	trans	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs6598955	0.612	rs12738188	chr1:26548029	G/C	cg04990556	chr1:26633338	UBXN11	-0.89	-8.56	-0.66	1.92e-13	Obesity-related traits;
THYM	cis	rs11048434	0.723	rs1805737	chr12:9084670	A/T	cg13575925	chr12:9217583	LOC144571	0.53	4.94	0.45	3.31e-6	Sjögren's syndrome;
THYM	cis	rs4523957	0.583	rs2760735	chr17:2036835	A/G	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs61931739	0.658	rs4476006	chr12:34237154	A/C	cg06521331	chr12:34319734	NA	-0.59	-4.99	-0.46	2.77e-6	Morning vs. evening chronotype;
THYM	cis	rs9650682	0.784	rs12093	chr9:15461506	T/C	cg20696139	chr9:15510574	PSIP1	-0.86	-4.58	-0.43	1.41e-5	Schizophrenia;
THYM	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg06784218	chr1:46089804	CCDC17	-0.32	-4.77	-0.44	6.73e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs662064	0.962	rs648399	chr1:10556485	T/C	cg20482658	chr1:10539492	PEX14	-0.47	-6.07	-0.53	2.66e-8	Asthma;
THYM	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg14895029	chr7:2775587	GNA12	-0.68	-4.93	-0.45	3.55e-6	Height;
THYM	cis	rs72717009	0.825	rs7539468	chr1:161477066	G/A	cg15358701	chr1:161410459	NA	-0.95	-5.06	-0.46	2.08e-6	Rheumatoid arthritis;
THYM	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg26441486	chr22:50317300	CRELD2	-0.42	-6.45	-0.55	4.58e-9	Schizophrenia;
THYM	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg19507638	chr5:93509721	C5orf36	-0.7	-4.71	-0.44	8.43e-6	Diabetic retinopathy;
THYM	cis	rs988913	1.000	rs4715492	chr6:54835178	C/T	cg18532076	chr6:54711417	FAM83B	0.5	4.91	0.45	3.78e-6	Menarche (age at onset);
THYM	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg06558623	chr16:89946397	TCF25	0.94	5.06	0.46	2.06e-6	Skin colour saturation;
THYM	cis	rs611744	0.870	rs423940	chr8:109093578	C/T	cg21045802	chr8:109455806	TTC35	0.58	5.07	0.46	1.99e-6	Dupuytren's disease;
THYM	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.88	-0.58	6.43e-10	Eye color traits;
THYM	cis	rs8018808	0.935	rs11623826	chr14:77912862	A/C	cg20045696	chr14:77926864	AHSA1	0.54	4.8	0.44	5.89e-6	Myeloid white cell count;
THYM	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22455342	chr2:225449267	CUL3	0.97	9.01	0.68	2.14e-14	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs5015933	0.801	rs11999662	chr9:128143928	T/A	cg13590414	chr9:128173245	NA	-0.52	-4.86	-0.45	4.61e-6	Body mass index;
THYM	cis	rs994014	0.961	rs2034629	chr4:82226349	C/T	cg17825130	chr4:82283507	NA	-0.47	-4.55	-0.42	1.59e-5	Height;
THYM	cis	rs1642645	1.000	rs1642645	chr1:42502281	A/C	cg10197057	chr1:42612518	NA	0.46	5.02	0.46	2.42e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg00173435	chr12:106696525	TCP11L2	0.7	4.78	0.44	6.4e-6	Tourette syndrome;
THYM	cis	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg10856724	chr12:34555212	NA	1.05	9.75	0.71	5.65e-16	Morning vs. evening chronotype;
THYM	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg21640587	chr11:117668038	DSCAML1	1.07	9.76	0.71	5.39e-16	Myopia;
THYM	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg14972814	chr11:95582409	MTMR2	-0.58	-5.3	-0.48	7.56e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2070677	0.708	rs12762259	chr10:135350365	C/T	cg20169779	chr10:135381914	SYCE1	0.81	5.79	0.51	8.91e-8	Gout;
THYM	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg11494091	chr17:61959527	GH2	1.09	17.51	0.87	1.71e-31	Prudent dietary pattern;
THYM	cis	rs2070488	0.965	rs1984312	chr3:38538466	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.76	-5.61	-0.5	1.98e-7	Electrocardiographic conduction measures;
THYM	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg18252515	chr7:66147081	NA	-0.63	-4.74	-0.44	7.61e-6	Aortic root size;
THYM	cis	rs9324022	0.858	rs1004572	chr14:101178330	G/A	cg18089426	chr14:101175970	NA	0.75	5.12	0.46	1.61e-6	Plateletcrit;
THYM	cis	rs34912216	0.619	rs36044400	chr7:4131651	T/C	cg03141780	chr7:4150753	SDK1	0.68	5.17	0.47	1.29e-6	Motion sickness;
THYM	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg06618935	chr21:46677482	NA	-0.96	-7.89	-0.63	5.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg00074818	chr8:8560427	CLDN23	0.59	5.5	0.49	3.26e-7	Obesity-related traits;
THYM	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs9814567	0.762	rs13067564	chr3:134209956	A/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.4	4.49	0.42	1.99e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6430585	0.697	rs115944351	chr2:136515458	G/A	cg23851026	chr2:136556271	LCT	0.79	7.53	0.61	2.86e-11	Corneal structure;
THYM	cis	rs4363385	0.719	rs6664823	chr1:152933424	A/C	cg07796016	chr1:152779584	LCE1C	-0.59	-4.72	-0.44	8.04e-6	Inflammatory skin disease;
THYM	cis	rs1050631	0.564	rs1785931	chr18:33722107	T/C	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.6	4.69	0.43	9.09e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg01264106	chr22:38071602	LGALS1	0.41	4.97	0.45	2.94e-6	Fat distribution (HIV);
THYM	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg13609457	chr4:120235615	NA	0.59	5.27	0.48	8.67e-7	Corneal astigmatism;
THYM	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg13609457	chr4:120235615	NA	0.66	5.19	0.47	1.17e-6	Corneal astigmatism;
THYM	cis	rs2016266	1.000	rs2016266	chr12:53727955	A/G	cg26875137	chr12:53738046	NA	-0.63	-5.06	-0.46	2e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg17644776	chr2:200775616	C2orf69	-0.76	-4.46	-0.42	2.24e-5	Schizophrenia;
THYM	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg18252515	chr7:66147081	NA	-0.71	-5.67	-0.5	1.56e-7	Aortic root size;
THYM	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg18128536	chr17:47092178	IGF2BP1	-0.43	-4.71	-0.44	8.43e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7546094	0.905	rs10776755	chr1:113082974	C/G	cg25616829	chr1:112535356	NA	-0.58	-4.84	-0.45	4.94e-6	Platelet distribution width;
THYM	trans	rs877282	0.891	rs10904557	chr10:797490	C/T	cg22713356	chr15:30763199	NA	-1.36	-11.37	-0.76	1.99e-19	Uric acid levels;
THYM	cis	rs7084402	0.935	rs1427195	chr10:60278967	T/C	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs8073060	0.927	rs7502331	chr17:33868858	A/G	cg07895132	chr17:33825172	SLFN12L	0.62	5.74	0.51	1.11e-7	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	trans	rs4262150	0.883	rs72802882	chr5:152242673	C/T	cg08281791	chr5:76607845	PDE8B	0.92	6.91	0.58	5.62e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs2016266	1.000	rs10783573	chr12:53728369	G/A	cg26875137	chr12:53738046	NA	0.63	5.06	0.46	2e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg02503808	chr4:7069936	GRPEL1	0.9	7.37	0.6	6.21e-11	Monocyte percentage of white cells;
THYM	cis	rs61931739	0.929	rs2389274	chr12:34075149	T/C	cg10856724	chr12:34555212	NA	0.6	5.36	0.48	5.8e-7	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg08000102	chr2:233561755	GIGYF2	0.7	6.28	0.54	9.92e-9	Coronary artery disease;
THYM	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg23758822	chr17:41437982	NA	1.22	11.98	0.78	1.07e-20	Menopause (age at onset);
THYM	cis	rs2282300	0.739	rs12577729	chr11:30257377	C/T	cg25418670	chr11:30344373	C11orf46	-0.81	-6.87	-0.58	6.66e-10	Morning vs. evening chronotype;
THYM	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg00974685	chr10:113759413	NA	-0.89	-6.89	-0.58	6.15e-10	Depressive symptoms;
THYM	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg03709012	chr19:19516395	GATAD2A	-0.77	-6.07	-0.53	2.56e-8	Tonsillectomy;
THYM	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg22875332	chr1:76189707	ACADM	0.9	10.56	0.73	1.07e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg01448562	chr3:133502909	NA	-0.69	-4.88	-0.45	4.34e-6	Iron status biomarkers;
THYM	cis	rs10779751	0.770	rs2261434	chr1:11170131	A/C	cg08854313	chr1:11322531	MTOR	0.88	7.82	0.63	7.34e-12	Body mass index;
THYM	cis	rs10779751	0.960	rs1883965	chr1:11322156	A/G	cg08854313	chr1:11322531	MTOR	0.92	7.8	0.62	7.95e-12	Body mass index;
THYM	cis	rs7078219	0.543	rs4919342	chr10:101282553	G/C	cg07044859	chr10:101282883	NA	-0.42	-4.64	-0.43	1.11e-5	Dental caries;
THYM	cis	rs965469	0.895	rs6051839	chr20:3391191	C/T	cg25506879	chr20:3388711	C20orf194	0.83	5.14	0.47	1.5e-6	IFN-related cytopenia;
THYM	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg25358565	chr5:93447407	FAM172A	1.34	10.59	0.74	9.3e-18	Diabetic retinopathy;
THYM	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg00310523	chr12:86230176	RASSF9	-0.57	-5.07	-0.46	1.98e-6	Major depressive disorder;
THYM	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg08109568	chr15:31115862	NA	-0.63	-5.93	-0.52	4.78e-8	Huntington's disease progression;
THYM	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg02734326	chr4:10020555	SLC2A9	-0.61	-5.09	-0.46	1.8e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.42	5.34	0.48	6.24e-7	Monocyte percentage of white cells;
THYM	cis	rs600550	0.528	rs12806720	chr11:59832433	C/A	cg02771260	chr11:59836817	MS4A3	0.72	5.33	0.48	6.48e-7	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg10636054	chr15:40330586	SRP14	0.98	5.17	0.47	1.28e-6	Corneal curvature;
THYM	cis	rs2219968	0.798	rs9657126	chr8:78942271	T/C	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	8.39	0.65	4.61e-13	Lung cancer in ever smokers;
THYM	cis	rs981844	0.775	rs17299519	chr4:154762123	C/T	cg09973105	chr4:154681532	RNF175	-0.62	-5.1	-0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs4732038	0.647	rs2161803	chr7:134261097	C/G	cg06906464	chr7:134288099	NA	-0.44	-4.5	-0.42	1.89e-5	Longevity;
THYM	cis	rs10216189	1.000	rs7799665	chr7:5527501	G/A	cg05318486	chr7:5553423	FBXL18	-0.65	-4.76	-0.44	6.9e-6	Relative hand skill in reading disability;
THYM	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg12963246	chr6:28129442	ZNF389	0.77	6.3	0.54	9.31e-9	Depression;
THYM	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg18876405	chr7:65276391	NA	0.76	7.17	0.59	1.61e-10	Calcium levels;
THYM	cis	rs7584330	0.554	rs3751109	chr2:238427194	T/C	cg08992911	chr2:238395768	MLPH	0.85	5.39	0.48	5.19e-7	Prostate cancer;
THYM	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg18305652	chr10:134549665	INPP5A	0.82	7.2	0.59	1.39e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7216064	0.861	rs73352810	chr17:65875184	G/A	cg12091567	chr17:66097778	LOC651250	-0.69	-4.65	-0.43	1.05e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs9399401	0.925	rs6929442	chr6:142742659	T/C	cg04461802	chr6:142623433	GPR126	0.46	4.6	0.43	1.33e-5	Chronic obstructive pulmonary disease;
THYM	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg02734326	chr4:10020555	SLC2A9	0.76	6.89	0.58	6.16e-10	Bone mineral density;
THYM	cis	rs67072384	0.818	rs2291293	chr11:72470653	C/T	cg01380194	chr11:72452482	ARAP1	-0.77	-4.52	-0.42	1.76e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg27102117	chr16:15229624	NA	0.58	4.45	0.42	2.29e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
THYM	cis	rs2742234	0.590	rs2503848	chr10:43672785	G/A	cg06632098	chr10:43605906	RET	-0.79	-5.1	-0.46	1.73e-6	Hirschsprung disease;
THYM	cis	rs988913	1.000	rs6941796	chr6:54837621	A/T	cg18532076	chr6:54711417	FAM83B	0.5	4.91	0.45	3.78e-6	Menarche (age at onset);
THYM	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg00645579	chr11:617140	IRF7;MUPCDH	-0.53	-6.0	-0.52	3.64e-8	Systemic lupus erythematosus;
THYM	cis	rs4595586	0.545	rs7136002	chr12:39369168	G/A	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg00129232	chr17:37814104	STARD3	0.76	5.25	0.47	9.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7940866	0.903	rs7940465	chr11:130861339	C/T	cg23692386	chr11:131799662	NTM	0.43	4.7	0.43	8.9e-6	Schizophrenia;
THYM	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg17845761	chr1:175162550	KIAA0040	-0.36	-4.57	-0.42	1.45e-5	Alcohol dependence;
THYM	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg10856724	chr12:34555212	NA	-0.88	-8.25	-0.65	8.84e-13	Morning vs. evening chronotype;
THYM	cis	rs34172651	0.917	rs172066	chr16:24756449	C/T	cg06028605	chr16:24865363	SLC5A11	0.58	5.69	0.5	1.42e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg00129232	chr17:37814104	STARD3	-0.67	-4.54	-0.42	1.63e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.64	0.5	1.77e-7	Height;
THYM	cis	rs11690935	0.632	rs12052246	chr2:172895606	G/T	cg13550731	chr2:172543902	DYNC1I2	0.69	5.91	0.52	5.3e-8	Schizophrenia;
THYM	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg16928487	chr17:17741425	SREBF1	0.51	5.14	0.47	1.48e-6	Total body bone mineral density;
THYM	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg06600287	chr1:53387719	ECHDC2	0.29	4.69	0.43	9.17e-6	Monocyte count;
THYM	cis	rs7119	0.717	rs12902925	chr15:77819141	T/C	cg27398640	chr15:77910606	LINGO1	-0.56	-5.61	-0.5	2.03e-7	Type 2 diabetes;
THYM	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	7.04	0.59	2.93e-10	Smoking behavior;
THYM	cis	rs1971762	0.583	rs2365345	chr12:54086820	C/T	cg16917193	chr12:54089295	NA	0.96	9.59	0.7	1.24e-15	Height;
THYM	trans	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg10856724	chr12:34555212	NA	-0.96	-8.66	-0.66	1.22e-13	Bladder cancer;
THYM	cis	rs10121009	0.635	rs17361814	chr9:35313054	G/A	cg15271616	chr9:35490515	RUSC2	0.75	5.11	0.46	1.69e-6	Parkinson's disease;
THYM	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg11812906	chr14:75593930	NEK9	-0.81	-7.31	-0.6	8.48e-11	Height;
THYM	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg27490568	chr2:178487706	NA	0.6	5.27	0.48	8.63e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7107174	1.000	rs72931639	chr11:78036703	C/T	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg17863274	chr19:49399704	TULP2	-1.01	-6.47	-0.55	4.29e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs3750965	1.000	rs1466222	chr11:68832848	G/A	cg06818126	chr11:68850279	TPCN2	-0.68	-4.64	-0.43	1.13e-5	Hair color;
THYM	cis	rs2046867	0.908	rs113001746	chr3:72824260	C/T	cg25664220	chr3:72788482	NA	-0.81	-6.11	-0.53	2.18e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7941600	1.000	rs7941600	chr11:9280284	G/A	cg19415743	chr11:9336845	TMEM41B	0.97	4.85	0.45	4.8e-6	Coronary artery disease;
THYM	cis	rs137603	1.000	rs137604	chr22:39694594	C/G	cg24268161	chr22:39747459	SYNGR1	0.57	5.08	0.46	1.87e-6	Primary biliary cholangitis;
THYM	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg09367891	chr1:107599246	PRMT6	0.74	5.06	0.46	2.05e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs10929159	0.928	rs10929157	chr2:236920156	C/G	cg20128773	chr2:236923534	AGAP1	0.36	4.75	0.44	7.13e-6	Parkinson's disease;
THYM	cis	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg09307838	chr4:120376055	NA	0.78	5.87	0.52	6.42e-8	Corneal astigmatism;
THYM	cis	rs10992471	0.603	rs4743873	chr9:95270781	C/T	cg14631576	chr9:95140430	CENPP	0.92	8.85	0.67	4.77e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2797160	1.000	rs6927161	chr6:126015954	T/C	cg16306078	chr6:126000798	NA	0.54	5.53	0.49	2.75e-7	Endometrial cancer;
THYM	cis	rs10992471	0.603	rs4744137	chr9:95288352	G/A	cg14631576	chr9:95140430	CENPP	-0.96	-9.19	-0.69	9.02e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg12908607	chr1:44402522	ARTN	-0.55	-4.67	-0.43	1e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg22664400	chr11:66445111	RBM4B	-0.66	-4.47	-0.42	2.14e-5	Crohn's disease;
THYM	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg07936489	chr17:37558343	FBXL20	-0.87	-5.78	-0.51	9.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11890956	chr21:40555474	PSMG1	0.65	6.01	0.53	3.34e-8	Menarche (age at onset);
THYM	cis	rs28595532	0.841	rs114175487	chr4:119733580	C/G	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.65	5.19	0.47	1.19e-6	Renal function-related traits (BUN);
THYM	cis	rs1209950	1.000	rs1013841	chr21:40173345	A/G	cg01359822	chr21:40176597	ETS2	0.7	5.64	0.5	1.75e-7	Non-small cell lung cancer (survival);
THYM	cis	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg24672777	chr11:48374446	OR4C45	-0.88	-5.4	-0.48	4.92e-7	Axial length;
THYM	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg03859395	chr2:55845619	SMEK2	0.66	6.02	0.53	3.29e-8	Metabolic syndrome;
THYM	cis	rs7809950	1.000	rs4727681	chr7:107096144	T/C	cg23024343	chr7:107201750	COG5	-0.92	-8.11	-0.64	1.73e-12	Coronary artery disease;
THYM	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg23574427	chr4:122746245	BBS7;CCNA2	-0.56	-5.1	-0.46	1.75e-6	Type 2 diabetes;
THYM	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg07212818	chr11:638076	DRD4	-0.76	-5.9	-0.52	5.56e-8	Systemic lupus erythematosus;
THYM	cis	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg06609049	chr19:2785107	THOP1	0.71	6.03	0.53	3.16e-8	Total cholesterol levels;
THYM	cis	rs3825942	1.000	rs3825942	chr15:74219582	G/A	cg23484268	chr15:74220776	LOXL1	0.5	4.81	0.44	5.74e-6	Glaucoma (exfoliation);
THYM	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17321999	1.000	rs10171296	chr2:30481309	A/G	cg05247661	chr2:30472410	LBH	0.7	4.67	0.43	9.96e-6	Systemic lupus erythematosus;
THYM	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg16586182	chr3:47516702	SCAP	-0.64	-5.61	-0.5	2.03e-7	Colorectal cancer;
THYM	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg23281280	chr6:28129359	ZNF389	0.65	5.02	0.46	2.45e-6	Parkinson's disease;
THYM	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg10018233	chr7:150070692	REPIN1	0.45	7.76	0.62	9.63e-12	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg01579765	chr21:45077557	HSF2BP	-0.54	-8.55	-0.66	2.11e-13	Mean corpuscular volume;
THYM	cis	rs4936894	0.500	rs11219533	chr11:124119298	T/A	cg23571170	chr11:124180298	OR8D1	-0.5	-4.45	-0.42	2.3e-5	Aging (time to death);
THYM	cis	rs28453840	1	rs28453840	chr2:136522941	G/A	cg04750100	chr2:136595281	LCT	-0.55	-6.27	-0.54	1.06e-8	Cholesterol, total;
THYM	cis	rs4595586	0.545	rs2388175	chr12:39389217	A/G	cg26384229	chr12:38710491	ALG10B	0.64	4.78	0.44	6.49e-6	Morning vs. evening chronotype;
THYM	cis	rs6840360	0.571	rs12648420	chr4:152543434	G/C	cg22705602	chr4:152727874	NA	-0.78	-8.16	-0.64	1.38e-12	Intelligence (multi-trait analysis);
THYM	cis	rs2439831	0.867	rs45585139	chr15:43700427	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	6.83	0.57	7.9e-10	Lung cancer in ever smokers;
THYM	cis	rs7635838	0.684	rs2606757	chr3:11358163	T/A	cg00170343	chr3:11313890	ATG7	0.57	4.56	0.42	1.51e-5	HDL cholesterol;
THYM	cis	rs11048434	0.723	rs12820395	chr12:9137096	T/G	cg04155231	chr12:9217510	LOC144571	0.5	4.95	0.45	3.27e-6	Sjögren's syndrome;
THYM	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs921968	0.542	rs588182	chr2:219412335	C/A	cg02176678	chr2:219576539	TTLL4	0.73	7.2	0.59	1.4e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs13082711	0.519	rs13091103	chr3:27229122	G/C	cg02860705	chr3:27208620	NA	1.05	6.96	0.58	4.36e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg00645579	chr11:617140	IRF7;MUPCDH	-0.41	-4.77	-0.44	6.56e-6	Systemic lupus erythematosus;
THYM	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.23	4.9	0.45	3.95e-6	Obesity-related traits;
THYM	cis	rs1267303	0.798	rs1267304	chr1:46990426	C/T	cg16387850	chr1:46982889	NA	0.43	4.98	0.45	2.88e-6	Monobrow;
THYM	cis	rs8077889	0.719	rs57227660	chr17:41858984	T/C	cg26893861	chr17:41843967	DUSP3	1.14	12.98	0.8	9.15e-23	Triglycerides;
THYM	cis	rs17102423	0.558	rs11628664	chr14:65615651	C/T	cg11161011	chr14:65562177	MAX	-0.58	-4.69	-0.43	9.25e-6	Obesity-related traits;
THYM	cis	rs9970807	0.688	rs2780857	chr1:56927348	C/T	cg11959316	chr1:57001742	PPAP2B	-0.63	-4.88	-0.45	4.29e-6	Myocardial infarction;Coronary artery disease;
THYM	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs9399401	0.884	rs6570510	chr6:142755024	C/T	cg04461802	chr6:142623433	GPR126	0.49	4.92	0.45	3.68e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg25072359	chr17:41440525	NA	0.67	4.71	0.44	8.34e-6	Menopause (age at onset);
THYM	cis	rs7246657	0.943	rs8111782	chr19:37867904	A/G	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.47	0.49	3.57e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10899021	0.790	rs12288525	chr11:74332589	T/A	cg25880958	chr11:74394337	NA	-0.72	-4.75	-0.44	7.16e-6	Response to metformin (IC50);
THYM	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.34	-0.48	6.24e-7	Monocyte percentage of white cells;
THYM	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg15247329	chr7:2764246	NA	-0.7	-5.77	-0.51	9.87e-8	Height;
THYM	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	4.76	0.44	6.83e-6	Obesity-related traits;
THYM	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg23711669	chr6:146136114	FBXO30	0.91	9.21	0.69	8.1e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11771526	0.901	rs11773754	chr7:32304801	A/G	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg12179176	chr11:130786555	SNX19	-0.87	-8.38	-0.65	4.85e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9326248	0.581	rs12804122	chr11:116902616	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.66	5.27	0.48	8.6e-7	Blood protein levels;
THYM	cis	rs6032067	0.929	rs6032044	chr20:43819416	C/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg27490568	chr2:178487706	NA	0.61	5.3	0.48	7.38e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg24209194	chr3:40518798	ZNF619	0.57	4.62	0.43	1.2e-5	Renal cell carcinoma;
THYM	cis	rs4664308	1.000	rs17831161	chr2:160909360	A/G	cg03641300	chr2:160917029	PLA2R1	-0.76	-6.83	-0.57	7.92e-10	Idiopathic membranous nephropathy;
THYM	cis	rs6087990	0.863	rs1569686	chr20:31367079	G/T	cg13636640	chr20:31349939	DNMT3B	0.93	9.97	0.72	1.89e-16	Ulcerative colitis;
THYM	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg03929089	chr4:120376271	NA	1.01	8.37	0.65	4.88e-13	Coronary artery disease;
THYM	cis	rs3825942	0.951	rs8041685	chr15:74225193	G/A	cg23484268	chr15:74220776	LOXL1	0.48	4.53	0.42	1.73e-5	Glaucoma (exfoliation);
THYM	cis	rs346785	0.692	rs4789274	chr17:74286106	C/T	cg09812376	chr17:74270190	QRICH2	-0.5	-5.15	-0.47	1.41e-6	White matter hyperintensities in ischemic stroke;
THYM	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Gout;
THYM	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg21028142	chr17:79581711	NPLOC4	0.49	4.82	0.44	5.34e-6	Eye color traits;
THYM	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs11771526	0.792	rs28394389	chr7:32298509	C/T	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg01579765	chr21:45077557	HSF2BP	-0.47	-7.12	-0.59	2.03e-10	Mean corpuscular volume;
THYM	cis	rs1124376	0.688	rs11715447	chr3:20140129	A/C	cg05072819	chr3:20081367	KAT2B	0.71	4.84	0.44	4.97e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg13695892	chr22:41940480	POLR3H	0.86	7.06	0.59	2.77e-10	Vitiligo;
THYM	cis	rs2239547	0.522	rs2564947	chr3:53046216	C/T	cg11645453	chr3:52864694	ITIH4	-0.29	-4.87	-0.45	4.4e-6	Schizophrenia;
THYM	cis	rs420259	0.516	rs4968008	chr16:23490353	G/T	cg00143387	chr16:23521605	GGA2	0.72	5.14	0.47	1.45e-6	Bipolar disorder;
THYM	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg11366901	chr6:160182831	ACAT2	1.08	9.54	0.7	1.56e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs96067	0.711	rs3754080	chr1:36616337	T/C	cg24686825	chr1:36642396	MAP7D1	-0.72	-5.28	-0.48	8.21e-7	Corneal structure;
THYM	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg04034577	chr2:241836375	C2orf54	0.44	7.69	0.62	1.33e-11	Urinary metabolites;
THYM	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg01097406	chr16:89675127	NA	0.64	5.35	0.48	5.95e-7	Vitiligo;
THYM	cis	rs3960554	0.808	rs78340819	chr7:75673833	C/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-4.47	-0.42	2.18e-5	Eotaxin levels;
THYM	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06850241	chr22:41845214	NA	-0.6	-5.32	-0.48	6.75e-7	Vitiligo;
THYM	cis	rs6032067	0.714	rs6032075	chr20:43884340	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.61	-6.81	-0.57	8.9e-10	Blood protein levels;
THYM	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg20503657	chr10:835505	NA	1.14	8.04	0.64	2.5e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs240764	0.621	rs6570930	chr6:101181258	C/A	cg21058520	chr6:100914733	NA	0.56	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg13147721	chr7:65941812	NA	-1.1	-7.08	-0.59	2.51e-10	Diabetic kidney disease;
THYM	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	4.87	0.45	4.4e-6	Total body bone mineral density;
THYM	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.15e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.29e-7	Corneal astigmatism;
THYM	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg01528321	chr10:82214614	TSPAN14	0.94	7.28	0.6	9.72e-11	Post bronchodilator FEV1;
THYM	cis	rs7607369	0.527	rs72966038	chr2:219656190	G/A	cg02176678	chr2:219576539	TTLL4	-0.63	-5.74	-0.51	1.14e-7	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg11266682	chr4:10021025	SLC2A9	-0.5	-6.4	-0.55	5.92e-9	Bone mineral density;
THYM	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg00129232	chr17:37814104	STARD3	0.7	4.79	0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7216064	1.000	rs56393562	chr17:65933918	C/T	cg12091567	chr17:66097778	LOC651250	-0.69	-4.51	-0.42	1.86e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg05347473	chr6:146136440	FBXO30	0.6	4.86	0.45	4.66e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1371867	0.875	rs1371868	chr8:101330267	C/T	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs6842047	1.000	rs4862668	chr4:187136443	A/T	cg09526685	chr4:187126073	CYP4V2	1.05	5.31	0.48	7.3e-7	Blood protein levels;
THYM	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg13736514	chr6:26305472	NA	-0.61	-7.55	-0.61	2.66e-11	Educational attainment;
THYM	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2811415	0.627	rs13313895	chr3:127752084	T/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg24818145	chr4:99064322	C4orf37	0.74	5.93	0.52	4.8e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg02083528	chr1:78280850	FAM73A	-0.95	-6.88	-0.58	6.27e-10	Depressive symptoms;
THYM	cis	rs11645898	0.748	rs56387295	chr16:72055336	C/A	cg14768367	chr16:72042858	DHODH	-0.79	-5.75	-0.51	1.09e-7	Blood protein levels;
THYM	cis	rs9814567	0.806	rs9841371	chr3:134320765	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.09e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg22947322	chr17:47091978	IGF2BP1	-0.56	-4.76	-0.44	6.98e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.48	-0.42	2.05e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs988913	0.957	rs9475098	chr6:54833177	A/G	cg18532076	chr6:54711417	FAM83B	0.52	4.93	0.45	3.45e-6	Menarche (age at onset);
THYM	cis	rs6754311	0.593	rs10195620	chr2:136495619	A/T	cg20242066	chr2:136595261	LCT	-0.56	-6.68	-0.57	1.57e-9	Mosquito bite size;
THYM	cis	rs4788570	0.615	rs7190487	chr16:71648617	A/G	cg06353428	chr16:71660113	MARVELD3	1.37	9.47	0.7	2.25e-15	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs4887067	1	rs4887067	chr15:78886947	G/A	cg04882995	chr15:78912658	CHRNA3	0.54	4.54	0.42	1.62e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs9517302	0.615	rs2274053	chr13:99098318	C/T	cg22223119	chr13:99095684	FARP1	-1.04	-7.49	-0.61	3.56e-11	Obesity-related traits;
THYM	cis	rs888194	0.686	rs11067376	chr12:110027795	A/G	cg10504392	chr12:110044639	NA	0.65	5.59	0.5	2.17e-7	Neuroticism;
THYM	cis	rs1467026	0.584	rs9880453	chr3:12804060	C/T	cg11882607	chr3:12858926	CAND2	-0.5	-5.66	-0.5	1.61e-7	P wave duration;
THYM	cis	rs7107174	0.681	rs10751288	chr11:78072658	A/T	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs7119	0.635	rs59745219	chr15:77884130	A/G	cg10437265	chr15:77819839	NA	-0.62	-6.04	-0.53	2.95e-8	Type 2 diabetes;
THYM	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg04287289	chr16:89883240	FANCA	0.62	5.81	0.51	8.26e-8	Vitiligo;
THYM	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg24803719	chr17:45855879	NA	-0.6	-6.36	-0.55	7.19e-9	IgG glycosylation;
THYM	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg23205692	chr1:25664452	TMEM50A	0.84	6.38	0.55	6.52e-9	Erythrocyte sedimentation rate;
THYM	cis	rs28595532	0.920	rs73842253	chr4:119721856	G/A	cg11846333	chr4:119757529	SEC24D	1.36	4.86	0.45	4.57e-6	Cannabis dependence symptom count;
THYM	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.02	0.46	2.4e-6	Obesity-related traits;
THYM	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg18681998	chr4:17616180	MED28	0.99	10.07	0.72	1.17e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg05340658	chr4:99064831	C4orf37	-0.53	-4.51	-0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1401999	0.621	rs1000952	chr3:183755822	G/A	cg20387954	chr3:183756860	HTR3D	0.78	6.76	0.57	1.1e-9	Anterior chamber depth;
THYM	cis	rs34779708	0.931	rs2384275	chr10:35297142	A/G	cg03585969	chr10:35415529	CREM	0.63	4.66	0.43	1.01e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg10856724	chr12:34555212	NA	-0.84	-7.62	-0.62	1.85e-11	Morning vs. evening chronotype;
THYM	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	4.66	0.43	1.04e-5	Diabetic retinopathy;
THYM	cis	rs4363385	0.669	rs2937264	chr1:153011026	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg06521331	chr12:34319734	NA	-0.99	-9.11	-0.68	1.32e-14	Morning vs. evening chronotype;
THYM	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.83	0.67	5.15e-14	Colorectal cancer;
THYM	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4849845	0.812	rs7593660	chr2:121026652	T/A	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs2239547	0.618	rs2071041	chr3:52864693	T/G	cg05299048	chr3:52828583	ITIH3	0.61	4.57	0.42	1.47e-5	Schizophrenia;
THYM	cis	rs988913	1.000	rs9475099	chr6:54839070	A/C	cg04690482	chr6:54711388	FAM83B	0.49	5.28	0.48	8.01e-7	Menarche (age at onset);
THYM	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06634786	chr22:41940651	POLR3H	-0.65	-5.16	-0.47	1.38e-6	Vitiligo;
THYM	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21659725	chr3:3221576	CRBN	-0.88	-9.81	-0.71	4.18e-16	Intelligence (multi-trait analysis);
THYM	cis	rs4474465	0.562	rs10793318	chr11:78215898	A/C	cg19901956	chr11:77921274	USP35	0.67	4.92	0.45	3.69e-6	Alzheimer's disease (survival time);
THYM	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.49	-0.55	3.89e-9	Chronic sinus infection;
THYM	cis	rs12579753	0.879	rs11115010	chr12:82165895	G/T	cg07988820	chr12:82153109	PPFIA2	-0.85	-5.59	-0.5	2.16e-7	Resting heart rate;
THYM	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg02734326	chr4:10020555	SLC2A9	0.7	6.0	0.52	3.58e-8	Bone mineral density;
THYM	cis	rs7558911	0.769	rs2881930	chr2:202075752	T/C	cg12105450	chr2:202048100	CASP10	0.51	4.62	0.43	1.21e-5	Chronic lymphocytic leukemia;
THYM	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg21226059	chr5:178986404	RUFY1	-0.62	-7.4	-0.6	5.53e-11	Lung cancer;
THYM	cis	rs757081	0.667	rs17641418	chr11:17161341	T/C	cg07093617	chr11:18158918	MRGPRX3	-0.49	-4.61	-0.43	1.23e-5	Systolic blood pressure;
THYM	cis	rs7589342	0.895	rs11901644	chr2:106432113	T/G	cg14210321	chr2:106509881	NCK2	-0.72	-5.12	-0.46	1.62e-6	Addiction;
THYM	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs2732480	0.577	rs2634678	chr12:48735538	C/G	cg21466736	chr12:48725269	NA	-0.59	-5.43	-0.49	4.36e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6876348	0.598	rs1898550	chr5:128285661	C/T	cg02841155	chr5:128301328	SLC27A6	-0.54	-5.63	-0.5	1.86e-7	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs9951602	0.512	rs58352488	chr18:76651113	T/A	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs9814567	0.762	rs13071253	chr3:134316653	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	5.94	0.52	4.69e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs17030434	0.953	rs74845915	chr4:154696778	G/T	cg14289246	chr4:154710475	SFRP2	-0.76	-5.24	-0.47	9.79e-7	Electrocardiographic conduction measures;
THYM	cis	rs1003719	0.715	rs2156077	chr21:38539357	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs1003719	0.707	rs9976360	chr21:38587860	C/T	cg01329690	chr21:38580129	DSCR9	-0.36	-4.98	-0.46	2.81e-6	Eye color traits;
THYM	cis	rs11671005	0.696	rs73066211	chr19:58997079	C/T	cg02808233	chr19:58920810	ZNF584	0.57	4.51	0.42	1.89e-5	Mean platelet volume;
THYM	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg04362960	chr10:104952993	NT5C2	0.57	4.67	0.43	9.99e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg03859395	chr2:55845619	SMEK2	0.61	5.64	0.5	1.76e-7	Metabolic syndrome;
THYM	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg08000102	chr2:233561755	GIGYF2	0.69	6.09	0.53	2.35e-8	Coronary artery disease;
THYM	cis	rs7106204	0.541	rs75552854	chr11:24231824	G/A	ch.11.24196551F	chr11:24239977	NA	0.92	4.92	0.45	3.58e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.72	5.53	0.49	2.8e-7	Height;
THYM	cis	rs9352866	0.967	rs6904934	chr6:81524035	A/G	cg08356243	chr6:80645827	ELOVL4	-0.45	-4.46	-0.42	2.23e-5	Antibody level in response to infection;
THYM	cis	rs7806994	1	rs7806994	chr7:56139505	A/T	cg21096502	chr7:56174374	CHCHD2	-0.79	-4.84	-0.44	5.11e-6	PR interval in Tripanosoma cruzi seropositivity;
THYM	cis	rs73787773	0.644	rs78455089	chr5:111478870	C/A	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.87	-4.54	-0.42	1.65e-5	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.31	0.6	8.45e-11	Obesity-related traits;
THYM	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.09	-0.64	1.93e-12	Mean corpuscular volume;
THYM	cis	rs10857712	0.904	rs36118799	chr10:135222369	T/G	cg17796960	chr10:135278976	LOC619207	-0.55	-4.65	-0.43	1.08e-5	Systemic lupus erythematosus;
THYM	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg26038318	chr20:34205095	SPAG4	0.6	4.7	0.43	8.76e-6	Total cholesterol levels;
THYM	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg08132940	chr7:1081526	C7orf50	-1.32	-7.61	-0.62	1.93e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg10802521	chr3:52805072	NEK4	0.71	5.96	0.52	4.22e-8	Bipolar disorder;
THYM	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg11317459	chr13:21872234	NA	1.16	8.71	0.67	9.24e-14	White matter hyperintensity burden;
THYM	cis	rs240764	0.621	rs10457844	chr6:101196532	T/A	cg21058520	chr6:100914733	NA	0.6	5.32	0.48	6.98e-7	Neuroticism;
THYM	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg23758822	chr17:41437982	NA	1.22	13.81	0.82	1.89e-24	Menopause (age at onset);
THYM	cis	rs892961	0.867	rs312909	chr17:75413954	T/C	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs3204270	0.516	rs62077189	chr17:79673088	G/A	cg13117272	chr17:79681052	SLC25A10	-0.79	-5.02	-0.46	2.38e-6	Dental caries;
THYM	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg23711669	chr6:146136114	FBXO30	-0.84	-7.61	-0.62	2.01e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg14893161	chr1:205819251	PM20D1	-0.6	-4.6	-0.43	1.32e-5	Menarche (age at onset);
THYM	cis	rs9470366	0.545	rs4711457	chr6:36633160	T/C	cg24425727	chr6:36645648	CDKN1A	0.7	6.66	0.56	1.79e-9	QRS duration;
THYM	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs10231759	0.617	rs7809861	chr7:150513061	A/T	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.66	4.97	0.45	3e-6	Height;
THYM	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.54e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7582403	0.510	rs7604592	chr2:148890535	A/G	cg23727674	chr2:148602993	ACVR2A	0.63	4.61	0.43	1.24e-5	Neuroticism;
THYM	cis	rs59698941	0.943	rs66483023	chr5:132257748	A/T	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg20295408	chr7:1910781	MAD1L1	-0.59	-4.77	-0.44	6.66e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs8014204	0.753	rs6574199	chr14:75356103	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.59	-5.9	-0.52	5.57e-8	Caffeine consumption;
THYM	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg21926883	chr2:100939477	LONRF2	-0.6	-5.46	-0.49	3.87e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg27170947	chr2:26402098	FAM59B	-0.58	-4.9	-0.45	3.87e-6	Gut microbiome composition (summer);
THYM	cis	rs5758511	0.773	rs62240997	chr22:42354567	T/G	cg08431931	chr22:42394659	WBP2NL	0.71	4.46	0.42	2.25e-5	Birth weight;
THYM	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg24803719	chr17:45855879	NA	-0.6	-6.26	-0.54	1.08e-8	IgG glycosylation;
THYM	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg22535103	chr8:58192502	C8orf71	-0.93	-4.56	-0.42	1.52e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg23711669	chr6:146136114	FBXO30	-0.96	-10.01	-0.72	1.54e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs61931739	0.926	rs1995966	chr12:34095420	G/A	cg10856724	chr12:34555212	NA	0.61	4.98	0.46	2.8e-6	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs1943345	0.642	rs11233500	chr11:82881407	C/T	cg07047830	chr11:82868014	PCF11	-0.67	-5.79	-0.51	9.02e-8	Obesity-related traits;
THYM	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg27534772	chr1:16042836	PLEKHM2	0.49	5.26	0.48	8.77e-7	Systolic blood pressure;
THYM	cis	rs61931739	0.782	rs7969373	chr12:34249655	T/G	cg10856724	chr12:34555212	NA	-0.62	-5.55	-0.49	2.62e-7	Morning vs. evening chronotype;
THYM	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg13319975	chr6:146136371	FBXO30	-0.64	-5.35	-0.48	6.16e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg07777115	chr5:623756	CEP72	-0.8	-4.78	-0.44	6.48e-6	Obesity-related traits;
THYM	cis	rs2251260	0.891	rs1088674	chr14:62006693	C/A	cg13564459	chr14:62004353	PRKCH	0.46	5.52	0.49	2.97e-7	Yeast infection;
THYM	cis	rs622217	0.656	rs371311	chr6:160717773	A/G	cg11363108	chr6:160501266	IGF2R	-0.57	-4.45	-0.42	2.36e-5	Type 2 diabetes;
THYM	cis	rs7582180	0.715	rs11123823	chr2:100916315	A/G	cg08017756	chr2:100939284	LONRF2	-0.61	-5.56	-0.5	2.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs669446	0.529	rs6697354	chr1:44151015	T/G	cg15962314	chr1:44399869	ARTN	0.43	4.5	0.42	1.95e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.88	5.64	0.5	1.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2016266	0.859	rs10876433	chr12:53734114	G/A	cg26875137	chr12:53738046	NA	-0.73	-5.22	-0.47	1.07e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg13319975	chr6:146136371	FBXO30	-0.69	-5.68	-0.5	1.5e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg00786635	chr1:25594202	NA	0.84	7.02	0.58	3.36e-10	Erythrocyte sedimentation rate;
THYM	cis	rs6032067	0.759	rs1007138	chr20:43816835	A/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.67	-7.66	-0.62	1.54e-11	Blood protein levels;
THYM	cis	rs2404602	0.622	rs2003344	chr15:76632301	T/C	cg23625390	chr15:77176239	SCAPER	-0.72	-5.23	-0.47	1.02e-6	Blood metabolite levels;
THYM	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg22105103	chr4:187893119	NA	0.95	10.29	0.73	3.97e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs59107033	0.509	rs60496964	chr3:123102795	T/C	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Lymphocyte counts;
THYM	cis	rs7089973	0.966	rs749649	chr10:116641999	G/A	cg23260525	chr10:116636907	FAM160B1	0.59	5.44	0.49	4.2e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9311676	0.632	rs62259780	chr3:58428078	T/G	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg02136620	chr5:178986620	RUFY1	0.64	6.13	0.53	2.03e-8	Lung cancer;
THYM	cis	rs2274459	1.000	rs2296749	chr6:33763127	G/A	cg06253072	chr6:33679850	C6orf125	0.52	4.67	0.43	1e-5	Obesity (extreme);
THYM	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg23281280	chr6:28129359	ZNF389	0.61	4.74	0.44	7.58e-6	Parkinson's disease;
THYM	cis	rs13102973	0.640	rs4864245	chr4:135882847	G/C	cg14419869	chr4:135874104	NA	-0.82	-6.86	-0.58	7.05e-10	Subjective well-being;
THYM	cis	rs7107174	1.000	rs1385600	chr11:77936166	C/T	cg19901956	chr11:77921274	USP35	0.68	5.34	0.48	6.28e-7	Testicular germ cell tumor;
THYM	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg02527881	chr3:46936655	PTH1R	-0.63	-6.29	-0.54	9.52e-9	Colorectal cancer;
THYM	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg09165964	chr15:75287851	SCAMP5	-1.06	-10.7	-0.74	5.29e-18	Blood trace element (Zn levels);
THYM	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg05738196	chr6:26577821	NA	0.84	8.48	0.66	2.87e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6840360	0.530	rs6839802	chr4:152485834	G/A	cg22705602	chr4:152727874	NA	-0.77	-8.64	-0.66	1.36e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7940866	0.801	rs10894296	chr11:130840433	T/G	cg23692386	chr11:131799662	NTM	0.48	5.08	0.46	1.91e-6	Schizophrenia;
THYM	cis	rs7319311	0.965	rs9583488	chr13:111031352	G/A	cg06243866	chr13:111019493	COL4A2	0.71	5.66	0.5	1.63e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg24818145	chr4:99064322	C4orf37	0.73	5.74	0.51	1.13e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4849845	0.886	rs1137385	chr2:121052268	A/T	cg03575764	chr2:121493832	NA	-0.63	-4.7	-0.43	8.69e-6	Mean platelet volume;
THYM	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg26963428	chr7:66367121	NA	-0.59	-4.69	-0.43	9.05e-6	Corneal structure;
THYM	cis	rs6430585	0.528	rs309151	chr2:136661150	C/T	cg23851026	chr2:136556271	LCT	0.77	7.03	0.58	3.16e-10	Corneal structure;
THYM	cis	rs7524258	0.868	rs2412152	chr1:7303213	C/T	cg07173049	chr1:7289937	CAMTA1	0.81	6.33	0.54	8.04e-9	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.68	-4.46	-0.42	2.22e-5	Menarche (age at onset);
THYM	cis	rs7072216	0.763	rs3750601	chr10:100174561	C/A	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs7264396	0.513	rs2425092	chr20:34306815	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.76	-0.44	6.84e-6	Total cholesterol levels;
THYM	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg08999081	chr20:33150536	PIGU	0.77	7.32	0.6	7.97e-11	Coronary artery disease;
THYM	cis	rs7584330	0.554	rs10185109	chr2:238435546	T/C	cg08992911	chr2:238395768	MLPH	0.66	4.48	0.42	2.1e-5	Prostate cancer;
THYM	cis	rs3818285	0.655	rs623980	chr10:111646147	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.48	-5.32	-0.48	7e-7	Superior crus of antihelix expression;
THYM	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs1557488	0.599	rs2187573	chr11:126678521	G/T	cg03950493	chr11:126582183	KIRREL3	-0.37	-4.47	-0.42	2.17e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs11711311	0.955	rs7617313	chr3:113391740	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.55	-4.58	-0.43	1.4e-5	IgG glycosylation;
THYM	cis	rs739401	0.595	rs2073843	chr11:2970855	A/G	cg08508325	chr11:3079039	CARS	-0.51	-6.18	-0.54	1.57e-8	Longevity;
THYM	cis	rs6570726	0.693	rs450921	chr6:145864260	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10504073	0.525	rs10081464	chr8:50058707	A/G	cg00325661	chr8:49890786	NA	0.66	5.43	0.49	4.31e-7	Blood metabolite ratios;
THYM	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.32	0.48	6.81e-7	Height;
THYM	cis	rs7216064	1.000	rs59950564	chr17:65860859	A/G	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg17178900	chr1:205818956	PM20D1	0.58	4.57	0.42	1.47e-5	Parkinson's disease;
THYM	cis	rs79149102	0.579	rs7173218	chr15:75315328	A/G	cg17294928	chr15:75287854	SCAMP5	-0.98	-5.33	-0.48	6.65e-7	Lung cancer;
THYM	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs684232	0.602	rs331010	chr17:547124	G/A	cg15660573	chr17:549704	VPS53	-1.0	-11.2	-0.75	4.65e-19	Prostate cancer;
THYM	cis	rs73198271	0.740	rs11781430	chr8:8651733	G/C	cg06636001	chr8:8085503	FLJ10661	-0.68	-4.63	-0.43	1.14e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.32	-0.48	7.02e-7	Monocyte percentage of white cells;
THYM	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg07636037	chr3:49044803	WDR6	0.96	10.42	0.73	2.05e-17	Parkinson's disease;
THYM	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03264133	chr6:25882463	NA	0.83	6.69	0.57	1.54e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1883415	0.534	rs760905	chr6:24479782	T/C	cg20631270	chr6:24437470	GPLD1	0.53	4.46	0.42	2.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg27129171	chr3:47204927	SETD2	0.8	7.67	0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs12711979	0.509	rs13035992	chr2:3826597	G/A	cg17052675	chr2:3827356	NA	-0.9	-14.65	-0.83	4.18e-26	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg10334053	chr1:2078117	PRKCZ	-0.45	-4.53	-0.42	1.73e-5	Height;
THYM	cis	rs34286592	0.929	rs10204	chr16:29826538	C/T	cg04633683	chr16:29837056	MVP	0.52	4.7	0.43	8.63e-6	Multiple sclerosis;
THYM	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg00814883	chr7:100076585	TSC22D4	-0.96	-6.41	-0.55	5.5e-9	Platelet count;
THYM	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg07930552	chr6:133119739	C6orf192	-1.03	-6.0	-0.52	3.63e-8	Type 2 diabetes nephropathy;
THYM	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg09307838	chr4:120376055	NA	0.62	4.73	0.44	7.88e-6	Corneal astigmatism;
THYM	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7772486	0.754	rs6570718	chr6:146088443	T/G	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.43e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg06850241	chr22:41845214	NA	0.53	4.56	0.42	1.54e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg27284194	chr4:1044797	NA	0.64	4.87	0.45	4.49e-6	Recombination rate (females);
THYM	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg18876405	chr7:65276391	NA	-0.57	-4.86	-0.45	4.62e-6	Aortic root size;
THYM	trans	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs67981189	0.788	rs34093157	chr14:71568683	T/A	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03517284	chr6:25882590	NA	-0.78	-6.24	-0.54	1.22e-8	Blood metabolite levels;
THYM	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg00024416	chr22:24240387	NA	-0.67	-7.02	-0.58	3.23e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg11764359	chr7:65958608	NA	0.67	4.77	0.44	6.52e-6	Aortic root size;
THYM	cis	rs56341938	0.935	rs62273761	chr3:168741403	G/A	cg09107232	chr3:169491072	MYNN	0.54	4.58	0.43	1.42e-5	Lung function (FEV1/FVC);
THYM	cis	rs524023	0.957	rs552307	chr11:64357539	G/A	cg19131476	chr11:64387923	NRXN2	0.35	4.84	0.44	4.98e-6	Urate levels in obese individuals;
THYM	cis	rs34638657	0.732	rs11866711	chr16:82201038	A/C	cg09439754	chr16:82129088	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	cis	rs116139393	0.517	rs77141752	chr7:6725475	C/T	cg03005310	chr7:6897353	NA	-0.63	-4.58	-0.43	1.39e-5	Alzheimer's disease (APOE e4 interaction);
THYM	cis	rs7267979	1.000	rs6115182	chr20:25410259	G/A	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg25208724	chr1:156163844	SLC25A44	1.18	13.2	0.8	3.2e-23	Testicular germ cell tumor;
THYM	cis	rs4481887	0.741	rs6682957	chr1:248535639	T/G	cg00666640	chr1:248458726	OR2T12	0.55	4.74	0.44	7.59e-6	Common traits (Other);
THYM	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-5.55	-0.49	2.58e-7	Monocyte percentage of white cells;
THYM	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg26031613	chr14:104095156	KLC1	0.81	5.35	0.48	6.02e-7	Body mass index;
THYM	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg02734326	chr4:10020555	SLC2A9	0.76	7.25	0.6	1.13e-10	Bone mineral density;
THYM	trans	rs4596713	0.507	rs2309424	chr9:71806370	A/G	cg16512924	chr15:28394682	HERC2	0.87	7.3	0.6	8.76e-11	Headache;
THYM	cis	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg05335186	chr13:53173507	NA	-0.48	-6.7	-0.57	1.49e-9	Lewy body disease;
THYM	cis	rs977987	0.735	rs166013	chr16:75434146	C/T	cg03315344	chr16:75512273	CHST6	-0.67	-5.32	-0.48	6.78e-7	Dupuytren's disease;
THYM	cis	rs12048904	0.541	rs1571046	chr1:101299216	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.9	7.29	0.6	9.18e-11	Multiple sclerosis;
THYM	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg13175981	chr1:150552382	MCL1	0.78	5.81	0.51	8.14e-8	Tonsillectomy;
THYM	cis	rs61931739	0.613	rs6488174	chr12:33756569	T/C	cg06521331	chr12:34319734	NA	-0.6	-4.45	-0.42	2.36e-5	Morning vs. evening chronotype;
THYM	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.63	0.5	1.79e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7226229	1.000	rs9797279	chr17:20908325	T/C	cg21263980	chr17:20946333	USP22	0.65	4.88	0.45	4.33e-6	Blood trace element (Se levels);
THYM	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg00376283	chr12:123451042	ABCB9	0.72	4.88	0.45	4.24e-6	Neutrophil percentage of white cells;
THYM	cis	rs10871290	0.881	rs3863439	chr16:74470644	T/C	cg01733217	chr16:74700730	RFWD3	-0.65	-5.66	-0.5	1.61e-7	Breast cancer;
THYM	cis	rs7582180	0.845	rs7607676	chr2:100896966	G/A	cg14675211	chr2:100938903	LONRF2	0.64	5.43	0.49	4.28e-7	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg04398451	chr17:18023971	MYO15A	0.83	7.73	0.62	1.1e-11	Total body bone mineral density;
THYM	cis	rs6032067	1.000	rs6032065	chr20:43855649	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.71	-7.46	-0.61	4.01e-11	Blood protein levels;
THYM	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg10047753	chr17:41438598	NA	0.98	8.08	0.64	2.01e-12	Menopause (age at onset);
THYM	cis	rs9361491	0.657	rs4706730	chr6:79467903	C/T	cg04547799	chr6:79944526	HMGN3	-0.63	-4.57	-0.42	1.49e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg11752832	chr7:134001865	SLC35B4	0.77	5.55	0.49	2.63e-7	Mean platelet volume;
THYM	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.63	-6.6	-0.56	2.36e-9	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs9788721	0.934	rs1317286	chr15:78896129	A/G	cg04882995	chr15:78912658	CHRNA3	0.54	4.57	0.42	1.45e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg27398817	chr8:82754497	SNX16	-0.71	-6.05	-0.53	2.89e-8	Diastolic blood pressure;
THYM	cis	rs9549260	0.755	rs7990923	chr13:41215972	A/G	cg21288729	chr13:41239152	FOXO1	0.73	5.55	0.5	2.52e-7	Red blood cell count;
THYM	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22496380	chr5:211416	CCDC127	-1.33	-7.99	-0.63	3.21e-12	Breast cancer;
THYM	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs4474465	1.000	rs2063729	chr11:78185969	C/T	cg19901956	chr11:77921274	USP35	-0.59	-4.52	-0.42	1.8e-5	Alzheimer's disease (survival time);
THYM	cis	rs1003719	0.715	rs2835658	chr21:38565201	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-4.54	-0.42	1.67e-5	Eye color traits;
THYM	cis	rs7582180	0.614	rs1530031	chr2:101009326	T/C	cg08017756	chr2:100939284	LONRF2	-0.73	-7.29	-0.6	9.05e-11	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg03806693	chr22:41940476	POLR3H	-1.22	-11.17	-0.75	5.43e-19	Vitiligo;
THYM	cis	rs35660623	0.850	rs6989930	chr8:10670108	A/G	cg12395012	chr8:11607386	GATA4	0.91	5.18	0.47	1.26e-6	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs950880	0.710	rs17027230	chr2:103079330	C/T	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.74	-0.44	7.54e-6	Serum protein levels (sST2);
THYM	cis	rs11792861	0.505	rs12377869	chr9:111907803	C/A	cg05043794	chr9:111880884	C9orf5	-0.42	-6.31	-0.54	8.63e-9	Menarche (age at onset);
THYM	cis	rs863345	0.604	rs11265015	chr1:158503252	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs2997447	0.748	rs2802346	chr1:26434354	G/A	cg03844060	chr1:26490628	NA	0.67	4.52	0.42	1.79e-5	QRS complex (12-leadsum);
THYM	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg16325326	chr1:53192061	ZYG11B	-0.73	-7.1	-0.59	2.23e-10	Monocyte count;
THYM	cis	rs12579753	0.917	rs7972839	chr12:82178920	C/T	cg21231944	chr12:82153410	PPFIA2	-0.7	-5.35	-0.48	6.01e-7	Resting heart rate;
THYM	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs1003719	0.591	rs1053984	chr21:38574018	C/T	cg01329690	chr21:38580129	DSCR9	-0.34	-4.58	-0.43	1.39e-5	Eye color traits;
THYM	cis	rs11225247	0.881	rs11605573	chr11:102259959	G/T	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg04842962	chr6:43655489	MRPS18A	1.41	15.7	0.85	3.85e-28	IgG glycosylation;
THYM	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6701037	0.512	rs4650716	chr1:175128711	C/A	cg00958927	chr1:175162553	KIAA0040	0.35	4.88	0.45	4.32e-6	Alcohol dependence;
THYM	cis	rs13185784	0.703	rs6894217	chr5:179667806	G/A	cg13944838	chr5:179740914	GFPT2	0.73	5.01	0.46	2.53e-6	TRAIL levels;
THYM	cis	rs4460079	0.531	rs9995469	chr4:114840479	A/G	cg02060584	chr4:113970739	ANK2	-0.56	-4.58	-0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg04429589	chr14:105992532	TMEM121	-0.48	-5.31	-0.48	7.29e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs7786808	0.588	rs4909078	chr7:158183835	C/G	cg01191920	chr7:158217561	PTPRN2	-0.91	-9.45	-0.7	2.51e-15	Obesity-related traits;
THYM	cis	rs7119	0.717	rs12901100	chr15:77815558	T/A	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg18252515	chr7:66147081	NA	0.72	5.6	0.5	2.03e-7	Aortic root size;
THYM	cis	rs910187	0.624	rs6063077	chr20:45787261	C/T	cg27589058	chr20:45804311	EYA2	-0.55	-4.55	-0.42	1.6e-5	Migraine;
THYM	cis	rs12348691	0.503	rs7046645	chr9:100617375	T/C	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Alopecia areata;
THYM	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.52	-5.11	-0.46	1.64e-6	Schizophrenia;
THYM	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg00256281	chr22:41985642	PMM1	-0.49	-4.52	-0.42	1.79e-5	Vitiligo;
THYM	cis	rs4938534	0.559	rs1944919	chr11:111259876	A/C	cg11362935	chr11:111250201	POU2AF1	0.55	5.25	0.47	9.34e-7	Primary biliary cholangitis;
THYM	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	5.09	0.46	1.8e-6	Menarche (age at onset);
THYM	cis	rs4242434	0.699	rs878051	chr8:22483836	T/C	cg01710189	chr8:22454888	PDLIM2	-0.5	-5.3	-0.48	7.45e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg02038168	chr22:39784481	NA	-0.77	-5.6	-0.5	2.04e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs4731207	0.596	rs12113765	chr7:124589684	G/C	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg22467129	chr15:76604101	ETFA	-0.56	-5.27	-0.48	8.62e-7	Blood metabolite levels;
THYM	cis	rs11112613	0.713	rs73184081	chr12:105951745	C/T	cg03607813	chr12:105948248	NA	0.99	8.21	0.64	1.08e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.83	-4.61	-0.43	1.25e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8067545	1.000	rs2108979	chr17:19928566	G/A	cg08626831	chr17:20841558	NA	-0.48	-4.5	-0.42	1.94e-5	Schizophrenia;
THYM	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs2455799	0.594	rs11128769	chr3:15926230	C/T	cg16303742	chr3:15540471	COLQ	-0.53	-5.53	-0.49	2.79e-7	Mean platelet volume;
THYM	cis	rs3008870	1.000	rs2755244	chr1:67484470	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.93	-7.76	-0.62	9.52e-12	Lymphocyte percentage of white cells;
THYM	cis	rs7909074	1.000	rs10900128	chr10:45393201	G/T	cg05187965	chr10:45406764	TMEM72	-0.54	-5.12	-0.46	1.62e-6	Mean corpuscular volume;
THYM	cis	rs7523273	0.606	rs2281289	chr1:207978916	C/T	cg22525895	chr1:207977042	MIR29B2	-0.98	-10.28	-0.73	4.23e-17	Schizophrenia;
THYM	cis	rs12681287	0.640	rs7841690	chr8:87365359	T/C	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs7084921	0.526	rs7088558	chr10:101884937	C/T	cg11344164	chr10:101878520	NA	-0.56	-5.44	-0.49	4.09e-7	Bone mineral density;
THYM	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg11965913	chr1:205819406	PM20D1	0.93	10.2	0.72	6.29e-17	Menarche (age at onset);
THYM	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg23851026	chr2:136556271	LCT	-0.56	-5.69	-0.5	1.42e-7	Mosquito bite size;
THYM	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.75	6.15	0.53	1.83e-8	Lung cancer in ever smokers;
THYM	cis	rs1421898	0.625	rs10515765	chr5:157947537	A/G	cg06698293	chr5:158690540	UBLCP1	-0.96	-4.56	-0.42	1.52e-5	Inflammatory skin disease;
THYM	cis	rs9549260	0.755	rs7986407	chr13:41179798	A/G	cg21288729	chr13:41239152	FOXO1	0.67	5.57	0.5	2.37e-7	Red blood cell count;
THYM	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	12.65	0.79	4.44e-22	Height;
THYM	cis	rs73110464	0.562	rs2363634	chr12:53354683	A/G	cg14581129	chr12:53358946	NA	-1.03	-7.41	-0.61	5.1e-11	Cancer (pleiotropy);
THYM	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg06481639	chr22:41940642	POLR3H	0.77	5.37	0.48	5.67e-7	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg06064525	chr11:970664	AP2A2	-0.35	-6.68	-0.57	1.63e-9	Alzheimer's disease (late onset);
THYM	cis	rs6032067	0.810	rs62208441	chr20:43839360	T/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.71	-8.16	-0.64	1.39e-12	Blood protein levels;
THYM	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs889398	1.000	rs889398	chr16:69556715	C/T	cg09409435	chr16:70099608	PDXDC2	-0.61	-4.57	-0.42	1.48e-5	Body mass index;
THYM	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg07930552	chr6:133119739	C6orf192	-0.97	-5.1	-0.46	1.71e-6	Type 2 diabetes nephropathy;
THYM	cis	rs4792901	0.797	rs118013810	chr17:41626144	C/A	cg21940313	chr17:41620911	ETV4	-0.52	-5.51	-0.49	3.08e-7	Dupuytren's disease;
THYM	cis	rs78587638	0.518	rs4073566	chr2:119161638	A/C	cg13355233	chr2:118771338	CCDC93	-0.67	-4.62	-0.43	1.23e-5	Mosquito bite size;
THYM	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-8.52	-0.66	2.33e-13	Schizophrenia;
THYM	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg15536230	chr21:44985092	HSF2BP	-0.41	-4.61	-0.43	1.24e-5	Mean corpuscular volume;
THYM	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06873352	chr17:61820015	STRADA	0.76	9.89	0.71	2.87e-16	Prudent dietary pattern;
THYM	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg06112835	chr11:68658793	MRPL21	0.44	6.24	0.54	1.23e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg18876405	chr7:65276391	NA	0.6	5.32	0.48	6.97e-7	Aortic root size;
THYM	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9325144	0.560	rs10506125	chr12:39120287	C/T	cg26384229	chr12:38710491	ALG10B	0.83	7.35	0.6	6.96e-11	Morning vs. evening chronotype;
THYM	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg04315214	chr1:2043799	PRKCZ	0.56	4.62	0.43	1.19e-5	Height;
THYM	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg02353165	chr6:42928485	GNMT	1.03	11.02	0.75	1.14e-18	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9329221	0.618	rs73197281	chr8:10263282	T/C	cg02178032	chr8:11213424	TDH	0.6	5.24	0.47	9.5e-7	Neuroticism;
THYM	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg02782426	chr3:40428986	ENTPD3	0.54	4.79	0.44	6.02e-6	Renal cell carcinoma;
THYM	trans	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg10856724	chr12:34555212	NA	0.76	6.96	0.58	4.29e-10	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs586688	0.556	rs981309	chr1:201674081	A/G	cg07139329	chr1:201708558	NAV1	-0.51	-4.88	-0.45	4.33e-6	Obesity-related traits;
THYM	cis	rs11031096	0.782	rs11031110	chr11:4162652	G/C	cg08557956	chr11:4115526	RRM1	-0.5	-4.9	-0.45	3.94e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs1568889	0.887	rs2062269	chr11:28116537	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs900145	0.770	rs10832018	chr11:13312424	G/A	cg13286116	chr11:13302098	ARNTL	-0.59	-4.73	-0.44	7.89e-6	Menarche (age at onset);
THYM	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs2404618	0.561	rs4242536	chr8:1477225	A/G	cg13402656	chr8:1511478	DLGAP2	-0.74	-6.73	-0.57	1.29e-9	Lung cancer;
THYM	cis	rs7119	0.717	rs8040702	chr15:77803615	G/A	cg27398640	chr15:77910606	LINGO1	-0.52	-5.21	-0.47	1.12e-6	Type 2 diabetes;
THYM	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg03452623	chr4:187889614	NA	-1.15	-19.23	-0.89	1.61e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs854765	0.663	rs3183702	chr17:17747289	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-5.87	-0.52	6.25e-8	Total body bone mineral density;
THYM	cis	rs2964802	0.505	rs6865234	chr5:10829742	C/A	cg14521931	chr5:10832172	NA	-0.63	-5.19	-0.47	1.2e-6	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs9467711	0.559	rs3799383	chr6:26510748	C/T	cg12826209	chr6:26865740	GUSBL1	0.9	4.96	0.45	3.09e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg13147721	chr7:65941812	NA	-1.1	-7.08	-0.59	2.45e-10	Diabetic kidney disease;
THYM	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-4.73	-0.44	7.71e-6	Mood instability;
THYM	cis	rs7267979	1.000	rs4815408	chr20:25346678	C/T	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6430585	0.878	rs9677760	chr2:136538939	T/A	cg07169764	chr2:136633963	MCM6	-0.93	-8.04	-0.64	2.51e-12	Corneal structure;
THYM	cis	rs2639990	1.000	rs655156	chr18:72898181	T/C	cg21330207	chr18:72916311	ZADH2	1.21	6.2	0.54	1.45e-8	Vascular endothelial growth factor levels;
THYM	cis	rs747334	0.777	rs11186385	chr10:92714957	A/G	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg26384229	chr12:38710491	ALG10B	-0.75	-5.99	-0.52	3.8e-8	Morning vs. evening chronotype;
THYM	cis	rs611744	0.967	rs653081	chr8:109230383	G/T	cg21045802	chr8:109455806	TTC35	0.59	5.25	0.47	9.08e-7	Dupuytren's disease;
THYM	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg27125505	chr17:43679177	LOC644172	0.77	7.03	0.58	3.12e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs5167	0.504	rs8100120	chr19:45466058	T/C	cg09555818	chr19:45449301	APOC2	0.67	7.58	0.61	2.27e-11	Blood protein levels;
THYM	cis	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg21775007	chr8:11205619	TDH	0.73	6.54	0.56	3.07e-9	Retinal vascular caliber;
THYM	cis	rs7523273	0.526	rs2952	chr1:208049077	C/T	cg22525895	chr1:207977042	MIR29B2	0.52	4.57	0.42	1.47e-5	Schizophrenia;
THYM	cis	rs12549902	1.000	rs12549902	chr8:41509259	C/T	cg21772509	chr8:41503840	NKX6-3	0.7	6.54	0.56	3.04e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
THYM	cis	rs11122272	0.701	rs7414807	chr1:231476874	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-4.46	-0.42	2.24e-5	Hemoglobin concentration;
THYM	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00908189	chr16:619842	PIGQ	1.06	9.31	0.69	5e-15	Height;
THYM	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg20891558	chr2:74357851	NA	1.18	12.27	0.78	2.67e-21	Gestational age at birth (maternal effect);
THYM	cis	rs9876781	1.000	rs9311423	chr3:48420308	C/A	cg06066452	chr3:48470258	PLXNB1	0.28	5.14	0.47	1.49e-6	Longevity;
THYM	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03647317	chr4:187891568	NA	-0.83	-9.53	-0.7	1.69e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg01097406	chr16:89675127	NA	-0.66	-5.81	-0.51	8.36e-8	Vitiligo;
THYM	cis	rs539096	0.872	rs3828150	chr1:44050856	T/C	cg00143623	chr1:44495758	SLC6A9	0.65	5.17	0.47	1.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4940575	0.786	rs6567327	chr18:60840750	G/A	cg24349668	chr18:61441546	SERPINB7	0.76	4.66	0.43	1.01e-5	Breast cancer;
THYM	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg12935359	chr14:103987150	CKB	-0.63	-6.45	-0.55	4.63e-9	Body mass index;
THYM	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg11663144	chr21:46675770	NA	-0.72	-10.28	-0.73	4.23e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1003719	0.679	rs1133001	chr21:38512956	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-4.72	-0.44	8.18e-6	Eye color traits;
THYM	cis	rs6754311	0.550	rs12994270	chr2:136518103	T/A	cg23851026	chr2:136556271	LCT	-0.57	-5.96	-0.52	4.29e-8	Mosquito bite size;
THYM	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg06453172	chr10:134556979	INPP5A	-0.64	-4.53	-0.42	1.69e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17712092	chr4:129076599	LARP1B	0.9	7.57	0.61	2.39e-11	Eosinophil percentage of white cells;
THYM	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg07884673	chr3:53033167	SFMBT1	1.25	6.34	0.55	7.83e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2273669	0.667	rs114481082	chr6:109280932	G/A	cg17117243	chr6:109341365	SESN1	-0.85	-4.84	-0.44	5.02e-6	Prostate cancer;
THYM	cis	rs870825	0.550	rs28525282	chr4:185631468	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs1198430	0.562	rs10917384	chr1:23798312	C/A	cg19827787	chr1:23763612	ASAP3	0.59	4.82	0.44	5.47e-6	Total cholesterol levels;
THYM	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg13877915	chr19:58951672	ZNF132	0.97	9.56	0.7	1.43e-15	Uric acid clearance;
THYM	cis	rs7172809	0.897	rs16968895	chr15:77825121	A/G	cg22256960	chr15:77711686	NA	-0.67	-4.61	-0.43	1.27e-5	Glucose homeostasis traits;
THYM	cis	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg13789015	chr9:136890014	NCRNA00094	0.82	6.9	0.58	5.69e-10	Platelet distribution width;
THYM	cis	rs988913	0.706	rs12664361	chr6:54910962	A/G	cg18532076	chr6:54711417	FAM83B	-0.51	-4.65	-0.43	1.08e-5	Menarche (age at onset);
THYM	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg00012203	chr2:219082015	ARPC2	-0.88	-8.84	-0.67	4.87e-14	Colorectal cancer;
THYM	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg03806693	chr22:41940476	POLR3H	1.16	10.2	0.72	6.06e-17	Vitiligo;
THYM	cis	rs7646881	0.504	rs4264773	chr3:158463225	G/T	cg18349298	chr3:158450550	RARRES1	0.54	4.77	0.44	6.75e-6	Tetralogy of Fallot;
THYM	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg14983838	chr19:29218262	NA	1.09	9.77	0.71	5e-16	Methadone dose in opioid dependence;
THYM	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs7119	0.604	rs939488	chr15:77867780	T/C	cg27398640	chr15:77910606	LINGO1	0.65	7.4	0.6	5.45e-11	Type 2 diabetes;
THYM	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg06108461	chr20:60628389	TAF4	-0.81	-6.62	-0.56	2.08e-9	Body mass index;
THYM	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg13397359	chr6:42928475	GNMT	0.61	5.56	0.5	2.48e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs611744	0.934	rs624311	chr8:109204437	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.28	-5.88	-0.52	6.18e-8	Obesity-related traits;
THYM	cis	rs7078219	0.714	rs60386053	chr10:101288861	G/A	cg23904955	chr10:101282759	NA	-0.42	-4.97	-0.45	2.99e-6	Dental caries;
THYM	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg00677455	chr12:58241039	CTDSP2	0.83	6.59	0.56	2.48e-9	Multiple sclerosis;
THYM	cis	rs8014204	0.773	rs2241275	chr14:75251440	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.58	-5.67	-0.5	1.53e-7	Caffeine consumption;
THYM	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg16405210	chr4:1374714	KIAA1530	-0.85	-7.25	-0.6	1.12e-10	Longevity;
THYM	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg22709100	chr7:91322751	NA	0.63	4.86	0.45	4.55e-6	Breast cancer;
THYM	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg16524936	chr4:1340807	KIAA1530	-0.6	-4.61	-0.43	1.24e-5	Longevity;
THYM	cis	rs6430585	0.583	rs3769008	chr2:136586183	C/T	cg07169764	chr2:136633963	MCM6	1.2	14.22	0.82	2.98e-25	Corneal structure;
THYM	cis	rs4660261	0.526	rs2485996	chr1:44354661	C/T	cg12908607	chr1:44402522	ARTN	-0.56	-4.88	-0.45	4.22e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg21433313	chr16:3507492	NAT15	0.72	5.44	0.49	4.11e-7	Tuberculosis;
THYM	cis	rs2835345	0.596	rs2409817	chr21:37827708	C/T	cg20643029	chr21:37915044	CLDN14	0.67	5.58	0.5	2.25e-7	Pulmonary function;
THYM	cis	rs9912789	0.744	rs9893755	chr17:79187432	C/T	cg16636204	chr17:79701561	NA	-0.42	-4.55	-0.42	1.62e-5	Frontotemporal dementia;
THYM	cis	rs7072216	0.763	rs3750601	chr10:100174561	C/A	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg24308560	chr3:49941425	MST1R	0.79	6.77	0.57	1.06e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg24154853	chr7:158122151	PTPRN2	-0.52	-4.74	-0.44	7.62e-6	Calcium levels;
THYM	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg00129232	chr17:37814104	STARD3	-0.96	-7.56	-0.61	2.57e-11	Asthma;
THYM	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22433210	chr17:43662623	NA	0.87	7.03	0.58	3.2e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6543140	0.929	rs6742530	chr2:103082280	G/A	cg03938978	chr2:103052716	IL18RAP	0.6	5.78	0.51	9.35e-8	Blood protein levels;
THYM	cis	rs7106204	0.514	rs12789549	chr11:24254726	C/G	ch.11.24196551F	chr11:24239977	NA	1.04	7.24	0.6	1.15e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs3773445	0.934	rs1631354	chr3:25619920	C/G	cg02315353	chr3:25825455	NGLY1	0.62	5.5	0.49	3.23e-7	Airway responsiveness in chronic obstructive pulmonary disease;
THYM	cis	rs889398	0.741	rs11075744	chr16:69909115	G/A	cg09409435	chr16:70099608	PDXDC2	0.61	4.91	0.45	3.81e-6	Body mass index;
THYM	cis	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.87	-7.37	-0.6	6.37e-11	Primary sclerosing cholangitis;
THYM	cis	rs12579753	0.917	rs76240969	chr12:82195236	C/A	cg21231944	chr12:82153410	PPFIA2	-0.66	-5.01	-0.46	2.51e-6	Resting heart rate;
THYM	cis	rs1372520	0.684	rs2737010	chr4:90746466	G/A	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs6750795	0.602	rs1667317	chr2:232412036	T/C	cg19187155	chr2:232395269	NMUR1	0.84	5.5	0.49	3.24e-7	Height;
THYM	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.65	-4.71	-0.44	8.31e-6	Colorectal cancer;
THYM	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg17074396	chr22:49843754	NA	-0.39	-4.61	-0.43	1.27e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg00271210	chr6:167070053	RPS6KA2	0.55	5.43	0.49	4.36e-7	Crohn's disease;
THYM	cis	rs4731207	0.596	rs6466989	chr7:124690963	A/G	cg05285228	chr7:124571219	POT1	-0.65	-5.0	-0.46	2.64e-6	Cutaneous malignant melanoma;
THYM	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg24257776	chr3:47051546	LOC100129354	0.41	4.69	0.43	9.15e-6	Colorectal cancer;
THYM	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10791097	0.967	rs1944142	chr11:130717440	C/T	cg05962950	chr11:130786565	SNX19	0.68	5.39	0.48	5.15e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg24642844	chr7:1081250	C7orf50	-1.05	-5.84	-0.51	7.35e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg26446133	chr18:72167187	CNDP2	-0.94	-8.07	-0.64	2.16e-12	Refractive error;
THYM	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.99	10.22	0.72	5.6e-17	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.583	rs7207043	chr17:17819188	A/G	cg16928487	chr17:17741425	SREBF1	-0.57	-5.63	-0.5	1.79e-7	Total body bone mineral density;
THYM	cis	rs3772130	1.000	rs17691170	chr3:121357626	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.74	4.48	0.42	2.12e-5	Cognitive performance;
THYM	cis	rs7523273	0.597	rs2796265	chr1:207920788	A/G	cg22525895	chr1:207977042	MIR29B2	-0.74	-4.83	-0.44	5.31e-6	Schizophrenia;
THYM	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg12310025	chr6:25882481	NA	0.93	8.59	0.66	1.68e-13	Blood metabolite levels;
THYM	cis	rs7772486	0.754	rs9390358	chr6:146145678	C/T	cg23711669	chr6:146136114	FBXO30	0.9	9.26	0.69	6.45e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs748404	0.660	rs689767	chr15:43722077	G/C	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg05182265	chr7:156933206	UBE3C	-0.69	-9.34	-0.69	4.32e-15	Body mass index;
THYM	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg03709012	chr19:19516395	GATAD2A	-0.74	-5.8	-0.51	8.48e-8	Tonsillectomy;
THYM	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.87	8.11	0.64	1.79e-12	Menarche (age at onset);
THYM	cis	rs2075230	1.000	rs2075230	chr17:7487108	A/G	cg10509001	chr17:7553872	ATP1B2	0.56	4.74	0.44	7.47e-6	Hormone measurements;
THYM	cis	rs16866061	1.000	rs11681451	chr2:225334104	T/C	cg22455342	chr2:225449267	CUL3	0.68	4.88	0.45	4.23e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg08439880	chr3:133502540	NA	-0.71	-6.05	-0.53	2.86e-8	Iron status biomarkers;
THYM	cis	rs4280164	0.551	rs882726	chr14:24797997	C/A	cg18846074	chr14:24801073	ADCY4	-0.6	-4.74	-0.44	7.53e-6	Parent of origin effect on language impairment (paternal);
THYM	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1784581	0.651	rs1784593	chr6:162386096	A/T	cg17173639	chr6:162384350	PARK2	-0.84	-7.88	-0.63	5.43e-12	Itch intensity from mosquito bite;
THYM	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg06009448	chr7:1102226	C7orf50	0.53	5.55	0.49	2.6e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2276314	0.857	rs6507158	chr18:33636066	A/C	cg05985134	chr18:33552581	C18orf21	0.66	4.84	0.44	5.02e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	trans	rs2540647	0.561	rs2518802	chr22:18975345	A/C	cg19521646	chr19:15197788	OR1I1	1.02	6.88	0.58	6.37e-10	Blood metabolite ratios;
THYM	cis	rs2505998	1.000	rs2506006	chr10:43581501	A/G	cg06632098	chr10:43605906	RET	-1.03	-9.18	-0.69	9.4e-15	Hirschsprung disease;
THYM	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6066825	0.627	rs6019349	chr20:47275245	A/G	cg18078177	chr20:47281410	PREX1	0.54	4.53	0.42	1.7e-5	Colorectal cancer;
THYM	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.75	-4.53	-0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs6867032	1.000	rs7729761	chr5:2015783	G/T	cg26168224	chr5:2018326	NA	1.29	15.56	0.85	7.19e-28	Gut microbiome composition (winter);
THYM	cis	rs761746	0.882	rs4820978	chr22:31912119	G/A	cg10537193	chr22:32026975	PISD	0.4	5.17	0.47	1.3e-6	Intelligence;
THYM	cis	rs2976388	0.609	rs2572907	chr8:143801938	G/A	cg06565975	chr8:143823917	SLURP1	0.45	4.97	0.45	2.99e-6	Urinary tract infection frequency;
THYM	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg02640540	chr1:67518911	SLC35D1	-0.64	-4.68	-0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg06387496	chr7:2775674	GNA12	-0.44	-4.64	-0.43	1.1e-5	Height;
THYM	cis	rs4919694	1.000	rs12245779	chr10:104645944	C/A	cg04362960	chr10:104952993	NT5C2	1.14	7.07	0.59	2.65e-10	Arsenic metabolism;
THYM	cis	rs9916302	0.706	rs8067511	chr17:37611352	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-5.35	-0.48	6.06e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.09	0.64	1.91e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg11663144	chr21:46675770	NA	-0.7	-9.65	-0.7	9.43e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg06074448	chr4:187884817	NA	-0.99	-12.8	-0.8	2.14e-22	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1008375	0.646	rs13103430	chr4:17567355	A/C	cg18681998	chr4:17616180	MED28	-0.75	-6.17	-0.53	1.65e-8	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-7.08	-0.59	2.42e-10	Chronic sinus infection;
THYM	cis	rs9515201	0.748	rs9583489	chr13:111032833	C/T	cg15455643	chr13:111040242	COL4A2	0.47	5.43	0.49	4.4e-7	White matter hyperintensity burden;
THYM	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg17775962	chr7:1200435	ZFAND2A	0.39	4.56	0.42	1.55e-5	Longevity;Endometriosis;
THYM	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg10360139	chr7:1886902	MAD1L1	-0.63	-5.22	-0.47	1.06e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs782590	0.643	rs13032503	chr2:55739093	C/T	cg03859395	chr2:55845619	SMEK2	-0.51	-4.79	-0.44	6.12e-6	Metabolic syndrome;
THYM	cis	rs7926906	1.000	rs10734138	chr11:90538063	A/C	cg26138821	chr11:89956704	CHORDC1	-0.57	-5.2	-0.47	1.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4595586	0.525	rs11613788	chr12:39390710	T/C	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs10256972	0.642	rs6961424	chr7:1004113	T/C	cg08883853	chr7:1026168	CYP2W1	-0.48	-4.96	-0.45	3.12e-6	Longevity;Endometriosis;
THYM	cis	rs11640436	0.565	rs12926676	chr16:77309505	G/T	cg06128999	chr16:77247126	NA	-0.39	-4.76	-0.44	6.84e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs981844	0.775	rs17371336	chr4:154749525	A/G	cg09973105	chr4:154681532	RNF175	-0.62	-5.1	-0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs870825	0.616	rs6552808	chr4:185642865	G/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg19507638	chr5:93509721	C5orf36	-0.68	-4.6	-0.43	1.28e-5	Diabetic retinopathy;
THYM	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg12698349	chr2:225449008	CUL3	0.73	5.47	0.49	3.64e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs3125734	0.660	rs4979780	chr10:63992740	A/C	cg09941381	chr10:64027924	RTKN2	-0.55	-4.56	-0.42	1.51e-5	Rheumatoid arthritis;
THYM	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg23602478	chr1:26503979	CNKSR1	0.36	4.97	0.45	2.96e-6	Height;
THYM	cis	rs9290065	0.519	rs2376475	chr3:160708942	C/T	cg03342759	chr3:160939853	NMD3	-0.59	-4.56	-0.42	1.52e-5	Kawasaki disease;
THYM	cis	rs926938	0.618	rs3121506	chr1:115363207	T/G	cg12756093	chr1:115239321	AMPD1	0.61	4.93	0.45	3.5e-6	Autism;
THYM	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	5.57	0.5	2.39e-7	Monocyte percentage of white cells;
THYM	cis	rs9381107	0.585	rs7756121	chr6:9442422	A/G	cg27283345	chr6:10416531	TFAP2A	-0.45	-4.67	-0.43	9.85e-6	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs6032067	0.714	rs6032076	chr20:43887682	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.58	-6.45	-0.55	4.75e-9	Blood protein levels;
THYM	trans	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg06636001	chr8:8085503	FLJ10661	0.76	6.84	0.57	7.63e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg25767906	chr1:53392781	SCP2	-0.49	-4.74	-0.44	7.63e-6	Monocyte count;
THYM	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00290607	chr11:67383545	NA	0.99	8.94	0.68	3.09e-14	Mean corpuscular volume;
THYM	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg26038318	chr20:34205095	SPAG4	0.59	4.68	0.43	9.62e-6	Total cholesterol levels;
THYM	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs6543140	0.964	rs6736135	chr2:103064924	A/G	cg03938978	chr2:103052716	IL18RAP	0.61	6.06	0.53	2.71e-8	Blood protein levels;
THYM	cis	rs6732160	0.691	rs7599223	chr2:73427103	A/G	cg24220031	chr2:73402428	NA	-0.79	-9.35	-0.69	3.98e-15	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg16928487	chr17:17741425	SREBF1	0.52	5.12	0.47	1.59e-6	Total body bone mineral density;
THYM	cis	rs7302981	0.667	rs1362984	chr12:50599984	T/A	cg20014596	chr12:50898483	DIP2B	-0.53	-4.79	-0.44	6.23e-6	Systolic blood pressure;
THYM	cis	rs9914988	0.943	rs9893782	chr17:27108132	C/T	cg20469991	chr17:27169893	C17orf63	-0.77	-4.59	-0.43	1.33e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs10489202	0.955	rs17557162	chr1:167985950	A/T	cg24449463	chr1:168025552	DCAF6	0.77	5.94	0.52	4.7e-8	Schizophrenia;
THYM	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg18825531	chr11:62321136	NA	-0.45	-5.11	-0.46	1.63e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg06002616	chr8:101225028	SPAG1	-0.46	-4.79	-0.44	6.22e-6	Atrioventricular conduction;
THYM	cis	rs6539288	0.705	rs1053051	chr12:107367225	T/C	cg26297688	chr12:107349093	C12orf23	-0.45	-4.76	-0.44	6.91e-6	Total body bone mineral density;
THYM	cis	rs13102973	0.640	rs11722290	chr4:135832268	C/T	cg14419869	chr4:135874104	NA	0.7	5.72	0.51	1.26e-7	Subjective well-being;
THYM	cis	rs1079204	1.000	rs13423003	chr2:219111341	G/C	cg05728596	chr2:219128475	GPBAR1	1.24	5.71	0.51	1.28e-7	Smooth-surface caries;
THYM	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg04398451	chr17:18023971	MYO15A	-0.95	-9.84	-0.71	3.63e-16	Total body bone mineral density;
THYM	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg25182066	chr10:30743637	MAP3K8	-0.54	-4.68	-0.43	9.53e-6	Inflammatory bowel disease;
THYM	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg25072359	chr17:41440525	NA	0.65	4.54	0.42	1.64e-5	Menopause (age at onset);
THYM	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg12863693	chr15:85201151	NMB	0.54	4.81	0.44	5.59e-6	Schizophrenia;
THYM	cis	rs1994135	0.647	rs1351681	chr12:33698724	G/A	cg10856724	chr12:34555212	NA	-0.74	-5.54	-0.49	2.74e-7	Resting heart rate;
THYM	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg08975724	chr8:8085496	FLJ10661	-0.67	-5.2	-0.47	1.16e-6	Neuroticism;
THYM	cis	rs7364180	0.515	rs6002503	chr22:42208672	A/G	cg13695892	chr22:41940480	POLR3H	-0.63	-5.09	-0.46	1.82e-6	Alzheimer's disease biomarkers;
THYM	cis	rs10911251	0.508	rs6424890	chr1:183112764	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.66	0.43	1.02e-5	Colorectal cancer;
THYM	cis	rs3812049	0.737	rs790154	chr5:127501235	A/G	cg05443326	chr5:126853169	PRRC1	-0.66	-4.54	-0.42	1.66e-5	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg23428387	chr22:49814324	NA	-0.57	-6.02	-0.53	3.28e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg09877947	chr5:131593287	PDLIM4	0.6	5.13	0.47	1.53e-6	Breast cancer;
THYM	cis	rs4953076	0.573	rs2054005	chr2:44401843	C/T	cg04920474	chr2:44395004	PPM1B	0.63	5.27	0.48	8.46e-7	Height;
THYM	cis	rs4455778	0.580	rs4541847	chr7:49109824	C/G	cg26309511	chr7:48887640	NA	-0.62	-5.7	-0.5	1.34e-7	Lung cancer in never smokers;
THYM	cis	rs4589258	0.933	rs35622960	chr11:90413653	G/C	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs977987	0.843	rs12443904	chr16:75438770	C/T	cg03315344	chr16:75512273	CHST6	0.77	6.43	0.55	5.19e-9	Dupuytren's disease;
THYM	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs10979	1.000	rs13197332	chr6:143888095	T/A	cg25407410	chr6:143891975	LOC285740	-0.63	-5.16	-0.47	1.36e-6	Hypospadias;
THYM	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg09704166	chr2:114031854	PAX8;LOC440839	-0.68	-5.66	-0.5	1.63e-7	Lymphocyte counts;
THYM	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs9677476	0.863	rs10202295	chr2:232084411	T/G	cg23338755	chr2:231921595	PSMD1	0.71	5.4	0.48	4.93e-7	Food antigen IgG levels;
THYM	cis	rs4866334	1.000	rs76355495	chr5:18487262	G/A	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg06784218	chr1:46089804	CCDC17	-0.3	-4.61	-0.43	1.28e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs4930103	0.935	rs11042167	chr11:2020901	G/A	cg18511798	chr11:2018149	H19;MIR675	-0.57	-5.57	-0.5	2.32e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs1065656	0.581	rs2575351	chr16:1836709	G/C	cg14074117	chr16:1909714	C16orf73	0.6	4.64	0.43	1.12e-5	Insulin-like growth factors;
THYM	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg16624210	chr5:671434	TPPP	0.76	5.61	0.5	2.03e-7	Obesity-related traits;
THYM	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03452623	chr4:187889614	NA	-1.19	-19.33	-0.89	1.1e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg03388043	chr17:80084554	CCDC57	-0.73	-6.06	-0.53	2.74e-8	Life satisfaction;
THYM	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg18105134	chr13:113819100	PROZ	-0.98	-9.05	-0.68	1.79e-14	Platelet distribution width;
THYM	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg08885076	chr2:99613938	TSGA10	-0.78	-6.9	-0.58	5.75e-10	Chronic sinus infection;
THYM	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg08999081	chr20:33150536	PIGU	0.79	7.16	0.59	1.72e-10	Coronary artery disease;
THYM	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg06728252	chr6:26598149	ABT1	-0.43	-5.08	-0.46	1.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4478037	1.000	rs59622575	chr3:33162249	A/C	cg19404215	chr3:33155277	CRTAP	1.18	8.15	0.64	1.49e-12	Major depressive disorder;
THYM	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg06766960	chr11:133703094	NA	-0.59	-5.56	-0.5	2.51e-7	Childhood ear infection;
THYM	cis	rs2046867	0.908	rs62251655	chr3:72821708	T/C	cg25664220	chr3:72788482	NA	-0.86	-6.56	-0.56	2.76e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs11563648	0.500	rs4728068	chr7:127021822	C/T	cg23081781	chr7:127225937	GCC1	-0.34	-4.64	-0.43	1.14e-5	Resting heart rate;
THYM	cis	rs1003719	0.788	rs9977314	chr21:38471963	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.67	4.61	0.43	1.25e-5	Eye color traits;
THYM	cis	rs17253792	0.545	rs12893676	chr14:56016159	G/A	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs34375054	0.660	rs900411	chr12:125612839	C/T	cg25124228	chr12:125621409	AACS	-0.75	-5.66	-0.5	1.59e-7	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-5.53	-0.49	2.8e-7	Morning vs. evening chronotype;
THYM	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.67	-5.26	-0.47	8.97e-7	Lung cancer in ever smokers;
THYM	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg11984989	chr7:158649758	WDR60	-1.02	-13.27	-0.81	2.39e-23	Height;
THYM	cis	rs1823778	0.609	rs11151559	chr18:67705420	A/G	cg13164537	chr18:67624071	CD226	1.11	4.94	0.45	3.28e-6	Mean platelet volume;
THYM	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11890956	chr21:40555474	PSMG1	-0.9	-9.57	-0.7	1.4e-15	Cognitive function;
THYM	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg06481639	chr22:41940642	POLR3H	0.84	5.85	0.51	6.94e-8	Vitiligo;
THYM	cis	rs7631605	0.905	rs4678944	chr3:37214685	C/T	cg21328643	chr3:37258149	NA	-0.47	-4.5	-0.42	1.9e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs10979	0.928	rs9496676	chr6:143895610	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-5.04	-0.46	2.22e-6	Hypospadias;
THYM	cis	rs6438424	1.000	rs10934420	chr3:117552111	A/G	cg07190778	chr3:117604296	NA	-0.36	-5.13	-0.47	1.53e-6	Menarche (age at onset);
THYM	cis	rs12956009	0.583	rs4331415	chr18:44885048	C/T	cg19077165	chr18:44547161	KATNAL2	-0.51	-4.89	-0.45	4.04e-6	Educational attainment (years of education);
THYM	cis	rs4343996	0.651	rs1357311	chr7:3505935	G/A	cg21248987	chr7:3385318	SDK1	0.4	4.82	0.44	5.39e-6	Motion sickness;
THYM	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg15691649	chr6:25882328	NA	-0.68	-5.13	-0.47	1.51e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg12011299	chr4:100065546	ADH4	0.75	7.3	0.6	8.58e-11	Alcohol dependence;
THYM	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg19747945	chr6:42946146	PEX6	-0.34	-5.08	-0.46	1.86e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg24209194	chr3:40518798	ZNF619	-0.73	-6.31	-0.54	8.87e-9	Renal cell carcinoma;
THYM	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg14779329	chr11:130786720	SNX19	0.53	5.71	0.51	1.28e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.16	9.2	0.69	8.54e-15	Cognitive test performance;
THYM	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg22920501	chr2:26401640	FAM59B	-0.83	-7.3	-0.6	8.69e-11	Gut microbiome composition (summer);
THYM	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs912057	0.833	rs1294418	chr6:6742185	A/G	cg13809441	chr6:6737631	NA	0.43	4.86	0.45	4.62e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs988913	1.000	rs9367601	chr6:54839162	G/T	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.75e-6	Menarche (age at onset);
THYM	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	8.81	0.67	5.71e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4845875	0.626	rs7538516	chr1:11836682	C/T	cg25341925	chr1:11908058	NPPA	0.42	4.49	0.42	1.99e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg10802521	chr3:52805072	NEK4	0.73	6.55	0.56	2.9e-9	Bipolar disorder;
THYM	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg22709100	chr7:91322751	NA	0.7	5.5	0.49	3.23e-7	Breast cancer;
THYM	cis	rs72627123	1.000	rs72627138	chr14:74401900	G/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs12367572	0.965	rs10880696	chr12:45234989	A/G	cg03114573	chr12:45410052	DBX2	0.54	5.12	0.47	1.59e-6	Gut microbiome composition (summer);
THYM	cis	rs6430585	0.528	rs309154	chr2:136726567	C/T	cg04750100	chr2:136595281	LCT	0.53	4.84	0.45	4.93e-6	Corneal structure;
THYM	cis	rs4654899	0.758	rs6668370	chr1:21369568	C/T	cg01072550	chr1:21505969	NA	-0.75	-7.17	-0.59	1.64e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg05340094	chr16:73095395	NA	0.69	5.25	0.47	9.45e-7	Energy expenditure (24h);
THYM	cis	rs2076222	1.000	rs2076350	chr1:209800341	C/T	cg00257659	chr1:209800214	LAMB3	-1.03	-4.57	-0.42	1.49e-5	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
THYM	cis	rs79149102	0.579	rs58294763	chr15:75299768	G/A	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg18357526	chr6:26021779	HIST1H4A	-0.59	-4.55	-0.42	1.61e-5	Blood metabolite levels;
THYM	cis	rs1062746	0.683	rs891094	chr16:87378001	C/G	cg27119004	chr16:87376851	FBXO31	-0.49	-5.08	-0.46	1.89e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs863345	0.604	rs6674656	chr1:158495431	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs4481887	1.000	rs10736378	chr1:248455769	T/G	cg13385794	chr1:248469461	NA	0.67	4.58	0.43	1.4e-5	Common traits (Other);
THYM	cis	rs36051895	0.659	rs11999076	chr9:5037694	C/T	cg02405213	chr9:5042618	JAK2	-1.03	-10.77	-0.74	3.78e-18	Pediatric autoimmune diseases;
THYM	cis	rs6547741	0.967	rs4665996	chr2:27814343	T/C	cg27432699	chr2:27873401	GPN1	0.68	5.97	0.52	4.14e-8	Oral cavity cancer;
THYM	cis	rs12956009	0.518	rs1560902	chr18:44898765	T/C	cg19077165	chr18:44547161	KATNAL2	-0.51	-4.93	-0.45	3.51e-6	Educational attainment (years of education);
THYM	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.68	-5.94	-0.52	4.77e-8	Calcium levels;
THYM	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs6754311	0.597	rs6760329	chr2:136544752	A/G	cg07169764	chr2:136633963	MCM6	-0.71	-6.02	-0.53	3.2e-8	Mosquito bite size;
THYM	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg10802521	chr3:52805072	NEK4	-0.71	-6.15	-0.53	1.83e-8	Bipolar disorder;
THYM	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg26545918	chr15:68124484	LBXCOR1	0.54	4.62	0.43	1.2e-5	Restless legs syndrome;
THYM	cis	rs9549260	0.755	rs7338669	chr13:41200091	C/T	cg21288729	chr13:41239152	FOXO1	-0.72	-5.55	-0.49	2.61e-7	Red blood cell count;
THYM	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg00078996	chr12:132293329	NA	-0.61	-5.36	-0.48	5.84e-7	Migraine;
THYM	cis	rs72827839	0.846	rs113187178	chr17:46117471	G/A	cg23391107	chr17:45924227	SP6	0.79	5.42	0.49	4.55e-7	Ease of getting up in the morning;
THYM	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg02070205	chr10:30722105	MAP3K8	0.64	5.68	0.5	1.45e-7	Inflammatory bowel disease;
THYM	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7084402	0.967	rs1303968	chr10:60298941	G/A	cg07615347	chr10:60278583	BICC1	0.57	5.36	0.48	5.86e-7	Refractive error;
THYM	cis	rs7246967	0.673	rs4932784	chr19:22874251	A/C	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs2637266	0.846	rs2637261	chr10:78320593	A/G	cg18941641	chr10:78392320	NA	-0.69	-5.84	-0.51	7.23e-8	Pulmonary function;
THYM	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg07169764	chr2:136633963	MCM6	-0.68	-6.23	-0.54	1.25e-8	Mosquito bite size;
THYM	cis	rs593982	0.920	rs76925283	chr11:65548108	C/T	cg08755490	chr11:65554678	OVOL1	-1.44	-7.91	-0.63	4.57e-12	Atopic dermatitis;
THYM	cis	rs6032067	0.777	rs34916007	chr20:43782952	T/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg25036284	chr2:26402008	FAM59B	-0.76	-5.03	-0.46	2.34e-6	Gut microbiome composition (summer);
THYM	cis	rs7113850	0.541	rs78737372	chr11:24233984	G/A	ch.11.24196551F	chr11:24239977	NA	0.98	5.14	0.47	1.49e-6	Bone fracture in osteoporosis;
THYM	cis	rs7668190	0.924	rs28622224	chr4:55088093	C/T	cg17187183	chr4:55093834	PDGFRA	0.59	4.56	0.42	1.5e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-5.53	-0.49	2.81e-7	Prostate cancer;
THYM	cis	rs295140	0.605	rs296818	chr2:201176944	C/T	cg23649088	chr2:200775458	C2orf69	0.61	5.01	0.46	2.53e-6	QT interval;
THYM	cis	rs308403	0.600	rs376131	chr4:123629225	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.67	5.0	0.46	2.62e-6	Blood protein levels;
THYM	cis	rs6558530	0.730	rs7014327	chr8:1724052	C/T	cg09410841	chr8:1729607	CLN8	0.78	6.01	0.53	3.36e-8	Systolic blood pressure;
THYM	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg26818010	chr10:134567672	INPP5A	-0.89	-7.01	-0.58	3.4e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7267979	1.000	rs6050609	chr20:25411751	A/G	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg04398451	chr17:18023971	MYO15A	0.8	7.75	0.62	1.02e-11	Total body bone mineral density;
THYM	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs4938330	0.680	rs4938329	chr11:116928112	C/T	cg20608306	chr11:116969690	SIK3	-0.54	-6.01	-0.52	3.45e-8	Blood protein levels;
THYM	cis	rs1448094	0.511	rs59858864	chr12:86166404	G/A	cg02569458	chr12:86230093	RASSF9	0.69	5.77	0.51	9.84e-8	Major depressive disorder;
THYM	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg20503657	chr10:835505	NA	1.34	8.98	0.68	2.55e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg08999081	chr20:33150536	PIGU	0.75	6.5	0.55	3.72e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs7851660	0.967	rs12348304	chr9:100611233	T/C	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.89	8.39	0.65	4.48e-13	Menarche (age at onset);
THYM	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.62	-4.82	-0.44	5.43e-6	Blood metabolite levels;
THYM	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg11871910	chr12:69753446	YEATS4	1.06	9.8	0.71	4.32e-16	Blood protein levels;
THYM	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg05182265	chr7:156933206	UBE3C	0.7	9.62	0.7	1.06e-15	Body mass index;
THYM	cis	rs17016200	0.513	rs73107711	chr3:78354683	C/T	cg24512093	chr3:78698151	ROBO1	0.95	5.0	0.46	2.64e-6	Facial emotion recognition;
THYM	cis	rs3820068	0.532	rs1547034	chr1:15919049	T/A	cg27534772	chr1:16042836	PLEKHM2	0.55	6.04	0.53	3.01e-8	Systolic blood pressure;
THYM	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg10018233	chr7:150070692	REPIN1	0.38	5.33	0.48	6.63e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.16	7.96	0.63	3.69e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg27572855	chr1:25598939	RHD	0.66	5.24	0.47	9.82e-7	Erythrocyte sedimentation rate;
THYM	cis	rs6163	0.540	rs11191385	chr10:104513049	G/T	cg15744005	chr10:104629667	AS3MT	-0.62	-4.87	-0.45	4.36e-6	Waist circumference;Hip circumference;
THYM	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.0	0.63	2.98e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg00376283	chr12:123451042	ABCB9	0.92	7.65	0.62	1.62e-11	Platelet count;
THYM	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg03476357	chr21:30257390	N6AMT1	-0.67	-5.02	-0.46	2.4e-6	Cognitive test performance;
THYM	cis	rs7173743	0.934	rs7168915	chr15:79128889	C/T	cg00540400	chr15:79124168	NA	0.55	5.65	0.5	1.67e-7	Coronary artery disease;
THYM	cis	rs524023	0.874	rs495130	chr11:64449307	C/T	cg19131476	chr11:64387923	NRXN2	-0.39	-5.54	-0.49	2.7e-7	Urate levels in obese individuals;
THYM	cis	rs12496230	0.953	rs12494775	chr3:66874105	A/G	cg04995300	chr3:66848608	NA	-1.03	-6.27	-0.54	1.04e-8	Type 2 diabetes;
THYM	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg09085632	chr11:111637200	PPP2R1B	1.11	11.16	0.75	5.56e-19	Primary sclerosing cholangitis;
THYM	cis	rs425535	0.757	rs352023	chr4:74797946	A/T	cg07868155	chr4:74864709	CXCL5	0.68	4.61	0.43	1.27e-5	Blood protein levels;
THYM	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg19901468	chr14:105411992	AHNAK2	-0.82	-6.74	-0.57	1.24e-9	Rheumatoid arthritis;
THYM	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.74	5.66	0.5	1.59e-7	Eosinophil percentage of white cells;
THYM	cis	rs55702914	0.652	rs12151726	chr2:198273591	C/T	cg00792783	chr2:198669748	PLCL1	0.69	4.82	0.44	5.46e-6	Major depression and alcohol dependence;
THYM	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg26441486	chr22:50317300	CRELD2	-0.42	-6.47	-0.55	4.34e-9	Schizophrenia;
THYM	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-6.42	-0.55	5.36e-9	Total body bone mineral density;
THYM	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg21226059	chr5:178986404	RUFY1	-0.65	-7.57	-0.61	2.36e-11	Lung cancer;
THYM	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg06219351	chr7:158114137	PTPRN2	-0.8	-7.12	-0.59	2.04e-10	Response to amphetamines;
THYM	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg24642439	chr20:33292090	TP53INP2	0.59	4.69	0.43	9.16e-6	Coronary artery disease;
THYM	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-5.96	-0.52	4.23e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs870825	0.616	rs55685500	chr4:185614810	G/A	cg04058563	chr4:185651563	MLF1IP	1.13	9.37	0.69	3.7e-15	Blood protein levels;
THYM	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs4563143	0.647	rs117946634	chr19:29256822	G/T	cg03161606	chr19:29218774	NA	0.94	8.06	0.64	2.27e-12	Methadone dose in opioid dependence;
THYM	cis	rs4523957	0.928	rs216201	chr17:2198800	C/T	cg16513277	chr17:2031491	SMG6	0.77	6.96	0.58	4.28e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs367615	0.506	rs2963013	chr5:108775811	C/T	cg17395555	chr5:108820864	NA	-0.65	-8.37	-0.65	4.86e-13	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg27454412	chr7:1067447	C7orf50	0.61	4.71	0.44	8.29e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg03676636	chr4:99064102	C4orf37	0.42	6.05	0.53	2.83e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-6.02	-0.53	3.27e-8	Prostate cancer;
THYM	cis	rs2229238	0.911	rs60368585	chr1:154509340	T/C	cg21262032	chr1:154437693	IL6R	-0.63	-5.65	-0.5	1.68e-7	Coronary heart disease;
THYM	cis	rs4789939	0.528	rs2377003	chr17:76878902	T/C	cg19944656	chr17:76876040	TIMP2	-1.3	-7.67	-0.62	1.47e-11	Dupuytren's disease;
THYM	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg06112835	chr11:68658793	MRPL21	0.42	6.19	0.54	1.54e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs10979	1.000	rs6570565	chr6:143899531	C/T	cg25407410	chr6:143891975	LOC285740	-0.6	-4.75	-0.44	7.32e-6	Hypospadias;
THYM	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	4.66	0.43	1.04e-5	Diabetic retinopathy;
THYM	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	trans	rs2075230	0.705	rs1641521	chr17:7550143	T/C	cg04140212	chr2:85829138	TMEM150A	-0.57	-6.87	-0.58	6.7e-10	Hormone measurements;
THYM	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg24530246	chr3:53118167	NA	-0.83	-4.78	-0.44	6.39e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs490234	0.805	rs517064	chr9:128348486	C/T	cg14078157	chr9:128172775	NA	0.63	4.79	0.44	6.06e-6	Mean arterial pressure;
THYM	cis	rs67460515	0.892	rs34016896	chr3:160992864	C/T	cg03342759	chr3:160939853	NMD3	-0.91	-7.79	-0.62	8.5e-12	Parkinson's disease;
THYM	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs9915657	0.870	rs12600458	chr17:70130545	C/T	cg06234051	chr17:70120541	SOX9	-0.7	-6.59	-0.56	2.4e-9	Thyroid hormone levels;
THYM	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg23711669	chr6:146136114	FBXO30	0.96	9.87	0.71	3.12e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg15744005	chr10:104629667	AS3MT	-0.83	-7.67	-0.62	1.47e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4638749	1.000	rs2198463	chr2:108875093	T/A	cg06795125	chr2:108905320	SULT1C2	-0.41	-5.43	-0.49	4.29e-7	Blood pressure;
THYM	cis	rs7000551	0.646	rs2979302	chr8:22359156	G/A	cg12081754	chr8:22256438	SLC39A14	0.65	5.72	0.51	1.21e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg07700843	chr1:2391317	NA	-0.57	-4.5	-0.42	1.96e-5	Non-obstructive azoospermia;
THYM	cis	rs11039798	0.541	rs12283728	chr11:48796407	G/A	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs1829883	0.835	rs2461972	chr5:98776454	G/A	cg08333243	chr5:99726346	NA	-0.55	-5.05	-0.46	2.15e-6	Hemostatic factors and hematological phenotypes;
THYM	cis	rs2072499	0.868	rs2758600	chr1:156195205	C/T	cg25208724	chr1:156163844	SLC25A44	1.12	11.98	0.78	1.06e-20	Testicular germ cell tumor;
THYM	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg02887458	chr19:19495540	GATAD2A	-0.45	-4.89	-0.45	4.05e-6	Bipolar disorder;
THYM	cis	rs208520	0.955	rs208532	chr6:66961280	T/A	cg07460842	chr6:66804631	NA	-0.85	-5.48	-0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7940866	0.903	rs10791109	chr11:130850377	A/C	cg23692386	chr11:131799662	NTM	0.43	4.69	0.43	9.27e-6	Schizophrenia;
THYM	cis	rs6748734	0.625	rs6437372	chr2:241822406	A/G	cg09990169	chr2:241835740	C2orf54	0.31	5.13	0.47	1.55e-6	Urinary metabolites;
THYM	cis	rs2964802	0.505	rs7728436	chr5:10814464	T/A	cg14521931	chr5:10832172	NA	-0.64	-5.33	-0.48	6.66e-7	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs7106204	0.609	rs75559464	chr11:24285585	C/T	ch.11.24196551F	chr11:24239977	NA	0.94	4.87	0.45	4.53e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs116095464	1.000	rs55847527	chr5:317520	T/C	cg22857025	chr5:266934	NA	-1.37	-4.98	-0.46	2.8e-6	Breast cancer;
THYM	cis	rs7560272	0.723	rs780395	chr2:73700853	G/A	cg19565262	chr2:73869966	NAT8	0.56	4.75	0.44	7.11e-6	Schizophrenia;
THYM	cis	rs2249694	0.919	rs10857769	chr10:135405047	T/C	cg20169779	chr10:135381914	SYCE1	-0.54	-4.53	-0.42	1.69e-5	Obesity-related traits;
THYM	cis	rs742614	0.533	rs2092737	chr20:32428135	A/C	cg06304546	chr20:32448765	NA	-0.96	-10.23	-0.72	5.43e-17	Stearic acid (18:0) levels;
THYM	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7980799	0.649	rs11052732	chr12:33657801	A/G	cg06521331	chr12:34319734	NA	0.67	4.64	0.43	1.11e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs4803468	0.967	rs11083619	chr19:41913267	A/C	cg09537434	chr19:41945824	ATP5SL	-1.09	-10.13	-0.72	8.87e-17	Height;
THYM	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg17426766	chr1:2046864	PRKCZ	-0.39	-4.59	-0.43	1.36e-5	Height;
THYM	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg06558623	chr16:89946397	TCF25	1.27	5.06	0.46	2.05e-6	Skin colour saturation;
THYM	trans	rs4596713	0.536	rs10217168	chr9:71794956	A/G	cg16512924	chr15:28394682	HERC2	0.83	6.93	0.58	5.02e-10	Headache;
THYM	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg16325326	chr1:53192061	ZYG11B	0.8	6.9	0.58	5.68e-10	Monocyte count;
THYM	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	8.57	0.66	1.87e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs735396	0.770	rs1169301	chr12:121431300	C/T	cg02403541	chr12:121454288	C12orf43	0.82	7.15	0.59	1.74e-10	N-glycan levels;
THYM	cis	rs988913	1.000	rs9370342	chr6:54820670	C/A	cg18532076	chr6:54711417	FAM83B	0.51	5.03	0.46	2.34e-6	Menarche (age at onset);
THYM	cis	rs72829446	0.556	rs12936464	chr17:7403942	A/C	cg02795151	chr17:7402630	POLR2A	-0.58	-6.33	-0.54	8.23e-9	Androgen levels;
THYM	cis	rs75059851	0.756	rs7122746	chr11:133838808	A/G	cg14047540	chr11:133829660	NA	-1.06	-7.03	-0.58	3.14e-10	Schizophrenia;
THYM	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	4.55	0.42	1.6e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg19747945	chr6:42946146	PEX6	-0.35	-5.06	-0.46	2.08e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1371867	0.817	rs1788208	chr8:101312515	T/C	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs7772486	0.875	rs9403764	chr6:146360582	G/A	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7772486	0.754	rs4895682	chr6:146062861	G/A	cg13319975	chr6:146136371	FBXO30	0.65	5.26	0.48	8.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg00990874	chr7:1149470	C7orf50	-0.61	-4.82	-0.44	5.35e-6	Bronchopulmonary dysplasia;
THYM	cis	rs56104184	0.725	rs1466896	chr19:49385253	C/G	cg21252483	chr19:49399788	TULP2	-0.89	-6.27	-0.54	1.05e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg26384229	chr12:38710491	ALG10B	0.94	7.9	0.63	4.92e-12	Drug-induced liver injury (flucloxacillin);
THYM	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg20290983	chr6:43655470	MRPS18A	1.44	16.17	0.86	4.93e-29	IgG glycosylation;
THYM	cis	rs3947	1.000	rs1736082	chr8:11703420	C/T	cg26752888	chr8:11627280	NEIL2	-0.72	-4.66	-0.43	1.05e-5	Blood protein levels;
THYM	cis	rs2070488	1.000	rs13072809	chr3:38468171	G/A	cg24069376	chr3:38537580	EXOG	0.64	6.41	0.55	5.68e-9	Electrocardiographic conduction measures;
THYM	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg17054759	chr22:49844102	NA	-0.52	-4.93	-0.45	3.54e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg05738196	chr6:26577821	NA	0.91	9.17	0.69	9.98e-15	Intelligence (multi-trait analysis);
THYM	cis	rs1371867	0.875	rs1788187	chr8:101336099	A/G	cg06636551	chr8:101224915	SPAG1	-0.63	-6.33	-0.54	8.05e-9	Atrioventricular conduction;
THYM	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03517284	chr6:25882590	NA	-1.01	-9.24	-0.69	6.85e-15	Blood metabolite levels;
THYM	cis	rs741677	0.507	rs2075443	chr17:465775	G/A	cg15660573	chr17:549704	VPS53	0.77	5.44	0.49	4.1e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
THYM	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs9563576	0.778	rs4886049	chr13:58552575	A/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs2742234	0.590	rs2503864	chr10:43666767	G/T	cg06632098	chr10:43605906	RET	-0.79	-5.1	-0.46	1.73e-6	Hirschsprung disease;
THYM	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg22683308	chr4:1340831	KIAA1530	-0.59	-4.79	-0.44	6.05e-6	Longevity;
THYM	cis	rs28595532	0.920	rs115500312	chr4:119752551	G/A	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg13446199	chr8:143762866	PSCA	-0.41	-4.53	-0.42	1.7e-5	Urinary tract infection frequency;
THYM	cis	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.59	6.1	0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11890956	chr21:40555474	PSMG1	1.08	7.04	0.59	2.95e-10	Cognitive function;
THYM	cis	rs7178572	0.568	rs3743479	chr15:77406396	A/G	cg22256960	chr15:77711686	NA	0.94	7.36	0.6	6.41e-11	Type 2 diabetes;
THYM	cis	rs7200543	0.961	rs3803573	chr16:15138413	C/T	cg01933576	chr16:15083564	PDXDC1	-1.0	-8.09	-0.64	1.92e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs1843834	0.858	rs4674933	chr2:225514923	C/T	cg10193763	chr2:225306901	NA	-0.51	-5.01	-0.46	2.49e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg12311346	chr5:56204834	C5orf35	0.61	4.61	0.43	1.23e-5	Initial pursuit acceleration;
THYM	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg27279351	chr12:120934652	DYNLL1	0.96	8.75	0.67	7.6e-14	High light scatter reticulocyte count;
THYM	cis	rs6840360	0.571	rs4696278	chr4:152558978	A/G	cg22705602	chr4:152727874	NA	-0.76	-7.92	-0.63	4.35e-12	Intelligence (multi-trait analysis);
THYM	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg01324343	chr3:183735012	ABCC5	0.84	11.87	0.77	1.78e-20	Anterior chamber depth;
THYM	cis	rs8016982	0.674	rs11850714	chr14:81662993	C/G	cg21807262	chr14:81713016	NA	-0.57	-5.28	-0.48	8.05e-7	Schizophrenia;
THYM	cis	rs7968440	1.000	rs2731442	chr12:51054655	C/T	cg20014596	chr12:50898483	DIP2B	0.56	4.55	0.42	1.57e-5	Fibrinogen;
THYM	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg07537917	chr2:241836409	C2orf54	-0.26	-6.21	-0.54	1.41e-8	Urinary metabolites;
THYM	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs5995756	0.666	rs926231	chr22:40006986	C/G	cg21377881	chr22:40064566	CACNA1I	-0.58	-4.97	-0.45	3e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1797885	0.564	rs2596819	chr3:12600529	T/C	cg05467012	chr3:12595696	NA	0.54	4.56	0.42	1.53e-5	Immature fraction of reticulocytes;
THYM	cis	rs1050631	0.563	rs685042	chr18:33743998	A/G	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.61	4.73	0.44	7.88e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg13010199	chr12:38710504	ALG10B	0.74	5.91	0.52	5.32e-8	Heart rate;
THYM	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg27286337	chr10:134555280	INPP5A	0.94	6.97	0.58	4.24e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.92	-9.24	-0.69	7.05e-15	Chronic sinus infection;
THYM	cis	rs654384	0.545	rs4723418	chr7:4174701	C/T	cg04612959	chr7:4183976	SDK1	0.51	4.47	0.42	2.13e-5	Positive affect;
THYM	cis	rs9906944	0.707	rs4794020	chr17:47111399	C/T	cg18128536	chr17:47092178	IGF2BP1	-0.43	-4.71	-0.44	8.43e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.97	6.83	0.57	8.03e-10	Schizophrenia;
THYM	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg20503657	chr10:835505	NA	1.17	8.29	0.65	7.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg23711669	chr6:146136114	FBXO30	0.96	9.81	0.71	4.28e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2075230	0.642	rs1641513	chr17:7554242	T/C	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	-0.32	-4.49	-0.42	1.99e-5	Hormone measurements;
THYM	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg08859206	chr1:53392774	SCP2	-0.66	-7.59	-0.61	2.19e-11	Monocyte count;
THYM	cis	rs3126085	0.734	rs3120653	chr1:152284854	A/G	cg26020982	chr1:152196106	HRNR	-0.35	-4.95	-0.45	3.26e-6	Atopic dermatitis;
THYM	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg27170947	chr2:26402098	FAM59B	-0.86	-6.14	-0.53	1.94e-8	Gut microbiome composition (summer);
THYM	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg00271210	chr6:167070053	RPS6KA2	0.72	7.96	0.63	3.73e-12	Crohn's disease;
THYM	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg15298719	chr17:7165255	CLDN7	0.36	5.87	0.52	6.24e-8	Diastolic blood pressure;
THYM	cis	rs7191439	0.583	rs9935872	chr16:88788477	A/G	cg02389323	chr16:88786976	FAM38A	0.89	5.47	0.49	3.7e-7	Plateletcrit;
THYM	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg06618935	chr21:46677482	NA	-0.98	-9.58	-0.7	1.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg03690763	chr11:133734501	NA	-0.62	-4.8	-0.44	6.01e-6	Childhood ear infection;
THYM	cis	rs2882877	0.648	rs17198955	chr2:190387243	C/T	cg10752008	chr2:190445175	SLC40A1	-0.72	-6.1	-0.53	2.26e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs919433	0.519	rs700658	chr2:198655007	A/T	cg00792783	chr2:198669748	PLCL1	0.81	5.68	0.5	1.44e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg06634786	chr22:41940651	POLR3H	0.68	4.97	0.45	3.01e-6	Vitiligo;
THYM	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg19746536	chr19:49375674	PPP1R15A	0.81	4.45	0.42	2.35e-5	Red cell distribution width;
THYM	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs526231	0.584	rs246914	chr5:102559407	T/C	cg23492399	chr5:102201601	PAM	-0.7	-4.95	-0.45	3.2e-6	Primary biliary cholangitis;
THYM	cis	rs34638657	0.732	rs62045963	chr16:82200661	A/G	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.25	-0.47	9.14e-7	Lung adenocarcinoma;
THYM	cis	rs1448094	0.512	rs1349063	chr12:86264237	C/T	cg00310523	chr12:86230176	RASSF9	0.52	4.73	0.44	7.79e-6	Major depressive disorder;
THYM	trans	rs34156428	0.929	rs7101556	chr11:16503466	G/A	cg02688867	chr12:133019854	NA	0.54	6.89	0.58	6.12e-10	Coronary artery disease;
THYM	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg05347473	chr6:146136440	FBXO30	0.59	4.61	0.43	1.23e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.94	7.85	0.63	6.24e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19346786	chr7:2764209	NA	-0.7	-5.86	-0.52	6.63e-8	Height;
THYM	cis	rs600806	0.888	rs3879449	chr1:109904971	A/T	cg23032129	chr1:109941072	SORT1	-0.57	-4.83	-0.44	5.22e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1050631	0.564	rs1785929	chr18:33725165	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.67	5.46	0.49	3.79e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs7000551	0.715	rs2461478	chr8:22378236	A/G	cg12081754	chr8:22256438	SLC39A14	0.64	5.83	0.51	7.7e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9905704	0.918	rs12949138	chr17:56934865	A/C	cg12560992	chr17:57184187	TRIM37	0.68	4.71	0.44	8.42e-6	Testicular germ cell tumor;
THYM	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.94	-0.63	4.09e-12	Personality dimensions;
THYM	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg05802129	chr4:122689817	NA	-0.57	-4.47	-0.42	2.17e-5	Type 2 diabetes;
THYM	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg10560079	chr2:191398806	TMEM194B	-0.92	-6.63	-0.56	2.07e-9	Diastolic blood pressure;
THYM	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg00256281	chr22:41985642	PMM1	0.61	4.56	0.42	1.54e-5	Vitiligo;
THYM	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	trans	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg10856724	chr12:34555212	NA	-0.99	-8.42	-0.65	3.84e-13	Bladder cancer;
THYM	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg09314803	chr17:79180344	AZI1	-0.48	-4.57	-0.42	1.49e-5	Frontotemporal dementia;
THYM	cis	rs2916260	0.800	rs77243374	chr6:40394185	C/T	cg08415973	chr6:40346114	TDRG1	0.75	4.73	0.44	7.67e-6	Incident coronary heart disease;
THYM	cis	rs2350702	0.511	rs34515904	chr2:49955209	G/T	cg22592722	chr2:49566210	NA	-0.58	-4.53	-0.42	1.71e-5	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg06634786	chr22:41940651	POLR3H	0.73	5.36	0.48	5.89e-7	Vitiligo;
THYM	cis	rs714027	0.605	rs2412976	chr22:30567907	C/G	cg27665648	chr22:30112403	NA	0.52	4.73	0.44	7.79e-6	Lymphocyte counts;
THYM	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg00750074	chr16:89608354	SPG7	-0.48	-4.47	-0.42	2.13e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg17063962	chr7:91808500	NA	1.13	12.83	0.8	1.9e-22	Breast cancer;
THYM	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg04117972	chr1:227635322	NA	-0.77	-4.59	-0.43	1.35e-5	Major depressive disorder;
THYM	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg00908189	chr16:619842	PIGQ	0.95	8.27	0.65	8.13e-13	Height;
THYM	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg25358565	chr5:93447407	FAM172A	1.36	10.94	0.75	1.62e-18	Diabetic retinopathy;
THYM	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg00684032	chr4:1343700	KIAA1530	-0.68	-5.77	-0.51	1e-7	Obesity-related traits;
THYM	cis	rs7901181	0.673	rs74116145	chr10:3674152	C/T	cg14302214	chr10:3805273	NA	-0.84	-4.88	-0.45	4.32e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs17789174	0.903	rs12597107	chr16:85070381	G/T	cg01715842	chr16:85045600	ZDHHC7	-0.49	-4.59	-0.43	1.35e-5	Dysphagia;
THYM	cis	rs9311676	0.632	rs34086582	chr3:58419944	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs2933343	0.553	rs789212	chr3:128686912	A/C	cg11901034	chr3:128598214	ACAD9	-0.7	-5.1	-0.46	1.74e-6	IgG glycosylation;
THYM	cis	rs4478037	1.000	rs4074417	chr3:33161153	A/C	cg19404215	chr3:33155277	CRTAP	1.18	8.15	0.64	1.49e-12	Major depressive disorder;
THYM	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg22841779	chr14:105766346	BRF1	-0.46	-5.67	-0.5	1.53e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs757081	0.667	rs476890	chr11:17209962	A/G	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.6	-0.43	1.29e-5	Systolic blood pressure;
THYM	cis	rs79149102	0.579	rs12593476	chr15:75282092	A/C	cg17294928	chr15:75287854	SCAMP5	-1.04	-5.53	-0.49	2.75e-7	Lung cancer;
THYM	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg17971929	chr21:40555470	PSMG1	0.73	4.75	0.44	7.29e-6	Cognitive function;
THYM	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-5.08	-0.46	1.91e-6	Gut microbiome composition (summer);
THYM	cis	rs11096990	0.594	rs2381373	chr4:39282303	A/C	cg24403649	chr4:39172243	NA	-0.67	-5.84	-0.51	7.33e-8	Cognitive function;
THYM	trans	rs629535	0.773	rs681534	chr8:70056964	A/C	cg21567404	chr3:27674614	NA	1.09	10.87	0.74	2.35e-18	Dupuytren's disease;
THYM	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19346786	chr7:2764209	NA	-0.7	-5.86	-0.52	6.63e-8	Height;
THYM	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg27034606	chr17:28928453	LRRC37B2	0.66	4.48	0.42	2.09e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs11622475	0.626	rs34533310	chr14:104352233	C/T	cg12183467	chr14:104352244	NA	-0.71	-6.29	-0.54	9.8e-9	Bipolar disorder;
THYM	cis	rs4746818	1.000	rs10762263	chr10:70970178	A/G	cg11621586	chr10:70884670	VPS26A	1.3	10.35	0.73	2.89e-17	Left atrial antero-posterior diameter;
THYM	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg22535103	chr8:58192502	C8orf71	-0.93	-4.56	-0.42	1.52e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg22875332	chr1:76189707	ACADM	0.88	9.09	0.68	1.44e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6032067	0.516	rs6017530	chr20:43899731	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.59	-5.8	-0.51	8.81e-8	Blood protein levels;
THYM	cis	rs2463822	0.583	rs72919477	chr11:62042403	G/C	cg06239285	chr11:62104954	ASRGL1	-1.05	-5.24	-0.47	9.59e-7	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9828933	0.938	rs2578011	chr3:64004819	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.79	-4.99	-0.46	2.73e-6	Type 2 diabetes;
THYM	cis	rs12478296	1.000	rs73007129	chr2:243000555	T/C	cg06360820	chr2:242988706	NA	-1.2	-7.28	-0.6	9.42e-11	Obesity-related traits;
THYM	cis	rs2125062	0.691	rs4917726	chr10:97982786	T/C	cg07577957	chr10:98803188	SLIT1	0.58	4.47	0.42	2.16e-5	Colorectal adenoma (advanced);
THYM	cis	rs236907	0.859	rs17650340	chr1:171757921	A/T	cg20598894	chr1:171756153	METTL13	-0.74	-5.59	-0.5	2.16e-7	Mean platelet volume;
THYM	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs16866061	1.000	rs72974205	chr2:225408468	C/T	cg22455342	chr2:225449267	CUL3	0.68	4.9	0.45	3.87e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg27068330	chr11:65405492	SIPA1	1.04	9.99	0.72	1.78e-16	Acne (severe);
THYM	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg14024328	chr4:719362	PCGF3	-0.7	-4.6	-0.43	1.29e-5	White blood cell count;
THYM	cis	rs3741151	1.000	rs75109191	chr11:73023532	T/C	cg17517138	chr11:73019481	ARHGEF17	0.99	5.88	0.52	5.97e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7172677	0.961	rs34511319	chr15:75429717	A/C	cg09165964	chr15:75287851	SCAMP5	-0.63	-4.75	-0.44	7.24e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs4733781	0.871	rs62525923	chr8:131284632	C/T	cg16277922	chr8:131349729	ASAP1	0.64	4.69	0.43	9.2e-6	Tuberculosis;
THYM	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg09877947	chr5:131593287	PDLIM4	0.57	4.77	0.44	6.71e-6	Breast cancer;
THYM	cis	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg23422044	chr7:1970798	MAD1L1	0.85	5.98	0.52	3.82e-8	Bipolar disorder;
THYM	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg00487526	chr15:90818384	NA	-0.58	-4.46	-0.42	2.24e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg09307838	chr4:120376055	NA	0.71	5.41	0.49	4.61e-7	Corneal astigmatism;
THYM	cis	rs921968	0.565	rs13408305	chr2:219628183	G/A	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11563648	0.553	rs951992	chr7:126986838	G/A	cg23081781	chr7:127225937	GCC1	-0.37	-5.19	-0.47	1.17e-6	Resting heart rate;
THYM	cis	rs6430585	0.591	rs724326	chr2:136485971	T/C	cg23851026	chr2:136556271	LCT	0.57	5.41	0.49	4.68e-7	Corneal structure;
THYM	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	4.96	0.45	3.07e-6	Hip circumference adjusted for BMI;
THYM	cis	rs9914544	0.678	rs28374894	chr17:18761659	C/A	cg26378065	chr17:18585709	ZNF286B	0.6	4.71	0.43	8.56e-6	Educational attainment (years of education);
THYM	cis	rs12935418	0.583	rs2549856	chr16:81026927	C/T	cg16651780	chr16:81037892	C16orf61	-0.81	-6.27	-0.54	1.06e-8	Mean corpuscular volume;
THYM	cis	rs500891	0.525	rs10943930	chr6:84060858	A/T	cg08257003	chr6:84140564	ME1	0.55	4.54	0.42	1.66e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs7084402	0.935	rs10763564	chr10:60360423	C/A	cg07615347	chr10:60278583	BICC1	0.53	4.97	0.45	2.99e-6	Refractive error;
THYM	cis	rs11690935	0.655	rs12052995	chr2:172537212	A/G	cg13550731	chr2:172543902	DYNC1I2	0.64	5.08	0.46	1.88e-6	Schizophrenia;
THYM	cis	rs12935418	0.672	rs2549879	chr16:81046101	A/G	cg16651780	chr16:81037892	C16orf61	-0.83	-6.51	-0.56	3.48e-9	Mean corpuscular volume;
THYM	cis	rs12971120	0.838	rs747176	chr18:72154931	G/A	cg25817165	chr18:72167213	CNDP2	-0.86	-7.19	-0.59	1.44e-10	Refractive error;
THYM	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.758	rs532242	chr1:53308665	C/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.93	-0.45	3.47e-6	Monocyte count;
THYM	cis	rs12681287	0.752	rs12548328	chr8:87311219	G/A	cg27223183	chr8:87520930	FAM82B	-0.68	-5.19	-0.47	1.2e-6	Caudate activity during reward;
THYM	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg01097406	chr16:89675127	NA	-0.58	-4.73	-0.44	7.89e-6	Vitiligo;
THYM	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg11663144	chr21:46675770	NA	-0.64	-8.93	-0.68	3.19e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs289828	0.560	rs2278090	chr2:152146658	T/C	cg05960677	chr2:152117363	RBM43	0.75	7.25	0.6	1.1e-10	Blood protein levels;
THYM	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg17863274	chr19:49399704	TULP2	0.93	5.69	0.5	1.43e-7	Red cell distribution width;
THYM	cis	rs262150	0.672	rs2730230	chr7:158788529	A/G	cg04111992	chr7:158790115	NA	-0.55	-4.68	-0.43	9.69e-6	Facial morphology (factor 20);
THYM	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg13319975	chr6:146136371	FBXO30	0.76	6.48	0.55	4.09e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg18681998	chr4:17616180	MED28	-0.81	-7.32	-0.6	8.09e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg14895029	chr7:2775587	GNA12	-0.68	-4.94	-0.45	3.41e-6	Height;
THYM	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg10117171	chr1:25599238	RHD	0.67	4.86	0.45	4.65e-6	Erythrocyte sedimentation rate;
THYM	cis	rs7408868	1.000	rs10410514	chr19:15277610	C/T	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg26818010	chr10:134567672	INPP5A	-0.75	-5.83	-0.51	7.69e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs909002	0.849	rs10914458	chr1:32096746	T/C	cg13919466	chr1:32135498	COL16A1	-0.48	-4.47	-0.42	2.19e-5	Intelligence (multi-trait analysis);
THYM	cis	rs59698941	0.765	rs66822519	chr5:132167742	C/T	cg02081065	chr5:132209139	LEAP2	-0.91	-5.94	-0.52	4.67e-8	Apolipoprotein A-IV levels;
THYM	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg06481639	chr22:41940642	POLR3H	0.71	5.15	0.47	1.43e-6	Vitiligo;
THYM	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg25256661	chr17:7137939	DVL2	0.97	8.43	0.65	3.76e-13	Adiponectin levels;
THYM	cis	rs6980334	0.680	rs10244249	chr7:137790650	A/C	cg22979093	chr7:137028410	PTN	0.62	4.95	0.45	3.19e-6	Blood metabolite ratios;
THYM	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg11764359	chr7:65958608	NA	-0.68	-5.13	-0.47	1.52e-6	Aortic root size;
THYM	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg17063962	chr7:91808500	NA	-1.11	-12.35	-0.78	1.82e-21	Breast cancer;
THYM	cis	rs4363385	0.693	rs7556517	chr1:152925755	G/T	cg07796016	chr1:152779584	LCE1C	0.58	4.65	0.43	1.05e-5	Inflammatory skin disease;
THYM	cis	rs3017493	0.685	rs61885467	chr11:70649857	C/T	cg19942459	chr11:70508110	SHANK2	1.04	4.61	0.43	1.23e-5	Renal transplant outcome;
THYM	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg14004847	chr7:1930337	MAD1L1	-0.64	-5.11	-0.46	1.67e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs28595532	0.920	rs116516492	chr4:119734247	C/G	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs6924995	0.501	rs9477052	chr6:16189921	C/A	cg11805552	chr6:16175128	NA	0.53	4.64	0.43	1.14e-5	Response to statins (LDL cholesterol change);
THYM	cis	rs6060717	0.610	rs2590964	chr20:34613376	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-5.28	-0.48	8.08e-7	Hip circumference adjusted for BMI;
THYM	cis	rs1729951	0.575	rs16844362	chr3:136704008	T/C	cg21827317	chr3:136751795	NA	0.76	6.74	0.57	1.23e-9	Neuroticism;
THYM	cis	rs11563648	0.553	rs1946107	chr7:127050750	A/G	cg23081781	chr7:127225937	GCC1	-0.33	-4.52	-0.42	1.78e-5	Resting heart rate;
THYM	cis	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg09307838	chr4:120376055	NA	0.62	4.46	0.42	2.24e-5	Corneal astigmatism;
THYM	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22496380	chr5:211416	CCDC127	-1.39	-8.13	-0.64	1.62e-12	Breast cancer;
THYM	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg18451016	chr1:38461880	NA	0.43	5.26	0.47	8.97e-7	Coronary artery disease;
THYM	cis	rs79149102	0.579	rs58645417	chr15:75325858	T/G	cg17294928	chr15:75287854	SCAMP5	-1.03	-5.57	-0.5	2.32e-7	Lung cancer;
THYM	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg19077165	chr18:44547161	KATNAL2	-0.63	-8.11	-0.64	1.74e-12	Personality dimensions;
THYM	cis	rs600806	0.821	rs3879447	chr1:109891403	C/T	cg16988986	chr1:109941118	SORT1	-0.43	-4.6	-0.43	1.32e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs75920871	0.528	rs10892071	chr11:116954565	C/T	cg20608306	chr11:116969690	SIK3	-0.52	-5.67	-0.5	1.51e-7	Subjective well-being;
THYM	cis	rs7572263	0.916	rs12995124	chr2:209057014	G/C	cg23998903	chr2:209048830	C2orf80	0.43	5.48	0.49	3.49e-7	Glioma;Non-glioblastoma glioma;
THYM	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg25767906	chr1:53392781	SCP2	-0.5	-4.86	-0.45	4.72e-6	Monocyte count;
THYM	cis	rs4642101	0.765	rs4321514	chr3:12825901	C/T	cg05775895	chr3:12838266	CAND2	0.77	6.91	0.58	5.5e-10	QRS complex (12-leadsum);
THYM	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg03295274	chr13:50190584	NA	0.69	5.19	0.47	1.18e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs4589258	0.737	rs2155072	chr11:90410124	C/T	cg26138821	chr11:89956704	CHORDC1	0.56	4.58	0.43	1.42e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2267137	0.868	rs5763178	chr22:29773869	A/G	cg26480862	chr22:28839667	TTC28	0.46	4.46	0.42	2.26e-5	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs11577318	0.579	rs11247936	chr1:26698884	A/G	cg00852783	chr1:26633632	UBXN11	-0.66	-4.55	-0.42	1.61e-5	Granulocyte percentage of myeloid white cells;
THYM	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg15604051	chr3:44754201	ZNF502	0.52	4.78	0.44	6.36e-6	Depressive symptoms;
THYM	cis	rs10924970	0.967	rs4481838	chr1:235442626	A/G	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs6032067	0.777	rs55767422	chr20:43802497	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.41	-0.65	4.05e-13	Blood protein levels;
THYM	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg25554036	chr4:6271136	WFS1	0.56	5.29	0.48	7.94e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg09640425	chr7:158790006	NA	0.53	4.7	0.43	8.93e-6	Facial morphology (factor 20);
THYM	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg00898013	chr13:113819073	PROZ	-0.83	-8.37	-0.65	4.88e-13	Platelet distribution width;
THYM	cis	rs7173743	0.756	rs4551997	chr15:79130433	G/A	cg15571903	chr15:79123663	NA	0.56	6.34	0.55	7.64e-9	Coronary artery disease;
THYM	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg03433033	chr1:76189801	ACADM	-0.76	-9.82	-0.71	3.96e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg24692254	chr21:30365293	RNF160	0.99	9.28	0.69	5.71e-15	Dental caries;
THYM	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg21775007	chr8:11205619	TDH	-0.73	-5.68	-0.5	1.49e-7	Retinal vascular caliber;
THYM	cis	rs7523273	0.548	rs2724381	chr1:207949017	T/C	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg08885076	chr2:99613938	TSGA10	-0.57	-5.31	-0.48	7.23e-7	Chronic sinus infection;
THYM	cis	rs684232	0.602	rs35206514	chr17:519859	T/C	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.39	-4.77	-0.44	6.73e-6	Prostate cancer;
THYM	cis	rs806215	1.000	rs2106187	chr7:127241353	C/T	cg08586737	chr7:127225949	GCC1	0.37	4.59	0.43	1.34e-5	Type 2 diabetes;
THYM	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg15445000	chr17:37608096	MED1	0.41	4.72	0.44	8.17e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2625529	0.824	rs16956452	chr15:72284092	T/C	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.6	-6.47	-0.55	4.21e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7107174	1.000	rs2450122	chr11:77930345	T/C	cg19901956	chr11:77921274	USP35	-0.77	-6.01	-0.53	3.34e-8	Testicular germ cell tumor;
THYM	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg18252515	chr7:66147081	NA	-1.37	-8.05	-0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg11846333	chr4:119757529	SEC24D	1.35	5.12	0.46	1.6e-6	Cannabis dependence symptom count;
THYM	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.85	-4.92	-0.45	3.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg12935359	chr14:103987150	CKB	-0.65	-6.4	-0.55	5.78e-9	Body mass index;
THYM	cis	rs12935418	0.672	rs7197370	chr16:81051125	A/G	cg16651780	chr16:81037892	C16orf61	0.77	5.66	0.5	1.63e-7	Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21659725	chr3:3221576	CRBN	0.9	9.83	0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg05872129	chr22:39784769	NA	-1.04	-10.98	-0.75	1.35e-18	Intelligence (multi-trait analysis);
THYM	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg10589385	chr1:150898437	SETDB1	0.62	5.17	0.47	1.27e-6	Melanoma;
THYM	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs4786125	0.879	rs11640468	chr16:6895945	C/T	cg03623568	chr16:6915990	A2BP1	-0.7	-5.63	-0.5	1.82e-7	Heart rate variability traits (SDNN);
THYM	cis	rs3796619	1.000	rs12647929	chr4:1092019	G/T	cg27284194	chr4:1044797	NA	0.53	4.95	0.45	3.22e-6	Recombination rate (males);
THYM	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg08847533	chr14:75593920	NEK9	-0.61	-5.38	-0.48	5.4e-7	Neuroticism;
THYM	cis	rs7107174	1.000	rs2510045	chr11:77920563	G/T	cg02023728	chr11:77925099	USP35	0.71	6.84	0.57	7.65e-10	Testicular germ cell tumor;
THYM	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg18402987	chr7:1209562	NA	1.03	6.06	0.53	2.77e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6032067	0.609	rs1011536	chr20:43793370	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.67	-7.93	-0.63	4.13e-12	Blood protein levels;
THYM	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg02389323	chr16:88786976	FAM38A	0.92	5.67	0.5	1.54e-7	Plateletcrit;
THYM	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg21252483	chr19:49399788	TULP2	-0.96	-7.25	-0.6	1.09e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg09436375	chr6:42928200	GNMT	-0.4	-5.14	-0.47	1.47e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs763014	0.865	rs8909	chr16:633851	T/C	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs7193541	0.694	rs8061942	chr16:74691362	C/T	cg01733217	chr16:74700730	RFWD3	0.95	11.09	0.75	8.04e-19	Multiple myeloma;
THYM	cis	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg22709100	chr7:91322751	NA	0.68	5.41	0.49	4.62e-7	Breast cancer;
THYM	cis	rs6558530	0.931	rs4639549	chr8:1708044	A/G	cg09410841	chr8:1729607	CLN8	0.75	5.54	0.49	2.74e-7	Systolic blood pressure;
THYM	cis	rs6570726	0.791	rs440477	chr6:145854188	C/T	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg08431931	chr22:42394659	WBP2NL	0.69	4.88	0.45	4.33e-6	Birth weight;
THYM	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg18105134	chr13:113819100	PROZ	-1.15	-9.23	-0.69	7.37e-15	Platelet distribution width;
THYM	cis	rs6956675	0.958	rs7779974	chr7:62576724	T/C	cg08930214	chr7:62859557	LOC100287834	0.61	4.48	0.42	2.1e-5	Obesity-related traits;
THYM	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg11965913	chr1:205819406	PM20D1	-0.55	-4.61	-0.43	1.25e-5	Parkinson's disease;
THYM	cis	rs7590720	0.788	rs4674050	chr2:216907322	G/T	cg25588852	chr2:216877276	MREG	-0.56	-5.05	-0.46	2.1e-6	Alcohol dependence;
THYM	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-5.1	-0.46	1.75e-6	Gut microbiome composition (summer);
THYM	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg19774624	chr17:42201019	HDAC5	-0.8	-6.41	-0.55	5.6e-9	Total body bone mineral density;
THYM	cis	rs73086581	0.838	rs56401022	chr20:4024281	A/G	cg02187196	chr20:3869020	PANK2	0.46	5.03	0.46	2.29e-6	Response to antidepressants in depression;
THYM	cis	rs6502050	0.835	rs34774430	chr17:80181919	T/C	cg21773646	chr17:80085082	CCDC57	-0.37	-5.31	-0.48	7.27e-7	Life satisfaction;
THYM	cis	rs4638749	1.000	rs10209928	chr2:108863898	C/T	cg25838818	chr2:108905173	SULT1C2	-0.61	-6.18	-0.54	1.6e-8	Blood pressure;
THYM	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg05738196	chr6:26577821	NA	0.95	9.38	0.69	3.53e-15	Intelligence (multi-trait analysis);
THYM	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg00339695	chr16:24857497	SLC5A11	-0.47	-4.7	-0.43	8.71e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg09904177	chr6:26538194	HMGN4	0.54	4.54	0.42	1.63e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6450176	1.000	rs60652351	chr5:53306140	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.13	-0.53	2.01e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs227425	0.525	rs2035011	chr14:70414619	A/C	cg12046056	chr14:71067695	MED6	-0.54	-5.03	-0.46	2.28e-6	Bone mineral density;
THYM	cis	rs9644630	0.897	rs6984644	chr8:19363425	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.8	8.28	0.65	7.74e-13	Oropharynx cancer;
THYM	cis	rs2282300	0.739	rs1717772	chr11:30340133	C/T	cg25418670	chr11:30344373	C11orf46	-0.82	-6.95	-0.58	4.6e-10	Morning vs. evening chronotype;
THYM	cis	rs654128	0.640	rs339338	chr6:117214706	T/C	cg12892004	chr6:117198278	RFX6	-0.72	-5.66	-0.5	1.61e-7	Telomere length;
THYM	cis	rs72949976	0.646	rs4673731	chr2:214028544	C/T	cg08319019	chr2:214017104	IKZF2	0.77	6.51	0.56	3.54e-9	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs13221852	0.714	rs34731314	chr7:3438362	T/C	cg21248987	chr7:3385318	SDK1	0.4	5.29	0.48	7.97e-7	Acute graft versus host disease in bone marrow transplantation (donor effect);
THYM	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg21226059	chr5:178986404	RUFY1	0.6	6.8	0.57	9.25e-10	Lung cancer;
THYM	cis	rs6542838	0.641	rs6741166	chr2:99534926	G/C	cg08885076	chr2:99613938	TSGA10	-0.54	-5.1	-0.46	1.75e-6	Fear of minor pain;
THYM	cis	rs4638749	0.734	rs4676191	chr2:108861242	A/G	cg25838818	chr2:108905173	SULT1C2	-0.54	-5.68	-0.5	1.45e-7	Blood pressure;
THYM	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03264133	chr6:25882463	NA	-0.73	-5.82	-0.51	7.95e-8	Blood metabolite levels;
THYM	cis	rs3892630	0.824	rs2287882	chr19:33332952	C/T	cg22980127	chr19:33182716	NUDT19	1.14	9.18	0.69	9.17e-15	Red blood cell traits;
THYM	trans	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg10856724	chr12:34555212	NA	-1.01	-9.17	-0.69	9.95e-15	Bladder cancer;
THYM	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg05855489	chr10:104503620	C10orf26	-0.8	-7.3	-0.6	8.88e-11	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg03806693	chr22:41940476	POLR3H	1.06	7.81	0.63	7.61e-12	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg10515332	chr4:99064459	C4orf37	0.71	5.67	0.5	1.51e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg11461670	chr8:22454935	PDLIM2	-0.39	-6.43	-0.55	5.18e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.24e-14	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg21773646	chr17:80085082	CCDC57	-0.34	-4.91	-0.45	3.76e-6	Life satisfaction;
THYM	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2133450	0.508	rs9825942	chr3:7350426	C/G	cg19930620	chr3:7340148	GRM7	-0.55	-5.63	-0.5	1.82e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Body mass index;
THYM	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg26516362	chr5:178986906	RUFY1	-0.42	-5.27	-0.48	8.63e-7	Lung cancer;
THYM	cis	rs7917772	0.582	rs12784963	chr10:104336986	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-5.7	-0.5	1.33e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg24692254	chr21:30365293	RNF160	0.66	4.68	0.43	9.38e-6	Selective IgA deficiency;
THYM	cis	rs4638749	0.677	rs12475343	chr2:108851373	T/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg12310025	chr6:25882481	NA	-0.91	-8.87	-0.67	4.22e-14	Intelligence (multi-trait analysis);
THYM	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg19346786	chr7:2764209	NA	-0.73	-6.2	-0.54	1.47e-8	Height;
THYM	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg14345882	chr6:26364793	BTN3A2	0.62	5.7	0.5	1.34e-7	Urinary tract infection frequency;
THYM	cis	rs6500395	0.962	rs868792	chr16:48640632	T/C	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs829883	0.639	rs829898	chr12:98857675	A/C	cg25150519	chr12:98850993	NA	0.55	5.49	0.49	3.29e-7	Colorectal adenoma (advanced);
THYM	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg11366901	chr6:160182831	ACAT2	0.93	7.42	0.61	4.93e-11	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7119	0.931	rs59418918	chr15:77833110	A/C	cg10437265	chr15:77819839	NA	0.76	7.47	0.61	3.81e-11	Type 2 diabetes;
THYM	cis	rs2072499	0.898	rs2758609	chr1:156202868	G/A	cg24450063	chr1:156163899	SLC25A44	1.02	11.45	0.76	1.41e-19	Testicular germ cell tumor;
THYM	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg12179176	chr11:130786555	SNX19	0.88	8.3	0.65	7.08e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs17407555	0.779	rs4459989	chr4:10112602	C/T	cg00071950	chr4:10020882	SLC2A9	-0.73	-5.37	-0.48	5.67e-7	Schizophrenia (age at onset);
THYM	cis	rs2108225	0.934	rs4730269	chr7:107455719	T/G	cg18560240	chr7:107437656	SLC26A3	-0.82	-6.31	-0.54	8.83e-9	Ulcerative colitis;
THYM	cis	rs67311347	0.544	rs67533651	chr3:40338367	T/A	cg24209194	chr3:40518798	ZNF619	0.55	4.6	0.43	1.29e-5	Renal cell carcinoma;
THYM	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg27494647	chr7:150038898	RARRES2	0.41	4.59	0.43	1.34e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11723261	0.582	rs6599293	chr4:133027	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.86	6.16	0.53	1.75e-8	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs62051538	0.602	rs7203199	chr16:31537574	C/G	cg10091996	chr16:31548640	NA	-0.5	-4.5	-0.42	1.96e-5	Mean corpuscular hemoglobin;
THYM	cis	rs3812049	0.693	rs9327468	chr5:127441861	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.42	0.49	4.45e-7	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg08439880	chr3:133502540	NA	-0.73	-6.46	-0.55	4.44e-9	Iron status biomarkers;
THYM	cis	rs9866391	0.607	rs1344672	chr3:141125705	C/G	cg13411656	chr3:141121016	ZBTB38	0.35	5.23	0.47	9.9e-7	Myopia;
THYM	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg13609457	chr4:120235615	NA	0.63	5.63	0.5	1.81e-7	Corneal astigmatism;
THYM	cis	rs13418717	0.793	rs4663053	chr2:127638990	A/G	cg25501666	chr2:127640322	NA	-1.3	-6.72	-0.57	1.32e-9	Heart failure;
THYM	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg10518543	chr12:38710700	ALG10B	-0.54	-4.54	-0.42	1.64e-5	Morning vs. evening chronotype;
THYM	cis	rs7078219	0.714	rs10883368	chr10:101289998	A/G	cg23904955	chr10:101282759	NA	-0.44	-5.19	-0.47	1.18e-6	Dental caries;
THYM	cis	rs7084402	0.967	rs1649043	chr10:60328209	C/T	cg07615347	chr10:60278583	BICC1	0.53	4.98	0.45	2.85e-6	Refractive error;
THYM	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg02734326	chr4:10020555	SLC2A9	0.79	6.92	0.58	5.27e-10	Bone mineral density;
THYM	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1065852	0.526	rs12166549	chr22:42410419	T/C	cg01059385	chr22:42394853	WBP2NL	0.57	4.66	0.43	1.04e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg01238044	chr22:24384105	GSTT1	-0.51	-4.6	-0.43	1.31e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6951245	0.542	rs28460147	chr7:1217192	G/A	cg03188948	chr7:1209495	NA	1.09	5.51	0.49	3.04e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg11494091	chr17:61959527	GH2	0.68	6.3	0.54	9.43e-9	Height;
THYM	cis	rs9810089	0.777	rs2688601	chr3:136252601	G/A	cg12473912	chr3:136751656	NA	0.62	5.27	0.48	8.44e-7	Gestational age at birth (child effect);
THYM	trans	rs8002861	0.664	rs1466005	chr13:44424210	T/C	cg17145862	chr1:211918768	LPGAT1	0.84	7.31	0.6	8.22e-11	Leprosy;
THYM	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg01917657	chr22:50617092	PANX2	-0.4	-4.49	-0.42	1.97e-5	Obesity-related traits;
THYM	cis	rs1978968	1.000	rs1110660	chr22:18444693	A/C	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs3820068	0.603	rs6695903	chr1:15985940	C/T	cg13390004	chr1:15929781	NA	0.61	4.68	0.43	9.54e-6	Systolic blood pressure;
THYM	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg11812906	chr14:75593930	NEK9	0.87	8.3	0.65	7.13e-13	Height;
THYM	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg13699009	chr12:122356056	WDR66	0.49	4.78	0.44	6.36e-6	Mean corpuscular volume;
THYM	cis	rs72699765	0.557	rs7496538	chr15:25845597	C/G	cg22934878	chr15:25227003	PAR-SN;SNORD107	1.04	4.77	0.44	6.76e-6	Obstructive sleep apnea trait (average respiratory event duration);
THYM	cis	rs2806561	0.929	rs9426694	chr1:23539742	T/C	cg08872493	chr1:23521417	HTR1D	0.37	4.61	0.43	1.27e-5	Height;
THYM	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg07570687	chr10:102243282	WNT8B	0.74	6.53	0.56	3.19e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs3017493	0.786	rs12295625	chr11:70671860	A/G	cg14537332	chr11:70508113	SHANK2	-1.05	-6.98	-0.58	4.05e-10	Renal transplant outcome;
THYM	cis	rs7524258	0.900	rs12035586	chr1:7273020	C/T	cg07173049	chr1:7289937	CAMTA1	-0.65	-5.16	-0.47	1.35e-6	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs17407555	1.000	rs17407555	chr4:10274994	A/G	cg11266682	chr4:10021025	SLC2A9	-0.49	-4.78	-0.44	6.27e-6	Schizophrenia (age at onset);
THYM	cis	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg01364799	chr7:75623366	TMEM120A	-0.64	-4.65	-0.43	1.08e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4843185	0.576	rs381624	chr16:85728679	G/A	cg26571870	chr16:85723150	GINS2	-0.39	-4.53	-0.42	1.73e-5	Platelet distribution width;
THYM	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg25817165	chr18:72167213	CNDP2	-0.99	-7.58	-0.61	2.27e-11	Refractive error;
THYM	cis	rs686320	1.000	rs72643572	chr11:65250967	A/G	cg19332572	chr11:65321591	LTBP3	0.92	5.31	0.48	7.27e-7	Hip circumference adjusted for BMI;
THYM	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-5.77	-0.51	9.69e-8	Gut microbiome composition (summer);
THYM	cis	rs59112743	0.510	rs11752196	chr6:15590652	C/T	cg10111214	chr6:14815676	NA	0.74	4.84	0.44	5.08e-6	Multiple keratinocyte cancers;
THYM	cis	rs4589258	0.933	rs7102571	chr11:90396513	A/G	cg26138821	chr11:89956704	CHORDC1	0.71	6.0	0.52	3.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs747782	0.537	rs10838835	chr11:48246457	C/T	cg24672777	chr11:48374446	OR4C45	1.17	7.15	0.59	1.78e-10	Intraocular pressure;
THYM	cis	rs7084402	0.967	rs1649028	chr10:60280428	A/G	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	trans	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg14779329	chr11:130786720	SNX19	0.56	6.17	0.54	1.63e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-7.23	-0.6	1.23e-10	Gut microbiome composition (summer);
THYM	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	6.88	0.58	6.27e-10	Platelet count;
THYM	cis	rs4273100	0.512	rs1355128	chr17:19299144	G/A	cg25447019	chr17:19030144	GRAPL	0.75	5.77	0.51	9.8e-8	Schizophrenia;
THYM	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg24675658	chr1:53192096	ZYG11B	0.71	6.38	0.55	6.49e-9	Monocyte count;
THYM	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg11494091	chr17:61959527	GH2	-1.09	-17.19	-0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs12681287	0.752	rs12675974	chr8:87247845	T/C	cg27223183	chr8:87520930	FAM82B	-0.6	-4.64	-0.43	1.1e-5	Caudate activity during reward;
THYM	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg20686234	chr17:26699485	SARM1	-1.35	-6.99	-0.58	3.87e-10	Pulmonary function decline;
THYM	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg23803603	chr1:2058230	PRKCZ	-0.58	-5.33	-0.48	6.69e-7	Height;
THYM	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg00383909	chr3:49044727	WDR6	1.07	6.29	0.54	9.72e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg27129171	chr3:47204927	SETD2	0.78	7.75	0.62	1.03e-11	Colorectal cancer;
THYM	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg15744005	chr10:104629667	AS3MT	-0.8	-7.36	-0.6	6.45e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg13683864	chr3:40499215	RPL14	1.09	12.73	0.79	3.04e-22	Renal cell carcinoma;
THYM	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.63	-4.48	-0.42	2.05e-5	Gut microbiome composition (summer);
THYM	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03264133	chr6:25882463	NA	-1.06	-9.58	-0.7	1.27e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7000551	0.725	rs2249102	chr8:22400193	C/G	cg12081754	chr8:22256438	SLC39A14	0.69	6.43	0.55	5.21e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs4733781	0.842	rs11774690	chr8:131190498	C/G	cg16277922	chr8:131349729	ASAP1	0.64	4.95	0.45	3.24e-6	Tuberculosis;
THYM	cis	rs1499972	0.941	rs62264782	chr3:117655445	C/A	cg07612923	chr3:117604196	NA	1.3	5.07	0.46	1.94e-6	Schizophrenia;
THYM	cis	rs11716531	0.512	rs7612312	chr3:27230230	C/A	cg02860705	chr3:27208620	NA	0.66	5.31	0.48	7.26e-7	Diastolic blood pressure;
THYM	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg25072359	chr17:41440525	NA	0.63	4.48	0.42	2.11e-5	Menopause (age at onset);
THYM	cis	rs7828089	0.967	rs7828414	chr8:22264585	T/C	cg12081754	chr8:22256438	SLC39A14	0.6	5.26	0.48	8.69e-7	Verbal declarative memory;
THYM	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg12560992	chr17:57184187	TRIM37	-0.8	-6.77	-0.57	1.07e-9	Intelligence (multi-trait analysis);
THYM	cis	rs240764	0.725	rs239193	chr6:101131848	T/C	cg21058520	chr6:100914733	NA	-0.59	-5.07	-0.46	2e-6	Neuroticism;
THYM	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg15693483	chr7:1102177	C7orf50	0.54	6.26	0.54	1.1e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg02136620	chr5:178986620	RUFY1	-0.59	-5.97	-0.52	4.05e-8	Lung cancer;
THYM	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg05393297	chr12:53359155	NA	-0.61	-6.96	-0.58	4.45e-10	Cancer (pleiotropy);
THYM	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg23958373	chr8:599963	NA	0.92	4.6	0.43	1.3e-5	IgG glycosylation;
THYM	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg04731861	chr2:219085781	ARPC2	0.56	5.39	0.48	5.21e-7	Colorectal cancer;
THYM	cis	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg06565975	chr8:143823917	SLURP1	0.44	4.93	0.45	3.51e-6	Urinary tract infection frequency;
THYM	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg08975724	chr8:8085496	FLJ10661	0.69	5.72	0.51	1.23e-7	Mood instability;
THYM	cis	rs17767294	0.708	rs72848776	chr6:27954826	G/A	cg08851530	chr6:28072375	NA	1.39	5.71	0.51	1.31e-7	Parkinson's disease;
THYM	cis	rs3960554	0.674	rs112742093	chr7:75800597	T/C	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.5	-0.42	1.92e-5	Eotaxin levels;
THYM	cis	rs7524258	0.900	rs6670323	chr1:7301947	C/A	cg07173049	chr1:7289937	CAMTA1	0.7	5.66	0.5	1.6e-7	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg13319975	chr6:146136371	FBXO30	-0.66	-5.35	-0.48	6.11e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg05657792	chr17:6899758	ALOX12	0.53	5.34	0.48	6.43e-7	Tonsillectomy;
THYM	cis	rs459571	1.000	rs467387	chr9:136907005	G/A	cg13789015	chr9:136890014	NCRNA00094	0.82	7.28	0.6	9.6e-11	Platelet distribution width;
THYM	cis	rs28595532	0.920	rs115294251	chr4:119772833	C/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.7	6.48	0.55	4.13e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs17750015	0.733	rs7506986	chr18:54404558	C/T	cg18434998	chr18:54306185	TXNL1	-0.58	-4.79	-0.44	6.18e-6	Depression and alcohol dependence;
THYM	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22857025	chr5:266934	NA	-1.41	-9.08	-0.68	1.5e-14	Breast cancer;
THYM	cis	rs7078219	0.714	rs10883369	chr10:101291367	C/T	cg17888390	chr10:101282816	NA	-0.53	-4.91	-0.45	3.7e-6	Dental caries;
THYM	cis	rs6754311	0.773	rs188680	chr2:136630989	A/G	cg07169764	chr2:136633963	MCM6	-0.71	-6.05	-0.53	2.81e-8	Mosquito bite size;
THYM	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03264133	chr6:25882463	NA	-0.69	-5.32	-0.48	7.03e-7	Blood metabolite levels;
THYM	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4523957	0.579	rs903162	chr17:2092200	C/T	cg16513277	chr17:2031491	SMG6	-0.96	-8.73	-0.67	8.34e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg00631329	chr6:26305371	NA	-0.72	-7.53	-0.61	2.89e-11	Educational attainment;
THYM	cis	rs988913	0.957	rs2064432	chr6:54782652	A/G	cg19716238	chr6:54711378	FAM83B	0.51	5.02	0.46	2.4e-6	Menarche (age at onset);
THYM	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs28785552	0.769	rs11669363	chr19:53232321	C/A	cg10871876	chr19:53194124	ZNF83	0.73	6.12	0.53	2.09e-8	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs6768930	0.509	rs7620169	chr3:57893050	A/G	cg24033633	chr3:57945695	NA	-0.36	-4.92	-0.45	3.63e-6	Obesity-related traits;
THYM	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg10117171	chr1:25599238	RHD	-0.67	-4.81	-0.44	5.71e-6	Erythrocyte sedimentation rate;
THYM	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.65	8.96	0.68	2.71e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs34375054	0.526	rs4412800	chr12:125674742	C/T	cg25124228	chr12:125621409	AACS	0.76	5.79	0.51	8.87e-8	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs17407555	0.821	rs17198197	chr4:10139157	A/G	cg11266682	chr4:10021025	SLC2A9	0.59	6.25	0.54	1.17e-8	Schizophrenia (age at onset);
THYM	cis	rs36051895	0.659	rs1159782	chr9:5078117	T/C	cg02405213	chr9:5042618	JAK2	-1.03	-11.11	-0.75	7.02e-19	Pediatric autoimmune diseases;
THYM	cis	rs9933309	1.000	rs9933309	chr16:88844932	A/G	cg27661460	chr16:88844969	FAM38A	0.68	5.96	0.52	4.3e-8	Glycated hemoglobin levels;
THYM	trans	rs11098499	0.874	rs28452522	chr4:120110784	A/G	cg25214090	chr10:38739885	LOC399744	0.87	7.14	0.59	1.91e-10	Corneal astigmatism;
THYM	cis	rs3849570	0.961	rs13340130	chr3:81790970	A/T	cg07356753	chr3:81810745	GBE1	-0.93	-7.51	-0.61	3.26e-11	Waist circumference;Body mass index;
THYM	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10197940	0.578	rs6718372	chr2:152345871	C/G	cg19508488	chr2:152266495	RIF1	0.72	5.66	0.5	1.57e-7	Lung cancer;
THYM	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg08859206	chr1:53392774	SCP2	0.81	8.47	0.66	3e-13	Monocyte count;
THYM	cis	rs7216064	1.000	rs8074078	chr17:65838743	A/C	cg12091567	chr17:66097778	LOC651250	-0.71	-4.76	-0.44	6.86e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17407555	0.865	rs115163648	chr4:10331926	G/T	cg11266682	chr4:10021025	SLC2A9	-0.49	-4.66	-0.43	1.02e-5	Schizophrenia (age at onset);
THYM	cis	rs4819052	0.851	rs2255774	chr21:46683851	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.0	8.95	0.68	2.9e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg00898013	chr13:113819073	PROZ	-1.04	-7.47	-0.61	3.89e-11	Platelet distribution width;
THYM	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg06221963	chr1:154839813	KCNN3	-0.89	-11.85	-0.77	2e-20	Prostate cancer;
THYM	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg14768367	chr16:72042858	DHODH	0.67	5.27	0.48	8.41e-7	Fibrinogen levels;
THYM	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg05738196	chr6:26577821	NA	0.95	9.89	0.71	2.78e-16	Intelligence (multi-trait analysis);
THYM	cis	rs367615	0.506	rs2963021	chr5:108800365	C/T	cg17395555	chr5:108820864	NA	0.71	9.09	0.68	1.46e-14	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs7589342	1.000	rs7589342	chr2:106433478	C/T	cg14210321	chr2:106509881	NCK2	-0.72	-5.12	-0.46	1.62e-6	Addiction;
THYM	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-7.03	-0.59	3.12e-10	Monocyte percentage of white cells;
THYM	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.99	-0.75	1.26e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs3126085	0.825	rs10788830	chr1:152206898	A/C	cg26020982	chr1:152196106	HRNR	0.37	5.06	0.46	2.05e-6	Atopic dermatitis;
THYM	cis	rs2913737	0.597	rs2963674	chr5:175937394	C/T	cg27658698	chr5:175955578	RNF44	0.59	4.63	0.43	1.15e-5	Obesity-related traits;
THYM	cis	rs4788570	0.615	rs8053745	chr16:71689693	A/G	cg06353428	chr16:71660113	MARVELD3	1.29	8.61	0.66	1.52e-13	Intelligence (multi-trait analysis);
THYM	cis	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg02317251	chr4:10116515	WDR1	-0.56	-4.95	-0.45	3.23e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg13695892	chr22:41940480	POLR3H	-1.06	-8.59	-0.66	1.69e-13	Vitiligo;
THYM	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg12311346	chr5:56204834	C5orf35	0.61	4.61	0.43	1.23e-5	Initial pursuit acceleration;
THYM	cis	rs728616	0.867	rs12412257	chr10:81729603	C/T	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs13006833	0.703	rs291459	chr2:191181527	T/C	cg11845111	chr2:191398756	TMEM194B	0.65	4.51	0.42	1.88e-5	Urinary metabolites;
THYM	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg08772003	chr10:104629869	AS3MT	-0.57	-4.92	-0.45	3.56e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7043114	0.525	rs10283572	chr9:95133074	G/A	cg14631576	chr9:95140430	CENPP	-0.85	-9.03	-0.68	1.99e-14	Height;
THYM	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg00071950	chr4:10020882	SLC2A9	-0.79	-8.15	-0.64	1.42e-12	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2797685	1.000	rs2859390	chr1:7847529	A/G	cg06712362	chr1:7811235	CAMTA1	0.82	6.01	0.52	3.45e-8	Crohn's disease;
THYM	cis	rs995000	0.931	rs9436221	chr1:62903359	T/C	cg06896770	chr1:63153194	DOCK7	0.92	7.12	0.59	2.07e-10	Triglyceride levels;
THYM	cis	rs1747683	0.867	rs3824655	chr10:13370779	G/C	cg25835351	chr10:13388524	SEPHS1	-0.34	-5.72	-0.51	1.24e-7	IgG glycosylation;
THYM	cis	rs76878669	0.561	rs6591217	chr11:66174653	G/A	cg14263139	chr11:66104018	RIN1	0.37	4.48	0.42	2.1e-5	Educational attainment (years of education);
THYM	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg22709100	chr7:91322751	NA	0.67	4.99	0.46	2.71e-6	Breast cancer;
THYM	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg11266682	chr4:10021025	SLC2A9	-0.52	-6.28	-0.54	1.03e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9470366	0.883	rs9462207	chr6:36627599	T/C	cg11920449	chr6:36645608	CDKN1A	-0.72	-5.32	-0.48	6.85e-7	QRS duration;
THYM	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs4919044	0.866	rs2478233	chr10:94778903	G/A	cg05127821	chr10:94822908	CYP26C1	-1.22	-6.4	-0.55	5.95e-9	Coronary artery disease;
THYM	cis	rs9902453	0.817	rs2729435	chr17:28121532	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-5.02	-0.46	2.43e-6	Coffee consumption (cups per day);
THYM	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg02527881	chr3:46936655	PTH1R	-0.66	-6.44	-0.55	4.76e-9	Colorectal cancer;
THYM	cis	rs7224314	1.000	rs8070689	chr17:65387405	G/T	cg01507342	chr17:65387096	PITPNC1	-0.97	-10.88	-0.74	2.26e-18	Diisocyanate-induced asthma;
THYM	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg00981070	chr1:2046702	PRKCZ	0.48	5.92	0.52	5.19e-8	Height;
THYM	cis	rs9880211	0.583	rs9870122	chr3:135820265	T/G	cg21827317	chr3:136751795	NA	-0.72	-5.21	-0.47	1.11e-6	Body mass index;Height;
THYM	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg26384229	chr12:38710491	ALG10B	1.06	11.07	0.75	8.9e-19	Heart rate;
THYM	cis	rs7474896	0.583	rs11011346	chr10:38009483	C/T	cg07661167	chr10:37990439	NA	-0.67	-4.54	-0.42	1.62e-5	Obesity (extreme);
THYM	cis	rs17102423	0.594	rs942626	chr14:65550082	C/T	cg11161011	chr14:65562177	MAX	-0.69	-5.58	-0.5	2.31e-7	Obesity-related traits;
THYM	cis	rs10779751	0.686	rs2791656	chr1:11128329	A/G	cg08854313	chr1:11322531	MTOR	0.83	6.22	0.54	1.33e-8	Body mass index;
THYM	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs10992471	0.580	rs10122383	chr9:95554675	A/G	cg14631576	chr9:95140430	CENPP	-0.93	-7.36	-0.6	6.42e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg12288994	chr5:1860383	NA	0.84	6.96	0.58	4.45e-10	Cardiovascular disease risk factors;
THYM	cis	rs314370	0.951	rs12666989	chr7:100486754	G/C	cg08558340	chr7:100472263	SRRT	0.61	4.99	0.46	2.75e-6	Resting heart rate;
THYM	cis	rs7512552	0.839	rs834229	chr1:150384665	G/C	cg15654264	chr1:150340011	RPRD2	0.45	5.2	0.47	1.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7246967	0.673	rs34376806	chr19:22900861	A/G	cg05241461	chr19:22816980	ZNF492	0.61	4.75	0.44	7.2e-6	Bronchopulmonary dysplasia;
THYM	cis	rs2836974	0.583	rs8132993	chr21:40716410	T/C	cg11890956	chr21:40555474	PSMG1	0.66	5.18	0.47	1.23e-6	Cognitive function;
THYM	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06850241	chr22:41845214	NA	-0.54	-4.78	-0.44	6.37e-6	Vitiligo;
THYM	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs72772090	0.539	rs3334	chr5:96115085	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24531977	chr5:56204891	C5orf35	-1.02	-8.44	-0.65	3.46e-13	Initial pursuit acceleration;
THYM	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg27286337	chr10:134555280	INPP5A	0.8	5.57	0.5	2.41e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7851660	0.967	rs3021526	chr9:100617021	C/T	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06481639	chr22:41940642	POLR3H	0.65	4.77	0.44	6.53e-6	Vitiligo;
THYM	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg26695010	chr11:65641043	EFEMP2	0.69	5.18	0.47	1.26e-6	Eosinophil percentage of white cells;
THYM	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg00757033	chr12:89920650	WDR51B	0.73	11.43	0.76	1.52e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg08999081	chr20:33150536	PIGU	0.81	7.94	0.63	4.05e-12	Coronary artery disease;
THYM	cis	rs28595532	0.920	rs115683389	chr4:119735557	T/G	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg14004847	chr7:1930337	MAD1L1	-0.64	-4.73	-0.44	7.83e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs988913	0.706	rs11753587	chr6:54950698	T/C	cg18532076	chr6:54711417	FAM83B	0.49	4.67	0.43	9.72e-6	Menarche (age at onset);
THYM	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg11871910	chr12:69753446	YEATS4	1.01	9.85	0.71	3.52e-16	Cerebrospinal fluid biomarker levels;
THYM	cis	rs10158481	0.727	rs9438892	chr1:25477754	A/G	cg09264742	chr1:25757510	TMEM57	-0.69	-5.1	-0.46	1.77e-6	Urate levels in obese individuals;
THYM	cis	rs6510489	1.000	rs8107732	chr19:35993919	A/T	cg15078284	chr19:36004994	DMKN	0.42	4.62	0.43	1.22e-5	Bipolar disorder;
THYM	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.53	-0.49	2.8e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9902453	0.967	rs56129908	chr17:28421382	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.76	0.44	6.86e-6	Coffee consumption (cups per day);
THYM	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02018176	chr4:1364513	KIAA1530	0.95	9.16	0.68	1.01e-14	Longevity;
THYM	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.59	-4.94	-0.45	3.36e-6	Renal function-related traits (BUN);
THYM	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.54	-0.42	1.67e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs2505998	0.843	rs2435344	chr10:43585874	T/C	cg06632098	chr10:43605906	RET	-1.1	-10.7	-0.74	5.44e-18	Hirschsprung disease;
THYM	cis	rs10140922	0.966	rs8003074	chr14:35821692	A/C	cg07166546	chr14:35805898	NA	-0.27	-6.66	-0.56	1.77e-9	Hip circumference adjusted for BMI;
THYM	cis	rs7104764	0.917	rs3825075	chr11:217140	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	-0.84	-7.84	-0.63	6.56e-12	Menarche (age at onset);
THYM	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.68	6.23	0.54	1.29e-8	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg22709100	chr7:91322751	NA	0.6	4.81	0.44	5.72e-6	Breast cancer;
THYM	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg23803603	chr1:2058230	PRKCZ	0.61	4.73	0.44	7.8e-6	Height;
THYM	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.78	5.09	0.46	1.82e-6	Smoking behavior;
THYM	cis	rs2692947	0.673	rs3111873	chr2:96781986	G/C	cg23100626	chr2:96804247	ASTL	-0.39	-4.76	-0.44	6.93e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.59	-0.43	1.37e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg13147721	chr7:65941812	NA	-1.16	-7.64	-0.62	1.7e-11	Diabetic kidney disease;
THYM	cis	rs7681440	0.606	rs2583976	chr4:90750173	T/C	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg03605463	chr16:89740564	NA	0.87	6.63	0.56	2.05e-9	Vitiligo;
THYM	cis	rs6988636	1.000	rs16898095	chr8:124193523	T/C	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs6700896	0.931	rs2154382	chr1:66131681	C/T	cg04111102	chr1:66153794	NA	0.56	5.27	0.48	8.45e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs7869969	0.509	rs4481672	chr9:96177221	G/A	cg13460858	chr9:96720652	NA	-0.55	-4.56	-0.42	1.51e-5	Childhood body mass index;
THYM	cis	rs3960554	0.569	rs10954750	chr7:75664921	C/G	cg16489192	chr7:75678113	MDH2;STYXL1	0.58	5.42	0.49	4.43e-7	Eotaxin levels;
THYM	cis	rs611744	0.631	rs681963	chr8:109255032	C/A	cg21045802	chr8:109455806	TTC35	0.65	5.91	0.52	5.3e-8	Dupuytren's disease;
THYM	cis	rs3126085	0.935	rs74129461	chr1:152285099	C/T	cg10321714	chr1:152280068	FLG	-0.7	-5.11	-0.46	1.68e-6	Atopic dermatitis;
THYM	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg13114125	chr14:105738426	BRF1	-0.71	-5.52	-0.49	2.98e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1214752	0.935	rs9394952	chr6:43401105	G/A	cg09674015	chr6:43045187	PTK7	-0.5	-4.67	-0.43	9.91e-6	Coronary artery disease;
THYM	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	5.42	0.49	4.57e-7	Height;
THYM	cis	rs9807841	0.592	rs10401513	chr19:10778763	A/T	cg17848348	chr19:10766748	ILF3	-0.62	-5.01	-0.46	2.46e-6	Inflammatory skin disease;
THYM	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg24250549	chr1:154909240	PMVK	0.67	5.3	0.48	7.42e-7	Prostate cancer;
THYM	cis	rs41005	0.967	rs41006	chr2:8109348	A/G	cg03155496	chr2:8117019	LOC339788	0.92	8.82	0.67	5.48e-14	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs7584330	0.780	rs937395	chr2:238378749	T/C	cg16989719	chr2:238392110	NA	-0.64	-5.82	-0.51	8.08e-8	Prostate cancer;
THYM	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.8	-7.5	-0.61	3.37e-11	Intelligence (multi-trait analysis);
THYM	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg03060546	chr3:49711283	APEH	0.79	6.43	0.55	5.02e-9	Resting heart rate;
THYM	cis	rs7078219	0.714	rs11190136	chr10:101287681	A/G	cg23904955	chr10:101282759	NA	-0.42	-4.97	-0.45	2.99e-6	Dental caries;
THYM	cis	rs11039798	0.588	rs59777067	chr11:49015350	C/T	cg24672777	chr11:48374446	OR4C45	-1.0	-6.4	-0.55	5.88e-9	Axial length;
THYM	cis	rs11048434	0.736	rs1805722	chr12:9145056	T/C	cg14913610	chr12:9142341	KLRG1	-0.29	-4.45	-0.42	2.33e-5	Sjögren's syndrome;
THYM	cis	rs10924970	0.967	rs2185021	chr1:235452744	G/A	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg03609598	chr5:56110824	MAP3K1	-0.76	-4.95	-0.45	3.17e-6	Type 2 diabetes;
THYM	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	9.51	0.7	1.8e-15	Platelet count;
THYM	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11644478	chr21:40555479	PSMG1	-0.8	-6.93	-0.58	4.93e-10	Cognitive function;
THYM	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg27490568	chr2:178487706	NA	0.61	5.63	0.5	1.82e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1113500	0.966	rs11185249	chr1:108611646	C/A	cg06207961	chr1:108661230	NA	0.7	5.68	0.5	1.48e-7	Growth-regulated protein alpha levels;
THYM	cis	rs4589258	0.933	rs7102571	chr11:90396513	A/G	cg26834418	chr11:89957033	CHORDC1	0.49	4.45	0.42	2.31e-5	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs115986613	chr4:119752156	G/A	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7580658	0.680	rs12468304	chr2:128193812	A/G	cg10021288	chr2:128175891	PROC	0.63	5.33	0.48	6.56e-7	Protein C levels;
THYM	cis	rs28829049	0.535	rs12565185	chr1:19498309	G/A	cg13387374	chr1:19411106	UBR4	0.67	4.96	0.45	3.08e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs3768617	0.510	rs12061219	chr1:183101471	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs4509693	1.000	rs4509693	chr10:102501571	C/T	cg24127310	chr10:102502104	NA	1.32	10.1	0.72	1.03e-16	Alzheimer's disease;
THYM	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.67	0.43	1e-5	Obesity-related traits;
THYM	cis	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg26384229	chr12:38710491	ALG10B	-0.9	-7.35	-0.6	6.77e-11	Bladder cancer;
THYM	cis	rs6967414	0.681	rs11979878	chr7:6753803	A/G	cg09896999	chr7:6746977	ZNF12	-0.64	-4.88	-0.45	4.2e-6	Hematocrit;Hemoglobin concentration;
THYM	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg12310025	chr6:25882481	NA	0.72	5.86	0.52	6.59e-8	Blood metabolite levels;
THYM	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg18301423	chr5:131593218	PDLIM4	0.53	5.17	0.47	1.32e-6	Acylcarnitine levels;
THYM	cis	rs11771526	0.901	rs17161084	chr7:32293192	G/C	cg27532318	chr7:32358331	NA	0.73	4.87	0.45	4.39e-6	Body mass index;
THYM	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg16579431	chr16:433439	TMEM8A;LOC100134368	0.65	5.32	0.48	6.88e-7	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg14893161	chr1:205819251	PM20D1	-0.62	-5.23	-0.47	1.03e-6	Prostate-specific antigen levels;
THYM	cis	rs7731657	0.537	rs4705925	chr5:130219200	C/T	cg08523029	chr5:130500466	HINT1	-0.79	-5.44	-0.49	4.06e-7	Fasting plasma glucose;
THYM	cis	rs526231	0.543	rs246915	chr5:102558044	G/A	cg23492399	chr5:102201601	PAM	-0.71	-5.37	-0.48	5.51e-7	Primary biliary cholangitis;
THYM	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18876405	chr7:65276391	NA	-0.55	-4.62	-0.43	1.23e-5	Aortic root size;
THYM	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg08999081	chr20:33150536	PIGU	0.77	6.93	0.58	4.98e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg15445000	chr17:37608096	MED1	0.4	4.71	0.43	8.51e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg03676636	chr4:99064102	C4orf37	0.42	6.05	0.53	2.83e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg26818010	chr10:134567672	INPP5A	-0.89	-7.01	-0.58	3.4e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg15110403	chr19:17392923	ANKLE1	-0.57	-4.64	-0.43	1.1e-5	Systemic lupus erythematosus;
THYM	cis	rs990171	0.913	rs1558627	chr2:102984684	G/A	cg13897122	chr2:103039542	IL18RAP	-0.4	-4.76	-0.44	6.87e-6	Lymphocyte counts;
THYM	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4722166	0.630	rs4722168	chr7:22779002	G/A	cg05472934	chr7:22766657	IL6	0.73	5.55	0.49	2.62e-7	Lung cancer;
THYM	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg11752832	chr7:134001865	SLC35B4	0.76	5.72	0.51	1.24e-7	Mean platelet volume;
THYM	cis	rs9527	1.000	rs4919690	chr10:104616500	C/T	cg08772003	chr10:104629869	AS3MT	0.65	4.81	0.44	5.76e-6	Arsenic metabolism;
THYM	cis	rs6964587	0.692	rs6970629	chr7:91846599	T/C	cg17063962	chr7:91808500	NA	0.98	8.49	0.66	2.78e-13	Breast cancer;
THYM	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.19	-9.36	-0.69	3.85e-15	Platelet count;
THYM	cis	rs61990749	0.597	rs1048147	chr14:78139988	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-1.17	-8.04	-0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs1061377	0.513	rs2711994	chr4:39149741	G/C	cg24403649	chr4:39172243	NA	-0.62	-5.14	-0.47	1.45e-6	Uric acid levels;
THYM	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg00080972	chr5:178986291	RUFY1	0.63	8.98	0.68	2.52e-14	Lung cancer;
THYM	cis	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7572733	0.534	rs700673	chr2:198692929	A/G	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg18252515	chr7:66147081	NA	-0.7	-5.29	-0.48	7.72e-7	Corneal structure;
THYM	cis	rs6906287	0.647	rs3951042	chr6:118722495	C/T	cg21191810	chr6:118973309	C6orf204	0.57	5.5	0.49	3.26e-7	Electrocardiographic conduction measures;
THYM	cis	rs3017493	0.786	rs74344478	chr11:70681107	G/A	cg21202716	chr11:70508022	SHANK2	1.01	4.85	0.45	4.85e-6	Renal transplant outcome;
THYM	cis	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg24692254	chr21:30365293	RNF160	-0.75	-4.5	-0.42	1.93e-5	Cognitive test performance;
THYM	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.06	11.37	0.76	2e-19	Intelligence (multi-trait analysis);
THYM	cis	rs4662750	0.583	rs2244880	chr2:128386644	G/C	cg01966334	chr2:128378434	MYO7B	0.88	9.24	0.69	7.01e-15	Renal cell carcinoma;
THYM	cis	rs6163	0.588	rs11191392	chr10:104526951	C/A	cg15744005	chr10:104629667	AS3MT	-0.77	-7.49	-0.61	3.5e-11	Waist circumference;Hip circumference;
THYM	cis	rs10911251	0.546	rs1051473	chr1:183114146	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	4.74	0.44	7.63e-6	Colorectal cancer;
THYM	cis	rs4845459	0.967	rs4112788	chr1:152551276	A/G	cg26135325	chr1:152595322	LCE3A	-0.45	-5.0	-0.46	2.63e-6	Psoriasis;
THYM	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg01073479	chr16:3509474	NAT15	0.57	4.83	0.44	5.33e-6	Tuberculosis;
THYM	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg22166914	chr1:53195759	ZYG11B	-0.82	-8.52	-0.66	2.41e-13	Monocyte count;
THYM	cis	rs7208859	0.614	rs216474	chr17:28865091	C/T	cg17105886	chr17:28927953	LRRC37B2	-1.04	-5.29	-0.48	7.66e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7127900	0.821	rs10840603	chr11:2233797	A/G	cg25635251	chr11:2234043	NA	0.74	4.79	0.44	6.19e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg04398451	chr17:18023971	MYO15A	-0.76	-6.93	-0.58	4.99e-10	Total body bone mineral density;
THYM	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg24503407	chr1:205819492	PM20D1	-0.63	-4.66	-0.43	1.03e-5	Menarche (age at onset);
THYM	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-5.12	-0.47	1.59e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7575217	0.767	rs796064	chr2:101729682	G/A	cg23907051	chr2:101730305	TBC1D8	-0.42	-5.73	-0.51	1.18e-7	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs7679	1.000	rs1057208	chr20:44563007	C/T	cg09053081	chr20:44746392	CD40	0.82	4.51	0.42	1.84e-5	Triglycerides;HDL cholesterol;Gut microbiota (functional units);
THYM	cis	rs12142240	0.698	rs72886907	chr1:46814265	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs1371867	0.846	rs1660317	chr8:101333252	G/T	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs828999	0.688	rs10785835	chr1:108696264	C/A	cg24323958	chr1:108741884	SLC25A24	0.54	5.33	0.48	6.7e-7	Monocyte percentage of white cells;
THYM	cis	rs9527	0.590	rs10883834	chr10:104881402	T/C	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs11648796	0.879	rs12448432	chr16:778820	G/A	cg01252526	chr16:711033	WDR90	-0.72	-6.53	-0.56	3.27e-9	Height;
THYM	cis	rs10540	1.000	rs61742833	chr11:490035	C/T	cg03576123	chr11:487126	PTDSS2	-1.26	-5.44	-0.49	4.11e-7	Body mass index;
THYM	cis	rs79149102	0.579	rs3816261	chr15:75336173	T/A	cg09165964	chr15:75287851	SCAMP5	-1.01	-5.02	-0.46	2.37e-6	Lung cancer;
THYM	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03517284	chr6:25882590	NA	-0.76	-5.98	-0.52	3.87e-8	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4363385	0.747	rs2339493	chr1:152975277	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.53	-0.42	1.74e-5	Inflammatory skin disease;
THYM	cis	rs259964	1.000	rs259956	chr20:57829301	T/C	cg09005679	chr20:57875326	EDN3	-0.43	-5.1	-0.46	1.74e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs4474465	0.850	rs10899538	chr11:78237749	C/T	cg19901956	chr11:77921274	USP35	0.65	4.92	0.45	3.7e-6	Alzheimer's disease (survival time);
THYM	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg10505658	chr17:80084571	CCDC57	-0.69	-7.95	-0.63	3.85e-12	Life satisfaction;
THYM	cis	rs2898681	0.650	rs6840325	chr4:53675549	A/G	cg00791764	chr4:53727839	RASL11B	0.43	5.25	0.47	9.11e-7	Optic nerve measurement (cup area);
THYM	cis	rs3768617	0.510	rs3768629	chr1:183074582	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.56	4.56	0.42	1.53e-5	Fuchs's corneal dystrophy;
THYM	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg01416388	chr22:39784598	NA	-0.73	-5.79	-0.51	8.95e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs11731175	1.000	rs62342329	chr4:189851213	G/A	cg00431894	chr4:189871012	NA	-0.81	-6.19	-0.54	1.52e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg05731713	chr7:157510257	PTPRN2	0.53	5.28	0.48	8.03e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg10515332	chr4:99064459	C4orf37	0.58	4.67	0.43	9.88e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4363385	0.719	rs2066005	chr1:152923113	G/C	cg07796016	chr1:152779584	LCE1C	-0.59	-4.57	-0.42	1.48e-5	Inflammatory skin disease;
THYM	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.16	7.96	0.63	3.69e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs1729951	0.545	rs1097288	chr3:136693721	C/T	cg21827317	chr3:136751795	NA	0.75	6.64	0.56	1.92e-9	Neuroticism;
THYM	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg02551604	chr5:131831745	NA	-0.78	-5.88	-0.52	5.99e-8	Asthma (sex interaction);
THYM	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg16325326	chr1:53192061	ZYG11B	0.68	5.61	0.5	1.96e-7	Monocyte count;
THYM	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg16586182	chr3:47516702	SCAP	-0.67	-5.62	-0.5	1.9e-7	Colorectal cancer;
THYM	cis	rs909002	0.800	rs11589306	chr1:32082822	C/G	cg13919466	chr1:32135498	COL16A1	-0.5	-5.06	-0.46	2.01e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.42	-4.98	-0.45	2.88e-6	Schizophrenia;
THYM	cis	rs1018836	0.923	rs12545279	chr8:91636373	C/G	cg16814680	chr8:91681699	NA	-0.84	-6.98	-0.58	4.03e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs1395	0.744	rs11679220	chr2:27476378	G/A	cg23587288	chr2:27483067	SLC30A3	-0.64	-5.72	-0.51	1.26e-7	Blood metabolite levels;
THYM	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.54e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs806215	0.951	rs327516	chr7:127255795	C/G	cg08586737	chr7:127225949	GCC1	0.39	4.66	0.43	1.04e-5	Type 2 diabetes;
THYM	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg01751800	chr4:77820391	ANKRD56	0.56	4.63	0.43	1.15e-5	Emphysema distribution in smoking;
THYM	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	4.46	0.42	2.21e-5	Diabetic retinopathy;
THYM	cis	rs1524976	1.000	rs2030732	chr3:65465766	T/C	cg16238336	chr3:65465873	MAGI1	1.0	6.82	0.57	8.28e-10	PR interval;
THYM	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg12963246	chr6:28129442	ZNF389	0.6	4.74	0.44	7.43e-6	Parkinson's disease;
THYM	cis	rs6840360	1.000	rs6810860	chr4:152603164	C/T	cg22705602	chr4:152727874	NA	0.59	6.33	0.54	8.03e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7523273	0.597	rs2724384	chr1:207930203	G/A	cg22525895	chr1:207977042	MIR29B2	0.76	5.16	0.47	1.36e-6	Schizophrenia;
THYM	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg13609457	chr4:120235615	NA	0.6	5.34	0.48	6.23e-7	Corneal astigmatism;
THYM	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs3849570	1.000	rs11915016	chr3:81833966	G/A	cg07356753	chr3:81810745	GBE1	-0.91	-7.45	-0.61	4.23e-11	Waist circumference;Body mass index;
THYM	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg17279839	chr7:150038598	RARRES2	-0.57	-5.5	-0.49	3.23e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.68	9.03	0.68	1.97e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg15691649	chr6:25882328	NA	0.61	4.58	0.42	1.43e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3741151	0.764	rs79892955	chr11:73096280	G/T	cg12959048	chr11:73096162	RELT	-0.54	-5.2	-0.47	1.13e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg26031613	chr14:104095156	KLC1	0.78	5.2	0.47	1.14e-6	Body mass index;
THYM	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6664467	1	rs6664467	chr1:151738403	G/A	cg07092448	chr1:151763213	TDRKH	-1.14	-6.39	-0.55	6.27e-9	Carotid plaque burden;
THYM	cis	rs76662990	0.610	rs7707483	chr5:73932763	A/C	cg13275603	chr5:73927487	ENC1	-0.78	-4.52	-0.42	1.81e-5	Residual cognition;
THYM	cis	rs977987	0.835	rs3851733	chr16:75370263	G/C	cg03315344	chr16:75512273	CHST6	0.79	6.54	0.56	3.09e-9	Dupuytren's disease;
THYM	cis	rs988913	0.768	rs9370337	chr6:54750488	C/T	cg04690482	chr6:54711388	FAM83B	0.51	6.18	0.54	1.59e-8	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1061377	1.000	rs9997089	chr4:39120883	T/C	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs36051895	0.695	rs10974921	chr9:5024427	T/A	cg02405213	chr9:5042618	JAK2	-1.02	-10.4	-0.73	2.31e-17	Pediatric autoimmune diseases;
THYM	cis	rs17030434	1.000	rs12646758	chr4:154731625	A/G	cg14289246	chr4:154710475	SFRP2	-0.86	-5.75	-0.51	1.08e-7	Electrocardiographic conduction measures;
THYM	cis	rs4919694	0.536	rs12414777	chr10:104697781	C/T	cg15744005	chr10:104629667	AS3MT	-0.88	-7.08	-0.59	2.45e-10	Arsenic metabolism;
THYM	cis	rs6838801	0.857	rs17002148	chr4:77580240	A/G	cg01477861	chr4:77609841	SHROOM3	-0.45	-4.54	-0.42	1.62e-5	Cleft lip with or without cleft palate;
THYM	cis	rs7551222	0.752	rs16853958	chr1:204528344	A/C	cg20240347	chr1:204465584	NA	-0.51	-4.53	-0.42	1.73e-5	Schizophrenia;
THYM	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg03875235	chr11:625052	MUPCDH	0.5	4.6	0.43	1.32e-5	Systemic lupus erythematosus;
THYM	cis	rs7113850	0.541	rs61875405	chr11:24376359	G/A	ch.11.24196551F	chr11:24239977	NA	0.96	5.35	0.48	6.13e-7	Bone fracture in osteoporosis;
THYM	cis	rs6728302	1.000	rs10933385	chr2:232916068	G/A	cg15348839	chr2:232224846	NA	1.12	4.49	0.42	1.98e-5	Height;
THYM	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.78	6.49	0.55	3.88e-9	Monocyte percentage of white cells;
THYM	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg06618935	chr21:46677482	NA	-0.98	-9.5	-0.7	1.95e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs910187	0.641	rs6124966	chr20:45813099	T/G	cg27589058	chr20:45804311	EYA2	-0.57	-5.12	-0.46	1.62e-6	Migraine;
THYM	cis	rs7267979	0.934	rs2261753	chr20:25262291	G/A	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1729951	0.575	rs1654904	chr3:136681149	T/C	cg21827317	chr3:136751795	NA	0.75	6.64	0.56	1.92e-9	Neuroticism;
THYM	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.92	5.88	0.52	6.04e-8	Platelet count;
THYM	cis	rs11039798	1.000	rs10160423	chr11:48457227	G/T	cg24672777	chr11:48374446	OR4C45	-1.14	-6.89	-0.58	6.15e-10	Axial length;
THYM	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg12573674	chr2:1569213	NA	-1.41	-8.91	-0.67	3.61e-14	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs7084402	0.967	rs12569559	chr10:60312711	T/G	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs17854409	0.881	rs12625401	chr20:61472939	A/T	cg06598544	chr20:61472147	COL9A3	-1.09	-7.18	-0.59	1.58e-10	Obesity-related traits;
THYM	cis	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg06521331	chr12:34319734	NA	-0.96	-8.88	-0.67	4.06e-14	Morning vs. evening chronotype;
THYM	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg26384229	chr12:38710491	ALG10B	0.72	5.56	0.5	2.48e-7	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6815814	0.898	rs73236616	chr4:38789675	G/A	cg06935464	chr4:38784597	TLR10	0.72	4.68	0.43	9.65e-6	Breast cancer;
THYM	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg26818010	chr10:134567672	INPP5A	-0.91	-7.38	-0.6	5.95e-11	Migraine;
THYM	cis	rs10789491	1.000	rs4553120	chr1:47165729	C/T	cg15501359	chr1:47185051	KIAA0494	1.14	8.24	0.65	9.45e-13	Response to hepatitis C treatment;
THYM	cis	rs9467711	0.790	rs13204572	chr6:26189356	G/C	cg16898833	chr6:26189333	HIST1H4D	1.28	4.86	0.45	4.61e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4654899	0.833	rs10127757	chr1:21490045	A/G	cg01072550	chr1:21505969	NA	-0.76	-6.77	-0.57	1.05e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg27572855	chr1:25598939	RHD	0.67	5.38	0.48	5.45e-7	Erythrocyte sedimentation rate;
THYM	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg02038168	chr22:39784481	NA	-0.65	-4.78	-0.44	6.29e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg13525197	chr6:28411240	ZSCAN23	-0.69	-4.7	-0.43	8.9e-6	Cardiac Troponin-T levels;
THYM	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg09044154	chr16:88155775	NA	-0.65	-4.53	-0.42	1.69e-5	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4792901	0.659	rs8073121	chr17:41542922	A/C	cg21940313	chr17:41620911	ETV4	-0.51	-4.95	-0.45	3.19e-6	Dupuytren's disease;
THYM	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg14004847	chr7:1930337	MAD1L1	-0.71	-5.51	-0.49	3.02e-7	Schizophrenia;
THYM	cis	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg02475374	chr8:10988117	XKR6	0.63	4.73	0.44	7.78e-6	Triglycerides;
THYM	cis	rs9581857	0.725	rs9319366	chr13:28017722	C/T	cg22138327	chr13:27999177	GTF3A	0.88	4.91	0.45	3.83e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs67460515	0.563	rs7618924	chr3:160855599	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-4.68	-0.43	9.42e-6	Parkinson's disease;
THYM	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.69	6.15	0.53	1.82e-8	Personality dimensions;
THYM	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg26384229	chr12:38710491	ALG10B	0.95	7.55	0.61	2.7e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2692947	0.673	rs2229169	chr2:96780716	T/G	cg23100626	chr2:96804247	ASTL	-0.39	-4.76	-0.44	6.93e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs3951016	0.501	rs6911599	chr6:119009913	C/T	cg21191810	chr6:118973309	C6orf204	0.49	4.6	0.43	1.28e-5	Resting heart rate;
THYM	cis	rs28595532	0.841	rs115987912	chr4:119737085	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg10856724	chr12:34555212	NA	-0.81	-6.88	-0.58	6.39e-10	Morning vs. evening chronotype;
THYM	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.61e-20	Menopause (age at onset);
THYM	cis	rs6032067	0.929	rs2143944	chr20:43819370	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs2029213	0.523	rs3773739	chr3:53268429	A/G	cg16894138	chr3:53270350	TKT	-0.79	-7.35	-0.6	6.93e-11	Heart rate;
THYM	cis	rs4523957	0.690	rs11867782	chr17:2090507	T/G	cg16513277	chr17:2031491	SMG6	-0.96	-8.73	-0.67	8.52e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6960043	0.875	rs6976381	chr7:15048814	T/C	cg19272540	chr7:15055459	NA	-0.56	-6.73	-0.57	1.26e-9	Type 2 diabetes;
THYM	cis	rs901683	1.000	rs76805415	chr10:46026163	G/A	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	trans	rs4262150	0.883	rs17488630	chr5:152244165	C/T	cg08281791	chr5:76607845	PDE8B	0.93	6.87	0.58	6.5e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg16414030	chr3:133502952	NA	-0.84	-8.28	-0.65	7.65e-13	Iron status biomarkers;
THYM	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs34638657	0.732	rs4889477	chr16:82201302	C/T	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.11	-0.64	1.73e-12	Lung adenocarcinoma;
THYM	cis	rs28829049	0.861	rs10492996	chr1:19365552	C/T	cg13387374	chr1:19411106	UBR4	0.65	5.4	0.48	4.84e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg08975724	chr8:8085496	FLJ10661	0.72	5.84	0.51	7.27e-8	Mood instability;
THYM	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg18252515	chr7:66147081	NA	-0.69	-5.46	-0.49	3.79e-7	Aortic root size;
THYM	cis	rs2574704	0.816	rs2443722	chr3:11663732	A/G	cg07643000	chr3:11666825	VGLL4	0.4	4.46	0.42	2.25e-5	Body mass index;
THYM	cis	rs966423	0.550	rs2618147	chr2:218302138	C/A	cg15335768	chr2:218268053	DIRC3	-0.37	-5.49	-0.49	3.34e-7	Thyroid cancer;
THYM	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs79387448	0.745	rs7587856	chr2:103144305	C/A	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs10911232	0.507	rs6672306	chr1:183058898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg08859206	chr1:53392774	SCP2	0.51	5.7	0.51	1.32e-7	Monocyte count;
THYM	trans	rs4866334	1.000	rs79036917	chr5:18441030	A/C	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg15704280	chr7:45808275	SEPT13	-1.04	-14.07	-0.82	5.85e-25	Height;
THYM	cis	rs1823778	0.609	rs7237171	chr18:67635948	C/T	cg13164537	chr18:67624071	CD226	1.15	4.8	0.44	5.83e-6	Mean platelet volume;
THYM	cis	rs10463554	0.824	rs427430	chr5:102432024	G/A	cg23492399	chr5:102201601	PAM	-0.68	-5.07	-0.46	1.95e-6	Parkinson's disease;
THYM	cis	rs11651000	0.894	rs17250932	chr17:45809307	T/C	cg24803719	chr17:45855879	NA	-0.66	-5.49	-0.49	3.33e-7	IgG glycosylation;
THYM	cis	rs9314614	1.000	rs2978894	chr8:6693629	G/C	cg27319216	chr8:6693540	XKR5	-0.72	-8.26	-0.65	8.64e-13	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs4242434	0.672	rs2404654	chr8:22484949	T/C	cg03733263	chr8:22462867	KIAA1967	1.0	11.13	0.75	6.58e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg06521331	chr12:34319734	NA	1.02	10.41	0.73	2.15e-17	Morning vs. evening chronotype;
THYM	trans	rs4262150	0.846	rs56313315	chr5:152307156	C/T	cg08281791	chr5:76607845	PDE8B	0.93	7.05	0.59	2.83e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg01097406	chr16:89675127	NA	-0.55	-4.51	-0.42	1.83e-5	Vitiligo;
THYM	cis	rs12220238	1.000	rs10824130	chr10:76008931	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.85	4.58	0.43	1.41e-5	Soluble interleukin-2 receptor subunit alpha;
THYM	cis	rs7131987	0.868	rs737160	chr12:29429012	T/C	cg09582351	chr12:29534625	ERGIC2	-0.47	-4.6	-0.43	1.3e-5	QT interval;
THYM	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.24	-10.08	-0.72	1.11e-16	Platelet count;
THYM	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9790314	1.000	rs9872514	chr3:161042833	T/C	cg03342759	chr3:160939853	NMD3	-0.76	-7.0	-0.58	3.68e-10	Morning vs. evening chronotype;
THYM	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg20290983	chr6:43655470	MRPS18A	1.43	15.91	0.85	1.54e-28	IgG glycosylation;
THYM	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg06784218	chr1:46089804	CCDC17	-0.34	-5.03	-0.46	2.28e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7705502	1.000	rs72812850	chr5:173378286	T/G	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs28595532	0.920	rs115576008	chr4:119736967	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs9359856	0.564	rs17584108	chr6:90458209	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.92	-8.03	-0.64	2.56e-12	Bipolar disorder;
THYM	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg01570182	chr17:44337453	NA	-0.84	-9.31	-0.69	5.04e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	trans	rs4866334	1.000	rs80033831	chr5:18481972	A/G	cg08675002	chr5:90437527	GPR98	-1.54	-7.01	-0.58	3.51e-10	IgG glycosylation;
THYM	cis	rs12530845	1.000	rs6979439	chr7:135329004	A/G	cg23117316	chr7:135346802	PL-5283	-0.66	-5.88	-0.52	6.21e-8	Red blood cell traits;
THYM	cis	rs7695732	0.595	rs4507326	chr4:89916739	T/G	cg17769793	chr4:89976368	FAM13A	-0.5	-5.27	-0.48	8.39e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs1572591	0.512	rs4112527	chr13:102119656	A/G	cg09276445	chr13:102106423	ITGBL1	-0.45	-4.78	-0.44	6.39e-6	Psychosis (atypical);
THYM	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg14018140	chr10:458528	DIP2C	-0.47	-4.72	-0.44	8.05e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs17407555	0.821	rs4473652	chr4:10141617	G/C	cg11266682	chr4:10021025	SLC2A9	-0.6	-5.82	-0.51	7.86e-8	Schizophrenia (age at onset);
THYM	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.64	-0.5	1.78e-7	Obesity-related traits;
THYM	cis	rs28476539	0.568	rs6832564	chr4:83556499	A/G	cg10249074	chr4:83542146	C4orf11	-0.62	-4.96	-0.45	3.12e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs6840360	1.000	rs6823421	chr4:152604719	T/C	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.86	-0.45	4.62e-6	Eye color traits;
THYM	cis	rs2448490	0.642	rs535111	chr11:65485337	A/G	cg17480646	chr11:65405466	SIPA1	0.71	5.64	0.5	1.74e-7	Platelet count;
THYM	cis	rs1669338	0.588	rs3931974	chr3:3186894	A/G	cg16797762	chr3:3221439	CRBN	0.94	5.22	0.47	1.06e-6	White matter integrity;
THYM	cis	rs17490626	0.512	rs12241097	chr10:71216678	T/G	cg08851181	chr10:71228077	TSPAN15	-0.71	-4.89	-0.45	4.09e-6	Thrombosis;
THYM	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg26031613	chr14:104095156	KLC1	0.94	7.39	0.6	5.77e-11	Body mass index;
THYM	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg00071950	chr4:10020882	SLC2A9	-0.75	-7.53	-0.61	2.88e-11	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg02527881	chr3:46936655	PTH1R	0.57	5.5	0.49	3.16e-7	Colorectal cancer;
THYM	cis	rs2139634	0.929	rs55950019	chr3:46511644	T/A	cg02332537	chr3:46540019	RTP3	0.46	4.69	0.43	9.11e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2637266	1.000	rs2637266	chr10:78331318	C/T	cg18941641	chr10:78392320	NA	-0.83	-7.17	-0.59	1.61e-10	Pulmonary function;
THYM	cis	rs2282300	0.739	rs34234618	chr11:30241701	T/C	cg25418670	chr11:30344373	C11orf46	-0.81	-6.87	-0.58	6.66e-10	Morning vs. evening chronotype;
THYM	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg02527881	chr3:46936655	PTH1R	-0.61	-5.7	-0.51	1.33e-7	Colorectal cancer;
THYM	cis	rs4372836	0.729	rs6547882	chr2:29037001	T/C	cg09522027	chr2:28974177	PPP1CB	-0.63	-5.0	-0.46	2.65e-6	Body mass index;
THYM	cis	rs6728302	1.000	rs59526832	chr2:233024408	C/T	cg15348839	chr2:232224846	NA	1.14	4.64	0.43	1.12e-5	Height;
THYM	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg15962314	chr1:44399869	ARTN	0.53	5.32	0.48	6.88e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg15704280	chr7:45808275	SEPT13	-1.04	-13.75	-0.82	2.5e-24	Height;
THYM	cis	rs17253792	0.822	rs79747476	chr14:56160485	C/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.11	8.07	0.64	2.15e-12	Cognitive test performance;
THYM	cis	rs13016963	0.546	rs11898821	chr2:202199688	T/C	cg12544106	chr2:202507780	ALS2CR4	-0.62	-4.52	-0.42	1.8e-5	Esophageal squamous cell carcinoma;Melanoma;
THYM	cis	rs748404	0.631	rs7163288	chr15:43671355	A/G	cg12861797	chr15:43585817	TGM7	0.45	4.58	0.43	1.4e-5	Lung cancer;
THYM	cis	rs13315871	0.929	rs77825960	chr3:58318677	A/G	cg12435725	chr3:58293450	RPP14	-0.52	-5.47	-0.49	3.67e-7	Cholesterol, total;
THYM	cis	rs611744	0.647	rs702808	chr8:109252554	T/C	cg21045802	chr8:109455806	TTC35	0.65	5.91	0.52	5.3e-8	Dupuytren's disease;
THYM	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg13319975	chr6:146136371	FBXO30	-0.66	-5.63	-0.5	1.85e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12142240	0.692	rs7532149	chr1:46824932	A/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs12042938	0.600	rs823161	chr1:231775017	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.72	5.23	0.47	1.02e-6	Neuranatomic and neurocognitive phenotypes;
THYM	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs739496	0.518	rs10744775	chr12:112096215	T/C	cg10833066	chr12:111807467	FAM109A	0.47	5.11	0.46	1.66e-6	Platelet count;
THYM	cis	rs7091068	0.532	rs637959	chr10:95399031	T/C	cg20715218	chr10:95462985	C10orf4	-0.64	-4.73	-0.44	7.93e-6	Urinary tract infection frequency;
THYM	cis	rs2364543	0.624	rs61774752	chr1:41847024	T/C	cg01193554	chr1:41846683	NA	-0.37	-5.2	-0.47	1.16e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12752838	0.777	rs11590606	chr1:8917669	C/T	cg19371916	chr1:8874984	RERE	-0.53	-4.96	-0.45	3.13e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.24	5.05	0.46	2.09e-6	Obesity-related traits;
THYM	trans	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg18335740	chr13:41363409	SLC25A15	0.73	7.78	0.62	8.87e-12	Lewy body disease;
THYM	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg00944433	chr1:107599041	PRMT6	-0.41	-5.15	-0.47	1.44e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs921968	0.643	rs2303561	chr2:219527005	C/T	cg02176678	chr2:219576539	TTLL4	-0.6	-5.84	-0.51	7.3e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg10018233	chr7:150070692	REPIN1	0.43	5.87	0.52	6.26e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs17407555	0.779	rs57757169	chr4:10115703	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-6.31	-0.54	8.83e-9	Schizophrenia (age at onset);
THYM	cis	rs9972944	0.656	rs10083855	chr17:63773139	T/C	cg07283582	chr17:63770753	CCDC46	0.68	5.54	0.49	2.69e-7	Total body bone mineral density;
THYM	cis	rs7809950	1.000	rs3801954	chr7:107117048	C/T	cg23024343	chr7:107201750	COG5	-0.93	-8.22	-0.64	1.04e-12	Coronary artery disease;
THYM	cis	rs4474465	0.920	rs10899532	chr11:78208470	T/G	cg19901956	chr11:77921274	USP35	0.66	4.95	0.45	3.22e-6	Alzheimer's disease (survival time);
THYM	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg03188948	chr7:1209495	NA	0.9	5.02	0.46	2.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg11764359	chr7:65958608	NA	0.75	5.99	0.52	3.74e-8	Aortic root size;
THYM	cis	rs886126	1.000	rs876027	chr12:111678458	A/T	cg10833066	chr12:111807467	FAM109A	0.44	5.36	0.48	5.76e-7	Coronary heart disease;
THYM	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg14159672	chr1:205819179	PM20D1	0.56	4.66	0.43	1.01e-5	Parkinson's disease;
THYM	cis	rs3806843	0.735	rs2563333	chr5:140052271	A/G	cg19875535	chr5:140030758	IK	-0.63	-5.24	-0.47	9.46e-7	Depressive symptoms (multi-trait analysis);
THYM	trans	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.12	-13.73	-0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22857025	chr5:266934	NA	-1.38	-9.05	-0.68	1.76e-14	Breast cancer;
THYM	cis	rs11190604	0.767	rs10883485	chr10:102174805	G/C	cg07570687	chr10:102243282	WNT8B	0.81	7.68	0.62	1.44e-11	Palmitoleic acid (16:1n-7) levels;
THYM	trans	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg10856724	chr12:34555212	NA	-0.82	-7.07	-0.59	2.55e-10	Bladder cancer;
THYM	cis	rs728616	0.867	rs55666905	chr10:81953639	C/T	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg18252515	chr7:66147081	NA	-0.63	-4.68	-0.43	9.63e-6	Aortic root size;
THYM	cis	rs6840360	0.571	rs6833814	chr4:152539679	A/G	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg15704280	chr7:45808275	SEPT13	-1.02	-13.18	-0.8	3.51e-23	Coronary artery disease;
THYM	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg05373962	chr22:49881684	NA	-0.66	-6.05	-0.53	2.82e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg19761014	chr17:28927070	LRRC37B2	0.86	4.78	0.44	6.47e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.07	-5.34	-0.48	6.29e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10489202	0.608	rs6657019	chr1:168079669	T/C	cg24449463	chr1:168025552	DCAF6	-0.79	-7.54	-0.61	2.77e-11	Schizophrenia;
THYM	cis	rs4919694	0.908	rs11191523	chr10:104792400	A/G	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg18758796	chr5:131593413	PDLIM4	0.63	6.2	0.54	1.49e-8	Breast cancer;
THYM	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg08847533	chr14:75593920	NEK9	0.83	8.39	0.65	4.49e-13	Coronary artery disease;
THYM	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	1.05	13.17	0.8	3.73e-23	Subjective well-being;
THYM	cis	rs2816062	0.786	rs2816055	chr1:18898248	A/G	cg18795169	chr1:18902165	NA	-0.99	-12.14	-0.78	5.02e-21	Urate levels in lean individuals;
THYM	cis	rs7322722	0.945	rs9530626	chr13:77803604	C/T	cg04565255	chr13:77565759	CLN5	-0.44	-4.49	-0.42	2.03e-5	Preeclampsia;
THYM	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg24154853	chr7:158122151	PTPRN2	-0.51	-4.69	-0.43	9.17e-6	Calcium levels;
THYM	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	6.9	0.58	5.76e-10	Smoking behavior;
THYM	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg02852791	chr16:710674	WDR90	0.51	4.77	0.44	6.7e-6	Height;
THYM	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg12826209	chr6:26865740	GUSBL1	0.87	4.6	0.43	1.28e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg01616529	chr11:638424	DRD4	-0.78	-6.62	-0.56	2.16e-9	Systemic lupus erythematosus;
THYM	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg11965913	chr1:205819406	PM20D1	0.85	8.36	0.65	5.21e-13	Monocyte percentage of white cells;
THYM	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg08645402	chr16:4508243	NA	0.72	6.44	0.55	4.84e-9	Schizophrenia;
THYM	cis	rs10193935	0.901	rs222471	chr2:42638057	C/T	cg27598129	chr2:42591480	NA	0.76	4.88	0.45	4.19e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg11245990	chr11:68621969	NA	0.57	7.2	0.59	1.41e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2976388	0.609	rs1469811	chr8:143787999	C/T	cg06565975	chr8:143823917	SLURP1	0.47	5.22	0.47	1.06e-6	Urinary tract infection frequency;
THYM	cis	rs4722166	0.508	rs2069832	chr7:22767433	A/G	cg05472934	chr7:22766657	IL6	0.89	7.63	0.62	1.82e-11	Lung cancer;
THYM	cis	rs6570726	0.935	rs411641	chr6:145827532	G/A	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs34638657	0.673	rs11645286	chr16:82201898	C/A	cg09439754	chr16:82129088	HSD17B2	-0.53	-5.32	-0.48	6.81e-7	Lung adenocarcinoma;
THYM	cis	rs933688	0.938	rs10942634	chr5:90658392	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.75	4.91	0.45	3.8e-6	Smoking behavior;
THYM	cis	rs1775715	0.678	rs2778649	chr10:32146803	C/G	cg04359828	chr10:32216031	ARHGAP12	0.39	4.83	0.44	5.32e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg27494647	chr7:150038898	RARRES2	0.43	5.42	0.49	4.44e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs1018836	0.608	rs1033347	chr8:91464137	G/A	cg16814680	chr8:91681699	NA	-0.71	-5.72	-0.51	1.22e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg08885076	chr2:99613938	TSGA10	-0.74	-6.98	-0.58	3.88e-10	Chronic sinus infection;
THYM	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg04731861	chr2:219085781	ARPC2	0.55	5.26	0.47	8.86e-7	Colorectal cancer;
THYM	cis	rs6840360	0.615	rs62329085	chr4:152470237	G/A	cg22705602	chr4:152727874	NA	-0.71	-7.43	-0.61	4.71e-11	Intelligence (multi-trait analysis);
THYM	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg07959070	chr22:50026188	C22orf34	-0.25	-4.69	-0.43	9.18e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs17744121	0.584	rs17813106	chr21:30499897	A/C	cg24692254	chr21:30365293	RNF160	0.93	4.47	0.42	2.18e-5	Visceral fat;
THYM	cis	rs1971762	0.583	rs12810378	chr12:54091838	G/T	cg00028308	chr12:54090754	NA	0.63	4.52	0.42	1.76e-5	Height;
THYM	cis	rs9611198	1.000	rs9611198	chr22:39955873	A/C	cg19570171	chr22:39239822	NPTXR	0.59	4.61	0.43	1.25e-5	Schizophrenia;
THYM	cis	rs5417	0.689	rs55868524	chr17:7170665	G/A	cg15298719	chr17:7165255	CLDN7	-0.38	-5.59	-0.5	2.21e-7	Diastolic blood pressure;
THYM	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg11526020	chr17:80870163	TBCD	0.45	4.46	0.42	2.26e-5	Glycated hemoglobin levels;
THYM	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg05738196	chr6:26577821	NA	0.95	9.89	0.71	2.78e-16	Intelligence (multi-trait analysis);
THYM	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg02136620	chr5:178986620	RUFY1	0.48	4.72	0.44	8.03e-6	Lung cancer;
THYM	cis	rs7580658	0.724	rs6712551	chr2:127998485	G/A	cg10021288	chr2:128175891	PROC	-0.67	-5.93	-0.52	4.89e-8	Protein C levels;
THYM	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg24803719	chr17:45855879	NA	-0.6	-6.3	-0.54	9.35e-9	IgG glycosylation;
THYM	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg10560079	chr2:191398806	TMEM194B	0.95	7.73	0.62	1.11e-11	Diastolic blood pressure;
THYM	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2050392	0.630	rs303428	chr10:30739058	C/T	cg13289132	chr10:30722225	MAP3K8	0.6	4.78	0.44	6.37e-6	Inflammatory bowel disease;
THYM	cis	rs9876781	1.000	rs9815103	chr3:48414215	G/A	cg06066452	chr3:48470258	PLXNB1	0.26	4.88	0.45	4.26e-6	Longevity;
THYM	cis	rs3126085	0.935	rs2291770	chr1:152179792	G/C	cg10321714	chr1:152280068	FLG	0.68	4.95	0.45	3.2e-6	Atopic dermatitis;
THYM	cis	rs9914544	0.545	rs8073436	chr17:18801841	A/G	cg26378065	chr17:18585709	ZNF286B	0.58	4.65	0.43	1.05e-5	Educational attainment (years of education);
THYM	cis	rs1021993	0.868	rs906351	chr1:209527925	C/T	cg06155620	chr1:209527581	NA	-0.63	-5.41	-0.49	4.62e-7	Gut microbiome composition (winter);
THYM	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11657217	1.000	rs8081537	chr17:77708264	A/G	cg06901238	chr17:77706717	ENPP7	0.69	5.7	0.5	1.34e-7	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
THYM	cis	rs854765	0.547	rs4459604	chr17:17888549	A/G	cg04398451	chr17:18023971	MYO15A	-0.96	-9.97	-0.72	1.87e-16	Total body bone mineral density;
THYM	cis	rs35264875	1.000	rs6591370	chr11:68843003	G/A	cg23845249	chr11:68861649	NA	0.54	5.48	0.49	3.53e-7	Blond vs. brown hair color;
THYM	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg11247378	chr22:39784982	NA	-1.06	-13.37	-0.81	1.49e-23	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.6	-0.56	2.37e-9	Chronic sinus infection;
THYM	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs7843479	0.601	rs4422769	chr8:21844265	A/G	cg17168535	chr8:21777572	XPO7	0.84	7.44	0.61	4.5e-11	Mean corpuscular volume;
THYM	cis	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg10856724	chr12:34555212	NA	1.07	9.98	0.72	1.83e-16	Morning vs. evening chronotype;
THYM	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg04731861	chr2:219085781	ARPC2	0.54	5.05	0.46	2.11e-6	Colorectal cancer;
THYM	cis	rs12291225	0.637	rs8570	chr11:14300759	C/G	cg19336497	chr11:14380999	RRAS2	-0.82	-9.53	-0.7	1.67e-15	Sense of smell;
THYM	cis	rs7646881	1.000	rs59918529	chr3:158452705	T/C	cg19483011	chr3:158453295	NA	-0.69	-4.93	-0.45	3.45e-6	Tetralogy of Fallot;
THYM	cis	rs931127	0.658	rs7926512	chr11:65464487	T/A	cg27068330	chr11:65405492	SIPA1	-0.82	-7.33	-0.6	7.54e-11	Systemic lupus erythematosus;
THYM	cis	rs986417	0.901	rs8020084	chr14:61001495	C/T	cg27398547	chr14:60952738	C14orf39	1.19	6.01	0.52	3.42e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg20387954	chr3:183756860	HTR3D	0.55	4.48	0.42	2.11e-5	Anterior chamber depth;
THYM	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg17810781	chr1:201082982	CACNA1S	0.66	6.85	0.57	7.45e-10	Permanent tooth development;
THYM	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg23428387	chr22:49814324	NA	-0.55	-5.65	-0.5	1.65e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1994135	0.654	rs1447872	chr12:33718343	C/A	cg06521331	chr12:34319734	NA	-0.72	-4.99	-0.46	2.68e-6	Resting heart rate;
THYM	cis	rs7267979	0.966	rs6050567	chr20:25354561	C/T	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	trans	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg25517755	chr10:38738941	LOC399744	-0.78	-7.2	-0.59	1.43e-10	Corneal astigmatism;
THYM	cis	rs2276314	0.857	rs9304155	chr18:33585710	A/C	cg19628046	chr18:33552617	C18orf21	0.73	5.32	0.48	6.76e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs1003719	0.788	rs7276917	chr21:38451334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs3785574	1.000	rs3785574	chr17:61763185	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.52	0.42	1.81e-5	Height;
THYM	cis	rs36051895	0.664	rs10815154	chr9:5095538	G/A	cg02405213	chr9:5042618	JAK2	-1.0	-11.31	-0.76	2.67e-19	Pediatric autoimmune diseases;
THYM	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg22907277	chr7:1156413	C7orf50	0.87	7.52	0.61	3.02e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg18252515	chr7:66147081	NA	-0.67	-5.13	-0.47	1.5e-6	Aortic root size;
THYM	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg08835221	chr22:38071607	LGALS1	0.34	4.55	0.42	1.56e-5	Fat distribution (HIV);
THYM	cis	rs7568458	0.684	rs60012532	chr2:85752474	A/C	cg02493740	chr2:85810744	VAMP5	-0.6	-4.55	-0.42	1.57e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs12681288	0.550	rs7000482	chr8:958380	T/C	cg08648136	chr8:956695	NA	0.57	4.93	0.45	3.44e-6	Schizophrenia;
THYM	cis	rs9906944	0.657	rs4643373	chr17:47123423	T/C	cg18128536	chr17:47092178	IGF2BP1	-0.43	-4.56	-0.42	1.54e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs8048589	1.000	rs12596549	chr16:12183500	C/A	cg02910054	chr16:12241554	SNX29	0.67	5.39	0.48	5.16e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs9314614	0.934	rs2978893	chr8:6696017	G/A	cg27319216	chr8:6693540	XKR5	-0.66	-7.15	-0.59	1.8e-10	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg12908607	chr1:44402522	ARTN	-0.6	-5.36	-0.48	5.73e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs35883536	0.565	rs2647322	chr1:101031962	G/T	cg09408571	chr1:101003634	GPR88	0.52	5.68	0.5	1.44e-7	Monocyte count;
THYM	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg24818145	chr4:99064322	C4orf37	0.74	5.89	0.52	5.92e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10203711	1.000	rs11682137	chr2:239588939	G/A	cg14580085	chr2:239553406	NA	0.62	5.61	0.5	1.96e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11671005	0.610	rs8103813	chr19:59072684	C/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.62	-4.95	-0.45	3.16e-6	Mean platelet volume;
THYM	cis	rs2276314	0.857	rs28435069	chr18:33628475	A/G	cg05985134	chr18:33552581	C18orf21	0.66	4.84	0.44	5.02e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg18131467	chr2:239335373	ASB1	1.1	11.05	0.75	9.8e-19	Multiple system atrophy;
THYM	cis	rs36051895	0.623	rs10118267	chr9:5243736	T/C	cg02405213	chr9:5042618	JAK2	-0.94	-9.53	-0.7	1.69e-15	Pediatric autoimmune diseases;
THYM	cis	rs10788264	0.569	rs3901289	chr10:124027433	T/C	cg09507567	chr10:124027408	NA	0.47	4.63	0.43	1.16e-5	Total body bone mineral density;
THYM	cis	rs10203711	1.000	rs4663940	chr2:239570382	C/T	cg14580085	chr2:239553406	NA	0.69	6.19	0.54	1.55e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs911119	1.000	rs13041070	chr20:23614261	G/A	cg16589663	chr20:23618590	CST3	0.78	4.77	0.44	6.71e-6	Chronic kidney disease;
THYM	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs12478296	0.581	rs56142391	chr2:242992248	C/T	cg18898632	chr2:242989856	NA	-0.68	-4.7	-0.43	8.72e-6	Obesity-related traits;
THYM	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs8008758	0.517	rs1772028	chr14:101693861	C/G	cg26224664	chr14:101693935	NA	-0.77	-8.35	-0.65	5.35e-13	Body mass index (alcohol intake interaction);
THYM	cis	rs2285947	1.000	rs10228845	chr7:21583617	G/A	cg04471919	chr7:21584483	DNAH11	0.45	4.46	0.42	2.29e-5	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
THYM	cis	rs72792324	1.000	rs17097227	chr5:140737992	C/G	cg21929183	chr5:140807225	PCDHGA4;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB8P;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	-0.89	-4.6	-0.43	1.31e-5	Mean platelet volume;
THYM	cis	rs2806561	1.000	rs2806558	chr1:23503456	T/C	cg19743168	chr1:23544995	NA	0.6	6.4	0.55	5.87e-9	Height;
THYM	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg22875332	chr1:76189707	ACADM	-0.74	-6.47	-0.55	4.26e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg19318889	chr4:1322082	MAEA	0.69	5.93	0.52	4.98e-8	Longevity;
THYM	cis	rs1401999	0.898	rs9876143	chr3:183731362	C/G	cg01324343	chr3:183735012	ABCC5	0.85	11.53	0.76	9.24e-20	Anterior chamber depth;
THYM	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg03188948	chr7:1209495	NA	1.12	6.69	0.57	1.52e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.82e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs6570726	0.791	rs407887	chr6:145843759	C/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.42	-0.49	4.53e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg18305652	chr10:134549665	INPP5A	0.74	5.82	0.51	7.97e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg17644776	chr2:200775616	C2orf69	-0.69	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.67	9.04	0.68	1.87e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1878931	0.582	rs27231	chr16:3434966	C/T	cg21433313	chr16:3507492	NAT15	-0.57	-4.77	-0.44	6.61e-6	Body mass index (adult);
THYM	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg03806693	chr22:41940476	POLR3H	-1.04	-7.62	-0.62	1.86e-11	Vitiligo;
THYM	cis	rs11771526	0.901	rs10223907	chr7:32297813	G/C	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.79e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg02187348	chr16:89574699	SPG7	0.68	4.89	0.45	4.04e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs244731	0.959	rs3105419	chr5:176551396	G/C	cg17509989	chr5:176798049	RGS14	0.69	6.08	0.53	2.53e-8	Urate levels in lean individuals;
THYM	cis	rs10197940	0.578	rs2432957	chr2:152287897	A/C	cg19508488	chr2:152266495	RIF1	0.65	5.08	0.46	1.88e-6	Lung cancer;
THYM	cis	rs1933112	1.000	rs2223582	chr1:168506535	A/C	cg00154920	chr1:168513310	XCL2	-0.5	-5.01	-0.46	2.51e-6	Blood protein levels;
THYM	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19346786	chr7:2764209	NA	-0.55	-4.72	-0.44	8.24e-6	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs7107174	1.000	rs901104	chr11:77930499	C/T	cg02023728	chr11:77925099	USP35	0.73	6.41	0.55	5.61e-9	Testicular germ cell tumor;
THYM	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg25703541	chr22:24373054	LOC391322	0.78	7.52	0.61	3.08e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs9467711	0.559	rs2295593	chr6:26501768	C/T	cg12826209	chr6:26865740	GUSBL1	0.9	4.96	0.45	3.09e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs673253	0.686	rs3791136	chr1:44049947	C/T	cg24466421	chr1:44070974	PTPRF	-0.6	-5.34	-0.48	6.24e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg05368731	chr17:41323189	NBR1	1.2	10.14	0.72	8.4e-17	Menopause (age at onset);
THYM	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg11327659	chr7:150037044	RARRES2	0.48	5.38	0.48	5.31e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg27284194	chr4:1044797	NA	-0.63	-4.81	-0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs10789491	1.000	rs1440487	chr1:47167075	C/T	cg15501359	chr1:47185051	KIAA0494	-1.14	-8.24	-0.65	9.45e-13	Response to hepatitis C treatment;
THYM	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg10589385	chr1:150898437	SETDB1	0.57	4.55	0.42	1.56e-5	Tonsillectomy;
THYM	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg07636037	chr3:49044803	WDR6	0.96	9.89	0.71	2.83e-16	Parkinson's disease;
THYM	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.5	-4.77	-0.44	6.67e-6	Crohn's disease;
THYM	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11009175	0.725	rs1832926	chr10:33303604	T/G	cg00146027	chr10:33299147	NA	-0.83	-5.29	-0.48	7.93e-7	Depression (quantitative trait);
THYM	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg18230493	chr5:56204884	C5orf35	0.64	4.8	0.44	5.87e-6	Initial pursuit acceleration;
THYM	cis	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg06521331	chr12:34319734	NA	-0.97	-8.51	-0.66	2.45e-13	Morning vs. evening chronotype;
THYM	cis	rs78366141	0.649	rs78179026	chr4:89657456	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	1.24	5.15	0.47	1.43e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg25554036	chr4:6271136	WFS1	0.56	5.29	0.48	7.94e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs1398942	0.545	rs13150503	chr4:89973243	G/A	cg17769793	chr4:89976368	FAM13A	-0.43	-4.54	-0.42	1.62e-5	Post bronchodilator FEV1;
THYM	cis	rs3820068	0.608	rs2057304	chr1:16017710	A/G	cg27534772	chr1:16042836	PLEKHM2	0.51	5.37	0.48	5.57e-7	Systolic blood pressure;
THYM	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg13695892	chr22:41940480	POLR3H	0.9	7.31	0.6	8.34e-11	Vitiligo;
THYM	cis	rs931127	0.624	rs2306364	chr11:65412467	G/A	cg27068330	chr11:65405492	SIPA1	-0.88	-8.35	-0.65	5.6e-13	Systemic lupus erythematosus;
THYM	cis	rs4242434	0.819	rs1059592	chr8:22477778	G/A	cg01710189	chr8:22454888	PDLIM2	-0.45	-4.78	-0.44	6.36e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9527	0.590	rs10509766	chr10:104926334	T/C	cg04362960	chr10:104952993	NT5C2	0.65	5.04	0.46	2.18e-6	Arsenic metabolism;
THYM	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg14458575	chr2:238380390	NA	-0.99	-8.26	-0.65	8.57e-13	Prostate cancer;
THYM	cis	rs526231	0.543	rs7709726	chr5:102327463	A/G	cg23492399	chr5:102201601	PAM	0.64	5.09	0.46	1.8e-6	Primary biliary cholangitis;
THYM	cis	rs2067615	0.524	rs1922436	chr12:107065258	A/G	cg15890332	chr12:107067104	RFX4	0.48	5.52	0.49	2.95e-7	Heart rate;
THYM	cis	rs7412746	0.611	rs12085336	chr1:150775780	A/T	cg10589385	chr1:150898437	SETDB1	0.62	5.34	0.48	6.42e-7	Melanoma;
THYM	cis	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg26384229	chr12:38710491	ALG10B	-0.71	-5.57	-0.5	2.4e-7	Morning vs. evening chronotype;
THYM	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg08847533	chr14:75593920	NEK9	-0.96	-10.3	-0.73	3.86e-17	Height;
THYM	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg12311346	chr5:56204834	C5orf35	-0.81	-5.9	-0.52	5.54e-8	Initial pursuit acceleration;
THYM	trans	rs17828380	0.841	rs34195340	chr15:63577624	T/C	cg14996143	chr2:172945328	MAP1D	-1.45	-6.99	-0.58	3.82e-10	Social communication problems;
THYM	cis	rs988913	0.678	rs9382440	chr6:54930374	A/G	cg18532076	chr6:54711417	FAM83B	0.49	4.59	0.43	1.33e-5	Menarche (age at onset);
THYM	cis	rs7804356	0.871	rs727450	chr7:26787642	G/A	cg24979288	chr7:27242424	NA	0.62	4.46	0.42	2.26e-5	Type 1 diabetes;
THYM	cis	rs7586879	0.828	rs7597157	chr2:25089166	C/T	cg01884057	chr2:25150051	NA	0.51	4.49	0.42	2.01e-5	Body mass index;
THYM	cis	rs7084921	0.552	rs12769652	chr10:101885536	A/G	cg11344164	chr10:101878520	NA	-0.56	-5.44	-0.49	4.09e-7	Bone mineral density;
THYM	cis	rs7119038	0.774	rs2004781	chr11:118619253	C/T	cg19308663	chr11:118741387	NA	0.57	5.33	0.48	6.51e-7	Sjögren's syndrome;
THYM	cis	rs1322639	0.618	rs9505942	chr6:169591793	T/C	cg04662567	chr6:169592167	NA	-0.65	-5.02	-0.46	2.36e-6	Pulse pressure;
THYM	cis	rs3796352	1.000	rs11707575	chr3:53113762	G/T	cg07884673	chr3:53033167	SFMBT1	0.99	4.88	0.45	4.2e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs13102973	0.645	rs11734870	chr4:135885118	T/A	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	cis	rs501916	0.761	rs79925748	chr15:48046412	G/C	cg20869673	chr15:48010124	SEMA6D	0.73	5.62	0.5	1.88e-7	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.94	0.75	1.62e-18	Diabetic retinopathy;
THYM	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg09436375	chr6:42928200	GNMT	-0.39	-4.89	-0.45	4.04e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4808199	0.894	rs9304960	chr19:19465529	G/A	cg03709012	chr19:19516395	GATAD2A	1.1	6.32	0.54	8.6e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs4888262	0.545	rs8052923	chr16:74680105	C/T	cg01733217	chr16:74700730	RFWD3	0.88	9.41	0.69	2.97e-15	Testicular germ cell tumor;
THYM	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg14159672	chr1:205819179	PM20D1	0.61	4.87	0.45	4.49e-6	Parkinson's disease;
THYM	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg14972814	chr11:95582409	MTMR2	-0.78	-6.52	-0.56	3.3e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg09703963	chr11:616879	IRF7;MUPCDH	-0.61	-4.75	-0.44	7.08e-6	Systemic lupus erythematosus;
THYM	cis	rs6733011	0.538	rs7565614	chr2:99464834	C/T	cg08885076	chr2:99613938	TSGA10	-0.49	-4.55	-0.42	1.61e-5	Bipolar disorder;
THYM	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg13770153	chr20:60521292	NA	-0.73	-4.73	-0.44	7.76e-6	Body mass index;
THYM	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg22189786	chr22:42395067	WBP2NL	0.56	5.09	0.46	1.79e-6	Birth weight;
THYM	cis	rs12282928	0.959	rs2007961	chr11:48273208	G/C	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg25801113	chr15:45476975	SHF	-0.39	-4.5	-0.42	1.91e-5	Uric acid levels;
THYM	cis	rs28595532	0.920	rs116105567	chr4:119746204	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs7394190	0.630	rs113799665	chr10:75575138	C/T	cg02286717	chr10:75415704	SYNPO2L	-0.86	-4.6	-0.43	1.33e-5	Incident atrial fibrillation;
THYM	cis	rs2067615	0.524	rs4275715	chr12:107062246	C/T	cg15890332	chr12:107067104	RFX4	0.45	5.08	0.46	1.86e-6	Heart rate;
THYM	cis	rs12257961	0.579	rs4748160	chr10:15360718	T/A	cg10616319	chr10:15468812	NA	-0.7	-5.31	-0.48	7.08e-7	Selective IgA deficiency;
THYM	cis	rs9905704	0.647	rs2286299	chr17:57043367	T/G	cg12560992	chr17:57184187	TRIM37	0.71	5.49	0.49	3.35e-7	Testicular germ cell tumor;
THYM	cis	rs35264875	0.846	rs2924534	chr11:68870516	C/G	cg23845249	chr11:68861649	NA	-0.51	-5.31	-0.48	7.13e-7	Blond vs. brown hair color;
THYM	cis	rs9297145	0.585	rs62473049	chr7:98777685	T/C	cg05967295	chr7:98741636	SMURF1	-0.72	-5.74	-0.51	1.12e-7	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg10589385	chr1:150898437	SETDB1	0.61	5.03	0.46	2.31e-6	Melanoma;
THYM	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg11752832	chr7:134001865	SLC35B4	0.76	5.72	0.51	1.24e-7	Mean platelet volume;
THYM	cis	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg24308560	chr3:49941425	MST1R	-0.72	-6.35	-0.55	7.36e-9	Intelligence (multi-trait analysis);
THYM	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg24399712	chr22:39784796	NA	-0.8	-7.28	-0.6	9.82e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg08885076	chr2:99613938	TSGA10	-0.68	-6.4	-0.55	5.79e-9	Chronic sinus infection;
THYM	cis	rs12681287	0.577	rs13257414	chr8:87494138	C/T	cg27223183	chr8:87520930	FAM82B	-0.71	-5.09	-0.46	1.82e-6	Caudate activity during reward;
THYM	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg01386294	chr6:25732093	NA	0.89	4.51	0.42	1.84e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10887741	0.532	rs791885	chr10:89410546	A/T	cg13926569	chr10:89418898	PAPSS2	0.62	5.89	0.52	5.75e-8	Exercise (leisure time);
THYM	cis	rs293526	0.959	rs3120809	chr6:83684434	A/G	cg23278060	chr6:83777448	DOPEY1	0.63	4.67	0.43	9.71e-6	Crohn's disease;
THYM	cis	rs7646881	0.504	rs61080878	chr3:158462897	C/T	cg18349298	chr3:158450550	RARRES1	0.53	4.67	0.43	9.81e-6	Tetralogy of Fallot;
THYM	cis	rs7428	0.545	rs1053561	chr2:85546052	A/G	cg24342717	chr2:85555507	TGOLN2	-0.74	-6.59	-0.56	2.43e-9	Ear protrusion;
THYM	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2456568	0.802	rs7115629	chr11:93635477	G/A	cg17347335	chr11:93583973	C11orf90	-0.48	-4.58	-0.43	1.39e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs3008870	0.755	rs2755271	chr1:67474977	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.79	6.88	0.58	6.22e-10	Lymphocyte percentage of white cells;
THYM	cis	rs7084402	0.967	rs1658435	chr10:60327527	A/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.67	-0.5	1.52e-7	Refractive error;
THYM	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg11266682	chr4:10021025	SLC2A9	0.68	9.68	0.7	7.95e-16	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2073300	1.000	rs6137966	chr20:23444359	A/T	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Gout;
THYM	cis	rs6930083	0.605	rs3829964	chr6:36644498	T/C	cg08179530	chr6:36648295	CDKN1A	0.82	6.18	0.54	1.6e-8	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10100465	0.961	rs7817912	chr8:118644565	C/G	cg09430518	chr8:118662568	NA	-0.34	-5.4	-0.48	4.83e-7	Leprosy;
THYM	cis	rs12410462	0.892	rs75757169	chr1:227629855	A/G	cg23173402	chr1:227635558	NA	0.68	6.15	0.53	1.79e-8	Major depressive disorder;
THYM	cis	rs17125944	0.615	rs1998779	chr14:53295950	T/A	cg00686598	chr14:53173677	PSMC6	-0.93	-4.67	-0.43	9.8200000000000008e-06	Alzheimer's disease (late onset);
THYM	cis	rs295140	0.526	rs295113	chr2:201197816	C/G	cg14106933	chr2:201194453	SPATS2L	-0.42	-4.49	-0.42	2e-5	QT interval;
THYM	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg03060546	chr3:49711283	APEH	0.7	4.87	0.45	4.48e-6	Resting heart rate;
THYM	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg06634786	chr22:41940651	POLR3H	0.66	5.13	0.47	1.54e-6	Vitiligo;
THYM	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg14004847	chr7:1930337	MAD1L1	-0.66	-4.87	-0.45	4.5e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg18681998	chr4:17616180	MED28	1.0	10.49	0.73	1.52e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg11166453	chr1:247681781	NA	0.65	5.18	0.47	1.25e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs7677751	0.767	rs890204	chr4:55064439	C/G	cg17187183	chr4:55093834	PDGFRA	0.65	4.97	0.45	2.95e-6	Corneal astigmatism;
THYM	cis	rs11651000	0.857	rs57171311	chr17:45826168	A/G	cg06532163	chr17:45867833	NA	0.58	5.47	0.49	3.58e-7	IgG glycosylation;
THYM	cis	rs9928842	0.770	rs8048371	chr16:75275547	C/T	cg09066997	chr16:75300724	BCAR1	0.74	4.55	0.42	1.61e-5	Alcoholic chronic pancreatitis;
THYM	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg26384229	chr12:38710491	ALG10B	1.02	8.46	0.66	3.1400000000000003e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6430585	0.697	rs6724569	chr2:136516970	G/A	cg07169764	chr2:136633963	MCM6	1.22	13.28	0.81	2.23e-23	Corneal structure;
THYM	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg21475434	chr5:93447410	FAM172A	0.95	6.03	0.53	3.16e-8	Diabetic retinopathy;
THYM	cis	rs7119	0.717	rs12912386	chr15:77817640	T/C	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs985746	0.614	rs4832819	chr4:36819193	A/G	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs7107174	1.000	rs55761949	chr11:77993860	A/G	cg02023728	chr11:77925099	USP35	0.67	6.02	0.53	3.25e-8	Testicular germ cell tumor;
THYM	cis	rs1387259	0.570	rs12368659	chr12:48562299	C/A	cg21466736	chr12:48725269	NA	-0.49	-4.9	-0.45	3.87e-6	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg22467129	chr15:76604101	ETFA	-0.56	-5.16	-0.47	1.37e-6	Blood metabolite levels;
THYM	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg06917634	chr15:78832804	PSMA4	0.83	7.46	0.61	4.07e-11	Sudden cardiac arrest;
THYM	cis	rs995000	0.931	rs1168044	chr1:62977558	A/C	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg13683864	chr3:40499215	RPL14	-0.91	-8.93	-0.68	3.18e-14	Renal cell carcinoma;
THYM	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg11266682	chr4:10021025	SLC2A9	0.52	6.37	0.55	6.84e-9	Bone mineral density;
THYM	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg09469691	chr10:81107165	PPIF	0.77	6.21	0.54	1.42e-8	Height;
THYM	cis	rs1371867	0.875	rs1962901	chr8:101326428	A/G	cg00191853	chr8:101177733	SPAG1	-0.51	-5.03	-0.46	2.29e-6	Atrioventricular conduction;
THYM	cis	rs2504916	0.668	rs2484240	chr6:160733839	C/T	cg19643109	chr6:160697625	NA	-0.64	-4.83	-0.44	5.17e-6	Response to hepatitis C treatment;
THYM	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs11948739	0.501	rs971699	chr5:130361558	A/G	cg08523029	chr5:130500466	HINT1	-0.85	-5.98	-0.52	3.88e-8	Pediatric bone mineral content (hip);
THYM	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8180040	0.726	rs9843075	chr3:47195630	A/G	cg27129171	chr3:47204927	SETD2	0.79	7.41	0.61	5.25e-11	Colorectal cancer;
THYM	cis	rs28647808	0.748	rs28721280	chr9:136267318	C/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	trans	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg25214090	chr10:38739885	LOC399744	0.83	7.17	0.59	1.61e-10	Corneal astigmatism;
THYM	cis	rs7677751	0.767	rs11133315	chr4:55082158	G/A	cg17187183	chr4:55093834	PDGFRA	0.72	5.59	0.5	2.19e-7	Corneal astigmatism;
THYM	cis	rs58688157	0.705	rs936468	chr11:607175	G/A	cg03909863	chr11:638404	DRD4	-0.77	-5.47	-0.49	3.71e-7	Systemic lupus erythematosus;
THYM	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00475322	chr7:917719	C7orf20	0.49	6.19	0.54	1.55e-8	Perceived unattractiveness to mosquitoes;
THYM	cis	rs921968	0.643	rs497983	chr2:219415189	A/G	cg02176678	chr2:219576539	TTLL4	0.64	6.08	0.53	2.49e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg08999081	chr20:33150536	PIGU	0.58	4.91	0.45	3.82e-6	Height;
THYM	trans	rs629535	0.911	rs490165	chr8:70014976	A/G	cg21567404	chr3:27674614	NA	-1.11	-10.75	-0.74	4.16e-18	Dupuytren's disease;
THYM	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.75	-4.88	-0.45	4.34e-6	Lung cancer in ever smokers;
THYM	cis	rs9470366	0.527	rs4711456	chr6:36632482	C/T	cg24425727	chr6:36645648	CDKN1A	0.7	6.66	0.56	1.79e-9	QRS duration;
THYM	cis	rs6084875	0.896	rs8114648	chr20:4733369	C/T	cg19614321	chr20:4804581	RASSF2	-0.46	-4.63	-0.43	1.16e-5	Systemic lupus erythematosus;
THYM	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg09354556	chr3:47051341	NA	0.46	4.71	0.44	8.28e-6	Colorectal cancer;
THYM	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg11317459	chr13:21872234	NA	-1.21	-9.22	-0.69	7.83e-15	White matter hyperintensity burden;
THYM	cis	rs17604090	1.000	rs17604090	chr7:29691438	C/T	cg19413766	chr7:29689036	LOC646762	-1.06	-5.82	-0.51	8.1e-8	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg06600287	chr1:53387719	ECHDC2	-0.34	-5.47	-0.49	3.64e-7	Monocyte count;
THYM	cis	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs2357013	0.658	rs13423867	chr2:53047108	C/T	cg07782112	chr2:53107842	NA	0.61	4.63	0.43	1.16e-5	Hemostatic factors and hematological phenotypes;
THYM	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-5.79	-0.51	9.2e-8	Chronic sinus infection;
THYM	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg26149184	chr10:133730230	NA	0.79	4.79	0.44	6.23e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs9733	0.519	rs11587444	chr1:150722844	A/G	cg10589385	chr1:150898437	SETDB1	0.64	5.48	0.49	3.48e-7	Tonsillectomy;
THYM	cis	rs2282930	0.512	rs2282928	chr7:50720320	C/T	cg08586669	chr7:50727761	GRB10	0.31	4.57	0.42	1.48e-5	Bone mineral density;
THYM	cis	rs6427356	0.513	rs10796973	chr1:157147158	T/C	cg27547283	chr1:156698502	C1orf66;ISG20L2	-0.58	-4.49	-0.42	2.02e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg26879891	chr1:152191343	HRNR	-0.56	-4.86	-0.45	4.69e-6	Inflammatory skin disease;
THYM	cis	rs4731207	0.698	rs2402753	chr7:124448259	A/G	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	7.5	0.61	3.41e-11	Platelet count;
THYM	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg27494647	chr7:150038898	RARRES2	0.46	5.19	0.47	1.17e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg17747265	chr1:1875780	NA	-0.69	-7.27	-0.6	9.89e-11	Body mass index;
THYM	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg09904177	chr6:26538194	HMGN4	0.62	4.96	0.45	3.06e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2456568	0.803	rs10831140	chr11:93640689	G/A	cg17347335	chr11:93583973	C11orf90	-0.48	-4.63	-0.43	1.18e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg14004847	chr7:1930337	MAD1L1	-0.62	-4.84	-0.44	5.04e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg13877915	chr19:58951672	ZNF132	0.95	9.52	0.7	1.76e-15	Uric acid clearance;
THYM	cis	rs3540	0.597	rs11639150	chr15:91042071	C/G	cg22089800	chr15:90895588	ZNF774	-0.68	-5.22	-0.47	1.05e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg23711669	chr6:146136114	FBXO30	-0.94	-9.29	-0.69	5.4e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg14779329	chr11:130786720	SNX19	0.56	6.33	0.54	7.99e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6723226	0.708	rs2710627	chr2:32758627	A/G	cg02381751	chr2:32503542	YIPF4	0.65	5.63	0.5	1.8e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4788570	0.655	rs1392484	chr16:71822101	T/A	cg06353428	chr16:71660113	MARVELD3	1.41	8.74	0.67	8.32e-14	Intelligence (multi-trait analysis);
THYM	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg00383909	chr3:49044727	WDR6	1.03	5.9	0.52	5.64e-8	Cognitive ability (multi-trait analysis);
THYM	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg00277334	chr10:82204260	NA	-0.54	-5.51	-0.49	3.03e-7	Post bronchodilator FEV1;
THYM	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	5.28	0.48	8.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4866334	1.000	rs114489248	chr5:18478969	C/A	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22857025	chr5:266934	NA	-1.5	-9.71	-0.71	6.9e-16	Breast cancer;
THYM	cis	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-5.9	-0.52	5.56e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs870825	0.872	rs12507711	chr4:185571776	C/T	cg04058563	chr4:185651563	MLF1IP	0.79	5.63	0.5	1.84e-7	Blood protein levels;
THYM	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9326248	0.581	rs10502222	chr11:116833730	C/T	cg20608306	chr11:116969690	SIK3	0.63	7.95	0.63	3.79e-12	Blood protein levels;
THYM	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg00071950	chr4:10020882	SLC2A9	0.88	9.22	0.69	7.56e-15	Bone mineral density;
THYM	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg12935359	chr14:103987150	CKB	-0.65	-6.4	-0.55	5.78e-9	Body mass index;
THYM	cis	rs778371	0.522	rs10205801	chr2:233597196	G/A	cg08000102	chr2:233561755	GIGYF2	0.73	6.96	0.58	4.42e-10	Schizophrenia;
THYM	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg26384229	chr12:38710491	ALG10B	-0.83	-8.3	-0.65	6.83e-13	Heart rate;
THYM	cis	rs1933112	1.000	rs1024177	chr1:168526715	T/C	cg00154920	chr1:168513310	XCL2	-0.5	-5.03	-0.46	2.31e-6	Blood protein levels;
THYM	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14240646	chr10:27532245	ACBD5	0.86	5.03	0.46	2.28e-6	Breast cancer;
THYM	cis	rs9905704	0.647	rs2036730	chr17:57038282	A/G	cg12560992	chr17:57184187	TRIM37	0.71	5.49	0.49	3.35e-7	Testicular germ cell tumor;
THYM	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg23791538	chr6:167370224	RNASET2	-0.6	-4.54	-0.42	1.67e-5	Crohn's disease;
THYM	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg07884673	chr3:53033167	SFMBT1	1.17	5.88	0.52	6.13e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2274459	0.778	rs2281917	chr6:33655728	G/C	cg06253072	chr6:33679850	C6orf125	0.47	4.7	0.43	8.63e-6	Obesity (extreme);
THYM	cis	rs10197940	0.578	rs1061305	chr2:152346979	T/C	cg19508488	chr2:152266495	RIF1	0.72	5.62	0.5	1.94e-7	Lung cancer;
THYM	cis	rs4595586	0.525	rs4511319	chr12:39340457	T/C	cg13010199	chr12:38710504	ALG10B	0.6	4.6	0.43	1.31e-5	Morning vs. evening chronotype;
THYM	cis	rs7584330	0.554	rs74832280	chr2:238426625	G/A	cg08992911	chr2:238395768	MLPH	0.85	5.39	0.48	5.19e-7	Prostate cancer;
THYM	trans	rs868153	0.625	rs6929586	chr6:122476615	T/G	cg25287149	chr4:125353337	NA	-0.64	-6.89	-0.58	6.19e-10	Vertical cup-disc ratio;
THYM	cis	rs2797160	1.000	rs1935774	chr6:125996661	A/G	cg16306078	chr6:126000798	NA	0.52	5.29	0.48	7.89e-7	Endometrial cancer;
THYM	cis	rs854765	0.647	rs712267	chr17:18021607	G/A	cg04398451	chr17:18023971	MYO15A	-0.98	-10.7	-0.74	5.36e-18	Total body bone mineral density;
THYM	cis	rs447921	0.861	rs12951513	chr17:74455069	C/T	cg17201438	chr17:74438067	UBE2O	0.76	5.44	0.49	4.18e-7	Mitochondrial DNA levels;
THYM	cis	rs4595586	0.566	rs11615585	chr12:39409351	C/T	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs4849845	0.889	rs10188430	chr2:121033418	C/T	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-5.36	-0.48	5.83e-7	Hemoglobin concentration;
THYM	cis	rs422249	0.720	rs174455	chr11:61656117	A/G	cg01500311	chr11:61656094	FADS3	-0.53	-5.09	-0.46	1.83e-6	Trans fatty acid levels;
THYM	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg22875332	chr1:76189707	ACADM	0.88	11.22	0.75	4.31e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg02734326	chr4:10020555	SLC2A9	0.74	6.66	0.56	1.73e-9	Bone mineral density;
THYM	cis	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg09085632	chr11:111637200	PPP2R1B	1.16	11.93	0.77	1.35e-20	Primary sclerosing cholangitis;
THYM	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg10518543	chr12:38710700	ALG10B	-0.57	-4.61	-0.43	1.24e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg18681998	chr4:17616180	MED28	0.97	9.8	0.71	4.41e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs10779751	0.734	rs1148485	chr1:11148759	G/A	cg08854313	chr1:11322531	MTOR	0.82	5.6	0.5	2.05e-7	Body mass index;
THYM	cis	rs9486719	0.895	rs12195315	chr6:96905711	T/G	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs8133932	0.701	rs2150454	chr21:47288142	T/C	cg20357416	chr21:47294739	PCBP3	-0.85	-5.24	-0.47	9.77e-7	Schizophrenia;
THYM	cis	rs4654899	0.897	rs7515308	chr1:21085653	G/C	cg01072550	chr1:21505969	NA	-0.61	-5.27	-0.48	8.41e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs2898681	1.000	rs2411281	chr4:53757057	G/A	cg21521518	chr4:53727714	RASL11B	0.51	5.64	0.5	1.73e-7	Optic nerve measurement (cup area);
THYM	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg23187316	chr7:1099788	C7orf50	0.58	4.53	0.42	1.73e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3796352	0.527	rs11714793	chr3:52924930	A/G	cg07884673	chr3:53033167	SFMBT1	0.97	5.84	0.51	7.42e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs17776563	0.853	rs72763822	chr15:89143949	C/T	cg01779732	chr15:90015521	RHCG	0.45	4.47	0.42	2.15e-5	Thyroid hormone levels;
THYM	cis	rs921968	0.612	rs573555	chr2:219348888	A/C	cg02176678	chr2:219576539	TTLL4	0.64	6.08	0.53	2.49e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg02753203	chr1:228287806	NA	0.94	9.75	0.71	5.72e-16	Diastolic blood pressure;
THYM	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg05347473	chr6:146136440	FBXO30	0.56	4.45	0.42	2.34e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs586688	0.625	rs606114	chr1:201664101	C/T	cg14168733	chr1:201708718	NAV1	0.57	5.17	0.47	1.27e-6	Obesity-related traits;
THYM	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg00376283	chr12:123451042	ABCB9	0.72	4.94	0.45	3.36e-6	Neutrophil percentage of white cells;
THYM	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.97	-7.62	-0.62	1.88e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs968451	0.789	rs1569501	chr22:39683534	A/T	cg24268161	chr22:39747459	SYNGR1	-0.63	-4.54	-0.42	1.67e-5	Primary biliary cholangitis;
THYM	cis	rs1278352	0.759	rs1278349	chr10:127772348	G/A	cg08295661	chr10:127769903	ADAM12	-0.54	-5.47	-0.49	3.63e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs8033133	0.836	rs11634716	chr15:25306646	C/T	cg14481604	chr15:25334117	SNORD116-22	0.7	4.73	0.44	7.74e-6	Blood osmolality (transformed sodium);
THYM	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg02782426	chr3:40428986	ENTPD3	0.54	4.79	0.44	6.02e-6	Renal cell carcinoma;
THYM	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg17644776	chr2:200775616	C2orf69	-0.77	-4.5	-0.42	1.95e-5	Schizophrenia;
THYM	cis	rs6500395	0.928	rs7199206	chr16:48702538	A/G	cg04672837	chr16:48644449	N4BP1	-0.54	-5.59	-0.5	2.2e-7	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg27588902	chr6:42928151	GNMT	-0.53	-5.47	-0.49	3.63e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.88	-7.78	-0.62	8.71e-12	Intelligence (multi-trait analysis);
THYM	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.75	8.38	0.65	4.66e-13	Eosinophil percentage of white cells;
THYM	cis	rs7580658	0.724	rs4662711	chr2:127990840	G/A	cg09152259	chr2:128156114	NA	-0.4	-5.25	-0.47	9.18e-7	Protein C levels;
THYM	cis	rs4919694	1.000	rs17727044	chr10:104821256	A/T	cg04362960	chr10:104952993	NT5C2	1.15	7.03	0.59	3.1e-10	Arsenic metabolism;
THYM	cis	rs7246967	0.604	rs58536761	chr19:22880331	G/C	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs10979	0.965	rs7754452	chr6:143889028	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg22535103	chr8:58192502	C8orf71	-0.97	-5.52	-0.49	2.97e-7	Developmental language disorder (linguistic errors);
THYM	trans	rs17685	0.884	rs8565	chr7:75630274	T/C	cg19862616	chr7:65841803	NCRNA00174	-1.02	-10.99	-0.75	1.31e-18	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.12	7.7	0.62	1.28e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs8073060	0.544	rs225244	chr17:33946581	A/G	cg19694781	chr19:47549865	TMEM160	0.87	7.29	0.6	9.04e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Body mass index;
THYM	cis	rs7106204	0.534	rs76397001	chr11:24254188	A/C	ch.11.24196551F	chr11:24239977	NA	0.89	4.62	0.43	1.22e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs57590327	0.583	rs13062245	chr3:81833718	G/T	cg07356753	chr3:81810745	GBE1	-0.86	-6.59	-0.56	2.41e-9	Extraversion;
THYM	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg23131131	chr22:24373011	LOC391322	0.84	8.04	0.64	2.47e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg21775007	chr8:11205619	TDH	0.65	5.29	0.48	7.91e-7	Retinal vascular caliber;
THYM	cis	rs7586879	0.639	rs4077678	chr2:25122840	C/G	cg01884057	chr2:25150051	NA	0.72	7.58	0.61	2.33e-11	Body mass index;
THYM	cis	rs7631605	0.875	rs7616105	chr3:37229522	G/A	cg21328643	chr3:37258149	NA	-0.48	-4.54	-0.42	1.67e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg24375607	chr4:120327624	NA	0.64	5.09	0.46	1.84e-6	Corneal astigmatism;
THYM	cis	rs6138458	1.000	rs6106984	chr20:24977006	T/C	cg06937882	chr20:24974362	C20orf3	-0.46	-4.64	-0.43	1.11e-5	Blood protein levels;
THYM	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg14972814	chr11:95582409	MTMR2	-0.59	-5.36	-0.48	5.87e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs858239	0.665	rs858306	chr7:23242754	A/T	cg18081818	chr7:23246105	NA	-0.6	-5.43	-0.49	4.39e-7	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2075230	0.705	rs1641517	chr17:7551730	T/G	cg27413385	chr17:7515425	FXR2	-0.36	-5.31	-0.48	7.3e-7	Hormone measurements;
THYM	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg20387954	chr3:183756860	HTR3D	-0.59	-4.9	-0.45	4.01e-6	Anterior chamber depth;
THYM	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg13114125	chr14:105738426	BRF1	-0.74	-5.73	-0.51	1.16e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9913156	0.589	rs7213481	chr17:4547906	C/T	cg19197139	chr17:4613644	ARRB2	0.81	4.82	0.44	5.44e-6	Lymphocyte counts;
THYM	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.6	-5.06	-0.46	2.06e-6	Coronary artery disease;
THYM	cis	rs4788570	0.578	rs8062188	chr16:71729825	T/C	cg06353428	chr16:71660113	MARVELD3	1.39	9.15	0.68	1.09e-14	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg07414643	chr4:187882934	NA	0.67	5.92	0.52	5.16e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7312774	0.618	rs3803122	chr12:107354680	G/A	cg16260113	chr12:107380972	MTERFD3	1.31	6.68	0.57	1.61e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs892961	0.932	rs11657961	chr17:75405407	C/T	cg05865280	chr17:75406074	SEPT9	0.5	8.56	0.66	1.99e-13	Airflow obstruction;
THYM	cis	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs946836	0.562	rs11211630	chr1:48382561	C/T	cg18376692	chr1:48452465	NA	-0.5	-4.97	-0.45	2.94e-6	White matter integrity;
THYM	trans	rs4460079	0.507	rs7672712	chr4:114766992	A/G	cg25329844	chr11:118015865	SCN4B	-0.81	-6.88	-0.58	6.35e-10	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.34	-0.48	6.28e-7	Menopause (age at onset);
THYM	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg03060546	chr3:49711283	APEH	-0.67	-5.39	-0.48	5.13e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs7582180	0.700	rs4640404	chr2:100980523	C/T	cg08017756	chr2:100939284	LONRF2	0.72	7.42	0.61	4.95e-11	Intelligence (multi-trait analysis);
THYM	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg27494647	chr7:150038898	RARRES2	0.46	5.82	0.51	8.06e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2236521	0.617	rs113604626	chr20:60893506	T/G	cg09594475	chr20:60884601	LAMA5	0.32	4.61	0.43	1.25e-5	Pelvic organ prolapse;
THYM	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg22105103	chr4:187893119	NA	0.95	10.14	0.72	8.21e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6499255	0.857	rs16959035	chr16:69707645	C/A	cg00738113	chr16:70207722	CLEC18C	-0.44	-4.57	-0.42	1.45e-5	IgE levels;
THYM	cis	rs600806	0.850	rs10858085	chr1:109914983	A/G	cg02175308	chr1:109941060	SORT1	-0.56	-4.99	-0.46	2.76e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6430585	0.527	rs62168836	chr2:136463117	G/A	cg07169764	chr2:136633963	MCM6	1.02	9.09	0.68	1.43e-14	Corneal structure;
THYM	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14442939	chr10:27389572	ANKRD26	0.86	4.61	0.43	1.25e-5	Breast cancer;
THYM	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.84	0.71	3.66e-16	Prudent dietary pattern;
THYM	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.17	11.49	0.76	1.16e-19	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7607369	0.580	rs7568196	chr2:219652373	G/A	cg02176678	chr2:219576539	TTLL4	-0.57	-4.97	-0.45	2.94e-6	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs2737618	0.551	rs2816989	chr1:200070765	G/T	cg21825944	chr1:200113062	NR5A2	0.61	5.37	0.48	5.67e-7	Uric acid levels;
THYM	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg21427119	chr20:30132790	HM13	-0.73	-4.94	-0.45	3.41e-6	Mean corpuscular hemoglobin;
THYM	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1371867	0.846	rs1660345	chr8:101322762	C/A	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12142240	0.698	rs10158130	chr1:46822600	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs2932538	0.922	rs6659677	chr1:113087076	G/C	cg22162597	chr1:113214053	CAPZA1	0.66	5.21	0.47	1.09e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg27129171	chr3:47204927	SETD2	-0.7	-6.22	-0.54	1.35e-8	Colorectal cancer;
THYM	cis	rs16922576	0.640	rs12343727	chr9:5215926	A/G	cg02405213	chr9:5042618	JAK2	-0.76	-7.04	-0.59	2.95e-10	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs1299926	0.702	rs9924807	chr16:8865963	G/T	cg03718620	chr16:8771680	ABAT	1.06	4.52	0.42	1.78e-5	Anger;
THYM	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.05	-7.29	-0.6	9.14e-11	Platelet count;
THYM	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg01264106	chr22:38071602	LGALS1	0.39	5.02	0.46	2.43e-6	Fat distribution (HIV);
THYM	cis	rs28595532	0.920	rs116559327	chr4:119754526	T/G	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs713587	0.967	rs10182181	chr2:25150296	C/T	cg15423357	chr2:25149977	NA	-0.68	-7.67	-0.62	1.49e-11	Body mass index in non-asthmatics;
THYM	cis	rs11771526	1.000	rs11770367	chr7:32354319	C/T	cg13207630	chr7:32358064	NA	1.08	6.32	0.54	8.55e-9	Body mass index;
THYM	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs9649465	0.967	rs3757505	chr7:123391641	C/T	cg15443791	chr7:124364398	NA	0.56	4.63	0.43	1.16e-5	Migraine;
THYM	cis	rs4731207	0.596	rs10270055	chr7:124649406	T/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs17253792	0.822	rs10083493	chr14:56045411	C/T	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg05768032	chr16:30646687	NA	0.54	5.46	0.49	3.83e-7	Multiple myeloma;
THYM	cis	rs1055129	0.560	rs9302994	chr17:73906934	G/A	cg12407791	chr17:73824354	UNC13D	-0.41	-4.46	-0.42	2.24e-5	White matter hyperintensity burden;
THYM	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg03806693	chr22:41940476	POLR3H	-1.18	-9.5	-0.7	1.96e-15	Vitiligo;
THYM	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06481639	chr22:41940642	POLR3H	0.82	5.77	0.51	9.74e-8	Vitiligo;
THYM	cis	rs2463822	0.583	rs72919462	chr11:62035663	G/A	cg06239285	chr11:62104954	ASRGL1	-0.98	-4.71	-0.43	8.58e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs3847687	0.565	rs11061294	chr12:131519661	G/A	cg25772418	chr12:131519998	GPR133	-0.35	-4.51	-0.42	1.89e-5	Longevity;
THYM	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg01831904	chr17:28903510	LRRC37B2	-1.02	-5.06	-0.46	2.05e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4474465	0.833	rs10793317	chr11:78212011	G/A	cg19901956	chr11:77921274	USP35	0.65	4.8	0.44	5.97e-6	Alzheimer's disease (survival time);
THYM	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg10047753	chr17:41438598	NA	-1.0	-8.2	-0.64	1.13e-12	Menopause (age at onset);
THYM	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22496380	chr5:211416	CCDC127	-1.36	-8.28	-0.65	7.59e-13	Breast cancer;
THYM	cis	rs220324	0.688	rs56184115	chr21:43560554	G/T	cg09727148	chr21:43560719	UMODL1	0.84	9.86	0.71	3.26e-16	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg13319975	chr6:146136371	FBXO30	-0.64	-5.37	-0.48	5.49e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.09	-7.74	-0.62	1.06e-11	Platelet count;
THYM	cis	rs1451375	0.698	rs11238226	chr7:50645827	A/G	cg18232548	chr7:50535776	DDC	0.69	5.35	0.48	6.04e-7	Malaria;
THYM	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.43	0.7	2.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs42648	0.837	rs3761804	chr7:89915338	C/T	cg25739043	chr7:89950458	NA	-0.53	-4.53	-0.42	1.72e-5	Homocysteine levels;
THYM	cis	rs17604090	0.938	rs10253264	chr7:29692543	T/C	cg19413766	chr7:29689036	LOC646762	-1.05	-5.89	-0.52	5.72e-8	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs2067615	0.599	rs10778508	chr12:107159405	A/G	cg15890332	chr12:107067104	RFX4	-0.49	-5.75	-0.51	1.1e-7	Heart rate;
THYM	cis	rs9311676	0.656	rs55964615	chr3:58389120	A/T	cg26110898	chr3:58419937	PDHB	0.45	4.79	0.44	6.17e-6	Systemic lupus erythematosus;
THYM	cis	rs868036	0.915	rs4489954	chr15:68072075	A/C	cg24579218	chr15:68104479	NA	0.63	6.11	0.53	2.2e-8	Restless legs syndrome;
THYM	cis	rs3804749	1.000	rs3804749	chr3:122833003	A/G	cg26084141	chr3:122786895	PDIA5	-0.46	-4.59	-0.43	1.34e-5	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg09035930	chr12:129282057	SLC15A4	0.87	11.85	0.77	1.96e-20	Systemic lupus erythematosus;
THYM	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg27168131	chr21:44088823	PDE9A	-0.46	-4.53	-0.42	1.74e-5	Mean corpuscular volume;
THYM	cis	rs4795419	1	rs4795419	chr17:38166003	G/A	cg17467752	chr17:38218738	THRA	0.86	7.09	0.59	2.4e-10	Monocyte percentage of white cells;
THYM	cis	rs56309584	0.715	rs74506939	chr17:8139463	G/A	cg08322244	chr17:8066669	VAMP2	-0.58	-5.09	-0.46	1.81e-6	Initial pursuit acceleration;
THYM	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-5.11	-0.46	1.65e-6	Hemoglobin concentration;
THYM	cis	rs887829	0.569	rs3806596	chr2:234637707	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.68	5.46	0.49	3.86e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg06634786	chr22:41940651	POLR3H	-0.72	-5.26	-0.48	8.73e-7	Vitiligo;
THYM	cis	rs17401966	0.931	rs11587854	chr1:10447622	G/A	cg19773385	chr1:10388646	KIF1B	-0.6	-4.7	-0.43	8.88e-6	Hepatocellular carcinoma;
THYM	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-5.25	-0.47	9.12e-7	Morning vs. evening chronotype;
THYM	cis	rs4363385	0.510	rs6673356	chr1:153041903	C/T	cg13444842	chr1:152974279	SPRR3	0.6	4.74	0.44	7.54e-6	Inflammatory skin disease;
THYM	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg11327659	chr7:150037044	RARRES2	0.4	4.63	0.43	1.15e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs11122895	1.000	rs11122892	chr2:112467836	C/T	cg23262488	chr2:112468472	NA	0.67	9.57	0.7	1.36e-15	Allergic sensitization;
THYM	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg07389463	chr12:132296394	NA	0.62	6.04	0.53	2.94e-8	Migraine;
THYM	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg03929089	chr4:120376271	NA	-1.02	-12.29	-0.78	2.4e-21	Height;
THYM	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg15691649	chr6:25882328	NA	-0.8	-6.45	-0.55	4.55e-9	Intelligence (multi-trait analysis);
THYM	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg04731861	chr2:219085781	ARPC2	0.56	5.38	0.48	5.29e-7	Colorectal cancer;
THYM	cis	rs4731207	0.735	rs12155120	chr7:124478232	T/C	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs910187	0.605	rs8124918	chr20:45811860	A/G	cg27589058	chr20:45804311	EYA2	-0.59	-5.04	-0.46	2.22e-6	Migraine;
THYM	cis	rs9563576	0.778	rs7999764	chr13:58576243	T/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs2688608	0.901	rs2459446	chr10:75601596	C/T	cg19442545	chr10:75533431	FUT11	0.44	4.68	0.43	9.37e-6	Inflammatory bowel disease;
THYM	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg12863693	chr15:85201151	NMB	0.55	4.74	0.44	7.47e-6	Schizophrenia;
THYM	cis	rs981844	0.826	rs1545604	chr4:154682733	C/T	cg22178613	chr4:154710499	SFRP2	-0.58	-4.67	-0.43	9.88e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg27414909	chr4:1201492	LOC100130872;LOC100130872-SPON2	0.62	4.69	0.43	9.18e-6	Longevity;
THYM	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg06028808	chr11:68637592	NA	0.68	7.24	0.6	1.18e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg21433313	chr16:3507492	NAT15	-0.51	-4.53	-0.42	1.7e-5	Body mass index (adult);
THYM	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg16586182	chr3:47516702	SCAP	0.67	5.62	0.5	1.9e-7	Colorectal cancer;
THYM	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg01324343	chr3:183735012	ABCC5	0.74	9.12	0.68	1.24e-14	Anterior chamber depth;
THYM	cis	rs240764	0.621	rs11752659	chr6:101212241	A/G	cg21058520	chr6:100914733	NA	0.6	5.28	0.48	8.25e-7	Neuroticism;
THYM	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.28	6.38	0.55	6.44e-9	Obesity-related traits;
THYM	cis	rs6429082	0.755	rs291384	chr1:235644300	C/T	cg26050004	chr1:235667680	B3GALNT2	0.74	6.18	0.54	1.6e-8	Adiposity;
THYM	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg26566898	chr11:117069891	TAGLN	0.38	4.74	0.44	7.46e-6	Blood protein levels;
THYM	cis	rs7508	0.509	rs414260	chr8:17904322	C/G	cg01800426	chr8:17659068	MTUS1	-0.66	-4.59	-0.43	1.37e-5	Atrial fibrillation;
THYM	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg24250549	chr1:154909240	PMVK	-0.67	-5.79	-0.51	8.88e-8	Prostate cancer;
THYM	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg25838465	chr1:92012736	NA	-0.9	-8.55	-0.66	2.09e-13	Breast cancer;
THYM	cis	rs4378999	0.660	rs9824444	chr3:50782765	C/T	cg27233566	chr3:49894142	TRAIP	0.77	4.47	0.42	2.16e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.38	0.48	5.3e-7	Tonsillectomy;
THYM	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs36051895	0.623	rs1120679	chr9:5248073	C/G	cg02405213	chr9:5042618	JAK2	-0.94	-9.67	-0.7	8.55e-16	Pediatric autoimmune diseases;
THYM	cis	rs12643440	0.574	rs1581400	chr4:17139504	A/G	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg01710189	chr8:22454888	PDLIM2	-0.55	-5.88	-0.52	6.08e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg00071950	chr4:10020882	SLC2A9	-0.88	-9.3	-0.69	5.18e-15	Bone mineral density;
THYM	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg13852791	chr20:30311386	BCL2L1	0.67	4.76	0.44	7.04e-6	Mean corpuscular hemoglobin;
THYM	cis	rs2637266	0.935	rs12772269	chr10:78394292	C/A	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg16342193	chr10:102329863	NA	-0.53	-5.32	-0.48	6.84e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7705502	0.962	rs17696407	chr5:173387335	C/A	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs9902453	0.838	rs3110495	chr17:27978455	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-5.23	-0.47	1.02e-6	Coffee consumption (cups per day);
THYM	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg21385522	chr1:16154831	NA	0.68	4.7	0.43	8.73e-6	Systolic blood pressure;
THYM	cis	rs1847202	0.793	rs11918132	chr3:72952144	C/T	cg25664220	chr3:72788482	NA	-0.65	-4.83	-0.44	5.21e-6	Motion sickness;
THYM	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg07424592	chr7:64974309	NA	1.16	5.55	0.5	2.55e-7	Diabetic kidney disease;
THYM	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg04234412	chr22:24373322	LOC391322	-0.8	-5.78	-0.51	9.64e-8	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs3862260	0.509	rs3862262	chr1:120161841	G/T	cg11530693	chr1:120165357	ZNF697	1.08	12.38	0.79	1.6e-21	Systemic lupus erythematosus;
THYM	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg12560992	chr17:57184187	TRIM37	0.94	8.84	0.67	5.01e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7607369	0.609	rs13391398	chr2:219282429	A/G	cg02176678	chr2:219576539	TTLL4	0.58	5.46	0.49	3.74e-7	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06634786	chr22:41940651	POLR3H	-0.81	-6.28	-0.54	1.03e-8	Vitiligo;
THYM	cis	rs11771526	0.710	rs7804577	chr7:32373104	A/G	cg27532318	chr7:32358331	NA	0.78	4.96	0.45	3.11e-6	Body mass index;
THYM	cis	rs8180040	0.768	rs11915074	chr3:47309757	A/T	cg27129171	chr3:47204927	SETD2	-0.75	-7.08	-0.59	2.48e-10	Colorectal cancer;
THYM	cis	rs2625529	0.590	rs2856929	chr15:72496762	T/C	cg16672083	chr15:72433130	SENP8	-0.52	-4.66	-0.43	1.03e-5	Red blood cell count;
THYM	cis	rs2932538	0.961	rs1238	chr1:113214097	G/A	cg22162597	chr1:113214053	CAPZA1	-0.65	-5.08	-0.46	1.91e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.91	-9.21	-0.69	7.91e-15	Chronic sinus infection;
THYM	cis	rs4363657	0.614	rs4149000	chr12:21447997	C/T	cg14622193	chr12:21587445	NA	0.87	5.14	0.47	1.46e-6	Bilirubin levels;Blood metabolite levels;
THYM	cis	rs11552708	0.504	rs8082166	chr17:7388728	G/C	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	IgM levels;
THYM	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg14779329	chr11:130786720	SNX19	0.54	5.88	0.52	6.12e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs240764	0.817	rs6905221	chr6:101151537	G/A	cg21058520	chr6:100914733	NA	0.6	5.37	0.48	5.6e-7	Neuroticism;
THYM	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg04731861	chr2:219085781	ARPC2	-0.54	-5.22	-0.47	1.03e-6	Colorectal cancer;
THYM	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg19016782	chr12:123741754	C12orf65	-0.7	-4.59	-0.43	1.35e-5	Height;Educational attainment;Head circumference (infant);
THYM	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg03188948	chr7:1209495	NA	1.13	6.46	0.55	4.45e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2461751	0.527	rs80274443	chr2:176492091	G/A	cg05500840	chr2:176972068	HOXD11	0.85	4.66	0.43	1.03e-5	Electrocardiographic conduction measures;
THYM	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg11812906	chr14:75593930	NEK9	-0.81	-7.31	-0.6	8.48e-11	Height;
THYM	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg00376283	chr12:123451042	ABCB9	0.68	5.2	0.47	1.12e-6	Height;Educational attainment;Head circumference (infant);
THYM	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg11871910	chr12:69753446	YEATS4	0.66	5.31	0.48	7.08e-7	Response to diuretic therapy;
THYM	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg23682913	chr1:2080710	PRKCZ	-0.59	-5.24	-0.47	9.66e-7	Height;
THYM	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg13319975	chr6:146136371	FBXO30	0.68	5.48	0.49	3.53e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs612683	0.560	rs491675	chr1:100902936	A/G	cg06223162	chr1:101003688	GPR88	0.76	6.59	0.56	2.44e-9	Breast cancer;
THYM	cis	rs72827839	0.802	rs72825584	chr17:46293089	G/A	cg23391107	chr17:45924227	SP6	0.85	5.05	0.46	2.17e-6	Ease of getting up in the morning;
THYM	cis	rs4866334	1.000	rs77695209	chr5:18483369	T/C	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs7584330	0.554	rs3751111	chr2:238426953	G/T	cg08992911	chr2:238395768	MLPH	0.85	5.39	0.48	5.19e-7	Prostate cancer;
THYM	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg01831904	chr17:28903510	LRRC37B2	-1.04	-5.14	-0.47	1.48e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg15921436	chr17:44337874	NA	0.95	6.92	0.58	5.33e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs61931739	0.853	rs11053002	chr12:34083499	T/C	cg06521331	chr12:34319734	NA	0.64	5.26	0.48	8.83e-7	Morning vs. evening chronotype;
THYM	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.05	6.65	0.56	1.88e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs8058578	1.000	rs67456513	chr16:30714828	A/T	cg05768032	chr16:30646687	NA	0.56	5.61	0.5	1.98e-7	Multiple myeloma;
THYM	cis	rs1161098	0.710	rs7304063	chr12:67812464	A/T	cg20473420	chr12:67782441	NA	0.76	5.06	0.46	2.02e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs4596713	0.568	rs10124710	chr9:71748279	G/A	cg16512924	chr15:28394682	HERC2	0.82	6.97	0.58	4.13e-10	Headache;
THYM	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg10661904	chr17:79619235	PDE6G	-0.57	-5.3	-0.48	7.61e-7	Eye color traits;
THYM	cis	rs11039798	0.764	rs1121450	chr11:48897476	C/T	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs6430585	0.583	rs3769013	chr2:136556182	C/T	cg04750100	chr2:136595281	LCT	0.49	4.76	0.44	6.96e-6	Corneal structure;
THYM	cis	rs990171	1.000	rs4851588	chr2:103073505	C/G	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.13	-0.47	1.5e-6	Lymphocyte counts;
THYM	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg04398451	chr17:18023971	MYO15A	-0.95	-10.8	-0.74	3.33e-18	Total body bone mineral density;
THYM	cis	rs300703	0.515	rs440617	chr2:189818	A/G	cg21211680	chr2:198530	NA	-0.87	-5.91	-0.52	5.26e-8	Blood protein levels;
THYM	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg17401067	chr22:41840292	TOB2	0.54	5.21	0.47	1.1e-6	Vitiligo;
THYM	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg00071950	chr4:10020882	SLC2A9	0.88	9.22	0.69	7.56e-15	Bone mineral density;
THYM	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg17063962	chr7:91808500	NA	-1.15	-12.48	-0.79	9.72e-22	Breast cancer;
THYM	cis	rs459482	1.000	rs464783	chr21:42796480	A/G	cg16817229	chr21:42798199	MX1	-0.57	-4.47	-0.42	2.2e-5	IgG glycosylation;
THYM	cis	rs9790314	0.905	rs7613358	chr3:160949296	T/C	cg03342759	chr3:160939853	NMD3	-0.93	-8.74	-0.67	8.11e-14	Morning vs. evening chronotype;
THYM	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg18252515	chr7:66147081	NA	0.65	4.73	0.44	7.72e-6	Aortic root size;
THYM	cis	rs7681440	0.606	rs2028535	chr4:90756421	C/G	cg06632027	chr4:90757378	SNCA	0.67	5.27	0.48	8.45e-7	Dementia with Lewy bodies;
THYM	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg09703963	chr11:616879	IRF7;MUPCDH	-0.64	-5.53	-0.49	2.78e-7	Systemic lupus erythematosus;
THYM	cis	rs2637266	0.935	rs2583048	chr10:78404507	C/G	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs2130392	0.926	rs4610379	chr4:185624388	A/G	cg04058563	chr4:185651563	MLF1IP	0.59	5.76	0.51	1.04e-7	Kawasaki disease;
THYM	cis	rs7614311	0.731	rs56126667	chr3:63866286	A/G	cg22134162	chr3:63841271	THOC7	-0.56	-6.61	-0.56	2.18e-9	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs912057	0.841	rs1294423	chr6:6743795	C/T	cg06612196	chr6:6737390	NA	0.69	9.83	0.71	3.75e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg27535305	chr1:53392650	SCP2	0.39	4.64	0.43	1.11e-5	Monocyte count;
THYM	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg06618935	chr21:46677482	NA	-0.97	-9.08	-0.68	1.51e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs35164067	0.805	rs12720270	chr19:10475760	G/A	cg01466491	chr19:10523363	NA	-0.68	-4.99	-0.46	2.76e-6	Inflammatory bowel disease;
THYM	trans	rs17001239	0.557	rs1740082	chr21:26935372	C/T	cg20081244	chr17:79859945	NPB	0.7	6.94	0.58	4.7e-10	Cognitive performance;
THYM	cis	rs11739663	0.574	rs67276442	chr5:583918	T/C	cg04476341	chr5:669733	TPPP	0.53	5.03	0.46	2.32e-6	Ulcerative colitis;
THYM	cis	rs4662945	0.688	rs10496679	chr2:130201113	G/A	cg05903289	chr2:130345205	NA	-0.59	-5.69	-0.5	1.38e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs367615	0.537	rs431669	chr5:108663115	G/A	cg17395555	chr5:108820864	NA	0.55	6.2	0.54	1.42e-8	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg18252515	chr7:66147081	NA	-0.62	-4.55	-0.42	1.59e-5	Aortic root size;
THYM	cis	rs8180040	0.903	rs7636423	chr3:47309134	C/G	cg16586182	chr3:47516702	SCAP	-0.64	-5.4	-0.48	4.81e-7	Colorectal cancer;
THYM	cis	rs7843479	0.930	rs2054713	chr8:21840534	A/G	cg17168535	chr8:21777572	XPO7	0.63	4.69	0.43	8.96e-6	Mean corpuscular volume;
THYM	cis	rs10979	1.000	rs9403507	chr6:143887821	C/G	cg25407410	chr6:143891975	LOC285740	0.65	5.2	0.47	1.13e-6	Hypospadias;
THYM	cis	rs12282928	0.592	rs7119161	chr11:48343565	C/T	cg22827986	chr11:48284249	OR4X1	0.53	5.59	0.5	2.21e-7	Migraine - clinic-based;
THYM	cis	rs1499972	0.941	rs56310214	chr3:117640127	G/A	cg07612923	chr3:117604196	NA	1.19	5.0	0.46	2.66e-6	Schizophrenia;
THYM	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg00271210	chr6:167070053	RPS6KA2	-0.51	-5.31	-0.48	7.23e-7	Primary biliary cholangitis;
THYM	cis	rs1385374	0.858	rs11059927	chr12:129294333	T/C	cg04043695	chr12:129287642	SLC15A4	-0.8	-4.83	-0.44	5.3e-6	Systemic lupus erythematosus;
THYM	cis	rs4731207	0.596	rs7794959	chr7:124649139	C/T	cg05285228	chr7:124571219	POT1	-0.72	-5.53	-0.49	2.81e-7	Cutaneous malignant melanoma;
THYM	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.79	6.34	0.55	7.85e-9	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs8180040	0.903	rs2276853	chr3:47282303	G/A	cg02527881	chr3:46936655	PTH1R	-0.63	-6.2	-0.54	1.44e-8	Colorectal cancer;
THYM	cis	rs1065852	0.526	rs2097561	chr22:42389431	T/C	cg08431931	chr22:42394659	WBP2NL	0.74	6.08	0.53	2.48e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs4938534	0.559	rs1944919	chr11:111259876	A/C	cg10694914	chr11:111250431	POU2AF1	0.56	4.86	0.45	4.72e-6	Primary biliary cholangitis;
THYM	cis	rs4604732	0.588	rs7552443	chr1:247628583	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.69	4.8	0.44	5.99e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-7.56	-0.61	2.52e-11	Chronic sinus infection;
THYM	cis	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg09085632	chr11:111637200	PPP2R1B	1.16	11.93	0.77	1.35e-20	Primary sclerosing cholangitis;
THYM	cis	rs7926906	0.875	rs2213084	chr11:90518158	G/A	cg26138821	chr11:89956704	CHORDC1	-0.55	-4.94	-0.45	3.37e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg09904177	chr6:26538194	HMGN4	0.64	5.4	0.48	4.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2933343	0.700	rs1683787	chr3:128627021	C/T	cg11901034	chr3:128598214	ACAD9	0.69	5.54	0.49	2.69e-7	IgG glycosylation;
THYM	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	6.08	0.53	2.46e-8	Schizophrenia;
THYM	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.76	-5.75	-0.51	1.1e-7	Prostate cancer;
THYM	cis	rs753778	1.000	rs753778	chr8:142228909	G/A	cg18755752	chr8:142205143	DENND3	-0.65	-4.86	-0.45	4.66e-6	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg07636037	chr3:49044803	WDR6	0.99	10.43	0.73	2.03e-17	Parkinson's disease;
THYM	cis	rs28795989	0.862	rs28631205	chr4:7889631	A/G	cg12728606	chr4:7903970	AFAP1	0.43	4.59	0.43	1.34e-5	Intraocular pressure;
THYM	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg18876405	chr7:65276391	NA	0.57	4.73	0.44	7.67e-6	Aortic root size;
THYM	cis	rs669446	0.533	rs11210913	chr1:44222597	G/A	cg12599982	chr1:44399894	ARTN	0.5	4.63	0.43	1.18e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.83	5.25	0.47	9.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs864643	0.812	rs7620264	chr3:39579030	G/T	cg20142358	chr3:39093977	WDR48	-0.69	-4.71	-0.44	8.37e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-4.6	-0.43	1.29e-5	Heart rate;
THYM	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg07636037	chr3:49044803	WDR6	0.78	5.53	0.49	2.84e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs113835537	0.529	rs7943327	chr11:66256581	G/C	cg24851651	chr11:66362959	CCS	0.63	4.51	0.42	1.86e-5	Airway imaging phenotypes;
THYM	cis	rs11031096	0.711	rs1348309	chr11:4202000	A/T	cg08557956	chr11:4115526	RRM1	-0.57	-5.17	-0.47	1.27e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg18252515	chr7:66147081	NA	0.91	6.96	0.58	4.36e-10	Corneal structure;
THYM	cis	rs985746	0.614	rs4832820	chr4:36819382	G/T	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs7020830	0.861	rs13295981	chr9:37330067	C/T	cg14294708	chr9:37120828	ZCCHC7	1.29	17.01	0.87	1.4e-30	Schizophrenia;
THYM	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg02527881	chr3:46936655	PTH1R	-0.69	-7.11	-0.59	2.11e-10	Colorectal cancer;
THYM	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg09165964	chr15:75287851	SCAMP5	1.1	11.58	0.76	7.45e-20	Blood trace element (Zn levels);
THYM	cis	rs9311676	0.656	rs11130638	chr3:58405947	A/G	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs7851660	0.967	rs10046805	chr9:100613956	G/A	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs7267979	0.903	rs6115109	chr20:25239667	G/A	cg08601574	chr20:25228251	PYGB	0.59	4.68	0.43	9.42e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg07159469	chr16:89355005	ANKRD11	-0.82	-4.46	-0.42	2.23e-5	Skin colour saturation;
THYM	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs7119	0.689	rs12916833	chr15:77819778	G/A	cg10437265	chr15:77819839	NA	0.76	7.54	0.61	2.76e-11	Type 2 diabetes;
THYM	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg06784218	chr1:46089804	CCDC17	-0.3	-4.64	-0.43	1.1e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg18681998	chr4:17616180	MED28	0.94	8.63	0.66	1.42e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg06618935	chr21:46677482	NA	-0.96	-9.24	-0.69	6.83e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs17006441	1.000	rs59913237	chr3:69841906	T/A	cg18496212	chr3:69797108	MITF	0.68	6.78	0.57	1.01e-9	Hemoglobin concentration;
THYM	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.47	-0.55	4.19e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg10518543	chr12:38710700	ALG10B	-0.54	-4.54	-0.42	1.64e-5	Morning vs. evening chronotype;
THYM	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg05347473	chr6:146136440	FBXO30	0.57	4.48	0.42	2.04e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7209460	0.556	rs12449600	chr17:1982246	G/A	cg27406664	chr17:2294951	MNT	-0.56	-4.79	-0.44	6.09e-6	Coronary artery disease;Total body bone mineral density;
THYM	cis	rs3847687	0.869	rs11061300	chr12:131523261	G/A	cg25772418	chr12:131519998	GPR133	-0.4	-5.36	-0.48	5.77e-7	Longevity;
THYM	trans	rs2136093	0.600	rs12126321	chr1:90909633	T/C	cg21057494	chr3:45066971	CLEC3B	0.53	7.07	0.59	2.65e-10	Response to antidepressants;
THYM	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg22920501	chr2:26401640	FAM59B	1.07	9.54	0.7	1.6e-15	Mean corpuscular hemoglobin;
THYM	cis	rs11039798	0.920	rs9667596	chr11:48691193	T/C	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.09e-8	Systolic blood pressure;
THYM	cis	rs7264396	0.676	rs6058380	chr20:34552900	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-4.8	-0.44	6.01e-6	Total cholesterol levels;
THYM	cis	rs34638657	0.732	rs11859473	chr16:82201072	T/C	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.11	-0.64	1.73e-12	Lung adenocarcinoma;
THYM	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg18132916	chr6:79620363	NA	0.58	5.25	0.47	9.24e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	5.26	0.47	9.02e-7	Schizophrenia;
THYM	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	9.51	0.7	1.85e-15	Platelet count;
THYM	cis	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg06789500	chr7:2109450	MAD1L1	-0.66	-4.48	-0.42	2.05e-5	Bipolar disorder;
THYM	cis	rs4655537	0.500	rs7532805	chr1:66183130	G/A	cg04111102	chr1:66153794	NA	0.5	4.51	0.42	1.83e-5	Blood protein levels;
THYM	cis	rs7000551	0.725	rs2248987	chr8:22399002	C/G	cg12081754	chr8:22256438	SLC39A14	0.67	6.24	0.54	1.19e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg23583168	chr7:148888333	NA	-1.0	-13.67	-0.81	3.71e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs7172809	0.643	rs4886874	chr15:77838086	A/C	cg22256960	chr15:77711686	NA	0.72	5.22	0.47	1.03e-6	Glucose homeostasis traits;
THYM	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg27446573	chr6:127587934	RNF146	0.91	8.68	0.67	1.09e-13	Breast cancer;
THYM	cis	rs7127900	1.000	rs6578999	chr11:2231774	G/T	cg25635251	chr11:2234043	NA	0.73	4.67	0.43	9.92e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs7131987	0.903	rs1991114	chr12:29392082	G/T	cg09582351	chr12:29534625	ERGIC2	-0.48	-4.59	-0.43	1.35e-5	QT interval;
THYM	cis	rs7224737	1.000	rs9903204	chr17:40288062	G/A	cg00647820	chr17:40259828	DHX58	-0.62	-4.65	-0.43	1.06e-5	Fibrinogen levels;
THYM	cis	rs57920188	0.585	rs12127463	chr1:4079127	C/T	cg20703997	chr1:4087676	NA	0.9	6.28	0.54	9.95e-9	Interleukin-17 levels;
THYM	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg04731861	chr2:219085781	ARPC2	0.54	5.05	0.46	2.11e-6	Colorectal cancer;
THYM	cis	rs986417	1.000	rs1072328	chr14:60876439	C/G	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg01579765	chr21:45077557	HSF2BP	-0.47	-7.74	-0.62	1.04e-11	Mean corpuscular volume;
THYM	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg04772025	chr11:68637568	NA	-0.59	-5.98	-0.52	3.92e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	trans	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg10856724	chr12:34555212	NA	-0.89	-8.13	-0.64	1.57e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.44	-4.84	-0.45	4.92e-6	Insulin-like growth factors;
THYM	cis	rs12410462	1.000	rs75360545	chr1:227625419	T/C	cg23173402	chr1:227635558	NA	0.68	6.15	0.53	1.79e-8	Major depressive disorder;
THYM	cis	rs1003719	0.523	rs1063949	chr21:38574675	T/C	cg01329690	chr21:38580129	DSCR9	-0.36	-5.0	-0.46	2.67e-6	Eye color traits;
THYM	cis	rs55665837	1.000	rs34980103	chr11:14512885	C/T	cg19336497	chr11:14380999	RRAS2	-0.64	-7.01	-0.58	3.49e-10	Vitamin D levels;
THYM	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg07570687	chr10:102243282	WNT8B	0.84	8.24	0.65	9.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg13319975	chr6:146136371	FBXO30	0.63	5.17	0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg00814883	chr7:100076585	TSC22D4	-1.0	-6.8	-0.57	9.22e-10	Platelet count;
THYM	cis	rs4790312	0.935	rs3865240	chr17:1991460	A/G	cg20777128	chr17:1945076	DPH1;OVCA2	-0.48	-4.63	-0.43	1.17e-5	Left atrial antero-posterior diameter;
THYM	cis	rs308403	0.509	rs309372	chr4:123682639	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.97	8.82	0.67	5.5e-14	Blood protein levels;
THYM	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg02569458	chr12:86230093	RASSF9	0.59	5.05	0.46	2.14e-6	Major depressive disorder;
THYM	cis	rs57244997	1.000	rs57244997	chr6:162397506	G/A	cg17173639	chr6:162384350	PARK2	-0.97	-5.63	-0.5	1.85e-7	Mosquito bite size;
THYM	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg18252515	chr7:66147081	NA	-1.41	-8.36	-0.65	5.11e-13	Diabetic kidney disease;
THYM	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg18252515	chr7:66147081	NA	0.67	4.92	0.45	3.65e-6	Aortic root size;
THYM	cis	rs11039798	0.588	rs584899	chr11:48431408	T/C	cg24672777	chr11:48374446	OR4C45	0.96	6.22	0.54	1.3e-8	Axial length;
THYM	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.58	-4.77	-0.44	6.57e-6	Bipolar disorder;
THYM	cis	rs7590720	1.000	rs934154	chr2:216901933	C/T	cg12620499	chr2:216877984	MREG	0.83	5.71	0.51	1.29e-7	Alcohol dependence;
THYM	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg00083206	chr6:110721305	DDO	0.57	6.66	0.56	1.77e-9	Platelet distribution width;
THYM	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.93	7.93	0.63	4.29e-12	Chronic sinus infection;
THYM	cis	rs4713118	0.662	rs9380045	chr6:28025279	A/G	cg08968635	chr6:28129556	ZNF389	0.59	4.57	0.42	1.46e-5	Parkinson's disease;
THYM	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22307029	chr19:49891270	CCDC155	0.78	6.8	0.57	9.16e-10	Multiple sclerosis;
THYM	cis	rs60843830	0.661	rs62116681	chr2:104197	A/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.57	4.63	0.43	1.18e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.77	-7.01	-0.58	3.49e-10	Personality dimensions;
THYM	cis	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg24672777	chr11:48374446	OR4C45	-0.92	-5.83	-0.51	7.65e-8	Axial length;
THYM	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg20503657	chr10:835505	NA	1.17	8.3	0.65	7.12e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs2273669	0.667	rs3734649	chr6:109294752	C/T	cg17117243	chr6:109341365	SESN1	-0.86	-4.9	-0.45	3.88e-6	Prostate cancer;
THYM	cis	rs1050631	0.592	rs1631346	chr18:33709664	T/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.22	0.47	1.03e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs4731207	0.724	rs4146110	chr7:124561208	A/G	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs3791556	0.501	rs3791536	chr2:240101713	G/A	cg03281426	chr2:240109471	HDAC4	0.47	4.49	0.42	1.96e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg23758822	chr17:41437982	NA	1.22	11.98	0.78	1.07e-20	Menopause (age at onset);
THYM	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg16230307	chr14:35515116	FAM177A1	0.83	5.29	0.48	7.72e-7	Psoriasis;
THYM	cis	rs113835537	0.529	rs11227514	chr11:66286627	G/A	cg24851651	chr11:66362959	CCS	0.7	4.89	0.45	4.04e-6	Airway imaging phenotypes;
THYM	cis	rs293526	0.959	rs293490	chr6:83624257	C/A	cg23278060	chr6:83777448	DOPEY1	0.62	4.56	0.42	1.55e-5	Crohn's disease;
THYM	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg23482746	chr15:76478102	C15orf27	-0.38	-4.55	-0.42	1.61e-5	Blood metabolite levels;
THYM	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg03161606	chr19:29218774	NA	0.87	7.3	0.6	8.75e-11	Methadone dose in opioid dependence;
THYM	cis	rs514406	0.858	rs564640	chr1:53285187	T/C	cg08736216	chr1:53307985	ZYG11A	0.62	5.7	0.5	1.37e-7	Monocyte count;
THYM	cis	rs4664308	0.870	rs1870104	chr2:161032285	A/G	cg03641300	chr2:160917029	PLA2R1	-0.74	-6.54	-0.56	3.03e-9	Idiopathic membranous nephropathy;
THYM	cis	rs919433	0.963	rs4850786	chr2:198178608	A/G	cg05783139	chr2:198650985	BOLL	0.56	4.45	0.42	2.34e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2505998	0.833	rs1864404	chr10:43604390	A/T	cg06632098	chr10:43605906	RET	-1.1	-10.64	-0.74	7.21e-18	Hirschsprung disease;
THYM	cis	rs4891159	0.513	rs2554831	chr18:74113513	C/G	cg24786174	chr18:74118243	ZNF516	0.95	13.95	0.82	9.99e-25	Longevity;
THYM	cis	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg19677267	chr1:26645161	CD52;UBXN11	0.49	4.49	0.42	2.04e-5	Obesity-related traits;
THYM	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg07424592	chr7:64974309	NA	1.03	5.26	0.47	8.88e-7	Diabetic kidney disease;
THYM	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	9.49	0.7	2.03e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs11731175	1.000	rs62342331	chr4:189858706	T/C	cg00431894	chr4:189871012	NA	-0.82	-6.24	-0.54	1.2e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4654899	0.965	rs2873424	chr1:21500701	C/A	cg01072550	chr1:21505969	NA	-0.74	-6.76	-0.57	1.11e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg12501888	chr15:85177176	SCAND2	-0.6	-4.5	-0.42	1.92e-5	P wave terminal force;
THYM	cis	rs7100689	0.622	rs10749569	chr10:82129892	G/A	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.67	5.5	0.49	3.21e-7	Blood metabolite levels;
THYM	trans	rs877282	0.945	rs11599043	chr10:777972	C/T	cg22713356	chr15:30763199	NA	1.33	11.05	0.75	9.68e-19	Uric acid levels;
THYM	cis	rs9420907	0.901	rs1265164	chr10:105674854	A/G	cg11005552	chr10:105648138	OBFC1	0.64	5.03	0.46	2.3e-6	Telomere length;
THYM	cis	rs6754311	0.551	rs313519	chr2:136439517	A/C	cg04750100	chr2:136595281	LCT	0.56	5.88	0.52	6.05e-8	Mosquito bite size;
THYM	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-1.13	-9.49	-0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs600806	0.854	rs367586	chr1:109850122	C/A	cg02175308	chr1:109941060	SORT1	-0.56	-4.81	-0.44	5.69e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg02527881	chr3:46936655	PTH1R	-0.59	-5.75	-0.51	1.06e-7	Colorectal cancer;
THYM	cis	rs8014204	0.748	rs12889277	chr14:75229376	A/T	cg06637938	chr14:75390232	RPS6KL1	0.55	5.29	0.48	7.79e-7	Caffeine consumption;
THYM	cis	rs7586879	1.000	rs7603153	chr2:25116966	T/C	cg15423357	chr2:25149977	NA	0.56	5.49	0.49	3.41e-7	Body mass index;
THYM	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.21	0.47	1.1e-6	Bipolar disorder;
THYM	cis	rs9807989	0.507	rs1420094	chr2:103015687	C/T	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs9420	0.961	rs7116341	chr11:57481155	G/A	cg19752551	chr11:57585705	CTNND1	-0.73	-8.02	-0.64	2.79e-12	Schizophrenia;
THYM	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg00191853	chr8:101177733	SPAG1	-0.56	-5.59	-0.5	2.15e-7	Atrioventricular conduction;
THYM	cis	rs9653442	0.675	rs1115910	chr2:100647872	A/G	cg22139774	chr2:100720529	AFF3	-0.35	-5.17	-0.47	1.29e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	trans	rs561341	0.941	rs501773	chr17:30314435	T/G	cg20587970	chr11:113659929	NA	-1.25	-9.01	-0.68	2.13e-14	Hip circumference adjusted for BMI;
THYM	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg05662444	chr5:154026397	NA	0.55	4.83	0.44	5.29e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs4595586	0.545	rs925827	chr12:39364307	C/T	cg13010199	chr12:38710504	ALG10B	0.61	4.68	0.43	9.49e-6	Morning vs. evening chronotype;
THYM	cis	rs6866344	0.697	rs61247551	chr5:178133503	G/A	cg03877680	chr5:178157825	ZNF354A	0.72	4.98	0.46	2.79e-6	Neutrophil percentage of white cells;
THYM	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg00256281	chr22:41985642	PMM1	-0.57	-4.69	-0.43	9.08e-6	Vitiligo;
THYM	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs28595532	0.920	rs116548907	chr4:119735285	G/A	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs6570726	0.846	rs9376954	chr6:145943737	T/A	cg23711669	chr6:146136114	FBXO30	0.85	8.17	0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9644630	0.658	rs4427190	chr8:19321385	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.64	-6.88	-0.58	6.39e-10	Oropharynx cancer;
THYM	cis	rs11039798	1.000	rs7123704	chr11:48580535	G/A	cg24672777	chr11:48374446	OR4C45	-1.16	-7.24	-0.6	1.16e-10	Axial length;
THYM	cis	rs11118844	0.843	rs7518806	chr1:221915633	T/A	cg04222084	chr1:221915650	DUSP10	-1.03	-5.43	-0.49	4.35e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03517284	chr6:25882590	NA	0.93	7.92	0.63	4.49e-12	Intelligence (multi-trait analysis);
THYM	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg12386194	chr3:101231763	SENP7	0.7	5.29	0.48	7.86e-7	Colorectal cancer;
THYM	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg23035555	chr19:3500370	DOHH	-0.77	-4.52	-0.42	1.81e-5	Total cholesterol levels;
THYM	cis	rs9549367	0.756	rs9549702	chr13:113881944	T/G	cg18105134	chr13:113819100	PROZ	-0.99	-9.15	-0.68	1.08e-14	Platelet distribution width;
THYM	cis	rs1483890	0.723	rs34184121	chr3:69411426	A/T	cg22125112	chr3:69402811	FRMD4B	0.54	6.85	0.58	7.21e-10	Resting heart rate;
THYM	cis	rs7927771	0.524	rs4752860	chr11:47705015	C/A	cg18512352	chr11:47633146	NA	-0.41	-4.47	-0.42	2.17e-5	Subjective well-being;
THYM	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg02153584	chr22:29168773	CCDC117	0.59	4.57	0.42	1.46e-5	Lymphocyte counts;
THYM	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg16680214	chr1:154839983	KCNN3	-0.48	-5.33	-0.48	6.64e-7	Prostate cancer;
THYM	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg26384229	chr12:38710491	ALG10B	1.05	10.43	0.73	1.96e-17	Heart rate;
THYM	cis	rs28595532	1.000	rs73842212	chr4:119638122	A/G	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg15212455	chr7:39170539	POU6F2	0.57	5.29	0.48	7.72e-7	IgG glycosylation;
THYM	cis	rs2235642	0.533	rs2667679	chr16:1654946	G/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.41	-4.62	-0.43	1.21e-5	Coronary artery disease;
THYM	cis	rs7072216	0.763	rs6584202	chr10:100170383	G/A	cg03852570	chr10:100175106	PYROXD2	0.38	5.03	0.46	2.35e-6	Metabolite levels;
THYM	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg11327659	chr7:150037044	RARRES2	-0.42	-4.9	-0.45	4e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg17105886	chr17:28927953	LRRC37B2	1.25	6.76	0.57	1.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg24209194	chr3:40518798	ZNF619	-0.73	-6.19	-0.54	1.54e-8	Renal cell carcinoma;
THYM	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg19346786	chr7:2764209	NA	-0.59	-5.08	-0.46	1.88e-6	Height;
THYM	cis	rs1957429	0.901	rs1951491	chr14:65346950	G/A	cg23373153	chr14:65346875	NA	1.07	6.45	0.55	4.75e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg11245990	chr11:68621969	NA	0.57	7.46	0.61	4.14e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg18904891	chr8:8559673	CLDN23	-0.58	-5.04	-0.46	2.24e-6	Joint mobility (Beighton score);
THYM	cis	rs35123781	0.502	rs440662	chr5:139003472	T/C	cg08720517	chr5:138729919	LOC389333	0.58	4.77	0.44	6.74e-6	Schizophrenia;
THYM	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg23791538	chr6:167370224	RNASET2	0.77	6.12	0.53	2.1e-8	Crohn's disease;
THYM	cis	rs9880211	1.000	rs28634226	chr3:136129882	G/A	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs2039659	0.719	rs2343058	chr13:86266026	G/A	cg25308322	chr13:86268291	NA	0.67	5.87	0.52	6.37e-8	Blood osmolality (transformed sodium);
THYM	cis	rs36051895	0.623	rs12349113	chr9:5254224	T/A	cg02405213	chr9:5042618	JAK2	-0.95	-9.54	-0.7	1.59e-15	Pediatric autoimmune diseases;
THYM	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg19875535	chr5:140030758	IK	-0.58	-4.55	-0.42	1.58e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	4.56	0.42	1.54e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs7172809	0.574	rs907398	chr15:77772003	G/A	cg22256960	chr15:77711686	NA	-0.61	-4.47	-0.42	2.18e-5	Glucose homeostasis traits;
THYM	cis	rs6032067	0.636	rs6104093	chr20:43908297	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.69	-7.27	-0.6	1e-10	Blood protein levels;
THYM	cis	rs6570726	0.791	rs1509213	chr6:145783360	G/A	cg13319975	chr6:146136371	FBXO30	0.66	5.34	0.48	6.33e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg11266682	chr4:10021025	SLC2A9	0.66	9.75	0.71	5.71e-16	Bone mineral density;
THYM	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg24733560	chr20:60626293	TAF4	0.6	4.82	0.44	5.55e-6	Body mass index;
THYM	cis	rs6840360	0.615	rs4696097	chr4:152479765	C/T	cg17479576	chr4:152424074	FAM160A1	0.83	6.46	0.55	4.43e-9	Intelligence (multi-trait analysis);
THYM	cis	rs752010	0.574	rs10890161	chr1:42121623	T/C	cg06885757	chr1:42089581	HIVEP3	0.48	5.41	0.49	4.71e-7	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs7267979	1.000	rs6083844	chr20:25386832	C/T	cg08601574	chr20:25228251	PYGB	-0.59	-4.78	-0.44	6.34e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs11671005	0.504	rs2305119	chr19:59067623	C/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.57	-4.7	-0.43	8.66e-6	Mean platelet volume;
THYM	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg03806693	chr22:41940476	POLR3H	-1.0	-8.57	-0.66	1.85e-13	Vitiligo;
THYM	cis	rs4631830	0.832	rs2843554	chr10:51523861	G/T	cg16070123	chr10:51489643	NA	-0.5	-4.56	-0.42	1.55e-5	Prostate-specific antigen levels;
THYM	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.64	-8.69	-0.67	1.02e-13	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs4478037	0.558	rs72854777	chr3:33069965	C/T	cg19404215	chr3:33155277	CRTAP	1.18	5.63	0.5	1.8e-7	Major depressive disorder;
THYM	cis	rs6980334	1.000	rs7795946	chr7:137785091	A/G	cg11874123	chr7:137028198	PTN	0.67	5.24	0.47	9.68e-7	Blood metabolite ratios;
THYM	cis	rs919433	0.783	rs788007	chr2:198233676	T/G	cg00792783	chr2:198669748	PLCL1	0.78	5.6	0.5	2.12e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs4378999	0.660	rs9824522	chr3:50771992	C/T	cg27233566	chr3:49894142	TRAIP	0.77	4.47	0.42	2.16e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs7695732	0.595	rs2178583	chr4:89891142	A/T	cg17769793	chr4:89976368	FAM13A	-0.45	-5.06	-0.46	2.07e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs1395	0.778	rs62128743	chr2:27390169	A/G	cg22903471	chr2:27725779	GCKR	-0.63	-4.63	-0.43	1.17e-5	Blood metabolite levels;
THYM	cis	rs4891159	0.548	rs690082	chr18:74116668	C/T	cg24786174	chr18:74118243	ZNF516	0.97	14.75	0.83	2.65e-26	Longevity;
THYM	cis	rs13102973	0.682	rs13107817	chr4:135885535	C/T	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs4889911	0.544	rs2650254	chr17:77833655	A/G	cg00646381	chr17:77835854	NA	0.45	4.97	0.45	3e-6	Electroencephalogram traits;
THYM	cis	rs6570726	0.791	rs9376945	chr6:145828080	T/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.44	-0.49	4.16e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs870825	0.860	rs28696121	chr4:185598743	G/A	cg04058563	chr4:185651563	MLF1IP	0.91	6.95	0.58	4.63e-10	Blood protein levels;
THYM	cis	rs9470366	0.509	rs4713996	chr6:36629714	C/T	cg08179530	chr6:36648295	CDKN1A	-0.62	-4.57	-0.42	1.46e-5	QRS duration;
THYM	cis	rs17152411	0.895	rs11245422	chr10:126588143	T/C	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs4478037	1.000	rs4074416	chr3:33161729	A/G	cg19404215	chr3:33155277	CRTAP	1.18	8.15	0.64	1.49e-12	Major depressive disorder;
THYM	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	18.96	0.89	4.77e-34	Chronic sinus infection;
THYM	cis	rs10818894	0.611	rs10117455	chr9:126692599	G/T	cg16191174	chr9:126692580	DENND1A	0.88	5.6	0.5	2.05e-7	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
THYM	cis	rs868036	0.718	rs922494	chr15:68120644	T/C	cg26545918	chr15:68124484	LBXCOR1	0.5	4.45	0.42	2.31e-5	Restless legs syndrome;
THYM	cis	rs35603048	0.881	rs11637681	chr15:40387971	A/G	cg02313495	chr15:40398007	BMF	-0.66	-5.52	-0.49	2.96e-7	B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
THYM	cis	rs4919694	1.000	rs7083328	chr10:104769268	G/A	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg10047753	chr17:41438598	NA	1.19	11.33	0.76	2.52e-19	Menopause (age at onset);
THYM	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg26967526	chr14:35346199	BAZ1A	-0.76	-4.97	-0.45	3e-6	Psoriasis;
THYM	cis	rs13040088	0.935	rs3787513	chr20:61573736	G/A	cg23096297	chr20:61557774	DIDO1	1.09	7.51	0.61	3.19e-11	Menopause (age at onset);
THYM	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg18252515	chr7:66147081	NA	0.66	4.87	0.45	4.38e-6	Aortic root size;
THYM	cis	rs1048238	0.506	rs848194	chr1:16285342	G/A	cg21385522	chr1:16154831	NA	-0.67	-5.55	-0.49	2.56e-7	Systolic blood pressure;
THYM	cis	rs2350702	0.617	rs12713073	chr2:49905028	A/G	cg22592722	chr2:49566210	NA	-0.64	-4.7	-0.43	8.85e-6	Morning vs. evening chronotype;
THYM	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg09238746	chr17:78121135	EIF4A3	-1.15	-10.61	-0.74	8.11e-18	Yeast infection;
THYM	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg07022442	chr13:21864356	NA	0.72	4.78	0.44	6.49e-6	White matter hyperintensity burden;
THYM	cis	rs2237457	0.965	rs4504586	chr7:50722460	C/G	cg08586669	chr7:50727761	GRB10	0.33	4.83	0.44	5.14e-6	Schizophrenia (treatment resistant);
THYM	cis	rs7084402	0.967	rs1658470	chr10:60292383	A/G	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs28595532	0.920	rs114928651	chr4:119734194	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg12288994	chr5:1860383	NA	0.84	6.91	0.58	5.41e-10	Cardiovascular disease risk factors;
THYM	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg08901578	chr4:187885870	NA	0.68	6.63	0.56	2.07e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs28595532	0.920	rs115430947	chr4:119737149	C/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg10047753	chr17:41438598	NA	1.07	8.84	0.67	5.07e-14	Menopause (age at onset);
THYM	cis	rs7586879	0.681	rs6705446	chr2:25118608	T/C	cg27107076	chr2:25050844	ADCY3	-0.29	-4.66	-0.43	1.04e-5	Body mass index;
THYM	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03452623	chr4:187889614	NA	-1.19	-19.33	-0.89	1.1e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg19847130	chr8:10466454	RP1L1	0.55	5.28	0.48	8.32e-7	Neuroticism;
THYM	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg11317459	chr13:21872234	NA	-1.24	-9.84	-0.71	3.65e-16	White matter hyperintensity burden;
THYM	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg21984481	chr17:79567631	NPLOC4	-0.5	-5.51	-0.49	3.08e-7	Eye color traits;
THYM	cis	rs9318086	0.648	rs7330140	chr13:24473074	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.55	4.66	0.43	1.03e-5	Myopia (pathological);
THYM	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg10802521	chr3:52805072	NEK4	-0.75	-7.03	-0.58	3.15e-10	Electroencephalogram traits;
THYM	trans	rs3118233	1	rs3118233	chr16:68733646	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-7.33	-0.6	7.57e-11	Red cell distribution width;
THYM	cis	rs113835537	0.559	rs74933537	chr11:66274958	A/C	cg24851651	chr11:66362959	CCS	0.77	5.58	0.5	2.3e-7	Airway imaging phenotypes;
THYM	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	5.52	0.49	2.88e-7	Hip circumference adjusted for BMI;
THYM	cis	rs7246657	0.943	rs12981532	chr19:37889280	G/A	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs7824557	0.614	rs4394351	chr8:11212875	G/C	cg21775007	chr8:11205619	TDH	0.7	6.08	0.53	2.51e-8	Retinal vascular caliber;
THYM	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs7216064	0.589	rs7213585	chr17:66062316	A/T	cg12091567	chr17:66097778	LOC651250	-0.95	-7.72	-0.62	1.15e-11	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs1050631	0.623	rs7242481	chr18:33709217	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.71	5.67	0.5	1.5e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs9486719	1.000	rs2472897	chr6:96870569	G/T	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs981844	0.689	rs7666762	chr4:154684197	C/T	cg09973105	chr4:154681532	RNF175	0.55	4.96	0.45	3.08e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs8062405	0.691	rs743590	chr16:28608230	G/A	cg04193835	chr16:28379378	NA	-0.49	-4.52	-0.42	1.77e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs116095464	1.000	rs2015774	chr5:312958	G/T	cg22857025	chr5:266934	NA	-1.41	-5.27	-0.48	8.69e-7	Breast cancer;
THYM	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs3087591	1.000	rs2952978	chr17:29474744	A/C	cg24425628	chr17:29625626	OMG;NF1	0.64	5.54	0.49	2.68e-7	Hip circumference;
THYM	cis	rs12928939	0.911	rs12919271	chr16:71792696	C/A	cg03805757	chr16:71968109	PKD1L3	-0.72	-5.51	-0.49	3.1e-7	Post bronchodilator FEV1;
THYM	cis	rs7106204	0.513	rs2165784	chr11:24249360	C/A	ch.11.24196551F	chr11:24239977	NA	0.96	6.94	0.58	4.88e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs921968	0.643	rs2556386	chr2:219534530	C/T	cg02176678	chr2:219576539	TTLL4	-0.6	-5.84	-0.51	7.3e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6992848	0.791	rs13281578	chr8:141165001	G/A	cg22504031	chr8:141147661	TRAPPC9	0.62	4.67	0.43	1e-5	Response to amphetamines;
THYM	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg06634786	chr22:41940651	POLR3H	0.71	5.04	0.46	2.19e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs5167	0.743	rs8111069	chr19:45483438	A/C	cg09555818	chr19:45449301	APOC2	0.43	4.46	0.42	2.26e-5	Blood protein levels;
THYM	cis	rs6500602	1.000	rs11647946	chr16:4462836	G/A	cg09549813	chr16:4587862	C16orf5	-0.47	-4.79	-0.44	6.04e-6	Schizophrenia;
THYM	cis	rs34779708	0.750	rs35032841	chr10:35312687	G/A	cg03585969	chr10:35415529	CREM	0.64	4.5	0.42	1.93e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs11190604	0.767	rs10786590	chr10:102164604	T/C	cg07570687	chr10:102243282	WNT8B	0.81	7.68	0.62	1.44e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs459571	0.959	rs392134	chr9:136909008	G/A	cg13789015	chr9:136890014	NCRNA00094	0.82	7.14	0.59	1.85e-10	Platelet distribution width;
THYM	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg08000102	chr2:233561755	GIGYF2	0.69	6.22	0.54	1.33e-8	Coronary artery disease;
THYM	cis	rs854765	0.583	rs7213225	chr17:17869111	T/C	cg04398451	chr17:18023971	MYO15A	-0.78	-7.23	-0.6	1.22e-10	Total body bone mineral density;
THYM	cis	rs11252926	0.797	rs61837235	chr10:489363	G/A	cg14018140	chr10:458528	DIP2C	0.62	6.25	0.54	1.16e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs2658782	0.901	rs11604909	chr11:93218355	C/G	cg15737290	chr11:93063684	CCDC67	0.93	6.79	0.57	9.79e-10	Pulmonary function decline;
THYM	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg13695892	chr22:41940480	POLR3H	-0.86	-5.96	-0.52	4.19e-8	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs3020333	0.653	rs851982	chr6:152024985	T/C	cg22157087	chr6:152012887	ESR1	0.46	4.99	0.46	2.76e-6	Total body bone mineral density;
THYM	trans	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg19862616	chr7:65841803	NCRNA00174	1.09	12.64	0.79	4.47e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.43	0.61	4.69e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs933688	0.818	rs10052492	chr5:90759930	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.78	5.01	0.46	2.47e-6	Smoking behavior;
THYM	cis	rs7940866	0.801	rs10894296	chr11:130840433	T/G	cg05962950	chr11:130786565	SNX19	0.71	5.6	0.5	2.11e-7	Schizophrenia;
THYM	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg17105886	chr17:28927953	LRRC37B2	1.25	6.76	0.57	1.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg16405210	chr4:1374714	KIAA1530	-1.09	-10.29	-0.73	4.03e-17	Longevity;
THYM	cis	rs7586879	0.558	rs6718510	chr2:25122323	A/C	cg15423357	chr2:25149977	NA	0.69	7.59	0.61	2.21e-11	Body mass index;
THYM	cis	rs289828	0.931	rs12617724	chr2:152140030	T/C	cg05960677	chr2:152117363	RBM43	0.59	5.58	0.5	2.25e-7	Blood protein levels;
THYM	cis	rs9814567	0.752	rs6779294	chr3:134329821	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs11989744	0.843	rs10481325	chr8:23560896	G/A	cg04349084	chr8:23602677	NA	0.5	5.34	0.48	6.22e-7	Waist-hip ratio;
THYM	cis	rs758324	0.687	rs246351	chr5:131509271	A/G	cg16205897	chr5:131564050	P4HA2	0.56	4.62	0.43	1.21e-5	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs1457614	0.694	rs58713254	chr12:13639385	C/T	cg16488639	chr12:12966464	DDX47	-0.79	-4.46	-0.42	2.24e-5	Major depressive disorder;
THYM	cis	rs2835345	0.507	rs7280011	chr21:37827554	C/T	cg20643029	chr21:37915044	CLDN14	0.69	5.87	0.52	6.36e-8	Pulmonary function;
THYM	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg06623918	chr6:96969491	KIAA0776	-1.09	-10.31	-0.73	3.58e-17	Headache;
THYM	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg26850624	chr5:429559	AHRR	-0.63	-5.04	-0.46	2.18e-6	Cystic fibrosis severity;
THYM	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg08772003	chr10:104629869	AS3MT	-0.59	-5.35	-0.48	5.97e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg21773646	chr17:80085082	CCDC57	0.31	4.49	0.42	2.02e-5	Life satisfaction;
THYM	cis	rs912057	1.000	rs912056	chr6:6736197	A/T	cg06612196	chr6:6737390	NA	0.66	8.63	0.66	1.43e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs7264396	0.778	rs6120959	chr20:34077848	G/A	cg26038318	chr20:34205095	SPAG4	0.56	4.73	0.44	7.84e-6	Total cholesterol levels;
THYM	cis	rs554111	0.891	rs604645	chr1:21043926	T/C	cg01072550	chr1:21505969	NA	-0.64	-4.83	-0.44	5.19e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs72627123	0.867	rs73301485	chr14:74468643	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs2933343	0.553	rs35979399	chr3:128697313	G/A	cg11901034	chr3:128598214	ACAD9	-0.69	-4.89	-0.45	4.03e-6	IgG glycosylation;
THYM	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg20587970	chr11:113659929	NA	-1.37	-8.96	-0.68	2.79e-14	Hip circumference adjusted for BMI;
THYM	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs4919694	1.000	rs79254677	chr10:104691567	A/G	cg15744005	chr10:104629667	AS3MT	-0.91	-5.09	-0.46	1.81e-6	Arsenic metabolism;
THYM	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg04944784	chr2:26401820	FAM59B	1.09	8.74	0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg00898013	chr13:113819073	PROZ	-0.89	-9.2	-0.69	8.65e-15	Platelet distribution width;
THYM	cis	rs12040273	0.908	rs11122271	chr1:230206696	A/G	cg04991747	chr1:230207211	GALNT2	0.75	4.85	0.45	4.86e-6	Carotid intima media thickness;
THYM	cis	rs10158481	0.727	rs2143161	chr1:25481364	A/G	cg09264742	chr1:25757510	TMEM57	-0.68	-4.96	-0.45	3.11e-6	Urate levels in obese individuals;
THYM	cis	rs2295359	1.000	rs10889664	chr1:67635475	C/T	cg11235152	chr1:67600687	NA	0.58	4.72	0.44	8.03e-6	Psoriasis;
THYM	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.14	6.64	0.56	1.9e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg11247378	chr22:39784982	NA	-0.87	-9.01	-0.68	2.16e-14	Intelligence (multi-trait analysis);
THYM	cis	rs4746818	0.643	rs2855020	chr10:70856510	C/T	cg11621586	chr10:70884670	VPS26A	0.85	4.95	0.45	3.16e-6	Left atrial antero-posterior diameter;
THYM	cis	rs308403	0.509	rs6811183	chr4:123671551	T/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.97	8.14	0.64	1.53e-12	Blood protein levels;
THYM	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg15704280	chr7:45808275	SEPT13	-1.02	-10.82	-0.74	2.92e-18	Height;
THYM	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg03433033	chr1:76189801	ACADM	0.77	10.09	0.72	1.07e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22133161	chr19:49891603	CCDC155	0.74	4.99	0.46	2.71e-6	Multiple sclerosis;
THYM	cis	rs981844	0.775	rs10517580	chr4:154744128	T/G	cg09973105	chr4:154681532	RNF175	-0.62	-5.1	-0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs7107770	1.000	rs34361497	chr11:125106565	C/T	cg07747661	chr11:125106135	PKNOX2	-0.92	-5.28	-0.48	8.31e-7	Photic sneeze reflex;
THYM	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg16325326	chr1:53192061	ZYG11B	0.82	7.77	0.62	9e-12	Monocyte count;
THYM	trans	rs11186	0.556	rs72906321	chr2:189957749	A/C	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg23711669	chr6:146136114	FBXO30	0.92	9.4	0.69	3.17e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9420	0.884	rs644883	chr11:57663522	C/G	cg19752551	chr11:57585705	CTNND1	0.72	7.34	0.6	7.26e-11	Schizophrenia;
THYM	cis	rs9826463	0.582	rs2306700	chr3:142123841	C/T	cg20824294	chr3:142316082	PLS1	0.75	5.11	0.46	1.69e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg15693483	chr7:1102177	C7orf50	0.48	5.6	0.5	2.08e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg06582575	chr6:163149167	PACRG;PARK2	1.09	7.2	0.59	1.43e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2235649	0.746	rs35104579	chr16:1848657	A/T	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg04772025	chr11:68637568	NA	0.65	6.95	0.58	4.61e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg09549813	chr16:4587862	C16orf5	-0.59	-6.82	-0.57	8.39e-10	Schizophrenia;
THYM	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg15605315	chr1:45957053	TESK2	0.78	6.5	0.55	3.7e-9	High light scatter reticulocyte count;
THYM	trans	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg11941060	chr3:133502564	NA	-0.73	-6.42	-0.55	5.36e-9	Iron status biomarkers;
THYM	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	trans	rs2136093	0.568	rs114447975	chr1:90891603	G/A	cg21057494	chr3:45066971	CLEC3B	0.54	7.15	0.59	1.8e-10	Response to antidepressants;
THYM	cis	rs859767	0.741	rs11682346	chr2:135388261	G/A	cg12500956	chr2:135428796	TMEM163	-0.51	-5.09	-0.46	1.79e-6	Neuroticism;
THYM	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg02353165	chr6:42928485	GNMT	0.87	8.22	0.64	1.02e-12	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7772486	0.686	rs6570701	chr6:145954090	A/G	cg13319975	chr6:146136371	FBXO30	-0.65	-5.22	-0.47	1.05e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6980334	0.911	rs10954602	chr7:137774930	A/G	cg11874123	chr7:137028198	PTN	0.66	5.13	0.47	1.54e-6	Blood metabolite ratios;
THYM	trans	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Bladder cancer;
THYM	cis	rs10911232	0.507	rs10911198	chr1:182997318	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg24733560	chr20:60626293	TAF4	0.6	4.82	0.44	5.55e-6	Body mass index;
THYM	cis	rs10823500	0.748	rs7072230	chr10:71978144	A/G	cg25502086	chr10:71892093	AIFM2	-0.56	-5.08	-0.46	1.87e-6	Blood protein levels;
THYM	cis	rs28595532	0.920	rs114420700	chr4:119751297	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs13064411	0.696	rs6438161	chr3:113227637	G/A	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg26384229	chr12:38710491	ALG10B	0.94	7.9	0.63	4.92e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs13279522	0.572	rs10113415	chr8:67009640	A/G	cg20171999	chr8:67343066	NA	-0.46	-4.6	-0.43	1.3e-5	Coronary heart disease event reduction (statin therapy interaction);
THYM	cis	rs4266144	0.592	rs1545854	chr3:156840138	A/G	cg14969094	chr3:156848003	NA	0.47	4.48	0.42	2.1e-5	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.874	rs28452522	chr4:120110784	A/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.82e-7	Corneal astigmatism;
THYM	cis	rs854765	0.583	rs4244602	chr17:17841456	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.8	0.57	9.12e-10	Total body bone mineral density;
THYM	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.67	5.55	0.49	2.63e-7	Prostate cancer;
THYM	cis	rs12579753	0.913	rs17749243	chr12:82178079	A/C	cg21231944	chr12:82153410	PPFIA2	-0.68	-5.17	-0.47	1.3e-6	Resting heart rate;
THYM	cis	rs7104764	1.000	rs10400248	chr11:247029	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	1.17	10.75	0.74	4.09e-18	Menarche (age at onset);
THYM	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg00256281	chr22:41985642	PMM1	-0.59	-4.62	-0.43	1.22e-5	Vitiligo;
THYM	cis	rs1642645	0.831	rs3856259	chr1:42475503	T/C	cg06092502	chr1:42611687	NA	0.61	4.76	0.44	7.05e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs2862064	1.000	rs2862064	chr5:156445827	C/G	cg12943317	chr5:156479607	HAVCR1	-0.83	-5.12	-0.46	1.61e-6	Platelet count;
THYM	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06634786	chr22:41940651	POLR3H	-0.83	-6.18	-0.54	1.59e-8	Vitiligo;
THYM	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg26850624	chr5:429559	AHRR	0.57	4.57	0.42	1.46e-5	Cystic fibrosis severity;
THYM	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg00944433	chr1:107599041	PRMT6	0.43	5.47	0.49	3.59e-7	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs1775715	0.737	rs11817598	chr10:32206259	A/G	cg04359828	chr10:32216031	ARHGAP12	0.41	5.12	0.46	1.62e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs9992101	0.547	rs2137153	chr4:77411660	G/A	cg27417997	chr4:77356416	SHROOM3	-0.37	-4.46	-0.42	2.22e-5	Creatinine levels;
THYM	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg24257776	chr3:47051546	LOC100129354	0.41	4.78	0.44	6.38e-6	Colorectal cancer;
THYM	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03517284	chr6:25882590	NA	-0.99	-9.74	-0.71	6.01e-16	Intelligence (multi-trait analysis);
THYM	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg04111992	chr7:158790115	NA	-0.58	-4.71	-0.43	8.52e-6	Facial morphology (factor 20);
THYM	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg00024416	chr22:24240387	NA	-0.66	-6.99	-0.58	3.82e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg26384229	chr12:38710491	ALG10B	-0.74	-5.8	-0.51	8.85e-8	Bladder cancer;
THYM	cis	rs4285028	0.747	rs6791882	chr3:121373058	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.84	-7.2	-0.59	1.37e-10	Multiple sclerosis;
THYM	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg13135455	chr2:241860318	NA	-0.41	-4.88	-0.45	4.24e-6	Urinary metabolites;
THYM	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs11008222	0.934	rs11812238	chr10:31041315	G/A	cg00941203	chr10:31016591	NA	-0.34	-4.71	-0.43	8.49e-6	Congenital left-sided heart lesions (maternal effect);
THYM	cis	rs8017423	0.967	rs11621431	chr14:90709221	C/T	cg04239629	chr14:90701769	NA	-0.61	-4.46	-0.42	2.28e-5	Mortality in heart failure;
THYM	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg18477163	chr1:228402036	OBSCN	0.59	6.68	0.57	1.63e-9	Diastolic blood pressure;
THYM	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg24399712	chr22:39784796	NA	-0.87	-9.65	-0.7	9.24e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg00310523	chr12:86230176	RASSF9	0.59	5.41	0.49	4.71e-7	Major depressive disorder;
THYM	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06481639	chr22:41940642	POLR3H	0.87	5.95	0.52	4.49e-8	Vitiligo;
THYM	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg16928487	chr17:17741425	SREBF1	0.57	5.63	0.5	1.81e-7	Total body bone mineral density;
THYM	cis	rs13064411	0.591	rs7628945	chr3:113201754	A/T	cg18753928	chr3:113234510	CCDC52	-0.84	-7.97	-0.63	3.49e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs1878931	0.615	rs6501171	chr16:3402610	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.93	8.8	0.67	6.2e-14	Body mass index (adult);
THYM	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg02524346	chr8:600233	NA	1.01	4.64	0.43	1.13e-5	IgG glycosylation;
THYM	trans	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.82	-8.92	-0.68	3.42e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2278491	0.557	rs10283129	chr8:117778673	G/A	cg23513447	chr8:117778558	UTP23	-0.66	-4.76	-0.44	6.92e-6	Body mass index;
THYM	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg09035930	chr12:129282057	SLC15A4	-0.85	-10.44	-0.73	1.93e-17	Systemic lupus erythematosus;
THYM	cis	rs13064411	0.518	rs9842559	chr3:113252705	A/C	cg18753928	chr3:113234510	CCDC52	-0.78	-7.18	-0.59	1.56e-10	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	1.02	12.81	0.8	2.07e-22	Subjective well-being;
THYM	cis	rs67072384	1.000	rs2365441	chr11:72450226	T/C	cg01380194	chr11:72452482	ARAP1	-0.97	-5.26	-0.47	8.93e-7	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs611744	0.806	rs374810	chr8:109096029	G/A	cg21045802	chr8:109455806	TTC35	0.6	5.37	0.48	5.48e-7	Dupuytren's disease;
THYM	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs3126085	0.935	rs10888467	chr1:152171707	C/T	cg26020982	chr1:152196106	HRNR	0.38	5.13	0.47	1.55e-6	Atopic dermatitis;
THYM	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg21433313	chr16:3507492	NAT15	0.86	9.14	0.68	1.13e-14	Tuberculosis;
THYM	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg12386194	chr3:101231763	SENP7	-0.67	-4.99	-0.46	2.75e-6	Colorectal cancer;
THYM	cis	rs7020830	0.898	rs7857936	chr9:37078491	T/C	cg14294708	chr9:37120828	ZCCHC7	1.26	15.38	0.84	1.57e-27	Schizophrenia;
THYM	cis	rs7192380	0.893	rs12921782	chr16:69780022	C/T	cg09409435	chr16:70099608	PDXDC2	-0.65	-4.85	-0.45	4.79e-6	Sjögren's syndrome;
THYM	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg10862848	chr6:42927986	GNMT	-0.56	-7.38	-0.6	5.89e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6840360	0.571	rs718801	chr4:152549247	C/T	cg17479576	chr4:152424074	FAM160A1	-0.79	-5.59	-0.5	2.19e-7	Intelligence (multi-trait analysis);
THYM	cis	rs17253792	0.659	rs34330219	chr14:56017375	G/A	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs10504073	0.647	rs1511359	chr8:50006448	T/A	cg00325661	chr8:49890786	NA	0.91	8.2	0.64	1.15e-12	Blood metabolite ratios;
THYM	cis	rs2180341	0.566	rs982306	chr6:127777039	T/C	cg27446573	chr6:127587934	RNF146	0.58	4.54	0.42	1.66e-5	Breast cancer;
THYM	cis	rs28595532	0.920	rs56027489	chr4:119780882	A/G	cg21605333	chr4:119757512	SEC24D	1.61	6.06	0.53	2.69e-8	Cannabis dependence symptom count;
THYM	cis	rs4889855	0.556	rs4890039	chr17:78517883	C/T	cg16591659	chr17:78472290	NA	0.42	4.79	0.44	6.21e-6	Fractional excretion of uric acid;
THYM	cis	rs9826463	0.702	rs73228762	chr3:142325220	A/C	cg20824294	chr3:142316082	PLS1	0.68	4.45	0.42	2.31e-5	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.32	0.48	6.97e-7	Height;
THYM	cis	rs72627123	0.867	rs72627105	chr14:74311720	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.13	5.88	0.52	5.96e-8	Morning vs. evening chronotype;
THYM	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg03929089	chr4:120376271	NA	-0.99	-10.08	-0.72	1.14e-16	Height;
THYM	cis	rs513349	1.000	rs210146	chr6:33549098	A/G	cg07679836	chr6:33548423	BAK1	0.35	4.75	0.44	7.13e-6	Platelet count;
THYM	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-6.2	-0.54	1.47e-8	Total body bone mineral density;
THYM	trans	rs10802346	0.524	rs10802356	chr1:246385857	T/C	cg13514129	chr1:39547527	MACF1	1.0	9.85	0.71	3.44e-16	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs4731207	0.596	rs6967707	chr7:124609355	G/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs7617773	0.746	rs4371540	chr3:48353543	G/A	cg02219026	chr3:48282209	ZNF589	-0.64	-4.54	-0.42	1.62e-5	Coronary artery disease;
THYM	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg26384229	chr12:38710491	ALG10B	0.92	7.34	0.6	7.32e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs6728302	1.000	rs77060225	chr2:233060816	T/C	cg15348839	chr2:232224846	NA	1.14	4.64	0.43	1.12e-5	Height;
THYM	cis	rs7646881	1.000	rs73015652	chr3:158451383	A/G	cg19483011	chr3:158453295	NA	-0.7	-4.85	-0.45	4.86e-6	Tetralogy of Fallot;
THYM	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.69	5.7	0.5	1.35e-7	Blood metabolite levels;
THYM	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg27121462	chr16:89883253	FANCA	-0.57	-4.54	-0.42	1.65e-5	Vitiligo;
THYM	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg00666640	chr1:248458726	OR2T12	0.56	4.61	0.43	1.26e-5	Common traits (Other);
THYM	cis	rs877282	0.628	rs11253435	chr10:824169	T/C	cg10556349	chr10:835070	NA	-0.8	-5.48	-0.49	3.52e-7	Uric acid levels;
THYM	cis	rs713587	0.626	rs62140636	chr2:25233811	T/C	cg15423357	chr2:25149977	NA	-0.59	-6.39	-0.55	6.11e-9	Body mass index in non-asthmatics;
THYM	cis	rs877282	0.947	rs12358875	chr10:757531	T/C	cg10556349	chr10:835070	NA	-0.77	-4.95	-0.45	3.24e-6	Uric acid levels;
THYM	cis	rs977987	0.806	rs8054769	chr16:75401113	T/C	cg03315344	chr16:75512273	CHST6	0.69	5.55	0.49	2.56e-7	Dupuytren's disease;
THYM	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg20608306	chr11:116969690	SIK3	0.54	5.84	0.51	7.35e-8	Blood protein levels;
THYM	cis	rs765787	0.530	rs12913123	chr15:45516425	C/T	cg24006582	chr15:45444508	DUOX1	0.81	6.51	0.56	3.6e-9	Uric acid levels;
THYM	cis	rs10504073	0.584	rs12546490	chr8:49932841	C/T	cg00325661	chr8:49890786	NA	1.04	10.84	0.74	2.66e-18	Blood metabolite ratios;
THYM	cis	rs981844	0.712	rs6855093	chr4:154754050	A/G	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs7551222	0.752	rs10900599	chr1:204541943	T/C	cg20240347	chr1:204465584	NA	-0.54	-4.91	-0.45	3.81e-6	Schizophrenia;
THYM	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg25767906	chr1:53392781	SCP2	-0.59	-5.73	-0.51	1.17e-7	Monocyte count;
THYM	cis	rs11690935	0.959	rs10497374	chr2:172640623	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.77	-5.58	-0.5	2.25e-7	Schizophrenia;
THYM	cis	rs4788570	0.647	rs904764	chr16:71772795	G/A	cg06353428	chr16:71660113	MARVELD3	1.31	8.68	0.67	1.08e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7725337	0.965	rs7715079	chr5:88359704	T/G	cg11280525	chr5:87955695	LOC645323	-0.42	-4.72	-0.44	8.15e-6	Total body bone mineral density;
THYM	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg23422044	chr7:1970798	MAD1L1	-0.79	-5.21	-0.47	1.09e-6	Bipolar disorder;
THYM	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.07	0.46	1.93e-6	Prudent dietary pattern;
THYM	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg27534772	chr1:16042836	PLEKHM2	0.54	5.92	0.52	5.1e-8	Systolic blood pressure;
THYM	cis	rs9549260	0.620	rs4325427	chr13:41216534	C/T	cg21288729	chr13:41239152	FOXO1	0.67	5.19	0.47	1.2e-6	Red blood cell count;
THYM	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg11657440	chr19:46296263	DMWD	0.68	6.09	0.53	2.44e-8	Coronary artery disease;
THYM	cis	rs12410462	1.000	rs80168344	chr1:227655804	C/T	cg23173402	chr1:227635558	NA	0.67	5.94	0.52	4.59e-8	Major depressive disorder;
THYM	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg15693483	chr7:1102177	C7orf50	0.54	6.26	0.54	1.1e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg05347473	chr6:146136440	FBXO30	-0.82	-7.32	-0.6	7.82e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12216545	0.737	rs1916006	chr7:150240556	T/C	cg08960815	chr7:150264767	GIMAP4	-0.89	-8.27	-0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg00898013	chr13:113819073	PROZ	-0.88	-8.96	-0.68	2.83e-14	Platelet distribution width;
THYM	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg09359103	chr1:154839909	KCNN3	0.76	9.41	0.69	3e-15	Prostate cancer;
THYM	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg26022315	chr17:47021804	SNF8	0.51	4.87	0.45	4.44e-6	Type 2 diabetes;
THYM	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg15782153	chr7:917662	C7orf20	0.6	6.8	0.57	9.24e-10	Perceived unattractiveness to mosquitoes;
THYM	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg11125805	chr5:150678162	SLC36A3	0.59	7.8	0.62	8.08e-12	Skin aging (microtopography measurement);
THYM	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg18357526	chr6:26021779	HIST1H4A	0.8	6.87	0.58	6.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7512552	0.803	rs9436125	chr1:150487961	C/G	cg15654264	chr1:150340011	RPRD2	0.45	5.23	0.47	1.02e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs6906287	0.647	rs7758614	chr6:118889894	T/C	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-6.23	-0.54	1.28e-8	Chronic sinus infection;
THYM	cis	rs2688608	0.592	rs11000759	chr10:75493726	G/A	cg19442545	chr10:75533431	FUT11	-0.58	-5.96	-0.52	4.22e-8	Inflammatory bowel disease;
THYM	cis	rs72627123	0.867	rs73301479	chr14:74467757	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.72	4.58	0.43	1.39e-5	Lung cancer in ever smokers;
THYM	cis	rs6032067	0.561	rs2741502	chr20:43936265	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.59	-5.35	-0.48	5.97e-7	Blood protein levels;
THYM	cis	rs12444261	0.925	rs67188401	chr16:11745762	G/C	cg09662852	chr16:11707685	NA	-0.49	-4.58	-0.43	1.39e-5	QT interval;
THYM	cis	rs2050392	0.965	rs1543725	chr10:30698873	A/G	cg02070205	chr10:30722105	MAP3K8	-0.51	-4.53	-0.42	1.74e-5	Inflammatory bowel disease;
THYM	cis	rs42648	0.869	rs42613	chr7:89950303	C/T	cg25739043	chr7:89950458	NA	-0.53	-4.53	-0.42	1.72e-5	Homocysteine levels;
THYM	cis	rs7769051	0.522	rs77103054	chr6:133136589	C/T	cg22852734	chr6:133119734	C6orf192	1.35	4.73	0.44	7.88e-6	Type 2 diabetes nephropathy;
THYM	cis	rs986417	0.748	rs10145546	chr14:61100892	A/G	cg27398547	chr14:60952738	C14orf39	0.94	5.21	0.47	1.07e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs2073300	1.000	rs6036423	chr20:23459810	A/C	cg12062639	chr20:23401060	NAPB	0.96	4.84	0.45	4.95e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6754311	0.731	rs12615624	chr2:136721603	A/G	cg04750100	chr2:136595281	LCT	0.53	5.96	0.52	4.24e-8	Mosquito bite size;
THYM	cis	rs8014204	0.804	rs7154845	chr14:75247746	A/G	cg06637938	chr14:75390232	RPS6KL1	0.56	5.49	0.49	3.27e-7	Caffeine consumption;
THYM	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg19507638	chr5:93509721	C5orf36	0.71	4.62	0.43	1.21e-5	Diabetic retinopathy;
THYM	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg23803603	chr1:2058230	PRKCZ	0.66	5.99	0.52	3.8e-8	Height;
THYM	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg18758796	chr5:131593413	PDLIM4	0.63	6.23	0.54	1.24e-8	Breast cancer;
THYM	cis	rs4819143	0.517	rs1736424	chr21:47373605	T/C	cg20357416	chr21:47294739	PCBP3	0.79	4.94	0.45	3.38e-6	Insulin resistance/response;
THYM	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg18681998	chr4:17616180	MED28	0.96	8.83	0.67	5.24e-14	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg03806693	chr22:41940476	POLR3H	-1.22	-11.17	-0.75	5.43e-19	Vitiligo;
THYM	cis	rs892961	0.932	rs9646396	chr17:75416755	G/A	cg05865280	chr17:75406074	SEPT9	0.49	7.43	0.61	4.7e-11	Airflow obstruction;
THYM	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22433210	chr17:43662623	NA	-0.89	-7.19	-0.59	1.5e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs854765	0.583	rs4553680	chr17:17857722	A/G	cg16928487	chr17:17741425	SREBF1	-0.54	-5.12	-0.46	1.63e-6	Total body bone mineral density;
THYM	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg03929089	chr4:120376271	NA	-0.97	-10.61	-0.74	8.11e-18	Coronary artery disease;
THYM	cis	rs7731657	0.537	rs6885379	chr5:130345372	C/G	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg17252645	chr8:143867129	LY6D	-0.85	-10.75	-0.74	4.1e-18	Urinary tract infection frequency;
THYM	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg12463550	chr7:65579703	CRCP	-0.56	-4.54	-0.42	1.67e-5	Aortic root size;
THYM	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg14829155	chr15:31115871	NA	-0.75	-6.3	-0.54	9.11e-9	Huntington's disease progression;
THYM	cis	rs6032067	0.586	rs62208373	chr20:43764426	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.47	-5.31	-0.48	7.26e-7	Blood protein levels;
THYM	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	12.82	0.8	1.97e-22	Chronic sinus infection;
THYM	trans	rs629535	0.734	rs659430	chr8:70009988	A/G	cg21567404	chr3:27674614	NA	0.98	9.52	0.7	1.73e-15	Dupuytren's disease;
THYM	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg13683864	chr3:40499215	RPL14	-0.85	-8.33	-0.65	6.13e-13	Renal cell carcinoma;
THYM	cis	rs56104184	0.775	rs73061699	chr19:49400511	T/C	cg17863274	chr19:49399704	TULP2	-1.01	-6.47	-0.55	4.29e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2456568	0.564	rs6483270	chr11:93624380	C/T	cg26875233	chr11:93583750	C11orf90	-0.52	-5.74	-0.51	1.15e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs9318086	0.600	rs9507185	chr13:24473734	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.57	4.72	0.44	8.19e-6	Myopia (pathological);
THYM	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-4.74	-0.44	7.47e-6	Chronic sinus infection;
THYM	cis	rs4474465	0.915	rs7128449	chr11:78206760	G/A	cg19901956	chr11:77921274	USP35	0.65	4.8	0.44	5.97e-6	Alzheimer's disease (survival time);
THYM	cis	rs2797160	0.967	rs1578793	chr6:126015057	A/G	cg16306078	chr6:126000798	NA	0.54	5.53	0.49	2.75e-7	Endometrial cancer;
THYM	cis	rs2034650	0.544	rs600791	chr15:40721067	G/C	cg12699599	chr15:40643142	PHGR1	-0.6	-5.2	-0.47	1.16e-6	Interstitial lung disease;
THYM	cis	rs28595532	0.920	rs114019902	chr4:119755564	G/A	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.48	-4.7	-0.43	8.95e-6	Crohn's disease;
THYM	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1448094	0.512	rs60986162	chr12:86247054	T/G	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs7553864	1.000	rs7515367	chr1:87615798	A/T	cg17420885	chr1:87600446	LOC339524	-0.71	-6.0	-0.52	3.49e-8	Smoking behavior;
THYM	cis	rs10276303	0.519	rs6462035	chr7:3397101	G/A	cg21248987	chr7:3385318	SDK1	-0.41	-5.15	-0.47	1.41e-6	Dupuytren's disease;
THYM	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg18252515	chr7:66147081	NA	-0.69	-5.46	-0.49	3.79e-7	Aortic root size;
THYM	cis	rs11264213	0.591	rs684594	chr1:36489977	G/A	cg27506609	chr1:36549197	TEKT2	-0.95	-5.02	-0.46	2.4e-6	Schizophrenia;
THYM	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-5.08	-0.46	1.91e-6	Gut microbiome composition (summer);
THYM	trans	rs112998813	0.571	rs9590394	chr13:114926891	C/T	cg22248471	chr2:239625280	NA	0.79	6.91	0.58	5.54e-10	Nodular sclerosis Hodgkin lymphoma;
THYM	cis	rs17407555	0.632	rs12510726	chr4:10271067	T/A	cg00071950	chr4:10020882	SLC2A9	0.59	5.53	0.49	2.81e-7	Schizophrenia (age at onset);
THYM	cis	rs2797685	1.000	rs707467	chr1:7861684	A/C	cg06712362	chr1:7811235	CAMTA1	0.65	4.81	0.44	5.69e-6	Crohn's disease;
THYM	cis	rs673253	1.000	rs673253	chr1:44062154	C/T	cg24466421	chr1:44070974	PTPRF	-0.59	-5.19	-0.47	1.2e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg10515332	chr4:99064459	C4orf37	0.62	4.96	0.45	3.14e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs75518195	0.504	rs28475346	chr4:64831920	A/G	cg14706739	chr8:21916355	EPB49	0.7	6.91	0.58	5.39e-10	Triptolide cytotoxicity;
THYM	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.68	6.04	0.53	2.94e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg16989719	chr2:238392110	NA	-0.66	-5.38	-0.48	5.29e-7	Prostate cancer;
THYM	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg15448220	chr1:150897856	SETDB1	0.86	7.41	0.61	5.19e-11	Tonsillectomy;
THYM	cis	rs4481887	1.000	rs7527822	chr1:248467301	A/G	cg13385794	chr1:248469461	NA	0.66	4.66	0.43	1.04e-5	Common traits (Other);
THYM	cis	rs1981331	1.000	rs118078026	chr21:48012129	T/C	cg23283320	chr21:48055893	PRMT2	1.21	5.82	0.51	7.84e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs7119	0.651	rs12915057	chr15:77847745	C/A	cg27398640	chr15:77910606	LINGO1	-0.59	-5.84	-0.51	7.15e-8	Type 2 diabetes;
THYM	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg24531977	chr5:56204891	C5orf35	0.66	5.33	0.48	6.61e-7	Initial pursuit acceleration;
THYM	cis	rs7119038	0.818	rs10892286	chr11:118642085	A/C	cg19308663	chr11:118741387	NA	0.58	5.41	0.49	4.72e-7	Sjögren's syndrome;
THYM	cis	rs4975709	0.758	rs4975756	chr5:1882443	T/C	cg12288994	chr5:1860383	NA	0.6	4.53	0.42	1.73e-5	Cardiovascular disease risk factors;
THYM	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.81	6.93	0.58	5.01e-10	Intelligence (multi-trait analysis);
THYM	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg27284194	chr4:1044797	NA	0.62	4.73	0.44	7.81e-6	Recombination rate (females);
THYM	cis	rs6032067	0.777	rs34163611	chr20:43778990	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.93	-0.58	5.03e-10	Blood protein levels;
THYM	cis	rs4944092	0.855	rs596339	chr11:75916507	T/C	cg04588336	chr11:75916460	WNT11	-0.68	-7.07	-0.59	2.6e-10	PR interval;
THYM	cis	rs6570726	0.764	rs9399553	chr6:145873664	A/T	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg02953382	chr22:24373134	LOC391322	0.73	6.6	0.56	2.36e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg23161317	chr6:28129485	ZNF389	-0.94	-7.17	-0.59	1.59e-10	Depression;
THYM	cis	rs12142240	0.698	rs41293285	chr1:46808426	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs595982	0.702	rs638050	chr19:49375676	A/G	cg19746536	chr19:49375674	PPP1R15A	1.26	16.71	0.86	4.96e-30	Red cell distribution width;
THYM	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg15448220	chr1:150897856	SETDB1	0.9	7.47	0.61	3.94e-11	Melanoma;
THYM	cis	rs67460515	0.892	rs11711413	chr3:160998910	C/G	cg03342759	chr3:160939853	NMD3	-0.93	-7.98	-0.63	3.34e-12	Parkinson's disease;
THYM	cis	rs6840360	0.718	rs2136960	chr4:152746189	A/G	cg22705602	chr4:152727874	NA	0.59	6.6	0.56	2.28e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7100689	0.646	rs11202721	chr10:82135762	G/A	cg01528321	chr10:82214614	TSPAN14	0.79	6.01	0.52	3.47e-8	Post bronchodilator FEV1;
THYM	trans	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg25517755	chr10:38738941	LOC399744	-0.8	-7.87	-0.63	5.58e-12	Corneal astigmatism;
THYM	cis	rs911555	0.755	rs17841064	chr14:103900609	A/G	cg12935359	chr14:103987150	CKB	-0.53	-5.96	-0.52	4.28e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg22920501	chr2:26401640	FAM59B	-1.08	-9.83	-0.71	3.84e-16	Gut microbiome composition (summer);
THYM	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Bladder cancer;
THYM	cis	rs7107174	0.892	rs11601195	chr11:78073501	A/G	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs8062405	0.723	rs62031562	chr16:28609329	A/T	cg04193835	chr16:28379378	NA	-0.51	-4.81	-0.44	5.76e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	trans	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg07211511	chr3:129823064	LOC729375	-1.26	-8.96	-0.68	2.75e-14	Blood pressure (smoking interaction);
THYM	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg18512352	chr11:47633146	NA	-0.51	-6.11	-0.53	2.21e-8	Subjective well-being;
THYM	cis	rs6543140	0.601	rs6543135	chr2:103062406	C/T	cg09003973	chr2:102972529	NA	0.72	4.8	0.44	5.87e-6	Blood protein levels;
THYM	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg03709012	chr19:19516395	GATAD2A	-0.82	-6.74	-0.57	1.21e-9	Tonsillectomy;
THYM	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg12031863	chr16:4587854	C16orf5	-0.43	-4.86	-0.45	4.7e-6	Schizophrenia;
THYM	cis	rs240764	0.817	rs239221	chr6:101113085	G/A	cg21058520	chr6:100914733	NA	-0.57	-5.03	-0.46	2.29e-6	Neuroticism;
THYM	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg06221963	chr1:154839813	KCNN3	-0.77	-9.84	-0.71	3.56e-16	Prostate cancer;
THYM	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg02524346	chr8:600233	NA	0.92	4.61	0.43	1.24e-5	IgG glycosylation;
THYM	cis	rs7428	0.527	rs4832164	chr2:85546932	A/C	cg24342717	chr2:85555507	TGOLN2	-0.77	-6.35	-0.55	7.51e-9	Ear protrusion;
THYM	cis	rs2637266	0.714	rs4475870	chr10:78450724	T/A	cg18941641	chr10:78392320	NA	0.73	5.85	0.51	7.02e-8	Pulmonary function;
THYM	cis	rs6084875	0.840	rs743252	chr20:4720667	C/T	cg19614321	chr20:4804581	RASSF2	0.45	4.53	0.42	1.7e-5	Systemic lupus erythematosus;
THYM	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg12292205	chr6:26970375	C6orf41	0.53	4.55	0.42	1.6e-5	Schizophrenia;
THYM	cis	rs2625529	0.591	rs7172158	chr15:72405313	T/C	cg16672083	chr15:72433130	SENP8	0.49	4.54	0.42	1.68e-5	Red blood cell count;
THYM	cis	rs2732480	0.577	rs2634681	chr12:48733084	C/T	cg21466736	chr12:48725269	NA	0.54	5.12	0.47	1.58e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs13315871	1.000	rs13327709	chr3:58408767	C/T	cg00563845	chr3:58318305	PXK	0.53	4.67	0.43	9.78e-6	Cholesterol, total;
THYM	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg26924012	chr15:45694286	SPATA5L1	1.03	9.11	0.68	1.29e-14	Homoarginine levels;
THYM	cis	rs9796	0.866	rs692155	chr15:41407061	A/G	cg21153102	chr15:41252147	NA	0.69	6.19	0.54	1.56e-8	Menopause (age at onset);
THYM	cis	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg12000587	chr17:30186630	C17orf79	-0.46	-6.96	-0.58	4.4e-10	Hip circumference adjusted for BMI;
THYM	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg15445000	chr17:37608096	MED1	0.44	5.22	0.47	1.07e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs10752881	1.000	rs10797807	chr1:182978873	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs4523957	0.928	rs8065650	chr17:2180823	A/G	cg16513277	chr17:2031491	SMG6	0.77	7.16	0.59	1.73e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg22166914	chr1:53195759	ZYG11B	0.74	6.73	0.57	1.28e-9	Monocyte count;
THYM	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg03806693	chr22:41940476	POLR3H	-0.88	-8.23	-0.65	9.64e-13	Vitiligo;
THYM	cis	rs4808199	0.947	rs4808960	chr19:19574277	G/C	cg03709012	chr19:19516395	GATAD2A	1.19	7.25	0.6	1.12e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs6570726	0.935	rs372378	chr6:145816227	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.67	5.35	0.48	5.98e-7	Tonsillectomy;
THYM	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.63	-5.25	-0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg15448220	chr1:150897856	SETDB1	0.89	7.44	0.61	4.54e-11	Melanoma;
THYM	cis	rs2404602	0.684	rs8029283	chr15:76837140	A/G	cg23625390	chr15:77176239	SCAPER	-0.84	-6.12	-0.53	2.1e-8	Blood metabolite levels;
THYM	cis	rs684232	0.602	rs401592	chr17:551316	T/C	cg15660573	chr17:549704	VPS53	-1.0	-11.2	-0.75	4.65e-19	Prostate cancer;
THYM	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg00271210	chr6:167070053	RPS6KA2	0.69	7.42	0.61	4.85e-11	Crohn's disease;
THYM	cis	rs4285028	0.948	rs12630486	chr3:121685267	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg22907277	chr7:1156413	C7orf50	0.52	4.81	0.44	5.6e-6	Longevity;Endometriosis;
THYM	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.26	0.47	8.97e-7	Lung cancer in ever smokers;
THYM	cis	rs7364180	0.582	rs139568	chr22:42210985	C/T	cg13695892	chr22:41940480	POLR3H	0.6	4.82	0.44	5.36e-6	Alzheimer's disease biomarkers;
THYM	cis	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg01364799	chr7:75623366	TMEM120A	0.61	4.46	0.42	2.27e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1878931	0.582	rs9937267	chr16:3421073	C/T	cg00484396	chr16:3507460	NAT15	-0.48	-4.62	-0.43	1.2e-5	Body mass index (adult);
THYM	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs7178572	1.000	rs7178572	chr15:77747190	A/G	cg22256960	chr15:77711686	NA	-0.94	-7.93	-0.63	4.23e-12	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.33	10.0	0.72	1.62e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg22841779	chr14:105766346	BRF1	-0.49	-6.09	-0.53	2.42e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs13177918	0.603	rs13175992	chr5:149830589	G/A	cg14059543	chr5:149831962	NA	-0.92	-7.37	-0.6	6.25e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg11494091	chr17:61959527	GH2	1.07	17.09	0.87	9.87e-31	Prudent dietary pattern;
THYM	cis	rs9311676	0.632	rs6777066	chr3:58361603	T/C	cg26110898	chr3:58419937	PDHB	0.44	4.6	0.43	1.29e-5	Systemic lupus erythematosus;
THYM	cis	rs8063160	0.561	rs12922197	chr16:89744809	G/C	cg07984980	chr16:89898383	SPIRE2	1.33	5.49	0.49	3.33e-7	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs72717009	0.825	rs9427398	chr1:161476205	A/G	cg23840854	chr1:161414152	NA	-1.03	-5.5	-0.49	3.16e-7	Rheumatoid arthritis;
THYM	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg13447684	chr7:1895903	MAD1L1	0.49	4.45	0.42	2.33e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs10892173	0.904	rs10892172	chr11:117672474	C/A	cg21640587	chr11:117668038	DSCAML1	0.58	4.82	0.44	5.55e-6	Myopia;
THYM	cis	rs4076764	0.846	rs10753616	chr1:163415855	G/T	cg06092702	chr1:163392909	NA	0.56	4.68	0.43	9.67e-6	Motion sickness;
THYM	cis	rs300703	0.719	rs437853	chr2:196973	C/T	cg21211680	chr2:198530	NA	-1.27	-8.26	-0.65	8.56e-13	Blood protein levels;
THYM	cis	rs6665290	0.901	rs61834004	chr1:227202782	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.05	-0.85	8.4e-29	Myeloid white cell count;
THYM	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg05717871	chr11:638507	DRD4	-0.69	-6.03	-0.53	3.1e-8	Systemic lupus erythematosus;
THYM	cis	rs4499344	0.921	rs12982788	chr19:33085501	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.76	-5.45	-0.49	3.97e-7	Mean platelet volume;
THYM	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.89	-8.7	-0.67	9.84e-14	Lung cancer;
THYM	cis	rs9296092	0.538	rs5000098	chr6:33519231	T/G	cg13560919	chr6:33536144	NA	-0.94	-9.23	-0.69	7.16e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-5.44	-0.49	4.14e-7	Monocyte percentage of white cells;
THYM	cis	rs6568490	0.556	rs2883360	chr6:108094827	C/T	cg03500965	chr6:108145777	SCML4	0.42	4.91	0.45	3.75e-6	Lymphocyte counts;
THYM	cis	rs72901758	0.700	rs1109279	chr17:76248130	T/C	cg25512537	chr17:76250053	NA	0.41	5.87	0.52	6.45e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
THYM	cis	rs9309473	0.500	rs10189578	chr2:73728609	C/A	cg19565262	chr2:73869966	NAT8	-0.54	-4.62	-0.43	1.19e-5	Metabolite levels;
THYM	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg18512352	chr11:47633146	NA	0.5	6.42	0.55	5.46e-9	Subjective well-being;
THYM	trans	rs561341	1.000	rs537166	chr17:30326827	C/T	cg20587970	chr11:113659929	NA	-1.26	-9.15	-0.68	1.09e-14	Hip circumference adjusted for BMI;
THYM	cis	rs7582180	0.764	rs4851293	chr2:100925106	A/T	cg14675211	chr2:100938903	LONRF2	0.76	8.22	0.64	1.01e-12	Intelligence (multi-trait analysis);
THYM	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg07570687	chr10:102243282	WNT8B	0.84	8.04	0.64	2.45e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg00757033	chr12:89920650	WDR51B	0.74	11.81	0.77	2.43e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg10856724	chr12:34555212	NA	-1.07	-9.86	-0.71	3.35e-16	Morning vs. evening chronotype;
THYM	cis	rs6596100	0.538	rs17166268	chr5:132180990	C/T	cg02081065	chr5:132209139	LEAP2	0.79	5.26	0.47	8.96e-7	Breast cancer;
THYM	cis	rs7575217	0.670	rs796061	chr2:101727327	T/C	cg23907051	chr2:101730305	TBC1D8	-0.42	-5.58	-0.5	2.29e-7	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs2742234	0.590	rs1254965	chr10:43689853	C/T	cg06632098	chr10:43605906	RET	0.79	5.1	0.46	1.73e-6	Hirschsprung disease;
THYM	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg05804949	chr7:23719620	C7orf46	-0.46	-5.28	-0.48	8.05e-7	Schizophrenia;
THYM	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg09667013	chr22:42394590	WBP2NL	-0.52	-4.48	-0.42	2.1e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg24308560	chr3:49941425	MST1R	-0.76	-6.4	-0.55	5.88e-9	Intelligence (multi-trait analysis);
THYM	cis	rs4466137	0.868	rs6866067	chr5:83022369	A/G	cg16102102	chr5:83017553	HAPLN1	-1.11	-10.21	-0.72	5.82e-17	Prostate cancer;
THYM	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg23131131	chr22:24373011	LOC391322	-0.83	-7.96	-0.63	3.63e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg08835221	chr22:38071607	LGALS1	0.37	5.17	0.47	1.32e-6	Fat distribution (HIV);
THYM	cis	rs9324022	0.929	rs59488041	chr14:101180041	T/A	cg18089426	chr14:101175970	NA	0.75	5.15	0.47	1.38e-6	Plateletcrit;
THYM	cis	rs77320796	1.000	rs7529794	chr1:40403370	G/T	cg05657805	chr1:40942785	ZNF642	0.75	4.65	0.43	1.06e-5	Platelet count;
THYM	cis	rs2273669	0.748	rs114830980	chr6:109297857	A/T	cg17117243	chr6:109341365	SESN1	-0.78	-4.79	-0.44	6.14e-6	Prostate cancer;
THYM	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg03806693	chr22:41940476	POLR3H	-0.99	-7.63	-0.62	1.82e-11	Vitiligo;
THYM	cis	rs7631605	0.905	rs61489663	chr3:37261734	T/A	cg21328643	chr3:37258149	NA	-0.58	-5.57	-0.5	2.39e-7	Cerebrospinal P-tau181p levels;
THYM	cis	rs708547	0.647	rs781666	chr4:57830981	A/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.54	-4.63	-0.43	1.18e-5	Response to bleomycin (chromatid breaks);
THYM	cis	rs8078723	0.966	rs57065891	chr17:38168227	C/T	cg17467752	chr17:38218738	THRA	0.86	7.09	0.59	2.4e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.18	-8.84	-0.67	5.1e-14	Schizophrenia;
THYM	cis	rs11186	0.556	rs35571278	chr2:189967456	A/C	cg11041835	chr2:189156425	GULP1	0.8	4.58	0.43	1.41e-5	Parkinson's disease;
THYM	cis	rs7582180	0.614	rs3748930	chr2:101010082	G/C	cg08017756	chr2:100939284	LONRF2	-0.73	-7.29	-0.6	9.05e-11	Intelligence (multi-trait analysis);
THYM	cis	rs990171	0.607	rs3917245	chr2:102775155	G/A	cg13315345	chr2:102803985	IL1RL2	0.57	4.96	0.45	3.04e-6	Lymphocyte counts;
THYM	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg04429589	chr14:105992532	TMEM121	-0.48	-5.28	-0.48	8.21e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg10057126	chr4:77819792	ANKRD56	0.71	6.05	0.53	2.8e-8	Emphysema distribution in smoking;
THYM	cis	rs12449964	0.524	rs7224756	chr17:17572342	G/A	cg04398451	chr17:18023971	MYO15A	0.58	4.6	0.43	1.33e-5	Coronary artery disease or ischemic stroke;
THYM	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.38	0.6	5.91e-11	Morning vs. evening chronotype;
THYM	cis	rs11924390	0.800	rs5030059	chr3:186452455	C/G	cg12454167	chr3:186435060	KNG1	0.46	6.08	0.53	2.55e-8	Adiponectin levels;
THYM	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg08048268	chr3:133502702	NA	0.71	5.88	0.52	6.18e-8	Iron status biomarkers;
THYM	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg13866156	chr1:1669148	SLC35E2	-0.74	-7.52	-0.61	3.02e-11	Body mass index;
THYM	cis	rs9768139	0.683	rs72505558	chr7:158113215	A/G	cg25566285	chr7:158114605	PTPRN2	0.95	12.11	0.78	5.62e-21	Calcium levels;
THYM	cis	rs6087990	0.806	rs910084	chr20:31379665	C/T	cg13636640	chr20:31349939	DNMT3B	0.95	10.77	0.74	3.72e-18	Ulcerative colitis;
THYM	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg11812906	chr14:75593930	NEK9	0.87	8.3	0.65	7.13e-13	Height;
THYM	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg10911889	chr6:126070802	HEY2	0.58	4.62	0.43	1.22e-5	Brugada syndrome;
THYM	cis	rs6570726	0.764	rs1912023	chr6:145824278	C/A	cg23711669	chr6:146136114	FBXO30	0.95	9.55	0.7	1.52e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4606347	0.932	rs1938499	chr1:66094928	A/T	cg04111102	chr1:66153794	NA	0.59	4.54	0.42	1.67e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs1005224	0.926	rs7143743	chr14:76127805	G/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.72	-6.01	-0.52	3.4e-8	Large artery stroke;
THYM	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg15744005	chr10:104629667	AS3MT	-0.8	-7.57	-0.61	2.4e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs754466	0.651	rs7895188	chr10:79623378	C/G	cg17075019	chr10:79541650	NA	0.67	5.73	0.51	1.18e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.27	0.69	5.96e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs854765	0.583	rs4244602	chr17:17841456	A/G	cg16928487	chr17:17741425	SREBF1	-0.55	-5.4	-0.48	4.98e-7	Total body bone mineral density;
THYM	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg13135455	chr2:241860318	NA	-0.4	-4.77	-0.44	6.57e-6	Urinary metabolites;
THYM	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg14972814	chr11:95582409	MTMR2	-0.59	-5.36	-0.48	5.87e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4372836	0.658	rs11127189	chr2:28992020	T/G	cg09522027	chr2:28974177	PPP1CB	-0.65	-5.12	-0.46	1.61e-6	Body mass index;
THYM	cis	rs9807989	0.839	rs13392100	chr2:102982094	C/A	cg03938978	chr2:103052716	IL18RAP	0.63	6.55	0.56	2.99e-9	Asthma;
THYM	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg23958373	chr8:599963	NA	-0.9	-4.55	-0.42	1.58e-5	IgG glycosylation;
THYM	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-4.79	-0.44	6.04e-6	Total cholesterol levels;
THYM	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg05738196	chr6:26577821	NA	0.57	4.74	0.44	7.46e-6	Schizophrenia;
THYM	cis	rs9902453	0.874	rs4474741	chr17:28148117	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.66	-0.43	1.05e-5	Coffee consumption (cups per day);
THYM	cis	rs4986172	0.655	rs1044977	chr17:43227214	T/C	cg06100756	chr17:43221575	NA	0.73	7.59	0.61	2.2e-11	Height;
THYM	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	8.18	0.64	1.27e-12	Monocyte percentage of white cells;
THYM	cis	rs2303759	0.709	rs10422677	chr19:49824290	C/T	cg22307029	chr19:49891270	CCDC155	0.58	4.66	0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg26513180	chr16:89883248	FANCA	0.51	4.59	0.43	1.36e-5	Vitiligo;
THYM	cis	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg10856724	chr12:34555212	NA	-0.88	-8.25	-0.65	8.84e-13	Morning vs. evening chronotype;
THYM	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg24910161	chr17:38119198	GSDMA	0.46	4.67	0.43	9.99e-6	Self-reported allergy;
THYM	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14240646	chr10:27532245	ACBD5	0.85	5.0	0.46	2.65e-6	Breast cancer;
THYM	cis	rs10819861	0.679	rs4623574	chr9:98849624	C/T	cg14508093	chr9:98862825	NA	-0.24	-4.65	-0.43	1.08e-5	Electrocardiographic traits;
THYM	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg09034736	chr1:150693464	HORMAD1	0.51	4.49	0.42	1.98e-5	Tonsillectomy;
THYM	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg13607699	chr17:42295918	UBTF	0.75	5.78	0.51	9.6e-8	Total body bone mineral density;
THYM	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg11266682	chr4:10021025	SLC2A9	0.72	10.58	0.74	9.81e-18	Bone mineral density;
THYM	cis	rs7197653	0.748	rs61460037	chr16:68336125	A/C	cg09835421	chr16:68378352	PRMT7	-0.75	-4.63	-0.43	1.18e-5	Magnesium levels;
THYM	cis	rs3820068	0.608	rs7552400	chr1:16035892	A/G	cg13390004	chr1:15929781	NA	0.65	4.81	0.44	5.56e-6	Systolic blood pressure;
THYM	cis	rs6531209	0.926	rs4666366	chr2:20340155	T/C	cg24416238	chr2:20211868	MATN3	-0.62	-5.02	-0.46	2.38e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg26924012	chr15:45694286	SPATA5L1	1.12	10.37	0.73	2.72e-17	Homoarginine levels;
THYM	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg26597838	chr10:835615	NA	1.08	7.25	0.6	1.1e-10	Eosinophil percentage of granulocytes;
THYM	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg24375607	chr4:120327624	NA	0.64	5.09	0.46	1.84e-6	Corneal astigmatism;
THYM	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg08859206	chr1:53392774	SCP2	-0.74	-8.59	-0.66	1.69e-13	Monocyte count;
THYM	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs6732160	0.588	rs72841902	chr2:73372212	T/A	cg24220031	chr2:73402428	NA	-0.71	-5.79	-0.51	8.94e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.7	6.78	0.57	1.03e-9	Lymphocyte counts;
THYM	cis	rs9611519	0.857	rs4820434	chr22:41637119	G/T	cg06481639	chr22:41940642	POLR3H	-0.69	-5.25	-0.47	9.45e-7	Neuroticism;
THYM	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg23352942	chr3:46931381	PTH1R	0.59	5.31	0.48	7.34e-7	Birth weight;
THYM	cis	rs7322722	0.842	rs687532	chr13:77621060	C/G	cg04565255	chr13:77565759	CLN5	0.5	4.97	0.45	2.96e-6	Preeclampsia;
THYM	cis	rs2702888	0.501	rs2702936	chr8:6751434	T/C	cg03082247	chr8:6756796	NA	-0.54	-4.51	-0.42	1.82e-5	Blood pressure;
THYM	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg03806693	chr22:41940476	POLR3H	-0.98	-8.22	-0.64	1.05e-12	Vitiligo;
THYM	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg18876405	chr7:65276391	NA	0.63	5.53	0.49	2.79e-7	Aortic root size;
THYM	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg10018233	chr7:150070692	REPIN1	0.4	5.66	0.5	1.63e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Body mass index;
THYM	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg00277334	chr10:82204260	NA	-0.83	-10.18	-0.72	6.99e-17	Post bronchodilator FEV1;
THYM	cis	rs7560272	0.723	rs7566315	chr2:73791808	C/T	cg19565262	chr2:73869966	NAT8	-0.62	-5.14	-0.47	1.49e-6	Schizophrenia;
THYM	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6570726	0.846	rs411468	chr6:145832792	A/G	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11890956	chr21:40555474	PSMG1	-0.68	-6.42	-0.55	5.42e-9	Menarche (age at onset);
THYM	cis	rs1994135	0.669	rs10844628	chr12:33697065	T/C	cg10856724	chr12:34555212	NA	-0.66	-5.37	-0.48	5.49e-7	Resting heart rate;
THYM	cis	rs7106204	0.609	rs11821417	chr11:24279139	G/T	ch.11.24196551F	chr11:24239977	NA	0.93	5.71	0.51	1.3e-7	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.84	0.57	7.6e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9515201	0.859	rs9521735	chr13:111037328	G/C	cg06243866	chr13:111019493	COL4A2	-0.95	-8.75	-0.67	7.7e-14	White matter hyperintensity burden;
THYM	cis	rs35264875	0.851	rs72930611	chr11:68863659	G/T	cg01993067	chr11:68851601	TPCN2	1.0	5.27	0.48	8.46e-7	Blond vs. brown hair color;
THYM	cis	rs4731207	0.596	rs10264288	chr7:124574527	A/G	cg05285228	chr7:124571219	POT1	-0.67	-5.2	-0.47	1.16e-6	Cutaneous malignant melanoma;
THYM	cis	rs684232	0.583	rs10521106	chr17:510707	C/T	cg15660573	chr17:549704	VPS53	-0.91	-9.25	-0.69	6.59e-15	Prostate cancer;
THYM	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg22920501	chr2:26401640	FAM59B	0.77	6.95	0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg09904177	chr6:26538194	HMGN4	0.53	4.5	0.42	1.95e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7181230	0.961	rs7183977	chr15:40377092	C/T	cg20592017	chr15:40364740	NA	-0.58	-4.85	-0.45	4.86e-6	Dehydroepiandrosterone sulphate levels;
THYM	cis	rs6138458	1.000	rs11906373	chr20:24938832	A/G	cg26195577	chr20:24973756	C20orf3	1.11	10.36	0.73	2.84e-17	Blood protein levels;
THYM	cis	rs6450176	0.564	rs31228	chr5:53325994	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.92	-7.98	-0.63	3.25e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg22166914	chr1:53195759	ZYG11B	0.94	11.08	0.75	8.2e-19	Monocyte count;
THYM	cis	rs7851660	0.844	rs993501	chr9:100623377	A/G	cg13688889	chr9:100608707	NA	0.77	5.31	0.48	7.25e-7	Strep throat;
THYM	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	4.56	0.42	1.55e-5	Hip circumference adjusted for BMI;
THYM	cis	rs514406	0.698	rs11206055	chr1:53436632	A/T	cg08736216	chr1:53307985	ZYG11A	0.63	5.56	0.5	2.51e-7	Monocyte count;
THYM	cis	rs1865721	0.771	rs72975985	chr18:73127648	C/T	cg26385618	chr18:73139727	C18orf62	-0.69	-5.19	-0.47	1.18e-6	Intelligence;
THYM	cis	rs6543140	0.601	rs78178597	chr2:103023596	G/T	cg09003973	chr2:102972529	NA	0.69	4.62	0.43	1.21e-5	Blood protein levels;
THYM	cis	rs12908161	1.000	rs35808647	chr15:85377441	G/A	cg17173187	chr15:85201210	NMB	0.53	5.12	0.47	1.57e-6	Schizophrenia;
THYM	cis	rs13315871	0.858	rs78946071	chr3:58318523	G/T	cg12435725	chr3:58293450	RPP14	-0.53	-5.51	-0.49	3.09e-7	Cholesterol, total;
THYM	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.9	4.89	0.45	4.15e-6	Initial pursuit acceleration;
THYM	cis	rs8133932	0.701	rs7280054	chr21:47301246	T/G	cg20357416	chr21:47294739	PCBP3	-0.89	-5.87	-0.52	6.3e-8	Schizophrenia;
THYM	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg23711669	chr6:146136114	FBXO30	0.92	9.46	0.7	2.34e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7631605	0.967	rs6801864	chr3:37257242	C/T	cg21328643	chr3:37258149	NA	0.49	4.66	0.43	1.04e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs6495367	1.000	rs755362	chr15:79376601	C/T	cg17916960	chr15:79447300	NA	-0.55	-6.01	-0.52	3.45e-8	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg25036284	chr2:26402008	FAM59B	-0.78	-5.19	-0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.0	8.1	0.64	1.86e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4435363	0.958	rs1030691	chr19:47064351	G/A	cg10017888	chr19:47105860	CALM3	-0.73	-4.88	-0.45	4.2e-6	Immature fraction of reticulocytes;P wave terminal force;
THYM	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg12031863	chr16:4587854	C16orf5	-0.46	-4.84	-0.44	4.99e-6	Schizophrenia;
THYM	cis	rs7084402	0.967	rs1649033	chr10:60279634	T/C	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs28647808	0.786	rs4962134	chr9:136256626	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs921665	0.831	rs4497900	chr2:3190754	A/G	cg16434511	chr2:3151078	NA	-0.87	-5.46	-0.49	3.8e-7	World class endurance athleticism;
THYM	cis	rs611744	0.560	rs58605513	chr8:109279122	A/C	cg21045802	chr8:109455806	TTC35	0.69	6.21	0.54	1.42e-8	Dupuytren's disease;
THYM	cis	rs13256369	0.802	rs2280560	chr8:8560602	C/T	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs346785	0.965	rs17509527	chr17:74286173	A/G	cg09812376	chr17:74270190	QRICH2	-0.6	-7.01	-0.58	3.37e-10	White matter hyperintensities in ischemic stroke;
THYM	cis	rs800586	0.788	rs800538	chr8:116722990	A/G	cg04656070	chr8:116661063	TRPS1	0.49	4.47	0.42	2.18e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg12373951	chr3:133503437	NA	0.54	5.56	0.5	2.49e-7	Iron status biomarkers;
THYM	cis	rs10186029	0.680	rs4673726	chr2:213981115	T/C	cg08319019	chr2:214017104	IKZF2	0.8	6.51	0.56	3.56e-9	Systemic sclerosis;
THYM	cis	rs8031584	1.000	rs11634216	chr15:31288670	G/A	cg08704250	chr15:31115839	NA	-0.55	-6.5	-0.56	3.63e-9	Huntington's disease progression;
THYM	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg27490568	chr2:178487706	NA	0.63	5.19	0.47	1.17e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg20295408	chr7:1910781	MAD1L1	0.62	5.02	0.46	2.37e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg23758822	chr17:41437982	NA	1.2	11.08	0.75	8.27e-19	Menopause (age at onset);
THYM	cis	rs6980334	0.817	rs10228704	chr7:137795206	T/C	cg06915773	chr7:137028165	PTN	0.58	4.74	0.44	7.59e-6	Blood metabolite ratios;
THYM	cis	rs16912285	0.786	rs112633506	chr11:24250766	G/A	ch.11.24196551F	chr11:24239977	NA	0.96	4.95	0.45	3.18e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7107174	0.901	rs10899498	chr11:78124575	C/G	cg19901956	chr11:77921274	USP35	-0.65	-5.17	-0.47	1.27e-6	Testicular germ cell tumor;
THYM	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg02018176	chr4:1364513	KIAA1530	0.58	4.57	0.42	1.46e-5	Obesity-related traits;
THYM	cis	rs9361491	0.608	rs9352627	chr6:79455586	T/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9902453	0.817	rs3115089	chr17:28031881	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	5.13	0.47	1.5e-6	Coffee consumption (cups per day);
THYM	cis	rs1062746	0.777	rs34400756	chr16:87372078	A/G	cg02258303	chr16:87377426	FBXO31	-0.63	-5.52	-0.49	2.89e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg22875332	chr1:76189707	ACADM	0.87	10.83	0.74	2.76e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs600806	0.821	rs407102	chr1:109846278	C/T	cg02175308	chr1:109941060	SORT1	-0.5	-4.45	-0.42	2.35e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg21926883	chr2:100939477	LONRF2	-0.66	-6.16	-0.53	1.71e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg00801512	chr17:28996047	NA	-0.79	-5.19	-0.47	1.2e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03264133	chr6:25882463	NA	-0.82	-6.53	-0.56	3.18e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Electroencephalogram traits;
THYM	cis	rs7584330	0.554	rs7598035	chr2:238434942	C/T	cg08992911	chr2:238395768	MLPH	0.89	5.81	0.51	8.24e-8	Prostate cancer;
THYM	cis	rs9649213	0.614	rs62479858	chr7:97924226	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.65	-5.31	-0.48	7.25e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg20242066	chr2:136595261	LCT	-0.57	-6.93	-0.58	4.9e-10	Mosquito bite size;
THYM	trans	rs4866334	1.000	rs77574409	chr5:18485477	G/T	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg24531977	chr5:56204891	C5orf35	1.01	8.29	0.65	7.47e-13	Initial pursuit acceleration;
THYM	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg26441486	chr22:50317300	CRELD2	0.44	7.08	0.59	2.46e-10	Schizophrenia;
THYM	cis	rs981844	0.807	rs10517577	chr4:154644537	T/C	cg09973105	chr4:154681532	RNF175	-0.57	-4.49	-0.42	1.99e-5	Response to statins (LDL cholesterol change);
THYM	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.92e-8	Systolic blood pressure;
THYM	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg23260525	chr10:116636907	FAM160B1	0.53	5.33	0.48	6.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7119	0.634	rs2682922	chr15:77865006	A/C	cg27398640	chr15:77910606	LINGO1	0.62	7.34	0.6	7.26e-11	Type 2 diabetes;
THYM	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg15744692	chr15:45671195	LOC145663;GATM	0.44	4.46	0.42	2.22e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs113835537	0.529	rs11227525	chr11:66308065	T/G	cg24851651	chr11:66362959	CCS	0.7	4.69	0.43	9.3e-6	Airway imaging phenotypes;
THYM	cis	rs11190604	0.767	rs11190534	chr10:102190930	G/A	cg07570687	chr10:102243282	WNT8B	0.85	8.46	0.66	3.16e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6496667	0.557	rs2589951	chr15:90958392	T/C	cg00425431	chr15:90792223	TTLL13	0.44	5.21	0.47	1.09e-6	Rheumatoid arthritis;
THYM	cis	rs4731207	0.619	rs4461840	chr7:124581065	A/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs59724122	0.542	rs28633173	chr8:27446980	A/G	cg04803944	chr8:27450844	NA	-0.58	-4.76	-0.44	6.93e-6	Bipolar disorder lithium response (categorical) or schizophrenia;
THYM	cis	rs6701037	0.625	rs72719370	chr1:175128536	G/C	cg00958927	chr1:175162553	KIAA0040	-0.33	-4.48	-0.42	2.06e-5	Alcohol dependence;
THYM	cis	rs3540	0.553	rs12592611	chr15:91004093	C/T	cg22089800	chr15:90895588	ZNF774	0.75	5.96	0.52	4.32e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs6570726	0.935	rs380883	chr6:145822992	A/G	cg13319975	chr6:146136371	FBXO30	-0.69	-5.81	-0.51	8.38e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg20891283	chr12:69753455	YEATS4	0.77	6.38	0.55	6.37e-9	Response to diuretic therapy;
THYM	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg14456004	chr13:21872349	NA	1.26	12.03	0.78	8.43e-21	White matter hyperintensity burden;
THYM	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06634786	chr22:41940651	POLR3H	-0.81	-6.28	-0.54	1.03e-8	Vitiligo;
THYM	cis	rs6701037	0.748	rs10912901	chr1:175138602	G/A	cg00958927	chr1:175162553	KIAA0040	-0.33	-4.48	-0.42	2.06e-5	Alcohol dependence;
THYM	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg01448562	chr3:133502909	NA	-0.84	-7.02	-0.58	3.24e-10	Iron status biomarkers;
THYM	cis	rs35883536	0.528	rs1577512	chr1:101030832	G/A	cg09408571	chr1:101003634	GPR88	0.56	5.96	0.52	4.27e-8	Monocyte count;
THYM	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg08999081	chr20:33150536	PIGU	0.6	5.44	0.49	4.05e-7	Height;
THYM	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs7572733	0.534	rs700681	chr2:198711502	C/A	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2456568	0.867	rs1827931	chr11:93663170	T/C	cg26875233	chr11:93583750	C11orf90	-0.5	-4.95	-0.45	3.22e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs10744422	0.858	rs7980541	chr12:123379477	C/T	cg25930673	chr12:123319894	HIP1R	-0.86	-4.99	-0.46	2.78e-6	Schizophrenia;
THYM	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg18032289	chr17:61959525	GH2	-0.5	-4.76	-0.44	6.95e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs748404	0.676	rs4401024	chr15:43650335	C/T	cg12861797	chr15:43585817	TGM7	0.44	4.67	0.43	9.79e-6	Lung cancer;
THYM	cis	rs9875589	0.509	rs2607761	chr3:14091428	A/G	cg03204825	chr3:13978759	TPRXL	-0.54	-4.67	-0.43	1.01e-5	Ovarian reserve;
THYM	cis	rs1003719	0.788	rs4411798	chr21:38453183	A/G	cg01329690	chr21:38580129	DSCR9	0.42	5.74	0.51	1.13e-7	Eye color traits;
THYM	cis	rs7943203	0.524	rs227060	chr11:108204881	C/T	cg04873221	chr11:107992290	ACAT1	-0.71	-4.72	-0.44	7.96e-6	Red blood cell count;Mean corpuscular volume;
THYM	cis	rs55883249	1.000	rs76964971	chr2:9763904	C/A	cg23886495	chr2:9695866	ADAM17	0.8	5.03	0.46	2.29e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg03806693	chr22:41940476	POLR3H	1.16	10.2	0.72	6.06e-17	Vitiligo;
THYM	cis	rs1278769	0.786	rs7998551	chr13:113540649	G/T	cg01161842	chr13:113518337	ATP11A	0.69	4.72	0.44	8.24e-6	Interstitial lung disease;
THYM	cis	rs2408955	0.568	rs12099462	chr12:48503104	T/C	cg21466736	chr12:48725269	NA	0.47	4.65	0.43	1.08e-5	Glycated hemoglobin levels;
THYM	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg12560992	chr17:57184187	TRIM37	0.91	8.17	0.64	1.29e-12	Intelligence (multi-trait analysis);
THYM	cis	rs1692580	0.840	rs263526	chr1:2173504	T/C	cg21194808	chr1:2205498	SKI	0.32	4.53	0.42	1.69e-5	Coronary artery disease;
THYM	cis	rs765787	0.530	rs12906537	chr15:45520061	T/C	cg25801113	chr15:45476975	SHF	-0.38	-4.53	-0.42	1.68e-5	Uric acid levels;
THYM	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg04043695	chr12:129287642	SLC15A4	0.61	5.09	0.46	1.83e-6	Systemic lupus erythematosus;
THYM	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg02524346	chr8:600233	NA	0.91	4.55	0.42	1.59e-5	IgG glycosylation;
THYM	cis	rs3008870	0.755	rs2815374	chr1:67507387	G/A	cg02640540	chr1:67518911	SLC35D1	0.6	4.78	0.44	6.47e-6	Lymphocyte percentage of white cells;
THYM	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg08704250	chr15:31115839	NA	0.47	5.54	0.49	2.68e-7	Huntington's disease progression;
THYM	cis	rs6032067	0.777	rs73907811	chr20:43801395	T/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.52	-5.89	-0.52	5.76e-8	Blood protein levels;
THYM	cis	rs7705502	1.000	rs72812817	chr5:173356748	A/G	cg18693985	chr5:173351052	CPEB4	-0.75	-5.7	-0.5	1.35e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-4.6	-0.43	1.29e-5	Heart rate;
THYM	cis	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg07235805	chr18:78004237	PARD6G	-0.43	-4.93	-0.45	3.51e-6	Opioid sensitivity;
THYM	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-4.68	-0.43	9.5e-6	Longevity;
THYM	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.37	-0.48	5.64e-7	Total cholesterol levels;
THYM	cis	rs6723226	0.803	rs387780	chr2:32502495	T/C	cg02381751	chr2:32503542	YIPF4	0.67	5.57	0.5	2.33e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2235642	0.964	rs2745181	chr16:1577056	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.61	-4.93	-0.45	3.44e-6	Coronary artery disease;
THYM	cis	rs7580658	0.680	rs6710535	chr2:128190960	C/G	cg10021288	chr2:128175891	PROC	0.67	5.92	0.52	5.13e-8	Protein C levels;
THYM	cis	rs7705042	0.897	rs7718955	chr5:141521459	A/G	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg11166453	chr1:247681781	NA	0.7	5.41	0.49	4.62e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9329289	0.510	rs35854428	chr10:2554280	T/C	cg15501526	chr10:2543763	NA	0.5	4.58	0.43	1.39e-5	Age-related hearing impairment;
THYM	cis	rs4646404	0.509	rs4646359	chr17:17470609	C/T	cg11245205	chr17:17398264	RASD1	-0.41	-4.8	-0.44	5.96e-6	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
THYM	cis	rs113835537	0.529	rs17580784	chr11:66214859	T/A	cg10315249	chr11:66235081	PELI3	0.44	4.72	0.44	8.05e-6	Airway imaging phenotypes;
THYM	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg07936489	chr17:37558343	FBXL20	0.83	5.84	0.51	7.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	trans	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg25214090	chr10:38739885	LOC399744	0.94	7.92	0.63	4.4e-12	Corneal astigmatism;
THYM	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg24531977	chr5:56204891	C5orf35	-1.01	-8.29	-0.65	7.47e-13	Initial pursuit acceleration;
THYM	cis	rs2797685	1.000	rs2797685	chr1:7879063	C/T	cg06712362	chr1:7811235	CAMTA1	0.68	4.96	0.45	3.09e-6	Crohn's disease;
THYM	cis	rs240764	0.717	rs6904959	chr6:101157916	C/T	cg21058520	chr6:100914733	NA	0.57	4.92	0.45	3.69e-6	Neuroticism;
THYM	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg21475434	chr5:93447410	FAM172A	-0.93	-5.76	-0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs763014	0.833	rs3743903	chr16:632736	T/C	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg13447684	chr7:1895903	MAD1L1	0.55	4.66	0.43	1.01e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs863345	0.564	rs1418844	chr1:158457569	A/T	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs2268241	0.938	rs9978223	chr21:34770358	G/A	cg14850771	chr21:34775459	IFNGR2	1.0	7.12	0.59	2.09e-10	Obesity-related traits;
THYM	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg25767906	chr1:53392781	SCP2	-0.7	-6.71	-0.57	1.39e-9	Monocyte count;
THYM	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg24675658	chr1:53192096	ZYG11B	0.71	6.38	0.55	6.49e-9	Monocyte count;
THYM	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg25358565	chr5:93447407	FAM172A	1.31	11.12	0.75	6.98e-19	Diabetic retinopathy;
THYM	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg22974920	chr21:40686053	BRWD1	-0.64	-5.09	-0.46	1.83e-6	Cognitive function;
THYM	cis	rs7772486	0.875	rs2474353	chr6:146323883	G/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.66	-0.5	1.62e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4266144	0.563	rs61124401	chr3:156840919	A/G	cg16248515	chr3:156840234	NA	-0.78	-7.02	-0.58	3.27e-10	Coronary artery disease;
THYM	cis	rs896854	0.517	rs9643353	chr8:95957063	A/G	cg16049864	chr8:95962084	TP53INP1	0.78	5.72	0.51	1.23e-7	Type 2 diabetes;
THYM	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg06634786	chr22:41940651	POLR3H	0.71	5.22	0.47	1.07e-6	Vitiligo;
THYM	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg11812906	chr14:75593930	NEK9	0.73	6.68	0.57	1.63e-9	Coronary artery disease;
THYM	cis	rs34638657	0.872	rs2967326	chr16:82188246	A/G	cg07307142	chr16:82071433	HSD17B2	-1.0	-7.8	-0.63	7.75e-12	Lung adenocarcinoma;
THYM	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg03806693	chr22:41940476	POLR3H	0.96	7.58	0.61	2.28e-11	Vitiligo;
THYM	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg08885076	chr2:99613938	TSGA10	-0.61	-5.79	-0.51	9.26e-8	Chronic sinus infection;
THYM	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22590775	chr19:49891494	CCDC155	0.67	5.1	0.46	1.76e-6	Multiple sclerosis;
THYM	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	6.88	0.58	6.35e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs662064	0.962	rs1188525	chr1:10550877	A/G	cg20482658	chr1:10539492	PEX14	-0.49	-6.13	-0.53	2e-8	Asthma;
THYM	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg06784218	chr1:46089804	CCDC17	0.31	4.57	0.42	1.46e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10504073	0.647	rs6997703	chr8:49998364	T/C	cg00325661	chr8:49890786	NA	0.93	8.79	0.67	6.32e-14	Blood metabolite ratios;
THYM	cis	rs8114671	0.562	rs2223881	chr20:33506463	A/C	cg08999081	chr20:33150536	PIGU	0.63	5.21	0.47	1.09e-6	Height;
THYM	cis	rs250677	0.522	rs55732303	chr5:148392538	C/T	cg18129178	chr5:148520854	ABLIM3	-0.71	-5.31	-0.48	7.05e-7	Breast cancer;
THYM	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg26531700	chr6:26746687	NA	0.56	4.77	0.44	6.62e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11563648	0.553	rs4731359	chr7:127055248	G/A	cg23081781	chr7:127225937	GCC1	-0.35	-4.85	-0.45	4.85e-6	Resting heart rate;
THYM	cis	rs1395	0.778	rs56364136	chr2:27451429	T/C	cg23587288	chr2:27483067	SLC30A3	-0.56	-5.03	-0.46	2.35e-6	Blood metabolite levels;
THYM	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22857025	chr5:266934	NA	-1.43	-9.3	-0.69	5.28e-15	Breast cancer;
THYM	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14893161	chr1:205819251	PM20D1	-0.77	-7.83	-0.63	6.81e-12	Monocyte percentage of white cells;
THYM	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs6696239	0.794	rs3088389	chr1:227919190	G/A	cg02736395	chr1:227748424	NA	-0.62	-4.89	-0.45	4.08e-6	Height;
THYM	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg11663144	chr21:46675770	NA	-0.49	-5.84	-0.51	7.42e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg23161317	chr6:28129485	ZNF389	-1.03	-7.42	-0.61	4.83e-11	Depression;
THYM	cis	rs9876781	1.000	rs9817615	chr3:48470756	T/C	cg06066452	chr3:48470258	PLXNB1	0.27	4.85	0.45	4.78e-6	Longevity;
THYM	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22968622	chr17:43663579	NA	0.82	7.02	0.58	3.23e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9902453	0.765	rs2259857	chr17:28097780	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs977102	0.556	rs977101	chr3:67373763	C/T	cg06096184	chr3:66549732	LRIG1	0.66	4.6	0.43	1.32e-5	Response to amphetamines;
THYM	cis	rs11690935	0.632	rs9789538	chr2:172618474	G/C	cg13550731	chr2:172543902	DYNC1I2	0.68	5.37	0.48	5.65e-7	Schizophrenia;
THYM	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg11266682	chr4:10021025	SLC2A9	0.75	11.19	0.75	4.79e-19	Bone mineral density;
THYM	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg22868518	chr11:507468	RNH1	1.05	4.49	0.42	1.97e-5	Body mass index;
THYM	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg07936489	chr17:37558343	FBXL20	0.82	5.42	0.49	4.49e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7731657	0.509	rs2250348	chr5:130243531	T/A	cg08523029	chr5:130500466	HINT1	-0.77	-5.3	-0.48	7.38e-7	Fasting plasma glucose;
THYM	trans	rs7952251	0.756	rs1945106	chr11:112397326	A/G	cg14154186	chr1:204970430	NFASC	-0.71	-7.27	-0.6	9.91e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4499344	0.768	rs10411319	chr19:33102805	C/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.42	0.61	4.96e-11	Mean platelet volume;
THYM	cis	rs11096990	0.572	rs35040563	chr4:39155882	G/A	cg24403649	chr4:39172243	NA	0.57	4.81	0.44	5.65e-6	Cognitive function;
THYM	cis	rs11048434	0.649	rs11613650	chr12:9060396	T/C	cg13575925	chr12:9217583	LOC144571	0.52	4.79	0.44	6.06e-6	Sjögren's syndrome;
THYM	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg13609457	chr4:120235615	NA	0.54	5.0	0.46	2.62e-6	Corneal astigmatism;
THYM	cis	rs10744422	1.000	rs4759355	chr12:123316566	A/G	cg25930673	chr12:123319894	HIP1R	-0.88	-5.15	-0.47	1.43e-6	Schizophrenia;
THYM	cis	rs7772486	0.817	rs9386145	chr6:146363519	A/T	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28595532	0.920	rs114382134	chr4:119733215	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg00256281	chr22:41985642	PMM1	0.64	4.98	0.46	2.78e-6	Vitiligo;
THYM	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg12863693	chr15:85201151	NMB	0.65	5.75	0.51	1.1e-7	Schizophrenia;
THYM	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.27	4.45	0.42	2.32e-5	Obesity-related traits;
THYM	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg06623918	chr6:96969491	KIAA0776	1.09	9.82	0.71	3.91e-16	Headache;
THYM	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg15556689	chr8:8085844	FLJ10661	0.7	6.07	0.53	2.64e-8	Mood instability;
THYM	cis	rs2237457	0.543	rs2529385	chr7:50702021	T/C	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.48e-6	Schizophrenia (treatment resistant);
THYM	cis	rs2109514	0.840	rs10228178	chr7:116132211	G/A	cg12739419	chr7:116140593	CAV2	-0.48	-4.72	-0.44	8.2e-6	Prevalent atrial fibrillation;
THYM	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg06027949	chr8:82754900	SNX16	0.64	5.35	0.48	6.18e-7	Diastolic blood pressure;
THYM	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg06636001	chr8:8085503	FLJ10661	-0.76	-6.87	-0.58	6.7e-10	Neuroticism;
THYM	cis	rs12586317	0.531	rs60049741	chr14:35719842	G/A	cg07166546	chr14:35805898	NA	-0.21	-5.07	-0.46	1.99e-6	Psoriasis;
THYM	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg24675658	chr1:53192096	ZYG11B	0.88	6.66	0.56	1.8e-9	Monocyte count;
THYM	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg11245990	chr11:68621969	NA	0.55	7.14	0.59	1.89e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9309711	0.772	rs9752251	chr2:3489869	C/T	cg10845886	chr2:3471009	TTC15	-0.61	-4.97	-0.45	3.01e-6	Neurofibrillary tangles;
THYM	cis	rs3008870	1.000	rs17497828	chr1:67452322	G/A	cg02640540	chr1:67518911	SLC35D1	-0.67	-4.67	-0.43	9.85e-6	Lymphocyte percentage of white cells;
THYM	cis	rs2625529	0.824	rs12902006	chr15:72252996	C/T	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs757081	0.636	rs214934	chr11:17193475	T/A	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.6	-0.43	1.29e-5	Systolic blood pressure;
THYM	cis	rs2810114	0.834	rs36559	chr14:71354949	A/T	cg15910301	chr14:71632612	NA	0.56	4.61	0.43	1.23e-5	Alcohol dependence;
THYM	cis	rs9790314	0.521	rs1376122	chr3:161087857	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-5.99	-0.52	3.81e-8	Morning vs. evening chronotype;
THYM	cis	rs11645898	0.687	rs72787058	chr16:72105084	C/T	cg03805757	chr16:71968109	PKD1L3	-0.6	-4.54	-0.42	1.68e-5	Blood protein levels;
THYM	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Blood protein levels;
THYM	cis	rs1322639	1.000	rs1322639	chr6:169587103	G/A	cg04662567	chr6:169592167	NA	0.78	7.07	0.59	2.58e-10	Pulse pressure;
THYM	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg06640241	chr16:89574553	SPG7	0.7	5.4	0.48	4.99e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg13609457	chr4:120235615	NA	-0.54	-5.02	-0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs17597773	0.638	rs7553447	chr1:220989534	C/T	cg16008148	chr1:221062819	NA	0.41	4.54	0.42	1.62e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06481639	chr22:41940642	POLR3H	-0.79	-5.36	-0.48	5.85e-7	Vitiligo;
THYM	cis	rs6496667	0.532	rs2601207	chr15:90963542	C/G	cg22089800	chr15:90895588	ZNF774	-0.63	-4.73	-0.44	7.79e-6	Rheumatoid arthritis;
THYM	cis	rs6964587	0.610	rs2888850	chr7:91430027	T/C	cg17063962	chr7:91808500	NA	1.01	8.74	0.67	7.97e-14	Breast cancer;
THYM	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg06713675	chr4:122721982	EXOSC9	-0.54	-5.0	-0.46	2.65e-6	Type 2 diabetes;
THYM	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg04865290	chr3:52927548	TMEM110	-0.97	-5.07	-0.46	1.97e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs3806843	0.868	rs2262574	chr5:140123635	G/T	cg19875535	chr5:140030758	IK	-0.62	-5.02	-0.46	2.42e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs2319125	0.628	rs10853067	chr17:63994568	G/A	cg04446870	chr17:64440273	PRKCA	-0.51	-4.55	-0.42	1.58e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg05802129	chr4:122689817	NA	-0.63	-5.1	-0.46	1.71e-6	Type 2 diabetes;
THYM	cis	rs6733011	0.628	rs6726156	chr2:99458607	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.51	-0.42	1.83e-5	Bipolar disorder;
THYM	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg01819863	chr10:32635814	EPC1	1.04	6.64	0.56	1.9e-9	Sexual dysfunction (female);
THYM	cis	rs7731657	0.537	rs112876284	chr5:130293884	G/C	cg08523029	chr5:130500466	HINT1	-0.76	-5.21	-0.47	1.11e-6	Fasting plasma glucose;
THYM	cis	rs4631830	0.733	rs4512771	chr10:51540906	C/A	cg10326726	chr10:51549505	MSMB	-0.59	-5.76	-0.51	1.02e-7	Prostate-specific antigen levels;
THYM	cis	rs9522267	0.535	rs7323631	chr13:112232269	A/G	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.69e-11	Aortic root size;
THYM	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg06808227	chr14:105710500	BRF1	-1.05	-9.14	-0.68	1.12e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11123610	0.520	rs13409381	chr2:3722579	A/G	cg25251562	chr2:3704773	ALLC	-0.79	-5.01	-0.46	2.51e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg11494091	chr17:61959527	GH2	-0.79	-7.96	-0.63	3.57e-12	Height;
THYM	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg02869364	chr7:1081709	C7orf50	-0.41	-5.0	-0.46	2.63e-6	Longevity;Endometriosis;
THYM	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7107174	1.000	rs10899455	chr11:77999163	T/C	cg19901956	chr11:77921274	USP35	-0.73	-5.52	-0.49	2.88e-7	Testicular germ cell tumor;
THYM	cis	rs4866334	0.850	rs75708102	chr5:18489975	C/A	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs12681287	0.640	rs10098356	chr8:87442667	A/G	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	trans	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg19862616	chr7:65841803	NCRNA00174	1.13	13.2	0.8	3.22e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.7	-5.21	-0.47	1.1e-6	Tonsillectomy;
THYM	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.8	-6.37	-0.55	6.73e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg12826209	chr6:26865740	GUSBL1	0.79	5.23	0.47	9.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7542375	0.534	rs1587024	chr1:221031219	C/T	cg16008148	chr1:221062819	NA	0.46	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg17063962	chr7:91808500	NA	1.08	11.54	0.76	8.71e-20	Breast cancer;
THYM	cis	rs7267979	1.000	rs3761117	chr20:25388070	G/A	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.03e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.66	5.17	0.47	1.32e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs59698941	0.943	rs997633	chr5:132219304	A/T	cg02081065	chr5:132209139	LEAP2	-0.85	-5.74	-0.51	1.14e-7	Apolipoprotein A-IV levels;
THYM	cis	rs10924970	0.967	rs2382617	chr1:235402230	A/G	cg26050004	chr1:235667680	B3GALNT2	0.6	4.5	0.42	1.92e-5	Asthma;
THYM	cis	rs939658	0.805	rs59104559	chr15:79438784	A/G	cg17916960	chr15:79447300	NA	-0.73	-8.59	-0.66	1.73e-13	Refractive error;
THYM	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg26818010	chr10:134567672	INPP5A	-0.91	-7.38	-0.6	5.95e-11	Migraine;
THYM	cis	rs3008870	0.755	rs1925410	chr1:67365230	C/T	cg02640540	chr1:67518911	SLC35D1	-0.63	-4.99	-0.46	2.7e-6	Lymphocyte percentage of white cells;
THYM	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-5.38	-0.48	5.28e-7	Longevity;Endometriosis;
THYM	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg10950924	chr17:47092072	IGF2BP1	-0.52	-4.76	-0.44	6.91e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs6430585	0.702	rs3213890	chr2:136552188	G/A	cg23851026	chr2:136556271	LCT	0.74	7.29	0.6	9.19e-11	Corneal structure;
THYM	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg21475434	chr5:93447410	FAM172A	0.97	6.1	0.53	2.3e-8	Diabetic retinopathy;
THYM	cis	rs4731207	0.698	rs6466955	chr7:124518766	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs6032067	0.929	rs13043503	chr20:43805835	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs686320	1.000	rs679643	chr11:65250590	C/A	cg19332572	chr11:65321591	LTBP3	0.86	5.23	0.47	9.91e-7	Hip circumference adjusted for BMI;
THYM	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg14004847	chr7:1930337	MAD1L1	-0.66	-4.87	-0.45	4.36e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12950390	1.000	rs8068453	chr17:45852354	A/G	cg06532163	chr17:45867833	NA	-0.58	-4.84	-0.44	5.04e-6	IgG glycosylation;
THYM	cis	rs899997	0.906	rs1994018	chr15:79025584	G/A	cg10852096	chr15:79043040	NA	0.75	4.81	0.44	5.58e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs36051895	0.664	rs10116560	chr9:5096433	A/G	cg02405213	chr9:5042618	JAK2	-1.0	-10.94	-0.75	1.67e-18	Pediatric autoimmune diseases;
THYM	cis	rs4711350	0.678	rs658087	chr6:33665020	A/T	cg16492833	chr6:33679775	C6orf125	-0.59	-4.87	-0.45	4.36e-6	Schizophrenia;
THYM	cis	rs6496667	0.510	rs16944405	chr15:90975517	A/G	cg00425431	chr15:90792223	TTLL13	0.41	4.72	0.44	8.05e-6	Rheumatoid arthritis;
THYM	cis	rs4792901	0.959	rs4792997	chr17:41652076	A/G	cg21940313	chr17:41620911	ETV4	0.45	4.76	0.44	6.89e-6	Dupuytren's disease;
THYM	cis	rs4363385	0.818	rs61811862	chr1:152995668	G/A	cg13444842	chr1:152974279	SPRR3	-0.59	-4.86	-0.45	4.68e-6	Inflammatory skin disease;
THYM	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg24920358	chr1:40204285	PPIE	0.56	4.88	0.45	4.25e-6	Blood protein levels;
THYM	cis	rs9426691	1	rs9426691	chr1:23484904	A/G	cg12483005	chr1:23474871	LUZP1	0.69	6.67	0.56	1.71e-9	Coenzyme Q10 levels;
THYM	cis	rs9915657	0.660	rs1558748	chr17:70066502	T/C	cg06234051	chr17:70120541	SOX9	-0.62	-5.56	-0.5	2.46e-7	Thyroid hormone levels;
THYM	cis	rs13082711	0.863	rs66743193	chr3:27471958	G/A	cg02860705	chr3:27208620	NA	0.83	5.74	0.51	1.11e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9470366	0.883	rs7756236	chr6:36627053	A/G	cg11920449	chr6:36645608	CDKN1A	-0.71	-5.48	-0.49	3.52e-7	QRS duration;
THYM	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg18230493	chr5:56204884	C5orf35	-0.64	-4.86	-0.45	4.56e-6	Initial pursuit acceleration;
THYM	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg23815491	chr16:72088622	HP	0.84	7.3	0.6	8.9e-11	Fibrinogen levels;
THYM	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11890956	chr21:40555474	PSMG1	1.17	13.11	0.8	4.95e-23	Cognitive function;
THYM	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg00147160	chr1:26503991	CNKSR1	0.53	7.17	0.59	1.65e-10	Height;
THYM	cis	rs28595532	0.920	rs115506655	chr4:119757667	A/G	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs910316	0.575	rs12889133	chr14:75465089	C/T	cg11812906	chr14:75593930	NEK9	0.75	6.16	0.53	1.72e-8	Height;
THYM	cis	rs56104184	0.887	rs4801778	chr19:49370609	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.99	-5.97	-0.52	4.09e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	trans	rs7952251	0.756	rs7125827	chr11:112398446	A/C	cg14154186	chr1:204970430	NFASC	-0.72	-7.41	-0.61	5.29e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs10752881	1.000	rs4233192	chr1:182970837	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.6	-4.86	-0.45	4.64e-6	Colorectal cancer;
THYM	cis	rs28829049	0.597	rs2296107	chr1:19476649	C/G	cg13387374	chr1:19411106	UBR4	0.67	4.98	0.46	2.8e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs2797160	1.000	rs1739362	chr6:126020703	A/T	cg16306078	chr6:126000798	NA	0.52	5.3	0.48	7.54e-7	Endometrial cancer;
THYM	cis	rs4474465	0.833	rs6592792	chr11:78271614	A/C	cg19901956	chr11:77921274	USP35	0.73	5.05	0.46	2.09e-6	Alzheimer's disease (survival time);
THYM	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg07424592	chr7:64974309	NA	1.02	5.34	0.48	6.42e-7	Diabetic kidney disease;
THYM	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	0.99	12.2	0.78	3.73e-21	Chronic sinus infection;
THYM	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg03709012	chr19:19516395	GATAD2A	1.05	6.22	0.54	1.34e-8	Nonalcoholic fatty liver disease;
THYM	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.15	6.86	0.58	7.08e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.58	-0.61	2.28e-11	Personality dimensions;
THYM	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg27446573	chr6:127587934	RNF146	0.69	5.7	0.5	1.37e-7	Breast cancer;
THYM	cis	rs4731207	0.564	rs6466972	chr7:124596249	T/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs6473252	0.584	rs59439286	chr8:81817148	T/C	cg08595989	chr8:81827712	NA	-0.51	-5.6	-0.5	2.12e-7	Breast cancer;
THYM	cis	rs28595532	0.920	rs115317002	chr4:119722809	T/C	cg14228332	chr4:119757509	SEC24D	1.35	5.15	0.47	1.39e-6	Cannabis dependence symptom count;
THYM	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg04546413	chr19:29218101	NA	0.85	5.48	0.49	3.44e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.99	6.62	0.56	2.09e-9	Platelet count;
THYM	trans	rs34156428	0.929	rs35843825	chr11:16483508	C/T	cg02688867	chr12:133019854	NA	0.54	6.89	0.58	6.12e-10	Coronary artery disease;
THYM	cis	rs752010	1.000	rs6656183	chr1:42094025	A/G	cg22486000	chr1:42919398	ZMYND12	-0.42	-4.95	-0.45	3.22e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg26418147	chr1:205743515	RAB7L1	-0.54	-4.71	-0.44	8.45e-6	Menarche (age at onset);
THYM	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg11266682	chr4:10021025	SLC2A9	-0.62	-7.96	-0.63	3.73e-12	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg11141652	chr22:24348549	GSTTP1	0.56	5.14	0.47	1.47e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.05	-5.39	-0.48	5.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7953508	0.750	rs7310389	chr12:93976636	A/G	cg13201927	chr12:93977447	NA	0.69	5.19	0.47	1.19e-6	Pubertal anthropometrics;
THYM	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg06634786	chr22:41940651	POLR3H	0.71	5.04	0.46	2.19e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs11731175	1.000	rs11722852	chr4:189861213	A/G	cg00431894	chr4:189871012	NA	-0.82	-6.23	-0.54	1.29e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-4.6	-0.43	1.3e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.93	-4.54	-0.42	1.64e-5	Alzheimer's disease;
THYM	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.75	8.38	0.65	4.74e-13	Eosinophil percentage of white cells;
THYM	cis	rs2073300	0.609	rs56334525	chr20:23365812	A/G	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs4944571	0.735	rs1452133	chr11:86146001	A/G	cg12273770	chr11:86667258	FZD4	0.53	4.5	0.42	1.93e-5	Urate levels in obese individuals;
THYM	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg22875332	chr1:76189707	ACADM	-0.9	-10.62	-0.74	7.94e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg25767906	chr1:53392781	SCP2	-0.67	-6.38	-0.55	6.52e-9	Monocyte count;
THYM	cis	rs8067545	0.611	rs12942568	chr17:20117893	G/T	cg20830565	chr17:20408647	MGC102966	0.49	4.48	0.42	2.05e-5	Schizophrenia;
THYM	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg10047753	chr17:41438598	NA	1.2	11.56	0.76	8.14e-20	Menopause (age at onset);
THYM	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg07061783	chr6:25882402	NA	-0.82	-7.2	-0.59	1.39e-10	Intelligence (multi-trait analysis);
THYM	cis	rs892961	0.932	rs67415822	chr17:75412678	A/G	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg20744362	chr22:50050164	C22orf34	-0.75	-7.28	-0.6	9.64e-11	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.27	0.54	1.07e-8	Platelet count;
THYM	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg11247378	chr22:39784982	NA	0.98	12.9	0.8	1.33e-22	IgG glycosylation;
THYM	cis	rs11838776	0.586	rs750598	chr13:111028978	C/T	cg06243866	chr13:111019493	COL4A2	-0.96	-11.15	-0.75	5.97e-19	Coronary artery disease;
THYM	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg03877680	chr5:178157825	ZNF354A	0.7	4.77	0.44	6.65e-6	Neutrophil percentage of white cells;
THYM	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs17030434	0.953	rs11099905	chr4:154686183	A/G	cg14289246	chr4:154710475	SFRP2	0.74	5.01	0.46	2.47e-6	Electrocardiographic conduction measures;
THYM	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg26031613	chr14:104095156	KLC1	0.78	5.2	0.47	1.14e-6	Body mass index;
THYM	cis	rs12889267	0.722	rs2319625	chr14:21565146	C/T	cg02988727	chr14:21567520	ZNF219;C14orf176	0.53	5.09	0.46	1.79e-6	Hematocrit;Resting heart rate;
THYM	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg06271696	chr7:157225062	NA	-0.7	-6.27	-0.54	1.05e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg21644426	chr2:191273491	MFSD6	-0.74	-5.1	-0.46	1.73e-6	Diastolic blood pressure;
THYM	cis	rs665401	0.965	rs2145173	chr6:117230339	G/C	cg20376953	chr6:117187980	NA	0.63	5.08	0.46	1.87e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg20891283	chr12:69753455	YEATS4	1.06	9.85	0.71	3.49e-16	Blood protein levels;
THYM	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9462846	0.881	rs9296402	chr6:42875650	G/A	cg21280719	chr6:42927975	GNMT	-0.38	-4.45	-0.42	2.32e-5	Blood protein levels;
THYM	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg19761014	chr17:28927070	LRRC37B2	-0.73	-4.51	-0.42	1.88e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4953076	0.613	rs11124981	chr2:44462133	A/T	cg04920474	chr2:44395004	PPM1B	0.62	5.2	0.47	1.12e-6	Height;
THYM	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs2991971	1.000	rs2991970	chr1:46011005	C/T	cg15605315	chr1:45957053	TESK2	0.78	6.36	0.55	7.18e-9	High light scatter reticulocyte count;
THYM	cis	rs6473252	0.584	rs7825743	chr8:81807098	G/A	cg08595989	chr8:81827712	NA	-0.5	-5.45	-0.49	4.02e-7	Breast cancer;
THYM	trans	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.16	-14.58	-0.83	5.71e-26	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs3126085	0.560	rs11204985	chr1:152333597	A/G	cg10321714	chr1:152280068	FLG	0.72	5.47	0.49	3.69e-7	Atopic dermatitis;
THYM	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.84	-5.79	-0.51	9.16e-8	Body mass index;
THYM	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.92	5.94	0.52	4.62e-8	Platelet count;
THYM	cis	rs7432375	0.580	rs4678441	chr3:136532828	T/C	cg21827317	chr3:136751795	NA	0.54	4.64	0.43	1.13e-5	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs4363385	0.719	rs6664411	chr1:152932857	T/C	cg07796016	chr1:152779584	LCE1C	-0.56	-4.59	-0.43	1.36e-5	Inflammatory skin disease;
THYM	cis	rs7584330	0.704	rs72620820	chr2:238358844	G/A	cg14458575	chr2:238380390	NA	1.15	8.2	0.64	1.16e-12	Prostate cancer;
THYM	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg26039829	chr8:22132926	PIWIL2	0.7	6.3	0.54	9.44e-9	Hypertriglyceridemia;
THYM	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg10047753	chr17:41438598	NA	1.18	11.26	0.76	3.4e-19	Menopause (age at onset);
THYM	cis	rs7640424	0.620	rs17231503	chr3:107817299	C/T	cg09227934	chr3:107805635	CD47	-0.59	-4.84	-0.45	4.94e-6	Body mass index;
THYM	cis	rs9807841	0.592	rs2043304	chr19:10772112	T/C	cg16900796	chr19:10755136	SLC44A2	0.39	6.11	0.53	2.14e-8	Inflammatory skin disease;
THYM	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg11317459	chr13:21872234	NA	-1.23	-9.7	-0.71	7.06e-16	White matter hyperintensity burden;
THYM	cis	rs4845459	0.967	rs4845446	chr1:152590750	C/T	cg27206522	chr1:152595629	LCE3A	0.51	4.54	0.42	1.66e-5	Psoriasis;
THYM	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg18252515	chr7:66147081	NA	-0.63	-4.68	-0.43	9.63e-6	Aortic root size;
THYM	cis	rs3820068	0.506	rs17448966	chr1:15990983	T/G	cg24675056	chr1:15929824	NA	0.78	6.24	0.54	1.21e-8	Systolic blood pressure;
THYM	cis	rs7851660	0.809	rs7032114	chr9:100656459	T/G	cg13688889	chr9:100608707	NA	-0.78	-5.67	-0.5	1.53e-7	Strep throat;
THYM	cis	rs11030122	0.702	rs12286710	chr11:3967171	T/G	cg22027985	chr11:4115532	RRM1	-0.48	-4.59	-0.43	1.36e-5	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6960043	1.000	rs12666046	chr7:15050381	A/G	cg19272540	chr7:15055459	NA	-0.53	-6.25	-0.54	1.15e-8	Type 2 diabetes;
THYM	cis	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg24672777	chr11:48374446	OR4C45	0.67	4.62	0.43	1.19e-5	Coronary artery disease;
THYM	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	5.87	0.52	6.41e-8	Rheumatoid arthritis;
THYM	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg15693483	chr7:1102177	C7orf50	0.53	6.19	0.54	1.52e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs889398	0.935	rs1364063	chr16:69588572	T/C	cg09409435	chr16:70099608	PDXDC2	-0.63	-4.81	-0.44	5.78e-6	Body mass index;
THYM	cis	rs1008375	0.835	rs13122181	chr4:17708815	C/A	cg18681998	chr4:17616180	MED28	-0.84	-6.88	-0.58	6.41e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06634786	chr22:41940651	POLR3H	0.69	5.31	0.48	7.18e-7	Vitiligo;
THYM	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg26384229	chr12:38710491	ALG10B	-0.87	-8.86	-0.67	4.62e-14	Heart rate;
THYM	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg27286337	chr10:134555280	INPP5A	0.87	6.67	0.56	1.7e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs9649213	0.593	rs7781916	chr7:97929738	A/G	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.6e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg20966754	chr17:47091339	IGF2BP1	-0.58	-7.51	-0.61	3.19e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs11030122	0.687	rs10835521	chr11:4056004	A/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.74	-0.51	1.11e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs75064307	0.834	rs9288870	chr3:108113469	G/C	cg03329597	chr3:108125523	MYH15	0.66	4.75	0.44	7.15e-6	Intelligence (multi-trait analysis);
THYM	trans	rs2289577	0.698	rs17513180	chr6:90634912	A/G	cg22698489	chr1:159893696	TAGLN2	-1.18	-6.86	-0.58	7.1e-10	Cognitive performance;
THYM	cis	rs4654899	1.000	rs885363	chr1:21325360	C/A	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.26e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs11690935	0.632	rs34531723	chr2:172564094	A/C	cg13550731	chr2:172543902	DYNC1I2	0.63	5.01	0.46	2.48e-6	Schizophrenia;
THYM	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg09455208	chr3:40491958	NA	0.44	4.56	0.42	1.53e-5	Renal cell carcinoma;
THYM	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03517284	chr6:25882590	NA	-0.99	-8.64	-0.66	1.34e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg13695892	chr22:41940480	POLR3H	0.86	6.31	0.54	8.99e-9	Vitiligo;
THYM	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs17253792	0.822	rs79873916	chr14:56172631	G/C	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22496380	chr5:211416	CCDC127	-1.33	-7.99	-0.63	3.21e-12	Breast cancer;
THYM	cis	rs1691799	0.831	rs6581678	chr12:66776656	A/G	cg16791601	chr12:66731901	HELB	-0.8	-7.68	-0.62	1.44e-11	White blood cell count (basophil);
THYM	cis	rs12039431	0.748	rs6692773	chr1:38025407	G/A	cg17933807	chr1:38061675	GNL2	-0.85	-6.36	-0.55	7.08e-9	Epithelial ovarian cancer;
THYM	cis	rs228769	0.653	rs2523162	chr17:42179281	A/G	cg19774624	chr17:42201019	HDAC5	0.67	5.2	0.47	1.12e-6	Bone mineral density (hip);Bone mineral density (spine);
THYM	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13012494	chr21:47604986	C21orf56	-0.85	-5.62	-0.5	1.87e-7	Testicular germ cell tumor;
THYM	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg12564285	chr5:131593104	PDLIM4	0.44	4.78	0.44	6.47e-6	Breast cancer;
THYM	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg06481639	chr22:41940642	POLR3H	-0.6	-4.47	-0.42	2.16e-5	Neuroticism;
THYM	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06634786	chr22:41940651	POLR3H	-0.77	-5.6	-0.5	2.06e-7	Vitiligo;
THYM	cis	rs17641971	0.684	rs11785391	chr8:49930203	G/T	cg00325661	chr8:49890786	NA	0.64	4.81	0.44	5.65e-6	Blood metabolite levels;
THYM	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg25566285	chr7:158114605	PTPRN2	-0.88	-10.98	-0.75	1.37e-18	Calcium levels;
THYM	cis	rs62245779	1	rs62245779	chr3:11665483	T/C	cg07643000	chr3:11666825	VGLL4	-0.57	-4.58	-0.43	1.4e-5	Chronic sinus infection;
THYM	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-5.33	-0.48	6.7e-7	Hemoglobin concentration;
THYM	cis	rs62103177	0.568	rs2365388	chr18:77973702	G/T	cg16238918	chr18:78004303	PARD6G	0.6	4.7	0.43	8.71e-6	Opioid sensitivity;
THYM	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg06238570	chr21:40685208	BRWD1	-0.96	-9.14	-0.68	1.13e-14	Cognitive function;
THYM	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg15247329	chr7:2764246	NA	-0.68	-5.57	-0.5	2.33e-7	Height;
THYM	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg12560992	chr17:57184187	TRIM37	0.92	8.69	0.67	1.04e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2898681	0.614	rs4864680	chr4:53708421	T/G	cg21521518	chr4:53727714	RASL11B	0.43	4.88	0.45	4.25e-6	Optic nerve measurement (cup area);
THYM	cis	rs600550	0.588	rs2304934	chr11:60102396	A/G	cg05040360	chr11:60102449	MS4A6E	-0.5	-4.72	-0.44	8.13e-6	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs7524258	0.868	rs7544314	chr1:7266744	G/C	cg07173049	chr1:7289937	CAMTA1	0.76	5.83	0.51	7.52e-8	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs17401966	1.000	rs12117765	chr1:10268170	A/G	cg20482658	chr1:10539492	PEX14	0.38	4.6	0.43	1.29e-5	Hepatocellular carcinoma;
THYM	cis	rs9314614	0.789	rs2951859	chr8:6713153	C/T	cg27319216	chr8:6693540	XKR5	-0.54	-5.71	-0.51	1.29e-7	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs7772486	0.754	rs1415746	chr6:146077107	A/G	cg23711669	chr6:146136114	FBXO30	-0.97	-10.49	-0.73	1.45e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs61774743	0.636	rs1892423	chr1:41849340	A/C	cg01193554	chr1:41846683	NA	-0.34	-4.85	-0.45	4.9e-6	Intelligence (multi-trait analysis);
THYM	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg07022442	chr13:21864356	NA	0.7	4.64	0.43	1.12e-5	White matter hyperintensity burden;
THYM	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg02782426	chr3:40428986	ENTPD3	0.55	5.04	0.46	2.2e-6	Renal cell carcinoma;
THYM	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg25554036	chr4:6271136	WFS1	0.61	5.47	0.49	3.69e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs2734839	0.964	rs2234690	chr11:113291748	T/A	cg14159747	chr11:113255604	NA	0.32	6.41	0.55	5.69e-9	Information processing speed;
THYM	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg06074448	chr4:187884817	NA	-1.0	-13.81	-0.82	1.9e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6430585	0.793	rs11684545	chr2:136539122	G/T	cg04750100	chr2:136595281	LCT	-0.53	-5.87	-0.52	6.23e-8	Corneal structure;
THYM	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg02187348	chr16:89574699	SPG7	0.76	6.62	0.56	2.16e-9	Multiple myeloma (IgH translocation);
THYM	cis	rs240764	0.680	rs239234	chr6:101101234	G/A	cg21058520	chr6:100914733	NA	-0.58	-4.91	-0.45	3.73e-6	Neuroticism;
THYM	cis	rs2319125	0.683	rs8069434	chr17:64042870	T/A	cg04446870	chr17:64440273	PRKCA	0.5	4.48	0.42	2.12e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg23758822	chr17:41437982	NA	1.17	11.04	0.75	1.02e-18	Menopause (age at onset);
THYM	cis	rs988913	0.706	rs9475130	chr6:54925466	C/T	cg18532076	chr6:54711417	FAM83B	0.51	4.75	0.44	7.32e-6	Menarche (age at onset);
THYM	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg13683864	chr3:40499215	RPL14	-1.06	-11.7	-0.77	4.07e-20	Renal cell carcinoma;
THYM	cis	rs13082711	0.911	rs13081368	chr3:27521998	G/T	cg02860705	chr3:27208620	NA	0.72	5.06	0.46	2.01e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg17747265	chr1:1875780	NA	-0.79	-8.56	-0.66	1.95e-13	Body mass index;
THYM	cis	rs1062746	0.834	rs9308347	chr16:87371752	C/T	cg02258303	chr16:87377426	FBXO31	-0.63	-5.52	-0.49	2.89e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs7189233	0.955	rs16952242	chr16:53474250	C/T	cg02965178	chr16:53538660	AKTIP	-0.58	-4.6	-0.43	1.32e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7818345	0.663	rs11786904	chr8:19327267	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.56	4.86	0.45	4.6e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg19623624	chr10:135278901	LOC619207	-0.66	-5.32	-0.48	6.79e-7	Systemic lupus erythematosus;
THYM	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg12935359	chr14:103987150	CKB	-0.52	-5.16	-0.47	1.36e-6	Body mass index;
THYM	cis	rs11122449	1	rs11122449	chr1:230300481	C/T	cg20703242	chr1:230279135	GALNT2	0.66	4.76	0.44	6.82e-6	Red cell distribution width;
THYM	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.75	5.75	0.51	1.1e-7	Eosinophil percentage of white cells;
THYM	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg27129171	chr3:47204927	SETD2	-0.78	-7.68	-0.62	1.43e-11	Colorectal cancer;
THYM	cis	rs4589258	0.933	rs56124711	chr11:90407295	A/T	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.782	rs7969373	chr12:34249655	T/G	cg06521331	chr12:34319734	NA	-0.64	-5.37	-0.48	5.62e-7	Morning vs. evening chronotype;
THYM	cis	rs1629083	0.967	rs17092740	chr11:118117614	G/A	cg25155064	chr11:118100782	MPZL3	-0.57	-5.03	-0.46	2.34e-6	Lung cancer;
THYM	cis	rs951188	0.688	rs57945412	chr2:150431423	G/A	cg17961725	chr2:150454027	NA	-0.97	-5.26	-0.47	8.85e-7	Daytime sleep phenotypes;
THYM	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg10117171	chr1:25599238	RHD	-0.67	-4.82	-0.44	5.52e-6	Erythrocyte sedimentation rate;
THYM	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg21926883	chr2:100939477	LONRF2	-0.65	-5.96	-0.52	4.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.21	8.59	0.66	1.71e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs478304	0.580	rs11606947	chr11:65508237	A/C	cg27068330	chr11:65405492	SIPA1	-0.96	-9.31	-0.69	4.93e-15	Acne (severe);
THYM	cis	rs1372520	0.532	rs2583972	chr4:90747411	T/G	cg01966878	chr4:90757139	SNCA	-0.64	-5.19	-0.47	1.21e-6	Neuroticism;
THYM	cis	rs11648796	0.765	rs3829492	chr16:781633	G/A	cg01252526	chr16:711033	WDR90	-0.73	-6.16	-0.53	1.78e-8	Height;
THYM	cis	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.62	0.43	1.23e-5	Obesity-related traits;
THYM	cis	rs7849270	1.000	rs7023900	chr9:131891152	C/G	cg14069949	chr9:131965419	NA	0.5	4.52	0.42	1.8e-5	Blood metabolite ratios;
THYM	cis	rs6960043	0.818	rs10267273	chr7:15053589	A/G	cg19272540	chr7:15055459	NA	-0.55	-6.04	-0.53	3.05e-8	Type 2 diabetes;
THYM	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs4638749	0.906	rs34974921	chr2:108860253	A/G	cg23163573	chr2:108905468	SULT1C2	-0.29	-4.47	-0.42	2.15e-5	Blood pressure;
THYM	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs293526	1.000	rs2813803	chr6:83644743	A/G	cg23278060	chr6:83777448	DOPEY1	0.61	4.49	0.42	2.02e-5	Crohn's disease;
THYM	cis	rs28595532	0.920	rs28797314	chr4:119783044	A/G	cg21605333	chr4:119757512	SEC24D	1.56	6.29	0.54	9.68e-9	Cannabis dependence symptom count;
THYM	cis	rs6906287	0.647	rs11153734	chr6:118726220	A/G	cg21191810	chr6:118973309	C6orf204	0.63	6.47	0.55	4.3e-9	Electrocardiographic conduction measures;
THYM	cis	rs11153147	0.730	rs2798646	chr6:109310596	C/A	cg17117243	chr6:109341365	SESN1	0.89	5.36	0.48	5.78e-7	Mean corpuscular volume;
THYM	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.76	-0.44	6.98e-6	Crohn's disease;
THYM	cis	rs17021463	0.966	rs10856908	chr4:95222755	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.51	-4.45	-0.42	2.32e-5	Testicular germ cell tumor;
THYM	cis	rs860554	0.705	rs832166	chr1:201255692	C/T	cg01022117	chr1:201258280	PKP1	0.66	4.9	0.45	3.93e-6	Panic disorder;
THYM	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg27068330	chr11:65405492	SIPA1	-1.03	-10.31	-0.73	3.55e-17	Acne (severe);
THYM	cis	rs7851660	0.809	rs10984235	chr9:100660896	C/T	cg13688889	chr9:100608707	NA	-0.79	-5.71	-0.51	1.28e-7	Strep throat;
THYM	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg04731861	chr2:219085781	ARPC2	0.55	5.12	0.46	1.62e-6	Colorectal cancer;
THYM	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-4.94	-0.45	3.37e-6	Lymphocyte counts;
THYM	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg01616529	chr11:638424	DRD4	-0.74	-5.68	-0.5	1.45e-7	Systemic lupus erythematosus;
THYM	cis	rs12122100	0.774	rs12723253	chr1:146523303	C/T	cg02487331	chr1:146550467	NA	-0.74	-4.53	-0.42	1.75e-5	HIV-1 control;
THYM	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.73	5.57	0.5	2.36e-7	Tonsillectomy;
THYM	cis	rs9527	0.568	rs1926036	chr10:104883812	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs10463554	0.727	rs34768	chr5:102491502	A/G	cg23492399	chr5:102201601	PAM	-0.7	-5.23	-0.47	9.9e-7	Parkinson's disease;
THYM	cis	rs7772486	0.754	rs9373475	chr6:146126419	C/T	cg23711669	chr6:146136114	FBXO30	0.98	10.47	0.73	1.68e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg07460842	chr6:66804631	NA	1.14	12.96	0.8	1.02e-22	Exhaled nitric oxide output;
THYM	cis	rs7107174	0.901	rs10899494	chr11:78122208	G/T	cg02023728	chr11:77925099	USP35	0.62	5.82	0.51	7.88e-8	Testicular germ cell tumor;
THYM	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg04287289	chr16:89883240	FANCA	0.5	4.46	0.42	2.2e-5	Vitiligo;
THYM	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg11871910	chr12:69753446	YEATS4	0.66	4.84	0.44	4.97e-6	Response to diuretic therapy;
THYM	trans	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg15655154	chr3:113604241	GRAMD1C	1.0	8.74	0.67	7.94e-14	Diastolic blood pressure;
THYM	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg01616529	chr11:638424	DRD4	-0.78	-6.62	-0.56	2.16e-9	Systemic lupus erythematosus;
THYM	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg18200150	chr17:30822561	MYO1D	-0.73	-5.89	-0.52	5.92e-8	Schizophrenia;
THYM	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.79	0.51	9.18e-8	Rheumatoid arthritis;
THYM	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg13319975	chr6:146136371	FBXO30	-0.72	-6.1	-0.53	2.24e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-5.4	-0.48	4.89e-7	Chronic sinus infection;
THYM	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	9.42	0.69	2.88e-15	Chronic sinus infection;
THYM	cis	rs17016200	0.513	rs73107704	chr3:78351063	T/C	cg24512093	chr3:78698151	ROBO1	0.95	5.0	0.46	2.64e-6	Facial emotion recognition;
THYM	cis	rs7107174	0.901	rs990706	chr11:78135704	C/T	cg19901956	chr11:77921274	USP35	-0.73	-5.57	-0.5	2.34e-7	Testicular germ cell tumor;
THYM	cis	rs4243830	0.850	rs12744992	chr1:6601290	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.11	-7.56	-0.61	2.57e-11	Body mass index;
THYM	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg14664628	chr15:75095509	CSK	-0.99	-8.15	-0.64	1.48e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg18305652	chr10:134549665	INPP5A	0.75	5.92	0.52	5e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg06521331	chr12:34319734	NA	-0.96	-8.88	-0.67	4.06e-14	Morning vs. evening chronotype;
THYM	cis	rs4731207	0.596	rs9332427	chr7:124576958	C/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs16912285	0.585	rs11027807	chr11:24346556	G/T	ch.11.24196551F	chr11:24239977	NA	0.87	5.88	0.52	5.96e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs11098499	0.821	rs56155624	chr4:120291026	C/G	cg24375607	chr4:120327624	NA	0.65	5.55	0.5	2.54e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg27494647	chr7:150038898	RARRES2	0.42	4.87	0.45	4.43e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg20203395	chr5:56204925	C5orf35	-0.65	-4.47	-0.42	2.15e-5	Initial pursuit acceleration;
THYM	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg10802521	chr3:52805072	NEK4	-0.74	-6.42	-0.55	5.45e-9	Bipolar disorder;
THYM	cis	rs11190604	1.000	rs11190601	chr10:102296730	A/G	cg07570687	chr10:102243282	WNT8B	0.76	6.63	0.56	2.06e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg02734326	chr4:10020555	SLC2A9	0.76	7.25	0.6	1.1e-10	Bone mineral density;
THYM	cis	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg24672777	chr11:48374446	OR4C45	0.73	4.6	0.43	1.28e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg19913688	chr11:428466	ANO9	-0.88	-4.58	-0.42	1.43e-5	Body mass index;
THYM	cis	rs6669072	0.669	rs712031	chr1:91243395	A/G	cg08895590	chr1:91227319	NA	-0.63	-7.66	-0.62	1.54e-11	Cognitive function;
THYM	cis	rs6032067	0.636	rs17335251	chr20:43902946	T/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.61	-6.01	-0.52	3.38e-8	Blood protein levels;
THYM	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg21361702	chr7:150065534	REPIN1	-0.68	-5.75	-0.51	1.08e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg16482183	chr6:26056742	HIST1H1C	0.82	5.32	0.48	6.78e-7	Iron status biomarkers;
THYM	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg23791538	chr6:167370224	RNASET2	0.81	6.62	0.56	2.16e-9	Crohn's disease;
THYM	cis	rs1669338	0.588	rs3864050	chr3:3186769	T/C	cg16797762	chr3:3221439	CRBN	-0.97	-5.43	-0.49	4.36e-7	White matter integrity;
THYM	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg11461670	chr8:22454935	PDLIM2	-0.36	-6.52	-0.56	3.3e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	5.7	0.5	1.35e-7	Platelet count;
THYM	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg14784868	chr12:69753453	YEATS4	1.13	12.35	0.79	1.8e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2456568	0.867	rs7114457	chr11:93657817	C/T	cg17595323	chr11:93583763	C11orf90	-0.58	-5.74	-0.51	1.11e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg19875535	chr5:140030758	IK	0.58	4.46	0.42	2.21e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7084402	0.967	rs1649043	chr10:60328209	C/T	cg09696939	chr10:60272079	BICC1	-0.46	-5.54	-0.49	2.74e-7	Refractive error;
THYM	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg00383909	chr3:49044727	WDR6	1.17	6.3	0.54	9.05e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs9807989	0.507	rs3213732	chr2:102998279	A/G	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs10911232	0.507	rs3934579	chr1:183027432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.61	5.22	0.47	1.03e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs875971	1.000	rs1167612	chr7:65567976	C/A	cg18876405	chr7:65276391	NA	-0.65	-5.53	-0.49	2.85e-7	Aortic root size;
THYM	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg02478829	chr6:26598070	ABT1	-0.33	-4.49	-0.42	1.97e-5	Intelligence (multi-trait analysis);
THYM	cis	rs11997175	0.624	rs4621768	chr8:33677452	T/C	ch.8.33884649F	chr8:33765107	NA	0.66	5.0	0.46	2.57e-6	Body mass index;
THYM	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14159672	chr1:205819179	PM20D1	-0.62	-4.87	-0.45	4.51e-6	Parkinson's disease;
THYM	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg02953382	chr22:24373134	LOC391322	-0.82	-8.95	-0.68	2.96e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg01699819	chr7:1052092	C7orf50	-0.6	-5.05	-0.46	2.13e-6	Bronchopulmonary dysplasia;
THYM	cis	rs2777491	1.000	rs2730057	chr15:41736275	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.13	-12.79	-0.8	2.28e-22	Ulcerative colitis;
THYM	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg12379764	chr21:47803548	PCNT	-0.77	-4.92	-0.45	3.59e-6	Testicular germ cell tumor;
THYM	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg01570182	chr17:44337453	NA	0.91	9.94	0.71	2.22e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7772486	0.774	rs6930181	chr6:146180974	A/T	cg23711669	chr6:146136114	FBXO30	-0.84	-8.1	-0.64	1.82e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs5769765	0.837	rs7284417	chr22:50314346	A/G	cg26441486	chr22:50317300	CRELD2	0.4	6.46	0.55	4.54e-9	Schizophrenia;
THYM	cis	rs7119	0.717	rs12917175	chr15:77818193	A/G	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs4713118	0.869	rs2056925	chr6:27690905	A/G	cg12963246	chr6:28129442	ZNF389	0.61	4.54	0.42	1.62e-5	Parkinson's disease;
THYM	cis	rs983545	0.745	rs9883633	chr3:16971248	T/G	cg24159436	chr3:16974681	PLCL2	0.34	4.98	0.45	2.87e-6	Blood protein levels;
THYM	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs854765	0.583	rs11650890	chr17:17790882	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.08	-0.53	2.48e-8	Total body bone mineral density;
THYM	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs7614311	0.681	rs12631045	chr3:63856085	T/C	cg22134162	chr3:63841271	THOC7	-0.56	-7.1	-0.59	2.22e-10	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg27398817	chr8:82754497	SNX16	0.84	6.69	0.57	1.51e-9	Diastolic blood pressure;
THYM	cis	rs8133932	0.861	rs74459266	chr21:47236206	C/T	cg20357416	chr21:47294739	PCBP3	0.85	4.93	0.45	3.46e-6	Schizophrenia;
THYM	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg15691649	chr6:25882328	NA	0.67	5.14	0.47	1.47e-6	Blood metabolite levels;
THYM	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg22166914	chr1:53195759	ZYG11B	-0.77	-8.25	-0.65	8.81e-13	Monocyte count;
THYM	cis	rs2639990	1.000	rs2639990	chr18:72915551	T/C	cg11568697	chr18:72916393	ZADH2	1.11	4.89	0.45	4.04e-6	Vascular endothelial growth factor levels;
THYM	cis	rs7940866	0.774	rs2162059	chr11:130831224	C/T	cg05962950	chr11:130786565	SNX19	0.74	5.89	0.52	5.83e-8	Schizophrenia;
THYM	cis	rs6988636	1.000	rs11988157	chr8:124194740	A/G	cg22384356	chr8:124195192	FAM83A	0.82	5.02	0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg21784768	chr11:537496	LRRC56	-1.3	-6.07	-0.53	2.55e-8	Body mass index;
THYM	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.71	-0.57	1.43e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg03474202	chr17:45855739	NA	-0.74	-6.48	-0.55	4.1e-9	IgG glycosylation;
THYM	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	7.84	0.63	6.55e-12	Lymphocyte percentage of white cells;
THYM	trans	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg19862616	chr7:65841803	NCRNA00174	1.05	11.42	0.76	1.59e-19	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs34375054	0.660	rs58624919	chr12:125596458	G/A	cg25124228	chr12:125621409	AACS	-0.76	-5.92	-0.52	5.08e-8	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs9796	0.870	rs4244584	chr15:41259523	A/G	cg21153102	chr15:41252147	NA	-0.69	-6.42	-0.55	5.39e-9	Menopause (age at onset);
THYM	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg15744005	chr10:104629667	AS3MT	-0.78	-7.33	-0.6	7.48e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs12257961	0.675	rs4748157	chr10:15346564	A/G	cg10616319	chr10:15468812	NA	0.6	4.83	0.44	5.12e-6	Selective IgA deficiency;
THYM	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg00666640	chr1:248458726	OR2T12	0.57	4.75	0.44	7.19e-6	Common traits (Other);
THYM	cis	rs4363385	0.693	rs689008	chr1:153047100	G/C	cg13444842	chr1:152974279	SPRR3	-0.61	-5.01	-0.46	2.46e-6	Inflammatory skin disease;
THYM	cis	rs7208859	0.778	rs6505219	chr17:29265621	A/C	cg17105886	chr17:28927953	LRRC37B2	0.79	4.81	0.44	5.66e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg05043794	chr9:111880884	C9orf5	-0.44	-6.39	-0.55	6.03e-9	Menarche (age at onset);
THYM	cis	rs6561151	0.681	rs10507521	chr13:44441834	C/G	cg14210620	chr13:44453864	C13orf31;CCDC122	-0.85	-4.64	-0.43	1.1e-5	Crohn's disease;
THYM	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg13944838	chr5:179740914	GFPT2	-0.82	-6.38	-0.55	6.42e-9	Height;
THYM	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.67	0.5	1.56e-7	Obesity-related traits;
THYM	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg26031613	chr14:104095156	KLC1	1.06	9.5	0.7	1.94e-15	Body mass index;
THYM	cis	rs7020830	0.931	rs6476613	chr9:37084340	A/G	cg14294708	chr9:37120828	ZCCHC7	1.24	15.16	0.84	4.26e-27	Schizophrenia;
THYM	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.82	7.53	0.61	2.9100000000000002e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs35264875	0.898	rs72928701	chr11:68861564	C/T	cg23845249	chr11:68861649	NA	0.55	6.45	0.55	4.67e-9	Blond vs. brown hair color;
THYM	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg18305652	chr10:134549665	INPP5A	0.91	8.78	0.67	6.7e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg27129171	chr3:47204927	SETD2	-0.7	-6.28	-0.54	1.03e-8	Colorectal cancer;
THYM	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg06808227	chr14:105710500	BRF1	-1.02	-8.76	-0.67	7.51e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11644478	chr21:40555479	PSMG1	-0.54	-4.53	-0.42	1.72e-5	Menarche (age at onset);
THYM	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	9.35	0.69	4.06e-15	Body mass index (adult);
THYM	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg21984481	chr17:79567631	NPLOC4	-0.58	-6.73	-0.57	1.29e-9	Eye color traits;
THYM	cis	rs3126085	0.935	rs6675889	chr1:152213066	G/A	cg10321714	chr1:152280068	FLG	0.63	4.53	0.42	1.68e-5	Atopic dermatitis;
THYM	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg26597838	chr10:835615	NA	-1.58	-12.04	-0.78	8.01e-21	Eosinophil percentage of granulocytes;
THYM	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg16586182	chr3:47516702	SCAP	-0.61	-5.17	-0.47	1.32e-6	Colorectal cancer;
THYM	cis	rs7614311	0.731	rs6445387	chr3:63962678	C/G	cg22134162	chr3:63841271	THOC7	-0.47	-5.42	-0.49	4.54e-7	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs733592	0.507	rs7299704	chr12:48444488	A/G	cg21466736	chr12:48725269	NA	-0.46	-4.96	-0.45	3.09e-6	Plateletcrit;
THYM	cis	rs10089	1.000	rs2898096	chr5:127433214	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.02	7.11	0.59	2.11e-10	Ileal carcinoids;
THYM	cis	rs9790314	1.000	rs1478565	chr3:161027464	C/T	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg08508325	chr11:3079039	CARS	-0.54	-6.67	-0.56	1.69e-9	Longevity;
THYM	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg06481639	chr22:41940642	POLR3H	0.72	4.68	0.43	9.65e-6	Vitiligo;
THYM	cis	rs67460515	0.859	rs7610800	chr3:161002582	C/T	cg03342759	chr3:160939853	NMD3	-0.93	-7.98	-0.63	3.34e-12	Parkinson's disease;
THYM	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg19508488	chr2:152266495	RIF1	0.82	6.51	0.56	3.53e-9	Lung cancer;
THYM	cis	rs921665	0.680	rs76494865	chr2:3191204	G/A	cg16434511	chr2:3151078	NA	-0.87	-5.46	-0.49	3.8e-7	World class endurance athleticism;
THYM	cis	rs4733781	0.509	rs6470811	chr8:131338933	G/T	cg16277922	chr8:131349729	ASAP1	-0.77	-7.22	-0.59	1.3100000000000001e-10	Tuberculosis;
THYM	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg11764359	chr7:65958608	NA	-0.67	-4.8	-0.44	5.81e-6	Aortic root size;
THYM	cis	rs2219968	0.525	rs873005	chr8:78894329	T/A	cg00738934	chr8:78996279	NA	0.61	4.95	0.45	3.21e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7426056	0.530	rs2140148	chr2:204572140	A/C	cg10240150	chr2:204570067	CD28	-0.62	-4.73	-0.44	7.67e-6	Primary sclerosing cholangitis;
THYM	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.42	0.49	4.5e-7	Height;
THYM	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg01699819	chr7:1052092	C7orf50	-0.57	-4.82	-0.44	5.34e-6	Bronchopulmonary dysplasia;
THYM	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg26441486	chr22:50317300	CRELD2	0.45	7.74	0.62	1.05e-11	Schizophrenia;
THYM	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs611744	0.647	rs1457211	chr8:109261318	C/T	cg21045802	chr8:109455806	TTC35	-0.65	-5.74	-0.51	1.15e-7	Dupuytren's disease;
THYM	cis	rs4654899	1.000	rs6703227	chr1:21374810	A/G	cg01072550	chr1:21505969	NA	-0.71	-6.29	-0.54	9.47e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs6591182	0.967	rs11227229	chr11:65354150	C/T	cg27068330	chr11:65405492	SIPA1	-0.81	-7.44	-0.61	4.48e-11	Non-alcoholic fatty liver disease histology (lobular);
THYM	cis	rs6732160	0.691	rs1960233	chr2:73421378	A/G	cg24220031	chr2:73402428	NA	-0.78	-9.27	-0.69	6.15e-15	Intelligence (multi-trait analysis);
THYM	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2658782	0.654	rs2248531	chr11:93255363	G/T	cg15737290	chr11:93063684	CCDC67	0.87	6.61	0.56	2.24e-9	Pulmonary function decline;
THYM	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg00071950	chr4:10020882	SLC2A9	-0.53	-4.67	-0.43	9.99e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg07075026	chr17:47091521	IGF2BP1	-0.61	-6.52	-0.56	3.42e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs4849845	0.886	rs10180682	chr2:121012033	A/G	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs757081	0.667	rs7108067	chr11:17200220	G/A	cg07093617	chr11:18158918	MRGPRX3	-0.49	-4.61	-0.43	1.23e-5	Systolic blood pressure;
THYM	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.45	-0.49	4.05e-7	Mean corpuscular volume;
THYM	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg01324343	chr3:183735012	ABCC5	0.89	13.33	0.81	1.82e-23	Anterior chamber depth;
THYM	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.7	-5.63	-0.5	1.83e-7	Prostate cancer;
THYM	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg19774624	chr17:42201019	HDAC5	-0.76	-7.12	-0.59	2.05e-10	Total body bone mineral density;
THYM	cis	rs6598955	0.543	rs4585968	chr1:26535146	G/A	cg04990556	chr1:26633338	UBXN11	0.96	6.06	0.53	2.7e-8	Obesity-related traits;
THYM	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg11335335	chr11:637885	DRD4	-0.64	-4.98	-0.45	2.85e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs870825	0.655	rs6552812	chr4:185653568	C/T	cg04058563	chr4:185651563	MLF1IP	-0.99	-7.56	-0.61	2.56e-11	Blood protein levels;
THYM	cis	rs7119	0.604	rs1055691	chr15:77864625	G/C	cg10437265	chr15:77819839	NA	-0.66	-6.82	-0.57	8.23e-10	Type 2 diabetes;
THYM	cis	rs736801	1.000	rs736801	chr5:131833599	C/T	cg00255919	chr5:131827918	IRF1	-0.44	-4.8	-0.44	6e-6	Breast cancer;Mosquito bite size;
THYM	cis	rs1348850	0.574	rs11691740	chr2:178445161	A/G	cg27490568	chr2:178487706	NA	-0.56	-4.89	-0.45	4.18e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4242434	0.854	rs3735893	chr8:22452704	A/G	cg01710189	chr8:22454888	PDLIM2	-0.57	-5.85	-0.51	6.82e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs17253792	0.822	rs10083431	chr14:56068348	G/A	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-5.41	-0.49	4.61e-7	Vitiligo;
THYM	cis	rs16866061	1.000	rs3768886	chr2:225450161	G/C	cg22455342	chr2:225449267	CUL3	0.67	4.86	0.45	4.7e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg12863693	chr15:85201151	NMB	0.55	4.76	0.44	7.02e-6	Schizophrenia;
THYM	trans	rs9929218	0.529	rs17715450	chr16:68729785	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.97	11.29	0.76	3e-19	Colorectal cancer;
THYM	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12956009	0.583	rs919979	chr18:44902739	C/T	cg19077165	chr18:44547161	KATNAL2	-0.49	-4.7	-0.43	8.81e-6	Educational attainment (years of education);
THYM	cis	rs7940866	0.801	rs10894296	chr11:130840433	T/G	cg12179176	chr11:130786555	SNX19	0.62	4.8	0.44	5.99e-6	Schizophrenia;
THYM	cis	rs17102423	0.723	rs8181938	chr14:65555712	A/G	cg11161011	chr14:65562177	MAX	-0.88	-7.49	-0.61	3.58e-11	Obesity-related traits;
THYM	cis	rs9788721	0.902	rs7180002	chr15:78873993	A/T	cg18825076	chr15:78729989	IREB2	-0.53	-4.74	-0.44	7.44e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs9326248	0.559	rs609177	chr11:116770517	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.67	5.31	0.48	7.31e-7	Blood protein levels;
THYM	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg26850624	chr5:429559	AHRR	0.53	4.5	0.42	1.93e-5	Cystic fibrosis severity;
THYM	cis	rs7961581	0.748	rs1798078	chr12:71595123	A/T	cg18078658	chr12:72374129	TPH2	0.66	4.62	0.43	1.19e-5	Type 2 diabetes;
THYM	cis	rs17739794	0.573	rs1105954	chr8:817847	C/T	cg07178994	chr8:816998	NA	0.53	5.23	0.47	9.95e-7	Clozapine-induced cytotoxicity;
THYM	trans	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg25214090	chr10:38739885	LOC399744	0.86	7.35	0.6	6.87e-11	Corneal astigmatism;
THYM	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg09085632	chr11:111637200	PPP2R1B	1.13	11.22	0.76	4.14e-19	Primary sclerosing cholangitis;
THYM	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg17775962	chr7:1200435	ZFAND2A	0.49	5.55	0.49	2.56e-7	Longevity;Endometriosis;
THYM	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg20476274	chr7:133979776	SLC35B4	0.67	4.62	0.43	1.22e-5	Mean platelet volume;
THYM	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg18758796	chr5:131593413	PDLIM4	0.5	4.64	0.43	1.1e-5	Breast cancer;
THYM	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg08901578	chr4:187885870	NA	-0.68	-6.86	-0.58	6.97e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14240646	chr10:27532245	ACBD5	0.86	5.03	0.46	2.28e-6	Breast cancer;
THYM	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg24818145	chr4:99064322	C4orf37	0.9	7.36	0.6	6.5e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9462846	0.652	rs115953673	chr6:42906243	T/A	cg21280719	chr6:42927975	GNMT	-0.42	-4.54	-0.42	1.65e-5	Blood protein levels;
THYM	cis	rs10896135	0.526	rs1987169	chr11:66448044	A/G	cg15964523	chr11:66469143	SPTBN2	0.82	6.51	0.56	3.54e-9	Bipolar disorder;
THYM	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.2e-16	Bone mineral density;
THYM	cis	rs9500256	0.903	rs726783	chr6:58332861	A/C	cg17976157	chr6:58263193	GUSBL2	-0.59	-4.45	-0.42	2.36e-5	Eosinophilic esophagitis (pediatric);
THYM	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs2637266	0.628	rs846632	chr10:78535759	C/A	cg18941641	chr10:78392320	NA	0.68	5.33	0.48	6.68e-7	Pulmonary function;
THYM	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg12756686	chr19:29218302	NA	0.93	7.58	0.61	2.25e-11	Methadone dose in opioid dependence;
THYM	cis	rs4803468	0.905	rs284662	chr19:41932275	T/C	cg09537434	chr19:41945824	ATP5SL	-0.98	-8.33	-0.65	5.91e-13	Height;
THYM	cis	rs6987853	0.787	rs2923442	chr8:42435493	T/C	cg09913449	chr8:42400586	C8orf40	1.07	12.64	0.79	4.53e-22	Mean corpuscular hemoglobin concentration;
THYM	cis	rs10779751	0.770	rs4845853	chr1:11243470	A/G	cg08854313	chr1:11322531	MTOR	0.83	7.47	0.61	3.81e-11	Body mass index;
THYM	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg27211696	chr2:191398769	TMEM194B	0.62	4.72	0.44	8.15e-6	Diastolic blood pressure;
THYM	cis	rs2463822	0.858	rs2513077	chr11:62105925	A/G	cg06239285	chr11:62104954	ASRGL1	-1.44	-7.7	-0.62	1.3e-11	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg21773646	chr17:80085082	CCDC57	-0.35	-4.89	-0.45	4.17e-6	Life satisfaction;
THYM	cis	rs539096	0.830	rs2494995	chr1:44022303	A/C	cg00143623	chr1:44495758	SLC6A9	-0.63	-4.79	-0.44	6.23e-6	Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg04315214	chr1:2043799	PRKCZ	0.68	5.67	0.5	1.54e-7	Height;
THYM	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs9430161	0.579	rs7542354	chr1:11040385	G/A	cg27631724	chr1:11040367	C1orf127	0.68	6.42	0.55	5.25e-9	Ewing sarcoma;
THYM	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg08498830	chr11:832797	CD151	-0.62	-4.51	-0.42	1.82e-5	Mean platelet volume;
THYM	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.79	7.24	0.6	1.17e-10	Prudent dietary pattern;
THYM	cis	rs4455778	0.580	rs10242641	chr7:49085748	G/A	cg26309511	chr7:48887640	NA	0.68	5.94	0.52	4.63e-8	Lung cancer in never smokers;
THYM	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg02696790	chr15:75250997	RPP25	0.5	4.47	0.42	2.16e-5	Breast cancer;
THYM	cis	rs112591243	0.570	rs117906758	chr21:48037968	T/C	cg26904215	chr21:47823096	PCNT	-0.99	-4.59	-0.43	1.36e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.56	0.81	6.23e-24	Height;
THYM	cis	rs6748734	0.625	rs6741220	chr2:241822432	C/T	cg02820040	chr2:241836501	C2orf54	0.24	4.7	0.43	8.65e-6	Urinary metabolites;
THYM	cis	rs3791406	0.929	rs3828202	chr2:240030122	A/G	cg27074582	chr2:240114406	HDAC4	-0.44	-4.48	-0.42	2.05e-5	Skin aging (microtopography measurement);
THYM	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg15445000	chr17:37608096	MED1	-0.44	-5.22	-0.47	1.07e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg12963246	chr6:28129442	ZNF389	0.47	4.58	0.43	1.41e-5	Parkinson's disease;
THYM	trans	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg25517755	chr10:38738941	LOC399744	-0.8	-7.87	-0.63	5.58e-12	Corneal astigmatism;
THYM	cis	rs7193541	0.684	rs9931225	chr16:74699293	T/C	cg01733217	chr16:74700730	RFWD3	1.04	12.99	0.8	8.92e-23	Multiple myeloma;
THYM	cis	rs733175	0.855	rs10018666	chr4:10004805	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	4.6	0.43	1.31e-5	Psychosis and Alzheimer's disease;
THYM	cis	rs6754311	0.689	rs191079	chr2:136633771	T/C	cg04750100	chr2:136595281	LCT	0.56	6.13	0.53	1.97e-8	Mosquito bite size;
THYM	cis	rs7927592	0.513	rs901823	chr11:68205578	T/C	cg16797656	chr11:68205561	LRP5	0.57	6.45	0.55	4.76e-9	Total body bone mineral density;
THYM	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg09307838	chr4:120376055	NA	0.73	5.51	0.49	3.11e-7	Corneal astigmatism;
THYM	cis	rs7688540	0.771	rs17164747	chr4:260587	G/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.68	4.82	0.44	5.43e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs8114671	0.967	rs2069948	chr20:33762489	C/T	cg08999081	chr20:33150536	PIGU	0.53	4.77	0.44	6.63e-6	Height;
THYM	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	6.52	0.56	3.31e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7760949	0.889	rs9475806	chr6:13934527	A/G	cg11053062	chr6:13924544	RNF182	-0.48	-4.51	-0.42	1.85e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6424115	1.000	rs58035855	chr1:24165248	G/C	cg15997130	chr1:24165203	NA	-0.76	-6.32	-0.54	8.49e-9	Immature fraction of reticulocytes;
THYM	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg23131131	chr22:24373011	LOC391322	-0.83	-7.77	-0.62	9.31e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg23583168	chr7:148888333	NA	1.1	16.73	0.86	4.47e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs1267303	0.642	rs116078607	chr1:46999238	G/A	cg16387850	chr1:46982889	NA	-0.45	-5.49	-0.49	3.34e-7	Monobrow;
THYM	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg03733263	chr8:22462867	KIAA1967	1.12	11.76	0.77	3.15e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs941408	1.000	rs1736177	chr19:2791624	C/T	cg06609049	chr19:2785107	THOP1	0.77	6.23	0.54	1.25e-8	Total cholesterol levels;
THYM	cis	rs7705502	0.890	rs67909753	chr5:173306058	G/A	cg18693985	chr5:173351052	CPEB4	-0.79	-5.61	-0.5	1.97e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs886126	0.901	rs10744770	chr12:111662578	G/A	cg10833066	chr12:111807467	FAM109A	0.43	5.32	0.48	6.8e-7	Coronary heart disease;
THYM	cis	rs9902453	0.967	rs9900911	chr17:28330280	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs10504073	0.669	rs818559	chr8:50035806	C/T	cg00325661	chr8:49890786	NA	0.78	7.03	0.59	3.11e-10	Blood metabolite ratios;
THYM	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg14895029	chr7:2775587	GNA12	-0.69	-5.08	-0.46	1.86e-6	Height;
THYM	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg23803603	chr1:2058230	PRKCZ	0.63	5.37	0.48	5.58e-7	Height;
THYM	cis	rs6430585	0.528	rs309133	chr2:136751842	A/C	cg23851026	chr2:136556271	LCT	0.67	6.51	0.56	3.54e-9	Corneal structure;
THYM	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg17810781	chr1:201082982	CACNA1S	0.72	7.72	0.62	1.19e-11	Permanent tooth development;
THYM	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg03474202	chr17:45855739	NA	-0.76	-6.7	-0.57	1.45e-9	IgG glycosylation;
THYM	cis	rs4499344	0.623	rs11670818	chr19:33099854	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.79	5.54	0.49	2.75e-7	Mean platelet volume;
THYM	cis	rs2625529	0.667	rs16956381	chr15:72193237	A/C	cg16672083	chr15:72433130	SENP8	-0.52	-4.66	-0.43	1.01e-5	Red blood cell count;
THYM	cis	rs12291225	0.585	rs12270374	chr11:14375079	T/C	cg19336497	chr11:14380999	RRAS2	-0.91	-13.68	-0.81	3.58e-24	Sense of smell;
THYM	cis	rs11096990	0.593	rs7685619	chr4:39213399	T/G	cg24403649	chr4:39172243	NA	0.6	5.16	0.47	1.35e-6	Cognitive function;
THYM	cis	rs10992471	0.603	rs968040	chr9:95279985	C/A	cg14631576	chr9:95140430	CENPP	-0.96	-9.19	-0.69	9.02e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg07747251	chr5:1868357	NA	0.68	5.87	0.52	6.45e-8	Cardiovascular disease risk factors;
THYM	cis	rs1641537	0.568	rs1641515	chr17:7551950	C/A	cg27413385	chr17:7515425	FXR2	-0.36	-5.29	-0.48	7.83e-7	Sex hormone-binding globulin levels;
THYM	trans	rs62103177	0.513	rs9945153	chr18:77598450	C/T	cg05926928	chr17:57297772	GDPD1	1.19	9.0	0.68	2.28e-14	Opioid sensitivity;
THYM	cis	rs2040771	0.804	rs1091013	chr22:19248587	C/T	cg02655711	chr22:19163373	SLC25A1	0.59	6.26	0.54	1.13e-8	Metabolite levels (small molecules and protein measures);
THYM	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs87938	0.830	rs6762550	chr3:41161576	G/A	cg02247160	chr3:41243829	CTNNB1	-0.34	-4.56	-0.42	1.54e-5	Bone mineral density (hip);
THYM	cis	rs12765878	0.603	rs10786773	chr10:105644275	A/T	cg04688330	chr10:105451802	SH3PXD2A	0.39	4.77	0.44	6.57e-6	Coronary artery disease;
THYM	cis	rs9388451	0.531	rs9321057	chr6:126156943	G/A	cg05901451	chr6:126070800	HEY2	-0.6	-4.48	-0.42	2.1e-5	Brugada syndrome;
THYM	cis	rs6541297	1.000	rs6658942	chr1:230287517	A/C	cg05784532	chr1:230284198	GALNT2	0.72	4.53	0.42	1.69e-5	Coronary artery disease;
THYM	cis	rs9826463	0.582	rs73238159	chr3:142078759	C/T	cg20824294	chr3:142316082	PLS1	0.76	5.16	0.47	1.36e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs6987853	0.933	rs2974353	chr8:42409165	A/C	cg09913449	chr8:42400586	C8orf40	0.95	8.91	0.67	3.58e-14	Mean corpuscular hemoglobin concentration;
THYM	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs8078723	1.000	rs8078723	chr17:38166879	A/G	cg17467752	chr17:38218738	THRA	0.86	7.09	0.59	2.4e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs3820716	0.507	rs12691779	chr2:148914963	T/C	cg23727674	chr2:148602993	ACVR2A	0.63	4.61	0.43	1.24e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg08125733	chr17:73851984	WBP2	1.19	8.97	0.68	2.69e-14	Psoriasis;
THYM	cis	rs4638749	0.501	rs750523	chr2:108746221	T/C	cg25838818	chr2:108905173	SULT1C2	-0.52	-4.89	-0.45	4.13e-6	Blood pressure;
THYM	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg09307838	chr4:120376055	NA	0.62	4.73	0.44	7.88e-6	Corneal astigmatism;
THYM	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg12560992	chr17:57184187	TRIM37	0.66	4.49	0.42	2.01e-5	Cognitive test performance;
THYM	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg09335314	chr2:216258430	FN1	-0.91	-6.85	-0.57	7.2e-10	Subcortical brain region volumes;
THYM	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg17554472	chr22:41940697	POLR3H	-0.59	-4.47	-0.42	2.12e-5	Vitiligo;
THYM	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg24209194	chr3:40518798	ZNF619	0.6	4.87	0.45	4.51e-6	Renal cell carcinoma;
THYM	cis	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg07460842	chr6:66804631	NA	-0.95	-6.81	-0.57	8.9e-10	Exhaled nitric oxide output;
THYM	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg07936489	chr17:37558343	FBXL20	0.83	5.69	0.5	1.41e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg19318889	chr4:1322082	MAEA	-0.52	-4.53	-0.42	1.7e-5	Obesity-related traits;
THYM	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8114671	0.967	rs6060285	chr20:33770487	G/T	cg08999081	chr20:33150536	PIGU	0.52	4.67	0.43	9.71e-6	Height;
THYM	cis	rs2333194	0.846	rs6574118	chr14:73811992	A/G	cg09844916	chr14:74004424	HEATR4;ACOT1	0.58	4.61	0.43	1.27e-5	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs9486719	0.947	rs11755945	chr6:96908038	G/C	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs4455778	0.658	rs111468777	chr7:49117642	A/G	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs2777491	0.957	rs1757454	chr15:41777934	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.11	-12.62	-0.79	5.02e-22	Ulcerative colitis;
THYM	cis	rs4499344	0.730	rs406470	chr19:33104472	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.61	0.62	2.02e-11	Mean platelet volume;
THYM	trans	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs17443541	0.507	rs4675699	chr2:200451389	A/C	cg01795955	chr2:200468626	NA	-0.73	-4.86	-0.45	4.61e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg10018233	chr7:150070692	REPIN1	0.39	5.63	0.5	1.83e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7178572	0.568	rs11636554	chr15:77608747	C/T	cg22256960	chr15:77711686	NA	-1.05	-8.69	-0.67	1.02e-13	Type 2 diabetes;
THYM	cis	rs6570726	0.738	rs6917199	chr6:145918320	G/A	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.88	7.0	0.58	3.55e-10	Intelligence (multi-trait analysis);
THYM	cis	rs240764	0.658	rs13196803	chr6:101188052	A/T	cg21058520	chr6:100914733	NA	0.6	5.32	0.48	6.98e-7	Neuroticism;
THYM	cis	rs2976388	0.566	rs2585146	chr8:143798641	A/C	cg06565975	chr8:143823917	SLURP1	0.7	8.27	0.65	8.24e-13	Urinary tract infection frequency;
THYM	cis	rs9467160	0.651	rs9393558	chr6:24454196	G/T	cg00346970	chr6:24499591	ALDH5A1	0.31	4.56	0.42	1.53e-5	Liver enzyme levels;
THYM	cis	rs2367725	1	rs2367725	chr1:44215828	C/T	cg09903430	chr1:44172605	ST3GAL3	0.53	4.71	0.44	8.32e-6	Aging (time to event);
THYM	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg02887458	chr19:19495540	GATAD2A	-0.42	-5.08	-0.46	1.87e-6	Bipolar disorder;
THYM	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg09367891	chr1:107599246	PRMT6	-0.67	-4.59	-0.43	1.38e-5	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg14895029	chr7:2775587	GNA12	0.68	5.03	0.46	2.27e-6	Height;
THYM	cis	rs713587	0.563	rs2033655	chr2:25101092	C/T	cg01884057	chr2:25150051	NA	0.66	6.57	0.56	2.7e-9	Body mass index in non-asthmatics;
THYM	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg24209194	chr3:40518798	ZNF619	0.57	4.62	0.43	1.2e-5	Renal cell carcinoma;
THYM	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg00012203	chr2:219082015	ARPC2	0.85	7.65	0.62	1.64e-11	Colorectal cancer;
THYM	cis	rs6733301	0.507	rs4665728	chr2:25055600	T/C	cg01884057	chr2:25150051	NA	-0.91	-4.67	-0.43	9.78e-6	Height;
THYM	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg11764359	chr7:65958608	NA	-0.65	-4.97	-0.45	2.95e-6	Aortic root size;
THYM	cis	rs7394190	0.748	rs3843939	chr10:75578948	T/C	cg07699608	chr10:75541558	CHCHD1	0.96	5.1	0.46	1.77e-6	Incident atrial fibrillation;
THYM	cis	rs4417704	0.551	rs6760411	chr2:241884867	C/T	cg15164180	chr2:241846931	NA	0.36	4.62	0.43	1.22e-5	Joint mobility (Beighton score);
THYM	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs804280	0.662	rs810738	chr8:11611206	A/G	cg12395012	chr8:11607386	GATA4	-0.56	-4.5	-0.42	1.92e-5	Myopia (pathological);
THYM	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg13010199	chr12:38710504	ALG10B	0.73	5.82	0.51	7.99e-8	Heart rate;
THYM	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06850241	chr22:41845214	NA	-0.48	-4.46	-0.42	2.25e-5	Vitiligo;
THYM	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.12e-6	Corneal astigmatism;
THYM	cis	rs1728785	0.901	rs698715	chr16:68560896	A/G	cg02972257	chr16:68554789	NA	-0.76	-4.76	-0.44	6.82e-6	Ulcerative colitis;
THYM	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2195525	0.572	rs3814755	chr11:119217945	G/A	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.44	4.92	0.45	3.64e-6	Urate levels;
THYM	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg03060546	chr3:49711283	APEH	0.74	6.04	0.53	2.97e-8	Resting heart rate;
THYM	cis	rs9393692	0.620	rs6930616	chr6:26331969	A/G	cg00631329	chr6:26305371	NA	-0.45	-4.53	-0.42	1.72e-5	Educational attainment;
THYM	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg27490568	chr2:178487706	NA	0.58	5.27	0.48	8.47e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.92	-10.65	-0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs34599045	0.522	rs71626737	chr1:152901930	A/G	cg07796016	chr1:152779584	LCE1C	-1.14	-4.45	-0.42	2.33e-5	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg16558253	chr16:72132732	DHX38	-0.54	-4.57	-0.42	1.47e-5	Fibrinogen levels;
THYM	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg18758796	chr5:131593413	PDLIM4	-0.53	-4.78	-0.44	6.37e-6	Breast cancer;Mosquito bite size;
THYM	cis	rs4731207	0.596	rs10081336	chr7:124575945	A/G	cg05285228	chr7:124571219	POT1	-0.68	-5.09	-0.46	1.77e-6	Cutaneous malignant melanoma;
THYM	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg00339695	chr16:24857497	SLC5A11	0.47	4.7	0.43	8.71e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6987853	0.527	rs3935700	chr8:42364121	T/C	cg09913449	chr8:42400586	C8orf40	-0.78	-6.71	-0.57	1.39e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6032067	0.777	rs2868237	chr20:43794189	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.64	-5.39	-0.48	5.2e-7	Blood metabolite levels;
THYM	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs1728785	1.000	rs1170434	chr16:68606590	A/G	cg02972257	chr16:68554789	NA	-0.76	-4.9	-0.45	3.93e-6	Ulcerative colitis;
THYM	cis	rs6087990	0.806	rs4911254	chr20:31357579	C/A	cg13636640	chr20:31349939	DNMT3B	0.93	9.86	0.71	3.33e-16	Ulcerative colitis;
THYM	cis	rs8016982	0.651	rs9806027	chr14:81668707	G/C	cg01989461	chr14:81687754	GTF2A1	0.83	7.89	0.63	5.22e-12	Schizophrenia;
THYM	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg22920501	chr2:26401640	FAM59B	-1.05	-9.24	-0.69	6.92e-15	Gut microbiome composition (summer);
THYM	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03264133	chr6:25882463	NA	-0.9	-8.04	-0.64	2.49e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7943358	0.910	rs4275592	chr11:15720053	G/A	cg11966998	chr11:15692519	NA	-0.46	-4.54	-0.42	1.65e-5	Gut microbiome composition (summer);
THYM	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg24675056	chr1:15929824	NA	0.73	5.89	0.52	5.95e-8	Systolic blood pressure;
THYM	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-13.87	-0.82	1.48e-24	Height;
THYM	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg01324343	chr3:183735012	ABCC5	0.64	8.63	0.66	1.42e-13	Anterior chamber depth;
THYM	cis	rs858239	0.539	rs2103281	chr7:23194231	A/G	cg09755872	chr7:23245557	NA	-0.5	-4.71	-0.43	8.55e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.63	-4.48	-0.42	2.05e-5	Gut microbiome composition (summer);
THYM	cis	rs2273669	0.588	rs76328768	chr6:109494951	G/A	cg17117243	chr6:109341365	SESN1	-0.82	-4.8	-0.44	5.98e-6	Prostate cancer;
THYM	cis	rs6570726	0.935	rs387965	chr6:145869366	A/G	cg23711669	chr6:146136114	FBXO30	0.84	8.52	0.66	2.44e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg11327659	chr7:150037044	RARRES2	0.37	4.69	0.43	9.28e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg17279839	chr7:150038598	RARRES2	0.54	5.39	0.48	5.08e-7	Blood protein levels;Circulating chemerin levels;
THYM	trans	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg19862616	chr7:65841803	NCRNA00174	1.08	12.96	0.8	1.02e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7917772	0.582	rs4917976	chr10:104360518	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.77	-6.73	-0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4595586	0.545	rs925828	chr12:39364222	A/G	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs72627123	0.867	rs8019192	chr14:74471267	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg17173187	chr15:85201210	NMB	0.55	5.34	0.48	6.21e-7	Schizophrenia;
THYM	cis	rs4072705	0.617	rs10283445	chr9:127243637	A/G	cg01786973	chr9:127249749	NR5A1	0.4	5.2	0.47	1.12e-6	Menarche (age at onset);
THYM	cis	rs2806561	0.808	rs12128178	chr1:23354814	C/T	cg19743168	chr1:23544995	NA	-0.59	-5.55	-0.49	2.55e-7	Height;
THYM	cis	rs6946131	0.869	rs10229619	chr7:54778870	C/A	cg16668896	chr7:54900801	NA	0.36	4.48	0.42	2.08e-5	Systemic lupus erythematosus;
THYM	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs951366	0.553	rs10900522	chr1:205684067	T/C	cg16031515	chr1:205743344	RAB7L1	0.54	4.6	0.43	1.32e-5	Menarche (age at onset);
THYM	cis	rs7607369	0.719	rs12613545	chr2:219623504	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg15704280	chr7:45808275	SEPT13	-0.84	-8.57	-0.66	1.89e-13	Height;
THYM	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg18825531	chr11:62321136	NA	-0.45	-5.11	-0.46	1.63e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs7250872	0.568	rs749109	chr19:1819736	G/A	cg10370574	chr19:1840461	REXO1	-1.03	-9.28	-0.69	5.77e-15	Bipolar disorder;
THYM	cis	rs4474465	0.850	rs4559714	chr11:78257302	C/T	cg19901956	chr11:77921274	USP35	0.61	4.6	0.43	1.3e-5	Alzheimer's disease (survival time);
THYM	cis	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg10856724	chr12:34555212	NA	-0.75	-6.61	-0.56	2.21e-9	Morning vs. evening chronotype;
THYM	cis	rs11651000	0.857	rs16947078	chr17:45825500	A/G	cg25856473	chr17:45174155	NA	0.65	5.0	0.46	2.57e-6	IgG glycosylation;
THYM	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg16031515	chr1:205743344	RAB7L1	-0.71	-7.47	-0.61	3.85e-11	Menarche (age at onset);
THYM	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg03929089	chr4:120376271	NA	-1.02	-11.88	-0.77	1.75e-20	Height;
THYM	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.49	-0.42	2.04e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs11771526	0.901	rs11767695	chr7:32315960	G/A	cg27532318	chr7:32358331	NA	0.77	5.06	0.46	2.03e-6	Body mass index;
THYM	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs9790314	0.967	rs7623206	chr3:160971518	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs11779988	0.571	rs208052	chr8:17825559	G/C	cg01800426	chr8:17659068	MTUS1	-0.71	-4.91	-0.45	3.85e-6	Breast cancer;
THYM	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg13609457	chr4:120235615	NA	0.61	5.53	0.49	2.87e-7	Corneal astigmatism;
THYM	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg06634786	chr22:41940651	POLR3H	0.73	5.33	0.48	6.69e-7	Vitiligo;
THYM	cis	rs13326165	0.543	rs73088785	chr3:52313214	T/G	cg08438690	chr3:52279403	PPM1M	-0.74	-4.64	-0.43	1.12e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg02527881	chr3:46936655	PTH1R	-0.6	-6.01	-0.52	3.48e-8	Colorectal cancer;
THYM	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg15247329	chr7:2764246	NA	-0.68	-5.65	-0.5	1.7e-7	Height;
THYM	cis	rs3849570	0.961	rs3849571	chr3:81777716	A/C	cg07356753	chr3:81810745	GBE1	-0.93	-7.58	-0.61	2.28e-11	Waist circumference;Body mass index;
THYM	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg24675056	chr1:15929824	NA	0.73	5.86	0.52	6.71e-8	Systolic blood pressure;
THYM	cis	rs6032067	0.929	rs13038355	chr20:43805555	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.67	9.16	0.68	1.04e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg14456004	chr13:21872349	NA	-1.26	-10.62	-0.74	7.97e-18	White matter hyperintensity burden;
THYM	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	6.25	0.54	1.16e-8	Smoking behavior;
THYM	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg12564285	chr5:131593104	PDLIM4	-0.62	-7.72	-0.62	1.17e-11	Acylcarnitine levels;
THYM	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.06	9.63	0.7	1.04e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg17911788	chr17:44343683	NA	0.71	6.76	0.57	1.09e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg10505658	chr17:80084571	CCDC57	-0.69	-7.95	-0.63	3.85e-12	Life satisfaction;
THYM	cis	rs1298062	0.790	rs25668	chr19:50965272	T/C	cg10687087	chr19:50962411	MYBPC2	0.53	4.53	0.42	1.69e-5	Age of smoking initiation;
THYM	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg03433033	chr1:76189801	ACADM	0.78	9.41	0.69	3.08e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs3771570	1.000	rs60209440	chr2:242260340	G/C	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs55665837	1.000	rs11023215	chr11:14436970	C/T	cg05501817	chr11:14380813	RRAS2	-0.58	-4.53	-0.42	1.73e-5	Vitamin D levels;
THYM	cis	rs12310956	0.532	rs11052954	chr12:33993512	C/G	cg06521331	chr12:34319734	NA	-0.96	-8.5	-0.66	2.7e-13	Morning vs. evening chronotype;
THYM	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg02725872	chr8:58115012	NA	-1.15	-7.43	-0.61	4.64e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs4430311	0.723	rs11586029	chr1:243910067	C/T	cg25706552	chr1:244017396	NA	-0.56	-4.89	-0.45	4.15e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4242434	0.927	rs11136093	chr8:22479988	C/G	cg11461670	chr8:22454935	PDLIM2	-0.39	-6.56	-0.56	2.77e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9875589	0.509	rs7648345	chr3:14039901	G/A	cg03204825	chr3:13978759	TPRXL	-0.55	-4.78	-0.44	6.32e-6	Ovarian reserve;
THYM	cis	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg23161317	chr6:28129485	ZNF389	0.76	4.69	0.43	9.05e-6	Depression;
THYM	cis	rs80180425	0.607	rs57924834	chr15:101231049	G/A	cg19187121	chr15:101628653	NA	-0.4	-5.72	-0.51	1.23e-7	Pediatric bone mineral content (spine);
THYM	cis	rs669446	0.528	rs7538463	chr1:44196416	T/A	cg12599982	chr1:44399894	ARTN	0.53	4.87	0.45	4.39e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7465272	1.000	rs7017842	chr8:143685116	G/A	cg10104451	chr8:143696006	ARC	-0.8	-5.49	-0.49	3.34e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs72627123	0.867	rs80298117	chr14:74447383	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	4.87	0.45	4.38e-6	Morning vs. evening chronotype;
THYM	cis	rs7762018	0.607	rs75010113	chr6:170057441	C/T	cg19338460	chr6:170058176	WDR27	-1.04	-6.21	-0.54	1.42e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs7614311	0.681	rs73117036	chr3:63892725	G/C	cg22134162	chr3:63841271	THOC7	-0.58	-6.75	-0.57	1.16e-9	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg05527609	chr1:210001259	C1orf107	-0.85	-6.23	-0.54	1.28e-8	Orofacial clefts;
THYM	cis	rs860818	1.000	rs858280	chr7:23250874	T/A	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs1448094	0.549	rs12308898	chr12:86233678	G/A	cg02569458	chr12:86230093	RASSF9	0.63	5.49	0.49	3.38e-7	Major depressive disorder;
THYM	cis	rs2964802	0.505	rs7447014	chr5:10814212	T/C	cg14521931	chr5:10832172	NA	-0.62	-5.1	-0.46	1.76e-6	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg02403541	chr12:121454288	C12orf43	0.81	7.13	0.59	1.96e-10	N-glycan levels;
THYM	cis	rs2976388	1.000	rs2976398	chr8:143764879	G/C	cg13446199	chr8:143762866	PSCA	0.51	6.41	0.55	5.48e-9	Urinary tract infection frequency;
THYM	cis	rs2276314	1.000	rs4799834	chr18:33566243	T/C	cg05985134	chr18:33552581	C18orf21	0.68	4.77	0.44	6.59e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7695732	0.595	rs7686954	chr4:89904156	A/G	cg17769793	chr4:89976368	FAM13A	0.5	5.63	0.5	1.84e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs72827839	1.000	rs72827885	chr17:46534423	C/G	cg23391107	chr17:45924227	SP6	0.77	4.61	0.43	1.24e-5	Ease of getting up in the morning;
THYM	cis	rs3820068	0.580	rs34426856	chr1:16006315	C/T	cg27534772	chr1:16042836	PLEKHM2	0.52	5.87	0.52	6.44e-8	Systolic blood pressure;
THYM	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg18252515	chr7:66147081	NA	-0.59	-4.51	-0.42	1.89e-5	Calcium levels;
THYM	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg04756594	chr16:24857601	SLC5A11	-0.77	-5.35	-0.48	6.1e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7264396	0.887	rs2281849	chr20:34060286	T/C	cg26038318	chr20:34205095	SPAG4	0.53	4.47	0.42	2.15e-5	Total cholesterol levels;
THYM	cis	rs6920965	0.545	rs2326242	chr6:126174859	A/C	cg05901451	chr6:126070800	HEY2	-0.62	-5.23	-0.47	1e-6	High light scatter reticulocyte count;
THYM	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	7.66	0.62	1.54e-11	Platelet count;
THYM	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.75e-6	Aortic root size;
THYM	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07167872	chr1:205819463	PM20D1	0.96	9.38	0.69	3.52e-15	Menarche (age at onset);
THYM	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg10523679	chr1:76189770	ACADM	0.9	9.47	0.7	2.2e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2455799	0.553	rs2262664	chr3:15768097	A/T	cg16303742	chr3:15540471	COLQ	-0.56	-5.98	-0.52	3.83e-8	Mean platelet volume;
THYM	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.76	0.67	7.26e-14	Colorectal cancer;
THYM	cis	rs7757969	1.000	rs9374289	chr6:112111394	C/A	cg08601457	chr6:112115117	FYN	0.42	4.78	0.44	6.49e-6	Schizophrenia;
THYM	cis	rs11625487	0.522	rs11845884	chr14:77966268	C/T	cg18872420	chr14:78023429	SPTLC2	0.58	4.46	0.42	2.25e-5	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
THYM	cis	rs9649213	0.593	rs35535338	chr7:97962319	C/T	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.57e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8070624	0.543	rs4299203	chr17:17878159	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	6.7	0.57	1.48e-9	Total body bone mineral density;
THYM	cis	rs7843479	0.965	rs4636204	chr8:21823206	T/G	cg17168535	chr8:21777572	XPO7	0.65	4.82	0.44	5.41e-6	Mean corpuscular volume;
THYM	cis	rs1670533	1.000	rs2045065	chr4:1052488	A/G	cg27284194	chr4:1044797	NA	0.62	4.73	0.44	7.81e-6	Recombination rate (females);
THYM	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs10751667	1.000	rs7394449	chr11:962190	T/C	ch.11.42038R	chr11:967971	AP2A2	0.55	4.45	0.42	2.32e-5	Alzheimer's disease (late onset);
THYM	cis	rs13006833	0.739	rs291470	chr2:191189558	T/A	cg27211696	chr2:191398769	TMEM194B	0.56	4.47	0.42	2.17e-5	Urinary metabolites;
THYM	cis	rs11039798	0.920	rs12279378	chr11:48571030	A/C	cg24672777	chr11:48374446	OR4C45	-1.14	-6.95	-0.58	4.55e-10	Axial length;
THYM	cis	rs7426056	0.530	rs7426281	chr2:204577559	A/G	cg07930752	chr2:204569955	CD28	-0.73	-5.28	-0.48	8.21e-7	Primary sclerosing cholangitis;
THYM	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg18681998	chr4:17616180	MED28	1.02	9.76	0.71	5.5e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs10782582	0.593	rs6675212	chr1:76230829	C/A	cg03433033	chr1:76189801	ACADM	-0.5	-5.11	-0.46	1.64e-6	Daytime sleep phenotypes;
THYM	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg15704280	chr7:45808275	SEPT13	1.0	7.71	0.62	1.23e-11	Coronary artery disease;
THYM	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg11764359	chr7:65958608	NA	0.82	6.12	0.53	2.13e-8	Aortic root size;
THYM	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs113835537	0.529	rs117112180	chr11:66293273	A/G	cg24851651	chr11:66362959	CCS	0.76	5.25	0.47	9.31e-7	Airway imaging phenotypes;
THYM	cis	rs7941600	0.581	rs12278189	chr11:9359844	G/T	cg21110646	chr11:9336536	TMEM41B	0.99	5.58	0.5	2.23e-7	Coronary artery disease;
THYM	cis	rs4474465	0.703	rs10899547	chr11:78254720	C/T	cg19901956	chr11:77921274	USP35	0.6	4.53	0.42	1.68e-5	Alzheimer's disease (survival time);
THYM	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg20999797	chr1:1681921	NA	0.49	5.36	0.48	5.75e-7	Body mass index;
THYM	cis	rs2235573	0.662	rs2076369	chr22:38463652	T/G	cg19171272	chr22:38449367	NA	-0.51	-5.29	-0.48	7.96e-7	Glioblastoma;Glioma;
THYM	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs2797160	1.000	rs2211420	chr6:125995549	A/G	cg16306078	chr6:126000798	NA	-0.54	-5.61	-0.5	2.02e-7	Endometrial cancer;
THYM	cis	rs11186	0.556	rs72906325	chr2:189957810	C/T	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg14851468	chr5:179071604	C5orf60	0.53	4.52	0.42	1.79e-5	Lung cancer;
THYM	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.8	-0.51	8.64e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4866334	1.000	rs76371744	chr5:18441614	T/G	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg10295955	chr4:187884368	NA	-1.17	-16.0	-0.85	1.07e-28	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg06618935	chr21:46677482	NA	-0.95	-7.77	-0.62	9.36e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs931127	0.719	rs2170082	chr11:65454795	A/G	cg27068330	chr11:65405492	SIPA1	-0.78	-7.05	-0.59	2.92e-10	Systemic lupus erythematosus;
THYM	cis	rs6430585	0.527	rs12467569	chr2:136413847	T/C	cg23851026	chr2:136556271	LCT	0.63	5.72	0.51	1.24e-7	Corneal structure;
THYM	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	trans	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg10856724	chr12:34555212	NA	-0.96	-8.66	-0.66	1.22e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9527	0.590	rs3781281	chr10:104852648	A/G	cg15744005	chr10:104629667	AS3MT	0.59	4.48	0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs12444261	1.000	rs61541101	chr16:11740024	T/A	cg09662852	chr16:11707685	NA	-0.49	-4.66	-0.43	1.05e-5	QT interval;
THYM	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg15704280	chr7:45808275	SEPT13	1.02	8.31	0.65	6.7e-13	Coronary artery disease;
THYM	trans	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg25214090	chr10:38739885	LOC399744	-0.93	-8.04	-0.64	2.45e-12	Corneal astigmatism;
THYM	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg20891283	chr12:69753455	YEATS4	0.62	4.51	0.42	1.85e-5	Response to diuretic therapy;
THYM	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg18512352	chr11:47633146	NA	-0.51	-6.23	-0.54	1.24e-8	Subjective well-being;
THYM	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7191439	0.728	rs8043924	chr16:88787704	G/C	cg27087555	chr16:88793112	FAM38A	-1.56	-11.29	-0.76	2.99e-19	Plateletcrit;
THYM	cis	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg19875535	chr5:140030758	IK	-0.58	-4.52	-0.42	1.76e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg18105134	chr13:113819100	PROZ	0.99	9.2	0.69	8.44e-15	Platelet distribution width;
THYM	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs75059851	0.932	rs73034295	chr11:133822133	G/A	cg14047540	chr11:133829660	NA	-1.21	-8.32	-0.65	6.5e-13	Schizophrenia;
THYM	cis	rs7731657	0.537	rs7732161	chr5:130341510	A/G	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs7211079	0.879	rs7221505	chr17:78128231	G/A	cg09238746	chr17:78121135	EIF4A3	-0.76	-4.74	-0.44	7.48e-6	Myocardial infarction;
THYM	cis	rs7107174	1.000	rs2510055	chr11:77961912	C/T	cg02023728	chr11:77925099	USP35	0.69	6.19	0.54	1.55e-8	Testicular germ cell tumor;
THYM	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg12963246	chr6:28129442	ZNF389	0.72	6.2	0.54	1.44e-8	Depression;
THYM	cis	rs6733011	0.578	rs12712038	chr2:99497710	A/G	cg08885076	chr2:99613938	TSGA10	-0.45	-4.45	-0.42	2.29e-5	Bipolar disorder;
THYM	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.1	12.01	0.78	9.06e-21	Intelligence (multi-trait analysis);
THYM	cis	rs7584330	0.737	rs11886117	chr2:238361650	A/T	cg04447362	chr2:237654635	NA	0.48	4.49	0.42	2.03e-5	Prostate cancer;
THYM	cis	rs2625529	0.878	rs16956302	chr15:72136243	C/T	cg16672083	chr15:72433130	SENP8	-0.55	-4.77	-0.44	6.71e-6	Red blood cell count;
THYM	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	9.42	0.69	2.93e-15	Chronic sinus infection;
THYM	cis	rs7592578	0.713	rs60915953	chr2:191331304	G/C	cg27211696	chr2:191398769	TMEM194B	-0.63	-4.45	-0.42	2.31e-5	Diastolic blood pressure;
THYM	cis	rs6424115	0.708	rs2076343	chr1:24129126	A/G	cg15997130	chr1:24165203	NA	-0.71	-5.26	-0.47	9e-7	Immature fraction of reticulocytes;
THYM	cis	rs9318086	0.712	rs66683041	chr13:24442090	T/A	cg24659858	chr13:24270321	NA	0.48	4.61	0.43	1.27e-5	Myopia (pathological);
THYM	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg05340658	chr4:99064831	C4orf37	0.54	4.55	0.42	1.58e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9302065	0.565	rs2993586	chr13:95962578	T/C	cg26751094	chr13:95954534	ABCC4	-0.48	-5.4	-0.48	4.82e-7	Blood metabolite levels;
THYM	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4836694	0.574	rs4837476	chr9:132937533	T/C	cg13414629	chr9:132935646	FREQ	0.75	5.24	0.47	9.58e-7	Alzheimer's disease (cognitive decline);
THYM	cis	rs9302065	0.681	rs9524902	chr13:95963518	C/T	cg24476569	chr13:95954382	ABCC4	-0.78	-7.93	-0.63	4.27e-12	Blood metabolite levels;
THYM	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	7.66	0.62	1.54e-11	Platelet count;
THYM	cis	rs11645898	0.748	rs72787056	chr16:72099694	C/T	cg03805757	chr16:71968109	PKD1L3	-0.72	-5.25	-0.47	9.38e-7	Blood protein levels;
THYM	cis	rs4642101	0.597	rs9865624	chr3:12822786	T/A	cg05775895	chr3:12838266	CAND2	0.76	6.79	0.57	9.61e-10	QRS complex (12-leadsum);
THYM	cis	rs6430585	0.528	rs6743537	chr2:136702601	C/T	cg20242066	chr2:136595261	LCT	0.5	4.72	0.44	8.26e-6	Corneal structure;
THYM	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg20295408	chr7:1910781	MAD1L1	-0.58	-4.63	-0.43	1.14e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7719624	0.967	rs10463536	chr5:135362682	T/C	cg12897067	chr5:135418308	NA	0.57	4.58	0.42	1.44e-5	Response to cytidine analogues (gemcitabine);
THYM	cis	rs7584330	0.657	rs10202292	chr2:238352185	A/T	cg16989719	chr2:238392110	NA	-0.6	-5.42	-0.49	4.42e-7	Prostate cancer;
THYM	cis	rs9549367	0.713	rs3024746	chr13:113821777	G/A	cg00898013	chr13:113819073	PROZ	-0.99	-8.94	-0.68	3.01e-14	Platelet distribution width;
THYM	cis	rs6918586	0.658	rs198838	chr6:26113340	C/T	cg12310025	chr6:25882481	NA	-0.65	-5.18	-0.47	1.26e-6	Schizophrenia;
THYM	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg23815491	chr16:72088622	HP	0.79	6.31	0.54	8.91e-9	Fibrinogen levels;
THYM	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg25251562	chr2:3704773	ALLC	-1.26	-9.68	-0.7	8.04e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs919433	0.713	rs10172961	chr2:198446859	T/C	cg00792783	chr2:198669748	PLCL1	0.8	5.6	0.5	2.11e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2456568	0.803	rs10831138	chr11:93640468	T/C	cg17595323	chr11:93583763	C11orf90	-0.6	-6.33	-0.54	8.23e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7192750	0.501	rs6499542	chr16:71859830	A/T	cg06353428	chr16:71660113	MARVELD3	0.78	5.26	0.47	8.97e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs55728055	0.661	rs5753700	chr22:31971258	C/T	cg01338084	chr22:32026380	PISD	1.35	5.48	0.49	3.55e-7	Age-related hearing impairment;
THYM	cis	rs4737010	0.501	rs55694640	chr8:41649439	T/G	cg08923054	chr8:41654455	ANK1	0.81	4.91	0.45	3.81e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
THYM	cis	rs6840360	1.000	rs4696104	chr4:152600451	A/G	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg23131131	chr22:24373011	LOC391322	-0.84	-8.01	-0.63	2.91e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7772486	0.686	rs1292337	chr6:145967807	A/G	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs807669	0.548	rs5746685	chr22:19192596	C/G	cg02655711	chr22:19163373	SLC25A1	-0.7	-7.86	-0.63	6.07e-12	Metabolite levels;
THYM	cis	rs11608355	1.000	rs7958625	chr12:109869218	A/T	cg11367159	chr12:110044531	NA	0.66	6.29	0.54	9.83e-9	Neuroticism;
THYM	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.11	8.07	0.64	2.15e-12	Cognitive test performance;
THYM	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg21211367	chr2:162094118	NA	0.66	5.4	0.48	4.85e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs2797160	0.602	rs4897150	chr6:125985540	C/T	cg16306078	chr6:126000798	NA	-0.48	-4.52	-0.42	1.78e-5	Endometrial cancer;
THYM	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg18252515	chr7:66147081	NA	1.37	8.05	0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg16524936	chr4:1340807	KIAA1530	-0.63	-4.85	-0.45	4.79e-6	Longevity;
THYM	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg08847533	chr14:75593920	NEK9	-1.0	-11.26	-0.76	3.48e-19	Height;
THYM	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	8.22	0.64	1.02e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg10047753	chr17:41438598	NA	1.17	10.89	0.75	2.11e-18	Menopause (age at onset);
THYM	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.67	9.16	0.68	1.04e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg04282206	chr17:62833786	PLEKHM1P	-0.79	-7.07	-0.59	2.57e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs828999	0.688	rs12047867	chr1:108726907	G/A	cg24323958	chr1:108741884	SLC25A24	0.56	5.58	0.5	2.22e-7	Monocyte percentage of white cells;
THYM	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg15445000	chr17:37608096	MED1	-0.44	-5.07	-0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs11249608	0.636	rs6868893	chr5:178449826	C/A	cg01312482	chr5:178451176	ZNF879	-0.75	-6.21	-0.54	1.37e-8	Pubertal anthropometrics;
THYM	cis	rs8028313	0.731	rs6494678	chr15:67946247	C/T	cg26545918	chr15:68124484	LBXCOR1	0.5	4.45	0.42	2.34e-5	Obesity;
THYM	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg15691649	chr6:25882328	NA	-0.76	-6.18	-0.54	1.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.54	-0.49	2.74e-7	Menopause (age at onset);
THYM	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.02	-0.53	3.32e-8	Life satisfaction;
THYM	cis	rs2885135	0.559	rs1148455	chr1:13914230	A/G	cg04886857	chr1:13914270	PDPN	0.33	4.8	0.44	5.88e-6	Response to cytadine analogues (cytosine arabinoside);
THYM	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg07167872	chr1:205819463	PM20D1	-0.67	-5.0	-0.46	2.62e-6	Menarche (age at onset);
THYM	cis	rs7572733	0.555	rs7561950	chr2:198754244	C/T	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs3768617	0.510	rs1886500	chr1:183095048	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs6665290	0.566	rs1513617	chr1:227447213	C/T	cg10327440	chr1:227177885	CDC42BPA	0.75	7.05	0.59	2.85e-10	Myeloid white cell count;
THYM	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.7	-5.78	-0.51	9.52e-8	Lymphocyte counts;
THYM	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3936840	0.964	rs10150698	chr14:102977876	A/G	cg06761850	chr14:102904469	TECPR2	0.37	4.55	0.42	1.59e-5	Plateletcrit;
THYM	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg15448220	chr1:150897856	SETDB1	0.88	7.27	0.6	1.02e-10	Tonsillectomy;
THYM	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg26769984	chr7:1090371	C7orf50	0.83	5.35	0.48	6.11e-7	Bronchopulmonary dysplasia;
THYM	cis	rs5985	0.687	rs55742486	chr6:6317589	T/C	cg22185065	chr6:6318785	F13A1	0.78	5.74	0.51	1.15e-7	End-stage coagulation;
THYM	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg03188948	chr7:1209495	NA	0.65	5.09	0.46	1.79e-6	Longevity;Endometriosis;
THYM	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.79	-0.51	9.2e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg05738196	chr6:26577821	NA	0.76	6.11	0.53	2.22e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg08835221	chr22:38071607	LGALS1	0.37	4.86	0.45	4.67e-6	Fat distribution (HIV);
THYM	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg14829155	chr15:31115871	NA	-0.57	-5.03	-0.46	2.35e-6	Huntington's disease progression;
THYM	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7769051	0.803	rs12193474	chr6:133186168	T/C	cg07930552	chr6:133119739	C6orf192	0.91	4.47	0.42	2.13e-5	Type 2 diabetes nephropathy;
THYM	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg13073564	chr4:8508604	NA	-0.48	-4.47	-0.42	2.16e-5	Response to antineoplastic agents;
THYM	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg22166914	chr1:53195759	ZYG11B	0.81	8.19	0.64	1.2e-12	Monocyte count;
THYM	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.14	-8.83	-0.67	5.34e-14	Schizophrenia;
THYM	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg21926883	chr2:100939477	LONRF2	-0.61	-5.56	-0.5	2.42e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs10463554	1.000	rs1593842	chr5:102334722	A/C	cg23492399	chr5:102201601	PAM	-0.64	-4.98	-0.46	2.83e-6	Parkinson's disease;
THYM	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg02734326	chr4:10020555	SLC2A9	0.75	6.26	0.54	1.1e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg07424592	chr7:64974309	NA	1.07	5.53	0.49	2.87e-7	Diabetic kidney disease;
THYM	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs1003719	0.788	rs4817849	chr21:38469796	A/G	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg24531977	chr5:56204891	C5orf35	-1.01	-8.29	-0.65	7.47e-13	Initial pursuit acceleration;
THYM	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg13147721	chr7:65941812	NA	-1.1	-7.08	-0.59	2.51e-10	Diabetic kidney disease;
THYM	cis	rs5769707	0.604	rs1018814	chr22:50036900	T/C	cg17054759	chr22:49844102	NA	-0.52	-4.71	-0.44	8.39e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg06481639	chr22:41940642	POLR3H	0.84	5.85	0.51	6.94e-8	Cannabis dependence symptom count;
THYM	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg22508957	chr16:3507546	NAT15	0.69	9.19	0.69	8.75e-15	Tuberculosis;
THYM	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs977987	0.931	rs1834013	chr16:75496163	G/T	cg03315344	chr16:75512273	CHST6	0.71	5.76	0.51	1.04e-7	Dupuytren's disease;
THYM	cis	rs4845570	1.000	rs7416415	chr1:151757798	C/T	cg07092448	chr1:151763213	TDRKH	1.03	6.71	0.57	1.42e-9	Coronary artery disease;
THYM	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg03452623	chr4:187889614	NA	-1.13	-16.03	-0.85	8.97e-29	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4866334	1.000	rs74776941	chr5:18489387	T/G	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg02915803	chr1:1606292	LOC728661;CDK11B	0.64	5.36	0.48	5.8e-7	Body mass index;
THYM	cis	rs2495707	0.624	rs1419177	chr10:102423699	G/C	cg07919443	chr10:102419409	NA	-0.68	-6.34	-0.55	7.85e-9	Body mass index;
THYM	cis	rs6906287	0.647	rs12203006	chr6:118917086	C/T	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg22709100	chr7:91322751	NA	0.69	5.41	0.49	4.7e-7	Breast cancer;
THYM	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11890956	chr21:40555474	PSMG1	-0.9	-9.57	-0.7	1.4e-15	Cognitive function;
THYM	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-4.48	-0.42	2.06e-5	Monocyte percentage of white cells;
THYM	cis	rs9393777	0.588	rs6926677	chr6:26478825	G/C	cg12826209	chr6:26865740	GUSBL1	1.02	6.88	0.58	6.48e-10	Intelligence (multi-trait analysis);
THYM	cis	rs79149102	0.579	rs3812943	chr15:75312715	C/G	cg09165964	chr15:75287851	SCAMP5	-1.0	-4.96	-0.45	3.08e-6	Lung cancer;
THYM	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs4731207	0.698	rs6942933	chr7:124444522	C/T	cg05285228	chr7:124571219	POT1	0.66	5.25	0.47	9.44e-7	Cutaneous malignant melanoma;
THYM	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg24642844	chr7:1081250	C7orf50	-0.74	-5.18	-0.47	1.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg20587970	chr11:113659929	NA	-1.27	-8.35	-0.65	5.36e-13	Hip circumference adjusted for BMI;
THYM	cis	rs4523957	0.893	rs11078018	chr17:2162119	A/G	cg16513277	chr17:2031491	SMG6	-0.79	-7.41	-0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7084402	0.967	rs1658485	chr10:60288331	A/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.82	-5.23	-0.47	9.93e-7	Resting heart rate;
THYM	trans	rs9747201	0.963	rs11077983	chr17:80185188	C/T	cg07393940	chr7:158741817	NA	1.07	7.98	0.63	3.3e-12	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7894051	1.000	rs7894051	chr10:135184421	C/G	cg20534287	chr10:135191450	PAOX	-0.78	-5.68	-0.5	1.49e-7	Lifespan;
THYM	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg15556689	chr8:8085844	FLJ10661	0.64	5.21	0.47	1.09e-6	Mood instability;
THYM	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg06219351	chr7:158114137	PTPRN2	-0.79	-8.18	-0.64	1.27e-12	Calcium levels;
THYM	cis	rs709400	0.588	rs61996718	chr14:104048834	G/A	cg26031613	chr14:104095156	KLC1	1.01	6.14	0.53	1.93e-8	Body mass index;
THYM	cis	rs71575922	0.599	rs584336	chr6:152616173	A/G	cg17720707	chr6:151818811	C6orf97	0.74	5.3	0.48	7.43e-7	Endometriosis;
THYM	cis	rs12643440	0.538	rs2314601	chr4:17139932	C/T	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs2730245	0.527	rs2527194	chr7:158732959	G/A	cg24397884	chr7:158709396	WDR60	-0.59	-5.55	-0.49	2.58e-7	Height;
THYM	cis	rs3020340	1.000	rs7772579	chr6:152042502	A/C	cg22157087	chr6:152012887	ESR1	0.44	4.54	0.42	1.66e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs10186029	0.582	rs1441166	chr2:214010105	T/C	cg08319019	chr2:214017104	IKZF2	0.76	5.81	0.51	8.17e-8	Systemic sclerosis;
THYM	cis	rs7173743	0.750	rs12903355	chr15:79129145	A/T	cg15571903	chr15:79123663	NA	0.55	6.25	0.54	1.14e-8	Coronary artery disease;
THYM	cis	rs72829446	0.932	rs62059824	chr17:7478213	C/T	cg07091842	chr17:7155530	C17orf81;DULLARD	-1.03	-4.58	-0.43	1.4e-5	Androgen levels;
THYM	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	7.77	0.62	9.07e-12	Smoking behavior;
THYM	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs6815814	0.847	rs11725309	chr4:38783848	T/C	cg02016764	chr4:38805732	TLR1	-0.55	-5.29	-0.48	7.91e-7	Breast cancer;
THYM	cis	rs9649213	0.533	rs1541409	chr7:98027580	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.65	-5.52	-0.49	2.99e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.84	0.44	5.01e-6	Breast cancer;
THYM	cis	rs9326248	0.581	rs12225187	chr11:116793231	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.69	5.44	0.49	4.22e-7	Blood protein levels;
THYM	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg16615211	chr3:44902933	MIR564;TMEM42	0.57	6.12	0.53	2.04e-8	Depressive symptoms;
THYM	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	5.33	0.48	6.47e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg24154853	chr7:158122151	PTPRN2	0.55	4.55	0.42	1.56e-5	Calcium levels;
THYM	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg12310025	chr6:25882481	NA	-0.89	-7.56	-0.61	2.52e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7011507	0.700	rs72639013	chr8:49332630	G/A	cg08774009	chr8:49309094	NA	-0.62	-4.83	-0.44	5.19e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs9443645	0.561	rs9341751	chr6:79479836	T/C	cg04547799	chr6:79944526	HMGN3	-0.69	-5.03	-0.46	2.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13064411	0.735	rs6778800	chr3:113149236	A/G	cg10517650	chr3:113235015	CCDC52	-0.54	-4.64	-0.43	1.13e-5	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs11039798	0.588	rs10838923	chr11:48534864	C/G	cg24672777	chr11:48374446	OR4C45	-0.96	-6.22	-0.54	1.35e-8	Axial length;
THYM	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.45	0.42	2.31e-5	Obesity-related traits;
THYM	cis	rs4499344	0.633	rs259229	chr19:33134425	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.95	-8.42	-0.65	3.96e-13	Mean platelet volume;
THYM	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg08847533	chr14:75593920	NEK9	1.0	10.83	0.74	2.78e-18	Height;
THYM	cis	rs11249608	0.636	rs62393070	chr5:178447943	A/G	cg01312482	chr5:178451176	ZNF879	-0.64	-4.93	-0.45	3.5e-6	Pubertal anthropometrics;
THYM	cis	rs3087591	0.922	rs2341348	chr17:29534867	C/T	cg24425628	chr17:29625626	OMG;NF1	0.62	5.12	0.46	1.62e-6	Hip circumference;
THYM	cis	rs3845702	0.736	rs72960701	chr2:180851202	A/T	cg01881094	chr2:180872142	CWC22	0.91	5.5	0.49	3.16e-7	Schizophrenia;
THYM	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg15556689	chr8:8085844	FLJ10661	0.7	5.63	0.5	1.79e-7	Mood instability;
THYM	cis	rs7267979	1.000	rs10966	chr20:25282944	A/G	cg08601574	chr20:25228251	PYGB	0.56	4.47	0.42	2.15e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs990171	1.000	rs10197284	chr2:102982703	G/A	cg13897122	chr2:103039542	IL18RAP	-0.4	-4.76	-0.44	6.87e-6	Lymphocyte counts;
THYM	cis	rs7246657	0.943	rs28373708	chr19:37976659	C/T	cg22634378	chr19:37742834	NA	0.6	5.08	0.46	1.91e-6	Coronary artery calcification;
THYM	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg02389323	chr16:88786976	FAM38A	0.93	5.79	0.51	8.94e-8	Plateletcrit;
THYM	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1797885	0.546	rs2454421	chr3:12601105	C/T	cg05467012	chr3:12595696	NA	0.57	4.97	0.45	2.95e-6	Immature fraction of reticulocytes;
THYM	cis	rs7084921	0.548	rs12776483	chr10:101828600	C/A	cg11344164	chr10:101878520	NA	-0.55	-4.76	-0.44	6.9e-6	Bone mineral density;
THYM	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg05043794	chr9:111880884	C9orf5	-0.43	-6.3	-0.54	9.17e-9	Menarche (age at onset);
THYM	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg26354017	chr1:205819088	PM20D1	0.96	10.41	0.73	2.19e-17	Menarche (age at onset);
THYM	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg08213375	chr14:104286397	PPP1R13B	0.5	6.09	0.53	2.39e-8	Schizophrenia;
THYM	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.0	8.18	0.64	1.23e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg11266682	chr4:10021025	SLC2A9	0.72	11.65	0.77	5.23e-20	Bone mineral density;
THYM	cis	rs870825	0.616	rs28672716	chr4:185647345	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs4237845	0.844	rs7306124	chr12:58303349	A/T	cg22764591	chr12:58329936	NA	0.87	6.71	0.57	1.4e-9	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg15704280	chr7:45808275	SEPT13	-0.81	-8.14	-0.64	1.54e-12	Height;
THYM	cis	rs7098414	0.531	rs4120852	chr10:82018594	G/T	cg01528321	chr10:82214614	TSPAN14	0.64	4.53	0.42	1.73e-5	Post bronchodilator FEV1;
THYM	cis	rs4438470	1.000	rs4416207	chr2:229016839	G/T	cg25310310	chr2:229546364	NA	0.74	4.66	0.43	1.04e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg20486651	chr6:167070296	RPS6KA2	0.5	4.68	0.43	9.47e-6	Crohn's disease;
THYM	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg00310523	chr12:86230176	RASSF9	0.53	4.6	0.43	1.32e-5	Major depressive disorder;
THYM	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1322639	1.000	rs9689079	chr6:169587148	A/G	cg04662567	chr6:169592167	NA	0.77	6.97	0.58	4.21e-10	Pulse pressure;
THYM	cis	rs10823500	0.777	rs10762348	chr10:71952322	C/A	cg25502086	chr10:71892093	AIFM2	-0.51	-4.66	-0.43	1.05e-5	Blood protein levels;
THYM	cis	rs17604090	0.628	rs875263	chr7:29711066	T/C	cg19413766	chr7:29689036	LOC646762	-0.81	-5.61	-0.5	1.97e-7	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs9796	0.689	rs692195	chr15:41444894	G/C	cg21153102	chr15:41252147	NA	0.6	4.98	0.45	2.84e-6	Menopause (age at onset);
THYM	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg23791538	chr6:167370224	RNASET2	-0.58	-4.53	-0.42	1.72e-5	Crohn's disease;
THYM	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg12483005	chr1:23474871	LUZP1	0.58	5.84	0.51	7.3900000000000007e-08	Height;
THYM	cis	rs9649465	1.000	rs9649465	chr7:123376560	G/A	cg15443791	chr7:124364398	NA	0.6	4.97	0.45	3.01e-6	Migraine;
THYM	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7084402	0.902	rs1582826	chr10:60297175	C/T	cg07615347	chr10:60278583	BICC1	0.56	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs6700896	0.966	rs10889570	chr1:66088084	C/G	cg04111102	chr1:66153794	NA	0.54	4.61	0.43	1.26e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg24818145	chr4:99064322	C4orf37	0.72	5.7	0.5	1.35e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg11764359	chr7:65958608	NA	0.7	4.83	0.44	5.32e-6	Aortic root size;
THYM	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03452623	chr4:187889614	NA	-1.17	-20.04	-0.9	6.92e-36	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12188164	1.000	rs72717411	chr5:429124	C/G	cg26850624	chr5:429559	AHRR	-0.69	-5.39	-0.48	5.09e-7	Cystic fibrosis severity;
THYM	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg15556689	chr8:8085844	FLJ10661	0.72	6.18	0.54	1.6e-8	Systolic blood pressure;
THYM	trans	rs877282	0.898	rs12356744	chr10:757477	G/C	cg22713356	chr15:30763199	NA	1.35	9.87	0.71	3.11e-16	Uric acid levels;
THYM	cis	rs877674	0.818	rs2297600	chr1:32207581	T/G	cg13438300	chr1:32254265	NA	-0.66	-4.47	-0.42	2.16e-5	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg18538332	chr22:24372958	LOC391322	-1.09	-14.89	-0.84	1.4e-26	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg09033563	chr22:24373618	LOC391322	-0.62	-5.58	-0.5	2.25e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs728616	0.867	rs61859766	chr10:81683040	G/A	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7617773	0.780	rs35297486	chr3:48378147	T/A	cg02219026	chr3:48282209	ZNF589	-0.69	-4.8	-0.44	6.01e-6	Coronary artery disease;
THYM	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg21385522	chr1:16154831	NA	-1.3	-14.69	-0.83	3.47e-26	Dilated cardiomyopathy;
THYM	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg06981504	chr1:1234844	ACAP3	0.56	4.96	0.45	3.09e-6	Body mass index;
THYM	cis	rs925255	0.617	rs12993460	chr2:28603637	A/C	cg01273330	chr2:28605224	NA	-0.63	-5.57	-0.5	2.33e-7	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg14895029	chr7:2775587	GNA12	-0.62	-4.5	-0.42	1.96e-5	Height;
THYM	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg12564285	chr5:131593104	PDLIM4	0.44	4.5	0.42	1.92e-5	Blood metabolite levels;
THYM	cis	rs6840360	1.000	rs4696291	chr4:152631637	G/A	cg22705602	chr4:152727874	NA	-0.6	-6.39	-0.55	6.18e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg03806693	chr22:41940476	POLR3H	0.95	7.85	0.63	6.34e-12	Vitiligo;
THYM	cis	rs4930103	0.935	rs2839698	chr11:2018853	G/A	cg06197492	chr11:2016605	H19	0.63	5.48	0.49	3.56e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs346785	0.640	rs9905488	chr17:74283535	A/G	cg09812376	chr17:74270190	QRICH2	0.5	5.31	0.48	7.24e-7	White matter hyperintensities in ischemic stroke;
THYM	cis	rs2076222	1.000	rs2076349	chr1:209800230	C/T	cg00257659	chr1:209800214	LAMB3	-1.03	-4.57	-0.42	1.49e-5	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
THYM	cis	rs8133932	0.701	rs2839054	chr21:47328449	A/G	cg20357416	chr21:47294739	PCBP3	-0.81	-4.93	-0.45	3.54e-6	Schizophrenia;
THYM	cis	rs10737909	1.000	rs10803369	chr1:15550525	G/T	cg03960804	chr1:15570129	NA	0.44	4.48	0.42	2.1e-5	Migraine;
THYM	cis	rs3845702	0.733	rs12693217	chr2:180841914	T/G	cg01881094	chr2:180872142	CWC22	-0.89	-5.34	-0.48	6.22e-7	Schizophrenia;
THYM	cis	rs6763768	0.606	rs9942027	chr3:53392663	C/T	cg16894138	chr3:53270350	TKT	0.72	5.5	0.49	3.2e-7	Bacterial meningitis;
THYM	cis	rs11030122	0.702	rs10835407	chr11:3993231	C/T	cg18678763	chr11:4115507	RRM1	0.43	5.44	0.49	4.21e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9486719	1.000	rs2472889	chr6:96866803	T/G	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg03433033	chr1:76189801	ACADM	0.77	10.09	0.72	1.07e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg06713675	chr4:122721982	EXOSC9	-0.51	-4.75	-0.44	7.13e-6	Type 2 diabetes;
THYM	cis	rs3126085	0.935	rs11204947	chr1:152218257	G/T	cg10321714	chr1:152280068	FLG	-0.69	-4.92	-0.45	3.67e-6	Atopic dermatitis;
THYM	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg24675056	chr1:15929824	NA	0.73	5.89	0.52	5.95e-8	Systolic blood pressure;
THYM	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg16342193	chr10:102329863	NA	-0.48	-4.85	-0.45	4.75e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4731207	0.698	rs6949341	chr7:124564176	C/A	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs8078723	0.668	rs4239225	chr17:38127112	G/A	cg17467752	chr17:38218738	THRA	0.74	5.44	0.49	4.1e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg04455712	chr21:45112962	RRP1B	0.51	4.71	0.44	8.41e-6	Mean corpuscular volume;
THYM	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12516959	chr21:47718080	NA	0.4	4.78	0.44	6.43e-6	Testicular germ cell tumor;
THYM	cis	rs9649213	0.537	rs6971825	chr7:97979548	C/T	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.2e-5	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg22433210	chr17:43662623	NA	1.12	8.59	0.66	1.69e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs8018808	0.935	rs8018513	chr14:77928288	T/C	cg20045696	chr14:77926864	AHSA1	0.53	4.76	0.44	6.98e-6	Myeloid white cell count;
THYM	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg07061783	chr6:25882402	NA	0.73	5.88	0.52	6.22e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg26924012	chr15:45694286	SPATA5L1	0.96	7.5	0.61	3.34e-11	Homoarginine levels;
THYM	cis	rs760805	1.000	rs4649037	chr1:25258301	G/T	cg22509179	chr1:25234806	RUNX3	-0.73	-6.72	-0.57	1.34e-9	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9311676	0.656	rs56198078	chr3:58392224	G/C	cg26110898	chr3:58419937	PDHB	0.45	4.79	0.44	6.17e-6	Systemic lupus erythematosus;
THYM	cis	rs526231	0.543	rs28025	chr5:102537379	A/G	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Primary biliary cholangitis;
THYM	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs2455799	0.613	rs4685260	chr3:15832417	C/T	cg16303742	chr3:15540471	COLQ	-0.56	-5.88	-0.52	6.13e-8	Mean platelet volume;
THYM	cis	rs3768617	0.510	rs10911254	chr1:183088627	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs2969070	0.898	rs2906165	chr7:2508177	T/C	cg25507518	chr7:2405875	EIF3B	-0.46	-4.49	-0.42	1.97e-5	Diastolic blood pressure;
THYM	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg10018233	chr7:150070692	REPIN1	0.37	5.34	0.48	6.26e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2033711	0.783	rs8113810	chr19:58932106	A/G	cg13877915	chr19:58951672	ZNF132	0.9	8.65	0.66	1.29e-13	Uric acid clearance;
THYM	cis	rs2463822	0.844	rs1919359	chr11:62055703	A/G	cg06239285	chr11:62104954	ASRGL1	1.23	5.84	0.51	7.11e-8	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg06981504	chr1:1234844	ACAP3	0.54	4.97	0.45	2.93e-6	Body mass index;
THYM	cis	rs79149102	0.579	rs8039433	chr15:75367367	T/C	cg09165964	chr15:75287851	SCAMP5	-0.87	-4.89	-0.45	4.07e-6	Lung cancer;
THYM	cis	rs11711311	0.911	rs28577577	chr3:113447276	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.27	-0.48	8.41e-7	IgG glycosylation;
THYM	cis	rs3741151	0.892	rs61705659	chr11:73012101	T/G	cg12959048	chr11:73096162	RELT	-0.42	-4.49	-0.42	1.97e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg16524936	chr4:1340807	KIAA1530	-0.65	-4.66	-0.43	1.02e-5	Obesity-related traits;
THYM	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg24257776	chr3:47051546	LOC100129354	0.4	4.52	0.42	1.75e-5	Colorectal cancer;
THYM	cis	rs7100689	0.646	rs1572819	chr10:82112488	A/G	cg01528321	chr10:82214614	TSPAN14	0.87	6.65	0.56	1.86e-9	Post bronchodilator FEV1;
THYM	cis	rs9563576	0.735	rs4886056	chr13:58593327	C/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.62	4.49	0.42	2.01e-5	Body mass index;
THYM	cis	rs12681287	0.608	rs13270090	chr8:87553297	T/A	cg27223183	chr8:87520930	FAM82B	0.68	5.33	0.48	6.62e-7	Caudate activity during reward;
THYM	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg18128536	chr17:47092178	IGF2BP1	-0.6	-9.25	-0.69	6.69e-15	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs11122895	1.000	rs17777974	chr2:112464044	A/G	cg23262488	chr2:112468472	NA	-0.67	-9.57	-0.7	1.36e-15	Allergic sensitization;
THYM	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg04398451	chr17:18023971	MYO15A	-0.78	-7.23	-0.6	1.22e-10	Total body bone mineral density;
THYM	cis	rs2241584	0.748	rs13171278	chr5:175944210	C/T	cg02270010	chr5:175958651	RNF44	-0.3	-4.56	-0.42	1.55e-5	Menopause (age at onset);
THYM	cis	rs2075230	0.705	rs1641519	chr17:7550166	C/A	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.63	-0.43	1.16e-5	Hormone measurements;
THYM	cis	rs11651000	0.817	rs7502875	chr17:45823227	A/C	cg25856473	chr17:45174155	NA	0.62	4.93	0.45	3.44e-6	IgG glycosylation;
THYM	cis	rs2836633	0.929	rs2836602	chr21:40039169	A/T	cg05519781	chr21:40033154	ERG	-0.81	-8.0	-0.63	3.02e-12	Coronary artery disease;
THYM	cis	rs7084402	0.967	rs1658494	chr10:60280323	C/T	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg17173187	chr15:85201210	NMB	0.56	5.66	0.5	1.6e-7	Schizophrenia;
THYM	cis	rs9816226	0.618	rs1516728	chr3:185829891	A/T	cg00760338	chr3:185826511	ETV5	0.88	8.26	0.65	8.65e-13	Obesity;Body mass index;
THYM	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.82	-4.55	-0.42	1.56e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs10501293	0.675	rs7103629	chr11:43044427	T/A	cg03447554	chr11:43094025	NA	0.61	4.51	0.42	1.83e-5	Cognitive performance;
THYM	cis	rs7149242	1.000	rs7149242	chr14:101159416	G/T	cg18089426	chr14:101175970	NA	0.58	5.78	0.51	9.52e-8	Platelet count;
THYM	cis	rs4589258	0.933	rs55643244	chr11:90414881	A/T	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs919433	0.588	rs11690163	chr2:198527507	A/T	cg05783139	chr2:198650985	BOLL	0.66	4.98	0.46	2.78e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg23352942	chr3:46931381	PTH1R	-0.76	-7.41	-0.61	5.18e-11	Birth weight;
THYM	cis	rs9653442	0.675	rs7605430	chr2:100647552	C/G	cg07810366	chr2:100720526	AFF3	0.39	5.37	0.48	5.47e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs113835537	0.627	rs11227534	chr11:66336171	C/A	cg24851651	chr11:66362959	CCS	0.75	5.36	0.48	5.75e-7	Airway imaging phenotypes;
THYM	cis	rs10425738	0.785	rs4090553	chr19:41426757	T/C	cg17435250	chr19:41386441	CYP2A7	-0.63	-4.52	-0.42	1.79e-5	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
THYM	cis	rs4363385	0.782	rs1933381	chr1:153003255	C/G	cg13444842	chr1:152974279	SPRR3	-0.55	-4.49	-0.42	1.96e-5	Inflammatory skin disease;
THYM	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg03709012	chr19:19516395	GATAD2A	0.84	7.26	0.6	1.05e-10	Tonsillectomy;
THYM	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.84	4.45	0.42	2.3e-5	Alzheimer's disease;
THYM	cis	rs9296092	0.538	rs62405941	chr6:33517297	G/A	cg13560919	chr6:33536144	NA	-0.92	-8.98	-0.68	2.48e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg12031863	chr16:4587854	C16orf5	-0.46	-4.96	-0.45	3.09e-6	Schizophrenia;
THYM	cis	rs3772130	0.962	rs13061326	chr3:121493125	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs12121840	0.790	rs16847083	chr1:165534130	C/T	cg19407955	chr1:165599744	MGST3	0.65	4.64	0.43	1.12e-5	Interleukin-1-receptor antagonist levels;
THYM	cis	rs986417	0.901	rs7160405	chr14:60970004	G/C	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1345301	1.000	rs12470560	chr2:102868840	T/C	cg03938978	chr2:103052716	IL18RAP	-0.6	-6.0	-0.52	3.55e-8	Waist circumference;
THYM	cis	rs55728055	0.661	rs9619217	chr22:32043611	A/G	cg01338084	chr22:32026380	PISD	1.1	5.49	0.49	3.33e-7	Age-related hearing impairment;
THYM	cis	rs7192380	0.931	rs9302604	chr16:69576894	A/G	cg09409435	chr16:70099608	PDXDC2	0.61	4.45	0.42	2.34e-5	Sjögren's syndrome;
THYM	cis	rs7267979	1.000	rs884613	chr20:25288505	C/T	cg08601574	chr20:25228251	PYGB	-0.57	-4.51	-0.42	1.87e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6867032	0.958	rs4463207	chr5:2017118	G/T	cg26168224	chr5:2018326	NA	1.29	15.56	0.85	7.19e-28	Gut microbiome composition (winter);
THYM	cis	rs1878931	0.597	rs37816	chr16:3456371	G/A	cg05754148	chr16:3507555	NAT15	0.57	4.62	0.43	1.23e-5	Body mass index (adult);
THYM	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg25703541	chr22:24373054	LOC391322	-0.95	-12.66	-0.79	4.09e-22	Liver enzyme levels (gamma-glutamyl transferase);
THYM	trans	rs877282	0.733	rs7092976	chr10:756358	G/A	cg22713356	chr15:30763199	NA	1.27	9.37	0.69	3.62e-15	Uric acid levels;
THYM	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg24257776	chr3:47051546	LOC100129354	0.41	4.79	0.44	6.12e-6	Colorectal cancer;
THYM	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs12216545	0.765	rs9986804	chr7:150256411	G/T	cg08960815	chr7:150264767	GIMAP4	-0.81	-6.74	-0.57	1.2e-9	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7626444	0.584	rs7633044	chr3:196490643	A/G	cg12930392	chr3:196481615	PAK2	0.42	5.22	0.47	1.04e-6	Monocyte count;
THYM	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg00129232	chr17:37814104	STARD3	0.71	4.8	0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs17598306	0.935	rs17598579	chr7:96590472	G/T	cg23184042	chr7:96615519	DLX6AS	0.61	4.76	0.44	6.82e-6	Radiation response;
THYM	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13242816	1.000	rs56063232	chr7:116172808	G/T	cg16553024	chr7:116138462	CAV2	-1.25	-5.56	-0.5	2.5e-7	P wave duration;
THYM	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg20887711	chr4:1340912	KIAA1530	0.66	5.15	0.47	1.42e-6	Obesity-related traits;
THYM	cis	rs4888262	0.545	rs12716768	chr16:74556486	A/G	cg01733217	chr16:74700730	RFWD3	-0.8	-7.89	-0.63	5.04e-12	Testicular germ cell tumor;
THYM	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg06636001	chr8:8085503	FLJ10661	0.69	5.71	0.51	1.28e-7	Neuroticism;
THYM	cis	rs887829	0.570	rs45615240	chr2:234599296	T/C	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.54	-4.57	-0.42	1.45e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	trans	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.91	-8.63	-0.66	1.42e-13	Brugada syndrome;
THYM	cis	rs6543140	0.855	rs4851591	chr2:103077423	T/C	cg03938978	chr2:103052716	IL18RAP	0.58	5.84	0.51	7.16e-8	Blood protein levels;
THYM	cis	rs4720575	1.000	rs4720574	chr7:47085597	A/C	cg00036614	chr7:47093842	NA	-0.6	-5.28	-0.48	8.3e-7	Angiotensin-converting enzyme inhibitor intolerance;
THYM	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs929596	0.561	rs6431625	chr2:234637912	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.83	-7.19	-0.59	1.49e-10	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs11574514	0.661	rs9925393	chr16:67780829	C/T	cg09738193	chr16:67926317	PSKH1	-0.75	-4.45	-0.42	2.34e-5	Crohn's disease;
THYM	trans	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg25517755	chr10:38738941	LOC399744	-0.79	-7.77	-0.62	9.18e-12	Corneal astigmatism;
THYM	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg25251562	chr2:3704773	ALLC	-0.81	-5.41	-0.49	4.62e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg14942906	chr11:67384040	NA	0.57	4.66	0.43	1.02e-5	Mean corpuscular volume;
THYM	cis	rs4478239	1.000	rs4478239	chr4:188191306	A/C	cg02596645	chr4:187628413	FAT1	0.79	4.46	0.42	2.22e-5	Major depressive disorder;
THYM	cis	rs2361710	0.704	rs4889979	chr17:78121707	T/A	cg09238746	chr17:78121135	EIF4A3	-0.78	-6.43	-0.55	5e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
THYM	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg04455712	chr21:45112962	RRP1B	0.56	4.98	0.45	2.84e-6	Mean corpuscular volume;
THYM	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.26	-5.63	-0.5	1.79e-7	Obesity-related traits;
THYM	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg10645314	chr2:3704589	ALLC	0.72	5.28	0.48	8.01e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg08994789	chr17:28903642	LRRC37B2	-1.01	-5.01	-0.46	2.5e-6	Body mass index;
THYM	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg17366294	chr4:99064904	C4orf37	0.56	6.68	0.57	1.6e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg22535103	chr8:58192502	C8orf71	-0.85	-5.98	-0.52	3.9e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg06808227	chr14:105710500	BRF1	-1.04	-9.14	-0.68	1.11e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs34912216	0.580	rs4526264	chr7:4129962	T/C	cg03141780	chr7:4150753	SDK1	0.68	5.17	0.47	1.29e-6	Motion sickness;
THYM	cis	rs6754311	0.593	rs1446584	chr2:136419961	C/T	cg07169764	chr2:136633963	MCM6	-0.7	-5.67	-0.5	1.55e-7	Mosquito bite size;
THYM	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg19875535	chr5:140030758	IK	-0.58	-4.53	-0.42	1.69e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs12496230	0.953	rs1036972	chr3:66846010	C/T	cg17646820	chr3:66848679	NA	0.84	4.83	0.44	5.31e-6	Type 2 diabetes;
THYM	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1061377	0.861	rs35739603	chr4:39109558	T/C	cg24403649	chr4:39172243	NA	0.56	4.5	0.42	1.92e-5	Uric acid levels;
THYM	cis	rs2075230	0.778	rs114255812	chr17:7476549	T/C	cg16696476	chr17:8191344	RANGRF;SLC25A35	0.29	4.64	0.43	1.09e-5	Hormone measurements;
THYM	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03517284	chr6:25882590	NA	-0.74	-5.89	-0.52	5.89e-8	Blood metabolite levels;
THYM	cis	rs7072216	0.763	rs733346	chr10:100164325	A/C	cg03852570	chr10:100175106	PYROXD2	0.37	4.78	0.44	6.49e-6	Metabolite levels;
THYM	cis	rs1797081	1.000	rs1797081	chr10:16874565	A/G	cg23933602	chr10:16859644	RSU1	0.84	8.74	0.67	8.29e-14	Platelet distribution width;
THYM	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7000551	0.715	rs1879793	chr8:22313986	G/A	cg12081754	chr8:22256438	SLC39A14	0.64	5.74	0.51	1.14e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg23649088	chr2:200775458	C2orf69	-0.77	-6.18	-0.54	1.57e-8	Schizophrenia;
THYM	cis	rs886774	0.526	rs722689	chr7:107500335	G/A	cg23293999	chr7:106826042	HBP1	-0.59	-4.59	-0.43	1.36e-5	Ulcerative colitis;
THYM	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs936229	0.749	rs8042694	chr15:75225415	G/A	cg14664628	chr15:75095509	CSK	-0.66	-4.73	-0.44	7.74e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg23583168	chr7:148888333	NA	-1.02	-13.89	-0.82	1.32e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg26384229	chr12:38710491	ALG10B	-1.05	-10.43	-0.73	1.96e-17	Heart rate;
THYM	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg07061783	chr6:25882402	NA	-1.03	-9.86	-0.71	3.25e-16	Intelligence (multi-trait analysis);
THYM	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	6.02	0.53	3.29e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg15693483	chr7:1102177	C7orf50	0.5	5.65	0.5	1.66e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.69	-4.62	-0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs754466	0.580	rs2289309	chr10:79571108	C/T	cg17075019	chr10:79541650	NA	-0.69	-5.72	-0.51	1.26e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs16944158	0.636	rs716629	chr16:49642859	G/T	cg05126388	chr16:49670144	ZNF423	-0.62	-4.46	-0.42	2.25e-5	IgG glycosylation;
THYM	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs4455778	0.580	rs12718320	chr7:49109447	A/C	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2820651	1.000	rs55971690	chr10:1470059	A/G	cg02445968	chr10:1449028	ADARB2	-1.22	-6.14	-0.53	1.93e-8	Migraine with aura;
THYM	cis	rs7172809	0.573	rs59831220	chr15:77455246	A/G	cg22256960	chr15:77711686	NA	-0.65	-4.83	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg03060546	chr3:49711283	APEH	-0.68	-5.46	-0.49	3.87e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs4731207	0.596	rs11980178	chr7:124604660	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg17054759	chr22:49844102	NA	-0.52	-5.02	-0.46	2.42e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9486719	0.895	rs3734238	chr6:96996228	A/T	cg18709589	chr6:96969512	KIAA0776	-0.68	-4.71	-0.44	8.44e-6	Migraine;Coronary artery disease;
THYM	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg14581129	chr12:53358946	NA	-1.02	-7.51	-0.61	3.22e-11	Prostate cancer;
THYM	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg09455208	chr3:40491958	NA	0.47	4.87	0.45	4.39e-6	Renal cell carcinoma;
THYM	cis	rs3925075	1.000	rs9674009	chr16:31347541	C/A	cg02846316	chr16:31340340	ITGAM	0.57	5.99	0.52	3.79e-8	IgA nephropathy;
THYM	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg15693483	chr7:1102177	C7orf50	0.53	6.19	0.54	1.52e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11696501	0.688	rs6124727	chr20:44325623	T/C	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	cis	rs1823778	0.609	rs12968104	chr18:67650781	G/C	cg13164537	chr18:67624071	CD226	1.15	4.8	0.44	5.83e-6	Mean platelet volume;
THYM	cis	rs11809207	0.855	rs17257155	chr1:26526439	C/T	cg03844060	chr1:26490628	NA	-0.64	-4.7	-0.43	8.88e-6	Height;
THYM	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.93	6.05	0.53	2.87e-8	Platelet count;
THYM	cis	rs11650494	0.908	rs9907478	chr17:47395729	C/T	cg08112188	chr17:47440006	ZNF652	1.25	5.41	0.49	4.62e-7	Prostate cancer;
THYM	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	ch.11.42038R	chr11:967971	AP2A2	0.6	4.76	0.44	7e-6	Alzheimer's disease (late onset);
THYM	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg07424592	chr7:64974309	NA	1.15	5.47	0.49	3.58e-7	Diabetic kidney disease;
THYM	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg25566285	chr7:158114605	PTPRN2	0.95	12.11	0.78	5.62e-21	Calcium levels;
THYM	cis	rs6430585	0.528	rs309152	chr2:136657252	C/T	cg23851026	chr2:136556271	LCT	-0.65	-6.42	-0.55	5.3e-9	Corneal structure;
THYM	cis	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs12594515	1.000	rs8043291	chr15:45996247	T/A	cg01629716	chr15:45996671	NA	0.53	5.27	0.48	8.45e-7	Waist circumference;Weight;
THYM	cis	rs4688759	0.764	rs11716961	chr3:49908338	G/A	cg00383909	chr3:49044727	WDR6	1.1	5.47	0.49	3.66e-7	Blood protein levels;
THYM	cis	rs782590	0.643	rs13032503	chr2:55739093	C/T	cg18811423	chr2:55921094	PNPT1	-0.55	-5.11	-0.46	1.65e-6	Metabolic syndrome;
THYM	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg05717871	chr11:638507	DRD4	-0.69	-6.03	-0.53	3.1e-8	Systemic lupus erythematosus;
THYM	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03647317	chr4:187891568	NA	-0.83	-9.1	-0.68	1.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs765787	0.530	rs12439643	chr15:45529767	A/G	cg24006582	chr15:45444508	DUOX1	0.74	6.08	0.53	2.49e-8	Uric acid levels;
THYM	cis	rs11969893	0.850	rs9498414	chr6:101322976	C/T	cg12253828	chr6:101329408	ASCC3	1.13	6.13	0.53	1.96e-8	Economic and political preferences (immigration/crime);
THYM	cis	rs929596	0.517	rs3806592	chr2:234625936	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.86	-7.09	-0.59	2.32e-10	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg05340658	chr4:99064831	C4orf37	-0.54	-4.5	-0.42	1.91e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12711979	0.509	rs13005405	chr2:3826324	C/T	cg17052675	chr2:3827356	NA	-0.88	-13.79	-0.82	2.09e-24	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg24642844	chr7:1081250	C7orf50	-0.74	-5.18	-0.47	1.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10857712	0.551	rs12252576	chr10:135227244	T/C	cg19904058	chr10:135279010	LOC619207	-0.47	-4.87	-0.45	4.37e-6	Systemic lupus erythematosus;
THYM	cis	rs4660306	0.677	rs6429566	chr1:45941852	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.66	-4.74	-0.44	7.56e-6	Homocysteine levels;
THYM	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg15605315	chr1:45957053	TESK2	0.78	6.48	0.55	4.03e-9	High light scatter reticulocyte count;
THYM	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21659725	chr3:3221576	CRBN	0.88	9.51	0.7	1.84e-15	Intelligence (multi-trait analysis);
THYM	cis	rs1524976	0.941	rs1404550	chr3:65487427	G/C	cg16238336	chr3:65465873	MAGI1	1.05	6.05	0.53	2.81e-8	PR interval;
THYM	cis	rs6987853	0.787	rs2923436	chr8:42425298	G/A	cg09913449	chr8:42400586	C8orf40	1.06	11.6	0.77	6.75e-20	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg03651054	chr13:50194643	NA	0.47	4.46	0.42	2.25e-5	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs6032067	0.714	rs4359712	chr20:43884861	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.59	-6.64	-0.56	1.97e-9	Blood protein levels;
THYM	cis	rs1003719	0.788	rs2156076	chr21:38452634	G/T	cg01329690	chr21:38580129	DSCR9	0.36	4.97	0.45	2.96e-6	Eye color traits;
THYM	cis	rs9880211	0.948	rs9872178	chr3:135986438	T/G	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg10661904	chr17:79619235	PDE6G	-0.54	-4.79	-0.44	6.25e-6	Eye color traits;
THYM	cis	rs9583531	0.527	rs2391866	chr13:111363294	A/T	cg24331049	chr13:111365604	ING1	0.72	6.1	0.53	2.25e-8	Coronary artery disease;
THYM	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.96	8.0	0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs2295359	0.892	rs11209005	chr1:67618678	A/G	cg11235152	chr1:67600687	NA	0.69	5.83	0.51	7.49e-8	Psoriasis;
THYM	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg24596788	chr1:163392923	NA	-0.77	-7.15	-0.59	1.78e-10	Motion sickness;
THYM	cis	rs3017493	0.685	rs78711146	chr11:70671687	G/A	cg04110224	chr11:70508463	SHANK2	0.91	4.5	0.42	1.91e-5	Renal transplant outcome;
THYM	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs6964587	0.626	rs10266424	chr7:91503228	C/T	cg22709100	chr7:91322751	NA	-0.64	-4.72	-0.44	8.02e-6	Breast cancer;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg24916116	chr12:76424973	PHLDA1	1.26	7.07	0.59	2.6200000000000003e-10	Pulmonary function decline;
THYM	cis	rs4731207	0.596	rs1383751	chr7:124579721	A/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs17253792	0.822	rs75555677	chr14:56096429	G/A	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06634786	chr22:41940651	POLR3H	0.75	5.79	0.51	9.13e-8	Vitiligo;
THYM	cis	rs2273669	0.504	rs76110214	chr6:109494689	G/A	cg17117243	chr6:109341365	SESN1	-0.82	-4.8	-0.44	5.98e-6	Prostate cancer;
THYM	cis	rs9914988	0.945	rs9279	chr17:27187636	G/T	cg20469991	chr17:27169893	C17orf63	0.8	5.05	0.46	2.13e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg01819863	chr10:32635814	EPC1	1.04	6.64	0.56	1.9e-9	Sexual dysfunction (female);
THYM	cis	rs859767	0.501	rs10171371	chr2:135372159	C/T	cg12500956	chr2:135428796	TMEM163	-0.52	-4.6	-0.43	1.3e-5	Neuroticism;
THYM	cis	rs4427176	0.765	rs11249943	chr8:9607863	A/C	cg04228628	chr8:9413457	TNKS	0.75	4.5	0.42	1.92e-5	Mosquito bite size;
THYM	cis	rs4731207	0.570	rs1600738	chr7:124639549	G/T	cg05285228	chr7:124571219	POT1	-0.68	-5.1	-0.46	1.76e-6	Cutaneous malignant melanoma;
THYM	cis	rs921968	0.541	rs634590	chr2:219372768	C/A	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11671005	0.568	rs73068325	chr19:59079096	C/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.62	-4.95	-0.45	3.16e-6	Mean platelet volume;
THYM	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg18681998	chr4:17616180	MED28	-0.8	-6.76	-0.57	1.11e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4662945	0.737	rs4662950	chr2:130238492	A/G	cg05903289	chr2:130345205	NA	-0.56	-5.33	-0.48	6.55e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg26441486	chr22:50317300	CRELD2	-0.41	-6.04	-0.53	2.99e-8	Schizophrenia;
THYM	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg24838063	chr12:130822603	PIWIL1	0.92	6.97	0.58	4.2e-10	Menopause (age at onset);
THYM	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.67	-5.18	-0.47	1.22e-6	Tonsillectomy;
THYM	cis	rs7107174	1.000	rs11237480	chr11:78110385	C/A	cg19901956	chr11:77921274	USP35	-0.65	-5.34	-0.48	6.41e-7	Testicular germ cell tumor;
THYM	cis	rs11760633	0.607	rs7789703	chr7:1829899	T/C	cg23422044	chr7:1970798	MAD1L1	-0.63	-4.63	-0.43	1.14e-5	Coronary artery disease;
THYM	cis	rs3781426	1.000	rs7073257	chr10:126711633	C/T	cg04494136	chr10:126703576	CTBP2	-0.41	-5.78	-0.51	9.55e-8	Height;
THYM	cis	rs595982	0.527	rs55670257	chr19:49382654	G/A	cg15549821	chr19:49342101	PLEKHA4	-0.89	-4.76	-0.44	7.01e-6	Red cell distribution width;
THYM	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg07519536	chr6:26501950	BTN1A1	0.56	5.16	0.47	1.36e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7589342	0.831	rs6731173	chr2:106522928	A/G	cg14210321	chr2:106509881	NCK2	-0.79	-5.99	-0.52	3.75e-8	Addiction;
THYM	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg25072359	chr17:41440525	NA	0.65	4.55	0.42	1.57e-5	Menopause (age at onset);
THYM	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs295140	0.710	rs1729421	chr2:201080113	G/C	cg23649088	chr2:200775458	C2orf69	0.56	4.57	0.42	1.49e-5	QT interval;
THYM	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.05	-0.46	2.1e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg04234412	chr22:24373322	LOC391322	-0.92	-9.28	-0.69	5.85e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg20242066	chr2:136595261	LCT	0.51	5.5	0.49	3.14e-7	Mosquito bite size;
THYM	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg08885076	chr2:99613938	TSGA10	0.69	6.47	0.55	4.31e-9	Chronic sinus infection;
THYM	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	4.46	0.42	2.23e-5	Rheumatoid arthritis;
THYM	cis	rs4148883	0.675	rs116265877	chr4:100096896	G/A	cg12011299	chr4:100065546	ADH4	0.66	5.65	0.5	1.65e-7	Alcohol dependence;
THYM	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.17	-0.53	1.69e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs6435862	0.636	rs717548	chr2:215676905	G/A	cg04530015	chr2:215796436	ABCA12	0.55	5.22	0.47	1.06e-6	Neuroblastoma (high-risk);
THYM	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg05368731	chr17:41323189	NBR1	1.26	11.55	0.76	8.34e-20	Menopause (age at onset);
THYM	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg00071950	chr4:10020882	SLC2A9	0.74	7.32	0.6	7.8e-11	Bone mineral density;
THYM	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.59	-8.35	-0.65	5.54e-13	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs57590327	0.555	rs13099615	chr3:81729101	T/A	cg07356753	chr3:81810745	GBE1	-0.88	-6.79	-0.57	9.52e-10	Extraversion;
THYM	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.88	8.59	0.66	1.73e-13	Menarche (age at onset);
THYM	trans	rs10802346	0.545	rs10924568	chr1:246385482	C/A	cg13514129	chr1:39547527	MACF1	1.0	9.85	0.71	3.44e-16	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs9905704	0.918	rs2611783	chr17:56808530	A/G	cg12560992	chr17:57184187	TRIM37	0.67	4.68	0.43	9.59e-6	Testicular germ cell tumor;
THYM	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.3	0.69	5.17e-15	Cognitive test performance;
THYM	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg22508957	chr16:3507546	NAT15	-0.7	-7.05	-0.59	2.91e-10	Tuberculosis;
THYM	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg23649088	chr2:200775458	C2orf69	0.83	6.97	0.58	4.07e-10	Osteoporosis;
THYM	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg10518543	chr12:38710700	ALG10B	-0.58	-4.52	-0.42	1.81e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6669072	0.647	rs814544	chr1:91241693	G/A	cg08895590	chr1:91227319	NA	-0.68	-8.44	-0.65	3.46e-13	Cognitive function;
THYM	cis	rs7828089	0.792	rs4871995	chr8:22233726	A/C	cg12081754	chr8:22256438	SLC39A14	0.6	5.13	0.47	1.53e-6	Verbal declarative memory;
THYM	cis	rs921968	0.565	rs7599568	chr2:219607819	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06634786	chr22:41940651	POLR3H	0.84	6.24	0.54	1.21e-8	Vitiligo;
THYM	cis	rs62344088	0.590	rs55655653	chr5:303446	C/T	cg22857025	chr5:266934	NA	-1.31	-4.82	-0.44	5.47e-6	Asthma (childhood onset);
THYM	cis	rs236352	0.576	rs9380618	chr6:36853543	A/G	cg03410223	chr6:36853544	C6orf89	0.69	5.44	0.49	4.22e-7	Heart rate;
THYM	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg02725872	chr8:58115012	NA	-0.71	-5.22	-0.47	1.05e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg18305652	chr10:134549665	INPP5A	0.78	7.6	0.61	2.09e-11	Migraine;
THYM	cis	rs28595532	0.841	rs10019311	chr4:119785458	G/A	cg21605333	chr4:119757512	SEC24D	1.58	6.06	0.53	2.73e-8	Cannabis dependence symptom count;
THYM	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.45	7.4	0.6	5.4e-11	Obesity-related traits;
THYM	cis	rs1499972	0.668	rs4146338	chr3:117493964	C/T	cg07612923	chr3:117604196	NA	-1.28	-5.34	-0.48	6.37e-7	Schizophrenia;
THYM	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg16486109	chr11:613632	IRF7	0.51	5.7	0.5	1.34e-7	Systemic lupus erythematosus;
THYM	cis	rs4343996	1.000	rs7794279	chr7:3341806	A/G	cg21248987	chr7:3385318	SDK1	0.4	4.84	0.44	5.08e-6	Motion sickness;
THYM	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg00376283	chr12:123451042	ABCB9	0.78	6.23	0.54	1.26e-8	Platelet count;
THYM	cis	rs28829049	0.597	rs12740975	chr1:19437923	G/A	cg13387374	chr1:19411106	UBR4	0.67	4.96	0.45	3.08e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs17253792	0.822	rs75663029	chr14:56092385	T/C	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg00639195	chr15:79103007	ADAMTS7	-0.83	-5.99	-0.52	3.81e-8	Coronary artery disease or large artery stroke;
THYM	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg08999081	chr20:33150536	PIGU	0.76	6.7	0.57	1.47e-9	Glomerular filtration rate (creatinine);
THYM	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs728616	0.867	rs4520539	chr10:81740529	C/G	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg18252515	chr7:66147081	NA	-1.45	-8.88	-0.67	4.01e-14	Diabetic kidney disease;
THYM	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03517284	chr6:25882590	NA	0.74	5.83	0.51	7.58e-8	Blood metabolite levels;
THYM	cis	rs78456975	0.943	rs6721243	chr2:1580250	A/G	cg12573674	chr2:1569213	NA	-0.91	-4.8	-0.44	5.8e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs2282300	0.739	rs1222216	chr11:30346052	C/T	cg06241208	chr11:30344200	C11orf46	-0.78	-5.65	-0.5	1.64e-7	Morning vs. evening chronotype;
THYM	cis	rs2439831	0.681	rs1837960	chr15:43698602	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	6.89	0.58	5.93e-10	Lung cancer in ever smokers;
THYM	cis	rs7917772	0.582	rs10786696	chr10:104378134	A/G	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg23815491	chr16:72088622	HP	0.78	6.16	0.53	1.75e-8	Fibrinogen levels;
THYM	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	6.66	0.56	1.74e-9	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7614311	0.636	rs3774702	chr3:63856870	G/A	cg22134162	chr3:63841271	THOC7	-0.53	-6.63	-0.56	2.02e-9	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs3804749	0.966	rs9820435	chr3:122846881	C/T	cg26084141	chr3:122786895	PDIA5	0.47	4.88	0.45	4.27e-6	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg26924012	chr15:45694286	SPATA5L1	0.62	4.51	0.42	1.84e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs2688608	0.672	rs4065	chr10:75676464	C/T	cg02947784	chr10:75434997	AGAP5	0.52	4.83	0.44	5.12e-6	Inflammatory bowel disease;
THYM	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg13695892	chr22:41940480	POLR3H	0.85	6.16	0.53	1.72e-8	Vitiligo;
THYM	cis	rs10203711	1.000	rs13028091	chr2:239569723	C/T	cg14580085	chr2:239553406	NA	0.69	6.19	0.54	1.55e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.32	-0.48	7.02e-7	Monocyte percentage of white cells;
THYM	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.16	-0.47	1.37e-6	Chronic sinus infection;
THYM	cis	rs1403694	0.695	rs11919484	chr3:186432839	G/T	cg12454167	chr3:186435060	KNG1	0.5	6.72	0.57	1.35e-9	Blood protein levels;
THYM	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg08132940	chr7:1081526	C7orf50	-0.78	-5.24	-0.47	9.57e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.77	-6.22	-0.54	1.31e-8	Prostate cancer;
THYM	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg23791538	chr6:167370224	RNASET2	-0.78	-6.28	-0.54	1.02e-8	Crohn's disease;
THYM	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg10518543	chr12:38710700	ALG10B	-0.56	-4.46	-0.42	2.27e-5	Morning vs. evening chronotype;
THYM	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg26384229	chr12:38710491	ALG10B	-0.7	-5.48	-0.49	3.56e-7	Morning vs. evening chronotype;
THYM	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg22920501	chr2:26401640	FAM59B	-1.04	-9.82	-0.71	4.01e-16	Gut microbiome composition (summer);
THYM	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg03609598	chr5:56110824	MAP3K1	-0.85	-5.83	-0.51	7.62e-8	Initial pursuit acceleration;
THYM	cis	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs76878669	0.561	rs4930363	chr11:66169676	C/T	cg14263139	chr11:66104018	RIN1	-0.38	-4.75	-0.44	7.34e-6	Educational attainment (years of education);
THYM	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.98	4.89	0.45	4.07e-6	Initial pursuit acceleration;
THYM	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs2806561	0.894	rs598438	chr1:23531563	C/T	cg19743168	chr1:23544995	NA	0.68	7.55	0.61	2.67e-11	Height;
THYM	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.73	-4.82	-0.44	5.35e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg25588787	chr5:154027256	NA	0.9	4.6	0.43	1.32e-5	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs10751667	1.000	rs7395632	chr11:958789	C/T	cg01483505	chr11:975446	AP2A2	-0.6	-4.83	-0.44	5.22e-6	Alzheimer's disease (late onset);
THYM	cis	rs7617773	0.676	rs13060020	chr3:48372646	C/T	cg02219026	chr3:48282209	ZNF589	-0.67	-4.69	-0.43	9.05e-6	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9972944	0.692	rs8071561	chr17:63763434	C/T	cg07283582	chr17:63770753	CCDC46	-0.66	-5.11	-0.46	1.67e-6	Total body bone mineral density;
THYM	cis	rs2439831	0.618	rs999026	chr15:43690215	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	6.89	0.58	5.93e-10	Lung cancer in ever smokers;
THYM	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs2242663	0.531	rs2511225	chr11:66248431	A/C	cg22973812	chr11:65786500	CATSPER1	-0.57	-4.94	-0.45	3.38e-6	Bipolar disorder;
THYM	cis	rs4595586	0.545	rs12812762	chr12:39371141	T/C	cg13010199	chr12:38710504	ALG10B	0.68	5.03	0.46	2.3e-6	Morning vs. evening chronotype;
THYM	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg16850897	chr7:100343110	ZAN	0.63	5.52	0.49	2.88e-7	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
THYM	cis	rs71403859	0.502	rs12927456	chr16:71505706	A/G	cg08717414	chr16:71523259	ZNF19	-1.46	-7.26	-0.6	1.05e-10	Post bronchodilator FEV1;
THYM	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.77	4.62	0.43	1.21e-5	Gut microbiome composition (summer);
THYM	cis	rs4747241	0.810	rs7088870	chr10:74053313	T/C	cg07828833	chr10:74069493	NA	0.57	4.72	0.44	8.11e-6	Heschl's gyrus morphology;
THYM	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg23758822	chr17:41437982	NA	1.21	12.96	0.8	1.02e-22	Menopause (age at onset);
THYM	cis	rs9430161	0.579	rs6696575	chr1:11037136	G/A	cg27631724	chr1:11040367	C1orf127	0.68	6.42	0.55	5.25e-9	Ewing sarcoma;
THYM	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11644478	chr21:40555479	PSMG1	0.64	4.66	0.43	1.04e-5	Cognitive function;
THYM	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg25072359	chr17:41440525	NA	0.7	4.92	0.45	3.6e-6	Menopause (age at onset);
THYM	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-5.85	-0.51	6.81e-8	Neuroticism;
THYM	cis	rs986417	1.000	rs1313249	chr14:60881997	C/G	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg06108461	chr20:60628389	TAF4	-0.8	-6.51	-0.56	3.54e-9	Body mass index;
THYM	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg26513180	chr16:89883248	FANCA	0.5	4.61	0.43	1.26e-5	Vitiligo;
THYM	cis	rs4919694	1.000	rs74749600	chr10:104732996	T/C	cg04362960	chr10:104952993	NT5C2	1.14	6.92	0.58	5.38e-10	Arsenic metabolism;
THYM	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg15704280	chr7:45808275	SEPT13	-1.04	-13.56	-0.81	6.23e-24	Height;
THYM	cis	rs9814567	1.000	rs9864346	chr3:134312352	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.49	-0.66	2.74e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs1056053	0.514	rs3127332	chr6:166573438	G/A	cg11088901	chr6:166572345	T	-0.57	-4.86	-0.45	4.54e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg27535305	chr1:53392650	SCP2	-0.58	-6.56	-0.56	2.85e-9	Monocyte count;
THYM	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg18404041	chr3:52824283	ITIH1	-0.53	-5.23	-0.47	9.96e-7	Bipolar disorder;
THYM	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg14298792	chr15:30685198	CHRFAM7A	0.81	5.63	0.5	1.81e-7	Huntington's disease progression;
THYM	cis	rs6430585	1.000	rs6732236	chr2:136501509	T/G	cg04750100	chr2:136595281	LCT	0.53	5.1	0.46	1.72e-6	Corneal structure;
THYM	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg16060761	chr17:80687452	NA	0.6	4.8	0.44	5.89e-6	Glycated hemoglobin levels;
THYM	cis	rs10887741	0.532	rs2762522	chr10:89415541	A/G	cg13926569	chr10:89418898	PAPSS2	-0.62	-5.87	-0.52	6.33e-8	Exercise (leisure time);
THYM	cis	rs6032067	0.929	rs6017510	chr20:43831785	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	9.42	0.69	2.88e-15	Chronic sinus infection;
THYM	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	6.35	0.55	7.5e-9	Smoking behavior;
THYM	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg07061783	chr6:25882402	NA	-0.86	-7.58	-0.61	2.3e-11	Intelligence (multi-trait analysis);
THYM	cis	rs9470366	0.816	rs4331968	chr6:36623243	A/T	cg11920449	chr6:36645608	CDKN1A	-0.68	-5.29	-0.48	7.7e-7	QRS duration;
THYM	cis	rs9287719	0.649	rs58633964	chr2:10736382	T/G	cg03983476	chr2:10830698	NOL10	-0.56	-5.17	-0.47	1.31e-6	Prostate cancer;
THYM	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg02725872	chr8:58115012	NA	-1.1	-8.38	-0.65	4.69e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.99	-0.75	1.26e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs11574514	1.000	rs9938862	chr16:67723801	T/C	cg04582263	chr16:67973788	LCAT	0.94	4.45	0.42	2.31e-5	Crohn's disease;
THYM	cis	rs8078723	0.714	rs8070444	chr17:38151960	A/G	cg17467752	chr17:38218738	THRA	-0.8	-6.7	-0.57	1.46e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg17644776	chr2:200775616	C2orf69	0.8	4.82	0.44	5.52e-6	Schizophrenia;
THYM	cis	rs6430585	0.528	rs75524146	chr2:136725459	C/T	cg07169764	chr2:136633963	MCM6	1.19	11.38	0.76	1.91e-19	Corneal structure;
THYM	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg05932139	chr16:680872	WFIKKN1	-0.59	-4.84	-0.44	5.07e-6	Height;
THYM	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6032067	0.673	rs13042474	chr20:43893068	G/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.66	-5.9	-0.52	5.68e-8	Blood protein levels;
THYM	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.5	6.41	0.55	5.69e-9	Schizophrenia;
THYM	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs500891	0.525	rs6940284	chr6:84063926	T/G	cg08257003	chr6:84140564	ME1	0.58	4.66	0.43	1.01e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg11764359	chr7:65958608	NA	0.87	7.45	0.61	4.16e-11	Aortic root size;
THYM	cis	rs6076065	0.723	rs2424545	chr20:23390876	A/G	cg11657817	chr20:23433608	CST11	-0.31	-4.57	-0.42	1.48e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs4509693	1.000	rs6584394	chr10:102497258	G/A	cg24127310	chr10:102502104	NA	1.3	10.12	0.72	9.09e-17	Alzheimer's disease;
THYM	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg13607699	chr17:42295918	UBTF	-0.66	-5.46	-0.49	3.76e-7	Total body bone mineral density;
THYM	cis	rs308403	0.600	rs309361	chr4:123657978	A/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.69	4.71	0.44	8.35e-6	Blood protein levels;
THYM	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg04731861	chr2:219085781	ARPC2	-0.56	-5.31	-0.48	7.06e-7	Colorectal cancer;
THYM	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.74	-0.51	1.13e-7	Mean corpuscular volume;
THYM	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.41	0.55	5.47e-9	Tonsillectomy;
THYM	cis	rs3796352	0.667	rs34288509	chr3:52849493	G/C	cg07884673	chr3:53033167	SFMBT1	0.79	4.47	0.42	2.19e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2732480	0.500	rs2450986	chr12:48661688	G/A	cg21466736	chr12:48725269	NA	-0.53	-4.91	-0.45	3.78e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs2249694	0.919	rs2987794	chr10:135378612	G/T	cg20169779	chr10:135381914	SYCE1	0.56	4.47	0.42	2.16e-5	Obesity-related traits;
THYM	cis	rs4319547	0.656	rs7397299	chr12:122821649	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.77	-5.16	-0.47	1.37e-6	Body mass index;
THYM	cis	rs1198430	0.562	rs10917388	chr1:23803138	A/G	cg19827787	chr1:23763612	ASAP3	0.6	4.92	0.45	3.62e-6	Total cholesterol levels;
THYM	cis	rs6669072	0.679	rs3896732	chr1:91313672	A/G	cg08895590	chr1:91227319	NA	0.51	5.8	0.51	8.6e-8	Cognitive function;
THYM	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs981844	0.712	rs1037646	chr4:154738015	C/T	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs1483890	0.723	rs2007578	chr3:69408982	T/A	cg22125112	chr3:69402811	FRMD4B	0.54	6.85	0.58	7.21e-10	Resting heart rate;
THYM	cis	rs7226229	1.000	rs4133914	chr17:20922023	G/A	cg21263980	chr17:20946333	USP22	0.65	4.88	0.45	4.33e-6	Blood trace element (Se levels);
THYM	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.65	5.62	0.5	1.88e-7	Personality dimensions;
THYM	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22496380	chr5:211416	CCDC127	-1.33	-7.99	-0.63	3.21e-12	Breast cancer;
THYM	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg00981070	chr1:2046702	PRKCZ	0.48	5.92	0.52	5.19e-8	Height;
THYM	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg03909863	chr11:638404	DRD4	-0.82	-5.92	-0.52	5.2e-8	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg02524346	chr8:600233	NA	0.92	4.51	0.42	1.85e-5	IgG glycosylation;
THYM	cis	rs12579753	0.917	rs7306043	chr12:82191282	G/A	cg21231944	chr12:82153410	PPFIA2	-0.67	-5.09	-0.46	1.84e-6	Resting heart rate;
THYM	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4589258	0.933	rs2511313	chr11:90444789	A/C	cg26138821	chr11:89956704	CHORDC1	0.7	5.9	0.52	5.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12310956	0.532	rs10844715	chr12:33968444	A/G	cg06521331	chr12:34319734	NA	-0.88	-8.26	-0.65	8.51e-13	Morning vs. evening chronotype;
THYM	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg18305652	chr10:134549665	INPP5A	0.87	8.04	0.64	2.48e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9362426	1.000	rs1203156	chr6:88079694	A/G	cg10393598	chr6:87862264	NA	-0.61	-4.81	-0.44	5.68e-6	Depressive episodes in bipolar disorder;
THYM	cis	rs4072705	0.967	rs4287038	chr9:127369679	A/G	cg01786973	chr9:127249749	NR5A1	-0.35	-4.61	-0.43	1.24e-5	Menarche (age at onset);
THYM	cis	rs4731207	0.671	rs5022495	chr7:124444024	A/T	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg10803722	chr21:46713166	LOC642852	-0.39	-5.02	-0.46	2.42e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12765878	1.000	rs10883942	chr10:105651386	A/G	cg11005552	chr10:105648138	OBFC1	0.87	11.39	0.76	1.84e-19	Coronary artery disease;
THYM	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg08430604	chr3:44902960	MIR564;TMEM42	0.48	4.48	0.42	2.07e-5	Depressive symptoms;
THYM	cis	rs951188	0.688	rs78687952	chr2:150425462	C/T	cg17961725	chr2:150454027	NA	-0.97	-5.26	-0.47	8.85e-7	Daytime sleep phenotypes;
THYM	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg05802129	chr4:122689817	NA	-0.65	-5.26	-0.47	8.85e-7	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4638749	0.734	rs4676191	chr2:108861242	A/G	cg06795125	chr2:108905320	SULT1C2	-0.34	-4.58	-0.42	1.43e-5	Blood pressure;
THYM	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg06565975	chr8:143823917	SLURP1	-0.76	-8.91	-0.67	3.46e-14	Urinary tract infection frequency;
THYM	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs6840360	0.582	rs2724555	chr4:152341878	A/G	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.3	-0.48	7.43e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1374313	0.843	rs6740107	chr2:120151913	G/T	cg18093372	chr2:119607603	NA	-0.46	-4.7	-0.43	8.81e-6	Obesity-related traits;
THYM	cis	rs3750965	0.959	rs2253658	chr11:68856804	C/G	cg01403660	chr11:68851641	TPCN2	0.72	5.75	0.51	1.07e-7	Hair color;
THYM	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg19875535	chr5:140030758	IK	-0.63	-5.69	-0.5	1.43e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs10744422	1.000	rs921808	chr12:123323135	A/G	cg25930673	chr12:123319894	HIP1R	0.88	5.15	0.47	1.43e-6	Schizophrenia;
THYM	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg24578937	chr1:2090814	PRKCZ	0.78	7.92	0.63	4.42e-12	Height;
THYM	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5758511	0.680	rs5751243	chr22:42617177	T/C	cg08431931	chr22:42394659	WBP2NL	0.64	4.7	0.43	8.87e-6	Birth weight;
THYM	cis	rs4792901	0.802	rs55989313	chr17:41606248	T/C	cg21940313	chr17:41620911	ETV4	-0.5	-4.59	-0.43	1.37e-5	Dupuytren's disease;
THYM	cis	rs28595532	0.920	rs114093638	chr4:119729819	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg06112835	chr11:68658793	MRPL21	0.44	6.39	0.55	6.23e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg08859206	chr1:53392774	SCP2	-0.66	-7.55	-0.61	2.7e-11	Monocyte count;
THYM	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg26597838	chr10:835615	NA	1.09	6.27	0.54	1.06e-8	Eosinophil percentage of granulocytes;
THYM	cis	rs10203711	1.000	rs4331454	chr2:239594474	G/A	cg14580085	chr2:239553406	NA	0.66	5.88	0.52	5.96e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10489202	0.608	rs3753934	chr1:168074677	C/T	cg24449463	chr1:168025552	DCAF6	-0.81	-7.9	-0.63	4.92e-12	Schizophrenia;
THYM	cis	rs651907	0.737	rs9844218	chr3:101584983	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	-0.66	-4.62	-0.43	1.19e-5	Colorectal cancer;
THYM	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs12496230	0.909	rs13075691	chr3:66857626	T/A	cg17646820	chr3:66848679	NA	0.82	5.58	0.5	2.28e-7	Type 2 diabetes;
THYM	cis	rs7524258	0.868	rs11120885	chr1:7306755	C/G	cg07173049	chr1:7289937	CAMTA1	0.75	5.95	0.52	4.46e-8	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs12540874	0.895	rs4245556	chr7:50661661	C/T	cg00647317	chr7:50633725	DDC	0.31	4.47	0.42	2.2e-5	Systemic sclerosis;
THYM	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg24399712	chr22:39784796	NA	-0.93	-10.65	-0.74	6.66e-18	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7394190	0.748	rs1057410	chr10:75574079	G/A	cg02286717	chr10:75415704	SYNPO2L	-0.86	-4.6	-0.43	1.33e-5	Incident atrial fibrillation;
THYM	cis	rs600550	0.528	rs12805696	chr11:59832571	G/C	cg02771260	chr11:59836817	MS4A3	0.67	4.76	0.44	6.84e-6	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg09462578	chr12:12878428	APOLD1	-0.91	-5.39	-0.48	5.01e-7	Systemic lupus erythematosus;
THYM	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg15744005	chr10:104629667	AS3MT	-0.89	-8.53	-0.66	2.29e-13	Arsenic metabolism;
THYM	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg10589385	chr1:150898437	SETDB1	0.66	5.58	0.5	2.27e-7	Tonsillectomy;
THYM	cis	rs4788570	0.616	rs11075901	chr16:71790812	A/C	cg06353428	chr16:71660113	MARVELD3	1.34	8.5	0.66	2.61e-13	Intelligence (multi-trait analysis);
THYM	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg06028605	chr16:24865363	SLC5A11	-0.63	-5.18	-0.47	1.26e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17712092	chr4:129076599	LARP1B	0.88	7.33	0.6	7.61e-11	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs4072705	1.000	rs10760374	chr9:127495508	C/T	cg13476313	chr9:127244764	NR5A1	0.31	4.78	0.44	6.45e-6	Menarche (age at onset);
THYM	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.37	-0.48	5.64e-7	Total cholesterol levels;
THYM	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg13683864	chr3:40499215	RPL14	-1.03	-11.15	-0.75	5.91e-19	Renal cell carcinoma;
THYM	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22496380	chr5:211416	CCDC127	-1.28	-7.77	-0.62	9.06e-12	Breast cancer;
THYM	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg03929089	chr4:120376271	NA	-0.99	-12.81	-0.8	2.07e-22	Height;
THYM	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg04317338	chr11:64019027	PLCB3	0.86	5.89	0.52	5.78e-8	Mean platelet volume;
THYM	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg18681998	chr4:17616180	MED28	0.81	6.85	0.58	7.23e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9527	0.590	rs7912517	chr10:104905529	G/A	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs977987	0.843	rs62062568	chr16:75445324	T/C	cg03315344	chr16:75512273	CHST6	0.76	6.42	0.55	5.42e-9	Dupuytren's disease;
THYM	cis	rs12550646	0.612	rs13439740	chr8:41686017	C/T	cg12180191	chr8:41686706	ANK1	-0.44	-4.82	-0.44	5.49e-6	Reticulocyte fraction of red cells;Reticulocyte count;
THYM	cis	rs35883536	0.647	rs2783703	chr1:101040794	T/C	cg06223162	chr1:101003688	GPR88	0.83	7.06	0.59	2.67e-10	Monocyte count;
THYM	cis	rs11771526	1.000	rs17351142	chr7:32339843	T/G	cg27511599	chr7:32358540	NA	0.71	4.9	0.45	4e-6	Body mass index;
THYM	cis	rs4986811	1.000	rs2234582	chr11:32456694	C/A	cg13301003	chr11:32449254	WT1	0.66	4.92	0.45	3.59e-6	Rubella-specific interleukin-6 secretion;
THYM	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg08901578	chr4:187885870	NA	-0.63	-5.79	-0.51	8.9e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17401966	0.798	rs12408435	chr1:10323342	T/A	cg20482658	chr1:10539492	PEX14	0.38	4.55	0.42	1.61e-5	Hepatocellular carcinoma;
THYM	cis	rs3780378	0.682	rs7861763	chr9:5273194	C/T	cg02405213	chr9:5042618	JAK2	-0.63	-5.52	-0.49	2.94e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg06028605	chr16:24865363	SLC5A11	0.54	5.07	0.46	1.99e-6	Intelligence (multi-trait analysis);
THYM	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg15536230	chr21:44985092	HSF2BP	-0.42	-4.98	-0.46	2.78e-6	Mean corpuscular volume;
THYM	cis	rs7757969	0.500	rs9487733	chr6:112158215	A/G	cg08601457	chr6:112115117	FYN	0.4	4.88	0.45	4.29e-6	Schizophrenia;
THYM	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg19507638	chr5:93509721	C5orf36	-0.66	-4.64	-0.43	1.11e-5	Diabetic retinopathy;
THYM	cis	rs9790314	1.000	rs336569	chr3:161072346	T/G	cg04691961	chr3:161091175	C3orf57	-0.6	-5.27	-0.48	8.6e-7	Morning vs. evening chronotype;
THYM	cis	rs10499694	0.933	rs11575352	chr7:50594982	A/G	cg18232548	chr7:50535776	DDC	-0.62	-5.21	-0.47	1.11e-6	Body mass index;
THYM	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg17202724	chr17:61916730	SMARCD2	-0.47	-4.58	-0.43	1.43e-5	Prudent dietary pattern;
THYM	cis	rs7616559	0.849	rs4680333	chr3:156756362	C/G	cg15697575	chr3:156784781	NA	0.42	5.37	0.48	5.54e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg01579765	chr21:45077557	HSF2BP	-0.45	-7.29	-0.6	9.02e-11	Mean corpuscular volume;
THYM	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg26384229	chr12:38710491	ALG10B	0.92	7.33	0.6	7.45e-11	Bladder cancer;
THYM	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10905065	0.804	rs2380203	chr10:5810897	A/G	cg11519256	chr10:5708881	ASB13	0.49	4.76	0.44	6.95e-6	Menopause (age at onset);
THYM	cis	rs9486719	0.843	rs2499789	chr6:96844510	T/C	cg18709589	chr6:96969512	KIAA0776	0.75	4.49	0.42	2.02e-5	Migraine;Coronary artery disease;
THYM	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg07636037	chr3:49044803	WDR6	0.99	9.94	0.71	2.19e-16	Parkinson's disease;
THYM	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg07169764	chr2:136633963	MCM6	0.7	6.6	0.56	2.38e-9	Mosquito bite size;
THYM	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg13683864	chr3:40499215	RPL14	-1.05	-11.45	-0.76	1.35e-19	Renal cell carcinoma;
THYM	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg12310025	chr6:25882481	NA	0.72	5.82	0.51	7.87e-8	Blood metabolite levels;
THYM	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs877282	0.898	rs36064821	chr10:760952	C/T	cg10556349	chr10:835070	NA	-0.79	-5.05	-0.46	2.14e-6	Uric acid levels;
THYM	cis	rs2976388	0.935	rs2978979	chr8:143757286	C/A	cg06565975	chr8:143823917	SLURP1	-0.44	-4.94	-0.45	3.37e-6	Urinary tract infection frequency;
THYM	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg03388025	chr16:89894329	SPIRE2	0.53	4.51	0.42	1.86e-5	Vitiligo;
THYM	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17443541	0.507	rs4675705	chr2:200456952	T/C	cg03741458	chr2:200468445	NA	-0.8	-6.04	-0.53	3.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7072216	0.806	rs9804285	chr10:100169472	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs1008375	1.000	rs6819132	chr4:17689752	G/T	cg18681998	chr4:17616180	MED28	-0.85	-6.97	-0.58	4.15e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg16188243	chr19:2783719	SGTA	0.72	5.29	0.48	7.76e-7	Total cholesterol levels;
THYM	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg13866156	chr1:1669148	SLC35E2	0.71	7.23	0.6	1.24e-10	Body mass index;
THYM	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg00012203	chr2:219082015	ARPC2	0.87	8.53	0.66	2.33e-13	Colorectal cancer;
THYM	cis	rs651907	0.588	rs9881690	chr3:101663317	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	5.42	0.49	4.47e-7	Colorectal cancer;
THYM	cis	rs859767	0.741	rs6430529	chr2:135433023	G/T	cg12500956	chr2:135428796	TMEM163	-0.5	-5.13	-0.47	1.54e-6	Neuroticism;
THYM	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs548181	0.611	rs609200	chr11:125383808	G/A	cg03464685	chr11:125439445	EI24	-1.63	-8.97	-0.68	2.64e-14	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs989978	0.532	rs10883364	chr10:101287586	A/G	cg17888390	chr10:101282816	NA	-0.53	-5.14	-0.47	1.46e-6	Red blood cell count;
THYM	cis	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6032067	0.929	rs6032044	chr20:43819416	C/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg27068330	chr11:65405492	SIPA1	-0.95	-8.8	-0.67	6.03e-14	Acne (severe);
THYM	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg14820908	chr5:178986412	RUFY1	-0.65	-7.03	-0.59	3.1e-10	Lung cancer;
THYM	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg25036284	chr2:26402008	FAM59B	-0.76	-5.02	-0.46	2.44e-6	Gut microbiome composition (summer);
THYM	cis	rs12643440	0.538	rs4698538	chr4:17150001	T/G	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs9790314	0.586	rs1811483	chr3:161130900	A/G	cg03342759	chr3:160939853	NMD3	-0.84	-7.2	-0.59	1.39e-10	Morning vs. evening chronotype;
THYM	cis	rs7809950	1.000	rs2237672	chr7:107131563	A/C	cg23024343	chr7:107201750	COG5	-0.91	-8.24	-0.65	9.37e-13	Coronary artery disease;
THYM	cis	rs7582180	0.739	rs10195793	chr2:100925803	A/G	cg08017756	chr2:100939284	LONRF2	-0.73	-7.51	-0.61	3.21e-11	Intelligence (multi-trait analysis);
THYM	cis	rs835154	0.900	rs835153	chr5:14877474	A/G	cg02107279	chr5:14870749	ANKH	0.61	5.03	0.46	2.33e-6	Blood metabolite levels;
THYM	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg18132916	chr6:79620363	NA	-0.6	-5.35	-0.48	6.07e-7	Intelligence (multi-trait analysis);
THYM	cis	rs73086581	1.000	rs14047	chr20:3914215	G/A	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs1729951	0.575	rs10935214	chr3:136693485	G/A	cg21827317	chr3:136751795	NA	0.75	6.64	0.56	1.92e-9	Neuroticism;
THYM	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg15448220	chr1:150897856	SETDB1	0.88	7.49	0.61	3.44e-11	Melanoma;
THYM	cis	rs9810089	0.868	rs4630889	chr3:136278251	T/C	cg12473912	chr3:136751656	NA	0.62	5.22	0.47	1.05e-6	Gestational age at birth (child effect);
THYM	cis	rs7000551	0.671	rs13267107	chr8:22288098	C/G	cg12081754	chr8:22256438	SLC39A14	1.03	8.87	0.67	4.31e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg22709100	chr7:91322751	NA	0.7	5.62	0.5	1.94e-7	Breast cancer;
THYM	cis	rs17739794	0.517	rs28362022	chr8:794120	G/A	cg01971667	chr8:817044	NA	0.89	7.99	0.63	3.15e-12	Clozapine-induced cytotoxicity;
THYM	cis	rs9905704	0.918	rs444393	chr17:56709222	A/G	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.74e-6	Testicular germ cell tumor;
THYM	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg09035930	chr12:129282057	SLC15A4	-0.87	-11.01	-0.75	1.18e-18	Systemic lupus erythematosus;
THYM	cis	rs854765	0.822	rs1889014	chr17:17767165	C/T	cg04398451	chr17:18023971	MYO15A	0.8	7.01	0.58	3.37e-10	Total body bone mineral density;
THYM	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4731207	0.596	rs10252072	chr7:124578636	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs990171	1.000	rs3771170	chr2:102985980	T/A	cg13897122	chr2:103039542	IL18RAP	-0.4	-4.76	-0.44	6.87e-6	Lymphocyte counts;
THYM	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg27532560	chr4:187881888	NA	-0.96	-11.4	-0.76	1.72e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg04944784	chr2:26401820	FAM59B	-0.65	-4.95	-0.45	3.28e-6	Gut microbiome composition (summer);
THYM	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg06728252	chr6:26598149	ABT1	-0.43	-5.11	-0.46	1.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.714	rs16989820	chr20:43837659	G/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.64	-7.37	-0.6	6.28e-11	Blood protein levels;
THYM	cis	rs75920871	0.528	rs11216244	chr11:116912730	C/T	cg20608306	chr11:116969690	SIK3	-0.54	-6.01	-0.52	3.45e-8	Subjective well-being;
THYM	cis	rs9549260	0.755	rs55920113	chr13:41222112	C/T	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs4077515	0.967	rs4078099	chr9:139267533	G/A	cg14115884	chr9:139300582	SDCCAG3	0.7	6.74	0.57	1.23e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs2276498	1.000	rs6123336	chr20:52617703	C/T	cg23682609	chr20:52687365	BCAS1	0.63	4.87	0.45	4.4e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs2495707	0.706	rs2489013	chr10:102391740	A/G	cg11283427	chr10:102986306	NA	-0.56	-4.8	-0.44	5.9e-6	Body mass index;
THYM	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.74	-8.22	-0.64	1.01e-12	Prudent dietary pattern;
THYM	cis	rs988913	1.000	rs7764641	chr6:54835469	A/T	cg04690482	chr6:54711388	FAM83B	0.46	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.81	7.42	0.61	4.97e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg02782426	chr3:40428986	ENTPD3	0.51	4.5	0.42	1.95e-5	Renal cell carcinoma;
THYM	cis	rs909002	0.800	rs6703093	chr1:32093561	C/T	cg13919466	chr1:32135498	COL16A1	-0.5	-5.13	-0.47	1.51e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8067545	0.611	rs7212500	chr17:20045658	A/G	cg13482628	chr17:19912719	NA	0.54	4.49	0.42	2e-5	Schizophrenia;
THYM	cis	rs9649213	0.593	rs10953255	chr7:97923198	A/G	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.63	-0.43	1.17e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg21100191	chr22:23484243	RTDR1	-0.76	-6.62	-0.56	2.08e-9	Bone mineral density;
THYM	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg01616529	chr11:638424	DRD4	-0.78	-6.62	-0.56	2.16e-9	Systemic lupus erythematosus;
THYM	cis	rs12791968	1.000	rs11038240	chr11:45002878	A/G	cg11846598	chr11:44996168	LOC221122	0.91	7.7	0.62	1.28e-11	Inhibitory control;
THYM	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs9916302	0.821	rs11078916	chr17:37746307	T/C	cg00129232	chr17:37814104	STARD3	-0.8	-5.48	-0.49	3.54e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2039659	0.719	rs1753780	chr13:86220760	C/T	cg25308322	chr13:86268291	NA	0.6	4.65	0.43	1.08e-5	Blood osmolality (transformed sodium);
THYM	cis	rs77320796	1.000	rs77320796	chr1:40395195	A/G	cg05657805	chr1:40942785	ZNF642	0.78	4.55	0.42	1.58e-5	Platelet count;
THYM	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.88	0.63	5.43e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg03188948	chr7:1209495	NA	0.9	5.02	0.46	2.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg04025307	chr7:1156635	C7orf50	0.78	6.72	0.57	1.32e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4273100	0.605	rs28591622	chr17:19175317	A/G	cg25447019	chr17:19030144	GRAPL	-0.79	-6.24	-0.54	1.2e-8	Schizophrenia;
THYM	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-4.47	-0.42	2.2e-5	Hemoglobin concentration;
THYM	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg03433033	chr1:76189801	ACADM	-0.64	-5.88	-0.52	6.11e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs17122693	0.748	rs72681608	chr14:51116090	C/T	cg04730355	chr14:51134070	SAV1	0.96	6.13	0.53	2e-8	Cognitive performance;
THYM	trans	rs1973993	0.507	rs2759670	chr1:97002864	A/G	cg10631902	chr5:14652156	NA	0.64	7.0	0.58	3.53e-10	Weight;
THYM	cis	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.04	4.76	0.44	6.85e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs6032067	1.000	rs34885285	chr20:43804789	C/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg02953382	chr22:24373134	LOC391322	0.78	7.07	0.59	2.6e-10	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7267979	0.932	rs6107052	chr20:25530838	G/A	cg03522245	chr20:25566470	NINL	0.59	4.59	0.43	1.33e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg06532163	chr17:45867833	NA	0.61	6.07	0.53	2.67e-8	IgG glycosylation;
THYM	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg00801512	chr17:28996047	NA	-0.76	-5.02	-0.46	2.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg26721908	chr21:47610096	LSS	1.07	8.67	0.66	1.12e-13	Testicular germ cell tumor;
THYM	cis	rs72712511	0.571	rs3796627	chr4:140761277	C/T	cg15010390	chr4:140216957	NDUFC1	0.68	4.98	0.46	2.8e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg12564285	chr5:131593104	PDLIM4	-0.43	-4.66	-0.43	1.04e-5	Breast cancer;
THYM	cis	rs67460515	0.892	rs2100238	chr3:161058055	T/A	cg03342759	chr3:160939853	NMD3	-0.91	-7.85	-0.63	6.11e-12	Parkinson's disease;
THYM	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg23131131	chr22:24373011	LOC391322	-0.69	-6.12	-0.53	2.08e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg01579765	chr21:45077557	HSF2BP	-0.49	-8.05	-0.64	2.4e-12	Mean corpuscular volume;
THYM	cis	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg07460842	chr6:66804631	NA	1.08	8.22	0.64	1.03e-12	Exhaled nitric oxide output;
THYM	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg17063962	chr7:91808500	NA	0.98	7.77	0.62	9.01e-12	Breast cancer;
THYM	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	12.82	0.8	1.97e-22	Chronic sinus infection;
THYM	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg26384229	chr12:38710491	ALG10B	0.97	7.44	0.61	4.48e-11	Bladder cancer;
THYM	cis	rs2412459	0.635	rs2307105	chr15:40265799	A/G	cg16127683	chr15:40268777	EIF2AK4	0.59	5.16	0.47	1.37e-6	Response to haloperidol in psychosis;
THYM	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg16586182	chr3:47516702	SCAP	-0.57	-4.93	-0.45	3.45e-6	Colorectal cancer;
THYM	cis	rs7009516	0.766	rs13279289	chr8:24232368	A/G	cg01759110	chr8:24241694	ADAMDEC1	-0.54	-4.85	-0.45	4.81e-6	Hair greying;
THYM	cis	rs763014	0.931	rs2071980	chr16:626346	A/C	cg00908189	chr16:619842	PIGQ	1.02	9.27	0.69	6.03e-15	Height;
THYM	cis	rs1021993	0.597	rs10494922	chr1:209525430	A/G	cg24997231	chr1:209527535	NA	-0.6	-5.42	-0.49	4.43e-7	Gut microbiome composition (winter);
THYM	cis	rs13177918	0.734	rs6579791	chr5:149844003	G/A	cg14059543	chr5:149831962	NA	-0.72	-5.08	-0.46	1.92e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs9355610	0.927	rs2757041	chr6:167370532	C/G	cg23791538	chr6:167370224	RNASET2	0.84	7.45	0.61	4.35e-11	Graves' disease;
THYM	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs977987	0.843	rs12927562	chr16:75482860	G/A	cg03315344	chr16:75512273	CHST6	0.74	5.92	0.52	5.02e-8	Dupuytren's disease;
THYM	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg22535103	chr8:58192502	C8orf71	-0.98	-5.84	-0.51	7.38e-8	Developmental language disorder (linguistic errors);
THYM	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg15704280	chr7:45808275	SEPT13	-0.81	-8.14	-0.64	1.49e-12	Height;
THYM	cis	rs12142240	0.660	rs7520497	chr1:46824919	C/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs9677476	0.818	rs13431424	chr2:232060553	G/A	cg23338755	chr2:231921595	PSMD1	0.68	4.93	0.45	3.41e-6	Food antigen IgG levels;
THYM	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg08017756	chr2:100939284	LONRF2	-0.74	-7.65	-0.62	1.65e-11	Intelligence (multi-trait analysis);
THYM	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg02734326	chr4:10020555	SLC2A9	0.72	6.48	0.55	4.06e-9	Bone mineral density;
THYM	cis	rs4866334	1.000	rs116309900	chr5:18430285	G/T	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs714027	0.967	rs4823077	chr22:30545149	A/G	cg11564601	chr22:30592435	NA	-0.3	-5.45	-0.49	3.98e-7	Lymphocyte counts;
THYM	cis	rs4474465	0.850	rs4245460	chr11:78258147	G/C	cg19901956	chr11:77921274	USP35	0.68	5.07	0.46	1.96e-6	Alzheimer's disease (survival time);
THYM	cis	rs11225247	0.772	rs12275349	chr11:102237720	C/T	cg06323957	chr11:102217781	BIRC2	1.02	4.74	0.44	7.52e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs754466	0.580	rs10762763	chr10:79560803	C/G	cg17075019	chr10:79541650	NA	-0.57	-4.75	-0.44	7.34e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg17063962	chr7:91808500	NA	-1.09	-12.11	-0.78	5.75e-21	Breast cancer;
THYM	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg09029085	chr17:47094198	IGF2BP1	0.47	6.5	0.55	3.76e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs9611565	1.000	rs9611565	chr22:41767486	T/C	cg03806693	chr22:41940476	POLR3H	-0.97	-8.39	-0.65	4.53e-13	Vitiligo;
THYM	cis	rs9858542	0.537	rs35869135	chr3:49359102	A/G	cg00383909	chr3:49044727	WDR6	0.76	5.0	0.46	2.62e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg00071950	chr4:10020882	SLC2A9	-0.65	-6.1	-0.53	2.28e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs28374715	0.681	rs7162231	chr15:41591859	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.56	-0.83	6.14e-26	Ulcerative colitis;
THYM	cis	rs2070488	1.000	rs4147025	chr3:38456531	C/T	cg24069376	chr3:38537580	EXOG	0.66	6.49	0.55	3.91e-9	Electrocardiographic conduction measures;
THYM	cis	rs9790314	0.779	rs1609688	chr3:160877096	T/G	cg04691961	chr3:161091175	C3orf57	-0.59	-4.83	-0.44	5.28e-6	Morning vs. evening chronotype;
THYM	cis	rs2219968	0.676	rs11781543	chr8:78836409	C/T	cg00738934	chr8:78996279	NA	-0.7	-6.24	-0.54	1.23e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg04944784	chr2:26401820	FAM59B	-1.07	-8.43	-0.65	3.69e-13	Gut microbiome composition (summer);
THYM	cis	rs3960554	0.808	rs78478514	chr7:75655896	C/T	cg17325771	chr7:75508891	RHBDD2	-0.39	-4.48	-0.42	2.07e-5	Eotaxin levels;
THYM	cis	rs3809566	0.710	rs4075583	chr15:63340227	C/T	cg00520135	chr15:63333846	TPM1	-0.51	-4.62	-0.43	1.19e-5	Platelet count;
THYM	trans	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs1981331	0.609	rs3088287	chr21:48079669	G/A	cg23283320	chr21:48055893	PRMT2	1.27	7.94	0.63	3.95e-12	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg26384229	chr12:38710491	ALG10B	1.06	11.01	0.75	1.2e-18	Heart rate;
THYM	cis	rs4631830	0.900	rs10763576	chr10:51538813	A/T	cg10326726	chr10:51549505	MSMB	-0.6	-5.96	-0.52	4.28e-8	Prostate-specific antigen levels;
THYM	cis	rs76878669	0.515	rs12576299	chr11:66132286	T/C	cg18002602	chr11:66138449	SLC29A2	0.49	4.98	0.45	2.86e-6	Educational attainment (years of education);
THYM	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg17054759	chr22:49844102	NA	-0.52	-4.72	-0.44	8.24e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9914988	1.000	rs901975	chr17:27189774	A/G	cg20469991	chr17:27169893	C17orf63	0.8	5.05	0.46	2.13e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2797160	0.935	rs926855	chr6:126021782	A/G	cg16306078	chr6:126000798	NA	0.51	5.12	0.47	1.57e-6	Endometrial cancer;
THYM	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg13683864	chr3:40499215	RPL14	-0.75	-6.99	-0.58	3.84e-10	Renal cell carcinoma;
THYM	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg06850241	chr22:41845214	NA	-0.54	-4.85	-0.45	4.87e-6	Vitiligo;
THYM	cis	rs17534004	1.000	rs17534109	chr13:31470937	C/G	cg13251181	chr13:31481184	C13orf33	-0.55	-4.81	-0.44	5.78e-6	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs7833986	0.501	rs2719245	chr8:56894359	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	6.4	0.55	5.76e-9	Height;
THYM	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg24154853	chr7:158122151	PTPRN2	0.55	4.82	0.44	5.35e-6	Calcium levels;
THYM	cis	rs113835537	0.529	rs116867234	chr11:66209024	C/T	cg10315249	chr11:66235081	PELI3	0.44	4.72	0.44	8.05e-6	Airway imaging phenotypes;
THYM	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.08	-7.42	-0.61	4.86e-11	Schizophrenia;
THYM	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.53	4.64	0.43	1.13e-5	Lymphocyte counts;
THYM	cis	rs9972944	0.651	rs9909246	chr17:63791547	C/G	cg07283582	chr17:63770753	CCDC46	-0.62	-4.81	-0.44	5.63e-6	Total body bone mineral density;
THYM	cis	rs11645898	0.872	rs34832584	chr16:72162966	G/T	cg03805757	chr16:71968109	PKD1L3	-0.76	-5.44	-0.49	4.11e-7	Blood protein levels;
THYM	cis	rs10484885	0.878	rs17763820	chr6:90569634	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.87	-7.73	-0.62	1.13e-11	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg12863693	chr15:85201151	NMB	0.62	5.57	0.5	2.41e-7	Schizophrenia;
THYM	cis	rs7432375	0.901	rs4038587	chr3:136381368	A/C	cg21827317	chr3:136751795	NA	-0.59	-5.05	-0.46	2.11e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg00129232	chr17:37814104	STARD3	-0.71	-4.8	-0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg06521331	chr12:34319734	NA	-1.04	-10.16	-0.72	7.37e-17	Morning vs. evening chronotype;
THYM	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg16322792	chr1:120165303	ZNF697	0.92	11.46	0.76	1.34e-19	Systemic lupus erythematosus;
THYM	cis	rs3820068	0.608	rs9660255	chr1:16031891	T/G	cg13390004	chr1:15929781	NA	0.65	4.81	0.44	5.56e-6	Systolic blood pressure;
THYM	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg13770153	chr20:60521292	NA	-1.24	-10.97	-0.75	1.44e-18	Obesity-related traits;
THYM	cis	rs4227	0.565	rs858526	chr17:7499382	C/T	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	0.28	4.87	0.45	4.36e-6	IgA nephropathy;
THYM	cis	rs1775715	0.737	rs2799018	chr10:32202069	C/T	cg04359828	chr10:32216031	ARHGAP12	0.41	5.12	0.46	1.62e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg11245990	chr11:68621969	NA	0.57	7.2	0.59	1.41e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1971762	0.527	rs7300936	chr12:54030586	C/T	cg16917193	chr12:54089295	NA	0.76	7.41	0.61	5.15e-11	Height;
THYM	cis	rs4919694	1.000	rs7099987	chr10:104807926	C/T	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	cis	rs7216064	1.000	rs6504549	chr17:65888784	A/G	cg12091567	chr17:66097778	LOC651250	-0.72	-5.0	-0.46	2.59e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs611744	0.810	rs672161	chr8:109164182	G/A	cg21045802	chr8:109455806	TTC35	0.7	6.78	0.57	1.02e-9	Dupuytren's disease;
THYM	cis	rs8092503	0.536	rs12606521	chr18:52451215	A/G	cg07519816	chr18:53447596	NA	0.73	4.45	0.42	2.35e-5	Childhood body mass index;
THYM	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg00376283	chr12:123451042	ABCB9	0.93	7.74	0.62	1.08e-11	Platelet count;
THYM	cis	rs7681440	0.606	rs2737012	chr4:90745707	G/A	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg26384229	chr12:38710491	ALG10B	0.94	7.38	0.6	5.97e-11	Bladder cancer;
THYM	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg03676636	chr4:99064102	C4orf37	0.43	6.32	0.54	8.55e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10493773	0.510	rs11161645	chr1:86092872	T/C	cg17807903	chr1:86174739	ZNHIT6	0.41	4.66	0.43	1.01e-5	Urate levels in overweight individuals;
THYM	cis	rs7084402	0.967	rs7087998	chr10:60271531	A/G	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg02782426	chr3:40428986	ENTPD3	-0.57	-5.25	-0.47	9.31e-7	Renal cell carcinoma;
THYM	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg16680214	chr1:154839983	KCNN3	-0.48	-5.33	-0.48	6.64e-7	Prostate cancer;
THYM	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg19774624	chr17:42201019	HDAC5	-0.79	-6.43	-0.55	5.21e-9	Total body bone mineral density;
THYM	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg19418458	chr7:158789849	NA	-0.6	-5.67	-0.5	1.52e-7	Facial morphology (factor 20);
THYM	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs3862030	0.720	rs3740414	chr10:104232809	T/G	cg00122347	chr10:104236741	TMEM180	0.48	7.03	0.59	3.09e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs7267979	1.000	rs2424716	chr20:25423538	G/A	cg08601574	chr20:25228251	PYGB	0.59	4.81	0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg05084668	chr3:125655381	ALG1L	-0.81	-4.94	-0.45	3.39e-6	Blood pressure (smoking interaction);
THYM	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg08847533	chr14:75593920	NEK9	-0.97	-10.19	-0.72	6.35e-17	Height;
THYM	cis	rs28785552	0.796	rs8112908	chr19:53248041	C/T	cg10871876	chr19:53194124	ZNF83	0.78	5.91	0.52	5.38e-8	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg04315214	chr1:2043799	PRKCZ	0.69	5.6	0.5	2.06e-7	Height;
THYM	cis	rs175714	0.845	rs175702	chr14:75971133	G/T	cg01624173	chr14:75981868	NA	-0.73	-8.74	-0.67	7.99e-14	Lymphocyte counts;
THYM	cis	rs1971762	0.527	rs1247956	chr12:53963814	G/T	cg16917193	chr12:54089295	NA	-0.75	-6.9	-0.58	5.81e-10	Height;
THYM	cis	rs9534288	0.699	rs2897028	chr13:46656915	C/T	cg15192986	chr13:46630673	CPB2	-0.65	-4.57	-0.42	1.44e-5	Blood protein levels;
THYM	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	7.86	0.63	6.06e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg22875332	chr1:76189707	ACADM	-0.54	-5.07	-0.46	1.96e-6	Daytime sleep phenotypes;
THYM	cis	rs477692	0.569	rs10764887	chr10:131321719	A/T	cg05714579	chr10:131428358	MGMT	0.59	4.8	0.44	5.91e-6	Response to temozolomide;
THYM	cis	rs859767	0.812	rs842360	chr2:135347885	T/C	cg12500956	chr2:135428796	TMEM163	0.54	5.25	0.47	9.3e-7	Neuroticism;
THYM	cis	rs4631830	0.900	rs10763546	chr10:51536399	C/G	cg10326726	chr10:51549505	MSMB	-0.63	-6.37	-0.55	6.82e-9	Prostate-specific antigen levels;
THYM	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg12288994	chr5:1860383	NA	0.81	6.72	0.57	1.34e-9	Cardiovascular disease risk factors;
THYM	cis	rs12540874	1.000	rs12540874	chr7:50664922	A/G	cg18232548	chr7:50535776	DDC	-0.63	-4.85	-0.45	4.75e-6	Systemic sclerosis;
THYM	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg06221963	chr1:154839813	KCNN3	-0.82	-10.68	-0.74	5.75e-18	Prostate cancer;
THYM	cis	rs17174870	0.911	rs79058693	chr2:112758559	T/A	cg17354880	chr2:112658759	MERTK	-0.59	-4.63	-0.43	1.16e-5	Multiple sclerosis;
THYM	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg04876069	chr12:132293656	NA	-0.54	-5.03	-0.46	2.35e-6	Migraine;
THYM	cis	rs4455778	0.600	rs4282517	chr7:49115450	C/T	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs13315871	1.000	rs13327709	chr3:58408767	C/T	cg12435725	chr3:58293450	RPP14	-0.46	-4.93	-0.45	3.54e-6	Cholesterol, total;
THYM	cis	rs1018836	0.847	rs2285231	chr8:91545387	G/T	cg16814680	chr8:91681699	NA	-0.86	-7.92	-0.63	4.47e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs754466	0.651	rs2004382	chr10:79650351	G/C	cg17075019	chr10:79541650	NA	-0.65	-5.3	-0.48	7.61e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs28595532	0.920	rs115154776	chr4:119774803	A/G	cg14228332	chr4:119757509	SEC24D	1.59	5.76	0.51	1.02e-7	Cannabis dependence symptom count;
THYM	cis	rs7772486	0.720	rs1890171	chr6:146072114	T/C	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.54e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2235649	0.828	rs9925354	chr16:1849866	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.46	-4.95	-0.45	3.2e-6	Blood metabolite levels;
THYM	cis	rs2041895	0.509	rs10861674	chr12:107304037	A/G	cg13944111	chr12:107296891	NA	0.65	5.2	0.47	1.13e-6	Glaucoma (low intraocular pressure);
THYM	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg00898013	chr13:113819073	PROZ	0.88	8.78	0.67	6.63e-14	Platelet distribution width;
THYM	cis	rs10779751	0.734	rs2791658	chr1:11127871	A/G	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg13390004	chr1:15929781	NA	0.63	4.79	0.44	6.2e-6	Systolic blood pressure;
THYM	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.75	4.64	0.43	1.14e-5	Gut microbiome composition (summer);
THYM	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.88	8.41	0.65	4e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22857025	chr5:266934	NA	-1.5	-9.71	-0.71	6.9e-16	Breast cancer;
THYM	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg06481639	chr22:41940642	POLR3H	0.7	4.53	0.42	1.73e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	4.93	0.45	3.51e-6	Motion sickness;
THYM	cis	rs6665290	0.558	rs1319103	chr1:227219314	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.71	-6.1	-0.53	2.26e-8	Myeloid white cell count;
THYM	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs3126085	0.935	rs3126091	chr1:152307338	T/C	cg10321714	chr1:152280068	FLG	-0.66	-4.77	-0.44	6.61e-6	Atopic dermatitis;
THYM	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.43	1.27e-5	Breast cancer;
THYM	cis	rs1061377	0.965	rs3796510	chr4:39114929	G/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs9560113	0.959	rs4771756	chr13:112176083	T/G	cg10483660	chr13:112241077	NA	0.53	4.76	0.44	6.81e-6	Menarche (age at onset);
THYM	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.66	-0.43	1.05e-5	Eye color traits;
THYM	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.16	9.31	0.69	4.92e-15	Cognitive test performance;
THYM	trans	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg19862616	chr7:65841803	NCRNA00174	1.08	11.95	0.77	1.23e-20	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.34	-0.65	5.7e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs4866334	1.000	rs76883636	chr5:18488763	G/T	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs8013055	0.796	rs4075104	chr14:106000214	C/A	cg23356831	chr14:105996513	TMEM121	0.61	6.24	0.54	1.23e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs7731657	0.537	rs2188957	chr5:130253459	C/T	cg08523029	chr5:130500466	HINT1	0.82	5.88	0.52	6.03e-8	Fasting plasma glucose;
THYM	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.22	9.08	0.68	1.54e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6669072	0.679	rs3845562	chr1:91313811	A/C	cg08895590	chr1:91227319	NA	0.51	5.8	0.51	8.6e-8	Cognitive function;
THYM	cis	rs10929159	0.928	rs2317303	chr2:236921702	A/G	cg20128773	chr2:236923534	AGAP1	0.35	4.66	0.43	1.01e-5	Parkinson's disease;
THYM	cis	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg13443165	chr9:33130375	B4GALT1	-0.74	-5.44	-0.49	4.08e-7	IgG glycosylation;
THYM	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg25208724	chr1:156163844	SLC25A44	1.11	8.57	0.66	1.83e-13	Testicular germ cell tumor;
THYM	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg01570182	chr17:44337453	NA	-0.84	-9.31	-0.69	5.04e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7639513	0.767	rs13060705	chr3:12710016	C/A	cg23032965	chr3:12705835	RAF1	0.99	7.86	0.63	5.93e-12	Itch intensity from mosquito bite;
THYM	cis	rs611744	0.573	rs674580	chr8:109251690	C/G	cg21045802	chr8:109455806	TTC35	0.75	7.25	0.6	1.13e-10	Dupuytren's disease;
THYM	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22857025	chr5:266934	NA	-1.5	-9.71	-0.71	6.9e-16	Breast cancer;
THYM	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg10360139	chr7:1886902	MAD1L1	-0.61	-4.94	-0.45	3.33e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6980334	0.817	rs11982192	chr7:137795842	G/T	cg18769353	chr7:137028617	PTN	0.64	5.06	0.46	2.01e-6	Blood metabolite ratios;
THYM	cis	rs10203711	1.000	rs6731675	chr2:239566943	T/C	cg14580085	chr2:239553406	NA	0.68	6.18	0.54	1.6e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-4.71	-0.44	8.39e-6	Schizophrenia;
THYM	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg02070205	chr10:30722105	MAP3K8	-0.7	-6.15	-0.53	1.79e-8	Inflammatory bowel disease;
THYM	cis	rs17125944	0.615	rs12587286	chr14:53304751	C/T	cg00686598	chr14:53173677	PSMC6	1.12	5.11	0.46	1.68e-6	Alzheimer's disease (late onset);
THYM	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg01097406	chr16:89675127	NA	0.62	5.54	0.49	2.68e-7	Vitiligo;
THYM	cis	rs3772130	0.962	rs6776670	chr3:121543120	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	5.55	0.49	2.6e-7	Bipolar disorder;
THYM	cis	rs12019136	1	rs12019136	chr19:5835677	G/A	cg25387410	chr19:5844109	FUT3	-0.99	-5.13	-0.47	1.55e-6	Advanced age-related macular degeneration;IgG N-glycosylation phenotypes (multivariate analysis);
THYM	cis	rs11048434	0.736	rs7302417	chr12:9091116	G/T	cg13575925	chr12:9217583	LOC144571	0.52	4.94	0.45	3.32e-6	Sjögren's syndrome;
THYM	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.67	9.16	0.68	1.04e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg24818145	chr4:99064322	C4orf37	0.7	5.51	0.49	3.09e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9914988	0.943	rs4795457	chr17:27087929	C/T	cg20469991	chr17:27169893	C17orf63	-0.83	-4.93	-0.45	3.55e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs1891275	0.509	rs76313529	chr10:93443076	T/C	cg07889827	chr10:93443413	NA	-0.47	-4.55	-0.42	1.57e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg10792982	chr14:105748885	BRF1	0.72	7.38	0.6	5.93e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg10360139	chr7:1886902	MAD1L1	-0.62	-5.35	-0.48	6.09e-7	Bipolar disorder and schizophrenia;
THYM	trans	rs6089829	0.926	rs73921625	chr20:61660891	C/T	cg13615516	chr5:77269221	NA	-0.94	-7.75	-0.62	9.9e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12367572	0.580	rs1495034	chr12:45414203	C/T	cg03114573	chr12:45410052	DBX2	-0.58	-5.36	-0.48	5.69e-7	Gut microbiome composition (summer);
THYM	cis	rs11249608	0.548	rs11951738	chr5:178491228	G/A	cg01312482	chr5:178451176	ZNF879	-0.76	-6.07	-0.53	2.63e-8	Pubertal anthropometrics;
THYM	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9826463	0.582	rs73238155	chr3:142073145	G/A	cg20824294	chr3:142316082	PLS1	0.76	5.28	0.48	8.31e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs2732480	0.500	rs7966829	chr12:48615603	G/T	cg21466736	chr12:48725269	NA	-0.51	-4.63	-0.43	1.17e-5	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs2639990	1.000	rs2639990	chr18:72915551	T/C	cg18449964	chr18:72917101	ZADH2	1.32	5.98	0.52	3.95e-8	Vascular endothelial growth factor levels;
THYM	cis	rs904251	0.797	rs1757181	chr6:37485728	A/G	cg25019722	chr6:37503610	NA	0.63	5.38	0.48	5.33e-7	Cognitive performance;
THYM	cis	rs7572733	0.534	rs11890137	chr2:198816662	G/A	cg00792783	chr2:198669748	PLCL1	0.82	5.75	0.51	1.08e-7	Dermatomyositis;
THYM	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.76	-6.52	-0.56	3.37e-9	Intelligence (multi-trait analysis);
THYM	cis	rs741677	0.713	rs516382	chr17:486431	A/G	cg15660573	chr17:549704	VPS53	0.71	5.99	0.52	3.77e-8	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
THYM	cis	rs2688608	0.725	rs2633314	chr10:75683590	C/T	cg02947784	chr10:75434997	AGAP5	0.49	4.61	0.43	1.26e-5	Inflammatory bowel disease;
THYM	cis	rs1011018	0.955	rs6464220	chr7:139454258	A/G	cg06079564	chr7:139468310	HIPK2	-0.77	-6.04	-0.53	3.05e-8	Systolic blood pressure;
THYM	cis	rs10208649	1.000	rs72906711	chr2:54263602	G/A	cg04546899	chr2:54196757	PSME4	0.68	4.73	0.44	7.94e-6	Body mass index;
THYM	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg01570182	chr17:44337453	NA	-0.82	-9.2	-0.69	8.67e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2276314	0.553	rs1789501	chr18:33617060	T/A	cg19628046	chr18:33552617	C18orf21	-0.65	-4.83	-0.44	5.25e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg18032289	chr17:61959525	GH2	-0.47	-4.63	-0.43	1.16e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg18032289	chr17:61959525	GH2	-0.5	-4.87	-0.45	4.43e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg03188948	chr7:1209495	NA	0.68	4.73	0.44	7.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9911578	0.730	rs55759249	chr17:57027135	A/G	cg12560992	chr17:57184187	TRIM37	-0.75	-6.09	-0.53	2.38e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4940575	0.679	rs12606418	chr18:60833672	G/T	cg24349668	chr18:61441546	SERPINB7	0.74	4.58	0.42	1.44e-5	Breast cancer;
THYM	cis	rs4638749	0.677	rs6741222	chr2:108841082	A/G	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg24692254	chr21:30365293	RNF160	-0.84	-5.22	-0.47	1.04e-6	Cognitive test performance;
THYM	cis	rs35660623	1.000	rs13277664	chr8:10668259	G/A	cg12395012	chr8:11607386	GATA4	0.96	5.3	0.48	7.48e-7	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg15693483	chr7:1102177	C7orf50	0.53	6.19	0.54	1.52e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg25358565	chr5:93447407	FAM172A	-0.96	-6.78	-0.57	1.01e-9	Diabetic retinopathy;
THYM	cis	rs846111	1.000	rs846111	chr1:6279370	G/C	cg15892785	chr1:6309343	GPR153	-0.68	-5.55	-0.49	2.56e-7	QT interval;
THYM	cis	rs889398	0.771	rs8048550	chr16:69891759	T/G	cg09409435	chr16:70099608	PDXDC2	0.65	5.13	0.47	1.5e-6	Body mass index;
THYM	cis	rs919433	0.679	rs1598469	chr2:198515658	T/C	cg00792783	chr2:198669748	PLCL1	0.81	5.31	0.48	7.04e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7174348	1	rs7174348	chr15:78792439	G/A	cg18825076	chr15:78729989	IREB2	0.7	5.57	0.5	2.39e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg07424592	chr7:64974309	NA	1.06	5.48	0.49	3.47e-7	Diabetic kidney disease;
THYM	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg13390004	chr1:15929781	NA	0.61	4.63	0.43	1.15e-5	Systolic blood pressure;
THYM	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg08999081	chr20:33150536	PIGU	-0.74	-6.59	-0.56	2.42e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs79387448	0.745	rs7572284	chr2:103119423	C/A	cg09003973	chr2:102972529	NA	0.78	4.85	0.45	4.84e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs11225247	0.881	rs80320836	chr11:102257140	C/T	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg22920501	chr2:26401640	FAM59B	-1.05	-7.38	-0.6	6.07e-11	Gut microbiome composition (summer);
THYM	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.66	8.4	0.65	4.32e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9419702	0.614	rs9419567	chr10:133535149	C/G	cg04492858	chr10:133558786	NA	0.44	4.57	0.42	1.48e-5	Survival in rectal cancer;
THYM	cis	rs11089937	0.616	rs66651705	chr22:22534363	G/A	cg06866756	chr22:22471216	NA	-0.43	-4.71	-0.44	8.4e-6	Periodontitis (PAL4Q3);
THYM	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg15445000	chr17:37608096	MED1	-0.41	-5.04	-0.46	2.26e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg13695892	chr22:41940480	POLR3H	0.77	7.14	0.59	1.86e-10	Vitiligo;
THYM	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11096990	0.892	rs7680520	chr4:39220633	A/T	cg24403649	chr4:39172243	NA	-0.66	-5.67	-0.5	1.51e-7	Cognitive function;
THYM	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg08968635	chr6:28129556	ZNF389	0.71	5.58	0.5	2.28e-7	Parkinson's disease;
THYM	cis	rs7404928	0.678	rs10221006	chr16:23933233	G/A	cg26685404	chr16:23957272	PRKCB	0.61	7.0	0.58	3.53e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs7524258	0.868	rs2157499	chr1:7271472	C/T	cg07173049	chr1:7289937	CAMTA1	0.55	4.54	0.42	1.62e-5	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs4731207	0.662	rs35630355	chr7:124549333	T/A	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs113835537	0.529	rs7928882	chr11:66234765	C/T	cg24851651	chr11:66362959	CCS	0.63	4.49	0.42	2.01e-5	Airway imaging phenotypes;
THYM	cis	rs4891159	0.790	rs4891018	chr18:74127082	A/T	cg24786174	chr18:74118243	ZNF516	-0.89	-10.52	-0.73	1.28e-17	Longevity;
THYM	cis	rs55871839	0.708	rs12115074	chr8:59817473	C/T	cg07426533	chr8:59803705	TOX	-0.82	-7.24	-0.6	1.15e-10	Pneumonia;
THYM	cis	rs2731664	0.740	rs2731670	chr5:176848019	G/T	cg14098951	chr5:176875120	PRR7	-0.59	-5.32	-0.48	6.84e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1829883	0.898	rs2460684	chr5:98776329	C/T	cg08333243	chr5:99726346	NA	-0.55	-5.05	-0.46	2.15e-6	Hemostatic factors and hematological phenotypes;
THYM	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg22508957	chr16:3507546	NAT15	0.45	4.98	0.46	2.81e-6	Body mass index (adult);
THYM	cis	rs10158481	0.759	rs9438894	chr1:25488791	G/A	cg09264742	chr1:25757510	TMEM57	-0.63	-4.5	-0.42	1.89e-5	Urate levels in obese individuals;
THYM	cis	rs11599315	0.507	rs12220555	chr10:1341858	C/T	cg01270228	chr10:1369114	ADARB2	0.72	5.82	0.51	7.86e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24549020	chr5:56110836	MAP3K1	0.69	4.52	0.42	1.8e-5	Initial pursuit acceleration;
THYM	trans	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg25214090	chr10:38739885	LOC399744	0.86	7.53	0.61	2.86e-11	Corneal astigmatism;
THYM	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg18681998	chr4:17616180	MED28	0.81	6.87	0.58	6.5e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg18305652	chr10:134549665	INPP5A	0.83	7.46	0.61	3.98e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg27068330	chr11:65405492	SIPA1	0.95	8.8	0.67	6.03e-14	Acne (severe);
THYM	cis	rs58235267	0.656	rs13410889	chr2:63087778	T/C	cg17519650	chr2:63277830	OTX1	0.63	5.26	0.48	8.72e-7	Prostate-specific antigen levels (conditioned on lead SNPs);
THYM	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11890956	chr21:40555474	PSMG1	-0.94	-10.56	-0.73	1.04e-17	Cognitive function;
THYM	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg10523679	chr1:76189770	ACADM	0.86	6.36	0.55	6.99e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg24675658	chr1:53192096	ZYG11B	-0.67	-5.23	-0.47	1.03e-6	Monocyte count;
THYM	cis	rs4925114	0.532	rs11655029	chr17:17649172	T/C	cg04398451	chr17:18023971	MYO15A	0.66	5.36	0.48	5.91e-7	Body mass index;
THYM	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg07936489	chr17:37558343	FBXL20	0.83	5.69	0.5	1.41e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs62051538	0.602	rs4499252	chr16:31538982	A/G	cg10091996	chr16:31548640	NA	-0.5	-4.5	-0.42	1.96e-5	Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg10515332	chr4:99064459	C4orf37	0.58	4.62	0.43	1.21e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg23583168	chr7:148888333	NA	-0.99	-13.46	-0.81	9.71e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs17253792	0.731	rs74823888	chr14:56049800	T/C	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg08901578	chr4:187885870	NA	-0.63	-5.75	-0.51	1.07e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg19016782	chr12:123741754	C12orf65	0.69	4.47	0.42	2.18e-5	Neutrophil percentage of white cells;
THYM	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg10047753	chr17:41438598	NA	1.19	11.33	0.76	2.52e-19	Menopause (age at onset);
THYM	cis	rs7809950	0.822	rs2712228	chr7:107300340	A/C	cg23024343	chr7:107201750	COG5	0.73	6.3	0.54	9.29e-9	Coronary artery disease;
THYM	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg17644776	chr2:200775616	C2orf69	0.8	4.82	0.44	5.52e-6	Schizophrenia;
THYM	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg21211367	chr2:162094118	NA	0.66	5.4	0.48	4.85e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	trans	rs12810016	0.667	rs34347089	chr12:83322122	G/A	cg04578774	chr11:44332664	ALX4	1.22	6.87	0.58	6.7e-10	Coronary artery aneurysm in Kawasaki disease;
THYM	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg02187348	chr16:89574699	SPG7	0.7	4.57	0.42	1.49e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs4919687	0.550	rs7904396	chr10:104456838	C/T	cg04362960	chr10:104952993	NT5C2	0.6	4.88	0.45	4.3e-6	Colorectal cancer;
THYM	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg26384229	chr12:38710491	ALG10B	-0.73	-6.01	-0.52	3.42e-8	Morning vs. evening chronotype;
THYM	cis	rs7000551	0.675	rs2443503	chr8:22381850	A/G	cg12081754	chr8:22256438	SLC39A14	0.64	5.98	0.52	3.89e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs4372836	0.729	rs7567861	chr2:29035849	C/T	cg09522027	chr2:28974177	PPP1CB	-0.66	-5.08	-0.46	1.9e-6	Body mass index;
THYM	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.33	-5.11	-0.46	1.64e-6	Obesity-related traits;
THYM	trans	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg10856724	chr12:34555212	NA	-0.9	-8.53	-0.66	2.28e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1129187	0.702	rs2296805	chr6:42928758	T/G	cg02353165	chr6:42928485	GNMT	0.76	6.73	0.57	1.27e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs17001868	0.568	rs9607699	chr22:40737036	G/A	cg07138101	chr22:40742427	ADSL	0.94	5.71	0.51	1.3e-7	Mammographic density (dense area);
THYM	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg11845111	chr2:191398756	TMEM194B	-0.96	-8.42	-0.65	3.87e-13	Pulse pressure;
THYM	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg16524733	chr11:117070046	TAGLN	0.42	4.6	0.43	1.29e-5	Blood protein levels;
THYM	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg26384229	chr12:38710491	ALG10B	-0.91	-7.45	-0.61	4.34e-11	Bladder cancer;
THYM	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.7	5.34	0.48	6.41e-7	Tonsillectomy;
THYM	cis	rs3135718	0.967	rs1219651	chr10:123344501	G/A	cg15049101	chr10:123353889	FGFR2	0.61	5.38	0.48	5.24e-7	Estrogen receptor status in breast cancer;
THYM	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg06850241	chr22:41845214	NA	0.53	4.72	0.44	8.08e-6	Vitiligo;
THYM	cis	rs4936891	0.543	rs7102393	chr11:123877696	C/T	cg22125253	chr11:123886957	OR10G4	-0.57	-4.88	-0.45	4.28e-6	Male fertility;
THYM	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg10295955	chr4:187884368	NA	-1.18	-15.92	-0.85	1.46e-28	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs939574	1.000	rs1024131	chr2:220117458	G/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.32	5.96	0.52	4.29e-8	Platelet distribution width;
THYM	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg24733560	chr20:60626293	TAF4	0.62	6.35	0.55	7.47e-9	Body mass index;
THYM	cis	rs67460515	0.563	rs4521287	chr3:160812752	C/T	cg12349858	chr3:160822545	B3GALNT1	0.58	4.71	0.44	8.42e-6	Parkinson's disease;
THYM	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg23803603	chr1:2058230	PRKCZ	0.59	4.56	0.42	1.52e-5	Height;
THYM	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs7107174	1.000	rs4492844	chr11:78026516	A/G	cg02023728	chr11:77925099	USP35	0.65	5.92	0.52	5.06e-8	Testicular germ cell tumor;
THYM	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.67	-5.18	-0.47	1.22e-6	Tonsillectomy;
THYM	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg19729930	chr2:74357872	NA	1.25	12.57	0.79	6.31e-22	Gestational age at birth (maternal effect);
THYM	cis	rs7412746	0.611	rs36008098	chr1:150856806	G/A	cg10589385	chr1:150898437	SETDB1	0.6	4.74	0.44	7.37e-6	Melanoma;
THYM	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.0	0.63	2.98e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs2219968	1.000	rs13263569	chr8:78954480	A/G	cg00738934	chr8:78996279	NA	0.91	9.88	0.71	3.04e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg03983476	chr2:10830698	NOL10	-0.59	-5.75	-0.51	1.08e-7	Prostate cancer;
THYM	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg22709100	chr7:91322751	NA	0.71	5.58	0.5	2.22e-7	Breast cancer;
THYM	cis	rs4888262	0.526	rs7205258	chr16:74642539	C/T	cg01733217	chr16:74700730	RFWD3	0.82	8.54	0.66	2.2e-13	Testicular germ cell tumor;
THYM	cis	rs9443189	0.570	rs72888705	chr6:76403114	A/G	cg01950844	chr6:76311363	SENP6	1.05	6.66	0.56	1.73e-9	Prostate cancer;
THYM	cis	rs425535	0.817	rs447206	chr4:74849923	A/G	cg07868155	chr4:74864709	CXCL5	0.65	4.82	0.44	5.47e-6	Blood protein levels;
THYM	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg04267008	chr7:1944627	MAD1L1	-0.69	-6.45	-0.55	4.67e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs10832963	1.000	rs10128711	chr11:18632984	A/G	cg09201001	chr11:18656081	SPTY2D1	1.07	9.87	0.71	3.19e-16	Breast cancer;
THYM	cis	rs1056053	0.514	rs3127331	chr6:166572744	C/T	cg11088901	chr6:166572345	T	-0.58	-5.22	-0.47	1.06e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg22974920	chr21:40686053	BRWD1	-0.6	-4.73	-0.44	7.86e-6	Cognitive function;
THYM	trans	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17712092	chr4:129076599	LARP1B	0.87	7.23	0.6	1.2e-10	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg02463440	chr8:22132932	PIWIL2	0.59	5.21	0.47	1.11e-6	Hypertriglyceridemia;
THYM	cis	rs7100689	0.580	rs10736366	chr10:82207921	C/T	cg01528321	chr10:82214614	TSPAN14	0.72	5.72	0.51	1.22e-7	Post bronchodilator FEV1;
THYM	cis	rs6815814	0.898	rs1873195	chr4:38891173	C/T	cg06935464	chr4:38784597	TLR10	0.71	4.88	0.45	4.27e-6	Breast cancer;
THYM	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.45	0.49	3.91e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6665290	0.904	rs6664955	chr1:227183434	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg22709100	chr7:91322751	NA	-0.6	-4.8	-0.44	5.84e-6	Breast cancer;
THYM	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg20587970	chr11:113659929	NA	-1.37	-8.96	-0.68	2.79e-14	Hip circumference adjusted for BMI;
THYM	cis	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg07460842	chr6:66804631	NA	-0.9	-6.58	-0.56	2.6e-9	Exhaled nitric oxide output;
THYM	cis	rs1003719	0.680	rs7276569	chr21:38578207	C/T	cg01329690	chr21:38580129	DSCR9	-0.36	-5.0	-0.46	2.67e-6	Eye color traits;
THYM	cis	rs4851266	1.000	rs7566527	chr2:100811970	C/T	cg14675211	chr2:100938903	LONRF2	0.57	4.51	0.42	1.84e-5	Educational attainment;
THYM	cis	rs7119	0.717	rs12901100	chr15:77815558	T/A	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg02915803	chr1:1606292	LOC728661;CDK11B	0.63	5.32	0.48	6.98e-7	Body mass index;
THYM	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg26384229	chr12:38710491	ALG10B	-0.69	-5.24	-0.47	9.71e-7	Morning vs. evening chronotype;
THYM	cis	rs1784581	1.000	rs1784581	chr6:162401127	A/C	cg17173639	chr6:162384350	PARK2	-0.94	-8.79	-0.67	6.3e-14	Itch intensity from mosquito bite;
THYM	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10037758	0.522	rs257903	chr5:128315434	A/G	cg25555059	chr5:128301488	SLC27A6	-0.46	-4.84	-0.45	4.92e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4731207	0.698	rs34600520	chr7:124490938	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg11905131	chr22:24372483	LOC391322	-0.93	-9.84	-0.71	3.71e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg14349672	chr11:133703707	NA	-0.54	-4.74	-0.44	7.5e-6	Childhood ear infection;
THYM	cis	rs7100689	0.784	rs7081903	chr10:82162509	T/C	cg09936400	chr10:82049201	MAT1A	0.45	4.6	0.43	1.29e-5	Post bronchodilator FEV1;
THYM	cis	rs6430585	0.583	rs3769008	chr2:136586183	C/T	cg20242066	chr2:136595261	LCT	0.47	4.64	0.43	1.1e-5	Corneal structure;
THYM	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg25072359	chr17:41440525	NA	0.7	4.92	0.45	3.6e-6	Menopause (age at onset);
THYM	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg12000587	chr17:30186630	C17orf79	0.47	6.92	0.58	5.19e-10	Hip circumference adjusted for BMI;
THYM	cis	rs7191439	0.858	rs6500489	chr16:88772046	T/C	cg27087555	chr16:88793112	FAM38A	-1.34	-7.39	-0.6	5.78e-11	Plateletcrit;
THYM	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg07930192	chr7:1003750	NA	0.58	4.8	0.44	5.88e-6	Longevity;Endometriosis;
THYM	cis	rs3791406	0.929	rs3828202	chr2:240030122	A/G	cg11903188	chr2:239195602	PER2	-0.43	-4.59	-0.43	1.37e-5	Skin aging (microtopography measurement);
THYM	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg19016782	chr12:123741754	C12orf65	0.68	4.5	0.42	1.94e-5	Neutrophil percentage of white cells;
THYM	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.84	0.44	5.07e-6	Obesity-related traits;
THYM	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg15704280	chr7:45808275	SEPT13	-1.06	-15.39	-0.84	1.51e-27	Height;
THYM	cis	rs6723226	0.806	rs6543658	chr2:32718849	G/A	cg02381751	chr2:32503542	YIPF4	0.7	5.82	0.51	8.07e-8	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs2898681	1.000	rs6833096	chr4:53744275	G/C	cg03786743	chr4:53727781	RASL11B	0.44	4.78	0.44	6.49e-6	Optic nerve measurement (cup area);
THYM	cis	rs9787249	0.957	rs6670841	chr1:40220284	C/G	cg19912559	chr1:40204330	PPIE	0.64	4.87	0.45	4.44e-6	Blood protein levels;
THYM	cis	rs7119	0.679	rs12902698	chr15:77809010	A/C	cg27398640	chr15:77910606	LINGO1	-0.57	-5.69	-0.5	1.4e-7	Type 2 diabetes;
THYM	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg01416388	chr22:39784598	NA	-0.93	-8.2	-0.64	1.12e-12	Intelligence (multi-trait analysis);
THYM	cis	rs10489202	0.865	rs744168	chr1:168094079	G/T	cg24449463	chr1:168025552	DCAF6	-0.67	-4.97	-0.45	2.94e-6	Schizophrenia;
THYM	cis	rs28595532	0.920	rs114684527	chr4:119749252	G/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg10295955	chr4:187884368	NA	-1.19	-17.25	-0.87	5.06e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg10117171	chr1:25599238	RHD	0.68	4.87	0.45	4.52e-6	Erythrocyte sedimentation rate;
THYM	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg21773646	chr17:80085082	CCDC57	-0.34	-4.91	-0.45	3.76e-6	Life satisfaction;
THYM	cis	rs57994353	0.897	rs35526483	chr9:139364940	G/A	cg14115884	chr9:139300582	SDCCAG3	0.68	4.7	0.43	8.9e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs7705502	1.000	rs7705507	chr5:173358337	C/T	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs12893597	0.715	rs12892786	chr14:76833888	C/T	cg20290672	chr14:76816747	NA	-0.71	-5.73	-0.51	1.17e-7	Maximal oxygen uptake response;
THYM	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg10792982	chr14:105748885	BRF1	0.7	7.07	0.59	2.55e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2456568	0.835	rs1518578	chr11:93656854	G/T	cg17595323	chr11:93583763	C11orf90	-0.57	-5.59	-0.5	2.21e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7267979	1.000	rs2257988	chr20:25270003	T/C	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs877282	0.945	rs11253391	chr10:788752	G/A	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs9929218	0.520	rs1078621	chr16:68778996	C/T	cg01251360	chr16:68772225	CDH1	-0.31	-4.71	-0.44	8.34e-6	Colorectal cancer;
THYM	cis	rs2841233	0.681	rs2841235	chr14:105348733	G/T	cg16576083	chr14:105354267	KIAA0284	0.61	5.99	0.52	3.81e-8	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg00922110	chr4:57842668	C4orf14	-0.46	-5.31	-0.48	7.04e-7	Response to bleomycin (chromatid breaks);
THYM	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg18811423	chr2:55921094	PNPT1	-0.8	-7.17	-0.59	1.61e-10	Metabolic syndrome;
THYM	cis	rs9302690	1.000	rs74809791	chr16:57472860	G/T	cg27017172	chr16:57497170	POLR2C	0.82	4.88	0.45	4.29e-6	Blood protein levels;
THYM	cis	rs921968	0.643	rs539451	chr2:219426972	T/C	cg02176678	chr2:219576539	TTLL4	0.64	6.08	0.53	2.49e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6988636	1.000	rs62521826	chr8:124186668	C/T	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs537626	1.000	rs612611	chr11:69307463	A/G	cg08353955	chr11:69289746	NA	-1.03	-5.39	-0.48	5.04e-7	Breast cancer (early onset);
THYM	cis	rs11039798	0.920	rs61448762	chr11:48923756	G/A	cg24672777	chr11:48374446	OR4C45	-1.1	-6.15	-0.53	1.81e-8	Axial length;
THYM	cis	rs11645898	0.872	rs72787093	chr16:72190766	C/T	cg03805757	chr16:71968109	PKD1L3	-0.69	-5.1	-0.46	1.74e-6	Blood protein levels;
THYM	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg06221963	chr1:154839813	KCNN3	0.55	5.6	0.5	2.09e-7	Prostate cancer;
THYM	cis	rs892961	0.965	rs312856	chr17:75401598	A/G	cg11351908	chr17:75402473	SEPT9	0.56	5.63	0.5	1.81e-7	Airflow obstruction;
THYM	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	8.03	0.64	2.55e-12	Monocyte percentage of white cells;
THYM	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg04025307	chr7:1156635	C7orf50	0.64	5.73	0.51	1.2e-7	Longevity;Endometriosis;
THYM	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs7586879	0.616	rs876186	chr2:25125585	C/T	cg15423357	chr2:25149977	NA	0.7	7.74	0.62	1.03e-11	Body mass index;
THYM	cis	rs4389656	0.784	rs274723	chr5:6718563	A/G	cg10857441	chr5:6722123	POLS	-0.45	-4.48	-0.42	2.1e-5	Coronary artery disease;
THYM	cis	rs7616559	0.749	rs6765256	chr3:156753738	T/C	cg15697575	chr3:156784781	NA	0.41	5.28	0.48	8.25e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	7.84	0.63	6.39e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7189233	1.000	rs7189819	chr16:53536345	C/T	cg02965178	chr16:53538660	AKTIP	-0.65	-5.23	-0.47	1.01e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg07936489	chr17:37558343	FBXL20	-0.82	-5.61	-0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg02269571	chr22:50332266	NA	-0.7	-4.86	-0.45	4.62e-6	Schizophrenia;
THYM	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4866334	1.000	rs114675067	chr5:18448226	G/A	cg24599790	chr5:18972260	NA	-1.14	-4.67	-0.43	9.77e-6	IgG glycosylation;
THYM	cis	rs2777491	0.957	rs8027626	chr15:41711514	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.12	-12.75	-0.79	2.77e-22	Ulcerative colitis;
THYM	cis	rs2898681	0.770	rs62336795	chr4:53737772	G/A	cg00338735	chr4:53728038	RASL11B	0.51	4.54	0.42	1.62e-5	Optic nerve measurement (cup area);
THYM	cis	rs9788682	0.747	rs2568488	chr15:78736593	T/A	cg18825076	chr15:78729989	IREB2	-0.7	-5.36	-0.48	5.71e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg19875535	chr5:140030758	IK	-0.65	-5.46	-0.49	3.85e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs11089937	0.651	rs6001216	chr22:22538145	T/C	cg21401457	chr22:22472743	NA	0.58	4.88	0.45	4.28e-6	Periodontitis (PAL4Q3);
THYM	cis	rs6840360	0.693	rs28622593	chr4:152374080	A/G	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs990171	0.954	rs6543137	chr2:103065908	T/G	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.13	-0.47	1.5e-6	Lymphocyte counts;
THYM	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs12200560	0.505	rs211165	chr6:97068520	A/T	cg06623918	chr6:96969491	KIAA0776	0.76	5.78	0.51	9.56e-8	Coronary heart disease;
THYM	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg23711669	chr6:146136114	FBXO30	0.83	7.91	0.63	4.62e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11577318	0.853	rs1071849	chr1:26646726	A/G	cg00852783	chr1:26633632	UBXN11	0.69	5.68	0.5	1.44e-7	Granulocyte percentage of myeloid white cells;
THYM	cis	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg06521331	chr12:34319734	NA	-0.98	-8.82	-0.67	5.46e-14	Morning vs. evening chronotype;
THYM	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg11812906	chr14:75593930	NEK9	-0.8	-7.19	-0.59	1.48e-10	Height;
THYM	cis	rs4523957	0.614	rs7217108	chr17:2059408	G/C	cg16513277	chr17:2031491	SMG6	-0.93	-8.54	-0.66	2.22e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs909002	0.925	rs7524405	chr1:32108579	A/C	cg13919466	chr1:32135498	COL16A1	0.48	4.48	0.42	2.07e-5	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg16586182	chr3:47516702	SCAP	0.61	5.14	0.47	1.45e-6	Colorectal cancer;
THYM	cis	rs11118844	0.793	rs7516292	chr1:221942413	C/T	cg04222084	chr1:221915650	DUSP10	-0.98	-5.37	-0.48	5.65e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs6032067	0.516	rs16989916	chr20:43899514	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.39	-4.67	-0.43	9.85e-6	Blood protein levels;
THYM	cis	rs1797885	0.624	rs299643	chr3:12574512	G/T	cg05467012	chr3:12595696	NA	0.55	4.67	0.43	1.01e-5	Immature fraction of reticulocytes;
THYM	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.79	6.34	0.55	7.85e-9	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs9905704	0.918	rs304283	chr17:56785725	C/T	cg12560992	chr17:57184187	TRIM37	0.67	4.68	0.43	9.59e-6	Testicular germ cell tumor;
THYM	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg03609598	chr5:56110824	MAP3K1	-0.89	-6.07	-0.53	2.63e-8	Initial pursuit acceleration;
THYM	cis	rs644148	0.704	rs2686761	chr19:44989752	T/C	cg15540054	chr19:45004280	ZNF180	-0.67	-4.65	-0.43	1.06e-5	Personality dimensions;
THYM	cis	rs782590	0.967	rs62165173	chr2:55741666	T/C	cg03859395	chr2:55845619	SMEK2	0.66	6.08	0.53	2.51e-8	Metabolic syndrome;
THYM	cis	rs12530845	0.945	rs73725433	chr7:135313251	C/T	cg23117316	chr7:135346802	PL-5283	-0.64	-5.62	-0.5	1.93e-7	Red blood cell traits;
THYM	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg07747251	chr5:1868357	NA	0.68	5.86	0.52	6.67e-8	Cardiovascular disease risk factors;
THYM	cis	rs10186029	0.509	rs13387516	chr2:213945341	T/C	cg08319019	chr2:214017104	IKZF2	-0.68	-5.14	-0.47	1.44e-6	Systemic sclerosis;
THYM	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg13147721	chr7:65941812	NA	-0.94	-5.74	-0.51	1.12e-7	Diabetic kidney disease;
THYM	cis	rs13102973	0.538	rs13139929	chr4:135912516	C/A	cg14419869	chr4:135874104	NA	0.69	5.54	0.49	2.65e-7	Subjective well-being;
THYM	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg13114125	chr14:105738426	BRF1	-0.75	-5.85	-0.51	6.89e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg06713675	chr4:122721982	EXOSC9	-0.85	-9.54	-0.7	1.57e-15	Type 2 diabetes;
THYM	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	4.94	0.45	3.4e-6	Height;
THYM	cis	rs1003719	0.788	rs13050757	chr21:38465345	C/T	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg05856015	chr4:467047	ZNF721;ABCA11P	-0.41	-4.47	-0.42	2.15e-5	White blood cell count;
THYM	cis	rs6032067	0.777	rs62208385	chr20:43789823	A/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs3820068	0.603	rs7516453	chr1:15972558	C/G	cg05660106	chr1:15850417	CASP9	0.7	5.12	0.46	1.62e-6	Systolic blood pressure;
THYM	cis	rs11574514	1.000	rs1123072	chr16:67898797	G/A	cg04582263	chr16:67973788	LCAT	1.07	5.05	0.46	2.16e-6	Crohn's disease;
THYM	cis	rs9733	0.519	rs1134067	chr1:150721175	G/T	cg15448220	chr1:150897856	SETDB1	0.86	7.21	0.59	1.33e-10	Tonsillectomy;
THYM	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg08000102	chr2:233561755	GIGYF2	-0.67	-6.04	-0.53	3e-8	Coronary artery disease;
THYM	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg03806693	chr22:41940476	POLR3H	-1.11	-8.99	-0.68	2.33e-14	Vitiligo;
THYM	cis	rs6951245	0.515	rs73257955	chr7:1007014	G/A	cg02869364	chr7:1081709	C7orf50	-0.79	-5.0	-0.46	2.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg06634786	chr22:41940651	POLR3H	0.71	5.22	0.47	1.07e-6	Vitiligo;
THYM	cis	rs3750965	1.000	rs7937006	chr11:68843932	C/T	cg01403660	chr11:68851641	TPCN2	0.73	5.81	0.51	8.29e-8	Hair color;
THYM	cis	rs931127	0.658	rs4930305	chr11:65464000	A/G	cg17480646	chr11:65405466	SIPA1	0.81	7.26	0.6	1.07e-10	Systemic lupus erythematosus;
THYM	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg27286337	chr10:134555280	INPP5A	0.98	7.48	0.61	3.62e-11	Migraine;
THYM	cis	rs6087990	0.842	rs4911253	chr20:31352585	A/G	cg13636640	chr20:31349939	DNMT3B	0.91	9.05	0.68	1.75e-14	Ulcerative colitis;
THYM	cis	rs7582180	0.700	rs4851303	chr2:100962064	T/C	cg21926883	chr2:100939477	LONRF2	-0.62	-5.86	-0.52	6.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg03806693	chr22:41940476	POLR3H	1.07	8.61	0.66	1.55e-13	Vitiligo;
THYM	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2034650	0.563	rs11070270	chr15:40708422	C/T	cg12699599	chr15:40643142	PHGR1	0.57	5.24	0.47	9.73e-7	Interstitial lung disease;
THYM	cis	rs4792901	0.765	rs9894264	chr17:41577997	G/A	cg21940313	chr17:41620911	ETV4	-0.53	-5.03	-0.46	2.28e-6	Dupuytren's disease;
THYM	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg18681998	chr4:17616180	MED28	0.89	8.24	0.65	9.2e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4460079	0.531	rs6829301	chr4:114837769	A/G	cg02060584	chr4:113970739	ANK2	-0.56	-4.58	-0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	trans	rs11165623	0.792	rs1931180	chr1:96914049	C/T	cg10631902	chr5:14652156	NA	-0.64	-7.29	-0.6	9.18e-11	Hip circumference;Waist circumference;
THYM	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg17775962	chr7:1200435	ZFAND2A	0.5	5.55	0.49	2.63e-7	Longevity;Endometriosis;
THYM	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	5.43	0.49	4.33e-7	Obesity-related traits;
THYM	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg06009448	chr7:1102226	C7orf50	0.44	4.46	0.42	2.23e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	5.85	0.51	6.95e-8	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.33	9.84	0.71	3.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2859741	0.967	rs822854	chr1:37485788	A/G	cg09363841	chr1:37513479	NA	-0.68	-6.29	-0.54	9.86e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs995000	0.931	rs6690733	chr1:63060311	A/C	cg06896770	chr1:63153194	DOCK7	0.92	7.57	0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs3806843	0.766	rs702397	chr5:140050265	A/G	cg19875535	chr5:140030758	IK	-0.64	-5.5	-0.49	3.19e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs10791323	0.628	rs4937838	chr11:133733406	T/C	cg14349672	chr11:133703707	NA	-0.52	-4.88	-0.45	4.32e-6	Childhood ear infection;
THYM	cis	rs6918586	0.658	rs198843	chr6:26110314	A/T	cg03264133	chr6:25882463	NA	0.64	4.94	0.45	3.41e-6	Schizophrenia;
THYM	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg01097406	chr16:89675127	NA	-0.57	-4.69	-0.43	9.13e-6	Vitiligo;
THYM	cis	rs6815814	0.861	rs17616434	chr4:38812876	T/C	cg25840354	chr4:38784158	TLR10	0.56	4.51	0.42	1.85e-5	Breast cancer;
THYM	cis	rs55728055	0.661	rs55648708	chr22:32032062	G/A	cg01338084	chr22:32026380	PISD	1.5	6.36	0.55	6.89e-9	Age-related hearing impairment;
THYM	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg04447362	chr2:237654635	NA	0.48	4.49	0.42	2.03e-5	Prostate cancer;
THYM	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg18105134	chr13:113819100	PROZ	-0.99	-9.17	-0.69	9.65e-15	Platelet distribution width;
THYM	cis	rs7186831	1	rs7186831	chr16:75473155	G/A	cg03315344	chr16:75512273	CHST6	0.74	5.92	0.52	5.08e-8	Chronic obstructive pulmonary disease;
THYM	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.85	-7.75	-0.62	1.01e-11	Schizophrenia;
THYM	cis	rs12530845	0.887	rs4492299	chr7:135315690	T/G	cg23117316	chr7:135346802	PL-5283	-0.68	-6.01	-0.53	3.37e-8	Red blood cell traits;
THYM	cis	rs10979	1.000	rs9496678	chr6:143896664	C/A	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg02725872	chr8:58115012	NA	-0.9	-5.24	-0.47	9.85e-7	Developmental language disorder (linguistic errors);
THYM	trans	rs9951602	1.000	rs9951602	chr18:76657779	C/T	cg02800362	chr5:177631904	HNRNPAB	1.23	7.13	0.59	1.91e-10	Obesity-related traits;
THYM	cis	rs17125944	0.686	rs8003683	chr14:53366605	G/T	cg00686598	chr14:53173677	PSMC6	1.01	4.55	0.42	1.56e-5	Alzheimer's disease (late onset);
THYM	cis	rs3947	0.855	rs1293327	chr8:11694986	G/A	cg26752888	chr8:11627280	NEIL2	-0.71	-4.67	-0.43	9.86e-6	Blood protein levels;
THYM	cis	rs17407555	0.683	rs7435841	chr4:10278552	C/T	cg00071950	chr4:10020882	SLC2A9	0.52	4.9	0.45	3.98e-6	Schizophrenia (age at onset);
THYM	cis	rs71403859	0.502	rs71403849	chr16:71484365	T/C	cg08717414	chr16:71523259	ZNF19	-1.2	-5.93	-0.52	4.82e-8	Post bronchodilator FEV1;
THYM	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg06108461	chr20:60628389	TAF4	-1.07	-9.18	-0.69	9.42e-15	Body mass index;
THYM	cis	rs11031096	0.711	rs4910891	chr11:4153408	A/G	cg22027985	chr11:4115532	RRM1	-0.53	-5.45	-0.49	4.02e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs3096299	0.606	rs2965960	chr16:89541795	G/A	cg06640241	chr16:89574553	SPG7	0.78	5.19	0.47	1.18e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg23711669	chr6:146136114	FBXO30	0.87	8.32	0.65	6.5e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs870825	0.746	rs1107908	chr4:185620113	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	5.45	0.49	3.89e-7	Lung cancer in ever smokers;
THYM	cis	rs6430585	0.528	rs79826902	chr2:136670419	G/A	cg23851026	chr2:136556271	LCT	0.77	6.81	0.57	8.95e-10	Corneal structure;
THYM	cis	rs62435770	1.000	rs62433642	chr6:169540712	T/A	cg07652237	chr6:170125491	PHF10	0.51	4.5	0.42	1.96e-5	Loneliness;
THYM	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg16031515	chr1:205743344	RAB7L1	-0.68	-6.75	-0.57	1.14e-9	Menarche (age at onset);
THYM	cis	rs868036	0.718	rs7170185	chr15:68117300	T/A	cg26545918	chr15:68124484	LBXCOR1	0.5	4.45	0.42	2.31e-5	Restless legs syndrome;
THYM	cis	rs7267979	1.000	rs2258769	chr20:25276680	G/C	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs208520	0.690	rs851467	chr6:66802721	A/G	cg07460842	chr6:66804631	NA	-1.06	-7.93	-0.63	4.23e-12	Exhaled nitric oxide output;
THYM	cis	rs1003719	0.788	rs4817843	chr21:38447040	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg19346786	chr7:2764209	NA	-0.55	-4.74	-0.44	7.61e-6	Height;
THYM	cis	rs754466	0.512	rs67607593	chr10:79649050	A/G	cg17075019	chr10:79541650	NA	-0.67	-5.49	-0.49	3.34e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg11845111	chr2:191398756	TMEM194B	-0.96	-6.77	-0.57	1.06e-9	Diastolic blood pressure;
THYM	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg08901578	chr4:187885870	NA	-0.68	-6.56	-0.56	2.86e-9	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs7952251	0.718	rs10891380	chr11:112397104	C/T	cg14154186	chr1:204970430	NFASC	-0.7	-7.23	-0.6	1.24e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg20503657	chr10:835505	NA	1.17	8.29	0.65	7.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs1345301	1.000	rs1345302	chr2:102873369	A/G	cg03938978	chr2:103052716	IL18RAP	-0.62	-6.09	-0.53	2.36e-8	Waist circumference;
THYM	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg23851026	chr2:136556271	LCT	-0.55	-5.56	-0.5	2.46e-7	Mosquito bite size;
THYM	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg17211192	chr8:82754475	SNX16	0.82	7.41	0.61	5.09e-11	Diastolic blood pressure;
THYM	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.44	-4.79	-0.44	6.14e-6	Schizophrenia;
THYM	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg24818145	chr4:99064322	C4orf37	0.74	5.93	0.52	4.8e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg25251562	chr2:3704773	ALLC	0.79	5.7	0.5	1.33e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs208520	0.690	rs207077	chr6:66769855	A/C	cg07460842	chr6:66804631	NA	-1.11	-8.11	-0.64	1.73e-12	Exhaled nitric oxide output;
THYM	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg13289132	chr10:30722225	MAP3K8	0.57	4.86	0.45	4.56e-6	Inflammatory bowel disease;
THYM	cis	rs80319144	1.000	rs112805856	chr2:159266371	G/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	5.43	0.49	4.39e-7	Rheumatoid arthritis;
THYM	cis	rs2239547	0.522	rs9865094	chr3:52985319	G/C	cg11645453	chr3:52864694	ITIH4	-0.29	-4.68	-0.43	9.49e-6	Schizophrenia;
THYM	cis	rs61931739	0.963	rs12298565	chr12:34036188	C/T	cg10856724	chr12:34555212	NA	0.63	5.33	0.48	6.57e-7	Morning vs. evening chronotype;
THYM	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg02136620	chr5:178986620	RUFY1	0.47	4.62	0.43	1.21e-5	Lung cancer;
THYM	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg15549821	chr19:49342101	PLEKHA4	-0.96	-5.51	-0.49	3e-7	Red cell distribution width;
THYM	cis	rs6748734	0.625	rs10172404	chr2:241820906	T/C	cg09990169	chr2:241835740	C2orf54	-0.32	-5.16	-0.47	1.33e-6	Urinary metabolites;
THYM	cis	rs9486719	1.000	rs2971608	chr6:97039757	T/C	cg06623918	chr6:96969491	KIAA0776	-0.78	-5.55	-0.49	2.61e-7	Migraine;Coronary artery disease;
THYM	cis	rs7705042	0.865	rs6882226	chr5:141503870	T/A	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs1059611	0.515	rs28413168	chr8:19674725	G/C	cg03894339	chr8:19674705	INTS10	0.98	7.67	0.62	1.49e-11	Lipid metabolism phenotypes;
THYM	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg24308560	chr3:49941425	MST1R	-0.76	-6.48	-0.55	4.12e-9	Intelligence (multi-trait analysis);
THYM	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg06191203	chr2:152266755	RIF1	-0.71	-5.35	-0.48	6.01e-7	Lung cancer;
THYM	cis	rs818427	0.710	rs187075	chr5:112164238	C/T	cg04614008	chr5:112630677	MCC	-0.63	-4.46	-0.42	2.29e-5	Total body bone mineral density;
THYM	cis	rs9633740	1.000	rs6586028	chr10:82253984	C/T	cg01528321	chr10:82214614	TSPAN14	0.94	4.5	0.42	1.9e-5	Post bronchodilator FEV1;
THYM	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg02551604	chr5:131831745	NA	0.81	6.25	0.54	1.17e-8	Asthma (sex interaction);
THYM	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg00129232	chr17:37814104	STARD3	-0.71	-4.8	-0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4242434	0.927	rs11136092	chr8:22466488	T/G	cg14690197	chr8:22456421	C8orf58	0.55	5.1	0.46	1.71e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs877282	1.000	rs12775643	chr10:773242	G/A	cg10556349	chr10:835070	NA	-0.69	-4.81	-0.44	5.75e-6	Uric acid levels;
THYM	cis	rs72712511	0.533	rs3796628	chr4:140761997	A/C	cg15010390	chr4:140216957	NDUFC1	-0.62	-4.67	-0.43	9.92e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg23758822	chr17:41437982	NA	1.23	13.11	0.8	4.87e-23	Menopause (age at onset);
THYM	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg02551604	chr5:131831745	NA	0.84	6.68	0.57	1.59e-9	Asthma (sex interaction);
THYM	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg13319975	chr6:146136371	FBXO30	-0.67	-5.2	-0.47	1.14e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg13695892	chr22:41940480	POLR3H	0.93	7.09	0.59	2.34e-10	Vitiligo;
THYM	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg23815491	chr16:72088622	HP	-0.7	-5.42	-0.49	4.45e-7	Fibrinogen levels;
THYM	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg07936489	chr17:37558343	FBXL20	0.81	5.85	0.51	6.81e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs9563576	0.778	rs9569819	chr13:58688382	T/C	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.67	4.97	0.45	2.97e-6	Body mass index;
THYM	cis	rs6554196	0.525	rs2192159	chr4:55505529	C/G	cg18836493	chr4:55524333	KIT	-0.54	-4.58	-0.42	1.43e-5	Monocyte count;
THYM	cis	rs870825	0.929	rs1405939	chr4:185591444	C/T	cg04058563	chr4:185651563	MLF1IP	0.9	6.08	0.53	2.5e-8	Blood protein levels;
THYM	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	4.82	0.44	5.5e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4769475	1.000	rs4770928	chr13:26730858	T/C	cg13319468	chr13:27597730	NA	-0.6	-4.65	-0.43	1.06e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs11166927	0.594	rs7828992	chr8:140826670	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.73	-6.56	-0.56	2.79e-9	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg07460842	chr6:66804631	NA	0.92	5.5	0.49	3.15e-7	Exhaled nitric oxide levels;
THYM	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg00024416	chr22:24240387	NA	0.68	7.08	0.59	2.47e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg18681998	chr4:17616180	MED28	-0.81	-6.85	-0.58	7.23e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4638749	0.953	rs12475415	chr2:108860477	G/A	cg23163573	chr2:108905468	SULT1C2	-0.29	-4.47	-0.42	2.15e-5	Blood pressure;
THYM	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg10515332	chr4:99064459	C4orf37	0.65	5.22	0.47	1.06e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9914578	1.000	rs10459917	chr17:2009752	G/T	cg16513277	chr17:2031491	SMG6	0.7	4.59	0.43	1.38e-5	Body mass index;
THYM	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg16928487	chr17:17741425	SREBF1	0.5	4.92	0.45	3.67e-6	Total body bone mineral density;
THYM	cis	rs10540	1.000	rs61876339	chr11:495283	T/C	cg03576123	chr11:487126	PTDSS2	-1.19	-5.96	-0.52	4.19e-8	Body mass index;
THYM	cis	rs17331151	0.505	rs79979130	chr3:52551010	C/T	cg17372223	chr3:52568218	NT5DC2	0.61	4.85	0.45	4.8e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg16624210	chr5:671434	TPPP	0.82	6.13	0.53	1.99e-8	Obesity-related traits;
THYM	cis	rs4474465	0.850	rs10793329	chr11:78265655	G/C	cg19901956	chr11:77921274	USP35	0.62	4.54	0.42	1.65e-5	Alzheimer's disease (survival time);
THYM	cis	rs853679	0.550	rs1233704	chr6:28166923	A/G	cg23281280	chr6:28129359	ZNF389	-0.63	-4.94	-0.45	3.33e-6	Depression;
THYM	trans	rs8073060	0.586	rs2626625	chr17:34027607	C/G	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg22852734	chr6:133119734	C6orf192	1.24	8.21	0.64	1.08e-12	Type 2 diabetes nephropathy;
THYM	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg20290983	chr6:43655470	MRPS18A	1.16	7.68	0.62	1.4e-11	IgG glycosylation;
THYM	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.53	-4.89	-0.45	4.12e-6	Lymphocyte counts;
THYM	cis	rs79387448	0.592	rs6728945	chr2:102986471	T/C	cg09003973	chr2:102972529	NA	1.26	7.12	0.59	2.08e-10	Gut microbiota (bacterial taxa);
THYM	cis	rs34638657	0.789	rs2303264	chr16:82203711	G/T	cg07307142	chr16:82071433	HSD17B2	-0.83	-6.74	-0.57	1.21e-9	Lung adenocarcinoma;
THYM	cis	rs1448094	0.512	rs12297441	chr12:86233980	C/T	cg00310523	chr12:86230176	RASSF9	0.53	4.86	0.45	4.65e-6	Major depressive disorder;
THYM	trans	rs9929218	0.953	rs3118235	chr16:68732977	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.87	7.13	0.59	1.92e-10	Colorectal cancer;
THYM	cis	rs2898681	0.650	rs6840325	chr4:53675549	A/G	cg00338735	chr4:53728038	RASL11B	0.56	4.92	0.45	3.66e-6	Optic nerve measurement (cup area);
THYM	cis	rs16825455	1.000	rs6703976	chr1:21836934	C/T	cg13963528	chr1:22612141	NA	-0.76	-4.68	-0.43	9.66e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs);
THYM	cis	rs3810291	1.000	rs7250850	chr19:47585517	C/G	cg12068280	chr19:46804528	HIF3A	0.4	4.49	0.42	2.03e-5	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);BMI in smokers;Hip circumference;Body mass index;Body mass index in physically active individuals;
THYM	cis	rs9563576	0.778	rs2121059	chr13:58627181	C/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.62	-5.38	-0.48	5.41e-7	Renal function-related traits (BUN);
THYM	cis	rs6088590	0.550	rs12624640	chr20:32952125	G/A	cg08999081	chr20:33150536	PIGU	0.64	5.4	0.48	4.93e-7	Coronary artery disease;
THYM	cis	rs7119	0.717	rs12904584	chr15:77815991	C/T	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs4731207	0.698	rs6960683	chr7:124530368	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg18904891	chr8:8559673	CLDN23	-0.58	-4.79	-0.44	6.21e-6	Mood instability;
THYM	cis	rs6032067	0.929	rs17424356	chr20:43804190	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs4924935	1.000	rs9905565	chr17:18758641	C/T	cg26378065	chr17:18585709	ZNF286B	0.67	5.33	0.48	6.55e-7	Pancreatic cancer;
THYM	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg22166914	chr1:53195759	ZYG11B	-0.96	-11.92	-0.77	1.4e-20	Monocyte count;
THYM	cis	rs6570726	0.577	rs9497315	chr6:145791967	C/T	cg05347473	chr6:146136440	FBXO30	-0.78	-6.73	-0.57	1.28e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6089829	0.888	rs4809268	chr20:61675249	C/G	cg08045932	chr20:61659980	NA	0.95	10.46	0.73	1.77e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs951188	0.688	rs75173941	chr2:150397874	C/A	cg17961725	chr2:150454027	NA	-1.0	-5.05	-0.46	2.17e-6	Daytime sleep phenotypes;
THYM	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02475777	chr4:1388615	CRIPAK	0.65	4.69	0.43	9.26e-6	Longevity;
THYM	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg18904891	chr8:8559673	CLDN23	0.68	5.08	0.46	1.89e-6	Obesity-related traits;
THYM	trans	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg19862616	chr7:65841803	NCRNA00174	-1.16	-14.58	-0.83	5.71e-26	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6906287	0.647	rs12665409	chr6:118685043	G/A	cg21191810	chr6:118973309	C6orf204	0.52	5.02	0.46	2.36e-6	Electrocardiographic conduction measures;
THYM	cis	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg24692254	chr21:30365293	RNF160	-0.86	-5.3	-0.48	7.35e-7	Cognitive test performance;
THYM	cis	rs4731207	0.505	rs7795233	chr7:124578468	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg00684032	chr4:1343700	KIAA1530	0.59	5.03	0.46	2.36e-6	Obesity-related traits;
THYM	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg13695892	chr22:41940480	POLR3H	-0.62	-4.95	-0.45	3.17e-6	Neuroticism;
THYM	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11890956	chr21:40555474	PSMG1	-0.9	-9.57	-0.7	1.4e-15	Cognitive function;
THYM	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14442939	chr10:27389572	ANKRD26	-0.94	-4.65	-0.43	1.07e-5	Breast cancer;
THYM	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg11245990	chr11:68621969	NA	0.53	6.68	0.57	1.65e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs131777	0.547	rs131753	chr22:51022862	A/G	cg25309564	chr22:51001381	C22orf41	0.63	5.04	0.46	2.26e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7115242	0.660	rs236911	chr11:117085270	A/C	cg01368799	chr11:117014884	PAFAH1B2	-0.84	-4.72	-0.44	8.1e-6	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
THYM	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg06009448	chr7:1102226	C7orf50	0.53	5.55	0.49	2.6e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7226229	1.000	rs899336	chr17:20898393	T/C	cg21263980	chr17:20946333	USP22	0.72	4.96	0.45	3.12e-6	Blood trace element (Se levels);
THYM	cis	rs56979318	1	rs56979318	chr17:80522718	A/T	cg11779900	chr17:80519722	FOXK2	-0.53	-4.53	-0.42	1.71e-5	Reticulocyte count;
THYM	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg24692254	chr21:30365293	RNF160	1.06	10.23	0.72	5.46e-17	Dental caries;
THYM	cis	rs67981189	0.896	rs12100737	chr14:71471100	A/G	cg15910301	chr14:71632612	NA	-0.5	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg18876405	chr7:65276391	NA	-0.61	-5.2	-0.47	1.13e-6	Aortic root size;
THYM	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg13683864	chr3:40499215	RPL14	-1.05	-11.46	-0.76	1.29e-19	Renal cell carcinoma;
THYM	cis	rs28647808	0.748	rs114667516	chr9:136258537	A/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.74	7.62	0.62	1.92e-11	Breast cancer;
THYM	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg10802521	chr3:52805072	NEK4	-0.73	-6.35	-0.55	7.48e-9	Bipolar disorder;
THYM	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	4.93	0.45	3.51e-6	Motion sickness;
THYM	cis	rs6430585	0.528	rs114760827	chr2:136661110	G/A	cg04750100	chr2:136595281	LCT	0.56	4.96	0.45	3.03e-6	Corneal structure;
THYM	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg24675658	chr1:53192096	ZYG11B	0.71	6.38	0.55	6.55e-9	Monocyte count;
THYM	cis	rs55637147	0.553	rs4570598	chr11:57123732	C/T	cg15971518	chr11:57159174	PRG2	-0.63	-5.24	-0.47	9.46e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs42648	0.935	rs2188232	chr7:89958314	A/C	cg25739043	chr7:89950458	NA	-0.58	-5.04	-0.46	2.25e-6	Homocysteine levels;
THYM	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg10057126	chr4:77819792	ANKRD56	0.71	6.06	0.53	2.78e-8	Emphysema distribution in smoking;
THYM	cis	rs6840360	0.571	rs875667	chr4:152525477	G/A	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	cis	rs12540874	0.794	rs1470750	chr7:50576648	C/G	cg00647317	chr7:50633725	DDC	0.35	4.87	0.45	4.37e-6	Systemic sclerosis;
THYM	cis	rs9972944	0.729	rs6504348	chr17:63763049	C/T	cg07283582	chr17:63770753	CCDC46	-0.66	-5.14	-0.47	1.49e-6	Total body bone mineral density;
THYM	cis	rs8064299	0.597	rs2016126	chr17:72784932	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.88	8.77	0.67	7.13e-14	Monocyte count;
THYM	cis	rs524023	1.000	rs9734313	chr11:64358311	C/T	cg19131476	chr11:64387923	NRXN2	-0.35	-4.84	-0.44	4.98e-6	Urate levels in obese individuals;
THYM	cis	rs6076065	0.676	rs6083085	chr20:23336119	C/T	cg11657817	chr20:23433608	CST11	-0.33	-4.58	-0.43	1.39e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.61	-0.43	1.24e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg09034736	chr1:150693464	HORMAD1	0.53	4.85	0.45	4.83e-6	Tonsillectomy;
THYM	cis	rs747334	0.846	rs10785979	chr10:92718314	T/A	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs6456156	0.846	rs9364891	chr6:167516319	C/T	cg09487078	chr6:167525398	CCR6	-0.46	-5.07	-0.46	1.98e-6	Primary biliary cholangitis;
THYM	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg00129232	chr17:37814104	STARD3	-0.88	-7.23	-0.6	1.24e-10	Asthma;
THYM	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-6.73	-0.57	1.3e-9	Total body bone mineral density;
THYM	cis	rs6598955	0.543	rs6690461	chr1:26543097	T/A	cg04990556	chr1:26633338	UBXN11	0.96	6.06	0.53	2.7e-8	Obesity-related traits;
THYM	cis	rs7247513	0.964	rs8105902	chr19:12718351	G/A	cg01871581	chr19:12707946	ZNF490	-0.85	-8.88	-0.67	4.05e-14	Bipolar disorder;
THYM	cis	rs10751667	0.961	rs10902263	chr11:992691	A/C	ch.11.42038R	chr11:967971	AP2A2	-0.59	-4.71	-0.44	8.31e-6	Alzheimer's disease (late onset);
THYM	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg06766960	chr11:133703094	NA	-0.6	-5.63	-0.5	1.83e-7	Childhood ear infection;
THYM	cis	rs9790314	1.000	rs4370045	chr3:160943865	A/G	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.69	-5.16	-0.47	1.36e-6	Tonsillectomy;
THYM	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg10803722	chr21:46713166	LOC642852	-0.41	-5.27	-0.48	8.42e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs35264875	1.000	rs7940235	chr11:68820121	C/T	cg23845249	chr11:68861649	NA	0.56	5.95	0.52	4.41e-8	Blond vs. brown hair color;
THYM	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7553864	0.966	rs11161936	chr1:87614507	G/C	cg17420885	chr1:87600446	LOC339524	-0.72	-6.03	-0.53	3.18e-8	Smoking behavior;
THYM	cis	rs4845875	0.559	rs4846047	chr1:11843632	C/G	cg24844545	chr1:11908347	NPPA	0.57	4.76	0.44	7.02e-6	Midregional pro atrial natriuretic peptide levels;
THYM	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg12310025	chr6:25882481	NA	-1.11	-11.25	-0.76	3.64e-19	Urate levels;
THYM	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg13319975	chr6:146136371	FBXO30	-0.63	-5.09	-0.46	1.8e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2637266	0.967	rs12244619	chr10:78352502	C/T	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs11690935	0.632	rs11690807	chr2:172628120	G/A	cg13550731	chr2:172543902	DYNC1I2	0.66	5.23	0.47	1.01e-6	Schizophrenia;
THYM	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg15744005	chr10:104629667	AS3MT	-0.8	-7.57	-0.61	2.4e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.51	4.7	0.43	8.85e-6	Birth weight;
THYM	cis	rs72627123	0.737	rs77361581	chr14:74465290	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.79	-7.25	-0.6	1.13e-10	Personality dimensions;
THYM	cis	rs2290159	0.706	rs6442319	chr3:12647029	G/A	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs7731657	0.537	rs916818	chr5:130277673	G/C	cg08523029	chr5:130500466	HINT1	0.83	6.04	0.53	2.99e-8	Fasting plasma glucose;
THYM	cis	rs7084402	0.967	rs1658496	chr10:60279909	G/A	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg14768367	chr16:72042858	DHODH	0.65	5.08	0.46	1.89e-6	Fibrinogen levels;
THYM	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg26314531	chr2:26401878	FAM59B	-0.76	-5.02	-0.46	2.37e-6	Gut microbiome composition (summer);
THYM	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	7.64	0.62	1.72e-11	Platelet count;
THYM	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg02725872	chr8:58115012	NA	-1.15	-7.43	-0.61	4.64e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs4595586	0.525	rs4441057	chr12:39420620	T/A	cg26384229	chr12:38710491	ALG10B	0.79	5.67	0.5	1.53e-7	Morning vs. evening chronotype;
THYM	cis	rs747334	0.846	rs4639845	chr10:92716298	G/A	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22857025	chr5:266934	NA	-1.5	-9.37	-0.69	3.66e-15	Breast cancer;
THYM	cis	rs2455799	0.574	rs2455798	chr3:15700505	G/C	cg16303742	chr3:15540471	COLQ	-0.58	-5.95	-0.52	4.53e-8	Mean platelet volume;
THYM	cis	rs11098499	0.690	rs7674713	chr4:120322257	T/C	cg13609457	chr4:120235615	NA	0.53	4.81	0.44	5.61e-6	Corneal astigmatism;
THYM	cis	rs11760633	0.526	rs73042701	chr7:1824758	T/C	cg27050990	chr7:2629313	IQCE	0.65	4.82	0.44	5.54e-6	Coronary artery disease;
THYM	cis	rs3741151	1.000	rs7129663	chr11:73045129	C/T	cg12959048	chr11:73096162	RELT	-0.5	-4.78	-0.44	6.38e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2932538	0.922	rs2273369	chr1:113072477	A/G	cg22162597	chr1:113214053	CAPZA1	0.6	5.07	0.46	1.96e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs7584330	0.554	rs10208231	chr2:238433225	C/T	cg14458575	chr2:238380390	NA	0.82	4.89	0.45	4.16e-6	Prostate cancer;
THYM	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9796	0.870	rs7169375	chr15:41311046	A/G	cg21153102	chr15:41252147	NA	0.7	6.38	0.55	6.34e-9	Menopause (age at onset);
THYM	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg20486651	chr6:167070296	RPS6KA2	-0.47	-4.5	-0.42	1.95e-5	Crohn's disease;
THYM	cis	rs62229266	0.605	rs11701331	chr21:37458392	T/C	cg08632701	chr21:37451849	NA	-0.7	-7.09	-0.59	2.33e-10	Mitral valve prolapse;
THYM	cis	rs6740731	0.894	rs7564469	chr2:145258445	A/G	cg17751438	chr2:145275197	ZEB2	0.79	4.67	0.43	1e-5	Coronary artery disease;
THYM	cis	rs7688540	0.771	rs11722197	chr4:281707	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.68	4.82	0.44	5.43e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs4266144	0.558	rs7623382	chr3:156832894	T/C	cg16248515	chr3:156840234	NA	-0.52	-4.72	-0.44	8.22e-6	Coronary artery disease;
THYM	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg03676636	chr4:99064102	C4orf37	0.5	7.59	0.61	2.14e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg20295408	chr7:1910781	MAD1L1	-0.65	-4.93	-0.45	3.42e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg02410480	chr12:132819930	GALNT9	-0.44	-4.93	-0.45	3.53e-6	Anti-saccade response;
THYM	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs5771242	0.769	rs4838865	chr22:50664612	A/G	cg16473166	chr22:50639996	SELO	0.74	4.79	0.44	6.17e-6	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
THYM	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg07648498	chr16:89883185	FANCA	0.66	4.89	0.45	4.06e-6	Vitiligo;
THYM	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg05872129	chr22:39784769	NA	-0.99	-10.01	-0.72	1.59e-16	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg03929089	chr4:120376271	NA	-1.01	-13.53	-0.81	6.96e-24	Height;
THYM	cis	rs10832963	0.625	rs4757673	chr11:18612468	A/T	cg09201001	chr11:18656081	SPTY2D1	0.79	5.6	0.5	2.12e-7	Breast cancer;
THYM	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg19774624	chr17:42201019	HDAC5	-0.76	-7.12	-0.59	2.05e-10	Total body bone mineral density;
THYM	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg18230493	chr5:56204884	C5orf35	0.91	6.71	0.57	1.43e-9	Initial pursuit acceleration;
THYM	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg24375607	chr4:120327624	NA	-0.66	-5.26	-0.47	8.84e-7	Corneal astigmatism;
THYM	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg08772003	chr10:104629869	AS3MT	-0.63	-5.59	-0.5	2.18e-7	Arsenic metabolism;
THYM	cis	rs13380717	0.657	rs12928641	chr16:86915098	C/T	cg05661093	chr16:86825505	NA	-0.53	-4.61	-0.43	1.24e-5	Sepsis in extremely premature infants;
THYM	trans	rs4262150	0.883	rs72802877	chr5:152241855	A/G	cg08281791	chr5:76607845	PDE8B	0.92	6.91	0.58	5.62e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs7264396	0.790	rs761825	chr20:34194054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-5.67	-0.5	1.56e-7	Total cholesterol levels;
THYM	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.84	-5.77	-0.51	1e-7	Body mass index;
THYM	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg08645402	chr16:4508243	NA	0.78	7.02	0.58	3.29e-10	Schizophrenia;
THYM	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg01616529	chr11:638424	DRD4	-0.74	-5.92	-0.52	5.2100000000000003e-08	Systemic lupus erythematosus;
THYM	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	7.5	0.61	3.41e-11	Platelet count;
THYM	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg26131816	chr17:42072204	PYY	0.52	4.52	0.42	1.76e-5	Menopause (age at onset);
THYM	cis	rs7584330	0.554	rs116656801	chr2:238431257	A/G	cg08992911	chr2:238395768	MLPH	0.9	5.8	0.51	8.78e-8	Prostate cancer;
THYM	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg02487422	chr3:49467188	NICN1	-0.63	-4.93	-0.45	3.55e-6	Resting heart rate;
THYM	cis	rs748404	0.631	rs1133395	chr15:43650384	G/A	cg12861797	chr15:43585817	TGM7	0.44	4.67	0.43	9.79e-6	Lung cancer;
THYM	trans	rs9929218	0.817	rs3114402	chr16:68719607	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.0	-8.21	-0.64	1.11e-12	Colorectal cancer;
THYM	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg02734326	chr4:10020555	SLC2A9	0.76	7.25	0.6	1.13e-10	Bone mineral density;
THYM	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7119038	0.818	rs10892280	chr11:118611817	C/T	cg19308663	chr11:118741387	NA	0.56	5.21	0.47	1.09e-6	Sjögren's syndrome;
THYM	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22496380	chr5:211416	CCDC127	-1.39	-8.13	-0.64	1.62e-12	Breast cancer;
THYM	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg02569458	chr12:86230093	RASSF9	0.69	5.77	0.51	9.84e-8	Major depressive disorder;
THYM	cis	rs67981189	0.766	rs2526852	chr14:71416167	T/C	cg15910301	chr14:71632612	NA	-0.5	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	trans	rs75518195	0.543	rs72641813	chr4:64666561	C/A	cg14706739	chr8:21916355	EPB49	0.75	7.37	0.6	6.34e-11	Triptolide cytotoxicity;
THYM	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg16615211	chr3:44902933	MIR564;TMEM42	0.52	5.64	0.5	1.77e-7	Depressive symptoms;
THYM	cis	rs9572053	0.550	rs9541669	chr13:69554694	G/A	cg16757992	chr13:69559194	NA	-0.61	-4.91	-0.45	3.8e-6	Subjective well-being;
THYM	cis	rs611744	0.967	rs536860	chr8:109230722	A/C	cg21045802	chr8:109455806	TTC35	0.59	5.25	0.47	9.08e-7	Dupuytren's disease;
THYM	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg04520793	chr17:42248056	ASB16	0.33	4.56	0.42	1.55e-5	Total body bone mineral density;
THYM	cis	rs11626933	0.851	rs2282031	chr14:90730943	A/G	cg14092571	chr14:90743983	NA	-0.64	-6.49	-0.55	3.85e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs11039798	0.925	rs12277669	chr11:48925316	A/T	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg05368731	chr17:41323189	NBR1	1.25	11.08	0.75	8.33e-19	Menopause (age at onset);
THYM	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg08847533	chr14:75593920	NEK9	1.0	11.04	0.75	1.04e-18	Height;
THYM	cis	rs6539288	0.835	rs2041893	chr12:107350376	C/G	cg26297688	chr12:107349093	C12orf23	-0.47	-4.96	-0.45	3.1e-6	Total body bone mineral density;
THYM	cis	rs2073300	0.793	rs75758241	chr20:23434696	A/G	cg12062639	chr20:23401060	NAPB	0.97	4.92	0.45	3.62e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7572263	0.724	rs6749281	chr2:209050696	C/A	cg23998903	chr2:209048830	C2orf80	-0.46	-4.75	-0.44	7.2e-6	Glioma;Non-glioblastoma glioma;
THYM	cis	rs4589258	0.788	rs2051462	chr11:90501133	A/G	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.96	-0.45	3.02e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg08975724	chr8:8085496	FLJ10661	-0.68	-5.72	-0.51	1.23e-7	Mood instability;
THYM	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg13607699	chr17:42295918	UBTF	-0.85	-7.87	-0.63	5.56e-12	Red cell distribution width;Reticulocyte count;
THYM	cis	rs3781426	0.924	rs7086797	chr10:126711691	C/T	cg04494136	chr10:126703576	CTBP2	-0.34	-4.83	-0.44	5.26e-6	Height;
THYM	cis	rs11077998	0.967	rs4789786	chr17:80504352	A/G	cg11779900	chr17:80519722	FOXK2	0.53	4.51	0.42	1.83e-5	Reticulocyte fraction of red cells;
THYM	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs1389724	0.648	rs1160414	chr1:111315561	C/T	cg25283465	chr1:111323341	NA	0.58	4.58	0.43	1.4e-5	Schizophrenia;
THYM	cis	rs6995541	0.505	rs2278335	chr8:10703453	C/T	cg13457217	chr8:10683266	MIR1322;PINX1	-0.63	-4.59	-0.43	1.35e-5	Triglyceride levels;
THYM	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2898681	0.581	rs731073	chr4:53680090	A/G	cg21521518	chr4:53727714	RASL11B	0.45	5.03	0.46	2.27e-6	Optic nerve measurement (cup area);
THYM	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg06784218	chr1:46089804	CCDC17	-0.3	-4.64	-0.43	1.1e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs1670533	1.000	rs651017	chr4:1091062	A/G	cg27284194	chr4:1044797	NA	0.71	5.4	0.48	5e-7	Recombination rate (females);
THYM	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs995000	0.965	rs10889333	chr1:62957030	G/A	cg06896770	chr1:63153194	DOCK7	0.96	7.88	0.63	5.37e-12	Triglyceride levels;
THYM	cis	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg05335186	chr13:53173507	NA	0.45	5.65	0.5	1.68e-7	Lewy body disease;
THYM	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg23422044	chr7:1970798	MAD1L1	-0.77	-4.68	-0.43	9.51e-6	Neuroticism;
THYM	cis	rs9543976	1.000	rs4885324	chr13:76173747	G/A	cg01531495	chr13:76123901	UCHL3	0.75	5.05	0.46	2.1e-6	Diabetic retinopathy;
THYM	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.56	0.56	2.86e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg06238570	chr21:40685208	BRWD1	-0.68	-5.75	-0.51	1.06e-7	Menarche (age at onset);
THYM	cis	rs3126085	0.932	rs11587676	chr1:152159961	C/T	cg10321714	chr1:152280068	FLG	-0.76	-5.39	-0.48	5.2e-7	Atopic dermatitis;
THYM	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg13010199	chr12:38710504	ALG10B	-0.62	-4.5	-0.42	1.95e-5	Bladder cancer;
THYM	cis	rs6754311	0.773	rs309137	chr2:136765951	A/G	cg04750100	chr2:136595281	LCT	0.57	5.94	0.52	4.68e-8	Mosquito bite size;
THYM	cis	rs2235642	0.893	rs8051295	chr16:1588087	A/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.61	-5.18	-0.47	1.23e-6	Coronary artery disease;
THYM	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg08859206	chr1:53392774	SCP2	-0.47	-4.72	-0.44	8.01e-6	Monocyte count;
THYM	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg22508957	chr16:3507546	NAT15	0.49	5.16	0.47	1.33e-6	Body mass index (adult);
THYM	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	4.97	0.45	2.96e-6	Obesity-related traits;
THYM	cis	rs6964587	0.692	rs4727268	chr7:91840724	T/C	cg22709100	chr7:91322751	NA	0.75	5.81	0.51	8.32e-8	Breast cancer;
THYM	cis	rs10791097	0.728	rs10894265	chr11:130714613	T/C	cg12179176	chr11:130786555	SNX19	-0.74	-6.09	-0.53	2.37e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs17401966	0.838	rs12139981	chr1:10390696	T/C	cg19773385	chr1:10388646	KIF1B	-0.57	-4.58	-0.43	1.4e-5	Hepatocellular carcinoma;
THYM	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08704250	chr15:31115839	NA	0.68	7.54	0.61	2.77e-11	Huntington's disease progression;
THYM	cis	rs7772486	0.686	rs2179323	chr6:145982786	T/G	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9902453	0.726	rs3115092	chr17:28036350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	6.01	0.52	3.49e-8	Coffee consumption (cups per day);
THYM	cis	rs9287719	0.810	rs7601748	chr2:10785446	A/G	cg03983476	chr2:10830698	NOL10	-0.58	-5.24	-0.47	9.54e-7	Prostate cancer;
THYM	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg06981504	chr1:1234844	ACAP3	0.56	5.09	0.46	1.78e-6	Body mass index;
THYM	cis	rs4786125	0.636	rs7192853	chr16:6918241	G/C	cg03623568	chr16:6915990	A2BP1	-1.02	-10.41	-0.73	2.2e-17	Heart rate variability traits (SDNN);
THYM	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	5.1	0.46	1.74e-6	Obesity-related traits;
THYM	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	4.93	0.45	3.51e-6	Motion sickness;
THYM	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg23791538	chr6:167370224	RNASET2	-0.62	-4.64	-0.43	1.1e-5	Crohn's disease;
THYM	cis	rs6598955	0.670	rs10902734	chr1:26617923	G/T	cg00852783	chr1:26633632	UBXN11	-0.86	-8.81	-0.67	5.74e-14	Obesity-related traits;
THYM	trans	rs17685	0.712	rs869805	chr7:75688596	C/T	cg19862616	chr7:65841803	NCRNA00174	1.12	13.73	0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg13695892	chr22:41940480	POLR3H	1.01	7.54	0.61	2.77e-11	Vitiligo;
THYM	cis	rs4845875	0.563	rs10864540	chr1:11838099	A/G	cg24844545	chr1:11908347	NPPA	0.57	4.77	0.44	6.74e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs61931739	0.890	rs1849160	chr12:34140191	A/G	cg06521331	chr12:34319734	NA	-0.6	-4.86	-0.45	4.59e-6	Morning vs. evening chronotype;
THYM	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg22467129	chr15:76604101	ETFA	-0.57	-5.41	-0.49	4.76e-7	Blood metabolite levels;
THYM	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg06636551	chr8:101224915	SPAG1	0.65	5.95	0.52	4.53e-8	Atrioventricular conduction;
THYM	cis	rs13064411	0.696	rs2399479	chr3:113227050	G/A	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22857025	chr5:266934	NA	-1.4	-9.26	-0.69	6.36e-15	Breast cancer;
THYM	cis	rs760805	1.000	rs4648884	chr1:25261386	C/T	cg22509179	chr1:25234806	RUNX3	0.74	6.94	0.58	4.8e-10	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.18	8.91	0.67	3.51e-14	Cognitive test performance;
THYM	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg24733560	chr20:60626293	TAF4	0.62	6.35	0.55	7.48e-9	Body mass index;
THYM	cis	rs3741151	0.656	rs73550316	chr11:73299799	G/A	cg17517138	chr11:73019481	ARHGEF17	0.9	4.71	0.43	8.56e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs11077998	0.967	rs4789786	chr17:80504352	A/G	cg10255544	chr17:80519551	FOXK2	-0.51	-4.48	-0.42	2.05e-5	Reticulocyte fraction of red cells;
THYM	cis	rs910187	0.605	rs2235907	chr20:45809652	A/G	cg27589058	chr20:45804311	EYA2	-0.59	-5.04	-0.46	2.2e-6	Migraine;
THYM	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.93	-0.45	3.52e-6	Monocyte count;
THYM	cis	rs7191700	0.673	rs12325495	chr16:11418328	C/T	cg00044050	chr16:11439710	C16orf75	0.83	6.58	0.56	2.6e-9	Multiple sclerosis;
THYM	cis	rs600550	0.551	rs12792791	chr11:60082497	G/A	cg05040360	chr11:60102449	MS4A6E	-0.49	-4.55	-0.42	1.58e-5	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Bladder cancer;
THYM	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg26149184	chr10:133730230	NA	0.8	4.85	0.45	4.86e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg26566898	chr11:117069891	TAGLN	0.39	4.93	0.45	3.47e-6	Blood protein levels;
THYM	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg07341220	chr16:1583899	IFT140;TMEM204	-0.56	-4.94	-0.45	3.34e-6	Coronary artery disease;
THYM	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.62	-5.58	-0.5	2.23e-7	Menarche (age at onset);
THYM	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	4.9	0.45	4e-6	Prudent dietary pattern;
THYM	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-5.24	-0.47	9.47e-7	Monocyte percentage of white cells;
THYM	cis	rs13424612	0.965	rs2289407	chr2:240954110	A/G	cg01812947	chr2:240904978	NDUFA10	0.56	4.47	0.42	2.19e-5	Odorant perception (isobutyraldehyde);
THYM	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg13319975	chr6:146136371	FBXO30	-0.69	-5.65	-0.5	1.7e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3771570	1.000	rs62193171	chr2:242276523	C/A	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs17443541	0.507	rs4675719	chr2:200472364	C/T	cg03741458	chr2:200468445	NA	-0.78	-5.63	-0.5	1.84e-7	Intelligence (multi-trait analysis);
THYM	cis	rs42648	0.935	rs7803012	chr7:90026166	A/T	cg25739043	chr7:89950458	NA	0.53	4.61	0.43	1.27e-5	Homocysteine levels;
THYM	cis	rs854765	0.663	rs6502618	chr17:17746741	A/G	cg16928487	chr17:17741425	SREBF1	0.54	5.18	0.47	1.22e-6	Total body bone mineral density;
THYM	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg01380346	chr19:18557039	ELL	-0.47	-4.69	-0.43	8.97e-6	Breast cancer;
THYM	cis	rs4072705	1.000	rs4524900	chr9:127343209	G/A	cg13476313	chr9:127244764	NR5A1	0.31	4.78	0.44	6.47e-6	Menarche (age at onset);
THYM	cis	rs11614062	1.000	rs11614062	chr12:93956672	A/T	cg18151635	chr12:93972918	NA	-0.95	-5.72	-0.51	1.23e-7	Height;
THYM	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	7.98	0.63	3.29e-12	Cognitive test performance;
THYM	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg00825309	chr19:58991885	ZNF446	-0.58	-4.55	-0.42	1.58e-5	Uric acid clearance;
THYM	cis	rs1003719	0.751	rs7280371	chr21:38450008	T/C	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	trans	rs4749080	0.573	rs3817416	chr10:26414106	A/T	cg00192819	chr18:76486611	NA	1.0	7.09	0.59	2.41e-10	Obesity-related traits;
THYM	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6539288	0.933	rs6539291	chr12:107309811	G/A	cg26297688	chr12:107349093	C12orf23	-0.47	-4.89	-0.45	4.15e-6	Total body bone mineral density;
THYM	cis	rs12282928	1.000	rs11039671	chr11:48332985	G/C	cg22827986	chr11:48284249	OR4X1	0.53	5.59	0.5	2.21e-7	Migraine - clinic-based;
THYM	cis	rs2290159	1.000	rs2290159	chr3:12628920	G/C	cg23032965	chr3:12705835	RAF1	0.77	5.25	0.47	9.21e-7	Cholesterol, total;
THYM	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	5.71	0.51	1.3e-7	Platelet count;
THYM	cis	rs2456568	1.000	rs2456568	chr11:93691332	A/T	cg17595323	chr11:93583763	C11orf90	-0.52	-5.05	-0.46	2.13e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7465272	1.000	rs7465272	chr8:143691838	A/T	cg01509843	chr8:143695822	ARC	0.75	5.02	0.46	2.42e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs4262150	0.842	rs55992747	chr5:152253548	C/T	cg06854687	chr5:151642065	NA	0.66	4.59	0.43	1.36e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg01579765	chr21:45077557	HSF2BP	-0.49	-7.92	-0.63	4.37e-12	Mean corpuscular volume;
THYM	cis	rs600806	0.889	rs681242	chr1:109841659	T/C	cg02175308	chr1:109941060	SORT1	-0.56	-4.68	-0.43	9.56e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2034088	0.828	rs2289620	chr17:415667	T/C	cg06217071	chr17:408420	NA	0.72	6.34	0.55	7.68e-9	Hip circumference adjusted for BMI;
THYM	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg03086067	chr10:82368399	SH2D4B	-0.38	-4.47	-0.42	2.2e-5	Post bronchodilator FEV1;
THYM	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs2279817	0.909	rs905390	chr1:18018255	A/C	cg21791023	chr1:18019539	ARHGEF10L	0.71	4.46	0.42	2.24e-5	Neuroticism;
THYM	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg16586182	chr3:47516702	SCAP	-0.67	-6.05	-0.53	2.82e-8	Colorectal cancer;
THYM	cis	rs2742234	0.541	rs10793424	chr10:43717116	G/T	cg06632098	chr10:43605906	RET	0.8	5.26	0.47	8.98e-7	Hirschsprung disease;
THYM	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg21385522	chr1:16154831	NA	0.76	5.61	0.5	2e-7	Dilated cardiomyopathy;
THYM	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg11266682	chr4:10021025	SLC2A9	0.74	12.07	0.78	6.92e-21	Bone mineral density;
THYM	cis	rs7119	0.717	rs62007348	chr15:77804501	C/T	cg27398640	chr15:77910606	LINGO1	-0.52	-5.21	-0.47	1.12e-6	Type 2 diabetes;
THYM	cis	rs8041943	0.643	rs3913524	chr15:79920949	T/A	cg20511832	chr15:78934280	CHRNB4	0.42	4.85	0.45	4.8e-6	Bone mineral density (spine) and age at menarche;
THYM	cis	rs6032067	0.777	rs56191952	chr20:43802487	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.52	-5.89	-0.52	5.76e-8	Blood protein levels;
THYM	cis	rs55637147	0.553	rs879646	chr11:57124196	C/T	cg15971518	chr11:57159174	PRG2	-0.62	-5.06	-0.46	2.02e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg02782426	chr3:40428986	ENTPD3	0.54	4.86	0.45	4.56e-6	Renal cell carcinoma;
THYM	cis	rs11249608	0.548	rs35568336	chr5:178451854	A/G	cg01312482	chr5:178451176	ZNF879	-0.75	-6.33	-0.54	8.01e-9	Pubertal anthropometrics;
THYM	cis	rs4919694	0.667	rs117927731	chr10:105112852	C/A	cg04362960	chr10:104952993	NT5C2	0.8	4.74	0.44	7.54e-6	Arsenic metabolism;
THYM	cis	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg05335186	chr13:53173507	NA	-0.37	-4.79	-0.44	6.11e-6	Lewy body disease;
THYM	cis	rs7178572	0.568	rs12905951	chr15:77649431	G/A	cg22256960	chr15:77711686	NA	-1.04	-8.25	-0.65	9.01e-13	Type 2 diabetes;
THYM	cis	rs2721195	0.816	rs4251689	chr8:145741130	C/T	cg11211951	chr8:145729740	GPT	0.63	6.32	0.54	8.37e-9	Age at first birth;
THYM	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg24112000	chr20:60950667	NA	-0.82	-7.21	-0.59	1.3100000000000001e-10	Colorectal cancer;
THYM	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg24874828	chr4:187887005	NA	0.72	7.44	0.61	4.48e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	6.03	0.53	3.14e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg09085632	chr11:111637200	PPP2R1B	0.97	8.52	0.66	2.39e-13	Primary sclerosing cholangitis;
THYM	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06634786	chr22:41940651	POLR3H	-0.77	-5.97	-0.52	4.11e-8	Vitiligo;
THYM	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg06784218	chr1:46089804	CCDC17	-0.32	-4.82	-0.44	5.41e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs2932538	0.885	rs6691025	chr1:113177070	G/T	cg22162597	chr1:113214053	CAPZA1	-0.65	-5.26	-0.47	8.98e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs3942852	0.868	rs10769315	chr11:48110367	A/G	cg25800328	chr11:47736132	AGBL2	-0.48	-4.57	-0.42	1.46e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs6430585	0.591	rs77096272	chr2:136663605	C/A	cg23851026	chr2:136556271	LCT	0.77	6.81	0.57	8.95e-10	Corneal structure;
THYM	cis	rs1267303	0.642	rs6696219	chr1:47000408	T/C	cg25110126	chr1:46999211	NA	0.69	5.39	0.48	5.13e-7	Monobrow;
THYM	cis	rs1915919	0.794	rs12488378	chr3:20022495	C/G	cg05072819	chr3:20081367	KAT2B	0.68	5.65	0.5	1.7e-7	Post-traumatic stress disorder;
THYM	cis	rs12310956	0.510	rs11052882	chr12:33890017	T/C	cg10856724	chr12:34555212	NA	-0.65	-5.93	-0.52	4.87e-8	Morning vs. evening chronotype;
THYM	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg20887711	chr4:1340912	KIAA1530	-0.62	-4.9	-0.45	3.9e-6	Obesity-related traits;
THYM	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg14784868	chr12:69753453	YEATS4	0.79	6.09	0.53	2.38e-8	Response to diuretic therapy;
THYM	cis	rs7224737	1.000	rs12603327	chr17:40290552	T/C	cg02228675	chr17:40259724	DHX58	-0.62	-5.13	-0.47	1.55e-6	Fibrinogen levels;
THYM	cis	rs2806561	0.704	rs7532266	chr1:23551623	A/C	cg12483005	chr1:23474871	LUZP1	-0.6	-6.22	-0.54	1.35e-8	Height;
THYM	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg19677267	chr1:26645161	CD52;UBXN11	-0.45	-5.89	-0.52	5.87e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg10021288	chr2:128175891	PROC	0.57	4.93	0.45	3.48e-6	Protein C levels;
THYM	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg22681709	chr2:178499509	PDE11A	-0.48	-4.57	-0.42	1.47e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2072499	0.865	rs2758603	chr1:156198994	T/C	cg06970220	chr1:156163860	SLC25A44	0.71	5.8	0.51	8.5e-8	Testicular germ cell tumor;
THYM	cis	rs7166081	0.672	rs3865018	chr15:67892766	A/G	cg24579218	chr15:68104479	NA	0.73	6.78	0.57	9.92e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9296092	0.517	rs113111213	chr6:33520790	A/G	cg13560919	chr6:33536144	NA	-0.94	-9.31	-0.69	4.9e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg07755735	chr2:20870362	GDF7	-0.83	-6.85	-0.57	7.4e-10	Abdominal aortic aneurysm;
THYM	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg05472934	chr7:22766657	IL6	0.75	5.86	0.52	6.58e-8	Lung cancer;
THYM	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03576123	chr11:487126	PTDSS2	-1.29	-6.68	-0.57	1.6e-9	Body mass index;
THYM	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg24692254	chr21:30365293	RNF160	1.03	10.1	0.72	1.03e-16	Dental caries;
THYM	cis	rs7208859	0.623	rs73263788	chr17:29216490	T/C	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3540	0.512	rs7176518	chr15:91079637	C/T	cg00487526	chr15:90818384	NA	0.59	4.5	0.42	1.89e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs6448317	0.539	rs13113895	chr4:24932077	T/C	cg21108841	chr4:24914750	CCDC149	-0.8	-6.99	-0.58	3.71e-10	Heschl's gyrus morphology;
THYM	cis	rs9326248	0.652	rs7128382	chr11:117023487	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.69	4.89	0.45	4.05e-6	Blood protein levels;
THYM	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg23583168	chr7:148888333	NA	-1.02	-14.09	-0.82	5.29e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs7809950	0.954	rs2189839	chr7:107230026	A/G	cg23024343	chr7:107201750	COG5	0.9	8.13	0.64	1.58e-12	Coronary artery disease;
THYM	cis	rs7901056	0.901	rs11595895	chr10:26734518	C/A	cg23318538	chr10:26883079	C10orf50	0.39	5.05	0.46	2.13e-6	Lymphocyte counts;
THYM	cis	rs6084875	0.840	rs762043	chr20:4731834	A/C	cg19614321	chr20:4804581	RASSF2	0.44	4.48	0.42	2.09e-5	Systemic lupus erythematosus;
THYM	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg04842962	chr6:43655489	MRPS18A	1.27	9.25	0.69	6.78e-15	IgG glycosylation;
THYM	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg06636001	chr8:8085503	FLJ10661	0.84	8.58	0.66	1.74e-13	Mood instability;
THYM	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg11764359	chr7:65958608	NA	0.88	7.53	0.61	2.88e-11	Aortic root size;
THYM	cis	rs172166	0.560	rs203878	chr6:28048996	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.71	-5.47	-0.49	3.65e-7	Cardiac Troponin-T levels;
THYM	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg13319975	chr6:146136371	FBXO30	0.63	5.02	0.46	2.39e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2050392	0.894	rs2480277	chr10:30703513	G/T	cg02070205	chr10:30722105	MAP3K8	0.54	4.83	0.44	5.27e-6	Inflammatory bowel disease;
THYM	cis	rs6893807	0.697	rs26582	chr5:87950290	C/T	cg02225085	chr5:87975992	LOC645323	-0.61	-4.58	-0.43	1.41e-5	Body mass index;
THYM	cis	rs2294693	0.579	rs10947939	chr6:40947618	C/G	cg14418226	chr6:40996092	UNC5CL	0.71	5.64	0.5	1.73e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs11756438	0.572	rs1771755	chr6:119018877	A/T	cg21191810	chr6:118973309	C6orf204	-0.56	-5.47	-0.49	3.57e-7	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg05368731	chr17:41323189	NBR1	1.25	11.64	0.77	5.42e-20	Menopause (age at onset);
THYM	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.04	-0.46	2.18e-6	Joint mobility (Beighton score);
THYM	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg11764359	chr7:65958608	NA	-0.7	-5.4	-0.48	4.99e-7	Aortic root size;
THYM	cis	rs9419702	0.614	rs9419567	chr10:133535149	C/G	cg20568497	chr10:133558893	NA	0.47	4.65	0.43	1.08e-5	Survival in rectal cancer;
THYM	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg10792982	chr14:105748885	BRF1	0.74	7.68	0.62	1.42e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.64	-4.68	-0.43	9.69e-6	Colorectal cancer;
THYM	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg08999081	chr20:33150536	PIGU	-0.77	-6.95	-0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg04398451	chr17:18023971	MYO15A	-0.98	-10.36	-0.73	2.83e-17	Total body bone mineral density;
THYM	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg25072359	chr17:41440525	NA	0.69	4.8	0.44	5.91e-6	Menopause (age at onset);
THYM	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg03115019	chr17:80708279	FN3K	0.67	4.75	0.44	7.24e-6	Glycated hemoglobin levels;
THYM	cis	rs7726839	0.578	rs112516582	chr5:584319	G/A	cg09021430	chr5:549028	NA	-0.85	-8.88	-0.67	4.08e-14	Obesity-related traits;
THYM	cis	rs6840360	0.571	rs10026670	chr4:152539212	C/T	cg22705602	chr4:152727874	NA	-0.78	-8.73	-0.67	8.56e-14	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs2637266	0.756	rs846623	chr10:78542819	C/T	cg18941641	chr10:78392320	NA	0.69	5.52	0.49	2.99e-7	Pulmonary function;
THYM	cis	rs2180341	0.842	rs9372860	chr6:127546605	G/A	cg27446573	chr6:127587934	RNF146	1.06	8.63	0.66	1.43e-13	Breast cancer;
THYM	cis	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg23231163	chr10:75533350	FUT11	-0.41	-5.84	-0.51	7.41e-8	Inflammatory bowel disease;
THYM	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.8	-6.95	-0.58	4.52e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg13114125	chr14:105738426	BRF1	-0.71	-5.45	-0.49	4.02e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2412459	0.635	rs2640645	chr15:40255400	T/C	cg16127683	chr15:40268777	EIF2AK4	0.53	4.63	0.43	1.16e-5	Response to haloperidol in psychosis;
THYM	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.3	-0.48	7.57e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs2404602	0.647	rs11072619	chr15:77043242	A/C	cg23625390	chr15:77176239	SCAPER	-0.83	-5.98	-0.52	3.96e-8	Blood metabolite levels;
THYM	cis	rs12282928	0.959	rs11500497	chr11:48304461	A/T	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs476633	0.708	rs28656781	chr15:41447440	C/G	cg21153102	chr15:41252147	NA	0.59	4.6	0.43	1.28e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs6980334	1.000	rs6977075	chr7:137775867	C/T	cg11874123	chr7:137028198	PTN	-0.67	-5.24	-0.47	9.68e-7	Blood metabolite ratios;
THYM	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg05425664	chr17:57184151	TRIM37	-0.56	-4.48	-0.42	2.06e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1129187	0.702	rs2296805	chr6:42928758	T/G	cg17345569	chr6:42928274	GNMT	-0.46	-4.5	-0.42	1.92e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg00376283	chr12:123451042	ABCB9	0.71	4.87	0.45	4.45e-6	Neutrophil percentage of white cells;
THYM	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg09904177	chr6:26538194	HMGN4	0.62	4.96	0.45	3.06e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7836436	1.000	rs60108234	chr8:121019582	C/G	cg05020510	chr8:120428057	NOV	0.93	4.85	0.45	4.73e-6	HIV-1 viral setpoint;
THYM	cis	rs977987	0.806	rs11860284	chr16:75412907	A/G	cg03315344	chr16:75512273	CHST6	0.71	6.13	0.53	1.96e-8	Dupuytren's disease;
THYM	cis	rs4343996	0.869	rs10232431	chr7:3511115	G/A	cg21248987	chr7:3385318	SDK1	0.4	4.68	0.43	9.52e-6	Motion sickness;
THYM	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg15440763	chr7:158190612	PTPRN2	-0.52	-4.91	-0.45	3.81e-6	Obesity-related traits;
THYM	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg08999081	chr20:33150536	PIGU	0.8	7.37	0.6	6.23e-11	Coronary artery disease;
THYM	cis	rs921968	0.521	rs56923478	chr2:219638539	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg07884673	chr3:53033167	SFMBT1	1.11	5.86	0.52	6.73e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs4481887	0.893	rs10888348	chr1:248448610	C/G	cg00666640	chr1:248458726	OR2T12	0.55	4.61	0.43	1.24e-5	Common traits (Other);
THYM	cis	rs1021993	0.672	rs2843167	chr1:209512897	A/T	cg24997231	chr1:209527535	NA	-0.51	-4.59	-0.43	1.35e-5	Gut microbiome composition (winter);
THYM	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg04607235	chr12:12878440	APOLD1	-0.93	-5.53	-0.49	2.79e-7	Systemic lupus erythematosus;
THYM	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	7.14	0.59	1.88e-10	Platelet count;
THYM	cis	rs1003719	0.788	rs2040341	chr21:38489753	T/C	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.68	-0.67	1.07e-13	Mean corpuscular volume;
THYM	cis	rs1371867	0.875	rs1788173	chr8:101330939	A/G	cg00191853	chr8:101177733	SPAG1	0.51	5.03	0.46	2.29e-6	Atrioventricular conduction;
THYM	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.79	-0.44	6.18e-6	Mean corpuscular volume;
THYM	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg03264133	chr6:25882463	NA	-0.88	-8.1	-0.64	1.87e-12	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg16928487	chr17:17741425	SREBF1	-0.56	-5.57	-0.5	2.37e-7	Total body bone mineral density;
THYM	cis	rs595982	0.702	rs609985	chr19:49370648	A/G	cg19746536	chr19:49375674	PPP1R15A	1.28	17.69	0.88	8.02e-32	Red cell distribution width;
THYM	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.58	0.43	1.41e-5	Bipolar disorder;
THYM	cis	rs4851254	0.618	rs13033732	chr2:100644797	A/G	cg22139774	chr2:100720529	AFF3	-0.39	-4.46	-0.42	2.21e-5	Intelligence (multi-trait analysis);
THYM	cis	rs11112613	0.713	rs12296355	chr12:105953321	C/A	cg03607813	chr12:105948248	NA	0.99	8.14	0.64	1.51e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs2625529	0.652	rs2957361	chr15:72345218	G/A	cg16672083	chr15:72433130	SENP8	0.5	4.53	0.42	1.69e-5	Red blood cell count;
THYM	cis	rs7546094	0.841	rs663533	chr1:113128804	G/C	cg25616829	chr1:112535356	NA	0.58	4.76	0.44	6.8e-6	Platelet distribution width;
THYM	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg22431228	chr1:16359049	CLCNKA	-0.57	-5.46	-0.49	3.78e-7	Systolic blood pressure;
THYM	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg03806693	chr22:41940476	POLR3H	1.25	10.88	0.74	2.22e-18	Vitiligo;
THYM	cis	rs7901056	0.967	rs3006807	chr10:26724944	G/C	cg23318538	chr10:26883079	C10orf50	-0.34	-4.46	-0.42	2.21e-5	Lymphocyte counts;
THYM	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	4.86	0.45	4.63e-6	Obesity-related traits;
THYM	cis	rs12476592	0.602	rs10865340	chr2:63824049	C/G	cg17519650	chr2:63277830	OTX1	-0.7	-4.71	-0.44	8.46e-6	Childhood ear infection;
THYM	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-5.16	-0.47	1.34e-6	Hemoglobin concentration;
THYM	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg00310523	chr12:86230176	RASSF9	0.61	5.33	0.48	6.57e-7	Major depressive disorder;
THYM	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg20295408	chr7:1910781	MAD1L1	-0.65	-4.93	-0.45	3.42e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs17739794	1.000	rs17739794	chr8:812946	G/A	cg01971667	chr8:817044	NA	0.58	4.91	0.45	3.84e-6	Clozapine-induced cytotoxicity;
THYM	cis	rs2806561	1.000	rs1757048	chr1:23510601	A/C	cg19743168	chr1:23544995	NA	0.62	6.64	0.56	1.93e-9	Height;
THYM	cis	rs898549	1.000	rs898549	chr10:44458714	C/T	cg08683644	chr10:44853092	NA	0.44	4.53	0.42	1.73e-5	Obesity-related traits;
THYM	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg00024416	chr22:24240387	NA	-0.62	-6.48	-0.55	4.11e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs539096	0.831	rs10789436	chr1:44040966	T/G	cg00143623	chr1:44495758	SLC6A9	0.7	5.39	0.48	5.12e-7	Intelligence (multi-trait analysis);
THYM	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg15704280	chr7:45808275	SEPT13	1.02	8.22	0.64	1.04e-12	Coronary artery disease;
THYM	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg24308560	chr3:49941425	MST1R	-0.75	-6.3	-0.54	9.13e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1021993	1.000	rs1027821	chr1:209511886	A/T	cg06155620	chr1:209527581	NA	0.58	4.69	0.43	8.99e-6	Gut microbiome composition (winter);
THYM	cis	rs4936891	0.520	rs11219399	chr11:123868425	C/T	cg22125253	chr11:123886957	OR10G4	-0.57	-4.94	-0.45	3.35e-6	Male fertility;
THYM	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg22907277	chr7:1156413	C7orf50	0.88	7.59	0.61	2.18e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-4.48	-0.42	2.05e-5	Aortic root size;
THYM	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg03264133	chr6:25882463	NA	0.71	5.79	0.51	8.98e-8	Blood metabolite levels;
THYM	cis	rs9326248	0.581	rs7120706	chr11:116830087	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.66	-5.36	-0.48	5.85e-7	Blood protein levels;
THYM	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg07424592	chr7:64974309	NA	1.12	5.24	0.47	9.64e-7	Diabetic kidney disease;
THYM	cis	rs669446	0.529	rs6697354	chr1:44151015	T/G	cg12599982	chr1:44399894	ARTN	0.53	4.79	0.44	6.21e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs713587	0.563	rs11686663	chr2:25107759	C/T	cg01884057	chr2:25150051	NA	0.64	6.32	0.54	8.32e-9	Body mass index in non-asthmatics;
THYM	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg27170947	chr2:26402098	FAM59B	-0.84	-6.46	-0.55	4.42e-9	Gut microbiome composition (summer);
THYM	cis	rs11651000	0.817	rs7502875	chr17:45823227	A/C	cg24803719	chr17:45855879	NA	-0.56	-5.75	-0.51	1.07e-7	IgG glycosylation;
THYM	cis	rs12579753	0.879	rs12579544	chr12:82164043	A/C	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.72	-0.44	7.99e-6	Resting heart rate;
THYM	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg10661904	chr17:79619235	PDE6G	-0.54	-4.79	-0.44	6.25e-6	Eye color traits;
THYM	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	6.7	0.57	1.44e-9	Total body bone mineral density;
THYM	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.09	0.64	1.96e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9677476	0.818	rs6749936	chr2:232055684	C/T	cg23338755	chr2:231921595	PSMD1	0.73	5.43	0.49	4.37e-7	Food antigen IgG levels;
THYM	cis	rs2235649	0.663	rs6600167	chr16:1848912	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.61	-5.31	-0.48	7.12e-7	Blood metabolite levels;
THYM	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg11317459	chr13:21872234	NA	-1.2	-9.08	-0.68	1.49e-14	White matter hyperintensity burden;
THYM	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs6754311	0.638	rs2322659	chr2:136555659	A/G	cg20242066	chr2:136595261	LCT	-0.56	-7.02	-0.58	3.22e-10	Mosquito bite size;
THYM	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg00757033	chr12:89920650	WDR51B	0.77	11.72	0.77	3.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs17641971	0.708	rs974781	chr8:49931055	T/A	cg00325661	chr8:49890786	NA	0.64	4.74	0.44	7.51e-6	Blood metabolite levels;
THYM	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg20007245	chr22:24372913	LOC391322	-0.68	-5.95	-0.52	4.5e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2073300	1.000	rs6137988	chr20:23491910	G/C	cg12062639	chr20:23401060	NAPB	1.24	5.03	0.46	2.3e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg23205692	chr1:25664452	TMEM50A	0.85	6.62	0.56	2.13e-9	Erythrocyte sedimentation rate;
THYM	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg12564285	chr5:131593104	PDLIM4	-0.43	-4.66	-0.43	1.04e-5	Breast cancer;
THYM	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	14.37	0.83	1.47e-25	Chronic sinus infection;
THYM	cis	rs263063	0.834	rs11673509	chr19:5080647	A/G	cg19489188	chr19:4183268	SIRT6;ANKRD24	-0.6	-4.61	-0.43	1.27e-5	Periodontitis (CDC/AAP);
THYM	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg03709012	chr19:19516395	GATAD2A	-0.82	-6.79	-0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs926938	0.765	rs1884296	chr1:115235716	A/C	cg12756093	chr1:115239321	AMPD1	-0.83	-6.37	-0.55	6.85e-9	Autism;
THYM	cis	rs28595532	0.920	rs116405053	chr4:119739352	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg23815491	chr16:72088622	HP	0.69	5.3	0.48	7.58e-7	Fibrinogen levels;
THYM	cis	rs7011507	0.662	rs56348830	chr8:49341995	G/C	cg08774009	chr8:49309094	NA	-0.61	-4.79	-0.44	6.03e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11644478	chr21:40555479	PSMG1	-0.79	-6.94	-0.58	4.72e-10	Cognitive function;
THYM	cis	rs9902453	0.765	rs9890747	chr17:28007442	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	6.52	0.56	3.31e-9	Coffee consumption (cups per day);
THYM	cis	rs611744	0.967	rs637358	chr8:109197454	C/T	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg18681998	chr4:17616180	MED28	0.85	7.68	0.62	1.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg05962950	chr11:130786565	SNX19	-0.98	-9.94	-0.71	2.2e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7107174	1.000	rs2510041	chr11:77945284	G/A	cg02023728	chr11:77925099	USP35	0.73	6.6	0.56	2.29e-9	Testicular germ cell tumor;
THYM	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg10117171	chr1:25599238	RHD	-0.68	-4.87	-0.45	4.52e-6	Erythrocyte sedimentation rate;
THYM	cis	rs9790314	0.934	rs9290074	chr3:160997823	T/C	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg18252515	chr7:66147081	NA	-0.69	-5.46	-0.49	3.79e-7	Aortic root size;
THYM	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg20887711	chr4:1340912	KIAA1530	-0.58	-4.64	-0.43	1.13e-5	Obesity-related traits;
THYM	cis	rs13315871	1.000	rs13078787	chr3:58430487	C/T	cg12435725	chr3:58293450	RPP14	-0.46	-4.93	-0.45	3.54e-6	Cholesterol, total;
THYM	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg19901468	chr14:105411992	AHNAK2	-0.82	-6.71	-0.57	1.42e-9	Rheumatoid arthritis;
THYM	cis	rs2976388	1.000	rs2976392	chr8:143762932	G/A	cg13446199	chr8:143762866	PSCA	0.51	6.42	0.55	5.46e-9	Urinary tract infection frequency;
THYM	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg15242686	chr22:24348715	GSTTP1	0.55	4.94	0.45	3.4e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg17644776	chr2:200775616	C2orf69	0.8	4.75	0.44	7.1e-6	Schizophrenia;
THYM	cis	rs7267979	0.932	rs6037125	chr20:25463382	G/A	cg03522245	chr20:25566470	NINL	0.57	4.48	0.42	2.1e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.79	-6.59	-0.56	2.4e-9	Intelligence (multi-trait analysis);
THYM	cis	rs11792861	0.566	rs67780641	chr9:111850710	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	5.08	0.46	1.85e-6	Menarche (age at onset);
THYM	cis	rs3092073	0.617	rs17448680	chr20:44594726	T/C	cg04940435	chr20:44420291	WFDC3;DNTTIP1	-0.48	-5.05	-0.46	2.16e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg13880726	chr7:1868755	MAD1L1	-0.7	-4.71	-0.43	8.6e-6	Bipolar disorder;
THYM	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg05638439	chr16:711235	WDR90	-0.5	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11644478	chr21:40555479	PSMG1	-0.76	-6.49	-0.55	3.85e-9	Cognitive function;
THYM	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	5.92	0.52	5.15e-8	Total body bone mineral density;
THYM	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg12756686	chr19:29218302	NA	0.87	6.49	0.55	3.86e-9	Methadone dose in opioid dependence;
THYM	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg09549813	chr16:4587862	C16orf5	0.57	6.62	0.56	2.13e-9	Schizophrenia;
THYM	cis	rs6450176	0.909	rs6866586	chr5:53295568	A/C	ch.5.1024479R	chr5:53302184	ARL15	-0.84	-6.38	-0.55	6.53e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg18252515	chr7:66147081	NA	-1.55	-8.6	-0.66	1.63e-13	Diabetic kidney disease;
THYM	cis	rs1797081	1.000	rs2603807	chr10:16872797	A/G	cg23933602	chr10:16859644	RSU1	0.83	8.44	0.65	3.46e-13	Platelet distribution width;
THYM	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.3	-0.48	7.34e-7	Monocyte percentage of white cells;
THYM	cis	rs9393777	0.844	rs28360634	chr6:27332891	T/C	cg23161317	chr6:28129485	ZNF389	1.1	4.63	0.43	1.18e-5	Intelligence (multi-trait analysis);
THYM	cis	rs672413	0.739	rs336526	chr5:78287579	T/G	cg18828365	chr5:78281819	ARSB	-0.57	-5.15	-0.47	1.38e-6	Blood and toenail selenium levels;Blood protein levels;
THYM	cis	rs34638657	0.872	rs7192444	chr16:82180338	C/G	cg09439754	chr16:82129088	HSD17B2	0.59	5.21	0.47	1.07e-6	Lung adenocarcinoma;
THYM	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg08807101	chr21:30365312	RNF160	0.8	6.41	0.55	5.7e-9	Dental caries;
THYM	cis	rs919433	0.679	rs1598469	chr2:198515658	T/C	cg05783139	chr2:198650985	BOLL	0.66	4.96	0.45	3.04e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs78366141	0.649	rs76884708	chr4:89692043	G/C	cg01026744	chr4:89619053	NAP1L5;HERC3	1.25	4.97	0.45	3e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg21475434	chr5:93447410	FAM172A	0.71	4.51	0.42	1.83e-5	Diabetic retinopathy;
THYM	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.56	7.42	0.61	4.92e-11	Monocyte percentage of white cells;
THYM	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg00277334	chr10:82204260	NA	-0.83	-10.18	-0.72	6.99e-17	Post bronchodilator FEV1;
THYM	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.39	0.6	5.71e-11	Lung cancer in ever smokers;
THYM	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg11494091	chr17:61959527	GH2	1.08	17.11	0.87	9.08e-31	Prudent dietary pattern;
THYM	cis	rs10411161	0.702	rs892039	chr19:52396541	G/A	cg25361850	chr19:52391789	ZNF577	0.74	4.96	0.45	3.14e-6	Breast cancer;
THYM	cis	rs12935418	0.583	rs2549837	chr16:81023115	G/A	cg16651780	chr16:81037892	C16orf61	-0.85	-6.53	-0.56	3.16e-9	Mean corpuscular volume;
THYM	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg21427119	chr20:30132790	HM13	0.71	4.79	0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs4731207	0.596	rs10231491	chr7:124574091	C/T	cg05285228	chr7:124571219	POT1	-0.69	-5.25	-0.47	9.35e-7	Cutaneous malignant melanoma;
THYM	cis	rs3849570	0.961	rs3772896	chr3:81751968	C/T	cg07356753	chr3:81810745	GBE1	-0.93	-7.68	-0.62	1.43e-11	Waist circumference;Body mass index;
THYM	cis	rs9653442	0.777	rs6732141	chr2:100743492	G/C	cg22139774	chr2:100720529	AFF3	-0.36	-5.68	-0.5	1.49e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs7523273	0.564	rs1570565	chr1:207881256	G/A	cg22525895	chr1:207977042	MIR29B2	0.5	4.59	0.43	1.34e-5	Schizophrenia;
THYM	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg10802521	chr3:52805072	NEK4	-0.67	-5.71	-0.51	1.31e-7	Bipolar disorder;
THYM	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg13395646	chr4:1353034	KIAA1530	-0.72	-6.59	-0.56	2.4e-9	Obesity-related traits;
THYM	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2354432	0.505	rs3737845	chr1:146724408	A/G	cg25205988	chr1:146714368	CHD1L	1.04	5.54	0.49	2.67e-7	Mitochondrial DNA levels;
THYM	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg20887711	chr4:1340912	KIAA1530	0.96	8.88	0.67	4.18e-14	Longevity;
THYM	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg24006582	chr15:45444508	DUOX1	0.77	6.04	0.53	3.05e-8	Uric acid levels;
THYM	cis	rs4940575	0.679	rs7228914	chr18:60833226	A/G	cg25271770	chr18:61057090	VPS4B	0.72	4.54	0.42	1.62e-5	Breast cancer;
THYM	cis	rs910187	1.000	rs6063085	chr20:45840459	A/C	cg27589058	chr20:45804311	EYA2	-0.58	-4.75	-0.44	7.21e-6	Migraine;
THYM	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg24209194	chr3:40518798	ZNF619	0.74	6.51	0.56	3.48e-9	Renal cell carcinoma;
THYM	cis	rs899997	0.906	rs62010552	chr15:78987686	T/C	cg04896959	chr15:78267971	NA	-0.95	-8.59	-0.66	1.68e-13	Coronary artery disease or large artery stroke;
THYM	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.87	0.45	4.53e-6	Bipolar disorder;
THYM	cis	rs7586879	0.575	rs6706316	chr2:25128351	C/G	cg01884057	chr2:25150051	NA	0.73	7.92	0.63	4.47e-12	Body mass index;
THYM	cis	rs8030485	0.716	rs12899109	chr15:79410970	T/C	cg17916960	chr15:79447300	NA	0.52	5.39	0.48	5.1e-7	Left ventricle wall thickness;
THYM	cis	rs1978968	0.717	rs35645198	chr22:18408322	C/T	cg01550578	chr22:18484421	MICAL3	0.63	4.7	0.43	8.75e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.76	6.74	0.57	1.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg18252515	chr7:66147081	NA	-1.51	-9.22	-0.69	7.87e-15	Diabetic kidney disease;
THYM	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.59	-4.54	-0.42	1.64e-5	Total body bone mineral density;
THYM	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg23791538	chr6:167370224	RNASET2	-0.78	-6.28	-0.54	1.02e-8	Crohn's disease;
THYM	cis	rs754466	0.580	rs10824576	chr10:79566040	G/C	cg17075019	chr10:79541650	NA	-0.59	-4.79	-0.44	6.24e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs1448094	0.511	rs10735486	chr12:86154352	T/A	cg00310523	chr12:86230176	RASSF9	-0.54	-4.74	-0.44	7.6e-6	Major depressive disorder;
THYM	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs34638657	0.646	rs72628279	chr16:82199664	A/C	cg09439754	chr16:82129088	HSD17B2	-0.51	-4.94	-0.45	3.31e-6	Lung adenocarcinoma;
THYM	cis	rs10871290	0.881	rs7498574	chr16:74472661	A/G	cg01733217	chr16:74700730	RFWD3	-0.66	-5.65	-0.5	1.67e-7	Breast cancer;
THYM	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg01579765	chr21:45077557	HSF2BP	-0.54	-9.11	-0.68	1.33e-14	Mean corpuscular volume;
THYM	cis	rs4660306	0.614	rs1765711	chr1:45936285	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.66	4.74	0.44	7.56e-6	Homocysteine levels;
THYM	cis	rs56309584	0.715	rs77224069	chr17:8124268	G/C	cg11257113	chr17:8062204	NA	-0.61	-4.45	-0.42	2.33e-5	Initial pursuit acceleration;
THYM	cis	rs4889855	0.556	rs74003969	chr17:78526212	C/T	cg16591659	chr17:78472290	NA	0.42	4.79	0.44	6.21e-6	Fractional excretion of uric acid;
THYM	cis	rs3796352	1.000	rs11717619	chr3:53003179	A/C	cg04865290	chr3:52927548	TMEM110	-0.88	-4.75	-0.44	7.08e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	12.82	0.8	1.97e-22	Chronic sinus infection;
THYM	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.78	5.42	0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs7568458	0.870	rs6757263	chr2:85803542	A/G	cg17127132	chr2:85788382	GGCX	0.65	5.14	0.47	1.45e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg06784218	chr1:46089804	CCDC17	-0.34	-5.03	-0.46	2.28e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs2718058	0.519	rs2598071	chr7:37875347	G/A	cg15028436	chr7:37888078	TXNDC3	0.7	4.52	0.42	1.79e-5	Alzheimer's disease (late onset);
THYM	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg16797656	chr11:68205561	LRP5	0.43	4.59	0.43	1.35e-5	Total body bone mineral density;
THYM	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6840360	0.642	rs2709842	chr4:152370637	C/T	cg17479576	chr4:152424074	FAM160A1	0.69	5.2	0.47	1.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4888262	0.545	rs58136167	chr16:74700628	G/A	cg01733217	chr16:74700730	RFWD3	0.88	9.59	0.7	1.24e-15	Testicular germ cell tumor;
THYM	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg10057126	chr4:77819792	ANKRD56	0.7	5.93	0.52	4.87e-8	Emphysema distribution in smoking;
THYM	cis	rs10906142	0.584	rs2768371	chr10:12459061	C/G	cg04745698	chr10:12084977	UPF2	-0.61	-4.46	-0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs6563943	1.000	rs9934609	chr16:83638578	C/T	cg01935413	chr16:83636749	CDH13	0.59	5.91	0.52	5.24e-8	Height;
THYM	cis	rs7107174	1.000	rs10899492	chr11:78109810	G/A	cg02023728	chr11:77925099	USP35	0.61	5.89	0.52	5.93e-8	Testicular germ cell tumor;
THYM	trans	rs10462794	0.789	rs7719895	chr5:4490338	C/T	cg12128740	chr1:62207888	INADL	-1.2	-6.88	-0.58	6.27e-10	DNA methylation (variation);
THYM	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.65	4.7	0.43	8.75e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.54	0.42	1.66e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12043259	0.571	rs737017	chr1:204863121	A/G	cg08830492	chr1:204899141	NFASC	-1.02	-4.71	-0.44	8.45e-6	Addiction;
THYM	cis	rs34779708	0.931	rs12768019	chr10:35389843	T/C	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7084402	0.967	rs2114564	chr10:60314729	T/C	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.93	-4.79	-0.44	6.14e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2991971	0.729	rs10890328	chr1:45905383	G/T	cg15605315	chr1:45957053	TESK2	-0.65	-5.24	-0.47	9.64e-7	High light scatter reticulocyte count;
THYM	cis	rs7772486	0.686	rs9497380	chr6:145955305	T/C	cg23711669	chr6:146136114	FBXO30	0.85	8.17	0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7772486	0.782	rs7747576	chr6:146277827	C/T	cg23711669	chr6:146136114	FBXO30	-0.93	-9.43	-0.7	2.71e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg03188948	chr7:1209495	NA	0.67	5.25	0.47	9.18e-7	Longevity;Endometriosis;
THYM	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg08645402	chr16:4508243	NA	0.61	5.39	0.48	5.16e-7	Schizophrenia;
THYM	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg02136620	chr5:178986620	RUFY1	-0.57	-5.7	-0.5	1.37e-7	Lung cancer;
THYM	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg17775962	chr7:1200435	ZFAND2A	0.42	4.91	0.45	3.81e-6	Longevity;Endometriosis;
THYM	cis	rs11166927	0.901	rs7014257	chr8:140802694	G/T	cg16909799	chr8:140841666	TRAPPC9	0.62	5.51	0.49	3.11e-7	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs6429082	0.783	rs390539	chr1:235679690	A/C	cg26050004	chr1:235667680	B3GALNT2	0.69	5.65	0.5	1.65e-7	Adiposity;
THYM	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg08772003	chr10:104629869	AS3MT	-0.73	-6.87	-0.58	6.77e-10	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs8030485	0.964	rs8032861	chr15:79412728	A/C	cg17916960	chr15:79447300	NA	0.53	5.47	0.49	3.6e-7	Left ventricle wall thickness;
THYM	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg07936489	chr17:37558343	FBXL20	0.83	5.77	0.51	1e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg00383909	chr3:49044727	WDR6	1.12	6.62	0.56	2.13e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg18681998	chr4:17616180	MED28	0.86	7.7	0.62	1.31e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg16586182	chr3:47516702	SCAP	-0.64	-5.61	-0.5	2.03e-7	Colorectal cancer;
THYM	cis	rs289828	0.519	rs115750653	chr2:152153572	G/A	cg05960677	chr2:152117363	RBM43	0.71	6.61	0.56	2.24e-9	Blood protein levels;
THYM	trans	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg16342193	chr10:102329863	NA	-0.52	-5.09	-0.46	1.83e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs55702914	0.809	rs2376407	chr2:198183465	A/G	cg00792783	chr2:198669748	PLCL1	-0.66	-5.07	-0.46	1.98e-6	Major depression and alcohol dependence;
THYM	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg06808227	chr14:105710500	BRF1	-1.05	-9.15	-0.68	1.07e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs34638657	0.687	rs2303265	chr16:82203705	A/C	cg09894383	chr16:82067445	HSD17B2	-0.44	-4.91	-0.45	3.8e-6	Lung adenocarcinoma;
THYM	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg24324837	chr19:49891574	CCDC155	0.52	4.68	0.43	9.63e-6	Multiple sclerosis;
THYM	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg24020549	chr11:64937741	SPDYC	-0.5	-4.68	-0.43	9.61e-6	Eosinophil percentage of white cells;
THYM	cis	rs490234	0.783	rs13283793	chr9:128441641	C/T	cg14078157	chr9:128172775	NA	-0.67	-5.3	-0.48	7.59e-7	Mean arterial pressure;
THYM	cis	rs9527	0.590	rs10786744	chr10:104945028	A/C	cg04362960	chr10:104952993	NT5C2	-0.59	-4.53	-0.42	1.74e-5	Arsenic metabolism;
THYM	cis	rs800586	0.500	rs2721960	chr8:116656729	G/A	cg04656070	chr8:116661063	TRPS1	-0.56	-6.66	-0.56	1.75e-9	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs919433	0.679	rs10203581	chr2:198515900	G/A	cg00792783	chr2:198669748	PLCL1	0.81	5.31	0.48	7.04e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-13.87	-0.82	1.48e-24	Height;
THYM	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.7	-5.63	-0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg08994789	chr17:28903642	LRRC37B2	-1.16	-5.63	-0.5	1.85e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg24678163	chr13:52769951	THSD1P	0.49	4.58	0.43	1.38e-5	Lewy body disease;
THYM	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg26818010	chr10:134567672	INPP5A	-0.8	-6.36	-0.55	6.97e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.32	0.54	8.42e-9	Platelet count;
THYM	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.78	-0.44	6.31e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg22431228	chr1:16359049	CLCNKA	-0.53	-5.13	-0.47	1.51e-6	Dilated cardiomyopathy;
THYM	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg14416269	chr4:6271139	WFS1	0.47	4.57	0.42	1.45e-5	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.88	7.97	0.63	3.46e-12	Monocyte percentage of white cells;
THYM	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg24308560	chr3:49941425	MST1R	-0.76	-6.34	-0.55	7.57e-9	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs208520	0.661	rs207090	chr6:66783963	T/A	cg07460842	chr6:66804631	NA	-1.06	-7.89	-0.63	5.14e-12	Exhaled nitric oxide output;
THYM	cis	rs7578361	0.959	rs4129904	chr2:150447741	C/G	cg17961725	chr2:150454027	NA	0.75	6.45	0.55	4.58e-9	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4747241	0.699	rs4596994	chr10:74078408	T/G	cg07828833	chr10:74069493	NA	-0.53	-4.52	-0.42	1.75e-5	Heschl's gyrus morphology;
THYM	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.6	5.61	0.5	1.96e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg09455208	chr3:40491958	NA	0.48	5.0	0.46	2.66e-6	Renal cell carcinoma;
THYM	cis	rs7267979	1.000	rs6083862	chr20:25411086	A/T	cg08601574	chr20:25228251	PYGB	-0.59	-4.71	-0.44	8.4e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs8067545	0.720	rs11204420	chr17:19889020	A/C	cg20830565	chr17:20408647	MGC102966	-0.52	-4.92	-0.45	3.69e-6	Schizophrenia;
THYM	cis	rs1568889	1.000	rs7112860	chr11:28151609	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.55e-6	Bipolar disorder;
THYM	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11186	0.556	rs58106884	chr2:189953508	C/T	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg01324343	chr3:183735012	ABCC5	0.89	13.33	0.81	1.82e-23	Anterior chamber depth;
THYM	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg26818010	chr10:134567672	INPP5A	-0.93	-7.48	-0.61	3.71e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs763014	0.898	rs4984895	chr16:623238	T/C	cg09263875	chr16:632152	PIGQ	0.71	6.15	0.53	1.85e-8	Height;
THYM	cis	rs747334	0.846	rs1001846	chr10:92717695	G/A	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg26418147	chr1:205743515	RAB7L1	-0.55	-4.69	-0.43	9.01e-6	Menarche (age at onset);
THYM	cis	rs4900538	0.787	rs11704	chr14:102808655	C/G	cg18135206	chr14:102964638	TECPR2	0.78	5.9	0.52	5.62e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs11264213	0.901	rs2791962	chr1:36371168	T/C	cg27506609	chr1:36549197	TEKT2	0.93	4.87	0.45	4.47e-6	Schizophrenia;
THYM	cis	rs3916	1.000	rs2014355	chr12:121175524	A/G	cg21892295	chr12:121157589	UNC119B	-0.5	-4.8	-0.44	5.9e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg20151795	chr6:28129481	ZNF389	0.76	4.66	0.43	1.05e-5	Parkinson's disease;
THYM	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg26924012	chr15:45694286	SPATA5L1	1.14	10.78	0.74	3.64e-18	Homoarginine levels;
THYM	cis	rs13102973	0.899	rs13104662	chr4:135904615	C/T	cg14419869	chr4:135874104	NA	0.82	6.86	0.58	7.03e-10	Subjective well-being;
THYM	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg22907277	chr7:1156413	C7orf50	0.81	4.97	0.45	2.94e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg09549813	chr16:4587862	C16orf5	-0.57	-6.04	-0.53	2.95e-8	Schizophrenia;
THYM	cis	rs9796	0.866	rs2928148	chr15:41401550	G/A	cg21153102	chr15:41252147	NA	-0.7	-6.28	-0.54	1.02e-8	Menopause (age at onset);
THYM	cis	rs72781680	1.000	rs72796327	chr2:24140372	T/C	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs7809950	0.815	rs62482495	chr7:106965009	A/G	cg23024343	chr7:107201750	COG5	-1.0	-8.43	-0.65	3.79e-13	Coronary artery disease;
THYM	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg16989719	chr2:238392110	NA	-0.65	-5.95	-0.52	4.44e-8	Prostate cancer;
THYM	cis	rs863345	0.604	rs2873594	chr1:158504790	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs72627123	0.867	rs72627134	chr14:74395582	T/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs9563576	0.778	rs34399097	chr13:58632133	T/C	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg02869364	chr7:1081709	C7orf50	-0.61	-4.9	-0.45	3.96e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs988913	1.000	rs9382403	chr6:54825687	A/C	cg04690482	chr6:54711388	FAM83B	0.46	5.17	0.47	1.31e-6	Menarche (age at onset);
THYM	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg11845111	chr2:191398756	TMEM194B	0.94	8.54	0.66	2.11e-13	Pulse pressure;
THYM	cis	rs2637266	0.967	rs4979898	chr10:78355672	G/A	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs7267979	0.668	rs2387977	chr20:25599776	C/T	cg24626310	chr20:25276739	ABHD12;PYGB	-0.27	-4.46	-0.42	2.24e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg17054759	chr22:49844102	NA	-0.53	-5.05	-0.46	2.09e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs995000	0.965	rs11207982	chr1:63007182	C/T	cg06896770	chr1:63153194	DOCK7	1.0	8.27	0.65	7.91e-13	Triglyceride levels;
THYM	cis	rs56104184	0.775	rs117744769	chr19:49402686	G/T	cg21252483	chr19:49399788	TULP2	-0.96	-7.25	-0.6	1.09e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs11771526	0.901	rs78065961	chr7:32300967	C/T	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs1728785	0.901	rs1170438	chr16:68608256	T/C	cg02972257	chr16:68554789	NA	-0.77	-4.75	-0.44	7.14e-6	Ulcerative colitis;
THYM	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg20486651	chr6:167070296	RPS6KA2	0.5	4.79	0.44	6.18e-6	Crohn's disease;
THYM	cis	rs7412746	0.611	rs11204726	chr1:150743492	T/C	cg15448220	chr1:150897856	SETDB1	0.88	7.31	0.6	8.31e-11	Melanoma;
THYM	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg08859206	chr1:53392774	SCP2	-0.51	-5.32	-0.48	7.04e-7	Monocyte count;
THYM	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg09904177	chr6:26538194	HMGN4	0.61	4.93	0.45	3.55e-6	Intelligence (multi-trait analysis);
THYM	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg16486109	chr11:613632	IRF7	0.51	5.7	0.5	1.34e-7	Systemic lupus erythematosus;
THYM	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs72781680	0.898	rs72796158	chr2:23935727	T/C	cg08917208	chr2:24149416	ATAD2B	1.1	4.81	0.44	5.71e-6	Lymphocyte counts;
THYM	cis	rs7582180	0.625	rs12612755	chr2:100906061	T/C	cg21926883	chr2:100939477	LONRF2	-0.59	-4.89	-0.45	4.08e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.78	-6.0	-0.52	3.58e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.75	-4.46	-0.42	2.26e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs6500395	0.775	rs4277341	chr16:48664387	T/G	cg04672837	chr16:48644449	N4BP1	0.47	4.62	0.43	1.18e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs6430585	0.941	rs6708957	chr2:136520043	C/T	cg04750100	chr2:136595281	LCT	0.53	5.13	0.47	1.55e-6	Corneal structure;
THYM	cis	rs3820068	0.705	rs4646072	chr1:15827711	G/A	cg05660106	chr1:15850417	CASP9	1.13	10.23	0.72	5.39e-17	Systolic blood pressure;
THYM	cis	rs10979	1.000	rs9386036	chr6:143890709	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg04043695	chr12:129287642	SLC15A4	0.58	4.54	0.42	1.64e-5	Systemic lupus erythematosus;
THYM	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg03806693	chr22:41940476	POLR3H	-0.8	-6.99	-0.58	3.81e-10	Neuroticism;
THYM	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg13114125	chr14:105738426	BRF1	-0.72	-5.61	-0.5	2.01e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1467026	0.584	rs9865381	chr3:12801685	C/T	cg05775895	chr3:12838266	CAND2	0.79	6.39	0.55	6.14e-9	P wave duration;
THYM	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg10505658	chr17:80084571	CCDC57	-0.69	-7.95	-0.63	3.85e-12	Life satisfaction;
THYM	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg19747945	chr6:42946146	PEX6	-0.33	-5.01	-0.46	2.48e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg24060327	chr5:131705240	SLC22A5	-0.71	-5.43	-0.49	4.3e-7	Breast cancer;
THYM	cis	rs1883415	0.552	rs2143083	chr6:24507054	C/T	cg00346970	chr6:24499591	ALDH5A1	0.4	6.44	0.55	4.96e-9	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4595586	0.545	rs2388174	chr12:39389237	G/A	cg26384229	chr12:38710491	ALG10B	0.65	4.81	0.44	5.76e-6	Morning vs. evening chronotype;
THYM	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.22	4.52	0.42	1.75e-5	Obesity-related traits;
THYM	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg08431931	chr22:42394659	WBP2NL	-0.71	-5.72	-0.51	1.23e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs5760092	0.717	rs5760101	chr22:24248712	T/C	cg02953382	chr22:24373134	LOC391322	-0.66	-4.93	-0.45	3.43e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs11731175	1.000	rs4863074	chr4:189854759	C/A	cg00431894	chr4:189871012	NA	-0.81	-6.19	-0.54	1.52e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	trans	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs13256369	1.000	rs13266699	chr8:8570313	A/T	cg18904891	chr8:8559673	CLDN23	-0.7	-5.21	-0.47	1.1e-6	Obesity-related traits;
THYM	cis	rs113835537	0.529	rs75685325	chr11:66235242	A/G	cg24851651	chr11:66362959	CCS	0.74	5.1	0.46	1.74e-6	Airway imaging phenotypes;
THYM	cis	rs1729951	0.575	rs1682356	chr3:136692037	T/C	cg12473912	chr3:136751656	NA	0.63	5.13	0.47	1.55e-6	Neuroticism;
THYM	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg11266682	chr4:10021025	SLC2A9	0.71	9.52	0.7	1.75e-15	Bone mineral density;
THYM	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7172809	0.573	rs8035526	chr15:77683247	T/G	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg14972814	chr11:95582409	MTMR2	-0.59	-5.36	-0.48	5.87e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs56322409	0.561	rs7099284	chr10:97366746	C/T	cg00110277	chr10:97668174	C10orf131	-0.58	-4.91	-0.45	3.72e-6	Blood metabolite levels;
THYM	cis	rs539096	0.671	rs513862	chr1:44114405	A/T	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg03709012	chr19:19516395	GATAD2A	0.75	5.77	0.51	9.88e-8	Tonsillectomy;
THYM	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-8.52	-0.66	2.33e-13	Schizophrenia;
THYM	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg16049864	chr8:95962084	TP53INP1	0.77	6.41	0.55	5.55e-9	Type 2 diabetes;
THYM	cis	rs10788264	0.504	rs1034533	chr10:124032434	A/G	cg09507567	chr10:124027408	NA	0.53	5.43	0.49	4.23e-7	Total body bone mineral density;
THYM	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg00256281	chr22:41985642	PMM1	-0.56	-4.47	-0.42	2.2e-5	Vitiligo;
THYM	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg16928487	chr17:17741425	SREBF1	-0.48	-4.48	-0.42	2.09e-5	Total body bone mineral density;
THYM	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg02493740	chr2:85810744	VAMP5	-0.64	-5.05	-0.46	2.12e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs11190604	0.943	rs11190568	chr10:102224277	C/T	cg07570687	chr10:102243282	WNT8B	0.81	7.2	0.59	1.38e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg04772025	chr11:68637568	NA	0.63	6.58	0.56	2.59e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg00801512	chr17:28996047	NA	-0.76	-4.9	-0.45	3.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg08847533	chr14:75593920	NEK9	-0.97	-10.03	-0.72	1.4e-16	Height;
THYM	cis	rs4072705	0.615	rs7028021	chr9:127249022	A/G	cg14219918	chr9:127249562	NR5A1	0.3	4.61	0.43	1.27e-5	Menarche (age at onset);
THYM	cis	rs700651	0.757	rs6748683	chr2:198878008	T/A	cg00792783	chr2:198669748	PLCL1	0.82	5.63	0.5	1.79e-7	Intracranial aneurysm;
THYM	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg12826209	chr6:26865740	GUSBL1	0.84	6.07	0.53	2.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg23281280	chr6:28129359	ZNF389	0.61	4.74	0.44	7.58e-6	Parkinson's disease;
THYM	cis	rs9311676	0.656	rs11130636	chr3:58380098	C/A	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg08133631	chr1:26527909	CATSPER4	-0.57	-4.69	-0.43	9.29e-6	Obesity-related traits;
THYM	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg12310025	chr6:25882481	NA	0.77	6.25	0.54	1.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg27129171	chr3:47204927	SETD2	-0.73	-7.07	-0.59	2.65e-10	Colorectal cancer;
THYM	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg24060327	chr5:131705240	SLC22A5	-0.81	-6.71	-0.57	1.4e-9	Breast cancer;
THYM	cis	rs9733	0.519	rs11800855	chr1:150800995	G/A	cg10589385	chr1:150898437	SETDB1	0.58	4.81	0.44	5.55e-6	Tonsillectomy;
THYM	cis	rs6570726	0.935	rs374000	chr6:145855290	C/T	cg13319975	chr6:146136371	FBXO30	-0.66	-5.63	-0.5	1.85e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg09395187	chr16:88023319	BANP	-0.69	-4.62	-0.43	1.19e-5	Menopause (age at onset);
THYM	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg27588902	chr6:42928151	GNMT	-0.48	-4.62	-0.43	1.19e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs34526934	0.830	rs13028842	chr2:177042261	A/G	cg26754761	chr2:177040938	NA	-0.7	-5.55	-0.49	2.6e-7	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs12216545	0.737	rs1522595	chr7:150235835	G/C	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7172809	0.573	rs1446313	chr15:77475380	G/T	cg22256960	chr15:77711686	NA	-0.65	-4.83	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs11190604	0.767	rs79106148	chr10:102184732	G/A	cg07570687	chr10:102243282	WNT8B	0.81	7.81	0.63	7.43e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg24812749	chr6:127587940	RNF146	1.01	6.68	0.57	1.61e-9	Breast cancer;
THYM	cis	rs12476592	0.602	rs10865337	chr2:63720906	C/T	cg17519650	chr2:63277830	OTX1	-0.7	-4.68	-0.43	9.57e-6	Childhood ear infection;
THYM	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg27490568	chr2:178487706	NA	0.61	5.57	0.5	2.4e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.18	0.64	1.26e-12	Corneal astigmatism;
THYM	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg25251562	chr2:3704773	ALLC	0.83	6.0	0.52	3.54e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg10281704	chr16:966864	LMF1	-0.26	-4.46	-0.42	2.24e-5	Height;
THYM	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs886774	0.526	rs6976266	chr7:107502141	G/T	cg23293999	chr7:106826042	HBP1	-0.59	-4.59	-0.43	1.36e-5	Ulcerative colitis;
THYM	cis	rs3862030	0.839	rs7078511	chr10:104283874	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.68	-5.74	-0.51	1.15e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg06634786	chr22:41940651	POLR3H	-0.74	-5.23	-0.47	9.94e-7	Vitiligo;
THYM	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg00495681	chr13:53174319	NA	0.75	6.93	0.58	4.94e-10	Lewy body disease;
THYM	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg22841779	chr14:105766346	BRF1	-0.46	-5.69	-0.5	1.42e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs9796	0.653	rs28516683	chr15:41446645	A/G	cg21153102	chr15:41252147	NA	0.6	5.05	0.46	2.09e-6	Menopause (age at onset);
THYM	cis	rs986417	0.818	rs7153263	chr14:61099261	G/A	cg27398547	chr14:60952738	C14orf39	0.94	5.21	0.47	1.07e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs4731207	0.596	rs10280341	chr7:124583935	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg12310025	chr6:25882481	NA	0.85	7.26	0.6	1.08e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9595908	0.965	rs8000071	chr13:33125373	C/G	cg12383807	chr13:33924137	NA	-0.54	-4.72	-0.44	8.02e-6	Body mass index;
THYM	cis	rs10463554	0.927	rs158396	chr5:102411719	G/A	cg23492399	chr5:102201601	PAM	-0.68	-5.13	-0.47	1.56e-6	Parkinson's disease;
THYM	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg25287198	chr4:183728479	NA	0.76	4.65	0.43	1.08e-5	Pediatric autoimmune diseases;
THYM	cis	rs12824058	0.844	rs10744458	chr12:130805820	C/T	cg26677194	chr12:130822605	PIWIL1	-0.62	-4.65	-0.43	1.07e-5	Menopause (age at onset);
THYM	cis	rs6500395	1.000	rs7191028	chr16:48626023	T/C	cg04672837	chr16:48644449	N4BP1	0.48	4.72	0.44	8.06e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-4.55	-0.42	1.59e-5	Tonsillectomy;
THYM	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg26513180	chr16:89883248	FANCA	-0.71	-6.96	-0.58	4.44e-10	Vitiligo;
THYM	cis	rs4363385	0.510	rs11590835	chr1:153047166	T/C	cg13444842	chr1:152974279	SPRR3	-0.6	-4.66	-0.43	1.03e-5	Inflammatory skin disease;
THYM	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg00640147	chr17:61958756	GH2	-0.43	-4.6	-0.43	1.3e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs12188164	0.930	rs11743825	chr5:475463	C/T	cg22025206	chr5:502436	SLC9A3	-0.57	-4.46	-0.42	2.27e-5	Cystic fibrosis severity;
THYM	cis	rs11645898	0.625	rs8047930	chr16:72106024	C/T	cg14768367	chr16:72042858	DHODH	-0.59	-4.47	-0.42	2.18e-5	Blood protein levels;
THYM	cis	rs11969893	0.850	rs9390697	chr6:101294431	G/A	cg12253828	chr6:101329408	ASCC3	1.21	6.92	0.58	5.19e-10	Economic and political preferences (immigration/crime);
THYM	cis	rs6424115	0.867	rs2501432	chr1:24201920	T/C	cg15997130	chr1:24165203	NA	0.76	6.39	0.55	6.14e-9	Immature fraction of reticulocytes;
THYM	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7927771	0.524	rs3758655	chr11:47703943	T/C	cg20307385	chr11:47447363	PSMC3	0.6	4.51	0.42	1.87e-5	Subjective well-being;
THYM	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg00080972	chr5:178986291	RUFY1	0.54	6.2	0.54	1.45e-8	Lung cancer;
THYM	cis	rs11048434	0.736	rs4309200	chr12:9121856	A/C	cg13575925	chr12:9217583	LOC144571	0.53	4.94	0.45	3.31e-6	Sjögren's syndrome;
THYM	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg02503808	chr4:7069936	GRPEL1	1.08	9.2	0.69	8.27e-15	Monocyte percentage of white cells;
THYM	cis	rs1371867	0.875	rs962452	chr8:101331369	G/A	cg00191853	chr8:101177733	SPAG1	-0.51	-5.03	-0.46	2.29e-6	Atrioventricular conduction;
THYM	cis	rs6500395	1.000	rs11076573	chr16:48632758	A/G	cg04672837	chr16:48644449	N4BP1	0.46	4.56	0.42	1.53e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs10492096	0.947	rs11064227	chr12:6598043	A/G	cg13857086	chr12:6580257	VAMP1	0.88	5.33	0.48	6.73e-7	Hip geometry;
THYM	cis	rs7084402	0.967	rs1427224	chr10:60290620	G/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.84	-5.3	-0.48	7.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg05340658	chr4:99064831	C4orf37	0.54	4.55	0.42	1.61e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7192750	0.539	rs7193731	chr16:71897399	T/C	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg16068833	chr1:26644515	UBXN11;CD52	0.26	4.5	0.42	1.9e-5	Obesity-related traits;
THYM	cis	rs2294693	0.853	rs9296350	chr6:40977623	G/A	cg14418226	chr6:40996092	UNC5CL	0.61	5.24	0.47	9.86e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg23260525	chr10:116636907	FAM160B1	0.51	5.24	0.47	9.53e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs61931739	0.749	rs11053093	chr12:34231095	A/G	cg06521331	chr12:34319734	NA	-0.59	-4.99	-0.46	2.77e-6	Morning vs. evening chronotype;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg08405910	chr2:106501075	NCK2	-0.96	-7.72	-0.62	1.14e-11	Depressive symptoms;
THYM	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg15212455	chr7:39170539	POU6F2	0.61	5.59	0.5	2.18e-7	IgG glycosylation;
THYM	cis	rs1747683	0.677	rs1095368	chr10:13355131	T/C	cg00142036	chr10:13388442	SEPHS1	0.32	6.24	0.54	1.23e-8	IgG glycosylation;
THYM	cis	rs7666738	0.606	rs4699606	chr4:99095074	A/C	cg17366294	chr4:99064904	C4orf37	-0.44	-4.71	-0.43	8.59e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9810089	0.868	rs4630889	chr3:136278251	T/C	cg21827317	chr3:136751795	NA	0.57	4.87	0.45	4.42e-6	Gestational age at birth (child effect);
THYM	cis	rs72828912	0.764	rs9379639	chr6:24090993	T/A	cg19882886	chr6:25043046	NA	-0.89	-4.62	-0.43	1.22e-5	Squamous cell lung carcinoma;
THYM	cis	rs4604732	0.588	rs6677477	chr1:247629411	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.7	4.84	0.45	4.93e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.66	4.63	0.43	1.18e-5	Aortic root size;
THYM	cis	rs7927771	0.864	rs3781627	chr11:47441472	T/A	cg20307385	chr11:47447363	PSMC3	0.61	4.89	0.45	4.18e-6	Subjective well-being;
THYM	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg07959070	chr22:50026188	C22orf34	-0.27	-4.67	-0.43	1e-5	Monocyte count;Monocyte percentage of white cells;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg20811730	chr1:150293902	PRPF3	-1.31	-6.91	-0.58	5.45e-10	Pulmonary function decline;
THYM	cis	rs7113850	0.541	rs7948382	chr11:24246608	T/C	ch.11.24196551F	chr11:24239977	NA	0.92	4.98	0.46	2.8e-6	Bone fracture in osteoporosis;
THYM	cis	rs12928939	0.517	rs11865456	chr16:71969497	C/T	cg03805757	chr16:71968109	PKD1L3	-0.99	-9.88	-0.71	2.99e-16	Post bronchodilator FEV1;
THYM	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06634786	chr22:41940651	POLR3H	-0.81	-5.97	-0.52	4.16e-8	Vitiligo;
THYM	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs12681288	0.550	rs4410933	chr8:959581	A/G	cg23354307	chr8:1885189	ARHGEF10	-0.56	-4.63	-0.43	1.17e-5	Schizophrenia;
THYM	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs240764	0.817	rs239216	chr6:101147892	T/G	cg21058520	chr6:100914733	NA	-0.58	-5.22	-0.47	1.04e-6	Neuroticism;
THYM	cis	rs6593803	0.728	rs11586163	chr1:147165272	T/C	cg06627043	chr1:147838662	NA	0.51	4.86	0.45	4.59e-6	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
THYM	cis	rs651907	0.967	rs694936	chr3:101587793	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	5.13	0.47	1.54e-6	Colorectal cancer;
THYM	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-6.12	-0.53	2.09e-8	Chronic sinus infection;
THYM	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg11247378	chr22:39784982	NA	-0.91	-6.33	-0.54	8.18e-9	IgG glycosylation;
THYM	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs863345	0.604	rs2317970	chr1:158504770	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs10751667	1.000	rs10794357	chr11:973374	T/C	ch.11.42038R	chr11:967971	AP2A2	0.56	4.49	0.42	1.98e-5	Alzheimer's disease (late onset);
THYM	cis	rs10463554	0.927	rs34373	chr5:102404294	T/C	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs9486719	0.895	rs11152960	chr6:96900398	A/G	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs4478858	0.698	rs10914370	chr1:31854955	T/C	cg00250761	chr1:31883323	NA	-0.42	-4.64	-0.43	1.09e-5	Alcohol dependence;
THYM	cis	rs7677751	0.806	rs4864861	chr4:55097685	C/T	cg17187183	chr4:55093834	PDGFRA	0.74	5.53	0.49	2.78e-7	Corneal astigmatism;
THYM	cis	rs3540	0.597	rs1978149	chr15:91036976	A/G	cg00487526	chr15:90818384	NA	-0.58	-4.47	-0.42	2.19e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs7757969	1.000	rs6908866	chr6:112118505	A/C	cg08601457	chr6:112115117	FYN	0.42	4.79	0.44	6.23e-6	Schizophrenia;
THYM	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg02018176	chr4:1364513	KIAA1530	0.85	7.75	0.62	1.02e-11	Longevity;
THYM	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	1.0	9.83	0.71	3.79e-16	Body mass index (adult);
THYM	cis	rs2242116	0.833	rs6442038	chr3:46960742	A/G	cg23352942	chr3:46931381	PTH1R	-0.63	-5.6	-0.5	2.06e-7	Birth weight;
THYM	cis	rs2282300	0.739	rs10742237	chr11:30310659	C/T	cg06241208	chr11:30344200	C11orf46	0.78	5.65	0.5	1.67e-7	Morning vs. evening chronotype;
THYM	cis	rs2820651	1.000	rs4448619	chr10:1468196	C/T	cg02445968	chr10:1449028	ADARB2	-1.22	-6.14	-0.53	1.93e-8	Migraine with aura;
THYM	cis	rs2281845	0.859	rs1325311	chr1:201079088	G/A	cg22815214	chr1:201083145	CACNA1S	0.75	7.37	0.6	6.1e-11	Permanent tooth development;
THYM	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg04520793	chr17:42248056	ASB16	-0.33	-4.56	-0.42	1.54e-5	Total body bone mineral density;
THYM	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg00463982	chr16:1583984	IFT140;TMEM204	-0.58	-4.96	-0.45	3.04e-6	Coronary artery disease;
THYM	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg16031515	chr1:205743344	RAB7L1	0.51	4.94	0.45	3.34e-6	Menarche (age at onset);
THYM	cis	rs539096	0.692	rs6669157	chr1:44216876	T/C	cg15962314	chr1:44399869	ARTN	0.47	5.12	0.46	1.61e-6	Intelligence (multi-trait analysis);
THYM	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg18252515	chr7:66147081	NA	0.6	4.52	0.42	1.76e-5	Aortic root size;
THYM	cis	rs9378357	0.850	rs9392474	chr6:3293731	G/A	cg08754725	chr6:3293098	SLC22A23	-0.92	-4.84	-0.44	4.98e-6	Obesity-related traits;
THYM	cis	rs7267979	0.744	rs6050463	chr20:25208990	G/A	cg08601574	chr20:25228251	PYGB	0.63	4.93	0.45	3.54e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.43	4.64	0.43	1.12e-5	Autism spectrum disorder or schizophrenia;
THYM	trans	rs8002861	0.935	rs1822969	chr13:44418164	G/A	cg17145862	chr1:211918768	LPGAT1	0.89	9.07	0.68	1.6e-14	Leprosy;
THYM	cis	rs804280	0.593	rs2645396	chr8:11608126	C/A	cg23916205	chr8:11614368	GATA4	-0.58	-4.52	-0.42	1.79e-5	Myopia (pathological);
THYM	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg11366901	chr6:160182831	ACAT2	1.04	8.69	0.67	1.03e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06481639	chr22:41940642	POLR3H	0.87	5.95	0.52	4.49e-8	Vitiligo;
THYM	cis	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg14656538	chr1:197783945	NA	-0.72	-4.66	-0.43	1.02e-5	Depressive symptoms;
THYM	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg00639195	chr15:79103007	ADAMTS7	-0.83	-5.99	-0.52	3.81e-8	Coronary artery disease or large artery stroke;
THYM	cis	rs10269006	0.727	rs7778948	chr7:94369491	C/G	cg00347863	chr7:94220697	SGCE	0.54	4.68	0.43	9.57e-6	Breast cancer;
THYM	cis	rs490234	0.871	rs4837019	chr9:128276081	C/G	cg14078157	chr9:128172775	NA	-0.66	-5.6	-0.5	2.04e-7	Mean arterial pressure;
THYM	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11890956	chr21:40555474	PSMG1	-0.68	-6.42	-0.55	5.42e-9	Menarche (age at onset);
THYM	cis	rs11250464	0.833	rs11250467	chr10:1409662	A/G	cg08668359	chr10:1443807	ADARB2	0.64	5.67	0.5	1.55e-7	Radiation response;
THYM	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg15536230	chr21:44985092	HSF2BP	-0.42	-5.04	-0.46	2.26e-6	Mean corpuscular volume;
THYM	cis	rs56104184	0.887	rs4801778	chr19:49370609	G/T	cg17863274	chr19:49399704	TULP2	-0.88	-5.53	-0.49	2.77e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg18681998	chr4:17616180	MED28	0.92	8.87	0.67	4.37e-14	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg02751453	chr18:77725136	HSBP1L1	0.54	4.52	0.42	1.8e-5	Opioid sensitivity;
THYM	cis	rs4731207	0.596	rs10274384	chr7:124650437	T/A	cg05285228	chr7:124571219	POT1	-0.72	-5.53	-0.49	2.81e-7	Cutaneous malignant melanoma;
THYM	cis	rs57244997	0.872	rs11759694	chr6:162405705	C/G	cg17173639	chr6:162384350	PARK2	0.99	5.52	0.49	2.92e-7	Mosquito bite size;
THYM	cis	rs921968	0.548	rs13427522	chr2:219438359	C/T	cg02176678	chr2:219576539	TTLL4	0.68	6.71	0.57	1.42e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs977987	0.843	rs59155720	chr16:75483806	A/G	cg03315344	chr16:75512273	CHST6	0.72	5.72	0.51	1.21e-7	Dupuytren's disease;
THYM	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg18681998	chr4:17616180	MED28	0.91	8.56	0.66	2e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg08133631	chr1:26527909	CATSPER4	-0.57	-4.69	-0.43	9.29e-6	Obesity-related traits;
THYM	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg12599982	chr1:44399894	ARTN	0.56	4.66	0.43	1.02e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs920590	0.758	rs62496731	chr8:19659543	C/G	cg01411142	chr8:19674711	INTS10	0.63	4.65	0.43	1.05e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs950880	0.710	rs17027258	chr2:103091540	A/G	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.74	-0.44	7.54e-6	Serum protein levels (sST2);
THYM	cis	rs735539	0.521	rs2585901	chr13:21420271	G/A	cg02792322	chr13:21280448	IL17D	-0.66	-4.78	-0.44	6.37e-6	Dental caries;
THYM	cis	rs4938330	0.739	rs11216266	chr11:116950150	T/C	cg20608306	chr11:116969690	SIK3	-0.52	-5.78	-0.51	9.38e-8	Blood protein levels;
THYM	cis	rs7973719	0.773	rs6486911	chr12:7356494	G/C	cg07052231	chr12:7363540	PEX5	0.61	5.26	0.48	8.71e-7	IgG glycosylation;
THYM	cis	rs1079204	0.826	rs6743642	chr2:219122466	C/T	cg05728596	chr2:219128475	GPBAR1	-1.38	-6.94	-0.58	4.82e-10	Smooth-surface caries;
THYM	cis	rs7584330	0.518	rs13420503	chr2:238437623	G/A	cg14458575	chr2:238380390	NA	0.81	4.86	0.45	4.63e-6	Prostate cancer;
THYM	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs11785693	0.862	rs11786186	chr8:4999059	G/C	cg26367366	chr8:4980734	NA	1.21	5.9	0.52	5.46e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.44e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg14004847	chr7:1930337	MAD1L1	0.66	5.53	0.49	2.79e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg00256281	chr22:41985642	PMM1	0.63	5.23	0.47	1.01e-6	Vitiligo;
THYM	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22857025	chr5:266934	NA	-1.37	-8.88	-0.67	4.08e-14	Breast cancer;
THYM	cis	rs6087990	0.735	rs2889703	chr20:31379184	C/A	cg13636640	chr20:31349939	DNMT3B	0.91	9.77	0.71	5.05e-16	Ulcerative colitis;
THYM	cis	rs245880	0.765	rs245893	chr7:29191507	G/C	cg17163760	chr7:29186267	CPVL	-0.61	-4.93	-0.45	3.54e-6	Warfarin maintenance dose;
THYM	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg13683864	chr3:40499215	RPL14	-1.07	-11.9	-0.77	1.58e-20	Renal cell carcinoma;
THYM	cis	rs4866334	1.000	rs76371744	chr5:18441614	T/G	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.68	0.43	9.35e-6	Tonsillectomy;
THYM	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg19507638	chr5:93509721	C5orf36	-0.65	-4.54	-0.42	1.63e-5	Diabetic retinopathy;
THYM	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg04681579	chr7:75027559	TRIM73;TRIM74	-0.9	-7.99	-0.63	3.23e-12	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs28595532	0.920	rs112097820	chr4:119746532	G/A	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs55871839	0.708	rs1562612	chr8:59817068	A/G	cg07426533	chr8:59803705	TOX	-0.72	-7.42	-0.61	4.84e-11	Pneumonia;
THYM	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg17105886	chr17:28927953	LRRC37B2	-1.29	-6.73	-0.57	1.26e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.81	-4.97	-0.45	2.91e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs4589258	0.864	rs7119442	chr11:90422874	T/C	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg05368731	chr17:41323189	NBR1	1.24	11.23	0.76	4.01e-19	Menopause (age at onset);
THYM	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.6	-4.56	-0.42	1.54e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg23583168	chr7:148888333	NA	-1.11	-17.3	-0.87	4.06e-31	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7246657	1.000	rs1529957	chr19:37739801	A/G	cg22634378	chr19:37742834	NA	0.61	4.99	0.46	2.7e-6	Coronary artery calcification;
THYM	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg01579765	chr21:45077557	HSF2BP	-0.48	-7.87	-0.63	5.72e-12	Mean corpuscular volume;
THYM	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-4.49	-0.42	2.03e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs924712	0.521	rs4712073	chr6:54673227	A/G	cg18532076	chr6:54711417	FAM83B	-0.51	-4.63	-0.43	1.17e-5	Breast cancer;
THYM	cis	rs6430585	0.528	rs16832440	chr2:136754183	G/A	cg07169764	chr2:136633963	MCM6	1.25	12.53	0.79	7.57e-22	Corneal structure;
THYM	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg05294307	chr14:35346193	BAZ1A	-0.93	-6.68	-0.57	1.64e-9	Psoriasis;
THYM	cis	rs13264970	0.622	rs16919670	chr8:83035709	C/T	cg17993027	chr8:82543125	NA	0.78	4.56	0.42	1.52e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1278352	0.928	rs1278350	chr10:127772435	C/T	cg08295661	chr10:127769903	ADAM12	-0.45	-4.89	-0.45	4.06e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs8067545	0.641	rs203460	chr17:19815286	G/C	cg20830565	chr17:20408647	MGC102966	-0.53	-4.82	-0.44	5.37e-6	Schizophrenia;
THYM	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.16	9.23	0.69	7.34e-15	Cognitive test performance;
THYM	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg15445000	chr17:37608096	MED1	0.44	5.07	0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg16624210	chr5:671434	TPPP	0.6	6.03	0.53	3.16e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-6.43	-0.55	5.17e-9	Chronic sinus infection;
THYM	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg18512352	chr11:47633146	NA	-0.5	-6.15	-0.53	1.83e-8	Subjective well-being;
THYM	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg07636037	chr3:49044803	WDR6	0.82	5.95	0.52	4.41e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs9790314	0.967	rs336541	chr3:161056698	A/C	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg18758796	chr5:131593413	PDLIM4	0.64	6.3	0.54	9.26e-9	Breast cancer;
THYM	cis	rs2708977	0.965	rs12717781	chr2:97249142	G/A	cg01950434	chr2:97203154	ARID5A	0.56	4.96	0.45	3.09e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs8013055	0.846	rs11624007	chr14:105992183	A/C	cg04429589	chr14:105992532	TMEM121	-0.48	-5.22	-0.47	1.04e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg12963246	chr6:28129442	ZNF389	0.85	7.0	0.58	3.55e-10	Parkinson's disease;
THYM	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1065852	0.526	rs7290907	chr22:42390209	G/A	cg09667013	chr22:42394590	WBP2NL	0.54	4.8	0.44	5.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg01579765	chr21:45077557	HSF2BP	-0.48	-7.55	-0.61	2.61e-11	Mean corpuscular volume;
THYM	cis	rs12643440	0.538	rs56290948	chr4:17138950	C/T	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg22974920	chr21:40686053	BRWD1	-0.57	-4.48	-0.42	2.04e-5	Cognitive function;
THYM	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg14972814	chr11:95582409	MTMR2	-0.58	-5.3	-0.48	7.56e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg03351412	chr1:154909251	PMVK	0.71	5.6	0.5	2.12e-7	Prostate cancer;
THYM	cis	rs6882076	0.961	rs58198139	chr5:156399039	C/T	cg12943317	chr5:156479607	HAVCR1	-0.72	-5.94	-0.52	4.63e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg06238570	chr21:40685208	BRWD1	-0.97	-9.35	-0.69	4.03e-15	Cognitive function;
THYM	cis	rs13102973	0.965	rs28799927	chr4:135867094	A/G	cg14419869	chr4:135874104	NA	-0.82	-7.94	-0.63	4.06e-12	Subjective well-being;
THYM	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg09263875	chr16:632152	PIGQ	0.67	5.33	0.48	6.59e-7	Height;
THYM	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.48	-4.76	-0.44	6.97e-6	Crohn's disease;
THYM	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg16989719	chr2:238392110	NA	-0.61	-5.58	-0.5	2.28e-7	Prostate cancer;
THYM	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg18252515	chr7:66147081	NA	-0.62	-4.55	-0.42	1.59e-5	Aortic root size;
THYM	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.65	-5.61	-0.5	1.97e-7	Systemic lupus erythematosus;
THYM	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg17264618	chr3:40429014	ENTPD3	-0.53	-5.08	-0.46	1.86e-6	Renal cell carcinoma;
THYM	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.27	0.54	1.07e-8	Platelet count;
THYM	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.77	-5.1	-0.46	1.73e-6	Mean platelet volume;
THYM	cis	rs4720575	1.000	rs7791050	chr7:47086452	T/C	cg00036614	chr7:47093842	NA	-0.6	-5.28	-0.48	8.3e-7	Angiotensin-converting enzyme inhibitor intolerance;
THYM	cis	rs6763768	0.606	rs7649323	chr3:53332706	C/G	cg16894138	chr3:53270350	TKT	0.74	5.6	0.5	2.05e-7	Bacterial meningitis;
THYM	cis	rs1062746	1.000	rs1062746	chr16:87364650	A/G	cg27365499	chr16:87376795	FBXO31	0.52	5.03	0.46	2.3e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg17366294	chr4:99064904	C4orf37	0.54	6.05	0.53	2.81e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs75920871	0.528	rs723955	chr11:116925042	G/A	cg20608306	chr11:116969690	SIK3	-0.54	-6.01	-0.52	3.45e-8	Subjective well-being;
THYM	cis	rs951366	0.531	rs12030754	chr1:205678043	G/C	cg14159672	chr1:205819179	PM20D1	-0.7	-5.33	-0.48	6.72e-7	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs240764	0.658	rs11155659	chr6:101222568	A/G	cg21058520	chr6:100914733	NA	0.6	5.32	0.48	6.98e-7	Neuroticism;
THYM	cis	rs17443541	0.507	rs4675698	chr2:200451350	T/C	cg03741458	chr2:200468445	NA	-0.8	-5.86	-0.52	6.75e-8	Intelligence (multi-trait analysis);
THYM	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.87e-6	Resting heart rate;
THYM	cis	rs11641365	0.959	rs11640071	chr16:88775614	G/C	cg00034003	chr16:88779146	CTU2	-0.56	-4.67	-0.43	9.76e-6	Autism spectrum disorder-related traits;
THYM	cis	rs6032067	0.777	rs62208382	chr20:43785549	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.68	-4.94	-0.45	3.38e-6	Aortic root size;
THYM	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg04025307	chr7:1156635	C7orf50	0.78	6.62	0.56	2.1e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg16680214	chr1:154839983	KCNN3	-0.39	-4.63	-0.43	1.15e-5	Prostate cancer;
THYM	cis	rs11190604	1.000	rs4244338	chr10:102272802	A/G	cg07570687	chr10:102243282	WNT8B	0.77	7.07	0.59	2.6e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7119038	0.779	rs11217045	chr11:118697865	C/A	cg19308663	chr11:118741387	NA	0.58	5.37	0.48	5.48e-7	Sjögren's syndrome;
THYM	cis	rs1499972	0.878	rs59470461	chr3:117616314	A/C	cg07612923	chr3:117604196	NA	1.2	5.04	0.46	2.19e-6	Schizophrenia;
THYM	cis	rs4072705	0.646	rs915032	chr9:127245682	G/C	cg13476313	chr9:127244764	NR5A1	0.36	5.27	0.48	8.38e-7	Menarche (age at onset);
THYM	cis	rs758324	0.732	rs45236	chr5:131440620	G/T	cg16205897	chr5:131564050	P4HA2	0.57	4.86	0.45	4.56e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg12940439	chr1:67600707	NA	-0.5	-4.46	-0.42	2.24e-5	Psoriasis;
THYM	cis	rs36051895	0.593	rs12340379	chr9:5176352	C/T	cg02405213	chr9:5042618	JAK2	-0.99	-10.66	-0.74	6.38e-18	Pediatric autoimmune diseases;
THYM	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg13695892	chr22:41940480	POLR3H	0.87	6.61	0.56	2.19e-9	Vitiligo;
THYM	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg11764359	chr7:65958608	NA	0.76	6.22	0.54	1.35e-8	Aortic root size;
THYM	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs3960554	0.808	rs60481386	chr7:75700962	A/G	cg19862616	chr7:65841803	NCRNA00174	0.97	7.31	0.6	8.48e-11	Eotaxin levels;
THYM	cis	rs960902	0.747	rs7595792	chr2:37729623	T/C	cg25341268	chr2:37734390	NA	0.58	4.88	0.45	4.33e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs459571	0.606	rs457420	chr9:136909261	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.64	-5.7	-0.5	1.36e-7	Platelet distribution width;
THYM	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg24920358	chr1:40204285	PPIE	0.6	5.49	0.49	3.35e-7	Blood protein levels;
THYM	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.65	-4.72	-0.44	8.09e-6	Colorectal cancer;
THYM	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg20744362	chr22:50050164	C22orf34	0.79	6.9	0.58	5.71e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg18402987	chr7:1209562	NA	1.04	6.25	0.54	1.16e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg24060327	chr5:131705240	SLC22A5	-0.73	-5.47	-0.49	3.61e-7	Blood metabolite levels;
THYM	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg15242686	chr22:24348715	GSTTP1	-0.56	-5.07	-0.46	1.97e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.07	-10.85	-0.74	2.51e-18	Primary sclerosing cholangitis;
THYM	cis	rs16866061	0.888	rs6748341	chr2:225377574	C/G	cg12698349	chr2:225449008	CUL3	1.11	9.47	0.7	2.22e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs7264396	0.563	rs2425132	chr20:34338390	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-4.75	-0.44	7.14e-6	Total cholesterol levels;
THYM	cis	rs4664308	0.692	rs4233681	chr2:160960058	T/C	cg03641300	chr2:160917029	PLA2R1	-0.57	-5.12	-0.47	1.58e-6	Idiopathic membranous nephropathy;
THYM	trans	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs7894051	1.000	rs7074435	chr10:135190570	G/T	cg20534287	chr10:135191450	PAOX	0.75	5.27	0.48	8.65e-7	Lifespan;
THYM	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg09549813	chr16:4587862	C16orf5	-0.59	-6.92	-0.58	5.32e-10	Schizophrenia;
THYM	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg00757033	chr12:89920650	WDR51B	-0.74	-10.95	-0.75	1.6e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs554111	0.634	rs1453265	chr1:21277711	C/T	cg00373020	chr1:21041521	KIF17	-0.53	-4.47	-0.42	2.14e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs3845702	0.668	rs6759271	chr2:180844303	T/C	cg01881094	chr2:180872142	CWC22	-0.89	-5.34	-0.48	6.22e-7	Schizophrenia;
THYM	cis	rs11096990	0.892	rs11729098	chr4:39233977	G/A	cg24403649	chr4:39172243	NA	-0.66	-5.54	-0.49	2.69e-7	Cognitive function;
THYM	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.55	-0.73	1.12e-17	Primary sclerosing cholangitis;
THYM	cis	rs662064	1.000	rs662064	chr1:10557251	T/C	cg20482658	chr1:10539492	PEX14	-0.47	-6.07	-0.53	2.66e-8	Asthma;
THYM	cis	rs28595532	0.841	rs56046449	chr4:119769302	T/C	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs7705042	0.865	rs6580228	chr5:141510448	C/T	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06850241	chr22:41845214	NA	-0.57	-5.26	-0.47	8.94e-7	Vitiligo;
THYM	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg05347473	chr6:146136440	FBXO30	0.58	4.52	0.42	1.8e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg08000102	chr2:233561755	GIGYF2	0.67	5.94	0.52	4.63e-8	Coronary artery disease;
THYM	cis	rs1467026	0.563	rs12629928	chr3:12811796	C/T	cg05775895	chr3:12838266	CAND2	0.87	7.21	0.59	1.34e-10	P wave duration;
THYM	cis	rs4662945	0.688	rs12993231	chr2:130206377	A/G	cg05903289	chr2:130345205	NA	-0.59	-5.69	-0.5	1.38e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs56309584	0.560	rs3027160	chr17:8057572	T/C	cg08322244	chr17:8066669	VAMP2	-0.55	-5.21	-0.47	1.09e-6	Initial pursuit acceleration;
THYM	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg05043794	chr9:111880884	C9orf5	-0.44	-6.39	-0.55	6.03e-9	Menarche (age at onset);
THYM	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11890956	chr21:40555474	PSMG1	-0.92	-10.2	-0.72	6.08e-17	Cognitive function;
THYM	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg24675658	chr1:53192096	ZYG11B	0.55	4.66	0.43	1.04e-5	Monocyte count;
THYM	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs929596	0.564	rs2602373	chr2:234561953	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.67	-4.54	-0.42	1.63e-5	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12756686	chr19:29218302	NA	0.86	6.94	0.58	4.77e-10	Methadone dose in opioid dependence;
THYM	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg13147721	chr7:65941812	NA	-1.16	-7.64	-0.62	1.7e-11	Diabetic kidney disease;
THYM	cis	rs752010	0.574	rs10890157	chr1:42117689	C/G	cg06885757	chr1:42089581	HIVEP3	0.5	5.27	0.48	8.68e-7	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg04025307	chr7:1156635	C7orf50	0.72	4.46	0.42	2.27e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg12564285	chr5:131593104	PDLIM4	0.53	5.75	0.51	1.06e-7	Blood metabolite levels;
THYM	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg14074117	chr16:1909714	C16orf73	-0.7	-4.45	-0.42	2.3e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs554111	0.656	rs10799682	chr1:21424030	G/C	cg00373020	chr1:21041521	KIF17	-0.55	-4.65	-0.43	1.06e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	trans	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs7131987	0.903	rs1035604	chr12:29393102	G/A	cg09582351	chr12:29534625	ERGIC2	-0.48	-4.59	-0.43	1.35e-5	QT interval;
THYM	cis	rs7829975	0.774	rs11249893	chr8:8700851	C/T	cg15556689	chr8:8085844	FLJ10661	0.66	5.64	0.5	1.73e-7	Mood instability;
THYM	cis	rs1050631	0.592	rs1785909	chr18:33731173	G/A	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.58	4.56	0.42	1.54e-5	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg24530246	chr3:53118167	NA	-0.83	-4.75	-0.44	7.34e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg05457628	chr5:178986728	RUFY1	0.61	6.09	0.53	2.34e-8	Lung cancer;
THYM	cis	rs34779708	0.966	rs10827493	chr10:35454976	C/T	cg03585969	chr10:35415529	CREM	0.66	4.76	0.44	6.85e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6502050	0.769	rs66670693	chr17:80181799	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.06	-0.64	2.21e-12	Life satisfaction;
THYM	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg03609598	chr5:56110824	MAP3K1	-0.82	-5.57	-0.5	2.35e-7	Initial pursuit acceleration;
THYM	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg17143192	chr8:8559678	CLDN23	0.91	6.72	0.57	1.33e-9	Obesity-related traits;
THYM	cis	rs11651000	0.817	rs7502875	chr17:45823227	A/C	cg06532163	chr17:45867833	NA	0.55	5.27	0.48	8.69e-7	IgG glycosylation;
THYM	cis	rs2806561	1.000	rs681753	chr1:23515216	T/C	cg08872493	chr1:23521417	HTR1D	0.38	4.87	0.45	4.46e-6	Height;
THYM	cis	rs4237845	0.804	rs11172372	chr12:58286273	T/C	cg22764591	chr12:58329936	NA	1.0	8.13	0.64	1.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.53	0.56	3.27e-9	Total body bone mineral density;
THYM	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg13395646	chr4:1353034	KIAA1530	-0.58	-5.53	-0.49	2.8e-7	Obesity-related traits;
THYM	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg11301795	chr4:187892539	NA	-1.11	-17.65	-0.88	9.45e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg23758822	chr17:41437982	NA	1.17	11.09	0.75	7.92e-19	Menopause (age at onset);
THYM	cis	rs9790314	0.967	rs339101	chr3:161064193	A/T	cg03342759	chr3:160939853	NMD3	-0.7	-5.9	-0.52	5.48e-8	Morning vs. evening chronotype;
THYM	cis	rs7107174	1.000	rs2256464	chr11:77917305	C/A	cg19901956	chr11:77921274	USP35	-0.68	-5.4	-0.48	4.97e-7	Testicular germ cell tumor;
THYM	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg14972814	chr11:95582409	MTMR2	0.66	4.99	0.46	2.7e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg15247329	chr7:2764246	NA	-0.7	-5.75	-0.51	1.1e-7	Height;
THYM	cis	rs7107174	1.000	rs72931642	chr11:78037862	A/T	cg19901956	chr11:77921274	USP35	-0.67	-5.55	-0.49	2.56e-7	Testicular germ cell tumor;
THYM	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg14820908	chr5:178986412	RUFY1	-0.64	-7.14	-0.59	1.84e-10	Lung cancer;
THYM	cis	rs7582180	0.715	rs764828	chr2:100908634	A/C	cg14675211	chr2:100938903	LONRF2	0.73	7.29	0.6	9.11e-11	Intelligence (multi-trait analysis);
THYM	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg07570687	chr10:102243282	WNT8B	0.78	7.26	0.6	1.06e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg12560992	chr17:57184187	TRIM37	0.88	7.82	0.63	7.3e-12	Intelligence (multi-trait analysis);
THYM	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg00080972	chr5:178986291	RUFY1	0.47	5.75	0.51	1.09e-7	Lung cancer;
THYM	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg13695892	chr22:41940480	POLR3H	-0.96	-7.4	-0.6	5.42e-11	Vitiligo;
THYM	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg26384229	chr12:38710491	ALG10B	0.89	6.85	0.57	7.32e-10	Heart rate;
THYM	cis	rs2777491	1.000	rs2777491	chr15:41735710	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.12	-12.55	-0.79	6.92e-22	Ulcerative colitis;
THYM	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs4888262	0.526	rs7191754	chr16:74610850	G/T	cg01733217	chr16:74700730	RFWD3	0.83	8.57	0.66	1.84e-13	Testicular germ cell tumor;
THYM	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg20887711	chr4:1340912	KIAA1530	0.98	9.51	0.7	1.87e-15	Longevity;
THYM	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg08109568	chr15:31115862	NA	0.54	5.23	0.47	1.02e-6	Huntington's disease progression;
THYM	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg07959070	chr22:50026188	C22orf34	-0.28	-5.11	-0.46	1.67e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg26721908	chr21:47610096	LSS	-0.87	-6.27	-0.54	1.05e-8	Testicular germ cell tumor;
THYM	cis	rs11096990	0.964	rs4974999	chr4:39263914	T/G	cg24403649	chr4:39172243	NA	0.67	5.86	0.52	6.6e-8	Cognitive function;
THYM	cis	rs10231759	0.617	rs12112782	chr7:150501635	C/T	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.66	5.09	0.46	1.8e-6	Height;
THYM	cis	rs9486719	0.947	rs12194971	chr6:96911073	T/C	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.94	-0.45	3.39e-6	Migraine;Coronary artery disease;
THYM	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg14582100	chr15:45693742	SPATA5L1	0.61	4.9	0.45	3.98e-6	Homoarginine levels;
THYM	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg23205692	chr1:25664452	TMEM50A	-0.89	-7.29	-0.6	9.09e-11	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg05425664	chr17:57184151	TRIM37	0.59	4.75	0.44	7.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg04267008	chr7:1944627	MAD1L1	-0.66	-5.45	-0.49	3.97e-7	Bipolar disorder and schizophrenia;
THYM	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg01341218	chr17:43662625	NA	1.1	9.4	0.69	3.24e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6087990	1.000	rs1007123	chr20:31345840	G/A	cg13636640	chr20:31349939	DNMT3B	0.93	9.85	0.71	3.45e-16	Ulcerative colitis;
THYM	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg27446573	chr6:127587934	RNF146	1.06	10.33	0.73	3.24e-17	Breast cancer;
THYM	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg05043794	chr9:111880884	C9orf5	-0.42	-6.01	-0.53	3.34e-8	Menarche (age at onset);
THYM	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg07636037	chr3:49044803	WDR6	0.78	5.53	0.49	2.84e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs4233567	0.559	rs4662327	chr2:144159751	G/A	cg17056048	chr2:144271431	ARHGAP15	-0.54	-4.58	-0.43	1.4e-5	Intelligence (multi-trait analysis);
THYM	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg05573699	chr3:52720067	GNL3;PBRM1	-0.57	-4.47	-0.42	2.12e-5	Bipolar disorder;
THYM	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg03060546	chr3:49711283	APEH	0.75	6.09	0.53	2.35e-8	Resting heart rate;
THYM	cis	rs79349575	0.783	rs62075838	chr17:46996432	C/T	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs28595532	0.920	rs116331303	chr4:119754542	T/C	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg20744362	chr22:50050164	C22orf34	0.79	6.96	0.58	4.37e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs3733631	0.557	rs78707220	chr4:104702701	C/T	cg24090629	chr4:104641072	TACR3	-0.87	-4.61	-0.43	1.26e-5	Menarche (age at onset);
THYM	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg00256281	chr22:41985642	PMM1	0.65	4.91	0.45	3.81e-6	Vitiligo;
THYM	cis	rs17253792	0.822	rs10083303	chr14:56068521	T/C	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg08999081	chr20:33150536	PIGU	0.57	5.01	0.46	2.53e-6	Height;
THYM	cis	rs13082711	0.911	rs6777272	chr3:27488310	T/G	cg02860705	chr3:27208620	NA	0.73	5.25	0.47	9.27e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs11096990	0.634	rs1057807	chr4:39289473	A/G	cg24403649	chr4:39172243	NA	-0.63	-5.31	-0.48	7.27e-7	Cognitive function;
THYM	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg10589385	chr1:150898437	SETDB1	0.66	5.58	0.5	2.27e-7	Tonsillectomy;
THYM	cis	rs3540	0.513	rs2589974	chr15:90891566	C/T	cg00487526	chr15:90818384	NA	0.62	4.85	0.45	4.78e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs400736	0.930	rs225100	chr1:8066914	C/T	cg22678073	chr1:8087421	ERRFI1	-0.48	-5.01	-0.46	2.56e-6	Response to antidepressants and depression;
THYM	cis	rs7107174	1.000	rs4128206	chr11:78015952	A/C	cg19901956	chr11:77921274	USP35	-0.71	-5.32	-0.48	6.84e-7	Testicular germ cell tumor;
THYM	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg13390004	chr1:15929781	NA	0.64	4.84	0.45	4.94e-6	Systolic blood pressure;
THYM	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg22535103	chr8:58192502	C8orf71	-0.86	-4.82	-0.44	5.4e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.62	-7.72	-0.62	1.16e-11	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg22433210	chr17:43662623	NA	1.1	8.29	0.65	7.36e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs10206020	0.921	rs9678719	chr2:1549628	A/G	cg12573674	chr2:1569213	NA	-1.35	-8.52	-0.66	2.42e-13	IgG glycosylation;
THYM	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg06981504	chr1:1234844	ACAP3	0.53	4.86	0.45	4.67e-6	Body mass index;
THYM	cis	rs7119	0.717	rs12898370	chr15:77808598	A/T	cg10437265	chr15:77819839	NA	0.77	7.7	0.62	1.29e-11	Type 2 diabetes;
THYM	cis	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.64	-0.43	1.14e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg18876405	chr7:65276391	NA	0.74	6.97	0.58	4.17e-10	Calcium levels;
THYM	cis	rs4919694	0.536	rs12256506	chr10:104963618	T/A	cg04362960	chr10:104952993	NT5C2	1.01	6.67	0.56	1.69e-9	Arsenic metabolism;
THYM	cis	rs4363385	0.747	rs3964619	chr1:152972811	A/C	cg13444842	chr1:152974279	SPRR3	-0.6	-4.79	-0.44	6.16e-6	Inflammatory skin disease;
THYM	cis	rs939574	1.000	rs11689596	chr2:220093423	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.25	-5.85	-0.51	7.09e-8	Platelet distribution width;
THYM	cis	rs73787773	0.644	rs73227498	chr5:111485904	A/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.87	-4.54	-0.42	1.65e-5	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs79387448	0.701	rs10515921	chr2:102981018	T/G	cg09003973	chr2:102972529	NA	1.38	7.38	0.6	5.96e-11	Gut microbiota (bacterial taxa);
THYM	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.97	9.6	0.7	1.2e-15	Cognitive ability;
THYM	cis	rs7000551	0.573	rs11777848	chr8:22269042	C/T	cg12081754	chr8:22256438	SLC39A14	1.2	12.23	0.78	3.28e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2404602	0.684	rs4886819	chr15:76901698	C/T	cg23625390	chr15:77176239	SCAPER	-0.92	-6.39	-0.55	6.18e-9	Blood metabolite levels;
THYM	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs7100689	0.646	rs4265545	chr10:82119271	G/T	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg10802521	chr3:52805072	NEK4	-0.75	-7.03	-0.58	3.15e-10	Electroencephalogram traits;
THYM	cis	rs11756438	0.572	rs2638541	chr6:119003743	A/T	cg21191810	chr6:118973309	C6orf204	0.56	5.47	0.49	3.57e-7	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-5.18	-0.47	1.27e-6	Morning vs. evening chronotype;
THYM	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg01324343	chr3:183735012	ABCC5	0.88	13.13	0.8	4.58e-23	Anterior chamber depth;
THYM	cis	rs7546094	0.792	rs6537748	chr1:113214381	T/G	cg25616829	chr1:112535356	NA	-0.58	-4.7	-0.43	8.91e-6	Platelet distribution width;
THYM	cis	rs6047844	0.569	rs973106	chr20:22119832	G/A	cg16502866	chr20:23015624	SSTR4	-0.59	-4.87	-0.45	4.46e-6	Male-pattern baldness;
THYM	cis	rs1387259	0.790	rs2732445	chr12:48645533	C/T	cg21466736	chr12:48725269	NA	-0.55	-5.02	-0.46	2.43e-6	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs72828912	0.665	rs9379637	chr6:24078475	A/G	cg19882886	chr6:25043046	NA	-0.88	-4.58	-0.43	1.42e-5	Squamous cell lung carcinoma;
THYM	cis	rs35883536	1.000	rs12409831	chr1:101107670	A/T	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs6700896	0.931	rs1892534	chr1:66105944	C/T	cg04111102	chr1:66153794	NA	0.55	5.11	0.46	1.63e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs28830936	0.625	rs8038764	chr15:41907905	A/C	cg17847044	chr15:42102381	MAPKBP1	0.32	5.63	0.5	1.83e-7	Diastolic blood pressure;
THYM	cis	rs2299587	0.560	rs11996792	chr8:17781012	C/G	cg01800426	chr8:17659068	MTUS1	-0.7	-5.44	-0.49	4.11e-7	Economic and political preferences;
THYM	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg05182265	chr7:156933206	UBE3C	-0.69	-9.38	-0.69	3.46e-15	Body mass index;
THYM	cis	rs11886999	0.767	rs62153029	chr2:96920993	C/T	cg18419276	chr2:96971862	SNRNP200	-0.51	-4.85	-0.45	4.85e-6	Cardiac Troponin-T levels;
THYM	cis	rs4523957	0.713	rs9906500	chr17:2129210	C/A	cg16513277	chr17:2031491	SMG6	-0.79	-7.74	-0.62	1.04e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10799590	1.000	rs7545574	chr1:224879127	T/C	cg01808320	chr1:224927238	CNIH3	-0.53	-4.71	-0.44	8.31e-6	Opioid dependence;
THYM	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.98	-9.83	-0.71	3.91e-16	Primary sclerosing cholangitis;
THYM	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg18404041	chr3:52824283	ITIH1	-0.52	-5.01	-0.46	2.49e-6	Bipolar disorder;
THYM	cis	rs7927771	0.524	rs11039329	chr11:47684908	A/G	cg18512352	chr11:47633146	NA	0.41	4.66	0.43	1.05e-5	Subjective well-being;
THYM	cis	rs977102	0.556	rs12493000	chr3:67357150	C/G	cg06096184	chr3:66549732	LRIG1	0.66	4.6	0.43	1.32e-5	Response to amphetamines;
THYM	trans	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg25517755	chr10:38738941	LOC399744	-0.79	-7.77	-0.62	9.18e-12	Corneal astigmatism;
THYM	cis	rs62435770	1.000	rs62435803	chr6:169500186	A/G	cg07652237	chr6:170125491	PHF10	0.57	5.18	0.47	1.26e-6	Loneliness;
THYM	cis	rs700651	0.789	rs6434949	chr2:198855510	T/A	cg00792783	chr2:198669748	PLCL1	0.82	5.63	0.5	1.79e-7	Intracranial aneurysm;
THYM	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg05738196	chr6:26577821	NA	0.57	4.73	0.44	7.77e-6	Schizophrenia;
THYM	cis	rs77372450	0.591	rs11740603	chr5:157098756	G/T	cg00312553	chr5:157098553	C5orf52	-0.66	-4.7	-0.43	8.79e-6	Bipolar disorder (body mass index interaction);
THYM	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg17747265	chr1:1875780	NA	-0.79	-9.01	-0.68	2.2e-14	Body mass index;
THYM	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg05660106	chr1:15850417	CASP9	0.71	5.75	0.51	1.07e-7	Systolic blood pressure;
THYM	cis	rs4642101	0.534	rs13316229	chr3:12807371	C/T	cg05775895	chr3:12838266	CAND2	0.74	5.93	0.52	4.79e-8	QRS complex (12-leadsum);
THYM	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg07648498	chr16:89883185	FANCA	0.66	4.89	0.45	4.06e-6	Vitiligo;
THYM	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg10150615	chr22:24372951	LOC391322	-0.75	-6.98	-0.58	4e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2730245	0.527	rs842707	chr7:158656012	C/T	cg24397884	chr7:158709396	WDR60	0.55	5.31	0.48	7.11e-7	Height;
THYM	cis	rs7631605	0.905	rs11717310	chr3:37175150	C/T	cg21328643	chr3:37258149	NA	-0.51	-4.88	-0.45	4.33e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg12935359	chr14:103987150	CKB	0.6	6.21	0.54	1.41e-8	Body mass index;
THYM	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9563576	0.778	rs9919848	chr13:58621261	C/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs11589568	0.891	rs35031220	chr1:114944681	T/C	cg19304150	chr1:114696350	SYT6	0.59	4.46	0.42	2.24e-5	Autism;
THYM	cis	rs1003719	0.715	rs7277820	chr21:38580309	A/G	cg01329690	chr21:38580129	DSCR9	-0.4	-5.56	-0.5	2.45e-7	Eye color traits;
THYM	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs9399401	0.770	rs7776375	chr6:142777064	A/G	cg04461802	chr6:142623433	GPR126	0.49	4.88	0.45	4.29e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg20242066	chr2:136595261	LCT	0.53	6.76	0.57	1.11e-9	Mosquito bite size;
THYM	cis	rs6946131	0.509	rs34296434	chr7:54776442	C/T	cg16668896	chr7:54900801	NA	0.44	4.52	0.42	1.76e-5	Systemic lupus erythematosus;
THYM	cis	rs11651000	0.947	rs59216876	chr17:45832965	G/A	cg24803719	chr17:45855879	NA	-0.63	-5.23	-0.47	1.01e-6	IgG glycosylation;
THYM	cis	rs911119	1.000	rs6515375	chr20:23610841	G/A	cg16589663	chr20:23618590	CST3	0.77	4.7	0.43	8.64e-6	Chronic kidney disease;
THYM	cis	rs2456568	0.548	rs7105031	chr11:93661207	C/T	cg26875233	chr11:93583750	C11orf90	-0.53	-5.86	-0.52	6.52e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs9467773	0.587	rs10946813	chr6:26345141	A/G	cg14345882	chr6:26364793	BTN3A2	-0.36	-5.08	-0.46	1.92e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg11494091	chr17:61959527	GH2	0.7	6.46	0.55	4.55e-9	Height;
THYM	trans	rs34156428	0.858	rs12796372	chr11:16487109	T/C	cg02688867	chr12:133019854	NA	0.54	6.89	0.58	6.12e-10	Coronary artery disease;
THYM	cis	rs146009840	1	rs146009840	chr15:78906177	A/T	cg18825076	chr15:78729989	IREB2	-0.57	-5.05	-0.46	2.14e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg17691542	chr6:26056736	HIST1H1C	0.79	5.2	0.47	1.16e-6	Iron status biomarkers;
THYM	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg08999081	chr20:33150536	PIGU	-0.55	-4.84	-0.44	4.97e-6	Height;
THYM	cis	rs988913	0.874	rs4712084	chr6:54861284	G/A	cg04690482	chr6:54711388	FAM83B	0.49	5.2	0.47	1.16e-6	Menarche (age at onset);
THYM	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg04602696	chr16:88846723	FAM38A	-0.66	-4.79	-0.44	6.11e-6	Plateletcrit;
THYM	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg12311346	chr5:56204834	C5orf35	-0.66	-4.81	-0.44	5.68e-6	Coronary artery disease;
THYM	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22496380	chr5:211416	CCDC127	-1.3	-8.28	-0.65	7.84e-13	Breast cancer;
THYM	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	7.04	0.59	3.02e-10	Electrocardiographic conduction measures;
THYM	cis	rs2069036	0.903	rs9988719	chr10:16077164	C/G	cg26633223	chr10:15133461	NA	0.67	4.91	0.45	3.85e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg02038168	chr22:39784481	NA	-0.67	-5.43	-0.49	4.32e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9915657	0.660	rs2241170	chr17:70070989	G/C	cg06234051	chr17:70120541	SOX9	-0.63	-5.75	-0.51	1.1e-7	Thyroid hormone levels;
THYM	cis	rs6956675	0.915	rs1609795	chr7:62650531	T/C	cg27518014	chr7:62859535	LOC100287834	0.58	4.65	0.43	1.06e-5	Obesity-related traits;
THYM	cis	rs7258465	1.000	rs2303695	chr19:18562624	C/T	cg04166595	chr19:18636596	NA	0.62	4.62	0.43	1.19e-5	Breast cancer;
THYM	cis	rs7818345	0.637	rs4599829	chr8:19358434	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.47	4.63	0.43	1.18e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs6748734	0.625	rs4675792	chr2:241819526	A/G	cg15164180	chr2:241846931	NA	0.34	4.54	0.42	1.67e-5	Urinary metabolites;
THYM	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg24733560	chr20:60626293	TAF4	0.62	6.28	0.54	1e-8	Body mass index;
THYM	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg15744005	chr10:104629667	AS3MT	-0.83	-7.75	-0.62	9.94e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs870825	0.932	rs13136635	chr4:185574807	C/T	cg04058563	chr4:185651563	MLF1IP	-0.86	-6.12	-0.53	2.07e-8	Blood protein levels;
THYM	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg26384229	chr12:38710491	ALG10B	0.97	7.47	0.61	3.8e-11	Bladder cancer;
THYM	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg00898013	chr13:113819073	PROZ	-0.88	-9.0	-0.68	2.24e-14	Platelet distribution width;
THYM	cis	rs3017493	0.786	rs79792601	chr11:70675171	G/A	cg21202716	chr11:70508022	SHANK2	1.02	5.29	0.48	7.89e-7	Renal transplant outcome;
THYM	cis	rs2505675	1.000	rs2479013	chr6:2356979	C/T	cg01959516	chr6:2449276	NA	0.56	5.2	0.47	1.12e-6	Tuberculosis;
THYM	cis	rs6456042	0.893	rs9348088	chr6:166572668	C/A	cg11088901	chr6:166572345	T	-0.51	-5.03	-0.46	2.35e-6	Asthma;
THYM	cis	rs4430311	0.688	rs4518884	chr1:243990833	C/T	cg25706552	chr1:244017396	NA	-0.57	-4.86	-0.45	4.67e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22433210	chr17:43662623	NA	1.12	8.59	0.66	1.69e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1178127	0.542	rs6963568	chr7:18836701	A/G	cg13420273	chr7:18810212	HDAC9	-0.66	-5.66	-0.5	1.63e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg22875332	chr1:76189707	ACADM	0.87	10.83	0.74	2.76e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.38	-4.85	-0.45	4.8e-6	Insulin-like growth factors;
THYM	cis	rs6429082	0.818	rs291344	chr1:235663860	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.74	-6.18	-0.54	1.6e-8	Adiposity;
THYM	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.71	9.43	0.7	2.67e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg14458575	chr2:238380390	NA	1.13	8.48	0.66	2.87e-13	Prostate cancer;
THYM	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg25918947	chr17:41365094	TMEM106A	0.56	4.62	0.43	1.22e-5	Menopause (age at onset);
THYM	cis	rs7264396	0.580	rs2425181	chr20:34447709	T/C	cg26038318	chr20:34205095	SPAG4	0.65	5.12	0.47	1.57e-6	Total cholesterol levels;
THYM	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg06640241	chr16:89574553	SPG7	0.61	4.61	0.43	1.25e-5	Multiple myeloma (IgH translocation);
THYM	trans	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17712092	chr4:129076599	LARP1B	0.92	7.74	0.62	1.04e-11	Eosinophil percentage of white cells;
THYM	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg09184832	chr6:79620586	NA	-0.58	-4.53	-0.42	1.68e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6980334	0.817	rs10954603	chr7:137794021	A/G	cg22979093	chr7:137028410	PTN	0.62	4.95	0.45	3.19e-6	Blood metabolite ratios;
THYM	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg23711669	chr6:146136114	FBXO30	0.9	9.23	0.69	7.15e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7917772	0.582	rs4919665	chr10:104366042	C/T	cg00122347	chr10:104236741	TMEM180	0.41	5.81	0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg18512352	chr11:47633146	NA	-0.5	-6.28	-0.54	1.03e-8	Subjective well-being;
THYM	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg22189786	chr22:42395067	WBP2NL	0.56	5.08	0.46	1.87e-6	Birth weight;
THYM	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg04362960	chr10:104952993	NT5C2	0.63	4.47	0.42	2.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.41	0.55	5.47e-9	Total body bone mineral density;
THYM	cis	rs354225	0.597	rs4347868	chr2:54830616	G/A	cg23486701	chr2:54789491	SPTBN1	0.37	4.77	0.44	6.61e-6	Schizophrenia;
THYM	cis	rs17102423	0.589	rs4899162	chr14:65614126	G/T	cg11161011	chr14:65562177	MAX	-0.58	-4.69	-0.43	9.25e-6	Obesity-related traits;
THYM	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg11247378	chr22:39784982	NA	-0.91	-8.77	-0.67	6.87e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-8.52	-0.66	2.33e-13	Schizophrenia;
THYM	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg03806693	chr22:41940476	POLR3H	1.1	8.41	0.65	4.11e-13	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4631830	0.568	rs12781411	chr10:51491589	C/T	cg10326726	chr10:51549505	MSMB	0.55	5.34	0.48	6.38e-7	Prostate-specific antigen levels;
THYM	trans	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.21	-14.12	-0.82	4.67e-25	Exhaled nitric oxide output;
THYM	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg23131131	chr22:24373011	LOC391322	-0.89	-8.89	-0.67	3.87e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10089	1.000	rs13356473	chr5:127478250	T/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs10992471	0.598	rs2031262	chr9:95170368	A/C	cg14631576	chr9:95140430	CENPP	-0.67	-5.94	-0.52	4.7e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4654899	1.000	rs10916921	chr1:21334542	C/T	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.26e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs17433780	0.504	rs1409150	chr1:89473175	A/G	cg10631373	chr1:89457642	RBMXL1;CCBL2	0.34	5.28	0.48	8e-7	Carotid intima media thickness;
THYM	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6430585	0.528	rs309158	chr2:136680534	A/G	cg20242066	chr2:136595261	LCT	0.51	5.39	0.48	5.21e-7	Corneal structure;
THYM	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg13695892	chr22:41940480	POLR3H	0.83	6.07	0.53	2.67e-8	Vitiligo;
THYM	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg03929089	chr4:120376271	NA	-0.99	-12.81	-0.8	2.07e-22	Height;
THYM	trans	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg04731861	chr2:219085781	ARPC2	0.53	4.87	0.45	4.49e-6	Colorectal cancer;
THYM	cis	rs9796	0.870	rs72737704	chr15:41323575	C/G	cg21153102	chr15:41252147	NA	0.71	6.51	0.56	3.61e-9	Menopause (age at onset);
THYM	cis	rs2073300	1.000	rs6137984	chr20:23469864	T/A	cg12062639	chr20:23401060	NAPB	1.3	5.7	0.5	1.35e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg07884673	chr3:53033167	SFMBT1	1.17	5.88	0.52	6.13e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg11266682	chr4:10021025	SLC2A9	-0.62	-7.81	-0.63	7.54e-12	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7084402	0.967	rs1649066	chr10:60305916	G/C	cg07615347	chr10:60278583	BICC1	0.56	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs4731207	0.596	rs7810643	chr7:124611410	G/A	cg05285228	chr7:124571219	POT1	-0.71	-5.45	-0.49	3.91e-7	Cutaneous malignant melanoma;
THYM	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.68	5.59	0.5	2.19e-7	Blood metabolite levels;
THYM	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg13319975	chr6:146136371	FBXO30	-0.63	-4.99	-0.46	2.75e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3087591	0.960	rs12943508	chr17:29599954	C/G	cg24425628	chr17:29625626	OMG;NF1	0.67	5.54	0.49	2.66e-7	Hip circumference;
THYM	cis	rs314370	1.000	rs12705089	chr7:100465355	C/T	cg10426581	chr7:100472382	SRRT	1.13	9.05	0.68	1.81e-14	Resting heart rate;
THYM	cis	rs13315871	0.932	rs35741271	chr3:58323091	A/G	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.52	0.56	3.42e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4460079	0.531	rs10017718	chr4:114840564	A/G	cg02060584	chr4:113970739	ANK2	0.58	4.81	0.44	5.55e-6	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs6539288	0.739	rs1053050	chr12:107367224	T/C	cg26297688	chr12:107349093	C12orf23	-0.45	-4.8	-0.44	5.92e-6	Total body bone mineral density;
THYM	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	4.78	0.44	6.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9814567	0.752	rs1534029	chr3:134330213	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg11965913	chr1:205819406	PM20D1	0.95	10.53	0.73	1.25e-17	Menarche (age at onset);
THYM	cis	rs1150668	0.796	rs2531832	chr6:28389222	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.63	-4.97	-0.45	3.02e-6	Pubertal anthropometrics;
THYM	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg24531977	chr5:56204891	C5orf35	-1.01	-8.29	-0.65	7.47e-13	Initial pursuit acceleration;
THYM	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.81	0.44	5.63e-6	Lung cancer in ever smokers;
THYM	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-5.53	-0.49	2.8e-7	Morning vs. evening chronotype;
THYM	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg02380750	chr20:61661411	NA	0.62	6.02	0.53	3.23e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg16329197	chr12:53359506	NA	-0.58	-4.58	-0.43	1.43e-5	Cancer (pleiotropy);
THYM	cis	rs1883415	0.567	rs807514	chr6:24518816	T/G	cg00346970	chr6:24499591	ALDH5A1	0.48	5.68	0.5	1.46e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg24209194	chr3:40518798	ZNF619	0.62	4.92	0.45	3.67e-6	Renal cell carcinoma;
THYM	cis	rs2637266	0.935	rs2579775	chr10:78401677	G/A	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	7.35	0.6	6.91e-11	Platelet count;
THYM	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7172809	0.599	rs2012756	chr15:77745301	G/C	cg10437265	chr15:77819839	NA	-0.5	-4.57	-0.42	1.47e-5	Glucose homeostasis traits;
THYM	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg06618935	chr21:46677482	NA	-0.99	-9.59	-0.7	1.22e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7523273	0.606	rs859706	chr1:207962270	G/A	cg22525895	chr1:207977042	MIR29B2	-0.97	-10.43	-0.73	1.98e-17	Schizophrenia;
THYM	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg15445000	chr17:37608096	MED1	0.4	4.71	0.43	8.51e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	4.86	0.45	4.63e-6	Obesity-related traits;
THYM	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg00677455	chr12:58241039	CTDSP2	0.72	4.87	0.45	4.51e-6	Multiple sclerosis;
THYM	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.4	6.55	0.56	2.95e-9	Obesity-related traits;
THYM	cis	rs7769051	0.522	rs60133731	chr6:133095818	T/C	cg07930552	chr6:133119739	C6orf192	1.3	5.36	0.48	5.74e-7	Type 2 diabetes nephropathy;
THYM	cis	rs9326248	0.530	rs579890	chr11:116798963	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.86	4.7	0.43	8.89e-6	Blood protein levels;
THYM	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs8192282	0.691	rs4845635	chr1:154474131	C/G	cg16683920	chr1:154474344	TDRD10;SHE	-0.61	-5.64	-0.5	1.75e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs988913	0.706	rs12664361	chr6:54910962	A/G	cg04690482	chr6:54711388	FAM83B	-0.45	-4.62	-0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg04476341	chr5:669733	TPPP	0.63	5.44	0.49	4.07e-7	Obesity-related traits;
THYM	cis	rs752010	0.714	rs10789403	chr1:42085869	G/A	cg06885757	chr1:42089581	HIVEP3	0.6	7.65	0.62	1.61e-11	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs6496667	0.509	rs2253419	chr15:90945875	A/G	cg00425431	chr15:90792223	TTLL13	0.39	4.57	0.42	1.49e-5	Rheumatoid arthritis;
THYM	cis	rs11225247	0.685	rs12273698	chr11:102234776	A/G	cg06323957	chr11:102217781	BIRC2	1.02	4.74	0.44	7.52e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg05283184	chr6:79620031	NA	0.94	9.23	0.69	7.31e-15	Intelligence (multi-trait analysis);
THYM	cis	rs501916	0.833	rs10519143	chr15:48055567	T/G	cg20869673	chr15:48010124	SEMA6D	0.72	5.33	0.48	6.65e-7	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11890956	chr21:40555474	PSMG1	-0.66	-6.44	-0.55	4.92e-9	Menarche (age at onset);
THYM	cis	rs4273100	0.646	rs6587216	chr17:19224397	G/C	cg25447019	chr17:19030144	GRAPL	0.7	5.4	0.48	4.94e-7	Schizophrenia;
THYM	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9880211	1.000	rs17200216	chr3:136067232	C/A	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs2319125	0.683	rs1373078	chr17:64050587	A/G	cg04446870	chr17:64440273	PRKCA	0.5	4.48	0.42	2.12e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs17854409	0.881	rs1046784	chr20:61472808	G/C	cg05147244	chr20:61493195	TCFL5	0.9	5.28	0.48	8.06e-7	Obesity-related traits;
THYM	cis	rs3093024	0.874	rs3093018	chr6:167539805	C/T	cg09487078	chr6:167525398	CCR6	-0.36	-4.66	-0.43	1.03e-5	Rheumatoid arthritis;
THYM	cis	rs2692947	0.644	rs1030864	chr2:96822373	A/G	cg23100626	chr2:96804247	ASTL	0.38	4.74	0.44	7.37e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs13082711	0.522	rs543882	chr3:27331854	T/C	cg02860705	chr3:27208620	NA	0.65	5.09	0.46	1.79e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	trans	rs4262150	0.883	rs72804778	chr5:152309607	G/A	cg08281791	chr5:76607845	PDE8B	0.93	7.1	0.59	2.24e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22455342	chr2:225449267	CUL3	0.96	8.91	0.67	3.56e-14	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs6665290	0.835	rs7549465	chr1:227214399	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.12	-14.93	-0.84	1.2e-26	Myeloid white cell count;
THYM	trans	rs1974653	0.672	rs9606235	chr22:20069172	A/G	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg11764359	chr7:65958608	NA	-0.82	-6.6	-0.56	2.29e-9	Aortic root size;
THYM	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg06028808	chr11:68637592	NA	0.71	7.73	0.62	1.13e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs12200560	0.505	rs984519	chr6:97076223	A/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-6.01	-0.52	3.39e-8	Coronary heart disease;
THYM	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03517284	chr6:25882590	NA	-0.99	-8.89	-0.67	3.85e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7568458	0.837	rs6547624	chr2:85802134	A/T	cg17127132	chr2:85788382	GGCX	0.67	5.32	0.48	7.01e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg23422044	chr7:1970798	MAD1L1	-0.95	-6.58	-0.56	2.51e-9	Bipolar disorder;
THYM	cis	rs7020830	0.825	rs7036132	chr9:37317241	A/G	cg14294708	chr9:37120828	ZCCHC7	1.25	14.12	0.82	4.53e-25	Schizophrenia;
THYM	cis	rs636291	0.517	rs2781233	chr1:10529194	T/C	cg20482658	chr1:10539492	PEX14	-0.34	-4.99	-0.46	2.69e-6	Prostate cancer;
THYM	cis	rs4988958	0.565	rs885088	chr2:103039044	A/G	cg03938978	chr2:103052716	IL18RAP	0.75	9.6	0.7	1.17e-15	Asthma (childhood onset);
THYM	cis	rs7177699	0.557	rs4389113	chr15:79121739	G/A	cg00540400	chr15:79124168	NA	-0.64	-6.76	-0.57	1.09e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg11764359	chr7:65958608	NA	-0.82	-6.6	-0.56	2.29e-9	Aortic root size;
THYM	cis	rs3760982	0.585	rs1386502	chr19:44293356	T/C	cg11993925	chr19:44307056	LYPD5	0.64	5.0	0.46	2.64e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs7322722	0.838	rs606861	chr13:77596408	C/G	cg04565255	chr13:77565759	CLN5	0.52	5.52	0.49	2.93e-7	Preeclampsia;
THYM	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg08975724	chr8:8085496	FLJ10661	0.67	5.39	0.48	5.22e-7	Neuroticism;
THYM	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg21226059	chr5:178986404	RUFY1	0.58	5.97	0.52	4.01e-8	Lung cancer;
THYM	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs343604	0.686	rs17026454	chr1:111322647	T/C	cg22165175	chr1:111148915	KCNA2	0.86	4.72	0.44	7.98e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs2139634	0.930	rs12637386	chr3:46528199	G/T	cg02332537	chr3:46540019	RTP3	0.45	4.61	0.43	1.26e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7944735	0.517	rs11039538	chr11:48154990	A/T	cg24672777	chr11:48374446	OR4C45	-0.99	-5.46	-0.49	3.87e-7	Intraocular pressure;
THYM	cis	rs10979	1.000	rs9496681	chr6:143896964	G/A	cg25407410	chr6:143891975	LOC285740	-0.59	-4.95	-0.45	3.15e-6	Hypospadias;
THYM	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg13010199	chr12:38710504	ALG10B	-0.57	-4.99	-0.46	2.74e-6	Heart rate;
THYM	cis	rs34779708	0.931	rs10508815	chr10:35332621	A/C	cg03585969	chr10:35415529	CREM	0.63	4.66	0.43	1.01e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4638749	0.677	rs10189396	chr2:108829637	A/G	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg19875535	chr5:140030758	IK	0.58	4.46	0.42	2.21e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10121009	0.567	rs10814226	chr9:35324818	T/C	cg15271616	chr9:35490515	RUSC2	0.74	4.99	0.46	2.73e-6	Parkinson's disease;
THYM	cis	rs6840360	0.571	rs4696101	chr4:152528513	A/G	cg17479576	chr4:152424074	FAM160A1	-0.83	-5.83	-0.51	7.69e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6840360	0.582	rs7691601	chr4:152321631	A/G	cg17479576	chr4:152424074	FAM160A1	-0.73	-5.45	-0.49	4.02e-7	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg04362960	chr10:104952993	NT5C2	0.58	4.93	0.45	3.52e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2227564	0.620	rs4746148	chr10:75534488	C/T	cg23231163	chr10:75533350	FUT11	-0.37	-4.65	-0.43	1.08e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg10047753	chr17:41438598	NA	1.21	10.99	0.75	1.31e-18	Menopause (age at onset);
THYM	cis	rs7246967	0.673	rs9676498	chr19:22910510	A/G	cg05241461	chr19:22816980	ZNF492	0.58	4.47	0.42	2.14e-5	Bronchopulmonary dysplasia;
THYM	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg01699819	chr7:1052092	C7orf50	-0.87	-7.92	-0.63	4.5e-12	Bronchopulmonary dysplasia;
THYM	cis	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg09307838	chr4:120376055	NA	0.7	5.27	0.48	8.48e-7	Corneal astigmatism;
THYM	cis	rs9394438	0.628	rs804843	chr6:37545923	A/G	cg00985040	chr6:37553208	NA	-0.43	-4.64	-0.43	1.11e-5	IgG glycosylation;
THYM	cis	rs4919044	0.735	rs835245	chr10:94759873	A/T	cg05127821	chr10:94822908	CYP26C1	-0.76	-4.75	-0.44	7.26e-6	Coronary artery disease;
THYM	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg05182265	chr7:156933206	UBE3C	0.66	8.5	0.66	2.6e-13	Body mass index;
THYM	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg11812906	chr14:75593930	NEK9	-0.81	-7.22	-0.6	1.29e-10	Height;
THYM	cis	rs6025261	0.520	rs1276452	chr20:55546044	G/A	cg04763273	chr20:55502381	NA	0.58	4.99	0.46	2.72e-6	Verbal memory performance (delayed recall level);
THYM	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg14675211	chr2:100938903	LONRF2	0.77	8.47	0.66	3.12e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg24910161	chr17:38119198	GSDMA	0.42	4.45	0.42	2.31e-5	Self-reported allergy;
THYM	cis	rs6593803	0.622	rs1001193	chr1:147166377	A/G	cg06627043	chr1:147838662	NA	0.51	4.75	0.44	7.16e-6	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
THYM	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg00012203	chr2:219082015	ARPC2	-0.67	-5.5	-0.49	3.17e-7	Pyoderma gangrenosum in inflammatory bowel disease;
THYM	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg06009448	chr7:1102226	C7orf50	0.46	4.69	0.43	9.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg14829155	chr15:31115871	NA	0.59	5.21	0.47	1.09e-6	Huntington's disease progression;
THYM	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.74	-6.76	-0.57	1.13e-9	Personality dimensions;
THYM	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg08807101	chr21:30365312	RNF160	0.94	7.64	0.62	1.69e-11	Dental caries;
THYM	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg11317459	chr13:21872234	NA	-1.2	-9.08	-0.68	1.49e-14	White matter hyperintensity burden;
THYM	trans	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg10856724	chr12:34555212	NA	-1.02	-9.56	-0.7	1.47e-15	Bladder cancer;
THYM	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.72	-0.67	9.16e-14	Mean corpuscular volume;
THYM	cis	rs4499344	0.633	rs259260	chr19:33153261	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.92	7.75	0.62	1.02e-11	Mean platelet volume;
THYM	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs34779708	0.966	rs2505639	chr10:35474421	A/G	cg03585969	chr10:35415529	CREM	-0.65	-4.69	-0.43	9.05e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6032067	0.929	rs6032063	chr20:43854475	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.5	-0.49	3.14e-7	Blood protein levels;
THYM	cis	rs12620999	1.000	rs28727919	chr2:238003313	C/T	cg15976283	chr2:238042351	NA	-0.61	-4.51	-0.42	1.88e-5	Systemic lupus erythematosus;
THYM	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg24675056	chr1:15929824	NA	0.73	5.86	0.52	6.71e-8	Systolic blood pressure;
THYM	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg22166914	chr1:53195759	ZYG11B	0.77	7.79	0.62	8.42e-12	Monocyte count;
THYM	cis	rs752010	0.905	rs4525030	chr1:42091307	G/C	cg22486000	chr1:42919398	ZMYND12	-0.5	-5.83	-0.51	7.6e-8	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs3820068	0.705	rs4646087	chr1:15822404	A/G	cg05660106	chr1:15850417	CASP9	1.13	10.23	0.72	5.39e-17	Systolic blood pressure;
THYM	cis	rs28595532	0.920	rs116634064	chr4:119736514	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg22467129	chr15:76604101	ETFA	0.52	5.41	0.49	4.74e-7	Blood metabolite levels;
THYM	cis	rs2637266	0.538	rs2637246	chr10:78272913	G/A	cg18941641	chr10:78392320	NA	0.63	5.2	0.47	1.12e-6	Pulmonary function;
THYM	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.06	9.59	0.7	1.27e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs34779708	0.966	rs10827491	chr10:35427395	G/A	cg03585969	chr10:35415529	CREM	0.66	4.76	0.44	6.85e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7894051	0.764	rs1049951	chr10:135184126	G/A	cg20534287	chr10:135191450	PAOX	-0.76	-5.92	-0.52	4.99e-8	Lifespan;
THYM	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.89	-8.79	-0.67	6.38e-14	Lung cancer;
THYM	cis	rs9790314	0.875	rs163327	chr3:161062724	A/G	cg04691961	chr3:161091175	C3orf57	-0.61	-5.45	-0.49	4.04e-7	Morning vs. evening chronotype;
THYM	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs3768617	0.510	rs4652776	chr1:183091920	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs10744422	1.000	rs4993320	chr12:123338092	T/C	cg25930673	chr12:123319894	HIP1R	-0.86	-4.84	-0.44	5.09e-6	Schizophrenia;
THYM	cis	rs62070183	1.000	rs62070183	chr17:31164367	T/C	cg23177095	chr17:30873196	MYO1D	0.63	4.86	0.45	4.63e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs11252926	0.603	rs11252670	chr10:529152	A/G	cg14018140	chr10:458528	DIP2C	0.49	5.25	0.47	9.4e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs111684993	1	rs111684993	chr15:41436737	A/G	cg21153102	chr15:41252147	NA	0.59	4.56	0.42	1.54e-5	Coronary artery disease;
THYM	cis	rs765787	0.505	rs11630884	chr15:45532246	C/T	cg24006582	chr15:45444508	DUOX1	-0.84	-7.2	-0.59	1.39e-10	Uric acid levels;
THYM	cis	rs6087990	0.735	rs6119946	chr20:31329704	A/G	cg13636640	chr20:31349939	DNMT3B	-0.88	-8.42	-0.65	3.87e-13	Ulcerative colitis;
THYM	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg10792982	chr14:105748885	BRF1	0.68	6.83	0.57	8.04e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg03806693	chr22:41940476	POLR3H	1.1	8.83	0.67	5.2e-14	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	4.72	0.44	8.15e-6	Hip circumference adjusted for BMI;
THYM	cis	rs9361491	0.657	rs9359344	chr6:79461033	G/A	cg04547799	chr6:79944526	HMGN3	-0.66	-4.58	-0.43	1.41e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-4.64	-0.43	1.13e-5	Alzheimer's disease;
THYM	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg11965913	chr1:205819406	PM20D1	0.95	10.65	0.74	6.71e-18	Menarche (age at onset);
THYM	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg25554036	chr4:6271136	WFS1	0.57	5.13	0.47	1.52e-6	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg15445000	chr17:37608096	MED1	-0.44	-5.22	-0.47	1.07e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2276314	0.857	rs28375959	chr18:33601534	T/G	cg05985134	chr18:33552581	C18orf21	0.69	4.88	0.45	4.22e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg17063962	chr7:91808500	NA	-1.1	-11.62	-0.77	5.94e-20	Breast cancer;
THYM	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg27423445	chr12:12879764	APOLD1	0.47	5.3	0.48	7.54e-7	Lymphocyte counts;
THYM	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs11622475	0.651	rs34982025	chr14:104360431	G/A	cg12183467	chr14:104352244	NA	-0.61	-5.29	-0.48	7.75e-7	Bipolar disorder;
THYM	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg16342193	chr10:102329863	NA	-0.51	-5.25	-0.47	9.26e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11648796	0.959	rs9928077	chr16:784765	C/T	cg20104307	chr16:778658	HAGHL	0.46	6.57	0.56	2.64e-9	Height;
THYM	cis	rs4363385	0.747	rs1933383	chr1:152963468	C/T	cg13444842	chr1:152974279	SPRR3	-0.59	-4.55	-0.42	1.57e-5	Inflammatory skin disease;
THYM	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs78707713	0.560	rs55668536	chr10:71242655	A/G	cg08851181	chr10:71228077	TSPAN15	-0.8	-5.95	-0.52	4.46e-8	Venous thromboembolism;
THYM	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7084402	0.764	rs2033149	chr10:60264741	A/T	cg09696939	chr10:60272079	BICC1	-0.4	-4.6	-0.43	1.32e-5	Refractive error;
THYM	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg16325326	chr1:53192061	ZYG11B	0.92	9.77	0.71	5.06e-16	Monocyte count;
THYM	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg27534772	chr1:16042836	PLEKHM2	0.53	5.9	0.52	5.65e-8	Systolic blood pressure;
THYM	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg02527881	chr3:46936655	PTH1R	-0.56	-5.47	-0.49	3.58e-7	Colorectal cancer;
THYM	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs877282	0.947	rs4133015	chr10:774131	T/C	cg10556349	chr10:835070	NA	-0.69	-4.77	-0.44	6.68e-6	Uric acid levels;
THYM	cis	rs9361491	0.608	rs1998252	chr6:79458001	C/T	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs42648	0.693	rs2106274	chr7:89880548	C/T	cg03688058	chr7:89840708	STEAP2	-0.56	-4.47	-0.42	2.18e-5	Homocysteine levels;
THYM	cis	rs7781977	0.554	rs7804185	chr7:50353144	T/C	cg01139861	chr7:50343298	IKZF1	0.58	5.41	0.49	4.64e-7	IgG glycosylation;
THYM	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg05890377	chr2:74357713	NA	1.06	9.98	0.72	1.83e-16	Gestational age at birth (maternal effect);
THYM	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs10203711	0.966	rs7594129	chr2:239600686	G/T	cg14580085	chr2:239553406	NA	0.63	5.73	0.51	1.18e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11809207	0.501	rs2232654	chr1:26496870	A/G	cg00300879	chr1:26503847	CNKSR1	0.38	4.81	0.44	5.74e-6	Height;
THYM	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg16342193	chr10:102329863	NA	-0.53	-5.42	-0.49	4.49e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs929596	0.793	rs2741046	chr2:234580249	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.83	-5.78	-0.51	9.28e-8	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	5.66	0.5	1.58e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg17264618	chr3:40429014	ENTPD3	0.54	5.25	0.47	9.3e-7	Renal cell carcinoma;
THYM	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg16325326	chr1:53192061	ZYG11B	0.82	7.77	0.62	9e-12	Monocyte count;
THYM	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg15557168	chr22:42548783	NA	-0.6	-4.55	-0.42	1.58e-5	Schizophrenia;
THYM	cis	rs7635838	0.617	rs346076	chr3:11292682	A/G	cg00170343	chr3:11313890	ATG7	-0.66	-5.1	-0.46	1.73e-6	HDL cholesterol;
THYM	cis	rs7224314	1.000	rs62085810	chr17:65372855	G/A	cg01507342	chr17:65387096	PITPNC1	-0.94	-10.03	-0.72	1.43e-16	Diisocyanate-induced asthma;
THYM	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22857025	chr5:266934	NA	-1.5	-9.71	-0.71	6.9e-16	Breast cancer;
THYM	cis	rs1021993	0.672	rs2495295	chr1:209489688	C/T	cg24997231	chr1:209527535	NA	0.5	4.54	0.42	1.66e-5	Gut microbiome composition (winter);
THYM	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg13147721	chr7:65941812	NA	-1.0	-6.2	-0.54	1.47e-8	Diabetic kidney disease;
THYM	cis	rs28785552	0.931	rs10424385	chr19:53239133	C/G	cg22067481	chr19:53234126	ZNF611	-1.01	-10.68	-0.74	5.86e-18	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg03433033	chr1:76189801	ACADM	-0.5	-5.08	-0.46	1.88e-6	Daytime sleep phenotypes;
THYM	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg17554472	chr22:41940697	POLR3H	-0.68	-4.54	-0.42	1.68e-5	Vitiligo;
THYM	cis	rs28785552	0.931	rs8112235	chr19:53239010	C/G	cg10871876	chr19:53194124	ZNF83	0.8	6.74	0.57	1.23e-9	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs2273669	0.667	rs11153147	chr6:109304058	A/G	cg17117243	chr6:109341365	SESN1	-0.85	-4.97	-0.45	2.94e-6	Prostate cancer;
THYM	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Gout;
THYM	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg13683864	chr3:40499215	RPL14	-0.76	-6.83	-0.57	8.03e-10	Renal cell carcinoma;
THYM	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg16342193	chr10:102329863	NA	-0.57	-6.1	-0.53	2.32e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg00801512	chr17:28996047	NA	0.76	4.83	0.44	5.22e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7267979	1.000	rs4815420	chr20:25383979	C/T	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg20887711	chr4:1340912	KIAA1530	0.99	9.57	0.7	1.37e-15	Longevity;
THYM	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg15247329	chr7:2764246	NA	0.66	5.46	0.49	3.85e-7	Height;
THYM	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg06481639	chr22:41940642	POLR3H	-0.66	-5.0	-0.46	2.63e-6	Neuroticism;
THYM	cis	rs17253792	0.545	rs71412688	chr14:56021539	A/G	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs986417	0.901	rs713449	chr14:61029084	C/G	cg27398547	chr14:60952738	C14orf39	1.21	6.17	0.53	1.69e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs7771547	0.642	rs605684	chr6:36493265	T/C	cg07856975	chr6:36356162	ETV7	0.52	4.83	0.44	5.33e-6	Platelet distribution width;
THYM	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg06784218	chr1:46089804	CCDC17	-0.3	-4.61	-0.43	1.28e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg07636037	chr3:49044803	WDR6	0.98	9.91	0.71	2.6e-16	Parkinson's disease;
THYM	cis	rs6500395	1.000	rs1004909	chr16:48725580	C/G	cg04672837	chr16:48644449	N4BP1	-0.48	-4.72	-0.44	8.24e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs600806	0.854	rs10745353	chr1:109877506	A/G	cg16988986	chr1:109941118	SORT1	-0.42	-4.47	-0.42	2.12e-5	Intelligence (multi-trait analysis);
THYM	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg18252515	chr7:66147081	NA	0.65	4.73	0.44	7.72e-6	Aortic root size;
THYM	cis	rs9653442	0.932	rs893245	chr2:100814893	C/T	cg07810366	chr2:100720526	AFF3	-0.36	-4.7	-0.43	8.73e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs3849570	0.925	rs7641973	chr3:81910489	G/A	cg07356753	chr3:81810745	GBE1	-0.8	-5.94	-0.52	4.58e-8	Waist circumference;Body mass index;
THYM	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg06221963	chr1:154839813	KCNN3	-0.9	-12.83	-0.8	1.87e-22	Prostate cancer;
THYM	cis	rs7567389	0.719	rs4662713	chr2:127994103	C/T	cg09760422	chr2:128146352	NA	-0.49	-4.98	-0.45	2.87e-6	Self-rated health;
THYM	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	5.73	0.51	1.18e-7	Blood metabolite levels;
THYM	cis	rs4975616	0.843	rs6866783	chr5:1312020	T/C	cg07493874	chr5:1342172	CLPTM1L	0.75	6.51	0.56	3.54e-9	Lung cancer;
THYM	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg01416388	chr22:39784598	NA	-0.74	-5.58	-0.5	2.22e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg08975724	chr8:8085496	FLJ10661	0.73	5.85	0.51	6.87e-8	Mood instability;
THYM	cis	rs778371	0.723	rs12999865	chr2:233627250	T/C	cg08000102	chr2:233561755	GIGYF2	0.83	7.52	0.61	3.07e-11	Schizophrenia;
THYM	cis	rs7731657	0.537	rs6595972	chr5:130325265	T/G	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs8050907	0.661	rs111579187	chr16:4603709	C/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.35	5.36	0.48	5.75e-7	Obesity-related traits;
THYM	cis	rs2652822	0.525	rs12148434	chr15:63510114	A/G	cg09251291	chr15:63483946	RAB8B	0.53	4.89	0.45	4.04e-6	Metabolic traits;
THYM	cis	rs28453840	1	rs28453840	chr2:136522941	G/A	cg07169764	chr2:136633963	MCM6	-0.67	-5.94	-0.52	4.75e-8	Cholesterol, total;
THYM	cis	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg12981288	chr8:11183844	MTMR9	0.45	4.74	0.44	7.45e-6	Retinal vascular caliber;
THYM	cis	rs7584330	0.666	rs7600317	chr2:238353513	C/T	cg16989719	chr2:238392110	NA	-0.65	-5.24	-0.47	9.68e-7	Prostate cancer;
THYM	cis	rs6924995	0.501	rs6905841	chr6:16187699	T/A	cg11805552	chr6:16175128	NA	0.58	4.8	0.44	5.89e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.61	-4.59	-0.43	1.37e-5	Tonsillectomy;
THYM	cis	rs6728642	1.000	rs113934577	chr2:97888047	G/A	cg26665480	chr2:98280029	ACTR1B	-1.04	-4.77	-0.44	6.53e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11890956	chr21:40555474	PSMG1	-0.65	-6.01	-0.53	3.34e-8	Menarche (age at onset);
THYM	cis	rs11186	0.556	rs7425816	chr2:189960559	T/C	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	cis	rs2731664	0.792	rs2630764	chr5:176880085	C/T	cg14098951	chr5:176875120	PRR7	0.56	4.9	0.45	3.89e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg06656553	chr16:89960601	TCF25	-0.8	-4.74	-0.44	7.37e-6	Skin colour saturation;
THYM	cis	rs7107174	0.901	rs1055248	chr11:77925573	T/C	cg19901956	chr11:77921274	USP35	-0.71	-5.63	-0.5	1.8e-7	Testicular germ cell tumor;
THYM	cis	rs7178572	0.633	rs12907746	chr15:77843326	A/G	cg22256960	chr15:77711686	NA	-0.77	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.42	4.47	0.42	2.17e-5	Hemoglobin concentration;
THYM	cis	rs7084402	0.967	rs1658423	chr10:60331627	T/G	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs4713118	0.869	rs6456802	chr6:27698355	A/G	cg08968635	chr6:28129556	ZNF389	0.71	5.58	0.5	2.28e-7	Parkinson's disease;
THYM	cis	rs1681630	0.545	rs1228001	chr11:47986994	A/T	cg18512352	chr11:47633146	NA	-0.37	-4.56	-0.42	1.53e-5	Height;
THYM	cis	rs113835537	0.529	rs11227509	chr11:66281194	T/C	cg24851651	chr11:66362959	CCS	0.7	4.89	0.45	4.04e-6	Airway imaging phenotypes;
THYM	cis	rs7107174	1.000	rs1385601	chr11:77936064	A/C	cg19901956	chr11:77921274	USP35	-0.67	-5.37	-0.48	5.68e-7	Testicular germ cell tumor;
THYM	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg06623918	chr6:96969491	KIAA0776	1.05	7.7	0.62	1.29e-11	Headache;
THYM	cis	rs9527	0.615	rs17725614	chr10:104685493	G/C	cg04362960	chr10:104952993	NT5C2	0.6	4.62	0.43	1.2e-5	Arsenic metabolism;
THYM	cis	rs4919694	1.000	rs10509758	chr10:104681710	T/C	cg15744005	chr10:104629667	AS3MT	-0.78	-4.45	-0.42	2.3e-5	Arsenic metabolism;
THYM	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs17666538	0.818	rs62486207	chr8:588932	G/T	cg23958373	chr8:599963	NA	-0.99	-4.6	-0.43	1.3e-5	IgG glycosylation;
THYM	cis	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg08133631	chr1:26527909	CATSPER4	-0.59	-4.94	-0.45	3.38e-6	Obesity-related traits;
THYM	cis	rs11077998	0.844	rs12185254	chr17:80498972	C/T	cg10255544	chr17:80519551	FOXK2	0.51	4.48	0.42	2.05e-5	Reticulocyte fraction of red cells;
THYM	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.61	8.13	0.64	1.62e-12	Monocyte percentage of white cells;
THYM	cis	rs12434047	0.502	rs72673671	chr14:53827087	C/T	cg10123347	chr14:53620162	DDHD1	-0.98	-6.7	-0.57	1.48e-9	Economic and political preferences (fairness);
THYM	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06481639	chr22:41940642	POLR3H	-0.81	-5.51	-0.49	3.11e-7	Vitiligo;
THYM	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg20891283	chr12:69753455	YEATS4	0.71	6.0	0.52	3.54e-8	Response to diuretic therapy;
THYM	cis	rs6570726	0.599	rs455001	chr6:145854450	A/T	cg05347473	chr6:146136440	FBXO30	0.81	7.24	0.6	1.13e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	4.93	0.45	3.54e-6	Bipolar disorder;
THYM	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg03605463	chr16:89740564	NA	-0.61	-4.55	-0.42	1.61e-5	Vitiligo;
THYM	cis	rs2067615	0.579	rs1922435	chr12:107082455	A/G	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs1451375	0.657	rs12672526	chr7:50657695	C/T	cg18232548	chr7:50535776	DDC	0.66	5.16	0.47	1.36e-6	Malaria;
THYM	cis	rs901683	1.000	rs35713143	chr10:46088159	G/A	cg18240400	chr10:46168597	ANUBL1	0.73	4.73	0.44	7.89e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs761746	0.921	rs12171042	chr22:32011225	T/C	cg10537193	chr22:32026975	PISD	-0.34	-4.83	-0.44	5.31e-6	Intelligence;
THYM	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg18131467	chr2:239335373	ASB1	1.08	10.28	0.73	4.19e-17	Multiple system atrophy;
THYM	cis	rs1448094	0.511	rs10863080	chr12:86153149	C/T	cg00310523	chr12:86230176	RASSF9	-0.57	-4.83	-0.44	5.15e-6	Major depressive disorder;
THYM	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg04398451	chr17:18023971	MYO15A	-0.99	-10.67	-0.74	6.11e-18	Total body bone mineral density;
THYM	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg26754761	chr2:177040938	NA	-0.72	-6.16	-0.53	1.72e-8	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs1728785	0.818	rs1069289	chr16:68585317	C/A	cg02972257	chr16:68554789	NA	-0.77	-4.9	-0.45	3.98e-6	Ulcerative colitis;
THYM	cis	rs2016266	0.859	rs2886129	chr12:53731984	G/A	cg26875137	chr12:53738046	NA	0.82	6.24	0.54	1.19e-8	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg05368731	chr17:41323189	NBR1	1.22	10.9	0.75	2.03e-18	Menopause (age at onset);
THYM	cis	rs1348850	0.958	rs10930800	chr2:178459669	T/C	cg27490568	chr2:178487706	NA	0.58	5.23	0.47	1.01e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg26031613	chr14:104095156	KLC1	1.2	12.48	0.79	9.64e-22	Body mass index;
THYM	cis	rs17125944	0.615	rs8003334	chr14:53374967	C/T	cg00686598	chr14:53173677	PSMC6	1.02	4.61	0.43	1.27e-5	Alzheimer's disease (late onset);
THYM	cis	rs131777	0.545	rs140514	chr22:51018579	A/G	cg00083937	chr22:51039805	MAPK8IP2	0.6	5.35	0.48	6.05e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.77	-7.02	-0.58	3.34e-10	Personality dimensions;
THYM	cis	rs870825	0.616	rs4386643	chr4:185624281	A/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs7267979	1.000	rs4815411	chr20:25350223	A/G	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	trans	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg26384229	chr12:38710491	ALG10B	0.87	7.04	0.59	2.94e-10	Morning vs. evening chronotype;
THYM	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.54	-0.42	1.66e-5	Morning vs. evening chronotype;
THYM	cis	rs7592578	0.537	rs62180982	chr2:191264485	G/T	cg10560079	chr2:191398806	TMEM194B	-0.83	-5.91	-0.52	5.29e-8	Diastolic blood pressure;
THYM	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg22920501	chr2:26401640	FAM59B	-0.72	-6.35	-0.55	7.2e-9	Gut microbiome composition (summer);
THYM	cis	rs859767	0.741	rs7571113	chr2:135427392	A/G	cg12500956	chr2:135428796	TMEM163	-0.51	-5.31	-0.48	7.1e-7	Neuroticism;
THYM	cis	rs9906944	0.707	rs9912906	chr17:47104432	A/T	cg10950924	chr17:47092072	IGF2BP1	-0.49	-4.47	-0.42	2.15e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs8033133	1.000	rs8033133	chr15:25350474	A/G	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.7	-5.07	-0.46	1.95e-6	Blood osmolality (transformed sodium);
THYM	cis	rs1018836	0.923	rs13267989	chr8:91581648	C/T	cg16814680	chr8:91681699	NA	-0.75	-6.17	-0.53	1.69e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg17644776	chr2:200775616	C2orf69	0.72	5.6	0.5	2.09e-7	Schizophrenia;
THYM	cis	rs790123	1.000	rs790125	chr3:122388464	A/G	cg17380795	chr3:122379686	NA	0.56	5.0	0.46	2.57e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs754466	0.580	rs1054608	chr10:79543308	T/G	cg17075019	chr10:79541650	NA	-0.71	-5.85	-0.51	6.89e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs595982	0.546	rs9941490	chr19:49396737	G/A	cg21252483	chr19:49399788	TULP2	-0.69	-6.82	-0.57	8.57e-10	Red cell distribution width;
THYM	cis	rs7000551	0.689	rs6997299	chr8:22324268	T/C	cg12081754	chr8:22256438	SLC39A14	0.65	5.56	0.5	2.52e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg02782426	chr3:40428986	ENTPD3	0.51	4.63	0.43	1.17e-5	Renal cell carcinoma;
THYM	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.0	-8.15	-0.64	1.44e-12	Schizophrenia;
THYM	cis	rs7523273	0.606	rs2761430	chr1:207912408	G/A	cg22525895	chr1:207977042	MIR29B2	0.96	10.51	0.73	1.36e-17	Schizophrenia;
THYM	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg15445000	chr17:37608096	MED1	-0.44	-5.22	-0.47	1.07e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg00757033	chr12:89920650	WDR51B	0.74	11.81	0.77	2.43e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg14584255	chr6:163149320	PACRG;PARK2	0.69	6.03	0.53	3.17e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg00981070	chr1:2046702	PRKCZ	0.39	4.92	0.45	3.67e-6	Height;
THYM	cis	rs6840360	0.901	rs6826799	chr4:152455700	G/A	cg17479576	chr4:152424074	FAM160A1	-0.63	-4.8	-0.44	5.81e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7264396	0.887	rs2236164	chr20:34097353	T/C	cg26038318	chr20:34205095	SPAG4	0.53	4.47	0.42	2.15e-5	Total cholesterol levels;
THYM	cis	rs13315871	1.000	rs36037390	chr3:58321954	C/T	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs11886999	1.000	rs7579553	chr2:96875297	T/A	cg18419276	chr2:96971862	SNRNP200	-0.45	-4.89	-0.45	4.03e-6	Cardiac Troponin-T levels;
THYM	cis	rs28830936	0.510	rs11070349	chr15:42085017	A/C	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.49	-4.55	-0.42	1.56e-5	Diastolic blood pressure;
THYM	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg13695892	chr22:41940480	POLR3H	-0.69	-6.37	-0.55	6.71e-9	Vitiligo;
THYM	cis	rs6430585	0.528	rs895285	chr2:136710554	A/G	cg07169764	chr2:136633963	MCM6	1.19	11.38	0.76	1.91e-19	Corneal structure;
THYM	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	6.88	0.58	6.35e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs9560113	0.573	rs9560132	chr13:112237456	C/T	cg10483660	chr13:112241077	NA	0.7	8.37	0.65	4.93e-13	Menarche (age at onset);
THYM	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg04362960	chr10:104952993	NT5C2	0.57	4.77	0.44	6.61e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6840360	0.615	rs2406973	chr4:152608339	G/T	cg22705602	chr4:152727874	NA	0.77	10.25	0.72	4.73e-17	Intelligence (multi-trait analysis);
THYM	cis	rs2811415	0.597	rs9814461	chr3:127792309	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11563648	0.573	rs2010417	chr7:126959186	A/G	cg23081781	chr7:127225937	GCC1	-0.34	-4.59	-0.43	1.36e-5	Resting heart rate;
THYM	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg11247378	chr22:39784982	NA	-0.97	-10.29	-0.73	4.06e-17	Intelligence (multi-trait analysis);
THYM	cis	rs6921919	0.583	rs9468368	chr6:28364949	G/A	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.5	-0.42	1.89e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs3916	0.955	rs35771722	chr12:121154000	A/G	cg10600917	chr12:121163489	ACADS	0.6	5.2	0.47	1.13e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs3892630	0.824	rs2287882	chr19:33332952	C/T	cg22928329	chr19:33183273	NUDT19	-0.75	-5.58	-0.5	2.24e-7	Red blood cell traits;
THYM	cis	rs2439831	0.681	rs7176849	chr15:43681427	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.68	4.7	0.43	8.71e-6	Lung cancer in ever smokers;
THYM	cis	rs3027234	0.668	rs75664430	chr17:8064779	C/G	cg08322244	chr17:8066669	VAMP2	-0.54	-5.12	-0.47	1.58e-6	Telomere length;
THYM	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg12011299	chr4:100065546	ADH4	-0.85	-8.12	-0.64	1.67e-12	Alcohol dependence;
THYM	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg23711669	chr6:146136114	FBXO30	0.97	10.56	0.73	1.05e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7000551	0.671	rs7833266	chr8:22288995	A/G	cg12081754	chr8:22256438	SLC39A14	1.03	8.87	0.67	4.31e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs12935418	0.583	rs2602449	chr16:81024273	C/T	cg16651780	chr16:81037892	C16orf61	-0.86	-6.73	-0.57	1.3e-9	Mean corpuscular volume;
THYM	cis	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg19847130	chr8:10466454	RP1L1	0.57	5.32	0.48	7.01e-7	Neuroticism;
THYM	cis	rs17818399	0.888	rs2346419	chr2:46845069	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.6	4.49	0.42	1.98e-5	Height;
THYM	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg16342193	chr10:102329863	NA	-0.53	-5.45	-0.49	4.01e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.31	0.6	8.34e-11	Obesity-related traits;
THYM	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24531977	chr5:56204891	C5orf35	-1.02	-8.69	-0.67	1.06e-13	Initial pursuit acceleration;
THYM	cis	rs889398	0.770	rs8052225	chr16:69883653	G/A	cg09409435	chr16:70099608	PDXDC2	0.64	5.08	0.46	1.86e-6	Body mass index;
THYM	cis	rs7191700	0.511	rs8043625	chr16:11361895	C/G	cg00044050	chr16:11439710	C16orf75	-0.74	-5.53	-0.49	2.78e-7	Multiple sclerosis;
THYM	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg03433033	chr1:76189801	ACADM	-0.83	-14.1	-0.82	5.02e-25	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6586111	1.000	rs6586109	chr10:82375514	A/G	cg03086067	chr10:82368399	SH2D4B	-0.56	-7.16	-0.59	1.68e-10	Capecitabine sensitivity;
THYM	cis	rs7584330	0.868	rs13408361	chr2:238382899	A/G	cg14458575	chr2:238380390	NA	1.01	8.37	0.65	5.09e-13	Prostate cancer;
THYM	cis	rs6060717	0.654	rs6058347	chr20:34483781	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-4.64	-0.43	1.1e-5	Hip circumference adjusted for BMI;
THYM	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg09703963	chr11:616879	IRF7;MUPCDH	-0.74	-5.52	-0.49	2.88e-7	Systemic lupus erythematosus;
THYM	cis	rs17174870	0.955	rs12470338	chr2:112709756	G/T	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03264133	chr6:25882463	NA	-0.87	-7.84	-0.63	6.38e-12	Intelligence (multi-trait analysis);
THYM	cis	rs62435770	1.000	rs73036168	chr6:169522032	T/C	cg07652237	chr6:170125491	PHF10	0.55	4.94	0.45	3.29e-6	Loneliness;
THYM	cis	rs11096990	0.634	rs6531703	chr4:39283406	G/T	cg24403649	chr4:39172243	NA	-0.68	-5.88	-0.52	6.19e-8	Cognitive function;
THYM	cis	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg21775007	chr8:11205619	TDH	-0.67	-5.29	-0.48	7.91e-7	Triglycerides;
THYM	cis	rs4654899	1.000	rs10916938	chr1:21446883	A/G	cg01072550	chr1:21505969	NA	-0.74	-6.82	-0.57	8.58e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg12165864	chr7:66369176	NA	-0.64	-4.86	-0.45	4.6e-6	Aortic root size;
THYM	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Body mass index;
THYM	cis	rs1270639	0.778	rs2906930	chr7:157446453	T/C	cg13357408	chr7:157437802	PTPRN2	0.46	4.92	0.45	3.65e-6	Colorectal cancer;
THYM	cis	rs8130944	1.000	rs8130944	chr21:44145907	A/G	cg03543861	chr21:44258195	NA	0.5	4.6	0.43	1.28e-5	Perceived unattractiveness to mosquitoes;
THYM	cis	rs55788414	0.505	rs7190949	chr16:81189583	C/T	cg06400318	chr16:81190750	PKD1L2	0.96	7.08	0.59	2.42e-10	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg02869364	chr7:1081709	C7orf50	-0.61	-4.96	-0.45	3.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03517284	chr6:25882590	NA	-0.93	-7.62	-0.62	1.88e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	-1.11	-10.32	-0.73	3.51e-17	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs977987	0.736	rs4888392	chr16:75412262	T/C	cg03315344	chr16:75512273	CHST6	0.71	6.13	0.53	1.96e-8	Dupuytren's disease;
THYM	cis	rs3008870	1.000	rs3008854	chr1:67385951	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.92	7.43	0.61	4.77e-11	Lymphocyte percentage of white cells;
THYM	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg01191920	chr7:158217561	PTPRN2	-0.95	-9.83	-0.71	3.88e-16	Obesity-related traits;
THYM	cis	rs9790314	0.934	rs462413	chr3:161101587	T/C	cg03342759	chr3:160939853	NMD3	-0.74	-6.64	-0.56	1.93e-9	Morning vs. evening chronotype;
THYM	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg22681709	chr2:178499509	PDE11A	-0.53	-5.05	-0.46	2.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.14	-0.59	1.89e-10	Alzheimer's disease (late onset);
THYM	cis	rs7640424	0.589	rs78673584	chr3:107813133	A/G	cg09227934	chr3:107805635	CD47	-0.7	-5.2	-0.47	1.16e-6	Body mass index;
THYM	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs921968	0.565	rs6436084	chr2:219639782	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1572438	0.811	rs9379179	chr6:879853	A/C	cg21062780	chr6:887772	NA	0.53	4.58	0.43	1.41e-5	Aging;
THYM	cis	rs9527	0.590	rs10883843	chr10:104947493	C/G	cg04362960	chr10:104952993	NT5C2	0.6	4.58	0.43	1.42e-5	Arsenic metabolism;
THYM	cis	rs7078219	0.505	rs4129133	chr10:101284570	T/C	cg04972745	chr10:101287846	NA	-0.5	-4.65	-0.43	1.09e-5	Dental caries;
THYM	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg03060546	chr3:49711283	APEH	0.77	6.37	0.55	6.65e-9	Resting heart rate;
THYM	cis	rs4660306	0.677	rs781061	chr1:45932887	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.66	4.74	0.44	7.56e-6	Homocysteine levels;
THYM	cis	rs7264396	0.790	rs3787166	chr20:34229072	A/T	cg26038318	chr20:34205095	SPAG4	0.65	5.31	0.48	7.23e-7	Total cholesterol levels;
THYM	cis	rs4845459	0.967	rs4085613	chr1:152550018	T/G	cg27206522	chr1:152595629	LCE3A	-0.51	-4.56	-0.42	1.55e-5	Psoriasis;
THYM	cis	rs75059851	0.756	rs11223655	chr11:133842707	G/A	cg14047540	chr11:133829660	NA	-1.1	-7.34	-0.6	7.1e-11	Schizophrenia;
THYM	cis	rs62435770	1.000	rs73034063	chr6:169486867	C/T	cg07652237	chr6:170125491	PHF10	0.55	4.78	0.44	6.36e-6	Loneliness;
THYM	cis	rs8028182	0.537	rs4371118	chr15:75898890	C/A	cg27328408	chr15:75615005	NA	-0.66	-4.78	-0.44	6.31e-6	Sudden cardiac arrest;
THYM	cis	rs6496667	0.557	rs2589951	chr15:90958392	T/C	cg00487526	chr15:90818384	NA	-0.62	-4.62	-0.43	1.23e-5	Rheumatoid arthritis;
THYM	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg02734326	chr4:10020555	SLC2A9	0.71	6.2	0.54	1.44e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs57590327	0.503	rs2049415	chr3:81901887	A/T	cg07356753	chr3:81810745	GBE1	-0.74	-5.43	-0.49	4.33e-7	Extraversion;
THYM	cis	rs4523957	0.553	rs2476355	chr17:2029559	A/G	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg11764359	chr7:65958608	NA	-0.82	-6.22	-0.54	1.32e-8	Aortic root size;
THYM	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg00024416	chr22:24240387	NA	-0.68	-8.03	-0.64	2.61e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg12826209	chr6:26865740	GUSBL1	0.94	5.02	0.46	2.37e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2811415	0.597	rs1057156	chr3:127800071	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	5.99	0.52	3.75e-8	Schizophrenia;
THYM	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg22709100	chr7:91322751	NA	0.63	4.86	0.45	4.55e-6	Breast cancer;
THYM	cis	rs1003719	0.646	rs2835672	chr21:38581234	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.5	-0.42	1.95e-5	Eye color traits;
THYM	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg06108461	chr20:60628389	TAF4	-1.03	-8.14	-0.64	1.49e-12	Body mass index;
THYM	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.67	5.5	0.49	3.21e-7	Blood metabolite levels;
THYM	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg23989207	chr17:80870107	TBCD	0.6	4.92	0.45	3.57e-6	Glycated hemoglobin levels;
THYM	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg24375607	chr4:120327624	NA	-0.65	-5.14	-0.47	1.44e-6	Corneal astigmatism;
THYM	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg23018236	chr17:30244563	NA	-0.6	-4.45	-0.42	2.3e-5	Hip circumference adjusted for BMI;
THYM	cis	rs72781680	1.000	rs72781683	chr2:24247423	T/C	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg23916205	chr8:11614368	GATA4	0.54	4.7	0.43	8.95e-6	Myopia (pathological);
THYM	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg13319975	chr6:146136371	FBXO30	-0.69	-6.01	-0.52	3.45e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2404602	0.735	rs3765115	chr15:76673716	T/C	cg23482746	chr15:76478102	C15orf27	0.45	4.57	0.42	1.44e-5	Blood metabolite levels;
THYM	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6840360	0.593	rs10022023	chr4:152560731	A/G	cg17479576	chr4:152424074	FAM160A1	-0.78	-5.66	-0.5	1.62e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7580658	0.963	rs12622436	chr2:128081682	C/A	cg10021288	chr2:128175891	PROC	-0.78	-6.82	-0.57	8.26e-10	Protein C levels;
THYM	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg19508488	chr2:152266495	RIF1	-0.79	-6.2	-0.54	1.45e-8	Lung cancer;
THYM	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	4.75	0.44	7.27e-6	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg18402987	chr7:1209562	NA	0.74	5.42	0.49	4.45e-7	Longevity;Endometriosis;
THYM	cis	rs13315871	1.000	rs75828026	chr3:58346736	C/T	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.0	0.63	2.98e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs501916	0.743	rs3743281	chr15:48056958	C/T	cg20869673	chr15:48010124	SEMA6D	0.68	4.98	0.46	2.83e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs4731207	0.651	rs1525619	chr7:124654541	T/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs12444261	1.000	rs67850232	chr16:11739049	G/A	cg09662852	chr16:11707685	NA	-0.49	-4.66	-0.43	1.05e-5	QT interval;
THYM	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg12501888	chr15:85177176	SCAND2	-0.6	-4.5	-0.42	1.92e-5	P wave terminal force;
THYM	cis	rs2625529	0.701	rs62025574	chr15:72236075	C/T	cg16672083	chr15:72433130	SENP8	-0.56	-5.03	-0.46	2.35e-6	Red blood cell count;
THYM	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg08885076	chr2:99613938	TSGA10	0.67	6.07	0.53	2.56e-8	Chronic sinus infection;
THYM	cis	rs6430585	0.759	rs4954623	chr2:136535876	G/A	cg07169764	chr2:136633963	MCM6	-1.2	-12.65	-0.79	4.3e-22	Corneal structure;
THYM	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.52	0.49	2.99e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg24675658	chr1:53192096	ZYG11B	0.55	4.66	0.43	1.04e-5	Monocyte count;
THYM	cis	rs13065560	0.659	rs4676476	chr3:38882009	C/T	cg15678707	chr3:39149194	GORASP1;TTC21A	0.59	4.69	0.43	9.28e-6	Interleukin-18 levels;
THYM	cis	rs13082711	0.554	rs4973729	chr3:27390637	G/A	cg02860705	chr3:27208620	NA	0.92	6.63	0.56	2.02e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs600231	0.665	rs2105608	chr11:65228618	T/A	cg17120908	chr11:65337727	SSSCA1	-0.59	-4.59	-0.43	1.36e-5	Bone mineral density;
THYM	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg09060608	chr5:178986726	RUFY1	-0.58	-6.62	-0.56	2.09e-9	Lung cancer;
THYM	trans	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.72	7.0	0.58	3.56e-10	Lymphocyte counts;
THYM	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg14196790	chr5:131705035	SLC22A5	-0.55	-4.93	-0.45	3.55e-6	Blood metabolite levels;
THYM	cis	rs2915864	1.000	rs2906068	chr5:141579781	T/C	cg00542992	chr5:141595654	NA	0.62	4.65	0.43	1.06e-5	Facial morphology (factor 20);
THYM	cis	rs28595532	0.920	rs114584210	chr4:119773363	G/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg17366294	chr4:99064904	C4orf37	0.57	6.14	0.53	1.95e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs954108	0.809	rs1592060	chr13:29368944	T/C	cg11788234	chr13:29393811	NA	-0.58	-4.55	-0.42	1.59e-5	Obesity-related traits;
THYM	cis	rs4638749	0.603	rs34153365	chr2:108846583	C/T	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs2273669	0.504	rs57212784	chr6:109481678	A/G	cg17117243	chr6:109341365	SESN1	-0.91	-5.4	-0.48	4.92e-7	Prostate cancer;
THYM	cis	rs3204270	0.639	rs11867543	chr17:79655046	C/T	cg13117272	chr17:79681052	SLC25A10	-0.76	-4.7	-0.43	8.93e-6	Dental caries;
THYM	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg03806693	chr22:41940476	POLR3H	1.11	8.99	0.68	2.33e-14	Vitiligo;
THYM	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg27279351	chr12:120934652	DYNLL1	0.95	8.56	0.66	1.93e-13	High light scatter reticulocyte count;
THYM	cis	rs2455799	0.593	rs2062823	chr3:15732256	G/T	cg16303742	chr3:15540471	COLQ	-0.54	-5.6	-0.5	2.04e-7	Mean platelet volume;
THYM	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg06850241	chr22:41845214	NA	0.5	4.53	0.42	1.69e-5	Vitiligo;
THYM	cis	rs713587	1.000	rs2384054	chr2:25156773	T/C	cg01884057	chr2:25150051	NA	0.68	7.38	0.6	5.97e-11	Body mass index in non-asthmatics;
THYM	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.52	5.6	0.5	2.07e-7	Mean corpuscular volume;
THYM	cis	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg10856724	chr12:34555212	NA	-0.79	-7.54	-0.61	2.73e-11	Morning vs. evening chronotype;
THYM	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs933688	0.941	rs11948056	chr5:90680468	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	6.21	0.54	1.38e-8	Smoking behavior;
THYM	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg18876405	chr7:65276391	NA	0.76	7.17	0.59	1.61e-10	Calcium levels;
THYM	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg14061069	chr19:46274453	DMPK	-0.57	-5.82	-0.51	8.08e-8	Coronary artery disease;
THYM	cis	rs3845702	0.736	rs56401468	chr2:180857757	C/T	cg01881094	chr2:180872142	CWC22	0.91	5.44	0.49	4.07e-7	Schizophrenia;
THYM	cis	rs761746	0.921	rs761747	chr22:32001835	C/A	cg10537193	chr22:32026975	PISD	-0.35	-5.16	-0.47	1.38e-6	Intelligence;
THYM	cis	rs1003719	0.667	rs8127148	chr21:38481292	G/A	cg01329690	chr21:38580129	DSCR9	0.35	4.76	0.44	7.03e-6	Eye color traits;
THYM	trans	rs2204008	0.682	rs10880321	chr12:38370110	C/G	cg10856724	chr12:34555212	NA	0.81	6.88	0.58	6.38e-10	Bladder cancer;
THYM	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03517284	chr6:25882590	NA	-1.02	-9.28	-0.69	5.72e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	9.51	0.7	1.8e-15	Platelet count;
THYM	cis	rs7224737	0.956	rs8081900	chr17:40289875	G/A	cg00647820	chr17:40259828	DHX58	-0.6	-4.53	-0.42	1.72e-5	Fibrinogen levels;
THYM	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg03609598	chr5:56110824	MAP3K1	-0.67	-4.85	-0.45	4.83e-6	Coronary artery disease;
THYM	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg20891283	chr12:69753455	YEATS4	1.06	10.19	0.72	6.52e-17	Blood protein levels;
THYM	cis	rs7572263	0.959	rs10804167	chr2:209049840	C/T	cg23998903	chr2:209048830	C2orf80	0.43	5.95	0.52	4.48e-8	Glioma;Non-glioblastoma glioma;
THYM	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg02038168	chr22:39784481	NA	-0.57	-4.45	-0.42	2.36e-5	Intelligence (multi-trait analysis);
THYM	cis	rs220324	0.738	rs9984147	chr21:43590428	A/T	cg09727148	chr21:43560719	UMODL1	0.64	5.97	0.52	4.04e-8	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs11563648	0.553	rs7777556	chr7:127042372	G/A	cg23081781	chr7:127225937	GCC1	-0.34	-4.58	-0.43	1.4e-5	Resting heart rate;
THYM	cis	rs35883536	0.647	rs55728953	chr1:101046863	T/C	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs988913	0.706	rs1155749	chr6:54730383	T/C	cg19716238	chr6:54711378	FAM83B	0.53	5.28	0.48	8.21e-7	Menarche (age at onset);
THYM	cis	rs9563576	0.825	rs9569794	chr13:58557714	G/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs6060717	0.610	rs1891154	chr20:34617129	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-5.41	-0.49	4.66e-7	Hip circumference adjusted for BMI;
THYM	cis	rs12594515	1.000	rs56220882	chr15:45997075	C/G	cg01629716	chr15:45996671	NA	0.53	5.27	0.48	8.45e-7	Waist circumference;Weight;
THYM	cis	rs55728055	0.661	rs7286496	chr22:31983760	G/A	cg01338084	chr22:32026380	PISD	1.39	6.92	0.58	5.23e-10	Age-related hearing impairment;
THYM	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg27494647	chr7:150038898	RARRES2	0.46	5.81	0.51	8.13e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg06808227	chr14:105710500	BRF1	-1.03	-8.96	-0.68	2.76e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11676855	1.000	rs11676855	chr2:235900171	C/T	cg14917874	chr2:235941519	SH3BP4	-0.51	-4.5	-0.42	1.94e-5	Dialysis-related mortality;
THYM	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg04518342	chr5:131593106	PDLIM4	0.54	5.78	0.51	9.47e-8	Acylcarnitine levels;
THYM	cis	rs1371867	0.846	rs1660347	chr8:101314980	G/A	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg24250549	chr1:154909240	PMVK	0.75	6.45	0.55	4.66e-9	Prostate cancer;
THYM	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg09877947	chr5:131593287	PDLIM4	0.57	4.6	0.43	1.29e-5	Blood metabolite levels;
THYM	cis	rs1003719	0.762	rs1015551	chr21:38449510	G/A	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs6430585	0.583	rs2304370	chr2:136561735	G/A	cg04750100	chr2:136595281	LCT	0.46	4.68	0.43	9.64e-6	Corneal structure;
THYM	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg11494091	chr17:61959527	GH2	0.7	6.38	0.55	6.38e-9	Height;
THYM	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg19761014	chr17:28927070	LRRC37B2	0.89	4.93	0.45	3.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg18681998	chr4:17616180	MED28	0.8	7.29	0.6	9.33e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.66	-5.57	-0.5	2.4e-7	Height;
THYM	cis	rs8064299	0.536	rs2290038	chr17:72786611	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.89	-8.33	-0.65	6.12e-13	Monocyte count;
THYM	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.17	0.47	1.29e-6	Bipolar disorder;
THYM	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs12928939	0.517	rs12934512	chr16:71965230	C/G	cg03805757	chr16:71968109	PKD1L3	-1.09	-11.04	-0.75	1.02e-18	Post bronchodilator FEV1;
THYM	cis	rs6032067	0.777	rs13037651	chr20:43782230	C/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs2361710	0.668	rs4889830	chr17:78114528	G/A	cg09238746	chr17:78121135	EIF4A3	-0.78	-6.43	-0.55	5e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
THYM	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg16342193	chr10:102329863	NA	-0.52	-5.29	-0.48	7.74e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg14675211	chr2:100938903	LONRF2	0.72	7.72	0.62	1.18e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg02493740	chr2:85810744	VAMP5	-0.6	-4.57	-0.42	1.48e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg01448562	chr3:133502909	NA	0.82	6.94	0.58	4.74e-10	Iron status biomarkers;
THYM	cis	rs7258015	1.000	rs7254041	chr19:10448636	T/G	cg01466491	chr19:10523363	NA	0.65	5.14	0.47	1.47e-6	Systemic lupus erythematosus or rheumatoid arthritis;
THYM	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg16586182	chr3:47516702	SCAP	0.63	5.4	0.48	4.96e-7	Colorectal cancer;
THYM	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.67	6.54	0.56	3.06e-9	Lymphocyte counts;
THYM	cis	rs7809615	0.901	rs1581492	chr7:99186826	C/T	cg12290671	chr7:99195819	NA	-0.98	-4.87	-0.45	4.41e-6	Blood metabolite ratios;
THYM	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg05973401	chr12:123451056	ABCB9	0.68	4.58	0.43	1.39e-5	Neutrophil percentage of white cells;
THYM	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg14349672	chr11:133703707	NA	-0.5	-4.52	-0.42	1.76e-5	Childhood ear infection;
THYM	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg11752832	chr7:134001865	SLC35B4	0.76	5.72	0.51	1.24e-7	Mean platelet volume;
THYM	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg21784768	chr11:537496	LRRC56	-1.06	-5.25	-0.47	9.25e-7	Body mass index;
THYM	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.74	-4.93	-0.45	3.42e-6	Body mass index;
THYM	cis	rs4730276	0.674	rs10953554	chr7:107575557	G/A	cg23293999	chr7:106826042	HBP1	-0.6	-4.91	-0.45	3.8e-6	Ulcerative colitis;
THYM	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg10281704	chr16:966864	LMF1	-0.26	-4.46	-0.42	2.24e-5	Height;
THYM	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg11764359	chr7:65958608	NA	0.81	6.42	0.55	5.31e-9	Aortic root size;
THYM	cis	rs611744	0.967	rs651814	chr8:109196571	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs747334	0.777	rs1072491	chr10:92723495	A/C	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs9393777	0.668	rs3800318	chr6:27263641	A/T	cg22548220	chr6:27277996	POM121L2	0.83	5.21	0.47	1.11e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4595586	0.545	rs7958118	chr12:39376685	C/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs12579753	0.917	rs11115032	chr12:82205073	T/C	cg21231944	chr12:82153410	PPFIA2	-0.66	-5.01	-0.46	2.51e-6	Resting heart rate;
THYM	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	4.97	0.45	3e-6	Obesity-related traits;
THYM	cis	rs1550582	0.662	rs6981748	chr8:135501309	A/C	cg09855544	chr8:135498122	ZFAT	-0.67	-4.65	-0.43	1.09e-5	Educational attainment;
THYM	cis	rs73198271	0.599	rs10103169	chr8:8650698	T/A	cg06636001	chr8:8085503	FLJ10661	-0.7	-4.77	-0.44	6.56e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs523522	0.571	rs11065120	chr12:120875456	C/T	cg27279351	chr12:120934652	DYNLL1	0.75	4.94	0.45	3.35e-6	High light scatter reticulocyte count;
THYM	cis	rs11711311	1.000	rs12695295	chr3:113474866	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.61	-5.45	-0.49	4.02e-7	IgG glycosylation;
THYM	cis	rs4654899	1.000	rs7535895	chr1:21439239	T/A	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.26e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs995000	0.899	rs10889356	chr1:63155349	G/A	cg06896770	chr1:63153194	DOCK7	0.87	5.95	0.52	4.45e-8	Triglyceride levels;
THYM	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg10360139	chr7:1886902	MAD1L1	-0.56	-4.85	-0.45	4.81e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2070677	0.935	rs11101885	chr10:135417088	T/C	cg20169779	chr10:135381914	SYCE1	-0.72	-5.3	-0.48	7.4e-7	Gout;
THYM	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg22496339	chr2:162101262	NA	0.73	5.82	0.51	7.83e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7178572	0.962	rs12324627	chr15:77767539	A/G	cg22256960	chr15:77711686	NA	-0.94	-7.93	-0.63	4.23e-12	Type 2 diabetes;
THYM	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg13319975	chr6:146136371	FBXO30	-0.66	-5.6	-0.5	2.04e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.54	-0.56	3.08e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg12963246	chr6:28129442	ZNF389	0.77	6.35	0.55	7.39e-9	Parkinson's disease;
THYM	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg18681998	chr4:17616180	MED28	0.86	7.7	0.62	1.31e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs5009270	0.524	rs11763053	chr7:112262623	C/T	cg23628563	chr7:112262597	NA	0.7	4.99	0.46	2.75e-6	Osteoarthritis (hip);
THYM	cis	rs12149862	1.000	rs7350852	chr16:69472608	T/A	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg21773646	chr17:80085082	CCDC57	0.31	4.49	0.42	2.02e-5	Life satisfaction;
THYM	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg05090351	chr10:126851162	NA	0.64	6.79	0.57	9.53e-10	Menarche (age at onset);
THYM	cis	rs2932538	0.961	rs4240534	chr1:113175429	T/A	cg22162597	chr1:113214053	CAPZA1	-0.65	-5.32	-0.48	6.9e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs2404602	0.647	rs12898810	chr15:76904738	T/C	cg23625390	chr15:77176239	SCAPER	-0.93	-6.31	-0.54	8.9e-9	Blood metabolite levels;
THYM	cis	rs7715811	1.000	rs7715552	chr5:13769959	A/T	cg07548982	chr5:13769939	DNAH5	-0.5	-4.48	-0.42	2.1e-5	Subclinical atherosclerosis traits (other);
THYM	cis	rs4523957	0.583	rs7212589	chr17:2042393	A/G	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs988913	0.957	rs4437472	chr6:54838438	C/T	cg18532076	chr6:54711417	FAM83B	0.52	4.95	0.45	3.25e-6	Menarche (age at onset);
THYM	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06873352	chr17:61820015	STRADA	-0.79	-9.97	-0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1461503	0.966	rs1461504	chr11:122845129	T/C	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs8067545	0.611	rs10491107	chr17:20188174	C/T	cg13482628	chr17:19912719	NA	0.53	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	7.91	0.63	4.73e-12	Lung cancer in ever smokers;
THYM	cis	rs9905704	0.918	rs304271	chr17:56802458	C/T	cg12560992	chr17:57184187	TRIM37	0.67	4.68	0.43	9.59e-6	Testicular germ cell tumor;
THYM	cis	rs6430585	0.583	rs111837148	chr2:136612036	G/A	cg23851026	chr2:136556271	LCT	0.79	7.51	0.61	3.2e-11	Corneal structure;
THYM	cis	rs7772486	0.776	rs4316025	chr6:146238032	C/T	cg13319975	chr6:146136371	FBXO30	0.72	6.08	0.53	2.45e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4363385	0.818	rs1890285	chr1:153015396	T/C	cg13444842	chr1:152974279	SPRR3	-0.59	-4.81	-0.44	5.72e-6	Inflammatory skin disease;
THYM	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg27286337	chr10:134555280	INPP5A	0.89	6.88	0.58	6.33e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs12039431	0.788	rs11749	chr1:38023316	C/T	cg17933807	chr1:38061675	GNL2	-0.87	-6.48	-0.55	4.07e-9	Epithelial ovarian cancer;
THYM	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.15	6.86	0.58	7.08e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg26384229	chr12:38710491	ALG10B	0.95	7.55	0.61	2.7e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs3112255	0.512	rs12479182	chr2:101338378	C/T	cg01042948	chr2:101319752	NA	0.47	4.61	0.43	1.23e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.71	9.43	0.7	2.67e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg20290983	chr6:43655470	MRPS18A	1.44	15.94	0.85	1.35e-28	IgG glycosylation;
THYM	cis	rs924712	0.844	rs10456176	chr6:54730180	T/C	cg04690482	chr6:54711388	FAM83B	-0.46	-5.08	-0.46	1.86e-6	Breast cancer;
THYM	cis	rs600806	0.850	rs4970846	chr1:109946095	A/C	cg23616212	chr1:109941201	SORT1	-0.48	-4.55	-0.42	1.6e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg10295955	chr4:187884368	NA	-1.22	-17.54	-0.87	1.51e-31	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs4866334	1.000	rs75393523	chr5:18488595	T/G	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg27490568	chr2:178487706	NA	0.56	4.86	0.45	4.56e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg21433313	chr16:3507492	NAT15	-0.77	-7.53	-0.61	2.86e-11	Tuberculosis;
THYM	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.63	5.42	0.49	4.42e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg12386194	chr3:101231763	SENP7	0.69	5.16	0.47	1.34e-6	Colorectal cancer;
THYM	cis	rs7267979	1.000	rs2482943	chr20:25380593	G/A	cg08601574	chr20:25228251	PYGB	-0.58	-4.67	-0.43	9.97e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6840360	1.000	rs4696285	chr4:152605449	A/G	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg02574844	chr11:5959923	NA	0.59	5.43	0.49	4.28e-7	DNA methylation (variation);
THYM	cis	rs6960043	0.818	rs10238625	chr7:15054232	A/G	cg19272540	chr7:15055459	NA	0.55	6.21	0.54	1.37e-8	Type 2 diabetes;
THYM	cis	rs752010	0.841	rs11210498	chr1:42077958	T/G	cg22486000	chr1:42919398	ZMYND12	-0.47	-5.24	-0.47	9.64e-7	Lupus nephritis in systemic lupus erythematosus;
THYM	trans	rs637571	0.780	rs653914	chr11:65676516	A/G	cg17712092	chr4:129076599	LARP1B	1.12	12.55	0.79	6.88e-22	Eosinophil percentage of white cells;
THYM	cis	rs684232	0.602	rs331014	chr17:532103	C/T	cg15660573	chr17:549704	VPS53	-1.01	-11.26	-0.76	3.54e-19	Prostate cancer;
THYM	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs6754311	0.773	rs4988226	chr2:136610598	A/G	cg23851026	chr2:136556271	LCT	-0.53	-5.14	-0.47	1.48e-6	Mosquito bite size;
THYM	cis	rs4918072	0.834	rs7073827	chr10:105708793	A/G	cg11005552	chr10:105648138	OBFC1	0.57	4.61	0.43	1.26e-5	Coronary artery disease;
THYM	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg12219531	chr12:120966889	COQ5	0.84	6.82	0.57	8.54e-10	High light scatter reticulocyte count;
THYM	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11644478	chr21:40555479	PSMG1	1.09	9.3	0.69	5.19e-15	Cognitive function;
THYM	cis	rs1178127	0.838	rs212672	chr7:18797190	T/A	cg13420273	chr7:18810212	HDAC9	0.52	4.7	0.43	8.83e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs6918586	0.658	rs198838	chr6:26113340	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.79	7.08	0.59	2.53e-10	Schizophrenia;
THYM	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg03806693	chr22:41940476	POLR3H	-0.77	-5.95	-0.52	4.56e-8	Neuroticism;
THYM	cis	rs7246967	0.673	rs2112610	chr19:22916851	C/T	cg05241461	chr19:22816980	ZNF492	0.59	4.61	0.43	1.26e-5	Bronchopulmonary dysplasia;
THYM	cis	rs3126085	0.935	rs4421596	chr1:152181673	G/A	cg10321714	chr1:152280068	FLG	0.68	4.95	0.45	3.2e-6	Atopic dermatitis;
THYM	cis	rs61931739	0.635	rs4442626	chr12:33912530	C/T	cg10856724	chr12:34555212	NA	-0.63	-5.9	-0.52	5.54e-8	Morning vs. evening chronotype;
THYM	cis	rs1865721	0.771	rs727893	chr18:73136931	G/A	cg26385618	chr18:73139727	C18orf62	-0.68	-5.0	-0.46	2.63e-6	Intelligence;
THYM	cis	rs5769765	0.646	rs9616205	chr22:50309915	A/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	5.67	0.5	1.56e-7	Schizophrenia;
THYM	cis	rs7107174	1.000	rs2511155	chr11:77969223	G/A	cg19901956	chr11:77921274	USP35	-0.74	-5.74	-0.51	1.14e-7	Testicular germ cell tumor;
THYM	cis	rs78761021	0.867	rs7213983	chr17:9792115	C/T	cg26853458	chr17:9805074	RCVRN	-0.52	-4.65	-0.43	1.08e-5	Type 2 diabetes;
THYM	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg26677194	chr12:130822605	PIWIL1	-0.63	-4.7	-0.43	8.89e-6	Menopause (age at onset);
THYM	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	5.52	0.49	2.88e-7	Hip circumference adjusted for BMI;
THYM	cis	rs80282103	0.850	rs7908590	chr10:952523	C/G	cg10556349	chr10:835070	NA	-0.95	-4.57	-0.42	1.47e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	9.79	0.71	4.61e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs3768617	0.510	rs4651145	chr1:183098900	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg18352616	chr4:3374830	RGS12	0.52	5.55	0.5	2.54e-7	Parental longevity (mother's age at death);
THYM	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg15691649	chr6:25882328	NA	0.68	5.17	0.47	1.31e-6	Blood metabolite levels;
THYM	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg18512352	chr11:47633146	NA	-0.51	-5.98	-0.52	3.91e-8	Subjective well-being;
THYM	cis	rs9311676	0.632	rs62258075	chr3:58359851	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.6	0.43	1.29e-5	Systemic lupus erythematosus;
THYM	cis	rs7107174	1.000	rs729354	chr11:77962453	T/A	cg02023728	chr11:77925099	USP35	0.68	6.03	0.53	3.06e-8	Testicular germ cell tumor;
THYM	cis	rs35110281	0.607	rs11701518	chr21:44987079	C/T	cg27168131	chr21:44088823	PDE9A	-0.48	-4.77	-0.44	6.71e-6	Mean corpuscular volume;
THYM	cis	rs11031096	0.678	rs12222136	chr11:4180148	T/C	cg08557956	chr11:4115526	RRM1	-0.52	-4.68	-0.43	9.36e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg00944433	chr1:107599041	PRMT6	-0.41	-5.36	-0.48	5.72e-7	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg17063962	chr7:91808500	NA	1.12	11.41	0.76	1.63e-19	Breast cancer;
THYM	cis	rs2292030	1	rs2292030	chr5:132161294	G/A	cg02081065	chr5:132209139	LEAP2	-0.91	-5.94	-0.52	4.76e-8	Apolipoprotein A-IV levels;
THYM	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg01483505	chr11:975446	AP2A2	0.58	4.7	0.43	8.64e-6	Alzheimer's disease (late onset);
THYM	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg02487422	chr3:49467188	NICN1	-0.61	-4.5	-0.42	1.94e-5	Resting heart rate;
THYM	cis	rs863345	0.604	rs1157525	chr1:158457253	T/C	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.54	-0.49	2.71e-7	Menopause (age at onset);
THYM	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1003719	0.715	rs2835647	chr21:38546773	C/T	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs870825	0.550	rs35981185	chr4:185639720	A/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs78456975	1.000	rs13392535	chr2:1542634	G/T	cg12573674	chr2:1569213	NA	-1.25	-4.59	-0.43	1.37e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9411298	0.630	rs9411299	chr9:139938793	C/G	cg09305224	chr9:139927245	C9orf139;FUT7	-0.58	-4.71	-0.43	8.55e-6	Monocyte percentage of white cells;
THYM	cis	rs61990749	0.686	rs11159288	chr14:78216972	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.02	0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg19901468	chr14:105411992	AHNAK2	-0.75	-6.27	-0.54	1.07e-8	Rheumatoid arthritis;
THYM	cis	rs1003719	0.715	rs2212742	chr21:38578685	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-4.53	-0.42	1.72e-5	Eye color traits;
THYM	cis	rs807669	0.586	rs5746671	chr22:19160899	A/G	cg02655711	chr22:19163373	SLC25A1	0.59	6.73	0.57	1.27e-9	Metabolite levels;
THYM	cis	rs2276314	1.000	rs1540042	chr18:33555236	C/T	cg19628046	chr18:33552617	C18orf21	0.77	5.47	0.49	3.68e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	trans	rs8002861	0.846	rs12428314	chr13:44476011	C/T	cg17145862	chr1:211918768	LPGAT1	-0.89	-8.3	-0.65	7.11e-13	Leprosy;
THYM	cis	rs11030122	0.702	rs17279635	chr11:3973083	A/C	cg18678763	chr11:4115507	RRM1	0.44	5.59	0.5	2.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg22467129	chr15:76604101	ETFA	-0.53	-5.01	-0.46	2.49e-6	Blood metabolite levels;
THYM	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-5.58	-0.5	2.3e-7	Personality dimensions;
THYM	cis	rs6768930	0.527	rs268766	chr3:57903413	G/A	cg07735586	chr3:57945651	NA	-0.33	-5.11	-0.46	1.64e-6	Obesity-related traits;
THYM	cis	rs13215566	1.000	rs35953049	chr6:89916692	G/A	cg08400210	chr6:89908154	GABRR1	0.74	4.5	0.42	1.9e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg07061783	chr6:25882402	NA	-0.82	-7.15	-0.59	1.81e-10	Blood metabolite levels;
THYM	cis	rs2732480	1.000	rs2732480	chr12:48736303	A/C	cg21466736	chr12:48725269	NA	0.52	5.0	0.46	2.62e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg21427119	chr20:30132790	HM13	-0.86	-6.14	-0.53	1.9e-8	Mean corpuscular hemoglobin;
THYM	cis	rs6570726	1.000	rs441477	chr6:145848243	C/T	cg23711669	chr6:146136114	FBXO30	0.9	8.61	0.66	1.56e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4731207	0.596	rs1011722	chr7:124605207	A/C	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg20295408	chr7:1910781	MAD1L1	-0.68	-5.59	-0.5	2.17e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-5.37	-0.48	5.67e-7	Monocyte percentage of white cells;
THYM	cis	rs4262150	0.883	rs72804781	chr5:152314450	T/C	cg06854687	chr5:151642065	NA	0.68	4.82	0.44	5.34e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-5.64	-0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg08736216	chr1:53307985	ZYG11A	-0.6	-5.56	-0.5	2.5e-7	Monocyte count;
THYM	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg10523679	chr1:76189770	ACADM	0.92	10.43	0.73	2.03e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg13852791	chr20:30311386	BCL2L1	0.74	5.35	0.48	6.15e-7	Mean corpuscular hemoglobin;
THYM	cis	rs420259	0.516	rs11074562	chr16:23499700	C/T	cg00143387	chr16:23521605	GGA2	-0.81	-5.83	-0.51	7.55e-8	Bipolar disorder;
THYM	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	5.89	0.52	5.81e-8	Platelet count;
THYM	cis	rs7917772	0.582	rs3977756	chr10:104398582	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.61	-4.63	-0.43	1.15e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg23187316	chr7:1099788	C7orf50	0.59	4.52	0.42	1.76e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs427394	0.582	rs4701751	chr5:6704137	C/T	cg10857441	chr5:6722123	POLS	-0.7	-7.46	-0.61	3.98e-11	Menopause (age at onset);
THYM	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg06808227	chr14:105710500	BRF1	-1.02	-8.85	-0.67	4.76e-14	Platelet count;
THYM	cis	rs9790314	0.502	rs2404342	chr3:161092562	C/T	cg03342759	chr3:160939853	NMD3	-0.9	-7.93	-0.63	4.25e-12	Morning vs. evening chronotype;
THYM	cis	rs981844	0.603	rs13132437	chr4:154748006	T/G	cg09973105	chr4:154681532	RNF175	0.5	4.65	0.43	1.08e-5	Response to statins (LDL cholesterol change);
THYM	cis	rs394563	0.602	rs409099	chr6:149766863	T/G	cg26849637	chr6:150530249	PPP1R14C	-0.41	-4.51	-0.42	1.86e-5	Dupuytren's disease;
THYM	cis	rs6686842	1.000	rs479493	chr1:41567202	G/A	cg03387723	chr1:41708464	SCMH1	0.44	5.22	0.47	1.04e-6	Height;
THYM	cis	rs4788570	0.667	rs8052910	chr16:71790221	A/G	cg06353428	chr16:71660113	MARVELD3	1.43	8.68	0.67	1.09e-13	Intelligence (multi-trait analysis);
THYM	cis	rs11186	0.556	rs72906336	chr2:189959092	C/A	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs12478296	1.000	rs56102931	chr2:243039936	A/G	cg06360820	chr2:242988706	NA	-0.88	-5.54	-0.49	2.72e-7	Obesity-related traits;
THYM	cis	rs9467711	0.591	rs41266779	chr6:26021872	C/T	cg16898833	chr6:26189333	HIST1H4D	1.33	4.61	0.43	1.24e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs7127900	0.644	rs72853954	chr11:2221765	T/C	cg25635251	chr11:2234043	NA	-0.78	-4.73	-0.44	7.88e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs17744026	0.649	rs2155362	chr11:123687286	G/A	cg00079598	chr11:123676903	OR6M1	-0.52	-4.79	-0.44	6.14e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Intelligence (multi-trait analysis);
THYM	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg18904891	chr8:8559673	CLDN23	0.68	4.97	0.45	2.95e-6	Obesity-related traits;
THYM	cis	rs13102973	0.640	rs13151892	chr4:135831375	G/A	cg14419869	chr4:135874104	NA	0.71	5.86	0.52	6.6e-8	Subjective well-being;
THYM	cis	rs10089	0.953	rs10223203	chr5:127527646	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.93	-5.99	-0.52	3.73e-8	Ileal carcinoids;
THYM	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg24375607	chr4:120327624	NA	0.64	4.47	0.42	2.18e-5	Corneal astigmatism;
THYM	trans	rs6089829	0.888	rs4809465	chr20:61671156	G/C	cg23505145	chr19:12996616	KLF1	1.03	10.12	0.72	9.21e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg26513180	chr16:89883248	FANCA	0.74	7.34	0.6	7.27e-11	Vitiligo;
THYM	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg11764359	chr7:65958608	NA	0.85	7.32	0.6	8.03e-11	Aortic root size;
THYM	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg25918947	chr17:41365094	TMEM106A	-0.69	-5.84	-0.51	7.34e-8	Menopause (age at onset);
THYM	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg17775962	chr7:1200435	ZFAND2A	0.42	5.15	0.47	1.4e-6	Longevity;Endometriosis;
THYM	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg03929089	chr4:120376271	NA	1.03	8.74	0.67	8.32e-14	Coronary artery disease;
THYM	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg11058730	chr11:34937778	PDHX;APIP	0.56	4.61	0.43	1.24e-5	Lung disease severity in cystic fibrosis;
THYM	cis	rs4455778	0.580	rs7780178	chr7:49085140	A/G	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.63	4.48	0.42	2.05e-5	Gut microbiome composition (summer);
THYM	cis	rs9915657	0.773	rs9916815	chr17:70105651	A/G	cg06234051	chr17:70120541	SOX9	-0.63	-5.67	-0.5	1.54e-7	Thyroid hormone levels;
THYM	cis	rs4718428	0.705	rs13227468	chr7:66433563	T/C	cg12165864	chr7:66369176	NA	-0.82	-6.07	-0.53	2.67e-8	Corneal structure;
THYM	cis	rs11850957	0.502	rs987056	chr14:25439630	G/A	cg26846476	chr14:24838993	NFATC4	0.92	4.73	0.44	7.83e-6	Subcutaneous adipose tissue;
THYM	cis	rs524023	0.881	rs544838	chr11:64429059	T/C	cg19131476	chr11:64387923	NRXN2	-0.39	-5.54	-0.49	2.7e-7	Urate levels in obese individuals;
THYM	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg19746536	chr19:49375674	PPP1R15A	0.81	4.59	0.43	1.34e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-5.4	-0.48	4.89e-7	Chronic sinus infection;
THYM	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22590775	chr19:49891494	CCDC155	0.82	6.7	0.57	1.49e-9	Multiple sclerosis;
THYM	cis	rs2820651	0.708	rs17156347	chr10:1478900	A/T	cg27404824	chr10:1454848	ADARB2	0.87	4.92	0.45	3.66e-6	Migraine with aura;
THYM	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg11245990	chr11:68621969	NA	0.57	7.46	0.61	4.14e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4851313	0.527	rs10183150	chr2:100939117	A/G	cg14675211	chr2:100938903	LONRF2	0.7	7.34	0.6	7.33e-11	Intelligence (multi-trait analysis);
THYM	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg13390004	chr1:15929781	NA	-0.68	-5.01	-0.46	2.49e-6	Systolic blood pressure;
THYM	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg12963246	chr6:28129442	ZNF389	0.72	6.12	0.53	2.05e-8	Depression;
THYM	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	11.87	0.77	1.82e-20	Chronic sinus infection;
THYM	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs6693036	1.000	rs6693036	chr1:17919817	C/T	cg13381844	chr1:17973557	ARHGEF10L	-0.97	-4.7	-0.43	8.94e-6	Obesity-related traits;
THYM	cis	rs4595586	0.525	rs7136425	chr12:39376005	C/A	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs12643440	0.538	rs2314602	chr4:17144535	A/G	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg07424592	chr7:64974309	NA	1.03	5.4	0.48	4.94e-7	Diabetic kidney disease;
THYM	cis	rs600806	0.850	rs10745354	chr1:109931908	C/T	cg02175308	chr1:109941060	SORT1	-0.6	-5.3	-0.48	7.58e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2806561	0.808	rs2294518	chr1:23372771	T/C	cg12483005	chr1:23474871	LUZP1	-0.51	-4.69	-0.43	9.25e-6	Height;
THYM	cis	rs10751647	0.804	rs3809112	chr11:307036	C/T	cg21052403	chr11:320889	IFITM3	0.49	4.67	0.43	9.85e-6	Monocyte count;
THYM	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs6866344	0.570	rs6896799	chr5:178147014	G/C	cg03877680	chr5:178157825	ZNF354A	0.75	5.13	0.47	1.52e-6	Neutrophil percentage of white cells;
THYM	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg26038318	chr20:34205095	SPAG4	0.59	4.65	0.43	1.08e-5	Total cholesterol levels;
THYM	trans	rs561341	1.000	rs693116	chr17:30246124	C/T	cg20587970	chr11:113659929	NA	-1.37	-8.96	-0.68	2.79e-14	Hip circumference adjusted for BMI;
THYM	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs4595586	0.525	rs7968566	chr12:39377200	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg10802521	chr3:52805072	NEK4	-0.66	-5.85	-0.51	6.97e-8	Bipolar disorder;
THYM	cis	rs7084402	0.967	rs1626532	chr10:60294685	A/T	cg07615347	chr10:60278583	BICC1	0.54	4.92	0.45	3.66e-6	Refractive error;
THYM	cis	rs7953249	0.564	rs11065385	chr12:121423386	A/G	cg02403541	chr12:121454288	C12orf43	-0.79	-7.09	-0.59	2.31e-10	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg06808227	chr14:105710500	BRF1	-1.05	-9.15	-0.68	1.07e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1729407	0.706	rs1268354	chr11:116690578	C/T	cg08985259	chr11:116699649	APOC3	-0.63	-5.51	-0.49	3.12e-7	Apolipoprotein A-IV levels;
THYM	cis	rs4731207	0.698	rs7793258	chr7:124448012	G/A	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs61931739	1.000	rs12298806	chr12:34036528	C/G	cg06521331	chr12:34319734	NA	0.61	4.76	0.44	6.95e-6	Morning vs. evening chronotype;
THYM	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.3	0.73	3.8e-17	Prudent dietary pattern;
THYM	cis	rs2257129	1.000	rs11199805	chr10:122919206	A/G	cg22762615	chr10:123358210	FGFR2	-1.33	-4.73	-0.44	7.77e-6	Coronary artery disease;Body mass index;
THYM	cis	rs3540	0.514	rs2601194	chr15:90937051	T/A	cg22089800	chr15:90895588	ZNF774	0.68	5.12	0.46	1.61e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs728616	0.867	rs61860417	chr10:81734727	C/T	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-6.47	-0.55	4.2e-9	Chronic sinus infection;
THYM	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg25358565	chr5:93447407	FAM172A	-0.83	-6.2	-0.54	1.42e-8	Diabetic retinopathy;
THYM	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg16928487	chr17:17741425	SREBF1	-0.56	-5.49	-0.49	3.33e-7	Total body bone mineral density;
THYM	cis	rs9403317	0.537	rs722252	chr6:142032339	T/C	cg15052665	chr6:141804349	NA	-0.76	-5.6	-0.5	2.06e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg08859206	chr1:53392774	SCP2	-0.77	-9.4	-0.69	3.24e-15	Monocyte count;
THYM	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg13695892	chr22:41940480	POLR3H	-0.95	-7.25	-0.6	1.08e-10	Vitiligo;
THYM	cis	rs9902453	0.808	rs4595850	chr17:28206326	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.65	0.43	1.08e-5	Coffee consumption (cups per day);
THYM	cis	rs8064299	0.655	rs895691	chr17:72766300	G/T	cg21922841	chr17:72744131	SLC9A3R1	0.36	4.9	0.45	3.92e-6	Monocyte count;
THYM	cis	rs904251	0.766	rs1757175	chr6:37486694	T/C	cg25019722	chr6:37503610	NA	-0.65	-5.57	-0.5	2.37e-7	Cognitive performance;
THYM	cis	rs7107174	1.000	rs2511182	chr11:77982130	G/C	cg02023728	chr11:77925099	USP35	0.65	5.95	0.52	4.47e-8	Testicular germ cell tumor;
THYM	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg06808227	chr14:105710500	BRF1	1.06	9.46	0.7	2.39e-15	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7107174	0.892	rs11237463	chr11:78060464	A/G	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs12496230	0.953	rs13096599	chr3:66848809	T/C	cg04995300	chr3:66848608	NA	1.14	6.75	0.57	1.17e-9	Type 2 diabetes;
THYM	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg23283495	chr1:209979779	IRF6	0.75	8.62	0.66	1.45e-13	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
THYM	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11890956	chr21:40555474	PSMG1	-0.97	-11.03	-0.75	1.05e-18	Cognitive function;
THYM	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg12935359	chr14:103987150	CKB	-0.65	-6.4	-0.55	5.78e-9	Body mass index;
THYM	cis	rs12208915	0.731	rs9361473	chr6:79657042	C/T	cg05283184	chr6:79620031	NA	0.61	4.55	0.42	1.56e-5	Left atrial antero-posterior diameter;
THYM	cis	rs6570726	0.967	rs6903252	chr6:145922777	A/G	cg23711669	chr6:146136114	FBXO30	0.83	7.78	0.62	8.94e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7107174	1.000	rs2510043	chr11:77977481	C/G	cg02023728	chr11:77925099	USP35	0.68	6.29	0.54	9.85e-9	Testicular germ cell tumor;
THYM	cis	rs600550	0.588	rs10431136	chr11:60074313	A/T	cg05040360	chr11:60102449	MS4A6E	-0.47	-4.46	-0.42	2.29e-5	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg26384229	chr12:38710491	ALG10B	1.03	7.9	0.63	4.9e-12	Bladder cancer;
THYM	cis	rs7528419	0.591	rs4970837	chr1:109822008	G/T	cg00908766	chr1:109817496	CELSR2	0.64	5.94	0.52	4.75e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
THYM	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11890956	chr21:40555474	PSMG1	-0.68	-6.42	-0.55	5.42e-9	Menarche (age at onset);
THYM	cis	rs4509693	1.000	rs4277047	chr10:102499416	T/A	cg24127310	chr10:102502104	NA	1.3	10.12	0.72	9.09e-17	Alzheimer's disease;
THYM	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg03806693	chr22:41940476	POLR3H	1.16	10.2	0.72	6.06e-17	Vitiligo;
THYM	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg08132940	chr7:1081526	C7orf50	-1.12	-6.27	-0.54	1.04e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg25358565	chr5:93447407	FAM172A	0.96	6.78	0.57	1.01e-9	Diabetic retinopathy;
THYM	cis	rs9814567	1.000	rs2887797	chr3:134202506	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-8.49	-0.66	2.78e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2133450	0.712	rs10510357	chr3:7367528	C/T	cg19930620	chr3:7340148	GRM7	-0.48	-4.49	-0.42	1.98e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs60843830	0.661	rs7561648	chr2:105171	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.57	4.63	0.43	1.18e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs4654899	1.000	rs6702110	chr1:21515906	A/G	cg01072550	chr1:21505969	NA	-0.71	-6.51	-0.56	3.48e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg02527881	chr3:46936655	PTH1R	0.52	4.99	0.46	2.77e-6	Colorectal cancer;
THYM	cis	rs3768617	0.510	rs10458355	chr1:183063993	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.76	0.44	6.83e-6	Fuchs's corneal dystrophy;
THYM	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg19318889	chr4:1322082	MAEA	0.69	5.99	0.52	3.67e-8	Longevity;
THYM	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg05660106	chr1:15850417	CASP9	0.71	5.74	0.51	1.14e-7	Systolic blood pressure;
THYM	trans	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg19862616	chr7:65841803	NCRNA00174	1.09	13.84	0.82	1.67e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs899997	0.862	rs8043123	chr15:78973393	C/T	cg00639195	chr15:79103007	ADAMTS7	0.66	4.55	0.42	1.58e-5	Coronary artery disease or large artery stroke;
THYM	cis	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg21775007	chr8:11205619	TDH	0.6	4.6	0.43	1.32e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg21775007	chr8:11205619	TDH	-0.71	-5.45	-0.49	3.88e-7	Retinal vascular caliber;
THYM	cis	rs4930103	0.935	rs4930098	chr11:2020955	G/C	cg21926276	chr11:2035255	NA	0.27	4.53	0.42	1.7e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg13852791	chr20:30311386	BCL2L1	0.82	6.4	0.55	5.76e-9	Mean corpuscular hemoglobin;
THYM	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg14779329	chr11:130786720	SNX19	0.53	5.52	0.49	2.93e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg21110456	chr7:2059412	MAD1L1	-0.45	-4.74	-0.44	7.54e-6	Neuroticism;
THYM	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-4.47	-0.42	2.12e-5	Hemoglobin concentration;
THYM	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg26384229	chr12:38710491	ALG10B	0.97	7.44	0.61	4.48e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7404928	0.651	rs8053880	chr16:23949912	C/T	cg26685404	chr16:23957272	PRKCB	-0.6	-6.95	-0.58	4.57e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg03351412	chr1:154909251	PMVK	0.67	4.65	0.43	1.06e-5	Prostate cancer;
THYM	cis	rs828999	0.688	rs10785837	chr1:108698133	G/A	cg24323958	chr1:108741884	SLC25A24	0.54	5.32	0.48	6.79e-7	Monocyte percentage of white cells;
THYM	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.67	-5.7	-0.5	1.37e-7	Coronary artery disease;
THYM	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg18806716	chr10:30721971	MAP3K8	-0.57	-5.58	-0.5	2.23e-7	Inflammatory bowel disease;
THYM	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg25767906	chr1:53392781	SCP2	0.72	6.48	0.55	4.15e-9	Monocyte count;
THYM	cis	rs1348850	0.645	rs10164417	chr2:178444130	A/G	cg27490568	chr2:178487706	NA	0.5	4.51	0.42	1.88e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs7267979	0.932	rs6138600	chr20:25521346	A/T	cg03522245	chr20:25566470	NINL	0.59	4.5	0.42	1.93e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg05660106	chr1:15850417	CASP9	0.76	6.27	0.54	1.06e-8	Systolic blood pressure;
THYM	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg10465839	chr16:1584050	IFT140;TMEM204	-0.54	-4.63	-0.43	1.15e-5	Coronary artery disease;
THYM	cis	rs79387448	0.745	rs17027421	chr2:103159882	A/G	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs950776	0.752	rs2869546	chr15:78907345	C/T	cg06917634	chr15:78832804	PSMA4	-0.82	-6.89	-0.58	6.18e-10	Sudden cardiac arrest;
THYM	cis	rs36051895	0.623	rs7027871	chr9:5236822	C/G	cg02405213	chr9:5042618	JAK2	0.96	9.42	0.7	2.85e-15	Pediatric autoimmune diseases;
THYM	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.7	-4.72	-0.44	8.27e-6	Gut microbiome composition (summer);
THYM	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg18681998	chr4:17616180	MED28	-0.84	-7.02	-0.58	3.24e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg20744362	chr22:50050164	C22orf34	0.79	7.19	0.59	1.5e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4595586	0.679	rs35743713	chr12:39318539	C/G	cg26384229	chr12:38710491	ALG10B	0.6	4.95	0.45	3.2e-6	Morning vs. evening chronotype;
THYM	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.47	-4.53	-0.42	1.68e-5	Crohn's disease;
THYM	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.07	-10.71	-0.74	5.17e-18	Primary sclerosing cholangitis;
THYM	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg24846680	chr1:228362309	C1orf69	0.52	4.72	0.44	8.06e-6	Diastolic blood pressure;
THYM	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg23326234	chr5:490647	SLC9A3	0.62	4.78	0.44	6.44e-6	Cystic fibrosis severity;
THYM	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.6	0.43	1.32e-5	Breast cancer;
THYM	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	cg06064525	chr11:970664	AP2A2	-0.35	-6.7	-0.57	1.46e-9	Alzheimer's disease (late onset);
THYM	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg10515332	chr4:99064459	C4orf37	0.57	4.54	0.42	1.68e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs757081	0.667	rs17473243	chr11:17266259	G/A	cg07093617	chr11:18158918	MRGPRX3	-0.49	-4.61	-0.43	1.23e-5	Systolic blood pressure;
THYM	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.77	0.51	1.01e-7	Rheumatoid arthritis;
THYM	cis	rs56341938	0.935	rs62275518	chr3:168731223	A/G	cg09107232	chr3:169491072	MYNN	0.55	4.75	0.44	7.23e-6	Lung function (FEV1/FVC);
THYM	cis	rs858239	0.665	rs858306	chr7:23242754	A/T	cg05407003	chr7:23246146	NA	-0.73	-6.39	-0.55	6e-9	Cerebrospinal fluid biomarker levels;
THYM	cis	rs34638657	0.732	rs12597534	chr16:82200276	G/T	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.11	-0.64	1.73e-12	Lung adenocarcinoma;
THYM	cis	rs9479482	0.789	rs12204988	chr6:150339315	T/G	cg25797454	chr6:150327115	RAET1K	0.46	5.03	0.46	2.33e-6	Alopecia areata;
THYM	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg08847533	chr14:75593920	NEK9	0.55	4.57	0.42	1.49e-5	Caffeine consumption;
THYM	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg18252515	chr7:66147081	NA	-0.62	-4.55	-0.42	1.59e-5	Aortic root size;
THYM	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.76	-6.35	-0.55	7.5e-9	Tonsillectomy;
THYM	cis	rs72627123	0.867	rs57482759	chr14:74485523	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.52	0.56	3.44e-9	Morning vs. evening chronotype;
THYM	cis	rs1904096	0.506	rs6823404	chr4:95197520	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.57	-4.94	-0.45	3.31e-6	Type 2 diabetes;
THYM	cis	rs834811	0.829	rs10252049	chr7:135903178	G/A	cg01726295	chr7:135938950	NA	-0.72	-6.29	-0.54	9.79e-9	Post-traumatic stress disorder;
THYM	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg24397884	chr7:158709396	WDR60	0.51	5.46	0.49	3.82e-7	Height;
THYM	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg10047753	chr17:41438598	NA	1.2	11.15	0.75	5.87e-19	Menopause (age at onset);
THYM	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg23743428	chr13:21893420	NA	-0.65	-5.49	-0.49	3.27e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg08736216	chr1:53307985	ZYG11A	-0.63	-5.73	-0.51	1.19e-7	Monocyte count;
THYM	cis	rs6547741	0.788	rs7595739	chr2:27874563	G/T	cg27432699	chr2:27873401	GPN1	-0.86	-7.63	-0.62	1.82e-11	Oral cavity cancer;
THYM	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg12560992	chr17:57184187	TRIM37	0.92	8.53	0.66	2.29e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9595908	0.965	rs9595877	chr13:33163649	A/G	cg12383807	chr13:33924137	NA	-0.54	-4.63	-0.43	1.17e-5	Body mass index;
THYM	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs2074585	0.806	rs8033813	chr15:90999715	A/T	cg22089800	chr15:90895588	ZNF774	0.71	5.67	0.5	1.53e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
THYM	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg06600287	chr1:53387719	ECHDC2	-0.32	-4.82	-0.44	5.34e-6	Monocyte count;
THYM	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg25918947	chr17:41365094	TMEM106A	-0.62	-5.01	-0.46	2.49e-6	Menopause (age at onset);
THYM	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg05973401	chr12:123451056	ABCB9	0.68	4.55	0.42	1.58e-5	Neutrophil percentage of white cells;
THYM	cis	rs524023	0.915	rs531763	chr11:64352063	A/G	cg19131476	chr11:64387923	NRXN2	0.32	4.57	0.42	1.48e-5	Urate levels in obese individuals;
THYM	cis	rs4662945	1.000	rs4662941	chr2:130215877	A/G	cg05903289	chr2:130345205	NA	-0.52	-5.1	-0.46	1.7e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs4242434	0.892	rs71513892	chr8:22456517	C/G	cg21658235	chr8:22456391	C8orf58	0.59	5.62	0.5	1.93e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7084402	0.902	rs1658484	chr10:60288543	G/A	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs1163251	0.902	rs483360	chr1:120200606	C/T	cg19096424	chr1:120255104	PHGDH	-0.6	-4.51	-0.42	1.86e-5	Blood metabolite levels;
THYM	cis	rs8048589	0.515	rs4780412	chr16:12232409	A/G	cg01990910	chr16:12207648	SNX29	-0.39	-4.74	-0.44	7.59e-6	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg12011299	chr4:100065546	ADH4	0.68	6.19	0.54	1.53e-8	Alcohol dependence;
THYM	cis	rs9394438	0.593	rs10947679	chr6:37543524	C/G	cg00985040	chr6:37553208	NA	0.42	4.59	0.43	1.34e-5	IgG glycosylation;
THYM	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg00495681	chr13:53174319	NA	0.97	9.92	0.71	2.43e-16	Lewy body disease;
THYM	trans	rs629535	0.748	rs58675625	chr8:70034924	T/C	cg21567404	chr3:27674614	NA	1.12	10.86	0.74	2.44e-18	Dupuytren's disease;
THYM	cis	rs11030122	0.632	rs714380	chr11:4059653	A/T	cg18678763	chr11:4115507	RRM1	-0.47	-6.27	-0.54	1.07e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9611565	0.506	rs1984839	chr22:41685937	G/C	cg03806693	chr22:41940476	POLR3H	-0.82	-6.85	-0.57	7.35e-10	Vitiligo;
THYM	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg13010199	chr12:38710504	ALG10B	0.75	5.67	0.5	1.51e-7	Heart rate;
THYM	trans	rs8073060	0.586	rs11080356	chr17:33895309	T/C	cg19694781	chr19:47549865	TMEM160	0.95	8.41	0.65	4.12e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs2069036	0.951	rs10904675	chr10:16120989	A/C	cg26633223	chr10:15133461	NA	0.71	5.28	0.48	8.26e-7	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs11771526	0.901	rs13438711	chr7:32297310	G/A	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg18681998	chr4:17616180	MED28	0.79	6.7	0.57	1.49e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2016266	0.855	rs930900	chr12:53727545	T/C	cg26875137	chr12:53738046	NA	0.71	5.62	0.5	1.89e-7	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs36051895	0.659	rs3780366	chr9:5068596	T/C	cg02405213	chr9:5042618	JAK2	-1.02	-11.39	-0.76	1.87e-19	Pediatric autoimmune diseases;
THYM	cis	rs75064307	0.834	rs4588370	chr3:108114050	G/A	cg03329597	chr3:108125523	MYH15	0.66	4.75	0.44	7.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs669446	0.527	rs667676	chr1:44082216	G/A	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7940866	0.801	rs2113928	chr11:130835975	A/G	cg23692386	chr11:131799662	NTM	0.49	5.02	0.46	2.4e-6	Schizophrenia;
THYM	cis	rs990171	1.000	rs4851575	chr2:103025203	G/A	cg13897122	chr2:103039542	IL18RAP	-0.4	-4.88	-0.45	4.23e-6	Lymphocyte counts;
THYM	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg06850241	chr22:41845214	NA	-0.54	-4.68	-0.43	9.37e-6	Vitiligo;
THYM	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg18876405	chr7:65276391	NA	-0.71	-6.62	-0.56	2.12e-9	Aortic root size;
THYM	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg22683308	chr4:1340831	KIAA1530	-0.64	-5.18	-0.47	1.26e-6	Longevity;
THYM	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03647317	chr4:187891568	NA	-0.84	-9.05	-0.68	1.74e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg17063962	chr7:91808500	NA	-1.12	-12.68	-0.79	3.85e-22	Breast cancer;
THYM	trans	rs6728642	0.901	rs7584641	chr2:97607655	A/T	cg24462260	chr19:8555123	PRAM1	0.62	7.09	0.59	2.31e-10	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs9420	0.961	rs11570190	chr11:57560452	A/C	cg19752551	chr11:57585705	CTNND1	-0.73	-7.98	-0.63	3.28e-12	Schizophrenia;
THYM	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg08132940	chr7:1081526	C7orf50	-1.03	-6.42	-0.55	5.3e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg11335335	chr11:637885	DRD4	-0.63	-5.17	-0.47	1.29e-6	Systemic lupus erythematosus;
THYM	cis	rs7940866	0.838	rs10750455	chr11:130800330	C/T	cg23692386	chr11:131799662	NTM	0.44	4.55	0.42	1.61e-5	Schizophrenia;
THYM	cis	rs6840360	0.571	rs4696270	chr4:152498289	G/A	cg17479576	chr4:152424074	FAM160A1	-0.8	-5.92	-0.52	5.02e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg22875332	chr1:76189707	ACADM	0.89	11.58	0.77	7.38e-20	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg11941060	chr3:133502564	NA	0.81	7.11	0.59	2.14e-10	Iron status biomarkers;
THYM	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg10117171	chr1:25599238	RHD	-0.8	-5.96	-0.52	4.21e-8	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs7524258	0.903	rs4908450	chr1:7292756	T/C	cg07173049	chr1:7289937	CAMTA1	0.82	6.34	0.55	7.82e-9	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs4747241	0.739	rs10740400	chr10:74060530	C/G	cg07828833	chr10:74069493	NA	0.59	4.83	0.44	5.3e-6	Heschl's gyrus morphology;
THYM	cis	rs7584330	0.666	rs7600317	chr2:238353513	C/T	cg14458575	chr2:238380390	NA	1.14	8.54	0.66	2.14e-13	Prostate cancer;
THYM	cis	rs7106204	0.544	rs16912364	chr11:24291549	A/G	ch.11.24196551F	chr11:24239977	NA	0.99	6.22	0.54	1.34e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg10248100	chr7:872053	UNC84A	0.74	4.99	0.46	2.75e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg03388025	chr16:89894329	SPIRE2	0.52	4.57	0.42	1.45e-5	Vitiligo;
THYM	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg14675211	chr2:100938903	LONRF2	0.77	8.32	0.65	6.49e-13	Intelligence (multi-trait analysis);
THYM	cis	rs1957429	0.901	rs1467569	chr14:65347986	T/C	cg23373153	chr14:65346875	NA	1.07	6.45	0.55	4.75e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.68	5.24	0.47	9.75e-7	Tonsillectomy;
THYM	cis	rs483180	0.512	rs597308	chr1:120214953	G/A	cg19096424	chr1:120255104	PHGDH	0.67	5.25	0.47	9.26e-7	Macular telangiectasia type 2;
THYM	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg19774624	chr17:42201019	HDAC5	0.76	7.12	0.59	2.05e-10	Total body bone mineral density;
THYM	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs12142240	0.659	rs72677591	chr1:46818219	T/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs931127	0.719	rs2127507	chr11:65454430	A/G	cg27068330	chr11:65405492	SIPA1	-0.79	-7.05	-0.59	2.85e-10	Systemic lupus erythematosus;
THYM	cis	rs9790314	0.967	rs336541	chr3:161056698	A/C	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs6785206	0.892	rs2712429	chr3:128336221	A/C	cg16766828	chr3:128327626	NA	-0.75	-7.34	-0.6	7.04e-11	Lymphocyte percentage of white cells;
THYM	cis	rs2898681	0.642	rs62336790	chr4:53728000	T/C	cg00812761	chr4:53799391	SCFD2	-0.54	-4.98	-0.45	2.86e-6	Optic nerve measurement (cup area);
THYM	cis	rs9443645	0.527	rs1413969	chr6:79790982	A/G	cg05283184	chr6:79620031	NA	-0.6	-4.67	-0.43	9.91e-6	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg25517755	chr10:38738941	LOC399744	-0.76	-6.92	-0.58	5.26e-10	Corneal astigmatism;
THYM	cis	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg16068833	chr1:26644515	UBXN11;CD52	0.26	4.49	0.42	2e-5	Obesity-related traits;
THYM	cis	rs1669338	0.588	rs55959448	chr3:3204000	C/T	cg16797762	chr3:3221439	CRBN	-1.0	-5.55	-0.5	2.54e-7	White matter integrity;
THYM	cis	rs4790333	0.537	rs898750	chr17:2255193	A/G	cg02569219	chr17:2266849	SGSM2	0.7	6.19	0.54	1.49e-8	Proinsulin levels;
THYM	cis	rs7127900	0.705	rs73407554	chr11:2224175	C/G	cg25635251	chr11:2234043	NA	-0.74	-4.66	-0.43	1.04e-5	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs7226229	0.904	rs2364330	chr17:20922920	G/C	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs3772130	0.962	rs11707518	chr3:121496568	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.78	4.92	0.45	3.65e-6	Cognitive performance;
THYM	cis	rs912057	0.833	rs1294421	chr6:6743149	A/C	cg13809441	chr6:6737631	NA	0.43	4.85	0.45	4.78e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs6032067	0.777	rs62208416	chr20:43803226	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.52	-5.89	-0.52	5.76e-8	Blood protein levels;
THYM	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg18876405	chr7:65276391	NA	0.67	5.76	0.51	1.04e-7	Aortic root size;
THYM	cis	rs2835345	0.563	rs78113480	chr21:37824320	T/C	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19346786	chr7:2764209	NA	-0.7	-5.86	-0.52	6.63e-8	Height;
THYM	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg20887711	chr4:1340912	KIAA1530	0.57	4.54	0.42	1.63e-5	Obesity-related traits;
THYM	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg03806693	chr22:41940476	POLR3H	1.11	8.4	0.65	4.3e-13	Vitiligo;
THYM	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg07341220	chr16:1583899	IFT140;TMEM204	-0.72	-6.12	-0.53	2.09e-8	Coronary artery disease;
THYM	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg20283391	chr11:68216788	NA	-0.61	-4.51	-0.42	1.85e-5	Total body bone mineral density;
THYM	cis	rs2073300	0.609	rs6137937	chr20:23385419	G/A	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs3750965	1.000	rs7950657	chr11:68834831	G/A	cg06818126	chr11:68850279	TPCN2	-0.68	-4.64	-0.43	1.13e-5	Hair color;
THYM	cis	rs73086581	1.000	rs73086512	chr20:3922772	C/A	cg02187196	chr20:3869020	PANK2	0.5	5.57	0.5	2.37e-7	Response to antidepressants in depression;
THYM	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg24642844	chr7:1081250	C7orf50	-1.29	-8.3	-0.65	7.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg23161317	chr6:28129485	ZNF389	0.94	7.03	0.58	3.18e-10	Parkinson's disease;
THYM	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/G	cg05922057	chr17:4047571	ZZEF1;CYB5D2	0.85	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9527	0.545	rs7100369	chr10:104956218	C/A	cg04362960	chr10:104952993	NT5C2	0.62	4.74	0.44	7.52e-6	Arsenic metabolism;
THYM	cis	rs3741151	1.000	rs1892856	chr11:73017971	G/C	cg17517138	chr11:73019481	ARHGEF17	1.01	5.83	0.51	7.72e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2730245	0.569	rs842692	chr7:158657228	T/C	cg23730037	chr7:158596552	ESYT2	-0.58	-6.12	-0.53	2.07e-8	Height;
THYM	cis	rs9355610	0.892	rs2247314	chr6:167370230	T/C	cg15592062	chr6:167189543	RPS6KA2	0.52	5.37	0.48	5.51e-7	Graves' disease;
THYM	cis	rs6456156	0.774	rs1556413	chr6:167524743	G/A	cg09487078	chr6:167525398	CCR6	-0.44	-4.82	-0.44	5.43e-6	Primary biliary cholangitis;
THYM	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg10760299	chr15:45669010	GATM	-0.74	-5.59	-0.5	2.19e-7	Homoarginine levels;
THYM	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg00083206	chr6:110721305	DDO	-0.58	-6.96	-0.58	4.26e-10	Platelet distribution width;
THYM	trans	rs2270927	0.510	rs67771044	chr5:75577819	A/G	cg13563193	chr19:33072644	PDCD5	1.51	6.84	0.57	7.67e-10	Mean corpuscular volume;
THYM	cis	rs6430585	0.941	rs12469551	chr2:136510012	T/G	cg23851026	chr2:136556271	LCT	-0.65	-5.9	-0.52	5.51e-8	Corneal structure;
THYM	cis	rs7394190	0.748	rs4082339	chr10:75539812	C/T	cg07699608	chr10:75541558	CHCHD1	-0.89	-4.91	-0.45	3.74e-6	Incident atrial fibrillation;
THYM	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg23583168	chr7:148888333	NA	-1.0	-13.46	-0.81	9.53e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg20503657	chr10:835505	NA	0.85	5.01	0.46	2.53e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg22920501	chr2:26401640	FAM59B	-1.05	-9.27	-0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.83	-0.44	5.29e-6	Mean corpuscular volume;
THYM	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg15440763	chr7:158190612	PTPRN2	0.48	4.46	0.42	2.29e-5	Obesity-related traits;
THYM	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg27286337	chr10:134555280	INPP5A	0.84	5.93	0.52	4.78e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg13114125	chr14:105738426	BRF1	-0.75	-5.91	-0.52	5.39e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg05025164	chr4:1340916	KIAA1530	-0.94	-7.7	-0.62	1.28e-11	Longevity;
THYM	cis	rs5769765	0.526	rs5770722	chr22:50253220	G/C	cg08270630	chr22:50330655	NA	0.72	4.68	0.43	9.6e-6	Schizophrenia;
THYM	cis	rs10489202	1.000	rs34058770	chr1:168057399	C/A	cg24449463	chr1:168025552	DCAF6	-0.79	-6.15	-0.53	1.86e-8	Schizophrenia;
THYM	cis	rs1198430	1.000	rs946268	chr1:23747766	A/G	cg27447006	chr1:23763279	ASAP3	0.83	4.45	0.42	2.29e-5	Total cholesterol levels;
THYM	cis	rs2976388	0.556	rs2572876	chr8:143830599	C/T	cg06565975	chr8:143823917	SLURP1	-0.71	-7.68	-0.62	1.4e-11	Urinary tract infection frequency;
THYM	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg23583168	chr7:148888333	NA	-1.01	-13.35	-0.81	1.66e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg20295408	chr7:1910781	MAD1L1	-0.68	-5.09	-0.46	1.81e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs11089937	0.523	rs4821832	chr22:22542888	T/C	cg21401457	chr22:22472743	NA	0.56	4.75	0.44	7.13e-6	Periodontitis (PAL4Q3);
THYM	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg01304814	chr3:48885189	PRKAR2A	0.92	4.51	0.42	1.82e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs61774743	0.681	rs10889959	chr1:41849735	T/C	cg08462924	chr1:41848221	NA	0.82	10.14	0.72	8.5e-17	Intelligence (multi-trait analysis);
THYM	cis	rs7408868	1.000	rs10407320	chr19:15275716	G/C	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs6430585	0.584	rs4954276	chr2:136402117	A/G	cg20242066	chr2:136595261	LCT	0.55	6.01	0.53	3.38e-8	Corneal structure;
THYM	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg14458575	chr2:238380390	NA	0.9	7.53	0.61	2.94e-11	Prostate cancer;
THYM	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg13397359	chr6:42928475	GNMT	0.57	4.91	0.45	3.86e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs11585357	0.895	rs72633812	chr1:17623140	T/C	cg08277548	chr1:17600880	PADI3	-0.88	-5.22	-0.47	1.05e-6	Hair shape;
THYM	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg00012203	chr2:219082015	ARPC2	0.83	7.56	0.61	2.54e-11	Colorectal cancer;
THYM	trans	rs480407	0.857	rs185625	chr2:161683785	C/A	cg06548410	chr19:1997657	BTBD2	0.72	7.08	0.59	2.46e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2976388	0.609	rs2572909	chr8:143806464	C/G	cg06565975	chr8:143823917	SLURP1	0.5	5.62	0.5	1.9e-7	Urinary tract infection frequency;
THYM	cis	rs9807989	0.839	rs1420099	chr2:102980543	C/G	cg03938978	chr2:103052716	IL18RAP	0.63	6.55	0.56	2.99e-9	Asthma;
THYM	cis	rs4845570	0.920	rs10788809	chr1:151760792	A/G	cg07092448	chr1:151763213	TDRKH	1.03	6.5	0.55	3.71e-9	Coronary artery disease;
THYM	cis	rs9905704	0.647	rs9898048	chr17:57108543	C/T	cg12560992	chr17:57184187	TRIM37	0.68	5.34	0.48	6.34e-7	Testicular germ cell tumor;
THYM	cis	rs1018836	0.632	rs9642910	chr8:91475724	G/T	cg16814680	chr8:91681699	NA	-0.74	-6.16	-0.53	1.76e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg01579765	chr21:45077557	HSF2BP	-0.43	-6.7	-0.57	1.44e-9	Mean corpuscular volume;
THYM	cis	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg19442545	chr10:75533431	FUT11	-0.53	-5.63	-0.5	1.82e-7	Inflammatory bowel disease;
THYM	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg19770292	chr5:1868693	NA	0.52	4.83	0.44	5.17e-6	Cardiovascular disease risk factors;
THYM	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg10589385	chr1:150898437	SETDB1	-0.58	-4.74	-0.44	7.58e-6	Urate levels;
THYM	cis	rs3768617	0.510	rs1413389	chr1:183096668	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs4595586	0.545	rs4438082	chr12:39363870	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs1062753	0.731	rs11090065	chr22:42384171	T/C	cg08431931	chr22:42394659	WBP2NL	0.64	4.92	0.45	3.61e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs10492096	0.947	rs61918022	chr12:6614521	C/T	cg13857086	chr12:6580257	VAMP1	0.87	5.27	0.48	8.47e-7	Hip geometry;
THYM	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg02820040	chr2:241836501	C2orf54	-0.33	-6.76	-0.57	1.12e-9	Urinary metabolites;
THYM	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg17127132	chr2:85788382	GGCX	0.7	6.22	0.54	1.32e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs35883536	0.545	rs56674564	chr1:101097718	T/C	cg09408571	chr1:101003634	GPR88	0.4	4.9	0.45	3.88e-6	Monocyte count;
THYM	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg06618935	chr21:46677482	NA	-0.97	-8.09	-0.64	1.92e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg22433210	chr17:43662623	NA	1.12	8.59	0.66	1.69e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7267979	0.966	rs2257705	chr20:25264664	T/C	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.54	-0.56	3.08e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2302612	0.528	rs3771181	chr2:102846706	A/G	cg13315345	chr2:102803985	IL1RL2	0.72	4.88	0.45	4.28e-6	Serum protein levels (sST2);
THYM	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.07	11.43	0.76	1.5e-19	Intelligence (multi-trait analysis);
THYM	cis	rs939574	1.000	rs3817424	chr2:220096903	A/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.28	5.88	0.52	5.96e-8	Platelet distribution width;
THYM	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.22	9.08	0.68	1.54e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7757969	0.941	rs9481191	chr6:112124438	C/G	cg08601457	chr6:112115117	FYN	0.42	4.88	0.45	4.22e-6	Schizophrenia;
THYM	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg10487659	chr16:4152081	ADCY9	0.69	4.55	0.42	1.56e-5	Tuberculosis;
THYM	cis	rs9807841	0.568	rs1560707	chr19:10750738	A/C	cg16900796	chr19:10755136	SLC44A2	0.37	5.55	0.49	2.58e-7	Inflammatory skin disease;
THYM	cis	rs459193	0.636	rs455660	chr5:55816888	C/T	cg17790372	chr5:56509962	GPBP1	0.65	4.64	0.43	1.11e-5	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs10886503	0.777	rs7101354	chr10:121267016	C/T	cg13260278	chr10:121265587	RGS10	-0.68	-6.46	-0.55	4.52e-9	Obstetric antiphospholipid syndrome;
THYM	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg22875332	chr1:76189707	ACADM	0.88	11.22	0.75	4.31e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	7.49	0.61	3.58e-11	Smoking behavior;
THYM	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg03060546	chr3:49711283	APEH	-0.7	-5.83	-0.51	7.58e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg21862992	chr11:68658383	NA	0.23	4.51	0.42	1.86e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2419577	0.599	rs7085620	chr10:112498568	A/G	cg20877679	chr10:112431836	RBM20	-0.52	-4.45	-0.42	2.34e-5	QRS complex (Sokolow-Lyon);
THYM	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg01699819	chr7:1052092	C7orf50	-0.87	-7.91	-0.63	4.74e-12	Bronchopulmonary dysplasia;
THYM	cis	rs7084402	0.967	rs1649018	chr10:60288150	T/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs854765	0.663	rs2236513	chr17:17747366	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-5.87	-0.52	6.25e-8	Total body bone mineral density;
THYM	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg12179176	chr11:130786555	SNX19	0.84	7.68	0.62	1.45e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7572733	0.534	rs7572123	chr2:198769637	A/G	cg00792783	chr2:198669748	PLCL1	0.84	5.97	0.52	4.15e-8	Dermatomyositis;
THYM	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4930103	0.935	rs2839698	chr11:2018853	G/A	cg21926276	chr11:2035255	NA	0.27	4.53	0.42	1.7e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs554111	0.660	rs12042978	chr1:21170811	T/C	cg01072550	chr1:21505969	NA	0.56	4.92	0.45	3.63e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg10360139	chr7:1886902	MAD1L1	-0.86	-7.83	-0.63	6.99e-12	Bipolar disorder and schizophrenia;
THYM	cis	rs11214589	0.774	rs7107223	chr11:113255574	A/T	cg14159747	chr11:113255604	NA	0.38	8.53	0.66	2.27e-13	Neuroticism;
THYM	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06634786	chr22:41940651	POLR3H	-0.78	-5.52	-0.49	2.93e-7	Vitiligo;
THYM	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg16325326	chr1:53192061	ZYG11B	0.82	7.77	0.62	9e-12	Monocyte count;
THYM	cis	rs8192282	0.739	rs4585969	chr1:154498957	C/T	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs314370	1.000	rs10278546	chr7:100516003	G/T	cg08558340	chr7:100472263	SRRT	-0.55	-4.77	-0.44	6.55e-6	Resting heart rate;
THYM	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg19729930	chr2:74357872	NA	1.25	12.57	0.79	6.31e-22	Gestational age at birth (maternal effect);
THYM	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg11327659	chr7:150037044	RARRES2	0.43	5.21	0.47	1.11e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg13683864	chr3:40499215	RPL14	-0.87	-8.55	-0.66	2.09e-13	Renal cell carcinoma;
THYM	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg27588902	chr6:42928151	GNMT	-0.53	-4.99	-0.46	2.68e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs28595532	0.920	rs114649974	chr4:119735341	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg00024416	chr22:24240387	NA	-0.82	-7.39	-0.6	5.73e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7572733	0.555	rs7590828	chr2:198940251	A/G	cg00792783	chr2:198669748	PLCL1	-0.69	-4.65	-0.43	1.09e-5	Dermatomyositis;
THYM	cis	rs4595586	0.679	rs35743713	chr12:39318539	C/G	cg13010199	chr12:38710504	ALG10B	0.59	4.95	0.45	3.25e-6	Morning vs. evening chronotype;
THYM	cis	rs34375054	0.624	rs73233307	chr12:125675873	G/C	cg25124228	chr12:125621409	AACS	-0.67	-4.87	-0.45	4.48e-6	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs4851254	0.618	rs4851243	chr2:100639482	G/A	cg22139774	chr2:100720529	AFF3	-0.39	-4.46	-0.42	2.21e-5	Intelligence (multi-trait analysis);
THYM	cis	rs17253792	0.822	rs77761669	chr14:56034216	G/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.91	-0.45	3.74e-6	Putamen volume;
THYM	cis	rs9355610	0.609	rs7772112	chr6:167408896	G/A	cg23791538	chr6:167370224	RNASET2	0.73	4.92	0.45	3.66e-6	Graves' disease;
THYM	cis	rs3126085	0.560	rs6693160	chr1:152341321	C/T	cg10321714	chr1:152280068	FLG	-0.69	-4.84	-0.44	5.1e-6	Atopic dermatitis;
THYM	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg11245990	chr11:68621969	NA	0.56	7.19	0.59	1.49e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg00495681	chr13:53174319	NA	0.75	6.93	0.58	4.94e-10	Lewy body disease;
THYM	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg13010199	chr12:38710504	ALG10B	0.73	5.82	0.51	7.99e-8	Heart rate;
THYM	cis	rs9866391	0.607	rs6763931	chr3:141102833	G/A	cg13411656	chr3:141121016	ZBTB38	-0.35	-5.14	-0.47	1.46e-6	Myopia;
THYM	cis	rs2160908	0.694	rs229515	chr22:37576072	C/T	cg26999345	chr22:37584441	C1QTNF6	-0.39	-4.58	-0.43	1.41e-5	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg02734326	chr4:10020555	SLC2A9	-0.72	-6.31	-0.54	8.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7567389	0.677	rs72848604	chr2:128120118	G/C	cg09760422	chr2:128146352	NA	0.4	4.52	0.42	1.8e-5	Self-rated health;
THYM	cis	rs2273669	0.667	rs12215736	chr6:109330367	A/G	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	cis	rs76878669	0.561	rs10791872	chr11:66138434	C/G	cg18002602	chr11:66138449	SLC29A2	-0.48	-4.72	-0.44	8.12e-6	Educational attainment (years of education);
THYM	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg13319975	chr6:146136371	FBXO30	-0.64	-5.19	-0.47	1.18e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs950169	0.519	rs7237	chr15:85186577	C/T	cg12863693	chr15:85201151	NMB	0.59	4.76	0.44	6.98e-6	Schizophrenia;
THYM	cis	rs7646881	1.000	rs61558956	chr3:158452655	T/A	cg18349298	chr3:158450550	RARRES1	0.51	4.95	0.45	3.15e-6	Tetralogy of Fallot;
THYM	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg05373962	chr22:49881684	NA	-0.65	-6.42	-0.55	5.4e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1747683	0.605	rs10752295	chr10:13369095	G/A	cg25835351	chr10:13388524	SEPHS1	-0.28	-4.89	-0.45	4.14e-6	IgG glycosylation;
THYM	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06634786	chr22:41940651	POLR3H	0.63	4.92	0.45	3.62e-6	Vitiligo;
THYM	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs56161922	0.818	rs4437879	chr1:207875977	G/A	cg09557387	chr1:207818395	CR1L	1.27	5.63	0.5	1.79e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.75	-4.53	-0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs1922291	0.528	rs12472862	chr2:102840994	A/G	cg13315345	chr2:102803985	IL1RL2	0.63	7.15	0.59	1.77e-10	Blood protein levels;
THYM	cis	rs2658782	1.000	rs2605585	chr11:93171862	C/T	cg15737290	chr11:93063684	CCDC67	0.88	6.29	0.54	9.61e-9	Pulmonary function decline;
THYM	cis	rs7809950	0.911	rs1015411	chr7:107135612	C/T	cg23024343	chr7:107201750	COG5	-0.9	-8.23	-0.65	9.69e-13	Coronary artery disease;
THYM	cis	rs8133932	0.906	rs79854527	chr21:47156852	G/A	cg20357416	chr21:47294739	PCBP3	0.77	4.63	0.43	1.17e-5	Schizophrenia;
THYM	cis	rs12410462	0.581	rs7543931	chr1:227550976	A/T	cg23173402	chr1:227635558	NA	0.67	5.37	0.48	5.63e-7	Major depressive disorder;
THYM	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg13736514	chr6:26305472	NA	-0.62	-7.42	-0.61	5.02e-11	Educational attainment;
THYM	cis	rs7107174	0.892	rs12284390	chr11:78103902	C/A	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg11752832	chr7:134001865	SLC35B4	0.72	5.43	0.49	4.28e-7	Mean platelet volume;
THYM	cis	rs8044868	0.606	rs7189591	chr16:72099011	G/T	cg16558253	chr16:72132732	DHX38	-0.55	-4.56	-0.42	1.55e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs9467711	0.651	rs17528178	chr6:25983777	C/T	cg16898833	chr6:26189333	HIST1H4D	1.33	4.61	0.43	1.28e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2235649	0.833	rs9927047	chr16:1851927	A/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs17006441	0.932	rs9825822	chr3:69878253	G/A	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg26769984	chr7:1090371	C7orf50	0.81	5.39	0.48	5.19e-7	Bronchopulmonary dysplasia;
THYM	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg16624210	chr5:671434	TPPP	0.82	6.13	0.53	1.99e-8	Obesity-related traits;
THYM	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg14019146	chr3:50243930	SLC38A3	0.77	6.58	0.56	2.55e-9	Intelligence (multi-trait analysis);
THYM	cis	rs2970992	0.764	rs3112258	chr2:101328375	T/C	cg01042948	chr2:101319752	NA	0.6	5.89	0.52	5.76e-8	Educational attainment;
THYM	cis	rs10197940	0.545	rs2444267	chr2:152308611	T/G	cg19508488	chr2:152266495	RIF1	0.7	5.56	0.5	2.42e-7	Lung cancer;
THYM	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg24692254	chr21:30365293	RNF160	-0.99	-9.28	-0.69	5.71e-15	Dental caries;
THYM	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg00129232	chr17:37814104	STARD3	-0.74	-4.99	-0.46	2.76e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.83	-6.48	-0.55	4.02e-9	IgG glycosylation;
THYM	cis	rs11031096	0.502	rs720571	chr11:4001328	G/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.69	-0.43	9.03e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs9326248	0.581	rs10892063	chr11:116896155	A/C	cg20608306	chr11:116969690	SIK3	0.62	7.41	0.61	5.21e-11	Blood protein levels;
THYM	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg12379764	chr21:47803548	PCNT	-0.83	-5.37	-0.48	5.52e-7	Testicular germ cell tumor;
THYM	cis	rs1981331	0.609	rs77725404	chr21:48080376	C/T	cg23283320	chr21:48055893	PRMT2	1.57	7.92	0.63	4.41e-12	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg06634786	chr22:41940651	POLR3H	0.72	5.22	0.47	1.04e-6	Vitiligo;
THYM	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9905704	0.647	rs12944274	chr17:57041293	C/G	cg12560992	chr17:57184187	TRIM37	-0.66	-5.18	-0.47	1.27e-6	Testicular germ cell tumor;
THYM	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg25554036	chr4:6271136	WFS1	0.59	5.42	0.49	4.46e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs293526	0.959	rs293482	chr6:83681318	T/A	cg23278060	chr6:83777448	DOPEY1	0.63	4.67	0.43	9.71e-6	Crohn's disease;
THYM	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg13902645	chr11:5959945	NA	0.58	5.28	0.48	8.02e-7	DNA methylation (variation);
THYM	cis	rs2742540	0.503	rs7106539	chr11:8897533	T/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.54	-4.47	-0.42	2.17e-5	Hematocrit;
THYM	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	7.98	0.63	3.34e-12	Platelet count;
THYM	cis	rs6690583	0.697	rs10782537	chr1:85484473	C/T	cg22153463	chr1:85462885	MCOLN2	-0.69	-4.74	-0.44	7.63e-6	Serum sulfate level;
THYM	cis	rs61931739	0.817	rs1705754	chr12:34145569	A/G	cg06521331	chr12:34319734	NA	-0.67	-5.63	-0.5	1.81e-7	Morning vs. evening chronotype;
THYM	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	5.03	0.46	2.33e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs8170	0.554	rs60397819	chr19:17451369	G/T	cg04749549	chr19:17459798	NA	-0.43	-5.12	-0.47	1.58e-6	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
THYM	cis	rs3125734	0.633	rs10821968	chr10:63993905	C/T	cg09941381	chr10:64027924	RTKN2	0.55	4.63	0.43	1.16e-5	Rheumatoid arthritis;
THYM	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg26886231	chr17:78936889	RPTOR	0.53	4.72	0.44	8.16e-6	Eye color traits;
THYM	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg04772025	chr11:68637568	NA	0.63	6.64	0.56	1.96e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	trans	rs10802346	0.545	rs1361408	chr1:246410054	T/G	cg13514129	chr1:39547527	MACF1	1.04	11.13	0.75	6.43e-19	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg24209194	chr3:40518798	ZNF619	-0.7	-6.13	-0.53	1.99e-8	Renal cell carcinoma;
THYM	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.58	-5.88	-0.52	6.01e-8	Crohn's disease;
THYM	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs10118776	0.677	rs13302749	chr9:6171731	T/C	cg02532923	chr16:89110004	NA	1.01	7.85	0.63	6.11e-12	Small cell lung carcinoma;
THYM	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg09165964	chr15:75287851	SCAMP5	-0.7	-5.0	-0.46	2.64e-6	Blood trace element (Zn levels);
THYM	cis	rs529866	0.500	rs918739	chr16:11439733	G/T	cg00044050	chr16:11439710	C16orf75	-0.84	-5.92	-0.52	5.2100000000000003e-08	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg16586182	chr3:47516702	SCAP	0.59	5.12	0.47	1.56e-6	Colorectal cancer;
THYM	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg15676542	chr6:26421231	BTN2A3	0.34	4.77	0.44	6.57e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg00376283	chr12:123451042	ABCB9	0.72	4.94	0.45	3.36e-6	Neutrophil percentage of white cells;
THYM	cis	rs8067545	0.750	rs888423	chr17:19999409	G/A	cg13482628	chr17:19912719	NA	0.56	4.7	0.43	8.78e-6	Schizophrenia;
THYM	cis	rs4478239	1.000	rs6553051	chr4:188190117	C/T	cg02596645	chr4:187628413	FAT1	-0.79	-4.46	-0.42	2.22e-5	Major depressive disorder;
THYM	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg19318889	chr4:1322082	MAEA	0.64	6.06	0.53	2.77e-8	Longevity;
THYM	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg19875535	chr5:140030758	IK	0.58	4.59	0.43	1.36e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.7	-4.71	-0.43	8.57e-6	Menarche (age at onset);
THYM	cis	rs11645898	0.935	rs4788611	chr16:72175256	A/G	cg14768367	chr16:72042858	DHODH	-0.77	-5.59	-0.5	2.21e-7	Blood protein levels;
THYM	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg03806693	chr22:41940476	POLR3H	1.11	8.99	0.68	2.33e-14	Vitiligo;
THYM	cis	rs9527	0.830	rs11191440	chr10:104641511	G/A	cg04362960	chr10:104952993	NT5C2	0.64	4.72	0.44	8.19e-6	Arsenic metabolism;
THYM	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg11764359	chr7:65958608	NA	-0.8	-6.38	-0.55	6.55e-9	Aortic root size;
THYM	trans	rs877282	1.000	rs11253370	chr10:773712	G/A	cg22713356	chr15:30763199	NA	1.26	10.12	0.72	9.24e-17	Uric acid levels;
THYM	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg04455712	chr21:45112962	RRP1B	0.54	5.04	0.46	2.22e-6	Mean corpuscular volume;
THYM	cis	rs9326248	0.581	rs11216242	chr11:116901549	G/A	cg20608306	chr11:116969690	SIK3	0.64	7.96	0.63	3.61e-12	Blood protein levels;
THYM	cis	rs9381040	0.692	rs3088370	chr6:41157670	T/C	cg03526776	chr6:41159608	TREML2	0.47	4.66	0.43	1.05e-5	Alzheimer's disease (late onset);
THYM	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg24812749	chr6:127587940	RNF146	0.93	6.81	0.57	8.62e-10	Breast cancer;
THYM	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg13852791	chr20:30311386	BCL2L1	0.92	6.83	0.57	7.98e-10	Mean corpuscular hemoglobin;
THYM	cis	rs4642101	0.628	rs1003080	chr3:12811628	C/T	cg05775895	chr3:12838266	CAND2	-0.64	-5.17	-0.47	1.31e-6	QRS complex (12-leadsum);
THYM	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg11764359	chr7:65958608	NA	-0.75	-6.05	-0.53	2.82e-8	Aortic root size;
THYM	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Bladder cancer;
THYM	cis	rs11677370	0.561	rs12986995	chr2:3826965	G/A	cg17052675	chr2:3827356	NA	-0.66	-6.48	-0.55	4.03e-9	Type 2 diabetes;
THYM	cis	rs2288884	0.767	rs17835716	chr19:52551042	A/G	cg05974498	chr19:52599256	ZNF841	0.36	4.52	0.42	1.78e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	6.08	0.53	2.48e-8	Schizophrenia;
THYM	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg15744692	chr15:45671195	LOC145663;GATM	0.44	4.46	0.42	2.22e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs654950	0.875	rs34227270	chr1:41998967	C/T	cg13396354	chr1:41153348	NA	-0.46	-4.74	-0.44	7.53e-6	Airway imaging phenotypes;
THYM	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg23281280	chr6:28129359	ZNF389	0.61	4.74	0.44	7.58e-6	Parkinson's disease;
THYM	cis	rs10847980	0.590	rs2292131	chr12:123332354	C/T	cg25930673	chr12:123319894	HIP1R	1.15	5.3	0.48	7.53e-7	Adiponectin levels;
THYM	cis	rs921968	0.541	rs593888	chr2:219427597	A/G	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9905704	0.647	rs11652713	chr17:57079742	C/T	cg12560992	chr17:57184187	TRIM37	0.61	4.76	0.44	6.99e-6	Testicular germ cell tumor;
THYM	cis	rs1461503	0.932	rs11218909	chr11:122842613	C/T	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg26384229	chr12:38710491	ALG10B	1.03	9.92	0.71	2.51e-16	Heart rate;
THYM	cis	rs12791968	1.000	rs1005935	chr11:45002498	A/C	cg11846598	chr11:44996168	LOC221122	-0.91	-7.7	-0.62	1.28e-11	Inhibitory control;
THYM	cis	rs10463554	0.963	rs61418746	chr5:102379618	T/A	cg23492399	chr5:102201601	PAM	-0.68	-5.13	-0.47	1.56e-6	Parkinson's disease;
THYM	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2464469	0.526	rs11071363	chr15:58333961	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.65	-5.04	-0.46	2.24e-6	Barrett's esophagus  or Esophageal adenocarcinoma;
THYM	cis	rs10779751	0.960	rs6661859	chr1:11301063	T/C	cg08854313	chr1:11322531	MTOR	0.99	9.0	0.68	2.29e-14	Body mass index;
THYM	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg24375607	chr4:120327624	NA	0.53	4.47	0.42	2.2e-5	Corneal astigmatism;
THYM	cis	rs7481584	0.669	rs12421922	chr11:3035070	A/G	cg03159660	chr11:2078197	NA	0.65	4.89	0.45	4.16e-6	Calcium levels;
THYM	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg23982607	chr1:1823379	GNB1	-0.91	-9.66	-0.7	8.93e-16	Body mass index;
THYM	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg08807101	chr21:30365312	RNF160	-0.81	-6.14	-0.53	1.93e-8	Dental caries;
THYM	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.41	-6.4	-0.55	5.78e-9	Obesity-related traits;
THYM	cis	rs6429082	0.633	rs1416473	chr1:235563259	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.62	-4.62	-0.43	1.19e-5	Adiposity;
THYM	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg08847533	chr14:75593920	NEK9	0.87	8.75	0.67	7.73e-14	Coronary artery disease;
THYM	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg05234568	chr11:5960015	NA	-0.65	-5.72	-0.51	1.21e-7	DNA methylation (variation);
THYM	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg03929089	chr4:120376271	NA	-0.95	-10.31	-0.73	3.62e-17	Coronary artery disease;
THYM	cis	rs2976388	0.609	rs2572899	chr8:143785549	A/G	cg06565975	chr8:143823917	SLURP1	0.47	5.22	0.47	1.06e-6	Urinary tract infection frequency;
THYM	cis	rs5769707	0.642	rs4824070	chr22:50031521	T/C	cg23428387	chr22:49814324	NA	-0.49	-4.66	-0.43	1.02e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg00757033	chr12:89920650	WDR51B	-0.73	-11.38	-0.76	1.96e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7772486	0.686	rs857880	chr6:145971115	T/C	cg23711669	chr6:146136114	FBXO30	-0.96	-9.91	-0.71	2.61e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8114671	0.967	rs6142320	chr20:33788193	A/G	cg08999081	chr20:33150536	PIGU	-0.53	-4.77	-0.44	6.63e-6	Height;
THYM	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.7	-5.12	-0.46	1.61e-6	Colorectal cancer;
THYM	cis	rs986417	1.000	rs2224410	chr14:60970531	T/C	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs7927592	0.513	rs608343	chr11:68196830	T/C	cg16797656	chr11:68205561	LRP5	0.53	6.16	0.53	1.72e-8	Total body bone mineral density;
THYM	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg03433033	chr1:76189801	ACADM	0.7	7.19	0.59	1.44e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.61	4.87	0.45	4.43e-6	Aortic root size;
THYM	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg23989207	chr17:80870107	TBCD	0.62	5.24	0.47	9.74e-7	Glycated hemoglobin levels;
THYM	cis	rs9457247	0.529	rs6907666	chr6:167523395	A/G	cg00271210	chr6:167070053	RPS6KA2	0.48	4.91	0.45	3.82e-6	Crohn's disease;
THYM	cis	rs6430585	0.583	rs4988163	chr2:136628121	G/T	cg20242066	chr2:136595261	LCT	0.49	4.81	0.44	5.63e-6	Corneal structure;
THYM	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg03959625	chr15:84868606	LOC388152	0.48	4.65	0.43	1.08e-5	Schizophrenia;
THYM	cis	rs4072705	0.967	rs4836986	chr9:127408059	C/T	cg13476313	chr9:127244764	NR5A1	0.32	4.75	0.44	7.27e-6	Menarche (age at onset);
THYM	cis	rs17828380	0.844	rs12909910	chr15:63606341	T/C	cg12013685	chr15:63243220	NA	-0.76	-4.58	-0.43	1.42e-5	Social communication problems;
THYM	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06634786	chr22:41940651	POLR3H	-0.8	-5.95	-0.52	4.53e-8	Vitiligo;
THYM	cis	rs12476592	0.602	rs262529	chr2:63903892	A/C	cg17519650	chr2:63277830	OTX1	-0.72	-4.68	-0.43	9.38e-6	Childhood ear infection;
THYM	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg21211367	chr2:162094118	NA	0.66	5.4	0.48	4.85e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg02475777	chr4:1388615	CRIPAK	0.73	5.23	0.47	1e-6	Longevity;
THYM	cis	rs4930103	0.711	rs217710	chr11:2007244	C/T	cg06197492	chr11:2016605	H19	0.61	5.49	0.49	3.29e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg21194808	chr1:2205498	SKI	-0.33	-4.47	-0.42	2.19e-5	Height;
THYM	cis	rs3820068	0.608	rs10927831	chr1:16028373	T/G	cg24675056	chr1:15929824	NA	0.78	6.16	0.53	1.73e-8	Systolic blood pressure;
THYM	cis	rs4731207	0.698	rs6466948	chr7:124444763	G/A	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs12681287	0.547	rs9297922	chr8:87542317	A/G	cg27223183	chr8:87520930	FAM82B	0.71	5.56	0.5	2.44e-7	Caudate activity during reward;
THYM	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg20283391	chr11:68216788	NA	-0.61	-4.58	-0.43	1.41e-5	Total body bone mineral density;
THYM	cis	rs3741151	0.892	rs7125949	chr11:73009084	G/A	cg12959048	chr11:73096162	RELT	-0.44	-4.81	-0.44	5.56e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs8114671	1.000	rs8114671	chr20:33789142	C/A	cg08999081	chr20:33150536	PIGU	-0.53	-4.77	-0.44	6.63e-6	Height;
THYM	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg15704280	chr7:45808275	SEPT13	-0.96	-8.41	-0.65	4.11e-13	Coronary artery disease;
THYM	cis	rs11792861	0.591	rs10979613	chr9:111687584	A/G	cg05043794	chr9:111880884	C9orf5	-0.34	-4.81	-0.44	5.64e-6	Menarche (age at onset);
THYM	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06850241	chr22:41845214	NA	-0.6	-5.24	-0.47	9.66e-7	Vitiligo;
THYM	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg05283184	chr6:79620031	NA	-0.88	-8.43	-0.65	3.67e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7084402	0.967	rs1649085	chr10:60292042	T/C	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs10504073	0.584	rs1511365	chr8:49975321	A/T	cg00325661	chr8:49890786	NA	1.08	10.51	0.73	1.32e-17	Blood metabolite ratios;
THYM	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg06219351	chr7:158114137	PTPRN2	-0.73	-7.13	-0.59	2e-10	Calcium levels;
THYM	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg24812749	chr6:127587940	RNF146	0.86	7.12	0.59	2.09e-10	Breast cancer;
THYM	cis	rs7771547	0.573	rs584418	chr6:36395437	G/A	cg07856975	chr6:36356162	ETV7	0.52	4.72	0.44	8.26e-6	Platelet distribution width;
THYM	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg24324837	chr19:49891574	CCDC155	0.47	4.81	0.44	5.64e-6	Multiple sclerosis;
THYM	cis	rs4242434	0.536	rs1871900	chr8:22481449	A/G	cg11461670	chr8:22454935	PDLIM2	-0.29	-4.6	-0.43	1.29e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg17366294	chr4:99064904	C4orf37	0.53	5.9	0.52	5.67e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg00576331	chr11:65640516	EFEMP2	0.68	4.58	0.43	1.42e-5	Crohn's disease;
THYM	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg13695892	chr22:41940480	POLR3H	0.85	6.16	0.53	1.72e-8	Vitiligo;
THYM	cis	rs3733589	0.590	rs3775936	chr4:10077542	G/C	cg17095147	chr4:10101400	WDR1	0.84	4.86	0.45	4.7e-6	Renal overload gout;
THYM	cis	rs9560113	1.000	rs9560109	chr13:112180468	C/T	cg14154082	chr13:112174009	NA	0.85	7.94	0.63	3.99e-12	Menarche (age at onset);
THYM	cis	rs25645	0.502	rs7207600	chr17:38091660	G/A	cg26162295	chr17:38119207	GSDMA	-0.42	-4.93	-0.45	3.54e-6	Myeloid white cell count;
THYM	cis	rs7246657	0.941	rs7259618	chr19:37750719	G/A	cg22634378	chr19:37742834	NA	0.63	5.29	0.48	7.79e-7	Coronary artery calcification;
THYM	cis	rs4907240	0.961	rs11691670	chr2:97238770	A/G	cg18419276	chr2:96971862	SNRNP200	-0.39	-4.57	-0.42	1.46e-5	Event-related brain oscillations;
THYM	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg04731861	chr2:219085781	ARPC2	0.56	5.38	0.48	5.39e-7	Colorectal cancer;
THYM	cis	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg06521331	chr12:34319734	NA	-0.95	-9.13	-0.68	1.19e-14	Morning vs. evening chronotype;
THYM	cis	rs2637266	0.935	rs2583053	chr10:78402416	A/G	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg26384229	chr12:38710491	ALG10B	1.08	10.89	0.75	2.06e-18	Heart rate;
THYM	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg13683864	chr3:40499215	RPL14	-0.86	-7.84	-0.63	6.38e-12	Renal cell carcinoma;
THYM	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg26597838	chr10:835615	NA	0.99	5.51	0.49	3.13e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg21100191	chr22:23484243	RTDR1	0.75	6.58	0.56	2.56e-9	Bone mineral density;
THYM	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs4845459	0.967	rs6700158	chr1:152592828	T/G	cg26135325	chr1:152595322	LCE3A	-0.46	-5.23	-0.47	1e-6	Psoriasis;
THYM	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.65e-6	Aortic root size;
THYM	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg00376283	chr12:123451042	ABCB9	0.86	6.89	0.58	6.19e-10	Platelet count;
THYM	cis	rs6733011	0.578	rs4851170	chr2:99504323	A/G	cg08885076	chr2:99613938	TSGA10	0.45	4.48	0.42	2.1e-5	Bipolar disorder;
THYM	cis	rs7542375	0.655	rs55703860	chr1:221081139	C/T	cg16008148	chr1:221062819	NA	0.5	5.65	0.5	1.65e-7	Obesity-related traits;
THYM	cis	rs1386478	0.669	rs13094677	chr3:113818348	A/G	cg14431476	chr3:113822413	NA	-0.64	-4.51	-0.42	1.82e-5	Crohn's disease and psoriasis;
THYM	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg09877947	chr5:131593287	PDLIM4	0.55	4.65	0.43	1.06e-5	Breast cancer;Mosquito bite size;
THYM	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg11764359	chr7:65958608	NA	-0.88	-7.56	-0.61	2.55e-11	Aortic root size;
THYM	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg24163568	chr5:669837	TPPP	0.59	5.48	0.49	3.53e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg06481639	chr22:41940642	POLR3H	0.7	5.12	0.47	1.57e-6	Vitiligo;
THYM	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg13395646	chr4:1353034	KIAA1530	-0.75	-7.14	-0.59	1.83e-10	Obesity-related traits;
THYM	cis	rs11608355	1.000	rs7969719	chr12:109883577	C/T	cg11367159	chr12:110044531	NA	0.66	6.13	0.53	2e-8	Neuroticism;
THYM	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg08772003	chr10:104629869	AS3MT	-0.57	-4.95	-0.45	3.23e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg04455712	chr21:45112962	RRP1B	0.52	4.62	0.43	1.2e-5	Mean corpuscular volume;
THYM	cis	rs4262150	0.883	rs72804789	chr5:152322621	C/T	cg06854687	chr5:151642065	NA	0.6	4.5	0.42	1.94e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg00271210	chr6:167070053	RPS6KA2	-0.51	-5.31	-0.48	7.23e-7	Primary biliary cholangitis;
THYM	trans	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg10856724	chr12:34555212	NA	-0.99	-8.92	-0.68	3.37e-14	Bladder cancer;
THYM	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg23422044	chr7:1970798	MAD1L1	-0.77	-4.68	-0.43	9.38e-6	Neuroticism;
THYM	cis	rs3126085	0.935	rs12401851	chr1:152259022	T/C	cg10321714	chr1:152280068	FLG	-0.7	-5.11	-0.46	1.67e-6	Atopic dermatitis;
THYM	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg02734326	chr4:10020555	SLC2A9	0.78	6.67	0.56	1.68e-9	Bone mineral density;
THYM	cis	rs3789868	0.546	rs2482078	chr9:117865376	G/A	cg01113597	chr9:116918183	COL27A1	-0.62	-4.48	-0.42	2.08e-5	Developmental language disorder (syntactic complexity);
THYM	cis	rs642743	0.517	rs157077	chr10:106037894	C/T	cg13968679	chr10:105235376	CALHM3	0.58	4.46	0.42	2.25e-5	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs1933112	1.000	rs2223582	chr1:168506535	A/C	cg17186328	chr1:168545835	XCL1	-0.55	-4.55	-0.42	1.56e-5	Blood protein levels;
THYM	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs61990749	0.597	rs8016447	chr14:78222068	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.04	0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs7777754	0.512	rs11238131	chr7:50538589	T/C	cg18232548	chr7:50535776	DDC	-0.92	-8.1	-0.64	1.85e-12	Response to zileuton treatment in asthma (FEV1 change interaction);
THYM	cis	rs2299587	0.610	rs7010747	chr8:17778651	A/C	cg01800426	chr8:17659068	MTUS1	-0.59	-4.53	-0.42	1.72e-5	Economic and political preferences;
THYM	cis	rs17666538	0.792	rs115204727	chr8:676639	G/A	cg23958373	chr8:599963	NA	-0.96	-4.54	-0.42	1.66e-5	IgG glycosylation;
THYM	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg09436375	chr6:42928200	GNMT	0.45	5.92	0.52	4.99e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg03188948	chr7:1209495	NA	0.9	5.02	0.46	2.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8074700	0.559	rs1057201	chr17:46716541	C/T	cg06602723	chr17:46693336	HOXB8	0.49	4.66	0.43	1.04e-5	Body mass index in non-asthmatics;
THYM	cis	rs9549260	0.599	rs12870023	chr13:41244222	T/A	cg21288729	chr13:41239152	FOXO1	0.66	4.98	0.46	2.83e-6	Red blood cell count;
THYM	cis	rs1061377	1.000	rs7657926	chr4:39134063	T/C	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs1061377	0.722	rs34803689	chr4:39118285	G/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg09260853	chr1:2094483	PRKCZ	0.5	4.65	0.43	1.06e-5	Height;
THYM	cis	rs9486719	0.895	rs12527021	chr6:97025496	C/T	cg18709589	chr6:96969512	KIAA0776	-0.68	-4.7	-0.43	8.62e-6	Migraine;Coronary artery disease;
THYM	cis	rs13185784	0.662	rs35759987	chr5:179679980	G/T	cg13944838	chr5:179740914	GFPT2	0.75	5.05	0.46	2.15e-6	TRAIL levels;
THYM	cis	rs12534701	0.904	rs3800577	chr7:154673469	G/T	cg24255201	chr7:154684926	DPP6	0.59	4.46	0.42	2.26e-5	Colorectal cancer (diet interaction);
THYM	cis	rs1847202	0.517	rs13062803	chr3:72951840	T/A	cg27402429	chr3:72788294	NA	-0.71	-4.55	-0.42	1.56e-5	Motion sickness;
THYM	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg23583168	chr7:148888333	NA	-1.02	-13.03	-0.8	7.19e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6496667	0.865	rs8035602	chr15:90909197	G/A	cg22089800	chr15:90895588	ZNF774	0.86	5.21	0.47	1.12e-6	Rheumatoid arthritis;
THYM	cis	rs11696501	0.739	rs6073846	chr20:44296323	G/T	cg11783356	chr20:44313418	WFDC10B	0.65	4.48	0.42	2.12e-5	Brain structure;
THYM	cis	rs36051895	0.664	rs17425637	chr9:5110000	C/T	cg02405213	chr9:5042618	JAK2	-0.99	-11.27	-0.76	3.27e-19	Pediatric autoimmune diseases;
THYM	cis	rs7646881	0.953	rs73015657	chr3:158451932	G/A	cg18349298	chr3:158450550	RARRES1	0.48	4.48	0.42	2.05e-5	Tetralogy of Fallot;
THYM	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs3741151	0.686	rs12288753	chr11:73136261	A/T	cg12959048	chr11:73096162	RELT	-0.46	-4.84	-0.45	4.94e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs61774743	0.681	rs10749805	chr1:41850182	C/T	cg01193554	chr1:41846683	NA	-0.34	-4.85	-0.45	4.86e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4499344	0.730	rs453804	chr19:33105612	T/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	6.97	0.58	4.16e-10	Mean platelet volume;
THYM	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg18252515	chr7:66147081	NA	-1.57	-8.55	-0.66	2.07e-13	Diabetic kidney disease;
THYM	cis	rs7084402	1.000	rs7910442	chr10:60270260	T/G	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs6665290	0.935	rs12403236	chr1:227196502	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.13	-15.82	-0.85	2.26e-28	Myeloid white cell count;
THYM	cis	rs901683	1.000	rs12779005	chr10:46087374	C/T	cg18240400	chr10:46168597	ANUBL1	0.73	4.73	0.44	7.89e-6	Red blood cell traits;Mean corpuscular volume;
THYM	trans	rs208515	0.560	rs207084	chr6:66776966	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.21	-14.06	-0.82	5.99e-25	Exhaled nitric oxide levels;
THYM	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7264396	0.676	rs58372200	chr20:34555445	C/A	cg26038318	chr20:34205095	SPAG4	0.59	4.81	0.44	5.6e-6	Total cholesterol levels;
THYM	cis	rs6430585	0.527	rs6753232	chr2:136436317	C/T	cg23851026	chr2:136556271	LCT	-0.69	-5.74	-0.51	1.13e-7	Corneal structure;
THYM	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs61931739	0.569	rs1872746	chr12:33985843	T/C	cg06521331	chr12:34319734	NA	-0.58	-4.89	-0.45	4.16e-6	Morning vs. evening chronotype;
THYM	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs10819861	0.621	rs4743536	chr9:98857986	T/C	cg14508093	chr9:98862825	NA	-0.23	-4.47	-0.42	2.17e-5	Electrocardiographic traits;
THYM	cis	rs9992101	0.547	rs7656186	chr4:77409818	C/T	cg20311846	chr4:77356250	SHROOM3	-0.45	-4.72	-0.44	8.12e-6	Creatinine levels;
THYM	cis	rs919433	0.680	rs3792160	chr2:198403519	G/A	cg00792783	chr2:198669748	PLCL1	0.86	6.08	0.53	2.49e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg25036284	chr2:26402008	FAM59B	-0.78	-5.19	-0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-5.83	-0.51	7.47e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg05552183	chr6:42928497	GNMT	0.58	4.52	0.42	1.79e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9378357	0.614	rs4959230	chr6:3289983	T/C	cg08754725	chr6:3293098	SLC22A23	-0.76	-5.32	-0.48	6.89e-7	Obesity-related traits;
THYM	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg12560992	chr17:57184187	TRIM37	0.92	8.53	0.66	2.29e-13	Intelligence (multi-trait analysis);
THYM	cis	rs17604090	0.550	rs111649163	chr7:29689176	C/T	cg19413766	chr7:29689036	LOC646762	-0.88	-4.71	-0.44	8.36e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs28374715	0.510	rs28478807	chr15:41558620	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.88	-7.35	-0.6	7.01e-11	Ulcerative colitis;
THYM	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg24642844	chr7:1081250	C7orf50	-1.29	-8.3	-0.65	7.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4731207	0.591	rs12535300	chr7:124613907	G/C	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs686320	1.000	rs616599	chr11:65254025	T/G	cg19332572	chr11:65321591	LTBP3	0.86	5.06	0.46	2.03e-6	Hip circumference adjusted for BMI;
THYM	trans	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg25214090	chr10:38739885	LOC399744	0.94	7.93	0.63	4.26e-12	Corneal astigmatism;
THYM	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-6.6	-0.56	2.38e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3781663	0.581	rs10793018	chr11:70004396	G/A	cg11240634	chr11:69519263	FGF19	0.66	4.53	0.42	1.73e-5	Survival in rectal cancer;
THYM	cis	rs7836436	1.000	rs7836569	chr8:121006882	C/T	cg05020510	chr8:120428057	NOV	1.23	5.79	0.51	8.92e-8	HIV-1 viral setpoint;
THYM	cis	rs2340727	1.000	rs2340727	chr1:161946727	C/T	cg06514368	chr1:161719587	DUSP12	0.84	4.86	0.45	4.58e-6	White blood cell count;Hematology traits;
THYM	cis	rs3087591	1.000	rs2854331	chr17:29711728	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.62	-5.05	-0.46	2.12e-6	Hip circumference;
THYM	cis	rs1059312	0.500	rs10734964	chr12:129286486	C/T	cg09035930	chr12:129282057	SLC15A4	0.6	5.36	0.48	5.72e-7	Systemic lupus erythematosus;
THYM	cis	rs11030122	0.702	rs1013351	chr11:3952303	A/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.73	-0.51	1.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg16586182	chr3:47516702	SCAP	-0.62	-5.25	-0.47	9.36e-7	Colorectal cancer;
THYM	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg11861562	chr11:117069780	TAGLN	0.32	4.7	0.43	8.75e-6	Blood protein levels;
THYM	cis	rs2882877	0.648	rs35209105	chr2:190395060	T/C	cg10752008	chr2:190445175	SLC40A1	0.72	6.14	0.53	1.9e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs10231759	0.530	rs741065	chr7:150500576	A/G	cg05726600	chr7:150498594	TMEM176B;TMEM176A	0.6	4.48	0.42	2.04e-5	Height;
THYM	cis	rs7523273	0.526	rs2724394	chr1:208017072	T/A	cg22525895	chr1:207977042	MIR29B2	-0.88	-9.3	-0.69	5.17e-15	Schizophrenia;
THYM	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg18512352	chr11:47633146	NA	0.49	5.69	0.5	1.38e-7	Subjective well-being;
THYM	cis	rs763014	0.500	rs11865749	chr16:717971	C/G	cg09781414	chr16:715207	WDR90	-0.6	-4.76	-0.44	6.83e-6	Height;
THYM	cis	rs7248779	0.874	rs12609648	chr19:2411841	G/T	cg16170346	chr19:2424006	TMPRSS9	0.86	5.51	0.49	3.04e-7	Cortisol levels (saliva);
THYM	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg24846343	chr22:24311635	DDTL	0.45	5.91	0.52	5.3e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs79387448	0.683	rs7571985	chr2:103147561	G/A	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg11673840	chr17:47092156	IGF2BP1	-0.56	-7.56	-0.61	2.48e-11	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs8050907	0.744	rs80031922	chr16:4538185	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.28	5.13	0.47	1.5e-6	Obesity-related traits;
THYM	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg20744362	chr22:50050164	C22orf34	0.69	6.33	0.54	7.96e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg09307838	chr4:120376055	NA	0.79	5.72	0.51	1.25e-7	Corneal astigmatism;
THYM	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg10253484	chr15:75165896	SCAMP2	-0.66	-4.59	-0.43	1.38e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs17006441	0.932	rs9826548	chr3:69878747	G/A	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg23989207	chr17:80870107	TBCD	0.63	5.32	0.48	6.91e-7	Glycated hemoglobin levels;
THYM	cis	rs2518683	0.808	rs131184	chr22:29681216	A/G	cg10230314	chr22:30552801	HORMAD2	-0.62	-4.68	-0.43	9.55e-6	Platelet count;
THYM	cis	rs6450176	0.625	rs3776725	chr5:53290138	C/A	ch.5.1024479R	chr5:53302184	ARL15	-1.01	-8.07	-0.64	2.17e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg10560079	chr2:191398806	TMEM194B	-0.93	-7.28	-0.6	9.81e-11	Diastolic blood pressure;
THYM	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg24692254	chr21:30365293	RNF160	-0.99	-8.66	-0.66	1.23e-13	Dental caries;
THYM	cis	rs6835098	1.000	rs1054497	chr4:174089048	A/T	cg08422745	chr4:174089978	GALNT7	1.02	8.74	0.67	8.01e-14	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.71	-5.85	-0.51	7.06e-8	Lung cancer;
THYM	cis	rs11577318	0.579	rs12131370	chr1:26698430	G/A	cg00852783	chr1:26633632	UBXN11	-0.66	-4.51	-0.42	1.87e-5	Granulocyte percentage of myeloid white cells;
THYM	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg03060546	chr3:49711283	APEH	-0.74	-6.21	-0.54	1.42e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg15448220	chr1:150897856	SETDB1	0.8	6.51	0.56	3.51e-9	Tonsillectomy;
THYM	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg14768367	chr16:72042858	DHODH	-0.6	-4.62	-0.43	1.21e-5	Fibrinogen levels;
THYM	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg10792982	chr14:105748885	BRF1	0.75	7.82	0.63	7.29e-12	Mean platelet volume;Platelet distribution width;
THYM	cis	rs17006441	0.901	rs10510991	chr3:69841628	C/T	cg18496212	chr3:69797108	MITF	0.66	6.42	0.55	5.41e-9	Hemoglobin concentration;
THYM	cis	rs62070183	0.882	rs17183600	chr17:31175079	T/C	cg02981443	chr17:31254875	TMEM98	-0.54	-4.78	-0.44	6.31e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs7772486	0.686	rs1011596	chr6:146076433	A/G	cg23711669	chr6:146136114	FBXO30	0.87	8.33	0.65	6.16e-13	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.12	8.09	0.64	1.9e-12	Exhaled nitric oxide output;
THYM	cis	rs919433	0.680	rs11680291	chr2:198409884	A/G	cg05783139	chr2:198650985	BOLL	0.59	4.52	0.42	1.79e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6930083	0.713	rs1321308	chr6:36638691	A/C	cg24425727	chr6:36645648	CDKN1A	0.75	6.82	0.57	8.27e-10	Coronary artery disease;
THYM	cis	rs4919687	0.577	rs12765459	chr10:104465687	G/C	cg05855489	chr10:104503620	C10orf26	0.69	5.36	0.48	5.94e-7	Colorectal cancer;
THYM	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg17211192	chr8:82754475	SNX16	0.89	7.25	0.6	1.13e-10	Diastolic blood pressure;
THYM	cis	rs3892630	0.588	rs7248798	chr19:33303684	G/T	cg22928329	chr19:33183273	NUDT19	-0.7	-5.54	-0.49	2.66e-7	Red blood cell traits;
THYM	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg08847533	chr14:75593920	NEK9	-0.96	-10.26	-0.73	4.5e-17	Height;
THYM	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg00071950	chr4:10020882	SLC2A9	-0.79	-7.94	-0.63	4.12e-12	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg05660106	chr1:15850417	CASP9	-0.74	-6.11	-0.53	2.15e-8	Systolic blood pressure;
THYM	cis	rs1843834	0.858	rs12105685	chr2:225513164	A/G	cg10193763	chr2:225306901	NA	-0.51	-5.01	-0.46	2.49e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg18252515	chr7:66147081	NA	-1.37	-8.05	-0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs3796352	1.000	rs17052727	chr3:53070914	T/C	cg24530246	chr3:53118167	NA	-0.75	-4.52	-0.42	1.78e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.79	-6.78	-0.57	1.01e-9	Lung cancer;
THYM	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg22683308	chr4:1340831	KIAA1530	-0.58	-4.68	-0.43	9.5e-6	Longevity;
THYM	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.72	-4.68	-0.43	9.44e-6	Mean platelet volume;
THYM	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg05294307	chr14:35346193	BAZ1A	-0.93	-6.68	-0.57	1.64e-9	Psoriasis;
THYM	cis	rs899997	1.000	rs12907207	chr15:79031290	G/A	cg22753661	chr15:79092743	ADAMTS7	0.72	4.59	0.43	1.36e-5	Coronary artery disease or large artery stroke;
THYM	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg19626725	chr5:178986131	RUFY1	0.33	5.15	0.47	1.39e-6	Lung cancer;
THYM	cis	rs10779751	0.770	rs1057079	chr1:11205058	A/G	cg08854313	chr1:11322531	MTOR	-0.88	-7.82	-0.63	7.34e-12	Body mass index;
THYM	cis	rs12643440	0.574	rs62296689	chr4:17139096	G/C	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg05335186	chr13:53173507	NA	-0.46	-5.86	-0.52	6.6e-8	Lewy body disease;
THYM	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1018836	0.545	rs7840203	chr8:91701223	A/G	cg16814680	chr8:91681699	NA	-0.89	-8.7	-0.67	9.71e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs67311347	0.544	rs4974040	chr3:40331059	G/A	cg13683864	chr3:40499215	RPL14	-0.76	-7.1	-0.59	2.3e-10	Renal cell carcinoma;
THYM	cis	rs5769707	0.592	rs6009783	chr22:50011001	C/G	cg05373962	chr22:49881684	NA	-0.7	-6.4	-0.55	5.81e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.6	4.46	0.42	2.24e-5	Renal function-related traits (BUN);
THYM	cis	rs11739663	0.553	rs60444023	chr5:586340	A/C	cg09021430	chr5:549028	NA	-0.78	-7.65	-0.62	1.64e-11	Ulcerative colitis;
THYM	cis	rs9633835	0.855	rs4757145	chr11:13331324	G/A	cg13286116	chr11:13302098	ARNTL	0.64	7.0	0.58	3.56e-10	Body mass index;
THYM	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.93	-0.45	3.52e-6	Monocyte count;
THYM	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg13607699	chr17:42295918	UBTF	-0.59	-4.86	-0.45	4.58e-6	Total body bone mineral density;
THYM	cis	rs1784581	0.532	rs7767219	chr6:162423088	T/C	cg17173639	chr6:162384350	PARK2	0.81	7.48	0.61	3.75e-11	Itch intensity from mosquito bite;
THYM	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.73	-5.81	-0.51	8.18e-8	Systemic lupus erythematosus;
THYM	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg09537434	chr19:41945824	ATP5SL	1.12	10.57	0.74	1.03e-17	Height;
THYM	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg10224037	chr5:178157518	ZNF354A	0.99	7.89	0.63	5.06e-12	Neutrophil percentage of white cells;
THYM	cis	rs11690935	0.918	rs12692978	chr2:172725981	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.79	-5.62	-0.5	1.9e-7	Schizophrenia;
THYM	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg17366294	chr4:99064904	C4orf37	-0.58	-6.98	-0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7122937	0.911	rs11821100	chr11:2491604	C/T	cg27115973	chr11:2481206	KCNQ1	0.61	5.95	0.52	4.42e-8	QT interval;
THYM	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg05025164	chr4:1340916	KIAA1530	0.95	7.7	0.62	1.31e-11	Longevity;
THYM	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg02524346	chr8:600233	NA	1.06	5.09	0.46	1.82e-6	IgG glycosylation;
THYM	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg10802521	chr3:52805072	NEK4	-0.75	-7.03	-0.59	3.06e-10	Bipolar disorder;
THYM	cis	rs4792901	0.719	rs28678593	chr17:41645675	C/T	cg21940313	chr17:41620911	ETV4	-0.46	-5.04	-0.46	2.22e-6	Dupuytren's disease;
THYM	cis	rs10865397	0.506	rs6546810	chr2:73389716	A/G	cg24220031	chr2:73402428	NA	-0.76	-6.94	-0.58	4.76e-10	Intelligence (multi-trait analysis);
THYM	cis	rs67072384	1.000	rs61489692	chr11:72445314	T/C	cg01380194	chr11:72452482	ARAP1	-0.83	-4.7	-0.43	8.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs35883536	0.626	rs11799819	chr1:101049382	G/A	cg06223162	chr1:101003688	GPR88	-0.89	-7.82	-0.63	7.35e-12	Monocyte count;
THYM	cis	rs1003719	0.788	rs4572679	chr21:38453227	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.71	5.03	0.46	2.32e-6	Eye color traits;
THYM	cis	rs2461751	0.527	rs80242318	chr2:176487179	G/A	cg00495775	chr2:176972041	HOXD11	0.82	4.46	0.42	2.26e-5	Electrocardiographic conduction measures;
THYM	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-4.93	-0.45	3.51e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs77236434	0.655	rs73562575	chr8:13181009	C/T	cg06835018	chr8:12272982	NA	-0.77	-4.63	-0.43	1.17e-5	Familial hepatitis B virus-related hepatocellular carcinoma;
THYM	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg00814883	chr7:100076585	TSC22D4	-1.0	-6.8	-0.57	9.22e-10	Platelet count;
THYM	cis	rs6539288	0.899	rs6539290	chr12:107309649	C/A	cg26297688	chr12:107349093	C12orf23	-0.47	-4.89	-0.45	4.15e-6	Total body bone mineral density;
THYM	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg26384229	chr12:38710491	ALG10B	0.7	5.35	0.48	6.05e-7	Morning vs. evening chronotype;
THYM	cis	rs7640424	0.652	rs12152307	chr3:107861766	T/C	cg09227934	chr3:107805635	CD47	-0.57	-4.92	-0.45	3.57e-6	Body mass index;
THYM	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.66	8.96	0.68	2.76e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg22920501	chr2:26401640	FAM59B	1.03	6.29	0.54	9.88e-9	Gut microbiome composition (summer);
THYM	cis	rs7586879	0.639	rs2033654	chr2:25103108	C/A	cg01884057	chr2:25150051	NA	0.7	7.49	0.61	3.49e-11	Body mass index;
THYM	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.78	0.51	9.58e-8	Hip circumference adjusted for BMI;
THYM	cis	rs3942852	0.868	rs11039514	chr11:48109598	A/G	cg25800328	chr11:47736132	AGBL2	-0.5	-4.7	-0.43	8.62e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs6032067	0.810	rs62208441	chr20:43839360	T/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.47	-5.49	-0.49	3.27e-7	Blood protein levels;
THYM	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg00376283	chr12:123451042	ABCB9	0.7	4.72	0.44	8.27e-6	Neutrophil percentage of white cells;
THYM	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg26384229	chr12:38710491	ALG10B	0.82	7.97	0.63	3.56e-12	Heart rate;
THYM	cis	rs644799	0.562	rs654345	chr11:95581865	T/C	cg14972814	chr11:95582409	MTMR2	-0.62	-5.1	-0.46	1.71e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg09359103	chr1:154839909	KCNN3	-0.69	-8.43	-0.65	3.66e-13	Prostate cancer;
THYM	cis	rs4891159	0.790	rs1056714	chr18:74149526	A/G	cg24786174	chr18:74118243	ZNF516	-0.85	-9.34	-0.69	4.17e-15	Longevity;
THYM	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs2816062	0.813	rs2816044	chr1:18892826	A/G	cg18795169	chr1:18902165	NA	-0.98	-11.6	-0.77	6.55e-20	Urate levels in lean individuals;
THYM	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg27129171	chr3:47204927	SETD2	0.69	6.63	0.56	2.04e-9	Colorectal cancer;
THYM	cis	rs10788264	0.513	rs10749455	chr10:124035030	A/G	cg09507567	chr10:124027408	NA	0.48	4.8	0.44	5.81e-6	Total body bone mineral density;
THYM	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg17971929	chr21:40555470	PSMG1	0.73	4.75	0.44	7.29e-6	Cognitive function;
THYM	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	6.44	0.55	4.77e-9	Platelet count;
THYM	cis	rs7598759	0.548	rs11693738	chr2:232360484	C/T	cg19187155	chr2:232395269	NMUR1	0.83	7.47	0.61	3.84e-11	Noise-induced hearing loss;
THYM	cis	rs1372520	0.684	rs2583978	chr4:90750326	A/C	cg01966878	chr4:90757139	SNCA	-0.59	-4.54	-0.42	1.64e-5	Neuroticism;
THYM	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs28595532	0.920	rs17259284	chr4:119779298	T/C	cg21605333	chr4:119757512	SEC24D	1.67	6.17	0.53	1.69e-8	Cannabis dependence symptom count;
THYM	cis	rs2806561	0.929	rs2903545	chr1:23541108	C/T	cg12483005	chr1:23474871	LUZP1	-0.55	-5.65	-0.5	1.66e-7	Height;
THYM	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs600550	0.558	rs4444096	chr11:60094004	G/C	cg05040360	chr11:60102449	MS4A6E	-0.5	-4.64	-0.43	1.1e-5	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg08999081	chr20:33150536	PIGU	0.58	4.98	0.46	2.79e-6	Coronary artery disease;
THYM	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs7553864	1.000	rs4626859	chr1:87614020	G/A	cg17420885	chr1:87600446	LOC339524	-0.77	-6.37	-0.55	6.71e-9	Smoking behavior;
THYM	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg13695892	chr22:41940480	POLR3H	-0.69	-6.37	-0.55	6.71e-9	Vitiligo;
THYM	cis	rs448720	0.875	rs338356	chr15:68194270	G/A	cg24579218	chr15:68104479	NA	-0.56	-5.03	-0.46	2.27e-6	Cognitive performance;
THYM	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg10523679	chr1:76189770	ACADM	0.94	8.52	0.66	2.42e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1011018	0.628	rs10230692	chr7:139421180	A/G	cg06079564	chr7:139468310	HIPK2	-0.72	-4.77	-0.44	6.71e-6	Systolic blood pressure;
THYM	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg03929089	chr4:120376271	NA	1.02	8.18	0.64	1.26e-12	Coronary artery disease;
THYM	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg05373962	chr22:49881684	NA	-0.67	-6.8	-0.57	9.16e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs3136516	0.537	rs752850	chr11:47175150	A/G	cg00724111	chr11:47209415	PACSIN3	0.38	4.71	0.43	8.51e-6	Venous thromboembolism;
THYM	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	5.29	0.48	7.97e-7	Hip circumference adjusted for BMI;
THYM	cis	rs6127978	0.702	rs2426704	chr20:55808230	T/C	cg15851418	chr20:55835831	BMP7	0.68	4.89	0.45	4.12e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.92	-6.03	-0.53	3.11e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs73086581	0.787	rs67202952	chr20:3869099	A/C	cg02187196	chr20:3869020	PANK2	0.47	5.04	0.46	2.23e-6	Response to antidepressants in depression;
THYM	cis	rs2836633	0.929	rs4143428	chr21:40030582	G/T	cg12884169	chr21:40033163	ERG	0.68	8.52	0.66	2.33e-13	Coronary artery disease;
THYM	cis	rs11948739	0.610	rs4318771	chr5:130195616	G/A	cg08523029	chr5:130500466	HINT1	-0.65	-4.65	-0.43	1.09e-5	Pediatric bone mineral content (hip);
THYM	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg10523679	chr1:76189770	ACADM	-0.95	-12.11	-0.78	5.63e-21	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg11317459	chr13:21872234	NA	-1.21	-9.22	-0.69	7.83e-15	White matter hyperintensity burden;
THYM	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg03474202	chr17:45855739	NA	-0.76	-6.7	-0.57	1.45e-9	IgG glycosylation;
THYM	cis	rs2204008	0.617	rs11831608	chr12:38210687	C/T	cg26384229	chr12:38710491	ALG10B	-0.74	-5.8	-0.51	8.85e-8	Bladder cancer;
THYM	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg12386194	chr3:101231763	SENP7	0.69	5.19	0.47	1.2e-6	Colorectal cancer;
THYM	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg05373962	chr22:49881684	NA	-0.62	-5.95	-0.52	4.5e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg18252515	chr7:66147081	NA	1.5	8.97	0.68	2.59e-14	Diabetic kidney disease;
THYM	trans	rs916888	0.779	rs199526	chr17:44847707	C/G	cg22968622	chr17:43663579	NA	-0.88	-7.44	-0.61	4.54e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg11301795	chr4:187892539	NA	-1.11	-17.65	-0.88	9.45e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-6.1	-0.53	2.31e-8	Colorectal cancer;
THYM	cis	rs7705042	0.793	rs1036207	chr5:141499041	A/G	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg11597832	chr14:105993747	TMEM121	-0.5	-4.54	-0.42	1.66e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03517284	chr6:25882590	NA	-0.74	-5.89	-0.52	5.89e-8	Blood metabolite levels;
THYM	cis	rs1466045	0.698	rs10833326	chr11:3158634	C/T	cg14568032	chr11:3122963	OSBPL5	0.59	4.89	0.45	4.04e-6	Cisplatin-induced ototoxicity;
THYM	cis	rs7729447	0.813	rs7715279	chr5:32689875	T/A	cg16267343	chr5:32710456	NPR3	0.79	7.08	0.59	2.42e-10	Blood pressure;
THYM	cis	rs4891159	0.526	rs2848961	chr18:74129886	C/G	cg24786174	chr18:74118243	ZNF516	-0.98	-14.33	-0.83	1.73e-25	Longevity;
THYM	cis	rs662064	0.748	rs12375	chr1:10596341	C/T	cg20482658	chr1:10539492	PEX14	0.5	6.32	0.54	8.53e-9	Asthma;
THYM	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-4.75	-0.44	7.13e-6	Type 2 diabetes;
THYM	cis	rs2075230	0.850	rs75853747	chr17:7476706	C/T	cg16696476	chr17:8191344	RANGRF;SLC25A35	0.29	4.64	0.43	1.09e-5	Hormone measurements;
THYM	cis	rs7582403	0.771	rs1238800	chr2:148843698	C/T	cg23727674	chr2:148602993	ACVR2A	-0.58	-4.79	-0.44	6.24e-6	Neuroticism;
THYM	cis	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg12000587	chr17:30186630	C17orf79	-0.46	-6.94	-0.58	4.78e-10	Hip circumference adjusted for BMI;
THYM	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg27494647	chr7:150038898	RARRES2	0.42	5.16	0.47	1.35e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06481639	chr22:41940642	POLR3H	-0.66	-4.56	-0.42	1.53e-5	Vitiligo;
THYM	cis	rs946836	0.537	rs7520317	chr1:48379119	T/A	cg18376692	chr1:48452465	NA	-0.5	-4.9	-0.45	3.98e-6	White matter integrity;
THYM	cis	rs7512552	0.839	rs2264418	chr1:150368579	G/A	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs11690935	0.959	rs10184866	chr2:172608956	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.82	-5.92	-0.52	5.07e-8	Schizophrenia;
THYM	cis	rs7100689	0.577	rs2236569	chr10:82043576	G/A	cg01528321	chr10:82214614	TSPAN14	0.97	7.34	0.6	7.3e-11	Post bronchodilator FEV1;
THYM	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.61	-5.09	-0.46	1.79e-6	Renal function-related traits (BUN);
THYM	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs654950	1.000	rs679449	chr1:41988634	G/T	cg06885757	chr1:42089581	HIVEP3	-0.58	-7.74	-0.62	1.05e-11	Airway imaging phenotypes;
THYM	cis	rs12188164	0.965	rs56182240	chr5:423169	C/T	cg26850624	chr5:429559	AHRR	-0.7	-5.5	-0.49	3.15e-7	Cystic fibrosis severity;
THYM	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg01416388	chr22:39784598	NA	-0.87	-8.1	-0.64	1.82e-12	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg09307838	chr4:120376055	NA	0.72	5.06	0.46	2.02e-6	Corneal astigmatism;
THYM	cis	rs7178572	0.568	rs62008452	chr15:77591007	A/G	cg22256960	chr15:77711686	NA	-1.03	-8.45	-0.66	3.3e-13	Type 2 diabetes;
THYM	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg06917634	chr15:78832804	PSMA4	0.96	8.76	0.67	7.4e-14	Sudden cardiac arrest;
THYM	cis	rs8030485	1.000	rs28652642	chr15:79411180	G/A	cg17916960	chr15:79447300	NA	0.53	5.49	0.49	3.41e-7	Left ventricle wall thickness;
THYM	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg03806693	chr22:41940476	POLR3H	-1.09	-8.62	-0.66	1.45e-13	Vitiligo;
THYM	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg15676542	chr6:26421231	BTN2A3	0.33	4.5	0.42	1.93e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs236907	0.859	rs17650310	chr1:171757204	A/G	cg20598894	chr1:171756153	METTL13	-0.74	-5.59	-0.5	2.16e-7	Mean platelet volume;
THYM	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs662064	0.748	rs2506892	chr1:10598216	G/A	cg20482658	chr1:10539492	PEX14	0.5	6.32	0.54	8.53e-9	Asthma;
THYM	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg06850241	chr22:41845214	NA	-0.54	-4.68	-0.43	9.37e-6	Vitiligo;
THYM	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg22105103	chr4:187893119	NA	0.92	10.09	0.72	1.04e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4853012	0.887	rs2122290	chr2:74358901	C/T	cg01017244	chr2:74357527	NA	1.17	9.91	0.71	2.64e-16	Gestational age at birth (maternal effect);
THYM	cis	rs8073060	1.000	rs8073060	chr17:33875262	T/A	cg07895132	chr17:33825172	SLFN12L	0.55	5.48	0.49	3.43e-7	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06850241	chr22:41845214	NA	-0.61	-5.47	-0.49	3.61e-7	Vitiligo;
THYM	trans	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.98	-8.84	-0.67	4.94e-14	Brugada syndrome;
THYM	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg04476341	chr5:669733	TPPP	-0.45	-4.51	-0.42	1.83e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs1878931	0.597	rs37816	chr16:3456371	G/A	cg22508957	chr16:3507546	NAT15	0.5	5.22	0.47	1.04e-6	Body mass index (adult);
THYM	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.49	0.49	3.33e-7	Platelet count;
THYM	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg24257776	chr3:47051546	LOC100129354	0.4	4.58	0.43	1.39e-5	Colorectal cancer;
THYM	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg12386194	chr3:101231763	SENP7	0.66	5.0	0.46	2.59e-6	Colorectal cancer;
THYM	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg05347473	chr6:146136440	FBXO30	0.58	4.52	0.42	1.8e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11644478	chr21:40555479	PSMG1	0.81	7.03	0.59	3.12e-10	Cognitive function;
THYM	cis	rs9814567	0.896	rs11915964	chr3:134348930	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	7.61	0.62	1.94e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs3750965	1.000	rs61881024	chr11:68837794	A/G	cg06818126	chr11:68850279	TPCN2	-0.68	-4.64	-0.43	1.13e-5	Hair color;
THYM	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03264133	chr6:25882463	NA	0.74	5.74	0.51	1.11e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7584330	0.554	rs6739456	chr2:238385092	G/C	cg08992911	chr2:238395768	MLPH	1.06	6.38	0.55	6.51e-9	Prostate cancer;
THYM	cis	rs7823896	0.929	rs73311387	chr8:110149910	C/T	cg18044723	chr8:109261011	EIF3E	-0.89	-4.68	-0.43	9.42e-6	Myopia (pathological);
THYM	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg17971929	chr21:40555470	PSMG1	0.74	4.84	0.44	5.09e-6	Cognitive function;
THYM	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg10515332	chr4:99064459	C4orf37	0.57	4.56	0.42	1.54e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11122895	1.000	rs12619033	chr2:112464137	A/G	cg23262488	chr2:112468472	NA	-0.67	-9.4	-0.69	3.21e-15	Allergic sensitization;
THYM	cis	rs7107174	1.000	rs10899476	chr11:78051794	A/G	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs7968679	1	rs7968679	chr12:9313304	A/G	cg26114124	chr12:9217669	LOC144571	-0.59	-5.13	-0.47	1.5e-6	Myopia;
THYM	cis	rs2286885	1.000	rs10733677	chr9:129242209	A/G	cg14294646	chr9:129243551	FAM125B	-0.69	-6.48	-0.55	4.15e-9	Intraocular pressure;
THYM	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg00810483	chr4:3375144	RGS12	0.32	4.93	0.45	3.55e-6	Serum sulfate level;
THYM	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg05340658	chr4:99064831	C4orf37	0.54	4.51	0.42	1.83e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4786125	0.587	rs12709158	chr16:6925056	A/G	cg03623568	chr16:6915990	A2BP1	-1.0	-9.83	-0.71	3.85e-16	Heart rate variability traits (SDNN);
THYM	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	4.93	0.45	3.5e-6	Diabetic retinopathy;
THYM	cis	rs17401966	0.894	rs12722830	chr1:10395134	A/G	cg19773385	chr1:10388646	KIF1B	-0.6	-4.7	-0.43	8.88e-6	Hepatocellular carcinoma;
THYM	cis	rs7027203	0.759	rs10761282	chr9:96586175	G/A	cg14598338	chr9:96623480	NA	-0.45	-4.7	-0.43	8.62e-6	DNA methylation (variation);
THYM	cis	rs10992471	0.528	rs6479423	chr9:95265580	A/T	cg14631576	chr9:95140430	CENPP	-0.81	-7.54	-0.61	2.79e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs62064224	0.589	rs9889607	chr17:30785585	A/C	cg18200150	chr17:30822561	MYO1D	-0.54	-4.5	-0.42	1.95e-5	Schizophrenia;
THYM	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg00484396	chr16:3507460	NAT15	-0.63	-7.04	-0.59	3e-10	Tuberculosis;
THYM	cis	rs4646404	0.526	rs12939945	chr17:17476914	T/C	cg11245205	chr17:17398264	RASD1	-0.42	-4.66	-0.43	1.03e-5	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
THYM	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg10047753	chr17:41438598	NA	1.19	11.15	0.75	5.97e-19	Menopause (age at onset);
THYM	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	7.38	0.6	6.08e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7267979	0.866	rs2424698	chr20:25256106	C/T	cg08601574	chr20:25228251	PYGB	0.58	4.5	0.42	1.92e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4930103	0.591	rs11042048	chr11:1986240	C/G	cg06197492	chr11:2016605	H19	0.56	4.88	0.45	4.35e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs2888674	1.000	rs2888674	chr7:150510915	G/A	cg10409299	chr7:150498843	TMEM176B;TMEM176A	0.48	4.63	0.43	1.15e-5	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
THYM	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.2	-9.43	-0.7	2.7e-15	Platelet count;
THYM	cis	rs4474465	1.000	rs10793315	chr11:78190716	C/G	cg19901956	chr11:77921274	USP35	-0.64	-4.77	-0.44	6.65e-6	Alzheimer's disease (survival time);
THYM	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23248424	chr5:179741104	GFPT2	-0.88	-6.4	-0.55	5.76e-9	Height;
THYM	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg05707623	chr12:122985044	ZCCHC8	0.71	4.74	0.44	7.5e-6	Body mass index;
THYM	cis	rs1371867	0.846	rs1660317	chr8:101333252	G/T	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs985746	0.614	rs1542018	chr4:36795881	G/A	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg09165964	chr15:75287851	SCAMP5	-1.08	-10.64	-0.74	7.02e-18	Blood trace element (Zn levels);
THYM	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-8.35	-0.65	5.52e-13	Height;
THYM	cis	rs80319144	0.951	rs74606352	chr2:159286301	A/G	cg24986868	chr2:159312599	PKP4;CCDC148	0.6	4.73	0.44	7.69e-6	Restless legs syndrome;
THYM	cis	rs4732038	0.510	rs28645396	chr7:134270576	C/T	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs4866334	0.867	rs76734676	chr5:18487735	G/T	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg18811423	chr2:55921094	PNPT1	0.69	6.41	0.55	5.6e-9	Metabolic syndrome;
THYM	cis	rs1322639	0.614	rs7751131	chr6:169578710	G/A	cg04662567	chr6:169592167	NA	-0.75	-6.2	-0.54	1.43e-8	Pulse pressure;
THYM	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg03806693	chr22:41940476	POLR3H	-1.02	-7.83	-0.63	6.94e-12	Vitiligo;
THYM	cis	rs2404602	0.735	rs2280306	chr15:76652258	C/G	cg23482746	chr15:76478102	C15orf27	0.45	4.57	0.42	1.44e-5	Blood metabolite levels;
THYM	cis	rs61931739	0.929	rs1490110	chr12:34091605	A/G	cg06521331	chr12:34319734	NA	0.6	4.85	0.45	4.82e-6	Morning vs. evening chronotype;
THYM	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg23231163	chr10:75533350	FUT11	0.43	6.18	0.54	1.6e-8	Inflammatory bowel disease;
THYM	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02463440	chr8:22132932	PIWIL2	0.58	5.04	0.46	2.26e-6	Hypertriglyceridemia;
THYM	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs9563576	0.778	rs9788392	chr13:58636500	G/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.63	4.68	0.43	9.64e-6	Body mass index;
THYM	cis	rs3845702	0.736	rs12465592	chr2:180862654	C/G	cg01881094	chr2:180872142	CWC22	0.92	5.53	0.49	2.76e-7	Schizophrenia;
THYM	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg08968635	chr6:28129556	ZNF389	0.71	5.58	0.5	2.28e-7	Parkinson's disease;
THYM	cis	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg10295955	chr4:187884368	NA	-1.19	-17.25	-0.87	5.06e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg09307838	chr4:120376055	NA	0.64	4.69	0.43	9.31e-6	Corneal astigmatism;
THYM	cis	rs6430585	0.583	rs6728946	chr2:136635343	C/G	cg04750100	chr2:136595281	LCT	0.56	5.26	0.47	8.94e-7	Corneal structure;
THYM	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg02734326	chr4:10020555	SLC2A9	-0.6	-4.85	-0.45	4.9100000000000004e-06	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs870825	0.929	rs72689261	chr4:185590897	C/A	cg04058563	chr4:185651563	MLF1IP	0.96	6.73	0.57	1.26e-9	Blood protein levels;
THYM	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg07549590	chr16:15018862	NA	-0.63	-4.83	-0.44	5.19e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
THYM	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.76	-4.99	-0.46	2.73e-6	Body mass index;
THYM	cis	rs17597773	0.755	rs10863570	chr1:221030589	T/C	cg16008148	chr1:221062819	NA	0.47	4.79	0.44	6.08e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.7	5.56	0.5	2.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs6565180	0.962	rs6565183	chr16:30382755	T/C	cg17640201	chr16:30407289	ZNF48	-0.91	-8.21	-0.64	1.09e-12	Tonsillectomy;
THYM	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg15592062	chr6:167189543	RPS6KA2	0.59	6.16	0.53	1.73e-8	Crohn's disease;
THYM	cis	rs9959145	1.000	rs111268621	chr18:12546289	C/T	cg14160804	chr18:12703040	PSMG2;CEP76	-0.92	-4.53	-0.42	1.74e-5	Immune response to smallpox vaccine (IL-6);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg16457675	chr8:107782577	ABRA	-0.92	-7.57	-0.61	2.39e-11	Depressive symptoms;
THYM	cis	rs11603151	0.622	rs7106125	chr11:134505804	G/C	cg02395454	chr11:134605862	NA	-0.53	-4.5	-0.42	1.92e-5	Schizophrenia;
THYM	cis	rs7926906	1.000	rs7944479	chr11:90524289	T/C	cg26138821	chr11:89956704	CHORDC1	-0.52	-4.71	-0.44	8.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg15242686	chr22:24348715	GSTTP1	-0.68	-7.23	-0.6	1.24e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3773445	0.716	rs66482848	chr3:25618347	G/A	cg02315353	chr3:25825455	NGLY1	0.54	4.67	0.43	9.98e-6	Airway responsiveness in chronic obstructive pulmonary disease;
THYM	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg22079354	chr11:130786696	SNX19	0.5	4.59	0.43	1.34e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs946836	0.537	rs7517415	chr1:48409214	A/T	cg18376692	chr1:48452465	NA	0.55	5.4	0.48	4.93e-7	White matter integrity;
THYM	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.49	0.49	3.33e-7	Platelet count;
THYM	cis	rs4481887	1.000	rs4244182	chr1:248471174	A/G	cg13385794	chr1:248469461	NA	0.65	4.66	0.43	1.04e-5	Common traits (Other);
THYM	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs921968	0.519	rs72966020	chr2:219642620	C/G	cg02176678	chr2:219576539	TTLL4	-0.62	-5.85	-0.51	7.01e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12756686	chr19:29218302	NA	0.98	8.72	0.67	9.12e-14	Methadone dose in opioid dependence;
THYM	cis	rs988913	0.678	rs4518495	chr6:54955122	A/G	cg18532076	chr6:54711417	FAM83B	0.49	4.67	0.43	9.72e-6	Menarche (age at onset);
THYM	cis	rs665401	0.965	rs339341	chr6:117215671	A/G	cg20376953	chr6:117187980	NA	0.6	4.82	0.44	5.5e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg15691649	chr6:25882328	NA	-0.73	-5.64	-0.5	1.76e-7	Intelligence (multi-trait analysis);
THYM	cis	rs75920871	0.588	rs7119185	chr11:116886096	C/T	cg20608306	chr11:116969690	SIK3	-0.5	-5.39	-0.48	5.09e-7	Subjective well-being;
THYM	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg08109568	chr15:31115862	NA	-0.68	-6.21	-0.54	1.4e-8	Huntington's disease progression;
THYM	cis	rs7851660	0.809	rs10512255	chr9:100652582	C/T	cg13688889	chr9:100608707	NA	-0.81	-5.78	-0.51	9.4e-8	Strep throat;
THYM	cis	rs7264396	0.580	rs2425173	chr20:34445142	G/A	cg26038318	chr20:34205095	SPAG4	0.65	5.12	0.47	1.57e-6	Total cholesterol levels;
THYM	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.72	-5.38	-0.48	5.27e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.66	-7.88	-0.63	5.51e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs9486719	1.000	rs3798296	chr6:97052286	G/A	cg18709589	chr6:96969512	KIAA0776	-0.67	-4.64	-0.43	1.1e-5	Migraine;Coronary artery disease;
THYM	cis	rs288326	0.561	rs78528869	chr2:183815502	C/T	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs7106204	0.614	rs117122818	chr11:24245880	C/T	ch.11.24196551F	chr11:24239977	NA	1.03	5.48	0.49	3.53e-7	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7937840	0.501	rs4963459	chr11:61877137	G/A	cg13875901	chr11:61879966	NA	0.51	4.47	0.42	2.16e-5	Breast cancer;
THYM	cis	rs2219968	1.000	rs7818353	chr8:78972826	C/A	cg00738934	chr8:78996279	NA	0.92	10.06	0.72	1.2e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg06656553	chr16:89960601	TCF25	1.03	4.77	0.44	6.62e-6	Skin colour saturation;
THYM	cis	rs11627756	0.958	rs4906238	chr14:103077702	G/A	cg27124170	chr14:102829869	TECPR2;CINP	-0.65	-4.47	-0.42	2.15e-5	Mean platelet volume;
THYM	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg22920501	chr2:26401640	FAM59B	-1.05	-9.27	-0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg03709012	chr19:19516395	GATAD2A	0.76	6.05	0.53	2.87e-8	Tonsillectomy;
THYM	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	5.12	0.47	1.57e-6	Rheumatoid arthritis;
THYM	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg26384229	chr12:38710491	ALG10B	-0.86	-7.72	-0.62	1.15e-11	Morning vs. evening chronotype;
THYM	cis	rs1113500	0.933	rs11185256	chr1:108633957	C/T	cg06207961	chr1:108661230	NA	0.64	5.09	0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs9399401	0.710	rs7765770	chr6:142687305	C/T	cg03128060	chr6:142623767	GPR126	0.7	9.41	0.69	2.99e-15	Chronic obstructive pulmonary disease;
THYM	cis	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs9326248	0.530	rs6589575	chr11:116733310	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.92	5.28	0.48	8.11e-7	Blood protein levels;
THYM	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg10360139	chr7:1886902	MAD1L1	-0.58	-4.61	-0.43	1.28e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs2458413	0.563	rs2458419	chr8:105337141	G/C	cg21295575	chr8:105352067	TM7SF4	0.3	4.58	0.43	1.43e-5	Paget's disease;
THYM	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg06634786	chr22:41940651	POLR3H	-0.57	-4.5	-0.42	1.91e-5	Vitiligo;
THYM	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg07570687	chr10:102243282	WNT8B	-0.84	-8.27	-0.65	7.91e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7851660	0.506	rs1912996	chr9:100598261	G/T	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Strep throat;
THYM	cis	rs2282300	0.739	rs16920406	chr11:30216158	A/C	cg06241208	chr11:30344200	C11orf46	-0.77	-5.69	-0.5	1.38e-7	Morning vs. evening chronotype;
THYM	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg06636001	chr8:8085503	FLJ10661	-0.71	-5.85	-0.51	6.8e-8	Joint mobility (Beighton score);
THYM	cis	rs1372520	0.684	rs3113355	chr4:90745345	A/T	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg15691649	chr6:25882328	NA	-0.88	-6.89	-0.58	6.05e-10	Urate levels;
THYM	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg20295408	chr7:1910781	MAD1L1	-0.59	-4.7	-0.43	8.91e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs1847202	0.859	rs13075769	chr3:72939295	C/T	cg25664220	chr3:72788482	NA	-0.61	-4.6	-0.43	1.28e-5	Motion sickness;
THYM	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9814567	1.000	rs10935120	chr3:134233092	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	8.41	0.65	4e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg12560992	chr17:57184187	TRIM37	-0.91	-8.51	-0.66	2.54e-13	Intelligence (multi-trait analysis);
THYM	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg13393036	chr8:95962371	TP53INP1	-0.48	-4.72	-0.44	8.22e-6	Type 2 diabetes;
THYM	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg13147721	chr7:65941812	NA	-0.94	-5.74	-0.51	1.13e-7	Diabetic kidney disease;
THYM	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg18032289	chr17:61959525	GH2	-0.5	-4.76	-0.44	6.95e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs877282	1.000	rs11253361	chr10:770387	T/C	cg10556349	chr10:835070	NA	-0.73	-5.07	-0.46	1.93e-6	Uric acid levels;
THYM	cis	rs478304	0.651	rs11604462	chr11:65551648	G/A	cg17480646	chr11:65405466	SIPA1	-0.94	-8.85	-0.67	4.72e-14	Acne (severe);
THYM	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg03929089	chr4:120376271	NA	-0.99	-9.9	-0.71	2.75e-16	Height;
THYM	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg07460842	chr6:66804631	NA	1.1	8.21	0.64	1.08e-12	Exhaled nitric oxide output;
THYM	cis	rs870825	0.616	rs4615214	chr4:185624129	G/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs11971779	1.000	rs75919582	chr7:139054919	G/A	cg07862535	chr7:139043722	LUC7L2	0.71	4.69	0.43	9e-6	Diisocyanate-induced asthma;
THYM	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg13319975	chr6:146136371	FBXO30	-0.62	-5.24	-0.47	9.86e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1003719	0.788	rs9981226	chr21:38452127	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.71	5.03	0.46	2.32e-6	Eye color traits;
THYM	cis	rs4792901	0.802	rs9903373	chr17:41557974	G/A	cg21940313	chr17:41620911	ETV4	-0.5	-4.85	-0.45	4.74e-6	Dupuytren's disease;
THYM	cis	rs11563648	0.535	rs6467122	chr7:127001087	A/C	cg23081781	chr7:127225937	GCC1	-0.34	-4.46	-0.42	2.28e-5	Resting heart rate;
THYM	cis	rs9326248	0.861	rs4938348	chr11:117021877	G/C	cg26566898	chr11:117069891	TAGLN	0.42	4.49	0.42	2.03e-5	Blood protein levels;
THYM	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.37	-0.55	6.76e-9	Total body bone mineral density;
THYM	cis	rs13082711	0.522	rs586229	chr3:27354520	A/G	cg02860705	chr3:27208620	NA	0.64	5.03	0.46	2.27e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg11245990	chr11:68621969	NA	0.55	7.14	0.59	1.89e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1056053	0.514	rs3127329	chr6:166572362	G/A	cg11088901	chr6:166572345	T	-0.58	-5.22	-0.47	1.06e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg14019146	chr3:50243930	SLC38A3	-0.58	-4.86	-0.45	4.58e-6	Body mass index;
THYM	cis	rs6815814	0.898	rs73236646	chr4:38871385	T/C	cg02016764	chr4:38805732	TLR1	-0.51	-5.02	-0.46	2.44e-6	Breast cancer;
THYM	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg25767906	chr1:53392781	SCP2	-0.64	-6.28	-0.54	1.01e-8	Monocyte count;
THYM	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg23131131	chr22:24373011	LOC391322	-0.84	-8.01	-0.63	2.91e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1050631	0.592	rs9958282	chr18:33710440	T/A	cg23776217	chr18:34409391	KIAA1328;C18orf10	-0.59	-4.51	-0.42	1.83e-5	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs10489202	1.000	rs17556487	chr1:167889094	T/A	cg24449463	chr1:168025552	DCAF6	-0.83	-6.51	-0.56	3.58e-9	Schizophrenia;
THYM	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg22709100	chr7:91322751	NA	-0.62	-4.93	-0.45	3.5e-6	Breast cancer;
THYM	cis	rs8067545	0.685	rs4479309	chr17:19971583	C/T	cg13482628	chr17:19912719	NA	0.54	4.56	0.42	1.51e-5	Schizophrenia;
THYM	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg15556689	chr8:8085844	FLJ10661	0.83	7.48	0.61	3.62e-11	Neuroticism;
THYM	cis	rs13177918	0.734	rs6579790	chr5:149843942	C/T	cg14059543	chr5:149831962	NA	-0.72	-5.08	-0.46	1.92e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.36	0.69	3.89e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7178572	1.000	rs12910361	chr15:77782335	A/G	cg22256960	chr15:77711686	NA	-0.93	-7.84	-0.63	6.46e-12	Type 2 diabetes;
THYM	trans	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg23505145	chr19:12996616	KLF1	-1.05	-10.29	-0.73	4.07e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.86	-7.67	-0.62	1.46e-11	Intelligence (multi-trait analysis);
THYM	cis	rs4780401	0.609	rs12927966	chr16:11814562	C/T	cg01061890	chr16:11836724	TXNDC11	-0.69	-5.7	-0.5	1.34e-7	Rheumatoid arthritis;
THYM	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg09165964	chr15:75287851	SCAMP5	0.6	4.59	0.43	1.38e-5	Breast cancer;
THYM	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg23187316	chr7:1099788	C7orf50	0.58	4.45	0.42	2.32e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg15536230	chr21:44985092	HSF2BP	-0.47	-5.58	-0.5	2.26e-7	Mean corpuscular volume;
THYM	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7917772	0.560	rs11595170	chr10:104339851	T/C	cg00122347	chr10:104236741	TMEM180	0.42	6.22	0.54	1.34e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs986417	1.000	rs1254323	chr14:60908378	G/A	cg27398547	chr14:60952738	C14orf39	-1.06	-5.59	-0.5	2.16e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg13683864	chr3:40499215	RPL14	1.11	6.46	0.55	4.38e-9	Renal cell carcinoma;
THYM	cis	rs28493229	0.786	rs3815912	chr19:41190726	G/A	cg21869046	chr19:41225005	ITPKC	0.56	5.28	0.48	8.29e-7	Kawasaki disease;
THYM	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg11189052	chr15:85197271	WDR73	-0.62	-4.8	-0.44	5.91e-6	P wave terminal force;
THYM	cis	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg06521331	chr12:34319734	NA	-0.96	-9.28	-0.69	5.69e-15	Morning vs. evening chronotype;
THYM	cis	rs2455799	0.613	rs4684261	chr3:15796505	G/A	cg16303742	chr3:15540471	COLQ	-0.56	-5.73	-0.51	1.18e-7	Mean platelet volume;
THYM	cis	rs11039798	0.588	rs1814768	chr11:48987455	T/C	cg24672777	chr11:48374446	OR4C45	-0.91	-5.73	-0.51	1.17e-7	Axial length;
THYM	cis	rs1401999	0.898	rs9876143	chr3:183731362	C/G	cg20387954	chr3:183756860	HTR3D	0.56	4.63	0.43	1.15e-5	Anterior chamber depth;
THYM	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg00012203	chr2:219082015	ARPC2	0.63	5.03	0.46	2.31e-6	Colorectal cancer;
THYM	cis	rs17331151	0.505	rs34182518	chr3:52743854	G/A	cg17372223	chr3:52568218	NT5DC2	0.6	4.58	0.43	1.43e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs877282	0.583	rs12358255	chr10:828626	C/T	cg10556349	chr10:835070	NA	-0.73	-4.91	-0.45	3.77e-6	Uric acid levels;
THYM	cis	rs7582403	0.510	rs12691775	chr2:148874090	T/G	cg23727674	chr2:148602993	ACVR2A	0.63	4.61	0.43	1.24e-5	Neuroticism;
THYM	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg26597838	chr10:835615	NA	1.08	7.25	0.6	1.1e-10	Eosinophil percentage of granulocytes;
THYM	cis	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.59	6.1	0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.38e-10	Prudent dietary pattern;
THYM	cis	rs9549260	0.651	rs57735994	chr13:41226561	C/G	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs6754311	0.593	rs4954279	chr2:136409073	G/A	cg07169764	chr2:136633963	MCM6	0.7	5.57	0.5	2.36e-7	Mosquito bite size;
THYM	cis	rs7219021	0.634	rs9905428	chr17:46948709	C/G	cg09029085	chr17:47094198	IGF2BP1	0.33	4.51	0.42	1.82e-5	Schizophrenia or bipolar disorder;
THYM	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg00999904	chr2:3704751	ALLC	-0.73	-4.99	-0.46	2.75e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.76	8.46	0.66	3.25e-13	Eosinophil percentage of white cells;
THYM	cis	rs354225	0.544	rs10184128	chr2:54803816	A/G	cg23486701	chr2:54789491	SPTBN1	0.37	4.88	0.45	4.18e-6	Schizophrenia;
THYM	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg13852791	chr20:30311386	BCL2L1	0.89	6.83	0.57	8.1e-10	Mean corpuscular hemoglobin;
THYM	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg00684032	chr4:1343700	KIAA1530	0.51	4.52	0.42	1.76e-5	Obesity-related traits;
THYM	cis	rs11779988	0.545	rs411531	chr8:17795934	A/G	cg01800426	chr8:17659068	MTUS1	-0.75	-5.22	-0.47	1.07e-6	Breast cancer;
THYM	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg13395646	chr4:1353034	KIAA1530	-0.56	-4.63	-0.43	1.14e-5	Longevity;
THYM	cis	rs338389	0.542	rs338342	chr15:68272052	C/T	cg07562100	chr15:68569975	FEM1B	-0.74	-5.14	-0.47	1.49e-6	Survival in rectal cancer;
THYM	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg01416388	chr22:39784598	NA	-0.9	-8.14	-0.64	1.5e-12	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg11764359	chr7:65958608	NA	-0.73	-5.55	-0.49	2.63e-7	Aortic root size;
THYM	cis	rs1642645	0.831	rs2886564	chr1:42496924	G/A	cg22816091	chr1:42611670	NA	0.62	5.52	0.49	2.99e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs2742417	0.603	rs2673032	chr3:45756927	C/T	cg04837898	chr3:45731254	SACM1L	-0.73	-5.29	-0.48	7.85e-7	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs7178572	0.568	rs8030074	chr15:77654232	C/T	cg22256960	chr15:77711686	NA	-1.05	-8.4	-0.65	4.29e-13	Type 2 diabetes;
THYM	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs2041895	0.509	rs12368448	chr12:107316796	A/C	cg26297688	chr12:107349093	C12orf23	0.49	4.81	0.44	5.66e-6	Glaucoma (low intraocular pressure);
THYM	cis	rs761746	0.960	rs4820979	chr22:31914399	A/G	cg10537193	chr22:32026975	PISD	0.42	5.48	0.49	3.45e-7	Intelligence;
THYM	cis	rs17767294	0.708	rs72851158	chr6:28060485	G/C	cg08851530	chr6:28072375	NA	1.15	4.46	0.42	2.28e-5	Parkinson's disease;
THYM	cis	rs7152530	0.545	rs1461583	chr14:98637995	A/G	cg05180522	chr14:98101740	NA	-0.59	-4.72	-0.44	8.03e-6	Staphylococcus aureus infection;
THYM	cis	rs425535	0.503	rs2115695	chr4:74805472	G/T	cg07868155	chr4:74864709	CXCL5	0.54	4.49	0.42	2.01e-5	Blood protein levels;
THYM	cis	rs10927875	0.550	rs12121918	chr1:16183556	C/A	cg21385522	chr1:16154831	NA	-1.09	-7.8	-0.62	7.98e-12	Dilated cardiomyopathy;
THYM	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg22307297	chr20:60903441	LAMA5	0.53	4.67	0.43	9.72e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs17818399	0.547	rs62134736	chr2:46766446	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.64	-4.54	-0.42	1.64e-5	Height;
THYM	cis	rs8067545	1.000	rs4925067	chr17:19921222	C/G	cg13482628	chr17:19912719	NA	0.57	4.79	0.44	6.23e-6	Schizophrenia;
THYM	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg17971929	chr21:40555470	PSMG1	0.7	4.52	0.42	1.76e-5	Cognitive function;
THYM	cis	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs67460515	0.892	rs11711695	chr3:161057593	A/G	cg03342759	chr3:160939853	NMD3	-0.9	-7.77	-0.62	9.28e-12	Parkinson's disease;
THYM	cis	rs4474465	1.000	rs7124092	chr11:78155086	T/C	cg19901956	chr11:77921274	USP35	-0.61	-4.66	-0.43	1.02e-5	Alzheimer's disease (survival time);
THYM	cis	rs9302065	0.529	rs2992904	chr13:95958173	A/C	cg26751094	chr13:95954534	ABCC4	-0.5	-5.69	-0.5	1.42e-7	Blood metabolite levels;
THYM	cis	rs12282928	0.959	rs1393791	chr11:48264183	T/G	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	4.59	0.43	1.35e-5	Rheumatoid arthritis;
THYM	cis	rs12889267	0.722	rs2319625	chr14:21565146	C/T	cg23374312	chr14:21565335	ZNF219	-0.79	-6.01	-0.53	3.35e-8	Hematocrit;Resting heart rate;
THYM	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4638749	0.677	rs7594896	chr2:108835502	C/T	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg18876405	chr7:65276391	NA	-0.61	-5.26	-0.47	8.91e-7	Aortic root size;
THYM	cis	rs2731664	0.792	rs335468	chr5:176892349	A/G	cg14098951	chr5:176875120	PRR7	-0.55	-4.75	-0.44	7.13e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6901250	0.807	rs1606366	chr6:117132438	C/G	cg12892004	chr6:117198278	RFX6	0.71	6.96	0.58	4.39e-10	C-reactive protein levels;
THYM	cis	rs2916260	0.800	rs55929843	chr6:40392146	G/A	cg08415973	chr6:40346114	TDRG1	0.75	4.71	0.43	8.6e-6	Incident coronary heart disease;
THYM	cis	rs36051895	0.664	rs62541915	chr9:5151275	A/T	cg02405213	chr9:5042618	JAK2	-1.09	-10.97	-0.75	1.41e-18	Pediatric autoimmune diseases;
THYM	cis	rs7580658	0.637	rs1566822	chr2:127987391	A/G	cg09152259	chr2:128156114	NA	-0.38	-4.99	-0.46	2.7e-6	Protein C levels;
THYM	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs11574514	1.000	rs9939085	chr16:67733237	C/T	cg04582263	chr16:67973788	LCAT	0.94	4.45	0.42	2.31e-5	Crohn's disease;
THYM	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg21433313	chr16:3507492	NAT15	-0.66	-5.0	-0.46	2.64e-6	Tuberculosis;
THYM	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg04546413	chr19:29218101	NA	1.09	9.4	0.69	3.15e-15	Methadone dose in opioid dependence;
THYM	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.27e-7	Corneal astigmatism;
THYM	cis	rs7809950	1.000	rs7782057	chr7:107098877	T/A	cg23024343	chr7:107201750	COG5	-0.92	-8.11	-0.64	1.73e-12	Coronary artery disease;
THYM	cis	rs4654899	0.865	rs12123300	chr1:21323568	T/C	cg01072550	chr1:21505969	NA	-0.75	-6.6	-0.56	2.29e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.46	0.49	3.85e-7	Platelet count;
THYM	cis	rs2554380	0.800	rs2562768	chr15:84382953	C/T	cg14598478	chr15:84363061	ADAMTSL3	0.63	4.98	0.46	2.79e-6	Height;
THYM	cis	rs11690935	0.959	rs2292815	chr2:172586651	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-6.5	-0.55	3.76e-9	Schizophrenia;
THYM	cis	rs4891159	0.790	rs8087557	chr18:74116848	G/C	cg24786174	chr18:74118243	ZNF516	-0.89	-10.3	-0.73	3.72e-17	Longevity;
THYM	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg00990874	chr7:1149470	C7orf50	-0.61	-4.59	-0.43	1.34e-5	Bronchopulmonary dysplasia;
THYM	cis	rs12478296	1.000	rs6743297	chr2:243013814	A/G	cg06360820	chr2:242988706	NA	-0.96	-6.27	-0.54	1.06e-8	Obesity-related traits;
THYM	cis	rs12530845	0.725	rs74873522	chr7:135339632	A/C	cg23117316	chr7:135346802	PL-5283	-0.73	-5.96	-0.52	4.36e-8	Red blood cell traits;
THYM	cis	rs918629	1.000	rs60482707	chr5:95307696	T/C	cg14587401	chr5:94890408	ARSK;TTC37	-0.66	-4.76	-0.44	6.82e-6	IgG glycosylation;
THYM	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg13918804	chr1:2043761	PRKCZ	-0.61	-4.62	-0.43	1.19e-5	Height;
THYM	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25427524	chr10:38739819	LOC399744	-0.73	-6.77	-0.57	1.04e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg12908607	chr1:44402522	ARTN	-0.52	-4.67	-0.43	9.88e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs4589258	0.788	rs10734136	chr11:90482567	G/A	cg26138821	chr11:89956704	CHORDC1	-0.58	-4.66	-0.43	1.05e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg02734326	chr4:10020555	SLC2A9	-0.56	-4.63	-0.43	1.17e-5	Bone mineral density;
THYM	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23248424	chr5:179741104	GFPT2	0.89	6.93	0.58	5.07e-10	Height;
THYM	cis	rs586688	1.000	rs525492	chr1:201638858	G/A	cg14168733	chr1:201708718	NAV1	0.57	5.28	0.48	8.05e-7	Obesity-related traits;
THYM	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs36051895	0.502	rs12347799	chr9:5215954	G/A	cg02405213	chr9:5042618	JAK2	-0.76	-7.04	-0.59	2.95e-10	Pediatric autoimmune diseases;
THYM	cis	rs593982	1.000	rs650619	chr11:65506483	G/A	cg08755490	chr11:65554678	OVOL1	1.36	8.73	0.67	8.51e-14	Atopic dermatitis;
THYM	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.94	6.12	0.53	2.08e-8	Smoking behavior;
THYM	cis	rs1371867	0.875	rs1660344	chr8:101324659	A/G	cg06636551	chr8:101224915	SPAG1	-0.67	-6.52	-0.56	3.33e-9	Atrioventricular conduction;
THYM	cis	rs12121840	0.680	rs79661923	chr1:165534822	A/T	cg19407955	chr1:165599744	MGST3	-0.65	-4.64	-0.43	1.12e-5	Interleukin-1-receptor antagonist levels;
THYM	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg11645453	chr3:52864694	ITIH4	0.29	4.67	0.43	9.71e-6	Schizophrenia;
THYM	cis	rs611744	0.967	rs598477	chr8:109187874	G/T	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs6906287	0.647	rs3752581	chr6:118869730	G/A	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs10752881	1.000	rs6424879	chr1:182986592	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.79	0.44	6.13e-6	Colorectal cancer;
THYM	cis	rs7107174	1.000	rs2510050	chr11:77982564	A/G	cg19901956	chr11:77921274	USP35	-0.68	-5.25	-0.47	9.31e-7	Testicular germ cell tumor;
THYM	cis	rs2652834	0.519	rs4075584	chr15:63340292	C/T	cg05507819	chr15:63340323	TPM1	0.97	5.82	0.51	7.86e-8	HDL cholesterol;
THYM	cis	rs34912216	0.542	rs12701400	chr7:4132004	A/T	cg03141780	chr7:4150753	SDK1	0.69	5.03	0.46	2.31e-6	Motion sickness;
THYM	cis	rs4589258	0.762	rs7939546	chr11:90410814	A/C	cg26138821	chr11:89956704	CHORDC1	0.56	4.74	0.44	7.42e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7944584	0.511	rs10838731	chr11:47607135	C/T	cg20307385	chr11:47447363	PSMC3	0.9	7.0	0.58	3.53e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
THYM	cis	rs9527	0.614	rs2153774	chr10:104881035	T/C	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs61990749	0.597	rs1477262	chr14:78226653	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.04	0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs1003719	0.715	rs13046581	chr21:38551985	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs7731657	0.537	rs2214532	chr5:130316001	C/T	cg08523029	chr5:130500466	HINT1	-0.84	-6.14	-0.53	1.87e-8	Fasting plasma glucose;
THYM	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg26039829	chr8:22132926	PIWIL2	0.7	6.29	0.54	9.49e-9	Hypertriglyceridemia;
THYM	cis	rs2290159	0.848	rs6771385	chr3:12639419	A/G	cg23032965	chr3:12705835	RAF1	0.71	4.75	0.44	7.24e-6	Cholesterol, total;
THYM	cis	rs4951018	0.526	rs6693913	chr1:205654061	G/C	cg26354017	chr1:205819088	PM20D1	-0.6	-4.7	-0.43	8.63e-6	Prostate-specific antigen levels;
THYM	cis	rs10911232	0.507	rs4369195	chr1:182996291	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg27398817	chr8:82754497	SNX16	0.84	6.69	0.57	1.51e-9	Diastolic blood pressure;
THYM	cis	rs7704138	0.639	rs4242058	chr5:55017444	G/A	cg18456523	chr5:54516805	NA	-0.58	-4.59	-0.43	1.34e-5	Height;
THYM	cis	rs72949976	0.584	rs13001511	chr2:214025262	G/A	cg08319019	chr2:214017104	IKZF2	0.82	7.28	0.6	9.55e-11	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg24154853	chr7:158122151	PTPRN2	0.52	4.83	0.44	5.3e-6	Calcium levels;
THYM	cis	rs7826238	0.543	rs2976908	chr8:8345774	T/G	cg06636001	chr8:8085503	FLJ10661	0.63	5.32	0.48	7.01e-7	Systolic blood pressure;
THYM	cis	rs3136516	0.537	rs752848	chr11:47175176	G/A	cg00724111	chr11:47209415	PACSIN3	0.38	4.71	0.43	8.51e-6	Venous thromboembolism;
THYM	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	7.76	0.62	9.5e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg08132940	chr7:1081526	C7orf50	-1.24	-7.36	-0.6	6.45e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4266144	0.558	rs34696078	chr3:156832664	G/A	cg16248515	chr3:156840234	NA	-0.52	-4.72	-0.44	8.22e-6	Coronary artery disease;
THYM	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs11031096	0.536	rs894459	chr11:4213590	A/G	cg08557956	chr11:4115526	RRM1	-0.58	-4.94	-0.45	3.34e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7605378	1.000	rs796363	chr2:200693668	T/C	cg17644776	chr2:200775616	C2orf69	0.64	4.97	0.45	2.96e-6	Osteoporosis;
THYM	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg03709012	chr19:19516395	GATAD2A	0.75	5.77	0.51	9.88e-8	Tonsillectomy;
THYM	cis	rs7926906	1.000	rs10741375	chr11:90521800	G/A	cg26138821	chr11:89956704	CHORDC1	-0.54	-4.93	-0.45	3.52e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9682041	0.740	rs6444929	chr3:170150076	C/T	cg11886554	chr3:170076028	SKIL	1.1	4.47	0.42	2.14e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-6.2	-0.54	1.47e-8	Total body bone mineral density;
THYM	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg24818145	chr4:99064322	C4orf37	0.67	5.2	0.47	1.13e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs919433	0.680	rs2565161	chr2:198285554	C/G	cg00792783	chr2:198669748	PLCL1	0.82	5.67	0.5	1.54e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7578361	1.000	rs12992696	chr2:150421937	T/A	cg17961725	chr2:150454027	NA	0.71	6.01	0.52	3.43e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg08835221	chr22:38071607	LGALS1	0.38	4.99	0.46	2.77e-6	Fat distribution (HIV);
THYM	cis	rs3772130	0.886	rs9825248	chr3:121568711	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.75	4.64	0.43	1.1e-5	Cognitive performance;
THYM	cis	rs13064411	0.696	rs35860985	chr3:113209828	C/T	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg02887458	chr19:19495540	GATAD2A	0.47	5.3	0.48	7.47e-7	Bipolar disorder;
THYM	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg18876405	chr7:65276391	NA	-0.55	-4.57	-0.42	1.49e-5	Aortic root size;
THYM	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg27423445	chr12:12879764	APOLD1	0.53	4.45	0.42	2.3e-5	Systemic lupus erythematosus;
THYM	cis	rs7107174	0.892	rs7115850	chr11:78045071	C/G	cg02023728	chr11:77925099	USP35	0.64	6.31	0.54	8.65e-9	Testicular germ cell tumor;
THYM	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg00071950	chr4:10020882	SLC2A9	0.79	8.69	0.67	1.02e-13	Bone mineral density;
THYM	cis	rs807029	0.533	rs67692077	chr10:102740271	T/C	cg14905631	chr10:102746534	C10orf2;MRPL43	0.36	4.93	0.45	3.49e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs28595532	0.920	rs17325129	chr4:119778284	T/C	cg21605333	chr4:119757512	SEC24D	1.67	6.17	0.53	1.69e-8	Cannabis dependence symptom count;
THYM	cis	rs7975161	0.630	rs4964257	chr12:104633262	T/C	cg25273343	chr12:104657179	TXNRD1	-0.77	-4.57	-0.42	1.48e-5	Toenail selenium levels;
THYM	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg02753203	chr1:228287806	NA	-0.85	-7.93	-0.63	4.22e-12	Diastolic blood pressure;
THYM	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.03	-10.67	-0.74	6.21e-18	Cognitive ability;
THYM	cis	rs988913	0.706	rs6910384	chr6:54743998	G/A	cg18532076	chr6:54711417	FAM83B	0.51	4.78	0.44	6.31e-6	Menarche (age at onset);
THYM	cis	rs329648	0.667	rs11223616	chr11:133772838	C/T	cg19961173	chr11:133788902	IGSF9B	0.52	4.5	0.42	1.89e-5	Parkinson's disease;
THYM	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs5769707	0.604	rs1018814	chr22:50036900	T/C	cg20744362	chr22:50050164	C22orf34	0.79	7.19	0.59	1.5e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6918586	0.658	rs198844	chr6:26108282	C/G	cg03517284	chr6:25882590	NA	0.71	5.57	0.5	2.4e-7	Schizophrenia;
THYM	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.6	-0.5	2.08e-7	Type 2 diabetes;
THYM	cis	rs4589258	1.000	rs10741371	chr11:90500153	A/T	cg26138821	chr11:89956704	CHORDC1	-0.7	-5.82	-0.51	8.1e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg00383909	chr3:49044727	WDR6	1.27	7.71	0.62	1.22e-11	Cognitive function;
THYM	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg25767906	chr1:53392781	SCP2	-0.53	-5.2	-0.47	1.13e-6	Monocyte count;
THYM	cis	rs7772486	0.686	rs4896827	chr6:145953338	T/A	cg23711669	chr6:146136114	FBXO30	0.92	9.06	0.68	1.72e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg15164180	chr2:241846931	NA	0.41	5.48	0.49	3.47e-7	Urinary metabolites;
THYM	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg06713675	chr4:122721982	EXOSC9	-0.88	-9.96	-0.71	1.96e-16	Type 2 diabetes;
THYM	cis	rs4845570	1.000	rs11586946	chr1:151769806	G/A	cg18019451	chr1:151746047	TDRKH	-0.76	-4.52	-0.42	1.75e-5	Coronary artery disease;
THYM	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg09165964	chr15:75287851	SCAMP5	-0.74	-5.2	-0.47	1.16e-6	Blood trace element (Zn levels);
THYM	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.95	0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs12496230	1.000	rs13079612	chr3:66840534	T/C	cg17646820	chr3:66848679	NA	0.79	4.81	0.44	5.66e-6	Type 2 diabetes;
THYM	cis	rs3017493	0.786	rs112552548	chr11:70675096	G/A	cg19942459	chr11:70508110	SHANK2	1.23	7.65	0.62	1.64e-11	Renal transplant outcome;
THYM	cis	rs6988636	1.000	rs17323510	chr8:124186089	A/G	cg23067535	chr8:124195133	FAM83A	1.09	6.01	0.53	3.34e-8	Urinary uromodulin levels;
THYM	cis	rs12476592	0.543	rs262531	chr2:63904951	A/C	cg17519650	chr2:63277830	OTX1	-0.69	-4.69	-0.43	9.3e-6	Childhood ear infection;
THYM	cis	rs988913	0.706	rs4715489	chr6:54732965	C/T	cg15217784	chr6:54722227	FAM83B	-0.53	-4.6	-0.43	1.31e-5	Menarche (age at onset);
THYM	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg17757837	chr7:157058334	UBE3C	-0.66	-5.32	-0.48	6.85e-7	Body mass index;
THYM	cis	rs10158481	0.759	rs6600260	chr1:25480027	T/A	cg09264742	chr1:25757510	TMEM57	-0.69	-5.06	-0.46	2.07e-6	Urate levels in obese individuals;
THYM	cis	rs7267979	1.000	rs4813563	chr20:25365340	T/C	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9462846	0.853	rs7740879	chr6:42873379	C/T	cg09436375	chr6:42928200	GNMT	0.37	4.51	0.42	1.82e-5	Blood protein levels;
THYM	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs919433	0.679	rs6737060	chr2:198524885	G/C	cg05783139	chr2:198650985	BOLL	0.66	4.98	0.46	2.78e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs10170846	0.893	rs1447108	chr2:223542231	A/G	cg25565276	chr2:223520875	FARSB	0.62	4.93	0.45	3.43e-6	Schizophrenia (inflammation and infection response interaction);
THYM	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg08807101	chr21:30365312	RNF160	0.8	6.25	0.54	1.15e-8	Dental caries;
THYM	cis	rs6138458	1.000	rs6114980	chr20:24974288	A/G	cg26195577	chr20:24973756	C20orf3	1.09	11.01	0.75	1.16e-18	Blood protein levels;
THYM	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Bladder cancer;
THYM	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg27087555	chr16:88793112	FAM38A	-1.25	-7.72	-0.62	1.14e-11	Plateletcrit;
THYM	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg08125733	chr17:73851984	WBP2	1.19	8.97	0.68	2.65e-14	Psoriasis;
THYM	cis	rs4731207	0.698	rs12536575	chr7:124510276	G/A	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs6733011	0.518	rs12712033	chr2:99457973	T/C	cg08885076	chr2:99613938	TSGA10	-0.47	-4.56	-0.42	1.51e-5	Bipolar disorder;
THYM	cis	rs3892630	0.878	rs8108621	chr19:33183291	G/A	cg22928329	chr19:33183273	NUDT19	-0.79	-6.13	-0.53	1.98e-8	Red blood cell traits;
THYM	cis	rs317689	0.690	rs618470	chr12:69672060	A/G	cg20891283	chr12:69753455	YEATS4	0.65	4.66	0.43	1.01e-5	Response to diuretic therapy;
THYM	cis	rs7828089	1.000	rs7828089	chr8:22264334	T/G	cg13512537	chr8:22265999	SLC39A14	-0.61	-5.13	-0.47	1.5e-6	Verbal declarative memory;
THYM	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg25358565	chr5:93447407	FAM172A	1.34	10.59	0.74	9.3e-18	Diabetic retinopathy;
THYM	cis	rs28595532	0.920	rs116098781	chr4:119771613	G/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg10523679	chr1:76189770	ACADM	0.9	9.5	0.7	1.96e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg25036284	chr2:26402008	FAM59B	0.8	5.36	0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs485842	1.000	rs485842	chr11:96023214	C/T	cg23866687	chr11:96026956	MAML2	0.44	6.23	0.54	1.28e-8	Corneal astigmatism;
THYM	cis	rs12681287	0.547	rs9942823	chr8:87509177	A/G	cg27223183	chr8:87520930	FAM82B	-0.71	-5.46	-0.49	3.8e-7	Caudate activity during reward;
THYM	cis	rs113835537	0.529	rs17147644	chr11:66256660	C/T	cg24851651	chr11:66362959	CCS	0.71	4.98	0.45	2.85e-6	Airway imaging phenotypes;
THYM	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs2797160	1.000	rs6904992	chr6:126016003	G/A	cg16306078	chr6:126000798	NA	0.54	5.56	0.5	2.5e-7	Endometrial cancer;
THYM	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg10515332	chr4:99064459	C4orf37	0.62	4.93	0.45	3.48e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg16414030	chr3:133502952	NA	-0.57	-4.97	-0.45	2.98e-6	Iron status biomarkers;
THYM	cis	rs35100037	0.803	rs10051504	chr5:128611870	A/G	cg05211662	chr5:128795605	ADAMTS19	-0.85	-5.05	-0.46	2.11e-6	Ankle injury;
THYM	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg22683308	chr4:1340831	KIAA1530	-0.64	-4.66	-0.43	1.01e-5	Obesity-related traits;
THYM	cis	rs9790314	0.967	rs336586	chr3:161081347	G/A	cg03342759	chr3:160939853	NMD3	-0.75	-6.76	-0.57	1.14e-9	Morning vs. evening chronotype;
THYM	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs6430585	0.591	rs309170	chr2:136672775	C/T	cg07169764	chr2:136633963	MCM6	0.95	8.88	0.67	4.06e-14	Corneal structure;
THYM	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg23982607	chr1:1823379	GNB1	-0.94	-10.03	-0.72	1.42e-16	Body mass index;
THYM	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11890956	chr21:40555474	PSMG1	1.1	10.98	0.75	1.36e-18	Cognitive function;
THYM	cis	rs34375054	0.660	rs57031290	chr12:125593053	A/G	cg25124228	chr12:125621409	AACS	-0.76	-5.92	-0.52	5.08e-8	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg11266682	chr4:10021025	SLC2A9	0.73	12.79	0.8	2.29e-22	Bone mineral density;
THYM	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg02725872	chr8:58115012	NA	-0.89	-5.38	-0.48	5.33e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs870825	0.616	rs28582728	chr4:185646920	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	trans	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg25214090	chr10:38739885	LOC399744	0.93	7.92	0.63	4.43e-12	Corneal astigmatism;
THYM	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg18402987	chr7:1209562	NA	1.2	6.19	0.54	1.53e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs62435770	1.000	rs62434683	chr6:169507933	T/C	cg07652237	chr6:170125491	PHF10	0.55	4.91	0.45	3.84e-6	Loneliness;
THYM	cis	rs3126085	0.935	rs3126094	chr1:152308243	T/C	cg10321714	chr1:152280068	FLG	-0.66	-4.87	-0.45	4.53e-6	Atopic dermatitis;
THYM	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg21984481	chr17:79567631	NPLOC4	-0.47	-4.95	-0.45	3.22e-6	Eye color traits;
THYM	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.25	4.91	0.45	3.72e-6	Obesity-related traits;
THYM	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs1075232	0.649	rs59591552	chr15:32238269	C/T	cg01030201	chr15:31746330	NA	-0.96	-4.5	-0.42	1.9e-5	Survival in colorectal cancer (non-distant metastatic);
THYM	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	5.09	0.46	1.8e-6	Menarche (age at onset);
THYM	cis	rs2806561	0.929	rs6660880	chr1:23540302	T/C	cg19743168	chr1:23544995	NA	-0.7	-7.68	-0.62	1.38e-11	Height;
THYM	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg26513180	chr16:89883248	FANCA	0.7	6.91	0.58	5.53e-10	Vitiligo;
THYM	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs960902	0.592	rs4450582	chr2:37734141	T/C	cg25341268	chr2:37734390	NA	-0.69	-6.28	-0.54	9.9e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.52	0.49	2.99e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7172677	1.000	rs62027286	chr15:75429720	T/C	cg09165964	chr15:75287851	SCAMP5	-0.63	-4.75	-0.44	7.24e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs686320	1.000	rs1194758	chr11:65238085	A/T	cg21144158	chr11:65211084	MIR612	-0.62	-4.55	-0.42	1.62e-5	Hip circumference adjusted for BMI;
THYM	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg02380750	chr20:61661411	NA	0.63	6.24	0.54	1.23e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6547741	0.904	rs1528403	chr2:27846645	C/G	cg27432699	chr2:27873401	GPN1	0.72	6.35	0.55	7.21e-9	Oral cavity cancer;
THYM	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg00256281	chr22:41985642	PMM1	0.63	4.9	0.45	3.93e-6	Vitiligo;
THYM	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg01191920	chr7:158217561	PTPRN2	-0.99	-10.9	-0.75	2.03e-18	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg09085632	chr11:111637200	PPP2R1B	1.04	10.46	0.73	1.69e-17	Primary sclerosing cholangitis;
THYM	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg05738196	chr6:26577821	NA	0.83	8.36	0.65	5.2e-13	Intelligence (multi-trait analysis);
THYM	cis	rs939574	1.000	rs56927225	chr2:220100922	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.32	5.96	0.52	4.29e-8	Platelet distribution width;
THYM	trans	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg10856724	chr12:34555212	NA	-0.96	-8.66	-0.66	1.22e-13	Bladder cancer;
THYM	cis	rs981844	0.816	rs74549610	chr4:154710464	C/G	cg09973105	chr4:154681532	RNF175	-0.69	-5.71	-0.51	1.27e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg18230493	chr5:56204884	C5orf35	-0.82	-5.98	-0.52	3.83e-8	Initial pursuit acceleration;
THYM	cis	rs2811415	0.561	rs9839328	chr3:127763216	T/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs710216	0.536	rs710221	chr1:43414200	G/A	cg03128534	chr1:43423976	SLC2A1	0.72	6.75	0.57	1.18e-9	Red cell distribution width;
THYM	cis	rs7586879	0.789	rs67221599	chr2:25131948	T/C	cg01884057	chr2:25150051	NA	0.52	4.64	0.43	1.12e-5	Body mass index;
THYM	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg09359103	chr1:154839909	KCNN3	-0.72	-9.45	-0.7	2.44e-15	Prostate cancer;
THYM	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg27129171	chr3:47204927	SETD2	-0.79	-7.87	-0.63	5.61e-12	Colorectal cancer;
THYM	cis	rs10216189	1.000	rs7799665	chr7:5527501	G/A	cg22586569	chr7:5524963	FBXL18	0.58	5.49	0.49	3.41e-7	Relative hand skill in reading disability;
THYM	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg10760299	chr15:45669010	GATM	0.87	6.71	0.57	1.37e-9	Metabolite levels (small molecules and protein measures);
THYM	cis	rs3820068	0.532	rs1547034	chr1:15919049	T/A	cg13390004	chr1:15929781	NA	0.66	5.06	0.46	2.05e-6	Systolic blood pressure;
THYM	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg24069376	chr3:38537580	EXOG	0.69	6.79	0.57	9.87e-10	Electrocardiographic conduction measures;
THYM	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg01304814	chr3:48885189	PRKAR2A	0.96	4.86	0.45	4.55e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs259282	0.538	rs8100917	chr19:33114702	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.62	4.78	0.44	6.5e-6	Schizophrenia;
THYM	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.54	-6.0	-0.52	3.58e-8	Autism spectrum disorder or schizophrenia;
THYM	cis	rs12190007	0.508	rs7452203	chr6:169741858	C/T	cg16388071	chr6:169726476	NA	-0.72	-6.2	-0.54	1.46e-8	Obesity-related traits;
THYM	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.92	0.45	3.58e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg18230493	chr5:56204884	C5orf35	-0.89	-6.62	-0.56	2.09e-9	Initial pursuit acceleration;
THYM	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	4.47	0.42	2.13e-5	Alzheimer's disease;
THYM	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-5.47	-0.49	3.64e-7	Monocyte percentage of white cells;
THYM	cis	rs11031096	0.505	rs10835743	chr11:4226692	C/T	cg08557956	chr11:4115526	RRM1	-0.66	-5.37	-0.48	5.63e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4654899	0.525	rs12035087	chr1:21471606	T/A	cg01072550	chr1:21505969	NA	0.76	7.43	0.61	4.71e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs2882877	0.648	rs35000023	chr2:190375710	G/T	cg10752008	chr2:190445175	SLC40A1	0.75	6.37	0.55	6.61e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7772486	0.875	rs2814876	chr6:146304030	C/T	cg23711669	chr6:146136114	FBXO30	0.93	9.82	0.71	4.07e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4243830	0.850	rs12760251	chr1:6601336	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.11	-7.56	-0.61	2.57e-11	Body mass index;
THYM	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg08017756	chr2:100939284	LONRF2	-0.72	-7.55	-0.61	2.67e-11	Intelligence (multi-trait analysis);
THYM	cis	rs533581	0.816	rs533406	chr16:88974860	A/G	cg07027457	chr16:89025522	CBFA2T3	-0.52	-4.64	-0.43	1.09e-5	Social autistic-like traits;
THYM	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.7	-5.35	-0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg16586182	chr3:47516702	SCAP	-0.61	-5.25	-0.47	9.2e-7	Colorectal cancer;
THYM	cis	rs6032067	0.641	rs761500	chr20:43772272	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	0.65	4.9	0.45	4.01e-6	Blood protein levels;
THYM	cis	rs17253792	0.558	rs10083353	chr14:56066370	G/T	cg01858014	chr14:56050164	KTN1	-1.24	-5.21	-0.47	1.11e-6	Putamen volume;
THYM	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg17911788	chr17:44343683	NA	-0.79	-7.48	-0.61	3.65e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1018697	0.518	rs2250301	chr10:104548393	G/A	cg04362960	chr10:104952993	NT5C2	-0.73	-4.97	-0.45	2.92e-6	Colorectal adenoma (advanced);
THYM	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg24733560	chr20:60626293	TAF4	0.63	6.78	0.57	9.97e-10	Body mass index;
THYM	cis	rs4731207	0.569	rs1600746	chr7:124585095	T/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs677665	0.537	rs72641831	chr1:9335173	G/T	cg03265564	chr1:9748971	PIK3CD	0.25	4.71	0.43	8.54e-6	Eosinophil percentage of white cells;
THYM	cis	rs6456042	1.000	rs4343903	chr6:166539594	T/A	cg11088901	chr6:166572345	T	-0.52	-4.9	-0.45	3.93e-6	Asthma;
THYM	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg15592062	chr6:167189543	RPS6KA2	-0.58	-5.91	-0.52	5.35e-8	Crohn's disease;
THYM	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg08132940	chr7:1081526	C7orf50	-1.1	-4.53	-0.42	1.73e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg02176678	chr2:219576539	TTLL4	0.72	7.17	0.59	1.63e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2361710	0.668	rs2304855	chr17:78118266	T/A	cg09238746	chr17:78121135	EIF4A3	-0.78	-6.43	-0.55	5e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
THYM	cis	rs1065852	0.526	rs9607869	chr22:42418110	T/A	cg22189786	chr22:42395067	WBP2NL	0.56	5.61	0.5	1.95e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs9297145	0.585	rs13235218	chr7:98785080	C/T	cg05967295	chr7:98741636	SMURF1	-0.67	-4.96	-0.45	3.09e-6	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg05368731	chr17:41323189	NBR1	1.21	10.98	0.75	1.38e-18	Menopause (age at onset);
THYM	trans	rs11722228	0.522	rs73212808	chr4:10055439	G/C	cg26043149	chr18:55253948	FECH	1.22	11.01	0.75	1.2e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg20503657	chr10:835505	NA	1.1	7.59	0.61	2.18e-11	Eosinophil percentage of granulocytes;
THYM	cis	rs3826795	0.530	rs117992292	chr19:46797295	A/G	cg15229275	chr19:46800054	HIF3A	0.92	5.54	0.49	2.69e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs10411161	0.702	rs2867319	chr19:52397160	T/C	cg25361850	chr19:52391789	ZNF577	0.74	4.96	0.45	3.14e-6	Breast cancer;
THYM	cis	rs7851660	0.805	rs4255258	chr9:100647545	A/G	cg13688889	chr9:100608707	NA	-0.7	-4.78	-0.44	6.3e-6	Strep throat;
THYM	trans	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg10856724	chr12:34555212	NA	-0.95	-8.39	-0.65	4.46e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	7.8	0.62	7.81e-12	Platelet count;
THYM	cis	rs1865721	0.771	rs4622605	chr18:73139008	T/C	cg26385618	chr18:73139727	C18orf62	-0.65	-4.75	-0.44	7.3e-6	Intelligence;
THYM	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg17747265	chr1:1875780	NA	-0.77	-9.13	-0.68	1.17e-14	Body mass index;
THYM	cis	rs4072705	0.646	rs2416933	chr9:127245529	C/T	cg01786973	chr9:127249749	NR5A1	-0.38	-4.75	-0.44	7.31e-6	Menarche (age at onset);
THYM	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg17264618	chr3:40429014	ENTPD3	-0.53	-5.15	-0.47	1.38e-6	Renal cell carcinoma;
THYM	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	4.99	0.46	2.76e-6	Schizophrenia;
THYM	cis	rs59112743	0.510	rs9476844	chr6:15554019	C/T	cg10111214	chr6:14815676	NA	0.77	5.0	0.46	2.66e-6	Multiple keratinocyte cancers;
THYM	cis	rs3126085	0.935	rs3126048	chr1:152260165	T/C	cg26020982	chr1:152196106	HRNR	-0.35	-4.95	-0.45	3.26e-6	Atopic dermatitis;
THYM	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg07636037	chr3:49044803	WDR6	1.0	10.57	0.73	1.03e-17	Parkinson's disease;
THYM	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg13918804	chr1:2043761	PRKCZ	-0.61	-4.62	-0.43	1.19e-5	Height;
THYM	cis	rs75059851	0.756	rs11223646	chr11:133839560	C/T	cg14047540	chr11:133829660	NA	-1.06	-7.03	-0.58	3.14e-10	Schizophrenia;
THYM	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs61612642	0.537	rs73434275	chr6:42156239	G/A	cg01092361	chr6:42185687	MRPS10	0.96	5.86	0.52	6.66e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs6938	0.640	rs2415251	chr15:75242155	T/C	cg02696790	chr15:75250997	RPP25	0.5	4.57	0.42	1.46e-5	Breast cancer;
THYM	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg22431228	chr1:16359049	CLCNKA	0.53	4.65	0.43	1.05e-5	Dilated cardiomyopathy;
THYM	cis	rs7731657	0.508	rs6595974	chr5:130327530	C/T	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg00801512	chr17:28996047	NA	-0.76	-5.02	-0.46	2.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4842666	0.765	rs4842675	chr12:90075243	C/T	cg00757033	chr12:89920650	WDR51B	0.46	4.58	0.43	1.42e-5	Blood pressure;
THYM	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg05717871	chr11:638507	DRD4	-0.67	-5.07	-0.46	1.95e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs4889855	0.516	rs4890041	chr17:78521114	A/T	cg16591659	chr17:78472290	NA	0.43	5.0	0.46	2.65e-6	Fractional excretion of uric acid;
THYM	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg18105134	chr13:113819100	PROZ	0.98	9.05	0.68	1.79e-14	Platelet distribution width;
THYM	cis	rs3847687	0.901	rs12370258	chr12:131527301	G/T	cg25772418	chr12:131519998	GPR133	-0.35	-4.66	-0.43	1.02e-5	Longevity;
THYM	cis	rs3924048	0.574	rs11121925	chr1:12613130	A/C	cg00291366	chr1:12616550	NA	0.38	5.86	0.52	6.62e-8	Optic cup area;
THYM	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg16031515	chr1:205743344	RAB7L1	0.53	4.58	0.43	1.43e-5	Menarche (age at onset);
THYM	cis	rs11112613	0.713	rs58066965	chr12:105952505	C/G	cg03607813	chr12:105948248	NA	0.99	8.2	0.64	1.17e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	trans	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17712092	chr4:129076599	LARP1B	0.91	7.62	0.62	1.87e-11	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs9581943	0.967	rs9554193	chr13:28471366	G/A	cg16302790	chr13:28498334	PDX1	0.52	4.59	0.43	1.33e-5	Pancreatic cancer;
THYM	cis	rs11252926	0.523	rs816596	chr10:548004	C/T	cg03684893	chr10:554711	DIP2C	-0.59	-4.98	-0.46	2.82e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs62064224	0.589	rs756785	chr17:30812845	T/C	cg18200150	chr17:30822561	MYO1D	0.55	4.5	0.42	1.96e-5	Schizophrenia;
THYM	cis	rs6921919	0.583	rs9468370	chr6:28368940	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.5	-0.42	1.89e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11039798	0.764	rs12418936	chr11:48986418	T/C	cg24672777	chr11:48374446	OR4C45	-1.1	-6.15	-0.53	1.81e-8	Axial length;
THYM	cis	rs2997447	0.846	rs3008415	chr1:26404441	C/T	cg03844060	chr1:26490628	NA	0.67	4.53	0.42	1.73e-5	QRS complex (12-leadsum);
THYM	cis	rs4924590	0.550	rs1426889	chr15:42231658	C/T	cg20935245	chr15:42234343	EHD4	-0.4	-4.49	-0.42	2.01e-5	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
THYM	cis	rs72827839	0.779	rs72827808	chr17:46352080	C/A	cg23391107	chr17:45924227	SP6	0.86	5.56	0.5	2.49e-7	Ease of getting up in the morning;
THYM	cis	rs2046867	0.908	rs62251639	chr3:72801214	G/A	cg25664220	chr3:72788482	NA	-0.86	-6.54	-0.56	3.05e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs9902453	0.933	rs4470197	chr17:28464474	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.84	0.44	5.09e-6	Coffee consumption (cups per day);
THYM	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg15733309	chr7:157513707	PTPRN2	0.52	5.79	0.51	9.15e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg21433313	chr16:3507492	NAT15	0.54	4.73	0.44	7.71e-6	Body mass index (adult);
THYM	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg02136620	chr5:178986620	RUFY1	-0.55	-5.63	-0.5	1.79e-7	Lung cancer;
THYM	cis	rs2235649	0.789	rs9939680	chr16:1852720	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs7084402	1.000	rs1427201	chr10:60269755	G/T	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs34779708	0.931	rs4934533	chr10:35359619	A/G	cg03585969	chr10:35415529	CREM	0.63	4.66	0.43	1.01e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6032067	0.598	rs2741500	chr20:43944958	G/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.59	-6.1	-0.53	2.33e-8	Blood protein levels;
THYM	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg16558253	chr16:72132732	DHX38	-0.59	-5.05	-0.46	2.17e-6	Fibrinogen levels;
THYM	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg17294928	chr15:75287854	SCAMP5	-1.02	-8.79	-0.67	6.45e-14	Blood trace element (Zn levels);
THYM	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7599312	0.534	rs10180824	chr2:213407975	G/A	cg20637307	chr2:213403960	ERBB4	1.0	10.5	0.73	1.43e-17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.81	-6.29	-0.54	9.55e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg07570687	chr10:102243282	WNT8B	0.75	6.92	0.58	5.2e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9522267	0.707	rs9522282	chr13:112222410	T/C	cg10483660	chr13:112241077	NA	-0.6	-6.31	-0.54	8.65e-9	Hepatitis;
THYM	cis	rs4589258	0.737	rs2186613	chr11:90418008	C/G	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg07021052	chr2:20871279	NA	-0.71	-5.71	-0.51	1.31e-7	Abdominal aortic aneurysm;
THYM	cis	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg12292205	chr6:26970375	C6orf41	-1.02	-5.06	-0.46	2.04e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg00981070	chr1:2046702	PRKCZ	0.47	5.24	0.47	9.63e-7	Height;
THYM	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs6754311	0.509	rs3820794	chr2:136505546	C/T	cg23851026	chr2:136556271	LCT	-0.61	-6.01	-0.53	3.36e-8	Mosquito bite size;
THYM	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg14196790	chr5:131705035	SLC22A5	-0.67	-6.69	-0.57	1.55e-9	Blood metabolite levels;
THYM	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg25811766	chr13:21894605	NA	0.78	5.13	0.47	1.52e-6	White matter hyperintensity burden;
THYM	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg06009448	chr7:1102226	C7orf50	0.5	5.2	0.47	1.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs968451	0.552	rs715505	chr22:39751251	G/C	cg24268161	chr22:39747459	SYNGR1	-0.67	-5.43	-0.49	4.38e-7	Primary biliary cholangitis;
THYM	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs67072384	1.000	rs7120605	chr11:72444615	A/G	cg01380194	chr11:72452482	ARAP1	-0.85	-4.84	-0.45	4.92e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.13	7.78	0.62	8.66e-12	Smoking behavior;
THYM	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg04362960	chr10:104952993	NT5C2	0.6	5.11	0.46	1.66e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg10661904	chr17:79619235	PDE6G	-0.58	-5.3	-0.48	7.36e-7	Eye color traits;
THYM	cis	rs554111	0.636	rs10916935	chr1:21432112	T/C	cg00373020	chr1:21041521	KIF17	-0.55	-4.65	-0.43	1.06e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg10047753	chr17:41438598	NA	-1.2	-11.56	-0.76	8.14e-20	Menopause (age at onset);
THYM	cis	rs2046867	0.862	rs11920131	chr3:72858630	C/G	cg25664220	chr3:72788482	NA	-0.86	-6.77	-0.57	1.04e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs17604090	0.701	rs60930239	chr7:29688544	A/G	cg19413766	chr7:29689036	LOC646762	-0.91	-5.02	-0.46	2.37e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg06789500	chr7:2109450	MAD1L1	-0.65	-4.46	-0.42	2.24e-5	Neuroticism;
THYM	cis	rs4660531	1.000	rs4660531	chr1:41839822	G/T	cg19619003	chr1:41846758	NA	-0.24	-4.51	-0.42	1.84e-5	Bipolar disorder;
THYM	cis	rs57590327	0.503	rs13079104	chr3:81886039	A/T	cg07356753	chr3:81810745	GBE1	-0.78	-5.68	-0.5	1.45e-7	Extraversion;
THYM	cis	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg06521331	chr12:34319734	NA	-1.01	-9.28	-0.69	5.59e-15	Morning vs. evening chronotype;
THYM	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg09436375	chr6:42928200	GNMT	-0.42	-5.48	-0.49	3.51e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg05738196	chr6:26577821	NA	0.94	10.05	0.72	1.28e-16	Intelligence (multi-trait analysis);
THYM	cis	rs7542939	1.000	rs35042965	chr1:14184325	C/G	cg14041921	chr1:15130959	KIAA1026	1.01	4.46	0.42	2.29e-5	Left ventricular function change in anthracycline treatment;
THYM	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg09323728	chr8:95962352	TP53INP1	-0.47	-4.66	-0.43	1.01e-5	Type 2 diabetes;
THYM	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg06850241	chr22:41845214	NA	0.54	4.77	0.44	6.68e-6	Vitiligo;
THYM	cis	rs2334880	0.836	rs9934715	chr16:71757387	C/G	cg06353428	chr16:71660113	MARVELD3	1.39	9.52	0.7	1.78e-15	Malaria;
THYM	cis	rs1011018	0.590	rs10278124	chr7:139416939	C/G	cg06079564	chr7:139468310	HIPK2	-0.75	-4.84	-0.44	5.09e-6	Systolic blood pressure;
THYM	cis	rs1775715	0.737	rs2799031	chr10:32173168	C/T	cg04359828	chr10:32216031	ARHGAP12	0.39	5.13	0.47	1.52e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg22172494	chr11:2017362	H19	-0.5	-4.56	-0.42	1.52e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61931739	0.529	rs1525900	chr12:33976652	T/G	cg10856724	chr12:34555212	NA	-0.65	-6.14	-0.53	1.9e-8	Morning vs. evening chronotype;
THYM	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg16049864	chr8:95962084	TP53INP1	-0.82	-7.41	-0.6	5.27e-11	Type 2 diabetes;
THYM	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg23583168	chr7:148888333	NA	-0.93	-10.3	-0.73	3.74e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs1023500	1.000	rs1023499	chr22:42340582	T/C	cg19448990	chr22:41842841	TOB2	-0.76	-4.89	-0.45	4.06e-6	Schizophrenia;
THYM	cis	rs7578361	0.959	rs12329354	chr2:150452719	C/G	cg17961725	chr2:150454027	NA	0.71	5.81	0.51	8.13e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg19677267	chr1:26645161	CD52;UBXN11	-0.49	-6.58	-0.56	2.58e-9	Monocyte percentage of white cells;
THYM	cis	rs11840576	0.643	rs149577	chr13:110318648	G/A	cg24915592	chr13:110319578	NA	-0.78	-6.22	-0.54	1.36e-8	Paclitaxel disposition in epithelial ovarian cancer;
THYM	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg09307838	chr4:120376055	NA	0.68	4.93	0.45	3.43e-6	Corneal astigmatism;
THYM	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs7582180	0.663	rs10199518	chr2:100946041	G/A	cg08017756	chr2:100939284	LONRF2	-0.74	-7.68	-0.62	1.41e-11	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.75	-5.5	-0.49	3.17e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2625529	0.668	rs34189331	chr15:72404573	A/T	cg16672083	chr15:72433130	SENP8	-0.6	-5.51	-0.49	3.03e-7	Red blood cell count;
THYM	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg18681998	chr4:17616180	MED28	1.02	10.17	0.72	7.03e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7426056	0.530	rs62183985	chr2:204577204	G/A	cg13651908	chr2:204570033	CD28	-0.7	-5.33	-0.48	6.55e-7	Primary sclerosing cholangitis;
THYM	cis	rs12476592	0.602	rs2305157	chr2:63822785	T/C	cg17519650	chr2:63277830	OTX1	-0.7	-4.71	-0.44	8.46e-6	Childhood ear infection;
THYM	cis	rs713587	0.776	rs1172294	chr2:25169200	A/G	cg15423357	chr2:25149977	NA	0.61	6.54	0.56	3.06e-9	Body mass index in non-asthmatics;
THYM	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg06009448	chr7:1102226	C7orf50	0.48	5.01	0.46	2.55e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17539620	0.624	rs62432739	chr6:154835926	A/G	cg20019720	chr6:154832845	CNKSR3	0.47	4.79	0.44	6.17e-6	Lipoprotein (a) levels;
THYM	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg17294928	chr15:75287854	SCAMP5	0.64	4.55	0.42	1.58e-5	Breast cancer;
THYM	cis	rs6748734	0.857	rs4675857	chr2:241842326	T/C	cg04034577	chr2:241836375	C2orf54	-0.47	-8.21	-0.64	1.11e-12	Urinary metabolites;
THYM	cis	rs250677	0.522	rs2895837	chr5:148357535	C/T	cg18129178	chr5:148520854	ABLIM3	0.72	5.42	0.49	4.44e-7	Breast cancer;
THYM	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg05738196	chr6:26577821	NA	-0.57	-4.55	-0.42	1.61e-5	Schizophrenia;
THYM	cis	rs4731207	0.596	rs1871774	chr7:124674898	A/G	cg05285228	chr7:124571219	POT1	-0.65	-4.98	-0.45	2.9e-6	Cutaneous malignant melanoma;
THYM	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs10037758	0.630	rs2577434	chr5:128309803	G/A	cg02841155	chr5:128301328	SLC27A6	-0.56	-5.69	-0.5	1.38e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs4866334	1.000	rs6866535	chr5:18431650	G/A	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs6429082	0.783	rs291364	chr1:235687179	A/G	cg26050004	chr1:235667680	B3GALNT2	0.78	6.83	0.57	8.01e-10	Adiposity;
THYM	cis	rs17122693	0.688	rs72681637	chr14:51152761	C/A	cg04730355	chr14:51134070	SAV1	0.95	5.86	0.52	6.6e-8	Cognitive performance;
THYM	cis	rs1994135	0.715	rs10844625	chr12:33693006	C/T	cg06521331	chr12:34319734	NA	-0.65	-4.68	-0.43	9.49e-6	Resting heart rate;
THYM	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg10515332	chr4:99064459	C4orf37	-0.63	-5.02	-0.46	2.42e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg16928487	chr17:17741425	SREBF1	-0.56	-5.36	-0.48	5.91e-7	Total body bone mineral density;
THYM	cis	rs1335645	1.000	rs2296380	chr1:111721354	A/C	cg00321911	chr1:111669324	DRAM2	1.05	6.06	0.53	2.7e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg21784768	chr11:537496	LRRC56	-1.37	-6.17	-0.53	1.7e-8	Body mass index;
THYM	cis	rs1697139	0.583	rs1428475	chr5:66543954	G/T	cg11553311	chr5:66541588	NA	0.71	7.63	0.62	1.78e-11	Breast cancer;
THYM	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg13319975	chr6:146136371	FBXO30	-0.67	-5.44	-0.49	4.21e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4866334	1.000	rs80007833	chr5:18489203	G/T	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs289828	0.519	rs289903	chr2:152084705	G/A	cg05960677	chr2:152117363	RBM43	-0.73	-7.34	-0.6	7.35e-11	Blood protein levels;
THYM	cis	rs7677751	0.806	rs6554163	chr4:55102559	A/T	cg17187183	chr4:55093834	PDGFRA	0.74	5.58	0.5	2.26e-7	Corneal astigmatism;
THYM	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.49e-10	Prudent dietary pattern;
THYM	trans	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.18	-12.56	-0.79	6.84e-22	Exhaled nitric oxide output;
THYM	cis	rs1348850	0.958	rs10930799	chr2:178459325	G/C	cg27490568	chr2:178487706	NA	0.62	5.73	0.51	1.19e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1448094	0.506	rs61930640	chr12:86173333	T/C	cg00310523	chr12:86230176	RASSF9	0.56	5.14	0.47	1.48e-6	Major depressive disorder;
THYM	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.56	-4.72	-0.44	8.05e-6	Platelet count;
THYM	cis	rs4481887	0.741	rs6587471	chr1:248560741	C/T	cg00666640	chr1:248458726	OR2T12	0.54	4.62	0.43	1.22e-5	Common traits (Other);
THYM	cis	rs34638657	0.500	rs7405197	chr16:82169833	C/A	cg07307142	chr16:82071433	HSD17B2	-0.87	-7.2	-0.59	1.37e-10	Lung adenocarcinoma;
THYM	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.25	-10.33	-0.73	3.19e-17	Platelet count;
THYM	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg04398451	chr17:18023971	MYO15A	0.9	9.71	0.71	6.98e-16	Total body bone mineral density;
THYM	cis	rs10492096	1.000	rs11064218	chr12:6586261	C/T	cg13857086	chr12:6580257	VAMP1	0.9	5.37	0.48	5.53e-7	Hip geometry;
THYM	cis	rs6598955	0.671	rs59143843	chr1:26641595	G/T	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.7	0.43	8.83e-6	Obesity-related traits;
THYM	cis	rs919433	0.680	rs67580728	chr2:198431258	C/T	cg00792783	chr2:198669748	PLCL1	0.82	5.8	0.51	8.74e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg05340658	chr4:99064831	C4orf37	0.54	4.52	0.42	1.76e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2108225	0.934	rs2283044	chr7:107440553	A/G	cg18560240	chr7:107437656	SLC26A3	0.72	5.02	0.46	2.44e-6	Ulcerative colitis;
THYM	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg15247329	chr7:2764246	NA	-0.69	-5.76	-0.51	1.02e-7	Height;
THYM	cis	rs6906287	0.647	rs3734381	chr6:118887303	A/G	cg21191810	chr6:118973309	C6orf204	0.54	5.24	0.47	9.58e-7	Electrocardiographic conduction measures;
THYM	cis	rs2248020	0.501	rs2263368	chr11:93264680	A/C	cg15737290	chr11:93063684	CCDC67	0.8	5.51	0.49	3.07e-7	Insulin levels in response to oral glucose tolerance test (30 minutes);
THYM	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs13315871	0.929	rs34676912	chr3:58320298	C/A	cg12435725	chr3:58293450	RPP14	-0.47	-4.91	-0.45	3.82e-6	Cholesterol, total;
THYM	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.39	5.44	0.49	4.06e-7	Obesity-related traits;
THYM	cis	rs4481887	0.893	rs10888349	chr1:248448625	T/C	cg00666640	chr1:248458726	OR2T12	0.54	4.57	0.42	1.48e-5	Common traits (Other);
THYM	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg22681709	chr2:178499509	PDE11A	-0.6	-5.78	-0.51	9.6e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.66	-5.7	-0.5	1.37e-7	Renal function-related traits (BUN);
THYM	cis	rs865483	0.929	rs853214	chr17:35860964	T/C	cg06716730	chr17:35851459	DUSP14	0.41	6.59	0.56	2.48e-9	Monocyte count;
THYM	cis	rs7586879	0.639	rs2384058	chr2:25100328	A/G	cg01884057	chr2:25150051	NA	0.7	7.38	0.6	6.09e-11	Body mass index;
THYM	cis	rs57590327	0.503	rs7631052	chr3:81866235	C/A	cg07356753	chr3:81810745	GBE1	-0.83	-6.13	-0.53	2e-8	Extraversion;
THYM	cis	rs10895275	0.649	rs4420227	chr11:102036484	C/T	cg24447756	chr11:102105824	NA	-0.52	-4.97	-0.45	2.91e-6	Migraine;
THYM	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg15242686	chr22:24348715	GSTTP1	0.68	7.23	0.6	1.19e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg27535305	chr1:53392650	SCP2	-0.4	-4.52	-0.42	1.78e-5	Monocyte count;
THYM	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg15445000	chr17:37608096	MED1	-0.44	-5.07	-0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg24675056	chr1:15929824	NA	0.73	5.86	0.52	6.71e-8	Systolic blood pressure;
THYM	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg19336497	chr11:14380999	RRAS2	0.54	5.8	0.51	8.71e-8	Mitochondrial DNA levels;
THYM	cis	rs1728785	0.901	rs698711	chr16:68561955	C/T	cg02972257	chr16:68554789	NA	-0.75	-4.63	-0.43	1.16e-5	Ulcerative colitis;
THYM	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.74	8.12	0.64	1.7e-12	Eosinophil percentage of white cells;
THYM	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg24060327	chr5:131705240	SLC22A5	-0.69	-5.15	-0.47	1.39e-6	Breast cancer;
THYM	cis	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg10360139	chr7:1886902	MAD1L1	-0.58	-4.61	-0.43	1.23e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg05283184	chr6:79620031	NA	-0.88	-8.42	-0.65	3.86e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg13447684	chr7:1895903	MAD1L1	0.58	4.87	0.45	4.38e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg00083206	chr6:110721305	DDO	-0.49	-5.62	-0.5	1.94e-7	Platelet distribution width;
THYM	cis	rs7851660	0.967	rs7043885	chr9:100596439	C/T	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs12627970	0.565	rs2072872	chr22:39713128	A/G	cg24268161	chr22:39747459	SYNGR1	-0.57	-4.46	-0.42	2.25e-5	Inflammatory bowel disease;
THYM	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg06981504	chr1:1234844	ACAP3	0.53	4.86	0.45	4.65e-6	Body mass index;
THYM	cis	rs611744	0.870	rs635941	chr8:109235457	G/A	cg21045802	chr8:109455806	TTC35	0.71	6.67	0.56	1.69e-9	Dupuytren's disease;
THYM	cis	rs7089973	0.604	rs12218498	chr10:116578489	T/C	cg23260525	chr10:116636907	FAM160B1	0.53	5.29	0.48	7.75e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7567389	0.505	rs1518760	chr2:128140500	T/G	cg06038358	chr2:128176007	PROC	0.46	4.91	0.45	3.83e-6	Self-rated health;
THYM	cis	rs6429082	0.791	rs61836205	chr1:235638753	C/G	cg26050004	chr1:235667680	B3GALNT2	0.73	6.03	0.53	3.16e-8	Adiposity;
THYM	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg12599982	chr1:44399894	ARTN	0.58	5.04	0.46	2.18e-6	Intelligence (multi-trait analysis);
THYM	cis	rs921968	0.565	rs12612395	chr2:219621642	G/C	cg02176678	chr2:219576539	TTLL4	-0.47	-4.56	-0.42	1.55e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6032067	0.929	rs1997892	chr20:43810961	A/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs128738	0.500	rs60168911	chr5:131565460	T/C	cg22598563	chr5:131563921	P4HA2	0.57	4.91	0.45	3.77e-6	Giant cell arteritis;
THYM	cis	rs2692947	0.683	rs1813381	chr2:96422939	C/T	cg22654517	chr2:96458247	NA	-0.79	-5.55	-0.5	2.53e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg23161317	chr6:28129485	ZNF389	-0.98	-7.27	-0.6	1.03e-10	Parkinson's disease;
THYM	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.07	-6.19	-0.54	1.52e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14159672	chr1:205819179	PM20D1	0.98	10.2	0.72	6.32e-17	Menarche (age at onset);
THYM	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg20712883	chr12:51590929	POU6F1	0.85	5.47	0.49	3.65e-7	Cisplatin-induced ototoxicity;
THYM	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg18876405	chr7:65276391	NA	0.76	7.17	0.59	1.61e-10	Calcium levels;
THYM	cis	rs1555322	0.530	rs2425047	chr20:33871675	G/T	cg08999081	chr20:33150536	PIGU	-0.6	-4.45	-0.42	2.29e-5	Attention deficit hyperactivity disorder;
THYM	cis	rs7722022	0.519	rs750168	chr5:172902359	A/C	cg18512156	chr5:172661970	NKX2-5	-0.55	-4.63	-0.43	1.16e-5	Adiponectin levels;
THYM	cis	rs6964587	0.626	rs4729014	chr7:91550707	A/G	cg22709100	chr7:91322751	NA	-0.62	-4.64	-0.43	1.1e-5	Breast cancer;
THYM	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.68	9.11	0.68	1.34e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4654899	0.714	rs12123093	chr1:21114416	C/T	cg01072550	chr1:21505969	NA	-0.64	-5.59	-0.5	2.18e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg00012203	chr2:219082015	ARPC2	0.89	8.63	0.66	1.37e-13	Colorectal cancer;
THYM	cis	rs9788682	0.694	rs10851906	chr15:78774676	A/G	cg18825076	chr15:78729989	IREB2	0.7	5.57	0.5	2.39e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg18105134	chr13:113819100	PROZ	0.98	9.05	0.68	1.79e-14	Platelet distribution width;
THYM	cis	rs2637266	1.000	rs10219021	chr10:78364516	C/T	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs4072705	0.646	rs2416933	chr9:127245529	C/T	cg13476313	chr9:127244764	NR5A1	-0.34	-4.77	-0.44	6.55e-6	Menarche (age at onset);
THYM	cis	rs9810089	0.527	rs661739	chr3:135953476	C/T	cg12473912	chr3:136751656	NA	0.7	6.49	0.55	3.95e-9	Gestational age at birth (child effect);
THYM	cis	rs7568458	0.846	rs6743030	chr2:85763520	C/T	cg17127132	chr2:85788382	GGCX	0.72	6.21	0.54	1.42e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs983545	0.548	rs1348109	chr3:16949514	A/G	cg19448816	chr3:16974217	PLCL2	0.51	4.66	0.43	1.03e-5	Blood protein levels;
THYM	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs514406	0.825	rs12089511	chr1:53436427	A/T	cg25767906	chr1:53392781	SCP2	0.58	5.84	0.51	7.3e-8	Monocyte count;
THYM	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.08	7.64	0.62	1.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4731207	0.662	rs6973134	chr7:124515373	G/A	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg22535103	chr8:58192502	C8orf71	-0.96	-5.47	-0.49	3.7e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs9611565	0.506	rs2024566	chr22:41697338	A/G	cg06481639	chr22:41940642	POLR3H	-0.62	-4.78	-0.44	6.36e-6	Vitiligo;
THYM	cis	rs28795989	0.795	rs6848540	chr4:7904779	T/A	cg00251875	chr4:7801337	AFAP1	0.61	4.93	0.45	3.53e-6	Intraocular pressure;
THYM	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg15445000	chr17:37608096	MED1	-0.44	-5.22	-0.47	1.07e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs10752881	0.740	rs1889307	chr1:183049389	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.74	0.44	7.58e-6	Colorectal cancer;
THYM	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs8002861	0.846	rs12867732	chr13:44483084	C/A	cg17145862	chr1:211918768	LPGAT1	-0.89	-8.33	-0.65	5.99e-13	Leprosy;
THYM	cis	rs7546094	0.508	rs12042407	chr1:113183879	A/T	cg25616829	chr1:112535356	NA	-0.58	-4.71	-0.44	8.34e-6	Platelet distribution width;
THYM	cis	rs4319547	0.695	rs6488939	chr12:122858250	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.7	-4.57	-0.42	1.46e-5	Body mass index;
THYM	cis	rs9296092	0.560	rs9469502	chr6:33526648	G/A	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs6918586	0.636	rs198816	chr6:26127184	C/T	cg03517284	chr6:25882590	NA	0.71	5.64	0.5	1.75e-7	Schizophrenia;
THYM	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg08999081	chr20:33150536	PIGU	0.62	5.04	0.46	2.25e-6	Coronary artery disease;
THYM	cis	rs36051895	0.659	rs12351277	chr9:5061405	A/C	cg02405213	chr9:5042618	JAK2	-1.0	-10.8	-0.74	3.19e-18	Pediatric autoimmune diseases;
THYM	cis	rs12928939	0.911	rs12917983	chr16:71835243	A/C	cg03805757	chr16:71968109	PKD1L3	-0.7	-5.31	-0.48	7.25e-7	Post bronchodilator FEV1;
THYM	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg02176678	chr2:219576539	TTLL4	0.73	7.25	0.6	1.09e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs73001065	0.591	rs57962361	chr19:19425025	C/T	cg03709012	chr19:19516395	GATAD2A	1.06	4.47	0.42	2.18e-5	LDL cholesterol;
THYM	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.93	7.86	0.63	5.86e-12	Multiple sclerosis;
THYM	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg20290983	chr6:43655470	MRPS18A	1.18	7.83	0.63	6.96e-12	IgG glycosylation;
THYM	cis	rs34112283	0.592	rs13011344	chr2:144186545	T/G	cg17056048	chr2:144271431	ARHGAP15	0.66	6.71	0.57	1.43e-9	Neuroticism;
THYM	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg13147721	chr7:65941812	NA	-0.73	-4.56	-0.42	1.52e-5	Diabetic kidney disease;
THYM	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.8	-5.37	-0.48	5.58e-7	Schizophrenia;
THYM	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg23803603	chr1:2058230	PRKCZ	-0.61	-5.54	-0.49	2.74e-7	Height;
THYM	cis	rs2209875	0.588	rs7469084	chr9:91981163	A/G	cg13881405	chr9:92220388	GADD45G	-0.48	-4.98	-0.45	2.89e-6	Pelvic organ prolapse (moderate/severe);
THYM	cis	rs7089973	0.872	rs7918388	chr10:116614563	T/C	cg08188268	chr10:116634841	FAM160B1	-0.3	-4.93	-0.45	3.54e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs6987853	0.933	rs2923401	chr8:42442208	T/C	cg09913449	chr8:42400586	C8orf40	0.85	7.97	0.63	3.56e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg06766960	chr11:133703094	NA	-0.61	-5.42	-0.49	4.41e-7	Childhood ear infection;
THYM	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg11245990	chr11:68621969	NA	-0.56	-7.38	-0.6	5.84e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.24e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.61	-5.44	-0.49	4.16e-7	Height;
THYM	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg12893428	chr3:195717962	SDHAP1	0.54	4.8	0.44	5.93e-6	Pancreatic cancer;
THYM	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg08999081	chr20:33150536	PIGU	-0.8	-7.22	-0.6	1.25e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs36051895	0.623	rs1830610	chr9:5260079	C/T	cg02405213	chr9:5042618	JAK2	-0.94	-9.63	-0.7	1.03e-15	Pediatric autoimmune diseases;
THYM	cis	rs3181245	0.641	rs3756821	chr6:24646821	C/T	cg02828016	chr6:24646676	KIAA0319	-0.62	-5.04	-0.46	2.22e-6	Colorectal or endometrial cancer;
THYM	cis	rs5760092	0.717	rs5760101	chr22:24248712	T/C	cg04234412	chr22:24373322	LOC391322	-0.75	-5.66	-0.5	1.6e-7	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs332034	0.591	rs7017739	chr8:8707639	C/G	cg06636001	chr8:8085503	FLJ10661	-0.86	-4.67	-0.43	9.98e-6	Conduct disorder (maternal expressed emotions interaction);
THYM	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg03806693	chr22:41940476	POLR3H	-1.2	-10.08	-0.72	1.13e-16	Vitiligo;
THYM	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg14517863	chr17:44321492	NA	0.45	4.97	0.45	2.91e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg24531977	chr5:56204891	C5orf35	-1.02	-8.43	-0.65	3.74e-13	Initial pursuit acceleration;
THYM	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg03929089	chr4:120376271	NA	-0.98	-12.21	-0.78	3.51e-21	Coronary artery disease;
THYM	cis	rs13137105	0.720	rs3775531	chr4:76408064	C/G	cg03209871	chr4:76438412	RCHY1;THAP6	-0.48	-5.58	-0.5	2.3e-7	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg07936489	chr17:37558343	FBXL20	0.82	5.61	0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs59698941	0.943	rs17691542	chr5:132279227	T/C	cg02081065	chr5:132209139	LEAP2	-0.84	-5.65	-0.5	1.65e-7	Apolipoprotein A-IV levels;
THYM	cis	rs7224685	0.501	rs11649992	chr17:4026823	A/G	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.87	4.72	0.44	8.19e-6	Type 2 diabetes;
THYM	cis	rs7103648	1.000	rs7947450	chr11:47429904	G/A	cg20307385	chr11:47447363	PSMC3	0.93	8.66	0.66	1.23e-13	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs6785206	0.667	rs6439139	chr3:128410285	T/C	cg16766828	chr3:128327626	NA	-0.77	-7.49	-0.61	3.53e-11	Lymphocyte percentage of white cells;
THYM	cis	rs8064299	0.584	rs2384957	chr17:72784630	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.88	8.77	0.67	7.13e-14	Monocyte count;
THYM	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.96e-6	Resting heart rate;
THYM	cis	rs62435770	1.000	rs62433595	chr6:169519081	T/C	cg07652237	chr6:170125491	PHF10	0.5	4.68	0.43	9.45e-6	Loneliness;
THYM	cis	rs6988636	1.000	rs4282551	chr8:124185916	G/A	cg23067535	chr8:124195133	FAM83A	-1.1	-5.77	-0.51	9.8e-8	Urinary uromodulin levels;
THYM	cis	rs9560113	1.000	rs2104790	chr13:112177412	C/T	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs6127978	0.759	rs162311	chr20:55802736	T/C	cg15851418	chr20:55835831	BMP7	0.63	4.96	0.45	3.02e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-4.8	-0.44	5.96e-6	Cognitive function;
THYM	cis	rs3540	0.533	rs11633692	chr15:91056043	G/A	cg22089800	chr15:90895588	ZNF774	-0.68	-5.13	-0.47	1.51e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg26924012	chr15:45694286	SPATA5L1	1.03	9.3	0.69	5.23e-15	Homoarginine levels;
THYM	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg20387954	chr3:183756860	HTR3D	0.55	4.61	0.43	1.23e-5	Anterior chamber depth;
THYM	cis	rs6490294	0.583	rs4767296	chr12:112463366	T/C	cg10833066	chr12:111807467	FAM109A	0.47	5.23	0.47	1.02e-6	Mean platelet volume;
THYM	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg23649088	chr2:200775458	C2orf69	0.85	6.24	0.54	1.24e-8	Schizophrenia;
THYM	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg05754148	chr16:3507555	NAT15	0.72	7.22	0.6	1.3e-10	Tuberculosis;
THYM	cis	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg10911889	chr6:126070802	HEY2	0.55	4.46	0.42	2.22e-5	Brugada syndrome;
THYM	cis	rs860818	1.000	rs858287	chr7:23249213	C/T	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs9486719	1.000	rs12207570	chr6:96987884	A/C	cg18709589	chr6:96969512	KIAA0776	-0.68	-4.71	-0.44	8.44e-6	Migraine;Coronary artery disease;
THYM	cis	rs7705042	0.828	rs1036209	chr5:141498632	T/A	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs11089937	0.667	rs11704024	chr22:22505588	T/C	cg21401457	chr22:22472743	NA	0.56	4.47	0.42	2.14e-5	Periodontitis (PAL4Q3);
THYM	cis	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.56	-0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs981844	0.712	rs4571310	chr4:154746832	T/C	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs7568458	0.663	rs699664	chr2:85780536	A/G	cg02493740	chr2:85810744	VAMP5	0.67	5.77	0.51	9.86e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	trans	rs629535	0.773	rs489206	chr8:70064883	T/C	cg21567404	chr3:27674614	NA	1.08	10.14	0.72	8.19e-17	Dupuytren's disease;
THYM	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg23758822	chr17:41437982	NA	1.16	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg08999081	chr20:33150536	PIGU	-0.55	-4.84	-0.44	5.05e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs10206020	0.921	rs2280127	chr2:1546531	C/T	cg12573674	chr2:1569213	NA	-1.33	-8.15	-0.64	1.45e-12	IgG glycosylation;
THYM	cis	rs12478296	0.901	rs7603560	chr2:243043256	C/T	cg06360820	chr2:242988706	NA	-1.07	-6.54	-0.56	3.06e-9	Obesity-related traits;
THYM	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg15744005	chr10:104629667	AS3MT	-0.78	-7.33	-0.6	7.48e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg07636037	chr3:49044803	WDR6	0.92	7.92	0.63	4.52e-12	Menarche (age at onset);
THYM	cis	rs7975161	0.521	rs4447242	chr12:104720708	T/G	cg25273343	chr12:104657179	TXNRD1	-0.74	-4.51	-0.42	1.83e-5	Toenail selenium levels;
THYM	cis	rs981844	0.885	rs62325082	chr4:154661274	A/G	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg05707623	chr12:122985044	ZCCHC8	0.81	5.57	0.5	2.37e-7	Body mass index;
THYM	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg04315214	chr1:2043799	PRKCZ	0.65	5.56	0.5	2.47e-7	Height;
THYM	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22496380	chr5:211416	CCDC127	-1.28	-7.77	-0.62	9.06e-12	Breast cancer;
THYM	cis	rs4731207	0.596	rs10274820	chr7:124629664	G/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs1691799	0.867	rs1168316	chr12:66746239	A/G	cg16791601	chr12:66731901	HELB	-0.75	-7.25	-0.6	1.08e-10	White blood cell count (basophil);
THYM	cis	rs9633835	0.620	rs34862781	chr11:13305263	G/A	cg13286116	chr11:13302098	ARNTL	-0.76	-8.92	-0.68	3.37e-14	Body mass index;
THYM	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg12179176	chr11:130786555	SNX19	0.86	8.17	0.64	1.31e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs255428	0.545	rs173881	chr5:62855602	A/G	cg13713523	chr5:63802877	RGS7BP	0.55	4.68	0.43	9.57e-6	Major depressive disorder;
THYM	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	8.57	0.66	1.87e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg08885076	chr2:99613938	TSGA10	0.53	5.11	0.46	1.64e-6	Chronic sinus infection;
THYM	cis	rs806215	1.000	rs806214	chr7:127237003	C/T	cg08586737	chr7:127225949	GCC1	-0.41	-5.04	-0.46	2.18e-6	Type 2 diabetes;
THYM	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs8180040	0.800	rs2088135	chr3:47280018	T/C	cg02527881	chr3:46936655	PTH1R	0.59	5.48	0.49	3.44e-7	Colorectal cancer;
THYM	cis	rs4888262	0.526	rs4887777	chr16:74637821	A/G	cg01733217	chr16:74700730	RFWD3	0.82	8.54	0.66	2.2e-13	Testicular germ cell tumor;
THYM	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg23708337	chr7:1209742	NA	0.81	4.48	0.42	2.1e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg03115019	chr17:80708279	FN3K	0.66	4.5	0.42	1.89e-5	Glycated hemoglobin levels;
THYM	cis	rs9359856	0.517	rs72919948	chr6:90509389	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.89	-8.13	-0.64	1.6e-12	Bipolar disorder;
THYM	cis	rs7580658	0.963	rs62157555	chr2:128107176	C/T	cg10021288	chr2:128175891	PROC	-0.81	-6.92	-0.58	5.3e-10	Protein C levels;
THYM	cis	rs3820068	0.603	rs7536654	chr1:15989141	C/G	cg05660106	chr1:15850417	CASP9	0.77	6.49	0.55	3.79e-9	Systolic blood pressure;
THYM	cis	rs4072705	0.646	rs915032	chr9:127245682	G/C	cg01786973	chr9:127249749	NR5A1	0.4	5.22	0.47	1.06e-6	Menarche (age at onset);
THYM	cis	rs7107174	1.000	rs10793295	chr11:77996521	C/G	cg19901956	chr11:77921274	USP35	0.66	5.13	0.47	1.55e-6	Testicular germ cell tumor;
THYM	cis	rs2688608	0.592	rs11000757	chr10:75486815	T/C	cg19442545	chr10:75533431	FUT11	-0.51	-5.22	-0.47	1.03e-6	Inflammatory bowel disease;
THYM	cis	rs6456156	0.846	rs7749827	chr6:167515624	C/T	cg09487078	chr6:167525398	CCR6	-0.46	-5.07	-0.46	1.98e-6	Primary biliary cholangitis;
THYM	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg10224037	chr5:178157518	ZNF354A	0.95	7.7	0.62	1.28e-11	Neutrophil percentage of white cells;
THYM	cis	rs9583531	0.689	rs9515273	chr13:111383427	G/C	cg24331049	chr13:111365604	ING1	0.62	5.07	0.46	1.95e-6	Coronary artery disease;
THYM	cis	rs10779751	0.734	rs2791650	chr1:11132541	G/C	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs7849270	1.000	rs7855278	chr9:131921365	A/C	cg14069949	chr9:131965419	NA	-0.54	-4.98	-0.45	2.87e-6	Blood metabolite ratios;
THYM	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg08470875	chr2:26401718	FAM59B	-0.74	-4.59	-0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs9633835	0.524	rs11826480	chr11:13279997	T/C	cg13286116	chr11:13302098	ARNTL	-0.68	-7.34	-0.6	7.12e-11	Body mass index;
THYM	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg19904058	chr10:135279010	LOC619207	-0.57	-5.32	-0.48	7.02e-7	Systemic lupus erythematosus;
THYM	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg08975724	chr8:8085496	FLJ10661	0.66	5.22	0.47	1.04e-6	Mood instability;
THYM	cis	rs3126085	0.935	rs4845733	chr1:152162568	T/C	cg26020982	chr1:152196106	HRNR	0.34	4.52	0.42	1.76e-5	Atopic dermatitis;
THYM	cis	rs4731207	0.564	rs1011721	chr7:124605159	G/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg08736216	chr1:53307985	ZYG11A	-0.57	-5.21	-0.47	1.11e-6	Monocyte count;
THYM	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg15704280	chr7:45808275	SEPT13	0.99	7.95	0.63	3.79e-12	Coronary artery disease;
THYM	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs4523957	0.928	rs177567	chr17:2197637	A/G	cg16513277	chr17:2031491	SMG6	-0.77	-7.16	-0.59	1.73e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7626444	0.625	rs1357287	chr3:196484967	A/G	cg12930392	chr3:196481615	PAK2	0.4	4.97	0.45	2.97e-6	Monocyte count;
THYM	cis	rs7719624	0.792	rs4976459	chr5:135362573	C/G	cg15329133	chr5:135467951	SMAD5;SMAD5OS	-0.56	-4.96	-0.45	3.04e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs2281845	0.895	rs7513829	chr1:201079590	C/A	cg17810781	chr1:201082982	CACNA1S	0.61	6.7	0.57	1.5e-9	Permanent tooth development;
THYM	cis	rs9314614	0.789	rs4840641	chr8:6712743	T/C	cg27319216	chr8:6693540	XKR5	-0.54	-5.71	-0.51	1.29e-7	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg18230493	chr5:56204884	C5orf35	-0.92	-6.88	-0.58	6.21e-10	Initial pursuit acceleration;
THYM	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg15247329	chr7:2764246	NA	-0.67	-5.55	-0.5	2.53e-7	Height;
THYM	cis	rs1395	0.778	rs6709602	chr2:27405497	C/T	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.4	-0.48	4.88e-7	Blood metabolite levels;
THYM	cis	rs72827839	1.000	rs72827885	chr17:46534423	C/G	cg03177231	chr17:45772386	TBKBP1	0.89	4.58	0.43	1.4e-5	Ease of getting up in the morning;
THYM	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs986417	0.901	rs1955698	chr14:61029936	C/T	cg27398547	chr14:60952738	C14orf39	1.1	6.18	0.54	1.59e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg20283391	chr11:68216788	NA	-0.6	-4.5	-0.42	1.9e-5	Bone mineral density (spine);
THYM	cis	rs13315871	0.929	rs11130628	chr3:58315835	T/C	cg12435725	chr3:58293450	RPP14	-0.53	-5.82	-0.51	7.92e-8	Cholesterol, total;
THYM	cis	rs870825	0.616	rs4444873	chr4:185628406	A/G	cg04058563	chr4:185651563	MLF1IP	1.03	8.21	0.64	1.08e-12	Blood protein levels;
THYM	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6700896	0.931	rs12035753	chr1:66116691	T/G	cg04111102	chr1:66153794	NA	0.55	5.22	0.47	1.06e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.82	-5.11	-0.46	1.63e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg12863693	chr15:85201151	NMB	0.62	5.39	0.48	5.18e-7	Schizophrenia;
THYM	cis	rs36051895	0.623	rs3780382	chr9:5232299	G/A	cg02405213	chr9:5042618	JAK2	-0.94	-9.82	-0.71	4.02e-16	Pediatric autoimmune diseases;
THYM	cis	rs12594515	1.000	rs58368732	chr15:45990531	G/C	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs4845459	0.967	rs4112788	chr1:152551276	A/G	cg27206522	chr1:152595629	LCE3A	-0.51	-4.49	-0.42	2.04e-5	Psoriasis;
THYM	cis	rs7084402	0.967	rs11817440	chr10:60272369	T/C	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs17253792	0.822	rs10142757	chr14:56074211	C/A	cg01858014	chr14:56050164	KTN1	-1.22	-5.13	-0.47	1.52e-6	Putamen volume;
THYM	cis	rs4970988	0.787	rs1532770	chr1:150725335	G/T	cg10589385	chr1:150898437	SETDB1	0.64	5.32	0.48	7.02e-7	Urate levels;
THYM	cis	rs17401966	0.964	rs34215045	chr1:10361679	G/A	cg20482658	chr1:10539492	PEX14	0.4	4.8	0.44	5.88e-6	Hepatocellular carcinoma;
THYM	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg04602696	chr16:88846723	FAM38A	-0.64	-4.56	-0.42	1.52e-5	Plateletcrit;
THYM	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg15921436	chr17:44337874	NA	0.91	6.69	0.57	1.56e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6674176	0.569	rs34830883	chr1:44405339	T/C	cg13246856	chr1:44399776	ARTN	0.49	4.55	0.42	1.59e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg02527881	chr3:46936655	PTH1R	0.56	5.42	0.49	4.49e-7	Colorectal cancer;
THYM	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg15704280	chr7:45808275	SEPT13	-0.84	-8.64	-0.66	1.3e-13	Height;
THYM	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs28595532	1.000	rs56225646	chr4:119651217	T/C	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs11214589	0.620	rs34601878	chr11:113260898	G/A	cg14159747	chr11:113255604	NA	0.37	7.8	0.62	8.01e-12	Neuroticism;
THYM	cis	rs9527	0.590	rs2148198	chr10:104915310	A/G	cg15744005	chr10:104629667	AS3MT	0.62	4.66	0.43	1.04e-5	Arsenic metabolism;
THYM	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	trans	rs9951602	0.512	rs4798994	chr18:76654327	T/G	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg03733263	chr8:22462867	KIAA1967	1.03	11.32	0.76	2.59e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs59698941	0.943	rs4705978	chr5:132245433	C/T	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs860554	0.595	rs12025174	chr1:201258309	G/A	cg01022117	chr1:201258280	PKP1	-0.65	-6.27	-0.54	1.06e-8	Panic disorder;
THYM	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg12560992	chr17:57184187	TRIM37	0.92	8.35	0.65	5.45e-13	Intelligence (multi-trait analysis);
THYM	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg01069141	chr11:67398826	TBX10;NUDT8	0.5	5.41	0.49	4.61e-7	Mean corpuscular volume;
THYM	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg12893697	chr11:970389	AP2A2	-0.31	-5.21	-0.47	1.08e-6	Alzheimer's disease (late onset);
THYM	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.58	0.5	2.29e-7	Rheumatoid arthritis;
THYM	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg22920501	chr2:26401640	FAM59B	1.04	9.12	0.68	1.26e-14	Gut microbiome composition (summer);
THYM	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg01191920	chr7:158217561	PTPRN2	-1.0	-10.34	-0.73	3.06e-17	Obesity-related traits;
THYM	cis	rs931127	0.505	rs2306362	chr11:65405510	G/T	cg27068330	chr11:65405492	SIPA1	-1.13	-12.67	-0.79	4.06e-22	Systemic lupus erythematosus;
THYM	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg11764359	chr7:65958608	NA	0.7	4.89	0.45	4.09e-6	Aortic root size;
THYM	cis	rs1775715	0.677	rs2808105	chr10:32110907	C/T	cg04359828	chr10:32216031	ARHGAP12	0.36	4.76	0.44	6.9e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg17264618	chr3:40429014	ENTPD3	0.49	4.7	0.43	8.65e-6	Renal cell carcinoma;
THYM	cis	rs174775	0.513	rs3788411	chr22:29728783	T/C	cg26480862	chr22:28839667	TTC28	-0.49	-4.83	-0.44	5.25e-6	Immature fraction of reticulocytes;
THYM	cis	rs4746818	1.000	rs7071904	chr10:70903005	C/T	cg11621586	chr10:70884670	VPS26A	1.28	11.0	0.75	1.26e-18	Left atrial antero-posterior diameter;
THYM	cis	rs4561483	0.801	rs40311	chr16:11963190	C/G	cg08843971	chr16:11963173	GSPT1	0.56	4.46	0.42	2.24e-5	Testicular germ cell tumor;
THYM	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg00645579	chr11:617140	IRF7;MUPCDH	-0.41	-4.77	-0.44	6.56e-6	Systemic lupus erythematosus;
THYM	cis	rs807029	0.758	rs807025	chr10:102764821	C/T	cg04662943	chr10:102668895	NA	0.67	4.49	0.42	1.97e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg18105134	chr13:113819100	PROZ	-0.99	-9.17	-0.69	9.97e-15	Platelet distribution width;
THYM	cis	rs17443541	0.507	rs6435020	chr2:200448356	C/T	cg03741458	chr2:200468445	NA	-0.8	-5.75	-0.51	1.1e-7	Intelligence (multi-trait analysis);
THYM	cis	rs477692	0.569	rs10764882	chr10:131306496	C/G	cg05714579	chr10:131428358	MGMT	0.59	4.8	0.44	5.91e-6	Response to temozolomide;
THYM	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg11764359	chr7:65958608	NA	0.81	6.42	0.55	5.31e-9	Aortic root size;
THYM	cis	rs7312774	0.618	rs4964503	chr12:107335937	C/G	cg16260113	chr12:107380972	MTERFD3	-1.4	-6.78	-0.57	1.02e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs28595532	0.920	rs116246794	chr4:119732491	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs9522267	0.535	rs9522284	chr13:112229343	C/T	cg10483660	chr13:112241077	NA	-0.58	-6.7	-0.57	1.49e-9	Hepatitis;
THYM	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg14196790	chr5:131705035	SLC22A5	-0.54	-5.08	-0.46	1.88e-6	Blood metabolite levels;
THYM	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg03609598	chr5:56110824	MAP3K1	-0.89	-6.07	-0.53	2.63e-8	Initial pursuit acceleration;
THYM	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.76	-0.44	7.03e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs859767	0.704	rs7558554	chr2:135357203	C/G	cg12500956	chr2:135428796	TMEM163	0.49	5.07	0.46	1.96e-6	Neuroticism;
THYM	cis	rs10208649	0.908	rs6715161	chr2:54240105	C/T	cg04546899	chr2:54196757	PSME4	0.68	4.73	0.44	7.94e-6	Body mass index;
THYM	trans	rs11186	0.556	rs72906330	chr2:189958751	T/C	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs2637266	1.000	rs6480824	chr10:78355705	G/A	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs3796352	1.000	rs13078971	chr3:53103645	G/C	cg24530246	chr3:53118167	NA	-0.83	-4.69	-0.43	9.1e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs11690935	0.959	rs10204501	chr2:172588865	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-6.5	-0.55	3.76e-9	Schizophrenia;
THYM	cis	rs644799	0.896	rs12146644	chr11:95492878	A/G	cg14972814	chr11:95582409	MTMR2	-0.73	-7.0	-0.58	3.65e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7572733	0.534	rs1401095	chr2:198779867	C/T	cg00792783	chr2:198669748	PLCL1	-0.84	-5.97	-0.52	4.15e-8	Dermatomyositis;
THYM	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg05896524	chr21:47604654	C21orf56	0.74	5.2	0.47	1.16e-6	Testicular germ cell tumor;
THYM	cis	rs7111341	0.571	rs7480120	chr11:2224958	C/G	cg25635251	chr11:2234043	NA	0.73	5.36	0.48	5.93e-7	Type 2 diabetes;Body mass index;Type 1 diabetes;
THYM	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.63	0.62	1.78e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs17253792	0.731	rs3736876	chr14:56120178	T/C	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs41005	1.000	rs41007	chr2:8109043	A/G	cg03155496	chr2:8117019	LOC339788	-0.94	-9.11	-0.68	1.33e-14	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs763014	0.898	rs4984669	chr16:624713	C/T	cg07343612	chr16:622815	PIGQ	-1.05	-10.74	-0.74	4.28e-18	Height;
THYM	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg05294307	chr14:35346193	BAZ1A	-0.73	-4.91	-0.45	3.75e-6	Psoriasis;
THYM	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg03433033	chr1:76189801	ACADM	0.77	9.34	0.69	4.27e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9522267	0.535	rs9522296	chr13:112234340	C/T	cg10483660	chr13:112241077	NA	0.6	6.98	0.58	3.9e-10	Hepatitis;
THYM	cis	rs6700896	0.966	rs1938485	chr1:66082084	A/G	cg04111102	chr1:66153794	NA	0.53	4.64	0.43	1.12e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg01364799	chr7:75623366	TMEM120A	0.63	4.56	0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4654899	0.865	rs61779073	chr1:21398740	C/A	cg01072550	chr1:21505969	NA	-0.75	-6.83	-0.57	8.17e-10	Superior frontal gyrus grey matter volume;
THYM	trans	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs4595586	0.545	rs1588970	chr12:39403122	C/A	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg14092571	chr14:90743983	NA	-0.95	-8.6	-0.66	1.61e-13	Gut microbiota (bacterial taxa);
THYM	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg26597838	chr10:835615	NA	0.86	4.92	0.45	3.62e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs1568889	0.838	rs6484347	chr11:28040969	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.79	-6.73	-0.57	1.25e-9	Bipolar disorder;
THYM	cis	rs61931739	0.817	rs11833948	chr12:34276942	G/T	cg10856724	chr12:34555212	NA	-0.64	-5.78	-0.51	9.43e-8	Morning vs. evening chronotype;
THYM	cis	rs2806561	0.808	rs4654834	chr1:23364919	T/C	cg08872493	chr1:23521417	HTR1D	-0.38	-4.52	-0.42	1.79e-5	Height;
THYM	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg25566285	chr7:158114605	PTPRN2	0.89	10.22	0.72	5.47e-17	Calcium levels;
THYM	cis	rs2495707	0.624	rs2489007	chr10:102422046	A/G	cg07099331	chr10:102419617	NA	0.48	5.6	0.5	2.11e-7	Body mass index;
THYM	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg11812906	chr14:75593930	NEK9	-0.85	-7.6	-0.61	2.07e-11	Height;
THYM	cis	rs921665	0.749	rs7563563	chr2:3201417	A/G	cg16434511	chr2:3151078	NA	0.82	5.28	0.48	8.03e-7	World class endurance athleticism;
THYM	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg20486651	chr6:167070296	RPS6KA2	0.5	4.79	0.44	6.18e-6	Crohn's disease;
THYM	cis	rs72717009	0.825	rs7552317	chr1:161479438	C/T	cg15358701	chr1:161410459	NA	-0.92	-4.89	-0.45	4.1e-6	Rheumatoid arthritis;
THYM	cis	rs4845570	0.831	rs11588258	chr1:151780728	A/T	cg07092448	chr1:151763213	TDRKH	-1.05	-5.96	-0.52	4.19e-8	Coronary artery disease;
THYM	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg22875332	chr1:76189707	ACADM	0.81	7.3	0.6	8.88e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6906287	0.647	rs12207209	chr6:118850375	T/G	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg11663144	chr21:46675770	NA	-0.7	-9.8	-0.71	4.38e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs13064411	0.696	rs6438159	chr3:113217341	T/C	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg06636001	chr8:8085503	FLJ10661	-0.62	-5.28	-0.48	8.27e-7	Joint mobility (Beighton score);
THYM	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg11366901	chr6:160182831	ACAT2	1.09	9.69	0.71	7.63e-16	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs738322	0.718	rs2899297	chr22:38594668	A/G	cg25457927	chr22:38595422	NA	-0.51	-5.31	-0.48	7.17e-7	Cutaneous nevi;
THYM	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg25838465	chr1:92012736	NA	-0.9	-8.53	-0.66	2.23e-13	Breast cancer;
THYM	cis	rs4687717	0.636	rs12494824	chr3:53279525	C/T	cg16894138	chr3:53270350	TKT	0.81	6.52	0.56	3.44e-9	Blood metabolite levels;Blood metabolite ratios;
THYM	cis	rs13223928	0.516	rs1872880	chr7:3148389	G/C	cg19214707	chr7:3157722	NA	-0.87	-7.6	-0.61	2.08e-11	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs17253792	0.822	rs113692713	chr14:56087424	C/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03517284	chr6:25882590	NA	-1.01	-8.89	-0.67	3.82e-14	Intelligence (multi-trait analysis);
THYM	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg24399712	chr22:39784796	NA	-0.95	-10.92	-0.75	1.82e-18	Intelligence (multi-trait analysis);
THYM	cis	rs11077998	0.844	rs8064433	chr17:80501046	A/T	cg11779900	chr17:80519722	FOXK2	-0.53	-4.52	-0.42	1.79e-5	Reticulocyte fraction of red cells;
THYM	cis	rs405460	0.557	rs388374	chr14:59308433	A/G	cg02291164	chr14:59296302	NA	0.62	5.58	0.5	2.27e-7	Obesity-related traits;
THYM	cis	rs2836633	0.931	rs2836635	chr21:40069850	A/G	cg12884169	chr21:40033163	ERG	0.62	7.31	0.6	8.46e-11	Coronary artery disease;
THYM	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg00898013	chr13:113819073	PROZ	-0.83	-8.33	-0.65	6.02e-13	Platelet distribution width;
THYM	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg25918947	chr17:41365094	TMEM106A	0.52	4.46	0.42	2.26e-5	Menopause (age at onset);
THYM	cis	rs9868809	1.000	rs2310997	chr3:48678011	G/C	cg00383909	chr3:49044727	WDR6	1.0	4.86	0.45	4.55e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg04398451	chr17:18023971	MYO15A	-0.74	-6.76	-0.57	1.11e-9	Total body bone mineral density;
THYM	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg03264133	chr6:25882463	NA	0.59	4.7	0.43	8.82e-6	Blood metabolite levels;
THYM	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg24642439	chr20:33292090	TP53INP2	-0.71	-5.31	-0.48	7.06e-7	Coronary artery disease;
THYM	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Bladder cancer;
THYM	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	5.47	0.49	3.58e-7	Personality dimensions;
THYM	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-5.16	-0.47	1.34e-6	Hemoglobin concentration;
THYM	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1950626	0.716	rs34158896	chr14:101447373	T/C	cg11887864	chr14:101510502	MIR1185-2	0.54	4.52	0.42	1.75e-5	Pelvic organ prolapse (moderate/severe);
THYM	cis	rs59698941	0.943	rs12519955	chr5:132283095	G/A	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs10779751	0.734	rs2259886	chr1:11137778	C/T	cg08854313	chr1:11322531	MTOR	0.85	7.33	0.6	7.43e-11	Body mass index;
THYM	cis	rs89107	0.549	rs17427116	chr6:118986198	G/A	cg01113488	chr6:119027122	NA	0.57	4.9	0.45	3.96e-6	Cardiac structure and function;
THYM	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg10150615	chr22:24372951	LOC391322	-0.92	-7.73	-0.62	1.1e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs4780401	0.782	rs933573	chr16:11793395	A/G	cg01061890	chr16:11836724	TXNDC11	0.65	4.81	0.44	5.6e-6	Rheumatoid arthritis;
THYM	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.01	-9.8	-0.71	4.35e-16	Primary sclerosing cholangitis;
THYM	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg13609457	chr4:120235615	NA	0.59	5.31	0.48	7.1e-7	Corneal astigmatism;
THYM	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg22117172	chr7:91764530	CYP51A1	-0.35	-4.47	-0.42	2.12e-5	Breast cancer;
THYM	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg06108461	chr20:60628389	TAF4	-0.84	-7.06	-0.59	2.77e-10	Body mass index;
THYM	cis	rs13256369	0.802	rs13255789	chr8:8562791	T/C	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs67397200	0.632	rs11666308	chr19:17437744	T/C	cg04248312	chr19:17393744	ANKLE1	-0.49	-4.5	-0.42	1.93e-5	Breast cancer;Breast Cancer in BRCA1 mutation carriers;Breast cancer (estrogen-receptor negative);
THYM	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg17757837	chr7:157058334	UBE3C	0.66	5.32	0.48	6.85e-7	Body mass index;
THYM	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg21784768	chr11:537496	LRRC56	-1.37	-6.17	-0.53	1.7e-8	Body mass index;
THYM	cis	rs2991971	0.810	rs998199	chr1:45912898	A/C	cg15605315	chr1:45957053	TESK2	-0.64	-5.12	-0.47	1.59e-6	High light scatter reticulocyte count;
THYM	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	4.56	0.42	1.54e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs2299587	0.662	rs6586671	chr8:17776084	T/C	cg01800426	chr8:17659068	MTUS1	-0.57	-4.62	-0.43	1.21e-5	Economic and political preferences;
THYM	cis	rs892961	0.932	rs3987885	chr17:75414990	A/G	cg05865280	chr17:75406074	SEPT9	0.5	8.37	0.65	5.06e-13	Airflow obstruction;
THYM	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg14345882	chr6:26364793	BTN3A2	0.59	5.52	0.49	2.89e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4595586	0.545	rs2388179	chr12:39364036	T/A	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg01364799	chr7:75623366	TMEM120A	-0.62	-4.61	-0.43	1.27e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg20486651	chr6:167070296	RPS6KA2	0.5	4.73	0.44	7.7e-6	Crohn's disease;
THYM	cis	rs6032067	0.636	rs6032095	chr20:43913255	A/T	cg20256260	chr20:43936981	MATN4;RBPJL	0.7	6.46	0.55	4.41e-9	Blood protein levels;
THYM	cis	rs1878931	0.582	rs9635562	chr16:3416689	G/A	cg21433313	chr16:3507492	NAT15	-0.57	-4.82	-0.44	5.36e-6	Body mass index (adult);
THYM	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2882877	0.621	rs17198934	chr2:190378371	C/G	cg10752008	chr2:190445175	SLC40A1	0.74	6.23	0.54	1.25e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11096990	0.656	rs6531709	chr4:39302249	T/G	cg24403649	chr4:39172243	NA	-0.62	-5.27	-0.48	8.42e-7	Cognitive function;
THYM	cis	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.59	6.1	0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs11785693	0.774	rs62489516	chr8:4946015	T/C	cg26367366	chr8:4980734	NA	1.05	4.83	0.44	5.25e-6	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs11779988	0.528	rs208029	chr8:17840987	A/C	cg01800426	chr8:17659068	MTUS1	-0.71	-4.94	-0.45	3.4e-6	Breast cancer;
THYM	cis	rs2806561	0.754	rs10917344	chr1:23342193	C/G	cg08872493	chr1:23521417	HTR1D	-0.37	-4.49	-0.42	1.97e-5	Height;
THYM	cis	rs4747241	0.626	rs4300326	chr10:74068696	A/G	cg07828833	chr10:74069493	NA	-0.53	-4.64	-0.43	1.11e-5	Heschl's gyrus morphology;
THYM	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg11266682	chr4:10021025	SLC2A9	0.73	12.79	0.8	2.29e-22	Bone mineral density;
THYM	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs11112613	0.713	rs4015312	chr12:105948757	A/G	cg03607813	chr12:105948248	NA	1.07	9.0	0.68	2.31e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg00757033	chr12:89920650	WDR51B	0.72	9.59	0.7	1.22e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs11096990	0.656	rs3733284	chr4:39301334	A/G	cg24403649	chr4:39172243	NA	-0.63	-5.43	-0.49	4.31e-7	Cognitive function;
THYM	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs8078723	0.966	rs2227322	chr17:38171668	C/G	cg17467752	chr17:38218738	THRA	0.83	6.68	0.57	1.59e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg04025307	chr7:1156635	C7orf50	0.77	6.59	0.56	2.5e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg20891283	chr12:69753455	YEATS4	1.06	10.14	0.72	8.47e-17	Blood protein levels;
THYM	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg00898013	chr13:113819073	PROZ	-0.83	-8.33	-0.65	6.02e-13	Platelet distribution width;
THYM	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.65	-0.5	1.64e-7	Prostate cancer;
THYM	cis	rs7119038	0.818	rs17122453	chr11:118683564	G/A	cg19308663	chr11:118741387	NA	0.44	4.63	0.43	1.15e-5	Sjögren's syndrome;
THYM	cis	rs1403694	0.695	rs3774292	chr3:186433574	A/T	cg12454167	chr3:186435060	KNG1	0.51	7.04	0.59	2.94e-10	Blood protein levels;
THYM	cis	rs7666738	0.785	rs11944120	chr4:99079932	A/C	cg10515332	chr4:99064459	C4orf37	0.68	4.87	0.45	4.47e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7267979	1.000	rs2500443	chr20:25331442	C/T	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg11301795	chr4:187892539	NA	1.11	18.07	0.88	1.66e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg07936489	chr17:37558343	FBXL20	-0.67	-4.8	-0.44	5.98e-6	Asthma;
THYM	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg00898013	chr13:113819073	PROZ	-0.88	-8.96	-0.68	2.83e-14	Platelet distribution width;
THYM	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg13683864	chr3:40499215	RPL14	-1.06	-11.61	-0.77	6.25e-20	Renal cell carcinoma;
THYM	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.45	-5.5	-0.49	3.26e-7	Monocyte percentage of white cells;
THYM	cis	rs72772090	0.539	rs111237997	chr5:96114953	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg11764359	chr7:65958608	NA	0.69	4.67	0.43	9.75e-6	Aortic root size;
THYM	cis	rs7177699	0.557	rs12898452	chr15:79112628	C/A	cg00540400	chr15:79124168	NA	0.62	6.51	0.56	3.49e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs9790314	0.560	rs4856701	chr3:161044106	G/T	cg03342759	chr3:160939853	NMD3	-0.7	-5.9	-0.52	5.67e-8	Morning vs. evening chronotype;
THYM	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.78	-6.97	-0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs6700896	0.931	rs12042807	chr1:66134052	T/C	cg04111102	chr1:66153794	NA	0.56	5.27	0.48	8.45e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7220711	1.000	rs1881107	chr17:41786076	A/G	cg26893861	chr17:41843967	DUSP3	0.65	5.63	0.5	1.83e-7	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs12367572	0.620	rs2731040	chr12:45416383	G/A	cg03114573	chr12:45410052	DBX2	-0.61	-5.83	-0.51	7.45e-8	Gut microbiome composition (summer);
THYM	cis	rs800586	0.788	rs2960151	chr8:116718620	C/A	cg04656070	chr8:116661063	TRPS1	0.48	4.57	0.42	1.47e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	trans	rs9929218	0.679	rs9924886	chr16:68743939	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.91	-7.9	-0.63	4.88e-12	Colorectal cancer;
THYM	cis	rs2816062	0.965	rs2816061	chr1:18903819	A/G	cg18795169	chr1:18902165	NA	0.87	10.18	0.72	6.85e-17	Urate levels in lean individuals;
THYM	cis	rs55728055	0.661	rs56411340	chr22:31984476	G/T	cg01338084	chr22:32026380	PISD	1.39	6.92	0.58	5.23e-10	Age-related hearing impairment;
THYM	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg17747265	chr1:1875780	NA	-0.79	-9.26	-0.69	6.2e-15	Body mass index;
THYM	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg03060546	chr3:49711283	APEH	0.75	6.08	0.53	2.55e-8	Resting heart rate;
THYM	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg00129232	chr17:37814104	STARD3	-0.69	-4.51	-0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs1113500	0.614	rs61797342	chr1:108608385	G/A	cg06207961	chr1:108661230	NA	0.65	4.72	0.44	8.11e-6	Growth-regulated protein alpha levels;
THYM	cis	rs901683	1.000	rs77204970	chr10:46034949	G/A	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs17253792	0.822	rs9323289	chr14:56106784	G/C	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs995000	0.931	rs7539035	chr1:63106767	G/T	cg06896770	chr1:63153194	DOCK7	0.91	7.48	0.61	3.73e-11	Triglyceride levels;
THYM	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	-0.63	-5.25	-0.47	9.3e-7	Spherical equivalent (joint analysis main effects and education interaction);
THYM	trans	rs2136093	0.600	rs10922862	chr1:90912379	T/A	cg21057494	chr3:45066971	CLEC3B	0.53	7.07	0.59	2.65e-10	Response to antidepressants;
THYM	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs7894051	1.000	rs7899476	chr10:135197214	A/G	cg20534287	chr10:135191450	PAOX	0.69	5.27	0.48	8.37e-7	Lifespan;
THYM	cis	rs8018808	0.936	rs10140302	chr14:77855693	C/A	cg20045696	chr14:77926864	AHSA1	-0.53	-4.73	-0.44	7.91e-6	Myeloid white cell count;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg18879177	chr6:105854768	NA	-0.93	-6.96	-0.58	4.39e-10	Depressive symptoms;
THYM	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg09034736	chr1:150693464	HORMAD1	0.52	4.68	0.43	9.35e-6	Melanoma;
THYM	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8067545	0.611	rs2158472	chr17:20171524	C/T	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs6840360	0.571	rs11940881	chr4:152501050	C/G	cg22705602	chr4:152727874	NA	-0.77	-8.05	-0.64	2.4e-12	Intelligence (multi-trait analysis);
THYM	cis	rs10463554	0.963	rs10463555	chr5:102319037	A/C	cg23492399	chr5:102201601	PAM	-0.63	-4.94	-0.45	3.36e-6	Parkinson's disease;
THYM	trans	rs4866334	1.000	rs114675067	chr5:18448226	G/A	cg08675002	chr5:90437527	GPR98	-1.55	-7.42	-0.61	4.85e-11	IgG glycosylation;
THYM	cis	rs1697139	0.583	rs1428474	chr5:66544015	C/A	cg11553311	chr5:66541588	NA	0.71	7.63	0.62	1.78e-11	Breast cancer;
THYM	cis	rs3796352	1.000	rs35507120	chr3:53053924	C/T	cg24530246	chr3:53118167	NA	-0.85	-4.82	-0.44	5.52e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs72720396	0.803	rs114993052	chr1:91190855	T/A	cg13456504	chr1:91191583	NA	1.03	6.98	0.58	3.91e-10	Morning vs. evening chronotype;Chronotype;
THYM	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg13695892	chr22:41940480	POLR3H	0.84	6.25	0.54	1.16e-8	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs9549260	0.755	rs7993233	chr13:41219434	T/A	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs4766646	0.542	rs4766489	chr12:110306345	G/A	cg10794374	chr12:110278745	NA	-0.22	-4.87	-0.45	4.41e-6	Metabolite levels (MHPG);
THYM	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg08999081	chr20:33150536	PIGU	0.59	5.18	0.47	1.26e-6	Coronary artery disease;
THYM	cis	rs7677751	0.708	rs2052699	chr4:55063994	C/T	cg17187183	chr4:55093834	PDGFRA	0.68	5.04	0.46	2.22e-6	Corneal astigmatism;
THYM	cis	rs10214930	1.000	rs6462050	chr7:27844503	G/A	cg04422003	chr7:28448295	CREB5	-0.62	-4.62	-0.43	1.19e-5	Hypospadias;
THYM	cis	rs4455778	0.538	rs6977073	chr7:49115340	C/T	cg26309511	chr7:48887640	NA	0.64	5.72	0.51	1.23e-7	Lung cancer in never smokers;
THYM	cis	rs9399401	0.677	rs6925979	chr6:142651052	G/A	cg03128060	chr6:142623767	GPR126	0.67	8.25	0.65	9.11e-13	Chronic obstructive pulmonary disease;
THYM	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg18876405	chr7:65276391	NA	-0.58	-4.99	-0.46	2.78e-6	Aortic root size;
THYM	cis	rs67460515	0.500	rs1562464	chr3:160681614	G/A	cg12349858	chr3:160822545	B3GALNT1	0.61	4.99	0.46	2.71e-6	Parkinson's disease;
THYM	cis	rs1747683	0.845	rs2254154	chr10:13363717	A/G	cg25835351	chr10:13388524	SEPHS1	0.3	5.07	0.46	1.99e-6	IgG glycosylation;
THYM	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs10779751	0.734	rs2039840	chr1:11125866	G/A	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs28595532	0.841	rs116582665	chr4:119487248	G/C	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.21e-7	Cannabis dependence symptom count;
THYM	cis	rs200895692	1	rs200895692	chr1:43421956	CGCCTGTAATCCCAG/C	cg03128534	chr1:43423976	SLC2A1	0.92	5.94	0.52	4.71e-8	Monocyte count;
THYM	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg04447362	chr2:237654635	NA	0.48	4.49	0.42	2.03e-5	Prostate cancer;
THYM	cis	rs2455799	0.573	rs2654650	chr3:15779214	C/T	cg16303742	chr3:15540471	COLQ	-0.56	-5.73	-0.51	1.18e-7	Mean platelet volume;
THYM	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg09307838	chr4:120376055	NA	0.72	5.2	0.47	1.17e-6	Corneal astigmatism;
THYM	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg27170947	chr2:26402098	FAM59B	-0.83	-6.65	-0.56	1.87e-9	Gut microbiome composition (summer);
THYM	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg00908189	chr16:619842	PIGQ	1.03	9.46	0.7	2.34e-15	Height;
THYM	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg04282206	chr17:62833786	PLEKHM1P	-0.83	-8.06	-0.64	2.23e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg15704280	chr7:45808275	SEPT13	-0.94	-7.13	-0.59	2e-10	Coronary artery disease;
THYM	cis	rs354225	0.544	rs1137645	chr2:54807592	C/G	cg23486701	chr2:54789491	SPTBN1	0.36	4.77	0.44	6.58e-6	Schizophrenia;
THYM	cis	rs539096	0.872	rs2478978	chr1:44031657	C/T	cg00143623	chr1:44495758	SLC6A9	-0.75	-5.91	-0.52	5.41e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11997175	0.624	rs67643247	chr8:33700790	G/A	ch.8.33884649F	chr8:33765107	NA	0.7	4.9	0.45	3.91e-6	Body mass index;
THYM	cis	rs7078219	0.714	rs888208	chr10:101295863	A/G	cg23904955	chr10:101282759	NA	-0.43	-4.96	-0.45	3.12e-6	Dental caries;
THYM	cis	rs4589258	0.933	rs7129615	chr11:90396225	A/G	cg26138821	chr11:89956704	CHORDC1	0.71	6.0	0.52	3.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9674544	0.556	rs1390154	chr17:47071483	A/G	cg22947322	chr17:47091978	IGF2BP1	-0.51	-5.26	-0.48	8.71e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg12756686	chr19:29218302	NA	0.61	4.59	0.43	1.36e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg13695892	chr22:41940480	POLR3H	-0.97	-7.85	-0.63	6.18e-12	Vitiligo;
THYM	cis	rs7107174	1.000	rs1318241	chr11:77930792	C/T	cg19901956	chr11:77921274	USP35	-0.81	-6.14	-0.53	1.93e-8	Testicular germ cell tumor;
THYM	cis	rs6732160	0.684	rs2043095	chr2:73407442	T/C	cg24220031	chr2:73402428	NA	-0.74	-8.56	-0.66	1.98e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg05283184	chr6:79620031	NA	-0.88	-8.19	-0.64	1.17e-12	Intelligence (multi-trait analysis);
THYM	trans	rs4650994	0.507	rs2811312	chr1:178617603	A/G	cg05059571	chr16:84539110	KIAA1609	0.84	8.57	0.66	1.84e-13	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs995000	0.965	rs10889338	chr1:62984897	C/T	cg06896770	chr1:63153194	DOCK7	1.0	8.17	0.64	1.31e-12	Triglyceride levels;
THYM	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1018836	0.828	rs7006279	chr8:91605364	A/G	cg16814680	chr8:91681699	NA	-0.93	-7.89	-0.63	5.06e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12367572	1.000	rs12367572	chr12:45290466	C/T	cg03114573	chr12:45410052	DBX2	0.55	5.2	0.47	1.13e-6	Gut microbiome composition (summer);
THYM	trans	rs11186	0.556	rs72906313	chr2:189956510	T/C	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg13695892	chr22:41940480	POLR3H	-0.72	-6.71	-0.57	1.39e-9	Vitiligo;
THYM	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg10248100	chr7:872053	UNC84A	0.74	4.99	0.46	2.75e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs67311347	0.544	rs12633295	chr3:40335292	G/T	cg24209194	chr3:40518798	ZNF619	-0.55	-4.74	-0.44	7.61e-6	Renal cell carcinoma;
THYM	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg18230493	chr5:56204884	C5orf35	-0.89	-6.62	-0.56	2.09e-9	Initial pursuit acceleration;
THYM	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs16857609	0.550	rs1351163	chr2:218267992	A/G	cg15335768	chr2:218268053	DIRC3	-0.53	-7.77	-0.62	9.01e-12	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-7.23	-0.6	1.2e-10	Schizophrenia;
THYM	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg12310025	chr6:25882481	NA	-0.93	-8.56	-0.66	2.01e-13	Intelligence (multi-trait analysis);
THYM	cis	rs865483	0.895	rs853211	chr17:35828164	T/C	cg06716730	chr17:35851459	DUSP14	0.43	7.3	0.6	8.71e-11	Monocyte count;
THYM	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	cis	rs11886999	0.812	rs12618133	chr2:96892134	C/T	cg18419276	chr2:96971862	SNRNP200	-0.51	-4.88	-0.45	4.21e-6	Cardiac Troponin-T levels;
THYM	cis	rs526231	0.543	rs34807	chr5:102428522	T/C	cg23492399	chr5:102201601	PAM	-0.67	-4.96	-0.45	3.05e-6	Primary biliary cholangitis;
THYM	cis	rs12530845	0.887	rs78641973	chr7:135324311	C/T	cg23117316	chr7:135346802	PL-5283	-0.68	-6.01	-0.53	3.37e-8	Red blood cell traits;
THYM	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg00990874	chr7:1149470	C7orf50	-0.63	-4.66	-0.43	1.01e-5	Bronchopulmonary dysplasia;
THYM	cis	rs4072705	0.967	rs4144630	chr9:127439200	A/G	cg01786973	chr9:127249749	NR5A1	0.35	4.69	0.43	9.25e-6	Menarche (age at onset);
THYM	cis	rs2742417	0.603	rs2742456	chr3:45767176	C/T	cg04837898	chr3:45731254	SACM1L	-0.67	-4.52	-0.42	1.75e-5	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg07959070	chr22:50026188	C22orf34	-0.28	-4.95	-0.45	3.17e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs10095849	0.576	rs1584683	chr8:39483679	G/C	cg22755526	chr8:38854673	TM2D2;ADAM9	-0.63	-4.65	-0.43	1.08e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs66887589	0.870	rs10518336	chr4:120522934	G/A	cg13609457	chr4:120235615	NA	0.48	5.0	0.46	2.57e-6	Diastolic blood pressure;
THYM	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.44	5.24	0.47	9.77e-7	Monocyte percentage of white cells;
THYM	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg01017244	chr2:74357527	NA	0.88	6.13	0.53	1.97e-8	Gestational age at birth (maternal effect);
THYM	cis	rs12681287	0.547	rs7459877	chr8:87505660	G/A	cg27223183	chr8:87520930	FAM82B	-0.71	-5.46	-0.49	3.8e-7	Caudate activity during reward;
THYM	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg26924012	chr15:45694286	SPATA5L1	0.66	4.87	0.45	4.49e-6	Response to fenofibrate (adiponectin levels);
THYM	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg08431931	chr22:42394659	WBP2NL	0.7	4.91	0.45	3.72e-6	Birth weight;
THYM	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs2279817	0.863	rs12749985	chr1:18026004	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.74	-4.54	-0.42	1.64e-5	Neuroticism;
THYM	cis	rs1003719	0.788	rs7275582	chr21:38451130	C/T	cg01329690	chr21:38580129	DSCR9	0.39	5.33	0.48	6.53e-7	Eye color traits;
THYM	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg23815491	chr16:72088622	HP	0.84	7.57	0.61	2.45e-11	Fibrinogen levels;
THYM	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg05368731	chr17:41323189	NBR1	1.24	10.81	0.74	3.04e-18	Menopause (age at onset);
THYM	cis	rs12121840	0.790	rs78906931	chr1:165532130	G/A	cg19407955	chr1:165599744	MGST3	-0.65	-4.63	-0.43	1.16e-5	Interleukin-1-receptor antagonist levels;
THYM	cis	rs10992471	0.603	rs11788523	chr9:95256593	G/A	cg14631576	chr9:95140430	CENPP	-0.99	-9.94	-0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2806561	0.765	rs679591	chr1:23499916	T/C	cg12483005	chr1:23474871	LUZP1	0.58	6.11	0.53	2.2e-8	Height;
THYM	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg12011299	chr4:100065546	ADH4	0.94	9.78	0.71	4.9e-16	Alcohol dependence;
THYM	cis	rs12549902	0.966	rs4737000	chr8:41509727	A/C	cg21772509	chr8:41503840	NKX6-3	0.7	6.54	0.56	3.04e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
THYM	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	7.84	0.63	6.6e-12	Platelet count;
THYM	cis	rs55788414	1.000	rs35667589	chr16:81180829	A/T	cg06400318	chr16:81190750	PKD1L2	-0.99	-4.99	-0.46	2.72e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs10186029	0.676	rs10932465	chr2:213968389	T/C	cg08319019	chr2:214017104	IKZF2	0.9	7.44	0.61	4.49e-11	Systemic sclerosis;
THYM	trans	rs11109072	0.655	rs11109074	chr12:97902846	G/A	cg17633015	chr7:2020501	MAD1L1	0.9	6.88	0.58	6.35e-10	Obesity (early onset extreme);
THYM	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg06219351	chr7:158114137	PTPRN2	-0.75	-7.63	-0.62	1.82e-11	Calcium levels;
THYM	cis	rs7508	0.511	rs208026	chr8:17878155	A/G	cg01800426	chr8:17659068	MTUS1	-0.71	-4.91	-0.45	3.8e-6	Atrial fibrillation;
THYM	cis	rs4919694	1.000	rs78214351	chr10:104822688	A/G	cg04362960	chr10:104952993	NT5C2	1.14	6.92	0.58	5.36e-10	Arsenic metabolism;
THYM	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg09044154	chr16:88155775	NA	-0.64	-4.5	-0.42	1.89e-5	Menopause (age at onset);
THYM	cis	rs41005	0.967	rs193928	chr2:8107899	T/C	cg03155496	chr2:8117019	LOC339788	0.95	9.15	0.68	1.09e-14	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg09549813	chr16:4587862	C16orf5	0.58	6.46	0.55	4.44e-9	Schizophrenia;
THYM	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg01304814	chr3:48885189	PRKAR2A	0.96	4.86	0.45	4.55e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg02389323	chr16:88786976	FAM38A	0.83	4.98	0.46	2.8e-6	Plateletcrit;
THYM	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.66	-0.43	1.03e-5	Mean corpuscular volume;
THYM	cis	rs75064307	0.834	rs4855562	chr3:108116835	C/T	cg03329597	chr3:108125523	MYH15	0.63	4.72	0.44	8.25e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg06074448	chr4:187884817	NA	-0.96	-12.19	-0.78	3.86e-21	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg20007245	chr22:24372913	LOC391322	-0.81	-8.26	-0.65	8.55e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg18538332	chr22:24372958	LOC391322	-0.92	-11.38	-0.76	1.96e-19	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg13609457	chr4:120235615	NA	-0.56	-5.09	-0.46	1.83e-6	Corneal astigmatism;
THYM	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21659725	chr3:3221576	CRBN	0.88	9.81	0.71	4.18e-16	Intelligence (multi-trait analysis);
THYM	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg17757837	chr7:157058334	UBE3C	-0.67	-5.43	-0.49	4.29e-7	Body mass index;
THYM	cis	rs28795989	0.795	rs4696778	chr4:7919308	C/G	cg00251875	chr4:7801337	AFAP1	-0.62	-4.94	-0.45	3.3e-6	Intraocular pressure;
THYM	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg11905131	chr22:24372483	LOC391322	-0.93	-11.04	-0.75	9.93e-19	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11039798	0.844	rs41431447	chr11:48983199	A/G	cg24672777	chr11:48374446	OR4C45	-1.08	-5.95	-0.52	4.42e-8	Axial length;
THYM	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg03806693	chr22:41940476	POLR3H	-1.08	-8.77	-0.67	7.1e-14	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg08645402	chr16:4508243	NA	-0.68	-6.13	-0.53	2e-8	Schizophrenia;
THYM	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg03676636	chr4:99064102	C4orf37	0.5	7.65	0.62	1.6e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-4.73	-0.44	7.65e-6	Alzheimer's disease;
THYM	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg05025164	chr4:1340916	KIAA1530	-0.7	-5.38	-0.48	5.36e-7	Obesity-related traits;
THYM	cis	rs8067545	0.641	rs850623	chr17:19837130	C/T	cg20830565	chr17:20408647	MGC102966	-0.54	-4.95	-0.45	3.16e-6	Schizophrenia;
THYM	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs6542838	0.611	rs7423519	chr2:99518319	G/A	cg08885076	chr2:99613938	TSGA10	-0.49	-4.57	-0.42	1.49e-5	Fear of minor pain;
THYM	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.69	-5.41	-0.49	4.62e-7	Tonsillectomy;
THYM	cis	rs10779751	0.770	rs7553827	chr1:11222393	C/T	cg08854313	chr1:11322531	MTOR	0.77	6.17	0.54	1.64e-8	Body mass index;
THYM	cis	rs9583531	0.600	rs754599	chr13:111354788	C/A	cg24331049	chr13:111365604	ING1	0.73	6.12	0.53	2.09e-8	Coronary artery disease;
THYM	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs6674970	1.000	rs7546304	chr1:151114484	C/G	cg11822372	chr1:151115635	SEMA6C	0.7	4.84	0.44	5.09e-6	Childhood ear infection;
THYM	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	5.33	0.48	6.52e-7	Schizophrenia;
THYM	cis	rs6988636	0.579	rs28528232	chr8:124189308	G/A	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs9876781	1.000	rs9876781	chr3:48487338	C/T	cg06066452	chr3:48470258	PLXNB1	0.27	4.85	0.45	4.87e-6	Longevity;
THYM	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg24675658	chr1:53192096	ZYG11B	0.56	4.63	0.43	1.15e-5	Monocyte count;
THYM	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg02734326	chr4:10020555	SLC2A9	-0.58	-4.5	-0.42	1.93e-5	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11048434	0.698	rs1805745	chr12:9065226	A/T	cg13575925	chr12:9217583	LOC144571	0.53	4.82	0.44	5.35e-6	Sjögren's syndrome;
THYM	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2562456	0.583	rs4809144	chr19:21772730	C/T	cg21751540	chr19:21541537	ZNF738	-0.68	-4.51	-0.42	1.87e-5	Pain;
THYM	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg26597838	chr10:835615	NA	1.23	8.86	0.67	4.56e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs4237845	0.837	rs7971877	chr12:58287630	T/G	cg22764591	chr12:58329936	NA	1.02	7.88	0.63	5.32e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg27398817	chr8:82754497	SNX16	-0.85	-7.33	-0.6	7.44e-11	Diastolic blood pressure;
THYM	cis	rs7626444	0.625	rs9826214	chr3:196478213	C/T	cg12930392	chr3:196481615	PAK2	0.4	4.92	0.45	3.58e-6	Monocyte count;
THYM	cis	rs13287066	0.967	rs7870079	chr9:96161300	A/G	cg13460858	chr9:96720652	NA	0.62	4.58	0.43	1.39e-5	Intelligence (multi-trait analysis);
THYM	cis	rs8077889	0.672	rs4793028	chr17:41857212	T/C	cg26893861	chr17:41843967	DUSP3	1.13	12.5	0.79	8.69e-22	Triglycerides;
THYM	cis	rs875971	0.642	rs35526611	chr7:66094008	C/T	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	6.89	0.58	5.96e-10	Electrocardiographic conduction measures;
THYM	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg24324837	chr19:49891574	CCDC155	0.63	6.09	0.53	2.42e-8	Multiple sclerosis;
THYM	cis	rs62070183	0.882	rs62070164	chr17:31086433	T/C	cg02981443	chr17:31254875	TMEM98	-0.54	-4.87	-0.45	4.46e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	trans	rs1974653	0.631	rs55929151	chr22:20082566	C/T	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs3204270	0.810	rs62077191	chr17:79678063	A/G	cg18367735	chr17:79674897	NA	0.78	4.62	0.43	1.23e-5	Dental caries;
THYM	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg09338302	chr7:1325757	NA	-0.48	-4.51	-0.42	1.86e-5	Bipolar disorder;
THYM	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.79	0.51	9.18e-8	Rheumatoid arthritis;
THYM	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28647808	1.000	rs35179461	chr9:136270293	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	trans	rs8073060	0.586	rs226090	chr17:34034059	C/T	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs17854409	0.803	rs1048109	chr20:61472120	G/A	cg05147244	chr20:61493195	TCFL5	0.9	4.96	0.45	3.07e-6	Obesity-related traits;
THYM	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1065852	0.526	rs2413663	chr22:42402399	T/A	cg09667013	chr22:42394590	WBP2NL	0.54	4.8	0.44	5.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs7119038	0.774	rs10892290	chr11:118653503	G/T	cg19308663	chr11:118741387	NA	0.59	5.6	0.5	2.06e-7	Sjögren's syndrome;
THYM	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg02269571	chr22:50332266	NA	-0.67	-4.82	-0.44	5.46e-6	Schizophrenia;
THYM	cis	rs6840360	1.000	rs12502055	chr4:152596668	G/A	cg22705602	chr4:152727874	NA	-0.63	-6.82	-0.57	8.24e-10	Intelligence (multi-trait analysis);
THYM	cis	rs17253792	0.822	rs12100949	chr14:56040787	T/C	cg01858014	chr14:56050164	KTN1	-1.17	-4.89	-0.45	4.1e-6	Putamen volume;
THYM	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-5.65	-0.5	1.64e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs9361491	0.610	rs7758474	chr6:79469174	G/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.47	-0.42	2.13e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6815814	0.861	rs10012017	chr4:38784633	G/T	cg06935464	chr4:38784597	TLR10	0.71	5.22	0.47	1.06e-6	Breast cancer;
THYM	cis	rs4919687	0.550	rs17784294	chr10:104479385	G/T	cg04362960	chr10:104952993	NT5C2	0.62	4.96	0.45	3.08e-6	Colorectal cancer;
THYM	cis	rs11690935	0.550	rs62183769	chr2:172838074	A/C	cg13550731	chr2:172543902	DYNC1I2	0.62	4.87	0.45	4.51e-6	Schizophrenia;
THYM	cis	rs8078723	0.714	rs2241244	chr17:38153554	G/C	cg17467752	chr17:38218738	THRA	-0.81	-6.73	-0.57	1.28e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs11252926	0.931	rs4881399	chr10:567325	A/G	cg03684893	chr10:554711	DIP2C	-0.59	-4.6	-0.43	1.31e-5	Psychosis in Alzheimer's disease;
THYM	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg16384552	chr7:74938386	SPDYE8P	-0.77	-6.1	-0.53	2.32e-8	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9515201	0.859	rs9521735	chr13:111037328	G/C	cg15455643	chr13:111040242	COL4A2	0.5	5.27	0.48	8.37e-7	White matter hyperintensity burden;
THYM	cis	rs2233152	0.656	rs10405633	chr19:41291703	G/A	cg26767443	chr19:41316244	NA	0.73	4.66	0.43	1.03e-5	Kawasaki disease;
THYM	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg10523679	chr1:76189770	ACADM	-0.94	-8.52	-0.66	2.42e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg17054759	chr22:49844102	NA	-0.52	-4.71	-0.44	8.39e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9876781	1.000	rs13076076	chr3:48479039	G/A	cg06066452	chr3:48470258	PLXNB1	0.27	4.85	0.45	4.78e-6	Longevity;
THYM	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg18404041	chr3:52824283	ITIH1	-0.57	-5.74	-0.51	1.13e-7	Bipolar disorder;
THYM	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg08885076	chr2:99613938	TSGA10	0.69	6.47	0.55	4.31e-9	Chronic sinus infection;
THYM	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg08000102	chr2:233561755	GIGYF2	-0.65	-5.67	-0.5	1.56e-7	Coronary artery disease;
THYM	cis	rs11186	0.591	rs55633056	chr2:189955694	A/C	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg24324837	chr19:49891574	CCDC155	0.52	4.75	0.44	7.07e-6	Multiple sclerosis;
THYM	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	5.73	0.51	1.18e-7	Blood metabolite levels;
THYM	cis	rs7553864	0.835	rs4415539	chr1:87604245	C/T	cg17420885	chr1:87600446	LOC339524	0.73	6.15	0.53	1.79e-8	Smoking behavior;
THYM	cis	rs7336332	0.598	rs76790205	chr13:28002885	C/T	cg22138327	chr13:27999177	GTF3A	0.67	4.97	0.45	3.02e-6	Weight;
THYM	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg12963246	chr6:28129442	ZNF389	0.72	6.12	0.53	2.05e-8	Depression;
THYM	cis	rs4343996	0.905	rs10233166	chr7:3343382	A/G	cg21248987	chr7:3385318	SDK1	0.4	4.83	0.44	5.22e-6	Motion sickness;
THYM	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg11247378	chr22:39784982	NA	-1.05	-11.88	-0.77	1.74e-20	Intelligence (multi-trait analysis);
THYM	cis	rs1371867	0.846	rs1788182	chr8:101334620	C/T	cg06636551	chr8:101224915	SPAG1	-0.63	-6.33	-0.54	8.05e-9	Atrioventricular conduction;
THYM	cis	rs7719624	0.869	rs6893691	chr5:135395433	A/G	cg15329133	chr5:135467951	SMAD5;SMAD5OS	0.58	5.03	0.46	2.31e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg15247329	chr7:2764246	NA	-0.7	-5.91	-0.52	5.43e-8	Height;
THYM	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17407555	0.657	rs10013452	chr4:10276990	G/A	cg00071950	chr4:10020882	SLC2A9	0.52	4.9	0.45	3.98e-6	Schizophrenia (age at onset);
THYM	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg23187316	chr7:1099788	C7orf50	0.59	4.52	0.42	1.76e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg22166914	chr1:53195759	ZYG11B	0.64	5.48	0.49	3.54e-7	Monocyte count;
THYM	cis	rs2862064	1.000	rs1501910	chr5:156418790	A/G	cg12943317	chr5:156479607	HAVCR1	-0.87	-5.18	-0.47	1.26e-6	Platelet count;
THYM	cis	rs34638657	0.687	rs2303265	chr16:82203705	A/C	cg07307142	chr16:82071433	HSD17B2	-0.86	-7.49	-0.61	3.58e-11	Lung adenocarcinoma;
THYM	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.11	7.46	0.61	3.98e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg04865290	chr3:52927548	TMEM110	-0.96	-4.97	-0.45	2.97e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg09877947	chr5:131593287	PDLIM4	0.56	4.56	0.42	1.51e-5	Blood metabolite levels;
THYM	cis	rs13064411	0.627	rs9872168	chr3:113233132	A/C	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7107174	0.579	rs1981405	chr11:77976208	C/T	cg02023728	chr11:77925099	USP35	0.62	4.61	0.43	1.24e-5	Testicular germ cell tumor;
THYM	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.61	4.64	0.43	1.1e-5	Renal function-related traits (BUN);
THYM	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg03909863	chr11:638404	DRD4	-0.78	-5.75	-0.51	1.07e-7	Systemic lupus erythematosus;
THYM	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg12698349	chr2:225449008	CUL3	1.13	12.54	0.79	7.33e-22	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	trans	rs480407	0.759	rs13014133	chr2:161751552	T/C	cg06548410	chr19:1997657	BTBD2	0.74	7.0	0.58	3.58e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	trans	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.62	5.65	0.5	1.69e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.71	5.65	0.5	1.69e-7	Tonsillectomy;
THYM	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.57	4.65	0.43	1.06e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7586673	1.000	rs7586673	chr2:161923520	C/A	cg22496339	chr2:162101262	NA	0.64	5.03	0.46	2.33e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg22875332	chr1:76189707	ACADM	-0.75	-6.46	-0.55	4.51e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg06108461	chr20:60628389	TAF4	-1.06	-8.54	-0.66	2.19e-13	Body mass index;
THYM	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs3862030	0.720	rs1056744	chr10:104236687	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-5.91	-0.52	5.34e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs11574514	1.000	rs117017165	chr16:67646311	G/A	cg09738193	chr16:67926317	PSKH1	-0.92	-4.49	-0.42	2e-5	Crohn's disease;
THYM	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg14458575	chr2:238380390	NA	-0.89	-6.76	-0.57	1.12e-9	Prostate cancer;
THYM	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs713587	0.967	rs10182181	chr2:25150296	C/T	cg01884057	chr2:25150051	NA	-0.72	-8.02	-0.64	2.78e-12	Body mass index in non-asthmatics;
THYM	cis	rs7264396	0.561	rs2064725	chr20:34569142	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-4.48	-0.42	2.06e-5	Total cholesterol levels;
THYM	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg15445000	chr17:37608096	MED1	0.41	4.61	0.43	1.27e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg03433033	chr1:76189801	ACADM	0.64	5.65	0.5	1.67e-7	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.65	-0.62	1.6e-11	Schizophrenia;
THYM	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.49	0.49	3.33e-7	Platelet count;
THYM	cis	rs2554380	0.800	rs8032414	chr15:84395969	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.65	-5.23	-0.47	1.02e-6	Height;
THYM	cis	rs7772486	0.875	rs56181683	chr6:146286620	A/G	cg13319975	chr6:146136371	FBXO30	0.76	6.24	0.54	1.2e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs800586	0.912	rs2736207	chr8:116809655	C/T	cg04656070	chr8:116661063	TRPS1	0.48	4.95	0.45	3.24e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7408868	0.831	rs7249115	chr19:15280765	A/G	cg14696996	chr19:15285081	NOTCH3	0.96	5.54	0.49	2.74e-7	Pulse pressure;
THYM	cis	rs7589342	0.895	rs2033008	chr2:106502585	T/A	cg14210321	chr2:106509881	NCK2	-0.8	-6.09	-0.53	2.42e-8	Addiction;
THYM	cis	rs17102423	0.623	rs2093989	chr14:65553939	C/T	cg11161011	chr14:65562177	MAX	-0.71	-5.77	-0.51	1.01e-7	Obesity-related traits;
THYM	cis	rs9902453	0.874	rs3936006	chr17:28257660	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.85	6.3	0.54	9.03e-9	Coffee consumption (cups per day);
THYM	cis	rs6882076	1.000	rs4704727	chr5:156380067	T/G	cg06200339	chr5:157079404	SOX30	0.45	4.54	0.42	1.66e-5	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg15744005	chr10:104629667	AS3MT	-0.76	-7.03	-0.58	3.13e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs11249608	0.789	rs7706393	chr5:178437737	G/T	cg01312482	chr5:178451176	ZNF879	0.59	4.78	0.44	6.34e-6	Pubertal anthropometrics;
THYM	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs9633835	0.611	rs11823635	chr11:13349479	C/G	cg13286116	chr11:13302098	ARNTL	-0.62	-6.47	-0.55	4.21e-9	Body mass index;
THYM	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg22509189	chr2:225307070	NA	-0.71	-5.77	-0.51	9.76e-8	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs4474465	1.000	rs10793316	chr11:78211928	C/A	cg19901956	chr11:77921274	USP35	0.65	4.8	0.44	5.97e-6	Alzheimer's disease (survival time);
THYM	cis	rs2075230	0.542	rs2955616	chr17:7544084	A/G	cg10509001	chr17:7553872	ATP1B2	-0.57	-4.61	-0.43	1.26e-5	Hormone measurements;
THYM	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.72	-5.59	-0.5	2.14e-7	Response to bleomycin (chromatid breaks);
THYM	cis	rs2455799	0.613	rs1969095	chr3:15733552	C/T	cg16303742	chr3:15540471	COLQ	-0.55	-5.94	-0.52	4.71e-8	Mean platelet volume;
THYM	cis	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg03213289	chr20:61660250	NA	-0.94	-9.64	-0.7	9.57e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg22683308	chr4:1340831	KIAA1530	-0.59	-4.62	-0.43	1.2e-5	Longevity;
THYM	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs7264396	0.790	rs10211771	chr20:34219994	T/C	cg26038318	chr20:34205095	SPAG4	0.66	5.39	0.48	5.12e-7	Total cholesterol levels;
THYM	cis	rs6456042	1.000	rs3099291	chr6:166528913	A/G	cg11088901	chr6:166572345	T	0.52	4.94	0.45	3.3e-6	Asthma;
THYM	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg12935359	chr14:103987150	CKB	-0.64	-6.43	-0.55	5.14e-9	Body mass index;
THYM	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg03264133	chr6:25882463	NA	-0.66	-4.49	-0.42	2.01e-5	Height;
THYM	cis	rs17152411	1.000	rs7089014	chr10:126590342	G/A	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg20007245	chr22:24372913	LOC391322	-0.8	-7.76	-0.62	9.48e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs17401966	0.838	rs35759975	chr1:10474430	A/T	cg19773385	chr1:10388646	KIF1B	-0.6	-4.89	-0.45	4.13e-6	Hepatocellular carcinoma;
THYM	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.53	4.64	0.43	1.13e-5	Lymphocyte counts;
THYM	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg07606381	chr6:8435919	SLC35B3	0.61	4.45	0.42	2.31e-5	Motion sickness;
THYM	cis	rs11771526	0.892	rs62457540	chr7:32372199	A/G	cg27532318	chr7:32358331	NA	0.95	5.63	0.5	1.85e-7	Body mass index;
THYM	cis	rs3812049	0.784	rs1560637	chr5:127448066	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.42	0.49	4.45e-7	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03264133	chr6:25882463	NA	0.72	5.71	0.51	1.29e-7	Blood metabolite levels;
THYM	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg17105886	chr17:28927953	LRRC37B2	1.21	7.24	0.6	1.14e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg07884673	chr3:53033167	SFMBT1	-1.17	-5.88	-0.52	6.13e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2257129	1.000	rs6585699	chr10:122921660	A/G	cg22762615	chr10:123358210	FGFR2	1.37	4.57	0.42	1.45e-5	Coronary artery disease;Body mass index;
THYM	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg08017756	chr2:100939284	LONRF2	-0.69	-7.09	-0.59	2.35e-10	Intelligence (multi-trait analysis);
THYM	cis	rs3820068	0.608	rs6668919	chr1:16049893	A/G	cg24675056	chr1:15929824	NA	-0.75	-5.95	-0.52	4.56e-8	Systolic blood pressure;
THYM	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.67	4.76	0.44	6.93e-6	Aortic root size;
THYM	trans	rs9296092	0.517	rs55683509	chr6:33471077	A/G	cg00929798	chr10:135150139	CALY	0.69	6.91	0.58	5.61e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg17063962	chr7:91808500	NA	1.15	10.64	0.74	7.09e-18	Breast cancer;
THYM	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg26384229	chr12:38710491	ALG10B	1.0	6.46	0.55	4.36e-9	Bladder cancer;
THYM	cis	rs16866061	1.000	rs72974222	chr2:225424143	C/T	cg12698349	chr2:225449008	CUL3	1.14	10.45	0.73	1.77e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs9318086	0.648	rs9507184	chr13:24473642	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.57	4.78	0.44	6.44e-6	Myopia (pathological);
THYM	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg10018233	chr7:150070692	REPIN1	0.38	5.39	0.48	5.05e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg00786635	chr1:25594202	NA	0.88	6.85	0.58	7.26e-10	Erythrocyte sedimentation rate;
THYM	cis	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg12981288	chr8:11183844	MTMR9	-0.49	-4.8	-0.44	5.86e-6	Retinal vascular caliber;
THYM	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.09	-7.74	-0.62	1.06e-11	Platelet count;
THYM	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg07414643	chr4:187882934	NA	0.64	5.75	0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2948294	0.566	rs13261997	chr8:8112295	C/T	cg06636001	chr8:8085503	FLJ10661	0.73	6.31	0.54	8.63e-9	Red cell distribution width;
THYM	cis	rs12889267	0.770	rs2319627	chr14:21565189	C/T	cg23374312	chr14:21565335	ZNF219	0.79	6.01	0.53	3.35e-8	Hematocrit;Resting heart rate;
THYM	cis	rs10463554	0.963	rs1595553	chr5:102378868	A/C	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs67981189	0.865	rs34488204	chr14:71495288	C/T	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg16680214	chr1:154839983	KCNN3	-0.45	-5.03	-0.46	2.32e-6	Prostate cancer;
THYM	cis	rs7666738	0.752	rs35436270	chr4:99088280	G/A	cg03676636	chr4:99064102	C4orf37	0.47	6.3	0.54	9.09e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg13010199	chr12:38710504	ALG10B	0.76	5.24	0.47	9.7e-7	Heart rate;
THYM	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg19610905	chr11:61596333	FADS2	-0.61	-5.16	-0.47	1.36e-6	LDL cholesterol;
THYM	cis	rs9326248	0.581	rs12804122	chr11:116902616	C/G	cg20608306	chr11:116969690	SIK3	0.64	7.96	0.63	3.61e-12	Blood protein levels;
THYM	cis	rs2836633	1.000	rs2836631	chr21:40065906	G/T	cg12884169	chr21:40033163	ERG	-0.6	-7.24	-0.6	1.13e-10	Coronary artery disease;
THYM	trans	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg00990874	chr7:1149470	C7orf50	-0.67	-4.88	-0.45	4.21e-6	Bronchopulmonary dysplasia;
THYM	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg24692254	chr21:30365293	RNF160	-0.99	-9.28	-0.69	5.71e-15	Dental caries;
THYM	cis	rs6456042	0.893	rs2277093	chr6:166570766	C/T	cg11088901	chr6:166572345	T	-0.54	-5.27	-0.48	8.52e-7	Asthma;
THYM	cis	rs12935418	0.616	rs13336292	chr16:81005692	G/A	cg16651780	chr16:81037892	C16orf61	0.74	5.18	0.47	1.25e-6	Mean corpuscular volume;
THYM	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-5.63	-0.5	1.84e-7	Chronic sinus infection;
THYM	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14893161	chr1:205819251	PM20D1	1.13	13.85	0.82	1.59e-24	Menarche (age at onset);
THYM	cis	rs68170813	0.559	rs76145119	chr7:107052368	C/T	cg00661777	chr7:106511741	PIK3CG	-0.67	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg05872129	chr22:39784769	NA	1.03	9.97	0.71	1.96e-16	Intelligence (multi-trait analysis);
THYM	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg12863693	chr15:85201151	NMB	0.63	5.5	0.49	3.17e-7	Schizophrenia;
THYM	cis	rs72781680	0.950	rs72796343	chr2:24147631	G/A	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs11776767	0.515	rs3808605	chr8:10698394	T/C	cg13457217	chr8:10683266	MIR1322;PINX1	-0.65	-4.74	-0.44	7.37e-6	Triglycerides;
THYM	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg12963246	chr6:28129442	ZNF389	0.72	6.12	0.53	2.05e-8	Depression;
THYM	cis	rs478304	0.593	rs2236682	chr11:65480090	G/T	cg27068330	chr11:65405492	SIPA1	-0.94	-9.05	-0.68	1.77e-14	Acne (severe);
THYM	cis	rs1568889	0.838	rs10835299	chr11:28277693	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.84	-7.39	-0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs854765	0.624	rs12938501	chr17:17737258	A/C	cg16928487	chr17:17741425	SREBF1	0.54	5.05	0.46	2.16e-6	Total body bone mineral density;
THYM	cis	rs7558911	0.802	rs11674246	chr2:202048123	C/T	cg12105450	chr2:202048100	CASP10	0.51	4.59	0.43	1.33e-5	Chronic lymphocytic leukemia;
THYM	cis	rs7172809	0.573	rs17384809	chr15:77622006	A/G	cg22256960	chr15:77711686	NA	0.62	4.52	0.42	1.76e-5	Glucose homeostasis traits;
THYM	cis	rs8048589	0.750	rs12926900	chr16:12184084	C/G	cg02910054	chr16:12241554	SNX29	0.65	5.74	0.51	1.15e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs1957429	0.901	rs7141985	chr14:65345670	C/T	cg23373153	chr14:65346875	NA	1.06	5.97	0.52	3.99e-8	Pediatric areal bone mineral density (radius);
THYM	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg21226059	chr5:178986404	RUFY1	-0.51	-5.4	-0.48	4.99e-7	Lung cancer;
THYM	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg20291162	chr17:40259547	DHX58	-0.7	-6.47	-0.55	4.18e-9	Fibrinogen levels;
THYM	trans	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Bladder cancer;
THYM	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.69	-0.62	1.33e-11	Personality dimensions;
THYM	cis	rs6546324	0.592	rs9309402	chr2:67869338	T/C	cg18237512	chr2:67827392	NA	-0.78	-4.63	-0.43	1.14e-5	Endometriosis;
THYM	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg24209194	chr3:40518798	ZNF619	0.56	4.56	0.42	1.52e-5	Renal cell carcinoma;
THYM	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.62	0.56	2.11e-9	Total body bone mineral density;
THYM	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg00757033	chr12:89920650	WDR51B	0.74	11.52	0.76	9.94e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg15052019	chr19:19431593	KIAA0892;SF4	-0.66	-5.22	-0.47	1.07e-6	Tonsillectomy;
THYM	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg15592062	chr6:167189543	RPS6KA2	0.59	6.16	0.53	1.73e-8	Crohn's disease;
THYM	cis	rs870825	0.860	rs72703521	chr4:185603080	T/C	cg04058563	chr4:185651563	MLF1IP	1.0	7.42	0.61	4.93e-11	Blood protein levels;
THYM	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg07936489	chr17:37558343	FBXL20	-0.76	-5.38	-0.48	5.39e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs13256369	0.853	rs13256216	chr8:8577883	C/T	cg00074818	chr8:8560427	CLDN23	0.57	5.13	0.47	1.55e-6	Obesity-related traits;
THYM	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg26354017	chr1:205819088	PM20D1	0.94	9.63	0.7	1e-15	Menarche (age at onset);
THYM	trans	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg10856724	chr12:34555212	NA	-0.94	-8.22	-0.64	1.01e-12	Bladder cancer;
THYM	cis	rs6840360	1.000	rs4696284	chr4:152595836	C/G	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg13147721	chr7:65941812	NA	-0.89	-5.31	-0.48	7.23e-7	Diabetic kidney disease;
THYM	cis	rs11792861	0.591	rs2282206	chr9:111746267	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.82	7.06	0.59	2.73e-10	Menarche (age at onset);
THYM	cis	rs2275731	0.505	rs7894216	chr10:16479251	C/G	cg00316341	chr10:16898311	CUBN	0.35	4.77	0.44	6.68e-6	Bone fracture in osteoporosis;
THYM	cis	rs13070279	1.000	rs13070279	chr3:71824685	G/A	cg19388776	chr3:71835112	PROK2	0.82	4.95	0.45	3.21e-6	Monocyte count;
THYM	cis	rs3862030	0.720	rs7341995	chr10:104223831	G/A	cg00122347	chr10:104236741	TMEM180	0.47	7.23	0.6	1.22e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs3087591	0.690	rs12103621	chr17:29607235	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.69	-5.47	-0.49	3.68e-7	Hip circumference;
THYM	cis	rs911119	1.000	rs3787499	chr20:23616807	G/A	cg16589663	chr20:23618590	CST3	0.78	4.79	0.44	6.1e-6	Chronic kidney disease;
THYM	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg00071950	chr4:10020882	SLC2A9	0.77	7.8	0.62	7.8e-12	Bone mineral density;
THYM	cis	rs823143	0.549	rs1094647	chr1:205655378	G/A	cg16031515	chr1:205743344	RAB7L1	-0.67	-6.72	-0.57	1.36e-9	Monocyte percentage of white cells;
THYM	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg23758822	chr17:41437982	NA	1.21	11.71	0.77	3.86e-20	Menopause (age at onset);
THYM	cis	rs656319	0.513	rs34990153	chr8:9996389	A/G	cg20181426	chr8:10469310	RP1L1	0.54	4.87	0.45	4.5e-6	Myopia (pathological);
THYM	cis	rs472402	0.580	rs8192186	chr5:6652009	G/A	cg12648172	chr5:5886274	NA	0.52	4.72	0.44	7.99e-6	Response to amphetamines;
THYM	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.71	5.38	0.48	5.41e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7104764	1.000	rs7482591	chr11:245861	G/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg18305652	chr10:134549665	INPP5A	0.86	7.82	0.63	7.22e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9549260	0.755	rs9549252	chr13:41230141	A/G	cg21288729	chr13:41239152	FOXO1	0.73	5.65	0.5	1.67e-7	Red blood cell count;
THYM	cis	rs9457247	0.534	rs12055488	chr6:167379570	A/G	cg23791538	chr6:167370224	RNASET2	0.8	7.06	0.59	2.78e-10	Crohn's disease;
THYM	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.8	5.92	0.52	5.13e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs990171	0.607	rs10153578	chr2:102764609	C/T	cg13315345	chr2:102803985	IL1RL2	-0.53	-4.46	-0.42	2.25e-5	Lymphocyte counts;
THYM	cis	rs8046696	1	rs8046696	chr16:75442143	T/G	cg03315344	chr16:75512273	CHST6	0.78	6.28	0.54	1.03e-8	Coronary artery disease;
THYM	cis	rs7715811	1.000	rs6554812	chr5:13762972	T/C	cg07548982	chr5:13769939	DNAH5	-0.5	-4.5	-0.42	1.95e-5	Subclinical atherosclerosis traits (other);
THYM	cis	rs8067354	0.645	rs7215180	chr17:57822354	A/G	cg20151207	chr17:57696971	CLTC	-0.7	-4.67	-0.43	9.76e-6	Hemoglobin concentration;
THYM	cis	rs4595586	0.545	rs12819061	chr12:39386976	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4907240	0.961	rs6749159	chr2:97267293	T/C	cg18419276	chr2:96971862	SNRNP200	-0.4	-4.73	-0.44	7.72e-6	Event-related brain oscillations;
THYM	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg07936489	chr17:37558343	FBXL20	0.83	5.84	0.51	7.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg13695892	chr22:41940480	POLR3H	0.99	7.48	0.61	3.75e-11	Vitiligo;
THYM	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg17063962	chr7:91808500	NA	-1.15	-12.33	-0.78	2.01e-21	Breast cancer;
THYM	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg17143192	chr8:8559678	CLDN23	0.96	7.32	0.6	7.85e-11	Obesity-related traits;
THYM	cis	rs7618501	0.699	rs11130224	chr3:49936910	T/A	cg24308560	chr3:49941425	MST1R	-0.77	-6.51	-0.56	3.57e-9	Intelligence (multi-trait analysis);
THYM	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg02038168	chr22:39784481	NA	-0.63	-4.64	-0.43	1.12e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs459571	0.959	rs467379	chr9:136905474	C/T	cg13789015	chr9:136890014	NCRNA00094	0.72	6.39	0.55	6.11e-9	Platelet distribution width;
THYM	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg03806693	chr22:41940476	POLR3H	0.97	8.04	0.64	2.5e-12	Cannabis dependence symptom count;
THYM	cis	rs9677476	0.818	rs6753393	chr2:232061967	G/C	cg07929768	chr2:232055508	NA	0.59	5.95	0.52	4.43e-8	Food antigen IgG levels;
THYM	cis	rs1018836	0.892	rs7819519	chr8:91565504	C/T	cg16814680	chr8:91681699	NA	-0.78	-6.42	-0.55	5.41e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs10924970	0.967	rs8179454	chr1:235460719	C/G	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.37e-5	Asthma;
THYM	cis	rs7524258	0.835	rs7521425	chr1:7306543	C/T	cg07173049	chr1:7289937	CAMTA1	0.71	5.83	0.51	7.48e-8	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs7937682	0.632	rs11214029	chr11:111761230	C/T	cg09085632	chr11:111637200	PPP2R1B	1.16	11.93	0.77	1.35e-20	Primary sclerosing cholangitis;
THYM	cis	rs17122693	0.748	rs72681636	chr14:51145871	G/T	cg04730355	chr14:51134070	SAV1	0.94	5.85	0.51	7.11e-8	Cognitive performance;
THYM	cis	rs17253792	0.822	rs28513551	chr14:56094993	G/A	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs1018697	0.518	rs284843	chr10:104553566	C/T	cg04362960	chr10:104952993	NT5C2	-0.74	-5.09	-0.46	1.84e-6	Colorectal adenoma (advanced);
THYM	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg07606381	chr6:8435919	SLC35B3	0.63	4.64	0.43	1.11e-5	Motion sickness;
THYM	cis	rs9443645	0.527	rs1413968	chr6:79791042	A/G	cg05283184	chr6:79620031	NA	-0.6	-4.67	-0.43	9.91e-6	Intelligence (multi-trait analysis);
THYM	cis	rs950880	0.710	rs11465633	chr2:102997733	G/T	cg03938978	chr2:103052716	IL18RAP	-0.5	-4.46	-0.42	2.24e-5	Serum protein levels (sST2);
THYM	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg09537434	chr19:41945824	ATP5SL	-0.97	-8.88	-0.67	4.01e-14	Height;
THYM	cis	rs9388451	0.531	rs9375414	chr6:126154475	G/A	cg10911889	chr6:126070802	HEY2	0.63	4.8	0.44	5.85e-6	Brugada syndrome;
THYM	cis	rs7917772	0.582	rs7087984	chr10:104380686	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.69	0.57	1.57e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs17253792	0.822	rs78615025	chr14:56168012	G/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg10117171	chr1:25599238	RHD	-0.68	-4.87	-0.45	4.4e-6	Erythrocyte sedimentation rate;
THYM	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg13010199	chr12:38710504	ALG10B	0.73	5.82	0.51	7.99e-8	Heart rate;
THYM	cis	rs13108904	0.521	rs11247998	chr4:1363602	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.35	5.01	0.46	2.46e-6	Obesity-related traits;
THYM	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg25072359	chr17:41440525	NA	0.77	5.74	0.51	1.15e-7	Menopause (age at onset);
THYM	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.32	-0.48	7.02e-7	Monocyte percentage of white cells;
THYM	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6032067	0.639	rs62205502	chr20:43864197	G/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.66	-7.59	-0.61	2.22e-11	Blood protein levels;
THYM	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg26721908	chr21:47610096	LSS	-0.85	-6.73	-0.57	1.26e-9	Testicular germ cell tumor;
THYM	cis	rs36051895	0.502	rs10975003	chr9:5213687	T/C	cg02405213	chr9:5042618	JAK2	-0.83	-8.0	-0.63	3.04e-12	Pediatric autoimmune diseases;
THYM	cis	rs977987	0.806	rs11640473	chr16:75403289	C/A	cg03315344	chr16:75512273	CHST6	0.73	6.07	0.53	2.66e-8	Dupuytren's disease;
THYM	cis	rs9677476	0.863	rs12478335	chr2:232064967	C/A	cg07929768	chr2:232055508	NA	0.63	6.28	0.54	1.01e-8	Food antigen IgG levels;
THYM	cis	rs7106204	0.748	rs11827778	chr11:24211321	G/A	ch.11.24196551F	chr11:24239977	NA	0.99	7.0	0.58	3.64e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs11087123	0.500	rs1743475	chr20:15120893	G/C	cg09937190	chr20:15177509	MACROD2	-0.48	-5.41	-0.49	4.63e-7	Eating disorders;
THYM	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-4.73	-0.44	7.8e-6	Chronic sinus infection;
THYM	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.6	-4.62	-0.43	1.22e-5	Eosinophil percentage of white cells;
THYM	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg26441486	chr22:50317300	CRELD2	0.43	6.59	0.56	2.39e-9	Schizophrenia;
THYM	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg14664628	chr15:75095509	CSK	0.67	5.11	0.46	1.66e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs7909074	0.899	rs2026428	chr10:45389452	T/C	cg05187965	chr10:45406764	TMEM72	-0.53	-4.96	-0.45	3.1e-6	Mean corpuscular volume;
THYM	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg06640241	chr16:89574553	SPG7	-0.61	-4.66	-0.43	1.03e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs6598955	0.724	rs12068388	chr1:26621596	G/A	cg00852783	chr1:26633632	UBXN11	0.86	8.81	0.67	5.74e-14	Obesity-related traits;
THYM	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.73	-4.84	-0.44	5.01e-6	Menarche (age at onset);
THYM	cis	rs6674176	0.932	rs4660761	chr1:44440146	G/A	cg26023051	chr1:45103896	RNF220	0.67	4.48	0.42	2.08e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs6754311	0.593	rs2034276	chr2:136422171	A/T	cg23851026	chr2:136556271	LCT	0.59	5.62	0.5	1.91e-7	Mosquito bite size;
THYM	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg17063962	chr7:91808500	NA	-1.13	-12.56	-0.79	6.81e-22	Breast cancer;
THYM	cis	rs4654899	0.865	rs6685831	chr1:21507888	G/A	cg01072550	chr1:21505969	NA	-0.74	-6.68	-0.57	1.63e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg18252515	chr7:66147081	NA	-0.89	-6.65	-0.56	1.85e-9	Corneal structure;
THYM	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg09085632	chr11:111637200	PPP2R1B	0.95	8.68	0.67	1.1e-13	Primary sclerosing cholangitis;
THYM	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.69	-0.5	1.38e-7	Mean corpuscular volume;
THYM	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg18128536	chr17:47092178	IGF2BP1	-0.44	-4.89	-0.45	4.13e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs586688	0.929	rs678092	chr1:201640266	G/A	cg14168733	chr1:201708718	NAV1	0.62	5.16	0.47	1.34e-6	Obesity-related traits;
THYM	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.38	-0.65	4.69e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg03609598	chr5:56110824	MAP3K1	-0.84	-5.73	-0.51	1.16e-7	Initial pursuit acceleration;
THYM	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	5.43	0.49	4.33e-7	Obesity-related traits;
THYM	cis	rs4072705	0.616	rs915033	chr9:127245558	C/G	cg13476313	chr9:127244764	NR5A1	0.36	5.27	0.48	8.48e-7	Menarche (age at onset);
THYM	cis	rs6430585	0.793	rs11684545	chr2:136539122	G/T	cg07169764	chr2:136633963	MCM6	-0.66	-5.68	-0.5	1.44e-7	Corneal structure;
THYM	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg00383909	chr3:49044727	WDR6	1.47	6.34	0.55	7.84e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs11648796	0.765	rs3829492	chr16:781633	G/A	cg09263875	chr16:632152	PIGQ	0.63	4.56	0.42	1.51e-5	Height;
THYM	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg07988820	chr12:82153109	PPFIA2	0.84	5.45	0.49	3.94e-7	Resting heart rate;
THYM	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.61	-0.74	8.26e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs6138458	1.000	rs6114988	chr20:24977586	C/T	cg26195577	chr20:24973756	C20orf3	1.09	11.01	0.75	1.16e-18	Blood protein levels;
THYM	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22307029	chr19:49891270	CCDC155	0.59	4.72	0.44	8.04e-6	Multiple sclerosis;
THYM	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg06481639	chr22:41940642	POLR3H	0.75	5.04	0.46	2.19e-6	Vitiligo;
THYM	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.59	-0.43	1.34e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg15691649	chr6:25882328	NA	-0.87	-6.58	-0.56	2.57e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7646881	0.953	rs73015657	chr3:158451932	G/A	cg19483011	chr3:158453295	NA	-0.77	-5.54	-0.49	2.65e-7	Tetralogy of Fallot;
THYM	cis	rs10752881	1.000	rs10752883	chr1:182980963	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs11586313	1.000	rs11586313	chr1:152890470	C/T	cg07796016	chr1:152779584	LCE1C	-0.7	-6.21	-0.54	1.37e-8	Vitamin D levels;
THYM	cis	rs7831492	0.564	rs6981979	chr8:41612255	C/T	cg17182837	chr8:41585554	ANK1	-0.59	-5.25	-0.47	9.09e-7	Colorectal cancer;
THYM	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.66	-4.76	-0.44	6.82e-6	Renal function-related traits (BUN);
THYM	cis	rs28595532	0.920	rs114410095	chr4:119731110	G/A	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.4	-0.48	4.99e-7	Menopause (age at onset);
THYM	cis	rs12291225	0.679	rs4756786	chr11:14285900	C/A	cg05501817	chr11:14380813	RRAS2	-0.73	-5.52	-0.49	2.94e-7	Sense of smell;
THYM	cis	rs888194	0.686	rs11067376	chr12:110027795	A/G	cg11367159	chr12:110044531	NA	0.61	5.23	0.47	9.89e-7	Neuroticism;
THYM	trans	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg19862616	chr7:65841803	NCRNA00174	1.09	12.64	0.79	4.47e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4930103	0.935	rs11042170	chr11:2021625	C/T	cg21926276	chr11:2035255	NA	0.27	4.53	0.42	1.7e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg07636037	chr3:49044803	WDR6	0.89	7.93	0.63	4.29e-12	Parkinson's disease;
THYM	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg18477163	chr1:228402036	OBSCN	0.57	6.23	0.54	1.28e-8	Diastolic blood pressure;
THYM	cis	rs354225	0.544	rs12713266	chr2:54805443	G/T	cg23486701	chr2:54789491	SPTBN1	0.34	4.49	0.42	2e-5	Schizophrenia;
THYM	cis	rs4930103	1.000	rs4929983	chr11:2024579	C/T	cg03175030	chr11:2018143	H19;MIR675	-0.43	-4.78	-0.44	6.35e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg03213289	chr20:61660250	NA	0.91	9.46	0.7	2.34e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg22841779	chr14:105766346	BRF1	-0.46	-5.72	-0.51	1.25e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-8.52	-0.66	2.33e-13	Schizophrenia;
THYM	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg03433033	chr1:76189801	ACADM	-0.82	-6.88	-0.58	6.2e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg02782426	chr3:40428986	ENTPD3	-0.51	-4.56	-0.42	1.55e-5	Renal cell carcinoma;
THYM	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg08017756	chr2:100939284	LONRF2	-0.69	-7.09	-0.59	2.35e-10	Intelligence (multi-trait analysis);
THYM	cis	rs593982	0.858	rs480989	chr11:65493992	A/G	cg08755490	chr11:65554678	OVOL1	1.33	7.98	0.63	3.3e-12	Atopic dermatitis;
THYM	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg07570687	chr10:102243282	WNT8B	0.76	6.78	0.57	9.91e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1371867	0.846	rs2439458	chr8:101297984	T/C	cg00191853	chr8:101177733	SPAG1	-0.5	-5.01	-0.46	2.54e-6	Atrioventricular conduction;
THYM	cis	rs10078	0.615	rs2720997	chr5:433654	A/G	cg08916839	chr5:415575	AHRR	0.74	4.8	0.44	5.78e-6	Fat distribution (HIV);
THYM	cis	rs2639990	0.744	rs640261	chr18:72905808	C/T	cg02750262	chr18:72916776	ZADH2	1.3	6.31	0.54	8.66e-9	Vascular endothelial growth factor levels;
THYM	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg24818145	chr4:99064322	C4orf37	0.69	5.41	0.49	4.61e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4788570	0.615	rs889568	chr16:71772399	T/C	cg06353428	chr16:71660113	MARVELD3	1.31	8.68	0.67	1.08e-13	Intelligence (multi-trait analysis);
THYM	cis	rs12765878	0.934	rs11191841	chr10:105639611	C/T	cg11005552	chr10:105648138	OBFC1	-0.79	-9.69	-0.7	7.64e-16	Coronary artery disease;
THYM	cis	rs887829	0.588	rs4663971	chr2:234674252	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.72	-5.74	-0.51	1.11e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs34638657	0.732	rs12102917	chr16:82196808	G/A	cg09439754	chr16:82129088	HSD17B2	-0.46	-4.64	-0.43	1.1e-5	Lung adenocarcinoma;
THYM	cis	rs6032067	0.852	rs2868240	chr20:43874039	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	0.71	7.45	0.61	4.33e-11	Blood protein levels;
THYM	cis	rs7027203	0.828	rs10821229	chr9:96595136	A/C	cg13679303	chr9:96623674	NA	-0.51	-5.35	-0.48	6.06e-7	DNA methylation (variation);
THYM	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg13395646	chr4:1353034	KIAA1530	-0.54	-5.15	-0.47	1.38e-6	Obesity-related traits;
THYM	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg10755058	chr3:40428713	ENTPD3	-0.53	-4.64	-0.43	1.12e-5	Renal cell carcinoma;
THYM	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg18512352	chr11:47633146	NA	-0.51	-6.09	-0.53	2.34e-8	Subjective well-being;
THYM	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg09904177	chr6:26538194	HMGN4	0.53	4.5	0.42	1.95e-5	Intelligence (multi-trait analysis);
THYM	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg23649088	chr2:200775458	C2orf69	-0.75	-5.55	-0.49	2.56e-7	Schizophrenia;
THYM	cis	rs2862064	0.932	rs2221267	chr5:156401533	G/C	cg12943317	chr5:156479607	HAVCR1	-0.84	-4.87	-0.45	4.38e-6	Platelet count;
THYM	cis	rs7926906	1.000	rs1524939	chr11:90535620	G/A	cg26138821	chr11:89956704	CHORDC1	-0.56	-5.04	-0.46	2.19e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1801251	0.727	rs35853577	chr2:233558879	T/C	cg08000102	chr2:233561755	GIGYF2	0.67	5.76	0.51	1.02e-7	Coronary artery disease;
THYM	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg06634786	chr22:41940651	POLR3H	0.73	5.33	0.48	6.69e-7	Vitiligo;
THYM	cis	rs2067615	0.579	rs1073261	chr12:107135942	A/G	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.82	4.59	0.43	1.37e-5	Initial pursuit acceleration;
THYM	cis	rs17534004	1.000	rs34538248	chr13:31468796	A/C	cg00367615	chr13:31480979	C13orf33	0.65	4.69	0.43	8.99e-6	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs11792861	0.926	rs10512391	chr9:111809530	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.7	5.74	0.51	1.13e-7	Menarche (age at onset);
THYM	cis	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg00495681	chr13:53174319	NA	0.71	6.53	0.56	3.19e-9	Lewy body disease;
THYM	cis	rs981844	0.775	rs55986083	chr4:154765640	A/C	cg09973105	chr4:154681532	RNF175	-0.62	-5.1	-0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg13607699	chr17:42295918	UBTF	0.63	5.15	0.47	1.43e-6	Total body bone mineral density;
THYM	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.63	-5.09	-0.46	1.82e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg13390004	chr1:15929781	NA	0.61	4.63	0.43	1.15e-5	Systolic blood pressure;
THYM	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg16524936	chr4:1340807	KIAA1530	-0.67	-5.19	-0.47	1.17e-6	Longevity;
THYM	cis	rs17106184	1.000	rs1474784	chr1:50944634	C/G	cg07174182	chr1:51127561	FAF1	-0.96	-4.7	-0.43	8.68e-6	Type 2 diabetes;
THYM	cis	rs1483890	0.505	rs7627492	chr3:69365781	G/A	cg22125112	chr3:69402811	FRMD4B	-0.43	-5.16	-0.47	1.36e-6	Resting heart rate;
THYM	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs78579285	0.622	rs4782322	chr16:88797669	T/G	cg04002220	chr16:89598305	SPG7	0.66	4.74	0.44	7.48e-6	Joint mobility (Beighton score);
THYM	cis	rs340630	0.967	rs13126334	chr4:87909890	A/G	cg10685359	chr4:87814065	C4orf36	0.45	5.78	0.51	9.52e-8	Systemic lupus erythematosus;
THYM	cis	rs6446298	0.738	rs6446296	chr3:49838052	G/A	cg03060546	chr3:49711283	APEH	-0.9	-6.12	-0.53	2.11e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1467026	0.584	rs11712581	chr3:12807781	T/C	cg05775895	chr3:12838266	CAND2	0.85	7.02	0.58	3.23e-10	P wave duration;
THYM	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg10802521	chr3:52805072	NEK4	-0.73	-6.21	-0.54	1.42e-8	Bipolar disorder;
THYM	cis	rs1448094	0.512	rs11832503	chr12:86240797	A/G	cg02569458	chr12:86230093	RASSF9	0.58	5.01	0.46	2.47e-6	Major depressive disorder;
THYM	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg26384229	chr12:38710491	ALG10B	-0.93	-7.72	-0.62	1.16e-11	Bladder cancer;
THYM	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg03264133	chr6:25882463	NA	-0.93	-8.29	-0.65	7.18e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7828089	0.646	rs3943520	chr8:22282732	A/G	cg13512537	chr8:22265999	SLC39A14	-0.66	-5.1	-0.46	1.71e-6	Verbal declarative memory;
THYM	cis	rs4866334	1.000	rs75393523	chr5:18488595	T/G	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg17063962	chr7:91808500	NA	1.15	12.05	0.78	7.68e-21	Breast cancer;
THYM	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg27446573	chr6:127587934	RNF146	0.76	6.64	0.56	1.9e-9	Breast cancer;
THYM	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	9.34	0.69	4.33e-15	Platelet count;
THYM	cis	rs73787773	0.867	rs73227496	chr5:111480685	A/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.91	-4.83	-0.44	5.23e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.77	-7.12	-0.59	2.03e-10	Personality dimensions;
THYM	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg18252515	chr7:66147081	NA	0.64	4.6	0.43	1.29e-5	Aortic root size;
THYM	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.09	0.64	1.96e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2404602	0.709	rs11072597	chr15:76763514	C/A	cg23482746	chr15:76478102	C15orf27	0.47	4.46	0.42	2.27e-5	Blood metabolite levels;
THYM	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg05025164	chr4:1340916	KIAA1530	0.95	7.7	0.62	1.31e-11	Longevity;
THYM	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg08772003	chr10:104629869	AS3MT	-0.64	-5.68	-0.5	1.45e-7	Arsenic metabolism;
THYM	cis	rs7264396	0.561	rs6060750	chr20:34596371	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-4.51	-0.42	1.88e-5	Total cholesterol levels;
THYM	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg16586182	chr3:47516702	SCAP	-0.62	-5.25	-0.47	9.36e-7	Colorectal cancer;
THYM	cis	rs7513165	0.867	rs4951318	chr1:204161513	G/C	cg04791601	chr1:204159016	NA	0.39	4.91	0.45	3.79e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
THYM	cis	rs6988636	1.000	rs58189203	chr8:124184739	G/T	cg26140120	chr8:124219575	FAM83A	0.87	4.81	0.44	5.77e-6	Urinary uromodulin levels;
THYM	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg22535103	chr8:58192502	C8orf71	-0.96	-5.47	-0.49	3.7e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs7107770	1.000	rs1025812	chr11:125088182	C/G	cg04164023	chr11:125106101	PKNOX2	-0.83	-4.97	-0.45	2.98e-6	Photic sneeze reflex;
THYM	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg18402987	chr7:1209562	NA	1.03	6.06	0.53	2.77e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1957429	0.808	rs7149922	chr14:65334541	C/T	cg23373153	chr14:65346875	NA	0.91	4.92	0.45	3.69e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs7940866	0.838	rs10736592	chr11:130800572	C/T	cg05962950	chr11:130786565	SNX19	0.84	7.07	0.59	2.6200000000000003e-10	Schizophrenia;
THYM	cis	rs4523957	0.928	rs12938295	chr17:2160854	A/G	cg16513277	chr17:2031491	SMG6	0.79	7.41	0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg14895029	chr7:2775587	GNA12	-0.67	-4.79	-0.44	6.16e-6	Height;
THYM	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13012494	chr21:47604986	C21orf56	-0.69	-4.8	-0.44	5.95e-6	Testicular germ cell tumor;
THYM	trans	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7267979	1.000	rs6115153	chr20:25325567	T/C	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg05457628	chr5:178986728	RUFY1	-0.65	-6.87	-0.58	6.69e-10	Lung cancer;
THYM	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg04546413	chr19:29218101	NA	0.71	5.15	0.47	1.39e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg18681998	chr4:17616180	MED28	-0.82	-7.31	-0.6	8.37e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs2282300	0.739	rs2225909	chr11:30329744	T/C	cg25418670	chr11:30344373	C11orf46	0.82	6.98	0.58	3.93e-10	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg24578937	chr1:2090814	PRKCZ	0.57	6.09	0.53	2.39e-8	Height;
THYM	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg15962314	chr1:44399869	ARTN	0.54	5.34	0.48	6.28e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-5.69	-0.5	1.4e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg12292205	chr6:26970375	C6orf41	-0.72	-4.71	-0.44	8.36e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg03609598	chr5:56110824	MAP3K1	-0.88	-5.97	-0.52	4.06e-8	Initial pursuit acceleration;
THYM	cis	rs3126085	0.935	rs11584427	chr1:152299788	A/G	cg10321714	chr1:152280068	FLG	-0.71	-4.96	-0.45	3.07e-6	Atopic dermatitis;
THYM	cis	rs7567389	0.573	rs11541137	chr2:128145771	C/T	cg06038358	chr2:128176007	PROC	0.43	4.49	0.42	2e-5	Self-rated health;
THYM	cis	rs6495122	0.662	rs11072508	chr15:75062397	C/T	cg14664628	chr15:75095509	CSK	-0.8	-6.08	-0.53	2.53e-8	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs6032067	0.704	rs62208390	chr20:43794844	A/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs8067545	1.000	rs3909258	chr17:19945819	C/G	cg08626831	chr17:20841558	NA	-0.47	-4.5	-0.42	1.91e-5	Schizophrenia;
THYM	cis	rs6500395	1.000	rs9931123	chr16:48614293	G/T	cg04672837	chr16:48644449	N4BP1	0.49	4.8	0.44	5.98e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg04476341	chr5:669733	TPPP	0.63	5.44	0.49	4.07e-7	Obesity-related traits;
THYM	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs28595532	0.841	rs114966236	chr4:119733437	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs4589258	0.933	rs11019133	chr11:90405440	A/G	cg26138821	chr11:89956704	CHORDC1	0.71	5.96	0.52	4.22e-8	Intelligence (multi-trait analysis);
THYM	cis	rs57927100	0.578	rs7221079	chr17:75345027	T/C	cg18271897	chr17:75316784	SEPT9	0.71	6.28	0.54	9.94e-9	Systolic blood pressure;
THYM	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg02153584	chr22:29168773	CCDC117	0.61	4.76	0.44	6.94e-6	Lymphocyte counts;
THYM	cis	rs7107174	0.681	rs10751288	chr11:78072658	A/T	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs7580658	0.750	rs4497825	chr2:128061053	A/G	cg09152259	chr2:128156114	NA	-0.34	-4.45	-0.42	2.31e-5	Protein C levels;
THYM	cis	rs9443189	0.570	rs6931578	chr6:76272310	C/T	cg01950844	chr6:76311363	SENP6	1.1	6.79	0.57	9.58e-10	Prostate cancer;
THYM	cis	rs57545798	0.963	rs8041256	chr15:100646133	T/C	cg20941820	chr15:100882334	ADAMTS17	0.57	4.83	0.44	5.15e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg00071950	chr4:10020882	SLC2A9	-0.59	-5.3	-0.48	7.65e-7	Bone mineral density;
THYM	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg04520793	chr17:42248056	ASB16	-0.34	-4.78	-0.44	6.45e-6	Total body bone mineral density;
THYM	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12756686	chr19:29218302	NA	0.98	8.72	0.67	9.12e-14	Methadone dose in opioid dependence;
THYM	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-5.1	-0.46	1.74e-6	Lymphocyte counts;
THYM	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11644478	chr21:40555479	PSMG1	0.8	6.91	0.58	5.38e-10	Cognitive function;
THYM	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14240646	chr10:27532245	ACBD5	0.86	5.03	0.46	2.28e-6	Breast cancer;
THYM	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.11	7.46	0.61	3.98e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs524281	0.773	rs2282568	chr11:66052832	C/G	cg00563793	chr11:65837595	PACS1	0.79	4.66	0.43	1.03e-5	Electroencephalogram traits;
THYM	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg11301795	chr4:187892539	NA	-1.07	-15.95	-0.85	1.31e-28	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2932538	0.922	rs12125361	chr1:113144779	C/T	cg22162597	chr1:113214053	CAPZA1	0.65	5.32	0.48	6.9e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg24642439	chr20:33292090	TP53INP2	0.68	5.14	0.47	1.47e-6	Coronary artery disease;
THYM	cis	rs877282	0.945	rs35342920	chr10:790484	T/C	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs1568889	1.000	rs1464897	chr11:28034844	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	4.51	0.42	1.82e-5	Bipolar disorder;
THYM	cis	rs7943358	0.758	rs747783	chr11:15713556	G/A	cg11966998	chr11:15692519	NA	-0.45	-4.52	-0.42	1.79e-5	Gut microbiome composition (summer);
THYM	cis	rs2637266	1.000	rs12258924	chr10:78364758	G/A	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg04944784	chr2:26401820	FAM59B	-1.06	-8.41	-0.65	4.15e-13	Gut microbiome composition (summer);
THYM	cis	rs6840360	0.642	rs1443090	chr4:152451819	T/C	cg17479576	chr4:152424074	FAM160A1	-0.66	-5.0	-0.46	2.67e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6496667	0.533	rs2074583	chr15:91009192	T/C	cg00425431	chr15:90792223	TTLL13	0.39	4.55	0.42	1.61e-5	Rheumatoid arthritis;
THYM	cis	rs6430585	0.591	rs12476135	chr2:136486340	T/C	cg07169764	chr2:136633963	MCM6	1.13	10.27	0.73	4.46e-17	Corneal structure;
THYM	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg02782426	chr3:40428986	ENTPD3	0.54	4.82	0.44	5.47e-6	Renal cell carcinoma;
THYM	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg23815491	chr16:72088622	HP	0.84	6.94	0.58	4.78e-10	Fibrinogen levels;
THYM	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg03929089	chr4:120376271	NA	0.97	10.53	0.73	1.25e-17	Coronary artery disease;
THYM	cis	rs6728642	0.572	rs7574488	chr2:97599618	T/C	cg01990225	chr2:97406019	LMAN2L	-0.79	-4.68	-0.43	9.64e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs36051895	0.623	rs7847811	chr9:5237081	T/C	cg02405213	chr9:5042618	JAK2	-0.93	-9.39	-0.69	3.26e-15	Pediatric autoimmune diseases;
THYM	cis	rs3862030	0.839	rs12570859	chr10:104257226	C/T	cg00122347	chr10:104236741	TMEM180	0.48	7.33	0.6	7.69e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg18512352	chr11:47633146	NA	-0.5	-6.42	-0.55	5.46e-9	Subjective well-being;
THYM	cis	rs2659067	1.000	rs1654523	chr19:51485194	C/T	cg06258834	chr19:51487136	KLK7	-0.77	-4.66	-0.43	1.04e-5	Blood protein levels;
THYM	cis	rs684232	0.583	rs17677436	chr17:520314	T/C	cg15660573	chr17:549704	VPS53	-1.01	-11.19	-0.75	4.87e-19	Prostate cancer;
THYM	cis	rs7043114	0.525	rs7026361	chr9:95138564	A/C	cg14631576	chr9:95140430	CENPP	0.89	9.32	0.69	4.61e-15	Height;
THYM	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg22920501	chr2:26401640	FAM59B	1.07	9.54	0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs892961	0.932	rs55661113	chr17:75408386	A/C	cg05865280	chr17:75406074	SEPT9	0.5	8.56	0.66	1.99e-13	Airflow obstruction;
THYM	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg08779649	chr13:50194554	NA	0.58	5.03	0.46	2.31e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg16558253	chr16:72132732	DHX38	-0.54	-4.57	-0.42	1.47e-5	Fibrinogen levels;
THYM	trans	rs11186	0.584	rs111915005	chr2:189961171	A/C	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg03396347	chr1:1875803	NA	-0.67	-6.81	-0.57	8.66e-10	Body mass index;
THYM	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.26	9.1	0.68	1.4e-14	Gut microbiome composition (summer);
THYM	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg25838465	chr1:92012736	NA	0.85	7.58	0.61	2.32e-11	Breast cancer;
THYM	cis	rs7084402	0.967	rs1649018	chr10:60288150	T/G	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs1497406	0.744	rs924203	chr1:16511539	G/T	cg20430773	chr1:16534157	ARHGEF19	0.5	5.65	0.5	1.71e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4595586	0.545	rs12821810	chr12:39375858	T/C	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs2067615	0.524	rs10778498	chr12:107063340	C/A	cg15890332	chr12:107067104	RFX4	0.45	5.08	0.46	1.86e-6	Heart rate;
THYM	cis	rs3204270	0.714	rs8074828	chr17:79657136	G/C	cg13117272	chr17:79681052	SLC25A10	-0.79	-5.0	-0.46	2.63e-6	Dental caries;
THYM	cis	rs554111	0.656	rs6695218	chr1:21190512	A/C	cg00373020	chr1:21041521	KIF17	-0.53	-4.53	-0.42	1.74e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs11767557	0.938	rs7791765	chr7:143099107	T/G	cg05908241	chr7:143109367	NA	-0.65	-6.47	-0.55	4.33e-9	Alzheimer's disease (late onset);
THYM	cis	rs5769707	0.681	rs4622843	chr22:50036916	T/G	cg23428387	chr22:49814324	NA	-0.51	-4.93	-0.45	3.48e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9790314	1.000	rs28515190	chr3:161028605	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg12419862	chr22:24373484	LOC391322	-0.71	-6.53	-0.56	3.24e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs888194	0.649	rs10774697	chr12:109875981	A/G	cg10504392	chr12:110044639	NA	0.6	5.49	0.49	3.28e-7	Neuroticism;
THYM	cis	rs80282103	1.000	rs35772020	chr10:863482	G/A	cg10556349	chr10:835070	NA	-1.09	-5.45	-0.49	3.92e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg11266682	chr4:10021025	SLC2A9	0.73	12.79	0.8	2.29e-22	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9682041	1.000	rs15709	chr3:170110529	T/A	cg11886554	chr3:170076028	SKIL	1.22	4.91	0.45	3.81e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg03433033	chr1:76189801	ACADM	0.76	8.16	0.64	1.4e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg23422044	chr7:1970798	MAD1L1	0.76	5.2	0.47	1.15e-6	Bipolar disorder;
THYM	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11890956	chr21:40555474	PSMG1	-0.92	-10.1	-0.72	1.01e-16	Cognitive function;
THYM	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg24399712	chr22:39784796	NA	-0.84	-8.53	-0.66	2.28e-13	Intelligence (multi-trait analysis);
THYM	cis	rs66887589	0.967	rs3775842	chr4:120427732	G/A	cg13609457	chr4:120235615	NA	0.47	4.93	0.45	3.5e-6	Diastolic blood pressure;
THYM	trans	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg10856724	chr12:34555212	NA	-0.94	-8.22	-0.64	1.01e-12	Bladder cancer;
THYM	cis	rs13082711	0.911	rs34316374	chr3:27437385	G/C	cg02860705	chr3:27208620	NA	0.67	4.7	0.43	8.96e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg20151795	chr6:28129481	ZNF389	0.73	4.5	0.42	1.91e-5	Parkinson's disease;
THYM	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg21100191	chr22:23484243	RTDR1	0.76	6.56	0.56	2.77e-9	Bone mineral density;
THYM	cis	rs13102973	0.564	rs4418034	chr4:135886650	T/A	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	cis	rs600806	0.821	rs1030522	chr1:109900707	C/G	cg23032129	chr1:109941072	SORT1	-0.57	-4.83	-0.44	5.22e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10904908	0.862	rs359281	chr10:17320144	A/G	cg01003015	chr10:17271136	VIM	0.56	4.49	0.42	2.03e-5	Total cholesterol levels;Cholesterol, total;
THYM	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg16006841	chr5:176797999	RGS14	0.51	5.74	0.51	1.11e-7	Urate levels in lean individuals;
THYM	cis	rs9926296	0.687	rs258323	chr16:89754694	G/C	cg03605463	chr16:89740564	NA	0.82	6.22	0.54	1.32e-8	Vitiligo;
THYM	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg22117172	chr7:91764530	CYP51A1	0.36	4.54	0.42	1.63e-5	Breast cancer;
THYM	cis	rs4788570	0.615	rs10852503	chr16:71652227	G/C	cg06353428	chr16:71660113	MARVELD3	1.38	9.65	0.7	9.48e-16	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg24818145	chr4:99064322	C4orf37	0.74	5.93	0.52	4.8e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7617773	0.780	rs11710257	chr3:48373214	T/G	cg02219026	chr3:48282209	ZNF589	-0.67	-4.69	-0.43	9.05e-6	Coronary artery disease;
THYM	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg21159260	chr5:475889	SLC9A3	0.43	5.23	0.47	1.01e-6	Cystic fibrosis severity;
THYM	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg06532163	chr17:45867833	NA	0.6	5.93	0.52	4.82e-8	IgG glycosylation;
THYM	cis	rs7089973	0.966	rs55711292	chr10:116604870	T/G	cg23260525	chr10:116636907	FAM160B1	0.57	5.1	0.46	1.74e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs36051895	0.632	rs12340617	chr9:5164492	G/C	cg02405213	chr9:5042618	JAK2	-1.07	-11.45	-0.76	1.35e-19	Pediatric autoimmune diseases;
THYM	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg17509989	chr5:176798049	RGS14	0.64	5.87	0.52	6.43e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs17604090	0.938	rs10276157	chr7:29665016	A/G	cg19413766	chr7:29689036	LOC646762	-0.94	-5.04	-0.46	2.19e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg01831904	chr17:28903510	LRRC37B2	-1.0	-5.11	-0.46	1.65e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9913156	0.793	rs72835643	chr17:4573612	G/A	cg19197139	chr17:4613644	ARRB2	0.82	4.96	0.45	3.05e-6	Lymphocyte counts;
THYM	cis	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg12560992	chr17:57184187	TRIM37	0.73	5.99	0.52	3.72e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4499344	0.730	rs8103269	chr19:33097503	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.48	0.61	3.64e-11	Mean platelet volume;
THYM	cis	rs78761021	0.720	rs55735457	chr17:9796710	C/T	cg26853458	chr17:9805074	RCVRN	0.53	4.46	0.42	2.24e-5	Type 2 diabetes;
THYM	cis	rs62064224	0.589	rs4523973	chr17:30809455	G/A	cg18200150	chr17:30822561	MYO1D	0.55	4.5	0.42	1.92e-5	Schizophrenia;
THYM	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11890956	chr21:40555474	PSMG1	1.17	13.11	0.8	4.95e-23	Cognitive function;
THYM	cis	rs700651	0.821	rs771005	chr2:198675948	C/T	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Intracranial aneurysm;
THYM	cis	rs36051895	0.632	rs10974982	chr9:5149382	G/C	cg02405213	chr9:5042618	JAK2	-1.04	-10.96	-0.75	1.47e-18	Pediatric autoimmune diseases;
THYM	cis	rs2692947	0.770	rs62153678	chr2:96558346	C/T	cg22654517	chr2:96458247	NA	0.71	5.17	0.47	1.28e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs9359856	0.636	rs1980878	chr6:90314749	A/C	cg13799429	chr6:90582589	CASP8AP2	0.75	6.81	0.57	9e-10	Bipolar disorder;
THYM	cis	rs11264213	0.686	rs625306	chr1:36454016	T/C	cg27506609	chr1:36549197	TEKT2	0.97	5.19	0.47	1.2e-6	Schizophrenia;
THYM	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg08885076	chr2:99613938	TSGA10	0.74	6.98	0.58	3.88e-10	Chronic sinus infection;
THYM	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Bladder cancer;
THYM	cis	rs981844	1.000	rs72731670	chr4:154662471	C/T	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg26408565	chr15:76604113	ETFA	-0.54	-4.64	-0.43	1.13e-5	Blood metabolite levels;
THYM	cis	rs35110281	0.575	rs2876854	chr21:44979232	A/G	cg15536230	chr21:44985092	HSF2BP	-0.41	-5.02	-0.46	2.43e-6	Mean corpuscular volume;
THYM	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs7777677	1.000	rs7777677	chr7:142371448	C/T	cg21785750	chr7:142428317	NA	0.67	5.88	0.52	6.07e-8	Alcoholic chronic pancreatitis;
THYM	cis	rs6570726	0.935	rs379164	chr6:145829093	A/T	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2219968	0.728	rs1988920	chr8:78841080	G/T	cg00738934	chr8:78996279	NA	-0.82	-7.83	-0.63	6.79e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg16928487	chr17:17741425	SREBF1	-0.56	-5.57	-0.5	2.37e-7	Total body bone mineral density;
THYM	cis	rs59698941	0.943	rs12516416	chr5:132248630	C/T	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg01191920	chr7:158217561	PTPRN2	0.99	10.38	0.73	2.57e-17	Obesity-related traits;
THYM	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg20891558	chr2:74357851	NA	1.2	12.27	0.78	2.71e-21	Gestational age at birth (maternal effect);
THYM	cis	rs757081	0.667	rs7108067	chr11:17200220	G/A	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.6	-0.43	1.29e-5	Systolic blood pressure;
THYM	cis	rs4919687	0.550	rs12780827	chr10:104467954	T/C	cg04362960	chr10:104952993	NT5C2	0.6	4.79	0.44	6.19e-6	Colorectal cancer;
THYM	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg24675658	chr1:53192096	ZYG11B	-0.63	-5.13	-0.47	1.51e-6	Monocyte count;
THYM	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg06634786	chr22:41940651	POLR3H	-0.59	-4.87	-0.45	4.52e-6	Vitiligo;
THYM	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg05425664	chr17:57184151	TRIM37	-0.59	-4.72	-0.44	8.07e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10186029	0.509	rs13417355	chr2:213943030	C/T	cg08319019	chr2:214017104	IKZF2	-0.64	-4.89	-0.45	4.11e-6	Systemic sclerosis;
THYM	cis	rs192264	0.680	rs1094968	chr16:65969391	C/T	cg02795155	chr16:66785218	DYNC1LI2	0.61	4.88	0.45	4.21e-6	Subjective well-being;
THYM	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs988913	1.000	rs9396007	chr6:54807622	T/A	cg19716238	chr6:54711378	FAM83B	0.52	5.2	0.47	1.14e-6	Menarche (age at onset);
THYM	cis	rs490234	0.966	rs542974	chr9:128373218	G/A	cg14078157	chr9:128172775	NA	0.59	4.58	0.43	1.39e-5	Mean arterial pressure;
THYM	cis	rs7772486	0.790	rs9497424	chr6:146225271	C/A	cg23711669	chr6:146136114	FBXO30	-0.9	-8.72	-0.67	9.04e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6032067	0.714	rs35770435	chr20:43788804	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.74	-6.84	-0.57	7.68e-10	Blood protein levels;
THYM	cis	rs7247513	1.000	rs2042947	chr19:12693103	A/G	cg01871581	chr19:12707946	ZNF490	-0.85	-8.69	-0.67	1.03e-13	Bipolar disorder;
THYM	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg15448220	chr1:150897856	SETDB1	0.85	7.1	0.59	2.25e-10	Tonsillectomy;
THYM	cis	rs13315871	1.000	rs9862969	chr3:58341917	A/G	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs4383453	0.539	rs56384012	chr3:123098176	G/A	cg04890266	chr3:123102914	ADCY5	-0.86	-8.67	-0.66	1.12e-13	Gestational age at birth (maternal effect);
THYM	cis	rs7940866	0.834	rs1594821	chr11:130835883	C/T	cg23692386	chr11:131799662	NTM	0.5	5.32	0.48	6.77e-7	Schizophrenia;
THYM	cis	rs10782582	0.593	rs6675076	chr1:76118503	A/C	cg03433033	chr1:76189801	ACADM	-0.5	-5.29	-0.48	7.94e-7	Daytime sleep phenotypes;
THYM	cis	rs2354432	0.607	rs10900350	chr1:146828017	T/G	cg25205988	chr1:146714368	CHD1L	1.01	5.52	0.49	2.91e-7	Mitochondrial DNA levels;
THYM	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs7578361	0.879	rs16827092	chr2:150344295	C/T	cg17961725	chr2:150454027	NA	-0.77	-5.69	-0.5	1.43e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg13010199	chr12:38710504	ALG10B	-0.59	-4.69	-0.43	9.25e-6	Morning vs. evening chronotype;
THYM	cis	rs13006833	0.668	rs291461	chr2:191181644	T/G	cg11845111	chr2:191398756	TMEM194B	0.65	4.51	0.42	1.88e-5	Urinary metabolites;
THYM	cis	rs921968	0.643	rs1344645	chr2:219538019	A/C	cg02176678	chr2:219576539	TTLL4	0.58	5.17	0.47	1.31e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg08885076	chr2:99613938	TSGA10	0.53	5.14	0.47	1.46e-6	Chronic sinus infection;
THYM	cis	rs67981189	0.896	rs34049963	chr14:71440746	A/G	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg21970626	chr13:21893289	NA	-0.67	-5.95	-0.52	4.5e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg11812906	chr14:75593930	NEK9	0.82	7.47	0.61	3.9e-11	Height;
THYM	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6901004	0.709	rs354534	chr6:111521030	T/A	cg15721981	chr6:111408429	SLC16A10	-0.56	-4.46	-0.42	2.28e-5	Blood metabolite levels;
THYM	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-6.02	-0.53	3.28e-8	Gut microbiome composition (summer);
THYM	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg14008862	chr17:28927542	LRRC37B2	0.88	4.55	0.42	1.57e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg11211951	chr8:145729740	GPT	0.58	5.46	0.49	3.76e-7	Age at first birth;
THYM	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg08847533	chr14:75593920	NEK9	1.01	11.32	0.76	2.63e-19	Height;
THYM	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg20476274	chr7:133979776	SLC35B4	0.68	4.54	0.42	1.65e-5	Mean platelet volume;
THYM	cis	rs910187	0.901	rs6124969	chr20:45816277	C/T	cg27589058	chr20:45804311	EYA2	-0.59	-4.71	-0.44	8.34e-6	Migraine;
THYM	cis	rs11190604	1.000	rs2489047	chr10:102347028	A/G	cg07570687	chr10:102243282	WNT8B	0.75	6.47	0.55	4.23e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4435363	0.874	rs2082495	chr19:47068688	A/C	cg10017888	chr19:47105860	CALM3	-0.8	-5.45	-0.49	3.91e-7	Immature fraction of reticulocytes;P wave terminal force;
THYM	cis	rs11031096	0.727	rs2268168	chr11:4142069	C/T	cg22027985	chr11:4115532	RRM1	-0.53	-5.45	-0.49	4.02e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2249694	0.620	rs9419079	chr10:135326985	G/A	cg20169779	chr10:135381914	SYCE1	0.62	4.59	0.43	1.36e-5	Obesity-related traits;
THYM	cis	rs4803468	1.000	rs4803469	chr19:41922775	A/C	cg09537434	chr19:41945824	ATP5SL	-1.06	-9.81	-0.71	4.27e-16	Height;
THYM	cis	rs2742234	0.554	rs1270015	chr10:43698240	G/T	cg06632098	chr10:43605906	RET	0.8	5.02	0.46	2.43e-6	Hirschsprung disease;
THYM	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg17366294	chr4:99064904	C4orf37	0.46	5.15	0.47	1.42e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg00278517	chr6:167070616	RPS6KA2	-0.35	-4.58	-0.42	1.44e-5	Crohn's disease;
THYM	cis	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg24692254	chr21:30365293	RNF160	-0.79	-4.48	-0.42	2.07e-5	Cognitive test performance;
THYM	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg00256281	chr22:41985642	PMM1	-0.57	-4.76	-0.44	7.03e-6	Vitiligo;
THYM	cis	rs754466	0.651	rs56138814	chr10:79625795	T/C	cg17075019	chr10:79541650	NA	-0.69	-5.85	-0.51	6.94e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs5758511	0.689	rs55906806	chr22:42644471	C/T	cg22189786	chr22:42395067	WBP2NL	0.63	4.6	0.43	1.29e-5	Birth weight;
THYM	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.57	-0.42	1.48e-5	Bipolar disorder;
THYM	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg01699819	chr7:1052092	C7orf50	-0.86	-7.87	-0.63	5.55e-12	Bronchopulmonary dysplasia;
THYM	cis	rs12149862	1.000	rs9783747	chr16:69458193	A/G	cg02524010	chr16:69117679	TMCO7	0.69	4.82	0.44	5.45e-6	Blood pressure (smoking interaction);
THYM	cis	rs7432375	0.901	rs4408829	chr3:136404683	C/T	cg12473912	chr3:136751656	NA	-0.6	-4.99	-0.46	2.73e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs11123610	0.520	rs13409381	chr2:3722579	A/G	cg19052272	chr2:3704530	ALLC	-0.64	-4.53	-0.42	1.69e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg10360139	chr7:1886902	MAD1L1	-0.6	-5.26	-0.47	8.89e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7651039	0.641	rs6773682	chr3:15676426	G/A	cg16303742	chr3:15540471	COLQ	0.71	7.01	0.58	3.39e-10	Coronary heart disease;
THYM	cis	rs7107174	0.892	rs2510033	chr11:77941771	T/G	cg02023728	chr11:77925099	USP35	0.73	6.32	0.54	8.61e-9	Testicular germ cell tumor;
THYM	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg16586182	chr3:47516702	SCAP	-0.67	-5.62	-0.5	1.9e-7	Colorectal cancer;
THYM	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg12000587	chr17:30186630	C17orf79	0.43	4.63	0.43	1.17e-5	Hip circumference adjusted for BMI;
THYM	cis	rs7584330	0.518	rs7585975	chr2:238439089	G/A	cg14458575	chr2:238380390	NA	1.0	5.68	0.5	1.47e-7	Prostate cancer;
THYM	cis	rs4903604	0.581	rs12879719	chr14:78035253	C/A	cg18872420	chr14:78023429	SPTLC2	0.53	4.53	0.42	1.69e-5	Gut microbiome composition (winter);
THYM	cis	rs9443645	0.527	rs2105143	chr6:79742947	G/A	cg05283184	chr6:79620031	NA	-0.6	-4.67	-0.43	9.91e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9902453	0.726	rs3115088	chr17:28031275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	6.53	0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs17376456	0.542	rs35672980	chr5:93284877	A/T	cg25358565	chr5:93447407	FAM172A	-0.83	-6.11	-0.53	2.18e-8	Diabetic retinopathy;
THYM	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg21658235	chr8:22456391	C8orf58	0.45	4.63	0.43	1.14e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2637266	0.935	rs2583059	chr10:78395178	G/C	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg04756594	chr16:24857601	SLC5A11	-0.77	-5.35	-0.48	6.1e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg04234412	chr22:24373322	LOC391322	-0.92	-8.54	-0.66	2.14e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg12863693	chr15:85201151	NMB	0.66	5.89	0.52	5.76e-8	Schizophrenia;
THYM	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06481639	chr22:41940642	POLR3H	-0.81	-5.51	-0.49	3.11e-7	Vitiligo;
THYM	cis	rs1061377	1.000	rs1036037	chr4:39112892	A/G	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs56079296	1.000	rs56079296	chr5:121276797	A/G	cg05256605	chr5:121412184	LOX	-0.61	-4.69	-0.43	9.14e-6	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4481887	0.927	rs4244181	chr1:248471118	A/G	cg13385794	chr1:248469461	NA	0.65	4.66	0.43	1.04e-5	Common traits (Other);
THYM	trans	rs1974653	0.672	rs2904565	chr22:20091628	C/T	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs4294134	0.608	rs12707239	chr7:135247183	C/T	cg08396481	chr7:135194601	CNOT4	-0.74	-4.48	-0.42	2.11e-5	Paget's disease;
THYM	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs9527	0.615	rs10883800	chr10:104671212	A/C	cg04362960	chr10:104952993	NT5C2	0.6	4.62	0.43	1.2e-5	Arsenic metabolism;
THYM	cis	rs6840360	0.571	rs11099823	chr4:152510565	T/G	cg17479576	chr4:152424074	FAM160A1	-0.78	-5.74	-0.51	1.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4478037	0.558	rs60462824	chr3:33085929	T/C	cg19404215	chr3:33155277	CRTAP	1.0	5.22	0.47	1.03e-6	Major depressive disorder;
THYM	cis	rs6754311	0.593	rs55825471	chr2:136526981	T/A	cg20242066	chr2:136595261	LCT	-0.57	-6.96	-0.58	4.3e-10	Mosquito bite size;
THYM	cis	rs220324	0.738	rs9975104	chr21:43579344	G/T	cg09727148	chr21:43560719	UMODL1	0.65	5.98	0.52	3.98e-8	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs2276314	0.857	rs9304155	chr18:33585710	A/C	cg05985134	chr18:33552581	C18orf21	0.66	4.79	0.44	6.02e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg09436375	chr6:42928200	GNMT	-0.44	-5.9	-0.52	5.58e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg15556689	chr8:8085844	FLJ10661	0.78	6.76	0.57	1.11e-9	Mood instability;
THYM	cis	rs7127900	0.846	rs72853963	chr11:2224664	G/A	cg25635251	chr11:2234043	NA	-0.84	-4.92	-0.45	3.63e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg02887458	chr19:19495540	GATAD2A	-0.44	-5.19	-0.47	1.17e-6	Bipolar disorder;
THYM	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10979	1.000	rs9403505	chr6:143885841	A/G	cg25407410	chr6:143891975	LOC285740	-0.63	-5.41	-0.49	4.6e-7	Hypospadias;
THYM	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg11266682	chr4:10021025	SLC2A9	0.74	12.07	0.78	6.92e-21	Bone mineral density;
THYM	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-5.12	-0.47	1.59e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg08772003	chr10:104629869	AS3MT	-0.57	-4.92	-0.45	3.56e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs35264875	1.000	rs72919430	chr11:68829817	G/T	cg01993067	chr11:68851601	TPCN2	1.0	4.68	0.43	9.62e-6	Blond vs. brown hair color;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg20095338	chr12:76478402	NAP1L1	-1.05	-7.59	-0.61	2.13e-11	Depressive symptoms;
THYM	cis	rs7107174	1.000	rs2512542	chr11:77981780	G/A	cg02023728	chr11:77925099	USP35	0.68	6.38	0.55	6.54e-9	Testicular germ cell tumor;
THYM	cis	rs2448490	0.642	rs573589	chr11:65483981	C/T	cg27068330	chr11:65405492	SIPA1	0.76	6.19	0.54	1.51e-8	Platelet count;
THYM	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	7.73	0.62	1.1e-11	Smoking behavior;
THYM	cis	rs593982	0.920	rs10896044	chr11:65554680	C/G	cg08755490	chr11:65554678	OVOL1	1.34	8.46	0.66	3.12e-13	Atopic dermatitis;
THYM	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.85	-7.0	-0.58	3.68e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12519773	0.717	rs6557063	chr5:92493318	T/C	cg18783429	chr5:92414398	NA	0.54	5.11	0.46	1.68e-6	Migraine;
THYM	cis	rs9928842	0.882	rs9927264	chr16:75260241	T/C	cg09066997	chr16:75300724	BCAR1	0.71	4.46	0.42	2.28e-5	Alcoholic chronic pancreatitis;
THYM	cis	rs4805272	0.582	rs11083652	chr19:29231569	G/C	cg04546413	chr19:29218101	NA	-0.72	-5.7	-0.5	1.37e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs1784581	0.588	rs9346893	chr6:162417511	C/G	cg17173639	chr6:162384350	PARK2	0.81	7.48	0.61	3.75e-11	Itch intensity from mosquito bite;
THYM	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg07870213	chr5:140052090	DND1	0.73	8.28	0.65	7.61e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs684232	0.666	rs838373	chr17:567171	T/C	cg15660573	chr17:549704	VPS53	-0.88	-8.37	-0.65	4.88e-13	Prostate cancer;
THYM	cis	rs761746	0.960	rs1543416	chr22:31925073	A/G	cg01338084	chr22:32026380	PISD	0.55	4.7	0.43	8.66e-6	Intelligence;
THYM	cis	rs9527	0.567	rs11191573	chr10:104896816	T/C	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs1050631	0.592	rs948417	chr18:33711274	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.32	0.48	6.94e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs12509991	0.634	rs58970909	chr4:127034507	T/C	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7943203	0.568	rs179110	chr11:108254999	T/C	cg04873221	chr11:107992290	ACAT1	-0.7	-4.65	-0.43	1.08e-5	Red blood cell count;Mean corpuscular volume;
THYM	cis	rs4790312	0.846	rs2131704	chr17:1970898	C/T	cg15816464	chr17:2026533	SMG6	0.36	4.7	0.43	8.77e-6	Left atrial antero-posterior diameter;
THYM	cis	rs4383453	0.559	rs903574	chr3:123099807	C/G	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs61931739	0.963	rs12307606	chr12:34016365	C/T	cg06521331	chr12:34319734	NA	0.58	4.57	0.42	1.49e-5	Morning vs. evening chronotype;
THYM	cis	rs4523957	0.614	rs7220685	chr17:2059385	A/G	cg16513277	chr17:2031491	SMG6	-0.94	-8.42	-0.65	3.95e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs12413816	0.784	rs35537139	chr10:13768894	G/A	cg16485048	chr10:13749193	FRMD4A	0.5	4.86	0.45	4.62e-6	Red cell distribution width;
THYM	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg20151795	chr6:28129481	ZNF389	0.75	4.59	0.43	1.36e-5	Parkinson's disease;
THYM	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-6.98	-0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg22907277	chr7:1156413	C7orf50	0.74	5.02	0.46	2.39e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7119	0.635	rs907374	chr15:77884026	C/T	cg27398640	chr15:77910606	LINGO1	0.7	8.38	0.65	4.78e-13	Type 2 diabetes;
THYM	cis	rs28595532	0.920	rs116405053	chr4:119739352	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs10979	0.964	rs35826562	chr6:143898672	G/A	cg25407410	chr6:143891975	LOC285740	-0.62	-4.88	-0.45	4.22e-6	Hypospadias;
THYM	cis	rs34112283	0.592	rs34657736	chr2:144234252	A/G	cg17056048	chr2:144271431	ARHGAP15	0.65	6.26	0.54	1.11e-8	Neuroticism;
THYM	cis	rs3862030	0.720	rs1056744	chr10:104236687	A/G	cg00122347	chr10:104236741	TMEM180	0.47	7.02	0.58	3.22e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg13531842	chr10:38383804	ZNF37A	-0.54	-4.53	-0.42	1.73e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs10992471	0.603	rs10118939	chr9:95293641	C/G	cg14631576	chr9:95140430	CENPP	-0.96	-9.19	-0.69	9.02e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22496380	chr5:211416	CCDC127	-1.42	-9.1	-0.68	1.38e-14	Breast cancer;
THYM	cis	rs74664507	0.527	rs7046326	chr9:16847520	G/A	cg13173848	chr9:16870893	BNC2	-0.72	-5.1	-0.46	1.77e-6	Squamous cell carcinoma;
THYM	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03647317	chr4:187891568	NA	-0.83	-9.53	-0.7	1.69e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs250677	0.522	rs919730	chr5:148352401	T/C	cg18129178	chr5:148520854	ABLIM3	0.69	5.06	0.46	2.05e-6	Breast cancer;
THYM	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg08885076	chr2:99613938	TSGA10	-0.68	-6.0	-0.52	3.54e-8	Chronic sinus infection;
THYM	cis	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg06521331	chr12:34319734	NA	-0.84	-6.6	-0.56	2.37e-9	Morning vs. evening chronotype;
THYM	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Gout;
THYM	cis	rs9900497	0.536	rs4646785	chr17:19651902	A/G	cg22552966	chr17:19620595	SLC47A2	-0.68	-5.51	-0.49	3.04e-7	Response to paliperidone in schizophrenia (CGI-S score);
THYM	cis	rs761746	0.960	rs9621279	chr22:31949800	T/A	cg01338084	chr22:32026380	PISD	0.53	4.59	0.43	1.35e-5	Intelligence;
THYM	cis	rs11696501	0.739	rs6073815	chr20:44234615	A/T	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.57	-0.42	1.46e-5	Brain structure;
THYM	cis	rs490234	0.841	rs512445	chr9:128329179	T/C	cg14078157	chr9:128172775	NA	0.64	5.3	0.48	7.53e-7	Mean arterial pressure;
THYM	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg15164180	chr2:241846931	NA	-0.4	-5.19	-0.47	1.17e-6	Urinary metabolites;
THYM	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	7.12	0.59	2.09e-10	Cognitive test performance;
THYM	cis	rs600806	0.854	rs3768496	chr1:109866569	T/A	cg02175308	chr1:109941060	SORT1	-0.54	-4.71	-0.43	8.55e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7980799	0.716	rs10161311	chr12:33623204	G/A	cg10856724	chr12:34555212	NA	0.62	4.58	0.43	1.39e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs1728785	0.901	rs1170444	chr16:68573287	T/C	cg02972257	chr16:68554789	NA	-0.75	-4.62	-0.43	1.22e-5	Ulcerative colitis;
THYM	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg21475434	chr5:93447410	FAM172A	-0.71	-4.51	-0.42	1.83e-5	Diabetic retinopathy;
THYM	cis	rs7027203	0.828	rs3957506	chr9:96588133	C/T	cg14598338	chr9:96623480	NA	-0.49	-5.24	-0.47	9.76e-7	DNA methylation (variation);
THYM	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs2066819	1.000	rs59626664	chr12:56636975	C/G	cg26714650	chr12:56694279	CS	-1.27	-6.32	-0.54	8.6e-9	Psoriasis vulgaris;
THYM	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs2456568	0.867	rs2511375	chr11:93671117	T/G	cg26875233	chr11:93583750	C11orf90	-0.5	-4.88	-0.45	4.2e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22133161	chr19:49891603	CCDC155	0.84	5.69	0.5	1.42e-7	Multiple sclerosis;
THYM	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg12908607	chr1:44402522	ARTN	-0.55	-5.12	-0.46	1.61e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs16866061	1.000	rs72974269	chr2:225454907	C/T	cg12698349	chr2:225449008	CUL3	1.14	10.37	0.73	2.69e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg22535103	chr8:58192502	C8orf71	-1.05	-6.52	-0.56	3.32e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs12310956	0.515	rs1872745	chr12:33985987	G/A	cg10856724	chr12:34555212	NA	-0.75	-6.8	-0.57	9.1e-10	Morning vs. evening chronotype;
THYM	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.59	-4.6	-0.43	1.33e-5	Longevity;Endometriosis;
THYM	trans	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg19862616	chr7:65841803	NCRNA00174	1.11	12.25	0.78	2.92e-21	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg25358565	chr5:93447407	FAM172A	0.96	6.78	0.57	1.01e-9	Diabetic retinopathy;
THYM	cis	rs12579753	0.879	rs7131927	chr12:82166313	T/C	cg07988820	chr12:82153109	PPFIA2	-0.85	-5.59	-0.5	2.16e-7	Resting heart rate;
THYM	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg20999797	chr1:1681921	NA	0.48	5.29	0.48	7.78e-7	Body mass index;
THYM	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg12599982	chr1:44399894	ARTN	0.58	4.67	0.43	9.88e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9470366	0.816	rs1321311	chr6:36622900	C/A	cg11920449	chr6:36645608	CDKN1A	-0.67	-5.17	-0.47	1.29e-6	QRS duration;
THYM	cis	rs1003719	0.667	rs73201942	chr21:38475164	G/C	cg01329690	chr21:38580129	DSCR9	0.36	4.77	0.44	6.72e-6	Eye color traits;
THYM	cis	rs1007190	0.881	rs16939676	chr17:42976347	C/A	cg15406952	chr17:42872593	NA	0.8	5.57	0.5	2.34e-7	DNA methylation (variation);
THYM	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs1559088	1.000	rs1559087	chr19:33551041	A/G	cg03563238	chr19:33554763	RHPN2	-0.5	-4.48	-0.42	2.04e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg03929089	chr4:120376271	NA	-0.95	-10.24	-0.72	5.05e-17	Coronary artery disease;
THYM	cis	rs2085601	0.566	rs2458545	chr4:89955369	C/T	cg17769793	chr4:89976368	FAM13A	-0.53	-5.85	-0.51	7.01e-8	Hair greying;
THYM	cis	rs4383453	0.520	rs6790286	chr3:123103037	G/A	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs9462846	0.821	rs10223860	chr6:42875383	T/G	cg09436375	chr6:42928200	GNMT	-0.37	-4.51	-0.42	1.86e-5	Blood protein levels;
THYM	cis	rs7084921	0.608	rs12761969	chr10:101832036	G/C	cg11344164	chr10:101878520	NA	-0.55	-4.76	-0.44	6.9e-6	Bone mineral density;
THYM	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg10515332	chr4:99064459	C4orf37	0.6	4.77	0.44	6.7e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg14768367	chr16:72042858	DHODH	0.68	5.29	0.48	7.98e-7	Fibrinogen levels;
THYM	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg13395646	chr4:1353034	KIAA1530	0.6	5.41	0.49	4.79e-7	Obesity-related traits;
THYM	cis	rs11167764	0.945	rs13161849	chr5:141473395	A/G	cg23435118	chr5:141488016	NDFIP1	-0.53	-4.51	-0.42	1.85e-5	Crohn's disease;
THYM	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg00484396	chr16:3507460	NAT15	0.56	5.53	0.49	2.86e-7	Body mass index (adult);
THYM	cis	rs9361491	0.608	rs9350769	chr6:79444561	G/A	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs28647808	0.881	rs28625799	chr9:136264557	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs6087990	0.871	rs4911252	chr20:31330115	A/G	cg13636640	chr20:31349939	DNMT3B	-0.92	-9.68	-0.7	8.12e-16	Ulcerative colitis;
THYM	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.86	-4.7	-0.43	8.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3112255	0.597	rs2970991	chr2:101322193	C/G	cg01042948	chr2:101319752	NA	-0.62	-6.33	-0.54	8.19e-9	Intelligence (multi-trait analysis);
THYM	cis	rs3741151	1.000	rs79038783	chr11:73038746	C/G	cg12959048	chr11:73096162	RELT	-0.5	-4.78	-0.44	6.38e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs80319144	1.000	rs75006818	chr2:159263874	C/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs7107174	1.000	rs4945268	chr11:78037936	T/C	cg19901956	chr11:77921274	USP35	-0.67	-5.55	-0.49	2.56e-7	Testicular germ cell tumor;
THYM	cis	rs11031096	0.655	rs10835695	chr11:4178962	G/T	cg22027985	chr11:4115532	RRM1	-0.5	-4.6	-0.43	1.3e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs11650494	0.908	rs74830554	chr17:47431950	G/A	cg08112188	chr17:47440006	ZNF652	1.25	5.41	0.49	4.62e-7	Prostate cancer;
THYM	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg08859206	chr1:53392774	SCP2	-0.66	-7.08	-0.59	2.43e-10	Monocyte count;
THYM	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06850241	chr22:41845214	NA	0.49	4.62	0.43	1.21e-5	Vitiligo;
THYM	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.12	7.7	0.62	1.28e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs11645898	0.872	rs55955726	chr16:72213691	G/C	cg03805757	chr16:71968109	PKD1L3	-0.67	-5.06	-0.46	2.07e-6	Blood protein levels;
THYM	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9902453	0.808	rs1986555	chr17:28014448	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.86	0.45	4.56e-6	Coffee consumption (cups per day);
THYM	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg05347473	chr6:146136440	FBXO30	-0.81	-7.24	-0.6	1.13e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1971762	0.583	rs3844370	chr12:54086137	G/C	cg16917193	chr12:54089295	NA	1.0	10.41	0.73	2.16e-17	Height;
THYM	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg22189786	chr22:42395067	WBP2NL	0.48	4.51	0.42	1.85e-5	Birth weight;
THYM	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg10047753	chr17:41438598	NA	1.2	11.14	0.75	6.14e-19	Menopause (age at onset);
THYM	cis	rs57244997	0.725	rs61574422	chr6:162425056	T/C	cg17173639	chr6:162384350	PARK2	-0.74	-4.72	-0.44	7.99e-6	Mosquito bite size;
THYM	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg23982607	chr1:1823379	GNB1	-0.94	-10.22	-0.72	5.7e-17	Body mass index;
THYM	cis	rs728616	0.867	rs75447386	chr10:81739647	G/A	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg17689763	chr4:710664	PCGF3	-1.08	-9.75	-0.71	5.54e-16	White blood cell count;
THYM	cis	rs7511006	0.893	rs2038049	chr22:50654888	G/C	cg16294310	chr22:50629110	TRABD	0.65	5.1	0.46	1.73e-6	Obesity-related traits;
THYM	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg00599163	chr2:162100495	NA	0.57	4.48	0.42	2.09e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7524258	0.868	rs4908451	chr1:7299618	C/G	cg07173049	chr1:7289937	CAMTA1	-0.79	-6.29	-0.54	9.55e-9	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs4836694	0.574	rs67899211	chr9:132935614	G/A	cg05251000	chr9:132935664	FREQ	0.8	5.36	0.48	5.73e-7	Alzheimer's disease (cognitive decline);
THYM	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg00191853	chr8:101177733	SPAG1	-0.56	-5.59	-0.5	2.15e-7	Atrioventricular conduction;
THYM	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg06238570	chr21:40685208	BRWD1	-0.96	-9.24	-0.69	7.07e-15	Cognitive function;
THYM	cis	rs57927100	0.881	rs77946446	chr17:75317932	C/T	cg18271897	chr17:75316784	SEPT9	0.76	7.73	0.62	1.1e-11	Systolic blood pressure;
THYM	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11644478	chr21:40555479	PSMG1	-0.8	-6.93	-0.58	4.93e-10	Cognitive function;
THYM	cis	rs2404602	0.647	rs12905181	chr15:77098431	A/G	cg23625390	chr15:77176239	SCAPER	-0.85	-6.21	-0.54	1.39e-8	Blood metabolite levels;
THYM	cis	rs912057	0.841	rs1294423	chr6:6743795	C/T	cg13809441	chr6:6737631	NA	0.43	4.86	0.45	4.62e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs16865717	0.513	rs6431837	chr2:7036811	C/T	cg20486407	chr2:7037101	RSAD2	-1.13	-11.45	-0.76	1.35e-19	Venous thromboembolism (SNP x SNP interaction);
THYM	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg27211696	chr2:191398769	TMEM194B	0.62	4.72	0.44	8.15e-6	Diastolic blood pressure;
THYM	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg13395646	chr4:1353034	KIAA1530	-0.58	-5.41	-0.49	4.76e-7	Obesity-related traits;
THYM	cis	rs7173389	0.551	rs74743553	chr15:73676535	A/G	cg15851312	chr15:73076263	ADPGK	-0.85	-4.46	-0.42	2.28e-5	Resting heart rate;
THYM	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg00310523	chr12:86230176	RASSF9	0.61	5.31	0.48	7.29e-7	Major depressive disorder;
THYM	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg08132940	chr7:1081526	C7orf50	-1.17	-6.48	-0.55	4.07e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2276314	0.947	rs16967319	chr18:33573525	A/G	cg19628046	chr18:33552617	C18orf21	0.78	5.34	0.48	6.23e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7575217	0.767	rs13400798	chr2:101750350	C/T	cg23907051	chr2:101730305	TBC1D8	-0.41	-5.5	-0.49	3.25e-7	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs5769707	0.609	rs2071890	chr22:50001291	G/A	cg07959070	chr22:50026188	C22orf34	-0.29	-5.14	-0.47	1.44e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg11845111	chr2:191398756	TMEM194B	-0.94	-8.54	-0.66	2.17e-13	Pulse pressure;
THYM	cis	rs9515201	0.787	rs9521734	chr13:111037289	A/T	cg06243866	chr13:111019493	COL4A2	-0.98	-9.69	-0.71	7.43e-16	White matter hyperintensity burden;
THYM	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	7.2	0.59	1.43e-10	Lung cancer in ever smokers;
THYM	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg11266682	chr4:10021025	SLC2A9	0.67	9.95	0.71	2.11e-16	Bone mineral density;
THYM	cis	rs1003719	0.788	rs2251161	chr21:38467857	C/G	cg01329690	chr21:38580129	DSCR9	0.37	5.09	0.46	1.79e-6	Eye color traits;
THYM	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	6.94	0.58	4.86e-10	Prudent dietary pattern;
THYM	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg27284194	chr4:1044797	NA	0.61	4.6	0.43	1.29e-5	Recombination rate (females);
THYM	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs1448094	0.534	rs11613070	chr12:86167544	T/A	cg02569458	chr12:86230093	RASSF9	0.62	5.34	0.48	6.31e-7	Major depressive disorder;
THYM	cis	rs7000551	0.689	rs4872000	chr8:22337323	G/T	cg12081754	chr8:22256438	SLC39A14	0.65	5.58	0.5	2.3e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.45	0.42	2.34e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg07424592	chr7:64974309	NA	0.99	5.15	0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg00684032	chr4:1343700	KIAA1530	0.51	4.53	0.42	1.71e-5	Obesity-related traits;
THYM	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Intelligence (multi-trait analysis);
THYM	cis	rs9311676	0.632	rs62258139	chr3:58406836	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs9581857	0.579	rs79653667	chr13:27961109	G/A	cg22138327	chr13:27999177	GTF3A	0.98	5.44	0.49	4.21e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg07212818	chr11:638076	DRD4	-0.77	-5.92	-0.52	5.09e-8	Systemic lupus erythematosus;
THYM	cis	rs4523957	0.757	rs216208	chr17:2195146	T/A	cg16513277	chr17:2031491	SMG6	0.81	7.72	0.62	1.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2637266	1.000	rs2579749	chr10:78332105	T/C	cg18941641	chr10:78392320	NA	0.8	6.91	0.58	5.42e-10	Pulmonary function;
THYM	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg06618935	chr21:46677482	NA	-0.96	-8.67	-0.66	1.15e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6032067	0.929	rs56168207	chr20:43803971	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.34	-0.65	5.7e-13	Blood protein levels;
THYM	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg23682913	chr1:2080710	PRKCZ	0.57	5.14	0.47	1.48e-6	Height;
THYM	cis	rs2797160	0.935	rs12717178	chr6:126016499	G/A	cg16306078	chr6:126000798	NA	0.54	5.56	0.5	2.5e-7	Endometrial cancer;
THYM	cis	rs4866334	1.000	rs77653879	chr5:18449396	A/G	cg02002538	chr5:17811409	NA	-1.09	-4.54	-0.42	1.67e-5	IgG glycosylation;
THYM	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg03929089	chr4:120376271	NA	-0.99	-12.81	-0.8	2.07e-22	Height;
THYM	cis	rs900145	0.773	rs11022752	chr11:13307622	A/G	cg13286116	chr11:13302098	ARNTL	0.61	4.82	0.44	5.39e-6	Menarche (age at onset);
THYM	cis	rs8033133	0.602	rs4906699	chr15:25321029	A/G	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	0.65	5.1	0.46	1.76e-6	Blood osmolality (transformed sodium);
THYM	cis	rs6598955	0.543	rs61608823	chr1:26555090	G/A	cg04990556	chr1:26633338	UBXN11	0.96	6.06	0.53	2.7e-8	Obesity-related traits;
THYM	cis	rs4866334	1.000	rs77052976	chr5:18453061	A/T	cg24599790	chr5:18972260	NA	-1.14	-4.67	-0.43	9.77e-6	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg12573674	chr2:1569213	NA	-1.35	-8.81	-0.67	5.84e-14	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg04944784	chr2:26401820	FAM59B	0.59	4.57	0.42	1.48e-5	Gut microbiome composition (summer);
THYM	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg10150615	chr22:24372951	LOC391322	0.87	7.47	0.61	3.89e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs1978968	0.707	rs13058527	chr22:18412929	G/A	cg01550578	chr22:18484421	MICAL3	0.62	4.57	0.42	1.47e-5	Presence of antiphospholipid antibodies;
THYM	cis	rs1950626	0.750	rs72700530	chr14:101429459	G/C	cg11887864	chr14:101510502	MIR1185-2	0.54	4.52	0.42	1.75e-5	Pelvic organ prolapse (moderate/severe);
THYM	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs11096990	0.964	rs16995206	chr4:39264507	C/T	cg24403649	chr4:39172243	NA	-0.68	-5.77	-0.51	9.87e-8	Cognitive function;
THYM	cis	rs11048434	0.723	rs2080116	chr12:9138183	A/G	cg26114124	chr12:9217669	LOC144571	0.47	4.66	0.43	1.01e-5	Sjögren's syndrome;
THYM	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs921968	0.541	rs6710383	chr2:219359685	T/G	cg02176678	chr2:219576539	TTLL4	0.73	7.09	0.59	2.4e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2282300	0.739	rs35229181	chr11:30241698	A/G	cg25418670	chr11:30344373	C11orf46	-0.81	-6.87	-0.58	6.66e-10	Morning vs. evening chronotype;
THYM	cis	rs28595532	0.920	rs114314373	chr4:119639128	G/A	cg21605333	chr4:119757512	SEC24D	1.42	4.79	0.44	6.16e-6	Cannabis dependence symptom count;
THYM	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg08999081	chr20:33150536	PIGU	0.77	6.93	0.58	4.99e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs7968440	1.000	rs2731443	chr12:51094138	C/T	cg20014596	chr12:50898483	DIP2B	0.54	4.46	0.42	2.29e-5	Fibrinogen;
THYM	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03452623	chr4:187889614	NA	-1.17	-20.42	-0.9	1.62e-36	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs10813766	0.556	rs10970043	chr9:319932	G/A	cg25905812	chr9:841632	DMRT1	-0.58	-4.46	-0.42	2.22e-5	Mean platelet volume;
THYM	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg09260853	chr1:2094483	PRKCZ	-0.43	-4.54	-0.42	1.62e-5	Height;
THYM	cis	rs6087990	0.806	rs4911257	chr20:31359574	T/C	cg13636640	chr20:31349939	DNMT3B	0.87	9.19	0.69	8.85e-15	Ulcerative colitis;
THYM	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg00129232	chr17:37814104	STARD3	0.69	4.51	0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs67072384	1.000	rs67809272	chr11:72450941	T/A	cg01380194	chr11:72452482	ARAP1	-0.93	-5.07	-0.46	1.98e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	trans	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg05347473	chr6:146136440	FBXO30	-0.58	-4.53	-0.42	1.71e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7084402	0.967	rs1649046	chr10:60326109	T/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg25554036	chr4:6271136	WFS1	0.56	5.27	0.48	8.6e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg00825309	chr19:58991885	ZNF446	-0.6	-4.69	-0.43	9.02e-6	Uric acid clearance;
THYM	cis	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg00495681	chr13:53174319	NA	0.63	5.75	0.51	1.07e-7	Lewy body disease;
THYM	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg18850127	chr7:39170497	POU6F2	0.54	4.9	0.45	3.86e-6	IgG glycosylation;
THYM	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg23758822	chr17:41437982	NA	1.16	10.91	0.75	1.87e-18	Menopause (age at onset);
THYM	cis	rs34779708	0.966	rs34776628	chr10:35426324	G/A	cg03585969	chr10:35415529	CREM	0.66	4.76	0.44	6.85e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg22709100	chr7:91322751	NA	0.59	4.56	0.42	1.55e-5	Breast cancer;
THYM	cis	rs11771526	0.792	rs10249413	chr7:32304259	G/C	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs4481887	0.962	rs12037921	chr1:248454167	T/G	cg13385794	chr1:248469461	NA	0.67	4.58	0.43	1.4e-5	Common traits (Other);
THYM	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs877282	0.947	rs7904978	chr10:768078	C/T	cg22713356	chr15:30763199	NA	1.38	11.2	0.75	4.69e-19	Uric acid levels;
THYM	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg00072720	chr17:7165831	CLDN7	0.41	4.45	0.42	2.35e-5	Diastolic blood pressure;
THYM	cis	rs4523957	0.553	rs9909515	chr17:2039733	T/C	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2458413	0.543	rs2514658	chr8:105337871	G/A	cg13045555	chr8:105342365	NA	-0.33	-6.43	-0.55	5.07e-9	Paget's disease;
THYM	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg01528321	chr10:82214614	TSPAN14	0.63	5.31	0.48	7.07e-7	Post bronchodilator FEV1;
THYM	cis	rs9913156	0.748	rs7215274	chr17:4561834	A/G	cg19197139	chr17:4613644	ARRB2	0.78	4.92	0.45	3.63e-6	Lymphocyte counts;
THYM	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg21784768	chr11:537496	LRRC56	1.08	5.27	0.48	8.39e-7	Body mass index;
THYM	trans	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg26043149	chr18:55253948	FECH	1.16	10.82	0.74	2.98e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg12560992	chr17:57184187	TRIM37	0.92	8.53	0.66	2.29e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4889855	0.530	rs12451459	chr17:78589668	G/A	cg16591659	chr17:78472290	NA	0.44	5.13	0.47	1.53e-6	Fractional excretion of uric acid;
THYM	cis	rs6988636	1.000	rs13260798	chr8:124190192	G/A	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg04362960	chr10:104952993	NT5C2	0.58	4.82	0.44	5.34e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs11723261	0.582	rs7679573	chr4:151605	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.82	5.69	0.5	1.38e-7	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs4866334	1.000	rs77016925	chr5:18487933	T/C	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs11671005	0.656	rs11672609	chr19:59006924	C/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.7	-5.18	-0.47	1.24e-6	Mean platelet volume;
THYM	cis	rs2734839	0.964	rs12808482	chr11:113294998	T/A	cg14159747	chr11:113255604	NA	0.32	6.33	0.54	8.07e-9	Information processing speed;
THYM	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg26441486	chr22:50317300	CRELD2	0.49	5.36	0.48	5.93e-7	Schizophrenia;
THYM	cis	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.7	0.43	8.74e-6	Obesity-related traits;
THYM	cis	rs28595532	0.920	rs55649377	chr4:119752745	T/A	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs1003719	0.788	rs2835602	chr21:38469069	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg14416269	chr4:6271139	WFS1	0.55	5.69	0.5	1.41e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs113835537	0.529	rs17496250	chr11:66270774	C/G	cg24851651	chr11:66362959	CCS	0.73	5.13	0.47	1.52e-6	Airway imaging phenotypes;
THYM	cis	rs6732160	0.564	rs60796597	chr2:73382914	C/T	cg24220031	chr2:73402428	NA	-0.71	-5.79	-0.51	8.94e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg13736514	chr6:26305472	NA	-0.61	-7.45	-0.61	4.16e-11	Educational attainment;
THYM	cis	rs8078723	0.714	rs12940405	chr17:38143768	C/T	cg17467752	chr17:38218738	THRA	-0.8	-6.7	-0.57	1.46e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg08048268	chr3:133502702	NA	-0.67	-5.61	-0.5	2e-7	Iron status biomarkers;
THYM	cis	rs7575217	0.697	rs6727703	chr2:101698533	G/T	cg23907051	chr2:101730305	TBC1D8	0.39	5.09	0.46	1.82e-6	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs865483	0.895	rs853191	chr17:35821758	A/T	cg06716730	chr17:35851459	DUSP14	0.43	7.3	0.6	8.71e-11	Monocyte count;
THYM	cis	rs13082711	0.522	rs653076	chr3:27343691	T/C	cg02860705	chr3:27208620	NA	0.65	5.07	0.46	1.94e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg00339695	chr16:24857497	SLC5A11	0.49	4.94	0.45	3.33e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3768617	0.528	rs10911240	chr1:183062948	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.76	0.44	6.83e-6	Fuchs's corneal dystrophy;
THYM	cis	rs28595532	0.841	rs55823625	chr4:119780600	T/A	cg11846333	chr4:119757529	SEC24D	1.36	4.83	0.44	5.31e-6	Cannabis dependence symptom count;
THYM	cis	rs2066819	1.000	rs117683816	chr12:56638267	T/C	cg26714650	chr12:56694279	CS	-1.27	-6.32	-0.54	8.6e-9	Psoriasis vulgaris;
THYM	cis	rs3820068	0.603	rs1980607	chr1:15975237	A/G	cg05660106	chr1:15850417	CASP9	0.77	6.29	0.54	9.83e-9	Systolic blood pressure;
THYM	cis	rs600806	0.850	rs1465607	chr1:109958035	T/C	cg23616212	chr1:109941201	SORT1	-0.5	-4.78	-0.44	6.34e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg09307838	chr4:120376055	NA	0.6	4.54	0.42	1.63e-5	Educational attainment;
THYM	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg14829155	chr15:31115871	NA	0.76	6.45	0.55	4.56e-9	Huntington's disease progression;
THYM	cis	rs7695732	0.572	rs9307053	chr4:89896892	G/A	cg17769793	chr4:89976368	FAM13A	-0.5	-5.57	-0.5	2.36e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs4664308	1.000	rs17341301	chr2:160902420	G/A	cg03641300	chr2:160917029	PLA2R1	-0.74	-6.77	-0.57	1.06e-9	Idiopathic membranous nephropathy;
THYM	cis	rs3733589	0.661	rs4697943	chr4:10165361	A/G	cg17095147	chr4:10101400	WDR1	1.19	5.0	0.46	2.64e-6	Renal overload gout;
THYM	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg22907277	chr7:1156413	C7orf50	0.84	7.09	0.59	2.31e-10	Longevity;Endometriosis;
THYM	cis	rs1278769	0.786	rs7998551	chr13:113540649	G/T	cg17842918	chr13:113540400	ATP11A	-0.43	-4.46	-0.42	2.22e-5	Interstitial lung disease;
THYM	cis	rs7084402	1.000	rs28426375	chr10:60285478	T/A	cg09696939	chr10:60272079	BICC1	-0.46	-5.25	-0.47	9.38e-7	Refractive error;
THYM	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg17063962	chr7:91808500	NA	-1.12	-12.68	-0.79	3.85e-22	Breast cancer;
THYM	cis	rs939658	0.805	rs36068099	chr15:79438598	G/C	cg17916960	chr15:79447300	NA	-0.73	-8.59	-0.66	1.73e-13	Refractive error;
THYM	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.56	-6.89	-0.58	6.11e-10	Schizophrenia;
THYM	cis	rs273218	0.573	rs11742692	chr5:53343576	C/T	ch.5.1024479R	chr5:53302184	ARL15	-1.08	-9.13	-0.68	1.22e-14	Migraine;
THYM	cis	rs10426930	0.700	rs10413045	chr19:5024099	G/T	cg25246084	chr19:4971487	KDM4B	-0.5	-5.18	-0.47	1.22e-6	Monocyte percentage of white cells;
THYM	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg12310025	chr6:25882481	NA	-0.92	-8.1	-0.64	1.84e-12	Intelligence (multi-trait analysis);
THYM	cis	rs1728785	1.000	rs1645928	chr16:68590610	G/T	cg02972257	chr16:68554789	NA	-0.77	-4.9	-0.45	3.98e-6	Ulcerative colitis;
THYM	cis	rs2067615	0.524	rs10778499	chr12:107068387	C/T	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	cis	rs61990749	0.597	rs2267758	chr14:78147429	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-1.17	-8.04	-0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs11599315	0.507	rs12217329	chr10:1341897	A/G	cg09624528	chr10:1369823	ADARB2	0.77	6.14	0.53	1.87e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg14664628	chr15:75095509	CSK	-0.99	-8.15	-0.64	1.48e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg12386194	chr3:101231763	SENP7	0.69	5.16	0.47	1.34e-6	Colorectal cancer;
THYM	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg07212818	chr11:638076	DRD4	-0.79	-6.69	-0.57	1.57e-9	Systemic lupus erythematosus;
THYM	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.06	11.07	0.75	8.56e-19	Intelligence (multi-trait analysis);
THYM	cis	rs4979906	1.000	rs11002246	chr10:79446777	T/A	cg07817648	chr10:79422355	NA	-0.77	-5.61	-0.5	1.98e-7	Mortality in heart failure;
THYM	cis	rs9563576	0.778	rs9788367	chr13:58640955	C/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.63	4.68	0.43	9.64e-6	Body mass index;
THYM	cis	rs1728785	1.000	rs11075680	chr16:68565700	G/C	cg02972257	chr16:68554789	NA	-0.75	-4.57	-0.42	1.47e-5	Ulcerative colitis;
THYM	cis	rs7173743	0.934	rs7168915	chr15:79128889	C/T	cg15571903	chr15:79123663	NA	0.55	6.18	0.54	1.57e-8	Coronary artery disease;
THYM	cis	rs753778	1.000	rs4961257	chr8:142232704	A/G	cg18755752	chr8:142205143	DENND3	0.61	4.64	0.43	1.1e-5	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg14018140	chr10:458528	DIP2C	-0.61	-7.19	-0.59	1.49e-10	Psychosis in Alzheimer's disease;
THYM	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg07930192	chr7:1003750	NA	0.56	4.74	0.44	7.54e-6	Longevity;Endometriosis;
THYM	cis	rs4523957	0.614	rs2760736	chr17:2036653	A/G	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6598955	0.640	rs1577507	chr1:26547179	C/T	cg04990556	chr1:26633338	UBXN11	-0.89	-8.56	-0.66	1.92e-13	Obesity-related traits;
THYM	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg22709100	chr7:91322751	NA	-0.61	-4.85	-0.45	4.9e-6	Breast cancer;
THYM	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-5.07	-0.46	2e-6	Chronic sinus infection;
THYM	cis	rs4631830	0.828	rs10763567	chr10:51538169	C/A	cg10326726	chr10:51549505	MSMB	0.57	5.73	0.51	1.18e-7	Prostate-specific antigen levels;
THYM	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06850241	chr22:41845214	NA	0.49	4.62	0.43	1.21e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs2219968	0.590	rs13261483	chr8:78899488	C/T	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.82	6.24	0.54	1.19e-8	IgG glycosylation;
THYM	cis	rs1021993	0.868	rs6674309	chr1:209530828	A/G	cg06155620	chr1:209527581	NA	-0.65	-5.28	-0.48	8.22e-7	Gut microbiome composition (winter);
THYM	cis	rs1878931	0.507	rs11648783	chr16:3406626	A/G	cg22508957	chr16:3507546	NAT15	-0.45	-4.98	-0.46	2.81e-6	Body mass index (adult);
THYM	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg04520793	chr17:42248056	ASB16	-0.35	-4.98	-0.45	2.85e-6	Total body bone mineral density;
THYM	cis	rs654128	0.640	rs339330	chr6:117209490	T/G	cg12892004	chr6:117198278	RFX6	-0.69	-5.16	-0.47	1.34e-6	Telomere length;
THYM	cis	rs742614	0.935	rs736264	chr20:32482386	C/T	cg06304546	chr20:32448765	NA	0.62	4.97	0.45	2.96e-6	Stearic acid (18:0) levels;
THYM	cis	rs2346177	0.513	rs1530625	chr2:46658067	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.59	4.76	0.44	6.97e-6	HDL cholesterol;
THYM	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg18904891	chr8:8559673	CLDN23	-0.58	-4.69	-0.43	8.98e-6	Joint mobility (Beighton score);
THYM	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg14019146	chr3:50243930	SLC38A3	0.54	4.56	0.42	1.53e-5	Body mass index;
THYM	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg24874828	chr4:187887005	NA	0.7	7.17	0.59	1.59e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg02931644	chr1:25747376	RHCE	0.57	4.52	0.42	1.77e-5	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.78	-0.44	6.31e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg19693284	chr19:2783607	SGTA	0.67	5.34	0.48	6.32e-7	Total cholesterol levels;
THYM	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	4.96	0.45	3.07e-6	Schizophrenia;
THYM	cis	rs28595532	0.841	rs114363775	chr4:119765587	G/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs4790312	0.901	rs8078625	chr17:1978334	C/T	cg15816464	chr17:2026533	SMG6	0.38	4.99	0.46	2.78e-6	Left atrial antero-posterior diameter;
THYM	cis	rs13082711	0.911	rs2371065	chr3:27494589	A/C	cg02860705	chr3:27208620	NA	0.73	5.25	0.47	9.27e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs447921	0.773	rs11077821	chr17:74455579	C/T	cg17201438	chr17:74438067	UBE2O	0.64	4.47	0.42	2.14e-5	Mitochondrial DNA levels;
THYM	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg18681998	chr4:17616180	MED28	0.99	10.27	0.73	4.28e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs73198271	0.740	rs10113326	chr8:8647630	A/T	cg15556689	chr8:8085844	FLJ10661	-0.73	-4.58	-0.43	1.39e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4474465	0.833	rs10793320	chr11:78217460	G/A	cg19901956	chr11:77921274	USP35	0.66	5.0	0.46	2.65e-6	Alzheimer's disease (survival time);
THYM	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg10523679	chr1:76189770	ACADM	0.94	8.52	0.66	2.42e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs10871290	0.881	rs4099290	chr16:74468889	A/G	cg01733217	chr16:74700730	RFWD3	-0.65	-5.57	-0.5	2.38e-7	Breast cancer;
THYM	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg10518543	chr12:38710700	ALG10B	-0.58	-4.6	-0.43	1.31e-5	Morning vs. evening chronotype;
THYM	cis	rs4478037	0.822	rs4528891	chr3:33121392	G/T	cg19404215	chr3:33155277	CRTAP	0.97	6.38	0.55	6.55e-9	Major depressive disorder;
THYM	cis	rs4919694	1.000	rs12261040	chr10:104665397	T/C	cg15744005	chr10:104629667	AS3MT	-0.78	-4.45	-0.42	2.3e-5	Arsenic metabolism;
THYM	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs10905099	0.505	rs7086005	chr10:7077572	C/T	cg04689582	chr10:7526744	NA	-0.32	-4.62	-0.43	1.22e-5	Orofacial clefts;
THYM	cis	rs870825	0.616	rs6810635	chr4:185616859	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.69	0.71	7.45e-16	Blood protein levels;
THYM	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg08807101	chr21:30365312	RNF160	-0.7	-5.24	-0.47	9.71e-7	Dental caries;
THYM	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg25918947	chr17:41365094	TMEM106A	-0.57	-4.69	-0.43	9.05e-6	Menopause (age at onset);
THYM	cis	rs2281845	0.859	rs4915217	chr1:201077470	T/A	cg17810781	chr1:201082982	CACNA1S	0.62	6.48	0.55	4.03e-9	Permanent tooth development;
THYM	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02788857	chr8:22132959	PIWIL2	0.58	5.36	0.48	5.94e-7	Hypertriglyceridemia;
THYM	cis	rs12579753	0.917	rs10778834	chr12:82199742	A/C	cg21231944	chr12:82153410	PPFIA2	-0.68	-5.23	-0.47	9.95e-7	Resting heart rate;
THYM	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg13114125	chr14:105738426	BRF1	-0.71	-5.48	-0.49	3.45e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs28785552	0.800	rs10853855	chr19:53232293	A/G	cg10871876	chr19:53194124	ZNF83	0.74	6.24	0.54	1.22e-8	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg05368731	chr17:41323189	NBR1	1.25	11.25	0.76	3.57e-19	Menopause (age at onset);
THYM	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs1670533	0.932	rs13140571	chr4:1054358	T/C	cg27284194	chr4:1044797	NA	0.61	4.6	0.43	1.29e-5	Recombination rate (females);
THYM	cis	rs988913	0.678	rs9396042	chr6:54976615	A/G	cg18532076	chr6:54711417	FAM83B	0.49	4.62	0.43	1.18e-5	Menarche (age at onset);
THYM	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg12564285	chr5:131593104	PDLIM4	0.52	5.7	0.5	1.33e-7	Breast cancer;
THYM	cis	rs240764	0.782	rs239223	chr6:101112345	A/G	cg21058520	chr6:100914733	NA	-0.57	-5.03	-0.46	2.29e-6	Neuroticism;
THYM	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg23989207	chr17:80870107	TBCD	0.62	5.18	0.47	1.24e-6	Glycated hemoglobin levels;
THYM	cis	rs3818717	0.539	rs12950737	chr17:17678573	G/A	cg04398451	chr17:18023971	MYO15A	0.64	5.32	0.48	6.94e-7	Lymphocyte counts;
THYM	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg18512352	chr11:47633146	NA	-0.55	-7.04	-0.59	3.05e-10	Subjective well-being;
THYM	cis	rs9443645	0.507	rs9352648	chr6:79479741	A/G	cg04547799	chr6:79944526	HMGN3	-0.69	-5.03	-0.46	2.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg21775007	chr8:11205619	TDH	-0.65	-5.08	-0.46	1.9e-6	Retinal vascular caliber;
THYM	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg20608306	chr11:116969690	SIK3	-0.47	-4.9	-0.45	3.93e-6	Blood protein levels;
THYM	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg07988820	chr12:82153109	PPFIA2	-0.85	-5.59	-0.5	2.16e-7	Resting heart rate;
THYM	cis	rs6430585	0.702	rs1042712	chr2:136545844	C/G	cg07169764	chr2:136633963	MCM6	-1.21	-13.15	-0.8	4.12e-23	Corneal structure;
THYM	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.67	-4.93	-0.45	3.42e-6	Colorectal cancer;
THYM	cis	rs17030434	0.834	rs28658020	chr4:154759048	C/T	cg14289246	chr4:154710475	SFRP2	-0.69	-4.98	-0.45	2.9e-6	Electrocardiographic conduction measures;
THYM	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg12940439	chr1:67600707	NA	0.59	5.39	0.48	5.02e-7	Psoriasis;
THYM	trans	rs12516208	0.579	rs10900709	chr5:115326695	A/C	cg27552493	chr12:62652662	NA	0.83	6.92	0.58	5.2e-10	Very long-chain saturated fatty acid levels (fatty acid 20:0);
THYM	cis	rs2970992	0.728	rs1543103	chr2:101326223	G/T	cg01042948	chr2:101319752	NA	0.57	5.61	0.5	2.02e-7	Educational attainment;
THYM	cis	rs4733781	0.736	rs4733776	chr8:131229180	C/T	cg16277922	chr8:131349729	ASAP1	0.6	4.56	0.42	1.52e-5	Tuberculosis;
THYM	trans	rs3789775	0.536	rs10948689	chr6:52109736	T/C	cg16516639	chr1:111050810	NA	0.97	7.06	0.59	2.69e-10	Pre-treatment pain in head and neck squamous cell carcinoma;
THYM	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg22508957	chr16:3507546	NAT15	0.49	5.17	0.47	1.29e-6	Body mass index (adult);
THYM	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg02380750	chr20:61661411	NA	0.61	6.16	0.53	1.78e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6987853	0.933	rs2974339	chr8:42397529	T/C	cg09913449	chr8:42400586	C8orf40	0.88	8.02	0.64	2.8e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7695732	0.595	rs2704576	chr4:89894602	T/C	cg17769793	chr4:89976368	FAM13A	-0.5	-5.57	-0.5	2.36e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs2070677	0.736	rs7099806	chr10:135414896	C/T	cg20169779	chr10:135381914	SYCE1	-0.76	-4.97	-0.45	2.99e-6	Gout;
THYM	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg13147721	chr7:65941812	NA	-0.74	-4.73	-0.44	7.94e-6	Diabetic kidney disease;
THYM	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg22683308	chr4:1340831	KIAA1530	-0.63	-4.52	-0.42	1.81e-5	Obesity-related traits;
THYM	cis	rs899997	0.906	rs1994018	chr15:79025584	G/A	cg00639195	chr15:79103007	ADAMTS7	0.79	4.86	0.45	4.59e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs4820539	0.934	rs3788351	chr22:23469181	T/C	cg21100191	chr22:23484243	RTDR1	0.74	6.45	0.55	4.58e-9	Bone mineral density;
THYM	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg15704280	chr7:45808275	SEPT13	-1.07	-14.8	-0.84	2.13e-26	Height;
THYM	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22857025	chr5:266934	NA	-1.59	-10.2	-0.72	6.04e-17	Breast cancer;
THYM	cis	rs1557488	0.565	rs10750349	chr11:126695955	T/C	cg03950493	chr11:126582183	KIRREL3	-0.4	-4.5	-0.42	1.93e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg11882607	chr3:12858926	CAND2	-0.42	-4.6	-0.43	1.31e-5	QRS complex (12-leadsum);
THYM	cis	rs2273669	0.667	rs10457187	chr6:109336051	G/A	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg15027190	chr1:90124886	LRRC8C	-0.95	-6.91	-0.58	5.47e-10	Depressive symptoms;
THYM	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11890956	chr21:40555474	PSMG1	1.17	13.11	0.8	4.95e-23	Cognitive function;
THYM	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg18252515	chr7:66147081	NA	-0.66	-5.0	-0.46	2.65e-6	Aortic root size;
THYM	cis	rs1122608	0.543	rs12611017	chr19:11065021	G/A	cg17326582	chr19:11976514	ZNF439	0.64	5.08	0.46	1.86e-6	Coronary artery disease or ischemic stroke;Coronary artery disease;Coronary artery disease or large artery stroke;Coronary heart disease;Myocardial infarction (early onset);
THYM	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg11764359	chr7:65958608	NA	-0.75	-6.04	-0.53	2.97e-8	Aortic root size;
THYM	cis	rs2637266	1.000	rs755824	chr10:78381348	A/G	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg15691649	chr6:25882328	NA	-0.6	-4.9	-0.45	3.93e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	trans	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.11	8.13	0.64	1.6e-12	Exhaled nitric oxide output;
THYM	cis	rs11168351	0.833	rs6580652	chr12:48447105	C/A	cg21466736	chr12:48725269	NA	0.51	5.11	0.46	1.69e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg03433033	chr1:76189801	ACADM	0.69	6.66	0.56	1.75e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs11209185	0.563	rs10889733	chr1:68424136	G/A	cg22082780	chr1:68452167	NA	-0.49	-5.34	-0.48	6.38e-7	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg06640241	chr16:89574553	SPG7	0.89	8.26	0.65	8.43e-13	Multiple myeloma (IgH translocation);
THYM	cis	rs13326165	0.585	rs11708581	chr3:52428988	C/A	cg08438690	chr3:52279403	PPM1M	-0.84	-4.6	-0.43	1.32e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs7586879	0.964	rs4077679	chr2:25122852	T/C	cg01884057	chr2:25150051	NA	0.65	6.42	0.55	5.27e-9	Body mass index;
THYM	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg09877947	chr5:131593287	PDLIM4	0.56	4.56	0.42	1.51e-5	Blood metabolite levels;
THYM	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg04842962	chr6:43655489	MRPS18A	1.4	15.48	0.85	1.01e-27	IgG glycosylation;
THYM	cis	rs9296092	0.517	rs56043172	chr6:33522363	T/G	cg13560919	chr6:33536144	NA	-0.94	-9.31	-0.69	4.9e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg16586182	chr3:47516702	SCAP	0.57	4.98	0.45	2.88e-6	Colorectal cancer;
THYM	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs57920188	0.535	rs12129515	chr1:4094101	G/A	cg20703997	chr1:4087676	NA	0.74	5.31	0.48	7.07e-7	Interleukin-17 levels;
THYM	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs3820068	0.532	rs74057713	chr1:15944620	G/C	cg24675056	chr1:15929824	NA	0.73	5.84	0.51	7.21e-8	Systolic blood pressure;
THYM	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg08000102	chr2:233561755	GIGYF2	-0.68	-5.94	-0.52	4.62e-8	Coronary artery disease;
THYM	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg14186256	chr22:23484241	RTDR1	0.96	9.73	0.71	6.25e-16	Bone mineral density;
THYM	cis	rs2747539	0.623	rs7271630	chr20:32449398	T/C	cg06304546	chr20:32448765	NA	-0.64	-4.45	-0.42	2.3e-5	Dysphagia;
THYM	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg05717871	chr11:638507	DRD4	-0.68	-5.48	-0.49	3.43e-7	Systemic lupus erythematosus;
THYM	cis	rs2046867	0.862	rs6778168	chr3:72840206	T/A	cg25664220	chr3:72788482	NA	-0.86	-6.77	-0.57	1.04e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	4.59	0.43	1.35e-5	Hip circumference adjusted for BMI;
THYM	cis	rs13255292	0.695	rs7007910	chr8:129081271	A/C	cg03076047	chr8:128748337	MYC	-0.57	-4.46	-0.42	2.22e-5	Diffuse large B cell lymphoma;
THYM	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs7668636	0.514	rs62306364	chr4:90024793	A/G	cg17769793	chr4:89976368	FAM13A	0.48	5.02	0.46	2.42e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	trans	rs629535	0.590	rs55988608	chr8:70133619	A/G	cg21567404	chr3:27674614	NA	-0.91	-7.35	-0.6	6.9e-11	Dupuytren's disease;
THYM	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg14458575	chr2:238380390	NA	0.95	7.97	0.63	3.54e-12	Prostate cancer;
THYM	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Body mass index;
THYM	cis	rs7582180	0.663	rs2053263	chr2:100971407	A/G	cg14675211	chr2:100938903	LONRF2	0.6	5.72	0.51	1.21e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg09395187	chr16:88023319	BANP	-0.72	-4.54	-0.42	1.64e-5	Menopause (age at onset);
THYM	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs11030122	0.702	rs10835403	chr11:3990941	A/C	cg22027985	chr11:4115532	RRM1	0.5	4.48	0.42	2.12e-5	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4148689	1.000	rs4148697	chr7:117172783	C/T	cg17204129	chr7:117119601	CFTR	-0.62	-4.79	-0.44	6.23e-6	Gout;
THYM	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.65	5.51	0.49	3.02e-7	Height;
THYM	cis	rs9790314	0.936	rs466399	chr3:161091194	G/T	cg03342759	chr3:160939853	NMD3	-0.7	-5.98	-0.52	3.86e-8	Morning vs. evening chronotype;
THYM	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg26850624	chr5:429559	AHRR	-0.72	-5.68	-0.5	1.45e-7	Cystic fibrosis severity;
THYM	cis	rs28374715	0.783	rs11635269	chr15:41570710	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.19	-12.36	-0.79	1.7e-21	Ulcerative colitis;
THYM	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg02782426	chr3:40428986	ENTPD3	0.55	4.92	0.45	3.58e-6	Renal cell carcinoma;
THYM	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg02734326	chr4:10020555	SLC2A9	0.78	6.67	0.56	1.68e-9	Bone mineral density;
THYM	cis	rs3916	0.911	rs7313271	chr12:121152667	C/T	cg21892295	chr12:121157589	UNC119B	-0.53	-5.18	-0.47	1.25e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg14186256	chr22:23484241	RTDR1	0.97	9.46	0.7	2.38e-15	Bone mineral density;
THYM	cis	rs13137105	0.614	rs2126852	chr4:76406846	T/C	cg03209871	chr4:76438412	RCHY1;THAP6	0.48	5.22	0.47	1.07e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg02527881	chr3:46936655	PTH1R	0.66	6.8	0.57	9.17e-10	Colorectal cancer;
THYM	cis	rs1385374	0.858	rs11059926	chr12:129294244	A/T	cg04043695	chr12:129287642	SLC15A4	-0.8	-4.83	-0.44	5.3e-6	Systemic lupus erythematosus;
THYM	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg13852791	chr20:30311386	BCL2L1	0.67	4.76	0.44	7.04e-6	Mean corpuscular hemoglobin;
THYM	cis	rs7296418	0.922	rs1727293	chr12:123648032	C/T	cg00376283	chr12:123451042	ABCB9	0.88	7.15	0.59	1.77e-10	Platelet count;
THYM	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg10047753	chr17:41438598	NA	1.2	10.92	0.75	1.85e-18	Menopause (age at onset);
THYM	cis	rs17331151	0.512	rs9637477	chr3:52891426	G/C	cg04865290	chr3:52927548	TMEM110	0.64	4.57	0.42	1.47e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg00129232	chr17:37814104	STARD3	0.73	4.98	0.45	2.87e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs10186029	0.680	rs12694293	chr2:213937221	T/C	cg08319019	chr2:214017104	IKZF2	0.82	6.78	0.57	1.02e-9	Systemic sclerosis;
THYM	cis	rs554111	0.634	rs1453265	chr1:21277711	C/T	cg01072550	chr1:21505969	NA	0.59	5.17	0.47	1.3e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg03684893	chr10:554711	DIP2C	0.74	5.51	0.49	3.08e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg06609049	chr19:2785107	THOP1	1.21	12.97	0.8	9.63e-23	Total cholesterol levels;
THYM	cis	rs4072705	0.617	rs10283445	chr9:127243637	A/G	cg13476313	chr9:127244764	NR5A1	0.36	5.28	0.48	8.04e-7	Menarche (age at onset);
THYM	cis	rs1451375	0.698	rs11489734	chr7:50635730	A/T	cg18232548	chr7:50535776	DDC	0.69	5.35	0.48	6.03e-7	Malaria;
THYM	cis	rs6840360	0.571	rs718800	chr4:152549307	A/T	cg22705602	chr4:152727874	NA	0.77	8.13	0.64	1.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg20608306	chr11:116969690	SIK3	0.55	6.41	0.55	5.57e-9	Blood protein levels;
THYM	cis	rs9790314	0.663	rs796609	chr3:160705600	C/G	cg04691961	chr3:161091175	C3orf57	-0.58	-4.63	-0.43	1.15e-5	Morning vs. evening chronotype;
THYM	cis	rs7830933	0.955	rs7004766	chr8:23595940	T/C	cg04349084	chr8:23602677	NA	0.6	6.44	0.55	4.86e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs2227564	0.533	rs3870402	chr10:75473787	A/C	cg23231163	chr10:75533350	FUT11	-0.37	-4.72	-0.44	8.23e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7267979	0.844	rs6132824	chr20:25238173	T/C	cg08601574	chr20:25228251	PYGB	0.7	5.75	0.51	1.1e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2970992	0.764	rs2137669	chr2:101330992	G/T	cg01042948	chr2:101319752	NA	0.6	5.89	0.52	5.76e-8	Educational attainment;
THYM	cis	rs9311676	0.632	rs11924677	chr3:58420542	T/C	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.59	0.5	2.13e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8130944	0.740	rs13049942	chr21:44120767	C/G	cg05030553	chr21:44061403	NA	-0.52	-4.53	-0.42	1.71e-5	Perceived unattractiveness to mosquitoes;
THYM	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg09455208	chr3:40491958	NA	0.5	5.15	0.47	1.39e-6	Renal cell carcinoma;
THYM	cis	rs899997	0.906	rs1809415	chr15:79028201	C/T	cg04896959	chr15:78267971	NA	-1.05	-8.08	-0.64	2.02e-12	Coronary artery disease or large artery stroke;
THYM	cis	rs1018836	0.923	rs2213886	chr8:91554163	G/C	cg16814680	chr8:91681699	NA	-0.79	-7.05	-0.59	2.89e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs12216545	0.640	rs1879867	chr7:150258106	C/G	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs61931739	0.853	rs7137146	chr12:34102394	G/A	cg10856724	chr12:34555212	NA	0.62	5.4	0.48	4.95e-7	Morning vs. evening chronotype;
THYM	cis	rs10851411	0.647	rs62022308	chr15:42734162	G/T	cg04857231	chr15:42782520	NA	-0.58	-5.11	-0.46	1.66e-6	Glucose homeostasis traits;
THYM	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg24910161	chr17:38119198	GSDMA	0.46	4.62	0.43	1.19e-5	Self-reported allergy;
THYM	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg14820908	chr5:178986412	RUFY1	0.64	6.95	0.58	4.6e-10	Lung cancer;
THYM	cis	rs236907	0.859	rs56365362	chr1:171752193	G/A	cg20598894	chr1:171756153	METTL13	-0.74	-5.59	-0.5	2.16e-7	Mean platelet volume;
THYM	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg00271210	chr6:167070053	RPS6KA2	0.72	7.96	0.63	3.73e-12	Crohn's disease;
THYM	cis	rs9326248	0.768	rs4936366	chr11:117026885	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.67	4.78	0.44	6.35e-6	Blood protein levels;
THYM	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs6121246	0.609	rs4453755	chr20:30331047	G/A	cg13852791	chr20:30311386	BCL2L1	0.87	8.17	0.64	1.31e-12	Mean corpuscular hemoglobin;
THYM	cis	rs7586879	1.000	rs6736711	chr2:25116456	C/T	cg01884057	chr2:25150051	NA	0.63	6.3	0.54	9.31e-9	Body mass index;
THYM	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	7.84	0.63	6.39e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3768617	0.510	rs10797837	chr1:183075121	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg00487526	chr15:90818384	NA	-0.58	-4.46	-0.42	2.24e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs1005224	0.853	rs2360035	chr14:76297093	A/T	cg04684003	chr14:76127793	TTLL5;C14orf1	0.72	6.02	0.53	3.24e-8	Large artery stroke;
THYM	cis	rs6674176	0.561	rs4660263	chr1:44421433	A/C	cg15962314	chr1:44399869	ARTN	0.52	4.99	0.46	2.72e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs1551570	0.819	rs11666402	chr19:10219076	A/G	cg16327482	chr19:10226339	EIF3G	0.4	5.59	0.5	2.19e-7	Narcolepsy;
THYM	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg06640241	chr16:89574553	SPG7	0.92	8.49	0.66	2.78e-13	Multiple myeloma (IgH translocation);
THYM	cis	rs7833986	0.501	rs17815934	chr8:57038395	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	6.79	0.57	9.74e-10	Height;
THYM	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.82	0.44	5.4e-6	Bipolar disorder;
THYM	cis	rs2404602	0.647	rs7178250	chr15:77099107	T/C	cg23625390	chr15:77176239	SCAPER	-0.85	-6.21	-0.54	1.39e-8	Blood metabolite levels;
THYM	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg18132916	chr6:79620363	NA	-0.55	-4.98	-0.46	2.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7582403	0.510	rs4436897	chr2:148868188	T/C	cg23727674	chr2:148602993	ACVR2A	0.63	4.61	0.43	1.24e-5	Neuroticism;
THYM	cis	rs17401966	1.000	rs7520935	chr1:10354271	G/T	cg20482658	chr1:10539492	PEX14	0.4	4.83	0.44	5.29e-6	Hepatocellular carcinoma;
THYM	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs4950928	0.823	rs2153101	chr1:203168474	A/T	cg17014757	chr1:203156097	CHI3L1	-1.11	-7.28	-0.6	9.63e-11	YKL-40 levels;
THYM	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg06766960	chr11:133703094	NA	0.58	5.07	0.46	1.94e-6	Childhood ear infection;
THYM	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg09307838	chr4:120376055	NA	0.77	5.57	0.5	2.37e-7	Corneal astigmatism;
THYM	cis	rs12049351	0.612	rs10916486	chr1:229609461	A/G	cg11742688	chr1:229674241	ABCB10	-0.54	-4.57	-0.42	1.46e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs7084402	0.967	rs1649063	chr10:60309215	G/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.65e-7	Refractive error;
THYM	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg10515332	chr4:99064459	C4orf37	0.73	4.47	0.42	2.17e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17125944	0.686	rs12884504	chr14:53360494	G/A	cg00686598	chr14:53173677	PSMC6	-1.01	-4.55	-0.42	1.56e-5	Alzheimer's disease (late onset);
THYM	cis	rs7772486	0.558	rs9497403	chr6:146054695	T/G	cg05347473	chr6:146136440	FBXO30	-0.82	-7.43	-0.61	4.73e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs883115	0.846	rs6697510	chr1:224810687	T/C	cg01808320	chr1:224927238	CNIH3	-0.54	-4.47	-0.42	2.18e-5	Cancer;
THYM	cis	rs17345786	0.520	rs12638134	chr3:101334609	G/T	cg11279151	chr3:101281821	RG9MTD1	-0.56	-4.71	-0.43	8.52e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9790314	0.503	rs6441374	chr3:161064540	A/T	cg03342759	chr3:160939853	NMD3	-0.79	-6.93	-0.58	5.07e-10	Morning vs. evening chronotype;
THYM	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg27534772	chr1:16042836	PLEKHM2	0.56	6.31	0.54	8.77e-9	Systolic blood pressure;
THYM	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg06618935	chr21:46677482	NA	-0.95	-9.38	-0.69	3.52e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg07936489	chr17:37558343	FBXL20	0.83	5.84	0.51	7.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs3819817	0.575	rs7487781	chr12:96355376	A/C	cg26410635	chr12:96350720	AMDHD1	0.53	5.02	0.46	2.38e-6	Vitamin D levels;
THYM	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg22535103	chr8:58192502	C8orf71	-1.03	-6.31	-0.54	8.85e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs2639990	0.744	rs640261	chr18:72905808	C/T	cg21330207	chr18:72916311	ZADH2	1.2	5.95	0.52	4.37e-8	Vascular endothelial growth factor levels;
THYM	cis	rs10791097	0.702	rs11222346	chr11:130715343	T/C	cg05962950	chr11:130786565	SNX19	-0.71	-5.64	-0.5	1.71e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9420	0.884	rs589914	chr11:57661032	A/G	cg19752551	chr11:57585705	CTNND1	0.72	7.34	0.6	7.26e-11	Schizophrenia;
THYM	cis	rs12681287	0.608	rs13273338	chr8:87453361	T/G	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs259282	0.584	rs10416758	chr19:33107716	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.57	4.73	0.44	7.88e-6	Schizophrenia;
THYM	cis	rs789852	0.764	rs2794668	chr3:194316895	C/T	cg18000598	chr3:194342907	TMEM44	-1.14	-6.96	-0.58	4.36e-10	QT interval;
THYM	cis	rs2732480	0.537	rs1061986	chr12:48736439	T/C	cg21466736	chr12:48725269	NA	-0.59	-5.43	-0.49	4.36e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs3771570	1.000	rs56383420	chr2:242219281	A/G	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg12179176	chr11:130786555	SNX19	0.87	8.18	0.64	1.27e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg03452623	chr4:187889614	NA	1.11	15.15	0.84	4.33e-27	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	5.75	0.51	1.08e-7	Blood metabolite levels;
THYM	cis	rs6960043	0.595	rs9986829	chr7:15019259	G/A	cg19272540	chr7:15055459	NA	0.51	6.08	0.53	2.54e-8	Type 2 diabetes;
THYM	cis	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg07460842	chr6:66804631	NA	-0.91	-6.58	-0.56	2.6e-9	Exhaled nitric oxide output;
THYM	cis	rs8060598	1.000	rs8060598	chr16:50781802	A/G	cg05261686	chr16:50743296	NOD2	0.34	4.48	0.42	2.09e-5	Leprosy;
THYM	cis	rs7941600	0.708	rs11042290	chr11:9357059	G/A	cg21110646	chr11:9336536	TMEM41B	1.18	6.49	0.55	3.84e-9	Coronary artery disease;
THYM	cis	rs11690935	0.959	rs11904009	chr2:172627343	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.87	-6.44	-0.55	4.78e-9	Schizophrenia;
THYM	cis	rs6138458	0.962	rs6036976	chr20:24901567	T/G	cg26195577	chr20:24973756	C20orf3	-1.12	-10.51	-0.73	1.38e-17	Blood protein levels;
THYM	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg23583168	chr7:148888333	NA	-0.93	-10.5	-0.73	1.41e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg15536230	chr21:44985092	HSF2BP	-0.43	-5.37	-0.48	5.47e-7	Mean corpuscular volume;
THYM	cis	rs6754311	0.731	rs218174	chr2:136658345	C/T	cg07169764	chr2:136633963	MCM6	-0.69	-5.69	-0.5	1.39e-7	Mosquito bite size;
THYM	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg22875332	chr1:76189707	ACADM	0.88	9.09	0.68	1.44e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22496380	chr5:211416	CCDC127	-1.39	-8.13	-0.64	1.62e-12	Breast cancer;
THYM	cis	rs17453880	0.890	rs28749810	chr5:152048630	C/A	cg12297329	chr5:152029980	NA	-0.6	-4.55	-0.42	1.59e-5	Subjective well-being;
THYM	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg24530246	chr3:53118167	NA	-0.85	-4.82	-0.44	5.52e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2279817	0.866	rs10788682	chr1:18022933	G/A	cg21791023	chr1:18019539	ARHGEF10L	0.74	4.8	0.44	5.97e-6	Neuroticism;
THYM	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg15921436	chr17:44337874	NA	0.84	6.11	0.53	2.17e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12915189	0.609	rs12901150	chr15:91116386	A/C	cg11164639	chr15:91192950	NA	0.69	4.49	0.42	2e-5	Information processing speed;
THYM	cis	rs2463822	0.748	rs2513053	chr11:62109473	T/A	cg06239285	chr11:62104954	ASRGL1	1.44	7.7	0.62	1.3e-11	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg18252515	chr7:66147081	NA	1.48	8.83	0.67	5.15e-14	Diabetic kidney disease;
THYM	cis	rs2456568	0.805	rs2032400	chr11:93676937	G/A	cg26875233	chr11:93583750	C11orf90	-0.5	-4.88	-0.45	4.28e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs11696845	0.776	rs6073538	chr20:43379264	A/C	cg09357268	chr20:43379437	KCNK15	0.48	4.59	0.43	1.33e-5	Obesity-related traits;
THYM	cis	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs4790333	0.715	rs2447110	chr17:2261677	A/G	cg02569219	chr17:2266849	SGSM2	0.68	6.06	0.53	2.74e-8	Proinsulin levels;
THYM	cis	rs17125944	0.615	rs4901301	chr14:53306485	C/T	cg00686598	chr14:53173677	PSMC6	-1.14	-5.43	-0.49	4.26e-7	Alzheimer's disease (late onset);
THYM	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	6.97	0.58	4.15e-10	Smoking behavior;
THYM	cis	rs10208649	0.908	rs13395751	chr2:54238794	G/C	cg04546899	chr2:54196757	PSME4	0.68	4.73	0.44	7.94e-6	Body mass index;
THYM	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg20887711	chr4:1340912	KIAA1530	0.96	8.77	0.67	7.02e-14	Longevity;
THYM	cis	rs6596100	0.538	rs67652061	chr5:132280347	T/G	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Breast cancer;
THYM	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg15691649	chr6:25882328	NA	-0.63	-4.5	-0.42	1.94e-5	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.693	rs4924822	chr17:17748013	A/G	cg04398451	chr17:18023971	MYO15A	0.81	7.56	0.61	2.51e-11	Total body bone mineral density;
THYM	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg06808227	chr14:105710500	BRF1	-1.07	-9.49	-0.7	2e-15	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7953249	0.656	rs6489786	chr12:121397875	A/G	cg14101638	chr12:121416612	HNF1A	-0.5	-5.22	-0.47	1.03e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg08999081	chr20:33150536	PIGU	-0.78	-7.16	-0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg16989719	chr2:238392110	NA	-0.6	-5.82	-0.51	8.08e-8	Prostate cancer;
THYM	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg03806693	chr22:41940476	POLR3H	-0.86	-8.43	-0.65	3.65e-13	Vitiligo;
THYM	cis	rs4242434	0.927	rs35952885	chr8:22491622	T/G	cg14690197	chr8:22456421	C8orf58	0.57	5.21	0.47	1.08e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs66887589	0.777	rs1814815	chr4:120258091	C/T	cg13609457	chr4:120235615	NA	0.49	4.96	0.45	3.09e-6	Diastolic blood pressure;
THYM	cis	rs8050907	1.000	rs114914341	chr16:4617621	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.34	5.32	0.48	7e-7	Obesity-related traits;
THYM	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	5.0	0.46	2.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8016982	0.674	rs759939	chr14:81663453	G/C	cg01989461	chr14:81687754	GTF2A1	0.86	7.64	0.62	1.67e-11	Schizophrenia;
THYM	cis	rs11711311	1.000	rs9854504	chr3:113532381	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.63	-5.45	-0.49	3.91e-7	IgG glycosylation;
THYM	cis	rs17102423	0.689	rs7158239	chr14:65520616	G/A	cg11161011	chr14:65562177	MAX	-0.55	-4.58	-0.42	1.44e-5	Obesity-related traits;
THYM	cis	rs367615	0.537	rs10463600	chr5:108663636	G/A	cg17395555	chr5:108820864	NA	0.55	6.2	0.54	1.42e-8	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg24578937	chr1:2090814	PRKCZ	0.57	5.73	0.51	1.16e-7	Height;
THYM	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg26769984	chr7:1090371	C7orf50	0.83	5.33	0.48	6.68e-7	Bronchopulmonary dysplasia;
THYM	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg02751453	chr18:77725136	HSBP1L1	0.55	4.6	0.43	1.28e-5	Opioid sensitivity;
THYM	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg22709100	chr7:91322751	NA	-0.63	-4.89	-0.45	4.05e-6	Breast cancer;
THYM	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg03959625	chr15:84868606	LOC388152	0.5	4.8	0.44	5.91e-6	Schizophrenia;
THYM	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg18876405	chr7:65276391	NA	0.76	7.28	0.6	9.64e-11	Calcium levels;
THYM	cis	rs600550	0.528	rs56661806	chr11:59848438	T/G	cg02771260	chr11:59836817	MS4A3	0.73	5.51	0.49	3.11e-7	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs1568889	0.877	rs7933326	chr11:28288416	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.55e-6	Bipolar disorder;
THYM	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg24846343	chr22:24311635	DDTL	0.44	5.47	0.49	3.59e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	trans	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg23758822	chr17:41437982	NA	-1.23	-13.02	-0.8	7.62e-23	Menopause (age at onset);
THYM	cis	rs3857067	0.772	rs4438731	chr4:95091384	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.48	-0.42	2.08e-5	QT interval;
THYM	cis	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg13531842	chr10:38383804	ZNF37A	-0.78	-4.88	-0.45	4.27e-6	Obesity (extreme);
THYM	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg24692254	chr21:30365293	RNF160	-0.85	-7.06	-0.59	2.74e-10	Dental caries;
THYM	cis	rs6084875	0.840	rs6084850	chr20:4725662	G/A	cg19614321	chr20:4804581	RASSF2	0.44	4.46	0.42	2.22e-5	Systemic lupus erythematosus;
THYM	cis	rs7542375	0.520	rs12141189	chr1:221053545	T/C	cg16008148	chr1:221062819	NA	0.44	4.75	0.44	7.29e-6	Obesity-related traits;
THYM	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs4889855	0.530	rs8072592	chr17:78615361	A/C	cg16591659	chr17:78472290	NA	0.41	5.16	0.47	1.36e-6	Fractional excretion of uric acid;
THYM	cis	rs757081	0.636	rs214934	chr11:17193475	T/A	cg07093617	chr11:18158918	MRGPRX3	-0.49	-4.61	-0.43	1.23e-5	Systolic blood pressure;
THYM	cis	rs1747683	0.966	rs7475361	chr10:13373716	C/T	cg25835351	chr10:13388524	SEPHS1	0.34	5.66	0.5	1.57e-7	IgG glycosylation;
THYM	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.68	5.16	0.47	1.33e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs61931739	1.000	rs11502817	chr12:34010676	T/C	cg10856724	chr12:34555212	NA	0.59	5.13	0.47	1.56e-6	Morning vs. evening chronotype;
THYM	cis	rs13064411	0.696	rs7610638	chr3:113139656	A/G	cg18753928	chr3:113234510	CCDC52	-0.91	-8.22	-0.64	1.04e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs6596100	0.538	rs67504728	chr5:132194045	G/A	cg02081065	chr5:132209139	LEAP2	-0.95	-6.14	-0.53	1.87e-8	Breast cancer;
THYM	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg05347473	chr6:146136440	FBXO30	0.58	4.52	0.42	1.8e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs901683	1.000	rs9422440	chr10:46045125	C/T	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs240110	0.588	rs9390675	chr6:101204973	A/G	cg21058520	chr6:100914733	NA	-0.58	-4.54	-0.42	1.66e-5	Neuroticism;
THYM	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg11245990	chr11:68621969	NA	0.58	7.52	0.61	3.09e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs13082711	0.911	rs4973770	chr3:27425815	C/T	cg02860705	chr3:27208620	NA	0.67	4.7	0.43	8.87e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs7582180	0.676	rs6542940	chr2:100982144	A/T	cg21926883	chr2:100939477	LONRF2	-0.67	-6.19	-0.54	1.49e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2067615	0.524	rs4246257	chr12:107062329	C/T	cg15890332	chr12:107067104	RFX4	0.45	5.08	0.46	1.86e-6	Heart rate;
THYM	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg23428387	chr22:49814324	NA	-0.5	-4.77	-0.44	6.53e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs67072384	1.000	rs67075228	chr11:72450775	C/T	cg01380194	chr11:72452482	ARAP1	-0.93	-5.07	-0.46	1.98e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	trans	rs877282	0.898	rs12358513	chr10:757571	A/G	cg22713356	chr15:30763199	NA	1.35	9.87	0.71	3.11e-16	Uric acid levels;
THYM	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg06656553	chr16:89960601	TCF25	-0.87	-4.98	-0.45	2.88e-6	Skin colour saturation;
THYM	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	13.59	0.81	5.3e-24	Chronic sinus infection;
THYM	cis	rs6032067	0.929	rs17333381	chr20:43804919	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs5758511	0.514	rs5751211	chr22:42486056	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.66	6.84	0.57	7.82e-10	Birth weight;
THYM	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg00898013	chr13:113819073	PROZ	-1.03	-10.22	-0.72	5.73e-17	Platelet distribution width;
THYM	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg18132916	chr6:79620363	NA	-0.6	-5.34	-0.48	6.26e-7	Intelligence (multi-trait analysis);
THYM	cis	rs986417	1.000	rs1269984	chr14:60898138	C/G	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs995000	0.929	rs636523	chr1:62920008	A/G	cg06896770	chr1:63153194	DOCK7	0.97	7.64	0.62	1.71e-11	Triglyceride levels;
THYM	cis	rs3781426	0.960	rs893857	chr10:126720788	G/A	cg04494136	chr10:126703576	CTBP2	-0.39	-5.3	-0.48	7.52e-7	Height;
THYM	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg19507638	chr5:93509721	C5orf36	-0.68	-4.57	-0.42	1.49e-5	Diabetic retinopathy;
THYM	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	9.38	0.69	3.49e-15	Chronic sinus infection;
THYM	cis	rs7177699	0.557	rs4380028	chr15:79111093	C/T	cg00540400	chr15:79124168	NA	-0.65	-6.99	-0.58	3.81e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg24812749	chr6:127587940	RNF146	0.98	7.94	0.63	4.04e-12	Breast cancer;
THYM	trans	rs12760731	0.623	rs10798604	chr1:178254568	A/G	cg06907405	chr16:48400475	SIAH1	1.07	7.17	0.59	1.6e-10	Obesity-related traits;
THYM	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg16926213	chr1:1841314	NA	0.55	5.79	0.51	8.89e-8	Body mass index;
THYM	cis	rs791888	0.688	rs1980649	chr10:89422375	T/C	cg13926569	chr10:89418898	PAPSS2	0.72	8.15	0.64	1.44e-12	Magnesium levels;
THYM	cis	rs12530845	0.832	rs56306315	chr7:135329107	C/T	cg23117316	chr7:135346802	PL-5283	-0.66	-5.88	-0.52	6.21e-8	Red blood cell traits;
THYM	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs8038465	0.622	rs7182124	chr15:73915254	C/T	cg15420318	chr15:73925796	NPTN	0.62	5.32	0.48	6.84e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs17407555	0.821	rs73222526	chr4:10203917	G/A	cg11266682	chr4:10021025	SLC2A9	-0.46	-4.45	-0.42	2.33e-5	Schizophrenia (age at onset);
THYM	cis	rs6500395	1.000	rs1362636	chr16:48712779	T/C	cg04672837	chr16:48644449	N4BP1	-0.52	-5.07	-0.46	1.93e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2120243	0.539	rs9878474	chr3:157123147	A/G	cg24825693	chr3:157122686	VEPH1	0.47	4.52	0.42	1.8e-5	Hepatocellular carcinoma in hepatitis B infection;
THYM	cis	rs7705042	0.865	rs6874308	chr5:141506911	C/T	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.04	10.1	0.72	1.03e-16	Colorectal cancer;
THYM	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9790314	0.846	rs4856738	chr3:160986637	C/G	cg03342759	chr3:160939853	NMD3	-0.93	-8.74	-0.67	8.11e-14	Morning vs. evening chronotype;
THYM	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg15997130	chr1:24165203	NA	0.77	7.11	0.59	2.11e-10	Immature fraction of reticulocytes;
THYM	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg27532560	chr4:187881888	NA	-0.92	-10.62	-0.74	7.75e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs79349575	0.594	rs1985785	chr17:46967788	T/C	cg26022315	chr17:47021804	SNF8	0.48	4.49	0.42	2e-5	Type 2 diabetes;
THYM	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg10523679	chr1:76189770	ACADM	0.9	9.47	0.7	2.2e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs3126085	0.935	rs6666382	chr1:152217226	C/G	cg26020982	chr1:152196106	HRNR	-0.36	-4.5	-0.42	1.92e-5	Atopic dermatitis;
THYM	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg03806693	chr22:41940476	POLR3H	-1.11	-8.99	-0.68	2.33e-14	Vitiligo;
THYM	cis	rs73787773	0.867	rs73227501	chr5:111488908	C/A	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.88	-4.76	-0.44	6.87e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg06238570	chr21:40685208	BRWD1	-0.72	-6.28	-0.54	9.9e-9	Menarche (age at onset);
THYM	cis	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg07167872	chr1:205819463	PM20D1	0.71	5.74	0.51	1.13e-7	Menarche (age at onset);
THYM	cis	rs9522267	0.535	rs11069898	chr13:112231512	C/T	cg15979348	chr13:112237479	NA	-0.48	-4.46	-0.42	2.22e-5	Hepatitis;
THYM	cis	rs11574514	1.000	rs79327462	chr16:67958058	G/A	cg09738193	chr16:67926317	PSKH1	-0.93	-4.57	-0.42	1.46e-5	Crohn's disease;
THYM	cis	rs6840360	0.554	rs62329088	chr4:152471289	C/T	cg17479576	chr4:152424074	FAM160A1	-0.83	-6.46	-0.55	4.43e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg02734326	chr4:10020555	SLC2A9	0.77	7.16	0.59	1.73e-10	Bone mineral density;
THYM	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg06558623	chr16:89946397	TCF25	1.3	6.32	0.54	8.4e-9	Interleukin-17 levels;
THYM	cis	rs12142240	0.698	rs67142569	chr1:46828460	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg21951975	chr1:209979733	IRF6	0.71	7.72	0.62	1.15e-11	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
THYM	cis	rs6921919	0.583	rs11755942	chr6:28369537	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.5	-0.42	1.89e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg12560992	chr17:57184187	TRIM37	0.88	8.01	0.63	2.91e-12	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg24675658	chr1:53192096	ZYG11B	0.55	4.66	0.43	1.04e-5	Monocyte count;
THYM	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg21784768	chr11:537496	LRRC56	-1.16	-5.64	-0.5	1.75e-7	Body mass index;
THYM	cis	rs9677476	0.909	rs6437010	chr2:232113263	G/C	cg07929768	chr2:232055508	NA	0.52	5.35	0.48	6e-7	Food antigen IgG levels;
THYM	cis	rs7614311	0.731	rs73130534	chr3:63859813	A/G	cg22134162	chr3:63841271	THOC7	-0.55	-6.26	-0.54	1.13e-8	Lung function (FVC);Lung function (FEV1);
THYM	trans	rs1973993	0.967	rs10489741	chr1:96942406	G/A	cg10631902	chr5:14652156	NA	0.6	6.85	0.57	7.28e-10	Weight;
THYM	cis	rs3126085	0.560	rs4378206	chr1:152369913	A/G	cg10321714	chr1:152280068	FLG	0.76	5.3	0.48	7.37e-7	Atopic dermatitis;
THYM	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg00310523	chr12:86230176	RASSF9	0.61	5.31	0.48	7.29e-7	Major depressive disorder;
THYM	cis	rs4953076	0.573	rs13008237	chr2:44404902	A/G	cg04920474	chr2:44395004	PPM1B	0.63	5.27	0.48	8.46e-7	Height;
THYM	cis	rs7394190	0.688	rs76033784	chr10:75535970	A/G	cg07699608	chr10:75541558	CHCHD1	0.91	4.93	0.45	3.49e-6	Incident atrial fibrillation;
THYM	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	10.0	0.72	1.67e-16	Platelet count;
THYM	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.51	4.57	0.42	1.48e-5	Bipolar disorder;
THYM	cis	rs2219968	0.962	rs4573260	chr8:78942894	T/C	cg00738934	chr8:78996279	NA	0.79	8.42	0.65	3.88e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs62070183	0.766	rs10512441	chr17:31239645	A/G	cg23177095	chr17:30873196	MYO1D	-0.64	-5.02	-0.46	2.39e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs9479482	1.000	rs13198863	chr6:150350781	T/G	cg25797454	chr6:150327115	RAET1K	0.43	4.47	0.42	2.18e-5	Alopecia areata;
THYM	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg06609049	chr19:2785107	THOP1	1.13	10.96	0.75	1.46e-18	Total cholesterol levels;
THYM	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs6500395	1.000	rs1486411	chr16:48587083	T/C	cg04672837	chr16:48644449	N4BP1	0.49	4.74	0.44	7.38e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg05973401	chr12:123451056	ABCB9	-0.64	-4.65	-0.43	1.09e-5	Platelet count;
THYM	cis	rs6964587	0.585	rs10266481	chr7:91554338	T/C	cg22709100	chr7:91322751	NA	-0.62	-4.64	-0.43	1.1e-5	Breast cancer;
THYM	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg04287289	chr16:89883240	FANCA	0.65	6.04	0.53	3.01e-8	Vitiligo;
THYM	cis	rs11031096	0.502	rs4910875	chr11:4047855	C/G	cg18678763	chr11:4115507	RRM1	-0.46	-6.09	-0.53	2.35e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03264133	chr6:25882463	NA	-0.89	-7.71	-0.62	1.23e-11	Intelligence (multi-trait analysis);
THYM	cis	rs2976388	1.000	rs1045531	chr8:143763547	C/A	cg06565975	chr8:143823917	SLURP1	-0.45	-5.23	-0.47	9.95e-7	Urinary tract infection frequency;
THYM	cis	rs6694672	0.764	rs6678066	chr1:197221904	A/G	cg13682187	chr1:196946512	CFHR5	0.84	4.53	0.42	1.73e-5	Asthma;
THYM	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg05347473	chr6:146136440	FBXO30	0.79	7.06	0.59	2.69e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg16680214	chr1:154839983	KCNN3	-0.5	-6.22	-0.54	1.32e-8	Prostate cancer;
THYM	cis	rs600806	0.850	rs115935180	chr1:109976775	C/G	cg02175308	chr1:109941060	SORT1	-0.59	-5.15	-0.47	1.38e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6480314	0.764	rs7898034	chr10:69977616	A/C	cg27159792	chr10:69524182	NA	-0.72	-4.57	-0.42	1.49e-5	Optic nerve measurement (disc area);
THYM	cis	rs7584330	0.554	rs6760890	chr2:238400645	G/A	cg08992911	chr2:238395768	MLPH	1.1	6.51	0.56	3.6e-9	Prostate cancer;
THYM	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg18032289	chr17:61959525	GH2	-0.5	-4.84	-0.44	5.07e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs55728055	0.661	rs58365021	chr22:32060838	G/C	cg10537193	chr22:32026975	PISD	-0.9	-5.66	-0.5	1.63e-7	Age-related hearing impairment;
THYM	cis	rs10887741	0.507	rs791874	chr10:89406070	T/G	cg13926569	chr10:89418898	PAPSS2	-0.62	-5.89	-0.52	5.75e-8	Exercise (leisure time);
THYM	cis	rs3087591	0.922	rs2905806	chr17:29502507	A/G	cg24425628	chr17:29625626	OMG;NF1	0.66	5.79	0.51	9.11e-8	Hip circumference;
THYM	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03647317	chr4:187891568	NA	0.82	8.87	0.67	4.21e-14	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs7952251	0.812	rs1945102	chr11:112400760	A/G	cg14154186	chr1:204970430	NFASC	-0.73	-7.54	-0.61	2.79e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	trans	rs58106596	0.848	rs2241742	chr2:232574807	C/G	cg01370599	chr3:116745421	NA	0.99	7.35	0.6	6.95e-11	White blood cell count;Lymphocyte counts;
THYM	cis	rs12519773	1.000	rs4869412	chr5:92455655	A/G	cg18783429	chr5:92414398	NA	0.48	4.54	0.42	1.64e-5	Migraine;
THYM	cis	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg06521331	chr12:34319734	NA	-0.73	-5.66	-0.5	1.59e-7	Morning vs. evening chronotype;
THYM	trans	rs4866334	0.867	rs76734676	chr5:18487735	G/T	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg26441486	chr22:50317300	CRELD2	-0.43	-7.76	-0.62	9.55e-12	Schizophrenia;
THYM	cis	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg13446199	chr8:143762866	PSCA	-0.41	-4.53	-0.42	1.7e-5	Urinary tract infection frequency;
THYM	cis	rs4767234	1.000	rs978500	chr12:114645639	G/A	cg13131185	chr12:113914611	NA	-0.47	-4.54	-0.42	1.64e-5	Airflow obstruction;
THYM	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg16989719	chr2:238392110	NA	-0.66	-6.0	-0.52	3.6e-8	Prostate cancer;
THYM	cis	rs7578361	0.918	rs1405574	chr2:150367748	T/G	cg17961725	chr2:150454027	NA	0.74	5.41	0.48	4.79e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs926938	0.520	rs6663115	chr1:115272254	G/A	cg12756093	chr1:115239321	AMPD1	-0.55	-4.47	-0.42	2.18e-5	Autism;
THYM	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg08439880	chr3:133502540	NA	0.7	5.85	0.51	7.06e-8	Iron status biomarkers;
THYM	cis	rs7582180	0.627	rs2241811	chr2:101011724	C/T	cg14675211	chr2:100938903	LONRF2	0.6	5.73	0.51	1.18e-7	Intelligence (multi-trait analysis);
THYM	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg05872129	chr22:39784769	NA	-0.88	-7.11	-0.59	2.1e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg15432903	chr11:17409602	KCNJ11	0.63	7.62	0.62	1.91e-11	Type 2 diabetes;
THYM	cis	rs6669072	0.565	rs10493841	chr1:91275431	C/G	cg08895590	chr1:91227319	NA	0.39	4.45	0.42	2.32e-5	Cognitive function;
THYM	cis	rs12282928	0.959	rs1566736	chr11:48238179	A/G	cg22827986	chr11:48284249	OR4X1	0.53	5.5	0.49	3.18e-7	Migraine - clinic-based;
THYM	cis	rs7772486	0.754	rs9497434	chr6:146260753	C/T	cg23711669	chr6:146136114	FBXO30	-0.96	-10.01	-0.72	1.54e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4389656	0.857	rs274703	chr5:6728372	A/C	cg10857441	chr5:6722123	POLS	-0.44	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs6032067	0.636	rs6032093	chr20:43912167	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.44	-4.82	-0.44	5.34e-6	Blood protein levels;
THYM	cis	rs56104184	0.779	rs2131093	chr19:49350693	A/T	cg16594139	chr19:49340574	PLEKHA4;HSD17B14	0.92	5.14	0.47	1.47e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg03684893	chr10:554711	DIP2C	-0.69	-6.09	-0.53	2.35e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs875971	0.965	rs697968	chr7:65535033	G/A	cg11764359	chr7:65958608	NA	-0.84	-6.74	-0.57	1.24e-9	Aortic root size;
THYM	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg12408189	chr10:30722286	MAP3K8	-0.59	-5.24	-0.47	9.66e-7	Inflammatory bowel disease;
THYM	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg02782426	chr3:40428986	ENTPD3	0.51	4.63	0.43	1.17e-5	Renal cell carcinoma;
THYM	cis	rs6570726	0.935	rs390252	chr6:145856896	A/G	cg13319975	chr6:146136371	FBXO30	-0.66	-5.63	-0.5	1.85e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1878931	0.624	rs28089	chr16:3446937	G/A	cg21433313	chr16:3507492	NAT15	0.57	4.6	0.43	1.28e-5	Body mass index (adult);
THYM	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03517284	chr6:25882590	NA	1.02	9.37	0.69	3.66e-15	Blood metabolite levels;
THYM	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg15448220	chr1:150897856	SETDB1	0.89	7.59	0.61	2.17e-11	Melanoma;
THYM	cis	rs12291225	0.535	rs10832248	chr11:14413087	G/A	cg05501817	chr11:14380813	RRAS2	-0.74	-6.1	-0.53	2.24e-8	Sense of smell;
THYM	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.76	8.53	0.66	2.25e-13	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg00631329	chr6:26305371	NA	-0.61	-7.35	-0.6	6.96e-11	Educational attainment;
THYM	cis	rs10799590	1.000	rs7535296	chr1:224831341	A/G	cg01808320	chr1:224927238	CNIH3	-0.56	-5.03	-0.46	2.35e-6	Opioid dependence;
THYM	cis	rs36051895	0.589	rs62543573	chr9:5201675	A/G	cg02405213	chr9:5042618	JAK2	-0.9	-8.7	-0.67	9.8e-14	Pediatric autoimmune diseases;
THYM	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.3	-0.48	7.34e-7	Monocyte percentage of white cells;
THYM	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg13880726	chr7:1868755	MAD1L1	-0.72	-4.8	-0.44	5.78e-6	Bipolar disorder;
THYM	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg07870213	chr5:140052090	DND1	-0.69	-8.1	-0.64	1.86e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4268898	0.560	rs2384007	chr2:24514841	A/G	cg06627628	chr2:24431161	ITSN2	-0.87	-5.47	-0.49	3.67e-7	Asthma;
THYM	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg26354017	chr1:205819088	PM20D1	0.96	10.19	0.72	6.47e-17	Menarche (age at onset);
THYM	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs28795989	0.795	rs1878325	chr4:7902838	T/A	cg00251875	chr4:7801337	AFAP1	0.61	4.93	0.45	3.53e-6	Intraocular pressure;
THYM	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg22920501	chr2:26401640	FAM59B	0.74	6.41	0.55	5.67e-9	Gut microbiome composition (summer);
THYM	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg08885076	chr2:99613938	TSGA10	-0.52	-5.28	-0.48	8.29e-7	Fear of minor pain;
THYM	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs4638749	0.501	rs3919943	chr2:108758865	G/A	cg25838818	chr2:108905173	SULT1C2	-0.51	-4.88	-0.45	4.25e-6	Blood pressure;
THYM	cis	rs2046867	0.862	rs2174062	chr3:72826901	T/C	cg25664220	chr3:72788482	NA	-0.81	-6.12	-0.53	2.07e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg15744005	chr10:104629667	AS3MT	-0.86	-8.2	-0.64	1.16e-12	Arsenic metabolism;
THYM	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg27170947	chr2:26402098	FAM59B	-0.8	-6.37	-0.55	6.74e-9	Gut microbiome composition (summer);
THYM	cis	rs7084402	0.934	rs1658426	chr10:60331542	A/T	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs11225247	1.000	rs60056981	chr11:102326788	T/C	cg06323957	chr11:102217781	BIRC2	1.21	4.88	0.45	4.22e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.62	5.61	0.5	2.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs490234	0.812	rs4838284	chr9:128446365	G/T	cg14078157	chr9:128172775	NA	-0.62	-4.58	-0.43	1.41e-5	Mean arterial pressure;
THYM	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.3	4.58	0.43	1.42e-5	Obesity-related traits;
THYM	cis	rs11078597	0.650	rs62090056	chr17:1645410	C/T	cg18436246	chr17:1640651	WDR81	0.64	4.67	0.43	9.85e-6	Serum albumin level;
THYM	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg06766960	chr11:133703094	NA	-0.61	-5.42	-0.49	4.41e-7	Childhood ear infection;
THYM	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06634786	chr22:41940651	POLR3H	-0.81	-5.97	-0.52	4.16e-8	Vitiligo;
THYM	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.02	-9.68	-0.7	8.14e-16	Primary sclerosing cholangitis;
THYM	cis	rs7089973	0.872	rs7094072	chr10:116627160	T/G	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.14	-0.47	1.5e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7084402	0.967	rs1649092	chr10:60289389	A/T	cg07615347	chr10:60278583	BICC1	0.55	4.91	0.45	3.78e-6	Refractive error;
THYM	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.59	-11.2	-0.75	4.73e-19	Hemostatic factors and hematological phenotypes;
THYM	cis	rs9534288	0.664	rs1926447	chr13:46629944	C/T	cg15192986	chr13:46630673	CPB2	0.91	6.14	0.53	1.94e-8	Blood protein levels;
THYM	cis	rs1003719	0.788	rs9975168	chr21:38450557	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.68	-4.86	-0.45	4.64e-6	Eye color traits;
THYM	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg06026331	chr20:60912101	LAMA5	0.78	6.08	0.53	2.45e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs9611519	0.780	rs2235852	chr22:41661154	G/T	cg06481639	chr22:41940642	POLR3H	-0.61	-4.62	-0.43	1.2e-5	Neuroticism;
THYM	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	6.07	0.53	2.66e-8	Platelet count;
THYM	cis	rs12149862	1.000	rs9937829	chr16:69473614	A/T	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs8180040	0.800	rs11920354	chr3:47262246	C/A	cg16586182	chr3:47516702	SCAP	0.64	5.55	0.49	2.62e-7	Colorectal cancer;
THYM	cis	rs28829049	0.597	rs12563386	chr1:19455205	T/C	cg13387374	chr1:19411106	UBR4	0.67	4.96	0.45	3.08e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs1065852	0.526	rs8138080	chr22:42396371	A/G	cg09667013	chr22:42394590	WBP2NL	-0.56	-4.84	-0.44	5.08e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg26031613	chr14:104095156	KLC1	0.76	5.12	0.47	1.58e-6	Body mass index;
THYM	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	10.27	0.73	4.38e-17	Chronic sinus infection;
THYM	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs3849570	0.922	rs3772895	chr3:81769493	A/G	cg07356753	chr3:81810745	GBE1	-0.93	-7.68	-0.62	1.43e-11	Waist circumference;Body mass index;
THYM	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.61	5.18	0.47	1.24e-6	Hemoglobin concentration;
THYM	cis	rs240764	0.697	rs12189562	chr6:101168679	A/G	cg21058520	chr6:100914733	NA	0.6	5.26	0.47	8.93e-7	Neuroticism;
THYM	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-10.93	-0.75	1.77e-18	Coronary artery disease;
THYM	cis	rs736408	0.812	rs9881468	chr3:52828628	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-5.32	-0.48	6.99e-7	Bipolar disorder;
THYM	cis	rs728616	0.867	rs28365998	chr10:81965436	C/A	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg10518543	chr12:38710700	ALG10B	-0.6	-5.05	-0.46	2.16e-6	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4589258	0.933	rs11019128	chr11:90393587	C/T	cg26138821	chr11:89956704	CHORDC1	0.7	5.78	0.51	9.56e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg05896524	chr21:47604654	C21orf56	0.69	4.87	0.45	4.4e-6	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg24818145	chr4:99064322	C4orf37	0.67	5.18	0.47	1.23e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61931739	0.963	rs3912355	chr12:34079616	A/G	cg06521331	chr12:34319734	NA	-0.6	-4.69	-0.43	9.15e-6	Morning vs. evening chronotype;
THYM	cis	rs17030434	0.682	rs1339	chr4:154631563	T/C	cg14289246	chr4:154710475	SFRP2	-0.71	-4.71	-0.43	8.53e-6	Electrocardiographic conduction measures;
THYM	cis	rs4886920	0.802	rs7164558	chr15:78146382	A/G	cg25212270	chr15:78015279	NA	-0.54	-4.71	-0.44	8.34e-6	Neuroticism;
THYM	cis	rs7894051	1.000	rs7907603	chr10:135195977	G/A	cg12428399	chr10:135191333	PAOX	-1.0	-4.61	-0.43	1.27e-5	Lifespan;
THYM	cis	rs10499694	0.933	rs7778349	chr7:50593157	C/T	cg18232548	chr7:50535776	DDC	-0.62	-5.1	-0.46	1.75e-6	Body mass index;
THYM	cis	rs7106204	1.000	rs12798139	chr11:24220907	A/G	ch.11.24196551F	chr11:24239977	NA	0.96	6.08	0.53	2.49e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs10411161	0.702	rs16983200	chr19:52386723	G/A	cg25361850	chr19:52391789	ZNF577	0.73	5.09	0.46	1.84e-6	Breast cancer;
THYM	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg26384229	chr12:38710491	ALG10B	0.97	7.38	0.6	5.91e-11	Morning vs. evening chronotype;
THYM	cis	rs76878669	0.561	rs1039594	chr11:66131149	C/T	cg18002602	chr11:66138449	SLC29A2	0.49	4.98	0.45	2.86e-6	Educational attainment (years of education);
THYM	cis	rs6076065	0.723	rs6083087	chr20:23341529	C/T	cg11657817	chr20:23433608	CST11	0.31	4.57	0.42	1.48e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs8063160	0.935	rs73283871	chr16:90067202	T/C	cg07984980	chr16:89898383	SPIRE2	1.26	5.08	0.46	1.9e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg10515332	chr4:99064459	C4orf37	0.6	4.75	0.44	7.27e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg03676636	chr4:99064102	C4orf37	0.42	6.37	0.55	6.64e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7104764	1.000	rs7395328	chr11:242624	T/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs4764487	0.735	rs2072370	chr12:6345080	A/G	cg08284733	chr12:6341482	CD9	-0.41	-4.53	-0.42	1.71e-5	Mean platelet volume;
THYM	cis	rs36051895	0.695	rs62541534	chr9:5028921	C/G	cg02405213	chr9:5042618	JAK2	-1.01	-10.5	-0.73	1.41e-17	Pediatric autoimmune diseases;
THYM	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg00684032	chr4:1343700	KIAA1530	0.55	4.8	0.44	5.9e-6	Obesity-related traits;
THYM	cis	rs2288884	0.806	rs11084142	chr19:52587917	A/G	cg05974498	chr19:52599256	ZNF841	0.38	5.01	0.46	2.53e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs4919687	0.550	rs10748828	chr10:104456794	C/T	cg04362960	chr10:104952993	NT5C2	-0.61	-4.9	-0.45	3.91e-6	Colorectal cancer;
THYM	cis	rs11650494	0.901	rs117087923	chr17:47364913	G/A	cg08112188	chr17:47440006	ZNF652	1.23	5.06	0.46	2.02e-6	Prostate cancer;
THYM	trans	rs629535	1.000	rs629535	chr8:70007938	C/T	cg21567404	chr3:27674614	NA	-1.1	-10.04	-0.72	1.36e-16	Dupuytren's disease;
THYM	cis	rs10873998	0.523	rs4650610	chr1:79281968	A/G	cg17415326	chr1:79350918	NA	-0.45	-5.09	-0.46	1.78e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg18252515	chr7:66147081	NA	0.66	4.87	0.45	4.38e-6	Aortic root size;
THYM	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11644478	chr21:40555479	PSMG1	0.99	8.01	0.63	2.85e-12	Cognitive function;
THYM	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg08975724	chr8:8085496	FLJ10661	0.77	6.2	0.54	1.42e-8	Mood instability;
THYM	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg03388043	chr17:80084554	CCDC57	0.69	5.87	0.52	6.36e-8	Life satisfaction;
THYM	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg24812749	chr6:127587940	RNF146	0.79	5.99	0.52	3.76e-8	Breast cancer;
THYM	cis	rs9633835	0.524	rs1481877	chr11:13272091	A/G	cg13286116	chr11:13302098	ARNTL	-0.76	-8.59	-0.66	1.73e-13	Body mass index;
THYM	cis	rs713587	0.713	rs4665276	chr2:25213333	C/T	cg01884057	chr2:25150051	NA	-0.56	-5.5	-0.49	3.26e-7	Body mass index in non-asthmatics;
THYM	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg13395646	chr4:1353034	KIAA1530	-0.55	-4.9	-0.45	3.92e-6	Obesity-related traits;
THYM	cis	rs12519773	0.597	rs17360518	chr5:92457899	A/C	cg18783429	chr5:92414398	NA	0.49	4.84	0.44	5.1e-6	Migraine;
THYM	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg10523679	chr1:76189770	ACADM	-0.84	-6.64	-0.56	1.96e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7568458	0.870	rs1058588	chr2:85808871	A/G	cg17127132	chr2:85788382	GGCX	-0.63	-4.84	-0.44	5.01e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.68	-0.43	9.42e-6	Type 2 diabetes;
THYM	cis	rs9913156	0.841	rs7223840	chr17:4562150	T/C	cg19197139	chr17:4613644	ARRB2	0.78	4.92	0.45	3.63e-6	Lymphocyte counts;
THYM	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-4.95	-0.45	3.19e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs17152411	1.000	rs7086447	chr10:126593553	C/A	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs13177918	0.750	rs58256223	chr5:149822019	T/A	cg14059543	chr5:149831962	NA	-0.92	-6.96	-0.58	4.39e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg00814883	chr7:100076585	TSC22D4	-0.96	-6.44	-0.55	4.85e-9	Platelet count;
THYM	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-4.45	-0.42	2.35e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs586688	1.000	rs571723	chr1:201642628	C/G	cg14168733	chr1:201708718	NAV1	0.67	5.73	0.51	1.17e-7	Obesity-related traits;
THYM	cis	rs67311347	0.640	rs7434088	chr3:40297288	T/C	cg13683864	chr3:40499215	RPL14	-0.63	-5.41	-0.49	4.72e-7	Renal cell carcinoma;
THYM	cis	rs13014235	0.532	rs6729982	chr2:202281136	A/G	cg12544106	chr2:202507780	ALS2CR4	-0.62	-4.59	-0.43	1.37e-5	Basal cell carcinoma;
THYM	cis	rs4589258	0.788	rs4753027	chr11:90475781	A/G	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.83	-0.44	5.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12496230	1.000	rs12495879	chr3:66861656	A/G	cg04995300	chr3:66848608	NA	-1.07	-6.8	-0.57	9.39e-10	Type 2 diabetes;
THYM	cis	rs172166	0.610	rs276369	chr6:27919243	A/T	cg09682330	chr6:28411287	ZSCAN23	-0.53	-4.86	-0.45	4.64e-6	Cardiac Troponin-T levels;
THYM	cis	rs926938	0.812	rs11102832	chr1:115244253	G/C	cg12756093	chr1:115239321	AMPD1	-0.74	-5.91	-0.52	5.29e-8	Autism;
THYM	cis	rs939658	0.805	rs4778924	chr15:79443363	T/C	cg17916960	chr15:79447300	NA	-0.75	-8.75	-0.67	7.92e-14	Refractive error;
THYM	cis	rs2213920	0.619	rs6478174	chr9:118252779	C/T	cg13918206	chr9:118159781	DEC1	0.84	4.63	0.43	1.17e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs9832461	0.948	rs116478517	chr3:39780970	C/A	cg21490179	chr3:40494492	NA	0.89	4.66	0.43	1.04e-5	Brain structure (temporal lobe volume);
THYM	cis	rs3892630	0.878	rs1559177	chr19:33210646	A/G	cg22928329	chr19:33183273	NUDT19	-0.77	-5.88	-0.52	6e-8	Red blood cell traits;
THYM	cis	rs72843506	0.656	rs79773274	chr17:19905931	C/T	cg12065943	chr17:19881925	AKAP10	-0.82	-4.5	-0.42	1.95e-5	Schizophrenia;
THYM	cis	rs6430585	0.646	rs12476116	chr2:136497199	A/G	cg07169764	chr2:136633963	MCM6	1.2	12.5	0.79	8.98e-22	Corneal structure;
THYM	trans	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05039488	chr6:79577232	IRAK1BP1	-0.84	-7.09	-0.59	2.32e-10	Brugada syndrome;
THYM	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg21361702	chr7:150065534	REPIN1	0.74	5.14	0.47	1.48e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs12889267	0.770	rs2319627	chr14:21565189	C/T	cg02988727	chr14:21567520	ZNF219;C14orf176	-0.53	-5.09	-0.46	1.79e-6	Hematocrit;Resting heart rate;
THYM	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg02527881	chr3:46936655	PTH1R	-0.67	-6.75	-0.57	1.18e-9	Colorectal cancer;
THYM	cis	rs7107174	1.000	rs55825352	chr11:78034424	C/T	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg24253500	chr15:84953950	NA	0.64	5.24	0.47	9.6e-7	Schizophrenia;
THYM	cis	rs886774	0.526	rs7811034	chr7:107515005	C/T	cg23293999	chr7:106826042	HBP1	0.58	4.59	0.43	1.35e-5	Ulcerative colitis;
THYM	cis	rs6598955	0.671	rs6686100	chr1:26617338	G/C	cg19677267	chr1:26645161	CD52;UBXN11	0.5	4.74	0.44	7.47e-6	Obesity-related traits;
THYM	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs3820068	0.603	rs7536654	chr1:15989141	C/G	cg27534772	chr1:16042836	PLEKHM2	0.54	5.99	0.52	3.81e-8	Systolic blood pressure;
THYM	cis	rs78456975	0.607	rs72776258	chr2:1530732	C/G	cg12573674	chr2:1569213	NA	-1.25	-4.59	-0.43	1.37e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg03909863	chr11:638404	DRD4	-0.78	-5.75	-0.51	1.07e-7	Systemic lupus erythematosus;
THYM	cis	rs6684428	1.000	rs61774842	chr1:56366173	A/G	cg11651538	chr1:56320950	NA	-0.59	-4.48	-0.42	2.05e-5	Airflow obstruction;
THYM	cis	rs4638749	0.501	rs1385957	chr2:108755104	T/G	cg25838818	chr2:108905173	SULT1C2	-0.52	-4.89	-0.45	4.13e-6	Blood pressure;
THYM	trans	rs877282	0.755	rs2486579	chr10:785647	G/A	cg22713356	chr15:30763199	NA	1.18	9.79	0.71	4.66e-16	Uric acid levels;
THYM	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg12373951	chr3:133503437	NA	0.56	6.17	0.53	1.69e-8	Iron status biomarkers;
THYM	cis	rs11645898	0.515	rs61747473	chr16:72258743	C/T	cg04170065	chr16:72153204	PMFBP1	-0.59	-4.63	-0.43	1.18e-5	Blood protein levels;
THYM	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg03517284	chr6:25882590	NA	0.67	4.47	0.42	2.14e-5	Height;
THYM	cis	rs12908161	0.959	rs17598603	chr15:85200211	C/G	cg12863693	chr15:85201151	NMB	-0.7	-6.34	-0.55	7.55e-9	Schizophrenia;
THYM	cis	rs1448094	0.511	rs4559760	chr12:86149414	G/A	cg00310523	chr12:86230176	RASSF9	-0.57	-5.07	-0.46	1.98e-6	Major depressive disorder;
THYM	cis	rs7113850	0.541	rs79932281	chr11:24231839	T/G	ch.11.24196551F	chr11:24239977	NA	0.92	4.92	0.45	3.58e-6	Bone fracture in osteoporosis;
THYM	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg00383909	chr3:49044727	WDR6	1.03	6.25	0.54	1.15e-8	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
THYM	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs4731207	0.565	rs7776744	chr7:124599749	A/G	cg05285228	chr7:124571219	POT1	-0.69	-5.31	-0.48	7.27e-7	Cutaneous malignant melanoma;
THYM	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg11335335	chr11:637885	DRD4	-0.65	-5.01	-0.46	2.47e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg06970220	chr1:156163860	SLC25A44	0.73	5.54	0.49	2.71e-7	Testicular germ cell tumor;
THYM	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.91	-6.56	-0.56	2.79e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.71	0.51	1.29e-7	Rheumatoid arthritis;
THYM	cis	rs8016982	0.630	rs61980900	chr14:81686436	T/C	cg01989461	chr14:81687754	GTF2A1	0.82	7.36	0.6	6.7e-11	Schizophrenia;
THYM	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs289828	0.579	rs6752617	chr2:152159428	C/G	cg05960677	chr2:152117363	RBM43	0.69	6.29	0.54	9.65e-9	Blood protein levels;
THYM	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg17279839	chr7:150038598	RARRES2	0.55	4.9	0.45	3.88e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6032067	0.561	rs2233093	chr20:43933196	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.54	-5.47	-0.49	3.59e-7	Blood protein levels;
THYM	cis	rs4664308	0.806	rs4665162	chr2:161060184	A/G	cg03641300	chr2:160917029	PLA2R1	-0.75	-6.59	-0.56	2.4e-9	Idiopathic membranous nephropathy;
THYM	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.6	4.93	0.45	3.42e-6	Hemoglobin concentration;
THYM	cis	rs2504916	0.784	rs2450970	chr6:160758986	T/C	cg19643109	chr6:160697625	NA	-0.66	-4.86	-0.45	4.54e-6	Response to hepatitis C treatment;
THYM	cis	rs4363385	0.818	rs2339492	chr1:152985552	G/C	cg13444842	chr1:152974279	SPRR3	-0.57	-4.76	-0.44	6.94e-6	Inflammatory skin disease;
THYM	cis	rs295140	0.605	rs296818	chr2:201176944	C/T	cg17644776	chr2:200775616	C2orf69	0.58	4.5	0.42	1.91e-5	QT interval;
THYM	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs7809615	0.892	rs58964157	chr7:99034055	G/A	cg12290671	chr7:99195819	NA	-0.99	-4.83	-0.44	5.27e-6	Blood metabolite ratios;
THYM	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg13114125	chr14:105738426	BRF1	-0.71	-5.58	-0.5	2.25e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1371867	0.846	rs1660332	chr8:101309490	A/G	cg06636551	chr8:101224915	SPAG1	0.63	6.26	0.54	1.12e-8	Atrioventricular conduction;
THYM	cis	rs10463554	0.927	rs257316	chr5:102422443	A/G	cg23492399	chr5:102201601	PAM	0.69	5.1	0.46	1.76e-6	Parkinson's disease;
THYM	cis	rs6960043	1.000	rs6960043	chr7:15052860	C/T	cg19272540	chr7:15055459	NA	0.53	6.58	0.56	2.61e-9	Type 2 diabetes;
THYM	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg15744005	chr10:104629667	AS3MT	-0.84	-8.11	-0.64	1.8e-12	Arsenic metabolism;
THYM	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg24818145	chr4:99064322	C4orf37	0.73	5.76	0.51	1.04e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6669072	0.565	rs7553927	chr1:91282962	A/T	cg08895590	chr1:91227319	NA	-0.39	-4.45	-0.42	2.32e-5	Cognitive function;
THYM	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg00339695	chr16:24857497	SLC5A11	0.68	6.32	0.54	8.53e-9	Intelligence (multi-trait analysis);
THYM	cis	rs4765905	1.000	rs1006737	chr12:2345295	A/G	cg09436713	chr12:2323135	CACNA1C	0.34	4.59	0.43	1.33e-5	Schizophrenia;
THYM	cis	rs526231	0.543	rs152134	chr5:102512447	C/G	cg23492399	chr5:102201601	PAM	-0.71	-5.32	-0.48	6.82e-7	Primary biliary cholangitis;
THYM	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg03676636	chr4:99064102	C4orf37	0.39	5.55	0.49	2.57e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17641971	0.684	rs4873095	chr8:49990166	A/T	cg00325661	chr8:49890786	NA	0.6	4.79	0.44	6.24e-6	Blood metabolite levels;
THYM	cis	rs4654899	0.965	rs6692244	chr1:21396886	C/A	cg01072550	chr1:21505969	NA	-0.75	-6.82	-0.57	8.26e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs714027	1.000	rs2412971	chr22:30494371	G/A	cg11564601	chr22:30592435	NA	-0.3	-5.45	-0.49	3.98e-7	Lymphocyte counts;
THYM	cis	rs10499694	0.933	rs11575352	chr7:50594982	A/G	cg00647317	chr7:50633725	DDC	0.3	4.6	0.43	1.32e-5	Body mass index;
THYM	cis	rs6546537	0.562	rs1985342	chr2:69758927	C/T	cg10773587	chr2:69614142	GFPT1	-0.59	-4.68	-0.43	9.48e-6	Serum thyroid-stimulating hormone levels;
THYM	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg26408565	chr15:76604113	ETFA	-0.55	-4.69	-0.43	9.15e-6	Blood metabolite levels;
THYM	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.8	-6.16	-0.53	1.72e-8	IgG glycosylation;
THYM	cis	rs10463554	0.963	rs3776857	chr5:102358160	A/G	cg23492399	chr5:102201601	PAM	-0.69	-5.17	-0.47	1.27e-6	Parkinson's disease;
THYM	cis	rs28647808	0.881	rs4549850	chr9:136265239	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg22907277	chr7:1156413	C7orf50	0.87	7.59	0.61	2.16e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg14074117	chr16:1909714	C16orf73	-0.7	-4.45	-0.42	2.3e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs72792324	1.000	rs58934519	chr5:140737947	A/G	cg21929183	chr5:140807225	PCDHGA4;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB8P;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	-0.97	-4.49	-0.42	2e-5	Mean platelet volume;
THYM	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-5.34	-0.48	6.41e-7	Lymphocyte counts;
THYM	cis	rs3087591	0.922	rs9892839	chr17:29618990	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.63	-5.4	-0.48	4.98e-7	Hip circumference;
THYM	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg11764359	chr7:65958608	NA	0.62	4.73	0.44	7.94e-6	Aortic root size;
THYM	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs6430585	0.528	rs309122	chr2:136761853	A/G	cg20242066	chr2:136595261	LCT	0.49	5.34	0.48	6.35e-7	Corneal structure;
THYM	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2041895	0.509	rs12368448	chr12:107316796	A/C	cg13944111	chr12:107296891	NA	-0.63	-5.02	-0.46	2.42e-6	Glaucoma (low intraocular pressure);
THYM	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg24450063	chr1:156163899	SLC25A44	1.15	14.39	0.83	1.33e-25	Testicular germ cell tumor;
THYM	cis	rs870825	0.655	rs10013685	chr4:185617785	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.69	0.71	7.45e-16	Blood protein levels;
THYM	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg19318889	chr4:1322082	MAEA	0.69	6.05	0.53	2.86e-8	Longevity;
THYM	cis	rs3796352	1.000	rs34933390	chr3:53006265	T/G	cg24530246	chr3:53118167	NA	-0.81	-4.62	-0.43	1.23e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs4343996	0.902	rs4722710	chr7:3388254	C/A	cg21248987	chr7:3385318	SDK1	-0.4	-4.88	-0.45	4.23e-6	Motion sickness;
THYM	cis	rs793571	0.522	rs11071398	chr15:59120077	A/G	cg05156742	chr15:59063176	FAM63B	0.55	4.6	0.43	1.31e-5	Schizophrenia;
THYM	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg09549813	chr16:4587862	C16orf5	-0.59	-6.25	-0.54	1.17e-8	Schizophrenia;
THYM	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9788721	0.902	rs114205691	chr15:78901113	C/T	cg18825076	chr15:78729989	IREB2	-0.55	-5.04	-0.46	2.26e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs10979	1.000	rs34960207	chr6:143886398	C/T	cg25407410	chr6:143891975	LOC285740	-0.63	-5.46	-0.49	3.76e-7	Hypospadias;
THYM	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg10760299	chr15:45669010	GATM	0.89	6.86	0.58	7.13e-10	Homoarginine levels;
THYM	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg02551604	chr5:131831745	NA	0.73	5.73	0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs800586	0.751	rs800536	chr8:116720406	A/T	cg04656070	chr8:116661063	TRPS1	-0.49	-5.24	-0.47	9.58e-7	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg26384229	chr12:38710491	ALG10B	1.02	10.24	0.72	4.98e-17	Heart rate;
THYM	cis	rs10851411	0.908	rs9302112	chr15:42820451	A/G	cg04308337	chr15:42867303	STARD9	0.62	4.72	0.44	8.06e-6	Glucose homeostasis traits;
THYM	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	5.2	0.47	1.16e-6	Rheumatoid arthritis;
THYM	cis	rs651907	0.935	rs2929922	chr3:101587934	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	5.12	0.46	1.6e-6	Colorectal cancer;
THYM	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg03877680	chr5:178157825	ZNF354A	0.74	5.12	0.47	1.59e-6	Neutrophil percentage of white cells;
THYM	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg01304814	chr3:48885189	PRKAR2A	0.88	4.58	0.43	1.39e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg14004847	chr7:1930337	MAD1L1	0.63	4.55	0.42	1.59e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs889398	0.771	rs12927431	chr16:69857047	G/A	cg09409435	chr16:70099608	PDXDC2	-0.62	-4.91	-0.45	3.77e-6	Body mass index;
THYM	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg00814883	chr7:100076585	TSC22D4	-1.0	-6.8	-0.57	9.22e-10	Platelet count;
THYM	cis	rs6840360	0.582	rs57585665	chr4:152327017	G/C	cg17479576	chr4:152424074	FAM160A1	-0.73	-5.45	-0.49	4.02e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs11651000	0.625	rs4794063	chr17:45804494	C/T	cg03474202	chr17:45855739	NA	-0.76	-6.71	-0.57	1.38e-9	IgG glycosylation;
THYM	cis	rs28595532	0.920	rs115226628	chr4:119639818	A/G	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg03388025	chr16:89894329	SPIRE2	0.53	4.49	0.42	1.99e-5	Vitiligo;
THYM	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg06582575	chr6:163149167	PACRG;PARK2	1.15	6.71	0.57	1.43e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg04362960	chr10:104952993	NT5C2	0.67	4.71	0.44	8.34e-6	Arsenic metabolism;
THYM	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg12373951	chr3:133503437	NA	0.57	6.22	0.54	1.35e-8	Iron status biomarkers;
THYM	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.56	4.55	0.42	1.56e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs595982	0.702	rs626974	chr19:49375900	T/C	cg21252483	chr19:49399788	TULP2	-0.54	-4.72	-0.44	8.15e-6	Red cell distribution width;
THYM	cis	rs8048589	0.549	rs4781176	chr16:12181080	A/G	cg02910054	chr16:12241554	SNX29	0.63	5.89	0.52	5.94e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	5.78	0.51	9.45e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg00645579	chr11:617140	IRF7;MUPCDH	-0.47	-5.18	-0.47	1.25e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs750460	1.000	rs750460	chr15:74241506	G/A	cg01349856	chr15:74220517	LOXL1	-0.62	-4.56	-0.42	1.5e-5	Height;
THYM	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg11845111	chr2:191398756	TMEM194B	1.02	7.86	0.63	5.79e-12	Diastolic blood pressure;
THYM	cis	rs67311347	0.577	rs11129870	chr3:40260406	G/A	cg09455208	chr3:40491958	NA	0.43	4.54	0.42	1.65e-5	Renal cell carcinoma;
THYM	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg18252515	chr7:66147081	NA	-0.89	-6.65	-0.56	1.85e-9	Corneal structure;
THYM	cis	rs4589258	0.898	rs35469130	chr11:90425960	G/C	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.32	-9.97	-0.72	1.91e-16	Gut microbiome composition (summer);
THYM	cis	rs67460515	0.500	rs1345156	chr3:160649272	G/T	cg12349858	chr3:160822545	B3GALNT1	-0.58	-4.87	-0.45	4.4e-6	Parkinson's disease;
THYM	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.13	7.78	0.62	8.66e-12	Smoking behavior;
THYM	cis	rs8064299	0.597	rs2053748	chr17:72775911	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.84	-7.79	-0.62	8.16e-12	Monocyte count;
THYM	cis	rs1978968	0.827	rs5992134	chr22:18433994	G/T	cg01550578	chr22:18484421	MICAL3	0.65	4.8	0.44	5.79e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs4919694	1.000	rs58317752	chr10:104799267	T/A	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg00300879	chr1:26503847	CNKSR1	0.43	5.74	0.51	1.15e-7	Height;
THYM	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03762994	chr17:6899332	ALOX12	-0.73	-10.62	-0.74	7.78e-18	Tonsillectomy;
THYM	cis	rs877282	0.583	rs7072970	chr10:822757	G/A	cg10556349	chr10:835070	NA	-0.84	-5.48	-0.49	3.43e-7	Uric acid levels;
THYM	cis	rs2273669	0.504	rs77043922	chr6:109488896	G/A	cg17117243	chr6:109341365	SESN1	-0.86	-5.04	-0.46	2.18e-6	Prostate cancer;
THYM	cis	rs4077515	0.649	rs3087886	chr9:139301583	T/C	cg14115884	chr9:139300582	SDCCAG3	0.75	7.51	0.61	3.21e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg06850241	chr22:41845214	NA	0.54	4.53	0.42	1.74e-5	Vitiligo;
THYM	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg16325326	chr1:53192061	ZYG11B	0.75	6.02	0.53	3.33e-8	Monocyte count;
THYM	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg24006582	chr15:45444508	DUOX1	-0.83	-7.16	-0.59	1.7e-10	Uric acid levels;
THYM	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg11752832	chr7:134001865	SLC35B4	0.73	5.5	0.49	3.22e-7	Mean platelet volume;
THYM	cis	rs9543976	0.920	rs9543972	chr13:76121675	T/C	cg01531495	chr13:76123901	UCHL3	0.75	4.97	0.45	3.01e-6	Diabetic retinopathy;
THYM	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg22920501	chr2:26401640	FAM59B	0.78	7.16	0.59	1.7e-10	Gut microbiome composition (summer);
THYM	cis	rs3112255	1.000	rs2942904	chr2:101306999	A/G	cg01042948	chr2:101319752	NA	0.72	6.28	0.54	1.02e-8	Intelligence (multi-trait analysis);
THYM	cis	rs3093024	0.839	rs968334	chr6:167526096	T/C	cg09487078	chr6:167525398	CCR6	-0.39	-4.89	-0.45	4.04e-6	Rheumatoid arthritis;
THYM	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.47	-0.49	3.59e-7	Mean corpuscular volume;
THYM	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg23711669	chr6:146136114	FBXO30	0.93	9.15	0.68	1.08e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7584330	0.737	rs6431540	chr2:238360966	T/C	cg04447362	chr2:237654635	NA	0.51	4.7	0.43	8.85e-6	Prostate cancer;
THYM	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.66	4.63	0.43	1.18e-5	Aortic root size;
THYM	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg17294928	chr15:75287854	SCAMP5	-1.02	-8.79	-0.67	6.45e-14	Blood trace element (Zn levels);
THYM	cis	rs9814567	0.752	rs1534030	chr3:134330083	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs150992	0.688	rs161947	chr5:98268572	C/T	cg25658278	chr12:52607461	LOC283404	-0.84	-8.62	-0.66	1.49e-13	Body mass index;
THYM	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg18538332	chr22:24372958	LOC391322	-0.69	-5.47	-0.49	3.6e-7	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg08048268	chr3:133502702	NA	-0.64	-5.68	-0.5	1.5e-7	Ankle injury;
THYM	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg10523679	chr1:76189770	ACADM	0.94	8.52	0.66	2.42e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg05025164	chr4:1340916	KIAA1530	0.6	4.66	0.43	1.05e-5	Longevity;
THYM	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg00129232	chr17:37814104	STARD3	0.7	4.79	0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg00071950	chr4:10020882	SLC2A9	0.88	9.22	0.69	7.56e-15	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg03676636	chr4:99064102	C4orf37	-0.45	-6.63	-0.56	2.05e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg27532560	chr4:187881888	NA	-0.96	-12.62	-0.79	5.09e-22	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08564027	chr20:61660810	NA	0.91	9.81	0.71	4.29e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15506890	chr2:3487001	NA	-0.55	-4.47	-0.42	2.17e-5	Neurofibrillary tangles;
THYM	cis	rs2898681	0.581	rs731073	chr4:53680090	A/G	cg00791764	chr4:53727839	RASL11B	0.42	5.11	0.46	1.68e-6	Optic nerve measurement (cup area);
THYM	trans	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg07211511	chr3:129823064	LOC729375	-1.33	-9.19	-0.69	8.79e-15	Blood pressure (smoking interaction);
THYM	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg04518342	chr5:131593106	PDLIM4	0.48	5.16	0.47	1.34e-6	Blood metabolite levels;
THYM	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg18512352	chr11:47633146	NA	-0.51	-6.33	-0.54	8.07e-9	Subjective well-being;
THYM	cis	rs4662945	0.762	rs1453155	chr2:130226369	G/A	cg05903289	chr2:130345205	NA	-0.55	-5.24	-0.47	9.63e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg08498830	chr11:832797	CD151	-0.63	-4.59	-0.43	1.35e-5	Mean platelet volume;
THYM	cis	rs13064411	0.696	rs2087129	chr3:113142769	T/A	cg18753928	chr3:113234510	CCDC52	-0.83	-7.29	-0.6	9.08e-11	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs11031096	0.711	rs17283923	chr11:4173841	C/T	cg22027985	chr11:4115532	RRM1	-0.51	-4.75	-0.44	7.26e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs36051895	0.530	rs4425810	chr9:5222208	A/G	cg02405213	chr9:5042618	JAK2	-0.8	-8.08	-0.64	2.01e-12	Pediatric autoimmune diseases;
THYM	cis	rs7100689	0.577	rs9420359	chr10:82054873	C/T	cg09936400	chr10:82049201	MAT1A	0.47	4.93	0.45	3.55e-6	Post bronchodilator FEV1;
THYM	cis	rs7607369	0.580	rs7594289	chr2:219652286	A/G	cg02176678	chr2:219576539	TTLL4	-0.6	-5.49	-0.49	3.28e-7	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg06521331	chr12:34319734	NA	-0.98	-8.55	-0.66	2.09e-13	Morning vs. evening chronotype;
THYM	cis	rs67072384	0.818	rs2291290	chr11:72465877	T/C	cg01380194	chr11:72452482	ARAP1	-0.81	-4.57	-0.42	1.49e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs9311676	0.632	rs1126722	chr3:58413518	T/G	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg06238570	chr21:40685208	BRWD1	-0.73	-6.27	-0.54	1.05e-8	Menarche (age at onset);
THYM	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg06970220	chr1:156163860	SLC25A44	0.72	5.59	0.5	2.18e-7	Testicular germ cell tumor;
THYM	cis	rs7968440	0.591	rs6580732	chr12:50646279	T/G	cg20014596	chr12:50898483	DIP2B	-0.51	-4.71	-0.44	8.41e-6	Fibrinogen;
THYM	cis	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg07460842	chr6:66804631	NA	-0.96	-5.86	-0.52	6.57e-8	Exhaled nitric oxide levels;
THYM	cis	rs9399401	0.626	rs13198644	chr6:142783233	A/G	cg03128060	chr6:142623767	GPR126	0.7	9.01	0.68	2.19e-14	Chronic obstructive pulmonary disease;
THYM	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg17757837	chr7:157058334	UBE3C	0.66	5.32	0.48	6.85e-7	Body mass index;
THYM	cis	rs17102423	0.660	rs7152277	chr14:65535391	G/C	cg11161011	chr14:65562177	MAX	-0.56	-4.55	-0.42	1.58e-5	Obesity-related traits;
THYM	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg06074448	chr4:187884817	NA	-1.01	-13.54	-0.81	6.7e-24	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.99	-0.75	1.26e-18	Extrinsic epigenetic age acceleration;
THYM	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-12.9	-0.8	1.33e-22	Height;
THYM	cis	rs983545	0.586	rs9880307	chr3:16974610	C/A	cg19448816	chr3:16974217	PLCL2	0.57	5.48	0.49	3.44e-7	Blood protein levels;
THYM	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg06937548	chr11:34938143	PDHX;APIP	0.67	5.84	0.51	7.4e-8	Lung disease severity in cystic fibrosis;
THYM	cis	rs55788414	0.652	rs1453324	chr16:81190613	A/G	cg06400318	chr16:81190750	PKD1L2	0.91	5.44	0.49	4.14e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs782590	0.643	rs5012561	chr2:55742032	G/C	cg03859395	chr2:55845619	SMEK2	-0.51	-4.76	-0.44	6.82e-6	Metabolic syndrome;
THYM	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg07936489	chr17:37558343	FBXL20	0.82	5.61	0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7681440	0.606	rs2737033	chr4:90707947	T/C	cg06632027	chr4:90757378	SNCA	-0.59	-4.61	-0.43	1.23e-5	Dementia with Lewy bodies;
THYM	cis	rs3134353	0.543	rs1376672	chr8:101939479	G/A	cg04962480	chr8:101962118	YWHAZ	-0.38	-5.83	-0.51	7.54e-8	Body mass index;
THYM	cis	rs2810114	0.916	rs2526851	chr14:71416280	G/C	cg15910301	chr14:71632612	NA	-0.56	-4.88	-0.45	4.23e-6	Alcohol dependence;
THYM	trans	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg10856724	chr12:34555212	NA	-0.9	-8.08	-0.64	2.05e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg17063962	chr7:91808500	NA	-1.09	-11.65	-0.77	5.37e-20	Breast cancer;
THYM	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg13609457	chr4:120235615	NA	0.64	5.08	0.46	1.86e-6	Corneal astigmatism;
THYM	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg16325326	chr1:53192061	ZYG11B	-0.82	-8.47	-0.66	3.12e-13	Monocyte count;
THYM	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg12165864	chr7:66369176	NA	-0.64	-5.04	-0.46	2.26e-6	Aortic root size;
THYM	cis	rs7084402	0.967	rs1649066	chr10:60305916	G/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.65e-7	Refractive error;
THYM	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg13319975	chr6:146136371	FBXO30	0.65	5.24	0.47	9.85e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg22709100	chr7:91322751	NA	0.61	4.86	0.45	4.66e-6	Breast cancer;
THYM	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg23989207	chr17:80870107	TBCD	0.54	4.58	0.42	1.44e-5	Glycated hemoglobin levels;
THYM	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6087990	0.806	rs6141814	chr20:31368960	C/A	cg13636640	chr20:31349939	DNMT3B	0.94	10.02	0.72	1.51e-16	Ulcerative colitis;
THYM	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg18876405	chr7:65276391	NA	0.56	5.0	0.46	2.62e-6	Calcium levels;
THYM	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg05855489	chr10:104503620	C10orf26	-0.6	-4.68	-0.43	9.37e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7740797	0.570	rs12201149	chr6:155162163	C/T	cg02865717	chr6:155053990	RBM16	-0.48	-4.78	-0.44	6.37e-6	Colorectal or endometrial cancer;
THYM	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg06623918	chr6:96969491	KIAA0776	1.09	10.04	0.72	1.34e-16	Headache;
THYM	cis	rs16912285	0.591	rs7929025	chr11:24363324	A/C	ch.11.24196551F	chr11:24239977	NA	0.84	5.9	0.52	5.47e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg27129171	chr3:47204927	SETD2	-0.69	-6.65	-0.56	1.82e-9	Colorectal cancer;
THYM	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg18357526	chr6:26021779	HIST1H4A	0.79	6.62	0.56	2.14e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg24642844	chr7:1081250	C7orf50	-1.17	-7.15	-0.59	1.75e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2932538	0.885	rs6661642	chr1:113090109	T/C	cg22162597	chr1:113214053	CAPZA1	0.66	5.21	0.47	1.09e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg20887711	chr4:1340912	KIAA1530	-0.62	-4.9	-0.45	3.9e-6	Obesity-related traits;
THYM	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg08975724	chr8:8085496	FLJ10661	-0.59	-4.66	-0.43	1.05e-5	Mood instability;
THYM	cis	rs951366	0.553	rs10900522	chr1:205684067	T/C	cg14159672	chr1:205819179	PM20D1	-0.71	-5.39	-0.48	5.2e-7	Menarche (age at onset);
THYM	cis	rs10504906	0.643	rs9283962	chr8:92419127	T/G	cg09373786	chr8:93156639	NA	1.28	4.51	0.42	1.88e-5	Fat distribution (HIV);
THYM	cis	rs4786125	0.636	rs7187960	chr16:6919183	G/T	cg03623568	chr16:6915990	A2BP1	-1.02	-10.42	-0.73	2.1e-17	Heart rate variability traits (SDNN);
THYM	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg08132940	chr7:1081526	C7orf50	-0.77	-5.18	-0.47	1.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs34912216	0.580	rs13223052	chr7:4131332	T/G	cg03141780	chr7:4150753	SDK1	0.65	4.89	0.45	4.1e-6	Motion sickness;
THYM	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.24	9.45	0.7	2.46e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg15536230	chr21:44985092	HSF2BP	-0.41	-4.84	-0.44	4.95e-6	Mean corpuscular volume;
THYM	trans	rs75518195	0.524	rs62302824	chr4:64739141	C/A	cg14706739	chr8:21916355	EPB49	0.73	6.98	0.58	3.99e-10	Triptolide cytotoxicity;
THYM	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg16778714	chr17:28903809	LRRC37B2	-0.76	-4.49	-0.42	2.03e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg22709100	chr7:91322751	NA	0.68	5.42	0.49	4.59e-7	Breast cancer;
THYM	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Bladder cancer;
THYM	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg01119278	chr6:110721349	DDO	-0.62	-7.41	-0.61	5.07e-11	Platelet distribution width;
THYM	cis	rs12893597	0.659	rs12587624	chr14:76845480	G/A	cg20290672	chr14:76816747	NA	-0.58	-4.82	-0.44	5.35e-6	Maximal oxygen uptake response;
THYM	trans	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg25214090	chr10:38739885	LOC399744	0.94	7.99	0.63	3.13e-12	Corneal astigmatism;
THYM	cis	rs2544523	0.511	rs2544536	chr2:15906854	T/C	cg26669897	chr2:15909070	NA	0.73	6.62	0.56	2.16e-9	Asthma or chronic obstructive pulmonary disease;
THYM	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg03929089	chr4:120376271	NA	-1.0	-12.58	-0.79	6.18e-22	Height;
THYM	cis	rs4595586	0.545	rs1607042	chr12:39368028	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs2637266	0.568	rs2579758	chr10:78262202	T/C	cg18941641	chr10:78392320	NA	0.6	4.62	0.43	1.22e-5	Pulmonary function;
THYM	cis	rs2154427	0.872	rs76446596	chr21:34098391	T/C	cg21871883	chr21:34145043	C21orf49;C21orf66	1.0	5.26	0.47	8.92e-7	Bilirubin levels;
THYM	cis	rs600806	0.888	rs3879450	chr1:109909149	C/T	cg23616212	chr1:109941201	SORT1	-0.48	-4.55	-0.42	1.57e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.596	rs11763920	chr7:124640880	G/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs4363385	0.719	rs6587714	chr1:152933023	T/C	cg07796016	chr1:152779584	LCE1C	-0.58	-4.73	-0.44	7.76e-6	Inflammatory skin disease;
THYM	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg10553204	chr2:20871195	GDF7	-0.75	-6.26	-0.54	1.12e-8	Abdominal aortic aneurysm;
THYM	cis	rs76662990	0.764	rs10061404	chr5:73915696	G/A	cg13275603	chr5:73927487	ENC1	-0.82	-4.73	-0.44	7.73e-6	Residual cognition;
THYM	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg25358565	chr5:93447407	FAM172A	1.32	11.24	0.76	3.75e-19	Diabetic retinopathy;
THYM	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg18681998	chr4:17616180	MED28	0.81	7.03	0.58	3.17e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs901683	1.000	rs35131026	chr10:46014759	G/A	cg18240400	chr10:46168597	ANUBL1	0.8	5.16	0.47	1.38e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs2075230	0.705	rs1642808	chr17:7545464	G/C	cg10509001	chr17:7553872	ATP1B2	-0.56	-4.52	-0.42	1.79e-5	Hormone measurements;
THYM	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg03433033	chr1:76189801	ACADM	-0.77	-9.42	-0.69	2.92e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg12826209	chr6:26865740	GUSBL1	0.94	5.02	0.46	2.37e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg21926883	chr2:100939477	LONRF2	-0.65	-5.96	-0.52	4.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg13683864	chr3:40499215	RPL14	-1.01	-10.37	-0.73	2.73e-17	Renal cell carcinoma;
THYM	cis	rs62244186	0.659	rs9311358	chr3:44538748	C/G	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.45	-4.77	-0.44	6.57e-6	Depressive symptoms;
THYM	cis	rs6510489	1.000	rs9973222	chr19:35984721	G/A	cg15078284	chr19:36004994	DMKN	0.42	4.91	0.45	3.76e-6	Bipolar disorder;
THYM	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg07424592	chr7:64974309	NA	1.04	5.27	0.48	8.52e-7	Diabetic kidney disease;
THYM	cis	rs12681287	0.673	rs4464946	chr8:87326259	G/A	cg27223183	chr8:87520930	FAM82B	-0.69	-5.12	-0.47	1.58e-6	Caudate activity during reward;
THYM	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg27129171	chr3:47204927	SETD2	0.71	6.32	0.54	8.49e-9	Colorectal cancer;
THYM	cis	rs6456156	0.586	rs9459853	chr6:167465774	C/A	cg00271210	chr6:167070053	RPS6KA2	-0.51	-5.31	-0.48	7.23e-7	Primary biliary cholangitis;
THYM	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg02524346	chr8:600233	NA	0.92	4.48	0.42	2.05e-5	IgG glycosylation;
THYM	cis	rs929596	0.597	rs10173355	chr2:234597321	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.81	-6.41	-0.55	5.5e-9	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg00376283	chr12:123451042	ABCB9	0.7	4.72	0.44	8.27e-6	Neutrophil percentage of white cells;
THYM	cis	rs7131987	0.903	rs7308125	chr12:29425211	T/C	cg09582351	chr12:29534625	ERGIC2	-0.48	-4.59	-0.43	1.35e-5	QT interval;
THYM	trans	rs877282	0.898	rs11253352	chr10:766598	C/A	cg22713356	chr15:30763199	NA	1.38	11.24	0.76	3.79e-19	Uric acid levels;
THYM	cis	rs10911232	0.507	rs10911194	chr1:182993025	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs9902453	1.000	rs4465649	chr17:28394747	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs67981189	0.896	rs2526882	chr14:71374702	G/A	cg15910301	chr14:71632612	NA	-0.54	-4.9	-0.45	3.97e-6	Schizophrenia;
THYM	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg07362569	chr17:61921086	SMARCD2	0.73	6.45	0.55	4.68e-9	Prudent dietary pattern;
THYM	cis	rs11563648	0.553	rs1361938	chr7:126998282	A/C	cg23081781	chr7:127225937	GCC1	0.35	4.79	0.44	6.03e-6	Resting heart rate;
THYM	cis	rs9788721	0.836	rs72738732	chr15:78752188	C/G	cg18825076	chr15:78729989	IREB2	-0.67	-6.17	-0.54	1.63e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg26384229	chr12:38710491	ALG10B	0.76	5.85	0.51	6.8e-8	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg22105103	chr4:187893119	NA	0.92	10.09	0.72	1.04e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg22907277	chr7:1156413	C7orf50	0.82	4.98	0.46	2.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7426056	0.671	rs56216383	chr2:204631712	A/G	cg07930752	chr2:204569955	CD28	-0.66	-4.46	-0.42	2.26e-5	Primary sclerosing cholangitis;
THYM	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.55	-4.69	-0.43	9.16e-6	Platelet count;
THYM	cis	rs8014204	1.000	rs4553560	chr14:75334199	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.58	-5.59	-0.5	2.13e-7	Caffeine consumption;
THYM	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg26384229	chr12:38710491	ALG10B	1.03	9.92	0.71	2.51e-16	Heart rate;
THYM	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg07570687	chr10:102243282	WNT8B	0.76	6.93	0.58	5.03e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2463822	0.669	rs72919475	chr11:62042361	T/A	cg06239285	chr11:62104954	ASRGL1	-1.05	-5.24	-0.47	9.59e-7	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs36051895	0.589	rs10491651	chr9:5200060	A/G	cg02405213	chr9:5042618	JAK2	-0.9	-8.7	-0.67	9.8e-14	Pediatric autoimmune diseases;
THYM	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg15110403	chr19:17392923	ANKLE1	-0.56	-4.75	-0.44	7.28e-6	Systemic lupus erythematosus;
THYM	cis	rs2504916	0.712	rs2457562	chr6:160750021	C/T	cg19643109	chr6:160697625	NA	-0.63	-4.8	-0.44	5.8e-6	Response to hepatitis C treatment;
THYM	cis	rs600806	0.850	rs4970751	chr1:109896600	A/C	cg23616212	chr1:109941201	SORT1	-0.5	-4.72	-0.44	8.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1018836	0.923	rs7812970	chr8:91541229	G/A	cg16814680	chr8:91681699	NA	-0.84	-7.67	-0.62	1.47e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4242434	0.597	rs876714	chr8:22482799	A/G	cg03733263	chr8:22462867	KIAA1967	0.98	9.44	0.7	2.56e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg15744005	chr10:104629667	AS3MT	-0.61	-4.57	-0.42	1.49e-5	Arsenic metabolism;
THYM	trans	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg07393940	chr7:158741817	NA	1.13	9.12	0.68	1.28e-14	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs870825	0.549	rs10015956	chr4:185614705	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs9921222	0.786	rs3848365	chr16:374617	C/T	cg01045337	chr16:374988	AXIN1	-0.62	-4.9	-0.45	3.86e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs611744	0.647	rs2859813	chr8:109263497	G/A	cg21045802	chr8:109455806	TTC35	0.63	5.66	0.5	1.62e-7	Dupuytren's disease;
THYM	cis	rs12282928	1.000	rs10769339	chr11:48294296	T/A	cg22827986	chr11:48284249	OR4X1	-0.53	-5.5	-0.49	3.18e-7	Migraine - clinic-based;
THYM	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4662945	1.000	rs4662944	chr2:130215940	G/T	cg05903289	chr2:130345205	NA	-0.52	-5.1	-0.46	1.7e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3087591	1.000	rs6505235	chr17:29688603	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.61	-5.18	-0.47	1.26e-6	Hip circumference;
THYM	cis	rs2229238	0.911	rs3811449	chr1:154517504	G/A	cg21262032	chr1:154437693	IL6R	-0.62	-5.23	-0.47	1.01e-6	Coronary heart disease;
THYM	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg04398451	chr17:18023971	MYO15A	-0.83	-7.74	-0.62	1.04e-11	Total body bone mineral density;
THYM	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg23018236	chr17:30244563	NA	-0.6	-4.45	-0.42	2.3e-5	Hip circumference adjusted for BMI;
THYM	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg24910161	chr17:38119198	GSDMA	0.45	4.57	0.42	1.44e-5	Self-reported allergy;
THYM	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg04455712	chr21:45112962	RRP1B	0.52	4.68	0.43	9.38e-6	Mean corpuscular volume;
THYM	cis	rs6946131	0.614	rs10272600	chr7:54790537	T/C	cg16668896	chr7:54900801	NA	0.45	4.78	0.44	6.45e-6	Systemic lupus erythematosus;
THYM	cis	rs240764	0.817	rs240143	chr6:101080621	G/A	cg21058520	chr6:100914733	NA	-0.57	-5.06	-0.46	2.04e-6	Neuroticism;
THYM	cis	rs36051895	0.589	rs7850294	chr9:5191128	C/T	cg02405213	chr9:5042618	JAK2	0.93	10.17	0.72	7.24e-17	Pediatric autoimmune diseases;
THYM	cis	rs4595586	0.525	rs34204378	chr12:39425759	C/T	cg26384229	chr12:38710491	ALG10B	0.78	5.55	0.49	2.62e-7	Morning vs. evening chronotype;
THYM	cis	rs17209837	0.607	rs7789645	chr7:87122603	G/C	cg04996195	chr7:87105398	ABCB4	0.64	4.68	0.43	9.48e-6	Gallbladder cancer;
THYM	cis	rs28785552	0.931	rs10424385	chr19:53239133	C/G	cg10871876	chr19:53194124	ZNF83	0.82	6.89	0.58	5.93e-10	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs4662750	0.580	rs7558838	chr2:128351346	T/C	cg01966334	chr2:128378434	MYO7B	0.6	5.36	0.48	5.7e-7	Renal cell carcinoma;
THYM	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	5.05	0.46	2.1e-6	Motion sickness;
THYM	cis	rs12291225	0.679	rs34238445	chr11:14315915	C/T	cg19336497	chr11:14380999	RRAS2	-0.82	-9.66	-0.7	8.92e-16	Sense of smell;
THYM	cis	rs800586	0.500	rs727582	chr8:116650468	A/G	cg04656070	chr8:116661063	TRPS1	-0.54	-5.89	-0.52	5.9e-8	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7809950	0.953	rs2237670	chr7:107131485	A/G	cg23024343	chr7:107201750	COG5	-0.92	-8.21	-0.64	1.06e-12	Coronary artery disease;
THYM	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg24375607	chr4:120327624	NA	0.62	5.0	0.46	2.63e-6	Corneal astigmatism;
THYM	cis	rs7508	0.511	rs208056	chr8:17822884	C/T	cg01800426	chr8:17659068	MTUS1	-0.75	-5.23	-0.47	1.01e-6	Atrial fibrillation;
THYM	cis	rs8018808	0.935	rs176772	chr14:77881808	A/G	cg20045696	chr14:77926864	AHSA1	0.59	5.46	0.49	3.88e-7	Myeloid white cell count;
THYM	cis	rs7100689	0.784	rs3802638	chr10:82179689	T/C	cg01528321	chr10:82214614	TSPAN14	1.13	8.8	0.67	6.09e-14	Post bronchodilator FEV1;
THYM	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.7	5.33	0.48	6.5e-7	Tonsillectomy;
THYM	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg27286337	chr10:134555280	INPP5A	0.88	6.88	0.58	6.37e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg17644776	chr2:200775616	C2orf69	0.9	7.45	0.61	4.33e-11	Osteoporosis;
THYM	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg27446573	chr6:127587934	RNF146	0.77	6.35	0.55	7.46e-9	Breast cancer;
THYM	cis	rs308447	0.516	rs6853540	chr4:123679848	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.7	4.67	0.43	9.76e-6	Perceived unattractiveness to mosquitoes;
THYM	cis	rs728616	0.867	rs17884637	chr10:81687922	G/C	cg05935833	chr10:81318306	SFTPA2	-0.77	-4.66	-0.43	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg18357526	chr6:26021779	HIST1H4A	0.77	6.57	0.56	2.74e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1971762	0.521	rs5009146	chr12:54089297	A/C	cg16917193	chr12:54089295	NA	1.0	10.41	0.73	2.16e-17	Height;
THYM	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs12291225	0.535	rs11023203	chr11:14409815	G/A	cg05501817	chr11:14380813	RRAS2	-0.74	-6.09	-0.53	2.43e-8	Sense of smell;
THYM	cis	rs40363	0.767	rs1003330	chr16:3541039	A/G	cg01073479	chr16:3509474	NAT15	-0.74	-5.45	-0.49	3.89e-7	Tuberculosis;
THYM	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs854765	0.927	rs4925138	chr17:17992793	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.63	-5.1	-0.46	1.76e-6	Total body bone mineral density;
THYM	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg11327659	chr7:150037044	RARRES2	0.42	5.0	0.46	2.62e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4474465	0.736	rs10899550	chr11:78256078	G/A	cg19901956	chr11:77921274	USP35	0.61	4.6	0.43	1.3e-5	Alzheimer's disease (survival time);
THYM	cis	rs12765878	0.603	rs2475216	chr10:105660651	G/A	cg04688330	chr10:105451802	SH3PXD2A	0.37	4.54	0.42	1.64e-5	Coronary artery disease;
THYM	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg18230493	chr5:56204884	C5orf35	-0.64	-4.86	-0.45	4.56e-6	Initial pursuit acceleration;
THYM	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg07917127	chr4:99064746	C4orf37	0.56	4.46	0.42	2.22e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.55	-5.53	-0.49	2.86e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	12.13	0.78	5.13e-21	Chronic sinus infection;
THYM	cis	rs11186	0.556	rs7421643	chr2:189961031	C/T	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs4343996	0.506	rs7790430	chr7:3432943	G/C	cg21248987	chr7:3385318	SDK1	0.4	5.17	0.47	1.27e-6	Motion sickness;
THYM	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg13609457	chr4:120235615	NA	0.51	4.8	0.44	5.83e-6	Corneal astigmatism;
THYM	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg15052019	chr19:19431593	KIAA0892;SF4	-0.62	-4.79	-0.44	6.15e-6	Tonsillectomy;
THYM	cis	rs885814	0.878	rs3767153	chr1:21889215	C/A	cg14781605	chr1:21864896	ALPL	-0.67	-5.06	-0.46	2.01e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.69	4.62	0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs7107770	1.000	rs12787799	chr11:125094342	T/C	cg07747661	chr11:125106135	PKNOX2	-0.88	-5.34	-0.48	6.29e-7	Photic sneeze reflex;
THYM	cis	rs72717009	0.825	rs7515174	chr1:161476949	C/G	cg15358701	chr1:161410459	NA	-0.95	-5.06	-0.46	2.08e-6	Rheumatoid arthritis;
THYM	cis	rs4918072	0.917	rs35041090	chr10:105648686	G/A	cg11005552	chr10:105648138	OBFC1	0.74	6.21	0.54	1.41e-8	Coronary artery disease;
THYM	cis	rs10979	1.000	rs12203151	chr6:143884856	C/T	cg25407410	chr6:143891975	LOC285740	-0.62	-5.0	-0.46	2.59e-6	Hypospadias;
THYM	cis	rs55728055	0.661	rs7285893	chr22:32010042	A/G	cg10537193	chr22:32026975	PISD	-0.72	-4.8	-0.44	5.78e-6	Age-related hearing impairment;
THYM	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg12501888	chr15:85177176	SCAND2	0.56	4.63	0.43	1.16e-5	P wave terminal force;
THYM	trans	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs4072705	0.967	rs4838195	chr9:127351217	G/A	cg01786973	chr9:127249749	NR5A1	0.34	4.52	0.42	1.76e-5	Menarche (age at onset);
THYM	cis	rs7078219	0.505	rs4129132	chr10:101284637	T/G	cg07044859	chr10:101282883	NA	-0.39	-4.52	-0.42	1.8e-5	Dental caries;
THYM	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg07936489	chr17:37558343	FBXL20	0.85	5.64	0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg24250549	chr1:154909240	PMVK	0.8	6.38	0.55	6.48e-9	Prostate cancer;
THYM	cis	rs1669338	0.588	rs3749360	chr3:3213775	G/A	cg16797762	chr3:3221439	CRBN	-1.02	-5.54	-0.49	2.7e-7	White matter integrity;
THYM	cis	rs2236918	0.687	rs1776136	chr1:242026845	G/A	cg21919602	chr1:242011447	EXO1	-0.6	-4.46	-0.42	2.27e-5	Menopause (age at onset);
THYM	cis	rs600806	0.850	rs10776807	chr1:109956156	A/G	cg23616212	chr1:109941201	SORT1	0.52	4.99	0.46	2.69e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg10360139	chr7:1886902	MAD1L1	0.86	7.94	0.63	4.12e-12	Bipolar disorder and schizophrenia;
THYM	cis	rs8044995	0.568	rs55675218	chr16:68323647	G/C	cg09835421	chr16:68378352	PRMT7	-0.74	-4.51	-0.42	1.83e-5	Schizophrenia;
THYM	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-5.35	-0.48	5.99e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs9790314	0.936	rs7629987	chr3:161002023	A/C	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg07870213	chr5:140052090	DND1	-0.69	-8.1	-0.64	1.86e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg27170947	chr2:26402098	FAM59B	-0.79	-6.27	-0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg18252515	chr7:66147081	NA	-0.69	-5.47	-0.49	3.59e-7	Aortic root size;
THYM	cis	rs858239	0.537	rs10279691	chr7:23228387	A/G	cg09755872	chr7:23245557	NA	-0.52	-4.85	-0.45	4.76e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs13102973	0.931	rs13103718	chr4:135843990	C/T	cg14419869	chr4:135874104	NA	0.9	8.46	0.66	3.24e-13	Subjective well-being;
THYM	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg18252515	chr7:66147081	NA	0.72	5.66	0.5	1.59e-7	Aortic root size;
THYM	cis	rs259282	0.524	rs4805006	chr19:33124136	G/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.72	6.45	0.55	4.73e-9	Schizophrenia;
THYM	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg12573674	chr2:1569213	NA	-1.34	-8.9	-0.67	3.68e-14	IgG glycosylation;
THYM	cis	rs2066819	1.000	rs11575232	chr12:56744422	G/A	cg26714650	chr12:56694279	CS	-1.34	-6.94	-0.58	4.73e-10	Psoriasis vulgaris;
THYM	trans	rs8073060	0.586	rs225294	chr17:33925762	G/A	cg19694781	chr19:47549865	TMEM160	-0.98	-8.52	-0.66	2.45e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs9443189	0.570	rs72884926	chr6:76266208	T/C	cg01950844	chr6:76311363	SENP6	1.1	6.24	0.54	1.21e-8	Prostate cancer;
THYM	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs742614	0.533	rs2626547	chr20:32404921	G/A	cg06304546	chr20:32448765	NA	-0.92	-9.68	-0.7	8.01e-16	Stearic acid (18:0) levels;
THYM	cis	rs3780378	0.935	rs7875908	chr9:5081334	C/T	cg02405213	chr9:5042618	JAK2	-0.74	-6.87	-0.58	6.79e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs56104184	0.775	rs17272700	chr19:49391770	G/A	cg21252483	chr19:49399788	TULP2	-0.91	-6.15	-0.53	1.83e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7084402	0.967	rs1658470	chr10:60292383	A/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg00786635	chr1:25594202	NA	0.94	7.92	0.63	4.49e-12	Erythrocyte sedimentation rate;
THYM	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg04520793	chr17:42248056	ASB16	-0.34	-4.78	-0.44	6.45e-6	Total body bone mineral density;
THYM	cis	rs2235642	0.505	rs56359342	chr16:1654948	G/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.44	-4.9	-0.45	3.96e-6	Coronary artery disease;
THYM	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg06627557	chr7:32535165	LSM5;AVL9	1.03	10.73	0.74	4.6e-18	Cognitive ability;
THYM	cis	rs4733781	0.787	rs6470812	chr8:131340265	G/A	cg16277922	chr8:131349729	ASAP1	-0.7	-5.05	-0.46	2.09e-6	Tuberculosis;
THYM	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs10499694	0.901	rs6975453	chr7:50585211	A/T	cg18232548	chr7:50535776	DDC	-0.62	-5.1	-0.46	1.7e-6	Body mass index;
THYM	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg24846680	chr1:228362309	C1orf69	0.53	4.9	0.45	3.92e-6	Diastolic blood pressure;
THYM	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.09	-7.59	-0.61	2.18e-11	Platelet count;
THYM	cis	rs7639513	0.545	rs13061104	chr3:12717321	G/T	cg23032965	chr3:12705835	RAF1	0.9	6.76	0.57	1.09e-9	Itch intensity from mosquito bite;
THYM	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg10802521	chr3:52805072	NEK4	-0.73	-6.43	-0.55	5.15e-9	Bipolar disorder;
THYM	cis	rs9902453	0.933	rs7225462	chr17:28321226	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.22	0.54	1.3e-8	Coffee consumption (cups per day);
THYM	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-4.51	-0.42	1.82e-5	Educational attainment;
THYM	cis	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg09307838	chr4:120376055	NA	0.69	4.97	0.45	2.93e-6	Corneal astigmatism;
THYM	cis	rs7568458	0.704	rs10176176	chr2:85762048	A/T	cg17127132	chr2:85788382	GGCX	0.7	6.04	0.53	2.93e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs6988636	0.901	rs16898076	chr8:124187721	T/C	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg25767906	chr1:53392781	SCP2	-0.58	-5.78	-0.51	9.55e-8	Monocyte count;
THYM	cis	rs2273669	0.504	rs17070181	chr6:109428184	C/A	cg17117243	chr6:109341365	SESN1	-0.85	-4.99	-0.46	2.77e-6	Prostate cancer;
THYM	cis	rs208520	1.000	rs208520	chr6:66952828	G/T	cg07460842	chr6:66804631	NA	-0.78	-5.07	-0.46	1.96e-6	Exhaled nitric oxide output;
THYM	cis	rs28795989	0.896	rs28715921	chr4:7887974	T/C	cg12728606	chr4:7903970	AFAP1	0.43	4.59	0.43	1.34e-5	Intraocular pressure;
THYM	cis	rs79387448	0.626	rs80256362	chr2:103025501	A/G	cg09003973	chr2:102972529	NA	1.06	5.44	0.49	4.09e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg07570687	chr10:102243282	WNT8B	0.75	6.56	0.56	2.75e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2075230	0.705	rs1641539	chr17:7545578	T/C	cg10509001	chr17:7553872	ATP1B2	-0.56	-4.52	-0.42	1.79e-5	Hormone measurements;
THYM	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg11663144	chr21:46675770	NA	-0.7	-9.97	-0.71	1.96e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg24812749	chr6:127587940	RNF146	0.97	7.72	0.62	1.14e-11	Breast cancer;
THYM	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg02524346	chr8:600233	NA	1.04	5.12	0.46	1.6e-6	IgG glycosylation;
THYM	cis	rs16866061	1.000	rs34345163	chr2:225459080	A/G	cg22455342	chr2:225449267	CUL3	0.67	4.71	0.44	8.31e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs831571	0.636	rs831565	chr3:64076358	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	0.69	4.45	0.42	2.35e-5	Type 2 diabetes;
THYM	cis	rs2073300	1.000	rs6137960	chr20:23442886	G/A	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg01616529	chr11:638424	DRD4	-0.74	-5.68	-0.5	1.45e-7	Systemic lupus erythematosus;
THYM	cis	rs11997175	0.624	rs17778980	chr8:33700926	T/C	ch.8.33884649F	chr8:33765107	NA	0.63	4.76	0.44	6.85e-6	Body mass index;
THYM	cis	rs5760092	0.717	rs5760101	chr22:24248712	T/C	cg18538332	chr22:24372958	LOC391322	-0.9	-7.62	-0.62	1.93e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg23332699	chr15:44069569	ELL3	0.72	4.74	0.44	7.46e-6	Lung cancer in ever smokers;
THYM	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg12826209	chr6:26865740	GUSBL1	1.04	6.68	0.57	1.63e-9	Intelligence (multi-trait analysis);
THYM	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg17757837	chr7:157058334	UBE3C	0.73	5.96	0.52	4.25e-8	Body mass index;
THYM	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs12291225	0.679	rs1043237	chr11:14289053	A/T	cg19336497	chr11:14380999	RRAS2	-0.81	-9.48	-0.7	2.1e-15	Sense of smell;
THYM	cis	rs11039798	0.841	rs7294179	chr11:48765408	G/A	cg24672777	chr11:48374446	OR4C45	-1.08	-5.95	-0.52	4.42e-8	Axial length;
THYM	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg23711669	chr6:146136114	FBXO30	-0.83	-7.72	-0.62	1.18e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4845875	0.600	rs10779765	chr1:11838011	T/C	cg14194983	chr1:11908298	NPPA	0.54	4.97	0.45	2.93e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs67981189	0.896	rs7157250	chr14:71457829	T/C	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg26384229	chr12:38710491	ALG10B	-0.74	-6.22	-0.54	1.33e-8	Morning vs. evening chronotype;
THYM	cis	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.49	-4.47	-0.42	2.15e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs9311676	0.632	rs4228	chr3:58413669	G/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.55	-5.53	-0.49	2.86e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg19746536	chr19:49375674	PPP1R15A	0.81	4.59	0.43	1.34e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	trans	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.12	-13.73	-0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg17426766	chr1:2046864	PRKCZ	0.37	4.53	0.42	1.68e-5	Height;
THYM	cis	rs912057	0.609	rs1294431	chr6:6745003	G/C	cg13809441	chr6:6737631	NA	0.44	5.32	0.48	6.97e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs17818399	0.533	rs13420857	chr2:46798005	C/G	cg02822958	chr2:46747628	ATP6V1E2	-0.7	-5.12	-0.47	1.58e-6	Height;
THYM	cis	rs13040088	1.000	rs6090159	chr20:61531351	C/G	cg23096297	chr20:61557774	DIDO1	1.07	7.4	0.6	5.37e-11	Menopause (age at onset);
THYM	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.22e-16	Bone mineral density;
THYM	cis	rs6840360	0.550	rs11723438	chr4:152531801	C/T	cg17479576	chr4:152424074	FAM160A1	0.82	5.82	0.51	7.78e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg15691649	chr6:25882328	NA	-0.7	-5.37	-0.48	5.56e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg26412358	chr1:26503933	CNKSR1	0.35	4.99	0.46	2.76e-6	Height;
THYM	cis	rs61931739	0.500	rs7133447	chr12:34041901	A/G	cg10856724	chr12:34555212	NA	-0.75	-6.73	-0.57	1.25e-9	Morning vs. evening chronotype;
THYM	cis	rs9992101	0.645	rs72657825	chr4:77290561	G/A	cg20311846	chr4:77356250	SHROOM3	-0.54	-5.96	-0.52	4.32e-8	Creatinine levels;
THYM	cis	rs28493229	0.881	rs10404911	chr19:41174903	A/T	cg21869046	chr19:41225005	ITPKC	0.55	5.05	0.46	2.12e-6	Kawasaki disease;
THYM	cis	rs2932538	0.961	rs6537746	chr1:113163529	C/T	cg22162597	chr1:113214053	CAPZA1	-0.65	-5.32	-0.48	6.9e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs7084402	0.967	rs1658418	chr10:60333003	G/A	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg05393297	chr12:53359155	NA	-0.6	-6.85	-0.57	7.37e-10	Cancer (pleiotropy);
THYM	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg05335186	chr13:53173507	NA	-0.5	-7.02	-0.58	3.22e-10	Lewy body disease;
THYM	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg10802521	chr3:52805072	NEK4	-0.7	-5.93	-0.52	4.97e-8	Bipolar disorder;
THYM	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9486719	1.000	rs11153064	chr6:97021959	A/G	cg18709589	chr6:96969512	KIAA0776	-0.68	-4.7	-0.43	8.62e-6	Migraine;Coronary artery disease;
THYM	cis	rs17407555	0.606	rs59871456	chr4:10014441	G/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-5.87	-0.52	6.48e-8	Schizophrenia (age at onset);
THYM	cis	rs2333194	0.772	rs12589739	chr14:73903056	A/G	cg09844916	chr14:74004424	HEATR4;ACOT1	0.63	4.88	0.45	4.32e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs9814567	0.712	rs9838119	chr3:134331980	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg05896524	chr21:47604654	C21orf56	-0.69	-4.87	-0.45	4.4e-6	Testicular germ cell tumor;
THYM	cis	rs2777491	1.000	rs7177641	chr15:41743426	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.04	-10.25	-0.72	4.81e-17	Ulcerative colitis;
THYM	cis	rs12754538	0.850	rs7545384	chr1:8580960	C/A	cg06159269	chr1:8767347	RERE	0.22	4.58	0.43	1.39e-5	Subjective well-being;
THYM	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg20387954	chr3:183756860	HTR3D	0.55	5.28	0.48	8.09e-7	Anterior chamber depth;
THYM	cis	rs12714314	0.914	rs12986730	chr2:1959401	G/A	cg05313794	chr2:1845466	MYT1L	-0.5	-4.5	-0.42	1.91e-5	Type 2 diabetes (age of onset);
THYM	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg26384229	chr12:38710491	ALG10B	0.94	7.62	0.62	1.86e-11	Morning vs. evening chronotype;
THYM	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg21394778	chr1:3037102	PRDM16	0.46	4.47	0.42	2.12e-5	Height;
THYM	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg26384229	chr12:38710491	ALG10B	1.05	10.43	0.73	1.96e-17	Heart rate;
THYM	cis	rs9359856	0.564	rs17506403	chr6:90499059	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.91	-8.45	-0.66	3.31e-13	Bipolar disorder;
THYM	cis	rs6906287	0.647	rs59671368	chr6:118911430	T/A	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs9677476	0.779	rs10173555	chr2:232108769	C/G	cg23338755	chr2:231921595	PSMD1	0.77	5.03	0.46	2.29e-6	Food antigen IgG levels;
THYM	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg10802521	chr3:52805072	NEK4	0.67	5.71	0.51	1.31e-7	Bipolar disorder;
THYM	cis	rs728616	0.614	rs10788321	chr10:81713795	T/A	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.62	5.67	0.5	1.54e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7226229	1.000	rs2364333	chr17:20909210	A/G	cg21263980	chr17:20946333	USP22	0.65	4.88	0.45	4.33e-6	Blood trace element (Se levels);
THYM	cis	rs56309584	0.673	rs11651993	chr17:8115774	A/G	cg08322244	chr17:8066669	VAMP2	-0.53	-5.02	-0.46	2.41e-6	Initial pursuit acceleration;
THYM	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg17063962	chr7:91808500	NA	1.16	13.12	0.8	4.77e-23	Breast cancer;
THYM	cis	rs1198430	0.925	rs487859	chr1:23801101	T/C	cg19827787	chr1:23763612	ASAP3	0.78	5.09	0.46	1.8e-6	Total cholesterol levels;
THYM	cis	rs3760982	0.585	rs8109812	chr19:44298494	C/A	cg11993925	chr19:44307056	LYPD5	0.64	5.02	0.46	2.4e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs9595908	0.931	rs11839309	chr13:33047990	A/G	cg12383807	chr13:33924137	NA	-0.52	-4.48	-0.42	2.09e-5	Body mass index;
THYM	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg03433033	chr1:76189801	ACADM	-0.51	-5.31	-0.48	7.2e-7	Daytime sleep phenotypes;
THYM	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg23730037	chr7:158596552	ESYT2	-0.55	-5.54	-0.49	2.73e-7	Height;
THYM	cis	rs7731657	0.509	rs10213682	chr5:130181595	A/C	cg08523029	chr5:130500466	HINT1	0.64	4.66	0.43	1.01e-5	Fasting plasma glucose;
THYM	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg09260853	chr1:2094483	PRKCZ	-0.45	-4.8	-0.44	6.01e-6	Height;
THYM	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs901683	1.000	rs35506889	chr10:46084637	T/C	cg18240400	chr10:46168597	ANUBL1	0.73	4.73	0.44	7.89e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs13102973	0.933	rs7656595	chr4:135875693	G/A	cg14419869	chr4:135874104	NA	0.88	8.62	0.66	1.45e-13	Subjective well-being;
THYM	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg17178900	chr1:205818956	PM20D1	-0.66	-5.06	-0.46	2.04e-6	Menarche (age at onset);
THYM	cis	rs7777677	1.000	rs7796160	chr7:142371453	A/C	cg21785750	chr7:142428317	NA	0.67	5.88	0.52	6.07e-8	Alcoholic chronic pancreatitis;
THYM	cis	rs7901056	0.967	rs3006811	chr10:26724504	A/G	cg23318538	chr10:26883079	C10orf50	-0.34	-4.46	-0.42	2.21e-5	Lymphocyte counts;
THYM	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg13147721	chr7:65941812	NA	0.73	4.58	0.43	1.42e-5	Diabetic kidney disease;
THYM	cis	rs1971762	0.527	rs784562	chr12:53919700	A/C	cg16917193	chr12:54089295	NA	-0.76	-6.73	-0.57	1.28e-9	Height;
THYM	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg10150615	chr22:24372951	LOC391322	-1.01	-11.99	-0.78	1.01e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7027203	0.797	rs57882762	chr9:96580825	T/G	cg13679303	chr9:96623674	NA	-0.48	-4.93	-0.45	3.45e-6	DNA methylation (variation);
THYM	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg07362569	chr17:61921086	SMARCD2	-0.72	-6.4	-0.55	5.96e-9	Prudent dietary pattern;
THYM	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	6.35	0.55	7.48e-9	Platelet count;
THYM	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg22535103	chr8:58192502	C8orf71	-0.86	-4.82	-0.44	5.4e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs12594515	0.904	rs8032875	chr15:45998010	A/C	cg01629716	chr15:45996671	NA	0.53	5.27	0.48	8.47e-7	Waist circumference;Weight;
THYM	cis	rs4767364	1.000	rs2285810	chr12:112699540	T/C	cg10833066	chr12:111807467	FAM109A	0.45	4.98	0.46	2.79e-6	Oral cavity and pharyngeal cancer;
THYM	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg13319975	chr6:146136371	FBXO30	0.64	4.95	0.45	3.15e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10791097	0.967	rs10894268	chr11:130717153	C/T	cg22079354	chr11:130786696	SNX19	0.5	4.47	0.42	2.19e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs526231	0.543	rs34789	chr5:102460739	A/T	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.49e-6	Primary biliary cholangitis;
THYM	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg12560992	chr17:57184187	TRIM37	-0.92	-8.68	-0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg10803722	chr21:46713166	LOC642852	-0.42	-5.58	-0.5	2.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg13395646	chr4:1353034	KIAA1530	-0.58	-5.64	-0.5	1.78e-7	Longevity;
THYM	cis	rs11779988	0.545	rs208763	chr8:17806482	G/A	cg01800426	chr8:17659068	MTUS1	-0.74	-5.29	-0.48	7.7e-7	Breast cancer;
THYM	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg15744005	chr10:104629667	AS3MT	-0.82	-7.79	-0.62	8.37e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs921968	0.643	rs537520	chr2:219381852	A/G	cg02176678	chr2:219576539	TTLL4	0.7	7.14	0.59	1.88e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg14798641	chr3:49314920	USP4;C3orf62	-0.67	-4.51	-0.42	1.83e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg00129232	chr17:37814104	STARD3	0.76	5.25	0.47	9.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10779751	0.960	rs2076657	chr1:11318763	C/G	cg08854313	chr1:11322531	MTOR	1.04	10.45	0.73	1.85e-17	Body mass index;
THYM	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	6.56	0.56	2.87e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2120243	0.572	rs3816528	chr3:157127290	C/T	cg24825693	chr3:157122686	VEPH1	0.46	4.46	0.42	2.24e-5	Hepatocellular carcinoma in hepatitis B infection;
THYM	cis	rs951188	0.688	rs78035654	chr2:150397613	T/C	cg17961725	chr2:150454027	NA	-1.0	-5.05	-0.46	2.17e-6	Daytime sleep phenotypes;
THYM	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg18825531	chr11:62321136	NA	-0.46	-5.32	-0.48	6.94e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg15592062	chr6:167189543	RPS6KA2	0.59	6.16	0.53	1.73e-8	Crohn's disease;
THYM	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg13390004	chr1:15929781	NA	0.61	4.63	0.43	1.15e-5	Systolic blood pressure;
THYM	cis	rs4478037	0.558	rs80167648	chr3:33069317	A/G	cg19404215	chr3:33155277	CRTAP	1.23	5.61	0.5	1.99e-7	Major depressive disorder;
THYM	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg06713675	chr4:122721982	EXOSC9	-0.86	-9.81	-0.71	4.29e-16	Type 2 diabetes;
THYM	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg13609457	chr4:120235615	NA	0.6	5.34	0.48	6.23e-7	Corneal astigmatism;
THYM	cis	rs2688608	0.560	rs10128354	chr10:75470045	T/C	cg23231163	chr10:75533350	FUT11	-0.47	-6.62	-0.56	2.13e-9	Inflammatory bowel disease;
THYM	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg14582100	chr15:45693742	SPATA5L1	0.62	5.12	0.47	1.57e-6	Homoarginine levels;
THYM	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg23281280	chr6:28129359	ZNF389	0.65	5.02	0.46	2.45e-6	Parkinson's disease;
THYM	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.53	-0.66	2.32e-13	Mean corpuscular volume;
THYM	cis	rs2073300	0.609	rs6137950	chr20:23418722	T/A	cg12062639	chr20:23401060	NAPB	1.1	5.73	0.51	1.16e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs714027	0.605	rs4820830	chr22:30531091	C/T	cg27665648	chr22:30112403	NA	-0.52	-4.73	-0.44	7.79e-6	Lymphocyte counts;
THYM	cis	rs4363385	0.818	rs946095	chr1:153006470	T/C	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg14004847	chr7:1930337	MAD1L1	-0.68	-5.12	-0.46	1.61e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg24803719	chr17:45855879	NA	0.6	6.26	0.54	1.08e-8	IgG glycosylation;
THYM	cis	rs1129187	0.755	rs2296804	chr6:42931261	C/G	cg17345569	chr6:42928274	GNMT	-0.46	-4.5	-0.42	1.92e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg06618935	chr21:46677482	NA	-0.98	-8.04	-0.64	2.54e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4951011	0.786	rs2095758	chr1:203757811	C/T	cg24343524	chr1:203763352	ZC3H11A	0.69	6.07	0.53	2.67e-8	Breast cancer;
THYM	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg25427524	chr10:38739819	LOC399744	-0.58	-5.11	-0.46	1.67e-6	Extrinsic epigenetic age acceleration;
THYM	cis	rs13102973	0.646	rs7670551	chr4:135895130	C/T	cg14419869	chr4:135874104	NA	0.89	8.25	0.65	8.72e-13	Subjective well-being;
THYM	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg02527881	chr3:46936655	PTH1R	-0.63	-6.29	-0.54	9.52e-9	Colorectal cancer;
THYM	cis	rs56309584	0.715	rs77224069	chr17:8124268	G/C	cg08322244	chr17:8066669	VAMP2	-0.56	-5.31	-0.48	7.15e-7	Initial pursuit acceleration;
THYM	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg13393036	chr8:95962371	TP53INP1	-0.44	-4.48	-0.42	2.07e-5	Type 2 diabetes;
THYM	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg01097406	chr16:89675127	NA	-0.6	-5.04	-0.46	2.23e-6	Vitiligo;
THYM	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg18477163	chr1:228402036	OBSCN	0.65	6.47	0.55	4.24e-9	Diastolic blood pressure;
THYM	cis	rs7100689	0.646	rs7098045	chr10:82123856	G/C	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs8133932	0.861	rs79965202	chr21:47078774	T/A	cg20357416	chr21:47294739	PCBP3	0.81	4.57	0.42	1.45e-5	Schizophrenia;
THYM	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg21773646	chr17:80085082	CCDC57	-0.34	-4.91	-0.45	3.76e-6	Life satisfaction;
THYM	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg19346786	chr7:2764209	NA	-0.53	-4.47	-0.42	2.16e-5	Height;
THYM	cis	rs7626444	0.647	rs843537	chr3:196473403	C/A	cg12930392	chr3:196481615	PAK2	0.43	5.35	0.48	6.1e-7	Monocyte count;
THYM	cis	rs6722750	0.933	rs1370390	chr2:64410193	G/T	cg22352474	chr2:64371530	PELI1	0.62	4.67	0.43	9.84e-6	Neuroticism;
THYM	cis	rs4242434	0.699	rs878053	chr8:22483849	T/C	cg21658235	chr8:22456391	C8orf58	0.46	4.49	0.42	1.99e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs5758511	0.680	rs1107554	chr22:42667594	C/G	cg08431931	chr22:42394659	WBP2NL	0.66	4.76	0.44	6.82e-6	Birth weight;
THYM	cis	rs1278352	0.798	rs1674892	chr10:127775658	G/A	cg08295661	chr10:127769903	ADAM12	-0.54	-5.43	-0.49	4.35e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg15556689	chr8:8085844	FLJ10661	0.7	5.84	0.51	7.29e-8	Mood instability;
THYM	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg08754478	chr10:133766260	PPP2R2D	-0.92	-6.03	-0.53	3.11e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs865483	0.895	rs853229	chr17:35800919	A/G	cg06716730	chr17:35851459	DUSP14	0.43	7.3	0.6	8.71e-11	Monocyte count;
THYM	cis	rs6586111	0.935	rs4933463	chr10:82372866	A/C	cg03086067	chr10:82368399	SH2D4B	-0.52	-6.55	-0.56	2.89e-9	Capecitabine sensitivity;
THYM	cis	rs1728785	0.892	rs1617749	chr16:68580890	A/G	cg02972257	chr16:68554789	NA	-0.77	-4.9	-0.45	3.98e-6	Ulcerative colitis;
THYM	cis	rs714031	0.967	rs4821910	chr22:40067470	T/C	cg21377881	chr22:40064566	CACNA1I	-0.59	-5.32	-0.48	6.98e-7	Schizophrenia;
THYM	cis	rs666930	0.519	rs483180	chr1:120267505	C/G	cg19096424	chr1:120255104	PHGDH	-0.93	-7.79	-0.62	8.18e-12	Breast cancer;
THYM	cis	rs7119	0.679	rs34075648	chr15:77847802	G/C	cg27398640	chr15:77910606	LINGO1	-0.59	-5.84	-0.51	7.15e-8	Type 2 diabetes;
THYM	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.05	-5.39	-0.48	5.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg00310523	chr12:86230176	RASSF9	0.59	5.31	0.48	7.04e-7	Major depressive disorder;
THYM	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg04455712	chr21:45112962	RRP1B	0.5	4.62	0.43	1.21e-5	Mean corpuscular volume;
THYM	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs7487075	0.790	rs4074773	chr12:46919181	C/T	cg11331445	chr12:47219877	SLC38A4	-0.5	-4.69	-0.43	9.26e-6	Itch intensity from mosquito bite;
THYM	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03264133	chr6:25882463	NA	0.75	5.83	0.51	7.7e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11148252	0.716	rs2760772	chr13:52780373	C/G	cg05335186	chr13:53173507	NA	-0.46	-5.6	-0.5	2.07e-7	Lewy body disease;
THYM	cis	rs7681440	0.583	rs2737035	chr4:90777213	C/T	cg06632027	chr4:90757378	SNCA	-0.66	-5.3	-0.48	7.38e-7	Dementia with Lewy bodies;
THYM	trans	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs245880	0.740	rs245898	chr7:29194143	G/A	cg17163760	chr7:29186267	CPVL	-0.61	-4.93	-0.45	3.54e-6	Warfarin maintenance dose;
THYM	cis	rs9913156	0.707	rs72835625	chr17:4560274	G/A	cg19197139	chr17:4613644	ARRB2	0.83	5.0	0.46	2.63e-6	Lymphocyte counts;
THYM	cis	rs3008870	0.959	rs56707923	chr1:67388016	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.92	7.43	0.61	4.77e-11	Lymphocyte percentage of white cells;
THYM	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs7584330	0.518	rs7561919	chr2:238435241	A/G	cg14458575	chr2:238380390	NA	1.03	5.54	0.49	2.71e-7	Prostate cancer;
THYM	cis	rs6665290	0.901	rs2104860	chr1:227208637	G/C	cg10327440	chr1:227177885	CDC42BPA	-1.12	-14.94	-0.84	1.14e-26	Myeloid white cell count;
THYM	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.6	5.48	0.49	3.44e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7523273	0.517	rs2985106	chr1:207892033	T/G	cg22525895	chr1:207977042	MIR29B2	-0.53	-4.96	-0.45	3.06e-6	Schizophrenia;
THYM	cis	rs9682041	1.000	rs6444920	chr3:170090374	A/G	cg11886554	chr3:170076028	SKIL	1.23	4.71	0.44	8.47e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs6840360	0.642	rs2709831	chr4:152379651	G/A	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4481887	0.741	rs6682953	chr1:248535626	T/C	cg00666640	chr1:248458726	OR2T12	0.55	4.74	0.44	7.59e-6	Common traits (Other);
THYM	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7683537	0.692	rs56317358	chr4:185659470	G/A	cg27112742	chr4:185696749	ACSL1	-0.94	-4.89	-0.45	4.04e-6	Systemic lupus erythematosus;
THYM	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg23989207	chr17:80870107	TBCD	0.62	5.21	0.47	1.09e-6	Glycated hemoglobin levels;
THYM	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg00383909	chr3:49044727	WDR6	1.21	7.52	0.61	3.1e-11	Cognitive function;
THYM	cis	rs859767	0.603	rs842359	chr2:135345568	G/C	cg12500956	chr2:135428796	TMEM163	0.62	5.27	0.48	8.68e-7	Neuroticism;
THYM	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg24006582	chr15:45444508	DUOX1	-0.83	-7.16	-0.59	1.7e-10	Uric acid levels;
THYM	cis	rs7187994	0.848	rs3764333	chr16:84793261	A/G	cg07647771	chr16:84786436	USP10	-0.54	-4.89	-0.45	4.02e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs2836633	1.000	rs11088437	chr21:40053372	A/G	cg05519781	chr21:40033154	ERG	0.7	6.71	0.57	1.4e-9	Coronary artery disease;
THYM	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4731207	0.596	rs10954062	chr7:124636460	T/C	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs28595532	0.920	rs116331303	chr4:119754542	T/C	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs6812193	0.518	rs7662031	chr4:77205338	T/C	cg20311846	chr4:77356250	SHROOM3	-0.51	-4.54	-0.42	1.62e-5	Parkinson's disease;
THYM	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg05973401	chr12:123451056	ABCB9	0.65	4.74	0.44	7.42e-6	Platelet count;
THYM	cis	rs4595586	0.545	rs6580896	chr12:39372223	C/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs17268829	0.613	rs4729137	chr7:94154284	G/A	cg00347863	chr7:94220697	SGCE	0.57	4.83	0.44	5.18e-6	Breast cancer;
THYM	cis	rs6450176	0.564	rs31227	chr5:53326467	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.94	-8.32	-0.65	6.26e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg06521331	chr12:34319734	NA	-1.0	-9.86	-0.71	3.37e-16	Morning vs. evening chronotype;
THYM	cis	rs921968	0.643	rs2556385	chr2:219532905	G/A	cg01872077	chr2:219646372	CYP27A1	-0.58	-4.49	-0.42	2e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.79	5.5	0.49	3.25e-7	Gut microbiome composition (summer);
THYM	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg00645731	chr22:42541494	CYP2D7P1	-0.41	-4.67	-0.43	1.01e-5	Cognitive function;
THYM	cis	rs1451375	0.617	rs10277662	chr7:50594836	C/T	cg18232548	chr7:50535776	DDC	0.67	5.03	0.46	2.31e-6	Malaria;
THYM	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg06637938	chr14:75390232	RPS6KL1	0.62	6.07	0.53	2.59e-8	Caffeine consumption;
THYM	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9972944	0.902	rs9972881	chr17:63771334	A/G	cg07283582	chr17:63770753	CCDC46	0.62	5.05	0.46	2.13e-6	Total body bone mineral density;
THYM	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg24375607	chr4:120327624	NA	0.65	5.19	0.47	1.19e-6	Corneal astigmatism;
THYM	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg03806693	chr22:41940476	POLR3H	1.17	10.14	0.72	8.43e-17	Vitiligo;
THYM	cis	rs786425	0.530	rs7398641	chr12:124218102	C/A	cg15249119	chr12:124971054	NCOR2	0.53	4.98	0.46	2.8e-6	Pubertal anthropometrics;
THYM	cis	rs7487075	0.754	rs10880962	chr12:46773444	C/G	cg15584813	chr12:47219626	SLC38A4	0.51	5.0	0.46	2.62e-6	Itch intensity from mosquito bite;
THYM	cis	rs926938	0.608	rs360612	chr1:115394747	G/A	cg12756093	chr1:115239321	AMPD1	0.59	4.67	0.43	9.8e-6	Autism;
THYM	cis	rs9381107	0.872	rs6457977	chr6:9420099	G/A	cg27283345	chr6:10416531	TFAP2A	-0.47	-4.61	-0.43	1.27e-5	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs60843830	0.661	rs7588043	chr2:104979	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.57	4.63	0.43	1.18e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg09307838	chr4:120376055	NA	0.73	5.19	0.47	1.21e-6	Corneal astigmatism;
THYM	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg23602909	chr7:157956050	PTPRN2	-0.69	-6.15	-0.53	1.85e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs9790314	0.747	rs1599378	chr3:160874511	A/C	cg03342759	chr3:160939853	NMD3	-0.58	-4.49	-0.42	2.04e-5	Morning vs. evening chronotype;
THYM	cis	rs17401966	0.800	rs12725210	chr1:10416993	G/A	cg19773385	chr1:10388646	KIF1B	-0.57	-4.58	-0.43	1.4e-5	Hepatocellular carcinoma;
THYM	cis	rs9790314	1.000	rs6794601	chr3:160946769	C/T	cg03342759	chr3:160939853	NMD3	-0.76	-7.0	-0.58	3.68e-10	Morning vs. evening chronotype;
THYM	cis	rs4638749	0.677	rs7581595	chr2:108847885	A/G	cg06795125	chr2:108905320	SULT1C2	-0.35	-4.58	-0.43	1.41e-5	Blood pressure;
THYM	cis	rs2663905	0.664	rs2460855	chr15:81361729	G/T	cg09888468	chr15:81410853	NA	-0.71	-6.33	-0.54	7.88e-9	QT interval (drug interaction);
THYM	cis	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg07460842	chr6:66804631	NA	-0.95	-6.74	-0.57	1.2e-9	Exhaled nitric oxide output;
THYM	cis	rs9379945	1	rs9379945	chr6:26907831	T/C	cg12826209	chr6:26865740	GUSBL1	0.99	5.61	0.5	1.95e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1728785	1.000	rs1728784	chr16:68591156	T/A	cg02972257	chr16:68554789	NA	-0.77	-4.9	-0.45	3.98e-6	Ulcerative colitis;
THYM	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	10.73	0.74	4.66e-18	Chronic sinus infection;
THYM	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg09549813	chr16:4587862	C16orf5	0.58	6.02	0.53	3.21e-8	Schizophrenia;
THYM	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.63	-0.66	1.37e-13	Mean corpuscular volume;
THYM	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg15693483	chr7:1102177	C7orf50	0.47	5.89	0.52	5.86e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9807841	0.670	rs8102380	chr19:10801185	G/A	cg16900796	chr19:10755136	SLC44A2	0.33	5.08	0.46	1.88e-6	Inflammatory skin disease;
THYM	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg05552183	chr6:42928497	GNMT	0.68	5.51	0.49	3.08e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg00129232	chr17:37814104	STARD3	0.7	4.79	0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs13064411	0.696	rs9860549	chr3:113148368	G/A	cg18753928	chr3:113234510	CCDC52	-0.83	-7.29	-0.6	9.08e-11	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7582403	0.510	rs4972329	chr2:148879813	C/G	cg23727674	chr2:148602993	ACVR2A	0.63	4.61	0.43	1.24e-5	Neuroticism;
THYM	cis	rs60871478	0.645	rs111968669	chr7:856683	C/T	cg10248100	chr7:872053	UNC84A	0.48	4.62	0.43	1.22e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg14458575	chr2:238380390	NA	1.12	7.97	0.63	3.42e-12	Prostate cancer;
THYM	cis	rs6032067	0.636	rs6104092	chr20:43906730	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	0.63	6.69	0.57	1.52e-9	Blood protein levels;
THYM	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg18128536	chr17:47092178	IGF2BP1	-0.63	-8.85	-0.67	4.77e-14	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg12310025	chr6:25882481	NA	-0.69	-5.47	-0.49	3.69e-7	Blood metabolite levels;
THYM	trans	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg10856724	chr12:34555212	NA	-0.94	-8.13	-0.64	1.61e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	9.42	0.69	2.88e-15	Chronic sinus infection;
THYM	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg23187316	chr7:1099788	C7orf50	0.61	4.66	0.43	1.04e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg01097406	chr16:89675127	NA	-0.53	-4.73	-0.44	7.82e-6	Hemoglobin concentration;
THYM	cis	rs4907240	0.961	rs11682934	chr2:97237153	C/T	cg18419276	chr2:96971862	SNRNP200	-0.39	-4.57	-0.42	1.46e-5	Event-related brain oscillations;
THYM	cis	rs965469	0.895	rs6139124	chr20:3398144	C/T	cg25506879	chr20:3388711	C20orf194	-0.84	-5.13	-0.47	1.51e-6	IFN-related cytopenia;
THYM	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg08470875	chr2:26401718	FAM59B	0.74	4.59	0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs988913	0.958	rs9475078	chr6:54809589	T/A	cg18532076	chr6:54711417	FAM83B	0.51	5.03	0.46	2.29e-6	Menarche (age at onset);
THYM	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg20891558	chr2:74357851	NA	1.2	12.27	0.78	2.71e-21	Gestational age at birth (maternal effect);
THYM	cis	rs13256369	0.951	rs13259955	chr8:8565885	C/G	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs8014204	0.550	rs7152906	chr14:75125540	T/C	cg06637938	chr14:75390232	RPS6KL1	0.57	5.27	0.48	8.58e-7	Caffeine consumption;
THYM	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg06981504	chr1:1234844	ACAP3	0.54	4.94	0.45	3.32e-6	Body mass index;
THYM	cis	rs420259	0.516	rs717998	chr16:23560771	C/A	cg00143387	chr16:23521605	GGA2	-0.72	-5.18	-0.47	1.26e-6	Bipolar disorder;
THYM	cis	rs2625529	0.824	rs35112434	chr15:72448326	G/T	cg16672083	chr15:72433130	SENP8	-0.55	-4.91	-0.45	3.77e-6	Red blood cell count;
THYM	cis	rs2806561	0.734	rs2806564	chr1:23506685	T/C	cg19743168	chr1:23544995	NA	0.55	5.57	0.5	2.38e-7	Height;
THYM	cis	rs539096	0.540	rs3011219	chr1:44306120	A/G	cg12908607	chr1:44402522	ARTN	-0.5	-4.64	-0.43	1.1e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4242434	0.672	rs6993302	chr8:22527457	T/C	cg01710189	chr8:22454888	PDLIM2	0.45	4.57	0.42	1.44e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg11494091	chr17:61959527	GH2	1.07	17.09	0.87	9.87e-31	Prudent dietary pattern;
THYM	cis	rs12282928	0.959	rs871248	chr11:48284258	C/A	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg08000102	chr2:233561755	GIGYF2	-0.68	-5.97	-0.52	4.08e-8	Coronary artery disease;
THYM	cis	rs36051895	0.623	rs6476955	chr9:5256533	C/G	cg02405213	chr9:5042618	JAK2	-0.96	-10.09	-0.72	1.04e-16	Pediatric autoimmune diseases;
THYM	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2747539	0.841	rs6087534	chr20:32443974	C/T	cg06304546	chr20:32448765	NA	-0.8	-4.98	-0.45	2.87e-6	Dysphagia;
THYM	cis	rs4731207	0.698	rs10227821	chr7:124449587	A/G	cg05285228	chr7:124571219	POT1	0.66	5.24	0.47	9.66e-7	Cutaneous malignant melanoma;
THYM	cis	rs2663905	0.605	rs2683235	chr15:81398791	A/G	cg26546864	chr15:81426434	C15orf26	-0.79	-4.84	-0.45	4.92e-6	QT interval (drug interaction);
THYM	trans	rs75518195	0.543	rs2347819	chr4:64716605	G/A	cg14706739	chr8:21916355	EPB49	0.76	7.25	0.6	1.09e-10	Triptolide cytotoxicity;
THYM	cis	rs2229238	0.911	rs58348886	chr1:154446198	T/C	cg21262032	chr1:154437693	IL6R	-0.58	-4.77	-0.44	6.78e-6	Coronary heart disease;
THYM	cis	rs3850699	0.666	rs7905481	chr10:104476292	T/C	cg18761893	chr10:103892519	PPRC1	0.61	4.66	0.43	1.02e-5	Prostate cancer;
THYM	cis	rs7428	0.527	rs4459734	chr2:85547429	G/T	cg24342717	chr2:85555507	TGOLN2	-0.79	-6.32	-0.54	8.53e-9	Ear protrusion;
THYM	cis	rs59107033	0.511	rs62262394	chr3:123105428	C/T	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Lymphocyte counts;
THYM	cis	rs3008870	1.000	rs2815361	chr1:67494591	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.92	7.55	0.61	2.6e-11	Lymphocyte percentage of white cells;
THYM	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg06064525	chr11:970664	AP2A2	-0.36	-6.98	-0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	trans	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg20290983	chr6:43655470	MRPS18A	1.38	13.48	0.81	8.75e-24	IgG glycosylation;
THYM	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg14517863	chr17:44321492	NA	0.46	5.11	0.46	1.69e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12824058	0.831	rs11608406	chr12:130805866	G/C	cg26677194	chr12:130822605	PIWIL1	0.8	6.06	0.53	2.77e-8	Menopause (age at onset);
THYM	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg23173402	chr1:227635558	NA	0.83	6.63	0.56	1.99e-9	Major depressive disorder;
THYM	cis	rs6748734	0.600	rs10202620	chr2:241820912	G/C	cg07537917	chr2:241836409	C2orf54	-0.21	-4.62	-0.43	1.22e-5	Urinary metabolites;
THYM	cis	rs2011503	0.941	rs10422893	chr19:19372185	G/C	cg02887458	chr19:19495540	GATAD2A	-0.43	-5.21	-0.47	1.1e-6	Bipolar disorder;
THYM	cis	rs7833790	0.777	rs10958042	chr8:82678393	G/T	cg27398817	chr8:82754497	SNX16	-0.8	-6.37	-0.55	6.59e-9	Diastolic blood pressure;
THYM	cis	rs4731207	0.698	rs7794710	chr7:124561115	C/G	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs2816062	0.786	rs742486	chr1:18900829	G/A	cg18795169	chr1:18902165	NA	-0.97	-11.58	-0.77	7.31e-20	Urate levels in lean individuals;
THYM	cis	rs988913	1.000	rs1393776	chr6:54763018	A/C	cg19716238	chr6:54711378	FAM83B	-0.49	-5.07	-0.46	2e-6	Menarche (age at onset);
THYM	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs12043259	0.730	rs11801589	chr1:204807500	G/A	cg06877462	chr1:205807181	PM20D1	-0.94	-4.48	-0.42	2.07e-5	Addiction;
THYM	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg23758822	chr17:41437982	NA	1.16	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs11048434	0.736	rs11048264	chr12:9113581	C/T	cg13575925	chr12:9217583	LOC144571	-0.49	-4.45	-0.42	2.34e-5	Sjögren's syndrome;
THYM	cis	rs478304	0.593	rs9666878	chr11:65475816	A/C	cg17480646	chr11:65405466	SIPA1	0.97	8.99	0.68	2.44e-14	Acne (severe);
THYM	cis	rs2985684	0.802	rs8015368	chr14:50020510	G/A	cg02151108	chr14:50098012	C14orf104	-0.75	-6.32	-0.54	8.55e-9	Carotid intima media thickness;
THYM	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05901451	chr6:126070800	HEY2	-0.98	-10.01	-0.72	1.54e-16	Brugada syndrome;
THYM	cis	rs887829	0.588	rs7556676	chr2:234658250	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-6.16	-0.53	1.72e-8	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs1448094	0.556	rs61930632	chr12:86168937	A/C	cg00310523	chr12:86230176	RASSF9	0.56	4.94	0.45	3.29e-6	Major depressive disorder;
THYM	cis	rs9682041	1.000	rs6773095	chr3:170082181	A/G	cg11886554	chr3:170076028	SKIL	1.23	4.71	0.44	8.47e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs478304	0.934	rs570954	chr11:65498261	A/G	cg27068330	chr11:65405492	SIPA1	0.82	7.91	0.63	4.72e-12	Acne (severe);
THYM	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg18305652	chr10:134549665	INPP5A	0.85	7.58	0.61	2.28e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs289828	0.501	rs114566240	chr2:152153473	G/C	cg05960677	chr2:152117363	RBM43	0.71	6.61	0.56	2.24e-9	Blood protein levels;
THYM	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg26384229	chr12:38710491	ALG10B	-0.89	-9.05	-0.68	1.77e-14	Heart rate;
THYM	cis	rs1006064	0.819	rs9535634	chr13:51851184	G/A	cg16046673	chr13:51483748	RNASEH2B	-0.63	-4.53	-0.42	1.74e-5	Cerebrospinal fluid clusterin levels;
THYM	cis	rs4866334	1.000	rs75393523	chr5:18488595	T/G	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs7941600	0.708	rs4537761	chr11:9323353	T/C	cg21110646	chr11:9336536	TMEM41B	1.31	7.47	0.61	3.78e-11	Coronary artery disease;
THYM	cis	rs11030122	0.702	rs10835340	chr11:3960420	A/G	cg18678763	chr11:4115507	RRM1	0.44	5.73	0.51	1.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs28595532	0.764	rs116302502	chr4:119748848	T/A	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg17211192	chr8:82754475	SNX16	0.91	7.3	0.6	8.57e-11	Diastolic blood pressure;
THYM	cis	rs3820068	0.626	rs61103742	chr1:15909153	A/C	cg05660106	chr1:15850417	CASP9	0.92	7.26	0.6	1.08e-10	Systolic blood pressure;
THYM	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg06108461	chr20:60628389	TAF4	-0.81	-6.42	-0.55	5.36e-9	Body mass index;
THYM	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg27534772	chr1:16042836	PLEKHM2	0.56	6.31	0.54	8.77e-9	Systolic blood pressure;
THYM	cis	rs4435363	1.000	rs6509285	chr19:47065723	C/T	cg10017888	chr19:47105860	CALM3	-0.73	-4.88	-0.45	4.2e-6	Immature fraction of reticulocytes;P wave terminal force;
THYM	cis	rs7688540	0.771	rs7665727	chr4:277057	A/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.68	4.82	0.44	5.43e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg08847533	chr14:75593920	NEK9	1.01	11.32	0.76	2.63e-19	Height;
THYM	cis	rs7264396	0.561	rs2050930	chr20:34579397	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-4.52	-0.42	1.75e-5	Total cholesterol levels;
THYM	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.12	9.04	0.68	1.9e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.7	-5.77	-0.51	1e-7	Lung cancer in ever smokers;
THYM	cis	rs11166927	0.548	rs28366721	chr8:140827797	C/G	cg16909799	chr8:140841666	TRAPPC9	-0.79	-7.18	-0.59	1.56e-10	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg10047753	chr17:41438598	NA	1.07	9.29	0.69	5.32e-15	Menopause (age at onset);
THYM	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg07936489	chr17:37558343	FBXL20	-0.67	-4.82	-0.44	5.53e-6	Asthma;
THYM	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg17211192	chr8:82754475	SNX16	0.82	7.41	0.61	5.09e-11	Diastolic blood pressure;
THYM	cis	rs8044868	0.586	rs6499557	chr16:72082654	A/G	cg06353428	chr16:71660113	MARVELD3	0.6	4.56	0.42	1.54e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg20295408	chr7:1910781	MAD1L1	-0.64	-4.69	-0.43	9.17e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2456568	0.802	rs8181567	chr11:93637209	C/T	cg26875233	chr11:93583750	C11orf90	-0.53	-5.53	-0.49	2.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg13246856	chr1:44399776	ARTN	0.48	4.83	0.44	5.3e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs9563576	0.778	rs11148426	chr13:58693112	T/C	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.6	4.5	0.42	1.92e-5	Body mass index;
THYM	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg09904177	chr6:26538194	HMGN4	0.53	4.47	0.42	2.16e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2073300	0.609	rs6137939	chr20:23390206	C/T	cg12062639	chr20:23401060	NAPB	-1.2	-6.43	-0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs920590	0.642	rs6993525	chr8:19671104	A/G	cg03894339	chr8:19674705	INTS10	-0.57	-4.71	-0.44	8.35e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg02825527	chr7:2087843	MAD1L1	-0.7	-4.47	-0.42	2.17e-5	Bipolar disorder;
THYM	cis	rs490234	0.783	rs937481	chr9:128194443	C/G	cg14078157	chr9:128172775	NA	-0.71	-5.64	-0.5	1.74e-7	Mean arterial pressure;
THYM	cis	rs4363385	0.818	rs561143	chr1:153010734	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg15604051	chr3:44754201	ZNF502	-0.6	-5.32	-0.48	6.91e-7	Depressive symptoms;
THYM	cis	rs4866334	1.000	rs1554786	chr5:18404421	T/C	cg18608440	chr5:17519013	NA	1.19	4.97	0.45	2.93e-6	IgG glycosylation;
THYM	cis	rs968451	0.685	rs61616683	chr22:39755773	C/T	cg24268161	chr22:39747459	SYNGR1	-0.65	-5.17	-0.47	1.27e-6	Primary biliary cholangitis;
THYM	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	8.39	0.65	4.55e-13	Lung cancer in ever smokers;
THYM	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg02640540	chr1:67518911	SLC35D1	0.57	4.57	0.42	1.49e-5	Lymphocyte percentage of white cells;
THYM	cis	rs17407555	0.710	rs10489072	chr4:10273244	T/C	cg00071950	chr4:10020882	SLC2A9	0.51	4.83	0.44	5.23e-6	Schizophrenia (age at onset);
THYM	cis	rs941408	1.000	rs1640266	chr19:2787832	T/G	cg19693284	chr19:2783607	SGTA	0.7	5.42	0.49	4.5e-7	Total cholesterol levels;
THYM	cis	rs7113850	0.541	rs56679749	chr11:24235649	G/A	ch.11.24196551F	chr11:24239977	NA	0.87	4.66	0.43	1.04e-5	Bone fracture in osteoporosis;
THYM	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg16405210	chr4:1374714	KIAA1530	-1.03	-9.4	-0.69	3.14e-15	Longevity;
THYM	trans	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg25214090	chr10:38739885	LOC399744	0.97	8.28	0.65	7.61e-13	Corneal astigmatism;
THYM	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.36	0.48	5.89e-7	Height;
THYM	cis	rs7107174	0.892	rs10899482	chr11:78060081	A/C	cg02023728	chr11:77925099	USP35	0.6	5.77	0.51	9.96e-8	Testicular germ cell tumor;
THYM	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg08901578	chr4:187885870	NA	-0.64	-6.03	-0.53	3.1e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg25918947	chr17:41365094	TMEM106A	-0.57	-4.8	-0.44	5.92e-6	Menopause (age at onset);
THYM	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg13736514	chr6:26305472	NA	0.62	7.54	0.61	2.81e-11	Educational attainment;
THYM	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs11563648	0.535	rs6962137	chr7:127026342	G/A	cg08586737	chr7:127225949	GCC1	-0.33	-4.53	-0.42	1.71e-5	Resting heart rate;
THYM	cis	rs950880	0.744	rs3771156	chr2:103036677	C/T	cg03938978	chr2:103052716	IL18RAP	-0.54	-4.6	-0.43	1.29e-5	Serum protein levels (sST2);
THYM	cis	rs1387259	0.929	rs11168484	chr12:48633589	A/C	cg21466736	chr12:48725269	NA	-0.55	-5.02	-0.46	2.43e-6	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.21	0.47	1.1e-6	Electroencephalogram traits;
THYM	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs11997175	0.562	rs58955533	chr8:33829692	C/T	ch.8.33884649F	chr8:33765107	NA	0.75	5.39	0.48	5.09e-7	Body mass index;
THYM	cis	rs6876348	0.516	rs257908	chr5:128327149	A/G	cg02841155	chr5:128301328	SLC27A6	-0.51	-5.07	-0.46	1.92e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9646944	0.501	rs10176820	chr2:103054420	T/C	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	cis	rs10463554	0.927	rs34806	chr5:102428437	T/C	cg23492399	chr5:102201601	PAM	-0.67	-5.18	-0.47	1.26e-6	Parkinson's disease;
THYM	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg01616529	chr11:638424	DRD4	-0.74	-5.68	-0.5	1.45e-7	Systemic lupus erythematosus;
THYM	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg15549821	chr19:49342101	PLEKHA4	-0.82	-4.55	-0.42	1.56e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7208859	0.673	rs75142521	chr17:29240537	G/A	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-5.19	-0.47	1.17e-6	Joint mobility (Beighton score);
THYM	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	6.73	0.57	1.29e-9	Prudent dietary pattern;
THYM	cis	rs2219968	0.698	rs62508259	chr8:78982403	T/C	cg00738934	chr8:78996279	NA	0.79	7.06	0.59	2.72e-10	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10191773	0.535	rs12477879	chr2:112969865	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.86	-5.78	-0.51	9.5e-8	Yeast infection;
THYM	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg22947322	chr17:47091978	IGF2BP1	-0.63	-6.48	-0.55	3.99e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg18402987	chr7:1209562	NA	0.77	5.88	0.52	6.22e-8	Longevity;Endometriosis;
THYM	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg03806693	chr22:41940476	POLR3H	1.24	10.81	0.74	3.08e-18	Vitiligo;
THYM	cis	rs883565	0.525	rs9833327	chr3:39029631	A/G	cg15678707	chr3:39149194	GORASP1;TTC21A	0.65	4.91	0.45	3.76e-6	Handedness;
THYM	cis	rs4295623	0.556	rs10903343	chr8:11695872	T/C	cg12395012	chr8:11607386	GATA4	-0.57	-4.64	-0.43	1.12e-5	Morning vs. evening chronotype;
THYM	cis	rs7100689	0.516	rs10788546	chr10:82034854	T/C	cg01528321	chr10:82214614	TSPAN14	0.81	6.3	0.54	9.35e-9	Post bronchodilator FEV1;
THYM	trans	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17712092	chr4:129076599	LARP1B	0.89	7.34	0.6	7.33e-11	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs4907240	0.961	rs11691670	chr2:97238770	A/G	cg01950434	chr2:97203154	ARID5A	-0.55	-4.62	-0.43	1.21e-5	Event-related brain oscillations;
THYM	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg27034606	chr17:28928453	LRRC37B2	-0.64	-4.51	-0.42	1.86e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg12667521	chr19:29218732	NA	0.84	6.98	0.58	3.94e-10	Methadone dose in opioid dependence;
THYM	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg27490568	chr2:178487706	NA	0.6	5.32	0.48	6.97e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	4.46	0.42	2.23e-5	Rheumatoid arthritis;
THYM	cis	rs2639990	1.000	rs632157	chr18:72911548	G/A	cg02750262	chr18:72916776	ZADH2	1.4	6.54	0.56	3.1e-9	Vascular endothelial growth factor levels;
THYM	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg13736514	chr6:26305472	NA	-0.62	-7.42	-0.61	5.02e-11	Educational attainment;
THYM	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg12756686	chr19:29218302	NA	0.92	7.43	0.61	4.58e-11	Methadone dose in opioid dependence;
THYM	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.75	8.37	0.65	4.89e-13	Eosinophil percentage of white cells;
THYM	cis	rs17102423	0.594	rs1957948	chr14:65542629	A/G	cg11161011	chr14:65562177	MAX	0.7	5.74	0.51	1.12e-7	Obesity-related traits;
THYM	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.26	0.47	8.97e-7	Lung cancer in ever smokers;
THYM	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs12048904	0.595	rs2295280	chr1:101342497	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.89	6.48	0.55	3.99e-9	Multiple sclerosis;
THYM	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs995000	0.931	rs641540	chr1:62908538	A/G	cg06896770	chr1:63153194	DOCK7	0.91	7.48	0.61	3.73e-11	Triglyceride levels;
THYM	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-6.95	-0.58	4.6e-10	Chronic sinus infection;
THYM	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	4.68	0.43	9.49e-6	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9796	0.866	rs1678750	chr15:41410705	G/A	cg21153102	chr15:41252147	NA	0.69	6.24	0.54	1.19e-8	Menopause (age at onset);
THYM	cis	rs7264396	0.635	rs6058346	chr20:34481043	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.17	-0.47	1.27e-6	Total cholesterol levels;
THYM	cis	rs1055129	0.655	rs7216615	chr17:73833910	T/C	cg12407791	chr17:73824354	UNC13D	-0.44	-4.94	-0.45	3.4e-6	White matter hyperintensity burden;
THYM	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg26924012	chr15:45694286	SPATA5L1	1.13	11.02	0.75	1.11e-18	Homoarginine levels;
THYM	cis	rs919433	0.929	rs1366836	chr2:198172148	T/G	cg00792783	chr2:198669748	PLCL1	-0.69	-5.03	-0.46	2.28e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4713118	0.869	rs9295742	chr6:27702832	G/A	cg23161317	chr6:28129485	ZNF389	0.72	4.79	0.44	6.09e-6	Parkinson's disease;
THYM	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg23958373	chr8:599963	NA	0.9	4.54	0.42	1.63e-5	IgG glycosylation;
THYM	cis	rs28595532	0.920	rs56046676	chr4:119766733	A/G	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12135062	0.755	rs1553287	chr1:3101277	G/A	cg00254258	chr1:3105189	PRDM16	-0.64	-5.26	-0.47	8.85e-7	Migraine;
THYM	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg02493740	chr2:85810744	VAMP5	-0.64	-4.97	-0.45	2.97e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs7172809	0.897	rs74026933	chr15:77826969	A/C	cg10437265	chr15:77819839	NA	-0.53	-4.57	-0.42	1.48e-5	Glucose homeostasis traits;
THYM	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg25039879	chr17:56429692	SUPT4H1	0.75	4.48	0.42	2.07e-5	Cognitive test performance;
THYM	cis	rs6163	0.588	rs67506723	chr10:104509064	G/T	cg08772003	chr10:104629869	AS3MT	-0.52	-4.62	-0.43	1.2e-5	Waist circumference;Hip circumference;
THYM	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg02380750	chr20:61661411	NA	0.6	5.99	0.52	3.69e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs35883536	0.967	rs4908085	chr1:101087901	C/G	cg06223162	chr1:101003688	GPR88	0.61	4.49	0.42	1.98e-5	Monocyte count;
THYM	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg10802521	chr3:52805072	NEK4	-0.68	-5.79	-0.51	8.87e-8	Bipolar disorder;
THYM	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg06636001	chr8:8085503	FLJ10661	-0.74	-6.74	-0.57	1.24e-9	Mood instability;
THYM	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg08048268	chr3:133502702	NA	0.65	5.14	0.47	1.49e-6	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs13006833	0.739	rs291468	chr2:191188119	A/G	cg11845111	chr2:191398756	TMEM194B	0.66	4.66	0.43	1.05e-5	Urinary metabolites;
THYM	cis	rs11031096	0.678	rs17284356	chr11:4189232	G/C	cg18678763	chr11:4115507	RRM1	-0.42	-4.95	-0.45	3.17e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg21433313	chr16:3507492	NAT15	0.81	6.83	0.57	7.98e-10	Tuberculosis;
THYM	cis	rs9326248	0.520	rs1446105	chr11:116798544	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.66	5.38	0.48	5.37e-7	Blood protein levels;
THYM	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg14983838	chr19:29218262	NA	0.91	6.72	0.57	1.36e-9	Methadone dose in opioid dependence;
THYM	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg15242686	chr22:24348715	GSTTP1	0.53	4.89	0.45	4.1e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-6.08	-0.53	2.53e-8	Total body bone mineral density;
THYM	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.93	-0.45	3.52e-6	Monocyte count;
THYM	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg21487550	chr3:127056955	NA	-0.73	-5.13	-0.47	1.53e-6	Interleukin-10 levels;Interleukin-13 levels;
THYM	cis	rs73044404	0.561	rs12321922	chr12:2147403	G/A	cg01349368	chr12:3000903	TULP3	-0.54	-4.63	-0.43	1.17e-5	Schizophrenia;
THYM	cis	rs4866334	1.000	rs77552202	chr5:18489043	A/T	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs7072216	0.763	rs2274246	chr10:100175060	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg18230493	chr5:56204884	C5orf35	-0.64	-4.86	-0.45	4.56e-6	Initial pursuit acceleration;
THYM	cis	rs1823778	0.609	rs8085823	chr18:67646939	C/T	cg13164537	chr18:67624071	CD226	1.28	5.33	0.48	6.67e-7	Mean platelet volume;
THYM	trans	rs3845441	0.806	rs11809772	chr1:181625486	A/C	cg19968228	chr14:78432211	NA	1.05	7.17	0.59	1.58e-10	IgG glycosylation;
THYM	cis	rs4383453	0.539	rs12633849	chr3:123102862	T/C	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs10489202	1.000	rs66950781	chr1:168018779	C/A	cg24449463	chr1:168025552	DCAF6	-0.82	-6.46	-0.55	4.49e-9	Schizophrenia;
THYM	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg10360139	chr7:1886902	MAD1L1	-0.57	-4.96	-0.45	3.11e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2663905	0.706	rs7162859	chr15:81360038	C/T	cg25029264	chr15:81426347	C15orf26	0.74	4.56	0.42	1.53e-5	QT interval (drug interaction);
THYM	cis	rs6062788	0.617	rs6090221	chr20:61706107	G/A	cg17296441	chr20:62284078	STMN3	0.61	4.45	0.42	2.35e-5	Body mass index;
THYM	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg13319975	chr6:146136371	FBXO30	-0.64	-5.2	-0.47	1.16e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs870825	0.860	rs72703525	chr4:185605154	T/C	cg04058563	chr4:185651563	MLF1IP	1.0	7.42	0.61	4.93e-11	Blood protein levels;
THYM	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg22683308	chr4:1340831	KIAA1530	-0.59	-4.58	-0.43	1.41e-5	Longevity;
THYM	trans	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg25214090	chr10:38739885	LOC399744	0.94	8.27	0.65	7.91e-13	Corneal astigmatism;
THYM	cis	rs4589258	0.933	rs34264659	chr11:90410419	A/G	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs2229238	0.911	rs4379670	chr1:154439865	T/A	cg21262032	chr1:154437693	IL6R	0.6	5.11	0.46	1.63e-6	Coronary heart disease;
THYM	cis	rs9303401	0.632	rs9915267	chr17:57244907	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	4.56	0.42	1.55e-5	Cognitive test performance;
THYM	cis	rs6570726	0.764	rs76635693	chr6:145834070	T/C	cg23711669	chr6:146136114	FBXO30	0.95	9.55	0.7	1.52e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7553864	0.700	rs4656146	chr1:87612825	A/G	cg17420885	chr1:87600446	LOC339524	-0.95	-8.5	-0.66	2.64e-13	Smoking behavior;
THYM	cis	rs877282	0.891	rs34383514	chr10:800181	T/C	cg10556349	chr10:835070	NA	-0.75	-4.84	-0.44	5.05e-6	Uric acid levels;
THYM	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg14829155	chr15:31115871	NA	-0.56	-5.3	-0.48	7.54e-7	Huntington's disease progression;
THYM	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg00810483	chr4:3375144	RGS12	0.31	4.59	0.43	1.38e-5	Serum sulfate level;
THYM	cis	rs514406	0.597	rs1241980	chr1:53286013	A/G	cg08736216	chr1:53307985	ZYG11A	0.72	5.58	0.5	2.26e-7	Monocyte count;
THYM	cis	rs1912528	0.783	rs10000502	chr4:140864757	G/T	cg11128457	chr4:140864437	MAML3	0.5	5.36	0.48	5.72e-7	Educational attainment (years of education);
THYM	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.88	5.63	0.5	1.83e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg07636037	chr3:49044803	WDR6	0.95	9.94	0.71	2.2e-16	Parkinson's disease;
THYM	cis	rs420259	0.516	rs2369009	chr16:23555726	C/T	cg00143387	chr16:23521605	GGA2	-0.72	-5.18	-0.47	1.26e-6	Bipolar disorder;
THYM	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11644478	chr21:40555479	PSMG1	0.81	7.24	0.6	1.14e-10	Cognitive function;
THYM	cis	rs6809651	0.524	rs1356292	chr3:185824903	C/T	cg00760338	chr3:185826511	ETV5	0.89	7.0	0.58	3.69e-10	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
THYM	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg01579765	chr21:45077557	HSF2BP	-0.51	-7.84	-0.63	6.65e-12	Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2637266	1.000	rs7392737	chr10:78366059	C/T	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.65	0.5	1.64e-7	Tonsillectomy;
THYM	cis	rs2290159	0.800	rs73812836	chr3:12655149	T/G	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs4986811	1.000	rs5030172	chr11:32449274	G/C	cg13301003	chr11:32449254	WT1	0.69	5.16	0.47	1.37e-6	Rubella-specific interleukin-6 secretion;
THYM	cis	rs977987	0.806	rs7185640	chr16:75394399	A/G	cg03315344	chr16:75512273	CHST6	0.72	6.11	0.53	2.19e-8	Dupuytren's disease;
THYM	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg03806693	chr22:41940476	POLR3H	-1.04	-7.62	-0.62	1.86e-11	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.0	-8.15	-0.64	1.44e-12	Schizophrenia;
THYM	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg09877947	chr5:131593287	PDLIM4	0.58	4.82	0.44	5.38e-6	Blood metabolite levels;
THYM	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19346786	chr7:2764209	NA	-0.67	-5.61	-0.5	1.95e-7	Height;
THYM	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg23711669	chr6:146136114	FBXO30	0.97	10.56	0.73	1.03e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13102973	0.931	rs116199858	chr4:135847256	G/C	cg14419869	chr4:135874104	NA	0.9	8.46	0.66	3.24e-13	Subjective well-being;
THYM	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.75	-0.67	7.74e-14	Mean corpuscular volume;
THYM	cis	rs7833986	0.501	rs72653951	chr8:56961837	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	7.0	0.58	3.62e-10	Height;
THYM	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9527	0.614	rs2153774	chr10:104881035	T/C	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg16524733	chr11:117070046	TAGLN	0.43	4.76	0.44	6.82e-6	Blood protein levels;
THYM	cis	rs34638657	0.656	rs2911429	chr16:82203443	T/C	cg09894383	chr16:82067445	HSD17B2	-0.48	-4.99	-0.46	2.69e-6	Lung adenocarcinoma;
THYM	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg19626725	chr5:178986131	RUFY1	0.33	5.15	0.47	1.39e-6	Lung cancer;
THYM	cis	rs752010	0.631	rs1073197	chr1:42059822	C/T	cg06885757	chr1:42089581	HIVEP3	-0.77	-11.43	-0.76	1.51e-19	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9790314	0.521	rs13084746	chr3:161086038	G/A	cg04691961	chr3:161091175	C3orf57	-0.59	-4.87	-0.45	4.45e-6	Morning vs. evening chronotype;
THYM	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg22841779	chr14:105766346	BRF1	-0.46	-5.71	-0.51	1.27e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.14	-0.47	1.49e-6	Total cholesterol levels;
THYM	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg16680214	chr1:154839983	KCNN3	-0.48	-5.5	-0.49	3.25e-7	Prostate cancer;
THYM	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg10792982	chr14:105748885	BRF1	0.67	6.69	0.57	1.5e-9	Mean platelet volume;Platelet distribution width;
THYM	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg20503657	chr10:835505	NA	1.37	9.33	0.69	4.52e-15	Eosinophil percentage of granulocytes;
THYM	cis	rs67460515	0.563	rs4679672	chr3:160901020	G/A	cg03342759	chr3:160939853	NMD3	-0.68	-5.11	-0.46	1.64e-6	Parkinson's disease;
THYM	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.69	-4.62	-0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs7818345	0.640	rs13267801	chr8:19326834	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.46	4.58	0.43	1.41e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg13918804	chr1:2043761	PRKCZ	0.87	8.39	0.65	4.56e-13	Height;
THYM	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.63	0.5	1.81e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs995000	0.931	rs10889354	chr1:63129082	T/C	cg06896770	chr1:63153194	DOCK7	0.99	8.03	0.64	2.63e-12	Triglyceride levels;
THYM	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg09904177	chr6:26538194	HMGN4	0.53	4.47	0.42	2.16e-5	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg17264618	chr3:40429014	ENTPD3	0.51	4.91	0.45	3.71e-6	Renal cell carcinoma;
THYM	cis	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs17253792	0.822	rs76055105	chr14:56069127	A/G	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs7937840	0.559	rs2000957	chr11:61877744	A/G	cg05871569	chr11:61891931	INCENP	0.64	4.9	0.45	3.93e-6	Breast cancer;
THYM	cis	rs8100891	0.614	rs6510243	chr19:32833671	A/G	cg16662424	chr19:32837316	ZNF507	-0.45	-4.86	-0.45	4.55e-6	Neuroticism;
THYM	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.08	-7.26	-0.6	1.07e-10	Schizophrenia;
THYM	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg11901034	chr3:128598214	ACAD9	-0.7	-5.68	-0.5	1.47e-7	IgG glycosylation;
THYM	trans	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs7312774	0.618	rs2888892	chr12:107328071	C/T	cg16260113	chr12:107380972	MTERFD3	1.34	6.39	0.55	6.14e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs17300741	0.509	rs12362644	chr11:64312153	A/G	cg08822897	chr11:64258103	NA	-0.7	-5.78	-0.51	9.29e-8	Uric acid levels;
THYM	cis	rs2898681	0.650	rs6840325	chr4:53675549	A/G	cg21521518	chr4:53727714	RASL11B	0.47	5.33	0.48	6.68e-7	Optic nerve measurement (cup area);
THYM	cis	rs420259	0.516	rs2106454	chr16:23560398	G/A	cg00143387	chr16:23521605	GGA2	-0.72	-5.18	-0.47	1.26e-6	Bipolar disorder;
THYM	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg06028808	chr11:68637592	NA	0.72	7.56	0.61	2.54e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs994014	0.727	rs7656390	chr4:82284314	C/T	cg17825130	chr4:82283507	NA	0.51	4.57	0.42	1.48e-5	Height;
THYM	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03264133	chr6:25882463	NA	0.96	8.41	0.65	4.02e-13	Blood metabolite levels;
THYM	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg13395646	chr4:1353034	KIAA1530	-0.56	-5.35	-0.48	6.09e-7	Obesity-related traits;
THYM	cis	rs7107174	1.000	rs2512533	chr11:77968674	A/C	cg19901956	chr11:77921274	USP35	-0.76	-5.83	-0.51	7.53e-8	Testicular germ cell tumor;
THYM	cis	rs6840360	0.642	rs1443089	chr4:152450300	A/G	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.0	5.02	0.46	2.42e-6	Initial pursuit acceleration;
THYM	cis	rs9302635	0.678	rs8054585	chr16:72225314	G/A	cg23815491	chr16:72088622	HP	0.67	4.9	0.45	4.01e-6	Blood protein levels;
THYM	cis	rs728616	0.867	rs117139504	chr10:81734207	C/A	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6563943	0.857	rs1833965	chr16:83636801	A/C	cg01935413	chr16:83636749	CDH13	-0.56	-5.7	-0.51	1.32e-7	Height;
THYM	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg00129232	chr17:37814104	STARD3	0.7	4.79	0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg12573674	chr2:1569213	NA	-1.34	-8.9	-0.67	3.68e-14	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs986417	0.818	rs2351173	chr14:61008755	C/T	cg27398547	chr14:60952738	C14orf39	1.12	6.0	0.52	3.61e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs1448094	0.512	rs4540904	chr12:86235472	A/G	cg02569458	chr12:86230093	RASSF9	0.58	5.04	0.46	2.22e-6	Major depressive disorder;
THYM	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg25811766	chr13:21894605	NA	-0.76	-4.97	-0.45	2.96e-6	White matter hyperintensity burden;
THYM	cis	rs10089	0.953	rs1432615	chr5:127395371	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.97	6.65	0.56	1.82e-9	Ileal carcinoids;
THYM	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg17173187	chr15:85201210	NMB	0.55	5.41	0.49	4.78e-7	Schizophrenia;
THYM	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg05294307	chr14:35346193	BAZ1A	-0.96	-6.84	-0.57	7.79e-10	Psoriasis;
THYM	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg24955955	chr5:415729	AHRR	0.83	5.07	0.46	2e-6	Fat distribution (HIV);
THYM	cis	rs12681287	0.752	rs13277670	chr8:87259920	T/G	cg27223183	chr8:87520930	FAM82B	-0.66	-5.0	-0.46	2.66e-6	Caudate activity during reward;
THYM	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg21798802	chr22:38057573	PDXP	0.46	5.29	0.48	7.74e-7	Fat distribution (HIV);
THYM	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg26441486	chr22:50317300	CRELD2	0.43	6.57	0.56	2.71e-9	Schizophrenia;
THYM	cis	rs9399401	0.677	rs6925979	chr6:142651052	G/A	cg04461802	chr6:142623433	GPR126	0.79	7.32	0.6	7.87e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg05368731	chr17:41323189	NBR1	1.26	11.5	0.76	1.1e-19	Menopause (age at onset);
THYM	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg18876405	chr7:65276391	NA	-0.64	-5.54	-0.49	2.68e-7	Aortic root size;
THYM	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg04546413	chr19:29218101	NA	1.07	8.46	0.66	3.27e-13	Methadone dose in opioid dependence;
THYM	cis	rs7944735	0.517	rs7952205	chr11:48199227	A/G	cg24672777	chr11:48374446	OR4C45	-1.08	-6.32	-0.54	8.31e-9	Intraocular pressure;
THYM	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14240646	chr10:27532245	ACBD5	0.86	5.03	0.46	2.28e-6	Breast cancer;
THYM	cis	rs4790333	0.562	rs2447108	chr17:2257993	C/T	cg02569219	chr17:2266849	SGSM2	0.7	5.87	0.52	6.33e-8	Proinsulin levels;
THYM	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg07936489	chr17:37558343	FBXL20	0.84	5.76	0.51	1.03e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7840202	0.524	rs10955286	chr8:103419938	G/A	cg09990700	chr8:103251014	RRM2B	-1.04	-4.96	-0.45	3.14e-6	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);
THYM	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg20608306	chr11:116969690	SIK3	0.51	5.5	0.49	3.2e-7	Blood protein levels;
THYM	cis	rs3820068	0.608	rs9660255	chr1:16031891	T/G	cg05660106	chr1:15850417	CASP9	0.72	5.59	0.5	2.2e-7	Systolic blood pressure;
THYM	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg08736216	chr1:53307985	ZYG11A	-0.57	-5.21	-0.47	1.09e-6	Monocyte count;
THYM	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg09826364	chr7:158789723	NA	0.52	4.58	0.43	1.43e-5	Facial morphology (factor 20);
THYM	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg24675658	chr1:53192096	ZYG11B	0.71	6.38	0.55	6.49e-9	Monocyte count;
THYM	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.43	1.27e-5	Breast cancer;
THYM	cis	rs7924197	0.518	rs913872	chr10:133916286	T/C	cg15338884	chr10:133913937	NA	0.66	5.34	0.48	6.37e-7	Antipsychotic drug-induced QTc interval change in schizophrenia;
THYM	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg06970220	chr1:156163860	SLC25A44	0.74	5.67	0.5	1.53e-7	Testicular germ cell tumor;
THYM	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg06637938	chr14:75390232	RPS6KL1	0.64	6.47	0.55	4.35e-9	Caffeine consumption;
THYM	cis	rs924712	0.522	rs1503133	chr6:54709911	G/T	cg19716238	chr6:54711378	FAM83B	-0.48	-4.51	-0.42	1.83e-5	Breast cancer;
THYM	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11644478	chr21:40555479	PSMG1	0.81	7.04	0.59	3.04e-10	Cognitive function;
THYM	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg11764359	chr7:65958608	NA	0.78	6.31	0.54	8.88e-9	Aortic root size;
THYM	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg20283391	chr11:68216788	NA	-0.59	-4.47	-0.42	2.16e-5	Total body bone mineral density;
THYM	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg16342193	chr10:102329863	NA	-0.5	-5.13	-0.47	1.54e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs10779751	0.734	rs6701726	chr1:11126941	C/T	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg14664628	chr15:75095509	CSK	-1.14	-10.15	-0.72	8.04e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg11871910	chr12:69753446	YEATS4	1.01	9.87	0.71	3.09e-16	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg06009448	chr7:1102226	C7orf50	0.53	5.55	0.49	2.6e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7940866	0.774	rs2162059	chr11:130831224	C/T	cg12179176	chr11:130786555	SNX19	0.65	5.08	0.46	1.92e-6	Schizophrenia;
THYM	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg20476274	chr7:133979776	SLC35B4	0.67	4.47	0.42	2.19e-5	Mean platelet volume;
THYM	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg26384229	chr12:38710491	ALG10B	0.7	5.28	0.48	8.04e-7	Morning vs. evening chronotype;
THYM	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg19508488	chr2:152266495	RIF1	0.74	5.74	0.51	1.11e-7	Lung cancer;
THYM	cis	rs4866334	1.000	rs79246642	chr5:18442878	C/T	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg16325326	chr1:53192061	ZYG11B	0.79	7.27	0.6	1.02e-10	Monocyte count;
THYM	cis	rs11089937	0.667	rs10483108	chr22:22507057	C/G	cg21401457	chr22:22472743	NA	0.56	4.47	0.42	2.14e-5	Periodontitis (PAL4Q3);
THYM	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg11965913	chr1:205819406	PM20D1	0.95	10.53	0.73	1.25e-17	Menarche (age at onset);
THYM	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg14664628	chr15:75095509	CSK	-0.68	-5.13	-0.47	1.51e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg08257088	chr16:3726052	TRAP1	-0.66	-4.94	-0.45	3.32e-6	Tuberculosis;
THYM	cis	rs9816226	0.590	rs872602	chr3:185826028	A/G	cg00760338	chr3:185826511	ETV5	0.87	7.53	0.61	2.85e-11	Obesity;Body mass index;
THYM	cis	rs12738007	0.544	rs12045777	chr1:29429004	A/G	cg01925633	chr1:29338769	EPB41	-0.58	-4.84	-0.44	4.96e-6	Schizophrenia;
THYM	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg02018176	chr4:1364513	KIAA1530	0.77	7.2	0.59	1.38e-10	Longevity;
THYM	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg01475377	chr6:109611718	NA	0.56	4.76	0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg18811423	chr2:55921094	PNPT1	0.75	7.09	0.59	2.4e-10	Metabolic syndrome;
THYM	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg07424592	chr7:64974309	NA	-1.03	-5.38	-0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg03433033	chr1:76189801	ACADM	0.79	11.21	0.75	4.52e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22496380	chr5:211416	CCDC127	-1.3	-8.28	-0.65	7.84e-13	Breast cancer;
THYM	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.62	-4.78	-0.44	6.49e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg19825600	chr2:3704501	ALLC	-0.69	-5.8	-0.51	8.78e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg22981736	chr15:31284413	MTMR10	-0.55	-4.78	-0.44	6.46e-6	Huntington's disease progression;
THYM	cis	rs7084402	0.935	rs10763558	chr10:60341934	A/C	cg27040468	chr10:60456715	BICC1	0.54	4.5	0.42	1.9e-5	Refractive error;
THYM	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg10248100	chr7:872053	UNC84A	0.74	4.99	0.46	2.75e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg12560992	chr17:57184187	TRIM37	-0.88	-7.82	-0.63	7.14e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg18105134	chr13:113819100	PROZ	-0.99	-9.19	-0.69	8.83e-15	Platelet distribution width;
THYM	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg11764359	chr7:65958608	NA	-0.86	-7.24	-0.6	1.17e-10	Aortic root size;
THYM	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg06028808	chr11:68637592	NA	0.68	7.24	0.6	1.18e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	trans	rs17286411	0.800	rs60740701	chr16:71875515	G/A	cg00109465	chr12:54121359	CALCOCO1	-1.03	-6.92	-0.58	5.27e-10	Blood protein levels;
THYM	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs6032067	0.641	rs761500	chr20:43772272	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	0.74	6.61	0.56	2.18e-9	Blood protein levels;
THYM	cis	rs2011503	0.941	rs76944848	chr19:19417512	C/T	cg02887458	chr19:19495540	GATAD2A	-0.49	-5.38	-0.48	5.37e-7	Bipolar disorder;
THYM	cis	rs9905704	0.918	rs12942969	chr17:56892872	A/T	cg12560992	chr17:57184187	TRIM37	0.68	4.72	0.44	8.17e-6	Testicular germ cell tumor;
THYM	cis	rs728616	0.614	rs61858842	chr10:81715039	C/T	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg25811766	chr13:21894605	NA	0.76	5.27	0.48	8.52e-7	White matter hyperintensity burden;
THYM	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg05738196	chr6:26577821	NA	0.6	4.91	0.45	3.71e-6	Schizophrenia;
THYM	cis	rs2195525	0.539	rs3814757	chr11:119217935	G/T	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.44	4.92	0.45	3.64e-6	Urate levels;
THYM	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg04111992	chr7:158790115	NA	0.56	4.95	0.45	3.15e-6	Facial morphology (factor 20);
THYM	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11190604	0.767	rs10736150	chr10:102195341	G/A	cg16342193	chr10:102329863	NA	0.49	4.98	0.46	2.81e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9486719	0.656	rs6924957	chr6:96853579	G/T	cg18709589	chr6:96969512	KIAA0776	0.67	4.7	0.43	8.84e-6	Migraine;Coronary artery disease;
THYM	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg22920501	chr2:26401640	FAM59B	-1.05	-8.66	-0.66	1.18e-13	Gut microbiome composition (summer);
THYM	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg03929089	chr4:120376271	NA	-0.75	-7.09	-0.59	2.41e-10	Coronary artery disease;
THYM	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg17911788	chr17:44343683	NA	-0.77	-7.15	-0.59	1.79e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs728616	0.764	rs1885549	chr10:81712550	G/A	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs888405	0.541	rs697287	chr3:64211102	G/A	cg25818214	chr3:64211155	PRICKLE2	0.58	4.83	0.44	5.23e-6	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
THYM	cis	rs1357245	0.631	rs9867014	chr3:27097722	C/G	cg03895047	chr3:27114861	NA	0.49	4.58	0.43	1.42e-5	Breast cancer;
THYM	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg00277334	chr10:82204260	NA	-0.84	-10.12	-0.72	9.08e-17	Post bronchodilator FEV1;
THYM	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg18357526	chr6:26021779	HIST1H4A	0.7	5.36	0.48	5.83e-7	Urate levels;
THYM	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg14517863	chr17:44321492	NA	0.43	4.81	0.44	5.57e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.6	4.56	0.42	1.54e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9543976	0.623	rs7139740	chr13:76166942	C/T	cg01531495	chr13:76123901	UCHL3	0.66	4.8	0.44	5.85e-6	Diabetic retinopathy;
THYM	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg26031613	chr14:104095156	KLC1	1.06	9.5	0.7	1.94e-15	Body mass index;
THYM	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg01236616	chr12:121019343	POP5	-1.24	-10.39	-0.73	2.47e-17	Type 1 diabetes nephropathy;
THYM	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg27129171	chr3:47204927	SETD2	-0.8	-7.67	-0.62	1.51e-11	Colorectal cancer;
THYM	cis	rs2835345	0.563	rs73204248	chr21:37824709	A/G	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg26384229	chr12:38710491	ALG10B	0.95	7.55	0.61	2.7e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1823778	0.609	rs12608079	chr18:67651050	C/G	cg12929678	chr18:67624393	CD226	1.28	4.87	0.45	4.4e-6	Mean platelet volume;
THYM	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg02527881	chr3:46936655	PTH1R	-0.69	-7.11	-0.59	2.11e-10	Colorectal cancer;
THYM	cis	rs7107174	1.000	rs2510037	chr11:77966099	A/G	cg02023728	chr11:77925099	USP35	0.71	6.54	0.56	3.14e-9	Testicular germ cell tumor;
THYM	cis	rs600806	0.815	rs10858088	chr1:109923586	C/T	cg16988986	chr1:109941118	SORT1	-0.43	-4.56	-0.42	1.5e-5	Intelligence (multi-trait analysis);
THYM	trans	rs629535	0.814	rs477200	chr8:70059584	A/G	cg21567404	chr3:27674614	NA	1.04	10.44	0.73	1.95e-17	Dupuytren's disease;
THYM	cis	rs4481887	0.676	rs1544177	chr1:248524683	C/G	cg00666640	chr1:248458726	OR2T12	0.54	4.62	0.43	1.2e-5	Common traits (Other);
THYM	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg17747265	chr1:1875780	NA	-0.8	-9.21	-0.69	8.04e-15	Body mass index;
THYM	cis	rs28795989	0.896	rs13151529	chr4:7885983	G/A	cg12728606	chr4:7903970	AFAP1	0.44	4.64	0.43	1.09e-5	Intraocular pressure;
THYM	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg17644776	chr2:200775616	C2orf69	-0.77	-4.5	-0.42	1.95e-5	Schizophrenia;
THYM	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-13.43	-0.81	1.13e-23	Height;
THYM	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg23803603	chr1:2058230	PRKCZ	0.59	4.56	0.42	1.52e-5	Height;
THYM	cis	rs9972944	0.756	rs6504344	chr17:63756668	C/T	cg07283582	chr17:63770753	CCDC46	-0.62	-4.8	-0.44	5.79e-6	Total body bone mineral density;
THYM	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg27129171	chr3:47204927	SETD2	0.73	7.17	0.59	1.64e-10	Colorectal cancer;
THYM	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg15744005	chr10:104629667	AS3MT	-0.83	-7.67	-0.62	1.47e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7523273	0.925	rs12749612	chr1:208006749	A/G	cg22525895	chr1:207977042	MIR29B2	-0.83	-7.9	-0.63	4.95e-12	Schizophrenia;
THYM	cis	rs12620999	0.774	rs2875726	chr2:237954576	T/C	cg15976283	chr2:238042351	NA	-0.6	-4.69	-0.43	9.29e-6	Systemic lupus erythematosus;
THYM	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg10518543	chr12:38710700	ALG10B	-0.59	-4.67	-0.43	9.89e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6499255	0.762	rs12325186	chr16:69658807	A/T	cg00738113	chr16:70207722	CLEC18C	-0.47	-4.57	-0.42	1.47e-5	IgE levels;
THYM	cis	rs1061377	1.000	rs6812540	chr4:39116423	A/G	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs28595532	0.920	rs115744897	chr4:119749064	A/G	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs7216064	0.628	rs62084702	chr17:66043157	C/T	cg12091567	chr17:66097778	LOC651250	0.98	8.02	0.64	2.7e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs59698941	0.825	rs4705974	chr5:132198942	C/T	cg02081065	chr5:132209139	LEAP2	-0.79	-5.26	-0.47	8.96e-7	Apolipoprotein A-IV levels;
THYM	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.85	-5.69	-0.5	1.43e-7	Body mass index;
THYM	cis	rs7312774	0.618	rs726943	chr12:107331647	A/G	cg16260113	chr12:107380972	MTERFD3	1.32	6.3	0.54	9.04e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs6586111	0.967	rs6586110	chr10:82376492	G/A	cg03086067	chr10:82368399	SH2D4B	-0.56	-7.07	-0.59	2.65e-10	Capecitabine sensitivity;
THYM	cis	rs6570726	0.599	rs9403725	chr6:145897622	A/T	cg05347473	chr6:146136440	FBXO30	-0.83	-7.72	-0.62	1.19e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg06640241	chr16:89574553	SPG7	0.92	8.22	0.64	1.04e-12	Multiple myeloma (IgH translocation);
THYM	cis	rs1864585	0.806	rs12156345	chr8:10752537	T/G	cg11824826	chr8:9953022	MSRA	0.65	4.61	0.43	1.25e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
THYM	cis	rs67460515	0.563	rs11922957	chr3:160828865	A/C	cg12349858	chr3:160822545	B3GALNT1	0.57	4.53	0.42	1.71e-5	Parkinson's disease;
THYM	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs17604090	0.557	rs10279965	chr7:29717082	C/G	cg19413766	chr7:29689036	LOC646762	-0.82	-5.65	-0.5	1.68e-7	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs910187	0.538	rs2868849	chr20:45802273	G/A	cg27589058	chr20:45804311	EYA2	-0.72	-6.57	-0.56	2.7e-9	Migraine;
THYM	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg01751800	chr4:77820391	ANKRD56	0.54	4.46	0.42	2.23e-5	Emphysema distribution in smoking;
THYM	cis	rs74338693	0.778	rs6713513	chr2:166809564	C/G	cg23808213	chr2:166948291	NA	-0.49	-4.58	-0.43	1.41e-5	Schizophrenia;
THYM	cis	rs6840360	0.642	rs28666858	chr4:152416382	T/C	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.73	5.09	0.46	1.77e-6	Height;
THYM	cis	rs11690935	0.610	rs3770458	chr2:172651287	C/T	cg13550731	chr2:172543902	DYNC1I2	0.65	5.28	0.48	8.24e-7	Schizophrenia;
THYM	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg11245990	chr11:68621969	NA	0.58	7.59	0.61	2.21e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11186	0.556	rs55784828	chr2:189956130	T/C	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs8050907	0.744	rs7194436	chr16:4539832	G/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.3	5.2	0.47	1.16e-6	Obesity-related traits;
THYM	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg25072359	chr17:41440525	NA	0.64	4.48	0.42	2.05e-5	Menopause (age at onset);
THYM	cis	rs12579753	0.871	rs35801863	chr12:82238818	A/T	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.67	-0.43	1.01e-5	Resting heart rate;
THYM	cis	rs11626933	0.885	rs28517514	chr14:90788709	G/A	cg14092571	chr14:90743983	NA	-0.77	-8.1	-0.64	1.85e-12	Gut microbiota (bacterial taxa);
THYM	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22857025	chr5:266934	NA	-1.5	-9.71	-0.71	6.9e-16	Breast cancer;
THYM	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg11812906	chr14:75593930	NEK9	-0.79	-7.5	-0.61	3.33e-11	Height;
THYM	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg03474202	chr17:45855739	NA	-0.76	-6.63	-0.56	2.04e-9	IgG glycosylation;
THYM	cis	rs9902453	0.933	rs2054846	chr17:28507693	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-4.6	-0.43	1.33e-5	Coffee consumption (cups per day);
THYM	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg14416269	chr4:6271139	WFS1	0.58	6.0	0.52	3.51e-8	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	5.64	0.5	1.76e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7941600	0.643	rs1353729	chr11:9159818	A/G	cg21110646	chr11:9336536	TMEM41B	0.77	4.59	0.43	1.33e-5	Coronary artery disease;
THYM	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg01475377	chr6:109611718	NA	-0.57	-4.8	-0.44	5.78e-6	Reticulocyte fraction of red cells;
THYM	cis	rs6430585	0.583	rs3087343	chr2:136622543	T/G	cg07169764	chr2:136633963	MCM6	1.24	13.85	0.82	1.58e-24	Corneal structure;
THYM	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg10057126	chr4:77819792	ANKRD56	0.72	6.18	0.54	1.61e-8	Emphysema distribution in smoking;
THYM	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg27211696	chr2:191398769	TMEM194B	-0.64	-4.99	-0.46	2.76e-6	Diastolic blood pressure;
THYM	cis	rs9583531	0.628	rs9521914	chr13:111382231	C/A	cg24331049	chr13:111365604	ING1	0.65	5.46	0.49	3.84e-7	Coronary artery disease;
THYM	cis	rs73198271	0.737	rs565203	chr8:8632957	T/C	cg15556689	chr8:8085844	FLJ10661	-0.67	-4.71	-0.44	8.29e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs10789491	1.000	rs1890473	chr1:47149794	C/T	cg15501359	chr1:47185051	KIAA0494	1.12	8.14	0.64	1.49e-12	Response to hepatitis C treatment;
THYM	cis	rs9672608	0.687	rs5019044	chr15:78796282	T/A	cg18825076	chr15:78729989	IREB2	0.71	5.5	0.49	3.21e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg25566285	chr7:158114605	PTPRN2	0.86	9.76	0.71	5.33e-16	Calcium levels;
THYM	cis	rs174449	0.603	rs174460	chr11:61657110	C/T	cg01500311	chr11:61656094	FADS3	0.55	4.76	0.44	6.86e-6	Trans fatty acid levels;
THYM	cis	rs4243830	0.850	rs57203351	chr1:6601319	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	1.18	7.94	0.63	4.05e-12	Body mass index;
THYM	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17685	0.753	rs10476	chr7:75696420	C/T	cg01364799	chr7:75623366	TMEM120A	0.64	4.56	0.42	1.52e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs13266463	0.830	rs7014552	chr8:143410423	A/G	cg16886403	chr8:143471632	TSNARE1	0.66	5.11	0.46	1.64e-6	Schizophrenia;
THYM	cis	rs2806561	1.000	rs2806561	chr1:23504795	C/T	cg19743168	chr1:23544995	NA	-0.58	-6.13	-0.53	2e-8	Height;
THYM	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg16624210	chr5:671434	TPPP	0.59	5.99	0.52	3.77e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-8.34	-0.65	5.69e-13	Chronic sinus infection;
THYM	cis	rs293526	0.959	rs293508	chr6:83643071	C/T	cg23278060	chr6:83777448	DOPEY1	0.61	4.48	0.42	2.1e-5	Crohn's disease;
THYM	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg05855489	chr10:104503620	C10orf26	-0.59	-4.62	-0.43	1.23e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg20999797	chr1:1681921	NA	0.48	5.28	0.48	8e-7	Body mass index;
THYM	cis	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg07460842	chr6:66804631	NA	1.11	8.12	0.64	1.7e-12	Exhaled nitric oxide output;
THYM	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg18132916	chr6:79620363	NA	-0.6	-5.35	-0.48	6.07e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9527	0.590	rs10883829	chr10:104840635	T/C	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg22655196	chr4:3374909	RGS12	0.64	7.71	0.62	1.23e-11	Serum sulfate level;
THYM	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg27102117	chr16:15229624	NA	0.62	4.87	0.45	4.52e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
THYM	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.59	-5.07	-0.46	1.94e-6	IgG glycosylation;
THYM	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg03795903	chr2:30669940	LCLAT1	1.24	5.33	0.48	6.7e-7	Midgestational circulating levels of PBDEs (fetal genetic effect);
THYM	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg07636037	chr3:49044803	WDR6	1.0	10.78	0.74	3.59e-18	Parkinson's disease;
THYM	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9992101	0.870	rs4859682	chr4:77410318	C/A	cg20311846	chr4:77356250	SHROOM3	-0.61	-6.2	-0.54	1.48e-8	Creatinine levels;
THYM	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.45	-0.49	3.91e-7	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7640424	0.754	rs182736	chr3:107838891	C/A	cg09227934	chr3:107805635	CD47	0.54	4.57	0.42	1.45e-5	Body mass index;
THYM	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg04082016	chr2:20871401	NA	0.67	6.01	0.53	3.34e-8	Abdominal aortic aneurysm;
THYM	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs9972944	0.729	rs7222147	chr17:63774100	C/T	cg07283582	chr17:63770753	CCDC46	0.68	5.54	0.49	2.69e-7	Total body bone mineral density;
THYM	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg21385522	chr1:16154831	NA	0.67	4.67	0.43	9.97e-6	Systolic blood pressure;
THYM	cis	rs758324	0.687	rs301834	chr5:131501905	T/C	cg16205897	chr5:131564050	P4HA2	0.61	4.99	0.46	2.74e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs711830	0.931	rs717852	chr2:177031623	C/T	cg13092806	chr2:177043255	NA	0.59	4.49	0.42	1.99e-5	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs7512552	0.724	rs7002	chr1:150445819	A/G	cg15654264	chr1:150340011	RPRD2	0.43	4.94	0.45	3.34e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs919433	0.680	rs788022	chr2:198280586	T/C	cg00792783	chr2:198669748	PLCL1	0.82	5.67	0.5	1.54e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs17006441	0.932	rs35183823	chr3:69871377	G/A	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs2913737	0.563	rs2963296	chr5:175931770	C/T	cg27658698	chr5:175955578	RNF44	0.6	4.69	0.43	9.27e-6	Obesity-related traits;
THYM	cis	rs6430585	0.583	rs12472293	chr2:136648077	T/C	cg04750100	chr2:136595281	LCT	0.54	4.99	0.46	2.71e-6	Corneal structure;
THYM	cis	rs6430585	0.528	rs6743537	chr2:136702601	C/T	cg07169764	chr2:136633963	MCM6	1.15	11.58	0.77	7.28e-20	Corneal structure;
THYM	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg06634786	chr22:41940651	POLR3H	0.7	5.26	0.47	8.85e-7	Vitiligo;
THYM	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg05335186	chr13:53173507	NA	0.49	7.21	0.59	1.36e-10	Lewy body disease;
THYM	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg08017756	chr2:100939284	LONRF2	-0.69	-7.09	-0.59	2.35e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9905704	0.846	rs304268	chr17:56799907	T/C	cg12560992	chr17:57184187	TRIM37	0.64	4.46	0.42	2.28e-5	Testicular germ cell tumor;
THYM	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg27535305	chr1:53392650	SCP2	-0.42	-4.91	-0.45	3.86e-6	Monocyte count;
THYM	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg22079354	chr11:130786696	SNX19	0.51	4.52	0.42	1.78e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03517284	chr6:25882590	NA	1.04	9.45	0.7	2.53e-15	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs114420700	chr4:119751297	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs3781426	0.765	rs11245465	chr10:126706991	A/T	cg04494136	chr10:126703576	CTBP2	-0.47	-7.43	-0.61	4.72e-11	Height;
THYM	cis	rs9790314	0.846	rs899275	chr3:161042104	T/C	cg03342759	chr3:160939853	NMD3	-0.95	-9.47	-0.7	2.2e-15	Morning vs. evening chronotype;
THYM	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg03351412	chr1:154909251	PMVK	0.73	5.58	0.5	2.3e-7	Prostate cancer;
THYM	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg18252515	chr7:66147081	NA	-0.69	-5.46	-0.49	3.79e-7	Aortic root size;
THYM	cis	rs8018808	0.935	rs11159261	chr14:77921120	A/G	cg20045696	chr14:77926864	AHSA1	0.58	5.24	0.47	9.62e-7	Myeloid white cell count;
THYM	cis	rs728616	0.702	rs78734698	chr10:81756449	G/A	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.71	-0.44	8.33e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs270601	0.817	rs460089	chr5:131629772	C/G	cg18758796	chr5:131593413	PDLIM4	0.55	4.99	0.46	2.67e-6	Acylcarnitine levels;
THYM	cis	rs13177918	0.677	rs3857421	chr5:149823147	C/T	cg14059543	chr5:149831962	NA	0.97	7.61	0.62	1.96e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.87	-0.45	4.51e-6	Eye color traits;
THYM	cis	rs2963155	0.518	rs853176	chr5:142636456	A/G	cg17617527	chr5:142782415	NR3C1	-1.19	-6.6	-0.56	2.33e-9	Breast cancer;
THYM	cis	rs9468199	0.505	rs72848793	chr6:27999578	A/G	cg08851530	chr6:28072375	NA	1.2	4.72	0.44	7.99e-6	Parkinson's disease;
THYM	cis	rs4242434	0.927	rs13271626	chr8:22467760	C/G	cg11461670	chr8:22454935	PDLIM2	-0.36	-6.52	-0.56	3.3e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs3741151	0.656	rs56884659	chr11:73252947	C/G	cg17517138	chr11:73019481	ARHGEF17	0.9	4.71	0.43	8.56e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg07424592	chr7:64974309	NA	1.08	4.97	0.45	2.94e-6	Diabetic kidney disease;
THYM	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg06481639	chr22:41940642	POLR3H	-0.7	-5.36	-0.48	5.8e-7	Neuroticism;
THYM	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg07936489	chr17:37558343	FBXL20	0.87	6.13	0.53	1.97e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4363385	0.655	rs11205163	chr1:152983677	C/T	cg13444842	chr1:152974279	SPRR3	-0.61	-4.98	-0.46	2.78e-6	Inflammatory skin disease;
THYM	cis	rs2806561	0.828	rs604030	chr1:23518227	T/C	cg19743168	chr1:23544995	NA	0.55	5.64	0.5	1.77e-7	Height;
THYM	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg13683864	chr3:40499215	RPL14	-1.07	-11.84	-0.77	2.14e-20	Renal cell carcinoma;
THYM	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg06981504	chr1:1234844	ACAP3	0.53	4.8	0.44	5.84e-6	Body mass index;
THYM	cis	rs12200560	0.505	rs1988040	chr6:97076271	G/A	cg06623918	chr6:96969491	KIAA0776	0.78	6.01	0.52	3.39e-8	Coronary heart disease;
THYM	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	1.0	9.47	0.7	2.25e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2039659	0.711	rs1753768	chr13:86237717	T/G	cg25308322	chr13:86268291	NA	0.63	5.21	0.47	1.11e-6	Blood osmolality (transformed sodium);
THYM	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg05335186	chr13:53173507	NA	-0.46	-5.86	-0.52	6.6e-8	Lewy body disease;
THYM	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg00898013	chr13:113819073	PROZ	0.85	8.56	0.66	2e-13	Platelet distribution width;
THYM	cis	rs988913	1.000	rs9382407	chr6:54836638	T/C	cg04690482	chr6:54711388	FAM83B	0.46	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	cis	rs8044868	0.586	rs7200854	chr16:72083318	G/A	cg16558253	chr16:72132732	DHX38	-0.55	-4.67	-0.43	1e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.72	-0.44	7.99e-6	Resting heart rate;
THYM	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg06092702	chr1:163392909	NA	0.61	5.35	0.48	5.97e-7	Motion sickness;
THYM	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg11663144	chr21:46675770	NA	0.71	10.14	0.72	8.48e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4466137	0.794	rs975595	chr5:83010095	G/A	cg16102102	chr5:83017553	HAPLN1	-0.96	-8.31	-0.65	6.61e-13	Prostate cancer;
THYM	cis	rs17006441	0.866	rs7626718	chr3:69845196	A/G	cg18496212	chr3:69797108	MITF	0.7	7.17	0.59	1.64e-10	Hemoglobin concentration;
THYM	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs56309584	0.673	rs11078735	chr17:8116861	C/A	cg11257113	chr17:8062204	NA	-0.64	-4.76	-0.44	6.94e-6	Initial pursuit acceleration;
THYM	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35883536	0.588	rs955338	chr1:101108794	G/C	cg09408571	chr1:101003634	GPR88	0.4	4.9	0.45	3.88e-6	Monocyte count;
THYM	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg26384229	chr12:38710491	ALG10B	-0.73	-6.01	-0.52	3.42e-8	Morning vs. evening chronotype;
THYM	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg26967526	chr14:35346199	BAZ1A	-0.8	-5.27	-0.48	8.47e-7	Psoriasis;
THYM	cis	rs79149102	0.579	rs6495138	chr15:75304692	A/G	cg17294928	chr15:75287854	SCAMP5	-1.06	-5.68	-0.5	1.49e-7	Lung cancer;
THYM	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg25358565	chr5:93447407	FAM172A	-0.97	-7.06	-0.59	2.76e-10	Diabetic retinopathy;
THYM	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg09165964	chr15:75287851	SCAMP5	-1.0	-9.02	-0.68	2.08e-14	Blood trace element (Zn levels);
THYM	cis	rs3011225	0.710	rs3011224	chr1:44318483	C/T	cg15962314	chr1:44399869	ARTN	0.53	5.39	0.48	5.01e-7	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4530754	0.619	rs6595458	chr5:122881000	A/G	cg20708411	chr5:122847581	CSNK1G3	0.4	5.01	0.46	2.47e-6	LDL cholesterol;Total cholesterol levels;Cholesterol, total;LDL cholesterol levels;
THYM	cis	rs7084402	0.967	rs1620404	chr10:60327830	G/A	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs9361491	0.608	rs4141594	chr6:79461195	A/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs425535	0.757	rs352027	chr4:74793922	A/C	cg07868155	chr4:74864709	CXCL5	-0.68	-4.6	-0.43	1.31e-5	Blood protein levels;
THYM	cis	rs67981189	0.758	rs221921	chr14:71586128	T/C	cg15910301	chr14:71632612	NA	-0.51	-4.46	-0.42	2.28e-5	Schizophrenia;
THYM	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg16346588	chr10:242978	ZMYND11	-0.58	-4.46	-0.42	2.23e-5	Psychosis in Alzheimer's disease;
THYM	cis	rs11563648	0.553	rs4731355	chr7:127021472	A/G	cg23081781	chr7:127225937	GCC1	-0.34	-4.64	-0.43	1.14e-5	Resting heart rate;
THYM	cis	rs758324	0.687	rs185616	chr5:131543766	G/A	cg16205897	chr5:131564050	P4HA2	0.56	4.62	0.43	1.18e-5	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs6754311	0.551	rs313526	chr2:136445526	C/T	cg20242066	chr2:136595261	LCT	0.55	6.04	0.53	3.05e-8	Mosquito bite size;
THYM	cis	rs9866391	0.771	rs1863868	chr3:141087623	T/C	cg13411656	chr3:141121016	ZBTB38	-0.36	-5.06	-0.46	2.05e-6	Myopia;
THYM	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg03676636	chr4:99064102	C4orf37	0.46	5.02	0.46	2.41e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs858239	0.539	rs10254544	chr7:23220235	T/C	cg09755872	chr7:23245557	NA	-0.51	-4.75	-0.44	7.31e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7246967	0.673	rs34676724	chr19:22918473	A/C	cg05241461	chr19:22816980	ZNF492	0.59	4.61	0.43	1.26e-5	Bronchopulmonary dysplasia;
THYM	cis	rs9790314	0.765	rs4856768	chr3:161004392	G/A	cg03342759	chr3:160939853	NMD3	-0.93	-8.74	-0.67	8.11e-14	Morning vs. evening chronotype;
THYM	cis	rs728616	0.867	rs17883671	chr10:81695193	C/T	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs3087591	0.960	rs2952979	chr17:29474298	T/A	cg24425628	chr17:29625626	OMG;NF1	0.64	5.54	0.49	2.68e-7	Hip circumference;
THYM	cis	rs7084402	0.967	rs1658427	chr10:60331504	G/A	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs1957429	0.614	rs73279823	chr14:65351315	A/G	cg23373153	chr14:65346875	NA	-1.29	-5.55	-0.49	2.56e-7	Pediatric areal bone mineral density (radius);
THYM	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg07936489	chr17:37558343	FBXL20	-0.7	-4.9	-0.45	3.97e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs76662990	1.000	rs10079756	chr5:73797377	A/C	cg01264639	chr5:73839484	NA	1.3	4.97	0.45	3.01e-6	Residual cognition;
THYM	cis	rs9788721	0.836	rs17483929	chr15:78742376	C/T	cg18825076	chr15:78729989	IREB2	-0.69	-6.42	-0.55	5.41e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg18402987	chr7:1209562	NA	1.03	6.06	0.53	2.77e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	5.09	0.46	1.82e-6	Motion sickness;
THYM	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg05043794	chr9:111880884	C9orf5	-0.44	-6.39	-0.55	6.03e-9	Menarche (age at onset);
THYM	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg13147721	chr7:65941812	NA	1.1	7.08	0.59	2.45e-10	Diabetic kidney disease;
THYM	cis	rs56104184	0.830	rs73061614	chr19:49343289	T/C	cg21252483	chr19:49399788	TULP2	-0.7	-4.86	-0.45	4.55e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs922692	0.744	rs12903203	chr15:79084933	T/C	cg15571903	chr15:79123663	NA	-0.52	-4.92	-0.45	3.62e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7926906	1.000	rs1404532	chr11:90538258	A/T	cg26138821	chr11:89956704	CHORDC1	0.55	4.97	0.45	2.94e-6	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-4.85	-0.45	4.85e-6	Total body bone mineral density;
THYM	cis	rs7187994	0.848	rs7498187	chr16:84770570	G/A	cg07647771	chr16:84786436	USP10	-0.57	-4.73	-0.44	7.95e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg26924012	chr15:45694286	SPATA5L1	0.57	4.51	0.42	1.85e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs35883536	0.626	rs34752753	chr1:101045193	T/G	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs11249608	0.548	rs10479520	chr5:178451447	C/A	cg01312482	chr5:178451176	ZNF879	-0.77	-6.31	-0.54	9e-9	Pubertal anthropometrics;
THYM	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg24675658	chr1:53192096	ZYG11B	-0.67	-5.48	-0.49	3.51e-7	Monocyte count;
THYM	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg00339695	chr16:24857497	SLC5A11	0.68	6.43	0.55	5.15e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9902453	0.765	rs2467334	chr17:28135508	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.54	-0.56	3.12e-9	Coffee consumption (cups per day);
THYM	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05901451	chr6:126070800	HEY2	0.92	9.26	0.69	6.26e-15	Brugada syndrome;
THYM	cis	rs829880	1.000	rs829880	chr12:98845331	G/T	cg25150519	chr12:98850993	NA	0.51	4.45	0.42	2.34e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12472274	0.646	rs35468889	chr2:239090959	G/A	cg17459225	chr2:239074497	NA	0.74	5.14	0.47	1.44e-6	Phospholipid levels (plasma);
THYM	cis	rs4917300	0.626	rs902821	chr8:143100074	G/A	cg26003909	chr8:143102224	NA	-0.32	-4.61	-0.43	1.26e-5	Amyotrophic lateral sclerosis;
THYM	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg23482746	chr15:76478102	C15orf27	-0.38	-4.55	-0.42	1.61e-5	Blood metabolite levels;
THYM	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.8	-6.38	-0.55	6.32e-9	Chronic sinus infection;
THYM	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs12579753	0.871	rs12822050	chr12:82183041	C/T	cg21231944	chr12:82153410	PPFIA2	-0.68	-5.12	-0.46	1.6e-6	Resting heart rate;
THYM	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg10589385	chr1:150898437	SETDB1	0.57	4.55	0.42	1.56e-5	Tonsillectomy;
THYM	cis	rs4638749	0.677	rs13398290	chr2:108833853	G/T	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs4523957	0.786	rs59428454	chr17:2114063	T/A	cg16513277	chr17:2031491	SMG6	-0.79	-7.76	-0.62	9.62e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg08999081	chr20:33150536	PIGU	0.77	6.95	0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg23711669	chr6:146136114	FBXO30	-0.94	-9.37	-0.69	3.75e-15	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs9532580	0.620	rs2755210	chr13:41141282	C/G	cg21288729	chr13:41239152	FOXO1	0.67	4.7	0.43	8.74e-6	Mean corpuscular hemoglobin;
THYM	cis	rs17253792	0.545	rs35294669	chr14:56017438	T/A	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs7677751	0.806	rs4864857	chr4:55089814	T/C	cg17187183	chr4:55093834	PDGFRA	0.72	5.59	0.5	2.19e-7	Corneal astigmatism;
THYM	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.87	-6.51	-0.56	3.61e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6546537	0.869	rs35024605	chr2:69820332	A/G	cg10773587	chr2:69614142	GFPT1	-0.53	-4.53	-0.42	1.72e-5	Serum thyroid-stimulating hormone levels;
THYM	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg10377582	chr12:51612794	POU6F1	-0.66	-4.75	-0.44	7.09e-6	Cisplatin-induced ototoxicity;
THYM	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.24	-4.55	-0.42	1.58e-5	Obesity-related traits;
THYM	cis	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs8031584	1.000	rs890159	chr15:31291634	G/A	cg14829155	chr15:31115871	NA	-0.55	-4.7	-0.43	8.7e-6	Huntington's disease progression;
THYM	cis	rs4343996	0.967	rs7803993	chr7:3353057	G/A	cg21248987	chr7:3385318	SDK1	-0.41	-4.95	-0.45	3.17e-6	Motion sickness;
THYM	cis	rs9796	0.870	rs2306083	chr15:41347658	C/T	cg21153102	chr15:41252147	NA	0.72	6.54	0.56	3.08e-9	Menopause (age at onset);
THYM	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg02070205	chr10:30722105	MAP3K8	0.62	5.6	0.5	2.06e-7	Inflammatory bowel disease;
THYM	cis	rs4417704	0.551	rs10179839	chr2:241898947	G/T	cg15164180	chr2:241846931	NA	-0.37	-4.58	-0.43	1.41e-5	Joint mobility (Beighton score);
THYM	cis	rs4786125	0.804	rs6500850	chr16:6896389	A/T	cg03623568	chr16:6915990	A2BP1	-0.72	-5.81	-0.51	8.38e-8	Heart rate variability traits (SDNN);
THYM	cis	rs958025	1	rs958025	chr15:78759348	C/T	cg18825076	chr15:78729989	IREB2	0.69	5.51	0.49	3.05e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg06850241	chr22:41845214	NA	0.53	4.56	0.42	1.54e-5	Vitiligo;
THYM	cis	rs9905704	0.647	rs12943705	chr17:57097047	T/C	cg12560992	chr17:57184187	TRIM37	-0.68	-5.32	-0.48	6.95e-7	Testicular germ cell tumor;
THYM	cis	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg21775007	chr8:11205619	TDH	0.65	5.29	0.48	7.91e-7	Retinal vascular caliber;
THYM	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg13695892	chr22:41940480	POLR3H	-1.07	-8.8	-0.67	6.05e-14	Vitiligo;
THYM	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg09990169	chr2:241835740	C2orf54	0.39	6.27	0.54	1.07e-8	Urinary metabolites;
THYM	cis	rs684232	0.644	rs2543781	chr17:602469	C/G	cg15660573	chr17:549704	VPS53	-0.87	-8.15	-0.64	1.45e-12	Prostate cancer;
THYM	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg23281280	chr6:28129359	ZNF389	0.64	5.1	0.46	1.74e-6	Depression;
THYM	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg14581129	chr12:53358946	NA	-1.06	-7.65	-0.62	1.65e-11	Cancer (pleiotropy);
THYM	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg24675658	chr1:53192096	ZYG11B	-0.77	-6.93	-0.58	5.04e-10	Monocyte count;
THYM	cis	rs950880	0.710	rs17027166	chr2:103055420	C/T	cg03938978	chr2:103052716	IL18RAP	-0.6	-5.01	-0.46	2.53e-6	Serum protein levels (sST2);
THYM	cis	rs1018836	0.828	rs10086462	chr8:91558089	A/G	cg16814680	chr8:91681699	NA	-0.9	-7.85	-0.63	6.31e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs1395	0.925	rs2580754	chr2:27398196	A/T	cg23587288	chr2:27483067	SLC30A3	-0.57	-5.06	-0.46	2.01e-6	Blood metabolite levels;
THYM	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg01324343	chr3:183735012	ABCC5	-0.64	-7.26	-0.6	1.05e-10	Anterior chamber depth;
THYM	cis	rs899997	0.862	rs57260218	chr15:78973772	C/T	cg00639195	chr15:79103007	ADAMTS7	0.66	4.45	0.42	2.33e-5	Coronary artery disease or large artery stroke;
THYM	cis	rs9814567	0.727	rs4435681	chr3:134344435	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.77	-7.5	-0.61	3.34e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs1847202	0.859	rs4501056	chr3:72948908	A/T	cg25664220	chr3:72788482	NA	-0.64	-4.88	-0.45	4.2e-6	Motion sickness;
THYM	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs986417	0.748	rs10136486	chr14:60946111	C/T	cg27398547	chr14:60952738	C14orf39	1.13	6.34	0.55	7.62e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs7267979	0.934	rs4815423	chr20:25387521	A/G	cg08601574	chr20:25228251	PYGB	-0.59	-4.82	-0.44	5.48e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4242434	0.819	rs55776566	chr8:22469492	T/C	cg03733263	chr8:22462867	KIAA1967	0.97	10.82	0.74	2.99e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.64	-0.74	7.23e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.39	-0.48	5.04e-7	Menopause (age at onset);
THYM	cis	rs807029	0.533	rs2863095	chr10:102746503	C/T	cg14905631	chr10:102746534	C10orf2;MRPL43	0.36	4.93	0.45	3.49e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.85	-0.51	6.97e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs17854409	1.000	rs17854409	chr20:61491494	T/C	cg06598544	chr20:61472147	COL9A3	-1.1	-7.56	-0.61	2.56e-11	Obesity-related traits;
THYM	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg12311346	chr5:56204834	C5orf35	-0.83	-6.15	-0.53	1.8e-8	Initial pursuit acceleration;
THYM	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-5.96	-0.52	4.22e-8	Bipolar disorder;
THYM	cis	rs8016982	0.633	rs8015423	chr14:81719357	C/T	cg01989461	chr14:81687754	GTF2A1	0.81	7.25	0.6	1.08e-10	Schizophrenia;
THYM	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs859767	0.774	rs6758396	chr2:135416857	T/C	cg12500956	chr2:135428796	TMEM163	-0.5	-5.18	-0.47	1.22e-6	Neuroticism;
THYM	cis	rs3768617	0.510	rs10752902	chr1:183090265	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg07870213	chr5:140052090	DND1	-0.69	-8.1	-0.64	1.86e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs807029	0.577	rs7902510	chr10:102757934	C/T	cg14905631	chr10:102746534	C10orf2;MRPL43	0.37	4.96	0.45	3.08e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg22133161	chr19:49891603	CCDC155	0.67	4.78	0.44	6.35e-6	Multiple sclerosis;
THYM	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg18512352	chr11:47633146	NA	-0.51	-6.21	-0.54	1.42e-8	Subjective well-being;
THYM	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg00012203	chr2:219082015	ARPC2	-0.64	-5.17	-0.47	1.3e-6	Colorectal cancer;
THYM	cis	rs7258015	1.000	rs10408916	chr19:10447770	T/G	cg01466491	chr19:10523363	NA	0.68	5.36	0.48	5.91e-7	Systemic lupus erythematosus or rheumatoid arthritis;
THYM	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg09307838	chr4:120376055	NA	0.72	5.48	0.49	3.51e-7	Corneal astigmatism;
THYM	cis	rs6591182	0.504	rs2306361	chr11:65374495	A/C	cg27068330	chr11:65405492	SIPA1	-0.9	-8.33	-0.65	5.99e-13	Non-alcoholic fatty liver disease histology (lobular);
THYM	cis	rs9329221	0.725	rs11250001	chr8:10255901	G/A	cg21915799	chr8:10282809	MSRA	-0.5	-4.71	-0.44	8.43e-6	Neuroticism;
THYM	cis	rs6785206	0.527	rs9844706	chr3:128380781	G/A	cg16766828	chr3:128327626	NA	-0.77	-7.81	-0.63	7.71e-12	Lymphocyte percentage of white cells;
THYM	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg11141652	chr22:24348549	GSTTP1	0.6	5.83	0.51	7.6e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg05660106	chr1:15850417	CASP9	0.76	6.27	0.54	1.06e-8	Systolic blood pressure;
THYM	cis	rs17401966	0.838	rs12120042	chr1:10345325	A/T	cg19773385	chr1:10388646	KIF1B	-0.57	-4.49	-0.42	2.04e-5	Hepatocellular carcinoma;
THYM	cis	rs9913156	0.748	rs7217849	chr17:4562165	G/C	cg19197139	chr17:4613644	ARRB2	0.78	4.92	0.45	3.63e-6	Lymphocyte counts;
THYM	cis	rs10208940	0.614	rs10180884	chr2:68811427	A/G	cg09157127	chr2:69201416	GKN1	0.86	4.51	0.42	1.88e-5	Urate levels in lean individuals;
THYM	cis	rs6430585	0.528	rs16832440	chr2:136754183	G/A	cg20242066	chr2:136595261	LCT	0.55	5.09	0.46	1.77e-6	Corneal structure;
THYM	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg04647918	chr11:67383862	NA	0.65	5.36	0.48	5.83e-7	Mean corpuscular volume;
THYM	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.61	-4.83	-0.44	5.3e-6	Longevity;Endometriosis;
THYM	cis	rs7914558	0.505	rs12260436	chr10:104741114	A/C	cg04362960	chr10:104952993	NT5C2	0.83	6.43	0.55	5.18e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4654899	0.733	rs10442633	chr1:21265097	C/T	cg01072550	chr1:21505969	NA	-0.75	-7.21	-0.59	1.34e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs9359856	0.600	rs11961825	chr6:90482250	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs5771225	0.505	rs2341111	chr22:50690322	G/C	cg16473166	chr22:50639996	SELO	0.62	4.55	0.42	1.59e-5	Late-onset Alzheimer's disease;
THYM	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	5.78	0.51	9.49e-8	Height;
THYM	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg26441486	chr22:50317300	CRELD2	0.43	6.59	0.56	2.39e-9	Schizophrenia;
THYM	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.69	4.51	0.42	1.83e-5	Gut microbiome composition (summer);
THYM	cis	rs6032067	0.683	rs34508373	chr20:43788087	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-6.26	-0.54	1.12e-8	Blood protein levels;
THYM	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg24060327	chr5:131705240	SLC22A5	0.73	5.47	0.49	3.61e-7	Blood metabolite levels;
THYM	cis	rs17253792	0.822	rs80174205	chr14:56058694	T/C	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs4866334	1.000	rs74851546	chr5:18487135	C/T	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg07061783	chr6:25882402	NA	0.83	7.28	0.6	9.41e-11	Blood metabolite levels;
THYM	cis	rs2046867	0.862	rs62251657	chr3:72832076	C/T	cg25664220	chr3:72788482	NA	-0.92	-7.27	-0.6	1.01e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	trans	rs6560039	1	rs6560039	chr9:90474946	C/T	cg24436365	chr6:63940138	NA	1.09	12.08	0.78	6.63e-21	Gait variability;
THYM	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07157834	chr1:205819609	PM20D1	1.01	10.3	0.73	3.75e-17	Menarche (age at onset);
THYM	cis	rs1823778	0.609	rs4891388	chr18:67704949	T/C	cg13164537	chr18:67624071	CD226	1.11	4.47	0.42	2.14e-5	Mean platelet volume;
THYM	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg06808227	chr14:105710500	BRF1	-1.08	-9.51	-0.7	1.82e-15	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg06219351	chr7:158114137	PTPRN2	-0.74	-7.14	-0.59	1.86e-10	Calcium levels;
THYM	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs7193541	0.662	rs8052367	chr16:74658867	G/A	cg01733217	chr16:74700730	RFWD3	1.04	12.91	0.8	1.3e-22	Multiple myeloma;
THYM	cis	rs7945705	0.870	rs4910156	chr11:8941197	T/G	cg21881798	chr11:8931708	C11orf17;ST5	0.49	5.33	0.48	6.69e-7	Hemoglobin concentration;
THYM	cis	rs981844	0.796	rs13140722	chr4:154712203	T/A	cg09973105	chr4:154681532	RNF175	0.68	6.36	0.55	6.91e-9	Response to statins (LDL cholesterol change);
THYM	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg03351412	chr1:154909251	PMVK	0.71	5.6	0.5	2.12e-7	Prostate cancer;
THYM	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.57	-5.18	-0.47	1.23e-6	Type 2 diabetes;
THYM	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs2124969	0.506	rs62175396	chr2:161043603	G/A	cg03641300	chr2:160917029	PLA2R1	-0.67	-4.69	-0.43	8.99e-6	Waist circumference adjusted for body mass index;
THYM	cis	rs61931739	0.533	rs4270002	chr12:34313126	G/T	cg06521331	chr12:34319734	NA	-0.64	-5.37	-0.48	5.62e-7	Morning vs. evening chronotype;
THYM	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg18252515	chr7:66147081	NA	-1.5	-9.13	-0.68	1.2e-14	Diabetic kidney disease;
THYM	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg09260853	chr1:2094483	PRKCZ	-0.43	-4.55	-0.42	1.61e-5	Height;
THYM	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg00645579	chr11:617140	IRF7;MUPCDH	-0.52	-6.46	-0.55	4.44e-9	Systemic lupus erythematosus;
THYM	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg12310025	chr6:25882481	NA	-1.09	-9.9	-0.71	2.72e-16	Intelligence (multi-trait analysis);
THYM	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg27446573	chr6:127587934	RNF146	0.87	6.74	0.57	1.22e-9	Breast cancer;
THYM	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.5	-4.96	-0.45	3.07e-6	Crohn's disease;
THYM	cis	rs4474465	0.736	rs10899542	chr11:78246572	T/G	cg19901956	chr11:77921274	USP35	0.57	4.49	0.42	1.97e-5	Alzheimer's disease (survival time);
THYM	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg26149184	chr10:133730230	NA	0.79	4.79	0.44	6.23e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.43	0.7	2.73e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg25214090	chr10:38739885	LOC399744	0.93	7.92	0.63	4.43e-12	Corneal astigmatism;
THYM	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.76	-6.63	-0.56	1.99e-9	Calcium levels;
THYM	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs12681287	0.605	rs13262672	chr8:87355812	T/C	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg24530246	chr3:53118167	NA	-0.82	-4.67	-0.43	9.89e-6	Immune reponse to smallpox (secreted IL-2);
THYM	trans	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg10856724	chr12:34555212	NA	-1.0	-9.24	-0.69	6.89e-15	Bladder cancer;
THYM	cis	rs4824093	0.610	rs73441745	chr22:50237606	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.04	-4.58	-0.43	1.39e-5	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.51e-15	Intelligence (multi-trait analysis);
THYM	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg22709100	chr7:91322751	NA	0.62	4.82	0.44	5.36e-6	Breast cancer;
THYM	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg14779329	chr11:130786720	SNX19	0.52	5.62	0.5	1.92e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	4.45	0.42	2.34e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs925255	0.810	rs7574996	chr2:28643523	G/C	cg01273330	chr2:28605224	NA	-0.55	-5.19	-0.47	1.17e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg22683308	chr4:1340831	KIAA1530	-0.64	-4.66	-0.43	1.01e-5	Obesity-related traits;
THYM	cis	rs11252926	0.510	rs4881371	chr10:554514	G/A	cg03684893	chr10:554711	DIP2C	-0.64	-5.2	-0.47	1.14e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs557074	0.950	rs1285885	chr6:7142891	G/A	cg20893838	chr6:7145478	RREB1	0.76	5.02	0.46	2.44e-6	Monocyte count;
THYM	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.81	5.63	0.5	1.81e-7	Huntington's disease progression;
THYM	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg17143192	chr8:8559678	CLDN23	-0.6	-4.54	-0.42	1.68e-5	Mood instability;
THYM	cis	rs9906944	0.707	rs9912906	chr17:47104432	A/T	cg18128536	chr17:47092178	IGF2BP1	-0.43	-4.71	-0.44	8.43e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs35883536	0.647	rs2647325	chr1:101040195	T/C	cg06223162	chr1:101003688	GPR88	0.83	7.06	0.59	2.67e-10	Monocyte count;
THYM	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg08807101	chr21:30365312	RNF160	-0.68	-4.51	-0.42	1.82e-5	Dental caries;
THYM	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.79	6.42	0.55	5.42e-9	Monocyte percentage of white cells;
THYM	cis	rs6032067	0.538	rs17331776	chr20:43744754	G/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.7	-7.21	-0.59	1.32e-10	Blood protein levels;
THYM	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg20607798	chr8:58055168	NA	0.89	4.7	0.43	8.78e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg11764359	chr7:65958608	NA	0.8	6.38	0.55	6.55e-9	Aortic root size;
THYM	cis	rs921968	0.643	rs678218	chr2:219379709	C/A	cg02176678	chr2:219576539	TTLL4	0.64	6.08	0.53	2.49e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15506890	chr2:3487001	NA	-0.54	-4.56	-0.42	1.51e-5	Neurofibrillary tangles;
THYM	cis	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg16898833	chr6:26189333	HIST1H4D	1.33	4.95	0.45	3.27e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg17063962	chr7:91808500	NA	1.16	13.12	0.8	4.77e-23	Breast cancer;
THYM	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg14664628	chr15:75095509	CSK	1.12	9.78	0.71	4.96e-16	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs4417704	0.551	rs10933524	chr2:241879795	A/G	cg15164180	chr2:241846931	NA	-0.36	-4.62	-0.43	1.22e-5	Joint mobility (Beighton score);
THYM	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Urate levels;
THYM	cis	rs13223928	0.666	rs9986825	chr7:3151177	C/T	cg19214707	chr7:3157722	NA	0.84	6.27	0.54	1.05e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs2237457	0.543	rs2237459	chr7:50729428	G/A	cg08586669	chr7:50727761	GRB10	-0.32	-5.05	-0.46	2.12e-6	Schizophrenia (treatment resistant);
THYM	cis	rs828999	0.688	rs10881507	chr1:108695137	C/T	cg24323958	chr1:108741884	SLC25A24	0.54	5.33	0.48	6.59e-7	Monocyte percentage of white cells;
THYM	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	5.52	0.49	2.88e-7	Hip circumference adjusted for BMI;
THYM	cis	rs11030122	0.702	rs10835399	chr11:3989182	G/A	cg22027985	chr11:4115532	RRM1	-0.48	-4.59	-0.43	1.36e-5	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9534288	0.699	rs2146885	chr13:46659853	A/G	cg15192986	chr13:46630673	CPB2	-0.65	-4.57	-0.42	1.44e-5	Blood protein levels;
THYM	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg05283184	chr6:79620031	NA	-0.94	-9.21	-0.69	7.9e-15	Intelligence (multi-trait analysis);
THYM	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	5.55	0.49	2.58e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs988913	0.706	rs10948880	chr6:54882003	G/T	cg04690482	chr6:54711388	FAM83B	0.44	4.58	0.43	1.39e-5	Menarche (age at onset);
THYM	cis	rs4638749	0.677	rs13022268	chr2:108837320	A/G	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs7592578	0.508	rs10931451	chr2:191270888	G/A	cg11845111	chr2:191398756	TMEM194B	-0.86	-6.48	-0.55	4.06e-9	Diastolic blood pressure;
THYM	cis	rs669446	0.562	rs304303	chr1:44178070	T/G	cg15962314	chr1:44399869	ARTN	0.46	4.92	0.45	3.66e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg20891283	chr12:69753455	YEATS4	0.71	5.96	0.52	4.19e-8	Blood protein levels;
THYM	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg06271696	chr7:157225062	NA	-0.61	-4.58	-0.43	1.42e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs34638657	0.687	rs2303261	chr16:82203768	G/T	cg07307142	chr16:82071433	HSD17B2	-0.86	-7.49	-0.61	3.58e-11	Lung adenocarcinoma;
THYM	trans	rs75518195	0.543	rs62302801	chr4:64718556	A/C	cg14706739	chr8:21916355	EPB49	0.76	7.25	0.6	1.09e-10	Triptolide cytotoxicity;
THYM	cis	rs7681440	0.606	rs2736998	chr4:90754336	A/C	cg06632027	chr4:90757378	SNCA	0.67	5.31	0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs7107174	1.000	rs2511186	chr11:77984306	C/G	cg02023728	chr11:77925099	USP35	0.65	5.95	0.52	4.47e-8	Testicular germ cell tumor;
THYM	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg00129232	chr17:37814104	STARD3	0.76	5.27	0.48	8.57e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs3812049	0.737	rs1993878	chr5:127476971	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.33	0.48	6.56e-7	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs459571	0.959	rs408307	chr9:136892523	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.84	-7.71	-0.62	1.21e-11	Platelet distribution width;
THYM	cis	rs9900062	0.921	rs8081799	chr17:62757092	G/C	cg02598441	chr17:62777298	LOC146880	-0.98	-4.45	-0.42	2.3e-5	QT interval;
THYM	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg21280719	chr6:42927975	GNMT	-0.51	-6.84	-0.57	7.67e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1371867	0.726	rs1660333	chr8:101309989	A/G	cg06636551	chr8:101224915	SPAG1	-0.64	-6.3	-0.54	9.23e-9	Atrioventricular conduction;
THYM	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs13102973	0.965	rs6535051	chr4:135874869	G/A	cg14419869	chr4:135874104	NA	-0.82	-7.94	-0.63	4.06e-12	Subjective well-being;
THYM	cis	rs77204473	0.547	rs17120035	chr11:116663851	C/T	cg01204606	chr11:116451788	NA	-1.06	-4.64	-0.43	1.12e-5	Eosinophil counts;Sum eosinophil basophil counts;
THYM	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg11317459	chr13:21872234	NA	-1.22	-9.26	-0.69	6.43e-15	White matter hyperintensity burden;
THYM	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg11266682	chr4:10021025	SLC2A9	0.73	12.79	0.8	2.25e-22	Bone mineral density;
THYM	cis	rs2777491	0.957	rs316614	chr15:41746625	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.11	-12.45	-0.79	1.12e-21	Ulcerative colitis;
THYM	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg27129171	chr3:47204927	SETD2	-0.79	-7.87	-0.63	5.61e-12	Colorectal cancer;
THYM	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg05234568	chr11:5960015	NA	-0.56	-4.48	-0.42	2.1e-5	DNA methylation (variation);
THYM	cis	rs7926906	1.000	rs7939348	chr11:90522401	T/A	cg26138821	chr11:89956704	CHORDC1	-0.54	-4.93	-0.45	3.52e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7072216	0.763	rs7910247	chr10:100172252	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg06115741	chr20:33292138	TP53INP2	0.7	4.65	0.43	1.06e-5	Coronary artery disease;
THYM	cis	rs1451375	0.785	rs10278338	chr7:50630270	C/T	cg18232548	chr7:50535776	DDC	0.71	5.32	0.48	6.75e-7	Malaria;
THYM	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg10053473	chr17:62856997	LRRC37A3	-0.98	-7.76	-0.62	9.68e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg23958373	chr8:599963	NA	0.91	4.47	0.42	2.15e-5	IgG glycosylation;
THYM	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg27532560	chr4:187881888	NA	-0.96	-11.4	-0.76	1.72e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg22166914	chr1:53195759	ZYG11B	-0.92	-10.93	-0.75	1.7e-18	Monocyte count;
THYM	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg12386194	chr3:101231763	SENP7	0.69	5.16	0.47	1.34e-6	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.76	0.44	6.93e-6	Diabetic retinopathy;
THYM	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg22535103	chr8:58192502	C8orf71	-0.96	-5.75	-0.51	1.06e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs501916	0.604	rs616871	chr15:48058259	T/A	cg20869673	chr15:48010124	SEMA6D	0.64	4.63	0.43	1.14e-5	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg22189786	chr22:42395067	WBP2NL	0.57	5.14	0.47	1.47e-6	Birth weight;
THYM	cis	rs7113850	0.541	rs4367945	chr11:24215605	A/C	ch.11.24196551F	chr11:24239977	NA	0.9	4.65	0.43	1.07e-5	Bone fracture in osteoporosis;
THYM	cis	rs2702888	0.501	rs2741718	chr8:6746641	A/G	cg03082247	chr8:6756796	NA	-0.62	-4.92	-0.45	3.57e-6	Blood pressure;
THYM	cis	rs995000	0.931	rs10157265	chr1:63093617	C/T	cg06896770	chr1:63153194	DOCK7	0.92	7.57	0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs10992471	0.580	rs724102	chr9:95383290	T/C	cg14631576	chr9:95140430	CENPP	-0.94	-7.58	-0.61	2.32e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg22709100	chr7:91322751	NA	-0.62	-4.77	-0.44	6.6e-6	Breast cancer;
THYM	cis	rs7104764	0.507	rs6598054	chr11:254010	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	-0.86	-5.65	-0.5	1.68e-7	Menarche (age at onset);
THYM	cis	rs9399401	0.626	rs6906468	chr6:142769386	A/G	cg04461802	chr6:142623433	GPR126	0.72	7.33	0.6	7.72e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs713587	0.525	rs11675457	chr2:25079770	C/T	cg15423357	chr2:25149977	NA	0.62	5.96	0.52	4.35e-8	Body mass index in non-asthmatics;
THYM	cis	rs34779708	0.931	rs11010125	chr10:35502953	A/G	cg03585969	chr10:35415529	CREM	0.63	4.48	0.42	2.09e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6596100	0.538	rs56157864	chr5:132267859	A/T	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Breast cancer;
THYM	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.64	4.59	0.43	1.36e-5	Lung cancer in ever smokers;
THYM	cis	rs6918586	1.000	rs6918586	chr6:26097384	T/C	cg07061783	chr6:25882402	NA	-0.58	-4.49	-0.42	1.97e-5	Schizophrenia;
THYM	cis	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg07460842	chr6:66804631	NA	0.76	4.98	0.45	2.9e-6	Exhaled nitric oxide output;
THYM	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7586879	0.639	rs6713978	chr2:25120851	T/C	cg27107076	chr2:25050844	ADCY3	-0.29	-4.66	-0.43	1.04e-5	Body mass index;
THYM	cis	rs1178127	0.798	rs1178121	chr7:18762652	A/C	cg13420273	chr7:18810212	HDAC9	-0.55	-4.53	-0.42	1.69e-5	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs9646944	0.501	rs11687768	chr2:103025738	A/G	cg01241218	chr2:102972058	NA	0.77	5.01	0.46	2.56e-6	Blood protein levels;
THYM	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg22535103	chr8:58192502	C8orf71	-1.02	-6.41	-0.55	5.49e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs3126085	0.935	rs4634913	chr1:152249932	T/C	cg26020982	chr1:152196106	HRNR	0.35	4.95	0.45	3.26e-6	Atopic dermatitis;
THYM	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4589258	0.737	rs2155071	chr11:90410159	T/A	cg26138821	chr11:89956704	CHORDC1	0.56	4.68	0.43	9.36e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg25817165	chr18:72167213	CNDP2	-0.96	-7.96	-0.63	3.71e-12	Refractive error;
THYM	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg22875332	chr1:76189707	ACADM	-0.55	-5.18	-0.47	1.22e-6	Daytime sleep phenotypes;
THYM	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.64	8.83	0.67	5.25e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7592578	0.508	rs62180987	chr2:191267173	A/G	cg21644426	chr2:191273491	MFSD6	-0.64	-4.52	-0.42	1.8e-5	Diastolic blood pressure;
THYM	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg03929089	chr4:120376271	NA	-1.03	-12.43	-0.79	1.26e-21	Height;
THYM	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12667521	chr19:29218732	NA	0.89	8.17	0.64	1.34e-12	Methadone dose in opioid dependence;
THYM	cis	rs8013055	0.846	rs8013827	chr14:105970176	C/T	cg23356831	chr14:105996513	TMEM121	-0.61	-6.39	-0.55	6.16e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs4638749	0.677	rs6711297	chr2:108818357	A/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg12373951	chr3:133503437	NA	0.51	5.03	0.46	2.31e-6	Iron status biomarkers;
THYM	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg10802521	chr3:52805072	NEK4	-0.65	-5.47	-0.49	3.7e-7	Electroencephalogram traits;
THYM	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg02852791	chr16:710674	WDR90	-0.52	-4.83	-0.44	5.18e-6	Height;
THYM	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg08968635	chr6:28129556	ZNF389	-0.7	-5.3	-0.48	7.53e-7	Depression;
THYM	cis	rs9560113	0.573	rs7988040	chr13:112226534	C/G	cg15979348	chr13:112237479	NA	0.6	5.65	0.5	1.64e-7	Menarche (age at onset);
THYM	cis	rs6995541	0.505	rs10046628	chr8:10702929	A/G	cg13457217	chr8:10683266	MIR1322;PINX1	-0.63	-4.59	-0.43	1.35e-5	Triglyceride levels;
THYM	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-5.48	-0.49	3.42e-7	Chronic sinus infection;
THYM	cis	rs9532580	0.656	rs2721068	chr13:41139712	T/C	cg21288729	chr13:41239152	FOXO1	0.67	4.7	0.43	8.74e-6	Mean corpuscular hemoglobin;
THYM	cis	rs2404602	0.647	rs1443115	chr15:77041829	T/C	cg23625390	chr15:77176239	SCAPER	-0.86	-5.88	-0.52	6.21e-8	Blood metabolite levels;
THYM	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg14779329	chr11:130786720	SNX19	0.54	5.78	0.51	9.34e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs3772130	0.564	rs35178434	chr3:121595936	G/A	cg20356878	chr3:121714668	ILDR1	0.71	6.34	0.55	7.58e-9	Cognitive performance;
THYM	cis	rs11048434	0.761	rs1805723	chr12:9142297	T/C	cg13575925	chr12:9217583	LOC144571	0.55	5.48	0.49	3.45e-7	Sjögren's syndrome;
THYM	cis	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg05335186	chr13:53173507	NA	0.48	5.49	0.49	3.32e-7	Lewy body disease;
THYM	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg23649088	chr2:200775458	C2orf69	-0.73	-5.14	-0.47	1.46e-6	Schizophrenia;
THYM	cis	rs7731657	0.537	rs7708430	chr5:130315958	T/C	cg08523029	chr5:130500466	HINT1	-0.81	-5.87	-0.52	6.45e-8	Fasting plasma glucose;
THYM	cis	rs13256369	0.950	rs13248096	chr8:8577476	C/T	cg00074818	chr8:8560427	CLDN23	0.56	5.05	0.46	2.15e-6	Obesity-related traits;
THYM	cis	rs7614311	0.681	rs2241822	chr3:63965304	A/G	cg22134162	chr3:63841271	THOC7	-0.57	-6.82	-0.57	8.5e-10	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs9902453	0.967	rs4325622	chr17:28526475	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	4.58	0.42	1.44e-5	Coffee consumption (cups per day);
THYM	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg20283391	chr11:68216788	NA	-0.62	-4.9	-0.45	3.88e-6	Total body bone mineral density;
THYM	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg05368731	chr17:41323189	NBR1	1.25	11.08	0.75	8.33e-19	Menopause (age at onset);
THYM	cis	rs2219968	0.525	rs10104780	chr8:78890544	C/T	cg00738934	chr8:78996279	NA	0.61	4.95	0.45	3.21e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05901451	chr6:126070800	HEY2	-0.68	-5.81	-0.51	8.25e-8	Brugada syndrome;
THYM	cis	rs7626444	0.625	rs1104375	chr3:196476043	C/G	cg12930392	chr3:196481615	PAK2	0.4	4.92	0.45	3.58e-6	Monocyte count;
THYM	cis	rs9733	0.519	rs3768005	chr1:150680988	A/T	cg15448220	chr1:150897856	SETDB1	0.88	7.27	0.6	1.02e-10	Tonsillectomy;
THYM	cis	rs1729951	0.575	rs361244	chr3:136697506	C/T	cg21827317	chr3:136751795	NA	0.75	6.64	0.56	1.92e-9	Neuroticism;
THYM	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.64	-4.68	-0.43	9.69e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4363385	0.747	rs9919227	chr1:152970867	A/G	cg13444842	chr1:152974279	SPRR3	-0.6	-4.79	-0.44	6.16e-6	Inflammatory skin disease;
THYM	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg20290983	chr6:43655470	MRPS18A	1.17	7.52	0.61	3.09e-11	IgG glycosylation;
THYM	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.75	-6.63	-0.56	2.03e-9	Prudent dietary pattern;
THYM	cis	rs9807841	0.592	rs1053007	chr19:10754400	A/G	cg16900796	chr19:10755136	SLC44A2	0.38	6.19	0.54	1.52e-8	Inflammatory skin disease;
THYM	cis	rs7704138	0.639	rs4865977	chr5:55015985	G/A	cg18456523	chr5:54516805	NA	-0.58	-4.59	-0.43	1.34e-5	Height;
THYM	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.72	-0.44	8.14e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7772486	0.686	rs1337839	chr6:146010239	A/G	cg13319975	chr6:146136371	FBXO30	0.68	5.49	0.49	3.41e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9543976	0.623	rs6562918	chr13:76174577	C/T	cg01531495	chr13:76123901	UCHL3	0.66	4.8	0.44	5.85e-6	Diabetic retinopathy;
THYM	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg05856015	chr4:467047	ZNF721;ABCA11P	-0.41	-4.47	-0.42	2.15e-5	White blood cell count;
THYM	cis	rs4866334	1.000	rs76533277	chr5:18488162	G/A	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs6547741	0.816	rs7560847	chr2:27882700	A/G	cg27432699	chr2:27873401	GPN1	-0.88	-8.03	-0.64	2.56e-12	Oral cavity cancer;
THYM	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg16325326	chr1:53192061	ZYG11B	0.77	6.13	0.53	2.03e-8	Monocyte count;
THYM	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg23422044	chr7:1970798	MAD1L1	-0.77	-5.3	-0.48	7.56e-7	Bipolar disorder;
THYM	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.56	4.53	0.42	1.7e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.17	-9.02	-0.68	2.06e-14	Platelet count;
THYM	cis	rs950880	0.710	rs17027060	chr2:103007567	T/C	cg03938978	chr2:103052716	IL18RAP	-0.5	-4.46	-0.42	2.24e-5	Serum protein levels (sST2);
THYM	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg12165864	chr7:66369176	NA	0.65	5.1	0.46	1.73e-6	Aortic root size;
THYM	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg20608306	chr11:116969690	SIK3	0.52	6.75	0.57	1.16e-9	Blood protein levels;
THYM	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg12923728	chr3:195709715	SDHAP1	-0.78	-6.47	-0.55	4.3e-9	Pancreatic cancer;
THYM	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg05182265	chr7:156933206	UBE3C	0.7	9.62	0.7	1.06e-15	Body mass index;
THYM	cis	rs10716631	1	rs10716631	chr2:219138170	T/G	cg00012203	chr2:219082015	ARPC2	0.85	7.66	0.62	1.52e-11	High light scatter reticulocyte percentage of red cells;Plateletcrit;
THYM	trans	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg07211511	chr3:129823064	LOC729375	-1.22	-9.75	-0.71	5.63e-16	Blood pressure (smoking interaction);
THYM	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg21385522	chr1:16154831	NA	0.76	5.61	0.5	2e-7	Dilated cardiomyopathy;
THYM	cis	rs9866391	0.607	rs6763927	chr3:141140366	A/T	cg13411656	chr3:141121016	ZBTB38	-0.35	-5.1	-0.46	1.74e-6	Myopia;
THYM	cis	rs981844	0.753	rs1105491	chr4:154726634	A/C	cg09973105	chr4:154681532	RNF175	-0.59	-5.45	-0.49	3.99e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs6500395	1.000	rs12599028	chr16:48713082	C/A	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg22709100	chr7:91322751	NA	0.61	4.86	0.45	4.66e-6	Breast cancer;
THYM	cis	rs7617773	0.780	rs6793223	chr3:48364101	C/T	cg02219026	chr3:48282209	ZNF589	-0.69	-4.83	-0.44	5.12e-6	Coronary artery disease;
THYM	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg03605463	chr16:89740564	NA	0.58	4.59	0.43	1.38e-5	Vitiligo;
THYM	cis	rs4509693	0.943	rs10732789	chr10:102496184	T/C	cg15234845	chr10:102496500	NA	0.64	4.53	0.42	1.71e-5	Alzheimer's disease;
THYM	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg23260525	chr10:116636907	FAM160B1	0.51	5.26	0.47	9.02e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs34779708	0.931	rs11010130	chr10:35513307	T/C	cg03585969	chr10:35415529	CREM	0.63	4.48	0.42	2.09e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.85	-7.17	-0.59	1.59e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.26	-5.24	-0.47	9.75e-7	Obesity-related traits;
THYM	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg09238746	chr17:78121135	EIF4A3	-1.12	-9.71	-0.71	6.75e-16	Yeast infection;
THYM	cis	rs9364687	0.639	rs9347762	chr6:163961081	G/T	cg01639524	chr6:163818125	NA	0.49	4.87	0.45	4.39e-6	Body mass index;
THYM	cis	rs67072384	0.786	rs60497375	chr11:72452645	A/G	cg01380194	chr11:72452482	ARAP1	-0.97	-5.26	-0.47	8.93e-7	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs4660306	0.677	rs10493120	chr1:45903488	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.66	4.65	0.43	1.06e-5	Homocysteine levels;
THYM	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg18876405	chr7:65276391	NA	0.76	7.16	0.59	1.66e-10	Aortic root size;
THYM	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg11301795	chr4:187892539	NA	-1.12	-16.92	-0.87	2.01e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg10150615	chr22:24372951	LOC391322	-1.02	-12.23	-0.78	3.19e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4242434	0.854	rs13258100	chr8:22451116	A/T	cg03733263	chr8:22462867	KIAA1967	1.15	11.14	0.75	6.15e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1691799	0.899	rs1168351	chr12:66752505	A/G	cg16791601	chr12:66731901	HELB	-0.73	-6.86	-0.58	6.83e-10	White blood cell count (basophil);
THYM	cis	rs7683537	0.692	rs12509936	chr4:185662203	G/A	cg04058563	chr4:185651563	MLF1IP	1.08	7.46	0.61	4.08e-11	Systemic lupus erythematosus;
THYM	cis	rs2742234	0.578	rs2435354	chr10:43652445	C/T	cg06632098	chr10:43605906	RET	-0.79	-5.1	-0.46	1.73e-6	Hirschsprung disease;
THYM	cis	rs1949733	0.917	rs10461079	chr4:8392724	G/A	cg11789530	chr4:8429930	ACOX3	-0.72	-5.62	-0.5	1.93e-7	Response to antineoplastic agents;
THYM	cis	rs9905704	0.918	rs2611779	chr17:56791832	A/G	cg12560992	chr17:57184187	TRIM37	0.68	4.68	0.43	9.37e-6	Testicular germ cell tumor;
THYM	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg05425664	chr17:57184151	TRIM37	0.57	4.72	0.44	8.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4664308	1.000	rs2175416	chr2:160904021	G/A	cg03641300	chr2:160917029	PLA2R1	-0.75	-6.95	-0.58	4.48e-10	Idiopathic membranous nephropathy;
THYM	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.75	-0.67	7.74e-14	Mean corpuscular volume;
THYM	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg15741354	chr8:8146129	NA	0.31	5.24	0.47	9.49e-7	Joint mobility (Beighton score);
THYM	cis	rs7043114	0.525	rs12353096	chr9:95031144	T/C	cg14631576	chr9:95140430	CENPP	-0.85	-9.0	-0.68	2.26e-14	Height;
THYM	cis	rs2463822	1.000	rs2463822	chr11:62103420	T/C	cg06239285	chr11:62104954	ASRGL1	1.41	7.12	0.59	2.06e-10	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs28595532	0.920	rs56212415	chr4:119737731	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg21775007	chr8:11205619	TDH	0.68	5.5	0.49	3.19e-7	Retinal vascular caliber;
THYM	cis	rs17125944	0.686	rs6572868	chr14:53325090	C/T	cg00686598	chr14:53173677	PSMC6	-1.12	-5.04	-0.46	2.19e-6	Alzheimer's disease (late onset);
THYM	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg26384229	chr12:38710491	ALG10B	1.0	7.56	0.61	2.54e-11	Bladder cancer;
THYM	cis	rs8067545	0.611	rs2703805	chr17:20107773	T/C	cg13482628	chr17:19912719	NA	-0.55	-4.51	-0.42	1.84e-5	Schizophrenia;
THYM	cis	rs1371867	0.875	rs1788169	chr8:101326314	C/T	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs7809950	1.000	rs2520260	chr7:107172794	A/G	cg23024343	chr7:107201750	COG5	-0.92	-8.37	-0.65	4.88e-13	Coronary artery disease;
THYM	cis	rs600806	0.850	rs10858085	chr1:109914983	A/G	cg23616212	chr1:109941201	SORT1	-0.49	-4.66	-0.43	1.01e-5	Intelligence (multi-trait analysis);
THYM	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg10755058	chr3:40428713	ENTPD3	-0.52	-4.51	-0.42	1.84e-5	Renal cell carcinoma;
THYM	cis	rs3087591	0.960	rs2952999	chr17:29509801	G/T	cg24425628	chr17:29625626	OMG;NF1	0.61	5.32	0.48	6.91e-7	Hip circumference;
THYM	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg20887711	chr4:1340912	KIAA1530	0.76	6.32	0.54	8.39e-9	Longevity;
THYM	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg04317338	chr11:64019027	PLCB3	0.87	5.62	0.5	1.91e-7	Mean platelet volume;
THYM	cis	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg06609049	chr19:2785107	THOP1	1.12	10.58	0.74	9.67e-18	Total cholesterol levels;
THYM	cis	rs1371867	0.839	rs1660313	chr8:101332712	G/A	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs4363385	0.782	rs2152993	chr1:152991695	C/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.76	-0.44	6.94e-6	Inflammatory skin disease;
THYM	cis	rs2219968	0.525	rs1352213	chr8:78878036	G/A	cg00738934	chr8:78996279	NA	0.61	4.93	0.45	3.5e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4273100	0.688	rs28760541	chr17:19172505	A/G	cg25447019	chr17:19030144	GRAPL	-0.79	-6.19	-0.54	1.49e-8	Schizophrenia;
THYM	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg17063962	chr7:91808500	NA	1.16	13.12	0.8	4.77e-23	Breast cancer;
THYM	cis	rs12049351	0.665	rs10753458	chr1:229575709	C/A	cg11742688	chr1:229674241	ABCB10	-0.54	-4.56	-0.42	1.54e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6828523	0.698	rs73869044	chr4:175852900	T/C	cg14561282	chr4:175839468	ADAM29	0.61	4.51	0.42	1.83e-5	Breast cancer;
THYM	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg06850241	chr22:41845214	NA	0.54	4.6	0.43	1.33e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs835154	0.900	rs835153	chr5:14877474	A/G	cg14843632	chr5:14870594	ANKH	0.74	7.9	0.63	4.83e-12	Blood metabolite levels;
THYM	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg27034606	chr17:28928453	LRRC37B2	0.83	5.47	0.49	3.6e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs9329289	0.608	rs2388097	chr10:2566085	C/T	cg15501526	chr10:2543763	NA	0.49	4.51	0.42	1.85e-5	Age-related hearing impairment;
THYM	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg06636001	chr8:8085503	FLJ10661	0.62	5.29	0.48	7.8e-7	Systolic blood pressure;
THYM	cis	rs1003719	0.788	rs1155787	chr21:38448069	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	8.1	0.64	1.82e-12	Platelet count;
THYM	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg18252515	chr7:66147081	NA	-0.66	-5.01	-0.46	2.55e-6	Aortic root size;
THYM	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg14582100	chr15:45693742	SPATA5L1	0.58	4.67	0.43	9.87e-6	Homoarginine levels;
THYM	cis	rs2012796	0.743	rs61986598	chr14:81856865	G/A	cg02996355	chr14:81879375	NA	0.85	6.59	0.56	2.48e-9	Night sleep phenotypes;
THYM	cis	rs1957429	0.808	rs1951492	chr14:65346895	G/A	cg23373153	chr14:65346875	NA	1.07	6.45	0.55	4.75e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs3741151	0.764	rs73548680	chr11:73271335	T/C	cg17517138	chr11:73019481	ARHGEF17	0.9	4.68	0.43	9.36e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.68	-5.86	-0.52	6.64e-8	Platelet count;
THYM	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg11266682	chr4:10021025	SLC2A9	0.74	12.06	0.78	7.3e-21	Bone mineral density;
THYM	cis	rs977987	0.843	rs11641801	chr16:75455448	A/C	cg03315344	chr16:75512273	CHST6	0.76	6.16	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg13246856	chr1:44399776	ARTN	0.48	4.95	0.45	3.27e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6430585	0.528	rs309119	chr2:136710372	T/C	cg23851026	chr2:136556271	LCT	0.69	6.68	0.57	1.64e-9	Corneal structure;
THYM	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg00129232	chr17:37814104	STARD3	-0.7	-4.93	-0.45	3.42e-6	Urinary metabolites;
THYM	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg13607699	chr17:42295918	UBTF	0.59	4.86	0.45	4.58e-6	Total body bone mineral density;
THYM	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-4.45	-0.42	2.34e-5	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs9929218	0.953	rs9927329	chr16:68750331	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.9	-7.81	-0.63	7.67e-12	Colorectal cancer;
THYM	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg21773646	chr17:80085082	CCDC57	-0.35	-4.89	-0.45	4.17e-6	Life satisfaction;
THYM	cis	rs9527	0.590	rs2148200	chr10:104879847	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22455342	chr2:225449267	CUL3	0.97	8.91	0.67	3.48e-14	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs6840360	1.000	rs7671651	chr4:152597202	C/G	cg22705602	chr4:152727874	NA	-0.61	-6.54	-0.56	3.02e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg25427524	chr10:38739819	LOC399744	0.65	6.11	0.53	2.18e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg26354017	chr1:205819088	PM20D1	0.84	7.82	0.63	7.08e-12	Monocyte percentage of white cells;
THYM	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg26031613	chr14:104095156	KLC1	0.79	5.11	0.46	1.66e-6	Body mass index;
THYM	cis	rs7851660	0.809	rs7044799	chr9:100665393	A/T	cg13688889	chr9:100608707	NA	-0.79	-5.75	-0.51	1.06e-7	Strep throat;
THYM	cis	rs7668636	0.514	rs4285052	chr4:90028653	A/G	cg17769793	chr4:89976368	FAM13A	0.48	5.02	0.46	2.42e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg27535305	chr1:53392650	SCP2	-0.54	-6.36	-0.55	7.06e-9	Monocyte count;
THYM	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg23815491	chr16:72088622	HP	0.84	6.94	0.58	4.88e-10	Fibrinogen levels;
THYM	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.5	-4.96	-0.45	3.07e-6	Rheumatoid arthritis;
THYM	cis	rs2811415	0.597	rs35944498	chr3:127731662	T/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs8180040	0.800	rs11920354	chr3:47262246	C/A	cg02527881	chr3:46936655	PTH1R	0.56	5.27	0.48	8.43e-7	Colorectal cancer;
THYM	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	5.76	0.51	1.03e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg08859206	chr1:53392774	SCP2	-0.77	-9.38	-0.69	3.55e-15	Monocyte count;
THYM	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg10295955	chr4:187884368	NA	1.16	16.24	0.86	3.64e-29	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6032067	0.714	rs6017527	chr20:43886291	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.56	-5.33	-0.48	6.58e-7	Blood protein levels;
THYM	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg04731861	chr2:219085781	ARPC2	0.54	5.05	0.46	2.11e-6	Colorectal cancer;
THYM	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs6750795	0.746	rs1667301	chr2:232423717	C/T	cg19187155	chr2:232395269	NMUR1	0.96	10.23	0.72	5.26e-17	Height;
THYM	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg05043794	chr9:111880884	C9orf5	-0.4	-5.64	-0.5	1.71e-7	Menarche (age at onset);
THYM	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.32	0.48	6.81e-7	Height;
THYM	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.85	-6.22	-0.54	1.32e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg26384229	chr12:38710491	ALG10B	0.73	5.35	0.48	6.04e-7	Morning vs. evening chronotype;
THYM	cis	rs7772486	0.754	rs2328709	chr6:146106819	A/G	cg05347473	chr6:146136440	FBXO30	-0.58	-4.55	-0.42	1.6e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12534093	0.602	rs11765452	chr7:23582555	C/G	cg05804949	chr7:23719620	C7orf46	-0.44	-4.49	-0.42	1.97e-5	Height;Infant length;
THYM	cis	rs662064	0.928	rs685746	chr1:10537437	C/G	cg20482658	chr1:10539492	PEX14	-0.48	-6.47	-0.55	4.21e-9	Asthma;
THYM	cis	rs28595532	0.920	rs116795224	chr4:119734570	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg17426766	chr1:2046864	PRKCZ	0.45	5.47	0.49	3.69e-7	Height;
THYM	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg12560992	chr17:57184187	TRIM37	0.89	8.0	0.63	3.07e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg13695892	chr22:41940480	POLR3H	-0.95	-7.25	-0.6	1.08e-10	Vitiligo;
THYM	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg11266682	chr4:10021025	SLC2A9	0.73	11.88	0.77	1.74e-20	Bone mineral density;
THYM	cis	rs1163251	0.837	rs611365	chr1:120242571	C/T	cg19096424	chr1:120255104	PHGDH	0.67	4.94	0.45	3.29e-6	Blood metabolite levels;
THYM	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg19746536	chr19:49375674	PPP1R15A	0.81	4.59	0.43	1.34e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs10911232	0.507	rs4596846	chr1:182976034	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Hypertriglyceridemia;
THYM	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18252515	chr7:66147081	NA	0.66	5.08	0.46	1.91e-6	Aortic root size;
THYM	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.85	7.62	0.62	1.88e-11	Cognitive ability;
THYM	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg06481639	chr22:41940642	POLR3H	0.82	5.68	0.5	1.49e-7	Vitiligo;
THYM	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs4731207	0.564	rs6466964	chr7:124572400	T/C	cg05285228	chr7:124571219	POT1	-0.69	-5.25	-0.47	9.35e-7	Cutaneous malignant melanoma;
THYM	cis	rs113835537	0.529	rs57207756	chr11:66270360	C/T	cg24851651	chr11:66362959	CCS	0.73	5.13	0.47	1.52e-6	Airway imaging phenotypes;
THYM	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg11327659	chr7:150037044	RARRES2	0.37	4.61	0.43	1.28e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.55	-0.73	1.12e-17	Primary sclerosing cholangitis;
THYM	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg18758796	chr5:131593413	PDLIM4	0.61	6.11	0.53	2.15e-8	Acylcarnitine levels;
THYM	cis	rs3136739	0.764	rs56068620	chr8:42071173	G/A	cg16230352	chr8:42123158	NA	0.69	4.8	0.44	5.85e-6	Plasma plasminogen activator levels;
THYM	cis	rs11118346	1.000	rs11118344	chr1:219742915	T/C	cg07908999	chr1:219785142	NA	-0.39	-4.47	-0.42	2.16e-5	Height;
THYM	cis	rs55665837	1.000	rs12792120	chr11:14469443	G/T	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs995000	0.899	rs1168030	chr1:62968491	C/T	cg06896770	chr1:63153194	DOCK7	-0.91	-7.48	-0.61	3.62e-11	Triglyceride levels;
THYM	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.83	0.63	6.72e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs10089	1.000	rs4836370	chr5:127499224	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.02	7.11	0.59	2.11e-10	Ileal carcinoids;
THYM	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-5.05	-0.46	2.12e-6	Lymphocyte counts;
THYM	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs17539620	0.624	rs62432738	chr6:154835674	T/C	cg20019720	chr6:154832845	CNKSR3	0.47	4.79	0.44	6.17e-6	Lipoprotein (a) levels;
THYM	cis	rs2302612	0.571	rs6731042	chr2:102848256	A/C	cg13315345	chr2:102803985	IL1RL2	-0.68	-5.23	-0.47	1e-6	Serum protein levels (sST2);
THYM	cis	rs1198430	0.500	rs968280	chr1:23801965	A/T	cg19827787	chr1:23763612	ASAP3	0.6	4.92	0.45	3.62e-6	Total cholesterol levels;
THYM	cis	rs7980799	0.716	rs1601008	chr12:33611352	A/G	cg06521331	chr12:34319734	NA	0.69	4.93	0.45	3.47e-6	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg10360139	chr7:1886902	MAD1L1	-0.86	-7.83	-0.63	6.99e-12	Bipolar disorder and schizophrenia;
THYM	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg08773314	chr2:239334832	ASB1	0.64	9.8	0.71	4.32e-16	Multiple system atrophy;
THYM	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg15592062	chr6:167189543	RPS6KA2	0.59	6.03	0.53	3.06e-8	Crohn's disease;
THYM	cis	rs7000551	0.715	rs1600877	chr8:22378118	C/T	cg12081754	chr8:22256438	SLC39A14	0.65	5.87	0.52	6.31e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs72772090	0.539	rs13601	chr5:96110596	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-4.67	-0.43	9.81e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg03433033	chr1:76189801	ACADM	-0.76	-9.02	-0.68	2.01e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg08772003	chr10:104629869	AS3MT	-0.61	-5.45	-0.49	3.91e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs11030122	0.604	rs10835557	chr11:4083121	A/G	cg18678763	chr11:4115507	RRM1	-0.43	-5.6	-0.5	2.12e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg08048268	chr3:133502702	NA	-0.65	-5.51	-0.49	3.06e-7	Iron status biomarkers;
THYM	cis	rs9527	0.590	rs7920868	chr10:104795409	C/T	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg11062466	chr8:58055876	NA	0.95	4.91	0.45	3.78e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2072499	0.833	rs2758605	chr1:156200445	G/C	cg24450063	chr1:156163899	SLC25A44	1.0	11.18	0.75	5.17e-19	Testicular germ cell tumor;
THYM	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11890956	chr21:40555474	PSMG1	-0.61	-4.66	-0.43	1.05e-5	Menarche (age at onset);
THYM	trans	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	Neuroticism;
THYM	cis	rs7512552	0.803	rs59898460	chr1:150493004	T/C	cg15654264	chr1:150340011	RPRD2	0.45	5.16	0.47	1.36e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs6831352	0.918	rs3919370	chr4:100064326	A/T	cg12011299	chr4:100065546	ADH4	-0.82	-7.61	-0.62	1.96e-11	Alcohol dependence;
THYM	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg00129232	chr17:37814104	STARD3	-0.96	-7.56	-0.61	2.57e-11	Asthma;
THYM	cis	rs6952809	0.532	rs10272548	chr7:2439467	G/A	cg23289794	chr7:2394357	EIF3B	-0.76	-4.72	-0.44	8.17e-6	Multiple sclerosis;
THYM	cis	rs7267979	1.000	rs2257809	chr20:25266476	C/T	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg18402987	chr7:1209562	NA	1.03	6.15	0.53	1.8e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg09455208	chr3:40491958	NA	0.5	5.15	0.47	1.39e-6	Renal cell carcinoma;
THYM	cis	rs981844	0.890	rs62325115	chr4:154694847	A/G	cg09973105	chr4:154681532	RNF175	-0.67	-5.54	-0.49	2.68e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg13695892	chr22:41940480	POLR3H	0.93	6.99	0.58	3.82e-10	Vitiligo;
THYM	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg09060608	chr5:178986726	RUFY1	0.58	5.81	0.51	8.21e-8	Lung cancer;
THYM	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg07362569	chr17:61921086	SMARCD2	0.7	6.23	0.54	1.25e-8	Prudent dietary pattern;
THYM	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg07414643	chr4:187882934	NA	0.67	5.92	0.52	5.16e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.27	5.49	0.49	3.38e-7	Obesity-related traits;
THYM	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg24910161	chr17:38119198	GSDMA	0.45	4.49	0.42	1.99e-5	Self-reported allergy;
THYM	cis	rs854765	0.693	rs9907287	chr17:17774118	C/T	cg16928487	chr17:17741425	SREBF1	0.49	4.82	0.44	5.45e-6	Total body bone mineral density;
THYM	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg14186256	chr22:23484241	RTDR1	0.96	9.57	0.7	1.38e-15	Bone mineral density;
THYM	cis	rs4907240	0.883	rs11678174	chr2:97249103	T/C	cg18419276	chr2:96971862	SNRNP200	-0.4	-4.76	-0.44	6.95e-6	Event-related brain oscillations;
THYM	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06850241	chr22:41845214	NA	-0.54	-4.74	-0.44	7.44e-6	Vitiligo;
THYM	cis	rs1011018	0.955	rs10952511	chr7:139431351	A/C	cg06079564	chr7:139468310	HIPK2	-0.73	-5.54	-0.49	2.65e-7	Systolic blood pressure;
THYM	cis	rs1062177	1.000	rs973529	chr5:151188158	T/C	cg14319409	chr5:151304409	GLRA1	0.54	4.49	0.42	2.02e-5	Preschool internalizing problems;
THYM	cis	rs79387448	0.745	rs57942521	chr2:103139849	A/G	cg09003973	chr2:102972529	NA	0.75	4.64	0.43	1.12e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs6032067	0.538	rs6017489	chr20:43731932	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.56	-5.94	-0.52	4.69e-8	Blood protein levels;
THYM	cis	rs4911259	0.552	rs6058926	chr20:31465450	T/C	cg13636640	chr20:31349939	DNMT3B	-0.63	-6.16	-0.53	1.74e-8	Inflammatory bowel disease;
THYM	cis	rs2658782	0.547	rs3133454	chr11:93059019	A/C	cg02384510	chr11:93059814	NA	-0.48	-4.6	-0.43	1.28e-5	Pulmonary function decline;
THYM	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg26149184	chr10:133730230	NA	0.77	4.65	0.43	1.07e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs1524976	0.943	rs11711510	chr3:65524312	C/T	cg16238336	chr3:65465873	MAGI1	-0.84	-4.46	-0.42	2.23e-5	PR interval;
THYM	cis	rs9796	0.611	rs691672	chr15:41444438	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.62	-4.92	-0.45	3.61e-6	Menopause (age at onset);
THYM	cis	rs2219968	1.000	rs28551624	chr8:78957333	A/G	cg00738934	chr8:78996279	NA	0.88	9.31	0.69	4.91e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2120019	0.505	rs77456790	chr15:75330095	G/T	cg09165964	chr15:75287851	SCAMP5	-1.01	-5.02	-0.46	2.37e-6	Blood trace element (Zn levels);
THYM	cis	rs490234	0.934	rs12553637	chr9:128277258	A/G	cg14078157	chr9:128172775	NA	-0.62	-4.98	-0.45	2.85e-6	Mean arterial pressure;
THYM	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg11494091	chr17:61959527	GH2	0.69	6.32	0.54	8.45e-9	Height;
THYM	trans	rs1974653	0.672	rs1558497	chr22:20071899	C/T	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs79149102	0.579	rs58645417	chr15:75325858	T/G	cg09165964	chr15:75287851	SCAMP5	-1.11	-6.35	-0.55	7.21e-9	Lung cancer;
THYM	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg17178900	chr1:205818956	PM20D1	-0.64	-4.88	-0.45	4.35e-6	Menarche (age at onset);
THYM	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg23711669	chr6:146136114	FBXO30	-0.98	-10.65	-0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4843185	0.576	rs380996	chr16:85728813	A/G	cg08899895	chr16:85684853	KIAA0182	-0.63	-4.97	-0.45	3.02e-6	Platelet distribution width;
THYM	cis	rs854765	0.624	rs9902941	chr17:17733760	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.62	-5.22	-0.47	1.05e-6	Total body bone mineral density;
THYM	cis	rs9314614	0.865	rs2978898	chr8:6692378	T/C	cg27319216	chr8:6693540	XKR5	-0.71	-8.35	-0.65	5.5e-13	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs17407555	0.606	rs3775945	chr4:10011996	A/T	cg13000635	chr4:9523653	NA	0.67	4.56	0.42	1.52e-5	Schizophrenia (age at onset);
THYM	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg23583168	chr7:148888333	NA	-1.02	-14.09	-0.82	5.29e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg13319975	chr6:146136371	FBXO30	-0.63	-4.99	-0.46	2.75e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17102423	0.723	rs55658675	chr14:65554638	C/T	cg11161011	chr14:65562177	MAX	-0.83	-6.62	-0.56	2.13e-9	Obesity-related traits;
THYM	cis	rs6570726	0.905	rs421032	chr6:145827771	A/G	cg23711669	chr6:146136114	FBXO30	0.9	8.87	0.67	4.4e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4654899	0.802	rs6685306	chr1:21219050	C/T	cg01072550	chr1:21505969	NA	-0.69	-5.99	-0.52	3.78e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg04896959	chr15:78267971	NA	0.89	8.06	0.64	2.29e-12	Coronary artery disease or large artery stroke;
THYM	cis	rs7264396	0.790	rs3746410	chr20:34190870	A/G	cg26038318	chr20:34205095	SPAG4	0.54	4.67	0.43	9.75e-6	Total cholesterol levels;
THYM	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg10518543	chr12:38710700	ALG10B	-0.56	-4.46	-0.42	2.29e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs250585	0.764	rs4967958	chr16:23528123	T/C	cg00143387	chr16:23521605	GGA2	-0.71	-4.45	-0.42	2.35e-5	Egg allergy;
THYM	cis	rs1003719	0.788	rs2835602	chr21:38469069	G/C	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs1451375	1.000	rs4452748	chr7:50625056	A/C	cg18232548	chr7:50535776	DDC	-0.73	-5.57	-0.5	2.35e-7	Malaria;
THYM	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg08772003	chr10:104629869	AS3MT	-0.66	-6.05	-0.53	2.91e-8	Arsenic metabolism;
THYM	cis	rs2777491	0.574	rs28700583	chr15:41714072	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.61	-0.83	4.87e-26	Ulcerative colitis;
THYM	cis	rs8067545	0.750	rs28637614	chr17:19985108	G/T	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.64e-6	Schizophrenia;
THYM	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg21984481	chr17:79567631	NPLOC4	-0.47	-4.95	-0.45	3.22e-6	Eye color traits;
THYM	cis	rs8038465	0.571	rs7176654	chr15:73999006	C/T	cg15420318	chr15:73925796	NPTN	-0.53	-4.54	-0.42	1.63e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7578361	0.959	rs1196669	chr2:150330618	A/G	cg17961725	chr2:150454027	NA	0.66	5.03	0.46	2.29e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-4.55	-0.42	1.58e-5	Chronic sinus infection;
THYM	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg16006841	chr5:176797999	RGS14	0.7	9.65	0.7	9.31e-16	Hemoglobin concentration;Hematocrit;
THYM	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg22709100	chr7:91322751	NA	0.69	5.44	0.49	4.14e-7	Breast cancer;
THYM	cis	rs929596	0.785	rs6747843	chr2:234664354	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.97	-8.3	-0.65	7.15e-13	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs933688	0.938	rs10942634	chr5:90658392	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	6.23	0.54	1.28e-8	Smoking behavior;
THYM	cis	rs7578361	0.918	rs10209100	chr2:150377115	C/T	cg17961725	chr2:150454027	NA	-0.77	-5.72	-0.51	1.25e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs3916	0.911	rs3999408	chr12:121167387	C/T	cg10600917	chr12:121163489	ACADS	0.57	4.91	0.45	3.79e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs7523273	0.626	rs2466572	chr1:207934487	A/C	cg22525895	chr1:207977042	MIR29B2	0.76	5.18	0.47	1.27e-6	Schizophrenia;
THYM	cis	rs7567389	0.719	rs4150402	chr2:128050134	C/T	cg06038358	chr2:128176007	PROC	0.43	4.53	0.42	1.7e-5	Self-rated health;
THYM	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg27588902	chr6:42928151	GNMT	-0.55	-5.52	-0.49	2.97e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9515201	0.859	rs9521732	chr13:111033821	G/T	cg26053697	chr13:111039873	COL4A2	0.56	4.56	0.42	1.53e-5	White matter hyperintensity burden;
THYM	cis	rs9311676	0.656	rs11915190	chr3:58409700	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs10744422	0.858	rs4759389	chr12:123308615	A/G	cg25930673	chr12:123319894	HIP1R	-0.91	-5.17	-0.47	1.29e-6	Schizophrenia;
THYM	cis	rs2069036	0.903	rs2355247	chr10:16099553	G/T	cg26633223	chr10:15133461	NA	0.68	4.76	0.44	6.94e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.84	0.44	4.97e-6	Bipolar disorder;
THYM	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg10523679	chr1:76189770	ACADM	-0.56	-4.77	-0.44	6.63e-6	Daytime sleep phenotypes;
THYM	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	4.88	0.45	4.24e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg08772003	chr10:104629869	AS3MT	-0.61	-5.42	-0.49	4.46e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs888194	0.677	rs10774696	chr12:109875753	C/T	cg11367159	chr12:110044531	NA	0.53	4.82	0.44	5.39e-6	Neuroticism;
THYM	cis	rs858239	0.670	rs6967526	chr7:23159241	C/A	cg18081818	chr7:23246105	NA	-0.53	-4.84	-0.44	5.09e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg12379764	chr21:47803548	PCNT	0.73	4.89	0.45	4.07e-6	Testicular germ cell tumor;
THYM	cis	rs6032067	0.527	rs35828065	chr20:43732374	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.41	-4.92	-0.45	3.6e-6	Blood protein levels;
THYM	cis	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg26963428	chr7:66367121	NA	0.55	4.52	0.42	1.77e-5	Aortic root size;
THYM	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg23161317	chr6:28129485	ZNF389	0.94	7.03	0.58	3.18e-10	Parkinson's disease;
THYM	cis	rs12530845	0.623	rs73721664	chr7:135343575	A/C	cg19897172	chr7:135347071	PL-5283	-0.64	-5.4	-0.48	4.85e-7	Red blood cell traits;
THYM	cis	rs3087591	0.922	rs12950236	chr17:29431034	A/G	cg24425628	chr17:29625626	OMG;NF1	0.65	5.59	0.5	2.16e-7	Hip circumference;
THYM	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg00383909	chr3:49044727	WDR6	1.12	6.61	0.56	2.27e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg17554472	chr22:41940697	POLR3H	0.67	4.73	0.44	7.66e-6	Vitiligo;
THYM	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs2072510	0.722	rs2540496	chr12:96406503	G/A	cg18817487	chr12:96390143	HAL	0.35	4.67	0.43	9.96e-6	Metabolite levels (small molecules and protein measures);
THYM	trans	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg10856724	chr12:34555212	NA	-0.8	-6.99	-0.58	3.71e-10	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg26038318	chr20:34205095	SPAG4	0.62	4.86	0.45	4.54e-6	Total cholesterol levels;
THYM	trans	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17712092	chr4:129076599	LARP1B	0.93	7.62	0.62	1.87e-11	Eosinophil percentage of white cells;
THYM	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg04034577	chr2:241836375	C2orf54	-0.43	-7.58	-0.61	2.31e-11	Urinary metabolites;
THYM	cis	rs73086581	0.787	rs67724338	chr20:3869057	A/G	cg02187196	chr20:3869020	PANK2	0.47	5.04	0.46	2.23e-6	Response to antidepressants in depression;
THYM	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg01097406	chr16:89675127	NA	-0.63	-5.55	-0.5	2.54e-7	Vitiligo;
THYM	cis	rs3087591	0.960	rs8080679	chr17:29602610	A/G	cg24425628	chr17:29625626	OMG;NF1	0.63	5.38	0.48	5.3e-7	Hip circumference;
THYM	cis	rs332507	0.830	rs13069961	chr3:124358715	A/G	cg14688451	chr3:124303035	KALRN	0.6	4.71	0.43	8.58e-6	Plateletcrit;
THYM	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg26384229	chr12:38710491	ALG10B	0.94	7.9	0.63	4.92e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11969893	0.737	rs6930051	chr6:101406108	A/G	cg12253828	chr6:101329408	ASCC3	1.08	6.2	0.54	1.43e-8	Economic and political preferences (immigration/crime);
THYM	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg08994789	chr17:28903642	LRRC37B2	-1.05	-5.39	-0.48	5.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg12863693	chr15:85201151	NMB	0.55	4.65	0.43	1.06e-5	Schizophrenia;
THYM	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg18105134	chr13:113819100	PROZ	1.12	7.77	0.62	9.14e-12	Platelet distribution width;
THYM	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg24578937	chr1:2090814	PRKCZ	-0.78	-8.44	-0.65	3.62e-13	Height;
THYM	cis	rs10892173	0.566	rs111578166	chr11:117666714	G/T	cg21014159	chr11:117668035	DSCAML1	0.68	4.92	0.45	3.7e-6	Myopia;
THYM	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs6728642	0.572	rs1320147	chr2:97600626	A/C	cg26665480	chr2:98280029	ACTR1B	0.74	5.01	0.46	2.56e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs669446	0.561	rs1143701	chr1:44084739	C/T	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg05481257	chr2:20870211	GDF7	-0.69	-5.56	-0.5	2.43e-7	Abdominal aortic aneurysm;
THYM	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg06092702	chr1:163392909	NA	0.61	5.35	0.48	5.97e-7	Motion sickness;
THYM	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg14004847	chr7:1930337	MAD1L1	0.73	5.98	0.52	3.83e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4343996	0.521	rs10233684	chr7:3424405	A/G	cg21248987	chr7:3385318	SDK1	0.39	4.99	0.46	2.68e-6	Motion sickness;
THYM	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg05738196	chr6:26577821	NA	0.85	8.69	0.67	1.03e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg00898013	chr13:113819073	PROZ	0.88	9.0	0.68	2.24e-14	Platelet distribution width;
THYM	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.77	7.81	0.63	7.42e-12	Lymphocyte counts;
THYM	cis	rs7119	0.717	rs62007350	chr15:77804590	G/A	cg27398640	chr15:77910606	LINGO1	-0.52	-5.21	-0.47	1.12e-6	Type 2 diabetes;
THYM	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg13699009	chr12:122356056	WDR66	0.53	5.66	0.5	1.63e-7	Mean corpuscular volume;
THYM	cis	rs8133932	0.654	rs10854474	chr21:47332700	A/G	cg20357416	chr21:47294739	PCBP3	-0.81	-4.93	-0.45	3.54e-6	Schizophrenia;
THYM	cis	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-5.43	-0.49	4.23e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs11651000	0.857	rs16947078	chr17:45825500	A/G	cg06532163	chr17:45867833	NA	0.58	5.43	0.49	4.31e-7	IgG glycosylation;
THYM	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg25566285	chr7:158114605	PTPRN2	0.77	6.92	0.58	5.36e-10	Response to amphetamines;
THYM	cis	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.64	0.43	1.12e-5	Obesity-related traits;
THYM	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-5.81	-0.51	8.27e-8	Total cholesterol levels;
THYM	cis	rs775227	0.574	rs16860849	chr3:113049993	C/T	cg18753928	chr3:113234510	CCDC52	0.75	5.16	0.47	1.35e-6	Dental caries;
THYM	cis	rs11731175	0.961	rs3913153	chr4:189852487	C/G	cg00431894	chr4:189871012	NA	0.81	6.15	0.53	1.83e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg22920501	chr2:26401640	FAM59B	-1.04	-9.12	-0.68	1.26e-14	Gut microbiome composition (summer);
THYM	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg13010199	chr12:38710504	ALG10B	-0.62	-4.56	-0.42	1.53e-5	Morning vs. evening chronotype;
THYM	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs2970992	0.624	rs2309905	chr2:101328575	T/A	cg01042948	chr2:101319752	NA	0.6	5.89	0.52	5.76e-8	Educational attainment;
THYM	cis	rs75059851	0.756	rs73036087	chr11:133842361	G/A	cg14047540	chr11:133829660	NA	-1.1	-7.34	-0.6	7.1e-11	Schizophrenia;
THYM	cis	rs9326248	0.559	rs1269329	chr11:116755041	T/C	cg20608306	chr11:116969690	SIK3	0.62	7.38	0.6	5.92e-11	Blood protein levels;
THYM	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg11752832	chr7:134001865	SLC35B4	0.68	4.93	0.45	3.53e-6	Mean platelet volume;
THYM	cis	rs17854409	1.000	rs17854409	chr20:61491494	T/C	cg05147244	chr20:61493195	TCFL5	1.03	6.5	0.55	3.76e-9	Obesity-related traits;
THYM	cis	rs4654899	0.965	rs4654907	chr1:21521094	C/T	cg01072550	chr1:21505969	NA	-0.71	-6.39	-0.55	6.24e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs4466137	0.830	rs6886695	chr5:82994293	T/A	cg16102102	chr5:83017553	HAPLN1	-1.07	-9.87	-0.71	3.19e-16	Prostate cancer;
THYM	cis	rs752010	0.967	rs10890151	chr1:42101843	C/A	cg22486000	chr1:42919398	ZMYND12	-0.43	-4.87	-0.45	4.36e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg23851026	chr2:136556271	LCT	0.54	5.65	0.5	1.69e-7	Mosquito bite size;
THYM	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg14129053	chr2:1895732	MYT1L	1.13	4.49	0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs17407555	0.633	rs10022367	chr4:10277093	C/A	cg00071950	chr4:10020882	SLC2A9	0.5	4.46	0.42	2.27e-5	Schizophrenia (age at onset);
THYM	cis	rs1878931	0.582	rs27239	chr16:3442140	T/C	cg21433313	chr16:3507492	NAT15	0.58	4.85	0.45	4.84e-6	Body mass index (adult);
THYM	cis	rs4363385	0.693	rs310102	chr1:153042423	T/C	cg13444842	chr1:152974279	SPRR3	-0.61	-5.01	-0.46	2.46e-6	Inflammatory skin disease;
THYM	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg25767906	chr1:53392781	SCP2	0.51	5.04	0.46	2.22e-6	Monocyte count;
THYM	cis	rs6435161	1.000	rs72928934	chr2:203562740	A/G	cg18429434	chr2:203499731	FAM117B	-0.77	-5.16	-0.47	1.35e-6	Total cholesterol levels;
THYM	cis	rs1451375	0.794	rs11238134	chr7:50542927	A/C	cg18232548	chr7:50535776	DDC	-0.76	-6.94	-0.58	4.75e-10	Malaria;
THYM	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg12310025	chr6:25882481	NA	-0.65	-5.12	-0.46	1.62e-6	Height;
THYM	cis	rs9913156	0.748	rs7219787	chr17:4562257	A/T	cg19197139	chr17:4613644	ARRB2	0.78	4.92	0.45	3.63e-6	Lymphocyte counts;
THYM	cis	rs7617773	0.925	rs35942721	chr3:48173069	C/T	cg02219026	chr3:48282209	ZNF589	-0.65	-4.58	-0.43	1.43e-5	Coronary artery disease;
THYM	cis	rs2562456	0.652	rs62110214	chr19:21775208	G/A	cg21751540	chr19:21541537	ZNF738	-0.68	-4.51	-0.42	1.87e-5	Pain;
THYM	cis	rs9796	0.835	rs11856848	chr15:41370961	C/T	cg21153102	chr15:41252147	NA	0.69	6.18	0.54	1.62e-8	Menopause (age at onset);
THYM	cis	rs7769051	0.522	rs6928933	chr6:133116073	G/A	cg22852734	chr6:133119734	C6orf192	1.45	6.1	0.53	2.32e-8	Type 2 diabetes nephropathy;
THYM	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.75	5.75	0.51	1.1e-7	Eosinophil percentage of white cells;
THYM	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg12564285	chr5:131593104	PDLIM4	-0.43	-4.66	-0.43	1.04e-5	Breast cancer;
THYM	cis	rs4242434	0.536	rs1871900	chr8:22481449	A/G	cg03733263	chr8:22462867	KIAA1967	0.99	9.03	0.68	1.93e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4595586	0.545	rs2197940	chr12:39401937	C/T	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs7131987	0.874	rs10843366	chr12:29407903	T/C	cg09582351	chr12:29534625	ERGIC2	-0.48	-4.59	-0.43	1.36e-5	QT interval;
THYM	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg14675211	chr2:100938903	LONRF2	0.77	8.32	0.65	6.49e-13	Intelligence (multi-trait analysis);
THYM	cis	rs12802200	0.561	rs12792868	chr11:566647	T/A	cg14433983	chr11:636460	DRD4	-0.66	-4.74	-0.44	7.53e-6	Systemic lupus erythematosus;
THYM	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg12310025	chr6:25882481	NA	0.69	5.64	0.5	1.74e-7	Schizophrenia;
THYM	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg08133631	chr1:26527909	CATSPER4	-0.63	-5.22	-0.47	1.05e-6	Obesity-related traits;
THYM	cis	rs921968	0.541	rs12619347	chr2:219419935	T/C	cg02176678	chr2:219576539	TTLL4	-0.73	-7.24	-0.6	1.18e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8060581	0.867	rs16952612	chr16:80224110	A/C	cg16408938	chr16:81111018	C16orf46	-1.16	-4.62	-0.43	1.23e-5	Presence of antiphospholipid antibodies;
THYM	cis	rs10895275	0.924	rs11225167	chr11:102090901	C/T	cg24447756	chr11:102105824	NA	0.53	4.62	0.43	1.22e-5	Migraine;
THYM	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs2456568	0.900	rs2000960	chr11:93682348	C/T	cg26875233	chr11:93583750	C11orf90	-0.5	-4.88	-0.45	4.28e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs72627123	0.867	rs118139038	chr14:74415553	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.1	6.43	0.55	5.04e-9	Morning vs. evening chronotype;
THYM	cis	rs7725337	1.000	rs13187246	chr5:88398602	T/A	cg11280525	chr5:87955695	LOC645323	-0.4	-4.48	-0.42	2.06e-5	Total body bone mineral density;
THYM	cis	rs9875589	0.509	rs1488375	chr3:14061563	G/A	cg03204825	chr3:13978759	TPRXL	-0.55	-4.78	-0.44	6.32e-6	Ovarian reserve;
THYM	trans	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs289828	0.560	rs6713041	chr2:152159318	T/C	cg05960677	chr2:152117363	RBM43	0.7	6.58	0.56	2.59e-9	Blood protein levels;
THYM	cis	rs6746082	0.519	rs503594	chr2:25757803	C/T	cg23192403	chr2:25781496	DTNB	-0.44	-5.87	-0.52	6.35e-8	Multiple myeloma;
THYM	cis	rs2505998	0.843	rs2506004	chr10:43582273	A/C	cg06632098	chr10:43605906	RET	-1.04	-9.21	-0.69	8.15e-15	Hirschsprung disease;
THYM	cis	rs728616	0.867	rs17885031	chr10:81696091	G/A	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg09990169	chr2:241835740	C2orf54	-0.36	-5.9	-0.52	5.56e-8	Urinary metabolites;
THYM	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg12573674	chr2:1569213	NA	-1.22	-4.82	-0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg00071950	chr4:10020882	SLC2A9	0.84	9.27	0.69	6.03e-15	Bone mineral density;
THYM	cis	rs6700896	0.931	rs12021623	chr1:66153586	A/C	cg04111102	chr1:66153794	NA	0.59	5.83	0.51	7.66e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs7084402	1.000	rs7073504	chr10:60271987	C/T	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg08439880	chr3:133502540	NA	0.73	6.38	0.55	6.45e-9	Iron status biomarkers;
THYM	cis	rs9522267	0.511	rs4773397	chr13:112245044	T/C	cg10483660	chr13:112241077	NA	-0.6	-6.79	-0.57	9.73e-10	Hepatitis;
THYM	cis	rs6429082	0.689	rs10802803	chr1:235709610	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.65	-4.86	-0.45	4.72e-6	Adiposity;
THYM	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg04414720	chr1:150670196	GOLPH3L	-0.64	-4.84	-0.44	5e-6	Tonsillectomy;
THYM	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg26384229	chr12:38710491	ALG10B	0.95	7.98	0.63	3.38e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg12935359	chr14:103987150	CKB	0.52	5.96	0.52	4.19e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2147904	0.934	rs812487	chr1:42366198	G/A	cg16685388	chr1:42384056	HIVEP3	0.56	4.65	0.43	1.05e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
THYM	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg14972814	chr11:95582409	MTMR2	-0.63	-5.31	-0.48	7.33e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.01	-5.45	-0.49	4.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9329289	0.510	rs1155447	chr10:2553240	C/T	cg07014206	chr10:2547000	NA	-0.53	-4.77	-0.44	6.72e-6	Age-related hearing impairment;
THYM	cis	rs919433	0.679	rs9967823	chr2:198531529	A/G	cg00792783	chr2:198669748	PLCL1	0.82	5.44	0.49	4.16e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs67981189	0.579	rs2240533	chr14:71541026	T/C	cg15910301	chr14:71632612	NA	0.51	4.64	0.43	1.12e-5	Schizophrenia;
THYM	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg24642439	chr20:33292090	TP53INP2	0.63	4.96	0.45	3.05e-6	Coronary artery disease;
THYM	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg25358565	chr5:93447407	FAM172A	1.34	10.59	0.74	9.3e-18	Diabetic retinopathy;
THYM	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg19748678	chr4:122722346	EXOSC9	0.75	5.37	0.48	5.52e-7	Type 2 diabetes;
THYM	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03264133	chr6:25882463	NA	-0.72	-5.52	-0.49	2.99e-7	Blood metabolite levels;
THYM	cis	rs4638749	1.000	rs12477202	chr2:108867112	G/A	cg06795125	chr2:108905320	SULT1C2	-0.43	-5.53	-0.49	2.83e-7	Blood pressure;
THYM	cis	rs9880211	1.000	rs34757183	chr3:136143668	G/T	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.86	0.45	4.66e-6	Obesity-related traits;
THYM	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg22117172	chr7:91764530	CYP51A1	0.39	4.79	0.44	6.17e-6	Breast cancer;
THYM	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg02574844	chr11:5959923	NA	-0.53	-4.67	-0.43	9.86e-6	DNA methylation (variation);
THYM	cis	rs8114671	0.967	rs6088734	chr20:33745046	A/T	cg08999081	chr20:33150536	PIGU	0.55	4.92	0.45	3.65e-6	Height;
THYM	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg07549590	chr16:15018862	NA	0.63	4.83	0.44	5.19e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
THYM	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg06481639	chr22:41940642	POLR3H	-0.84	-5.93	-0.52	4.87e-8	Vitiligo;
THYM	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg06766960	chr11:133703094	NA	-0.51	-4.68	-0.43	9.42e-6	Childhood ear infection;
THYM	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg08885076	chr2:99613938	TSGA10	0.63	5.66	0.5	1.57e-7	Chronic sinus infection;
THYM	cis	rs3008870	1.000	rs12041926	chr1:67434602	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	7.9	0.63	4.84e-12	Lymphocyte percentage of white cells;
THYM	cis	rs314370	0.951	rs3757868	chr7:100482720	G/A	cg10426581	chr7:100472382	SRRT	1.13	8.97	0.68	2.57e-14	Resting heart rate;
THYM	cis	rs12142240	0.698	rs1984490	chr1:46858734	C/T	cg00530320	chr1:46809349	NSUN4	-0.77	-5.47	-0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs654950	0.875	rs600109	chr1:41998246	A/G	cg13396354	chr1:41153348	NA	0.44	4.56	0.42	1.5e-5	Airway imaging phenotypes;
THYM	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	6.7	0.57	1.5e-9	Total body bone mineral density;
THYM	cis	rs1395	0.744	rs11686131	chr2:27508710	C/T	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.3	-0.48	7.55e-7	Blood metabolite levels;
THYM	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg20302533	chr7:39170763	POU6F2	0.6	4.51	0.42	1.83e-5	IgG glycosylation;
THYM	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg05962950	chr11:130786565	SNX19	0.85	7.6	0.61	2.1e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9399401	0.633	rs6570511	chr6:142757368	G/A	cg03128060	chr6:142623767	GPR126	0.65	8.53	0.66	2.28e-13	Chronic obstructive pulmonary disease;
THYM	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg20476274	chr7:133979776	SLC35B4	0.66	4.58	0.43	1.42e-5	Mean platelet volume;
THYM	cis	rs1965732	0.588	rs13385033	chr2:3715071	C/T	cg25251562	chr2:3704773	ALLC	-0.6	-4.88	-0.45	4.24e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs1580019	0.922	rs766658	chr7:32499391	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.62	0.56	2.16e-9	Cognitive ability;
THYM	cis	rs6840360	1.000	rs2840130	chr4:152600699	T/C	cg22705602	chr4:152727874	NA	-0.59	-6.33	-0.54	8.23e-9	Intelligence (multi-trait analysis);
THYM	cis	rs77236434	0.826	rs73562576	chr8:13181063	A/C	cg06835018	chr8:12272982	NA	-0.77	-4.63	-0.43	1.17e-5	Familial hepatitis B virus-related hepatocellular carcinoma;
THYM	cis	rs28647808	0.881	rs41316982	chr9:136259117	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg23205692	chr1:25664452	TMEM50A	-0.79	-6.3	-0.54	9.43e-9	Erythrocyte sedimentation rate;
THYM	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg11871910	chr12:69753446	YEATS4	0.73	6.01	0.52	3.49e-8	Blood protein levels;
THYM	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg15744005	chr10:104629667	AS3MT	-0.82	-7.74	-0.62	1.05e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg27446573	chr6:127587934	RNF146	1.03	9.76	0.71	5.36e-16	Breast cancer;
THYM	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9677476	1.000	rs6724253	chr2:232121998	A/G	cg07929768	chr2:232055508	NA	0.53	5.43	0.49	4.24e-7	Food antigen IgG levels;
THYM	cis	rs13326165	0.585	rs17052051	chr3:52331266	C/G	cg08438690	chr3:52279403	PPM1M	-0.74	-4.64	-0.43	1.12e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs9352866	0.934	rs6907806	chr6:81519389	G/A	cg08356243	chr6:80645827	ELOVL4	-0.45	-4.46	-0.42	2.23e-5	Antibody level in response to infection;
THYM	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg16325326	chr1:53192061	ZYG11B	-0.98	-11.01	-0.75	1.18e-18	Monocyte count;
THYM	cis	rs28595532	0.920	rs114928651	chr4:119734194	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs4731207	0.662	rs6466950	chr7:124453074	G/C	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs1005224	0.929	rs11625260	chr14:76162293	G/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.72	-5.9	-0.52	5.48e-8	Large artery stroke;
THYM	cis	rs10463554	0.927	rs158403	chr5:102415768	C/G	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs11577318	0.528	rs11247935	chr1:26698622	G/C	cg16664472	chr1:26644822	UBXN11;CD52	0.33	4.7	0.43	8.78e-6	Granulocyte percentage of myeloid white cells;
THYM	cis	rs4631830	0.720	rs898343	chr10:51505403	A/G	cg10326726	chr10:51549505	MSMB	0.5	4.99	0.46	2.68e-6	Prostate-specific antigen levels;
THYM	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg02734326	chr4:10020555	SLC2A9	0.59	5.02	0.46	2.46e-6	Bone mineral density;
THYM	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg20887711	chr4:1340912	KIAA1530	0.73	6.07	0.53	2.62e-8	Longevity;
THYM	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg11812906	chr14:75593930	NEK9	0.88	8.1	0.64	1.87e-12	Height;
THYM	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg25918947	chr17:41365094	TMEM106A	-0.69	-5.84	-0.51	7.34e-8	Menopause (age at onset);
THYM	cis	rs7193541	0.662	rs8063458	chr16:74469121	G/T	cg01733217	chr16:74700730	RFWD3	-0.83	-8.9	-0.67	3.65e-14	Multiple myeloma;
THYM	cis	rs910187	0.605	rs8184673	chr20:45806262	C/T	cg27589058	chr20:45804311	EYA2	-0.7	-6.45	-0.55	4.68e-9	Migraine;
THYM	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg05347473	chr6:146136440	FBXO30	0.6	4.86	0.45	4.66e-6	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	5.93	0.52	4.8e-8	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg09260853	chr1:2094483	PRKCZ	-0.47	-4.79	-0.44	6.1e-6	Height;
THYM	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg24675658	chr1:53192096	ZYG11B	-0.77	-6.93	-0.58	5.04e-10	Monocyte count;
THYM	cis	rs10992471	0.603	rs9299405	chr9:95284873	A/G	cg14631576	chr9:95140430	CENPP	-0.96	-9.19	-0.69	9.02e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs901683	1.000	rs9422652	chr10:46047934	G/A	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs13064411	0.518	rs2669909	chr3:113265727	A/G	cg18753928	chr3:113234510	CCDC52	0.74	6.95	0.58	4.66e-10	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs72712511	0.641	rs11100308	chr4:140769923	T/G	cg15010390	chr4:140216957	NDUFC1	0.63	4.5	0.42	1.89e-5	Intelligence (multi-trait analysis);
THYM	cis	rs59698941	0.943	rs12517073	chr5:132240151	T/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs4460079	0.531	rs12506510	chr4:114834215	A/G	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs57994353	0.578	rs10448340	chr9:139320069	A/C	cg14115884	chr9:139300582	SDCCAG3	0.64	4.6	0.43	1.3e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs6430585	0.528	rs499483	chr2:136652524	G/A	cg20242066	chr2:136595261	LCT	0.55	5.17	0.47	1.31e-6	Corneal structure;
THYM	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg02221750	chr19:17393354	ANKLE1	0.96	8.86	0.67	4.58e-14	Systemic lupus erythematosus;
THYM	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg23161317	chr6:28129485	ZNF389	0.66	5.26	0.47	8.9e-7	Parkinson's disease;
THYM	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg26384229	chr12:38710491	ALG10B	0.93	7.78	0.62	8.55e-12	Heart rate;
THYM	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg05294307	chr14:35346193	BAZ1A	-0.77	-4.87	-0.45	4.48e-6	Psoriasis;
THYM	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg06784218	chr1:46089804	CCDC17	-0.3	-4.64	-0.43	1.1e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg06028808	chr11:68637592	NA	0.71	7.61	0.62	1.99e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1050631	0.564	rs1785905	chr18:33713287	T/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.28	0.48	8.32e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg22535103	chr8:58192502	C8orf71	-0.96	-6.0	-0.52	3.5e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs7084402	0.967	rs1649039	chr10:60330041	C/T	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg01528321	chr10:82214614	TSPAN14	0.65	5.03	0.46	2.35e-6	Post bronchodilator FEV1;
THYM	trans	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.07e-11	Bladder cancer;
THYM	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg12310025	chr6:25882481	NA	-0.69	-5.47	-0.49	3.69e-7	Blood metabolite levels;
THYM	cis	rs3862030	0.594	rs7923675	chr10:104235809	G/T	cg00122347	chr10:104236741	TMEM180	-0.46	-6.76	-0.57	1.11e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs7567389	0.638	rs12105051	chr2:127990177	T/G	cg09760422	chr2:128146352	NA	-0.52	-5.96	-0.52	4.27e-8	Self-rated health;
THYM	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg22105103	chr4:187893119	NA	0.92	10.09	0.72	1.04e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg04546413	chr19:29218101	NA	1.08	8.66	0.66	1.22e-13	Methadone dose in opioid dependence;
THYM	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	6.09	0.53	2.36e-8	Platelet count;
THYM	cis	rs6686842	0.932	rs3157	chr1:41493111	A/G	cg03387723	chr1:41708464	SCMH1	-0.4	-4.74	-0.44	7.46e-6	Height;
THYM	cis	rs17270561	0.943	rs76703022	chr6:25703529	A/C	cg16482183	chr6:26056742	HIST1H1C	0.7	4.76	0.44	6.79e-6	Iron status biomarkers;
THYM	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg17279839	chr7:150038598	RARRES2	0.55	5.34	0.48	6.26e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg23583168	chr7:148888333	NA	-1.0	-13.2	-0.8	3.29e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Body mass index;
THYM	cis	rs2637266	0.935	rs1907323	chr10:78336015	C/T	cg18941641	chr10:78392320	NA	0.67	5.43	0.49	4.31e-7	Pulmonary function;
THYM	cis	rs3092073	0.617	rs56324610	chr20:44564030	G/C	cg04940435	chr20:44420291	WFDC3;DNTTIP1	-0.47	-5.0	-0.46	2.58e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2219968	0.683	rs12677681	chr8:78903856	G/A	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg00383909	chr3:49044727	WDR6	1.12	6.62	0.56	2.13e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg23000734	chr10:126850823	CTBP2	-0.84	-10.94	-0.75	1.62e-18	Menarche (age at onset);
THYM	cis	rs9527	0.615	rs7096452	chr10:104736563	G/A	cg15744005	chr10:104629667	AS3MT	-0.61	-4.55	-0.42	1.61e-5	Arsenic metabolism;
THYM	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg18252515	chr7:66147081	NA	-1.52	-8.02	-0.64	2.72e-12	Diabetic kidney disease;
THYM	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg21773646	chr17:80085082	CCDC57	0.31	4.49	0.42	2.02e-5	Life satisfaction;
THYM	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs941408	1.000	rs1736177	chr19:2791624	C/T	cg19693284	chr19:2783607	SGTA	0.7	5.23	0.47	1.02e-6	Total cholesterol levels;
THYM	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs7107174	0.892	rs3018313	chr11:77989644	C/T	cg02023728	chr11:77925099	USP35	0.65	5.95	0.52	4.47e-8	Testicular germ cell tumor;
THYM	cis	rs7937682	0.575	rs7930208	chr11:111741463	T/C	cg09085632	chr11:111637200	PPP2R1B	1.19	12.58	0.79	6.05e-22	Primary sclerosing cholangitis;
THYM	cis	rs9790314	1.000	rs460508	chr3:161091089	C/G	cg03342759	chr3:160939853	NMD3	0.79	7.04	0.59	3.04e-10	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	cis	rs526231	0.511	rs11951374	chr5:102355798	C/A	cg23492399	chr5:102201601	PAM	-0.69	-5.24	-0.47	9.68e-7	Primary biliary cholangitis;
THYM	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.32	9.94	0.71	2.24e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg17264618	chr3:40429014	ENTPD3	0.49	4.56	0.42	1.55e-5	Renal cell carcinoma;
THYM	cis	rs9933309	0.916	rs57953994	chr16:88846803	G/A	cg27661460	chr16:88844969	FAM38A	-0.65	-5.83	-0.51	7.44e-8	Glycated hemoglobin levels;
THYM	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-5.28	-0.48	7.99e-7	Mood instability;
THYM	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg17178900	chr1:205818956	PM20D1	-0.98	-10.62	-0.74	7.77e-18	Menarche (age at onset);
THYM	trans	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg10856724	chr12:34555212	NA	-1.03	-9.34	-0.69	4.28e-15	Morning vs. evening chronotype;
THYM	cis	rs2637266	0.626	rs2583067	chr10:78555804	A/G	cg18941641	chr10:78392320	NA	0.74	5.85	0.51	6.96e-8	Pulmonary function;
THYM	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg00801512	chr17:28996047	NA	-0.84	-5.46	-0.49	3.83e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg23187316	chr7:1099788	C7orf50	0.59	4.52	0.42	1.76e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4747241	0.626	rs4409753	chr10:74069126	T/C	cg07828833	chr10:74069493	NA	0.59	5.02	0.46	2.37e-6	Heschl's gyrus morphology;
THYM	cis	rs420259	0.516	rs432477	chr16:23600573	T/C	cg00143387	chr16:23521605	GGA2	0.76	5.6	0.5	2.1e-7	Bipolar disorder;
THYM	cis	rs7940866	0.738	rs10791114	chr11:130889850	G/A	cg05962950	chr11:130786565	SNX19	0.77	6.49	0.55	3.96e-9	Schizophrenia;
THYM	cis	rs7187994	0.848	rs16974558	chr16:84787111	G/A	cg07647771	chr16:84786436	USP10	-0.55	-5.05	-0.46	2.15e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs9460635	0.959	rs9466092	chr6:21452800	C/T	cg11817533	chr6:21523501	NA	-0.59	-4.62	-0.43	1.18e-5	Metabolite levels (HVA-5-HIAA Factor score);
THYM	cis	rs928736	0.557	rs2834083	chr21:34436973	A/G	cg04836472	chr21:34405997	NA	0.5	5.48	0.49	3.51e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11890956	chr21:40555474	PSMG1	-0.66	-6.38	-0.55	6.51e-9	Menarche (age at onset);
THYM	cis	rs6905628	1	rs6905628	chr6:90344869	C/G	cg13799429	chr6:90582589	CASP8AP2	0.57	5.42	0.49	4.49e-7	Coronary artery disease;
THYM	cis	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg12826209	chr6:26865740	GUSBL1	1.02	5.47	0.49	3.59e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg09640425	chr7:158790006	NA	-0.54	-4.55	-0.42	1.58e-5	Facial morphology (factor 20);
THYM	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg06481639	chr22:41940642	POLR3H	0.84	5.85	0.51	6.94e-8	Vitiligo;
THYM	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.58	4.73	0.44	7.87e-6	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs6565180	0.926	rs4787643	chr16:30393660	G/A	cg17640201	chr16:30407289	ZNF48	0.85	7.23	0.6	1.2e-10	Tonsillectomy;
THYM	cis	rs9902453	0.791	rs3115086	chr17:28025949	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	6.01	0.52	3.47e-8	Coffee consumption (cups per day);
THYM	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg10515332	chr4:99064459	C4orf37	0.71	5.67	0.5	1.51e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg24375607	chr4:120327624	NA	0.6	5.03	0.46	2.31e-6	Corneal astigmatism;
THYM	cis	rs3017493	0.786	rs59579317	chr11:70684569	A/G	cg19942459	chr11:70508110	SHANK2	1.26	7.35	0.6	6.88e-11	Renal transplant outcome;
THYM	cis	rs12681287	0.640	rs7816275	chr8:87373404	A/G	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs72627123	0.867	rs72627121	chr14:74366378	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs7586879	0.616	rs6545809	chr2:25126715	C/T	cg15423357	chr2:25149977	NA	0.7	7.74	0.62	1.03e-11	Body mass index;
THYM	cis	rs6938	0.640	rs11639413	chr15:75243294	C/T	cg02696790	chr15:75250997	RPP25	0.5	4.57	0.42	1.46e-5	Breast cancer;
THYM	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-5.44	-0.49	4.17e-7	Vitiligo;
THYM	cis	rs1065852	0.526	rs2097561	chr22:42389431	T/C	cg01059385	chr22:42394853	WBP2NL	0.57	4.66	0.43	1.04e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11644478	chr21:40555479	PSMG1	1.1	9.84	0.71	3.61e-16	Cognitive function;
THYM	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg18876405	chr7:65276391	NA	-0.55	-4.73	-0.44	7.84e-6	Aortic root size;
THYM	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs7084402	0.967	rs1658481	chr10:60289339	A/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.5	-0.49	3.25e-7	Refractive error;
THYM	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg08847533	chr14:75593920	NEK9	-0.95	-9.92	-0.71	2.4e-16	Height;
THYM	cis	rs2404602	0.647	rs907594	chr15:77197745	C/A	cg23625390	chr15:77176239	SCAPER	-0.86	-5.98	-0.52	3.85e-8	Blood metabolite levels;
THYM	cis	rs1978968	0.956	rs7291304	chr22:18421821	C/A	cg01550578	chr22:18484421	MICAL3	0.63	4.71	0.44	8.32e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs8067545	0.611	rs7219908	chr17:20043036	A/G	cg13482628	chr17:19912719	NA	0.55	4.68	0.43	9.41e-6	Schizophrenia;
THYM	cis	rs6754311	0.731	rs13404551	chr2:136721995	T/C	cg07169764	chr2:136633963	MCM6	0.67	5.75	0.51	1.1e-7	Mosquito bite size;
THYM	cis	rs9303401	0.703	rs9909925	chr17:57210069	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.66	-4.51	-0.42	1.83e-5	Cognitive test performance;
THYM	cis	rs2797685	0.786	rs72632093	chr1:7897988	G/A	cg06712362	chr1:7811235	CAMTA1	1.01	5.82	0.51	7.79e-8	Crohn's disease;
THYM	cis	rs7192380	1.000	rs8049728	chr16:69654790	G/T	cg09409435	chr16:70099608	PDXDC2	0.62	4.73	0.44	7.92e-6	Sjögren's syndrome;
THYM	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg03433033	chr1:76189801	ACADM	0.76	8.16	0.64	1.4e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.8	8.17	0.64	1.33e-12	Lymphocyte counts;
THYM	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.32	-9.88	-0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs981844	0.740	rs6858578	chr4:154682058	G/T	cg09973105	chr4:154681532	RNF175	0.52	4.8	0.44	5.91e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs3892630	0.817	rs12609866	chr19:33184412	C/T	cg22928329	chr19:33183273	NUDT19	-0.78	-5.86	-0.52	6.74e-8	Red blood cell traits;
THYM	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.36	-0.48	5.84e-7	Bipolar disorder;
THYM	cis	rs17209837	0.527	rs45479991	chr7:87083339	A/T	cg04996195	chr7:87105398	ABCB4	0.63	4.79	0.44	6.03e-6	Gallbladder cancer;
THYM	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs10248619	0.505	rs2190503	chr7:50742617	C/T	cg12248358	chr7:50534670	DDC	0.92	4.48	0.42	2.06e-5	Fasting blood glucose;Fasting blood glucose (BMI interaction);
THYM	cis	rs7172809	0.615	rs76499944	chr15:77804814	A/G	cg22256960	chr15:77711686	NA	-0.61	-4.46	-0.42	2.24e-5	Glucose homeostasis traits;
THYM	cis	rs7100689	0.577	rs1143694	chr10:82040052	C/T	cg01528321	chr10:82214614	TSPAN14	-0.96	-7.48	-0.61	3.7e-11	Post bronchodilator FEV1;
THYM	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14893161	chr1:205819251	PM20D1	0.74	7.37	0.6	6.28e-11	Menarche (age at onset);
THYM	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg02734326	chr4:10020555	SLC2A9	-0.62	-5.04	-0.46	2.21e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13732083	chr21:47605072	C21orf56	0.79	5.07	0.46	1.96e-6	Testicular germ cell tumor;
THYM	cis	rs2050392	0.767	rs1536833	chr10:30699265	C/T	cg02070205	chr10:30722105	MAP3K8	0.64	5.68	0.5	1.45e-7	Inflammatory bowel disease;
THYM	cis	rs7746082	0.596	rs73516757	chr6:106460357	A/G	cg02270332	chr6:106475062	NA	-0.58	-5.54	-0.49	2.64e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs2811415	0.597	rs11721156	chr3:127796627	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs12620999	0.938	rs4575672	chr2:238070572	T/C	cg15976283	chr2:238042351	NA	0.63	4.94	0.45	3.33e-6	Systemic lupus erythematosus;
THYM	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg06212747	chr3:49208901	KLHDC8B	0.58	4.64	0.43	1.09e-5	Menarche (age at onset);
THYM	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg08847533	chr14:75593920	NEK9	-0.93	-9.75	-0.71	5.55e-16	Height;
THYM	cis	rs7432375	0.966	rs6808312	chr3:136371504	C/T	cg21827317	chr3:136751795	NA	-0.57	-4.86	-0.45	4.62e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg00631329	chr6:26305371	NA	-0.6	-7.22	-0.6	1.27e-10	Educational attainment;
THYM	cis	rs854765	0.583	rs9913724	chr17:17819101	A/G	cg16928487	chr17:17741425	SREBF1	-0.57	-5.63	-0.5	1.79e-7	Total body bone mineral density;
THYM	cis	rs6835098	0.961	rs2078475	chr4:174098226	A/C	cg08422745	chr4:174089978	GALNT7	1.0	7.77	0.62	9.23e-12	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs61931739	0.534	rs11052986	chr12:34052578	T/C	cg06521331	chr12:34319734	NA	-0.92	-8.92	-0.68	3.4e-14	Morning vs. evening chronotype;
THYM	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg15744005	chr10:104629667	AS3MT	-0.85	-8.52	-0.66	2.38e-13	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg12826209	chr6:26865740	GUSBL1	0.86	4.94	0.45	3.4e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg09455208	chr3:40491958	NA	0.5	5.15	0.47	1.39e-6	Renal cell carcinoma;
THYM	cis	rs2976388	1.000	rs2920296	chr8:143763109	A/G	cg06565975	chr8:143823917	SLURP1	-0.45	-5.23	-0.47	9.95e-7	Urinary tract infection frequency;
THYM	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg24642844	chr7:1081250	C7orf50	-1.17	-5.03	-0.46	2.32e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg08885076	chr2:99613938	TSGA10	-0.74	-6.98	-0.58	3.88e-10	Chronic sinus infection;
THYM	cis	rs7173743	0.784	rs11072810	chr15:79132206	C/T	cg15571903	chr15:79123663	NA	-0.58	-6.3	-0.54	9.07e-9	Coronary artery disease;
THYM	cis	rs4642101	0.793	rs12714880	chr3:12832101	G/A	cg05775895	chr3:12838266	CAND2	0.81	6.98	0.58	3.99e-10	QRS complex (12-leadsum);
THYM	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg03909863	chr11:638404	DRD4	-0.76	-6.04	-0.53	2.95e-8	Systemic lupus erythematosus;
THYM	cis	rs57920188	0.535	rs4520388	chr1:4092671	T/G	cg20703997	chr1:4087676	NA	0.74	5.39	0.48	5.18e-7	Interleukin-17 levels;
THYM	cis	rs7487075	0.930	rs4076484	chr12:46833912	C/G	cg21428710	chr12:47219797	SLC38A4	0.46	4.54	0.42	1.63e-5	Itch intensity from mosquito bite;
THYM	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg05527609	chr1:210001259	C1orf107	1.05	8.63	0.66	1.38e-13	Orofacial clefts;
THYM	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.86	-5.69	-0.5	1.42e-7	Body mass index;
THYM	cis	rs8133932	0.668	rs3788226	chr21:47300115	A/G	cg08707771	chr21:46690014	POFUT2	0.78	4.77	0.44	6.52e-6	Schizophrenia;
THYM	cis	rs58235267	0.543	rs2539990	chr2:63170185	C/T	cg17519650	chr2:63277830	OTX1	0.69	5.37	0.48	5.5e-7	Prostate-specific antigen levels (conditioned on lead SNPs);
THYM	cis	rs12681287	0.640	rs13252046	chr8:87477751	G/T	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs9560113	0.580	rs9560115	chr13:112193619	G/A	cg14154082	chr13:112174009	NA	0.53	4.61	0.43	1.27e-5	Menarche (age at onset);
THYM	cis	rs748404	0.660	rs694725	chr15:43756210	A/G	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs8133932	0.724	rs11701130	chr21:47041808	A/C	cg20357416	chr21:47294739	PCBP3	-0.71	-4.47	-0.42	2.14e-5	Schizophrenia;
THYM	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.65	4.98	0.46	2.8e-6	Renal function-related traits (BUN);
THYM	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg14768367	chr16:72042858	DHODH	0.65	5.08	0.46	1.89e-6	Fibrinogen levels;
THYM	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg02187348	chr16:89574699	SPG7	0.8	6.51	0.56	3.48e-9	Multiple myeloma (IgH translocation);
THYM	cis	rs6430585	0.591	rs12475553	chr2:136483355	G/T	cg23851026	chr2:136556271	LCT	0.66	5.64	0.5	1.76e-7	Corneal structure;
THYM	cis	rs59698941	0.943	rs67656232	chr5:132254426	T/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg24324837	chr19:49891574	CCDC155	0.52	4.75	0.44	7.07e-6	Multiple sclerosis;
THYM	cis	rs2963155	0.518	rs258748	chr5:142656454	C/G	cg17617527	chr5:142782415	NR3C1	1.17	6.43	0.55	5.04e-9	Breast cancer;
THYM	cis	rs2708977	0.933	rs2708976	chr2:97184532	C/G	cg01950434	chr2:97203154	ARID5A	-0.53	-4.75	-0.44	7.12e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs9443645	0.810	rs7767711	chr6:79810700	G/A	cg18132916	chr6:79620363	NA	-0.55	-4.47	-0.42	2.12e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7078219	0.714	rs10883368	chr10:101289998	A/G	cg00674004	chr10:101280750	NA	0.51	4.63	0.43	1.16e-5	Dental caries;
THYM	cis	rs907612	0.638	rs11041476	chr11:1875067	C/T	cg26158194	chr11:1874320	LSP1	0.51	5.09	0.46	1.8e-6	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
THYM	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg17063962	chr7:91808500	NA	0.99	7.94	0.63	3.99e-12	Breast cancer;
THYM	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg16624210	chr5:671434	TPPP	0.64	4.56	0.42	1.53e-5	Lung disease severity in cystic fibrosis;
THYM	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9972944	0.899	rs9972954	chr17:63771050	T/C	cg07283582	chr17:63770753	CCDC46	0.65	5.25	0.47	9.39e-7	Total body bone mineral density;
THYM	cis	rs1847202	0.592	rs13073005	chr3:72951007	C/T	cg27402429	chr3:72788294	NA	-0.71	-4.55	-0.42	1.56e-5	Motion sickness;
THYM	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg02788857	chr8:22132959	PIWIL2	0.6	5.53	0.49	2.87e-7	Hypertriglyceridemia;
THYM	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg18904891	chr8:8559673	CLDN23	0.71	5.32	0.48	6.91e-7	Obesity-related traits;
THYM	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg13609457	chr4:120235615	NA	-0.54	-5.0	-0.46	2.63e-6	Corneal astigmatism;
THYM	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg13683864	chr3:40499215	RPL14	-1.05	-11.46	-0.76	1.29e-19	Renal cell carcinoma;
THYM	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg21280719	chr6:42927975	GNMT	-0.51	-6.84	-0.57	7.67e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs262150	0.530	rs2730232	chr7:158784469	C/T	cg19418458	chr7:158789849	NA	0.57	4.53	0.42	1.74e-5	Facial morphology (factor 20);
THYM	cis	rs12216545	0.961	rs12536876	chr7:150207765	A/G	cg08960815	chr7:150264767	GIMAP4	0.74	6.1	0.53	2.31e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg11752832	chr7:134001865	SLC35B4	0.77	5.54	0.49	2.64e-7	Mean platelet volume;
THYM	cis	rs8051149	0.688	rs12444533	chr16:87869711	C/T	cg01412419	chr16:87856264	NA	0.69	5.41	0.49	4.69e-7	Blood metabolite levels;
THYM	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-4.95	-0.45	3.16e-6	Chronic sinus infection;
THYM	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-6.98	-0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg11764359	chr7:65958608	NA	0.64	5.0	0.46	2.58e-6	Aortic root size;
THYM	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg16322479	chr5:444228	EXOC3;C5orf55	0.56	4.61	0.43	1.24e-5	Cystic fibrosis severity;
THYM	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg17105886	chr17:28927953	LRRC37B2	1.26	7.32	0.6	8.11e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg09455208	chr3:40491958	NA	0.46	4.66	0.43	1.03e-5	Renal cell carcinoma;
THYM	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg16099169	chr2:106886729	NA	-0.83	-5.78	-0.51	9.59e-8	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
THYM	cis	rs478304	0.651	rs11227299	chr11:65549570	C/G	cg27068330	chr11:65405492	SIPA1	-0.96	-9.31	-0.69	4.93e-15	Acne (severe);
THYM	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg21775007	chr8:11205619	TDH	0.66	5.26	0.47	8.9e-7	Retinal vascular caliber;
THYM	cis	rs61990749	0.571	rs2364841	chr14:78284036	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.94	6.16	0.53	1.77e-8	Fibroblast growth factor basic levels;
THYM	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg19318889	chr4:1322082	MAEA	0.69	5.93	0.52	4.98e-8	Longevity;
THYM	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg06970220	chr1:156163860	SLC25A44	0.72	5.59	0.5	2.18e-7	Testicular germ cell tumor;
THYM	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg15536230	chr21:44985092	HSF2BP	-0.41	-5.06	-0.46	2.07e-6	Mean corpuscular volume;
THYM	cis	rs12121840	0.736	rs12142937	chr1:165540692	G/A	cg19407955	chr1:165599744	MGST3	-0.65	-4.64	-0.43	1.12e-5	Interleukin-1-receptor antagonist levels;
THYM	cis	rs10911251	0.528	rs2093982	chr1:183094191	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Colorectal cancer;
THYM	cis	rs2404602	0.647	rs11633869	chr15:77133322	G/T	cg23625390	chr15:77176239	SCAPER	0.86	6.32	0.54	8.54e-9	Blood metabolite levels;
THYM	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg20295408	chr7:1910781	MAD1L1	-0.67	-5.54	-0.49	2.71e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs6754311	0.517	rs1865452	chr2:136539330	C/T	cg04750100	chr2:136595281	LCT	0.53	5.13	0.47	1.55e-6	Mosquito bite size;
THYM	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg22535103	chr8:58192502	C8orf71	-0.86	-4.82	-0.44	5.4e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1129187	0.702	rs2296805	chr6:42928758	T/G	cg21280719	chr6:42927975	GNMT	-0.53	-7.41	-0.61	5.24e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-6.16	-0.53	1.75e-8	Extrinsic epigenetic age acceleration;
THYM	trans	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg23505145	chr19:12996616	KLF1	0.96	7.94	0.63	4.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg10661904	chr17:79619235	PDE6G	0.57	5.3	0.48	7.61e-7	Eye color traits;
THYM	cis	rs11563648	0.573	rs10241265	chr7:126948370	C/T	cg23081781	chr7:127225937	GCC1	-0.37	-5.13	-0.47	1.55e-6	Resting heart rate;
THYM	cis	rs34638657	0.656	rs1134847	chr16:82203742	C/T	cg09439754	chr16:82129088	HSD17B2	0.51	4.96	0.45	3.09e-6	Lung adenocarcinoma;
THYM	cis	rs1003719	0.715	rs2252893	chr21:38507572	T/C	cg01329690	chr21:38580129	DSCR9	-0.38	-5.21	-0.47	1.09e-6	Eye color traits;
THYM	trans	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.11	8.17	0.64	1.3e-12	Exhaled nitric oxide output;
THYM	trans	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg10856724	chr12:34555212	NA	-0.9	-8.08	-0.64	2.05e-12	Bladder cancer;
THYM	cis	rs7772486	0.875	rs6914813	chr6:146397798	A/G	cg13319975	chr6:146136371	FBXO30	-0.63	-5.21	-0.47	1.08e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2108225	1.000	rs6466191	chr7:107453511	A/T	cg18560240	chr7:107437656	SLC26A3	-0.81	-5.93	-0.52	4.92e-8	Ulcerative colitis;
THYM	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg15448220	chr1:150897856	SETDB1	0.86	6.94	0.58	4.73e-10	Melanoma;
THYM	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg00256281	chr22:41985642	PMM1	0.62	4.77	0.44	6.73e-6	Vitiligo;
THYM	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg17105886	chr17:28927953	LRRC37B2	1.26	6.38	0.55	6.49e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg06521331	chr12:34319734	NA	-0.99	-9.11	-0.68	1.32e-14	Morning vs. evening chronotype;
THYM	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.86	-5.67	-0.5	1.56e-7	Body mass index;
THYM	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26314531	chr2:26401878	FAM59B	0.78	5.13	0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03452623	chr4:187889614	NA	1.11	13.7	0.81	3.23e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg07414643	chr4:187882934	NA	-0.58	-5.13	-0.47	1.54e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2455799	0.634	rs4685266	chr3:15908766	A/G	cg16303742	chr3:15540471	COLQ	-0.55	-5.82	-0.51	7.87e-8	Mean platelet volume;
THYM	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg13852791	chr20:30311386	BCL2L1	0.79	5.87	0.52	6.5e-8	Mean corpuscular hemoglobin;
THYM	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg15536230	chr21:44985092	HSF2BP	-0.38	-4.64	-0.43	1.11e-5	Mean corpuscular volume;
THYM	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg09549813	chr16:4587862	C16orf5	0.57	6.23	0.54	1.24e-8	Schizophrenia;
THYM	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg11871910	chr12:69753446	YEATS4	-0.62	-5.01	-0.46	2.49e-6	Blood protein levels;
THYM	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg15704280	chr7:45808275	SEPT13	-0.82	-8.42	-0.65	3.96e-13	Height;
THYM	trans	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17712092	chr4:129076599	LARP1B	0.9	7.36	0.6	6.44e-11	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22496380	chr5:211416	CCDC127	1.33	7.99	0.63	3.21e-12	Breast cancer;
THYM	trans	rs4262150	0.883	rs17489682	chr5:152312444	T/G	cg08281791	chr5:76607845	PDE8B	0.93	7.1	0.59	2.24e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg06108461	chr20:60628389	TAF4	-1.06	-8.54	-0.66	2.19e-13	Body mass index;
THYM	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs1371867	0.875	rs1660311	chr8:101330579	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg06453172	chr10:134556979	INPP5A	-0.63	-4.53	-0.42	1.71e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg13319975	chr6:146136371	FBXO30	-0.6	-4.92	-0.45	3.66e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17597773	0.598	rs11118616	chr1:221005656	C/T	cg16008148	chr1:221062819	NA	0.43	4.47	0.42	2.2e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs861020	1.000	rs7555285	chr1:209970355	C/G	cg05527609	chr1:210001259	C1orf107	-0.89	-7.1	-0.59	2.22e-10	Orofacial clefts;
THYM	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg12310025	chr6:25882481	NA	0.92	8.34	0.65	5.62e-13	Blood metabolite levels;
THYM	cis	rs2777491	0.957	rs6493002	chr15:41709195	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.12	-12.75	-0.79	2.77e-22	Ulcerative colitis;
THYM	cis	rs155076	0.666	rs4638420	chr13:21872348	A/G	cg11317459	chr13:21872234	NA	1.18	9.79	0.71	4.6e-16	White matter hyperintensity burden;
THYM	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg15536230	chr21:44985092	HSF2BP	0.4	4.83	0.44	5.23e-6	Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7843479	0.601	rs2306645	chr8:21845428	C/T	cg17168535	chr8:21777572	XPO7	-0.8	-7.04	-0.59	2.93e-10	Mean corpuscular volume;
THYM	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg24399712	chr22:39784796	NA	-0.85	-9.78	-0.71	4.86e-16	Intelligence (multi-trait analysis);
THYM	cis	rs3126085	0.935	rs877776	chr1:152178018	C/G	cg10321714	chr1:152280068	FLG	0.67	4.81	0.44	5.71e-6	Atopic dermatitis;
THYM	cis	rs9611519	1.000	rs5758268	chr22:41622419	A/T	cg06481639	chr22:41940642	POLR3H	-0.67	-4.87	-0.45	4.53e-6	Neuroticism;
THYM	cis	rs9329221	0.525	rs4394398	chr8:10084394	C/T	ch.8.9203391F	chr8:9165981	NA	0.54	4.47	0.42	2.16e-5	Neuroticism;
THYM	cis	rs2688608	0.780	rs2688619	chr10:75682176	A/G	cg02947784	chr10:75434997	AGAP5	0.49	4.61	0.43	1.26e-5	Inflammatory bowel disease;
THYM	cis	rs6087990	1.000	rs1007124	chr20:31345752	G/C	cg13636640	chr20:31349939	DNMT3B	0.96	10.76	0.74	4.02e-18	Ulcerative colitis;
THYM	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg12419862	chr22:24373484	LOC391322	-0.77	-8.19	-0.64	1.17e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg23583168	chr7:148888333	NA	-1.02	-14.09	-0.82	5.29e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs7267979	1.000	rs13038834	chr20:25441433	C/T	cg08601574	chr20:25228251	PYGB	0.57	4.55	0.42	1.6e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7432375	0.901	rs9836231	chr3:136414321	C/T	cg21827317	chr3:136751795	NA	-0.59	-5.05	-0.46	2.11e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.64	-4.68	-0.43	9.69e-6	Colorectal cancer;
THYM	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg06009448	chr7:1102226	C7orf50	0.46	4.92	0.45	3.6e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs60871478	0.588	rs73038184	chr7:845094	G/A	cg10248100	chr7:872053	UNC84A	0.72	4.61	0.43	1.27e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg22875332	chr1:76189707	ACADM	-0.52	-4.82	-0.44	5.5e-6	Daytime sleep phenotypes;
THYM	cis	rs12579753	1.000	rs12827923	chr12:82242067	G/A	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.67	-0.43	1.01e-5	Resting heart rate;
THYM	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg10515332	chr4:99064459	C4orf37	0.56	4.47	0.42	2.15e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg20387954	chr3:183756860	HTR3D	0.58	4.73	0.44	7.72e-6	Anterior chamber depth;
THYM	cis	rs7917772	0.604	rs10883756	chr10:104400112	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.71	-5.52	-0.49	2.94e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg10465839	chr16:1584050	IFT140;TMEM204	-0.54	-4.63	-0.43	1.15e-5	Coronary artery disease;
THYM	cis	rs9403317	0.960	rs9373314	chr6:141820687	A/T	cg15052665	chr6:141804349	NA	0.83	8.3	0.65	7.11e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.7	5.56	0.5	2.49e-7	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs4788570	0.538	rs72797728	chr16:71552789	C/T	cg06353428	chr16:71660113	MARVELD3	-1.02	-5.08	-0.46	1.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg07988820	chr12:82153109	PPFIA2	-0.83	-5.29	-0.48	7.71e-7	Resting heart rate;
THYM	cis	rs11168351	0.517	rs10875754	chr12:48557922	G/C	cg21466736	chr12:48725269	NA	-0.42	-4.56	-0.42	1.51e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs2658782	1.000	rs2019814	chr11:93168885	A/G	cg16424440	chr11:93231842	C11orf75	-0.74	-4.69	-0.43	9.19e-6	Pulmonary function decline;
THYM	cis	rs2109514	0.840	rs6953982	chr7:116129290	C/T	cg12739419	chr7:116140593	CAV2	-0.48	-4.7	-0.43	8.75e-6	Prevalent atrial fibrillation;
THYM	cis	rs11771526	0.892	rs76035550	chr7:32371359	G/A	cg27511599	chr7:32358540	NA	0.75	5.02	0.46	2.42e-6	Body mass index;
THYM	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.8e-7	Monocyte count;
THYM	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg05717871	chr11:638507	DRD4	-0.64	-4.85	-0.45	4.87e-6	Systemic lupus erythematosus;
THYM	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg09263875	chr16:632152	PIGQ	0.7	5.71	0.51	1.27e-7	Height;
THYM	cis	rs7429990	0.901	rs7431567	chr3:48027832	G/T	cg02219026	chr3:48282209	ZNF589	0.64	4.71	0.44	8.47e-6	Educational attainment (years of education);
THYM	cis	rs877282	0.838	rs34912955	chr10:772222	T/C	cg10556349	chr10:835070	NA	-0.77	-5.28	-0.48	8.04e-7	Uric acid levels;
THYM	cis	rs4499344	0.604	rs259287	chr19:33164859	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.88	7.61	0.62	2.03e-11	Mean platelet volume;
THYM	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs7616559	0.849	rs9852415	chr3:156754191	A/G	cg15697575	chr3:156784781	NA	0.4	5.15	0.47	1.4e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg02221750	chr19:17393354	ANKLE1	-0.96	-8.86	-0.67	4.58e-14	Systemic lupus erythematosus;
THYM	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg13683864	chr3:40499215	RPL14	-1.08	-12.72	-0.79	3.14e-22	Renal cell carcinoma;
THYM	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg17054759	chr22:49844102	NA	-0.53	-4.93	-0.45	3.54e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-4.95	-0.45	3.19e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4474465	0.850	rs7942371	chr11:78219975	A/G	cg19901956	chr11:77921274	USP35	0.66	4.84	0.44	4.99e-6	Alzheimer's disease (survival time);
THYM	cis	rs6500395	1.000	rs9938308	chr16:48607229	A/G	cg04672837	chr16:48644449	N4BP1	0.54	5.5	0.49	3.25e-7	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg12893428	chr3:195717962	SDHAP1	0.53	4.68	0.43	9.61e-6	Pancreatic cancer;
THYM	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	trans	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg06636001	chr8:8085503	FLJ10661	-0.78	-7.17	-0.59	1.65e-10	Triglycerides;
THYM	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.86	5.33	0.48	6.74e-7	Platelet count;
THYM	cis	rs11039798	0.688	rs12277029	chr11:48852833	G/T	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.7	-5.33	-0.48	6.74e-7	Response to bleomycin (chromatid breaks);
THYM	cis	rs7666738	0.512	rs1648536	chr4:99019881	G/T	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11997175	0.583	rs17780571	chr8:33817821	G/C	ch.8.33884649F	chr8:33765107	NA	0.73	5.24	0.47	9.7e-7	Body mass index;
THYM	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg03351412	chr1:154909251	PMVK	0.7	5.38	0.48	5.4e-7	Prostate cancer;
THYM	cis	rs2235649	0.833	rs4335769	chr16:1849376	G/A	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.33	10.11	0.72	9.63e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs13412757	0.512	rs7601045	chr2:8491886	A/T	cg27527593	chr2:8818326	NA	-0.67	-4.55	-0.42	1.57e-5	Asthma;Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1048238	0.506	rs12023422	chr1:16187625	G/A	cg21385522	chr1:16154831	NA	0.66	5.38	0.48	5.32e-7	Systolic blood pressure;
THYM	cis	rs55728055	0.661	rs62237773	chr22:31965054	A/G	cg10537193	chr22:32026975	PISD	-0.92	-5.7	-0.5	1.35e-7	Age-related hearing impairment;
THYM	cis	rs9814567	0.806	rs4955526	chr3:134317337	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-8.2	-0.64	1.16e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7582180	0.845	rs11683088	chr2:100920667	C/T	cg21926883	chr2:100939477	LONRF2	-0.66	-6.01	-0.52	3.43e-8	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.38	0.73	2.5e-17	Prudent dietary pattern;
THYM	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg24060327	chr5:131705240	SLC22A5	-0.76	-5.73	-0.51	1.16e-7	Blood metabolite levels;
THYM	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg23260525	chr10:116636907	FAM160B1	0.53	5.33	0.48	6.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9650657	0.615	rs1549796	chr8:10692359	C/T	cg12981288	chr8:11183844	MTMR9	-0.5	-4.7	-0.43	8.65e-6	Neuroticism;
THYM	cis	rs6500395	1.000	rs2129243	chr16:48646852	A/T	cg04672837	chr16:48644449	N4BP1	0.52	5.25	0.47	9.45e-7	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg00271210	chr6:167070053	RPS6KA2	-0.56	-5.81	-0.51	8.42e-8	Crohn's disease;
THYM	cis	rs131777	0.526	rs86337	chr22:51020668	C/A	cg00083937	chr22:51039805	MAPK8IP2	0.6	5.41	0.49	4.64e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs8060598	0.933	rs9940175	chr16:50780552	C/T	cg05261686	chr16:50743296	NOD2	0.36	4.64	0.43	1.13e-5	Leprosy;
THYM	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg22968622	chr17:43663579	NA	-1.1	-9.99	-0.72	1.7e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg03433033	chr1:76189801	ACADM	0.74	7.28	0.6	9.54e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs921968	0.608	rs678814	chr2:219359287	T/C	cg02176678	chr2:219576539	TTLL4	0.68	6.56	0.56	2.74e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs3126085	0.935	rs6587647	chr1:152192631	C/T	cg10321714	chr1:152280068	FLG	0.64	4.6	0.43	1.29e-5	Atopic dermatitis;
THYM	cis	rs2688608	0.587	rs2894040	chr10:75478159	A/C	cg23231163	chr10:75533350	FUT11	-0.41	-5.9	-0.52	5.54e-8	Inflammatory bowel disease;
THYM	cis	rs9914544	0.545	rs9912568	chr17:18792719	G/A	cg26378065	chr17:18585709	ZNF286B	0.58	4.65	0.43	1.05e-5	Educational attainment (years of education);
THYM	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg25072359	chr17:41440525	NA	0.64	4.48	0.42	2.05e-5	Menopause (age at onset);
THYM	cis	rs12367572	0.601	rs1495036	chr12:45410643	T/C	cg03114573	chr12:45410052	DBX2	-0.53	-4.96	-0.45	3.11e-6	Gut microbiome composition (summer);
THYM	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.69	-4.62	-0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs6674176	0.561	rs7161	chr1:44438974	A/G	cg15962314	chr1:44399869	ARTN	-0.51	-4.86	-0.45	4.55e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs9457247	0.534	rs2345568	chr6:167381804	A/G	cg23791538	chr6:167370224	RNASET2	0.86	7.61	0.62	1.96e-11	Crohn's disease;
THYM	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg13736514	chr6:26305472	NA	-0.61	-7.53	-0.61	2.93e-11	Educational attainment;
THYM	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs240764	0.610	rs41288423	chr6:101166095	G/A	cg21058520	chr6:100914733	NA	0.59	5.07	0.46	1.99e-6	Neuroticism;
THYM	cis	rs2219968	0.798	rs4397393	chr8:78937569	G/C	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12754538	0.777	rs1000184	chr1:8640831	G/C	cg06159269	chr1:8767347	RERE	0.22	4.58	0.43	1.39e-5	Subjective well-being;
THYM	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs986417	0.818	rs1998189	chr14:60974987	A/T	cg27398547	chr14:60952738	C14orf39	1.13	5.43	0.49	4.26e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs62435770	1.000	rs73036152	chr6:169514319	T/A	cg07652237	chr6:170125491	PHF10	0.54	4.82	0.44	5.48e-6	Loneliness;
THYM	cis	rs9361491	0.608	rs6900794	chr6:79477844	C/T	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.88e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7172809	0.573	rs60079927	chr15:77591614	T/C	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs10992471	0.580	rs1535756	chr9:95202032	G/A	cg14631576	chr9:95140430	CENPP	-0.99	-9.94	-0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg21475434	chr5:93447410	FAM172A	0.9	4.96	0.45	3.05e-6	Diabetic retinopathy;
THYM	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg26384229	chr12:38710491	ALG10B	-0.89	-7.49	-0.61	3.48e-11	Bladder cancer;
THYM	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs2073300	0.609	rs6137917	chr20:23360369	G/A	cg12062639	chr20:23401060	NAPB	1.2	6.44	0.55	4.94e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs9611519	0.780	rs1983631	chr22:41644074	C/T	cg06481639	chr22:41940642	POLR3H	-0.69	-5.41	-0.49	4.75e-7	Neuroticism;
THYM	cis	rs34638657	0.872	rs2967355	chr16:82200103	G/T	cg09894383	chr16:82067445	HSD17B2	0.51	5.2	0.47	1.15e-6	Lung adenocarcinoma;
THYM	cis	rs2976388	0.609	rs2585149	chr8:143793320	T/C	cg06565975	chr8:143823917	SLURP1	0.47	5.22	0.47	1.06e-6	Urinary tract infection frequency;
THYM	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg14983838	chr19:29218262	NA	1.09	9.77	0.71	5e-16	Methadone dose in opioid dependence;
THYM	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg02725872	chr8:58115012	NA	-1.08	-8.12	-0.64	1.68e-12	Developmental language disorder (linguistic errors);
THYM	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg03433033	chr1:76189801	ACADM	-0.51	-5.31	-0.48	7.2e-7	Daytime sleep phenotypes;
THYM	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg13918804	chr1:2043761	PRKCZ	-0.81	-7.45	-0.61	4.33e-11	Height;
THYM	cis	rs6484504	0.576	rs208072	chr11:31141288	A/G	cg14844989	chr11:31128820	NA	0.4	4.55	0.42	1.57e-5	Red blood cell count;
THYM	cis	rs2072499	0.966	rs2853643	chr1:156184831	G/A	cg06970220	chr1:156163860	SLC25A44	0.73	5.66	0.5	1.62e-7	Testicular germ cell tumor;
THYM	cis	rs13064411	0.696	rs9814395	chr3:113188885	C/T	cg18753928	chr3:113234510	CCDC52	-0.9	-8.68	-0.66	1.1e-13	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7107174	0.901	rs2450133	chr11:77925759	A/C	cg02023728	chr11:77925099	USP35	0.68	6.29	0.54	9.53e-9	Testicular germ cell tumor;
THYM	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05901451	chr6:126070800	HEY2	0.95	9.52	0.7	1.78e-15	Brugada syndrome;
THYM	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg18105134	chr13:113819100	PROZ	-0.99	-9.19	-0.69	8.83e-15	Platelet distribution width;
THYM	cis	rs17598306	1.000	rs722470	chr7:96581466	C/G	cg13449377	chr7:96631089	DLX6AS	0.76	4.78	0.44	6.38e-6	Radiation response;
THYM	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg23281280	chr6:28129359	ZNF389	0.61	4.88	0.45	4.21e-6	Depression;
THYM	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg05738196	chr6:26577821	NA	0.96	9.94	0.71	2.27e-16	Intelligence (multi-trait analysis);
THYM	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.79	6.89	0.58	6.16e-10	Tonsillectomy;
THYM	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg16797656	chr11:68205561	LRP5	-0.43	-4.62	-0.43	1.23e-5	Total body bone mineral density;
THYM	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4731207	0.698	rs10954045	chr7:124498155	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs4631830	0.600	rs11004324	chr10:51496623	G/T	cg16070123	chr10:51489643	NA	-0.58	-5.46	-0.49	3.86e-7	Prostate-specific antigen levels;
THYM	cis	rs916888	0.647	rs199520	chr17:44853872	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.53	-4.45	-0.42	2.35e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.69	-0.67	1.03e-13	Monocyte count;
THYM	cis	rs11690935	0.632	rs2292816	chr2:172586714	G/C	cg13550731	chr2:172543902	DYNC1I2	0.68	5.43	0.49	4.3e-7	Schizophrenia;
THYM	cis	rs5758511	0.773	rs10154700	chr22:42365073	G/T	cg08431931	chr22:42394659	WBP2NL	0.73	4.56	0.42	1.51e-5	Birth weight;
THYM	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg08999081	chr20:33150536	PIGU	-0.81	-7.04	-0.59	2.97e-10	Coronary artery disease;
THYM	cis	rs1620921	0.524	rs7450979	chr6:161186889	A/C	cg01280913	chr6:161186852	NA	0.51	4.62	0.43	1.21e-5	Lipoprotein (a) - cholesterol levels;
THYM	cis	rs11771526	0.901	rs17161124	chr7:32307324	A/T	cg27511599	chr7:32358540	NA	-0.6	-4.49	-0.42	2e-5	Body mass index;
THYM	cis	rs137603	0.933	rs137591	chr22:39685450	A/G	cg24268161	chr22:39747459	SYNGR1	0.56	4.83	0.44	5.23e-6	Primary biliary cholangitis;
THYM	cis	rs7107174	0.901	rs10899473	chr11:78042983	A/C	cg19901956	chr11:77921274	USP35	-0.67	-5.5	-0.49	3.14e-7	Testicular germ cell tumor;
THYM	cis	rs7011507	0.700	rs72639016	chr8:49333078	C/T	cg08774009	chr8:49309094	NA	-0.63	-4.89	-0.45	4.18e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg22508957	chr16:3507546	NAT15	0.68	9.74	0.71	5.81e-16	Tuberculosis;
THYM	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs7172809	0.607	rs78510848	chr15:77842308	G/C	cg10437265	chr15:77819839	NA	-0.51	-4.68	-0.43	9.7e-6	Glucose homeostasis traits;
THYM	cis	rs10751667	0.961	rs6597954	chr11:987677	G/A	cg01483505	chr11:975446	AP2A2	0.63	4.9	0.45	4.01e-6	Alzheimer's disease (late onset);
THYM	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg20503657	chr10:835505	NA	1.09	7.73	0.62	1.13e-11	Eosinophil percentage of granulocytes;
THYM	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg06600287	chr1:53387719	ECHDC2	-0.35	-5.73	-0.51	1.2e-7	Monocyte count;
THYM	cis	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg16898833	chr6:26189333	HIST1H4D	1.3	4.47	0.42	2.14e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1278352	0.929	rs1278368	chr10:127777021	G/A	cg08295661	chr10:127769903	ADAM12	-0.46	-4.9	-0.45	3.89e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs7104764	0.879	rs6598070	chr11:225466	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.11	9.57	0.7	1.4e-15	Menarche (age at onset);
THYM	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg00814883	chr7:100076585	TSC22D4	-0.95	-6.39	-0.55	6.08e-9	Platelet count;
THYM	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg14798641	chr3:49314920	USP4;C3orf62	-0.65	-4.57	-0.42	1.47e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22496380	chr5:211416	CCDC127	-1.3	-8.28	-0.65	7.84e-13	Breast cancer;
THYM	cis	rs3862030	0.839	rs7078511	chr10:104283874	C/A	cg00122347	chr10:104236741	TMEM180	0.48	7.33	0.6	7.69e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs1883415	0.553	rs807526	chr6:24543720	G/A	cg00346970	chr6:24499591	ALDH5A1	0.36	4.49	0.42	1.97e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs285406	0.506	rs285402	chr8:87041727	C/T	cg06689659	chr8:87110279	ATP6V0D2	-0.59	-4.57	-0.42	1.48e-5	Adverse response to lamotrigine and phenytoin;
THYM	cis	rs1865721	0.771	rs7236311	chr18:73137450	A/G	cg26385618	chr18:73139727	C18orf62	-0.65	-4.88	-0.45	4.33e-6	Intelligence;
THYM	cis	rs1691799	0.899	rs1168357	chr12:66749879	T/C	cg16791601	chr12:66731901	HELB	-0.73	-6.86	-0.58	6.96e-10	White blood cell count (basophil);
THYM	cis	rs7127900	1.000	rs4076054	chr11:2231341	G/A	cg25635251	chr11:2234043	NA	0.74	4.71	0.44	8.43e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg06766960	chr11:133703094	NA	0.62	5.66	0.5	1.6e-7	Childhood ear infection;
THYM	cis	rs4919694	1.000	rs75691516	chr10:104652045	C/T	cg04362960	chr10:104952993	NT5C2	1.06	6.74	0.57	1.22e-9	Arsenic metabolism;
THYM	cis	rs1348850	0.958	rs10930801	chr2:178459861	G/A	cg27490568	chr2:178487706	NA	0.63	5.83	0.51	7.73e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg18876405	chr7:65276391	NA	0.63	5.56	0.5	2.48e-7	Aortic root size;
THYM	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg12165864	chr7:66369176	NA	-0.65	-5.08	-0.46	1.89e-6	Aortic root size;
THYM	cis	rs3917265	0.694	rs3917243	chr2:102774988	C/T	cg13315345	chr2:102803985	IL1RL2	0.5	4.95	0.45	3.2e-6	Atopic dermatitis;
THYM	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg12963246	chr6:28129442	ZNF389	0.72	5.78	0.51	9.62e-8	Parkinson's disease;
THYM	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs7404928	0.651	rs9939895	chr16:23948430	A/G	cg26685404	chr16:23957272	PRKCB	0.61	7.05	0.59	2.91e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs863345	0.604	rs12133794	chr1:158506697	C/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg25382214	chr1:3105252	PRDM16	0.55	4.71	0.44	8.37e-6	Migraine;
THYM	cis	rs886144	0.628	rs1467928	chr15:91715848	G/A	cg21594043	chr15:92491578	SLCO3A1	-0.47	-4.45	-0.42	2.33e-5	Metabolite levels;
THYM	cis	rs7712401	0.537	rs57182281	chr5:122353725	C/T	cg19808643	chr5:122110361	SNX2	-0.64	-5.45	-0.49	3.98e-7	Mean platelet volume;
THYM	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg06634786	chr22:41940651	POLR3H	0.67	5.36	0.48	5.7e-7	Vitiligo;
THYM	cis	rs2404602	0.647	rs11631959	chr15:77040048	T/C	cg23625390	chr15:77176239	SCAPER	-0.83	-5.98	-0.52	3.96e-8	Blood metabolite levels;
THYM	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs11771526	0.579	rs77818421	chr7:32375129	G/T	cg27532318	chr7:32358331	NA	0.84	4.68	0.43	9.64e-6	Body mass index;
THYM	cis	rs4343996	0.543	rs2140114	chr7:3407568	C/T	cg21248987	chr7:3385318	SDK1	0.41	5.17	0.47	1.28e-6	Motion sickness;
THYM	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg03929089	chr4:120376271	NA	-1.01	-13.71	-0.82	3.1e-24	Height;
THYM	cis	rs28785552	0.897	rs7259466	chr19:53239369	G/A	cg10871876	chr19:53194124	ZNF83	0.78	6.53	0.56	3.28e-9	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs7119	0.717	rs12916973	chr15:77808099	C/T	cg10437265	chr15:77819839	NA	-0.76	-7.61	-0.62	1.98e-11	Type 2 diabetes;
THYM	cis	rs1003719	0.762	rs34273703	chr21:38475019	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg11663144	chr21:46675770	NA	-0.69	-9.27	-0.69	6.12e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10089	1.000	rs3805612	chr5:127505316	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.93	6.03	0.53	3.15e-8	Ileal carcinoids;
THYM	cis	rs17174870	0.955	rs6730521	chr2:112783957	A/G	cg17354880	chr2:112658759	MERTK	-0.59	-4.47	-0.42	2.13e-5	Multiple sclerosis;
THYM	cis	rs1065852	0.526	rs7290655	chr22:42390225	C/G	cg09667013	chr22:42394590	WBP2NL	0.54	4.8	0.44	5.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg03806693	chr22:41940476	POLR3H	1.01	7.83	0.63	6.73e-12	Vitiligo;
THYM	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg10334053	chr1:2078117	PRKCZ	-0.45	-4.53	-0.42	1.73e-5	Height;
THYM	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.94	6.5	0.55	3.77e-9	Schizophrenia;
THYM	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg13609457	chr4:120235615	NA	0.5	4.76	0.44	6.95e-6	Corneal astigmatism;
THYM	cis	rs8106542	0.906	rs2288904	chr19:10742170	A/G	cg17848348	chr19:10766748	ILF3	-0.8	-6.9	-0.58	5.89e-10	Platelet distribution width;
THYM	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs9309711	0.772	rs9309715	chr2:3492318	C/G	cg10845886	chr2:3471009	TTC15	0.58	4.68	0.43	9.58e-6	Neurofibrillary tangles;
THYM	cis	rs2717559	0.522	rs2949872	chr8:143872904	T/C	cg03405983	chr8:143858548	LYNX1	0.54	5.92	0.52	5.02e-8	Urinary tract infection frequency;
THYM	cis	rs2495707	0.602	rs75205635	chr10:102416299	G/T	cg03943218	chr10:102419600	NA	-0.59	-5.91	-0.52	5.34e-8	Body mass index;
THYM	trans	rs9951602	0.512	rs7241419	chr18:76640778	C/G	cg02800362	chr5:177631904	HNRNPAB	1.11	8.66	0.66	1.21e-13	Obesity-related traits;
THYM	cis	rs28595532	0.764	rs116302502	chr4:119748848	T/A	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs6570726	1.000	rs1935617	chr6:145943326	C/T	cg23711669	chr6:146136114	FBXO30	0.77	7.11	0.59	2.19e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28795989	0.795	rs7694650	chr4:7903416	A/G	cg00251875	chr4:7801337	AFAP1	0.61	4.93	0.45	3.53e-6	Intraocular pressure;
THYM	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg00684032	chr4:1343700	KIAA1530	0.54	4.79	0.44	6.19e-6	Longevity;
THYM	cis	rs9633740	0.545	rs2343306	chr10:82230146	A/G	cg01528321	chr10:82214614	TSPAN14	-1.03	-5.41	-0.49	4.71e-7	Post bronchodilator FEV1;
THYM	cis	rs7616559	0.739	rs10936060	chr3:156786437	T/C	cg15697575	chr3:156784781	NA	0.46	5.32	0.48	6.83e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs2862064	1.000	rs6867207	chr5:156450106	G/A	cg12943317	chr5:156479607	HAVCR1	-0.86	-5.28	-0.48	8.3e-7	Platelet count;
THYM	cis	rs7195287	0.591	rs63744561	chr16:2828172	T/G	cg05687563	chr16:2837658	PRSS33	0.58	4.78	0.44	6.44e-6	Eosinophil counts;
THYM	cis	rs709400	0.894	rs61996721	chr14:104061352	G/A	cg26031613	chr14:104095156	KLC1	1.1	9.99	0.72	1.73e-16	Body mass index;
THYM	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg00484396	chr16:3507460	NAT15	0.71	9.1	0.68	1.41e-14	Tuberculosis;
THYM	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg22947322	chr17:47091978	IGF2BP1	0.67	6.87	0.58	6.6e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs7107174	1.000	rs4945261	chr11:77990260	A/G	cg19901956	chr11:77921274	USP35	0.69	5.3	0.48	7.42e-7	Testicular germ cell tumor;
THYM	cis	rs7772486	0.774	rs2748503	chr6:146295042	T/C	cg23711669	chr6:146136114	FBXO30	0.75	6.76	0.57	1.12e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	5.79	0.51	9.14e-8	Rheumatoid arthritis;
THYM	cis	rs3112255	0.512	rs10174721	chr2:101337013	A/C	cg01042948	chr2:101319752	NA	0.49	4.67	0.43	9.72e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg15448220	chr1:150897856	SETDB1	0.88	6.95	0.58	4.5e-10	Melanoma;
THYM	cis	rs7447927	0.950	rs13153461	chr5:138852369	G/A	cg26929925	chr5:138714136	SLC23A1	0.6	5.28	0.48	8.19e-7	Esophageal squamous cell carcinoma;
THYM	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg14820908	chr5:178986412	RUFY1	0.55	5.68	0.5	1.46e-7	Lung cancer;
THYM	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg18402987	chr7:1209562	NA	0.61	4.7	0.43	8.83e-6	Longevity;Endometriosis;
THYM	cis	rs34526934	0.608	rs67508915	chr2:177032560	T/C	cg14324370	chr2:177042789	NA	-0.7	-5.97	-0.52	4.16e-8	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs4589258	0.788	rs7942155	chr11:90467518	C/T	cg26138821	chr11:89956704	CHORDC1	-0.57	-4.64	-0.43	1.13e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8114671	0.967	rs6058202	chr20:33777983	A/G	cg08999081	chr20:33150536	PIGU	0.53	4.77	0.44	6.63e-6	Height;
THYM	cis	rs8030485	0.545	rs939662	chr15:79428249	A/T	cg17916960	chr15:79447300	NA	0.59	5.89	0.52	5.88e-8	Left ventricle wall thickness;
THYM	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg06640241	chr16:89574553	SPG7	0.6	4.46	0.42	2.24e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs61931739	0.517	rs2636074	chr12:34064056	C/T	cg06521331	chr12:34319734	NA	-0.95	-9.13	-0.68	1.19e-14	Morning vs. evening chronotype;
THYM	cis	rs3845702	0.736	rs72962575	chr2:180862133	C/G	cg01881094	chr2:180872142	CWC22	0.92	5.53	0.49	2.76e-7	Schizophrenia;
THYM	cis	rs80319144	1.000	rs77432849	chr2:159234529	T/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/T	cg02778551	chr7:1045947	C7orf50	-0.99	-5.03	-0.46	2.36e-6	Longevity;Endometriosis;
THYM	cis	rs9611519	0.929	rs9611474	chr22:41434858	G/A	cg03806693	chr22:41940476	POLR3H	-0.77	-5.95	-0.52	4.56e-8	Neuroticism;
THYM	cis	rs7084402	0.967	rs1658432	chr10:60329069	C/G	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg14121845	chr20:25566513	NINL	0.56	5.04	0.46	2.18e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4077515	0.839	rs3812563	chr9:139271106	A/G	cg14115884	chr9:139300582	SDCCAG3	0.76	8.15	0.64	1.43e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs2882877	0.610	rs1123109	chr2:190444392	C/T	cg10752008	chr2:190445175	SLC40A1	-0.71	-5.23	-0.47	1e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg25811766	chr13:21894605	NA	-0.78	-5.02	-0.46	2.38e-6	White matter hyperintensity burden;
THYM	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg09307838	chr4:120376055	NA	0.77	5.56	0.5	2.5e-7	Corneal astigmatism;
THYM	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs9814567	0.702	rs9871226	chr3:134331466	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs1975974	0.590	rs113830378	chr17:21744147	G/C	cg18423549	chr17:21743878	NA	-0.65	-5.22	-0.47	1.04e-6	Psoriasis;
THYM	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.5	0.55	3.72e-9	Schizophrenia;
THYM	cis	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg10856724	chr12:34555212	NA	0.92	9.45	0.7	2.5e-15	Morning vs. evening chronotype;
THYM	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg01324343	chr3:183735012	ABCC5	-0.6	-8.02	-0.64	2.75e-12	Anterior chamber depth;
THYM	trans	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg26043149	chr18:55253948	FECH	1.16	10.82	0.74	2.98e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg05313129	chr8:58192883	C8orf71	-0.75	-4.57	-0.42	1.46e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg05043794	chr9:111880884	C9orf5	-0.4	-5.64	-0.5	1.71e-7	Menarche (age at onset);
THYM	cis	rs2294693	0.947	rs4714417	chr6:40987782	A/G	cg21128951	chr6:40996213	UNC5CL	0.61	4.95	0.45	3.24e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs9560113	1.000	rs9555811	chr13:112181532	A/C	cg10483660	chr13:112241077	NA	0.55	5.02	0.46	2.43e-6	Menarche (age at onset);
THYM	cis	rs9430161	0.579	rs11121667	chr1:11038476	C/T	cg27631724	chr1:11040367	C1orf127	0.67	6.55	0.56	2.92e-9	Ewing sarcoma;
THYM	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg14779329	chr11:130786720	SNX19	0.49	5.07	0.46	1.98e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.03	9.07	0.68	1.61e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg09085632	chr11:111637200	PPP2R1B	1.25	17.14	0.87	7.86e-31	Primary sclerosing cholangitis;
THYM	cis	rs11039798	0.582	rs1483119	chr11:48382334	A/G	cg24672777	chr11:48374446	OR4C45	0.96	6.27	0.54	1.05e-8	Axial length;
THYM	cis	rs1160297	0.633	rs12477231	chr2:53084648	T/G	cg07782112	chr2:53107842	NA	0.76	6.36	0.55	6.99e-9	Hemostatic factors and hematological phenotypes;
THYM	trans	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg10856724	chr12:34555212	NA	-0.82	-7.45	-0.61	4.33e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs829883	0.664	rs829874	chr12:98840615	G/A	cg25150519	chr12:98850993	NA	0.53	5.22	0.47	1.05e-6	Colorectal adenoma (advanced);
THYM	cis	rs12579753	1.000	rs34894912	chr12:82228721	A/G	cg07988820	chr12:82153109	PPFIA2	-0.73	-4.53	-0.42	1.71e-5	Resting heart rate;
THYM	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg04944784	chr2:26401820	FAM59B	-0.75	-5.49	-0.49	3.33e-7	Gut microbiome composition (summer);
THYM	cis	rs2294693	0.945	rs13216361	chr6:41007046	C/T	cg14418226	chr6:40996092	UNC5CL	0.75	6.13	0.53	1.97e-8	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg12288994	chr5:1860383	NA	0.86	7.08	0.59	2.44e-10	Cardiovascular disease risk factors;
THYM	cis	rs2836633	0.929	rs11701577	chr21:40028906	C/T	cg05519781	chr21:40033154	ERG	0.75	7.28	0.6	9.39e-11	Coronary artery disease;
THYM	cis	rs12928939	0.911	rs11645704	chr16:71826611	G/T	cg03805757	chr16:71968109	PKD1L3	-0.7	-5.31	-0.48	7.25e-7	Post bronchodilator FEV1;
THYM	cis	rs7103648	1.000	rs10838709	chr11:47447346	C/T	cg20307385	chr11:47447363	PSMC3	0.93	8.66	0.66	1.23e-13	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg25182066	chr10:30743637	MAP3K8	-0.57	-4.88	-0.45	4.28e-6	Inflammatory bowel disease;
THYM	cis	rs2361718	0.545	rs7221675	chr17:78085213	C/T	cg09238746	chr17:78121135	EIF4A3	-0.91	-6.71	-0.57	1.41e-9	Yeast infection;
THYM	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg26963428	chr7:66367121	NA	-0.59	-4.72	-0.44	8.08e-6	Corneal structure;
THYM	cis	rs11997175	0.510	rs34465523	chr8:33796849	C/T	ch.8.33884649F	chr8:33765107	NA	0.67	5.17	0.47	1.32e-6	Body mass index;
THYM	cis	rs9649213	0.593	rs6945554	chr7:97972946	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg03609598	chr5:56110824	MAP3K1	-0.91	-5.77	-0.51	9.92e-8	Initial pursuit acceleration;
THYM	cis	rs7586879	0.598	rs6545806	chr2:25124348	G/A	cg01884057	chr2:25150051	NA	0.73	7.9	0.63	4.81e-12	Body mass index;
THYM	cis	rs34638657	0.872	rs6420435	chr16:82184201	A/C	cg07307142	chr16:82071433	HSD17B2	-1.0	-7.83	-0.63	6.82e-12	Lung adenocarcinoma;
THYM	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg02018176	chr4:1364513	KIAA1530	0.95	8.86	0.67	4.46e-14	Longevity;
THYM	cis	rs11085466	1.000	rs73552479	chr19:21778816	G/T	cg23004160	chr19:21646329	NA	-0.63	-4.57	-0.42	1.44e-5	Colorectal or endometrial cancer;
THYM	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg01483505	chr11:975446	AP2A2	-0.58	-4.85	-0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs9522267	0.535	rs9522303	chr13:112237301	T/C	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs9287719	1.000	rs9287719	chr2:10710730	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs12310956	0.510	rs1565026	chr12:33887499	A/G	cg10856724	chr12:34555212	NA	-0.65	-6.0	-0.52	3.63e-8	Morning vs. evening chronotype;
THYM	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg22508957	chr16:3507546	NAT15	-0.6	-7.94	-0.63	3.98e-12	Tuberculosis;
THYM	cis	rs9972944	1.000	rs9972944	chr17:63771079	A/G	cg07283582	chr17:63770753	CCDC46	0.65	5.25	0.47	9.39e-7	Total body bone mineral density;
THYM	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg04990556	chr1:26633338	UBXN11	0.87	8.35	0.65	5.48e-13	Obesity-related traits;
THYM	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg21433313	chr16:3507492	NAT15	0.81	8.84	0.67	4.96e-14	Tuberculosis;
THYM	cis	rs4918072	0.667	rs4439443	chr10:105704814	G/T	cg11005552	chr10:105648138	OBFC1	0.58	4.77	0.44	6.69e-6	Coronary artery disease;
THYM	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs425535	0.817	rs191601	chr4:74850705	C/T	cg07868155	chr4:74864709	CXCL5	0.66	5.57	0.5	2.41e-7	Blood protein levels;
THYM	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg06981504	chr1:1234844	ACAP3	0.54	4.94	0.45	3.32e-6	Body mass index;
THYM	cis	rs6531656	0.663	rs337641	chr4:38611802	A/G	cg24279243	chr4:38676559	KLF3	-0.8	-7.01	-0.58	3.42e-10	Lymphocyte counts;
THYM	cis	rs56104184	0.775	rs73061694	chr19:49399978	T/C	cg21252483	chr19:49399788	TULP2	-0.96	-7.25	-0.6	1.09e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg13010199	chr12:38710504	ALG10B	0.64	4.61	0.43	1.25e-5	Morning vs. evening chronotype;
THYM	trans	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.1	8.0	0.63	3.04e-12	Exhaled nitric oxide output;
THYM	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg07010633	chr17:73824396	UNC13D	0.42	4.45	0.42	2.29e-5	White matter hyperintensity burden;
THYM	trans	rs8073060	0.559	rs10438814	chr17:34007065	A/G	cg19694781	chr19:47549865	TMEM160	-1.02	-8.69	-0.67	1.01e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg17143192	chr8:8559678	CLDN23	0.91	6.72	0.57	1.33e-9	Obesity-related traits;
THYM	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg12963246	chr6:28129442	ZNF389	0.56	5.05	0.46	2.12e-6	Cardiac Troponin-T levels;
THYM	cis	rs888194	0.544	rs2196612	chr12:109849535	A/G	cg11367159	chr12:110044531	NA	0.62	5.61	0.5	1.95e-7	Neuroticism;
THYM	cis	rs6815814	0.851	rs73236644	chr4:38863193	A/G	cg02016764	chr4:38805732	TLR1	-0.54	-4.79	-0.44	6.23e-6	Breast cancer;
THYM	cis	rs9378357	0.850	rs9392473	chr6:3291236	C/T	cg10513992	chr6:3293720	SLC22A23	-1.01	-5.39	-0.48	5.11e-7	Obesity-related traits;
THYM	cis	rs1003719	0.713	rs7277150	chr21:38490006	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs12049351	0.612	rs10753459	chr1:229575764	G/A	cg11742688	chr1:229674241	ABCB10	-0.54	-4.56	-0.42	1.54e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg02753203	chr1:228287806	NA	-0.61	-5.27	-0.48	8.54e-7	Diastolic blood pressure;
THYM	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	1.12	5.24	0.47	9.75e-7	Schizophrenia;
THYM	cis	rs7072216	0.655	rs3830024	chr10:100176106	G/A	cg03852570	chr10:100175106	PYROXD2	0.39	5.14	0.47	1.44e-6	Metabolite levels;
THYM	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.78	-0.44	6.31e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg06850241	chr22:41845214	NA	0.53	4.56	0.42	1.54e-5	Vitiligo;
THYM	cis	rs367615	0.552	rs2416210	chr5:108741137	C/T	cg17395555	chr5:108820864	NA	-0.54	-6.77	-0.57	1.04e-9	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs11838776	0.522	rs7318424	chr13:111021623	C/G	cg05272587	chr13:111038400	COL4A2	0.51	4.75	0.44	7.12e-6	Coronary artery disease;
THYM	cis	rs11771526	0.901	rs62457470	chr7:32303516	A/G	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs4731207	0.596	rs6466979	chr7:124648029	T/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg03433033	chr1:76189801	ACADM	-0.66	-6.32	-0.54	8.39e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9814567	0.762	rs13071852	chr3:134223217	C/G	cg15484384	chr3:134203672	ANAPC13;CEP63	0.4	4.49	0.42	1.99e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs10504073	0.565	rs12056536	chr8:49890132	C/T	cg00325661	chr8:49890786	NA	-1.04	-10.9	-0.75	2.02e-18	Blood metabolite ratios;
THYM	trans	rs1908814	0.509	rs13282439	chr8:11794901	A/G	cg06636001	chr8:8085503	FLJ10661	0.78	6.84	0.57	7.7e-10	Neuroticism;
THYM	cis	rs17604090	0.938	rs115369413	chr7:29685040	T/G	cg19413766	chr7:29689036	LOC646762	-0.93	-5.09	-0.46	1.77e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg23711669	chr6:146136114	FBXO30	0.92	9.0	0.68	2.32e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7772486	0.840	rs2777478	chr6:146309117	T/C	cg23711669	chr6:146136114	FBXO30	0.96	10.29	0.73	3.99e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17433780	0.860	rs10922545	chr1:89492201	C/T	cg09516651	chr1:89888402	LOC400759	0.96	7.66	0.62	1.58e-11	Carotid intima media thickness;
THYM	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg12419862	chr22:24373484	LOC391322	-0.97	-12.05	-0.78	7.65e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	trans	rs79886049	0.702	rs4812635	chr20:41336742	T/C	cg13067095	chr11:64621915	EHD1	-0.98	-6.91	-0.58	5.43e-10	Response to paliperidone in schizophrenia (negative Marder score);
THYM	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.26	-9.1	-0.68	1.4e-14	Gut microbiome composition (summer);
THYM	cis	rs7567389	0.677	rs72848604	chr2:128120118	G/C	cg06038358	chr2:128176007	PROC	0.43	4.53	0.42	1.7e-5	Self-rated health;
THYM	cis	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs870825	0.698	rs7673203	chr4:185625397	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19346786	chr7:2764209	NA	-0.78	-7.06	-0.59	2.68e-10	Height;
THYM	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs72627123	0.867	rs59675549	chr14:74469480	A/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg12386194	chr3:101231763	SENP7	0.66	5.0	0.46	2.59e-6	Colorectal cancer;
THYM	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6496667	0.821	rs77731392	chr15:90897450	G/C	cg22089800	chr15:90895588	ZNF774	0.84	4.96	0.45	3.04e-6	Rheumatoid arthritis;
THYM	cis	rs72720396	0.789	rs12048450	chr1:91199660	G/A	cg13456504	chr1:91191583	NA	0.78	5.3	0.48	7.56e-7	Morning vs. evening chronotype;Chronotype;
THYM	cis	rs2404602	0.684	rs62026898	chr15:76944371	C/A	cg23625390	chr15:77176239	SCAPER	-0.85	-6.21	-0.54	1.39e-8	Blood metabolite levels;
THYM	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.9	-6.33	-0.54	8.15e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs72627123	0.867	rs61522544	chr14:74481953	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.52	0.56	3.44e-9	Morning vs. evening chronotype;
THYM	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.14	0.47	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-4.51	-0.42	1.87e-5	Monocyte percentage of white cells;
THYM	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg09260853	chr1:2094483	PRKCZ	0.47	4.67	0.43	9.79e-6	Height;
THYM	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg11764359	chr7:65958608	NA	-0.8	-6.38	-0.55	6.55e-9	Aortic root size;
THYM	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg02734326	chr4:10020555	SLC2A9	0.62	4.97	0.45	2.97e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs8073060	0.559	rs17550632	chr17:33890883	G/C	cg19694781	chr19:47549865	TMEM160	1.01	8.58	0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs1461503	0.932	rs10892944	chr11:122843895	T/C	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs13082711	0.911	rs13082777	chr3:27421942	A/G	cg02860705	chr3:27208620	NA	0.71	5.01	0.46	2.52e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs597539	0.545	rs3794027	chr11:68697336	T/C	cg04772025	chr11:68637568	NA	0.59	5.94	0.52	4.57e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg10862848	chr6:42927986	GNMT	-0.52	-7.05	-0.59	2.89e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg01831904	chr17:28903510	LRRC37B2	-1.02	-5.06	-0.46	2.05e-6	Body mass index;
THYM	trans	rs8002861	0.870	rs2875541	chr13:44417441	G/T	cg17145862	chr1:211918768	LPGAT1	0.87	9.02	0.68	2.02e-14	Leprosy;
THYM	cis	rs600806	0.854	rs10745353	chr1:109877506	A/G	cg23616212	chr1:109941201	SORT1	-0.5	-4.76	-0.44	6.95e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2350702	0.625	rs10200783	chr2:49936924	G/C	cg22592722	chr2:49566210	NA	-0.65	-5.19	-0.47	1.17e-6	Morning vs. evening chronotype;
THYM	cis	rs6032067	1.000	rs6032042	chr20:43815949	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs7618501	0.699	rs1062633	chr3:49924940	T/C	cg24308560	chr3:49941425	MST1R	-0.77	-6.63	-0.56	2.03e-9	Intelligence (multi-trait analysis);
THYM	cis	rs4919044	0.866	rs11187265	chr10:94824166	G/A	cg05127821	chr10:94822908	CYP26C1	-1.24	-6.68	-0.57	1.64e-9	Coronary artery disease;
THYM	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg23260525	chr10:116636907	FAM160B1	0.51	5.21	0.47	1.09e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18252515	chr7:66147081	NA	-0.66	-5.05	-0.46	2.16e-6	Aortic root size;
THYM	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs314370	0.951	rs12705095	chr7:100484381	T/G	cg10426581	chr7:100472382	SRRT	1.13	8.97	0.68	2.57e-14	Resting heart rate;
THYM	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs1003719	0.715	rs35199609	chr21:38510262	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-4.75	-0.44	7.3e-6	Eye color traits;
THYM	cis	rs61931739	0.817	rs1705771	chr12:34174950	C/G	cg10856724	chr12:34555212	NA	-0.63	-5.8	-0.51	8.48e-8	Morning vs. evening chronotype;
THYM	cis	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs13315871	1.000	rs9864325	chr3:58336846	A/C	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg05025164	chr4:1340916	KIAA1530	0.91	7.06	0.59	2.68e-10	Longevity;
THYM	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03264133	chr6:25882463	NA	-0.82	-6.35	-0.55	7.36e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6591182	0.504	rs2306361	chr11:65374495	A/C	cg17480646	chr11:65405466	SIPA1	-0.79	-6.71	-0.57	1.41e-9	Non-alcoholic fatty liver disease histology (lobular);
THYM	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg07362569	chr17:61921086	SMARCD2	0.73	6.56	0.56	2.84e-9	Prudent dietary pattern;
THYM	cis	rs28476539	0.640	rs17005896	chr4:83550168	T/A	cg10249074	chr4:83542146	C4orf11	-0.64	-5.06	-0.46	2.05e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.49	-4.97	-0.45	2.93e-6	Crohn's disease;
THYM	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg24675658	chr1:53192096	ZYG11B	-0.76	-5.9	-0.52	5.56e-8	Monocyte count;
THYM	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg16325326	chr1:53192061	ZYG11B	-0.86	-8.54	-0.66	2.14e-13	Monocyte count;
THYM	cis	rs34638657	0.732	rs12597010	chr16:82199971	G/A	cg09439754	chr16:82129088	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg05368731	chr17:41323189	NBR1	1.28	11.44	0.76	1.46e-19	Menopause (age at onset);
THYM	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs901683	0.850	rs112997714	chr10:46097216	A/G	cg18240400	chr10:46168597	ANUBL1	0.63	4.71	0.43	8.58e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-6.68	-0.57	1.62e-9	Platelet count;
THYM	cis	rs113835537	0.877	rs3867132	chr11:66309269	C/T	cg24851651	chr11:66362959	CCS	0.84	4.47	0.42	2.17e-5	Airway imaging phenotypes;
THYM	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg14690197	chr8:22456421	C8orf58	0.48	4.68	0.43	9.65e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg07022442	chr13:21864356	NA	0.72	4.76	0.44	6.91e-6	White matter hyperintensity burden;
THYM	trans	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg25517755	chr10:38738941	LOC399744	-0.8	-7.87	-0.63	5.58e-12	Corneal astigmatism;
THYM	cis	rs2073300	1.000	rs6132631	chr20:23461848	T/C	cg12062639	chr20:23401060	NAPB	0.96	4.84	0.45	4.95e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg14416269	chr4:6271139	WFS1	0.55	5.67	0.5	1.5e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.83	0.67	5.15e-14	Colorectal cancer;
THYM	cis	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs7084402	0.967	rs1658491	chr10:60281354	C/T	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs10203711	0.789	rs6431616	chr2:239540279	A/G	cg01050266	chr2:239948729	NA	-0.29	-4.66	-0.43	1.02e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs67311347	0.910	rs13089215	chr3:40495894	T/C	cg02782426	chr3:40428986	ENTPD3	-0.54	-4.99	-0.46	2.7e-6	Renal cell carcinoma;
THYM	cis	rs13082711	0.911	rs923940	chr3:27459341	C/G	cg02860705	chr3:27208620	NA	0.66	4.77	0.44	6.76e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06481639	chr22:41940642	POLR3H	-0.84	-5.94	-0.52	4.61e-8	Vitiligo;
THYM	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg18252515	chr7:66147081	NA	-1.45	-8.59	-0.66	1.72e-13	Diabetic kidney disease;
THYM	cis	rs9515201	0.627	rs61963197	chr13:111038395	G/A	cg15455643	chr13:111040242	COL4A2	0.56	6.29	0.54	9.53e-9	White matter hyperintensity burden;
THYM	cis	rs3126085	0.935	rs12409762	chr1:152175398	G/A	cg10321714	chr1:152280068	FLG	-0.7	-5.17	-0.47	1.28e-6	Atopic dermatitis;
THYM	cis	rs7620363	0.963	rs4423717	chr3:34039160	G/A	cg25105657	chr3:33925802	NA	0.4	4.6	0.43	1.3e-5	Non-substance related behavioral disinhibition;
THYM	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg16102102	chr5:83017553	HAPLN1	0.87	7.31	0.6	8.22e-11	Prostate cancer;
THYM	cis	rs2836633	0.929	rs62217517	chr21:40033177	T/A	cg05519781	chr21:40033154	ERG	0.75	7.28	0.6	9.39e-11	Coronary artery disease;
THYM	cis	rs2250402	1.000	rs2250402	chr15:40322552	G/T	cg10636054	chr15:40330586	SRP14	0.95	4.67	0.43	9.85e-6	Corneal curvature;
THYM	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg03806693	chr22:41940476	POLR3H	1.05	8.42	0.65	3.85e-13	Vitiligo;
THYM	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15506890	chr2:3487001	NA	-0.54	-4.56	-0.42	1.51e-5	Neurofibrillary tangles;
THYM	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg06784218	chr1:46089804	CCDC17	0.3	4.73	0.44	7.66e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.43	0.7	2.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs3849570	1.000	rs9826270	chr3:81841869	C/T	cg07356753	chr3:81810745	GBE1	-0.92	-7.4	-0.6	5.29e-11	Waist circumference;Body mass index;
THYM	cis	rs13102973	0.538	rs4626266	chr4:135914123	A/G	cg14419869	chr4:135874104	NA	0.65	5.34	0.48	6.37e-7	Subjective well-being;
THYM	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg01200585	chr1:228362443	C1orf69	0.42	4.51	0.42	1.85e-5	Diastolic blood pressure;
THYM	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	7.5	0.61	3.33e-11	Platelet count;
THYM	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs189798	0.807	rs330909	chr8:8995387	A/G	cg18904891	chr8:8559673	CLDN23	0.63	4.81	0.44	5.68e-6	Myopia (pathological);
THYM	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.9	10.53	0.73	1.24e-17	Prudent dietary pattern;
THYM	cis	rs7017697	1.000	rs2410612	chr8:19681647	A/G	cg01411142	chr8:19674711	INTS10	0.54	4.68	0.43	9.5e-6	Breast cancer;
THYM	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg07936489	chr17:37558343	FBXL20	0.82	5.69	0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg23682913	chr1:2080710	PRKCZ	0.64	5.78	0.51	9.66e-8	Height;
THYM	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-4.49	-0.42	1.98e-5	Monocyte percentage of white cells;
THYM	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg04234412	chr22:24373322	LOC391322	-0.9	-9.01	-0.68	2.14e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg15704280	chr7:45808275	SEPT13	-1.07	-15.26	-0.84	2.74e-27	Height;
THYM	cis	rs1957429	0.901	rs6573583	chr14:65351211	G/T	cg23373153	chr14:65346875	NA	1.07	6.45	0.55	4.75e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg03433033	chr1:76189801	ACADM	-0.83	-14.1	-0.82	5.02e-25	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs3741151	1.000	rs76610873	chr11:73084387	C/T	cg17517138	chr11:73019481	ARHGEF17	1.0	5.89	0.52	5.75e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg21194808	chr1:2205498	SKI	-0.33	-4.49	-0.42	2.03e-5	Height;
THYM	cis	rs42648	0.869	rs6970376	chr7:89938086	A/G	cg25739043	chr7:89950458	NA	0.53	4.53	0.42	1.72e-5	Homocysteine levels;
THYM	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg12179176	chr11:130786555	SNX19	0.88	8.3	0.65	7.08e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs13102973	0.965	rs4331828	chr4:135849100	C/G	cg14419869	chr4:135874104	NA	0.9	8.46	0.66	3.24e-13	Subjective well-being;
THYM	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg02734326	chr4:10020555	SLC2A9	-0.59	-4.81	-0.44	5.66e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9646944	0.501	rs10202813	chr2:103019740	A/C	cg01241218	chr2:102972058	NA	-0.72	-4.88	-0.45	4.24e-6	Blood protein levels;
THYM	cis	rs11214589	0.747	rs11214582	chr11:113218050	C/T	cg14159747	chr11:113255604	NA	0.29	5.7	0.5	1.35e-7	Neuroticism;
THYM	cis	rs2692947	0.702	rs2312955	chr2:96777168	T/G	cg23100626	chr2:96804247	ASTL	-0.37	-4.48	-0.42	2.07e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs9790314	0.846	rs4290817	chr3:160967354	G/A	cg03342759	chr3:160939853	NMD3	-0.95	-9.47	-0.7	2.2e-15	Morning vs. evening chronotype;
THYM	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg00129232	chr17:37814104	STARD3	-0.87	-7.11	-0.59	2.12e-10	Asthma;
THYM	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg22467129	chr15:76604101	ETFA	-0.51	-5.02	-0.46	2.42e-6	Blood metabolite levels;
THYM	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg23131131	chr22:24373011	LOC391322	-0.87	-8.85	-0.67	4.7e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7119	0.667	rs907393	chr15:77903447	T/C	cg27398640	chr15:77910606	LINGO1	0.68	8.73	0.67	8.58e-14	Type 2 diabetes;
THYM	cis	rs8114671	0.967	rs6142324	chr20:33789043	C/T	cg08999081	chr20:33150536	PIGU	-0.52	-4.72	-0.44	7.98e-6	Height;
THYM	cis	rs8114671	0.869	rs1544047	chr20:33670753	T/C	cg08999081	chr20:33150536	PIGU	-0.56	-4.83	-0.44	5.18e-6	Height;
THYM	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg24818145	chr4:99064322	C4orf37	0.74	5.93	0.52	4.8e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8067545	0.935	rs7209734	chr17:19988543	C/A	cg13482628	chr17:19912719	NA	0.65	5.43	0.49	4.26e-7	Schizophrenia;
THYM	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	5.43	0.49	4.24e-7	Obesity-related traits;
THYM	cis	rs1160297	0.576	rs12990843	chr2:53108688	A/G	cg07782112	chr2:53107842	NA	0.78	6.64	0.56	1.94e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs7843479	0.601	rs11135764	chr8:21814004	A/G	cg17168535	chr8:21777572	XPO7	0.94	8.69	0.67	1.06e-13	Mean corpuscular volume;
THYM	cis	rs9646944	0.501	rs10169676	chr2:103074919	G/A	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	cis	rs753778	0.570	rs4961335	chr8:142209142	A/G	cg18755752	chr8:142205143	DENND3	-0.74	-7.51	-0.61	3.14e-11	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs4953404	0.631	rs4953403	chr2:46885394	A/G	cg09399716	chr2:46890238	NA	-0.48	-4.46	-0.42	2.23e-5	Pulse pressure (alcohol consumption interaction);
THYM	cis	rs7626444	0.625	rs2669638	chr3:196477398	T/G	cg12930392	chr3:196481615	PAK2	0.4	4.92	0.45	3.58e-6	Monocyte count;
THYM	cis	rs2702888	0.563	rs2741064	chr8:6760152	C/T	cg26795848	chr8:6756730	NA	0.62	5.2	0.47	1.13e-6	Blood pressure;
THYM	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg02734326	chr4:10020555	SLC2A9	0.77	7.16	0.59	1.73e-10	Bone mineral density;
THYM	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-6.23	-0.54	1.28e-8	Chronic sinus infection;
THYM	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg25918947	chr17:41365094	TMEM106A	-0.57	-4.8	-0.44	5.92e-6	Menopause (age at onset);
THYM	cis	rs259282	0.524	rs3760941	chr19:33130866	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.58	4.51	0.42	1.86e-5	Schizophrenia;
THYM	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg03404566	chr17:6899310	ALOX12	0.73	9.32	0.69	4.71e-15	Tonsillectomy;
THYM	cis	rs7107174	1.000	rs7113042	chr11:78035832	C/T	cg02023728	chr11:77925099	USP35	-0.63	-6.11	-0.53	2.23e-8	Testicular germ cell tumor;
THYM	cis	rs2074977	0.500	rs10153493	chr19:3447745	C/T	cg08380311	chr19:3435252	NFIC	-0.54	-4.69	-0.43	9.29e-6	Height;
THYM	cis	rs4589258	0.762	rs12294086	chr11:90397561	T/C	cg26138821	chr11:89956704	CHORDC1	0.57	4.76	0.44	7.05e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10911232	0.507	rs10752891	chr1:183023283	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg12935359	chr14:103987150	CKB	0.52	5.96	0.52	4.19e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs7631605	0.935	rs3733029	chr3:37170750	G/C	cg21328643	chr3:37258149	NA	-0.48	-4.61	-0.43	1.25e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs2862064	1.000	rs4407618	chr5:156445875	A/C	cg12943317	chr5:156479607	HAVCR1	-0.84	-5.29	-0.48	7.74e-7	Platelet count;
THYM	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg26441486	chr22:50317300	CRELD2	0.45	7.6	0.62	2.04e-11	Schizophrenia;
THYM	cis	rs6987853	0.966	rs2974338	chr8:42391945	A/G	cg09913449	chr8:42400586	C8orf40	0.88	8.02	0.64	2.8e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1775715	0.707	rs2808081	chr10:32162342	C/T	cg04359828	chr10:32216031	ARHGAP12	-0.37	-4.66	-0.43	1.05e-5	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs7546094	0.935	rs9429486	chr1:113157372	T/C	cg22162597	chr1:113214053	CAPZA1	0.48	4.52	0.42	1.76e-5	Platelet distribution width;
THYM	cis	rs4918072	0.917	rs17573075	chr10:105649940	C/G	cg11005552	chr10:105648138	OBFC1	0.75	6.25	0.54	1.15e-8	Coronary artery disease;
THYM	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.27	5.56	0.5	2.45e-7	Obesity-related traits;
THYM	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg06028605	chr16:24865363	SLC5A11	-0.63	-5.02	-0.46	2.43e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12935418	0.616	rs9931292	chr16:81009568	C/G	cg16651780	chr16:81037892	C16orf61	0.88	6.52	0.56	3.34e-9	Mean corpuscular volume;
THYM	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg11494091	chr17:61959527	GH2	0.71	6.65	0.56	1.81e-9	Height;
THYM	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.7	-0.81	3.17e-24	Height;
THYM	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg24675056	chr1:15929824	NA	0.73	5.79	0.51	9.09e-8	Systolic blood pressure;
THYM	cis	rs1299926	0.850	rs1273421	chr16:8867626	G/A	cg08365638	chr16:9212442	C16orf72	-0.99	-4.5	-0.42	1.94e-5	Anger;
THYM	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9560113	1.000	rs9560103	chr13:112174253	G/A	cg10483660	chr13:112241077	NA	0.53	4.76	0.44	6.81e-6	Menarche (age at onset);
THYM	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg00852783	chr1:26633632	UBXN11	0.68	5.61	0.5	1.97e-7	Granulocyte percentage of myeloid white cells;
THYM	cis	rs4604732	0.631	rs4436425	chr1:247632323	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.74	4.97	0.45	2.93e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg12863693	chr15:85201151	NMB	0.62	5.39	0.48	5.18e-7	Schizophrenia;
THYM	cis	rs9393692	0.620	rs9379844	chr6:26291527	A/G	cg00631329	chr6:26305371	NA	0.47	4.91	0.45	3.81e-6	Educational attainment;
THYM	cis	rs4746818	1.000	rs7476357	chr10:70935660	G/A	cg11621586	chr10:70884670	VPS26A	1.28	11.12	0.75	6.73e-19	Left atrial antero-posterior diameter;
THYM	cis	rs9790314	0.875	rs336568	chr3:161072763	G/C	cg03342759	chr3:160939853	NMD3	-0.73	-6.32	-0.54	8.42e-9	Morning vs. evening chronotype;
THYM	cis	rs1499972	0.941	rs817506	chr3:117679394	A/G	cg07612923	chr3:117604196	NA	-1.42	-5.49	-0.49	3.4e-7	Schizophrenia;
THYM	cis	rs2625529	0.586	rs7170456	chr15:72469946	G/C	cg16672083	chr15:72433130	SENP8	0.51	4.63	0.43	1.18e-5	Red blood cell count;
THYM	cis	rs3741151	0.773	rs28400367	chr11:73112421	C/A	cg12959048	chr11:73096162	RELT	-0.5	-4.72	-0.44	7.97e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg02915803	chr1:1606292	LOC728661;CDK11B	0.59	4.91	0.45	3.74e-6	Body mass index;
THYM	cis	rs853679	0.550	rs9295762	chr6:28155418	C/T	cg23281280	chr6:28129359	ZNF389	-0.69	-5.11	-0.46	1.66e-6	Depression;
THYM	trans	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg23750338	chr8:142222470	SLC45A4	0.51	4.81	0.44	5.7e-6	Immature fraction of reticulocytes;
THYM	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg02018176	chr4:1364513	KIAA1530	0.73	6.62	0.56	2.16e-9	Longevity;
THYM	cis	rs7586879	0.616	rs10206196	chr2:25137323	T/C	cg01884057	chr2:25150051	NA	0.73	7.52	0.61	2.98e-11	Body mass index;
THYM	cis	rs6500395	1.000	rs36077931	chr16:48594221	A/G	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2235649	0.833	rs9939694	chr16:1852760	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg20415053	chr1:26527928	CATSPER4	-0.57	-4.71	-0.44	8.4e-6	Obesity-related traits;
THYM	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg01304814	chr3:48885189	PRKAR2A	0.96	4.86	0.45	4.55e-6	Cognitive function;
THYM	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg19747945	chr6:42946146	PEX6	-0.32	-4.65	-0.43	1.06e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.76	0.44	6.99e-6	Aortic root size;
THYM	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg26384229	chr12:38710491	ALG10B	-0.9	-7.52	-0.61	3.07e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9814567	1.000	rs9990351	chr3:134239191	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	8.41	0.65	4e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs889398	0.651	rs1566455	chr16:69900164	G/T	cg09409435	chr16:70099608	PDXDC2	0.66	5.25	0.47	9.17e-7	Body mass index;
THYM	cis	rs4919687	0.550	rs11191371	chr10:104459897	G/C	cg15744005	chr10:104629667	AS3MT	-0.58	-4.58	-0.43	1.4e-5	Colorectal cancer;
THYM	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg09260853	chr1:2094483	PRKCZ	0.48	4.95	0.45	3.26e-6	Height;
THYM	cis	rs7084402	0.967	rs1658479	chr10:60289398	C/A	cg07615347	chr10:60278583	BICC1	0.55	4.97	0.45	2.97e-6	Refractive error;
THYM	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg14074117	chr16:1909714	C16orf73	-0.7	-4.45	-0.42	2.3e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs576982	1	rs576982	chr15:78870803	C/T	cg18825076	chr15:78729989	IREB2	0.59	4.8	0.44	5.97e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg27423445	chr12:12879764	APOLD1	0.53	4.45	0.42	2.3e-5	Systemic lupus erythematosus;
THYM	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs1933112	1.000	rs7529824	chr1:168500458	G/A	cg00154920	chr1:168513310	XCL2	-0.46	-4.58	-0.43	1.39e-5	Blood protein levels;
THYM	cis	rs1178127	0.611	rs3901892	chr7:18819605	C/T	cg13420273	chr7:18810212	HDAC9	-0.6	-5.41	-0.49	4.64e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg10518543	chr12:38710700	ALG10B	-0.56	-4.51	-0.42	1.87e-5	Morning vs. evening chronotype;
THYM	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg11764359	chr7:65958608	NA	-0.82	-6.65	-0.56	1.85e-9	Aortic root size;
THYM	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6430585	0.583	rs3769008	chr2:136586183	C/T	cg04750100	chr2:136595281	LCT	0.52	4.96	0.45	3.05e-6	Corneal structure;
THYM	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	5.76	0.51	1.05e-7	Lung cancer in ever smokers;
THYM	cis	rs7426056	0.671	rs62183988	chr2:204605029	C/T	cg07930752	chr2:204569955	CD28	-0.76	-5.38	-0.48	5.3e-7	Primary sclerosing cholangitis;
THYM	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg02454025	chr1:11042201	C1orf127	0.92	11.36	0.76	2.14e-19	Ewing sarcoma;
THYM	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7267979	0.844	rs6107017	chr20:25232300	A/G	cg08601574	chr20:25228251	PYGB	0.7	5.75	0.51	1.1e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2552220	0.605	rs2552221	chr8:5999354	T/G	cg03082247	chr8:6756796	NA	-0.56	-4.98	-0.45	2.86e-6	Interleukin-8 levels;
THYM	cis	rs12956009	0.518	rs953291	chr18:44870499	T/C	cg19077165	chr18:44547161	KATNAL2	-0.51	-4.93	-0.45	3.51e-6	Educational attainment (years of education);
THYM	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg10334053	chr1:2078117	PRKCZ	-0.45	-4.86	-0.45	4.56e-6	Height;
THYM	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7582180	0.627	rs4149523	chr2:101007039	T/C	cg14675211	chr2:100938903	LONRF2	0.6	5.73	0.51	1.18e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg01710189	chr8:22454888	PDLIM2	-0.53	-5.38	-0.48	5.33e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg01324343	chr3:183735012	ABCC5	0.88	13.13	0.8	4.58e-23	Anterior chamber depth;
THYM	cis	rs7017697	1.000	rs6980875	chr8:19685948	C/T	cg01411142	chr8:19674711	INTS10	-0.53	-4.52	-0.42	1.77e-5	Breast cancer;
THYM	cis	rs4481887	0.741	rs6682953	chr1:248535626	T/C	cg17299007	chr1:248814626	OR2T27	0.42	4.52	0.42	1.81e-5	Common traits (Other);
THYM	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg26967526	chr14:35346199	BAZ1A	-0.76	-4.97	-0.45	3e-6	Psoriasis;
THYM	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12681287	0.517	rs68008113	chr8:87520894	C/A	cg27223183	chr8:87520930	FAM82B	-0.71	-5.38	-0.48	5.37e-7	Caudate activity during reward;
THYM	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg07492924	chr16:433825	LOC100134368	0.45	4.98	0.45	2.86e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs4866334	1.000	rs76790673	chr5:18502463	G/C	cg02002538	chr5:17811409	NA	-1.1	-4.55	-0.42	1.61e-5	IgG glycosylation;
THYM	cis	rs12532960	0.749	rs17172040	chr7:42364924	T/C	cg23473276	chr7:42834405	NA	0.87	4.77	0.44	6.71e-6	Inflammatory biomarkers;
THYM	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs1499972	0.941	rs73168378	chr3:117636234	G/T	cg07612923	chr3:117604196	NA	1.19	5.0	0.46	2.66e-6	Schizophrenia;
THYM	cis	rs7926906	1.000	rs2177680	chr11:90532256	A/T	cg26138821	chr11:89956704	CHORDC1	-0.53	-4.78	-0.44	6.35e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg15448220	chr1:150897856	SETDB1	0.89	7.59	0.61	2.17e-11	Melanoma;
THYM	cis	rs8050907	0.744	rs17887050	chr16:4524584	C/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.22	4.58	0.43	1.43e-5	Obesity-related traits;
THYM	cis	rs67385638	0.962	rs10128556	chr11:5263683	C/T	cg12559170	chr11:5275217	HBG2	0.88	8.71	0.67	9.37e-14	Hemoglobin levels;
THYM	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg16486109	chr11:613632	IRF7	0.51	5.7	0.5	1.34e-7	Systemic lupus erythematosus;
THYM	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg18305652	chr10:134549665	INPP5A	0.75	5.9	0.52	5.46e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs2692947	0.655	rs60090597	chr2:96406266	G/A	cg22654517	chr2:96458247	NA	0.71	5.34	0.48	6.39e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs2637266	0.655	rs846628	chr10:78538392	G/A	cg18941641	chr10:78392320	NA	0.74	5.81	0.51	8.27e-8	Pulmonary function;
THYM	cis	rs892961	0.899	rs72896163	chr17:75412525	C/T	cg05865280	chr17:75406074	SEPT9	0.49	8.15	0.64	1.42e-12	Airflow obstruction;
THYM	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg18681998	chr4:17616180	MED28	0.94	8.65	0.66	1.25e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6754311	0.773	rs4988226	chr2:136610598	A/G	cg04750100	chr2:136595281	LCT	-0.56	-6.14	-0.53	1.92e-8	Mosquito bite size;
THYM	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg03433033	chr1:76189801	ACADM	-0.76	-8.16	-0.64	1.4e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	6.39	0.55	6.06e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg02187348	chr16:89574699	SPG7	-0.76	-6.44	-0.55	4.98e-9	Multiple myeloma (IgH translocation);
THYM	cis	rs2070488	0.730	rs2268759	chr3:38514327	G/A	cg24069376	chr3:38537580	EXOG	0.44	4.74	0.44	7.49e-6	Electrocardiographic conduction measures;
THYM	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg15448220	chr1:150897856	SETDB1	0.9	7.66	0.62	1.56e-11	Melanoma;
THYM	cis	rs3796352	1.000	rs9874517	chr3:53128371	A/G	cg07884673	chr3:53033167	SFMBT1	0.92	4.54	0.42	1.62e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs11785693	0.909	rs11784246	chr8:4970497	A/G	cg26367366	chr8:4980734	NA	1.15	5.39	0.48	5.08e-7	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.7	-4.81	-0.44	5.57e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4803468	1.000	rs3213861	chr19:41919944	A/C	cg09537434	chr19:41945824	ATP5SL	-1.06	-9.81	-0.71	4.27e-16	Height;
THYM	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg20387954	chr3:183756860	HTR3D	-0.49	-4.77	-0.44	6.77e-6	Anterior chamber depth;
THYM	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg09260853	chr1:2094483	PRKCZ	0.47	4.67	0.43	9.79e-6	Height;
THYM	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg06784218	chr1:46089804	CCDC17	0.29	4.57	0.42	1.48e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg04731861	chr2:219085781	ARPC2	0.53	4.88	0.45	4.33e-6	Colorectal cancer;
THYM	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg02269571	chr22:50332266	NA	0.67	4.82	0.44	5.46e-6	Schizophrenia;
THYM	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6956675	0.830	rs4585626	chr7:62671592	C/G	cg08930214	chr7:62859557	LOC100287834	-0.7	-5.2	-0.47	1.15e-6	Obesity-related traits;
THYM	cis	rs2637266	0.783	rs860165	chr10:78492807	A/G	cg18941641	chr10:78392320	NA	0.75	6.01	0.53	3.35e-8	Pulmonary function;
THYM	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs651907	0.817	rs675779	chr3:101599019	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	5.18	0.47	1.23e-6	Colorectal cancer;
THYM	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg22433210	chr17:43662623	NA	-1.05	-8.08	-0.64	2e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs870825	0.550	rs10000507	chr4:185619281	C/T	cg04058563	chr4:185651563	MLF1IP	1.04	9.02	0.68	2.05e-14	Blood protein levels;
THYM	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg03647317	chr4:187891568	NA	-0.76	-7.69	-0.62	1.37e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs1214752	0.935	rs9349256	chr6:43404511	G/A	cg09674015	chr6:43045187	PTK7	-0.5	-4.73	-0.44	7.67e-6	Coronary artery disease;
THYM	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.29	4.5	0.42	1.94e-5	Obesity-related traits;
THYM	cis	rs526231	0.511	rs3776861	chr5:102349662	A/C	cg23492399	chr5:102201601	PAM	-0.7	-5.24	-0.47	9.47e-7	Primary biliary cholangitis;
THYM	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg22764044	chr5:178986830	RUFY1	0.52	5.23	0.47	9.96e-7	Lung cancer;
THYM	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs61990749	0.597	rs72685264	chr14:78152998	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-1.17	-8.04	-0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg22166914	chr1:53195759	ZYG11B	0.63	5.44	0.49	4.16e-7	Monocyte count;
THYM	cis	rs4866334	1.000	rs77766662	chr5:18485586	A/C	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg25358565	chr5:93447407	FAM172A	1.37	10.94	0.75	1.67e-18	Diabetic retinopathy;
THYM	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg06600287	chr1:53387719	ECHDC2	-0.29	-4.54	-0.42	1.67e-5	Monocyte count;
THYM	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg03161606	chr19:29218774	NA	0.87	7.71	0.62	1.23e-11	Methadone dose in opioid dependence;
THYM	cis	rs9677476	0.863	rs57199832	chr2:232069083	T/G	cg07929768	chr2:232055508	NA	0.64	6.58	0.56	2.55e-9	Food antigen IgG levels;
THYM	cis	rs1003719	0.591	rs2835633	chr21:38525019	G/A	cg01329690	chr21:38580129	DSCR9	-0.34	-4.67	-0.43	9.8e-6	Eye color traits;
THYM	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg05347473	chr6:146136440	FBXO30	0.56	4.51	0.42	1.84e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg05084668	chr3:125655381	ALG1L	-0.84	-4.98	-0.46	2.78e-6	Blood pressure (smoking interaction);
THYM	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg05855489	chr10:104503620	C10orf26	0.58	4.69	0.43	9.04e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7713065	0.531	rs2522051	chr5:131797578	C/T	cg14196790	chr5:131705035	SLC22A5	0.48	4.77	0.44	6.64e-6	Lung function (FEV1/FVC);
THYM	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.0	0.63	3.07e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.29e-7	Corneal astigmatism;
THYM	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg15247329	chr7:2764246	NA	-0.72	-5.92	-0.52	5.18e-8	Height;
THYM	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg07424592	chr7:64974309	NA	1.09	5.01	0.46	2.55e-6	Diabetic kidney disease;
THYM	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg05973401	chr12:123451056	ABCB9	0.66	4.81	0.44	5.72e-6	Platelet count;
THYM	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03264133	chr6:25882463	NA	-0.69	-5.32	-0.48	7.03e-7	Blood metabolite levels;
THYM	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.7	-5.63	-0.5	1.83e-7	Prostate cancer;
THYM	cis	rs7100689	0.577	rs2185427	chr10:82056667	G/T	cg01528321	chr10:82214614	TSPAN14	-0.91	-6.78	-0.57	1.03e-9	Post bronchodilator FEV1;
THYM	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg26031613	chr14:104095156	KLC1	0.76	5.12	0.47	1.58e-6	Body mass index;
THYM	cis	rs7712401	0.502	rs1871180	chr5:122348548	C/T	cg19808643	chr5:122110361	SNX2	-0.57	-4.89	-0.45	4.04e-6	Mean platelet volume;
THYM	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg13395646	chr4:1353034	KIAA1530	0.59	5.31	0.48	7.33e-7	Obesity-related traits;
THYM	trans	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.09	-13.24	-0.81	2.77e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2439831	0.681	rs999047	chr15:43688916	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.68	4.7	0.43	8.71e-6	Lung cancer in ever smokers;
THYM	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.72	-5.36	-0.48	5.71e-7	Tonsillectomy;
THYM	cis	rs78456975	0.739	rs11896906	chr2:1519550	A/G	cg12573674	chr2:1569213	NA	-1.35	-6.39	-0.55	6.13e-9	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.71	6.5	0.56	3.64e-9	Personality dimensions;
THYM	cis	rs12216545	0.737	rs1916007	chr7:150240289	A/G	cg00323915	chr7:150264987	GIMAP4	-0.49	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg25214090	chr10:38739885	LOC399744	0.95	8.19	0.64	1.19e-12	Corneal astigmatism;
THYM	cis	rs7586879	0.639	rs6545776	chr2:25099357	A/C	cg01884057	chr2:25150051	NA	0.72	7.74	0.62	1.08e-11	Body mass index;
THYM	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg00376283	chr12:123451042	ABCB9	0.73	5.07	0.46	1.99e-6	Neutrophil percentage of white cells;
THYM	cis	rs7772486	0.623	rs735535	chr6:146036829	C/T	cg23711669	chr6:146136114	FBXO30	-0.89	-8.4	-0.65	4.24e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.73	0.51	1.19e-7	Rheumatoid arthritis;
THYM	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	10.09	0.72	1.05e-16	Platelet count;
THYM	cis	rs6960043	0.738	rs10950548	chr7:15057728	G/A	cg19272540	chr7:15055459	NA	0.49	5.21	0.47	1.09e-6	Type 2 diabetes;
THYM	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg14784868	chr12:69753453	YEATS4	0.81	6.43	0.55	5.14e-9	Blood protein levels;
THYM	cis	rs736408	0.583	rs2302417	chr3:52814256	T/A	cg10802521	chr3:52805072	NEK4	-0.55	-4.66	-0.43	1.01e-5	Bipolar disorder;
THYM	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg11764359	chr7:65958608	NA	-0.84	-7.04	-0.59	2.94e-10	Aortic root size;
THYM	cis	rs16854884	0.582	rs34402874	chr3:143643249	T/A	cg05063096	chr3:143689810	C3orf58	0.76	5.01	0.46	2.56e-6	Economic and political preferences (feminism/equality);
THYM	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg20242066	chr2:136595261	LCT	-0.54	-6.83	-0.57	7.89e-10	Mosquito bite size;
THYM	cis	rs354225	0.584	rs6749802	chr2:54824146	A/G	cg23486701	chr2:54789491	SPTBN1	0.35	4.68	0.43	9.65e-6	Schizophrenia;
THYM	cis	rs4731207	0.564	rs12531311	chr7:124625546	A/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs3126085	0.825	rs116321073	chr1:152240413	A/T	cg10321714	chr1:152280068	FLG	0.68	5.25	0.47	9.18e-7	Atopic dermatitis;
THYM	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg22841779	chr14:105766346	BRF1	0.49	6.25	0.54	1.15e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4866334	1.000	rs74720949	chr5:18503571	T/C	cg02002538	chr5:17811409	NA	-1.1	-4.55	-0.42	1.61e-5	IgG glycosylation;
THYM	cis	rs9796	0.689	rs11855797	chr15:41434679	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.62	-4.92	-0.45	3.62e-6	Menopause (age at onset);
THYM	cis	rs714027	1.000	rs5763767	chr22:30493882	G/A	cg11564601	chr22:30592435	NA	-0.3	-5.45	-0.49	3.98e-7	Lymphocyte counts;
THYM	cis	rs6980334	0.767	rs10274304	chr7:137790882	G/A	cg18769353	chr7:137028617	PTN	0.62	4.87	0.45	4.42e-6	Blood metabolite ratios;
THYM	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg15448220	chr1:150897856	SETDB1	0.88	7.27	0.6	1.02e-10	Tonsillectomy;
THYM	cis	rs12681288	0.576	rs7002793	chr8:963467	T/C	cg08648136	chr8:956695	NA	0.56	4.67	0.43	9.71e-6	Schizophrenia;
THYM	cis	rs7100689	0.577	rs1143694	chr10:82040052	C/T	cg09936400	chr10:82049201	MAT1A	-0.43	-4.54	-0.42	1.64e-5	Post bronchodilator FEV1;
THYM	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs7119038	0.629	rs11216994	chr11:118603520	C/T	cg19308663	chr11:118741387	NA	0.47	4.55	0.42	1.58e-5	Sjögren's syndrome;
THYM	cis	rs7731657	0.537	rs10066004	chr5:130304689	G/A	cg08523029	chr5:130500466	HINT1	-0.74	-5.01	-0.46	2.49e-6	Fasting plasma glucose;
THYM	cis	rs4386084	1.000	rs34649541	chr15:50233924	G/C	cg21557108	chr15:50410962	ATP8B4	0.46	4.45	0.42	2.35e-5	Basophil percentage of white cells;Basophil percentage of granulocytes;
THYM	cis	rs7178572	1.000	rs1565756	chr15:77741640	G/A	cg22256960	chr15:77711686	NA	-0.94	-7.99	-0.63	3.15e-12	Type 2 diabetes;
THYM	cis	rs7119	0.604	rs907383	chr15:77870646	A/G	cg27398640	chr15:77910606	LINGO1	0.63	7.02	0.58	3.26e-10	Type 2 diabetes;
THYM	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg07884673	chr3:53033167	SFMBT1	1.25	6.34	0.55	7.83e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg06873352	chr17:61820015	STRADA	0.54	5.35	0.48	5.99e-7	Height;
THYM	cis	rs2067615	0.507	rs10746064	chr12:107086245	G/T	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg11245990	chr11:68621969	NA	0.58	7.52	0.61	3.09e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6669072	0.647	rs814547	chr1:91238821	T/C	cg08895590	chr1:91227319	NA	-0.65	-8.25	-0.65	9.1e-13	Cognitive function;
THYM	cis	rs2235649	0.663	rs6600168	chr16:1848927	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.93	-0.45	3.45e-6	Blood metabolite levels;
THYM	cis	rs7731657	0.537	rs4637539	chr5:130311944	T/C	cg08523029	chr5:130500466	HINT1	-0.77	-5.3	-0.48	7.38e-7	Fasting plasma glucose;
THYM	cis	rs985746	0.614	rs2376233	chr4:36799046	A/G	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg03859395	chr2:55845619	SMEK2	0.61	5.47	0.49	3.72e-7	Metabolic syndrome;
THYM	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.83	-4.61	-0.43	1.25e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg12011299	chr4:100065546	ADH4	0.86	8.24	0.65	9.48e-13	Alcohol dependence;
THYM	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg04518342	chr5:131593106	PDLIM4	0.47	5.2	0.47	1.15e-6	Breast cancer;
THYM	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg18301423	chr5:131593218	PDLIM4	0.48	4.47	0.42	2.14e-5	Breast cancer;
THYM	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg04398451	chr17:18023971	MYO15A	-0.76	-6.96	-0.58	4.39e-10	Total body bone mineral density;
THYM	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg02487422	chr3:49467188	NICN1	0.63	4.82	0.44	5.48e-6	Resting heart rate;
THYM	cis	rs9810259	0.522	rs9875338	chr3:12296469	A/G	cg05467012	chr3:12595696	NA	-0.53	-4.89	-0.45	4.11e-6	Platelet count;
THYM	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg16586182	chr3:47516702	SCAP	0.65	5.53	0.49	2.84e-7	Colorectal cancer;
THYM	cis	rs4919669	0.668	rs10786701	chr10:104412308	C/T	cg24934431	chr10:104597864	CYP17A1	0.57	4.82	0.44	5.42e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
THYM	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg01324343	chr3:183735012	ABCC5	0.88	13.13	0.8	4.58e-23	Anterior chamber depth;
THYM	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg06238570	chr21:40685208	BRWD1	0.83	5.82	0.51	8.02e-8	Cognitive function;
THYM	cis	rs7851660	0.874	rs7860144	chr9:100626884	A/G	cg13688889	chr9:100608707	NA	-0.79	-5.92	-0.52	5.07e-8	Strep throat;
THYM	cis	rs6032067	0.777	rs2868236	chr20:43794070	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg16680214	chr1:154839983	KCNN3	0.37	4.58	0.43	1.43e-5	Prostate cancer;
THYM	cis	rs7131987	0.650	rs7301188	chr12:29455391	C/T	cg09582351	chr12:29534625	ERGIC2	-0.53	-4.68	-0.43	9.37e-6	QT interval;
THYM	cis	rs6785206	0.614	rs35732133	chr3:128476978	A/C	cg16766828	chr3:128327626	NA	0.46	4.54	0.42	1.62e-5	Lymphocyte percentage of white cells;
THYM	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg08645402	chr16:4508243	NA	0.75	6.86	0.58	7.1e-10	Schizophrenia;
THYM	cis	rs2235649	0.833	rs7190337	chr16:1850469	A/C	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs4378999	0.800	rs7621650	chr3:50797071	C/G	cg27233566	chr3:49894142	TRAIP	0.77	4.47	0.42	2.16e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg09455208	chr3:40491958	NA	0.43	4.47	0.42	2.14e-5	Renal cell carcinoma;
THYM	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4343996	0.558	rs10273728	chr7:3414854	A/G	cg21248987	chr7:3385318	SDK1	0.4	4.91	0.45	3.72e-6	Motion sickness;
THYM	cis	rs7107174	0.901	rs2450140	chr11:77924388	T/C	cg19901956	chr11:77921274	USP35	-0.73	-5.81	-0.51	8.26e-8	Testicular germ cell tumor;
THYM	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.05	-10.37	-0.73	2.72e-17	Primary sclerosing cholangitis;
THYM	cis	rs921968	0.643	rs2556385	chr2:219532905	G/A	cg02176678	chr2:219576539	TTLL4	-0.6	-5.84	-0.51	7.3e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs921968	0.541	rs561570	chr2:219379348	T/A	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-7.84	-0.63	6.55e-12	Lymphocyte percentage of white cells;
THYM	cis	rs859767	0.741	rs6729090	chr2:135401878	G/A	cg12500956	chr2:135428796	TMEM163	-0.48	-4.88	-0.45	4.29e-6	Neuroticism;
THYM	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg14582100	chr15:45693742	SPATA5L1	0.62	4.99	0.46	2.71e-6	Homoarginine levels;
THYM	cis	rs7084402	0.967	rs1658494	chr10:60280323	C/T	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs713587	0.646	rs34697209	chr2:25127394	A/G	cg15423357	chr2:25149977	NA	0.64	6.41	0.55	5.48e-9	Body mass index in non-asthmatics;
THYM	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg20891283	chr12:69753455	YEATS4	1.06	10.24	0.72	5.15e-17	Blood protein levels;
THYM	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg00990874	chr7:1149470	C7orf50	-0.7	-5.25	-0.47	9.13e-7	Bronchopulmonary dysplasia;
THYM	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg23711669	chr6:146136114	FBXO30	0.9	9.02	0.68	2.06e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg00129232	chr17:37814104	STARD3	-0.8	-5.5	-0.49	3.24e-7	Asthma;
THYM	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg23708337	chr7:1209742	NA	0.81	4.48	0.42	2.1e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg15693483	chr7:1102177	C7orf50	0.54	6.29	0.54	9.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1728785	0.818	rs1814299	chr16:68581332	G/A	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg19196401	chr6:110721138	DDO	0.54	6.01	0.52	3.49e-8	Platelet distribution width;
THYM	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs10982256	0.817	rs10817632	chr9:117270853	T/C	cg15903421	chr9:117267460	DFNB31	-0.56	-5.37	-0.48	5.63e-7	Bipolar disorder;
THYM	cis	rs7772486	0.790	rs2265917	chr6:146212285	A/G	cg13319975	chr6:146136371	FBXO30	-0.74	-6.33	-0.54	7.91e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9902453	1.000	rs55971458	chr17:28427016	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.76	0.44	6.86e-6	Coffee consumption (cups per day);
THYM	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg06640241	chr16:89574553	SPG7	0.76	5.49	0.49	3.33e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs988913	0.793	rs9370332	chr6:54727075	A/G	cg19716238	chr6:54711378	FAM83B	0.51	4.89	0.45	4.08e-6	Menarche (age at onset);
THYM	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg00645579	chr11:617140	IRF7;MUPCDH	-0.52	-6.36	-0.55	7.1e-9	Systemic lupus erythematosus;
THYM	cis	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg23422044	chr7:1970798	MAD1L1	-0.87	-6.09	-0.53	2.4e-8	Bipolar disorder;
THYM	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg19610905	chr11:61596333	FADS2	-0.62	-5.08	-0.46	1.89e-6	Trans fatty acid levels;
THYM	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg22535103	chr8:58192502	C8orf71	-0.93	-5.25	-0.47	9.15e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs11214589	0.807	rs2155463	chr11:113242301	T/C	cg14159747	chr11:113255604	NA	0.35	7.61	0.62	1.94e-11	Neuroticism;
THYM	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg03929089	chr4:120376271	NA	-1.04	-8.56	-0.66	1.93e-13	Coronary artery disease;
THYM	cis	rs73787773	0.867	rs73787778	chr5:111477958	G/C	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.88	-4.76	-0.44	6.87e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg03388025	chr16:89894329	SPIRE2	0.53	4.49	0.42	1.97e-5	Vitiligo;
THYM	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg16060761	chr17:80687452	NA	0.61	4.86	0.45	4.7e-6	Glycated hemoglobin levels;
THYM	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg00012203	chr2:219082015	ARPC2	0.87	8.52	0.66	2.38e-13	Colorectal cancer;
THYM	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06481639	chr22:41940642	POLR3H	-0.84	-5.94	-0.52	4.61e-8	Vitiligo;
THYM	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg15921436	chr17:44337874	NA	-0.91	-6.85	-0.58	7.19e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7119	0.717	rs8040702	chr15:77803615	G/A	cg10437265	chr15:77819839	NA	0.76	7.61	0.62	1.98e-11	Type 2 diabetes;
THYM	trans	rs10802346	0.545	rs2362252	chr1:246371574	A/C	cg13514129	chr1:39547527	MACF1	1.0	10.48	0.73	1.59e-17	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.01	9.08	0.68	1.5e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg08470875	chr2:26401718	FAM59B	-0.77	-4.6	-0.43	1.29e-5	Gut microbiome composition (summer);
THYM	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg07414643	chr4:187882934	NA	0.67	5.92	0.52	5.16e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg13607699	chr17:42295918	UBTF	-0.75	-5.99	-0.52	3.69e-8	Total body bone mineral density;
THYM	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02018176	chr4:1364513	KIAA1530	0.95	8.95	0.68	2.83e-14	Longevity;
THYM	cis	rs2625529	0.761	rs4776582	chr15:72207520	A/T	cg16672083	chr15:72433130	SENP8	-0.56	-5.03	-0.46	2.35e-6	Red blood cell count;
THYM	cis	rs669446	0.561	rs643445	chr1:44089632	C/T	cg00143623	chr1:44495758	SLC6A9	-0.59	-4.51	-0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs892961	0.932	rs747481	chr17:75412143	A/G	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs2688608	0.592	rs7909544	chr10:75484004	G/C	cg19442545	chr10:75533431	FUT11	-0.58	-5.96	-0.52	4.22e-8	Inflammatory bowel disease;
THYM	cis	rs554111	0.634	rs34740989	chr1:21316782	C/T	cg01072550	chr1:21505969	NA	0.59	5.17	0.47	1.3e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs78366141	0.536	rs76806573	chr4:89682729	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	1.14	4.83	0.44	5.28e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7264396	0.836	rs41293080	chr20:34187697	A/G	cg26038318	chr20:34205095	SPAG4	0.57	4.88	0.45	4.22e-6	Total cholesterol levels;
THYM	cis	rs7264396	0.563	rs2425137	chr20:34345396	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-4.59	-0.43	1.34e-5	Total cholesterol levels;
THYM	cis	rs3768617	0.510	rs10752904	chr1:183101038	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg17063962	chr7:91808500	NA	1.1	11.52	0.76	1e-19	Breast cancer;
THYM	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg12165864	chr7:66369176	NA	0.81	5.95	0.52	4.41e-8	Corneal structure;
THYM	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg11764359	chr7:65958608	NA	0.66	4.69	0.43	8.98e-6	Aortic root size;
THYM	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22496380	chr5:211416	CCDC127	-1.26	-7.53	-0.61	2.88e-11	Breast cancer;
THYM	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-12.59	-0.79	5.89e-22	Coronary artery disease;
THYM	cis	rs752010	0.714	rs7513753	chr1:42079232	A/G	cg06885757	chr1:42089581	HIVEP3	0.6	7.93	0.63	4.31e-12	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs951188	0.688	rs73968617	chr2:150400375	T/C	cg17961725	chr2:150454027	NA	-0.85	-4.59	-0.43	1.35e-5	Daytime sleep phenotypes;
THYM	cis	rs7072216	0.763	rs12763326	chr10:100167396	A/G	cg03852570	chr10:100175106	PYROXD2	-0.37	-4.74	-0.44	7.6e-6	Metabolite levels;
THYM	cis	rs2354432	0.556	rs11239964	chr1:146753902	G/C	cg25205988	chr1:146714368	CHD1L	-1.07	-5.61	-0.5	2.01e-7	Mitochondrial DNA levels;
THYM	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.61	4.6	0.43	1.29e-5	Renal function-related traits (BUN);
THYM	cis	rs432925	0.576	rs11866815	chr16:387867	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.3	4.81	0.44	5.61e-6	Morning vs. evening chronotype;
THYM	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.09	0.64	1.96e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg17644776	chr2:200775616	C2orf69	0.77	5.4	0.48	5.01e-7	Schizophrenia;
THYM	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs10779751	1.000	rs11121703	chr1:11293792	G/T	cg08854313	chr1:11322531	MTOR	-0.99	-9.0	-0.68	2.29e-14	Body mass index;
THYM	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.49	0.42	1.97e-5	Diabetic retinopathy;
THYM	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg18402987	chr7:1209562	NA	0.67	5.12	0.47	1.56e-6	Longevity;Endometriosis;
THYM	cis	rs36051895	0.658	rs7875265	chr9:5033882	C/A	cg02405213	chr9:5042618	JAK2	-1.06	-11.2	-0.75	4.6e-19	Pediatric autoimmune diseases;
THYM	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg01097406	chr16:89675127	NA	-0.64	-5.29	-0.48	7.95e-7	Vitiligo;
THYM	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22496380	chr5:211416	CCDC127	-1.3	-8.28	-0.65	7.84e-13	Breast cancer;
THYM	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-6.11	-0.53	2.19e-8	Total body bone mineral density;
THYM	cis	rs2273669	0.915	rs4992382	chr6:109292826	T/A	cg17117243	chr6:109341365	SESN1	-0.76	-4.55	-0.42	1.6e-5	Prostate cancer;
THYM	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg10589385	chr1:150898437	SETDB1	0.6	4.74	0.44	7.37e-6	Melanoma;
THYM	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg23803603	chr1:2058230	PRKCZ	0.59	4.51	0.42	1.86e-5	Height;
THYM	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	5.06	0.46	2.07e-6	Menarche (age at onset);
THYM	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.56	-5.27	-0.48	8.6e-7	Lymphocyte counts;
THYM	cis	rs250585	0.790	rs437647	chr16:23462055	G/A	cg00143387	chr16:23521605	GGA2	0.77	5.54	0.49	2.68e-7	Egg allergy;
THYM	cis	rs11039798	1.000	rs11039798	chr11:48540223	G/A	cg24672777	chr11:48374446	OR4C45	-1.08	-5.88	-0.52	6.11e-8	Axial length;
THYM	cis	rs7084402	0.967	rs1621227	chr10:60327734	C/G	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg01073479	chr16:3509474	NAT15	-0.63	-5.1	-0.46	1.72e-6	Tuberculosis;
THYM	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg18252515	chr7:66147081	NA	-1.37	-8.05	-0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs7616559	0.573	rs9812759	chr3:156788928	C/A	cg15697575	chr3:156784781	NA	0.34	4.93	0.45	3.46e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs911263	0.961	rs28498223	chr14:68728425	C/T	cg18825221	chr14:68749962	RAD51L1	-0.59	-6.32	-0.54	8.43e-9	Primary biliary cholangitis;
THYM	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg26384229	chr12:38710491	ALG10B	1.0	7.58	0.61	2.27e-11	Bladder cancer;
THYM	cis	rs684232	0.666	rs461521	chr17:622497	G/T	cg15660573	chr17:549704	VPS53	-0.82	-7.34	-0.6	7.14e-11	Prostate cancer;
THYM	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg18252515	chr7:66147081	NA	-0.67	-5.13	-0.47	1.5e-6	Aortic root size;
THYM	cis	rs2067615	0.579	rs1811458	chr12:107203683	G/A	cg15890332	chr12:107067104	RFX4	0.48	5.63	0.5	1.81e-7	Heart rate;
THYM	cis	rs977987	0.815	rs1364078	chr16:75396881	T/C	cg03315344	chr16:75512273	CHST6	0.74	6.24	0.54	1.2e-8	Dupuytren's disease;
THYM	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg23711669	chr6:146136114	FBXO30	-0.98	-10.65	-0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg26408565	chr15:76604113	ETFA	-0.55	-4.77	-0.44	6.53e-6	Blood metabolite levels;
THYM	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg10661904	chr17:79619235	PDE6G	0.52	4.66	0.43	1.03e-5	Eye color traits;
THYM	cis	rs4907240	0.925	rs7575254	chr2:97275760	T/C	cg18419276	chr2:96971862	SNRNP200	-0.4	-4.76	-0.44	6.95e-6	Event-related brain oscillations;
THYM	cis	rs7524258	0.835	rs75096060	chr1:7270248	G/C	cg07173049	chr1:7289937	CAMTA1	0.56	4.56	0.42	1.54e-5	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs295140	0.743	rs1729412	chr2:201083598	T/C	cg23649088	chr2:200775458	C2orf69	0.56	4.58	0.42	1.43e-5	QT interval;
THYM	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg24642844	chr7:1081250	C7orf50	-1.13	-6.41	-0.55	5.68e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg27490568	chr2:178487706	NA	-0.6	-5.27	-0.48	8.63e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs16912285	0.786	rs76326641	chr11:24253072	G/A	ch.11.24196551F	chr11:24239977	NA	0.89	4.62	0.43	1.22e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2286885	0.965	rs10987301	chr9:129250688	T/C	cg14294646	chr9:129243551	FAM125B	0.56	5.14	0.47	1.46e-6	Intraocular pressure;
THYM	cis	rs1267303	1.000	rs1267303	chr1:46990457	A/G	cg16387850	chr1:46982889	NA	-0.36	-4.58	-0.43	1.4e-5	Monobrow;
THYM	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg09307838	chr4:120376055	NA	0.77	5.56	0.5	2.5e-7	Corneal astigmatism;
THYM	cis	rs4237845	0.844	rs4630335	chr12:58302258	A/G	cg22764591	chr12:58329936	NA	0.78	5.7	0.51	1.32e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg07570687	chr10:102243282	WNT8B	0.72	6.43	0.55	5.11e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg23815491	chr16:72088622	HP	0.69	5.3	0.48	7.58e-7	Fibrinogen levels;
THYM	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg18512352	chr11:47633146	NA	-0.53	-6.56	-0.56	2.75e-9	Subjective well-being;
THYM	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg06009448	chr7:1102226	C7orf50	0.53	5.59	0.5	2.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs300703	0.816	rs449725	chr2:202993	C/G	cg21211680	chr2:198530	NA	-1.12	-5.6	-0.5	2.06e-7	Blood protein levels;
THYM	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.42	4.47	0.42	2.17e-5	Hemoglobin concentration;
THYM	cis	rs12714314	0.957	rs10190598	chr2:1955017	T/C	cg05313794	chr2:1845466	MYT1L	-0.51	-4.55	-0.42	1.58e-5	Type 2 diabetes (age of onset);
THYM	cis	rs7119	0.651	rs17394732	chr15:77835657	A/G	cg27398640	chr15:77910606	LINGO1	0.56	5.88	0.52	6.03e-8	Type 2 diabetes;
THYM	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg01448562	chr3:133502909	NA	-0.83	-7.15	-0.59	1.82e-10	Iron status biomarkers;
THYM	cis	rs1971762	0.545	rs9788134	chr12:54046067	A/T	cg16917193	chr12:54089295	NA	0.77	7.34	0.6	7.04e-11	Height;
THYM	cis	rs35934224	0.783	rs7288061	chr22:19864239	C/T	cg11182965	chr22:19864308	TXNRD2	-0.94	-7.2	-0.59	1.37e-10	Glaucoma (primary open-angle);
THYM	cis	rs4986172	0.690	rs11657325	chr17:43242694	C/T	cg24180402	chr17:43221464	ACBD4	0.65	5.38	0.48	5.4e-7	Height;
THYM	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg04414720	chr1:150670196	GOLPH3L	0.59	4.46	0.42	2.24e-5	Tonsillectomy;
THYM	cis	rs6815814	0.851	rs11466645	chr4:38778203	A/T	cg02016764	chr4:38805732	TLR1	-0.6	-5.32	-0.48	6.96e-7	Breast cancer;
THYM	cis	rs854765	0.583	rs6502622	chr17:17834691	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.41	0.55	5.47e-9	Total body bone mineral density;
THYM	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg16486109	chr11:613632	IRF7	0.49	5.44	0.49	4.08e-7	Systemic lupus erythematosus;
THYM	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg18512352	chr11:47633146	NA	0.56	7.54	0.61	2.79e-11	Subjective well-being;
THYM	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg02931644	chr1:25747376	RHCE	0.62	4.83	0.44	5.24e-6	Erythrocyte sedimentation rate;
THYM	cis	rs854765	0.583	rs4414547	chr17:17859052	G/T	cg16928487	chr17:17741425	SREBF1	-0.55	-5.47	-0.49	3.62e-7	Total body bone mineral density;
THYM	cis	rs2898681	0.511	rs881743	chr4:53727450	A/G	cg21521518	chr4:53727714	RASL11B	0.46	5.97	0.52	4.15e-8	Optic nerve measurement (cup area);
THYM	cis	rs2862064	1.000	rs7731951	chr5:156449685	A/T	cg12943317	chr5:156479607	HAVCR1	0.86	5.28	0.48	8.3e-7	Platelet count;
THYM	cis	rs12291225	0.753	rs1431374	chr11:14303975	T/C	cg05501817	chr11:14380813	RRAS2	-0.75	-5.76	-0.51	1.02e-7	Sense of smell;
THYM	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg04756594	chr16:24857601	SLC5A11	0.77	5.27	0.48	8.63e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg06582575	chr6:163149167	PACRG;PARK2	1.15	6.71	0.57	1.43e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs67311347	0.567	rs11718621	chr3:40362122	T/C	cg24209194	chr3:40518798	ZNF619	-0.57	-4.76	-0.44	6.87e-6	Renal cell carcinoma;
THYM	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg13147721	chr7:65941812	NA	-1.1	-7.08	-0.59	2.45e-10	Diabetic kidney disease;
THYM	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg00717180	chr2:96193071	NA	-0.7	-7.27	-0.6	9.92e-11	HDL cholesterol;
THYM	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg27034606	chr17:28928453	LRRC37B2	0.79	4.89	0.45	4.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg13609457	chr4:120235615	NA	0.51	4.8	0.44	5.83e-6	Corneal astigmatism;
THYM	cis	rs12738007	0.544	rs12408688	chr1:29431072	C/T	cg01925633	chr1:29338769	EPB41	0.57	4.95	0.45	3.26e-6	Schizophrenia;
THYM	cis	rs6840360	0.557	rs1143036	chr4:152329404	A/G	cg17479576	chr4:152424074	FAM160A1	-0.74	-5.64	-0.5	1.73e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4713118	0.505	rs276371	chr6:27910708	A/T	cg13525197	chr6:28411240	ZSCAN23	-0.7	-5.32	-0.48	7.02e-7	Parkinson's disease;
THYM	cis	rs800586	0.788	rs800520	chr8:116744586	G/T	cg04656070	chr8:116661063	TRPS1	0.5	4.54	0.42	1.68e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg08270630	chr22:50330655	NA	0.88	4.82	0.44	5.39e-6	Schizophrenia;
THYM	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03452623	chr4:187889614	NA	-1.19	-19.33	-0.89	1.1e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4430311	0.723	rs4639743	chr1:243946072	G/A	cg25706552	chr1:244017396	NA	-0.56	-4.92	-0.45	3.57e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg11663144	chr21:46675770	NA	-0.72	-9.23	-0.69	7.18e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs977102	0.556	rs67625416	chr3:67375700	A/G	cg06096184	chr3:66549732	LRIG1	0.66	4.6	0.43	1.32e-5	Response to amphetamines;
THYM	cis	rs1691799	0.899	rs1060724	chr12:66740444	T/C	cg16791601	chr12:66731901	HELB	-0.76	-7.23	-0.6	1.21e-10	White blood cell count (basophil);
THYM	cis	rs4888262	0.564	rs8062404	chr16:74611675	T/C	cg01733217	chr16:74700730	RFWD3	0.83	8.61	0.66	1.55e-13	Testicular germ cell tumor;
THYM	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg06636001	chr8:8085503	FLJ10661	0.83	8.36	0.65	5.27e-13	Mood instability;
THYM	cis	rs2970992	1.000	rs2970992	chr2:101322309	C/A	cg01042948	chr2:101319752	NA	0.62	6.27	0.54	1.06e-8	Educational attainment;
THYM	cis	rs17122693	0.748	rs57198801	chr14:51119456	T/C	cg04730355	chr14:51134070	SAV1	0.96	6.13	0.53	2e-8	Cognitive performance;
THYM	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg24675056	chr1:15929824	NA	0.73	5.79	0.51	9.09e-8	Systolic blood pressure;
THYM	cis	rs2463822	1.000	rs12279819	chr11:62137245	G/A	cg06239285	chr11:62104954	ASRGL1	-1.41	-7.07	-0.59	2.63e-10	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs3820068	0.580	rs12747696	chr1:16002978	A/G	cg24675056	chr1:15929824	NA	0.69	5.65	0.5	1.66e-7	Systolic blood pressure;
THYM	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg19875535	chr5:140030758	IK	-0.63	-5.69	-0.5	1.43e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs9399401	0.601	rs262120	chr6:142842360	C/A	cg03128060	chr6:142623767	GPR126	0.55	6.75	0.57	1.16e-9	Chronic obstructive pulmonary disease;
THYM	cis	rs11118844	0.696	rs11118859	chr1:221953193	A/T	cg04222084	chr1:221915650	DUSP10	-0.95	-4.72	-0.44	8.22e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg13010199	chr12:38710504	ALG10B	0.72	5.92	0.52	5.01e-8	Heart rate;
THYM	cis	rs7072216	0.763	rs12763326	chr10:100167396	A/G	cg26618903	chr10:100175079	PYROXD2	0.51	4.79	0.44	6.22e-6	Metabolite levels;
THYM	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg15556689	chr8:8085844	FLJ10661	-0.69	-5.73	-0.51	1.18e-7	Neuroticism;
THYM	cis	rs7715811	1.000	rs7715811	chr5:13769974	C/T	cg07548982	chr5:13769939	DNAH5	-0.5	-4.48	-0.42	2.1e-5	Subclinical atherosclerosis traits (other);
THYM	cis	rs8067545	0.611	rs2703781	chr17:20144714	A/G	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs1448094	0.512	rs11503595	chr12:86244075	T/A	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs12042938	0.600	rs823165	chr1:231769446	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.79	5.76	0.51	1.05e-7	Neuranatomic and neurocognitive phenotypes;
THYM	cis	rs6785206	0.614	rs61292315	chr3:128542609	C/T	cg16766828	chr3:128327626	NA	0.5	4.51	0.42	1.82e-5	Lymphocyte percentage of white cells;
THYM	cis	rs728616	0.764	rs117833443	chr10:81738136	A/C	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6570726	0.935	rs9390329	chr6:145828026	T/C	cg23711669	chr6:146136114	FBXO30	0.9	8.87	0.67	4.4e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg22875332	chr1:76189707	ACADM	0.83	8.04	0.64	2.48e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs8063160	0.799	rs1805007	chr16:89986117	A/G	cg07984980	chr16:89898383	SPIRE2	-1.5	-6.38	-0.55	6.31e-9	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs36051895	0.623	rs6476952	chr9:5236924	T/C	cg02405213	chr9:5042618	JAK2	-0.94	-9.5	-0.7	1.92e-15	Pediatric autoimmune diseases;
THYM	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg16325326	chr1:53192061	ZYG11B	0.84	8.36	0.65	5.23e-13	Monocyte count;
THYM	cis	rs6694672	0.850	rs4915156	chr1:197062820	A/T	cg13682187	chr1:196946512	CFHR5	0.82	4.5	0.42	1.89e-5	Asthma;
THYM	cis	rs7773324	1.000	rs7773324	chr6:382559	A/G	cg23785612	chr6:387171	NA	0.45	4.57	0.42	1.5e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs9915657	0.933	rs4793272	chr17:70139257	A/T	cg06234051	chr17:70120541	SOX9	-0.61	-5.6	-0.5	2.03e-7	Thyroid hormone levels;
THYM	cis	rs6500395	1.000	rs12597569	chr16:48693342	C/T	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10979	0.964	rs9496682	chr6:143898805	A/G	cg25407410	chr6:143891975	LOC285740	-0.59	-4.81	-0.44	5.6e-6	Hypospadias;
THYM	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg23188684	chr11:67383651	NA	-0.59	-4.48	-0.42	2.12e-5	Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.9e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg23711669	chr6:146136114	FBXO30	-0.97	-10.49	-0.73	1.45e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6840360	1.000	rs4696111	chr4:152671405	T/C	cg22705602	chr4:152727874	NA	-0.58	-6.26	-0.54	1.1e-8	Intelligence (multi-trait analysis);
THYM	cis	rs10140922	0.966	rs4982260	chr14:35822105	T/A	cg07166546	chr14:35805898	NA	-0.27	-6.66	-0.56	1.77e-9	Hip circumference adjusted for BMI;
THYM	cis	rs6032067	0.777	rs2868234	chr20:43794026	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs3741151	0.686	rs7129990	chr11:73124441	A/G	cg17517138	chr11:73019481	ARHGEF17	0.76	4.8	0.44	5.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg15744005	chr10:104629667	AS3MT	-0.84	-7.66	-0.62	1.59e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs12579753	1.000	rs10862373	chr12:82250657	A/G	cg21231944	chr12:82153410	PPFIA2	-0.58	-4.67	-0.43	1.01e-5	Resting heart rate;
THYM	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg23018236	chr17:30244563	NA	-0.6	-4.45	-0.42	2.3e-5	Hip circumference adjusted for BMI;
THYM	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg03396347	chr1:1875803	NA	0.47	4.48	0.42	2.05e-5	Body mass index;
THYM	cis	rs911119	1.000	rs3787498	chr20:23616781	C/T	cg16589663	chr20:23618590	CST3	0.78	4.79	0.44	6.1e-6	Chronic kidney disease;
THYM	cis	rs6920965	0.563	rs1544292	chr6:126175093	G/C	cg05901451	chr6:126070800	HEY2	-0.62	-5.23	-0.47	1.02e-6	High light scatter reticulocyte count;
THYM	cis	rs2404602	0.647	rs10851892	chr15:77176491	T/C	cg23625390	chr15:77176239	SCAPER	-0.81	-5.61	-0.5	1.96e-7	Blood metabolite levels;
THYM	cis	rs4731207	0.596	rs9641759	chr7:124666210	C/T	cg05285228	chr7:124571219	POT1	-0.62	-4.74	-0.44	7.4e-6	Cutaneous malignant melanoma;
THYM	cis	rs7246967	0.611	rs16999571	chr19:22904764	C/A	cg05241461	chr19:22816980	ZNF492	0.61	4.75	0.44	7.2e-6	Bronchopulmonary dysplasia;
THYM	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg23205692	chr1:25664452	TMEM50A	0.85	6.62	0.56	2.11e-9	Erythrocyte sedimentation rate;
THYM	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg07636037	chr3:49044803	WDR6	0.89	9.18	0.69	9.44e-15	Parkinson's disease;
THYM	cis	rs6542838	0.611	rs1878589	chr2:99517979	C/T	cg08885076	chr2:99613938	TSGA10	-0.49	-4.57	-0.42	1.49e-5	Fear of minor pain;
THYM	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg27121462	chr16:89883253	FANCA	0.58	4.52	0.42	1.81e-5	Vitiligo;
THYM	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs7940866	0.801	rs2113929	chr11:130835974	G/A	cg12179176	chr11:130786555	SNX19	0.62	4.8	0.44	5.99e-6	Schizophrenia;
THYM	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.92	-6.03	-0.53	3.11e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs3796352	0.892	rs11718388	chr3:53076415	G/A	cg24530246	chr3:53118167	NA	-0.76	-4.57	-0.42	1.47e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7107770	0.739	rs4936994	chr11:125081440	G/C	cg04164023	chr11:125106101	PKNOX2	-0.7	-4.49	-0.42	1.98e-5	Photic sneeze reflex;
THYM	cis	rs11711311	0.911	rs3773681	chr3:113523901	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.59	-5.13	-0.47	1.52e-6	IgG glycosylation;
THYM	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg24130564	chr14:104152367	KLC1	-0.52	-4.78	-0.44	6.37e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11585357	0.842	rs72633804	chr1:17617024	T/C	cg08277548	chr1:17600880	PADI3	-0.9	-5.43	-0.49	4.38e-7	Hair shape;
THYM	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-1.07	-9.37	-0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs4262150	0.883	rs72804786	chr5:152317799	G/A	cg08281791	chr5:76607845	PDE8B	0.93	7.09	0.59	2.41e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs9296092	0.538	rs9461881	chr6:33520041	C/T	cg13560919	chr6:33536144	NA	-0.94	-9.31	-0.69	4.9e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg20891283	chr12:69753455	YEATS4	0.76	6.01	0.52	3.47e-8	Response to diuretic therapy;
THYM	cis	rs514406	0.893	rs6588446	chr1:53425260	G/A	cg16325326	chr1:53192061	ZYG11B	-0.8	-7.44	-0.61	4.48e-11	Monocyte count;
THYM	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.58	0.43	1.41e-5	Bipolar disorder;
THYM	cis	rs17152411	0.843	rs7904691	chr10:126582927	G/T	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	9.83e-6	Height;
THYM	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg01073479	chr16:3509474	NAT15	0.53	5.25	0.47	9.14e-7	Tuberculosis;
THYM	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg14784868	chr12:69753453	YEATS4	1.12	10.87	0.74	2.32e-18	Blood protein levels;
THYM	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg22875332	chr1:76189707	ACADM	0.9	10.62	0.74	7.94e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	9.38	0.69	3.49e-15	Chronic sinus infection;
THYM	cis	rs11089937	0.616	rs928896	chr22:22540319	G/A	cg06866756	chr22:22471216	NA	-0.46	-5.09	-0.46	1.79e-6	Periodontitis (PAL4Q3);
THYM	cis	rs863345	0.604	rs12122663	chr1:158506724	A/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs7119	0.717	rs12916682	chr15:77807937	A/T	cg27398640	chr15:77910606	LINGO1	-0.52	-5.21	-0.47	1.12e-6	Type 2 diabetes;
THYM	cis	rs13185784	0.709	rs6703	chr5:179660786	A/T	cg23248424	chr5:179741104	GFPT2	-0.67	-4.57	-0.42	1.47e-5	TRAIL levels;
THYM	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.54	5.02	0.46	2.36e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg02782426	chr3:40428986	ENTPD3	0.54	4.75	0.44	7.19e-6	Renal cell carcinoma;
THYM	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg13010199	chr12:38710504	ALG10B	0.64	4.61	0.43	1.25e-5	Morning vs. evening chronotype;
THYM	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg24642439	chr20:33292090	TP53INP2	0.59	4.48	0.42	2.09e-5	Coronary artery disease;
THYM	cis	rs57994353	0.826	rs34619169	chr9:139327277	G/A	cg14115884	chr9:139300582	SDCCAG3	0.62	4.53	0.42	1.72e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs7586879	0.616	rs11900505	chr2:25131986	A/C	cg27107076	chr2:25050844	ADCY3	-0.29	-4.73	-0.44	7.91e-6	Body mass index;
THYM	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg01341218	chr17:43662625	NA	1.15	9.87	0.71	3.19e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7582403	0.844	rs1375859	chr2:148892355	T/G	cg23727674	chr2:148602993	ACVR2A	-0.61	-5.05	-0.46	2.17e-6	Neuroticism;
THYM	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg10047753	chr17:41438598	NA	1.14	10.51	0.73	1.38e-17	Menopause (age at onset);
THYM	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg00376283	chr12:123451042	ABCB9	0.75	5.19	0.47	1.2e-6	Neutrophil percentage of white cells;
THYM	cis	rs9311676	0.656	rs4681682	chr3:58337833	A/G	cg26110898	chr3:58419937	PDHB	-0.44	-4.58	-0.43	1.41e-5	Systemic lupus erythematosus;
THYM	cis	rs4589258	0.933	rs7102601	chr11:90396378	T/C	cg26834418	chr11:89957033	CHORDC1	0.49	4.45	0.42	2.31e-5	Intelligence (multi-trait analysis);
THYM	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg26850624	chr5:429559	AHRR	0.53	4.5	0.42	1.93e-5	Cystic fibrosis severity;
THYM	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	trans	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg18252515	chr7:66147081	NA	0.65	4.73	0.44	7.72e-6	Aortic root size;
THYM	cis	rs804280	0.504	rs2645457	chr8:11614112	T/G	cg12395012	chr8:11607386	GATA4	0.64	6.17	0.53	1.69e-8	Myopia (pathological);
THYM	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg18512352	chr11:47633146	NA	0.49	5.88	0.52	6.07e-8	Subjective well-being;
THYM	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg14416269	chr4:6271139	WFS1	0.55	5.69	0.5	1.41e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs11563648	0.573	rs1419392	chr7:126945510	G/A	cg23081781	chr7:127225937	GCC1	-0.36	-5.09	-0.46	1.83e-6	Resting heart rate;
THYM	cis	rs7264396	0.561	rs6060753	chr20:34598430	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-4.53	-0.42	1.71e-5	Total cholesterol levels;
THYM	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg04414720	chr1:150670196	GOLPH3L	0.62	4.58	0.43	1.41e-5	Tonsillectomy;
THYM	cis	rs7084402	0.967	rs1593674	chr10:60291908	A/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs1395	0.744	rs57881048	chr2:27474165	T/C	cg23587288	chr2:27483067	SLC30A3	-0.69	-6.19	-0.54	1.53e-8	Blood metabolite levels;
THYM	cis	rs13315871	1.000	rs3196769	chr3:58409361	A/T	cg00563845	chr3:58318305	PXK	0.53	4.67	0.43	9.78e-6	Cholesterol, total;
THYM	cis	rs7250872	0.619	rs2396359	chr19:1819125	T/C	cg18850929	chr19:1828978	REXO1	0.59	5.04	0.46	2.26e-6	Bipolar disorder;
THYM	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg27535305	chr1:53392650	SCP2	0.42	4.82	0.44	5.53e-6	Monocyte count;
THYM	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg10589385	chr1:150898437	SETDB1	0.64	5.26	0.48	8.81e-7	Melanoma;
THYM	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg02640540	chr1:67518911	SLC35D1	0.59	4.64	0.43	1.09e-5	Lymphocyte percentage of white cells;
THYM	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg17074396	chr22:49843754	NA	-0.39	-4.59	-0.43	1.33e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs13082711	0.911	rs6773733	chr3:27502131	C/A	cg02860705	chr3:27208620	NA	0.72	5.14	0.47	1.46e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg27494647	chr7:150038898	RARRES2	0.48	5.98	0.52	3.96e-8	Blood protein levels;Circulating chemerin levels;
THYM	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs763014	0.931	rs7199839	chr16:636126	T/C	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg11871910	chr12:69753446	YEATS4	-0.75	-6.09	-0.53	2.39e-8	Blood protein levels;
THYM	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg10589385	chr1:150898437	SETDB1	-0.62	-5.08	-0.46	1.9e-6	Melanoma;
THYM	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.55	-5.38	-0.48	5.34e-7	Crohn's disease;
THYM	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg05043794	chr9:111880884	C9orf5	-0.41	-6.15	-0.53	1.8e-8	Menarche (age at onset);
THYM	cis	rs1003719	0.788	rs1543750	chr21:38446918	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg00666640	chr1:248458726	OR2T12	0.57	4.75	0.44	7.19e-6	Common traits (Other);
THYM	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6992820	0.967	rs4737418	chr8:56711267	A/G	cg06880721	chr8:56792545	LYN	-0.73	-6.26	-0.54	1.12e-8	Mean platelet volume;
THYM	cis	rs7635838	0.617	rs346084	chr3:11281159	C/T	cg00170343	chr3:11313890	ATG7	0.64	4.87	0.45	4.41e-6	HDL cholesterol;
THYM	cis	rs4792901	0.959	rs2293015	chr17:41621999	G/A	cg21940313	chr17:41620911	ETV4	-0.52	-5.51	-0.49	3.08e-7	Dupuytren's disease;
THYM	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg13114125	chr14:105738426	BRF1	-0.71	-5.48	-0.49	3.45e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7267979	0.966	rs4815414	chr20:25361701	A/G	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	7.14	0.59	1.88e-10	Platelet count;
THYM	cis	rs9914544	0.689	rs8073236	chr17:18787182	C/G	cg26378065	chr17:18585709	ZNF286B	0.55	4.55	0.42	1.56e-5	Educational attainment (years of education);
THYM	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	7.7	0.62	1.29e-11	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg03433033	chr1:76189801	ACADM	0.7	6.85	0.58	7.17e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs79149102	0.579	rs12593542	chr15:75282147	C/G	cg09165964	chr15:75287851	SCAMP5	-1.09	-6.19	-0.54	1.49e-8	Lung cancer;
THYM	cis	rs9875589	0.509	rs1906538	chr3:14014169	C/T	cg03204825	chr3:13978759	TPRXL	-0.55	-4.78	-0.44	6.32e-6	Ovarian reserve;
THYM	cis	rs10484885	0.715	rs2585013	chr6:90553402	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.9	-9.3	-0.69	5.14e-15	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg17554472	chr22:41940697	POLR3H	0.64	4.81	0.44	5.67e-6	Vitiligo;
THYM	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg08742575	chr21:47604166	C21orf56	0.65	4.98	0.45	2.84e-6	Testicular germ cell tumor;
THYM	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg17211192	chr8:82754475	SNX16	-0.82	-7.41	-0.61	5.09e-11	Diastolic blood pressure;
THYM	cis	rs7942486	0.895	rs11022721	chr11:13270501	A/C	cg13286116	chr11:13302098	ARNTL	-0.72	-8.02	-0.64	2.79e-12	Neuroticism;
THYM	cis	rs12509991	0.582	rs10452202	chr4:127049657	T/C	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7511006	0.893	rs2038049	chr22:50654888	G/C	cg01917657	chr22:50617092	PANX2	-0.4	-4.47	-0.42	2.14e-5	Obesity-related traits;
THYM	cis	rs2835345	0.563	rs73204244	chr21:37824671	A/C	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg17143192	chr8:8559678	CLDN23	0.97	7.28	0.6	9.72e-11	Obesity-related traits;
THYM	cis	rs9318086	0.578	rs75752641	chr13:24473240	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.57	4.71	0.43	8.58e-6	Myopia (pathological);
THYM	cis	rs12291225	0.535	rs11023203	chr11:14409815	G/A	cg19336497	chr11:14380999	RRAS2	-0.83	-11.13	-0.75	6.64e-19	Sense of smell;
THYM	cis	rs7172677	1.000	rs7172677	chr15:75424593	G/T	cg09165964	chr15:75287851	SCAMP5	0.61	4.75	0.44	7.13e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg03929089	chr4:120376271	NA	-1.03	-12.22	-0.78	3.45e-21	Height;
THYM	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg07636037	chr3:49044803	WDR6	0.95	9.55	0.7	1.53e-15	Parkinson's disease;
THYM	cis	rs1061377	1.000	rs28607301	chr4:39138080	C/T	cg24403649	chr4:39172243	NA	0.59	4.78	0.44	6.29e-6	Uric acid levels;
THYM	cis	rs7127900	1.000	rs7123312	chr11:2232359	A/G	cg25635251	chr11:2234043	NA	0.74	4.71	0.44	8.43e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg20744362	chr22:50050164	C22orf34	0.78	7.04	0.59	3e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg08132940	chr7:1081526	C7orf50	-1.17	-6.67	-0.56	1.7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg26612409	chr5:160335	PLEKHG4B	0.67	4.52	0.42	1.81e-5	Cystic fibrosis severity;
THYM	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg26752003	chr8:145688521	CYHR1	0.82	6.75	0.57	1.18e-9	Age at first birth;
THYM	cis	rs10274279	1.000	rs6459798	chr7:157381735	C/T	cg25259479	chr7:157408632	PTPRN2	-0.81	-4.57	-0.42	1.48e-5	Myopia (pathological);
THYM	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg13683864	chr3:40499215	RPL14	-0.91	-8.79	-0.67	6.47e-14	Renal cell carcinoma;
THYM	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs2712184	0.756	rs2541388	chr2:217664284	A/G	cg05032264	chr2:217675019	NA	0.56	4.76	0.44	6.99e-6	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs9914544	0.545	rs8066636	chr17:18761109	G/A	cg26378065	chr17:18585709	ZNF286B	0.6	4.71	0.43	8.56e-6	Educational attainment (years of education);
THYM	cis	rs9457247	0.534	rs9356551	chr6:167400345	T/C	cg00271210	chr6:167070053	RPS6KA2	0.48	4.72	0.44	8e-6	Crohn's disease;
THYM	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03517284	chr6:25882590	NA	-0.93	-8.1	-0.64	1.81e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7152530	0.571	rs17096587	chr14:98635098	C/G	cg05180522	chr14:98101740	NA	-0.59	-4.7	-0.43	8.79e-6	Staphylococcus aureus infection;
THYM	cis	rs7187994	0.848	rs16974527	chr16:84782822	C/T	cg07647771	chr16:84786436	USP10	-0.53	-4.91	-0.45	3.81e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs1451375	0.617	rs17733244	chr7:50575495	T/C	cg18232548	chr7:50535776	DDC	0.68	4.83	0.44	5.3e-6	Malaria;
THYM	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg15693483	chr7:1102177	C7orf50	0.5	5.79	0.51	8.93e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7872515	0.536	rs7852989	chr9:94782453	G/C	cg13922115	chr9:95397568	IPPK	0.88	4.46	0.42	2.25e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs6570726	0.935	rs453609	chr6:145812332	T/C	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	6.03	0.53	3.08e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9581943	0.901	rs9551414	chr13:28474237	C/T	cg16302790	chr13:28498334	PDX1	0.52	4.6	0.43	1.33e-5	Pancreatic cancer;
THYM	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs9595908	1.000	rs9591165	chr13:33185153	G/A	cg12383807	chr13:33924137	NA	-0.54	-4.78	-0.44	6.39e-6	Body mass index;
THYM	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg26038318	chr20:34205095	SPAG4	0.58	4.6	0.43	1.3e-5	Total cholesterol levels;
THYM	cis	rs8078723	0.510	rs3087852	chr17:38137364	G/A	cg25038082	chr17:37896074	GRB7	-0.59	-4.8	-0.44	5.85e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs7943358	0.774	rs7944134	chr11:15686360	A/G	cg11966998	chr11:15692519	NA	-0.45	-4.7	-0.43	8.83e-6	Gut microbiome composition (summer);
THYM	cis	rs11628318	0.515	rs4906239	chr14:103078073	A/G	cg27124170	chr14:102829869	TECPR2;CINP	-0.65	-4.47	-0.42	2.15e-5	Platelet count;
THYM	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg07636037	chr3:49044803	WDR6	0.81	5.86	0.52	6.7e-8	Menarche (age at onset);
THYM	cis	rs7523273	0.568	rs11118668	chr1:208017915	A/G	cg22525895	chr1:207977042	MIR29B2	0.65	4.63	0.43	1.14e-5	Schizophrenia;
THYM	cis	rs422249	0.547	rs174533	chr11:61549025	G/A	cg19610905	chr11:61596333	FADS2	-0.57	-4.77	-0.44	6.58e-6	Trans fatty acid levels;
THYM	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg11494091	chr17:61959527	GH2	-1.07	-17.33	-0.87	3.67e-31	Prudent dietary pattern;
THYM	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg24020549	chr11:64937741	SPDYC	-0.46	-4.46	-0.42	2.23e-5	Eosinophil percentage of white cells;
THYM	cis	rs6499129	0.557	rs2031005	chr16:67105149	A/G	cg03615565	chr16:67572595	FAM65A	-0.6	-4.68	-0.43	9.37e-6	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs8018808	0.902	rs147316	chr14:77888664	C/T	cg20045696	chr14:77926864	AHSA1	0.5	4.46	0.42	2.27e-5	Myeloid white cell count;
THYM	cis	rs1978968	1.000	rs13057203	chr22:18446024	A/G	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg14895029	chr7:2775587	GNA12	-0.67	-4.87	-0.45	4.51e-6	Height;
THYM	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg11211951	chr8:145729740	GPT	0.6	6.08	0.53	2.53e-8	Age at first birth;
THYM	cis	rs6558530	0.965	rs730379	chr8:1708093	A/C	cg09410841	chr8:1729607	CLN8	0.75	5.76	0.51	1.02e-7	Systolic blood pressure;
THYM	cis	rs763014	0.931	rs7199839	chr16:636126	T/C	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs17253792	0.822	rs78922774	chr14:56115302	T/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg19901468	chr14:105411992	AHNAK2	-0.82	-6.74	-0.57	1.24e-9	Rheumatoid arthritis;
THYM	cis	rs684232	0.602	rs34167561	chr17:509268	G/A	cg15660573	chr17:549704	VPS53	-1.01	-9.89	-0.71	2.89e-16	Prostate cancer;
THYM	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg13012494	chr21:47604986	C21orf56	0.61	4.66	0.43	1.01e-5	Testicular germ cell tumor;
THYM	cis	rs7119	0.635	rs907374	chr15:77884026	C/T	cg10437265	chr15:77819839	NA	-0.63	-6.05	-0.53	2.84e-8	Type 2 diabetes;
THYM	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg16586182	chr3:47516702	SCAP	-0.58	-4.96	-0.45	3.05e-6	Colorectal cancer;
THYM	cis	rs4478037	1.000	rs59229836	chr3:33162622	T/C	cg19404215	chr3:33155277	CRTAP	1.12	7.55	0.61	2.6e-11	Major depressive disorder;
THYM	cis	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs1421811	0.532	rs72740626	chr5:32692220	G/C	cg16267343	chr5:32710456	NPR3	0.85	7.04	0.59	2.98e-10	Blood pressure;
THYM	cis	rs4888262	0.514	rs8048239	chr16:74578317	A/T	cg01733217	chr16:74700730	RFWD3	0.8	8.45	0.66	3.35e-13	Testicular germ cell tumor;
THYM	cis	rs7927771	0.524	rs11039345	chr11:47720228	A/G	cg20307385	chr11:47447363	PSMC3	0.6	4.49	0.42	2.02e-5	Subjective well-being;
THYM	cis	rs870825	0.616	rs4623061	chr4:185643161	A/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	4.67	0.43	1e-5	Diabetic retinopathy;
THYM	cis	rs7809950	0.620	rs2248464	chr7:107303622	A/T	cg23024343	chr7:107201750	COG5	0.85	7.18	0.59	1.54e-10	Coronary artery disease;
THYM	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg01966878	chr4:90757139	SNCA	-0.54	-4.48	-0.42	2.07e-5	Neuroticism;
THYM	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg03188948	chr7:1209495	NA	0.6	4.67	0.43	9.79e-6	Longevity;Endometriosis;
THYM	cis	rs651907	0.565	rs2925323	chr3:101658926	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	5.42	0.49	4.47e-7	Colorectal cancer;
THYM	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg20203395	chr5:56204925	C5orf35	-0.67	-4.58	-0.42	1.44e-5	Initial pursuit acceleration;
THYM	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg07424592	chr7:64974309	NA	1.16	5.55	0.5	2.55e-7	Diabetic kidney disease;
THYM	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg15133208	chr4:90757351	SNCA	-0.52	-4.47	-0.42	2.16e-5	Neuroticism;
THYM	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs11605275	1.000	rs11604179	chr11:20024759	G/A	cg14835545	chr11:20032148	NAV2	-1.38	-6.36	-0.55	6.98e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs4638749	0.501	rs2129145	chr2:108758322	C/T	cg25838818	chr2:108905173	SULT1C2	-0.52	-4.89	-0.45	4.13e-6	Blood pressure;
THYM	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4242434	0.854	rs4872007	chr8:22538879	G/A	cg21658235	chr8:22456391	C8orf58	-0.51	-4.53	-0.42	1.68e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs12142240	0.698	rs1053628	chr1:46827769	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7107174	0.901	rs4944199	chr11:78122779	A/G	cg19901956	chr11:77921274	USP35	-0.67	-5.42	-0.49	4.59e-7	Testicular germ cell tumor;
THYM	cis	rs6500395	1.000	rs1039340	chr16:48574637	A/C	cg04672837	chr16:48644449	N4BP1	0.49	4.79	0.44	6.02e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs10095849	0.680	rs61467426	chr8:39447328	A/G	cg22755526	chr8:38854673	TM2D2;ADAM9	0.66	4.53	0.42	1.73e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg04362960	chr10:104952993	NT5C2	0.6	5.11	0.46	1.66e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7823896	0.929	rs73311376	chr8:110143959	G/A	cg18044723	chr8:109261011	EIF3E	-0.89	-4.68	-0.43	9.42e-6	Myopia (pathological);
THYM	cis	rs854765	0.551	rs6502626	chr17:17849450	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	6.81	0.57	8.85e-10	Total body bone mineral density;
THYM	cis	rs4654899	0.929	rs7515845	chr1:21314455	G/A	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.26e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg22166914	chr1:53195759	ZYG11B	0.81	8.2	0.64	1.13e-12	Monocyte count;
THYM	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg16482183	chr6:26056742	HIST1H1C	1.03	6.45	0.55	4.59e-9	Iron status biomarkers;
THYM	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10463554	0.927	rs34821	chr5:102437617	T/A	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Parkinson's disease;
THYM	cis	rs960902	0.592	rs7571760	chr2:37742758	A/G	cg25341268	chr2:37734390	NA	-0.7	-6.49	-0.55	3.95e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4824093	0.535	rs73443931	chr22:50291603	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.05	-4.79	-0.44	6.23e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs11048434	0.736	rs1805761	chr12:9099533	T/C	cg13575925	chr12:9217583	LOC144571	0.52	4.94	0.45	3.32e-6	Sjögren's syndrome;
THYM	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.09	0.64	1.96e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg00339695	chr16:24857497	SLC5A11	0.7	6.31	0.54	8.96e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg22166914	chr1:53195759	ZYG11B	-0.77	-8.25	-0.65	8.99e-13	Monocyte count;
THYM	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg12501888	chr15:85177176	SCAND2	-0.58	-4.59	-0.43	1.35e-5	P wave terminal force;
THYM	cis	rs12216545	0.765	rs6464080	chr7:150260388	T/C	cg08960815	chr7:150264767	GIMAP4	-0.87	-7.97	-0.63	3.41e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs13082711	0.911	rs2887926	chr3:27494475	T/C	cg02860705	chr3:27208620	NA	0.74	5.33	0.48	6.47e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs4363385	0.818	rs3806223	chr1:153002646	T/C	cg13444842	chr1:152974279	SPRR3	-0.59	-4.81	-0.44	5.61e-6	Inflammatory skin disease;
THYM	cis	rs72653721	0.838	rs3798717	chr6:11026471	G/A	cg24724428	chr6:11044888	ELOVL2	0.55	4.53	0.42	1.71e-5	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
THYM	cis	rs346785	0.692	rs2279054	chr17:74287594	G/A	cg09812376	chr17:74270190	QRICH2	-0.48	-4.91	-0.45	3.79e-6	White matter hyperintensities in ischemic stroke;
THYM	cis	rs7267979	0.903	rs6107015	chr20:25216764	G/A	cg08601574	chr20:25228251	PYGB	0.61	4.72	0.44	8.27e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs490234	0.805	rs562004	chr9:128321771	T/C	cg14078157	chr9:128172775	NA	0.67	5.24	0.47	9.8e-7	Mean arterial pressure;
THYM	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg03609598	chr5:56110824	MAP3K1	-0.67	-4.69	-0.43	9.21e-6	Coronary artery disease;
THYM	cis	rs539096	0.872	rs663618	chr1:44043105	T/C	cg00143623	chr1:44495758	SLC6A9	0.68	5.34	0.48	6.31e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.564	rs6977313	chr7:124681732	C/T	cg05285228	chr7:124571219	POT1	-0.63	-4.74	-0.44	7.37e-6	Cutaneous malignant melanoma;
THYM	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22433210	chr17:43662623	NA	1.12	8.59	0.66	1.69e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7633857	0.536	rs2889391	chr3:160696186	A/G	cg03342759	chr3:160939853	NMD3	-0.59	-4.59	-0.43	1.37e-5	Educational attainment (years of education);
THYM	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg18240062	chr17:79603768	NPLOC4	0.73	6.55	0.56	2.9e-9	Eye color traits;
THYM	cis	rs6684428	1.000	rs6684428	chr1:56359813	T/A	cg11651538	chr1:56320950	NA	-0.6	-4.54	-0.42	1.63e-5	Airflow obstruction;
THYM	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg03060546	chr3:49711283	APEH	0.71	5.0	0.46	2.62e-6	Resting heart rate;
THYM	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg08999081	chr20:33150536	PIGU	0.57	4.78	0.44	6.41e-6	Coronary artery disease;
THYM	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg12373951	chr3:133503437	NA	0.59	6.56	0.56	2.8e-9	Iron status biomarkers;
THYM	cis	rs9549367	0.724	rs7985335	chr13:113869244	G/T	cg00898013	chr13:113819073	PROZ	0.83	8.57	0.66	1.86e-13	Platelet distribution width;
THYM	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg06636001	chr8:8085503	FLJ10661	0.77	7.36	0.6	6.58e-11	Mood instability;
THYM	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg05368731	chr17:41323189	NBR1	1.2	10.98	0.75	1.36e-18	Menopause (age at onset);
THYM	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg00814883	chr7:100076585	TSC22D4	-0.95	-6.39	-0.55	6.08e-9	Platelet count;
THYM	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg26924012	chr15:45694286	SPATA5L1	1.14	11.02	0.75	1.09e-18	Homoarginine levels;
THYM	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg15592062	chr6:167189543	RPS6KA2	0.59	6.1	0.53	2.29e-8	Crohn's disease;
THYM	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs10489202	0.583	rs203777	chr1:167876616	C/T	cg24449463	chr1:168025552	DCAF6	-0.86	-7.98	-0.63	3.39e-12	Schizophrenia;
THYM	cis	rs9324022	0.929	rs1004574	chr14:101178067	C/G	cg18089426	chr14:101175970	NA	0.75	5.12	0.46	1.61e-6	Plateletcrit;
THYM	cis	rs34526934	0.619	rs17336374	chr2:177068638	T/G	cg14324370	chr2:177042789	NA	-0.64	-4.97	-0.45	2.99e-6	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg16486109	chr11:613632	IRF7	0.47	5.59	0.5	2.19e-7	Systemic lupus erythematosus;
THYM	cis	rs514406	0.893	rs6588446	chr1:53425260	G/A	cg08859206	chr1:53392774	SCP2	0.66	7.64	0.62	1.75e-11	Monocyte count;
THYM	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.78	-4.65	-0.43	1.07e-5	Yeast infection;
THYM	cis	rs34638657	0.732	rs11645372	chr16:82202136	C/T	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.11	-0.64	1.73e-12	Lung adenocarcinoma;
THYM	cis	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg21775007	chr8:11205619	TDH	-0.68	-5.26	-0.47	8.84e-7	Retinal vascular caliber;
THYM	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg13246856	chr1:44399776	ARTN	0.5	4.76	0.44	6.88e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg12386194	chr3:101231763	SENP7	0.66	5.0	0.46	2.59e-6	Colorectal cancer;
THYM	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg17063962	chr7:91808500	NA	1.16	13.16	0.8	3.92e-23	Breast cancer;
THYM	cis	rs6693295	0.536	rs12132151	chr1:246229264	C/T	cg11798871	chr1:246315928	SMYD3	-0.78	-4.72	-0.44	8.16e-6	Migraine - clinic-based;Migraine with aura;
THYM	cis	rs17174870	0.955	rs76514293	chr2:112751516	A/C	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs35264875	0.796	rs72930637	chr11:68869967	C/T	cg01993067	chr11:68851601	TPCN2	1.07	5.5	0.49	3.22e-7	Blond vs. brown hair color;
THYM	cis	rs611744	0.967	rs594405	chr8:109193607	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4930776	1.000	rs251780	chr12:5773312	A/G	cg02086166	chr12:5775618	ANO2	0.6	6.08	0.53	2.54e-8	Plasma clusterin levels;
THYM	trans	rs629535	0.508	rs56207225	chr8:70146628	C/A	cg21567404	chr3:27674614	NA	-0.88	-7.0	-0.58	3.66e-10	Dupuytren's disease;
THYM	cis	rs7586879	0.789	rs7560156	chr2:25124794	T/C	cg01884057	chr2:25150051	NA	0.52	4.59	0.43	1.35e-5	Body mass index;
THYM	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg17366294	chr4:99064904	C4orf37	0.57	6.92	0.58	5.21e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg11764359	chr7:65958608	NA	-0.61	-4.58	-0.43	1.42e-5	Aortic root size;
THYM	cis	rs654384	0.507	rs2342505	chr7:4175710	C/T	cg04612959	chr7:4183976	SDK1	0.51	4.46	0.42	2.27e-5	Positive affect;
THYM	cis	rs2836633	0.929	rs62217518	chr21:40033189	T/G	cg05519781	chr21:40033154	ERG	0.75	7.28	0.6	9.39e-11	Coronary artery disease;
THYM	cis	rs17001868	0.568	rs12484697	chr22:40736472	A/G	cg07138101	chr22:40742427	ADSL	-0.94	-5.71	-0.51	1.3e-7	Mammographic density (dense area);
THYM	cis	rs7572733	0.555	rs700671	chr2:198690001	T/C	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg15733309	chr7:157513707	PTPRN2	0.56	5.98	0.52	3.95e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs7248779	1.000	rs7248779	chr19:2403564	G/T	cg22729335	chr19:2427816	TIMM13	-0.84	-6.92	-0.58	5.25e-10	Cortisol levels (saliva);
THYM	cis	rs240764	0.619	rs9399652	chr6:101120006	C/T	cg21058520	chr6:100914733	NA	0.62	5.27	0.48	8.56e-7	Neuroticism;
THYM	cis	rs6665290	0.836	rs12593	chr1:227172290	A/G	cg10327440	chr1:227177885	CDC42BPA	1.13	15.91	0.85	1.53e-28	Myeloid white cell count;
THYM	cis	rs7851660	0.844	rs12342417	chr9:100639065	G/A	cg13688889	chr9:100608707	NA	-0.73	-5.39	-0.48	5.2e-7	Strep throat;
THYM	trans	rs4596713	0.538	rs10781456	chr9:71782869	G/A	cg16512924	chr15:28394682	HERC2	0.83	7.08	0.59	2.49e-10	Headache;
THYM	cis	rs921968	0.613	rs2710250	chr2:219543277	A/G	cg02176678	chr2:219576539	TTLL4	-0.55	-5.46	-0.49	3.79e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7465272	0.957	rs11994668	chr8:143687392	G/T	cg01509843	chr8:143695822	ARC	0.72	4.82	0.44	5.49e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg06481639	chr22:41940642	POLR3H	-0.8	-5.6	-0.5	2.11e-7	Vitiligo;
THYM	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg14416269	chr4:6271139	WFS1	0.49	4.99	0.46	2.68e-6	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs854765	0.583	rs4534911	chr17:17852330	A/G	cg04398451	chr17:18023971	MYO15A	-0.83	-7.64	-0.62	1.72e-11	Total body bone mineral density;
THYM	cis	rs864643	0.704	rs4441592	chr3:39592263	G/A	cg20142358	chr3:39093977	WDR48	-0.64	-4.57	-0.42	1.49e-5	Attention deficit hyperactivity disorder;
THYM	cis	rs9486719	1.000	rs35487471	chr6:96879715	C/T	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs4363385	0.818	rs2787629	chr1:153011966	A/G	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg12386194	chr3:101231763	SENP7	0.71	5.23	0.47	1e-6	Colorectal cancer;
THYM	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg16325326	chr1:53192061	ZYG11B	0.94	10.11	0.72	9.59e-17	Monocyte count;
THYM	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	10.61	0.74	8.08e-18	Platelet count;
THYM	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg21028142	chr17:79581711	NPLOC4	-0.52	-5.13	-0.47	1.52e-6	Eye color traits;
THYM	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs886126	0.684	rs3858704	chr12:111705893	A/G	cg10833066	chr12:111807467	FAM109A	0.53	6.8	0.57	9.22e-10	Coronary heart disease;
THYM	cis	rs6089829	0.926	rs73921625	chr20:61660891	C/T	cg08564027	chr20:61660810	NA	-0.76	-6.0	-0.52	3.59e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6510489	1.000	rs10410228	chr19:35979696	C/T	cg15078284	chr19:36004994	DMKN	0.41	4.77	0.44	6.65e-6	Bipolar disorder;
THYM	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	4.56	0.42	1.5e-5	Alzheimer's disease;
THYM	cis	rs1981331	0.609	rs8127722	chr21:48077293	A/C	cg23283320	chr21:48055893	PRMT2	1.52	6.93	0.58	5.09e-10	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs34638657	0.828	rs7194734	chr16:82199980	C/T	cg19807685	chr16:82068980	HSD17B2	-0.62	-4.86	-0.45	4.56e-6	Lung adenocarcinoma;
THYM	cis	rs10744422	1.000	rs10744422	chr12:123336789	T/C	cg25930673	chr12:123319894	HIP1R	-0.86	-4.84	-0.44	5.09e-6	Schizophrenia;
THYM	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03517284	chr6:25882590	NA	0.71	5.35	0.48	6.18e-7	Blood metabolite levels;
THYM	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.65	-4.72	-0.44	8.09e-6	Colorectal cancer;
THYM	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	15.57	0.85	6.94e-28	Chronic sinus infection;
THYM	cis	rs34286592	0.929	rs35901559	chr16:29829615	T/C	cg04633683	chr16:29837056	MVP	0.61	4.93	0.45	3.45e-6	Multiple sclerosis;
THYM	cis	rs9649465	0.967	rs12537072	chr7:123377213	A/G	cg15443791	chr7:124364398	NA	0.6	4.97	0.45	3.01e-6	Migraine;
THYM	cis	rs9649213	0.593	rs7787858	chr7:98009914	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2404602	0.735	rs1607017	chr15:76726465	G/T	cg23482746	chr15:76478102	C15orf27	0.46	4.46	0.42	2.27e-5	Blood metabolite levels;
THYM	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-6.65	-0.56	1.84e-9	Chronic sinus infection;
THYM	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8032315	0.965	rs7497304	chr15:91429176	G/T	cg04510874	chr15:91427884	FES	0.62	4.64	0.43	1.12e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs600806	0.888	rs3853500	chr1:109864269	T/C	cg02175308	chr1:109941060	SORT1	-0.57	-4.96	-0.45	3.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg18876405	chr7:65276391	NA	0.57	4.73	0.44	7.67e-6	Aortic root size;
THYM	trans	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17712092	chr4:129076599	LARP1B	0.92	7.74	0.62	1.07e-11	Eosinophil percentage of white cells;
THYM	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg03929089	chr4:120376271	NA	-0.94	-10.56	-0.73	1.03e-17	Height;
THYM	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs1129187	0.748	rs6458312	chr6:42904274	G/T	cg27588902	chr6:42928151	GNMT	-0.6	-6.1	-0.53	2.24e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22968622	chr17:43663579	NA	0.82	6.99	0.58	3.76e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg02018176	chr4:1364513	KIAA1530	0.57	4.89	0.45	4.12e-6	Obesity-related traits;
THYM	cis	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg06521331	chr12:34319734	NA	-0.73	-5.46	-0.49	3.74e-7	Morning vs. evening chronotype;
THYM	cis	rs2456568	0.802	rs10765640	chr11:93636462	C/T	cg17347335	chr11:93583973	C11orf90	-0.48	-4.58	-0.43	1.39e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs1050631	0.564	rs1785910	chr18:33729871	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.28	0.48	8.32e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg13695892	chr22:41940480	POLR3H	-0.97	-7.51	-0.61	3.25e-11	Vitiligo;
THYM	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg20290983	chr6:43655470	MRPS18A	1.44	16.17	0.86	4.93e-29	IgG glycosylation;
THYM	trans	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg20587970	chr11:113659929	NA	-1.37	-8.96	-0.68	2.79e-14	Hip circumference adjusted for BMI;
THYM	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs2688608	0.839	rs2675662	chr10:75599127	A/G	cg15838173	chr10:75533400	FUT11	0.44	4.72	0.44	8.22e-6	Inflammatory bowel disease;
THYM	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg02569458	chr12:86230093	RASSF9	0.69	5.77	0.51	9.84e-8	Major depressive disorder;
THYM	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	5.91	0.52	5.41e-8	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6840360	0.615	rs56319216	chr4:152463716	C/T	cg17479576	chr4:152424074	FAM160A1	-0.85	-6.4	-0.55	5.9e-9	Intelligence (multi-trait analysis);
THYM	cis	rs55665837	1.000	rs12804549	chr11:14437758	A/T	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	8.56	0.66	1.97e-13	Platelet count;
THYM	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg24675658	chr1:53192096	ZYG11B	-0.74	-6.63	-0.56	2.05e-9	Monocyte count;
THYM	cis	rs9807841	0.670	rs1982075	chr19:10787744	C/G	cg17848348	chr19:10766748	ILF3	-0.85	-7.48	-0.61	3.69e-11	Inflammatory skin disease;
THYM	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg15536230	chr21:44985092	HSF2BP	-0.46	-5.62	-0.5	1.9e-7	Mean corpuscular volume;
THYM	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg07936489	chr17:37558343	FBXL20	0.8	5.79	0.51	9.24e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs2133450	0.526	rs13327304	chr3:7341120	C/G	cg19930620	chr3:7340148	GRM7	-0.5	-5.41	-0.49	4.76e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs2562456	0.917	rs2681377	chr19:21716520	T/C	cg21751540	chr19:21541537	ZNF738	0.67	4.66	0.43	1.04e-5	Pain;
THYM	cis	rs7106204	0.514	rs12805363	chr11:24258357	T/G	ch.11.24196551F	chr11:24239977	NA	0.93	5.71	0.51	1.3e-7	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11890956	chr21:40555474	PSMG1	-0.95	-10.91	-0.75	1.91e-18	Cognitive function;
THYM	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg02640540	chr1:67518911	SLC35D1	-0.64	-4.68	-0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg12564285	chr5:131593104	PDLIM4	-0.43	-4.76	-0.44	6.88e-6	Acylcarnitine levels;
THYM	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg04546413	chr19:29218101	NA	-0.7	-4.53	-0.42	1.69e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.14	-7.18	-0.59	1.55e-10	Gut microbiome composition (summer);
THYM	cis	rs59698941	0.943	rs12515752	chr5:132312960	C/G	cg27099455	chr5:132201840	GDF9;UQCRQ	0.63	4.74	0.44	7.44e-6	Apolipoprotein A-IV levels;
THYM	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.82e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg09184832	chr6:79620586	NA	-0.58	-4.53	-0.42	1.68e-5	Intelligence (multi-trait analysis);
THYM	cis	rs17253792	0.545	rs3742570	chr14:56016434	A/C	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs9364687	0.664	rs724826	chr6:163938594	C/T	cg01639524	chr6:163818125	NA	0.49	4.87	0.45	4.52e-6	Body mass index;
THYM	cis	rs2932538	0.922	rs4838961	chr1:113163967	T/C	cg22162597	chr1:113214053	CAPZA1	-0.65	-5.32	-0.48	6.9e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs2204008	0.527	rs8189480	chr12:38345648	C/T	cg10518543	chr12:38710700	ALG10B	-0.6	-4.82	-0.44	5.54e-6	Bladder cancer;
THYM	cis	rs4975709	1.000	rs4975709	chr5:1877280	A/C	cg12288994	chr5:1860383	NA	0.59	4.58	0.43	1.43e-5	Cardiovascular disease risk factors;
THYM	cis	rs72901758	0.700	rs34219567	chr17:76248036	A/G	cg25512537	chr17:76250053	NA	0.41	5.76	0.51	1.02e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
THYM	cis	rs10733271	0.792	rs62533246	chr9:13765628	C/A	cg21251203	chr9:14238640	NFIB	0.51	4.91	0.45	3.83e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs877282	1.000	rs112522746	chr10:772288	T/C	cg10556349	chr10:835070	NA	-0.69	-4.81	-0.44	5.75e-6	Uric acid levels;
THYM	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg26818010	chr10:134567672	INPP5A	0.63	5.18	0.47	1.25e-6	Migraine;
THYM	cis	rs9329221	0.527	rs4452832	chr8:10320554	G/C	cg19847130	chr8:10466454	RP1L1	0.49	4.56	0.42	1.5e-5	Neuroticism;
THYM	cis	rs1524976	1.000	rs11719771	chr3:65481987	G/T	cg16238336	chr3:65465873	MAGI1	-1.01	-5.89	-0.52	5.83e-8	PR interval;
THYM	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg25767906	chr1:53392781	SCP2	0.67	6.01	0.52	3.47e-8	Monocyte count;
THYM	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg05347473	chr6:146136440	FBXO30	0.56	4.51	0.42	1.84e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3820068	0.608	rs12091644	chr1:16044945	G/A	cg13390004	chr1:15929781	NA	0.65	4.81	0.44	5.56e-6	Systolic blood pressure;
THYM	cis	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg06521331	chr12:34319734	NA	-1.02	-11.22	-0.75	4.22e-19	Morning vs. evening chronotype;
THYM	cis	rs799165	1.000	rs13234805	chr7:73049182	G/A	cg22888238	chr7:73256761	WBSCR27	-0.93	-4.48	-0.42	2.12e-5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
THYM	cis	rs12049351	0.774	rs6673421	chr1:229636388	A/G	cg11742688	chr1:229674241	ABCB10	-0.54	-4.47	-0.42	2.14e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs13392177	0.647	rs10932761	chr2:219064391	T/A	cg00012203	chr2:219082015	ARPC2	-0.68	-5.62	-0.5	1.92e-7	Pyoderma gangrenosum in inflammatory bowel disease;
THYM	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg18512352	chr11:47633146	NA	-0.5	-6.15	-0.53	1.83e-8	Subjective well-being;
THYM	cis	rs2803122	0.501	rs10811140	chr9:19230399	T/C	cg19584733	chr9:19298547	DENND4C	-0.73	-5.87	-0.52	6.48e-8	Pulse pressure;
THYM	cis	rs9880211	1.000	rs9880211	chr3:136107549	G/A	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg00376283	chr12:123451042	ABCB9	0.86	6.89	0.58	6.19e-10	Platelet count;
THYM	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg22166914	chr1:53195759	ZYG11B	0.91	10.7	0.74	5.4e-18	Monocyte count;
THYM	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg03929089	chr4:120376271	NA	-0.94	-10.62	-0.74	7.99e-18	Height;
THYM	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg13695892	chr22:41940480	POLR3H	-0.93	-8.26	-0.65	8.63e-13	Vitiligo;
THYM	cis	rs4363385	0.765	rs11205165	chr1:152986928	G/T	cg13444842	chr1:152974279	SPRR3	-0.61	-5.11	-0.46	1.68e-6	Inflammatory skin disease;
THYM	cis	rs7264396	0.563	rs2425071	chr20:34292961	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	0.76	4.76	0.44	6.84e-6	Total cholesterol levels;
THYM	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg03188948	chr7:1209495	NA	0.7	4.87	0.45	4.46e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg23803603	chr1:2058230	PRKCZ	0.59	4.56	0.42	1.52e-5	Height;
THYM	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg21775007	chr8:11205619	TDH	0.65	5.27	0.48	8.6e-7	Retinal vascular caliber;
THYM	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.59	-9.23	-0.69	7.42e-15	Urate levels in overweight individuals;
THYM	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg10792982	chr14:105748885	BRF1	0.67	6.69	0.57	1.5e-9	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7943203	0.568	rs11212614	chr11:108281089	T/C	cg04873221	chr11:107992290	ACAT1	-0.72	-4.71	-0.43	8.56e-6	Red blood cell count;Mean corpuscular volume;
THYM	cis	rs7818345	0.967	rs11204039	chr8:19280442	A/C	cg11303988	chr8:19266685	CSGALNACT1	0.43	4.65	0.43	1.08e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg11247378	chr22:39784982	NA	-1.03	-10.09	-0.72	1.04e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs13315871	1.000	rs35542947	chr3:58323244	C/T	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs250585	0.736	rs30012	chr16:23420943	A/G	cg00143387	chr16:23521605	GGA2	0.69	4.84	0.44	5.05e-6	Egg allergy;
THYM	cis	rs6840360	0.550	rs6816471	chr4:152494869	A/G	cg17479576	chr4:152424074	FAM160A1	-0.82	-5.82	-0.51	7.78e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7731657	0.537	rs10073487	chr5:130373397	G/A	cg08523029	chr5:130500466	HINT1	-0.85	-5.98	-0.52	3.88e-8	Fasting plasma glucose;
THYM	cis	rs10851411	0.618	rs72707484	chr15:42752254	A/G	cg04857231	chr15:42782520	NA	-0.57	-5.16	-0.47	1.37e-6	Glucose homeostasis traits;
THYM	cis	rs939658	0.776	rs35382567	chr15:79440897	C/T	cg17916960	chr15:79447300	NA	-0.73	-8.58	-0.66	1.81e-13	Refractive error;
THYM	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg10589385	chr1:150898437	SETDB1	0.57	4.55	0.42	1.56e-5	Melanoma;
THYM	cis	rs9527	0.615	rs10883811	chr10:104727279	A/G	cg04362960	chr10:104952993	NT5C2	0.63	4.71	0.44	8.42e-6	Arsenic metabolism;
THYM	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg05340658	chr4:99064831	C4orf37	0.56	4.75	0.44	7.27e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3806843	0.518	rs2569191	chr5:140013903	C/T	cg19875535	chr5:140030758	IK	-0.52	-4.5	-0.42	1.93e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.93	7.76	0.62	9.52e-12	Lymphocyte percentage of white cells;
THYM	cis	rs1823778	0.520	rs2365742	chr18:67700998	A/C	cg13164537	chr18:67624071	CD226	1.15	4.8	0.44	5.83e-6	Mean platelet volume;
THYM	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	5.2	0.47	1.12e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg06108461	chr20:60628389	TAF4	-0.82	-7.06	-0.59	2.77e-10	Body mass index;
THYM	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.71	-7.66	-0.62	1.54e-11	Crohn's disease;
THYM	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.42	0.49	4.44e-7	Height;
THYM	cis	rs12348691	0.503	rs7023267	chr9:100603935	G/A	cg13688889	chr9:100608707	NA	-0.87	-5.91	-0.52	5.25e-8	Alopecia areata;
THYM	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs7119	0.717	rs12910513	chr15:77817258	C/T	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs9479482	1.000	rs9479405	chr6:150338065	G/A	cg07578070	chr6:150326732	RAET1K	0.54	4.47	0.42	2.19e-5	Alopecia areata;
THYM	cis	rs954108	0.966	rs9508155	chr13:29372016	C/T	cg11788234	chr13:29393811	NA	0.64	4.98	0.46	2.83e-6	Obesity-related traits;
THYM	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg07414643	chr4:187882934	NA	0.64	5.75	0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs360798	0.817	rs6745862	chr2:62906197	G/A	cg00752480	chr2:62680940	NA	-0.26	-4.69	-0.43	9.13e-6	Coronary artery disease;
THYM	cis	rs4953076	0.573	rs6734443	chr2:44408282	G/C	cg04920474	chr2:44395004	PPM1B	0.66	5.51	0.49	3.11e-7	Height;
THYM	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg01236616	chr12:121019343	POP5	-1.17	-9.34	-0.69	4.22e-15	Type 1 diabetes nephropathy;
THYM	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs1451375	0.698	rs7797131	chr7:50647934	A/G	cg18232548	chr7:50535776	DDC	0.69	5.35	0.48	6.03e-7	Malaria;
THYM	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.04	-9.74	-0.71	6.05e-16	Primary sclerosing cholangitis;
THYM	cis	rs7264396	0.623	rs2425127	chr20:34332037	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-4.69	-0.43	9.11e-6	Total cholesterol levels;
THYM	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg02503808	chr4:7069936	GRPEL1	0.82	5.74	0.51	1.14e-7	Monocyte percentage of white cells;
THYM	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.57	-5.57	-0.5	2.41e-7	Lymphocyte counts;
THYM	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg00757033	chr12:89920650	WDR51B	0.77	11.72	0.77	3.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg06640241	chr16:89574553	SPG7	0.86	7.44	0.61	4.44e-11	Multiple myeloma (IgH translocation);
THYM	cis	rs4731207	0.623	rs719973	chr7:124631727	G/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg18876405	chr7:65276391	NA	0.6	5.04	0.46	2.21e-6	Aortic root size;
THYM	cis	rs7177699	0.557	rs4389112	chr15:79122099	G/A	cg15571903	chr15:79123663	NA	-0.65	-6.7	-0.57	1.46e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg16926213	chr1:1841314	NA	0.55	5.8	0.51	8.77e-8	Body mass index;
THYM	cis	rs11671005	0.616	rs12980907	chr19:58956326	C/T	cg02808233	chr19:58920810	ZNF584	0.57	4.77	0.44	6.77e-6	Mean platelet volume;
THYM	cis	rs4606347	0.858	rs61781313	chr1:66092457	G/T	cg04111102	chr1:66153794	NA	0.59	4.54	0.42	1.67e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg24060327	chr5:131705240	SLC22A5	0.8	6.52	0.56	3.35e-9	Breast cancer;
THYM	cis	rs12935418	0.523	rs2549846	chr16:81024127	A/T	cg16651780	chr16:81037892	C16orf61	-0.84	-6.56	-0.56	2.82e-9	Mean corpuscular volume;
THYM	cis	rs7592578	0.882	rs16832765	chr2:191468762	T/C	cg11845111	chr2:191398756	TMEM194B	-1.0	-7.14	-0.59	1.89e-10	Diastolic blood pressure;
THYM	cis	rs11249608	0.548	rs7732719	chr5:178463054	A/G	cg01312482	chr5:178451176	ZNF879	-0.76	-6.3	-0.54	9.29e-9	Pubertal anthropometrics;
THYM	cis	rs7262634	1.000	rs73302077	chr20:45839939	T/C	cg18599129	chr20:45867857	ZMYND8	0.82	4.83	0.44	5.14e-6	Response to protease inhibitor treatment in hepatitis c (bilirubin toxicity);
THYM	cis	rs4595586	0.525	rs7136425	chr12:39376005	C/A	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-13.34	-0.81	1.66e-23	Coronary artery disease;
THYM	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg18681998	chr4:17616180	MED28	1.01	9.68	0.7	8.07e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg06521331	chr12:34319734	NA	-0.84	-6.43	-0.55	5.14e-9	Morning vs. evening chronotype;
THYM	cis	rs12188164	0.840	rs957791	chr5:430217	C/T	cg00049323	chr5:472564	LOC25845	-0.44	-5.22	-0.47	1.06e-6	Cystic fibrosis severity;
THYM	cis	rs7917772	0.582	rs7906115	chr10:104327164	A/G	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs17744026	0.649	rs11219300	chr11:123679598	T/G	cg00079598	chr11:123676903	OR6M1	-0.51	-4.62	-0.43	1.19e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg17644776	chr2:200775616	C2orf69	-0.72	-4.89	-0.45	4.11e-6	Schizophrenia;
THYM	cis	rs12122100	0.545	rs1984615	chr1:146506206	G/A	cg03526459	chr1:146549940	NA	-0.58	-5.28	-0.48	8.3e-7	HIV-1 control;
THYM	cis	rs9633835	0.855	rs7396943	chr11:13328979	G/C	cg13286116	chr11:13302098	ARNTL	0.64	6.87	0.58	6.62e-10	Body mass index;
THYM	cis	rs61931739	0.929	rs1490110	chr12:34091605	A/G	cg10856724	chr12:34555212	NA	0.62	5.39	0.48	5.06e-7	Morning vs. evening chronotype;
THYM	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg08807101	chr21:30365312	RNF160	-0.67	-4.87	-0.45	4.5e-6	Dental caries;
THYM	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg27534772	chr1:16042836	PLEKHM2	0.56	6.31	0.54	8.77e-9	Systolic blood pressure;
THYM	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg04034577	chr2:241836375	C2orf54	-0.4	-6.48	-0.55	3.99e-9	Urinary metabolites;
THYM	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg25427524	chr10:38739819	LOC399744	0.63	5.61	0.5	1.95e-7	Extrinsic epigenetic age acceleration;
THYM	cis	rs7688540	0.511	rs4522818	chr4:181762	G/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.91	5.56	0.5	2.45e-7	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg18904891	chr8:8559673	CLDN23	-0.59	-4.72	-0.44	8.09e-6	Mood instability;
THYM	cis	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg10856724	chr12:34555212	NA	-0.74	-5.54	-0.49	2.74e-7	Resting heart rate;
THYM	cis	rs10929159	0.928	rs2317303	chr2:236921702	A/G	cg14895183	chr2:236924282	AGAP1	0.54	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs9611565	1.000	rs5758314	chr22:41762523	T/G	cg13695892	chr22:41940480	POLR3H	-0.7	-5.83	-0.51	7.73e-8	Vitiligo;
THYM	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg17554472	chr22:41940697	POLR3H	0.66	4.69	0.43	9.23e-6	Vitiligo;
THYM	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg06238570	chr21:40685208	BRWD1	-0.69	-5.71	-0.51	1.31e-7	Menarche (age at onset);
THYM	cis	rs28595532	1.000	rs17323012	chr4:119605671	A/G	cg14228332	chr4:119757509	SEC24D	1.37	4.59	0.43	1.34e-5	Cannabis dependence symptom count;
THYM	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs9611519	1.000	rs5758267	chr22:41619350	A/T	cg03806693	chr22:41940476	POLR3H	0.78	5.77	0.51	1e-7	Neuroticism;
THYM	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	9.75	0.71	5.57e-16	Platelet count;
THYM	cis	rs1178127	0.719	rs1178165	chr7:18789991	C/T	cg13420273	chr7:18810212	HDAC9	0.53	4.61	0.43	1.26e-5	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs2668423	0.922	rs2668417	chr19:1365827	C/G	cg02639931	chr19:1387894	NDUFS7	-0.49	-5.7	-0.5	1.37e-7	Nonalcoholic fatty liver disease;
THYM	cis	rs6047844	0.722	rs6137526	chr20:22038726	C/T	cg16502866	chr20:23015624	SSTR4	-0.58	-4.45	-0.42	2.3e-5	Male-pattern baldness;
THYM	cis	rs17030434	0.784	rs11099896	chr4:154664697	T/G	cg14289246	chr4:154710475	SFRP2	-0.69	-5.4	-0.48	4.96e-7	Electrocardiographic conduction measures;
THYM	cis	rs738321	0.701	rs4821754	chr22:38581503	A/G	cg25457927	chr22:38595422	NA	0.49	4.64	0.43	1.1e-5	Breast cancer;
THYM	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs198389	0.568	rs12406667	chr1:11873851	C/T	cg25341925	chr1:11908058	NPPA	0.44	4.46	0.42	2.21e-5	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
THYM	cis	rs2050392	0.771	rs303446	chr10:30728489	C/T	cg02070205	chr10:30722105	MAP3K8	-0.53	-4.55	-0.42	1.57e-5	Inflammatory bowel disease;
THYM	cis	rs7200543	1.000	rs2740	chr16:15132108	A/G	cg01933576	chr16:15083564	PDXDC1	-1.0	-8.15	-0.64	1.42e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs295140	0.605	rs295149	chr2:201175244	A/G	cg23649088	chr2:200775458	C2orf69	-0.61	-5.1	-0.46	1.75e-6	QT interval;
THYM	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg12310025	chr6:25882481	NA	-0.85	-7.07	-0.59	2.61e-10	Intelligence (multi-trait analysis);
THYM	cis	rs17209837	0.607	rs1014283	chr7:87076587	C/A	cg04996195	chr7:87105398	ABCB4	0.63	4.52	0.42	1.76e-5	Gallbladder cancer;
THYM	cis	rs6912958	0.500	rs3828759	chr6:87806640	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.65	-5.42	-0.49	4.59e-7	Monocyte percentage of white cells;
THYM	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg03517284	chr6:25882590	NA	0.71	5.64	0.5	1.75e-7	Schizophrenia;
THYM	cis	rs6815814	0.808	rs7673348	chr4:38845198	G/A	cg06935464	chr4:38784597	TLR10	0.65	4.73	0.44	7.8e-6	Breast cancer;
THYM	cis	rs11264213	0.591	rs408986	chr1:36551895	C/T	cg27506609	chr1:36549197	TEKT2	1.26	5.39	0.48	5.05e-7	Schizophrenia;
THYM	cis	rs7323507	0.636	rs2095531	chr13:110603337	A/G	cg07669776	chr13:110975691	COL4A2	-0.54	-4.89	-0.45	4.1e-6	Lung function (FVC);
THYM	cis	rs11671005	0.735	rs3826681	chr19:58918764	A/G	cg18639983	chr19:58920768	ZNF584	0.59	5.0	0.46	2.63e-6	Mean platelet volume;
THYM	cis	rs798766	0.723	rs3134865	chr4:1723279	T/C	cg00006948	chr4:1768889	NA	-0.96	-5.12	-0.46	1.62e-6	Bladder cancer;Urinary bladder cancer;
THYM	cis	rs240764	0.645	rs240111	chr6:101059499	C/A	cg21058520	chr6:100914733	NA	-0.58	-4.9	-0.45	3.98e-6	Neuroticism;
THYM	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg12016809	chr21:47604291	C21orf56	0.7	5.22	0.47	1.05e-6	Testicular germ cell tumor;
THYM	cis	rs2075230	0.705	rs2543554	chr17:7548028	C/T	cg10509001	chr17:7553872	ATP1B2	-0.56	-4.46	-0.42	2.22e-5	Hormone measurements;
THYM	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg26384229	chr12:38710491	ALG10B	-0.61	-4.6	-0.43	1.29e-5	Heart rate;
THYM	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg22907277	chr7:1156413	C7orf50	0.83	5.1	0.46	1.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10904908	0.733	rs7080366	chr10:17254832	C/T	cg01003015	chr10:17271136	VIM	-0.56	-4.79	-0.44	6.18e-6	Total cholesterol levels;Cholesterol, total;
THYM	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg11247378	chr22:39784982	NA	-0.97	-10.67	-0.74	6.08e-18	Intelligence (multi-trait analysis);
THYM	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg02734326	chr4:10020555	SLC2A9	0.72	6.5	0.56	3.65e-9	Bone mineral density;
THYM	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg26408565	chr15:76604113	ETFA	-0.55	-4.77	-0.44	6.55e-6	Blood metabolite levels;
THYM	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg03929089	chr4:120376271	NA	-0.99	-12.15	-0.78	4.84e-21	Height;
THYM	cis	rs7669967	0.595	rs10019919	chr4:156057933	C/T	cg17641028	chr4:156585641	NA	-0.59	-5.24	-0.47	9.58e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg05368731	chr17:41323189	NBR1	1.07	6.7	0.57	1.48e-9	Menopause (age at onset);
THYM	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs897984	0.683	rs72799316	chr16:30827205	A/G	cg02466173	chr16:30829666	NA	-0.53	-4.56	-0.42	1.51e-5	Dementia with Lewy bodies;
THYM	cis	rs28476539	0.640	rs17005891	chr4:83547862	G/A	cg10249074	chr4:83542146	C4orf11	-0.62	-4.7	-0.43	8.67e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg04248312	chr19:17393744	ANKLE1	-1.01	-12.99	-0.8	8.74e-23	Systemic lupus erythematosus;
THYM	trans	rs637571	0.726	rs689274	chr11:65665988	A/G	cg17712092	chr4:129076599	LARP1B	-1.03	-10.39	-0.73	2.49e-17	Eosinophil percentage of white cells;
THYM	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg21475434	chr5:93447410	FAM172A	-0.68	-4.74	-0.44	7.44e-6	Diabetic retinopathy;
THYM	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	5.76	0.51	1.02e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg11871910	chr12:69753446	YEATS4	0.69	5.7	0.5	1.34e-7	Blood protein levels;
THYM	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg21862992	chr11:68658383	NA	0.23	4.49	0.42	2.03e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg16558253	chr16:72132732	DHX38	-0.59	-5.05	-0.46	2.17e-6	Fibrinogen levels;
THYM	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs8064299	0.560	rs11077763	chr17:72786029	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.88	8.77	0.67	7.13e-14	Monocyte count;
THYM	cis	rs9583531	0.527	rs6492302	chr13:111352354	C/T	cg24331049	chr13:111365604	ING1	-0.73	-6.07	-0.53	2.57e-8	Coronary artery disease;
THYM	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs7731657	0.537	rs10073388	chr5:130188080	C/T	cg08523029	chr5:130500466	HINT1	-0.74	-5.19	-0.47	1.2e-6	Fasting plasma glucose;
THYM	cis	rs12446552	0.661	rs72781040	chr16:11702851	C/A	cg09662852	chr16:11707685	NA	-0.66	-5.94	-0.52	4.74e-8	Colorectal or endometrial cancer;
THYM	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg02725872	chr8:58115012	NA	-0.91	-5.43	-0.49	4.32e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs2806561	0.765	rs1738470	chr1:23511911	G/A	cg19743168	chr1:23544995	NA	0.55	5.59	0.5	2.18e-7	Height;
THYM	cis	rs500891	0.525	rs1145901	chr6:84038605	T/C	cg21688264	chr6:84418724	SNAP91	0.74	4.51	0.42	1.87e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg23711669	chr6:146136114	FBXO30	-0.96	-10.36	-0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg08847533	chr14:75593920	NEK9	-1.0	-11.26	-0.76	3.48e-19	Height;
THYM	cis	rs36051895	0.664	rs2274649	chr9:5090934	A/T	cg02405213	chr9:5042618	JAK2	-1.0	-10.94	-0.75	1.67e-18	Pediatric autoimmune diseases;
THYM	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs1278769	0.786	rs3742238	chr13:113540425	C/T	cg17842918	chr13:113540400	ATP11A	-0.43	-4.46	-0.42	2.22e-5	Interstitial lung disease;
THYM	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg09359103	chr1:154839909	KCNN3	-0.69	-8.46	-0.66	3.21e-13	Prostate cancer;
THYM	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	4.93	0.45	3.51e-6	Motion sickness;
THYM	cis	rs4499344	0.622	rs7246407	chr19:33061209	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.7	-4.65	-0.43	1.07e-5	Mean platelet volume;
THYM	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	5.04	0.46	2.2e-6	Schizophrenia;
THYM	cis	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg10856724	chr12:34555212	NA	-0.78	-6.99	-0.58	3.83e-10	Morning vs. evening chronotype;
THYM	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg06028605	chr16:24865363	SLC5A11	0.56	5.26	0.47	8.84e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1448094	0.512	rs57278040	chr12:86237886	A/G	cg00310523	chr12:86230176	RASSF9	0.53	4.84	0.44	5.02e-6	Major depressive disorder;
THYM	cis	rs72781680	1.000	rs72781671	chr2:24231123	A/G	cg08917208	chr2:24149416	ATAD2B	1.11	4.95	0.45	3.17e-6	Lymphocyte counts;
THYM	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg03354898	chr7:1950403	MAD1L1	-0.5	-4.62	-0.43	1.22e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs514406	0.825	rs12089511	chr1:53436427	A/T	cg08736216	chr1:53307985	ZYG11A	0.61	5.57	0.5	2.41e-7	Monocyte count;
THYM	cis	rs7267979	1.000	rs7020	chr20:25278600	G/A	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.82	0.44	5.4e-6	Bipolar disorder;
THYM	cis	rs7582180	0.652	rs4443016	chr2:100876628	C/G	cg08017756	chr2:100939284	LONRF2	-0.6	-5.54	-0.49	2.75e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3924048	0.519	rs11121927	chr1:12614403	G/C	cg00291366	chr1:12616550	NA	0.44	5.21	0.47	1.09e-6	Optic cup area;
THYM	cis	rs3820068	0.506	rs17448966	chr1:15990983	T/G	cg05660106	chr1:15850417	CASP9	0.77	6.21	0.54	1.39e-8	Systolic blood pressure;
THYM	cis	rs72627123	0.867	rs57685514	chr14:74487592	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg11327659	chr7:150037044	RARRES2	0.43	5.21	0.47	1.11e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs10216189	1.000	rs7799970	chr7:5527714	G/C	cg05318486	chr7:5553423	FBXL18	-0.65	-4.76	-0.44	7.03e-6	Relative hand skill in reading disability;
THYM	cis	rs1994135	0.617	rs10743824	chr12:33733764	C/T	cg10856724	chr12:34555212	NA	-0.58	-4.59	-0.43	1.35e-5	Resting heart rate;
THYM	cis	rs7582403	0.510	rs4001	chr2:148875643	A/G	cg23727674	chr2:148602993	ACVR2A	0.63	4.64	0.43	1.13e-5	Neuroticism;
THYM	cis	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg10518543	chr12:38710700	ALG10B	-0.54	-4.52	-0.42	1.78e-5	Morning vs. evening chronotype;
THYM	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg05738196	chr6:26577821	NA	0.95	9.91	0.71	2.53e-16	Intelligence (multi-trait analysis);
THYM	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg21854759	chr1:92012499	NA	0.67	4.76	0.44	6.82e-6	Eosinophil percentage of white cells;
THYM	cis	rs28719689	0.655	rs58892423	chr8:1276014	A/C	cg11592242	chr8:1263433	NA	0.73	4.53	0.42	1.72e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg03806693	chr22:41940476	POLR3H	1.07	8.61	0.66	1.55e-13	Vitiligo;
THYM	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg21475434	chr5:93447410	FAM172A	0.93	5.33	0.48	6.66e-7	Diabetic retinopathy;
THYM	cis	rs10739663	0.520	rs3122935	chr9:128154203	A/G	cg14078157	chr9:128172775	NA	0.91	8.14	0.64	1.49e-12	Resting heart rate;
THYM	cis	rs7078219	0.714	rs11190137	chr10:101287944	G/T	cg23904955	chr10:101282759	NA	0.42	4.87	0.45	4.39e-6	Dental caries;
THYM	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	7.84	0.63	6.55e-12	Lymphocyte percentage of white cells;
THYM	cis	rs9311676	0.609	rs62258133	chr3:58398318	C/G	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs8038465	0.615	rs8024862	chr15:73958290	C/T	cg15420318	chr15:73925796	NPTN	0.62	5.46	0.49	3.74e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4808199	0.895	rs8105094	chr19:19374061	C/T	cg03709012	chr19:19516395	GATAD2A	1.18	6.78	0.57	1.03e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs3020333	0.703	rs862346	chr6:152016369	A/T	cg22157087	chr6:152012887	ESR1	0.54	6.48	0.55	3.99e-9	Total body bone mineral density;
THYM	cis	rs9633740	1.000	rs1902660	chr10:82263683	G/C	cg01528321	chr10:82214614	TSPAN14	0.94	4.48	0.42	2.08e-5	Post bronchodilator FEV1;
THYM	cis	rs9372253	0.678	rs9487392	chr6:110708626	C/T	cg01119278	chr6:110721349	DDO	0.55	6.3	0.54	9.29e-9	Platelet distribution width;
THYM	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	5.99	0.52	3.67e-8	Rheumatoid arthritis;
THYM	cis	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg05335186	chr13:53173507	NA	-0.4	-5.03	-0.46	2.36e-6	Lewy body disease;
THYM	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	6.91	0.58	5.42e-10	Bone mineral density;
THYM	cis	rs7618501	0.699	rs9862795	chr3:49915506	A/T	cg24308560	chr3:49941425	MST1R	-0.75	-6.57	-0.56	2.73e-9	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg08885076	chr2:99613938	TSGA10	0.66	5.97	0.52	4.17e-8	Chronic sinus infection;
THYM	cis	rs941408	0.515	rs56000942	chr19:2774104	G/C	cg19693284	chr19:2783607	SGTA	0.69	4.92	0.45	3.64e-6	Total cholesterol levels;
THYM	cis	rs13223928	0.572	rs16870744	chr7:3135781	G/A	cg19214707	chr7:3157722	NA	-0.79	-5.74	-0.51	1.11e-7	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg15592062	chr6:167189543	RPS6KA2	0.59	6.16	0.53	1.73e-8	Crohn's disease;
THYM	cis	rs9649213	0.555	rs6956686	chr7:97997945	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs76878669	0.561	rs7107191	chr11:66140397	G/A	cg18002602	chr11:66138449	SLC29A2	0.49	4.98	0.45	2.86e-6	Educational attainment (years of education);
THYM	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg26597838	chr10:835615	NA	1.52	11.37	0.76	2.05e-19	Eosinophil percentage of granulocytes;
THYM	cis	rs7078219	0.505	rs6584282	chr10:101286495	A/G	cg04972745	chr10:101287846	NA	-0.5	-4.65	-0.43	1.08e-5	Dental caries;
THYM	cis	rs7084921	0.552	rs12772030	chr10:101880585	C/G	cg11344164	chr10:101878520	NA	-0.6	-5.71	-0.51	1.26e-7	Bone mineral density;
THYM	cis	rs34293785	0.565	rs59710023	chr1:66137193	T/C	cg04111102	chr1:66153794	NA	0.56	5.16	0.47	1.37e-6	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;
THYM	cis	rs1048238	0.935	rs761760	chr1:16342419	A/G	cg22431228	chr1:16359049	CLCNKA	-0.53	-5.13	-0.47	1.51e-6	Systolic blood pressure;
THYM	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	10.0	0.72	1.67e-16	Platelet count;
THYM	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	4.94	0.45	3.4e-6	Height;
THYM	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg26690334	chr16:1524521	CLCN7	-0.46	-5.96	-0.52	4.32e-8	Bone mineral density;
THYM	cis	rs7402982	0.934	rs8027457	chr15:99204101	A/G	cg03437748	chr15:99193247	IGF1R	0.78	6.69	0.57	1.57e-9	Birth weight;
THYM	cis	rs4474465	1.000	rs7935292	chr11:78169885	C/G	cg02023728	chr11:77925099	USP35	0.52	4.54	0.42	1.67e-5	Alzheimer's disease (survival time);
THYM	cis	rs7599312	0.534	rs6751692	chr2:213408120	C/T	cg20637307	chr2:213403960	ERBB4	1.0	10.5	0.73	1.43e-17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4654899	0.812	rs7539512	chr1:21410791	A/G	cg01072550	chr1:21505969	NA	-0.79	-7.73	-0.62	1.11e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs7267979	0.933	rs11699203	chr20:25435169	G/C	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg20387954	chr3:183756860	HTR3D	0.56	4.64	0.43	1.11e-5	Anterior chamber depth;
THYM	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg03877680	chr5:178157825	ZNF354A	0.73	4.97	0.45	2.93e-6	Neutrophil percentage of white cells;
THYM	cis	rs3087591	0.960	rs4795587	chr17:29587917	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.63	-5.18	-0.47	1.26e-6	Hip circumference;
THYM	cis	rs4243830	0.850	rs4908915	chr1:6601607	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.11	-7.56	-0.61	2.57e-11	Body mass index;
THYM	cis	rs4474465	0.850	rs10793328	chr11:78256868	A/G	cg19901956	chr11:77921274	USP35	0.68	5.07	0.46	1.96e-6	Alzheimer's disease (survival time);
THYM	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg06636001	chr8:8085503	FLJ10661	0.63	5.37	0.48	5.67e-7	Mood instability;
THYM	cis	rs17867775	0.623	rs11563761	chr7:126695508	A/G	cg02090654	chr7:126698344	MIR592;GRM8	0.83	4.67	0.43	9.93e-6	Anti-saccade response;
THYM	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03647317	chr4:187891568	NA	-0.83	-9.2	-0.69	8.27e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11890956	chr21:40555474	PSMG1	-0.65	-6.03	-0.53	3.17e-8	Menarche (age at onset);
THYM	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg07424592	chr7:64974309	NA	-0.8	-4.87	-0.45	4.45e-6	Diabetic kidney disease;
THYM	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg05283184	chr6:79620031	NA	-0.91	-8.88	-0.67	4.11e-14	Intelligence (multi-trait analysis);
THYM	cis	rs988913	0.706	rs10948880	chr6:54882003	G/T	cg19716238	chr6:54711378	FAM83B	0.47	4.49	0.42	2.03e-5	Menarche (age at onset);
THYM	cis	rs4833407	0.593	rs4833406	chr4:113304812	G/A	cg10344245	chr4:114288822	ANK2	-0.6	-4.68	-0.43	9.59e-6	Obesity;
THYM	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg04455712	chr21:45112962	RRP1B	0.52	4.88	0.45	4.28e-6	Mean corpuscular volume;
THYM	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg03676636	chr4:99064102	C4orf37	0.43	6.38	0.55	6.28e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs62070183	0.938	rs9912761	chr17:31036493	A/G	cg23177095	chr17:30873196	MYO1D	0.65	5.15	0.47	1.43e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg06850241	chr22:41845214	NA	0.53	4.56	0.42	1.54e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs28476539	0.640	rs17005923	chr4:83555874	A/G	cg10249074	chr4:83542146	C4orf11	0.64	5.06	0.46	2.05e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg06009448	chr7:1102226	C7orf50	0.47	5.37	0.48	5.62e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7226229	1.000	rs7226229	chr17:20924077	C/T	cg21263980	chr17:20946333	USP22	0.68	4.97	0.45	2.9e-6	Blood trace element (Se levels);
THYM	cis	rs9560113	1.000	rs9555804	chr13:112179751	T/C	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs5167	0.781	rs909134	chr19:45493061	T/C	cg09555818	chr19:45449301	APOC2	0.43	4.46	0.42	2.26e-5	Blood protein levels;
THYM	cis	rs886774	0.526	rs2108229	chr7:107500994	A/C	cg23293999	chr7:106826042	HBP1	-0.59	-4.59	-0.43	1.36e-5	Ulcerative colitis;
THYM	cis	rs9560113	1.000	rs9560113	chr13:112183348	A/G	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs7512552	0.839	rs1694385	chr1:150377960	G/A	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	9.51	0.7	1.8e-15	Platelet count;
THYM	cis	rs12681287	0.752	rs4389908	chr8:87274852	A/G	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg14186256	chr22:23484241	RTDR1	0.92	9.42	0.69	2.85e-15	Bone mineral density;
THYM	cis	rs988913	0.634	rs9464182	chr6:54921938	A/G	cg18532076	chr6:54711417	FAM83B	0.51	4.75	0.44	7.32e-6	Menarche (age at onset);
THYM	cis	rs12935418	0.673	rs2549887	chr16:81061827	G/A	cg16651780	chr16:81037892	C16orf61	-0.77	-5.66	-0.5	1.57e-7	Mean corpuscular volume;
THYM	cis	rs17497526	0.585	rs56181331	chr10:71571769	T/C	cg17446739	chr10:71892768	AIFM2	0.71	4.47	0.42	2.14e-5	Parkinson's disease;
THYM	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg26566898	chr11:117069891	TAGLN	0.37	4.53	0.42	1.74e-5	Blood protein levels;
THYM	cis	rs2688608	0.901	rs2664282	chr10:75620757	T/C	cg15838173	chr10:75533400	FUT11	-0.45	-4.78	-0.44	6.48e-6	Inflammatory bowel disease;
THYM	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg23187316	chr7:1099788	C7orf50	0.48	5.42	0.49	4.44e-7	Longevity;Endometriosis;
THYM	cis	rs55665837	1.000	rs10832276	chr11:14483274	C/T	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg06970220	chr1:156163860	SLC25A44	0.76	5.75	0.51	1.08e-7	Testicular germ cell tumor;
THYM	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-5.53	-0.49	2.8e-7	Prostate cancer;
THYM	cis	rs9359856	0.564	rs17292425	chr6:90372128	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.91	-8.21	-0.64	1.08e-12	Bipolar disorder;
THYM	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg20891283	chr12:69753455	YEATS4	0.7	5.42	0.49	4.51e-7	Response to diuretic therapy;
THYM	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg18825531	chr11:62321136	NA	-0.45	-5.11	-0.46	1.63e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9790314	0.502	rs34972965	chr3:160984296	G/A	cg03342759	chr3:160939853	NMD3	-0.93	-7.98	-0.63	3.34e-12	Morning vs. evening chronotype;
THYM	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg27034606	chr17:28928453	LRRC37B2	0.76	5.06	0.46	2.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs986417	0.901	rs1955693	chr14:61012331	T/C	cg27398547	chr14:60952738	C14orf39	1.0	5.05	0.46	2.14e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs757081	0.667	rs615424	chr11:17210481	G/A	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.6	-0.43	1.29e-5	Systolic blood pressure;
THYM	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg15921436	chr17:44337874	NA	0.78	6.25	0.54	1.17e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.05	-0.82	6.23e-25	Height;
THYM	cis	rs1371867	0.875	rs1660319	chr8:101337530	A/G	cg06636551	chr8:101224915	SPAG1	-0.64	-6.42	-0.55	5.25e-9	Atrioventricular conduction;
THYM	cis	rs6429082	0.846	rs2270538	chr1:235602404	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.71	-5.88	-0.52	6.19e-8	Adiposity;
THYM	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg05368731	chr17:41323189	NBR1	1.18	9.78	0.71	4.79e-16	Menopause (age at onset);
THYM	cis	rs7681440	0.583	rs2737019	chr4:90744903	G/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs367615	0.959	rs4957830	chr5:108911758	G/T	cg17395555	chr5:108820864	NA	0.56	5.26	0.48	8.79e-7	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg23583168	chr7:148888333	NA	-0.92	-10.09	-0.72	1.07e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.53	-4.51	-0.42	1.87e-5	Menarche (age at onset);
THYM	cis	rs2404602	0.684	rs8037847	chr15:76856551	C/T	cg23625390	chr15:77176239	SCAPER	-0.9	-6.37	-0.55	6.74e-9	Blood metabolite levels;
THYM	cis	rs116095464	0.850	rs6896163	chr5:303686	A/G	cg22857025	chr5:266934	NA	-1.33	-4.92	-0.45	3.65e-6	Breast cancer;
THYM	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg02915803	chr1:1606292	LOC728661;CDK11B	0.62	5.3	0.48	7.63e-7	Body mass index;
THYM	cis	rs28595532	0.764	rs56359736	chr4:119769689	G/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs2625529	0.652	rs8036307	chr15:72175120	A/G	cg16672083	chr15:72433130	SENP8	0.5	4.63	0.43	1.15e-5	Red blood cell count;
THYM	cis	rs12496230	1.000	rs3899502	chr3:66856411	A/G	cg04995300	chr3:66848608	NA	-1.04	-7.04	-0.59	2.96e-10	Type 2 diabetes;
THYM	cis	rs1003719	0.646	rs2835672	chr21:38581234	T/C	cg01329690	chr21:38580129	DSCR9	-0.36	-4.98	-0.46	2.81e-6	Eye color traits;
THYM	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1933112	1.000	rs2223583	chr1:168525416	C/T	cg17186328	chr1:168545835	XCL1	-0.55	-4.59	-0.43	1.37e-5	Blood protein levels;
THYM	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	8.52	0.66	2.36e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs981844	0.857	rs56198877	chr4:154718970	A/G	cg09973105	chr4:154681532	RNF175	-0.67	-5.58	-0.5	2.25e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg08999081	chr20:33150536	PIGU	-0.78	-7.16	-0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg13609457	chr4:120235615	NA	0.54	5.0	0.46	2.61e-6	Corneal astigmatism;
THYM	cis	rs11785693	0.862	rs62491196	chr8:4995690	C/T	cg26367366	chr8:4980734	NA	1.25	6.1	0.53	2.28e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs9309711	0.922	rs13385119	chr2:3484521	G/A	cg10845886	chr2:3471009	TTC15	-0.6	-5.08	-0.46	1.91e-6	Neurofibrillary tangles;
THYM	cis	rs2195525	1.000	rs2195525	chr11:119235404	C/T	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.46	5.15	0.47	1.4e-6	Urate levels;
THYM	cis	rs6758955	0.850	rs77216765	chr2:10475706	C/T	cg15773312	chr2:10472214	HPCAL1	-0.65	-4.59	-0.43	1.38e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg25703541	chr22:24373054	LOC391322	-0.84	-9.08	-0.68	1.5e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2997447	0.761	rs56078964	chr1:26442600	C/A	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg22764044	chr5:178986830	RUFY1	-0.55	-5.7	-0.5	1.34e-7	Lung cancer;
THYM	cis	rs7523273	1.000	rs34385765	chr1:207993637	A/G	cg22525895	chr1:207977042	MIR29B2	-0.85	-8.21	-0.64	1.06e-12	Schizophrenia;
THYM	cis	rs9814567	1.000	rs2056604	chr3:134312648	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.5	-0.66	2.69e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.01	-0.46	2.56e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs11030122	0.661	rs4910877	chr11:4062153	A/G	cg18678763	chr11:4115507	RRM1	-0.44	-5.76	-0.51	1.03e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg07930552	chr6:133119739	C6orf192	0.99	5.89	0.52	5.77e-8	Type 2 diabetes nephropathy;
THYM	cis	rs6815814	0.904	rs73236628	chr4:38825443	C/T	cg14665413	chr4:38859728	TLR6	-0.41	-4.85	-0.45	4.82e-6	Breast cancer;
THYM	cis	rs7084402	0.934	rs1658471	chr10:60291911	A/T	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs1050631	0.592	rs1785909	chr18:33731173	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.32	0.48	6.94e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg16423285	chr20:60520624	NA	1.15	10.07	0.72	1.17e-16	Obesity-related traits;
THYM	cis	rs7616559	0.962	rs1032042	chr3:156746699	A/C	cg15697575	chr3:156784781	NA	-0.4	-5.03	-0.46	2.35e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.59	6.09	0.53	2.4e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg16898833	chr6:26189333	HIST1H4D	1.18	5.31	0.48	7.34e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg08999081	chr20:33150536	PIGU	-0.57	-5.09	-0.46	1.8e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9796	0.870	rs12905926	chr15:41283408	G/A	cg21153102	chr15:41252147	NA	-0.64	-5.56	-0.5	2.51e-7	Menopause (age at onset);
THYM	cis	rs74417235	0.684	rs13186731	chr5:154056002	C/T	cg25588787	chr5:154027256	NA	0.9	4.6	0.43	1.32e-5	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg02725872	chr8:58115012	NA	-1.08	-8.26	-0.65	8.3e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs986417	0.818	rs1955702	chr14:61074301	T/A	cg27398547	chr14:60952738	C14orf39	1.05	5.71	0.51	1.29e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.7	6.22	0.54	1.31e-8	Chronic sinus infection;
THYM	cis	rs35934224	0.891	rs12158214	chr22:19871691	C/T	cg11182965	chr22:19864308	TXNRD2	-0.89	-7.01	-0.58	3.42e-10	Glaucoma (primary open-angle);
THYM	cis	rs863345	0.604	rs11265008	chr1:158498671	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg00898013	chr13:113819073	PROZ	-1.03	-10.22	-0.72	5.73e-17	Platelet distribution width;
THYM	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg08645402	chr16:4508243	NA	0.6	4.56	0.42	1.5e-5	Schizophrenia;
THYM	cis	rs7809950	1.000	rs2520277	chr7:107130234	C/T	cg23024343	chr7:107201750	COG5	-0.92	-8.21	-0.64	1.06e-12	Coronary artery disease;
THYM	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs10463554	0.927	rs257311	chr5:102419098	C/G	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs1775715	0.678	rs7096139	chr10:32217404	A/C	cg04359828	chr10:32216031	ARHGAP12	0.4	5.16	0.47	1.37e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs4072705	0.646	rs7865700	chr9:127246184	G/A	cg13476313	chr9:127244764	NR5A1	-0.34	-4.7	-0.43	8.88e-6	Menarche (age at onset);
THYM	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg15744005	chr10:104629667	AS3MT	-0.78	-5.61	-0.5	2.01e-7	Arsenic metabolism;
THYM	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg22852734	chr6:133119734	C6orf192	1.32	8.71	0.67	9.24e-14	Type 2 diabetes nephropathy;
THYM	cis	rs6840360	1.000	rs10023298	chr4:152666768	A/C	cg22705602	chr4:152727874	NA	-0.58	-6.26	-0.54	1.1e-8	Intelligence (multi-trait analysis);
THYM	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg25801113	chr15:45476975	SHF	-0.39	-4.5	-0.42	1.91e-5	Uric acid levels;
THYM	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg13695892	chr22:41940480	POLR3H	-0.88	-7.36	-0.6	6.44e-11	Vitiligo;
THYM	cis	rs2109514	0.542	rs1011442	chr7:116088301	G/A	cg12739419	chr7:116140593	CAV2	-0.45	-4.49	-0.42	2.03e-5	Prevalent atrial fibrillation;
THYM	cis	rs3780378	0.967	rs62543876	chr9:5085859	G/C	cg02405213	chr9:5042618	JAK2	-0.62	-5.63	-0.5	1.82e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs7512552	0.839	rs12040949	chr1:150447462	C/T	cg15654264	chr1:150340011	RPRD2	0.45	5.21	0.47	1.09e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs714027	0.585	rs2007446	chr22:30388601	C/T	cg27665648	chr22:30112403	NA	0.5	4.58	0.43	1.4e-5	Lymphocyte counts;
THYM	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg25358565	chr5:93447407	FAM172A	1.34	10.76	0.74	4.03e-18	Diabetic retinopathy;
THYM	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg24308560	chr3:49941425	MST1R	0.63	4.78	0.44	6.37e-6	Body mass index;
THYM	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg11764359	chr7:65958608	NA	-0.74	-6.15	-0.53	1.85e-8	Aortic root size;
THYM	cis	rs3772130	0.540	rs57791671	chr3:121608433	T/A	cg20356878	chr3:121714668	ILDR1	0.68	5.86	0.52	6.66e-8	Cognitive performance;
THYM	cis	rs4718428	0.924	rs6971897	chr7:66412774	T/A	cg26963428	chr7:66367121	NA	-0.6	-5.02	-0.46	2.39e-6	Corneal structure;
THYM	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs11031096	0.678	rs970329	chr11:4189803	G/T	cg18678763	chr11:4115507	RRM1	-0.42	-4.95	-0.45	3.17e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2219968	0.683	rs4607596	chr8:78902651	C/T	cg00738934	chr8:78996279	NA	0.63	5.13	0.47	1.53e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1371867	0.875	rs2439456	chr8:101336874	C/T	cg00191853	chr8:101177733	SPAG1	-0.51	-5.14	-0.47	1.46e-6	Atrioventricular conduction;
THYM	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg16486109	chr11:613632	IRF7	0.49	5.17	0.47	1.27e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg02487422	chr3:49467188	NICN1	0.63	4.82	0.44	5.48e-6	Resting heart rate;
THYM	cis	rs7572733	0.534	rs700667	chr2:198677508	T/C	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs4363385	0.510	rs6661063	chr1:153036048	C/A	cg13444842	chr1:152974279	SPRR3	-0.61	-4.8	-0.44	5.82e-6	Inflammatory skin disease;
THYM	cis	rs4077515	0.839	rs4307445	chr9:139279776	C/G	cg14115884	chr9:139300582	SDCCAG3	0.74	7.68	0.62	1.42e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7582180	0.627	rs4149523	chr2:101007039	T/C	cg08017756	chr2:100939284	LONRF2	-0.71	-7.26	-0.6	1.07e-10	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs2219968	0.962	rs6999835	chr8:78948855	T/C	cg00738934	chr8:78996279	NA	0.8	8.43	0.65	3.79e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg11266682	chr4:10021025	SLC2A9	0.73	11.88	0.77	1.74e-20	Bone mineral density;
THYM	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg10505658	chr17:80084571	CCDC57	0.68	7.45	0.61	4.18e-11	Life satisfaction;
THYM	cis	rs12200560	0.505	rs211172	chr6:97070691	C/A	cg06623918	chr6:96969491	KIAA0776	0.76	5.81	0.51	8.28e-8	Coronary heart disease;
THYM	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg02725872	chr8:58115012	NA	-1.15	-7.43	-0.61	4.64e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06873352	chr17:61820015	STRADA	0.79	9.87	0.71	3.15e-16	Prudent dietary pattern;
THYM	cis	rs295140	0.526	rs295114	chr2:201195602	C/T	cg23649088	chr2:200775458	C2orf69	0.57	4.92	0.45	3.59e-6	QT interval;
THYM	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg12963246	chr6:28129442	ZNF389	0.57	5.03	0.46	2.32e-6	Cardiac Troponin-T levels;
THYM	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9790314	1.000	rs1600209	chr3:161038217	A/T	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs12765878	1.000	rs2067832	chr10:105643134	G/A	cg11005552	chr10:105648138	OBFC1	0.85	11.02	0.75	1.12e-18	Coronary artery disease;
THYM	cis	rs600806	0.888	rs6695482	chr1:109870859	C/G	cg23032129	chr1:109941072	SORT1	-0.57	-4.84	-0.44	5.11e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg23758822	chr17:41437982	NA	1.17	11.04	0.75	1.02e-18	Menopause (age at onset);
THYM	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg10505658	chr17:80084571	CCDC57	-0.74	-8.16	-0.64	1.36e-12	Life satisfaction;
THYM	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg02527881	chr3:46936655	PTH1R	0.63	6.08	0.53	2.46e-8	Colorectal cancer;
THYM	cis	rs478304	0.817	rs524475	chr11:65518065	T/A	cg17480646	chr11:65405466	SIPA1	0.7	6.13	0.53	2e-8	Acne (severe);
THYM	cis	rs4665809	1.000	rs11126340	chr2:26253255	A/G	cg27170947	chr2:26402098	FAM59B	-0.57	-4.86	-0.45	4.58e-6	Gut microbiome composition (summer);
THYM	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg08807101	chr21:30365312	RNF160	0.94	8.18	0.64	1.24e-12	Dental caries;
THYM	cis	rs9318086	0.663	rs2312295	chr13:24457744	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.56	4.67	0.43	9.76e-6	Myopia (pathological);
THYM	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-5.05	-0.46	2.12e-6	Lymphocyte counts;
THYM	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg27535305	chr1:53392650	SCP2	-0.4	-4.59	-0.43	1.36e-5	Monocyte count;
THYM	cis	rs1021993	1.000	rs2660642	chr1:209494843	G/A	cg06155620	chr1:209527581	NA	0.58	4.69	0.43	8.99e-6	Gut microbiome composition (winter);
THYM	cis	rs2398893	0.960	rs56335449	chr9:96748795	G/A	cg14459158	chr9:96720562	NA	0.53	4.63	0.43	1.14e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs34368983	0.681	rs11013250	chr10:23308170	A/G	cg17782713	chr10:22613360	BMI1	0.96	4.71	0.44	8.42e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	9.78	0.71	4.77e-16	Platelet count;
THYM	cis	rs3820068	0.577	rs9728986	chr1:16040603	G/A	cg05660106	chr1:15850417	CASP9	0.72	5.59	0.5	2.2e-7	Systolic blood pressure;
THYM	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg09034736	chr1:150693464	HORMAD1	0.51	4.49	0.42	1.98e-5	Tonsillectomy;
THYM	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22496380	chr5:211416	CCDC127	-1.32	-7.26	-0.6	1.04e-10	Breast cancer;
THYM	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg19346786	chr7:2764209	NA	-0.73	-6.18	-0.54	1.61e-8	Height;
THYM	cis	rs4148689	1.000	rs4148692	chr7:117150129	C/T	cg17204129	chr7:117119601	CFTR	-0.63	-4.92	-0.45	3.69e-6	Gout;
THYM	cis	rs858239	0.699	rs1881200	chr7:23201637	T/C	cg05407003	chr7:23246146	NA	0.72	6.12	0.53	2.1e-8	Cerebrospinal fluid biomarker levels;
THYM	cis	rs478304	0.651	rs4930313	chr11:65500428	C/T	cg17480646	chr11:65405466	SIPA1	-0.94	-8.68	-0.67	1.07e-13	Acne (severe);
THYM	cis	rs72949976	0.606	rs1922797	chr2:214027642	G/A	cg08319019	chr2:214017104	IKZF2	0.74	6.14	0.53	1.92e-8	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs2964802	0.505	rs6872243	chr5:10818337	C/T	cg14521931	chr5:10832172	NA	-0.62	-5.12	-0.46	1.63e-6	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs258322	0.636	rs4968051	chr16:89714981	T/C	cg07984980	chr16:89898383	SPIRE2	1.3	5.19	0.47	1.17e-6	Melanoma;Black vs. red hair color;
THYM	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	6.06	0.53	2.75e-8	Obesity-related traits;
THYM	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg11494091	chr17:61959527	GH2	0.7	6.46	0.55	4.55e-9	Height;
THYM	cis	rs7267979	1.000	rs2482911	chr20:25395528	T/C	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs28830936	0.510	rs12440605	chr15:42102285	A/G	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	0.48	4.56	0.42	1.5e-5	Diastolic blood pressure;
THYM	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg16325326	chr1:53192061	ZYG11B	0.77	7.37	0.6	6.38e-11	Monocyte count;
THYM	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg15242686	chr22:24348715	GSTTP1	-0.74	-7.95	-0.63	3.82e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs977987	0.806	rs11648176	chr16:75456423	C/G	cg03315344	chr16:75512273	CHST6	0.76	6.16	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	7.32	0.6	7.96e-11	Platelet count;
THYM	cis	rs8067545	0.611	rs2526465	chr17:20167611	T/C	cg13482628	chr17:19912719	NA	-0.54	-4.47	-0.42	2.13e-5	Schizophrenia;
THYM	cis	rs11563648	0.553	rs67076804	chr7:126981607	C/T	cg08586737	chr7:127225949	GCC1	-0.33	-4.53	-0.42	1.74e-5	Resting heart rate;
THYM	cis	rs7542375	0.524	rs2807869	chr1:221094068	A/G	cg16008148	chr1:221062819	NA	0.37	5.55	0.49	2.56e-7	Obesity-related traits;
THYM	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg01073479	chr16:3509474	NAT15	0.54	5.23	0.47	1e-6	Tuberculosis;
THYM	cis	rs2637266	0.905	rs11001834	chr10:78360494	T/C	cg18941641	chr10:78392320	NA	0.6	4.79	0.44	6.09e-6	Pulmonary function;
THYM	cis	rs9486815	0.909	rs9320257	chr6:108429784	A/G	cg14310890	chr6:108881016	FOXO3	-0.65	-4.54	-0.42	1.62e-5	Major depressive disorder;
THYM	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg23332699	chr15:44069569	ELL3	0.79	4.81	0.44	5.75e-6	Lung cancer in ever smokers;
THYM	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22307029	chr19:49891270	CCDC155	0.59	4.72	0.44	8.04e-6	Multiple sclerosis;
THYM	cis	rs7953508	0.711	rs10492321	chr12:93980088	T/A	cg18151635	chr12:93972918	NA	-0.74	-5.12	-0.47	1.58e-6	Pubertal anthropometrics;
THYM	cis	rs2282300	0.739	rs1933342	chr11:30312825	C/T	cg09906309	chr11:30344399	C11orf46	0.73	5.37	0.48	5.47e-7	Morning vs. evening chronotype;
THYM	cis	rs17321999	0.904	rs72787716	chr2:30472355	C/T	cg05247661	chr2:30472410	LBH	0.67	4.91	0.45	3.85e-6	Systemic lupus erythematosus;
THYM	cis	rs13082711	0.911	rs35262121	chr3:27508277	G/A	cg02860705	chr3:27208620	NA	0.72	5.15	0.47	1.39e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg09877947	chr5:131593287	PDLIM4	0.7	6.33	0.54	7.92e-9	Acylcarnitine levels;
THYM	cis	rs4604732	0.536	rs4925674	chr1:247636906	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.66	4.67	0.43	1.01e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg18252515	chr7:66147081	NA	-0.63	-4.68	-0.43	9.63e-6	Aortic root size;
THYM	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg24733560	chr20:60626293	TAF4	0.62	6.35	0.55	7.47e-9	Body mass index;
THYM	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14159672	chr1:205819179	PM20D1	0.62	4.87	0.45	4.51e-6	Parkinson's disease;
THYM	cis	rs2039659	0.719	rs1753764	chr13:86260919	G/A	cg25308322	chr13:86268291	NA	0.66	5.72	0.51	1.21e-7	Blood osmolality (transformed sodium);
THYM	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.8	-4.67	-0.43	9.99e-6	Lung function (FEV1/FVC);
THYM	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg12573674	chr2:1569213	NA	-1.24	-5.86	-0.52	6.51e-8	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg06221963	chr1:154839813	KCNN3	-0.78	-9.74	-0.71	5.93e-16	Prostate cancer;
THYM	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg13683864	chr3:40499215	RPL14	-1.05	-11.57	-0.76	7.71e-20	Renal cell carcinoma;
THYM	cis	rs907683	0.559	rs4674394	chr2:220289870	C/T	cg15015639	chr2:220282977	DES	-0.42	-5.72	-0.51	1.25e-7	Resting heart rate;
THYM	cis	rs6906287	0.647	rs67832971	chr6:118832205	C/T	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs2742234	0.541	rs11238476	chr10:43711436	G/T	cg06632098	chr10:43605906	RET	0.82	5.24	0.47	9.49e-7	Hirschsprung disease;
THYM	trans	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg10856724	chr12:34555212	NA	-1.02	-9.32	-0.69	4.7e-15	Morning vs. evening chronotype;
THYM	cis	rs2404602	0.598	rs11855999	chr15:76627333	A/C	cg23625390	chr15:77176239	SCAPER	-0.71	-5.17	-0.47	1.27e-6	Blood metabolite levels;
THYM	cis	rs35934224	0.783	rs13053818	chr22:19859652	G/A	cg11182965	chr22:19864308	TXNRD2	-0.91	-6.94	-0.58	4.76e-10	Glaucoma (primary open-angle);
THYM	cis	rs2282300	0.956	rs594937	chr11:30390132	A/G	cg09906309	chr11:30344399	C11orf46	0.73	5.14	0.47	1.5e-6	Morning vs. evening chronotype;
THYM	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg18252515	chr7:66147081	NA	-0.66	-4.84	-0.44	4.96e-6	Aortic root size;
THYM	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg00129232	chr17:37814104	STARD3	-0.76	-5.25	-0.47	9.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs950394	1.000	rs17029774	chr2:104990036	G/C	cg20302975	chr2:105468274	NA	-0.78	-4.58	-0.43	1.4e-5	Schizophrenia;
THYM	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg00129232	chr17:37814104	STARD3	0.74	4.99	0.46	2.76e-6	Glomerular filtration rate (creatinine);
THYM	trans	rs11186	0.556	rs56667101	chr2:189957471	G/A	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs2070488	0.930	rs2370840	chr3:38529825	C/T	cg24069376	chr3:38537580	EXOG	0.67	6.88	0.58	6.46e-10	Electrocardiographic conduction measures;
THYM	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg09549813	chr16:4587862	C16orf5	-0.53	-5.22	-0.47	1.06e-6	Schizophrenia;
THYM	cis	rs9359856	0.673	rs1179901	chr6:90321196	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.77	-7.08	-0.59	2.53e-10	Bipolar disorder;
THYM	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg07936489	chr17:37558343	FBXL20	0.82	5.61	0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs13424612	0.839	rs4853976	chr2:240906028	T/C	cg01812947	chr2:240904978	NDUFA10	0.56	4.59	0.43	1.35e-5	Odorant perception (isobutyraldehyde);
THYM	cis	rs960902	0.592	rs4503968	chr2:37734216	T/C	cg25341268	chr2:37734390	NA	-0.69	-6.36	-0.55	6.92e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs7578361	0.959	rs4129903	chr2:150447676	A/T	cg17961725	chr2:150454027	NA	0.75	6.45	0.55	4.58e-9	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg18352616	chr4:3374830	RGS12	0.72	8.1	0.64	1.86e-12	Serum sulfate level;
THYM	cis	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg23422044	chr7:1970798	MAD1L1	-0.89	-6.61	-0.56	2.22e-9	Bipolar disorder;
THYM	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg20203395	chr5:56204925	C5orf35	-0.66	-4.57	-0.42	1.48e-5	Initial pursuit acceleration;
THYM	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1403694	0.695	rs3806689	chr3:186435077	A/G	cg12454167	chr3:186435060	KNG1	0.53	7.54	0.61	2.83e-11	Blood protein levels;
THYM	cis	rs4918072	0.716	rs2902638	chr10:105636989	T/C	cg11005552	chr10:105648138	OBFC1	0.67	5.04	0.46	2.18e-6	Coronary artery disease;
THYM	cis	rs12579753	1.000	rs12366580	chr12:82222784	G/A	cg21231944	chr12:82153410	PPFIA2	-0.65	-4.93	-0.45	3.52e-6	Resting heart rate;
THYM	cis	rs3812049	0.737	rs1112956	chr5:127433798	C/T	cg05443326	chr5:126853169	PRRC1	0.65	4.49	0.42	2.02e-5	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-5.56	-0.5	2.46e-7	Monocyte percentage of white cells;
THYM	cis	rs3791556	0.853	rs35245395	chr2:240107661	C/T	cg03281426	chr2:240109471	HDAC4	0.57	5.56	0.5	2.46e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg26384229	chr12:38710491	ALG10B	0.98	7.45	0.61	4.19e-11	Morning vs. evening chronotype;
THYM	cis	rs12142240	0.731	rs6658556	chr1:46844180	A/C	cg00530320	chr1:46809349	NSUN4	0.79	5.43	0.49	4.26e-7	Menopause (age at onset);
THYM	cis	rs896854	0.517	rs1011795	chr8:95951073	G/A	cg16049864	chr8:95962084	TP53INP1	-0.79	-5.75	-0.51	1.08e-7	Type 2 diabetes;
THYM	trans	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Educational attainment;
THYM	cis	rs7851660	0.844	rs12343182	chr9:100624259	G/C	cg13688889	chr9:100608707	NA	-0.79	-5.92	-0.52	5.07e-8	Strep throat;
THYM	cis	rs66731853	0.769	rs657624	chr1:20888348	C/T	cg04087271	chr1:20915334	CDA	-0.72	-5.94	-0.52	4.64e-8	Mean corpuscular volume;
THYM	cis	rs7084402	1.000	rs6481400	chr10:60268783	T/C	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	4.76	0.44	6.83e-6	Obesity-related traits;
THYM	cis	rs2290159	0.747	rs6777175	chr3:12646255	A/T	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs2235649	0.833	rs9929264	chr16:1851934	T/C	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg24642844	chr7:1081250	C7orf50	-1.29	-5.83	-0.51	7.65e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7432375	0.899	rs6439655	chr3:136466599	A/G	cg12473912	chr3:136751656	NA	-0.63	-5.08	-0.46	1.91e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg08859206	chr1:53392774	SCP2	-0.66	-7.55	-0.61	2.7e-11	Monocyte count;
THYM	cis	rs742614	0.935	rs6057929	chr20:32477633	A/G	cg06304546	chr20:32448765	NA	-0.74	-5.7	-0.5	1.35e-7	Stearic acid (18:0) levels;
THYM	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg00898013	chr13:113819073	PROZ	-0.89	-9.2	-0.69	8.65e-15	Platelet distribution width;
THYM	cis	rs9807989	0.839	rs9808453	chr2:102971306	C/A	cg03938978	chr2:103052716	IL18RAP	0.63	6.46	0.55	4.36e-9	Asthma;
THYM	cis	rs34526934	0.608	rs7591820	chr2:177028144	G/T	cg14324370	chr2:177042789	NA	-0.69	-5.82	-0.51	7.82e-8	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-7.74	-0.62	1.04e-11	Chronic sinus infection;
THYM	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg05717871	chr11:638507	DRD4	-0.69	-6.03	-0.53	3.1e-8	Systemic lupus erythematosus;
THYM	cis	rs2281845	0.965	rs7516023	chr1:201085521	C/T	cg17810781	chr1:201082982	CACNA1S	0.72	7.72	0.62	1.19e-11	Permanent tooth development;
THYM	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg18825531	chr11:62321136	NA	-0.42	-4.65	-0.43	1.07e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg00981070	chr1:2046702	PRKCZ	0.47	5.24	0.47	9.63e-7	Height;
THYM	cis	rs2836633	0.895	rs991816	chr21:40042150	C/A	cg12884169	chr21:40033163	ERG	0.7	8.7	0.67	9.9e-14	Coronary artery disease;
THYM	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg22433210	chr17:43662623	NA	1.12	8.59	0.66	1.69e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	10.0	0.72	1.68e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2309752	1	rs2309752	chr2:100762169	T/A	cg22139774	chr2:100720529	AFF3	-0.35	-5.66	-0.5	1.57e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg10802521	chr3:52805072	NEK4	0.79	7.54	0.61	2.78e-11	Bipolar disorder;
THYM	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg27279351	chr12:120934652	DYNLL1	0.94	8.49	0.66	2.83e-13	High light scatter reticulocyte count;
THYM	trans	rs208520	0.690	rs207108	chr6:66794096	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.66	-0.62	1.53e-11	Exhaled nitric oxide output;
THYM	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg22166914	chr1:53195759	ZYG11B	-0.69	-5.33	-0.48	6.5e-7	Monocyte count;
THYM	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg22907277	chr7:1156413	C7orf50	0.88	7.59	0.61	2.18e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs1729951	0.575	rs361241	chr3:136699561	C/A	cg12473912	chr3:136751656	NA	0.63	5.12	0.47	1.59e-6	Neuroticism;
THYM	cis	rs5015933	0.801	rs4837016	chr9:128141809	A/G	cg14078157	chr9:128172775	NA	0.54	4.66	0.43	1.01e-5	Body mass index;
THYM	cis	rs4285028	0.747	rs1574133	chr3:121468794	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.85	-7.37	-0.6	6.22e-11	Multiple sclerosis;
THYM	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.93	-0.45	3.52e-6	Monocyte count;
THYM	cis	rs6032067	0.641	rs17332243	chr20:43756071	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.39	-0.48	5.13e-7	Blood protein levels;
THYM	cis	rs1451375	0.572	rs3807558	chr7:50571022	A/G	cg18232548	chr7:50535776	DDC	-0.69	-5.23	-0.47	9.94e-7	Malaria;
THYM	cis	rs478304	0.654	rs10896034	chr11:65460783	T/A	cg17480646	chr11:65405466	SIPA1	-0.97	-8.99	-0.68	2.44e-14	Acne (severe);
THYM	cis	rs5746492	0.515	rs9604802	chr22:18398018	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.54	-4.99	-0.46	2.72e-6	Eotaxin levels;
THYM	cis	rs10203711	1.000	rs10187717	chr2:239558168	T/C	cg14580085	chr2:239553406	NA	0.71	6.63	0.56	1.99e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2069036	0.855	rs7900574	chr10:16079897	A/G	cg26633223	chr10:15133461	NA	0.64	4.52	0.42	1.8e-5	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs8067545	0.611	rs10491107	chr17:20188174	C/T	cg20830565	chr17:20408647	MGC102966	-0.48	-4.46	-0.42	2.28e-5	Schizophrenia;
THYM	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg14972814	chr11:95582409	MTMR2	-0.58	-5.3	-0.48	7.56e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4499344	0.622	rs4805767	chr19:33049056	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.7	-4.76	-0.44	6.9e-6	Mean platelet volume;
THYM	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06873352	chr17:61820015	STRADA	-0.56	-5.47	-0.49	3.7e-7	Height;
THYM	cis	rs36051895	0.589	rs6476948	chr9:5204404	C/T	cg02405213	chr9:5042618	JAK2	-0.9	-9.02	-0.68	2.02e-14	Pediatric autoimmune diseases;
THYM	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg22841779	chr14:105766346	BRF1	-0.5	-6.24	-0.54	1.2e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.87	-6.47	-0.55	4.16e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs941408	1.000	rs1736183	chr19:2809672	A/G	cg17333051	chr19:2783644	SGTA	0.56	5.11	0.46	1.65e-6	Total cholesterol levels;
THYM	cis	rs4460079	0.531	rs13107911	chr4:114834823	A/G	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg05313129	chr8:58192883	C8orf71	-0.84	-4.82	-0.44	5.33e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg06766960	chr11:133703094	NA	-0.61	-5.52	-0.49	2.94e-7	Childhood ear infection;
THYM	cis	rs2730245	0.527	rs2527205	chr7:158706393	G/T	cg24397884	chr7:158709396	WDR60	-0.55	-5.36	-0.48	5.79e-7	Height;
THYM	cis	rs13064411	0.696	rs1552432	chr3:113225660	G/C	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.76	-6.99	-0.58	3.86e-10	Personality dimensions;
THYM	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs713587	0.806	rs6737082	chr2:25138040	A/C	cg15423357	chr2:25149977	NA	0.65	7.25	0.6	1.12e-10	Body mass index in non-asthmatics;
THYM	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.82	7.64	0.62	1.73e-11	Prudent dietary pattern;
THYM	cis	rs6500395	1.000	rs7187513	chr16:48591638	T/C	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-5.65	-0.5	1.71e-7	Gut microbiome composition (summer);
THYM	cis	rs2333194	0.772	rs8016034	chr14:73812188	C/A	cg09844916	chr14:74004424	HEATR4;ACOT1	0.62	4.92	0.45	3.7e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.32	-9.88	-0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs910316	0.503	rs4903273	chr14:75441795	G/A	cg08847533	chr14:75593920	NEK9	-0.8	-7.5	-0.61	3.28e-11	Height;
THYM	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg04772025	chr11:68637568	NA	0.63	6.58	0.56	2.59e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2898681	0.519	rs3811781	chr4:53729166	T/G	cg00791764	chr4:53727839	RASL11B	0.61	6.91	0.58	5.51e-10	Optic nerve measurement (cup area);
THYM	cis	rs858239	0.698	rs858295	chr7:23245569	A/G	cg05407003	chr7:23246146	NA	-0.73	-6.39	-0.55	6e-9	Cerebrospinal fluid biomarker levels;
THYM	cis	rs1878931	0.597	rs2680221	chr16:3462595	A/G	cg05754148	chr16:3507555	NAT15	0.58	4.75	0.44	7.3e-6	Body mass index (adult);
THYM	cis	rs12681287	0.640	rs7820234	chr8:87350950	A/C	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg02503808	chr4:7069936	GRPEL1	0.97	8.3	0.65	7e-13	Monocyte percentage of white cells;
THYM	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg04772025	chr11:68637568	NA	0.62	6.61	0.56	2.21e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg22875332	chr1:76189707	ACADM	0.88	11.17	0.75	5.31e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg26384229	chr12:38710491	ALG10B	0.92	7.03	0.58	3.08e-10	Morning vs. evening chronotype;
THYM	cis	rs6840360	0.571	rs17360385	chr4:152587970	C/A	cg22705602	chr4:152727874	NA	-0.82	-8.33	-0.65	6.01e-13	Intelligence (multi-trait analysis);
THYM	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg03929089	chr4:120376271	NA	1.03	8.74	0.67	8.32e-14	Coronary artery disease;
THYM	cis	rs6840360	0.530	rs11946622	chr4:152486018	C/T	cg17479576	chr4:152424074	FAM160A1	-0.83	-5.88	-0.52	6.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg06789500	chr7:2109450	MAD1L1	0.65	4.46	0.42	2.24e-5	Bipolar disorder;
THYM	cis	rs35883536	0.626	rs80052576	chr1:101039229	A/G	cg06223162	chr1:101003688	GPR88	-0.87	-7.54	-0.61	2.71e-11	Monocyte count;
THYM	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg12386194	chr3:101231763	SENP7	0.92	6.91	0.58	5.63e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg10505658	chr17:80084571	CCDC57	0.7	8.07	0.64	2.18e-12	Life satisfaction;
THYM	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.47	-0.49	3.59e-7	Mean corpuscular volume;
THYM	cis	rs17001868	0.568	rs3788579	chr22:40742989	T/C	cg07138101	chr22:40742427	ADSL	0.94	5.71	0.51	1.3e-7	Mammographic density (dense area);
THYM	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg13390004	chr1:15929781	NA	0.61	4.67	0.43	9.86e-6	Systolic blood pressure;
THYM	cis	rs72829446	0.860	rs72827590	chr17:7498271	A/G	cg07091842	chr17:7155530	C17orf81;DULLARD	-1.04	-4.62	-0.43	1.22e-5	Androgen levels;
THYM	cis	rs6032067	0.636	rs6104093	chr20:43908297	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.43	-4.67	-0.43	1e-5	Blood protein levels;
THYM	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14893161	chr1:205819251	PM20D1	1.13	13.63	0.81	4.37e-24	Menarche (age at onset);
THYM	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.99	0.58	3.81e-10	Prudent dietary pattern;
THYM	cis	rs7582180	0.739	rs11123824	chr2:100924029	G/A	cg21926883	chr2:100939477	LONRF2	-0.61	-5.52	-0.49	2.91e-7	Intelligence (multi-trait analysis);
THYM	cis	rs35883536	0.933	rs1409419	chr1:101183396	T/C	cg06223162	chr1:101003688	GPR88	0.72	5.4	0.48	4.83e-7	Monocyte count;
THYM	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	6.26	0.54	1.13e-8	Hip circumference adjusted for BMI;
THYM	cis	rs12509991	0.654	rs10452157	chr4:127049990	G/A	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7769051	0.614	rs76404165	chr6:133235936	T/G	cg22852734	chr6:133119734	C6orf192	0.96	5.0	0.46	2.64e-6	Type 2 diabetes nephropathy;
THYM	cis	rs6987853	0.527	rs2923412	chr8:42455281	G/A	cg09913449	chr8:42400586	C8orf40	0.58	4.91	0.45	3.82e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs56161922	0.915	rs12563415	chr1:207856666	G/T	cg09557387	chr1:207818395	CR1L	1.15	5.31	0.48	7.12e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg24397884	chr7:158709396	WDR60	0.44	4.62	0.43	1.22e-5	Height;
THYM	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg07936489	chr17:37558343	FBXL20	-0.82	-5.61	-0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7631605	0.967	rs9860764	chr3:37259144	C/T	cg21328643	chr3:37258149	NA	-0.51	-4.88	-0.45	4.18e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs6840360	0.571	rs4696276	chr4:152532682	G/A	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.841	rs116329146	chr4:119733438	G/A	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs7219021	0.892	rs9913867	chr17:46849602	G/T	cg09029085	chr17:47094198	IGF2BP1	0.33	4.48	0.42	2.07e-5	Schizophrenia or bipolar disorder;
THYM	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg10047753	chr17:41438598	NA	1.14	10.51	0.73	1.38e-17	Menopause (age at onset);
THYM	cis	rs7582180	0.726	rs2871340	chr2:100884117	A/C	cg14675211	chr2:100938903	LONRF2	-0.54	-5.0	-0.46	2.57e-6	Intelligence (multi-trait analysis);
THYM	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg15744005	chr10:104629667	AS3MT	-0.8	-7.57	-0.61	2.4e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs55728055	0.661	rs73158601	chr22:31790417	C/A	cg01338084	chr22:32026380	PISD	1.35	4.93	0.45	3.5e-6	Age-related hearing impairment;
THYM	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg17345569	chr6:42928274	GNMT	-0.48	-4.53	-0.42	1.68e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs714031	1.000	rs4821909	chr22:40066418	T/C	cg21377881	chr22:40064566	CACNA1I	-0.59	-5.32	-0.48	6.98e-7	Schizophrenia;
THYM	cis	rs728616	0.867	rs61860041	chr10:81944331	G/A	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs11577318	0.537	rs12030833	chr1:26689220	A/G	cg00852783	chr1:26633632	UBXN11	-0.66	-4.53	-0.42	1.7e-5	Granulocyte percentage of myeloid white cells;
THYM	cis	rs4866334	1.000	rs76790673	chr5:18502463	G/C	cg04591469	chr5:17810299	NA	-1.14	-4.6	-0.43	1.28e-5	IgG glycosylation;
THYM	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg26408565	chr15:76604113	ETFA	-0.53	-4.64	-0.43	1.13e-5	Blood metabolite levels;
THYM	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.64	-4.68	-0.43	9.69e-6	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9595908	1.000	rs9591145	chr13:33161459	G/T	cg12383807	chr13:33924137	NA	-0.53	-4.71	-0.43	8.6e-6	Body mass index;
THYM	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg16579431	chr16:433439	TMEM8A;LOC100134368	0.6	4.96	0.45	3.09e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg21775007	chr8:11205619	TDH	-0.73	-5.68	-0.5	1.49e-7	Retinal vascular caliber;
THYM	cis	rs728616	0.510	rs12416084	chr10:81749215	A/G	cg27452691	chr10:81370291	SFTPA1	0.64	4.47	0.42	2.12e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs12935418	0.672	rs9889194	chr16:81050817	T/C	cg16651780	chr16:81037892	C16orf61	0.8	5.77	0.51	9.79e-8	Mean corpuscular volume;
THYM	cis	rs13256369	0.951	rs10503394	chr8:8565775	A/G	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs10927875	0.864	rs6674071	chr1:16144855	G/C	cg21385522	chr1:16154831	NA	-1.28	-10.29	-0.73	4.06e-17	Dilated cardiomyopathy;
THYM	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg27446573	chr6:127587934	RNF146	-0.98	-8.97	-0.68	2.6e-14	Breast cancer;
THYM	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg18876405	chr7:65276391	NA	-0.64	-5.54	-0.49	2.68e-7	Aortic root size;
THYM	cis	rs886774	0.507	rs6961243	chr7:107521404	G/A	cg23293999	chr7:106826042	HBP1	-0.58	-4.47	-0.42	2.18e-5	Ulcerative colitis;
THYM	cis	rs1697139	0.935	rs1623654	chr5:66512819	A/T	cg11553311	chr5:66541588	NA	0.48	5.22	0.47	1.03e-6	Breast cancer;
THYM	cis	rs76878669	0.833	rs10791866	chr11:66070884	C/T	cg18002602	chr11:66138449	SLC29A2	-0.62	-5.16	-0.47	1.37e-6	Educational attainment (years of education);
THYM	cis	rs35934224	0.891	rs8141451	chr22:19870036	C/G	cg11182965	chr22:19864308	TXNRD2	-0.93	-6.94	-0.58	4.79e-10	Glaucoma (primary open-angle);
THYM	cis	rs791888	0.767	rs2255684	chr10:89419971	C/T	cg10377144	chr10:89419177	PAPSS2	-0.42	-6.96	-0.58	4.37e-10	Magnesium levels;
THYM	cis	rs2916260	0.800	rs9394691	chr6:40390291	T/C	cg17190781	chr6:40387783	LRFN2	-1.07	-5.02	-0.46	2.4e-6	Incident coronary heart disease;
THYM	cis	rs10992471	0.627	rs4744138	chr9:95291909	A/G	cg14631576	chr9:95140430	CENPP	-0.97	-9.01	-0.68	2.2e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs1395	0.744	rs3739092	chr2:27462076	C/T	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.52	-0.49	2.95e-7	Blood metabolite levels;
THYM	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.86	-6.28	-0.54	1.02e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1018836	0.923	rs4735256	chr8:91612145	C/G	cg16814680	chr8:91681699	NA	-0.87	-7.52	-0.61	2.98e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg06558623	chr16:89946397	TCF25	1.33	5.65	0.5	1.64e-7	Skin colour saturation;
THYM	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg14784868	chr12:69753453	YEATS4	0.65	5.21	0.47	1.1e-6	Response to diuretic therapy;
THYM	cis	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.64	-0.5	1.73e-7	Menopause (age at onset);
THYM	cis	rs11696501	0.688	rs6065859	chr20:44302697	C/T	cg11783356	chr20:44313418	WFDC10B	-0.69	-4.75	-0.44	7.18e-6	Brain structure;
THYM	cis	rs995000	0.931	rs4350231	chr1:62922660	C/T	cg06896770	chr1:63153194	DOCK7	0.99	8.22	0.64	1.05e-12	Triglyceride levels;
THYM	cis	rs10992471	0.603	rs2094281	chr9:95290654	C/G	cg14631576	chr9:95140430	CENPP	0.92	8.95	0.68	2.9e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs11223731	0.672	rs12292140	chr11:134122461	C/T	cg18040241	chr11:134201582	GLB1L2	-0.71	-4.46	-0.42	2.26e-5	Verbal declarative memory;
THYM	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg13246856	chr1:44399776	ARTN	0.48	4.95	0.45	3.27e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2730245	0.527	rs842707	chr7:158656012	C/T	cg01219135	chr7:158766336	NA	0.57	4.54	0.42	1.65e-5	Height;
THYM	cis	rs34779708	0.931	rs35126129	chr10:35452141	G/A	cg03585969	chr10:35415529	CREM	0.65	4.51	0.42	1.87e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg12560992	chr17:57184187	TRIM37	-0.73	-6.14	-0.53	1.89e-8	Primary tooth development (time to first tooth eruption);
THYM	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg13683864	chr3:40499215	RPL14	-0.86	-8.55	-0.66	2.05e-13	Renal cell carcinoma;
THYM	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg24209194	chr3:40518798	ZNF619	0.67	5.5	0.49	3.17e-7	Renal cell carcinoma;
THYM	cis	rs6840360	1.000	rs6535811	chr4:152598992	C/T	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2898681	0.618	rs79471207	chr4:53738524	C/T	cg03786743	chr4:53727781	RASL11B	0.56	5.03	0.46	2.34e-6	Optic nerve measurement (cup area);
THYM	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg08807101	chr21:30365312	RNF160	-0.93	-7.66	-0.62	1.52e-11	Dental caries;
THYM	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg02782426	chr3:40428986	ENTPD3	0.54	4.99	0.46	2.77e-6	Renal cell carcinoma;
THYM	cis	rs9649465	1.000	rs6963231	chr7:123374766	A/G	cg15443791	chr7:124364398	NA	0.6	4.97	0.45	3.01e-6	Migraine;
THYM	cis	rs1003719	0.591	rs13046303	chr21:38551976	A/G	cg01329690	chr21:38580129	DSCR9	-0.35	-4.87	-0.45	4.36e-6	Eye color traits;
THYM	cis	rs7631605	0.934	rs9876275	chr3:37261697	G/C	cg21328643	chr3:37258149	NA	-0.51	-4.88	-0.45	4.18e-6	Cerebrospinal P-tau181p levels;
THYM	trans	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg19862616	chr7:65841803	NCRNA00174	1.11	12.92	0.8	1.21e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg01097406	chr16:89675127	NA	-0.55	-4.51	-0.42	1.83e-5	Vitiligo;
THYM	trans	rs6089829	0.888	rs4809465	chr20:61671156	G/C	cg13615516	chr5:77269221	NA	0.83	7.27	0.6	9.91e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs995000	0.899	rs11207976	chr1:62976751	G/A	cg06896770	chr1:63153194	DOCK7	0.92	7.77	0.62	9.35e-12	Triglyceride levels;
THYM	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg17264618	chr3:40429014	ENTPD3	0.53	5.1	0.46	1.71e-6	Renal cell carcinoma;
THYM	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg09035930	chr12:129282057	SLC15A4	0.88	11.58	0.77	7.31e-20	Systemic lupus erythematosus;
THYM	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg18876405	chr7:65276391	NA	0.57	4.75	0.44	7.2e-6	Aortic root size;
THYM	cis	rs8014204	0.836	rs7153700	chr14:75268544	C/T	cg06637938	chr14:75390232	RPS6KL1	0.55	5.34	0.48	6.42e-7	Caffeine consumption;
THYM	cis	rs9311676	0.656	rs62258140	chr3:58407083	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg12386194	chr3:101231763	SENP7	0.66	4.88	0.45	4.28e-6	Colorectal cancer;
THYM	cis	rs17174870	0.955	rs11887652	chr2:112769339	A/G	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg03517284	chr6:25882590	NA	-0.71	-5.6	-0.5	2.11e-7	Schizophrenia;
THYM	cis	rs2456568	0.802	rs10831136	chr11:93636860	T/C	cg17595323	chr11:93583763	C11orf90	-0.58	-6.09	-0.53	2.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs912057	0.671	rs1294433	chr6:6745163	G/A	cg06612196	chr6:6737390	NA	0.71	11.9	0.77	1.57e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs11690935	0.610	rs59844139	chr2:172731983	C/A	cg13550731	chr2:172543902	DYNC1I2	0.57	4.48	0.42	2.06e-5	Schizophrenia;
THYM	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg22166914	chr1:53195759	ZYG11B	-0.69	-5.33	-0.48	6.5e-7	Monocyte count;
THYM	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg24375607	chr4:120327624	NA	0.66	5.3	0.48	7.66e-7	Corneal astigmatism;
THYM	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4589258	0.933	rs61905335	chr11:90409963	C/G	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	trans	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg07211511	chr3:129823064	LOC729375	-1.22	-9.75	-0.71	5.63e-16	Blood pressure (smoking interaction);
THYM	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg03517284	chr6:25882590	NA	-0.67	-4.47	-0.42	2.14e-5	Height;
THYM	cis	rs7616559	0.606	rs931246	chr3:156784003	G/A	cg15697575	chr3:156784781	NA	0.46	6.81	0.57	8.89e-10	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg04362960	chr10:104952993	NT5C2	0.6	5.11	0.46	1.66e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7246657	0.525	rs10401417	chr19:37467540	C/T	cg22634378	chr19:37742834	NA	0.66	4.83	0.44	5.32e-6	Coronary artery calcification;
THYM	cis	rs6087990	0.735	rs6057647	chr20:31381690	A/T	cg13636640	chr20:31349939	DNMT3B	0.9	9.45	0.7	2.54e-15	Ulcerative colitis;
THYM	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg27211696	chr2:191398769	TMEM194B	-0.64	-4.99	-0.46	2.71e-6	Diastolic blood pressure;
THYM	cis	rs7582180	0.627	rs6749018	chr2:101001859	G/T	cg21926883	chr2:100939477	LONRF2	-0.71	-6.91	-0.58	5.51e-10	Intelligence (multi-trait analysis);
THYM	cis	rs367615	0.552	rs2963022	chr5:108727185	A/G	cg17395555	chr5:108820864	NA	-0.54	-6.77	-0.57	1.04e-9	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs11648796	0.765	rs2003832	chr16:769538	G/A	cg01252526	chr16:711033	WDR90	-0.73	-6.75	-0.57	1.15e-9	Height;
THYM	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.24	-10.02	-0.72	1.53e-16	Platelet count;
THYM	cis	rs17539620	0.624	rs12665520	chr6:154835273	C/T	cg20019720	chr6:154832845	CNKSR3	0.49	5.05	0.46	2.16e-6	Lipoprotein (a) levels;
THYM	trans	rs10489764	1.000	rs10489764	chr1:188085833	A/G	cg22842717	chr12:57939823	DCTN2	0.74	7.02	0.58	3.22e-10	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs4638749	0.677	rs1522021	chr2:108833263	C/T	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg14581129	chr12:53358946	NA	-1.04	-7.43	-0.61	4.58e-11	Cancer (pleiotropy);
THYM	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg15556689	chr8:8085844	FLJ10661	0.71	5.78	0.51	9.3e-8	Mood instability;
THYM	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg00376283	chr12:123451042	ABCB9	0.71	4.71	0.44	8.31e-6	Neutrophil percentage of white cells;
THYM	cis	rs6430585	0.528	rs6711493	chr2:136692553	A/G	cg20242066	chr2:136595261	LCT	0.51	5.54	0.49	2.71e-7	Corneal structure;
THYM	cis	rs2276314	1.000	rs1789513	chr18:33545630	A/G	cg19628046	chr18:33552617	C18orf21	-0.71	-4.85	-0.45	4.83e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg19507638	chr5:93509721	C5orf36	-0.73	-4.73	-0.44	7.78e-6	Diabetic retinopathy;
THYM	cis	rs7084402	0.967	rs1649063	chr10:60309215	G/A	cg07615347	chr10:60278583	BICC1	0.56	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs9788682	0.747	rs2656069	chr15:78745707	C/T	cg18825076	chr15:78729989	IREB2	-0.69	-5.51	-0.49	3.05e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7072216	0.763	rs9787550	chr10:100169051	C/T	cg03852570	chr10:100175106	PYROXD2	0.38	4.89	0.45	4.04e-6	Metabolite levels;
THYM	cis	rs6032067	0.929	rs35475980	chr20:43821080	A/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	5.57	0.5	2.36e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2658782	0.901	rs7116173	chr11:93222311	C/T	cg15737290	chr11:93063684	CCDC67	-1.05	-7.36	-0.6	6.42e-11	Pulmonary function decline;
THYM	cis	rs6866344	0.569	rs56070635	chr5:178150169	A/C	cg10224037	chr5:178157518	ZNF354A	0.99	8.07	0.64	2.1e-12	Neutrophil percentage of white cells;
THYM	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1048238	0.506	rs848210	chr1:16259813	A/G	cg21385522	chr1:16154831	NA	-0.68	-5.72	-0.51	1.23e-7	Systolic blood pressure;
THYM	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03576123	chr11:487126	PTDSS2	-1.24	-5.21	-0.47	1.1e-6	Body mass index;
THYM	cis	rs9916302	0.706	rs11655972	chr17:37407072	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-5.59	-0.5	2.16e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.72	0.57	1.34e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg17747265	chr1:1875780	NA	-0.79	-9.12	-0.68	1.24e-14	Body mass index;
THYM	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7940866	0.874	rs10894306	chr11:130873882	A/C	cg12179176	chr11:130786555	SNX19	0.58	4.45	0.42	2.33e-5	Schizophrenia;
THYM	cis	rs10463554	0.963	rs32850	chr5:102470029	G/C	cg23492399	chr5:102201601	PAM	-0.68	-5.15	-0.47	1.39e-6	Parkinson's disease;
THYM	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg14196790	chr5:131705035	SLC22A5	0.51	4.62	0.43	1.23e-5	Blood metabolite levels;
THYM	cis	rs7809950	0.731	rs2712196	chr7:107128797	G/T	cg23024343	chr7:107201750	COG5	-1.01	-8.76	-0.67	7.29e-14	Coronary artery disease;
THYM	cis	rs476633	0.708	rs13329237	chr15:41450808	A/C	cg21153102	chr15:41252147	NA	0.59	4.55	0.42	1.58e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs1163251	0.902	rs640195	chr1:120217650	T/A	cg19096424	chr1:120255104	PHGDH	0.67	5.25	0.47	9.26e-7	Blood metabolite levels;
THYM	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg06600287	chr1:53387719	ECHDC2	-0.31	-5.11	-0.46	1.68e-6	Monocyte count;
THYM	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg08645402	chr16:4508243	NA	0.71	6.32	0.54	8.29e-9	Schizophrenia;
THYM	cis	rs28595532	0.920	rs115797971	chr4:119779620	A/G	cg14228332	chr4:119757509	SEC24D	1.59	5.76	0.51	1.02e-7	Cannabis dependence symptom count;
THYM	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6450176	0.909	rs3776712	chr5:53304179	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-6.2	-0.54	1.45e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs8067545	0.935	rs7209734	chr17:19988543	C/A	cg20830565	chr17:20408647	MGC102966	-0.54	-4.95	-0.45	3.15e-6	Schizophrenia;
THYM	cis	rs6772849	0.796	rs9841521	chr3:128392274	A/G	cg23732725	chr3:128766093	NA	-0.51	-4.86	-0.45	4.71e-6	Monocyte percentage of white cells;Monocyte count;
THYM	cis	rs9287719	0.781	rs6714413	chr2:10758859	C/T	cg03983476	chr2:10830698	NOL10	-0.58	-5.35	-0.48	6.15e-7	Prostate cancer;
THYM	cis	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg21775007	chr8:11205619	TDH	0.7	5.78	0.51	9.67e-8	Retinal vascular caliber;
THYM	cis	rs17401966	0.931	rs17034821	chr1:10414645	A/G	cg19773385	chr1:10388646	KIF1B	-0.6	-4.7	-0.43	8.88e-6	Hepatocellular carcinoma;
THYM	cis	rs2133450	0.526	rs12485342	chr3:7349051	G/A	cg19930620	chr3:7340148	GRM7	-0.52	-5.62	-0.5	1.86e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.21	0.47	1.1e-6	Electroencephalogram traits;
THYM	cis	rs17001868	0.568	rs9611314	chr22:40735798	C/G	cg07138101	chr22:40742427	ADSL	0.94	5.7	0.5	1.36e-7	Mammographic density (dense area);
THYM	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.95	7.71	0.62	1.25e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg01579765	chr21:45077557	HSF2BP	-0.48	-8.19	-0.64	1.21e-12	Mean corpuscular volume;
THYM	cis	rs6763768	0.606	rs7648309	chr3:53291982	C/T	cg16894138	chr3:53270350	TKT	0.85	5.44	0.49	4.12e-7	Bacterial meningitis;
THYM	cis	rs4849845	0.889	rs3860373	chr2:121037233	A/C	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg24846680	chr1:228362309	C1orf69	0.59	4.78	0.44	6.29e-6	Diastolic blood pressure;
THYM	cis	rs3960554	0.808	rs4728587	chr7:75803132	C/T	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.5	-0.42	1.92e-5	Eotaxin levels;
THYM	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	trans	rs2136093	0.600	rs10922861	chr1:90910074	A/G	cg21057494	chr3:45066971	CLEC3B	0.53	7.07	0.59	2.65e-10	Response to antidepressants;
THYM	cis	rs36051895	0.623	rs2146040	chr9:5260039	C/G	cg02405213	chr9:5042618	JAK2	0.96	9.72	0.71	6.71e-16	Pediatric autoimmune diseases;
THYM	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg16342193	chr10:102329863	NA	-0.54	-5.44	-0.49	4.16e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs10895275	0.961	rs10895277	chr11:102084940	A/G	cg24447756	chr11:102105824	NA	0.53	4.65	0.43	1.07e-5	Migraine;
THYM	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg04518342	chr5:131593106	PDLIM4	0.46	5.13	0.47	1.55e-6	Breast cancer;
THYM	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg00071950	chr4:10020882	SLC2A9	0.88	9.22	0.69	7.56e-15	Bone mineral density;
THYM	cis	rs17001868	0.568	rs2294350	chr22:40784278	C/T	cg07138101	chr22:40742427	ADSL	0.97	5.83	0.51	7.64e-8	Mammographic density (dense area);
THYM	cis	rs4589258	0.933	rs1783796	chr11:90441670	C/A	cg26138821	chr11:89956704	CHORDC1	0.7	5.9	0.52	5.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.34	-0.48	6.28e-7	Menopause (age at onset);
THYM	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg12963246	chr6:28129442	ZNF389	-0.63	-4.56	-0.42	1.52e-5	Parkinson's disease;
THYM	cis	rs73086581	1.000	rs73088421	chr20:3997871	A/G	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.23e-7	Response to antidepressants in depression;
THYM	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg25072359	chr17:41440525	NA	0.64	4.48	0.42	2.05e-5	Menopause (age at onset);
THYM	cis	rs10851411	0.697	rs62022316	chr15:42770362	T/C	cg04857231	chr15:42782520	NA	-0.57	-5.07	-0.46	1.99e-6	Glucose homeostasis traits;
THYM	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg27588902	chr6:42928151	GNMT	-0.48	-4.62	-0.43	1.19e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6450176	0.625	rs3776726	chr5:53290052	T/A	ch.5.1024479R	chr5:53302184	ARL15	-1.01	-8.07	-0.64	2.17e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs28493229	0.881	rs73931345	chr19:41180347	G/A	cg21869046	chr19:41225005	ITPKC	0.59	5.58	0.5	2.29e-7	Kawasaki disease;
THYM	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg00686598	chr14:53173677	PSMC6	1.52	7.73	0.62	1.09e-11	Alzheimer's disease (late onset);
THYM	cis	rs4907240	1.000	rs4907240	chr2:97228039	G/A	cg01950434	chr2:97203154	ARID5A	-0.55	-4.51	-0.42	1.87e-5	Event-related brain oscillations;
THYM	cis	rs2777491	0.707	rs8024774	chr15:41792560	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.05	-11.2	-0.75	4.58e-19	Ulcerative colitis;
THYM	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs3750965	1.000	rs731974	chr11:68847156	C/T	cg01403660	chr11:68851641	TPCN2	0.75	5.92	0.52	5.02e-8	Hair color;
THYM	cis	rs860818	1.000	rs858298	chr7:23244920	C/G	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs9611519	0.780	rs1983631	chr22:41644074	C/T	cg06634786	chr22:41940651	POLR3H	-0.56	-4.61	-0.43	1.24e-5	Neuroticism;
THYM	cis	rs9733	0.596	rs12077833	chr1:150674333	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03264133	chr6:25882463	NA	-1.1	-9.72	-0.71	6.64e-16	Intelligence (multi-trait analysis);
THYM	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg18230493	chr5:56204884	C5orf35	-0.86	-6.17	-0.54	1.63e-8	Initial pursuit acceleration;
THYM	cis	rs17209837	0.607	rs12539936	chr7:87110017	A/G	cg04996195	chr7:87105398	ABCB4	-0.65	-4.81	-0.44	5.67e-6	Gallbladder cancer;
THYM	cis	rs11585357	0.947	rs11584287	chr1:17607501	G/C	cg08277548	chr1:17600880	PADI3	-0.93	-6.24	-0.54	1.23e-8	Hair shape;
THYM	cis	rs72717009	0.825	rs9427399	chr1:161476533	T/C	cg15358701	chr1:161410459	NA	-0.95	-5.06	-0.46	2.08e-6	Rheumatoid arthritis;
THYM	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg06558623	chr16:89946397	TCF25	1.07	5.6	0.5	2.11e-7	Skin colour saturation;
THYM	cis	rs4589258	0.933	rs7117293	chr11:90396387	C/A	cg26834418	chr11:89957033	CHORDC1	0.49	4.45	0.42	2.31e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.536	rs10254199	chr7:124655116	C/T	cg05285228	chr7:124571219	POT1	-0.68	-5.08	-0.46	1.88e-6	Cutaneous malignant melanoma;
THYM	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg24531977	chr5:56204891	C5orf35	-1.0	-8.22	-0.64	1.02e-12	Initial pursuit acceleration;
THYM	cis	rs2970992	0.817	rs10165648	chr2:101335235	A/G	cg01042948	chr2:101319752	NA	0.59	5.84	0.51	7.15e-8	Educational attainment;
THYM	cis	rs929596	0.518	rs13401281	chr2:234628679	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.88	-7.32	-0.6	7.9e-11	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs2811415	0.597	rs11720351	chr3:127751252	T/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg26384229	chr12:38710491	ALG10B	1.02	8.46	0.66	3.1400000000000003e-13	Heart rate;
THYM	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	7.48	0.61	3.78e-11	Smoking behavior;
THYM	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs3857067	0.806	rs72665629	chr4:95112160	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs1113500	0.965	rs10881495	chr1:108610986	C/A	cg06207961	chr1:108661230	NA	0.7	5.66	0.5	1.57e-7	Growth-regulated protein alpha levels;
THYM	cis	rs7246657	0.943	rs4803460	chr19:37885228	T/C	cg22634378	chr19:37742834	NA	0.61	5.17	0.47	1.32e-6	Coronary artery calcification;
THYM	cis	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg00012203	chr2:219082015	ARPC2	-0.65	-5.32	-0.48	6.78e-7	Colorectal cancer;
THYM	cis	rs7772486	0.713	rs2328704	chr6:146020494	T/C	cg13319975	chr6:146136371	FBXO30	0.65	5.35	0.48	6.11e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4631830	0.863	rs2843549	chr10:51521247	C/A	cg16070123	chr10:51489643	NA	-0.5	-4.53	-0.42	1.71e-5	Prostate-specific antigen levels;
THYM	cis	rs1371867	0.641	rs1788209	chr8:101337056	C/T	cg00191853	chr8:101177733	SPAG1	-0.51	-5.14	-0.47	1.44e-6	Atrioventricular conduction;
THYM	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg16928487	chr17:17741425	SREBF1	-0.48	-4.48	-0.42	2.09e-5	Total body bone mineral density;
THYM	cis	rs9403317	1.000	rs10499226	chr6:141862767	G/C	cg15052665	chr6:141804349	NA	0.85	7.41	0.61	5.2e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg21475434	chr5:93447410	FAM172A	0.96	6.08	0.53	2.55e-8	Diabetic retinopathy;
THYM	cis	rs72781680	0.752	rs72796138	chr2:23926233	C/T	cg08917208	chr2:24149416	ATAD2B	1.11	4.97	0.45	2.9e-6	Lymphocyte counts;
THYM	cis	rs3126085	0.825	rs4845428	chr1:152225261	T/C	cg10321714	chr1:152280068	FLG	0.65	4.64	0.43	1.1e-5	Atopic dermatitis;
THYM	cis	rs9653442	0.593	rs6737502	chr2:100862903	C/T	cg08017756	chr2:100939284	LONRF2	-0.68	-5.13	-0.47	1.53e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs7607369	0.648	rs7582193	chr2:219652532	T/C	cg02176678	chr2:219576539	TTLL4	-0.6	-5.49	-0.49	3.28e-7	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs4383453	0.539	rs4678015	chr3:123100463	A/G	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs2276314	1.000	rs2298716	chr18:33552598	C/T	cg19628046	chr18:33552617	C18orf21	0.75	5.36	0.48	5.91e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg25487775	chr2:162093969	NA	0.68	5.82	0.51	8e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs1559088	1.000	rs8106453	chr19:33557412	C/T	cg03563238	chr19:33554763	RHPN2	-0.51	-4.53	-0.42	1.69e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg17757837	chr7:157058334	UBE3C	-0.66	-5.33	-0.48	6.62e-7	Body mass index;
THYM	cis	rs8048589	1.000	rs16958964	chr16:12186586	T/C	cg01990910	chr16:12207648	SNX29	-0.43	-4.58	-0.43	1.39e-5	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg01448562	chr3:133502909	NA	-0.83	-7.15	-0.59	1.82e-10	Iron status biomarkers;
THYM	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg09085632	chr11:111637200	PPP2R1B	1.11	11.2	0.75	4.58e-19	Primary sclerosing cholangitis;
THYM	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg12463550	chr7:65579703	CRCP	-0.55	-4.5	-0.42	1.95e-5	Aortic root size;
THYM	cis	rs4849845	0.886	rs934724	chr2:121012869	T/C	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs9326248	0.530	rs1242229	chr11:117062370	A/G	cg01368799	chr11:117014884	PAFAH1B2	1.0	5.63	0.5	1.81e-7	Blood protein levels;
THYM	cis	rs728616	0.764	rs11201025	chr10:81742158	T/G	cg27452691	chr10:81370291	SFTPA1	0.59	4.6	0.43	1.33e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg09904177	chr6:26538194	HMGN4	0.53	4.47	0.42	2.16e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3733585	0.566	rs35955619	chr4:9918986	T/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-5.75	-0.51	1.07e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9814567	0.806	rs1880374	chr3:134322113	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.09e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7772486	0.790	rs9403755	chr6:146231470	C/A	cg23711669	chr6:146136114	FBXO30	-0.93	-9.39	-0.69	3.39e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9595908	0.931	rs9595617	chr13:33057345	G/T	cg12383807	chr13:33924137	NA	-0.52	-4.48	-0.42	2.09e-5	Body mass index;
THYM	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg18758796	chr5:131593413	PDLIM4	0.64	6.37	0.55	6.83e-9	Breast cancer;
THYM	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg26408565	chr15:76604113	ETFA	-0.55	-4.85	-0.45	4.73e-6	Blood metabolite levels;
THYM	cis	rs227425	0.544	rs227423	chr14:70457644	A/G	cg12046056	chr14:71067695	MED6	0.56	4.58	0.43	1.43e-5	Bone mineral density;
THYM	cis	rs10752881	0.933	rs2027086	chr1:183057933	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Colorectal cancer;
THYM	cis	rs7584330	0.554	rs74449293	chr2:238426458	G/A	cg08992911	chr2:238395768	MLPH	0.85	5.39	0.48	5.19e-7	Prostate cancer;
THYM	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.0	9.3	0.69	5.08e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg01483505	chr11:975446	AP2A2	0.58	4.75	0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	9.75	0.71	5.74e-16	Platelet count;
THYM	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg19912559	chr1:40204330	PPIE	0.64	4.92	0.45	3.61e-6	Blood protein levels;
THYM	cis	rs40363	1.000	rs37773	chr16:3512834	G/A	cg00484396	chr16:3507460	NAT15	0.69	7.26	0.6	1.06e-10	Tuberculosis;
THYM	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg18252515	chr7:66147081	NA	-0.66	-4.85	-0.45	4.8e-6	Aortic root size;
THYM	cis	rs62435770	1.000	rs62435800	chr6:169498739	A/G	cg07652237	chr6:170125491	PHF10	0.54	4.87	0.45	4.49e-6	Loneliness;
THYM	cis	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.7	0.43	8.83e-6	Obesity-related traits;
THYM	cis	rs4974559	0.895	rs57037487	chr4:1386652	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.38	-4.55	-0.42	1.56e-5	Systolic blood pressure;
THYM	cis	rs3008870	1.000	rs2755250	chr1:67495283	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.93	7.76	0.62	9.52e-12	Lymphocyte percentage of white cells;
THYM	cis	rs3784262	0.528	rs4553566	chr15:58336319	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.65	-5.04	-0.46	2.24e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
THYM	cis	rs4243830	0.737	rs11122085	chr1:6597861	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	1.13	6.56	0.56	2.85e-9	Body mass index;
THYM	cis	rs2288884	1.000	rs12609219	chr19:52580996	T/C	cg05974498	chr19:52599256	ZNF841	0.35	4.64	0.43	1.12e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs59698941	0.943	rs66732439	chr5:132234702	A/G	cg02081065	chr5:132209139	LEAP2	-0.86	-5.85	-0.51	7.09e-8	Apolipoprotein A-IV levels;
THYM	cis	rs977987	0.806	rs1895490	chr16:75392806	G/A	cg03315344	chr16:75512273	CHST6	0.73	6.08	0.53	2.5e-8	Dupuytren's disease;
THYM	trans	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg10856724	chr12:34555212	NA	0.94	8.13	0.64	1.61e-12	Bladder cancer;
THYM	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg12311346	chr5:56204834	C5orf35	0.61	4.71	0.43	8.52e-6	Initial pursuit acceleration;
THYM	cis	rs3826795	0.569	rs73059725	chr19:46796768	G/A	cg15229275	chr19:46800054	HIF3A	0.92	5.54	0.49	2.69e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg13683864	chr3:40499215	RPL14	-0.88	-8.67	-0.66	1.14e-13	Renal cell carcinoma;
THYM	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg00310523	chr12:86230176	RASSF9	0.56	4.94	0.45	3.29e-6	Major depressive disorder;
THYM	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg15744005	chr10:104629667	AS3MT	-0.78	-7.33	-0.6	7.48e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs96067	0.711	rs737381	chr1:36621186	G/C	cg24686825	chr1:36642396	MAP7D1	-0.82	-6.45	-0.55	4.57e-9	Corneal structure;
THYM	cis	rs7173743	0.756	rs8034804	chr15:79129600	C/T	cg00540400	chr15:79124168	NA	0.57	5.87	0.52	6.5e-8	Coronary artery disease;
THYM	cis	rs926938	0.584	rs1299780	chr1:115366014	G/A	cg12756093	chr1:115239321	AMPD1	0.6	4.91	0.45	3.72e-6	Autism;
THYM	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg21658235	chr8:22456391	C8orf58	0.52	4.7	0.43	8.78e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg04520793	chr17:42248056	ASB16	-0.35	-4.98	-0.45	2.85e-6	Total body bone mineral density;
THYM	cis	rs854765	0.624	rs11657423	chr17:17728574	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.64	-5.45	-0.49	4.04e-7	Total body bone mineral density;
THYM	cis	rs72829446	0.530	rs4796421	chr17:7379650	C/T	cg02795151	chr17:7402630	POLR2A	0.55	5.21	0.47	1.1e-6	Androgen levels;
THYM	cis	rs2862064	1.000	rs1910053	chr5:156463063	G/A	cg12943317	chr5:156479607	HAVCR1	-0.86	-5.28	-0.48	8e-7	Platelet count;
THYM	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg26384229	chr12:38710491	ALG10B	0.95	7.64	0.62	1.72e-11	Bladder cancer;
THYM	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg08999081	chr20:33150536	PIGU	0.79	7.39	0.6	5.8e-11	Coronary artery disease;
THYM	trans	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.12	8.09	0.64	1.9e-12	Exhaled nitric oxide output;
THYM	cis	rs56079296	0.929	rs7715363	chr5:121283915	G/C	cg01191064	chr5:121408893	LOX	-0.66	-4.53	-0.42	1.73e-5	Coronary artery disease;
THYM	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg18876405	chr7:65276391	NA	0.63	5.53	0.49	2.83e-7	Aortic root size;
THYM	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	12.13	0.78	5.13e-21	Chronic sinus infection;
THYM	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	7.77	0.62	9.07e-12	Smoking behavior;
THYM	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg24578937	chr1:2090814	PRKCZ	0.81	8.54	0.66	2.22e-13	Height;
THYM	cis	rs3126085	0.560	rs2282303	chr1:152329435	C/T	cg10321714	chr1:152280068	FLG	-0.69	-5.0	-0.46	2.62e-6	Atopic dermatitis;
THYM	cis	rs11214589	0.905	rs1078	chr11:113241877	C/T	cg14159747	chr11:113255604	NA	0.36	7.77	0.62	9.29e-12	Neuroticism;
THYM	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg26384229	chr12:38710491	ALG10B	0.73	5.4	0.48	5.01e-7	Morning vs. evening chronotype;
THYM	cis	rs11711311	0.955	rs12636240	chr3:113391282	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.55	-4.58	-0.43	1.4e-5	IgG glycosylation;
THYM	cis	rs12476592	0.516	rs6706123	chr2:63801522	G/A	cg17519650	chr2:63277830	OTX1	-0.67	-4.47	-0.42	2.17e-5	Childhood ear infection;
THYM	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg08645402	chr16:4508243	NA	0.76	6.6	0.56	2.31e-9	Schizophrenia;
THYM	cis	rs12410462	0.681	rs114950580	chr1:227673334	G/C	cg04117972	chr1:227635322	NA	0.86	4.75	0.44	7.06e-6	Major depressive disorder;
THYM	cis	rs921968	0.541	rs636723	chr2:219373197	A/G	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4343996	0.967	rs4588749	chr7:3363992	A/G	cg21248987	chr7:3385318	SDK1	-0.43	-5.16	-0.47	1.36e-6	Motion sickness;
THYM	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg10560079	chr2:191398806	TMEM194B	-0.85	-6.33	-0.54	8.22e-9	Diastolic blood pressure;
THYM	cis	rs34172651	0.797	rs12920941	chr16:24830866	T/A	cg06028605	chr16:24865363	SLC5A11	0.56	5.47	0.49	3.58e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.24	-0.47	9.67e-7	Monocyte percentage of white cells;
THYM	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg25072359	chr17:41440525	NA	0.64	4.48	0.42	2.05e-5	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg06238570	chr21:40685208	BRWD1	-0.96	-9.16	-0.68	1.02e-14	Cognitive function;
THYM	cis	rs2439831	1.000	rs689826	chr15:43749916	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs28595532	0.920	rs56322132	chr4:119742496	T/A	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs2340727	0.668	rs12081397	chr1:161817371	A/G	cg06514368	chr1:161719587	DUSP12	-0.81	-4.62	-0.43	1.2e-5	White blood cell count;Hematology traits;
THYM	cis	rs8032315	0.965	rs8027450	chr15:91418394	C/T	cg04510874	chr15:91427884	FES	0.59	4.57	0.42	1.49e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg11663144	chr21:46675770	NA	-0.71	-8.52	-0.66	2.34e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7809950	0.678	rs79902674	chr7:106866498	A/C	cg23024343	chr7:107201750	COG5	-1.0	-8.43	-0.65	3.79e-13	Coronary artery disease;
THYM	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.21	-9.73	-0.71	6.35e-16	Platelet count;
THYM	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg19507638	chr5:93509721	C5orf36	0.7	4.71	0.43	8.55e-6	Diabetic retinopathy;
THYM	cis	rs4262150	0.767	rs4958596	chr5:152327668	A/G	cg01566342	chr5:151774043	NMUR2	-0.74	-4.76	-0.44	6.91e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg26446133	chr18:72167187	CNDP2	-0.93	-7.89	-0.63	5.19e-12	Refractive error;
THYM	cis	rs28408315	0.958	rs3129	chr15:79214215	A/G	cg00540400	chr15:79124168	NA	-0.62	-4.91	-0.45	3.72e-6	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;
THYM	cis	rs6980334	0.871	rs2859828	chr7:137758578	A/G	cg18769353	chr7:137028617	PTN	0.57	4.5	0.42	1.9e-5	Blood metabolite ratios;
THYM	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg26566898	chr11:117069891	TAGLN	0.39	4.96	0.45	3.13e-6	Blood protein levels;
THYM	trans	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg06437703	chr8:37914619	EIF4EBP1	0.79	6.92	0.58	5.34e-10	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	trans	rs8002861	0.846	rs12869355	chr13:44478193	A/C	cg17145862	chr1:211918768	LPGAT1	0.89	8.3	0.65	7.11e-13	Leprosy;
THYM	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg00684032	chr4:1343700	KIAA1530	0.78	6.72	0.57	1.36e-9	Obesity-related traits;
THYM	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg08017756	chr2:100939284	LONRF2	-0.75	-7.76	-0.62	9.51e-12	Intelligence (multi-trait analysis);
THYM	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg23161317	chr6:28129485	ZNF389	0.85	6.33	0.54	8.19e-9	Depression;
THYM	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg00129232	chr17:37814104	STARD3	-0.69	-4.51	-0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs9880211	0.644	rs6799320	chr3:135802439	G/A	cg21827317	chr3:136751795	NA	-0.71	-5.16	-0.47	1.33e-6	Body mass index;Height;
THYM	cis	rs1971762	0.563	rs10747679	chr12:54077750	C/T	cg16917193	chr12:54089295	NA	0.9	9.22	0.69	7.82e-15	Height;
THYM	cis	rs10982256	0.805	rs10759714	chr9:117267591	C/T	cg15903421	chr9:117267460	DFNB31	-0.57	-5.37	-0.48	5.49e-7	Bipolar disorder;
THYM	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg24308560	chr3:49941425	MST1R	-0.75	-6.42	-0.55	5.45e-9	Intelligence (multi-trait analysis);
THYM	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg17173187	chr15:85201210	NMB	0.56	5.57	0.5	2.38e-7	Schizophrenia;
THYM	cis	rs62103177	0.525	rs8086024	chr18:77746623	A/G	cg07235805	chr18:78004237	PARD6G	-0.46	-5.41	-0.49	4.7e-7	Opioid sensitivity;
THYM	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs34638657	0.752	rs2967374	chr16:82209861	A/G	cg09894383	chr16:82067445	HSD17B2	-0.51	-4.88	-0.45	4.28e-6	Lung adenocarcinoma;
THYM	cis	rs823143	0.549	rs1094647	chr1:205655378	G/A	cg24503407	chr1:205819492	PM20D1	0.84	7.31	0.6	8.45e-11	Monocyte percentage of white cells;
THYM	cis	rs7107770	1.000	rs35183670	chr11:125090912	G/A	cg04164023	chr11:125106101	PKNOX2	-0.81	-4.57	-0.42	1.49e-5	Photic sneeze reflex;
THYM	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9318086	0.648	rs35449605	chr13:24472582	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.55	4.66	0.43	1.03e-5	Myopia (pathological);
THYM	cis	rs11711311	0.955	rs9813630	chr3:113377361	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.57	-4.77	-0.44	6.67e-6	IgG glycosylation;
THYM	cis	rs9443645	0.723	rs9343820	chr6:79480458	T/A	cg05283184	chr6:79620031	NA	-0.76	-6.7	-0.57	1.45e-9	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs56252481	chr4:119754023	C/T	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg24308560	chr3:49941425	MST1R	0.65	4.78	0.44	6.48e-6	Body mass index;
THYM	cis	rs28595532	0.920	rs114916728	chr4:119776886	G/A	cg11846333	chr4:119757529	SEC24D	1.45	5.08	0.46	1.92e-6	Cannabis dependence symptom count;
THYM	cis	rs2625529	0.652	rs2929532	chr15:72345110	C/T	cg16672083	chr15:72433130	SENP8	0.49	4.52	0.42	1.76e-5	Red blood cell count;
THYM	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg24812749	chr6:127587940	RNF146	0.87	6.2	0.54	1.44e-8	Breast cancer;
THYM	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg05962950	chr11:130786565	SNX19	0.92	8.93	0.68	3.24e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9443189	0.813	rs2842561	chr6:76434273	A/C	cg01950844	chr6:76311363	SENP6	-0.8	-4.57	-0.42	1.46e-5	Prostate cancer;
THYM	cis	rs10140922	0.931	rs4982261	chr14:35822159	C/T	cg07166546	chr14:35805898	NA	-0.27	-6.45	-0.55	4.69e-9	Hip circumference adjusted for BMI;
THYM	cis	rs2820651	0.614	rs56203704	chr10:1490143	G/A	cg02445968	chr10:1449028	ADARB2	-1.07	-5.42	-0.49	4.48e-7	Migraine with aura;
THYM	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg13918804	chr1:2043761	PRKCZ	-0.64	-4.8	-0.44	5.78e-6	Height;
THYM	cis	rs936229	0.654	rs762551	chr15:75041917	C/A	cg14664628	chr15:75095509	CSK	-0.82	-5.85	-0.51	7.09e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs9875589	0.509	rs1844107	chr3:14065319	C/G	cg03204825	chr3:13978759	TPRXL	-0.51	-4.46	-0.42	2.26e-5	Ovarian reserve;
THYM	cis	rs4730276	0.674	rs6466207	chr7:107555179	G/T	cg23293999	chr7:106826042	HBP1	-0.61	-5.07	-0.46	1.95e-6	Ulcerative colitis;
THYM	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs514406	0.893	rs4584343	chr1:53434539	A/C	cg25767906	chr1:53392781	SCP2	0.58	5.84	0.51	7.3e-8	Monocyte count;
THYM	cis	rs4889855	0.556	rs56873925	chr17:78536611	C/T	cg16591659	chr17:78472290	NA	0.42	4.84	0.44	5.05e-6	Fractional excretion of uric acid;
THYM	cis	rs1267303	0.675	rs1267308	chr1:46987718	A/G	cg16387850	chr1:46982889	NA	0.48	5.8	0.51	8.61e-8	Monobrow;
THYM	cis	rs6918586	0.658	rs198843	chr6:26110314	A/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.59	-0.61	2.21e-11	Schizophrenia;
THYM	cis	rs11214589	0.747	rs11493880	chr11:113225144	C/T	cg14159747	chr11:113255604	NA	0.29	5.7	0.5	1.35e-7	Neuroticism;
THYM	cis	rs10186029	0.509	rs1122846	chr2:213939354	C/G	cg08319019	chr2:214017104	IKZF2	0.68	5.22	0.47	1.05e-6	Systemic sclerosis;
THYM	cis	rs4788570	0.584	rs9934301	chr16:71756845	C/G	cg06353428	chr16:71660113	MARVELD3	1.39	9.12	0.68	1.28e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7010267	0.869	rs1982763	chr8:119947828	C/T	cg17171407	chr8:119960777	TNFRSF11B	-0.58	-4.72	-0.44	7.97e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs11792861	0.619	rs2289481	chr9:111712924	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.82	7.09	0.59	2.42e-10	Menarche (age at onset);
THYM	cis	rs6924995	0.501	rs6459451	chr6:16187335	A/C	cg11805552	chr6:16175128	NA	0.51	4.55	0.42	1.56e-5	Response to statins (LDL cholesterol change);
THYM	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.72	0.51	1.23e-7	Lung cancer in ever smokers;
THYM	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg26384229	chr12:38710491	ALG10B	0.93	7.31	0.6	8.37e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg21100191	chr22:23484243	RTDR1	0.75	6.59	0.56	2.47e-9	Bone mineral density;
THYM	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg11764359	chr7:65958608	NA	-0.74	-6.02	-0.53	3.33e-8	Aortic root size;
THYM	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg26597838	chr10:835615	NA	1.11	7.5	0.61	3.36e-11	Eosinophil percentage of granulocytes;
THYM	cis	rs8067545	0.750	rs34290687	chr17:19991211	G/A	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.63e-6	Schizophrenia;
THYM	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg03404566	chr17:6899310	ALOX12	0.74	9.09	0.68	1.48e-14	Tonsillectomy;
THYM	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg02275930	chr1:2372054	NA	-0.7	-5.99	-0.52	3.72e-8	Schizophrenia;
THYM	cis	rs11186	0.556	rs60396510	chr2:189952875	G/T	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg17264618	chr3:40429014	ENTPD3	-0.53	-5.15	-0.47	1.38e-6	Renal cell carcinoma;
THYM	cis	rs1728785	1.000	rs698728	chr16:68625253	T/C	cg02972257	chr16:68554789	NA	-0.71	-4.59	-0.43	1.37e-5	Ulcerative colitis;
THYM	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg06027949	chr8:82754900	SNX16	-0.62	-5.06	-0.46	2.01e-6	Diastolic blood pressure;
THYM	cis	rs863345	0.604	rs10908670	chr1:158502113	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg10523679	chr1:76189770	ACADM	-0.84	-6.64	-0.56	1.96e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg13390004	chr1:15929781	NA	0.62	4.72	0.44	8.11e-6	Systolic blood pressure;
THYM	cis	rs4664308	0.870	rs2198918	chr2:161015052	C/T	cg03641300	chr2:160917029	PLA2R1	-0.74	-6.47	-0.55	4.18e-9	Idiopathic membranous nephropathy;
THYM	cis	rs1299926	0.850	rs1657081	chr16:8870762	C/T	cg03718620	chr16:8771680	ABAT	-1.06	-4.47	-0.42	2.19e-5	Anger;
THYM	cis	rs1371867	0.846	rs1660328	chr8:101303450	A/G	cg06636551	chr8:101224915	SPAG1	-0.63	-6.29	-0.54	9.77e-9	Atrioventricular conduction;
THYM	cis	rs11214589	0.774	rs10891544	chr11:113256152	A/C	cg14159747	chr11:113255604	NA	-0.38	-8.65	-0.66	1.25e-13	Neuroticism;
THYM	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg04156016	chr5:1868137	NA	0.5	4.63	0.43	1.17e-5	Cardiovascular disease risk factors;
THYM	cis	rs753778	0.570	rs10875465	chr8:142210500	A/G	cg18755752	chr8:142205143	DENND3	-0.74	-7.5	-0.61	3.37e-11	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs12802200	0.535	rs12290412	chr11:569230	T/C	cg14433983	chr11:636460	DRD4	-0.62	-4.47	-0.42	2.13e-5	Systemic lupus erythematosus;
THYM	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg26818010	chr10:134567672	INPP5A	0.7	5.83	0.51	7.51e-8	Migraine;
THYM	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg25918947	chr17:41365094	TMEM106A	-0.68	-5.74	-0.51	1.15e-7	Menopause (age at onset);
THYM	cis	rs1865721	0.804	rs72977818	chr18:73146852	T/C	cg26385618	chr18:73139727	C18orf62	-0.63	-4.56	-0.42	1.5e-5	Intelligence;
THYM	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.37	0.55	6.61e-9	Tonsillectomy;
THYM	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg20503657	chr10:835505	NA	1.17	8.29	0.65	7.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs7172809	0.599	rs74026918	chr15:77762851	G/C	cg22256960	chr15:77711686	NA	-0.61	-4.47	-0.42	2.18e-5	Glucose homeostasis traits;
THYM	cis	rs9914988	0.619	rs12451955	chr17:27314224	A/G	cg26182037	chr17:27055700	NEK8	0.82	5.09	0.46	1.82e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs6496667	0.533	rs2601206	chr15:90962699	C/T	cg22089800	chr15:90895588	ZNF774	0.72	5.29	0.48	7.97e-7	Rheumatoid arthritis;
THYM	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	trans	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg25214090	chr10:38739885	LOC399744	0.97	8.33	0.65	5.98e-13	Corneal astigmatism;
THYM	cis	rs9467160	0.765	rs793717	chr6:24444534	A/C	cg20631270	chr6:24437470	GPLD1	-0.67	-4.64	-0.43	1.1e-5	Liver enzyme levels;
THYM	cis	rs13326165	0.760	rs9844183	chr3:52315192	A/G	cg08438690	chr3:52279403	PPM1M	-0.65	-4.72	-0.44	8.02e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg15247329	chr7:2764246	NA	-0.7	-5.79	-0.51	9.11e-8	Height;
THYM	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg13695892	chr22:41940480	POLR3H	0.99	7.48	0.61	3.75e-11	Vitiligo;
THYM	cis	rs1021993	0.597	rs2055698	chr1:209548546	G/A	cg24997231	chr1:209527535	NA	-0.58	-5.26	-0.48	8.81e-7	Gut microbiome composition (winter);
THYM	cis	rs11779988	0.629	rs7465361	chr8:17854155	T/C	cg01800426	chr8:17659068	MTUS1	-0.69	-5.09	-0.46	1.79e-6	Breast cancer;
THYM	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs11096990	0.892	rs6531696	chr4:39191754	A/G	cg24403649	chr4:39172243	NA	-0.62	-5.17	-0.47	1.31e-6	Cognitive function;
THYM	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg09034736	chr1:150693464	HORMAD1	0.53	4.67	0.43	9.84e-6	Melanoma;
THYM	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg22508957	chr16:3507546	NAT15	0.53	5.68	0.5	1.47e-7	Body mass index (adult);
THYM	cis	rs714027	0.605	rs41176	chr22:30432403	G/T	cg27665648	chr22:30112403	NA	-0.52	-4.73	-0.44	7.82e-6	Lymphocyte counts;
THYM	cis	rs78456975	0.527	rs72776299	chr2:1570300	G/C	cg12573674	chr2:1569213	NA	-1.36	-7.81	-0.63	7.43e-12	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg09307838	chr4:120376055	NA	-0.6	-4.54	-0.42	1.63e-5	Corneal astigmatism;
THYM	cis	rs56390833	1	rs56390833	chr15:78877381	C/A	cg04882995	chr15:78912658	CHRNA3	0.54	4.63	0.43	1.16e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.77	7.81	0.63	7.42e-12	Lymphocyte counts;
THYM	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg25703541	chr22:24373054	LOC391322	-0.9	-11.69	-0.77	4.25e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10463554	0.963	rs26261	chr5:102545693	A/G	cg23492399	chr5:102201601	PAM	-0.68	-5.13	-0.47	1.51e-6	Parkinson's disease;
THYM	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs28493229	0.708	rs10425069	chr19:41152847	C/T	cg21869046	chr19:41225005	ITPKC	0.48	4.56	0.42	1.52e-5	Kawasaki disease;
THYM	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg12826209	chr6:26865740	GUSBL1	0.75	5.3	0.48	7.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs12282928	1.000	rs1566730	chr11:48250854	G/A	cg22827986	chr11:48284249	OR4X1	0.53	5.52	0.49	2.95e-7	Migraine - clinic-based;
THYM	cis	rs2067615	0.579	rs4964489	chr12:107171808	A/G	cg15890332	chr12:107067104	RFX4	0.48	5.63	0.5	1.81e-7	Heart rate;
THYM	cis	rs4747241	0.593	rs3924190	chr10:74068076	C/G	cg07828833	chr10:74069493	NA	0.59	5.02	0.46	2.43e-6	Heschl's gyrus morphology;
THYM	cis	rs72827839	0.779	rs58953228	chr17:46513814	A/G	cg23391107	chr17:45924227	SP6	0.86	5.55	0.5	2.54e-7	Ease of getting up in the morning;
THYM	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg10560079	chr2:191398806	TMEM194B	-0.89	-7.93	-0.63	4.3e-12	Pulse pressure;
THYM	cis	rs6593803	0.622	rs12747247	chr1:147166010	A/C	cg06627043	chr1:147838662	NA	0.51	4.75	0.44	7.16e-6	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
THYM	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.05	-0.82	6.23e-25	Height;
THYM	cis	rs3135718	0.935	rs1078806	chr10:123338975	C/T	cg15049101	chr10:123353889	FGFR2	-0.54	-4.55	-0.42	1.61e-5	Estrogen receptor status in breast cancer;
THYM	cis	rs12142240	0.698	rs17361950	chr1:46864150	C/T	cg00530320	chr1:46809349	NSUN4	0.78	5.3	0.48	7.6e-7	Menopause (age at onset);
THYM	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg24375607	chr4:120327624	NA	0.66	5.09	0.46	1.77e-6	Corneal astigmatism;
THYM	trans	rs10487112	0.625	rs714498	chr7:90167839	A/T	cg11223184	chr2:198033295	ANKRD44	0.71	7.01	0.58	3.43e-10	Perceived unattractiveness to mosquitoes;
THYM	cis	rs7084402	0.967	rs1658457	chr10:60302716	T/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.64	-0.5	1.72e-7	Refractive error;
THYM	trans	rs8073060	0.544	rs225268	chr17:33966224	A/C	cg19694781	chr19:47549865	TMEM160	-0.95	-7.8	-0.62	7.8e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs4919694	1.000	rs12245779	chr10:104645944	C/A	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs713587	0.691	rs754537	chr2:25176277	A/T	cg15423357	chr2:25149977	NA	-0.61	-6.55	-0.56	2.91e-9	Body mass index in non-asthmatics;
THYM	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg24910161	chr17:38119198	GSDMA	0.45	4.67	0.43	9.96e-6	Self-reported allergy;
THYM	cis	rs4845875	0.600	rs1889293	chr1:11840862	G/A	cg06193043	chr1:11908199	NPPA	0.59	5.04	0.46	2.26e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs4568518	0.535	rs4236292	chr7:18057333	G/C	cg00911873	chr7:18067463	PRPS1L1	-0.59	-4.69	-0.43	9.26e-6	Measles;
THYM	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg11764359	chr7:65958608	NA	0.69	4.67	0.43	9.75e-6	Aortic root size;
THYM	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11644478	chr21:40555479	PSMG1	1.07	9.23	0.69	7.24e-15	Cognitive function;
THYM	cis	rs11264213	0.901	rs663163	chr1:36390527	A/G	cg27506609	chr1:36549197	TEKT2	0.94	4.89	0.45	4.03e-6	Schizophrenia;
THYM	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg25072359	chr17:41440525	NA	0.64	4.48	0.42	2.05e-5	Menopause (age at onset);
THYM	cis	rs2235649	0.833	rs55684627	chr16:1848817	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg18252515	chr7:66147081	NA	1.43	8.6	0.66	1.65e-13	Diabetic kidney disease;
THYM	trans	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17818399	0.926	rs13032670	chr2:46830794	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.63	4.5	0.42	1.93e-5	Height;
THYM	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg17644776	chr2:200775616	C2orf69	0.9	7.45	0.61	4.33e-11	Osteoporosis;
THYM	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg18758796	chr5:131593413	PDLIM4	0.6	5.9	0.52	5.68e-8	Acylcarnitine levels;
THYM	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg07075026	chr17:47091521	IGF2BP1	-0.56	-5.99	-0.52	3.79e-8	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs9814567	0.752	rs4955544	chr3:134332776	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs10089	1.000	rs4836366	chr5:127482494	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.02	7.11	0.59	2.11e-10	Ileal carcinoids;
THYM	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg24818145	chr4:99064322	C4orf37	0.67	5.2	0.47	1.15e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg02353165	chr6:42928485	GNMT	0.86	7.87	0.63	5.67e-12	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs2730245	0.527	rs924910	chr7:158672272	C/T	cg11984989	chr7:158649758	WDR60	1.01	8.5	0.66	2.65e-13	Height;
THYM	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg20821713	chr7:1055600	C7orf50	-0.44	-4.59	-0.43	1.35e-5	Bronchopulmonary dysplasia;
THYM	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg07884673	chr3:53033167	SFMBT1	1.11	5.86	0.52	6.73e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs4888262	0.526	rs7193508	chr16:74628630	G/T	cg01733217	chr16:74700730	RFWD3	0.82	8.54	0.66	2.2e-13	Testicular germ cell tumor;
THYM	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg08017756	chr2:100939284	LONRF2	-0.69	-7.09	-0.59	2.35e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg00852783	chr1:26633632	UBXN11	0.85	8.56	0.66	1.95e-13	Obesity-related traits;
THYM	cis	rs1011018	0.955	rs2058265	chr7:139462249	G/T	cg06079564	chr7:139468310	HIPK2	-0.73	-5.73	-0.51	1.2e-7	Systolic blood pressure;
THYM	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.16	-5.63	-0.5	1.85e-7	Body mass index;
THYM	cis	rs9970807	0.892	rs72664324	chr1:56972353	G/A	cg11959316	chr1:57001742	PPAP2B	0.74	5.33	0.48	6.64e-7	Myocardial infarction;Coronary artery disease;
THYM	cis	rs754466	0.580	rs12356063	chr10:79558131	G/C	cg17075019	chr10:79541650	NA	-0.69	-5.7	-0.5	1.35e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs969413	0.624	rs9914093	chr17:79260653	C/G	cg15215033	chr17:79258732	SLC38A10	0.4	4.95	0.45	3.18e-6	Frontotemporal dementia;
THYM	cis	rs860818	1.000	rs858233	chr7:23241533	T/G	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs6815814	0.808	rs4833093	chr4:38789740	G/T	cg06935464	chr4:38784597	TLR10	0.74	5.45	0.49	4.04e-7	Breast cancer;
THYM	cis	rs73086581	1.000	rs3746666	chr20:3910861	A/G	cg02187196	chr20:3869020	PANK2	0.47	5.24	0.47	9.85e-7	Response to antidepressants in depression;
THYM	cis	rs919433	1.000	rs1560277	chr2:198187903	C/T	cg00792783	chr2:198669748	PLCL1	0.73	5.36	0.48	5.78e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6570726	0.791	rs436498	chr6:145876347	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg04772025	chr11:68637568	NA	0.66	6.99	0.58	3.79e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2836950	0.545	rs2836949	chr21:40602456	C/A	cg06238570	chr21:40685208	BRWD1	-0.66	-5.48	-0.49	3.43e-7	Menarche (age at onset);
THYM	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg05973401	chr12:123451056	ABCB9	0.68	4.55	0.42	1.58e-5	Neutrophil percentage of white cells;
THYM	cis	rs4242434	0.672	rs11785031	chr8:22486612	A/G	cg01710189	chr8:22454888	PDLIM2	-0.48	-5.12	-0.47	1.56e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6815814	0.904	rs67712706	chr4:38820616	A/G	cg06935464	chr4:38784597	TLR10	0.7	4.68	0.43	9.42e-6	Breast cancer;
THYM	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-6.89	-0.58	6.1e-10	Monocyte percentage of white cells;
THYM	cis	rs2282930	0.512	rs17133922	chr7:50715083	A/C	cg08586669	chr7:50727761	GRB10	0.33	4.89	0.45	4.18e-6	Bone mineral density;
THYM	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg26039829	chr8:22132926	PIWIL2	0.71	6.36	0.55	7.01e-9	Hypertriglyceridemia;
THYM	cis	rs4460079	0.531	rs6834673	chr4:114837989	G/A	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs3916	0.955	rs35525135	chr12:121140064	T/C	cg10600917	chr12:121163489	ACADS	0.6	5.19	0.47	1.2e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs7098414	0.530	rs10749572	chr10:82136664	G/T	cg01528321	chr10:82214614	TSPAN14	0.61	5.03	0.46	2.27e-6	Post bronchodilator FEV1;
THYM	cis	rs11039798	0.920	rs7478904	chr11:48630323	C/T	cg24672777	chr11:48374446	OR4C45	-1.08	-5.95	-0.52	4.42e-8	Axial length;
THYM	cis	rs1298062	0.790	rs1274596	chr19:50973476	A/G	cg10687087	chr19:50962411	MYBPC2	0.51	4.45	0.42	2.36e-5	Age of smoking initiation;
THYM	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500395	1.000	rs904818	chr16:48622582	T/C	cg04672837	chr16:48644449	N4BP1	0.51	4.98	0.45	2.85e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg03433033	chr1:76189801	ACADM	0.72	8.64	0.66	1.31e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs34779708	0.966	rs1545757	chr10:35445588	A/T	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg17644776	chr2:200775616	C2orf69	0.71	5.46	0.49	3.85e-7	Schizophrenia;
THYM	cis	rs73086581	1.000	rs73086508	chr20:3921715	C/T	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs2688608	0.592	rs11000757	chr10:75486815	T/C	cg23231163	chr10:75533350	FUT11	-0.41	-5.9	-0.52	5.54e-8	Inflammatory bowel disease;
THYM	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg11764359	chr7:65958608	NA	0.82	6.56	0.56	2.81e-9	Aortic root size;
THYM	cis	rs2637266	0.935	rs7477361	chr10:78393586	G/A	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs1346	0.552	rs10791820	chr11:65366847	C/T	cg27068330	chr11:65405492	SIPA1	0.7	4.54	0.42	1.67e-5	Vertical cup-disc ratio;Optic cup area;
THYM	cis	rs2639990	1.000	rs655156	chr18:72898181	T/C	cg02750262	chr18:72916776	ZADH2	1.29	6.44	0.55	4.98e-9	Vascular endothelial growth factor levels;
THYM	cis	rs4720575	1.000	rs4724535	chr7:47100396	G/A	cg00036614	chr7:47093842	NA	-0.59	-5.24	-0.47	9.71e-7	Angiotensin-converting enzyme inhibitor intolerance;
THYM	cis	rs11577318	0.853	rs4526602	chr1:26648034	C/T	cg19677267	chr1:26645161	CD52;UBXN11	-0.48	-6.27	-0.54	1.06e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs12200560	0.505	rs9400167	chr6:97077192	G/T	cg06623918	chr6:96969491	KIAA0776	0.78	6.01	0.52	3.39e-8	Coronary heart disease;
THYM	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg13880726	chr7:1868755	MAD1L1	0.79	5.35	0.48	6.03e-7	Bipolar disorder;
THYM	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg27125505	chr17:43679177	LOC644172	0.77	6.97	0.58	4.25e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.81	7.97	0.63	3.44e-12	Lymphocyte counts;
THYM	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg06481639	chr22:41940642	POLR3H	-0.72	-5.25	-0.47	9.4e-7	Neuroticism;
THYM	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg05373962	chr22:49881684	NA	-0.65	-6.14	-0.53	1.94e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg08999081	chr20:33150536	PIGU	0.62	5.04	0.46	2.25e-6	Coronary artery disease;
THYM	cis	rs476633	0.708	rs28629856	chr15:41446950	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.69	-5.4	-0.48	4.82e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg13397359	chr6:42928475	GNMT	0.56	5.08	0.46	1.89e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg14018140	chr10:458528	DIP2C	-0.51	-5.08	-0.46	1.91e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-7.5	-0.61	3.41e-11	Platelet count;
THYM	cis	rs6430585	0.527	rs12467569	chr2:136413847	T/C	cg07169764	chr2:136633963	MCM6	0.97	8.76	0.67	7.3e-14	Corneal structure;
THYM	cis	rs3741151	0.687	rs56857598	chr11:73234173	G/A	cg12959048	chr11:73096162	RELT	-0.51	-4.51	-0.42	1.87e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs6084875	0.840	rs1885357	chr20:4727427	G/A	cg19614321	chr20:4804581	RASSF2	0.44	4.48	0.42	2.09e-5	Systemic lupus erythematosus;
THYM	cis	rs4523957	0.855	rs12602764	chr17:2123200	A/T	cg16513277	chr17:2031491	SMG6	-0.8	-7.85	-0.63	6.16e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg17105886	chr17:28927953	LRRC37B2	1.26	7.32	0.6	8.11e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.16	-0.75	5.56e-19	Primary sclerosing cholangitis;
THYM	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg27398817	chr8:82754497	SNX16	-0.84	-6.56	-0.56	2.79e-9	Diastolic blood pressure;
THYM	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg25358565	chr5:93447407	FAM172A	1.31	10.15	0.72	7.84e-17	Diabetic retinopathy;
THYM	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg15691649	chr6:25882328	NA	0.68	5.2	0.47	1.17e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg02478829	chr6:26598070	ABT1	0.34	4.62	0.43	1.21e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9868809	0.772	rs9809222	chr3:48714411	C/T	cg00383909	chr3:49044727	WDR6	0.87	4.54	0.42	1.63e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2970992	0.728	rs2309920	chr2:101329860	C/T	cg01042948	chr2:101319752	NA	0.6	5.89	0.52	5.76e-8	Educational attainment;
THYM	cis	rs2041895	0.509	rs10861676	chr12:107311235	G/A	cg26297688	chr12:107349093	C12orf23	-0.49	-4.81	-0.44	5.66e-6	Glaucoma (low intraocular pressure);
THYM	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.68	9.03	0.68	1.97e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4523957	0.928	rs216180	chr17:2172416	C/G	cg16513277	chr17:2031491	SMG6	0.79	7.45	0.61	4.21e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg02915803	chr1:1606292	LOC728661;CDK11B	0.64	5.69	0.5	1.43e-7	Body mass index;
THYM	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg11764359	chr7:65958608	NA	-0.89	-7.51	-0.61	3.14e-11	Aortic root size;
THYM	cis	rs28595532	0.920	rs116094766	chr4:119729291	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg14458575	chr2:238380390	NA	1.12	7.97	0.63	3.42e-12	Prostate cancer;
THYM	cis	rs7772486	0.754	rs6921073	chr6:146144377	G/A	cg23711669	chr6:146136114	FBXO30	0.92	9.0	0.68	2.32e-14	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs4866334	1.000	rs79246642	chr5:18442878	C/T	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.02	6.98	0.58	4.02e-10	Smoking behavior;
THYM	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.72	-0.67	9.16e-14	Mean corpuscular volume;
THYM	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs16828019	0.704	rs35071528	chr1:41612657	C/G	cg16989117	chr1:40781907	COL9A2	0.96	4.71	0.44	8.49e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6424115	1.000	rs12121387	chr1:24166536	T/G	cg15997130	chr1:24165203	NA	-0.78	-6.94	-0.58	4.88e-10	Immature fraction of reticulocytes;
THYM	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4654899	0.865	rs957163	chr1:21416181	G/T	cg01072550	chr1:21505969	NA	-0.75	-6.6	-0.56	2.29e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg04476341	chr5:669733	TPPP	-0.45	-4.51	-0.42	1.83e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg08807101	chr21:30365312	RNF160	0.8	6.25	0.54	1.15e-8	Dental caries;
THYM	cis	rs3849570	0.961	rs11915042	chr3:81834060	G/A	cg07356753	chr3:81810745	GBE1	-0.91	-7.45	-0.61	4.23e-11	Waist circumference;Body mass index;
THYM	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg06074448	chr4:187884817	NA	-0.99	-12.8	-0.8	2.14e-22	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg19016782	chr12:123741754	C12orf65	-0.7	-4.61	-0.43	1.25e-5	Neutrophil percentage of white cells;
THYM	cis	rs791888	0.965	rs791873	chr10:89405558	C/T	cg10377144	chr10:89419177	PAPSS2	-0.38	-5.97	-0.52	4.1e-8	Magnesium levels;
THYM	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg20503657	chr10:835505	NA	1.13	7.89	0.63	5.22e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	trans	rs877282	0.898	rs12354872	chr10:763362	G/A	cg22713356	chr15:30763199	NA	1.36	10.13	0.72	8.77e-17	Uric acid levels;
THYM	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs2235649	0.833	rs9933168	chr16:1848361	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.14	-0.64	1.54e-12	Mean corpuscular volume;
THYM	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg24060327	chr5:131705240	SLC22A5	-0.74	-5.38	-0.48	5.28e-7	Blood metabolite levels;
THYM	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg12560992	chr17:57184187	TRIM37	0.75	6.06	0.53	2.77e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6450176	0.564	rs34360866	chr5:53332737	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.93	-8.27	-0.65	8.09e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg16325326	chr1:53192061	ZYG11B	-0.98	-11.09	-0.75	7.79e-19	Monocyte count;
THYM	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06873352	chr17:61820015	STRADA	0.57	5.68	0.5	1.46e-7	Height;
THYM	cis	rs11031096	0.782	rs10767845	chr11:4156922	C/T	cg08557956	chr11:4115526	RRM1	-0.5	-4.9	-0.45	3.94e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7772486	0.536	rs9373467	chr6:145955605	C/T	cg05347473	chr6:146136440	FBXO30	0.81	7.23	0.6	1.23e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg00944433	chr1:107599041	PRMT6	0.42	5.39	0.48	5.04e-7	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs4455778	0.860	rs6973983	chr7:49069524	T/A	cg26309511	chr7:48887640	NA	0.51	4.47	0.42	2.16e-5	Lung cancer in never smokers;
THYM	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg06481639	chr22:41940642	POLR3H	-0.72	-5.23	-0.47	1.02e-6	Vitiligo;
THYM	cis	rs270601	0.866	rs460271	chr5:131630062	C/G	cg18758796	chr5:131593413	PDLIM4	0.55	4.99	0.46	2.67e-6	Acylcarnitine levels;
THYM	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.22	0.47	1.05e-6	Bipolar disorder;
THYM	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs1061377	1.000	rs3733274	chr4:39122577	A/G	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs3960554	0.867	rs79359354	chr7:75702597	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-4.78	-0.44	6.28e-6	Eotaxin levels;
THYM	cis	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg11879182	chr18:77439856	CTDP1	-0.81	-7.86	-0.63	5.87e-12	Monocyte count;
THYM	cis	rs7572733	0.534	rs700680	chr2:198707950	A/T	cg00792783	chr2:198669748	PLCL1	-0.84	-5.89	-0.52	5.95e-8	Dermatomyositis;
THYM	cis	rs9880211	1.000	rs67949818	chr3:136212978	G/A	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs611744	0.967	rs702801	chr8:109211802	T/C	cg21045802	chr8:109455806	TTC35	0.59	5.31	0.48	7.16e-7	Dupuytren's disease;
THYM	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg14345882	chr6:26364793	BTN3A2	0.62	5.7	0.5	1.34e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs470093	0.668	rs138069	chr22:44229492	G/C	cg09142166	chr22:44276013	PNPLA5	-0.6	-5.77	-0.51	9.87e-8	Staphylococcus aureus infection;
THYM	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg02773041	chr1:40204384	PPIE	0.77	5.99	0.52	3.8e-8	Blood protein levels;
THYM	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg02269571	chr22:50332266	NA	-0.82	-5.79	-0.51	9.16e-8	Schizophrenia;
THYM	cis	rs2997447	0.655	rs55820521	chr1:26374286	C/T	cg19633962	chr1:26362018	EXTL1	-0.73	-4.73	-0.44	7.82e-6	QRS complex (12-leadsum);
THYM	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg23758822	chr17:41437982	NA	1.16	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs2976388	0.935	rs2978979	chr8:143757286	C/A	cg13446199	chr8:143762866	PSCA	0.5	5.96	0.52	4.36e-8	Urinary tract infection frequency;
THYM	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.02	-9.68	-0.7	8.14e-16	Primary sclerosing cholangitis;
THYM	cis	rs3741151	0.773	rs73544729	chr11:73183418	G/T	cg12959048	chr11:73096162	RELT	-0.53	-5.08	-0.46	1.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs17401966	0.838	rs7553935	chr1:10375179	G/A	cg19773385	chr1:10388646	KIF1B	-0.59	-4.82	-0.44	5.39e-6	Hepatocellular carcinoma;
THYM	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg20503657	chr10:835505	NA	1.42	9.74	0.71	5.94e-16	Eosinophil percentage of granulocytes;
THYM	cis	rs28595532	0.920	rs56331118	chr4:119767054	G/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs6430585	0.583	rs4594504	chr2:136625113	A/C	cg20242066	chr2:136595261	LCT	0.51	4.87	0.45	4.44e-6	Corneal structure;
THYM	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7084402	0.935	rs1896246	chr10:60276068	A/G	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs12137294	0.866	rs1172151	chr1:205221659	A/C	cg17889831	chr1:205181581	DSTYK	-0.41	-5.09	-0.46	1.82e-6	Red cell distribution width;
THYM	cis	rs10208940	0.541	rs35293396	chr2:68749848	T/C	cg09157127	chr2:69201416	GKN1	0.84	4.54	0.42	1.66e-5	Urate levels in lean individuals;
THYM	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg24503407	chr1:205819492	PM20D1	0.97	9.46	0.7	2.35e-15	Menarche (age at onset);
THYM	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg18252515	chr7:66147081	NA	0.66	5.09	0.46	1.84e-6	Aortic root size;
THYM	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.74	0.44	7.36e-6	Obesity-related traits;
THYM	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.04	7.56	0.61	2.56e-11	Smoking behavior;
THYM	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg27129171	chr3:47204927	SETD2	-0.7	-6.73	-0.57	1.3e-9	Colorectal cancer;
THYM	cis	rs55665837	1.000	rs12283797	chr11:14442262	C/G	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg14583973	chr4:3374767	RGS12	0.66	6.43	0.55	5.09e-9	Serum sulfate level;
THYM	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg03060546	chr3:49711283	APEH	-0.7	-5.83	-0.51	7.58e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg20887711	chr4:1340912	KIAA1530	0.6	4.62	0.43	1.21e-5	Obesity-related traits;
THYM	cis	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.17	-0.47	1.3e-6	Neuroticism;
THYM	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg18404041	chr3:52824283	ITIH1	-0.52	-4.69	-0.43	8.99e-6	Bipolar disorder;
THYM	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg19748678	chr4:122722346	EXOSC9	0.71	4.93	0.45	3.44e-6	Type 2 diabetes;
THYM	cis	rs6496667	0.509	rs6496677	chr15:90990358	A/G	cg00425431	chr15:90792223	TTLL13	0.4	4.64	0.43	1.11e-5	Rheumatoid arthritis;
THYM	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	4.79	0.44	6.13e-6	Neuroticism;
THYM	cis	rs7020830	0.898	rs12000309	chr9:37230844	G/A	cg14294708	chr9:37120828	ZCCHC7	1.27	16.62	0.86	7.11e-30	Schizophrenia;
THYM	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.76	8.53	0.66	2.25e-13	Eosinophil percentage of white cells;
THYM	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg06640241	chr16:89574553	SPG7	0.9	8.01	0.64	2.81e-12	Multiple myeloma (IgH translocation);
THYM	cis	rs367615	0.918	rs72797472	chr5:108881343	C/T	cg17395555	chr5:108820864	NA	0.53	4.8	0.44	5.95e-6	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg22968622	chr17:43663579	NA	1.18	10.56	0.73	1.05e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6430585	0.591	rs3098103	chr2:136656094	T/C	cg23851026	chr2:136556271	LCT	0.75	6.78	0.57	9.95e-10	Corneal structure;
THYM	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg12373951	chr3:133503437	NA	0.56	6.17	0.53	1.69e-8	Iron status biomarkers;
THYM	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-4.46	-0.42	2.22e-5	Neuroticism;
THYM	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.88	8.0	0.63	3.02e-12	Monocyte percentage of white cells;
THYM	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg20891283	chr12:69753455	YEATS4	0.72	5.54	0.49	2.75e-7	Response to diuretic therapy;
THYM	cis	rs9361491	0.608	rs7382311	chr6:79455943	G/A	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg22535103	chr8:58192502	C8orf71	-0.93	-4.56	-0.42	1.52e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs8050907	0.744	rs77430528	chr16:4523389	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.28	5.13	0.47	1.5e-6	Obesity-related traits;
THYM	cis	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg10416294	chr15:28049119	OCA2	-0.54	-4.54	-0.42	1.62e-5	Hepatitis;
THYM	cis	rs7465272	1.000	rs35868630	chr8:143685933	G/A	cg01509843	chr8:143695822	ARC	0.72	4.85	0.45	4.73e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs240764	0.659	rs1006398	chr6:101037718	T/A	cg21058520	chr6:100914733	NA	-0.59	-4.62	-0.43	1.21e-5	Neuroticism;
THYM	cis	rs2303759	0.709	rs10411679	chr19:49826480	A/T	cg22590775	chr19:49891494	CCDC155	0.63	4.8	0.44	5.89e-6	Multiple sclerosis;
THYM	cis	rs34330	0.562	rs10845615	chr12:12863470	C/T	cg04607235	chr12:12878440	APOLD1	-0.95	-5.71	-0.51	1.29e-7	Systemic lupus erythematosus;
THYM	cis	rs7432375	0.901	rs1017882	chr3:136357705	T/C	cg21827317	chr3:136751795	NA	0.59	5.04	0.46	2.22e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs4786125	0.581	rs1967404	chr16:6921483	G/A	cg03623568	chr16:6915990	A2BP1	-0.99	-9.71	-0.71	6.74e-16	Heart rate variability traits (SDNN);
THYM	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg01324343	chr3:183735012	ABCC5	0.9	13.08	0.8	5.7e-23	Anterior chamber depth;
THYM	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg18681998	chr4:17616180	MED28	0.96	9.73	0.71	6.38e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6987853	0.527	rs2974298	chr8:42376477	T/C	cg09913449	chr8:42400586	C8orf40	-0.78	-6.7	-0.57	1.44e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6815814	0.950	rs73236632	chr4:38836071	G/A	cg06935464	chr4:38784597	TLR10	0.72	4.97	0.45	2.94e-6	Breast cancer;
THYM	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg22683308	chr4:1340831	KIAA1530	-0.61	-4.83	-0.44	5.15e-6	Longevity;
THYM	cis	rs654950	0.875	rs116747365	chr1:41994792	C/T	cg06885757	chr1:42089581	HIVEP3	-0.44	-5.26	-0.47	9e-7	Airway imaging phenotypes;
THYM	cis	rs7246657	1.000	rs12709812	chr19:37794850	A/G	cg23950597	chr19:37808831	NA	0.71	4.49	0.42	1.96e-5	Coronary artery calcification;
THYM	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg23131131	chr22:24373011	LOC391322	-0.8	-7.79	-0.62	8.15e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg10505658	chr17:80084571	CCDC57	-0.69	-7.95	-0.63	3.85e-12	Life satisfaction;
THYM	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.88	0.63	5.43e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2340727	0.524	rs6693980	chr1:161943202	A/G	cg06514368	chr1:161719587	DUSP12	0.62	4.49	0.42	1.97e-5	White blood cell count;Hematology traits;
THYM	trans	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs1499972	0.941	rs817508	chr3:117685576	T/C	cg07612923	chr3:117604196	NA	-1.42	-5.49	-0.49	3.4e-7	Schizophrenia;
THYM	cis	rs3885907	0.870	rs9315038	chr13:31293780	G/T	cg19953038	chr13:31306303	NA	0.69	5.72	0.51	1.22e-7	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
THYM	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg02082929	chr2:109068933	GCC2	0.65	6.32	0.54	8.35e-9	Mean platelet volume;
THYM	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg21427119	chr20:30132790	HM13	-0.68	-4.77	-0.44	6.72e-6	Mean corpuscular hemoglobin;
THYM	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.99	-0.75	1.26e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg00256281	chr22:41985642	PMM1	-0.58	-4.86	-0.45	4.7e-6	Vitiligo;
THYM	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg00898013	chr13:113819073	PROZ	-0.87	-8.78	-0.67	6.82e-14	Platelet distribution width;
THYM	cis	rs7258465	1.000	rs7252707	chr19:18612257	G/A	cg04166595	chr19:18636596	NA	0.61	4.56	0.42	1.53e-5	Breast cancer;
THYM	cis	rs7794273	0.963	rs2520354	chr7:18854050	G/A	cg13420273	chr7:18810212	HDAC9	0.54	4.47	0.42	2.15e-5	Night sleep phenotypes;
THYM	cis	rs9359856	0.564	rs72915918	chr6:90430792	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs13102973	0.640	rs6833827	chr4:135839731	T/C	cg14419869	chr4:135874104	NA	0.72	5.86	0.51	6.78e-8	Subjective well-being;
THYM	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg00256281	chr22:41985642	PMM1	-0.62	-4.67	-0.43	9.91e-6	Vitiligo;
THYM	cis	rs9837602	0.882	rs9875664	chr3:99729130	C/T	cg00175735	chr3:99903386	TMEM30C	-0.77	-4.63	-0.43	1.15e-5	Breast cancer;
THYM	cis	rs2235642	0.533	rs9922661	chr16:1605163	C/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.59	-5.75	-0.51	1.06e-7	Coronary artery disease;
THYM	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg06636001	chr8:8085503	FLJ10661	0.62	5.35	0.48	6.07e-7	Neuroticism;
THYM	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg00999904	chr2:3704751	ALLC	0.72	4.79	0.44	6.22e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs6728642	0.908	rs11901495	chr2:98017804	A/G	cg26665480	chr2:98280029	ACTR1B	0.78	5.09	0.46	1.83e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs6988636	1.000	rs62521841	chr8:124194625	G/A	cg23067535	chr8:124195133	FAM83A	-1.06	-5.55	-0.49	2.61e-7	Urinary uromodulin levels;
THYM	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg22920501	chr2:26401640	FAM59B	-0.68	-5.72	-0.51	1.24e-7	Gut microbiome composition (summer);
THYM	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg13852791	chr20:30311386	BCL2L1	-0.88	-7.22	-0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.62	-5.39	-0.48	5.14e-7	Height;
THYM	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg08807101	chr21:30365312	RNF160	-0.97	-7.58	-0.61	2.29e-11	Dental caries;
THYM	cis	rs2073300	1.000	rs6132622	chr20:23442240	A/T	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs981844	0.857	rs62325142	chr4:154717790	A/G	cg09973105	chr4:154681532	RNF175	-0.67	-5.58	-0.5	2.25e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs2932538	0.961	rs6537747	chr1:113179597	C/T	cg22162597	chr1:113214053	CAPZA1	-0.63	-5.21	-0.47	1.08e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg23711669	chr6:146136114	FBXO30	-0.97	-10.49	-0.73	1.45e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg12031863	chr16:4587854	C16orf5	0.44	4.8	0.44	5.81e-6	Schizophrenia;
THYM	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03517284	chr6:25882590	NA	-0.99	-9.66	-0.7	8.77e-16	Intelligence (multi-trait analysis);
THYM	cis	rs995000	0.931	rs1168098	chr1:63121294	G/A	cg06896770	chr1:63153194	DOCK7	-0.92	-7.54	-0.61	2.71e-11	Triglyceride levels;
THYM	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg16414030	chr3:133502952	NA	-0.94	-9.35	-0.69	4.11e-15	Iron status biomarkers;
THYM	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg17173187	chr15:85201210	NMB	0.54	5.31	0.48	7.33e-7	Schizophrenia;
THYM	cis	rs8033133	0.706	rs12594112	chr15:25350127	A/C	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.64	-4.69	-0.43	9.11e-6	Blood osmolality (transformed sodium);
THYM	cis	rs17443541	0.507	rs2122534	chr2:200459294	C/G	cg01795955	chr2:200468626	NA	-0.72	-5.0	-0.46	2.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs885814	0.959	rs12135465	chr1:21867600	C/T	cg14781605	chr1:21864896	ALPL	-0.68	-5.11	-0.46	1.65e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs6748734	0.857	rs4675857	chr2:241842326	T/C	cg07537917	chr2:241836409	C2orf54	-0.28	-6.47	-0.55	4.22e-9	Urinary metabolites;
THYM	cis	rs863345	0.604	rs7518708	chr1:158504274	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs9807989	0.507	rs1592459	chr2:103031569	A/G	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg21226059	chr5:178986404	RUFY1	-0.61	-6.97	-0.58	4.14e-10	Lung cancer;
THYM	cis	rs9788721	1.000	rs8034191	chr15:78806023	A/G	cg18825076	chr15:78729989	IREB2	-0.6	-5.36	-0.48	5.92e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg27446573	chr6:127587934	RNF146	1.04	9.87	0.71	3.12e-16	Breast cancer;
THYM	cis	rs6960043	0.818	rs10487796	chr7:15063430	T/A	cg19272540	chr7:15055459	NA	0.44	4.86	0.45	4.56e-6	Type 2 diabetes;
THYM	trans	rs4650994	1.000	rs4650993	chr1:178515187	A/G	cg05059571	chr16:84539110	KIAA1609	-0.75	-7.95	-0.63	3.83e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg22907277	chr7:1156413	C7orf50	0.58	4.92	0.45	3.56e-6	Longevity;Endometriosis;
THYM	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.15	8.37	0.65	4.99e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs72781680	1.000	rs6751655	chr2:24155478	A/G	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs262150	0.501	rs1062610	chr7:158821175	C/T	cg19418458	chr7:158789849	NA	-0.62	-5.88	-0.52	6.1e-8	Facial morphology (factor 20);
THYM	cis	rs10489202	0.683	rs2294817	chr1:168073601	C/A	cg24449463	chr1:168025552	DCAF6	-0.7	-6.06	-0.53	2.77e-8	Schizophrenia;
THYM	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg17105886	chr17:28927953	LRRC37B2	1.25	6.76	0.57	1.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg16230307	chr14:35515116	FAM177A1	0.87	5.56	0.5	2.47e-7	Psoriasis;
THYM	cis	rs870825	0.616	rs4623060	chr4:185642943	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.69	0.71	7.45e-16	Blood protein levels;
THYM	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg22974920	chr21:40686053	BRWD1	-0.59	-4.64	-0.43	1.13e-5	Cognitive function;
THYM	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.95	7.44	0.61	4.54e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12137294	0.634	rs1172132	chr1:205242901	A/G	cg17889831	chr1:205181581	DSTYK	-0.4	-4.92	-0.45	3.57e-6	Red cell distribution width;
THYM	cis	rs10752881	0.935	rs4652771	chr1:183023503	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Colorectal cancer;
THYM	cis	rs931812	0.825	rs34235568	chr8:101895761	C/T	cg07239293	chr8:101170671	SPAG1	0.69	4.75	0.44	7.11e-6	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg07157834	chr1:205819609	PM20D1	-0.55	-4.5	-0.42	1.94e-5	Prostate-specific antigen levels;
THYM	cis	rs490234	0.775	rs12341245	chr9:128340941	C/T	cg14078157	chr9:128172775	NA	-0.65	-4.96	-0.45	3.07e-6	Mean arterial pressure;
THYM	cis	rs3741151	0.686	rs7118982	chr11:73110668	T/C	cg12959048	chr11:73096162	RELT	-0.46	-4.84	-0.45	4.94e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs684232	0.583	rs2657626	chr17:603052	A/G	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.39	-4.72	-0.44	8.25e-6	Prostate cancer;
THYM	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg26384229	chr12:38710491	ALG10B	1.03	10.41	0.73	2.18e-17	Heart rate;
THYM	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg17264618	chr3:40429014	ENTPD3	0.52	4.95	0.45	3.22e-6	Renal cell carcinoma;
THYM	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg09033563	chr22:24373618	LOC391322	-0.56	-4.56	-0.42	1.52e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7940866	0.838	rs12790299	chr11:130803634	A/G	cg05962950	chr11:130786565	SNX19	0.78	6.31	0.54	8.98e-9	Schizophrenia;
THYM	cis	rs9677476	0.863	rs10202295	chr2:232084411	T/G	cg07929768	chr2:232055508	NA	0.59	6.03	0.53	3.09e-8	Food antigen IgG levels;
THYM	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.76	6.74	0.57	1.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03517284	chr6:25882590	NA	-0.83	-6.74	-0.57	1.23e-9	Intelligence (multi-trait analysis);
THYM	cis	rs13380717	0.774	rs34528289	chr16:86907297	C/T	cg05661093	chr16:86825505	NA	-0.54	-4.7	-0.43	8.86e-6	Sepsis in extremely premature infants;
THYM	cis	rs6964587	0.839	rs62466159	chr7:91450507	A/G	cg22709100	chr7:91322751	NA	0.68	5.07	0.46	1.97e-6	Breast cancer;
THYM	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg03351412	chr1:154909251	PMVK	0.7	5.38	0.48	5.4e-7	Prostate cancer;
THYM	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg08000102	chr2:233561755	GIGYF2	-0.54	-4.87	-0.45	4.52e-6	Coronary artery disease;
THYM	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.76	-0.44	6.97e-6	Mean corpuscular volume;
THYM	cis	rs7107174	0.792	rs10899488	chr11:78088754	A/G	cg02023728	chr11:77925099	USP35	0.6	5.55	0.49	2.6e-7	Testicular germ cell tumor;
THYM	cis	rs2458413	0.521	rs2458427	chr8:105339594	G/T	cg23108931	chr8:105342351	NA	-0.33	-5.93	-0.52	4.87e-8	Paget's disease;
THYM	cis	rs2404602	0.735	rs2454454	chr15:76823647	A/G	cg23625390	chr15:77176239	SCAPER	-0.57	-4.51	-0.42	1.83e-5	Blood metabolite levels;
THYM	cis	rs4642101	0.855	rs9836128	chr3:12845426	G/C	cg05775895	chr3:12838266	CAND2	0.94	8.62	0.66	1.49e-13	QRS complex (12-leadsum);
THYM	cis	rs977987	0.806	rs2285225	chr16:75429252	T/C	cg03315344	chr16:75512273	CHST6	0.73	6.16	0.53	1.73e-8	Dupuytren's disease;
THYM	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg26924012	chr15:45694286	SPATA5L1	1.0	9.44	0.7	2.65e-15	Homoarginine levels;
THYM	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg18252515	chr7:66147081	NA	-0.71	-5.67	-0.5	1.56e-7	Aortic root size;
THYM	cis	rs6987853	0.787	rs1343874	chr8:42424746	C/T	cg09913449	chr8:42400586	C8orf40	1.06	10.94	0.75	1.68e-18	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2276314	0.857	rs59649576	chr18:33616075	G/T	cg05985134	chr18:33552581	C18orf21	0.66	4.84	0.44	5.02e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7084402	0.967	rs1614258	chr10:60308407	C/T	cg07615347	chr10:60278583	BICC1	0.56	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs4631830	0.695	rs11004584	chr10:51500088	G/T	cg16070123	chr10:51489643	NA	-0.53	-4.83	-0.44	5.16e-6	Prostate-specific antigen levels;
THYM	cis	rs728616	0.867	rs61860044	chr10:81946538	C/G	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg17074396	chr22:49843754	NA	-0.39	-4.47	-0.42	2.15e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs35934224	0.724	rs16984286	chr22:19858114	A/G	cg11182965	chr22:19864308	TXNRD2	-0.68	-5.58	-0.5	2.3e-7	Glaucoma (primary open-angle);
THYM	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg04043695	chr12:129287642	SLC15A4	0.6	4.83	0.44	5.27e-6	Systemic lupus erythematosus;
THYM	cis	rs11190604	0.767	rs11190533	chr10:102190792	T/C	cg07570687	chr10:102243282	WNT8B	0.85	8.46	0.66	3.16e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs3820068	0.532	rs1547034	chr1:15919049	T/A	cg24675056	chr1:15929824	NA	0.75	5.99	0.52	3.67e-8	Systolic blood pressure;
THYM	cis	rs12282928	1.000	rs12282928	chr11:48332028	A/G	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg00981070	chr1:2046702	PRKCZ	-0.47	-5.57	-0.5	2.4e-7	Height;
THYM	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg08999081	chr20:33150536	PIGU	0.73	6.56	0.56	2.86e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs7809950	1.000	rs7778270	chr7:107224667	A/G	cg23024343	chr7:107201750	COG5	0.9	8.13	0.64	1.57e-12	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg13695892	chr22:41940480	POLR3H	-1.0	-7.69	-0.62	1.37e-11	Vitiligo;
THYM	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg12560992	chr17:57184187	TRIM37	0.93	8.57	0.66	1.83e-13	Intelligence (multi-trait analysis);
THYM	cis	rs61990749	0.597	rs176952	chr14:78180736	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.02	0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs66887589	0.837	rs7661498	chr4:120408108	T/C	cg13609457	chr4:120235615	NA	0.47	4.88	0.45	4.3e-6	Diastolic blood pressure;
THYM	cis	rs754466	0.580	rs10762765	chr10:79566407	T/C	cg17075019	chr10:79541650	NA	-0.63	-5.06	-0.46	2.01e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg20242066	chr2:136595261	LCT	-0.58	-7.42	-0.61	4.87e-11	Mosquito bite size;
THYM	cis	rs1497406	0.744	rs6690317	chr1:16516585	T/C	cg20430773	chr1:16534157	ARHGEF19	0.42	4.63	0.43	1.15e-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg07424592	chr7:64974309	NA	1.03	5.4	0.48	4.94e-7	Diabetic kidney disease;
THYM	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg24209194	chr3:40518798	ZNF619	0.75	6.36	0.55	7.13e-9	Renal cell carcinoma;
THYM	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg02136620	chr5:178986620	RUFY1	-0.6	-6.03	-0.53	3.1e-8	Lung cancer;
THYM	cis	rs2439831	0.867	rs486301	chr15:43836949	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	6.36	0.55	6.96e-9	Lung cancer in ever smokers;
THYM	cis	rs11971779	0.938	rs11981688	chr7:139088895	A/G	cg07862535	chr7:139043722	LUC7L2	0.66	4.47	0.42	2.2e-5	Diisocyanate-induced asthma;
THYM	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg20203395	chr5:56204925	C5orf35	0.69	4.65	0.43	1.05e-5	Initial pursuit acceleration;
THYM	cis	rs6596100	0.500	rs58840150	chr5:132248041	A/G	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Breast cancer;
THYM	cis	rs9311676	0.656	rs62258081	chr3:58367705	A/C	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	trans	rs2136093	0.600	rs12126859	chr1:90907842	G/T	cg21057494	chr3:45066971	CLEC3B	0.52	7.16	0.59	1.68e-10	Response to antidepressants;
THYM	cis	rs67311347	0.544	rs13097602	chr3:40339247	T/C	cg24209194	chr3:40518798	ZNF619	-0.57	-4.91	-0.45	3.81e-6	Renal cell carcinoma;
THYM	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg18352616	chr4:3374830	RGS12	0.75	7.91	0.63	4.65e-12	Serum sulfate level;
THYM	cis	rs61931739	0.817	rs11053071	chr12:34201400	A/G	cg10856724	chr12:34555212	NA	-0.6	-5.47	-0.49	3.6e-7	Morning vs. evening chronotype;
THYM	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg24642844	chr7:1081250	C7orf50	-1.29	-8.3	-0.65	7.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg13683864	chr3:40499215	RPL14	1.08	12.78	0.8	2.33e-22	Renal cell carcinoma;
THYM	cis	rs1371867	0.846	rs1660324	chr8:101281271	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-4.79	-0.44	6.22e-6	Atrioventricular conduction;
THYM	cis	rs2219968	1.000	rs13276123	chr8:78975338	G/A	cg00738934	chr8:78996279	NA	0.92	10.06	0.72	1.2e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3825942	1.000	rs1078967	chr15:74222987	C/T	cg23484268	chr15:74220776	LOXL1	0.5	4.81	0.44	5.74e-6	Glaucoma (exfoliation);
THYM	cis	rs11608355	0.597	rs10850070	chr12:109793882	A/G	cg10504392	chr12:110044639	NA	0.54	4.91	0.45	3.73e-6	Neuroticism;
THYM	cis	rs4866334	1.000	rs116117462	chr5:18452827	C/A	cg04591469	chr5:17810299	NA	-1.12	-4.54	-0.42	1.65e-5	IgG glycosylation;
THYM	cis	rs2354432	1.000	rs7514864	chr1:146690102	T/C	cg25205988	chr1:146714368	CHD1L	1.1	7.31	0.6	8.32e-11	Mitochondrial DNA levels;
THYM	cis	rs36051895	0.623	rs12720	chr9:5231712	T/A	cg02405213	chr9:5042618	JAK2	-0.93	-9.68	-0.7	7.79e-16	Pediatric autoimmune diseases;
THYM	cis	rs76935404	0.811	rs11083589	chr19:41428416	A/T	cg19493303	chr19:41414353	NA	0.58	5.1	0.46	1.77e-6	nicotine metabolite ratio in current smokers;
THYM	cis	rs73086581	0.787	rs68127408	chr20:3868447	T/C	cg02187196	chr20:3869020	PANK2	0.47	5.04	0.46	2.23e-6	Response to antidepressants in depression;
THYM	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.63	-4.85	-0.45	4.77e-6	Longevity;Endometriosis;
THYM	cis	rs6840360	0.558	rs2709821	chr4:152342190	C/T	cg17479576	chr4:152424074	FAM160A1	-0.72	-5.67	-0.5	1.53e-7	Intelligence (multi-trait analysis);
THYM	trans	rs1973993	0.967	rs1555543	chr1:96944797	A/C	cg10631902	chr5:14652156	NA	0.63	7.05	0.59	2.8e-10	Weight;
THYM	cis	rs6127978	0.702	rs6127980	chr20:55823762	C/T	cg15851418	chr20:55835831	BMP7	0.68	4.66	0.43	1.03e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg11871910	chr12:69753446	YEATS4	-0.99	-9.43	-0.7	2.67e-15	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6032067	0.777	rs34163611	chr20:43778990	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.41	-0.65	4.05e-13	Blood protein levels;
THYM	cis	rs2404602	0.647	rs907593	chr15:77196953	G/A	cg23625390	chr15:77176239	SCAPER	-0.85	-5.75	-0.51	1.07e-7	Blood metabolite levels;
THYM	cis	rs17019602	0.666	rs12036368	chr1:108159901	T/C	cg02990361	chr1:107599529	PRMT6	0.84	5.0	0.46	2.58e-6	IgA nephropathy;
THYM	cis	rs924712	0.644	rs2134539	chr6:54858234	C/T	cg04690482	chr6:54711388	FAM83B	-0.45	-5.29	-0.48	7.92e-7	Breast cancer;
THYM	cis	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg07460842	chr6:66804631	NA	1.11	8.22	0.64	1.06e-12	Exhaled nitric oxide output;
THYM	cis	rs72627123	0.867	rs112965033	chr14:74461117	T/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg13411962	chr8:28243934	ZNF395	-1.02	-7.49	-0.61	3.45e-11	Depressive symptoms;
THYM	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg08859206	chr1:53392774	SCP2	-0.5	-5.26	-0.48	8.81e-7	Monocyte count;
THYM	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg06558623	chr16:89946397	TCF25	1.33	5.65	0.5	1.64e-7	Skin colour saturation;
THYM	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs79149102	0.579	rs6495146	chr15:75367630	A/T	cg09165964	chr15:75287851	SCAMP5	-0.87	-4.89	-0.45	4.07e-6	Lung cancer;
THYM	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg17757837	chr7:157058334	UBE3C	0.65	5.24	0.47	9.83e-7	Body mass index;
THYM	cis	rs138544659	1	rs138544659	chr15:78900701	T/G	cg18825076	chr15:78729989	IREB2	-0.55	-5.04	-0.46	2.26e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs9359856	0.564	rs41273329	chr6:90393483	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3820068	0.580	rs36100011	chr1:16046920	C/T	cg24675056	chr1:15929824	NA	0.76	6.12	0.53	2.08e-8	Systolic blood pressure;
THYM	cis	rs9296092	0.517	rs56069946	chr6:33511136	G/A	cg13560919	chr6:33536144	NA	-0.89	-7.69	-0.62	1.32e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg06481639	chr22:41940642	POLR3H	-0.57	-4.46	-0.42	2.27e-5	Vitiligo;
THYM	cis	rs9443645	0.527	rs9343870	chr6:79789473	T/G	cg05283184	chr6:79620031	NA	-0.6	-4.67	-0.43	9.91e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg15164180	chr2:241846931	NA	-0.37	-4.96	-0.45	3.07e-6	Urinary metabolites;
THYM	cis	rs28595532	0.920	rs114792862	chr4:119759938	G/A	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs870825	0.616	rs7667449	chr4:185641711	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.69	0.71	7.45e-16	Blood protein levels;
THYM	cis	rs3916	0.911	rs34673751	chr12:121171891	G/A	cg10600917	chr12:121163489	ACADS	0.59	5.0	0.46	2.59e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs3780378	0.967	rs12339774	chr9:5045916	C/T	cg02405213	chr9:5042618	JAK2	-0.78	-7.34	-0.6	7.17e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs7119	0.931	rs59418918	chr15:77833110	A/C	cg27398640	chr15:77910606	LINGO1	-0.55	-5.42	-0.49	4.55e-7	Type 2 diabetes;
THYM	trans	rs10462794	0.789	rs7719895	chr5:4490338	C/T	cg00733288	chr13:111358885	CARS2	-1.17	-6.97	-0.58	4.24e-10	DNA methylation (variation);
THYM	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg21385522	chr1:16154831	NA	0.78	5.97	0.52	4e-8	Dilated cardiomyopathy;
THYM	cis	rs1003719	0.762	rs11088381	chr21:38478429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg01616529	chr11:638424	DRD4	-0.78	-6.62	-0.56	2.16e-9	Systemic lupus erythematosus;
THYM	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg04518342	chr5:131593106	PDLIM4	0.58	6.54	0.56	3.04e-9	Acylcarnitine levels;
THYM	cis	rs7705502	1.000	rs17695555	chr5:173351081	C/T	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg05373962	chr22:49881684	NA	-0.6	-5.74	-0.51	1.12e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg27490568	chr2:178487706	NA	0.57	5.36	0.48	5.7e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg19016782	chr12:123741754	C12orf65	-0.69	-4.47	-0.42	2.18e-5	Neutrophil percentage of white cells;
THYM	trans	rs75518195	0.572	rs62302807	chr4:64723119	C/G	cg14706739	chr8:21916355	EPB49	0.75	7.28	0.6	9.73e-11	Triptolide cytotoxicity;
THYM	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg26384229	chr12:38710491	ALG10B	0.89	6.74	0.57	1.24e-9	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11644478	chr21:40555479	PSMG1	-0.54	-4.53	-0.42	1.72e-5	Menarche (age at onset);
THYM	cis	rs35264875	0.950	rs35337391	chr11:68854012	A/G	cg23845249	chr11:68861649	NA	0.56	6.56	0.56	2.84e-9	Blond vs. brown hair color;
THYM	cis	rs2074409	0.509	rs853193	chr17:35823113	G/A	cg06716730	chr17:35851459	DUSP14	0.29	4.5	0.42	1.9e-5	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.04	-7.12	-0.59	2.06e-10	Platelet count;
THYM	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg18681998	chr4:17616180	MED28	0.79	6.67	0.56	1.66e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs8067545	0.611	rs2703788	chr17:20159686	T/C	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs7264396	0.635	rs6060720	chr20:34548336	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-4.8	-0.44	6.01e-6	Total cholesterol levels;
THYM	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg00686598	chr14:53173677	PSMC6	1.52	7.73	0.62	1.09e-11	Alzheimer's disease (late onset);
THYM	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg04267008	chr7:1944627	MAD1L1	-0.66	-5.45	-0.49	3.89e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg24503407	chr1:205819492	PM20D1	0.96	9.18	0.69	9.34e-15	Menarche (age at onset);
THYM	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.45	7.4	0.6	5.4e-11	Obesity-related traits;
THYM	cis	rs2820651	0.614	rs56203704	chr10:1490143	G/A	cg27404824	chr10:1454848	ADARB2	0.88	4.74	0.44	7.37e-6	Migraine with aura;
THYM	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg00801512	chr17:28996047	NA	-0.88	-5.73	-0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3804749	1.000	rs3804749	chr3:122833003	A/G	cg10259872	chr3:122802215	PDIA5	-0.48	-5.17	-0.47	1.3e-6	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs11645898	0.748	rs3852785	chr16:72198642	G/A	cg03805757	chr16:71968109	PKD1L3	-0.78	-5.86	-0.52	6.72e-8	Blood protein levels;
THYM	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	9.76	0.71	5.3e-16	Platelet count;
THYM	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg26314531	chr2:26401878	FAM59B	0.78	5.13	0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs34526934	0.566	rs62624470	chr2:177040907	C/T	cg14324370	chr2:177042789	NA	-0.68	-5.92	-0.52	5.11e-8	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs12410462	1.000	rs6672162	chr1:227632335	G/A	cg04117972	chr1:227635322	NA	0.71	4.8	0.44	5.85e-6	Major depressive disorder;
THYM	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg15704280	chr7:45808275	SEPT13	-0.78	-7.17	-0.59	1.6e-10	Coronary artery disease;
THYM	cis	rs988913	0.706	rs7453866	chr6:54753626	A/C	cg04690482	chr6:54711388	FAM83B	0.52	6.3	0.54	9.33e-9	Menarche (age at onset);
THYM	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg17366294	chr4:99064904	C4orf37	0.45	4.95	0.45	3.24e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10498870	0.534	rs3805956	chr6:70596935	A/C	cg03001484	chr6:70507230	LMBRD1	0.29	4.74	0.44	7.58e-6	Subjective well-being (multi-trait analysis);
THYM	cis	rs75059851	0.756	rs2000852	chr11:133838221	C/T	cg14047540	chr11:133829660	NA	-1.1	-7.34	-0.6	7.1e-11	Schizophrenia;
THYM	cis	rs7107174	0.748	rs7105835	chr11:78075725	T/C	cg19901956	chr11:77921274	USP35	-0.62	-5.04	-0.46	2.2e-6	Testicular germ cell tumor;
THYM	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg09455208	chr3:40491958	NA	0.46	4.87	0.45	4.42e-6	Renal cell carcinoma;
THYM	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg12893697	chr11:970389	AP2A2	-0.33	-5.52	-0.49	2.92e-7	Alzheimer's disease (late onset);
THYM	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs11650494	0.901	rs74659133	chr17:47336931	C/T	cg08112188	chr17:47440006	ZNF652	1.2	4.94	0.45	3.37e-6	Prostate cancer;
THYM	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg06766960	chr11:133703094	NA	-0.61	-5.52	-0.49	2.94e-7	Childhood ear infection;
THYM	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg13175981	chr1:150552382	MCL1	0.81	6.23	0.54	1.25e-8	Tonsillectomy;
THYM	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg22974920	chr21:40686053	BRWD1	-0.62	-4.95	-0.45	3.22e-6	Cognitive function;
THYM	cis	rs2976388	0.609	rs2717605	chr8:143801015	T/G	cg13446199	chr8:143762866	PSCA	-0.41	-4.54	-0.42	1.67e-5	Urinary tract infection frequency;
THYM	cis	rs995000	0.931	rs61471917	chr1:63084030	G/A	cg06896770	chr1:63153194	DOCK7	0.92	7.57	0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs9733	0.596	rs12089989	chr1:150715782	G/A	cg09034736	chr1:150693464	HORMAD1	0.5	4.51	0.42	1.86e-5	Tonsillectomy;
THYM	cis	rs539096	0.500	rs2527776	chr1:44345292	G/A	cg13246856	chr1:44399776	ARTN	0.49	4.95	0.45	3.26e-6	Intelligence (multi-trait analysis);
THYM	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg11247378	chr22:39784982	NA	1.01	10.93	0.75	1.71e-18	Intelligence (multi-trait analysis);
THYM	cis	rs4595586	0.545	rs3914596	chr12:39388538	T/C	cg26384229	chr12:38710491	ALG10B	0.69	5.19	0.47	1.18e-6	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg25811766	chr13:21894605	NA	-0.77	-4.99	-0.46	2.77e-6	White matter hyperintensity burden;
THYM	cis	rs9326248	0.861	rs7931335	chr11:117036805	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.67	4.78	0.44	6.35e-6	Blood protein levels;
THYM	cis	rs7072216	0.806	rs9804285	chr10:100169472	C/T	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs10158481	0.759	rs926461	chr1:25486203	A/G	cg09264742	chr1:25757510	TMEM57	0.65	4.65	0.43	1.07e-5	Urate levels in obese individuals;
THYM	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg05347473	chr6:146136440	FBXO30	0.6	4.86	0.45	4.66e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg02038168	chr22:39784481	NA	-0.65	-4.93	-0.45	3.46e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg19442545	chr10:75533431	FUT11	0.58	6.08	0.53	2.52e-8	Inflammatory bowel disease;
THYM	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg18758796	chr5:131593413	PDLIM4	0.5	4.8	0.44	5.79e-6	Breast cancer;
THYM	cis	rs524023	0.914	rs11231845	chr11:64407419	G/A	cg19131476	chr11:64387923	NRXN2	-0.39	-5.54	-0.49	2.7e-7	Urate levels in obese individuals;
THYM	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg15744005	chr10:104629667	AS3MT	-0.8	-7.6	-0.61	2.08e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg08883853	chr7:1026168	CYP2W1	-0.45	-5.02	-0.46	2.42e-6	Longevity;Endometriosis;
THYM	cis	rs919433	0.680	rs788021	chr2:198293691	T/C	cg05783139	chr2:198650985	BOLL	0.63	4.93	0.45	3.48e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs12282928	0.917	rs7115127	chr11:48275890	T/C	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.72	0.51	1.23e-7	Lung cancer in ever smokers;
THYM	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg22907277	chr7:1156413	C7orf50	0.93	9.44	0.7	2.62e-15	Longevity;Endometriosis;
THYM	cis	rs988913	0.736	rs9367607	chr6:54932457	A/C	cg18532076	chr6:54711417	FAM83B	0.49	4.62	0.43	1.18e-5	Menarche (age at onset);
THYM	cis	rs1079204	1.000	rs57616694	chr2:219051496	A/T	cg05728596	chr2:219128475	GPBAR1	1.01	4.62	0.43	1.22e-5	Smooth-surface caries;
THYM	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg15691649	chr6:25882328	NA	-0.79	-6.05	-0.53	2.8e-8	Intelligence (multi-trait analysis);
THYM	cis	rs36051895	0.659	rs67006981	chr9:5070401	A/G	cg02405213	chr9:5042618	JAK2	-1.01	-11.29	-0.76	2.97e-19	Pediatric autoimmune diseases;
THYM	cis	rs470093	0.932	rs138079	chr22:44239499	A/G	cg09142166	chr22:44276013	PNPLA5	-0.6	-5.77	-0.51	9.87e-8	Staphylococcus aureus infection;
THYM	cis	rs13064411	0.696	rs6783965	chr3:113198722	C/T	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs4595586	0.545	rs12820138	chr12:39357049	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs34779708	0.966	rs10508816	chr10:35459976	G/A	cg03585969	chr10:35415529	CREM	0.67	5.01	0.46	2.51e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs4499344	0.526	rs17832981	chr19:33034461	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.65	4.45	0.42	2.36e-5	Mean platelet volume;
THYM	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg06238570	chr21:40685208	BRWD1	-0.72	-6.28	-0.54	9.9e-9	Menarche (age at onset);
THYM	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4833407	0.593	rs4833406	chr4:113304812	G/A	cg25935669	chr4:113448283	NA	-0.5	-4.58	-0.43	1.39e-5	Obesity;
THYM	cis	rs950776	0.752	rs7182583	chr15:78899210	G/C	cg06917634	chr15:78832804	PSMA4	0.83	6.98	0.58	3.91e-10	Sudden cardiac arrest;
THYM	cis	rs6430585	0.528	rs309119	chr2:136710372	T/C	cg20242066	chr2:136595261	LCT	0.56	5.82	0.51	7.85e-8	Corneal structure;
THYM	cis	rs79349575	0.721	rs9904645	chr17:46969665	A/T	cg26022315	chr17:47021804	SNF8	0.48	4.49	0.42	2e-5	Type 2 diabetes;
THYM	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-4.93	-0.45	3.51e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2806561	0.578	rs6702719	chr1:23302576	T/C	cg19743168	chr1:23544995	NA	0.49	4.7	0.43	8.64e-6	Height;
THYM	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs854765	0.929	rs2955360	chr17:17974887	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-4.93	-0.45	3.5e-6	Total body bone mineral density;
THYM	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg23758822	chr17:41437982	NA	1.2	11.6	0.77	6.75e-20	Menopause (age at onset);
THYM	cis	rs56104184	0.887	rs16982311	chr19:49342188	C/T	cg19024700	chr19:49340765	PLEKHA4;HSD17B14	0.64	4.75	0.44	7.09e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs6099847	0.685	rs17433555	chr20:56489648	A/G	cg03401480	chr20:57087179	APCDD1L	-0.87	-4.68	-0.43	9.49e-6	Obesity-related traits;
THYM	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg24060327	chr5:131705240	SLC22A5	0.8	6.52	0.56	3.35e-9	Breast cancer;
THYM	cis	rs8030485	0.679	rs7173995	chr15:79413534	C/G	cg17916960	chr15:79447300	NA	0.5	4.79	0.44	6.08e-6	Left ventricle wall thickness;
THYM	cis	rs11997175	0.583	rs12680755	chr8:33815282	G/A	ch.8.33884649F	chr8:33765107	NA	0.75	5.39	0.48	5.09e-7	Body mass index;
THYM	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg04082016	chr2:20871401	NA	-0.79	-6.4	-0.55	5.73e-9	Abdominal aortic aneurysm;
THYM	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg13319975	chr6:146136371	FBXO30	0.67	5.5	0.49	3.15e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg07537917	chr2:241836409	C2orf54	-0.27	-6.41	-0.55	5.57e-9	Urinary metabolites;
THYM	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg26384229	chr12:38710491	ALG10B	0.94	7.9	0.63	4.92e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs13315871	1.000	rs9824965	chr3:58433505	T/A	cg12435725	chr3:58293450	RPP14	-0.46	-4.93	-0.45	3.54e-6	Cholesterol, total;
THYM	cis	rs7119038	0.774	rs874621	chr11:118655645	G/A	cg19308663	chr11:118741387	NA	0.59	5.88	0.52	6.14e-8	Sjögren's syndrome;
THYM	cis	rs4280164	0.551	rs3212260	chr14:24804088	A/T	cg18846074	chr14:24801073	ADCY4	-0.61	-4.81	-0.44	5.6e-6	Parent of origin effect on language impairment (paternal);
THYM	cis	rs6815814	0.950	rs73236632	chr4:38836071	G/A	cg14665413	chr4:38859728	TLR6	-0.41	-4.87	-0.45	4.51e-6	Breast cancer;
THYM	cis	rs9906944	0.707	rs1523136	chr17:47144532	A/G	cg14634687	chr17:47094252	IGF2BP1	0.31	4.77	0.44	6.72e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs860818	1.000	rs860817	chr7:23251469	G/A	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs7586879	0.609	rs7608976	chr2:25075281	G/A	cg27107076	chr2:25050844	ADCY3	-0.3	-4.76	-0.44	6.88e-6	Body mass index;
THYM	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs13191362	0.573	rs1877769	chr6:163252315	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.76	5.66	0.5	1.61e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	7.35	0.6	6.79e-11	Platelet count;
THYM	cis	rs59698941	0.943	rs67843388	chr5:132288007	C/T	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Body mass index;
THYM	cis	rs7843479	0.601	rs10453141	chr8:21847235	T/C	cg17168535	chr8:21777572	XPO7	0.84	7.34	0.6	7.09e-11	Mean corpuscular volume;
THYM	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg01579765	chr21:45077557	HSF2BP	-0.47	-7.4	-0.6	5.4e-11	Mean corpuscular volume;
THYM	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg24209194	chr3:40518798	ZNF619	-0.6	-4.88	-0.45	4.24e-6	Renal cell carcinoma;
THYM	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg13402656	chr8:1511478	DLGAP2	-0.79	-7.77	-0.62	9.15e-12	Lung cancer;
THYM	cis	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.59	-0.43	1.37e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6754311	0.773	rs309130	chr2:136631031	C/A	cg04750100	chr2:136595281	LCT	-0.56	-6.13	-0.53	1.97e-8	Mosquito bite size;
THYM	cis	rs7178572	0.568	rs11857294	chr15:77596725	C/T	cg22256960	chr15:77711686	NA	-1.03	-8.45	-0.66	3.3e-13	Type 2 diabetes;
THYM	cis	rs79149102	0.579	rs7182286	chr15:75293839	A/G	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	cis	rs4481887	1.000	rs4306162	chr1:248468509	C/T	cg13385794	chr1:248469461	NA	0.65	4.66	0.43	1.04e-5	Common traits (Other);
THYM	cis	rs7113850	0.541	rs7131336	chr11:24219418	C/T	ch.11.24196551F	chr11:24239977	NA	0.86	4.57	0.42	1.46e-5	Bone fracture in osteoporosis;
THYM	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg13319975	chr6:146136371	FBXO30	-0.63	-5.02	-0.46	2.43e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7961581	0.748	rs1798078	chr12:71595123	A/T	cg00603625	chr12:70636487	CNOT2	-0.74	-4.45	-0.42	2.29e-5	Type 2 diabetes;
THYM	cis	rs1784581	0.588	rs6415086	chr6:162418147	C/T	cg17173639	chr6:162384350	PARK2	0.81	7.48	0.61	3.75e-11	Itch intensity from mosquito bite;
THYM	cis	rs985746	0.614	rs10013184	chr4:36809918	C/T	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs539096	0.874	rs2842175	chr1:44023615	G/A	cg00143623	chr1:44495758	SLC6A9	-0.62	-4.8	-0.44	5.85e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8101881	0.576	rs12462086	chr19:33359079	T/G	cg05467458	chr19:33361032	SLC7A9	0.57	5.21	0.47	1.09e-6	Blood metabolite levels;Urinary metabolites;Urinary metabolites (H-NMR features);
THYM	cis	rs6964587	0.626	rs10234074	chr7:91520119	C/T	cg22709100	chr7:91322751	NA	-0.62	-4.67	-0.43	9.72e-6	Breast cancer;
THYM	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg27532560	chr4:187881888	NA	-0.96	-11.4	-0.76	1.72e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11608355	0.618	rs2075435	chr12:109796832	C/T	cg10504392	chr12:110044639	NA	0.55	5.07	0.46	2e-6	Neuroticism;
THYM	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg21475434	chr5:93447410	FAM172A	-0.71	-4.51	-0.42	1.83e-5	Diabetic retinopathy;
THYM	cis	rs12509991	0.582	rs4834089	chr4:127039836	C/T	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg06558623	chr16:89946397	TCF25	1.42	6.85	0.58	7.17e-10	Skin colour saturation;
THYM	cis	rs735539	0.521	rs1348370	chr13:21404658	A/C	cg02792322	chr13:21280448	IL17D	-0.66	-4.78	-0.44	6.37e-6	Dental caries;
THYM	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg15247329	chr7:2764246	NA	0.73	6.12	0.53	2.07e-8	Height;
THYM	cis	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg10856724	chr12:34555212	NA	-1.05	-10.84	-0.74	2.69e-18	Morning vs. evening chronotype;
THYM	cis	rs775227	0.574	rs35765657	chr3:113078384	C/T	cg18753928	chr3:113234510	CCDC52	-0.76	-5.24	-0.47	9.81e-7	Dental caries;
THYM	cis	rs7833986	0.501	rs72653981	chr8:57027814	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	6.88	0.58	6.47e-10	Height;
THYM	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.61	-4.84	-0.45	4.93e-6	Coronary artery disease;
THYM	cis	rs28374715	0.635	rs8023530	chr15:41647775	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.17	-14.17	-0.82	3.66e-25	Ulcerative colitis;
THYM	trans	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg06636001	chr8:8085503	FLJ10661	-0.75	-6.85	-0.57	7.15e-10	Monocyte count;
THYM	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg22467129	chr15:76604101	ETFA	-0.56	-5.26	-0.47	9.01e-7	Blood metabolite levels;
THYM	cis	rs6754311	0.593	rs313524	chr2:136444123	C/T	cg20242066	chr2:136595261	LCT	0.55	6.04	0.53	3.05e-8	Mosquito bite size;
THYM	cis	rs7084402	0.935	rs4948523	chr10:60339098	A/C	cg09696939	chr10:60272079	BICC1	-0.48	-5.67	-0.5	1.55e-7	Refractive error;
THYM	cis	rs7631605	0.967	rs6806487	chr3:37121092	C/T	cg21328643	chr3:37258149	NA	-0.5	-4.78	-0.44	6.39e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs2985684	0.894	rs4900928	chr14:50020817	A/G	cg02151108	chr14:50098012	C14orf104	-0.77	-6.44	-0.55	4.96e-9	Carotid intima media thickness;
THYM	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9543976	0.545	rs2328963	chr13:76175526	C/T	cg01531495	chr13:76123901	UCHL3	0.66	4.8	0.44	5.85e-6	Diabetic retinopathy;
THYM	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs644799	0.896	rs12146644	chr11:95492878	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	5.84	0.51	7.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs4466137	0.868	rs1975801	chr5:83022127	A/G	cg16102102	chr5:83017553	HAPLN1	-1.1	-10.25	-0.72	4.89e-17	Prostate cancer;
THYM	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg04455712	chr21:45112962	RRP1B	0.6	5.89	0.52	5.8e-8	Mean corpuscular volume;
THYM	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg15962314	chr1:44399869	ARTN	0.53	5.06	0.46	2.05e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2692947	0.770	rs72492163	chr2:96417816	G/A	cg22654517	chr2:96458247	NA	0.71	5.34	0.48	6.39e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg26769984	chr7:1090371	C7orf50	0.81	5.42	0.49	4.45e-7	Bronchopulmonary dysplasia;
THYM	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg27502298	chr12:9555721	NA	0.98	10.23	0.72	5.46e-17	IgG glycosylation;
THYM	cis	rs6840360	0.550	rs11723438	chr4:152531801	C/T	cg22705602	chr4:152727874	NA	0.77	8.05	0.64	2.4e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg08305652	chr11:111469057	NA	0.52	4.47	0.42	2.2e-5	Primary sclerosing cholangitis;
THYM	cis	rs995000	0.931	rs9436222	chr1:62903363	C/G	cg06896770	chr1:63153194	DOCK7	0.95	7.26	0.6	1.03e-10	Triglyceride levels;
THYM	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg00999904	chr2:3704751	ALLC	0.74	5.42	0.49	4.56e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs17255340	0.520	rs1145913	chr6:83993928	A/C	cg21688264	chr6:84418724	SNAP91	0.66	4.46	0.42	2.22e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs11948739	0.610	rs2189505	chr5:130300448	T/C	cg08523029	chr5:130500466	HINT1	-0.78	-5.46	-0.49	3.78e-7	Pediatric bone mineral content (hip);
THYM	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	6.66	0.56	1.74e-9	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9914988	0.943	rs2043032	chr17:27136692	A/G	cg08900864	chr17:27696160	NA	1.01	5.06	0.46	2.06e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs11771526	0.681	rs62457535	chr7:32358710	C/G	cg27511599	chr7:32358540	NA	0.75	5.02	0.46	2.42e-6	Body mass index;
THYM	cis	rs6546324	0.592	rs2861648	chr2:67803908	C/T	cg18237512	chr2:67827392	NA	-0.78	-4.63	-0.43	1.16e-5	Endometriosis;
THYM	cis	rs9532580	0.778	rs61963319	chr13:41244220	A/T	cg21288729	chr13:41239152	FOXO1	0.66	4.98	0.46	2.83e-6	Mean corpuscular hemoglobin;
THYM	cis	rs7772486	0.754	rs4896839	chr6:146019689	T/G	cg13319975	chr6:146136371	FBXO30	0.64	5.21	0.47	1.09e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg15448220	chr1:150897856	SETDB1	0.88	7.49	0.61	3.44e-11	Melanoma;
THYM	cis	rs67072384	1.000	rs55957377	chr11:72445476	A/G	cg01380194	chr11:72452482	ARAP1	-0.85	-4.84	-0.45	4.92e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs9796	0.689	rs692153	chr15:41452681	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.58	-4.63	-0.43	1.17e-5	Menopause (age at onset);
THYM	cis	rs2692947	0.550	rs4613327	chr2:96583823	G/A	cg22654517	chr2:96458247	NA	0.71	5.17	0.47	1.28e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg06532163	chr17:45867833	NA	-0.64	-6.45	-0.55	4.65e-9	IgG glycosylation;
THYM	cis	rs7078219	0.543	rs10786556	chr10:101278324	C/T	cg04972745	chr10:101287846	NA	-0.52	-4.8	-0.44	5.8e-6	Dental caries;
THYM	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	8.22	0.64	1.02e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg09904177	chr6:26538194	HMGN4	0.53	4.5	0.42	1.95e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-5.83	-0.51	7.7e-8	Total cholesterol levels;
THYM	cis	rs7106204	0.534	rs16912285	chr11:24252528	A/G	ch.11.24196551F	chr11:24239977	NA	0.89	4.62	0.43	1.22e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg10760299	chr15:45669010	GATM	0.93	7.63	0.62	1.79e-11	Homoarginine levels;
THYM	cis	rs888194	0.966	rs1558804	chr12:109898732	A/G	cg10504392	chr12:110044639	NA	0.6	5.61	0.5	1.99e-7	Neuroticism;
THYM	cis	rs4454254	0.500	rs4633040	chr8:141057383	T/G	cg05910124	chr8:141057427	TRAPPC9	-0.61	-4.8	-0.44	5.99e-6	Pulse pressure;
THYM	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg25767906	chr1:53392781	SCP2	-0.64	-6.4	-0.55	5.85e-9	Monocyte count;
THYM	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg17173187	chr15:85201210	NMB	-0.59	-6.06	-0.53	2.74e-8	Schizophrenia;
THYM	cis	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg24286174	chr3:188697399	NA	-0.74	-4.82	-0.44	5.49e-6	Lung adenocarcinoma;
THYM	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg12016809	chr21:47604291	C21orf56	0.68	4.63	0.43	1.17e-5	Testicular germ cell tumor;
THYM	cis	rs7582180	0.700	rs4851303	chr2:100962064	T/C	cg08017756	chr2:100939284	LONRF2	-0.72	-7.58	-0.61	2.31e-11	Intelligence (multi-trait analysis);
THYM	cis	rs4730268	0.950	rs2158837	chr7:107440451	C/T	cg18560240	chr7:107437656	SLC26A3	-0.9	-5.07	-0.46	1.94e-6	IgG glycosylation;
THYM	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg21433313	chr16:3507492	NAT15	0.81	8.84	0.67	4.96e-14	Tuberculosis;
THYM	cis	rs12216545	0.644	rs62491782	chr7:150309413	A/G	cg08960815	chr7:150264767	GIMAP4	-0.83	-7.51	-0.61	3.22e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg16325326	chr1:53192061	ZYG11B	-0.73	-6.9	-0.58	5.91e-10	Monocyte count;
THYM	cis	rs7572733	0.555	rs2341778	chr2:198776546	G/A	cg00792783	chr2:198669748	PLCL1	-0.84	-5.97	-0.52	4.15e-8	Dermatomyositis;
THYM	cis	rs10203711	0.966	rs6716938	chr2:239599283	A/G	cg14580085	chr2:239553406	NA	0.63	5.73	0.51	1.18e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	5.07	0.46	2e-6	Rheumatoid arthritis;
THYM	cis	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg26384229	chr12:38710491	ALG10B	0.97	7.89	0.63	5.19e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg26384229	chr12:38710491	ALG10B	1.03	9.92	0.71	2.51e-16	Heart rate;
THYM	cis	rs9399401	0.667	rs6900233	chr6:142717283	C/G	cg03128060	chr6:142623767	GPR126	0.7	9.47	0.7	2.29e-15	Chronic obstructive pulmonary disease;
THYM	cis	rs6754311	0.510	rs1374329	chr2:136421323	A/G	cg07169764	chr2:136633963	MCM6	0.73	6.02	0.53	3.28e-8	Mosquito bite size;
THYM	cis	rs7078219	0.524	rs1548963	chr10:101289703	C/G	cg04972745	chr10:101287846	NA	-0.51	-4.84	-0.44	5.09e-6	Dental caries;
THYM	cis	rs9677476	0.818	rs16827879	chr2:232092301	C/T	cg07929768	chr2:232055508	NA	0.61	6.19	0.54	1.54e-8	Food antigen IgG levels;
THYM	cis	rs7926906	1.000	rs12291122	chr11:90531578	A/C	cg26138821	chr11:89956704	CHORDC1	-0.57	-5.06	-0.46	2.07e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.62	4.55	0.42	1.57e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6840360	0.870	rs1372978	chr4:152456180	A/G	cg17479576	chr4:152424074	FAM160A1	-0.63	-4.8	-0.44	5.81e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg22974920	chr21:40686053	BRWD1	-0.62	-4.95	-0.45	3.22e-6	Cognitive function;
THYM	trans	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg25214090	chr10:38739885	LOC399744	0.95	7.9	0.63	4.94e-12	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7084402	0.934	rs1158212	chr10:60318276	G/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs1723838	0.510	rs2735572	chr11:73688492	C/T	cg13953458	chr11:73681281	DNAJB13	-0.7	-4.7	-0.43	8.83e-6	Obesity-related traits;
THYM	cis	rs6430585	0.583	rs3769001	chr2:136626078	A/G	cg04750100	chr2:136595281	LCT	0.57	5.29	0.48	7.86e-7	Corneal structure;
THYM	cis	rs6424115	0.830	rs4649124	chr1:24201357	A/G	cg15997130	chr1:24165203	NA	0.76	6.39	0.55	6.14e-9	Immature fraction of reticulocytes;
THYM	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg11812906	chr14:75593930	NEK9	-0.89	-8.22	-0.64	1.03e-12	Height;
THYM	cis	rs10487112	1.000	rs6962296	chr7:90068176	T/G	cg26521402	chr7:89842741	STEAP2	0.51	4.55	0.42	1.6e-5	Perceived unattractiveness to mosquitoes;
THYM	cis	rs11122272	0.735	rs2486727	chr1:231539245	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-5.32	-0.48	6.84e-7	Hemoglobin concentration;
THYM	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg03388043	chr17:80084554	CCDC57	0.69	5.87	0.52	6.32e-8	Life satisfaction;
THYM	cis	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.55	-5.53	-0.49	2.86e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs12216545	0.765	rs2272092	chr7:150264645	C/T	cg00323915	chr7:150264987	GIMAP4	-0.49	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg09517075	chr8:22133004	PIWIL2	0.63	5.74	0.51	1.14e-7	Hypertriglyceridemia;
THYM	cis	rs8050907	0.744	rs80031922	chr16:4538185	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.22	4.58	0.43	1.43e-5	Obesity-related traits;
THYM	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg17644776	chr2:200775616	C2orf69	-0.9	-7.45	-0.61	4.33e-11	Osteoporosis;
THYM	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	4.79	0.44	6.04e-6	Menarche (age at onset);
THYM	cis	rs7177699	0.557	rs7164479	chr15:79123054	C/T	cg15571903	chr15:79123663	NA	0.58	6.56	0.56	2.77e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg27129171	chr3:47204927	SETD2	0.69	6.63	0.56	2.04e-9	Colorectal cancer;
THYM	cis	rs7757969	1.000	rs9387040	chr6:112131578	G/A	cg08601457	chr6:112115117	FYN	0.42	4.79	0.44	6.23e-6	Schizophrenia;
THYM	cis	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg06521331	chr12:34319734	NA	0.84	6.44	0.55	4.78e-9	Morning vs. evening chronotype;
THYM	cis	rs2115536	0.967	rs3826008	chr15:80189805	G/T	cg00225070	chr15:80189496	MTHFS	0.65	5.77	0.51	9.71e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg04362960	chr10:104952993	NT5C2	0.57	4.68	0.43	9.7e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7107174	1.000	rs901103	chr11:77931346	C/T	cg19901956	chr11:77921274	USP35	-0.81	-6.14	-0.53	1.93e-8	Testicular germ cell tumor;
THYM	cis	rs9807989	0.801	rs11123925	chr2:102977511	G/A	cg03938978	chr2:103052716	IL18RAP	0.63	6.55	0.56	2.99e-9	Asthma;
THYM	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg03433033	chr1:76189801	ACADM	0.77	10.18	0.72	6.87e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.75	-0.57	1.18e-9	Chronic sinus infection;
THYM	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs35883536	0.566	rs10783141	chr1:101043897	G/A	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs7772486	0.790	rs6924159	chr6:146267873	A/G	cg13319975	chr6:146136371	FBXO30	0.7	5.77	0.51	1.01e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7178572	0.889	rs907388	chr15:77828668	G/A	cg22256960	chr15:77711686	NA	-0.96	-7.99	-0.63	3.15e-12	Type 2 diabetes;
THYM	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg16778714	chr17:28903809	LRRC37B2	-0.76	-4.49	-0.42	2.03e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg26818010	chr10:134567672	INPP5A	-0.82	-6.62	-0.56	2.15e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7940866	0.770	rs10750456	chr11:130819634	A/G	cg12179176	chr11:130786555	SNX19	0.63	4.84	0.44	5.02e-6	Schizophrenia;
THYM	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg16586182	chr3:47516702	SCAP	0.67	5.61	0.5	1.99e-7	Colorectal cancer;
THYM	cis	rs8048589	0.604	rs12929519	chr16:12207439	A/G	cg02910054	chr16:12241554	SNX29	-0.81	-6.7	-0.57	1.46e-9	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs11690935	0.632	rs6723259	chr2:172622527	A/C	cg13550731	chr2:172543902	DYNC1I2	0.66	5.23	0.47	1.01e-6	Schizophrenia;
THYM	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg04824913	chr4:887549	GAK	-0.78	-6.08	-0.53	2.53e-8	Systemic sclerosis;
THYM	cis	rs977987	0.931	rs11641430	chr16:75495276	T/C	cg03315344	chr16:75512273	CHST6	0.73	5.69	0.5	1.39e-7	Dupuytren's disease;
THYM	cis	rs4690686	0.500	rs11728314	chr4:177268373	G/A	cg17059388	chr4:177262070	NA	0.48	6.73	0.57	1.29e-9	Essential tremor;
THYM	cis	rs2730245	0.527	rs2709858	chr7:158675266	C/G	cg11984989	chr7:158649758	WDR60	1.01	8.5	0.66	2.65e-13	Height;
THYM	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg09455208	chr3:40491958	NA	0.53	5.54	0.49	2.67e-7	Renal cell carcinoma;
THYM	cis	rs3960554	0.808	rs2302434	chr7:75630183	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.6	-5.09	-0.46	1.8e-6	Eotaxin levels;
THYM	cis	rs6430585	0.527	rs59413285	chr2:136444185	G/T	cg23851026	chr2:136556271	LCT	0.67	5.98	0.52	3.89e-8	Corneal structure;
THYM	cis	rs1395	1.000	rs1275522	chr2:27426878	C/T	cg23587288	chr2:27483067	SLC30A3	0.58	5.09	0.46	1.78e-6	Blood metabolite levels;
THYM	cis	rs11997175	0.583	rs7009719	chr8:33834824	C/G	ch.8.33884649F	chr8:33765107	NA	0.67	5.0	0.46	2.61e-6	Body mass index;
THYM	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg19761014	chr17:28927070	LRRC37B2	0.78	4.99	0.46	2.76e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs3806843	0.766	rs801399	chr5:140034844	C/T	cg19875535	chr5:140030758	IK	-0.64	-5.57	-0.5	2.32e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs67460515	0.500	rs9860537	chr3:160660500	G/T	cg12349858	chr3:160822545	B3GALNT1	-0.6	-4.99	-0.46	2.69e-6	Parkinson's disease;
THYM	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg24675658	chr1:53192096	ZYG11B	-0.57	-4.54	-0.42	1.62e-5	Monocyte count;
THYM	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg03213289	chr20:61660250	NA	0.91	9.43	0.7	2.75e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.56	0.81	6.23e-24	Height;
THYM	cis	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg12501888	chr15:85177176	SCAND2	-0.62	-5.02	-0.46	2.38e-6	P wave terminal force;
THYM	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg02527881	chr3:46936655	PTH1R	0.52	4.99	0.46	2.77e-6	Colorectal cancer;
THYM	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg27490568	chr2:178487706	NA	0.68	5.9	0.52	5.53e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4662945	1.000	rs4662942	chr2:130215888	T/C	cg05903289	chr2:130345205	NA	-0.52	-5.1	-0.46	1.7e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs2835345	0.563	rs58602880	chr21:37826908	C/G	cg20643029	chr21:37915044	CLDN14	0.69	6.03	0.53	3.15e-8	Pulmonary function;
THYM	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg21862992	chr11:68658383	NA	0.23	4.49	0.42	2.03e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6992848	0.759	rs11166958	chr8:141177498	G/A	cg22504031	chr8:141147661	TRAPPC9	0.61	4.69	0.43	9.21e-6	Response to amphetamines;
THYM	cis	rs4372836	0.543	rs6747852	chr2:29009840	A/T	cg09522027	chr2:28974177	PPP1CB	-0.58	-4.49	-0.42	2e-5	Body mass index;
THYM	cis	rs13082711	0.911	rs2131205	chr3:27428501	A/G	cg02860705	chr3:27208620	NA	0.74	4.58	0.43	1.4e-5	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg10862848	chr6:42927986	GNMT	-0.51	-6.85	-0.57	7.42e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs10799590	0.964	rs67817586	chr1:224835465	A/G	cg01808320	chr1:224927238	CNIH3	-0.57	-5.06	-0.46	2.06e-6	Opioid dependence;
THYM	cis	rs2073300	0.793	rs6114094	chr20:23434267	A/G	cg12062639	chr20:23401060	NAPB	0.92	4.7	0.43	8.9e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs155076	1.000	rs567166	chr13:21837519	T/C	cg11317459	chr13:21872234	NA	-1.2	-8.92	-0.68	3.4e-14	White matter hyperintensity burden;
THYM	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs7404928	0.651	rs9924991	chr16:23950155	A/C	cg26685404	chr16:23957272	PRKCB	0.61	7.09	0.59	2.38e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs61931739	0.817	rs1705771	chr12:34174950	C/G	cg06521331	chr12:34319734	NA	-0.61	-5.11	-0.46	1.67e-6	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.57	-5.6	-0.5	2.1e-7	Schizophrenia;
THYM	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg12292205	chr6:26970375	C6orf41	-0.69	-4.53	-0.42	1.69e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg05084668	chr3:125655381	ALG1L	-0.71	-4.61	-0.43	1.23e-5	Blood pressure (smoking interaction);
THYM	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg18252515	chr7:66147081	NA	0.66	4.96	0.45	3.11e-6	Aortic root size;
THYM	cis	rs6032067	0.673	rs13042474	chr20:43893068	G/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.64	-6.49	-0.55	3.95e-9	Blood protein levels;
THYM	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg23649088	chr2:200775458	C2orf69	0.81	6.14	0.53	1.88e-8	Schizophrenia;
THYM	cis	rs2282300	0.739	rs1222211	chr11:30362239	A/C	cg25418670	chr11:30344373	C11orf46	-0.78	-6.29	-0.54	9.75e-9	Morning vs. evening chronotype;
THYM	cis	rs7246657	0.943	rs12709813	chr19:37844983	G/A	cg22634378	chr19:37742834	NA	0.65	5.34	0.48	6.2e-7	Coronary artery calcification;
THYM	cis	rs950880	0.710	rs55927292	chr2:102964861	C/T	cg03938978	chr2:103052716	IL18RAP	-0.54	-4.73	-0.44	7.78e-6	Serum protein levels (sST2);
THYM	cis	rs861020	1.000	rs680923	chr1:209986672	T/C	cg05527609	chr1:210001259	C1orf107	1.02	7.65	0.62	1.6e-11	Orofacial clefts;
THYM	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.29	0.48	7.75e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg13114125	chr14:105738426	BRF1	-0.73	-5.75	-0.51	1.09e-7	Mean platelet volume;Platelet distribution width;
THYM	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg07870213	chr5:140052090	DND1	0.64	7.15	0.59	1.79e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4595586	0.545	rs1156705	chr12:39372672	C/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs13126513	0.550	rs1442486	chr4:100400122	T/C	cg05468953	chr4:100565104	NA	-0.65	-5.49	-0.49	3.3e-7	Metabolite levels (MHPG);
THYM	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg11871910	chr12:69753446	YEATS4	0.65	4.73	0.44	7.91e-6	Response to diuretic therapy;
THYM	cis	rs9914988	0.943	rs12453504	chr17:27119524	C/A	cg20469991	chr17:27169893	C17orf63	-0.78	-4.64	-0.43	1.11e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2862064	1.000	rs1948760	chr5:156442784	T/A	cg12943317	chr5:156479607	HAVCR1	-0.71	-4.68	-0.43	9.33e-6	Platelet count;
THYM	cis	rs924712	0.816	rs971526	chr6:54728129	G/T	cg19716238	chr6:54711378	FAM83B	-0.45	-4.54	-0.42	1.64e-5	Breast cancer;
THYM	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.24	-0.47	9.73e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg18240062	chr17:79603768	NPLOC4	0.73	6.55	0.56	2.9e-9	Eye color traits;
THYM	cis	rs8067545	0.611	rs2703771	chr17:20130154	C/G	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs7731657	0.537	rs2189510	chr5:130316231	C/T	cg08523029	chr5:130500466	HINT1	-0.77	-5.3	-0.48	7.38e-7	Fasting plasma glucose;
THYM	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg07936489	chr17:37558343	FBXL20	-0.82	-5.42	-0.49	4.49e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs919433	0.648	rs6434933	chr2:198426960	G/A	cg00792783	chr2:198669748	PLCL1	0.82	5.8	0.51	8.74e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	trans	rs4650994	0.625	rs6681354	chr1:178526279	A/G	cg05059571	chr16:84539110	KIAA1609	-0.75	-8.15	-0.64	1.43e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs514406	0.893	rs6682024	chr1:53439525	T/C	cg08736216	chr1:53307985	ZYG11A	0.6	5.47	0.49	3.69e-7	Monocyte count;
THYM	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg16414030	chr3:133502952	NA	-0.84	-8.28	-0.65	7.65e-13	Iron status biomarkers;
THYM	cis	rs7336332	0.598	rs74183666	chr13:28007765	A/T	cg22138327	chr13:27999177	GTF3A	0.64	4.75	0.44	7.06e-6	Weight;
THYM	cis	rs7191439	0.858	rs6500489	chr16:88772046	T/C	cg04602696	chr16:88846723	FAM38A	-0.73	-5.09	-0.46	1.81e-6	Plateletcrit;
THYM	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg10523679	chr1:76189770	ACADM	-0.83	-6.52	-0.56	3.44e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg24531977	chr5:56204891	C5orf35	0.89	6.38	0.55	6.29e-9	Initial pursuit acceleration;
THYM	cis	rs2637266	0.626	rs2583069	chr10:78546775	T/C	cg18941641	chr10:78392320	NA	0.77	6.1	0.53	2.25e-8	Pulmonary function;
THYM	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg03388043	chr17:80084554	CCDC57	-0.66	-5.66	-0.5	1.61e-7	Life satisfaction;
THYM	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg05182265	chr7:156933206	UBE3C	-0.7	-9.62	-0.7	1.06e-15	Body mass index;
THYM	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg12981288	chr8:11183844	MTMR9	-0.49	-4.8	-0.44	5.86e-6	Retinal vascular caliber;
THYM	cis	rs11190604	0.767	rs7090150	chr10:102173446	G/T	cg07570687	chr10:102243282	WNT8B	0.82	7.71	0.62	1.25e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs5985	0.659	rs3024321	chr6:6318126	A/G	cg22185065	chr6:6318785	F13A1	0.78	5.74	0.51	1.15e-7	End-stage coagulation;
THYM	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.52e-15	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs17716202	0.826	rs35837891	chr5:55909317	T/C	cg01557754	chr17:7342661	FGF11	0.97	6.95	0.58	4.61e-10	Psychosis in Alzheimer's disease;
THYM	cis	rs7843479	0.601	rs727693	chr8:21850116	A/G	cg17168535	chr8:21777572	XPO7	0.85	7.48	0.61	3.73e-11	Mean corpuscular volume;
THYM	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg27129171	chr3:47204927	SETD2	-0.71	-6.66	-0.56	1.81e-9	Colorectal cancer;
THYM	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg13736514	chr6:26305472	NA	-0.66	-6.64	-0.56	1.91e-9	Educational attainment;
THYM	cis	rs2811415	0.597	rs11711138	chr3:127762761	T/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg03204825	chr3:13978759	TPRXL	0.88	6.97	0.58	4.22e-10	Energy expenditure (24h);
THYM	cis	rs4282339	0.794	rs2974428	chr5:168265244	C/T	cg18364770	chr5:168310523	SLIT3	0.36	4.72	0.44	8.04e-6	Height;
THYM	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg24675658	chr1:53192096	ZYG11B	-0.63	-5.13	-0.47	1.51e-6	Monocyte count;
THYM	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.37	-0.55	6.73e-9	Personality dimensions;
THYM	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg06640241	chr16:89574553	SPG7	0.86	8.18	0.64	1.27e-12	Multiple myeloma (IgH translocation);
THYM	cis	rs6665290	0.594	rs17592479	chr1:227173892	T/A	cg10327440	chr1:227177885	CDC42BPA	-1.05	-11.38	-0.76	1.96e-19	Myeloid white cell count;
THYM	cis	rs4589258	0.933	rs1783791	chr11:90439576	G/T	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6840360	0.869	rs55668815	chr4:152473828	C/G	cg17479576	chr4:152424074	FAM160A1	-0.59	-4.52	-0.42	1.77e-5	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.534	rs1843733	chr12:34047626	T/C	cg06521331	chr12:34319734	NA	-0.93	-8.67	-0.66	1.15e-13	Morning vs. evening chronotype;
THYM	cis	rs17641971	0.708	rs1567555	chr8:49900154	G/A	cg00325661	chr8:49890786	NA	0.64	4.69	0.43	9.01e-6	Blood metabolite levels;
THYM	cis	rs3772130	0.583	rs12695415	chr3:121398853	C/T	cg20356878	chr3:121714668	ILDR1	0.63	4.89	0.45	4.07e-6	Cognitive performance;
THYM	cis	rs9787249	0.957	rs41267029	chr1:40214367	A/G	cg02773041	chr1:40204384	PPIE	0.77	5.99	0.52	3.8e-8	Blood protein levels;
THYM	cis	rs6087990	0.806	rs2424918	chr20:31382770	C/T	cg13636640	chr20:31349939	DNMT3B	0.94	10.59	0.74	8.98e-18	Ulcerative colitis;
THYM	cis	rs3741151	0.773	rs73544710	chr11:73162273	A/G	cg17517138	chr11:73019481	ARHGEF17	0.94	5.48	0.49	3.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg05872129	chr22:39784769	NA	-1.06	-12.08	-0.78	6.6e-21	Intelligence (multi-trait analysis);
THYM	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg26384229	chr12:38710491	ALG10B	0.72	5.56	0.5	2.48e-7	Morning vs. evening chronotype;
THYM	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.98	4.89	0.45	4.07e-6	Initial pursuit acceleration;
THYM	cis	rs11186	0.556	rs13421823	chr2:189938960	C/T	cg11041835	chr2:189156425	GULP1	0.78	4.69	0.43	9.21e-6	Parkinson's disease;
THYM	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg22875332	chr1:76189707	ACADM	0.87	10.83	0.74	2.76e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2067615	0.579	rs10861655	chr12:107129419	A/G	cg15890332	chr12:107067104	RFX4	-0.49	-5.75	-0.51	1.1e-7	Heart rate;
THYM	cis	rs12928939	0.954	rs34998650	chr16:71829329	T/C	cg03805757	chr16:71968109	PKD1L3	-0.7	-5.31	-0.48	7.25e-7	Post bronchodilator FEV1;
THYM	cis	rs7772486	0.686	rs857877	chr6:145976230	A/C	cg23711669	chr6:146136114	FBXO30	-0.96	-10.03	-0.72	1.41e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg09307838	chr4:120376055	NA	0.77	5.56	0.5	2.5e-7	Corneal astigmatism;
THYM	cis	rs55788414	0.932	rs9936302	chr16:81190790	C/T	cg06400318	chr16:81190750	PKD1L2	-0.9	-5.18	-0.47	1.26e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs1160297	0.576	rs1376567	chr2:53098515	C/G	cg07782112	chr2:53107842	NA	0.74	5.97	0.52	4.17e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg13246856	chr1:44399776	ARTN	0.51	4.68	0.43	9.53e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs12711979	1.000	rs12711979	chr2:3869559	A/G	cg17052675	chr2:3827356	NA	-0.46	-4.58	-0.43	1.41e-5	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs950881	0.932	rs3771180	chr2:102953617	G/T	cg20060108	chr2:102954350	IL1RL1	0.85	4.68	0.43	9.48e-6	Allergy;
THYM	cis	rs4936891	0.520	rs61908592	chr11:123871602	G/T	cg22125253	chr11:123886957	OR10G4	-0.57	-4.88	-0.45	4.28e-6	Male fertility;
THYM	cis	rs2133450	0.524	rs56209862	chr3:7349037	G/A	cg19930620	chr3:7340148	GRM7	-0.52	-5.62	-0.5	1.86e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs56104184	1.000	rs56104184	chr19:49370310	C/T	cg19746536	chr19:49375674	PPP1R15A	0.85	5.02	0.46	2.42e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.86	-5.62	-0.5	1.94e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg23422044	chr7:1970798	MAD1L1	0.76	5.29	0.48	7.67e-7	Bipolar disorder;
THYM	cis	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg10856724	chr12:34555212	NA	-0.83	-7.32	-0.6	7.93e-11	Morning vs. evening chronotype;
THYM	cis	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg06521331	chr12:34319734	NA	-0.96	-8.88	-0.67	4.06e-14	Morning vs. evening chronotype;
THYM	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg09549813	chr16:4587862	C16orf5	-0.58	-6.32	-0.54	8.61e-9	Schizophrenia;
THYM	cis	rs3772130	0.962	rs11706783	chr3:121534322	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg04234412	chr22:24373322	LOC391322	-1.08	-14.27	-0.83	2.34e-25	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs295140	0.933	rs10931900	chr2:201177193	T/C	cg04283868	chr2:201171347	SPATS2L	0.69	5.19	0.47	1.2e-6	QT interval;
THYM	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	4.66	0.43	1.04e-5	Diabetic retinopathy;
THYM	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7651736	1.000	rs7651736	chr3:136760598	A/G	cg12473912	chr3:136751656	NA	0.53	4.92	0.45	3.62e-6	Neuroticism;
THYM	cis	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg13443165	chr9:33130375	B4GALT1	0.86	7.96	0.63	3.71e-12	IgG glycosylation;
THYM	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	5.54	0.49	2.69e-7	Menarche (age at onset);
THYM	cis	rs7224737	0.956	rs8081900	chr17:40289875	G/A	cg20291162	chr17:40259547	DHX58	-0.69	-6.44	-0.55	4.96e-9	Fibrinogen levels;
THYM	cis	rs2797685	0.755	rs41402249	chr1:7822723	C/G	cg06712362	chr1:7811235	CAMTA1	-0.94	-5.54	-0.49	2.65e-7	Crohn's disease;
THYM	cis	rs977987	0.843	rs4888427	chr16:75478447	A/G	cg03315344	chr16:75512273	CHST6	0.73	5.98	0.52	3.87e-8	Dupuytren's disease;
THYM	cis	rs7119	0.634	rs2667782	chr15:77862296	A/C	cg27398640	chr15:77910606	LINGO1	0.62	7.12	0.59	2.05e-10	Type 2 diabetes;
THYM	cis	rs752010	0.619	rs4393146	chr1:42118766	A/G	cg06885757	chr1:42089581	HIVEP3	0.72	10.16	0.72	7.58e-17	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs9814567	0.762	rs13075332	chr3:134329836	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	5.76	0.51	1.03e-7	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg24060327	chr5:131705240	SLC22A5	-0.76	-5.58	-0.5	2.26e-7	Blood metabolite levels;
THYM	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12458462	0.665	rs2035085	chr18:77485280	C/T	cg11879182	chr18:77439856	CTDP1	0.82	7.9	0.63	4.96e-12	Monocyte count;
THYM	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg04362960	chr10:104952993	NT5C2	0.59	4.81	0.44	5.64e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4072705	0.967	rs6478677	chr9:127422179	C/G	cg01786973	chr9:127249749	NR5A1	0.35	4.69	0.43	9.25e-6	Menarche (age at onset);
THYM	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg22968622	chr17:43663579	NA	1.18	10.66	0.74	6.45e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs34638657	0.828	rs7194734	chr16:82199980	C/T	cg07307142	chr16:82071433	HSD17B2	-1.0	-8.1	-0.64	1.84e-12	Lung adenocarcinoma;
THYM	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs12208915	0.848	rs2321896	chr6:79509744	G/C	cg05283184	chr6:79620031	NA	0.74	4.84	0.44	5.06e-6	Left atrial antero-posterior diameter;
THYM	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg15691649	chr6:25882328	NA	-0.76	-6.1	-0.53	2.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg27535305	chr1:53392650	SCP2	-0.49	-5.46	-0.49	3.8e-7	Monocyte count;
THYM	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg05347473	chr6:146136440	FBXO30	0.56	4.51	0.42	1.84e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4886920	0.894	rs4886932	chr15:78131097	A/G	cg10461261	chr15:78109450	NA	-0.47	-4.69	-0.43	8.98e-6	Neuroticism;
THYM	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs946836	0.562	rs12722901	chr1:48371696	C/T	cg18376692	chr1:48452465	NA	-0.52	-5.08	-0.46	1.84e-6	White matter integrity;
THYM	cis	rs7968440	1.000	rs2700482	chr12:51083265	C/T	cg20014596	chr12:50898483	DIP2B	0.56	4.55	0.42	1.57e-5	Fibrinogen;
THYM	cis	rs72781680	0.800	rs56398785	chr2:24091515	T/A	cg08917208	chr2:24149416	ATAD2B	1.09	4.95	0.45	3.16e-6	Lymphocyte counts;
THYM	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg05182265	chr7:156933206	UBE3C	0.59	7.11	0.59	2.15e-10	Body mass index;
THYM	cis	rs6496667	0.533	rs7172909	chr15:90991416	C/T	cg22089800	chr15:90895588	ZNF774	0.65	4.73	0.44	7.89e-6	Rheumatoid arthritis;
THYM	cis	rs6541297	0.878	rs4846905	chr1:230279582	C/T	cg05784532	chr1:230284198	GALNT2	-0.81	-5.68	-0.5	1.47e-7	Coronary artery disease;
THYM	cis	rs6906287	0.647	rs12660455	chr6:118717382	C/T	cg21191810	chr6:118973309	C6orf204	0.57	5.5	0.49	3.26e-7	Electrocardiographic conduction measures;
THYM	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg03859395	chr2:55845619	SMEK2	0.6	5.52	0.49	2.95e-7	Metabolic syndrome;
THYM	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6901250	0.587	rs339357	chr6:117198291	G/C	cg12892004	chr6:117198278	RFX6	-0.67	-6.21	-0.54	1.41e-8	C-reactive protein levels;
THYM	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg11494091	chr17:61959527	GH2	0.7	6.45	0.55	4.76e-9	Height;
THYM	cis	rs9361491	0.608	rs4590227	chr6:79463910	G/A	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg00383909	chr3:49044727	WDR6	1.1	6.34	0.54	7.87e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs9399401	0.667	rs12213892	chr6:142702234	A/G	cg04461802	chr6:142623433	GPR126	0.77	7.46	0.61	3.98e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs4951011	0.938	rs7414107	chr1:203756859	A/G	cg24343524	chr1:203763352	ZC3H11A	0.71	6.05	0.53	2.9e-8	Breast cancer;
THYM	cis	rs7940866	0.770	rs10791104	chr11:130814893	A/T	cg23692386	chr11:131799662	NTM	0.44	4.51	0.42	1.89e-5	Schizophrenia;
THYM	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.47	0.49	3.63e-7	Bipolar disorder;
THYM	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg03433033	chr1:76189801	ACADM	0.79	11.21	0.75	4.52e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg17554472	chr22:41940697	POLR3H	0.71	4.58	0.43	1.41e-5	Vitiligo;
THYM	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg13319975	chr6:146136371	FBXO30	0.75	6.26	0.54	1.11e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs7719624	0.870	rs58759191	chr5:135395827	C/G	cg15329133	chr5:135467951	SMAD5;SMAD5OS	0.55	4.92	0.45	3.64e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs11264213	0.901	rs636832	chr1:36363475	G/A	cg27506609	chr1:36549197	TEKT2	0.92	4.83	0.44	5.3e-6	Schizophrenia;
THYM	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg27068330	chr11:65405492	SIPA1	-0.95	-8.8	-0.67	6.03e-14	Acne (severe);
THYM	cis	rs4409675	0.576	rs11247705	chr1:28212272	G/A	cg23691781	chr1:28212827	C1orf38	0.44	4.5	0.42	1.91e-5	Corneal astigmatism;
THYM	cis	rs6570726	0.791	rs447992	chr6:145817184	C/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.44	-0.49	4.16e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6686842	0.897	rs2802565	chr1:41551819	T/A	cg03387723	chr1:41708464	SCMH1	0.44	5.28	0.48	8.08e-7	Height;
THYM	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg18230493	chr5:56204884	C5orf35	0.64	4.86	0.45	4.56e-6	Initial pursuit acceleration;
THYM	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg27535305	chr1:53392650	SCP2	0.4	4.68	0.43	9.51e-6	Monocyte count;
THYM	cis	rs2625529	0.617	rs16956369	chr15:72182813	C/T	cg16672083	chr15:72433130	SENP8	0.51	4.5	0.42	1.93e-5	Red blood cell count;
THYM	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs57920188	0.703	rs3813810	chr1:4088339	G/T	cg20703997	chr1:4087676	NA	0.99	6.85	0.58	7.15e-10	Interleukin-17 levels;
THYM	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg05294307	chr14:35346193	BAZ1A	-0.88	-6.16	-0.53	1.74e-8	Psoriasis;
THYM	cis	rs12908161	0.683	rs12903256	chr15:85308141	G/T	cg17173187	chr15:85201210	NMB	0.48	4.48	0.42	2.06e-5	Schizophrenia;
THYM	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg21385522	chr1:16154831	NA	-1.27	-10.37	-0.73	2.73e-17	Dilated cardiomyopathy;
THYM	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg25036284	chr2:26402008	FAM59B	0.8	5.36	0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg08885076	chr2:99613938	TSGA10	0.65	5.96	0.52	4.31e-8	Chronic sinus infection;
THYM	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg18357526	chr6:26021779	HIST1H4A	0.7	5.36	0.48	5.83e-7	Urate levels;
THYM	cis	rs17006441	0.966	rs13073599	chr3:69808638	C/T	cg18496212	chr3:69797108	MITF	-0.57	-5.87	-0.52	6.37e-8	Hemoglobin concentration;
THYM	cis	rs2294693	0.947	rs9381025	chr6:40986623	C/T	cg14769373	chr6:40998127	UNC5CL	-0.58	-4.66	-0.43	1.02e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg10760299	chr15:45669010	GATM	0.83	6.25	0.54	1.19e-8	Homoarginine levels;
THYM	trans	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.12	8.09	0.64	1.9e-12	Exhaled nitric oxide output;
THYM	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	7.56	0.61	2.57e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg02018176	chr4:1364513	KIAA1530	-0.56	-4.57	-0.42	1.46e-5	Obesity-related traits;
THYM	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg03806693	chr22:41940476	POLR3H	1.1	8.83	0.67	5.2e-14	Vitiligo;
THYM	cis	rs919433	0.680	rs2564383	chr2:198310862	A/G	cg05783139	chr2:198650985	BOLL	0.63	4.93	0.45	3.48e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg03806693	chr22:41940476	POLR3H	-0.86	-8.43	-0.65	3.65e-13	Vitiligo;
THYM	cis	rs61990749	0.571	rs4448861	chr14:78307735	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.91	5.65	0.5	1.65e-7	Fibroblast growth factor basic levels;
THYM	cis	rs13064411	0.696	rs6769516	chr3:113219905	T/C	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs9563576	0.778	rs9569807	chr13:58618852	G/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs7474896	0.583	rs7071147	chr10:38003376	T/C	cg07661167	chr10:37990439	NA	-0.67	-4.54	-0.42	1.62e-5	Obesity (extreme);
THYM	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg05335186	chr13:53173507	NA	-0.49	-6.9	-0.58	5.74e-10	Lewy body disease;
THYM	cis	rs7264396	0.690	rs2425157	chr20:34419083	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.72	-5.1	-0.46	1.75e-6	Total cholesterol levels;
THYM	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg11965913	chr1:205819406	PM20D1	0.54	4.47	0.42	2.18e-5	Parkinson's disease;
THYM	trans	rs11186	0.556	rs58106884	chr2:189953508	C/T	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs4523957	0.579	rs903161	chr17:2092006	A/T	cg16513277	chr17:2031491	SMG6	-0.97	-8.81	-0.67	5.78e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs59698941	0.943	rs67437142	chr5:132306722	T/C	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	trans	rs877282	0.797	rs11253329	chr10:753200	A/T	cg22713356	chr15:30763199	NA	1.27	9.37	0.69	3.62e-15	Uric acid levels;
THYM	cis	rs6754311	0.689	rs191079	chr2:136633771	T/C	cg23851026	chr2:136556271	LCT	0.5	4.76	0.44	6.97e-6	Mosquito bite size;
THYM	cis	rs10819861	0.598	rs7041954	chr9:98856401	T/C	cg14508093	chr9:98862825	NA	-0.24	-4.6	-0.43	1.28e-5	Electrocardiographic traits;
THYM	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg07424592	chr7:64974309	NA	1.04	5.27	0.48	8.52e-7	Diabetic kidney disease;
THYM	cis	rs9303280	0.747	rs1453559	chr17:38020419	T/C	cg24910161	chr17:38119198	GSDMA	0.46	4.69	0.43	9.15e-6	Self-reported allergy;
THYM	cis	rs654950	0.841	rs676383	chr1:41993753	C/T	cg06885757	chr1:42089581	HIVEP3	-0.49	-6.02	-0.53	3.25e-8	Airway imaging phenotypes;
THYM	cis	rs7679	1.000	rs4465830	chr20:44585420	A/G	cg09053081	chr20:44746392	CD40	0.83	4.45	0.42	2.29e-5	Triglycerides;HDL cholesterol;Gut microbiota (functional units);
THYM	cis	rs2811415	0.531	rs13081382	chr3:127740304	C/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg26677194	chr12:130822605	PIWIL1	0.81	6.27	0.54	1.07e-8	Menopause (age at onset);
THYM	cis	rs8008758	0.517	rs1620117	chr14:101696931	C/A	cg26393534	chr14:101700091	NA	-0.54	-7.1	-0.59	2.21e-10	Body mass index (alcohol intake interaction);
THYM	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.51	0.81	7.55e-24	Height;
THYM	cis	rs2276314	0.857	rs56230698	chr18:33628885	A/G	cg05985134	chr18:33552581	C18orf21	0.66	4.84	0.44	5.02e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs9970807	0.748	rs72664303	chr1:56945666	T/C	cg11959316	chr1:57001742	PPAP2B	0.64	4.8	0.44	5.93e-6	Myocardial infarction;Coronary artery disease;
THYM	cis	rs11651000	0.817	rs11657479	chr17:45822901	T/C	cg24803719	chr17:45855879	NA	-0.53	-5.27	-0.48	8.68e-7	IgG glycosylation;
THYM	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg11764359	chr7:65958608	NA	0.62	4.73	0.44	7.94e-6	Aortic root size;
THYM	cis	rs12478296	0.792	rs3924263	chr2:243005167	A/C	cg18898632	chr2:242989856	NA	-0.66	-4.46	-0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs11690935	0.788	rs10201053	chr2:172889558	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.78	-5.89	-0.52	5.87e-8	Schizophrenia;
THYM	cis	rs9560113	0.960	rs9560102	chr13:112173825	G/A	cg14154082	chr13:112174009	NA	0.86	8.0	0.63	2.95e-12	Menarche (age at onset);
THYM	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg01699819	chr7:1052092	C7orf50	-0.84	-7.66	-0.62	1.59e-11	Bronchopulmonary dysplasia;
THYM	cis	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg06360820	chr2:242988706	NA	-0.97	-6.62	-0.56	2.16e-9	Obesity-related traits;
THYM	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg15744005	chr10:104629667	AS3MT	-0.89	-8.53	-0.66	2.29e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7399018	0.739	rs7399073	chr12:51614050	C/A	cg12163867	chr12:51592794	POU6F1	-0.71	-4.51	-0.42	1.87e-5	Cisplatin-induced ototoxicity;
THYM	cis	rs9906944	0.657	rs4643373	chr17:47123423	T/C	cg09029085	chr17:47094198	IGF2BP1	0.49	6.54	0.56	3.08e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg11752832	chr7:134001865	SLC35B4	0.76	5.57	0.5	2.34e-7	Mean platelet volume;
THYM	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg02038168	chr22:39784481	NA	-0.69	-5.59	-0.5	2.15e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg07414643	chr4:187882934	NA	0.64	5.75	0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs919433	0.662	rs2043018	chr2:198236958	G/A	cg05783139	chr2:198650985	BOLL	0.56	4.5	0.42	1.96e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs75920871	0.588	rs7101763	chr11:116941985	G/T	cg20608306	chr11:116969690	SIK3	-0.54	-5.98	-0.52	3.96e-8	Subjective well-being;
THYM	cis	rs79149102	0.579	rs7163390	chr15:75280426	T/C	cg17294928	chr15:75287854	SCAMP5	-1.05	-5.58	-0.5	2.3e-7	Lung cancer;
THYM	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs938554	0.513	rs3775946	chr4:9995256	A/G	cg26689780	chr4:10079554	WDR1	-0.4	-4.67	-0.43	9.92e-6	Blood metabolite levels;
THYM	cis	rs9814567	0.762	rs13093893	chr3:134292131	C/T	cg15484384	chr3:134203672	ANAPC13;CEP63	0.4	4.49	0.42	1.99e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6430585	0.528	rs2278682	chr2:136743143	G/C	cg23851026	chr2:136556271	LCT	0.69	6.68	0.57	1.64e-9	Corneal structure;
THYM	cis	rs1122401	0.515	rs2564985	chr5:53864297	A/C	cg04014864	chr5:54603544	SKIV2L2;DHX29	0.79	5.11	0.46	1.67e-6	Smoking initiation;
THYM	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.53e-12	Life satisfaction;
THYM	cis	rs2692947	0.630	rs1168966	chr2:96798510	G/A	cg23100626	chr2:96804247	ASTL	0.37	4.98	0.46	2.79e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg16031515	chr1:205743344	RAB7L1	-0.71	-7.44	-0.61	4.5e-11	Menarche (age at onset);
THYM	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg02569458	chr12:86230093	RASSF9	0.69	5.77	0.51	9.84e-8	Major depressive disorder;
THYM	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg11764359	chr7:65958608	NA	0.81	6.42	0.55	5.31e-9	Aortic root size;
THYM	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg14416269	chr4:6271139	WFS1	0.55	5.69	0.5	1.41e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg17426766	chr1:2046864	PRKCZ	-0.41	-4.81	-0.44	5.67e-6	Height;
THYM	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg00071950	chr4:10020882	SLC2A9	0.54	4.73	0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9378357	0.558	rs6923235	chr6:3289757	T/C	cg08754725	chr6:3293098	SLC22A23	-0.77	-5.22	-0.47	1.05e-6	Obesity-related traits;
THYM	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs113835537	0.529	rs57724777	chr11:66236431	G/A	cg24851651	chr11:66362959	CCS	0.74	5.1	0.46	1.74e-6	Airway imaging phenotypes;
THYM	cis	rs12282928	1.000	rs7946076	chr11:48308318	A/G	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg21427119	chr20:30132790	HM13	-1.0	-7.05	-0.59	2.92e-10	Mean corpuscular hemoglobin;
THYM	cis	rs12410462	0.502	rs115241368	chr1:227795465	A/G	cg23173402	chr1:227635558	NA	0.75	5.56	0.5	2.45e-7	Major depressive disorder;
THYM	cis	rs7772486	0.622	rs1292333	chr6:145982344	C/T	cg13319975	chr6:146136371	FBXO30	0.65	5.22	0.47	1.05e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs42648	0.935	rs42644	chr7:89974864	G/A	cg25739043	chr7:89950458	NA	-0.54	-4.55	-0.42	1.59e-5	Homocysteine levels;
THYM	cis	rs7107770	1.000	rs35447666	chr11:125107211	G/T	cg07747661	chr11:125106135	PKNOX2	-0.92	-5.28	-0.48	8.31e-7	Photic sneeze reflex;
THYM	cis	rs9311676	0.632	rs6774357	chr3:58361530	A/C	cg26110898	chr3:58419937	PDHB	0.44	4.6	0.43	1.29e-5	Systemic lupus erythematosus;
THYM	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg06453172	chr10:134556979	INPP5A	-0.67	-4.84	-0.44	5.1e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg10057126	chr4:77819792	ANKRD56	0.71	6.06	0.53	2.78e-8	Emphysema distribution in smoking;
THYM	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg05738196	chr6:26577821	NA	0.83	8.34	0.65	5.8e-13	Intelligence (multi-trait analysis);
THYM	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg18252515	chr7:66147081	NA	-0.66	-5.03	-0.46	2.34e-6	Aortic root size;
THYM	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg13609457	chr4:120235615	NA	0.61	5.28	0.48	8.28e-7	Corneal astigmatism;
THYM	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg01236616	chr12:121019343	POP5	1.31	10.47	0.73	1.61e-17	Type 1 diabetes nephropathy;
THYM	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg03060546	chr3:49711283	APEH	0.75	6.08	0.53	2.55e-8	Resting heart rate;
THYM	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg06808227	chr14:105710500	BRF1	-1.02	-8.87	-0.67	4.38e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg00908189	chr16:619842	PIGQ	1.05	9.25	0.69	6.62e-15	Height;
THYM	cis	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg14345882	chr6:26364793	BTN3A2	0.56	5.13	0.47	1.55e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs877674	0.818	rs3766823	chr1:32197257	G/A	cg13438300	chr1:32254265	NA	-0.69	-4.67	-0.43	9.81e-6	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs3126085	0.935	rs11204952	chr1:152227321	G/A	cg26020982	chr1:152196106	HRNR	0.34	4.59	0.43	1.34e-5	Atopic dermatitis;
THYM	cis	rs11096990	0.964	rs6831700	chr4:39256964	G/T	cg24403649	chr4:39172243	NA	0.69	5.76	0.51	1.03e-7	Cognitive function;
THYM	cis	rs700651	0.821	rs700663	chr2:198670478	T/A	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Intracranial aneurysm;
THYM	cis	rs2108225	0.967	rs6466189	chr7:107448516	C/T	cg18560240	chr7:107437656	SLC26A3	-0.78	-5.63	-0.5	1.82e-7	Ulcerative colitis;
THYM	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg03433033	chr1:76189801	ACADM	-0.5	-4.93	-0.45	3.51e-6	Daytime sleep phenotypes;
THYM	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.25	-0.47	9.24e-7	Hemoglobin concentration;
THYM	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg02782426	chr3:40428986	ENTPD3	0.53	4.68	0.43	9.67e-6	Renal cell carcinoma;
THYM	cis	rs4481887	1.000	rs4430369	chr1:248464330	A/G	cg00666640	chr1:248458726	OR2T12	0.56	4.61	0.43	1.26e-5	Common traits (Other);
THYM	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.47	0.49	3.63e-7	Bipolar disorder;
THYM	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg13319975	chr6:146136371	FBXO30	-0.65	-5.34	-0.48	6.37e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg19635926	chr16:89946313	TCF25	0.98	4.46	0.42	2.26e-5	Skin colour saturation;
THYM	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2835345	0.563	rs4481073	chr21:37824955	T/C	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.87	-5.94	-0.52	4.67e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg00129232	chr17:37814104	STARD3	0.71	4.8	0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs611744	0.625	rs11779824	chr8:109278689	G/A	cg21045802	chr8:109455806	TTC35	0.68	6.04	0.53	3.03e-8	Dupuytren's disease;
THYM	cis	rs2574704	0.651	rs2616552	chr3:11666798	G/T	cg07643000	chr3:11666825	VGLL4	-0.57	-6.46	-0.55	4.39e-9	Body mass index;
THYM	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg09455208	chr3:40491958	NA	0.49	5.1	0.46	1.75e-6	Renal cell carcinoma;
THYM	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg04315214	chr1:2043799	PRKCZ	0.66	5.58	0.5	2.27e-7	Height;
THYM	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg04455712	chr21:45112962	RRP1B	0.56	5.4	0.48	4.86e-7	Mean corpuscular volume;
THYM	cis	rs10791097	0.967	rs10894268	chr11:130717153	C/T	cg05962950	chr11:130786565	SNX19	0.68	5.38	0.48	5.34e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg00376283	chr12:123451042	ABCB9	0.7	4.57	0.42	1.44e-5	Neutrophil percentage of white cells;
THYM	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2554380	0.943	rs2585040	chr15:84340468	G/C	cg14598478	chr15:84363061	ADAMTSL3	-0.65	-5.11	-0.46	1.68e-6	Height;
THYM	cis	rs17253792	0.822	rs2296181	chr14:56107051	G/A	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs28595532	0.920	rs114333298	chr4:119765305	C/A	cg14228332	chr4:119757509	SEC24D	1.59	5.76	0.51	1.04e-7	Cannabis dependence symptom count;
THYM	cis	rs7772486	0.875	rs10457795	chr6:146415665	A/G	cg23711669	chr6:146136114	FBXO30	0.96	10.33	0.73	3.19e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.85	5.65	0.5	1.7e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg04944784	chr2:26401820	FAM59B	-0.79	-6.18	-0.54	1.61e-8	Gut microbiome composition (summer);
THYM	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.84	-5.3	-0.48	7.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9527	0.615	rs2152915	chr10:104691732	A/T	cg15744005	chr10:104629667	AS3MT	-0.6	-4.58	-0.42	1.43e-5	Arsenic metabolism;
THYM	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.75e-6	Aortic root size;
THYM	cis	rs6565180	0.926	rs4788413	chr16:30410445	C/T	cg17640201	chr16:30407289	ZNF48	0.87	7.05	0.59	2.85e-10	Tonsillectomy;
THYM	cis	rs9549260	0.664	rs1360719	chr13:41225874	G/C	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs7777677	0.963	rs7796324	chr7:142371540	A/G	cg21785750	chr7:142428317	NA	0.67	5.85	0.51	6.91e-8	Alcoholic chronic pancreatitis;
THYM	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs7084402	0.967	rs1658489	chr10:60285924	A/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs4243830	1.000	rs4243832	chr1:6577962	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.06	-5.92	-0.52	5.12e-8	Body mass index;
THYM	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	9.38	0.69	3.49e-15	Chronic sinus infection;
THYM	cis	rs7107174	0.792	rs10751287	chr11:78072476	T/C	cg02023728	chr11:77925099	USP35	0.62	6.08	0.53	2.49e-8	Testicular germ cell tumor;
THYM	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg11247378	chr22:39784982	NA	-0.97	-10.67	-0.74	6.08e-18	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.817	rs11053125	chr12:34265417	C/T	cg10856724	chr12:34555212	NA	-0.66	-5.76	-0.51	1.04e-7	Morning vs. evening chronotype;
THYM	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg06130144	chr11:64578348	MEN1	0.72	4.51	0.42	1.85e-5	Mean platelet volume;
THYM	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg17264618	chr3:40429014	ENTPD3	0.58	5.59	0.5	2.17e-7	Renal cell carcinoma;
THYM	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg13683864	chr3:40499215	RPL14	1.11	13.93	0.82	1.12e-24	Renal cell carcinoma;
THYM	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg07362569	chr17:61921086	SMARCD2	0.71	6.23	0.54	1.3e-8	Prudent dietary pattern;
THYM	cis	rs17744026	0.617	rs724467	chr11:123680571	C/T	cg00079598	chr11:123676903	OR6M1	-0.51	-4.63	-0.43	1.15e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs2237457	0.543	rs2237446	chr7:50700298	T/C	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.48e-6	Schizophrenia (treatment resistant);
THYM	cis	rs477692	0.569	rs10764885	chr10:131310207	G/A	cg05714579	chr10:131428358	MGMT	0.59	4.8	0.44	5.91e-6	Response to temozolomide;
THYM	cis	rs4595586	0.545	rs12813151	chr12:39363405	C/G	cg13010199	chr12:38710504	ALG10B	-0.6	-4.48	-0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg11812906	chr14:75593930	NEK9	-0.75	-6.56	-0.56	2.83e-9	Height;
THYM	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg00376283	chr12:123451042	ABCB9	0.69	4.65	0.43	1.09e-5	Neutrophil percentage of white cells;
THYM	cis	rs2997447	0.595	rs3008425	chr1:26385660	T/C	cg19633962	chr1:26362018	EXTL1	-0.68	-4.77	-0.44	6.58e-6	QRS complex (12-leadsum);
THYM	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg03929089	chr4:120376271	NA	1.03	8.55	0.66	2.06e-13	Coronary artery disease;
THYM	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg15557168	chr22:42548783	NA	-0.58	-4.68	-0.43	9.66e-6	Schizophrenia;
THYM	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs10426930	0.700	rs7253212	chr19:5021391	G/A	cg25246084	chr19:4971487	KDM4B	-0.51	-5.3	-0.48	7.37e-7	Monocyte percentage of white cells;
THYM	cis	rs56775891	0.959	rs11663602	chr18:77578191	G/T	cg13263691	chr18:77568018	NA	0.6	4.63	0.43	1.14e-5	Schizophrenia;
THYM	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg09021430	chr5:549028	NA	-0.87	-9.0	-0.68	2.32e-14	Obesity-related traits;
THYM	cis	rs4654899	0.772	rs12404954	chr1:21074727	A/G	cg01072550	chr1:21505969	NA	-0.64	-5.53	-0.49	2.79e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs7762018	0.607	rs75438963	chr6:170047695	G/A	cg19338460	chr6:170058176	WDR27	-1.06	-6.21	-0.54	1.39e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg01579765	chr21:45077557	HSF2BP	-0.49	-7.73	-0.62	1.11e-11	Mean corpuscular volume;
THYM	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg09359103	chr1:154839909	KCNN3	-0.75	-8.52	-0.66	2.42e-13	Prostate cancer;
THYM	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.48	-4.71	-0.44	8.34e-6	Crohn's disease;
THYM	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg00484396	chr16:3507460	NAT15	0.66	6.44	0.55	4.97e-9	Tuberculosis;
THYM	cis	rs10845606	0.581	rs10772591	chr12:12834802	A/G	cg04118741	chr12:12551013	LOH12CR1	0.5	4.59	0.43	1.34e-5	Systemic lupus erythematosus;
THYM	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg03433033	chr1:76189801	ACADM	0.77	10.21	0.72	6.01e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg00495681	chr13:53174319	NA	0.63	5.75	0.51	1.07e-7	Lewy body disease;
THYM	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg08132940	chr7:1081526	C7orf50	-1.16	-6.65	-0.56	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1461503	0.900	rs7119398	chr11:122832492	C/A	cg27398637	chr11:122830231	C11orf63	-0.66	-5.61	-0.5	2.02e-7	Menarche (age at onset);
THYM	cis	rs10779751	1.000	rs12032364	chr1:11286872	G/T	cg08854313	chr1:11322531	MTOR	0.95	7.85	0.63	6.28e-12	Body mass index;
THYM	cis	rs4792901	0.879	rs12600482	chr17:41630597	T/G	cg21940313	chr17:41620911	ETV4	-0.52	-5.51	-0.49	3.08e-7	Dupuytren's disease;
THYM	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg00376283	chr12:123451042	ABCB9	0.8	6.41	0.55	5.49e-9	Platelet count;
THYM	cis	rs10899021	0.512	rs10219168	chr11:74374453	A/T	cg25880958	chr11:74394337	NA	0.59	5.38	0.48	5.35e-7	Response to metformin (IC50);
THYM	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg05896524	chr21:47604654	C21orf56	0.73	4.83	0.44	5.21e-6	Testicular germ cell tumor;
THYM	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.93	5.98	0.52	3.95e-8	Smoking behavior;
THYM	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	trans	rs10043228	0.793	rs62384211	chr5:115521104	T/C	cg12255298	chr19:3976193	EEF2	1.07	6.99	0.58	3.79e-10	Asthma or chronic obstructive pulmonary disease;
THYM	cis	rs12142240	0.660	rs6679080	chr1:46819779	A/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs9359856	0.517	rs112527288	chr6:90509141	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.89	-8.13	-0.64	1.6e-12	Bipolar disorder;
THYM	cis	rs5015933	0.801	rs6478703	chr9:128141348	A/G	cg14078157	chr9:128172775	NA	0.55	4.61	0.43	1.27e-5	Body mass index;
THYM	cis	rs7487075	0.930	rs6582656	chr12:46843416	A/G	cg17501823	chr12:47219793	SLC38A4	0.46	4.51	0.42	1.85e-5	Itch intensity from mosquito bite;
THYM	cis	rs12594515	1.000	rs11854554	chr15:45994546	C/G	cg01629716	chr15:45996671	NA	0.53	5.27	0.48	8.45e-7	Waist circumference;Weight;
THYM	cis	rs8050907	1.000	rs114914341	chr16:4617621	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.57	0.42	1.47e-5	Obesity-related traits;
THYM	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg12165864	chr7:66369176	NA	0.65	5.05	0.46	2.12e-6	Aortic root size;
THYM	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-6.42	-0.55	5.23e-9	Chronic sinus infection;
THYM	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	5.44	0.49	4.08e-7	Lung cancer in ever smokers;
THYM	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg05335186	chr13:53173507	NA	-0.45	-5.28	-0.48	8.14e-7	Lewy body disease;
THYM	cis	rs1747683	0.966	rs7901303	chr10:13378690	T/G	cg00142036	chr10:13388442	SEPHS1	-0.28	-4.99	-0.46	2.75e-6	IgG glycosylation;
THYM	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg11166453	chr1:247681781	NA	0.69	5.38	0.48	5.45e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs17253792	0.822	rs78522049	chr14:56071203	A/C	cg01858014	chr14:56050164	KTN1	-1.22	-5.13	-0.47	1.52e-6	Putamen volume;
THYM	cis	rs289828	0.579	rs13030194	chr2:152149052	C/T	cg05960677	chr2:152117363	RBM43	0.69	6.52	0.56	3.35e-9	Blood protein levels;
THYM	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.08	-7.42	-0.61	4.86e-11	Schizophrenia;
THYM	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg22189786	chr22:42395067	WBP2NL	0.57	5.14	0.47	1.47e-6	Birth weight;
THYM	cis	rs4851254	0.660	rs4851250	chr2:100729293	T/C	cg22139774	chr2:100720529	AFF3	-0.4	-4.51	-0.42	1.86e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.11e-8	Systolic blood pressure;
THYM	cis	rs2932538	0.922	rs12401734	chr1:113071834	A/G	cg22162597	chr1:113214053	CAPZA1	0.58	4.71	0.44	8.39e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs6456156	0.967	rs150108	chr6:167513153	C/T	cg09487078	chr6:167525398	CCR6	0.42	4.52	0.42	1.77e-5	Primary biliary cholangitis;
THYM	cis	rs8067545	0.611	rs2703777	chr17:20138891	C/T	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs9810089	0.527	rs3957816	chr3:135955852	C/T	cg12473912	chr3:136751656	NA	0.7	6.49	0.55	3.95e-9	Gestational age at birth (child effect);
THYM	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg18252515	chr7:66147081	NA	-1.37	-8.05	-0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs13064411	0.696	rs6787026	chr3:113162117	A/G	cg18753928	chr3:113234510	CCDC52	-0.9	-7.98	-0.63	3.34e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs11574514	0.661	rs8058638	chr16:67544009	C/T	cg09738193	chr16:67926317	PSKH1	-0.82	-4.48	-0.42	2.09e-5	Crohn's disease;
THYM	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg06238570	chr21:40685208	BRWD1	-0.69	-6.08	-0.53	2.47e-8	Menarche (age at onset);
THYM	cis	rs9868809	0.772	rs2286651	chr3:48694147	G/A	cg00383909	chr3:49044727	WDR6	1.13	5.77	0.51	1e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4631830	0.863	rs2611507	chr10:51518673	T/C	cg10326726	chr10:51549505	MSMB	-0.5	-5.1	-0.46	1.71e-6	Prostate-specific antigen levels;
THYM	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg22907277	chr7:1156413	C7orf50	0.81	4.97	0.45	2.94e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7681440	0.606	rs2737013	chr4:90745503	C/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs2267708	0.509	rs6959972	chr7:124617108	T/C	cg05285228	chr7:124571219	POT1	-0.72	-5.5	-0.49	3.2e-7	Chronic lymphocytic leukemia;
THYM	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg11494091	chr17:61959527	GH2	0.71	6.37	0.55	6.65e-9	Height;
THYM	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.97	-7.62	-0.62	1.88e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	12.82	0.8	1.97e-22	Chronic sinus infection;
THYM	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.56	-10.9	-0.75	2.04e-18	Hemostatic factors and hematological phenotypes;
THYM	cis	rs3008870	0.755	rs1925410	chr1:67365230	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.81	-6.88	-0.58	6.25e-10	Lymphocyte percentage of white cells;
THYM	cis	rs3767633	0.764	rs2490429	chr1:161942509	A/G	cg27495845	chr1:161693088	FCRLB	-0.59	-4.46	-0.42	2.29e-5	IgG glycosylation;
THYM	cis	rs4148689	1.000	rs12673260	chr7:117137400	A/C	cg17204129	chr7:117119601	CFTR	-0.59	-4.7	-0.43	8.7e-6	Gout;
THYM	cis	rs9326248	0.530	rs562179	chr11:116805204	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.88	4.81	0.44	5.71e-6	Blood protein levels;
THYM	cis	rs17854409	1.000	rs66956644	chr20:61484499	T/C	cg05147244	chr20:61493195	TCFL5	1.03	6.29	0.54	9.88e-9	Obesity-related traits;
THYM	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg08645402	chr16:4508243	NA	0.75	6.71	0.57	1.42e-9	Schizophrenia;
THYM	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg16928487	chr17:17741425	SREBF1	0.51	5.14	0.47	1.46e-6	Total body bone mineral density;
THYM	cis	rs8048589	0.898	rs11648235	chr16:12181079	C/T	cg01990910	chr16:12207648	SNX29	-0.42	-4.69	-0.43	9.21e-6	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg02018176	chr4:1364513	KIAA1530	0.55	4.69	0.43	9.28e-6	Obesity-related traits;
THYM	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg12599982	chr1:44399894	ARTN	0.56	4.66	0.43	1.02e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg13147721	chr7:65941812	NA	-0.73	-4.58	-0.43	1.42e-5	Diabetic kidney disease;
THYM	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg14008862	chr17:28927542	LRRC37B2	0.92	4.79	0.44	6.05e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg03433033	chr1:76189801	ACADM	-0.51	-5.4	-0.48	4.98e-7	Daytime sleep phenotypes;
THYM	cis	rs3847687	0.966	rs3847689	chr12:131525534	T/G	cg25772418	chr12:131519998	GPR133	-0.5	-7.34	-0.6	7.1e-11	Longevity;
THYM	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg18357526	chr6:26021779	HIST1H4A	0.75	6.24	0.54	1.21e-8	Intelligence (multi-trait analysis);
THYM	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg01416388	chr22:39784598	NA	-0.95	-9.15	-0.68	1.11e-14	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg27532560	chr4:187881888	NA	-0.95	-11.83	-0.77	2.15e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6876348	1.000	rs6876348	chr5:128120452	A/C	cg25555059	chr5:128301488	SLC27A6	-0.46	-4.89	-0.45	4.15e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs34912216	0.587	rs11979803	chr7:4121578	A/G	cg03141780	chr7:4150753	SDK1	0.7	5.3	0.48	7.4e-7	Motion sickness;
THYM	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg24733560	chr20:60626293	TAF4	0.53	4.65	0.43	1.08e-5	Body mass index;
THYM	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg12386194	chr3:101231763	SENP7	0.7	5.31	0.48	7.21e-7	Colorectal cancer;
THYM	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06873352	chr17:61820015	STRADA	0.56	5.63	0.5	1.84e-7	Height;
THYM	cis	rs7107174	0.688	rs10793294	chr11:77996403	G/T	cg02023728	chr11:77925099	USP35	-0.49	-4.55	-0.42	1.59e-5	Testicular germ cell tumor;
THYM	cis	rs919433	0.519	rs700656	chr2:198653667	T/C	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2219968	0.620	rs12675858	chr8:78900503	G/T	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg09455208	chr3:40491958	NA	0.47	4.8	0.44	5.84e-6	Renal cell carcinoma;
THYM	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg17757837	chr7:157058334	UBE3C	0.66	5.29	0.48	7.81e-7	Body mass index;
THYM	cis	rs17539620	0.519	rs4077066	chr6:154838448	C/G	cg20019720	chr6:154832845	CNKSR3	0.61	6.8	0.57	9.42e-10	Lipoprotein (a) levels;
THYM	cis	rs2299587	0.610	rs7001974	chr8:17773295	C/T	cg01800426	chr8:17659068	MTUS1	-0.68	-5.18	-0.47	1.26e-6	Economic and political preferences;
THYM	cis	rs1448094	0.556	rs17279916	chr12:86170647	G/A	cg02569458	chr12:86230093	RASSF9	0.62	5.34	0.48	6.31e-7	Major depressive disorder;
THYM	cis	rs6920965	0.507	rs9385388	chr6:126215296	C/T	cg10911889	chr6:126070802	HEY2	0.7	4.98	0.45	2.9e-6	High light scatter reticulocyte count;
THYM	cis	rs501916	0.761	rs589889	chr15:48019016	C/G	cg20869673	chr15:48010124	SEMA6D	0.72	5.54	0.49	2.66e-7	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs9505118	0.620	rs2842370	chr6:7308047	T/C	cg01785233	chr6:7260807	NA	0.39	4.57	0.42	1.46e-5	Type 2 diabetes;
THYM	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2658782	0.756	rs3019222	chr11:93079718	C/T	cg15737290	chr11:93063684	CCDC67	0.99	8.21	0.64	1.09e-12	Pulmonary function decline;
THYM	cis	rs7762018	0.556	rs80250989	chr6:170105553	T/C	cg19338460	chr6:170058176	WDR27	-1.03	-6.18	-0.54	1.57e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs6956675	1.000	rs4718791	chr7:62577991	G/C	cg08930214	chr7:62859557	LOC100287834	0.62	4.58	0.43	1.42e-5	Obesity-related traits;
THYM	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg07936489	chr17:37558343	FBXL20	-0.82	-5.61	-0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4072705	0.967	rs4838200	chr9:127451057	A/G	cg01786973	chr9:127249749	NR5A1	-0.35	-4.69	-0.43	9.25e-6	Menarche (age at onset);
THYM	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg18305652	chr10:134549665	INPP5A	0.81	7.16	0.59	1.68e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs172166	0.538	rs149956	chr6:28036251	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.59	-5.12	-0.47	1.58e-6	Cardiac Troponin-T levels;
THYM	cis	rs986417	1.000	rs1116854	chr14:60917496	C/A	cg27398547	chr14:60952738	C14orf39	-1.15	-5.91	-0.52	5.37e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs12257961	0.646	rs10752365	chr10:15355625	C/T	cg10616319	chr10:15468812	NA	-0.6	-4.78	-0.44	6.33e-6	Selective IgA deficiency;
THYM	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg03929089	chr4:120376271	NA	-1.02	-13.31	-0.81	1.91e-23	Height;
THYM	cis	rs80319144	0.953	rs11686762	chr2:159195225	T/G	cg24986868	chr2:159312599	PKP4;CCDC148	0.59	4.73	0.44	7.69e-6	Restless legs syndrome;
THYM	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06634786	chr22:41940651	POLR3H	-0.81	-6.11	-0.53	2.22e-8	Vitiligo;
THYM	cis	rs9311676	0.632	rs56026131	chr3:58422483	C/G	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg07424592	chr7:64974309	NA	1.1	5.08	0.46	1.87e-6	Diabetic kidney disease;
THYM	cis	rs4888262	0.545	rs4243108	chr16:74692453	A/G	cg01733217	chr16:74700730	RFWD3	-0.87	-9.37	-0.69	3.62e-15	Testicular germ cell tumor;
THYM	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	5.18	0.47	1.25e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22496380	chr5:211416	CCDC127	-1.32	-7.26	-0.6	1.04e-10	Breast cancer;
THYM	trans	rs4866334	1.000	rs79107423	chr5:18501522	A/G	cg08675002	chr5:90437527	GPR98	-1.55	-7.42	-0.61	4.86e-11	IgG glycosylation;
THYM	cis	rs11563648	0.573	rs6467120	chr7:126961533	G/A	cg23081781	chr7:127225937	GCC1	-0.35	-4.79	-0.44	6.03e-6	Resting heart rate;
THYM	cis	rs919433	0.929	rs4850788	chr2:198182940	G/A	cg00792783	chr2:198669748	PLCL1	-0.71	-5.38	-0.48	5.46e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6502050	0.835	rs35038106	chr17:80180346	C/T	cg10505658	chr17:80084571	CCDC57	-0.72	-7.86	-0.63	6.04e-12	Life satisfaction;
THYM	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg24920358	chr1:40204285	PPIE	0.6	5.52	0.49	2.96e-7	Blood protein levels;
THYM	trans	rs6089829	0.589	rs73921629	chr20:61676036	G/C	cg13615516	chr5:77269221	NA	-0.9	-6.84	-0.57	7.71e-10	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg11247378	chr22:39784982	NA	1.06	13.09	0.8	5.42e-23	Intelligence (multi-trait analysis);
THYM	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg03929089	chr4:120376271	NA	-0.95	-10.84	-0.74	2.75e-18	Coronary artery disease;
THYM	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.04	8.71	0.67	9.28e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3087591	0.960	rs2952991	chr17:29526742	T/C	cg24425628	chr17:29625626	OMG;NF1	0.66	5.79	0.51	9.11e-8	Hip circumference;
THYM	trans	rs10802346	0.545	rs2362253	chr1:246371676	G/A	cg22732515	chr19:44031385	ETHE1	1.03	9.03	0.68	1.93e-14	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg19748678	chr4:122722346	EXOSC9	0.73	5.15	0.47	1.42e-6	Type 2 diabetes;
THYM	cis	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg05084668	chr3:125655381	ALG1L	-0.83	-4.69	-0.43	9.13e-6	Blood pressure (smoking interaction);
THYM	cis	rs7917772	0.560	rs4919664	chr10:104363408	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg02569458	chr12:86230093	RASSF9	0.58	5.01	0.46	2.47e-6	Major depressive disorder;
THYM	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.75	5.74	0.51	1.13e-7	Eosinophil percentage of white cells;
THYM	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg08859206	chr1:53392774	SCP2	-0.48	-5.03	-0.46	2.28e-6	Monocyte count;
THYM	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg12179176	chr11:130786555	SNX19	0.87	8.21	0.64	1.08e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.25	-5.11	-0.46	1.64e-6	Obesity-related traits;
THYM	cis	rs36051895	0.632	rs11790841	chr9:5166273	G/C	cg02405213	chr9:5042618	JAK2	-1.06	-9.85	-0.71	3.44e-16	Pediatric autoimmune diseases;
THYM	cis	rs1357245	0.565	rs12330276	chr3:27096513	A/T	cg03895047	chr3:27114861	NA	0.49	4.58	0.43	1.42e-5	Breast cancer;
THYM	cis	rs8067354	0.645	rs28516945	chr17:57816578	T/C	cg20151207	chr17:57696971	CLTC	-0.7	-4.67	-0.43	9.76e-6	Hemoglobin concentration;
THYM	cis	rs12704876	0.509	rs1464808	chr7:96363633	A/T	cg03808172	chr7:96339361	SHFM1	0.73	5.11	0.46	1.68e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.71	-6.5	-0.55	3.76e-9	Total body bone mineral density;
THYM	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg07636037	chr3:49044803	WDR6	0.99	10.4	0.73	2.28e-17	Parkinson's disease;
THYM	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.52	-0.49	2.94e-7	Type 2 diabetes;
THYM	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.07	-0.46	1.93e-6	Life satisfaction;
THYM	cis	rs2658782	0.547	rs3020064	chr11:93060851	A/G	cg15737290	chr11:93063684	CCDC67	1.16	11.14	0.75	6.15e-19	Pulmonary function decline;
THYM	cis	rs3850699	0.666	rs7905481	chr10:104476292	T/C	cg15744005	chr10:104629667	AS3MT	-0.59	-4.67	-0.43	9.79e-6	Prostate cancer;
THYM	cis	rs765787	0.530	rs12903149	chr15:45539076	G/A	cg25801113	chr15:45476975	SHF	-0.39	-4.57	-0.42	1.48e-5	Uric acid levels;
THYM	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg06002616	chr8:101225028	SPAG1	-0.46	-4.79	-0.44	6.22e-6	Atrioventricular conduction;
THYM	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03264133	chr6:25882463	NA	0.93	8.24	0.65	9.46e-13	Blood metabolite levels;
THYM	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg04756594	chr16:24857601	SLC5A11	0.79	5.68	0.5	1.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg10802521	chr3:52805072	NEK4	-0.68	-5.78	-0.51	9.31e-8	Bipolar disorder;
THYM	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg10802521	chr3:52805072	NEK4	-0.8	-7.53	-0.61	2.92e-11	Electroencephalogram traits;
THYM	cis	rs7100689	0.646	rs2095994	chr10:82127956	G/A	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs17443541	0.507	rs1823489	chr2:200463825	C/G	cg01795955	chr2:200468626	NA	-0.72	-5.0	-0.46	2.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.698	rs720615	chr7:124452706	C/T	cg05285228	chr7:124571219	POT1	0.66	5.24	0.47	9.54e-7	Cutaneous malignant melanoma;
THYM	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg08885076	chr2:99613938	TSGA10	0.57	5.3	0.48	7.37e-7	Chronic sinus infection;
THYM	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg14004847	chr7:1930337	MAD1L1	-0.62	-4.86	-0.45	4.7e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6964587	0.610	rs7788951	chr7:91468765	A/T	cg17063962	chr7:91808500	NA	1.0	8.63	0.66	1.4e-13	Breast cancer;
THYM	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg16405210	chr4:1374714	KIAA1530	0.93	8.14	0.64	1.49e-12	Longevity;
THYM	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg06074448	chr4:187884817	NA	-1.0	-13.48	-0.81	8.89e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9326248	0.559	rs10892052	chr11:116834313	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.66	5.39	0.48	5.22e-7	Blood protein levels;
THYM	cis	rs7084921	0.552	rs7913374	chr10:101879686	C/G	cg11344164	chr10:101878520	NA	0.58	5.36	0.48	5.8e-7	Bone mineral density;
THYM	cis	rs1971762	0.527	rs6580953	chr12:54021138	T/C	cg16917193	chr12:54089295	NA	0.76	7.41	0.61	5.15e-11	Height;
THYM	cis	rs9807989	0.507	rs1420097	chr2:103009354	C/G	cg03938978	chr2:103052716	IL18RAP	-0.75	-9.77	-0.71	5.14e-16	Asthma;
THYM	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg00271210	chr6:167070053	RPS6KA2	-0.69	-7.4	-0.6	5.3e-11	Crohn's disease;
THYM	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg14074117	chr16:1909714	C16orf73	-0.7	-4.45	-0.42	2.3e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg04398451	chr17:18023971	MYO15A	-0.95	-9.6	-0.7	1.19e-15	Total body bone mineral density;
THYM	cis	rs9790314	0.540	rs9844862	chr3:161076188	G/A	cg04691961	chr3:161091175	C3orf57	-0.59	-4.87	-0.45	4.45e-6	Morning vs. evening chronotype;
THYM	cis	rs7769051	0.522	rs7762248	chr6:133105303	A/C	cg22852734	chr6:133119734	C6orf192	1.44	5.87	0.52	6.36e-8	Type 2 diabetes nephropathy;
THYM	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs7429990	0.932	rs2361684	chr3:48152618	G/C	cg02219026	chr3:48282209	ZNF589	0.59	4.46	0.42	2.23e-5	Educational attainment (years of education);
THYM	cis	rs9796	0.717	rs476633	chr15:41392134	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.62	-4.88	-0.45	4.3e-6	Menopause (age at onset);
THYM	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.5	0.73	1.4e-17	Prudent dietary pattern;
THYM	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	5.12	0.47	1.57e-6	Rheumatoid arthritis;
THYM	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	6.61	0.56	2.26e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs1499972	0.941	rs62263076	chr3:117599798	C/T	cg07612923	chr3:117604196	NA	1.3	5.57	0.5	2.35e-7	Schizophrenia;
THYM	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg22868518	chr11:507468	RNH1	-1.13	-4.56	-0.42	1.53e-5	Body mass index;
THYM	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg11266682	chr4:10021025	SLC2A9	0.74	12.07	0.78	6.92e-21	Bone mineral density;
THYM	cis	rs7909074	0.831	rs11239271	chr10:45376294	A/G	cg04218760	chr10:45406644	TMEM72	-0.56	-5.1	-0.46	1.73e-6	Mean corpuscular volume;
THYM	cis	rs2139634	1.000	rs11706090	chr3:46519345	A/T	cg02332537	chr3:46540019	RTP3	0.49	4.92	0.45	3.69e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg05368731	chr17:41323189	NBR1	1.24	11.23	0.76	4.01e-19	Menopause (age at onset);
THYM	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg26131816	chr17:42072204	PYY	0.53	4.6	0.43	1.28e-5	Menopause (age at onset);
THYM	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg05347473	chr6:146136440	FBXO30	-0.58	-4.59	-0.43	1.38e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17253792	0.822	rs17685078	chr14:56127202	T/C	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg24209194	chr3:40518798	ZNF619	0.67	5.5	0.49	3.17e-7	Renal cell carcinoma;
THYM	cis	rs921968	0.565	rs1554622	chr2:219606218	T/G	cg02176678	chr2:219576539	TTLL4	-0.47	-4.56	-0.42	1.55e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg03517284	chr6:25882590	NA	-0.69	-4.66	-0.43	1.02e-5	Height;
THYM	cis	rs66887589	0.934	rs7681980	chr4:120533223	G/A	cg13609457	chr4:120235615	NA	-0.47	-4.95	-0.45	3.24e-6	Diastolic blood pressure;
THYM	cis	rs8050907	0.744	rs28680621	chr16:4518994	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.58	0.43	1.38e-5	Obesity-related traits;
THYM	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg12310025	chr6:25882481	NA	-0.9	-8.45	-0.66	3.34e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	8.22	0.64	1.02e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22307029	chr19:49891270	CCDC155	0.58	4.66	0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg24060327	chr5:131705240	SLC22A5	-0.75	-6.06	-0.53	2.71e-8	Breast cancer;
THYM	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg25554036	chr4:6271136	WFS1	0.56	5.29	0.48	7.94e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs1062753	0.961	rs9620007	chr22:42405657	C/G	cg01059385	chr22:42394853	WBP2NL	0.57	4.66	0.43	1.04e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs2050392	0.517	rs302423	chr10:30772513	A/G	cg13289132	chr10:30722225	MAP3K8	-0.66	-5.26	-0.48	8.74e-7	Inflammatory bowel disease;
THYM	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg15744692	chr15:45671195	LOC145663;GATM	-0.45	-4.48	-0.42	2.08e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs807029	0.544	rs55646950	chr10:102760996	C/T	cg14905631	chr10:102746534	C10orf2;MRPL43	0.37	4.96	0.45	3.08e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6674176	0.660	rs11210936	chr1:44391438	A/T	cg13246856	chr1:44399776	ARTN	0.5	4.8	0.44	5.97e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-5.16	-0.47	1.35e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs950880	0.710	rs4851582	chr2:103051558	T/C	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.68	-0.43	9.39e-6	Serum protein levels (sST2);
THYM	cis	rs2080501	0.628	rs1344530	chr16:49665122	T/C	cg05126388	chr16:49670144	ZNF423	0.87	11.46	0.76	1.33e-19	IgG glycosylation;
THYM	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.28	10.82	0.74	2.95e-18	Platelet count;
THYM	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg11764359	chr7:65958608	NA	-0.83	-6.6	-0.56	2.37e-9	Aortic root size;
THYM	cis	rs8180040	0.871	rs11716661	chr3:47517773	G/T	cg27129171	chr3:47204927	SETD2	-0.69	-6.69	-0.57	1.54e-9	Colorectal cancer;
THYM	cis	rs4343996	0.558	rs1554498	chr7:3415568	A/G	cg21248987	chr7:3385318	SDK1	0.4	4.91	0.45	3.72e-6	Motion sickness;
THYM	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg20295408	chr7:1910781	MAD1L1	-0.65	-5.23	-0.47	1.02e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.43	1.27e-5	Breast cancer;
THYM	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg13918804	chr1:2043761	PRKCZ	-0.61	-4.62	-0.43	1.19e-5	Height;
THYM	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg17294928	chr15:75287854	SCAMP5	0.98	5.33	0.48	6.65e-7	Lung cancer;
THYM	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg22535103	chr8:58192502	C8orf71	-0.93	-5.54	-0.49	2.64e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg03909863	chr11:638404	DRD4	-0.76	-6.04	-0.53	2.95e-8	Systemic lupus erythematosus;
THYM	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg24818145	chr4:99064322	C4orf37	0.73	5.76	0.51	1.04e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg00990874	chr7:1149470	C7orf50	-0.55	-4.51	-0.42	1.89e-5	Longevity;Endometriosis;
THYM	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg18876405	chr7:65276391	NA	0.76	7.16	0.59	1.66e-10	Aortic root size;
THYM	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7100689	0.622	rs4536152	chr10:82119242	C/T	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs600806	0.821	rs10127790	chr1:109891133	C/T	cg02175308	chr1:109941060	SORT1	-0.59	-5.13	-0.47	1.51e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1670533	1.000	rs676561	chr4:1083112	C/T	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.91	0.45	3.71e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3135718	0.967	rs2912774	chr10:123348662	A/C	cg15049101	chr10:123353889	FGFR2	-0.59	-5.21	-0.47	1.08e-6	Estrogen receptor status in breast cancer;
THYM	cis	rs714031	0.900	rs5757762	chr22:40064581	C/T	cg21377881	chr22:40064566	CACNA1I	-0.68	-6.1	-0.53	2.27e-8	Schizophrenia;
THYM	cis	rs7107174	1.000	rs1017908	chr11:77948095	A/G	cg19901956	chr11:77921274	USP35	-0.81	-6.18	-0.54	1.56e-8	Testicular germ cell tumor;
THYM	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg04287289	chr16:89883240	FANCA	0.65	5.87	0.52	6.49e-8	Vitiligo;
THYM	cis	rs12291225	0.679	rs7934671	chr11:14305101	C/T	cg19336497	chr11:14380999	RRAS2	-0.82	-9.66	-0.7	8.92e-16	Sense of smell;
THYM	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	5.12	0.47	1.57e-6	Rheumatoid arthritis;
THYM	cis	rs11997175	0.692	rs6468202	chr8:33747720	C/A	ch.8.33884649F	chr8:33765107	NA	0.72	5.49	0.49	3.3e-7	Body mass index;
THYM	cis	rs10779751	1.000	rs12120734	chr1:11262020	A/G	cg08854313	chr1:11322531	MTOR	1.02	9.88	0.71	2.98e-16	Body mass index;
THYM	cis	rs4474465	0.790	rs12363982	chr11:78229167	C/T	cg19901956	chr11:77921274	USP35	0.63	4.67	0.43	9.89e-6	Alzheimer's disease (survival time);
THYM	cis	rs2073300	0.609	rs6132606	chr20:23367453	G/A	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg10360139	chr7:1886902	MAD1L1	-0.58	-4.61	-0.43	1.28e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs6906287	0.609	rs11153759	chr6:118920860	T/A	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs7107174	1.000	rs9651768	chr11:77996020	C/T	cg19901956	chr11:77921274	USP35	-0.69	-5.19	-0.47	1.17e-6	Testicular germ cell tumor;
THYM	cis	rs1062746	0.738	rs2303764	chr16:87377455	C/G	cg27119004	chr16:87376851	FBXO31	-0.48	-4.67	-0.43	9.86e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs6032067	0.929	rs6032055	chr20:43833336	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs1642645	0.831	rs7535305	chr1:42489602	C/A	cg22816091	chr1:42611670	NA	0.62	5.52	0.49	2.99e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg05299048	chr3:52828583	ITIH3	0.6	4.45	0.42	2.3e-5	Bipolar disorder;
THYM	cis	rs4845459	0.967	rs4085613	chr1:152550018	T/G	cg26135325	chr1:152595322	LCE3A	-0.44	-4.97	-0.45	2.97e-6	Psoriasis;
THYM	cis	rs10089	0.953	rs6887674	chr5:127531183	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.94	5.48	0.49	3.55e-7	Ileal carcinoids;
THYM	cis	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg03060546	chr3:49711283	APEH	-0.64	-4.9	-0.45	3.86e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg21028142	chr17:79581711	NPLOC4	0.64	6.74	0.57	1.23e-9	Eye color traits;
THYM	cis	rs2075230	0.705	rs1641521	chr17:7550143	T/C	cg27413385	chr17:7515425	FXR2	-0.37	-5.39	-0.48	5.16e-7	Hormone measurements;
THYM	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06873352	chr17:61820015	STRADA	0.56	5.63	0.5	1.84e-7	Height;
THYM	cis	rs6763768	0.606	rs13082092	chr3:53373204	T/G	cg16894138	chr3:53270350	TKT	0.72	5.47	0.49	3.68e-7	Bacterial meningitis;
THYM	cis	rs28374715	0.510	rs28468975	chr15:41564592	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.9	-7.49	-0.61	3.49e-11	Ulcerative colitis;
THYM	cis	rs611744	0.967	rs662591	chr8:109211358	C/T	cg21045802	chr8:109455806	TTC35	0.59	5.31	0.48	7.16e-7	Dupuytren's disease;
THYM	cis	rs1915919	0.794	rs4398451	chr3:20010886	T/C	cg05072819	chr3:20081367	KAT2B	0.63	5.08	0.46	1.91e-6	Post-traumatic stress disorder;
THYM	cis	rs4730276	0.674	rs17412104	chr7:107545586	C/T	cg23293999	chr7:106826042	HBP1	-0.64	-4.87	-0.45	4.43e-6	Ulcerative colitis;
THYM	cis	rs1003719	0.762	rs6517402	chr21:38447423	A/C	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs231513	1.000	rs231513	chr17:41965200	C/G	cg25868286	chr17:42092488	TMEM101	-0.49	-4.48	-0.42	2.11e-5	Cognitive function;
THYM	cis	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs17854409	0.803	rs3210314	chr20:61472117	C/A	cg05147244	chr20:61493195	TCFL5	0.9	4.96	0.45	3.07e-6	Obesity-related traits;
THYM	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg22920501	chr2:26401640	FAM59B	-0.71	-6.33	-0.54	7.92e-9	Gut microbiome composition (summer);
THYM	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg18352616	chr4:3374830	RGS12	0.75	8.19	0.64	1.21e-12	Serum sulfate level;
THYM	cis	rs8008758	0.500	rs1763212	chr14:101693911	G/A	cg26224664	chr14:101693935	NA	-0.78	-8.43	-0.65	3.71e-13	Body mass index (alcohol intake interaction);
THYM	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg06481639	chr22:41940642	POLR3H	-0.65	-4.73	-0.44	7.76e-6	Neuroticism;
THYM	cis	rs11190604	1.000	rs10883513	chr10:102316964	A/G	cg16342193	chr10:102329863	NA	-0.54	-5.43	-0.49	4.29e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22496380	chr5:211416	CCDC127	-1.3	-8.28	-0.65	7.84e-13	Breast cancer;
THYM	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.97	-0.45	2.98e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs12310956	0.510	rs7302434	chr12:33886819	G/A	cg06521331	chr12:34319734	NA	-0.57	-4.58	-0.43	1.42e-5	Morning vs. evening chronotype;
THYM	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.47	-0.49	3.59e-7	Mean corpuscular volume;
THYM	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs6722750	0.506	rs12612392	chr2:64373635	G/A	cg22352474	chr2:64371530	PELI1	0.81	6.91	0.58	5.6e-10	Neuroticism;
THYM	cis	rs9361491	0.580	rs13204088	chr6:79757438	A/C	cg05283184	chr6:79620031	NA	-0.6	-4.67	-0.43	9.91e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg22709100	chr7:91322751	NA	0.6	4.68	0.43	9.41e-6	Breast cancer;
THYM	cis	rs9522267	0.535	rs9522302	chr13:112236874	C/T	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.1	8.1	0.64	1.82e-12	Platelet count;
THYM	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg24324837	chr19:49891574	CCDC155	0.66	6.62	0.56	2.09e-9	Multiple sclerosis;
THYM	cis	rs877282	0.583	rs11253441	chr10:828288	C/T	cg10556349	chr10:835070	NA	0.84	5.48	0.49	3.43e-7	Uric acid levels;
THYM	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg04731861	chr2:219085781	ARPC2	0.49	4.67	0.43	9.98e-6	Colorectal cancer;
THYM	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg03806693	chr22:41940476	POLR3H	-1.23	-11.12	-0.75	6.71e-19	Vitiligo;
THYM	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg16586182	chr3:47516702	SCAP	-0.64	-5.49	-0.49	3.39e-7	Colorectal cancer;
THYM	cis	rs2806561	0.734	rs2235548	chr1:23394062	G/A	cg12483005	chr1:23474871	LUZP1	0.54	5.49	0.49	3.4e-7	Height;
THYM	cis	rs910187	0.678	rs6122561	chr20:45813809	A/G	cg27589058	chr20:45804311	EYA2	-0.59	-5.07	-0.46	1.95e-6	Migraine;
THYM	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12681287	0.547	rs6471360	chr8:87513469	C/T	cg27223183	chr8:87520930	FAM82B	0.71	5.46	0.49	3.8e-7	Caudate activity during reward;
THYM	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg25208724	chr1:156163844	SLC25A44	1.13	12.94	0.8	1.09e-22	Testicular germ cell tumor;
THYM	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.29	-9.45	-0.7	2.43e-15	Gut microbiome composition (summer);
THYM	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg08999081	chr20:33150536	PIGU	0.62	5.02	0.46	2.41e-6	Coronary artery disease;
THYM	cis	rs807029	0.577	rs701834	chr10:102761801	C/T	cg14905631	chr10:102746534	C10orf2;MRPL43	0.37	4.97	0.45	2.92e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.24	0.47	9.59e-7	Bipolar disorder;
THYM	cis	rs7586879	0.681	rs6752483	chr2:25120086	C/T	cg01884057	chr2:25150051	NA	0.71	7.71	0.62	1.22e-11	Body mass index;
THYM	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg23422044	chr7:1970798	MAD1L1	-0.79	-5.21	-0.47	1.09e-6	Bipolar disorder;
THYM	cis	rs3849570	1.000	rs78242412	chr3:81747219	A/G	cg07356753	chr3:81810745	GBE1	-0.91	-7.36	-0.6	6.66e-11	Waist circumference;Body mass index;
THYM	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg06917634	chr15:78832804	PSMA4	-0.84	-6.93	-0.58	5.08e-10	Sudden cardiac arrest;
THYM	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg10560079	chr2:191398806	TMEM194B	0.87	8.03	0.64	2.55e-12	Pulse pressure;
THYM	cis	rs763014	0.931	rs2071980	chr16:626346	A/C	cg07343612	chr16:622815	PIGQ	-1.05	-10.74	-0.74	4.28e-18	Height;
THYM	cis	rs17209837	0.607	rs1558376	chr7:87079103	T/A	cg04996195	chr7:87105398	ABCB4	0.63	4.81	0.44	5.63e-6	Gallbladder cancer;
THYM	cis	rs427394	1.000	rs427394	chr5:6745875	A/G	cg10857441	chr5:6722123	POLS	-0.66	-8.01	-0.63	2.92e-12	Menopause (age at onset);
THYM	cis	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg12981288	chr8:11183844	MTMR9	-0.47	-4.48	-0.42	2.06e-5	Retinal vascular caliber;
THYM	cis	rs12935418	0.672	rs6564814	chr16:81050172	A/G	cg16651780	chr16:81037892	C16orf61	0.78	5.77	0.51	9.68e-8	Mean corpuscular volume;
THYM	cis	rs12594515	0.967	rs67854274	chr15:45990518	A/G	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg02136620	chr5:178986620	RUFY1	0.55	5.56	0.5	2.45e-7	Lung cancer;
THYM	cis	rs7607369	0.714	rs4674338	chr2:219647487	A/G	cg02176678	chr2:219576539	TTLL4	0.54	4.92	0.45	3.64e-6	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs240764	0.697	rs239199	chr6:101134108	C/T	cg21058520	chr6:100914733	NA	-0.59	-5.23	-0.47	9.96e-7	Neuroticism;
THYM	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.65	-0.62	1.6e-11	Schizophrenia;
THYM	cis	rs9527	0.521	rs12259163	chr10:104961477	A/G	cg04362960	chr10:104952993	NT5C2	0.66	4.9	0.45	3.86e-6	Arsenic metabolism;
THYM	cis	rs6032067	0.714	rs6032075	chr20:43884340	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.4	-4.72	-0.44	8.03e-6	Blood protein levels;
THYM	cis	rs2747539	1.000	rs2747539	chr20:32418368	C/T	cg06304546	chr20:32448765	NA	-0.81	-5.08	-0.46	1.9e-6	Dysphagia;
THYM	cis	rs61931739	0.890	rs1705748	chr12:34133171	A/G	cg06521331	chr12:34319734	NA	-0.6	-4.84	-0.44	4.98e-6	Morning vs. evening chronotype;
THYM	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg11764359	chr7:65958608	NA	-0.82	-6.45	-0.55	4.58e-9	Aortic root size;
THYM	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg18904891	chr8:8559673	CLDN23	0.61	4.85	0.45	4.87e-6	Neuroticism;
THYM	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg17757837	chr7:157058334	UBE3C	-0.79	-6.82	-0.57	8.2e-10	Body mass index;
THYM	cis	rs3087591	0.920	rs11080150	chr17:29629326	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.66	-5.64	-0.5	1.74e-7	Hip circumference;
THYM	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg26721908	chr21:47610096	LSS	0.87	6.77	0.57	1.08e-9	Testicular germ cell tumor;
THYM	cis	rs1692580	0.870	rs590367	chr1:2162944	C/T	cg21194808	chr1:2205498	SKI	0.32	4.46	0.42	2.21e-5	Coronary artery disease;
THYM	cis	rs2458413	0.500	rs2514665	chr8:105351531	C/T	cg21295575	chr8:105352067	TM7SF4	-0.37	-5.34	-0.48	6.2e-7	Paget's disease;
THYM	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg16329650	chr2:213403929	ERBB4	-0.63	-5.37	-0.48	5.61e-7	Symmetrical dimethylarginine levels;
THYM	cis	rs981844	1.000	rs1116636	chr4:154657151	C/T	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg11941060	chr3:133502564	NA	-0.81	-6.84	-0.57	7.74e-10	Iron status biomarkers;
THYM	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.33	9.84	0.71	3.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg03732007	chr1:2071316	PRKCZ	0.52	4.78	0.44	6.28e-6	Height;
THYM	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg05182265	chr7:156933206	UBE3C	0.59	7.06	0.59	2.68e-10	Body mass index;
THYM	cis	rs7828089	0.582	rs7825938	chr8:22266866	G/A	cg13512537	chr8:22265999	SLC39A14	-0.67	-5.57	-0.5	2.39e-7	Verbal declarative memory;
THYM	cis	rs12291225	0.585	rs12270374	chr11:14375079	T/C	cg05501817	chr11:14380813	RRAS2	-0.8	-6.65	-0.56	1.88e-9	Sense of smell;
THYM	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg15962314	chr1:44399869	ARTN	-0.51	-4.64	-0.43	1.13e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg01350728	chr13:21893604	NA	-0.59	-4.45	-0.42	2.36e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs7432375	0.933	rs55970317	chr3:136353193	T/G	cg12473912	chr3:136751656	NA	0.62	5.19	0.47	1.18e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg11247378	chr22:39784982	NA	-0.94	-9.48	-0.7	2.09e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.68	5.59	0.5	2.19e-7	Blood metabolite levels;
THYM	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg17166802	chr3:112709596	GTPBP8	-0.93	-7.19	-0.59	1.47e-10	Energy expenditure (24h);
THYM	cis	rs3126085	1.000	rs3126097	chr1:152311026	G/A	cg10321714	chr1:152280068	FLG	-0.66	-4.8	-0.44	5.86e-6	Atopic dermatitis;
THYM	cis	rs9314614	0.934	rs2980955	chr8:6694434	A/G	cg27319216	chr8:6693540	XKR5	-0.67	-7.65	-0.62	1.63e-11	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs7681440	0.606	rs13142587	chr4:90750169	G/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs7106204	0.686	rs12790317	chr11:24254405	T/C	ch.11.24196551F	chr11:24239977	NA	1.01	6.28	0.54	1.02e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg15736062	chr7:158136485	PTPRN2	-0.61	-4.9	-0.45	3.94e-6	Response to amphetamines;
THYM	cis	rs6490294	0.659	rs7133964	chr12:112198021	C/G	cg10833066	chr12:111807467	FAM109A	0.5	5.4	0.48	4.84e-7	Mean platelet volume;
THYM	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg08439880	chr3:133502540	NA	-0.67	-5.22	-0.47	1.06e-6	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg23711669	chr6:146136114	FBXO30	0.96	10.07	0.72	1.15e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg14675211	chr2:100938903	LONRF2	0.73	7.27	0.6	1.02e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg17063962	chr7:91808500	NA	1.14	12.62	0.79	4.97e-22	Breast cancer;
THYM	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.84	4.66	0.43	1.04e-5	Initial pursuit acceleration;
THYM	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg06713675	chr4:122721982	EXOSC9	-0.51	-4.7	-0.43	8.75e-6	Type 2 diabetes;
THYM	cis	rs6840360	0.967	rs1105534	chr4:152605312	C/A	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg06027949	chr8:82754900	SNX16	-0.62	-5.13	-0.47	1.54e-6	Diastolic blood pressure;
THYM	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg24069376	chr3:38537580	EXOG	0.69	6.79	0.57	9.87e-10	Electrocardiographic conduction measures;
THYM	cis	rs12765878	1.000	rs9325507	chr10:105645622	C/T	cg11005552	chr10:105648138	OBFC1	0.85	11.16	0.75	5.73e-19	Coronary artery disease;
THYM	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg08847533	chr14:75593920	NEK9	-0.61	-5.38	-0.48	5.4e-7	Neuroticism;
THYM	cis	rs17253792	0.822	rs9972178	chr14:56073480	A/G	cg01858014	chr14:56050164	KTN1	-1.22	-5.13	-0.47	1.52e-6	Putamen volume;
THYM	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.66	-5.51	-0.49	3.13e-7	Renal function-related traits (BUN);
THYM	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg19774624	chr17:42201019	HDAC5	-0.76	-7.12	-0.59	2.05e-10	Total body bone mineral density;
THYM	cis	rs6570726	0.791	rs1280276	chr6:145892350	A/C	cg23711669	chr6:146136114	FBXO30	0.98	10.77	0.74	3.75e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg08213375	chr14:104286397	PPP1R13B	0.52	6.25	0.54	1.18e-8	Schizophrenia;
THYM	cis	rs9443189	0.723	rs2748947	chr6:76437921	C/T	cg01950844	chr6:76311363	SENP6	-0.78	-4.54	-0.42	1.67e-5	Prostate cancer;
THYM	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.62	-5.15	-0.47	1.39e-6	Age at first birth;
THYM	cis	rs868036	0.881	rs12708496	chr15:68054098	T/C	cg24579218	chr15:68104479	NA	0.65	6.18	0.54	1.6e-8	Restless legs syndrome;
THYM	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs36051895	0.659	rs12348771	chr9:5083634	T/C	cg02405213	chr9:5042618	JAK2	-1.03	-11.11	-0.75	7.02e-19	Pediatric autoimmune diseases;
THYM	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	5.1	0.46	1.73e-6	Obesity-related traits;
THYM	cis	rs9911578	0.805	rs12601867	chr17:56455260	C/G	cg12560992	chr17:57184187	TRIM37	-0.81	-6.76	-0.57	1.13e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs7926906	1.000	rs10741374	chr11:90521749	C/T	cg26138821	chr11:89956704	CHORDC1	-0.54	-4.93	-0.45	3.52e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6867032	0.527	rs13162781	chr5:2012235	C/T	cg26168224	chr5:2018326	NA	1.09	9.67	0.7	8.22e-16	Gut microbiome composition (winter);
THYM	cis	rs11031096	0.811	rs4910599	chr11:4156040	T/A	cg18678763	chr11:4115507	RRM1	-0.38	-5.17	-0.47	1.27e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9902453	0.765	rs2617883	chr17:28120488	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg15536230	chr21:44985092	HSF2BP	-0.41	-4.96	-0.45	3.06e-6	Mean corpuscular volume;
THYM	cis	rs9549260	0.755	rs4943800	chr13:41216831	A/G	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs6087990	0.965	rs2424899	chr20:31343543	A/C	cg13636640	chr20:31349939	DNMT3B	0.96	10.76	0.74	4.02e-18	Ulcerative colitis;
THYM	cis	rs6598541	0.862	rs2018860	chr15:99258710	A/T	cg13297560	chr15:99320054	IGF1R	0.47	4.88	0.45	4.25e-6	Urate levels;
THYM	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg27494647	chr7:150038898	RARRES2	0.39	4.51	0.42	1.84e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4242434	0.672	rs11785031	chr8:22486612	A/G	cg21658235	chr8:22456391	C8orf58	0.45	4.57	0.42	1.48e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2072510	0.593	rs2660838	chr12:96416383	T/C	cg18817487	chr12:96390143	HAL	0.45	5.47	0.49	3.61e-7	Metabolite levels (small molecules and protein measures);
THYM	trans	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg25214090	chr10:38739885	LOC399744	0.85	7.16	0.59	1.7e-10	Corneal astigmatism;
THYM	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs7084402	0.967	rs1649030	chr10:60279830	G/A	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg17264618	chr3:40429014	ENTPD3	0.53	4.99	0.46	2.69e-6	Renal cell carcinoma;
THYM	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg12179176	chr11:130786555	SNX19	0.7	5.61	0.5	1.99e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7818345	0.649	rs13250181	chr8:19328766	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.45	4.59	0.43	1.34e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg09197432	chr4:183729176	NA	0.87	5.54	0.49	2.66e-7	Pediatric autoimmune diseases;
THYM	cis	rs1048238	0.605	rs1010069	chr1:16352937	G/A	cg22431228	chr1:16359049	CLCNKA	-0.56	-5.48	-0.49	3.49e-7	Systolic blood pressure;
THYM	cis	rs2505998	0.871	rs2505990	chr10:43565348	C/A	cg06632098	chr10:43605906	RET	-1.05	-8.73	-0.67	8.42e-14	Hirschsprung disease;
THYM	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg06238570	chr21:40685208	BRWD1	-0.72	-6.28	-0.54	9.9e-9	Menarche (age at onset);
THYM	cis	rs250585	0.790	rs181835	chr16:23397113	T/C	cg00143387	chr16:23521605	GGA2	0.73	4.99	0.46	2.73e-6	Egg allergy;
THYM	cis	rs9814567	0.752	rs13075253	chr3:134329600	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	7.38	0.6	5.86e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg02086790	chr16:375327	AXIN1	-0.44	-4.6	-0.43	1.29e-5	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs35883536	0.647	rs1335765	chr1:101048612	A/T	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg09354556	chr3:47051341	NA	0.46	4.71	0.44	8.28e-6	Colorectal cancer;
THYM	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg26513180	chr16:89883248	FANCA	0.74	7.34	0.6	7.27e-11	Vitiligo;
THYM	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs1957429	0.901	rs1467571	chr14:65347682	C/T	cg23373153	chr14:65346875	NA	1.07	6.45	0.55	4.75e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg08017756	chr2:100939284	LONRF2	-0.75	-7.8	-0.62	7.89e-12	Intelligence (multi-trait analysis);
THYM	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg27168131	chr21:44088823	PDE9A	0.46	4.58	0.43	1.39e-5	Mean corpuscular volume;
THYM	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg22117172	chr7:91764530	CYP51A1	0.37	4.72	0.44	8.16e-6	Breast cancer;
THYM	cis	rs2040771	0.804	rs7286849	chr22:19223579	C/A	cg02655711	chr22:19163373	SLC25A1	0.58	6.13	0.53	1.96e-8	Metabolite levels (small molecules and protein measures);
THYM	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg16586182	chr3:47516702	SCAP	0.64	5.62	0.5	1.93e-7	Colorectal cancer;
THYM	cis	rs910187	0.605	rs6066224	chr20:45806632	T/A	cg27589058	chr20:45804311	EYA2	-0.7	-6.42	-0.55	5.42e-9	Migraine;
THYM	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03647317	chr4:187891568	NA	-0.83	-9.26	-0.69	6.42e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7084402	0.967	rs1593677	chr10:60291642	A/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs2237457	0.543	rs2237445	chr7:50700208	C/T	cg08586669	chr7:50727761	GRB10	-0.29	-4.62	-0.43	1.19e-5	Schizophrenia (treatment resistant);
THYM	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg13395646	chr4:1353034	KIAA1530	-0.53	-4.84	-0.44	5.01e-6	Longevity;
THYM	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7917772	0.560	rs729023	chr10:104341887	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.77	-6.73	-0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4654899	0.865	rs72975078	chr1:21476196	A/G	cg01072550	chr1:21505969	NA	-0.75	-6.78	-0.57	1.02e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg26384229	chr12:38710491	ALG10B	1.07	10.43	0.73	2.04e-17	Heart rate;
THYM	cis	rs10203711	0.966	rs4605316	chr2:239595344	C/T	cg14580085	chr2:239553406	NA	0.66	5.88	0.52	5.96e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7107174	1.000	rs10793302	chr11:78040961	C/T	cg19901956	chr11:77921274	USP35	-0.69	-5.57	-0.5	2.4e-7	Testicular germ cell tumor;
THYM	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg17366294	chr4:99064904	C4orf37	0.57	6.8	0.57	9.22e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Bladder cancer;
THYM	cis	rs7968440	1.000	rs2250752	chr12:51106091	A/C	cg20014596	chr12:50898483	DIP2B	0.54	4.46	0.42	2.29e-5	Fibrinogen;
THYM	cis	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg00495681	chr13:53174319	NA	0.6	5.68	0.5	1.44e-7	Lewy body disease;
THYM	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg13175981	chr1:150552382	MCL1	0.7	4.99	0.46	2.72e-6	Tonsillectomy;
THYM	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg12407791	chr17:73824354	UNC13D	-0.42	-4.6	-0.43	1.3e-5	White matter hyperintensity burden;
THYM	cis	rs6835098	0.961	rs1574314	chr4:174106663	C/T	cg08422745	chr4:174089978	GALNT7	-0.99	-8.26	-0.65	8.41e-13	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs1641537	0.568	rs1641515	chr17:7551950	C/A	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.65	-0.43	1.05e-5	Sex hormone-binding globulin levels;
THYM	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg09826364	chr7:158789723	NA	-0.52	-4.59	-0.43	1.36e-5	Facial morphology (factor 20);
THYM	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg06808227	chr14:105710500	BRF1	-1.02	-8.8	-0.67	6.1e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs11048434	0.736	rs1805722	chr12:9145056	T/C	cg13575925	chr12:9217583	LOC144571	0.55	5.48	0.49	3.45e-7	Sjögren's syndrome;
THYM	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.24	-4.55	-0.42	1.58e-5	Obesity-related traits;
THYM	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg00631329	chr6:26305371	NA	-0.48	-5.0	-0.46	2.58e-6	Educational attainment;
THYM	cis	rs2898681	0.519	rs73814886	chr4:53733251	C/T	cg00791764	chr4:53727839	RASL11B	0.6	6.58	0.56	2.51e-9	Optic nerve measurement (cup area);
THYM	cis	rs7799006	0.723	rs12673108	chr7:2286487	C/A	cg08027265	chr7:2291960	NA	-0.44	-5.22	-0.47	1.06e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs17253792	0.822	rs113649689	chr14:56088065	G/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs12310956	0.532	rs1352209	chr12:33983408	G/A	cg06521331	chr12:34319734	NA	-0.92	-8.57	-0.66	1.89e-13	Morning vs. evening chronotype;
THYM	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg09737314	chr17:6899359	ALOX12	0.82	11.07	0.75	8.81e-19	Tonsillectomy;
THYM	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08704250	chr15:31115839	NA	-0.54	-6.18	-0.54	1.59e-8	Huntington's disease progression;
THYM	cis	rs303386	0.501	rs6703819	chr1:99574494	T/C	cg03593336	chr1:99471295	LPPR5	0.41	4.58	0.43	1.41e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
THYM	cis	rs3819817	0.575	rs10777757	chr12:96358181	A/T	cg26410635	chr12:96350720	AMDHD1	0.53	5.02	0.46	2.38e-6	Vitamin D levels;
THYM	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg07606381	chr6:8435919	SLC35B3	0.65	4.91	0.45	3.71e-6	Motion sickness;
THYM	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.57	-4.8	-0.44	5.9e-6	Blood metabolite levels;
THYM	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg24642844	chr7:1081250	C7orf50	-1.24	-7.88	-0.63	5.51e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4731207	0.698	rs10954049	chr7:124535450	G/A	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7513165	0.867	rs7524621	chr1:204160938	A/G	cg04791601	chr1:204159016	NA	-0.38	-4.89	-0.45	4.16e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
THYM	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg02753203	chr1:228287806	NA	0.74	6.42	0.55	5.31e-9	Diastolic blood pressure;
THYM	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg20476274	chr7:133979776	SLC35B4	0.67	4.62	0.43	1.22e-5	Mean platelet volume;
THYM	cis	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs8073060	0.963	rs11080354	chr17:33872407	A/G	cg24895173	chr17:33825374	SLFN12L	-0.58	-4.54	-0.42	1.64e-5	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.61	6.17	0.54	1.63e-8	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.69	-6.08	-0.53	2.51e-8	Total body bone mineral density;
THYM	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg23649088	chr2:200775458	C2orf69	0.78	6.68	0.57	1.6e-9	Schizophrenia;
THYM	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2916260	0.800	rs55683048	chr6:40391939	A/G	cg08415973	chr6:40346114	TDRG1	0.71	4.55	0.42	1.59e-5	Incident coronary heart disease;
THYM	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg16006841	chr5:176797999	RGS14	-0.51	-5.75	-0.51	1.07e-7	Urate levels in lean individuals;
THYM	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg12667521	chr19:29218732	NA	0.7	5.38	0.48	5.45e-7	Methadone dose in opioid dependence;
THYM	cis	rs28829049	0.597	rs12745238	chr1:19393710	C/T	cg13387374	chr1:19411106	UBR4	0.7	5.4	0.48	4.91e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	cg20946044	chr11:1010712	AP2A2	-0.55	-4.6	-0.43	1.29e-5	Alzheimer's disease (late onset);
THYM	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg10334053	chr1:2078117	PRKCZ	-0.5	-4.83	-0.44	5.24e-6	Height;
THYM	cis	rs6076065	0.723	rs2253924	chr20:23388020	G/A	cg11657817	chr20:23433608	CST11	0.31	4.57	0.42	1.48e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg11266682	chr4:10021025	SLC2A9	0.72	10.3	0.73	3.72e-17	Bone mineral density;
THYM	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg27279351	chr12:120934652	DYNLL1	0.92	8.35	0.65	5.35e-13	High light scatter reticulocyte count;
THYM	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs2073300	0.609	rs6137938	chr20:23389127	C/G	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7192380	0.630	rs2965749	chr16:69771914	C/T	cg06765324	chr16:70207801	CLEC18C	-0.48	-4.58	-0.43	1.4e-5	Sjögren's syndrome;
THYM	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg24692254	chr21:30365293	RNF160	0.99	9.36	0.69	3.83e-15	Dental caries;
THYM	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.53	-4.89	-0.45	4.12e-6	Lymphocyte counts;
THYM	cis	rs921968	0.608	rs658378	chr2:219483881	T/A	cg02176678	chr2:219576539	TTLL4	0.63	6.15	0.53	1.85e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8018808	1.000	rs12101153	chr14:77863091	A/C	cg20045696	chr14:77926864	AHSA1	-0.58	-5.36	-0.48	5.86e-7	Myeloid white cell count;
THYM	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg10018233	chr7:150070692	REPIN1	0.43	5.71	0.51	1.28e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg00495681	chr13:53174319	NA	0.73	6.85	0.57	7.36e-10	Lewy body disease;
THYM	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg24375607	chr4:120327624	NA	0.64	5.02	0.46	2.37e-6	Corneal astigmatism;
THYM	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg02503808	chr4:7069936	GRPEL1	0.97	7.64	0.62	1.73e-11	Monocyte percentage of white cells;
THYM	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-5.01	-0.46	2.5e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs77236434	0.826	rs73562565	chr8:13179345	C/T	cg06835018	chr8:12272982	NA	-0.77	-4.63	-0.43	1.17e-5	Familial hepatitis B virus-related hepatocellular carcinoma;
THYM	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg18230493	chr5:56204884	C5orf35	0.89	6.53	0.56	3.25e-9	Initial pursuit acceleration;
THYM	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs13418717	1.000	rs13411697	chr2:127657951	C/T	cg25501666	chr2:127640322	NA	1.61	6.45	0.55	4.76e-9	Heart failure;
THYM	cis	rs3126085	0.935	rs4534386	chr1:152251714	A/G	cg26020982	chr1:152196106	HRNR	0.35	4.95	0.45	3.26e-6	Atopic dermatitis;
THYM	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.44	5.47	0.49	3.61e-7	Monocyte percentage of white cells;
THYM	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg26384229	chr12:38710491	ALG10B	0.95	7.98	0.63	3.38e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg24910161	chr17:38119198	GSDMA	0.47	4.93	0.45	3.55e-6	Self-reported allergy;
THYM	cis	rs919433	0.680	rs2564389	chr2:198260098	A/T	cg00792783	chr2:198669748	PLCL1	0.81	5.58	0.5	2.25e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg03929089	chr4:120376271	NA	-1.04	-12.38	-0.79	1.54e-21	Height;
THYM	cis	rs9296092	0.560	rs62407561	chr6:33528103	T/C	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg01831904	chr17:28903510	LRRC37B2	-1.0	-5.11	-0.46	1.65e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs240764	0.853	rs4461738	chr6:100977940	T/C	cg21058520	chr6:100914733	NA	0.57	5.03	0.46	2.35e-6	Neuroticism;
THYM	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg26597838	chr10:835615	NA	1.58	12.04	0.78	8.01e-21	Eosinophil percentage of granulocytes;
THYM	cis	rs8170	0.603	rs971693	chr19:17422649	G/C	cg04749549	chr19:17459798	NA	-0.41	-5.08	-0.46	1.86e-6	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
THYM	trans	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg12863693	chr15:85201151	NMB	0.52	4.45	0.42	2.3e-5	Schizophrenia;
THYM	cis	rs10779751	1.000	rs7525957	chr1:11318236	C/T	cg08854313	chr1:11322531	MTOR	0.99	9.0	0.68	2.29e-14	Body mass index;
THYM	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg02725872	chr8:58115012	NA	-1.12	-8.75	-0.67	7.93e-14	Developmental language disorder (linguistic errors);
THYM	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg07570687	chr10:102243282	WNT8B	0.77	6.93	0.58	4.99e-10	Palmitoleic acid (16:1n-7) levels;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg13591377	chr11:112037102	TEX12	-0.99	-7.0	-0.58	3.66e-10	Depressive symptoms;
THYM	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8016982	0.674	rs1951615	chr14:81671762	G/A	cg01989461	chr14:81687754	GTF2A1	0.86	7.64	0.62	1.67e-11	Schizophrenia;
THYM	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg05768032	chr16:30646687	NA	0.54	5.56	0.5	2.45e-7	Multiple myeloma;
THYM	cis	rs7688540	0.739	rs11729659	chr4:237284	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.68	4.96	0.45	3.03e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg07460842	chr6:66804631	NA	1.11	8.25	0.65	8.78e-13	Exhaled nitric oxide output;
THYM	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.77	7.02	0.58	3.36e-10	Menarche (age at onset);
THYM	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg07755735	chr2:20870362	GDF7	-0.76	-5.96	-0.52	4.26e-8	Abdominal aortic aneurysm;
THYM	cis	rs2133450	0.712	rs10510358	chr3:7368190	C/T	cg19930620	chr3:7340148	GRM7	-0.48	-4.5	-0.42	1.95e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg23682913	chr1:2080710	PRKCZ	0.5	4.52	0.42	1.75e-5	Height;
THYM	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs35264875	1.000	rs72919412	chr11:68826855	G/T	cg23845249	chr11:68861649	NA	0.52	5.43	0.49	4.36e-7	Blond vs. brown hair color;
THYM	cis	rs10927875	0.832	rs4661342	chr1:16160773	C/G	cg21385522	chr1:16154831	NA	-1.28	-10.29	-0.73	4.06e-17	Dilated cardiomyopathy;
THYM	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg03709012	chr19:19516395	GATAD2A	0.79	6.0	0.52	3.51e-8	Tonsillectomy;
THYM	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg15556689	chr8:8085844	FLJ10661	0.73	6.59	0.56	2.43e-9	Mood instability;
THYM	cis	rs1144700	0.628	rs1144699	chr6:16743425	T/C	cg15250073	chr6:16769480	NA	-0.31	-4.49	-0.42	2.01e-5	Neutrophil count;White blood cell count;Granulocyte count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
THYM	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21582582	chr3:182698605	DCUN1D1	0.8	7.0	0.58	3.67e-10	Intelligence (multi-trait analysis);
THYM	cis	rs990171	0.721	rs6543115	chr2:102927641	C/G	cg13897122	chr2:103039542	IL18RAP	-0.42	-4.85	-0.45	4.89e-6	Lymphocyte counts;
THYM	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg00495681	chr13:53174319	NA	0.97	9.96	0.71	2e-16	Lewy body disease;
THYM	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs988913	1.000	rs7764641	chr6:54835469	A/T	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.75e-6	Menarche (age at onset);
THYM	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.76	0.44	7.04e-6	Bipolar disorder;
THYM	cis	rs600806	0.850	rs1343465	chr1:109937426	T/C	cg23616212	chr1:109941201	SORT1	-0.5	-4.65	-0.43	1.06e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg21970626	chr13:21893289	NA	-0.67	-5.95	-0.52	4.5e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg27535305	chr1:53392650	SCP2	-0.49	-5.46	-0.49	3.8e-7	Monocyte count;
THYM	cis	rs208520	0.955	rs12216176	chr6:67005130	G/T	cg07460842	chr6:66804631	NA	0.83	4.83	0.44	5.23e-6	Exhaled nitric oxide output;
THYM	cis	rs2905072	0.564	rs3011257	chr9:135837360	T/G	cg13899420	chr9:135853978	GFI1B	0.7	5.16	0.47	1.36e-6	Bipolar disorder;
THYM	trans	rs9951602	0.512	rs9958497	chr18:76655296	G/C	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.67	4.76	0.44	6.93e-6	Aortic root size;
THYM	cis	rs1003719	0.788	rs7276917	chr21:38451334	T/C	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg02725872	chr8:58115012	NA	-1.11	-8.72	-0.67	9.11e-14	Developmental language disorder (linguistic errors);
THYM	cis	rs1568889	1.000	rs12791341	chr11:28335452	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.74	0.44	7.51e-6	Bipolar disorder;
THYM	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg11247378	chr22:39784982	NA	-1.06	-13.37	-0.81	1.49e-23	Intelligence (multi-trait analysis);
THYM	cis	rs35934224	0.783	rs34143881	chr22:19860093	A/G	cg11182965	chr22:19864308	TXNRD2	-0.71	-5.85	-0.51	7.1e-8	Glaucoma (primary open-angle);
THYM	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.93	10.35	0.73	2.93e-17	Prudent dietary pattern;
THYM	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg03264133	chr6:25882463	NA	0.63	4.85	0.45	4.86e-6	Schizophrenia;
THYM	cis	rs76878669	0.519	rs10791869	chr11:66117113	C/T	cg18002602	chr11:66138449	SLC29A2	-0.49	-4.77	-0.44	6.59e-6	Educational attainment (years of education);
THYM	cis	rs9296092	0.500	rs9469504	chr6:33527243	G/A	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs7103648	0.808	rs7103835	chr11:47461693	G/A	cg20307385	chr11:47447363	PSMC3	0.81	5.68	0.5	1.46e-7	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs946836	0.562	rs34523805	chr1:48374908	C/T	cg18376692	chr1:48452465	NA	-0.5	-4.9	-0.45	3.98e-6	White matter integrity;
THYM	cis	rs4792901	0.722	rs8074904	chr17:41571577	G/A	cg21940313	chr17:41620911	ETV4	-0.54	-5.17	-0.47	1.32e-6	Dupuytren's disease;
THYM	cis	rs11148252	0.583	rs9536048	chr13:52958788	T/C	cg05335186	chr13:53173507	NA	-0.51	-5.87	-0.52	6.3e-8	Lewy body disease;
THYM	cis	rs7851660	0.654	rs2120264	chr9:100645728	A/G	cg13688889	chr9:100608707	NA	-0.73	-5.39	-0.48	5.2e-7	Strep throat;
THYM	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs7705042	0.897	rs12515668	chr5:141496090	G/T	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs4654899	0.833	rs12135548	chr1:21084367	G/A	cg01072550	chr1:21505969	NA	-0.61	-5.27	-0.48	8.41e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg11366901	chr6:160182831	ACAT2	1.09	10.12	0.72	9.06e-17	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.73	-5.44	-0.49	4.12e-7	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg21100191	chr22:23484243	RTDR1	0.73	6.5	0.55	3.66e-9	Bone mineral density;
THYM	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	5.54	0.49	2.64e-7	Monocyte percentage of white cells;
THYM	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg17264618	chr3:40429014	ENTPD3	0.54	5.14	0.47	1.49e-6	Renal cell carcinoma;
THYM	cis	rs807669	0.505	rs2236759	chr22:19187427	C/G	cg02655711	chr22:19163373	SLC25A1	0.59	6.45	0.55	4.75e-9	Metabolite levels;
THYM	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg26031613	chr14:104095156	KLC1	1.06	9.5	0.7	1.94e-15	Body mass index;
THYM	cis	rs9534288	0.797	rs9526132	chr13:46609364	A/G	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg22496339	chr2:162101262	NA	0.94	9.01	0.68	2.19e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg16624210	chr5:671434	TPPP	0.64	6.66	0.56	1.76e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg06634786	chr22:41940651	POLR3H	0.68	5.0	0.46	2.65e-6	Vitiligo;
THYM	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg05038881	chr1:10490043	APITD1	0.28	5.62	0.5	1.89e-7	Prostate cancer;
THYM	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs919433	0.680	rs2565160	chr2:198286474	A/G	cg05783139	chr2:198650985	BOLL	0.63	4.93	0.45	3.48e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg17252645	chr8:143867129	LY6D	-0.81	-9.96	-0.71	1.98e-16	Urinary tract infection frequency;
THYM	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.29	4.46	0.42	2.27e-5	Obesity-related traits;
THYM	cis	rs34286592	0.929	rs9923649	chr16:29832138	G/A	cg04633683	chr16:29837056	MVP	0.61	4.93	0.45	3.45e-6	Multiple sclerosis;
THYM	cis	rs4285028	0.747	rs1920299	chr3:121593769	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.81	5.78	0.51	9.34e-8	Multiple sclerosis;
THYM	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg11663144	chr21:46675770	NA	-0.7	-9.97	-0.71	1.96e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg06064525	chr11:970664	AP2A2	-0.38	-7.23	-0.6	1.21e-10	Alzheimer's disease (late onset);
THYM	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.11	10.32	0.73	3.51e-17	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28647808	0.881	rs41297211	chr9:136260721	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg04111992	chr7:158790115	NA	-0.58	-4.93	-0.45	3.46e-6	Facial morphology (factor 20);
THYM	trans	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.16e-6	Corneal astigmatism;
THYM	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg25214090	chr10:38739885	LOC399744	0.93	7.85	0.63	6.16e-12	Corneal astigmatism;
THYM	cis	rs13326165	0.585	rs56002041	chr3:52409421	A/G	cg08438690	chr3:52279403	PPM1M	-0.84	-4.6	-0.43	1.32e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs8070740	0.898	rs9896735	chr17:5325808	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	-0.72	-6.03	-0.53	3.15e-8	Menopause (age at onset);
THYM	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg10792982	chr14:105748885	BRF1	-0.72	-7.36	-0.6	6.58e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg02018176	chr4:1364513	KIAA1530	-0.8	-7.57	-0.61	2.41e-11	Obesity-related traits;
THYM	cis	rs67460515	0.500	rs964533	chr3:160749019	C/A	cg12349858	chr3:160822545	B3GALNT1	0.6	4.74	0.44	7.35e-6	Parkinson's disease;
THYM	cis	rs13256369	1.000	rs7820159	chr8:8576215	T/C	cg17143192	chr8:8559678	CLDN23	0.91	6.52	0.56	3.35e-9	Obesity-related traits;
THYM	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg19770292	chr5:1868693	NA	0.54	4.97	0.45	2.95e-6	Cardiovascular disease risk factors;
THYM	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg05340658	chr4:99064831	C4orf37	0.54	4.53	0.42	1.68e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs524281	0.731	rs7931167	chr11:65803750	A/G	cg14541915	chr11:65894463	PACS1	-0.89	-4.49	-0.42	1.99e-5	Electroencephalogram traits;
THYM	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.9	0.63	4.79e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg25036284	chr2:26402008	FAM59B	-0.81	-5.58	-0.5	2.24e-7	Gut microbiome composition (summer);
THYM	cis	rs7729447	0.566	rs3828589	chr5:32713327	T/C	cg14311471	chr5:32711095	NPR3	0.58	4.79	0.44	6.08e-6	Blood pressure;
THYM	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg24375607	chr4:120327624	NA	0.64	5.09	0.46	1.82e-6	Corneal astigmatism;
THYM	cis	rs728616	0.850	rs3889823	chr10:81918362	T/C	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.12	-0.46	1.6e-6	Life satisfaction;
THYM	cis	rs12579753	0.956	rs11115038	chr12:82214660	T/G	cg07988820	chr12:82153109	PPFIA2	-0.72	-4.47	-0.42	2.15e-5	Resting heart rate;
THYM	cis	rs7191439	0.583	rs9935872	chr16:88788477	A/G	cg27087555	chr16:88793112	FAM38A	-1.49	-10.82	-0.74	2.98e-18	Plateletcrit;
THYM	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg26441486	chr22:50317300	CRELD2	0.41	6.12	0.53	2.05e-8	Schizophrenia;
THYM	cis	rs775227	0.574	rs13083453	chr3:113096943	G/A	cg18753928	chr3:113234510	CCDC52	-0.76	-5.35	-0.48	6.02e-7	Dental caries;
THYM	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.49	-5.14	-0.47	1.45e-6	Depressive symptoms;
THYM	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg14517863	chr17:44321492	NA	0.46	5.11	0.46	1.69e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7828089	0.935	rs2293144	chr8:22262418	A/G	cg12081754	chr8:22256438	SLC39A14	0.62	5.4	0.48	4.85e-7	Verbal declarative memory;
THYM	cis	rs16944158	0.636	rs7500184	chr16:49650076	A/G	cg05126388	chr16:49670144	ZNF423	0.75	4.95	0.45	3.16e-6	IgG glycosylation;
THYM	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg26314531	chr2:26401878	FAM59B	-0.72	-4.45	-0.42	2.31e-5	Gut microbiome composition (summer);
THYM	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg12419862	chr22:24373484	LOC391322	-0.75	-7.11	-0.59	2.19e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4604732	0.588	rs4925551	chr1:247631724	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.7	4.88	0.45	4.32e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg22920501	chr2:26401640	FAM59B	-1.07	-9.68	-0.7	7.92e-16	Gut microbiome composition (summer);
THYM	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg04117972	chr1:227635322	NA	0.68	4.46	0.42	2.26e-5	Major depressive disorder;
THYM	cis	rs3892630	0.878	rs66788054	chr19:33190146	G/T	cg02283691	chr19:33182526	NUDT19	-0.41	-4.86	-0.45	4.59e-6	Red blood cell traits;
THYM	cis	rs2625529	0.775	rs4777477	chr15:72269612	G/A	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs9470366	0.509	rs4714001	chr6:36638175	G/A	cg24425727	chr6:36645648	CDKN1A	0.72	6.76	0.57	1.09e-9	QRS duration;
THYM	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.44	5.47	0.49	3.61e-7	Monocyte percentage of white cells;
THYM	cis	rs8049040	0.521	rs12935725	chr16:71569388	T/C	cg08717414	chr16:71523259	ZNF19	-0.83	-4.74	-0.44	7.61e-6	Blood protein levels;
THYM	cis	rs863345	0.625	rs11265006	chr1:158498485	C/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs6448317	1.000	rs11934149	chr4:24938953	T/C	cg22968281	chr4:24586266	DHX15	0.7	4.79	0.44	6.02e-6	Heschl's gyrus morphology;
THYM	cis	rs11096990	0.855	rs2711933	chr4:39157710	G/A	cg24403649	chr4:39172243	NA	-0.6	-5.09	-0.46	1.77e-6	Cognitive function;
THYM	cis	rs2637266	0.935	rs751770	chr10:78393956	A/G	cg18941641	chr10:78392320	NA	0.77	6.64	0.56	1.92e-9	Pulmonary function;
THYM	cis	rs6586111	1.000	rs4934372	chr10:82372981	A/G	cg03086067	chr10:82368399	SH2D4B	0.57	7.35	0.6	6.97e-11	Capecitabine sensitivity;
THYM	cis	rs35883536	0.647	rs10493929	chr1:101043928	A/C	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs7394190	0.748	rs2306327	chr10:75573778	A/T	cg02286717	chr10:75415704	SYNPO2L	-0.86	-4.6	-0.43	1.33e-5	Incident atrial fibrillation;
THYM	cis	rs7828089	1.000	rs7837521	chr8:22264151	G/T	cg12081754	chr8:22256438	SLC39A14	0.63	5.5	0.49	3.15e-7	Verbal declarative memory;
THYM	cis	rs6918586	0.658	rs198822	chr6:26123539	G/C	cg07061783	chr6:25882402	NA	0.57	4.48	0.42	2.07e-5	Schizophrenia;
THYM	cis	rs1620921	0.967	rs783174	chr6:161171919	C/T	cg17993073	chr6:160527228	IGF2R	0.58	4.56	0.42	1.52e-5	Lipoprotein (a) - cholesterol levels;
THYM	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7580658	0.750	rs4497825	chr2:128061053	A/G	cg10021288	chr2:128175891	PROC	-0.66	-6.32	-0.54	8.6e-9	Protein C levels;
THYM	cis	rs12207186	1.000	rs76350372	chr6:162310182	C/A	cg27627911	chr6:161695453	AGPAT4	-1.1	-4.49	-0.42	1.99e-5	IgG glycosylation;
THYM	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs747334	0.791	rs4933202	chr10:92735473	A/G	cg07620928	chr10:92689909	NA	0.61	5.35	0.48	6.09e-7	Fibroblast growth factor basic levels;
THYM	cis	rs10214930	1.000	rs4722740	chr7:27787009	T/C	cg04422003	chr7:28448295	CREB5	-0.62	-4.62	-0.43	1.19e-5	Hypospadias;
THYM	cis	rs10425738	0.830	rs3843043	chr19:41433931	C/T	cg17435250	chr19:41386441	CYP2A7	-0.63	-4.52	-0.42	1.79e-5	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
THYM	cis	rs28595532	0.920	rs114057512	chr4:119750179	G/A	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.77	-5.33	-0.48	6.69e-7	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg25517755	chr10:38738941	LOC399744	-0.77	-7.48	-0.61	3.65e-11	Corneal astigmatism;
THYM	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg08000102	chr2:233561755	GIGYF2	-0.68	-6.11	-0.53	2.16e-8	Coronary artery disease;
THYM	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.77	7.59	0.61	2.14e-11	Lymphocyte counts;
THYM	cis	rs36051895	0.559	rs1590268	chr9:5209433	T/A	cg02405213	chr9:5042618	JAK2	-0.88	-8.68	-0.66	1.11e-13	Pediatric autoimmune diseases;
THYM	cis	rs2294693	0.531	rs1883595	chr6:40935728	A/G	cg21128951	chr6:40996213	UNC5CL	-0.62	-4.6	-0.43	1.3e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs73198271	0.740	rs10105690	chr8:8649232	G/T	cg06636001	chr8:8085503	FLJ10661	-0.8	-5.64	-0.5	1.77e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4654899	0.571	rs1888759	chr1:21065167	G/A	cg01072550	chr1:21505969	NA	-0.62	-5.65	-0.5	1.67e-7	Superior frontal gyrus grey matter volume;
THYM	trans	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs17152411	0.895	rs7094116	chr10:126587644	T/G	cg07906193	chr10:126599966	NA	0.68	4.65	0.43	1.08e-5	Height;
THYM	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg12031863	chr16:4587854	C16orf5	0.48	5.41	0.49	4.77e-7	Schizophrenia;
THYM	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg24675056	chr1:15929824	NA	0.73	5.86	0.52	6.71e-8	Systolic blood pressure;
THYM	cis	rs2295499	0.643	rs4690086	chr4:2698524	G/A	cg14003022	chr4:3043019	NA	0.53	4.64	0.43	1.09e-5	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs3020340	0.906	rs11756568	chr6:152042413	A/T	cg22157087	chr6:152012887	ESR1	0.49	4.76	0.44	7.03e-6	Bone mineral density (Ward's triangle area);
THYM	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg25072359	chr17:41440525	NA	-0.75	-5.75	-0.51	1.07e-7	Menopause (age at onset);
THYM	trans	rs4866334	1.000	rs74851546	chr5:18487135	C/T	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg04398451	chr17:18023971	MYO15A	-0.95	-10.09	-0.72	1.06e-16	Total body bone mineral density;
THYM	cis	rs11577318	0.853	rs7416513	chr1:26647949	G/C	cg19677267	chr1:26645161	CD52;UBXN11	-0.49	-6.47	-0.55	4.27e-9	Granulocyte percentage of myeloid white cells;
THYM	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg22920501	chr2:26401640	FAM59B	1.05	9.16	0.68	1.04e-14	Gut microbiome composition (summer);
THYM	cis	rs7851660	0.844	rs10123699	chr9:100637859	A/G	cg13688889	chr9:100608707	NA	-0.7	-4.86	-0.45	4.55e-6	Strep throat;
THYM	cis	rs1971762	1.000	rs916134	chr12:54069803	A/G	cg22997177	chr12:54070527	ATP5G2	-0.48	-5.15	-0.47	1.38e-6	Height;
THYM	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg23428387	chr22:49814324	NA	-0.55	-5.64	-0.5	1.78e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs28595532	0.920	rs56104443	chr4:119752052	G/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg08999081	chr20:33150536	PIGU	-0.56	-4.92	-0.45	3.63e-6	Height;
THYM	cis	rs4243830	1.000	rs12046884	chr1:6594561	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	1.13	6.32	0.54	8.56e-9	Body mass index;
THYM	cis	rs76878669	0.561	rs7105015	chr11:66159390	A/G	cg18002602	chr11:66138449	SLC29A2	0.46	4.66	0.43	1.01e-5	Educational attainment (years of education);
THYM	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.78	-5.14	-0.47	1.48e-6	Mean platelet volume;
THYM	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg18876405	chr7:65276391	NA	0.6	5.32	0.48	6.97e-7	Aortic root size;
THYM	cis	rs1331623	1.000	rs1331623	chr9:122199203	A/T	cg25935911	chr9:122132261	DBC1	-0.56	-5.21	-0.47	1.08e-6	Height;
THYM	cis	rs6987853	0.933	rs2923430	chr8:42391195	T/C	cg09913449	chr8:42400586	C8orf40	0.95	9.01	0.68	2.14e-14	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4243830	0.737	rs4908909	chr1:6599041	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.06	-6.24	-0.54	1.21e-8	Body mass index;
THYM	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg08305652	chr11:111469057	NA	0.53	4.58	0.43	1.41e-5	Primary sclerosing cholangitis;
THYM	cis	rs113835537	0.529	rs11227495	chr11:66263243	C/T	cg24851651	chr11:66362959	CCS	0.7	4.92	0.45	3.61e-6	Airway imaging phenotypes;
THYM	cis	rs7589342	0.831	rs11124062	chr2:106455967	G/A	cg14210321	chr2:106509881	NCK2	-0.73	-5.14	-0.47	1.46e-6	Addiction;
THYM	cis	rs10216189	0.967	rs10215480	chr7:5524682	C/T	cg05318486	chr7:5553423	FBXL18	-0.65	-4.76	-0.44	6.82e-6	Relative hand skill in reading disability;
THYM	cis	rs924712	0.844	rs6937970	chr6:54736717	C/G	cg04690482	chr6:54711388	FAM83B	-0.46	-4.97	-0.45	2.93e-6	Breast cancer;
THYM	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg08885076	chr2:99613938	TSGA10	-0.46	-4.62	-0.43	1.18e-5	Fear of minor pain;
THYM	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg09990169	chr2:241835740	C2orf54	-0.37	-6.3	-0.54	9.42e-9	Urinary metabolites;
THYM	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg11494091	chr17:61959527	GH2	1.08	16.92	0.87	2.03e-30	Prudent dietary pattern;
THYM	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00475322	chr7:917719	C7orf20	0.5	6.28	0.54	1.02e-8	Perceived unattractiveness to mosquitoes;
THYM	cis	rs17253792	0.545	rs35418987	chr14:56017407	T/G	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs2294693	0.531	rs12210310	chr6:40950807	T/C	cg14418226	chr6:40996092	UNC5CL	0.72	5.42	0.49	4.49e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs554111	0.656	rs10799682	chr1:21424030	G/C	cg01072550	chr1:21505969	NA	0.58	5.06	0.46	2.06e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs595982	0.517	rs10404905	chr19:49406175	A/T	cg19746536	chr19:49375674	PPP1R15A	-0.99	-9.63	-0.7	1.03e-15	Red cell distribution width;
THYM	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11890956	chr21:40555474	PSMG1	-0.66	-6.38	-0.55	6.51e-9	Menarche (age at onset);
THYM	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.11	8.07	0.64	2.15e-12	Cognitive test performance;
THYM	cis	rs6835098	0.692	rs6553680	chr4:174077044	A/G	cg08422745	chr4:174089978	GALNT7	-0.93	-7.38	-0.6	5.97e-11	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs4731207	0.698	rs4731222	chr7:124481635	G/A	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg12310025	chr6:25882481	NA	-0.66	-4.59	-0.43	1.36e-5	Height;
THYM	cis	rs600806	0.854	rs10745353	chr1:109877506	A/G	cg23032129	chr1:109941072	SORT1	-0.58	-4.93	-0.45	3.43e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11785693	0.862	rs11774842	chr8:4979769	A/C	cg26367366	chr8:4980734	NA	1.22	5.99	0.52	3.74e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg06027949	chr8:82754900	SNX16	0.64	5.35	0.48	6.18e-7	Diastolic blood pressure;
THYM	cis	rs9467711	0.722	rs35825164	chr6:26117404	T/C	cg01386294	chr6:25732093	NA	0.88	4.7	0.43	8.83e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg27572855	chr1:25598939	RHD	-0.63	-4.96	-0.45	3.14e-6	Erythrocyte sedimentation rate;
THYM	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg23187316	chr7:1099788	C7orf50	0.58	4.45	0.42	2.32e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7814319	0.561	rs7815834	chr8:97272144	T/A	cg20787634	chr8:97240163	UQCRB	-0.73	-6.62	-0.56	2.08e-9	Lung function (FVC);
THYM	cis	rs2073300	1.000	rs6132621	chr20:23442180	C/T	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg12379764	chr21:47803548	PCNT	-0.78	-4.89	-0.45	4.03e-6	Testicular germ cell tumor;
THYM	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg21984481	chr17:79567631	NPLOC4	-0.47	-4.95	-0.45	3.22e-6	Eye color traits;
THYM	cis	rs747334	0.811	rs7071323	chr10:92721334	C/G	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.72	5.8	0.51	8.86e-8	Prostate cancer;
THYM	cis	rs12134245	0.776	rs625525	chr1:91997593	C/T	cg02896835	chr1:92012615	NA	-0.66	-6.16	-0.53	1.77e-8	Breast cancer;
THYM	cis	rs977987	0.931	rs8057084	chr16:75492706	G/T	cg03315344	chr16:75512273	CHST6	-0.73	-5.6	-0.5	2.1e-7	Dupuytren's disease;
THYM	cis	rs3771570	1.000	rs62193208	chr2:242322430	G/A	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs7772486	0.686	rs9485019	chr6:146046381	C/G	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs56322409	0.561	rs58419111	chr10:97367227	A/C	cg00110277	chr10:97668174	C10orf131	-0.58	-4.91	-0.45	3.72e-6	Blood metabolite levels;
THYM	cis	rs2066819	1.000	rs77032009	chr12:56679971	A/G	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs35934224	0.783	rs56291622	chr22:19858734	C/T	cg11182965	chr22:19864308	TXNRD2	-0.68	-5.58	-0.5	2.3e-7	Glaucoma (primary open-angle);
THYM	cis	rs656319	0.605	rs60278284	chr8:10003210	G/C	cg20181426	chr8:10469310	RP1L1	0.49	4.5	0.42	1.91e-5	Myopia (pathological);
THYM	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2777491	0.874	rs11633799	chr15:41576538	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.04	-9.37	-0.69	3.64e-15	Ulcerative colitis;
THYM	cis	rs11997175	0.624	rs7465686	chr8:33718321	G/A	ch.8.33884649F	chr8:33765107	NA	0.72	5.08	0.46	1.88e-6	Body mass index;
THYM	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.68	5.08	0.46	1.89e-6	Tonsillectomy;
THYM	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs4919044	0.866	rs11187264	chr10:94824024	C/A	cg05127821	chr10:94822908	CYP26C1	-1.24	-6.68	-0.57	1.64e-9	Coronary artery disease;
THYM	cis	rs6500395	1.000	rs8059819	chr16:48682834	A/G	cg04672837	chr16:48644449	N4BP1	-0.49	-4.82	-0.44	5.43e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2898681	0.519	rs76606067	chr4:53728221	G/T	cg21521518	chr4:53727714	RASL11B	0.52	4.83	0.44	5.21e-6	Optic nerve measurement (cup area);
THYM	cis	rs3820068	0.608	rs12091644	chr1:16044945	G/A	cg05660106	chr1:15850417	CASP9	0.72	5.59	0.5	2.2e-7	Systolic blood pressure;
THYM	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.22	8.51	0.66	2.49e-13	Cognitive test performance;
THYM	cis	rs7487075	0.780	rs12320197	chr12:46738883	A/G	cg21428710	chr12:47219797	SLC38A4	0.49	4.7	0.43	8.8e-6	Itch intensity from mosquito bite;
THYM	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg05340658	chr4:99064831	C4orf37	0.54	4.52	0.42	1.76e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg21475434	chr5:93447410	FAM172A	0.96	6.1	0.53	2.29e-8	Diabetic retinopathy;
THYM	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg24006582	chr15:45444508	DUOX1	0.81	6.55	0.56	2.99e-9	Uric acid levels;
THYM	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.92	8.2	0.64	1.14e-12	Chronic sinus infection;
THYM	cis	rs2219968	0.651	rs936887	chr8:78897797	A/T	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs919433	0.680	rs11680291	chr2:198409884	A/G	cg00792783	chr2:198669748	PLCL1	0.84	5.85	0.51	7.04e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9905704	0.846	rs11079356	chr17:56864242	C/A	cg12560992	chr17:57184187	TRIM37	0.64	4.5	0.42	1.93e-5	Testicular germ cell tumor;
THYM	cis	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.76	0.44	7.03e-6	Obesity-related traits;
THYM	cis	rs7799006	0.606	rs34262822	chr7:2304275	C/T	cg08027265	chr7:2291960	NA	-0.42	-5.05	-0.46	2.13e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg15838173	chr10:75533400	FUT11	-0.62	-6.3	-0.54	9.28e-9	Inflammatory bowel disease;
THYM	cis	rs6754311	0.589	rs2011724	chr2:136818006	A/G	cg07169764	chr2:136633963	MCM6	-0.63	-4.48	-0.42	2.1e-5	Mosquito bite size;
THYM	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg17757837	chr7:157058334	UBE3C	0.65	5.24	0.47	9.83e-7	Body mass index;
THYM	cis	rs600550	0.588	rs11230248	chr11:60085893	T/C	cg05040360	chr11:60102449	MS4A6E	-0.5	-4.64	-0.43	1.1e-5	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs4631830	0.863	rs2249986	chr10:51521684	T/G	cg10326726	chr10:51549505	MSMB	-0.61	-6.23	-0.54	1.25e-8	Prostate-specific antigen levels;
THYM	cis	rs36051895	0.632	rs1581927	chr9:5177462	C/T	cg02405213	chr9:5042618	JAK2	-1.0	-10.98	-0.75	1.39e-18	Pediatric autoimmune diseases;
THYM	cis	rs7177699	0.534	rs7403708	chr15:79123885	T/C	cg00540400	chr15:79124168	NA	-0.64	-6.85	-0.58	7.18e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg10505658	chr17:80084571	CCDC57	0.7	8.07	0.64	2.18e-12	Life satisfaction;
THYM	cis	rs308447	0.576	rs10019442	chr4:123700613	T/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.85	6.76	0.57	1.12e-9	Perceived unattractiveness to mosquitoes;
THYM	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg14784868	chr12:69753453	YEATS4	1.13	10.92	0.75	1.82e-18	Blood protein levels;
THYM	cis	rs10739663	0.520	rs2819624	chr9:128156519	A/G	cg14078157	chr9:128172775	NA	-0.91	-7.95	-0.63	3.88e-12	Resting heart rate;
THYM	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg00684032	chr4:1343700	KIAA1530	0.59	5.36	0.48	5.75e-7	Obesity-related traits;
THYM	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg06558623	chr16:89946397	TCF25	1.48	7.81	0.63	7.43e-12	Skin colour saturation;
THYM	cis	rs4363385	0.747	rs10788850	chr1:152963932	A/T	cg13444842	chr1:152974279	SPRR3	-0.61	-4.88	-0.45	4.33e-6	Inflammatory skin disease;
THYM	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg22875332	chr1:76189707	ACADM	0.9	10.62	0.74	7.94e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2070488	0.965	rs3749386	chr3:38496065	C/T	cg24069376	chr3:38537580	EXOG	0.66	6.8	0.57	9.12e-10	Electrocardiographic conduction measures;
THYM	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg06627628	chr2:24431161	ITSN2	-0.67	-4.55	-0.42	1.57e-5	Asthma;
THYM	cis	rs9543976	1.000	rs73223984	chr13:76181141	G/A	cg01531495	chr13:76123901	UCHL3	-0.79	-4.99	-0.46	2.74e-6	Diabetic retinopathy;
THYM	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2070488	1.000	rs13058903	chr3:38513365	C/T	cg24069376	chr3:38537580	EXOG	-0.67	-6.54	-0.56	3.14e-9	Electrocardiographic conduction measures;
THYM	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs995000	0.965	rs11207995	chr1:63049551	G/T	cg06896770	chr1:63153194	DOCK7	-0.97	-8.07	-0.64	2.19e-12	Triglyceride levels;
THYM	cis	rs11822910	0.911	rs11828218	chr11:57196223	C/G	cg00522883	chr11:57194120	SLC43A3	0.68	5.57	0.5	2.4e-7	Platelet distribution width;
THYM	cis	rs6933660	0.610	rs71549125	chr6:151770796	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.78	7.55	0.61	2.68e-11	Menarche (age at onset);
THYM	cis	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg24692254	chr21:30365293	RNF160	-0.79	-4.48	-0.42	2.07e-5	Cognitive test performance;
THYM	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg14820908	chr5:178986412	RUFY1	0.64	7.29	0.6	9.26e-11	Lung cancer;
THYM	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg06623918	chr6:96969491	KIAA0776	-1.1	-11.31	-0.76	2.69e-19	Headache;
THYM	cis	rs35995292	0.963	rs2240555	chr7:38949424	T/C	cg19166347	chr7:37955598	SFRP4	0.62	5.01	0.46	2.47e-6	Subjective well-being (multi-trait analysis);
THYM	cis	rs2439831	1.000	rs550239	chr15:43720197	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg26031613	chr14:104095156	KLC1	1.21	12.87	0.8	1.52e-22	Body mass index;
THYM	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg22709100	chr7:91322751	NA	-0.62	-4.96	-0.45	3.05e-6	Breast cancer;
THYM	cis	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-5.83	-0.51	7.47e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg12599982	chr1:44399894	ARTN	0.58	4.67	0.43	9.88e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg26850624	chr5:429559	AHRR	-0.7	-5.6	-0.5	2.07e-7	Cystic fibrosis severity;
THYM	cis	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.57	-5.94	-0.52	4.68e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg18357526	chr6:26021779	HIST1H4A	0.75	6.4	0.55	5.75e-9	Intelligence (multi-trait analysis);
THYM	cis	rs58873874	0.737	rs9313608	chr5:156900047	A/G	cg08916508	chr5:156566250	MED7	1.13	4.45	0.42	2.3e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs34779708	0.966	rs17591857	chr10:35499043	A/G	cg03585969	chr10:35415529	CREM	-0.63	-4.48	-0.42	2.09e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg04181038	chr4:183730758	NA	0.96	7.79	0.62	8.28e-12	Pediatric autoimmune diseases;
THYM	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg14768367	chr16:72042858	DHODH	0.65	4.98	0.46	2.83e-6	Fibrinogen levels;
THYM	cis	rs896543	0.657	rs10179774	chr2:237487588	C/T	cg25295825	chr2:237489920	CXCR7	0.77	4.8	0.44	5.98e-6	Alcohol dependence (age at onset);
THYM	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg05973401	chr12:123451056	ABCB9	0.64	4.63	0.43	1.17e-5	Platelet count;
THYM	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg14129053	chr2:1895732	MYT1L	1.13	4.49	0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs8049040	0.609	rs9940485	chr16:71486105	C/T	cg08717414	chr16:71523259	ZNF19	-0.74	-4.64	-0.43	1.13e-5	Blood protein levels;
THYM	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.28	-0.48	8.27e-7	Hemoglobin concentration;
THYM	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg23583168	chr7:148888333	NA	-0.98	-12.37	-0.79	1.66e-21	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg18128536	chr17:47092178	IGF2BP1	-0.56	-8.28	-0.65	7.63e-13	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs11997175	0.646	rs2006792	chr8:33694423	G/A	ch.8.33884649F	chr8:33765107	NA	0.66	5.06	0.46	2.01e-6	Body mass index;
THYM	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08109568	chr15:31115862	NA	-0.78	-6.95	-0.58	4.56e-10	Huntington's disease progression;
THYM	cis	rs2073300	0.609	rs34648279	chr20:23402935	T/G	cg12062639	chr20:23401060	NAPB	1.1	5.73	0.51	1.16e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs3796352	1.000	rs750474	chr3:53085280	A/C	cg04865290	chr3:52927548	TMEM110	-0.72	-4.56	-0.42	1.52e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs17253792	0.822	rs78395034	chr14:56069783	G/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg17366294	chr4:99064904	C4orf37	0.54	6.33	0.54	8.05e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg27446573	chr6:127587934	RNF146	0.69	6.12	0.53	2.04e-8	Breast cancer;
THYM	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg03388043	chr17:80084554	CCDC57	-0.7	-5.69	-0.5	1.37e-7	Life satisfaction;
THYM	trans	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg10856724	chr12:34555212	NA	-1.01	-9.17	-0.69	9.95e-15	Bladder cancer;
THYM	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg21361702	chr7:150065534	REPIN1	0.69	4.92	0.45	3.65e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11771526	0.901	rs11771230	chr7:32315546	C/T	cg13207630	chr7:32358064	NA	-0.84	-5.28	-0.48	8.15e-7	Body mass index;
THYM	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03264133	chr6:25882463	NA	-0.84	-7.01	-0.58	3.49e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg03433033	chr1:76189801	ACADM	0.77	10.09	0.72	1.07e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7617773	0.780	rs7632297	chr3:48348163	A/C	cg02219026	chr3:48282209	ZNF589	-0.64	-4.58	-0.43	1.39e-5	Coronary artery disease;
THYM	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg03388043	chr17:80084554	CCDC57	0.69	5.98	0.52	3.85e-8	Life satisfaction;
THYM	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg03433033	chr1:76189801	ACADM	-0.51	-5.24	-0.47	9.83e-7	Daytime sleep phenotypes;
THYM	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg06850241	chr22:41845214	NA	0.54	4.6	0.43	1.33e-5	Vitiligo;
THYM	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg08901578	chr4:187885870	NA	-0.63	-5.79	-0.51	8.9e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2658782	0.950	rs2446061	chr11:93149277	C/T	cg16424440	chr11:93231842	C11orf75	-0.74	-4.69	-0.43	9.19e-6	Pulmonary function decline;
THYM	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	4.61	0.43	1.23e-5	Prudent dietary pattern;
THYM	trans	rs4650994	0.525	rs10913574	chr1:178536482	G/C	cg05059571	chr16:84539110	KIAA1609	-0.89	-10.47	-0.73	1.64e-17	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg27535305	chr1:53392650	SCP2	0.39	4.64	0.43	1.11e-5	Monocyte count;
THYM	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg23428387	chr22:49814324	NA	-0.53	-4.89	-0.45	4.02e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2964802	0.505	rs13164697	chr5:10831212	C/T	cg14521931	chr5:10832172	NA	-0.7	-5.97	-0.52	4.06e-8	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.58	5.03	0.46	2.3e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7084402	0.967	rs1649015	chr10:60289031	A/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs7084402	0.967	rs12259990	chr10:60297574	A/G	cg09696939	chr10:60272079	BICC1	0.47	5.54	0.49	2.65e-7	Refractive error;
THYM	trans	rs10980508	0.818	rs75349897	chr9:113432856	G/T	cg08591668	chr11:94150725	MRE11A	0.91	6.89	0.58	6.08e-10	Type 2 diabetes (dietary heme iron intake interaction);
THYM	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg26384229	chr12:38710491	ALG10B	0.97	7.44	0.61	4.48e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg16989719	chr2:238392110	NA	-0.65	-5.57	-0.5	2.41e-7	Prostate cancer;
THYM	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg08859206	chr1:53392774	SCP2	-0.5	-5.23	-0.47	1e-6	Monocyte count;
THYM	cis	rs921968	0.643	rs545779	chr2:219336108	A/G	cg02176678	chr2:219576539	TTLL4	0.68	6.71	0.57	1.42e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg07061783	chr6:25882402	NA	-0.87	-7.81	-0.63	7.49e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10887741	0.624	rs6586092	chr10:89428994	A/T	cg13926569	chr10:89418898	PAPSS2	0.62	7.19	0.59	1.47e-10	Exercise (leisure time);
THYM	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg03188948	chr7:1209495	NA	1.04	6.09	0.53	2.41e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1823778	0.609	rs1960819	chr18:67702586	A/G	cg12929678	chr18:67624393	CD226	1.28	4.87	0.45	4.4e-6	Mean platelet volume;
THYM	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg19770292	chr5:1868693	NA	0.54	4.97	0.45	2.95e-6	Cardiovascular disease risk factors;
THYM	cis	rs57994353	0.897	rs3812594	chr9:139368953	G/A	cg14115884	chr9:139300582	SDCCAG3	0.68	4.7	0.43	8.9e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs9302065	0.565	rs2992910	chr13:95962216	T/A	cg24476569	chr13:95954382	ABCC4	-0.79	-8.08	-0.64	2.05e-12	Blood metabolite levels;
THYM	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs7635838	0.684	rs384989	chr3:11320120	C/T	cg00170343	chr3:11313890	ATG7	0.59	4.58	0.43	1.42e-5	HDL cholesterol;
THYM	cis	rs4722585	0.605	rs3753098	chr7:26198040	C/T	cg07876897	chr7:26191696	NFE2L3	-0.62	-4.94	-0.45	3.37e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs10752881	1.000	rs12028732	chr1:182985525	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.79	0.44	6.13e-6	Colorectal cancer;
THYM	cis	rs2273669	0.504	rs74421833	chr6:109409274	A/G	cg17117243	chr6:109341365	SESN1	-0.92	-5.47	-0.49	3.63e-7	Prostate cancer;
THYM	cis	rs2067615	0.579	rs7486905	chr12:107160169	G/A	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg06191203	chr2:152266755	RIF1	-0.73	-5.0	-0.46	2.62e-6	Lung cancer;
THYM	cis	rs245880	0.740	rs245886	chr7:29189336	G/T	cg17163760	chr7:29186267	CPVL	-0.59	-4.94	-0.45	3.3e-6	Warfarin maintenance dose;
THYM	cis	rs2806561	1.000	rs681753	chr1:23515216	T/C	cg12483005	chr1:23474871	LUZP1	0.55	5.69	0.5	1.38e-7	Height;
THYM	cis	rs6547741	0.874	rs28381983	chr2:27804432	T/C	cg27432699	chr2:27873401	GPN1	0.7	6.07	0.53	2.57e-8	Oral cavity cancer;
THYM	cis	rs600806	0.850	rs4120621	chr1:109949008	A/G	cg23616212	chr1:109941201	SORT1	-0.49	-4.66	-0.43	1.01e-5	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs4281086	0.561	rs4997498	chr8:10352622	G/C	cg02525722	chr8:10404760	NA	0.54	4.54	0.42	1.68e-5	Obesity-related traits;
THYM	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg11871910	chr12:69753446	YEATS4	0.75	6.09	0.53	2.39e-8	Blood protein levels;
THYM	cis	rs526231	0.543	rs34783	chr5:102457041	C/A	cg23492399	chr5:102201601	PAM	-0.7	-5.23	-0.47	9.9e-7	Primary biliary cholangitis;
THYM	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg10117171	chr1:25599238	RHD	-0.8	-6.19	-0.54	1.49e-8	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs4595586	0.525	rs35046524	chr12:39414535	A/G	cg26384229	chr12:38710491	ALG10B	0.79	5.69	0.5	1.4e-7	Morning vs. evening chronotype;
THYM	cis	rs28595532	0.920	rs17325192	chr4:119780345	A/G	cg11846333	chr4:119757529	SEC24D	-1.21	-5.17	-0.47	1.27e-6	Cannabis dependence symptom count;
THYM	cis	rs637571	0.676	rs634534	chr11:65665256	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.62	-4.67	-0.43	9.91e-6	Eosinophil percentage of white cells;
THYM	cis	rs3087591	0.960	rs2905869	chr17:29519016	C/A	cg24425628	chr17:29625626	OMG;NF1	0.61	5.32	0.48	6.91e-7	Hip circumference;
THYM	cis	rs4363385	0.818	rs406350	chr1:153007492	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs17539620	0.624	rs62432740	chr6:154836054	C/T	cg20019720	chr6:154832845	CNKSR3	0.47	4.79	0.44	6.17e-6	Lipoprotein (a) levels;
THYM	cis	rs10782582	0.545	rs111927462	chr1:76195422	A/G	cg03433033	chr1:76189801	ACADM	-0.53	-5.47	-0.49	3.64e-7	Daytime sleep phenotypes;
THYM	cis	rs2070488	0.965	rs2366119	chr3:38484453	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	7.18	0.59	1.57e-10	Electrocardiographic conduction measures;
THYM	cis	rs986417	0.818	rs7156107	chr14:61059153	C/G	cg27398547	chr14:60952738	C14orf39	-0.77	-5.09	-0.46	1.78e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.95	0.71	2.08e-16	Colorectal cancer;
THYM	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	5.64	0.5	1.76e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs8070740	0.898	rs4442872	chr17:5324236	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.72	6.06	0.53	2.72e-8	Menopause (age at onset);
THYM	cis	rs4919694	0.572	rs7080935	chr10:104929113	C/A	cg04362960	chr10:104952993	NT5C2	0.98	6.42	0.55	5.4e-9	Arsenic metabolism;
THYM	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg19346786	chr7:2764209	NA	-0.71	-5.97	-0.52	4.13e-8	Height;
THYM	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg17173187	chr15:85201210	NMB	0.55	5.34	0.48	6.21e-7	Schizophrenia;
THYM	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg23248424	chr5:179741104	GFPT2	-0.82	-6.48	-0.55	4e-9	Height;
THYM	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	7.56	0.61	2.49e-11	Platelet count;
THYM	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg07777115	chr5:623756	CEP72	-0.81	-4.8	-0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.68	8.69	0.67	1.04e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs990171	0.865	rs6717915	chr2:103079619	A/C	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.13	-0.47	1.56e-6	Lymphocyte counts;
THYM	cis	rs988913	0.706	rs1155749	chr6:54730383	T/C	cg15217784	chr6:54722227	FAM83B	-0.53	-4.6	-0.43	1.28e-5	Menarche (age at onset);
THYM	trans	rs11186	0.556	rs60762885	chr2:189953679	T/G	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs7131987	0.903	rs7302129	chr12:29415280	A/T	cg09582351	chr12:29534625	ERGIC2	-0.48	-4.59	-0.43	1.35e-5	QT interval;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg14543104	chr11:62442981	NA	-0.98	-7.04	-0.59	2.92e-10	Depressive symptoms;
THYM	cis	rs7216064	0.648	rs61676547	chr17:65892507	G/C	cg12091567	chr17:66097778	LOC651250	-0.73	-5.18	-0.47	1.25e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs910316	0.904	rs7156089	chr14:75645527	A/G	cg11812906	chr14:75593930	NEK9	-0.86	-7.86	-0.63	6.03e-12	Height;
THYM	cis	rs2976388	0.967	rs2585183	chr8:143766059	C/G	cg06565975	chr8:143823917	SLURP1	-0.54	-6.2	-0.54	1.45e-8	Urinary tract infection frequency;
THYM	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg07599136	chr5:415885	AHRR	0.98	5.46	0.49	3.84e-7	Fat distribution (HIV);
THYM	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6132905	0.767	rs6138678	chr20:2633296	G/C	cg10544093	chr20:2632942	MIR1292;NOP56	-0.75	-4.73	-0.44	7.68e-6	Mumps;
THYM	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.9	-6.56	-0.56	2.78e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg17063962	chr7:91808500	NA	0.96	7.44	0.61	4.47e-11	Breast cancer;
THYM	cis	rs56104184	0.775	rs73061697	chr19:49400000	C/T	cg17863274	chr19:49399704	TULP2	-1.01	-6.47	-0.55	4.29e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg12564285	chr5:131593104	PDLIM4	-0.43	-4.51	-0.42	1.87e-5	Blood metabolite levels;
THYM	cis	rs7193541	0.682	rs28681530	chr16:74682496	C/T	cg01733217	chr16:74700730	RFWD3	0.99	11.69	0.77	4.4e-20	Multiple myeloma;
THYM	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg26038318	chr20:34205095	SPAG4	0.6	4.76	0.44	7.02e-6	Total cholesterol levels;
THYM	cis	rs7408868	1.000	rs757475	chr19:15273749	C/T	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.32	9.94	0.71	2.24e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.29e-7	Corneal astigmatism;
THYM	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.24	4.94	0.45	3.29e-6	Obesity-related traits;
THYM	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg17173187	chr15:85201210	NMB	0.56	5.49	0.49	3.32e-7	Schizophrenia;
THYM	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg24006582	chr15:45444508	DUOX1	-0.8	-7.1	-0.59	2.24e-10	Uric acid levels;
THYM	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.16	9.2	0.69	8.54e-15	Cognitive test performance;
THYM	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg09021430	chr5:549028	NA	-0.72	-5.39	-0.48	5.07e-7	Obesity-related traits;
THYM	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-4.52	-0.42	1.76e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs858239	0.539	rs2390757	chr7:23191492	A/G	cg09755872	chr7:23245557	NA	-0.5	-4.71	-0.43	8.55e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-5.91	-0.52	5.44e-8	Bone mineral density;
THYM	cis	rs2985684	0.557	rs2985689	chr14:50098031	C/A	cg02151108	chr14:50098012	C14orf104	-0.74	-4.62	-0.43	1.22e-5	Carotid intima media thickness;
THYM	cis	rs7584330	0.554	rs6740722	chr2:238393288	T/C	cg08992911	chr2:238395768	MLPH	1.18	7.09	0.59	2.41e-10	Prostate cancer;
THYM	cis	rs9790314	0.586	rs11713185	chr3:161111357	C/G	cg03342759	chr3:160939853	NMD3	-0.84	-7.31	-0.6	8.38e-11	Morning vs. evening chronotype;
THYM	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs6906287	0.609	rs6938041	chr6:118852468	C/A	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs9420	0.784	rs10896656	chr11:57668941	C/G	cg19752551	chr11:57585705	CTNND1	-0.72	-7.2	-0.59	1.42e-10	Schizophrenia;
THYM	cis	rs1011018	0.955	rs11770283	chr7:139436551	G/T	cg06079564	chr7:139468310	HIPK2	-0.73	-5.54	-0.49	2.65e-7	Systolic blood pressure;
THYM	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.69	-5.16	-0.47	1.36e-6	Tonsillectomy;
THYM	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg08999081	chr20:33150536	PIGU	0.64	5.33	0.48	6.63e-7	Coronary artery disease;
THYM	cis	rs3741151	0.773	rs73544711	chr11:73164870	T/A	cg12959048	chr11:73096162	RELT	-0.53	-5.08	-0.46	1.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs13315871	0.929	rs28659863	chr3:58328072	C/T	cg12435725	chr3:58293450	RPP14	-0.46	-4.63	-0.43	1.15e-5	Cholesterol, total;
THYM	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg11845111	chr2:191398756	TMEM194B	1.01	7.25	0.6	1.08e-10	Diastolic blood pressure;
THYM	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-5.11	-0.46	1.64e-6	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs6499129	0.702	rs9934160	chr16:67211447	C/T	cg16283183	chr3:45718805	LIMD1	0.98	6.96	0.58	4.27e-10	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6840360	0.615	rs4696290	chr4:152631472	A/G	cg22705602	chr4:152727874	NA	-0.81	-10.73	-0.74	4.59e-18	Intelligence (multi-trait analysis);
THYM	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs1933112	1.000	rs1323534	chr1:168503277	A/C	cg00154920	chr1:168513310	XCL2	-0.5	-4.94	-0.45	3.33e-6	Blood protein levels;
THYM	cis	rs4808199	0.947	rs2099333	chr19:19605963	C/T	cg03709012	chr19:19516395	GATAD2A	1.19	7.25	0.6	1.12e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs6084875	0.812	rs2422938	chr20:4721926	G/C	cg19614321	chr20:4804581	RASSF2	0.44	4.47	0.42	2.17e-5	Systemic lupus erythematosus;
THYM	cis	rs2976388	1.000	rs1045605	chr8:143764101	C/G	cg06565975	chr8:143823917	SLURP1	-0.45	-5.23	-0.47	9.95e-7	Urinary tract infection frequency;
THYM	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg18240062	chr17:79603768	NPLOC4	0.56	4.75	0.44	7.07e-6	Eye color traits;
THYM	cis	rs4819143	0.504	rs6518259	chr21:47317886	C/G	cg20357416	chr21:47294739	PCBP3	-0.81	-4.89	-0.45	4.07e-6	Insulin resistance/response;
THYM	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg03806693	chr22:41940476	POLR3H	1.05	8.42	0.65	3.85e-13	Vitiligo;
THYM	cis	rs7107174	1.000	rs7104222	chr11:78007169	G/A	cg19901956	chr11:77921274	USP35	-0.69	-5.29	-0.48	7.94e-7	Testicular germ cell tumor;
THYM	cis	rs1823778	0.609	rs10871660	chr18:67690201	T/C	cg13164537	chr18:67624071	CD226	1.11	4.47	0.42	2.14e-5	Mean platelet volume;
THYM	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg12573674	chr2:1569213	NA	-1.22	-4.82	-0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg18252515	chr7:66147081	NA	-1.6	-8.8	-0.67	6.03e-14	Diabetic kidney disease;
THYM	cis	rs733592	0.507	rs10875739	chr12:48480919	C/T	cg21466736	chr12:48725269	NA	-0.45	-4.85	-0.45	4.88e-6	Plateletcrit;
THYM	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg15242686	chr22:24348715	GSTTP1	-0.67	-7.26	-0.6	1.06e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg11266682	chr4:10021025	SLC2A9	-0.52	-6.42	-0.55	5.41e-9	Bone mineral density;
THYM	cis	rs7119	0.651	rs12902449	chr15:77850926	A/G	cg27398640	chr15:77910606	LINGO1	-0.59	-5.88	-0.52	6.15e-8	Type 2 diabetes;
THYM	cis	rs1443512	1.000	rs1443512	chr12:54342684	A/C	cg15261861	chr12:54132255	NA	-0.47	-4.54	-0.42	1.64e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg11941060	chr3:133502564	NA	0.73	6.33	0.54	8.21e-9	Iron status biomarkers;
THYM	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9581857	1.000	rs9581857	chr13:28027714	A/C	cg22138327	chr13:27999177	GTF3A	0.84	4.74	0.44	7.35e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg18357526	chr6:26021779	HIST1H4A	0.74	6.38	0.55	6.36e-9	Intelligence (multi-trait analysis);
THYM	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg02734326	chr4:10020555	SLC2A9	-0.59	-4.86	-0.45	4.63e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs34779708	0.966	rs4934735	chr10:35496730	C/T	cg03585969	chr10:35415529	CREM	-0.63	-4.48	-0.42	2.09e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg26850624	chr5:429559	AHRR	-0.72	-5.31	-0.48	7.13e-7	Cystic fibrosis severity;
THYM	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg12165864	chr7:66369176	NA	-0.62	-4.79	-0.44	6.02e-6	Aortic root size;
THYM	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg27394845	chr17:28928406	LRRC37B2	0.91	4.58	0.42	1.44e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	4.93	0.45	3.51e-6	Motion sickness;
THYM	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg00757033	chr12:89920650	WDR51B	0.74	11.52	0.76	9.94e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs6901250	0.851	rs339322	chr6:117193356	T/C	cg12892004	chr6:117198278	RFX6	-0.7	-6.78	-0.57	9.91e-10	C-reactive protein levels;
THYM	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.78	0.51	9.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg12564285	chr5:131593104	PDLIM4	0.53	5.95	0.52	4.4e-8	Breast cancer;
THYM	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.69	0.43	9.17e-6	Bipolar disorder;
THYM	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg22105103	chr4:187893119	NA	0.92	10.09	0.72	1.04e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9644630	0.504	rs62496181	chr8:19318989	A/T	cg01280390	chr8:19363452	CSGALNACT1	0.65	6.96	0.58	4.31e-10	Oropharynx cancer;
THYM	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs71403859	0.730	rs35390364	chr16:71740049	A/G	cg08717414	chr16:71523259	ZNF19	-0.89	-4.98	-0.45	2.88e-6	Post bronchodilator FEV1;
THYM	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg23711669	chr6:146136114	FBXO30	0.86	8.21	0.64	1.08e-12	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.24	-15.08	-0.84	5.92e-27	Exhaled nitric oxide output;
THYM	cis	rs4731207	0.596	rs1871773	chr7:124674939	A/G	cg05285228	chr7:124571219	POT1	-0.65	-4.98	-0.45	2.9e-6	Cutaneous malignant melanoma;
THYM	cis	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg06636001	chr8:8085503	FLJ10661	-0.72	-7.06	-0.59	2.75e-10	Mood instability;
THYM	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs12282928	1.000	rs7129742	chr11:48326592	G/A	cg22827986	chr11:48284249	OR4X1	0.51	5.29	0.48	7.88e-7	Migraine - clinic-based;
THYM	cis	rs7267979	1.000	rs397119	chr20:25440187	C/A	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs7647973	0.961	rs7638750	chr3:49452957	A/T	cg07690219	chr3:49449608	TCTA;RHOA	0.7	4.46	0.42	2.26e-5	Menarche (age at onset);
THYM	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7599312	0.534	rs7607363	chr2:213402705	A/G	cg20637307	chr2:213403960	ERBB4	1.04	11.16	0.75	5.66e-19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg07424592	chr7:64974309	NA	1.05	4.76	0.44	6.92e-6	Diabetic kidney disease;
THYM	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg05368731	chr17:41323189	NBR1	1.24	11.39	0.76	1.87e-19	Menopause (age at onset);
THYM	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg16898833	chr6:26189333	HIST1H4D	1.18	5.31	0.48	7.34e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg13695892	chr22:41940480	POLR3H	-0.89	-6.49	-0.55	3.95e-9	Vitiligo;
THYM	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs3892630	0.529	rs35300319	chr19:33409948	G/A	cg22980127	chr19:33182716	NUDT19	0.77	5.05	0.46	2.15e-6	Red blood cell traits;
THYM	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg05973401	chr12:123451056	ABCB9	0.67	4.49	0.42	2.02e-5	Neutrophil percentage of white cells;
THYM	cis	rs28647808	0.618	rs7025970	chr9:136267173	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg20290983	chr6:43655470	MRPS18A	1.44	16.17	0.86	4.93e-29	IgG glycosylation;
THYM	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.7	-6.16	-0.53	1.72e-8	Renal function-related traits (BUN);
THYM	cis	rs853679	0.882	rs9380069	chr6:28203300	A/G	cg23161317	chr6:28129485	ZNF389	0.91	5.32	0.48	6.96e-7	Depression;
THYM	cis	rs554111	0.613	rs10753510	chr1:21412248	G/A	cg01072550	chr1:21505969	NA	0.58	5.06	0.46	2.06e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg23231163	chr10:75533350	FUT11	-0.46	-6.57	-0.56	2.65e-9	Inflammatory bowel disease;
THYM	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	1.03	7.08	0.59	2.43e-10	Platelet count;
THYM	cis	rs7408868	1.000	rs1548554	chr19:15277938	C/T	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs8013055	0.796	rs4074937	chr14:106000977	A/G	cg04429589	chr14:105992532	TMEM121	-0.49	-5.34	-0.48	6.34e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs6032067	1.000	rs6032052	chr20:43829883	C/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs1018836	0.608	rs2142147	chr8:91468200	A/G	cg16814680	chr8:91681699	NA	-0.71	-5.68	-0.5	1.47e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs476633	0.708	rs28770904	chr15:41438881	T/C	cg21153102	chr15:41252147	NA	0.59	4.59	0.43	1.34e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs7107174	1.000	rs7101429	chr11:77992967	A/G	cg02023728	chr11:77925099	USP35	0.67	5.89	0.52	5.85e-8	Testicular germ cell tumor;
THYM	trans	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs7084402	0.967	rs1649019	chr10:60288111	T/C	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs7772486	0.720	rs6570713	chr6:146075085	G/A	cg23711669	chr6:146136114	FBXO30	-0.97	-10.49	-0.73	1.45e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg04731861	chr2:219085781	ARPC2	-0.51	-4.78	-0.44	6.29e-6	Colorectal cancer;
THYM	cis	rs3772130	0.961	rs1573819	chr3:121469646	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.72	4.49	0.42	2.03e-5	Cognitive performance;
THYM	cis	rs3796352	0.892	rs9756317	chr3:53088815	T/C	cg07884673	chr3:53033167	SFMBT1	-1.04	-6.05	-0.53	2.79e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs990171	1.000	rs2110734	chr2:103052206	C/T	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.17	-0.47	1.27e-6	Lymphocyte counts;
THYM	cis	rs654384	0.545	rs4723419	chr7:4174716	C/T	cg04612959	chr7:4183976	SDK1	0.52	4.47	0.42	2.19e-5	Positive affect;
THYM	cis	rs9649465	1.000	rs627689	chr7:123400543	C/T	cg15443791	chr7:124364398	NA	0.57	4.8	0.44	5.88e-6	Migraine;
THYM	cis	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg13443165	chr9:33130375	B4GALT1	-0.87	-7.99	-0.63	3.23e-12	IgG glycosylation;
THYM	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg06808227	chr14:105710500	BRF1	-1.03	-8.81	-0.67	5.87e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7264396	1.000	rs224418	chr20:34142527	T/C	cg26038318	chr20:34205095	SPAG4	0.52	4.51	0.42	1.83e-5	Total cholesterol levels;
THYM	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg24250549	chr1:154909240	PMVK	0.75	6.45	0.55	4.66e-9	Prostate cancer;
THYM	cis	rs11077998	0.967	rs4789782	chr17:80489323	G/T	cg10255544	chr17:80519551	FOXK2	-0.51	-4.55	-0.42	1.61e-5	Reticulocyte fraction of red cells;
THYM	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs12579753	1.000	rs10862374	chr12:82250809	G/C	cg21231944	chr12:82153410	PPFIA2	-0.6	-4.65	-0.43	1.07e-5	Resting heart rate;
THYM	cis	rs2340727	0.673	rs28505989	chr1:161941382	C/G	cg06514368	chr1:161719587	DUSP12	-0.86	-5.12	-0.46	1.62e-6	White blood cell count;Hematology traits;
THYM	cis	rs4919087	0.962	rs10882891	chr10:99059645	C/A	cg19453742	chr10:98862320	SLIT1	-0.63	-4.96	-0.45	3.11e-6	Monocyte count;
THYM	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg05962950	chr11:130786565	SNX19	0.82	7.4	0.6	5.52e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs72843506	0.656	rs79406817	chr17:19915127	C/T	cg12065943	chr17:19881925	AKAP10	-0.82	-4.5	-0.42	1.95e-5	Schizophrenia;
THYM	cis	rs11690935	0.959	rs75922913	chr2:172620152	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.8	-5.67	-0.5	1.52e-7	Schizophrenia;
THYM	cis	rs7614311	0.731	rs3774719	chr3:63950338	C/A	cg22134162	chr3:63841271	THOC7	-0.55	-6.58	-0.56	2.51e-9	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs9399401	0.626	rs9373347	chr6:142779885	C/T	cg04461802	chr6:142623433	GPR126	0.72	7.43	0.61	4.78e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs600806	0.850	rs3879452	chr1:109929237	G/A	cg23616212	chr1:109941201	SORT1	-0.5	-4.65	-0.43	1.06e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2732480	0.557	rs923397	chr12:48720392	G/A	cg21466736	chr12:48725269	NA	-0.54	-4.91	-0.45	3.72e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs11225247	1.000	rs76479943	chr11:102305200	T/C	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs910187	0.678	rs6018330	chr20:45813216	C/T	cg27589058	chr20:45804311	EYA2	-0.59	-5.07	-0.46	1.95e-6	Migraine;
THYM	cis	rs8014204	0.804	rs35641442	chr14:75207263	G/A	cg06637938	chr14:75390232	RPS6KL1	0.54	5.22	0.47	1.05e-6	Caffeine consumption;
THYM	cis	rs2070488	0.930	rs2370840	chr3:38529825	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	6.93	0.58	5.1e-10	Electrocardiographic conduction measures;
THYM	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg21475434	chr5:93447410	FAM172A	0.92	5.19	0.47	1.2e-6	Diabetic retinopathy;
THYM	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg01017244	chr2:74357527	NA	1.09	9.69	0.71	7.45e-16	Gestational age at birth (maternal effect);
THYM	cis	rs10463554	0.927	rs34375	chr5:102401123	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs2456568	0.570	rs1827932	chr11:93663319	A/T	cg26875233	chr11:93583750	C11orf90	-0.52	-5.79	-0.51	8.93e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg10687131	chr2:20871002	GDF7	0.61	4.92	0.45	3.56e-6	Abdominal aortic aneurysm;
THYM	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg06191203	chr2:152266755	RIF1	0.71	4.71	0.43	8.5e-6	Lung cancer;
THYM	cis	rs447921	0.817	rs11077822	chr17:74455605	G/A	cg17201438	chr17:74438067	UBE2O	-0.64	-4.47	-0.42	2.14e-5	Mitochondrial DNA levels;
THYM	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg00810483	chr4:3375144	RGS12	0.32	4.85	0.45	4.79e-6	Serum sulfate level;
THYM	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg26267310	chr19:49340593	PLEKHA4;HSD17B14	0.79	4.75	0.44	7.28e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg05234568	chr11:5960015	NA	-0.62	-4.97	-0.45	2.95e-6	DNA methylation (variation);
THYM	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg11764359	chr7:65958608	NA	-0.81	-6.92	-0.58	5.2400000000000005e-10	Aortic root size;
THYM	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg04181038	chr4:183730758	NA	1.02	8.45	0.66	3.35e-13	Pediatric autoimmune diseases;
THYM	cis	rs4076764	0.881	rs10917758	chr1:163430652	G/A	cg24596788	chr1:163392923	NA	-0.72	-6.35	-0.55	7.29e-9	Motion sickness;
THYM	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.32	-9.95	-0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.72	0.57	1.37e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs3892630	0.612	rs10413282	chr19:33182751	A/G	cg22980127	chr19:33182716	NUDT19	1.15	11.55	0.76	8.32e-20	Red blood cell traits;
THYM	cis	rs55871839	0.643	rs10109566	chr8:59800446	A/G	cg07426533	chr8:59803705	TOX	-0.61	-6.02	-0.53	3.2e-8	Pneumonia;
THYM	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg13147721	chr7:65941812	NA	-1.1	-7.08	-0.59	2.51e-10	Diabetic kidney disease;
THYM	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.27	5.89	0.52	5.88e-8	Obesity-related traits;
THYM	cis	rs12216545	0.711	rs1403221	chr7:150253636	G/A	cg08960815	chr7:150264767	GIMAP4	-0.87	-7.96	-0.63	3.61e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7192750	0.562	rs9302631	chr16:71943414	C/T	cg06353428	chr16:71660113	MARVELD3	0.71	5.08	0.46	1.91e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs1448094	0.549	rs57614821	chr12:86235361	A/C	cg02569458	chr12:86230093	RASSF9	0.63	5.56	0.5	2.51e-7	Major depressive disorder;
THYM	cis	rs4242434	0.819	rs7843128	chr8:22473465	T/C	cg11461670	chr8:22454935	PDLIM2	-0.32	-6.17	-0.53	1.68e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs5758511	0.773	rs73165164	chr22:42355549	T/C	cg08431931	chr22:42394659	WBP2NL	0.71	4.46	0.42	2.25e-5	Birth weight;
THYM	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg18252515	chr7:66147081	NA	-0.88	-6.73	-0.57	1.26e-9	Corneal structure;
THYM	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg08999081	chr20:33150536	PIGU	0.78	7.2	0.59	1.38e-10	Coronary artery disease;
THYM	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg00129232	chr17:37814104	STARD3	0.71	4.8	0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs807669	0.777	rs9605972	chr22:19253274	C/T	cg02655711	chr22:19163373	SLC25A1	0.65	7.5	0.61	3.36e-11	Metabolite levels;
THYM	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg11301795	chr4:187892539	NA	-1.1	-16.51	-0.86	1.17e-29	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg21775007	chr8:11205619	TDH	0.74	6.67	0.57	1.65e-9	Retinal vascular caliber;
THYM	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg12573674	chr2:1569213	NA	-1.34	-8.9	-0.67	3.68e-14	IgG glycosylation;
THYM	cis	rs6832951	1	rs6832951	chr4:83556706	A/G	cg10249074	chr4:83542146	C4orf11	-0.62	-4.94	-0.45	3.33e-6	Lymphocyte counts;
THYM	cis	rs1497406	0.744	rs4661718	chr1:16505908	C/T	cg20430773	chr1:16534157	ARHGEF19	0.49	5.46	0.49	3.78e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.38	0.6	5.91e-11	Bladder cancer;
THYM	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs4866334	1.000	rs6866535	chr5:18431650	G/A	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs17102423	0.594	rs1270074	chr14:65564856	T/C	cg11161011	chr14:65562177	MAX	-0.76	-6.25	-0.54	1.14e-8	Obesity-related traits;
THYM	cis	rs750460	1.000	rs12440667	chr15:74231439	C/T	cg01349856	chr15:74220517	LOXL1	-0.62	-4.56	-0.42	1.51e-5	Height;
THYM	cis	rs3126085	0.935	rs10749670	chr1:152220467	G/A	cg10321714	chr1:152280068	FLG	0.68	5.07	0.46	1.98e-6	Atopic dermatitis;
THYM	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg27129171	chr3:47204927	SETD2	-0.71	-6.63	-0.56	2e-9	Colorectal cancer;
THYM	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs4930103	0.602	rs170101	chr11:2008936	C/T	cg18511798	chr11:2018149	H19;MIR675	-0.59	-5.93	-0.52	4.8e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs2404602	0.735	rs4886493	chr15:76679026	A/G	cg23625390	chr15:77176239	SCAPER	-0.65	-4.7	-0.43	8.68e-6	Blood metabolite levels;
THYM	cis	rs12530845	0.623	rs73721677	chr7:135354238	C/A	cg19897172	chr7:135347071	PL-5283	-0.66	-5.51	-0.49	3.11e-7	Red blood cell traits;
THYM	cis	rs1403694	0.655	rs3806688	chr3:186434819	T/C	cg12454167	chr3:186435060	KNG1	0.53	7.54	0.61	2.83e-11	Blood protein levels;
THYM	cis	rs8133932	0.667	rs760436	chr21:47278055	C/T	cg08707771	chr21:46690014	POFUT2	-0.81	-5.08	-0.46	1.87e-6	Schizophrenia;
THYM	cis	rs7512552	0.839	rs17596326	chr1:150433819	A/G	cg15654264	chr1:150340011	RPRD2	0.44	5.12	0.47	1.58e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.55	0.42	1.57e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg18709589	chr6:96969512	KIAA0776	-0.61	-4.46	-0.42	2.21e-5	Headache;
THYM	cis	rs12410462	0.581	rs77837509	chr1:227559873	C/T	cg23173402	chr1:227635558	NA	0.75	5.92	0.52	5.2e-8	Major depressive disorder;
THYM	cis	rs7681423	0.951	rs13130318	chr4:155538470	T/G	cg20735720	chr4:155535218	FGG	-0.74	-5.81	-0.51	8.33e-8	Fibrinogen;
THYM	cis	rs899997	1.000	rs12904489	chr15:79033925	T/A	cg22753661	chr15:79092743	ADAMTS7	0.72	4.61	0.43	1.23e-5	Coronary artery disease or large artery stroke;
THYM	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg06481639	chr22:41940642	POLR3H	-0.63	-4.6	-0.43	1.32e-5	Neuroticism;
THYM	cis	rs10979	0.838	rs12208649	chr6:143893321	G/T	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs9361491	0.608	rs2321774	chr6:79476450	C/T	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.88e-5	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg17264618	chr3:40429014	ENTPD3	0.52	4.86	0.45	4.57e-6	Renal cell carcinoma;
THYM	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg15838173	chr10:75533400	FUT11	-0.48	-4.91	-0.45	3.72e-6	Inflammatory bowel disease;
THYM	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg21028142	chr17:79581711	NPLOC4	0.61	6.22	0.54	1.32e-8	Eye color traits;
THYM	cis	rs9348792	1	rs9348792	chr6:28042274	C/T	cg13525197	chr6:28411240	ZSCAN23	-1.43	-4.5	-0.42	1.96e-5	Mean corpuscular hemoglobin;
THYM	cis	rs7177699	0.557	rs62011002	chr15:79120578	C/T	cg15571903	chr15:79123663	NA	0.58	6.75	0.57	1.15e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs4919694	1.000	rs11191545	chr10:104829793	C/T	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs7072216	0.763	rs12763044	chr10:100167451	C/G	cg03852570	chr10:100175106	PYROXD2	0.38	4.89	0.45	4.04e-6	Metabolite levels;
THYM	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs12368653	0.534	rs923828	chr12:58015494	G/A	cg12615879	chr12:58013172	SLC26A10	0.67	6.75	0.57	1.18e-9	Multiple sclerosis;
THYM	cis	rs4638749	0.501	rs2378095	chr2:108764899	G/A	cg25838818	chr2:108905173	SULT1C2	-0.52	-4.89	-0.45	4.13e-6	Blood pressure;
THYM	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg17063962	chr7:91808500	NA	0.98	7.77	0.62	9.01e-12	Breast cancer;
THYM	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg10792982	chr14:105748885	BRF1	0.7	6.95	0.58	4.6e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs66887589	0.967	rs56173225	chr4:120509972	G/A	cg13609457	chr4:120235615	NA	-0.47	-4.92	-0.45	3.59e-6	Diastolic blood pressure;
THYM	cis	rs10895275	0.886	rs4754041	chr11:102049946	T/C	cg24447756	chr11:102105824	NA	-0.51	-4.64	-0.43	1.11e-5	Migraine;
THYM	cis	rs981844	1.000	rs62325105	chr4:154673846	T/C	cg09973105	chr4:154681532	RNF175	-0.65	-5.33	-0.48	6.48e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs7828089	0.715	rs11136029	chr8:22253485	A/G	cg12081754	chr8:22256438	SLC39A14	-0.67	-6.16	-0.53	1.73e-8	Verbal declarative memory;
THYM	cis	rs7267979	0.966	rs2500417	chr20:25383287	A/G	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg01097406	chr16:89675127	NA	-0.63	-5.55	-0.5	2.54e-7	Vitiligo;
THYM	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg10589385	chr1:150898437	SETDB1	-0.57	-4.55	-0.42	1.56e-5	Melanoma;
THYM	cis	rs748404	0.660	rs2439845	chr15:43722610	C/G	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs17209837	0.607	rs117917293	chr7:87114824	G/C	cg04996195	chr7:87105398	ABCB4	0.65	4.72	0.44	8e-6	Gallbladder cancer;
THYM	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7512552	0.839	rs1260386	chr1:150369622	G/T	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs34526934	0.608	rs72927183	chr2:177033779	C/T	cg14324370	chr2:177042789	NA	-0.69	-5.83	-0.51	7.48e-8	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg10047753	chr17:41438598	NA	1.19	11.15	0.75	5.97e-19	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs10009206	chr4:99056900	A/C	cg03676636	chr4:99064102	C4orf37	-0.45	-6.48	-0.55	4.01e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs12579753	1.000	rs7966755	chr12:82221604	A/G	cg21231944	chr12:82153410	PPFIA2	-0.65	-4.93	-0.45	3.52e-6	Resting heart rate;
THYM	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg04772025	chr11:68637568	NA	-0.65	-6.93	-0.58	5.09e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg12311346	chr5:56204834	C5orf35	-0.81	-5.9	-0.52	5.54e-8	Initial pursuit acceleration;
THYM	cis	rs11948739	0.501	rs79115810	chr5:130374516	A/G	cg08523029	chr5:130500466	HINT1	-0.84	-5.88	-0.52	6.17e-8	Pediatric bone mineral content (hip);
THYM	cis	rs7786808	0.552	rs12539355	chr7:158187565	C/T	cg01191920	chr7:158217561	PTPRN2	-0.93	-9.5	-0.7	1.93e-15	Obesity-related traits;
THYM	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg24733560	chr20:60626293	TAF4	0.62	6.35	0.55	7.48e-9	Body mass index;
THYM	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg19904058	chr10:135279010	LOC619207	-0.56	-5.25	-0.47	9.14e-7	Systemic lupus erythematosus;
THYM	cis	rs6906287	0.647	rs28655926	chr6:118688962	A/G	cg21191810	chr6:118973309	C6orf204	0.52	5.02	0.46	2.36e-6	Electrocardiographic conduction measures;
THYM	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg18252515	chr7:66147081	NA	-1.48	-8.83	-0.67	5.15e-14	Diabetic kidney disease;
THYM	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs9902453	0.765	rs2628185	chr17:28070107	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg09455208	chr3:40491958	NA	0.51	5.24	0.47	9.48e-7	Renal cell carcinoma;
THYM	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg12863693	chr15:85201151	NMB	0.51	4.66	0.43	1.02e-5	Schizophrenia;
THYM	cis	rs4866334	1.000	rs76883636	chr5:18488763	G/T	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg12564285	chr5:131593104	PDLIM4	0.54	5.91	0.52	5.24e-8	Blood metabolite levels;
THYM	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg06618935	chr21:46677482	NA	-0.98	-9.58	-0.7	1.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4720575	0.839	rs10255464	chr7:47097043	A/G	cg00036614	chr7:47093842	NA	-0.6	-5.28	-0.48	8.3e-7	Angiotensin-converting enzyme inhibitor intolerance;
THYM	cis	rs1520896	0.818	rs77804893	chr11:20261385	T/A	cg21745110	chr11:19798742	NAV2	0.76	4.55	0.42	1.59e-5	Response to platinum-based chemotherapy (cisplatin);
THYM	cis	rs7616559	0.573	rs4680337	chr3:156788451	A/G	cg15697575	chr3:156784781	NA	-0.32	-4.57	-0.42	1.47e-5	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs56104184	0.830	rs28556985	chr19:49351149	C/T	cg21252483	chr19:49399788	TULP2	-0.77	-5.03	-0.46	2.28e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs752010	1.000	rs6656183	chr1:42094025	A/G	cg06885757	chr1:42089581	HIVEP3	0.41	4.67	0.43	9.9e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs714027	0.605	rs5753025	chr22:30542157	T/C	cg27665648	chr22:30112403	NA	-0.52	-4.73	-0.44	7.79e-6	Lymphocyte counts;
THYM	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg14983838	chr19:29218262	NA	0.97	6.89	0.58	6.14e-10	Methadone dose in opioid dependence;
THYM	cis	rs2976388	0.935	rs2976386	chr8:143757409	G/A	cg13446199	chr8:143762866	PSCA	0.5	5.96	0.52	4.36e-8	Urinary tract infection frequency;
THYM	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg12310025	chr6:25882481	NA	-0.93	-8.98	-0.68	2.48e-14	Intelligence (multi-trait analysis);
THYM	cis	rs735396	0.770	rs1169300	chr12:121431225	G/A	cg02403541	chr12:121454288	C12orf43	0.82	7.19	0.59	1.45e-10	N-glycan levels;
THYM	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg05855489	chr10:104503620	C10orf26	-0.8	-7.23	-0.6	1.19e-10	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs300703	0.542	rs300697	chr2:184496	C/T	cg21211680	chr2:198530	NA	-0.96	-6.35	-0.55	7.3e-9	Blood protein levels;
THYM	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg10018233	chr7:150070692	REPIN1	0.35	4.93	0.45	3.45e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2637266	1.000	rs7897348	chr10:78359620	G/A	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg12599982	chr1:44399894	ARTN	0.57	4.89	0.45	4.18e-6	Intelligence (multi-trait analysis);
THYM	cis	rs898549	0.555	rs955584	chr10:44518915	C/A	cg27599783	chr10:45480162	RASSF4	0.49	4.5	0.42	1.96e-5	Obesity-related traits;
THYM	cis	rs10799590	1.000	rs6667034	chr1:224823056	C/T	cg01808320	chr1:224927238	CNIH3	-0.58	-5.11	-0.46	1.68e-6	Opioid dependence;
THYM	cis	rs4900538	0.855	rs12590993	chr14:102844064	A/G	cg18135206	chr14:102964638	TECPR2	-0.81	-6.24	-0.54	1.2e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs12893597	0.632	rs720967	chr14:76855084	C/T	cg20290672	chr14:76816747	NA	-0.56	-4.7	-0.43	8.91e-6	Maximal oxygen uptake response;
THYM	trans	rs877282	0.898	rs12357016	chr10:765675	C/T	cg22713356	chr15:30763199	NA	1.36	9.83	0.71	3.89e-16	Uric acid levels;
THYM	cis	rs9826463	0.582	rs11709758	chr3:142104427	T/C	cg20824294	chr3:142316082	PLS1	0.77	5.31	0.48	7.08e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19346786	chr7:2764209	NA	-0.82	-7.44	-0.61	4.58e-11	Height;
THYM	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg13695892	chr22:41940480	POLR3H	-0.86	-6.24	-0.54	1.22e-8	Vitiligo;
THYM	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg09184832	chr6:79620586	NA	-0.58	-4.58	-0.43	1.39e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	7.56	0.61	2.49e-11	Platelet count;
THYM	cis	rs17006441	0.866	rs6795249	chr3:69879741	A/T	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs68170813	0.559	rs7807648	chr7:106965091	C/T	cg00661777	chr7:106511741	PIK3CG	-0.68	-4.45	-0.42	2.35e-5	Coronary artery disease;
THYM	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.87	-8.5	-0.66	2.65e-13	Lung cancer;
THYM	cis	rs4589258	0.788	rs4298860	chr11:90478535	G/A	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.83	-0.44	5.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22857025	chr5:266934	NA	-1.5	-9.71	-0.71	6.9e-16	Breast cancer;
THYM	cis	rs4077515	0.934	rs78428995	chr9:139281847	T/C	cg14115884	chr9:139300582	SDCCAG3	0.73	6.9	0.58	5.79e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg26038318	chr20:34205095	SPAG4	0.6	4.7	0.43	8.69e-6	Total cholesterol levels;
THYM	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg11812906	chr14:75593930	NEK9	-0.8	-7.19	-0.59	1.48e-10	Height;
THYM	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.67	4.46	0.42	2.27e-5	Lung cancer in ever smokers;
THYM	cis	rs735539	0.521	rs2585896	chr13:21398861	A/G	cg02792322	chr13:21280448	IL17D	-0.65	-4.63	-0.43	1.16e-5	Dental caries;
THYM	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.07	0.46	1.93e-6	Prudent dietary pattern;
THYM	cis	rs7172809	0.897	rs869302	chr15:77830430	T/C	cg22256960	chr15:77711686	NA	-0.67	-4.67	-0.43	1.01e-5	Glucose homeostasis traits;
THYM	cis	rs28595532	0.841	rs114465037	chr4:119778165	A/G	cg14228332	chr4:119757509	SEC24D	1.59	5.76	0.51	1.02e-7	Cannabis dependence symptom count;
THYM	trans	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg10856724	chr12:34555212	NA	-0.88	-7.53	-0.61	2.92e-11	Bladder cancer;
THYM	cis	rs295137	0.836	rs10804097	chr2:201104924	A/T	cg23649088	chr2:200775458	C2orf69	0.63	5.46	0.49	3.75e-7	Asthma (bronchodilator response);
THYM	cis	rs72949976	0.646	rs1441170	chr2:214033563	A/G	cg08319019	chr2:214017104	IKZF2	-0.74	-6.11	-0.53	2.16e-8	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs9443645	0.507	rs1475046	chr6:79461801	G/A	cg04547799	chr6:79944526	HMGN3	-0.68	-5.07	-0.46	1.93e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2903698	0.585	rs6535429	chr4:76350536	A/G	cg03209871	chr4:76438412	RCHY1;THAP6	-0.44	-5.04	-0.46	2.25e-6	Prion diseases;
THYM	cis	rs4731207	0.596	rs7791399	chr7:124577972	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg24818145	chr4:99064322	C4orf37	0.69	5.43	0.49	4.34e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs916888	0.647	rs199517	chr17:44854587	A/G	cg17911788	chr17:44343683	NA	0.51	4.87	0.45	4.53e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9788721	0.775	rs8040868	chr15:78911181	C/T	cg18825076	chr15:78729989	IREB2	0.51	4.56	0.42	1.53e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs9677476	0.731	rs28690417	chr2:232064182	G/A	cg23338755	chr2:231921595	PSMD1	0.71	4.61	0.43	1.26e-5	Food antigen IgG levels;
THYM	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg02012338	chr4:187126139	CYP4V2	-0.97	-4.59	-0.43	1.36e-5	Blood protein levels;
THYM	cis	rs41311933	1.000	rs41311867	chr9:123753600	G/T	cg13567360	chr9:123745713	C5	-1.02	-5.4	-0.48	4.86e-7	Coronary artery disease;
THYM	cis	rs7224737	1.000	rs9915255	chr17:40284191	C/T	cg02228675	chr17:40259724	DHX58	-0.66	-5.49	-0.49	3.28e-7	Fibrinogen levels;
THYM	cis	rs7586879	0.639	rs2033654	chr2:25103108	C/A	cg27107076	chr2:25050844	ADCY3	-0.29	-4.68	-0.43	9.61e-6	Body mass index;
THYM	cis	rs6430585	0.528	rs12476127	chr2:136763242	A/G	cg07169764	chr2:136633963	MCM6	1.23	14.81	0.84	1.97e-26	Corneal structure;
THYM	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg26384229	chr12:38710491	ALG10B	0.95	7.55	0.61	2.7e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9972944	0.756	rs7218844	chr17:63768289	G/A	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs4604732	0.536	rs4433437	chr1:247636580	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.73	5.04	0.46	2.18e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs67460515	0.529	rs11712713	chr3:160852471	A/G	cg04691961	chr3:161091175	C3orf57	-0.54	-4.47	-0.42	2.16e-5	Parkinson's disease;
THYM	cis	rs6510489	0.848	rs59551721	chr19:35993327	C/T	cg15078284	chr19:36004994	DMKN	0.4	4.46	0.42	2.24e-5	Bipolar disorder;
THYM	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	12.77	0.8	2.43e-22	Chronic sinus infection;
THYM	cis	rs13223928	0.565	rs10240820	chr7:3154415	T/C	cg19214707	chr7:3157722	NA	-0.9	-7.97	-0.63	3.54e-12	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs9810089	0.749	rs664088	chr3:136036986	T/C	cg12473912	chr3:136751656	NA	0.57	4.65	0.43	1.07e-5	Gestational age at birth (child effect);
THYM	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg22166914	chr1:53195759	ZYG11B	0.82	8.68	0.66	1.1e-13	Monocyte count;
THYM	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-5.16	-0.47	1.34e-6	Hemoglobin concentration;
THYM	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg09549813	chr16:4587862	C16orf5	-0.59	-6.14	-0.53	1.92e-8	Schizophrenia;
THYM	cis	rs7000551	0.638	rs2469771	chr8:22376627	T/C	cg12081754	chr8:22256438	SLC39A14	0.64	5.98	0.52	3.89e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg03690763	chr11:133734501	NA	-0.57	-4.88	-0.45	4.29e-6	Childhood ear infection;
THYM	cis	rs7917772	0.582	rs7091252	chr10:104328859	G/T	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7772486	0.875	rs2748498	chr6:146319166	C/G	cg23711669	chr6:146136114	FBXO30	0.97	10.74	0.74	4.42e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9902453	0.868	rs9890075	chr17:28470464	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	6.58	0.56	2.55e-9	Coffee consumption (cups per day);
THYM	cis	rs6748734	0.553	rs7340215	chr2:241805851	A/G	cg04034577	chr2:241836375	C2orf54	-0.3	-5.13	-0.47	1.55e-6	Urinary metabolites;
THYM	cis	rs7432375	0.901	rs7648531	chr3:136462223	T/A	cg21827317	chr3:136751795	NA	-0.58	-4.95	-0.45	3.21e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg04602696	chr16:88846723	FAM38A	0.68	5.29	0.48	7.7e-7	Plateletcrit;
THYM	cis	rs7607369	0.626	rs4672892	chr2:219278630	A/G	cg02176678	chr2:219576539	TTLL4	-0.6	-5.18	-0.47	1.24e-6	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs13418717	1.000	rs1397340	chr2:127660818	G/T	cg25501666	chr2:127640322	NA	1.58	6.72	0.57	1.31e-9	Heart failure;
THYM	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Body mass index;
THYM	cis	rs9522267	0.535	rs9522298	chr13:112234457	C/A	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs807669	0.742	rs1206544	chr22:19215039	C/T	cg02655711	chr22:19163373	SLC25A1	0.64	7.22	0.59	1.3e-10	Metabolite levels;
THYM	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	5.29	0.48	7.97e-7	Hip circumference adjusted for BMI;
THYM	cis	rs6956675	0.534	rs1879840	chr7:62653307	C/T	cg27518014	chr7:62859535	LOC100287834	-0.53	-4.53	-0.42	1.7e-5	Obesity-related traits;
THYM	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg05738196	chr6:26577821	NA	0.95	9.38	0.69	3.53e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7589342	0.839	rs11895235	chr2:106432355	C/G	cg14210321	chr2:106509881	NCK2	-0.69	-4.9	-0.45	3.95e-6	Addiction;
THYM	cis	rs4919694	0.901	rs74376228	chr10:104677662	G/C	cg15744005	chr10:104629667	AS3MT	-0.85	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs12291225	0.585	rs10832246	chr11:14380828	G/A	cg05501817	chr11:14380813	RRAS2	-0.8	-6.65	-0.56	1.88e-9	Sense of smell;
THYM	cis	rs877282	1.000	rs2004479	chr10:770854	G/A	cg10556349	chr10:835070	NA	-0.77	-5.25	-0.47	9.15e-7	Uric acid levels;
THYM	cis	rs71403859	0.502	rs12708914	chr16:71470636	G/A	cg08717414	chr16:71523259	ZNF19	-0.86	-4.59	-0.43	1.36e-5	Post bronchodilator FEV1;
THYM	cis	rs4285028	0.847	rs1986712	chr3:121710986	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.75	-5.18	-0.47	1.26e-6	Multiple sclerosis;
THYM	cis	rs700651	0.789	rs1978889	chr2:198889366	G/A	cg00792783	chr2:198669748	PLCL1	0.83	5.9	0.52	5.65e-8	Intracranial aneurysm;
THYM	cis	rs1729407	0.659	rs2542050	chr11:116697117	C/A	cg08985259	chr11:116699649	APOC3	-0.61	-5.44	-0.49	4.15e-7	Apolipoprotein A-IV levels;
THYM	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9309473	0.519	rs13009035	chr2:73845709	T/C	cg19565262	chr2:73869966	NAT8	0.56	4.7	0.43	8.68e-6	Metabolite levels;
THYM	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg04546413	chr19:29218101	NA	-0.8	-5.35	-0.48	5.98e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11644478	chr21:40555479	PSMG1	1.1	9.84	0.71	3.61e-16	Cognitive function;
THYM	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg10523679	chr1:76189770	ACADM	-0.56	-4.6	-0.43	1.28e-5	Daytime sleep phenotypes;
THYM	cis	rs61612642	0.537	rs6915565	chr6:42192582	G/A	cg01092361	chr6:42185687	MRPS10	0.98	5.87	0.52	6.38e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg08508325	chr11:3079039	CARS	-0.49	-6.34	-0.55	7.54e-9	Longevity;
THYM	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg01304814	chr3:48885189	PRKAR2A	0.96	4.86	0.45	4.55e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	trans	rs11175492	0.764	rs78689302	chr12:65033149	T/G	cg12514734	chr12:3216258	TSPAN9	1.59	7.44	0.61	4.38e-11	Platelet count;
THYM	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg13683864	chr3:40499215	RPL14	0.73	6.54	0.56	3.14e-9	Renal cell carcinoma;
THYM	cis	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg01579765	chr21:45077557	HSF2BP	0.42	5.61	0.5	1.99e-7	Mean corpuscular volume;
THYM	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg20891558	chr2:74357851	NA	-1.21	-11.15	-0.75	5.9e-19	Gestational age at birth (maternal effect);
THYM	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg04654363	chr8:8581213	NA	-0.48	-4.62	-0.43	1.22e-5	Obesity-related traits;
THYM	cis	rs2932538	0.922	rs6698030	chr1:113138318	G/A	cg22162597	chr1:113214053	CAPZA1	0.63	4.96	0.45	3.13e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg10515332	chr4:99064459	C4orf37	0.63	5.02	0.46	2.42e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg07936489	chr17:37558343	FBXL20	-0.84	-5.54	-0.49	2.66e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs13185784	0.667	rs4700728	chr5:179647551	T/G	cg23248424	chr5:179741104	GFPT2	-0.7	-4.57	-0.42	1.48e-5	TRAIL levels;
THYM	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08704250	chr15:31115839	NA	-0.66	-7.4	-0.6	5.52e-11	Huntington's disease progression;
THYM	cis	rs57920188	0.537	rs4440829	chr1:4080780	A/G	cg20703997	chr1:4087676	NA	-0.67	-4.54	-0.42	1.67e-5	Interleukin-17 levels;
THYM	cis	rs10256972	0.640	rs10271082	chr7:1081562	G/C	cg01699819	chr7:1052092	C7orf50	-0.5	-4.47	-0.42	2.14e-5	Longevity;Endometriosis;
THYM	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.7	-0.43	8.72e-6	Crohn's disease;
THYM	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg18758796	chr5:131593413	PDLIM4	-0.49	-4.63	-0.43	1.16e-5	Breast cancer;
THYM	cis	rs9913156	0.793	rs11655166	chr17:4559302	T/A	cg19197139	chr17:4613644	ARRB2	-0.86	-5.22	-0.47	1.05e-6	Lymphocyte counts;
THYM	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	5.55	0.49	2.62e-7	Lung cancer in ever smokers;
THYM	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg22920501	chr2:26401640	FAM59B	1.07	9.54	0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg22974920	chr21:40686053	BRWD1	-0.59	-4.58	-0.43	1.4e-5	Cognitive function;
THYM	cis	rs7178572	0.633	rs11857860	chr15:77839761	T/C	cg22256960	chr15:77711686	NA	-0.77	-5.95	-0.52	4.39e-8	Type 2 diabetes;
THYM	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg17063962	chr7:91808500	NA	1.16	13.2	0.8	3.33e-23	Breast cancer;
THYM	cis	rs72772090	0.539	rs17481856	chr5:96116808	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs8033133	0.678	rs7496110	chr15:25347013	A/G	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.63	-4.66	-0.43	1.05e-5	Blood osmolality (transformed sodium);
THYM	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg00074818	chr8:8560427	CLDN23	0.58	5.4	0.48	4.91e-7	Obesity-related traits;
THYM	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg04398451	chr17:18023971	MYO15A	-0.92	-9.26	-0.69	6.26e-15	Total body bone mineral density;
THYM	cis	rs1775715	0.737	rs1541260	chr10:32105570	C/T	cg04359828	chr10:32216031	ARHGAP12	0.37	4.91	0.45	3.75e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs4731207	0.596	rs6964090	chr7:124667116	G/A	cg05285228	chr7:124571219	POT1	-0.62	-4.73	-0.44	7.68e-6	Cutaneous malignant melanoma;
THYM	cis	rs34638657	0.828	rs7194734	chr16:82199980	C/T	cg09439754	chr16:82129088	HSD17B2	-0.59	-5.25	-0.47	9.27e-7	Lung adenocarcinoma;
THYM	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg18825531	chr11:62321136	NA	0.44	4.96	0.45	3.1e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg03388025	chr16:89894329	SPIRE2	0.55	4.68	0.43	9.33e-6	Vitiligo;
THYM	cis	rs3960554	0.808	rs112962015	chr7:75659303	C/T	cg17325771	chr7:75508891	RHBDD2	-0.39	-4.49	-0.42	1.97e-5	Eotaxin levels;
THYM	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg14416269	chr4:6271139	WFS1	0.55	5.69	0.5	1.41e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg22431228	chr1:16359049	CLCNKA	-0.51	-5.43	-0.49	4.27e-7	Dilated cardiomyopathy;
THYM	cis	rs7084402	0.967	rs1658443	chr10:60316926	G/T	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg06221963	chr1:154839813	KCNN3	-0.78	-9.71	-0.71	7.02e-16	Prostate cancer;
THYM	cis	rs73086581	1.000	rs73086549	chr20:3954662	C/A	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs2933343	0.729	rs1680785	chr3:128644816	C/T	cg11901034	chr3:128598214	ACAD9	-0.69	-5.57	-0.5	2.32e-7	IgG glycosylation;
THYM	cis	rs2658782	0.694	rs3019221	chr11:93079700	C/G	cg15737290	chr11:93063684	CCDC67	0.92	7.62	0.62	1.93e-11	Pulmonary function decline;
THYM	cis	rs56309584	0.597	rs78296773	chr17:8167962	G/T	cg08322244	chr17:8066669	VAMP2	-0.57	-5.0	-0.46	2.57e-6	Initial pursuit acceleration;
THYM	cis	rs6754311	0.731	rs309168	chr2:136670298	C/T	cg04750100	chr2:136595281	LCT	0.59	6.31	0.54	8.79e-9	Mosquito bite size;
THYM	cis	rs17401966	0.838	rs946501	chr1:10309580	C/G	cg19773385	chr1:10388646	KIF1B	-0.57	-4.49	-0.42	2.04e-5	Hepatocellular carcinoma;
THYM	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg13609457	chr4:120235615	NA	0.59	5.22	0.47	1.04e-6	Corneal astigmatism;
THYM	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	8.49	0.66	2.72e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2797160	1.000	rs6910933	chr6:126017155	C/G	cg16306078	chr6:126000798	NA	0.53	5.29	0.48	7.67e-7	Endometrial cancer;
THYM	cis	rs4074961	0.565	rs4415526	chr1:38071728	T/C	cg17933807	chr1:38061675	GNL2	1.12	15.77	0.85	2.86e-28	Axial length;
THYM	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg00786635	chr1:25594202	NA	0.92	7.28	0.6	9.7e-11	Erythrocyte sedimentation rate;
THYM	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg01831904	chr17:28903510	LRRC37B2	0.98	4.88	0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7941600	0.643	rs11828205	chr11:9335284	T/A	cg19415743	chr11:9336845	TMEM41B	1.08	5.34	0.48	6.4e-7	Coronary artery disease;
THYM	cis	rs863345	0.604	rs10908658	chr1:158465256	A/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs16830122	0.509	rs7520918	chr1:154692601	A/T	cg26876647	chr1:155291345	RUSC1;C1orf104	-0.62	-4.67	-0.43	9.91e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs1775715	0.737	rs11008695	chr10:32216887	T/G	cg04359828	chr10:32216031	ARHGAP12	0.39	5.14	0.47	1.45e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs12444261	1.000	rs57439922	chr16:11739853	G/T	cg09662852	chr16:11707685	NA	-0.49	-4.66	-0.43	1.05e-5	QT interval;
THYM	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg02734326	chr4:10020555	SLC2A9	0.76	6.89	0.58	6.16e-10	Bone mineral density;
THYM	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs743002	0.554	rs5751014	chr22:41358092	A/T	cg24512644	chr22:41248902	ST13	0.87	4.52	0.42	1.75e-5	Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;Eosinophil counts;
THYM	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7323507	0.636	rs7984646	chr13:110618831	G/T	cg07669776	chr13:110975691	COL4A2	-0.51	-4.78	-0.44	6.38e-6	Lung function (FVC);
THYM	cis	rs9430161	0.564	rs12081176	chr1:11034145	T/C	cg27631724	chr1:11040367	C1orf127	0.64	5.61	0.5	1.98e-7	Ewing sarcoma;
THYM	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg12292205	chr6:26970375	C6orf41	0.53	4.55	0.42	1.6e-5	Schizophrenia;
THYM	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg15445000	chr17:37608096	MED1	0.44	5.18	0.47	1.23e-6	Lung function (FEV1);
THYM	cis	rs1023500	1.000	rs6002548	chr22:42337040	T/G	cg19448990	chr22:41842841	TOB2	-0.74	-4.66	-0.43	1.05e-5	Schizophrenia;
THYM	cis	rs7103648	0.695	rs11039290	chr11:47572279	G/A	cg20307385	chr11:47447363	PSMC3	0.88	6.93	0.58	5.09e-10	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs12200560	0.505	rs211163	chr6:97067654	A/G	cg06623918	chr6:96969491	KIAA0776	0.76	5.77	0.51	9.9e-8	Coronary heart disease;
THYM	cis	rs35934224	0.783	rs58714937	chr22:19856710	C/T	cg11182965	chr22:19864308	TXNRD2	-0.75	-6.18	-0.54	1.59e-8	Glaucoma (primary open-angle);
THYM	cis	rs1403694	0.695	rs13317089	chr3:186436217	G/C	cg12454167	chr3:186435060	KNG1	0.53	7.54	0.61	2.83e-11	Blood protein levels;
THYM	cis	rs2456568	0.867	rs2511375	chr11:93671117	T/G	cg17595323	chr11:93583763	C11orf90	-0.54	-5.23	-0.47	1.02e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg06784218	chr1:46089804	CCDC17	-0.34	-5.03	-0.46	2.28e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg06219351	chr7:158114137	PTPRN2	-0.74	-7.17	-0.59	1.6e-10	Calcium levels;
THYM	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg09436375	chr6:42928200	GNMT	-0.43	-5.59	-0.5	2.13e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6063312	1.000	rs11699576	chr20:47349878	A/C	cg18078177	chr20:47281410	PREX1	0.75	4.74	0.44	7.5e-6	Tonometry;
THYM	cis	rs4343996	0.870	rs6974257	chr7:3392195	A/G	cg21248987	chr7:3385318	SDK1	-0.41	-5.06	-0.46	2.02e-6	Motion sickness;
THYM	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg08859206	chr1:53392774	SCP2	-0.64	-7.26	-0.6	1.07e-10	Monocyte count;
THYM	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg14784868	chr12:69753453	YEATS4	1.13	12.26	0.78	2.8e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs815815	0.583	rs11125126	chr2:47395379	C/T	cg27223769	chr2:47403360	CALM2	-0.76	-4.48	-0.42	2.09e-5	Dialysis-related mortality;
THYM	cis	rs73195822	0.649	rs56408169	chr12:110901953	G/C	cg24010859	chr12:110868153	NA	0.67	4.76	0.44	6.79e-6	Itch intensity from mosquito bite;
THYM	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg20744362	chr22:50050164	C22orf34	0.69	6.05	0.53	2.91e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg13699009	chr12:122356056	WDR66	0.47	4.61	0.43	1.27e-5	Mean corpuscular volume;
THYM	cis	rs2898681	0.528	rs73814883	chr4:53728054	G/C	cg03786743	chr4:53727781	RASL11B	0.65	5.93	0.52	4.9e-8	Optic nerve measurement (cup area);
THYM	cis	rs11989744	1.000	rs17089546	chr8:23571807	G/A	cg04349084	chr8:23602677	NA	0.49	5.06	0.46	2.05e-6	Waist-hip ratio;
THYM	cis	rs10751667	1.000	rs10794349	chr11:945678	T/C	cg01483505	chr11:975446	AP2A2	0.69	5.59	0.5	2.14e-7	Alzheimer's disease (late onset);
THYM	cis	rs2282300	0.739	rs67670125	chr11:30214914	C/T	cg25418670	chr11:30344373	C11orf46	-0.8	-6.95	-0.58	4.48e-10	Morning vs. evening chronotype;
THYM	cis	rs4664308	1.000	rs10929966	chr2:160908341	C/T	cg03641300	chr2:160917029	PLA2R1	-0.76	-6.83	-0.57	7.92e-10	Idiopathic membranous nephropathy;
THYM	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg06481639	chr22:41940642	POLR3H	0.71	5.16	0.47	1.37e-6	Neuroticism;
THYM	cis	rs2625529	0.824	rs12903484	chr15:72299481	G/A	cg16672083	chr15:72433130	SENP8	-0.55	-4.92	-0.45	3.61e-6	Red blood cell count;
THYM	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg02527881	chr3:46936655	PTH1R	-0.65	-6.42	-0.55	5.45e-9	Colorectal cancer;
THYM	cis	rs7246657	0.598	rs10405372	chr19:37668775	A/C	cg23950597	chr19:37808831	NA	-0.81	-4.88	-0.45	4.35e-6	Coronary artery calcification;
THYM	cis	rs6992820	0.967	rs13254746	chr8:56719430	C/G	cg06880721	chr8:56792545	LYN	-0.71	-5.75	-0.51	1.09e-7	Mean platelet volume;
THYM	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg07936489	chr17:37558343	FBXL20	-0.66	-4.54	-0.42	1.62e-5	Asthma;
THYM	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg27284194	chr4:1044797	NA	0.61	4.6	0.43	1.29e-5	Recombination rate (females);
THYM	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg02527881	chr3:46936655	PTH1R	0.56	5.47	0.49	3.58e-7	Colorectal cancer;
THYM	cis	rs11030122	0.673	rs10835601	chr11:4106416	G/A	cg18678763	chr11:4115507	RRM1	-0.43	-5.6	-0.5	2.05e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6500395	0.962	rs11648101	chr16:48714178	C/T	cg04672837	chr16:48644449	N4BP1	0.48	4.65	0.43	1.06e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9992101	0.838	rs17253722	chr4:77367287	C/T	cg20311846	chr4:77356250	SHROOM3	-0.59	-5.49	-0.49	3.29e-7	Creatinine levels;
THYM	cis	rs7683537	0.554	rs55830081	chr4:185666477	A/C	cg04058563	chr4:185651563	MLF1IP	0.97	6.43	0.55	5.08e-9	Systemic lupus erythematosus;
THYM	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs7681440	0.606	rs990086	chr4:90755090	A/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs17102423	0.594	rs4902360	chr14:65546722	A/C	cg11161011	chr14:65562177	MAX	-0.76	-6.25	-0.54	1.14e-8	Obesity-related traits;
THYM	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg00981070	chr1:2046702	PRKCZ	0.47	5.21	0.47	1.1e-6	Height;
THYM	cis	rs863345	0.604	rs10797011	chr1:158465371	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs6570726	0.935	rs421268	chr6:145845558	A/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.75	-0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9534288	0.702	rs7331472	chr13:46644173	C/T	cg15192986	chr13:46630673	CPB2	-0.64	-4.61	-0.43	1.24e-5	Blood protein levels;
THYM	cis	rs7575873	1	rs7575873	chr2:23962647	A/G	cg08917208	chr2:24149416	ATAD2B	1.1	4.81	0.44	5.71e-6	Birth weight;
THYM	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs13185784	0.703	rs62406991	chr5:179658323	A/G	cg13944838	chr5:179740914	GFPT2	0.75	5.05	0.46	2.15e-6	TRAIL levels;
THYM	cis	rs7646881	0.812	rs61696028	chr3:158455703	A/C	cg19483011	chr3:158453295	NA	-0.72	-4.68	-0.43	9.34e-6	Tetralogy of Fallot;
THYM	cis	rs11048434	0.761	rs10842662	chr12:9139344	G/A	cg26114124	chr12:9217669	LOC144571	0.47	4.73	0.44	7.93e-6	Sjögren's syndrome;
THYM	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11112613	0.762	rs66754070	chr12:105949779	G/A	cg03607813	chr12:105948248	NA	1.07	9.36	0.69	3.87e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs9549260	0.620	rs9532580	chr13:41244260	T/C	cg21288729	chr13:41239152	FOXO1	0.63	4.49	0.42	1.99e-5	Red blood cell count;
THYM	trans	rs561341	0.714	rs473535	chr17:30312365	A/G	cg20587970	chr11:113659929	NA	-1.34	-8.78	-0.67	6.74e-14	Hip circumference adjusted for BMI;
THYM	cis	rs700651	0.789	rs1371663	chr2:198900305	C/T	cg00792783	chr2:198669748	PLCL1	-0.72	-4.68	-0.43	9.67e-6	Intracranial aneurysm;
THYM	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	4.88	0.45	4.24e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6815814	0.898	rs6848423	chr4:38887933	C/T	cg02016764	chr4:38805732	TLR1	-0.46	-4.52	-0.42	1.76e-5	Breast cancer;
THYM	cis	rs61931739	0.749	rs7315233	chr12:34271975	G/T	cg10856724	chr12:34555212	NA	-0.62	-5.55	-0.49	2.62e-7	Morning vs. evening chronotype;
THYM	cis	rs6700896	0.931	rs10889569	chr1:66086194	A/T	cg04111102	chr1:66153794	NA	0.53	4.64	0.43	1.12e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	trans	rs10462794	0.789	rs7719895	chr5:4490338	C/T	cg23807559	chr17:71189217	COG1	1.19	6.88	0.58	6.3e-10	DNA methylation (variation);
THYM	cis	rs2302729	0.932	rs10848683	chr12:2791130	C/T	cg19945202	chr12:2788847	CACNA1C	-0.85	-5.65	-0.5	1.65e-7	Sleep quality;
THYM	cis	rs6952809	0.516	rs6952959	chr7:2440722	C/T	cg13581527	chr7:1708566	NA	-0.77	-5.3	-0.48	7.55e-7	Multiple sclerosis;
THYM	cis	rs728616	0.867	rs12414877	chr10:81780708	A/G	cg18148530	chr10:81370782	SFTPA1	0.78	4.96	0.45	3.13e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-5.81	-0.51	8.27e-8	Total cholesterol levels;
THYM	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg07936489	chr17:37558343	FBXL20	-0.79	-5.36	-0.48	5.79e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg02753203	chr1:228287806	NA	0.72	6.15	0.53	1.8e-8	Diastolic blood pressure;
THYM	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg06238570	chr21:40685208	BRWD1	0.92	6.85	0.57	7.35e-10	Cognitive function;
THYM	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg20283391	chr11:68216788	NA	-0.61	-4.87	-0.45	4.42e-6	Total body bone mineral density;
THYM	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12073837	0.784	rs61830288	chr1:220988741	C/T	cg16008148	chr1:221062819	NA	0.41	4.45	0.42	2.32e-5	F-cell distribution;
THYM	cis	rs10949662	1.000	rs11765189	chr7:157535977	A/G	cg15733309	chr7:157513707	PTPRN2	0.69	7.17	0.59	1.63e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7572733	0.534	rs2060488	chr2:198751637	T/G	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs9527	0.590	rs7897663	chr10:104905604	T/C	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg25358565	chr5:93447407	FAM172A	-1.33	-10.47	-0.73	1.67e-17	Diabetic retinopathy;
THYM	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg19746536	chr19:49375674	PPP1R15A	0.79	4.46	0.42	2.28e-5	Red cell distribution width;
THYM	cis	rs28595532	0.920	rs115354352	chr4:119750358	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs7731657	0.537	rs114713366	chr5:130292286	C/T	cg08523029	chr5:130500466	HINT1	-0.79	-5.38	-0.48	5.39e-7	Fasting plasma glucose;
THYM	cis	rs9790314	0.687	rs62280331	chr3:160682092	C/A	cg04691961	chr3:161091175	C3orf57	0.57	4.61	0.43	1.27e-5	Morning vs. evening chronotype;
THYM	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg22907277	chr7:1156413	C7orf50	0.81	4.97	0.45	2.94e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs28595532	0.841	rs114363775	chr4:119765587	G/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs8050907	0.744	rs11862204	chr16:4519586	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.58	0.43	1.38e-5	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs192264	0.614	rs254366	chr16:65982789	T/A	cg02795155	chr16:66785218	DYNC1LI2	0.62	5.02	0.46	2.36e-6	Subjective well-being;
THYM	trans	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg18335740	chr13:41363409	SLC25A15	0.74	8.22	0.64	1.05e-12	Lewy body disease;
THYM	cis	rs7000551	0.505	rs13258195	chr8:22227271	A/G	cg12081754	chr8:22256438	SLC39A14	-1.12	-9.86	-0.71	3.33e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs11112613	0.762	rs73184077	chr12:105949999	G/A	cg03607813	chr12:105948248	NA	1.07	9.36	0.69	3.87e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg18252515	chr7:66147081	NA	0.65	4.73	0.44	7.72e-6	Aortic root size;
THYM	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg08017756	chr2:100939284	LONRF2	-0.75	-7.8	-0.62	7.89e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg01699819	chr7:1052092	C7orf50	-0.6	-5.09	-0.46	1.83e-6	Bronchopulmonary dysplasia;
THYM	cis	rs12802200	0.561	rs7940600	chr11:572105	A/G	cg03909863	chr11:638404	DRD4	-0.67	-4.79	-0.44	6.2e-6	Systemic lupus erythematosus;
THYM	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.72	-6.25	-0.54	1.15e-8	Calcium levels;
THYM	cis	rs800586	0.500	rs2737254	chr8:116664451	C/T	cg04656070	chr8:116661063	TRPS1	-0.55	-6.52	-0.56	3.44e-9	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg02725872	chr8:58115012	NA	-1.08	-8.0	-0.63	3.04e-12	Developmental language disorder (linguistic errors);
THYM	cis	rs2439831	0.681	rs7176849	chr15:43681427	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	6.89	0.58	5.93e-10	Lung cancer in ever smokers;
THYM	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg21280719	chr6:42927975	GNMT	-0.44	-4.75	-0.44	7.25e-6	Blood protein levels;
THYM	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13732083	chr21:47605072	C21orf56	0.71	4.99	0.46	2.78e-6	Testicular germ cell tumor;
THYM	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg12826209	chr6:26865740	GUSBL1	-1.03	-6.64	-0.56	1.94e-9	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs10025640	chr4:119787451	G/A	cg21605333	chr4:119757512	SEC24D	1.58	6.06	0.53	2.73e-8	Cannabis dependence symptom count;
THYM	cis	rs765787	0.530	rs3759892	chr15:45542709	A/G	cg25801113	chr15:45476975	SHF	-0.38	-4.47	-0.42	2.14e-5	Uric acid levels;
THYM	cis	rs7432375	0.901	rs4038587	chr3:136381368	A/C	cg12473912	chr3:136751656	NA	-0.62	-5.27	-0.48	8.44e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs9486719	1.000	rs9486719	chr6:97060124	G/A	cg18709589	chr6:96969512	KIAA0776	-0.62	-4.74	-0.44	7.56e-6	Migraine;Coronary artery disease;
THYM	cis	rs12530845	0.887	rs73725434	chr7:135313657	T/C	cg23117316	chr7:135346802	PL-5283	-0.67	-5.9	-0.52	5.68e-8	Red blood cell traits;
THYM	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg11663144	chr21:46675770	NA	-0.71	-9.92	-0.71	2.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9733	0.650	rs11204668	chr1:150543686	G/A	cg18016565	chr1:150552671	MCL1	-0.57	-4.54	-0.42	1.62e-5	Tonsillectomy;
THYM	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg07424592	chr7:64974309	NA	1.03	5.43	0.49	4.4e-7	Diabetic kidney disease;
THYM	cis	rs6860806	0.531	rs270612	chr5:131637338	G/A	cg18758796	chr5:131593413	PDLIM4	0.54	5.1	0.46	1.73e-6	Breast cancer;
THYM	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg09034736	chr1:150693464	HORMAD1	0.55	5.18	0.47	1.26e-6	Tonsillectomy;
THYM	cis	rs2688608	1.000	rs2688610	chr10:75654931	A/G	cg19442545	chr10:75533431	FUT11	0.42	4.63	0.43	1.16e-5	Inflammatory bowel disease;
THYM	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg06221963	chr1:154839813	KCNN3	-0.78	-9.71	-0.71	7.02e-16	Prostate cancer;
THYM	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg05373962	chr22:49881684	NA	-0.67	-6.8	-0.57	9.16e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2811415	0.597	rs11709484	chr3:127745068	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg13866156	chr1:1669148	SLC35E2	-0.7	-7.02	-0.58	3.31e-10	Body mass index;
THYM	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg12908607	chr1:44402522	ARTN	-0.63	-5.52	-0.49	2.93e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs17152411	0.895	rs7079153	chr10:126587146	C/G	cg07906193	chr10:126599966	NA	0.68	4.65	0.43	1.08e-5	Height;
THYM	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.42	0.49	4.44e-7	Height;
THYM	cis	rs4654899	0.931	rs4654887	chr1:21234923	A/G	cg01072550	chr1:21505969	NA	0.67	6.17	0.53	1.69e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg10523679	chr1:76189770	ACADM	0.9	9.45	0.7	2.52e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg09307838	chr4:120376055	NA	0.69	5.12	0.46	1.61e-6	Corneal astigmatism;
THYM	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg23574427	chr4:122746245	BBS7;CCNA2	-0.57	-5.18	-0.47	1.23e-6	Type 2 diabetes;
THYM	cis	rs13315871	0.929	rs13077539	chr3:58267846	T/C	cg00563845	chr3:58318305	PXK	0.55	4.88	0.45	4.32e-6	Cholesterol, total;
THYM	cis	rs1059611	0.515	rs28413168	chr8:19674725	G/C	cg01411142	chr8:19674711	INTS10	0.98	7.58	0.61	2.31e-11	Lipid metabolism phenotypes;
THYM	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg09201001	chr11:18656081	SPTY2D1	1.05	9.37	0.69	3.67e-15	Breast cancer;
THYM	cis	rs2625529	0.824	rs4776581	chr15:72207071	G/A	cg16672083	chr15:72433130	SENP8	-0.56	-5.03	-0.46	2.35e-6	Red blood cell count;
THYM	cis	rs8070624	0.543	rs11870660	chr17:17877096	C/T	cg16928487	chr17:17741425	SREBF1	-0.51	-4.63	-0.43	1.18e-5	Total body bone mineral density;
THYM	cis	rs11771526	0.901	rs28709683	chr7:32301989	A/G	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg24818145	chr4:99064322	C4orf37	0.74	5.84	0.51	7.19e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs76878669	0.917	rs10896110	chr11:66101978	G/A	cg18002602	chr11:66138449	SLC29A2	-0.62	-5.21	-0.47	1.09e-6	Educational attainment (years of education);
THYM	cis	rs7772486	0.713	rs79248977	chr6:146319388	C/A	cg13319975	chr6:146136371	FBXO30	-0.64	-5.05	-0.46	2.14e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7107174	1.000	rs2510035	chr11:77953175	A/C	cg02023728	chr11:77925099	USP35	0.73	6.33	0.54	7.98e-9	Testicular germ cell tumor;
THYM	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.78	-6.87	-0.58	6.69e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9393777	0.920	rs13195040	chr6:27413924	C/T	cg23161317	chr6:28129485	ZNF389	-1.11	-4.75	-0.44	7.25e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9876781	1.000	rs7651407	chr3:48443816	C/T	cg06066452	chr3:48470258	PLXNB1	0.26	4.88	0.45	4.26e-6	Longevity;
THYM	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg09904177	chr6:26538194	HMGN4	0.62	5.04	0.46	2.21e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg00271210	chr6:167070053	RPS6KA2	-0.56	-5.81	-0.51	8.42e-8	Crohn's disease;
THYM	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg21775007	chr8:11205619	TDH	0.65	5.28	0.48	8.03e-7	Retinal vascular caliber;
THYM	cis	rs2732480	0.577	rs2634680	chr12:48734564	T/C	cg21466736	chr12:48725269	NA	-0.59	-5.43	-0.49	4.36e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs6665290	0.935	rs11588904	chr1:227196211	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs4808199	1.000	rs12977524	chr19:19568244	A/G	cg03709012	chr19:19516395	GATAD2A	1.19	7.25	0.6	1.12e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg08048268	chr3:133502702	NA	-0.66	-5.71	-0.51	1.27e-7	Iron status biomarkers;
THYM	cis	rs2625529	0.627	rs12902661	chr15:72480158	T/G	cg16672083	chr15:72433130	SENP8	-0.55	-4.93	-0.45	3.51e-6	Red blood cell count;
THYM	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg23332699	chr15:44069569	ELL3	0.7	4.63	0.43	1.14e-5	Lung cancer in ever smokers;
THYM	cis	rs9457247	0.534	rs9355610	chr6:167383075	G/A	cg15592062	chr6:167189543	RPS6KA2	0.51	5.27	0.48	8.58e-7	Crohn's disease;
THYM	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg17644776	chr2:200775616	C2orf69	-0.7	-5.15	-0.47	1.43e-6	Schizophrenia;
THYM	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg07936489	chr17:37558343	FBXL20	0.82	5.61	0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg11494091	chr17:61959527	GH2	1.07	15.98	0.85	1.16e-28	Prudent dietary pattern;
THYM	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg08859206	chr1:53392774	SCP2	-0.75	-8.97	-0.68	2.58e-14	Monocyte count;
THYM	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.77	7.57	0.61	2.4e-11	Lymphocyte counts;
THYM	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg06808227	chr14:105710500	BRF1	-1.02	-8.87	-0.67	4.38e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7894051	1.000	rs10776675	chr10:135183094	C/A	cg07511014	chr10:135191624	PAOX	-0.71	-5.0	-0.46	2.62e-6	Lifespan;
THYM	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg03388043	chr17:80084554	CCDC57	-0.66	-5.66	-0.5	1.61e-7	Life satisfaction;
THYM	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs72960926	0.744	rs72964209	chr6:74861734	C/T	cg03266952	chr6:74778945	NA	-0.9	-5.14	-0.47	1.49e-6	Metabolite levels (MHPG);
THYM	trans	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg25517755	chr10:38738941	LOC399744	-0.77	-7.48	-0.61	3.65e-11	Corneal astigmatism;
THYM	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg08885076	chr2:99613938	TSGA10	0.52	5.04	0.46	2.24e-6	Chronic sinus infection;
THYM	cis	rs9527	0.640	rs7089061	chr10:104723015	C/A	cg15744005	chr10:104629667	AS3MT	-0.6	-4.58	-0.42	1.43e-5	Arsenic metabolism;
THYM	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg13695892	chr22:41940480	POLR3H	0.87	7.2	0.59	1.4e-10	Vitiligo;
THYM	cis	rs2637266	1.000	rs12251434	chr10:78345468	C/A	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg11335335	chr11:637885	DRD4	-0.66	-4.9	-0.45	3.93e-6	Systemic lupus erythematosus;
THYM	cis	rs2229238	0.911	rs6672087	chr1:154516122	A/C	cg21262032	chr1:154437693	IL6R	-0.62	-5.23	-0.47	1.01e-6	Coronary heart disease;
THYM	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11971779	0.711	rs6961204	chr7:139047399	T/G	cg07862535	chr7:139043722	LUC7L2	0.63	4.46	0.42	2.24e-5	Diisocyanate-induced asthma;
THYM	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	5.75	0.51	1.08e-7	Blood metabolite levels;
THYM	trans	rs8073060	0.586	rs6505487	chr17:33996850	A/G	cg19694781	chr19:47549865	TMEM160	-0.91	-7.32	-0.6	8.08e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs11722228	0.964	rs10939614	chr4:9926613	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-4.75	-0.44	7.06e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.57	5.32	0.48	6.76e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.29e-7	Corneal astigmatism;
THYM	trans	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg10856724	chr12:34555212	NA	-1.02	-9.56	-0.7	1.47e-15	Bladder cancer;
THYM	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg12564285	chr5:131593104	PDLIM4	0.55	5.83	0.51	7.73e-8	Blood metabolite levels;
THYM	cis	rs6032067	0.602	rs2741523	chr20:43920446	C/T	cg24575067	chr20:44746902	CD40	-0.72	-5.23	-0.47	1.02e-6	Blood protein levels;
THYM	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg01475377	chr6:109611718	NA	-0.57	-4.88	-0.45	4.28e-6	Reticulocyte fraction of red cells;
THYM	cis	rs6598955	0.671	rs17163866	chr1:26648088	A/G	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.52	0.42	1.77e-5	Obesity-related traits;
THYM	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg17911788	chr17:44343683	NA	-0.79	-7.48	-0.61	3.65e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg00071950	chr4:10020882	SLC2A9	0.77	7.71	0.62	1.24e-11	Bone mineral density;
THYM	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg23711669	chr6:146136114	FBXO30	0.87	8.33	0.65	6.16e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9527	0.590	rs3781281	chr10:104852648	A/G	cg04362960	chr10:104952993	NT5C2	-0.65	-5.06	-0.46	2e-6	Arsenic metabolism;
THYM	cis	rs8078723	0.510	rs9898547	chr17:38136026	G/T	cg25038082	chr17:37896074	GRB7	-0.58	-4.67	-0.43	9.8200000000000008e-06	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg27398817	chr8:82754497	SNX16	-0.71	-6.11	-0.53	2.14e-8	Diastolic blood pressure;
THYM	cis	rs4892230	1	rs4892230	chr18:72155572	G/A	cg25817165	chr18:72167213	CNDP2	-0.77	-6.66	-0.56	1.8e-9	Mononucleosis;
THYM	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.35	-0.73	2.93e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg08000102	chr2:233561755	GIGYF2	-0.56	-4.98	-0.45	2.88e-6	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg03676636	chr4:99064102	C4orf37	0.4	5.62	0.5	1.91e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67460515	0.563	rs35914913	chr3:160826561	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-4.68	-0.43	9.48e-6	Parkinson's disease;
THYM	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs7106204	0.534	rs56157310	chr11:24260694	A/G	ch.11.24196551F	chr11:24239977	NA	0.93	5.71	0.51	1.3e-7	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs981844	1.000	rs56331473	chr4:154668052	C/A	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg23428387	chr22:49814324	NA	-0.57	-5.41	-0.49	4.67e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg02887458	chr19:19495540	GATAD2A	0.42	4.78	0.44	6.35e-6	Bipolar disorder;
THYM	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.02	8.91	0.67	3.55e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg24579218	chr15:68104479	NA	-0.85	-8.21	-0.64	1.09e-12	Restless legs syndrome;
THYM	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg04315214	chr1:2043799	PRKCZ	0.65	5.4	0.48	4.97e-7	Height;
THYM	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg22764044	chr5:178986830	RUFY1	0.52	5.26	0.47	8.97e-7	Lung cancer;
THYM	cis	rs7511006	0.798	rs11703673	chr22:50652427	A/G	cg16294310	chr22:50629110	TRABD	-0.68	-5.19	-0.47	1.2e-6	Obesity-related traits;
THYM	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg05368731	chr17:41323189	NBR1	1.19	10.93	0.75	1.74e-18	Menopause (age at onset);
THYM	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg12935359	chr14:103987150	CKB	-0.66	-6.52	-0.56	3.33e-9	Body mass index;
THYM	cis	rs7020830	0.858	rs13293465	chr9:37127678	C/T	cg14294708	chr9:37120828	ZCCHC7	1.3	15.57	0.85	6.87e-28	Schizophrenia;
THYM	cis	rs11696501	0.539	rs6073849	chr20:44299385	A/T	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	cis	rs59372292	0.619	rs12609437	chr19:8554787	C/T	cg00564862	chr19:9362003	OR7E24	-0.49	-4.56	-0.42	1.54e-5	Coronary artery disease;
THYM	cis	rs4638749	0.677	rs6741222	chr2:108841082	A/G	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs17641971	0.684	rs4873094	chr8:49989578	G/T	cg00325661	chr8:49890786	NA	0.6	4.79	0.44	6.24e-6	Blood metabolite levels;
THYM	cis	rs10752881	1.000	rs10911190	chr1:182979080	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs17253792	0.822	rs17683728	chr14:56060389	C/T	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs7246657	0.943	rs13343471	chr19:37932130	A/G	cg23950597	chr19:37808831	NA	-0.74	-4.6	-0.43	1.32e-5	Coronary artery calcification;
THYM	cis	rs10905065	0.965	rs10795541	chr10:5811954	A/G	cg11519256	chr10:5708881	ASB13	-0.49	-4.76	-0.44	6.95e-6	Menopause (age at onset);
THYM	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-5.16	-0.47	1.34e-6	Hemoglobin concentration;
THYM	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14893161	chr1:205819251	PM20D1	0.94	10.13	0.72	8.71e-17	Menarche (age at onset);
THYM	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Parkinson's disease;
THYM	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg03281154	chr5:1086625	SLC12A7	0.63	5.0	0.46	2.66e-6	Cystic fibrosis severity;
THYM	cis	rs4455778	0.757	rs1072376	chr7:49011373	A/C	cg26309511	chr7:48887640	NA	-0.53	-4.86	-0.45	4.63e-6	Lung cancer in never smokers;
THYM	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg25767906	chr1:53392781	SCP2	-0.53	-5.2	-0.47	1.13e-6	Monocyte count;
THYM	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg23711669	chr6:146136114	FBXO30	0.96	9.68	0.7	7.83e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs59197085	0.515	rs2402938	chr7:128444295	T/C	cg00734629	chr7:128471146	FLNC	0.76	4.49	0.42	1.98e-5	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
THYM	cis	rs198389	0.617	rs503040	chr1:11890695	C/T	cg24844545	chr1:11908347	NPPA	-0.49	-4.69	-0.43	9.05e-6	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
THYM	cis	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg23422044	chr7:1970798	MAD1L1	-0.77	-4.63	-0.43	1.16e-5	Neuroticism;
THYM	cis	rs752010	0.841	rs7519983	chr1:42083369	C/T	cg22486000	chr1:42919398	ZMYND12	-0.46	-5.24	-0.47	9.63e-7	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs7719624	0.632	rs13189180	chr5:135400035	A/G	cg15329133	chr5:135467951	SMAD5;SMAD5OS	-0.58	-5.15	-0.47	1.42e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs1158570	0.500	rs2791342	chr8:131314429	C/T	cg16277922	chr8:131349729	ASAP1	-0.59	-4.66	-0.43	1.02e-5	Platelet count;
THYM	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg21862992	chr11:68658383	NA	0.23	4.49	0.42	2.03e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg03806693	chr22:41940476	POLR3H	-1.04	-8.41	-0.65	3.99e-13	Vitiligo;
THYM	cis	rs728616	0.867	rs726289	chr10:81706951	C/T	cg18148530	chr10:81370782	SFTPA1	0.75	5.26	0.47	9.01e-7	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2131877	0.830	rs1874100	chr3:194849022	G/A	cg21937377	chr3:194868750	C3orf21	0.42	4.89	0.45	4.03e-6	Non-small cell lung cancer;
THYM	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg06028605	chr16:24865363	SLC5A11	0.63	5.12	0.47	1.59e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7582180	0.903	rs7421891	chr2:100902166	G/A	cg14675211	chr2:100938903	LONRF2	0.65	5.52	0.49	2.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs34912216	0.542	rs12701398	chr7:4129330	G/T	cg03141780	chr7:4150753	SDK1	0.69	5.03	0.46	2.31e-6	Motion sickness;
THYM	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs1580019	0.961	rs958217	chr7:32493417	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.76	6.82	0.57	8.42e-10	Cognitive ability;
THYM	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs250585	0.736	rs3096175	chr16:23457583	C/T	cg00143387	chr16:23521605	GGA2	0.78	5.6	0.5	2.08e-7	Egg allergy;
THYM	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg09549813	chr16:4587862	C16orf5	0.59	6.72	0.57	1.34e-9	Schizophrenia;
THYM	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg14972814	chr11:95582409	MTMR2	-0.7	-6.18	-0.54	1.56e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2404602	0.552	rs11636612	chr15:76959530	C/T	cg23625390	chr15:77176239	SCAPER	-0.82	-4.98	-0.45	2.88e-6	Blood metabolite levels;
THYM	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg03806693	chr22:41940476	POLR3H	-1.13	-10.01	-0.72	1.59e-16	Vitiligo;
THYM	cis	rs4589258	0.843	rs7128572	chr11:90482989	T/A	cg26138821	chr11:89956704	CHORDC1	-0.68	-5.64	-0.5	1.73e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6510489	1.000	rs6510489	chr19:35973289	A/G	cg15078284	chr19:36004994	DMKN	0.41	4.93	0.45	3.48e-6	Bipolar disorder;
THYM	cis	rs868036	1.000	rs4776974	chr15:68095927	G/A	cg24579218	chr15:68104479	NA	-0.65	-6.51	-0.56	3.59e-9	Restless legs syndrome;
THYM	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg02527881	chr3:46936655	PTH1R	-0.6	-6.01	-0.52	3.48e-8	Colorectal cancer;
THYM	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs9467603	0.920	rs13213957	chr6:25786226	T/C	cg16898833	chr6:26189333	HIST1H4D	1.33	4.6	0.43	1.32e-5	Intelligence (multi-trait analysis);
THYM	cis	rs911119	1.000	rs71334202	chr20:23618652	A/C	cg16589663	chr20:23618590	CST3	0.76	4.67	0.43	9.96e-6	Chronic kidney disease;
THYM	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg04156016	chr5:1868137	NA	0.49	4.57	0.42	1.46e-5	Cardiovascular disease risk factors;
THYM	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg26850624	chr5:429559	AHRR	-0.71	-5.23	-0.47	1.02e-6	Cystic fibrosis severity;
THYM	cis	rs60695258	0.594	rs6531946	chr4:87965391	T/A	cg10685359	chr4:87814065	C4orf36	-0.45	-5.79	-0.51	9.05e-8	Hematocrit;
THYM	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg11494091	chr17:61959527	GH2	0.73	6.78	0.57	9.99e-10	Height;
THYM	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg23682913	chr1:2080710	PRKCZ	-0.66	-5.85	-0.51	7.07e-8	Height;
THYM	cis	rs728616	0.867	rs61860044	chr10:81946538	C/G	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg00376283	chr12:123451042	ABCB9	0.72	4.94	0.45	3.36e-6	Height;Educational attainment;Head circumference (infant);
THYM	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.41	0.61	5.2e-11	Morning vs. evening chronotype;
THYM	cis	rs2276314	0.857	rs72883058	chr18:33612917	G/A	cg05985134	chr18:33552581	C18orf21	0.66	4.84	0.44	5.02e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs524023	0.874	rs7102344	chr11:64396569	A/T	cg19131476	chr11:64387923	NRXN2	-0.39	-5.54	-0.49	2.7e-7	Urate levels in obese individuals;
THYM	cis	rs28647808	1.000	rs28709650	chr9:136276699	G/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs2745959	0.611	rs2785644	chr1:208059691	C/T	cg11195082	chr1:207670065	CR1	-0.54	-4.48	-0.42	2.09e-5	Resting heart rate;
THYM	cis	rs860818	1.000	rs858285	chr7:23249518	C/T	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs6430585	0.528	rs309133	chr2:136751842	A/C	cg20242066	chr2:136595261	LCT	0.51	5.31	0.48	7.12e-7	Corneal structure;
THYM	cis	rs7089973	0.604	rs11196924	chr10:116571796	A/C	cg23260525	chr10:116636907	FAM160B1	-0.52	-5.17	-0.47	1.28e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs921665	0.748	rs11677991	chr2:3185321	G/A	cg16434511	chr2:3151078	NA	-0.76	-5.18	-0.47	1.24e-6	World class endurance athleticism;
THYM	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs990171	0.607	rs3917246	chr2:102775164	T/C	cg13315345	chr2:102803985	IL1RL2	0.58	4.74	0.44	7.57e-6	Lymphocyte counts;
THYM	cis	rs4523957	0.890	rs8076939	chr17:2099931	C/A	cg16513277	chr17:2031491	SMG6	-0.83	-8.22	-0.64	1.01e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg02887458	chr19:19495540	GATAD2A	0.42	4.93	0.45	3.51e-6	Bipolar disorder;
THYM	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs892961	0.932	rs2170863	chr17:75415037	C/T	cg05865280	chr17:75406074	SEPT9	0.49	8.27	0.65	8.21e-13	Airflow obstruction;
THYM	cis	rs700651	0.821	rs700666	chr2:198673544	G/A	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Intracranial aneurysm;
THYM	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	12.13	0.78	5.13e-21	Chronic sinus infection;
THYM	cis	rs7106204	0.688	rs7131103	chr11:24219299	A/G	ch.11.24196551F	chr11:24239977	NA	0.86	4.57	0.42	1.46e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7833986	0.501	rs2719257	chr8:56940173	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.62	7.48	0.61	3.61e-11	Height;
THYM	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg13010199	chr12:38710504	ALG10B	0.65	4.65	0.43	1.06e-5	Morning vs. evening chronotype;
THYM	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.91	0.63	4.62e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg13289132	chr10:30722225	MAP3K8	-0.54	-4.59	-0.43	1.38e-5	Itch intensity from mosquito bite;
THYM	cis	rs34526934	0.524	rs1124052	chr2:177040084	G/A	cg26754761	chr2:177040938	NA	-0.79	-6.91	-0.58	5.53e-10	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.36	-0.48	5.83e-7	Mood instability;
THYM	cis	rs6693295	0.877	rs10924515	chr1:246306225	C/T	cg11798871	chr1:246315928	SMYD3	0.64	4.6	0.43	1.3e-5	Migraine - clinic-based;Migraine with aura;
THYM	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg07959070	chr22:50026188	C22orf34	-0.25	-4.68	-0.43	9.42e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs36051895	0.695	rs4527935	chr9:5016455	A/T	cg02405213	chr9:5042618	JAK2	-1.02	-10.51	-0.73	1.37e-17	Pediatric autoimmune diseases;
THYM	cis	rs28374715	0.662	rs521890	chr15:41473143	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.04	-8.82	-0.67	5.6e-14	Ulcerative colitis;
THYM	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg21427119	chr20:30132790	HM13	0.71	4.79	0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs12681287	0.604	rs28378899	chr8:87434500	G/C	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg07936489	chr17:37558343	FBXL20	0.74	5.33	0.48	6.57e-7	Glomerular filtration rate (creatinine);
THYM	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg03929089	chr4:120376271	NA	-0.94	-10.74	-0.74	4.27e-18	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17854409	0.803	rs1063247	chr20:61472118	C/G	cg05147244	chr20:61493195	TCFL5	0.9	4.96	0.45	3.07e-6	Obesity-related traits;
THYM	cis	rs7617773	0.778	rs11707997	chr3:48377875	A/G	cg02219026	chr3:48282209	ZNF589	-0.69	-4.77	-0.44	6.55e-6	Coronary artery disease;
THYM	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg10760299	chr15:45669010	GATM	0.8	6.09	0.53	2.42e-8	Homoarginine levels;
THYM	cis	rs6089584	0.627	rs34496616	chr20:60561944	G/A	cg06108461	chr20:60628389	TAF4	-0.78	-5.95	-0.52	4.46e-8	Body mass index;
THYM	cis	rs35934224	0.783	rs58195087	chr22:19858547	A/G	cg11182965	chr22:19864308	TXNRD2	-0.68	-5.58	-0.5	2.3e-7	Glaucoma (primary open-angle);
THYM	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs11997175	0.624	rs10435522	chr8:33698608	G/A	ch.8.33884649F	chr8:33765107	NA	0.72	5.08	0.46	1.88e-6	Body mass index;
THYM	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg02527881	chr3:46936655	PTH1R	-0.67	-7.11	-0.59	2.16e-10	Colorectal cancer;
THYM	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.65	-0.62	1.6e-11	Schizophrenia;
THYM	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg22681709	chr2:178499509	PDE11A	-0.53	-5.09	-0.46	1.79e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7107174	1.000	rs11237438	chr11:77998488	T/C	cg19901956	chr11:77921274	USP35	-0.73	-5.52	-0.49	2.88e-7	Testicular germ cell tumor;
THYM	cis	rs988913	0.706	rs10948884	chr6:54941841	C/T	cg18532076	chr6:54711417	FAM83B	0.49	4.51	0.42	1.83e-5	Menarche (age at onset);
THYM	cis	rs28595532	0.920	rs114611353	chr4:119736607	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg10334053	chr1:2078117	PRKCZ	-0.51	-4.92	-0.45	3.56e-6	Height;
THYM	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.06	7.49	0.61	3.45e-11	Smoking behavior;
THYM	cis	rs6835098	0.923	rs9997477	chr4:174112543	C/T	cg08422745	chr4:174089978	GALNT7	-1.0	-8.37	-0.65	5e-13	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs4805272	0.539	rs7256211	chr19:29333063	C/G	cg04546413	chr19:29218101	NA	0.79	5.08	0.46	1.9e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg02915803	chr1:1606292	LOC728661;CDK11B	0.63	5.32	0.48	6.93e-7	Body mass index;
THYM	cis	rs8114671	0.869	rs2038503	chr20:33675900	G/A	cg08999081	chr20:33150536	PIGU	-0.56	-4.83	-0.44	5.18e-6	Height;
THYM	cis	rs11118844	0.739	rs10863653	chr1:221943926	T/C	cg04222084	chr1:221915650	DUSP10	-1.02	-5.31	-0.48	7.05e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg18681998	chr4:17616180	MED28	0.81	6.85	0.58	7.23e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs6570726	0.791	rs6918814	chr6:145906028	G/A	cg23711669	chr6:146136114	FBXO30	0.93	9.27	0.69	6.09e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs259282	0.560	rs4805786	chr19:33120265	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.68	5.85	0.51	6.9e-8	Schizophrenia;
THYM	cis	rs951188	0.688	rs77061204	chr2:150427196	A/T	cg17961725	chr2:150454027	NA	-0.97	-5.26	-0.47	8.85e-7	Daytime sleep phenotypes;
THYM	cis	rs2806561	0.514	rs11801120	chr1:23543307	C/T	cg19743168	chr1:23544995	NA	0.92	8.02	0.64	2.67e-12	Height;
THYM	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg01097406	chr16:89675127	NA	-0.56	-4.67	-0.43	1.01e-5	Vitiligo;
THYM	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg17554472	chr22:41940697	POLR3H	-0.72	-4.84	-0.44	5e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs10504073	0.669	rs62507253	chr8:50028836	C/T	cg00325661	chr8:49890786	NA	0.87	7.77	0.62	9.33e-12	Blood metabolite ratios;
THYM	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg14456004	chr13:21872349	NA	-1.24	-10.0	-0.72	1.63e-16	White matter hyperintensity burden;
THYM	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg08645402	chr16:4508243	NA	0.62	5.52	0.49	2.89e-7	Schizophrenia;
THYM	cis	rs7011507	0.594	rs72639023	chr8:49343544	C/T	cg08774009	chr8:49309094	NA	-0.6	-4.71	-0.44	8.47e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs6840360	0.571	rs11939356	chr4:152505234	G/C	cg22705602	chr4:152727874	NA	-0.8	-8.5	-0.66	2.58e-13	Intelligence (multi-trait analysis);
THYM	cis	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg17333051	chr19:2783644	SGTA	0.57	5.27	0.48	8.41e-7	Total cholesterol levels;
THYM	cis	rs11166927	0.716	rs4736094	chr8:140802186	G/A	cg16909799	chr8:140841666	TRAPPC9	0.56	4.48	0.42	2.05e-5	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs6964587	0.626	rs34404183	chr7:91551249	T/C	cg17063962	chr7:91808500	NA	-1.02	-9.26	-0.69	6.44e-15	Breast cancer;
THYM	trans	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs35883536	0.967	rs4991930	chr1:101122755	T/C	cg06223162	chr1:101003688	GPR88	0.62	4.74	0.44	7.46e-6	Monocyte count;
THYM	cis	rs8078723	0.933	rs4794822	chr17:38156712	C/T	cg17467752	chr17:38218738	THRA	0.87	7.22	0.59	1.3e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg10505658	chr17:80084571	CCDC57	-0.72	-7.71	-0.62	1.22e-11	Life satisfaction;
THYM	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.75	0.44	7.34e-6	Obesity-related traits;
THYM	cis	rs2294693	0.531	rs2179518	chr6:40938370	C/G	cg21128951	chr6:40996213	UNC5CL	0.64	4.61	0.43	1.25e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs2997447	0.761	rs61776620	chr1:26457980	T/C	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs798766	0.779	rs3134866	chr4:1723265	A/G	cg00006948	chr4:1768889	NA	-0.96	-5.12	-0.46	1.62e-6	Bladder cancer;Urinary bladder cancer;
THYM	cis	rs28595532	0.920	rs17324807	chr4:119770638	G/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs11249608	0.548	rs11960161	chr5:178453837	A/G	cg01312482	chr5:178451176	ZNF879	-0.76	-6.3	-0.54	9.29e-9	Pubertal anthropometrics;
THYM	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg26384229	chr12:38710491	ALG10B	0.9	7.62	0.62	1.92e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2555603	1.000	rs2555602	chr13:33817647	C/T	cg07499182	chr13:33825496	STARD13	-0.51	-4.89	-0.45	4.07e-6	Body mass index in asthmatics;
THYM	cis	rs73086581	1.000	rs73084594	chr20:3916380	T/G	cg02187196	chr20:3869020	PANK2	0.51	5.78	0.51	9.61e-8	Response to antidepressants in depression;
THYM	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg11789530	chr4:8429930	ACOX3	0.7	5.53	0.49	2.82e-7	Response to antineoplastic agents;
THYM	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg22655196	chr4:3374909	RGS12	0.62	7.48	0.61	3.7e-11	Serum sulfate level;
THYM	cis	rs3741151	0.686	rs17851510	chr11:73106294	A/C	cg17517138	chr11:73019481	ARHGEF17	0.77	4.75	0.44	7.25e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.71e-7	Alzheimer's disease (late onset);
THYM	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	4.47	0.42	2.13e-5	Age-related macular degeneration (geographic atrophy);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg07797030	chr22:20073477	MIR1306;DGCR8	-0.98	-7.33	-0.6	7.58e-11	Depressive symptoms;
THYM	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7917772	0.582	rs10748826	chr10:104354804	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	trans	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg26043149	chr18:55253948	FECH	1.19	11.16	0.75	5.56e-19	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.86	9.19	0.69	8.9e-15	Menarche (age at onset);
THYM	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg03453431	chr7:157225567	NA	-0.65	-6.37	-0.55	6.81e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs3812049	0.784	rs1560637	chr5:127448066	A/C	cg05443326	chr5:126853169	PRRC1	-0.65	-4.49	-0.42	2.02e-5	Lymphocyte counts;Red cell distribution width;
THYM	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	trans	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg19862616	chr7:65841803	NCRNA00174	1.09	12.64	0.79	4.47e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7071206	0.891	rs10824559	chr10:79409222	A/G	cg07817648	chr10:79422355	NA	-0.98	-7.48	-0.61	3.64e-11	Bone mineral density;
THYM	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg23711669	chr6:146136114	FBXO30	0.86	8.06	0.64	2.28e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg14517863	chr17:44321492	NA	0.47	5.22	0.47	1.04e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6598955	0.724	rs3924934	chr1:26644079	A/G	cg00852783	chr1:26633632	UBXN11	0.83	8.41	0.65	4.05e-13	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7824557	0.614	rs2293858	chr8:11213881	G/C	cg21775007	chr8:11205619	TDH	0.72	6.33	0.54	8.04e-9	Retinal vascular caliber;
THYM	cis	rs10799590	0.964	rs1603918	chr1:224827497	G/T	cg01808320	chr1:224927238	CNIH3	0.59	5.22	0.47	1.04e-6	Opioid dependence;
THYM	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg15557168	chr22:42548783	NA	0.6	4.59	0.43	1.33e-5	Schizophrenia;
THYM	cis	rs11031096	0.727	rs7940013	chr11:4138304	C/T	cg18678763	chr11:4115507	RRM1	-0.38	-5.17	-0.47	1.27e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg12935359	chr14:103987150	CKB	0.61	6.24	0.54	1.2e-8	Body mass index;
THYM	cis	rs3917265	0.616	rs2302621	chr2:102842124	G/T	cg13315345	chr2:102803985	IL1RL2	0.64	7.47	0.61	3.93e-11	Atopic dermatitis;
THYM	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg04398451	chr17:18023971	MYO15A	0.78	7.61	0.62	2.01e-11	Total body bone mineral density;
THYM	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.57	-4.69	-0.43	9.01e-6	Homoarginine levels;
THYM	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg17279839	chr7:150038598	RARRES2	0.56	5.41	0.49	4.78e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs912057	0.526	rs746453	chr6:6734221	C/A	cg13809441	chr6:6737631	NA	0.51	6.0	0.52	3.58e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.16	-0.47	1.35e-6	Obesity-related traits;
THYM	cis	rs2456568	0.900	rs2511373	chr11:93671414	T/C	cg17595323	chr11:93583763	C11orf90	-0.54	-5.23	-0.47	1.02e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg01710189	chr8:22454888	PDLIM2	-0.54	-4.94	-0.45	3.32e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7909074	1.000	rs4948926	chr10:45392604	G/C	cg04218760	chr10:45406644	TMEM72	-0.67	-6.26	-0.54	1.1e-8	Mean corpuscular volume;
THYM	cis	rs1691799	0.899	rs1185244	chr12:66725160	C/T	cg16791601	chr12:66731901	HELB	-0.76	-7.33	-0.6	7.6e-11	White blood cell count (basophil);
THYM	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg03806693	chr22:41940476	POLR3H	-0.77	-5.84	-0.51	7.19e-8	Neuroticism;
THYM	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg18451016	chr1:38461880	NA	0.42	5.28	0.48	8.18e-7	Coronary artery disease;
THYM	cis	rs76878669	0.561	rs10791876	chr11:66169646	C/T	cg18002602	chr11:66138449	SLC29A2	-0.46	-4.54	-0.42	1.66e-5	Educational attainment (years of education);
THYM	cis	rs4888262	0.508	rs7193583	chr16:74649589	C/G	cg01733217	chr16:74700730	RFWD3	0.82	8.54	0.66	2.2e-13	Testicular germ cell tumor;
THYM	cis	rs9906944	0.707	rs3816272	chr17:47120467	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.54	-5.48	-0.49	3.55e-7	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs4589258	0.737	rs1783798	chr11:90443346	A/G	cg26138821	chr11:89956704	CHORDC1	0.61	5.16	0.47	1.35e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1728785	0.901	rs1645974	chr16:68564774	C/G	cg02972257	chr16:68554789	NA	-0.74	-4.54	-0.42	1.63e-5	Ulcerative colitis;
THYM	cis	rs7224737	1.000	rs7225608	chr17:40298326	G/A	cg02228675	chr17:40259724	DHX58	-0.67	-5.5	-0.49	3.27e-7	Fibrinogen levels;
THYM	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg08975724	chr8:8085496	FLJ10661	-0.58	-4.48	-0.42	2.06e-5	Mood instability;
THYM	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg14983838	chr19:29218262	NA	0.74	5.83	0.51	7.63e-8	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs2213920	0.679	rs10759780	chr9:118196088	A/C	cg13918206	chr9:118159781	DEC1	0.86	4.9	0.45	3.86e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg07648498	chr16:89883185	FANCA	-0.62	-4.47	-0.42	2.19e-5	Vitiligo;
THYM	cis	rs11811982	0.793	rs80311310	chr1:227415803	G/T	cg09853570	chr1:228403422	OBSCN	1.21	4.67	0.43	9.81e-6	Optic disc area;
THYM	cis	rs2652822	0.525	rs11632192	chr15:63515946	A/G	cg09251291	chr15:63483946	RAB8B	0.53	4.89	0.45	4.04e-6	Metabolic traits;
THYM	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg18681998	chr4:17616180	MED28	0.95	9.51	0.7	1.88e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	5.16	0.47	1.36e-6	Schizophrenia;
THYM	cis	rs35160687	0.862	rs12476706	chr2:86528370	C/T	cg10973622	chr2:86423274	IMMT	0.52	4.52	0.42	1.8e-5	Night sleep phenotypes;
THYM	cis	rs1018836	0.859	rs10808614	chr8:91569677	C/G	cg16814680	chr8:91681699	NA	-0.9	-7.83	-0.63	6.74e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.25	6.17	0.53	1.66e-8	Obesity-related traits;
THYM	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg27170947	chr2:26402098	FAM59B	0.6	5.02	0.46	2.43e-6	Gut microbiome composition (summer);
THYM	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06634786	chr22:41940651	POLR3H	0.78	6.01	0.53	3.36e-8	Vitiligo;
THYM	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.7	0.71	7.32e-16	Colorectal cancer;
THYM	cis	rs1691799	0.899	rs1168322	chr12:66743769	C/T	cg16791601	chr12:66731901	HELB	-0.75	-7.25	-0.6	1.08e-10	White blood cell count (basophil);
THYM	cis	rs11563648	0.573	rs7789922	chr7:126958628	T/C	cg23081781	chr7:127225937	GCC1	-0.37	-5.19	-0.47	1.17e-6	Resting heart rate;
THYM	cis	rs858239	0.669	rs1006709	chr7:23140099	C/T	cg18081818	chr7:23246105	NA	-0.53	-4.84	-0.44	5.09e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs79149102	0.579	rs8031545	chr15:75290496	T/C	cg17294928	chr15:75287854	SCAMP5	-1.06	-5.68	-0.5	1.49e-7	Lung cancer;
THYM	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg08999081	chr20:33150536	PIGU	-0.57	-5.03	-0.46	2.3e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7089973	0.872	rs17092542	chr10:116630289	G/A	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.14	-0.47	1.5e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg12923728	chr3:195709715	SDHAP1	-0.78	-6.38	-0.55	6.41e-9	Pancreatic cancer;
THYM	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg14019146	chr3:50243930	SLC38A3	-0.61	-5.3	-0.48	7.4e-7	Body mass index;
THYM	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg05025164	chr4:1340916	KIAA1530	0.96	7.72	0.62	1.19e-11	Longevity;
THYM	cis	rs611744	0.837	rs422847	chr8:109103274	C/T	cg21045802	chr8:109455806	TTC35	-0.59	-5.24	-0.47	9.84e-7	Dupuytren's disease;
THYM	cis	rs11249608	0.548	rs2132672	chr5:178457742	A/C	cg01312482	chr5:178451176	ZNF879	-0.75	-6.25	-0.54	1.18e-8	Pubertal anthropometrics;
THYM	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg26513180	chr16:89883248	FANCA	-0.51	-4.92	-0.45	3.65e-6	Vitiligo;
THYM	cis	rs6076065	0.723	rs2424546	chr20:23391751	G/T	cg11657817	chr20:23433608	CST11	0.31	4.57	0.42	1.48e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.78	0.51	9.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	12.83	0.8	1.88e-22	Chronic sinus infection;
THYM	cis	rs2282300	0.739	rs34951229	chr11:30265166	C/G	cg09906309	chr11:30344399	C11orf46	-0.72	-5.34	-0.48	6.24e-7	Morning vs. evening chronotype;
THYM	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs12410462	0.636	rs2819515	chr1:227632125	G/A	cg22525281	chr1:228134933	WNT9A	0.59	4.84	0.44	5.1e-6	Major depressive disorder;
THYM	cis	rs9768139	0.658	rs73746486	chr7:158113191	A/G	cg25566285	chr7:158114605	PTPRN2	0.95	12.11	0.78	5.62e-21	Calcium levels;
THYM	cis	rs10992471	0.528	rs1535754	chr9:95201917	T/G	cg14631576	chr9:95140430	CENPP	-0.84	-8.02	-0.64	2.69e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg11752832	chr7:134001865	SLC35B4	0.74	5.65	0.5	1.69e-7	Mean platelet volume;
THYM	cis	rs13424612	0.839	rs4854065	chr2:240910158	A/G	cg01812947	chr2:240904978	NDUFA10	0.56	4.59	0.43	1.35e-5	Odorant perception (isobutyraldehyde);
THYM	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg06009448	chr7:1102226	C7orf50	0.51	5.35	0.48	5.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05901451	chr6:126070800	HEY2	-0.95	-9.33	-0.69	4.41e-15	Brugada syndrome;
THYM	cis	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg12193833	chr17:30244370	NA	-0.63	-4.75	-0.44	7.26e-6	Hip circumference adjusted for BMI;
THYM	cis	rs7089973	0.934	rs12771956	chr10:116576228	C/G	cg23260525	chr10:116636907	FAM160B1	0.56	5.0	0.46	2.67e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg20283391	chr11:68216788	NA	-0.69	-5.14	-0.47	1.49e-6	Total body bone mineral density;
THYM	cis	rs12476592	0.602	rs2121353	chr2:63899330	C/T	cg17519650	chr2:63277830	OTX1	-0.72	-4.68	-0.43	9.38e-6	Childhood ear infection;
THYM	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.14	0.47	1.49e-6	Height;
THYM	cis	rs786425	0.585	rs2271660	chr12:124220055	A/G	cg15249119	chr12:124971054	NCOR2	0.55	5.0	0.46	2.61e-6	Pubertal anthropometrics;
THYM	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg18876405	chr7:65276391	NA	0.52	4.47	0.42	2.2e-5	Calcium levels;
THYM	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg27535305	chr1:53392650	SCP2	-0.4	-4.7	-0.43	8.8e-6	Monocyte count;
THYM	cis	rs10889850	0.675	rs987013	chr1:70192159	G/A	cg01711146	chr1:70671364	SFRS11;LRRC40	0.78	4.54	0.42	1.62e-5	Body mass index;
THYM	cis	rs490234	0.841	rs476819	chr9:128362737	C/T	cg14078157	chr9:128172775	NA	-0.67	-5.36	-0.48	5.78e-7	Mean arterial pressure;
THYM	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-4.64	-0.43	1.11e-5	Acne (severe);
THYM	cis	rs4919694	1.000	rs12254254	chr10:104765605	C/T	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg00074818	chr8:8560427	CLDN23	0.5	4.63	0.43	1.16e-5	Obesity-related traits;
THYM	cis	rs7666738	0.648	rs33988750	chr4:98985386	T/C	cg03676636	chr4:99064102	C4orf37	0.51	5.29	0.48	7.77e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg23711669	chr6:146136114	FBXO30	-0.89	-8.76	-0.67	7.32e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg27490568	chr2:178487706	NA	0.85	7.08	0.59	2.42e-10	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs9790314	0.791	rs6809256	chr3:161026513	G/A	cg03342759	chr3:160939853	NMD3	-0.95	-9.47	-0.7	2.2e-15	Morning vs. evening chronotype;
THYM	cis	rs7578361	0.959	rs4667416	chr2:150457139	G/A	cg17961725	chr2:150454027	NA	0.71	6.07	0.53	2.63e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs2286885	1.000	rs2277159	chr9:129243383	C/T	cg14319473	chr9:129242481	FAM125B	0.65	4.91	0.45	3.78e-6	Intraocular pressure;
THYM	cis	rs9527	0.830	rs12249194	chr10:104643698	T/C	cg15744005	chr10:104629667	AS3MT	-0.66	-4.82	-0.44	5.36e-6	Arsenic metabolism;
THYM	cis	rs12936587	0.564	rs7208561	chr17:17615528	C/T	cg04398451	chr17:18023971	MYO15A	-0.63	-5.29	-0.48	7.85e-7	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
THYM	cis	rs1535500	0.967	rs11756070	chr6:39282748	G/A	cg00012638	chr6:39280541	KCNK17	0.61	8.08	0.64	2.06e-12	Type 2 diabetes;
THYM	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg02887458	chr19:19495540	GATAD2A	0.42	5.0	0.46	2.58e-6	Bipolar disorder;
THYM	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08109568	chr15:31115862	NA	-0.63	-5.88	-0.52	6.14e-8	Huntington's disease progression;
THYM	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg21926883	chr2:100939477	LONRF2	-0.55	-4.99	-0.46	2.74e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6860806	0.507	rs270615	chr5:131641573	G/C	cg24060327	chr5:131705240	SLC22A5	-0.8	-6.4	-0.55	5.8e-9	Breast cancer;
THYM	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg01341218	chr17:43662625	NA	0.86	7.43	0.61	4.66e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg00278517	chr6:167070616	RPS6KA2	-0.35	-4.58	-0.42	1.44e-5	Crohn's disease;
THYM	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg23161317	chr6:28129485	ZNF389	0.84	6.3	0.54	9.31e-9	Depression;
THYM	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg16850897	chr7:100343110	ZAN	-0.7	-5.25	-0.47	9.34e-7	Other erythrocyte phenotypes;
THYM	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg13447684	chr7:1895903	MAD1L1	0.49	4.45	0.42	2.33e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg19016782	chr12:123741754	C12orf65	-0.68	-4.48	-0.42	2.05e-5	Neutrophil percentage of white cells;
THYM	cis	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg13463167	chr1:197523608	DENND1B	-0.78	-5.34	-0.48	6.45e-7	Depressive symptoms;
THYM	cis	rs791590	0.941	rs11597237	chr10:6079017	C/T	cg17191567	chr10:6178319	NA	0.7	4.58	0.43	1.39e-5	Soluble interleukin-2 receptor subunit alpha;
THYM	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg15592062	chr6:167189543	RPS6KA2	-0.47	-4.76	-0.44	7.02e-6	Crohn's disease;
THYM	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.27	9.78	0.71	4.84e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs684232	0.712	rs2955626	chr17:618100	C/G	cg08489349	chr17:656181	ELP2P;GEMIN4	0.43	5.09	0.46	1.77e-6	Prostate cancer;
THYM	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs7107174	1.000	rs10899474	chr11:78043636	T/C	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs7590720	0.959	rs2372684	chr2:216884764	C/A	cg12620499	chr2:216877984	MREG	0.88	6.23	0.54	1.24e-8	Alcohol dependence;
THYM	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg04842962	chr6:43655489	MRPS18A	-0.87	-7.19	-0.59	1.47e-10	IgG glycosylation;
THYM	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg26031613	chr14:104095156	KLC1	0.7	4.57	0.42	1.47e-5	Body mass index;
THYM	cis	rs11209185	0.563	rs4655763	chr1:68438400	G/A	cg22082780	chr1:68452167	NA	-0.51	-6.18	-0.54	1.6e-8	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs907612	0.638	rs907611	chr11:1874072	G/A	cg26158194	chr11:1874320	LSP1	0.5	4.83	0.44	5.31e-6	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
THYM	cis	rs12936587	0.535	rs8065154	chr17:17614947	A/G	cg04398451	chr17:18023971	MYO15A	-0.57	-4.74	-0.44	7.5e-6	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
THYM	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs9951602	0.512	rs8098115	chr18:76653986	G/T	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg23682913	chr1:2080710	PRKCZ	0.57	5.14	0.47	1.48e-6	Height;
THYM	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-6.2	-0.54	1.47e-8	Total body bone mineral density;
THYM	cis	rs7119	0.666	rs2516302	chr15:77879842	C/G	cg27398640	chr15:77910606	LINGO1	0.7	8.44	0.65	3.49e-13	Type 2 diabetes;
THYM	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg03609598	chr5:56110824	MAP3K1	0.86	5.8	0.51	8.78e-8	Initial pursuit acceleration;
THYM	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg03929089	chr4:120376271	NA	-0.96	-10.47	-0.73	1.66e-17	Coronary artery disease;
THYM	cis	rs7941600	0.708	rs4627080	chr11:9336349	G/T	cg21110646	chr11:9336536	TMEM41B	-1.29	-7.83	-0.63	6.85e-12	Coronary artery disease;
THYM	cis	rs4731207	0.671	rs12706626	chr7:124531370	G/A	cg05285228	chr7:124571219	POT1	0.74	5.11	0.46	1.67e-6	Cutaneous malignant melanoma;
THYM	cis	rs9796	0.649	rs8035828	chr15:41467287	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.57	-4.67	-0.43	9.76e-6	Menopause (age at onset);
THYM	cis	rs2139634	1.000	rs12638228	chr3:46516722	A/G	cg02332537	chr3:46540019	RTP3	0.48	4.89	0.45	4.06e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg04750100	chr2:136595281	LCT	-0.54	-6.51	-0.56	3.59e-9	Mosquito bite size;
THYM	cis	rs7586879	0.639	rs6749170	chr2:25110962	A/G	cg27107076	chr2:25050844	ADCY3	-0.29	-4.68	-0.43	9.36e-6	Body mass index;
THYM	cis	rs9611519	0.894	rs4821990	chr22:41438710	A/C	cg03806693	chr22:41940476	POLR3H	-0.76	-5.98	-0.52	3.99e-8	Neuroticism;
THYM	cis	rs62103177	0.535	rs34299914	chr18:77949236	C/A	cg16238918	chr18:78004303	PARD6G	0.59	4.69	0.43	9.22e-6	Opioid sensitivity;
THYM	cis	rs7705042	0.865	rs7733850	chr5:141515564	C/T	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg19077165	chr18:44547161	KATNAL2	-0.58	-7.25	-0.6	1.11e-10	Personality dimensions;
THYM	cis	rs10752881	0.875	rs10797825	chr1:183024581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Colorectal cancer;
THYM	cis	rs4281086	0.544	rs6601476	chr8:10355179	C/G	cg02525722	chr8:10404760	NA	0.54	4.45	0.42	2.3e-5	Obesity-related traits;
THYM	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg03806693	chr22:41940476	POLR3H	1.19	8.81	0.67	5.85e-14	Vitiligo;
THYM	cis	rs2717559	0.522	rs2585159	chr8:143875817	G/A	cg03405983	chr8:143858548	LYNX1	0.55	6.03	0.53	3.17e-8	Urinary tract infection frequency;
THYM	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-6.0	-0.52	3.63e-8	Prostate cancer;
THYM	cis	rs131805	0.794	rs131813	chr22:50961169	A/G	cg25309564	chr22:51001381	C22orf41	0.71	4.81	0.44	5.76e-6	Granulocyte percentage of myeloid white cells;
THYM	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg13695892	chr22:41940480	POLR3H	-0.63	-4.88	-0.45	4.18e-6	Neuroticism;
THYM	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg26384229	chr12:38710491	ALG10B	-1.02	-8.46	-0.66	3.1400000000000003e-13	Bladder cancer;
THYM	cis	rs10095849	0.529	rs7839626	chr8:39393445	T/A	cg01911981	chr8:39380341	ADAM3A	0.56	4.67	0.43	9.84e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.8	-5.44	-0.49	4.14e-7	Body mass index;
THYM	cis	rs4790333	0.845	rs2429910	chr17:2270777	T/C	cg02569219	chr17:2266849	SGSM2	0.72	6.17	0.53	1.69e-8	Proinsulin levels;
THYM	cis	rs9837602	0.882	rs6807176	chr3:99760864	A/G	cg00175735	chr3:99903386	TMEM30C	-0.76	-4.57	-0.42	1.44e-5	Breast cancer;
THYM	cis	rs2976388	0.609	rs2717602	chr8:143805683	G/A	cg06565975	chr8:143823917	SLURP1	0.47	5.16	0.47	1.33e-6	Urinary tract infection frequency;
THYM	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.46	-4.92	-0.45	3.63e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
THYM	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg11327659	chr7:150037044	RARRES2	0.42	5.0	0.46	2.67e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg13609457	chr4:120235615	NA	0.63	5.53	0.49	2.83e-7	Corneal astigmatism;
THYM	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg15704280	chr7:45808275	SEPT13	1.01	8.51	0.66	2.52e-13	Coronary artery disease;
THYM	cis	rs7020830	0.522	rs10814509	chr9:37111057	A/G	cg14294708	chr9:37120828	ZCCHC7	0.79	7.2	0.59	1.41e-10	Schizophrenia;
THYM	cis	rs6500395	0.962	rs9937568	chr16:48612361	C/T	cg04672837	chr16:48644449	N4BP1	-0.51	-5.14	-0.47	1.45e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs11731175	0.883	rs78004272	chr4:189858113	C/T	cg00431894	chr4:189871012	NA	-0.88	-6.75	-0.57	1.15e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs524023	0.874	rs504915	chr11:64464085	T/A	cg19131476	chr11:64387923	NRXN2	-0.37	-5.07	-0.46	1.95e-6	Urate levels in obese individuals;
THYM	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg18681998	chr4:17616180	MED28	0.79	6.7	0.57	1.49e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs11723261	0.509	rs61792240	chr4:128619	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.86	5.68	0.5	1.48e-7	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg03859395	chr2:55845619	SMEK2	-0.57	-5.58	-0.5	2.29e-7	Metabolic syndrome;
THYM	cis	rs6754311	0.593	rs7355359	chr2:136462441	C/T	cg04750100	chr2:136595281	LCT	-0.56	-5.88	-0.52	6.05e-8	Mosquito bite size;
THYM	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg12863693	chr15:85201151	NMB	0.63	5.45	0.49	3.97e-7	Schizophrenia;
THYM	cis	rs17401966	0.931	rs3748579	chr1:10420937	C/T	cg19773385	chr1:10388646	KIF1B	-0.6	-4.7	-0.43	8.88e-6	Hepatocellular carcinoma;
THYM	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg05802129	chr4:122689817	NA	-0.59	-4.65	-0.43	1.08e-5	Type 2 diabetes;
THYM	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg04990556	chr1:26633338	UBXN11	-0.87	-8.33	-0.65	6.04e-13	Obesity-related traits;
THYM	cis	rs9913156	0.789	rs72824966	chr17:4596679	T/C	cg19197139	chr17:4613644	ARRB2	0.84	4.97	0.45	2.92e-6	Lymphocyte counts;
THYM	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg16405210	chr4:1374714	KIAA1530	-0.69	-5.62	-0.5	1.92e-7	Longevity;
THYM	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg24675056	chr1:15929824	NA	0.73	5.92	0.52	5.06e-8	Systolic blood pressure;
THYM	cis	rs2797369	0.546	rs11963911	chr6:101308421	T/C	cg12253828	chr6:101329408	ASCC3	0.64	4.5	0.42	1.95e-5	Renal function-related traits (eGRFcrea);
THYM	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.0	0.63	2.98e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg02953382	chr22:24373134	LOC391322	-0.88	-9.53	-0.7	1.68e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24549020	chr5:56110836	MAP3K1	0.71	4.63	0.43	1.15e-5	Initial pursuit acceleration;
THYM	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg17105886	chr17:28927953	LRRC37B2	1.32	6.56	0.56	2.79e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg08885076	chr2:99613938	TSGA10	0.52	5.02	0.46	2.4e-6	Chronic sinus infection;
THYM	cis	rs6906287	0.609	rs767139	chr6:118884799	A/G	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg08772003	chr10:104629869	AS3MT	-0.57	-4.87	-0.45	4.45e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7546094	0.935	rs9429486	chr1:113157372	T/C	cg25616829	chr1:112535356	NA	0.55	4.51	0.42	1.88e-5	Platelet distribution width;
THYM	cis	rs1461503	0.868	rs10790543	chr11:122838311	A/C	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs6964587	0.626	rs10280301	chr7:91524258	A/T	cg22709100	chr7:91322751	NA	-0.62	-4.67	-0.43	9.72e-6	Breast cancer;
THYM	cis	rs12149862	1.000	rs9930094	chr16:69465673	C/A	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs9992101	0.547	rs2137154	chr4:77411501	C/G	cg20311846	chr4:77356250	SHROOM3	-0.46	-4.78	-0.44	6.39e-6	Creatinine levels;
THYM	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs2658782	1.000	rs2608216	chr11:93149172	G/A	cg15737290	chr11:93063684	CCDC67	1.05	7.97	0.63	3.42e-12	Pulmonary function decline;
THYM	cis	rs600806	0.813	rs6664236	chr1:109986672	C/A	cg02175308	chr1:109941060	SORT1	-0.59	-5.15	-0.47	1.38e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4845875	0.600	rs6696752	chr1:11835935	T/C	cg24844545	chr1:11908347	NPPA	0.57	4.77	0.44	6.74e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs2275731	0.525	rs7922050	chr10:16479007	C/G	cg00316341	chr10:16898311	CUBN	0.35	4.77	0.44	6.68e-6	Bone fracture in osteoporosis;
THYM	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg19645103	chr12:69753606	YEATS4	-0.56	-4.54	-0.42	1.63e-5	Response to diuretic therapy;
THYM	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg21138405	chr5:131827807	IRF1	0.84	9.6	0.7	1.16e-15	Asthma (sex interaction);
THYM	cis	rs9876781	0.868	rs9875280	chr3:48428911	A/G	cg06066452	chr3:48470258	PLXNB1	0.26	4.88	0.45	4.26e-6	Longevity;
THYM	cis	rs67311347	0.567	rs11718621	chr3:40362122	T/C	cg13683864	chr3:40499215	RPL14	0.66	5.72	0.51	1.21e-7	Renal cell carcinoma;
THYM	cis	rs9921222	0.509	rs2301522	chr16:359953	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.44	7.19	0.59	1.5e-10	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs901683	1.000	rs17157880	chr10:46014488	A/G	cg18240400	chr10:46168597	ANUBL1	0.8	5.16	0.47	1.38e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs4253772	0.515	rs6007891	chr22:46756833	C/T	cg24881330	chr22:46731750	TRMU	0.93	5.16	0.47	1.37e-6	LDL cholesterol;Cholesterol, total;
THYM	trans	rs8073060	0.586	rs35542792	chr17:33903886	A/G	cg19694781	chr19:47549865	TMEM160	0.98	8.52	0.66	2.45e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs35883536	0.647	rs10875328	chr1:101169328	C/T	cg09408571	chr1:101003634	GPR88	-0.45	-4.89	-0.45	4.13e-6	Monocyte count;
THYM	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg26384229	chr12:38710491	ALG10B	0.94	7.9	0.63	4.92e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg12599982	chr1:44399894	ARTN	0.58	4.7	0.43	8.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7226229	1.000	rs6587115	chr17:20960911	C/G	cg21263980	chr17:20946333	USP22	0.65	4.55	0.42	1.61e-5	Blood trace element (Se levels);
THYM	cis	rs988913	0.957	rs9367597	chr6:54784652	C/T	cg18532076	chr6:54711417	FAM83B	0.49	4.61	0.43	1.26e-5	Menarche (age at onset);
THYM	cis	rs1348850	0.526	rs9288003	chr2:178446572	T/G	cg27490568	chr2:178487706	NA	0.59	4.88	0.45	4.2e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg04455712	chr21:45112962	RRP1B	0.51	4.72	0.44	8.23e-6	Mean corpuscular volume;
THYM	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-6.1	-0.53	2.27e-8	Bipolar disorder;
THYM	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg23682913	chr1:2080710	PRKCZ	-0.51	-4.55	-0.42	1.57e-5	Height;
THYM	cis	rs2279817	0.913	rs2270979	chr1:18023290	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.75	4.73	0.44	7.76e-6	Neuroticism;
THYM	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg22903471	chr2:27725779	GCKR	-0.66	-4.47	-0.42	2.2e-5	Blood metabolite levels;
THYM	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg08999081	chr20:33150536	PIGU	0.62	4.98	0.45	2.85e-6	Coronary artery disease;
THYM	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.27	6.45	0.55	4.67e-9	Gut microbiome composition (summer);
THYM	cis	rs77320796	0.953	rs77692382	chr1:40406715	C/T	cg05657805	chr1:40942785	ZNF642	0.76	4.46	0.42	2.26e-5	Platelet count;
THYM	cis	rs2602836	0.600	rs6858148	chr4:100065917	T/C	cg12011299	chr4:100065546	ADH4	-0.92	-10.36	-0.73	2.86e-17	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs4731207	0.596	rs1481343	chr7:124652271	T/C	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs35883536	1.000	rs11547648	chr1:101106268	G/T	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs7973719	0.865	rs12830671	chr12:7347278	T/G	cg07052231	chr12:7363540	PEX5	0.62	5.15	0.47	1.39e-6	IgG glycosylation;
THYM	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.49	-4.94	-0.45	3.39e-6	Depressive symptoms;
THYM	cis	rs4642101	0.662	rs3901664	chr3:12824660	T/C	cg11882607	chr3:12858926	CAND2	-0.42	-4.6	-0.43	1.32e-5	QRS complex (12-leadsum);
THYM	cis	rs6450176	0.909	rs67721004	chr5:53290571	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-6.61	-0.56	2.22e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs6906287	0.559	rs7751467	chr6:118893861	T/A	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg04248312	chr19:17393744	ANKLE1	-0.96	-12.68	-0.79	3.82e-22	Systemic lupus erythematosus;
THYM	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg18811423	chr2:55921094	PNPT1	0.78	7.28	0.6	9.58e-11	Metabolic syndrome;
THYM	cis	rs995000	0.895	rs11208001	chr1:63130431	C/T	cg06896770	chr1:63153194	DOCK7	0.93	7.64	0.62	1.73e-11	Triglyceride levels;
THYM	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg01264106	chr22:38071602	LGALS1	0.36	4.55	0.42	1.56e-5	Fat distribution (HIV);
THYM	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9992101	0.547	rs2137152	chr4:77411710	T/C	cg27417997	chr4:77356416	SHROOM3	-0.37	-4.46	-0.42	2.22e-5	Creatinine levels;
THYM	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg00376283	chr12:123451042	ABCB9	-0.77	-5.06	-0.46	2.06e-6	Neutrophil percentage of white cells;
THYM	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.04	0.53	2.94e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11644478	chr21:40555479	PSMG1	1.02	8.54	0.66	2.14e-13	Cognitive function;
THYM	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg06970220	chr1:156163860	SLC25A44	0.73	5.95	0.52	4.37e-8	Testicular germ cell tumor;
THYM	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg22920501	chr2:26401640	FAM59B	-0.83	-7.3	-0.6	8.69e-11	Gut microbiome composition (summer);
THYM	cis	rs472402	0.580	rs7706809	chr5:6635971	G/T	cg12648172	chr5:5886274	NA	0.55	5.29	0.48	7.82e-7	Response to amphetamines;
THYM	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg03690763	chr11:133734501	NA	-0.61	-4.73	-0.44	7.77e-6	Childhood ear infection;
THYM	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg00981070	chr1:2046702	PRKCZ	0.48	5.34	0.48	6.36e-7	Height;
THYM	cis	rs1018836	0.828	rs10956730	chr8:91597428	T/G	cg16814680	chr8:91681699	NA	-0.93	-7.89	-0.63	5.06e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	5.56	0.5	2.46e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.21	-0.47	1.08e-6	Mean corpuscular volume;
THYM	cis	rs35125029	0.540	rs7604665	chr2:144252082	A/C	cg17056048	chr2:144271431	ARHGAP15	-0.53	-4.98	-0.45	2.84e-6	Morning vs. evening chronotype;
THYM	cis	rs4727027	0.522	rs6956736	chr7:148893472	G/C	cg23583168	chr7:148888333	NA	-0.95	-9.48	-0.7	2.11e-15	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6763768	0.606	rs6798771	chr3:53312915	C/T	cg22900224	chr3:52804907	NEK4	0.7	4.51	0.42	1.87e-5	Bacterial meningitis;
THYM	cis	rs10489202	0.583	rs203782	chr1:167882386	A/G	cg24449463	chr1:168025552	DCAF6	0.9	8.81	0.67	5.81e-14	Schizophrenia;
THYM	trans	rs11186	0.591	rs7420331	chr2:189960329	A/G	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg06728252	chr6:26598149	ABT1	0.41	4.8	0.44	5.82e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg24531977	chr5:56204891	C5orf35	-0.66	-5.11	-0.46	1.64e-6	Coronary artery disease;
THYM	cis	rs155076	1.000	rs567166	chr13:21837519	T/C	cg25811766	chr13:21894605	NA	-0.75	-4.75	-0.44	7.29e-6	White matter hyperintensity burden;
THYM	cis	rs2985684	1.000	rs56098064	chr14:50105849	T/C	cg02151108	chr14:50098012	C14orf104	-0.67	-5.33	-0.48	6.48e-7	Carotid intima media thickness;
THYM	cis	rs6754311	0.731	rs687670	chr2:136740900	T/C	cg04750100	chr2:136595281	LCT	0.57	6.17	0.54	1.65e-8	Mosquito bite size;
THYM	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg26031613	chr14:104095156	KLC1	-0.68	-4.45	-0.42	2.34e-5	Body mass index;
THYM	cis	rs6087990	0.731	rs2424897	chr20:31338098	A/T	cg13636640	chr20:31349939	DNMT3B	0.92	9.68	0.7	8.12e-16	Ulcerative colitis;
THYM	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.73	-0.44	7.73e-6	Mean corpuscular volume;
THYM	cis	rs6840360	0.571	rs1822347	chr4:152525319	A/G	cg17479576	chr4:152424074	FAM160A1	-0.78	-5.74	-0.51	1.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1372520	0.577	rs2737021	chr4:90739992	T/A	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg17279839	chr7:150038598	RARRES2	0.56	5.41	0.49	4.78e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg04034577	chr2:241836375	C2orf54	-0.45	-7.16	-0.59	1.72e-10	Urinary metabolites;
THYM	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs28453840	1	rs28453840	chr2:136522941	G/A	cg23851026	chr2:136556271	LCT	-0.58	-6.01	-0.52	3.4e-8	Cholesterol, total;
THYM	cis	rs7224737	1.000	rs739636	chr17:40281063	T/G	cg02228675	chr17:40259724	DHX58	-0.71	-5.87	-0.52	6.37e-8	Fibrinogen levels;
THYM	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg27532560	chr4:187881888	NA	-0.96	-11.45	-0.76	1.41e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg10518543	chr12:38710700	ALG10B	-0.59	-4.76	-0.44	6.84e-6	Heart rate;
THYM	cis	rs6584283	0.713	rs1332100	chr10:101301346	C/T	cg03036592	chr10:101287839	NA	0.53	4.9	0.45	3.97e-6	Ulcerative colitis;
THYM	cis	rs9532580	0.619	rs2755211	chr13:41142223	C/T	cg21288729	chr13:41239152	FOXO1	0.67	4.7	0.43	8.74e-6	Mean corpuscular hemoglobin;
THYM	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg01238044	chr22:24384105	GSTT1	-0.54	-4.82	-0.44	5.5e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.93	-0.52	4.84e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	12.37	0.79	1.67e-21	Height;
THYM	cis	rs10499694	0.933	rs12538938	chr7:50592313	A/G	cg00647317	chr7:50633725	DDC	0.3	4.56	0.42	1.52e-5	Body mass index;
THYM	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg20295408	chr7:1910781	MAD1L1	-0.67	-5.04	-0.46	2.27e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs8078723	0.690	rs3785549	chr17:38149724	T/C	cg17467752	chr17:38218738	THRA	-0.8	-6.7	-0.57	1.46e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs4474465	1.000	rs10793313	chr11:78169310	C/T	cg19901956	chr11:77921274	USP35	-0.6	-4.55	-0.42	1.56e-5	Alzheimer's disease (survival time);
THYM	cis	rs7943358	0.910	rs1484423	chr11:15692521	A/G	cg11966998	chr11:15692519	NA	-0.5	-5.27	-0.48	8.66e-7	Gut microbiome composition (summer);
THYM	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg22508957	chr16:3507546	NAT15	0.72	7.97	0.63	3.4e-12	Tuberculosis;
THYM	cis	rs11690935	1.000	rs3795999	chr2:172544483	A/G	cg13550731	chr2:172543902	DYNC1I2	0.87	6.39	0.55	6.22e-9	Schizophrenia;
THYM	cis	rs3768617	0.510	rs6424884	chr1:183065904	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.76	0.44	6.83e-6	Fuchs's corneal dystrophy;
THYM	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs2075230	0.642	rs1641528	chr17:7548320	A/G	cg10509001	chr17:7553872	ATP1B2	-0.64	-5.14	-0.47	1.49e-6	Hormone measurements;
THYM	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.67	0.5	1.56e-7	Obesity-related traits;
THYM	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs885814	1.000	rs885814	chr1:21875916	C/T	cg14781605	chr1:21864896	ALPL	-0.68	-5.19	-0.47	1.17e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs763014	0.931	rs3752567	chr16:628130	A/G	cg00908189	chr16:619842	PIGQ	1.0	8.84	0.67	4.92e-14	Height;
THYM	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg10360139	chr7:1886902	MAD1L1	-0.83	-7.4	-0.6	5.4e-11	Bipolar disorder and schizophrenia;
THYM	cis	rs1113500	0.836	rs1618973	chr1:108586767	T/C	cg06207961	chr1:108661230	NA	-0.7	-5.56	-0.5	2.49e-7	Growth-regulated protein alpha levels;
THYM	cis	rs6430585	0.759	rs12467770	chr2:136536095	G/A	cg04750100	chr2:136595281	LCT	0.53	4.86	0.45	4.59e-6	Corneal structure;
THYM	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg19747945	chr6:42946146	PEX6	-0.34	-5.12	-0.46	1.61e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.22	0.64	1.03e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs34779708	0.931	rs11593858	chr10:35381373	G/A	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	trans	rs4650994	0.544	rs2761469	chr1:178590638	A/C	cg05059571	chr16:84539110	KIAA1609	0.89	9.78	0.71	4.98e-16	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg03609598	chr5:56110824	MAP3K1	-0.67	-4.7	-0.43	8.63e-6	Coronary artery disease;
THYM	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg18105134	chr13:113819100	PROZ	1.02	9.35	0.69	4.08e-15	Platelet distribution width;
THYM	cis	rs28595532	0.920	rs115850161	chr4:119732447	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs791888	0.858	rs2180968	chr10:89418730	A/C	cg17916473	chr10:89419373	PAPSS2	0.42	4.58	0.43	1.42e-5	Magnesium levels;
THYM	cis	rs1847202	1.000	rs6807627	chr3:72939767	C/T	cg25664220	chr3:72788482	NA	-0.59	-4.6	-0.43	1.31e-5	Motion sickness;
THYM	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs12367572	0.620	rs2643140	chr12:45418311	C/T	cg03114573	chr12:45410052	DBX2	-0.61	-5.93	-0.52	4.95e-8	Gut microbiome composition (summer);
THYM	cis	rs8050907	1.000	rs8050907	chr16:4646878	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.2	4.92	0.45	3.66e-6	Obesity-related traits;
THYM	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg00810483	chr4:3375144	RGS12	0.31	4.49	0.42	1.99e-5	Serum sulfate level;
THYM	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg24733560	chr20:60626293	TAF4	0.51	4.58	0.43	1.41e-5	Body mass index;
THYM	cis	rs11098499	0.526	rs10026625	chr4:120280136	T/C	cg13609457	chr4:120235615	NA	0.52	4.89	0.45	4.05e-6	Corneal astigmatism;
THYM	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg26043149	chr18:55253948	FECH	1.16	10.82	0.74	2.98e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg22431228	chr1:16359049	CLCNKA	-0.51	-4.93	-0.45	3.47e-6	Dilated cardiomyopathy;
THYM	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg06197492	chr11:2016605	H19	0.63	5.52	0.49	2.97e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs72627123	0.867	rs74635757	chr14:74489225	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.52	0.56	3.44e-9	Morning vs. evening chronotype;
THYM	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg17105886	chr17:28927953	LRRC37B2	1.29	6.89	0.58	5.99e-10	Body mass index;
THYM	cis	rs7084402	0.817	rs7099496	chr10:60265242	G/A	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	4.68	0.43	9.45e-6	Aortic root size;
THYM	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg05368731	chr17:41323189	NBR1	1.24	11.42	0.76	1.59e-19	Menopause (age at onset);
THYM	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg13319975	chr6:146136371	FBXO30	0.62	5.05	0.46	2.11e-6	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.94	-8.83	-0.67	5.33e-14	Brugada syndrome;
THYM	cis	rs2050392	1.000	rs7077496	chr10:30692028	G/A	cg02070205	chr10:30722105	MAP3K8	0.51	4.5	0.42	1.95e-5	Inflammatory bowel disease;
THYM	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03264133	chr6:25882463	NA	-0.91	-7.85	-0.63	6.29e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg20283391	chr11:68216788	NA	-0.74	-5.43	-0.49	4.25e-7	Total body bone mineral density;
THYM	cis	rs1113500	0.897	rs2336127	chr1:108640870	G/A	cg06207961	chr1:108661230	NA	0.66	5.23	0.47	1.03e-6	Growth-regulated protein alpha levels;
THYM	cis	rs11711311	0.955	rs9823423	chr3:113419741	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.55	-4.69	-0.43	9.3e-6	IgG glycosylation;
THYM	cis	rs11771526	1.000	rs10231440	chr7:32299435	C/A	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs7246657	0.943	rs13343502	chr19:37962292	C/T	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg04315214	chr1:2043799	PRKCZ	0.6	4.57	0.42	1.45e-5	Height;
THYM	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg18252515	chr7:66147081	NA	-1.62	-8.8	-0.67	5.99e-14	Diabetic kidney disease;
THYM	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg24397884	chr7:158709396	WDR60	0.51	5.46	0.49	3.82e-7	Height;
THYM	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg06636001	chr8:8085503	FLJ10661	0.77	7.74	0.62	1.06e-11	Mood instability;
THYM	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg02915803	chr1:1606292	LOC728661;CDK11B	-0.61	-5.24	-0.47	9.65e-7	Body mass index;
THYM	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs7620457	1.000	rs7620457	chr3:183747266	A/G	cg03417191	chr3:183542750	MAP6D1	-0.84	-5.03	-0.46	2.32e-6	Body mass index;
THYM	trans	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg25214090	chr10:38739885	LOC399744	0.91	7.93	0.63	4.24e-12	Corneal astigmatism;
THYM	cis	rs8014204	0.550	rs2302832	chr14:75137664	T/C	cg06637938	chr14:75390232	RPS6KL1	0.59	5.43	0.49	4.24e-7	Caffeine consumption;
THYM	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.93	-0.45	3.52e-6	Monocyte count;
THYM	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg23711669	chr6:146136114	FBXO30	0.81	7.71	0.62	1.25e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.94	-6.1	-0.53	2.26e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg11141652	chr22:24348549	GSTTP1	-0.57	-4.67	-0.43	1.01e-5	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg14004847	chr7:1930337	MAD1L1	-0.69	-5.55	-0.49	2.57e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7731657	0.537	rs6595973	chr5:130327126	C/A	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs11696501	0.947	rs11696176	chr20:44115425	G/C	cg11783356	chr20:44313418	WFDC10B	-0.76	-4.74	-0.44	7.55e-6	Brain structure;
THYM	cis	rs259282	0.514	rs10420153	chr19:33112957	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.6	4.59	0.43	1.36e-5	Schizophrenia;
THYM	cis	rs7917772	0.628	rs4604806	chr10:104373904	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg10792982	chr14:105748885	BRF1	0.68	6.8	0.57	9.14e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg03188948	chr7:1209495	NA	0.91	5.04	0.46	2.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13126513	0.612	rs1596178	chr4:100406139	T/C	cg05468953	chr4:100565104	NA	-0.65	-5.56	-0.5	2.43e-7	Metabolite levels (MHPG);
THYM	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs11645898	0.748	rs56387295	chr16:72055336	C/A	cg03805757	chr16:71968109	PKD1L3	-0.75	-5.56	-0.5	2.47e-7	Blood protein levels;
THYM	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg15704280	chr7:45808275	SEPT13	-1.02	-11.38	-0.76	1.93e-19	Coronary artery disease;
THYM	cis	rs6047844	0.750	rs6113520	chr20:22087924	A/G	cg16502866	chr20:23015624	SSTR4	-0.57	-4.46	-0.42	2.21e-5	Male-pattern baldness;
THYM	cis	rs7103648	0.643	rs12365079	chr11:47696596	A/T	cg20307385	chr11:47447363	PSMC3	0.83	6.6	0.56	2.29e-9	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs40363	0.868	rs37772	chr16:3512843	A/G	cg05754148	chr16:3507555	NAT15	0.66	6.03	0.53	3.11e-8	Tuberculosis;
THYM	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg18105134	chr13:113819100	PROZ	-0.98	-9.05	-0.68	1.79e-14	Platelet distribution width;
THYM	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg23958373	chr8:599963	NA	1.04	5.28	0.48	8.07e-7	IgG glycosylation;
THYM	cis	rs11608355	1.000	rs7970482	chr12:109862335	G/A	cg10504392	chr12:110044639	NA	0.65	5.98	0.52	3.93e-8	Neuroticism;
THYM	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg06697600	chr4:7070879	GRPEL1	-0.56	-4.99	-0.46	2.68e-6	Monocyte percentage of white cells;
THYM	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg22105103	chr4:187893119	NA	0.95	10.29	0.73	3.97e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2239785	0.959	rs136159	chr22:36657023	T/C	cg15716373	chr22:36655542	APOL1	-0.4	-4.79	-0.44	6.23e-6	Glomerulosclerosis;
THYM	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg05985134	chr18:33552581	C18orf21	0.68	4.77	0.44	6.59e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs4363385	0.667	rs454245	chr1:153031979	A/C	cg13444842	chr1:152974279	SPRR3	0.61	5.1	0.46	1.71e-6	Inflammatory skin disease;
THYM	cis	rs4746818	1.000	rs10998614	chr10:70923347	G/T	cg11621586	chr10:70884670	VPS26A	1.28	11.12	0.75	6.73e-19	Left atrial antero-posterior diameter;
THYM	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg22681709	chr2:178499509	PDE11A	-0.53	-4.74	-0.44	7.51e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg13147721	chr7:65941812	NA	-1.11	-7.08	-0.59	2.44e-10	Diabetic kidney disease;
THYM	cis	rs1018836	0.632	rs7002775	chr8:91476765	C/T	cg16814680	chr8:91681699	NA	0.77	6.4	0.55	5.78e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs939658	0.805	rs11635757	chr15:79432737	T/C	cg17916960	chr15:79447300	NA	-0.73	-8.58	-0.66	1.81e-13	Refractive error;
THYM	cis	rs7107174	1.000	rs2292573	chr11:78053139	A/G	cg19901956	chr11:77921274	USP35	-0.65	-5.4	-0.48	5.01e-7	Testicular germ cell tumor;
THYM	cis	rs4732038	0.565	rs1708406	chr7:134276365	T/C	cg06906464	chr7:134288099	NA	-0.48	-4.76	-0.44	7e-6	Longevity;
THYM	cis	rs1692120	0.669	rs10897172	chr11:61427469	G/A	cg19838087	chr11:61442541	NA	0.59	6.41	0.55	5.57e-9	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
THYM	trans	rs9532669	0.890	rs2149570	chr13:41432669	T/G	cg10989634	chr1:111813745	NA	0.63	6.93	0.58	4.99e-10	Cervical cancer;
THYM	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.68	-5.05	-0.46	2.11e-6	Tonsillectomy;
THYM	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg20503657	chr10:835505	NA	1.17	8.29	0.65	7.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs883115	0.686	rs12730234	chr1:224863428	C/T	cg01808320	chr1:224927238	CNIH3	0.54	4.55	0.42	1.56e-5	Cancer;
THYM	cis	rs1395	0.778	rs2078616	chr2:27441904	A/G	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.54	-0.49	2.7e-7	Blood metabolite levels;
THYM	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11785693	0.865	rs11784227	chr8:4970485	A/C	cg26367366	chr8:4980734	NA	1.15	5.39	0.48	5.08e-7	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg05890377	chr2:74357713	NA	1.08	9.83	0.71	3.73e-16	Gestational age at birth (maternal effect);
THYM	cis	rs11630290	0.736	rs7174738	chr15:64144813	A/T	cg12036633	chr15:63758958	NA	-0.84	-4.5	-0.42	1.95e-5	Iris characteristics;
THYM	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg14582100	chr15:45693742	SPATA5L1	0.65	5.42	0.49	4.45e-7	Homoarginine levels;
THYM	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg18811423	chr2:55921094	PNPT1	0.72	6.92	0.58	5.22e-10	Metabolic syndrome;
THYM	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg18230493	chr5:56204884	C5orf35	-0.91	-6.74	-0.57	1.25e-9	Type 2 diabetes;
THYM	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg26721908	chr21:47610096	LSS	-0.72	-4.8	-0.44	5.79e-6	Testicular germ cell tumor;
THYM	cis	rs8077889	0.956	rs6503476	chr17:41850163	C/T	cg26893861	chr17:41843967	DUSP3	1.1	10.09	0.72	1.05e-16	Triglycerides;
THYM	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-5.89	-0.52	5.91e-8	Total cholesterol levels;
THYM	cis	rs7113850	0.541	rs80031332	chr11:24211553	A/G	ch.11.24196551F	chr11:24239977	NA	0.89	4.57	0.42	1.48e-5	Bone fracture in osteoporosis;
THYM	cis	rs7103648	0.897	rs11606287	chr11:47407439	C/A	cg20307385	chr11:47447363	PSMC3	0.84	6.78	0.57	1.02e-9	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg06092702	chr1:163392909	NA	-0.62	-5.65	-0.5	1.69e-7	Motion sickness;
THYM	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg00898013	chr13:113819073	PROZ	-0.89	-9.2	-0.69	8.65e-15	Platelet distribution width;
THYM	cis	rs12142240	0.698	rs6679898	chr1:46820589	A/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7119	0.717	rs7181283	chr15:77814544	G/A	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg16928487	chr17:17741425	SREBF1	-0.56	-5.53	-0.49	2.81e-7	Total body bone mineral density;
THYM	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg22467129	chr15:76604101	ETFA	-0.5	-4.94	-0.45	3.32e-6	Blood metabolite levels;
THYM	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg19346786	chr7:2764209	NA	-0.71	-6.01	-0.53	3.36e-8	Height;
THYM	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg09021430	chr5:549028	NA	-0.6	-5.64	-0.5	1.71e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs11690935	0.959	rs973889	chr2:172579954	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-6.5	-0.55	3.76e-9	Schizophrenia;
THYM	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.6	-5.03	-0.46	2.3e-6	Coronary artery disease;
THYM	cis	rs73036520	0.560	rs346750	chr19:45737218	G/T	cg01416317	chr19:45737208	EXOC3L2	-0.62	-5.01	-0.46	2.52e-6	Monocyte percentage of white cells;
THYM	cis	rs2039659	0.719	rs1011902	chr13:86278911	T/C	cg25308322	chr13:86268291	NA	0.59	4.94	0.45	3.39e-6	Blood osmolality (transformed sodium);
THYM	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg13918804	chr1:2043761	PRKCZ	0.77	7.51	0.61	3.18e-11	Height;
THYM	cis	rs3772130	0.924	rs55643643	chr3:121440197	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.76	4.85	0.45	4.78e-6	Cognitive performance;
THYM	cis	rs9807841	0.670	rs2738039	chr19:10793749	A/G	cg16900796	chr19:10755136	SLC44A2	0.33	5.08	0.46	1.88e-6	Inflammatory skin disease;
THYM	cis	rs2276314	1.000	rs9304153	chr18:33562150	T/C	cg19628046	chr18:33552617	C18orf21	0.79	5.46	0.49	3.74e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12348691	0.503	rs894672	chr9:100612185	C/T	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Alopecia areata;
THYM	cis	rs600806	0.888	rs4970749	chr1:109873573	G/A	cg23032129	chr1:109941072	SORT1	-0.57	-4.84	-0.44	5.11e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2456568	0.867	rs2456569	chr11:93691393	C/A	cg17595323	chr11:93583763	C11orf90	-0.52	-5.05	-0.46	2.13e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs6032067	0.777	rs56063128	chr20:43783210	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg04842962	chr6:43655489	MRPS18A	1.4	15.42	0.85	1.3e-27	IgG glycosylation;
THYM	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg09035930	chr12:129282057	SLC15A4	0.87	11.78	0.77	2.86e-20	Systemic lupus erythematosus;
THYM	cis	rs1389724	0.648	rs1908298	chr1:111316215	C/T	cg25283465	chr1:111323341	NA	0.58	4.58	0.43	1.4e-5	Schizophrenia;
THYM	cis	rs7584330	0.554	rs3751110	chr2:238427142	T/C	cg08992911	chr2:238395768	MLPH	0.85	5.39	0.48	5.19e-7	Prostate cancer;
THYM	cis	rs2731664	0.792	rs652242	chr5:176873010	C/G	cg14098951	chr5:176875120	PRR7	0.56	5.05	0.46	2.1e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10186029	0.648	rs13022006	chr2:213940309	A/C	cg08319019	chr2:214017104	IKZF2	0.91	7.53	0.61	2.93e-11	Systemic sclerosis;
THYM	cis	rs1978968	0.525	rs4819649	chr22:18396329	A/C	cg03078520	chr22:18463400	MICAL3	0.58	4.67	0.43	1.01e-5	Presence of antiphospholipid antibodies;
THYM	cis	rs3858526	0.651	rs10838713	chr11:5858434	T/C	cg25319279	chr11:5960081	NA	-0.6	-4.67	-0.43	9.71e-6	DNA methylation (variation);
THYM	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12667521	chr19:29218732	NA	0.89	8.17	0.64	1.34e-12	Methadone dose in opioid dependence;
THYM	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg10047753	chr17:41438598	NA	1.16	10.76	0.74	3.96e-18	Menopause (age at onset);
THYM	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg03709012	chr19:19516395	GATAD2A	0.76	6.05	0.53	2.87e-8	Tonsillectomy;
THYM	cis	rs6430585	0.583	rs58116536	chr2:136585323	C/T	cg07169764	chr2:136633963	MCM6	1.21	14.22	0.82	2.97e-25	Corneal structure;
THYM	cis	rs754466	0.651	rs11002317	chr10:79617648	G/A	cg17075019	chr10:79541650	NA	-0.69	-5.92	-0.52	5.14e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs76693355	0.850	rs2282537	chr11:120187971	A/G	cg09120934	chr11:120187999	POU2F3	0.38	4.71	0.44	8.39e-6	Intraocular pressure;
THYM	cis	rs11771526	0.901	rs62457470	chr7:32303516	A/G	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs67981189	0.821	rs8007026	chr14:71464384	C/G	cg15910301	chr14:71632612	NA	0.5	4.7	0.43	8.69e-6	Schizophrenia;
THYM	cis	rs6598955	0.671	rs10902735	chr1:26617936	C/T	cg08133631	chr1:26527909	CATSPER4	-0.57	-4.68	-0.43	9.33e-6	Obesity-related traits;
THYM	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg26597838	chr10:835615	NA	1.21	8.65	0.66	1.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02788857	chr8:22132959	PIWIL2	0.61	5.78	0.51	9.47e-8	Hypertriglyceridemia;
THYM	cis	rs7027203	0.828	rs10122041	chr9:96615517	A/G	cg13679303	chr9:96623674	NA	-0.5	-5.08	-0.46	1.89e-6	DNA methylation (variation);
THYM	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg15388900	chr16:88312269	NA	0.6	4.57	0.42	1.48e-5	Social autistic-like traits;
THYM	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg00383909	chr3:49044727	WDR6	1.07	6.29	0.54	9.72e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs7799006	0.593	rs12531150	chr7:2289888	C/T	cg08027265	chr7:2291960	NA	-0.45	-5.37	-0.48	5.47e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg11461670	chr8:22454935	PDLIM2	-0.34	-6.23	-0.54	1.25e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2073300	1.000	rs6137971	chr20:23456429	G/T	cg12062639	chr20:23401060	NAPB	1.32	6.2	0.54	1.42e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg04234412	chr22:24373322	LOC391322	-0.89	-10.0	-0.72	1.61e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12478296	1.000	rs55742408	chr2:243041077	G/A	cg06360820	chr2:242988706	NA	-0.94	-5.73	-0.51	1.17e-7	Obesity-related traits;
THYM	cis	rs6430585	0.583	rs59243420	chr2:136584538	A/T	cg04750100	chr2:136595281	LCT	0.53	5.03	0.46	2.31e-6	Corneal structure;
THYM	cis	rs3820068	0.608	rs2057304	chr1:16017710	A/G	cg13390004	chr1:15929781	NA	0.65	4.87	0.45	4.52e-6	Systolic blood pressure;
THYM	cis	rs17376456	0.569	rs12653528	chr5:93212833	T/C	cg25358565	chr5:93447407	FAM172A	-0.91	-6.59	-0.56	2.49e-9	Diabetic retinopathy;
THYM	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg19346786	chr7:2764209	NA	-0.56	-4.72	-0.44	7.96e-6	Height;
THYM	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg06026331	chr20:60912101	LAMA5	-0.62	-4.94	-0.45	3.34e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs3741151	1.000	rs7930880	chr11:73068769	A/C	cg12959048	chr11:73096162	RELT	-0.43	-4.55	-0.42	1.61e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg27129171	chr3:47204927	SETD2	0.67	6.37	0.55	6.79e-9	Colorectal cancer;
THYM	cis	rs11250464	0.833	rs2387653	chr10:1407826	A/G	cg08668359	chr10:1443807	ADARB2	-0.64	-5.69	-0.5	1.4e-7	Radiation response;
THYM	cis	rs35160687	0.722	rs6728029	chr2:86555381	C/T	cg10973622	chr2:86423274	IMMT	-0.52	-4.82	-0.44	5.35e-6	Night sleep phenotypes;
THYM	cis	rs6074022	0.743	rs2425752	chr20:44702120	C/T	cg20003638	chr20:44687730	SLC12A5	0.76	5.21	0.47	1.1e-6	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
THYM	cis	rs2229238	0.826	rs111742980	chr1:154508764	T/A	cg21262032	chr1:154437693	IL6R	-0.63	-5.65	-0.5	1.68e-7	Coronary heart disease;
THYM	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg09165964	chr15:75287851	SCAMP5	-1.08	-10.64	-0.74	7.02e-18	Blood trace element (Zn levels);
THYM	cis	rs9905704	0.918	rs302880	chr17:56761411	C/T	cg12560992	chr17:57184187	TRIM37	0.67	4.68	0.43	9.59e-6	Testicular germ cell tumor;
THYM	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12923728	chr3:195709715	SDHAP1	-0.78	-6.38	-0.55	6.41e-9	Pancreatic cancer;
THYM	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg17757837	chr7:157058334	UBE3C	-0.66	-5.33	-0.48	6.62e-7	Body mass index;
THYM	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg06115741	chr20:33292138	TP53INP2	0.69	4.55	0.42	1.57e-5	Coronary artery disease;
THYM	cis	rs10140922	0.864	rs72666622	chr14:35820138	T/A	cg07166546	chr14:35805898	NA	-0.26	-6.42	-0.55	5.39e-9	Hip circumference adjusted for BMI;
THYM	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-5.98	-0.52	3.86e-8	Prostate cancer;
THYM	cis	rs7172677	0.961	rs62027287	chr15:75429721	A/C	cg09165964	chr15:75287851	SCAMP5	-0.63	-4.75	-0.44	7.24e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg18477163	chr1:228402036	OBSCN	0.57	6.22	0.54	1.36e-8	Diastolic blood pressure;
THYM	cis	rs28595532	0.925	rs28627331	chr4:119665345	T/C	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.85	7.7	0.62	1.29e-11	Intelligence (multi-trait analysis);
THYM	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg09033563	chr22:24373618	LOC391322	-0.62	-6.01	-0.53	3.34e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2290159	0.800	rs9817675	chr3:12676113	C/T	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg20887711	chr4:1340912	KIAA1530	-0.82	-7.15	-0.59	1.74e-10	Longevity;
THYM	cis	rs986417	1.000	rs1955699	chr14:61045989	A/G	cg27398547	chr14:60952738	C14orf39	1.21	6.17	0.53	1.69e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs4455778	0.580	rs10229899	chr7:49110363	C/T	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs944722	0.749	rs8081248	chr17:26081964	A/G	cg07704981	chr17:26127537	NOS2	-0.49	-4.49	-0.42	1.99e-5	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs59698941	0.843	rs61541414	chr5:132226106	G/A	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.5	0.42	1.9e-5	Apolipoprotein A-IV levels;
THYM	cis	rs5769707	0.604	rs1018814	chr22:50036900	T/C	cg07959070	chr22:50026188	C22orf34	-0.28	-4.98	-0.46	2.82e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4474465	1.000	rs10899525	chr11:78201454	T/G	cg19901956	chr11:77921274	USP35	-0.65	-4.8	-0.44	5.97e-6	Alzheimer's disease (survival time);
THYM	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg24060327	chr5:131705240	SLC22A5	-0.7	-5.29	-0.48	7.83e-7	Blood metabolite levels;
THYM	cis	rs59482735	1	rs59482735	chr9:123643426	T/TAA	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	4.64	0.43	1.11e-5	Prostate-specific antigen levels;
THYM	cis	rs28595532	0.920	rs114751999	chr4:119759651	G/A	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	trans	rs28595532	1.000	rs75497896	chr4:119636703	T/C	cg13773247	chr2:42276988	PKDCC	0.89	6.93	0.58	4.92e-10	Cannabis dependence symptom count;
THYM	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg10852096	chr15:79043040	NA	0.65	4.5	0.42	1.91e-5	Coronary artery disease or large artery stroke;
THYM	cis	rs2282300	0.696	rs12578061	chr11:30249365	T/A	cg25418670	chr11:30344373	C11orf46	-0.81	-6.87	-0.58	6.66e-10	Morning vs. evening chronotype;
THYM	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.25	10.07	0.72	1.18e-16	Platelet count;
THYM	cis	rs5417	0.761	rs6503010	chr17:7180435	C/T	cg15298719	chr17:7165255	CLDN7	-0.36	-5.16	-0.47	1.34e-6	Diastolic blood pressure;
THYM	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg12419862	chr22:24373484	LOC391322	0.76	7.23	0.6	1.19e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	4.96	0.45	3.13e-6	Motion sickness;
THYM	cis	rs8067354	0.645	rs9910518	chr17:57812067	T/C	cg20151207	chr17:57696971	CLTC	-0.7	-4.67	-0.43	9.76e-6	Hemoglobin concentration;
THYM	cis	rs4660306	0.677	rs781062	chr1:45932738	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.66	4.74	0.44	7.56e-6	Homocysteine levels;
THYM	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg24642439	chr20:33292090	TP53INP2	0.68	5.14	0.47	1.47e-6	Coronary artery disease;
THYM	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg05283184	chr6:79620031	NA	-0.92	-9.26	-0.69	6.35e-15	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs7814319	0.646	rs938828	chr8:97316821	A/C	cg20787634	chr8:97240163	UQCRB	-0.62	-6.5	-0.55	3.78e-9	Lung function (FVC);
THYM	cis	rs12291225	0.585	rs10832246	chr11:14380828	G/A	cg19336497	chr11:14380999	RRAS2	-0.91	-13.68	-0.81	3.58e-24	Sense of smell;
THYM	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs9929218	0.906	rs10852450	chr16:68749529	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.91	-7.97	-0.63	3.47e-12	Colorectal cancer;
THYM	cis	rs10214930	0.957	rs10230973	chr7:27782924	T/A	cg04422003	chr7:28448295	CREB5	-0.62	-4.62	-0.43	1.19e-5	Hypospadias;
THYM	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg06028605	chr16:24865363	SLC5A11	0.58	5.69	0.5	1.42e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg20283391	chr11:68216788	NA	-0.74	-5.43	-0.49	4.25e-7	Total body bone mineral density;
THYM	cis	rs7107174	1.000	rs4245459	chr11:78065959	T/G	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs994014	0.804	rs2011962	chr4:82220324	A/C	cg17825130	chr4:82283507	NA	0.53	4.76	0.44	6.98e-6	Height;
THYM	cis	rs3741151	0.773	rs7931767	chr11:73239207	A/G	cg17517138	chr11:73019481	ARHGEF17	0.9	4.73	0.44	7.74e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg25487775	chr2:162093969	NA	0.68	5.82	0.51	8e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg14798641	chr3:49314920	USP4;C3orf62	-0.69	-4.69	-0.43	9.23e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg11301795	chr4:187892539	NA	-1.11	-17.65	-0.88	9.45e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07167872	chr1:205819463	PM20D1	0.99	9.9	0.71	2.71e-16	Menarche (age at onset);
THYM	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg14784868	chr12:69753453	YEATS4	1.12	10.87	0.74	2.32e-18	Blood protein levels;
THYM	cis	rs4400599	1.000	rs4540651	chr1:154128672	G/A	cg05139571	chr1:154127138	NUP210L	0.54	4.6	0.43	1.33e-5	Platelet distribution width;
THYM	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg06453172	chr10:134556979	INPP5A	-0.67	-4.84	-0.44	5.1e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs12148329	0.545	rs12591734	chr15:81026638	A/G	cg01654770	chr15:80543586	NA	-0.85	-4.54	-0.42	1.63e-5	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg24397884	chr7:158709396	WDR60	0.42	4.94	0.45	3.29e-6	Height;
THYM	cis	rs981844	0.740	rs10024619	chr4:154684441	A/T	cg09973105	chr4:154681532	RNF175	0.54	4.98	0.45	2.88e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg22764591	chr12:58329936	NA	0.84	5.9	0.52	5.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6840360	0.571	rs1978955	chr4:152509509	G/A	cg17479576	chr4:152424074	FAM160A1	-0.8	-5.65	-0.5	1.68e-7	Intelligence (multi-trait analysis);
THYM	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.68	5.84	0.51	7.34e-8	Birth weight;
THYM	cis	rs1994135	0.669	rs11052747	chr12:33697913	C/G	cg10856724	chr12:34555212	NA	-0.7	-5.59	-0.5	2.2e-7	Resting heart rate;
THYM	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg09238746	chr17:78121135	EIF4A3	-1.12	-9.31	-0.69	4.99e-15	Yeast infection;
THYM	cis	rs6723226	1.000	rs6723226	chr2:32849207	C/T	cg02381751	chr2:32503542	YIPF4	0.61	4.99	0.46	2.71e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4460079	0.531	rs10001850	chr4:114833650	T/C	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs9303401	0.703	rs9910629	chr17:57210301	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.71	5.21	0.47	1.1e-6	Cognitive test performance;
THYM	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg05731713	chr7:157510257	PTPRN2	0.51	5.16	0.47	1.35e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	6.08	0.53	2.49e-8	Obesity-related traits;
THYM	cis	rs9933309	1.000	rs9933309	chr16:88844932	A/G	cg00153919	chr16:88859944	NA	0.62	5.28	0.48	8e-7	Glycated hemoglobin levels;
THYM	cis	rs2229238	0.911	rs60760897	chr1:154504849	C/T	cg21262032	chr1:154437693	IL6R	-0.63	-5.65	-0.5	1.68e-7	Coronary heart disease;
THYM	cis	rs7216064	1.000	rs62084246	chr17:65867911	G/C	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg23803603	chr1:2058230	PRKCZ	-0.58	-4.63	-0.43	1.17e-5	Height;
THYM	cis	rs78472555	0.954	rs2123926	chr15:100264518	T/C	cg18869061	chr15:100272053	LYSMD4	-0.8	-4.69	-0.43	9.03e-6	Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg13736514	chr6:26305472	NA	-0.61	-7.45	-0.61	4.16e-11	Educational attainment;
THYM	cis	rs9914988	0.887	rs2070265	chr17:27075423	A/G	cg20469991	chr17:27169893	C17orf63	0.77	4.87	0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.73	7.65	0.62	1.64e-11	Eosinophil percentage of white cells;
THYM	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs11756438	0.572	rs1844963	chr6:119002679	C/G	cg21191810	chr6:118973309	C6orf204	0.57	5.48	0.49	3.52e-7	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg13683864	chr3:40499215	RPL14	1.07	12.42	0.79	1.31e-21	Renal cell carcinoma;
THYM	cis	rs57920188	0.535	rs112660254	chr1:4089921	T/G	cg20703997	chr1:4087676	NA	0.89	5.65	0.5	1.68e-7	Interleukin-17 levels;
THYM	cis	rs7599762	0.882	rs10929232	chr2:238321676	C/T	cg25591469	chr2:238322789	COL6A3	-0.41	-4.94	-0.45	3.29e-6	Intraocular pressure;
THYM	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg10803722	chr21:46713166	LOC642852	-0.5	-6.52	-0.56	3.44e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg27490568	chr2:178487706	NA	0.6	5.16	0.47	1.32e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2806561	0.894	rs629107	chr1:23537971	C/T	cg19743168	chr1:23544995	NA	0.7	7.69	0.62	1.38e-11	Height;
THYM	cis	rs425535	0.757	rs4694656	chr4:74811199	G/A	cg07868155	chr4:74864709	CXCL5	0.63	4.47	0.42	2.15e-5	Blood protein levels;
THYM	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg18538332	chr22:24372958	LOC391322	1.09	14.7	0.83	3.24e-26	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6032067	0.866	rs1007137	chr20:43816593	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.67	-7.66	-0.62	1.54e-11	Blood protein levels;
THYM	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.51	0.81	7.55e-24	Height;
THYM	cis	rs28595532	0.925	rs56200441	chr4:119497440	T/G	cg14228332	chr4:119757509	SEC24D	1.38	4.98	0.45	2.89e-6	Cannabis dependence symptom count;
THYM	cis	rs6032067	0.639	rs62205502	chr20:43864197	G/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-6.24	-0.54	1.22e-8	Blood protein levels;
THYM	cis	rs28595532	0.920	rs114639588	chr4:119736176	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg22467129	chr15:76604101	ETFA	-0.51	-5.02	-0.46	2.42e-6	Blood metabolite levels;
THYM	cis	rs9929218	0.559	rs12923775	chr16:68756450	C/T	cg01251360	chr16:68772225	CDH1	-0.29	-4.53	-0.42	1.74e-5	Colorectal cancer;
THYM	trans	rs8002861	0.875	rs12867890	chr13:44423088	A/G	cg17145862	chr1:211918768	LPGAT1	-0.95	-9.18	-0.69	9.16e-15	Leprosy;
THYM	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg06623918	chr6:96969491	KIAA0776	1.09	10.37	0.73	2.65e-17	Headache;
THYM	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.79	-5.26	-0.47	8.93e-7	Schizophrenia;
THYM	cis	rs7246967	0.544	rs391308	chr19:23009560	T/C	cg05241461	chr19:22816980	ZNF492	0.55	4.67	0.43	1e-5	Bronchopulmonary dysplasia;
THYM	cis	rs524281	0.647	rs2302883	chr11:65824994	T/C	cg00563793	chr11:65837595	PACS1	0.71	4.99	0.46	2.76e-6	Electroencephalogram traits;
THYM	cis	rs4363385	0.818	rs1750309	chr1:153013630	G/C	cg13444842	chr1:152974279	SPRR3	-0.59	-4.83	-0.44	5.24e-6	Inflammatory skin disease;
THYM	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.76	0.44	6.99e-6	Aortic root size;
THYM	cis	rs9326248	0.539	rs10892058	chr11:116876621	C/T	cg20608306	chr11:116969690	SIK3	0.58	6.98	0.58	4.04e-10	Blood protein levels;
THYM	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg18105134	chr13:113819100	PROZ	-0.98	-9.11	-0.68	1.32e-14	Platelet distribution width;
THYM	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg14972814	chr11:95582409	MTMR2	-0.58	-5.3	-0.48	7.56e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg08498830	chr11:832797	CD151	-0.62	-4.51	-0.42	1.82e-5	Mean platelet volume;
THYM	cis	rs2985684	0.802	rs10150823	chr14:50051751	C/T	cg02151108	chr14:50098012	C14orf104	-0.69	-5.7	-0.5	1.34e-7	Carotid intima media thickness;
THYM	cis	rs11264213	0.901	rs811114	chr1:36345758	G/A	cg27506609	chr1:36549197	TEKT2	0.92	4.83	0.44	5.3e-6	Schizophrenia;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg06963192	chr1:172557938	C1orf9	-0.91	-6.87	-0.58	6.74e-10	Depressive symptoms;
THYM	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	9.39	0.69	3.37e-15	Chronic sinus infection;
THYM	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg25554036	chr4:6271136	WFS1	0.59	5.47	0.49	3.68e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs2340727	0.668	rs3767636	chr1:161817031	T/A	cg06514368	chr1:161719587	DUSP12	-0.81	-4.62	-0.43	1.2e-5	White blood cell count;Hematology traits;
THYM	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg27572855	chr1:25598939	RHD	0.65	5.12	0.47	1.58e-6	Erythrocyte sedimentation rate;
THYM	cis	rs7312774	0.618	rs7975954	chr12:107345750	C/T	cg16260113	chr12:107380972	MTERFD3	1.3	6.63	0.56	2.04e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs714031	1.000	rs5757765	chr22:40067840	T/C	cg21377881	chr22:40064566	CACNA1I	-0.59	-5.32	-0.48	6.98e-7	Schizophrenia;
THYM	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg01448562	chr3:133502909	NA	-0.82	-6.84	-0.57	7.51e-10	Iron status biomarkers;
THYM	cis	rs11997175	0.624	rs79944133	chr8:33730588	A/G	ch.8.33884649F	chr8:33765107	NA	0.74	5.12	0.46	1.6e-6	Body mass index;
THYM	cis	rs6570726	0.967	rs439017	chr6:145806123	T/C	cg23711669	chr6:146136114	FBXO30	0.88	8.52	0.66	2.34e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4589258	0.788	rs10741365	chr11:90490863	A/T	cg26138821	chr11:89956704	CHORDC1	0.55	4.52	0.42	1.81e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1847202	0.563	rs13095184	chr3:72951008	A/G	cg27402429	chr3:72788294	NA	-0.71	-4.55	-0.42	1.56e-5	Motion sickness;
THYM	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs4650994	1.000	rs6660445	chr1:178528871	C/T	cg05059571	chr16:84539110	KIAA1609	-0.75	-8.15	-0.64	1.43e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg17554472	chr22:41940697	POLR3H	-0.71	-5.02	-0.46	2.42e-6	Vitiligo;
THYM	cis	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg06521331	chr12:34319734	NA	-0.96	-8.88	-0.67	4.06e-14	Morning vs. evening chronotype;
THYM	trans	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.09	-7.38	-0.6	5.96e-11	Body mass index;
THYM	cis	rs8038465	0.622	rs17185294	chr15:73858415	C/T	cg15420318	chr15:73925796	NPTN	-0.63	-5.56	-0.5	2.49e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg07570687	chr10:102243282	WNT8B	-0.74	-6.46	-0.55	4.49e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg08736216	chr1:53307985	ZYG11A	0.59	5.54	0.49	2.74e-7	Monocyte count;
THYM	cis	rs6430585	0.528	rs309119	chr2:136710372	T/C	cg07169764	chr2:136633963	MCM6	0.95	8.49	0.66	2.72e-13	Corneal structure;
THYM	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg08885076	chr2:99613938	TSGA10	-0.66	-6.08	-0.53	2.47e-8	Chronic sinus infection;
THYM	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-6.68	-0.57	1.63e-9	Alzheimer's disease (late onset);
THYM	cis	rs12681287	0.547	rs7837569	chr8:87507366	C/T	cg27223183	chr8:87520930	FAM82B	-0.71	-5.46	-0.49	3.8e-7	Caudate activity during reward;
THYM	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg03676636	chr4:99064102	C4orf37	0.45	6.84	0.57	7.55e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61931739	0.853	rs10844751	chr12:34099651	T/G	cg10856724	chr12:34555212	NA	0.6	5.27	0.48	8.53e-7	Morning vs. evening chronotype;
THYM	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg25811766	chr13:21894605	NA	-0.78	-5.02	-0.46	2.38e-6	White matter hyperintensity burden;
THYM	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg16778714	chr17:28903809	LRRC37B2	-0.76	-4.49	-0.42	2.03e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4790333	0.537	rs2447106	chr17:2257819	A/T	cg02569219	chr17:2266849	SGSM2	-0.7	-5.87	-0.52	6.33e-8	Proinsulin levels;
THYM	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg18758796	chr5:131593413	PDLIM4	0.5	4.74	0.44	7.49e-6	Breast cancer;
THYM	cis	rs11077998	0.933	rs2291395	chr17:80526139	A/G	cg10255544	chr17:80519551	FOXK2	0.51	4.51	0.42	1.84e-5	Reticulocyte fraction of red cells;
THYM	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg18876405	chr7:65276391	NA	0.56	4.64	0.43	1.09e-5	Aortic root size;
THYM	cis	rs946836	0.562	rs12739172	chr1:48367471	C/T	cg18376692	chr1:48452465	NA	-0.52	-5.08	-0.46	1.84e-6	White matter integrity;
THYM	cis	rs8078723	0.738	rs8066582	chr17:38146929	A/G	cg17467752	chr17:38218738	THRA	-0.81	-6.74	-0.57	1.2e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs7586879	0.752	rs11683748	chr2:25130434	C/T	cg01884057	chr2:25150051	NA	0.52	4.61	0.43	1.28e-5	Body mass index;
THYM	cis	rs642803	0.933	rs644740	chr11:65561468	C/T	cg17480646	chr11:65405466	SIPA1	0.63	4.66	0.43	1.01e-5	Urate levels;
THYM	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg18105134	chr13:113819100	PROZ	1.05	9.76	0.71	5.26e-16	Platelet distribution width;
THYM	cis	rs7937840	0.581	rs4963286	chr11:61887232	C/A	cg05871569	chr11:61891931	INCENP	0.62	4.74	0.44	7.5e-6	Breast cancer;
THYM	cis	rs941408	0.964	rs1736186	chr19:2815372	A/G	cg19693284	chr19:2783607	SGTA	0.67	5.17	0.47	1.3e-6	Total cholesterol levels;
THYM	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg12935359	chr14:103987150	CKB	-0.53	-6.3	-0.54	9.24e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9361491	0.657	rs9343801	chr6:79462275	G/A	cg04547799	chr6:79944526	HMGN3	-0.66	-4.58	-0.43	1.41e-5	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg06521331	chr12:34319734	NA	-0.95	-9.13	-0.68	1.19e-14	Morning vs. evening chronotype;
THYM	cis	rs6424115	0.867	rs34902309	chr1:24192200	A/G	cg15997130	chr1:24165203	NA	-0.69	-5.81	-0.51	8.25e-8	Immature fraction of reticulocytes;
THYM	cis	rs59698941	0.943	rs57880964	chr5:132210674	G/C	cg02081065	chr5:132209139	LEAP2	-0.85	-5.74	-0.51	1.14e-7	Apolipoprotein A-IV levels;
THYM	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg13918804	chr1:2043761	PRKCZ	0.84	7.49	0.61	3.51e-11	Height;
THYM	cis	rs1728785	0.901	rs1631910	chr16:68603335	G/A	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	trans	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10276381	0.579	rs73072539	chr7:28146255	C/G	cg23204968	chr7:27183816	HOXA5	0.62	4.46	0.42	2.25e-5	Crohn's disease;
THYM	cis	rs2294693	0.891	rs1072119	chr6:40993072	G/A	cg14418226	chr6:40996092	UNC5CL	0.75	6.53	0.56	3.18e-9	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22496380	chr5:211416	CCDC127	1.35	8.74	0.67	8.11e-14	Breast cancer;
THYM	cis	rs684232	0.623	rs12601935	chr17:519325	G/A	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.39	-4.77	-0.44	6.73e-6	Prostate cancer;
THYM	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	13.06	0.8	6.27e-23	Height;
THYM	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.32	0.54	8.42e-9	Platelet count;
THYM	cis	rs57590327	0.528	rs2229519	chr3:81698130	T/C	cg07356753	chr3:81810745	GBE1	-0.84	-5.95	-0.52	4.37e-8	Extraversion;
THYM	cis	rs4660306	1.000	rs10157597	chr1:45990278	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.4	-0.48	4.87e-7	Homocysteine levels;
THYM	cis	rs985746	0.614	rs2045584	chr4:36812644	C/T	cg04301614	chr4:37585993	C4orf19	-0.55	-4.53	-0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs7843479	0.562	rs11774629	chr8:21859315	C/T	cg17168535	chr8:21777572	XPO7	0.81	7.06	0.59	2.76e-10	Mean corpuscular volume;
THYM	cis	rs2282300	1.000	rs12575085	chr11:30428262	G/T	cg25418670	chr11:30344373	C11orf46	-0.65	-5.06	-0.46	2.08e-6	Morning vs. evening chronotype;
THYM	cis	rs73198271	1.000	rs55971558	chr8:8614403	G/T	cg06636001	chr8:8085503	FLJ10661	-0.78	-5.01	-0.46	2.47e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4959799	0.655	rs61422318	chr6:3287916	T/G	cg05248351	chr6:4032322	PRPF4B	1.29	4.52	0.42	1.76e-5	Survival in rectal cancer;
THYM	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg08999081	chr20:33150536	PIGU	-0.77	-6.73	-0.57	1.3e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs3087591	0.922	rs12950506	chr17:29598392	A/G	cg24425628	chr17:29625626	OMG;NF1	0.63	5.38	0.48	5.3e-7	Hip circumference;
THYM	cis	rs7592578	0.679	rs59929070	chr2:191327852	A/G	cg11845111	chr2:191398756	TMEM194B	-0.96	-7.22	-0.6	1.26e-10	Diastolic blood pressure;
THYM	cis	rs3087591	1.000	rs7406983	chr17:29703374	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.61	-5.11	-0.46	1.63e-6	Hip circumference;
THYM	cis	rs1003719	0.788	rs2835597	chr21:38466539	C/T	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg03929089	chr4:120376271	NA	-1.01	-13.5	-0.81	8.23e-24	Height;
THYM	cis	rs886774	0.526	rs11978486	chr7:107500560	A/G	cg23293999	chr7:106826042	HBP1	-0.58	-4.64	-0.43	1.12e-5	Ulcerative colitis;
THYM	cis	rs11096990	0.892	rs11937540	chr4:39181517	A/G	cg24403649	chr4:39172243	NA	-0.66	-5.59	-0.5	2.14e-7	Cognitive function;
THYM	cis	rs11910985	0.546	rs113970410	chr21:48080896	C/G	cg17243659	chr21:48055224	PRMT2	1.36	6.3	0.54	9.09e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg00383909	chr3:49044727	WDR6	1.22	7.2	0.59	1.39e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg09462578	chr12:12878428	APOLD1	-1.11	-11.47	-0.76	1.24e-19	Lymphocyte counts;
THYM	cis	rs9992101	0.645	rs61402764	chr4:77327339	C/T	cg20311846	chr4:77356250	SHROOM3	-0.53	-5.83	-0.51	7.6e-8	Creatinine levels;
THYM	cis	rs611744	0.905	rs408506	chr8:109154233	A/C	cg21045802	chr8:109455806	TTC35	-0.57	-4.91	-0.45	3.8e-6	Dupuytren's disease;
THYM	cis	rs10057188	0.569	rs10037240	chr5:77920183	T/C	cg02642549	chr5:77805886	LHFPL2	0.53	4.5	0.42	1.95e-5	Pulse pressure;
THYM	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	4.96	0.45	3.07e-6	Hip circumference adjusted for BMI;
THYM	cis	rs6430585	0.528	rs78274583	chr2:136734569	C/T	cg23851026	chr2:136556271	LCT	0.78	6.95	0.58	4.47e-10	Corneal structure;
THYM	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg10515332	chr4:99064459	C4orf37	0.71	4.49	0.42	1.99e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg10589385	chr1:150898437	SETDB1	0.64	5.24	0.47	9.73e-7	Melanoma;
THYM	cis	rs859767	0.741	rs10803548	chr2:135396738	C/A	cg12500956	chr2:135428796	TMEM163	-0.51	-5.09	-0.46	1.78e-6	Neuroticism;
THYM	cis	rs1551570	0.755	rs11667630	chr19:10229297	A/C	cg07753644	chr19:10222175	PPAN-P2RY11;P2RY11	0.43	4.71	0.43	8.52e-6	Narcolepsy;
THYM	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22590775	chr19:49891494	CCDC155	0.63	4.8	0.44	5.89e-6	Multiple sclerosis;
THYM	cis	rs7119	0.604	rs939488	chr15:77867780	T/C	cg10437265	chr15:77819839	NA	-0.7	-6.99	-0.58	3.77e-10	Type 2 diabetes;
THYM	cis	rs916888	0.558	rs199521	chr17:44853456	G/C	cg17911788	chr17:44343683	NA	0.54	5.13	0.47	1.51e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2282300	0.956	rs2685286	chr11:30381588	G/A	cg06241208	chr11:30344200	C11orf46	-0.8	-5.64	-0.5	1.73e-7	Morning vs. evening chronotype;
THYM	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg10523679	chr1:76189770	ACADM	0.89	8.64	0.66	1.32e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg15704280	chr7:45808275	SEPT13	-1.04	-13.94	-0.82	1.07e-24	Height;
THYM	cis	rs12930096	0.878	rs12917676	chr16:11680268	A/G	cg00403955	chr16:11680241	LITAF	-0.46	-4.72	-0.44	8.1e-6	QT interval;
THYM	cis	rs250677	0.522	rs4562031	chr5:148368451	A/G	cg18129178	chr5:148520854	ABLIM3	0.72	5.38	0.48	5.29e-7	Breast cancer;
THYM	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg02153584	chr22:29168773	CCDC117	0.64	4.94	0.45	3.36e-6	Lymphocyte counts;
THYM	cis	rs12643440	0.538	rs1522079	chr4:17134960	A/G	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg03806693	chr22:41940476	POLR3H	1.05	9.57	0.7	1.37e-15	Vitiligo;
THYM	cis	rs2276498	0.751	rs2299715	chr20:52639242	T/G	cg23682609	chr20:52687365	BCAS1	0.56	4.57	0.42	1.45e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg12379764	chr21:47803548	PCNT	-0.79	-5.07	-0.46	1.95e-6	Testicular germ cell tumor;
THYM	cis	rs420259	0.516	rs4968014	chr16:23523875	G/T	cg00143387	chr16:23521605	GGA2	-0.71	-4.96	-0.45	3.05e-6	Bipolar disorder;
THYM	cis	rs6546324	0.625	rs2902025	chr2:67842424	A/G	cg18237512	chr2:67827392	NA	-0.8	-4.77	-0.44	6.69e-6	Endometriosis;
THYM	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg14004847	chr7:1930337	MAD1L1	-0.65	-4.6	-0.43	1.3e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg06360820	chr2:242988706	NA	-1.08	-6.69	-0.57	1.56e-9	Obesity-related traits;
THYM	cis	rs10992471	0.603	rs10992342	chr9:95212068	C/T	cg14631576	chr9:95140430	CENPP	-0.99	-9.94	-0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs868036	0.681	rs28376010	chr15:68063739	G/T	cg24579218	chr15:68104479	NA	-0.81	-7.73	-0.62	1.12e-11	Restless legs syndrome;
THYM	cis	rs2108225	0.872	rs2051954	chr7:107441097	G/C	cg18560240	chr7:107437656	SLC26A3	-0.88	-6.44	-0.55	4.82e-9	Ulcerative colitis;
THYM	cis	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg10856724	chr12:34555212	NA	-0.87	-7.69	-0.62	1.32e-11	Morning vs. evening chronotype;
THYM	cis	rs7794273	0.963	rs2588637	chr7:18854186	C/T	cg13420273	chr7:18810212	HDAC9	0.54	4.47	0.42	2.15e-5	Night sleep phenotypes;
THYM	cis	rs6429082	0.608	rs4659838	chr1:235565315	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.62	-4.62	-0.43	1.19e-5	Adiposity;
THYM	cis	rs2625529	0.824	rs55854204	chr15:72433182	C/T	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg23711669	chr6:146136114	FBXO30	0.91	9.57	0.7	1.4e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg23711669	chr6:146136114	FBXO30	0.89	8.8	0.67	5.96e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11031096	0.621	rs11031159	chr11:4179695	T/G	cg22027985	chr11:4115532	RRM1	-0.53	-4.96	-0.45	3.07e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg22907277	chr7:1156413	C7orf50	0.8	4.85	0.45	4.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22857025	chr5:266934	NA	-1.43	-9.3	-0.69	5.28e-15	Breast cancer;
THYM	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg00376283	chr12:123451042	ABCB9	-0.81	-6.72	-0.57	1.32e-9	Neutrophil percentage of white cells;
THYM	cis	rs12893597	0.580	rs12586708	chr14:76840497	C/T	cg20290672	chr14:76816747	NA	0.55	4.54	0.42	1.67e-5	Maximal oxygen uptake response;
THYM	cis	rs8017423	0.967	rs7147809	chr14:90715025	A/G	cg04239629	chr14:90701769	NA	-0.62	-4.52	-0.42	1.81e-5	Mortality in heart failure;
THYM	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg16342193	chr10:102329863	NA	-0.6	-6.21	-0.54	1.41e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs8180040	0.767	rs11920853	chr3:47308183	G/A	cg16586182	chr3:47516702	SCAP	0.69	6.0	0.52	3.63e-8	Colorectal cancer;
THYM	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg20607798	chr8:58055168	NA	-0.83	-4.76	-0.44	6.86e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs41311933	1.000	rs10514838	chr9:123746796	T/C	cg13567360	chr9:123745713	C5	-0.94	-5.45	-0.49	4e-7	Coronary artery disease;
THYM	cis	rs2811415	0.597	rs10934843	chr3:127749605	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs9928842	0.771	rs4888363	chr16:75277344	A/T	cg09066997	chr16:75300724	BCAR1	0.7	4.55	0.42	1.6e-5	Alcoholic chronic pancreatitis;
THYM	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.83	-7.18	-0.59	1.56e-10	Chronic sinus infection;
THYM	cis	rs3087591	0.922	rs2953013	chr17:29496343	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.69	-5.42	-0.49	4.53e-7	Hip circumference;
THYM	cis	rs17209837	0.607	rs2072384	chr7:87082868	A/T	cg04996195	chr7:87105398	ABCB4	0.63	4.79	0.44	6.03e-6	Gallbladder cancer;
THYM	cis	rs7646881	1.000	rs73015651	chr3:158450922	C/T	cg19483011	chr3:158453295	NA	-0.7	-4.65	-0.43	1.08e-5	Tetralogy of Fallot;
THYM	cis	rs7968440	1.000	rs7968440	chr12:51134741	A/G	cg20014596	chr12:50898483	DIP2B	0.54	4.46	0.42	2.29e-5	Fibrinogen;
THYM	cis	rs12142240	0.738	rs17361749	chr1:46806480	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.61	4.82	0.44	5.41e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg06108461	chr20:60628389	TAF4	-1.01	-7.85	-0.63	6.17e-12	Body mass index;
THYM	cis	rs2803122	0.756	rs1129101	chr9:19372990	C/T	cg19584733	chr9:19298547	DENND4C	0.53	4.69	0.43	9.26e-6	Pulse pressure;
THYM	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg17143192	chr8:8559678	CLDN23	-0.66	-4.98	-0.45	2.88e-6	Mood instability;
THYM	cis	rs2274459	0.841	rs10456075	chr6:33681603	G/A	cg06253072	chr6:33679850	C6orf125	0.5	4.93	0.45	3.43e-6	Obesity (extreme);
THYM	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg20007245	chr22:24372913	LOC391322	-0.77	-7.71	-0.62	1.23e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9419702	0.614	rs4897816	chr10:133533646	G/A	cg20568497	chr10:133558893	NA	0.49	4.58	0.43	1.39e-5	Survival in rectal cancer;
THYM	cis	rs9443189	0.763	rs2647411	chr6:76433692	C/T	cg01950844	chr6:76311363	SENP6	-0.9	-5.19	-0.47	1.2e-6	Prostate cancer;
THYM	cis	rs877282	0.898	rs12357016	chr10:765675	C/T	cg10556349	chr10:835070	NA	-0.79	-5.05	-0.46	2.14e-6	Uric acid levels;
THYM	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg09904177	chr6:26538194	HMGN4	0.54	4.57	0.42	1.47e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg03605463	chr16:89740564	NA	0.88	6.5	0.55	3.65e-9	Vitiligo;
THYM	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg24846680	chr1:228362309	C1orf69	0.51	4.53	0.42	1.72e-5	Diastolic blood pressure;
THYM	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs651907	0.640	rs771573	chr3:101620896	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.7	6.04	0.53	2.97e-8	Colorectal cancer;
THYM	cis	rs3820068	0.603	rs6429753	chr1:15900537	A/G	cg27534772	chr1:16042836	PLEKHM2	0.48	4.59	0.43	1.36e-5	Systolic blood pressure;
THYM	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs61931739	0.892	rs73309466	chr12:34093146	A/G	cg10856724	chr12:34555212	NA	0.59	4.89	0.45	4.13e-6	Morning vs. evening chronotype;
THYM	cis	rs478304	0.637	rs11227255	chr11:65454044	C/T	cg27068330	chr11:65405492	SIPA1	-1.03	-10.31	-0.73	3.55e-17	Acne (severe);
THYM	cis	rs586688	0.625	rs624041	chr1:201652769	C/G	cg14168733	chr1:201708718	NAV1	-0.61	-5.6	-0.5	2.1e-7	Obesity-related traits;
THYM	cis	rs9560113	0.573	rs9560132	chr13:112237456	C/T	cg15979348	chr13:112237479	NA	0.6	5.65	0.5	1.64e-7	Menarche (age at onset);
THYM	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg12560992	chr17:57184187	TRIM37	-0.92	-8.68	-0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg15445000	chr17:37608096	MED1	0.41	5.04	0.46	2.26e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7119	0.604	rs1055691	chr15:77864625	G/C	cg27398640	chr15:77910606	LINGO1	0.62	7.34	0.6	7.26e-11	Type 2 diabetes;
THYM	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg08000102	chr2:233561755	GIGYF2	-0.67	-5.88	-0.52	6.09e-8	Coronary artery disease;
THYM	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg05335186	chr13:53173507	NA	-0.53	-6.8	-0.57	9.37e-10	Lewy body disease;
THYM	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg13010199	chr12:38710504	ALG10B	-0.62	-5.41	-0.49	4.72e-7	Heart rate;
THYM	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg20295408	chr7:1910781	MAD1L1	-0.59	-4.62	-0.43	1.19e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs7584330	0.910	rs12465081	chr2:238401784	A/G	cg14458575	chr2:238380390	NA	0.99	8.13	0.64	1.59e-12	Prostate cancer;
THYM	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg02353165	chr6:42928485	GNMT	0.86	8.35	0.65	5.53e-13	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs34638657	0.687	rs2303261	chr16:82203768	G/T	cg09439754	chr16:82129088	HSD17B2	-0.51	-4.99	-0.46	2.72e-6	Lung adenocarcinoma;
THYM	cis	rs11048434	0.761	rs1805723	chr12:9142297	T/C	cg14913610	chr12:9142341	KLRG1	-0.29	-4.45	-0.42	2.33e-5	Sjögren's syndrome;
THYM	cis	rs12042938	0.507	rs1765778	chr1:231732356	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-5.81	-0.51	8.3e-8	Neuranatomic and neurocognitive phenotypes;
THYM	cis	rs3087591	0.960	rs1124918	chr17:29492423	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.66	-5.79	-0.51	9.11e-8	Hip circumference;
THYM	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2108225	0.872	rs6980029	chr7:107446127	T/C	cg18560240	chr7:107437656	SLC26A3	-0.91	-6.69	-0.57	1.57e-9	Ulcerative colitis;
THYM	cis	rs7043114	0.544	rs4302908	chr9:95321641	A/G	cg14631576	chr9:95140430	CENPP	-0.76	-7.28	-0.6	9.4e-11	Height;
THYM	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg00908189	chr16:619842	PIGQ	1.05	9.25	0.69	6.62e-15	Height;
THYM	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg24399712	chr22:39784796	NA	-0.91	-9.57	-0.7	1.35e-15	Intelligence (multi-trait analysis);
THYM	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg00129232	chr17:37814104	STARD3	-0.9	-7.1	-0.59	2.26e-10	Asthma;
THYM	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg03676636	chr4:99064102	C4orf37	0.43	6.32	0.54	8.55e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10929159	0.928	rs7565059	chr2:236926347	A/G	cg20128773	chr2:236923534	AGAP1	0.35	4.67	0.43	9.88e-6	Parkinson's disease;
THYM	cis	rs4731207	0.596	rs1481332	chr7:124577262	G/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.8e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs11696501	0.694	rs6094184	chr20:44256575	G/A	cg11783356	chr20:44313418	WFDC10B	-0.66	-4.52	-0.42	1.77e-5	Brain structure;
THYM	cis	rs9467711	0.538	rs13191445	chr6:26015489	G/A	cg16898833	chr6:26189333	HIST1H4D	1.33	4.61	0.43	1.24e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg22709100	chr7:91322751	NA	0.59	4.67	0.43	9.87e-6	Breast cancer;
THYM	cis	rs428668	0.523	rs3926389	chr5:150677806	C/T	cg11125805	chr5:150678162	SLC36A3	0.59	8.16	0.64	1.36e-12	Skin aging (microtopography measurement);
THYM	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg03188948	chr7:1209495	NA	0.77	5.98	0.52	3.82e-8	Longevity;Endometriosis;
THYM	cis	rs921968	0.509	rs655441	chr2:219357545	C/T	cg02176678	chr2:219576539	TTLL4	0.73	7.09	0.59	2.4e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7620363	1.000	rs13059998	chr3:34036195	G/T	cg25105657	chr3:33925802	NA	0.41	4.51	0.42	1.88e-5	Non-substance related behavioral disinhibition;
THYM	cis	rs2404602	0.735	rs12903874	chr15:76693318	A/T	cg23482746	chr15:76478102	C15orf27	0.45	4.57	0.42	1.44e-5	Blood metabolite levels;
THYM	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg08999081	chr20:33150536	PIGU	0.57	4.78	0.44	6.41e-6	Coronary artery disease;
THYM	cis	rs11997175	0.646	rs6468195	chr8:33724817	A/G	ch.8.33884649F	chr8:33765107	NA	0.64	4.74	0.44	7.46e-6	Body mass index;
THYM	cis	rs4481887	1.000	rs10788775	chr1:248471945	C/G	cg13385794	chr1:248469461	NA	0.62	4.46	0.42	2.29e-5	Common traits (Other);
THYM	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg00981070	chr1:2046702	PRKCZ	0.47	5.28	0.48	8.31e-7	Height;
THYM	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg13393036	chr8:95962371	TP53INP1	-0.48	-4.72	-0.44	8.23e-6	Type 2 diabetes;
THYM	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg13607699	chr17:42295918	UBTF	0.66	5.44	0.49	4.13e-7	Total body bone mineral density;
THYM	trans	rs10504229	0.516	rs11781671	chr8:57992733	T/C	cg06642219	chr1:5586147	NA	0.64	6.87	0.58	6.74e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg05802129	chr4:122689817	NA	-0.58	-4.55	-0.42	1.56e-5	Type 2 diabetes;
THYM	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg25767906	chr1:53392781	SCP2	-0.52	-5.26	-0.47	8.98e-7	Monocyte count;
THYM	trans	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg10856724	chr12:34555212	NA	-0.94	-8.22	-0.64	1.01e-12	Bladder cancer;
THYM	cis	rs11096990	0.613	rs4974990	chr4:39193265	T/C	cg24403649	chr4:39172243	NA	0.6	5.16	0.47	1.35e-6	Cognitive function;
THYM	cis	rs907612	0.638	rs907613	chr11:1874292	G/A	cg26158194	chr11:1874320	LSP1	0.49	4.72	0.44	8e-6	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
THYM	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22496380	chr5:211416	CCDC127	-1.28	-7.77	-0.62	9.06e-12	Breast cancer;
THYM	cis	rs2963155	1.000	rs2963155	chr5:142756004	C/T	cg17617527	chr5:142782415	NR3C1	-0.81	-5.33	-0.48	6.54e-7	Breast cancer;
THYM	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg13695892	chr22:41940480	POLR3H	-0.77	-6.64	-0.56	1.92e-9	Vitiligo;
THYM	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg00376283	chr12:123451042	ABCB9	0.71	4.75	0.44	7.32e-6	Neutrophil percentage of white cells;
THYM	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg09359103	chr1:154839909	KCNN3	-0.56	-5.75	-0.51	1.07e-7	Prostate cancer;
THYM	cis	rs9914544	0.545	rs2386404	chr17:18769349	T/C	cg26378065	chr17:18585709	ZNF286B	0.59	4.5	0.42	1.9e-5	Educational attainment (years of education);
THYM	cis	rs2562456	0.917	rs11085463	chr19:21751302	G/T	cg21751540	chr19:21541537	ZNF738	-0.67	-4.68	-0.43	9.61e-6	Pain;
THYM	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg18758796	chr5:131593413	PDLIM4	0.63	6.13	0.53	1.96e-8	Breast cancer;
THYM	cis	rs61931739	0.635	rs4442626	chr12:33912530	C/T	cg06521331	chr12:34319734	NA	-0.57	-4.76	-0.44	7e-6	Morning vs. evening chronotype;
THYM	cis	rs17473412	1.000	rs1047484	chr5:122680667	T/G	cg18093572	chr5:122598329	NA	0.6	5.11	0.46	1.64e-6	Total body bone mineral density;
THYM	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.12	8.13	0.64	1.64e-12	Cognitive test performance;
THYM	cis	rs17253792	0.822	rs10147431	chr14:56091841	G/A	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7107174	0.892	rs1893449	chr11:77968977	G/C	cg19901956	chr11:77921274	USP35	-0.76	-5.83	-0.51	7.53e-8	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1580019	0.885	rs4460269	chr7:32496445	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.59	0.56	2.42e-9	Cognitive ability;
THYM	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs9902453	0.935	rs9898424	chr17:28392946	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs1003719	0.715	rs2835667	chr21:38579914	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.5	-0.42	1.95e-5	Eye color traits;
THYM	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg03684893	chr10:554711	DIP2C	-0.74	-6.31	-0.54	8.85e-9	Psychosis in Alzheimer's disease;
THYM	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.61	-4.81	-0.44	5.61e-6	Systemic lupus erythematosus;
THYM	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg17105886	chr17:28927953	LRRC37B2	1.13	6.42	0.55	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg26384229	chr12:38710491	ALG10B	-0.98	-7.51	-0.61	3.24e-11	Heart rate;
THYM	cis	rs56104184	0.887	rs55869333	chr19:49342145	T/G	cg15549821	chr19:49342101	PLEKHA4	-1.27	-8.94	-0.68	3.1e-14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs6785206	0.614	rs35962268	chr3:128465270	C/T	cg16766828	chr3:128327626	NA	0.46	4.54	0.42	1.62e-5	Lymphocyte percentage of white cells;
THYM	cis	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs2456568	0.543	rs4144616	chr11:93621900	A/G	cg17347335	chr11:93583973	C11orf90	-0.58	-5.97	-0.52	4.15e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7695732	0.595	rs4693981	chr4:89917563	C/T	cg17769793	chr4:89976368	FAM13A	0.51	5.49	0.49	3.34e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7084402	0.967	rs1658493	chr10:60281090	C/T	cg07615347	chr10:60278583	BICC1	-0.56	-5.23	-0.47	9.94e-7	Refractive error;
THYM	cis	rs4866334	1.000	rs76355495	chr5:18487262	G/A	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg12379764	chr21:47803548	PCNT	-0.83	-5.37	-0.48	5.52e-7	Testicular germ cell tumor;
THYM	cis	rs1034435	0.755	rs5767173	chr22:48892473	T/C	cg05992904	chr22:48892994	FAM19A5	-0.83	-9.23	-0.69	7.31e-15	Late-onset Alzheimer's disease;
THYM	cis	rs4589258	0.788	rs2156829	chr11:90462961	G/C	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.93	-0.45	3.53e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg27211696	chr2:191398769	TMEM194B	0.64	4.57	0.42	1.49e-5	Diastolic blood pressure;
THYM	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.69	-5.14	-0.47	1.49e-6	Total cholesterol levels;
THYM	cis	rs4523957	0.620	rs58187837	chr17:2073272	G/C	cg16513277	chr17:2031491	SMG6	-1.02	-9.98	-0.72	1.78e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg17775962	chr7:1200435	ZFAND2A	0.42	5.32	0.48	6.75e-7	Longevity;Endometriosis;
THYM	cis	rs16917546	0.967	rs10995256	chr10:64402434	G/T	cg03961010	chr10:64397487	ZNF365	-0.79	-6.52	-0.56	3.41e-9	Basal cell carcinoma;
THYM	cis	rs1003719	0.788	rs2835589	chr21:38463342	A/G	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs8133932	0.701	rs7280054	chr21:47301246	T/G	cg08707771	chr21:46690014	POFUT2	-0.76	-4.62	-0.43	1.22e-5	Schizophrenia;
THYM	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg02896835	chr1:92012615	NA	-0.66	-6.16	-0.53	1.77e-8	Breast cancer;
THYM	cis	rs7100689	0.622	rs10749595	chr10:82172975	C/T	cg01528321	chr10:82214614	TSPAN14	1.1	9.02	0.68	2.1e-14	Post bronchodilator FEV1;
THYM	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg26384229	chr12:38710491	ALG10B	-0.71	-5.53	-0.49	2.8e-7	Morning vs. evening chronotype;
THYM	cis	rs62344088	0.744	rs76038312	chr5:229005	A/G	cg22857025	chr5:266934	NA	-1.59	-5.22	-0.47	1.03e-6	Asthma (childhood onset);
THYM	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.76	-0.44	6.98e-6	Crohn's disease;
THYM	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg12560992	chr17:57184187	TRIM37	-0.8	-6.77	-0.57	1.07e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9787249	0.957	rs2274949	chr1:40221067	G/A	cg19912559	chr1:40204330	PPIE	0.62	4.71	0.44	8.35e-6	Blood protein levels;
THYM	cis	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg09085632	chr11:111637200	PPP2R1B	1.15	11.15	0.75	6.06e-19	Primary sclerosing cholangitis;
THYM	cis	rs931127	0.747	rs11820062	chr11:65429936	T/C	cg27068330	chr11:65405492	SIPA1	-0.85	-7.62	-0.62	1.84e-11	Systemic lupus erythematosus;
THYM	cis	rs12765878	0.756	rs6584579	chr10:105645725	A/G	cg11005552	chr10:105648138	OBFC1	-0.64	-6.14	-0.53	1.91e-8	Coronary artery disease;
THYM	cis	rs12200560	0.505	rs211175	chr6:97073320	C/T	cg06623918	chr6:96969491	KIAA0776	0.79	6.15	0.53	1.82e-8	Coronary heart disease;
THYM	cis	rs2070433	0.528	rs68063691	chr21:47759237	T/C	cg12379764	chr21:47803548	PCNT	0.85	4.99	0.46	2.68e-6	Lymphocyte counts;
THYM	cis	rs6032067	0.929	rs2664581	chr20:43804522	A/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.66	-6.07	-0.53	2.65e-8	Blood protein levels;
THYM	cis	rs4343996	0.747	rs7457146	chr7:3465254	A/C	cg21248987	chr7:3385318	SDK1	0.39	4.69	0.43	9e-6	Motion sickness;
THYM	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg24375607	chr4:120327624	NA	0.64	5.06	0.46	2.05e-6	Corneal astigmatism;
THYM	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg21028142	chr17:79581711	NPLOC4	0.52	5.13	0.47	1.52e-6	Eye color traits;
THYM	cis	rs10992471	0.603	rs7864575	chr9:95304647	G/A	cg14631576	chr9:95140430	CENPP	-0.96	-8.92	-0.68	3.33e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg04546413	chr19:29218101	NA	1.09	9.4	0.69	3.15e-15	Methadone dose in opioid dependence;
THYM	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg03929089	chr4:120376271	NA	1.03	8.74	0.67	8.32e-14	Coronary artery disease;
THYM	cis	rs2991971	0.810	rs12738318	chr1:45929589	A/G	cg15605315	chr1:45957053	TESK2	-0.66	-5.22	-0.47	1.04e-6	High light scatter reticulocyte count;
THYM	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	0.839	rs10808086	chr7:91447515	T/C	cg17063962	chr7:91808500	NA	1.18	12.0	0.78	9.81e-21	Breast cancer;
THYM	cis	rs1371867	0.817	rs1788185	chr8:101335529	T/C	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	5.72	0.51	1.25e-7	Blood metabolite levels;
THYM	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg19774624	chr17:42201019	HDAC5	0.85	8.23	0.65	9.73e-13	Total body bone mineral density;
THYM	cis	rs6840360	1.000	rs6840678	chr4:152604331	C/G	cg22705602	chr4:152727874	NA	0.63	6.62	0.56	2.13e-9	Intelligence (multi-trait analysis);
THYM	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg17294928	chr15:75287854	SCAMP5	-0.99	-9.14	-0.68	1.15e-14	Blood trace element (Zn levels);
THYM	cis	rs921968	0.565	rs7586384	chr2:219582897	T/C	cg02176678	chr2:219576539	TTLL4	-0.47	-4.56	-0.42	1.55e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11089937	0.616	rs4991799	chr22:22533328	C/T	cg06866756	chr22:22471216	NA	-0.46	-4.86	-0.45	4.66e-6	Periodontitis (PAL4Q3);
THYM	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.41	-4.7	-0.43	8.68e-6	Schizophrenia;
THYM	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2299587	0.560	rs7814692	chr8:17780157	G/A	cg01800426	chr8:17659068	MTUS1	-0.68	-5.24	-0.47	9.79e-7	Economic and political preferences;
THYM	cis	rs9549260	0.755	rs2297627	chr13:41233931	A/G	cg21288729	chr13:41239152	FOXO1	0.71	5.55	0.5	2.53e-7	Red blood cell count;
THYM	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg07936489	chr17:37558343	FBXL20	-0.82	-5.61	-0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	7.05	0.59	2.87e-10	Platelet count;
THYM	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg00071950	chr4:10020882	SLC2A9	0.75	7.72	0.62	1.17e-11	Bone mineral density;
THYM	cis	rs2039659	0.752	rs1753738	chr13:86252159	A/G	cg25308322	chr13:86268291	NA	0.62	5.08	0.46	1.9e-6	Blood osmolality (transformed sodium);
THYM	cis	rs72901758	0.768	rs72901762	chr17:76244926	A/G	cg25512537	chr17:76250053	NA	0.42	5.85	0.51	6.93e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
THYM	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg11764359	chr7:65958608	NA	-0.81	-6.42	-0.55	5.45e-9	Aortic root size;
THYM	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Schizophrenia;
THYM	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg11366901	chr6:160182831	ACAT2	1.09	10.12	0.72	9.06e-17	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg22907277	chr7:1156413	C7orf50	0.79	5.04	0.46	2.26e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg11845111	chr2:191398756	TMEM194B	0.97	9.11	0.68	1.34e-14	Pulse pressure;
THYM	cis	rs1215050	0.740	rs783916	chr4:99026264	A/C	cg17366294	chr4:99064904	C4orf37	-0.46	-5.25	-0.47	9.27e-7	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.26	-0.47	8.87e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg15704280	chr7:45808275	SEPT13	-1.07	-15.24	-0.84	2.93e-27	Height;
THYM	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs1499972	0.887	rs6799997	chr3:117520297	A/C	cg07612923	chr3:117604196	NA	1.31	5.35	0.48	6.02e-7	Schizophrenia;
THYM	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg14798641	chr3:49314920	USP4;C3orf62	-0.69	-4.69	-0.43	9.23e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs7177699	0.567	rs67745769	chr15:79124832	G/A	cg15571903	chr15:79123663	NA	-0.56	-6.03	-0.53	3.12e-8	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg13395646	chr4:1353034	KIAA1530	-0.58	-5.47	-0.49	3.64e-7	Obesity-related traits;
THYM	cis	rs4919694	1.000	rs77505796	chr10:104647774	A/T	cg15744005	chr10:104629667	AS3MT	-0.84	-4.61	-0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg08132940	chr7:1081526	C7orf50	-1.16	-6.65	-0.56	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg07570687	chr10:102243282	WNT8B	0.72	6.43	0.55	5.11e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs13315871	0.929	rs9871725	chr3:58292525	T/G	cg12435725	chr3:58293450	RPP14	-0.53	-5.57	-0.5	2.32e-7	Cholesterol, total;
THYM	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.13	8.96	0.68	2.8e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9826463	0.582	rs73238176	chr3:142114256	G/A	cg20824294	chr3:142316082	PLS1	0.77	5.31	0.48	7.08e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg03351412	chr1:154909251	PMVK	0.7	5.38	0.48	5.4e-7	Prostate cancer;
THYM	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg12863693	chr15:85201151	NMB	0.64	5.71	0.51	1.27e-7	Schizophrenia;
THYM	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06850241	chr22:41845214	NA	0.59	5.13	0.47	1.55e-6	Vitiligo;
THYM	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.7	-5.63	-0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg27532560	chr4:187881888	NA	0.95	11.83	0.77	2.15e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-4.92	-0.45	3.67e-6	Chronic sinus infection;
THYM	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs977987	0.966	rs6564261	chr16:75492242	C/T	cg03315344	chr16:75512273	CHST6	0.74	5.99	0.52	3.7e-8	Dupuytren's disease;
THYM	cis	rs11122895	1.000	rs11122891	chr2:112467601	C/G	cg23262488	chr2:112468472	NA	0.67	9.4	0.69	3.21e-15	Allergic sensitization;
THYM	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg02696790	chr15:75250997	RPP25	0.49	4.71	0.44	8.48e-6	Breast cancer;
THYM	cis	rs7107174	0.892	rs10899487	chr11:78085474	G/A	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs2663905	0.706	rs2683260	chr15:81385552	A/C	cg09888468	chr15:81410853	NA	-0.69	-5.47	-0.49	3.61e-7	QT interval (drug interaction);
THYM	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg08999081	chr20:33150536	PIGU	0.59	5.18	0.47	1.26e-6	Height;
THYM	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.65	0.5	1.69e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs55637147	0.553	rs55756513	chr11:57129633	A/G	cg15971518	chr11:57159174	PRG2	-0.62	-5.12	-0.47	1.59e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg13609457	chr4:120235615	NA	0.6	5.34	0.48	6.23e-7	Corneal astigmatism;
THYM	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg24803719	chr17:45855879	NA	-0.6	-6.31	-0.54	8.89e-9	IgG glycosylation;
THYM	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg08847533	chr14:75593920	NEK9	0.95	9.8	0.71	4.36e-16	Height;
THYM	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg06623918	chr6:96969491	KIAA0776	1.09	10.37	0.73	2.65e-17	Headache;
THYM	cis	rs7917772	0.560	rs729023	chr10:104341887	A/G	cg00122347	chr10:104236741	TMEM180	0.41	5.81	0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4900538	0.855	rs1210074	chr14:102889098	G/A	cg18135206	chr14:102964638	TECPR2	-0.8	-6.21	-0.54	1.37e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	8.22	0.64	1.02e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg07606381	chr6:8435919	SLC35B3	0.62	4.62	0.43	1.21e-5	Motion sickness;
THYM	cis	rs912057	0.965	rs1294415	chr6:6740633	G/A	cg13809441	chr6:6737631	NA	0.43	4.85	0.45	4.72e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg02038168	chr22:39784481	NA	-0.67	-5.43	-0.49	4.32e-7	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs56162974	chr4:119742333	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg03517284	chr6:25882590	NA	-0.67	-4.47	-0.42	2.14e-5	Height;
THYM	cis	rs1357245	0.533	rs9811838	chr3:27097794	T/C	cg03895047	chr3:27114861	NA	0.49	4.58	0.43	1.42e-5	Breast cancer;
THYM	cis	rs16866061	0.517	rs7580488	chr2:225473263	C/T	cg10193763	chr2:225306901	NA	-0.43	-4.5	-0.42	1.89e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs6831352	0.691	rs2602887	chr4:100041473	A/G	cg12011299	chr4:100065546	ADH4	0.79	7.22	0.6	1.3e-10	Alcohol dependence;
THYM	cis	rs2658782	1.000	rs2605582	chr11:93163799	C/T	cg16424440	chr11:93231842	C11orf75	-0.74	-4.69	-0.43	9.19e-6	Pulmonary function decline;
THYM	cis	rs4363385	0.818	rs4452994	chr1:152986871	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.76	-0.44	6.94e-6	Inflammatory skin disease;
THYM	cis	rs7072216	0.763	rs6584205	chr10:100173806	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg12311346	chr5:56204834	C5orf35	-0.81	-5.9	-0.52	5.54e-8	Initial pursuit acceleration;
THYM	cis	rs11214589	0.774	rs7116782	chr11:113250938	A/G	cg14159747	chr11:113255604	NA	0.38	8.48	0.66	2.97e-13	Neuroticism;
THYM	cis	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg06521331	chr12:34319734	NA	-0.86	-6.28	-0.54	1.01e-8	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg03806693	chr22:41940476	POLR3H	1.1	8.41	0.65	4.11e-13	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg13114125	chr14:105738426	BRF1	-0.71	-5.48	-0.49	3.48e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6570726	0.837	rs419991	chr6:145864212	C/T	cg13319975	chr6:146136371	FBXO30	-0.66	-5.62	-0.5	1.89e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4595586	0.545	rs4768505	chr12:39380338	C/A	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs7843479	0.965	rs11784535	chr8:21857787	G/A	cg17168535	chr8:21777572	XPO7	0.64	4.74	0.44	7.36e-6	Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs8028313	0.630	rs8035989	chr15:67965620	G/A	cg24579218	chr15:68104479	NA	-0.72	-6.74	-0.57	1.19e-9	Obesity;
THYM	cis	rs11031096	0.568	rs10767891	chr11:4234524	A/G	cg18678763	chr11:4115507	RRM1	-0.43	-4.48	-0.42	2.1e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7213347	0.579	rs8072532	chr17:2045273	G/A	cg16513277	chr17:2031491	SMG6	-0.64	-4.96	-0.45	3.02e-6	Total body bone mineral density;
THYM	trans	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.2	13.67	0.81	3.71e-24	Exhaled nitric oxide output;
THYM	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg06600287	chr1:53387719	ECHDC2	-0.3	-4.78	-0.44	6.51e-6	Monocyte count;
THYM	cis	rs12137294	0.866	rs896320	chr1:205205347	T/C	cg17889831	chr1:205181581	DSTYK	-0.41	-5.05	-0.46	2.13e-6	Red cell distribution width;
THYM	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg24818145	chr4:99064322	C4orf37	0.74	5.93	0.52	4.8e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg11375102	chr16:1583810	IFT140;TMEM204	-0.6	-5.01	-0.46	2.5e-6	Coronary artery disease;
THYM	cis	rs35934224	0.504	rs35169076	chr22:19841501	T/C	cg11182965	chr22:19864308	TXNRD2	-0.68	-5.03	-0.46	2.29e-6	Glaucoma (primary open-angle);
THYM	cis	rs986417	0.901	rs6573315	chr14:60996831	A/C	cg27398547	chr14:60952738	C14orf39	1.0	5.05	0.46	2.14e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg17644776	chr2:200775616	C2orf69	-0.79	-4.49	-0.42	2.01e-5	Schizophrenia;
THYM	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs7941600	0.786	rs7930192	chr11:9188816	C/G	cg21110646	chr11:9336536	TMEM41B	0.89	4.72	0.44	8.08e-6	Coronary artery disease;
THYM	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg04362960	chr10:104952993	NT5C2	0.58	4.69	0.43	9.04e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg18876405	chr7:65276391	NA	-0.55	-4.73	-0.44	7.84e-6	Aortic root size;
THYM	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg07424592	chr7:64974309	NA	-1.04	-4.78	-0.44	6.31e-6	Diabetic kidney disease;
THYM	cis	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.33e-5	Retinal vascular caliber;
THYM	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg04663057	chr3:46933782	PTH1R	0.54	5.38	0.48	5.31e-7	Birth weight;
THYM	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg24920358	chr1:40204285	PPIE	0.6	5.59	0.5	2.19e-7	Blood protein levels;
THYM	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg15212455	chr7:39170539	POU6F2	0.64	6.01	0.52	3.44e-8	IgG glycosylation;
THYM	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg15556689	chr8:8085844	FLJ10661	-0.63	-5.35	-0.48	6.11e-7	Mood instability;
THYM	cis	rs4499344	0.526	rs11084655	chr19:33034698	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.71	4.79	0.44	6.07e-6	Mean platelet volume;
THYM	cis	rs17209837	0.607	rs60040620	chr7:87085379	C/A	cg04996195	chr7:87105398	ABCB4	0.63	4.79	0.44	6.03e-6	Gallbladder cancer;
THYM	cis	rs7043114	0.525	rs2025388	chr9:95128740	T/C	cg14631576	chr9:95140430	CENPP	-0.86	-9.03	-0.68	1.97e-14	Height;
THYM	cis	rs6546537	0.562	rs7565783	chr2:69750113	C/T	cg10773587	chr2:69614142	GFPT1	-0.59	-4.68	-0.43	9.48e-6	Serum thyroid-stimulating hormone levels;
THYM	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg27494647	chr7:150038898	RARRES2	0.46	5.82	0.51	8.06e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7940866	0.834	rs10791105	chr11:130839161	A/G	cg05962950	chr11:130786565	SNX19	0.73	5.79	0.51	8.99e-8	Schizophrenia;
THYM	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	-0.49	-4.59	-0.43	1.34e-5	Lymphocyte counts;
THYM	cis	rs35883536	0.587	rs2809812	chr1:101032087	G/T	cg06223162	chr1:101003688	GPR88	0.82	7.16	0.59	1.69e-10	Monocyte count;
THYM	cis	rs3126085	0.935	rs74127901	chr1:152195579	G/A	cg10321714	chr1:152280068	FLG	-0.68	-4.96	-0.45	3.08e-6	Atopic dermatitis;
THYM	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg02782426	chr3:40428986	ENTPD3	0.58	5.2	0.47	1.14e-6	Renal cell carcinoma;
THYM	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.55	4.49	0.42	2e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs12216545	0.737	rs6464075	chr7:150234541	G/A	cg00323915	chr7:150264987	GIMAP4	-0.49	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.43	-0.55	5.2e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs10484885	0.887	rs114928443	chr6:90602455	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.8	-6.83	-0.57	8.08e-10	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs7089973	0.668	rs7077148	chr10:116644896	A/G	cg23260525	chr10:116636907	FAM160B1	0.59	6.2	0.54	1.43e-8	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2811415	0.627	rs9833276	chr3:127797793	T/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs2237457	0.525	rs4947757	chr7:50728084	A/G	cg08586669	chr7:50727761	GRB10	-0.3	-4.8	-0.44	5.97e-6	Schizophrenia (treatment resistant);
THYM	cis	rs7246657	0.943	rs10415024	chr19:37814724	A/G	cg22634378	chr19:37742834	NA	0.68	5.67	0.5	1.55e-7	Coronary artery calcification;
THYM	trans	rs8073060	0.561	rs225260	chr17:33958422	T/C	cg19694781	chr19:47549865	TMEM160	-0.94	-7.87	-0.63	5.77e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs4474465	1.000	rs11237499	chr11:78163164	A/T	cg19901956	chr11:77921274	USP35	-0.61	-4.53	-0.42	1.7e-5	Alzheimer's disease (survival time);
THYM	cis	rs758324	0.687	rs473753	chr5:131501134	T/C	cg16205897	chr5:131564050	P4HA2	0.54	4.71	0.43	8.57e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg04944784	chr2:26401820	FAM59B	-0.64	-4.79	-0.44	6.11e-6	Gut microbiome composition (summer);
THYM	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	13.05	0.8	6.7e-23	Chronic sinus infection;
THYM	cis	rs981844	0.775	rs72733610	chr4:154732336	A/G	cg09973105	chr4:154681532	RNF175	-0.62	-5.1	-0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	trans	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.12	8.09	0.64	1.9e-12	Exhaled nitric oxide output;
THYM	cis	rs10489202	0.632	rs275137	chr1:168051266	A/C	cg24449463	chr1:168025552	DCAF6	0.89	9.09	0.68	1.46e-14	Schizophrenia;
THYM	cis	rs1003719	0.788	rs61701101	chr21:38450317	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs909002	0.830	rs10914461	chr1:32113217	G/A	cg13919466	chr1:32135498	COL16A1	-0.46	-4.52	-0.42	1.81e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7084402	0.902	rs1582826	chr10:60297175	C/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.65e-7	Refractive error;
THYM	cis	rs4838594	1.000	rs4838594	chr10:49669142	C/T	cg22796704	chr10:49673534	ARHGAP22	-0.32	-4.62	-0.43	1.23e-5	Daytime sleep phenotypes;
THYM	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg17911788	chr17:44343683	NA	-0.75	-6.91	-0.58	5.52e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9826463	0.582	rs73238185	chr3:142141177	T/C	cg20824294	chr3:142316082	PLS1	0.76	5.3	0.48	7.53e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-14.05	-0.82	6.23e-25	Height;
THYM	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs860818	1.000	rs858302	chr7:23244243	G/T	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7100689	0.599	rs7077847	chr10:82134952	A/G	cg01528321	chr10:82214614	TSPAN14	0.8	5.96	0.52	4.32e-8	Post bronchodilator FEV1;
THYM	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.55	-4.47	-0.42	2.16e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs1670533	0.697	rs658846	chr4:1084723	G/C	cg27284194	chr4:1044797	NA	0.69	4.82	0.44	5.53e-6	Recombination rate (females);
THYM	cis	rs8070128	0.600	rs8071238	chr17:17900990	T/C	cg04398451	chr17:18023971	MYO15A	-0.86	-8.47	-0.66	3.02e-13	Total body bone mineral density;
THYM	cis	rs775227	0.574	rs35274817	chr3:113266391	A/G	cg18753928	chr3:113234510	CCDC52	-0.77	-5.33	-0.48	6.5e-7	Dental caries;
THYM	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.71	-4.92	-0.45	3.67e-6	Body mass index;
THYM	cis	rs6761276	0.649	rs3811055	chr2:113831182	A/T	cg12858261	chr2:113808755	IL1F8	0.54	4.47	0.42	2.16e-5	Protein quantitative trait loci;
THYM	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	4.54	0.42	1.66e-5	Hip circumference adjusted for BMI;
THYM	cis	rs6700896	0.931	rs10749755	chr1:66129530	C/T	cg04111102	chr1:66153794	NA	0.56	5.27	0.48	8.45e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg16405210	chr4:1374714	KIAA1530	0.96	8.51	0.66	2.53e-13	Longevity;
THYM	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.64	8.49	0.66	2.73e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg02782426	chr3:40428986	ENTPD3	0.53	4.66	0.43	1.04e-5	Renal cell carcinoma;
THYM	cis	rs62158800	0.568	rs62162980	chr2:108374371	C/T	cg09155462	chr2:109189131	NA	1.11	4.51	0.42	1.86e-5	Facial morphology (factor 22);
THYM	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg17366294	chr4:99064904	C4orf37	0.56	6.62	0.56	2.09e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6987853	0.761	rs2974322	chr8:42424724	T/C	cg09913449	chr8:42400586	C8orf40	1.08	11.86	0.77	1.8899999999999998e-20	Mean corpuscular hemoglobin concentration;
THYM	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg17863274	chr19:49399704	TULP2	-0.93	-5.69	-0.5	1.43e-7	Red cell distribution width;
THYM	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.8	-6.38	-0.55	6.32e-9	Chronic sinus infection;
THYM	cis	rs192264	0.582	rs254367	chr16:65981726	A/G	cg02795155	chr16:66785218	DYNC1LI2	0.62	5.02	0.46	2.36e-6	Subjective well-being;
THYM	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg14196790	chr5:131705035	SLC22A5	0.55	5.03	0.46	2.34e-6	Blood metabolite levels;
THYM	cis	rs13256369	0.590	rs10113115	chr8:8559588	A/G	cg17143192	chr8:8559678	CLDN23	0.8	6.17	0.53	1.69e-8	Obesity-related traits;
THYM	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg25358565	chr5:93447407	FAM172A	-1.0	-7.59	-0.61	2.22e-11	Diabetic retinopathy;
THYM	cis	rs936229	1.000	rs936228	chr15:75132164	T/C	cg14664628	chr15:75095509	CSK	-1.03	-8.07	-0.64	2.12e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs13082711	0.554	rs674798	chr3:27332302	G/T	cg02860705	chr3:27208620	NA	0.65	5.09	0.46	1.79e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.91	-0.52	5.44e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs700651	0.856	rs9288280	chr2:198744324	A/G	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Intracranial aneurysm;
THYM	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg05754148	chr16:3507555	NAT15	0.72	7.22	0.6	1.3e-10	Tuberculosis;
THYM	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg21984481	chr17:79567631	NPLOC4	0.46	4.86	0.45	4.62e-6	Eye color traits;
THYM	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg07636037	chr3:49044803	WDR6	0.96	9.68	0.7	8e-16	Parkinson's disease;
THYM	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg06600287	chr1:53387719	ECHDC2	-0.34	-5.47	-0.49	3.64e-7	Monocyte count;
THYM	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg17105886	chr17:28927953	LRRC37B2	1.18	7.09	0.59	2.34e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs854765	0.663	rs12941550	chr17:17753828	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.64	-5.75	-0.51	1.1e-7	Total body bone mineral density;
THYM	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg15704280	chr7:45808275	SEPT13	-0.98	-11.44	-0.76	1.43e-19	Coronary artery disease;
THYM	cis	rs7084402	0.967	rs1649080	chr10:60293294	C/T	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs1448094	0.511	rs61930579	chr12:86157044	G/A	cg02569458	chr12:86230093	RASSF9	0.62	5.13	0.47	1.56e-6	Major depressive disorder;
THYM	cis	rs921968	0.528	rs13382651	chr2:219628191	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9457247	0.638	rs239933	chr6:167413230	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.49	-5.03	-0.46	2.36e-6	Crohn's disease;
THYM	cis	rs9549260	0.785	rs6563842	chr13:41244297	G/T	cg21288729	chr13:41239152	FOXO1	0.74	5.87	0.52	6.49e-8	Red blood cell count;
THYM	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg25036284	chr2:26402008	FAM59B	0.8	5.36	0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs526231	0.543	rs158400	chr5:102413332	T/C	cg23492399	chr5:102201601	PAM	-0.67	-4.96	-0.45	3.05e-6	Primary biliary cholangitis;
THYM	cis	rs7122937	0.953	rs58558735	chr11:2491261	G/A	cg27115973	chr11:2481206	KCNQ1	0.55	5.73	0.51	1.2e-7	QT interval;
THYM	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg16928487	chr17:17741425	SREBF1	-0.57	-5.63	-0.5	1.79e-7	Total body bone mineral density;
THYM	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg26131816	chr17:42072204	PYY	0.53	4.6	0.43	1.28e-5	Menopause (age at onset);
THYM	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg10515332	chr4:99064459	C4orf37	0.71	5.67	0.5	1.51e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg02725872	chr8:58115012	NA	-1.09	-8.15	-0.64	1.43e-12	Developmental language disorder (linguistic errors);
THYM	cis	rs344364	0.577	rs2745194	chr16:1854038	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.46	5.29	0.48	7.66e-7	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.73	0.44	7.73e-6	Alzheimer's disease (late onset);
THYM	cis	rs2273669	0.667	rs75671532	chr6:109341298	A/G	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs686320	1.000	rs3132770	chr11:65251317	G/A	cg19332572	chr11:65321591	LTBP3	0.86	5.23	0.47	9.91e-7	Hip circumference adjusted for BMI;
THYM	cis	rs11771526	0.901	rs11767695	chr7:32315960	G/A	cg13207630	chr7:32358064	NA	0.84	5.28	0.48	8.15e-7	Body mass index;
THYM	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg09990169	chr2:241835740	C2orf54	-0.37	-6.3	-0.54	9.4e-9	Urinary metabolites;
THYM	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs3126085	0.935	rs11204976	chr1:152273777	C/T	cg10321714	chr1:152280068	FLG	-0.7	-5.11	-0.46	1.68e-6	Atopic dermatitis;
THYM	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg23131131	chr22:24373011	LOC391322	-0.83	-7.75	-0.62	1e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3768617	0.510	rs10797839	chr1:183077797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs113835537	0.529	rs17065	chr11:66277035	G/A	cg24851651	chr11:66362959	CCS	0.73	5.13	0.47	1.52e-6	Airway imaging phenotypes;
THYM	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.31	-0.48	7.28e-7	Mean corpuscular volume;
THYM	cis	rs2070488	1.000	rs34258593	chr3:38464565	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	7.02	0.58	3.33e-10	Electrocardiographic conduction measures;
THYM	cis	rs9515201	0.740	rs9555695	chr13:111033125	C/T	cg15455643	chr13:111040242	COL4A2	0.55	6.76	0.57	1.1e-9	White matter hyperintensity burden;
THYM	cis	rs7695732	0.550	rs6827857	chr4:89917266	G/A	cg17769793	chr4:89976368	FAM13A	-0.5	-5.27	-0.48	8.39e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6032067	0.777	rs34343273	chr20:43795293	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.69e-11	Aortic root size;
THYM	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg06027949	chr8:82754900	SNX16	-0.62	-5.26	-0.47	8.98e-7	Diastolic blood pressure;
THYM	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg24112000	chr20:60950667	NA	-0.66	-5.45	-0.49	4.02e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs2120019	0.508	rs8030528	chr15:75171825	C/T	cg17294928	chr15:75287854	SCAMP5	-0.67	-4.59	-0.43	1.37e-5	Blood trace element (Zn levels);
THYM	cis	rs9486719	1.000	rs12190507	chr6:96898265	T/G	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg06634786	chr22:41940651	POLR3H	-0.7	-4.92	-0.45	3.59e-6	Vitiligo;
THYM	cis	rs654950	0.806	rs941971	chr1:42040893	T/C	cg06885757	chr1:42089581	HIVEP3	-0.58	-7.82	-0.63	7.37e-12	Airway imaging phenotypes;
THYM	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg20295408	chr7:1910781	MAD1L1	-0.57	-4.5	-0.42	1.94e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg02527881	chr3:46936655	PTH1R	-0.69	-7.14	-0.59	1.9e-10	Colorectal cancer;
THYM	cis	rs6860806	0.661	rs2136188	chr5:131577514	A/G	cg24060327	chr5:131705240	SLC22A5	0.69	5.27	0.48	8.64e-7	Breast cancer;
THYM	cis	rs55883249	1.000	rs62119391	chr2:9712272	A/G	cg23886495	chr2:9695866	ADAM17	0.85	5.28	0.48	8.25e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs6032067	0.777	rs17332620	chr20:43777506	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.41	-0.65	4.05e-13	Blood protein levels;
THYM	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	6.96	0.58	4.33e-10	Smoking behavior;
THYM	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.33	10.11	0.72	9.63e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg16414030	chr3:133502952	NA	-0.84	-8.47	-0.66	3.08e-13	Iron status biomarkers;
THYM	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg05362011	chr13:21860987	NA	0.56	4.55	0.42	1.6e-5	White matter hyperintensity burden;
THYM	cis	rs6138458	1.000	rs227621	chr20:24910528	A/C	cg26195577	chr20:24973756	C20orf3	1.11	10.52	0.73	1.29e-17	Blood protein levels;
THYM	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg21427119	chr20:30132790	HM13	-0.86	-5.96	-0.52	4.2e-8	Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7980799	0.654	rs1482987	chr12:33614283	G/C	cg06521331	chr12:34319734	NA	0.69	4.93	0.45	3.47e-6	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs41005	1.000	rs35398717	chr2:8115041	A/T	cg03155496	chr2:8117019	LOC339788	-0.98	-9.1	-0.68	1.42e-14	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs1003719	0.788	rs2835582	chr21:38458773	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.65	4.61	0.43	1.23e-5	Eye color traits;
THYM	cis	rs12142240	0.698	rs17361819	chr1:46828109	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg22496380	chr5:211416	CCDC127	1.25	7.81	0.63	7.43e-12	Breast cancer;
THYM	cis	rs6992820	0.900	rs12678930	chr8:56726277	A/G	cg06880721	chr8:56792545	LYN	-0.71	-5.94	-0.52	4.77e-8	Mean platelet volume;
THYM	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg24069376	chr3:38537580	EXOG	-0.64	-6.35	-0.55	7.43e-9	Electrocardiographic conduction measures;
THYM	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg01819863	chr10:32635814	EPC1	1.12	6.59	0.56	2.46e-9	Sexual dysfunction (female);
THYM	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg06130144	chr11:64578348	MEN1	0.71	4.48	0.42	2.07e-5	Mean platelet volume;
THYM	cis	rs7191439	0.789	rs4598894	chr16:88776141	G/A	cg04602696	chr16:88846723	FAM38A	-0.72	-5.21	-0.47	1.08e-6	Plateletcrit;
THYM	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03264133	chr6:25882463	NA	-0.88	-7.33	-0.6	7.43e-11	Intelligence (multi-trait analysis);
THYM	cis	rs2290159	0.706	rs11923427	chr3:12663835	C/G	cg05467012	chr3:12595696	NA	0.9	5.74	0.51	1.12e-7	Cholesterol, total;
THYM	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg21475434	chr5:93447410	FAM172A	0.97	6.06	0.53	2.72e-8	Diabetic retinopathy;
THYM	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.3	-0.48	7.34e-7	Monocyte percentage of white cells;
THYM	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg17757837	chr7:157058334	UBE3C	0.65	5.34	0.48	6.37e-7	Body mass index;
THYM	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg18252515	chr7:66147081	NA	0.67	5.24	0.47	9.7e-7	Aortic root size;
THYM	cis	rs7614311	0.681	rs10510903	chr3:63970192	C/G	cg22134162	chr3:63841271	THOC7	-0.55	-6.69	-0.57	1.53e-9	Lung function (FVC);Lung function (FEV1);
THYM	trans	rs877282	0.838	rs11253373	chr10:774857	A/G	cg22713356	chr15:30763199	NA	1.4	11.9	0.77	1.6e-20	Uric acid levels;
THYM	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg00129232	chr17:37814104	STARD3	0.69	4.51	0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs2668423	1.000	rs2526140	chr19:1374450	G/C	cg02639931	chr19:1387894	NDUFS7	-0.49	-5.72	-0.51	1.24e-7	Nonalcoholic fatty liver disease;
THYM	cis	rs7614311	0.731	rs17401592	chr3:63954490	A/G	cg22134162	chr3:63841271	THOC7	-0.57	-6.82	-0.57	8.37e-10	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg25554036	chr4:6271136	WFS1	0.56	5.29	0.48	7.94e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs9677476	0.863	rs11558174	chr2:232072912	T/C	cg07929768	chr2:232055508	NA	0.63	6.33	0.54	8.2e-9	Food antigen IgG levels;
THYM	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.69	-6.17	-0.53	1.67e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg00852783	chr1:26633632	UBXN11	0.82	7.95	0.63	3.8e-12	Obesity-related traits;
THYM	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.67	-5.5	-0.49	3.15e-7	Blood metabolite levels;
THYM	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Gout;
THYM	cis	rs6980334	0.906	rs10264658	chr7:137779000	T/C	cg18769353	chr7:137028617	PTN	0.63	5.06	0.46	2.01e-6	Blood metabolite ratios;
THYM	cis	rs4919694	1.000	rs58700372	chr10:104800205	T/C	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg09640425	chr7:158790006	NA	0.58	4.86	0.45	4.63e-6	Facial morphology (factor 20);
THYM	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg07362569	chr17:61921086	SMARCD2	-0.65	-6.15	-0.53	1.86e-8	Prudent dietary pattern;
THYM	cis	rs6430585	0.528	rs75524146	chr2:136725459	C/T	cg04750100	chr2:136595281	LCT	0.56	4.94	0.45	3.41e-6	Corneal structure;
THYM	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9595908	0.900	rs731414	chr13:33175297	T/G	cg12383807	chr13:33924137	NA	-0.53	-4.74	-0.44	7.41e-6	Body mass index;
THYM	cis	rs901683	1.000	rs34574958	chr10:46087040	C/T	cg18240400	chr10:46168597	ANUBL1	0.73	4.73	0.44	7.89e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs7582180	0.677	rs11694723	chr2:100878122	C/T	cg08017756	chr2:100939284	LONRF2	-0.56	-4.95	-0.45	3.26e-6	Intelligence (multi-trait analysis);
THYM	cis	rs34381861	0.520	rs74382390	chr16:71458526	C/G	cg08717414	chr16:71523259	ZNF19	-1.17	-4.96	-0.45	3.1e-6	Post bronchodilator FEV1;
THYM	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg14972814	chr11:95582409	MTMR2	-0.72	-6.08	-0.53	2.51e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs250677	0.522	rs6875902	chr5:148407893	C/A	cg18129178	chr5:148520854	ABLIM3	-0.72	-5.34	-0.48	6.32e-7	Breast cancer;
THYM	trans	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg01304814	chr3:48885189	PRKAR2A	0.92	4.6	0.43	1.33e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs7746082	0.563	rs12209696	chr6:106489157	A/G	cg02270332	chr6:106475062	NA	-0.64	-6.07	-0.53	2.67e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg03433033	chr1:76189801	ACADM	0.67	5.81	0.51	8.19e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg11812906	chr14:75593930	NEK9	0.75	6.68	0.57	1.62e-9	Height;
THYM	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.96	-7.5	-0.61	3.34e-11	Homoarginine levels;
THYM	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	11.6	0.77	6.69e-20	Height;
THYM	cis	rs748404	0.660	rs690472	chr15:43764368	A/C	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs6957923	0.655	rs7781714	chr7:23593479	A/G	cg20265043	chr7:23510089	IGF2BP3	0.51	5.58	0.5	2.28e-7	Height;
THYM	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg12386194	chr3:101231763	SENP7	0.69	5.16	0.47	1.34e-6	Colorectal cancer;
THYM	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.48	-0.42	2.05e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs10992471	0.603	rs7033979	chr9:95223980	A/G	cg14631576	chr9:95140430	CENPP	-0.99	-9.93	-0.71	2.34e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs12921479	0.962	rs12597391	chr16:88928290	C/T	cg13946872	chr16:87991595	BANP	-0.5	-4.6	-0.43	1.29e-5	Parkinson disease and lewy body pathology;
THYM	cis	rs9296092	0.538	rs62405943	chr6:33517359	A/G	cg13560919	chr6:33536144	NA	-0.94	-9.16	-0.68	1.03e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs877282	0.898	rs11253347	chr10:765769	A/G	cg10556349	chr10:835070	NA	-0.79	-5.05	-0.46	2.14e-6	Uric acid levels;
THYM	cis	rs7772486	0.742	rs4896851	chr6:146278959	T/C	cg13319975	chr6:146136371	FBXO30	0.68	5.71	0.51	1.27e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs6674176	0.628	rs3791119	chr1:44431362	C/G	cg13246856	chr1:44399776	ARTN	0.47	4.86	0.45	4.68e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs12472274	0.941	rs11677230	chr2:239092054	T/C	cg17459225	chr2:239074497	NA	0.77	5.59	0.5	2.13e-7	Phospholipid levels (plasma);
THYM	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg12011299	chr4:100065546	ADH4	0.85	8.06	0.64	2.26e-12	Alcohol dependence;
THYM	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg06074448	chr4:187884817	NA	-1.02	-13.05	-0.8	6.55e-23	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2073300	0.609	rs6132605	chr20:23354839	A/C	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs11969893	0.737	rs1358758	chr6:101411891	T/C	cg20232986	chr6:100915767	NA	0.73	4.6	0.43	1.31e-5	Economic and political preferences (immigration/crime);
THYM	cis	rs516946	1.000	rs3802316	chr8:41528228	G/C	cg19441908	chr8:41529140	ANK1	0.62	4.9	0.45	3.95e-6	Type 2 diabetes;
THYM	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg03929089	chr4:120376271	NA	-1.01	-13.5	-0.81	8.17e-24	Height;
THYM	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.28	6.38	0.55	6.44e-9	Obesity-related traits;
THYM	cis	rs1609391	0.561	rs9817967	chr3:136629490	G/A	cg15507776	chr3:136538369	TMEM22	0.64	4.9	0.45	4.02e-6	Neuroticism;
THYM	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-5.45	-0.49	3.93e-7	Monocyte percentage of white cells;
THYM	cis	rs13256369	0.950	rs1522839	chr8:8580453	C/T	cg18904891	chr8:8559673	CLDN23	0.64	4.61	0.43	1.27e-5	Obesity-related traits;
THYM	cis	rs950880	0.710	rs1035130	chr2:103001402	C/T	cg03938978	chr2:103052716	IL18RAP	-0.5	-4.46	-0.42	2.24e-5	Serum protein levels (sST2);
THYM	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg16680214	chr1:154839983	KCNN3	-0.53	-6.43	-0.55	5.03e-9	Prostate cancer;
THYM	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg05855489	chr10:104503620	C10orf26	0.58	4.69	0.43	9.11e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs12824058	0.831	rs11608407	chr12:130805869	G/A	cg26677194	chr12:130822605	PIWIL1	0.8	6.09	0.53	2.4e-8	Menopause (age at onset);
THYM	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg21644426	chr2:191273491	MFSD6	0.8	6.55	0.56	2.94e-9	Pulse pressure;
THYM	cis	rs34779708	0.966	rs12257770	chr10:35517234	A/G	cg03585969	chr10:35415529	CREM	0.63	4.48	0.42	2.09e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7772486	0.837	rs2474354	chr6:146323795	T/A	cg23711669	chr6:146136114	FBXO30	0.87	8.52	0.66	2.36e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	trans	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	trans	rs8073060	0.505	rs225270	chr17:33968871	A/T	cg19694781	chr19:47549865	TMEM160	-0.95	-7.8	-0.62	7.8e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs11696845	0.626	rs1111032	chr20:43378770	A/G	cg09357268	chr20:43379437	KCNK15	0.49	4.95	0.45	3.25e-6	Obesity-related traits;
THYM	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg13114125	chr14:105738426	BRF1	-0.71	-5.48	-0.49	3.45e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs3916	1.000	rs1799958	chr12:121176083	G/A	cg10600917	chr12:121163489	ACADS	0.59	4.98	0.45	2.84e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs921968	0.541	rs549026	chr2:219339283	T/C	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7044106	0.791	rs2900177	chr9:123497645	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	7.49	0.61	3.6e-11	Hip circumference adjusted for BMI;
THYM	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs7809615	0.901	rs6947974	chr7:99156506	G/A	cg12290671	chr7:99195819	NA	-0.99	-4.83	-0.44	5.27e-6	Blood metabolite ratios;
THYM	cis	rs877282	0.898	rs12358513	chr10:757571	A/G	cg10556349	chr10:835070	NA	-0.77	-4.95	-0.45	3.24e-6	Uric acid levels;
THYM	trans	rs4866334	1.000	rs114489248	chr5:18478969	C/A	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs1065852	0.526	rs12166549	chr22:42410419	T/C	cg08431931	chr22:42394659	WBP2NL	0.74	6.08	0.53	2.48e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg10515332	chr4:99064459	C4orf37	0.66	5.17	0.47	1.29e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.85	-5.32	-0.48	6.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22307029	chr19:49891270	CCDC155	0.59	4.72	0.44	8.04e-6	Multiple sclerosis;
THYM	cis	rs1892700	0.853	rs2239563	chr21:34941063	G/A	cg24865779	chr21:34775042	IFNGR2	0.48	4.62	0.43	1.2e-5	Educational attainment;
THYM	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg13918804	chr1:2043761	PRKCZ	0.81	7.2	0.59	1.42e-10	Height;
THYM	cis	rs1878931	0.559	rs1968055	chr16:3392053	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.68	4.97	0.45	2.95e-6	Body mass index (adult);
THYM	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg16524733	chr11:117070046	TAGLN	0.43	4.76	0.44	6.82e-6	Blood protein levels;
THYM	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg26116260	chr4:7069785	GRPEL1	1.13	10.72	0.74	4.88e-18	Monocyte percentage of white cells;
THYM	cis	rs2075230	0.705	rs2955611	chr17:7549574	C/A	cg27413385	chr17:7515425	FXR2	-0.36	-5.31	-0.48	7.3e-7	Hormone measurements;
THYM	cis	rs1691799	0.899	rs1168300	chr12:66736467	C/A	cg16791601	chr12:66731901	HELB	-0.76	-7.14	-0.59	1.9e-10	White blood cell count (basophil);
THYM	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7106204	0.609	rs11828535	chr11:24295565	G/C	ch.11.24196551F	chr11:24239977	NA	1.0	6.17	0.53	1.65e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg18252515	chr7:66147081	NA	-0.7	-5.28	-0.48	8.21e-7	Corneal structure;
THYM	cis	rs12348691	0.503	rs7024345	chr9:100595238	A/G	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Alopecia areata;
THYM	cis	rs988913	0.957	rs9475098	chr6:54833177	A/G	cg19716238	chr6:54711378	FAM83B	0.5	5.02	0.46	2.44e-6	Menarche (age at onset);
THYM	cis	rs9486719	0.843	rs2472876	chr6:96845723	A/G	cg18709589	chr6:96969512	KIAA0776	0.75	4.49	0.42	2.02e-5	Migraine;Coronary artery disease;
THYM	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs12478296	1.000	rs73007140	chr2:243010756	T/C	cg06360820	chr2:242988706	NA	-0.9	-5.86	-0.52	6.71e-8	Obesity-related traits;
THYM	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg18904891	chr8:8559673	CLDN23	0.68	5.08	0.46	1.89e-6	Obesity-related traits;
THYM	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg10589385	chr1:150898437	SETDB1	0.57	4.55	0.42	1.56e-5	Melanoma;
THYM	cis	rs887829	0.569	rs2008595	chr2:234637192	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.68	-5.4	-0.48	4.81e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs34638657	0.732	rs12597171	chr16:82200119	A/G	cg09439754	chr16:82129088	HSD17B2	0.54	5.27	0.48	8.65e-7	Lung adenocarcinoma;
THYM	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg18453174	chr20:61662111	NA	0.5	4.51	0.42	1.86e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.69	-5.16	-0.47	1.36e-6	Tonsillectomy;
THYM	cis	rs7582180	0.903	rs13033057	chr2:100896415	C/T	cg14675211	chr2:100938903	LONRF2	0.64	5.43	0.49	4.28e-7	Intelligence (multi-trait analysis);
THYM	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg10023613	chr17:42248099	ASB16	-0.27	-4.53	-0.42	1.69e-5	Bone mineral density (hip);Bone mineral density;
THYM	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg08508325	chr11:3079039	CARS	-0.52	-6.46	-0.55	4.45e-9	Longevity;
THYM	cis	rs899997	0.862	rs11072787	chr15:78972977	T/C	cg00639195	chr15:79103007	ADAMTS7	0.69	4.61	0.43	1.23e-5	Coronary artery disease or large artery stroke;
THYM	cis	rs4523957	0.553	rs2131703	chr17:2025360	G/T	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg03474202	chr17:45855739	NA	-0.74	-6.44	-0.55	4.93e-9	IgG glycosylation;
THYM	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg23161317	chr6:28129485	ZNF389	0.72	4.79	0.44	6.09e-6	Parkinson's disease;
THYM	cis	rs9814567	0.929	rs1863911	chr3:134205231	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.86	-8.85	-0.67	4.76e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg03676636	chr4:99064102	C4orf37	0.36	4.98	0.46	2.79e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9515201	0.627	rs61963197	chr13:111038395	G/A	cg05272587	chr13:111038400	COL4A2	-0.69	-5.78	-0.51	9.55e-8	White matter hyperintensity burden;
THYM	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg01191920	chr7:158217561	PTPRN2	0.88	8.38	0.65	4.84e-13	Obesity-related traits;
THYM	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg16586182	chr3:47516702	SCAP	-0.64	-5.61	-0.5	2.03e-7	Colorectal cancer;
THYM	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs67311347	0.544	rs9864601	chr3:40345318	C/T	cg24209194	chr3:40518798	ZNF619	0.55	4.6	0.43	1.3e-5	Renal cell carcinoma;
THYM	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg23583168	chr7:148888333	NA	-1.03	-13.7	-0.81	3.25e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4237845	0.773	rs6650217	chr12:58289072	T/G	cg22764591	chr12:58329936	NA	1.0	8.13	0.64	1.62e-12	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs1065852	0.526	rs9607869	chr22:42418110	T/A	cg01059385	chr22:42394853	WBP2NL	0.57	4.5	0.42	1.95e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs1461503	0.966	rs10892939	chr11:122841959	T/C	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs9549260	0.755	rs9549244	chr13:41218685	C/T	cg21288729	chr13:41239152	FOXO1	0.74	5.84	0.51	7.15e-8	Red blood cell count;
THYM	cis	rs17253792	0.822	rs75936910	chr14:56149351	T/C	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg09085632	chr11:111637200	PPP2R1B	1.1	11.1	0.75	7.4e-19	Primary sclerosing cholangitis;
THYM	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg08873628	chr1:175162347	KIAA0040	0.5	4.5	0.42	1.93e-5	Alcohol dependence;
THYM	cis	rs3134353	0.740	rs3134359	chr8:101958568	G/C	cg04962480	chr8:101962118	YWHAZ	-0.33	-4.49	-0.42	2.01e-5	Body mass index;
THYM	cis	rs10929159	0.928	rs10929157	chr2:236920156	C/G	cg14895183	chr2:236924282	AGAP1	0.54	4.67	0.43	9.81e-6	Parkinson's disease;
THYM	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg12165864	chr7:66369176	NA	-0.67	-5.26	-0.47	8.99e-7	Aortic root size;
THYM	cis	rs7582180	0.739	rs11123822	chr2:100911582	G/T	cg14675211	chr2:100938903	LONRF2	0.73	7.33	0.6	7.47e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7177026	0.500	rs17193414	chr15:79929610	C/T	cg20511832	chr15:78934280	CHRNB4	0.44	5.04	0.46	2.21e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg15691649	chr6:25882328	NA	0.65	5.01	0.46	2.48e-6	Blood metabolite levels;
THYM	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.72	-0.67	9.16e-14	Mean corpuscular volume;
THYM	cis	rs1003719	0.715	rs9980353	chr21:38558812	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg20999797	chr1:1681921	NA	0.51	5.52	0.49	2.94e-7	Body mass index;
THYM	cis	rs4986811	1.000	rs11031781	chr11:32454262	C/T	cg13301003	chr11:32449254	WT1	0.66	4.92	0.45	3.59e-6	Rubella-specific interleukin-6 secretion;
THYM	cis	rs2066819	1.000	rs59811639	chr12:56695954	C/T	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs752010	0.714	rs7552928	chr1:42086664	C/T	cg06885757	chr1:42089581	HIVEP3	0.6	7.65	0.62	1.61e-11	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg04248312	chr19:17393744	ANKLE1	0.96	12.68	0.79	3.82e-22	Systemic lupus erythematosus;
THYM	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg27168131	chr21:44088823	PDE9A	-0.46	-4.47	-0.42	2.2e-5	Mean corpuscular volume;
THYM	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs870825	0.616	rs36022027	chr4:185639192	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9486719	1.000	rs3798289	chr6:97023632	T/C	cg18709589	chr6:96969512	KIAA0776	-0.68	-4.7	-0.43	8.62e-6	Migraine;Coronary artery disease;
THYM	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg22907277	chr7:1156413	C7orf50	0.87	7.58	0.61	2.31e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9905704	0.881	rs302846	chr17:56687536	T/A	cg12560992	chr17:57184187	TRIM37	0.65	4.51	0.42	1.89e-5	Testicular germ cell tumor;
THYM	cis	rs8073060	0.927	rs7502331	chr17:33868858	A/G	cg24895173	chr17:33825374	SLFN12L	0.6	4.87	0.45	4.48e-6	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg15693483	chr7:1102177	C7orf50	0.54	6.29	0.54	9.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs113835537	0.529	rs75003264	chr11:66256099	G/A	cg24851651	chr11:66362959	CCS	0.71	4.92	0.45	3.62e-6	Airway imaging phenotypes;
THYM	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06850241	chr22:41845214	NA	0.59	5.16	0.47	1.37e-6	Vitiligo;
THYM	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg06558623	chr16:89946397	TCF25	1.33	5.65	0.5	1.64e-7	Skin colour saturation;
THYM	cis	rs2070488	1.000	rs4147025	chr3:38456531	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	6.83	0.57	7.89e-10	Electrocardiographic conduction measures;
THYM	cis	rs89107	0.575	rs72958930	chr6:118983681	G/C	cg01113488	chr6:119027122	NA	0.56	4.81	0.44	5.56e-6	Cardiac structure and function;
THYM	cis	rs6543140	0.964	rs2141781	chr2:103082906	G/A	cg03938978	chr2:103052716	IL18RAP	0.6	5.78	0.51	9.35e-8	Blood protein levels;
THYM	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg20007245	chr22:24372913	LOC391322	-0.8	-7.96	-0.63	3.72e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg18240062	chr17:79603768	NPLOC4	0.73	6.55	0.56	2.9e-9	Eye color traits;
THYM	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg09877947	chr5:131593287	PDLIM4	0.56	4.48	0.42	2.04e-5	Blood metabolite levels;
THYM	cis	rs1355223	0.752	rs286893	chr11:34674882	C/G	cg20014960	chr11:35547311	PAMR1	-0.6	-4.71	-0.43	8.54e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs9364687	0.664	rs4709717	chr6:163894664	A/T	cg01639524	chr6:163818125	NA	0.46	4.48	0.42	2.06e-5	Body mass index;
THYM	cis	rs3796352	1.000	rs34933390	chr3:53006265	T/G	cg07884673	chr3:53033167	SFMBT1	1.19	6.0	0.52	3.59e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs6840360	0.901	rs1946999	chr4:152455339	T/C	cg17479576	chr4:152424074	FAM160A1	-0.63	-4.8	-0.44	5.81e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4731207	0.598	rs2301930	chr7:124465097	A/T	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7216064	0.953	rs2086744	chr17:65849275	C/G	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg18252515	chr7:66147081	NA	-0.6	-4.54	-0.42	1.65e-5	Calcium levels;
THYM	cis	rs4766566	0.501	rs3742004	chr12:111798553	A/G	cg10833066	chr12:111807467	FAM109A	0.61	7.37	0.6	6.38e-11	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
THYM	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg17628894	chr11:804452	LRDD	0.33	4.65	0.43	1.08e-5	Breast cancer;
THYM	cis	rs995000	0.931	rs11208000	chr1:63108374	A/G	cg06896770	chr1:63153194	DOCK7	0.9	7.29	0.6	8.97e-11	Triglyceride levels;
THYM	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg23711669	chr6:146136114	FBXO30	0.96	10.03	0.72	1.41e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4950928	0.823	rs4950929	chr1:203160126	A/C	cg14085262	chr1:203155938	CHI3L1	0.75	5.11	0.46	1.67e-6	YKL-40 levels;
THYM	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg05347473	chr6:146136440	FBXO30	0.79	7.19	0.59	1.5e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs736801	0.704	rs56399423	chr5:131672657	T/C	cg14196790	chr5:131705035	SLC22A5	0.51	4.63	0.43	1.14e-5	Breast cancer;Mosquito bite size;
THYM	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.48	4.52	0.42	1.76e-5	Birth weight;
THYM	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	6.86	0.58	7.07e-10	Total body bone mineral density;
THYM	trans	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg25214090	chr10:38739885	LOC399744	0.86	7.44	0.61	4.54e-11	Corneal astigmatism;
THYM	cis	rs546131	0.600	rs525202	chr11:34821948	A/C	cg06937548	chr11:34938143	PDHX;APIP	0.58	4.59	0.43	1.37e-5	Lung disease severity in cystic fibrosis;
THYM	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg12893697	chr11:970389	AP2A2	-0.33	-5.47	-0.49	3.71e-7	Alzheimer's disease (late onset);
THYM	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg11317459	chr13:21872234	NA	-1.2	-9.08	-0.68	1.49e-14	White matter hyperintensity burden;
THYM	trans	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg10856724	chr12:34555212	NA	-0.89	-8.35	-0.65	5.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.23e-16	Bone mineral density;
THYM	cis	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg02825527	chr7:2087843	MAD1L1	-0.75	-4.92	-0.45	3.62e-6	Bipolar disorder;
THYM	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg18305652	chr10:134549665	INPP5A	0.87	8.04	0.64	2.48e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs1448094	0.512	rs56082822	chr12:86255475	C/T	cg00310523	chr12:86230176	RASSF9	0.53	4.82	0.44	5.5e-6	Major depressive disorder;
THYM	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.45	0.49	3.89e-7	Melanoma;
THYM	cis	rs7178572	0.568	rs12908262	chr15:77493256	G/A	cg22256960	chr15:77711686	NA	-1.04	-8.57	-0.66	1.83e-13	Type 2 diabetes;
THYM	cis	rs9816226	1.000	rs73052033	chr3:185828465	T/C	cg00760338	chr3:185826511	ETV5	-0.77	-4.76	-0.44	7.02e-6	Obesity;Body mass index;
THYM	cis	rs2279817	1.000	rs1339800	chr1:18020201	C/G	cg21791023	chr1:18019539	ARHGEF10L	-0.79	-5.1	-0.46	1.72e-6	Neuroticism;
THYM	cis	rs477692	0.544	rs7894836	chr10:131442595	T/A	cg05714579	chr10:131428358	MGMT	-0.94	-9.65	-0.7	9.22e-16	Response to temozolomide;
THYM	cis	rs5758511	0.508	rs2854827	chr22:42461918	G/A	cg09667013	chr22:42394590	WBP2NL	0.66	4.85	0.45	4.9e-6	Birth weight;
THYM	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg10360139	chr7:1886902	MAD1L1	-0.85	-7.79	-0.62	8.37e-12	Bipolar disorder and schizophrenia;
THYM	cis	rs9543976	0.800	rs4885318	chr13:76151537	G/A	cg01531495	chr13:76123901	UCHL3	0.75	4.97	0.45	3.01e-6	Diabetic retinopathy;
THYM	cis	rs988913	0.957	rs1503147	chr6:54759483	A/G	cg19716238	chr6:54711378	FAM83B	0.51	5.18	0.47	1.22e-6	Menarche (age at onset);
THYM	cis	rs7772486	0.817	rs2144477	chr6:146406248	C/T	cg13319975	chr6:146136371	FBXO30	-0.58	-4.66	-0.43	1.04e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7572733	0.555	rs35563720	chr2:198923075	A/G	cg00792783	chr2:198669748	PLCL1	0.73	4.79	0.44	6.22e-6	Dermatomyositis;
THYM	cis	rs2997447	0.761	rs56299762	chr1:26441638	G/A	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.05	-0.46	2.1e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg01528321	chr10:82214614	TSPAN14	0.69	5.91	0.52	5.3e-8	Post bronchodilator FEV1;
THYM	cis	rs924712	0.615	rs6459034	chr6:54748681	C/T	cg04690482	chr6:54711388	FAM83B	0.44	5.09	0.46	1.78e-6	Breast cancer;
THYM	cis	rs9543976	1.000	rs9573592	chr13:76197843	G/A	cg01531495	chr13:76123901	UCHL3	-0.78	-5.02	-0.46	2.41e-6	Diabetic retinopathy;
THYM	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg02527881	chr3:46936655	PTH1R	0.59	5.63	0.5	1.86e-7	Colorectal cancer;
THYM	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.85	5.47	0.49	3.66e-7	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs728616	0.614	rs1885551	chr10:81712353	A/G	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	trans	rs877282	0.891	rs12767062	chr10:797961	C/T	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg24642439	chr20:33292090	TP53INP2	0.67	4.98	0.46	2.82e-6	Coronary artery disease;
THYM	cis	rs7578361	0.918	rs6756703	chr2:150368964	T/C	cg17961725	chr2:150454027	NA	0.74	5.41	0.48	4.79e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs6876348	0.598	rs2577539	chr5:128301211	A/G	cg25555059	chr5:128301488	SLC27A6	-0.5	-5.56	-0.5	2.5e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1065852	0.526	rs9607869	chr22:42418110	T/A	cg09667013	chr22:42394590	WBP2NL	0.58	5.03	0.46	2.34e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg18681998	chr4:17616180	MED28	0.79	6.79	0.57	9.51e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg10661904	chr17:79619235	PDE6G	0.53	4.74	0.44	7.56e-6	Eye color traits;
THYM	cis	rs4589258	0.933	rs1792600	chr11:90440907	C/G	cg26138821	chr11:89956704	CHORDC1	0.7	5.9	0.52	5.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4455778	0.536	rs38770	chr7:48940586	A/G	cg26309511	chr7:48887640	NA	0.64	6.22	0.54	1.33e-8	Lung cancer in never smokers;
THYM	cis	rs7104764	1.000	rs7483951	chr11:231758	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.1	9.77	0.71	5.16e-16	Menarche (age at onset);
THYM	cis	rs4638749	0.677	rs13423385	chr2:108826435	C/G	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs9658691	0.607	rs9658766	chr10:90771612	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.88	-5.87	-0.52	6.48e-8	Mosquito bite size;
THYM	cis	rs782590	0.870	rs2586950	chr2:55868966	T/G	cg18811423	chr2:55921094	PNPT1	0.75	6.82	0.57	8.38e-10	Metabolic syndrome;
THYM	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg17554472	chr22:41940697	POLR3H	0.68	4.88	0.45	4.34e-6	Vitiligo;
THYM	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs6495122	0.699	rs1378942	chr15:75077367	A/C	cg14664628	chr15:75095509	CSK	0.79	6.28	0.54	9.94e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs4237845	0.804	rs10877034	chr12:58286444	T/C	cg22764591	chr12:58329936	NA	1.02	7.88	0.63	5.32e-12	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.44	5.27	0.48	8.52e-7	Monocyte percentage of white cells;
THYM	cis	rs877282	0.945	rs71491311	chr10:791747	G/A	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg06558623	chr16:89946397	TCF25	1.34	5.7	0.51	1.32e-7	Skin colour saturation;
THYM	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg21028142	chr17:79581711	NPLOC4	0.64	6.74	0.57	1.23e-9	Eye color traits;
THYM	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg05025164	chr4:1340916	KIAA1530	-0.68	-5.31	-0.48	7.31e-7	Obesity-related traits;
THYM	trans	rs8002861	0.781	rs9525857	chr13:44437072	T/C	cg17145862	chr1:211918768	LPGAT1	0.87	9.02	0.68	2.02e-14	Leprosy;
THYM	cis	rs919433	0.890	rs979020	chr2:198169749	T/C	cg00792783	chr2:198669748	PLCL1	-0.67	-4.53	-0.42	1.74e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg26384229	chr12:38710491	ALG10B	0.97	7.47	0.61	3.8e-11	Bladder cancer;
THYM	cis	rs9790314	0.521	rs60625846	chr3:161084525	G/T	cg04691961	chr3:161091175	C3orf57	-0.59	-4.87	-0.45	4.45e-6	Morning vs. evening chronotype;
THYM	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg12564285	chr5:131593104	PDLIM4	0.62	7.53	0.61	2.86e-11	Acylcarnitine levels;
THYM	cis	rs2976388	1.000	rs10216533	chr8:143763690	G/A	cg13446199	chr8:143762866	PSCA	0.51	6.42	0.55	5.46e-9	Urinary tract infection frequency;
THYM	cis	rs11252926	0.617	rs11253319	chr10:722732	C/T	cg14018140	chr10:458528	DIP2C	0.58	5.38	0.48	5.36e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs12681287	0.752	rs10103229	chr8:87248954	C/T	cg27223183	chr8:87520930	FAM82B	0.66	5.0	0.46	2.66e-6	Caudate activity during reward;
THYM	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4720575	0.868	rs7779776	chr7:47092914	C/G	cg00036614	chr7:47093842	NA	-0.59	-5.19	-0.47	1.19e-6	Angiotensin-converting enzyme inhibitor intolerance;
THYM	cis	rs6754311	0.773	rs4988183	chr2:136622046	T/C	cg20242066	chr2:136595261	LCT	0.49	5.16	0.47	1.38e-6	Mosquito bite size;
THYM	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg05896524	chr21:47604654	C21orf56	0.83	5.44	0.49	4.15e-7	Testicular germ cell tumor;
THYM	cis	rs17253792	0.822	rs80085988	chr14:56096173	A/G	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg16414030	chr3:133502952	NA	-0.65	-5.4	-0.48	4.98e-7	Iron status biomarkers;
THYM	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg00383909	chr3:49044727	WDR6	1.12	6.62	0.56	2.13e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg00071950	chr4:10020882	SLC2A9	0.58	5.14	0.47	1.46e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg13447684	chr7:1895903	MAD1L1	-0.55	-5.1	-0.46	1.76e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg14972814	chr11:95582409	MTMR2	-0.58	-4.95	-0.45	3.26e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs858239	0.665	rs858305	chr7:23242830	C/G	cg05407003	chr7:23246146	NA	0.7	6.14	0.53	1.9e-8	Cerebrospinal fluid biomarker levels;
THYM	cis	rs11711311	0.910	rs62265549	chr3:113396234	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.57	-4.78	-0.44	6.38e-6	IgG glycosylation;
THYM	cis	rs4555082	1.000	rs66777564	chr14:105760245	A/G	cg22841779	chr14:105766346	BRF1	-0.49	-6.32	-0.54	8.46e-9	Mean platelet volume;Platelet distribution width;
THYM	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg21856205	chr7:94953877	PON1	0.75	6.96	0.58	4.36e-10	Paraoxonase activity;
THYM	cis	rs6499255	0.951	rs11641233	chr16:69734563	C/T	cg00738113	chr16:70207722	CLEC18C	-0.44	-4.57	-0.42	1.45e-5	IgE levels;
THYM	cis	rs10479542	0.766	rs9286047	chr5:178969147	C/A	cg21226059	chr5:178986404	RUFY1	-0.47	-4.6	-0.43	1.33e-5	Lung cancer;
THYM	cis	rs67981189	0.529	rs61990387	chr14:71491567	A/G	cg15910301	chr14:71632612	NA	0.56	4.88	0.45	4.23e-6	Schizophrenia;
THYM	cis	rs752010	0.934	rs11210503	chr1:42101134	A/G	cg22486000	chr1:42919398	ZMYND12	-0.41	-4.62	-0.43	1.23e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs34638657	0.732	rs7205534	chr16:82201618	C/T	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.07	-0.64	2.15e-12	Lung adenocarcinoma;
THYM	cis	rs7618501	0.521	rs3733134	chr3:49939503	C/T	cg24308560	chr3:49941425	MST1R	-0.61	-4.51	-0.42	1.83e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg14598338	chr9:96623480	NA	-0.61	-7.09	-0.59	2.41e-10	DNA methylation (variation);
THYM	cis	rs7586879	0.616	rs11900505	chr2:25131986	A/C	cg15423357	chr2:25149977	NA	0.7	7.76	0.62	9.56e-12	Body mass index;
THYM	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg25039879	chr17:56429692	SUPT4H1	0.75	4.47	0.42	2.18e-5	Cognitive test performance;
THYM	cis	rs3857067	0.806	rs12507575	chr4:95114920	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.6	-0.5	2.08e-7	Type 2 diabetes;
THYM	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.87	7.81	0.63	7.38e-12	Monocyte percentage of white cells;
THYM	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg04990556	chr1:26633338	UBXN11	-0.89	-8.52	-0.66	2.34e-13	Obesity-related traits;
THYM	cis	rs9876781	1.000	rs6442119	chr3:48440178	G/T	cg06066452	chr3:48470258	PLXNB1	0.25	4.5	0.42	1.93e-5	Longevity;
THYM	cis	rs858239	0.699	rs955187	chr7:23194605	A/G	cg05407003	chr7:23246146	NA	0.6	4.9	0.45	3.9e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9560113	0.573	rs61955236	chr13:112242861	G/A	cg15979348	chr13:112237479	NA	0.55	5.15	0.47	1.39e-6	Menarche (age at onset);
THYM	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg22664400	chr11:66445111	RBM4B	0.66	4.47	0.42	2.14e-5	Crohn's disease;
THYM	cis	rs7705042	0.865	rs249641	chr5:141525305	A/G	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg04731861	chr2:219085781	ARPC2	-0.5	-4.5	-0.42	1.93e-5	Colorectal cancer;
THYM	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg21385522	chr1:16154831	NA	0.64	5.17	0.47	1.31e-6	Systolic blood pressure;
THYM	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs7100689	0.646	rs2486302	chr10:82076600	G/A	cg01528321	chr10:82214614	TSPAN14	0.84	6.43	0.55	5.15e-9	Post bronchodilator FEV1;
THYM	cis	rs7646881	1.000	rs73015649	chr3:158450298	C/G	cg19483011	chr3:158453295	NA	-0.78	-5.48	-0.49	3.51e-7	Tetralogy of Fallot;
THYM	cis	rs1775715	0.870	rs11008700	chr10:32236937	A/G	cg04359828	chr10:32216031	ARHGAP12	0.39	4.87	0.45	4.38e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg07424592	chr7:64974309	NA	1.15	5.47	0.49	3.58e-7	Diabetic kidney disease;
THYM	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg05660106	chr1:15850417	CASP9	0.76	6.27	0.54	1.06e-8	Systolic blood pressure;
THYM	cis	rs988913	0.706	rs4715489	chr6:54732965	C/T	cg19716238	chr6:54711378	FAM83B	0.52	5.23	0.47	1.02e-6	Menarche (age at onset);
THYM	cis	rs2115630	1.000	rs2115630	chr15:85364516	C/T	cg11189052	chr15:85197271	WDR73	-0.62	-4.81	-0.44	5.63e-6	P wave terminal force;
THYM	cis	rs28595532	0.764	rs115011450	chr4:119778171	C/T	cg21605333	chr4:119757512	SEC24D	1.67	6.17	0.53	1.69e-8	Cannabis dependence symptom count;
THYM	trans	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.8	8.98	0.68	2.52e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg19418458	chr7:158789849	NA	0.68	5.98	0.52	3.88e-8	Facial morphology (factor 20);
THYM	cis	rs4731207	0.596	rs10274513	chr7:124650537	T/C	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs8133932	0.637	rs7283688	chr21:47301354	T/A	cg20357416	chr21:47294739	PCBP3	-0.89	-5.87	-0.52	6.3e-8	Schizophrenia;
THYM	cis	rs11252926	0.501	rs2050971	chr10:525530	T/G	cg14018140	chr10:458528	DIP2C	0.54	5.58	0.5	2.27e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg11764359	chr7:65958608	NA	-0.82	-6.44	-0.55	4.87e-9	Aortic root size;
THYM	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg09307838	chr4:120376055	NA	0.71	5.08	0.46	1.91e-6	Corneal astigmatism;
THYM	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg14798641	chr3:49314920	USP4;C3orf62	-0.66	-4.63	-0.43	1.17e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg02725872	chr8:58115012	NA	-0.88	-6.24	-0.54	1.24e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg05157140	chr7:1272545	UNCX	0.45	4.45	0.42	2.35e-5	Subjective well-being;
THYM	cis	rs12142240	0.698	rs6683192	chr1:46830257	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg19077165	chr18:44547161	KATNAL2	-0.6	-7.6	-0.62	2.04e-11	Personality dimensions;
THYM	cis	rs16866061	1.000	rs11681451	chr2:225334104	T/C	cg12698349	chr2:225449008	CUL3	1.1	9.52	0.7	1.78e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs4455778	0.536	rs38773	chr7:48939501	T/C	cg26309511	chr7:48887640	NA	0.65	6.19	0.54	1.51e-8	Lung cancer in never smokers;
THYM	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg02018176	chr4:1364513	KIAA1530	0.68	6.05	0.53	2.86e-8	Longevity;
THYM	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg05283184	chr6:79620031	NA	0.89	8.86	0.67	4.59e-14	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs1150668	0.768	rs1150716	chr6:28262698	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.65	-5.06	-0.46	2.06e-6	Pubertal anthropometrics;
THYM	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg15556689	chr8:8085844	FLJ10661	0.74	5.97	0.52	4.09e-8	Red cell distribution width;
THYM	cis	rs863345	0.625	rs11264978	chr1:158447921	T/C	cg12129480	chr1:158549410	OR10X1	-0.49	-4.77	-0.44	6.59e-6	Pneumococcal bacteremia;
THYM	cis	rs7822232	0.908	rs7821112	chr8:145147169	G/A	cg12091641	chr8:145180933	NA	1.01	4.87	0.45	4.36e-6	Blood metabolite levels;
THYM	cis	rs9549260	0.755	rs9532577	chr13:41231542	A/G	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg07936489	chr17:37558343	FBXL20	0.84	6.13	0.53	2.01e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs9287719	0.753	rs2018512	chr2:10759279	T/G	cg02196655	chr2:10830764	NOL10	-0.45	-4.77	-0.44	6.77e-6	Prostate cancer;
THYM	cis	rs79839061	0.732	rs73207773	chr4:827249	G/A	cg11017086	chr4:979022	SLC26A1	0.82	4.48	0.42	2.09e-5	Intelligence (multi-trait analysis);
THYM	cis	rs631288	0.793	rs11239952	chr1:146715204	A/G	cg25205988	chr1:146714368	CHD1L	1.17	4.48	0.42	2.04e-5	PR interval in Tripanosoma cruzi seropositivity;
THYM	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg25358565	chr5:93447407	FAM172A	1.27	10.36	0.73	2.76e-17	Diabetic retinopathy;
THYM	cis	rs2997447	0.761	rs12088601	chr1:26445504	G/A	cg03844060	chr1:26490628	NA	0.67	4.52	0.42	1.79e-5	QRS complex (12-leadsum);
THYM	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.57	-5.57	-0.5	2.41e-7	Lymphocyte counts;
THYM	cis	rs10197940	0.532	rs13425170	chr2:152387112	A/C	cg19508488	chr2:152266495	RIF1	0.82	5.87	0.52	6.45e-8	Lung cancer;
THYM	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg17054759	chr22:49844102	NA	-0.53	-5.17	-0.47	1.32e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg02782426	chr3:40428986	ENTPD3	0.51	4.58	0.43	1.43e-5	Renal cell carcinoma;
THYM	cis	rs3796619	1.000	rs1453605	chr4:1075771	C/T	cg27284194	chr4:1044797	NA	0.53	4.95	0.45	3.22e-6	Recombination rate (males);
THYM	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg04654363	chr8:8581213	NA	-0.46	-4.48	-0.42	2.07e-5	Obesity-related traits;
THYM	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg03433033	chr1:76189801	ACADM	-0.51	-5.31	-0.48	7.2e-7	Daytime sleep phenotypes;
THYM	cis	rs4638749	0.677	rs4676187	chr2:108842936	T/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg03806693	chr22:41940476	POLR3H	-0.86	-8.52	-0.66	2.43e-13	Vitiligo;
THYM	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg18538332	chr22:24372958	LOC391322	-0.98	-12.33	-0.78	2e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs4731207	0.596	rs12534466	chr7:124668423	A/G	cg05285228	chr7:124571219	POT1	-0.6	-4.52	-0.42	1.81e-5	Cutaneous malignant melanoma;
THYM	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg13319975	chr6:146136371	FBXO30	-0.72	-6.1	-0.53	2.24e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7631605	0.905	rs17811658	chr3:37214204	T/C	cg21328643	chr3:37258149	NA	-0.52	-4.95	-0.45	3.22e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg01710189	chr8:22454888	PDLIM2	-0.55	-5.13	-0.47	1.52e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7640424	0.819	rs34154497	chr3:107824222	T/C	cg09227934	chr3:107805635	CD47	-0.54	-4.56	-0.42	1.52e-5	Body mass index;
THYM	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	4.46	0.42	2.23e-5	Rheumatoid arthritis;
THYM	cis	rs2404602	0.709	rs11072591	chr15:76649562	A/G	cg23625390	chr15:77176239	SCAPER	0.68	4.97	0.45	3.02e-6	Blood metabolite levels;
THYM	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg13695892	chr22:41940480	POLR3H	-0.87	-6.35	-0.55	7.28e-9	Vitiligo;
THYM	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg23356831	chr14:105996513	TMEM121	0.61	6.45	0.55	4.64e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs9399401	0.626	rs12664563	chr6:142785201	A/G	cg03128060	chr6:142623767	GPR126	0.69	8.91	0.67	3.5e-14	Chronic obstructive pulmonary disease;
THYM	cis	rs1029738	0.659	rs1608553	chr7:22896231	G/C	cg04907244	chr7:22894795	SNORD93	-0.38	-4.89	-0.45	4.1e-6	Fibrinogen levels;
THYM	cis	rs2282300	0.739	rs1933342	chr11:30312825	C/T	cg06241208	chr11:30344200	C11orf46	0.78	5.65	0.5	1.64e-7	Morning vs. evening chronotype;
THYM	cis	rs6720763	0.742	rs16852941	chr2:167927237	C/G	cg10633051	chr2:168042982	XIRP2	0.65	4.96	0.45	3.12e-6	Atopic dermatitis;
THYM	cis	rs728616	0.867	rs12413715	chr10:81687360	G/T	cg18148530	chr10:81370782	SFTPA1	0.77	4.85	0.45	4.76e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9361491	0.608	rs4706729	chr6:79467592	T/G	cg04547799	chr6:79944526	HMGN3	-0.64	-4.47	-0.42	2.13e-5	Intelligence (multi-trait analysis);
THYM	trans	rs4596713	0.539	rs953812	chr9:71787631	T/C	cg16512924	chr15:28394682	HERC2	0.83	6.92	0.58	5.28e-10	Headache;
THYM	cis	rs6754311	0.861	rs12475139	chr2:136786651	A/T	cg07169764	chr2:136633963	MCM6	0.84	7.56	0.61	2.51e-11	Mosquito bite size;
THYM	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9462846	0.853	rs9296401	chr6:42875465	A/G	cg09436375	chr6:42928200	GNMT	-0.37	-4.52	-0.42	1.77e-5	Blood protein levels;
THYM	cis	rs7762018	0.556	rs78233989	chr6:170102041	C/G	cg19338460	chr6:170058176	WDR27	-1.03	-6.18	-0.54	1.57e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.2e-16	Bone mineral density;
THYM	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs34638657	0.872	rs2911423	chr16:82188801	C/T	cg07307142	chr16:82071433	HSD17B2	-1.0	-7.8	-0.63	7.75e-12	Lung adenocarcinoma;
THYM	cis	rs7172809	0.599	rs59386622	chr15:77752693	G/A	cg10437265	chr15:77819839	NA	-0.5	-4.57	-0.42	1.47e-5	Glucose homeostasis traits;
THYM	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs7394190	0.748	rs11000775	chr10:75539010	T/C	cg07699608	chr10:75541558	CHCHD1	0.91	5.04	0.46	2.18e-6	Incident atrial fibrillation;
THYM	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg12560992	chr17:57184187	TRIM37	-0.8	-6.77	-0.57	1.07e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.88	5.51	0.49	3.02e-7	Platelet count;
THYM	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.65	5.92	0.52	5.18e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg24675658	chr1:53192096	ZYG11B	0.55	4.66	0.43	1.04e-5	Monocyte count;
THYM	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg05717871	chr11:638507	DRD4	-0.69	-6.03	-0.53	3.1e-8	Systemic lupus erythematosus;
THYM	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg00024416	chr22:24240387	NA	-0.62	-6.59	-0.56	2.45e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611519	0.929	rs9611466	chr22:41426299	A/T	cg03806693	chr22:41940476	POLR3H	-0.77	-6.07	-0.53	2.59e-8	Neuroticism;
THYM	cis	rs7119	0.717	rs12910975	chr15:77817487	C/T	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg24375607	chr4:120327624	NA	0.59	4.68	0.43	9.43e-6	Corneal astigmatism;
THYM	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg06808227	chr14:105710500	BRF1	-1.07	-9.59	-0.7	1.27e-15	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg26131816	chr17:42072204	PYY	0.55	4.65	0.43	1.08e-5	Menopause (age at onset);
THYM	cis	rs9361491	0.608	rs7451373	chr6:79464171	T/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg09436375	chr6:42928200	GNMT	-0.43	-5.63	-0.5	1.82e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs714027	0.605	rs2899147	chr22:30533065	A/G	cg27665648	chr22:30112403	NA	-0.52	-4.73	-0.44	7.79e-6	Lymphocyte counts;
THYM	trans	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg26043149	chr18:55253948	FECH	1.16	10.82	0.74	2.98e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs922692	0.744	rs2277545	chr15:79083591	T/C	cg22753661	chr15:79092743	ADAMTS7	0.65	4.98	0.45	2.86e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	trans	rs59551326	0.517	rs2829644	chr21:26586324	A/G	cg17452615	chr12:122019080	KDM2B	-0.8	-6.84	-0.57	7.67e-10	Alcohol dependence;
THYM	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg09307838	chr4:120376055	NA	0.71	5.41	0.49	4.61e-7	Corneal astigmatism;
THYM	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg19623624	chr10:135278901	LOC619207	-0.59	-4.72	-0.44	8.28e-6	Systemic lupus erythematosus;
THYM	cis	rs734999	0.524	rs4648448	chr1:2695687	C/T	cg04866029	chr1:2707161	NA	0.43	4.55	0.42	1.61e-5	Ulcerative colitis;
THYM	cis	rs2734839	0.964	rs1076563	chr11:113295909	A/C	cg14159747	chr11:113255604	NA	0.32	6.33	0.54	8.07e-9	Information processing speed;
THYM	cis	rs62435770	1.000	rs980777	chr6:169506833	C/T	cg07652237	chr6:170125491	PHF10	0.54	4.92	0.45	3.56e-6	Loneliness;
THYM	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg18305652	chr10:134549665	INPP5A	0.79	6.5	0.55	3.69e-9	Migraine;
THYM	cis	rs2464469	0.654	rs2067062	chr15:58341954	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.63	-4.7	-0.43	8.77e-6	Barrett's esophagus  or Esophageal adenocarcinoma;
THYM	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg02018176	chr4:1364513	KIAA1530	0.85	7.99	0.63	3.13e-12	Longevity;
THYM	cis	rs11229030	0.893	rs2264054	chr11:57209488	G/A	cg00522883	chr11:57194120	SLC43A3	-0.63	-4.97	-0.45	2.99e-6	Crohn's disease;
THYM	cis	rs7772486	0.875	rs10457794	chr6:146415608	A/G	cg13319975	chr6:146136371	FBXO30	-0.61	-4.96	-0.45	3.05e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1050631	0.564	rs1789549	chr18:33722425	A/G	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.6	4.69	0.43	9.09e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs6719884	1.000	rs6545703	chr2:59032635	G/T	cg09452692	chr2:58468460	FANCL	-0.58	-4.46	-0.42	2.25e-5	Myasthenia gravis;
THYM	cis	rs61931739	0.500	rs7133447	chr12:34041901	A/G	cg06521331	chr12:34319734	NA	-0.93	-8.67	-0.66	1.15e-13	Morning vs. evening chronotype;
THYM	cis	rs12188164	1.000	rs72717410	chr5:428785	A/T	cg26850624	chr5:429559	AHRR	-0.69	-5.39	-0.48	5.09e-7	Cystic fibrosis severity;
THYM	cis	rs12509991	0.617	rs66493452	chr4:127051222	A/G	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg06238570	chr21:40685208	BRWD1	0.89	6.24	0.54	1.19e-8	Cognitive function;
THYM	cis	rs3091242	0.900	rs1811832	chr1:25753565	G/A	cg10117171	chr1:25599238	RHD	-0.72	-5.46	-0.49	3.79e-7	Erythrocyte sedimentation rate;
THYM	cis	rs17641971	0.684	rs4873310	chr8:49990006	A/T	cg00325661	chr8:49890786	NA	0.6	4.79	0.44	6.24e-6	Blood metabolite levels;
THYM	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs2070488	1.000	rs3792527	chr3:38493212	T/C	cg24069376	chr3:38537580	EXOG	0.68	6.73	0.57	1.26e-9	Electrocardiographic conduction measures;
THYM	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	5.52	0.49	2.88e-7	Hip circumference adjusted for BMI;
THYM	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg06074448	chr4:187884817	NA	-1.01	-13.54	-0.81	6.7e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10789491	0.953	rs11211337	chr1:47133811	T/C	cg15501359	chr1:47185051	KIAA0494	1.13	8.17	0.64	1.3e-12	Response to hepatitis C treatment;
THYM	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg03929089	chr4:120376271	NA	-1.01	-11.49	-0.76	1.14e-19	Height;
THYM	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg26752003	chr8:145688521	CYHR1	-0.82	-7.11	-0.59	2.17e-10	Age at first birth;
THYM	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs854765	0.583	rs4925123	chr17:17784374	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-5.9	-0.52	5.6e-8	Total body bone mineral density;
THYM	cis	rs6032067	0.777	rs13042694	chr20:43799368	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.72	-6.77	-0.57	1.05e-9	Blood protein levels;
THYM	cis	rs6121246	0.609	rs2149281	chr20:30417918	G/A	cg13852791	chr20:30311386	BCL2L1	0.89	8.22	0.64	1.01e-12	Mean corpuscular hemoglobin;
THYM	cis	rs12681287	0.752	rs2917557	chr8:87314071	C/T	cg27223183	chr8:87520930	FAM82B	-0.75	-5.64	-0.5	1.74e-7	Caudate activity during reward;
THYM	cis	rs983545	0.745	rs9883633	chr3:16971248	T/G	cg19448816	chr3:16974217	PLCL2	0.55	4.65	0.43	1.08e-5	Blood protein levels;
THYM	cis	rs6988636	1.000	rs58189203	chr8:124184739	G/T	cg23067535	chr8:124195133	FAM83A	-1.1	-5.77	-0.51	9.8e-8	Urinary uromodulin levels;
THYM	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg03476357	chr21:30257390	N6AMT1	-0.62	-4.62	-0.43	1.23e-5	Dental caries;
THYM	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11644478	chr21:40555479	PSMG1	0.64	4.66	0.43	1.04e-5	Cognitive function;
THYM	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg11301795	chr4:187892539	NA	-1.08	-14.93	-0.84	1.17e-26	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2073300	1.000	rs6106656	chr20:23444301	A/G	cg12062639	chr20:23401060	NAPB	1.32	6.06	0.53	2.7e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs11169225	0.756	rs377470	chr12:50339290	T/G	cg23855989	chr12:50355821	AQP5	0.54	4.79	0.44	6.15e-6	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg00684032	chr4:1343700	KIAA1530	-0.66	-5.62	-0.5	1.9e-7	Obesity-related traits;
THYM	cis	rs4509693	0.943	rs10732789	chr10:102496184	T/C	cg24127310	chr10:102502104	NA	1.29	10.03	0.72	1.4e-16	Alzheimer's disease;
THYM	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg03806693	chr22:41940476	POLR3H	1.18	10.82	0.74	2.93e-18	Vitiligo;
THYM	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg11645453	chr3:52864694	ITIH4	0.3	4.69	0.43	8.99e-6	Schizophrenia;
THYM	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-6.52	-0.56	3.32e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs289828	0.507	rs55775354	chr2:152118271	G/A	cg05960677	chr2:152117363	RBM43	0.75	7.67	0.62	1.48e-11	Blood protein levels;
THYM	cis	rs17407555	0.697	rs73212821	chr4:10069451	T/A	cg00071950	chr4:10020882	SLC2A9	-0.76	-6.14	-0.53	1.87e-8	Schizophrenia (age at onset);
THYM	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg10117171	chr1:25599238	RHD	-0.65	-4.78	-0.44	6.32e-6	Erythrocyte sedimentation rate;
THYM	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg10523679	chr1:76189770	ACADM	0.9	9.47	0.7	2.2e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs835154	1.000	rs835154	chr5:14876569	A/G	cg02107279	chr5:14870749	ANKH	-0.59	-4.72	-0.44	8.06e-6	Blood metabolite levels;
THYM	cis	rs9527	0.590	rs2281877	chr10:104866062	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs17739794	0.557	rs7816977	chr8:814612	A/G	cg01971667	chr8:817044	NA	0.62	5.7	0.5	1.34e-7	Clozapine-induced cytotoxicity;
THYM	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg13175981	chr1:150552382	MCL1	0.78	6.02	0.53	3.28e-8	Tonsillectomy;
THYM	cis	rs986417	0.818	rs965455	chr14:60960314	A/C	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03517284	chr6:25882590	NA	-0.74	-5.89	-0.52	5.89e-8	Blood metabolite levels;
THYM	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg05738196	chr6:26577821	NA	-0.63	-5.0	-0.46	2.59e-6	Schizophrenia;
THYM	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg23428387	chr22:49814324	NA	-0.5	-4.77	-0.44	6.53e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs28374715	0.578	rs7169543	chr15:41620405	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.78	-0.83	2.3e-26	Ulcerative colitis;
THYM	cis	rs3135718	0.967	rs2981575	chr10:123346116	A/G	cg15049101	chr10:123353889	FGFR2	0.57	5.08	0.46	1.91e-6	Estrogen receptor status in breast cancer;
THYM	cis	rs3204270	0.500	rs62077175	chr17:79649568	G/T	cg13117272	chr17:79681052	SLC25A10	-0.76	-4.7	-0.43	8.93e-6	Dental caries;
THYM	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg17279839	chr7:150038598	RARRES2	0.52	4.63	0.43	1.15e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs36051895	0.626	rs3780368	chr9:5093188	G/C	cg02405213	chr9:5042618	JAK2	-1.0	-10.94	-0.75	1.67e-18	Pediatric autoimmune diseases;
THYM	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg15744005	chr10:104629667	AS3MT	-0.76	-7.03	-0.58	3.13e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.93	-7.18	-0.59	1.56e-10	Homoarginine levels;
THYM	cis	rs17253792	0.822	rs78824140	chr14:56042715	G/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs113835537	0.569	rs17496586	chr11:66315512	G/C	cg24851651	chr11:66362959	CCS	0.67	4.57	0.42	1.45e-5	Airway imaging phenotypes;
THYM	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg12564285	chr5:131593104	PDLIM4	0.54	5.91	0.52	5.24e-8	Blood metabolite levels;
THYM	cis	rs807669	0.933	rs712959	chr22:19159015	C/T	cg02655711	chr22:19163373	SLC25A1	0.7	7.96	0.63	3.63e-12	Metabolite levels;
THYM	cis	rs995000	0.895	rs597470	chr1:62917796	T/G	cg06896770	chr1:63153194	DOCK7	0.89	7.21	0.59	1.3100000000000001e-10	Triglyceride levels;
THYM	cis	rs7586879	0.638	rs10203482	chr2:25136916	T/C	cg27107076	chr2:25050844	ADCY3	-0.29	-4.72	-0.44	8.04e-6	Body mass index;
THYM	cis	rs11605275	1.000	rs11603592	chr11:20023522	C/T	cg14835545	chr11:20032148	NAV2	-1.36	-6.31	-0.54	9.01e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg06582575	chr6:163149167	PACRG;PARK2	1.2	8.02	0.64	2.74e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg19346786	chr7:2764209	NA	-0.55	-4.74	-0.44	7.61e-6	Height;
THYM	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg15693483	chr7:1102177	C7orf50	0.41	5.96	0.52	4.33e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg20891283	chr12:69753455	YEATS4	0.74	6.23	0.54	1.27e-8	Blood protein levels;
THYM	cis	rs360798	0.711	rs6760804	chr2:62906084	T/C	cg00752480	chr2:62680940	NA	-0.26	-4.73	-0.44	7.91e-6	Coronary artery disease;
THYM	cis	rs7208859	0.673	rs3816780	chr17:29161358	C/T	cg19761014	chr17:28927070	LRRC37B2	0.83	5.13	0.47	1.55e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.61	-0.43	1.27e-5	Type 2 diabetes;
THYM	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg16482183	chr6:26056742	HIST1H1C	0.98	6.08	0.53	2.5e-8	Iron status biomarkers;
THYM	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg14664628	chr15:75095509	CSK	-0.74	-5.26	-0.48	8.82e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs800586	0.564	rs2737240	chr8:116657235	A/G	cg04656070	chr8:116661063	TRPS1	-0.5	-5.12	-0.47	1.59e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs1335645	0.570	rs67493833	chr1:111649241	A/T	cg00321911	chr1:111669324	DRAM2	-1.12	-6.15	-0.53	1.8e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4631830	0.720	rs2125770	chr10:51514824	T/C	cg16070123	chr10:51489643	NA	-0.48	-4.5	-0.42	1.92e-5	Prostate-specific antigen levels;
THYM	cis	rs782590	0.902	rs7582278	chr2:55742924	C/G	cg18811423	chr2:55921094	PNPT1	0.74	6.88	0.58	6.26e-10	Metabolic syndrome;
THYM	cis	rs7084402	0.967	rs11006171	chr10:60278487	C/T	cg07615347	chr10:60278583	BICC1	-0.56	-5.15	-0.47	1.42e-6	Refractive error;
THYM	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg18402987	chr7:1209562	NA	0.72	5.21	0.47	1.1e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.58	-0.5	2.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1061377	1.000	rs7655122	chr4:39122016	A/G	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs7582180	0.627	rs4851312	chr2:101011241	G/A	cg08017756	chr2:100939284	LONRF2	-0.71	-7.26	-0.6	1.07e-10	Intelligence (multi-trait analysis);
THYM	cis	rs10191773	0.535	rs56187472	chr2:113111668	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.79	-5.16	-0.47	1.34e-6	Yeast infection;
THYM	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg25072359	chr17:41440525	NA	0.71	5.22	0.47	1.04e-6	Menopause (age at onset);
THYM	cis	rs6686842	1.000	rs213733	chr1:41576989	T/C	cg03387723	chr1:41708464	SCMH1	0.44	5.22	0.47	1.04e-6	Height;
THYM	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg06618935	chr21:46677482	NA	-0.98	-9.58	-0.7	1.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6500395	0.926	rs11076570	chr16:48597915	G/A	cg04672837	chr16:48644449	N4BP1	0.48	4.61	0.43	1.24e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg13609457	chr4:120235615	NA	-0.6	-5.42	-0.49	4.6e-7	Corneal astigmatism;
THYM	cis	rs12643440	0.574	rs12651694	chr4:17139359	G/A	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs990171	1.000	rs2058660	chr2:103054449	G/A	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.17	-0.47	1.27e-6	Lymphocyte counts;
THYM	cis	rs3796619	1.000	rs55741287	chr4:1094670	T/C	cg27284194	chr4:1044797	NA	0.55	4.94	0.45	3.35e-6	Recombination rate (males);
THYM	cis	rs6138458	0.887	rs227622	chr20:24910597	T/C	cg26195577	chr20:24973756	C20orf3	1.11	10.52	0.73	1.29e-17	Blood protein levels;
THYM	cis	rs12971120	0.838	rs747176	chr18:72154931	G/A	cg26446133	chr18:72167187	CNDP2	-0.87	-6.92	-0.58	5.2400000000000005e-10	Refractive error;
THYM	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg13010199	chr12:38710504	ALG10B	0.64	4.61	0.43	1.25e-5	Morning vs. evening chronotype;
THYM	cis	rs901683	1.000	rs71496613	chr10:46032573	A/C	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg20887711	chr4:1340912	KIAA1530	-0.71	-6.11	-0.53	2.14e-8	Obesity-related traits;
THYM	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.53	0.49	2.84e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.88	5.74	0.51	1.15e-7	Smoking behavior;
THYM	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg14517863	chr17:44321492	NA	-0.47	-5.22	-0.47	1.07e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs3820068	0.608	rs12760450	chr1:16037282	G/A	cg13390004	chr1:15929781	NA	0.65	4.82	0.44	5.45e-6	Systolic blood pressure;
THYM	cis	rs9534288	0.830	rs2296641	chr13:46632226	A/C	cg15192986	chr13:46630673	CPB2	-0.66	-4.66	-0.43	1.03e-5	Blood protein levels;
THYM	cis	rs11711311	0.955	rs34048496	chr3:113414121	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.56	-4.78	-0.44	6.37e-6	IgG glycosylation;
THYM	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg00814883	chr7:100076585	TSC22D4	-1.0	-6.73	-0.57	1.26e-9	Platelet count;
THYM	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg15704280	chr7:45808275	SEPT13	-1.06	-15.39	-0.84	1.51e-27	Height;
THYM	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	5.45	0.49	4.01e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs332507	0.830	rs62265580	chr3:124359842	C/T	cg14688451	chr3:124303035	KALRN	0.59	4.64	0.43	1.1e-5	Plateletcrit;
THYM	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg27129171	chr3:47204927	SETD2	0.8	7.67	0.62	1.5e-11	Colorectal cancer;
THYM	trans	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs4285028	0.699	rs1920298	chr3:121597888	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.81	-5.78	-0.51	9.34e-8	Multiple sclerosis;
THYM	cis	rs921968	0.643	rs711191	chr2:219386084	T/A	cg02176678	chr2:219576539	TTLL4	0.68	6.71	0.57	1.42e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg00684032	chr4:1343700	KIAA1530	0.55	4.76	0.44	7e-6	Obesity-related traits;
THYM	cis	rs2276314	0.857	rs4799408	chr18:33588982	C/T	cg19628046	chr18:33552617	C18orf21	-0.74	-5.43	-0.49	4.29e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs7000551	0.689	rs2122878	chr8:22311916	T/C	cg12081754	chr8:22256438	SLC39A14	0.63	5.47	0.49	3.57e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs3126085	0.935	rs10749669	chr1:152177289	A/C	cg26020982	chr1:152196106	HRNR	-0.36	-5.0	-0.46	2.61e-6	Atopic dermatitis;
THYM	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg14196790	chr5:131705035	SLC22A5	0.51	4.57	0.42	1.47e-5	Breast cancer;Mosquito bite size;
THYM	cis	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg00495681	chr13:53174319	NA	0.73	6.69	0.57	1.57e-9	Lewy body disease;
THYM	trans	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.81	-8.67	-0.66	1.17e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs985746	0.527	rs11096835	chr4:36808033	T/C	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg18252515	chr7:66147081	NA	1.48	8.83	0.67	5.15e-14	Diabetic kidney disease;
THYM	cis	rs4460079	0.531	rs4401517	chr4:114846759	T/C	cg02060584	chr4:113970739	ANK2	0.59	4.93	0.45	3.48e-6	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs2932538	0.922	rs11102508	chr1:113141175	T/C	cg22162597	chr1:113214053	CAPZA1	0.63	5.21	0.47	1.08e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg21427119	chr20:30132790	HM13	-0.86	-5.91	-0.52	5.26e-8	Mean corpuscular hemoglobin;
THYM	cis	rs6450176	0.909	rs10940353	chr5:53299959	A/C	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-6.2	-0.54	1.45e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs7084921	0.578	rs12776318	chr10:101868677	T/G	cg11344164	chr10:101878520	NA	-0.55	-4.69	-0.43	9.12e-6	Bone mineral density;
THYM	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg02640540	chr1:67518911	SLC35D1	0.57	4.57	0.42	1.49e-5	Lymphocyte percentage of white cells;
THYM	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg08885076	chr2:99613938	TSGA10	0.7	6.51	0.56	3.59e-9	Chronic sinus infection;
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg20406758	chr11:2703128	KCNQ1;KCNQ1OT1	0.92	6.84	0.57	7.54e-10	Energy expenditure (24h);
THYM	cis	rs17401966	0.931	rs2236678	chr1:10471789	A/T	cg19773385	chr1:10388646	KIF1B	-0.61	-4.75	-0.44	7.06e-6	Hepatocellular carcinoma;
THYM	trans	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg10856724	chr12:34555212	NA	-0.9	-8.08	-0.64	2.05e-12	Bladder cancer;
THYM	cis	rs11648796	0.717	rs10682	chr16:767430	C/G	cg27144592	chr16:783916	NARFL	0.48	5.18	0.47	1.24e-6	Height;
THYM	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg27121462	chr16:89883253	FANCA	0.58	4.61	0.43	1.24e-5	Vitiligo;
THYM	cis	rs977987	0.778	rs2865528	chr16:75455942	T/C	cg03315344	chr16:75512273	CHST6	0.76	6.27	0.54	1.05e-8	Dupuytren's disease;
THYM	cis	rs6500395	1.000	rs9922734	chr16:48603192	A/G	cg04672837	chr16:48644449	N4BP1	-0.51	-4.98	-0.46	2.78e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs245880	0.740	rs245888	chr7:29190414	C/T	cg17163760	chr7:29186267	CPVL	-0.59	-4.94	-0.45	3.3e-6	Warfarin maintenance dose;
THYM	cis	rs10493773	0.532	rs1889919	chr1:86180034	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.61	-9.14	-0.68	1.15e-14	Urate levels in overweight individuals;
THYM	cis	rs988913	0.706	rs10948880	chr6:54882003	G/T	cg18532076	chr6:54711417	FAM83B	0.5	4.61	0.43	1.27e-5	Menarche (age at onset);
THYM	trans	rs480407	0.857	rs270972	chr2:161691202	G/C	cg06548410	chr19:1997657	BTBD2	0.71	6.92	0.58	5.23e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg21475434	chr5:93447410	FAM172A	0.94	5.59	0.5	2.14e-7	Diabetic retinopathy;
THYM	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg03647317	chr4:187891568	NA	-0.8	-8.72	-0.67	9.02e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs289828	0.507	rs13027425	chr2:152123586	C/G	cg05960677	chr2:152117363	RBM43	0.76	8.12	0.64	1.65e-12	Blood protein levels;
THYM	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg12935359	chr14:103987150	CKB	0.51	5.58	0.5	2.22e-7	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg08885076	chr2:99613938	TSGA10	-0.6	-5.83	-0.51	7.48e-8	Chronic sinus infection;
THYM	cis	rs34783982	0.881	rs2351489	chr15:89501870	A/G	cg26213453	chr15:89455860	MFGE8	0.52	4.69	0.43	9.22e-6	Squamous cell lung carcinoma;
THYM	cis	rs684232	0.644	rs2657613	chr17:623902	T/C	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.39	-4.71	-0.43	8.55e-6	Prostate cancer;
THYM	cis	rs800586	0.500	rs2721956	chr8:116653656	C/T	cg04656070	chr8:116661063	TRPS1	-0.54	-5.99	-0.52	3.67e-8	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg17264618	chr3:40429014	ENTPD3	-0.52	-5.11	-0.46	1.66e-6	Renal cell carcinoma;
THYM	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg17757837	chr7:157058334	UBE3C	0.66	5.32	0.48	6.85e-7	Body mass index;
THYM	cis	rs6032067	0.641	rs34919068	chr20:43755830	C/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.39	-0.48	5.13e-7	Blood protein levels;
THYM	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg12756686	chr19:29218302	NA	0.73	4.85	0.45	4.76e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg16926213	chr1:1841314	NA	0.56	5.87	0.52	6.45e-8	Body mass index;
THYM	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg17554472	chr22:41940697	POLR3H	0.72	5.06	0.46	2.07e-6	Vitiligo;
THYM	cis	rs6499255	0.904	rs12447883	chr16:69722797	T/C	cg00738113	chr16:70207722	CLEC18C	-0.46	-4.59	-0.43	1.35e-5	IgE levels;
THYM	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.39	0.55	6.01e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs7940866	0.803	rs1865296	chr11:130882944	C/T	cg05962950	chr11:130786565	SNX19	-0.73	-5.65	-0.5	1.7e-7	Schizophrenia;
THYM	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg04750100	chr2:136595281	LCT	-0.56	-6.13	-0.53	1.97e-8	Mosquito bite size;
THYM	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg12935359	chr14:103987150	CKB	-0.63	-6.45	-0.55	4.63e-9	Body mass index;
THYM	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7264396	0.563	rs78084033	chr20:34219990	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.58	-0.43	1.38e-5	Total cholesterol levels;
THYM	cis	rs17006441	0.932	rs7613400	chr3:69869519	A/G	cg18496212	chr3:69797108	MITF	-0.67	-6.7	-0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs8180040	0.800	rs11921117	chr3:47294000	T/C	cg27129171	chr3:47204927	SETD2	-0.75	-7.08	-0.59	2.48e-10	Colorectal cancer;
THYM	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg11327659	chr7:150037044	RARRES2	0.42	5.0	0.46	2.62e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs425277	0.917	rs78609670	chr1:2045886	G/T	cg24578937	chr1:2090814	PRKCZ	0.76	7.24	0.6	1.14e-10	Height;
THYM	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg07959070	chr22:50026188	C22orf34	-0.25	-4.68	-0.43	9.42e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.76	-6.38	-0.55	6.46e-9	Systemic lupus erythematosus;
THYM	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3096299	0.781	rs3102381	chr16:89409720	G/C	cg10164272	chr16:89456328	ANKRD11	0.61	4.5	0.42	1.92e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs9560113	0.550	rs1163632	chr13:112231530	T/C	cg10483660	chr13:112241077	NA	-0.66	-7.77	-0.62	9.06e-12	Menarche (age at onset);
THYM	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg17757837	chr7:157058334	UBE3C	0.65	5.24	0.47	9.83e-7	Body mass index;
THYM	cis	rs7616559	0.606	rs931245	chr3:156781395	G/A	cg15697575	chr3:156784781	NA	0.46	6.65	0.56	1.84e-9	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg09904177	chr6:26538194	HMGN4	0.54	4.57	0.42	1.47e-5	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg13395646	chr4:1353034	KIAA1530	-0.56	-5.31	-0.48	7.2e-7	Obesity-related traits;
THYM	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg08736216	chr1:53307985	ZYG11A	-0.6	-5.46	-0.49	3.73e-7	Monocyte count;
THYM	cis	rs1775715	0.737	rs2799012	chr10:32103077	C/T	cg04359828	chr10:32216031	ARHGAP12	0.37	4.91	0.45	3.75e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs9902453	0.817	rs62068625	chr17:28176581	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.66	0.43	1.03e-5	Coffee consumption (cups per day);
THYM	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg18252515	chr7:66147081	NA	0.64	4.9	0.45	3.89e-6	Aortic root size;
THYM	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg02038168	chr22:39784481	NA	0.66	5.51	0.49	3.07e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7107174	0.901	rs10899498	chr11:78124575	C/G	cg02023728	chr11:77925099	USP35	0.63	5.93	0.52	4.98e-8	Testicular germ cell tumor;
THYM	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg24733560	chr20:60626293	TAF4	0.51	4.58	0.43	1.41e-5	Body mass index;
THYM	cis	rs12935418	0.672	rs2602423	chr16:81042028	G/T	cg16651780	chr16:81037892	C16orf61	-0.85	-6.62	-0.56	2.11e-9	Mean corpuscular volume;
THYM	cis	rs1981331	0.609	rs7279368	chr21:48065999	A/G	cg17243659	chr21:48055224	PRMT2	1.36	6.3	0.54	9.09e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs1499972	0.817	rs62263118	chr3:117629053	C/T	cg07612923	chr3:117604196	NA	1.19	5.0	0.46	2.66e-6	Schizophrenia;
THYM	cis	rs3126085	0.935	rs1552993	chr1:152171483	A/G	cg10321714	chr1:152280068	FLG	0.68	5.07	0.46	1.98e-6	Atopic dermatitis;
THYM	cis	rs3772130	0.540	rs7627354	chr3:121562434	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.86	7.17	0.59	1.63e-10	Cognitive performance;
THYM	cis	rs4242434	0.672	rs900267	chr8:22485258	T/C	cg11461670	chr8:22454935	PDLIM2	-0.33	-6.26	-0.54	1.09e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg12463550	chr7:65579703	CRCP	-0.55	-4.48	-0.42	2.07e-5	Aortic root size;
THYM	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7447927	0.950	rs13153461	chr5:138852369	G/A	cg11459648	chr5:138714337	SLC23A1	0.61	5.09	0.46	1.81e-6	Esophageal squamous cell carcinoma;
THYM	cis	rs17407555	0.560	rs73229842	chr4:10044524	C/T	cg00071950	chr4:10020882	SLC2A9	-0.74	-5.62	-0.5	1.87e-7	Schizophrenia (age at onset);
THYM	cis	rs4654899	0.865	rs6673455	chr1:21361048	T/C	cg01072550	chr1:21505969	NA	-0.75	-6.83	-0.57	8.17e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-7.08	-0.59	2.42e-10	Chronic sinus infection;
THYM	cis	rs11785693	0.862	rs17350978	chr8:4983418	G/C	cg26367366	chr8:4980734	NA	1.21	6.11	0.53	2.2e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs9649213	0.555	rs67132564	chr7:98014900	T/A	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg27534772	chr1:16042836	PLEKHM2	0.53	5.9	0.52	5.65e-8	Systolic blood pressure;
THYM	cis	rs921968	0.608	rs832817	chr2:219358603	C/T	cg02176678	chr2:219576539	TTLL4	0.68	6.56	0.56	2.74e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08109568	chr15:31115862	NA	0.64	6.04	0.53	2.98e-8	Huntington's disease progression;
THYM	cis	rs4731207	0.596	rs6971413	chr7:124592668	C/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs2650000	0.798	rs2701175	chr12:121391671	C/A	cg14101638	chr12:121416612	HNF1A	-0.48	-5.23	-0.47	1.01e-6	Metabolic traits;LDL cholesterol;
THYM	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg10515332	chr4:99064459	C4orf37	0.6	4.77	0.44	6.7e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg19077165	chr18:44547161	KATNAL2	-0.59	-7.29	-0.6	9.19e-11	Personality dimensions;
THYM	cis	rs28830936	0.510	rs7174099	chr15:42099059	A/G	cg11010575	chr15:42129464	JMJD7-PLA2G4B;JMJD7	-0.49	-4.59	-0.43	1.35e-5	Diastolic blood pressure;
THYM	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7772486	0.790	rs9386141	chr6:146268623	T/A	cg23711669	chr6:146136114	FBXO30	-0.9	-8.72	-0.67	9.04e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg07532245	chr17:28927093	LRRC37B2	0.71	4.48	0.42	2.04e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	0.515	rs73257955	chr7:1007014	G/A	cg07131210	chr7:1025825	CYP2W1	-0.87	-4.9	-0.45	3.98e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2898681	0.618	rs79471207	chr4:53738524	C/T	cg21521518	chr4:53727714	RASL11B	0.61	5.48	0.49	3.43e-7	Optic nerve measurement (cup area);
THYM	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2645424	0.602	rs3779663	chr8:11671362	C/T	cg09232555	chr8:11619866	NA	-0.42	-4.54	-0.42	1.63e-5	Non-alcoholic fatty liver disease histology (other);Non-alcoholic fatty liver disease histology (lobular);
THYM	cis	rs28595532	0.920	rs115675321	chr4:119742153	A/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs7172809	0.573	rs74025104	chr15:77552587	G/A	cg22256960	chr15:77711686	NA	-0.65	-4.86	-0.45	4.71e-6	Glucose homeostasis traits;
THYM	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg12963246	chr6:28129442	ZNF389	0.53	4.71	0.44	8.3e-6	Parkinson's disease;
THYM	cis	rs800586	0.522	rs2721966	chr8:116665777	C/T	cg04656070	chr8:116661063	TRPS1	-0.53	-6.21	-0.54	1.42e-8	Response to tocilizumab in rheumatoid arthritis;
THYM	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg03929089	chr4:120376271	NA	-1.0	-8.06	-0.64	2.23e-12	Coronary artery disease;
THYM	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg11752832	chr7:134001865	SLC35B4	0.72	4.89	0.45	4.16e-6	Mean platelet volume;
THYM	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7107174	0.892	rs4944196	chr11:78008731	G/A	cg02023728	chr11:77925099	USP35	0.65	5.83	0.51	7.52e-8	Testicular germ cell tumor;
THYM	cis	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg13609457	chr4:120235615	NA	0.59	5.39	0.48	5.05e-7	Corneal astigmatism;
THYM	cis	rs11225247	1.000	rs11605133	chr11:102321203	T/C	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg07061783	chr6:25882402	NA	0.82	7.15	0.59	1.81e-10	Blood metabolite levels;
THYM	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg20503657	chr10:835505	NA	1.37	9.33	0.69	4.52e-15	Eosinophil percentage of granulocytes;
THYM	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08449448	chr8:58056501	NA	0.65	4.65	0.43	1.07e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg27286337	chr10:134555280	INPP5A	0.89	6.84	0.57	7.69e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs1021993	0.857	rs1395756	chr1:209463697	C/A	cg06155620	chr1:209527581	NA	0.57	4.54	0.42	1.68e-5	Gut microbiome composition (winter);
THYM	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg10465839	chr16:1584050	IFT140;TMEM204	-0.61	-5.36	-0.48	5.79e-7	Coronary artery disease;
THYM	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg06532163	chr17:45867833	NA	0.64	6.46	0.55	4.42e-9	IgG glycosylation;
THYM	cis	rs1554120	0.877	rs1017348	chr3:150898634	A/G	cg25117092	chr3:150948274	MED12L;P2RY14	-0.29	-4.7	-0.43	8.68e-6	Heschl's gyrus morphology;
THYM	cis	rs3820068	0.532	rs74057713	chr1:15944620	G/C	cg05660106	chr1:15850417	CASP9	0.77	6.33	0.54	7.9e-9	Systolic blood pressure;
THYM	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg20891283	chr12:69753455	YEATS4	0.79	6.26	0.54	1.11e-8	Response to diuretic therapy;
THYM	cis	rs1003719	0.586	rs2298685	chr21:38533390	C/T	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs6496667	0.683	rs2589973	chr15:90892293	C/T	cg22089800	chr15:90895588	ZNF774	0.81	6.29	0.54	9.53e-9	Rheumatoid arthritis;
THYM	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg12034118	chr1:209979487	IRF6	0.63	5.36	0.48	5.94e-7	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
THYM	cis	rs6987853	0.712	rs2974343	chr8:42400679	G/A	cg09913449	chr8:42400586	C8orf40	1.09	12.3	0.78	2.28e-21	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7267979	1.000	rs6115146	chr20:25304507	G/A	cg08601574	chr20:25228251	PYGB	-0.57	-4.59	-0.43	1.35e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7107174	1.000	rs2512549	chr11:77940163	A/G	cg19901956	chr11:77921274	USP35	0.66	5.27	0.48	8.5e-7	Testicular germ cell tumor;
THYM	cis	rs7264396	0.635	rs3827030	chr20:34474947	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.68	5.15	0.47	1.4e-6	Total cholesterol levels;
THYM	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg04520793	chr17:42248056	ASB16	-0.35	-4.62	-0.43	1.2e-5	Total body bone mineral density;
THYM	cis	rs9534288	0.797	rs6561278	chr13:46572937	T/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg04398451	chr17:18023971	MYO15A	0.88	7.53	0.61	2.85e-11	Total body bone mineral density;
THYM	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg03676636	chr4:99064102	C4orf37	-0.5	-7.54	-0.61	2.74e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6840360	0.615	rs6535822	chr4:152679722	A/G	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06634786	chr22:41940651	POLR3H	0.82	6.08	0.53	2.53e-8	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs2976388	0.533	rs12543368	chr8:143819450	T/C	cg06565975	chr8:143823917	SLURP1	-0.76	-8.91	-0.67	3.46e-14	Urinary tract infection frequency;
THYM	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg00801512	chr17:28996047	NA	-0.79	-5.15	-0.47	1.39e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg24874828	chr4:187887005	NA	-0.76	-8.27	-0.65	8.23e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs73787773	0.668	rs17266115	chr5:111497307	T/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.93	-5.0	-0.46	2.61e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg21773646	chr17:80085082	CCDC57	0.32	4.5	0.42	1.93e-5	Life satisfaction;
THYM	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg02725872	chr8:58115012	NA	-0.74	-5.52	-0.49	2.98e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg12386194	chr3:101231763	SENP7	0.95	7.47	0.61	3.85e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs854765	0.583	rs4341796	chr17:17839024	C/A	cg04398451	chr17:18023971	MYO15A	-0.83	-7.74	-0.62	1.04e-11	Total body bone mineral density;
THYM	cis	rs3741489	1.000	rs4758915	chr12:133477147	A/G	cg03157182	chr12:132655797	NA	-0.65	-4.73	-0.44	7.78e-6	Cognitive function;
THYM	cis	rs62070183	0.938	rs62068432	chr17:31066497	A/G	cg02981443	chr17:31254875	TMEM98	-0.54	-4.81	-0.44	5.69e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs2562456	0.876	rs62110202	chr19:21754601	C/T	cg21751540	chr19:21541537	ZNF738	-0.75	-5.37	-0.48	5.6e-7	Pain;
THYM	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg05552183	chr6:42928497	GNMT	0.59	4.69	0.43	9.17e-6	Plasma homocysteine levels (post-methionine load test);
THYM	cis	rs7107174	1.000	rs10899475	chr11:78051610	T/C	cg19901956	chr11:77921274	USP35	-0.65	-5.38	-0.48	5.38e-7	Testicular germ cell tumor;
THYM	cis	rs929354	1.000	rs1182381	chr7:157043473	G/A	cg05182265	chr7:156933206	UBE3C	0.63	7.91	0.63	4.71e-12	Body mass index;
THYM	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg10518543	chr12:38710700	ALG10B	-0.54	-4.62	-0.43	1.22e-5	Morning vs. evening chronotype;
THYM	cis	rs10203711	0.966	rs907105	chr2:239565052	A/G	cg14580085	chr2:239553406	NA	0.68	6.07	0.53	2.58e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10744422	1.000	rs12255	chr12:123350204	C/T	cg25930673	chr12:123319894	HIP1R	-0.88	-5.11	-0.46	1.65e-6	Schizophrenia;
THYM	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500395	0.735	rs74017013	chr16:48664120	G/A	cg04672837	chr16:48644449	N4BP1	0.47	4.62	0.43	1.18e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg20119798	chr7:94954144	PON1	-0.63	-5.8	-0.51	8.58e-8	Paraoxonase activity;
THYM	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11890956	chr21:40555474	PSMG1	-0.97	-11.25	-0.76	3.73e-19	Cognitive function;
THYM	cis	rs9311676	0.632	rs1126735	chr3:58413408	A/G	cg26110898	chr3:58419937	PDHB	0.45	4.79	0.44	6.17e-6	Systemic lupus erythematosus;
THYM	cis	rs888194	0.677	rs7956194	chr12:109877825	C/T	cg11367159	chr12:110044531	NA	0.56	5.14	0.47	1.45e-6	Neuroticism;
THYM	cis	rs595982	0.527	rs73061658	chr19:49372376	G/C	cg17863274	chr19:49399704	TULP2	-1.01	-6.26	-0.54	1.12e-8	Red cell distribution width;
THYM	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg24308560	chr3:49941425	MST1R	-0.79	-6.93	-0.58	5.04e-10	Intelligence (multi-trait analysis);
THYM	cis	rs116095464	1.000	rs2721025	chr5:347444	G/C	cg00420510	chr5:1089571	SLC12A7	0.78	4.49	0.42	1.98e-5	Breast cancer;
THYM	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg18252515	chr7:66147081	NA	0.72	5.62	0.5	1.87e-7	Aortic root size;
THYM	cis	rs17739794	0.517	rs34109064	chr8:772796	T/C	cg01971667	chr8:817044	NA	-0.74	-6.06	-0.53	2.68e-8	Clozapine-induced cytotoxicity;
THYM	cis	rs1371867	0.846	rs1788197	chr8:101290928	T/C	cg00191853	chr8:101177733	SPAG1	-0.5	-4.87	-0.45	4.39e-6	Atrioventricular conduction;
THYM	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg10862848	chr6:42927986	GNMT	0.53	7.03	0.59	3.06e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs17401966	0.965	rs12751375	chr1:10291874	C/G	cg20482658	chr1:10539492	PEX14	0.39	4.66	0.43	1.04e-5	Hepatocellular carcinoma;
THYM	cis	rs933688	1.000	rs933688	chr5:90762748	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.86	5.85	0.51	6.83e-8	Smoking behavior;
THYM	cis	rs62070183	0.938	rs17781142	chr17:31187216	C/G	cg02981443	chr17:31254875	TMEM98	0.52	4.61	0.43	1.25e-5	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs17641971	0.619	rs7013425	chr8:49953085	G/A	cg00325661	chr8:49890786	NA	0.67	5.17	0.47	1.31e-6	Blood metabolite levels;
THYM	cis	rs7590720	0.802	rs12694383	chr2:216915838	A/G	cg12620499	chr2:216877984	MREG	0.82	5.36	0.48	5.9e-7	Alcohol dependence;
THYM	cis	rs8067545	1.000	rs7211535	chr17:19922364	A/G	cg08626831	chr17:20841558	NA	-0.48	-4.5	-0.42	1.94e-5	Schizophrenia;
THYM	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg17911788	chr17:44343683	NA	-0.56	-5.47	-0.49	3.61e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6032067	0.929	rs2233898	chr20:43850525	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.71	-7.53	-0.61	2.95e-11	Blood protein levels;
THYM	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs28595532	0.920	rs17259284	chr4:119779298	T/C	cg11846333	chr4:119757529	SEC24D	1.45	5.08	0.46	1.92e-6	Cannabis dependence symptom count;
THYM	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg03452623	chr4:187889614	NA	-1.19	-19.02	-0.89	3.66e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2688608	0.647	rs2633319	chr10:75691247	A/T	cg02947784	chr10:75434997	AGAP5	0.48	4.48	0.42	2.08e-5	Inflammatory bowel disease;
THYM	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26314531	chr2:26401878	FAM59B	-0.76	-4.99	-0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg18252515	chr7:66147081	NA	-0.71	-5.67	-0.5	1.56e-7	Aortic root size;
THYM	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg18252515	chr7:66147081	NA	-1.44	-7.65	-0.62	1.61e-11	Diabetic kidney disease;
THYM	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg07648498	chr16:89883185	FANCA	0.61	4.49	0.42	1.99e-5	Vitiligo;
THYM	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.1	12.27	0.78	2.72e-21	Subjective well-being;
THYM	cis	rs6032067	0.641	rs62206437	chr20:43759316	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.73	-7.71	-0.62	1.23e-11	Blood protein levels;
THYM	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg01097406	chr16:89675127	NA	-0.62	-5.04	-0.46	2.23e-6	Vitiligo;
THYM	cis	rs666930	0.967	rs637868	chr1:120257110	A/G	cg19096424	chr1:120255104	PHGDH	0.6	4.71	0.44	8.48e-6	Breast cancer;
THYM	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg04896959	chr15:78267971	NA	0.93	8.6	0.66	1.6e-13	Coronary artery disease or large artery stroke;
THYM	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs10484885	0.775	rs62416027	chr6:90608054	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.69	-5.63	-0.5	1.79e-7	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs2130392	0.926	rs7677893	chr4:185625523	T/C	cg04058563	chr4:185651563	MLF1IP	0.61	6.1	0.53	2.31e-8	Kawasaki disease;
THYM	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg26384229	chr12:38710491	ALG10B	-0.71	-5.62	-0.5	1.9e-7	Morning vs. evening chronotype;
THYM	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs57244997	0.725	rs73028490	chr6:162421657	T/C	cg17173639	chr6:162384350	PARK2	-0.73	-4.64	-0.43	1.13e-5	Mosquito bite size;
THYM	cis	rs1728785	1.000	rs7195979	chr16:68586801	G/A	cg02972257	chr16:68554789	NA	-0.77	-4.85	-0.45	4.84e-6	Ulcerative colitis;
THYM	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.02	0.46	2.4e-6	Prudent dietary pattern;
THYM	cis	rs4731207	0.570	rs10954055	chr7:124589232	C/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.03	-7.08	-0.59	2.43e-10	Platelet count;
THYM	cis	rs7927592	0.513	rs607887	chr11:68196961	C/T	cg16797656	chr11:68205561	LRP5	0.53	6.12	0.53	2.08e-8	Total body bone mineral density;
THYM	trans	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg10856724	chr12:34555212	NA	-0.89	-7.85	-0.63	6.11e-12	Bladder cancer;
THYM	cis	rs829883	0.763	rs249843	chr12:98870987	G/A	cg25150519	chr12:98850993	NA	0.51	5.08	0.46	1.91e-6	Colorectal adenoma (advanced);
THYM	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11098499	0.710	rs4145952	chr4:120155806	C/A	cg09307838	chr4:120376055	NA	0.6	4.67	0.43	9.89e-6	Corneal astigmatism;
THYM	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06850241	chr22:41845214	NA	0.6	5.26	0.47	8.97e-7	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg08847533	chr14:75593920	NEK9	1.04	11.58	0.76	7.45e-20	Height;
THYM	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg10150615	chr22:24372951	LOC391322	-1.01	-11.99	-0.78	1.01e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4638749	1.000	rs10209928	chr2:108863898	C/T	cg06795125	chr2:108905320	SULT1C2	-0.42	-5.48	-0.49	3.42e-7	Blood pressure;
THYM	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg01097406	chr16:89675127	NA	0.89	7.96	0.63	3.68e-12	Vitiligo;
THYM	cis	rs6694672	1.000	rs1412639	chr1:197003593	G/A	cg13682187	chr1:196946512	CFHR5	0.82	4.5	0.42	1.89e-5	Asthma;
THYM	cis	rs3820068	0.705	rs16851731	chr1:15860240	A/G	cg05660106	chr1:15850417	CASP9	1.11	9.62	0.7	1.09e-15	Systolic blood pressure;
THYM	cis	rs4243830	1.000	rs10158949	chr1:6583701	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.09	-6.2	-0.54	1.47e-8	Body mass index;
THYM	cis	rs4595586	0.545	rs1303886	chr12:39366876	G/A	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs4660306	1.000	rs6667191	chr1:45982844	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.43	-0.49	4.37e-7	Homocysteine levels;
THYM	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10887741	0.646	rs1358863	chr10:89426508	T/G	cg13926569	chr10:89418898	PAPSS2	0.62	6.95	0.58	4.46e-10	Exercise (leisure time);
THYM	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg08645402	chr16:4508243	NA	0.79	7.63	0.62	1.82e-11	Schizophrenia;
THYM	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Body mass index;
THYM	cis	rs17253792	0.822	rs17685102	chr14:56129214	A/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg16414030	chr3:133502952	NA	0.84	8.35	0.65	5.49e-13	Iron status biomarkers;
THYM	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg02725872	chr8:58115012	NA	0.88	5.21	0.47	1.1e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7224737	1.000	rs35184688	chr17:40272406	G/C	cg02228675	chr17:40259724	DHX58	-0.66	-5.49	-0.49	3.28e-7	Fibrinogen levels;
THYM	cis	rs34526934	0.672	rs6710142	chr2:177054769	G/A	cg26754761	chr2:177040938	NA	-0.61	-4.71	-0.43	8.6e-6	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs9612	1.000	rs28446957	chr19:44246600	T/A	cg08581076	chr19:44259116	C19orf61	0.68	4.56	0.42	1.5e-5	Exhaled nitric oxide output;
THYM	cis	rs34638657	0.702	rs12599946	chr16:82199831	T/C	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.25	-0.47	9.14e-7	Lung adenocarcinoma;
THYM	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg10515332	chr4:99064459	C4orf37	0.59	4.65	0.43	1.08e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03264133	chr6:25882463	NA	-0.9	-7.51	-0.61	3.23e-11	Intelligence (multi-trait analysis);
THYM	cis	rs4481887	1.000	rs4579792	chr1:248463742	C/T	cg00666640	chr1:248458726	OR2T12	-0.55	-4.5	-0.42	1.89e-5	Common traits (Other);
THYM	cis	rs28735056	0.592	rs12455965	chr18:77688830	G/C	cg20368463	chr18:77673604	PQLC1	-0.67	-5.05	-0.46	2.16e-6	Schizophrenia;
THYM	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg20295408	chr7:1910781	MAD1L1	-0.62	-4.47	-0.42	2.16e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg10018233	chr7:150070692	REPIN1	0.48	6.93	0.58	5.13e-10	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6930083	0.527	rs9470367	chr6:36626932	G/C	cg08179530	chr6:36648295	CDKN1A	-0.83	-5.75	-0.51	1.07e-7	Coronary artery disease;
THYM	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg09184832	chr6:79620586	NA	-0.57	-4.52	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg03467027	chr4:99064603	C4orf37	0.59	4.5	0.42	1.92e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg08132940	chr7:1081526	C7orf50	-1.17	-6.67	-0.56	1.7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6558530	0.965	rs6558529	chr8:1706206	C/T	cg09410841	chr8:1729607	CLN8	0.68	5.14	0.47	1.5e-6	Systolic blood pressure;
THYM	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26314531	chr2:26401878	FAM59B	-0.76	-4.99	-0.46	2.75e-6	Gut microbiome composition (summer);
THYM	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg04842962	chr6:43655489	MRPS18A	0.88	7.39	0.6	5.6e-11	IgG glycosylation;
THYM	cis	rs4523957	0.570	rs2126202	chr17:2095712	G/T	cg16513277	chr17:2031491	SMG6	0.64	5.47	0.49	3.65e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg14893161	chr1:205819251	PM20D1	-0.63	-5.04	-0.46	2.24e-6	Menarche (age at onset);
THYM	cis	rs2932538	0.922	rs12136781	chr1:113090655	C/T	cg22162597	chr1:113214053	CAPZA1	0.66	5.21	0.47	1.09e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs1994135	0.669	rs10844629	chr12:33697096	T/A	cg10856724	chr12:34555212	NA	-0.66	-5.37	-0.48	5.49e-7	Resting heart rate;
THYM	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg12373951	chr3:133503437	NA	0.59	6.56	0.56	2.8e-9	Iron status biomarkers;
THYM	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg11941060	chr3:133502564	NA	-0.82	-6.98	-0.58	4.04e-10	Iron status biomarkers;
THYM	cis	rs7639513	0.591	rs9849171	chr3:12622623	G/C	cg23032965	chr3:12705835	RAF1	1.0	7.83	0.63	6.97e-12	Itch intensity from mosquito bite;
THYM	cis	rs6733011	0.578	rs12468024	chr2:99495980	C/T	cg08885076	chr2:99613938	TSGA10	-0.45	-4.47	-0.42	2.15e-5	Bipolar disorder;
THYM	cis	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs2816062	0.786	rs2745316	chr1:18896830	G/A	cg18795169	chr1:18902165	NA	-0.99	-11.47	-0.76	1.24e-19	Urate levels in lean individuals;
THYM	cis	rs4589258	0.933	rs1783809	chr11:90429251	G/T	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg17509989	chr5:176798049	RGS14	0.68	6.41	0.55	5.63e-9	Hemoglobin concentration;Hematocrit;
THYM	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg23205692	chr1:25664452	TMEM50A	-0.83	-6.37	-0.55	6.66e-9	Erythrocyte sedimentation rate;
THYM	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.68	9.08	0.68	1.5e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7772486	0.875	rs6570736	chr6:146388320	C/T	cg13319975	chr6:146136371	FBXO30	-0.69	-5.77	-0.51	9.86e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2732480	0.500	rs12828309	chr12:48641160	C/T	cg21466736	chr12:48725269	NA	-0.53	-4.93	-0.45	3.44e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs6450176	0.564	rs391470	chr5:53332338	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.93	-8.27	-0.65	8.09e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs7830933	0.955	rs13274775	chr8:23583754	A/C	cg04349084	chr8:23602677	NA	0.68	7.15	0.59	1.82e-10	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.58	-5.51	-0.49	3.05e-7	Lymphocyte counts;
THYM	cis	rs10463554	0.963	rs187427	chr5:102512803	C/T	cg23492399	chr5:102201601	PAM	-0.68	-4.95	-0.45	3.21e-6	Parkinson's disease;
THYM	cis	rs17818399	0.890	rs34544165	chr2:46836906	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.67	4.86	0.45	4.57e-6	Height;
THYM	cis	rs747782	0.582	rs7949865	chr11:48346202	A/C	cg24672777	chr11:48374446	OR4C45	1.16	7.24	0.6	1.16e-10	Intraocular pressure;
THYM	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg24060327	chr5:131705240	SLC22A5	-0.73	-5.47	-0.49	3.61e-7	Blood metabolite levels;
THYM	cis	rs74417235	0.684	rs71590150	chr5:154060512	A/T	cg07371521	chr5:154026371	NA	0.48	4.45	0.42	2.36e-5	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs6988636	1.000	rs61422480	chr8:124188940	C/A	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg26597838	chr10:835615	NA	0.99	5.41	0.49	4.77e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs2898681	0.519	rs6848200	chr4:53730181	A/G	cg00791764	chr4:53727839	RASL11B	0.6	6.58	0.56	2.51e-9	Optic nerve measurement (cup area);
THYM	cis	rs747334	0.846	rs4411211	chr10:92716619	A/G	cg07620928	chr10:92689909	NA	-0.58	-5.12	-0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23248424	chr5:179741104	GFPT2	-0.87	-6.88	-0.58	6.37e-10	Height;
THYM	cis	rs2945412	0.695	rs10775412	chr17:25869033	A/C	cg07487925	chr17:25620950	WSB1	0.62	4.46	0.42	2.29e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg23711669	chr6:146136114	FBXO30	0.89	9.21	0.69	7.96e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs941408	1.000	rs1736183	chr19:2809672	A/G	cg19693284	chr19:2783607	SGTA	0.69	5.48	0.49	3.47e-7	Total cholesterol levels;
THYM	cis	rs17125944	0.615	rs2025632	chr14:53294319	T/C	cg00686598	chr14:53173677	PSMC6	-1.01	-4.78	-0.44	6.39e-6	Alzheimer's disease (late onset);
THYM	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg12963246	chr6:28129442	ZNF389	0.54	4.77	0.44	6.6e-6	Parkinson's disease;
THYM	cis	rs9928842	1.000	rs7202566	chr16:75247644	C/A	cg09066997	chr16:75300724	BCAR1	0.75	4.81	0.44	5.64e-6	Alcoholic chronic pancreatitis;
THYM	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs12643440	0.538	rs56235875	chr4:17138883	T/C	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg14582100	chr15:45693742	SPATA5L1	0.56	4.77	0.44	6.63e-6	Homoarginine levels;
THYM	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg00814883	chr7:100076585	TSC22D4	-0.95	-6.39	-0.55	6.08e-9	Platelet count;
THYM	cis	rs554111	0.656	rs10799680	chr1:21361181	C/T	cg01072550	chr1:21505969	NA	0.59	5.14	0.47	1.45e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs12401457	1.000	rs3738533	chr1:236187365	A/G	cg23056033	chr1:235267807	NA	0.84	4.51	0.42	1.88e-5	Urate levels in overweight individuals;
THYM	cis	rs9972944	0.902	rs9972885	chr17:63771264	G/T	cg07283582	chr17:63770753	CCDC46	0.65	5.25	0.47	9.39e-7	Total body bone mineral density;
THYM	cis	rs1729951	0.575	rs10935213	chr3:136693459	A/G	cg21827317	chr3:136751795	NA	0.75	6.64	0.56	1.92e-9	Neuroticism;
THYM	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg26384229	chr12:38710491	ALG10B	-0.89	-7.28	-0.6	9.77e-11	Bladder cancer;
THYM	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg05738196	chr6:26577821	NA	-0.68	-5.42	-0.49	4.52e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs714027	0.605	rs193476	chr22:30450521	G/A	cg27665648	chr22:30112403	NA	-0.52	-4.73	-0.44	7.79e-6	Lymphocyte counts;
THYM	cis	rs79349575	0.729	rs62075824	chr17:46986679	A/G	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs7551222	0.721	rs1460036	chr1:204527379	A/G	cg20240347	chr1:204465584	NA	-0.51	-4.63	-0.43	1.18e-5	Schizophrenia;
THYM	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs1003719	0.715	rs2835613	chr21:38496883	A/G	cg01329690	chr21:38580129	DSCR9	-0.37	-5.01	-0.46	2.53e-6	Eye color traits;
THYM	cis	rs7104764	1.000	rs7128029	chr11:244141	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs6582630	0.539	rs12308081	chr12:38342881	C/G	cg10518543	chr12:38710700	ALG10B	-0.6	-4.74	-0.44	7.43e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6722750	1.000	rs35573827	chr2:64394433	C/G	cg22352474	chr2:64371530	PELI1	0.65	5.01	0.46	2.46e-6	Neuroticism;
THYM	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2070677	0.736	rs4498943	chr10:135422505	A/T	cg20169779	chr10:135381914	SYCE1	0.74	4.91	0.45	3.86e-6	Gout;
THYM	cis	rs4631830	0.863	rs2611508	chr10:51518047	T/A	cg16070123	chr10:51489643	NA	-0.5	-4.71	-0.44	8.32e-6	Prostate-specific antigen levels;
THYM	cis	rs9534288	0.797	rs1319712	chr13:46591707	T/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs16917546	0.967	rs10995243	chr10:64391208	G/C	cg03961010	chr10:64397487	ZNF365	-0.8	-6.76	-0.57	1.13e-9	Basal cell carcinoma;
THYM	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.83	-7.63	-0.62	1.78e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9311676	0.632	rs11130643	chr3:58423288	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs79387448	0.745	rs74560841	chr2:103149210	G/A	cg09003973	chr2:102972529	NA	0.77	4.7	0.43	8.83e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs6840360	0.967	rs10028410	chr4:152606573	T/C	cg22705602	chr4:152727874	NA	-0.63	-6.84	-0.57	7.53e-10	Intelligence (multi-trait analysis);
THYM	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.33e-5	Alzheimer's disease;
THYM	cis	rs4919087	0.962	rs10882889	chr10:99045890	A/G	cg19453742	chr10:98862320	SLIT1	-0.67	-5.21	-0.47	1.09e-6	Monocyte count;
THYM	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg11845111	chr2:191398756	TMEM194B	-1.01	-8.0	-0.63	2.97e-12	Diastolic blood pressure;
THYM	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	6.45	0.55	4.55e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.96	0.45	3.04e-6	Obesity-related traits;
THYM	cis	rs3741151	0.892	rs76854106	chr11:73027110	G/A	cg12959048	chr11:73096162	RELT	-0.47	-4.53	-0.42	1.69e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg15536230	chr21:44985092	HSF2BP	-0.42	-5.18	-0.47	1.26e-6	Mean corpuscular volume;
THYM	trans	rs916888	0.779	rs199526	chr17:44847707	C/G	cg10053473	chr17:62856997	LRRC37A3	0.87	7.45	0.61	4.36e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs8073060	0.963	rs4795082	chr17:33873501	C/T	cg07895132	chr17:33825172	SLFN12L	0.63	5.67	0.5	1.54e-7	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.38	0.55	6.27e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs72627123	0.867	rs8018226	chr14:74471377	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs899997	1.000	rs12899201	chr15:79033534	G/A	cg00639195	chr15:79103007	ADAMTS7	-0.76	-5.36	-0.48	5.78e-7	Coronary artery disease or large artery stroke;
THYM	cis	rs6429082	0.818	rs291386	chr1:235647050	C/T	cg26050004	chr1:235667680	B3GALNT2	0.74	6.18	0.54	1.6e-8	Adiposity;
THYM	cis	rs216026	0.689	rs216052	chr12:2766942	A/G	cg19945202	chr12:2788847	CACNA1C	0.75	4.97	0.45	2.94e-6	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs981844	0.857	rs62325140	chr4:154714161	C/A	cg09973105	chr4:154681532	RNF175	-0.67	-5.58	-0.5	2.25e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs3847687	1.000	rs3847687	chr12:131525053	C/T	cg25772418	chr12:131519998	GPR133	-0.49	-7.32	-0.6	7.9e-11	Longevity;
THYM	cis	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg23422044	chr7:1970798	MAD1L1	-0.77	-4.99	-0.46	2.71e-6	Neuroticism;
THYM	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs6570726	0.791	rs1280275	chr6:145892402	C/T	cg05347473	chr6:146136440	FBXO30	0.58	4.52	0.42	1.8e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg12379764	chr21:47803548	PCNT	-0.83	-5.37	-0.48	5.52e-7	Testicular germ cell tumor;
THYM	cis	rs931812	0.825	rs34153562	chr8:101893441	T/C	cg07239293	chr8:101170671	SPAG1	0.68	4.63	0.43	1.17e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs6960043	0.818	rs10228066	chr7:15063569	C/T	cg19272540	chr7:15055459	NA	-0.42	-4.71	-0.44	8.42e-6	Type 2 diabetes;
THYM	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9470366	0.883	rs9462207	chr6:36627599	T/C	cg24425727	chr6:36645648	CDKN1A	-0.61	-4.63	-0.43	1.16e-5	QRS duration;
THYM	cis	rs757110	0.900	rs2074314	chr11:17411821	C/T	cg15432903	chr11:17409602	KCNJ11	0.64	7.59	0.61	2.14e-11	Type 2 diabetes;
THYM	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg08736216	chr1:53307985	ZYG11A	0.71	6.26	0.54	1.1e-8	Monocyte count;
THYM	cis	rs1483890	0.642	rs1843049	chr3:69404078	T/C	cg22125112	chr3:69402811	FRMD4B	0.54	6.78	0.57	1.02e-9	Resting heart rate;
THYM	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg12963246	chr6:28129442	ZNF389	0.62	4.72	0.44	8.16e-6	Parkinson's disease;
THYM	cis	rs36051895	0.658	rs62541531	chr9:5011795	C/T	cg02405213	chr9:5042618	JAK2	-1.05	-11.55	-0.76	8.48e-20	Pediatric autoimmune diseases;
THYM	cis	rs9902453	0.967	rs56326816	chr17:28492805	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	4.6	0.43	1.33e-5	Coffee consumption (cups per day);
THYM	cis	rs7187994	0.848	rs35019923	chr16:84782214	A/C	cg07647771	chr16:84786436	USP10	-0.55	-5.06	-0.46	2.03e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg22875332	chr1:76189707	ACADM	0.89	12.06	0.78	7.38e-21	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4917300	0.549	rs902819	chr8:143098548	C/T	cg25363559	chr8:143086065	NA	-0.56	-5.12	-0.47	1.59e-6	Amyotrophic lateral sclerosis;
THYM	cis	rs425277	1.000	rs809912	chr1:2078385	C/T	cg13918804	chr1:2043761	PRKCZ	-0.61	-4.62	-0.43	1.19e-5	Height;
THYM	cis	rs10463554	0.963	rs13340364	chr5:102339110	G/A	cg23492399	chr5:102201601	PAM	-0.68	-5.27	-0.48	8.54e-7	Parkinson's disease;
THYM	cis	rs735396	1.000	rs2464195	chr12:121435475	G/A	cg02403541	chr12:121454288	C12orf43	0.59	4.74	0.44	7.63e-6	N-glycan levels;
THYM	cis	rs12122100	0.526	rs12122534	chr1:146504399	A/G	cg03526459	chr1:146549940	NA	0.57	5.13	0.47	1.55e-6	HIV-1 control;
THYM	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg00631329	chr6:26305371	NA	-0.63	-7.46	-0.61	3.99e-11	Educational attainment;
THYM	cis	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg21775007	chr8:11205619	TDH	0.58	4.52	0.42	1.82e-5	Retinal vascular caliber;
THYM	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg05932139	chr16:680872	WFIKKN1	-0.61	-5.15	-0.47	1.39e-6	Height;
THYM	cis	rs7027203	0.797	rs7870672	chr9:96606693	A/C	cg14598338	chr9:96623480	NA	-0.49	-5.22	-0.47	1.07e-6	DNA methylation (variation);
THYM	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg13319975	chr6:146136371	FBXO30	0.75	6.25	0.54	1.17e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2294693	0.947	rs736793	chr6:40997919	A/T	cg14418226	chr6:40996092	UNC5CL	0.76	6.98	0.58	3.88e-10	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs8018808	0.967	rs4903579	chr14:77850940	T/A	cg20045696	chr14:77926864	AHSA1	-0.59	-5.39	-0.48	5.16e-7	Myeloid white cell count;
THYM	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg02527881	chr3:46936655	PTH1R	0.58	5.31	0.48	7.1e-7	QT interval;
THYM	cis	rs56104184	0.830	rs73061614	chr19:49343289	T/C	cg26267310	chr19:49340593	PLEKHA4;HSD17B14	0.88	5.54	0.49	2.75e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs6877440	1.000	rs10072541	chr5:109041844	T/C	cg17395555	chr5:108820864	NA	0.55	4.65	0.43	1.09e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2219968	0.700	rs12541492	chr8:78863766	C/G	cg00738934	chr8:78996279	NA	-0.78	-7.47	-0.61	3.92e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9814567	0.727	rs4245908	chr3:134349205	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-7.37	-0.6	6.34e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.59	-7.39	-0.6	5.73e-11	Longevity;Endometriosis;
THYM	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg19729930	chr2:74357872	NA	1.23	10.61	0.74	8.43e-18	Gestational age at birth (maternal effect);
THYM	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg10589385	chr1:150898437	SETDB1	0.62	5.08	0.46	1.9e-6	Melanoma;
THYM	cis	rs611744	0.819	rs424012	chr8:109154652	A/G	cg21045802	chr8:109455806	TTC35	0.61	5.07	0.46	1.93e-6	Dupuytren's disease;
THYM	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg13607699	chr17:42295918	UBTF	-0.91	-9.45	-0.7	2.47e-15	Total body bone mineral density;
THYM	trans	rs11722228	0.508	rs61335146	chr4:10130793	G/C	cg26043149	chr18:55253948	FECH	1.13	10.55	0.73	1.12e-17	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs7264396	0.836	rs6058282	chr20:34212590	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-5.79	-0.51	9.19e-8	Total cholesterol levels;
THYM	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.57	-5.64	-0.5	1.78e-7	Longevity;Endometriosis;
THYM	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg26031613	chr14:104095156	KLC1	0.68	4.59	0.43	1.37e-5	Body mass index;
THYM	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4631830	0.720	rs2012677	chr10:51504797	T/A	cg10326726	chr10:51549505	MSMB	-0.59	-5.97	-0.52	4.13e-8	Prostate-specific antigen levels;
THYM	cis	rs6598955	0.670	rs12733645	chr1:26540356	G/T	cg00852783	chr1:26633632	UBXN11	0.82	7.95	0.63	3.8e-12	Obesity-related traits;
THYM	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg17054759	chr22:49844102	NA	-0.51	-4.88	-0.45	4.3e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs62045849	0.557	rs4782444	chr16:89183973	A/G	cg06035645	chr16:89190857	ACSF3	-0.88	-5.55	-0.5	2.53e-7	Red blood cell count;
THYM	cis	rs7078219	0.714	rs60386053	chr10:101288861	G/A	cg17888390	chr10:101282816	NA	-0.53	-5.14	-0.47	1.46e-6	Dental caries;
THYM	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg17264618	chr3:40429014	ENTPD3	0.53	4.93	0.45	3.52e-6	Renal cell carcinoma;
THYM	cis	rs7100689	0.753	rs1361458	chr10:82090339	A/T	cg01528321	chr10:82214614	TSPAN14	1.02	7.84	0.63	6.52e-12	Post bronchodilator FEV1;
THYM	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.31	4.71	0.44	8.36e-6	Obesity-related traits;
THYM	cis	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg09307838	chr4:120376055	NA	0.71	5.41	0.49	4.61e-7	Corneal astigmatism;
THYM	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs11225247	0.881	rs77227803	chr11:102255684	T/C	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs11563648	0.573	rs1419394	chr7:126962068	C/T	cg08586737	chr7:127225949	GCC1	0.33	4.53	0.42	1.74e-5	Resting heart rate;
THYM	cis	rs12310956	0.515	rs1852221	chr12:33945489	G/T	cg10856724	chr12:34555212	NA	-0.74	-6.6	-0.56	2.36e-9	Morning vs. evening chronotype;
THYM	cis	rs1050631	0.574	rs1789507	chr18:33732354	A/C	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.6	4.69	0.43	9.09e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs6733011	0.628	rs4263159	chr2:99456151	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.46	-0.42	2.26e-5	Bipolar disorder;
THYM	cis	rs1023500	1.000	rs1023500	chr22:42340844	C/T	cg19448990	chr22:41842841	TOB2	0.73	4.71	0.44	8.43e-6	Schizophrenia;
THYM	cis	rs7940866	0.845	rs1991899	chr11:130801649	C/T	cg05962950	chr11:130786565	SNX19	-0.62	-4.94	-0.45	3.33e-6	Schizophrenia;
THYM	cis	rs9486719	1.000	rs2472882	chr6:96863474	C/T	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg12011299	chr4:100065546	ADH4	0.86	8.22	0.64	1.02e-12	Alcohol dependence;
THYM	cis	rs1278769	0.735	rs9577395	chr13:113534984	C/G	cg01161842	chr13:113518337	ATP11A	0.68	4.64	0.43	1.11e-5	Interstitial lung disease;
THYM	cis	rs7582180	0.663	rs6542944	chr2:100988038	T/C	cg21926883	chr2:100939477	LONRF2	-0.65	-6.1	-0.53	2.25e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg18132916	chr6:79620363	NA	-0.58	-5.27	-0.48	8.5e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg01069141	chr11:67398826	TBX10;NUDT8	-0.44	-4.57	-0.42	1.46e-5	Mean corpuscular volume;
THYM	cis	rs526231	0.543	rs246913	chr5:102560370	G/C	cg23492399	chr5:102201601	PAM	-0.69	-5.17	-0.47	1.28e-6	Primary biliary cholangitis;
THYM	cis	rs9311676	0.656	rs7647184	chr3:58370046	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs2408955	0.541	rs11168428	chr12:48547128	A/G	cg21466736	chr12:48725269	NA	0.47	4.71	0.43	8.53e-6	Glycated hemoglobin levels;
THYM	cis	rs1298062	0.763	rs2387112	chr19:50984853	A/G	cg11430371	chr19:50961752	MYBPC2	0.46	4.52	0.42	1.77e-5	Age of smoking initiation;
THYM	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	5.73	0.51	1.18e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs3106136	0.546	rs4693003	chr4:95145469	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.1	-0.46	1.7e-6	Capecitabine sensitivity;
THYM	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg17105886	chr17:28927953	LRRC37B2	1.25	6.76	0.57	1.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1018836	0.818	rs2285232	chr8:91546162	C/G	cg16814680	chr8:91681699	NA	-0.87	-7.42	-0.61	5e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg03929089	chr4:120376271	NA	-0.97	-10.53	-0.73	1.25e-17	Coronary artery disease;
THYM	cis	rs7085104	0.513	rs619824	chr10:104581288	G/T	cg04362960	chr10:104952993	NT5C2	0.63	5.48	0.49	3.49e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs1205863	0.764	rs9470768	chr6:12027052	G/A	cg01709473	chr6:12010960	NA	0.55	4.66	0.43	1.01e-5	Disc degeneration (lumbar);
THYM	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg08017756	chr2:100939284	LONRF2	-0.74	-7.65	-0.62	1.65e-11	Intelligence (multi-trait analysis);
THYM	cis	rs2075230	0.705	rs1641538	chr17:7545588	C/T	cg10509001	chr17:7553872	ATP1B2	-0.56	-4.52	-0.42	1.79e-5	Hormone measurements;
THYM	cis	rs4664308	0.618	rs35771982	chr2:160885418	G/C	cg03641300	chr2:160917029	PLA2R1	-0.63	-5.3	-0.48	7.6e-7	Idiopathic membranous nephropathy;
THYM	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg07636037	chr3:49044803	WDR6	0.99	10.4	0.73	2.28e-17	Parkinson's disease;
THYM	cis	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg24672777	chr11:48374446	OR4C45	0.66	4.59	0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs259282	0.562	rs2021772	chr19:33107651	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.57	4.73	0.44	7.88e-6	Schizophrenia;
THYM	cis	rs2276314	0.857	rs4799408	chr18:33588982	C/T	cg05985134	chr18:33552581	C18orf21	-0.66	-4.84	-0.44	5.02e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs865483	0.895	rs2680718	chr17:35816451	T/C	cg06716730	chr17:35851459	DUSP14	0.43	7.3	0.6	8.71e-11	Monocyte count;
THYM	cis	rs10463554	0.963	rs40322	chr5:102446957	A/G	cg23492399	chr5:102201601	PAM	-0.69	-5.09	-0.46	1.83e-6	Parkinson's disease;
THYM	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg23758822	chr17:41437982	NA	1.12	10.64	0.74	7.25e-18	Menopause (age at onset);
THYM	cis	rs59698941	0.943	rs67268447	chr5:132303194	G/A	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-6.68	-0.57	1.63e-9	Alzheimer's disease (late onset);
THYM	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg24920358	chr1:40204285	PPIE	-0.6	-5.57	-0.5	2.39e-7	Blood protein levels;
THYM	cis	rs4523957	0.583	rs2984940	chr17:2023825	A/G	cg16513277	chr17:2031491	SMG6	-0.96	-8.72	-0.67	9.17e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg02136620	chr5:178986620	RUFY1	0.5	4.86	0.45	4.64e-6	Lung cancer;
THYM	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg06618935	chr21:46677482	NA	-0.97	-9.1	-0.68	1.38e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1061377	1.000	rs56119980	chr4:39141010	A/G	cg24403649	chr4:39172243	NA	0.59	4.77	0.44	6.76e-6	Uric acid levels;
THYM	cis	rs1050631	0.564	rs1785904	chr18:33713132	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.28	0.48	8.32e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs2439831	1.000	rs2467426	chr15:43989518	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.78	5.98	0.52	3.98e-8	Lung cancer in ever smokers;
THYM	cis	rs4919044	0.866	rs11187243	chr10:94776499	A/G	cg05127821	chr10:94822908	CYP26C1	-1.29	-6.48	-0.55	4.03e-9	Coronary artery disease;
THYM	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.75	0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg08975724	chr8:8085496	FLJ10661	0.67	4.99	0.46	2.68e-6	Neuroticism;
THYM	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs10489202	0.608	rs7533646	chr1:168077593	A/C	cg24449463	chr1:168025552	DCAF6	-0.69	-5.96	-0.52	4.22e-8	Schizophrenia;
THYM	cis	rs6430585	0.583	rs11886852	chr2:136589379	G/A	cg04750100	chr2:136595281	LCT	0.56	5.91	0.52	5.22e-8	Corneal structure;
THYM	cis	rs4660306	0.961	rs12145526	chr1:45969036	G/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.43	-0.49	4.37e-7	Homocysteine levels;
THYM	cis	rs7681440	0.606	rs2619358	chr4:90752670	A/C	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs4601821	0.823	rs4938013	chr11:113264470	A/C	cg14159747	chr11:113255604	NA	0.25	4.67	0.43	9.7e-6	Alcoholic chronic pancreatitis;
THYM	cis	rs4654899	0.758	rs6689852	chr1:21341051	T/C	cg01072550	chr1:21505969	NA	-0.76	-7.43	-0.61	4.71e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs886774	0.526	rs13243525	chr7:107505518	A/G	cg23293999	chr7:106826042	HBP1	-0.58	-4.65	-0.43	1.07e-5	Ulcerative colitis;
THYM	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.65	-0.5	1.64e-7	Prostate cancer;
THYM	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs4722166	0.630	rs2091115	chr7:22810166	G/T	cg26061582	chr7:22766209	IL6	0.61	4.9	0.45	3.97e-6	Lung cancer;
THYM	cis	rs7917772	0.582	rs7907417	chr10:104370662	A/G	cg00122347	chr10:104236741	TMEM180	0.41	5.81	0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.65	6.75	0.57	1.18e-9	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs2361710	1.000	rs2361710	chr17:78111877	C/T	cg09238746	chr17:78121135	EIF4A3	0.6	4.77	0.44	6.72e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
THYM	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06481639	chr22:41940642	POLR3H	-0.81	-5.86	-0.52	6.73e-8	Vitiligo;
THYM	cis	rs9595908	0.900	rs1324414	chr13:33174225	C/T	cg12383807	chr13:33924137	NA	-0.54	-4.85	-0.45	4.72e-6	Body mass index;
THYM	cis	rs41005	1.000	rs193929	chr2:8107620	G/T	cg03155496	chr2:8117019	LOC339788	0.96	9.33	0.69	4.46e-15	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs6988636	1.000	rs16898086	chr8:124190445	A/G	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs1048238	0.506	rs848212	chr1:16263452	A/G	cg21385522	chr1:16154831	NA	-0.71	-5.88	-0.52	6.18e-8	Systolic blood pressure;
THYM	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg11266682	chr4:10021025	SLC2A9	0.72	10.76	0.74	3.94e-18	Bone mineral density;
THYM	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg00484396	chr16:3507460	NAT15	0.68	6.6	0.56	2.35e-9	Tuberculosis;
THYM	cis	rs9876781	1.000	rs11712561	chr3:48435272	C/A	cg06066452	chr3:48470258	PLXNB1	0.28	5.13	0.47	1.54e-6	Longevity;
THYM	cis	rs6547741	0.563	rs10196039	chr2:27971195	C/T	cg27432699	chr2:27873401	GPN1	-0.89	-8.0	-0.63	2.98e-12	Oral cavity cancer;
THYM	cis	rs737337	0.623	rs4804154	chr19:11334179	C/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.66	4.7	0.43	8.89e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg16031515	chr1:205743344	RAB7L1	-0.54	-5.27	-0.48	8.39e-7	Monocyte percentage of white cells;
THYM	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.61	-0.43	1.27e-5	Type 2 diabetes;
THYM	cis	rs7027203	0.828	rs4744291	chr9:96598297	A/G	cg13679303	chr9:96623674	NA	-0.5	-5.08	-0.46	1.89e-6	DNA methylation (variation);
THYM	cis	rs4474465	0.850	rs10793323	chr11:78244170	C/T	cg19901956	chr11:77921274	USP35	0.61	4.6	0.43	1.3e-5	Alzheimer's disease (survival time);
THYM	cis	rs2229238	0.774	rs4341355	chr1:154436404	C/G	cg21262032	chr1:154437693	IL6R	0.68	6.72	0.57	1.32e-9	Coronary heart disease;
THYM	cis	rs16854884	0.657	rs16854772	chr3:143703890	A/G	cg05063096	chr3:143689810	C3orf58	0.69	4.53	0.42	1.69e-5	Economic and political preferences (feminism/equality);
THYM	trans	rs208520	0.690	rs207740	chr6:66764132	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.1	8.0	0.63	3.04e-12	Exhaled nitric oxide output;
THYM	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.27e-5	Gut microbiome composition (summer);
THYM	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg13175981	chr1:150552382	MCL1	0.81	6.23	0.54	1.25e-8	Tonsillectomy;
THYM	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg21226059	chr5:178986404	RUFY1	0.48	5.21	0.47	1.1e-6	Lung cancer;
THYM	cis	rs55883249	1.000	rs17362902	chr2:9768564	C/T	cg23886495	chr2:9695866	ADAM17	-0.81	-5.13	-0.47	1.52e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.71	-4.77	-0.44	6.71e-6	Body mass index;
THYM	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg25072359	chr17:41440525	NA	0.75	4.69	0.43	9.01e-6	Menopause (age at onset);
THYM	cis	rs17194885	1.000	rs17194885	chr20:36068389	A/C	cg23969976	chr20:36156592	BLCAP	-1.41	-5.1	-0.46	1.77e-6	Retinopathy in non-diabetics;
THYM	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg12311346	chr5:56204834	C5orf35	-0.81	-5.9	-0.52	5.54e-8	Initial pursuit acceleration;
THYM	cis	rs113835537	0.597	rs4576	chr11:66331000	A/G	cg24851651	chr11:66362959	CCS	0.73	5.08	0.46	1.89e-6	Airway imaging phenotypes;
THYM	cis	rs116095464	1.000	rs62331560	chr5:346785	G/C	cg02557110	chr5:1089654	SLC12A7	0.99	4.46	0.42	2.26e-5	Breast cancer;
THYM	cis	rs67460515	0.500	rs6806015	chr3:160724766	G/A	cg12349858	chr3:160822545	B3GALNT1	0.6	4.79	0.44	6.15e-6	Parkinson's disease;
THYM	cis	rs17739794	0.687	rs982351	chr8:823711	T/C	cg01971667	chr8:817044	NA	0.58	5.14	0.47	1.44e-6	Clozapine-induced cytotoxicity;
THYM	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-5.1	-0.46	1.74e-6	Lymphocyte counts;
THYM	cis	rs9633835	0.594	rs34560638	chr11:13288851	T/A	cg13286116	chr11:13302098	ARNTL	-0.75	-8.79	-0.67	6.29e-14	Body mass index;
THYM	cis	rs7312774	0.618	rs4964510	chr12:107357251	A/G	cg16260113	chr12:107380972	MTERFD3	1.44	6.84	0.57	7.53e-10	Severe influenza A (H1N1) infection;
THYM	cis	rs6754311	0.517	rs60453613	chr2:136527120	G/C	cg23851026	chr2:136556271	LCT	0.64	5.85	0.51	6.99e-8	Mosquito bite size;
THYM	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg19748678	chr4:122722346	EXOSC9	0.71	4.9	0.45	3.87e-6	Type 2 diabetes;
THYM	cis	rs10170846	0.861	rs12694582	chr2:223521955	G/C	cg25565276	chr2:223520875	FARSB	0.61	4.9	0.45	3.94e-6	Schizophrenia (inflammation and infection response interaction);
THYM	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg04362960	chr10:104952993	NT5C2	0.58	4.93	0.45	3.55e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs11039798	1.000	rs10769370	chr11:48515430	A/G	cg24672777	chr11:48374446	OR4C45	-1.16	-7.17	-0.59	1.64e-10	Axial length;
THYM	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-5.71	-0.51	1.31e-7	Total cholesterol levels;
THYM	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg07169764	chr2:136633963	MCM6	-0.71	-6.05	-0.53	2.81e-8	Mosquito bite size;
THYM	trans	rs75518195	0.504	rs62302060	chr4:64854221	C/G	cg14706739	chr8:21916355	EPB49	0.69	6.85	0.57	7.17e-10	Triptolide cytotoxicity;
THYM	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg06873352	chr17:61820015	STRADA	-0.69	-8.91	-0.67	3.5e-14	Prudent dietary pattern;
THYM	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg02753203	chr1:228287806	NA	-0.66	-5.88	-0.52	6.12e-8	Diastolic blood pressure;
THYM	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg13397359	chr6:42928475	GNMT	0.61	5.42	0.49	4.58e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs240764	0.853	rs2398132	chr6:100981200	A/C	cg21058520	chr6:100914733	NA	0.56	5.01	0.46	2.55e-6	Neuroticism;
THYM	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg08772003	chr10:104629869	AS3MT	-0.66	-6.06	-0.53	2.68e-8	Arsenic metabolism;
THYM	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.91	0.45	3.84e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs56104184	0.723	rs73063524	chr19:49409004	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.83	-4.61	-0.43	1.25e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs778371	0.788	rs2675959	chr2:233791988	T/A	cg08000102	chr2:233561755	GIGYF2	-0.63	-4.46	-0.42	2.28e-5	Schizophrenia;
THYM	cis	rs714515	0.546	rs1894633	chr1:172331059	A/G	cg01573306	chr1:172330400	DNM3	-0.62	-5.42	-0.49	4.46e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg19729930	chr2:74357872	NA	1.2	12.14	0.78	5.01e-21	Gestational age at birth (maternal effect);
THYM	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.96	8.0	0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs11008222	0.840	rs903276	chr10:31053282	C/G	cg00941203	chr10:31016591	NA	0.37	5.25	0.47	9.18e-7	Congenital left-sided heart lesions (maternal effect);
THYM	cis	rs11690935	0.921	rs4668414	chr2:172704291	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.81	-5.84	-0.51	7.21e-8	Schizophrenia;
THYM	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg08648136	chr8:956695	NA	0.55	4.63	0.43	1.16e-5	Schizophrenia;
THYM	cis	rs7681440	0.606	rs990087	chr4:90755177	A/C	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs924712	0.677	rs1112224	chr6:54859769	C/T	cg04690482	chr6:54711388	FAM83B	0.43	5.19	0.47	1.18e-6	Breast cancer;
THYM	cis	rs722599	0.961	rs2359239	chr14:75326771	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.6	-5.62	-0.5	1.92e-7	IgG glycosylation;
THYM	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg23803603	chr1:2058230	PRKCZ	-0.63	-5.31	-0.48	7.29e-7	Height;
THYM	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg27170947	chr2:26402098	FAM59B	0.79	6.27	0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs7404928	1.000	rs3785397	chr16:23903132	A/G	cg26685404	chr16:23957272	PRKCB	0.48	4.83	0.44	5.27e-6	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	trans	rs4866334	1.000	rs114400023	chr5:18432893	T/C	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg17366294	chr4:99064904	C4orf37	0.52	6.01	0.52	3.45e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.99	0.58	3.81e-10	Prudent dietary pattern;
THYM	cis	rs2717559	0.622	rs13255523	chr8:143887054	A/G	cg02415014	chr8:143852576	LYNX1	0.54	5.02	0.46	2.4e-6	Urinary tract infection frequency;
THYM	cis	rs4595586	0.525	rs12809307	chr12:39365927	A/G	cg26384229	chr12:38710491	ALG10B	0.69	5.35	0.48	6.11e-7	Morning vs. evening chronotype;
THYM	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg26597838	chr10:835615	NA	1.52	11.37	0.76	2.05e-19	Eosinophil percentage of granulocytes;
THYM	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg20290983	chr6:43655470	MRPS18A	1.44	16.17	0.86	4.93e-29	IgG glycosylation;
THYM	cis	rs7127900	0.519	rs7112959	chr11:2233609	G/A	cg25635251	chr11:2234043	NA	0.67	5.0	0.46	2.6e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs9361491	0.608	rs6924048	chr6:79478199	T/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.88e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg14004847	chr7:1930337	MAD1L1	-0.67	-5.17	-0.47	1.3e-6	Schizophrenia;
THYM	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg13695892	chr22:41940480	POLR3H	0.99	7.46	0.61	4.15e-11	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs919433	0.783	rs3097383	chr2:198236887	A/G	cg00792783	chr2:198669748	PLCL1	0.78	5.6	0.5	2.12e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs17030434	1.000	rs78249279	chr4:154718783	C/T	cg14289246	chr4:154710475	SFRP2	-0.76	-5.24	-0.47	9.79e-7	Electrocardiographic conduction measures;
THYM	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.6	-0.56	2.37e-9	Chronic sinus infection;
THYM	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg09517075	chr8:22133004	PIWIL2	0.64	5.77	0.51	1e-7	Hypertriglyceridemia;
THYM	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg09338302	chr7:1325757	NA	0.48	4.5	0.42	1.96e-5	Bipolar disorder;
THYM	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg15921436	chr17:44337874	NA	0.95	6.92	0.58	5.33e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7616559	0.887	rs7621842	chr3:156711427	G/C	cg15697575	chr3:156784781	NA	0.39	4.63	0.43	1.14e-5	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs11723261	0.582	rs61792238	chr4:112283	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.9	5.94	0.52	4.61e-8	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg23352942	chr3:46931381	PTH1R	0.59	5.27	0.48	8.6e-7	Birth weight;
THYM	cis	rs7267979	1.000	rs2387884	chr20:25379069	C/T	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9309473	0.519	rs2178154	chr2:73661738	C/T	cg19565262	chr2:73869966	NAT8	0.64	5.14	0.47	1.47e-6	Metabolite levels;
THYM	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg04248312	chr19:17393744	ANKLE1	-1.0	-13.52	-0.81	7.26e-24	Systemic lupus erythematosus;
THYM	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs995000	0.931	rs10889339	chr1:63012056	A/G	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs6429082	0.523	rs704718	chr1:235666159	A/T	cg26050004	chr1:235667680	B3GALNT2	0.92	8.84	0.67	4.96e-14	Adiposity;
THYM	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg03983476	chr2:10830698	NOL10	0.6	5.71	0.51	1.28e-7	Prostate cancer;
THYM	cis	rs526231	0.511	rs158402	chr5:102415525	G/A	cg23492399	chr5:102201601	PAM	-0.67	-4.96	-0.45	3.05e-6	Primary biliary cholangitis;
THYM	cis	rs2857078	0.627	rs1476512	chr17:42330122	C/T	cg13607699	chr17:42295918	UBTF	-0.66	-6.05	-0.53	2.87e-8	Red cell distribution width;Reticulocyte count;
THYM	cis	rs1401999	0.546	rs4148593	chr3:183649870	A/G	cg01324343	chr3:183735012	ABCC5	0.6	6.51	0.56	3.61e-9	Anterior chamber depth;
THYM	cis	rs36051895	0.632	rs7850484	chr9:5147817	C/T	cg02405213	chr9:5042618	JAK2	-1.0	-10.86	-0.74	2.45e-18	Pediatric autoimmune diseases;
THYM	cis	rs7843479	0.524	rs1031884	chr8:21788984	C/T	cg17168535	chr8:21777572	XPO7	0.95	8.86	0.67	4.4e-14	Mean corpuscular volume;
THYM	cis	rs611744	0.934	rs672591	chr8:109192453	T/A	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs2273669	0.915	rs12191613	chr6:109289203	G/A	cg17117243	chr6:109341365	SESN1	-0.78	-4.79	-0.44	6.05e-6	Prostate cancer;
THYM	cis	rs10089	1.000	rs7703634	chr5:127509223	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.88	5.46	0.49	3.81e-7	Ileal carcinoids;
THYM	cis	rs13064411	0.696	rs36054418	chr3:113204762	G/T	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs174775	0.513	rs2283849	chr22:29743482	T/C	cg26480862	chr22:28839667	TTC28	-0.49	-4.79	-0.44	6.04e-6	Immature fraction of reticulocytes;
THYM	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.64	-4.68	-0.43	9.69e-6	Colorectal cancer;
THYM	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg04234412	chr22:24373322	LOC391322	-0.98	-12.22	-0.78	3.39e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06850241	chr22:41845214	NA	0.59	5.41	0.49	4.76e-7	Vitiligo;
THYM	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg14004847	chr7:1930337	MAD1L1	-0.61	-4.78	-0.44	6.3e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12478296	0.901	rs6731775	chr2:242999443	T/C	cg18898632	chr2:242989856	NA	-0.71	-4.83	-0.44	5.32e-6	Obesity-related traits;
THYM	cis	rs4733781	0.527	rs7002892	chr8:131235135	A/T	cg16277922	chr8:131349729	ASAP1	0.59	4.96	0.45	3.14e-6	Tuberculosis;
THYM	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.67	8.57	0.66	1.83e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	trans	rs4596713	0.507	rs10217120	chr9:71794919	A/G	cg16512924	chr15:28394682	HERC2	0.83	6.89	0.58	6.02e-10	Headache;
THYM	cis	rs4730276	0.703	rs7778092	chr7:107522092	T/C	cg23293999	chr7:106826042	HBP1	-0.58	-4.54	-0.42	1.66e-5	Ulcerative colitis;
THYM	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg01579765	chr21:45077557	HSF2BP	-0.49	-7.92	-0.63	4.37e-12	Mean corpuscular volume;
THYM	cis	rs977987	0.528	rs9926933	chr16:75501567	A/G	cg07303275	chr16:75499416	TMEM170A	-0.81	-5.57	-0.5	2.36e-7	Dupuytren's disease;
THYM	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.71	5.63	0.5	1.8e-7	Tonsillectomy;
THYM	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg22907277	chr7:1156413	C7orf50	0.82	4.98	0.46	2.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg26149184	chr10:133730230	NA	0.77	4.65	0.43	1.05e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg06636551	chr8:101224915	SPAG1	-0.67	-6.52	-0.56	3.36e-9	Atrioventricular conduction;
THYM	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.59	4.5	0.42	1.91e-5	Tonsillectomy;
THYM	cis	rs6543140	1.000	rs6543140	chr2:103074274	G/T	cg03938978	chr2:103052716	IL18RAP	0.58	5.84	0.51	7.16e-8	Blood protein levels;
THYM	cis	rs6723226	0.882	rs13035097	chr2:32836362	A/G	cg02381751	chr2:32503542	YIPF4	-0.62	-4.94	-0.45	3.41e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7200543	1.000	rs6498540	chr16:15130594	A/G	cg01933576	chr16:15083564	PDXDC1	-0.99	-8.04	-0.64	2.48e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.48	-4.62	-0.43	1.21e-5	Crohn's disease;
THYM	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Body mass index;
THYM	cis	rs3126085	0.935	rs1496049	chr1:152161949	C/T	cg10321714	chr1:152280068	FLG	-0.67	-4.7	-0.43	8.94e-6	Atopic dermatitis;
THYM	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg11764359	chr7:65958608	NA	0.69	4.78	0.44	6.35e-6	Aortic root size;
THYM	cis	rs2075165	0.935	rs933489	chr1:156235120	T/C	cg20302342	chr1:156215951	PAQR6	0.46	4.61	0.43	1.23e-5	Tonsillectomy;
THYM	cis	rs7131987	0.834	rs1989478	chr12:29442229	C/T	cg09582351	chr12:29534625	ERGIC2	-0.52	-4.95	-0.45	3.25e-6	QT interval;
THYM	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg27534772	chr1:16042836	PLEKHM2	0.58	6.8	0.57	9.36e-10	Systolic blood pressure;
THYM	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg24250549	chr1:154909240	PMVK	0.67	5.3	0.48	7.42e-7	Prostate cancer;
THYM	cis	rs7107770	1.000	rs4936999	chr11:125106840	A/C	cg07747661	chr11:125106135	PKNOX2	-0.92	-5.28	-0.48	8.31e-7	Photic sneeze reflex;
THYM	cis	rs4664308	0.935	rs17216980	chr2:160960932	G/A	cg03641300	chr2:160917029	PLA2R1	-0.75	-6.87	-0.58	6.63e-10	Idiopathic membranous nephropathy;
THYM	cis	rs240764	0.853	rs12190903	chr6:100983505	C/T	cg21058520	chr6:100914733	NA	0.58	5.14	0.47	1.46e-6	Neuroticism;
THYM	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg03188948	chr7:1209495	NA	0.92	5.2	0.47	1.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.1	-0.53	2.29e-8	Crohn's disease;
THYM	cis	rs1278352	0.660	rs1278366	chr10:127776788	T/C	cg08295661	chr10:127769903	ADAM12	-0.54	-5.44	-0.49	4.07e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs7216064	0.532	rs8065296	chr17:66018562	T/A	cg12091567	chr17:66097778	LOC651250	0.99	8.2	0.64	1.12e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg06636001	chr8:8085503	FLJ10661	0.76	6.85	0.57	7.39e-10	Myopia (pathological);
THYM	cis	rs2820651	0.614	rs78492247	chr10:1488937	G/C	cg02445968	chr10:1449028	ADARB2	-0.93	-4.8	-0.44	6.01e-6	Migraine with aura;
THYM	cis	rs946836	0.528	rs4927267	chr1:48422383	C/G	cg18376692	chr1:48452465	NA	-0.55	-5.71	-0.51	1.26e-7	White matter integrity;
THYM	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.03	10.73	0.74	4.6e-18	Cognitive ability;
THYM	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06481639	chr22:41940642	POLR3H	-0.82	-5.68	-0.5	1.49e-7	Vitiligo;
THYM	cis	rs2276314	0.857	rs28530656	chr18:33588700	C/T	cg19628046	chr18:33552617	C18orf21	-0.74	-5.43	-0.49	4.29e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs13177918	0.677	rs57890152	chr5:149821472	T/C	cg14059543	chr5:149831962	NA	-0.97	-7.18	-0.59	1.56e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg02725872	chr8:58115012	NA	-0.82	-5.69	-0.5	1.43e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs9938149	0.706	rs7403826	chr16:88321167	A/T	cg05067156	chr16:88591451	ZFPM1	-0.44	-4.81	-0.44	5.72e-6	Corneal structure;Central corneal thickness;
THYM	cis	rs261532	0.861	rs2434576	chr5:138917674	A/G	cg08720517	chr5:138729919	LOC389333	0.58	4.67	0.43	9.81e-6	Immune reponse to smallpox (secreted IFN-alpha);
THYM	cis	rs654950	0.875	rs2759248	chr1:41990795	T/C	cg06885757	chr1:42089581	HIVEP3	-0.42	-4.88	-0.45	4.25e-6	Airway imaging phenotypes;
THYM	cis	rs7246967	0.673	rs34174596	chr19:22933519	G/A	cg05241461	chr19:22816980	ZNF492	0.59	4.61	0.43	1.26e-5	Bronchopulmonary dysplasia;
THYM	cis	rs12049351	0.774	rs1444727	chr1:229616758	T/C	cg11742688	chr1:229674241	ABCB10	-0.54	-4.48	-0.42	2.07e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	5.88	0.52	6.2e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg16989719	chr2:238392110	NA	-0.64	-5.54	-0.49	2.73e-7	Prostate cancer;
THYM	cis	rs1389724	0.648	rs1160412	chr1:111315946	A/G	cg25283465	chr1:111323341	NA	-0.59	-4.53	-0.42	1.74e-5	Schizophrenia;
THYM	cis	rs10982256	0.789	rs10817629	chr9:117261987	C/T	cg15903421	chr9:117267460	DFNB31	-0.53	-4.86	-0.45	4.6e-6	Bipolar disorder;
THYM	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg25427524	chr10:38739819	LOC399744	0.66	6.36	0.55	6.98e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs7043114	0.525	rs10761153	chr9:95130769	A/G	cg14631576	chr9:95140430	CENPP	-0.85	-9.03	-0.68	1.99e-14	Height;
THYM	cis	rs10208649	0.908	rs2161083	chr2:54251798	C/A	cg04546899	chr2:54196757	PSME4	0.68	4.73	0.44	7.94e-6	Body mass index;
THYM	cis	rs10924970	0.967	rs2382615	chr1:235454955	G/A	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs12496230	1.000	rs34508066	chr3:66837509	G/T	cg04995300	chr3:66848608	NA	1.02	6.16	0.53	1.71e-8	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs55728055	0.661	rs60324934	chr22:31875654	A/G	cg10537193	chr22:32026975	PISD	-0.9	-5.14	-0.47	1.46e-6	Age-related hearing impairment;
THYM	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg19761014	chr17:28927070	LRRC37B2	0.77	4.66	0.43	1.03e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3126085	0.696	rs41266112	chr1:152185762	C/G	cg10321714	chr1:152280068	FLG	0.64	4.6	0.43	1.29e-5	Atopic dermatitis;
THYM	cis	rs4430311	0.723	rs12739344	chr1:243791312	C/G	cg25706552	chr1:244017396	NA	0.54	4.51	0.42	1.87e-5	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.61e-20	Menopause (age at onset);
THYM	cis	rs12586317	0.620	rs28404080	chr14:35539418	G/T	cg16230307	chr14:35515116	FAM177A1	0.93	5.99	0.52	3.67e-8	Psoriasis;
THYM	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg15445000	chr17:37608096	MED1	-0.44	-5.1	-0.46	1.72e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7523273	0.606	rs1962149	chr1:207956559	G/A	cg22525895	chr1:207977042	MIR29B2	-0.93	-9.48	-0.7	2.11e-15	Schizophrenia;
THYM	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg24642844	chr7:1081250	C7orf50	-1.28	-8.22	-0.64	1.06e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg26384229	chr12:38710491	ALG10B	-0.89	-9.05	-0.68	1.77e-14	Heart rate;
THYM	cis	rs6754311	0.773	rs309137	chr2:136765951	A/G	cg20242066	chr2:136595261	LCT	0.62	7.08	0.59	2.42e-10	Mosquito bite size;
THYM	cis	rs2455799	0.613	rs2166759	chr3:15856285	A/G	cg16303742	chr3:15540471	COLQ	0.53	5.56	0.5	2.46e-7	Mean platelet volume;
THYM	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg10523679	chr1:76189770	ACADM	0.9	7.36	0.6	6.48e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4919044	0.641	rs7905234	chr10:94719384	A/G	cg05127821	chr10:94822908	CYP26C1	-1.19	-7.27	-0.6	9.84e-11	Coronary artery disease;
THYM	cis	rs946836	0.562	rs9660630	chr1:48421627	C/T	cg18376692	chr1:48452465	NA	0.54	5.33	0.48	6.66e-7	White matter integrity;
THYM	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg15133208	chr4:90757351	SNCA	-0.52	-4.47	-0.42	2.16e-5	Neuroticism;
THYM	cis	rs11190604	0.943	rs3750631	chr10:102279294	A/G	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg15921436	chr17:44337874	NA	0.82	5.57	0.5	2.41e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2070488	0.932	rs1841776	chr3:38480727	C/T	cg24069376	chr3:38537580	EXOG	0.68	6.73	0.57	1.26e-9	Electrocardiographic conduction measures;
THYM	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg02734326	chr4:10020555	SLC2A9	-0.61	-5.0	-0.46	2.66e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4646404	0.509	rs4646368	chr17:17465458	G/A	cg11245205	chr17:17398264	RASD1	-0.41	-4.79	-0.44	6.23e-6	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
THYM	cis	rs13006833	0.668	rs906916	chr2:191166212	G/A	cg11845111	chr2:191398756	TMEM194B	0.65	4.48	0.42	2.1e-5	Urinary metabolites;
THYM	cis	rs4363385	0.667	rs11803197	chr1:152934420	G/A	cg07796016	chr1:152779584	LCE1C	-0.56	-4.53	-0.42	1.72e-5	Inflammatory skin disease;
THYM	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg27129171	chr3:47204927	SETD2	-0.8	-7.88	-0.63	5.43e-12	Colorectal cancer;
THYM	cis	rs9309473	0.519	rs1083922	chr2:73704003	A/G	cg19565262	chr2:73869966	NAT8	0.56	4.75	0.44	7.11e-6	Metabolite levels;
THYM	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs865483	0.895	rs1016678	chr17:35874192	A/G	cg06716730	chr17:35851459	DUSP14	0.41	6.6	0.56	2.36e-9	Monocyte count;
THYM	cis	rs6429082	0.715	rs2131923	chr1:235580821	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.63	-5.31	-0.48	7.25e-7	Adiposity;
THYM	cis	rs35881094	0.933	rs1861413	chr2:58892962	A/G	cg09452692	chr2:58468460	FANCL	0.59	4.53	0.42	1.7e-5	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-4.85	-0.45	4.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1933112	1.000	rs1933109	chr1:168523624	C/G	cg00154920	chr1:168513310	XCL2	-0.5	-5.03	-0.46	2.31e-6	Blood protein levels;
THYM	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg24675056	chr1:15929824	NA	0.73	5.86	0.52	6.71e-8	Systolic blood pressure;
THYM	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14240646	chr10:27532245	ACBD5	-0.82	-4.7	-0.43	8.74e-6	Breast cancer;
THYM	cis	rs4474465	0.790	rs6592785	chr11:78235095	C/T	cg19901956	chr11:77921274	USP35	0.67	4.95	0.45	3.24e-6	Alzheimer's disease (survival time);
THYM	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg06623918	chr6:96969491	KIAA0776	-1.05	-10.59	-0.74	9.01e-18	Headache;
THYM	cis	rs3126085	0.935	rs12045496	chr1:152253910	A/G	cg10321714	chr1:152280068	FLG	0.64	4.81	0.44	5.57e-6	Atopic dermatitis;
THYM	cis	rs17854409	1.000	rs6010770	chr20:61494225	G/T	cg06598544	chr20:61472147	COL9A3	-1.1	-7.56	-0.61	2.56e-11	Obesity-related traits;
THYM	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg05368731	chr17:41323189	NBR1	1.22	11.32	0.76	2.56e-19	Menopause (age at onset);
THYM	cis	rs7831492	0.564	rs7831530	chr8:41614567	G/A	cg17182837	chr8:41585554	ANK1	-0.58	-5.02	-0.46	2.37e-6	Colorectal cancer;
THYM	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.71	-5.62	-0.5	1.93e-7	Prostate cancer;
THYM	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs13102973	0.965	rs6838419	chr4:135875682	T/C	cg14419869	chr4:135874104	NA	-0.82	-7.94	-0.63	4.06e-12	Subjective well-being;
THYM	cis	rs10895275	0.566	rs10895270	chr11:102062064	A/G	cg24447756	chr11:102105824	NA	0.5	4.74	0.44	7.56e-6	Migraine;
THYM	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6430585	0.583	rs6728946	chr2:136635343	C/G	cg23851026	chr2:136556271	LCT	0.8	7.65	0.62	1.64e-11	Corneal structure;
THYM	cis	rs2273669	0.667	rs116189763	chr6:109302894	T/C	cg17117243	chr6:109341365	SESN1	-0.84	-4.94	-0.45	3.41e-6	Prostate cancer;
THYM	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg16797656	chr11:68205561	LRP5	0.45	4.79	0.44	6.07e-6	Total body bone mineral density;
THYM	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg04842962	chr6:43655489	MRPS18A	1.4	15.48	0.85	1.01e-27	IgG glycosylation;
THYM	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4631830	0.720	rs2611512	chr10:51515534	A/G	cg16070123	chr10:51489643	NA	-0.48	-4.5	-0.42	1.92e-5	Prostate-specific antigen levels;
THYM	cis	rs6163	0.508	rs11191381	chr10:104493444	C/T	cg15744005	chr10:104629667	AS3MT	-0.62	-4.87	-0.45	4.36e-6	Waist circumference;Hip circumference;
THYM	cis	rs9905759	0.570	rs7215436	chr17:7931284	G/T	cg14438174	chr17:7137923	DVL2	-0.6	-4.85	-0.45	4.76e-6	Childhood ear infection;
THYM	cis	rs62229266	0.605	rs2835275	chr21:37460001	C/T	cg12218747	chr21:37451666	NA	-0.69	-6.76	-0.57	1.09e-9	Mitral valve prolapse;
THYM	cis	rs6099847	0.636	rs73915176	chr20:56506439	T/C	cg03401480	chr20:57087179	APCDD1L	0.79	4.51	0.42	1.82e-5	Obesity-related traits;
THYM	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg00814883	chr7:100076585	TSC22D4	-1.01	-6.78	-0.57	1.01e-9	Platelet count;
THYM	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg18681998	chr4:17616180	MED28	0.98	9.91	0.71	2.55e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.51	5.06	0.46	2.07e-6	Schizophrenia;
THYM	cis	rs11671005	0.779	rs55875034	chr19:58983558	T/G	cg02808233	chr19:58920810	ZNF584	0.58	4.59	0.43	1.33e-5	Mean platelet volume;
THYM	cis	rs12681288	0.578	rs56702775	chr8:968860	G/A	cg08648136	chr8:956695	NA	0.55	4.63	0.43	1.16e-5	Schizophrenia;
THYM	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs6665290	0.868	rs2183836	chr1:227199404	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.14	-14.34	-0.83	1.67e-25	Myeloid white cell count;
THYM	cis	rs72627123	0.867	rs73303116	chr14:74483615	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs9595908	0.785	rs4942804	chr13:33258502	T/C	cg12383807	chr13:33924137	NA	-0.53	-4.69	-0.43	9e-6	Body mass index;
THYM	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg06618935	chr21:46677482	NA	-0.92	-9.19	-0.69	9.04e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg00852783	chr1:26633632	UBXN11	0.83	8.39	0.65	4.45e-13	Obesity-related traits;
THYM	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg07636037	chr3:49044803	WDR6	1.0	10.57	0.73	1.03e-17	Parkinson's disease;
THYM	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg05347473	chr6:146136440	FBXO30	0.81	7.17	0.59	1.64e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg18681998	chr4:17616180	MED28	0.96	8.23	0.65	9.94e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6032067	0.929	rs876835	chr20:43827241	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs79149102	0.579	rs7167415	chr15:75302570	C/T	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	cis	rs2235642	0.507	rs2235645	chr16:1597924	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.59	-5.75	-0.51	1.06e-7	Coronary artery disease;
THYM	cis	rs11785693	0.862	rs6994150	chr8:4996630	T/G	cg26367366	chr8:4980734	NA	1.18	5.88	0.52	5.99e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	trans	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg10856724	chr12:34555212	NA	-0.92	-8.06	-0.64	2.24e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg15691649	chr6:25882328	NA	-0.61	-4.49	-0.42	1.97e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3733631	1.000	rs1482582	chr4:104651553	A/C	cg24090629	chr4:104641072	TACR3	-0.86	-5.52	-0.49	2.9e-7	Menarche (age at onset);
THYM	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg05754148	chr16:3507555	NAT15	0.72	7.22	0.6	1.3e-10	Tuberculosis;
THYM	cis	rs35883536	0.513	rs4907910	chr1:101013277	T/A	cg06223162	chr1:101003688	GPR88	0.95	8.29	0.65	7.53e-13	Monocyte count;
THYM	cis	rs597583	0.760	rs688968	chr11:117406739	C/G	cg27161313	chr11:117392002	DSCAML1	-0.66	-4.91	-0.45	3.75e-6	Putamen volume;
THYM	cis	rs6980334	0.679	rs3816829	chr7:137792420	A/G	cg06915773	chr7:137028165	PTN	0.58	4.74	0.44	7.59e-6	Blood metabolite ratios;
THYM	trans	rs62408225	0.802	rs2325261	chr6:90921407	T/A	cg12877335	chr12:94539319	NA	-1.05	-7.22	-0.6	1.26e-10	Eosinophil counts;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg24874828	chr4:187887005	NA	0.71	6.76	0.57	1.12e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg24531977	chr5:56204891	C5orf35	-0.72	-5.83	-0.51	7.64e-8	Initial pursuit acceleration;
THYM	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg22709100	chr7:91322751	NA	0.61	4.86	0.45	4.66e-6	Breast cancer;
THYM	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg15242686	chr22:24348715	GSTTP1	0.75	7.98	0.63	3.36e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4786125	0.587	rs12920700	chr16:6926397	C/T	cg03623568	chr16:6915990	A2BP1	-1.0	-9.73	-0.71	6.14e-16	Heart rate variability traits (SDNN);
THYM	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg16586182	chr3:47516702	SCAP	0.63	5.58	0.5	2.26e-7	Colorectal cancer;
THYM	cis	rs789852	0.867	rs6437391	chr3:194316826	C/T	cg18000598	chr3:194342907	TMEM44	-1.14	-6.96	-0.58	4.36e-10	QT interval;
THYM	cis	rs981844	0.775	rs17371261	chr4:154738479	G/T	cg09973105	chr4:154681532	RNF175	0.62	5.1	0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs863345	0.604	rs10797021	chr1:158490341	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-7.18	-0.59	1.58e-10	Chronic sinus infection;
THYM	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg05457628	chr5:178986728	RUFY1	0.65	6.1	0.53	2.28e-8	Lung cancer;
THYM	cis	rs7336332	0.598	rs75439483	chr13:28010512	A/G	cg22138327	chr13:27999177	GTF3A	0.62	4.62	0.43	1.21e-5	Weight;
THYM	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.29	5.96	0.52	4.18e-8	Obesity-related traits;
THYM	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg06713675	chr4:122721982	EXOSC9	-0.86	-9.81	-0.71	4.17e-16	Type 2 diabetes;
THYM	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg18252515	chr7:66147081	NA	-1.56	-8.47	-0.66	3e-13	Diabetic kidney disease;
THYM	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg02018176	chr4:1364513	KIAA1530	0.56	4.5	0.42	1.92e-5	Obesity-related traits;
THYM	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs2074038	1.000	rs2074038	chr11:44087989	G/T	cg17479956	chr11:44115929	EXT2	0.69	7.59	0.61	2.2e-11	IgA nephropathy;
THYM	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg12981288	chr8:11183844	MTMR9	-0.48	-4.66	-0.43	1.02e-5	Retinal vascular caliber;
THYM	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg16342193	chr10:102329863	NA	-0.54	-5.35	-0.48	6.03e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2562456	0.793	rs7259708	chr19:21750648	T/C	cg21751540	chr19:21541537	ZNF738	-0.72	-4.99	-0.46	2.76e-6	Pain;
THYM	cis	rs6089584	0.821	rs4925332	chr20:60604639	C/T	cg16423285	chr20:60520624	NA	-0.7	-4.86	-0.45	4.59e-6	Body mass index;
THYM	cis	rs6429082	0.791	rs291394	chr1:235651682	A/G	cg26050004	chr1:235667680	B3GALNT2	0.74	6.18	0.54	1.6e-8	Adiposity;
THYM	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg13395646	chr4:1353034	KIAA1530	-0.58	-4.98	-0.46	2.79e-6	Obesity-related traits;
THYM	cis	rs877282	0.947	rs7904978	chr10:768078	C/T	cg10556349	chr10:835070	NA	-0.81	-5.51	-0.49	3.06e-7	Uric acid levels;
THYM	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg23982607	chr1:1823379	GNB1	-0.94	-10.04	-0.72	1.37e-16	Body mass index;
THYM	cis	rs17001868	0.568	rs742140	chr22:40781586	G/A	cg07138101	chr22:40742427	ADSL	0.92	5.48	0.49	3.43e-7	Mammographic density (dense area);
THYM	cis	rs7301826	0.934	rs10848212	chr12:131322000	C/G	cg11011512	chr12:131303247	STX2	-0.54	-4.77	-0.44	6.59e-6	Plasma plasminogen activator levels;
THYM	cis	rs62103177	0.535	rs62101568	chr18:77934671	G/A	cg16238918	chr18:78004303	PARD6G	0.58	4.68	0.43	9.64e-6	Opioid sensitivity;
THYM	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	13.05	0.8	6.7e-23	Chronic sinus infection;
THYM	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg01579765	chr21:45077557	HSF2BP	-0.45	-6.58	-0.56	2.59e-9	Mean corpuscular volume;
THYM	cis	rs6987853	0.787	rs2923405	chr8:42448126	T/G	cg09913449	chr8:42400586	C8orf40	1.03	10.73	0.74	4.7e-18	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2046867	0.862	rs2322612	chr3:72830058	A/G	cg25664220	chr3:72788482	NA	-0.74	-5.69	-0.5	1.43e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8067545	0.750	rs7208365	chr17:19998017	T/G	cg13482628	chr17:19912719	NA	0.55	4.62	0.43	1.2e-5	Schizophrenia;
THYM	cis	rs7580658	0.613	rs6754999	chr2:128195387	G/A	cg10021288	chr2:128175891	PROC	-0.64	-5.57	-0.5	2.37e-7	Protein C levels;
THYM	cis	rs4764487	0.735	rs3181291	chr12:6341499	C/T	cg08284733	chr12:6341482	CD9	0.45	5.09	0.46	1.79e-6	Mean platelet volume;
THYM	cis	rs4852324	0.541	rs7568898	chr2:74271577	C/T	cg02237855	chr2:74329332	TET3	0.97	4.61	0.43	1.28e-5	Systemic lupus erythematosus;
THYM	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9303280	0.754	rs3816470	chr17:37985801	A/G	cg24910161	chr17:38119198	GSDMA	0.47	4.87	0.45	4.39e-6	Self-reported allergy;
THYM	cis	rs1788820	0.957	rs1652342	chr18:21099583	C/T	cg14672496	chr18:21087552	C18orf8	0.78	6.19	0.54	1.54e-8	Body mass index;
THYM	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.02	10.21	0.72	5.91e-17	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs7104764	1.000	rs6598069	chr11:240664	T/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs6430585	0.583	rs7561565	chr2:136640787	A/C	cg07169764	chr2:136633963	MCM6	1.19	13.3	0.81	2.04e-23	Corneal structure;
THYM	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg13866156	chr1:1669148	SLC35E2	-0.72	-7.33	-0.6	7.71e-11	Body mass index;
THYM	cis	rs75059851	0.756	rs7106806	chr11:133838837	G/C	cg14047540	chr11:133829660	NA	-1.06	-7.03	-0.58	3.14e-10	Schizophrenia;
THYM	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.97	-7.62	-0.62	1.88e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg22841779	chr14:105766346	BRF1	-0.49	-6.27	-0.54	1.04e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg08975724	chr8:8085496	FLJ10661	0.72	5.84	0.51	7.27e-8	Mood instability;
THYM	cis	rs35883536	0.647	rs12023028	chr1:101042717	C/T	cg09408571	chr1:101003634	GPR88	-0.48	-5.2	-0.47	1.14e-6	Monocyte count;
THYM	cis	rs7584330	0.740	rs13404177	chr2:238441412	T/C	cg16989719	chr2:238392110	NA	-0.48	-4.78	-0.44	6.27e-6	Prostate cancer;
THYM	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg18105134	chr13:113819100	PROZ	-0.98	-9.05	-0.68	1.79e-14	Platelet distribution width;
THYM	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg06481639	chr22:41940642	POLR3H	0.82	5.68	0.5	1.49e-7	Vitiligo;
THYM	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg10505658	chr17:80084571	CCDC57	0.7	8.07	0.64	2.18e-12	Life satisfaction;
THYM	cis	rs9324022	0.584	rs72698722	chr14:101181881	C/T	cg18089426	chr14:101175970	NA	0.78	5.88	0.52	6.02e-8	Plateletcrit;
THYM	cis	rs1784581	0.588	rs9295180	chr6:162420579	T/C	cg17173639	chr6:162384350	PARK2	0.81	7.48	0.61	3.75e-11	Itch intensity from mosquito bite;
THYM	cis	rs742614	0.875	rs3888736	chr20:32479793	C/A	cg06304546	chr20:32448765	NA	-0.69	-5.42	-0.49	4.53e-7	Stearic acid (18:0) levels;
THYM	cis	rs12188164	0.930	rs11743825	chr5:475463	C/T	cg14137381	chr5:502291	SLC9A3	-0.67	-4.61	-0.43	1.26e-5	Cystic fibrosis severity;
THYM	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg07936489	chr17:37558343	FBXL20	-0.75	-5.16	-0.47	1.34e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg17279839	chr7:150038598	RARRES2	0.55	5.34	0.48	6.26e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs3741151	1.000	rs78433080	chr11:73067565	G/A	cg12959048	chr11:73096162	RELT	-0.5	-4.78	-0.44	6.38e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg22968622	chr17:43663579	NA	-1.1	-9.99	-0.72	1.7e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4919687	0.550	rs12780827	chr10:104467954	T/C	cg05855489	chr10:104503620	C10orf26	0.69	5.42	0.49	4.43e-7	Colorectal cancer;
THYM	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs13315871	0.929	rs13080508	chr3:58300116	G/A	cg00563845	chr3:58318305	PXK	0.56	4.83	0.44	5.15e-6	Cholesterol, total;
THYM	cis	rs13082711	0.522	rs4973760	chr3:27349047	G/A	cg02860705	chr3:27208620	NA	0.65	5.07	0.46	1.94e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs747782	0.527	rs3741410	chr11:48168664	A/C	cg24672777	chr11:48374446	OR4C45	-0.87	-4.79	-0.44	6.06e-6	Intraocular pressure;
THYM	cis	rs4808199	0.948	rs7250368	chr19:19452763	G/A	cg03709012	chr19:19516395	GATAD2A	1.06	6.0	0.52	3.62e-8	Nonalcoholic fatty liver disease;
THYM	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.67	0.66	1.16e-13	Lung cancer in ever smokers;
THYM	cis	rs73206853	0.764	rs28569834	chr12:110826208	T/G	cg24703420	chr12:111373904	NA	0.71	4.52	0.42	1.75e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
THYM	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg20503657	chr10:835505	NA	1.01	5.76	0.51	1.04e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs7224737	0.750	rs12325861	chr17:40289412	T/C	cg20291162	chr17:40259547	DHX58	-0.66	-5.2	-0.47	1.16e-6	Fibrinogen levels;
THYM	cis	rs17102423	0.826	rs17825846	chr14:65598752	C/G	cg11161011	chr14:65562177	MAX	-0.82	-6.77	-0.57	1.06e-9	Obesity-related traits;
THYM	cis	rs2219968	0.828	rs4739190	chr8:78928417	A/G	cg00738934	chr8:78996279	NA	-0.78	-8.08	-0.64	2.01e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg03321784	chr17:37729644	NA	0.55	4.49	0.42	1.98e-5	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg00484396	chr16:3507460	NAT15	0.67	6.49	0.55	3.84e-9	Tuberculosis;
THYM	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs7107174	1.000	rs2292573	chr11:78053139	A/G	cg02023728	chr11:77925099	USP35	0.6	5.77	0.51	9.96e-8	Testicular germ cell tumor;
THYM	cis	rs28595532	0.920	rs115118317	chr4:119736613	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg23758822	chr17:41437982	NA	1.22	13.08	0.8	5.68e-23	Menopause (age at onset);
THYM	trans	rs4650994	0.544	rs6682815	chr1:178501109	T/C	cg05059571	chr16:84539110	KIAA1609	-0.85	-9.89	-0.71	2.84e-16	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs289828	0.538	rs4665167	chr2:152152071	C/T	cg05960677	chr2:152117363	RBM43	0.72	6.74	0.57	1.23e-9	Blood protein levels;
THYM	cis	rs2069036	0.903	rs2883624	chr10:16079077	A/G	cg26633223	chr10:15133461	NA	0.64	4.62	0.43	1.22e-5	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7107174	1.000	rs7116611	chr11:78030046	A/G	cg02023728	chr11:77925099	USP35	0.63	5.64	0.5	1.75e-7	Testicular germ cell tumor;
THYM	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-1.08	-6.87	-0.58	6.62e-10	Cognitive test performance;
THYM	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg15110403	chr19:17392923	ANKLE1	-0.56	-4.67	-0.43	9.97e-6	Systemic lupus erythematosus;
THYM	cis	rs7727544	0.582	rs4361509	chr5:131536753	A/G	cg16205897	chr5:131564050	P4HA2	0.46	4.78	0.44	6.33e-6	Blood metabolite levels;
THYM	cis	rs6032067	1.000	rs6032067	chr20:43864809	G/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.42	-0.49	4.55e-7	Blood protein levels;
THYM	cis	rs9914988	0.778	rs9907185	chr17:27122414	C/T	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.72	5.4	0.48	4.89e-7	Cognitive test performance;
THYM	cis	rs13102973	0.931	rs12643821	chr4:135859614	A/G	cg14419869	chr4:135874104	NA	-0.82	-7.94	-0.63	4.06e-12	Subjective well-being;
THYM	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.58	-5.88	-0.52	6.01e-8	Crohn's disease;
THYM	cis	rs2985684	0.740	rs2883438	chr14:50044392	T/C	cg02151108	chr14:50098012	C14orf104	-0.73	-5.78	-0.51	9.62e-8	Carotid intima media thickness;
THYM	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg27121462	chr16:89883253	FANCA	0.59	5.01	0.46	2.55e-6	Vitiligo;
THYM	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg23428387	chr22:49814324	NA	-0.5	-4.84	-0.44	4.99e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg10515332	chr4:99064459	C4orf37	0.58	4.62	0.43	1.21e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg15704280	chr7:45808275	SEPT13	-1.06	-15.41	-0.85	1.38e-27	Height;
THYM	cis	rs12681288	0.550	rs72507624	chr8:961324	G/A	cg08648136	chr8:956695	NA	0.55	4.62	0.43	1.19e-5	Schizophrenia;
THYM	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg08975724	chr8:8085496	FLJ10661	0.58	4.53	0.42	1.73e-5	Mood instability;
THYM	cis	rs7098100	0.812	rs11012732	chr10:21830104	A/G	cg04231319	chr10:21824447	MLLT10	-0.32	-4.69	-0.43	9.06e-6	Breast cancer;
THYM	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg16342193	chr10:102329863	NA	-0.52	-5.38	-0.48	5.4e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs3820928	0.692	rs2396434	chr2:227775223	G/T	cg11843606	chr2:227700838	RHBDD1	-0.57	-4.59	-0.43	1.34e-5	Pulmonary function;
THYM	cis	rs324014	0.845	rs2122692	chr12:57510511	C/G	cg21147422	chr12:56664361	COQ10A	0.52	4.62	0.43	1.19e-5	Itch intensity from mosquito bite adjusted by bite size;Itch intensity from mosquito bite;
THYM	cis	rs595982	0.527	rs55670257	chr19:49382654	G/A	cg17863274	chr19:49399704	TULP2	-0.91	-5.35	-0.48	6.11e-7	Red cell distribution width;
THYM	cis	rs1883415	0.727	rs2817219	chr6:24503898	G/A	cg00346970	chr6:24499591	ALDH5A1	0.43	5.75	0.51	1.08e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs1215050	0.740	rs700740	chr4:98976003	A/C	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs1448094	0.512	rs12313775	chr12:86241197	G/A	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs262150	0.530	rs2730232	chr7:158784469	C/T	cg04111992	chr7:158790115	NA	0.61	4.76	0.44	6.81e-6	Facial morphology (factor 20);
THYM	cis	rs4974559	0.790	rs6850727	chr4:1323273	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.44	-5.0	-0.46	2.63e-6	Systolic blood pressure;
THYM	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.67	-4.72	-0.44	8.08e-6	Aortic root size;
THYM	cis	rs11077998	0.967	rs4789790	chr17:80510789	G/A	cg11779900	chr17:80519722	FOXK2	-0.53	-4.52	-0.42	1.79e-5	Reticulocyte fraction of red cells;
THYM	cis	rs2502731	0.539	rs3003608	chr9:130984430	C/A	cg09976142	chr9:130955436	CIZ1	0.49	4.74	0.44	7.35e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs6980334	0.906	rs10264658	chr7:137779000	T/C	cg06915773	chr7:137028165	PTN	0.58	4.79	0.44	6.22e-6	Blood metabolite ratios;
THYM	cis	rs7236492	0.872	rs78538334	chr18:77223322	G/A	cg15644404	chr18:77186268	NFATC1	-1.06	-4.94	-0.45	3.41e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg10760299	chr15:45669010	GATM	0.72	5.03	0.46	2.27e-6	Homoarginine levels;
THYM	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg14004847	chr7:1930337	MAD1L1	-0.68	-5.36	-0.48	5.74e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg24578937	chr1:2090814	PRKCZ	-0.57	-5.46	-0.49	3.75e-7	Height;
THYM	cis	rs7043114	0.525	rs7847929	chr9:95154244	C/T	cg14631576	chr9:95140430	CENPP	-0.85	-9.03	-0.68	1.99e-14	Height;
THYM	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs870825	0.616	rs61539306	chr4:185650276	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs754466	1.000	rs2278218	chr10:79680399	G/A	cg17075019	chr10:79541650	NA	-0.61	-4.53	-0.42	1.7e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11711311	1.000	rs7645473	chr3:113516187	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.63	-5.59	-0.5	2.18e-7	IgG glycosylation;
THYM	cis	rs9486719	1.000	rs13208422	chr6:96892119	C/T	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs1823778	0.609	rs11660872	chr18:67686635	T/G	cg13164537	chr18:67624071	CD226	1.15	4.8	0.44	5.83e-6	Mean platelet volume;
THYM	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg08772003	chr10:104629869	AS3MT	-0.57	-4.95	-0.45	3.23e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg20966754	chr17:47091339	IGF2BP1	-0.57	-7.14	-0.59	1.84e-10	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.76	0.44	6.99e-6	Aortic root size;
THYM	cis	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg21775007	chr8:11205619	TDH	0.64	5.06	0.46	2.06e-6	Retinal vascular caliber;
THYM	cis	rs6992820	0.967	rs7816281	chr8:56696726	G/A	cg06880721	chr8:56792545	LYN	-0.71	-5.94	-0.52	4.57e-8	Mean platelet volume;
THYM	cis	rs6906287	0.647	rs12206329	chr6:118863789	G/T	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg23422044	chr7:1970798	MAD1L1	-0.95	-6.61	-0.56	2.24e-9	Bipolar disorder;
THYM	cis	rs11684202	0.867	rs6738958	chr2:25892403	A/C	cg04726446	chr2:26624865	C2orf39	-0.54	-4.7	-0.43	8.68e-6	LDL cholesterol;
THYM	cis	rs17174870	1.000	rs79559916	chr2:112665080	C/G	cg17354880	chr2:112658759	MERTK	-0.59	-4.6	-0.43	1.31e-5	Multiple sclerosis;
THYM	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06850241	chr22:41845214	NA	0.59	5.16	0.47	1.37e-6	Vitiligo;
THYM	cis	rs6867032	1.000	rs4074914	chr5:2020274	C/T	cg26168224	chr5:2018326	NA	1.31	15.78	0.85	2.71e-28	Gut microbiome composition (winter);
THYM	cis	rs4731207	0.596	rs1481337	chr7:124667796	G/A	cg05285228	chr7:124571219	POT1	-0.62	-4.73	-0.44	7.68e-6	Cutaneous malignant melanoma;
THYM	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	4.75	0.44	7.21e-6	Prudent dietary pattern;
THYM	cis	rs478304	0.934	rs517115	chr11:65526988	C/T	cg27068330	chr11:65405492	SIPA1	0.84	8.34	0.65	5.78e-13	Acne (severe);
THYM	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg03859395	chr2:55845619	SMEK2	-0.59	-5.04	-0.46	2.21e-6	Metabolic syndrome;
THYM	cis	rs397020	0.904	rs203547	chr20:1195245	T/A	cg23117778	chr20:1206693	RAD21L1	0.92	11.29	0.76	2.95e-19	Multiple sclerosis;
THYM	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs629535	0.821	rs497398	chr8:70037434	A/T	cg21567404	chr3:27674614	NA	1.12	10.86	0.74	2.44e-18	Dupuytren's disease;
THYM	cis	rs11948739	0.501	rs9327584	chr5:130336059	C/T	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Pediatric bone mineral content (hip);
THYM	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22496380	chr5:211416	CCDC127	-1.31	-8.26	-0.65	8.38e-13	Breast cancer;
THYM	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9796	0.870	rs28581803	chr15:41326513	G/A	cg21153102	chr15:41252147	NA	0.71	6.51	0.56	3.61e-9	Menopause (age at onset);
THYM	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg06850241	chr22:41845214	NA	-0.54	-4.68	-0.43	9.37e-6	Vitiligo;
THYM	cis	rs2976388	1.000	rs2920292	chr8:143765699	A/G	cg06565975	chr8:143823917	SLURP1	-0.45	-5.16	-0.47	1.38e-6	Urinary tract infection frequency;
THYM	cis	rs17376456	0.696	rs6860390	chr5:93494731	G/T	cg25358565	chr5:93447407	FAM172A	-0.86	-6.58	-0.56	2.51e-9	Diabetic retinopathy;
THYM	cis	rs3136739	0.764	rs10090918	chr8:42089393	G/C	cg12091331	chr8:42065314	PLAT	-0.64	-5.0	-0.46	2.64e-6	Plasma plasminogen activator levels;
THYM	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg24530246	chr3:53118167	NA	-0.82	-4.66	-0.43	1.04e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs4604732	0.642	rs10925048	chr1:247640736	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	4.72	0.44	8.06e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs2456568	0.531	rs7105060	chr11:93661268	C/A	cg26875233	chr11:93583750	C11orf90	-0.53	-5.86	-0.52	6.52e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg02725872	chr8:58115012	NA	-0.83	-5.68	-0.5	1.5e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg12311346	chr5:56204834	C5orf35	-0.61	-4.67	-0.43	9.99e-6	Initial pursuit acceleration;
THYM	cis	rs2281727	0.500	rs2169356	chr17:2138016	A/T	cg16513277	chr17:2031491	SMG6	-0.83	-8.32	-0.65	6.21e-13	Coronary artery disease;Body mass index;
THYM	cis	rs9788682	0.747	rs8043009	chr15:78908154	G/C	cg18825076	chr15:78729989	IREB2	0.62	5.16	0.47	1.36e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg03609598	chr5:56110824	MAP3K1	-0.82	-5.57	-0.5	2.35e-7	Initial pursuit acceleration;
THYM	cis	rs9534288	0.797	rs9534279	chr13:46584999	T/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg05373962	chr22:49881684	NA	-0.71	-7.16	-0.59	1.69e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg04944784	chr2:26401820	FAM59B	1.09	8.74	0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs921968	0.643	rs520095	chr2:219329485	C/T	cg02176678	chr2:219576539	TTLL4	0.65	6.27	0.54	1.05e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs12142240	0.698	rs28578741	chr1:46825176	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7226229	0.898	rs4985948	chr17:20885727	T/A	cg21263980	chr17:20946333	USP22	0.72	5.05	0.46	2.16e-6	Blood trace element (Se levels);
THYM	cis	rs897984	0.683	rs12447534	chr16:30804257	C/T	cg02466173	chr16:30829666	NA	0.55	4.8	0.44	5.79e-6	Dementia with Lewy bodies;
THYM	cis	rs16857609	1.000	rs12990503	chr2:218294217	C/G	cg15335768	chr2:218268053	DIRC3	0.34	5.03	0.46	2.34e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg14675211	chr2:100938903	LONRF2	0.76	8.42	0.65	3.99e-13	Intelligence (multi-trait analysis);
THYM	cis	rs11190604	0.697	rs4559619	chr10:102199884	C/T	cg07570687	chr10:102243282	WNT8B	-0.82	-7.91	-0.63	4.72e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs3126085	1.000	rs3126085	chr1:152300817	G/A	cg26020982	chr1:152196106	HRNR	-0.36	-4.95	-0.45	3.19e-6	Atopic dermatitis;
THYM	cis	rs2229238	0.868	rs41308419	chr1:154507197	T/C	cg21262032	chr1:154437693	IL6R	-0.63	-5.65	-0.5	1.68e-7	Coronary heart disease;
THYM	cis	rs9303029	0.866	rs72857495	chr17:80412867	A/C	cg21720206	chr17:80877845	TBCD	0.77	4.78	0.44	6.45e-6	Protein quantitative trait loci;
THYM	cis	rs6840360	0.515	rs11099811	chr4:152320532	C/A	cg17479576	chr4:152424074	FAM160A1	-0.73	-5.45	-0.49	4.02e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11608355	1.000	rs10850135	chr12:109866528	C/A	cg11367159	chr12:110044531	NA	0.66	6.29	0.54	9.83e-9	Neuroticism;
THYM	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg13395646	chr4:1353034	KIAA1530	-0.55	-4.9	-0.45	3.96e-6	Obesity-related traits;
THYM	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg14829155	chr15:31115871	NA	-0.58	-5.15	-0.47	1.4e-6	Huntington's disease progression;
THYM	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg03609598	chr5:56110824	MAP3K1	-0.63	-4.53	-0.42	1.73e-5	Coronary artery disease;
THYM	cis	rs12410462	0.681	rs4486420	chr1:227572321	T/A	cg04117972	chr1:227635322	NA	0.8	4.82	0.44	5.36e-6	Major depressive disorder;
THYM	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg19508488	chr2:152266495	RIF1	0.71	4.83	0.44	5.25e-6	Lung cancer;
THYM	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.57	-4.81	-0.44	5.57e-6	Renal function-related traits (BUN);
THYM	cis	rs9826463	0.582	rs73238158	chr3:142078215	G/A	cg20824294	chr3:142316082	PLS1	0.76	5.28	0.48	8.31e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs7560272	0.564	rs4852939	chr2:73856769	C/G	cg19565262	chr2:73869966	NAT8	-0.52	-4.56	-0.42	1.5e-5	Schizophrenia;
THYM	cis	rs7264396	0.513	rs3787169	chr20:34419884	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-4.57	-0.42	1.45e-5	Total cholesterol levels;
THYM	cis	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg06238570	chr21:40685208	BRWD1	-0.91	-6.69	-0.57	1.54e-9	Cognitive function;
THYM	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg12311346	chr5:56204834	C5orf35	-0.84	-6.23	-0.54	1.28e-8	Initial pursuit acceleration;
THYM	cis	rs67969689	0.515	rs1965786	chr2:19486628	C/T	cg16234068	chr2:18544572	NA	-0.55	-4.51	-0.42	1.88e-5	Myringotomy;
THYM	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2070677	0.935	rs12242613	chr10:135419831	C/T	cg20169779	chr10:135381914	SYCE1	-0.75	-5.76	-0.51	1.03e-7	Gout;
THYM	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg13289132	chr10:30722225	MAP3K8	-0.68	-5.71	-0.51	1.31e-7	Inflammatory bowel disease;
THYM	cis	rs7917772	0.582	rs6584512	chr10:104329685	A/G	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.83	5.25	0.47	9.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7828089	1.000	rs7838127	chr8:22264561	G/A	cg13512537	chr8:22265999	SLC39A14	-0.61	-5.13	-0.47	1.55e-6	Verbal declarative memory;
THYM	cis	rs35883536	0.647	rs17402665	chr1:101046940	C/T	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg27535305	chr1:53392650	SCP2	0.42	4.82	0.44	5.53e-6	Monocyte count;
THYM	cis	rs12216545	0.737	rs6962143	chr7:150245934	A/G	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs12282928	1.000	rs12294937	chr11:48337466	T/C	cg22827986	chr11:48284249	OR4X1	0.53	5.59	0.5	2.21e-7	Migraine - clinic-based;
THYM	cis	rs6032067	0.929	rs17424578	chr20:43806321	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs2229238	0.911	rs10047079	chr1:154468135	T/C	cg21262032	chr1:154437693	IL6R	-0.55	-4.81	-0.44	5.6e-6	Coronary heart disease;
THYM	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22496380	chr5:211416	CCDC127	-1.31	-8.26	-0.65	8.38e-13	Breast cancer;
THYM	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg11301795	chr4:187892539	NA	-1.12	-18.54	-0.89	2.54e-33	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28595532	1.000	rs28595532	chr4:119716950	A/C	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11850957	0.502	rs80290239	chr14:25450181	T/C	cg26846476	chr14:24838993	NFATC4	0.88	4.55	0.42	1.61e-5	Subcutaneous adipose tissue;
THYM	cis	rs739401	0.619	rs10766482	chr11:2961600	C/T	cg08508325	chr11:3079039	CARS	-0.52	-6.16	-0.53	1.78e-8	Longevity;
THYM	cis	rs6032067	0.929	rs17424696	chr20:43810734	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.64	-0.5	1.76e-7	Blood protein levels;
THYM	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg03186999	chr17:7165420	CLDN7	0.51	6.05	0.53	2.92e-8	Adiponectin levels;
THYM	cis	rs4595586	0.545	rs12823721	chr12:39386461	G/A	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs6467136	0.740	rs57867532	chr7:127179938	G/T	cg08586737	chr7:127225949	GCC1	-0.31	-4.61	-0.43	1.25e-5	Type 2 diabetes;
THYM	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg26384229	chr12:38710491	ALG10B	0.95	7.59	0.61	2.17e-11	Morning vs. evening chronotype;
THYM	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg27398817	chr8:82754497	SNX16	0.84	6.56	0.56	2.79e-9	Diastolic blood pressure;
THYM	cis	rs11690462	0.500	rs34952935	chr2:26627940	C/T	cg11525280	chr2:26624667	C2orf39	-0.51	-5.23	-0.47	1.02e-6	Coronary artery disease;
THYM	cis	rs2290159	0.800	rs3730269	chr3:12653233	G/T	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg24399712	chr22:39784796	NA	-0.93	-10.65	-0.74	6.66e-18	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg07936489	chr17:37558343	FBXL20	0.87	5.78	0.51	9.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs4474465	0.790	rs4945293	chr11:78254554	T/C	cg19901956	chr11:77921274	USP35	0.61	4.64	0.43	1.1e-5	Alzheimer's disease (survival time);
THYM	cis	rs6876348	0.516	rs11953704	chr5:128326950	G/A	cg25555059	chr5:128301488	SLC27A6	0.45	4.74	0.44	7.63e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg17264618	chr3:40429014	ENTPD3	-0.53	-5.08	-0.46	1.86e-6	Renal cell carcinoma;
THYM	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs7246657	0.551	rs10404069	chr19:37638404	C/T	cg22634378	chr19:37742834	NA	0.63	4.53	0.42	1.72e-5	Coronary artery calcification;
THYM	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg04362960	chr10:104952993	NT5C2	0.58	4.95	0.45	3.18e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs478304	0.934	rs669742	chr11:65501291	C/T	cg17480646	chr11:65405466	SIPA1	0.7	6.13	0.53	2e-8	Acne (severe);
THYM	cis	rs295140	0.605	rs295149	chr2:201175244	A/G	cg14106933	chr2:201194453	SPATS2L	0.43	4.66	0.43	1.01e-5	QT interval;
THYM	cis	rs1670533	0.615	rs59985183	chr4:1087171	G/T	cg27284194	chr4:1044797	NA	0.64	4.93	0.45	3.5e-6	Recombination rate (females);
THYM	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.37	-0.48	5.57e-7	Menopause (age at onset);
THYM	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.83	-5.65	-0.5	1.7e-7	Body mass index;
THYM	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg04455712	chr21:45112962	RRP1B	0.53	4.93	0.45	3.42e-6	Mean corpuscular volume;
THYM	cis	rs2637266	1.000	rs1907298	chr10:78329928	A/T	cg18941641	chr10:78392320	NA	0.73	6.32	0.54	8.37e-9	Pulmonary function;
THYM	cis	rs600806	0.888	rs3879449	chr1:109904971	A/T	cg16988986	chr1:109941118	SORT1	-0.43	-4.6	-0.43	1.32e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg00647820	chr17:40259828	DHX58	-0.6	-4.53	-0.42	1.72e-5	Fibrinogen levels;
THYM	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	7.27	0.6	9.98e-11	Smoking behavior;
THYM	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.0	-6.7	-0.57	1.44e-9	Platelet count;
THYM	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.05	-0.53	2.81e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs9913156	0.793	rs9916135	chr17:4568115	A/C	cg19197139	chr17:4613644	ARRB2	-0.85	-5.19	-0.47	1.21e-6	Lymphocyte counts;
THYM	cis	rs473651	0.904	rs551859	chr2:239371836	T/C	cg08773314	chr2:239334832	ASB1	0.63	8.82	0.67	5.41e-14	Multiple system atrophy;
THYM	cis	rs72627509	0.857	rs56155140	chr4:57824451	G/A	cg26694713	chr4:57773883	REST	0.75	4.72	0.44	7.97e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg01579765	chr21:45077557	HSF2BP	-0.49	-7.86	-0.63	5.97e-12	Mean corpuscular volume;
THYM	cis	rs2289328	1.000	rs11634187	chr15:40722781	T/G	cg13931752	chr15:40660718	DISP2	0.7	5.17	0.47	1.31e-6	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
THYM	cis	rs4523957	0.928	rs216179	chr17:2168878	T/A	cg16513277	chr17:2031491	SMG6	0.79	7.45	0.61	4.21e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg27446573	chr6:127587934	RNF146	1.04	9.87	0.71	3.12e-16	Breast cancer;
THYM	cis	rs9457247	0.534	rs2757053	chr6:167380338	A/C	cg23791538	chr6:167370224	RNASET2	0.83	7.37	0.6	6.18e-11	Crohn's disease;
THYM	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg15448220	chr1:150897856	SETDB1	-0.8	-6.41	-0.55	5.59e-9	Urate levels;
THYM	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg26597838	chr10:835615	NA	1.26	9.07	0.68	1.62e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs10463554	0.927	rs12055075	chr5:102380257	T/C	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs4595586	0.525	rs12825567	chr12:39386621	C/T	cg26384229	chr12:38710491	ALG10B	0.69	5.35	0.48	6.11e-7	Morning vs. evening chronotype;
THYM	cis	rs4953076	0.573	rs2053456	chr2:44448632	G/A	cg04920474	chr2:44395004	PPM1B	0.65	5.35	0.48	6.04e-7	Height;
THYM	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg04842962	chr6:43655489	MRPS18A	1.4	15.42	0.85	1.3e-27	IgG glycosylation;
THYM	cis	rs11190604	1.000	rs28522614	chr10:102323141	T/A	cg16342193	chr10:102329863	NA	-0.57	-5.85	-0.51	6.91e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11030122	0.702	rs10835402	chr11:3990914	T/C	cg18678763	chr11:4115507	RRM1	-0.44	-5.73	-0.51	1.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs193541	0.527	rs899188	chr5:122244505	G/C	cg19808643	chr5:122110361	SNX2	-0.64	-5.37	-0.48	5.46e-7	Glucose homeostasis traits;
THYM	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs8014204	0.935	rs10141438	chr14:75354600	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.59	-5.9	-0.52	5.57e-8	Caffeine consumption;
THYM	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21659725	chr3:3221576	CRBN	0.9	9.83	0.71	3.87e-16	Intelligence (multi-trait analysis);
THYM	cis	rs804292	0.724	rs8191518	chr8:11627261	C/G	cg26752888	chr8:11627280	NEIL2	1.2	8.39	0.65	4.49e-13	Alcohol dependence;Nicotine use;
THYM	cis	rs1278352	0.737	rs1278367	chr10:127776900	G/T	cg08295661	chr10:127769903	ADAM12	-0.55	-5.24	-0.47	9.47e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg14345882	chr6:26364793	BTN3A2	0.62	5.7	0.5	1.34e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs757081	0.667	rs12577388	chr11:17101155	C/T	cg15432903	chr11:17409602	KCNJ11	-0.49	-4.58	-0.43	1.43e-5	Systolic blood pressure;
THYM	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7119	0.717	rs7176307	chr15:77816684	G/C	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs500891	0.525	rs1145898	chr6:84039566	T/C	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs2039659	0.719	rs1753789	chr13:86255424	T/C	cg25308322	chr13:86268291	NA	0.65	5.44	0.49	4.08e-7	Blood osmolality (transformed sodium);
THYM	cis	rs3820068	0.608	rs12091326	chr1:16048005	A/G	cg05660106	chr1:15850417	CASP9	0.73	5.79	0.51	8.96e-8	Systolic blood pressure;
THYM	cis	rs4891159	0.757	rs11665518	chr18:74147054	C/T	cg24786174	chr18:74118243	ZNF516	-0.87	-9.72	-0.71	6.43e-16	Longevity;
THYM	cis	rs2806561	0.765	rs641032	chr1:23513980	C/T	cg19743168	chr1:23544995	NA	-0.53	-5.43	-0.49	4.29e-7	Height;
THYM	cis	rs2236521	0.659	rs73144993	chr20:60893458	A/G	cg06026331	chr20:60912101	LAMA5	0.8	5.77	0.51	9.83e-8	Pelvic organ prolapse;
THYM	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg14004847	chr7:1930337	MAD1L1	-0.63	-4.79	-0.44	6.15e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg27286337	chr10:134555280	INPP5A	0.88	6.26	0.54	1.13e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs533581	0.866	rs865102	chr16:88969969	A/G	cg08484992	chr16:88977278	CBFA2T3	0.39	4.82	0.44	5.55e-6	Social autistic-like traits;
THYM	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg02725872	chr8:58115012	NA	-0.88	-6.21	-0.54	1.38e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg26597838	chr10:835615	NA	1.58	12.04	0.78	8.01e-21	Eosinophil percentage of granulocytes;
THYM	cis	rs12289510	1.000	rs12289510	chr11:124947051	C/T	cg03868193	chr11:124958746	SLC37A2	0.7	6.86	0.58	6.99e-10	Platelet-derived growth factor BB levels;
THYM	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11890956	chr21:40555474	PSMG1	-0.95	-10.91	-0.75	1.91e-18	Cognitive function;
THYM	cis	rs9649213	0.574	rs3801257	chr7:97991792	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4383453	0.539	rs2877709	chr3:123100304	A/G	cg04890266	chr3:123102914	ADCY5	0.83	8.75	0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs4731207	0.698	rs10260227	chr7:124446486	T/C	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg08999081	chr20:33150536	PIGU	0.56	4.71	0.43	8.58e-6	Height;
THYM	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg24531977	chr5:56204891	C5orf35	-1.02	-8.69	-0.67	1.06e-13	Initial pursuit acceleration;
THYM	cis	rs11186	0.556	rs56380683	chr2:189964891	A/G	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg05890377	chr2:74357713	NA	1.08	9.83	0.71	3.73e-16	Gestational age at birth (maternal effect);
THYM	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.95	7.71	0.62	1.25e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs904251	0.772	rs2252920	chr6:37418327	A/G	cg25019722	chr6:37503610	NA	-0.62	-4.63	-0.43	1.14e-5	Cognitive performance;
THYM	cis	rs12282928	0.917	rs1503175	chr11:48269192	A/G	cg22827986	chr11:48284249	OR4X1	-0.53	-5.48	-0.49	3.41e-7	Migraine - clinic-based;
THYM	cis	rs3126085	0.735	rs4845744	chr1:152185095	T/A	cg10321714	chr1:152280068	FLG	0.68	4.95	0.45	3.2e-6	Atopic dermatitis;
THYM	cis	rs11096990	0.613	rs12643415	chr4:39271995	G/C	cg24403649	chr4:39172243	NA	-0.72	-6.28	-0.54	1.02e-8	Cognitive function;
THYM	cis	rs6429082	0.818	rs61836206	chr1:235638754	C/G	cg26050004	chr1:235667680	B3GALNT2	0.73	6.03	0.53	3.16e-8	Adiposity;
THYM	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg24642844	chr7:1081250	C7orf50	-1.26	-8.22	-0.64	1.03e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg22968622	chr17:43663579	NA	-1.1	-9.99	-0.72	1.7e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg27284194	chr4:1044797	NA	-0.92	-10.05	-0.72	1.3e-16	Recombination rate (males);
THYM	cis	rs6732160	0.613	rs57208378	chr2:73389999	G/A	cg24220031	chr2:73402428	NA	-0.72	-5.95	-0.52	4.41e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9796	0.516	rs28473405	chr15:41293170	C/T	cg21153102	chr15:41252147	NA	0.6	5.24	0.47	9.53e-7	Menopause (age at onset);
THYM	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg06112835	chr11:68658793	MRPL21	0.45	6.39	0.55	6.21e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4792901	0.802	rs28532791	chr17:41589479	G/A	cg21940313	chr17:41620911	ETV4	-0.54	-5.13	-0.47	1.5e-6	Dupuytren's disease;
THYM	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg18032289	chr17:61959525	GH2	-0.5	-4.76	-0.44	6.95e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs1670533	1.000	rs688785	chr4:1082707	G/C	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs5029614	0.534	rs12215248	chr6:18073320	A/C	cg01426125	chr6:17817690	KIF13A	0.51	4.52	0.42	1.77e-5	Cancer;
THYM	cis	rs6032067	0.866	rs1007137	chr20:43816593	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-6.1	-0.53	2.33e-8	Blood protein levels;
THYM	cis	rs2404602	0.684	rs11072600	chr15:76867915	T/C	cg23625390	chr15:77176239	SCAPER	-0.9	-6.37	-0.55	6.74e-9	Blood metabolite levels;
THYM	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg13010199	chr12:38710504	ALG10B	0.71	5.77	0.51	9.75e-8	Heart rate;
THYM	cis	rs4930103	0.935	rs2075744	chr11:2018449	A/G	cg21926276	chr11:2035255	NA	0.27	4.53	0.42	1.7e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs72781680	1.000	rs72796359	chr2:24160545	T/C	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-5.98	-0.52	3.98e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs1978968	1.000	rs2099943	chr22:18438559	A/G	cg01550578	chr22:18484421	MICAL3	0.69	5.15	0.47	1.41e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.91	8.79	0.67	6.37e-14	Menarche (age at onset);
THYM	cis	rs8063160	0.576	rs34265416	chr16:89769725	C/A	cg07984980	chr16:89898383	SPIRE2	1.17	5.09	0.46	1.83e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg17294928	chr15:75287854	SCAMP5	-1.02	-9.41	-0.69	2.99e-15	Blood trace element (Zn levels);
THYM	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9311676	0.609	rs11921259	chr3:58368646	A/G	cg26110898	chr3:58419937	PDHB	0.44	4.58	0.43	1.41e-5	Systemic lupus erythematosus;
THYM	cis	rs7258465	1.000	rs4808801	chr19:18571141	A/G	cg04166595	chr19:18636596	NA	0.62	4.62	0.43	1.19e-5	Breast cancer;
THYM	cis	rs6430585	0.583	rs76097170	chr2:136593498	C/T	cg20242066	chr2:136595261	LCT	0.57	6.08	0.53	2.52e-8	Corneal structure;
THYM	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg15212455	chr7:39170539	POU6F2	0.63	5.72	0.51	1.25e-7	IgG glycosylation;
THYM	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg23583168	chr7:148888333	NA	-1.02	-13.92	-0.82	1.16e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs870825	0.616	rs55674580	chr4:185626605	C/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs4242434	0.889	rs11785755	chr8:22453223	C/A	cg21658235	chr8:22456391	C8orf58	0.62	5.75	0.51	1.1e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs870825	0.616	rs28524599	chr4:185647414	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs6430585	0.528	rs309142	chr2:136715324	T/C	cg20242066	chr2:136595261	LCT	0.49	5.34	0.48	6.35e-7	Corneal structure;
THYM	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg00256281	chr22:41985642	PMM1	0.56	4.47	0.42	2.2e-5	Vitiligo;
THYM	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg08885076	chr2:99613938	TSGA10	0.69	6.47	0.55	4.31e-9	Chronic sinus infection;
THYM	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg08807101	chr21:30365312	RNF160	-0.93	-7.5	-0.61	3.42e-11	Dental caries;
THYM	cis	rs9326248	0.581	rs10892048	chr11:116814596	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.67	5.44	0.49	4.11e-7	Blood protein levels;
THYM	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg26597838	chr10:835615	NA	1.19	7.92	0.63	4.47e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg12000587	chr17:30186630	C17orf79	0.4	4.65	0.43	1.07e-5	Hip circumference adjusted for BMI;
THYM	cis	rs9527	0.545	rs7915816	chr10:104881750	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg15997130	chr1:24165203	NA	0.77	7.11	0.59	2.15e-10	Immature fraction of reticulocytes;
THYM	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.86	-6.56	-0.56	2.87e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.77	-0.51	1.01e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg07930552	chr6:133119739	C6orf192	0.99	5.89	0.52	5.77e-8	Type 2 diabetes nephropathy;
THYM	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg15557168	chr22:42548783	NA	0.58	4.68	0.43	9.66e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2456568	0.548	rs10765647	chr11:93662459	T/C	cg26875233	chr11:93583750	C11orf90	-0.52	-5.79	-0.51	8.93e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg03676636	chr4:99064102	C4orf37	0.5	7.59	0.61	2.14e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.71	5.83	0.51	7.7e-8	Menarche (age at onset);
THYM	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg05347473	chr6:146136440	FBXO30	0.6	4.86	0.45	4.54e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4654899	0.802	rs10916906	chr1:21255675	C/A	cg01072550	chr1:21505969	NA	-0.7	-6.34	-0.54	7.88e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg18131467	chr2:239335373	ASB1	1.0	9.21	0.69	8.09e-15	Multiple system atrophy;
THYM	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.64	-0.74	7.23e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs6456042	1.000	rs6456042	chr6:166534742	G/T	cg11088901	chr6:166572345	T	0.51	4.82	0.44	5.5e-6	Asthma;
THYM	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg14196790	chr5:131705035	SLC22A5	0.55	4.93	0.45	3.55e-6	Blood metabolite levels;
THYM	cis	rs12935418	0.552	rs2549833	chr16:81022232	T/C	cg16651780	chr16:81037892	C16orf61	-0.85	-6.53	-0.56	3.16e-9	Mean corpuscular volume;
THYM	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg23583168	chr7:148888333	NA	-1.0	-12.94	-0.8	1.13e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6032067	0.925	rs35875037	chr20:43859921	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.73	-7.62	-0.62	1.9e-11	Blood protein levels;
THYM	cis	rs514406	0.505	rs269289	chr1:53167151	A/C	cg08859206	chr1:53392774	SCP2	-0.52	-5.43	-0.49	4.3e-7	Monocyte count;
THYM	cis	rs13082711	0.911	rs35904501	chr3:27443317	T/C	cg02860705	chr3:27208620	NA	0.67	4.7	0.43	8.96e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg24531977	chr5:56204891	C5orf35	-1.01	-8.38	-0.65	4.79e-13	Initial pursuit acceleration;
THYM	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg06532163	chr17:45867833	NA	0.65	6.55	0.56	2.91e-9	IgG glycosylation;
THYM	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg15549821	chr19:49342101	PLEKHA4	-1.03	-6.14	-0.53	1.94e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs12142240	1.000	rs12142240	chr1:46747301	T/C	cg00530320	chr1:46809349	NSUN4	0.86	5.58	0.5	2.26e-7	Menopause (age at onset);
THYM	cis	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg21775007	chr8:11205619	TDH	-0.61	-4.97	-0.45	2.94e-6	Retinal vascular caliber;
THYM	cis	rs7894051	0.614	rs11101707	chr10:135175844	T/C	cg06270799	chr10:135191613	PAOX	-0.82	-4.94	-0.45	3.32e-6	Lifespan;
THYM	cis	rs853679	1.000	rs10456362	chr6:28221816	A/G	cg23161317	chr6:28129485	ZNF389	-0.86	-5.44	-0.49	4.2e-7	Depression;
THYM	cis	rs300703	0.719	rs446488	chr2:195365	T/C	cg21211680	chr2:198530	NA	1.3	8.23	0.65	9.98e-13	Blood protein levels;
THYM	cis	rs6430585	0.583	rs3087343	chr2:136622543	T/G	cg23851026	chr2:136556271	LCT	0.79	7.51	0.61	3.2e-11	Corneal structure;
THYM	cis	rs1957429	0.808	rs11158564	chr14:65335082	G/A	cg23373153	chr14:65346875	NA	0.91	4.92	0.45	3.69e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs600806	0.850	rs4970752	chr1:109930852	C/T	cg16988986	chr1:109941118	SORT1	-0.43	-4.56	-0.42	1.5e-5	Intelligence (multi-trait analysis);
THYM	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg12386194	chr3:101231763	SENP7	0.66	5.0	0.46	2.59e-6	Colorectal cancer;
THYM	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.69	6.15	0.53	1.82e-8	Personality dimensions;
THYM	cis	rs13191362	0.573	rs1877769	chr6:163252315	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	7.2	0.59	1.4e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10892173	0.588	rs12363806	chr11:117658211	G/A	cg21014159	chr11:117668035	DSCAML1	0.79	5.7	0.5	1.37e-7	Myopia;
THYM	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg09703963	chr11:616879	IRF7;MUPCDH	-0.76	-6.38	-0.55	6.46e-9	Systemic lupus erythematosus;
THYM	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg17211192	chr8:82754475	SNX16	0.82	7.41	0.61	5.09e-11	Diastolic blood pressure;
THYM	cis	rs7267979	0.868	rs6138553	chr20:25239233	G/A	cg08601574	chr20:25228251	PYGB	0.59	4.68	0.43	9.42e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg04398451	chr17:18023971	MYO15A	0.9	9.71	0.71	6.98e-16	Total body bone mineral density;
THYM	trans	rs4866334	1.000	rs74776941	chr5:18489387	T/G	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs2072510	0.722	rs2540495	chr12:96406723	G/T	cg18817487	chr12:96390143	HAL	0.35	4.67	0.43	9.96e-6	Metabolite levels (small molecules and protein measures);
THYM	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	7.53	0.61	2.85e-11	Platelet count;
THYM	cis	rs9361491	0.657	rs9343798	chr6:79455282	A/G	cg04547799	chr6:79944526	HMGN3	-0.66	-4.58	-0.43	1.41e-5	Intelligence (multi-trait analysis);
THYM	cis	rs11096990	0.892	rs11932351	chr4:39231457	A/G	cg24403649	chr4:39172243	NA	-0.66	-5.65	-0.5	1.68e-7	Cognitive function;
THYM	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg00071950	chr4:10020882	SLC2A9	-0.55	-4.78	-0.44	6.41e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10256972	0.552	rs6953538	chr7:1196974	A/G	cg18402987	chr7:1209562	NA	0.72	5.33	0.48	6.68e-7	Longevity;Endometriosis;
THYM	cis	rs870825	0.518	rs2696051	chr4:185604780	G/T	cg04058563	chr4:185651563	MLF1IP	-0.59	-5.48	-0.49	3.53e-7	Blood protein levels;
THYM	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg06970220	chr1:156163860	SLC25A44	-0.74	-5.64	-0.5	1.78e-7	Testicular germ cell tumor;
THYM	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg05754148	chr16:3507555	NAT15	-0.87	-6.93	-0.58	4.92e-10	Tuberculosis;
THYM	cis	rs7408868	1.000	rs7254735	chr19:15263385	A/G	cg14696996	chr19:15285081	NOTCH3	0.8	4.84	0.44	4.95e-6	Pulse pressure;
THYM	cis	rs2554380	0.943	rs2585042	chr15:84341748	T/C	cg14598478	chr15:84363061	ADAMTSL3	-0.65	-5.11	-0.46	1.64e-6	Height;
THYM	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg27446573	chr6:127587934	RNF146	0.74	5.98	0.52	3.83e-8	Breast cancer;
THYM	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg06558623	chr16:89946397	TCF25	0.98	5.43	0.49	4.39e-7	Skin colour saturation;
THYM	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg03909863	chr11:638404	DRD4	-0.76	-6.04	-0.53	2.95e-8	Systemic lupus erythematosus;
THYM	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg00383909	chr3:49044727	WDR6	1.27	7.71	0.62	1.22e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs61990749	0.597	rs176971	chr14:78191599	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.04	0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs1051424	0.651	rs1292063	chr17:57907768	T/A	cg20151207	chr17:57696971	CLTC	0.67	4.53	0.42	1.74e-5	Obesity-related traits;
THYM	cis	rs2964802	0.505	rs4410623	chr5:10832271	A/C	cg14521931	chr5:10832172	NA	0.63	5.55	0.5	2.53e-7	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs6988636	1.000	rs16898097	chr8:124195034	G/C	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs12478296	0.901	rs59477854	chr2:243015490	T/C	cg06360820	chr2:242988706	NA	-0.96	-6.27	-0.54	1.06e-8	Obesity-related traits;
THYM	cis	rs9905704	0.918	rs654743	chr17:56736490	T/C	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.74e-6	Testicular germ cell tumor;
THYM	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.84e-8	Systolic blood pressure;
THYM	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg13695892	chr22:41940480	POLR3H	-0.99	-7.52	-0.61	2.99e-11	Vitiligo;
THYM	trans	rs8002861	0.664	rs9533686	chr13:44468494	A/G	cg17145862	chr1:211918768	LPGAT1	0.89	8.72	0.67	9.08e-14	Leprosy;
THYM	cis	rs7851660	0.874	rs10120412	chr9:100628238	T/C	cg13688889	chr9:100608707	NA	-0.78	-5.72	-0.51	1.21e-7	Strep throat;
THYM	cis	rs6980334	0.817	rs3805360	chr7:137794589	G/A	cg06915773	chr7:137028165	PTN	0.58	4.74	0.44	7.59e-6	Blood metabolite ratios;
THYM	cis	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg12826209	chr6:26865740	GUSBL1	0.97	5.18	0.47	1.26e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg10523679	chr1:76189770	ACADM	0.9	7.47	0.61	3.94e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg13266496	chr6:110720918	DDO	-0.47	-4.83	-0.44	5.15e-6	Platelet distribution width;
THYM	cis	rs4589258	0.788	rs10734133	chr11:90457190	G/T	cg26138821	chr11:89956704	CHORDC1	-0.58	-4.8	-0.44	6.01e-6	Intelligence (multi-trait analysis);
THYM	trans	rs8073060	0.586	rs7217533	chr17:34015876	A/G	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs11190604	1.000	rs2273695	chr10:102259568	A/G	cg07570687	chr10:102243282	WNT8B	0.75	6.65	0.56	1.85e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs995000	0.965	rs11207980	chr1:62992749	T/C	cg06896770	chr1:63153194	DOCK7	1.0	8.17	0.64	1.31e-12	Triglyceride levels;
THYM	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg13319975	chr6:146136371	FBXO30	-0.67	-5.89	-0.52	5.9e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg04731861	chr2:219085781	ARPC2	0.55	5.26	0.47	8.86e-7	Colorectal cancer;
THYM	cis	rs1692580	0.840	rs262679	chr1:2169792	C/T	cg21442419	chr1:2182373	SKI	-0.44	-4.79	-0.44	6.11e-6	Coronary artery disease;
THYM	cis	rs500891	0.525	rs3757011	chr6:84081069	G/C	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs1003719	0.715	rs2835653	chr21:38558636	G/A	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg08736216	chr1:53307985	ZYG11A	-0.71	-6.26	-0.54	1.1e-8	Monocyte count;
THYM	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg18876405	chr7:65276391	NA	-0.58	-4.99	-0.46	2.78e-6	Aortic root size;
THYM	cis	rs7084402	0.967	rs7079648	chr10:60273155	C/A	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs7072216	0.763	rs1061437	chr10:100176154	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.53	-0.42	1.74e-5	Metabolite levels;
THYM	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs35430959	0.779	rs11886716	chr2:76432642	C/T	cg25389065	chr2:75938167	C2orf3	-0.58	-4.47	-0.42	2.13e-5	Schizophrenia;
THYM	cis	rs586688	1.000	rs635979	chr1:201637811	C/T	cg14168733	chr1:201708718	NAV1	0.55	5.34	0.48	6.24e-7	Obesity-related traits;
THYM	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.75	-0.44	7.08e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs12983728	0.831	rs35081008	chr19:58662235	C/T	cg07378217	chr19:58662286	ZNF329	-0.93	-5.55	-0.49	2.58e-7	Cholesterol, total;
THYM	cis	rs9361491	0.608	rs7766517	chr6:79458748	C/T	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg14074117	chr16:1909714	C16orf73	-0.7	-4.45	-0.42	2.3e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs7607369	0.596	rs56304256	chr2:219276138	T/C	cg02176678	chr2:219576539	TTLL4	-0.61	-5.27	-0.48	8.62e-7	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs11792861	0.591	rs10979632	chr9:111732140	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.82	7.09	0.59	2.31e-10	Menarche (age at onset);
THYM	cis	rs12801636	0.512	rs2075660	chr11:65414709	C/A	cg19646538	chr11:65837255	PACS1	-0.47	-4.47	-0.42	2.14e-5	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.66	-4.63	-0.43	1.18e-5	Aortic root size;
THYM	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg06115741	chr20:33292138	TP53INP2	0.73	5.07	0.46	1.98e-6	Coronary artery disease;
THYM	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg10523679	chr1:76189770	ACADM	-0.55	-4.67	-0.43	9.97e-6	Daytime sleep phenotypes;
THYM	cis	rs7715811	1.000	rs6860236	chr5:13762013	C/T	cg07548982	chr5:13769939	DNAH5	-0.5	-4.5	-0.42	1.95e-5	Subclinical atherosclerosis traits (other);
THYM	cis	rs1801251	0.727	rs6437071	chr2:233568793	G/A	cg08000102	chr2:233561755	GIGYF2	0.66	5.79	0.51	9.04e-8	Coronary artery disease;
THYM	cis	rs1322639	0.657	rs12203887	chr6:169572252	C/T	cg04662567	chr6:169592167	NA	-0.81	-6.65	-0.56	1.83e-9	Pulse pressure;
THYM	cis	rs3820068	0.544	rs7551750	chr1:16035008	T/C	cg24675056	chr1:15929824	NA	0.78	6.16	0.53	1.73e-8	Systolic blood pressure;
THYM	cis	rs6700896	0.931	rs4655764	chr1:66126159	C/T	cg04111102	chr1:66153794	NA	0.53	4.94	0.45	3.33e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9796	0.866	rs66818965	chr15:41402279	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.58	-4.73	-0.44	7.81e-6	Menopause (age at onset);
THYM	cis	rs9486719	1.000	rs2145535	chr6:97034715	G/A	cg18709589	chr6:96969512	KIAA0776	-0.67	-4.64	-0.43	1.1e-5	Migraine;Coronary artery disease;
THYM	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg00129232	chr17:37814104	STARD3	-0.7	-4.52	-0.42	1.78e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs4631830	0.863	rs2843546	chr10:51518688	A/C	cg16070123	chr10:51489643	NA	-0.52	-4.81	-0.44	5.7e-6	Prostate-specific antigen levels;
THYM	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.46	-4.92	-0.45	3.63e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
THYM	cis	rs7172809	0.599	rs17471697	chr15:77762493	A/G	cg22256960	chr15:77711686	NA	0.61	4.47	0.42	2.18e-5	Glucose homeostasis traits;
THYM	cis	rs7089973	0.872	rs35010779	chr10:116631816	A/C	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.05	-0.46	2.15e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs10100465	0.961	rs1508569	chr8:118662557	T/C	cg09430518	chr8:118662568	NA	-0.33	-5.33	-0.48	6.58e-7	Leprosy;
THYM	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg17775962	chr7:1200435	ZFAND2A	0.48	5.36	0.48	5.75e-7	Longevity;Endometriosis;
THYM	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Alcohol dependence;
THYM	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.57	-4.88	-0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs4460079	0.531	rs11098210	chr4:114838387	C/G	cg02060584	chr4:113970739	ANK2	-0.54	-4.46	-0.42	2.22e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg13866156	chr1:1669148	SLC35E2	-0.72	-7.33	-0.6	7.71e-11	Body mass index;
THYM	cis	rs9399401	0.710	rs6900087	chr6:142717303	A/T	cg03128060	chr6:142623767	GPR126	0.7	9.47	0.7	2.29e-15	Chronic obstructive pulmonary disease;
THYM	cis	rs9303280	0.901	rs2290400	chr17:38066240	A/G	cg24910161	chr17:38119198	GSDMA	0.45	4.74	0.44	7.51e-6	Self-reported allergy;
THYM	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg23791538	chr6:167370224	RNASET2	-0.78	-6.28	-0.54	1.02e-8	Crohn's disease;
THYM	cis	rs9527	0.615	rs10883781	chr10:104581130	A/G	cg05855489	chr10:104503620	C10orf26	0.62	4.64	0.43	1.12e-5	Arsenic metabolism;
THYM	cis	rs2737265	0.723	rs2737248	chr8:116660459	A/G	cg04656070	chr8:116661063	TRPS1	-0.55	-6.41	-0.55	5.59e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;
THYM	cis	rs6510489	1.000	rs11880364	chr19:35988794	A/G	cg15078284	chr19:36004994	DMKN	0.42	4.96	0.45	3.14e-6	Bipolar disorder;
THYM	cis	rs2133450	0.724	rs1858060	chr3:7361224	C/T	cg19930620	chr3:7340148	GRM7	-0.49	-4.66	-0.43	1.02e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs6032067	0.852	rs2868240	chr20:43874039	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	0.49	5.37	0.48	5.52e-7	Blood protein levels;
THYM	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg08508325	chr11:3079039	CARS	-0.52	-6.46	-0.55	4.45e-9	Longevity;
THYM	cis	rs4654899	0.965	rs7525620	chr1:21458392	G/A	cg01072550	chr1:21505969	NA	-0.74	-6.69	-0.57	1.54e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13202913	0.733	rs13215869	chr6:151803659	G/A	cg03596678	chr6:151814994	C6orf97	-0.76	-4.8	-0.44	5.88e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs7226229	0.904	rs1904230	chr17:20944220	G/C	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs1348850	0.560	rs13019660	chr2:178498214	C/T	cg22681709	chr2:178499509	PDE11A	-0.57	-5.19	-0.47	1.17e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs11642862	0.792	rs75586365	chr16:30996363	C/T	cg01070095	chr16:30968205	SETD1A	0.73	4.79	0.44	6.24e-6	Tonsillectomy;
THYM	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06873352	chr17:61820015	STRADA	0.81	10.19	0.72	6.54e-17	Prudent dietary pattern;
THYM	trans	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1829883	0.931	rs7713876	chr5:98878187	C/G	cg08333243	chr5:99726346	NA	-0.54	-5.0	-0.46	2.59e-6	Hemostatic factors and hematological phenotypes;
THYM	trans	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7211079	0.957	rs8082247	chr17:78114991	T/C	cg09238746	chr17:78121135	EIF4A3	-0.75	-4.63	-0.43	1.14e-5	Myocardial infarction;
THYM	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg10018233	chr7:150070692	REPIN1	0.38	5.41	0.48	4.8e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7772486	0.875	rs2748483	chr6:146335560	A/T	cg13319975	chr6:146136371	FBXO30	0.7	5.96	0.52	4.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg20290983	chr6:43655470	MRPS18A	1.44	16.02	0.85	9.41e-29	IgG glycosylation;
THYM	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg11189052	chr15:85197271	WDR73	-0.62	-4.63	-0.43	1.16e-5	P wave terminal force;
THYM	cis	rs3768617	0.510	rs723014	chr1:183076287	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs6032067	0.852	rs17333180	chr20:43803708	C/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.41	-0.65	4.05e-13	Blood protein levels;
THYM	cis	rs1003719	0.680	rs2835668	chr21:38580151	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.5	-0.42	1.95e-5	Eye color traits;
THYM	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg26566898	chr11:117069891	TAGLN	0.39	4.96	0.45	3.13e-6	Blood protein levels;
THYM	cis	rs2115536	1.000	rs2903105	chr15:80189523	C/G	cg00225070	chr15:80189496	MTHFS	0.65	5.77	0.51	9.71e-8	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs6542838	0.671	rs35929117	chr2:99389490	A/G	cg08885076	chr2:99613938	TSGA10	-0.57	-4.87	-0.45	4.36e-6	Fear of minor pain;
THYM	cis	rs6665290	0.904	rs6426559	chr1:227195876	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg16624210	chr5:671434	TPPP	0.76	5.54	0.49	2.71e-7	Obesity-related traits;
THYM	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg20151795	chr6:28129481	ZNF389	-0.75	-4.59	-0.43	1.36e-5	Parkinson's disease;
THYM	cis	rs12478296	1.000	rs56292923	chr2:243039986	C/T	cg06360820	chr2:242988706	NA	-0.87	-5.41	-0.49	4.65e-7	Obesity-related traits;
THYM	trans	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg10856724	chr12:34555212	NA	-0.9	-7.78	-0.62	8.57e-12	Bladder cancer;
THYM	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg05368731	chr17:41323189	NBR1	1.26	11.54	0.76	9.06e-20	Menopause (age at onset);
THYM	cis	rs40363	0.645	rs1690446	chr16:3519009	T/C	cg22508957	chr16:3507546	NAT15	0.69	9.19	0.69	8.75e-15	Tuberculosis;
THYM	cis	rs72829446	0.530	rs17732878	chr17:7362359	C/T	cg02795151	chr17:7402630	POLR2A	-0.51	-5.36	-0.48	5.93e-7	Androgen levels;
THYM	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg02527881	chr3:46936655	PTH1R	-0.63	-6.29	-0.54	9.52e-9	Colorectal cancer;
THYM	cis	rs4889855	0.530	rs8080678	chr17:78544003	G/T	cg16591659	chr17:78472290	NA	0.43	5.05	0.46	2.14e-6	Fractional excretion of uric acid;
THYM	cis	rs11779988	0.501	rs3760	chr8:17886345	T/C	cg01800426	chr8:17659068	MTUS1	-0.6	-4.51	-0.42	1.88e-5	Breast cancer;
THYM	cis	rs2281845	1.000	rs2281845	chr1:201081943	C/T	cg17810781	chr1:201082982	CACNA1S	0.69	7.3	0.6	8.77e-11	Permanent tooth development;
THYM	cis	rs89107	0.575	rs10872167	chr6:118988362	C/T	cg01113488	chr6:119027122	NA	-0.56	-4.76	-0.44	6.96e-6	Cardiac structure and function;
THYM	cis	rs7772486	0.641	rs9390370	chr6:146357569	C/T	cg13319975	chr6:146136371	FBXO30	-0.69	-5.67	-0.5	1.51e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg26038318	chr20:34205095	SPAG4	0.59	4.7	0.43	8.69e-6	Total cholesterol levels;
THYM	cis	rs4474465	1.000	rs10899502	chr11:78141021	C/T	cg19901956	chr11:77921274	USP35	-0.59	-4.52	-0.42	1.8e-5	Alzheimer's disease (survival time);
THYM	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg02753203	chr1:228287806	NA	0.76	6.53	0.56	3.21e-9	Diastolic blood pressure;
THYM	cis	rs7084402	0.934	rs1649067	chr10:60305240	T/C	cg07615347	chr10:60278583	BICC1	0.56	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.48	-4.86	-0.45	4.64e-6	Crohn's disease;
THYM	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg19346786	chr7:2764209	NA	-0.72	-6.08	-0.53	2.55e-8	Height;
THYM	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.61	4.55	0.42	1.58e-5	Chronic sinus infection;
THYM	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg18402987	chr7:1209562	NA	1.03	6.17	0.53	1.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9522267	0.535	rs9522291	chr13:112233761	T/C	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	12.82	0.8	1.97e-22	Chronic sinus infection;
THYM	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg10518543	chr12:38710700	ALG10B	0.58	4.51	0.42	1.85e-5	Morning vs. evening chronotype;
THYM	cis	rs3015497	0.789	rs1389652	chr14:51125240	T/C	cg04730355	chr14:51134070	SAV1	-0.54	-4.76	-0.44	6.85e-6	Mean platelet volume;
THYM	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg05973401	chr12:123451056	ABCB9	0.69	4.59	0.43	1.36e-5	Neutrophil percentage of white cells;
THYM	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs3960554	0.808	rs3779419	chr7:75695081	G/A	cg17398381	chr7:75624190	TMEM120A	-0.45	-4.46	-0.42	2.21e-5	Eotaxin levels;
THYM	cis	rs80319144	1.000	rs115983109	chr2:159273472	A/G	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs901683	1.000	rs12776291	chr10:46038507	T/C	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg05373962	chr22:49881684	NA	-0.67	-6.07	-0.53	2.57e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2154427	0.872	rs10446070	chr21:34010624	C/T	cg21871883	chr21:34145043	C21orf49;C21orf66	1.02	5.12	0.47	1.57e-6	Bilirubin levels;
THYM	cis	rs2456568	0.805	rs55784864	chr11:93682887	G/A	cg26875233	chr11:93583750	C11orf90	-0.5	-4.88	-0.45	4.28e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg01416388	chr22:39784598	NA	-0.96	-9.39	-0.69	3.31e-15	Intelligence (multi-trait analysis);
THYM	cis	rs1018836	0.663	rs12674903	chr8:91475774	T/C	cg16814680	chr8:91681699	NA	-0.76	-6.44	-0.55	4.86e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs4601821	0.858	rs2298489	chr11:113235419	C/T	cg14159747	chr11:113255604	NA	-0.26	-4.72	-0.44	8.05e-6	Alcoholic chronic pancreatitis;
THYM	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg22709100	chr7:91322751	NA	0.68	5.42	0.49	4.59e-7	Breast cancer;
THYM	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg24375607	chr4:120327624	NA	0.62	4.77	0.44	6.59e-6	Corneal astigmatism;
THYM	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03264133	chr6:25882463	NA	-0.7	-5.51	-0.49	3.06e-7	Blood metabolite levels;
THYM	cis	rs822354	0.926	rs266740	chr3:186477329	C/A	cg23249140	chr3:186560453	ADIPOQ	-0.47	-4.46	-0.42	2.22e-5	Adiponectin levels;
THYM	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg08213375	chr14:104286397	PPP1R13B	0.44	4.46	0.42	2.22e-5	Reticulocyte count;
THYM	cis	rs6430585	0.583	rs2304371	chr2:136561557	A/G	cg07169764	chr2:136633963	MCM6	1.06	12.19	0.78	3.93e-21	Corneal structure;
THYM	cis	rs9902453	1.000	rs6505152	chr17:28331466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs8112211	0.911	rs2286476	chr19:38850759	G/A	cg09474229	chr19:39360330	RINL	-0.49	-4.46	-0.42	2.23e-5	Blood protein levels;
THYM	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.66	5.8	0.51	8.62e-8	Hemoglobin concentration;
THYM	cis	rs9876781	1.000	rs3774808	chr3:48481647	G/A	cg06066452	chr3:48470258	PLXNB1	0.27	4.77	0.44	6.64e-6	Longevity;
THYM	cis	rs3820068	0.705	rs41270255	chr1:15892980	G/A	cg05660106	chr1:15850417	CASP9	1.16	10.06	0.72	1.25e-16	Systolic blood pressure;
THYM	cis	rs6443245	0.963	rs2648573	chr3:9635471	C/T	cg20517764	chr3:9027454	SRGAP3	-0.62	-4.46	-0.42	2.26e-5	Daytime sleep phenotypes;
THYM	cis	rs192264	0.680	rs1103776	chr16:65972141	C/A	cg02795155	chr16:66785218	DYNC1LI2	0.58	4.68	0.43	9.41e-6	Subjective well-being;
THYM	cis	rs7640424	0.628	rs7628325	chr3:107816314	G/A	cg09227934	chr3:107805635	CD47	-0.65	-4.99	-0.46	2.68e-6	Body mass index;
THYM	cis	rs3087591	1.000	rs2525578	chr17:29711411	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.64	-5.35	-0.48	6.17e-7	Hip circumference;
THYM	cis	rs13223928	0.572	rs12538887	chr7:3134821	G/A	cg19214707	chr7:3157722	NA	-0.9	-7.81	-0.63	7.58e-12	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg06600287	chr1:53387719	ECHDC2	-0.33	-4.84	-0.44	5.1e-6	Monocyte count;
THYM	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg27446573	chr6:127587934	RNF146	0.74	5.98	0.52	3.83e-8	Breast cancer;
THYM	cis	rs4731207	0.596	rs7795611	chr7:124578456	G/C	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg11009520	chr8:12052164	FAM86B1	0.57	4.51	0.42	1.83e-5	Neuroticism;
THYM	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg22709100	chr7:91322751	NA	0.6	4.68	0.43	9.41e-6	Breast cancer;
THYM	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg27446573	chr6:127587934	RNF146	1.03	9.76	0.71	5.36e-16	Breast cancer;
THYM	cis	rs919433	0.679	rs9967823	chr2:198531529	A/G	cg05783139	chr2:198650985	BOLL	0.66	4.98	0.46	2.78e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.46	0.55	4.38e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06481639	chr22:41940642	POLR3H	0.83	5.86	0.52	6.65e-8	Vitiligo;
THYM	cis	rs4523957	0.788	rs11078865	chr17:2109109	T/A	cg16513277	chr17:2031491	SMG6	-0.81	-7.8	-0.63	7.74e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg26597838	chr10:835615	NA	1.2	8.64	0.66	1.3e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg10802521	chr3:52805072	NEK4	-0.76	-7.11	-0.59	2.2e-10	Bipolar disorder;
THYM	cis	rs7584330	0.554	rs113271883	chr2:238425594	A/G	cg08992911	chr2:238395768	MLPH	0.85	5.39	0.48	5.19e-7	Prostate cancer;
THYM	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg07747251	chr5:1868357	NA	0.62	5.31	0.48	7.14e-7	Cardiovascular disease risk factors;
THYM	cis	rs4845570	1.000	rs6659705	chr1:151769750	T/C	cg07092448	chr1:151763213	TDRKH	-1.02	-6.25	-0.54	1.19e-8	Coronary artery disease;
THYM	cis	rs7614311	0.594	rs58473894	chr3:63857208	G/C	cg22134162	chr3:63841271	THOC7	-0.55	-7.07	-0.59	2.57e-10	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg17554472	chr22:41940697	POLR3H	0.73	5.15	0.47	1.39e-6	Vitiligo;
THYM	cis	rs61931739	0.817	rs866515	chr12:34215479	A/G	cg10856724	chr12:34555212	NA	-0.61	-5.61	-0.5	1.95e-7	Morning vs. evening chronotype;
THYM	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs112916054	1	rs112916054	chr17:31124262	C/T	cg23177095	chr17:30873196	MYO1D	0.64	4.96	0.45	3.03e-6	Immature fraction of reticulocytes;
THYM	cis	rs4589258	0.788	rs1894136	chr11:90498019	C/T	cg26138821	chr11:89956704	CHORDC1	0.59	4.83	0.44	5.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4460079	0.531	rs7664471	chr4:114836312	C/T	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs990171	0.913	rs4851009	chr2:103055644	G/A	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.17	-0.47	1.27e-6	Lymphocyte counts;
THYM	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg12165864	chr7:66369176	NA	0.6	4.69	0.43	9.14e-6	Aortic root size;
THYM	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg00006948	chr4:1768889	NA	0.93	5.0	0.46	2.58e-6	Bladder cancer;Urinary bladder cancer;
THYM	cis	rs2625529	0.652	rs2957728	chr15:72236432	G/T	cg16672083	chr15:72433130	SENP8	0.5	4.56	0.42	1.55e-5	Red blood cell count;
THYM	cis	rs2404602	0.684	rs11072602	chr15:76873467	T/C	cg23625390	chr15:77176239	SCAPER	-0.9	-6.41	-0.55	5.72e-9	Blood metabolite levels;
THYM	cis	rs7078219	0.714	rs60386053	chr10:101288861	G/A	cg07044859	chr10:101282883	NA	-0.48	-5.23	-0.47	1.01e-6	Dental caries;
THYM	cis	rs60871478	0.588	rs73043546	chr7:857513	C/G	cg10248100	chr7:872053	UNC84A	0.71	4.55	0.42	1.6e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg00677455	chr12:58241039	CTDSP2	0.83	6.59	0.56	2.48e-9	Multiple sclerosis;
THYM	cis	rs7772486	0.658	rs6570706	chr6:145962922	T/C	cg23711669	chr6:146136114	FBXO30	0.85	8.17	0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg03161606	chr19:29218774	NA	0.87	7.3	0.6	8.75e-11	Methadone dose in opioid dependence;
THYM	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs988913	0.706	rs10948870	chr6:54745098	G/A	cg15217784	chr6:54722227	FAM83B	-0.52	-4.6	-0.43	1.28e-5	Menarche (age at onset);
THYM	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg03733263	chr8:22462867	KIAA1967	1.15	12.26	0.78	2.8e-21	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs11608355	0.618	rs11066368	chr12:109790342	C/T	cg11367159	chr12:110044531	NA	0.49	4.54	0.42	1.62e-5	Neuroticism;
THYM	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg06634786	chr22:41940651	POLR3H	0.66	5.15	0.47	1.39e-6	Vitiligo;
THYM	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg11214544	chr1:2391121	NA	-0.63	-5.84	-0.51	7.21e-8	Non-obstructive azoospermia;
THYM	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg22166914	chr1:53195759	ZYG11B	0.73	6.2	0.54	1.46e-8	Monocyte count;
THYM	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.83	-6.95	-0.58	4.49e-10	Systemic lupus erythematosus;
THYM	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs3126085	0.935	rs3126056	chr1:152266503	G/A	cg26020982	chr1:152196106	HRNR	-0.35	-4.95	-0.45	3.26e-6	Atopic dermatitis;
THYM	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg13695892	chr22:41940480	POLR3H	-0.91	-7.25	-0.6	1.09e-10	Vitiligo;
THYM	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg00786635	chr1:25594202	NA	0.87	7.02	0.58	3.24e-10	Erythrocyte sedimentation rate;
THYM	cis	rs1847202	1.000	rs7634188	chr3:72941289	A/G	cg25664220	chr3:72788482	NA	0.61	4.71	0.43	8.55e-6	Motion sickness;
THYM	cis	rs60843830	0.661	rs62116682	chr2:104618	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.57	4.63	0.43	1.18e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs2236918	0.710	rs2797602	chr1:242029206	G/T	cg21919602	chr1:242011447	EXO1	-0.6	-4.45	-0.42	2.35e-5	Menopause (age at onset);
THYM	trans	rs58106596	0.800	rs11693819	chr2:232566206	G/A	cg01370599	chr3:116745421	NA	1.02	7.23	0.6	1.23e-10	White blood cell count;Lymphocyte counts;
THYM	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.73	-5.9	-0.52	5.54e-8	Tonsillectomy;
THYM	cis	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg13609457	chr4:120235615	NA	0.55	5.07	0.46	1.94e-6	Corneal astigmatism;
THYM	cis	rs6876348	0.516	rs185411	chr5:128313024	A/G	cg25555059	chr5:128301488	SLC27A6	-0.46	-4.84	-0.45	4.92e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg05335186	chr13:53173507	NA	-0.5	-7.02	-0.58	3.22e-10	Lewy body disease;
THYM	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.63	-5.91	-0.52	5.44e-8	Bone mineral density;
THYM	cis	rs2404602	0.647	rs11072618	chr15:77019342	A/G	cg23625390	chr15:77176239	SCAPER	-0.86	-5.88	-0.52	6.21e-8	Blood metabolite levels;
THYM	cis	rs4455778	0.536	rs10266289	chr7:48941456	C/T	cg26309511	chr7:48887640	NA	-0.62	-6.31	-0.54	8.85e-9	Lung cancer in never smokers;
THYM	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs189798	0.807	rs9949	chr8:8994512	A/G	cg18904891	chr8:8559673	CLDN23	0.65	4.64	0.43	1.12e-5	Myopia (pathological);
THYM	cis	rs1387259	0.929	rs2634666	chr12:48663670	G/T	cg21466736	chr12:48725269	NA	-0.53	-4.91	-0.45	3.78e-6	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs17006441	0.932	rs7634549	chr3:69869358	C/T	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs9790314	0.637	rs778649	chr3:160709377	C/T	cg04691961	chr3:161091175	C3orf57	-0.57	-4.59	-0.43	1.35e-5	Morning vs. evening chronotype;
THYM	cis	rs4792901	0.765	rs9908030	chr17:41587891	A/G	cg21940313	chr17:41620911	ETV4	-0.53	-5.03	-0.46	2.28e-6	Dupuytren's disease;
THYM	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.85	0.74	2.52e-18	Chronic sinus infection;
THYM	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg08885076	chr2:99613938	TSGA10	0.65	5.96	0.52	4.31e-8	Chronic sinus infection;
THYM	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg08859206	chr1:53392774	SCP2	-0.85	-10.09	-0.72	1.05e-16	Monocyte count;
THYM	cis	rs7586879	0.639	rs4077678	chr2:25122840	C/G	cg15423357	chr2:25149977	NA	0.71	7.66	0.62	1.53e-11	Body mass index;
THYM	cis	rs7267979	1.000	rs6050561	chr20:25334855	C/T	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7078219	1.000	rs6584278	chr10:101278099	C/T	cg23904955	chr10:101282759	NA	-0.44	-5.25	-0.47	9.32e-7	Dental caries;
THYM	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.21	0.47	1.1e-6	Electroencephalogram traits;
THYM	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg23583168	chr7:148888333	NA	-1.1	-16.73	-0.86	4.47e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs757081	0.702	rs522619	chr11:17204448	A/G	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.6	-0.43	1.29e-5	Systolic blood pressure;
THYM	cis	rs4409675	0.576	rs6662916	chr1:28219873	G/T	cg23691781	chr1:28212827	C1orf38	0.44	4.5	0.42	1.92e-5	Corneal astigmatism;
THYM	cis	rs7772486	0.597	rs2485631	chr6:146190077	G/C	cg23711669	chr6:146136114	FBXO30	0.85	8.06	0.64	2.25e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs990171	0.837	rs1568681	chr2:103014696	C/T	cg13897122	chr2:103039542	IL18RAP	-0.38	-4.67	-0.43	9.77e-6	Lymphocyte counts;
THYM	cis	rs2522056	0.932	rs1012793	chr5:131781345	G/C	cg24060327	chr5:131705240	SLC22A5	0.73	4.7	0.43	8.8e-6	Lymphocyte counts;Fibrinogen;
THYM	cis	rs3126085	0.935	rs1390485	chr1:152182168	C/T	cg26020982	chr1:152196106	HRNR	-0.34	-4.47	-0.42	2.14e-5	Atopic dermatitis;
THYM	cis	rs2976388	0.609	rs1594999	chr8:143790574	G/A	cg06565975	chr8:143823917	SLURP1	0.47	5.22	0.47	1.06e-6	Urinary tract infection frequency;
THYM	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg06558623	chr16:89946397	TCF25	1.33	6.02	0.53	3.25e-8	Skin colour saturation;
THYM	cis	rs12621445	1	rs12621445	chr2:24154964	C/T	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Immature fraction of reticulocytes;
THYM	cis	rs1003719	0.688	rs2835660	chr21:38568882	G/C	cg01329690	chr21:38580129	DSCR9	-0.36	-5.0	-0.46	2.57e-6	Eye color traits;
THYM	cis	rs11096990	0.964	rs6828598	chr4:39261470	G/A	cg24403649	chr4:39172243	NA	-0.68	-5.77	-0.51	9.87e-8	Cognitive function;
THYM	cis	rs2050392	0.965	rs2265368	chr10:30690289	G/C	cg02070205	chr10:30722105	MAP3K8	-0.5	-4.47	-0.42	2.18e-5	Inflammatory bowel disease;
THYM	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.83	-4.94	-0.45	3.28e-6	Lung function (FEV1/FVC);
THYM	cis	rs7084402	0.934	rs1649067	chr10:60305240	T/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.65e-7	Refractive error;
THYM	cis	rs13253111	0.967	rs11136036	chr8:28061310	C/T	cg26534493	chr8:28060551	NA	-0.53	-4.78	-0.44	6.36e-6	Childhood body mass index;
THYM	cis	rs9902453	0.900	rs9910970	chr17:28478329	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	6.58	0.56	2.55e-9	Coffee consumption (cups per day);
THYM	cis	rs11771526	0.892	rs62457504	chr7:32336097	G/A	cg27511599	chr7:32358540	NA	0.69	4.78	0.44	6.26e-6	Body mass index;
THYM	cis	rs899997	1.000	rs12907207	chr15:79031290	G/A	cg00639195	chr15:79103007	ADAMTS7	-0.81	-5.72	-0.51	1.24e-7	Coronary artery disease or large artery stroke;
THYM	cis	rs9790314	1.000	rs9870059	chr3:161017240	T/C	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs7107174	1.000	rs7113042	chr11:78035832	C/T	cg19901956	chr11:77921274	USP35	0.65	5.34	0.48	6.41e-7	Testicular germ cell tumor;
THYM	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg10047753	chr17:41438598	NA	1.0	8.45	0.65	3.4e-13	Menopause (age at onset);
THYM	cis	rs2811415	0.597	rs6802633	chr3:127774722	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08704250	chr15:31115839	NA	-0.69	-7.64	-0.62	1.7e-11	Huntington's disease progression;
THYM	cis	rs988913	1.000	rs6922186	chr6:54811092	A/T	cg18532076	chr6:54711417	FAM83B	0.51	5.02	0.46	2.38e-6	Menarche (age at onset);
THYM	cis	rs2404602	0.735	rs56246286	chr15:76690731	C/T	cg23625390	chr15:77176239	SCAPER	-0.65	-4.7	-0.43	8.68e-6	Blood metabolite levels;
THYM	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06481639	chr22:41940642	POLR3H	0.87	5.95	0.52	4.49e-8	Vitiligo;
THYM	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg17718321	chr1:152188247	HRNR	-0.51	-4.85	-0.45	4.73e-6	Inflammatory skin disease;
THYM	cis	rs4242434	0.854	rs3735893	chr8:22452704	A/G	cg03733263	chr8:22462867	KIAA1967	1.14	12.79	0.8	2.23e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.77	0.51	9.78e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6032067	0.527	rs6104011	chr20:43733503	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.51	-4.78	-0.44	6.47e-6	Blood protein levels;
THYM	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Body mass index;
THYM	cis	rs4845570	1.000	rs11586946	chr1:151769806	G/A	cg07092448	chr1:151763213	TDRKH	-1.0	-6.13	-0.53	2e-8	Coronary artery disease;
THYM	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg20476274	chr7:133979776	SLC35B4	0.66	4.61	0.43	1.25e-5	Mean platelet volume;
THYM	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg00639195	chr15:79103007	ADAMTS7	-0.79	-6.15	-0.53	1.81e-8	Coronary artery disease or large artery stroke;
THYM	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg13390004	chr1:15929781	NA	0.62	4.72	0.44	8.11e-6	Systolic blood pressure;
THYM	cis	rs4986172	0.700	rs71373536	chr17:43221808	G/A	cg06100756	chr17:43221575	NA	0.72	6.98	0.58	4.04e-10	Height;
THYM	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg24154853	chr7:158122151	PTPRN2	-0.52	-4.71	-0.43	8.52e-6	Calcium levels;
THYM	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg26384229	chr12:38710491	ALG10B	0.95	7.4	0.6	5.52e-11	Drug-induced liver injury (flucloxacillin);
THYM	trans	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs16917546	1.000	rs10995248	chr10:64396042	A/G	cg03961010	chr10:64397487	ZNF365	0.8	6.78	0.57	1.01e-9	Basal cell carcinoma;
THYM	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs7216064	1.000	rs34872586	chr17:65863466	T/C	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs10095849	0.608	rs10108123	chr8:39439581	T/C	cg01911981	chr8:39380341	ADAM3A	-0.62	-5.13	-0.47	1.51e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6450176	1.000	rs4334835	chr5:53300612	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-6.19	-0.54	1.54e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs8180040	0.800	rs62248905	chr3:47274082	A/G	cg02527881	chr3:46936655	PTH1R	0.59	5.48	0.49	3.44e-7	Colorectal cancer;
THYM	cis	rs10911232	0.507	rs4652764	chr1:182994115	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs420259	0.516	rs2072062	chr16:23540798	C/T	cg00143387	chr16:23521605	GGA2	-0.75	-5.37	-0.48	5.57e-7	Bipolar disorder;
THYM	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg15448220	chr1:150897856	SETDB1	0.88	7.27	0.6	1.02e-10	Tonsillectomy;
THYM	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs1322639	0.614	rs6925950	chr6:169563958	A/G	cg04662567	chr6:169592167	NA	-0.79	-6.17	-0.53	1.69e-8	Pulse pressure;
THYM	cis	rs9677476	0.731	rs1477470	chr2:232076724	A/C	cg07929768	chr2:232055508	NA	0.63	6.39	0.55	6.12e-9	Food antigen IgG levels;
THYM	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg04833646	chr19:10679720	CDKN2D	-1.09	-10.12	-0.72	9.28e-17	Red cell distribution width;
THYM	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg05368731	chr17:41323189	NBR1	1.25	11.17	0.75	5.29e-19	Menopause (age at onset);
THYM	cis	rs11608355	1.000	rs10850134	chr12:109861454	G/C	cg10504392	chr12:110044639	NA	0.67	6.21	0.54	1.41e-8	Neuroticism;
THYM	cis	rs539096	0.872	rs2842186	chr1:44035093	A/G	cg00143623	chr1:44495758	SLC6A9	-0.73	-5.7	-0.5	1.34e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9302635	0.513	rs8050238	chr16:72154187	C/T	cg16558253	chr16:72132732	DHX38	-0.55	-4.49	-0.42	2.01e-5	Blood protein levels;
THYM	cis	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.59	-0.43	1.37e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg26384229	chr12:38710491	ALG10B	-0.87	-8.84	-0.67	4.86e-14	Heart rate;
THYM	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg17294928	chr15:75287854	SCAMP5	-1.01	-9.1	-0.68	1.4e-14	Blood trace element (Zn levels);
THYM	cis	rs35883536	0.588	rs12568329	chr1:101104588	A/G	cg09408571	chr1:101003634	GPR88	-0.43	-5.16	-0.47	1.34e-6	Monocyte count;
THYM	cis	rs863345	0.604	rs4276920	chr1:158504972	G/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs854765	0.663	rs3744113	chr17:17748645	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-5.58	-0.5	2.3e-7	Total body bone mineral density;
THYM	cis	rs2898681	0.642	rs62336790	chr4:53728000	T/C	cg00791764	chr4:53727839	RASL11B	0.47	6.22	0.54	1.32e-8	Optic nerve measurement (cup area);
THYM	cis	rs4746818	1.000	rs7918066	chr10:70913116	C/T	cg11621586	chr10:70884670	VPS26A	1.28	11.12	0.75	6.73e-19	Left atrial antero-posterior diameter;
THYM	cis	rs1075232	0.579	rs67675646	chr15:32239912	A/G	cg01030201	chr15:31746330	NA	-0.96	-4.5	-0.42	1.9e-5	Survival in colorectal cancer (non-distant metastatic);
THYM	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg07884673	chr3:53033167	SFMBT1	1.15	5.67	0.5	1.51e-7	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2439831	0.850	rs544122	chr15:43775732	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.8	6.39	0.55	6.21e-9	Lung cancer in ever smokers;
THYM	cis	rs12579753	0.956	rs34146892	chr12:82188581	T/G	cg07988820	chr12:82153109	PPFIA2	-0.74	-4.62	-0.43	1.2e-5	Resting heart rate;
THYM	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg06558623	chr16:89946397	TCF25	-1.23	-5.3	-0.48	7.63e-7	Skin colour saturation;
THYM	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg00310523	chr12:86230176	RASSF9	-0.54	-4.74	-0.44	7.6e-6	Major depressive disorder;
THYM	cis	rs76878669	0.516	rs7104570	chr11:66159098	A/G	cg18002602	chr11:66138449	SLC29A2	0.46	4.66	0.43	1.01e-5	Educational attainment (years of education);
THYM	cis	rs405460	0.517	rs392030	chr14:59298856	C/T	cg02291164	chr14:59296302	NA	-0.65	-5.88	-0.52	6.14e-8	Obesity-related traits;
THYM	cis	rs1448094	0.512	rs61930137	chr12:86242930	C/T	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs7104764	0.879	rs6598072	chr11:219793	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	1.1	9.77	0.71	5.16e-16	Menarche (age at onset);
THYM	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg02725872	chr8:58115012	NA	-1.15	-7.43	-0.61	4.64e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs10493773	0.609	rs11161664	chr1:86185379	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.6	-9.26	-0.69	6.23e-15	Urate levels in overweight individuals;
THYM	cis	rs1003719	0.788	rs3787783	chr21:38462959	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	5.51	0.49	3.1e-7	Schizophrenia;
THYM	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg11247378	chr22:39784982	NA	-1.03	-10.09	-0.72	1.04e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs4343996	0.566	rs4236326	chr7:3400105	C/T	cg21248987	chr7:3385318	SDK1	-0.41	-5.31	-0.48	7.27e-7	Motion sickness;
THYM	cis	rs7258465	1.000	rs7258465	chr19:18533642	A/G	cg04166595	chr19:18636596	NA	0.67	5.04	0.46	2.26e-6	Breast cancer;
THYM	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg21014159	chr11:117668035	DSCAML1	0.7	5.07	0.46	1.95e-6	Myopia;
THYM	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg26314531	chr2:26401878	FAM59B	-0.76	-5.02	-0.46	2.37e-6	Gut microbiome composition (summer);
THYM	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg23649088	chr2:200775458	C2orf69	0.81	6.14	0.53	1.88e-8	Schizophrenia;
THYM	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg24397884	chr7:158709396	WDR60	0.44	4.62	0.43	1.22e-5	Height;
THYM	cis	rs2133450	0.712	rs1546237	chr3:7366674	T/C	cg19930620	chr3:7340148	GRM7	-0.48	-4.49	-0.42	1.98e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs6988636	0.792	rs62521803	chr8:124152970	A/C	cg23067535	chr8:124195133	FAM83A	-0.99	-4.82	-0.44	5.52e-6	Urinary uromodulin levels;
THYM	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs4631830	0.863	rs3101227	chr10:51520203	C/A	cg10326726	chr10:51549505	MSMB	-0.54	-5.28	-0.48	8.09e-7	Prostate-specific antigen levels;
THYM	cis	rs7937682	0.632	rs11214009	chr11:111683142	T/C	cg09085632	chr11:111637200	PPP2R1B	1.22	13.43	0.81	1.13e-23	Primary sclerosing cholangitis;
THYM	cis	rs4889855	0.530	rs4890047	chr17:78549439	A/G	cg16591659	chr17:78472290	NA	-0.44	-5.08	-0.46	1.92e-6	Fractional excretion of uric acid;
THYM	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs208520	0.874	rs208517	chr6:66947040	G/T	cg07460842	chr6:66804631	NA	-0.85	-5.46	-0.49	3.87e-7	Exhaled nitric oxide output;
THYM	cis	rs9534288	0.763	rs9534273	chr13:46566988	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-4.52	-0.42	1.8e-5	Blood protein levels;
THYM	cis	rs9902453	0.967	rs7212741	chr17:28322941	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.81	0.44	5.74e-6	Coffee consumption (cups per day);
THYM	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4638749	0.677	rs1563112	chr2:108850579	C/T	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.63	-4.6	-0.43	1.31e-5	Aortic root size;
THYM	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg20503657	chr10:835505	NA	1.2	8.58	0.66	1.78e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg16049864	chr8:95962084	TP53INP1	-0.82	-7.42	-0.61	4.99e-11	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9296092	0.560	rs62407569	chr6:33538865	A/G	cg13560919	chr6:33536144	NA	-0.89	-8.41	-0.65	4.09e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg06521331	chr12:34319734	NA	-0.98	-8.55	-0.66	2.09e-13	Morning vs. evening chronotype;
THYM	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg25918947	chr17:41365094	TMEM106A	-0.68	-5.74	-0.51	1.15e-7	Menopause (age at onset);
THYM	trans	rs877282	0.947	rs12358875	chr10:757531	T/C	cg22713356	chr15:30763199	NA	1.35	9.87	0.71	3.11e-16	Uric acid levels;
THYM	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg12573674	chr2:1569213	NA	-1.33	-8.16	-0.64	1.42e-12	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs9790314	0.747	rs7650703	chr3:160851639	T/C	cg04691961	chr3:161091175	C3orf57	-0.61	-4.71	-0.44	8.33e-6	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.97	-5.16	-0.47	1.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg01616529	chr11:638424	DRD4	-0.78	-6.62	-0.56	2.16e-9	Systemic lupus erythematosus;
THYM	cis	rs7084402	0.967	rs7100474	chr10:60273121	T/C	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs4523957	0.928	rs375245	chr17:2199754	G/A	cg16513277	chr17:2031491	SMG6	0.77	6.96	0.58	4.26e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg08305652	chr11:111469057	NA	0.52	4.46	0.42	2.25e-5	Primary sclerosing cholangitis;
THYM	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg23187316	chr7:1099788	C7orf50	0.48	5.41	0.49	4.63e-7	Longevity;Endometriosis;
THYM	trans	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg25214090	chr10:38739885	LOC399744	0.87	7.52	0.61	2.99e-11	Corneal astigmatism;
THYM	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11771526	0.901	rs7791914	chr7:32296754	A/G	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.5	-4.67	-0.43	1e-5	Lymphocyte counts;
THYM	cis	rs6032067	0.929	rs6032070	chr20:43869795	A/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.72	-6.57	-0.56	2.73e-9	Blood protein levels;
THYM	cis	rs4474465	0.915	rs10128737	chr11:78186687	G/A	cg19901956	chr11:77921274	USP35	-0.62	-4.67	-0.43	9.83e-6	Alzheimer's disease (survival time);
THYM	cis	rs9527	0.590	rs10883818	chr10:104759586	A/G	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs4595586	0.525	rs4450203	chr12:39381493	T/G	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs10203711	1.000	rs10203711	chr2:239553368	C/T	cg14580085	chr2:239553406	NA	0.72	6.63	0.56	2.05e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4363385	0.693	rs6690549	chr1:152930426	C/T	cg07796016	chr1:152779584	LCE1C	-0.58	-4.65	-0.43	1.05e-5	Inflammatory skin disease;
THYM	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg04362960	chr10:104952993	NT5C2	0.58	4.68	0.43	9.68e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg03684893	chr10:554711	DIP2C	-0.76	-6.76	-0.57	1.13e-9	Psychosis in Alzheimer's disease;
THYM	cis	rs4148689	0.951	rs2027945	chr7:117187822	G/A	cg17204129	chr7:117119601	CFTR	-0.57	-4.47	-0.42	2.2e-5	Gout;
THYM	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4589258	0.737	rs1792609	chr11:90432837	G/T	cg26138821	chr11:89956704	CHORDC1	0.56	4.68	0.43	9.36e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg03877680	chr5:178157825	ZNF354A	0.71	4.77	0.44	6.78e-6	Neutrophil percentage of white cells;
THYM	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg07362569	chr17:61921086	SMARCD2	0.69	6.16	0.53	1.78e-8	Prudent dietary pattern;
THYM	cis	rs1008375	0.618	rs6842764	chr4:17568420	C/T	cg18681998	chr4:17616180	MED28	-0.72	-5.92	-0.52	5.09e-8	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6430585	0.528	rs614193	chr2:136653925	A/T	cg20242066	chr2:136595261	LCT	0.54	5.58	0.5	2.23e-7	Corneal structure;
THYM	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs4919687	0.550	rs17784294	chr10:104479385	G/T	cg18761893	chr10:103892519	PPRC1	0.63	4.83	0.44	5.13e-6	Colorectal cancer;
THYM	cis	rs1163251	0.902	rs639761	chr1:120217558	G/A	cg19096424	chr1:120255104	PHGDH	0.67	5.25	0.47	9.26e-7	Blood metabolite levels;
THYM	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg01069141	chr11:67398826	TBX10;NUDT8	0.54	5.76	0.51	1.02e-7	Mean corpuscular volume;
THYM	trans	rs877282	0.945	rs10904555	chr10:787740	C/A	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs76878669	0.561	rs56321771	chr11:66161072	C/T	cg18002602	chr11:66138449	SLC29A2	0.47	4.84	0.44	5.1e-6	Educational attainment (years of education);
THYM	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg23958373	chr8:599963	NA	0.94	4.61	0.43	1.26e-5	IgG glycosylation;
THYM	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.53	0.56	3.27e-9	Total body bone mineral density;
THYM	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg18132916	chr6:79620363	NA	-0.61	-5.49	-0.49	3.3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.752	rs676882	chr17:37433424	A/T	cg07936489	chr17:37558343	FBXL20	0.84	5.58	0.5	2.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg26384229	chr12:38710491	ALG10B	0.61	4.6	0.43	1.29e-5	Heart rate;
THYM	cis	rs2290159	0.800	rs28462331	chr3:12660466	G/C	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg08885076	chr2:99613938	TSGA10	-0.48	-4.8	-0.44	5.82e-6	Fear of minor pain;
THYM	cis	rs7828089	0.561	rs13266541	chr8:22266135	G/A	cg12081754	chr8:22256438	SLC39A14	0.89	9.12	0.68	1.26e-14	Verbal declarative memory;
THYM	cis	rs11574514	1.000	rs117298895	chr16:67883262	C/A	cg09738193	chr16:67926317	PSKH1	-0.91	-4.66	-0.43	1.01e-5	Crohn's disease;
THYM	cis	rs9902453	1.000	rs7222308	chr17:28277041	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	4.69	0.43	9.31e-6	Coffee consumption (cups per day);
THYM	cis	rs57920188	0.535	rs4295856	chr1:4094842	C/T	cg08764037	chr1:3634867	TP73	-0.45	-4.68	-0.43	9.66e-6	Interleukin-17 levels;
THYM	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg08109568	chr15:31115862	NA	0.54	5.23	0.47	1.02e-6	Huntington's disease progression;
THYM	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg27572855	chr1:25598939	RHD	0.69	5.3	0.48	7.61e-7	Erythrocyte sedimentation rate;
THYM	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6946131	0.593	rs2709294	chr7:54831659	A/C	cg16668896	chr7:54900801	NA	0.43	4.48	0.42	2.06e-5	Systemic lupus erythematosus;
THYM	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg20891283	chr12:69753455	YEATS4	1.06	10.24	0.72	5.15e-17	Blood protein levels;
THYM	cis	rs933688	1.000	rs6452951	chr5:90653868	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	6.7	0.57	1.48e-9	Smoking behavior;
THYM	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.71	5.65	0.5	1.69e-7	Tonsillectomy;
THYM	cis	rs9359856	0.510	rs17294495	chr6:90445753	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.84	-7.98	-0.63	3.27e-12	Bipolar disorder;
THYM	cis	rs3768617	0.510	rs7518957	chr1:183093028	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.59	-4.92	-0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs2625529	0.878	rs2929511	chr15:72231682	C/T	cg16672083	chr15:72433130	SENP8	0.49	4.45	0.42	2.31e-5	Red blood cell count;
THYM	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.91	8.79	0.67	6.37e-14	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg02725872	chr8:58115012	NA	-0.88	-6.3	-0.54	9.14e-9	Developmental language disorder (linguistic errors);
THYM	trans	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg19862616	chr7:65841803	NCRNA00174	1.09	12.64	0.79	4.47e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1129187	0.748	rs9471968	chr6:42905235	A/G	cg21280719	chr6:42927975	GNMT	-0.51	-6.73	-0.57	1.28e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7404928	0.557	rs195991	chr16:23947673	G/A	cg26685404	chr16:23957272	PRKCB	-0.58	-6.47	-0.55	4.31e-9	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg04234412	chr22:24373322	LOC391322	-0.97	-11.97	-0.78	1.11e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg13736514	chr6:26305472	NA	-0.59	-6.6	-0.56	2.33e-9	Educational attainment;
THYM	cis	rs3540	0.512	rs17263706	chr15:91078803	G/T	cg22089800	chr15:90895588	ZNF774	0.74	5.49	0.49	3.28e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs4604732	0.642	rs6426252	chr1:247639887	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	4.68	0.43	9.46e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	6.13	0.53	2e-8	Schizophrenia;
THYM	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.54	-6.53	-0.56	3.2e-9	Schizophrenia;
THYM	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs72627509	0.857	rs2227901	chr4:57798189	A/G	cg26694713	chr4:57773883	REST	-0.79	-4.98	-0.46	2.83e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg00990874	chr7:1149470	C7orf50	-0.69	-5.17	-0.47	1.29e-6	Bronchopulmonary dysplasia;
THYM	cis	rs7772486	0.686	rs6570705	chr6:145961201	C/T	cg13319975	chr6:146136371	FBXO30	-0.67	-5.46	-0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.54	-5.17	-0.47	1.31e-6	Lymphocyte counts;
THYM	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg02574844	chr11:5959923	NA	-0.54	-4.71	-0.43	8.55e-6	DNA methylation (variation);
THYM	cis	rs17407555	0.697	rs73224468	chr4:10388708	G/A	cg11266682	chr4:10021025	SLC2A9	-0.52	-5.18	-0.47	1.23e-6	Schizophrenia (age at onset);
THYM	cis	rs2289328	0.943	rs3803360	chr15:40662669	C/T	cg13931752	chr15:40660718	DISP2	0.65	5.34	0.48	6.31e-7	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
THYM	cis	rs4148689	0.951	rs34683806	chr7:117165147	A/G	cg17204129	chr7:117119601	CFTR	-0.62	-4.79	-0.44	6.23e-6	Gout;
THYM	cis	rs7107174	1.000	rs10899469	chr11:78018313	T/C	cg02023728	chr11:77925099	USP35	0.67	5.86	0.52	6.61e-8	Testicular germ cell tumor;
THYM	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg26314531	chr2:26401878	FAM59B	0.78	5.13	0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs7715811	1.000	rs9688222	chr5:13760906	C/A	cg07548982	chr5:13769939	DNAH5	-0.5	-4.46	-0.42	2.25e-5	Subclinical atherosclerosis traits (other);
THYM	cis	rs56309584	0.673	rs11078735	chr17:8116861	C/A	cg08322244	chr17:8066669	VAMP2	-0.53	-5.05	-0.46	2.17e-6	Initial pursuit acceleration;
THYM	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg02070205	chr10:30722105	MAP3K8	-0.54	-4.53	-0.42	1.71e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg16579431	chr16:433439	TMEM8A;LOC100134368	0.65	5.37	0.48	5.6e-7	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs2806561	0.704	rs6426779	chr1:23310485	T/C	cg19743168	chr1:23544995	NA	-0.58	-5.46	-0.49	3.81e-7	Height;
THYM	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg03676636	chr4:99064102	C4orf37	0.43	6.32	0.54	8.55e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg07460842	chr6:66804631	NA	0.97	6.01	0.52	3.49e-8	Exhaled nitric oxide levels;
THYM	cis	rs6448317	0.954	rs7666033	chr4:24925272	A/G	cg22968281	chr4:24586266	DHX15	0.66	4.53	0.42	1.69e-5	Heschl's gyrus morphology;
THYM	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg03684893	chr10:554711	DIP2C	-0.7	-6.26	-0.54	1.09e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs10752881	1.000	rs10797813	chr1:182989366	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Colorectal cancer;
THYM	cis	rs9462846	1.000	rs1150797	chr6:42841231	G/A	cg10862848	chr6:42927986	GNMT	-0.45	-4.68	-0.43	9.33e-6	Blood protein levels;
THYM	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg10360139	chr7:1886902	MAD1L1	-0.57	-4.53	-0.42	1.69e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs2303759	0.543	rs7255778	chr19:49906608	G/A	cg24324837	chr19:49891574	CCDC155	0.52	5.26	0.47	8.98e-7	Multiple sclerosis;
THYM	cis	rs6592284	0.577	rs7944482	chr11:86091532	C/T	cg23817893	chr11:86085932	CCDC81	-0.45	-4.48	-0.42	2.06e-5	Cognitive performance;
THYM	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg02825527	chr7:2087843	MAD1L1	-0.77	-5.17	-0.47	1.29e-6	Bipolar disorder;
THYM	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg11871910	chr12:69753446	YEATS4	-1.01	-9.83	-0.71	3.8e-16	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg08017756	chr2:100939284	LONRF2	-0.74	-7.77	-0.62	9.06e-12	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.714	rs6104065	chr20:43848079	C/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.64	-7.37	-0.6	6.28e-11	Blood protein levels;
THYM	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg04282206	chr17:62833786	PLEKHM1P	-0.83	-8.06	-0.64	2.23e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg10792982	chr14:105748885	BRF1	0.7	7.03	0.59	3.1e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg17911788	chr17:44343683	NA	-0.6	-6.01	-0.52	3.4e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.35	0.55	7.35e-9	Tonsillectomy;
THYM	cis	rs4664308	1.000	rs6707458	chr2:160914540	G/T	cg03641300	chr2:160917029	PLA2R1	-0.76	-6.89	-0.58	6.12e-10	Idiopathic membranous nephropathy;
THYM	cis	rs9378357	0.850	rs9391986	chr6:3290583	A/G	cg11647493	chr6:4134485	PECI	0.71	4.95	0.45	3.27e-6	Obesity-related traits;
THYM	cis	rs3755605	0.833	rs7635670	chr3:169778625	A/G	cg18444028	chr3:169782040	GPR160	0.59	4.94	0.45	3.4e-6	Testicular germ cell tumor;
THYM	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6121246	0.559	rs6087779	chr20:30370566	T/C	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs6840360	0.615	rs62329085	chr4:152470237	G/A	cg17479576	chr4:152424074	FAM160A1	-0.85	-6.4	-0.55	5.9e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg12042659	chr19:58951599	ZNF132	0.65	5.03	0.46	2.34e-6	Mean platelet volume;
THYM	cis	rs1483890	0.723	rs12631128	chr3:69411416	G/T	cg22125112	chr3:69402811	FRMD4B	0.54	6.85	0.58	7.21e-10	Resting heart rate;
THYM	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg06028605	chr16:24865363	SLC5A11	0.6	4.67	0.43	9.94e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6543140	0.601	rs7558013	chr2:102992806	G/T	cg09003973	chr2:102972529	NA	0.69	4.57	0.42	1.46e-5	Blood protein levels;
THYM	cis	rs6750795	0.569	rs1667305	chr2:232403829	A/G	cg19187155	chr2:232395269	NMUR1	0.9	9.04	0.68	1.87e-14	Height;
THYM	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg06009448	chr7:1102226	C7orf50	0.53	5.55	0.49	2.6e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs36051895	0.623	rs10283467	chr9:5244356	C/G	cg02405213	chr9:5042618	JAK2	0.9	9.23	0.69	7.33e-15	Pediatric autoimmune diseases;
THYM	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11890956	chr21:40555474	PSMG1	-0.67	-6.25	-0.54	1.17e-8	Menarche (age at onset);
THYM	cis	rs4988958	0.527	rs6756161	chr2:103048417	C/A	cg03938978	chr2:103052716	IL18RAP	0.75	9.8	0.71	4.43e-16	Asthma (childhood onset);
THYM	cis	rs296381	0.866	rs2547231	chr19:48385057	A/C	cg23328124	chr19:47421913	GRLF1	0.92	4.48	0.42	2.07e-5	Blood metabolite levels;
THYM	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg15242686	chr22:24348715	GSTTP1	0.55	4.9	0.45	4e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11048434	0.761	rs12828902	chr12:9132231	C/T	cg04155231	chr12:9217510	LOC144571	0.49	4.69	0.43	9.28e-6	Sjögren's syndrome;
THYM	cis	rs11190604	0.943	rs3750631	chr10:102279294	A/G	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg03684893	chr10:554711	DIP2C	-0.7	-6.21	-0.54	1.37e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg18132916	chr6:79620363	NA	-0.6	-5.35	-0.48	6.07e-7	Intelligence (multi-trait analysis);
THYM	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg03929089	chr4:120376271	NA	-0.93	-9.43	-0.7	2.8e-15	Coronary artery disease;
THYM	cis	rs2916260	0.866	rs56382632	chr6:40380071	A/G	cg08415973	chr6:40346114	TDRG1	0.75	4.56	0.42	1.55e-5	Incident coronary heart disease;
THYM	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.29e-7	Corneal astigmatism;
THYM	cis	rs2286885	1.000	rs10733678	chr9:129242280	G/A	cg14319473	chr9:129242481	FAM125B	0.66	5.01	0.46	2.52e-6	Intraocular pressure;
THYM	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg26418147	chr1:205743515	RAB7L1	-0.55	-4.74	-0.44	7.4e-6	Menarche (age at onset);
THYM	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg13918804	chr1:2043761	PRKCZ	-0.61	-4.62	-0.43	1.19e-5	Height;
THYM	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg18105134	chr13:113819100	PROZ	-0.98	-9.0	-0.68	2.28e-14	Platelet distribution width;
THYM	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg10117171	chr1:25599238	RHD	-0.8	-5.96	-0.52	4.29e-8	Erythrocyte sedimentation rate;
THYM	cis	rs6138458	1.000	rs227627	chr20:24912107	T/C	cg26195577	chr20:24973756	C20orf3	1.11	10.52	0.73	1.29e-17	Blood protein levels;
THYM	cis	rs6723226	0.750	rs1033751	chr2:32695759	T/C	cg02381751	chr2:32503542	YIPF4	0.59	4.56	0.42	1.54e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2334880	0.638	rs17343777	chr16:71439172	T/A	cg06353428	chr16:71660113	MARVELD3	-0.99	-5.42	-0.49	4.52e-7	Malaria;
THYM	cis	rs7799265	1.000	rs7799265	chr7:28432476	C/G	cg11093548	chr7:28450001	CREB5	-0.94	-5.25	-0.47	9.16e-7	Airflow obstruction;
THYM	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg15693483	chr7:1102177	C7orf50	0.41	5.93	0.52	4.81e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2235649	0.843	rs9932890	chr16:1847868	G/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.44	4.78	0.44	6.27e-6	Blood metabolite levels;
THYM	cis	rs9470366	0.509	rs4714001	chr6:36638175	G/A	cg11920449	chr6:36645608	CDKN1A	0.69	5.81	0.51	8.25e-8	QRS duration;
THYM	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg03209412	chr4:183728196	NA	0.66	5.98	0.52	3.88e-8	Pediatric autoimmune diseases;
THYM	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg02773041	chr1:40204384	PPIE	-0.77	-5.99	-0.52	3.8e-8	Blood protein levels;
THYM	cis	rs7567389	0.677	rs6757492	chr2:127995332	G/A	cg06038358	chr2:128176007	PROC	-0.5	-5.12	-0.47	1.59e-6	Self-rated health;
THYM	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg04654363	chr8:8581213	NA	-0.48	-4.52	-0.42	1.77e-5	Obesity-related traits;
THYM	trans	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg10856724	chr12:34555212	NA	-0.88	-7.53	-0.61	2.92e-11	Bladder cancer;
THYM	cis	rs2213920	0.516	rs71505548	chr9:118169753	G/A	cg13918206	chr9:118159781	DEC1	-1.03	-6.0	-0.52	3.51e-8	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg11327659	chr7:150037044	RARRES2	0.37	4.69	0.43	9.28e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg19761014	chr17:28927070	LRRC37B2	0.81	4.73	0.44	7.95e-6	Body mass index;
THYM	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg01699819	chr7:1052092	C7orf50	0.85	7.65	0.62	1.63e-11	Bronchopulmonary dysplasia;
THYM	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg25358565	chr5:93447407	FAM172A	1.34	10.59	0.74	9.3e-18	Diabetic retinopathy;
THYM	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg22907277	chr7:1156413	C7orf50	0.82	5.05	0.46	2.09e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6686842	1.000	rs213734	chr1:41575699	C/T	cg03387723	chr1:41708464	SCMH1	0.44	5.22	0.47	1.04e-6	Height;
THYM	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg05481257	chr2:20870211	GDF7	-0.73	-6.19	-0.54	1.52e-8	Abdominal aortic aneurysm;
THYM	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.85	7.62	0.62	1.88e-11	Cognitive ability;
THYM	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg22709100	chr7:91322751	NA	-0.61	-4.85	-0.45	4.9e-6	Breast cancer;
THYM	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	trans	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg10856724	chr12:34555212	NA	-1.0	-8.86	-0.67	4.42e-14	Bladder cancer;
THYM	cis	rs2456568	0.803	rs10765641	chr11:93640312	T/C	cg17347335	chr11:93583973	C11orf90	-0.48	-4.63	-0.43	1.18e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs11997175	0.603	rs12234894	chr8:33699275	G/C	ch.8.33884649F	chr8:33765107	NA	0.66	4.99	0.46	2.67e-6	Body mass index;
THYM	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg08772003	chr10:104629869	AS3MT	-0.6	-5.54	-0.49	2.68e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg05887092	chr17:76393375	PGS1	0.39	4.49	0.42	1.99e-5	HDL cholesterol levels;
THYM	cis	rs16866061	1.000	rs72974269	chr2:225454907	C/T	cg22455342	chr2:225449267	CUL3	0.68	4.9	0.45	3.87e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs7084402	1.000	rs7917717	chr10:60269100	C/A	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs2456568	0.867	rs1395384	chr11:93663250	C/T	cg26875233	chr11:93583750	C11orf90	0.49	4.84	0.44	5.09e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg00376283	chr12:123451042	ABCB9	0.72	4.74	0.44	7.46e-6	Neutrophil percentage of white cells;
THYM	cis	rs4595586	0.545	rs12823586	chr12:39391677	C/G	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg18252515	chr7:66147081	NA	-1.57	-8.55	-0.66	2.07e-13	Diabetic kidney disease;
THYM	cis	rs654950	0.901	rs607586	chr1:42004379	C/T	cg06885757	chr1:42089581	HIVEP3	-0.59	-7.86	-0.63	5.82e-12	Airway imaging phenotypes;
THYM	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06481639	chr22:41940642	POLR3H	0.85	5.83	0.51	7.73e-8	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs4866334	1.000	rs80012640	chr5:18455247	C/T	cg18608440	chr5:17519013	NA	1.16	5.19	0.47	1.17e-6	IgG glycosylation;
THYM	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg23730037	chr7:158596552	ESYT2	-0.51	-5.09	-0.46	1.8e-6	Height;
THYM	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg09033563	chr22:24373618	LOC391322	-0.6	-5.37	-0.48	5.52e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6882076	1.000	rs9715911	chr5:156394441	G/A	cg12943317	chr5:156479607	HAVCR1	-0.72	-5.96	-0.52	4.36e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs2404602	0.647	rs34103231	chr15:76912690	A/G	cg23625390	chr15:77176239	SCAPER	-0.93	-6.31	-0.54	8.9e-9	Blood metabolite levels;
THYM	cis	rs7598759	0.548	rs1584462	chr2:232369798	A/G	cg19187155	chr2:232395269	NMUR1	0.84	7.65	0.62	1.62e-11	Noise-induced hearing loss;
THYM	cis	rs420259	0.516	rs2072061	chr16:23541223	G/A	cg00143387	chr16:23521605	GGA2	-0.72	-5.18	-0.47	1.26e-6	Bipolar disorder;
THYM	cis	rs892961	0.932	rs9916143	chr17:75409282	C/G	cg05865280	chr17:75406074	SEPT9	-0.48	-8.14	-0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg24503407	chr1:205819492	PM20D1	1.06	11.24	0.76	3.79e-19	Menarche (age at onset);
THYM	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg06108461	chr20:60628389	TAF4	-0.79	-6.2	-0.54	1.46e-8	Body mass index;
THYM	cis	rs4595586	0.545	rs6580895	chr12:39372011	C/T	cg13010199	chr12:38710504	ALG10B	-0.61	-4.68	-0.43	9.49e-6	Morning vs. evening chronotype;
THYM	cis	rs7567389	0.677	rs10496661	chr2:128090144	G/T	cg06038358	chr2:128176007	PROC	0.43	4.53	0.42	1.7e-5	Self-rated health;
THYM	cis	rs11651000	0.761	rs11079788	chr17:45820723	C/T	cg06532163	chr17:45867833	NA	0.58	5.76	0.51	1.03e-7	IgG glycosylation;
THYM	cis	rs9988450	1	rs9988450	chr1:62924448	C/T	cg06896770	chr1:63153194	DOCK7	0.93	7.76	0.62	9.83e-12	Triglycerides;
THYM	cis	rs665401	0.965	rs339326	chr6:117206395	G/A	cg20376953	chr6:117187980	NA	0.6	4.82	0.44	5.5e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg25817165	chr18:72167213	CNDP2	-0.98	-7.7	-0.62	1.31e-11	Refractive error;
THYM	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg12893697	chr11:970389	AP2A2	-0.32	-5.35	-0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	4.69	0.43	9e-6	Menarche (age at onset);
THYM	cis	rs600806	0.850	rs10745355	chr1:109951711	T/C	cg23616212	chr1:109941201	SORT1	-0.49	-4.66	-0.43	1.01e-5	Intelligence (multi-trait analysis);
THYM	cis	rs863345	0.526	rs2051666	chr1:158507160	T/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs56079296	0.929	rs10045728	chr5:121277101	A/G	cg01191064	chr5:121408893	LOX	-0.66	-4.53	-0.42	1.73e-5	Coronary artery disease;
THYM	cis	rs17209837	0.646	rs11532733	chr7:87117982	A/G	cg04996195	chr7:87105398	ABCB4	0.64	4.68	0.43	9.48e-6	Gallbladder cancer;
THYM	cis	rs919433	0.929	rs10931779	chr2:198166825	A/G	cg00792783	chr2:198669748	PLCL1	-0.66	-4.77	-0.44	6.65e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg01616529	chr11:638424	DRD4	-0.76	-5.38	-0.48	5.42e-7	Systemic lupus erythematosus;
THYM	cis	rs6430585	0.528	rs75524146	chr2:136725459	C/T	cg23851026	chr2:136556271	LCT	0.78	6.95	0.58	4.47e-10	Corneal structure;
THYM	cis	rs1469039	1.000	rs1469039	chr8:140651779	G/A	cg17290943	chr8:141107717	TRAPPC9	0.63	4.59	0.43	1.35e-5	Menarche (age at onset);
THYM	cis	rs10911232	0.507	rs4129857	chr1:183004547	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs7719624	0.811	rs13159365	chr5:135389433	C/T	cg15329133	chr5:135467951	SMAD5;SMAD5OS	-0.58	-5.17	-0.47	1.3e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg10515332	chr4:99064459	C4orf37	0.67	5.33	0.48	6.48e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	6.3	0.54	9.15e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg26314531	chr2:26401878	FAM59B	0.74	4.81	0.44	5.7e-6	Gut microbiome composition (summer);
THYM	cis	rs6495367	0.966	rs745029	chr15:79381779	C/T	cg17916960	chr15:79447300	NA	0.62	6.86	0.58	6.99e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7131987	0.903	rs11050161	chr12:29420049	A/G	cg09582351	chr12:29534625	ERGIC2	-0.48	-4.54	-0.42	1.66e-5	QT interval;
THYM	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg10018233	chr7:150070692	REPIN1	0.37	5.34	0.48	6.26e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11711311	0.822	rs9850256	chr3:113408382	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.61	-5.11	-0.46	1.65e-6	IgG glycosylation;
THYM	trans	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg26043149	chr18:55253948	FECH	1.16	10.82	0.74	2.98e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs11992162	0.569	rs11786149	chr8:11800818	G/A	cg21775007	chr8:11205619	TDH	-0.59	-4.57	-0.42	1.46e-5	Monocyte count;
THYM	trans	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg10856724	chr12:34555212	NA	-1.0	-8.86	-0.67	4.42e-14	Bladder cancer;
THYM	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg08999081	chr20:33150536	PIGU	0.55	4.63	0.43	1.16e-5	Coronary artery disease;
THYM	cis	rs7617773	0.780	rs4541431	chr3:48365218	G/C	cg02219026	chr3:48282209	ZNF589	-0.67	-4.69	-0.43	9.05e-6	Coronary artery disease;
THYM	cis	rs1823778	0.609	rs11151559	chr18:67705420	A/G	cg12929678	chr18:67624393	CD226	1.28	4.87	0.45	4.4e-6	Mean platelet volume;
THYM	cis	rs4731207	0.565	rs2402760	chr7:124595920	C/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs12643440	0.538	rs6834807	chr4:17138244	T/C	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg10803722	chr21:46713166	LOC642852	-0.41	-5.33	-0.48	6.47e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9364687	0.689	rs9364689	chr6:163929340	A/C	cg01639524	chr6:163818125	NA	0.49	4.86	0.45	4.57e-6	Body mass index;
THYM	cis	rs425277	0.606	rs262653	chr1:2090095	T/G	cg24578937	chr1:2090814	PRKCZ	0.55	5.35	0.48	6.12e-7	Height;
THYM	cis	rs4845459	0.967	rs6677595	chr1:152590187	C/T	cg26135325	chr1:152595322	LCE3A	-0.45	-5.21	-0.47	1.09e-6	Psoriasis;
THYM	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg23758822	chr17:41437982	NA	-1.22	-13.08	-0.8	5.68e-23	Menopause (age at onset);
THYM	cis	rs2404602	0.735	rs11638767	chr15:76655938	T/C	cg23482746	chr15:76478102	C15orf27	0.45	4.57	0.42	1.44e-5	Blood metabolite levels;
THYM	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg01483505	chr11:975446	AP2A2	0.58	4.73	0.44	7.82e-6	Alzheimer's disease (late onset);
THYM	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg25427524	chr10:38739819	LOC399744	-0.64	-5.87	-0.52	6.38e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg00495681	chr13:53174319	NA	0.73	6.85	0.57	7.36e-10	Lewy body disease;
THYM	cis	rs7941600	0.581	rs7103596	chr11:9338052	T/C	cg21110646	chr11:9336536	TMEM41B	1.28	7.69	0.62	1.36e-11	Coronary artery disease;
THYM	cis	rs4242434	0.927	rs11136092	chr8:22466488	T/G	cg01710189	chr8:22454888	PDLIM2	-0.55	-5.16	-0.47	1.34e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg02887458	chr19:19495540	GATAD2A	-0.44	-5.19	-0.47	1.17e-6	Bipolar disorder;
THYM	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg24503407	chr1:205819492	PM20D1	0.71	6.35	0.55	7.33e-9	Menarche (age at onset);
THYM	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg15556689	chr8:8085844	FLJ10661	-0.62	-5.09	-0.46	1.83e-6	Mood instability;
THYM	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg07493874	chr5:1342172	CLPTM1L	-0.86	-8.53	-0.66	2.23e-13	Lung cancer;
THYM	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg12311346	chr5:56204834	C5orf35	-0.81	-5.9	-0.52	5.54e-8	Initial pursuit acceleration;
THYM	cis	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg25834613	chr7:1915315	MAD1L1	-0.5	-4.52	-0.42	1.81e-5	Bipolar disorder;
THYM	cis	rs2281845	0.859	rs58364051	chr1:201077667	A/G	cg17810781	chr1:201082982	CACNA1S	0.64	6.86	0.58	6.97e-10	Permanent tooth development;
THYM	cis	rs34912216	0.636	rs34163017	chr7:4119883	C/T	cg03141780	chr7:4150753	SDK1	0.71	5.09	0.46	1.78e-6	Motion sickness;
THYM	cis	rs6430585	0.583	rs7581814	chr2:136641593	C/G	cg23851026	chr2:136556271	LCT	-0.8	-7.65	-0.62	1.64e-11	Corneal structure;
THYM	cis	rs6840360	0.571	rs4696098	chr4:152489053	C/T	cg17479576	chr4:152424074	FAM160A1	-0.82	-5.82	-0.51	7.78e-8	Intelligence (multi-trait analysis);
THYM	cis	rs539096	1.000	rs539096	chr1:44072420	C/T	cg00143623	chr1:44495758	SLC6A9	-0.65	-5.12	-0.47	1.58e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.89	-8.78	-0.67	6.71e-14	Lung cancer;
THYM	cis	rs11250464	0.755	rs11250468	chr10:1410060	A/G	cg08668359	chr10:1443807	ADARB2	0.64	5.67	0.5	1.55e-7	Radiation response;
THYM	cis	rs4808199	0.842	rs11085259	chr19:19445856	C/T	cg03709012	chr19:19516395	GATAD2A	1.1	6.32	0.54	8.6e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs12282928	0.918	rs1503174	chr11:48246336	A/G	cg22827986	chr11:48284249	OR4X1	-0.51	-5.43	-0.49	4.28e-7	Migraine - clinic-based;
THYM	cis	rs2806561	1.000	rs2776822	chr1:23492782	A/G	cg12483005	chr1:23474871	LUZP1	-0.59	-6.05	-0.53	2.8e-8	Height;
THYM	cis	rs7127900	0.904	rs11043132	chr11:2232624	T/C	cg25635251	chr11:2234043	NA	0.74	4.71	0.44	8.43e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg24874828	chr4:187887005	NA	-0.72	-7.11	-0.59	2.16e-10	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-14.07	-0.82	5.85e-25	Height;
THYM	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg13390004	chr1:15929781	NA	0.61	4.73	0.44	7.79e-6	Systolic blood pressure;
THYM	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg12165864	chr7:66369176	NA	-0.67	-5.26	-0.47	8.99e-7	Aortic root size;
THYM	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg22907277	chr7:1156413	C7orf50	0.86	8.98	0.68	2.55e-14	Longevity;Endometriosis;
THYM	cis	rs34779708	0.897	rs12764820	chr10:35386321	G/A	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg22875332	chr1:76189707	ACADM	-0.53	-5.02	-0.46	2.42e-6	Daytime sleep phenotypes;
THYM	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg18904891	chr8:8559673	CLDN23	-0.59	-4.96	-0.45	3.04e-6	Joint mobility (Beighton score);
THYM	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg18252515	chr7:66147081	NA	-0.66	-5.19	-0.47	1.18e-6	Aortic root size;
THYM	cis	rs2806561	0.808	rs1413974	chr1:23347125	C/T	cg12483005	chr1:23474871	LUZP1	-0.51	-4.63	-0.43	1.17e-5	Height;
THYM	cis	rs7524258	0.868	rs7538921	chr1:7267007	T/C	cg07173049	chr1:7289937	CAMTA1	0.77	5.84	0.51	7.14e-8	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03517284	chr6:25882590	NA	-0.76	-5.98	-0.52	3.87e-8	Blood metabolite levels;
THYM	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg00631329	chr6:26305371	NA	-0.72	-7.5	-0.61	3.39e-11	Educational attainment;
THYM	cis	rs3008870	1.000	rs2815371	chr1:67504313	A/G	cg02640540	chr1:67518911	SLC35D1	0.65	4.83	0.44	5.32e-6	Lymphocyte percentage of white cells;
THYM	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg21361702	chr7:150065534	REPIN1	0.67	4.93	0.45	3.53e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs72828912	0.731	rs9379634	chr6:24061896	A/G	cg19882886	chr6:25043046	NA	-0.86	-4.47	-0.42	2.14e-5	Squamous cell lung carcinoma;
THYM	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg15704280	chr7:45808275	SEPT13	-0.82	-8.29	-0.65	7.46e-13	Height;
THYM	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg16928487	chr17:17741425	SREBF1	-0.55	-5.47	-0.49	3.62e-7	Total body bone mineral density;
THYM	cis	rs62070183	0.882	rs17780981	chr17:31119037	A/G	cg02981443	chr17:31254875	TMEM98	-0.54	-4.87	-0.45	4.46e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs921968	0.541	rs933994	chr2:219650616	C/T	cg02176678	chr2:219576539	TTLL4	-0.46	-4.52	-0.42	1.8e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg06026331	chr20:60912101	LAMA5	-0.58	-4.57	-0.42	1.45e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs11771526	1.000	rs117890465	chr7:32351009	A/C	cg13207630	chr7:32358064	NA	0.87	5.19	0.47	1.21e-6	Body mass index;
THYM	cis	rs11223731	0.615	rs10894791	chr11:134142033	A/G	cg18040241	chr11:134201582	GLB1L2	-0.77	-4.75	-0.44	7.29e-6	Verbal declarative memory;
THYM	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg15242686	chr22:24348715	GSTTP1	0.67	7.21	0.59	1.33e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.27	9.78	0.71	4.84e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10463554	0.853	rs458598	chr5:102569378	C/G	cg23492399	chr5:102201601	PAM	-0.67	-5.04	-0.46	2.2e-6	Parkinson's disease;
THYM	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg15448220	chr1:150897856	SETDB1	-0.87	-7.15	-0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs7851660	0.967	rs10818133	chr9:100610348	C/G	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs2663905	0.611	rs1509558	chr15:81391244	C/T	cg09888468	chr15:81410853	NA	-0.75	-6.65	-0.56	1.83e-9	QT interval (drug interaction);
THYM	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03264133	chr6:25882463	NA	-0.85	-7.04	-0.59	3e-10	Intelligence (multi-trait analysis);
THYM	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	6.38	0.55	6.45e-9	Smoking behavior;
THYM	cis	rs337100	0.540	rs337086	chr5:122555501	C/T	cg04547002	chr5:122551801	NA	0.61	4.82	0.44	5.37e-6	Pulse pressure;
THYM	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg21926883	chr2:100939477	LONRF2	-0.67	-6.3	-0.54	9.28e-9	Intelligence (multi-trait analysis);
THYM	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg19052272	chr2:3704530	ALLC	0.72	5.26	0.48	8.76e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11166927	0.524	rs2035088	chr8:140831403	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.85	-7.97	-0.63	3.52e-12	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs2692947	0.770	rs6719831	chr2:96502590	A/C	cg23100626	chr2:96804247	ASTL	0.35	4.57	0.42	1.49e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs1450985	0.931	rs6785145	chr3:64019206	A/G	cg06859735	chr3:64012970	NA	-0.41	-4.5	-0.42	1.9e-5	Breast cancer;
THYM	cis	rs6748734	0.895	rs4417704	chr2:241846573	A/G	cg07537917	chr2:241836409	C2orf54	-0.27	-4.98	-0.45	2.88e-6	Urinary metabolites;
THYM	cis	rs2637266	1.000	rs2395386	chr10:78341623	C/T	cg18941641	chr10:78392320	NA	0.72	6.33	0.54	8.03e-9	Pulmonary function;
THYM	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg00495681	chr13:53174319	NA	0.84	8.67	0.66	1.17e-13	Lewy body disease;
THYM	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg16586182	chr3:47516702	SCAP	-0.66	-5.46	-0.49	3.76e-7	Colorectal cancer;
THYM	cis	rs12780046	0.656	rs10786510	chr10:100899295	C/T	cg03201262	chr10:101835788	CPN1	0.48	4.47	0.42	2.17e-5	Non-glioblastoma glioma;
THYM	cis	rs735539	0.521	rs2818994	chr13:21418410	G/A	cg02792322	chr13:21280448	IL17D	-0.66	-4.78	-0.44	6.37e-6	Dental caries;
THYM	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg21226059	chr5:178986404	RUFY1	-0.61	-6.92	-0.58	5.36e-10	Lung cancer;
THYM	cis	rs6032067	0.777	rs62208386	chr20:43790872	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs1975974	0.935	rs67979358	chr17:21723834	G/C	cg18423549	chr17:21743878	NA	-0.57	-4.46	-0.42	2.28e-5	Psoriasis;
THYM	cis	rs7084402	0.902	rs1649016	chr10:60288540	T/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.7e-7	Refractive error;
THYM	cis	rs778371	0.723	rs737027	chr2:233641083	G/C	cg08000102	chr2:233561755	GIGYF2	0.83	7.46	0.61	4.14e-11	Schizophrenia;
THYM	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs6570726	0.935	rs408723	chr6:145838535	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7771547	0.508	rs1570368	chr6:36437136	C/G	cg07856975	chr6:36356162	ETV7	0.61	6.12	0.53	2.04e-8	Platelet distribution width;
THYM	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg09436375	chr6:42928200	GNMT	-0.45	-5.89	-0.52	5.93e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.56	-4.54	-0.42	1.66e-5	Hip circumference adjusted for BMI;
THYM	cis	rs863345	0.604	rs12059669	chr1:158501480	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs600806	0.850	rs3768493	chr1:109935505	C/T	cg02175308	chr1:109941060	SORT1	-0.6	-5.3	-0.48	7.58e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9658691	0.607	rs12412701	chr10:90782323	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.87	-5.85	-0.51	7.05e-8	Mosquito bite size;
THYM	cis	rs28595532	0.920	rs116401323	chr4:119721727	C/T	cg21605333	chr4:119757512	SEC24D	1.61	6.33	0.54	8.03e-9	Cannabis dependence symptom count;
THYM	cis	rs12310956	0.532	rs1352209	chr12:33983408	G/A	cg10856724	chr12:34555212	NA	-0.75	-6.8	-0.57	9.1e-10	Morning vs. evening chronotype;
THYM	cis	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg25427524	chr10:38739819	LOC399744	-0.72	-6.09	-0.53	2.4e-8	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.88	-0.58	6.43e-10	Eye color traits;
THYM	cis	rs7169223	0.653	rs3971703	chr15:79092481	G/C	cg21242079	chr15:79101063	ADAMTS7	0.6	5.55	0.5	2.53e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg00376283	chr12:123451042	ABCB9	0.68	5.22	0.47	1.04e-6	Neutrophil percentage of white cells;
THYM	cis	rs1065852	0.526	rs7290907	chr22:42390209	G/A	cg22189786	chr22:42395067	WBP2NL	0.54	5.55	0.49	2.6e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs2073300	0.609	rs6137920	chr20:23363436	C/T	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg22105103	chr4:187893119	NA	0.88	9.57	0.7	1.35e-15	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg25214090	chr10:38739885	LOC399744	-0.96	-8.24	-0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg04546413	chr19:29218101	NA	1.09	9.4	0.69	3.15e-15	Methadone dose in opioid dependence;
THYM	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg19862616	chr7:65841803	NCRNA00174	1.13	13.2	0.8	3.22e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4363385	0.747	rs946100	chr1:152971663	C/T	cg13444842	chr1:152974279	SPRR3	0.6	4.79	0.44	6.16e-6	Inflammatory skin disease;
THYM	cis	rs6748734	0.581	rs4234092	chr2:241866389	T/C	cg15164180	chr2:241846931	NA	-0.41	-4.93	-0.45	3.44e-6	Urinary metabolites;
THYM	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg08807101	chr21:30365312	RNF160	-0.93	-7.5	-0.61	3.42e-11	Dental caries;
THYM	cis	rs3857067	0.806	rs6858342	chr4:95112318	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs1335645	0.570	rs61804624	chr1:111653917	A/G	cg00321911	chr1:111669324	DRAM2	-1.14	-6.19	-0.54	1.49e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs72772090	0.539	rs11740375	chr5:96112897	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.9	-5.09	-0.46	1.83e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs854765	0.583	rs12452254	chr17:17829434	G/A	cg04398451	chr17:18023971	MYO15A	-0.8	-7.33	-0.6	7.5e-11	Total body bone mineral density;
THYM	cis	rs8077889	0.672	rs2106764	chr17:41852717	T/A	cg26893861	chr17:41843967	DUSP3	1.14	12.69	0.79	3.55e-22	Triglycerides;
THYM	cis	rs7705502	0.926	rs72812804	chr5:173340496	T/G	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg16680214	chr1:154839983	KCNN3	-0.45	-5.03	-0.46	2.32e-6	Prostate cancer;
THYM	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg17971929	chr21:40555470	PSMG1	0.72	4.61	0.43	1.24e-5	Cognitive function;
THYM	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs2219968	1.000	rs6473086	chr8:78974646	T/C	cg00738934	chr8:78996279	NA	0.88	9.31	0.69	5.05e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs823143	0.549	rs1094647	chr1:205655378	G/A	cg14159672	chr1:205819179	PM20D1	0.88	8.22	0.64	1.02e-12	Monocyte percentage of white cells;
THYM	cis	rs651907	0.640	rs771575	chr3:101619359	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	6.21	0.54	1.41e-8	Colorectal cancer;
THYM	cis	rs9796	0.689	rs576336	chr15:41452771	C/T	cg21153102	chr15:41252147	NA	0.6	4.92	0.45	3.66e-6	Menopause (age at onset);
THYM	cis	rs2976388	0.669	rs2585135	chr8:143814193	A/G	cg13446199	chr8:143762866	PSCA	0.41	4.52	0.42	1.77e-5	Urinary tract infection frequency;
THYM	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.07	-10.46	-0.73	1.72e-17	Primary sclerosing cholangitis;
THYM	cis	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg13609457	chr4:120235615	NA	-0.55	-5.18	-0.47	1.25e-6	Corneal astigmatism;
THYM	cis	rs6032067	0.777	rs13044826	chr20:43801865	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.75	-6.76	-0.57	1.09e-9	Blood protein levels;
THYM	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.22e-16	Bone mineral density;
THYM	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.84	-6.63	-0.56	2.06e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6032067	1.000	rs6017509	chr20:43830362	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.7	-6.47	-0.55	4.24e-9	Blood protein levels;
THYM	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg00757033	chr12:89920650	WDR51B	0.74	11.52	0.76	9.94e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg10047753	chr17:41438598	NA	1.06	9.08	0.68	1.5e-14	Menopause (age at onset);
THYM	cis	rs2070488	0.965	rs35091896	chr3:38443320	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	6.65	0.56	1.89e-9	Electrocardiographic conduction measures;
THYM	cis	rs3771570	1.000	rs62186422	chr2:242249499	A/G	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs477692	0.569	rs10764884	chr10:131308370	G/C	cg05714579	chr10:131428358	MGMT	0.59	4.8	0.44	5.91e-6	Response to temozolomide;
THYM	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.02	9.6	0.7	1.18e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg17105886	chr17:28927953	LRRC37B2	-1.32	-6.7	-0.57	1.5e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.84	0.44	5.01e-6	Breast cancer;
THYM	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg15556689	chr8:8085844	FLJ10661	0.6	4.61	0.43	1.25e-5	Mood instability;
THYM	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.06	9.32	0.69	4.59e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs858239	0.699	rs858260	chr7:23212934	G/T	cg09755872	chr7:23245557	NA	-0.51	-4.86	-0.45	4.6e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs977987	0.806	rs12449170	chr16:75463012	C/T	cg03315344	chr16:75512273	CHST6	0.76	6.17	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg03209412	chr4:183728196	NA	0.67	6.03	0.53	3.07e-8	Pediatric autoimmune diseases;
THYM	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg12560992	chr17:57184187	TRIM37	-0.83	-7.39	-0.6	5.71e-11	Intelligence (multi-trait analysis);
THYM	cis	rs192264	0.614	rs254364	chr16:65984076	A/G	cg02795155	chr16:66785218	DYNC1LI2	-0.57	-4.66	-0.43	1.03e-5	Subjective well-being;
THYM	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.43	0.7	2.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.63	-5.21	-0.47	1.09e-6	Homoarginine levels;
THYM	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg14972814	chr11:95582409	MTMR2	-0.64	-5.4	-0.48	4.89e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg08847533	chr14:75593920	NEK9	-1.0	-11.26	-0.76	3.48e-19	Height;
THYM	cis	rs6570726	0.846	rs441575	chr6:145849205	A/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.75	-0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.53	-5.15	-0.47	1.43e-6	Lymphocyte counts;
THYM	cis	rs2857078	0.772	rs4793086	chr17:42320751	C/T	cg13607699	chr17:42295918	UBTF	-0.82	-7.16	-0.59	1.66e-10	Red cell distribution width;Reticulocyte count;
THYM	cis	rs12530845	1.000	rs73721606	chr7:135335678	C/T	cg23117316	chr7:135346802	PL-5283	-0.66	-5.88	-0.52	6.21e-8	Red blood cell traits;
THYM	cis	rs7586879	0.861	rs10164466	chr2:25114069	T/C	cg01884057	chr2:25150051	NA	0.52	4.59	0.43	1.37e-5	Body mass index;
THYM	cis	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg10856724	chr12:34555212	NA	-0.92	-9.27	-0.69	6.02e-15	Morning vs. evening chronotype;
THYM	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.85	-5.32	-0.48	6.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg21028142	chr17:79581711	NPLOC4	0.62	6.4	0.55	5.97e-9	Eye color traits;
THYM	cis	rs61931739	0.635	rs3937819	chr12:33942715	A/G	cg10856724	chr12:34555212	NA	-0.63	-5.9	-0.52	5.54e-8	Morning vs. evening chronotype;
THYM	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg26597838	chr10:835615	NA	0.88	5.11	0.46	1.67e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs8135828	0.739	rs468224	chr22:29955252	A/G	cg16189954	chr22:29138267	HSCB;CHEK2	-0.73	-4.74	-0.44	7.4e-6	Lipid traits;
THYM	cis	rs1018836	0.923	rs7013893	chr8:91563137	G/A	cg16814680	chr8:91681699	NA	-0.75	-6.25	-0.54	1.16e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs2446066	0.872	rs10876447	chr12:53770941	C/T	cg04105511	chr12:54409207	HOXC4;HOXC6;HOXC5	-0.67	-4.49	-0.42	1.97e-5	Red blood cell count;
THYM	cis	rs6500602	1.000	rs6500602	chr16:4497451	T/C	cg08645402	chr16:4508243	NA	0.6	5.11	0.46	1.64e-6	Schizophrenia;
THYM	cis	rs981844	1.000	rs2251994	chr4:154654097	C/T	cg09973105	chr4:154681532	RNF175	-0.59	-4.89	-0.45	4.1e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs13064411	0.696	rs7622740	chr3:113206771	G/A	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg02187348	chr16:89574699	SPG7	0.68	5.02	0.46	2.38e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs6665290	0.901	rs11580229	chr1:227210820	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.12	-14.94	-0.84	1.14e-26	Myeloid white cell count;
THYM	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7584330	0.826	rs7604315	chr2:238381729	C/G	cg14458575	chr2:238380390	NA	1.07	8.76	0.67	7.42e-14	Prostate cancer;
THYM	cis	rs17608059	0.566	rs17676459	chr17:13910515	A/G	cg11395062	chr17:14139857	CDRT15	0.67	5.36	0.48	5.77e-7	Temperament;
THYM	cis	rs67311347	0.568	rs57287242	chr3:40335538	T/C	cg13683864	chr3:40499215	RPL14	-0.79	-7.44	-0.61	4.43e-11	Renal cell carcinoma;
THYM	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8133932	0.813	rs75761084	chr21:47057422	C/A	cg20357416	chr21:47294739	PCBP3	0.8	4.88	0.45	4.33e-6	Schizophrenia;
THYM	cis	rs4389656	0.857	rs274699	chr5:6730332	A/C	cg10857441	chr5:6722123	POLS	-0.44	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs6121246	0.609	rs6060652	chr20:30266845	A/G	cg13852791	chr20:30311386	BCL2L1	0.87	8.51	0.66	2.54e-13	Mean corpuscular hemoglobin;
THYM	cis	rs9467160	0.581	rs2244216	chr6:24466721	C/T	cg00346970	chr6:24499591	ALDH5A1	0.35	4.69	0.43	9.25e-6	Liver enzyme levels;
THYM	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg08847533	chr14:75593920	NEK9	-0.98	-10.57	-0.74	1.01e-17	Height;
THYM	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg00271210	chr6:167070053	RPS6KA2	0.56	5.62	0.5	1.92e-7	Crohn's disease;
THYM	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg27535305	chr1:53392650	SCP2	-0.6	-6.84	-0.57	7.52e-10	Monocyte count;
THYM	cis	rs1003719	0.713	rs7277150	chr21:38490006	T/C	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs2219968	0.962	rs62508224	chr8:78941659	C/T	cg00738934	chr8:78996279	NA	0.79	8.42	0.65	3.88e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs34638657	0.702	rs67612167	chr16:82199598	A/G	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.17	-0.47	1.31e-6	Lung adenocarcinoma;
THYM	cis	rs2806561	0.808	rs4654834	chr1:23364919	T/C	cg19743168	chr1:23544995	NA	-0.6	-5.92	-0.52	5.1e-8	Height;
THYM	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg26384229	chr12:38710491	ALG10B	-0.61	-4.6	-0.43	1.29e-5	Heart rate;
THYM	cis	rs9611519	0.780	rs5751071	chr22:41656332	G/A	cg06481639	chr22:41940642	POLR3H	-0.6	-4.82	-0.44	5.37e-6	Neuroticism;
THYM	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg13114125	chr14:105738426	BRF1	-0.73	-5.67	-0.5	1.52e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg20283391	chr11:68216788	NA	-0.64	-4.58	-0.43	1.41e-5	Total body bone mineral density;
THYM	cis	rs665401	0.965	rs6568967	chr6:117230721	T/A	cg20376953	chr6:117187980	NA	0.63	5.08	0.46	1.87e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs62158800	0.568	rs72826922	chr2:108370643	C/T	cg10013287	chr2:108537568	NA	1.12	5.41	0.49	4.61e-7	Facial morphology (factor 22);
THYM	cis	rs4713118	0.786	rs200503	chr6:27785882	A/G	cg08968635	chr6:28129556	ZNF389	0.61	5.96	0.52	4.34e-8	Parkinson's disease;
THYM	cis	rs8041943	0.643	rs2902950	chr15:79923626	T/G	cg20511832	chr15:78934280	CHRNB4	0.41	4.73	0.44	7.74e-6	Bone mineral density (spine) and age at menarche;
THYM	cis	rs7943203	0.525	rs665293	chr11:108142617	G/A	cg04873221	chr11:107992290	ACAT1	-0.73	-4.95	-0.45	3.15e-6	Red blood cell count;Mean corpuscular volume;
THYM	cis	rs55871839	0.559	rs4737527	chr8:59823491	A/G	cg07426533	chr8:59803705	TOX	0.62	5.09	0.46	1.84e-6	Pneumonia;
THYM	cis	rs1178127	0.765	rs1178133	chr7:18772031	A/G	cg13420273	chr7:18810212	HDAC9	0.63	5.0	0.46	2.65e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs250677	0.522	rs6580590	chr5:148360374	C/T	cg18129178	chr5:148520854	ABLIM3	0.72	5.4	0.48	4.94e-7	Breast cancer;
THYM	cis	rs7104764	0.833	rs12574034	chr11:212262	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	-0.84	-7.73	-0.62	1.11e-11	Menarche (age at onset);
THYM	cis	rs112591243	0.685	rs73379602	chr21:48027317	G/A	cg26697654	chr21:47851941	PCNT	0.77	4.77	0.44	6.75e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs3741151	0.881	rs79623427	chr11:73094896	C/T	cg12959048	chr11:73096162	RELT	-0.54	-5.2	-0.47	1.15e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs13315871	0.932	rs35741271	chr3:58323091	A/G	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs13256369	1.000	rs10095733	chr8:8574646	A/G	cg00074818	chr8:8560427	CLDN23	0.53	4.76	0.44	6.82e-6	Obesity-related traits;
THYM	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs6570726	0.935	rs366308	chr6:145814532	T/A	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	trans	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg10856724	chr12:34555212	NA	0.79	6.9	0.58	5.77e-10	Bladder cancer;
THYM	cis	rs6964587	0.692	rs4729025	chr7:91847504	C/T	cg17063962	chr7:91808500	NA	0.98	8.49	0.66	2.78e-13	Breast cancer;
THYM	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs4788570	0.615	rs2052584	chr16:71688977	A/G	cg06353428	chr16:71660113	MARVELD3	-1.27	-8.49	-0.66	2.74e-13	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.66e-11	Aortic root size;
THYM	cis	rs2072499	0.966	rs2853646	chr1:156189626	C/T	cg25208724	chr1:156163844	SLC25A44	1.15	12.34	0.78	1.91e-21	Testicular germ cell tumor;
THYM	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg22875332	chr1:76189707	ACADM	0.88	11.22	0.75	4.31e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11890956	chr21:40555474	PSMG1	-0.89	-8.99	-0.68	2.36e-14	Cognitive function;
THYM	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg18252515	chr7:66147081	NA	0.65	4.73	0.44	7.72e-6	Aortic root size;
THYM	cis	rs1005224	0.963	rs11626062	chr14:76136329	T/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.72	-5.8	-0.51	8.78e-8	Large artery stroke;
THYM	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg00852783	chr1:26633632	UBXN11	0.86	8.81	0.67	5.74e-14	Obesity-related traits;
THYM	cis	rs2803122	0.745	rs6475325	chr9:19386373	T/C	cg19584733	chr9:19298547	DENND4C	0.61	5.35	0.48	5.99e-7	Pulse pressure;
THYM	cis	rs317689	0.600	rs478188	chr12:69639215	A/G	cg20891283	chr12:69753455	YEATS4	0.62	4.55	0.42	1.59e-5	Response to diuretic therapy;
THYM	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.43	-0.49	4.24e-7	Mean corpuscular volume;
THYM	cis	rs1971762	0.509	rs10783592	chr12:54037430	G/A	cg16917193	chr12:54089295	NA	0.76	7.41	0.6	5.28e-11	Height;
THYM	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg23758822	chr17:41437982	NA	1.2	12.73	0.79	2.99e-22	Menopause (age at onset);
THYM	cis	rs7474896	0.537	rs1208683	chr10:38093723	A/G	cg07661167	chr10:37990439	NA	0.71	4.61	0.43	1.24e-5	Obesity (extreme);
THYM	cis	rs931127	0.719	rs2127507	chr11:65454430	A/G	cg17480646	chr11:65405466	SIPA1	-0.77	-6.7	-0.57	1.44e-9	Systemic lupus erythematosus;
THYM	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg24250549	chr1:154909240	PMVK	0.79	6.71	0.57	1.41e-9	Prostate cancer;
THYM	cis	rs59698941	0.943	rs66746130	chr5:132245615	A/G	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs67460515	0.563	rs1599375	chr3:160897771	C/T	cg03342759	chr3:160939853	NMD3	0.69	5.07	0.46	1.99e-6	Parkinson's disease;
THYM	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg21475434	chr5:93447410	FAM172A	0.71	4.51	0.42	1.83e-5	Diabetic retinopathy;
THYM	cis	rs4589258	1.000	rs7109167	chr11:90453217	G/A	cg26138821	chr11:89956704	CHORDC1	-0.69	-5.55	-0.49	2.57e-7	Intelligence (multi-trait analysis);
THYM	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg12963246	chr6:28129442	ZNF389	0.52	4.59	0.43	1.33e-5	Cardiac Troponin-T levels;
THYM	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg01341218	chr17:43662625	NA	0.87	7.55	0.61	2.7e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4731207	0.596	rs1026836	chr7:124683632	A/G	cg05285228	chr7:124571219	POT1	-0.63	-4.74	-0.44	7.37e-6	Cutaneous malignant melanoma;
THYM	cis	rs34638657	0.702	rs12599988	chr16:82200063	T/C	cg09439754	chr16:82129088	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	cis	rs9831754	1.000	rs9855903	chr3:78347988	C/A	cg06138941	chr3:78371609	NA	-0.66	-4.5	-0.42	1.95e-5	Calcium levels;
THYM	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg21252483	chr19:49399788	TULP2	-0.96	-7.25	-0.6	1.09e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs66731853	0.769	rs476582	chr1:20894450	A/G	cg04087271	chr1:20915334	CDA	-0.69	-5.65	-0.5	1.69e-7	Mean corpuscular volume;
THYM	cis	rs7107174	1.000	rs1567890	chr11:78101700	T/C	cg19901956	chr11:77921274	USP35	-0.69	-5.7	-0.5	1.35e-7	Testicular germ cell tumor;
THYM	cis	rs6987853	0.761	rs2923391	chr8:42415942	G/A	cg09913449	chr8:42400586	C8orf40	1.09	12.37	0.79	1.63e-21	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.7	6.53	0.56	3.28e-9	Total body bone mineral density;
THYM	cis	rs478304	1.000	rs478304	chr11:65494260	G/T	cg17480646	chr11:65405466	SIPA1	0.7	5.96	0.52	4.35e-8	Acne (severe);
THYM	cis	rs8070740	1.000	rs4790772	chr17:5330959	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.67	5.26	0.47	8.92e-7	Menopause (age at onset);
THYM	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg10360139	chr7:1886902	MAD1L1	-0.63	-5.67	-0.5	1.53e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs8067545	0.750	rs36077949	chr17:19985782	C/T	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.64e-6	Schizophrenia;
THYM	cis	rs7618501	0.699	rs9862795	chr3:49915506	A/T	cg14019146	chr3:50243930	SLC38A3	-0.51	-4.47	-0.42	2.17e-5	Intelligence (multi-trait analysis);
THYM	cis	rs17789174	0.953	rs11149708	chr16:85104919	T/G	cg01715842	chr16:85045600	ZDHHC7	-0.46	-4.96	-0.45	3.08e-6	Dysphagia;
THYM	cis	rs1003719	0.680	rs2835621	chr21:38510616	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-4.75	-0.44	7.3e-6	Eye color traits;
THYM	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg12386194	chr3:101231763	SENP7	0.93	6.98	0.58	3.93e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg06713675	chr4:122721982	EXOSC9	-0.86	-9.81	-0.71	4.29e-16	Type 2 diabetes;
THYM	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg23815491	chr16:72088622	HP	0.72	5.48	0.49	3.46e-7	Fibrinogen levels;
THYM	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg02493798	chr17:6899577	ALOX12	0.62	7.85	0.63	6.16e-12	Tonsillectomy;
THYM	cis	rs7666738	0.570	rs1921415	chr4:99093804	C/T	cg24818145	chr4:99064322	C4orf37	0.67	5.2	0.47	1.13e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8133932	0.654	rs7410105	chr21:47332181	A/G	cg20357416	chr21:47294739	PCBP3	-0.8	-4.57	-0.42	1.47e-5	Schizophrenia;
THYM	cis	rs599083	0.530	rs583545	chr11:68178635	T/C	cg16797656	chr11:68205561	LRP5	-0.47	-5.03	-0.46	2.35e-6	Bone mineral density (spine);
THYM	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08109568	chr15:31115862	NA	-0.53	-5.26	-0.48	8.75e-7	Huntington's disease progression;
THYM	cis	rs921968	0.565	rs2272189	chr2:219610322	G/A	cg02176678	chr2:219576539	TTLL4	-0.47	-4.56	-0.42	1.55e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.31	-0.48	7.34e-7	Mean corpuscular volume;
THYM	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7833986	0.501	rs72653978	chr8:57018393	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	6.82	0.57	8.29e-10	Height;
THYM	cis	rs526231	0.575	rs10463990	chr5:102317418	G/A	cg23492399	chr5:102201601	PAM	-0.66	-5.15	-0.47	1.4e-6	Primary biliary cholangitis;
THYM	cis	rs6490294	0.500	rs4767284	chr12:112440731	G/A	cg10833066	chr12:111807467	FAM109A	0.47	5.23	0.47	1.02e-6	Mean platelet volume;
THYM	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10095849	0.546	rs12550405	chr8:39470136	T/G	cg01911981	chr8:39380341	ADAM3A	-0.54	-4.52	-0.42	1.81e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs208520	0.690	rs207108	chr6:66794096	T/C	cg07460842	chr6:66804631	NA	-1.06	-7.89	-0.63	5.14e-12	Exhaled nitric oxide output;
THYM	cis	rs35881094	0.933	rs1861412	chr2:58893065	G/A	cg09452692	chr2:58468460	FANCL	0.59	4.53	0.42	1.7e-5	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg03476357	chr21:30257390	N6AMT1	-0.59	-4.6	-0.43	1.31e-5	Dental caries;
THYM	cis	rs916888	0.779	rs199526	chr17:44847707	C/G	cg15921436	chr17:44337874	NA	-0.85	-6.83	-0.57	8.17e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs72712511	0.641	rs11100307	chr4:140767703	T/C	cg15010390	chr4:140216957	NDUFC1	0.63	4.55	0.42	1.59e-5	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg21784768	chr11:537496	LRRC56	-1.37	-6.17	-0.53	1.7e-8	Body mass index;
THYM	cis	rs860818	1.000	rs860818	chr7:23250363	C/T	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs7901056	0.967	rs2184571	chr10:26722509	T/C	cg23318538	chr10:26883079	C10orf50	-0.37	-4.96	-0.45	3.12e-6	Lymphocyte counts;
THYM	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	trans	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg19862616	chr7:65841803	NCRNA00174	1.03	10.86	0.74	2.49e-18	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9326248	0.581	rs10892072	chr11:116960313	G/A	cg20608306	chr11:116969690	SIK3	0.63	7.8	0.62	7.98e-12	Blood protein levels;
THYM	cis	rs6906287	0.647	rs7746778	chr6:118725871	C/A	cg21191810	chr6:118973309	C6orf204	0.62	6.2	0.54	1.48e-8	Electrocardiographic conduction measures;
THYM	cis	rs4460079	0.531	rs4631117	chr4:114839147	C/T	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs6570726	0.791	rs370654	chr6:145879005	C/G	cg23711669	chr6:146136114	FBXO30	0.98	10.7	0.74	5.26e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg26384229	chr12:38710491	ALG10B	0.95	7.61	0.62	1.97e-11	Bladder cancer;
THYM	cis	rs11225247	0.655	rs112276332	chr11:102226953	A/G	cg11690896	chr11:102217788	BIRC2	1.12	5.18	0.47	1.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg10589385	chr1:150898437	SETDB1	0.62	5.26	0.47	8.86e-7	Tonsillectomy;
THYM	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg06138931	chr13:21896616	NA	0.62	5.08	0.46	1.87e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs4523957	0.928	rs749240	chr17:2186100	A/G	cg16513277	chr17:2031491	SMG6	0.8	7.52	0.61	3e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg01616529	chr11:638424	DRD4	-0.78	-6.62	-0.56	2.16e-9	Systemic lupus erythematosus;
THYM	cis	rs728616	0.867	rs61860043	chr10:81946398	G/A	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs13315871	0.929	rs79813245	chr3:58318475	G/A	cg00563845	chr3:58318305	PXK	0.59	5.02	0.46	2.37e-6	Cholesterol, total;
THYM	cis	rs912057	1.000	rs1294410	chr6:6738752	C/T	cg06612196	chr6:6737390	NA	-0.69	-9.84	-0.71	3.66e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7568458	0.837	rs3731827	chr2:85806068	T/C	cg17127132	chr2:85788382	GGCX	0.65	5.14	0.47	1.47e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg04772025	chr11:68637568	NA	0.61	6.29	0.54	9.45e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg15536230	chr21:44985092	HSF2BP	0.42	5.04	0.46	2.26e-6	Mean corpuscular volume;
THYM	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06481639	chr22:41940642	POLR3H	-0.81	-5.43	-0.49	4.38e-7	Vitiligo;
THYM	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	trans	rs9951602	0.512	rs6506868	chr18:76642559	C/G	cg02800362	chr5:177631904	HNRNPAB	1.11	8.66	0.66	1.21e-13	Obesity-related traits;
THYM	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs12791968	0.765	rs12794846	chr11:44998943	C/T	cg11846598	chr11:44996168	LOC221122	0.81	5.91	0.52	5.28e-8	Inhibitory control;
THYM	cis	rs72627123	1.000	rs12050300	chr14:74386523	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs7771547	0.607	rs584196	chr6:36456243	G/C	cg07856975	chr6:36356162	ETV7	0.52	5.01	0.46	2.48e-6	Platelet distribution width;
THYM	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg08847533	chr14:75593920	NEK9	-0.91	-9.34	-0.69	4.24e-15	Height;
THYM	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg02725872	chr8:58115012	NA	-1.09	-8.15	-0.64	1.43e-12	Developmental language disorder (linguistic errors);
THYM	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg04944784	chr2:26401820	FAM59B	0.85	6.61	0.56	2.23e-9	Gut microbiome composition (summer);
THYM	trans	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs877282	0.891	rs12767062	chr10:797961	C/T	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs2456568	0.548	rs10466335	chr11:93663820	G/C	cg17595323	chr11:93583763	C11orf90	-0.51	-5.46	-0.49	3.83e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg09034736	chr1:150693464	HORMAD1	0.53	4.85	0.45	4.83e-6	Tonsillectomy;
THYM	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg01416388	chr22:39784598	NA	-0.95	-9.15	-0.68	1.11e-14	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg11764359	chr7:65958608	NA	0.77	6.31	0.54	8.95e-9	Aortic root size;
THYM	cis	rs13191362	0.573	rs9365499	chr6:163271833	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.87	7.17	0.59	1.64e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg10802521	chr3:52805072	NEK4	-0.72	-6.17	-0.53	1.66e-8	Bipolar disorder;
THYM	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	6.14	0.53	1.88e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg18252515	chr7:66147081	NA	-1.61	-8.73	-0.67	8.74e-14	Diabetic kidney disease;
THYM	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg18252515	chr7:66147081	NA	-0.66	-4.87	-0.45	4.38e-6	Aortic root size;
THYM	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg02527881	chr3:46936655	PTH1R	-0.68	-7.13	-0.59	1.97e-10	Colorectal cancer;
THYM	cis	rs8063160	0.622	rs34659644	chr16:89796017	G/A	cg27050730	chr16:88968896	CBFA2T3	0.96	4.45	0.42	2.33e-5	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs10847980	0.590	rs1979237	chr12:123325895	C/T	cg25930673	chr12:123319894	HIP1R	1.05	5.01	0.46	2.48e-6	Adiponectin levels;
THYM	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg23815491	chr16:72088622	HP	0.69	5.3	0.48	7.58e-7	Fibrinogen levels;
THYM	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg11494091	chr17:61959527	GH2	-0.95	-13.5	-0.81	7.92e-24	Prudent dietary pattern;
THYM	cis	rs367615	0.704	rs4320313	chr5:108828687	A/G	cg17395555	chr5:108820864	NA	0.76	9.36	0.69	3.82e-15	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg18681998	chr4:17616180	MED28	0.88	8.09	0.64	1.94e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg19761014	chr17:28927070	LRRC37B2	0.74	4.66	0.43	1.04e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4919694	1.000	rs11191490	chr10:104745174	T/A	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg24642439	chr20:33292090	TP53INP2	0.59	4.48	0.42	2.04e-5	Coronary artery disease;
THYM	cis	rs1018836	0.851	rs7007129	chr8:91629790	T/G	cg16814680	chr8:91681699	NA	-0.99	-9.24	-0.69	7.07e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg00990874	chr7:1149470	C7orf50	-0.64	-4.66	-0.43	1.04e-5	Bronchopulmonary dysplasia;
THYM	cis	rs985746	0.614	rs4833157	chr4:36799732	C/T	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs5769707	0.632	rs135871	chr22:50008969	A/G	cg17054759	chr22:49844102	NA	-0.52	-4.56	-0.42	1.54e-5	Monocyte count;Monocyte percentage of white cells;
THYM	trans	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg10856724	chr12:34555212	NA	-0.89	-8.05	-0.64	2.41e-12	Bladder cancer;
THYM	cis	rs11077998	0.933	rs7215465	chr17:80532532	C/T	cg10255544	chr17:80519551	FOXK2	0.51	4.49	0.42	2.02e-5	Reticulocyte fraction of red cells;
THYM	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs2625529	0.824	rs2279283	chr15:72243666	T/C	cg16672083	chr15:72433130	SENP8	-0.56	-5.07	-0.46	1.98e-6	Red blood cell count;
THYM	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg01045337	chr16:374988	AXIN1	-0.6	-4.76	-0.44	7.03e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs6964587	0.626	rs2188841	chr7:91522641	A/G	cg17063962	chr7:91808500	NA	-1.01	-9.03	-0.68	1.96e-14	Breast cancer;
THYM	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg12178445	chr6:8436263	SLC35B3	-0.28	-4.63	-0.43	1.18e-5	Motion sickness;
THYM	cis	rs2273669	0.667	rs6651000	chr6:109281411	G/T	cg17117243	chr6:109341365	SESN1	-0.79	-4.69	-0.43	9.19e-6	Prostate cancer;
THYM	cis	rs6450176	0.564	rs401449	chr5:53326735	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.94	-8.32	-0.65	6.26e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs12142240	0.698	rs6429599	chr1:46827871	G/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg02953382	chr22:24373134	LOC391322	-0.68	-5.64	-0.5	1.72e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs863345	0.565	rs2220633	chr1:158445272	A/G	cg12129480	chr1:158549410	OR10X1	-0.47	-4.62	-0.43	1.23e-5	Pneumococcal bacteremia;
THYM	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg10560079	chr2:191398806	TMEM194B	0.88	7.91	0.63	4.69e-12	Pulse pressure;
THYM	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg03929089	chr4:120376271	NA	-0.99	-12.81	-0.8	2.07e-22	Height;
THYM	cis	rs3020333	0.875	rs2982570	chr6:152013748	C/T	cg22157087	chr6:152012887	ESR1	0.42	4.58	0.43	1.4e-5	Total body bone mineral density;
THYM	cis	rs714027	1.000	rs5997579	chr22:30537526	A/G	cg11564601	chr22:30592435	NA	-0.32	-5.75	-0.51	1.1e-7	Lymphocyte counts;
THYM	cis	rs367615	0.918	rs4270746	chr5:108876839	T/C	cg17395555	chr5:108820864	NA	0.53	4.8	0.44	5.95e-6	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs7084402	0.934	rs1658455	chr10:60306089	G/C	cg07615347	chr10:60278583	BICC1	0.56	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs4974559	0.740	rs11933854	chr4:1315172	G/A	cg16185996	chr4:1008614	FGFRL1	-0.42	-4.59	-0.43	1.36e-5	Systolic blood pressure;
THYM	cis	rs7809950	0.559	rs2248465	chr7:107303628	C/T	cg23024343	chr7:107201750	COG5	0.66	5.51	0.49	3.01e-7	Coronary artery disease;
THYM	cis	rs6540559	1.000	rs6540559	chr1:209982025	G/A	cg22029157	chr1:209979665	IRF6	0.61	4.49	0.42	2.02e-5	Cleft lip with or without cleft palate;
THYM	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs1461503	0.900	rs7110039	chr11:122834001	C/T	cg27398637	chr11:122830231	C11orf63	0.68	6.09	0.53	2.41e-8	Menarche (age at onset);
THYM	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg22920501	chr2:26401640	FAM59B	-1.07	-9.54	-0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs28595532	0.920	rs115472708	chr4:119773407	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs554111	0.656	rs6695218	chr1:21190512	A/C	cg01072550	chr1:21505969	NA	0.55	4.76	0.44	6.99e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs4722166	0.695	rs35779989	chr7:22800314	A/C	cg05472934	chr7:22766657	IL6	0.68	5.89	0.52	5.86e-8	Lung cancer;
THYM	cis	rs548181	0.536	rs503287	chr11:125461788	C/T	cg03464685	chr11:125439445	EI24	1.28	7.66	0.62	1.56e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22496380	chr5:211416	CCDC127	-1.3	-8.28	-0.65	7.84e-13	Breast cancer;
THYM	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg22709100	chr7:91322751	NA	0.63	4.86	0.45	4.55e-6	Breast cancer;
THYM	trans	rs6089829	0.589	rs73921629	chr20:61676036	G/C	cg23505145	chr19:12996616	KLF1	-1.06	-8.28	-0.65	7.88e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs921968	0.541	rs10205073	chr2:219412784	C/A	cg02176678	chr2:219576539	TTLL4	-0.73	-7.24	-0.6	1.18e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs12142240	0.621	rs13374968	chr1:46843908	T/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg03929089	chr4:120376271	NA	0.99	8.48	0.66	2.85e-13	Coronary artery disease;
THYM	cis	rs6754311	0.593	rs12619365	chr2:136398174	C/T	cg04750100	chr2:136595281	LCT	0.56	5.89	0.52	5.87e-8	Mosquito bite size;
THYM	cis	rs79349575	0.783	rs4255820	chr17:46996583	T/A	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg10802521	chr3:52805072	NEK4	-0.73	-6.33	-0.54	7.99e-9	Bipolar disorder;
THYM	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	2.94e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs853679	0.550	rs1225599	chr6:28165190	C/T	cg12963246	chr6:28129442	ZNF389	0.64	5.93	0.52	4.86e-8	Depression;
THYM	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.26	10.1	0.72	1.01e-16	Platelet count;
THYM	cis	rs7267979	0.844	rs8184820	chr20:25250577	C/T	cg08601574	chr20:25228251	PYGB	-0.7	-5.75	-0.51	1.1e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs7523273	0.526	rs2745975	chr1:208013620	C/T	cg22525895	chr1:207977042	MIR29B2	-0.86	-9.29	-0.69	5.57e-15	Schizophrenia;
THYM	cis	rs10492096	1.000	rs12427239	chr12:6590626	C/T	cg13857086	chr12:6580257	VAMP1	0.9	5.47	0.49	3.64e-7	Hip geometry;
THYM	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg08999081	chr20:33150536	PIGU	0.78	7.16	0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs240764	0.619	rs6903665	chr6:101148234	T/C	cg21058520	chr6:100914733	NA	-0.6	-4.97	-0.45	2.92e-6	Neuroticism;
THYM	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg23758822	chr17:41437982	NA	1.27	14.18	0.82	3.54e-25	Menopause (age at onset);
THYM	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg03609598	chr5:56110824	MAP3K1	0.75	4.73	0.44	7.72e-6	Initial pursuit acceleration;
THYM	cis	rs6429082	0.818	rs453315	chr1:235680585	C/T	cg26050004	chr1:235667680	B3GALNT2	0.72	5.84	0.51	7.2e-8	Adiposity;
THYM	cis	rs1728785	1.000	rs1645976	chr16:68563509	T/C	cg02972257	chr16:68554789	NA	-0.74	-4.54	-0.42	1.63e-5	Ulcerative colitis;
THYM	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg10852096	chr15:79043040	NA	-0.63	-4.93	-0.45	3.46e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	7.35	0.6	6.91e-11	Platelet count;
THYM	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Educational attainment;
THYM	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg14129053	chr2:1895732	MYT1L	1.13	4.49	0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg16342193	chr10:102329863	NA	-0.54	-5.48	-0.49	3.43e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg16928487	chr17:17741425	SREBF1	0.52	5.12	0.47	1.59e-6	Total body bone mineral density;
THYM	cis	rs12530845	0.623	rs76485854	chr7:135352668	T/C	cg23117316	chr7:135346802	PL-5283	-0.83	-6.31	-0.54	8.67e-9	Red blood cell traits;
THYM	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg26354017	chr1:205819088	PM20D1	0.82	8.33	0.65	6.15e-13	Menarche (age at onset);
THYM	cis	rs7000551	0.689	rs7007673	chr8:22316687	G/T	cg12081754	chr8:22256438	SLC39A14	0.6	5.15	0.47	1.43e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg17911788	chr17:44343683	NA	0.71	6.76	0.57	1.09e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9543976	1.000	rs55927305	chr13:76135349	A/G	cg01531495	chr13:76123901	UCHL3	-0.76	-4.77	-0.44	6.72e-6	Diabetic retinopathy;
THYM	cis	rs4563143	0.577	rs73025093	chr19:29254618	T/G	cg03161606	chr19:29218774	NA	0.87	7.31	0.6	8.22e-11	Methadone dose in opioid dependence;
THYM	cis	rs2219968	0.525	rs1486922	chr8:78880320	C/A	cg00738934	chr8:78996279	NA	0.61	4.95	0.45	3.21e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg25703541	chr22:24373054	LOC391322	1.0	13.68	0.81	3.53e-24	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg11301795	chr4:187892539	NA	-1.12	-16.92	-0.87	2.01e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs228769	0.673	rs228787	chr17:42099488	C/T	cg19774624	chr17:42201019	HDAC5	0.61	4.68	0.43	9.33e-6	Bone mineral density (hip);Bone mineral density (spine);
THYM	cis	rs1555322	0.505	rs639763	chr20:33861904	C/T	cg08999081	chr20:33150536	PIGU	0.6	4.48	0.42	2.1e-5	Attention deficit hyperactivity disorder;
THYM	cis	rs12681287	0.547	rs10087788	chr8:87544174	G/A	cg27223183	chr8:87520930	FAM82B	0.71	5.56	0.5	2.44e-7	Caudate activity during reward;
THYM	cis	rs7584330	0.518	rs74003105	chr2:238446851	T/C	cg14458575	chr2:238380390	NA	0.82	4.53	0.42	1.74e-5	Prostate cancer;
THYM	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg22535103	chr8:58192502	C8orf71	-0.96	-5.47	-0.49	3.7e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs4930103	0.935	rs2075744	chr11:2018449	A/G	cg06197492	chr11:2016605	H19	0.63	5.48	0.49	3.56e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.67	-0.81	3.63e-24	Height;
THYM	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg05973401	chr12:123451056	ABCB9	0.67	4.54	0.42	1.63e-5	Neutrophil percentage of white cells;
THYM	cis	rs2227564	0.620	rs11000765	chr10:75512452	G/C	cg00564723	chr10:75632066	CAMK2G	-0.57	-5.16	-0.47	1.33e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7216064	1.000	rs56404791	chr17:65893019	T/G	cg12091567	chr17:66097778	LOC651250	-0.73	-5.18	-0.47	1.25e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs2282930	0.512	rs886823	chr7:50717977	G/A	cg08586669	chr7:50727761	GRB10	0.33	4.89	0.45	4.18e-6	Bone mineral density;
THYM	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg10360139	chr7:1886902	MAD1L1	-0.61	-5.4	-0.48	4.86e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs62435770	0.929	rs62435790	chr6:169476031	C/A	cg07652237	chr6:170125491	PHF10	0.56	4.87	0.45	4.47e-6	Loneliness;
THYM	cis	rs3087591	0.801	rs2012535	chr17:29561391	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.63	-5.38	-0.48	5.24e-7	Hip circumference;
THYM	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.86	0.74	2.46e-18	Chronic sinus infection;
THYM	cis	rs1050631	0.536	rs1785928	chr18:33725931	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.66	-5.28	-0.48	8.32e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs1802575	1.000	rs11899380	chr2:56079609	G/A	cg22104478	chr2:55845289	SMEK2	0.97	4.54	0.42	1.65e-5	Childhood ear infection;
THYM	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg17911788	chr17:44343683	NA	0.71	6.76	0.57	1.09e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg14972814	chr11:95582409	MTMR2	-0.58	-5.3	-0.48	7.56e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg13010199	chr12:38710504	ALG10B	0.61	4.61	0.43	1.27e-5	Morning vs. evening chronotype;
THYM	cis	rs7586879	1.000	rs7586879	chr2:25116977	C/T	cg15423357	chr2:25149977	NA	0.56	5.49	0.49	3.41e-7	Body mass index;
THYM	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.71	-5.53	-0.49	2.85e-7	Blood protein levels;
THYM	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg00271210	chr6:167070053	RPS6KA2	0.66	6.65	0.56	1.87e-9	Crohn's disease;
THYM	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.841	rs114970257	chr4:119756937	G/A	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg00071950	chr4:10020882	SLC2A9	0.87	9.93	0.71	2.28e-16	Bone mineral density;
THYM	cis	rs7084402	0.967	rs10763552	chr10:60273977	C/T	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg08999081	chr20:33150536	PIGU	0.56	4.8	0.44	5.98e-6	Height;
THYM	cis	rs853679	0.599	rs149949	chr6:28011516	T/C	cg12963246	chr6:28129442	ZNF389	0.92	5.12	0.47	1.58e-6	Depression;
THYM	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.78	0.51	9.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs546131	0.890	rs485845	chr11:34830389	G/T	cg06937548	chr11:34938143	PDHX;APIP	-0.66	-5.42	-0.49	4.5e-7	Lung disease severity in cystic fibrosis;
THYM	cis	rs1957429	0.731	rs10144554	chr14:65321514	T/G	cg10794733	chr14:65257245	SPTB	-0.46	-4.46	-0.42	2.21e-5	Pediatric areal bone mineral density (radius);
THYM	trans	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg10856724	chr12:34555212	NA	-0.94	-8.13	-0.64	1.61e-12	Bladder cancer;
THYM	cis	rs700651	0.752	rs1850631	chr2:198829468	T/G	cg00792783	chr2:198669748	PLCL1	0.82	5.75	0.51	1.08e-7	Intracranial aneurysm;
THYM	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22857025	chr5:266934	NA	-1.37	-8.88	-0.67	4.08e-14	Breast cancer;
THYM	cis	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg06609049	chr19:2785107	THOP1	0.69	5.77	0.51	9.77e-8	Total cholesterol levels;
THYM	cis	rs288326	0.561	rs74869113	chr2:183858306	C/T	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg02782426	chr3:40428986	ENTPD3	-0.5	-4.48	-0.42	2.1e-5	Renal cell carcinoma;
THYM	cis	rs9796	0.558	rs8043253	chr15:41503730	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.57	-4.77	-0.44	6.76e-6	Menopause (age at onset);
THYM	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg10248100	chr7:872053	UNC84A	0.67	4.59	0.43	1.36e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs7582403	0.510	rs6430292	chr2:148875007	G/T	cg23727674	chr2:148602993	ACVR2A	0.63	4.61	0.43	1.24e-5	Neuroticism;
THYM	cis	rs7106204	0.686	rs12803558	chr11:24288205	C/A	ch.11.24196551F	chr11:24239977	NA	0.86	4.81	0.44	5.61e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg23161317	chr6:28129485	ZNF389	-1.07	-8.09	-0.64	1.92e-12	Depression;
THYM	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	5.78	0.51	9.59e-8	Height;
THYM	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg21427119	chr20:30132790	HM13	-0.96	-7.02	-0.58	3.34e-10	Mean corpuscular hemoglobin;
THYM	cis	rs7583236	0.500	rs7601899	chr2:70335973	C/G	cg19638749	chr2:70312615	NA	0.76	4.61	0.43	1.26e-5	Obesity-related traits;
THYM	cis	rs9303401	0.703	rs9911583	chr17:57210721	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.64	-4.48	-0.42	2.09e-5	Cognitive test performance;
THYM	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg10636054	chr15:40330586	SRP14	1.05	5.44	0.49	4.22e-7	Corneal curvature;
THYM	cis	rs28595532	0.841	rs114768988	chr4:119744451	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg07362569	chr17:61921086	SMARCD2	0.69	6.16	0.53	1.78e-8	Prudent dietary pattern;
THYM	cis	rs616402	0.527	rs11584327	chr1:10578791	T/C	cg20482658	chr1:10539492	PEX14	-0.37	-5.8	-0.51	8.8e-8	Breast size;
THYM	cis	rs2274459	0.841	rs13214874	chr6:33686368	G/A	cg06253072	chr6:33679850	C6orf125	0.5	4.93	0.45	3.43e-6	Obesity (extreme);
THYM	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10170846	0.789	rs972650	chr2:223520287	C/T	cg25565276	chr2:223520875	FARSB	0.61	4.9	0.45	3.94e-6	Schizophrenia (inflammation and infection response interaction);
THYM	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs73198271	0.710	rs11779565	chr8:8680020	G/A	cg08975724	chr8:8085496	FLJ10661	-0.71	-4.57	-0.42	1.48e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg23205692	chr1:25664452	TMEM50A	0.86	6.69	0.57	1.54e-9	Erythrocyte sedimentation rate;
THYM	cis	rs616402	0.527	rs589151	chr1:10567711	C/T	cg06719487	chr1:10489962	APITD1	0.4	4.56	0.42	1.54e-5	Breast size;
THYM	cis	rs76878669	0.561	rs4244813	chr11:66129488	G/C	cg18002602	chr11:66138449	SLC29A2	0.49	4.98	0.45	2.86e-6	Educational attainment (years of education);
THYM	cis	rs6565180	0.962	rs11642676	chr16:30371655	C/G	cg10017167	chr16:30683065	NA	0.41	4.46	0.42	2.22e-5	Tonsillectomy;
THYM	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg15448220	chr1:150897856	SETDB1	0.86	6.86	0.58	6.9e-10	Melanoma;
THYM	cis	rs77372450	0.551	rs57823519	chr5:157101500	G/A	cg00312553	chr5:157098553	C5orf52	-0.66	-4.7	-0.43	8.79e-6	Bipolar disorder (body mass index interaction);
THYM	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg10890681	chr4:74279174	ALB	-0.95	-6.94	-0.58	4.83e-10	Subcortical brain region volumes;
THYM	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg17480646	chr11:65405466	SIPA1	-0.94	-8.68	-0.67	1.07e-13	Acne (severe);
THYM	cis	rs11190604	0.767	rs10736150	chr10:102195341	G/A	cg07570687	chr10:102243282	WNT8B	-0.82	-7.91	-0.63	4.72e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg24375607	chr4:120327624	NA	0.64	5.1	0.46	1.73e-6	Corneal astigmatism;
THYM	cis	rs2806561	0.765	rs652783	chr1:23514313	G/T	cg19743168	chr1:23544995	NA	0.55	5.64	0.5	1.74e-7	Height;
THYM	cis	rs2268241	0.938	rs17879003	chr21:34778527	C/T	cg14850771	chr21:34775459	IFNGR2	1.04	6.96	0.58	4.26e-10	Obesity-related traits;
THYM	cis	rs198389	0.589	rs12404124	chr1:11873869	A/C	cg24844545	chr1:11908347	NPPA	-0.48	-4.78	-0.44	6.27e-6	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
THYM	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg07022442	chr13:21864356	NA	0.7	4.64	0.43	1.12e-5	White matter hyperintensity burden;
THYM	cis	rs7192750	0.586	rs6499552	chr16:71943169	G/C	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs2637266	1.000	rs2395410	chr10:78381767	C/T	cg18941641	chr10:78392320	NA	0.72	6.33	0.54	8.03e-9	Pulmonary function;
THYM	cis	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.59	6.1	0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6565180	0.632	rs8050812	chr16:30385837	C/T	cg17640201	chr16:30407289	ZNF48	-0.77	-5.92	-0.52	4.99e-8	Tonsillectomy;
THYM	cis	rs2806561	0.765	rs2806565	chr1:23507068	A/G	cg12483005	chr1:23474871	LUZP1	0.59	6.31	0.54	9.03e-9	Height;
THYM	cis	rs293526	0.959	rs293515	chr6:83639103	G/A	cg23278060	chr6:83777448	DOPEY1	0.61	4.48	0.42	2.1e-5	Crohn's disease;
THYM	cis	rs12600856	1	rs12600856	chr17:38163295	T/C	cg17467752	chr17:38218738	THRA	0.86	7.09	0.59	2.4e-10	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
THYM	cis	rs4919044	0.641	rs7914449	chr10:94723370	G/T	cg05127821	chr10:94822908	CYP26C1	-1.12	-6.77	-0.57	1.08e-9	Coronary artery disease;
THYM	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg23260525	chr10:116636907	FAM160B1	0.52	5.37	0.48	5.66e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg13395646	chr4:1353034	KIAA1530	-0.56	-5.35	-0.48	6.16e-7	Obesity-related traits;
THYM	cis	rs36051895	0.623	rs7025005	chr9:5261794	T/C	cg02405213	chr9:5042618	JAK2	-0.95	-9.46	-0.7	2.41e-15	Pediatric autoimmune diseases;
THYM	cis	rs2398893	0.960	rs34849895	chr9:96751069	T/C	cg14459158	chr9:96720562	NA	0.52	4.9	0.45	3.9e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg10505658	chr17:80084571	CCDC57	0.74	8.13	0.64	1.59e-12	Life satisfaction;
THYM	cis	rs9653442	0.900	rs6740838	chr2:100813499	T/G	cg07810366	chr2:100720526	AFF3	-0.36	-4.7	-0.43	8.73e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs1568889	0.887	rs7102237	chr11:28344296	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	6.97	0.58	4.24e-10	Bipolar disorder;
THYM	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6987853	0.787	rs2923448	chr8:42406008	G/A	cg09913449	chr8:42400586	C8orf40	1.1	12.33	0.78	1.96e-21	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6598955	0.671	rs11247880	chr1:26568926	G/A	cg08133631	chr1:26527909	CATSPER4	-0.56	-4.61	-0.43	1.25e-5	Obesity-related traits;
THYM	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs2797160	1.000	rs1777225	chr6:126018270	T/C	cg16306078	chr6:126000798	NA	0.52	5.19	0.47	1.19e-6	Endometrial cancer;
THYM	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg19748678	chr4:122722346	EXOSC9	0.68	4.78	0.44	6.27e-6	Type 2 diabetes;
THYM	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg05347473	chr6:146136440	FBXO30	0.59	4.62	0.43	1.22e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs56309584	0.715	rs74252612	chr17:8142100	G/A	cg08322244	chr17:8066669	VAMP2	-0.59	-5.17	-0.47	1.29e-6	Initial pursuit acceleration;
THYM	cis	rs4930776	0.932	rs367206	chr12:5757029	C/T	cg02086166	chr12:5775618	ANO2	0.62	6.27	0.54	1.04e-8	Plasma clusterin levels;
THYM	cis	rs1003719	0.715	rs58008706	chr21:38540506	A/G	cg01329690	chr21:38580129	DSCR9	-0.36	-5.01	-0.46	2.54e-6	Eye color traits;
THYM	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg12908607	chr1:44402522	ARTN	-0.69	-5.98	-0.52	3.85e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg02734326	chr4:10020555	SLC2A9	0.71	5.63	0.5	1.81e-7	Bone mineral density;
THYM	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg26441486	chr22:50317300	CRELD2	-0.42	-6.47	-0.55	4.34e-9	Schizophrenia;
THYM	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg02038168	chr22:39784481	NA	-0.62	-4.97	-0.45	2.96e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg08772003	chr10:104629869	AS3MT	0.66	6.29	0.54	9.68e-9	Waist circumference;Hip circumference;
THYM	cis	rs4589258	0.933	rs10830574	chr11:90507561	A/G	cg26138821	chr11:89956704	CHORDC1	0.58	4.78	0.44	6.31e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11937061	0.539	rs716025	chr4:78145233	G/A	cg01930676	chr4:78783082	MRPL1	-0.56	-4.47	-0.42	2.17e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs11048434	0.736	rs2041625	chr12:9112005	C/T	cg13575925	chr12:9217583	LOC144571	0.51	4.87	0.45	4.42e-6	Sjögren's syndrome;
THYM	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg10515332	chr4:99064459	C4orf37	0.58	4.56	0.42	1.52e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs665401	0.692	rs6901971	chr6:117114403	G/A	cg20376953	chr6:117187980	NA	-0.6	-4.69	-0.43	8.97e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg10193763	chr2:225306901	NA	-0.51	-5.36	-0.48	5.86e-7	IgE levels in asthmatics (D.p. specific);
THYM	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.82	7.53	0.61	2.9100000000000002e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4819852	0.958	rs12628032	chr22:19967980	C/T	cg07821417	chr22:19972146	ARVCF	0.46	5.53	0.49	2.8e-7	Pulse pressure;
THYM	cis	rs2933343	0.679	rs789229	chr3:128602526	C/T	cg11901034	chr3:128598214	ACAD9	-0.71	-5.55	-0.49	2.56e-7	IgG glycosylation;
THYM	cis	rs3008870	0.920	rs3008860	chr1:67391003	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.92	7.43	0.61	4.77e-11	Lymphocyte percentage of white cells;
THYM	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.6	-5.03	-0.46	2.27e-6	Renal function-related traits (BUN);
THYM	cis	rs6570726	0.755	rs2092297	chr6:145893765	A/G	cg13319975	chr6:146136371	FBXO30	-0.63	-4.99	-0.46	2.75e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg18230493	chr5:56204884	C5orf35	-0.89	-6.53	-0.56	3.25e-9	Initial pursuit acceleration;
THYM	cis	rs6032067	0.673	rs6017532	chr20:43904095	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.42	-4.48	-0.42	2.05e-5	Blood protein levels;
THYM	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	7.14	0.59	1.88e-10	Platelet count;
THYM	trans	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.82	5.17	0.47	1.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs662064	0.755	rs6667629	chr1:10524467	T/C	cg24365837	chr1:10509935	APITD1;CORT	-0.62	-4.91	-0.45	3.71e-6	Asthma;
THYM	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg13609457	chr4:120235615	NA	0.58	5.33	0.48	6.55e-7	Corneal astigmatism;
THYM	cis	rs3096299	0.838	rs3102376	chr16:89402473	A/C	cg06640241	chr16:89574553	SPG7	0.61	4.59	0.43	1.33e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs10208940	0.614	rs10166882	chr2:68724945	C/A	cg09157127	chr2:69201416	GKN1	0.79	4.46	0.42	2.29e-5	Urate levels in lean individuals;
THYM	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7107174	1.000	rs2511187	chr11:77985849	T/A	cg02023728	chr11:77925099	USP35	0.65	5.95	0.52	4.47e-8	Testicular germ cell tumor;
THYM	cis	rs7973719	0.833	rs11044332	chr12:7358768	C/A	cg07052231	chr12:7363540	PEX5	0.61	5.26	0.48	8.71e-7	IgG glycosylation;
THYM	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg10053473	chr17:62856997	LRRC37A3	0.92	7.34	0.6	7.17e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg06636001	chr8:8085503	FLJ10661	0.85	8.53	0.66	2.29e-13	Mood instability;
THYM	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg04455712	chr21:45112962	RRP1B	0.55	5.02	0.46	2.45e-6	Mean corpuscular volume;
THYM	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03264133	chr6:25882463	NA	-0.87	-7.17	-0.59	1.58e-10	Intelligence (multi-trait analysis);
THYM	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg02503808	chr4:7069936	GRPEL1	-0.85	-5.8	-0.51	8.66e-8	Monocyte percentage of white cells;
THYM	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg03188948	chr7:1209495	NA	1.08	6.16	0.53	1.77e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg13393036	chr8:95962371	TP53INP1	-0.46	-4.61	-0.43	1.24e-5	Type 2 diabetes;
THYM	cis	rs807669	0.525	rs9604934	chr22:19194868	C/T	cg02655711	chr22:19163373	SLC25A1	0.59	6.37	0.55	6.66e-9	Metabolite levels;
THYM	cis	rs354225	0.544	rs13403284	chr2:54805749	A/G	cg23486701	chr2:54789491	SPTBN1	0.34	4.49	0.42	2e-5	Schizophrenia;
THYM	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg27490568	chr2:178487706	NA	0.63	5.71	0.51	1.28e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6430585	0.528	rs3099429	chr2:136655582	T/A	cg04750100	chr2:136595281	LCT	0.57	5.76	0.51	1.03e-7	Corneal structure;
THYM	cis	rs11008222	0.935	rs7905456	chr10:31051786	A/G	cg00941203	chr10:31016591	NA	-0.37	-5.05	-0.46	2.12e-6	Congenital left-sided heart lesions (maternal effect);
THYM	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03517284	chr6:25882590	NA	0.83	6.7	0.57	1.47e-9	Intelligence (multi-trait analysis);
THYM	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg06917634	chr15:78832804	PSMA4	-0.91	-7.9	-0.63	4.85e-12	Sudden cardiac arrest;
THYM	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs6835098	1.000	rs6814857	chr4:174082805	T/A	cg08422745	chr4:174089978	GALNT7	-0.94	-7.73	-0.62	1.11e-11	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs245880	0.666	rs245894	chr7:29192686	G/C	cg17163760	chr7:29186267	CPVL	-0.61	-4.93	-0.45	3.54e-6	Warfarin maintenance dose;
THYM	cis	rs6956675	0.915	rs7795023	chr7:62652291	C/T	cg27518014	chr7:62859535	LOC100287834	0.58	4.74	0.44	7.51e-6	Obesity-related traits;
THYM	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg01097406	chr16:89675127	NA	-0.64	-5.33	-0.48	6.54e-7	Vitiligo;
THYM	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg17105886	chr17:28927953	LRRC37B2	1.31	7.85	0.63	6.35e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11671005	0.656	rs55652736	chr19:59007566	G/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.71	-5.23	-0.47	1.02e-6	Mean platelet volume;
THYM	cis	rs8114671	0.967	rs6088747	chr20:33754604	G/T	cg08999081	chr20:33150536	PIGU	0.55	4.9	0.45	3.97e-6	Height;
THYM	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg10505658	chr17:80084571	CCDC57	-0.67	-7.23	-0.6	1.23e-10	Life satisfaction;
THYM	cis	rs7968440	1.000	rs2252589	chr12:51041957	A/G	cg20014596	chr12:50898483	DIP2B	0.56	4.55	0.42	1.57e-5	Fibrinogen;
THYM	cis	rs13064411	0.627	rs28710051	chr3:113143531	G/A	cg18753928	chr3:113234510	CCDC52	-0.91	-8.22	-0.64	1.04e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg07636037	chr3:49044803	WDR6	0.93	9.91	0.71	2.57e-16	Parkinson's disease;
THYM	cis	rs8025790	0.508	rs12902812	chr15:67909279	C/T	cg24579218	chr15:68104479	NA	-0.73	-6.7	-0.57	1.49e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs55692411	0.517	rs62262106	chr3:49991427	A/G	cg14019146	chr3:50243930	SLC38A3	-0.59	-4.56	-0.42	1.55e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10949834	0.504	rs77541100	chr7:73555605	C/T	cg07137043	chr7:73588983	EIF4H	-0.74	-4.84	-0.44	5.01e-6	Verbal memory performance (residualized delayed recall change);
THYM	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs4713118	0.869	rs6922574	chr6:27693003	A/T	cg08968635	chr6:28129556	ZNF389	0.64	4.72	0.44	8.14e-6	Parkinson's disease;
THYM	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-5.53	-0.49	2.81e-7	Prostate cancer;
THYM	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg03806693	chr22:41940476	POLR3H	1.1	8.41	0.65	4.11e-13	Vitiligo;
THYM	cis	rs6430585	0.528	rs309123	chr2:136761175	C/G	cg07169764	chr2:136633963	MCM6	1.02	10.87	0.74	2.29e-18	Corneal structure;
THYM	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg18758796	chr5:131593413	PDLIM4	0.61	6.06	0.53	2.71e-8	Breast cancer;
THYM	cis	rs6840360	0.692	rs4479686	chr4:152399324	C/T	cg22705602	chr4:152727874	NA	-0.54	-5.5	-0.49	3.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10911232	0.507	rs5022057	chr1:182997761	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs3820068	0.608	rs10927840	chr1:16045250	A/G	cg27534772	chr1:16042836	PLEKHM2	0.49	4.97	0.45	2.94e-6	Systolic blood pressure;
THYM	cis	rs4732038	0.510	rs10085674	chr7:134269597	G/T	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs73086581	0.735	rs6037730	chr20:4026818	A/G	cg02187196	chr20:3869020	PANK2	0.46	5.09	0.46	1.8e-6	Response to antidepressants in depression;
THYM	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg26384229	chr12:38710491	ALG10B	-0.89	-9.06	-0.68	1.67e-14	Heart rate;
THYM	cis	rs28595532	0.920	rs115446044	chr4:119754635	T/C	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs793571	0.502	rs411007	chr15:59078502	G/C	cg05156742	chr15:59063176	FAM63B	0.6	5.09	0.46	1.81e-6	Schizophrenia;
THYM	cis	rs2276314	0.857	rs62101379	chr18:33584902	G/A	cg05985134	chr18:33552581	C18orf21	0.69	4.84	0.44	5.07e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg19748678	chr4:122722346	EXOSC9	0.7	4.87	0.45	4.53e-6	Type 2 diabetes;
THYM	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg17333051	chr19:2783644	SGTA	0.57	5.34	0.48	6.21e-7	Total cholesterol levels;
THYM	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.6	0.56	2.37e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs11608355	0.597	rs12579285	chr12:109832712	T/C	cg10504392	chr12:110044639	NA	0.53	4.66	0.43	1.04e-5	Neuroticism;
THYM	cis	rs1448094	0.511	rs7959372	chr12:86160680	T/C	cg02569458	chr12:86230093	RASSF9	0.68	5.77	0.51	9.71e-8	Major depressive disorder;
THYM	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg01097406	chr16:89675127	NA	0.63	5.86	0.52	6.52e-8	Vitiligo;
THYM	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg17211192	chr8:82754475	SNX16	-0.8	-7.08	-0.59	2.52e-10	Diastolic blood pressure;
THYM	cis	rs4664308	0.618	rs62175488	chr2:160892758	T/C	cg03641300	chr2:160917029	PLA2R1	-0.66	-5.58	-0.5	2.24e-7	Idiopathic membranous nephropathy;
THYM	cis	rs6032067	1.000	rs62205501	chr20:43864089	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.73	-7.62	-0.62	1.9e-11	Blood protein levels;
THYM	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg06238570	chr21:40685208	BRWD1	0.91	6.77	0.57	1.08e-9	Cognitive function;
THYM	cis	rs3741151	0.773	rs57673166	chr11:73232557	T/A	cg12959048	chr11:73096162	RELT	-0.51	-4.51	-0.42	1.87e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs622217	0.629	rs415317	chr6:160716361	T/G	cg11363108	chr6:160501266	IGF2R	-0.57	-4.46	-0.42	2.25e-5	Type 2 diabetes;
THYM	cis	rs6665290	0.669	rs3768424	chr1:227177444	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.08	-12.43	-0.79	1.26e-21	Myeloid white cell count;
THYM	cis	rs13064411	0.696	rs2087129	chr3:113142769	T/A	cg10517650	chr3:113235015	CCDC52	-0.54	-4.64	-0.43	1.13e-5	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs4654899	1.000	rs4654896	chr1:21356930	T/C	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.26e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28595532	0.920	rs115738062	chr4:119725490	C/T	cg21605333	chr4:119757512	SEC24D	1.54	6.13	0.53	1.97e-8	Cannabis dependence symptom count;
THYM	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg11764359	chr7:65958608	NA	0.75	5.99	0.52	3.7e-8	Aortic root size;
THYM	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.26	0.47	8.97e-7	Lung cancer in ever smokers;
THYM	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg17509989	chr5:176798049	RGS14	0.64	5.96	0.52	4.25e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg03433033	chr1:76189801	ACADM	0.66	5.7	0.51	1.32e-7	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs860554	0.705	rs832170	chr1:201257016	G/A	cg01022117	chr1:201258280	PKP1	0.66	4.9	0.45	3.93e-6	Panic disorder;
THYM	cis	rs6087990	0.899	rs4911107	chr20:31374991	G/A	cg13636640	chr20:31349939	DNMT3B	0.96	10.83	0.74	2.78e-18	Ulcerative colitis;
THYM	trans	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg19862616	chr7:65841803	NCRNA00174	1.12	13.73	0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs8133932	0.736	rs2839030	chr21:47292007	A/C	cg20357416	chr21:47294739	PCBP3	-0.85	-5.24	-0.47	9.77e-7	Schizophrenia;
THYM	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg06697600	chr4:7070879	GRPEL1	-0.54	-4.8	-0.44	5.88e-6	Monocyte percentage of white cells;
THYM	cis	rs2273669	0.667	rs76367548	chr6:109356589	C/T	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.58	0.56	2.61e-9	Total body bone mineral density;
THYM	cis	rs12410462	0.579	rs77529417	chr1:227547895	T/C	cg23173402	chr1:227635558	NA	0.67	5.39	0.48	5.02e-7	Major depressive disorder;
THYM	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg24257776	chr3:47051546	LOC100129354	0.41	4.78	0.44	6.38e-6	Colorectal cancer;
THYM	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg16342193	chr10:102329863	NA	-0.54	-5.64	-0.5	1.77e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg03806693	chr22:41940476	POLR3H	1.24	10.61	0.74	8.15e-18	Vitiligo;
THYM	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs7572733	0.534	rs1589162	chr2:198782692	A/G	cg05783139	chr2:198650985	BOLL	0.63	4.95	0.45	3.16e-6	Dermatomyositis;
THYM	cis	rs599083	0.530	rs491347	chr11:68169688	G/A	cg16797656	chr11:68205561	LRP5	-0.45	-4.85	-0.45	4.76e-6	Bone mineral density (spine);
THYM	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg21775007	chr8:11205619	TDH	-0.73	-5.66	-0.5	1.63e-7	Retinal vascular caliber;
THYM	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.5	-6.55	-0.56	3e-9	Monocyte percentage of white cells;
THYM	cis	rs7119	0.717	rs11631274	chr15:77816431	A/T	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03264133	chr6:25882463	NA	0.92	8.02	0.64	2.72e-12	Blood metabolite levels;
THYM	cis	rs4523957	0.583	rs2760743	chr17:2017079	A/C	cg16513277	chr17:2031491	SMG6	1.0	9.29	0.69	5.42e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs17401966	1.000	rs12118323	chr1:10469641	A/G	cg19773385	chr1:10388646	KIF1B	-0.61	-4.75	-0.44	7.06e-6	Hepatocellular carcinoma;
THYM	cis	rs4253772	0.745	rs78023664	chr22:46647844	G/A	cg09461388	chr22:46763229	CELSR1	-0.73	-4.69	-0.43	9.13e-6	LDL cholesterol;Cholesterol, total;
THYM	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg02869364	chr7:1081709	C7orf50	-0.6	-5.37	-0.48	5.46e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg21984481	chr17:79567631	NPLOC4	-0.47	-4.97	-0.45	2.98e-6	Eye color traits;
THYM	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg25072359	chr17:41440525	NA	0.65	4.54	0.42	1.64e-5	Menopause (age at onset);
THYM	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.68	5.25	0.47	9.09e-7	Tonsillectomy;
THYM	cis	rs6456042	0.965	rs3127425	chr6:166539227	A/G	cg11088901	chr6:166572345	T	-0.52	-4.9	-0.45	3.93e-6	Asthma;
THYM	cis	rs4919694	1.000	rs12266291	chr10:104806884	G/A	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs11118993	0.936	rs9661909	chr1:206714818	C/T	cg19452316	chr1:206680966	RASSF5	0.59	4.63	0.43	1.15e-5	Neurofibrillary tangles;
THYM	cis	rs7404928	0.557	rs11074587	chr16:23914703	G/C	cg26685404	chr16:23957272	PRKCB	-0.56	-6.14	-0.53	1.9e-8	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg11861562	chr11:117069780	TAGLN	0.32	4.62	0.43	1.21e-5	Blood protein levels;
THYM	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg01324343	chr3:183735012	ABCC5	0.63	8.78	0.67	6.53e-14	Anterior chamber depth;
THYM	cis	rs611744	0.967	rs612265	chr8:109188650	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs6957923	0.659	rs10280508	chr7:23584058	A/G	cg20265043	chr7:23510089	IGF2BP3	0.48	5.24	0.47	9.74e-7	Height;
THYM	cis	rs8073060	0.963	rs11080353	chr17:33871281	C/T	cg24895173	chr17:33825374	SLFN12L	0.62	5.09	0.46	1.78e-6	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.81	-6.74	-0.57	1.21e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg21775007	chr8:11205619	TDH	0.63	5.08	0.46	1.86e-6	Retinal vascular caliber;
THYM	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg22508957	chr16:3507546	NAT15	0.49	5.16	0.47	1.33e-6	Body mass index (adult);
THYM	cis	rs3741151	0.686	rs11828904	chr11:73139116	T/C	cg17517138	chr11:73019481	ARHGEF17	0.79	4.86	0.45	4.54e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg01819863	chr10:32635814	EPC1	1.04	6.64	0.56	1.9e-9	Sexual dysfunction (female);
THYM	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg10047753	chr17:41438598	NA	1.18	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs6430585	0.528	rs79826902	chr2:136670419	G/A	cg04750100	chr2:136595281	LCT	0.56	4.96	0.45	3.03e-6	Corneal structure;
THYM	cis	rs155076	1.000	rs567166	chr13:21837519	T/C	cg14456004	chr13:21872349	NA	-1.22	-9.62	-0.7	1.06e-15	White matter hyperintensity burden;
THYM	cis	rs34638657	0.872	rs2967352	chr16:82196676	T/C	cg09894383	chr16:82067445	HSD17B2	-0.54	-5.46	-0.49	3.8e-7	Lung adenocarcinoma;
THYM	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg03433033	chr1:76189801	ACADM	-0.77	-10.32	-0.73	3.49e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1062746	0.777	rs34400756	chr16:87372078	A/G	cg27119004	chr16:87376851	FBXO31	0.52	5.02	0.46	2.45e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs9560113	0.922	rs4773377	chr13:112174152	G/C	cg10483660	chr13:112241077	NA	0.53	4.76	0.44	6.81e-6	Menarche (age at onset);
THYM	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg06784218	chr1:46089804	CCDC17	-0.29	-4.54	-0.42	1.65e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg16205897	chr5:131564050	P4HA2	-0.49	-4.51	-0.42	1.87e-5	Blood metabolite levels;
THYM	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg25817165	chr18:72167213	CNDP2	-0.95	-7.9	-0.63	4.91e-12	Refractive error;
THYM	cis	rs4455778	0.580	rs4304291	chr7:49116983	T/C	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg23161317	chr6:28129485	ZNF389	1.0	7.58	0.61	2.29e-11	Parkinson's disease;
THYM	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs921968	0.541	rs642520	chr2:219423605	A/G	cg02176678	chr2:219576539	TTLL4	-0.71	-6.9	-0.58	5.73e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2439831	0.867	rs2255440	chr15:43830467	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	6.36	0.55	6.96e-9	Lung cancer in ever smokers;
THYM	cis	rs17407555	1.000	rs73224437	chr4:10329825	C/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-4.68	-0.43	9.67e-6	Schizophrenia (age at onset);
THYM	cis	rs4919087	0.926	rs7072078	chr10:99026509	G/A	cg19453742	chr10:98862320	SLIT1	-0.61	-4.5	-0.42	1.96e-5	Monocyte count;
THYM	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg19628046	chr18:33552617	C18orf21	0.77	5.47	0.49	3.68e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs10214930	1.000	rs17155876	chr7:27851055	A/G	cg04422003	chr7:28448295	CREB5	-0.61	-4.58	-0.43	1.41e-5	Hypospadias;
THYM	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs1018836	0.923	rs9693182	chr8:91621876	T/C	cg16814680	chr8:91681699	NA	-0.85	-7.17	-0.59	1.59e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs2273669	0.667	rs78550764	chr6:109312239	C/T	cg17117243	chr6:109341365	SESN1	-0.9	-5.38	-0.48	5.45e-7	Prostate cancer;
THYM	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.55	-0.73	1.12e-17	Primary sclerosing cholangitis;
THYM	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg13319975	chr6:146136371	FBXO30	0.64	5.16	0.47	1.37e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1878931	0.582	rs27239	chr16:3442140	T/C	cg22508957	chr16:3507546	NAT15	0.49	5.16	0.47	1.35e-6	Body mass index (adult);
THYM	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-5.7	-0.5	1.34e-7	Extrinsic epigenetic age acceleration;
THYM	cis	rs8070740	0.947	rs3809842	chr17:5329199	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.67	5.26	0.47	8.92e-7	Menopause (age at onset);
THYM	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg16342193	chr10:102329863	NA	-0.6	-6.27	-0.54	1.08e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs116095464	0.558	rs6962	chr5:256509	G/A	cg22857025	chr5:266934	NA	-1.46	-9.39	-0.69	3.3e-15	Breast cancer;
THYM	cis	rs6723226	0.842	rs2754522	chr2:32801257	C/G	cg02381751	chr2:32503542	YIPF4	0.7	5.83	0.51	7.69e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1075232	0.649	rs66816272	chr15:32238389	T/C	cg01030201	chr15:31746330	NA	-0.96	-4.5	-0.42	1.9e-5	Survival in colorectal cancer (non-distant metastatic);
THYM	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs1129187	0.748	rs9471968	chr6:42905235	A/G	cg09436375	chr6:42928200	GNMT	-0.47	-6.22	-0.54	1.31e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs4919694	1.000	rs7100592	chr10:104769098	T/G	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg04654363	chr8:8581213	NA	-0.48	-4.62	-0.43	1.22e-5	Obesity-related traits;
THYM	cis	rs1456522	0.500	rs1526070	chr2:199783596	C/T	ch.2.199792288R	chr2:200084043	NA	0.6	4.54	0.42	1.63e-5	Menarche (age at onset);
THYM	cis	rs929596	0.785	rs34352510	chr2:234650562	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.95	-7.72	-0.62	1.17e-11	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg18681998	chr4:17616180	MED28	0.91	8.59	0.66	1.66e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.36	0.48	5.75e-7	Height;
THYM	cis	rs7078219	1.000	rs61872688	chr10:101273546	G/A	cg23904955	chr10:101282759	NA	-0.44	-5.25	-0.47	9.32e-7	Dental caries;
THYM	cis	rs10779751	0.879	rs7543400	chr1:11283964	C/G	cg08854313	chr1:11322531	MTOR	1.01	9.78	0.71	4.97e-16	Body mass index;
THYM	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg27490568	chr2:178487706	NA	0.62	5.81	0.51	8.38e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	6.09	0.53	2.42e-8	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg13114125	chr14:105738426	BRF1	-0.73	-5.75	-0.51	1.09e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs3771570	1.000	rs1056801	chr2:242292307	T/C	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg12165864	chr7:66369176	NA	0.67	5.26	0.47	8.99e-7	Aortic root size;
THYM	cis	rs710216	0.843	rs710220	chr1:43415346	G/T	cg16738646	chr1:43409193	SLC2A1	-0.54	-4.83	-0.44	5.22e-6	Red cell distribution width;
THYM	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg23743428	chr13:21893420	NA	-0.69	-6.27	-0.54	1.08e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs2456568	0.771	rs8181530	chr11:93638678	G/A	cg17347335	chr11:93583973	C11orf90	-0.48	-4.58	-0.43	1.39e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs208520	0.802	rs208516	chr6:66946119	T/C	cg07460842	chr6:66804631	NA	-0.85	-5.46	-0.49	3.87e-7	Exhaled nitric oxide output;
THYM	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg05717871	chr11:638507	DRD4	-0.69	-6.03	-0.53	3.1e-8	Systemic lupus erythematosus;
THYM	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg10760299	chr15:45669010	GATM	0.86	6.61	0.56	2.25e-9	Homoarginine levels;
THYM	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg26384229	chr12:38710491	ALG10B	-0.89	-9.05	-0.68	1.77e-14	Heart rate;
THYM	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.95	0.71	2.08e-16	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg00071950	chr4:10020882	SLC2A9	0.77	7.71	0.62	1.24e-11	Bone mineral density;
THYM	cis	rs13082711	0.871	rs73046194	chr3:27454558	C/T	cg02860705	chr3:27208620	NA	0.69	4.99	0.46	2.75e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs747782	0.527	rs76142260	chr11:48331068	T/C	cg24672777	chr11:48374446	OR4C45	-1.05	-5.38	-0.48	5.43e-7	Intraocular pressure;
THYM	cis	rs12950390	1.000	rs12950390	chr17:45830948	A/G	cg24803719	chr17:45855879	NA	-0.61	-5.61	-0.5	2e-7	IgG glycosylation;
THYM	cis	rs113835537	0.529	rs2298806	chr11:66282095	G/A	cg24851651	chr11:66362959	CCS	0.7	4.89	0.45	4.04e-6	Airway imaging phenotypes;
THYM	cis	rs3008870	1.000	rs2815370	chr1:67503727	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-7.53	-0.61	2.9e-11	Lymphocyte percentage of white cells;
THYM	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg12310025	chr6:25882481	NA	-0.76	-6.28	-0.54	9.94e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6500395	0.926	rs1039344	chr16:48577569	A/G	cg04672837	chr16:48644449	N4BP1	0.47	4.46	0.42	2.23e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs912057	0.833	rs1294418	chr6:6742185	A/G	cg06612196	chr6:6737390	NA	0.69	9.83	0.71	3.75e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs2777491	0.789	rs316617	chr15:41795900	C/T	cg18705301	chr15:41695430	NDUFAF1	0.99	10.82	0.74	2.9e-18	Ulcerative colitis;
THYM	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg27446573	chr6:127587934	RNF146	0.79	6.53	0.56	3.28e-9	Breast cancer;
THYM	cis	rs12310956	0.510	rs1386936	chr12:33875369	G/A	cg10856724	chr12:34555212	NA	-0.64	-5.78	-0.51	9.56e-8	Morning vs. evening chronotype;
THYM	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs9906944	0.933	rs12945020	chr17:47082775	G/A	cg09029085	chr17:47094198	IGF2BP1	0.47	6.35	0.55	7.51e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg22105103	chr4:187893119	NA	0.95	10.29	0.73	3.97e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg12599982	chr1:44399894	ARTN	0.56	4.66	0.43	1.02e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.51	5.15	0.47	1.39e-6	Schizophrenia;
THYM	cis	rs7084402	0.967	rs2393448	chr10:60333260	T/G	cg09696939	chr10:60272079	BICC1	-0.46	-5.63	-0.5	1.85e-7	Refractive error;
THYM	cis	rs208520	0.690	rs207740	chr6:66764132	T/G	cg07460842	chr6:66804631	NA	1.11	8.25	0.65	8.78e-13	Exhaled nitric oxide output;
THYM	cis	rs10129255	0.500	rs2105989	chr14:107138216	C/T	cg16555411	chr14:107062160	NA	-0.37	-4.52	-0.42	1.81e-5	Kawasaki disease;
THYM	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg20290983	chr6:43655470	MRPS18A	1.43	15.91	0.85	1.54e-28	IgG glycosylation;
THYM	cis	rs12474201	0.894	rs34401107	chr2:46972768	A/C	cg09399716	chr2:46890238	NA	-0.54	-4.94	-0.45	3.35e-6	Height;
THYM	cis	rs4808199	0.947	rs754255	chr19:19578890	T/C	cg03709012	chr19:19516395	GATAD2A	1.19	7.25	0.6	1.12e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg12373951	chr3:133503437	NA	-0.49	-4.89	-0.45	4.12e-6	Iron status biomarkers;
THYM	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg02869364	chr7:1081709	C7orf50	-0.57	-4.55	-0.42	1.58e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7781977	0.554	rs7789913	chr7:50352695	C/T	cg01139861	chr7:50343298	IKZF1	0.55	5.15	0.47	1.39e-6	IgG glycosylation;
THYM	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06850241	chr22:41845214	NA	-0.6	-5.37	-0.48	5.63e-7	Vitiligo;
THYM	cis	rs4731207	0.591	rs1471571	chr7:124650874	C/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs2276314	0.802	rs9963714	chr18:33592056	T/C	cg05985134	chr18:33552581	C18orf21	0.69	4.88	0.45	4.22e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg04944784	chr2:26401820	FAM59B	-1.08	-8.57	-0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs12466960	0.846	rs4665411	chr2:28582193	G/A	cg11535839	chr2:28582676	NA	0.59	4.84	0.44	5.07e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.81	6.04	0.53	3e-8	Cognitive test performance;
THYM	cis	rs7267979	1.000	rs453329	chr20:25440593	G/A	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6570726	0.935	rs401888	chr6:145831535	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12950390	0.512	rs11655306	chr17:45858744	C/T	cg03474202	chr17:45855739	NA	-0.71	-4.78	-0.44	6.29e-6	IgG glycosylation;
THYM	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.37	-0.48	5.53e-7	Monocyte percentage of white cells;
THYM	cis	rs7119	0.651	rs12917431	chr15:77850184	C/G	cg27398640	chr15:77910606	LINGO1	-0.57	-5.71	-0.51	1.31e-7	Type 2 diabetes;
THYM	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06873352	chr17:61820015	STRADA	0.56	5.66	0.5	1.63e-7	Height;
THYM	cis	rs7818345	0.534	rs34221121	chr8:19319625	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.52	4.64	0.43	1.1e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg08885076	chr2:99613938	TSGA10	0.52	5.04	0.46	2.24e-6	Chronic sinus infection;
THYM	cis	rs2282300	0.739	rs1222210	chr11:30362125	A/G	cg25418670	chr11:30344373	C11orf46	0.78	6.29	0.54	9.75e-9	Morning vs. evening chronotype;
THYM	cis	rs2455799	0.634	rs11128764	chr3:15902836	G/C	cg16303742	chr3:15540471	COLQ	-0.57	-5.76	-0.51	1.04e-7	Mean platelet volume;
THYM	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.34	-0.48	6.33e-7	Monocyte percentage of white cells;
THYM	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg06238570	chr21:40685208	BRWD1	0.89	6.43	0.55	5.03e-9	Cognitive function;
THYM	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06850241	chr22:41845214	NA	0.57	5.09	0.46	1.82e-6	Vitiligo;
THYM	cis	rs208520	0.874	rs208518	chr6:66948501	C/G	cg07460842	chr6:66804631	NA	0.85	5.46	0.49	3.87e-7	Exhaled nitric oxide output;
THYM	cis	rs11690935	0.885	rs6725388	chr2:172730015	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.69	-4.78	-0.44	6.39e-6	Schizophrenia;
THYM	cis	rs7172809	0.643	rs16953967	chr15:77836521	C/T	cg22256960	chr15:77711686	NA	-0.77	-5.68	-0.5	1.49e-7	Glucose homeostasis traits;
THYM	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg07362569	chr17:61921086	SMARCD2	-0.64	-6.06	-0.53	2.79e-8	Prudent dietary pattern;
THYM	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg14008862	chr17:28927542	LRRC37B2	0.97	5.19	0.47	1.22e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg07371521	chr5:154026371	NA	0.57	5.45	0.49	3.96e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs4803468	0.967	rs16975238	chr19:41944985	T/A	cg09537434	chr19:41945824	ATP5SL	1.1	10.47	0.73	1.63e-17	Height;
THYM	cis	rs1729951	0.575	rs168635	chr3:136699078	A/G	cg21827317	chr3:136751795	NA	0.74	6.68	0.57	1.58e-9	Neuroticism;
THYM	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg23978390	chr7:1156363	C7orf50	0.61	4.7	0.43	8.62e-6	Longevity;Endometriosis;
THYM	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg11764359	chr7:65958608	NA	0.64	4.85	0.45	4.82e-6	Aortic root size;
THYM	cis	rs909002	0.749	rs10914462	chr1:32125943	A/G	cg13919466	chr1:32135498	COL16A1	0.52	4.86	0.45	4.65e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg02018176	chr4:1364513	KIAA1530	0.7	6.36	0.55	7.08e-9	Longevity;
THYM	cis	rs1445130	0.892	rs10495689	chr2:18832132	C/T	cg21927971	chr2:17837235	VSNL1	0.74	4.47	0.42	2.14e-5	Bulimia nervosa;
THYM	cis	rs11645898	0.935	rs17603936	chr16:72169002	C/A	cg14768367	chr16:72042858	DHODH	-0.77	-5.59	-0.5	2.21e-7	Blood protein levels;
THYM	cis	rs2124499	1.000	rs2124499	chr3:123093541	G/C	cg04890266	chr3:123102914	ADCY5	0.65	5.33	0.48	6.48e-7	Body mass index;
THYM	trans	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg10856724	chr12:34555212	NA	-1.02	-9.32	-0.69	4.7e-15	Morning vs. evening chronotype;
THYM	cis	rs273218	1.000	rs273218	chr5:53380555	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.93	8.07	0.64	2.18e-12	Migraine;
THYM	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	7.82	0.63	7.06e-12	Smoking behavior;
THYM	cis	rs7100689	0.516	rs10887711	chr10:82034842	A/G	cg01528321	chr10:82214614	TSPAN14	0.81	6.3	0.54	9.35e-9	Post bronchodilator FEV1;
THYM	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg26597838	chr10:835615	NA	0.81	4.94	0.45	3.34e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs854765	0.624	rs7359509	chr17:17741875	A/G	cg16928487	chr17:17741425	SREBF1	0.55	5.12	0.47	1.59e-6	Total body bone mineral density;
THYM	cis	rs12142240	0.698	rs17361915	chr1:46847321	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs17401966	1.000	rs17411502	chr1:10431158	T/C	cg19773385	chr1:10388646	KIF1B	-0.65	-4.72	-0.44	8.03e-6	Hepatocellular carcinoma;
THYM	cis	rs9970807	0.792	rs72664353	chr1:57001898	C/T	cg11959316	chr1:57001742	PPAP2B	0.81	5.91	0.52	5.4e-8	Myocardial infarction;Coronary artery disease;
THYM	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg05738196	chr6:26577821	NA	0.86	8.72	0.67	9.13e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.02	-9.57	-0.7	1.39e-15	Primary sclerosing cholangitis;
THYM	cis	rs55728055	0.661	rs16989620	chr22:31839244	G/A	cg10537193	chr22:32026975	PISD	-0.91	-5.25	-0.47	9.24e-7	Age-related hearing impairment;
THYM	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	4.93	0.45	3.5e-6	Diabetic retinopathy;
THYM	cis	rs8063160	0.808	rs45610233	chr16:90048395	C/T	cg07984980	chr16:89898383	SPIRE2	1.31	4.67	0.43	9.92e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs654128	0.640	rs2184343	chr6:117237584	T/G	cg12892004	chr6:117198278	RFX6	-0.73	-5.5	-0.49	3.18e-7	Telomere length;
THYM	cis	rs35123781	0.654	rs356486	chr5:139085103	C/G	cg10513866	chr5:139070639	NA	-0.51	-4.6	-0.43	1.33e-5	Schizophrenia;
THYM	cis	rs17443541	0.507	rs2122535	chr2:200456289	G/A	cg01795955	chr2:200468626	NA	-0.72	-5.0	-0.46	2.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8051149	0.576	rs731710	chr16:87884547	A/G	cg01690119	chr16:88511822	NA	-0.37	-4.76	-0.44	7.01e-6	Blood metabolite levels;
THYM	cis	rs1421898	0.625	rs17624884	chr5:157974138	T/C	cg06698293	chr5:158690540	UBLCP1	-0.97	-4.6	-0.43	1.28e-5	Inflammatory skin disease;
THYM	cis	rs524023	0.874	rs518053	chr11:64456099	C/T	cg19131476	chr11:64387923	NRXN2	-0.35	-4.89	-0.45	4.18e-6	Urate levels in obese individuals;
THYM	cis	rs7578361	0.959	rs6435556	chr2:150418840	A/G	cg17961725	chr2:150454027	NA	0.77	6.18	0.54	1.6e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg02493740	chr2:85810744	VAMP5	-0.64	-5.05	-0.46	2.12e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg23711669	chr6:146136114	FBXO30	0.85	7.9	0.63	4.99e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg24675056	chr1:15929824	NA	0.73	5.79	0.51	9.09e-8	Systolic blood pressure;
THYM	cis	rs7178572	0.568	rs11858641	chr15:77585820	C/T	cg22256960	chr15:77711686	NA	-1.03	-8.45	-0.66	3.3e-13	Type 2 diabetes;
THYM	cis	rs4252134	0.551	rs6926947	chr6:161272676	T/C	cg23738424	chr6:160515210	LOC729603;IGF2R	-0.65	-4.65	-0.43	1.05e-5	Giant cell arteritis;
THYM	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg03433033	chr1:76189801	ACADM	0.79	11.21	0.75	4.52e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs57994353	0.508	rs7874956	chr9:139336813	T/G	cg14115884	chr9:139300582	SDCCAG3	0.7	6.28	0.54	1.01e-8	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg17554472	chr22:41940697	POLR3H	0.68	4.67	0.43	9.89e-6	Vitiligo;
THYM	cis	rs4638749	0.651	rs13385677	chr2:108826152	T/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg23352942	chr3:46931381	PTH1R	-0.76	-7.41	-0.61	5.18e-11	Birth weight;
THYM	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs11186	0.556	rs72906398	chr2:189967702	G/A	cg11041835	chr2:189156425	GULP1	0.8	4.58	0.43	1.41e-5	Parkinson's disease;
THYM	cis	rs988913	0.706	rs7749072	chr6:54951918	A/G	cg18532076	chr6:54711417	FAM83B	0.49	4.62	0.43	1.18e-5	Menarche (age at onset);
THYM	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg22907277	chr7:1156413	C7orf50	0.9	8.35	0.65	5.54e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs270601	0.710	rs371709	chr5:131583240	A/G	cg12564285	chr5:131593104	PDLIM4	0.55	5.8	0.51	8.54e-8	Acylcarnitine levels;
THYM	cis	rs12714314	0.834	rs4241293	chr2:1953555	A/G	cg05313794	chr2:1845466	MYT1L	-0.51	-4.55	-0.42	1.58e-5	Type 2 diabetes (age of onset);
THYM	cis	rs4792901	0.918	rs12603189	chr17:41618677	C/G	cg21940313	chr17:41620911	ETV4	0.5	5.02	0.46	2.41e-6	Dupuytren's disease;
THYM	cis	rs6840360	0.642	rs2709817	chr4:152382050	A/G	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg08439880	chr3:133502540	NA	0.71	5.59	0.5	2.18e-7	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs2133450	0.526	rs17047058	chr3:7343176	T/C	cg19930620	chr3:7340148	GRM7	-0.5	-5.46	-0.49	3.72e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs7567389	0.504	rs13030463	chr2:128188871	G/A	cg09760422	chr2:128146352	NA	0.4	4.74	0.44	7.47e-6	Self-rated health;
THYM	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-4.96	-0.45	3.03e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.92	-10.5	-0.73	1.4e-17	Prudent dietary pattern;
THYM	cis	rs1642645	0.831	rs1327711	chr1:42495949	A/G	cg22816091	chr1:42611670	NA	0.6	5.33	0.48	6.47e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.68	4.68	0.43	9.7e-6	Body mass index (adult);
THYM	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg08736216	chr1:53307985	ZYG11A	-0.58	-5.29	-0.48	7.85e-7	Monocyte count;
THYM	cis	rs1448094	0.648	rs10863093	chr12:86285792	T/G	cg02569458	chr12:86230093	RASSF9	0.52	4.71	0.44	8.37e-6	Major depressive disorder;
THYM	cis	rs887829	0.570	rs6736508	chr2:234595747	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-6.64	-0.56	1.98e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs6763768	0.606	rs3732834	chr3:53324915	A/G	cg16894138	chr3:53270350	TKT	-0.74	-5.58	-0.5	2.31e-7	Bacterial meningitis;
THYM	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg23815491	chr16:72088622	HP	0.68	5.23	0.47	1.01e-6	Fibrinogen levels;
THYM	cis	rs4845875	0.563	rs10864540	chr1:11838099	A/G	cg14194983	chr1:11908298	NPPA	0.54	4.97	0.45	2.93e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13012494	chr21:47604986	C21orf56	-0.75	-5.19	-0.47	1.18e-6	Testicular germ cell tumor;
THYM	cis	rs73416724	0.858	rs4466248	chr6:43279652	T/C	cg26312998	chr6:43337775	ZNF318	-0.99	-4.93	-0.45	3.47e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7106204	1.000	rs6484025	chr11:24214514	C/G	ch.11.24196551F	chr11:24239977	NA	0.84	5.28	0.48	8.05e-7	Response to Homoharringtonine (cytotoxicity);
THYM	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg10053473	chr17:62856997	LRRC37A3	-0.81	-6.93	-0.58	4.99e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7941600	0.581	rs11042273	chr11:9322132	T/G	cg21110646	chr11:9336536	TMEM41B	1.31	7.47	0.61	3.78e-11	Coronary artery disease;
THYM	cis	rs17255340	0.520	rs1170504	chr6:83993569	A/C	cg21688264	chr6:84418724	SNAP91	0.66	4.46	0.42	2.22e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg04362960	chr10:104952993	NT5C2	0.63	4.47	0.42	2.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs28595532	0.920	rs115706007	chr4:119733638	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.99	9.66	0.7	8.84e-16	Colorectal cancer;
THYM	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg04842962	chr6:43655489	MRPS18A	1.24	12.32	0.78	2.14e-21	IgG glycosylation;
THYM	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs7267979	1.000	rs6050544	chr20:25320228	T/A	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg13012494	chr21:47604986	C21orf56	0.8	5.26	0.48	8.81e-7	Testicular germ cell tumor;
THYM	cis	rs750460	0.899	rs8023330	chr15:74220599	A/G	cg01349856	chr15:74220517	LOXL1	-0.61	-4.51	-0.42	1.83e-5	Height;
THYM	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg00814883	chr7:100076585	TSC22D4	-0.96	-6.41	-0.55	5.64e-9	Platelet count;
THYM	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg16342193	chr10:102329863	NA	-0.51	-5.14	-0.47	1.48e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9880211	0.679	rs9818740	chr3:135939586	G/A	cg21827317	chr3:136751795	NA	-0.68	-4.76	-0.44	7e-6	Body mass index;Height;
THYM	cis	rs2070677	0.935	rs12261048	chr10:135407923	A/G	cg20169779	chr10:135381914	SYCE1	-0.76	-5.95	-0.52	4.55e-8	Gout;
THYM	cis	rs7586879	1.000	rs6736711	chr2:25116456	C/T	cg15423357	chr2:25149977	NA	0.56	5.49	0.49	3.41e-7	Body mass index;
THYM	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg22105103	chr4:187893119	NA	0.95	10.14	0.72	8.41e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11186	0.591	rs72906361	chr2:189962558	T/G	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg12573674	chr2:1569213	NA	-1.15	-8.0	-0.63	3.02e-12	IgG glycosylation;
THYM	cis	rs988913	0.914	rs9396006	chr6:54787888	G/A	cg04690482	chr6:54711388	FAM83B	0.5	5.29	0.48	7.88e-7	Menarche (age at onset);
THYM	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.08	7.68	0.62	1.43e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.01	8.34	0.65	5.62e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg18512352	chr11:47633146	NA	-0.49	-5.93	-0.52	4.9e-8	Subjective well-being;
THYM	cis	rs6674176	1.000	rs6674176	chr1:44379957	G/A	cg12908607	chr1:44402522	ARTN	-0.61	-4.87	-0.45	4.49e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg26441486	chr22:50317300	CRELD2	0.44	6.33	0.54	8.23e-9	Schizophrenia;
THYM	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg05973401	chr12:123451056	ABCB9	0.7	4.6	0.43	1.28e-5	Neutrophil percentage of white cells;
THYM	cis	rs4509693	1.000	rs6584392	chr10:102497166	G/A	cg24127310	chr10:102502104	NA	1.3	10.12	0.72	9.09e-17	Alzheimer's disease;
THYM	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg07511668	chr11:68622177	NA	0.44	4.63	0.43	1.16e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4148689	1.000	rs6957317	chr7:117147205	T/C	cg17204129	chr7:117119601	CFTR	-0.65	-5.08	-0.46	1.87e-6	Gout;
THYM	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.21	8.51	0.66	2.47e-13	Cognitive test performance;
THYM	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg07061783	chr6:25882402	NA	-0.6	-4.6	-0.43	1.31e-5	Height;
THYM	cis	rs3791556	0.504	rs1001285	chr2:240107814	A/G	cg03475776	chr2:240114298	HDAC4	0.51	5.23	0.47	1.01e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.28	4.55	0.42	1.56e-5	Obesity-related traits;
THYM	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg09307838	chr4:120376055	NA	0.78	5.64	0.5	1.76e-7	Corneal astigmatism;
THYM	cis	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg20978766	chr1:197704881	DENND1B	-0.71	-4.53	-0.42	1.69e-5	Depressive symptoms;
THYM	cis	rs7119	0.931	rs62009087	chr15:77833064	C/T	cg27398640	chr15:77910606	LINGO1	-0.53	-5.06	-0.46	2.04e-6	Type 2 diabetes;
THYM	cis	rs4924935	0.851	rs17743944	chr17:18809268	A/G	cg26378065	chr17:18585709	ZNF286B	-0.71	-4.96	-0.45	3.1e-6	Pancreatic cancer;
THYM	cis	rs8078723	0.690	rs56326707	chr17:38130139	C/T	cg17467752	chr17:38218738	THRA	0.73	5.48	0.49	3.47e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg13390004	chr1:15929781	NA	0.59	4.57	0.42	1.47e-5	Systolic blood pressure;
THYM	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg15445000	chr17:37608096	MED1	-0.4	-4.64	-0.43	1.13e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg13289132	chr10:30722225	MAP3K8	-0.57	-4.82	-0.44	5.47e-6	Inflammatory bowel disease;
THYM	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg16342193	chr10:102329863	NA	-0.53	-5.45	-0.49	4.01e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg06221963	chr1:154839813	KCNN3	-0.73	-8.77	-0.67	7.12e-14	Prostate cancer;
THYM	cis	rs7166081	0.688	rs4776361	chr15:67762056	G/A	cg24579218	chr15:68104479	NA	-0.73	-7.01	-0.58	3.44e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	trans	rs8002861	0.664	rs9525873	chr13:44482204	T/C	cg17145862	chr1:211918768	LPGAT1	0.92	8.98	0.68	2.56e-14	Leprosy;
THYM	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg22683308	chr4:1340831	KIAA1530	-0.61	-4.93	-0.45	3.54e-6	Longevity;
THYM	cis	rs10886503	1.000	rs10886503	chr10:121255749	T/C	cg13260278	chr10:121265587	RGS10	-0.73	-6.25	-0.54	1.15e-8	Obstetric antiphospholipid syndrome;
THYM	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg18230493	chr5:56204884	C5orf35	0.64	4.8	0.44	5.87e-6	Initial pursuit acceleration;
THYM	cis	rs8067545	0.611	rs9893832	chr17:20038273	A/G	cg13482628	chr17:19912719	NA	0.55	4.68	0.43	9.41e-6	Schizophrenia;
THYM	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg04398451	chr17:18023971	MYO15A	0.93	10.28	0.73	4.22e-17	Total body bone mineral density;
THYM	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg11245990	chr11:68621969	NA	0.56	7.23	0.6	1.2e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg16006841	chr5:176797999	RGS14	-0.53	-6.9	-0.58	5.84e-10	Urinary electrolytes (magnesium/calcium ratio);
THYM	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.79	6.34	0.55	7.85e-9	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg23711669	chr6:146136114	FBXO30	0.9	8.81	0.67	5.83e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17253792	0.822	rs75232282	chr14:56067290	G/C	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg08999081	chr20:33150536	PIGU	-0.78	-6.98	-0.58	3.99e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs7508	0.511	rs371922	chr8:17900003	T/C	cg01800426	chr8:17659068	MTUS1	-0.69	-4.87	-0.45	4.36e-6	Atrial fibrillation;
THYM	cis	rs10949834	0.504	rs12539781	chr7:73568425	C/T	cg07137043	chr7:73588983	EIF4H	-0.75	-4.91	-0.45	3.75e-6	Verbal memory performance (residualized delayed recall change);
THYM	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17407555	0.955	rs56099802	chr4:10179379	C/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-5.15	-0.47	1.42e-6	Schizophrenia (age at onset);
THYM	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg02527881	chr3:46936655	PTH1R	-0.6	-6.01	-0.52	3.48e-8	Colorectal cancer;
THYM	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-4.93	-0.45	3.51e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg20503657	chr10:835505	NA	1.14	8.1	0.64	1.82e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.05	0.53	2.89e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs924712	0.645	rs239854	chr6:54758628	G/A	cg04690482	chr6:54711388	FAM83B	0.44	5.06	0.46	2.01e-6	Breast cancer;
THYM	cis	rs3733631	1.000	rs1905172	chr4:104636034	C/T	cg24090629	chr4:104641072	TACR3	-0.86	-5.51	-0.49	3.1e-7	Menarche (age at onset);
THYM	cis	rs6496667	0.821	rs79731978	chr15:90876013	G/A	cg22089800	chr15:90895588	ZNF774	0.73	4.5	0.42	1.93e-5	Rheumatoid arthritis;
THYM	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg00376283	chr12:123451042	ABCB9	0.72	4.74	0.44	7.46e-6	Neutrophil percentage of white cells;
THYM	cis	rs10779751	0.734	rs910660	chr1:11130643	C/T	cg08854313	chr1:11322531	MTOR	-0.86	-7.01	-0.58	3.51e-10	Body mass index;
THYM	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg11279151	chr3:101281821	RG9MTD1	1.05	8.75	0.67	7.65e-14	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg07606381	chr6:8435919	SLC35B3	0.63	4.64	0.43	1.11e-5	Motion sickness;
THYM	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg08807101	chr21:30365312	RNF160	0.8	6.25	0.54	1.15e-8	Dental caries;
THYM	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg22974920	chr21:40686053	BRWD1	-0.57	-4.48	-0.42	2.04e-5	Cognitive function;
THYM	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg02734326	chr4:10020555	SLC2A9	0.76	6.89	0.58	6.16e-10	Bone mineral density;
THYM	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg03115019	chr17:80708279	FN3K	0.68	4.79	0.44	6.06e-6	Glycated hemoglobin levels;
THYM	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg12826209	chr6:26865740	GUSBL1	0.94	5.02	0.46	2.37e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11644478	chr21:40555479	PSMG1	-0.56	-4.69	-0.43	9.07e-6	Menarche (age at onset);
THYM	cis	rs977987	0.771	rs12929673	chr16:75470295	C/T	cg03315344	chr16:75512273	CHST6	0.73	5.88	0.52	6.15e-8	Dupuytren's disease;
THYM	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg06238570	chr21:40685208	BRWD1	-0.9	-6.54	-0.56	3.06e-9	Cognitive function;
THYM	cis	rs1691799	0.899	rs903587	chr12:66746061	C/A	cg16791601	chr12:66731901	HELB	-0.74	-7.18	-0.59	1.55e-10	White blood cell count (basophil);
THYM	trans	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs4460079	0.531	rs13140683	chr4:114844121	A/G	cg02060584	chr4:113970739	ANK2	-0.59	-4.93	-0.45	3.48e-6	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs13242816	0.881	rs55930206	chr7:116172850	C/T	cg16553024	chr7:116138462	CAV2	-1.25	-5.56	-0.5	2.5e-7	P wave duration;
THYM	cis	rs1823778	0.609	rs8085823	chr18:67646939	C/T	cg12929678	chr18:67624393	CD226	1.52	5.5	0.49	3.22e-7	Mean platelet volume;
THYM	cis	rs9549260	0.567	rs7332730	chr13:41265979	C/A	cg21288729	chr13:41239152	FOXO1	0.67	5.0	0.46	2.59e-6	Red blood cell count;
THYM	cis	rs2806561	0.765	rs681395	chr1:23500314	G/A	cg19743168	chr1:23544995	NA	0.57	5.85	0.51	6.96e-8	Height;
THYM	cis	rs2227564	0.649	rs2243610	chr10:75601653	A/T	cg00564723	chr10:75632066	CAMK2G	-0.54	-5.24	-0.47	9.62e-7	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg18904891	chr8:8559673	CLDN23	0.67	4.97	0.45	3e-6	Obesity-related traits;
THYM	cis	rs4907240	0.961	rs60959055	chr2:97313450	C/G	cg01950434	chr2:97203154	ARID5A	-0.59	-4.89	-0.45	4.09e-6	Event-related brain oscillations;
THYM	cis	rs7762018	0.607	rs77392231	chr6:170057634	G/A	cg19338460	chr6:170058176	WDR27	-1.04	-6.25	-0.54	1.18e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs9595908	1.000	rs9591134	chr13:33148216	T/A	cg12383807	chr13:33924137	NA	-0.55	-4.87	-0.45	4.38e-6	Body mass index;
THYM	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg06981504	chr1:1234844	ACAP3	0.54	4.91	0.45	3.85e-6	Body mass index;
THYM	cis	rs28785552	0.554	rs8112079	chr19:53216544	T/A	cg10871876	chr19:53194124	ZNF83	0.71	5.51	0.49	3.02e-7	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg00074818	chr8:8560427	CLDN23	0.53	4.76	0.44	6.82e-6	Obesity-related traits;
THYM	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg10515332	chr4:99064459	C4orf37	0.71	5.67	0.5	1.51e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.720	rs4896837	chr6:146014168	C/T	cg23711669	chr6:146136114	FBXO30	-0.97	-10.39	-0.73	2.4e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg00339695	chr16:24857497	SLC5A11	0.71	6.45	0.55	4.71e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs2133450	0.745	rs7639597	chr3:7364047	T/A	cg19930620	chr3:7340148	GRM7	-0.5	-4.7	-0.43	8.83e-6	Early response to risperidone in schizophrenia;
THYM	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7762018	0.505	rs79843499	chr6:170068420	A/G	cg19338460	chr6:170058176	WDR27	-1.04	-6.19	-0.54	1.5e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs6593803	0.622	rs11585427	chr1:147168846	T/G	cg06627043	chr1:147838662	NA	0.51	4.71	0.44	8.3e-6	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
THYM	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg06627557	chr7:32535165	LSM5;AVL9	1.04	9.96	0.71	1.99e-16	Cognitive ability;
THYM	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg08564027	chr20:61660810	NA	0.94	9.88	0.71	2.92e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2562456	0.720	rs6511250	chr19:21656046	C/T	cg21751540	chr19:21541537	ZNF738	0.68	4.76	0.44	6.92e-6	Pain;
THYM	cis	rs9902453	1.000	rs56280226	chr17:28429575	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.76	0.44	6.86e-6	Coffee consumption (cups per day);
THYM	cis	rs7106204	0.534	rs79475764	chr11:24278384	C/A	ch.11.24196551F	chr11:24239977	NA	0.92	4.75	0.44	7.06e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg03983476	chr2:10830698	NOL10	0.59	5.59	0.5	2.17e-7	Prostate cancer;
THYM	cis	rs2658782	0.756	rs3019205	chr11:93109553	A/G	cg15737290	chr11:93063684	CCDC67	0.9	7.19	0.59	1.49e-10	Pulmonary function decline;
THYM	cis	rs9902453	1.000	rs7212497	chr17:28335949	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg08847533	chr14:75593920	NEK9	0.87	8.78	0.67	6.77e-14	Height;
THYM	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg11077631	chr22:50617003	PANX2	-0.53	-5.95	-0.52	4.37e-8	Obesity-related traits;
THYM	cis	rs1950500	0.550	rs7148384	chr14:24828814	C/T	cg07162820	chr14:24837146	NFATC4	0.56	4.93	0.45	3.55e-6	Height;
THYM	cis	rs10216189	0.967	rs10215480	chr7:5524682	C/T	cg22586569	chr7:5524963	FBXL18	0.58	5.48	0.49	3.44e-7	Relative hand skill in reading disability;
THYM	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg06850241	chr22:41845214	NA	0.53	4.56	0.42	1.54e-5	Vitiligo;
THYM	cis	rs4788570	0.566	rs72795881	chr16:71500229	A/G	cg06353428	chr16:71660113	MARVELD3	-1.04	-5.01	-0.46	2.5e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg17366294	chr4:99064904	C4orf37	0.58	7.0	0.58	3.58e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2070433	0.539	rs1008548	chr21:47959692	G/A	cg12379764	chr21:47803548	PCNT	0.64	4.68	0.43	9.34e-6	Lymphocyte counts;
THYM	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg00898013	chr13:113819073	PROZ	-1.02	-10.0	-0.72	1.62e-16	Platelet distribution width;
THYM	cis	rs89107	0.576	rs11965985	chr6:118789834	T/C	cg21191810	chr6:118973309	C6orf204	0.5	5.04	0.46	2.25e-6	Cardiac structure and function;
THYM	cis	rs868036	0.681	rs3784718	chr15:68098004	C/T	cg24579218	chr15:68104479	NA	-0.82	-8.85	-0.67	4.77e-14	Restless legs syndrome;
THYM	cis	rs6430585	0.583	rs4988201	chr2:136618507	A/G	cg07169764	chr2:136633963	MCM6	1.24	13.85	0.82	1.58e-24	Corneal structure;
THYM	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	5.87	0.52	6.25e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6430585	0.528	rs309113	chr2:136737460	C/A	cg04750100	chr2:136595281	LCT	0.54	5.46	0.49	3.78e-7	Corneal structure;
THYM	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg23173402	chr1:227635558	NA	0.68	6.07	0.53	2.59e-8	Major depressive disorder;
THYM	cis	rs747334	0.846	rs4933630	chr10:92719339	C/T	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs7103648	1.000	rs10838705	chr11:47424931	G/A	cg20307385	chr11:47447363	PSMC3	0.93	8.66	0.66	1.23e-13	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg21926883	chr2:100939477	LONRF2	-0.68	-6.43	-0.55	5.11e-9	Intelligence (multi-trait analysis);
THYM	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg10150615	chr22:24372951	LOC391322	-1.01	-11.87	-0.77	1.77e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs921665	0.584	rs5019161	chr2:3174761	A/G	cg16434511	chr2:3151078	NA	-0.86	-5.19	-0.47	1.18e-6	World class endurance athleticism;
THYM	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg04414720	chr1:150670196	GOLPH3L	0.62	4.63	0.43	1.15e-5	Tonsillectomy;
THYM	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	5.92	0.52	5.04e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs3824535	0.541	rs3860155	chr9:125984527	C/T	cg01693284	chr9:125437568	OR1L3	-0.61	-4.58	-0.43	1.42e-5	Subjective well-being (multi-trait analysis);
THYM	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs73206853	0.841	rs118053970	chr12:110932820	C/G	cg24010859	chr12:110868153	NA	0.68	4.81	0.44	5.74e-6	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
THYM	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg12826209	chr6:26865740	GUSBL1	-0.79	-5.62	-0.5	1.92e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7731657	0.509	rs11950036	chr5:130350876	T/C	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg26384229	chr12:38710491	ALG10B	-0.72	-5.56	-0.5	2.48e-7	Morning vs. evening chronotype;
THYM	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg03396347	chr1:1875803	NA	0.65	6.59	0.56	2.47e-9	Body mass index;
THYM	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	5.72	0.51	1.23e-7	Platelet count;
THYM	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg04756594	chr16:24857601	SLC5A11	0.75	5.23	0.47	1.01e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg15693483	chr7:1102177	C7orf50	0.41	5.82	0.51	7.95e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11031096	0.678	rs12292724	chr11:4176671	T/A	cg08557956	chr11:4115526	RRM1	-0.51	-4.56	-0.42	1.52e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2070488	0.965	rs13093640	chr3:38487176	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	7.18	0.59	1.57e-10	Electrocardiographic conduction measures;
THYM	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	5.37	0.48	5.69e-7	Obesity-related traits;
THYM	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg26384229	chr12:38710491	ALG10B	-0.72	-5.64	-0.5	1.75e-7	Morning vs. evening chronotype;
THYM	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg02187348	chr16:89574699	SPG7	0.79	6.87	0.58	6.59e-10	Multiple myeloma (IgH translocation);
THYM	cis	rs7843479	0.965	rs11775479	chr8:21859991	C/T	cg17168535	chr8:21777572	XPO7	0.64	4.74	0.44	7.36e-6	Mean corpuscular volume;
THYM	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg00383909	chr3:49044727	WDR6	1.27	7.71	0.62	1.22e-11	Cognitive function;
THYM	cis	rs16944613	0.541	rs4288973	chr15:91093676	G/A	cg26821196	chr15:91095069	CRTC3	0.79	4.57	0.42	1.49e-5	Colorectal cancer;
THYM	cis	rs7513165	0.935	rs7538038	chr1:204161026	C/T	cg04791601	chr1:204159016	NA	-0.4	-5.05	-0.46	2.12e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
THYM	cis	rs2273669	0.588	rs111353760	chr6:109306493	T/G	cg17117243	chr6:109341365	SESN1	-0.84	-4.94	-0.45	3.41e-6	Prostate cancer;
THYM	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.58	4.97	0.45	2.98e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg16049864	chr8:95962084	TP53INP1	-0.72	-6.42	-0.55	5.29e-9	Type 2 diabetes;
THYM	cis	rs7578361	0.959	rs12463479	chr2:150452249	A/G	cg17961725	chr2:150454027	NA	0.75	6.45	0.55	4.58e-9	Acute lymphoblastic leukemia (childhood);
THYM	trans	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg05926928	chr17:57297772	GDPD1	1.26	10.02	0.72	1.5e-16	Opioid sensitivity;
THYM	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.65	4.96	0.45	3.04e-6	Glycated hemoglobin levels;
THYM	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg13447684	chr7:1895903	MAD1L1	0.59	5.03	0.46	2.3e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9361491	0.608	rs9361438	chr6:79479561	C/T	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.88e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg03609598	chr5:56110824	MAP3K1	-0.89	-6.07	-0.53	2.63e-8	Initial pursuit acceleration;
THYM	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg00677455	chr12:58241039	CTDSP2	0.72	4.87	0.45	4.51e-6	Multiple sclerosis;
THYM	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs995000	0.965	rs10889332	chr1:62950858	A/G	cg06896770	chr1:63153194	DOCK7	-0.92	-7.77	-0.62	9.35e-12	Triglyceride levels;
THYM	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg15691649	chr6:25882328	NA	0.68	5.17	0.47	1.31e-6	Blood metabolite levels;
THYM	cis	rs7940866	0.838	rs12790299	chr11:130803634	A/G	cg12179176	chr11:130786555	SNX19	0.67	5.21	0.47	1.09e-6	Schizophrenia;
THYM	trans	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg10856724	chr12:34555212	NA	-0.96	-8.66	-0.66	1.22e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg20744362	chr22:50050164	C22orf34	0.87	8.56	0.66	1.96e-13	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg00256281	chr22:41985642	PMM1	0.51	4.49	0.42	1.99e-5	Vitiligo;
THYM	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Body mass index;
THYM	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg00981070	chr1:2046702	PRKCZ	0.47	5.25	0.47	9.44e-7	Height;
THYM	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg06002616	chr8:101225028	SPAG1	-0.46	-4.79	-0.44	6.1e-6	Atrioventricular conduction;
THYM	cis	rs986417	1.000	rs1254292	chr14:60863636	T/C	cg27398547	chr14:60952738	C14orf39	-1.17	-6.74	-0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs6835098	0.962	rs3733477	chr4:174090004	G/A	cg08422745	chr4:174089978	GALNT7	-1.01	-8.56	-0.66	1.97e-13	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg14664628	chr15:75095509	CSK	-1.14	-10.15	-0.72	8.04e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg24818145	chr4:99064322	C4orf37	0.87	7.23	0.6	1.19e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.32	9.94	0.71	2.24e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17376456	0.597	rs7733142	chr5:93322795	C/A	cg25358565	chr5:93447407	FAM172A	-0.82	-6.02	-0.53	3.32e-8	Diabetic retinopathy;
THYM	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg22709100	chr7:91322751	NA	0.62	4.85	0.45	4.77e-6	Breast cancer;
THYM	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.55	-0.49	2.58e-7	Obesity-related traits;
THYM	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg08736216	chr1:53307985	ZYG11A	-0.57	-5.13	-0.47	1.52e-6	Monocyte count;
THYM	cis	rs7567389	0.677	rs61422716	chr2:128087651	C/T	cg06038358	chr2:128176007	PROC	0.43	4.53	0.42	1.7e-5	Self-rated health;
THYM	cis	rs35264875	1.000	rs1542334	chr11:68850773	G/C	cg23845249	chr11:68861649	NA	0.55	6.53	0.56	3.22e-9	Blond vs. brown hair color;
THYM	cis	rs9359856	0.564	rs61739327	chr6:90340446	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.05	-0.64	2.39e-12	Bipolar disorder;
THYM	cis	rs7917772	0.582	rs6584512	chr10:104329685	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg03351412	chr1:154909251	PMVK	0.71	5.6	0.5	2.12e-7	Prostate cancer;
THYM	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg13010199	chr12:38710504	ALG10B	0.58	4.55	0.42	1.61e-5	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg24818145	chr4:99064322	C4orf37	0.87	7.23	0.6	1.19e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs34112283	0.561	rs35648233	chr2:144223391	T/C	cg17056048	chr2:144271431	ARHGAP15	0.64	6.15	0.53	1.86e-8	Neuroticism;
THYM	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06850241	chr22:41845214	NA	0.59	5.16	0.47	1.37e-6	Vitiligo;
THYM	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg21926612	chr6:163149169	PACRG;PARK2	1.24	9.45	0.7	2.46e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7119038	0.629	rs11216995	chr11:118603526	G/A	cg19308663	chr11:118741387	NA	0.47	4.55	0.42	1.58e-5	Sjögren's syndrome;
THYM	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg22655196	chr4:3374909	RGS12	0.66	8.3	0.65	6.97e-13	Serum sulfate level;
THYM	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg07061783	chr6:25882402	NA	-0.6	-4.64	-0.43	1.13e-5	Height;
THYM	cis	rs7000551	0.689	rs6984908	chr8:22316901	A/G	cg12081754	chr8:22256438	SLC39A14	-0.61	-5.43	-0.49	4.4e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs17102423	0.964	rs868814	chr14:65584508	C/T	cg11161011	chr14:65562177	MAX	-0.74	-6.73	-0.57	1.3e-9	Obesity-related traits;
THYM	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg12386194	chr3:101231763	SENP7	0.7	5.22	0.47	1.07e-6	Colorectal cancer;
THYM	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg01579765	chr21:45077557	HSF2BP	-0.47	-7.83	-0.63	6.79e-12	Mean corpuscular volume;
THYM	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg27121462	chr16:89883253	FANCA	0.58	4.71	0.44	8.32e-6	Vitiligo;
THYM	cis	rs8078723	1.000	rs8070454	chr17:38160754	C/T	cg17467752	chr17:38218738	THRA	0.87	7.22	0.59	1.3e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg15536230	chr21:44985092	HSF2BP	-0.39	-4.46	-0.42	2.24e-5	Mean corpuscular volume;
THYM	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg02070205	chr10:30722105	MAP3K8	-0.61	-4.94	-0.45	3.39e-6	Itch intensity from mosquito bite;
THYM	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.7	-5.72	-0.51	1.23e-7	Blood metabolite levels;
THYM	cis	rs66887589	0.967	rs1480933	chr4:120433248	C/T	cg13609457	chr4:120235615	NA	0.44	4.58	0.42	1.43e-5	Diastolic blood pressure;
THYM	cis	rs4889911	0.544	rs1285273	chr17:77830885	A/G	cg00646381	chr17:77835854	NA	0.47	5.37	0.48	5.53e-7	Electroencephalogram traits;
THYM	cis	rs6570726	0.846	rs870491	chr6:145933390	T/G	cg13319975	chr6:146136371	FBXO30	-0.65	-5.24	-0.47	9.55e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs977987	0.843	rs10871312	chr16:75486202	C/T	cg03315344	chr16:75512273	CHST6	0.71	5.75	0.51	1.07e-7	Dupuytren's disease;
THYM	cis	rs1395	0.778	rs11693660	chr2:27468856	T/C	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.52	-0.49	2.95e-7	Blood metabolite levels;
THYM	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg22709100	chr7:91322751	NA	0.6	4.68	0.43	9.41e-6	Breast cancer;
THYM	cis	rs6499255	0.951	rs9921045	chr16:69708698	C/T	cg00738113	chr16:70207722	CLEC18C	-0.44	-4.46	-0.42	2.29e-5	IgE levels;
THYM	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	5.52	0.49	2.88e-7	Hip circumference adjusted for BMI;
THYM	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg04772025	chr11:68637568	NA	0.65	6.69	0.57	1.57e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7729356	0.761	rs4957548	chr5:107490014	G/A	cg12405754	chr5:107005487	EFNA5	-0.52	-4.45	-0.42	2.31e-5	Educational attainment;
THYM	trans	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs791888	0.723	rs1980648	chr10:89422369	T/C	cg10377144	chr10:89419177	PAPSS2	0.45	7.48	0.61	3.78e-11	Magnesium levels;
THYM	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs10911232	0.507	rs3934697	chr1:183027512	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs62120679	0.551	rs4807228	chr19:2319273	C/T	cg26843498	chr19:2361574	NA	0.6	7.95	0.63	3.79e-12	Parkinson's disease;
THYM	cis	rs6084875	0.785	rs2050370	chr20:4719781	G/T	cg19614321	chr20:4804581	RASSF2	0.45	4.53	0.42	1.7e-5	Systemic lupus erythematosus;
THYM	cis	rs72781680	0.898	rs72780125	chr2:24000145	T/C	cg08917208	chr2:24149416	ATAD2B	1.11	4.97	0.45	2.9e-6	Lymphocyte counts;
THYM	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg02869364	chr7:1081709	C7orf50	-0.61	-4.91	-0.45	3.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11690935	0.959	rs12692974	chr2:172663256	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.81	-5.87	-0.52	6.34e-8	Schizophrenia;
THYM	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg23758822	chr17:41437982	NA	1.2	11.6	0.77	6.75e-20	Menopause (age at onset);
THYM	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg18252515	chr7:66147081	NA	0.68	5.41	0.49	4.65e-7	Aortic root size;
THYM	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg24803719	chr17:45855879	NA	-0.6	-6.3	-0.54	9.35e-9	IgG glycosylation;
THYM	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	4.54	0.42	1.63e-5	Neuroticism;
THYM	cis	rs7580658	0.929	rs11886231	chr2:128028130	G/A	cg10021288	chr2:128175891	PROC	-0.78	-6.82	-0.57	8.26e-10	Protein C levels;
THYM	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg20503657	chr10:835505	NA	1.22	7.89	0.63	5.09e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg20744362	chr22:50050164	C22orf34	0.69	6.33	0.54	7.96e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs3845702	0.736	rs72960664	chr2:180832672	C/T	cg01881094	chr2:180872142	CWC22	0.89	5.34	0.48	6.22e-7	Schizophrenia;
THYM	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg23260525	chr10:116636907	FAM160B1	0.53	5.33	0.48	6.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7172809	0.599	rs2864840	chr15:77732001	C/T	cg22256960	chr15:77711686	NA	-0.62	-4.57	-0.42	1.45e-5	Glucose homeostasis traits;
THYM	cis	rs12643440	0.538	rs2041443	chr4:17137996	G/A	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg04865290	chr3:52927548	TMEM110	-0.96	-4.97	-0.45	2.97e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs870825	0.616	rs6810600	chr4:185616814	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg17074396	chr22:49843754	NA	-0.39	-4.59	-0.43	1.33e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2898681	0.837	rs2017237	chr4:53748515	A/G	cg00791764	chr4:53727839	RASL11B	0.49	6.38	0.55	6.32e-9	Optic nerve measurement (cup area);
THYM	cis	rs35934224	0.769	rs77611691	chr22:19846257	T/G	cg11182965	chr22:19864308	TXNRD2	-0.79	-4.93	-0.45	3.51e-6	Glaucoma (primary open-angle);
THYM	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg26967526	chr14:35346199	BAZ1A	-0.8	-5.27	-0.48	8.47e-7	Psoriasis;
THYM	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg24399712	chr22:39784796	NA	-0.8	-7.28	-0.6	9.82e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs7578361	0.918	rs10203060	chr2:150378019	G/T	cg17961725	chr2:150454027	NA	-0.77	-5.72	-0.51	1.25e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs859767	0.519	rs6707326	chr2:135357705	G/A	cg12500956	chr2:135428796	TMEM163	-0.57	-4.8	-0.44	5.8e-6	Neuroticism;
THYM	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg03806693	chr22:41940476	POLR3H	0.98	8.1	0.64	1.84e-12	Vitiligo;
THYM	cis	rs9595908	0.897	rs10083285	chr13:33131342	A/G	cg12383807	chr13:33924137	NA	-0.58	-5.29	-0.48	7.83e-7	Body mass index;
THYM	cis	rs669446	0.533	rs3791041	chr1:44202991	A/G	cg15962314	chr1:44399869	ARTN	0.47	5.05	0.46	2.16e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs11599315	0.507	rs12217329	chr10:1341897	A/G	cg01270228	chr10:1369114	ADARB2	0.72	5.82	0.51	7.86e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs3015497	0.575	rs8023035	chr14:51162419	A/G	cg04730355	chr14:51134070	SAV1	-0.57	-4.89	-0.45	4.13e-6	Mean platelet volume;
THYM	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg13147721	chr7:65941812	NA	-0.94	-5.74	-0.51	1.12e-7	Diabetic kidney disease;
THYM	cis	rs7731657	0.509	rs10068016	chr5:130358695	A/G	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs171748	0.727	rs159540	chr5:60484660	A/G	cg20565082	chr5:60525509	NA	-0.51	-4.92	-0.45	3.68e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6500596	0.506	rs1530088	chr16:4439131	C/T	cg08645402	chr16:4508243	NA	0.66	5.13	0.47	1.52e-6	Schizophrenia;
THYM	cis	rs9359856	0.564	rs1179902	chr6:90321545	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.07	-0.64	2.1e-12	Bipolar disorder;
THYM	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg13246856	chr1:44399776	ARTN	-0.49	-4.47	-0.42	2.18e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs2290159	0.800	rs5746191	chr3:12658774	G/A	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs6840360	0.593	rs6857073	chr4:152689274	A/G	cg22705602	chr4:152727874	NA	0.82	11.14	0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs596169	0.655	rs1700870	chr1:219181936	C/T	cg19270308	chr1:218458869	RRP15	-1.24	-4.52	-0.42	1.81e-5	Intraocular pressure;
THYM	trans	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg25214090	chr10:38739885	LOC399744	0.97	8.33	0.65	5.98e-13	Corneal astigmatism;
THYM	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs6840360	0.550	rs62327267	chr4:152518753	G/T	cg17479576	chr4:152424074	FAM160A1	-0.78	-5.74	-0.51	1.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg16423285	chr20:60520624	NA	1.11	8.69	0.67	1.03e-13	Obesity-related traits;
THYM	cis	rs8018808	0.935	rs11159263	chr14:77930188	G/C	cg20045696	chr14:77926864	AHSA1	0.5	4.54	0.42	1.63e-5	Myeloid white cell count;
THYM	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg27170947	chr2:26402098	FAM59B	0.79	6.27	0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs9311676	0.632	rs11130630	chr3:58360800	A/G	cg26110898	chr3:58419937	PDHB	0.44	4.6	0.43	1.29e-5	Systemic lupus erythematosus;
THYM	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg26384229	chr12:38710491	ALG10B	0.95	7.06	0.59	2.68e-10	Bladder cancer;
THYM	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	6.46	0.55	4.53e-9	Obesity-related traits;
THYM	cis	rs12042938	0.507	rs2570408	chr1:231732934	C/T	cg04892437	chr1:231737901	TSNAX-DISC1	-0.46	-4.5	-0.42	1.93e-5	Neuranatomic and neurocognitive phenotypes;
THYM	cis	rs3791406	0.963	rs3791408	chr2:240030591	C/T	cg14550559	chr2:240039617	HDAC4	-0.6	-5.42	-0.49	4.58e-7	Skin aging (microtopography measurement);
THYM	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg26721908	chr21:47610096	LSS	-0.75	-5.11	-0.46	1.63e-6	Testicular germ cell tumor;
THYM	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg20587970	chr11:113659929	NA	-1.37	-8.96	-0.68	2.79e-14	Hip circumference adjusted for BMI;
THYM	cis	rs155076	1.000	rs2783107	chr13:21837532	C/A	cg25811766	chr13:21894605	NA	-0.75	-4.75	-0.44	7.29e-6	White matter hyperintensity burden;
THYM	cis	rs1395	0.744	rs11126931	chr2:27474306	C/T	cg23587288	chr2:27483067	SLC30A3	-0.65	-5.82	-0.51	7.88e-8	Blood metabolite levels;
THYM	cis	rs7103648	0.569	rs11039266	chr11:47532395	T/G	cg20307385	chr11:47447363	PSMC3	0.8	5.55	0.49	2.58e-7	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg04398451	chr17:18023971	MYO15A	-0.77	-7.09	-0.59	2.4e-10	Total body bone mineral density;
THYM	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg07511668	chr11:68622177	NA	0.44	4.63	0.43	1.16e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4919694	0.808	rs4918001	chr10:105013147	G/T	cg04362960	chr10:104952993	NT5C2	-0.89	-5.3	-0.48	7.55e-7	Arsenic metabolism;
THYM	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg06238570	chr21:40685208	BRWD1	-0.96	-9.14	-0.68	1.13e-14	Cognitive function;
THYM	cis	rs6701037	0.748	rs11585368	chr1:175135448	G/A	cg00958927	chr1:175162553	KIAA0040	-0.33	-4.48	-0.42	2.06e-5	Alcohol dependence;
THYM	cis	rs6987853	0.933	rs1343875	chr8:42424749	C/T	cg09913449	chr8:42400586	C8orf40	0.85	7.63	0.62	1.84e-11	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8114671	0.967	rs6142321	chr20:33788474	G/A	cg08999081	chr20:33150536	PIGU	-0.53	-4.77	-0.44	6.63e-6	Height;
THYM	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg00256281	chr22:41985642	PMM1	0.61	4.57	0.42	1.47e-5	Vitiligo;
THYM	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.51	0.81	7.55e-24	Height;
THYM	cis	rs4575098	0.681	rs10797093	chr1:161103445	T/G	cg24329783	chr1:161160887	ADAMTS4	-0.61	-5.71	-0.51	1.27e-7	Monocyte percentage of white cells;
THYM	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg23428387	chr22:49814324	NA	-0.53	-5.87	-0.52	6.38e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs59698941	0.943	rs10900812	chr5:132268567	G/A	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs2239547	0.522	rs2581823	chr3:53022076	C/G	cg11645453	chr3:52864694	ITIH4	-0.29	-4.49	-0.42	2.04e-5	Schizophrenia;
THYM	cis	rs11648796	0.765	rs3829492	chr16:781633	G/A	cg20104307	chr16:778658	HAGHL	0.44	6.18	0.54	1.59e-8	Height;
THYM	cis	rs1395	0.922	rs11898114	chr2:27515527	C/T	cg23587288	chr2:27483067	SLC30A3	-0.6	-5.0	-0.46	2.59e-6	Blood metabolite levels;
THYM	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg13010199	chr12:38710504	ALG10B	-0.62	-5.38	-0.48	5.28e-7	Heart rate;
THYM	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.76	6.46	0.55	4.35e-9	Lymphocyte percentage of white cells;
THYM	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg11375102	chr16:1583810	IFT140;TMEM204	-0.55	-4.68	-0.43	9.35e-6	Coronary artery disease;
THYM	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.41	-5.2	-0.47	1.15e-6	Monocyte percentage of white cells;
THYM	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg02187348	chr16:89574699	SPG7	0.73	5.66	0.5	1.59e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs2282300	1.000	rs12575085	chr11:30428262	G/T	cg06241208	chr11:30344200	C11orf46	-0.69	-4.8	-0.44	5.94e-6	Morning vs. evening chronotype;
THYM	cis	rs2046867	0.818	rs7637138	chr3:72910886	A/G	cg25664220	chr3:72788482	NA	-0.89	-7.11	-0.59	2.15e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg12826209	chr6:26865740	GUSBL1	1.03	6.64	0.56	1.94e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7106204	0.764	rs7933686	chr11:24246790	G/C	ch.11.24196551F	chr11:24239977	NA	0.96	4.87	0.45	4.53e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg16325326	chr1:53192061	ZYG11B	0.8	6.52	0.56	3.35e-9	Monocyte count;
THYM	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.78	-5.09	-0.46	1.8e-6	Mean platelet volume;
THYM	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg22508957	chr16:3507546	NAT15	-0.64	-6.43	-0.55	5.12e-9	Tuberculosis;
THYM	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.75	-6.14	-0.53	1.92e-8	Blood metabolite levels;
THYM	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg07424592	chr7:64974309	NA	1.03	5.4	0.48	4.94e-7	Diabetic kidney disease;
THYM	cis	rs7843479	0.601	rs4872207	chr8:21842751	C/G	cg17168535	chr8:21777572	XPO7	-0.8	-7.04	-0.59	2.93e-10	Mean corpuscular volume;
THYM	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9486719	0.843	rs3860230	chr6:97036560	T/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-4.84	-0.44	5.06e-6	Migraine;Coronary artery disease;
THYM	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg10802521	chr3:52805072	NEK4	-0.75	-7.07	-0.59	2.65e-10	Intelligence (multi-trait analysis);
THYM	cis	rs4631830	0.896	rs7077830	chr10:51522276	C/G	cg10326726	chr10:51549505	MSMB	0.55	5.48	0.49	3.43e-7	Prostate-specific antigen levels;
THYM	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg09877947	chr5:131593287	PDLIM4	0.59	4.95	0.45	3.16e-6	Breast cancer;
THYM	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg23958373	chr8:599963	NA	1.01	4.74	0.44	7.48e-6	IgG glycosylation;
THYM	cis	rs611744	0.625	rs11991891	chr8:109294858	G/A	cg21045802	chr8:109455806	TTC35	0.71	6.5	0.55	3.66e-9	Dupuytren's disease;
THYM	cis	rs9902453	1.000	rs8065261	chr17:28418041	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-4.97	-0.45	2.96e-6	Coffee consumption (cups per day);
THYM	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg19077165	chr18:44547161	KATNAL2	0.55	6.81	0.57	8.63e-10	Personality dimensions;
THYM	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg24060327	chr5:131705240	SLC22A5	0.74	5.38	0.48	5.28e-7	Blood metabolite levels;
THYM	trans	rs10802346	0.545	rs10924568	chr1:246385482	C/A	cg22732515	chr19:44031385	ETHE1	1.02	8.5	0.66	2.63e-13	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg17105886	chr17:28927953	LRRC37B2	1.25	6.76	0.57	1.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.67	5.34	0.48	6.38e-7	Platelet count;
THYM	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg07936489	chr17:37558343	FBXL20	-0.66	-4.54	-0.42	1.62e-5	Asthma;
THYM	cis	rs11937061	0.539	rs13116796	chr4:78152466	G/C	cg01930676	chr4:78783082	MRPL1	-0.57	-4.55	-0.42	1.59e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg24955955	chr5:415729	AHRR	1.02	5.72	0.51	1.21e-7	Fat distribution (HIV);
THYM	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg10295955	chr4:187884368	NA	-1.22	-17.54	-0.87	1.51e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs977987	0.872	rs1542864	chr16:75471378	G/A	cg03315344	chr16:75512273	CHST6	0.73	5.98	0.52	3.87e-8	Dupuytren's disease;
THYM	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg22907277	chr7:1156413	C7orf50	0.82	4.98	0.46	2.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs921968	0.565	rs6436083	chr2:219639719	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1538970	0.816	rs11211123	chr1:45957609	G/A	cg05343316	chr1:45956843	TESK2	0.85	5.45	0.49	3.93e-7	Platelet count;
THYM	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6570726	0.935	rs377130	chr6:145836632	C/T	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg11663144	chr21:46675770	NA	-0.71	-9.92	-0.71	2.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs941408	1.000	rs4807332	chr19:2793289	T/C	cg19693284	chr19:2783607	SGTA	0.74	5.76	0.51	1.03e-7	Total cholesterol levels;
THYM	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg14972814	chr11:95582409	MTMR2	-0.64	-5.43	-0.49	4.34e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2816062	0.775	rs2745315	chr1:18897118	G/A	cg18795169	chr1:18902165	NA	-0.99	-12.16	-0.78	4.55e-21	Urate levels in lean individuals;
THYM	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg18230493	chr5:56204884	C5orf35	-0.91	-6.68	-0.57	1.58e-9	Initial pursuit acceleration;
THYM	cis	rs10819861	0.645	rs7862829	chr9:98856744	C/T	cg14508093	chr9:98862825	NA	-0.24	-4.6	-0.43	1.28e-5	Electrocardiographic traits;
THYM	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg07636037	chr3:49044803	WDR6	0.84	7.39	0.6	5.67e-11	Menarche (age at onset);
THYM	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg26354017	chr1:205819088	PM20D1	-0.7	-6.04	-0.53	3.05e-8	Prostate-specific antigen levels;
THYM	cis	rs9527	0.662	rs10883783	chr10:104591152	T/A	cg04362960	chr10:104952993	NT5C2	0.63	4.93	0.45	3.44e-6	Arsenic metabolism;
THYM	trans	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg05926928	chr17:57297772	GDPD1	1.26	10.02	0.72	1.5e-16	Opioid sensitivity;
THYM	cis	rs4792901	0.802	rs2279191	chr17:41570427	A/G	cg21940313	chr17:41620911	ETV4	-0.52	-4.9	-0.45	3.96e-6	Dupuytren's disease;
THYM	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14893161	chr1:205819251	PM20D1	0.94	10.13	0.72	8.71e-17	Menarche (age at onset);
THYM	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg22875332	chr1:76189707	ACADM	0.9	10.62	0.74	7.94e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7772486	0.720	rs7752286	chr6:146072662	C/T	cg05347473	chr6:146136440	FBXO30	-0.56	-4.45	-0.42	2.34e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg01191920	chr7:158217561	PTPRN2	0.88	8.38	0.65	4.78e-13	Obesity-related traits;
THYM	trans	rs8002861	0.935	rs4942256	chr13:44455920	A/T	cg17145862	chr1:211918768	LPGAT1	1.03	11.49	0.76	1.12e-19	Leprosy;
THYM	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg14004847	chr7:1930337	MAD1L1	-0.67	-5.46	-0.49	3.74e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs11723261	0.582	rs11732336	chr4:140512	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.81	5.62	0.5	1.94e-7	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg09436375	chr6:42928200	GNMT	-0.44	-5.86	-0.52	6.75e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs11711311	0.955	rs11715350	chr3:113418376	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.56	-4.75	-0.44	7.12e-6	IgG glycosylation;
THYM	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg14196790	chr5:131705035	SLC22A5	0.51	4.68	0.43	9.41e-6	Blood metabolite levels;
THYM	cis	rs1371867	0.726	rs1660333	chr8:101309989	A/G	cg00191853	chr8:101177733	SPAG1	-0.53	-5.29	-0.48	7.82e-7	Atrioventricular conduction;
THYM	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg14972814	chr11:95582409	MTMR2	-0.72	-6.7	-0.57	1.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg27534772	chr1:16042836	PLEKHM2	0.53	5.9	0.52	5.65e-8	Systolic blood pressure;
THYM	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg26818010	chr10:134567672	INPP5A	-0.93	-7.6	-0.62	2.05e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7631605	0.875	rs9823120	chr3:37199050	A/G	cg21328643	chr3:37258149	NA	-0.52	-5.0	-0.46	2.65e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg06221963	chr1:154839813	KCNN3	-0.74	-8.92	-0.68	3.29e-14	Prostate cancer;
THYM	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg20387954	chr3:183756860	HTR3D	0.58	4.74	0.44	7.61e-6	Anterior chamber depth;
THYM	cis	rs4713118	0.869	rs4713121	chr6:27722064	T/C	cg08968635	chr6:28129556	ZNF389	0.64	4.84	0.44	5.04e-6	Parkinson's disease;
THYM	cis	rs1371867	0.846	rs1788191	chr8:101260844	C/T	cg00191853	chr8:101177733	SPAG1	0.57	5.46	0.49	3.85e-7	Atrioventricular conduction;
THYM	cis	rs314370	1.000	rs10278546	chr7:100516003	G/T	cg10426581	chr7:100472382	SRRT	-0.91	-7.13	-0.59	1.93e-10	Resting heart rate;
THYM	cis	rs8014204	1.000	rs8014374	chr14:75322914	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.58	-5.59	-0.5	2.13e-7	Caffeine consumption;
THYM	cis	rs73086581	1.000	rs17214621	chr20:3925924	T/C	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs17401966	1.000	rs58053556	chr1:10442903	A/G	cg19773385	chr1:10388646	KIF1B	-0.64	-4.79	-0.44	6.15e-6	Hepatocellular carcinoma;
THYM	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg02487422	chr3:49467188	NICN1	0.63	4.82	0.44	5.48e-6	Resting heart rate;
THYM	cis	rs716316	0.590	rs6135309	chr20:14902522	C/T	cg04470754	chr20:14904432	MACROD2	-0.63	-4.89	-0.45	4.02e-6	Advanced glycation end-product levels;
THYM	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg23743428	chr13:21893420	NA	-0.72	-6.45	-0.55	4.71e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs2303759	0.709	rs8102574	chr19:49828897	A/G	cg22307029	chr19:49891270	CCDC155	0.58	4.66	0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg05973401	chr12:123451056	ABCB9	-0.7	-4.46	-0.42	2.23e-5	Neutrophil percentage of white cells;
THYM	cis	rs6121246	0.559	rs6060621	chr20:30261562	G/C	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs6733011	0.628	rs4851163	chr2:99466664	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.56	-0.42	1.54e-5	Bipolar disorder;
THYM	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10782582	0.564	rs17647711	chr1:76241710	C/G	cg03433033	chr1:76189801	ACADM	-0.47	-4.55	-0.42	1.61e-5	Daytime sleep phenotypes;
THYM	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs72829446	0.530	rs12325773	chr17:7393871	G/A	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs985746	0.730	rs7676880	chr4:36818961	A/G	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg21926883	chr2:100939477	LONRF2	-0.6	-5.39	-0.48	5.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg13609457	chr4:120235615	NA	0.51	4.76	0.44	6.87e-6	Corneal astigmatism;
THYM	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.07	7.53	0.61	2.93e-11	Smoking behavior;
THYM	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs3126085	0.560	rs3120666	chr1:152316981	G/C	cg10321714	chr1:152280068	FLG	-0.75	-5.29	-0.48	7.81e-7	Atopic dermatitis;
THYM	cis	rs2282300	0.739	rs1616223	chr11:30338783	A/C	cg06241208	chr11:30344200	C11orf46	-0.78	-5.65	-0.5	1.64e-7	Morning vs. evening chronotype;
THYM	cis	rs752010	0.838	rs11210505	chr1:42104731	G/C	cg22486000	chr1:42919398	ZMYND12	-0.39	-4.5	-0.42	1.91e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg12179176	chr11:130786555	SNX19	0.78	6.67	0.56	1.68e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs78366141	0.649	rs76401410	chr4:89694624	A/G	cg01026744	chr4:89619053	NAP1L5;HERC3	1.4	5.5	0.49	3.22e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.66	4.72	0.44	8.03e-6	Aortic root size;
THYM	cis	rs2976388	1.000	rs2920280	chr8:143761144	G/C	cg13446199	chr8:143762866	PSCA	0.53	5.86	0.52	6.72e-8	Urinary tract infection frequency;
THYM	cis	rs977987	0.585	rs62059845	chr16:75430713	A/G	cg03315344	chr16:75512273	CHST6	0.73	6.16	0.53	1.73e-8	Dupuytren's disease;
THYM	cis	rs3784262	0.528	rs4238327	chr15:58336218	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.65	-5.04	-0.46	2.23e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
THYM	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg10589385	chr1:150898437	SETDB1	0.57	4.55	0.42	1.56e-5	Melanoma;
THYM	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg00339695	chr16:24857497	SLC5A11	0.68	6.41	0.55	5.69e-9	Intelligence (multi-trait analysis);
THYM	cis	rs3791406	0.654	rs3791409	chr2:240030606	C/G	cg14550559	chr2:240039617	HDAC4	-0.52	-4.84	-0.44	5.11e-6	Skin aging (microtopography measurement);
THYM	cis	rs2811415	0.597	rs2304018	chr3:127779306	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs9908552	0.621	rs8069030	chr17:1233067	G/C	cg08875357	chr17:1839554	RTN4RL1	-0.61	-4.71	-0.44	8.31e-6	Schizophrenia;
THYM	cis	rs34638657	0.797	rs11645045	chr16:82202137	G/A	cg09894383	chr16:82067445	HSD17B2	-0.47	-5.13	-0.47	1.56e-6	Lung adenocarcinoma;
THYM	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	7.35	0.6	6.78e-11	Platelet count;
THYM	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.7	-5.63	-0.5	1.83e-7	Prostate cancer;
THYM	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.64	4.59	0.43	1.36e-5	Lung cancer in ever smokers;
THYM	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg23161317	chr6:28129485	ZNF389	0.7	5.47	0.49	3.66e-7	Cardiac Troponin-T levels;
THYM	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg19875535	chr5:140030758	IK	-0.63	-5.69	-0.5	1.43e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs17453880	0.890	rs28842566	chr5:152048590	A/G	cg12297329	chr5:152029980	NA	-0.6	-4.55	-0.42	1.59e-5	Subjective well-being;
THYM	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.8e-10	Alzheimer's disease (late onset);
THYM	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg12219531	chr12:120966889	COQ5	0.82	6.79	0.57	9.88e-10	High light scatter reticulocyte count;
THYM	cis	rs4455778	0.691	rs10229690	chr7:49003172	A/G	cg26309511	chr7:48887640	NA	-0.51	-4.57	-0.42	1.44e-5	Lung cancer in never smokers;
THYM	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg14004847	chr7:1930337	MAD1L1	-0.6	-4.63	-0.43	1.14e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg17178900	chr1:205818956	PM20D1	-0.78	-7.22	-0.6	1.25e-10	Menarche (age at onset);
THYM	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg06634786	chr22:41940651	POLR3H	-0.57	-4.55	-0.42	1.57e-5	Neuroticism;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg17414733	chr19:21688647	ZNF429	-1.0	-6.9	-0.58	5.74e-10	Depressive symptoms;
THYM	cis	rs4589258	0.788	rs10765388	chr11:90498840	A/G	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.96	-0.45	3.02e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg00495681	chr13:53174319	NA	0.72	6.68	0.57	1.64e-9	Lewy body disease;
THYM	cis	rs6570726	0.791	rs383841	chr6:145888329	G/T	cg05347473	chr6:146136440	FBXO30	-0.6	-4.85	-0.45	4.85e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg15556689	chr8:8085844	FLJ10661	-0.59	-4.61	-0.43	1.26e-5	Joint mobility (Beighton score);
THYM	cis	rs807669	0.548	rs723414	chr22:19185736	G/A	cg02655711	chr22:19163373	SLC25A1	0.7	8.01	0.64	2.81e-12	Metabolite levels;
THYM	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg27129171	chr3:47204927	SETD2	0.69	5.56	0.5	2.51e-7	Birth weight;
THYM	cis	rs2280630	0.505	rs2249736	chr3:39195462	G/T	cg15678707	chr3:39149194	GORASP1;TTC21A	-0.55	-4.54	-0.42	1.67e-5	Verbal declarative memory;
THYM	cis	rs11190604	0.767	rs11190519	chr10:102175133	C/T	cg07570687	chr10:102243282	WNT8B	0.82	7.71	0.62	1.25e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs72627123	0.867	rs72627128	chr14:74373609	T/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs1335645	0.570	rs12403848	chr1:111627231	C/T	cg00321911	chr1:111669324	DRAM2	-1.38	-7.97	-0.63	3.51e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg24675658	chr1:53192096	ZYG11B	0.78	7.02	0.58	3.33e-10	Monocyte count;
THYM	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg24579218	chr15:68104479	NA	-0.69	-6.44	-0.55	4.78e-9	Obesity;
THYM	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg25817165	chr18:72167213	CNDP2	-0.64	-5.77	-0.51	1.01e-7	Refractive error;
THYM	cis	rs2034088	1.000	rs3744731	chr17:420467	T/C	cg06217071	chr17:408420	NA	0.76	7.66	0.62	1.58e-11	Hip circumference adjusted for BMI;
THYM	cis	rs981844	1.000	rs72731669	chr4:154662464	G/A	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs79349575	0.594	rs62078375	chr17:47034974	A/G	cg26022315	chr17:47021804	SNF8	0.51	4.85	0.45	4.88e-6	Type 2 diabetes;
THYM	cis	rs7011507	0.594	rs72639028	chr8:49349765	G/A	cg08774009	chr8:49309094	NA	-0.6	-4.71	-0.44	8.47e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.68	5.6	0.5	2.08e-7	Lung disease severity in cystic fibrosis;
THYM	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.76	6.74	0.57	1.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2046867	0.818	rs17010188	chr3:72870351	T/C	cg25664220	chr3:72788482	NA	-0.95	-7.97	-0.63	3.52e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs2456568	0.508	rs1607403	chr11:93660514	A/G	cg14065697	chr11:93583672	C11orf90	-0.48	-4.52	-0.42	1.77e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7124681	0.528	rs74608150	chr11:47696214	A/T	cg18512352	chr11:47633146	NA	0.4	4.47	0.42	2.14e-5	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs3750965	0.959	rs4930264	chr11:68852181	C/T	cg01403660	chr11:68851641	TPCN2	0.75	5.98	0.52	3.86e-8	Hair color;
THYM	cis	rs4780401	0.632	rs7192366	chr16:11835209	C/G	cg01061890	chr16:11836724	TXNDC11	-0.61	-4.65	-0.43	1.09e-5	Rheumatoid arthritis;
THYM	cis	rs734999	0.588	rs3748819	chr1:2524966	C/T	cg04866029	chr1:2707161	NA	0.43	4.49	0.42	1.96e-5	Ulcerative colitis;
THYM	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.76	-0.51	1.03e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7695732	0.572	rs9307060	chr4:89913550	C/T	cg17769793	chr4:89976368	FAM13A	-0.49	-5.2	-0.47	1.17e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg03806693	chr22:41940476	POLR3H	1.03	9.17	0.69	9.96e-15	Vitiligo;
THYM	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs9894429	0.646	rs7217415	chr17:79618252	G/A	cg10661904	chr17:79619235	PDE6G	-0.65	-6.33	-0.54	7.93e-9	Eye color traits;
THYM	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg06766960	chr11:133703094	NA	0.49	4.58	0.43	1.42e-5	Childhood ear infection;
THYM	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg19747945	chr6:42946146	PEX6	-0.33	-4.82	-0.44	5.43e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs7666738	0.962	rs11728816	chr4:98951767	C/T	cg03467027	chr4:99064603	C4orf37	0.59	4.5	0.42	1.92e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg25036284	chr2:26402008	FAM59B	-0.72	-4.95	-0.45	3.2e-6	Gut microbiome composition (summer);
THYM	cis	rs9443645	0.509	rs9352668	chr6:79572678	A/G	cg09184832	chr6:79620586	NA	-0.65	-5.5	-0.49	3.15e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2294693	0.685	rs67525613	chr6:41008956	G/T	cg14418226	chr6:40996092	UNC5CL	0.69	5.34	0.48	6.39e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs9790314	0.902	rs9863590	chr3:161116445	T/C	cg04691961	chr3:161091175	C3orf57	-0.56	-4.74	-0.44	7.51e-6	Morning vs. evening chronotype;
THYM	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg00981070	chr1:2046702	PRKCZ	0.48	5.9	0.52	5.46e-8	Height;
THYM	cis	rs7119038	0.818	rs2077579	chr11:118619047	T/G	cg19308663	chr11:118741387	NA	0.57	5.33	0.48	6.51e-7	Sjögren's syndrome;
THYM	cis	rs4720575	0.931	rs10242850	chr7:47099868	A/C	cg00036614	chr7:47093842	NA	-0.59	-5.24	-0.47	9.71e-7	Angiotensin-converting enzyme inhibitor intolerance;
THYM	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg26149184	chr10:133730230	NA	0.78	4.77	0.44	6.6e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg09549813	chr16:4587862	C16orf5	-0.58	-6.03	-0.53	3.06e-8	Schizophrenia;
THYM	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg13683864	chr3:40499215	RPL14	-1.03	-11.44	-0.76	1.45e-19	Renal cell carcinoma;
THYM	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg07424592	chr7:64974309	NA	-1.04	-5.27	-0.48	8.52e-7	Diabetic kidney disease;
THYM	cis	rs4788815	0.532	rs59709630	chr16:71978608	G/T	cg06353428	chr16:71660113	MARVELD3	0.8	5.81	0.51	8.12e-8	Metabolite levels;
THYM	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg08017756	chr2:100939284	LONRF2	-0.73	-7.58	-0.61	2.26e-11	Intelligence (multi-trait analysis);
THYM	trans	rs637571	0.565	rs633800	chr11:65638719	G/A	cg17712092	chr4:129076599	LARP1B	-0.95	-8.09	-0.64	1.91e-12	Eosinophil percentage of white cells;
THYM	cis	rs1003719	0.788	rs4817844	chr21:38447064	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.68	-4.86	-0.45	4.64e-6	Eye color traits;
THYM	cis	rs988913	0.957	rs1503146	chr6:54759495	G/T	cg19716238	chr6:54711378	FAM83B	0.51	5.18	0.47	1.22e-6	Menarche (age at onset);
THYM	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg01324343	chr3:183735012	ABCC5	0.64	8.63	0.66	1.42e-13	Anterior chamber depth;
THYM	cis	rs6076065	0.723	rs6083104	chr20:23366038	C/T	cg11657817	chr20:23433608	CST11	0.31	4.57	0.42	1.48e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs1133926	0.560	rs74467744	chr3:24071872	A/G	cg21910673	chr3:24143257	LOC152024	0.56	4.71	0.43	8.54e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6840360	0.901	rs4696293	chr4:152707380	C/T	cg22705602	chr4:152727874	NA	0.59	6.36	0.55	7.14e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg13866156	chr1:1669148	SLC35E2	-0.75	-7.52	-0.61	2.98e-11	Body mass index;
THYM	cis	rs2552220	1.000	rs13270906	chr8:6007865	G/A	cg06481462	chr8:7005678	NA	0.47	4.77	0.44	6.77e-6	Interleukin-8 levels;
THYM	cis	rs3126085	0.935	rs1496045	chr1:152184704	C/T	cg26020982	chr1:152196106	HRNR	0.35	4.57	0.42	1.45e-5	Atopic dermatitis;
THYM	cis	rs11657217	0.502	rs4442854	chr17:77698224	C/T	cg06901238	chr17:77706717	ENPP7	0.79	7.98	0.63	3.27e-12	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
THYM	cis	rs3768617	0.510	rs1413387	chr1:183096774	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	4.98	0.46	2.84e-6	Fuchs's corneal dystrophy;
THYM	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-6.68	-0.57	1.62e-9	Platelet count;
THYM	cis	rs11190604	1.000	rs3750720	chr10:102248884	C/T	cg07570687	chr10:102243282	WNT8B	0.77	6.96	0.58	4.42e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	10.29	0.73	4e-17	Chronic sinus infection;
THYM	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs12681288	0.723	rs35425201	chr8:971062	C/T	cg08648136	chr8:956695	NA	0.68	6.07	0.53	2.61e-8	Schizophrenia;
THYM	cis	rs7552404	0.672	rs8763	chr1:76229120	T/C	cg10523679	chr1:76189770	ACADM	0.7	4.55	0.42	1.61e-5	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg10360139	chr7:1886902	MAD1L1	-0.59	-4.83	-0.44	5.23e-6	Bipolar disorder and schizophrenia;
THYM	trans	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg25517755	chr10:38738941	LOC399744	0.77	7.48	0.61	3.65e-11	Corneal astigmatism;
THYM	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg24209194	chr3:40518798	ZNF619	-0.73	-6.31	-0.54	8.87e-9	Renal cell carcinoma;
THYM	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg08048268	chr3:133502702	NA	-0.71	-5.89	-0.52	5.76e-8	Iron status biomarkers;
THYM	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs2219968	0.525	rs4628250	chr8:78882550	T/C	cg00738934	chr8:78996279	NA	0.61	4.95	0.45	3.21e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg10856724	chr12:34555212	NA	-0.78	-6.99	-0.58	3.83e-10	Morning vs. evening chronotype;
THYM	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg17888033	chr8:143858414	LYNX1	-0.46	-5.13	-0.47	1.55e-6	Urinary tract infection frequency;
THYM	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg26384229	chr12:38710491	ALG10B	0.73	5.5	0.49	3.16e-7	Morning vs. evening chronotype;
THYM	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg13607699	chr17:42295918	UBTF	-0.65	-5.29	-0.48	7.89e-7	Total body bone mineral density;
THYM	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.63	-4.6	-0.43	1.31e-5	Aortic root size;
THYM	cis	rs2820651	0.614	rs56003778	chr10:1490006	C/T	cg02445968	chr10:1449028	ADARB2	-1.05	-5.34	-0.48	6.32e-7	Migraine with aura;
THYM	cis	rs1448094	0.621	rs10863091	chr12:86282240	T/C	cg02569458	chr12:86230093	RASSF9	0.52	4.73	0.44	7.8e-6	Major depressive disorder;
THYM	cis	rs7084402	0.967	rs1649037	chr10:60331135	C/T	cg07615347	chr10:60278583	BICC1	0.55	5.11	0.46	1.64e-6	Refractive error;
THYM	cis	rs4631830	0.900	rs10763588	chr10:51539762	G/T	cg16070123	chr10:51489643	NA	-0.53	-4.78	-0.44	6.27e-6	Prostate-specific antigen levels;
THYM	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg07424592	chr7:64974309	NA	-1.03	-5.4	-0.48	4.94e-7	Diabetic kidney disease;
THYM	cis	rs7000551	0.597	rs11785943	chr8:22287870	C/T	cg12081754	chr8:22256438	SLC39A14	1.03	8.87	0.67	4.31e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg08999081	chr20:33150536	PIGU	-0.61	-5.59	-0.5	2.16e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7246967	0.736	rs411131	chr19:22993439	G/A	cg05241461	chr19:22816980	ZNF492	0.58	4.77	0.44	6.72e-6	Bronchopulmonary dysplasia;
THYM	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg07537917	chr2:241836409	C2orf54	-0.25	-5.93	-0.52	4.97e-8	Urinary metabolites;
THYM	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg26513180	chr16:89883248	FANCA	-0.55	-5.05	-0.46	2.11e-6	Vitiligo;
THYM	cis	rs7725337	0.965	rs13178887	chr5:88355993	T/C	cg11280525	chr5:87955695	LOC645323	-0.4	-4.5	-0.42	1.91e-5	Total body bone mineral density;
THYM	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg06108461	chr20:60628389	TAF4	0.79	6.43	0.55	5.17e-9	Body mass index;
THYM	cis	rs514406	0.861	rs35581164	chr1:53271373	C/G	cg08859206	chr1:53392774	SCP2	-0.6	-6.9	-0.58	5.7e-10	Monocyte count;
THYM	trans	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg17691542	chr6:26056736	HIST1H1C	0.88	5.35	0.48	5.99e-7	Iron status biomarkers;
THYM	cis	rs4780401	0.755	rs8191285	chr16:11765408	A/G	cg01061890	chr16:11836724	TXNDC11	-0.61	-4.66	-0.43	1.02e-5	Rheumatoid arthritis;
THYM	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg12935359	chr14:103987150	CKB	0.61	6.24	0.54	1.2e-8	Body mass index;
THYM	cis	rs7772486	0.603	rs2223411	chr6:146028767	T/C	cg23711669	chr6:146136114	FBXO30	-0.83	-7.77	-0.62	9.16e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg19077165	chr18:44547161	KATNAL2	-0.64	-7.86	-0.63	5.86e-12	Personality dimensions;
THYM	cis	rs10463554	0.892	rs34830	chr5:102444053	A/G	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Parkinson's disease;
THYM	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg23791538	chr6:167370224	RNASET2	-0.77	-6.24	-0.54	1.23e-8	Crohn's disease;
THYM	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.21	8.56	0.66	1.96e-13	Cognitive test performance;
THYM	cis	rs11574514	1.000	rs75843134	chr16:67767553	C/T	cg09738193	chr16:67926317	PSKH1	-0.91	-4.66	-0.43	1.01e-5	Crohn's disease;
THYM	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg06028605	chr16:24865363	SLC5A11	-0.55	-5.4	-0.48	4.99e-7	Intelligence (multi-trait analysis);
THYM	cis	rs8014204	0.566	rs11629369	chr14:75162021	G/A	cg06637938	chr14:75390232	RPS6KL1	0.59	5.38	0.48	5.39e-7	Caffeine consumption;
THYM	cis	rs7224737	1.000	rs12603327	chr17:40290552	T/C	cg20291162	chr17:40259547	DHX58	-0.69	-6.44	-0.55	4.96e-9	Fibrinogen levels;
THYM	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg24308560	chr3:49941425	MST1R	0.61	4.57	0.42	1.47e-5	Body mass index;
THYM	cis	rs72827839	0.846	rs72825504	chr17:46139479	C/T	cg23391107	chr17:45924227	SP6	0.83	5.6	0.5	2.08e-7	Ease of getting up in the morning;
THYM	cis	rs9790314	0.936	rs336572	chr3:161068014	G/A	cg04691961	chr3:161091175	C3orf57	-0.58	-4.83	-0.44	5.26e-6	Morning vs. evening chronotype;
THYM	cis	rs2836633	1.000	rs2836633	chr21:40067445	C/T	cg12884169	chr21:40033163	ERG	-0.6	-7.45	-0.61	4.2e-11	Coronary artery disease;
THYM	cis	rs6450176	0.633	rs617777	chr5:53330440	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.94	-8.27	-0.65	8.11e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg02734326	chr4:10020555	SLC2A9	0.78	6.67	0.56	1.68e-9	Bone mineral density;
THYM	cis	rs17102423	0.654	rs8015921	chr14:65523015	G/A	cg11161011	chr14:65562177	MAX	-0.56	-4.76	-0.44	6.8e-6	Obesity-related traits;
THYM	cis	rs2299587	0.582	rs17515033	chr8:17898518	A/T	cg18067069	chr8:17937731	ASAH1	-0.6	-4.5	-0.42	1.92e-5	Economic and political preferences;
THYM	trans	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg25517755	chr10:38738941	LOC399744	-0.8	-7.86	-0.63	6e-12	Corneal astigmatism;
THYM	cis	rs8078723	0.714	rs3859187	chr17:38150613	C/A	cg17467752	chr17:38218738	THRA	-0.8	-6.7	-0.57	1.46e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg04414720	chr1:150670196	GOLPH3L	-0.64	-4.84	-0.44	5e-6	Tonsillectomy;
THYM	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg02353165	chr6:42928485	GNMT	-0.87	-8.22	-0.64	1.02e-12	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4786125	0.920	rs6500851	chr16:6896521	A/G	cg03623568	chr16:6915990	A2BP1	-0.79	-6.25	-0.54	1.17e-8	Heart rate variability traits (SDNN);
THYM	cis	rs9644630	0.804	rs11779939	chr8:19327487	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.61	4.9	0.45	3.92e-6	Oropharynx cancer;
THYM	cis	rs59698941	0.943	rs41298946	chr5:132268390	A/G	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs7572733	0.534	rs700688	chr2:198723833	A/G	cg05783139	chr2:198650985	BOLL	-0.64	-5.0	-0.46	2.6e-6	Dermatomyositis;
THYM	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg06808227	chr14:105710500	BRF1	-1.03	-8.93	-0.68	3.17e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg11327659	chr7:150037044	RARRES2	0.43	5.27	0.48	8.39e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg11764359	chr7:65958608	NA	-0.75	-6.04	-0.53	2.97e-8	Aortic root size;
THYM	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Body mass index;
THYM	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg10360139	chr7:1886902	MAD1L1	-0.6	-5.26	-0.47	8.94e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs6121246	0.559	rs6060952	chr20:30382108	T/G	cg13852791	chr20:30311386	BCL2L1	0.87	8.17	0.64	1.31e-12	Mean corpuscular hemoglobin;
THYM	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg12419862	chr22:24373484	LOC391322	0.73	6.82	0.57	8.4e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg01364799	chr7:75623366	TMEM120A	-0.62	-4.46	-0.42	2.22e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg20891283	chr12:69753455	YEATS4	1.06	10.24	0.72	5.15e-17	Blood protein levels;
THYM	cis	rs863345	0.604	rs12075228	chr1:158502256	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg18904891	chr8:8559673	CLDN23	-0.59	-5.06	-0.46	2.03e-6	Mood instability;
THYM	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg17178900	chr1:205818956	PM20D1	-0.67	-5.11	-0.46	1.67e-6	Menarche (age at onset);
THYM	cis	rs4713118	0.911	rs9461406	chr6:27719764	C/T	cg08968635	chr6:28129556	ZNF389	-0.64	-4.71	-0.43	8.53e-6	Parkinson's disease;
THYM	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	4.97	0.45	2.93e-6	Tonsillectomy;
THYM	cis	rs4482178	0.850	rs1753740	chr13:86250828	G/T	cg25308322	chr13:86268291	NA	0.69	4.59	0.43	1.36e-5	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg03433033	chr1:76189801	ACADM	0.77	10.21	0.72	6.01e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7246657	0.943	rs8109632	chr19:37931125	A/T	cg22634378	chr19:37742834	NA	0.62	5.18	0.47	1.22e-6	Coronary artery calcification;
THYM	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg26924012	chr15:45694286	SPATA5L1	1.05	9.19	0.69	8.87e-15	Homoarginine levels;
THYM	cis	rs6060717	0.654	rs8122716	chr20:34607001	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-4.6	-0.43	1.31e-5	Hip circumference adjusted for BMI;
THYM	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6700896	0.864	rs11208718	chr1:66158995	G/A	cg04111102	chr1:66153794	NA	0.52	4.94	0.45	3.32e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg06238570	chr21:40685208	BRWD1	-0.72	-6.28	-0.54	9.9e-9	Menarche (age at onset);
THYM	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg10057126	chr4:77819792	ANKRD56	0.7	5.93	0.52	4.87e-8	Emphysema distribution in smoking;
THYM	cis	rs4285028	0.948	rs7651226	chr3:121670802	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs713587	0.563	rs7591460	chr2:25103967	A/C	cg01884057	chr2:25150051	NA	0.62	5.89	0.52	5.8e-8	Body mass index in non-asthmatics;
THYM	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg00599273	chr12:58146742	CDK4	-0.4	-4.67	-0.43	9.72e-6	Multiple sclerosis;
THYM	cis	rs7814319	0.727	rs3808386	chr8:97273543	G/A	cg20787634	chr8:97240163	UQCRB	-0.74	-6.78	-0.57	1e-9	Lung function (FVC);
THYM	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.8	6.06	0.53	2.67e-8	IgG glycosylation;
THYM	cis	rs113835537	0.597	rs3737525	chr11:66306355	A/G	cg10315249	chr11:66235081	PELI3	0.44	4.6	0.43	1.3e-5	Airway imaging phenotypes;
THYM	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs870825	0.616	rs7678864	chr4:185635158	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg24450063	chr1:156163899	SLC25A44	1.13	13.45	0.81	9.96e-24	Testicular germ cell tumor;
THYM	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg24675056	chr1:15929824	NA	0.72	5.69	0.5	1.43e-7	Systolic blood pressure;
THYM	cis	rs9549328	0.731	rs7983602	chr13:113620482	A/G	cg17524180	chr13:113633600	MCF2L	-0.51	-4.59	-0.43	1.38e-5	Systolic blood pressure;
THYM	cis	rs2276314	0.802	rs4799838	chr18:33597530	T/C	cg19628046	chr18:33552617	C18orf21	0.75	5.33	0.48	6.55e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg09323728	chr8:95962352	TP53INP1	-0.44	-4.56	-0.42	1.53e-5	Type 2 diabetes;
THYM	cis	rs3126085	0.935	rs4845429	chr1:152225376	G/C	cg10321714	chr1:152280068	FLG	0.68	4.99	0.46	2.72e-6	Atopic dermatitis;
THYM	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs2811415	0.597	rs6796874	chr3:127801198	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg15556689	chr8:8085844	FLJ10661	0.64	5.21	0.47	1.1e-6	Mood instability;
THYM	cis	rs7772486	0.754	rs4896838	chr6:146015451	T/C	cg23711669	chr6:146136114	FBXO30	-0.97	-9.85	-0.71	3.5e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4072705	0.904	rs4593661	chr9:127410515	C/A	cg01786973	chr9:127249749	NR5A1	-0.38	-4.97	-0.45	2.94e-6	Menarche (age at onset);
THYM	cis	rs9914988	0.943	rs2043032	chr17:27136692	A/G	cg07195577	chr17:27052828	TLCD1	0.63	4.54	0.42	1.66e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs4789939	0.528	rs2377003	chr17:76878902	T/C	cg13694343	chr17:76876206	TIMP2	-1.32	-8.38	-0.65	4.68e-13	Dupuytren's disease;
THYM	cis	rs2115536	1.000	rs2115536	chr15:80194247	C/T	cg00225070	chr15:80189496	MTHFS	0.62	5.5	0.49	3.15e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg07414643	chr4:187882934	NA	-0.67	-5.92	-0.52	5e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg06238570	chr21:40685208	BRWD1	-0.67	-5.57	-0.5	2.34e-7	Menarche (age at onset);
THYM	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs865483	0.895	rs7501983	chr17:35783812	A/G	cg06716730	chr17:35851459	DUSP14	-0.43	-7.32	-0.6	7.91e-11	Monocyte count;
THYM	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg16342193	chr10:102329863	NA	0.54	5.64	0.5	1.77e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg18305652	chr10:134549665	INPP5A	0.75	5.9	0.52	5.46e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg16482183	chr6:26056742	HIST1H1C	0.88	5.74	0.51	1.13e-7	Iron status biomarkers;
THYM	cis	rs34311866	0.748	rs10029038	chr4:899352	T/C	cg07828340	chr4:882639	GAK	0.97	4.49	0.42	1.97e-5	Parkinson's disease;
THYM	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg13319975	chr6:146136371	FBXO30	-0.62	-4.99	-0.46	2.73e-6	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg03929089	chr4:120376271	NA	-0.97	-7.63	-0.62	1.81e-11	Coronary artery disease;
THYM	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9972944	0.651	rs9906040	chr17:63840825	A/G	cg07283582	chr17:63770753	CCDC46	-0.63	-4.9	-0.45	3.94e-6	Total body bone mineral density;
THYM	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg12963246	chr6:28129442	ZNF389	0.62	5.34	0.48	6.28e-7	Cardiac Troponin-T levels;
THYM	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg21984481	chr17:79567631	NPLOC4	0.46	4.87	0.45	4.45e-6	Eye color traits;
THYM	cis	rs7980799	0.682	rs10161491	chr12:33623806	T/C	cg06521331	chr12:34319734	NA	0.69	4.85	0.45	4.81e-6	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs13082711	0.911	rs3755652	chr3:27472936	A/G	cg02860705	chr3:27208620	NA	-0.74	-5.3	-0.48	7.62e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg10047753	chr17:41438598	NA	1.18	11.26	0.76	3.4e-19	Menopause (age at onset);
THYM	cis	rs9467711	0.656	rs34961555	chr6:26199903	C/T	cg16898833	chr6:26189333	HIST1H4D	1.33	4.6	0.43	1.32e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg02527881	chr3:46936655	PTH1R	-0.65	-6.44	-0.55	4.94e-9	Colorectal cancer;
THYM	cis	rs4919687	0.550	rs12259058	chr10:104484799	A/G	cg15744005	chr10:104629667	AS3MT	-0.61	-4.76	-0.44	6.95e-6	Colorectal cancer;
THYM	trans	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg10856724	chr12:34555212	NA	-0.89	-8.05	-0.64	2.41e-12	Bladder cancer;
THYM	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg24846343	chr22:24311635	DDTL	0.47	6.32	0.54	8.26e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg21926276	chr11:2035255	NA	0.27	4.57	0.42	1.44e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs10927875	0.541	rs1739841	chr1:16342727	A/G	cg21385522	chr1:16154831	NA	0.65	4.54	0.42	1.65e-5	Dilated cardiomyopathy;
THYM	cis	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg10856724	chr12:34555212	NA	-0.92	-9.1	-0.68	1.41e-14	Morning vs. evening chronotype;
THYM	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22857025	chr5:266934	NA	-1.4	-8.88	-0.67	4.04e-14	Breast cancer;
THYM	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg18252515	chr7:66147081	NA	0.6	4.52	0.42	1.76e-5	Aortic root size;
THYM	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg13695892	chr22:41940480	POLR3H	-0.86	-5.96	-0.52	4.19e-8	Vitiligo;
THYM	cis	rs11651000	0.857	rs16947078	chr17:45825500	A/G	cg03474202	chr17:45855739	NA	-0.78	-6.66	-0.56	1.75e-9	IgG glycosylation;
THYM	cis	rs4786125	0.581	rs7194903	chr16:6918194	A/G	cg03623568	chr16:6915990	A2BP1	-1.0	-10.07	-0.72	1.18e-16	Heart rate variability traits (SDNN);
THYM	cis	rs2273669	0.667	rs1407241	chr6:109328432	G/A	cg17117243	chr6:109341365	SESN1	-0.9	-5.32	-0.48	7.02e-7	Prostate cancer;
THYM	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg26384229	chr12:38710491	ALG10B	-0.74	-6.24	-0.54	1.22e-8	Morning vs. evening chronotype;
THYM	cis	rs28595532	0.920	rs115986613	chr4:119752156	G/A	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg14458575	chr2:238380390	NA	1.09	8.62	0.66	1.43e-13	Prostate cancer;
THYM	cis	rs7084402	0.967	rs11817440	chr10:60272369	T/C	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg14675211	chr2:100938903	LONRF2	0.75	7.93	0.63	4.32e-12	Intelligence (multi-trait analysis);
THYM	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg16615211	chr3:44902933	MIR564;TMEM42	0.56	6.07	0.53	2.65e-8	Depressive symptoms;
THYM	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg20887711	chr4:1340912	KIAA1530	-0.71	-6.11	-0.53	2.14e-8	Obesity-related traits;
THYM	cis	rs2985684	0.841	rs7158577	chr14:50058633	C/T	cg02151108	chr14:50098012	C14orf104	-0.72	-5.63	-0.5	1.86e-7	Carotid intima media thickness;
THYM	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.15	-0.59	1.75e-10	Triglycerides;
THYM	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.87	-7.46	-0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs7193541	0.684	rs8062783	chr16:74691264	C/T	cg01733217	chr16:74700730	RFWD3	-0.95	-10.72	-0.74	4.73e-18	Multiple myeloma;
THYM	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11644478	chr21:40555479	PSMG1	-0.8	-6.93	-0.58	5.09e-10	Cognitive function;
THYM	cis	rs6754311	0.593	rs313518	chr2:136439090	C/T	cg20242066	chr2:136595261	LCT	0.55	6.04	0.53	3.05e-8	Mosquito bite size;
THYM	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg07061783	chr6:25882402	NA	-0.57	-4.45	-0.42	2.3e-5	Height;
THYM	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg17509989	chr5:176798049	RGS14	-0.68	-6.7	-0.57	1.43e-9	Urinary electrolytes (magnesium/calcium ratio);
THYM	cis	rs7523273	0.526	rs3849274	chr1:208021557	T/A	cg22525895	chr1:207977042	MIR29B2	-0.92	-9.48	-0.7	2.12e-15	Schizophrenia;
THYM	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.12	0.59	2.08e-10	Obesity-related traits;
THYM	cis	rs611744	0.967	rs686265	chr8:109199763	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs6748734	0.625	rs4563218	chr2:241820035	G/A	cg09990169	chr2:241835740	C2orf54	-0.31	-5.08	-0.46	1.92e-6	Urinary metabolites;
THYM	cis	rs9361491	0.579	rs2321772	chr6:79476190	T/G	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.88e-5	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.52e-10	Prudent dietary pattern;
THYM	cis	rs10089	1.000	rs4836363	chr5:127462737	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs4383453	0.511	rs6803100	chr3:123103246	T/C	cg04890266	chr3:123102914	ADCY5	-0.82	-8.58	-0.66	1.75e-13	Gestational age at birth (maternal effect);
THYM	cis	rs2456568	0.802	rs10765638	chr11:93636171	A/T	cg26875233	chr11:93583750	C11orf90	-0.53	-5.53	-0.49	2.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg23428387	chr22:49814324	NA	-0.55	-5.65	-0.5	1.65e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg12935359	chr14:103987150	CKB	-0.63	-6.3	-0.54	9.4e-9	Body mass index;
THYM	cis	rs1018836	0.608	rs7821069	chr8:91465548	C/G	cg16814680	chr8:91681699	NA	-0.71	-5.68	-0.5	1.47e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg06112835	chr11:68658793	MRPL21	0.44	6.35	0.55	7.47e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs28595532	0.920	rs115154776	chr4:119774803	A/G	cg11846333	chr4:119757529	SEC24D	1.45	5.08	0.46	1.92e-6	Cannabis dependence symptom count;
THYM	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg12179176	chr11:130786555	SNX19	0.89	8.25	0.65	8.93e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2310173	0.651	rs11685537	chr2:102674440	C/T	cg12682972	chr2:102444908	MAP4K4	0.42	4.51	0.42	1.84e-5	Ankylosing spondylitis;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Ulcerative colitis;
THYM	cis	rs7614311	1.000	rs2637983	chr3:63821632	G/A	cg22134162	chr3:63841271	THOC7	-0.44	-5.34	-0.48	6.44e-7	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs12446552	0.661	rs72781038	chr16:11700928	A/G	cg09662852	chr16:11707685	NA	-0.64	-6.06	-0.53	2.68e-8	Colorectal or endometrial cancer;
THYM	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg20283391	chr11:68216788	NA	-0.69	-5.14	-0.47	1.49e-6	Total body bone mineral density;
THYM	cis	rs7084402	0.967	rs1649022	chr10:60285867	A/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg05368731	chr17:41323189	NBR1	1.2	9.53	0.7	1.71e-15	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg02931644	chr1:25747376	RHCE	0.58	4.59	0.43	1.35e-5	Erythrocyte sedimentation rate;
THYM	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg23711669	chr6:146136114	FBXO30	-0.96	-10.02	-0.72	1.48e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6570726	0.967	rs9403707	chr6:145800010	A/G	cg23711669	chr6:146136114	FBXO30	0.82	7.83	0.63	6.97e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg23851026	chr2:136556271	LCT	-0.56	-6.05	-0.53	2.91e-8	Mosquito bite size;
THYM	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg25817165	chr18:72167213	CNDP2	-0.89	-7.92	-0.63	4.44e-12	Refractive error;
THYM	cis	rs13315871	0.929	rs13322000	chr3:58286929	G/A	cg00563845	chr3:58318305	PXK	0.59	5.03	0.46	2.29e-6	Cholesterol, total;
THYM	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	4.97	0.45	3e-6	Height;
THYM	cis	rs919433	0.926	rs787997	chr2:198216271	A/G	cg00792783	chr2:198669748	PLCL1	0.78	5.67	0.5	1.53e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6430585	0.697	rs6724569	chr2:136516970	G/A	cg23851026	chr2:136556271	LCT	0.79	7.53	0.61	2.86e-11	Corneal structure;
THYM	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg00071950	chr4:10020882	SLC2A9	0.76	7.91	0.63	4.56e-12	Bone mineral density;
THYM	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg24375607	chr4:120327624	NA	0.65	5.19	0.47	1.18e-6	Corneal astigmatism;
THYM	cis	rs870825	0.616	rs4616798	chr4:185634144	C/T	cg04058563	chr4:185651563	MLF1IP	-1.07	-9.65	-0.7	9.06e-16	Blood protein levels;
THYM	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs7084402	0.967	rs1649065	chr10:60306386	T/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.65e-7	Refractive error;
THYM	cis	rs11018874	0.597	rs4268468	chr11:89886284	C/T	cg23743573	chr11:89867420	NAALAD2	0.8	5.4	0.48	4.95e-7	White blood cell types;
THYM	cis	rs1915146	0.904	rs28414241	chr10:126851739	A/T	cg23000734	chr10:126850823	CTBP2	0.85	10.93	0.75	1.74e-18	Menarche (age at onset);
THYM	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg08132940	chr7:1081526	C7orf50	-0.75	-5.06	-0.46	2.04e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg26384229	chr12:38710491	ALG10B	-0.71	-5.49	-0.49	3.29e-7	Morning vs. evening chronotype;
THYM	cis	rs1150668	0.835	rs203869	chr6:28040819	T/A	cg13525197	chr6:28411240	ZSCAN23	-0.71	-5.47	-0.49	3.65e-7	Pubertal anthropometrics;
THYM	cis	rs6430585	0.527	rs62168792	chr2:136415217	A/G	cg23851026	chr2:136556271	LCT	0.63	5.72	0.51	1.24e-7	Corneal structure;
THYM	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg06618935	chr21:46677482	NA	-0.98	-9.5	-0.7	1.95e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg26384229	chr12:38710491	ALG10B	1.02	8.22	0.64	1.05e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg02070205	chr10:30722105	MAP3K8	-0.59	-4.79	-0.44	6.07e-6	Inflammatory bowel disease;
THYM	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg06130144	chr11:64578348	MEN1	0.72	4.46	0.42	2.22e-5	Mean platelet volume;
THYM	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg03517284	chr6:25882590	NA	-0.67	-4.47	-0.42	2.14e-5	Height;
THYM	cis	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.76	0.44	7.03e-6	Obesity-related traits;
THYM	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg13147721	chr7:65941812	NA	-0.94	-5.74	-0.51	1.13e-7	Diabetic kidney disease;
THYM	cis	rs4262150	0.883	rs4260728	chr5:152225997	C/A	cg06854687	chr5:151642065	NA	0.67	4.68	0.43	9.56e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg24838063	chr12:130822603	PIWIL1	0.91	7.04	0.59	2.94e-10	Menopause (age at onset);
THYM	cis	rs4780401	0.539	rs62040604	chr16:11803641	G/A	cg01061890	chr16:11836724	TXNDC11	-0.69	-5.54	-0.49	2.64e-7	Rheumatoid arthritis;
THYM	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs4866334	0.867	rs78373067	chr5:18463912	A/G	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs1267303	0.642	rs3737740	chr1:47000596	G/A	cg16387850	chr1:46982889	NA	-0.45	-5.49	-0.49	3.34e-7	Monobrow;
THYM	trans	rs877282	1.000	rs877282	chr10:771532	G/A	cg22713356	chr15:30763199	NA	1.4	11.86	0.77	1.9e-20	Uric acid levels;
THYM	cis	rs4930103	0.935	rs2839698	chr11:2018853	G/A	cg18511798	chr11:2018149	H19;MIR675	-0.57	-5.57	-0.5	2.39e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24549020	chr5:56110836	MAP3K1	0.71	4.63	0.43	1.15e-5	Initial pursuit acceleration;
THYM	cis	rs7084921	0.521	rs11592640	chr10:101878409	C/T	cg11344164	chr10:101878520	NA	-0.59	-5.68	-0.5	1.46e-7	Bone mineral density;
THYM	cis	rs2302729	0.860	rs7138079	chr12:2781304	G/A	cg19945202	chr12:2788847	CACNA1C	-0.96	-6.33	-0.54	8e-9	Sleep quality;
THYM	cis	rs669446	0.562	rs10890273	chr1:44186444	T/A	cg15962314	chr1:44399869	ARTN	0.44	4.66	0.43	1.05e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.89	5.72	0.51	1.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg26384229	chr12:38710491	ALG10B	0.99	7.62	0.62	1.85e-11	Bladder cancer;
THYM	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg00786635	chr1:25594202	NA	0.89	7.21	0.59	1.3100000000000001e-10	Erythrocyte sedimentation rate;
THYM	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg15445000	chr17:37608096	MED1	-0.44	-5.1	-0.46	1.72e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2290159	0.800	rs5746214	chr3:12644753	A/G	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg02398342	chr17:80708632	TBCD;FN3K	0.72	5.44	0.49	4.19e-7	Glycated hemoglobin levels;
THYM	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg00310523	chr12:86230176	RASSF9	0.61	5.31	0.48	7.29e-7	Major depressive disorder;
THYM	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs17539620	0.624	rs62432737	chr6:154834772	G/A	cg20019720	chr6:154832845	CNKSR3	0.47	4.79	0.44	6.17e-6	Lipoprotein (a) levels;
THYM	cis	rs7127900	1.000	rs11043143	chr11:2234093	T/C	cg25635251	chr11:2234043	NA	0.74	4.79	0.44	6.19e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs10411161	0.702	rs8110546	chr19:52383556	C/A	cg25361850	chr19:52391789	ZNF577	0.72	4.96	0.45	3.09e-6	Breast cancer;
THYM	cis	rs67385638	0.802	rs72872555	chr11:5310169	G/A	cg12559170	chr11:5275217	HBG2	0.71	6.09	0.53	2.44e-8	Hemoglobin levels;
THYM	cis	rs7942486	0.893	rs11022725	chr11:13273156	A/C	cg13286116	chr11:13302098	ARNTL	-0.75	-8.31	-0.65	6.72e-13	Neuroticism;
THYM	cis	rs12142240	0.698	rs41294456	chr1:46809782	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs1650123	0.645	rs831684	chr12:104020461	T/C	cg23227824	chr12:103980017	STAB2	0.46	4.75	0.44	7.3e-6	IgG glycosylation;
THYM	cis	rs7072216	0.763	rs12259939	chr10:100169021	T/C	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg03806693	chr22:41940476	POLR3H	-0.86	-7.54	-0.61	2.72e-11	Vitiligo;
THYM	cis	rs9677476	0.528	rs62197317	chr2:232054467	T/C	cg07929768	chr2:232055508	NA	0.61	5.21	0.47	1.09e-6	Food antigen IgG levels;
THYM	cis	rs1401999	0.510	rs17817736	chr3:183720313	A/T	cg01324343	chr3:183735012	ABCC5	-0.52	-5.31	-0.48	7.11e-7	Anterior chamber depth;
THYM	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg17372223	chr3:52568218	NT5DC2	0.38	6.03	0.53	3.15e-8	Electroencephalogram traits;
THYM	cis	rs55871839	0.708	rs4738730	chr8:59808935	A/T	cg07426533	chr8:59803705	TOX	-0.64	-6.4	-0.55	5.92e-9	Pneumonia;
THYM	cis	rs9309711	0.922	rs13431788	chr2:3482912	G/A	cg10845886	chr2:3471009	TTC15	-0.61	-5.09	-0.46	1.84e-6	Neurofibrillary tangles;
THYM	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg09307838	chr4:120376055	NA	0.71	5.07	0.46	1.98e-6	Corneal astigmatism;
THYM	trans	rs59551326	0.517	rs2829646	chr21:26590668	C/T	cg17452615	chr12:122019080	KDM2B	-0.8	-6.84	-0.57	7.67e-10	Alcohol dependence;
THYM	cis	rs904251	0.861	rs1757173	chr6:37486952	A/C	cg25019722	chr6:37503610	NA	-0.65	-5.57	-0.5	2.37e-7	Cognitive performance;
THYM	cis	rs16912285	0.688	rs11827298	chr11:24324000	G/A	ch.11.24196551F	chr11:24239977	NA	1.01	7.15	0.59	1.75e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg11335335	chr11:637885	DRD4	-0.69	-6.23	-0.54	1.24e-8	Systemic lupus erythematosus;
THYM	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	5.02	0.46	2.39e-6	Menarche (age at onset);
THYM	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg04731861	chr2:219085781	ARPC2	0.55	5.26	0.47	8.86e-7	Colorectal cancer;
THYM	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg20503657	chr10:835505	NA	1.42	9.74	0.71	5.94e-16	Eosinophil percentage of granulocytes;
THYM	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg24531977	chr5:56204891	C5orf35	-1.0	-8.34	-0.65	5.78e-13	Initial pursuit acceleration;
THYM	cis	rs1461503	1.000	rs1461503	chr11:122845075	A/C	cg27398637	chr11:122830231	C11orf63	-0.61	-5.17	-0.47	1.31e-6	Menarche (age at onset);
THYM	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg18806716	chr10:30721971	MAP3K8	-0.49	-4.58	-0.43	1.42e-5	Inflammatory bowel disease;
THYM	cis	rs3204270	0.639	rs62080199	chr17:79627906	T/G	cg18367735	chr17:79674897	NA	0.76	4.66	0.43	1.02e-5	Dental caries;
THYM	cis	rs7107174	1.000	rs1893447	chr11:77973182	A/G	cg19901956	chr11:77921274	USP35	-0.71	-5.53	-0.49	2.87e-7	Testicular germ cell tumor;
THYM	cis	rs4767364	1.000	rs7977534	chr12:112717920	T/C	cg10833066	chr12:111807467	FAM109A	0.45	5.11	0.46	1.64e-6	Oral cavity and pharyngeal cancer;
THYM	cis	rs56104184	0.887	rs67286688	chr19:49343329	T/C	cg21252483	chr19:49399788	TULP2	-0.7	-4.86	-0.45	4.55e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2456568	0.503	rs11020603	chr11:93667439	A/G	cg14065697	chr11:93583672	C11orf90	0.48	4.62	0.43	1.19e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs5758511	0.508	rs2854827	chr22:42461918	G/A	cg08431931	chr22:42394659	WBP2NL	0.78	5.1	0.46	1.73e-6	Birth weight;
THYM	cis	rs11096990	0.613	rs2060805	chr4:39234408	A/G	cg24403649	chr4:39172243	NA	0.66	5.74	0.51	1.13e-7	Cognitive function;
THYM	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Autism spectrum disorder or schizophrenia;
THYM	trans	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.22	-14.33	-0.83	1.74e-25	Exhaled nitric oxide output;
THYM	cis	rs6570726	0.755	rs2103633	chr6:145894021	C/T	cg05347473	chr6:146136440	FBXO30	0.58	4.52	0.42	1.8e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2658782	0.654	rs2248524	chr11:93255715	G/A	cg15737290	chr11:93063684	CCDC67	0.87	6.61	0.56	2.24e-9	Pulmonary function decline;
THYM	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06873352	chr17:61820015	STRADA	0.53	5.18	0.47	1.24e-6	Height;
THYM	cis	rs863345	0.604	rs10908666	chr1:158500098	G/T	cg12129480	chr1:158549410	OR10X1	-0.51	-4.88	-0.45	4.22e-6	Pneumococcal bacteremia;
THYM	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg12165864	chr7:66369176	NA	-0.67	-5.26	-0.47	8.99e-7	Aortic root size;
THYM	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg09165964	chr15:75287851	SCAMP5	1.1	6.31	0.54	8.71e-9	Lung cancer;
THYM	cis	rs4907240	0.922	rs4907246	chr2:97326286	T/C	cg18419276	chr2:96971862	SNRNP200	-0.39	-4.5	-0.42	1.93e-5	Event-related brain oscillations;
THYM	cis	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg10856724	chr12:34555212	NA	-0.81	-6.88	-0.58	6.39e-10	Morning vs. evening chronotype;
THYM	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg08999081	chr20:33150536	PIGU	-0.73	-6.56	-0.56	2.86e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg04731861	chr2:219085781	ARPC2	0.54	4.93	0.45	3.47e-6	Colorectal cancer;
THYM	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.64	-5.54	-0.49	2.74e-7	Total body bone mineral density;
THYM	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg18221576	chr1:22213934	HSPG2	-0.55	-4.67	-0.43	9.87e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs10463554	0.963	rs257115	chr5:102531808	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.13	-0.47	1.51e-6	Parkinson's disease;
THYM	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg09323728	chr8:95962352	TP53INP1	-0.44	-4.62	-0.43	1.18e-5	Type 2 diabetes;
THYM	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.63	4.46	0.42	2.28e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs854765	0.663	rs1052299	chr17:17750419	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-5.73	-0.51	1.17e-7	Total body bone mineral density;
THYM	cis	rs6674970	0.777	rs11204782	chr1:151118035	C/G	cg11822372	chr1:151115635	SEMA6C	-1.1	-8.3	-0.65	7.13e-13	Childhood ear infection;
THYM	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg20503657	chr10:835505	NA	1.17	8.29	0.65	7.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs6089829	0.888	rs6011559	chr20:61675620	C/T	cg02380750	chr20:61661411	NA	-0.66	-6.35	-0.55	7.25e-9	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11677370	0.561	rs10191326	chr2:3827524	G/C	cg17052675	chr2:3827356	NA	-0.66	-6.33	-0.54	8.1e-9	Type 2 diabetes;
THYM	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg08508325	chr11:3079039	CARS	-0.54	-6.93	-0.58	4.93e-10	Longevity;
THYM	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg11812906	chr14:75593930	NEK9	-0.86	-8.02	-0.64	2.74e-12	Height;
THYM	cis	rs12049351	0.774	rs4148757	chr1:229693846	A/C	cg11742688	chr1:229674241	ABCB10	-0.56	-4.63	-0.43	1.17e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.77	-5.02	-0.46	2.44e-6	Diabetic retinopathy;
THYM	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	15.13	0.84	4.91e-27	Chronic sinus infection;
THYM	cis	rs9807841	0.617	rs2229383	chr19:10794630	G/T	cg17848348	chr19:10766748	ILF3	-0.75	-5.97	-0.52	4.09e-8	Inflammatory skin disease;
THYM	cis	rs3892630	0.588	rs7260037	chr19:33242701	G/A	cg22928329	chr19:33183273	NUDT19	-0.66	-5.14	-0.47	1.44e-6	Red blood cell traits;
THYM	cis	rs13323323	0.691	rs9814256	chr3:44668037	A/T	cg16615211	chr3:44902933	MIR564;TMEM42	0.55	4.81	0.44	5.71e-6	IgG glycosylation;
THYM	cis	rs8067545	0.559	rs3874846	chr17:20297545	T/G	cg20830565	chr17:20408647	MGC102966	-0.49	-4.56	-0.42	1.51e-5	Schizophrenia;
THYM	cis	rs6032067	0.929	rs13043503	chr20:43805835	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs1461503	0.966	rs1461501	chr11:122844416	A/G	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs394563	0.810	rs480870	chr6:149784818	T/C	cg26849637	chr6:150530249	PPP1R14C	-0.43	-4.76	-0.44	6.79e-6	Dupuytren's disease;
THYM	cis	rs4595586	0.545	rs969468	chr12:39367278	A/C	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs6032067	0.852	rs17333103	chr20:43803613	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.41	-0.65	4.05e-13	Blood protein levels;
THYM	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg18252515	chr7:66147081	NA	-0.62	-4.64	-0.43	1.12e-5	Aortic root size;
THYM	cis	rs72828912	0.665	rs9379637	chr6:24078475	A/G	cg26336265	chr6:25042955	NA	-0.87	-5.53	-0.49	2.85e-7	Squamous cell lung carcinoma;
THYM	cis	rs9467160	0.734	rs35901848	chr6:24443640	G/A	cg20631270	chr6:24437470	GPLD1	0.77	6.14	0.53	1.91e-8	Liver enzyme levels;
THYM	cis	rs6032067	1.000	rs6032067	chr20:43864809	G/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.73	-7.62	-0.62	1.9e-11	Blood protein levels;
THYM	cis	rs9527	0.615	rs3897401	chr10:104696379	T/C	cg15744005	chr10:104629667	AS3MT	-0.6	-4.58	-0.42	1.43e-5	Arsenic metabolism;
THYM	cis	rs2072732	0.904	rs717795	chr1:2970464	T/C	cg08733933	chr1:2954429	NA	-0.57	-4.53	-0.42	1.69e-5	Plateletcrit;
THYM	cis	rs791590	0.715	rs41295079	chr10:6119154	C/T	cg17191567	chr10:6178319	NA	0.69	4.8	0.44	5.92e-6	Soluble interleukin-2 receptor subunit alpha;
THYM	cis	rs7843479	0.601	rs4872204	chr8:21841396	T/C	cg17168535	chr8:21777572	XPO7	0.82	7.34	0.6	7.35e-11	Mean corpuscular volume;
THYM	cis	rs1843834	0.929	rs4674934	chr2:225516468	A/T	cg22509189	chr2:225307070	NA	0.6	4.5	0.42	1.94e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs7220401	0.789	rs3760456	chr17:27948844	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-5.42	-0.49	4.42e-7	Coronary artery disease;
THYM	cis	rs7851660	0.901	rs7873389	chr9:100609230	C/T	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs61931739	0.853	rs7133716	chr12:34041847	G/C	cg10856724	chr12:34555212	NA	0.63	5.33	0.48	6.57e-7	Morning vs. evening chronotype;
THYM	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg00129232	chr17:37814104	STARD3	-0.76	-5.25	-0.47	9.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg11335335	chr11:637885	DRD4	-0.7	-6.32	-0.54	8.37e-9	Systemic lupus erythematosus;
THYM	cis	rs9457247	0.534	rs9356551	chr6:167400345	T/C	cg23791538	chr6:167370224	RNASET2	0.83	7.32	0.6	7.9e-11	Crohn's disease;
THYM	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg06713675	chr4:122721982	EXOSC9	-0.89	-10.43	-0.73	1.96e-17	Type 2 diabetes;
THYM	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg13319975	chr6:146136371	FBXO30	0.66	5.33	0.48	6.53e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.56	4.77	0.44	6.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg09307838	chr4:120376055	NA	-0.77	-5.63	-0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6531209	0.888	rs975950	chr2:20331128	T/A	cg24416238	chr2:20211868	MATN3	-0.65	-5.5	-0.49	3.17e-7	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs28595532	0.920	rs116834347	chr4:119774155	C/A	cg11846333	chr4:119757529	SEC24D	1.45	5.08	0.46	1.92e-6	Cannabis dependence symptom count;
THYM	cis	rs11209185	0.602	rs1926282	chr1:68448753	C/G	cg22082780	chr1:68452167	NA	-0.5	-5.89	-0.52	5.74e-8	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg22683308	chr4:1340831	KIAA1530	-0.6	-4.78	-0.44	6.48e-6	Longevity;
THYM	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg26384229	chr12:38710491	ALG10B	0.94	7.23	0.6	1.19e-10	Bladder cancer;
THYM	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.39	6.05	0.53	2.9e-8	Obesity-related traits;
THYM	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg26384229	chr12:38710491	ALG10B	-0.7	-5.47	-0.49	3.56e-7	Morning vs. evening chronotype;
THYM	cis	rs4076764	0.846	rs12035840	chr1:163419177	G/C	cg24596788	chr1:163392923	NA	-0.74	-6.47	-0.55	4.33e-9	Motion sickness;
THYM	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg17143192	chr8:8559678	CLDN23	0.91	6.72	0.57	1.33e-9	Obesity-related traits;
THYM	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.75	-0.67	7.74e-14	Mean corpuscular volume;
THYM	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg02869364	chr7:1081709	C7orf50	-0.55	-4.93	-0.45	3.44e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs514406	0.893	rs10888759	chr1:53433274	A/G	cg16325326	chr1:53192061	ZYG11B	-0.81	-7.52	-0.61	3.05e-11	Monocyte count;
THYM	cis	rs13082711	0.522	rs9310842	chr3:27369765	A/T	cg02860705	chr3:27208620	NA	-0.65	-5.0	-0.46	2.6e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs12519773	0.611	rs6873704	chr5:92490864	A/C	cg18783429	chr5:92414398	NA	0.54	5.11	0.46	1.68e-6	Migraine;
THYM	cis	rs3017493	0.786	rs79792601	chr11:70675171	G/A	cg14537332	chr11:70508113	SHANK2	1.14	7.77	0.62	9.22e-12	Renal transplant outcome;
THYM	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg08999081	chr20:33150536	PIGU	0.55	4.6	0.43	1.3e-5	Coronary artery disease;
THYM	cis	rs6723226	0.765	rs12612824	chr2:32579759	C/T	cg02381751	chr2:32503542	YIPF4	-0.65	-5.83	-0.51	7.48e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7582180	0.874	rs6727623	chr2:100916724	A/T	cg14675211	chr2:100938903	LONRF2	0.59	4.53	0.42	1.75e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	8.1	0.64	1.86e-12	Monocyte percentage of white cells;
THYM	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg23758822	chr17:41437982	NA	-1.22	-13.81	-0.82	1.89e-24	Menopause (age at onset);
THYM	cis	rs11096990	0.855	rs57488936	chr4:39222246	C/T	cg24403649	chr4:39172243	NA	-0.65	-5.59	-0.5	2.13e-7	Cognitive function;
THYM	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7322722	0.945	rs34408900	chr13:77828894	C/T	cg04565255	chr13:77565759	CLN5	-0.44	-4.51	-0.42	1.82e-5	Preeclampsia;
THYM	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg10515332	chr4:99064459	C4orf37	0.6	4.76	0.44	6.83e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03452623	chr4:187889614	NA	1.17	18.19	0.88	1.04e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg06634786	chr22:41940651	POLR3H	-0.7	-5.38	-0.48	5.4e-7	Vitiligo;
THYM	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg18876405	chr7:65276391	NA	0.6	5.26	0.47	8.96e-7	Aortic root size;
THYM	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg11812906	chr14:75593930	NEK9	0.87	8.3	0.65	7.13e-13	Height;
THYM	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-5.78	-0.51	9.67e-8	Systemic lupus erythematosus;
THYM	cis	rs3126085	1.000	rs2338556	chr1:152309427	T/A	cg10321714	chr1:152280068	FLG	-0.72	-5.44	-0.49	4.14e-7	Atopic dermatitis;
THYM	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg22920501	chr2:26401640	FAM59B	1.07	9.54	0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.7	-5.63	-0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs34779708	0.966	rs11599606	chr10:35406626	G/A	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.52e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg02018176	chr4:1364513	KIAA1530	0.75	7.09	0.59	2.33e-10	Longevity;
THYM	cis	rs9420	0.961	rs7936998	chr11:57639017	G/A	cg19752551	chr11:57585705	CTNND1	-0.74	-8.1	-0.64	1.86e-12	Schizophrenia;
THYM	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg24375607	chr4:120327624	NA	0.64	4.74	0.44	7.41e-6	Corneal astigmatism;
THYM	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.72	-5.56	-0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	trans	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg10856724	chr12:34555212	NA	-0.88	-7.73	-0.62	1.09e-11	Bladder cancer;
THYM	cis	rs4786125	0.516	rs7203888	chr16:6915483	T/C	cg03623568	chr16:6915990	A2BP1	-1.03	-10.58	-0.74	9.66e-18	Heart rate variability traits (SDNN);
THYM	cis	rs7186908	1.000	rs7186908	chr16:72220373	G/C	cg23815491	chr16:72088622	HP	0.76	5.11	0.46	1.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs12148329	0.545	rs12592860	chr15:81033590	C/T	cg01654770	chr15:80543586	NA	-0.88	-4.51	-0.42	1.85e-5	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg13695892	chr22:41940480	POLR3H	-0.9	-7.19	-0.59	1.49e-10	Vitiligo;
THYM	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg15448220	chr1:150897856	SETDB1	0.86	6.94	0.58	4.73e-10	Melanoma;
THYM	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg22852734	chr6:133119734	C6orf192	1.23	7.73	0.62	1.1e-11	Type 2 diabetes nephropathy;
THYM	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	10.22	0.72	5.61e-17	Chronic sinus infection;
THYM	cis	rs7731657	0.537	rs72801772	chr5:130341294	G/T	cg08523029	chr5:130500466	HINT1	-0.81	-5.6	-0.5	2.04e-7	Fasting plasma glucose;
THYM	cis	rs7020830	0.931	rs13293916	chr9:37136359	C/G	cg14294708	chr9:37120828	ZCCHC7	1.33	17.45	0.87	2.19e-31	Schizophrenia;
THYM	cis	rs6987853	0.787	rs2974300	chr8:42440532	C/T	cg09913449	chr8:42400586	C8orf40	1.04	11.18	0.75	5.21e-19	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2439831	0.867	rs2243434	chr15:43689867	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs13185784	0.709	rs6703	chr5:179660786	A/T	cg13944838	chr5:179740914	GFPT2	-0.7	-4.87	-0.45	4.41e-6	TRAIL levels;
THYM	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg04663057	chr3:46933782	PTH1R	-0.47	-4.52	-0.42	1.79e-5	Birth weight;
THYM	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1524976	1.000	rs2037670	chr3:65488142	C/A	cg16238336	chr3:65465873	MAGI1	-0.93	-5.13	-0.47	1.5e-6	PR interval;
THYM	cis	rs9303280	0.617	rs8079416	chr17:38092713	T/C	cg24910161	chr17:38119198	GSDMA	-0.55	-6.65	-0.56	1.89e-9	Self-reported allergy;
THYM	cis	rs34734847	0.703	rs3794215	chr12:121168083	T/C	cg21892295	chr12:121157589	UNC119B	-0.46	-4.72	-0.44	8.04e-6	Mean corpuscular volume;
THYM	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg10295955	chr4:187884368	NA	-1.17	-17.33	-0.87	3.66e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1775715	0.870	rs1775737	chr10:32256871	T/C	cg04359828	chr10:32216031	ARHGAP12	0.41	5.21	0.47	1.11e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg08045932	chr20:61659980	NA	0.95	10.41	0.73	2.18e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12216545	0.765	rs939958	chr7:150257768	C/A	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg21775007	chr8:11205619	TDH	0.76	6.69	0.57	1.5e-9	Retinal vascular caliber;
THYM	cis	rs7192750	0.586	rs4788564	chr16:71891862	G/A	cg06353428	chr16:71660113	MARVELD3	0.73	5.17	0.47	1.3e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg00677455	chr12:58241039	CTDSP2	0.75	5.59	0.5	2.18e-7	Intelligence (multi-trait analysis);
THYM	cis	rs8049040	0.609	rs16972805	chr16:71478249	A/G	cg08717414	chr16:71523259	ZNF19	0.79	4.72	0.44	8.2e-6	Blood protein levels;
THYM	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg26354017	chr1:205819088	PM20D1	0.97	10.36	0.73	2.85e-17	Menarche (age at onset);
THYM	cis	rs3772130	0.923	rs13090798	chr3:121482768	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs6687430	0.526	rs12127400	chr1:10613660	C/T	cg20482658	chr1:10539492	PEX14	-0.39	-5.52	-0.49	2.99e-7	Hand grip strength;
THYM	cis	rs654950	0.875	rs689076	chr1:41999127	C/T	cg06885757	chr1:42089581	HIVEP3	0.47	5.68	0.5	1.47e-7	Airway imaging phenotypes;
THYM	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06850241	chr22:41845214	NA	-0.57	-5.06	-0.46	2.01e-6	Vitiligo;
THYM	cis	rs66569888	0.507	rs17032699	chr2:106886471	A/G	cg16099169	chr2:106886729	NA	-0.72	-8.21	-0.64	1.08e-12	Facial morphology (factor 23);
THYM	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg27168131	chr21:44088823	PDE9A	-0.48	-4.86	-0.45	4.63e-6	Mean corpuscular volume;
THYM	cis	rs7178572	0.889	rs59153558	chr15:77806770	A/G	cg22256960	chr15:77711686	NA	-0.94	-7.78	-0.62	8.6e-12	Type 2 diabetes;
THYM	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.76	8.46	0.66	3.25e-13	Eosinophil percentage of white cells;
THYM	cis	rs4243830	0.850	rs4908558	chr1:6584101	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.1	-7.69	-0.62	1.33e-11	Body mass index;
THYM	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4148689	0.951	rs2237724	chr7:117154159	G/A	cg17204129	chr7:117119601	CFTR	-0.64	-4.95	-0.45	3.18e-6	Gout;
THYM	cis	rs11186	0.556	rs61199451	chr2:189952711	C/T	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7584330	0.554	rs1343768	chr2:238444881	G/A	cg08992911	chr2:238395768	MLPH	0.71	4.69	0.43	9.14e-6	Prostate cancer;
THYM	cis	rs9467711	0.651	rs34888489	chr6:26073375	C/A	cg16898833	chr6:26189333	HIST1H4D	1.33	4.61	0.43	1.24e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs113835537	0.529	rs75685325	chr11:66235242	A/G	cg10315249	chr11:66235081	PELI3	0.43	4.63	0.43	1.17e-5	Airway imaging phenotypes;
THYM	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg11494091	chr17:61959527	GH2	1.09	16.89	0.87	2.34e-30	Prudent dietary pattern;
THYM	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.81	-7.08	-0.59	2.45e-10	Lung cancer;
THYM	cis	rs2274459	1.000	rs12195409	chr6:33757482	T/C	cg06253072	chr6:33679850	C6orf125	0.51	4.49	0.42	1.99e-5	Obesity (extreme);
THYM	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg03060546	chr3:49711283	APEH	-0.74	-5.87	-0.52	6.45e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs6570726	0.846	rs7773939	chr6:145927384	C/T	cg13319975	chr6:146136371	FBXO30	0.6	4.75	0.44	7.34e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg07747251	chr5:1868357	NA	0.68	5.86	0.52	6.66e-8	Cardiovascular disease risk factors;
THYM	trans	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg01121180	chr19:51302454	C19orf48;SNORD88B	-0.77	-6.9	-0.58	5.82e-10	Bone mineral density;
THYM	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg11494091	chr17:61959527	GH2	1.08	16.72	0.86	4.66e-30	Prudent dietary pattern;
THYM	cis	rs7084402	0.967	rs1649084	chr10:60292117	T/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs4918072	0.606	rs78381949	chr10:105612418	G/A	cg11005552	chr10:105648138	OBFC1	0.7	5.33	0.48	6.71e-7	Coronary artery disease;
THYM	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg13880726	chr7:1868755	MAD1L1	-0.72	-4.8	-0.44	5.78e-6	Bipolar disorder;
THYM	cis	rs10501293	0.746	rs7104602	chr11:43018295	C/T	cg03447554	chr11:43094025	NA	0.6	4.46	0.42	2.21e-5	Cognitive performance;
THYM	cis	rs9527	0.590	rs7897663	chr10:104905604	T/C	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg26850624	chr5:429559	AHRR	-0.72	-5.68	-0.5	1.45e-7	Cystic fibrosis severity;
THYM	cis	rs2130392	0.702	rs12108497	chr4:185571557	C/T	cg04058563	chr4:185651563	MLF1IP	0.57	4.89	0.45	4.07e-6	Kawasaki disease;
THYM	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg19747945	chr6:42946146	PEX6	-0.32	-4.59	-0.43	1.34e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9807841	0.592	rs3810154	chr19:10764914	G/A	cg16900796	chr19:10755136	SLC44A2	0.4	6.29	0.54	9.76e-9	Inflammatory skin disease;
THYM	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg25358565	chr5:93447407	FAM172A	-1.35	-10.97	-0.75	1.43e-18	Diabetic retinopathy;
THYM	cis	rs904251	0.861	rs1757183	chr6:37484790	C/T	cg01843034	chr6:37503916	NA	0.63	4.74	0.44	7.55e-6	Cognitive performance;
THYM	cis	rs7567389	0.719	rs4150476	chr2:128032822	A/T	cg06038358	chr2:128176007	PROC	-0.43	-4.53	-0.42	1.7e-5	Self-rated health;
THYM	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.16	-8.66	-0.66	1.18e-13	Platelet count;
THYM	cis	rs2276314	1.000	rs2298716	chr18:33552598	C/T	cg05985134	chr18:33552581	C18orf21	0.66	4.65	0.43	1.09e-5	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs939658	1.000	rs17175798	chr15:79463960	A/G	cg17916960	chr15:79447300	NA	0.73	8.33	0.65	5.9e-13	Refractive error;
THYM	cis	rs3820068	0.608	rs7514858	chr1:16035246	G/A	cg24675056	chr1:15929824	NA	0.78	6.16	0.53	1.73e-8	Systolic blood pressure;
THYM	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	5.43	0.49	4.24e-7	Obesity-related traits;
THYM	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg23422044	chr7:1970798	MAD1L1	-0.77	-4.68	-0.43	9.51e-6	Neuroticism;
THYM	cis	rs7172809	0.897	rs907387	chr15:77828751	T/C	cg10437265	chr15:77819839	NA	-0.53	-4.56	-0.42	1.54e-5	Glucose homeostasis traits;
THYM	cis	rs919433	0.617	rs4850807	chr2:198575975	G/A	cg00792783	chr2:198669748	PLCL1	-0.77	-5.4	-0.48	4.91e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7572733	0.555	rs700671	chr2:198690001	T/C	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs2839186	0.504	rs11702278	chr21:47936295	T/G	cg12379764	chr21:47803548	PCNT	0.91	7.3	0.6	8.7e-11	Testicular germ cell tumor;
THYM	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg24257776	chr3:47051546	LOC100129354	0.41	4.79	0.44	6.1e-6	Colorectal cancer;
THYM	cis	rs7193541	0.684	rs4888265	chr16:74683737	T/C	cg01733217	chr16:74700730	RFWD3	0.99	11.69	0.77	4.32e-20	Multiple myeloma;
THYM	cis	rs11031096	0.727	rs7932702	chr11:4124372	C/T	cg22027985	chr11:4115532	RRM1	-0.53	-5.45	-0.49	4.02e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs911119	0.909	rs3761279	chr20:23620075	C/G	cg16589663	chr20:23618590	CST3	0.76	4.69	0.43	9.26e-6	Chronic kidney disease;
THYM	cis	rs700651	0.789	rs116165148	chr2:198888347	T/G	cg00792783	chr2:198669748	PLCL1	0.83	5.9	0.52	5.65e-8	Intracranial aneurysm;
THYM	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs1021993	0.868	rs6685498	chr1:209530832	G/A	cg06155620	chr1:209527581	NA	-0.65	-5.13	-0.47	1.52e-6	Gut microbiome composition (winter);
THYM	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg09307838	chr4:120376055	NA	0.71	5.07	0.46	1.98e-6	Corneal astigmatism;
THYM	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.63	4.46	0.42	2.28e-5	Age-related macular degeneration (geographic atrophy);
THYM	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg15704280	chr7:45808275	SEPT13	-0.82	-8.19	-0.64	1.17e-12	Height;
THYM	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs4722166	0.695	rs6946509	chr7:22809490	T/C	cg05472934	chr7:22766657	IL6	0.69	6.1	0.53	2.25e-8	Lung cancer;
THYM	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg17105886	chr17:28927953	LRRC37B2	1.32	6.56	0.56	2.79e-9	Body mass index;
THYM	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.62	5.18	0.47	1.25e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs16865717	0.513	rs6431838	chr2:7036838	G/C	cg20486407	chr2:7037101	RSAD2	-1.1	-11.78	-0.77	2.82e-20	Venous thromboembolism (SNP x SNP interaction);
THYM	cis	rs7394190	0.748	rs11000773	chr10:75534115	G/T	cg07699608	chr10:75541558	CHCHD1	0.91	4.93	0.45	3.49e-6	Incident atrial fibrillation;
THYM	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg06453172	chr10:134556979	INPP5A	-0.67	-4.84	-0.44	5.1e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg12386194	chr3:101231763	SENP7	0.85	6.53	0.56	3.19e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg11235152	chr1:67600687	NA	-0.61	-4.83	-0.44	5.22e-6	Psoriasis;
THYM	cis	rs2139634	0.965	rs56233078	chr3:46511969	G/A	cg02332537	chr3:46540019	RTP3	0.45	4.69	0.43	9.18e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs12496230	1.000	rs4856828	chr3:66868008	A/T	cg23477460	chr3:66848765	NA	1.04	6.57	0.56	2.68e-9	Type 2 diabetes;
THYM	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg17426766	chr1:2046864	PRKCZ	0.44	5.23	0.47	1.02e-6	Height;
THYM	cis	rs7586879	0.796	rs11684619	chr2:25078859	G/A	cg01884057	chr2:25150051	NA	0.51	4.73	0.44	7.92e-6	Body mass index;
THYM	cis	rs2913737	0.563	rs2335415	chr5:175893576	T/G	cg27658698	chr5:175955578	RNF44	0.53	4.54	0.42	1.65e-5	Obesity-related traits;
THYM	cis	rs10751667	0.580	rs7396041	chr11:1001607	G/A	cg20248691	chr11:532330	HRAS	-0.46	-4.58	-0.43	1.39e-5	Alzheimer's disease (late onset);
THYM	cis	rs1198430	0.562	rs504145	chr1:23788310	C/T	cg19827787	chr1:23763612	ASAP3	0.59	4.82	0.44	5.47e-6	Total cholesterol levels;
THYM	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-5.74	-0.51	1.15e-7	Total cholesterol levels;
THYM	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg08132940	chr7:1081526	C7orf50	-1.08	-6.01	-0.53	3.36e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg04896959	chr15:78267971	NA	0.93	7.69	0.62	1.38e-11	Coronary artery disease or large artery stroke;
THYM	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.67	-5.7	-0.5	1.37e-7	Coronary artery disease;
THYM	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs4642101	0.680	rs7626609	chr3:12806080	A/G	cg05775895	chr3:12838266	CAND2	-0.69	-5.79	-0.51	8.99e-8	QRS complex (12-leadsum);
THYM	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg04362960	chr10:104952993	NT5C2	0.63	4.47	0.42	2.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg21773646	chr17:80085082	CCDC57	-0.34	-4.91	-0.45	3.76e-6	Life satisfaction;
THYM	cis	rs10789491	1.000	rs1258061	chr1:47105000	G/A	cg15501359	chr1:47185051	KIAA0494	-1.12	-8.14	-0.64	1.49e-12	Response to hepatitis C treatment;
THYM	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg08999081	chr20:33150536	PIGU	-0.57	-4.95	-0.45	3.25e-6	Height;
THYM	cis	rs6430585	0.583	rs2322813	chr2:136582809	A/G	cg04750100	chr2:136595281	LCT	0.54	4.97	0.45	3e-6	Corneal structure;
THYM	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-5.37	-0.48	5.6e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs28595532	0.920	rs17257039	chr4:119603703	G/A	cg21605333	chr4:119757512	SEC24D	1.42	4.79	0.44	6.16e-6	Cannabis dependence symptom count;
THYM	cis	rs7968440	1.000	rs2731439	chr12:51060350	C/T	cg20014596	chr12:50898483	DIP2B	0.56	4.55	0.42	1.57e-5	Fibrinogen;
THYM	cis	rs4363385	0.747	rs946101	chr1:152972032	C/T	cg13444842	chr1:152974279	SPRR3	0.59	4.68	0.43	9.41e-6	Inflammatory skin disease;
THYM	cis	rs12042938	0.600	rs823163	chr1:231771108	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.75	5.6	0.5	2.08e-7	Neuranatomic and neurocognitive phenotypes;
THYM	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.81	-0.63	7.44e-12	Chronic sinus infection;
THYM	cis	rs11723261	0.582	rs11248005	chr4:166615	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.82	5.69	0.5	1.38e-7	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs78707713	0.560	rs35060419	chr10:71229539	A/G	cg08851181	chr10:71228077	TSPAN15	-0.8	-5.95	-0.52	4.46e-8	Venous thromboembolism;
THYM	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	10.77	0.74	3.77e-18	Chronic sinus infection;
THYM	cis	rs7267979	0.934	rs2500399	chr20:25354694	T/G	cg08601574	chr20:25228251	PYGB	-0.58	-4.71	-0.43	8.54e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs3771570	1.000	rs73018141	chr2:242221570	G/A	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg07936489	chr17:37558343	FBXL20	-0.73	-5.03	-0.46	2.32e-6	Asthma;
THYM	cis	rs7599312	0.534	rs6751692	chr2:213408120	C/T	cg16329650	chr2:213403929	ERBB4	0.99	11.32	0.76	2.57e-19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1003719	0.715	rs8128387	chr21:38556787	G/C	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg22535103	chr8:58192502	C8orf71	-0.94	-5.62	-0.5	1.86e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.18	8.91	0.67	3.51e-14	Cognitive test performance;
THYM	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	6.35	0.55	7.5e-9	Smoking behavior;
THYM	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.72	7.49	0.61	3.58e-11	Lymphocyte counts;
THYM	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg23422044	chr7:1970798	MAD1L1	-0.79	-5.24	-0.47	9.83e-7	Bipolar disorder;
THYM	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg13010199	chr12:38710504	ALG10B	0.76	6.07	0.53	2.59e-8	Heart rate;
THYM	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	9.76	0.71	5.3e-16	Platelet count;
THYM	cis	rs2213920	0.619	rs7042718	chr9:118202187	C/T	cg13918206	chr9:118159781	DEC1	0.85	4.85	0.45	4.86e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9549260	0.564	rs9577110	chr13:41271878	T/G	cg21288729	chr13:41239152	FOXO1	0.67	4.77	0.44	6.74e-6	Red blood cell count;
THYM	cis	rs10752881	1.000	rs6673559	chr1:182983197	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg12935359	chr14:103987150	CKB	-0.62	-6.48	-0.55	3.97e-9	Body mass index;
THYM	trans	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg06437703	chr8:37914619	EIF4EBP1	0.82	6.84	0.57	7.65e-10	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg12863693	chr15:85201151	NMB	0.55	4.74	0.44	7.47e-6	Schizophrenia;
THYM	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg13695892	chr22:41940480	POLR3H	0.83	6.07	0.53	2.67e-8	Vitiligo;
THYM	cis	rs55665837	0.524	rs2882128	chr11:14414634	A/C	cg05501817	chr11:14380813	RRAS2	-0.74	-6.1	-0.53	2.24e-8	Vitamin D levels;
THYM	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.77	-7.13	-0.59	1.95e-10	Personality dimensions;
THYM	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1550582	0.662	rs7812708	chr8:135500832	C/T	cg09855544	chr8:135498122	ZFAT	0.67	4.65	0.43	1.09e-5	Educational attainment;
THYM	cis	rs10173297	0.686	rs6705562	chr2:3712897	T/G	cg10083149	chr2:3321068	TSSC1	-0.8	-4.66	-0.43	1.01e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg24642844	chr7:1081250	C7orf50	-1.29	-8.3	-0.65	7.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg11266682	chr4:10021025	SLC2A9	0.71	11.05	0.75	9.64e-19	Bone mineral density;
THYM	cis	rs17102423	0.602	rs1270073	chr14:65566257	C/A	cg11161011	chr14:65562177	MAX	-0.68	-5.69	-0.5	1.4e-7	Obesity-related traits;
THYM	trans	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg13615516	chr5:77269221	NA	-0.89	-8.22	-0.64	1.02e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.11	0.46	1.64e-6	Obesity-related traits;
THYM	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg03806693	chr22:41940476	POLR3H	1.1	8.94	0.68	3.12e-14	Vitiligo;
THYM	cis	rs8014204	0.604	rs7156590	chr14:75388183	C/T	cg08847533	chr14:75593920	NEK9	0.54	4.54	0.42	1.63e-5	Caffeine consumption;
THYM	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg09184832	chr6:79620586	NA	-0.57	-4.45	-0.42	2.3e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-4.48	-0.42	2.05e-5	Axial length;
THYM	cis	rs757081	0.643	rs665311	chr11:17206740	A/T	cg07093617	chr11:18158918	MRGPRX3	-0.49	-4.61	-0.43	1.23e-5	Systolic blood pressure;
THYM	cis	rs35883536	1.000	rs17403857	chr1:101105216	A/C	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs7246657	0.943	rs10405325	chr19:37883477	G/C	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg23851026	chr2:136556271	LCT	-0.57	-5.96	-0.52	4.29e-8	Mosquito bite size;
THYM	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg10862848	chr6:42927986	GNMT	-0.51	-6.83	-0.57	8.14e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs10147992	0.565	rs10141316	chr14:25505085	G/A	cg01495907	chr14:24842974	NFATC4	-0.65	-4.85	-0.45	4.88e-6	White blood cell types;
THYM	cis	rs4866334	1.000	rs76836105	chr5:18467089	T/G	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs9677476	0.779	rs10177091	chr2:232109889	C/T	cg07929768	chr2:232055508	NA	0.59	5.0	0.46	2.61e-6	Food antigen IgG levels;
THYM	cis	rs4638749	0.677	rs12611470	chr2:108839349	C/T	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs728616	0.867	rs61860421	chr10:81743399	C/T	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7000551	0.700	rs2461491	chr8:22361252	C/T	cg12081754	chr8:22256438	SLC39A14	-0.65	-5.97	-0.52	4.11e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2066819	1.000	rs75754909	chr12:56726349	A/G	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs7107174	1.000	rs2450131	chr11:77944568	A/C	cg02023728	chr11:77925099	USP35	0.73	6.33	0.54	7.9e-9	Testicular germ cell tumor;
THYM	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs13315871	0.929	rs1047335	chr3:58280942	A/G	cg00563845	chr3:58318305	PXK	0.55	4.83	0.44	5.15e-6	Cholesterol, total;
THYM	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg20891283	chr12:69753455	YEATS4	-1.07	-11.5	-0.76	1.1e-19	Cerebrospinal fluid biomarker levels;
THYM	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.11e-8	Systolic blood pressure;
THYM	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg18477163	chr1:228402036	OBSCN	-0.55	-6.03	-0.53	3.12e-8	Diastolic blood pressure;
THYM	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg10518543	chr12:38710700	ALG10B	-0.59	-4.7	-0.43	8.88e-6	Morning vs. evening chronotype;
THYM	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg21773646	chr17:80085082	CCDC57	-0.35	-5.02	-0.46	2.39e-6	Life satisfaction;
THYM	cis	rs6998277	1.000	rs62523306	chr8:103640752	C/A	cg10187029	chr8:103597600	NA	0.58	4.58	0.43	1.42e-5	Migraine;
THYM	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12310956	0.510	rs4931759	chr12:33871969	T/C	cg10856724	chr12:34555212	NA	-0.64	-5.82	-0.51	7.77e-8	Morning vs. evening chronotype;
THYM	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg10018233	chr7:150070692	REPIN1	0.54	7.93	0.63	4.16e-12	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg06618935	chr21:46677482	NA	-0.95	-9.03	-0.68	1.91e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7695732	0.595	rs11737016	chr4:89908727	T/C	cg17769793	chr4:89976368	FAM13A	-0.49	-5.39	-0.48	5.23e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7172809	0.599	rs74026918	chr15:77762851	G/C	cg10437265	chr15:77819839	NA	-0.5	-4.57	-0.42	1.47e-5	Glucose homeostasis traits;
THYM	cis	rs4886920	0.672	rs4886933	chr15:78131240	G/A	cg10461261	chr15:78109450	NA	0.47	4.6	0.43	1.31e-5	Neuroticism;
THYM	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg16586182	chr3:47516702	SCAP	0.68	5.65	0.5	1.69e-7	Colorectal cancer;
THYM	cis	rs34112283	0.568	rs34587631	chr2:144220173	G/A	cg17056048	chr2:144271431	ARHGAP15	0.66	6.55	0.56	2.92e-9	Neuroticism;
THYM	cis	rs6988636	1.000	rs10096350	chr8:124184470	T/C	cg22384356	chr8:124195192	FAM83A	-0.86	-5.15	-0.47	1.41e-6	Urinary uromodulin levels;
THYM	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg20608306	chr11:116969690	SIK3	-0.47	-5.12	-0.46	1.6e-6	Blood protein levels;
THYM	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg19508488	chr2:152266495	RIF1	0.84	6.94	0.58	4.77e-10	Lung cancer;
THYM	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg08449448	chr8:58056501	NA	0.81	4.65	0.43	1.06e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg10523679	chr1:76189770	ACADM	0.91	9.7	0.71	7.37e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg02317251	chr4:10116515	WDR1	-0.56	-4.95	-0.45	3.23e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.04	-0.46	2.24e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.73	6.11	0.53	2.22e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg24846680	chr1:228362309	C1orf69	0.59	4.83	0.44	5.21e-6	Diastolic blood pressure;
THYM	cis	rs3812049	0.737	rs1112956	chr5:127433798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.74	-5.42	-0.49	4.45e-7	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg03806693	chr22:41940476	POLR3H	0.97	8.04	0.64	2.5e-12	Vitiligo;
THYM	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg09367891	chr1:107599246	PRMT6	0.68	4.45	0.42	2.33e-5	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg14004847	chr7:1930337	MAD1L1	-0.65	-5.01	-0.46	2.55e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg02269571	chr22:50332266	NA	-0.71	-4.91	-0.45	3.78e-6	Schizophrenia;
THYM	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg04234412	chr22:24373322	LOC391322	1.02	13.08	0.8	5.76e-23	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg02527881	chr3:46936655	PTH1R	0.88	9.48	0.7	2.1e-15	Birth weight;
THYM	cis	rs7122539	0.603	rs508443	chr11:66509369	C/T	cg24851651	chr11:66362959	CCS	-0.65	-5.64	-0.5	1.75e-7	HIV-1 susceptibility;
THYM	cis	rs12413816	0.963	rs10796116	chr10:13762786	C/T	cg16485048	chr10:13749193	FRMD4A	-0.56	-5.89	-0.52	5.81e-8	Red cell distribution width;
THYM	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg25703541	chr22:24373054	LOC391322	-0.75	-5.82	-0.51	7.94e-8	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.28	5.68	0.5	1.49e-7	Obesity-related traits;
THYM	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg19774624	chr17:42201019	HDAC5	-0.77	-6.96	-0.58	4.45e-10	Total body bone mineral density;
THYM	cis	rs10791097	0.967	rs6590512	chr11:130717916	A/G	cg12179176	chr11:130786555	SNX19	-0.67	-5.52	-0.49	2.9e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	trans	rs9747201	0.792	rs4296310	chr17:80132940	G/C	cg07393940	chr7:158741817	NA	-1.13	-8.69	-0.67	1.02e-13	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg00278517	chr6:167070616	RPS6KA2	-0.34	-4.64	-0.43	1.13e-5	Crohn's disease;
THYM	cis	rs665401	0.932	rs6936629	chr6:117239141	T/C	cg20376953	chr6:117187980	NA	0.6	4.67	0.43	9.78e-6	Neutrophil percentage of granulocytes;
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg15183258	chr15:42061865	MGA	0.85	6.94	0.58	4.85e-10	Energy expenditure (24h);
THYM	cis	rs6960043	1.000	rs6972516	chr7:15051789	G/T	cg19272540	chr7:15055459	NA	-0.46	-5.44	-0.49	4.17e-7	Type 2 diabetes;
THYM	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg16586182	chr3:47516702	SCAP	-0.63	-5.25	-0.47	9.07e-7	Colorectal cancer;
THYM	cis	rs60871478	0.592	rs4275123	chr7:857352	A/G	cg10248100	chr7:872053	UNC84A	0.48	4.62	0.43	1.22e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.23	-8.86	-0.67	4.44e-14	Gut microbiome composition (summer);
THYM	cis	rs17407555	0.683	rs6852641	chr4:10275746	G/C	cg00071950	chr4:10020882	SLC2A9	0.57	5.25	0.47	9.17e-7	Schizophrenia (age at onset);
THYM	cis	rs6032067	0.925	rs6032061	chr20:43853276	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.71	-7.53	-0.61	2.95e-11	Blood protein levels;
THYM	cis	rs9902453	0.904	rs7213076	chr17:28419428	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.84	-6.68	-0.57	1.64e-9	Coffee consumption (cups per day);
THYM	cis	rs2354432	0.882	rs11576360	chr1:146740576	G/A	cg25205988	chr1:146714368	CHD1L	1.36	10.52	0.73	1.28e-17	Mitochondrial DNA levels;
THYM	cis	rs9462846	0.887	rs2395938	chr6:42850659	C/A	cg09436375	chr6:42928200	GNMT	-0.39	-4.69	-0.43	9.03e-6	Blood protein levels;
THYM	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9309473	0.519	rs2421584	chr2:73898852	G/A	cg19565262	chr2:73869966	NAT8	0.54	4.58	0.43	1.43e-5	Metabolite levels;
THYM	cis	rs892961	0.836	rs8071497	chr17:75414358	T/C	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs6956675	1.000	rs10229492	chr7:62580546	G/A	cg27518014	chr7:62859535	LOC100287834	0.64	4.96	0.45	3.15e-6	Obesity-related traits;
THYM	cis	rs8014204	0.570	rs7147721	chr14:75186010	A/G	cg06637938	chr14:75390232	RPS6KL1	0.54	5.22	0.47	1.05e-6	Caffeine consumption;
THYM	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg04772025	chr11:68637568	NA	0.66	6.99	0.58	3.79e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9486719	1.000	rs11153058	chr6:97012746	C/T	cg18709589	chr6:96969512	KIAA0776	-0.68	-4.71	-0.44	8.44e-6	Migraine;Coronary artery disease;
THYM	cis	rs9649213	0.593	rs62478233	chr7:98023092	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-5.49	-0.49	3.38e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs6918586	0.658	rs198814	chr6:26127759	A/G	cg12310025	chr6:25882481	NA	0.68	5.56	0.5	2.47e-7	Schizophrenia;
THYM	cis	rs2354432	0.546	rs7539416	chr1:146881586	C/T	cg25205988	chr1:146714368	CHD1L	0.89	4.6	0.43	1.29e-5	Mitochondrial DNA levels;
THYM	cis	rs6887276	0.934	rs790153	chr5:127458770	A/G	cg05443326	chr5:126853169	PRRC1	-0.6	-4.53	-0.42	1.72e-5	Height;
THYM	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg12000587	chr17:30186630	C17orf79	0.39	4.48	0.42	2.1e-5	Hip circumference adjusted for BMI;
THYM	cis	rs17152411	0.793	rs12569669	chr10:126592671	A/G	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs9787249	0.957	rs12086750	chr1:40210468	G/C	cg24920358	chr1:40204285	PPIE	0.6	5.57	0.5	2.39e-7	Blood protein levels;
THYM	cis	rs9359856	0.564	rs34766278	chr6:90397132	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg09307838	chr4:120376055	NA	0.7	5.24	0.47	9.74e-7	Corneal astigmatism;
THYM	cis	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg11494091	chr17:61959527	GH2	1.08	17.11	0.87	9.08e-31	Prudent dietary pattern;
THYM	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg26446133	chr18:72167187	CNDP2	-1.02	-10.4	-0.73	2.35e-17	Refractive error;
THYM	cis	rs6987853	0.563	rs10958723	chr8:42448188	T/C	cg09913449	chr8:42400586	C8orf40	0.65	5.55	0.49	2.62e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs79149102	0.579	rs8033125	chr15:75374970	G/C	cg17294928	chr15:75287854	SCAMP5	-0.82	-4.47	-0.42	2.17e-5	Lung cancer;
THYM	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg04287289	chr16:89883240	FANCA	0.63	5.71	0.51	1.3e-7	Vitiligo;
THYM	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg02153584	chr22:29168773	CCDC117	0.58	4.56	0.42	1.52e-5	Lymphocyte counts;
THYM	cis	rs35883536	0.626	rs7536054	chr1:101047849	A/G	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg02527881	chr3:46936655	PTH1R	-0.86	-9.21	-0.69	7.92e-15	Birth weight;
THYM	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg05335186	chr13:53173507	NA	-0.48	-6.08	-0.53	2.5e-8	Lewy body disease;
THYM	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg08000102	chr2:233561755	GIGYF2	-0.69	-6.17	-0.53	1.69e-8	Coronary artery disease;
THYM	cis	rs4690686	1.000	rs2278904	chr4:177248622	C/G	cg17059388	chr4:177262070	NA	-0.4	-5.34	-0.48	6.37e-7	Essential tremor;
THYM	cis	rs7849270	1.000	rs3124514	chr9:131904608	C/T	cg14069949	chr9:131965419	NA	-0.5	-4.52	-0.42	1.8e-5	Blood metabolite ratios;
THYM	cis	rs1003719	0.715	rs2835640	chr21:38537380	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs981844	1.000	rs2606329	chr4:154654643	A/C	cg09973105	chr4:154681532	RNF175	-0.63	-5.18	-0.47	1.23e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Bladder cancer;
THYM	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg24642844	chr7:1081250	C7orf50	-1.26	-8.22	-0.64	1.03e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9790314	0.521	rs13084731	chr3:161086020	G/A	cg03342759	chr3:160939853	NMD3	-0.71	-5.99	-0.52	3.81e-8	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs16958440	0.867	rs2117373	chr18:44671834	C/T	cg17192377	chr18:44677553	HDHD2	0.85	4.79	0.44	6.22e-6	Sitting height ratio;
THYM	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg15242686	chr22:24348715	GSTTP1	-0.56	-5.07	-0.46	1.97e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	12.82	0.8	1.97e-22	Chronic sinus infection;
THYM	cis	rs28512361	0.502	rs134859	chr22:46066043	G/C	cg04955856	chr22:47022567	GRAMD4	0.69	4.58	0.43	1.42e-5	Breast cancer;
THYM	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg13695892	chr22:41940480	POLR3H	0.97	7.24	0.6	1.13e-10	Vitiligo;
THYM	cis	rs8067545	0.563	rs3850780	chr17:20181902	A/C	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg00129232	chr17:37814104	STARD3	0.71	4.8	0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg06713675	chr4:122721982	EXOSC9	-0.88	-10.3	-0.73	3.83e-17	Type 2 diabetes;
THYM	cis	rs791888	0.858	rs1555434	chr10:89419143	G/C	cg13926569	chr10:89418898	PAPSS2	-0.74	-9.04	-0.68	1.89e-14	Magnesium levels;
THYM	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2285947	0.901	rs2285943	chr7:21582963	G/T	cg04471919	chr7:21584483	DNAH11	0.45	4.47	0.42	2.16e-5	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
THYM	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg11812906	chr14:75593930	NEK9	0.87	7.92	0.63	4.45e-12	Height;
THYM	cis	rs77372450	0.551	rs7728747	chr5:157083635	C/T	cg00312553	chr5:157098553	C5orf52	-0.65	-4.63	-0.43	1.16e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg18402987	chr7:1209562	NA	0.75	5.49	0.49	3.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9797861	1	rs9797861	chr19:10743126	C/T	cg16900796	chr19:10755136	SLC44A2	0.32	4.61	0.43	1.26e-5	Thrombosis;
THYM	cis	rs12478296	0.786	rs72620862	chr2:243044787	T/C	cg06360820	chr2:242988706	NA	-0.95	-5.75	-0.51	1.08e-7	Obesity-related traits;
THYM	cis	rs6866344	0.697	rs72812613	chr5:178135257	G/A	cg03877680	chr5:178157825	ZNF354A	0.75	5.03	0.46	2.29e-6	Neutrophil percentage of white cells;
THYM	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg16586182	chr3:47516702	SCAP	-0.68	-5.92	-0.52	5.07e-8	Colorectal cancer;
THYM	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Gout;
THYM	cis	rs2663905	1.000	rs2663905	chr15:81359137	G/A	cg05624577	chr15:81411055	NA	-0.74	-5.44	-0.49	4.06e-7	QT interval (drug interaction);
THYM	cis	rs1160297	0.576	rs36130286	chr2:53106720	C/T	cg07782112	chr2:53107842	NA	-0.71	-4.45	-0.42	2.34e-5	Hemostatic factors and hematological phenotypes;
THYM	cis	rs7267979	1.000	rs4815412	chr20:25350325	A/G	cg08601574	chr20:25228251	PYGB	0.56	4.47	0.42	2.15e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg03351412	chr1:154909251	PMVK	0.68	5.21	0.47	1.11e-6	Prostate cancer;
THYM	cis	rs7027203	0.828	rs4743934	chr9:96581893	A/G	cg14598338	chr9:96623480	NA	-0.51	-5.74	-0.51	1.11e-7	DNA methylation (variation);
THYM	cis	rs6754311	0.593	rs10928542	chr2:136410299	G/A	cg04750100	chr2:136595281	LCT	0.56	5.89	0.52	5.87e-8	Mosquito bite size;
THYM	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg01831904	chr17:28903510	LRRC37B2	-1.13	-5.5	-0.49	3.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.27	0.6	1.01e-10	Obesity-related traits;
THYM	cis	rs10489202	0.583	rs201539	chr1:167995407	A/G	cg24449463	chr1:168025552	DCAF6	-0.88	-8.85	-0.67	4.67e-14	Schizophrenia;
THYM	cis	rs1371867	0.817	rs1660314	chr8:101332953	C/T	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs4638749	0.734	rs35184015	chr2:108870540	C/T	cg06795125	chr2:108905320	SULT1C2	-0.34	-4.58	-0.42	1.43e-5	Blood pressure;
THYM	cis	rs7814319	0.700	rs7838479	chr8:97268077	G/A	cg20787634	chr8:97240163	UQCRB	-0.74	-6.78	-0.57	1e-9	Lung function (FVC);
THYM	cis	rs4072705	0.614	rs1570581	chr9:127234059	A/G	cg01786973	chr9:127249749	NR5A1	0.4	5.08	0.46	1.85e-6	Menarche (age at onset);
THYM	cis	rs6032067	0.673	rs6017532	chr20:43904095	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.65	-5.9	-0.52	5.65e-8	Blood protein levels;
THYM	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs12410462	0.681	rs114950580	chr1:227673334	G/C	cg23173402	chr1:227635558	NA	0.85	6.41	0.55	5.5e-9	Major depressive disorder;
THYM	cis	rs61931739	0.544	rs6488163	chr12:33599127	C/T	cg06521331	chr12:34319734	NA	0.63	4.63	0.43	1.16e-5	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500395	1.000	rs4785536	chr16:48712980	C/T	cg04672837	chr16:48644449	N4BP1	-0.52	-5.07	-0.46	1.93e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs728616	0.558	rs116434658	chr10:81754626	G/A	cg27452691	chr10:81370291	SFTPA1	0.64	4.47	0.42	2.12e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9894429	0.624	rs9910935	chr17:79613949	T/C	cg10661904	chr17:79619235	PDE6G	-0.57	-4.95	-0.45	3.26e-6	Eye color traits;
THYM	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	9.35	0.69	4.06e-15	Body mass index (adult);
THYM	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg13114125	chr14:105738426	BRF1	-0.75	-5.91	-0.52	5.39e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs3008870	1.000	rs2065001	chr1:67486509	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.9	7.53	0.61	2.96e-11	Lymphocyte percentage of white cells;
THYM	cis	rs865483	0.861	rs72828246	chr17:35766475	A/G	cg06716730	chr17:35851459	DUSP14	-0.44	-7.64	-0.62	1.73e-11	Monocyte count;
THYM	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg10760299	chr15:45669010	GATM	0.76	5.79	0.51	8.99e-8	Homoarginine levels;
THYM	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg26597838	chr10:835615	NA	1.21	8.66	0.66	1.19e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs6032067	0.516	rs16989916	chr20:43899514	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.61	-6.91	-0.58	5.45e-10	Blood protein levels;
THYM	cis	rs7010267	0.681	rs7842942	chr8:120008587	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.6	4.89	0.45	4.12e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs250585	0.736	rs250581	chr16:23411837	G/A	cg00143387	chr16:23521605	GGA2	0.75	5.3	0.48	7.61e-7	Egg allergy;
THYM	cis	rs13631	0.965	rs7853589	chr9:140003844	A/G	cg03717367	chr9:139980219	LOC100289341;MAN1B1	-0.58	-5.03	-0.46	2.29e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs6867032	1.000	rs16902318	chr5:2013568	A/G	cg26168224	chr5:2018326	NA	1.28	15.48	0.85	1e-27	Gut microbiome composition (winter);
THYM	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg22117172	chr7:91764530	CYP51A1	0.36	4.47	0.42	2.14e-5	Breast cancer;
THYM	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg14018140	chr10:458528	DIP2C	-0.61	-7.17	-0.59	1.64e-10	Psychosis in Alzheimer's disease;
THYM	cis	rs11126435	0.591	rs6546909	chr2:74746322	A/T	cg04255230	chr2:74727010	LBX2	0.54	4.65	0.43	1.07e-5	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	4.54	0.42	1.65e-5	Hip circumference adjusted for BMI;
THYM	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg01416388	chr22:39784598	NA	-0.91	-8.26	-0.65	8.64e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2236521	0.617	rs113604626	chr20:60893506	T/G	cg06026331	chr20:60912101	LAMA5	0.8	5.77	0.51	9.83e-8	Pelvic organ prolapse;
THYM	cis	rs2066819	1.000	rs11575229	chr12:56750737	C/T	cg26714650	chr12:56694279	CS	-1.38	-6.84	-0.57	7.68e-10	Psoriasis vulgaris;
THYM	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg12419862	chr22:24373484	LOC391322	-0.8	-8.56	-0.66	1.95e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9788682	0.747	rs2568497	chr15:78721397	G/T	cg18825076	chr15:78729989	IREB2	-0.67	-5.14	-0.47	1.5e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.34	-0.65	5.7e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	5.42	0.49	4.47e-7	Schizophrenia;
THYM	cis	rs7173743	0.756	rs8032771	chr15:79126059	A/G	cg00540400	chr15:79124168	NA	0.62	6.61	0.56	2.2e-9	Coronary artery disease;
THYM	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg18252515	chr7:66147081	NA	0.66	4.87	0.45	4.38e-6	Aortic root size;
THYM	cis	rs8033133	0.602	rs12439159	chr15:25323874	T/C	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.63	-4.7	-0.43	8.66e-6	Blood osmolality (transformed sodium);
THYM	cis	rs2637266	0.655	rs861744	chr10:78519132	T/G	cg18941641	chr10:78392320	NA	0.73	5.84	0.51	7.29e-8	Pulmonary function;
THYM	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	5.44	0.49	4.18e-7	Obesity-related traits;
THYM	trans	rs9929218	0.953	rs3118227	chr16:68734855	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-7.29	-0.6	9.13e-11	Colorectal cancer;
THYM	cis	rs28595532	0.920	rs116331303	chr4:119754542	T/C	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg19418458	chr7:158789849	NA	0.64	4.65	0.43	1.05e-5	Facial morphology (factor 20);
THYM	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg19077165	chr18:44547161	KATNAL2	0.48	5.74	0.51	1.11e-7	Personality dimensions;
THYM	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg02734326	chr4:10020555	SLC2A9	0.72	6.38	0.55	6.4e-9	Bone mineral density;
THYM	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.71	-4.94	-0.45	3.3e-6	Multiple sclerosis;
THYM	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg00074818	chr8:8560427	CLDN23	0.53	4.8	0.44	5.95e-6	Obesity-related traits;
THYM	cis	rs7553864	1.000	rs4514217	chr1:87614094	G/A	cg17420885	chr1:87600446	LOC339524	-0.77	-6.37	-0.55	6.71e-9	Smoking behavior;
THYM	cis	rs714027	1.000	rs1003342	chr22:30570022	A/G	cg11564601	chr22:30592435	NA	0.3	5.45	0.49	3.93e-7	Lymphocyte counts;
THYM	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg02734326	chr4:10020555	SLC2A9	-0.69	-5.8	-0.51	8.62e-8	Bone mineral density;
THYM	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg08847533	chr14:75593920	NEK9	1.02	11.25	0.76	3.61e-19	Height;
THYM	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.44	5.4	0.48	4.98e-7	Monocyte percentage of white cells;
THYM	cis	rs1348850	0.609	rs1348851	chr2:178418677	C/T	cg27490568	chr2:178487706	NA	-0.7	-5.88	-0.52	6.06e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.01	10.61	0.74	8.47e-18	Intelligence (multi-trait analysis);
THYM	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg08835221	chr22:38071607	LGALS1	0.38	5.04	0.46	2.21e-6	Fat distribution (HIV);
THYM	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg18252515	chr7:66147081	NA	-0.67	-5.08	-0.46	1.86e-6	Aortic root size;
THYM	cis	rs11048434	0.736	rs1049925	chr12:9086898	A/G	cg13575925	chr12:9217583	LOC144571	0.52	4.84	0.44	5.1e-6	Sjögren's syndrome;
THYM	cis	rs11112613	0.713	rs68053161	chr12:105950035	G/C	cg03607813	chr12:105948248	NA	1.07	9.36	0.69	3.87e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs314370	0.951	rs17884589	chr7:100493711	G/A	cg08558340	chr7:100472263	SRRT	0.61	4.99	0.46	2.75e-6	Resting heart rate;
THYM	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg22907277	chr7:1156413	C7orf50	0.92	9.38	0.69	3.41e-15	Longevity;Endometriosis;
THYM	cis	rs7107174	0.786	rs4945262	chr11:77990831	T/C	cg02023728	chr11:77925099	USP35	0.68	6.0	0.52	3.51e-8	Testicular germ cell tumor;
THYM	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs55788414	0.725	rs13339333	chr16:81189028	C/A	cg06400318	chr16:81190750	PKD1L2	-0.82	-5.05	-0.46	2.15e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12310956	0.510	rs10743832	chr12:33884146	A/C	cg10856724	chr12:34555212	NA	-0.65	-5.93	-0.52	4.87e-8	Morning vs. evening chronotype;
THYM	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg26031613	chr14:104095156	KLC1	0.79	5.22	0.47	1.06e-6	Body mass index;
THYM	cis	rs2204008	0.583	rs12307593	chr12:38317803	A/G	cg26384229	chr12:38710491	ALG10B	0.62	4.56	0.42	1.52e-5	Bladder cancer;
THYM	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg21605333	chr4:119757512	SEC24D	-1.5	-6.09	-0.53	2.36e-8	Cannabis dependence symptom count;
THYM	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg24069376	chr3:38537580	EXOG	0.69	6.79	0.57	9.87e-10	Electrocardiographic conduction measures;
THYM	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg24375607	chr4:120327624	NA	0.68	5.47	0.49	3.59e-7	Corneal astigmatism;
THYM	cis	rs11078597	0.731	rs4790285	chr17:1651697	C/T	cg18436246	chr17:1640651	WDR81	-0.65	-4.73	-0.44	7.89e-6	Serum albumin level;
THYM	cis	rs877282	1.000	rs11253362	chr10:770979	G/T	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs17604090	1.000	rs17661938	chr7:29693378	C/T	cg19413766	chr7:29689036	LOC646762	-1.05	-5.89	-0.52	5.72e-8	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs6906287	0.647	rs2213857	chr6:118806780	A/G	cg21191810	chr6:118973309	C6orf204	0.58	5.75	0.51	1.06e-7	Electrocardiographic conduction measures;
THYM	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	7.2	0.59	1.38e-10	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg23161317	chr6:28129485	ZNF389	0.85	6.33	0.54	8.19e-9	Parkinson's disease;
THYM	cis	rs924712	0.574	rs9370328	chr6:54680686	C/T	cg19716238	chr6:54711378	FAM83B	-0.47	-4.47	-0.42	2.14e-5	Breast cancer;
THYM	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg08916839	chr5:415575	AHRR	1.14	6.87	0.58	6.77e-10	Fat distribution (HIV);
THYM	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg16031515	chr1:205743344	RAB7L1	-0.53	-4.84	-0.45	4.92e-6	Menarche (age at onset);
THYM	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg25319279	chr11:5960081	NA	0.57	4.85	0.45	4.78e-6	DNA methylation (variation);
THYM	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg00129232	chr17:37814104	STARD3	-0.9	-7.1	-0.59	2.26e-10	Asthma;
THYM	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg11965913	chr1:205819406	PM20D1	0.69	6.75	0.57	1.18e-9	Menarche (age at onset);
THYM	cis	rs10489202	0.657	rs3767478	chr1:168069626	G/A	cg24449463	chr1:168025552	DCAF6	-0.73	-6.43	-0.55	5.07e-9	Schizophrenia;
THYM	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	7.66	0.62	1.54e-11	Platelet count;
THYM	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg02487422	chr3:49467188	NICN1	0.63	4.82	0.44	5.48e-6	Resting heart rate;
THYM	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg08772003	chr10:104629869	AS3MT	-0.54	-4.62	-0.43	1.22e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg05025164	chr4:1340916	KIAA1530	-0.7	-5.4	-0.48	4.85e-7	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9905704	0.708	rs304263	chr17:56749941	C/T	cg12560992	chr17:57184187	TRIM37	0.64	4.46	0.42	2.28e-5	Testicular germ cell tumor;
THYM	cis	rs17152411	0.895	rs3940439	chr10:126584531	C/G	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	9.83e-6	Height;
THYM	cis	rs939658	1.000	rs4778935	chr15:79453282	T/C	cg17916960	chr15:79447300	NA	0.75	8.81	0.67	5.71e-14	Refractive error;
THYM	cis	rs7177699	0.557	rs9920493	chr15:79113846	A/C	cg15571903	chr15:79123663	NA	0.57	6.57	0.56	2.71e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg10150615	chr22:24372951	LOC391322	-0.87	-9.45	-0.7	2.44e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg23428387	chr22:49814324	NA	-0.57	-6.05	-0.53	2.91e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg07636037	chr3:49044803	WDR6	0.75	6.17	0.53	1.67e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs3796619	1.000	rs28620427	chr4:1086247	T/G	cg27284194	chr4:1044797	NA	0.53	4.95	0.45	3.22e-6	Recombination rate (males);
THYM	cis	rs1011018	0.628	rs56840127	chr7:139438467	G/C	cg06079564	chr7:139468310	HIPK2	-0.73	-4.8	-0.44	6e-6	Systolic blood pressure;
THYM	cis	rs2073300	1.000	rs6048813	chr20:23448221	G/A	cg12062639	chr20:23401060	NAPB	1.2	5.64	0.5	1.73e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs4731207	0.596	rs6971179	chr7:124592351	G/A	cg05285228	chr7:124571219	POT1	-0.68	-5.08	-0.46	1.88e-6	Cutaneous malignant melanoma;
THYM	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg16524936	chr4:1340807	KIAA1530	-0.68	-5.38	-0.48	5.34e-7	Longevity;
THYM	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg06600287	chr1:53387719	ECHDC2	-0.29	-4.69	-0.43	9.17e-6	Monocyte count;
THYM	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg04398451	chr17:18023971	MYO15A	-0.76	-6.96	-0.58	4.39e-10	Total body bone mineral density;
THYM	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06481639	chr22:41940642	POLR3H	-0.79	-5.3	-0.48	7.5e-7	Vitiligo;
THYM	cis	rs3796352	1.000	rs3097417	chr3:53088601	C/G	cg07884673	chr3:53033167	SFMBT1	-1.05	-6.02	-0.53	3.24e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2455799	0.613	rs2470537	chr3:15716898	C/T	cg16303742	chr3:15540471	COLQ	-0.52	-5.47	-0.49	3.72e-7	Mean platelet volume;
THYM	cis	rs11039798	0.699	rs7120775	chr11:48266736	C/G	cg24672777	chr11:48374446	OR4C45	-1.17	-7.15	-0.59	1.78e-10	Axial length;
THYM	trans	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg07393940	chr7:158741817	NA	1.11	8.12	0.64	1.69e-12	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs11634944	0.676	rs2732031	chr15:25242936	G/T	cg10601234	chr15:25523666	NA	-0.51	-4.66	-0.43	1.04e-5	Interleukin-8 levels;
THYM	cis	rs9326248	0.520	rs7127881	chr11:116880798	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.62	4.97	0.45	3.01e-6	Blood protein levels;
THYM	cis	rs7926906	0.688	rs2213085	chr11:90528586	A/G	cg26138821	chr11:89956704	CHORDC1	-0.53	-4.72	-0.44	8.21e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4919044	0.641	rs11187231	chr10:94736462	T/A	cg05127821	chr10:94822908	CYP26C1	-1.1	-6.18	-0.54	1.62e-8	Coronary artery disease;
THYM	cis	rs13256369	1.000	rs13267501	chr8:8574058	G/A	cg18904891	chr8:8559673	CLDN23	0.68	5.08	0.46	1.89e-6	Obesity-related traits;
THYM	cis	rs7572733	0.555	rs6729473	chr2:198763928	G/A	cg00792783	chr2:198669748	PLCL1	0.84	5.97	0.52	4.15e-8	Dermatomyositis;
THYM	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg18230493	chr5:56204884	C5orf35	0.65	4.89	0.45	4.11e-6	Initial pursuit acceleration;
THYM	cis	rs367615	0.918	rs10051855	chr5:108859958	G/A	cg17395555	chr5:108820864	NA	0.53	4.68	0.43	9.47e-6	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg00898013	chr13:113819073	PROZ	0.88	8.78	0.67	6.63e-14	Platelet distribution width;
THYM	cis	rs595982	0.546	rs12461075	chr19:49399821	G/A	cg21252483	chr19:49399788	TULP2	-0.69	-6.93	-0.58	5.07e-10	Red cell distribution width;
THYM	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg08847533	chr14:75593920	NEK9	-0.98	-10.21	-0.72	5.88e-17	Height;
THYM	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg16423285	chr20:60520624	NA	-0.65	-4.56	-0.42	1.52e-5	Body mass index;
THYM	cis	rs1933112	1.000	rs2179500	chr1:168515827	A/G	cg17186328	chr1:168545835	XCL1	-0.56	-4.62	-0.43	1.22e-5	Blood protein levels;
THYM	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg02380750	chr20:61661411	NA	0.61	6.17	0.53	1.65e-8	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs9951602	0.512	rs9958376	chr18:76655167	G/T	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs10992471	0.528	rs10429459	chr9:95258119	C/T	cg14631576	chr9:95140430	CENPP	0.81	7.54	0.61	2.79e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	trans	rs4866334	0.850	rs75708102	chr5:18489975	C/A	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs8078723	0.866	rs11078934	chr17:38189793	C/T	cg17467752	chr17:38218738	THRA	0.9	7.43	0.61	4.71e-11	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs259964	0.874	rs259958	chr20:57828583	C/A	cg09005679	chr20:57875326	EDN3	-0.43	-5.15	-0.47	1.39e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg03709012	chr19:19516395	GATAD2A	0.76	6.05	0.53	2.87e-8	Tonsillectomy;
THYM	cis	rs4243830	0.737	rs11122091	chr1:6609559	C/A	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.81	-4.51	-0.42	1.86e-5	Body mass index;
THYM	cis	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg13443165	chr9:33130375	B4GALT1	-0.71	-5.1	-0.46	1.7e-6	IgG glycosylation;
THYM	cis	rs6557876	0.511	rs6557881	chr8:25926986	C/G	cg12393552	chr8:26481666	DPYSL2	-0.31	-4.6	-0.43	1.3e-5	Systolic blood pressure;
THYM	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg27129171	chr3:47204927	SETD2	-0.72	-5.96	-0.52	4.3e-8	Birth weight;
THYM	cis	rs559389	0.775	rs34914877	chr11:71861454	C/T	cg23619769	chr11:71952356	PHOX2A	-0.63	-4.46	-0.42	2.27e-5	Pulmonary function in asthmatics;
THYM	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg18512352	chr11:47633146	NA	-0.53	-7.11	-0.59	2.1e-10	Subjective well-being;
THYM	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg19678392	chr7:94953810	PON1	-0.64	-5.07	-0.46	1.96e-6	Paraoxonase activity;
THYM	cis	rs981844	0.712	rs897611	chr4:154755519	T/C	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs11085466	1.000	rs75079001	chr19:21757375	A/G	cg23004160	chr19:21646329	NA	-0.65	-4.7	-0.43	8.62e-6	Colorectal or endometrial cancer;
THYM	trans	rs8187707	0.655	rs72840109	chr10:101687950	T/C	cg07700925	chr10:129540267	NA	1.07	7.24	0.6	1.15e-10	Carboplatin disposition in epthelial ovarian cancer;
THYM	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg18131467	chr2:239335373	ASB1	-1.12	-11.49	-0.76	1.11e-19	Multiple system atrophy;
THYM	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg00071950	chr4:10020882	SLC2A9	0.9	10.63	0.74	7.49e-18	Bone mineral density;
THYM	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs6546324	0.625	rs2861698	chr2:67854808	A/G	cg18237512	chr2:67827392	NA	-0.79	-4.75	-0.44	7.23e-6	Endometriosis;
THYM	cis	rs4730276	0.674	rs6466206	chr7:107551759	C/G	cg23293999	chr7:106826042	HBP1	-0.57	-4.56	-0.42	1.53e-5	Ulcerative colitis;
THYM	cis	rs240764	0.594	rs7356804	chr6:101078438	A/G	cg21058520	chr6:100914733	NA	-0.61	-5.13	-0.47	1.53e-6	Neuroticism;
THYM	cis	rs7582180	0.590	rs11123828	chr2:100960918	T/G	cg14675211	chr2:100938903	LONRF2	0.67	6.48	0.55	4.06e-9	Intelligence (multi-trait analysis);
THYM	cis	rs8112449	0.964	rs6417247	chr19:10522597	G/A	cg01466491	chr19:10523363	NA	-0.68	-6.58	-0.56	2.59e-9	Multiple sclerosis;Gastritis;
THYM	cis	rs4889855	0.530	rs7209279	chr17:78598055	T/A	cg16591659	chr17:78472290	NA	-0.4	-5.08	-0.46	1.9e-6	Fractional excretion of uric acid;
THYM	cis	rs2455799	0.573	rs2455829	chr3:15746937	G/A	cg16303742	chr3:15540471	COLQ	-0.54	-5.74	-0.51	1.12e-7	Mean platelet volume;
THYM	cis	rs55728055	0.661	rs1018488	chr22:31992376	A/G	cg10537193	chr22:32026975	PISD	-0.66	-4.61	-0.43	1.26e-5	Age-related hearing impairment;
THYM	cis	rs2688608	0.647	rs2227575	chr10:75677840	C/A	cg02947784	chr10:75434997	AGAP5	0.51	4.83	0.44	5.29e-6	Inflammatory bowel disease;
THYM	cis	rs4731207	0.565	rs7777126	chr7:124599742	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs11785693	0.730	rs62489549	chr8:4954185	G/C	cg26367366	chr8:4980734	NA	1.05	4.83	0.44	5.25e-6	Neuroticism (multi-trait analysis);Neuroticism;
THYM	trans	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg10856724	chr12:34555212	NA	0.79	6.9	0.58	5.77e-10	Bladder cancer;
THYM	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg20007245	chr22:24372913	LOC391322	0.75	6.78	0.57	1.03e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs73787773	1.000	rs73787773	chr5:111471712	T/C	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.88	-4.76	-0.44	6.87e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs870825	0.860	rs2705886	chr4:185608591	T/C	cg04058563	chr4:185651563	MLF1IP	-1.0	-7.48	-0.61	3.69e-11	Blood protein levels;
THYM	cis	rs61931739	0.635	rs6488185	chr12:33933127	G/C	cg10856724	chr12:34555212	NA	-0.63	-5.9	-0.52	5.54e-8	Morning vs. evening chronotype;
THYM	cis	rs7688540	0.511	rs10003260	chr4:184842	A/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.85	5.33	0.48	6.7e-7	Facial morphology (factor 6, height of vermillion lower lip);
THYM	trans	rs17065868	1.000	rs17278318	chr13:45139146	A/G	cg07768103	chr5:175956344	RNF44	-0.81	-7.6	-0.61	2.11e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
THYM	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg08779649	chr13:50194554	NA	0.58	5.05	0.46	2.16e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.89	8.09	0.64	1.91e-12	Monocyte percentage of white cells;
THYM	cis	rs1003719	0.715	rs2835640	chr21:38537380	G/A	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg06656553	chr16:89960601	TCF25	-0.95	-4.58	-0.43	1.41e-5	Skin colour saturation;
THYM	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7429990	0.930	rs11130152	chr3:48056409	T/C	cg02219026	chr3:48282209	ZNF589	0.6	4.52	0.42	1.75e-5	Educational attainment (years of education);
THYM	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs2346177	0.542	rs6757564	chr2:46702619	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.63	4.58	0.43	1.43e-5	HDL cholesterol;
THYM	cis	rs8067545	1.000	rs28807825	chr17:19942850	G/A	cg13482628	chr17:19912719	NA	0.59	5.13	0.47	1.54e-6	Schizophrenia;
THYM	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg04414720	chr1:150670196	GOLPH3L	0.62	4.58	0.43	1.41e-5	Tonsillectomy;
THYM	cis	rs34779708	0.931	rs68039650	chr10:35385499	C/A	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4589258	0.933	rs2155068	chr11:90417822	T/C	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg00640147	chr17:61958756	GH2	-0.43	-4.54	-0.42	1.64e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg07460842	chr6:66804631	NA	1.11	8.12	0.64	1.7e-12	Exhaled nitric oxide output;
THYM	cis	rs2274459	1.000	rs12193658	chr6:33705528	G/T	cg06253072	chr6:33679850	C6orf125	0.5	5.08	0.46	1.92e-6	Obesity (extreme);
THYM	cis	rs6570726	0.935	rs415590	chr6:145851244	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.75	-0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1371867	0.846	rs1788182	chr8:101334620	C/T	cg00191853	chr8:101177733	SPAG1	-0.51	-5.03	-0.46	2.29e-6	Atrioventricular conduction;
THYM	cis	rs3771317	1.000	rs16832836	chr2:191558030	C/G	cg17118478	chr2:191543902	NAB1	-0.62	-4.58	-0.43	1.41e-5	Primary biliary cholangitis;
THYM	cis	rs72627123	0.867	rs117818304	chr14:74474396	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	4.83	0.44	5.2e-6	Morning vs. evening chronotype;
THYM	cis	rs2731664	0.721	rs2450333	chr5:176899546	G/A	cg14098951	chr5:176875120	PRR7	0.52	4.57	0.42	1.47e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg02773041	chr1:40204384	PPIE	0.74	5.73	0.51	1.17e-7	Blood protein levels;
THYM	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg26412358	chr1:26503933	CNKSR1	0.36	5.01	0.46	2.48e-6	Height;
THYM	cis	rs7582180	0.676	rs10048665	chr2:100933085	A/G	cg08017756	chr2:100939284	LONRF2	-0.75	-7.76	-0.62	9.51e-12	Intelligence (multi-trait analysis);
THYM	cis	rs858239	0.932	rs1624451	chr7:23262435	A/T	cg05407003	chr7:23246146	NA	0.59	4.75	0.44	7.07e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg25208724	chr1:156163844	SLC25A44	1.05	8.4	0.65	4.31e-13	Testicular germ cell tumor;
THYM	trans	rs4866334	1.000	rs74805322	chr5:18487623	C/A	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg27588902	chr6:42928151	GNMT	0.56	5.6	0.5	2.05e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs929596	0.755	rs887829	chr2:234668570	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.93	8.09	0.64	1.96e-12	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs6701037	0.748	rs2685	chr1:175127771	A/G	cg17845761	chr1:175162550	KIAA0040	0.36	4.57	0.42	1.45e-5	Alcohol dependence;
THYM	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg16898833	chr6:26189333	HIST1H4D	1.42	5.27	0.48	8.69e-7	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs6596100	0.538	rs56157864	chr5:132267859	A/T	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Breast cancer;
THYM	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg01570182	chr17:44337453	NA	-0.84	-9.31	-0.69	5.04e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs34638657	0.828	rs7194734	chr16:82199980	C/T	cg09894383	chr16:82067445	HSD17B2	-0.53	-5.44	-0.49	4.1e-7	Lung adenocarcinoma;
THYM	cis	rs2273669	0.588	rs111773102	chr6:109306480	C/T	cg17117243	chr6:109341365	SESN1	-0.83	-4.88	-0.45	4.34e-6	Prostate cancer;
THYM	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg27572855	chr1:25598939	RHD	0.64	4.9	0.45	3.95e-6	Erythrocyte sedimentation rate;
THYM	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg02820040	chr2:241836501	C2orf54	-0.3	-6.29	-0.54	9.52e-9	Urinary metabolites;
THYM	cis	rs172166	0.516	rs1225715	chr6:28113373	C/T	cg13525197	chr6:28411240	ZSCAN23	0.73	4.79	0.44	6.14e-6	Cardiac Troponin-T levels;
THYM	cis	rs7586879	0.593	rs6733224	chr2:25130907	C/T	cg27107076	chr2:25050844	ADCY3	0.29	4.73	0.44	7.91e-6	Body mass index;
THYM	cis	rs600806	0.854	rs11102974	chr1:109886371	G/A	cg02175308	chr1:109941060	SORT1	-0.57	-5.06	-0.46	2.05e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6598955	0.670	rs6676619	chr1:26539035	T/G	cg04990556	chr1:26633338	UBXN11	-0.88	-7.99	-0.63	3.1e-12	Obesity-related traits;
THYM	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg17178900	chr1:205818956	PM20D1	1.1	12.06	0.78	7.32e-21	Menarche (age at onset);
THYM	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.29	8.36	0.65	5.15e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3020333	1.000	rs3020332	chr6:152008924	C/T	cg22157087	chr6:152012887	ESR1	0.56	6.68	0.57	1.61e-9	Total body bone mineral density;
THYM	cis	rs1784581	0.721	rs9365356	chr6:162414789	A/G	cg17173639	chr6:162384350	PARK2	0.8	8.01	0.64	2.8e-12	Itch intensity from mosquito bite;
THYM	cis	rs4523957	0.583	rs7225168	chr17:2023089	T/G	cg16513277	chr17:2031491	SMG6	-0.96	-8.72	-0.67	9.17e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2456568	0.802	rs10831136	chr11:93636860	T/C	cg17347335	chr11:93583973	C11orf90	-0.48	-4.58	-0.43	1.39e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.6	-0.5	2.08e-7	Type 2 diabetes;
THYM	cis	rs1978968	0.956	rs35089989	chr22:18424298	T/C	cg01550578	chr22:18484421	MICAL3	0.64	4.73	0.44	7.83e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs7224314	1.000	rs62084081	chr17:65387148	G/C	cg01507342	chr17:65387096	PITPNC1	-0.93	-10.79	-0.74	3.35e-18	Diisocyanate-induced asthma;
THYM	cis	rs11225247	1.000	rs75055689	chr11:102269738	G/T	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg10803722	chr21:46713166	LOC642852	0.42	5.58	0.5	2.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs2898681	0.614	rs58260946	chr4:53675420	A/G	cg00338735	chr4:53728038	RASL11B	0.56	4.86	0.45	4.72e-6	Optic nerve measurement (cup area);
THYM	cis	rs7000551	0.581	rs4872487	chr8:22256414	C/T	cg12081754	chr8:22256438	SLC39A14	1.19	12.59	0.79	5.77e-22	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs3008870	1.000	rs17497828	chr1:67452322	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.0	-8.07	-0.64	2.18e-12	Lymphocyte percentage of white cells;
THYM	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg07777115	chr5:623756	CEP72	-0.78	-4.58	-0.43	1.38e-5	Obesity-related traits;
THYM	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg12935359	chr14:103987150	CKB	-0.62	-6.48	-0.55	3.97e-9	Body mass index;
THYM	cis	rs2346160	0.836	rs206991	chr6:167699378	A/G	cg21686812	chr6:168078911	NA	-0.53	-4.69	-0.43	8.97e-6	Parental extreme longevity (95 years and older);
THYM	cis	rs10276303	0.519	rs11768463	chr7:3396160	A/G	cg21248987	chr7:3385318	SDK1	-0.4	-4.97	-0.45	3e-6	Dupuytren's disease;
THYM	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg10792982	chr14:105748885	BRF1	0.75	7.8	0.62	7.96e-12	Mean platelet volume;Platelet distribution width;
THYM	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg00990874	chr7:1149470	C7orf50	-0.69	-5.17	-0.47	1.29e-6	Bronchopulmonary dysplasia;
THYM	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg06238570	chr21:40685208	BRWD1	-0.96	-9.14	-0.68	1.13e-14	Cognitive function;
THYM	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.07	0.46	1.93e-6	Prudent dietary pattern;
THYM	cis	rs2276498	0.687	rs2299707	chr20:52657071	A/T	cg23682609	chr20:52687365	BCAS1	0.54	4.49	0.42	2.04e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs34779708	0.966	rs12761675	chr10:35438337	C/T	cg03585969	chr10:35415529	CREM	-0.65	-4.51	-0.42	1.87e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg00071950	chr4:10020882	SLC2A9	-0.53	-4.67	-0.43	9.99e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs3087591	0.960	rs2285812	chr17:29533871	A/G	cg24425628	chr17:29625626	OMG;NF1	0.6	5.16	0.47	1.35e-6	Hip circumference;
THYM	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg05043794	chr9:111880884	C9orf5	-0.43	-6.21	-0.54	1.39e-8	Menarche (age at onset);
THYM	cis	rs2554380	0.943	rs979543	chr15:84352564	C/A	cg14598478	chr15:84363061	ADAMTSL3	-0.64	-5.03	-0.46	2.29e-6	Height;
THYM	cis	rs7091068	0.532	rs554062	chr10:95399535	T/A	cg20715218	chr10:95462985	C10orf4	-0.67	-4.92	-0.45	3.62e-6	Urinary tract infection frequency;
THYM	cis	rs6754311	0.593	rs6755383	chr2:136416941	C/T	cg07169764	chr2:136633963	MCM6	0.7	5.67	0.5	1.55e-7	Mosquito bite size;
THYM	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg24846680	chr1:228362309	C1orf69	0.57	4.54	0.42	1.68e-5	Diastolic blood pressure;
THYM	cis	rs981844	0.712	rs6855082	chr4:154754039	A/G	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs6988636	1.000	rs13260626	chr8:124190317	C/T	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs13315871	0.929	rs11720747	chr3:58267833	G/A	cg00563845	chr3:58318305	PXK	0.58	4.96	0.45	3.06e-6	Cholesterol, total;
THYM	cis	rs2502731	0.561	rs3003606	chr9:130982416	C/T	cg13642260	chr9:130955380	CIZ1	0.67	5.34	0.48	6.4e-7	Attention deficit hyperactivity disorder;
THYM	cis	rs3733585	0.577	rs28558552	chr4:9964913	G/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.55	-0.42	1.57e-5	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4589258	0.933	rs7129615	chr11:90396225	A/G	cg26834418	chr11:89957033	CHORDC1	0.49	4.45	0.42	2.31e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4930776	1.000	rs393179	chr12:5772332	C/T	cg02086166	chr12:5775618	ANO2	0.6	6.11	0.53	2.2e-8	Plasma clusterin levels;
THYM	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg17911788	chr17:44343683	NA	0.71	6.76	0.57	1.09e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2295359	1.000	rs9729046	chr1:67607082	C/G	cg11235152	chr1:67600687	NA	0.59	4.93	0.45	3.42e-6	Psoriasis;
THYM	cis	rs7119	0.717	rs11635567	chr15:77819515	A/G	cg10437265	chr15:77819839	NA	0.76	7.54	0.61	2.76e-11	Type 2 diabetes;
THYM	cis	rs7915131	1.000	rs7068361	chr10:64408367	C/T	cg03961010	chr10:64397487	ZNF365	-0.71	-5.29	-0.48	7.89e-7	Schizophrenia;
THYM	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg24818145	chr4:99064322	C4orf37	0.74	5.93	0.52	4.8e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6876348	0.516	rs257901	chr5:128315224	T/C	cg02841155	chr5:128301328	SLC27A6	-0.5	-4.86	-0.45	4.54e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1878931	0.597	rs37814	chr16:3455247	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.68	-4.5	-0.42	1.91e-5	Body mass index (adult);
THYM	cis	rs735539	0.521	rs693489	chr13:21423005	A/G	cg02792322	chr13:21280448	IL17D	-0.66	-4.78	-0.44	6.37e-6	Dental caries;
THYM	cis	rs548181	0.611	rs2849225	chr11:125415936	A/G	cg03464685	chr11:125439445	EI24	1.64	9.67	0.7	8.31e-16	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg00981070	chr1:2046702	PRKCZ	-0.46	-5.41	-0.49	4.63e-7	Height;
THYM	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg14972814	chr11:95582409	MTMR2	-0.66	-5.1	-0.46	1.72e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4786125	0.665	rs1492371	chr16:6921285	A/C	cg03623568	chr16:6915990	A2BP1	-1.01	-10.06	-0.72	1.22e-16	Heart rate variability traits (SDNN);
THYM	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg16797656	chr11:68205561	LRP5	0.45	4.78	0.44	6.46e-6	Total body bone mineral density;
THYM	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.67	5.22	0.47	1.06e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7582180	0.607	rs6723909	chr2:100880058	A/T	cg14675211	chr2:100938903	LONRF2	0.56	5.13	0.47	1.55e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2404602	0.647	rs2404604	chr15:76991105	A/G	cg23625390	chr15:77176239	SCAPER	-0.83	-5.7	-0.5	1.36e-7	Blood metabolite levels;
THYM	trans	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	3.97e-12	Bladder cancer;
THYM	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs2555603	0.951	rs41327350	chr13:33792241	A/C	cg07499182	chr13:33825496	STARD13	-0.52	-4.94	-0.45	3.28e-6	Body mass index in asthmatics;
THYM	cis	rs1728785	0.901	rs1183956	chr16:68606726	G/A	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.39e-6	Ulcerative colitis;
THYM	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg17173187	chr15:85201210	NMB	0.55	5.41	0.49	4.78e-7	Schizophrenia;
THYM	cis	rs7589342	0.862	rs12613864	chr2:106515869	G/A	cg14210321	chr2:106509881	NCK2	-0.82	-6.26	-0.54	1.1e-8	Addiction;
THYM	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs713587	0.713	rs11125884	chr2:25239264	C/T	cg01884057	chr2:25150051	NA	0.56	5.85	0.51	7.11e-8	Body mass index in non-asthmatics;
THYM	cis	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg24678163	chr13:52769951	THSD1P	0.49	4.58	0.43	1.38e-5	Lewy body disease;
THYM	cis	rs4731207	0.596	rs10264210	chr7:124611594	G/C	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.04e-7	Cutaneous malignant melanoma;
THYM	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg00666640	chr1:248458726	OR2T12	0.56	4.61	0.43	1.26e-5	Common traits (Other);
THYM	cis	rs10504073	0.631	rs341813	chr8:50039916	T/C	cg00325661	chr8:49890786	NA	0.79	7.03	0.59	3.09e-10	Blood metabolite ratios;
THYM	cis	rs1003719	0.788	rs2006941	chr21:38467616	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs34779708	0.931	rs2505631	chr10:35368385	A/T	cg03585969	chr10:35415529	CREM	-0.62	-4.45	-0.42	2.31e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs478304	0.934	rs506853	chr11:65521247	C/T	cg17480646	chr11:65405466	SIPA1	0.7	6.13	0.53	2e-8	Acne (severe);
THYM	cis	rs9527	0.615	rs7089065	chr10:104723022	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-5.01	-0.46	2.51e-6	Arsenic metabolism;
THYM	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg08885076	chr2:99613938	TSGA10	-0.52	-5.04	-0.46	2.24e-6	Chronic sinus infection;
THYM	cis	rs11225247	1.000	rs117983416	chr11:102315169	G/A	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg15549821	chr19:49342101	PLEKHA4	-0.96	-5.51	-0.49	3e-7	Red cell distribution width;
THYM	cis	rs7614311	0.731	rs73117087	chr3:63948696	A/G	cg22134162	chr3:63841271	THOC7	-0.56	-6.75	-0.57	1.18e-9	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs7216064	1.000	rs8071463	chr17:65938655	C/T	cg12091567	chr17:66097778	LOC651250	0.73	4.99	0.46	2.68e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg21644426	chr2:191273491	MFSD6	-0.74	-5.2	-0.47	1.13e-6	Diastolic blood pressure;
THYM	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg23649088	chr2:200775458	C2orf69	-0.83	-6.97	-0.58	4.07e-10	Osteoporosis;
THYM	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg23574427	chr4:122746245	BBS7;CCNA2	-0.55	-5.06	-0.46	2.05e-6	Type 2 diabetes;
THYM	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg25918947	chr17:41365094	TMEM106A	-0.55	-4.55	-0.42	1.56e-5	Menopause (age at onset);
THYM	cis	rs2273669	0.504	rs74991574	chr6:109482270	A/G	cg17117243	chr6:109341365	SESN1	-0.85	-4.99	-0.46	2.77e-6	Prostate cancer;
THYM	cis	rs4733781	0.933	rs9643252	chr8:131332667	G/A	cg16277922	chr8:131349729	ASAP1	0.7	5.05	0.46	2.09e-6	Tuberculosis;
THYM	cis	rs2976388	0.935	rs2978980	chr8:143757708	T/G	cg13446199	chr8:143762866	PSCA	0.5	5.96	0.52	4.36e-8	Urinary tract infection frequency;
THYM	cis	rs7917772	0.582	rs3936017	chr10:104354424	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.26	7.06	0.59	2.75e-10	Gut microbiome composition (summer);
THYM	cis	rs4919687	0.550	rs7907503	chr10:104440050	C/T	cg05855489	chr10:104503620	C10orf26	0.62	4.8	0.44	5.99e-6	Colorectal cancer;
THYM	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg07930552	chr6:133119739	C6orf192	1.03	6.0	0.52	3.63e-8	Type 2 diabetes nephropathy;
THYM	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg23281280	chr6:28129359	ZNF389	0.61	4.94	0.45	3.3e-6	Parkinson's disease;
THYM	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg22683308	chr4:1340831	KIAA1530	-0.64	-5.07	-0.46	1.99e-6	Longevity;
THYM	cis	rs7681440	0.583	rs2619348	chr4:90746321	C/G	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg10334053	chr1:2078117	PRKCZ	0.45	4.46	0.42	2.21e-5	Height;
THYM	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9790314	1.000	rs4273380	chr3:160950314	A/G	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg11764359	chr7:65958608	NA	0.75	5.86	0.52	6.54e-8	Aortic root size;
THYM	cis	rs7523273	0.568	rs6669384	chr1:208025926	T/C	cg22525895	chr1:207977042	MIR29B2	-0.7	-4.7	-0.43	8.8e-6	Schizophrenia;
THYM	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg23161317	chr6:28129485	ZNF389	0.66	5.26	0.47	8.9e-7	Parkinson's disease;
THYM	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs55728055	0.661	rs16989379	chr22:32058269	G/A	cg10537193	chr22:32026975	PISD	-0.92	-5.68	-0.5	1.45e-7	Age-related hearing impairment;
THYM	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs1823778	0.609	rs4891390	chr18:67705600	G/A	cg13164537	chr18:67624071	CD226	1.11	4.47	0.42	2.14e-5	Mean platelet volume;
THYM	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.6	5.5	0.49	3.26e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11671005	0.656	rs73066228	chr19:59013196	A/G	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.72	-5.27	-0.48	8.6e-7	Mean platelet volume;
THYM	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg14456004	chr13:21872349	NA	-1.23	-9.72	-0.71	6.42e-16	White matter hyperintensity burden;
THYM	cis	rs6430585	0.759	rs4954623	chr2:136535876	G/A	cg04750100	chr2:136595281	LCT	-0.53	-4.82	-0.44	5.35e-6	Corneal structure;
THYM	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg16615211	chr3:44902933	MIR564;TMEM42	0.57	6.1	0.53	2.29e-8	Depressive symptoms;
THYM	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg16414030	chr3:133502952	NA	-0.84	-8.47	-0.66	3.08e-13	Iron status biomarkers;
THYM	cis	rs17744026	0.525	rs11219321	chr11:123713565	A/G	cg00079598	chr11:123676903	OR6M1	-0.5	-4.63	-0.43	1.17e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs453301	0.574	rs10081437	chr8:8948979	T/C	cg15556689	chr8:8085844	FLJ10661	-0.61	-4.61	-0.43	1.23e-5	Joint mobility (Beighton score);
THYM	cis	rs4851254	0.584	rs35774174	chr2:100655130	T/A	cg22139774	chr2:100720529	AFF3	-0.4	-4.52	-0.42	1.78e-5	Intelligence (multi-trait analysis);
THYM	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	4.5	0.42	1.9e-5	Calcium levels;
THYM	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg18825531	chr11:62321136	NA	-0.42	-4.66	-0.43	1.05e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg26384229	chr12:38710491	ALG10B	0.98	7.15	0.59	1.8e-10	Bladder cancer;
THYM	cis	rs9595908	0.929	rs7328939	chr13:33126848	A/G	cg12383807	chr13:33924137	NA	-0.57	-5.0	-0.46	2.58e-6	Body mass index;
THYM	cis	rs9486719	0.843	rs3860231	chr6:97036563	G/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-4.84	-0.44	5.06e-6	Migraine;Coronary artery disease;
THYM	cis	rs12142240	0.698	rs72677594	chr1:46824371	A/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	8.23	0.65	9.9e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg08508325	chr11:3079039	CARS	-0.5	-6.36	-0.55	7.01e-9	Longevity;
THYM	cis	rs289828	0.868	rs289829	chr2:152136901	A/G	cg05960677	chr2:152117363	RBM43	0.62	6.31	0.54	8.74e-9	Blood protein levels;
THYM	cis	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg24678163	chr13:52769951	THSD1P	0.49	4.58	0.43	1.38e-5	Lewy body disease;
THYM	trans	rs4262150	0.883	rs12652844	chr5:152315418	T/C	cg08281791	chr5:76607845	PDE8B	0.94	7.09	0.59	2.41e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs4654899	0.931	rs1152998	chr1:21124290	C/T	cg01072550	chr1:21505969	NA	-0.68	-6.2	-0.54	1.45e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg02825527	chr7:2087843	MAD1L1	-0.75	-4.96	-0.45	3.1e-6	Neuroticism;
THYM	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	5.12	0.47	1.57e-6	Rheumatoid arthritis;
THYM	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg05896524	chr21:47604654	C21orf56	0.74	5.2	0.47	1.16e-6	Testicular germ cell tumor;
THYM	cis	rs747334	0.738	rs7099639	chr10:92742722	A/G	cg07620928	chr10:92689909	NA	-0.7	-6.4	-0.55	5.92e-9	Fibroblast growth factor basic levels;
THYM	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg27534772	chr1:16042836	PLEKHM2	0.53	5.9	0.52	5.65e-8	Systolic blood pressure;
THYM	cis	rs189798	0.807	rs12785	chr8:8994936	A/T	cg18904891	chr8:8559673	CLDN23	0.63	4.78	0.44	6.37e-6	Myopia (pathological);
THYM	trans	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg17712092	chr4:129076599	LARP1B	1.12	12.59	0.79	5.83e-22	Eosinophil percentage of white cells;
THYM	cis	rs4718428	0.705	rs2901311	chr7:66415069	T/C	cg18252515	chr7:66147081	NA	-0.81	-5.67	-0.5	1.5e-7	Corneal structure;
THYM	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg25208724	chr1:156163844	SLC25A44	-1.17	-13.23	-0.81	2.88e-23	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg25918947	chr17:41365094	TMEM106A	-0.56	-4.6	-0.43	1.32e-5	Menopause (age at onset);
THYM	cis	rs2209875	0.519	rs13283164	chr9:91979438	A/G	cg13881405	chr9:92220388	GADD45G	-0.47	-4.77	-0.44	6.69e-6	Pelvic organ prolapse (moderate/severe);
THYM	cis	rs10493773	0.609	rs12058974	chr1:86192235	T/A	cg17807903	chr1:86174739	ZNHIT6	-0.59	-9.23	-0.69	7.42e-15	Urate levels in overweight individuals;
THYM	cis	rs986417	0.748	rs1955700	chr14:61046481	A/G	cg27398547	chr14:60952738	C14orf39	1.1	6.03	0.53	3.13e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs748404	0.660	rs690512	chr15:43717678	A/G	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg14784868	chr12:69753453	YEATS4	0.89	7.69	0.62	1.33e-11	Response to diuretic therapy;
THYM	cis	rs9560113	0.573	rs1888304	chr13:112242454	A/G	cg10483660	chr13:112241077	NA	0.7	8.63	0.66	1.41e-13	Menarche (age at onset);
THYM	cis	rs2237234	0.848	rs2237235	chr6:26391395	A/G	cg12826209	chr6:26865740	GUSBL1	0.72	4.91	0.45	3.85e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs828999	0.628	rs10218750	chr1:108713316	A/T	cg24323958	chr1:108741884	SLC25A24	0.57	5.61	0.5	1.97e-7	Monocyte percentage of white cells;
THYM	cis	rs9527	0.590	rs11191578	chr10:104902337	A/T	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs6430585	0.528	rs78274583	chr2:136734569	C/T	cg04750100	chr2:136595281	LCT	0.56	4.94	0.45	3.41e-6	Corneal structure;
THYM	cis	rs2820651	0.614	rs80334103	chr10:1489460	T/C	cg02445968	chr10:1449028	ADARB2	-1.05	-5.34	-0.48	6.32e-7	Migraine with aura;
THYM	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg22467129	chr15:76604101	ETFA	-0.5	-4.97	-0.45	2.99e-6	Blood metabolite levels;
THYM	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg04156016	chr5:1868137	NA	0.5	4.63	0.43	1.17e-5	Cardiovascular disease risk factors;
THYM	cis	rs7772486	0.790	rs2265474	chr6:146182092	G/A	cg13319975	chr6:146136371	FBXO30	-0.69	-5.71	-0.51	1.27e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6025261	0.761	rs6092390	chr20:55510339	C/T	cg04763273	chr20:55502381	NA	0.58	4.99	0.46	2.77e-6	Verbal memory performance (delayed recall level);
THYM	cis	rs9896933	0.708	rs9908751	chr17:80791830	C/T	cg00809820	chr17:80708513	TBCD;FN3K	-0.78	-5.08	-0.46	1.88e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
THYM	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg06238570	chr21:40685208	BRWD1	-0.69	-6.08	-0.53	2.47e-8	Menarche (age at onset);
THYM	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg08132940	chr7:1081526	C7orf50	-1.12	-6.61	-0.56	2.22e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg02527881	chr3:46936655	PTH1R	-0.66	-6.44	-0.55	4.86e-9	Colorectal cancer;
THYM	cis	rs11048434	0.761	rs10842662	chr12:9139344	G/A	cg13575925	chr12:9217583	LOC144571	0.55	5.48	0.49	3.45e-7	Sjögren's syndrome;
THYM	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.67	-5.62	-0.5	1.92e-7	Renal function-related traits (BUN);
THYM	cis	rs887829	0.570	rs6753569	chr2:234595817	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-6.64	-0.56	1.98e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22496380	chr5:211416	CCDC127	-1.28	-8.11	-0.64	1.75e-12	Breast cancer;
THYM	cis	rs6430585	0.527	rs60966546	chr2:136401843	C/T	cg23851026	chr2:136556271	LCT	0.64	5.84	0.51	7.37e-8	Corneal structure;
THYM	cis	rs6876348	0.598	rs2526252	chr5:128310259	C/G	cg25555059	chr5:128301488	SLC27A6	-0.49	-5.46	-0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs35883536	0.626	rs10783140	chr1:101042083	A/G	cg06223162	chr1:101003688	GPR88	-0.8	-6.9	-0.58	5.77e-10	Monocyte count;
THYM	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg06028808	chr11:68637592	NA	0.68	7.28	0.6	9.39e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs478304	0.651	rs4014195	chr11:65506822	C/G	cg17480646	chr11:65405466	SIPA1	0.94	8.68	0.67	1.07e-13	Acne (severe);
THYM	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg06763375	chr16:89025547	CBFA2T3	-0.54	-4.54	-0.42	1.65e-5	Social autistic-like traits;
THYM	trans	rs682457	0.573	rs9971436	chr11:87947490	G/A	cg25852200	chr11:1328419	TOLLIP	1.0	7.8	0.62	8.07e-12	Post-traumatic stress disorder;
THYM	cis	rs76878669	0.561	rs4630308	chr11:66162587	G/A	cg14263139	chr11:66104018	RIN1	-0.36	-4.46	-0.42	2.29e-5	Educational attainment (years of education);
THYM	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg21984481	chr17:79567631	NPLOC4	-0.58	-6.73	-0.57	1.29e-9	Eye color traits;
THYM	cis	rs337100	0.540	rs337099	chr5:122546333	C/T	cg04547002	chr5:122551801	NA	-0.61	-4.93	-0.45	3.53e-6	Pulse pressure;
THYM	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.22	0.64	1.03e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs10095849	0.576	rs4584120	chr8:39447072	C/T	cg01911981	chr8:39380341	ADAM3A	-0.58	-5.0	-0.46	2.57e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg02887458	chr19:19495540	GATAD2A	-0.45	-4.89	-0.45	4.05e-6	Bipolar disorder;
THYM	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg23428387	chr22:49814324	NA	-0.48	-4.63	-0.43	1.17e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg07131210	chr7:1025825	CYP2W1	-0.83	-4.6	-0.43	1.33e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs268134	0.530	rs62139122	chr2:65587626	C/T	cg03233656	chr2:65214625	SLC1A4	0.63	4.64	0.43	1.1e-5	Educational attainment (years of education);Systemic lupus erythematosus;
THYM	cis	rs4889855	0.556	rs11651818	chr17:78530300	A/G	cg16591659	chr17:78472290	NA	0.42	4.88	0.45	4.27e-6	Fractional excretion of uric acid;
THYM	cis	rs854765	0.663	rs9915248	chr17:17747514	C/T	cg16928487	chr17:17741425	SREBF1	0.55	5.26	0.48	8.83e-7	Total body bone mineral density;
THYM	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.24	-0.65	9.17e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg08999081	chr20:33150536	PIGU	0.8	7.69	0.62	1.37e-11	Coronary artery disease;
THYM	cis	rs10911251	0.528	rs10911255	chr1:183088868	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Colorectal cancer;
THYM	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.22	-0.47	1.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6840360	1.000	rs10049991	chr4:152664163	A/T	cg22705602	chr4:152727874	NA	-0.58	-6.27	-0.54	1.04e-8	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg09455208	chr3:40491958	NA	-0.49	-5.1	-0.46	1.75e-6	Renal cell carcinoma;
THYM	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg11062466	chr8:58055876	NA	0.94	4.8	0.44	5.85e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7567389	0.677	rs72848616	chr2:128135097	T/C	cg09760422	chr2:128146352	NA	0.4	4.53	0.42	1.7e-5	Self-rated health;
THYM	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22496380	chr5:211416	CCDC127	-1.33	-7.99	-0.63	3.21e-12	Breast cancer;
THYM	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs4866334	1.000	rs75533364	chr5:18453341	G/A	cg04591469	chr5:17810299	NA	-1.12	-4.54	-0.42	1.65e-5	IgG glycosylation;
THYM	cis	rs6089829	0.962	rs2314131	chr20:61665225	A/G	cg03213289	chr20:61660250	NA	0.81	6.94	0.58	4.77e-10	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg13395646	chr4:1353034	KIAA1530	-0.52	-4.71	-0.43	8.6e-6	Obesity-related traits;
THYM	cis	rs6570726	0.846	rs371186	chr6:145886971	T/C	cg23711669	chr6:146136114	FBXO30	0.85	7.9	0.63	4.99e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06481639	chr22:41940642	POLR3H	-0.8	-5.59	-0.5	2.2e-7	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg15592062	chr6:167189543	RPS6KA2	-0.48	-4.74	-0.44	7.39e-6	Crohn's disease;
THYM	cis	rs4509693	0.943	rs4917907	chr10:102498140	A/G	cg15234845	chr10:102496500	NA	0.65	4.6	0.43	1.3e-5	Alzheimer's disease;
THYM	cis	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg23231163	chr10:75533350	FUT11	-0.49	-7.03	-0.59	3.06e-10	Inflammatory bowel disease;
THYM	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg14643075	chr5:176755449	NA	0.48	4.48	0.42	2.11e-5	Hemoglobin concentration;Hematocrit;
THYM	cis	rs11186	0.630	rs72906341	chr2:189959947	G/A	cg11041835	chr2:189156425	GULP1	0.79	4.6	0.43	1.33e-5	Parkinson's disease;
THYM	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22496380	chr5:211416	CCDC127	-1.25	-7.51	-0.61	3.27e-11	Breast cancer;
THYM	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs17604090	0.648	rs823384	chr7:29657615	A/T	cg19413766	chr7:29689036	LOC646762	-0.89	-6.14	-0.53	1.88e-8	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg08999081	chr20:33150536	PIGU	0.76	6.73	0.57	1.27e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg13010199	chr12:38710504	ALG10B	0.72	5.82	0.51	7.96e-8	Heart rate;
THYM	cis	rs68170813	0.559	rs79564258	chr7:107059803	C/A	cg00661777	chr7:106511741	PIK3CG	-0.66	-4.49	-0.42	2.03e-5	Coronary artery disease;
THYM	cis	rs300703	0.515	rs364431	chr2:191399	C/A	cg21211680	chr2:198530	NA	0.94	6.1	0.53	2.26e-8	Blood protein levels;
THYM	cis	rs5771069	0.931	rs137857	chr22:50444577	A/G	cg08241514	chr22:50438769	IL17REL	-0.41	-4.46	-0.42	2.22e-5	Ulcerative colitis;
THYM	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg06877462	chr1:205807181	PM20D1	0.6	4.52	0.42	1.76e-5	Menarche (age at onset);
THYM	cis	rs490234	0.718	rs2047502	chr9:128178894	C/A	cg14078157	chr9:128172775	NA	-0.78	-6.12	-0.53	2.05e-8	Mean arterial pressure;
THYM	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg08847533	chr14:75593920	NEK9	0.55	4.56	0.42	1.52e-5	Caffeine consumption;
THYM	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	5.38	0.48	5.27e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg26441486	chr22:50317300	CRELD2	0.42	6.65	0.56	1.83e-9	Schizophrenia;
THYM	cis	rs9467603	0.920	rs68006638	chr6:25710571	G/A	cg16898833	chr6:26189333	HIST1H4D	1.33	4.6	0.43	1.32e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4589258	0.902	rs4753295	chr11:90468658	T/C	cg26138821	chr11:89956704	CHORDC1	-0.69	-5.52	-0.49	3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs877282	0.898	rs11253353	chr10:766862	C/A	cg10556349	chr10:835070	NA	-0.76	-4.73	-0.44	7.86e-6	Uric acid levels;
THYM	cis	rs75920871	0.528	rs3886960	chr11:116924990	G/T	cg20608306	chr11:116969690	SIK3	-0.54	-6.01	-0.52	3.45e-8	Subjective well-being;
THYM	cis	rs4509693	0.843	rs4403743	chr10:102496740	A/C	cg24127310	chr10:102502104	NA	1.3	10.12	0.72	9.09e-17	Alzheimer's disease;
THYM	cis	rs7894051	0.614	rs11101707	chr10:135175844	T/C	cg07511014	chr10:135191624	PAOX	-0.83	-5.79	-0.51	9.06e-8	Lifespan;
THYM	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg01416388	chr22:39784598	NA	-0.87	-8.13	-0.64	1.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg12386194	chr3:101231763	SENP7	0.96	7.53	0.61	2.97e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg14675211	chr2:100938903	LONRF2	0.76	7.9	0.63	4.93e-12	Intelligence (multi-trait analysis);
THYM	cis	rs2219968	1.000	rs7003907	chr8:78976336	A/G	cg00738934	chr8:78996279	NA	0.91	9.75	0.71	5.64e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs877282	0.842	rs35872126	chr10:764545	G/A	cg22713356	chr15:30763199	NA	1.36	10.13	0.72	8.77e-17	Uric acid levels;
THYM	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg22841779	chr14:105766346	BRF1	0.45	5.48	0.49	3.56e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg18252515	chr7:66147081	NA	-0.71	-5.67	-0.5	1.56e-7	Aortic root size;
THYM	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg23262073	chr20:60523788	NA	0.95	6.44	0.55	4.82e-9	Obesity-related traits;
THYM	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.57	-0.66	1.86e-13	Mean corpuscular volume;
THYM	cis	rs3772130	0.962	rs6784571	chr3:121539991	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs854765	0.647	rs854817	chr17:18021882	T/C	cg04320152	chr17:18167836	SMCR7	0.61	4.75	0.44	7.33e-6	Total body bone mineral density;
THYM	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg07570687	chr10:102243282	WNT8B	0.74	6.43	0.55	5.18e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	trans	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg10856724	chr12:34555212	NA	-0.87	-7.75	-0.62	9.89e-12	Morning vs. evening chronotype;
THYM	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg23281280	chr6:28129359	ZNF389	-0.67	-5.28	-0.48	8.33e-7	Depression;
THYM	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg23161317	chr6:28129485	ZNF389	0.71	5.59	0.5	2.21e-7	Cardiac Troponin-T levels;
THYM	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7731657	0.537	rs2419934	chr5:130295768	T/C	cg08523029	chr5:130500466	HINT1	-0.76	-5.21	-0.47	1.11e-6	Fasting plasma glucose;
THYM	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg20503657	chr10:835505	NA	1.17	8.29	0.65	7.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg26031613	chr14:104095156	KLC1	1.21	12.73	0.79	3.03e-22	Body mass index;
THYM	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11644478	chr21:40555479	PSMG1	1.1	9.84	0.71	3.61e-16	Cognitive function;
THYM	cis	rs4355801	0.548	rs3103968	chr8:119866163	C/T	cg17171407	chr8:119960777	TNFRSF11B	-0.62	-4.78	-0.44	6.46e-6	Bone mineral density;
THYM	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg15704280	chr7:45808275	SEPT13	-1.0	-10.97	-0.75	1.44e-18	Coronary artery disease;
THYM	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.42	-0.55	5.32e-9	Personality dimensions;
THYM	cis	rs7704138	0.639	rs6870859	chr5:55017018	G/T	cg18456523	chr5:54516805	NA	-0.58	-4.59	-0.43	1.34e-5	Height;
THYM	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-4.47	-0.42	2.18e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs12681287	0.927	rs2953517	chr8:87332013	C/T	cg00550725	chr8:87521180	FAM82B	0.57	4.58	0.42	1.44e-5	Caudate activity during reward;
THYM	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg02782426	chr3:40428986	ENTPD3	-0.51	-4.61	-0.43	1.23e-5	Renal cell carcinoma;
THYM	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs288326	0.561	rs78177114	chr2:183730429	A/G	cg09997497	chr2:183902928	NCKAP1	1.11	5.07	0.46	1.94e-6	Blood protein levels;
THYM	cis	rs9462846	0.853	rs7758629	chr6:42871264	C/A	cg09436375	chr6:42928200	GNMT	-0.37	-4.51	-0.42	1.82e-5	Blood protein levels;
THYM	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg14159672	chr1:205819179	PM20D1	-0.76	-6.16	-0.53	1.74e-8	Menarche (age at onset);
THYM	cis	rs7193541	0.673	rs12716769	chr16:74652537	T/C	cg01733217	chr16:74700730	RFWD3	1.04	12.95	0.8	1.08e-22	Multiple myeloma;
THYM	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03647317	chr4:187891568	NA	0.79	8.41	0.65	4.15e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10992471	0.575	rs1152759	chr9:95129359	T/C	cg14631576	chr9:95140430	CENPP	0.71	6.41	0.55	5.55e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg02896835	chr1:92012615	NA	-0.65	-5.74	-0.51	1.15e-7	Breast cancer;
THYM	cis	rs6558530	0.730	rs10097891	chr8:1726809	C/A	cg09410841	chr8:1729607	CLN8	0.78	6.03	0.53	3.14e-8	Systolic blood pressure;
THYM	cis	rs4866334	1.000	rs74776941	chr5:18489387	T/G	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs4481887	1.000	rs6666690	chr1:248465323	T/C	cg13385794	chr1:248469461	NA	0.67	4.6	0.43	1.29e-5	Common traits (Other);
THYM	cis	rs4555082	1.000	rs66777564	chr14:105760245	A/G	cg13114125	chr14:105738426	BRF1	-0.74	-5.88	-0.52	6.13e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg07884673	chr3:53033167	SFMBT1	1.17	5.88	0.52	6.13e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg17105886	chr17:28927953	LRRC37B2	1.29	6.49	0.55	3.84e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	9.7	0.71	7.1e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7119	0.635	rs867916	chr15:77882860	A/G	cg10437265	chr15:77819839	NA	-0.67	-6.44	-0.55	4.9e-9	Type 2 diabetes;
THYM	cis	rs2692947	0.740	rs11695514	chr2:96548068	C/T	cg23100626	chr2:96804247	ASTL	0.37	4.79	0.44	6.21e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs686320	1.000	rs1787666	chr11:65249089	A/C	cg23743554	chr11:65321226	LTBP3	0.78	4.96	0.45	3.08e-6	Hip circumference adjusted for BMI;
THYM	cis	rs2836633	1.000	rs2836633	chr21:40067445	C/T	cg05519781	chr21:40033154	ERG	-0.64	-6.09	-0.53	2.35e-8	Coronary artery disease;
THYM	cis	rs11122895	0.509	rs3860380	chr2:112451387	A/G	cg23262488	chr2:112468472	NA	-0.5	-6.46	-0.55	4.46e-9	Allergic sensitization;
THYM	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg27490568	chr2:178487706	NA	0.6	5.32	0.48	6.97e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs892961	0.932	rs7207891	chr17:75413922	G/C	cg11351908	chr17:75402473	SEPT9	0.56	5.52	0.49	2.95e-7	Airflow obstruction;
THYM	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg24530246	chr3:53118167	NA	-0.81	-4.62	-0.43	1.23e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	6.27	0.54	1.08e-8	Obesity-related traits;
THYM	cis	rs259964	1.000	rs259962	chr20:57824960	A/G	cg09005679	chr20:57875326	EDN3	-0.44	-5.21	-0.47	1.1e-6	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg23682913	chr1:2080710	PRKCZ	-0.66	-5.85	-0.51	7.07e-8	Height;
THYM	cis	rs12681287	0.640	rs13258126	chr8:87453378	G/T	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg12373951	chr3:133503437	NA	0.57	6.19	0.54	1.51e-8	Iron status biomarkers;
THYM	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg14972814	chr11:95582409	MTMR2	-0.58	-5.31	-0.48	7.17e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4662945	0.699	rs35045564	chr2:130213210	G/A	cg05903289	chr2:130345205	NA	-0.59	-5.69	-0.5	1.39e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg26314531	chr2:26401878	FAM59B	-0.75	-4.93	-0.45	3.44e-6	Gut microbiome composition (summer);
THYM	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs4930103	0.935	rs4930110	chr11:2026701	G/C	cg06197492	chr11:2016605	H19	0.64	5.56	0.5	2.45e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs11771526	0.901	rs62457467	chr7:32301101	T/A	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs7705502	1.000	rs72812852	chr5:173379347	G/T	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs2806561	0.734	rs667211	chr1:23516142	T/C	cg12483005	chr1:23474871	LUZP1	0.59	6.29	0.54	9.59e-9	Height;
THYM	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-6.65	-0.56	1.82e-9	Colorectal cancer;
THYM	cis	rs59698941	0.943	rs4705873	chr5:132267167	G/A	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs5771069	0.931	rs137864	chr22:50446988	C/T	cg27467552	chr22:50353597	PIM3	-0.46	-4.77	-0.44	6.73e-6	Ulcerative colitis;
THYM	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg07601488	chr5:169797	PLEKHG4B	0.59	5.11	0.46	1.63e-6	Cystic fibrosis severity;
THYM	cis	rs8077889	1.000	rs2342310	chr17:41866199	T/C	cg26893861	chr17:41843967	DUSP3	1.07	9.57	0.7	1.39e-15	Triglycerides;
THYM	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs425277	0.917	rs12410859	chr1:2038732	C/T	cg13918804	chr1:2043761	PRKCZ	-0.64	-4.75	-0.44	7.11e-6	Height;
THYM	cis	rs2562456	0.833	rs2562507	chr19:21726337	C/T	cg21751540	chr19:21541537	ZNF738	0.66	4.62	0.43	1.2e-5	Pain;
THYM	cis	rs9992101	0.547	rs7654978	chr4:77409945	G/T	cg20311846	chr4:77356250	SHROOM3	-0.45	-4.72	-0.44	8.12e-6	Creatinine levels;
THYM	cis	rs1448094	0.533	rs2169572	chr12:86170370	G/T	cg02569458	chr12:86230093	RASSF9	-0.59	-5.21	-0.47	1.11e-6	Major depressive disorder;
THYM	cis	rs61931739	0.824	rs406753	chr12:34117408	A/G	cg06521331	chr12:34319734	NA	-0.6	-4.84	-0.44	4.98e-6	Morning vs. evening chronotype;
THYM	cis	rs4773144	0.966	rs4773143	chr13:110960685	T/C	cg02050376	chr13:109984684	NA	0.25	4.92	0.45	3.66e-6	Coronary artery disease;Coronary heart disease;
THYM	cis	rs7818345	0.967	rs11786847	chr8:19277200	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.65	0.43	1.07e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg08999081	chr20:33150536	PIGU	-0.77	-6.95	-0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs12476592	0.602	rs7608470	chr2:63691478	T/C	cg17519650	chr2:63277830	OTX1	-0.68	-4.51	-0.42	1.83e-5	Childhood ear infection;
THYM	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg21984481	chr17:79567631	NPLOC4	-0.6	-6.66	-0.56	1.74e-9	Eye color traits;
THYM	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg27129171	chr3:47204927	SETD2	0.8	7.93	0.63	4.18e-12	Colorectal cancer;
THYM	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg06112835	chr11:68658793	MRPL21	0.43	6.17	0.53	1.69e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	8.1	0.64	1.86e-12	Monocyte percentage of white cells;
THYM	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg06115741	chr20:33292138	TP53INP2	0.75	4.97	0.45	2.99e-6	Coronary artery disease;
THYM	cis	rs3820068	0.581	rs68052904	chr1:15916714	T/C	cg24675056	chr1:15929824	NA	0.76	6.13	0.53	1.95e-8	Systolic blood pressure;
THYM	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg11845111	chr2:191398756	TMEM194B	0.94	8.49	0.66	2.76e-13	Pulse pressure;
THYM	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.66e-11	Aortic root size;
THYM	cis	rs711830	1.000	rs711830	chr2:177037311	C/T	cg13092806	chr2:177043255	NA	-0.55	-4.47	-0.42	2.15e-5	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs17534004	1.000	rs17534004	chr13:31469665	C/T	cg00367615	chr13:31480979	C13orf33	0.62	4.46	0.42	2.25e-5	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs62244186	0.606	rs6798590	chr3:44556861	T/A	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.45	-4.76	-0.44	6.82e-6	Depressive symptoms;
THYM	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg15556689	chr8:8085844	FLJ10661	0.69	5.56	0.5	2.43e-7	Mood instability;
THYM	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22509189	chr2:225307070	NA	-0.88	-7.52	-0.61	3.1e-11	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs4660306	0.744	rs11211115	chr1:45926438	A/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.62	4.59	0.43	1.34e-5	Homocysteine levels;
THYM	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.79	6.89	0.58	6.16e-10	Tonsillectomy;
THYM	cis	rs7177699	0.526	rs7165042	chr15:79123338	C/G	cg15571903	chr15:79123663	NA	0.58	6.56	0.56	2.77e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg27286337	chr10:134555280	INPP5A	0.84	5.93	0.52	4.78e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	trans	rs3213961	0.683	rs10514775	chr2:33789032	C/T	cg19997179	chr2:620310	NA	-0.54	-6.87	-0.58	6.55e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
THYM	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.82	0.44	5.4e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg00801512	chr17:28996047	NA	-0.84	-5.46	-0.49	3.83e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13102973	0.797	rs4453983	chr4:135905424	A/C	cg14419869	chr4:135874104	NA	0.82	6.86	0.58	7.03e-10	Subjective well-being;
THYM	cis	rs9462846	0.853	rs7740252	chr6:42871045	T/C	cg09436375	chr6:42928200	GNMT	-0.37	-4.51	-0.42	1.82e-5	Blood protein levels;
THYM	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg07601488	chr5:169797	PLEKHG4B	0.59	5.11	0.46	1.63e-6	Cystic fibrosis severity;
THYM	cis	rs4363385	0.818	rs684305	chr1:153006242	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs4766566	0.651	rs4766505	chr12:111758620	A/G	cg10833066	chr12:111807467	FAM109A	0.66	9.37	0.69	3.63e-15	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
THYM	cis	rs6074578	0.597	rs7353361	chr20:134400	G/A	cg16931068	chr20:139680	DEFB127	0.43	4.63	0.43	1.15e-5	Hirschsprung disease;
THYM	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg13385794	chr1:248469461	NA	0.67	4.58	0.43	1.4e-5	Common traits (Other);
THYM	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg07061783	chr6:25882402	NA	0.89	7.98	0.63	3.24e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg04944784	chr2:26401820	FAM59B	-1.02	-7.9	-0.63	4.9e-12	Gut microbiome composition (summer);
THYM	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg12386194	chr3:101231763	SENP7	0.69	5.14	0.47	1.48e-6	Colorectal cancer;
THYM	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg04248312	chr19:17393744	ANKLE1	-0.97	-12.86	-0.8	1.59e-22	Systemic lupus erythematosus;
THYM	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6430585	0.702	rs746857	chr2:136554890	G/A	cg04750100	chr2:136595281	LCT	-0.52	-4.75	-0.44	7.21e-6	Corneal structure;
THYM	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.42	0.49	4.44e-7	Height;
THYM	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	5.23	0.47	1.02e-6	Schizophrenia;
THYM	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg13683864	chr3:40499215	RPL14	0.94	9.74	0.71	6.07e-16	Renal cell carcinoma;
THYM	cis	rs8064299	0.967	rs880827	chr17:72767435	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.62	-5.34	-0.48	6.29e-7	Monocyte count;
THYM	cis	rs8064299	1.000	rs8064299	chr17:72762646	C/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.62	5.24	0.47	9.49e-7	Monocyte count;
THYM	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg07169764	chr2:136633963	MCM6	0.71	6.39	0.55	6.06e-9	Mosquito bite size;
THYM	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg13393036	chr8:95962371	TP53INP1	-0.49	-4.98	-0.46	2.81e-6	Type 2 diabetes;
THYM	cis	rs2688608	0.592	rs7909544	chr10:75484004	G/C	cg15838173	chr10:75533400	FUT11	-0.54	-5.36	-0.48	5.84e-7	Inflammatory bowel disease;
THYM	cis	rs4595586	0.545	rs6580892	chr12:39370237	G/C	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs12216545	0.737	rs7788188	chr7:150226669	G/A	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg14456004	chr13:21872349	NA	-1.24	-10.0	-0.72	1.63e-16	White matter hyperintensity burden;
THYM	cis	rs7822232	1.000	rs6558296	chr8:145143802	G/A	cg12091641	chr8:145180933	NA	-1.01	-4.87	-0.45	4.36e-6	Blood metabolite levels;
THYM	cis	rs9914988	0.725	rs66531973	chr17:27125993	G/T	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg24596788	chr1:163392923	NA	-0.77	-7.43	-0.61	4.68e-11	Motion sickness;
THYM	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.59	-4.77	-0.44	6.69e-6	Response to bleomycin (chromatid breaks);
THYM	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg10295955	chr4:187884368	NA	-1.19	-17.25	-0.87	5.06e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg07636037	chr3:49044803	WDR6	0.97	9.94	0.71	2.24e-16	Parkinson's disease;
THYM	cis	rs9443645	0.810	rs7767711	chr6:79810700	G/A	cg05283184	chr6:79620031	NA	-0.92	-8.17	-0.64	1.31e-12	Intelligence (multi-trait analysis);
THYM	trans	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg07211511	chr3:129823064	LOC729375	-1.22	-9.75	-0.71	5.63e-16	Blood pressure (smoking interaction);
THYM	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.46	0.55	4.39e-9	Total body bone mineral density;
THYM	cis	rs6860806	0.661	rs6890009	chr5:131580033	G/T	cg18301423	chr5:131593218	PDLIM4	0.48	4.47	0.42	2.14e-5	Breast cancer;
THYM	cis	rs600806	0.888	rs652651	chr1:109844532	A/G	cg02175308	chr1:109941060	SORT1	-0.53	-4.57	-0.42	1.47e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg10515332	chr4:99064459	C4orf37	0.58	4.62	0.43	1.21e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	5.75	0.51	1.08e-7	Blood metabolite levels;
THYM	cis	rs7084402	0.967	rs7078900	chr10:60273430	G/A	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs8040855	0.770	rs8023774	chr15:85698916	A/G	cg04831495	chr15:85060580	GOLGA6L5	0.64	4.85	0.45	4.89e-6	Bulimia nervosa;
THYM	cis	rs7818345	1.000	rs11780343	chr8:19290963	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.43	4.71	0.43	8.5e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35883536	0.566	rs10783141	chr1:101043897	G/A	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg08772003	chr10:104629869	AS3MT	-0.56	-4.94	-0.45	3.28e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7084402	0.967	rs1649019	chr10:60288111	T/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg16797656	chr11:68205561	LRP5	-0.45	-4.75	-0.44	7.08e-6	Total body bone mineral density;
THYM	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg15605315	chr1:45957053	TESK2	0.78	6.5	0.55	3.7e-9	High light scatter reticulocyte count;
THYM	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg03806693	chr22:41940476	POLR3H	0.99	7.63	0.62	1.82e-11	Vitiligo;
THYM	cis	rs11779988	0.571	rs208053	chr8:17825327	G/A	cg01800426	chr8:17659068	MTUS1	-0.74	-5.17	-0.47	1.28e-6	Breast cancer;
THYM	cis	rs17030434	1.000	rs6853522	chr4:154706220	A/C	cg14289246	chr4:154710475	SFRP2	0.83	5.58	0.5	2.24e-7	Electrocardiographic conduction measures;
THYM	cis	rs611744	0.967	rs645070	chr8:109216345	A/C	cg21045802	chr8:109455806	TTC35	0.59	5.31	0.48	7.16e-7	Dupuytren's disease;
THYM	cis	rs7131987	0.834	rs7139273	chr12:29434650	T/C	cg09582351	chr12:29534625	ERGIC2	-0.47	-4.54	-0.42	1.63e-5	QT interval;
THYM	cis	rs10037758	0.630	rs2577434	chr5:128309803	G/A	cg25555059	chr5:128301488	SLC27A6	-0.48	-5.08	-0.46	1.91e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg02551604	chr5:131831745	NA	0.78	6.17	0.53	1.66e-8	Asthma (sex interaction);
THYM	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg03709012	chr19:19516395	GATAD2A	0.74	5.71	0.51	1.31e-7	Tonsillectomy;
THYM	cis	rs6500395	1.000	rs2080508	chr16:48690665	G/C	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs6089829	0.888	rs4809471	chr20:61684287	G/A	cg03213289	chr20:61660250	NA	0.97	10.63	0.74	7.33e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2404602	0.530	rs11072614	chr15:76967205	G/A	cg23625390	chr15:77176239	SCAPER	-0.8	-5.08	-0.46	1.86e-6	Blood metabolite levels;
THYM	cis	rs13082711	0.863	rs36055621	chr3:27436797	T/C	cg02860705	chr3:27208620	NA	0.69	4.99	0.46	2.75e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	9.39	0.69	3.37e-15	Chronic sinus infection;
THYM	cis	rs11096990	0.613	rs35391082	chr4:39192653	C/T	cg24403649	chr4:39172243	NA	0.6	5.16	0.47	1.35e-6	Cognitive function;
THYM	cis	rs3781426	1.000	rs3781424	chr10:126704700	T/C	cg04494136	chr10:126703576	CTBP2	-0.34	-4.57	-0.42	1.47e-5	Height;
THYM	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg10523679	chr1:76189770	ACADM	0.9	9.47	0.7	2.2e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7909074	1.000	rs1408814	chr10:45399088	A/G	cg05187965	chr10:45406764	TMEM72	-0.51	-4.85	-0.45	4.86e-6	Mean corpuscular volume;
THYM	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg16325326	chr1:53192061	ZYG11B	0.84	8.29	0.65	7.48e-13	Monocyte count;
THYM	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21582582	chr3:182698605	DCUN1D1	0.81	7.07	0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs35883536	0.513	rs6577180	chr1:101016939	G/A	cg09408571	chr1:101003634	GPR88	0.57	6.27	0.54	1.04e-8	Monocyte count;
THYM	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg00383909	chr3:49044727	WDR6	1.05	5.99	0.52	3.79e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.49	0.42	1.97e-5	Diabetic retinopathy;
THYM	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg21427119	chr20:30132790	HM13	-0.72	-4.8	-0.44	5.95e-6	Monocyte count;
THYM	cis	rs7705502	1.000	rs75738222	chr5:173349404	C/T	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs7020830	0.894	rs12337316	chr9:37148105	G/A	cg14294708	chr9:37120828	ZCCHC7	1.27	14.73	0.83	2.93e-26	Schizophrenia;
THYM	cis	rs11711311	1.000	rs9826465	chr3:113432254	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.59	-5.19	-0.47	1.2e-6	IgG glycosylation;
THYM	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg17775962	chr7:1200435	ZFAND2A	0.5	5.65	0.5	1.66e-7	Longevity;Endometriosis;
THYM	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg03605463	chr16:89740564	NA	-0.63	-4.56	-0.42	1.53e-5	Vitiligo;
THYM	cis	rs800586	0.500	rs2721962	chr8:116658551	T/A	cg04656070	chr8:116661063	TRPS1	-0.54	-6.22	-0.54	1.32e-8	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg10018233	chr7:150070692	REPIN1	0.47	6.82	0.57	8.33e-10	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg23260525	chr10:116636907	FAM160B1	0.52	5.2	0.47	1.15e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1747683	0.528	rs10752299	chr10:13388578	A/G	cg25835351	chr10:13388524	SEPHS1	-0.28	-4.89	-0.45	4.14e-6	IgG glycosylation;
THYM	cis	rs4455778	0.500	rs7783586	chr7:49057244	C/A	cg26309511	chr7:48887640	NA	0.63	5.5	0.49	3.13e-7	Lung cancer in never smokers;
THYM	cis	rs7727544	0.788	rs270613	chr5:131640583	A/G	cg14196790	chr5:131705035	SLC22A5	0.58	5.09	0.46	1.81e-6	Blood metabolite levels;
THYM	cis	rs6754311	0.597	rs6760329	chr2:136544752	A/G	cg20242066	chr2:136595261	LCT	-0.51	-5.6	-0.5	2.06e-7	Mosquito bite size;
THYM	cis	rs13006833	0.703	rs291427	chr2:191194059	C/T	cg21644426	chr2:191273491	MFSD6	0.66	4.64	0.43	1.11e-5	Urinary metabolites;
THYM	cis	rs9611519	1.000	rs6002271	chr22:41566595	C/T	cg06481639	chr22:41940642	POLR3H	-0.71	-5.14	-0.47	1.45e-6	Neuroticism;
THYM	cis	rs10895275	0.847	rs4447144	chr11:102050321	G/A	cg24447756	chr11:102105824	NA	-0.51	-4.59	-0.43	1.34e-5	Migraine;
THYM	cis	rs10158481	0.759	rs926462	chr1:25486299	A/G	cg09264742	chr1:25757510	TMEM57	-0.63	-4.6	-0.43	1.31e-5	Urate levels in obese individuals;
THYM	cis	rs11608355	0.515	rs11611012	chr12:109945203	G/A	cg11367159	chr12:110044531	NA	0.69	4.97	0.45	2.92e-6	Neuroticism;
THYM	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg01299579	chr2:10830716	NOL10	-0.5	-4.8	-0.44	5.86e-6	Prostate cancer;
THYM	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg00684032	chr4:1343700	KIAA1530	0.53	4.47	0.42	2.17e-5	Longevity;
THYM	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg16325326	chr1:53192061	ZYG11B	0.98	11.37	0.76	2.04e-19	Monocyte count;
THYM	cis	rs888194	0.544	rs2196612	chr12:109849535	A/G	cg10504392	chr12:110044639	NA	0.66	5.93	0.52	4.85e-8	Neuroticism;
THYM	cis	rs2282300	0.739	rs1222221	chr11:30342738	A/G	cg09906309	chr11:30344399	C11orf46	-0.72	-5.54	-0.49	2.73e-7	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2074409	0.509	rs2074412	chr17:35839066	C/T	cg06716730	chr17:35851459	DUSP14	0.29	4.51	0.42	1.85e-5	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs35164067	1.000	rs34953890	chr19:10526854	C/A	cg01466491	chr19:10523363	NA	-0.62	-4.83	-0.44	5.17e-6	Inflammatory bowel disease;
THYM	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs988913	0.957	rs12525787	chr6:54789072	C/T	cg18532076	chr6:54711417	FAM83B	0.52	4.83	0.44	5.13e-6	Menarche (age at onset);
THYM	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.52	0.42	1.8e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Body mass index;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg18078658	chr12:72374129	TPH2	-0.88	-7.29	-0.6	9.21e-11	Depressive symptoms;
THYM	cis	rs921968	0.643	rs600057	chr2:219456737	A/G	cg02176678	chr2:219576539	TTLL4	0.67	6.66	0.56	1.78e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11645898	0.574	rs17604349	chr16:72210865	C/T	cg03805757	chr16:71968109	PKD1L3	-0.76	-6.84	-0.57	7.79e-10	Blood protein levels;
THYM	cis	rs12142240	0.698	rs72677592	chr1:46818288	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.67	-4.49	-0.42	1.98e-5	Menarche (age at onset);
THYM	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs11096990	0.613	rs4974996	chr4:39227548	C/A	cg24403649	chr4:39172243	NA	0.62	5.42	0.49	4.43e-7	Cognitive function;
THYM	cis	rs9807841	0.592	rs11085743	chr19:10759442	G/A	cg17848348	chr19:10766748	ILF3	-0.73	-6.05	-0.53	2.88e-8	Inflammatory skin disease;
THYM	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg26031613	chr14:104095156	KLC1	0.78	5.2	0.47	1.14e-6	Body mass index;
THYM	cis	rs11696501	0.688	rs11696685	chr20:44295134	A/G	cg11783356	chr20:44313418	WFDC10B	-0.71	-4.79	-0.44	6.07e-6	Brain structure;
THYM	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	8.52	0.66	2.36e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs11031096	0.678	rs11031219	chr11:4197578	G/A	cg22027985	chr11:4115532	RRM1	-0.56	-5.25	-0.47	9.12e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg06636001	chr8:8085503	FLJ10661	-0.75	-6.51	-0.56	3.61e-9	Mood instability;
THYM	cis	rs9479482	1.000	rs9478362	chr6:150340526	T/C	cg25797454	chr6:150327115	RAET1K	0.46	5.03	0.46	2.33e-6	Alopecia areata;
THYM	cis	rs7902587	0.850	rs2995264	chr10:105668843	G/A	cg11005552	chr10:105648138	OBFC1	0.68	4.45	0.42	2.35e-5	Lung cancer;Serous borderline ovarian cancer;Thyroid cancer;Low-grade serous and serous borderline ovarian cancer;
THYM	cis	rs733175	0.855	rs9291640	chr4:10007086	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	4.6	0.43	1.31e-5	Psychosis and Alzheimer's disease;
THYM	cis	rs9992101	0.547	rs11722924	chr4:77396854	G/C	cg27417997	chr4:77356416	SHROOM3	-0.4	-4.79	-0.44	6.02e-6	Creatinine levels;
THYM	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg21784768	chr11:537496	LRRC56	-1.14	-5.19	-0.47	1.17e-6	Body mass index;
THYM	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11890956	chr21:40555474	PSMG1	-0.9	-9.57	-0.7	1.4e-15	Cognitive function;
THYM	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg03959625	chr15:84868606	LOC388152	-0.48	-4.53	-0.42	1.7e-5	Schizophrenia;
THYM	cis	rs6089829	0.888	rs4809268	chr20:61675249	C/G	cg02380750	chr20:61661411	NA	0.63	6.2	0.54	1.43e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg06600287	chr1:53387719	ECHDC2	-0.35	-5.32	-0.48	7.02e-7	Monocyte count;
THYM	cis	rs501916	0.833	rs11855134	chr15:48047676	A/G	cg20869673	chr15:48010124	SEMA6D	0.72	5.41	0.49	4.74e-7	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg10224037	chr5:178157518	ZNF354A	0.99	7.89	0.63	5.06e-12	Neutrophil percentage of white cells;
THYM	cis	rs12765878	0.812	rs7076119	chr10:105667110	T/C	cg11005552	chr10:105648138	OBFC1	-0.6	-5.81	-0.51	8.13e-8	Coronary artery disease;
THYM	cis	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg13446199	chr8:143762866	PSCA	-0.41	-4.53	-0.42	1.7e-5	Urinary tract infection frequency;
THYM	cis	rs747334	0.818	rs12573344	chr10:92702786	T/A	cg07620928	chr10:92689909	NA	0.54	4.87	0.45	4.5e-6	Fibroblast growth factor basic levels;
THYM	cis	rs2412488	0.850	rs6828559	chr4:54235363	A/C	cg19408398	chr4:54243328	FIP1L1	-0.44	-4.51	-0.42	1.86e-5	DNA methylation (variation);
THYM	cis	rs6087990	0.836	rs2424909	chr20:31361861	T/C	cg13636640	chr20:31349939	DNMT3B	0.92	9.55	0.7	1.48e-15	Ulcerative colitis;
THYM	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg00484396	chr16:3507460	NAT15	0.74	9.01	0.68	2.2e-14	Tuberculosis;
THYM	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg11764359	chr7:65958608	NA	0.75	5.55	0.5	2.54e-7	Aortic root size;
THYM	cis	rs8041943	0.550	rs11856245	chr15:79894020	T/C	cg20511832	chr15:78934280	CHRNB4	0.44	4.52	0.42	1.8e-5	Bone mineral density (spine) and age at menarche;
THYM	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg11494091	chr17:61959527	GH2	1.07	16.45	0.86	1.5e-29	Prudent dietary pattern;
THYM	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg15691649	chr6:25882328	NA	-0.78	-6.6	-0.56	2.35e-9	Intelligence (multi-trait analysis);
THYM	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg13390004	chr1:15929781	NA	0.63	4.78	0.44	6.46e-6	Systolic blood pressure;
THYM	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg03929089	chr4:120376271	NA	-0.97	-11.87	-0.77	1.78e-20	Coronary artery disease;
THYM	cis	rs9677476	1.000	rs9677476	chr2:232126290	C/T	cg07929768	chr2:232055508	NA	-0.49	-5.01	-0.46	2.56e-6	Food antigen IgG levels;
THYM	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg02018176	chr4:1364513	KIAA1530	-0.77	-7.32	-0.6	7.83e-11	Obesity-related traits;
THYM	cis	rs525592	1	rs525592	chr11:68195104	C/T	cg16797656	chr11:68205561	LRP5	0.54	6.23	0.54	1.25e-8	Bone mineral density;
THYM	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1003719	0.788	rs2835595	chr21:38466203	G/T	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs4077515	0.967	rs11794847	chr9:139271747	G/A	cg14115884	chr9:139300582	SDCCAG3	0.73	6.9	0.58	5.79e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs17443541	0.507	rs10196195	chr2:200456620	C/T	cg03741458	chr2:200468445	NA	-0.8	-6.04	-0.53	3.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6121246	0.567	rs6060399	chr20:30220823	C/T	cg21427119	chr20:30132790	HM13	-0.96	-6.95	-0.58	4.65e-10	Mean corpuscular hemoglobin;
THYM	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg04772025	chr11:68637568	NA	0.66	6.9	0.58	5.88e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7818345	0.967	rs6992893	chr8:19287504	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.65	0.43	1.09e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.96	-8.0	-0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs4731207	0.596	rs12538171	chr7:124645570	A/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs7404928	0.651	rs8055773	chr16:23941760	T/C	cg26685404	chr16:23957272	PRKCB	0.61	7.0	0.58	3.53e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4606347	0.932	rs2375804	chr1:66152919	A/G	cg04111102	chr1:66153794	NA	0.57	4.53	0.42	1.73e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg08859206	chr1:53392774	SCP2	0.78	8.18	0.64	1.25e-12	Monocyte count;
THYM	cis	rs4523957	0.928	rs216198	chr17:2201735	C/T	cg16513277	chr17:2031491	SMG6	0.77	7.08	0.59	2.47e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs4499344	0.526	rs8100915	chr19:33032310	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.69	-4.54	-0.42	1.64e-5	Mean platelet volume;
THYM	cis	rs6546324	0.625	rs4671817	chr2:67866437	T/G	cg18237512	chr2:67827392	NA	-0.79	-4.66	-0.43	1.03e-5	Endometriosis;
THYM	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg13683864	chr3:40499215	RPL14	-0.75	-6.78	-0.57	1.03e-9	Renal cell carcinoma;
THYM	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	6.03	0.53	3.08e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7208859	0.623	rs73263788	chr17:29216490	T/C	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3771570	0.681	rs12151655	chr2:242281438	T/A	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs1883415	0.667	rs2817214	chr6:24497385	C/T	cg00346970	chr6:24499591	ALDH5A1	0.42	4.78	0.44	6.48e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg10802521	chr3:52805072	NEK4	-0.73	-6.43	-0.55	5.15e-9	Bipolar disorder;
THYM	cis	rs2652822	0.509	rs8468	chr15:63434110	C/T	cg09251291	chr15:63483946	RAB8B	0.54	4.73	0.44	7.82e-6	Metabolic traits;
THYM	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg12000587	chr17:30186630	C17orf79	-0.39	-4.74	-0.44	7.55e-6	Hip circumference adjusted for BMI;
THYM	cis	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg24375607	chr4:120327624	NA	0.58	4.74	0.44	7.42e-6	Corneal astigmatism;
THYM	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg08213375	chr14:104286397	PPP1R13B	0.43	4.51	0.42	1.88e-5	Reticulocyte count;
THYM	cis	rs7940866	0.838	rs7949071	chr11:130877478	T/C	cg12179176	chr11:130786555	SNX19	0.57	4.52	0.42	1.76e-5	Schizophrenia;
THYM	cis	rs67981189	0.858	rs221927	chr14:71578741	G/A	cg15910301	chr14:71632612	NA	-0.5	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	trans	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg26043149	chr18:55253948	FECH	1.16	10.82	0.74	2.98e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs6987853	0.966	rs2974342	chr8:42436651	A/C	cg09913449	chr8:42400586	C8orf40	0.87	8.22	0.64	1.02e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-5.13	-0.47	1.55e-6	Lymphocyte counts;
THYM	cis	rs11997175	0.646	rs4463379	chr8:33692719	G/A	ch.8.33884649F	chr8:33765107	NA	0.63	4.76	0.44	6.85e-6	Body mass index;
THYM	cis	rs4690686	0.500	rs11723131	chr4:177268602	G/A	cg17059388	chr4:177262070	NA	0.48	6.73	0.57	1.29e-9	Essential tremor;
THYM	cis	rs11625487	0.645	rs8006951	chr14:77965304	G/A	cg20045696	chr14:77926864	AHSA1	0.66	4.65	0.43	1.05e-5	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
THYM	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg11845111	chr2:191398756	TMEM194B	-0.96	-6.77	-0.57	1.06e-9	Diastolic blood pressure;
THYM	cis	rs42648	0.869	rs1015404	chr7:89913946	G/C	cg25739043	chr7:89950458	NA	-0.55	-4.75	-0.44	7.09e-6	Homocysteine levels;
THYM	cis	rs6035126	1.000	rs13433131	chr20:1931666	A/G	cg07210840	chr20:1927816	NA	-1.04	-4.75	-0.44	7.18e-6	Liver enzyme levels (alanine transaminase);
THYM	cis	rs28595532	0.920	rs114659035	chr4:119740028	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg05084668	chr3:125655381	ALG1L	-0.81	-4.94	-0.45	3.39e-6	Blood pressure (smoking interaction);
THYM	cis	rs61931739	0.890	rs694706	chr12:34135323	T/C	cg06521331	chr12:34319734	NA	-0.6	-4.85	-0.45	4.77e-6	Morning vs. evening chronotype;
THYM	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg06481639	chr22:41940642	POLR3H	0.77	5.37	0.48	5.67e-7	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4803468	1.000	rs2241711	chr19:41911980	T/C	cg09537434	chr19:41945824	ATP5SL	-1.13	-10.61	-0.74	8.09e-18	Height;
THYM	cis	rs113835537	0.529	rs3816492	chr11:66297363	C/T	cg10315249	chr11:66235081	PELI3	0.45	4.75	0.44	7.1e-6	Airway imaging phenotypes;
THYM	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg08999081	chr20:33150536	PIGU	0.79	7.47	0.61	3.82e-11	Coronary artery disease;
THYM	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg04025307	chr7:1156635	C7orf50	0.67	6.4	0.55	5.82e-9	Longevity;Endometriosis;
THYM	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.68	5.24	0.47	9.75e-7	Tonsillectomy;
THYM	cis	rs2073300	1.000	rs6137961	chr20:23443102	G/T	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs9296092	0.538	rs9461875	chr6:33516644	C/T	cg13560919	chr6:33536144	NA	-0.93	-9.07	-0.68	1.58e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg19761014	chr17:28927070	LRRC37B2	0.89	4.93	0.45	3.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.76	0.74	3.96e-18	Chronic sinus infection;
THYM	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	8.01	0.64	2.84e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs208520	0.690	rs207096	chr6:66797287	T/C	cg07460842	chr6:66804631	NA	-1.06	-7.89	-0.63	5.14e-12	Exhaled nitric oxide output;
THYM	cis	rs6951245	0.515	rs78461900	chr7:1007033	C/A	cg07131210	chr7:1025825	CYP2W1	-0.85	-4.8	-0.44	5.91e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12594515	1.000	rs8027000	chr15:45987795	T/C	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs1629083	0.967	rs4936425	chr11:118126904	C/T	cg25155064	chr11:118100782	MPZL3	-0.57	-5.03	-0.46	2.34e-6	Lung cancer;
THYM	cis	rs2039659	0.608	rs1764959	chr13:86260365	A/G	cg25308322	chr13:86268291	NA	0.66	5.72	0.51	1.21e-7	Blood osmolality (transformed sodium);
THYM	cis	rs7226229	1.000	rs1993901	chr17:20938791	A/G	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs2070677	0.935	rs13376793	chr10:135421344	C/G	cg20169779	chr10:135381914	SYCE1	-0.75	-5.76	-0.51	1.03e-7	Gout;
THYM	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg24910161	chr17:38119198	GSDMA	0.42	4.45	0.42	2.31e-5	Self-reported allergy;
THYM	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg02527881	chr3:46936655	PTH1R	0.54	4.98	0.46	2.79e-6	Colorectal cancer;
THYM	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg21280719	chr6:42927975	GNMT	-0.43	-4.51	-0.42	1.83e-5	Blood protein levels;
THYM	cis	rs67072384	1.000	rs7124056	chr11:72444747	C/T	cg01380194	chr11:72452482	ARAP1	0.85	4.84	0.45	4.92e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs11731175	1.000	rs1597227	chr4:189859598	T/C	cg00431894	chr4:189871012	NA	-0.82	-6.24	-0.54	1.2e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9788682	0.747	rs2036533	chr15:78781687	G/A	cg18825076	chr15:78729989	IREB2	0.7	5.57	0.5	2.39e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs3087591	1.000	rs2905800	chr17:29531980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.61	5.23	0.47	1.02e-6	Hip circumference;
THYM	cis	rs954108	0.522	rs7983818	chr13:29383182	A/C	cg11788234	chr13:29393811	NA	-0.64	-5.02	-0.46	2.44e-6	Obesity-related traits;
THYM	cis	rs2219968	0.683	rs936889	chr8:78897926	A/G	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7408868	0.908	rs1044006	chr19:15285052	T/C	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg18240062	chr17:79603768	NPLOC4	-0.73	-6.55	-0.56	2.9e-9	Eye color traits;
THYM	cis	rs2997447	0.723	rs61776623	chr1:26474490	A/G	cg03844060	chr1:26490628	NA	0.68	4.96	0.45	3.12e-6	QRS complex (12-leadsum);
THYM	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs34638657	0.732	rs7205534	chr16:82201618	C/T	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.16	-0.47	1.33e-6	Lung adenocarcinoma;
THYM	cis	rs7078219	0.965	rs11190134	chr10:101282200	C/T	cg17888390	chr10:101282816	NA	-0.52	-4.9	-0.45	3.92e-6	Dental caries;
THYM	cis	rs4819052	0.851	rs2838867	chr21:46713092	C/T	cg11663144	chr21:46675770	NA	-0.68	-9.5	-0.7	1.98e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9457247	0.638	rs239933	chr6:167413230	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.56	-5.78	-0.51	9.5e-8	Crohn's disease;
THYM	cis	rs6076699	0.623	rs297757	chr20:4503605	C/T	cg22147446	chr20:4879261	SLC23A2	0.9	4.46	0.42	2.24e-5	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (smoking interaction);
THYM	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg22841779	chr14:105766346	BRF1	-0.49	-6.41	-0.55	5.6e-9	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.8	6.52	0.56	3.41e-9	Blood protein levels;
THYM	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg25358565	chr5:93447407	FAM172A	1.34	10.59	0.74	9.3e-18	Diabetic retinopathy;
THYM	cis	rs35883536	0.967	rs1055044	chr1:101171354	A/G	cg06223162	chr1:101003688	GPR88	0.67	5.12	0.46	1.62e-6	Monocyte count;
THYM	cis	rs747334	0.846	rs4933632	chr10:92727381	A/G	cg07620928	chr10:92689909	NA	0.62	5.47	0.49	3.69e-7	Fibroblast growth factor basic levels;
THYM	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs4072705	1.000	rs4836991	chr9:127512040	A/G	cg01786973	chr9:127249749	NR5A1	-0.38	-5.0	-0.46	2.57e-6	Menarche (age at onset);
THYM	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06481639	chr22:41940642	POLR3H	-0.87	-5.95	-0.52	4.49e-8	Vitiligo;
THYM	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08109568	chr15:31115862	NA	-0.59	-5.74	-0.51	1.15e-7	Huntington's disease progression;
THYM	cis	rs73219805	0.838	rs7840859	chr8:26235017	A/G	cg22461835	chr8:26723365	ADRA1A	-0.54	-4.5	-0.42	1.93e-5	Schizophrenia;
THYM	cis	rs9583531	0.600	rs7984468	chr13:111362093	C/A	cg24331049	chr13:111365604	ING1	0.72	6.04	0.53	2.96e-8	Coronary artery disease;
THYM	cis	rs2073300	0.793	rs36165478	chr20:23457261	C/T	cg12062639	chr20:23401060	NAPB	0.99	4.96	0.45	3.07e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs600806	0.815	rs10858089	chr1:109926828	T/C	cg16988986	chr1:109941118	SORT1	-0.43	-4.56	-0.42	1.5e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7551222	0.752	rs2290854	chr1:204516025	A/G	cg20240347	chr1:204465584	NA	-0.51	-4.63	-0.43	1.18e-5	Schizophrenia;
THYM	cis	rs2637266	1.000	rs7477433	chr10:78358116	C/T	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4389656	0.857	rs274677	chr5:6754402	T/C	cg10857441	chr5:6722123	POLS	-0.43	-4.52	-0.42	1.81e-5	Coronary artery disease;
THYM	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg26924012	chr15:45694286	SPATA5L1	0.66	4.86	0.45	4.65e-6	Response to fenofibrate (adiponectin levels);
THYM	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.69	7.21	0.59	1.35e-10	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg13736514	chr6:26305472	NA	-0.61	-7.45	-0.61	4.16e-11	Educational attainment;
THYM	trans	rs4650994	0.524	rs2476558	chr1:178580953	C/T	cg05059571	chr16:84539110	KIAA1609	0.92	10.39	0.73	2.4e-17	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs3925075	1.000	rs3925075	chr16:31347748	C/T	cg02846316	chr16:31340340	ITGAM	-0.58	-6.08	-0.53	2.44e-8	IgA nephropathy;
THYM	cis	rs901683	1.000	rs35824277	chr10:46030477	C/T	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs6032067	0.929	rs6032049	chr20:43825556	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs4803468	0.967	rs3786553	chr19:41902746	T/G	cg09537434	chr19:41945824	ATP5SL	-1.06	-10.09	-0.72	1.07e-16	Height;
THYM	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.13	0.68	1.18e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7084402	0.935	rs10740731	chr10:60348886	G/A	cg07615347	chr10:60278583	BICC1	0.54	5.06	0.46	2.04e-6	Refractive error;
THYM	cis	rs2276498	1.000	rs2276499	chr20:52610443	C/T	cg23682609	chr20:52687365	BCAS1	-0.65	-4.95	-0.45	3.25e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs870825	0.616	rs7682557	chr4:185640773	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg19875535	chr5:140030758	IK	-0.63	-5.69	-0.5	1.43e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg06558623	chr16:89946397	TCF25	1.2	5.79	0.51	9.08e-8	Skin colour saturation;
THYM	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.54	-0.42	1.67e-5	Morning vs. evening chronotype;
THYM	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg25703541	chr22:24373054	LOC391322	-0.82	-8.42	-0.65	3.89e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6138458	1.000	rs2387361	chr20:24899905	C/T	cg26195577	chr20:24973756	C20orf3	-1.11	-10.52	-0.73	1.29e-17	Blood protein levels;
THYM	cis	rs10992471	0.528	rs3780347	chr9:95266812	A/G	cg14631576	chr9:95140430	CENPP	-0.81	-7.54	-0.61	2.79e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg01966878	chr4:90757139	SNCA	-0.62	-4.95	-0.45	3.15e-6	Neuroticism;
THYM	cis	rs61931739	1.000	rs12304768	chr12:34000986	T/G	cg10856724	chr12:34555212	NA	0.59	5.13	0.47	1.56e-6	Morning vs. evening chronotype;
THYM	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg20203395	chr5:56204925	C5orf35	-0.66	-4.57	-0.42	1.48e-5	Initial pursuit acceleration;
THYM	cis	rs4747241	0.738	rs4747244	chr10:74051642	G/C	cg07828833	chr10:74069493	NA	0.59	5.03	0.46	2.3e-6	Heschl's gyrus morphology;
THYM	cis	rs7772486	0.875	rs2777484	chr6:146334162	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg07930552	chr6:133119739	C6orf192	1.03	6.0	0.52	3.63e-8	Type 2 diabetes nephropathy;
THYM	cis	rs2933343	0.601	rs1680759	chr3:128594896	C/G	cg11901034	chr3:128598214	ACAD9	-0.7	-5.68	-0.5	1.47e-7	IgG glycosylation;
THYM	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg19077165	chr18:44547161	KATNAL2	0.61	7.58	0.61	2.28e-11	Personality dimensions;
THYM	cis	rs17744026	0.586	rs12276179	chr11:123749658	C/A	cg00079598	chr11:123676903	OR6M1	-0.48	-4.48	-0.42	2.04e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg10792982	chr14:105748885	BRF1	0.75	7.74	0.62	1.05e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg19418458	chr7:158789849	NA	-0.61	-5.8	-0.51	8.75e-8	Facial morphology (factor 20);
THYM	cis	rs7084402	1.000	rs7084402	chr10:60265404	C/T	cg07615347	chr10:60278583	BICC1	0.56	5.14	0.47	1.5e-6	Refractive error;
THYM	cis	rs16866061	1.000	rs1568750	chr2:225342597	A/T	cg12698349	chr2:225449008	CUL3	1.1	9.52	0.7	1.78e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs2505998	0.833	rs2742243	chr10:43601749	T/C	cg06632098	chr10:43605906	RET	-1.11	-11.1	-0.75	7.48e-19	Hirschsprung disease;
THYM	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg13147721	chr7:65941812	NA	-1.1	-7.08	-0.59	2.51e-10	Diabetic kidney disease;
THYM	cis	rs3126085	0.935	rs1552993	chr1:152171483	A/G	cg26020982	chr1:152196106	HRNR	0.37	5.06	0.46	2.05e-6	Atopic dermatitis;
THYM	cis	rs6732160	0.845	rs11894833	chr2:73388418	G/T	cg24220031	chr2:73402428	NA	0.76	8.22	0.64	1.05e-12	Intelligence (multi-trait analysis);
THYM	cis	rs11223731	0.672	rs4362160	chr11:134112033	C/T	cg18040241	chr11:134201582	GLB1L2	-0.71	-4.6	-0.43	1.31e-5	Verbal declarative memory;
THYM	cis	rs28595532	0.920	rs115103359	chr4:119739608	A/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs7429990	0.965	rs7642590	chr3:48099750	G/A	cg02219026	chr3:48282209	ZNF589	0.63	4.62	0.43	1.18e-5	Educational attainment (years of education);
THYM	cis	rs6960043	0.818	rs10950550	chr7:15063923	T/G	cg19272540	chr7:15055459	NA	0.43	4.71	0.43	8.56e-6	Type 2 diabetes;
THYM	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg04362960	chr10:104952993	NT5C2	0.63	5.16	0.47	1.36e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs2585417	0.601	rs34981402	chr20:52825202	A/C	cg14415559	chr20:52836060	PFDN4	-0.5	-4.56	-0.42	1.51e-5	Obesity-related traits;
THYM	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg15556689	chr8:8085844	FLJ10661	0.65	5.8	0.51	8.64e-8	Mood instability;
THYM	cis	rs7216064	0.553	rs62084690	chr17:66035411	A/G	cg12091567	chr17:66097778	LOC651250	0.74	5.59	0.5	2.17e-7	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs4731207	0.698	rs7789859	chr7:124519472	C/G	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg09455208	chr3:40491958	NA	0.51	5.28	0.48	8.24e-7	Renal cell carcinoma;
THYM	cis	rs7072216	0.763	rs7910014	chr10:100172110	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs3942852	0.868	rs7118232	chr11:48106274	T/C	cg25800328	chr11:47736132	AGBL2	-0.51	-4.68	-0.43	9.4e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs4940575	0.786	rs6567326	chr18:60840608	G/T	cg24349668	chr18:61441546	SERPINB7	0.76	4.66	0.43	1.01e-5	Breast cancer;
THYM	cis	rs1021993	1.000	rs1021993	chr1:209512373	C/T	cg06155620	chr1:209527581	NA	-0.55	-4.46	-0.42	2.26e-5	Gut microbiome composition (winter);
THYM	cis	rs6032067	0.636	rs6032095	chr20:43913255	A/T	cg16667508	chr20:43936853	MATN4;RBPJL	0.69	7.36	0.6	6.44e-11	Blood protein levels;
THYM	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg12560992	chr17:57184187	TRIM37	0.93	8.61	0.66	1.5700000000000001e-13	Intelligence (multi-trait analysis);
THYM	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg18131467	chr2:239335373	ASB1	0.73	5.34	0.48	6.45e-7	Multiple system atrophy;
THYM	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.78	0.51	9.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7172809	0.643	rs75334741	chr15:77841492	T/C	cg22256960	chr15:77711686	NA	-0.72	-5.04	-0.46	2.21e-6	Glucose homeostasis traits;
THYM	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.01	10.51	0.73	1.37e-17	Intelligence (multi-trait analysis);
THYM	cis	rs75920871	0.528	rs1241655	chr11:116837808	G/T	cg20608306	chr11:116969690	SIK3	-0.52	-5.57	-0.5	2.32e-7	Subjective well-being;
THYM	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg07690219	chr3:49449608	TCTA;RHOA	0.69	4.62	0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs9467160	0.532	rs2744565	chr6:24458461	G/T	cg20631270	chr6:24437470	GPLD1	-0.59	-4.73	-0.44	7.85e-6	Liver enzyme levels;
THYM	cis	rs6876348	0.598	rs1898550	chr5:128285661	C/T	cg25555059	chr5:128301488	SLC27A6	-0.53	-6.13	-0.53	2.01e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg13683864	chr3:40499215	RPL14	-0.88	-8.8	-0.67	5.95e-14	Renal cell carcinoma;
THYM	cis	rs10845606	0.581	rs11055015	chr12:12836679	T/G	cg04118741	chr12:12551013	LOH12CR1	0.5	4.65	0.43	1.08e-5	Systemic lupus erythematosus;
THYM	cis	rs2075230	0.705	rs1641542	chr17:7544272	T/C	cg27413385	chr17:7515425	FXR2	-0.36	-5.1	-0.46	1.74e-6	Hormone measurements;
THYM	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs709400	0.663	rs11626787	chr14:103991749	A/G	cg12935359	chr14:103987150	CKB	-0.59	-5.41	-0.49	4.62e-7	Body mass index;
THYM	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg14972814	chr11:95582409	MTMR2	-0.59	-5.36	-0.48	5.87e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg09307838	chr4:120376055	NA	0.73	5.06	0.46	2.06e-6	Corneal astigmatism;
THYM	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg09549813	chr16:4587862	C16orf5	0.49	5.34	0.48	6.42e-7	Schizophrenia;
THYM	cis	rs919433	0.617	rs10460394	chr2:198548741	G/A	cg00792783	chr2:198669748	PLCL1	-0.75	-5.03	-0.46	2.29e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs17253792	0.822	rs17683614	chr14:56041058	G/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs28795989	0.896	rs13140108	chr4:7886532	C/T	cg12728606	chr4:7903970	AFAP1	0.44	4.64	0.43	1.09e-5	Intraocular pressure;
THYM	cis	rs2688608	0.592	rs11000760	chr10:75493734	G/A	cg19442545	chr10:75533431	FUT11	-0.51	-5.22	-0.47	1.03e-6	Inflammatory bowel disease;
THYM	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs67072384	1.000	rs72964181	chr11:72440124	C/G	cg01380194	chr11:72452482	ARAP1	-0.83	-4.59	-0.43	1.35e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs9972944	0.692	rs6504346	chr17:63757175	C/A	cg07283582	chr17:63770753	CCDC46	-0.64	-4.97	-0.45	3e-6	Total body bone mineral density;
THYM	cis	rs11195062	0.729	rs10884940	chr10:111989799	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.46	-4.74	-0.44	7.62e-6	Multiple myeloma;
THYM	cis	rs189218934	1	rs189218934	chr15:78903987	T/C	cg18825076	chr15:78729989	IREB2	-0.58	-4.71	-0.44	8.33e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs2637266	1.000	rs1907319	chr10:78337049	A/G	cg18941641	chr10:78392320	NA	-0.75	-6.48	-0.55	4.12e-9	Pulmonary function;
THYM	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg18252515	chr7:66147081	NA	0.66	4.87	0.45	4.38e-6	Aortic root size;
THYM	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg01579765	chr21:45077557	HSF2BP	-0.49	-8.02	-0.64	2.74e-12	Mean corpuscular volume;
THYM	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10499694	0.933	rs12538938	chr7:50592313	A/G	cg18232548	chr7:50535776	DDC	-0.62	-5.1	-0.46	1.75e-6	Body mass index;
THYM	cis	rs7567389	0.510	rs1473623	chr2:128196220	T/C	cg06038358	chr2:128176007	PROC	-0.42	-4.96	-0.45	3.13e-6	Self-rated health;
THYM	cis	rs6032067	0.516	rs6104085	chr20:43901302	A/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.59	-5.8	-0.51	8.81e-8	Blood protein levels;
THYM	cis	rs8063160	0.935	rs73283859	chr16:90062520	G/C	cg07984980	chr16:89898383	SPIRE2	1.42	5.82	0.51	7.91e-8	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg24324837	chr19:49891574	CCDC155	0.63	6.09	0.53	2.42e-8	Multiple sclerosis;
THYM	cis	rs11645898	0.872	rs4788459	chr16:72153125	C/G	cg14768367	chr16:72042858	DHODH	-0.73	-5.18	-0.47	1.23e-6	Blood protein levels;
THYM	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg22709100	chr7:91322751	NA	-0.6	-4.8	-0.44	5.84e-6	Breast cancer;
THYM	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg24692254	chr21:30365293	RNF160	-0.99	-9.06	-0.68	1.67e-14	Dental caries;
THYM	cis	rs61931739	1.000	rs12427279	chr12:34025898	T/G	cg10856724	chr12:34555212	NA	0.63	5.42	0.49	4.43e-7	Morning vs. evening chronotype;
THYM	cis	rs11585357	0.947	rs6666990	chr1:17611520	G/A	cg08277548	chr1:17600880	PADI3	0.87	5.92	0.52	5.07e-8	Hair shape;
THYM	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg03396347	chr1:1875803	NA	-0.67	-6.86	-0.58	6.84e-10	Body mass index;
THYM	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg24503407	chr1:205819492	PM20D1	-0.63	-4.66	-0.43	1.03e-5	Menarche (age at onset);
THYM	cis	rs7688540	0.511	rs75433628	chr4:178352	T/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.91	5.56	0.5	2.45e-7	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs12643440	0.538	rs6852278	chr4:17138490	A/C	cg22650099	chr4:17144496	NA	0.64	4.49	0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg06623918	chr6:96969491	KIAA0776	-1.05	-10.47	-0.73	1.63e-17	Headache;
THYM	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg15556689	chr8:8085844	FLJ10661	0.64	4.75	0.44	7.12e-6	Mood instability;
THYM	cis	rs61931739	0.890	rs1705753	chr12:34144594	C/T	cg06521331	chr12:34319734	NA	-0.61	-4.98	-0.45	2.85e-6	Morning vs. evening chronotype;
THYM	trans	rs10496034	0.541	rs72913519	chr2:54948606	G/C	cg25815024	chr2:219696567	PRKAG3	1.09	7.27	0.6	9.9e-11	Refractive astigmatism;
THYM	cis	rs7572733	0.534	rs1518363	chr2:198810131	C/T	cg00792783	chr2:198669748	PLCL1	0.82	5.75	0.51	1.08e-7	Dermatomyositis;
THYM	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg10360139	chr7:1886902	MAD1L1	-0.61	-5.4	-0.48	4.86e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs921968	0.541	rs581013	chr2:219432040	G/T	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17122693	0.748	rs72681609	chr14:51117376	A/G	cg04730355	chr14:51134070	SAV1	0.92	5.34	0.48	6.27e-7	Cognitive performance;
THYM	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.6	5.13	0.47	1.51e-6	Hip circumference adjusted for BMI;
THYM	cis	rs6495122	0.699	rs12905199	chr15:75070196	A/G	cg14664628	chr15:75095509	CSK	-0.79	-6.28	-0.54	9.94e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg12011299	chr4:100065546	ADH4	0.81	7.8	0.62	7.91e-12	Alcohol dependence;
THYM	cis	rs929596	0.785	rs17864701	chr2:234652717	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.95	-7.72	-0.62	1.17e-11	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg11965913	chr1:205819406	PM20D1	1.1	13.25	0.81	2.57e-23	Menarche (age at onset);
THYM	cis	rs1122608	0.580	rs12610607	chr19:11084994	A/G	cg17326582	chr19:11976514	ZNF439	0.6	4.62	0.43	1.19e-5	Coronary artery disease or ischemic stroke;Coronary artery disease;Coronary artery disease or large artery stroke;Coronary heart disease;Myocardial infarction (early onset);
THYM	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg25358565	chr5:93447407	FAM172A	1.32	11.28	0.76	3.22e-19	Diabetic retinopathy;
THYM	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg15242686	chr22:24348715	GSTTP1	0.7	7.25	0.6	1.08e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	14.47	0.83	9.53e-26	Chronic sinus infection;
THYM	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg12560992	chr17:57184187	TRIM37	0.89	7.91	0.63	4.68e-12	Intelligence (multi-trait analysis);
THYM	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg05373962	chr22:49881684	NA	-0.67	-6.31	-0.54	8.78e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg22325292	chr17:80708367	FN3K	0.62	4.48	0.42	2.09e-5	Glycated hemoglobin levels;
THYM	cis	rs7119	0.717	rs7176307	chr15:77816684	G/C	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg11941060	chr3:133502564	NA	-0.73	-6.42	-0.55	5.36e-9	Iron status biomarkers;
THYM	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg22974920	chr21:40686053	BRWD1	-0.64	-5.1	-0.46	1.74e-6	Cognitive function;
THYM	cis	rs1185460	0.804	rs13929	chr11:118915755	G/C	cg19721609	chr11:118800731	NA	0.59	4.88	0.45	4.26e-6	Coronary artery disease;
THYM	cis	rs7575217	0.767	rs7590479	chr2:101759938	C/T	cg23907051	chr2:101730305	TBC1D8	-0.4	-5.42	-0.49	4.58e-7	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	trans	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg07936489	chr17:37558343	FBXL20	-0.69	-4.83	-0.44	5.25e-6	Asthma;
THYM	cis	rs12802200	0.561	rs12792868	chr11:566647	T/A	cg00645579	chr11:617140	IRF7;MUPCDH	-0.41	-4.73	-0.44	7.71e-6	Systemic lupus erythematosus;
THYM	trans	rs480407	0.857	rs270998	chr2:161671547	A/G	cg06548410	chr19:1997657	BTBD2	0.72	7.08	0.59	2.46e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg06728252	chr6:26598149	ABT1	-0.46	-5.25	-0.47	9.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.505	rs427319	chr1:53178807	T/G	cg16325326	chr1:53192061	ZYG11B	0.97	11.07	0.75	8.85e-19	Monocyte count;
THYM	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg20007245	chr22:24372913	LOC391322	0.8	7.77	0.62	8.99e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22133161	chr19:49891603	CCDC155	0.73	4.69	0.43	9.14e-6	Multiple sclerosis;
THYM	cis	rs79149102	0.579	rs7179097	chr15:75279240	T/G	cg17294928	chr15:75287854	SCAMP5	-1.05	-5.58	-0.5	2.3e-7	Lung cancer;
THYM	cis	rs16866061	1.000	rs11686590	chr2:225334070	A/G	cg22455342	chr2:225449267	CUL3	0.68	4.88	0.45	4.23e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg00129232	chr17:37814104	STARD3	0.76	5.25	0.47	9.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs17407555	0.779	rs73218769	chr4:10157280	A/G	cg00071950	chr4:10020882	SLC2A9	-0.74	-5.46	-0.49	3.76e-7	Schizophrenia (age at onset);
THYM	cis	rs9972944	0.756	rs7221131	chr17:63764848	G/A	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs13315871	0.929	rs11717783	chr3:58267642	A/T	cg12435725	chr3:58293450	RPP14	-0.48	-5.21	-0.47	1.11e-6	Cholesterol, total;
THYM	cis	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg15009913	chr1:2287741	MORN1	0.48	4.56	0.42	1.53e-5	Body mass index;
THYM	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg23743428	chr13:21893420	NA	-0.73	-6.47	-0.55	4.17e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs9866391	0.809	rs7613516	chr3:141079309	A/C	cg13411656	chr3:141121016	ZBTB38	-0.33	-4.51	-0.42	1.82e-5	Myopia;
THYM	cis	rs4731207	0.698	rs12154816	chr7:124478299	G/A	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg03676636	chr4:99064102	C4orf37	0.42	6.01	0.53	3.34e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg22467129	chr15:76604101	ETFA	-0.56	-5.26	-0.47	9.01e-7	Blood metabolite levels;
THYM	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg18477163	chr1:228402036	OBSCN	0.63	6.0	0.52	3.57e-8	Diastolic blood pressure;
THYM	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs7769051	0.522	rs7761207	chr6:133110430	G/A	cg22852734	chr6:133119734	C6orf192	1.47	6.85	0.57	7.36e-10	Type 2 diabetes nephropathy;
THYM	cis	rs7246657	0.943	rs1015849	chr19:37946180	G/A	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.14	-0.64	1.51e-12	Personality dimensions;
THYM	cis	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg09321965	chr1:198201193	NEK7	-0.66	-4.48	-0.42	2.06e-5	Depressive symptoms;
THYM	cis	rs11771526	0.686	rs62457463	chr7:32289856	C/T	cg27532318	chr7:32358331	NA	0.77	5.06	0.46	2.03e-6	Body mass index;
THYM	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg16414030	chr3:133502952	NA	0.81	8.29	0.65	7.27e-13	Iron status biomarkers;
THYM	cis	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg08133631	chr1:26527909	CATSPER4	-0.61	-5.08	-0.46	1.92e-6	Obesity-related traits;
THYM	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg08017756	chr2:100939284	LONRF2	-0.73	-7.58	-0.61	2.26e-11	Intelligence (multi-trait analysis);
THYM	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg12386194	chr3:101231763	SENP7	0.95	7.47	0.61	3.85e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs11809207	0.810	rs17356937	chr1:26504036	G/A	cg03844060	chr1:26490628	NA	0.74	5.54	0.49	2.69e-7	Height;
THYM	cis	rs56309584	0.673	rs56256903	chr17:8123128	T/G	cg11257113	chr17:8062204	NA	-0.61	-4.45	-0.42	2.33e-5	Initial pursuit acceleration;
THYM	cis	rs11077998	0.869	rs6502123	chr17:80532170	T/C	cg10255544	chr17:80519551	FOXK2	0.53	4.71	0.44	8.3e-6	Reticulocyte fraction of red cells;
THYM	cis	rs6840360	0.615	rs12647465	chr4:152607318	C/A	cg22705602	chr4:152727874	NA	-0.79	-10.67	-0.74	6.25e-18	Intelligence (multi-trait analysis);
THYM	cis	rs9611519	0.929	rs4820425	chr22:41431342	C/A	cg03806693	chr22:41940476	POLR3H	-0.77	-5.95	-0.52	4.56e-8	Neuroticism;
THYM	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg04362960	chr10:104952993	NT5C2	0.59	4.74	0.44	7.62e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg14675211	chr2:100938903	LONRF2	0.76	8.01	0.64	2.81e-12	Intelligence (multi-trait analysis);
THYM	cis	rs889398	0.741	rs4146819	chr16:69923563	C/A	cg09409435	chr16:70099608	PDXDC2	0.63	4.89	0.45	4.04e-6	Body mass index;
THYM	cis	rs995000	0.965	rs1979722	chr1:62940097	G/A	cg06896770	chr1:63153194	DOCK7	1.0	8.17	0.64	1.31e-12	Triglyceride levels;
THYM	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg11812906	chr14:75593930	NEK9	-0.81	-7.31	-0.6	8.48e-11	Height;
THYM	cis	rs9649213	0.533	rs62478235	chr7:98030349	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.6	-4.87	-0.45	4.51e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg07936489	chr17:37558343	FBXL20	-0.67	-4.82	-0.44	5.35e-6	Asthma;
THYM	cis	rs13315871	0.929	rs1554124	chr3:58268968	C/G	cg00563845	chr3:58318305	PXK	0.56	5.17	0.47	1.3e-6	Cholesterol, total;
THYM	cis	rs354225	0.544	rs7599241	chr2:54801856	G/A	cg23486701	chr2:54789491	SPTBN1	0.34	4.49	0.42	2e-5	Schizophrenia;
THYM	cis	rs12530845	0.561	rs73725182	chr7:135291001	C/T	cg23117316	chr7:135346802	PL-5283	-0.64	-4.47	-0.42	2.14e-5	Red blood cell traits;
THYM	cis	rs4698048	0.506	rs6833292	chr4:10272429	C/T	cg13000635	chr4:9523653	NA	-0.57	-5.12	-0.47	1.57e-6	Skin aging (microtopography measurement);
THYM	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg00129232	chr17:37814104	STARD3	-0.69	-4.51	-0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs459571	0.834	rs379417	chr9:136890704	G/A	cg13789015	chr9:136890014	NCRNA00094	0.83	7.19	0.59	1.45e-10	Platelet distribution width;
THYM	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.27	-6.03	-0.53	3.13e-8	Obesity-related traits;
THYM	cis	rs36051895	0.659	rs61284219	chr9:5062816	C/A	cg02405213	chr9:5042618	JAK2	-1.03	-11.21	-0.75	4.34e-19	Pediatric autoimmune diseases;
THYM	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs300703	0.748	rs4484059	chr2:286812	G/A	cg21211680	chr2:198530	NA	1.33	5.61	0.5	1.97e-7	Blood protein levels;
THYM	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg22535103	chr8:58192502	C8orf71	-0.93	-5.25	-0.47	9.15e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg17279839	chr7:150038598	RARRES2	-0.55	-5.44	-0.49	4.08e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2412459	0.635	rs2307106	chr15:40265404	T/C	cg16127683	chr15:40268777	EIF2AK4	0.59	5.16	0.47	1.37e-6	Response to haloperidol in psychosis;
THYM	cis	rs9457247	0.515	rs1951459	chr6:167402536	G/A	cg00271210	chr6:167070053	RPS6KA2	0.48	4.72	0.44	8e-6	Crohn's disease;
THYM	cis	rs4455778	0.580	rs7783777	chr7:49082560	G/A	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs2124969	0.548	rs72979963	chr2:161014483	A/G	cg03641300	chr2:160917029	PLA2R1	-0.65	-4.58	-0.43	1.38e-5	Waist circumference adjusted for body mass index;
THYM	cis	rs7216064	1.000	rs7224923	chr17:65842265	T/G	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs9902453	0.933	rs7221154	chr17:28505024	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.66	-4.83	-0.44	5.26e-6	Coffee consumption (cups per day);
THYM	cis	rs786425	0.530	rs1040156	chr12:124223364	A/G	cg15249119	chr12:124971054	NCOR2	0.55	5.09	0.46	1.79e-6	Pubertal anthropometrics;
THYM	cis	rs7429990	0.932	rs6803741	chr3:48123540	C/T	cg02219026	chr3:48282209	ZNF589	0.62	4.54	0.42	1.66e-5	Educational attainment (years of education);
THYM	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7195287	0.779	rs2335454	chr16:2828157	G/C	cg05687563	chr16:2837658	PRSS33	0.56	4.73	0.44	7.75e-6	Eosinophil counts;
THYM	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg21028142	chr17:79581711	NPLOC4	-0.64	-6.74	-0.57	1.23e-9	Eye color traits;
THYM	cis	rs7927771	0.524	rs12286721	chr11:47701528	G/T	cg18512352	chr11:47633146	NA	-0.41	-4.47	-0.42	2.17e-5	Subjective well-being;
THYM	cis	rs1568889	1.000	rs12797155	chr11:28290866	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.7	4.56	0.42	1.54e-5	Bipolar disorder;
THYM	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg01448562	chr3:133502909	NA	-0.83	-7.15	-0.59	1.82e-10	Iron status biomarkers;
THYM	cis	rs7586879	0.639	rs7580081	chr2:25097072	G/C	cg15423357	chr2:25149977	NA	0.66	7.01	0.58	3.49e-10	Body mass index;
THYM	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg05802129	chr4:122689817	NA	-0.62	-5.03	-0.46	2.3e-6	Type 2 diabetes;
THYM	cis	rs2282930	0.512	rs3807547	chr7:50712820	T/C	cg08586669	chr7:50727761	GRB10	0.33	4.89	0.45	4.18e-6	Bone mineral density;
THYM	cis	rs2976388	0.507	rs7813604	chr8:143838062	G/A	cg17252645	chr8:143867129	LY6D	0.55	5.49	0.49	3.27e-7	Urinary tract infection frequency;
THYM	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs9311676	0.656	rs55783924	chr3:58403610	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4148689	0.951	rs1557630	chr7:117130643	G/C	cg17204129	chr7:117119601	CFTR	-0.62	-5.0	-0.46	2.66e-6	Gout;
THYM	cis	rs8070740	0.898	rs4790770	chr17:5324893	A/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.72	6.03	0.53	3.15e-8	Menopause (age at onset);
THYM	cis	rs4262150	0.883	rs4958587	chr5:152251201	T/C	cg06854687	chr5:151642065	NA	0.64	4.46	0.42	2.27e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs79387448	0.745	rs723292	chr2:103166804	A/G	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs6840360	0.642	rs7657747	chr4:152394254	A/G	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg05973401	chr12:123451056	ABCB9	0.7	4.76	0.44	6.93e-6	Neutrophil percentage of white cells;
THYM	cis	rs4845875	0.514	rs198393	chr1:11879685	C/T	cg24844545	chr1:11908347	NPPA	-0.5	-4.8	-0.44	5.97e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs9303401	0.632	rs7222087	chr17:57221619	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.67	4.97	0.45	2.92e-6	Cognitive test performance;
THYM	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg00495681	chr13:53174319	NA	-0.69	-7.03	-0.58	3.15e-10	Lewy body disease;
THYM	cis	rs34638657	0.673	rs11645286	chr16:82201898	C/A	cg07307142	chr16:82071433	HSD17B2	-0.86	-7.68	-0.62	1.4e-11	Lung adenocarcinoma;
THYM	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.88	0.63	5.43e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9318086	0.712	rs9510916	chr13:24442789	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.53	4.63	0.43	1.17e-5	Myopia (pathological);
THYM	cis	rs10799590	1.000	rs2648746	chr1:224838006	G/A	cg01808320	chr1:224927238	CNIH3	-0.57	-5.16	-0.47	1.35e-6	Opioid dependence;
THYM	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg06634786	chr22:41940651	POLR3H	0.73	5.36	0.48	5.89e-7	Vitiligo;
THYM	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg10047753	chr17:41438598	NA	0.95	7.66	0.62	1.58e-11	Menopause (age at onset);
THYM	cis	rs9311676	0.656	rs4681679	chr3:58332068	A/G	cg26110898	chr3:58419937	PDHB	-0.44	-4.58	-0.43	1.41e-5	Systemic lupus erythematosus;
THYM	cis	rs28595532	0.920	rs115860482	chr4:119759546	A/G	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg14820908	chr5:178986412	RUFY1	0.54	5.58	0.5	2.22e-7	Lung cancer;
THYM	cis	rs61931739	0.746	rs1687003	chr12:34170099	T/A	cg10856724	chr12:34555212	NA	-0.65	-5.78	-0.51	9.33e-8	Morning vs. evening chronotype;
THYM	cis	rs6543140	0.964	rs6748390	chr2:103062175	A/G	cg03938978	chr2:103052716	IL18RAP	0.61	6.06	0.53	2.71e-8	Blood protein levels;
THYM	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-4.93	-0.45	3.47e-6	Schizophrenia;
THYM	cis	rs9563576	0.778	rs34959468	chr13:58643354	C/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.63	4.68	0.43	9.64e-6	Body mass index;
THYM	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22496380	chr5:211416	CCDC127	-1.32	-7.26	-0.6	1.04e-10	Breast cancer;
THYM	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7584330	0.554	rs74001386	chr2:238425333	T/A	cg08992911	chr2:238395768	MLPH	0.85	5.39	0.48	5.19e-7	Prostate cancer;
THYM	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg02086790	chr16:375327	AXIN1	-0.44	-4.45	-0.42	2.33e-5	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs6430585	0.528	rs309159	chr2:136684940	C/T	cg04750100	chr2:136595281	LCT	0.58	5.79	0.51	9.13e-8	Corneal structure;
THYM	cis	rs652260	1.000	rs604938	chr19:7903484	A/G	cg15974673	chr19:7926970	EVI5L	0.53	4.89	0.45	4.14e-6	Menarche (age at onset);
THYM	cis	rs6500395	0.962	rs1564979	chr16:48647017	C/A	cg04672837	chr16:48644449	N4BP1	0.48	4.59	0.43	1.35e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2836633	0.895	rs2212606	chr21:40044940	A/C	cg12884169	chr21:40033163	ERG	0.66	7.84	0.63	6.47e-12	Coronary artery disease;
THYM	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14240646	chr10:27532245	ACBD5	-1.01	-5.55	-0.49	2.6e-7	Breast cancer;
THYM	cis	rs977987	0.806	rs2161684	chr16:75479153	T/C	cg03315344	chr16:75512273	CHST6	0.74	5.92	0.52	5.07e-8	Dupuytren's disease;
THYM	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg15556689	chr8:8085844	FLJ10661	-0.64	-4.92	-0.45	3.65e-6	Mood instability;
THYM	cis	rs6732160	0.619	rs12105975	chr2:73406049	T/A	cg24220031	chr2:73402428	NA	-0.69	-7.78	-0.62	8.79e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg17366294	chr4:99064904	C4orf37	0.53	5.9	0.52	5.67e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg26597838	chr10:835615	NA	1.05	6.33	0.54	8.17e-9	Eosinophil percentage of granulocytes;
THYM	cis	rs600806	0.888	rs3879450	chr1:109909149	C/T	cg02175308	chr1:109941060	SORT1	-0.56	-4.87	-0.45	4.42e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg20283391	chr11:68216788	NA	-0.61	-4.58	-0.43	1.41e-5	Total body bone mineral density;
THYM	cis	rs17193922	0.798	rs7203644	chr16:53547209	C/T	cg04059762	chr16:53544020	NA	-0.6	-5.05	-0.46	2.14e-6	Hip circumference adjusted for BMI;
THYM	cis	rs11166927	1.000	rs11166929	chr8:140801430	G/A	cg16909799	chr8:140841666	TRAPPC9	0.62	5.51	0.49	3.11e-7	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs7084402	0.935	rs717453	chr10:60268398	C/T	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg27129171	chr3:47204927	SETD2	0.8	7.67	0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg00339695	chr16:24857497	SLC5A11	0.69	6.38	0.55	6.46e-9	Intelligence (multi-trait analysis);
THYM	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg01579765	chr21:45077557	HSF2BP	-0.49	-8.05	-0.64	2.4e-12	Mean corpuscular volume;
THYM	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg06917634	chr15:78832804	PSMA4	0.96	8.76	0.67	7.4e-14	Sudden cardiac arrest;
THYM	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.95	0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs2219968	0.683	rs34707546	chr8:78908630	C/T	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7178572	0.539	rs16968809	chr15:77672118	C/T	cg22256960	chr15:77711686	NA	0.88	6.74	0.57	1.19e-9	Type 2 diabetes;
THYM	cis	rs728616	0.867	rs12412226	chr10:81735288	C/T	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs798766	1.000	rs798755	chr4:1720824	A/G	cg00006948	chr4:1768889	NA	-0.92	-5.24	-0.47	9.51e-7	Bladder cancer;Urinary bladder cancer;
THYM	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg08484992	chr16:88977278	CBFA2T3	-0.44	-5.27	-0.48	8.67e-7	Social autistic-like traits;
THYM	cis	rs9814567	0.712	rs9838467	chr3:134332222	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2404602	0.672	rs35374222	chr15:77071394	G/T	cg23625390	chr15:77176239	SCAPER	-0.88	-6.13	-0.53	1.98e-8	Blood metabolite levels;
THYM	cis	rs67460515	0.892	rs4856703	chr3:161047720	G/T	cg03342759	chr3:160939853	NMD3	-0.94	-8.14	-0.64	1.55e-12	Parkinson's disease;
THYM	cis	rs425277	0.958	rs262688	chr1:2113565	T/G	cg13918804	chr1:2043761	PRKCZ	-0.62	-4.6	-0.43	1.28e-5	Height;
THYM	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.1	7.87	0.63	5.7e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9527	0.590	rs12785223	chr10:104844011	C/T	cg04362960	chr10:104952993	NT5C2	-0.61	-4.61	-0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs3820068	0.705	rs4646077	chr1:15827136	C/T	cg05660106	chr1:15850417	CASP9	1.13	10.23	0.72	5.39e-17	Systolic blood pressure;
THYM	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	4.59	0.43	1.35e-5	Aortic root size;
THYM	cis	rs4638749	0.677	rs12712017	chr2:108843556	C/T	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs55665837	1.000	rs34382046	chr11:14451318	C/T	cg19336497	chr11:14380999	RRAS2	-0.64	-7.04	-0.59	3e-10	Vitamin D levels;
THYM	cis	rs7614311	0.731	rs3774721	chr3:63954649	A/G	cg22134162	chr3:63841271	THOC7	-0.57	-6.82	-0.57	8.37e-10	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg24308560	chr3:49941425	MST1R	0.76	6.34	0.55	7.57e-9	Intelligence (multi-trait analysis);
THYM	cis	rs4866334	1.000	rs76533277	chr5:18488162	G/A	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs35934224	0.783	rs12106549	chr22:19846987	G/T	cg11182965	chr22:19864308	TXNRD2	-0.73	-6.29	-0.54	9.69e-9	Glaucoma (primary open-angle);
THYM	cis	rs6496667	0.533	rs886491	chr15:90993215	G/A	cg22089800	chr15:90895588	ZNF774	0.65	4.73	0.44	7.89e-6	Rheumatoid arthritis;
THYM	cis	rs4731207	0.565	rs1994025	chr7:124663859	A/G	cg05285228	chr7:124571219	POT1	-0.6	-4.52	-0.42	1.76e-5	Cutaneous malignant melanoma;
THYM	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	4.51	0.42	1.83e-5	Aortic root size;
THYM	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg09549813	chr16:4587862	C16orf5	-0.49	-5.46	-0.49	3.73e-7	Schizophrenia;
THYM	cis	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg07807169	chr1:197168091	ZBTB41	-0.79	-6.18	-0.54	1.57e-8	Depressive symptoms;
THYM	cis	rs12594515	1.000	rs11070467	chr15:45985001	C/T	cg01629716	chr15:45996671	NA	-0.51	-5.21	-0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs7578361	0.918	rs6716959	chr2:150350535	C/T	cg17961725	chr2:150454027	NA	0.72	5.25	0.47	9.22e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs6076065	0.723	rs16985308	chr20:23359780	A/T	cg11657817	chr20:23433608	CST11	0.31	4.57	0.42	1.48e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg00071950	chr4:10020882	SLC2A9	0.86	10.33	0.73	3.3e-17	Bone mineral density;
THYM	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18402987	chr7:1209562	NA	0.75	5.64	0.5	1.73e-7	Longevity;Endometriosis;
THYM	cis	rs3112255	0.512	rs62154051	chr2:101337447	G/A	cg01042948	chr2:101319752	NA	0.46	4.57	0.42	1.47e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2072499	0.833	rs2251847	chr1:156204047	G/A	cg06970220	chr1:156163860	SLC25A44	0.71	5.82	0.51	7.94e-8	Testicular germ cell tumor;
THYM	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.88	5.97	0.52	4.05e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg05901451	chr6:126070800	HEY2	-0.53	-4.51	-0.42	1.88e-5	Endometrial cancer;
THYM	cis	rs4689388	0.890	rs3821941	chr4:6286954	A/G	cg14416269	chr4:6271139	WFS1	0.51	5.08	0.46	1.89e-6	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs921968	0.643	rs645796	chr2:219389236	A/G	cg02176678	chr2:219576539	TTLL4	0.68	6.71	0.57	1.42e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	10.77	0.74	3.77e-18	Chronic sinus infection;
THYM	cis	rs8067545	1.000	rs2108980	chr17:19920518	G/A	cg13482628	chr17:19912719	NA	0.57	4.79	0.44	6.23e-6	Schizophrenia;
THYM	cis	rs11779988	0.545	rs427168	chr8:17784829	G/A	cg01800426	chr8:17659068	MTUS1	-0.76	-5.32	-0.48	6.94e-7	Breast cancer;
THYM	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg09904177	chr6:26538194	HMGN4	0.62	4.96	0.45	3.06e-6	Intelligence (multi-trait analysis);
THYM	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg03929089	chr4:120376271	NA	0.97	10.61	0.74	8.11e-18	Coronary artery disease;
THYM	cis	rs752010	0.746	rs10890146	chr1:42089389	G/A	cg06885757	chr1:42089581	HIVEP3	0.58	7.33	0.6	7.48e-11	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg02551604	chr5:131831745	NA	-0.76	-6.02	-0.53	3.2e-8	Asthma (sex interaction);
THYM	cis	rs2294693	0.947	rs736795	chr6:40998141	G/A	cg14769373	chr6:40998127	UNC5CL	-0.61	-4.9	-0.45	4e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	5.09	0.46	1.82e-6	Motion sickness;
THYM	trans	rs9929218	0.859	rs9936682	chr16:68748223	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-7.29	-0.6	9.13e-11	Colorectal cancer;
THYM	cis	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22496380	chr5:211416	CCDC127	-1.33	-7.99	-0.63	3.21e-12	Breast cancer;
THYM	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs10208940	0.614	rs71413136	chr2:68748653	A/G	cg09157127	chr2:69201416	GKN1	0.84	4.54	0.42	1.66e-5	Urate levels in lean individuals;
THYM	cis	rs10411161	0.702	rs6509592	chr19:52393150	G/A	cg25361850	chr19:52391789	ZNF577	0.72	4.85	0.45	4.82e-6	Breast cancer;
THYM	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg24818145	chr4:99064322	C4orf37	0.67	5.2	0.47	1.13e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg00129232	chr17:37814104	STARD3	0.75	5.4	0.48	4.93e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7582180	0.669	rs4455176	chr2:100876629	T/A	cg08017756	chr2:100939284	LONRF2	-0.6	-5.54	-0.49	2.75e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1971762	0.583	rs12319789	chr12:54090450	G/C	cg16917193	chr12:54089295	NA	0.98	9.82	0.71	3.92e-16	Height;
THYM	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg01699819	chr7:1052092	C7orf50	-0.56	-5.34	-0.48	6.45e-7	Bronchopulmonary dysplasia;
THYM	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs629535	0.911	rs627382	chr8:70014081	C/T	cg21567404	chr3:27674614	NA	-1.11	-10.75	-0.74	4.16e-18	Dupuytren's disease;
THYM	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg07636037	chr3:49044803	WDR6	0.82	5.97	0.52	4.02e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs3857067	0.806	rs4693375	chr4:95133241	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.48	-0.42	2.07e-5	QT interval;
THYM	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg27170947	chr2:26402098	FAM59B	-0.8	-6.3	-0.54	9.35e-9	Gut microbiome composition (summer);
THYM	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg06009448	chr7:1102226	C7orf50	0.48	5.01	0.46	2.55e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4851266	0.898	rs13010010	chr2:100852734	C/T	cg14675211	chr2:100938903	LONRF2	0.67	5.59	0.5	2.15e-7	Educational attainment;
THYM	cis	rs7809950	0.817	rs2253833	chr7:107205669	A/G	cg23024343	chr7:107201750	COG5	1.04	9.04	0.68	1.82e-14	Coronary artery disease;
THYM	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg20503657	chr10:835505	NA	0.92	5.02	0.46	2.4e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs6128386	0.597	rs6100139	chr20:57195469	C/T	cg00138126	chr20:56286697	PMEPA1	0.6	4.68	0.43	9.63e-6	Response to cytadine analogues (cytosine arabinoside);
THYM	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg02953382	chr22:24373134	LOC391322	0.83	6.82	0.57	8.34e-10	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs6570726	0.905	rs430248	chr6:145874104	A/G	cg13319975	chr6:146136371	FBXO30	-0.66	-5.62	-0.5	1.89e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs988913	0.957	rs6908170	chr6:54821152	C/T	cg04690482	chr6:54711388	FAM83B	0.5	5.29	0.48	7.93e-7	Menarche (age at onset);
THYM	cis	rs4930103	0.935	rs2075745	chr11:2018336	A/T	cg06197492	chr11:2016605	H19	0.63	5.48	0.49	3.56e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs72627123	0.867	rs17094045	chr14:74396251	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs739496	0.542	rs7300400	chr12:111792179	A/C	cg10833066	chr12:111807467	FAM109A	0.52	5.92	0.52	5e-8	Platelet count;
THYM	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg00024416	chr22:24240387	NA	-0.68	-6.99	-0.58	3.76e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4792901	0.802	rs28581728	chr17:41609336	T/C	cg21940313	chr17:41620911	ETV4	-0.5	-4.59	-0.43	1.37e-5	Dupuytren's disease;
THYM	cis	rs3126085	0.935	rs10749670	chr1:152220467	G/A	cg26020982	chr1:152196106	HRNR	0.37	5.06	0.46	2.05e-6	Atopic dermatitis;
THYM	cis	rs13082711	0.513	rs66472045	chr3:27242887	G/A	cg02860705	chr3:27208620	NA	0.94	7.52	0.61	3.03e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg13010199	chr12:38710504	ALG10B	-0.59	-4.72	-0.44	8.19e-6	Morning vs. evening chronotype;
THYM	cis	rs3733631	0.557	rs56880262	chr4:104635863	A/G	cg24090629	chr4:104641072	TACR3	-0.82	-4.48	-0.42	2.07e-5	Menarche (age at onset);
THYM	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg07936489	chr17:37558343	FBXL20	0.77	5.03	0.46	2.28e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg08213375	chr14:104286397	PPP1R13B	0.54	6.52	0.56	3.32e-9	Schizophrenia;
THYM	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.75	-5.5	-0.49	3.17e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg12908607	chr1:44402522	ARTN	-0.52	-4.67	-0.43	9.88e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs59197085	0.636	rs60389668	chr7:128452556	T/G	cg00734629	chr7:128471146	FLNC	0.77	4.55	0.42	1.58e-5	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
THYM	cis	rs9287719	0.781	rs6732671	chr2:10759149	T/G	cg02196655	chr2:10830764	NOL10	-0.45	-4.77	-0.44	6.77e-6	Prostate cancer;
THYM	cis	rs7432375	1.000	rs6439649	chr3:136371691	G/T	cg12473912	chr3:136751656	NA	-0.62	-5.19	-0.47	1.18e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg22681709	chr2:178499509	PDE11A	-0.59	-5.62	-0.5	1.91e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1950500	0.509	rs12888965	chr14:24834291	C/T	cg22990158	chr14:24802150	ADCY4	-0.41	-4.49	-0.42	2.02e-5	Height;
THYM	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg11247378	chr22:39784982	NA	-1.05	-14.1	-0.82	5.05e-25	Intelligence (multi-trait analysis);
THYM	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.9	-7.92	-0.63	4.36e-12	Lung cancer in ever smokers;
THYM	cis	rs9486719	1.000	rs2205755	chr6:96864704	A/G	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs7772486	0.790	rs1062068	chr6:146207465	A/G	cg13319975	chr6:146136371	FBXO30	-0.71	-5.99	-0.52	3.78e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs5758511	0.773	rs62241023	chr22:42385429	G/A	cg08431931	chr22:42394659	WBP2NL	0.72	4.61	0.43	1.24e-5	Birth weight;
THYM	cis	rs2836633	0.895	rs2836597	chr21:40024424	A/G	cg12884169	chr21:40033163	ERG	0.62	7.55	0.61	2.7e-11	Coronary artery disease;
THYM	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg16624210	chr5:671434	TPPP	-0.66	-6.88	-0.58	6.41e-10	Obesity-related traits;
THYM	cis	rs3540	0.512	rs11633872	chr15:91080512	G/A	cg22089800	chr15:90895588	ZNF774	-0.69	-5.14	-0.47	1.48e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10929159	0.928	rs2123512	chr2:236920731	C/T	cg20128773	chr2:236923534	AGAP1	0.35	4.72	0.44	8.19e-6	Parkinson's disease;
THYM	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg05738196	chr6:26577821	NA	0.92	8.68	0.67	1.07e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg27068330	chr11:65405492	SIPA1	-0.64	-4.45	-0.42	2.3e-5	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg00981070	chr1:2046702	PRKCZ	0.47	5.21	0.47	1.1e-6	Height;
THYM	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg26384229	chr12:38710491	ALG10B	0.95	7.55	0.61	2.7e-11	Bladder cancer;
THYM	cis	rs6840360	0.571	rs4696098	chr4:152489053	C/T	cg22705602	chr4:152727874	NA	-0.77	-8.05	-0.64	2.4e-12	Intelligence (multi-trait analysis);
THYM	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg05368731	chr17:41323189	NBR1	1.26	11.54	0.76	9.06e-20	Menopause (age at onset);
THYM	cis	rs977987	0.645	rs10871311	chr16:75450912	T/A	cg03315344	chr16:75512273	CHST6	0.76	6.08	0.53	2.47e-8	Dupuytren's disease;
THYM	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.79	-0.44	6.18e-6	Mean corpuscular volume;
THYM	cis	rs7512552	0.839	rs6703652	chr1:150465953	T/G	cg15654264	chr1:150340011	RPRD2	0.45	5.19	0.47	1.18e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg08901578	chr4:187885870	NA	-0.68	-6.86	-0.58	6.97e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9921192	1.000	rs251733	chr16:4321605	A/T	cg00021532	chr16:4324280	TFAP4	0.91	8.2	0.64	1.15e-12	Prostate-specific antigen levels;
THYM	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg14517863	chr17:44321492	NA	0.46	5.11	0.46	1.69e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7020830	0.825	rs13297152	chr9:37075623	C/T	cg14294708	chr9:37120828	ZCCHC7	1.31	15.09	0.84	5.71e-27	Schizophrenia;
THYM	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.64e-20	Menopause (age at onset);
THYM	cis	rs2688608	0.592	rs11000760	chr10:75493734	G/A	cg23231163	chr10:75533350	FUT11	-0.41	-5.9	-0.52	5.54e-8	Inflammatory bowel disease;
THYM	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg14074117	chr16:1909714	C16orf73	-0.7	-4.45	-0.42	2.3e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs13401104	0.587	rs62190972	chr2:237145164	T/C	cg19324714	chr2:237145437	ASB18	0.63	4.68	0.43	9.6e-6	Educational attainment;
THYM	cis	rs4845875	0.563	rs10864540	chr1:11838099	A/G	cg06193043	chr1:11908199	NPPA	0.58	4.95	0.45	3.18e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs9361491	0.608	rs7743640	chr6:79454075	A/G	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.8	6.76	0.57	1.09e-9	Lymphocyte percentage of white cells;
THYM	cis	rs1371867	0.875	rs7830342	chr8:101327738	T/A	cg06636551	chr8:101224915	SPAG1	-0.63	-6.33	-0.54	8.05e-9	Atrioventricular conduction;
THYM	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg06028605	chr16:24865363	SLC5A11	0.64	5.19	0.47	1.2e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4072705	1.000	rs10760372	chr9:127468816	T/C	cg01786973	chr9:127249749	NR5A1	0.36	4.74	0.44	7.61e-6	Menarche (age at onset);
THYM	cis	rs175714	0.845	rs175706	chr14:75976200	G/A	cg01624173	chr14:75981868	NA	0.71	8.33	0.65	6.09e-13	Lymphocyte counts;
THYM	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	cis	rs7586879	0.796	rs916486	chr2:25082629	C/A	cg01884057	chr2:25150051	NA	0.51	4.66	0.43	1.04e-5	Body mass index;
THYM	cis	rs5769707	0.777	rs739243	chr22:50057211	C/T	cg23428387	chr22:49814324	NA	-0.54	-6.03	-0.53	3.14e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs752010	0.902	rs28635337	chr1:42101391	G/A	cg22486000	chr1:42919398	ZMYND12	-0.43	-4.86	-0.45	4.67e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs11574514	0.744	rs78962063	chr16:68052481	T/C	cg09738193	chr16:67926317	PSKH1	-0.92	-4.53	-0.42	1.72e-5	Crohn's disease;
THYM	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg19024700	chr19:49340765	PLEKHA4;HSD17B14	-0.74	-5.56	-0.5	2.48e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs1557488	1.000	rs1557488	chr11:126619190	T/C	cg03950493	chr11:126582183	KIRREL3	-0.41	-4.77	-0.44	6.75e-6	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg18681998	chr4:17616180	MED28	0.75	6.17	0.53	1.65e-8	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	trans	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.64	4.6	0.43	1.32e-5	Body mass index (adult);
THYM	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg20503657	chr10:835505	NA	-1.1	-7.49	-0.61	3.6e-11	Eosinophil percentage of granulocytes;
THYM	cis	rs2276314	0.857	rs28431958	chr18:33578401	T/G	cg05985134	chr18:33552581	C18orf21	0.69	4.84	0.44	5.07e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7586879	0.616	rs6545813	chr2:25131287	C/T	cg27107076	chr2:25050844	ADCY3	-0.29	-4.73	-0.44	7.91e-6	Body mass index;
THYM	cis	rs4790333	1.000	rs2003968	chr17:2266812	T/C	cg02569219	chr17:2266849	SGSM2	0.72	6.28	0.54	1.03e-8	Proinsulin levels;
THYM	cis	rs2730245	0.527	rs712197	chr7:158660846	C/G	cg24397884	chr7:158709396	WDR60	0.58	5.59	0.5	2.15e-7	Height;
THYM	cis	rs490647	0.948	rs2135595	chr1:37229092	G/A	cg09088576	chr1:36947785	CSF3R	-0.46	-4.52	-0.42	1.8e-5	Neuroticism;
THYM	cis	rs5769765	0.542	rs738707	chr22:50250827	G/A	cg08270630	chr22:50330655	NA	0.73	4.64	0.43	1.11e-5	Schizophrenia;
THYM	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg12963246	chr6:28129442	ZNF389	-0.62	-4.72	-0.44	8.16e-6	Parkinson's disease;
THYM	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs10992471	0.676	rs13286566	chr9:95473178	C/T	cg14631576	chr9:95140430	CENPP	-0.94	-8.39	-0.65	4.43e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs59698941	0.943	rs66500331	chr5:132261693	G/A	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs6918586	0.658	rs198840	chr6:26112164	T/G	cg03517284	chr6:25882590	NA	0.71	5.57	0.5	2.4e-7	Schizophrenia;
THYM	cis	rs36051895	0.623	rs7859286	chr9:5260940	G/T	cg02405213	chr9:5042618	JAK2	-0.96	-9.77	-0.71	5.02e-16	Pediatric autoimmune diseases;
THYM	cis	rs9393692	0.572	rs4145878	chr6:26198046	A/T	cg13736514	chr6:26305472	NA	-0.53	-5.86	-0.52	6.59e-8	Educational attainment;
THYM	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg23682913	chr1:2080710	PRKCZ	0.6	4.83	0.44	5.19e-6	Height;
THYM	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg24818145	chr4:99064322	C4orf37	0.75	6.02	0.53	3.32e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61931739	0.517	rs2101396	chr12:34048927	T/A	cg10856724	chr12:34555212	NA	-0.75	-6.73	-0.57	1.25e-9	Morning vs. evening chronotype;
THYM	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg16423285	chr20:60520624	NA	-0.64	-4.48	-0.42	2.08e-5	Body mass index;
THYM	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.83	-5.07	-0.46	1.98e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs11822910	0.911	rs61886978	chr11:57194848	G/C	cg00522883	chr11:57194120	SLC43A3	0.66	5.45	0.49	3.97e-7	Platelet distribution width;
THYM	cis	rs7953249	0.564	rs11065385	chr12:121423386	A/G	cg14101638	chr12:121416612	HNF1A	-0.51	-5.16	-0.47	1.36e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs1345301	0.905	rs2310243	chr2:102877560	A/G	cg03938978	chr2:103052716	IL18RAP	-0.62	-6.09	-0.53	2.36e-8	Waist circumference;
THYM	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19346786	chr7:2764209	NA	-0.78	-7.06	-0.59	2.68e-10	Height;
THYM	cis	rs6541297	1.000	rs11122405	chr1:230282997	C/A	cg20703242	chr1:230279135	GALNT2	0.92	5.97	0.52	4e-8	Coronary artery disease;
THYM	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11644478	chr21:40555479	PSMG1	-0.79	-6.78	-0.57	1e-9	Cognitive function;
THYM	cis	rs9906944	1.000	rs9906944	chr17:47091420	C/T	cg18128536	chr17:47092178	IGF2BP1	-0.41	-4.63	-0.43	1.17e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg19336497	chr11:14380999	RRAS2	-0.52	-5.64	-0.5	1.73e-7	Mitochondrial DNA levels;
THYM	cis	rs74417235	0.673	rs6873342	chr5:154051835	A/G	cg08754654	chr5:154026448	NA	-0.5	-4.5	-0.42	1.91e-5	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs747334	0.818	rs10881861	chr10:92704517	T/G	cg07620928	chr10:92689909	NA	0.54	4.84	0.44	5.04e-6	Fibroblast growth factor basic levels;
THYM	cis	rs8067545	0.967	rs4924801	chr17:19921070	T/C	cg08626831	chr17:20841558	NA	-0.49	-4.7	-0.43	8.68e-6	Schizophrenia;
THYM	cis	rs76935404	0.868	rs73034462	chr19:41418134	G/A	cg19493303	chr19:41414353	NA	0.57	5.1	0.46	1.74e-6	nicotine metabolite ratio in current smokers;
THYM	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg23958373	chr8:599963	NA	1.05	5.2	0.47	1.16e-6	IgG glycosylation;
THYM	cis	rs7523273	0.568	rs6669384	chr1:208025926	T/C	cg00085493	chr1:208040203	NA	0.61	4.69	0.43	9.24e-6	Schizophrenia;
THYM	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg18252515	chr7:66147081	NA	-0.67	-5.1	-0.46	1.72e-6	Aortic root size;
THYM	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.42	0.49	4.5e-7	Height;
THYM	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg13114125	chr14:105738426	BRF1	-0.74	-5.72	-0.51	1.22e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7177699	0.557	rs7403593	chr15:79111962	A/G	cg15571903	chr15:79123663	NA	-0.58	-6.53	-0.56	3.25e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7172809	0.897	rs74026931	chr15:77825474	A/C	cg10437265	chr15:77819839	NA	-0.53	-4.57	-0.42	1.48e-5	Glucose homeostasis traits;
THYM	cis	rs2274459	0.841	rs2281919	chr6:33663171	A/C	cg06253072	chr6:33679850	C6orf125	0.49	4.97	0.45	2.98e-6	Obesity (extreme);
THYM	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg03605463	chr16:89740564	NA	-0.88	-6.83	-0.57	7.83e-10	Vitiligo;
THYM	cis	rs9309711	0.922	rs11679058	chr2:3483813	C/G	cg10845886	chr2:3471009	TTC15	-0.6	-4.94	-0.45	3.37e-6	Neurofibrillary tangles;
THYM	cis	rs3768617	0.510	rs10737245	chr1:183100884	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	trans	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs6570726	0.935	rs406343	chr6:145874388	A/G	cg13319975	chr6:146136371	FBXO30	-0.66	-5.62	-0.5	1.89e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg03188948	chr7:1209495	NA	0.82	6.34	0.55	7.53e-9	Longevity;Endometriosis;
THYM	cis	rs4746818	1.000	rs1506770	chr10:70964357	G/A	cg11621586	chr10:70884670	VPS26A	1.28	11.12	0.75	6.73e-19	Left atrial antero-posterior diameter;
THYM	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg21773646	chr17:80085082	CCDC57	-0.34	-4.91	-0.45	3.76e-6	Life satisfaction;
THYM	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg08999081	chr20:33150536	PIGU	-0.57	-5.02	-0.46	2.37e-6	Height;
THYM	cis	rs1048238	0.506	rs1262788	chr1:16215608	G/C	cg21385522	chr1:16154831	NA	-0.67	-5.62	-0.5	1.89e-7	Systolic blood pressure;
THYM	cis	rs778371	0.697	rs11893358	chr2:233636922	T/C	cg08000102	chr2:233561755	GIGYF2	0.83	7.52	0.61	3.07e-11	Schizophrenia;
THYM	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg18681998	chr4:17616180	MED28	0.95	8.92	0.67	3.41e-14	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg00129232	chr17:37814104	STARD3	0.69	4.51	0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg09184832	chr6:79620586	NA	-0.58	-4.53	-0.42	1.68e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23221052	chr5:179740743	GFPT2	-0.85	-6.92	-0.58	5.14e-10	Height;
THYM	cis	rs4731207	0.596	rs1871772	chr7:124678872	G/T	cg05285228	chr7:124571219	POT1	-0.65	-4.98	-0.45	2.9e-6	Cutaneous malignant melanoma;
THYM	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg03295274	chr13:50190584	NA	-0.68	-5.22	-0.47	1.07e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg15448220	chr1:150897856	SETDB1	0.9	7.66	0.62	1.56e-11	Melanoma;
THYM	cis	rs2915864	0.846	rs2961690	chr5:141569574	T/A	cg00542992	chr5:141595654	NA	0.62	4.68	0.43	9.4e-6	Facial morphology (factor 20);
THYM	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg02187348	chr16:89574699	SPG7	0.69	5.28	0.48	8.17e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs7809615	0.901	rs17161761	chr7:99156934	C/T	cg12290671	chr7:99195819	NA	-0.99	-4.83	-0.44	5.27e-6	Blood metabolite ratios;
THYM	cis	rs988913	0.874	rs12662124	chr6:54802336	A/G	cg19716238	chr6:54711378	FAM83B	0.52	5.2	0.47	1.14e-6	Menarche (age at onset);
THYM	cis	rs1003719	0.680	rs2187577	chr21:38533341	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	4.5	0.42	1.93e-5	Aortic root size;
THYM	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg11764359	chr7:65958608	NA	-0.74	-6.02	-0.53	3.33e-8	Aortic root size;
THYM	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg11752832	chr7:134001865	SLC35B4	0.76	5.72	0.51	1.23e-7	Mean platelet volume;
THYM	cis	rs9787249	0.874	rs12094291	chr1:40226046	G/A	cg02773041	chr1:40204384	PPIE	0.75	5.74	0.51	1.11e-7	Blood protein levels;
THYM	cis	rs1448094	0.511	rs61930037	chr12:86154503	G/A	cg02569458	chr12:86230093	RASSF9	0.62	5.13	0.47	1.56e-6	Major depressive disorder;
THYM	cis	rs12310956	0.532	rs7306007	chr12:33975209	C/G	cg10856724	chr12:34555212	NA	-0.75	-6.8	-0.57	9.1e-10	Morning vs. evening chronotype;
THYM	cis	rs6450176	1.000	rs10805455	chr5:53302302	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.14	-0.53	1.94e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs1372520	0.748	rs2737002	chr4:90753180	A/G	cg01966878	chr4:90757139	SNCA	-0.63	-4.93	-0.45	3.54e-6	Neuroticism;
THYM	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg08213375	chr14:104286397	PPP1R13B	0.45	4.63	0.43	1.17e-5	Reticulocyte count;
THYM	trans	rs9951602	0.512	rs6506872	chr18:76649695	T/C	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs1150668	0.835	rs203869	chr6:28040819	T/A	cg09682330	chr6:28411287	ZSCAN23	-0.6	-5.32	-0.48	6.93e-7	Pubertal anthropometrics;
THYM	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg14664628	chr15:75095509	CSK	0.74	5.26	0.48	8.82e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.43	-0.49	4.24e-7	Mean corpuscular volume;
THYM	cis	rs78456975	1.000	rs72776298	chr2:1570163	C/G	cg14129053	chr2:1895732	MYT1L	1.35	4.96	0.45	3.08e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11644478	chr21:40555479	PSMG1	0.95	7.1	0.59	2.31e-10	Cognitive function;
THYM	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg08901578	chr4:187885870	NA	-0.63	-5.72	-0.51	1.21e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg19901468	chr14:105411992	AHNAK2	-0.82	-6.74	-0.57	1.24e-9	Rheumatoid arthritis;
THYM	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg02269571	chr22:50332266	NA	-1.15	-5.53	-0.49	2.78e-7	Schizophrenia;
THYM	cis	rs13232179	1.000	rs9655607	chr7:151114229	G/A	cg01177956	chr7:150756509	SLC4A2;CDK5	-0.78	-4.55	-0.42	1.6e-5	Coronary heart disease;
THYM	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg11663144	chr21:46675770	NA	-0.65	-8.64	-0.66	1.31e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.47	0.55	4.29e-9	Total body bone mineral density;
THYM	cis	rs877282	0.853	rs11595510	chr10:756757	C/G	cg10556349	chr10:835070	NA	-0.68	-4.63	-0.43	1.17e-5	Uric acid levels;
THYM	cis	rs3771570	0.901	rs9052	chr2:242434809	G/T	cg21155796	chr2:242212141	HDLBP	0.97	5.81	0.51	8.32e-8	Prostate cancer;
THYM	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg18252515	chr7:66147081	NA	0.6	4.52	0.42	1.76e-5	Aortic root size;
THYM	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs11645898	0.935	rs17603936	chr16:72169002	C/A	cg03805757	chr16:71968109	PKD1L3	-0.73	-5.37	-0.48	5.49e-7	Blood protein levels;
THYM	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg21427119	chr20:30132790	HM13	-0.96	-7.02	-0.58	3.34e-10	Mean corpuscular hemoglobin;
THYM	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg07424592	chr7:64974309	NA	0.99	5.15	0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs3008870	0.755	rs10749766	chr1:67376921	A/G	cg02640540	chr1:67518911	SLC35D1	0.6	4.77	0.44	6.68e-6	Lymphocyte percentage of white cells;
THYM	cis	rs62103177	0.584	rs9956207	chr18:77968392	A/G	cg07235805	chr18:78004237	PARD6G	-0.48	-5.67	-0.5	1.54e-7	Opioid sensitivity;
THYM	cis	rs6980334	0.817	rs3805360	chr7:137794589	G/A	cg22979093	chr7:137028410	PTN	0.62	4.95	0.45	3.19e-6	Blood metabolite ratios;
THYM	cis	rs7103648	0.669	rs10437655	chr11:47391948	G/A	cg20307385	chr11:47447363	PSMC3	0.88	7.72	0.62	1.16e-11	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg05738196	chr6:26577821	NA	0.83	8.34	0.65	5.8e-13	Intelligence (multi-trait analysis);
THYM	cis	rs12519773	0.576	rs1496337	chr5:92411293	C/T	cg18783429	chr5:92414398	NA	0.49	4.54	0.42	1.63e-5	Migraine;
THYM	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.01	-5.02	-0.46	2.37e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs262150	0.536	rs73167296	chr7:158783129	C/T	cg23058037	chr7:158824108	VIPR2	0.49	4.5	0.42	1.95e-5	Facial morphology (factor 20);
THYM	cis	rs7580658	0.637	rs1566822	chr2:127987391	A/G	cg10021288	chr2:128175891	PROC	-0.63	-5.61	-0.5	2.03e-7	Protein C levels;
THYM	cis	rs10917477	0.655	rs34980758	chr1:19892785	A/G	cg09356672	chr1:19665131	NA	0.51	4.9	0.45	3.95e-6	Thyroid function;
THYM	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7106204	0.748	rs4636667	chr11:24238615	T/C	ch.11.24196551F	chr11:24239977	NA	1.0	7.01	0.58	3.4e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs10911232	0.507	rs7547953	chr1:183031641	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs7078219	0.543	rs7092009	chr10:101277239	A/G	cg07044859	chr10:101282883	NA	-0.44	-5.14	-0.47	1.48e-6	Dental caries;
THYM	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg03929089	chr4:120376271	NA	0.98	10.82	0.74	2.92e-18	Coronary artery disease;
THYM	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg03433033	chr1:76189801	ACADM	0.77	10.21	0.72	6.01e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg17211192	chr8:82754475	SNX16	0.91	7.3	0.6	8.57e-11	Diastolic blood pressure;
THYM	cis	rs863345	0.604	rs10908653	chr1:158455353	A/G	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs4595586	0.525	rs6580891	chr12:39370127	C/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-5.4	-0.48	4.89e-7	Chronic sinus infection;
THYM	cis	rs67981189	0.896	rs58133478	chr14:71525087	C/T	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs10895275	0.961	rs10895274	chr11:102083069	A/C	cg24447756	chr11:102105824	NA	0.53	4.7	0.43	8.77e-6	Migraine;
THYM	cis	rs8078723	0.510	rs3859189	chr17:38137033	A/G	cg25038082	chr17:37896074	GRB7	-0.59	-4.8	-0.44	5.85e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	cis	rs10158481	0.759	rs4648900	chr1:25478644	C/T	cg09264742	chr1:25757510	TMEM57	-0.67	-4.83	-0.44	5.21e-6	Urate levels in obese individuals;
THYM	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg18876405	chr7:65276391	NA	0.63	5.56	0.5	2.42e-7	Aortic root size;
THYM	cis	rs7216064	0.911	rs6504551	chr17:65903326	T/G	cg12091567	chr17:66097778	LOC651250	-0.83	-6.17	-0.53	1.65e-8	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs490234	0.702	rs3814129	chr9:128365953	A/G	cg14078157	chr9:128172775	NA	-0.75	-6.05	-0.53	2.85e-8	Mean arterial pressure;
THYM	cis	rs7127900	0.950	rs7123299	chr11:2232344	A/G	cg25635251	chr11:2234043	NA	0.85	5.23	0.47	1.01e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg02725872	chr8:58115012	NA	-0.9	-5.24	-0.47	9.85e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg08431931	chr22:42394659	WBP2NL	0.71	5.72	0.51	1.23e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs4285028	0.948	rs73855480	chr3:121676646	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7772486	0.692	rs2265915	chr6:146194332	A/T	cg13319975	chr6:146136371	FBXO30	-0.63	-5.11	-0.46	1.64e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2115630	1.000	rs56074163	chr15:85351332	C/T	cg11189052	chr15:85197271	WDR73	-0.6	-4.67	-0.43	9.9e-6	P wave terminal force;
THYM	cis	rs3820068	0.734	rs6669156	chr1:15905206	T/A	cg05660106	chr1:15850417	CASP9	1.15	9.45	0.7	2.49e-15	Systolic blood pressure;
THYM	cis	rs2361701	0.543	rs59252872	chr17:78071247	A/G	cg09238746	chr17:78121135	EIF4A3	-0.76	-4.85	-0.45	4.86e-6	IgG glycosylation;
THYM	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.98	9.35	0.69	4.06e-15	Body mass index (adult);
THYM	cis	rs2976388	0.647	rs2244163	chr8:143784500	T/G	cg06565975	chr8:143823917	SLURP1	0.44	4.93	0.45	3.51e-6	Urinary tract infection frequency;
THYM	cis	rs13631	1.000	rs13631	chr9:140006202	G/A	cg03717367	chr9:139980219	LOC100289341;MAN1B1	0.57	4.78	0.44	6.42e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs6032067	0.929	rs6032070	chr20:43869795	A/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.71	-7.45	-0.61	4.33e-11	Blood protein levels;
THYM	cis	rs4853012	0.887	rs2122290	chr2:74358901	C/T	cg20891558	chr2:74357851	NA	1.26	12.33	0.78	2e-21	Gestational age at birth (maternal effect);
THYM	cis	rs6835098	0.962	rs4419455	chr4:174083622	C/T	cg08422745	chr4:174089978	GALNT7	0.96	7.88	0.63	5.37e-12	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs8077889	0.871	rs72836549	chr17:41904360	G/T	cg26893861	chr17:41843967	DUSP3	1.11	10.19	0.72	6.43e-17	Triglycerides;
THYM	cis	rs7236492	0.688	rs7241538	chr18:77191247	C/T	cg15644404	chr18:77186268	NFATC1	-1.02	-4.63	-0.43	1.16e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs8067545	1.000	rs8071730	chr17:19932731	C/T	cg13482628	chr17:19912719	NA	0.58	4.92	0.45	3.65e-6	Schizophrenia;
THYM	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12667521	chr19:29218732	NA	0.88	7.82	0.63	7.26e-12	Methadone dose in opioid dependence;
THYM	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg11663144	chr21:46675770	NA	-0.7	-9.97	-0.71	1.96e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7258465	1.000	rs10164319	chr19:18569833	G/A	cg04166595	chr19:18636596	NA	0.62	4.62	0.43	1.19e-5	Breast cancer;
THYM	cis	rs1003719	0.715	rs6517405	chr21:38560334	T/C	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs3733631	0.557	rs73838913	chr4:104635228	C/G	cg24090629	chr4:104641072	TACR3	-0.82	-4.48	-0.42	2.07e-5	Menarche (age at onset);
THYM	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.89	5.72	0.51	1.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.22e-7	Corneal astigmatism;
THYM	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg18681998	chr4:17616180	MED28	0.91	8.56	0.66	2e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg03452623	chr4:187889614	NA	-1.13	-17.85	-0.88	4.09e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9814567	0.806	rs2293293	chr3:134322742	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.09e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs4363385	0.818	rs11205164	chr1:152986023	A/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.76	-0.44	6.94e-6	Inflammatory skin disease;
THYM	cis	rs72792324	0.655	rs6873480	chr5:140749326	G/A	cg07628577	chr5:140772408	PCDHGA4;PCDHGA6;PCDHGA1;PCDHGA5;PCDHGB1;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA8;PCDHGA7;PCDHGB2;PCDHGB3	-0.95	-4.95	-0.45	3.19e-6	Mean platelet volume;
THYM	cis	rs7511006	1.000	rs17836662	chr22:50672154	A/G	cg11077631	chr22:50617003	PANX2	0.5	5.48	0.49	3.42e-7	Obesity-related traits;
THYM	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg08859206	chr1:53392774	SCP2	-0.65	-7.37	-0.6	6.31e-11	Monocyte count;
THYM	cis	rs7917772	0.512	rs11594073	chr10:104308193	T/C	cg00122347	chr10:104236741	TMEM180	0.42	6.18	0.54	1.62e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg10057126	chr4:77819792	ANKRD56	0.7	5.93	0.52	4.87e-8	Emphysema distribution in smoking;
THYM	cis	rs62435770	1.000	rs73034034	chr6:169480123	A/G	cg07652237	chr6:170125491	PHF10	0.55	4.81	0.44	5.64e-6	Loneliness;
THYM	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.89	-7.3	-0.6	8.68e-11	Intelligence (multi-trait analysis);
THYM	cis	rs3916	0.955	rs12828810	chr12:121152017	T/G	cg10600917	chr12:121163489	ACADS	0.6	5.19	0.47	1.2e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg05368731	chr17:41323189	NBR1	1.25	11.64	0.77	5.42e-20	Menopause (age at onset);
THYM	cis	rs2456568	0.695	rs55756119	chr11:93689909	A/G	cg17595323	chr11:93583763	C11orf90	0.51	4.83	0.44	5.33e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Body mass index;
THYM	cis	rs476633	0.691	rs28409265	chr15:41539404	G/A	cg21153102	chr15:41252147	NA	0.55	4.58	0.43	1.42e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg00012203	chr2:219082015	ARPC2	0.85	7.65	0.62	1.64e-11	Colorectal cancer;
THYM	cis	rs854765	0.583	rs950966	chr17:17783748	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.13	-0.53	2.04e-8	Total body bone mineral density;
THYM	cis	rs308403	0.509	rs309382	chr4:123669772	T/C	cg10495464	chr4:123653540	BBS12;LOC729338	0.98	8.84	0.67	4.9e-14	Blood protein levels;
THYM	cis	rs4731207	0.698	rs6977407	chr7:124499002	A/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg15744692	chr15:45671195	LOC145663;GATM	0.45	4.6	0.43	1.32e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs73086581	0.838	rs6052265	chr20:4026835	C/T	cg02187196	chr20:3869020	PANK2	0.46	5.09	0.46	1.8e-6	Response to antidepressants in depression;
THYM	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg00071950	chr4:10020882	SLC2A9	0.86	10.33	0.73	3.3e-17	Bone mineral density;
THYM	cis	rs7705042	0.865	rs12653866	chr5:141489921	C/T	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs259282	0.538	rs6510270	chr19:33114514	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.61	4.66	0.43	1.04e-5	Schizophrenia;
THYM	cis	rs4455778	0.580	rs6951015	chr7:49115139	T/A	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg07167872	chr1:205819463	PM20D1	-0.64	-4.68	-0.43	9.68e-6	Menarche (age at onset);
THYM	cis	rs3960554	0.808	rs2302434	chr7:75630183	C/T	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.72	-0.44	8.25e-6	Eotaxin levels;
THYM	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.03	10.73	0.74	4.6e-18	Cognitive ability;
THYM	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg13114125	chr14:105738426	BRF1	-0.7	-5.37	-0.48	5.63e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg22467129	chr15:76604101	ETFA	-0.53	-5.01	-0.46	2.49e-6	Blood metabolite levels;
THYM	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg23815491	chr16:72088622	HP	0.87	7.21	0.59	1.32e-10	Fibrinogen levels;
THYM	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.63	-5.78	-0.51	9.5e-8	Prudent dietary pattern;
THYM	cis	rs3820068	0.544	rs7551750	chr1:16035008	T/C	cg05660106	chr1:15850417	CASP9	0.72	5.59	0.5	2.2e-7	Systolic blood pressure;
THYM	cis	rs7772486	0.686	rs1292336	chr6:145967818	T/C	cg13319975	chr6:146136371	FBXO30	0.67	5.47	0.49	3.62e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6473252	0.522	rs1348673	chr8:81825086	A/T	cg08595989	chr8:81827712	NA	0.45	4.7	0.43	8.76e-6	Breast cancer;
THYM	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg23161317	chr6:28129485	ZNF389	0.84	6.3	0.54	9.31e-9	Parkinson's disease;
THYM	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.43	-5.32	-0.48	6.78e-7	Longevity;Endometriosis;
THYM	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg11764359	chr7:65958608	NA	-0.83	-6.95	-0.58	4.49e-10	Aortic root size;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg11497017	chr12:63117540	PPM1H	-0.86	-7.01	-0.58	3.51e-10	Depressive symptoms;
THYM	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.7	-5.67	-0.5	1.53e-7	Lung cancer in ever smokers;
THYM	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.67	0.43	9.95e-6	Bipolar disorder;
THYM	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg23583168	chr7:148888333	NA	-1.01	-13.01	-0.8	7.84e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs2067615	0.579	rs10861657	chr12:107131314	A/G	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs7106204	1.000	rs7110656	chr11:24216034	G/T	ch.11.24196551F	chr11:24239977	NA	0.94	5.88	0.52	6.09e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07167872	chr1:205819463	PM20D1	0.81	7.23	0.6	1.19e-10	Monocyte percentage of white cells;
THYM	trans	rs4650994	1.000	rs10798615	chr1:178513895	T/G	cg05059571	chr16:84539110	KIAA1609	-0.75	-7.94	-0.63	4.01e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg16928487	chr17:17741425	SREBF1	-0.55	-5.47	-0.49	3.62e-7	Total body bone mineral density;
THYM	cis	rs6087771	0.851	rs6087775	chr20:30325765	G/A	cg13852791	chr20:30311386	BCL2L1	0.87	8.17	0.64	1.31e-12	Subcortical brain region volumes;Putamen volume;
THYM	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg10334053	chr1:2078117	PRKCZ	-0.45	-4.69	-0.43	9.27e-6	Height;
THYM	cis	rs2882877	0.621	rs2119070	chr2:190372919	C/T	cg10752008	chr2:190445175	SLC40A1	-0.74	-6.31	-0.54	8.67e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg00149659	chr3:10157352	C3orf10	0.77	4.46	0.42	2.24e-5	Alzheimer's disease;
THYM	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	14.79	0.83	2.2e-26	Chronic sinus infection;
THYM	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg17054759	chr22:49844102	NA	-0.53	-5.05	-0.46	2.09e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7614311	1.000	rs2678352	chr3:63825640	T/C	cg22134162	chr3:63841271	THOC7	-0.49	-5.75	-0.51	1.09e-7	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs367615	0.918	rs10055528	chr5:108861129	G/T	cg17395555	chr5:108820864	NA	0.53	4.68	0.43	9.47e-6	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-6.28	-0.54	9.97e-9	Gut microbiome composition (summer);
THYM	cis	rs9914544	0.564	rs11548434	chr17:18761508	G/A	cg26378065	chr17:18585709	ZNF286B	0.6	4.71	0.43	8.56e-6	Educational attainment (years of education);
THYM	cis	rs343604	0.686	rs4839567	chr1:111331017	G/C	cg22165175	chr1:111148915	KCNA2	0.82	4.45	0.42	2.36e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs765787	0.530	rs1648289	chr15:45516494	A/G	cg24006582	chr15:45444508	DUOX1	-0.84	-7.2	-0.59	1.39e-10	Uric acid levels;
THYM	cis	rs7107174	1.000	rs10899481	chr11:78058721	A/T	cg02023728	chr11:77925099	USP35	-0.61	-5.96	-0.52	4.24e-8	Testicular germ cell tumor;
THYM	trans	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg25517755	chr10:38738941	LOC399744	-0.77	-7.48	-0.61	3.65e-11	Corneal astigmatism;
THYM	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg17211192	chr8:82754475	SNX16	-0.82	-7.41	-0.61	5.09e-11	Diastolic blood pressure;
THYM	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	5.8	0.51	8.48e-8	Monocyte percentage of white cells;
THYM	trans	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-6.85	-0.57	7.29e-10	Exhaled nitric oxide output;
THYM	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg06634786	chr22:41940651	POLR3H	0.68	5.0	0.46	2.62e-6	Vitiligo;
THYM	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.98	-5.47	-0.49	3.57e-7	Body mass index;
THYM	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg06238570	chr21:40685208	BRWD1	-0.92	-6.91	-0.58	5.61e-10	Cognitive function;
THYM	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg15704280	chr7:45808275	SEPT13	-1.06	-15.39	-0.84	1.51e-27	Height;
THYM	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.1	-0.53	2.29e-8	Crohn's disease;
THYM	cis	rs4595586	0.545	rs12816776	chr12:39375817	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs6995541	0.505	rs1055329	chr8:10703909	C/T	cg13457217	chr8:10683266	MIR1322;PINX1	-0.63	-4.53	-0.42	1.71e-5	Triglyceride levels;
THYM	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg24531977	chr5:56204891	C5orf35	-1.01	-8.29	-0.65	7.47e-13	Initial pursuit acceleration;
THYM	cis	rs7107174	1.000	rs2510050	chr11:77982564	A/G	cg02023728	chr11:77925099	USP35	0.65	5.95	0.52	4.47e-8	Testicular germ cell tumor;
THYM	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg03929089	chr4:120376271	NA	-1.01	-13.5	-0.81	8.23e-24	Height;
THYM	cis	rs2544523	0.511	rs10929387	chr2:15912926	A/G	cg26669897	chr2:15909070	NA	0.62	5.04	0.46	2.18e-6	Asthma or chronic obstructive pulmonary disease;
THYM	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg23161317	chr6:28129485	ZNF389	0.69	5.78	0.51	9.52e-8	Parkinson's disease;
THYM	cis	rs80033912	0.626	rs71324982	chr3:49669948	G/A	cg25090325	chr3:49755764	AMIGO3;RNF123	0.77	4.99	0.46	2.68e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2070488	1.000	rs4147024	chr3:38456664	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	6.83	0.57	7.89e-10	Electrocardiographic conduction measures;
THYM	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg18806716	chr10:30721971	MAP3K8	-0.57	-5.58	-0.5	2.23e-7	Inflammatory bowel disease;
THYM	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg03188948	chr7:1209495	NA	0.91	5.01	0.46	2.47e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11112613	0.653	rs941101	chr12:105937098	T/G	cg03607813	chr12:105948248	NA	1.09	9.15	0.68	1.1e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg02725872	chr8:58115012	NA	-1.11	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs8028313	0.630	rs28565266	chr15:67938011	C/G	cg26545918	chr15:68124484	LBXCOR1	0.53	4.75	0.44	7.26e-6	Obesity;
THYM	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg27398817	chr8:82754497	SNX16	-0.69	-5.81	-0.51	8.17e-8	Diastolic blood pressure;
THYM	cis	rs11671005	0.735	rs11881000	chr19:58932788	C/T	cg18639983	chr19:58920768	ZNF584	0.61	5.02	0.46	2.37e-6	Mean platelet volume;
THYM	cis	rs1160297	0.609	rs1451455	chr2:53101529	T/C	cg07782112	chr2:53107842	NA	0.8	6.67	0.56	1.72e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs919433	0.680	rs2565163	chr2:198354414	T/C	cg00792783	chr2:198669748	PLCL1	0.82	5.69	0.5	1.4e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9959145	1.000	rs79785672	chr18:12552109	C/T	cg14160804	chr18:12703040	PSMG2;CEP76	-0.92	-4.53	-0.42	1.74e-5	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs295140	0.566	rs295141	chr2:201163556	C/T	cg23649088	chr2:200775458	C2orf69	-0.61	-5.02	-0.46	2.4e-6	QT interval;
THYM	cis	rs7000551	0.606	rs13256933	chr8:22267199	T/G	cg12081754	chr8:22256438	SLC39A14	1.15	11.77	0.77	2.99e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs800586	0.843	rs1526461	chr8:116823448	A/G	cg04656070	chr8:116661063	TRPS1	0.48	4.98	0.45	2.88e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.46	0.55	4.53e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7267979	1.000	rs2500432	chr20:25290512	A/C	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg24642439	chr20:33292090	TP53INP2	0.59	4.68	0.43	9.49e-6	Coronary artery disease;
THYM	cis	rs17016200	0.513	rs73107725	chr3:78364260	G/A	cg24512093	chr3:78698151	ROBO1	0.99	5.11	0.46	1.63e-6	Facial emotion recognition;
THYM	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs4343996	0.558	rs7794534	chr7:3416396	T/C	cg21248987	chr7:3385318	SDK1	0.4	4.91	0.45	3.72e-6	Motion sickness;
THYM	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2235642	0.859	rs9927529	chr16:1619488	C/T	cg07341220	chr16:1583899	IFT140;TMEM204	-0.66	-5.52	-0.49	2.88e-7	Coronary artery disease;
THYM	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.65	-11.76	-0.77	3.01e-20	Hemostatic factors and hematological phenotypes;
THYM	cis	rs877282	0.947	rs957642	chr10:773966	C/T	cg10556349	chr10:835070	NA	-0.69	-4.81	-0.44	5.75e-6	Uric acid levels;
THYM	cis	rs11225247	0.881	rs11604008	chr11:102259744	T/A	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg25358565	chr5:93447407	FAM172A	1.42	9.93	0.71	2.33e-16	Diabetic retinopathy;
THYM	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg03929089	chr4:120376271	NA	-0.8	-7.9	-0.63	4.8e-12	Height;
THYM	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02018176	chr4:1364513	KIAA1530	1.0	9.74	0.71	5.82e-16	Longevity;
THYM	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg08994789	chr17:28903642	LRRC37B2	-1.07	-6.19	-0.54	1.52e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg06238570	chr21:40685208	BRWD1	0.83	5.82	0.51	8.02e-8	Cognitive function;
THYM	cis	rs6546537	0.714	rs17036759	chr2:69767029	C/T	cg10773587	chr2:69614142	GFPT1	-0.6	-4.95	-0.45	3.15e-6	Serum thyroid-stimulating hormone levels;
THYM	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	18.96	0.89	4.77e-34	Chronic sinus infection;
THYM	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.65	6.68	0.57	1.64e-9	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg14004847	chr7:1930337	MAD1L1	-0.65	-5.16	-0.47	1.35e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7172809	0.573	rs4886865	chr15:77686876	C/T	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs9527	0.640	rs35195396	chr10:104928770	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.49	-0.42	1.98e-5	Arsenic metabolism;
THYM	cis	rs6500395	0.775	rs13331298	chr16:48661489	G/A	cg04672837	chr16:48644449	N4BP1	0.47	4.62	0.43	1.18e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9866391	0.706	rs7624084	chr3:141093285	T/C	cg13411656	chr3:141121016	ZBTB38	-0.38	-5.72	-0.51	1.23e-7	Myopia;
THYM	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06634786	chr22:41940651	POLR3H	0.79	6.02	0.53	3.27e-8	Vitiligo;
THYM	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg12863693	chr15:85201151	NMB	0.63	5.57	0.5	2.41e-7	Schizophrenia;
THYM	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg00071950	chr4:10020882	SLC2A9	-0.65	-5.73	-0.51	1.17e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg14768367	chr16:72042858	DHODH	0.66	5.06	0.46	2.02e-6	Fibrinogen levels;
THYM	cis	rs7113850	0.541	rs11819948	chr11:24231257	A/C	ch.11.24196551F	chr11:24239977	NA	0.92	4.92	0.45	3.58e-6	Bone fracture in osteoporosis;
THYM	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03576123	chr11:487126	PTDSS2	-1.31	-5.86	-0.52	6.57e-8	Body mass index;
THYM	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg26384229	chr12:38710491	ALG10B	1.02	8.22	0.64	1.05e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs13102973	0.640	rs11737779	chr4:135831516	C/T	cg14419869	chr4:135874104	NA	0.7	5.72	0.51	1.26e-7	Subjective well-being;
THYM	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg12826209	chr6:26865740	GUSBL1	0.85	4.68	0.43	9.63e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1050631	0.592	rs1785900	chr18:33710170	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.28	0.48	8.32e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs236352	0.576	rs2303993	chr6:36842427	C/G	cg03410223	chr6:36853544	C6orf89	0.71	5.65	0.5	1.69e-7	Heart rate;
THYM	trans	rs4262150	0.883	rs72802883	chr5:152246607	A/C	cg08281791	chr5:76607845	PDE8B	0.92	6.91	0.58	5.62e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03264133	chr6:25882463	NA	-0.7	-5.51	-0.49	3.06e-7	Blood metabolite levels;
THYM	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg13010199	chr12:38710504	ALG10B	0.7	5.47	0.49	3.58e-7	Heart rate;
THYM	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg07537917	chr2:241836409	C2orf54	-0.26	-5.83	-0.51	7.57e-8	Urinary metabolites;
THYM	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg08859206	chr1:53392774	SCP2	-0.73	-8.5	-0.66	2.66e-13	Monocyte count;
THYM	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg22764591	chr12:58329936	NA	-1.24	-17.24	-0.87	5.17e-31	Intelligence (multi-trait analysis);
THYM	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg00757033	chr12:89920650	WDR51B	0.75	12.04	0.78	7.96e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs4660261	0.526	rs3011228	chr1:44325995	A/G	cg15962314	chr1:44399869	ARTN	0.53	5.39	0.48	5.01e-7	Intelligence (multi-trait analysis);
THYM	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg16405210	chr4:1374714	KIAA1530	-0.61	-4.97	-0.45	2.97e-6	Longevity;
THYM	cis	rs6987853	0.787	rs2923427	chr8:42385748	A/C	cg09913449	chr8:42400586	C8orf40	1.09	12.36	0.79	1.71e-21	Mean corpuscular hemoglobin concentration;
THYM	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.68	6.05	0.53	2.9e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7084402	0.967	rs1658485	chr10:60288331	A/G	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs13256369	1.000	rs9329165	chr8:8576642	C/T	cg17143192	chr8:8559678	CLDN23	-0.88	-6.56	-0.56	2.83e-9	Obesity-related traits;
THYM	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs2933343	0.679	rs789254	chr3:128574593	A/G	cg11901034	chr3:128598214	ACAD9	-0.7	-5.65	-0.5	1.67e-7	IgG glycosylation;
THYM	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg18825531	chr11:62321136	NA	0.45	5.07	0.46	2e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg06808227	chr14:105710500	BRF1	-1.02	-8.84	-0.67	4.97e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg17264618	chr3:40429014	ENTPD3	0.55	5.21	0.47	1.08e-6	Renal cell carcinoma;
THYM	cis	rs1374313	0.872	rs11123521	chr2:120148826	A/G	cg18093372	chr2:119607603	NA	-0.46	-4.65	-0.43	1.07e-5	Obesity-related traits;
THYM	cis	rs983545	0.800	rs1837698	chr3:16959075	C/A	cg19448816	chr3:16974217	PLCL2	0.55	4.94	0.45	3.37e-6	Blood protein levels;
THYM	cis	rs2458413	0.542	rs2669451	chr8:105371096	C/A	cg21295575	chr8:105352067	TM7SF4	-0.35	-5.3	-0.48	7.58e-7	Paget's disease;
THYM	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg08439880	chr3:133502540	NA	-0.73	-6.29	-0.54	9.52e-9	Iron status biomarkers;
THYM	cis	rs8067545	0.720	rs11204419	chr17:19888997	A/G	cg20830565	chr17:20408647	MGC102966	-0.52	-4.92	-0.45	3.69e-6	Schizophrenia;
THYM	cis	rs10752881	1.000	rs10752886	chr1:182987248	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.79	0.44	6.13e-6	Colorectal cancer;
THYM	cis	rs1775715	0.651	rs2808033	chr10:32194127	A/T	cg04359828	chr10:32216031	ARHGAP12	0.39	5.14	0.47	1.45e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs883115	0.748	rs10799588	chr1:224819109	A/G	cg21444086	chr1:224821584	CNIH3	-0.51	-4.9	-0.45	4e-6	Cancer;
THYM	cis	rs17122693	1.000	rs72679584	chr14:51092320	T/C	cg04730355	chr14:51134070	SAV1	0.97	5.42	0.49	4.46e-7	Cognitive performance;
THYM	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg03060546	chr3:49711283	APEH	-0.7	-5.86	-0.52	6.71e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs941408	0.964	rs1736186	chr19:2815372	A/G	cg06609049	chr19:2785107	THOP1	0.67	5.33	0.48	6.61e-7	Total cholesterol levels;
THYM	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg13877915	chr19:58951672	ZNF132	-0.9	-8.65	-0.66	1.24e-13	Uric acid clearance;
THYM	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg02887458	chr19:19495540	GATAD2A	0.49	5.24	0.47	9.51e-7	Bipolar disorder;
THYM	cis	rs3816788	0.596	rs4872083	chr8:21770372	C/T	cg17168535	chr8:21777572	XPO7	0.83	6.85	0.58	7.13e-10	Lung cancer in ever smokers;
THYM	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg07936489	chr17:37558343	FBXL20	0.77	5.03	0.46	2.28e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs55702914	0.746	rs4850425	chr2:198152786	T/C	cg00792783	chr2:198669748	PLCL1	-0.6	-4.56	-0.42	1.55e-5	Major depression and alcohol dependence;
THYM	cis	rs9581857	0.579	rs3759433	chr13:27997999	C/T	cg22138327	chr13:27999177	GTF3A	0.91	6.95	0.58	4.56e-10	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	5.46	0.49	3.85e-7	Lung cancer in ever smokers;
THYM	cis	rs72781680	1.000	rs17712391	chr2:24245659	C/T	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs1003719	0.715	rs2835642	chr21:38539066	A/G	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.99	4.67	0.43	9.89e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg03060546	chr3:49711283	APEH	0.77	6.22	0.54	1.34e-8	Resting heart rate;
THYM	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.16	7.95	0.63	3.91e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs793108	0.742	rs793095	chr10:31385974	C/T	cg07137701	chr10:31611868	ZEB1	-0.54	-4.8	-0.44	5.99e-6	Multiple sclerosis;Rheumatoid arthritis;
THYM	cis	rs79149102	0.579	rs8039433	chr15:75367367	T/C	cg17294928	chr15:75287854	SCAMP5	-0.86	-4.73	-0.44	7.75e-6	Lung cancer;
THYM	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg16586182	chr3:47516702	SCAP	-0.67	-5.62	-0.5	1.9e-7	Colorectal cancer;
THYM	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.03	10.73	0.74	4.6e-18	Cognitive ability;
THYM	cis	rs1723838	0.510	rs17132534	chr11:73691774	A/G	cg13953458	chr11:73681281	DNAJB13	-0.66	-4.59	-0.43	1.36e-5	Obesity-related traits;
THYM	cis	rs9866391	0.607	rs6785012	chr3:141109348	C/T	cg13411656	chr3:141121016	ZBTB38	-0.32	-4.73	-0.44	7.89e-6	Myopia;
THYM	cis	rs28595532	0.920	rs6818519	chr4:119787820	G/T	cg14228332	chr4:119757509	SEC24D	1.22	4.46	0.42	2.29e-5	Cannabis dependence symptom count;
THYM	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	trans	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Bladder cancer;
THYM	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg12419862	chr22:24373484	LOC391322	0.81	6.68	0.57	1.63e-9	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs4606347	0.789	rs61780873	chr1:66164724	G/A	cg04111102	chr1:66153794	NA	0.62	4.69	0.43	9.13e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg22907277	chr7:1156413	C7orf50	0.83	5.1	0.46	1.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9913156	0.789	rs55999196	chr17:4600655	A/G	cg19197139	chr17:4613644	ARRB2	0.84	4.97	0.45	2.92e-6	Lymphocyte counts;
THYM	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg25918947	chr17:41365094	TMEM106A	-0.56	-4.62	-0.43	1.22e-5	Menopause (age at onset);
THYM	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg22681709	chr2:178499509	PDE11A	-0.49	-4.51	-0.42	1.87e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg24675056	chr1:15929824	NA	0.73	5.86	0.52	6.71e-8	Systolic blood pressure;
THYM	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg00981070	chr1:2046702	PRKCZ	-0.39	-4.98	-0.45	2.86e-6	Height;
THYM	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg00786635	chr1:25594202	NA	-0.92	-7.28	-0.6	9.7e-11	Erythrocyte sedimentation rate;
THYM	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.1	7.87	0.63	5.7e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Body mass index;
THYM	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg16586182	chr3:47516702	SCAP	-0.63	-5.52	-0.49	2.96e-7	Colorectal cancer;
THYM	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.7	5.13	0.47	1.51e-6	Lung cancer in ever smokers;
THYM	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg21798802	chr22:38057573	PDXP	0.47	5.37	0.48	5.51e-7	Fat distribution (HIV);
THYM	cis	rs929596	0.585	rs2018985	chr2:234648860	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-6.4	-0.55	5.82e-9	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs113835537	0.502	rs7104378	chr11:66216675	A/G	cg24851651	chr11:66362959	CCS	0.64	4.65	0.43	1.09e-5	Airway imaging phenotypes;
THYM	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg26597838	chr10:835615	NA	1.52	11.37	0.76	2.05e-19	Eosinophil percentage of granulocytes;
THYM	cis	rs7072216	0.763	rs2274245	chr10:100175082	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs2404602	0.610	rs28823285	chr15:77050395	T/C	cg23625390	chr15:77176239	SCAPER	-0.83	-5.98	-0.52	3.96e-8	Blood metabolite levels;
THYM	cis	rs35362007	0.530	rs10484053	chr14:96011645	C/T	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.93	4.54	0.42	1.63e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9682041	0.800	rs7643085	chr3:170070371	A/G	cg11886554	chr3:170076028	SKIL	1.17	4.52	0.42	1.79e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs17193922	0.876	rs17194040	chr16:53550898	C/T	cg04059762	chr16:53544020	NA	-0.56	-4.9	-0.45	3.95e-6	Hip circumference adjusted for BMI;
THYM	cis	rs12291225	0.679	rs10832240	chr11:14304744	C/T	cg05501817	chr11:14380813	RRAS2	-0.75	-5.76	-0.51	1.02e-7	Sense of smell;
THYM	cis	rs6032067	0.929	rs6017510	chr20:43831785	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	trans	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg20587970	chr11:113659929	NA	-1.21	-7.97	-0.63	3.45e-12	Hip circumference adjusted for BMI;
THYM	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg11764359	chr7:65958608	NA	0.8	6.31	0.54	8.7e-9	Aortic root size;
THYM	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03264133	chr6:25882463	NA	-1.08	-10.17	-0.72	7.02e-17	Uric acid levels;
THYM	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg06640241	chr16:89574553	SPG7	0.9	8.19	0.64	1.17e-12	Multiple myeloma (IgH translocation);
THYM	cis	rs9866391	0.619	rs2871960	chr3:141121814	A/C	cg13411656	chr3:141121016	ZBTB38	-0.35	-5.23	-0.47	9.9e-7	Myopia;
THYM	cis	rs41311933	1.000	rs2900181	chr9:123756881	T/A	cg13567360	chr9:123745713	C5	-0.92	-5.24	-0.47	9.59e-7	Coronary artery disease;
THYM	cis	rs9876781	1.000	rs4490383	chr3:48484683	T/C	cg06066452	chr3:48470258	PLXNB1	0.27	4.85	0.45	4.87e-6	Longevity;
THYM	trans	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.09	-13.24	-0.81	2.77e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11645898	0.935	rs3812985	chr16:72187957	A/T	cg03805757	chr16:71968109	PKD1L3	-0.6	-4.49	-0.42	2e-5	Blood protein levels;
THYM	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg23602478	chr1:26503979	CNKSR1	0.36	4.97	0.45	2.96e-6	Height;
THYM	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg06636001	chr8:8085503	FLJ10661	0.71	5.93	0.52	4.96e-8	Neuroticism;
THYM	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg06453172	chr10:134556979	INPP5A	-0.66	-4.77	-0.44	6.78e-6	Migraine;
THYM	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.1	-0.46	1.75e-6	Life satisfaction;
THYM	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg11247378	chr22:39784982	NA	-0.99	-9.81	-0.71	4.19e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs7487075	0.754	rs10880962	chr12:46773444	C/G	cg21428710	chr12:47219797	SLC38A4	0.55	5.61	0.5	2e-7	Itch intensity from mosquito bite;
THYM	cis	rs10189230	0.967	rs11692482	chr2:222352405	C/T	cg14652038	chr2:222343519	EPHA4	0.54	4.53	0.42	1.7e-5	Urate levels in lean individuals;
THYM	cis	rs2085601	0.542	rs28498689	chr4:89972316	T/C	cg17769793	chr4:89976368	FAM13A	-0.59	-6.62	-0.56	2.17e-9	Hair greying;
THYM	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg08885076	chr2:99613938	TSGA10	-0.46	-4.53	-0.42	1.71e-5	Fear of minor pain;
THYM	cis	rs6500395	0.962	rs9938126	chr16:48572121	A/T	cg04672837	chr16:48644449	N4BP1	0.47	4.46	0.42	2.23e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs1461503	0.868	rs11602682	chr11:122842315	A/T	cg27398637	chr11:122830231	C11orf63	-0.7	-6.62	-0.56	2.08e-9	Menarche (age at onset);
THYM	cis	rs10089	1.000	rs1842006	chr5:127508687	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.93	6.03	0.53	3.15e-8	Ileal carcinoids;
THYM	cis	rs3087591	0.960	rs2018634	chr17:29560678	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.62	-5.29	-0.48	7.89e-7	Hip circumference;
THYM	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg06481639	chr22:41940642	POLR3H	-0.73	-5.49	-0.49	3.38e-7	Vitiligo;
THYM	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg07606381	chr6:8435919	SLC35B3	0.62	4.48	0.42	2.1e-5	Motion sickness;
THYM	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg24675056	chr1:15929824	NA	0.73	5.9	0.52	5.62e-8	Systolic blood pressure;
THYM	cis	rs78366141	0.649	rs78959409	chr4:89659712	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	1.24	5.15	0.47	1.43e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg20503657	chr10:835505	NA	1.01	5.76	0.51	1.04e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg11247378	chr22:39784982	NA	-1.02	-12.79	-0.8	2.28e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs13064411	0.735	rs7631138	chr3:113231925	A/T	cg10517650	chr3:113235015	CCDC52	-0.61	-5.34	-0.48	6.3e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg02734326	chr4:10020555	SLC2A9	0.76	6.89	0.58	6.16e-10	Bone mineral density;
THYM	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg15704280	chr7:45808275	SEPT13	1.03	11.84	0.77	2.09e-20	Coronary artery disease;
THYM	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs1298062	0.790	rs1274604	chr19:50969325	A/G	cg10687087	chr19:50962411	MYBPC2	0.54	4.64	0.43	1.11e-5	Age of smoking initiation;
THYM	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg12564285	chr5:131593104	PDLIM4	-0.43	-4.66	-0.43	1.04e-5	Blood metabolite levels;
THYM	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg15448220	chr1:150897856	SETDB1	0.86	6.94	0.58	4.73e-10	Melanoma;
THYM	cis	rs1018836	0.770	rs12543806	chr8:91664011	C/T	cg16814680	chr8:91681699	NA	-0.97	-9.11	-0.68	1.34e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.67	0.43	9.99e-6	Obesity-related traits;
THYM	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg20503657	chr10:835505	NA	1.16	8.13	0.64	1.6e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs273218	0.568	rs1644814	chr5:53365452	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.61	4.87	0.45	4.36e-6	Migraine;
THYM	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg09021430	chr5:549028	NA	-0.6	-5.63	-0.5	1.82e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs9403317	0.537	rs9376648	chr6:142011451	T/C	cg15052665	chr6:141804349	NA	0.74	5.38	0.48	5.31e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2637266	1.000	rs2637268	chr10:78332213	G/T	cg18941641	chr10:78392320	NA	0.8	6.91	0.58	5.42e-10	Pulmonary function;
THYM	cis	rs7809950	0.784	rs7803102	chr7:107248929	T/G	cg23024343	chr7:107201750	COG5	0.89	7.51	0.61	3.13e-11	Coronary artery disease;
THYM	cis	rs4077515	0.901	rs11791262	chr9:139271919	C/T	cg14115884	chr9:139300582	SDCCAG3	0.73	6.9	0.58	5.79e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs62070183	0.938	rs4795719	chr17:31103975	C/T	cg02981443	chr17:31254875	TMEM98	-0.54	-4.87	-0.45	4.46e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs67311347	0.544	rs9864664	chr3:40336226	T/C	cg13683864	chr3:40499215	RPL14	-0.79	-7.44	-0.61	4.43e-11	Renal cell carcinoma;
THYM	cis	rs7020830	0.789	rs17408112	chr9:37114065	A/G	cg14294708	chr9:37120828	ZCCHC7	1.26	16.19	0.86	4.51e-29	Schizophrenia;
THYM	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg11752832	chr7:134001865	SLC35B4	0.68	4.92	0.45	3.63e-6	Mean platelet volume;
THYM	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.29	8.36	0.65	5.15e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.92	6.0	0.52	3.5e-8	Smoking behavior;
THYM	cis	rs79149102	0.579	rs6495135	chr15:75295030	T/C	cg17294928	chr15:75287854	SCAMP5	-1.06	-5.68	-0.5	1.49e-7	Lung cancer;
THYM	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg05738196	chr6:26577821	NA	0.57	4.7	0.43	8.7e-6	Schizophrenia;
THYM	cis	rs4654899	0.895	rs10916865	chr1:21136610	C/T	cg01072550	chr1:21505969	NA	0.69	6.27	0.54	1.05e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.49	-0.42	2.02e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4733781	0.842	rs4733768	chr8:131147397	A/G	cg16277922	chr8:131349729	ASAP1	-0.68	-5.42	-0.49	4.49e-7	Tuberculosis;
THYM	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.84e-8	Systolic blood pressure;
THYM	cis	rs7078219	0.714	rs888208	chr10:101295863	A/G	cg17888390	chr10:101282816	NA	-0.54	-5.19	-0.47	1.18e-6	Dental caries;
THYM	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg24578937	chr1:2090814	PRKCZ	0.81	8.54	0.66	2.22e-13	Height;
THYM	cis	rs763014	0.898	rs4984894	chr16:623103	T/C	cg00908189	chr16:619842	PIGQ	1.02	9.27	0.69	6.03e-15	Height;
THYM	cis	rs12200560	0.505	rs4240555	chr6:97076274	T/C	cg06623918	chr6:96969491	KIAA0776	0.78	6.01	0.52	3.39e-8	Coronary heart disease;
THYM	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg22968622	chr17:43663579	NA	1.2	10.71	0.74	5.16e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs55728055	0.661	rs62239172	chr22:32047941	G/A	cg10537193	chr22:32026975	PISD	-0.73	-4.94	-0.45	3.29e-6	Age-related hearing impairment;
THYM	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg26384229	chr12:38710491	ALG10B	0.73	5.61	0.5	2e-7	Morning vs. evening chronotype;
THYM	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg07362569	chr17:61921086	SMARCD2	0.69	6.15	0.53	1.86e-8	Prudent dietary pattern;
THYM	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg11301795	chr4:187892539	NA	1.1	17.01	0.87	1.39e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg02487422	chr3:49467188	NICN1	0.63	4.82	0.44	5.48e-6	Resting heart rate;
THYM	cis	rs820077	1.000	rs820077	chr6:35033854	C/T	cg05593667	chr6:35490744	NA	0.48	4.94	0.45	3.4e-6	Systemic lupus erythematosus;
THYM	cis	rs6582630	0.548	rs8189608	chr12:38327775	T/G	cg10518543	chr12:38710700	ALG10B	-0.57	-4.48	-0.42	2.1e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs714031	0.934	rs738315	chr22:40069245	T/C	cg21377881	chr22:40064566	CACNA1I	-0.55	-4.95	-0.45	3.16e-6	Schizophrenia;
THYM	cis	rs526231	0.543	rs27698	chr5:102526175	C/T	cg23492399	chr5:102201601	PAM	0.68	4.98	0.45	2.88e-6	Primary biliary cholangitis;
THYM	cis	rs4642101	0.765	rs6791647	chr3:12826425	C/T	cg05775895	chr3:12838266	CAND2	-0.81	-7.33	-0.6	7.48e-11	QRS complex (12-leadsum);
THYM	cis	rs2562456	0.876	rs11085465	chr19:21751790	A/G	cg21751540	chr19:21541537	ZNF738	0.65	4.53	0.42	1.73e-5	Pain;
THYM	cis	rs10899021	0.920	rs61901540	chr11:74314865	A/G	cg25880958	chr11:74394337	NA	-0.77	-4.66	-0.43	1.04e-5	Response to metformin (IC50);
THYM	cis	rs62070183	0.938	rs4795719	chr17:31103975	C/T	cg23177095	chr17:30873196	MYO1D	0.64	5.02	0.46	2.41e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.99	7.77	0.62	8.97e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9972944	0.756	rs8076925	chr17:63764616	A/C	cg07283582	chr17:63770753	CCDC46	-0.62	-4.63	-0.43	1.16e-5	Total body bone mineral density;
THYM	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg15921436	chr17:44337874	NA	0.78	6.25	0.54	1.17e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1034435	0.547	rs6008741	chr22:48897881	G/A	cg05992904	chr22:48892994	FAM19A5	-0.7	-6.32	-0.54	8.42e-9	Late-onset Alzheimer's disease;
THYM	cis	rs6500602	1.000	rs12447826	chr16:4464617	T/C	cg08645402	chr16:4508243	NA	0.62	5.11	0.46	1.65e-6	Schizophrenia;
THYM	cis	rs10992471	0.603	rs12336415	chr9:95195458	G/T	cg14631576	chr9:95140430	CENPP	-0.99	-9.94	-0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs995000	0.868	rs1168113	chr1:63156098	T/C	cg06896770	chr1:63153194	DOCK7	-0.68	-4.71	-0.44	8.35e-6	Triglyceride levels;
THYM	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg06027949	chr8:82754900	SNX16	-0.61	-4.49	-0.42	2.02e-5	Diastolic blood pressure;
THYM	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg00129232	chr17:37814104	STARD3	0.77	5.27	0.48	8.58e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg04362960	chr10:104952993	NT5C2	0.57	4.68	0.43	9.61e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs17253792	0.822	rs78820104	chr14:56068854	C/T	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.43	-6.6	-0.56	2.33e-9	Obesity-related traits;
THYM	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-5.44	-0.49	4.14e-7	Monocyte percentage of white cells;
THYM	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg06453172	chr10:134556979	INPP5A	-0.61	-4.54	-0.42	1.64e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7917772	0.560	rs7912339	chr10:104373758	G/C	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7828089	0.542	rs7332050	chr8:22265294	G/T	cg13512537	chr8:22265999	SLC39A14	-0.62	-4.9	-0.45	3.98e-6	Verbal declarative memory;
THYM	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg03929089	chr4:120376271	NA	-0.99	-12.83	-0.8	1.9e-22	Height;
THYM	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg08484992	chr16:88977278	CBFA2T3	0.37	4.55	0.42	1.56e-5	Social autistic-like traits;
THYM	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg26418147	chr1:205743515	RAB7L1	-0.58	-5.06	-0.46	2.03e-6	Menarche (age at onset);
THYM	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	trans	rs9951602	0.573	rs8098953	chr18:76648734	A/G	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs2970992	0.764	rs12712081	chr2:101329232	T/C	cg01042948	chr2:101319752	NA	0.6	5.89	0.52	5.76e-8	Educational attainment;
THYM	cis	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg10856724	chr12:34555212	NA	-0.91	-8.9	-0.67	3.68e-14	Morning vs. evening chronotype;
THYM	cis	rs1160297	0.576	rs12475542	chr2:53111504	A/G	cg07782112	chr2:53107842	NA	-0.74	-5.91	-0.52	5.41e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs4654899	1.000	rs7550267	chr1:21448792	T/C	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.26e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs4845875	0.530	rs4846048	chr1:11846252	A/G	cg06193043	chr1:11908199	NPPA	-0.6	-5.19	-0.47	1.18e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs11997175	0.603	rs7001603	chr8:33680978	T/G	ch.8.33884649F	chr8:33765107	NA	0.67	5.09	0.46	1.84e-6	Body mass index;
THYM	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg15556689	chr8:8085844	FLJ10661	0.7	5.84	0.51	7.29e-8	Mood instability;
THYM	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.49	-4.59	-0.43	1.34e-5	Lymphocyte counts;
THYM	cis	rs728616	0.614	rs2146191	chr10:81715754	G/A	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs1981331	0.609	rs7282611	chr21:48043297	C/A	cg23283320	chr21:48055893	PRMT2	1.39	6.71	0.57	1.39e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.64	-0.5	1.73e-7	Menopause (age at onset);
THYM	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg15536230	chr21:44985092	HSF2BP	-0.46	-5.5	-0.49	3.14e-7	Mean corpuscular volume;
THYM	cis	rs4474465	0.850	rs4441045	chr11:78220436	G/T	cg19901956	chr11:77921274	USP35	0.66	4.84	0.44	4.99e-6	Alzheimer's disease (survival time);
THYM	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.79	-0.51	8.87e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8103278	1.000	rs8108590	chr19:46301620	A/G	cg14061069	chr19:46274453	DMPK	-0.58	-5.72	-0.51	1.21e-7	Coronary artery disease;
THYM	cis	rs7731657	0.537	rs10076495	chr5:130362953	A/C	cg08523029	chr5:130500466	HINT1	-0.81	-5.62	-0.5	1.92e-7	Fasting plasma glucose;
THYM	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg14018140	chr10:458528	DIP2C	-0.5	-5.08	-0.46	1.88e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.71	4.87	0.45	4.48e-6	Height;
THYM	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg21926883	chr2:100939477	LONRF2	-0.67	-6.3	-0.54	9.28e-9	Intelligence (multi-trait analysis);
THYM	cis	rs17153755	0.796	rs2645456	chr8:11615182	A/G	cg12395012	chr8:11607386	GATA4	-0.65	-5.2	-0.47	1.15e-6	Testicular germ cell tumor;
THYM	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg03609598	chr5:56110824	MAP3K1	-0.89	-6.07	-0.53	2.63e-8	Initial pursuit acceleration;
THYM	cis	rs73198271	0.740	rs10112989	chr8:8647334	A/C	cg15556689	chr8:8085844	FLJ10661	-0.73	-4.58	-0.43	1.39e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs1843834	0.755	rs10194591	chr2:225574276	T/A	cg10193763	chr2:225306901	NA	-0.43	-4.64	-0.43	1.09e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg16624210	chr5:671434	TPPP	0.76	5.63	0.5	1.86e-7	Obesity-related traits;
THYM	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg08742575	chr21:47604166	C21orf56	0.68	5.41	0.49	4.7e-7	Testicular germ cell tumor;
THYM	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.97	-0.45	2.98e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg15744005	chr10:104629667	AS3MT	0.89	8.97	0.68	2.64e-14	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs3917265	0.591	rs6743219	chr2:102831711	T/C	cg13315345	chr2:102803985	IL1RL2	0.66	7.85	0.63	6.08e-12	Atopic dermatitis;
THYM	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg01017244	chr2:74357527	NA	1.1	9.09	0.68	1.43e-14	Gestational age at birth (maternal effect);
THYM	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg27532560	chr4:187881888	NA	-0.95	-11.83	-0.77	2.15e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.11e-8	Systolic blood pressure;
THYM	cis	rs11190604	1.000	rs6584383	chr10:102303065	C/G	cg16342193	chr10:102329863	NA	-0.53	-5.43	-0.49	4.35e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1430128	0.584	rs11686077	chr2:218458029	A/G	cg27640316	chr2:217799104	NA	0.68	4.87	0.45	4.48e-6	Congenital heart disease (inherited effect);
THYM	cis	rs10256972	0.706	rs7784559	chr7:1002973	A/G	cg02602264	chr7:1026310	CYP2W1	-0.54	-5.13	-0.47	1.54e-6	Longevity;Endometriosis;
THYM	cis	rs4076764	0.846	rs12036398	chr1:163422204	C/T	cg24596788	chr1:163392923	NA	0.76	6.75	0.57	1.16e-9	Motion sickness;
THYM	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg10661904	chr17:79619235	PDE6G	-0.57	-5.3	-0.48	7.61e-7	Eye color traits;
THYM	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg27286337	chr10:134555280	INPP5A	0.9	7.56	0.61	2.49e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs10832963	0.658	rs1972960	chr11:18613336	G/A	cg20219074	chr11:18656078	SPTY2D1	0.65	4.75	0.44	7.28e-6	Breast cancer;
THYM	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg21926883	chr2:100939477	LONRF2	-0.6	-5.46	-0.49	3.87e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7523273	0.565	rs2796232	chr1:207900368	T/A	cg22525895	chr1:207977042	MIR29B2	-0.54	-5.14	-0.47	1.44e-6	Schizophrenia;
THYM	cis	rs9868809	0.656	rs73078362	chr3:48703917	G/C	cg00383909	chr3:49044727	WDR6	1.5	6.61	0.56	2.23e-9	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	5.38	0.48	5.27e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4363385	0.818	rs946096	chr1:153006529	T/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs9399401	0.601	rs262113	chr6:142824950	T/G	cg04461802	chr6:142623433	GPR126	0.58	5.21	0.47	1.07e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg13397359	chr6:42928475	GNMT	0.61	5.49	0.49	3.39e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2732480	0.577	rs2732479	chr12:48736260	A/C	cg21466736	chr12:48725269	NA	-0.59	-5.43	-0.49	4.36e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg20387954	chr3:183756860	HTR3D	0.57	4.76	0.44	6.96e-6	Anterior chamber depth;
THYM	cis	rs28493229	0.522	rs17713068	chr19:41270055	A/C	cg21869046	chr19:41225005	ITPKC	0.51	4.9	0.45	3.96e-6	Kawasaki disease;
THYM	cis	rs12956009	0.583	rs9653016	chr18:44894189	G/A	cg19077165	chr18:44547161	KATNAL2	-0.49	-4.7	-0.43	8.81e-6	Educational attainment (years of education);
THYM	cis	rs9928842	0.941	rs8057145	chr16:75256251	A/G	cg09066997	chr16:75300724	BCAR1	0.77	4.98	0.45	2.87e-6	Alcoholic chronic pancreatitis;
THYM	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-4.45	-0.42	2.35e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg11366901	chr6:160182831	ACAT2	1.05	9.61	0.7	1.11e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9560113	0.597	rs1163644	chr13:112241223	C/T	cg15979348	chr13:112237479	NA	-0.54	-5.14	-0.47	1.48e-6	Menarche (age at onset);
THYM	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg16325326	chr1:53192061	ZYG11B	0.76	5.99	0.52	3.68e-8	Monocyte count;
THYM	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg12310025	chr6:25882481	NA	-0.66	-4.58	-0.43	1.4e-5	Height;
THYM	cis	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg01416388	chr22:39784598	NA	-0.92	-7.18	-0.59	1.53e-10	Post bronchodilator FEV1;
THYM	cis	rs3087591	0.922	rs2905801	chr17:29524974	C/T	cg24425628	chr17:29625626	OMG;NF1	0.68	5.44	0.49	4.14e-7	Hip circumference;
THYM	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.36	0.48	5.75e-7	Height;
THYM	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg24675658	chr1:53192096	ZYG11B	-0.74	-6.03	-0.53	3.17e-8	Monocyte count;
THYM	cis	rs7722022	0.635	rs17738166	chr5:172997978	C/T	cg20434911	chr5:173954559	NA	-0.52	-4.67	-0.43	9.74e-6	Adiponectin levels;
THYM	cis	rs11577318	0.579	rs11247936	chr1:26698884	A/G	cg19677267	chr1:26645161	CD52;UBXN11	0.5	5.56	0.5	2.52e-7	Granulocyte percentage of myeloid white cells;
THYM	cis	rs11048434	0.736	rs35870866	chr12:9129091	C/A	cg13575925	chr12:9217583	LOC144571	0.52	5.04	0.46	2.24e-6	Sjögren's syndrome;
THYM	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg20486651	chr6:167070296	RPS6KA2	0.5	4.73	0.44	7.7e-6	Lung cancer;
THYM	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.91	7.42	0.61	4.82e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7772486	0.875	rs9322043	chr6:146352690	A/G	cg23711669	chr6:146136114	FBXO30	0.97	10.4	0.73	2.29e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg22920501	chr2:26401640	FAM59B	-0.82	-7.38	-0.6	5.95e-11	Gut microbiome composition (summer);
THYM	cis	rs7917772	0.582	rs4408249	chr10:104374653	T/A	cg00122347	chr10:104236741	TMEM180	-0.41	-5.83	-0.51	7.59e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs9326248	0.861	rs4938353	chr11:117046197	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.67	4.78	0.44	6.35e-6	Blood protein levels;
THYM	cis	rs10779751	0.922	rs2295079	chr1:11322565	C/G	cg08854313	chr1:11322531	MTOR	1.02	9.98	0.72	1.8e-16	Body mass index;
THYM	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg05373962	chr22:49881684	NA	-0.67	-6.8	-0.57	9.16e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs56104184	0.887	rs55869333	chr19:49342145	T/G	cg21252483	chr19:49399788	TULP2	-0.67	-4.66	-0.43	1.03e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs1461503	0.966	rs7944630	chr11:122838844	G/A	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	trans	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg25214090	chr10:38739885	LOC399744	-0.93	-7.97	-0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs747782	0.585	rs1604655	chr11:48274778	G/A	cg24672777	chr11:48374446	OR4C45	-1.17	-7.15	-0.59	1.78e-10	Intraocular pressure;
THYM	cis	rs3826795	0.569	rs73059726	chr19:46797194	G/A	cg15229275	chr19:46800054	HIF3A	0.92	5.54	0.49	2.69e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs877282	0.898	rs12356709	chr10:763365	A/G	cg10556349	chr10:835070	NA	-0.78	-5.06	-0.46	2.06e-6	Uric acid levels;
THYM	cis	rs59197085	0.636	rs4731515	chr7:128450592	A/G	cg00734629	chr7:128471146	FLNC	0.77	4.61	0.43	1.27e-5	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
THYM	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg18904891	chr8:8559673	CLDN23	0.65	4.9	0.45	3.88e-6	Obesity-related traits;
THYM	cis	rs919433	0.679	rs61155920	chr2:198528881	C/T	cg00792783	chr2:198669748	PLCL1	0.82	5.44	0.49	4.16e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs1692120	0.669	rs61898510	chr11:61425464	T/C	cg19838087	chr11:61442541	NA	0.61	7.2	0.59	1.41e-10	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
THYM	cis	rs10431058	1.000	rs10431058	chr11:107481518	A/G	cg18204760	chr11:107461044	ELMOD1;LOC643923	-0.76	-5.87	-0.52	6.31e-8	Common traits (Other);
THYM	cis	rs7772486	0.840	rs2814864	chr6:146345046	A/C	cg13319975	chr6:146136371	FBXO30	-0.69	-6.03	-0.53	3.14e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg11812906	chr14:75593930	NEK9	0.8	7.18	0.59	1.51e-10	Height;
THYM	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg24375607	chr4:120327624	NA	0.64	5.37	0.48	5.67e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg26384229	chr12:38710491	ALG10B	0.7	5.28	0.48	8.04e-7	Morning vs. evening chronotype;
THYM	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg02398342	chr17:80708632	TBCD;FN3K	0.7	5.27	0.48	8.69e-7	Glycated hemoglobin levels;
THYM	cis	rs9522267	0.708	rs914032	chr13:112241019	G/A	cg10483660	chr13:112241077	NA	0.6	6.35	0.55	7.41e-9	Hepatitis;
THYM	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg22535103	chr8:58192502	C8orf71	-0.93	-4.56	-0.42	1.52e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.91	-6.52	-0.56	3.31e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg10018233	chr7:150070692	REPIN1	0.47	6.85	0.58	7.26e-10	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7695732	0.595	rs7692455	chr4:89908249	A/G	cg17769793	chr4:89976368	FAM13A	-0.49	-5.4	-0.48	4.81e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Bladder cancer;
THYM	cis	rs28785552	0.800	rs10853854	chr19:53232128	A/G	cg22067481	chr19:53234126	ZNF611	0.92	9.88	0.71	2.91e-16	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg24818145	chr4:99064322	C4orf37	0.9	7.36	0.6	6.5e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs863345	0.604	rs59427353	chr1:158500621	A/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs7246657	0.765	rs10402455	chr19:37728707	G/A	cg22634378	chr19:37742834	NA	0.68	5.62	0.5	1.91e-7	Coronary artery calcification;
THYM	cis	rs7107174	1.000	rs2510043	chr11:77977481	C/G	cg19901956	chr11:77921274	USP35	-0.65	-5.02	-0.46	2.45e-6	Testicular germ cell tumor;
THYM	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg02136620	chr5:178986620	RUFY1	-0.55	-5.56	-0.5	2.45e-7	Lung cancer;
THYM	cis	rs4901869	0.902	rs2162491	chr14:59296247	C/T	cg02291164	chr14:59296302	NA	0.99	10.83	0.74	2.81e-18	Panic disorder;
THYM	cis	rs3126085	0.935	rs1466757	chr1:152212469	G/A	cg26020982	chr1:152196106	HRNR	0.37	5.06	0.46	2.05e-6	Atopic dermatitis;
THYM	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7084921	0.558	rs2862925	chr10:101817557	C/T	cg20925178	chr10:102027628	CWF19L1	0.73	5.75	0.51	1.09e-7	Bone mineral density;
THYM	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg17372223	chr3:52568218	NT5DC2	0.31	4.78	0.44	6.34e-6	Cognitive function;
THYM	cis	rs4363385	0.588	rs11205180	chr1:153022070	A/G	cg13444842	chr1:152974279	SPRR3	-0.62	-4.98	-0.45	2.89e-6	Inflammatory skin disease;
THYM	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.49	-0.55	3.89e-9	Chronic sinus infection;
THYM	cis	rs35995292	1.000	rs9638944	chr7:38947417	T/C	cg19166347	chr7:37955598	SFRP4	0.61	4.84	0.44	4.99e-6	Subjective well-being (multi-trait analysis);
THYM	cis	rs950880	0.710	rs10490204	chr2:103056534	A/C	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.66	-0.43	1.04e-5	Serum protein levels (sST2);
THYM	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg11494091	chr17:61959527	GH2	0.69	6.23	0.54	1.27e-8	Height;
THYM	cis	rs600550	0.588	rs12225299	chr11:60084465	C/T	cg05040360	chr11:60102449	MS4A6E	-0.52	-4.97	-0.45	3.02e-6	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs236907	0.859	rs17649609	chr1:171738453	G/A	cg20598894	chr1:171756153	METTL13	-0.72	-5.04	-0.46	2.23e-6	Mean platelet volume;
THYM	cis	rs10489202	0.608	rs10800334	chr1:168075613	T/C	cg24449463	chr1:168025552	DCAF6	-0.69	-5.96	-0.52	4.22e-8	Schizophrenia;
THYM	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg08048268	chr3:133502702	NA	-0.67	-5.37	-0.48	5.6e-7	Iron status biomarkers;
THYM	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg11764359	chr7:65958608	NA	-0.7	-4.89	-0.45	4.09e-6	Aortic root size;
THYM	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg08045932	chr20:61659980	NA	0.95	10.49	0.73	1.46e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11671005	0.695	rs12972898	chr19:58956888	A/G	cg02808233	chr19:58920810	ZNF584	0.57	4.53	0.42	1.73e-5	Mean platelet volume;
THYM	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg00071950	chr4:10020882	SLC2A9	-0.74	-7.2	-0.59	1.42e-10	Bone mineral density;
THYM	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.77	6.96	0.58	4.42e-10	Menarche (age at onset);
THYM	cis	rs6732160	0.691	rs6728147	chr2:73423490	A/G	cg24220031	chr2:73402428	NA	0.79	9.35	0.69	3.98e-15	Intelligence (multi-trait analysis);
THYM	cis	rs2456568	0.709	rs1354765	chr11:93637776	G/T	cg26875233	chr11:93583750	C11orf90	0.49	5.37	0.48	5.63e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg16049864	chr8:95962084	TP53INP1	0.77	6.41	0.55	5.47e-9	Type 2 diabetes;
THYM	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg16797656	chr11:68205561	LRP5	-0.45	-4.78	-0.44	6.46e-6	Total body bone mineral density;
THYM	cis	rs854765	0.718	rs12943500	chr17:17790588	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-5.77	-0.51	1e-7	Total body bone mineral density;
THYM	cis	rs2270875	0.696	rs10464871	chr8:132931374	C/T	cg15420926	chr8:132929147	EFR3A	0.63	4.82	0.44	5.33e-6	Response to cholinesterase inhibitors in Alzheimer's disease;
THYM	cis	rs939658	1.000	rs939658	chr15:79451869	A/G	cg17916960	chr15:79447300	NA	0.75	8.81	0.67	5.71e-14	Refractive error;
THYM	cis	rs7412746	0.571	rs12402939	chr1:150615094	A/C	cg10589385	chr1:150898437	SETDB1	0.71	5.9	0.52	5.47e-8	Melanoma;
THYM	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg12310025	chr6:25882481	NA	-0.93	-8.16	-0.64	1.36e-12	Intelligence (multi-trait analysis);
THYM	cis	rs17854409	1.000	rs6011427	chr20:61496680	C/T	cg05147244	chr20:61493195	TCFL5	0.99	6.31	0.54	8.71e-9	Obesity-related traits;
THYM	cis	rs472402	0.580	rs4702373	chr5:6633222	C/T	cg12648172	chr5:5886274	NA	0.5	4.55	0.42	1.58e-5	Response to amphetamines;
THYM	cis	rs17020663	0.552	rs6705837	chr2:101652733	G/A	cg12594615	chr2:101643137	TBC1D8	-0.78	-4.79	-0.44	6.2e-6	Pulse pressure;
THYM	cis	rs7191700	0.511	rs8058983	chr16:11360849	A/G	cg00044050	chr16:11439710	C16orf75	-0.74	-5.53	-0.49	2.78e-7	Multiple sclerosis;
THYM	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.99	-0.75	1.26e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg05657792	chr17:6899758	ALOX12	0.48	4.88	0.45	4.33e-6	Tonsillectomy;
THYM	cis	rs4836694	0.574	rs3780712	chr9:132943082	A/G	cg13414629	chr9:132935646	FREQ	0.74	5.2	0.47	1.13e-6	Alzheimer's disease (cognitive decline);
THYM	cis	rs2219968	0.923	rs11779013	chr8:78930177	T/C	cg00738934	chr8:78996279	NA	0.81	8.73	0.67	8.35e-14	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs17401966	0.964	rs2027331	chr1:10276718	C/T	cg20482658	chr1:10539492	PEX14	0.4	4.79	0.44	6.2e-6	Hepatocellular carcinoma;
THYM	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg11247378	chr22:39784982	NA	-1.07	-13.85	-0.82	1.61e-24	Intelligence (multi-trait analysis);
THYM	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg18758796	chr5:131593413	PDLIM4	-0.5	-4.8	-0.44	5.79e-6	Acylcarnitine levels;
THYM	cis	rs7255045	0.742	rs4804738	chr19:12953183	T/G	cg26870725	chr19:12978805	MAST1	-0.62	-4.61	-0.43	1.27e-5	Mean corpuscular volume;
THYM	cis	rs7589342	0.839	rs7589790	chr2:106433909	C/G	cg14210321	chr2:106509881	NCK2	0.69	4.86	0.45	4.58e-6	Addiction;
THYM	cis	rs367615	0.918	rs10070104	chr5:108866438	C/T	cg17395555	chr5:108820864	NA	-0.53	-4.8	-0.44	5.95e-6	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs4482178	0.511	rs17648233	chr13:86293462	C/T	cg25308322	chr13:86268291	NA	0.68	4.55	0.42	1.57e-5	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg13695892	chr22:41940480	POLR3H	-0.78	-6.67	-0.56	1.66e-9	Vitiligo;
THYM	cis	rs490234	0.676	rs12202	chr9:128200299	C/G	cg14078157	chr9:128172775	NA	-0.72	-5.55	-0.49	2.6e-7	Mean arterial pressure;
THYM	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.32	8.79	0.67	6.27e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg06634786	chr22:41940651	POLR3H	0.69	4.54	0.42	1.65e-5	Vitiligo;
THYM	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg11764359	chr7:65958608	NA	0.62	4.73	0.44	7.94e-6	Aortic root size;
THYM	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg16230307	chr14:35515116	FAM177A1	0.83	5.29	0.48	7.72e-7	Psoriasis;
THYM	cis	rs7829975	0.653	rs13259070	chr8:8690787	C/T	cg06636001	chr8:8085503	FLJ10661	0.74	6.55	0.56	2.93e-9	Mood instability;
THYM	cis	rs870825	0.616	rs3184982	chr4:185615768	T/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs5758659	0.819	rs134871	chr22:42652716	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.38	-4.52	-0.42	1.78e-5	Cognitive function;
THYM	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg23332699	chr15:44069569	ELL3	0.73	4.71	0.43	8.55e-6	Lung cancer in ever smokers;
THYM	cis	rs41005	0.967	rs6753101	chr2:8104849	G/T	cg03155496	chr2:8117019	LOC339788	-0.99	-9.09	-0.68	1.44e-14	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs6546324	0.625	rs2861645	chr2:67800338	T/A	cg18237512	chr2:67827392	NA	-0.8	-4.74	-0.44	7.44e-6	Endometriosis;
THYM	cis	rs9399401	0.523	rs171915	chr6:142866845	C/T	cg03128060	chr6:142623767	GPR126	0.51	6.13	0.53	1.99e-8	Chronic obstructive pulmonary disease;
THYM	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg24399712	chr22:39784796	NA	-0.93	-11.14	-0.75	6.12e-19	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg25214090	chr10:38739885	LOC399744	0.85	7.16	0.59	1.7e-10	Corneal astigmatism;
THYM	cis	rs946836	0.537	rs12724210	chr1:48367147	T/C	cg18376692	chr1:48452465	NA	-0.52	-5.08	-0.46	1.84e-6	White matter integrity;
THYM	cis	rs2898681	1.000	rs2046364	chr4:53743218	G/T	cg00791764	chr4:53727839	RASL11B	0.46	5.5	0.49	3.2e-7	Optic nerve measurement (cup area);
THYM	cis	rs9826463	0.582	rs114066728	chr3:142022265	T/C	cg20824294	chr3:142316082	PLS1	0.76	5.28	0.48	8.31e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs12280210	0.557	rs11216225	chr11:116878014	A/G	cg20608306	chr11:116969690	SIK3	-0.71	-5.22	-0.47	1.04e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg02493798	chr17:6899577	ALOX12	0.62	8.08	0.64	2.06e-12	Tonsillectomy;
THYM	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17125944	0.686	rs4901305	chr14:53364271	C/T	cg00686598	chr14:53173677	PSMC6	-1.01	-4.55	-0.42	1.56e-5	Alzheimer's disease (late onset);
THYM	cis	rs4788570	0.584	rs7204608	chr16:71678679	C/G	cg06353428	chr16:71660113	MARVELD3	-1.02	-7.08	-0.59	2.45e-10	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.73	5.1	0.46	1.72e-6	Gut microbiome composition (summer);
THYM	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4950928	0.823	rs946262	chr1:203158229	C/T	cg14085262	chr1:203155938	CHI3L1	0.67	4.47	0.42	2.12e-5	YKL-40 levels;
THYM	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg24531977	chr5:56204891	C5orf35	0.98	7.71	0.62	1.22e-11	Initial pursuit acceleration;
THYM	cis	rs28595532	0.841	rs112953035	chr4:119752450	T/C	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs2033562	0.965	rs13250010	chr8:103545983	T/G	cg20611272	chr8:103548145	NA	0.4	4.78	0.44	6.49e-6	IgA nephropathy;
THYM	cis	rs4849845	0.889	rs4849846	chr2:121026891	T/C	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs4242434	0.672	rs3758042	chr8:22486951	T/C	cg03733263	chr8:22462867	KIAA1967	1.0	11.13	0.75	6.58e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7224314	1.000	rs8066725	chr17:65387326	G/A	cg01507342	chr17:65387096	PITPNC1	-0.97	-10.88	-0.74	2.26e-18	Diisocyanate-induced asthma;
THYM	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	5.56	0.5	2.45e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10206020	0.921	rs72778005	chr2:1573122	C/G	cg12573674	chr2:1569213	NA	-1.35	-9.07	-0.68	1.57e-14	IgG glycosylation;
THYM	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg00376283	chr12:123451042	ABCB9	0.68	5.22	0.47	1.04e-6	Neutrophil percentage of white cells;
THYM	cis	rs2290159	0.800	rs3773345	chr3:12642945	G/C	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs4845459	0.967	rs6700290	chr1:152592978	T/A	cg26135325	chr1:152595322	LCE3A	-0.45	-5.13	-0.47	1.54e-6	Psoriasis;
THYM	cis	rs6840360	0.571	rs4696271	chr4:152509118	G/A	cg22705602	chr4:152727874	NA	-0.77	-8.21	-0.64	1.08e-12	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	trans	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg19862616	chr7:65841803	NCRNA00174	1.11	13.58	0.81	5.5e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.24	-0.47	9.51e-7	Menopause (age at onset);
THYM	cis	rs793571	0.521	rs12594872	chr15:58912749	T/C	cg05156742	chr15:59063176	FAM63B	0.6	5.0	0.46	2.65e-6	Schizophrenia;
THYM	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg09323728	chr8:95962352	TP53INP1	-0.47	-4.53	-0.42	1.72e-5	Type 2 diabetes;
THYM	cis	rs9649213	0.593	rs6973775	chr7:98004685	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Gout;
THYM	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7172809	0.548	rs11856513	chr15:77471105	A/C	cg22256960	chr15:77711686	NA	0.64	4.76	0.44	6.83e-6	Glucose homeostasis traits;
THYM	cis	rs2219968	0.525	rs4626583	chr8:78882733	C/T	cg00738934	chr8:78996279	NA	0.61	4.95	0.45	3.21e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9311676	0.656	rs34579268	chr3:58410554	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg20887711	chr4:1340912	KIAA1530	0.97	8.91	0.67	3.52e-14	Longevity;
THYM	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg19610905	chr11:61596333	FADS2	-0.62	-5.13	-0.47	1.55e-6	Trans fatty acid levels;
THYM	cis	rs8048589	1.000	rs12596549	chr16:12183500	C/A	cg01990910	chr16:12207648	SNX29	-0.43	-4.81	-0.44	5.72e-6	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg03690763	chr11:133734501	NA	-0.61	-4.7	-0.43	8.84e-6	Childhood ear infection;
THYM	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg08847533	chr14:75593920	NEK9	-0.91	-9.52	-0.7	1.8e-15	Height;
THYM	cis	rs514406	0.825	rs12089511	chr1:53436427	A/T	cg22166914	chr1:53195759	ZYG11B	-0.77	-7.61	-0.62	1.98e-11	Monocyte count;
THYM	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg03929089	chr4:120376271	NA	-0.98	-7.35	-0.6	6.73e-11	Coronary artery disease;
THYM	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg18252515	chr7:66147081	NA	-0.67	-5.08	-0.46	1.86e-6	Aortic root size;
THYM	cis	rs7119038	0.818	rs11217033	chr11:118673706	T/C	cg19308663	chr11:118741387	NA	0.57	5.87	0.52	6.34e-8	Sjögren's syndrome;
THYM	cis	rs12216545	0.765	rs10235836	chr7:150231373	C/T	cg00323915	chr7:150264987	GIMAP4	0.49	4.47	0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs900145	0.814	rs12290622	chr11:13314307	A/G	cg13286116	chr11:13302098	ARNTL	0.59	4.73	0.44	7.89e-6	Menarche (age at onset);
THYM	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg18876405	chr7:65276391	NA	-0.61	-5.2	-0.47	1.13e-6	Aortic root size;
THYM	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg11245990	chr11:68621969	NA	0.54	6.64	0.56	1.92e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs3126085	0.877	rs7543541	chr1:152230878	T/C	cg10321714	chr1:152280068	FLG	0.64	4.81	0.44	5.57e-6	Atopic dermatitis;
THYM	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg06481639	chr22:41940642	POLR3H	-0.74	-4.85	-0.45	4.81e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg17554472	chr22:41940697	POLR3H	0.57	4.51	0.42	1.87e-5	Vitiligo;
THYM	cis	rs42648	0.869	rs12374728	chr7:89941884	T/C	cg25739043	chr7:89950458	NA	-0.53	-4.53	-0.42	1.72e-5	Homocysteine levels;
THYM	cis	rs7264396	0.887	rs224362	chr20:34062642	C/T	cg26038318	chr20:34205095	SPAG4	0.55	4.59	0.43	1.38e-5	Total cholesterol levels;
THYM	cis	rs7901056	0.935	rs35055608	chr10:26715547	A/T	cg23318538	chr10:26883079	C10orf50	0.37	4.95	0.45	3.23e-6	Lymphocyte counts;
THYM	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg24209194	chr3:40518798	ZNF619	0.62	4.91	0.45	3.77e-6	Renal cell carcinoma;
THYM	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg16586182	chr3:47516702	SCAP	-0.63	-5.25	-0.47	9.07e-7	Colorectal cancer;
THYM	cis	rs7580658	0.724	rs6712213	chr2:127998230	G/A	cg10021288	chr2:128175891	PROC	-0.7	-6.14	-0.53	1.93e-8	Protein C levels;
THYM	cis	rs12446552	0.960	rs12444013	chr16:11708846	C/T	cg09662852	chr16:11707685	NA	-0.61	-5.77	-0.51	1.01e-7	Colorectal or endometrial cancer;
THYM	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg23978390	chr7:1156363	C7orf50	0.59	4.48	0.42	2.1e-5	Longevity;Endometriosis;
THYM	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg17294928	chr15:75287854	SCAMP5	-1.02	-9.12	-0.68	1.26e-14	Blood trace element (Zn levels);
THYM	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg23161317	chr6:28129485	ZNF389	1.02	7.95	0.63	3.81e-12	Depression;
THYM	cis	rs9807989	0.524	rs7591246	chr2:102999403	C/A	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs2108225	0.934	rs2190392	chr7:107452685	T/C	cg18560240	chr7:107437656	SLC26A3	-0.82	-6.28	-0.54	1.01e-8	Ulcerative colitis;
THYM	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg24154853	chr7:158122151	PTPRN2	0.58	5.2	0.47	1.16e-6	Calcium levels;
THYM	cis	rs888405	0.588	rs222336	chr3:64232104	A/C	cg25818214	chr3:64211155	PRICKLE2	-0.62	-4.77	-0.44	6.76e-6	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
THYM	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg07636037	chr3:49044803	WDR6	1.02	10.58	0.74	9.59e-18	Parkinson's disease;
THYM	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg21394778	chr1:3037102	PRDM16	0.49	4.77	0.44	6.57e-6	Height;
THYM	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg18252515	chr7:66147081	NA	0.65	4.75	0.44	7.28e-6	Aortic root size;
THYM	cis	rs11960314	0.717	rs883848	chr5:170070942	A/C	cg00239490	chr5:170221919	GABRP	0.72	4.54	0.42	1.65e-5	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg02527881	chr3:46936655	PTH1R	-0.68	-6.97	-0.58	4.19e-10	Colorectal cancer;
THYM	cis	rs611744	0.967	rs859788	chr8:109227570	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.15	0.47	1.38e-6	Dupuytren's disease;
THYM	cis	rs7312774	0.881	rs1822737	chr12:107309175	A/G	cg16260113	chr12:107380972	MTERFD3	0.97	5.63	0.5	1.84e-7	Severe influenza A (H1N1) infection;
THYM	cis	rs6964587	0.610	rs6465338	chr7:91450624	T/C	cg22709100	chr7:91322751	NA	0.62	4.47	0.42	2.19e-5	Breast cancer;
THYM	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	4.92	0.45	3.66e-6	Hip circumference adjusted for BMI;
THYM	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg01831904	chr17:28903510	LRRC37B2	0.9	4.93	0.45	3.55e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg24955955	chr5:415729	AHRR	1.02	5.72	0.51	1.21e-7	Fat distribution (HIV);
THYM	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg24642844	chr7:1081250	C7orf50	-1.29	-8.31	-0.65	6.62e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg11526020	chr17:80870163	TBCD	0.43	4.52	0.42	1.75e-5	Glycated hemoglobin levels;
THYM	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg07636037	chr3:49044803	WDR6	0.8	5.08	0.46	1.89e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs919433	0.680	rs1116734	chr2:198365043	C/G	cg05783139	chr2:198650985	BOLL	0.59	4.49	0.42	2.02e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2898681	0.770	rs10032190	chr4:53734940	C/A	cg21521518	chr4:53727714	RASL11B	0.43	4.89	0.45	4.13e-6	Optic nerve measurement (cup area);
THYM	cis	rs9649213	0.593	rs10808107	chr7:97951671	T/C	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.52	-0.42	1.79e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg03929089	chr4:120376271	NA	-0.81	-8.23	-0.65	9.73e-13	Height;
THYM	cis	rs7582180	0.614	rs1530031	chr2:101009326	T/C	cg14675211	chr2:100938903	LONRF2	0.64	6.17	0.53	1.69e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7772486	0.754	rs702306	chr6:145991029	T/C	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.54e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg22467129	chr15:76604101	ETFA	-0.56	-5.26	-0.47	9.01e-7	Blood metabolite levels;
THYM	cis	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg07460842	chr6:66804631	NA	1.11	8.12	0.64	1.7e-12	Exhaled nitric oxide output;
THYM	cis	rs8180040	0.739	rs66539935	chr3:47025327	C/T	cg16586182	chr3:47516702	SCAP	0.57	4.97	0.45	2.96e-6	Colorectal cancer;
THYM	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg13695892	chr22:41940480	POLR3H	0.87	6.35	0.55	7.28e-9	Vitiligo;
THYM	cis	rs34526934	0.830	rs13028842	chr2:177042261	A/G	cg14324370	chr2:177042789	NA	-0.72	-5.74	-0.51	1.14e-7	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs72828912	0.665	rs11756314	chr6:24074700	C/A	cg26336265	chr6:25042955	NA	-0.87	-5.53	-0.49	2.85e-7	Squamous cell lung carcinoma;
THYM	cis	rs9796	0.689	rs9888718	chr15:41446254	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.6	-4.76	-0.44	6.79e-6	Menopause (age at onset);
THYM	cis	rs12216545	0.765	rs12538768	chr7:150250000	A/G	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.54	-0.56	3.08e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs629535	0.814	rs56326813	chr8:70107736	T/A	cg21567404	chr3:27674614	NA	-1.06	-9.7	-0.71	7.22e-16	Dupuytren's disease;
THYM	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg04476341	chr5:669733	TPPP	0.63	5.44	0.49	4.07e-7	Obesity-related traits;
THYM	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg14186256	chr22:23484241	RTDR1	0.93	8.55	0.66	2.02e-13	Bone mineral density;
THYM	cis	rs6785206	0.614	rs35904610	chr3:128452108	T/C	cg16766828	chr3:128327626	NA	0.47	4.6	0.43	1.29e-5	Lymphocyte percentage of white cells;
THYM	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7943358	0.955	rs10741681	chr11:15704840	C/T	cg11966998	chr11:15692519	NA	-0.51	-5.29	-0.48	7.75e-7	Gut microbiome composition (summer);
THYM	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg11845111	chr2:191398756	TMEM194B	-1.01	-8.13	-0.64	1.61e-12	Diastolic blood pressure;
THYM	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg04518342	chr5:131593106	PDLIM4	0.47	5.06	0.46	2.05e-6	Blood metabolite levels;
THYM	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg13246856	chr1:44399776	ARTN	0.47	4.86	0.45	4.68e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs548181	0.736	rs556884	chr11:125550049	G/A	cg03464685	chr11:125439445	EI24	1.41	7.71	0.62	1.21e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs17739167	0.550	rs6493013	chr15:42224824	T/C	cg20935245	chr15:42234343	EHD4	0.4	4.59	0.43	1.38e-5	Monocyte count;
THYM	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg01483505	chr11:975446	AP2A2	0.58	4.75	0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9388451	0.874	rs9388454	chr6:126115383	A/C	cg10911889	chr6:126070802	HEY2	0.56	4.47	0.42	2.18e-5	Brugada syndrome;
THYM	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg01264106	chr22:38071602	LGALS1	0.36	4.55	0.42	1.56e-5	Fat distribution (HIV);
THYM	cis	rs7894051	0.764	rs1049951	chr10:135184126	G/A	cg14353649	chr10:135191496	PAOX	-0.79	-4.9	-0.45	3.96e-6	Lifespan;
THYM	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg15592062	chr6:167189543	RPS6KA2	0.58	5.8	0.51	8.65e-8	Crohn's disease;
THYM	cis	rs688020	1.000	rs673500	chr7:4229445	C/G	cg05697832	chr7:4257050	SDK1	0.75	6.73	0.57	1.31e-9	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
THYM	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg15744005	chr10:104629667	AS3MT	-0.83	-7.67	-0.62	1.47e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg20891558	chr2:74357851	NA	1.21	13.1	0.8	5.25e-23	Gestational age at birth (maternal effect);
THYM	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg05425664	chr17:57184151	TRIM37	0.59	4.75	0.44	7.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11249608	0.548	rs11958355	chr5:178451640	T/C	cg01312482	chr5:178451176	ZNF879	-0.76	-6.36	-0.55	7.14e-9	Pubertal anthropometrics;
THYM	cis	rs854765	0.583	rs8065416	chr17:17851162	C/T	cg04398451	chr17:18023971	MYO15A	-0.78	-7.23	-0.6	1.22e-10	Total body bone mineral density;
THYM	cis	rs11651000	0.857	rs11658383	chr17:45842354	A/C	cg06532163	chr17:45867833	NA	0.62	6.16	0.53	1.72e-8	IgG glycosylation;
THYM	cis	rs314370	0.904	rs13244629	chr7:100509253	A/C	cg08558340	chr7:100472263	SRRT	0.61	4.99	0.46	2.75e-6	Resting heart rate;
THYM	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg03351412	chr1:154909251	PMVK	0.68	5.08	0.46	1.89e-6	Prostate cancer;
THYM	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	5.3	0.48	7.48e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg00278517	chr6:167070616	RPS6KA2	-0.35	-4.58	-0.42	1.44e-5	Crohn's disease;
THYM	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg17279839	chr7:150038598	RARRES2	0.53	5.17	0.47	1.31e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	4.62	0.43	1.22e-5	Cognitive test performance;
THYM	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg11871910	chr12:69753446	YEATS4	1.01	9.87	0.71	3.09e-16	Cerebrospinal fluid biomarker levels;
THYM	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg18876405	chr7:65276391	NA	0.61	5.2	0.47	1.13e-6	Aortic root size;
THYM	cis	rs10857712	0.528	rs2265638	chr10:135217175	A/G	cg00491522	chr10:135256596	NA	0.69	6.01	0.52	3.47e-8	Systemic lupus erythematosus;
THYM	cis	rs7524258	0.900	rs4908611	chr1:7313861	G/A	cg07173049	chr1:7289937	CAMTA1	0.69	5.64	0.5	1.76e-7	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg12379764	chr21:47803548	PCNT	-0.77	-4.73	-0.44	7.87e-6	Testicular germ cell tumor;
THYM	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg14582100	chr15:45693742	SPATA5L1	0.61	4.97	0.45	2.99e-6	Homoarginine levels;
THYM	cis	rs3857067	0.806	rs17374832	chr4:95114394	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg05717871	chr11:638507	DRD4	-0.64	-5.11	-0.46	1.69e-6	Systemic lupus erythematosus;
THYM	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg07636037	chr3:49044803	WDR6	0.75	4.65	0.43	1.06e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	trans	rs8002861	0.870	rs4942254	chr13:44451820	C/T	cg17145862	chr1:211918768	LPGAT1	0.94	9.74	0.71	6.04e-16	Leprosy;
THYM	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2625529	0.652	rs2929518	chr15:72332748	A/C	cg16672083	chr15:72433130	SENP8	0.49	4.56	0.42	1.55e-5	Red blood cell count;
THYM	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg12826209	chr6:26865740	GUSBL1	0.79	5.62	0.5	1.92e-7	Intelligence (multi-trait analysis);
THYM	cis	rs921968	0.509	rs626432	chr2:219355658	C/A	cg02176678	chr2:219576539	TTLL4	0.73	7.09	0.59	2.4e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs526231	0.543	rs158395	chr5:102411389	T/C	cg23492399	chr5:102201601	PAM	-0.67	-4.96	-0.45	3.05e-6	Primary biliary cholangitis;
THYM	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg26408565	chr15:76604113	ETFA	-0.55	-4.77	-0.44	6.55e-6	Blood metabolite levels;
THYM	cis	rs863345	0.604	rs1873511	chr1:158461366	C/T	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg06636001	chr8:8085503	FLJ10661	0.61	5.22	0.47	1.06e-6	Neuroticism;
THYM	cis	rs7772486	0.566	rs735536	chr6:146036832	A/C	cg13319975	chr6:146136371	FBXO30	0.67	5.31	0.48	7.2e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg24308560	chr3:49941425	MST1R	-0.79	-6.8	-0.57	9.05e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7620363	0.928	rs34796816	chr3:34013455	T/G	cg25105657	chr3:33925802	NA	0.4	4.69	0.43	9.27e-6	Non-substance related behavioral disinhibition;
THYM	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg09307838	chr4:120376055	NA	0.71	5.07	0.46	1.98e-6	Corneal astigmatism;
THYM	cis	rs11690935	0.550	rs11676438	chr2:172826668	G/A	cg13550731	chr2:172543902	DYNC1I2	0.58	4.48	0.42	2.07e-5	Schizophrenia;
THYM	cis	rs1371867	0.846	rs1788197	chr8:101290928	T/C	cg06636551	chr8:101224915	SPAG1	-0.61	-5.91	-0.52	5.3e-8	Atrioventricular conduction;
THYM	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs4638749	0.677	rs7595399	chr2:108835943	C/G	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.78	-6.74	-0.57	1.22e-9	Intelligence (multi-trait analysis);
THYM	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg26412358	chr1:26503933	CNKSR1	-0.36	-5.01	-0.46	2.48e-6	Height;
THYM	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg08736216	chr1:53307985	ZYG11A	-0.75	-6.62	-0.56	2.12e-9	Monocyte count;
THYM	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg22841779	chr14:105766346	BRF1	-0.49	-6.09	-0.53	2.42e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs73198271	0.700	rs10090152	chr8:8652104	C/A	cg15556689	chr8:8085844	FLJ10661	-0.75	-4.95	-0.45	3.2e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg08859206	chr1:53392774	SCP2	-0.66	-7.55	-0.61	2.7e-11	Monocyte count;
THYM	cis	rs1865721	0.771	rs7228890	chr18:73137492	C/A	cg26385618	chr18:73139727	C18orf62	-0.65	-4.75	-0.44	7.3e-6	Intelligence;
THYM	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg09904177	chr6:26538194	HMGN4	0.59	4.64	0.43	1.13e-5	Intelligence (multi-trait analysis);
THYM	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg11764359	chr7:65958608	NA	0.64	5.06	0.46	2.02e-6	Aortic root size;
THYM	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg08835221	chr22:38071607	LGALS1	0.36	4.64	0.43	1.13e-5	Fat distribution (HIV);
THYM	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg20887711	chr4:1340912	KIAA1530	0.97	8.88	0.67	4.02e-14	Longevity;
THYM	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg00255919	chr5:131827918	IRF1	0.47	5.22	0.47	1.06e-6	Asthma (sex interaction);
THYM	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg01324343	chr3:183735012	ABCC5	0.64	8.63	0.66	1.42e-13	Anterior chamber depth;
THYM	cis	rs17152411	0.895	rs7900929	chr10:126584999	A/C	cg07906193	chr10:126599966	NA	0.68	4.65	0.43	1.08e-5	Height;
THYM	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg02038168	chr22:39784481	NA	-0.72	-5.31	-0.48	7.08e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs6733011	0.506	rs11123755	chr2:99507948	C/G	cg08885076	chr2:99613938	TSGA10	-0.45	-4.48	-0.42	2.1e-5	Bipolar disorder;
THYM	cis	rs10992471	0.580	rs7869521	chr9:95411059	G/T	cg14631576	chr9:95140430	CENPP	-0.94	-7.64	-0.62	1.75e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg05340658	chr4:99064831	C4orf37	0.54	4.55	0.42	1.58e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs828999	0.654	rs6678223	chr1:108697190	G/C	cg24323958	chr1:108741884	SLC25A24	0.54	5.32	0.48	6.79e-7	Monocyte percentage of white cells;
THYM	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg08048268	chr3:133502702	NA	-0.66	-5.59	-0.5	2.13e-7	Iron status biomarkers;
THYM	cis	rs10484885	0.763	rs56401039	chr6:90522486	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.87	-7.73	-0.62	1.13e-11	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg04756594	chr16:24857601	SLC5A11	-0.8	-5.79	-0.51	9.08e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11209185	0.602	rs6662249	chr1:68447214	C/A	cg22082780	chr1:68452167	NA	0.49	5.74	0.51	1.14e-7	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs6987853	0.686	rs10087350	chr8:42359484	G/A	cg09913449	chr8:42400586	C8orf40	-0.92	-8.57	-0.66	1.9e-13	Mean corpuscular hemoglobin concentration;
THYM	cis	rs55637147	0.521	rs56077100	chr11:57124634	T/A	cg15971518	chr11:57159174	PRG2	-0.67	-5.34	-0.48	6.43e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs8031584	0.672	rs17227989	chr15:31293774	T/C	cg08704250	chr15:31115839	NA	-0.49	-4.74	-0.44	7.39e-6	Huntington's disease progression;
THYM	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg19746536	chr19:49375674	PPP1R15A	0.81	4.6	0.43	1.33e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	4.66	0.43	1.04e-5	Diabetic retinopathy;
THYM	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06481639	chr22:41940642	POLR3H	0.8	5.63	0.5	1.81e-7	Vitiligo;
THYM	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg07424592	chr7:64974309	NA	-1.09	-5.01	-0.46	2.55e-6	Diabetic kidney disease;
THYM	cis	rs6828523	0.698	rs78557674	chr4:175853032	T/A	cg14561282	chr4:175839468	ADAM29	0.61	4.51	0.42	1.83e-5	Breast cancer;
THYM	cis	rs7688540	0.771	rs2353605	chr4:219538	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.7	5.1	0.46	1.7e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg27490568	chr2:178487706	NA	0.63	5.91	0.52	5.39e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.43	0.7	2.73e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1883415	0.698	rs2817216	chr6:24500832	G/A	cg00346970	chr6:24499591	ALDH5A1	0.39	5.08	0.46	1.89e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs11671005	0.610	rs4756	chr19:59074653	T/C	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.53	-4.66	-0.43	1.01e-5	Mean platelet volume;
THYM	cis	rs12216545	0.765	rs3946494	chr7:150253318	A/G	cg08960815	chr7:150264767	GIMAP4	-0.77	-7.01	-0.58	3.47e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs2573210	0.645	rs1881492	chr2:233406998	A/C	cg05875017	chr2:233390771	CHRND	-0.48	-5.1	-0.46	1.71e-6	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.85	-5.77	-0.51	9.99e-8	Yeast infection;
THYM	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg17054759	chr22:49844102	NA	-0.52	-4.99	-0.46	2.77e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs11966931	1.000	rs7755216	chr6:108147875	G/T	cg25323841	chr6:108444506	NA	0.69	4.81	0.44	5.64e-6	Neutrophil percentage of white cells;
THYM	cis	rs12310956	0.510	rs2054867	chr12:33835462	C/G	cg10856724	chr12:34555212	NA	0.67	5.87	0.52	6.42e-8	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2505998	0.833	rs2505536	chr10:43592204	A/T	cg06632098	chr10:43605906	RET	1.1	10.64	0.74	7.21e-18	Hirschsprung disease;
THYM	cis	rs2731664	0.765	rs2630766	chr5:176874941	A/C	cg14098951	chr5:176875120	PRR7	0.57	5.02	0.46	2.45e-6	Intelligence (multi-trait analysis);
THYM	cis	rs40363	1.000	rs37773	chr16:3512834	G/A	cg01073479	chr16:3509474	NAT15	0.56	4.88	0.45	4.24e-6	Tuberculosis;
THYM	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg18252515	chr7:66147081	NA	0.72	5.6	0.5	2.03e-7	Aortic root size;
THYM	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.88	8.14	0.64	1.56e-12	Menarche (age at onset);
THYM	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg22907277	chr7:1156413	C7orf50	0.84	5.14	0.47	1.46e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1034435	0.755	rs9615336	chr22:48893090	G/C	cg05992904	chr22:48892994	FAM19A5	-0.81	-8.89	-0.67	3.91e-14	Late-onset Alzheimer's disease;
THYM	cis	rs747782	0.528	rs7937670	chr11:48313216	C/T	cg24672777	chr11:48374446	OR4C45	-1.17	-7.15	-0.59	1.78e-10	Intraocular pressure;
THYM	cis	rs2235649	0.833	rs9929262	chr16:1851928	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs9527	0.590	rs7897663	chr10:104905604	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02018176	chr4:1364513	KIAA1530	1.0	10.17	0.72	7e-17	Longevity;
THYM	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg24399712	chr22:39784796	NA	-0.84	-5.86	-0.52	6.63e-8	IgG glycosylation;
THYM	cis	rs17033702	0.585	rs11903638	chr2:67751340	C/G	cg03239202	chr2:68694299	FBXO48;APLF	-0.65	-4.57	-0.42	1.45e-5	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
THYM	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg14784868	chr12:69753453	YEATS4	0.7	5.64	0.5	1.76e-7	Blood protein levels;
THYM	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13012494	chr21:47604986	C21orf56	0.85	5.46	0.49	3.86e-7	Testicular germ cell tumor;
THYM	cis	rs804280	0.525	rs809203	chr8:11619504	T/A	cg23916205	chr8:11614368	GATA4	-0.64	-5.13	-0.47	1.53e-6	Myopia (pathological);
THYM	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.62	5.61	0.5	2.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.65	5.53	0.49	2.76e-7	Lung disease severity in cystic fibrosis;
THYM	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg08994789	chr17:28903642	LRRC37B2	-1.05	-5.39	-0.48	5.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg27129171	chr3:47204927	SETD2	0.7	6.3	0.54	9.04e-9	Colorectal cancer;
THYM	cis	rs7681440	0.583	rs2619362	chr4:90757845	C/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.33	-0.48	6.7e-7	Dementia with Lewy bodies;
THYM	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg00898013	chr13:113819073	PROZ	-0.87	-8.78	-0.67	6.82e-14	Platelet distribution width;
THYM	cis	rs2070488	0.804	rs1870914	chr3:38494220	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.59	4.63	0.43	1.14e-5	Electrocardiographic conduction measures;
THYM	cis	rs7084402	1.000	rs6481402	chr10:60268977	T/C	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs3917265	0.602	rs3771200	chr2:102788774	G/A	cg13315345	chr2:102803985	IL1RL2	0.54	5.41	0.49	4.68e-7	Atopic dermatitis;
THYM	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg26038318	chr20:34205095	SPAG4	0.63	5.16	0.47	1.36e-6	Total cholesterol levels;
THYM	cis	rs6032067	0.683	rs16989763	chr20:43779963	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.67	-8.06	-0.64	2.29e-12	Blood protein levels;
THYM	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg19318889	chr4:1322082	MAEA	-0.64	-5.52	-0.49	2.93e-7	Longevity;
THYM	cis	rs12496230	0.951	rs34954762	chr3:66853890	A/G	cg04995300	chr3:66848608	NA	1.1	7.04	0.59	2.96e-10	Type 2 diabetes;
THYM	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg24675658	chr1:53192096	ZYG11B	-0.59	-4.77	-0.44	6.67e-6	Monocyte count;
THYM	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg24209194	chr3:40518798	ZNF619	0.56	4.48	0.42	2.11e-5	Renal cell carcinoma;
THYM	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg06808227	chr14:105710500	BRF1	-1.06	-9.31	-0.69	4.99e-15	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg05738196	chr6:26577821	NA	0.95	9.38	0.69	3.53e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7607369	0.782	rs639913	chr2:219365971	A/C	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs62344088	0.590	rs62345236	chr5:283519	G/A	cg22857025	chr5:266934	NA	-1.45	-5.27	-0.48	8.45e-7	Asthma (childhood onset);
THYM	cis	rs7546094	0.935	rs6700673	chr1:113157054	C/T	cg22162597	chr1:113214053	CAPZA1	0.48	4.91	0.45	3.81e-6	Platelet distribution width;
THYM	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs4944092	1.000	rs4944092	chr11:75909619	C/T	cg04588336	chr11:75916460	WNT11	-0.64	-6.62	-0.56	2.16e-9	PR interval;
THYM	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1371867	0.875	rs1125706	chr8:101326739	T/A	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg09877947	chr5:131593287	PDLIM4	0.58	4.91	0.45	3.77e-6	Breast cancer;
THYM	cis	rs2235649	0.704	rs1742425	chr16:1904524	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.48	-4.67	-0.43	9.98e-6	Blood metabolite levels;
THYM	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg01528321	chr10:82214614	TSPAN14	0.66	5.16	0.47	1.35e-6	Post bronchodilator FEV1;
THYM	cis	rs5746492	0.568	rs5747408	chr22:18397120	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.49	-4.56	-0.42	1.5e-5	Eotaxin levels;
THYM	cis	rs912057	0.632	rs1294429	chr6:6744652	G/A	cg06612196	chr6:6737390	NA	0.71	11.9	0.77	1.57e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg27494647	chr7:150038898	RARRES2	0.46	5.82	0.51	8.06e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4372836	0.681	rs6419696	chr2:29010339	G/A	cg09522027	chr2:28974177	PPP1CB	-0.62	-4.78	-0.44	6.45e-6	Body mass index;
THYM	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.83	0.44	5.13e-6	Prudent dietary pattern;
THYM	cis	rs4845459	0.967	rs9633406	chr1:152591446	C/G	cg26135325	chr1:152595322	LCE3A	-0.44	-5.01	-0.46	2.47e-6	Psoriasis;
THYM	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg09904177	chr6:26538194	HMGN4	0.53	4.47	0.42	2.16e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg01097406	chr16:89675127	NA	-0.58	-4.81	-0.44	5.64e-6	Vitiligo;
THYM	cis	rs1050631	0.564	rs1625385	chr18:33717364	C/A	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.6	4.69	0.43	9.09e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs3780378	1.000	rs1328918	chr9:5107394	A/G	cg02405213	chr9:5042618	JAK2	-0.66	-5.9	-0.52	5.63e-8	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg11764359	chr7:65958608	NA	0.78	6.31	0.54	8.88e-9	Aortic root size;
THYM	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg00786635	chr1:25594202	NA	0.8	6.28	0.54	1.02e-8	Erythrocyte sedimentation rate;
THYM	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg09703963	chr11:616879	IRF7;MUPCDH	-0.61	-4.76	-0.44	6.98e-6	Systemic lupus erythematosus;
THYM	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg24578937	chr1:2090814	PRKCZ	-0.58	-6.17	-0.53	1.68e-8	Height;
THYM	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg06009448	chr7:1102226	C7orf50	0.52	5.44	0.49	4.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3741151	1.000	rs79778136	chr11:73041339	T/C	cg17517138	chr11:73019481	ARHGEF17	0.99	5.88	0.52	5.97e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs4919044	0.688	rs59539045	chr10:94776594	C/A	cg05127821	chr10:94822908	CYP26C1	-1.31	-6.9	-0.58	5.75e-10	Coronary artery disease;
THYM	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.27	6.27	0.54	1.04e-8	Obesity-related traits;
THYM	cis	rs61931739	0.817	rs11053125	chr12:34265417	C/T	cg06521331	chr12:34319734	NA	-0.66	-5.27	-0.48	8.41e-7	Morning vs. evening chronotype;
THYM	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg17173187	chr15:85201210	NMB	0.56	5.55	0.49	2.61e-7	Schizophrenia;
THYM	cis	rs3892630	0.500	rs6510301	chr19:33359791	A/T	cg22980127	chr19:33182716	NUDT19	1.11	7.51	0.61	3.23e-11	Red blood cell traits;
THYM	cis	rs9549260	0.755	rs7324319	chr13:41233505	G/C	cg21288729	chr13:41239152	FOXO1	0.71	5.65	0.5	1.7e-7	Red blood cell count;
THYM	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg02038168	chr22:39784481	NA	0.65	5.0	0.46	2.57e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg04654363	chr8:8581213	NA	-0.48	-4.62	-0.43	1.22e-5	Obesity-related traits;
THYM	cis	rs11096990	0.656	rs2066786	chr4:39302029	T/C	cg24403649	chr4:39172243	NA	0.64	5.47	0.49	3.69e-7	Cognitive function;
THYM	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs500891	0.525	rs3778201	chr6:84081405	C/T	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg17178900	chr1:205818956	PM20D1	-0.73	-6.73	-0.57	1.3e-9	Menarche (age at onset);
THYM	trans	rs4650994	0.967	rs4650992	chr1:178515135	A/T	cg05059571	chr16:84539110	KIAA1609	-0.75	-7.95	-0.63	3.83e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs897984	0.683	rs8046001	chr16:30833321	C/T	cg05768032	chr16:30646687	NA	0.43	4.58	0.43	1.41e-5	Dementia with Lewy bodies;
THYM	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg27588902	chr6:42928151	GNMT	-0.56	-5.79	-0.51	9.08e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs10463554	0.759	rs34815	chr5:102434265	C/T	cg23492399	chr5:102201601	PAM	-0.67	-4.96	-0.45	3.05e-6	Parkinson's disease;
THYM	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg22455342	chr2:225449267	CUL3	0.57	4.5	0.42	1.96e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06850241	chr22:41845214	NA	-0.61	-5.46	-0.49	3.87e-7	Vitiligo;
THYM	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg27129171	chr3:47204927	SETD2	-0.69	-6.65	-0.56	1.82e-9	Colorectal cancer;
THYM	cis	rs7610301	1.000	rs7610512	chr3:46646222	G/C	cg10242476	chr3:46619364	LRRC2;TDGF1	0.45	4.5	0.42	1.94e-5	Blood protein levels;
THYM	cis	rs13326165	0.585	rs73088800	chr3:52332292	A/G	cg08438690	chr3:52279403	PPM1M	-0.74	-4.64	-0.43	1.12e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs7084402	0.967	rs1658478	chr10:60289551	C/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs2637266	0.626	rs2583066	chr10:78555839	T/C	cg18941641	chr10:78392320	NA	0.74	5.85	0.51	6.96e-8	Pulmonary function;
THYM	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg10515332	chr4:99064459	C4orf37	0.6	4.8	0.44	5.93e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4478037	0.822	rs9875140	chr3:33117068	T/A	cg19404215	chr3:33155277	CRTAP	1.07	6.96	0.58	4.27e-10	Major depressive disorder;
THYM	cis	rs4638749	0.680	rs12612935	chr2:108818409	A/G	cg13968390	chr2:108904812	SULT1C2	-0.66	-4.66	-0.43	1.04e-5	Blood pressure;
THYM	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg09737314	chr17:6899359	ALOX12	0.78	10.16	0.72	7.52e-17	Tonsillectomy;
THYM	cis	rs9902453	0.791	rs3115090	chr17:28035014	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.76	6.01	0.52	3.49e-8	Coffee consumption (cups per day);
THYM	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg02725872	chr8:58115012	NA	-0.65	-4.72	-0.44	8.13e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs1729951	0.575	rs361237	chr3:136702414	A/G	cg12473912	chr3:136751656	NA	0.58	4.74	0.44	7.56e-6	Neuroticism;
THYM	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg21605333	chr4:119757512	SEC24D	1.54	6.13	0.53	1.97e-8	Cannabis dependence symptom count;
THYM	cis	rs892961	0.932	rs66886702	chr17:75412714	G/A	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.49	-5.0	-0.46	2.64e-6	Depressive symptoms;
THYM	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg12826209	chr6:26865740	GUSBL1	0.92	4.98	0.45	2.89e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg11764359	chr7:65958608	NA	0.65	5.05	0.46	2.11e-6	Aortic root size;
THYM	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs2067615	0.542	rs7133161	chr12:107139540	A/G	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs28595532	0.920	rs116516492	chr4:119734247	C/G	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg08885076	chr2:99613938	TSGA10	-0.64	-5.68	-0.5	1.46e-7	Chronic sinus infection;
THYM	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg21773646	chr17:80085082	CCDC57	0.32	4.5	0.42	1.93e-5	Life satisfaction;
THYM	cis	rs642803	0.591	rs620088	chr11:65508986	G/A	cg27068330	chr11:65405492	SIPA1	0.73	5.34	0.48	6.42e-7	Urate levels;
THYM	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.68	5.34	0.48	6.26e-7	Tonsillectomy;
THYM	cis	rs2195525	0.572	rs12417736	chr11:119220946	T/C	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.44	4.78	0.44	6.36e-6	Urate levels;
THYM	cis	rs28595532	0.920	rs115994240	chr4:119744622	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg00640147	chr17:61958756	GH2	-0.44	-4.68	-0.43	9.69e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.64	-5.56	-0.5	2.51e-7	Coronary artery disease;
THYM	cis	rs13315871	0.929	rs17059171	chr3:58302586	A/G	cg12435725	chr3:58293450	RPP14	-0.5	-5.35	-0.48	6.13e-7	Cholesterol, total;
THYM	cis	rs12711979	0.509	rs10200764	chr2:3827772	C/G	cg17052675	chr2:3827356	NA	-0.91	-15.53	-0.85	8.23e-28	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg03877680	chr5:178157825	ZNF354A	0.69	4.73	0.44	7.66e-6	Neutrophil percentage of white cells;
THYM	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg20290983	chr6:43655470	MRPS18A	1.44	15.94	0.85	1.35e-28	IgG glycosylation;
THYM	cis	rs9563576	0.735	rs7333967	chr13:58597227	C/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.62	4.49	0.42	2.01e-5	Body mass index;
THYM	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg15693483	chr7:1102177	C7orf50	0.39	5.75	0.51	1.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4242434	0.819	rs2291230	chr8:22463697	C/G	cg01710189	chr8:22454888	PDLIM2	-0.5	-5.7	-0.5	1.34e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs3772130	0.962	rs17742508	chr3:121559895	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.75	4.64	0.43	1.1e-5	Cognitive performance;
THYM	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg08772003	chr10:104629869	AS3MT	-0.63	-5.59	-0.5	2.18e-7	Arsenic metabolism;
THYM	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg00024416	chr22:24240387	NA	-0.61	-6.43	-0.55	5.12e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7772486	0.754	rs6910790	chr6:146255330	G/A	cg23711669	chr6:146136114	FBXO30	-0.93	-9.39	-0.69	3.39e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs3960554	0.867	rs10239209	chr7:75804085	G/A	cg17398381	chr7:75624190	TMEM120A	-0.48	-4.73	-0.44	7.75e-6	Eotaxin levels;
THYM	cis	rs7771547	0.573	rs7744363	chr6:36424665	A/C	cg07856975	chr6:36356162	ETV7	-0.52	-5.02	-0.46	2.39e-6	Platelet distribution width;
THYM	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg04944784	chr2:26401820	FAM59B	1.09	8.74	0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs28595532	0.920	rs17324968	chr4:119772316	A/G	cg14228332	chr4:119757509	SEC24D	1.46	5.36	0.48	5.83e-7	Cannabis dependence symptom count;
THYM	cis	rs7917772	0.582	rs4917978	chr10:104366353	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.77	-6.73	-0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7524258	0.900	rs6577426	chr1:7306451	A/G	cg07173049	chr1:7289937	CAMTA1	0.69	5.63	0.5	1.83e-7	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs4589258	0.966	rs2187535	chr11:90507142	A/G	cg26138821	chr11:89956704	CHORDC1	-0.72	-5.84	-0.51	7.16e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6546537	0.955	rs2312215	chr2:69839825	T/A	cg10773587	chr2:69614142	GFPT1	-0.56	-4.85	-0.45	4.8e-6	Serum thyroid-stimulating hormone levels;
THYM	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-5.13	-0.47	1.55e-6	Lymphocyte counts;
THYM	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg03929089	chr4:120376271	NA	1.02	8.78	0.67	6.68e-14	Coronary artery disease;
THYM	cis	rs12620999	0.941	rs2875690	chr2:237977737	G/A	cg15976283	chr2:238042351	NA	-0.59	-4.54	-0.42	1.65e-5	Systemic lupus erythematosus;
THYM	cis	rs1580019	0.961	rs4255041	chr7:32496383	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.59	0.56	2.42e-9	Cognitive ability;
THYM	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg22166914	chr1:53195759	ZYG11B	-0.91	-10.68	-0.74	5.96e-18	Monocyte count;
THYM	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2075230	0.850	rs111633209	chr17:7476635	G/A	cg10509001	chr17:7553872	ATP1B2	0.59	4.69	0.43	9e-6	Hormone measurements;
THYM	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg12373951	chr3:133503437	NA	0.59	6.56	0.56	2.8e-9	Iron status biomarkers;
THYM	cis	rs36051895	0.658	rs11999928	chr9:5006743	T/G	cg02405213	chr9:5042618	JAK2	-1.03	-10.68	-0.74	5.97e-18	Pediatric autoimmune diseases;
THYM	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg18305652	chr10:134549665	INPP5A	0.81	6.63	0.56	1.99e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	trans	rs208520	0.690	rs851458	chr6:66813279	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.66	-0.62	1.53e-11	Exhaled nitric oxide output;
THYM	cis	rs192264	0.680	rs1094976	chr16:65973780	G/C	cg02795155	chr16:66785218	DYNC1LI2	0.6	4.77	0.44	6.61e-6	Subjective well-being;
THYM	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs870825	0.616	rs10025167	chr4:185649551	A/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs1971762	0.545	rs10747676	chr12:54049930	T/C	cg16917193	chr12:54089295	NA	0.83	8.02	0.64	2.7e-12	Height;
THYM	trans	rs208520	0.690	rs207102	chr6:66795671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.66	-0.62	1.53e-11	Exhaled nitric oxide output;
THYM	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs67460515	0.563	rs11922959	chr3:160828871	A/G	cg12349858	chr3:160822545	B3GALNT1	0.57	4.53	0.42	1.71e-5	Parkinson's disease;
THYM	cis	rs7649443	0.959	rs6782349	chr3:196948807	C/T	cg20744464	chr3:196756875	MFI2	0.63	4.64	0.43	1.12e-5	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs10979	1.000	rs9373394	chr6:143890776	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg00129232	chr17:37814104	STARD3	0.69	4.51	0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg09455208	chr3:40491958	NA	0.49	5.1	0.46	1.75e-6	Renal cell carcinoma;
THYM	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03264133	chr6:25882463	NA	-0.81	-6.25	-0.54	1.14e-8	Intelligence (multi-trait analysis);
THYM	cis	rs977987	0.806	rs4887823	chr16:75433074	T/A	cg03315344	chr16:75512273	CHST6	0.73	6.16	0.53	1.73e-8	Dupuytren's disease;
THYM	cis	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.59	-0.43	1.37e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg02782426	chr3:40428986	ENTPD3	0.53	4.66	0.43	1.04e-5	Renal cell carcinoma;
THYM	cis	rs2456568	0.503	rs11020603	chr11:93667439	A/G	cg17595323	chr11:93583763	C11orf90	0.52	5.62	0.5	1.94e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs6500395	1.000	rs9925406	chr16:48671436	C/A	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2404602	0.622	rs11637296	chr15:77207885	C/A	cg23625390	chr15:77176239	SCAPER	-0.86	-5.75	-0.51	1.06e-7	Blood metabolite levels;
THYM	cis	rs6840360	0.606	rs2709813	chr4:152357444	T/C	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6988636	1.000	rs28542077	chr8:124190896	T/C	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg23815491	chr16:72088622	HP	0.87	7.8	0.62	7.82e-12	Fibrinogen levels;
THYM	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.82	-4.55	-0.42	1.56e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg11764359	chr7:65958608	NA	0.63	4.92	0.45	3.66e-6	Aortic root size;
THYM	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg18681998	chr4:17616180	MED28	0.85	7.68	0.62	1.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs8077889	0.957	rs17742929	chr17:41891437	C/T	cg26893861	chr17:41843967	DUSP3	1.09	10.15	0.72	8.08e-17	Triglycerides;
THYM	cis	rs7426056	0.671	rs3116486	chr2:204585502	T/C	cg07930752	chr2:204569955	CD28	-0.67	-4.74	-0.44	7.48e-6	Primary sclerosing cholangitis;
THYM	cis	rs11771526	0.901	rs10252303	chr7:32304438	C/T	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.01	-9.8	-0.71	4.35e-16	Primary sclerosing cholangitis;
THYM	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg05660106	chr1:15850417	CASP9	0.75	6.05	0.53	2.87e-8	Systolic blood pressure;
THYM	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg04654363	chr8:8581213	NA	-0.48	-4.62	-0.43	1.22e-5	Obesity-related traits;
THYM	cis	rs1161098	0.723	rs1152887	chr12:67819968	A/G	cg20473420	chr12:67782441	NA	0.88	4.45	0.42	2.3e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs6964587	0.869	rs10250641	chr7:91490746	C/T	cg17063962	chr7:91808500	NA	1.1	11.95	0.77	1.22e-20	Breast cancer;
THYM	cis	rs8180040	0.800	rs11921117	chr3:47294000	T/C	cg12976108	chr3:47324180	KIF9;KLHL18	0.5	4.5	0.42	1.92e-5	Colorectal cancer;
THYM	cis	rs11771526	0.579	rs77818421	chr7:32375129	G/T	cg13207630	chr7:32358064	NA	0.97	5.35	0.48	6.08e-7	Body mass index;
THYM	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg16586182	chr3:47516702	SCAP	-0.59	-4.91	-0.45	3.8e-6	Colorectal cancer;
THYM	cis	rs11671005	0.616	rs12980907	chr19:58956326	C/T	cg18639983	chr19:58920768	ZNF584	0.57	4.59	0.43	1.33e-5	Mean platelet volume;
THYM	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs72949976	0.646	rs1441171	chr2:214033637	G/T	cg08319019	chr2:214017104	IKZF2	0.74	6.22	0.54	1.32e-8	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs36051895	0.659	rs57204002	chr9:5062610	T/C	cg02405213	chr9:5042618	JAK2	-0.99	-11.45	-0.76	1.4e-19	Pediatric autoimmune diseases;
THYM	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	trans	rs8073060	0.586	rs8064895	chr17:34001121	T/C	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg24818145	chr4:99064322	C4orf37	0.74	5.97	0.52	4.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.68	9.03	0.68	1.97e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg10018233	chr7:150070692	REPIN1	0.5	7.69	0.62	1.32e-11	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs9876781	0.967	rs34761139	chr3:48427979	C/T	cg06066452	chr3:48470258	PLXNB1	0.26	4.88	0.45	4.26e-6	Longevity;
THYM	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.77	-0.51	1.01e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg11009520	chr8:12052164	FAM86B1	0.59	4.73	0.44	7.8e-6	Morning vs. evening chronotype;
THYM	cis	rs4786125	0.879	rs7187208	chr16:6894716	T/C	cg03623568	chr16:6915990	A2BP1	-0.77	-6.09	-0.53	2.34e-8	Heart rate variability traits (SDNN);
THYM	cis	rs17174870	0.955	rs4434006	chr2:112728811	C/G	cg17354880	chr2:112658759	MERTK	-0.58	-4.48	-0.42	2.11e-5	Multiple sclerosis;
THYM	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg09549813	chr16:4587862	C16orf5	-0.56	-6.13	-0.53	1.97e-8	Schizophrenia;
THYM	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg23131131	chr22:24373011	LOC391322	-0.78	-7.99	-0.63	3.19e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg08999081	chr20:33150536	PIGU	-0.62	-5.04	-0.46	2.23e-6	Height;
THYM	cis	rs939574	0.929	rs10190834	chr2:220070301	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.2	-5.46	-0.49	3.84e-7	Platelet distribution width;
THYM	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg26384229	chr12:38710491	ALG10B	0.95	7.55	0.61	2.7e-11	Bladder cancer;
THYM	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg02640540	chr1:67518911	SLC35D1	0.64	4.73	0.44	7.69e-6	Lymphocyte percentage of white cells;
THYM	cis	rs7614311	0.731	rs3774727	chr3:63977875	A/G	cg22134162	chr3:63841271	THOC7	-0.52	-6.39	-0.55	6.06e-9	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14442939	chr10:27389572	ANKRD26	-0.72	-4.49	-0.42	1.97e-5	Breast cancer;
THYM	trans	rs2552220	1.000	rs2552220	chr8:5999311	G/A	cg20122981	chr2:62450705	B3GNT2	-0.72	-6.85	-0.57	7.42e-10	Interleukin-8 levels;
THYM	cis	rs6722750	0.933	rs4671555	chr2:64411137	C/G	cg22352474	chr2:64371530	PELI1	-0.64	-4.72	-0.44	8.22e-6	Neuroticism;
THYM	cis	rs7107770	1.000	rs12787088	chr11:125094583	G/A	cg04164023	chr11:125106101	PKNOX2	-0.79	-4.72	-0.44	8.1e-6	Photic sneeze reflex;
THYM	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg25427524	chr10:38739819	LOC399744	-0.65	-5.96	-0.52	4.23e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs2898681	0.618	rs116241740	chr4:53733523	A/G	cg03786743	chr4:53727781	RASL11B	0.63	5.65	0.5	1.66e-7	Optic nerve measurement (cup area);
THYM	cis	rs4731207	0.565	rs998054	chr7:124640487	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs57920188	0.585	rs4077389	chr1:4070616	C/T	cg20703997	chr1:4087676	NA	1.06	7.6	0.61	2.13e-11	Interleukin-17 levels;
THYM	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg13390004	chr1:15929781	NA	0.63	4.8	0.44	5.87e-6	Systolic blood pressure;
THYM	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.49e-10	Prudent dietary pattern;
THYM	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg08975724	chr8:8085496	FLJ10661	0.69	5.21	0.47	1.1e-6	Neuroticism;
THYM	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg14159672	chr1:205819179	PM20D1	-0.6	-4.86	-0.45	4.68e-6	Parkinson's disease;
THYM	cis	rs854765	0.724	rs62072049	chr17:17906520	T/C	cg04398451	chr17:18023971	MYO15A	-0.86	-8.25	-0.65	8.82e-13	Total body bone mineral density;
THYM	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg00684032	chr4:1343700	KIAA1530	0.57	4.74	0.44	7.43e-6	Obesity-related traits;
THYM	cis	rs539096	0.781	rs2916568	chr1:44091274	A/G	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2282300	0.956	rs2685286	chr11:30381588	G/A	cg09906309	chr11:30344399	C11orf46	-0.73	-5.14	-0.47	1.5e-6	Morning vs. evening chronotype;
THYM	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg09260853	chr1:2094483	PRKCZ	-0.48	-4.9	-0.45	3.91e-6	Height;
THYM	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg10862848	chr6:42927986	GNMT	-0.51	-6.72	-0.57	1.36e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg04287289	chr16:89883240	FANCA	0.5	4.46	0.42	2.2e-5	Vitiligo;
THYM	cis	rs2777491	0.915	rs9302109	chr15:41612180	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.14	-12.89	-0.8	1.38e-22	Ulcerative colitis;
THYM	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg17063962	chr7:91808500	NA	-1.12	-12.18	-0.78	4.12e-21	Breast cancer;
THYM	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs11031096	0.678	rs61899754	chr11:4201312	A/T	cg18678763	chr11:4115507	RRM1	-0.41	-4.82	-0.44	5.4e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	trans	rs4596713	0.507	rs1339546	chr9:71790297	G/A	cg16512924	chr15:28394682	HERC2	0.83	6.92	0.58	5.28e-10	Headache;
THYM	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg18538332	chr22:24372958	LOC391322	-0.95	-7.8	-0.62	7.8e-12	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs6500596	0.570	rs758045	chr16:4434198	A/G	cg08645402	chr16:4508243	NA	0.7	5.72	0.51	1.21e-7	Schizophrenia;
THYM	cis	rs13631	0.928	rs9411308	chr9:140000115	C/T	cg03717367	chr9:139980219	LOC100289341;MAN1B1	0.62	5.53	0.49	2.86e-7	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2235573	0.625	rs139901	chr22:38406147	T/C	cg19171272	chr22:38449367	NA	-0.52	-5.27	-0.48	8.38e-7	Glioblastoma;Glioma;
THYM	cis	rs7818345	0.967	rs4433156	chr8:19284247	A/C	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.54	0.42	1.63e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs9527	0.590	rs34104646	chr10:104896078	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg07492924	chr16:433825	LOC100134368	0.52	5.36	0.48	5.78e-7	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs9595908	0.965	rs7318297	chr13:33137972	G/A	cg12383807	chr13:33924137	NA	-0.54	-4.74	-0.44	7.57e-6	Body mass index;
THYM	cis	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg19847130	chr8:10466454	RP1L1	0.53	4.93	0.45	3.43e-6	Neuroticism;
THYM	cis	rs2354432	0.607	rs7511989	chr1:146720160	A/G	cg25205988	chr1:146714368	CHD1L	-1.04	-5.54	-0.49	2.67e-7	Mitochondrial DNA levels;
THYM	cis	rs13014235	0.532	rs3731709	chr2:202246034	G/C	cg08939942	chr2:202838362	NA	-0.58	-4.54	-0.42	1.65e-5	Basal cell carcinoma;
THYM	cis	rs2688608	0.592	rs11000758	chr10:75493610	A/T	cg23231163	chr10:75533350	FUT11	-0.41	-5.9	-0.52	5.54e-8	Inflammatory bowel disease;
THYM	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg06634786	chr22:41940651	POLR3H	0.71	5.04	0.46	2.19e-6	Vitiligo;
THYM	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg12963246	chr6:28129442	ZNF389	0.6	4.83	0.44	5.14e-6	Parkinson's disease;
THYM	cis	rs11585357	0.793	rs11587669	chr1:17616259	C/T	cg08277548	chr1:17600880	PADI3	-0.9	-5.43	-0.49	4.38e-7	Hair shape;
THYM	cis	rs4466137	0.830	rs10039752	chr5:82974532	G/A	cg16102102	chr5:83017553	HAPLN1	-0.82	-6.58	-0.56	2.61e-9	Prostate cancer;
THYM	cis	rs1847202	0.859	rs6771288	chr3:72939471	A/G	cg25664220	chr3:72788482	NA	-0.57	-4.63	-0.43	1.14e-5	Motion sickness;
THYM	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg21737444	chr22:38071591	LGALS1	0.25	4.6	0.43	1.28e-5	Fat distribution (HIV);
THYM	cis	rs9807841	0.670	rs8107719	chr19:10804389	T/C	cg17848348	chr19:10766748	ILF3	-0.87	-7.74	-0.62	1.06e-11	Inflammatory skin disease;
THYM	cis	rs7224314	1.000	rs62084076	chr17:65383102	G/A	cg01507342	chr17:65387096	PITPNC1	-0.91	-10.3	-0.73	3.76e-17	Diisocyanate-induced asthma;
THYM	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs73086581	1.000	rs56069856	chr20:3965709	A/C	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg07636037	chr3:49044803	WDR6	0.99	10.43	0.73	2.03e-17	Parkinson's disease;
THYM	cis	rs2637266	0.622	rs4745816	chr10:78216814	C/T	cg18941641	chr10:78392320	NA	-0.6	-4.68	-0.43	9.38e-6	Pulmonary function;
THYM	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg14675211	chr2:100938903	LONRF2	-0.71	-7.38	-0.6	6.02e-11	Intelligence (multi-trait analysis);
THYM	cis	rs59698941	0.882	rs72801412	chr5:132314039	T/C	cg02081065	chr5:132209139	LEAP2	-0.86	-5.74	-0.51	1.11e-7	Apolipoprotein A-IV levels;
THYM	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg20387954	chr3:183756860	HTR3D	0.55	4.53	0.42	1.74e-5	Anterior chamber depth;
THYM	cis	rs863345	0.547	rs10908675	chr1:158504129	A/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg13683864	chr3:40499215	RPL14	-1.05	-11.57	-0.76	7.71e-20	Renal cell carcinoma;
THYM	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg09359103	chr1:154839909	KCNN3	-0.72	-9.45	-0.7	2.44e-15	Prostate cancer;
THYM	cis	rs6842789	0.546	rs35500317	chr4:124937040	T/A	cg01723706	chr4:124814442	LOC285419	0.66	4.56	0.42	1.54e-5	Neuroticism;
THYM	cis	rs490234	0.702	rs2416964	chr9:128360413	C/T	cg14078157	chr9:128172775	NA	-0.77	-6.1	-0.53	2.27e-8	Mean arterial pressure;
THYM	cis	rs2273669	0.667	rs74582170	chr6:109312689	C/T	cg17117243	chr6:109341365	SESN1	-0.9	-5.38	-0.48	5.45e-7	Prostate cancer;
THYM	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.79	-0.51	9.2e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg02725872	chr8:58115012	NA	-0.9	-5.24	-0.47	9.85e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1642645	0.831	rs2042064	chr1:42491429	C/T	cg22816091	chr1:42611670	NA	0.62	5.52	0.49	2.99e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs6430585	0.697	rs115944351	chr2:136515458	G/A	cg04750100	chr2:136595281	LCT	0.53	4.86	0.45	4.59e-6	Corneal structure;
THYM	cis	rs12960472	0.539	rs9748423	chr18:52311094	G/C	cg26630735	chr18:52626848	CCDC68	-0.71	-4.56	-0.42	1.55e-5	Positive affect;
THYM	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.54	-5.42	-0.49	4.43e-7	Crohn's disease;
THYM	cis	rs6570726	0.935	rs430561	chr6:145813140	C/T	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg15693483	chr7:1102177	C7orf50	0.54	6.29	0.54	9.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7809950	1.000	rs10243340	chr7:107090955	A/G	cg23024343	chr7:107201750	COG5	-0.9	-8.07	-0.64	2.19e-12	Coronary artery disease;
THYM	cis	rs4930103	1.000	rs4930103	chr11:2024544	G/A	cg03175030	chr11:2018143	H19;MIR675	-0.47	-5.04	-0.46	2.26e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs9790314	0.540	rs9844862	chr3:161076188	G/A	cg03342759	chr3:160939853	NMD3	-0.71	-5.99	-0.52	3.81e-8	Morning vs. evening chronotype;
THYM	cis	rs11785693	0.602	rs73190403	chr8:4954798	T/C	cg26367366	chr8:4980734	NA	1.06	4.92	0.45	3.7e-6	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs2456568	0.802	rs7101791	chr11:93638998	A/G	cg26875233	chr11:93583750	C11orf90	-0.53	-5.53	-0.49	2.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg16926213	chr1:1841314	NA	0.55	5.8	0.51	8.83e-8	Body mass index;
THYM	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg23730037	chr7:158596552	ESYT2	0.43	4.47	0.42	2.15e-5	Height;
THYM	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg27279351	chr12:120934652	DYNLL1	0.96	8.75	0.67	7.6e-14	High light scatter reticulocyte count;
THYM	cis	rs12681287	0.752	rs10086569	chr8:87247209	C/T	cg27223183	chr8:87520930	FAM82B	-0.6	-4.64	-0.43	1.1e-5	Caudate activity during reward;
THYM	cis	rs7705502	1.000	rs17763772	chr5:173380934	A/G	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg23711669	chr6:146136114	FBXO30	-1.03	-10.35	-0.73	2.98e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.87	-7.37	-0.6	6.37e-11	Primary sclerosing cholangitis;
THYM	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg17366294	chr4:99064904	C4orf37	0.47	5.13	0.47	1.52e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs17739794	0.573	rs1105954	chr8:817847	C/T	cg01971667	chr8:817044	NA	0.71	6.6	0.56	2.32e-9	Clozapine-induced cytotoxicity;
THYM	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg25072359	chr17:41440525	NA	0.64	4.48	0.42	2.05e-5	Menopause (age at onset);
THYM	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg07460842	chr6:66804631	NA	1.1	8.21	0.64	1.08e-12	Exhaled nitric oxide output;
THYM	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg16558253	chr16:72132732	DHX38	-0.58	-5.31	-0.48	7.15e-7	Fibrinogen levels;
THYM	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6424115	0.545	rs11576333	chr1:24065770	C/T	cg15997130	chr1:24165203	NA	-0.68	-4.74	-0.44	7.63e-6	Immature fraction of reticulocytes;
THYM	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg04362960	chr10:104952993	NT5C2	-0.61	-5.32	-0.48	6.92e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.86	-8.22	-0.64	1.03e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11563648	0.553	rs67076804	chr7:126981607	C/T	cg23081781	chr7:127225937	GCC1	-0.37	-5.19	-0.47	1.17e-6	Resting heart rate;
THYM	cis	rs10089	1.000	rs17764954	chr5:127514436	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.92	5.45	0.49	3.92e-7	Ileal carcinoids;
THYM	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg10802521	chr3:52805072	NEK4	-0.75	-6.39	-0.55	6.13e-9	Bipolar disorder;
THYM	cis	rs6964587	0.692	rs7807490	chr7:91773359	A/G	cg17063962	chr7:91808500	NA	0.98	8.49	0.66	2.78e-13	Breast cancer;
THYM	cis	rs4786125	0.587	rs1473515	chr16:6923092	T/G	cg03623568	chr16:6915990	A2BP1	-1.0	-9.63	-0.7	1.02e-15	Heart rate variability traits (SDNN);
THYM	cis	rs6918586	0.616	rs1056314	chr6:26114653	G/A	cg03517284	chr6:25882590	NA	-0.71	-5.57	-0.5	2.33e-7	Schizophrenia;
THYM	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg11366901	chr6:160182831	ACAT2	1.06	9.39	0.69	3.35e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg24060327	chr5:131705240	SLC22A5	-0.84	-7.01	-0.58	3.43e-10	Breast cancer;
THYM	cis	rs62070183	0.766	rs62070229	chr17:31227593	A/G	cg23177095	chr17:30873196	MYO1D	0.63	4.85	0.45	4.76e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg13104385	chr7:22767384	IL6	0.46	4.46	0.42	2.24e-5	Lung cancer;
THYM	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11671005	0.735	rs1122955	chr19:58946203	C/T	cg18639983	chr19:58920768	ZNF584	0.59	4.82	0.44	5.48e-6	Mean platelet volume;
THYM	cis	rs2404618	0.506	rs12156177	chr8:1493684	C/T	cg13402656	chr8:1511478	DLGAP2	-0.64	-5.84	-0.51	7.29e-8	Lung cancer;
THYM	cis	rs4747241	0.626	rs4275534	chr10:74068151	T/C	cg07828833	chr10:74069493	NA	0.59	5.02	0.46	2.43e-6	Heschl's gyrus morphology;
THYM	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg20891558	chr2:74357851	NA	1.17	12.02	0.78	8.7e-21	Gestational age at birth (maternal effect);
THYM	cis	rs7089973	0.565	rs7082836	chr10:116646237	G/A	cg23260525	chr10:116636907	FAM160B1	0.48	4.78	0.44	6.5e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg15592062	chr6:167189543	RPS6KA2	0.57	5.59	0.5	2.15e-7	Crohn's disease;
THYM	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	6.97	0.58	4.15e-10	Smoking behavior;
THYM	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67460515	0.596	rs4856700	chr3:160922951	A/C	cg03342759	chr3:160939853	NMD3	-0.69	-5.14	-0.47	1.44e-6	Parkinson's disease;
THYM	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.37	-0.48	5.64e-7	Total cholesterol levels;
THYM	cis	rs6988636	1.000	rs4282551	chr8:124185916	G/A	cg22384356	chr8:124195192	FAM83A	-0.86	-5.15	-0.47	1.41e-6	Urinary uromodulin levels;
THYM	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg08645402	chr16:4508243	NA	0.76	6.82	0.57	8.2e-10	Schizophrenia;
THYM	cis	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg00495681	chr13:53174319	NA	-0.73	-6.71	-0.57	1.43e-9	Lewy body disease;
THYM	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.51	0.42	1.87e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1729951	0.575	rs361242	chr3:136698330	C/G	cg21827317	chr3:136751795	NA	0.74	6.6	0.56	2.29e-9	Neuroticism;
THYM	cis	rs75059851	1.000	rs73036063	chr11:133828758	G/A	cg14047540	chr11:133829660	NA	-1.15	-7.96	-0.63	3.61e-12	Schizophrenia;
THYM	cis	rs13064411	0.696	rs11921931	chr3:113015091	G/A	cg18753928	chr3:113234510	CCDC52	-0.77	-6.04	-0.53	3.05e-8	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs300703	0.654	rs300771	chr2:117241	A/G	cg21211680	chr2:198530	NA	-1.33	-7.55	-0.61	2.66e-11	Blood protein levels;
THYM	cis	rs3112255	0.935	rs1467130	chr2:101306319	T/C	cg01042948	chr2:101319752	NA	0.72	6.28	0.54	1.02e-8	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg16586182	chr3:47516702	SCAP	0.65	5.63	0.5	1.85e-7	Colorectal cancer;
THYM	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs11166927	0.967	rs56343024	chr8:140803580	G/A	cg16909799	chr8:140841666	TRAPPC9	0.62	5.46	0.49	3.78e-7	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs1691799	0.899	rs1168329	chr12:66731864	C/A	cg16791601	chr12:66731901	HELB	-0.75	-7.25	-0.6	1.08e-10	White blood cell count (basophil);
THYM	cis	rs2675662	0.525	rs12264025	chr10:75494450	A/G	cg15838173	chr10:75533400	FUT11	-0.5	-5.09	-0.46	1.82e-6	Psoriasis vulgaris;Psoriasis;
THYM	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg19016782	chr12:123741754	C12orf65	-0.69	-4.5	-0.42	1.94e-5	Neutrophil percentage of white cells;
THYM	cis	rs2067615	0.524	rs10778503	chr12:107090616	C/T	cg15890332	chr12:107067104	RFX4	0.46	5.38	0.48	5.42e-7	Heart rate;
THYM	cis	rs2731664	0.792	rs2545795	chr5:176887106	A/C	cg14098951	chr5:176875120	PRR7	0.57	5.01	0.46	2.54e-6	Intelligence (multi-trait analysis);
THYM	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg03388025	chr16:89894329	SPIRE2	0.53	4.49	0.42	1.97e-5	Vitiligo;
THYM	cis	rs11731175	1.000	rs10032287	chr4:189858607	A/G	cg00431894	chr4:189871012	NA	-0.82	-6.24	-0.54	1.2e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg22875332	chr1:76189707	ACADM	0.88	11.22	0.75	4.31e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs782590	0.807	rs782642	chr2:55928444	G/T	cg18811423	chr2:55921094	PNPT1	0.8	7.54	0.61	2.71e-11	Metabolic syndrome;
THYM	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg06221963	chr1:154839813	KCNN3	-0.56	-5.49	-0.49	3.4e-7	Prostate cancer;
THYM	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg05962950	chr11:130786565	SNX19	0.84	7.27	0.6	9.89e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9359856	0.564	rs7682	chr6:90352862	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.91	-8.11	-0.64	1.79e-12	Bipolar disorder;
THYM	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs863345	0.604	rs12044283	chr1:158463833	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02018176	chr4:1364513	KIAA1530	1.0	10.18	0.72	6.72e-17	Longevity;
THYM	cis	rs9653442	0.675	rs7605430	chr2:100647552	C/G	cg22139774	chr2:100720529	AFF3	0.33	4.68	0.43	9.47e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs6840360	0.571	rs55808836	chr4:152554991	C/T	cg17479576	chr4:152424074	FAM160A1	-0.83	-5.86	-0.52	6.62e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg02734326	chr4:10020555	SLC2A9	0.79	7.27	0.6	1.03e-10	Bone mineral density;
THYM	cis	rs728616	0.867	rs17879726	chr10:81698723	G/A	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6032067	1.000	rs6017519	chr20:43854677	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.41	-0.55	5.57e-9	Blood protein levels;
THYM	cis	rs6918586	0.636	rs198816	chr6:26127184	C/T	cg12310025	chr6:25882481	NA	0.68	5.56	0.5	2.47e-7	Schizophrenia;
THYM	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	10.62	0.74	7.85e-18	Chronic sinus infection;
THYM	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Body mass index;
THYM	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg11247378	chr22:39784982	NA	0.99	13.37	0.81	1.48e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg06640241	chr16:89574553	SPG7	0.67	5.14	0.47	1.48e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs2067615	0.579	rs12424114	chr12:107144328	A/G	cg15890332	chr12:107067104	RFX4	0.49	5.74	0.51	1.11e-7	Heart rate;
THYM	cis	rs13064411	0.696	rs1486897	chr3:113215818	G/A	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs611744	0.647	rs587340	chr8:109246032	C/A	cg21045802	chr8:109455806	TTC35	0.65	5.91	0.52	5.3e-8	Dupuytren's disease;
THYM	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6087990	1.000	rs2424901	chr20:31344512	A/G	cg13636640	chr20:31349939	DNMT3B	0.93	9.85	0.71	3.45e-16	Ulcerative colitis;
THYM	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg03161606	chr19:29218774	NA	0.87	7.71	0.62	1.23e-11	Methadone dose in opioid dependence;
THYM	cis	rs9311676	0.656	rs62258120	chr3:58391128	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs4363385	0.510	rs11205187	chr1:153053323	T/C	cg13444842	chr1:152974279	SPRR3	-0.61	-4.85	-0.45	4.82e-6	Inflammatory skin disease;
THYM	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg27211696	chr2:191398769	TMEM194B	-0.62	-4.72	-0.44	8.15e-6	Diastolic blood pressure;
THYM	cis	rs6032067	0.850	rs4566421	chr20:43783761	G/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.64	-5.47	-0.49	3.62e-7	Blood protein levels;
THYM	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg01579765	chr21:45077557	HSF2BP	0.43	5.53	0.49	2.76e-7	Mean corpuscular hemoglobin;
THYM	cis	rs9595908	0.965	rs9595893	chr13:33175793	G/T	cg12383807	chr13:33924137	NA	-0.53	-4.68	-0.43	9.69e-6	Body mass index;
THYM	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg10661904	chr17:79619235	PDE6G	-0.57	-5.3	-0.48	7.61e-7	Eye color traits;
THYM	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg08807101	chr21:30365312	RNF160	0.93	7.99	0.63	3.1e-12	Dental caries;
THYM	cis	rs1011108	1.000	rs1011108	chr2:26782621	A/G	cg18742855	chr2:26800399	C2orf70	-0.32	-4.62	-0.43	1.2e-5	Periodontal microbiota;
THYM	cis	rs72772090	0.539	rs3333	chr5:96115111	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6956675	0.793	rs6946559	chr7:62660568	A/T	cg27518014	chr7:62859535	LOC100287834	0.61	4.98	0.45	2.89e-6	Obesity-related traits;
THYM	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg20744362	chr22:50050164	C22orf34	0.75	6.64	0.56	1.94e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg02176678	chr2:219576539	TTLL4	0.68	6.85	0.58	7.25e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs28595532	0.920	rs115259971	chr4:119762654	T/C	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg03806693	chr22:41940476	POLR3H	-1.21	-10.85	-0.74	2.54e-18	Vitiligo;
THYM	cis	rs728616	0.867	rs17885031	chr10:81696091	G/A	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.929	rs876835	chr20:43827241	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg18538332	chr22:24372958	LOC391322	-0.89	-6.96	-0.58	4.32e-10	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7246657	0.943	rs13343502	chr19:37962292	C/T	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg21775007	chr8:11205619	TDH	0.74	6.67	0.57	1.65e-9	Retinal vascular caliber;
THYM	cis	rs67478160	0.595	rs12433109	chr14:104196607	G/A	cg26031613	chr14:104095156	KLC1	-0.57	-4.87	-0.45	4.41e-6	Schizophrenia;
THYM	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg08213375	chr14:104286397	PPP1R13B	0.44	5.34	0.48	6.26e-7	Schizophrenia;
THYM	cis	rs12282928	1.000	rs7949513	chr11:48329713	T/C	cg22827986	chr11:48284249	OR4X1	0.51	5.43	0.49	4.28e-7	Migraine - clinic-based;
THYM	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg24675056	chr1:15929824	NA	0.73	5.86	0.52	6.71e-8	Systolic blood pressure;
THYM	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-6.57	-0.56	2.64e-9	Chronic sinus infection;
THYM	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg08807101	chr21:30365312	RNF160	-0.7	-5.28	-0.48	8.18e-7	Dental caries;
THYM	cis	rs919433	0.680	rs2565161	chr2:198285554	C/G	cg05783139	chr2:198650985	BOLL	0.63	4.93	0.45	3.48e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs11937061	0.539	rs10518168	chr4:78157899	C/T	cg01930676	chr4:78783082	MRPL1	-0.57	-4.63	-0.43	1.17e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9938149	0.966	rs12448211	chr16:88330513	C/T	cg04379563	chr16:87392076	FBXO31	-0.59	-4.87	-0.45	4.51e-6	Corneal structure;Central corneal thickness;
THYM	cis	rs7267979	0.966	rs2261747	chr20:25261784	G/A	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1729951	0.575	rs35289288	chr3:136680568	C/T	cg12473912	chr3:136751656	NA	0.63	5.13	0.47	1.55e-6	Neuroticism;
THYM	cis	rs8114671	0.967	rs3746427	chr20:33730464	A/G	cg08999081	chr20:33150536	PIGU	0.55	4.92	0.45	3.65e-6	Height;
THYM	cis	rs6586111	0.967	rs6586106	chr10:82372300	A/C	cg03086067	chr10:82368399	SH2D4B	-0.51	-6.5	-0.56	3.64e-9	Capecitabine sensitivity;
THYM	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-5.33	-0.48	6.7e-7	Hemoglobin concentration;
THYM	cis	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.72	-0.44	7.99e-6	Resting heart rate;
THYM	cis	rs1003719	0.680	rs7275984	chr21:38505696	C/A	cg01329690	chr21:38580129	DSCR9	-0.38	-5.21	-0.47	1.09e-6	Eye color traits;
THYM	cis	rs8014204	0.967	rs1319171	chr14:75334096	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.58	-5.59	-0.5	2.13e-7	Caffeine consumption;
THYM	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.7	6.82	0.57	8.42e-10	Lymphocyte counts;
THYM	cis	rs7084402	0.935	rs12264028	chr10:60278140	C/T	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg03709012	chr19:19516395	GATAD2A	-0.84	-7.09	-0.59	2.37e-10	Tonsillectomy;
THYM	cis	rs4638749	0.773	rs4676190	chr2:108858619	A/G	cg23163573	chr2:108905468	SULT1C2	-0.4	-5.44	-0.49	4.12e-7	Blood pressure;
THYM	cis	rs10489202	1.000	rs7535138	chr1:167931462	T/G	cg24449463	chr1:168025552	DCAF6	-0.85	-6.66	-0.56	1.81e-9	Schizophrenia;
THYM	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg20887711	chr4:1340912	KIAA1530	-0.58	-4.64	-0.43	1.13e-5	Obesity-related traits;
THYM	cis	rs9493341	1.000	rs9493341	chr6:132830944	A/G	cg10097215	chr6:132834914	STX7	-0.38	-5.11	-0.46	1.67e-6	Red cell distribution width;
THYM	cis	rs9790314	1.000	rs62279921	chr3:161065441	T/C	cg04691961	chr3:161091175	C3orf57	-0.7	-6.22	-0.54	1.3e-8	Morning vs. evening chronotype;
THYM	cis	rs35883536	0.565	rs2647322	chr1:101031962	G/T	cg06223162	chr1:101003688	GPR88	0.85	7.33	0.6	7.63e-11	Monocyte count;
THYM	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.76	0.44	7.04e-6	Bipolar disorder;
THYM	cis	rs7705042	0.796	rs1835965	chr5:141501771	G/A	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs67981189	0.892	rs221899	chr14:71605268	C/T	cg15910301	chr14:71632612	NA	0.51	4.87	0.45	4.41e-6	Schizophrenia;
THYM	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs72828912	0.808	rs9358746	chr6:24058264	C/G	cg19882886	chr6:25043046	NA	-0.86	-4.47	-0.42	2.14e-5	Squamous cell lung carcinoma;
THYM	cis	rs4474465	1.000	rs11237514	chr11:78180179	A/G	cg19901956	chr11:77921274	USP35	-0.65	-4.82	-0.44	5.34e-6	Alzheimer's disease (survival time);
THYM	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg22431228	chr1:16359049	CLCNKA	-0.52	-4.99	-0.46	2.71e-6	Dilated cardiomyopathy;
THYM	cis	rs17006441	0.932	rs62251035	chr3:69868148	A/G	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.47	0.42	2.16e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg02891314	chr5:179741120	GFPT2	-0.88	-7.19	-0.59	1.45e-10	Height;
THYM	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg18512352	chr11:47633146	NA	-0.52	-6.14	-0.53	1.92e-8	Subjective well-being;
THYM	cis	rs9549260	0.755	rs17061491	chr13:41228210	T/A	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs7589342	0.831	rs13429270	chr2:106453060	C/T	cg14210321	chr2:106509881	NCK2	-0.75	-5.36	-0.48	5.72e-7	Addiction;
THYM	cis	rs7507204	0.530	rs4807470	chr19:3443470	A/T	cg08380311	chr19:3435252	NFIC	1.14	14.73	0.83	2.87e-26	Height;
THYM	trans	rs480407	0.857	rs270983	chr2:161686239	A/G	cg06548410	chr19:1997657	BTBD2	0.72	7.08	0.59	2.46e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs34638657	0.732	rs2967359	chr16:82202968	G/C	cg09439754	chr16:82129088	HSD17B2	-0.53	-5.14	-0.47	1.5e-6	Lung adenocarcinoma;
THYM	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg14583973	chr4:3374767	RGS12	0.61	5.87	0.52	6.43e-8	Serum sulfate level;
THYM	cis	rs17443541	0.507	rs1823488	chr2:200463830	G/A	cg03741458	chr2:200468445	NA	-0.8	-6.04	-0.53	3.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg08133631	chr1:26527909	CATSPER4	-0.59	-4.94	-0.45	3.38e-6	Obesity-related traits;
THYM	trans	rs877282	0.853	rs10904544	chr10:756966	A/G	cg22713356	chr15:30763199	NA	1.3	9.62	0.7	1.09e-15	Uric acid levels;
THYM	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg24006582	chr15:45444508	DUOX1	0.81	7.15	0.59	1.8e-10	Uric acid levels;
THYM	cis	rs9810089	0.711	rs711972	chr3:136110018	C/T	cg12473912	chr3:136751656	NA	0.58	4.93	0.45	3.53e-6	Gestational age at birth (child effect);
THYM	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs79387448	0.655	rs79091585	chr2:102917243	C/T	cg09003973	chr2:102972529	NA	1.29	6.87	0.58	6.55e-10	Gut microbiota (bacterial taxa);
THYM	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg24874828	chr4:187887005	NA	-0.72	-7.15	-0.59	1.75e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs754466	0.510	rs55893027	chr10:79588209	C/T	cg17075019	chr10:79541650	NA	-0.66	-5.41	-0.49	4.64e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7572733	0.534	rs13026569	chr2:198783330	C/G	cg00792783	chr2:198669748	PLCL1	-0.84	-6.0	-0.52	3.54e-8	Dermatomyositis;
THYM	cis	rs3087591	0.960	rs9903754	chr17:29634468	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.63	-5.33	-0.48	6.51e-7	Hip circumference;
THYM	cis	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg01364799	chr7:75623366	TMEM120A	-0.62	-4.46	-0.42	2.22e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs829883	0.664	rs865509	chr12:98854444	T/A	cg25150519	chr12:98850993	NA	0.55	5.49	0.49	3.29e-7	Colorectal adenoma (advanced);
THYM	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg22676075	chr6:135203613	NA	0.76	5.8	0.51	8.81e-8	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7582180	0.614	rs4340543	chr2:101005511	G/A	cg14675211	chr2:100938903	LONRF2	0.65	6.27	0.54	1.08e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9443645	0.527	rs9352663	chr6:79558164	T/C	cg05283184	chr6:79620031	NA	-0.58	-4.53	-0.42	1.71e-5	Intelligence (multi-trait analysis);
THYM	cis	rs13102973	0.720	rs13122447	chr4:135887524	C/T	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	trans	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg25427524	chr10:38739819	LOC399744	-0.57	-4.94	-0.45	3.32e-6	Extrinsic epigenetic age acceleration;
THYM	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg09307838	chr4:120376055	NA	0.71	5.07	0.46	1.98e-6	Corneal astigmatism;
THYM	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg27170947	chr2:26402098	FAM59B	0.6	5.11	0.46	1.67e-6	Gut microbiome composition (summer);
THYM	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg08807101	chr21:30365312	RNF160	-0.8	-6.25	-0.54	1.15e-8	Dental caries;
THYM	cis	rs2281845	0.859	rs1325311	chr1:201079088	G/A	cg17810781	chr1:201082982	CACNA1S	0.64	6.86	0.58	7.11e-10	Permanent tooth development;
THYM	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.53	-4.92	-0.45	3.67e-6	Lymphocyte counts;
THYM	cis	rs4866334	1.000	rs77523779	chr5:18486747	C/A	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs4262150	0.883	rs12659715	chr5:152310058	A/G	cg06854687	chr5:151642065	NA	0.66	4.7	0.43	8.85e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12530845	0.945	rs7799891	chr7:135322853	T/C	cg23117316	chr7:135346802	PL-5283	-0.65	-5.74	-0.51	1.15e-7	Red blood cell traits;
THYM	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg26924012	chr15:45694286	SPATA5L1	-1.04	-9.15	-0.68	1.09e-14	Homoarginine levels;
THYM	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg22974920	chr21:40686053	BRWD1	0.74	5.03	0.46	2.36e-6	Cognitive function;
THYM	cis	rs11992162	0.551	rs13268217	chr8:11782609	T/A	cg21775007	chr8:11205619	TDH	-0.59	-4.55	-0.42	1.56e-5	Monocyte count;
THYM	cis	rs7666738	0.791	rs11097610	chr4:99011795	C/G	cg17366294	chr4:99064904	C4orf37	0.57	6.8	0.57	9.3e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs6570726	0.935	rs386344	chr6:145855622	A/G	cg23711669	chr6:146136114	FBXO30	0.85	8.7	0.67	9.74e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg15962314	chr1:44399869	ARTN	0.53	5.39	0.48	5.01e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7258465	0.965	rs10408290	chr19:18542701	C/T	cg04166595	chr19:18636596	NA	0.62	4.7	0.43	8.77e-6	Breast cancer;
THYM	cis	rs72828912	0.731	rs9379635	chr6:24067548	C/T	cg26336265	chr6:25042955	NA	0.89	5.85	0.51	6.83e-8	Squamous cell lung carcinoma;
THYM	trans	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg10856724	chr12:34555212	NA	-1.02	-9.32	-0.69	4.7e-15	Morning vs. evening chronotype;
THYM	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-1.16	-9.09	-0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg02725872	chr8:58115012	NA	-0.71	-5.75	-0.51	1.06e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs4660306	0.961	rs1337902	chr1:45952066	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.43	-0.49	4.37e-7	Homocysteine levels;
THYM	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg10802521	chr3:52805072	NEK4	-0.73	-6.4	-0.55	5.97e-9	Bipolar disorder;
THYM	cis	rs11676855	1.000	rs729866	chr2:235899359	G/A	cg14917874	chr2:235941519	SH3BP4	0.51	4.46	0.42	2.25e-5	Dialysis-related mortality;
THYM	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg08885076	chr2:99613938	TSGA10	0.53	5.14	0.47	1.46e-6	Chronic sinus infection;
THYM	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	4.55	0.42	1.61e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9287719	0.810	rs1990612	chr2:10781944	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-4.59	-0.43	1.37e-5	Prostate cancer;
THYM	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.1	7.87	0.63	5.7e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs635808	0.500	rs13198549	chr6:167173697	G/A	cg17732216	chr6:167178280	RPS6KA2	0.59	4.79	0.44	6.24e-6	Dental caries;
THYM	cis	rs11048434	0.761	rs1805721	chr12:9147569	A/G	cg13575925	chr12:9217583	LOC144571	-0.55	-5.45	-0.49	3.89e-7	Sjögren's syndrome;
THYM	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg22968622	chr17:43663579	NA	1.16	10.21	0.72	5.86e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg27490568	chr2:178487706	NA	0.58	5.35	0.48	6.1e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14240646	chr10:27532245	ACBD5	-0.86	-4.94	-0.45	3.36e-6	Breast cancer;
THYM	cis	rs28647808	0.881	rs7019683	chr9:136215642	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.1	-4.73	-0.44	7.89e-6	Blood protein levels;
THYM	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg06808227	chr14:105710500	BRF1	-1.02	-8.92	-0.68	3.29e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg08213375	chr14:104286397	PPP1R13B	0.45	4.63	0.43	1.16e-5	Reticulocyte count;
THYM	cis	rs500891	0.525	rs750384	chr6:84030422	C/T	cg08257003	chr6:84140564	ME1	0.56	4.47	0.42	2.19e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg24672777	chr11:48374446	OR4C45	-0.97	-6.29	-0.54	9.63e-9	Axial length;
THYM	cis	rs988913	1.000	rs9475081	chr6:54813738	G/T	cg19716238	chr6:54711378	FAM83B	0.52	5.2	0.47	1.14e-6	Menarche (age at onset);
THYM	cis	rs2732480	0.500	rs7297824	chr12:48598650	T/C	cg21466736	chr12:48725269	NA	-0.54	-4.88	-0.45	4.33e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg16031515	chr1:205743344	RAB7L1	0.53	5.12	0.47	1.6e-6	Menarche (age at onset);
THYM	cis	rs67311347	0.544	rs2278927	chr3:40350447	G/A	cg24209194	chr3:40518798	ZNF619	0.54	4.48	0.42	2.06e-5	Renal cell carcinoma;
THYM	cis	rs7695732	0.595	rs35232147	chr4:89916224	T/C	cg17769793	chr4:89976368	FAM13A	-0.51	-5.49	-0.49	3.34e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg24675056	chr1:15929824	NA	0.73	5.79	0.51	9.09e-8	Systolic blood pressure;
THYM	cis	rs9443645	0.509	rs9352668	chr6:79572678	A/G	cg05283184	chr6:79620031	NA	-0.7	-6.21	-0.54	1.38e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2034088	0.965	rs11651340	chr17:425099	A/C	cg06217071	chr17:408420	NA	-0.77	-7.55	-0.61	2.65e-11	Hip circumference adjusted for BMI;
THYM	cis	rs10899021	0.920	rs76121309	chr11:74343921	A/T	cg25880958	chr11:74394337	NA	-0.78	-4.75	-0.44	7.24e-6	Response to metformin (IC50);
THYM	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg03188948	chr7:1209495	NA	0.9	5.0	0.46	2.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.39	-0.48	5.14e-7	Menopause (age at onset);
THYM	cis	rs6754311	0.509	rs13412397	chr2:136470714	G/A	cg07169764	chr2:136633963	MCM6	-0.71	-5.75	-0.51	1.06e-7	Mosquito bite size;
THYM	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08280861	chr8:58055591	NA	0.7	5.15	0.47	1.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg15448220	chr1:150897856	SETDB1	0.85	7.1	0.59	2.25e-10	Tonsillectomy;
THYM	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg05717871	chr11:638507	DRD4	-0.65	-5.34	-0.48	6.42e-7	Systemic lupus erythematosus;
THYM	cis	rs4908768	0.555	rs11582339	chr1:8898807	A/C	cg06972019	chr1:8937448	ENO1	0.56	4.86	0.45	4.55e-6	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
THYM	cis	rs6502050	0.723	rs4789698	chr17:80179786	C/T	cg21773646	chr17:80085082	CCDC57	-0.35	-4.91	-0.45	3.72e-6	Life satisfaction;
THYM	cis	rs1113500	0.933	rs12035689	chr1:108636756	T/C	cg06207961	chr1:108661230	NA	0.64	5.09	0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	trans	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg08901578	chr4:187885870	NA	-0.68	-6.61	-0.56	2.18e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg08772003	chr10:104629869	AS3MT	-0.57	-5.13	-0.47	1.54e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	4.88	0.45	4.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7107174	0.748	rs11237458	chr11:78050849	A/T	cg19901956	chr11:77921274	USP35	-0.64	-5.3	-0.48	7.43e-7	Testicular germ cell tumor;
THYM	cis	rs941408	1.000	rs1736179	chr19:2795516	T/A	cg19693284	chr19:2783607	SGTA	0.69	5.42	0.49	4.42e-7	Total cholesterol levels;
THYM	cis	rs6840360	0.571	rs718801	chr4:152549247	C/T	cg22705602	chr4:152727874	NA	-0.78	-8.36	-0.65	5.29e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg11905131	chr22:24372483	LOC391322	-0.81	-7.22	-0.6	1.26e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs208520	0.661	rs207099	chr6:66796373	A/C	cg07460842	chr6:66804631	NA	-1.06	-7.89	-0.63	5.14e-12	Exhaled nitric oxide output;
THYM	cis	rs6429082	0.764	rs291369	chr1:235691913	T/C	cg26050004	chr1:235667680	B3GALNT2	0.76	6.32	0.54	8.3e-9	Adiposity;
THYM	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg00383909	chr3:49044727	WDR6	1.12	6.66	0.56	1.75e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs757081	0.667	rs17561348	chr11:17161615	C/T	cg15432903	chr11:17409602	KCNJ11	0.48	4.6	0.43	1.29e-5	Systolic blood pressure;
THYM	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg21433313	chr16:3507492	NAT15	0.56	4.67	0.43	9.93e-6	Body mass index (adult);
THYM	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg00647820	chr17:40259828	DHX58	-0.62	-4.65	-0.43	1.06e-5	Fibrinogen levels;
THYM	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg10518543	chr12:38710700	ALG10B	-0.59	-4.7	-0.43	8.88e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7849270	0.879	rs2229419	chr9:131857630	C/T	cg14069949	chr9:131965419	NA	-0.5	-4.46	-0.42	2.28e-5	Blood metabolite ratios;
THYM	cis	rs7679	1.000	rs7679	chr20:44576502	C/T	cg09053081	chr20:44746392	CD40	-0.82	-4.55	-0.42	1.6e-5	Triglycerides;HDL cholesterol;Gut microbiota (functional units);
THYM	cis	rs2777491	0.574	rs316616	chr15:41746276	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.39	-0.83	1.36e-25	Ulcerative colitis;
THYM	cis	rs7580658	0.676	rs4150407	chr2:128049631	C/T	cg10021288	chr2:128175891	PROC	0.63	5.89	0.52	5.79e-8	Protein C levels;
THYM	cis	rs17253792	0.822	rs7150841	chr14:56088986	T/C	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs2820651	0.614	rs55691140	chr10:1491025	G/A	cg27404824	chr10:1454848	ADARB2	0.87	4.72	0.44	8.03e-6	Migraine with aura;
THYM	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg11327659	chr7:150037044	RARRES2	0.43	5.21	0.47	1.11e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11048434	0.723	rs2080116	chr12:9138183	A/G	cg04155231	chr12:9217510	LOC144571	0.5	4.86	0.45	4.7e-6	Sjögren's syndrome;
THYM	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.58	-0.5	2.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11809207	1.000	rs55695238	chr1:26521931	C/G	cg03844060	chr1:26490628	NA	0.68	4.87	0.45	4.36e-6	Height;
THYM	cis	rs854765	0.624	rs7501812	chr17:17750907	G/A	cg16928487	chr17:17741425	SREBF1	0.53	5.11	0.46	1.69e-6	Total body bone mineral density;
THYM	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.55	-0.56	2.92e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.96e-6	Intelligence (multi-trait analysis);
THYM	cis	rs354225	0.544	rs7340302	chr2:54803671	A/C	cg23486701	chr2:54789491	SPTBN1	0.34	4.49	0.42	2e-5	Schizophrenia;
THYM	cis	rs7572733	0.534	rs11899188	chr2:198740121	C/T	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs295140	1.000	rs13005573	chr2:201164696	G/C	cg04283868	chr2:201171347	SPATS2L	0.74	5.53	0.49	2.81e-7	QT interval;
THYM	cis	rs9826463	0.582	rs73238143	chr3:142054935	A/G	cg20824294	chr3:142316082	PLS1	0.79	5.44	0.49	4.19e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs672413	0.620	rs663646	chr5:78285778	G/A	cg17845680	chr5:78281827	ARSB	-0.56	-5.18	-0.47	1.24e-6	Blood and toenail selenium levels;Blood protein levels;
THYM	cis	rs17253792	0.822	rs17253723	chr14:56154015	A/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg05182265	chr7:156933206	UBE3C	-0.69	-9.32	-0.69	4.58e-15	Body mass index;
THYM	cis	rs2404602	0.647	rs11072620	chr15:77048770	T/A	cg23625390	chr15:77176239	SCAPER	-0.83	-5.98	-0.52	3.96e-8	Blood metabolite levels;
THYM	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg27286337	chr10:134555280	INPP5A	0.87	6.66	0.56	1.75e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs6840360	0.571	rs10007653	chr4:152524055	A/G	cg22705602	chr4:152727874	NA	-0.78	-8.73	-0.67	8.56e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs240764	0.782	rs151637	chr6:101104191	C/T	cg21058520	chr6:100914733	NA	-0.57	-5.07	-0.46	1.96e-6	Neuroticism;
THYM	cis	rs12348691	0.503	rs1348386	chr9:100612807	A/G	cg13688889	chr9:100608707	NA	-1.05	-6.18	-0.54	1.61e-8	Alopecia areata;
THYM	cis	rs12754538	0.777	rs12029303	chr1:8638666	T/C	cg06159269	chr1:8767347	RERE	0.22	4.58	0.43	1.39e-5	Subjective well-being;
THYM	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg00814883	chr7:100076585	TSC22D4	-0.95	-6.39	-0.55	6.08e-9	Platelet count;
THYM	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.76	6.96	0.58	4.27e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg17644776	chr2:200775616	C2orf69	-0.73	-5.13	-0.47	1.54e-6	Schizophrenia;
THYM	cis	rs728616	0.867	rs3088308	chr10:81697868	A/T	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg03388043	chr17:80084554	CCDC57	0.69	5.98	0.52	3.85e-8	Life satisfaction;
THYM	cis	rs9911578	0.813	rs12452313	chr17:57129882	C/A	cg12560992	chr17:57184187	TRIM37	-0.85	-7.51	-0.61	3.25e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg06636001	chr8:8085503	FLJ10661	0.77	7.34	0.6	7.25e-11	Systolic blood pressure;
THYM	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.29	5.03	0.46	2.33e-6	Obesity-related traits;
THYM	cis	rs9831754	0.865	rs9842838	chr3:78387904	A/C	cg06138941	chr3:78371609	NA	-0.63	-4.49	-0.42	2e-5	Calcium levels;
THYM	cis	rs7582180	0.568	rs10186134	chr2:100939501	T/A	cg14675211	chr2:100938903	LONRF2	0.62	5.99	0.52	3.73e-8	Intelligence (multi-trait analysis);
THYM	cis	rs36051895	0.623	rs7023639	chr9:5244058	A/C	cg02405213	chr9:5042618	JAK2	-0.94	-9.72	-0.71	6.6e-16	Pediatric autoimmune diseases;
THYM	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	7.01	0.58	3.42e-10	Platelet count;
THYM	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg23711669	chr6:146136114	FBXO30	-0.88	-8.57	-0.66	1.89e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg02725872	chr8:58115012	NA	-0.81	-5.05	-0.46	2.12e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs346785	0.666	rs8072620	chr17:74283253	A/G	cg09812376	chr17:74270190	QRICH2	-0.51	-5.14	-0.47	1.48e-6	White matter hyperintensities in ischemic stroke;
THYM	cis	rs2282300	1.000	rs12796693	chr11:30429583	A/C	cg25418670	chr11:30344373	C11orf46	-0.65	-5.06	-0.46	2.08e-6	Morning vs. evening chronotype;
THYM	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22509189	chr2:225307070	NA	-0.89	-7.54	-0.61	2.77e-11	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg09877947	chr5:131593287	PDLIM4	0.58	4.76	0.44	6.94e-6	Blood metabolite levels;
THYM	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg00757033	chr12:89920650	WDR51B	0.74	11.52	0.76	9.94e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs8192282	0.739	rs6697103	chr1:154499926	C/T	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7267979	0.933	rs2261109	chr20:25259200	T/C	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs28595532	0.920	rs116795224	chr4:119734570	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs11077998	0.935	rs12185276	chr17:80498997	T/C	cg11779900	chr17:80519722	FOXK2	-0.53	-4.51	-0.42	1.83e-5	Reticulocyte fraction of red cells;
THYM	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg17054759	chr22:49844102	NA	-0.48	-4.49	-0.42	2e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs977987	0.750	rs4888414	chr16:75447233	A/G	cg03315344	chr16:75512273	CHST6	0.76	6.16	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg04315214	chr1:2043799	PRKCZ	0.56	4.66	0.43	1.02e-5	Height;
THYM	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg27170947	chr2:26402098	FAM59B	0.81	5.23	0.47	1.02e-6	Gut microbiome composition (summer);
THYM	cis	rs12310956	0.510	rs7965329	chr12:33868199	C/A	cg10856724	chr12:34555212	NA	-0.64	-5.78	-0.51	9.56e-8	Morning vs. evening chronotype;
THYM	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg15247329	chr7:2764246	NA	-0.74	-6.31	-0.54	8.64e-9	Height;
THYM	cis	rs7586879	0.828	rs11685125	chr2:25092104	A/G	cg01884057	chr2:25150051	NA	0.51	4.49	0.42	2.01e-5	Body mass index;
THYM	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg11941060	chr3:133502564	NA	-0.81	-6.78	-0.57	1e-9	Iron status biomarkers;
THYM	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.72	-5.21	-0.47	1.08e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs600806	0.850	rs11102976	chr1:109917540	G/C	cg02175308	chr1:109941060	SORT1	-0.56	-4.99	-0.46	2.76e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1696756	0.638	rs1285274	chr17:77829907	G/A	cg00646381	chr17:77835854	NA	0.47	5.43	0.49	4.26e-7	Glucocorticoid-induced osteonecrosis (age 10 years and older);
THYM	cis	rs4891159	0.824	rs17059362	chr18:74144307	G/A	cg24786174	chr18:74118243	ZNF516	-0.87	-9.72	-0.71	6.43e-16	Longevity;
THYM	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.7	8.98	0.68	2.44e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2976388	1.000	rs2920280	chr8:143761144	G/C	cg06565975	chr8:143823917	SLURP1	-0.53	-5.69	-0.5	1.41e-7	Urinary tract infection frequency;
THYM	cis	rs9326248	0.510	rs4938332	chr11:116930798	A/G	cg20608306	chr11:116969690	SIK3	0.64	7.97	0.63	3.42e-12	Blood protein levels;
THYM	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs11227306	0.934	rs2303385	chr11:65640562	G/A	cg00576331	chr11:65640516	EFEMP2	0.71	5.48	0.49	3.49e-7	DNA methylation (variation);
THYM	cis	rs4769475	1.000	rs9512130	chr13:26733193	T/A	cg13319468	chr13:27597730	NA	-0.64	-5.18	-0.47	1.26e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs10504073	0.669	rs57085792	chr8:50018355	T/C	cg00325661	chr8:49890786	NA	0.86	7.69	0.62	1.35e-11	Blood metabolite ratios;
THYM	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg11266682	chr4:10021025	SLC2A9	-0.52	-6.28	-0.54	1.03e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.62	-0.5	1.93e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7678296	0.649	rs60691639	chr4:37239925	T/C	cg06805348	chr4:37245195	KIAA1239	1.03	5.19	0.47	1.19e-6	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs35883536	0.647	rs10875328	chr1:101169328	C/T	cg06223162	chr1:101003688	GPR88	-0.75	-6.26	-0.54	1.12e-8	Monocyte count;
THYM	cis	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg09307838	chr4:120376055	NA	-0.7	-5.3	-0.48	7.43e-7	Corneal astigmatism;
THYM	cis	rs910187	0.596	rs12329631	chr20:45794427	C/T	cg27589058	chr20:45804311	EYA2	-0.56	-4.73	-0.44	7.74e-6	Migraine;
THYM	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9948	1.000	rs9948	chr2:97500800	C/G	cg01990225	chr2:97406019	LMAN2L	0.88	4.83	0.44	5.13e-6	Erectile dysfunction and prostate cancer treatment;
THYM	cis	rs354225	0.544	rs11902987	chr2:54805587	C/T	cg23486701	chr2:54789491	SPTBN1	0.36	4.69	0.43	9.11e-6	Schizophrenia;
THYM	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg00277334	chr10:82204260	NA	-0.83	-10.18	-0.72	6.99e-17	Post bronchodilator FEV1;
THYM	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.42	-5.09	-0.46	1.78e-6	Longevity;Endometriosis;
THYM	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg22535103	chr8:58192502	C8orf71	0.91	4.59	0.43	1.36e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs912057	0.932	rs1294406	chr6:6737737	A/G	cg13809441	chr6:6737631	NA	0.44	4.92	0.45	3.64e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg19052272	chr2:3704530	ALLC	-0.68	-5.08	-0.46	1.92e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg07507251	chr3:52567010	NT5DC2	0.42	4.98	0.45	2.85e-6	Bipolar disorder;
THYM	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.72	-5.76	-0.51	1.05e-7	Tonsillectomy;
THYM	cis	rs4481887	0.676	rs1538704	chr1:248523554	C/T	cg00666640	chr1:248458726	OR2T12	0.55	4.79	0.44	6.14e-6	Common traits (Other);
THYM	cis	rs6032067	0.538	rs17422688	chr20:43739119	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.6	-6.08	-0.53	2.48e-8	Blood protein levels;
THYM	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg00277334	chr10:82204260	NA	-0.82	-9.99	-0.72	1.75e-16	Post bronchodilator FEV1;
THYM	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg17173187	chr15:85201210	NMB	0.56	5.66	0.5	1.6e-7	Schizophrenia;
THYM	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	cis	rs2404602	0.647	rs4312276	chr15:77164361	T/C	cg23625390	chr15:77176239	SCAPER	-0.81	-5.61	-0.5	1.96e-7	Blood metabolite levels;
THYM	cis	rs11039798	0.841	rs11039760	chr11:48479009	C/T	cg24672777	chr11:48374446	OR4C45	-1.08	-5.88	-0.52	6.11e-8	Axial length;
THYM	cis	rs6032067	0.714	rs6104069	chr20:43852243	C/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.61	-5.97	-0.52	4.08e-8	Blood protein levels;
THYM	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg13695892	chr22:41940480	POLR3H	0.91	6.53	0.56	3.27e-9	Vitiligo;
THYM	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22857025	chr5:266934	NA	-1.5	-9.71	-0.71	6.9e-16	Breast cancer;
THYM	cis	rs9560113	1.000	rs4773387	chr13:112180955	T/C	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs9359856	0.636	rs4706345	chr6:90301565	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-6.75	-0.57	1.16e-9	Bipolar disorder;
THYM	cis	rs3741151	0.773	rs17310374	chr11:73274874	T/C	cg12959048	chr11:73096162	RELT	-0.52	-4.62	-0.43	1.21e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7267979	0.966	rs2257712	chr20:25264910	T/C	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg19077165	chr18:44547161	KATNAL2	0.61	7.58	0.61	2.28e-11	Personality dimensions;
THYM	cis	rs7833986	0.501	rs2953901	chr8:56981824	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.4	0.6	5.43e-11	Height;
THYM	cis	rs9810089	0.903	rs711975	chr3:136235908	T/C	cg12473912	chr3:136751656	NA	0.62	5.22	0.47	1.05e-6	Gestational age at birth (child effect);
THYM	cis	rs7772486	0.790	rs4280983	chr6:146280790	G/C	cg13319975	chr6:146136371	FBXO30	0.7	5.77	0.51	9.94e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg16325326	chr1:53192061	ZYG11B	0.82	7.77	0.62	9e-12	Monocyte count;
THYM	cis	rs3916	0.955	rs34030695	chr12:121156496	G/A	cg10600917	chr12:121163489	ACADS	0.6	5.2	0.47	1.13e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg26384229	chr12:38710491	ALG10B	0.97	7.44	0.61	4.48e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg19913688	chr11:428466	ANO9	0.89	4.6	0.43	1.28e-5	Body mass index;
THYM	cis	rs7582403	0.789	rs1597406	chr2:148876998	T/A	cg23727674	chr2:148602993	ACVR2A	-0.62	-5.11	-0.46	1.69e-6	Neuroticism;
THYM	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg05552183	chr6:42928497	GNMT	0.59	4.69	0.43	9.17e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs28595532	0.688	rs116053430	chr4:119731375	G/A	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg16342193	chr10:102329863	NA	-0.46	-4.48	-0.42	2.1e-5	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7582180	0.676	rs6542940	chr2:100982144	A/T	cg08017756	chr2:100939284	LONRF2	-0.74	-7.57	-0.61	2.4e-11	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs995000	0.868	rs9787156	chr1:63179212	G/A	cg06896770	chr1:63153194	DOCK7	-0.68	-4.66	-0.43	1.01e-5	Triglyceride levels;
THYM	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.9	-6.56	-0.56	2.78e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9796	0.662	rs8033435	chr15:41436479	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.62	-4.92	-0.45	3.62e-6	Menopause (age at onset);
THYM	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.72	5.72	0.51	1.24e-7	Blood protein levels;
THYM	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg17173187	chr15:85201210	NMB	0.55	5.34	0.48	6.21e-7	Schizophrenia;
THYM	cis	rs7323507	0.636	rs7329400	chr13:110621437	T/C	cg07669776	chr13:110975691	COL4A2	-0.53	-4.93	-0.45	3.55e-6	Lung function (FVC);
THYM	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg04362960	chr10:104952993	NT5C2	0.65	5.6	0.5	2.04e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs4792901	0.765	rs9905358	chr17:41555474	A/G	cg21940313	chr17:41620911	ETV4	-0.54	-5.13	-0.47	1.5e-6	Dupuytren's disease;
THYM	cis	rs7809950	0.817	rs2807	chr7:107260778	G/A	cg23024343	chr7:107201750	COG5	0.99	8.18	0.64	1.26e-12	Coronary artery disease;
THYM	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg17279839	chr7:150038598	RARRES2	0.55	5.44	0.49	4.08e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.76	-0.44	6.98e-6	Crohn's disease;
THYM	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs9992101	0.547	rs10029777	chr4:77411030	C/T	cg20311846	chr4:77356250	SHROOM3	-0.45	-4.72	-0.44	8.12e-6	Creatinine levels;
THYM	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg11764359	chr7:65958608	NA	0.67	4.77	0.44	6.52e-6	Aortic root size;
THYM	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	5.16	0.47	1.38e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2455799	0.613	rs1393969	chr3:15730257	G/A	cg16303742	chr3:15540471	COLQ	-0.54	-5.62	-0.5	1.92e-7	Mean platelet volume;
THYM	cis	rs1747683	0.809	rs1547772	chr10:13383449	T/C	cg00142036	chr10:13388442	SEPHS1	-0.29	-5.17	-0.47	1.27e-6	IgG glycosylation;
THYM	cis	rs9549260	0.755	rs2721066	chr13:41156188	C/T	cg21288729	chr13:41239152	FOXO1	-0.71	-5.53	-0.49	2.84e-7	Red blood cell count;
THYM	cis	rs2354432	0.556	rs2275249	chr1:146759320	C/G	cg25205988	chr1:146714368	CHD1L	1.07	5.61	0.5	2.01e-7	Mitochondrial DNA levels;
THYM	cis	rs72901758	0.662	rs56326958	chr17:76250439	C/G	cg25512537	chr17:76250053	NA	0.44	6.11	0.53	2.17e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
THYM	cis	rs2235642	0.893	rs8051295	chr16:1588087	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.66	-5.8	-0.51	8.5e-8	Coronary artery disease;
THYM	cis	rs4266144	0.569	rs729257	chr3:156828823	G/A	cg16248515	chr3:156840234	NA	-0.57	-5.28	-0.48	8.33e-7	Coronary artery disease;
THYM	cis	rs7072216	0.727	rs942808	chr10:100168102	C/A	cg26618903	chr10:100175079	PYROXD2	-0.48	-4.6	-0.43	1.33e-5	Metabolite levels;
THYM	cis	rs7772486	0.875	rs2814877	chr6:146299763	C/G	cg23711669	chr6:146136114	FBXO30	0.96	10.33	0.73	3.3e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs72827839	0.846	rs16954078	chr17:46306127	T/A	cg23391107	chr17:45924227	SP6	0.85	5.05	0.46	2.17e-6	Ease of getting up in the morning;
THYM	cis	rs7089973	0.565	rs7082836	chr10:116646237	G/A	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.65	-0.43	1.06e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs11771526	0.792	rs62457499	chr7:32319197	T/C	cg27532318	chr7:32358331	NA	0.77	5.06	0.46	2.03e-6	Body mass index;
THYM	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg17264618	chr3:40429014	ENTPD3	-0.56	-5.45	-0.49	3.96e-7	Renal cell carcinoma;
THYM	cis	rs12291225	0.535	rs12806025	chr11:14413817	G/A	cg05501817	chr11:14380813	RRAS2	-0.74	-6.1	-0.53	2.24e-8	Sense of smell;
THYM	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg04455712	chr21:45112962	RRP1B	-0.51	-4.72	-0.44	8.23e-6	Mean corpuscular volume;
THYM	cis	rs919433	0.680	rs788018	chr2:198265526	A/G	cg00792783	chr2:198669748	PLCL1	0.82	5.67	0.5	1.54e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4808199	0.948	rs2074300	chr19:19380996	G/T	cg03709012	chr19:19516395	GATAD2A	1.16	6.77	0.57	1.04e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg10589385	chr1:150898437	SETDB1	0.59	4.68	0.43	9.37e-6	Melanoma;
THYM	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	4.96	0.45	3.07e-6	Hip circumference adjusted for BMI;
THYM	cis	rs4769475	0.957	rs301070	chr13:26718016	T/C	cg13319468	chr13:27597730	NA	-0.67	-5.5	-0.49	3.27e-7	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs11089937	0.651	rs2330015	chr22:22536956	A/G	cg06866756	chr22:22471216	NA	0.45	5.09	0.46	1.83e-6	Periodontitis (PAL4Q3);
THYM	cis	rs11089937	0.616	rs12484472	chr22:22534526	C/T	cg06866756	chr22:22471216	NA	-0.41	-4.52	-0.42	1.76e-5	Periodontitis (PAL4Q3);
THYM	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg02782426	chr3:40428986	ENTPD3	0.52	4.58	0.43	1.4e-5	Renal cell carcinoma;
THYM	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg02753203	chr1:228287806	NA	-0.65	-5.71	-0.51	1.3e-7	Diastolic blood pressure;
THYM	cis	rs79349575	0.783	rs903567	chr17:46980318	C/T	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs17784882	0.524	rs7433300	chr3:47120640	G/A	cg02527881	chr3:46936655	PTH1R	-0.58	-5.31	-0.48	7.1e-7	QT interval;
THYM	cis	rs6089584	0.566	rs12373885	chr20:60556393	A/C	cg06108461	chr20:60628389	TAF4	-0.79	-6.32	-0.54	8.42e-9	Body mass index;
THYM	cis	rs2806561	0.704	rs663942	chr1:23522476	G/A	cg19743168	chr1:23544995	NA	0.62	6.31	0.54	8.74e-9	Height;
THYM	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg03159660	chr11:2078197	NA	-0.62	-4.52	-0.42	1.77e-5	Longevity;
THYM	cis	rs7695732	0.550	rs34869341	chr4:89916004	T/G	cg17769793	chr4:89976368	FAM13A	-0.5	-5.27	-0.48	8.39e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	trans	rs6462411	0.818	rs2057920	chr7:3909819	G/A	cg14907788	chr19:2555976	GNG7	0.69	7.12	0.59	2.06e-10	Quantitative traits;
THYM	cis	rs909002	0.789	rs2139539	chr1:32117779	C/T	cg13919466	chr1:32135498	COL16A1	-0.5	-4.92	-0.45	3.69e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3126085	0.935	rs4845733	chr1:152162568	T/C	cg10321714	chr1:152280068	FLG	0.65	4.72	0.44	8.02e-6	Atopic dermatitis;
THYM	cis	rs9644630	0.897	rs13266857	chr8:19364515	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.8	-8.55	-0.66	2.07e-13	Oropharynx cancer;
THYM	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	-0.49	-4.59	-0.43	1.37e-5	Lymphocyte counts;
THYM	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg06221963	chr1:154839813	KCNN3	-0.9	-11.47	-0.76	1.28e-19	Prostate cancer;
THYM	cis	rs11608355	0.960	rs10774691	chr12:109859830	C/T	cg11367159	chr12:110044531	NA	0.66	6.29	0.54	9.83e-9	Neuroticism;
THYM	cis	rs654384	0.507	rs4723420	chr7:4174889	A/T	cg04612959	chr7:4183976	SDK1	0.51	4.47	0.42	2.13e-5	Positive affect;
THYM	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg03684893	chr10:554711	DIP2C	-0.73	-6.51	-0.56	3.56e-9	Psychosis in Alzheimer's disease;
THYM	cis	rs6424115	0.931	rs11800561	chr1:24164398	T/G	cg15997130	chr1:24165203	NA	0.76	6.58	0.56	2.53e-9	Immature fraction of reticulocytes;
THYM	cis	rs713587	0.713	rs11125884	chr2:25239264	C/T	cg15423357	chr2:25149977	NA	0.58	6.33	0.54	8.24e-9	Body mass index in non-asthmatics;
THYM	cis	rs6924995	0.501	rs2142671	chr6:16197349	A/G	cg11805552	chr6:16175128	NA	0.57	4.85	0.45	4.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg03161606	chr19:29218774	NA	0.86	7.67	0.62	1.52e-11	Methadone dose in opioid dependence;
THYM	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg09469691	chr10:81107165	PPIF	0.73	6.01	0.52	3.46e-8	Height;
THYM	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg11871910	chr12:69753446	YEATS4	0.68	5.5	0.49	3.17e-7	Response to diuretic therapy;
THYM	cis	rs6032067	0.759	rs2868239	chr20:43873368	T/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-6.24	-0.54	1.22e-8	Blood protein levels;
THYM	cis	rs1568889	0.877	rs34351528	chr11:28304293	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	4.58	0.43	1.4e-5	Bipolar disorder;
THYM	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	5.46	0.49	3.85e-7	Lung cancer in ever smokers;
THYM	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg22683308	chr4:1340831	KIAA1530	-0.6	-4.67	-0.43	9.77e-6	Longevity;
THYM	cis	rs9814567	1.000	rs1863913	chr3:134200205	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-8.35	-0.65	5.56e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg09354556	chr3:47051341	NA	0.44	4.57	0.42	1.46e-5	Colorectal cancer;
THYM	cis	rs4907240	0.961	rs4907241	chr2:97241928	C/T	cg01950434	chr2:97203154	ARID5A	0.58	4.89	0.45	4.17e-6	Event-related brain oscillations;
THYM	cis	rs7084921	0.608	rs11597561	chr10:101863041	T/C	cg11344164	chr10:101878520	NA	-0.57	-4.93	-0.45	3.47e-6	Bone mineral density;
THYM	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg07636037	chr3:49044803	WDR6	0.73	5.06	0.46	2.02e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs4363385	0.647	rs1995308	chr1:153014082	A/T	cg06563695	chr1:153756334	NA	-0.59	-4.57	-0.42	1.49e-5	Inflammatory skin disease;
THYM	cis	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg08133631	chr1:26527909	CATSPER4	-0.55	-4.59	-0.43	1.34e-5	Obesity-related traits;
THYM	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg03929089	chr4:120376271	NA	-0.97	-11.74	-0.77	3.41e-20	Height;
THYM	cis	rs2213920	0.619	rs4979529	chr9:118197686	T/A	cg13918206	chr9:118159781	DEC1	0.86	4.9	0.45	3.86e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg12000587	chr17:30186630	C17orf79	0.43	4.67	0.43	1.01e-5	Hip circumference adjusted for BMI;
THYM	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	5.46	0.49	3.85e-7	Lung cancer in ever smokers;
THYM	cis	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg08133631	chr1:26527909	CATSPER4	-0.55	-4.59	-0.43	1.34e-5	Obesity-related traits;
THYM	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.58	0.5	2.29e-7	Rheumatoid arthritis;
THYM	cis	rs67311347	0.549	rs60249586	chr3:40246659	G/A	cg13683864	chr3:40499215	RPL14	-0.69	-6.02	-0.53	3.21e-8	Renal cell carcinoma;
THYM	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	11.87	0.77	1.82e-20	Chronic sinus infection;
THYM	cis	rs4788815	0.718	rs6499545	chr16:71889173	C/T	cg06353428	chr16:71660113	MARVELD3	0.73	5.17	0.47	1.3e-6	Metabolite levels;
THYM	cis	rs259964	1.000	rs259956	chr20:57829301	T/C	cg20910807	chr20:57875384	EDN3	-0.42	-4.52	-0.42	1.77e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs12200782	0.530	rs6929908	chr6:26555289	C/A	cg11502198	chr6:26597334	ABT1	0.82	4.6	0.43	1.29e-5	Small cell lung carcinoma;
THYM	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg26038318	chr20:34205095	SPAG4	0.59	4.65	0.43	1.08e-5	Total cholesterol levels;
THYM	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	6.16	0.53	1.72e-8	Monocyte percentage of white cells;
THYM	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg11789530	chr4:8429930	ACOX3	-0.74	-5.99	-0.52	3.74e-8	Response to antineoplastic agents;
THYM	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg03161606	chr19:29218774	NA	0.71	5.58	0.5	2.25e-7	Methadone dose in opioid dependence;
THYM	cis	rs2404602	0.647	rs35710279	chr15:77082234	T/A	cg23625390	chr15:77176239	SCAPER	-0.88	-6.13	-0.53	1.98e-8	Blood metabolite levels;
THYM	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg00310523	chr12:86230176	RASSF9	0.61	5.31	0.48	7.29e-7	Major depressive disorder;
THYM	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg10760299	chr15:45669010	GATM	0.89	6.86	0.58	7.13e-10	Homoarginine levels;
THYM	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg17366294	chr4:99064904	C4orf37	0.5	5.73	0.51	1.2e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06850241	chr22:41845214	NA	0.54	5.04	0.46	2.24e-6	Vitiligo;
THYM	cis	rs7187994	0.848	rs7498516	chr16:84774452	A/G	cg07647771	chr16:84786436	USP10	0.57	4.91	0.45	3.73e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg13010199	chr12:38710504	ALG10B	-0.62	-5.38	-0.48	5.28e-7	Heart rate;
THYM	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07167872	chr1:205819463	PM20D1	0.96	9.46	0.7	2.38e-15	Menarche (age at onset);
THYM	cis	rs11671005	0.735	rs12981649	chr19:58930043	G/C	cg18639983	chr19:58920768	ZNF584	0.61	5.02	0.46	2.37e-6	Mean platelet volume;
THYM	cis	rs17001868	0.568	rs9611312	chr22:40734790	T/C	cg07138101	chr22:40742427	ADSL	0.82	4.85	0.45	4.8e-6	Mammographic density (dense area);
THYM	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg02527881	chr3:46936655	PTH1R	-0.68	-6.78	-0.57	1e-9	Colorectal cancer;
THYM	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg23422044	chr7:1970798	MAD1L1	-0.79	-5.34	-0.48	6.39e-7	Bipolar disorder;
THYM	cis	rs8070740	0.731	rs1071648	chr17:5326089	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.72	6.03	0.53	3.15e-8	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg17366294	chr4:99064904	C4orf37	-0.58	-6.98	-0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7127900	0.950	rs11603101	chr11:2232814	C/T	cg25635251	chr11:2234043	NA	0.74	4.71	0.44	8.43e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs12200560	0.505	rs211179	chr6:97074103	A/G	cg06623918	chr6:96969491	KIAA0776	0.76	5.87	0.52	6.31e-8	Coronary heart disease;
THYM	cis	rs4789939	0.851	rs2009187	chr17:76870675	A/G	cg08012219	chr17:76913036	TIMP2	-0.74	-4.94	-0.45	3.39e-6	Dupuytren's disease;
THYM	cis	rs642803	1.000	rs557675	chr11:65566719	G/T	cg22182781	chr11:66436559	RBM4B	0.58	4.47	0.42	2.16e-5	Urate levels;
THYM	cis	rs1158570	0.564	rs2554372	chr8:131333913	A/G	cg16277922	chr8:131349729	ASAP1	0.62	5.0	0.46	2.64e-6	Platelet count;
THYM	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg00383909	chr3:49044727	WDR6	1.21	7.5	0.61	3.38e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg17509989	chr5:176798049	RGS14	-0.63	-6.01	-0.53	3.37e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs3820068	0.580	rs12746773	chr1:16001588	C/T	cg05660106	chr1:15850417	CASP9	0.64	5.05	0.46	2.1e-6	Systolic blood pressure;
THYM	trans	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg25214090	chr10:38739885	LOC399744	0.83	7.11	0.59	2.14e-10	Corneal astigmatism;
THYM	cis	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg21775007	chr8:11205619	TDH	0.65	5.29	0.48	7.91e-7	Retinal vascular caliber;
THYM	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg12386194	chr3:101231763	SENP7	0.97	7.89	0.63	5.1e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9660180	0.836	rs72634845	chr1:1704899	G/A	cg02915803	chr1:1606292	LOC728661;CDK11B	0.6	4.96	0.45	3.05e-6	Body mass index;
THYM	cis	rs259282	0.532	rs259283	chr19:33163103	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	1.09	9.04	0.68	1.9e-14	Schizophrenia;
THYM	cis	rs12711979	0.509	rs10205540	chr2:3827839	A/G	cg17052675	chr2:3827356	NA	-0.91	-15.53	-0.85	8.23e-28	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs2456568	0.900	rs1518571	chr11:93667420	C/A	cg17595323	chr11:93583763	C11orf90	-0.54	-5.23	-0.47	1.02e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg04282206	chr17:62833786	PLEKHM1P	-0.83	-8.06	-0.64	2.23e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg19913688	chr11:428466	ANO9	-0.86	-4.53	-0.42	1.69e-5	Body mass index;
THYM	cis	rs4455778	0.600	rs34886560	chr7:49120470	G/T	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg23791538	chr6:167370224	RNASET2	0.74	5.92	0.52	5.06e-8	Crohn's disease;
THYM	cis	rs877282	0.898	rs11253350	chr10:765968	G/A	cg10556349	chr10:835070	NA	-0.79	-5.05	-0.46	2.14e-6	Uric acid levels;
THYM	cis	rs6570726	0.875	rs1883407	chr6:145823432	T/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.36e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg08999081	chr20:33150536	PIGU	-0.57	-4.95	-0.45	3.25e-6	Height;
THYM	cis	rs9790314	0.586	rs16832246	chr3:161109916	A/G	cg03342759	chr3:160939853	NMD3	0.87	7.63	0.62	1.82e-11	Morning vs. evening chronotype;
THYM	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg18681998	chr4:17616180	MED28	0.96	9.17	0.69	9.69e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7704138	0.639	rs7713670	chr5:55019646	T/C	cg18456523	chr5:54516805	NA	-0.58	-4.59	-0.43	1.34e-5	Height;
THYM	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg03806693	chr22:41940476	POLR3H	1.11	9.0	0.68	2.27e-14	Vitiligo;
THYM	cis	rs10752881	0.839	rs6692207	chr1:183085304	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Colorectal cancer;
THYM	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs7226229	1.000	rs9908446	chr17:20935471	G/A	cg21263980	chr17:20946333	USP22	0.62	4.5	0.42	1.96e-5	Blood trace element (Se levels);
THYM	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.94	7.07	0.59	2.59e-10	Platelet count;
THYM	cis	rs1160297	0.576	rs1451460	chr2:53088148	C/T	cg07782112	chr2:53107842	NA	0.77	6.31	0.54	8.76e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.64	4.59	0.43	1.36e-5	Lung cancer in ever smokers;
THYM	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg17863274	chr19:49399704	TULP2	-1.01	-6.47	-0.55	4.29e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg12935359	chr14:103987150	CKB	-0.53	-5.96	-0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02788857	chr8:22132959	PIWIL2	0.61	5.78	0.51	9.47e-8	Hypertriglyceridemia;
THYM	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg22875332	chr1:76189707	ACADM	0.54	5.07	0.46	1.96e-6	Daytime sleep phenotypes;
THYM	cis	rs7107174	1.000	rs2450131	chr11:77944568	A/C	cg19901956	chr11:77921274	USP35	-0.83	-6.25	-0.54	1.14e-8	Testicular germ cell tumor;
THYM	cis	rs7084921	0.608	rs12780514	chr10:101865884	T/C	cg11344164	chr10:101878520	NA	-0.55	-4.74	-0.44	7.56e-6	Bone mineral density;
THYM	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg08645402	chr16:4508243	NA	-0.69	-6.09	-0.53	2.42e-8	Schizophrenia;
THYM	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.57	4.65	0.43	1.06e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs548181	0.611	rs562599	chr11:125459951	A/C	cg03464685	chr11:125439445	EI24	1.47	8.56	0.66	1.94e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg10687131	chr2:20871002	GDF7	-0.69	-5.05	-0.46	2.09e-6	Abdominal aortic aneurysm;
THYM	cis	rs367615	0.552	rs2963023	chr5:108730070	C/T	cg17395555	chr5:108820864	NA	-0.54	-6.77	-0.57	1.04e-9	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs7246657	0.943	rs7255952	chr19:37988797	A/G	cg23950597	chr19:37808831	NA	-0.75	-4.81	-0.44	5.66e-6	Coronary artery calcification;
THYM	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg03929089	chr4:120376271	NA	-0.84	-8.58	-0.66	1.76e-13	Height;
THYM	cis	rs2976388	0.967	rs2976387	chr8:143759364	G/A	cg06565975	chr8:143823917	SLURP1	-0.53	-5.69	-0.5	1.41e-7	Urinary tract infection frequency;
THYM	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg03388043	chr17:80084554	CCDC57	-0.66	-5.66	-0.5	1.61e-7	Life satisfaction;
THYM	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg16325326	chr1:53192061	ZYG11B	0.87	8.92	0.67	3.42e-14	Monocyte count;
THYM	cis	rs6763768	0.705	rs312483	chr3:53524051	A/G	cg16894138	chr3:53270350	TKT	-0.65	-4.64	-0.43	1.11e-5	Bacterial meningitis;
THYM	cis	rs1933112	1.000	rs10918925	chr1:168525247	C/T	cg17186328	chr1:168545835	XCL1	0.58	4.71	0.44	8.37e-6	Blood protein levels;
THYM	cis	rs2073300	1.000	rs12625999	chr20:23442085	A/G	cg12062639	chr20:23401060	NAPB	-1.18	-5.31	-0.48	7.21e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6500602	0.826	rs9932461	chr16:4454170	A/G	cg08645402	chr16:4508243	NA	0.64	4.76	0.44	6.92e-6	Schizophrenia;
THYM	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg11279151	chr3:101281821	RG9MTD1	-0.64	-4.68	-0.43	9.69e-6	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4654899	0.865	rs10916951	chr1:21528835	A/G	cg01072550	chr1:21505969	NA	0.75	6.73	0.57	1.29e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs994014	0.691	rs7699600	chr4:82271857	C/T	cg17825130	chr4:82283507	NA	0.51	4.64	0.43	1.11e-5	Height;
THYM	cis	rs7772486	0.641	rs67882056	chr6:146416301	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.51	-0.49	3.02e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11644478	chr21:40555479	PSMG1	-0.76	-6.51	-0.56	3.49e-9	Cognitive function;
THYM	trans	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg25214090	chr10:38739885	LOC399744	0.87	7.52	0.61	2.99e-11	Corneal astigmatism;
THYM	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg06064525	chr11:970664	AP2A2	-0.36	-6.98	-0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	cis	rs7119	0.717	rs12910951	chr15:77806797	A/G	cg10437265	chr15:77819839	NA	0.76	7.61	0.62	1.98e-11	Type 2 diabetes;
THYM	cis	rs11186	0.556	rs57547130	chr2:189912371	T/G	cg11041835	chr2:189156425	GULP1	0.78	4.69	0.43	9.21e-6	Parkinson's disease;
THYM	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg26967526	chr14:35346199	BAZ1A	-0.8	-5.27	-0.48	8.47e-7	Psoriasis;
THYM	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg19693284	chr19:2783607	SGTA	0.81	6.08	0.53	2.54e-8	Total cholesterol levels;
THYM	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg07599136	chr5:415885	AHRR	0.92	5.12	0.47	1.59e-6	Fat distribution (HIV);
THYM	cis	rs9916302	0.706	rs597069	chr17:37458512	G/T	cg07936489	chr17:37558343	FBXL20	0.86	5.49	0.49	3.4e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs36051895	0.659	rs62543863	chr9:5085417	C/T	cg02405213	chr9:5042618	JAK2	-1.03	-11.11	-0.75	7.02e-19	Pediatric autoimmune diseases;
THYM	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg13010199	chr12:38710504	ALG10B	0.74	5.08	0.46	1.84e-6	Morning vs. evening chronotype;
THYM	cis	rs2072510	0.593	rs2540498	chr12:96400569	T/A	cg18817487	chr12:96390143	HAL	0.48	6.21	0.54	1.41e-8	Metabolite levels (small molecules and protein measures);
THYM	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg00981070	chr1:2046702	PRKCZ	0.47	5.21	0.47	1.1e-6	Height;
THYM	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs6427356	0.513	rs10752619	chr1:157144333	T/C	cg27547283	chr1:156698502	C1orf66;ISG20L2	-0.58	-4.49	-0.42	2.02e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs6490294	0.583	rs4346023	chr12:112285542	C/T	cg10833066	chr12:111807467	FAM109A	-0.49	-5.5	-0.49	3.2e-7	Mean platelet volume;
THYM	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.16	-8.93	-0.68	3.25e-14	Platelet count;
THYM	cis	rs8005962	0.785	rs8006973	chr14:96048645	T/C	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.65	4.73	0.44	7.67e-6	Tuberculosis;
THYM	cis	rs1062746	0.834	rs9308347	chr16:87371752	C/T	cg27119004	chr16:87376851	FBXO31	0.52	5.02	0.46	2.45e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg15445000	chr17:37608096	MED1	-0.44	-5.1	-0.46	1.72e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs10851411	0.789	rs28886308	chr15:42770032	A/G	cg04308337	chr15:42867303	STARD9	0.69	5.24	0.47	9.5e-7	Glucose homeostasis traits;
THYM	cis	rs2562456	0.917	rs2650825	chr19:21699225	A/G	cg21751540	chr19:21541537	ZNF738	-0.7	-4.67	-0.43	9.93e-6	Pain;
THYM	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg15921436	chr17:44337874	NA	-0.91	-6.85	-0.58	7.19e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs13202913	0.652	rs9383578	chr6:151838192	C/T	cg03596678	chr6:151814994	C6orf97	-0.7	-4.51	-0.42	1.84e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg17105886	chr17:28927953	LRRC37B2	1.26	7.46	0.61	4.13e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3771570	0.901	rs4675969	chr2:242217627	C/T	cg21155796	chr2:242212141	HDLBP	1.1	6.53	0.56	3.24e-9	Prostate cancer;
THYM	cis	rs79387448	0.745	rs6709719	chr2:103144953	G/A	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg18252515	chr7:66147081	NA	-0.63	-4.68	-0.43	9.63e-6	Aortic root size;
THYM	cis	rs3741798	1.000	rs78028836	chr12:12485448	G/A	cg08615371	chr12:12503544	MANSC1	0.88	4.89	0.45	4.17e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs17253792	0.822	rs10147380	chr14:56054354	T/C	cg01858014	chr14:56050164	KTN1	-1.17	-4.89	-0.45	4.1e-6	Putamen volume;
THYM	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg16586182	chr3:47516702	SCAP	-0.63	-5.25	-0.47	9.32e-7	Colorectal cancer;
THYM	cis	rs11030122	0.673	rs10835474	chr11:4020819	G/T	cg18678763	chr11:4115507	RRM1	-0.45	-5.92	-0.52	5.06e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg02734326	chr4:10020555	SLC2A9	0.78	6.67	0.56	1.68e-9	Bone mineral density;
THYM	cis	rs208520	0.690	rs207119	chr6:66786408	C/T	cg07460842	chr6:66804631	NA	-1.06	-7.89	-0.63	5.14e-12	Exhaled nitric oxide output;
THYM	cis	rs7719624	0.680	rs1442	chr5:135382989	G/C	cg15329133	chr5:135467951	SMAD5;SMAD5OS	-0.62	-5.69	-0.5	1.38e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.69	-4.62	-0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs3820928	0.692	rs17416354	chr2:227770844	A/G	cg11843606	chr2:227700838	RHBDD1	-0.58	-4.63	-0.43	1.15e-5	Pulmonary function;
THYM	cis	rs57994353	0.540	rs12379380	chr9:139279981	C/T	cg14115884	chr9:139300582	SDCCAG3	0.61	4.57	0.42	1.46e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs4891159	0.548	rs609487	chr18:74134382	C/G	cg24786174	chr18:74118243	ZNF516	-0.96	-13.61	-0.81	4.84e-24	Longevity;
THYM	cis	rs4900538	0.819	rs72698591	chr14:102838896	G/A	cg18135206	chr14:102964638	TECPR2	-0.87	-6.69	-0.57	1.52e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	10.29	0.73	4e-17	Chronic sinus infection;
THYM	cis	rs977987	0.806	rs11862095	chr16:75385418	T/A	cg03315344	chr16:75512273	CHST6	0.72	5.9	0.52	5.66e-8	Dupuytren's disease;
THYM	cis	rs6988636	0.818	rs73339658	chr8:124173007	A/G	cg22384356	chr8:124195192	FAM83A	-0.79	-4.48	-0.42	2.1e-5	Urinary uromodulin levels;
THYM	cis	rs2668423	1.000	rs2668423	chr19:1370526	T/G	cg02639931	chr19:1387894	NDUFS7	-0.49	-5.76	-0.51	1.05e-7	Nonalcoholic fatty liver disease;
THYM	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg11764359	chr7:65958608	NA	0.63	4.92	0.45	3.67e-6	Aortic root size;
THYM	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs8102476	0.703	rs4803899	chr19:38727640	A/T	cg08052629	chr19:38746615	PPP1R14A	0.55	6.57	0.56	2.66e-9	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg10150615	chr22:24372951	LOC391322	0.96	10.31	0.73	3.54e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11642862	0.892	rs11646082	chr16:30911950	T/G	cg01070095	chr16:30968205	SETD1A	0.74	4.79	0.44	6.12e-6	Tonsillectomy;
THYM	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg03806693	chr22:41940476	POLR3H	1.16	10.2	0.72	6.06e-17	Vitiligo;
THYM	cis	rs907683	0.584	rs2070927	chr2:220282955	C/T	cg15015639	chr2:220282977	DES	0.38	4.92	0.45	3.59e-6	Resting heart rate;
THYM	cis	rs600806	0.850	rs4970751	chr1:109896600	A/C	cg16988986	chr1:109941118	SORT1	-0.43	-4.6	-0.43	1.32e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1270639	0.778	rs2530405	chr7:157446021	C/G	cg13357408	chr7:157437802	PTPRN2	0.46	4.92	0.45	3.65e-6	Colorectal cancer;
THYM	cis	rs62103177	0.564	rs3930042	chr18:77723843	G/A	cg07235805	chr18:78004237	PARD6G	0.41	4.45	0.42	2.34e-5	Opioid sensitivity;
THYM	cis	rs11777345	0.908	rs79134240	chr8:5423690	T/A	cg08879886	chr8:5909880	NA	0.77	4.56	0.42	1.52e-5	Waist-hip ratio;
THYM	cis	rs6570726	0.935	rs391524	chr6:145823844	A/G	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11771526	0.892	rs1376282	chr7:32370492	A/G	cg13207630	chr7:32358064	NA	1.06	6.2	0.54	1.44e-8	Body mass index;
THYM	cis	rs28595532	0.920	rs115046587	chr4:119779604	T/C	cg11846333	chr4:119757529	SEC24D	1.45	5.08	0.46	1.92e-6	Cannabis dependence symptom count;
THYM	cis	rs995000	0.965	rs1168023	chr1:63006595	A/T	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs6722750	1.000	rs6722750	chr2:64381259	T/G	cg22352474	chr2:64371530	PELI1	0.63	4.92	0.45	3.66e-6	Neuroticism;
THYM	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg20744362	chr22:50050164	C22orf34	0.79	6.96	0.58	4.37e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2290159	0.800	rs2290162	chr3:12647457	A/G	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg13609457	chr4:120235615	NA	-0.54	-4.69	-0.43	9.09e-6	Corneal astigmatism;
THYM	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.85	0.45	4.76e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11563648	0.573	rs7789922	chr7:126958628	T/C	cg08586737	chr7:127225949	GCC1	-0.33	-4.53	-0.42	1.74e-5	Resting heart rate;
THYM	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg05299048	chr3:52828583	ITIH3	0.6	4.45	0.42	2.3e-5	Bipolar disorder;
THYM	cis	rs4242434	0.892	rs71513892	chr8:22456517	C/G	cg11461670	chr8:22454935	PDLIM2	-0.38	-6.5	-0.55	3.73e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg09253696	chr17:73873529	TRIM47	-0.84	-4.46	-0.42	2.29e-5	Psoriasis;
THYM	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg11871910	chr12:69753446	YEATS4	1.06	9.8	0.71	4.32e-16	Blood protein levels;
THYM	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg18252515	chr7:66147081	NA	0.62	4.6	0.43	1.31e-5	Aortic root size;
THYM	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg04455712	chr21:45112962	RRP1B	0.52	4.62	0.43	1.2e-5	Mean corpuscular volume;
THYM	cis	rs4638749	0.677	rs13023102	chr2:108837663	C/T	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg18105134	chr13:113819100	PROZ	1.04	9.64	0.7	9.57e-16	Platelet distribution width;
THYM	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg18904891	chr8:8559673	CLDN23	0.74	5.54	0.49	2.67e-7	Obesity-related traits;
THYM	cis	rs4363385	0.747	rs2339494	chr1:152975143	G/C	cg13444842	chr1:152974279	SPRR3	-0.6	-4.79	-0.44	6.06e-6	Inflammatory skin disease;
THYM	cis	rs10197940	0.662	rs13555	chr2:152333304	C/A	cg19508488	chr2:152266495	RIF1	0.76	5.95	0.52	4.46e-8	Lung cancer;
THYM	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.43	0.7	2.73e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3126085	0.935	rs1390488	chr1:152199500	T/C	cg10321714	chr1:152280068	FLG	0.65	4.72	0.44	8.02e-6	Atopic dermatitis;
THYM	cis	rs3857067	0.804	rs6821438	chr4:95091911	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.48	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4595586	0.545	rs1349257	chr12:39397139	A/G	cg13010199	chr12:38710504	ALG10B	0.61	4.62	0.43	1.21e-5	Morning vs. evening chronotype;
THYM	cis	rs886126	1.000	rs886126	chr12:111679214	C/T	cg10833066	chr12:111807467	FAM109A	0.47	5.67	0.5	1.54e-7	Coronary heart disease;
THYM	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg02825527	chr7:2087843	MAD1L1	-0.7	-4.55	-0.42	1.58e-5	Bipolar disorder;
THYM	cis	rs79387448	0.745	rs7583683	chr2:103113763	C/T	cg09003973	chr2:102972529	NA	-0.78	-4.85	-0.45	4.84e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg16342193	chr10:102329863	NA	-0.6	-6.21	-0.54	1.41e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	7.86	0.63	6.01e-12	Smoking behavior;
THYM	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg03684893	chr10:554711	DIP2C	0.72	4.79	0.44	6.06e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg02725872	chr8:58115012	NA	-0.88	-6.56	-0.56	2.82e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs10911232	0.507	rs4575047	chr1:182976028	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Hypertriglyceridemia;
THYM	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2282300	0.696	rs12578061	chr11:30249365	T/A	cg06241208	chr11:30344200	C11orf46	-0.77	-5.59	-0.5	2.15e-7	Morning vs. evening chronotype;
THYM	cis	rs9534288	0.797	rs2104515	chr13:46569846	T/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs5769765	0.565	rs8137232	chr22:50256885	G/C	cg08270630	chr22:50330655	NA	0.72	4.68	0.43	9.6e-6	Schizophrenia;
THYM	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg18681998	chr4:17616180	MED28	0.88	7.17	0.59	1.6e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9906944	0.933	rs12945020	chr17:47082775	G/A	cg10950924	chr17:47092072	IGF2BP1	-0.5	-4.46	-0.42	2.24e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs752010	0.806	rs1109255	chr1:42091708	C/T	cg22486000	chr1:42919398	ZMYND12	-0.43	-4.83	-0.44	5.16e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs478304	0.934	rs12801731	chr11:65549606	T/C	cg17480646	chr11:65405466	SIPA1	0.7	6.27	0.54	1.07e-8	Acne (severe);
THYM	cis	rs11696501	0.739	rs2235600	chr20:44238299	T/G	cg11783356	chr20:44313418	WFDC10B	-0.66	-4.51	-0.42	1.84e-5	Brain structure;
THYM	cis	rs12530845	0.623	rs73721673	chr7:135349573	A/T	cg19897172	chr7:135347071	PL-5283	-0.66	-5.45	-0.49	3.9e-7	Red blood cell traits;
THYM	cis	rs747334	0.777	rs7079028	chr10:92711623	T/C	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs526231	0.508	rs34805	chr5:102428312	A/G	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Primary biliary cholangitis;
THYM	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-4.87	-0.45	4.47e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs40363	0.645	rs40447	chr16:3514841	G/A	cg22508957	chr16:3507546	NAT15	0.67	9.07	0.68	1.59e-14	Tuberculosis;
THYM	cis	rs2806561	0.765	rs2806557	chr1:23503372	T/A	cg19743168	chr1:23544995	NA	0.54	5.62	0.5	1.91e-7	Height;
THYM	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.62	7.88	0.63	5.3e-12	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg01191920	chr7:158217561	PTPRN2	-1.07	-12.04	-0.78	8.13e-21	Obesity-related traits;
THYM	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg17105886	chr17:28927953	LRRC37B2	-1.12	-6.74	-0.57	1.24e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg23161317	chr6:28129485	ZNF389	0.67	5.33	0.48	6.55e-7	Parkinson's disease;
THYM	cis	rs10924970	0.870	rs12095886	chr1:235432249	A/G	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs11039798	0.588	rs643668	chr11:48413399	C/G	cg24672777	chr11:48374446	OR4C45	0.96	6.22	0.54	1.3e-8	Axial length;
THYM	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg10803722	chr21:46713166	LOC642852	-0.42	-5.57	-0.5	2.4e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6987853	0.931	rs2923444	chr8:42397004	C/T	cg09913449	chr8:42400586	C8orf40	0.88	8.02	0.64	2.8e-12	Mean corpuscular hemoglobin concentration;
THYM	trans	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg25517755	chr10:38738941	LOC399744	-0.77	-6.98	-0.58	4.03e-10	Corneal astigmatism;
THYM	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.64	5.0	0.46	2.66e-6	Tonsillectomy;
THYM	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg05887092	chr17:76393375	PGS1	0.42	4.82	0.44	5.41e-6	HDL cholesterol levels;
THYM	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg27034606	chr17:28928453	LRRC37B2	0.65	4.52	0.42	1.78e-5	Body mass index;
THYM	cis	rs5771225	0.563	rs738334	chr22:50688235	T/C	cg16473166	chr22:50639996	SELO	0.63	4.55	0.42	1.57e-5	Late-onset Alzheimer's disease;
THYM	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg24675056	chr1:15929824	NA	0.73	5.9	0.52	5.62e-8	Systolic blood pressure;
THYM	cis	rs13082711	0.911	rs3816881	chr3:27432888	T/C	cg02860705	chr3:27208620	NA	0.64	4.46	0.42	2.27e-5	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs2742417	0.603	rs2673055	chr3:45772772	G/A	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg18758796	chr5:131593413	PDLIM4	0.64	6.37	0.55	6.83e-9	Breast cancer;
THYM	trans	rs877282	1.000	rs71491304	chr10:772982	C/T	cg22713356	chr15:30763199	NA	1.26	10.12	0.72	9.24e-17	Uric acid levels;
THYM	cis	rs902774	0.597	rs7299694	chr12:53352572	A/C	cg05393297	chr12:53359155	NA	-0.45	-5.13	-0.47	1.54e-6	Prostate cancer;
THYM	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg05738196	chr6:26577821	NA	0.95	9.91	0.71	2.53e-16	Intelligence (multi-trait analysis);
THYM	cis	rs28476539	0.600	rs67445452	chr4:83542616	C/T	cg10249074	chr4:83542146	C4orf11	-0.68	-5.43	-0.49	4.25e-7	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03264133	chr6:25882463	NA	-0.87	-7.32	-0.6	8.06e-11	Intelligence (multi-trait analysis);
THYM	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg21775007	chr8:11205619	TDH	0.7	5.78	0.51	9.67e-8	Retinal vascular caliber;
THYM	cis	rs16866061	1.000	rs11686590	chr2:225334070	A/G	cg12698349	chr2:225449008	CUL3	1.1	9.52	0.7	1.78e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.43	0.7	2.73e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3820068	0.603	rs17448778	chr1:15985306	A/G	cg05660106	chr1:15850417	CASP9	0.76	6.19	0.54	1.55e-8	Systolic blood pressure;
THYM	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg03159660	chr11:2078197	NA	0.62	4.52	0.42	1.77e-5	Longevity;
THYM	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg27535305	chr1:53392650	SCP2	-0.49	-5.49	-0.49	3.28e-7	Monocyte count;
THYM	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg27446573	chr6:127587934	RNF146	0.77	6.35	0.55	7.46e-9	Breast cancer;
THYM	cis	rs9486719	0.857	rs4839833	chr6:96882069	T/C	cg18709589	chr6:96969512	KIAA0776	0.68	4.66	0.43	1.04e-5	Migraine;Coronary artery disease;
THYM	cis	rs1883415	0.534	rs2760145	chr6:24478813	T/C	cg20631270	chr6:24437470	GPLD1	0.53	4.46	0.42	2.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs4074961	0.692	rs11264075	chr1:38083941	C/G	cg17933807	chr1:38061675	GNL2	1.08	13.22	0.8	2.97e-23	Axial length;
THYM	cis	rs2239785	0.920	rs136154	chr22:36656138	A/T	cg15716373	chr22:36655542	APOL1	-0.41	-4.78	-0.44	6.38e-6	Glomerulosclerosis;
THYM	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg06640241	chr16:89574553	SPG7	-0.64	-4.45	-0.42	2.34e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs865483	0.860	rs853220	chr17:35787666	C/T	cg06716730	chr17:35851459	DUSP14	0.43	7.3	0.6	8.71e-11	Monocyte count;
THYM	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg27394845	chr17:28928406	LRRC37B2	1.0	4.88	0.45	4.28e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2072732	0.821	rs12033401	chr1:2944086	C/T	cg08733933	chr1:2954429	NA	-0.63	-4.53	-0.42	1.68e-5	Plateletcrit;
THYM	cis	rs2742234	0.541	rs4648313	chr10:43716739	G/A	cg06632098	chr10:43605906	RET	0.8	5.26	0.47	8.98e-7	Hirschsprung disease;
THYM	cis	rs7719624	0.846	rs2237066	chr5:135367603	C/T	cg15329133	chr5:135467951	SMAD5;SMAD5OS	-0.56	-4.96	-0.45	3.09e-6	Response to cytidine analogues (gemcitabine);
THYM	trans	rs11186	0.556	rs55784828	chr2:189956130	T/C	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs28595532	1.000	rs115706377	chr4:119628481	G/A	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs612683	0.664	rs6702766	chr1:100997635	A/G	cg06223162	chr1:101003688	GPR88	-0.8	-7.24	-0.6	1.15e-10	Breast cancer;
THYM	cis	rs6748734	0.625	rs6741220	chr2:241822432	C/T	cg09990169	chr2:241835740	C2orf54	0.32	5.33	0.48	6.48e-7	Urinary metabolites;
THYM	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg02931644	chr1:25747376	RHCE	0.58	4.47	0.42	2.18e-5	Erythrocyte sedimentation rate;
THYM	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg21784768	chr11:537496	LRRC56	-1.02	-5.17	-0.47	1.3e-6	Body mass index;
THYM	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg13147721	chr7:65941812	NA	-1.1	-7.08	-0.59	2.45e-10	Diabetic kidney disease;
THYM	cis	rs909002	0.849	rs7546297	chr1:32106494	A/G	cg13919466	chr1:32135498	COL16A1	-0.51	-4.76	-0.44	6.93e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg05457628	chr5:178986728	RUFY1	-0.63	-6.64	-0.56	1.91e-9	Lung cancer;
THYM	cis	rs6763768	0.606	rs3732834	chr3:53324915	A/G	cg22900224	chr3:52804907	NEK4	-0.73	-4.74	-0.44	7.64e-6	Bacterial meningitis;
THYM	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg02887458	chr19:19495540	GATAD2A	-0.45	-4.89	-0.45	4.05e-6	Bipolar disorder;
THYM	cis	rs17253792	0.822	rs75351812	chr14:56082192	G/A	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.63	-5.35	-0.48	6.11e-7	Renal function-related traits (BUN);
THYM	cis	rs6840360	0.571	rs11726892	chr4:152555106	A/G	cg17479576	chr4:152424074	FAM160A1	-0.83	-5.86	-0.52	6.62e-8	Intelligence (multi-trait analysis);
THYM	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.2e-16	Bone mineral density;
THYM	cis	rs2335455	1	rs2335455	chr16:2828173	T/C	cg05687563	chr16:2837658	PRSS33	0.58	4.78	0.44	6.44e-6	Sum eosinophil basophil counts;
THYM	cis	rs2463822	0.583	rs7129536	chr11:62030829	C/T	cg06239285	chr11:62104954	ASRGL1	-0.98	-4.71	-0.43	8.58e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-8.52	-0.66	2.33e-13	Schizophrenia;
THYM	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg04267008	chr7:1944627	MAD1L1	-0.56	-4.58	-0.43	1.39e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg21361702	chr7:150065534	REPIN1	0.67	4.9	0.45	3.86e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs12579753	0.917	rs12372724	chr12:82193628	C/T	cg21231944	chr12:82153410	PPFIA2	-0.66	-5.01	-0.46	2.51e-6	Resting heart rate;
THYM	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs600806	0.889	rs681242	chr1:109841659	T/C	cg23032129	chr1:109941072	SORT1	-0.55	-4.5	-0.42	1.92e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg26384229	chr12:38710491	ALG10B	-0.73	-6.64	-0.56	1.96e-9	Morning vs. evening chronotype;
THYM	cis	rs7705502	1.000	rs72812842	chr5:173374760	C/T	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	trans	rs10186458	0.500	rs17670898	chr2:20599304	C/T	cg27368651	chr22:31829985	DRG1	0.73	7.23	0.6	1.23e-10	Kidney disease (early stage) in type 1 diabetes;
THYM	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg24399712	chr22:39784796	NA	-0.87	-7.99	-0.63	3.22e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs586688	0.556	rs981309	chr1:201674081	A/G	cg14168733	chr1:201708718	NAV1	-0.67	-6.31	-0.54	8.93e-9	Obesity-related traits;
THYM	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.7	-5.21	-0.47	1.1e-6	Tonsillectomy;
THYM	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg24812749	chr6:127587940	RNF146	0.8	5.99	0.52	3.74e-8	Breast cancer;
THYM	cis	rs2806561	0.929	rs6694445	chr1:23540428	A/G	cg19743168	chr1:23544995	NA	0.7	7.68	0.62	1.38e-11	Height;
THYM	cis	rs597539	0.545	rs3794027	chr11:68697336	T/C	cg06112835	chr11:68658793	MRPL21	0.45	6.31	0.54	8.87e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6732160	0.549	rs6744529	chr2:73480869	A/G	cg24220031	chr2:73402428	NA	-0.8	-9.64	-0.7	9.8e-16	Intelligence (multi-trait analysis);
THYM	cis	rs6988636	1.000	rs13261066	chr8:124190276	G/A	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg00278517	chr6:167070616	RPS6KA2	-0.33	-4.52	-0.42	1.79e-5	Crohn's disease;
THYM	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg09359103	chr1:154839909	KCNN3	-0.76	-8.62	-0.66	1.46e-13	Prostate cancer;
THYM	cis	rs7119	0.651	rs12902898	chr15:77849191	A/G	cg10437265	chr15:77819839	NA	0.76	7.27	0.6	9.9e-11	Type 2 diabetes;
THYM	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg00898013	chr13:113819073	PROZ	-0.87	-8.78	-0.67	6.82e-14	Platelet distribution width;
THYM	cis	rs17407555	0.520	rs4292327	chr4:9943700	G/A	cg13000635	chr4:9523653	NA	0.67	4.48	0.42	2.12e-5	Schizophrenia (age at onset);
THYM	cis	rs7953508	0.750	rs11107119	chr12:93983132	T/A	cg18151635	chr12:93972918	NA	-0.74	-5.12	-0.47	1.58e-6	Pubertal anthropometrics;
THYM	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg00271210	chr6:167070053	RPS6KA2	-0.51	-5.31	-0.48	7.23e-7	Primary biliary cholangitis;
THYM	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg14416269	chr4:6271139	WFS1	0.48	4.7	0.43	8.69e-6	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs7255045	0.742	rs10411443	chr19:12950948	C/G	cg26870725	chr19:12978805	MAST1	0.64	4.79	0.44	6.19e-6	Mean corpuscular volume;
THYM	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg11366901	chr6:160182831	ACAT2	1.01	8.95	0.68	2.91e-14	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs11809207	1.000	rs11247865	chr1:26517773	T/C	cg03844060	chr1:26490628	NA	0.7	5.01	0.46	2.51e-6	Height;
THYM	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11890956	chr21:40555474	PSMG1	-0.97	-11.25	-0.76	3.73e-19	Cognitive function;
THYM	cis	rs1466662	0.508	rs13125339	chr4:155294643	G/T	cg05574313	chr4:155338166	DCHS2	-0.68	-5.08	-0.46	1.87e-6	Alzheimer's disease (age of onset);
THYM	cis	rs2012796	0.785	rs61986597	chr14:81853107	T/C	cg02996355	chr14:81879375	NA	0.84	6.35	0.55	7.22e-9	Night sleep phenotypes;
THYM	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg09549813	chr16:4587862	C16orf5	-0.49	-5.36	-0.48	5.77e-7	Schizophrenia;
THYM	cis	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg14019146	chr3:50243930	SLC38A3	0.64	5.51	0.49	3.02e-7	Intelligence (multi-trait analysis);
THYM	cis	rs35883536	0.967	rs2050471	chr1:101175651	C/T	cg06223162	chr1:101003688	GPR88	0.67	5.12	0.46	1.62e-6	Monocyte count;
THYM	cis	rs1499614	1.000	rs34250985	chr7:66161062	A/T	cg18252515	chr7:66147081	NA	-1.58	-8.42	-0.65	3.87e-13	Gout;
THYM	cis	rs981844	1.000	rs1371161	chr4:154655171	T/C	cg09973105	chr4:154681532	RNF175	-0.63	-5.18	-0.47	1.23e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg23422044	chr7:1970798	MAD1L1	-0.95	-6.58	-0.56	2.51e-9	Bipolar disorder;
THYM	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg23161317	chr6:28129485	ZNF389	0.85	6.33	0.54	8.19e-9	Depression;
THYM	cis	rs939574	1.000	rs939574	chr2:220118531	G/C	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.23	-5.59	-0.5	2.13e-7	Platelet distribution width;
THYM	cis	rs8067545	0.611	rs1974745	chr17:20059824	C/G	cg13482628	chr17:19912719	NA	0.56	4.8	0.44	6.01e-6	Schizophrenia;
THYM	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg24675658	chr1:53192096	ZYG11B	0.58	4.66	0.43	1.04e-5	Monocyte count;
THYM	cis	rs55728055	0.661	rs73162112	chr22:32045449	G/A	cg01338084	chr22:32026380	PISD	1.29	6.01	0.52	3.45e-8	Age-related hearing impairment;
THYM	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg09703963	chr11:616879	IRF7;MUPCDH	-0.64	-5.53	-0.49	2.78e-7	Systemic lupus erythematosus;
THYM	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg06238570	chr21:40685208	BRWD1	0.92	6.85	0.57	7.35e-10	Cognitive function;
THYM	cis	rs2639990	1.000	rs2639990	chr18:72915551	T/C	cg21330207	chr18:72916311	ZADH2	1.19	5.73	0.51	1.16e-7	Vascular endothelial growth factor levels;
THYM	trans	rs8002861	0.619	rs9562516	chr13:44431738	T/C	cg17145862	chr1:211918768	LPGAT1	0.86	7.27	0.6	1.02e-10	Leprosy;
THYM	cis	rs7592578	0.599	rs62180992	chr2:191285732	A/G	cg11845111	chr2:191398756	TMEM194B	-0.92	-6.15	-0.53	1.82e-8	Diastolic blood pressure;
THYM	cis	rs4889855	0.556	rs11150863	chr17:78532321	A/G	cg16591659	chr17:78472290	NA	-0.41	-4.71	-0.44	8.43e-6	Fractional excretion of uric acid;
THYM	cis	rs17321999	1.000	rs72787724	chr2:30491746	T/C	cg05247661	chr2:30472410	LBH	0.71	4.75	0.44	7.32e-6	Systemic lupus erythematosus;
THYM	cis	rs7119	0.717	rs12901471	chr15:77818992	A/G	cg27398640	chr15:77910606	LINGO1	-0.56	-5.68	-0.5	1.49e-7	Type 2 diabetes;
THYM	cis	rs7004484	1.000	rs7004484	chr8:132934538	A/C	cg15420926	chr8:132929147	EFR3A	0.48	4.62	0.43	1.18e-5	Survival in rectal cancer;
THYM	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	10.29	0.73	3.95e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg03433033	chr1:76189801	ACADM	0.7	7.19	0.59	1.44e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg11266682	chr4:10021025	SLC2A9	-0.68	-9.74	-0.71	5.95e-16	Bone mineral density;
THYM	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.68	-4.89	-0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs754466	0.651	rs10762767	chr10:79645070	C/A	cg17075019	chr10:79541650	NA	-0.69	-5.85	-0.51	6.94e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs28595532	0.844	rs55845920	chr4:119490085	C/T	cg21605333	chr4:119757512	SEC24D	1.44	5.22	0.47	1.03e-6	Cannabis dependence symptom count;
THYM	cis	rs16866061	0.926	rs1523919	chr2:225403615	G/A	cg12698349	chr2:225449008	CUL3	1.14	9.51	0.7	1.83e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg04717802	chr22:42394638	WBP2NL	0.74	4.66	0.43	1.02e-5	Birth weight;
THYM	cis	rs7089973	0.836	rs1046492	chr10:116624067	C/T	cg23260525	chr10:116636907	FAM160B1	0.52	4.72	0.44	8.04e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs2562456	0.917	rs6511253	chr19:21678798	A/G	cg21751540	chr19:21541537	ZNF738	0.64	4.51	0.42	1.82e-5	Pain;
THYM	cis	rs669446	0.562	rs4660260	chr1:44195353	A/G	cg15962314	chr1:44399869	ARTN	0.47	5.18	0.47	1.22e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-11.43	-0.76	1.48e-19	Height;
THYM	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg18252515	chr7:66147081	NA	-1.65	-9.03	-0.68	1.94e-14	Diabetic kidney disease;
THYM	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs10857712	0.904	rs2265641	chr10:135221869	G/A	cg17796960	chr10:135278976	LOC619207	0.55	4.65	0.43	1.08e-5	Systemic lupus erythematosus;
THYM	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.67	6.02	0.53	3.23e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg00074818	chr8:8560427	CLDN23	0.53	4.76	0.44	6.82e-6	Obesity-related traits;
THYM	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg18252515	chr7:66147081	NA	-0.69	-5.5	-0.49	3.21e-7	Aortic root size;
THYM	cis	rs6665290	0.901	rs61834001	chr1:227197411	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg11301795	chr4:187892539	NA	-1.11	-18.94	-0.89	5.16e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg12386194	chr3:101231763	SENP7	0.69	5.13	0.47	1.52e-6	Colorectal cancer;
THYM	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2836974	0.544	rs2776312	chr21:40718518	A/G	cg11890956	chr21:40555474	PSMG1	0.66	5.15	0.47	1.4e-6	Cognitive function;
THYM	cis	rs73198271	0.960	rs73198290	chr8:8616009	A/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-4.48	-0.42	2.04e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7646881	0.812	rs7635704	chr3:158459720	T/C	cg18349298	chr3:158450550	RARRES1	0.51	4.49	0.42	2e-5	Tetralogy of Fallot;
THYM	cis	rs6076065	0.723	rs6083088	chr20:23343793	G/T	cg11657817	chr20:23433608	CST11	0.33	4.66	0.43	1.03e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg25427524	chr10:38739819	LOC399744	-0.73	-6.77	-0.57	1.04e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2916260	0.800	rs75804413	chr6:40386790	G/A	cg08415973	chr6:40346114	TDRG1	0.77	4.67	0.43	9.84e-6	Incident coronary heart disease;
THYM	cis	rs684232	0.602	rs8064796	chr17:525937	A/C	cg15660573	chr17:549704	VPS53	-1.01	-11.19	-0.75	4.87e-19	Prostate cancer;
THYM	cis	rs2303759	0.709	rs7256363	chr19:49827804	C/T	cg22590775	chr19:49891494	CCDC155	0.61	4.71	0.43	8.55e-6	Multiple sclerosis;
THYM	cis	rs675209	0.576	rs11755724	chr6:7118990	C/T	cg24899545	chr6:7112846	RREB1	0.47	4.87	0.45	4.38e-6	Urate levels;
THYM	cis	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg06521331	chr12:34319734	NA	-0.99	-9.11	-0.68	1.32e-14	Morning vs. evening chronotype;
THYM	trans	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg10856724	chr12:34555212	NA	-0.99	-8.92	-0.68	3.37e-14	Bladder cancer;
THYM	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg25072359	chr17:41440525	NA	0.68	4.74	0.44	7.46e-6	Menopause (age at onset);
THYM	cis	rs34734847	0.766	rs3794214	chr12:121168245	C/T	cg21892295	chr12:121157589	UNC119B	0.46	4.61	0.43	1.25e-5	Mean corpuscular volume;
THYM	cis	rs870825	0.616	rs72703531	chr4:185611092	C/T	cg04058563	chr4:185651563	MLF1IP	1.14	9.4	0.69	3.16e-15	Blood protein levels;
THYM	cis	rs8050907	0.744	rs28629405	chr16:4525933	G/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.58	0.43	1.38e-5	Obesity-related traits;
THYM	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg06850241	chr22:41845214	NA	0.53	4.56	0.42	1.54e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08109568	chr15:31115862	NA	0.76	6.82	0.57	8.54e-10	Huntington's disease progression;
THYM	cis	rs9913156	0.793	rs9436	chr17:4574751	T/A	cg19197139	chr17:4613644	ARRB2	0.82	4.96	0.45	3.05e-6	Lymphocyte counts;
THYM	cis	rs7524258	1.000	rs7524258	chr1:7292229	T/C	cg07173049	chr1:7289937	CAMTA1	0.71	5.69	0.5	1.41e-7	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg11279151	chr3:101281821	RG9MTD1	-0.63	-4.61	-0.43	1.27e-5	Colorectal cancer;
THYM	cis	rs7772486	0.790	rs9376971	chr6:146259505	C/T	cg13319975	chr6:146136371	FBXO30	0.73	6.11	0.53	2.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2933343	0.700	rs1680779	chr3:128614770	G/A	cg11901034	chr3:128598214	ACAD9	-0.71	-5.66	-0.5	1.59e-7	IgG glycosylation;
THYM	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg22875332	chr1:76189707	ACADM	0.88	11.22	0.75	4.31e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg05527609	chr1:210001259	C1orf107	0.99	8.07	0.64	2.11e-12	Orofacial clefts;
THYM	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg15704280	chr7:45808275	SEPT13	-1.08	-13.67	-0.81	3.63e-24	Height;
THYM	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg10117171	chr1:25599238	RHD	-0.68	-4.87	-0.45	4.52e-6	Erythrocyte sedimentation rate;
THYM	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg06112835	chr11:68658793	MRPL21	0.42	6.19	0.54	1.54e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs289828	0.519	rs34639984	chr2:152154196	G/C	cg05960677	chr2:152117363	RBM43	0.71	6.6	0.56	2.29e-9	Blood protein levels;
THYM	cis	rs912057	0.965	rs1294409	chr6:6738355	A/G	cg13809441	chr6:6737631	NA	-0.44	-4.96	-0.45	3.14e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06481639	chr22:41940642	POLR3H	-0.86	-5.91	-0.52	5.28e-8	Vitiligo;
THYM	cis	rs752010	0.902	rs60743712	chr1:42076629	G/A	cg13396354	chr1:41153348	NA	-0.49	-4.82	-0.44	5.37e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg16797656	chr11:68205561	LRP5	0.44	4.51	0.42	1.83e-5	Total body bone mineral density;
THYM	cis	rs4565302	0.673	rs72851460	chr6:38341605	C/A	cg06347083	chr6:39282316	KCNK17	-0.44	-4.85	-0.45	4.86e-6	Mammographic density;
THYM	cis	rs4455778	0.580	rs4492325	chr7:49096154	G/A	cg26309511	chr7:48887640	NA	0.68	5.94	0.52	4.63e-8	Lung cancer in never smokers;
THYM	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg12560992	chr17:57184187	TRIM37	-0.91	-8.51	-0.66	2.54e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg00898013	chr13:113819073	PROZ	-0.87	-8.78	-0.67	6.82e-14	Platelet distribution width;
THYM	cis	rs7616559	0.606	rs922864	chr3:156780866	G/C	cg15697575	chr3:156784781	NA	0.44	6.38	0.55	6.46e-9	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs3741151	0.686	rs73546735	chr11:73256797	C/T	cg12959048	chr11:73096162	RELT	-0.52	-4.58	-0.43	1.43e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14240646	chr10:27532245	ACBD5	-0.82	-4.7	-0.43	8.74e-6	Breast cancer;
THYM	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg10515332	chr4:99064459	C4orf37	0.59	4.65	0.43	1.08e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4907240	0.658	rs4907319	chr2:97138525	G/A	cg18419276	chr2:96971862	SNRNP200	-0.41	-5.13	-0.47	1.55e-6	Event-related brain oscillations;
THYM	cis	rs9814567	0.806	rs13076825	chr3:134317239	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	7.55	0.61	2.7e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs524023	0.958	rs11231825	chr11:64360274	T/C	cg19131476	chr11:64387923	NRXN2	-0.36	-5.02	-0.46	2.37e-6	Urate levels in obese individuals;
THYM	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg08847533	chr14:75593920	NEK9	0.88	7.98	0.63	3.28e-12	Height;
THYM	cis	rs7830933	0.911	rs13251678	chr8:23594229	C/T	cg04349084	chr8:23602677	NA	0.66	7.09	0.59	2.33e-10	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs858239	0.862	rs1728292	chr7:23263474	C/G	cg05407003	chr7:23246146	NA	-0.67	-5.57	-0.5	2.34e-7	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg17366294	chr4:99064904	C4orf37	0.49	5.43	0.49	4.32e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.66	-6.13	-0.53	2e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7119	0.717	rs12898656	chr15:77807995	C/T	cg27398640	chr15:77910606	LINGO1	0.52	5.21	0.47	1.12e-6	Type 2 diabetes;
THYM	cis	rs59698941	0.943	rs12516416	chr5:132248630	C/T	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.27	-0.65	8.15e-13	Mean corpuscular volume;
THYM	cis	rs7917772	0.546	rs10883743	chr10:104338389	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg06634786	chr22:41940651	POLR3H	-0.7	-4.92	-0.45	3.59e-6	Vitiligo;
THYM	cis	rs16857609	0.564	rs1478580	chr2:218291649	C/T	cg15335768	chr2:218268053	DIRC3	-0.53	-7.53	-0.61	2.94e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	cis	rs524023	1.000	rs505802	chr11:64357072	T/C	cg19131476	chr11:64387923	NRXN2	0.35	4.84	0.44	4.98e-6	Urate levels in obese individuals;
THYM	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2072732	0.861	rs56176404	chr1:2940998	A/G	cg08733933	chr1:2954429	NA	-0.63	-4.53	-0.42	1.68e-5	Plateletcrit;
THYM	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.89	0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs346785	0.641	rs4789264	chr17:74263048	A/C	cg09812376	chr17:74270190	QRICH2	0.49	5.27	0.48	8.44e-7	White matter hyperintensities in ischemic stroke;
THYM	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg26597838	chr10:835615	NA	1.25	9.08	0.68	1.54e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs9527	0.615	rs7073295	chr10:104672233	A/G	cg15744005	chr10:104629667	AS3MT	-0.6	-4.58	-0.42	1.43e-5	Arsenic metabolism;
THYM	cis	rs7009516	0.819	rs13257101	chr8:24223583	A/T	cg01759110	chr8:24241694	ADAMDEC1	-0.54	-4.8	-0.44	5.92e-6	Hair greying;
THYM	cis	rs1345301	0.514	rs57738191	chr2:102868359	T/A	cg03938978	chr2:103052716	IL18RAP	-0.48	-4.45	-0.42	2.35e-5	Waist circumference;
THYM	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg09904177	chr6:26538194	HMGN4	0.59	4.64	0.43	1.13e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg25237894	chr2:233734115	C2orf82	-0.35	-4.99	-0.46	2.7e-6	Coronary artery disease;
THYM	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg03060546	chr3:49711283	APEH	0.77	6.37	0.55	6.65e-9	Resting heart rate;
THYM	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg24733560	chr20:60626293	TAF4	0.52	4.69	0.43	9.24e-6	Body mass index;
THYM	cis	rs36051895	0.603	rs11795305	chr9:5179920	G/C	cg02405213	chr9:5042618	JAK2	-1.02	-10.5	-0.73	1.44e-17	Pediatric autoimmune diseases;
THYM	cis	rs10095849	0.546	rs12550405	chr8:39470136	T/G	cg22755526	chr8:38854673	TM2D2;ADAM9	-0.64	-4.7	-0.43	8.71e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs9653442	0.576	rs6542921	chr2:100864498	C/A	cg08017756	chr2:100939284	LONRF2	-0.67	-5.1	-0.46	1.7e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs6584283	0.766	rs7911680	chr10:101293468	A/C	cg04972745	chr10:101287846	NA	-0.52	-4.96	-0.45	3.13e-6	Ulcerative colitis;
THYM	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.75	5.33	0.48	6.53e-7	Height;
THYM	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14240646	chr10:27532245	ACBD5	-0.82	-4.58	-0.43	1.39e-5	Breast cancer;
THYM	trans	rs877282	0.853	rs11595510	chr10:756757	C/G	cg22713356	chr15:30763199	NA	1.21	9.17	0.69	9.82e-15	Uric acid levels;
THYM	cis	rs6499129	0.571	rs2346676	chr16:67223803	A/G	cg26912222	chr16:68000829	SLC12A4	0.69	4.58	0.42	1.44e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1065852	0.526	rs1062753	chr22:42392811	G/A	cg09667013	chr22:42394590	WBP2NL	0.54	4.8	0.44	5.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg00071950	chr4:10020882	SLC2A9	0.68	7.07	0.59	2.61e-10	Bone mineral density;
THYM	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg10760299	chr15:45669010	GATM	0.83	6.51	0.56	3.5e-9	Homoarginine levels;
THYM	cis	rs2067615	0.524	rs10778505	chr12:107143126	G/C	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg26818010	chr10:134567672	INPP5A	-0.91	-7.38	-0.6	5.95e-11	Migraine;
THYM	cis	rs1678542	1.000	rs11172254	chr12:57968738	C/T	cg12615879	chr12:58013172	SLC26A10	0.54	4.85	0.45	4.79e-6	Rheumatoid arthritis;
THYM	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22496380	chr5:211416	CCDC127	-1.39	-8.13	-0.64	1.62e-12	Breast cancer;
THYM	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.65	5.92	0.52	5.18e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg24675658	chr1:53192096	ZYG11B	-0.82	-7.61	-0.62	1.94e-11	Monocyte count;
THYM	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg11752832	chr7:134001865	SLC35B4	0.76	5.72	0.51	1.24e-7	Mean platelet volume;
THYM	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.82	-4.8	-0.44	5.9e-6	Lung function (FEV1/FVC);
THYM	cis	rs7980799	0.654	rs10844618	chr12:33625010	A/G	cg06521331	chr12:34319734	NA	0.69	4.93	0.45	3.47e-6	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs7119	0.745	rs12911649	chr15:77807127	C/T	cg27398640	chr15:77910606	LINGO1	-0.52	-5.21	-0.47	1.12e-6	Type 2 diabetes;
THYM	cis	rs17407555	0.738	rs73212895	chr4:10121025	C/T	cg11266682	chr4:10021025	SLC2A9	-0.61	-5.58	-0.5	2.26e-7	Schizophrenia (age at onset);
THYM	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg26384229	chr12:38710491	ALG10B	-0.71	-5.74	-0.51	1.12e-7	Morning vs. evening chronotype;
THYM	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg27398817	chr8:82754497	SNX16	-0.71	-6.05	-0.53	2.89e-8	Diastolic blood pressure;
THYM	cis	rs7927771	0.839	rs11039308	chr11:47622412	G/A	cg18512352	chr11:47633146	NA	-0.46	-5.56	-0.5	2.48e-7	Subjective well-being;
THYM	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg16797656	chr11:68205561	LRP5	0.44	4.55	0.42	1.59e-5	Total body bone mineral density;
THYM	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg18252515	chr7:66147081	NA	1.37	7.89	0.63	5.1e-12	Diabetic kidney disease;
THYM	cis	rs2440129	0.632	rs2292353	chr17:6903537	C/T	cg05215272	chr17:6899095	ALOX12	0.62	8.71	0.67	9.37e-14	Tonsillectomy;
THYM	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg03517284	chr6:25882590	NA	0.71	5.64	0.5	1.75e-7	Schizophrenia;
THYM	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg26441486	chr22:50317300	CRELD2	-0.45	-6.88	-0.58	6.34e-10	Schizophrenia;
THYM	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg15592062	chr6:167189543	RPS6KA2	0.59	6.16	0.53	1.73e-8	Crohn's disease;
THYM	cis	rs16857609	0.564	rs13425215	chr2:218288580	A/G	cg15335768	chr2:218268053	DIRC3	-0.49	-7.24	-0.6	1.18e-10	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	cis	rs7688540	0.771	rs11248013	chr4:311425	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.72	4.79	0.44	6.21e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.8	-5.59	-0.5	2.21e-7	Huntington's disease progression;
THYM	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	10.0	0.72	1.67e-16	Platelet count;
THYM	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.76	-0.44	6.95e-6	Mean corpuscular volume;
THYM	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg08431931	chr22:42394659	WBP2NL	0.71	5.07	0.46	1.98e-6	Birth weight;
THYM	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg11764359	chr7:65958608	NA	-0.78	-6.18	-0.54	1.62e-8	Aortic root size;
THYM	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7100689	0.646	rs7092237	chr10:82165640	A/G	cg09936400	chr10:82049201	MAT1A	0.42	4.72	0.44	8.06e-6	Post bronchodilator FEV1;
THYM	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg27494647	chr7:150038898	RARRES2	0.47	5.41	0.49	4.77e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs72627123	0.867	rs118113209	chr14:74432158	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	4.87	0.45	4.38e-6	Morning vs. evening chronotype;
THYM	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.71	5.32	0.48	7.02e-7	Height;
THYM	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs4654899	0.865	rs6426674	chr1:21483906	C/T	cg01072550	chr1:21505969	NA	-0.74	-6.68	-0.57	1.63e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg05717871	chr11:638507	DRD4	-0.68	-5.18	-0.47	1.22e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs2018683	0.707	rs7799357	chr7:28970118	A/G	cg27487796	chr7:28973253	NA	-0.26	-4.62	-0.43	1.19e-5	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
THYM	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg18850127	chr7:39170497	POU6F2	0.61	5.63	0.5	1.85e-7	IgG glycosylation;
THYM	cis	rs7000551	0.700	rs2469761	chr8:22367274	A/G	cg12081754	chr8:22256438	SLC39A14	0.7	6.59	0.56	2.39e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg04398451	chr17:18023971	MYO15A	-0.78	-7.23	-0.6	1.22e-10	Total body bone mineral density;
THYM	cis	rs1691799	0.899	rs1168303	chr12:66738586	A/G	cg16791601	chr12:66731901	HELB	-0.76	-7.14	-0.59	1.9e-10	White blood cell count (basophil);
THYM	cis	rs7107174	1.000	rs10793308	chr11:78086005	C/T	cg02023728	chr11:77925099	USP35	0.63	6.11	0.53	2.23e-8	Testicular germ cell tumor;
THYM	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg18230493	chr5:56204884	C5orf35	-0.89	-6.53	-0.56	3.25e-9	Initial pursuit acceleration;
THYM	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg10295955	chr4:187884368	NA	-1.22	-17.54	-0.87	1.51e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg26752003	chr8:145688521	CYHR1	0.92	8.25	0.65	8.94e-13	Age at first birth;
THYM	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg09165964	chr15:75287851	SCAMP5	-1.0	-9.02	-0.68	2.08e-14	Blood trace element (Zn levels);
THYM	cis	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg06521331	chr12:34319734	NA	-1.02	-10.14	-0.72	8.47e-17	Morning vs. evening chronotype;
THYM	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg04117972	chr1:227635322	NA	0.89	5.32	0.48	6.93e-7	Major depressive disorder;
THYM	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg27490568	chr2:178487706	NA	-0.67	-5.35	-0.48	6.09e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4986172	0.726	rs12051846	chr17:43226887	A/G	cg06100756	chr17:43221575	NA	0.73	7.59	0.61	2.2e-11	Height;
THYM	cis	rs941408	1.000	rs1736181	chr19:2797703	C/T	cg06609049	chr19:2785107	THOP1	0.7	5.7	0.5	1.37e-7	Total cholesterol levels;
THYM	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg23711669	chr6:146136114	FBXO30	0.9	8.95	0.68	2.91e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2625529	0.529	rs7183055	chr15:72377048	C/T	cg16672083	chr15:72433130	SENP8	0.49	4.52	0.42	1.76e-5	Red blood cell count;
THYM	cis	rs2637266	0.626	rs1660914	chr10:78525319	T/A	cg18941641	chr10:78392320	NA	0.73	5.84	0.51	7.29e-8	Pulmonary function;
THYM	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg06634786	chr22:41940651	POLR3H	0.71	5.22	0.47	1.07e-6	Vitiligo;
THYM	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg07636037	chr3:49044803	WDR6	0.97	9.94	0.71	2.24e-16	Parkinson's disease;
THYM	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg27129171	chr3:47204927	SETD2	-0.79	-7.84	-0.63	6.4e-12	Colorectal cancer;
THYM	cis	rs9733	0.569	rs11588404	chr1:150688529	C/A	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.72	0.44	8.16e-6	Breast cancer;
THYM	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.82	7.11	0.59	2.16e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4731207	0.565	rs1031959	chr7:124627313	T/C	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg02478829	chr6:26598070	ABT1	-0.33	-4.49	-0.42	1.97e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3892630	0.824	rs12327732	chr19:33221767	C/T	cg02283691	chr19:33182526	NUDT19	-0.41	-4.85	-0.45	4.83e-6	Red blood cell traits;
THYM	cis	rs7940866	0.903	rs2324316	chr11:130872353	G/T	cg12179176	chr11:130786555	SNX19	0.64	5.02	0.46	2.41e-6	Schizophrenia;
THYM	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg15448220	chr1:150897856	SETDB1	0.9	7.47	0.61	3.94e-11	Melanoma;
THYM	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg24596788	chr1:163392923	NA	0.77	6.88	0.58	6.42e-10	Motion sickness;
THYM	cis	rs858239	0.669	rs56400441	chr7:23143564	A/G	cg18081818	chr7:23246105	NA	-0.54	-4.68	-0.43	9.41e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg24812749	chr6:127587940	RNF146	1.0	8.15	0.64	1.44e-12	Breast cancer;
THYM	cis	rs6867032	0.834	rs4526149	chr5:1990166	G/A	cg26168224	chr5:2018326	NA	-1.08	-9.68	-0.7	7.83e-16	Gut microbiome composition (winter);
THYM	cis	rs3015497	0.789	rs2934688	chr14:51112360	G/A	cg04730355	chr14:51134070	SAV1	-0.54	-4.76	-0.44	6.85e-6	Mean platelet volume;
THYM	cis	rs67981189	0.529	rs2526872	chr14:71384885	C/T	cg15910301	chr14:71632612	NA	-0.56	-4.88	-0.45	4.23e-6	Schizophrenia;
THYM	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg08000102	chr2:233561755	GIGYF2	-0.69	-6.26	-0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg14582100	chr15:45693742	SPATA5L1	0.62	5.08	0.46	1.87e-6	Homoarginine levels;
THYM	cis	rs1775715	0.707	rs2778669	chr10:32161541	C/T	cg04359828	chr10:32216031	ARHGAP12	0.39	5.03	0.46	2.32e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs8078723	1.000	rs4795415	chr17:38157995	C/T	cg17467752	chr17:38218738	THRA	0.87	7.22	0.59	1.3e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg27129171	chr3:47204927	SETD2	0.71	6.66	0.56	1.81e-9	Colorectal cancer;
THYM	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg12000587	chr17:30186630	C17orf79	-0.46	-6.97	-0.58	4.08e-10	Height;
THYM	cis	rs6960043	0.714	rs6976086	chr7:15048611	T/G	cg19272540	chr7:15055459	NA	0.53	5.72	0.51	1.24e-7	Type 2 diabetes;
THYM	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.87	-0.82	1.48e-24	Height;
THYM	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	7.71	0.62	1.23e-11	Monocyte percentage of white cells;
THYM	cis	rs713587	0.563	rs11686663	chr2:25107759	C/T	cg15423357	chr2:25149977	NA	0.61	6.11	0.53	2.19e-8	Body mass index in non-asthmatics;
THYM	cis	rs526231	0.543	rs6880911	chr5:102307471	T/C	cg23492399	chr5:102201601	PAM	-0.61	-4.6	-0.43	1.31e-5	Primary biliary cholangitis;
THYM	cis	rs4285028	0.747	rs3732407	chr3:121416623	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.78	-5.48	-0.49	3.46e-7	Multiple sclerosis;
THYM	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.25	-0.47	9.38e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg05084668	chr3:125655381	ALG1L	-0.74	-4.68	-0.43	9.36e-6	Blood pressure (smoking interaction);
THYM	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg08807101	chr21:30365312	RNF160	-0.79	-6.04	-0.53	2.98e-8	Dental caries;
THYM	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg08885076	chr2:99613938	TSGA10	0.52	5.02	0.46	2.4e-6	Chronic sinus infection;
THYM	cis	rs17511627	0.808	rs4770935	chr13:26742038	T/C	cg13319468	chr13:27597730	NA	-0.7	-5.5	-0.49	3.14e-7	Alzheimer's disease;
THYM	cis	rs10927875	0.541	rs1739844	chr1:16343322	T/C	cg21385522	chr1:16154831	NA	0.65	4.65	0.43	1.08e-5	Dilated cardiomyopathy;
THYM	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg09197432	chr4:183729176	NA	0.83	5.14	0.47	1.48e-6	Pediatric autoimmune diseases;
THYM	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg11366901	chr6:160182831	ACAT2	1.07	9.53	0.7	1.68e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg23161317	chr6:28129485	ZNF389	0.72	4.79	0.44	6.09e-6	Parkinson's disease;
THYM	trans	rs877282	1.000	rs12775643	chr10:773242	G/A	cg22713356	chr15:30763199	NA	1.26	10.12	0.72	9.24e-17	Uric acid levels;
THYM	cis	rs2050392	1.000	rs2250714	chr10:30697396	G/C	cg02070205	chr10:30722105	MAP3K8	-0.5	-4.45	-0.42	2.31e-5	Inflammatory bowel disease;
THYM	cis	rs2777491	0.574	rs316611	chr15:41751678	A/G	cg18705301	chr15:41695430	NDUFAF1	1.16	11.96	0.78	1.2e-20	Ulcerative colitis;
THYM	cis	rs7043114	0.525	rs7047089	chr9:95117980	C/T	cg14631576	chr9:95140430	CENPP	-0.86	-9.03	-0.68	1.97e-14	Height;
THYM	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.76	-6.82	-0.57	8.36e-10	Personality dimensions;
THYM	cis	rs8077889	0.956	rs55768269	chr17:41888997	C/T	cg26893861	chr17:41843967	DUSP3	1.09	10.05	0.72	1.3e-16	Triglycerides;
THYM	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg11965913	chr1:205819406	PM20D1	0.54	4.47	0.42	2.18e-5	Parkinson's disease;
THYM	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg13010199	chr12:38710504	ALG10B	-0.59	-4.71	-0.44	8.37e-6	Morning vs. evening chronotype;
THYM	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg17775962	chr7:1200435	ZFAND2A	0.4	4.85	0.45	4.9100000000000004e-06	Longevity;Endometriosis;
THYM	cis	rs7584330	0.554	rs10176035	chr2:238433449	T/C	cg08992911	chr2:238395768	MLPH	0.88	5.73	0.51	1.17e-7	Prostate cancer;
THYM	cis	rs8030485	1.000	rs12593555	chr15:79411268	G/T	cg17916960	chr15:79447300	NA	0.48	4.83	0.44	5.25e-6	Left ventricle wall thickness;
THYM	cis	rs289828	0.868	rs6751802	chr2:152139022	A/G	cg05960677	chr2:152117363	RBM43	0.62	6.31	0.54	8.74e-9	Blood protein levels;
THYM	cis	rs7572733	0.534	rs700682	chr2:198712310	C/A	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg05527609	chr1:210001259	C1orf107	1.03	8.48	0.66	2.97e-13	Orofacial clefts;
THYM	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg08109568	chr15:31115862	NA	-0.61	-5.94	-0.52	4.72e-8	Huntington's disease progression;
THYM	cis	rs11671005	0.610	rs3794966	chr19:59068996	C/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.62	-4.98	-0.45	2.85e-6	Mean platelet volume;
THYM	cis	rs58804349	0.605	rs72779330	chr10:43522315	C/G	cg08461752	chr10:43522343	NA	-0.97	-5.58	-0.5	2.24e-7	Pediatric bone mineral content (radius);
THYM	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg11266682	chr4:10021025	SLC2A9	-0.55	-6.93	-0.58	5.09e-10	Bone mineral density;
THYM	cis	rs3924048	0.574	rs11121931	chr1:12617009	G/A	cg00291366	chr1:12616550	NA	0.38	5.85	0.51	7.04e-8	Optic cup area;
THYM	cis	rs892961	0.932	rs3987887	chr17:75414862	T/C	cg11351908	chr17:75402473	SEPT9	0.56	5.52	0.49	2.95e-7	Airflow obstruction;
THYM	cis	rs17253792	0.822	rs74653073	chr14:56079528	T/C	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg14598338	chr9:96623480	NA	-0.61	-7.1	-0.59	2.31e-10	DNA methylation (variation);
THYM	cis	rs6570726	0.935	rs409725	chr6:145840340	G/A	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg24308560	chr3:49941425	MST1R	-0.74	-6.33	-0.54	8.22e-9	Intelligence (multi-trait analysis);
THYM	cis	rs113835537	0.529	rs17580784	chr11:66214859	T/A	cg24851651	chr11:66362959	CCS	0.74	5.16	0.47	1.33e-6	Airway imaging phenotypes;
THYM	cis	rs7727544	0.606	rs10058074	chr5:131686146	G/A	cg14196790	chr5:131705035	SLC22A5	0.56	5.28	0.48	8.19e-7	Blood metabolite levels;
THYM	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg20283391	chr11:68216788	NA	-0.74	-5.43	-0.49	4.25e-7	Total body bone mineral density;
THYM	cis	rs11645898	0.872	rs72791121	chr16:72225294	C/T	cg14768367	chr16:72042858	DHODH	-0.68	-4.95	-0.45	3.23e-6	Blood protein levels;
THYM	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-8.1	-0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg05043794	chr9:111880884	C9orf5	-0.43	-6.35	-0.55	7.29e-9	Menarche (age at onset);
THYM	cis	rs2932538	0.922	rs7551933	chr1:113086706	C/T	cg22162597	chr1:113214053	CAPZA1	-0.66	-5.21	-0.47	1.09e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs2455601	1.000	rs56336128	chr11:8908299	G/A	cg00249584	chr11:8833047	ST5	0.34	4.57	0.42	1.49e-5	Schizophrenia;
THYM	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg15490075	chr13:100150979	NA	0.77	4.49	0.42	1.98e-5	Obesity-related traits;
THYM	cis	rs9650657	0.584	rs28613656	chr8:10695419	G/A	cg12981288	chr8:11183844	MTMR9	-0.5	-4.71	-0.44	8.34e-6	Neuroticism;
THYM	cis	rs7809615	1.000	rs7809615	chr7:99184778	G/T	cg12290671	chr7:99195819	NA	-0.99	-4.83	-0.44	5.27e-6	Blood metabolite ratios;
THYM	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg25566285	chr7:158114605	PTPRN2	0.87	9.85	0.71	3.44e-16	Calcium levels;
THYM	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	7.12	0.59	2.09e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7264396	0.887	rs4911510	chr20:34093153	G/A	cg26038318	chr20:34205095	SPAG4	0.53	4.45	0.42	2.33e-5	Total cholesterol levels;
THYM	cis	rs7009516	0.669	rs13280953	chr8:24250161	C/T	cg01759110	chr8:24241694	ADAMDEC1	-0.54	-4.88	-0.45	4.35e-6	Hair greying;
THYM	cis	rs8062405	0.755	rs62031607	chr16:28631530	A/T	cg09046979	chr16:28333134	SBK1	-0.55	-4.82	-0.44	5.41e-6	Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg06623918	chr6:96969491	KIAA0776	1.09	10.37	0.73	2.65e-17	Headache;
THYM	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg01570182	chr17:44337453	NA	-0.84	-9.31	-0.69	5.04e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2811415	0.597	rs56143290	chr3:127737383	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs870825	0.616	rs6814278	chr4:185644417	G/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg13695892	chr22:41940480	POLR3H	-0.62	-4.73	-0.44	7.72e-6	Vitiligo;
THYM	cis	rs11771526	0.642	rs11762517	chr7:32336793	T/C	cg13207630	chr7:32358064	NA	0.71	4.73	0.44	7.9e-6	Body mass index;
THYM	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.09e-8	Systolic blood pressure;
THYM	cis	rs7326068	0.510	rs4432108	chr13:21342151	G/A	cg02792322	chr13:21280448	IL17D	-0.64	-4.46	-0.42	2.27e-5	Schizophrenia, bipolar disorder and depression (combined);
THYM	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg02782426	chr3:40428986	ENTPD3	0.51	4.54	0.42	1.67e-5	Renal cell carcinoma;
THYM	cis	rs4363385	0.818	rs454993	chr1:153008992	C/G	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg15247329	chr7:2764246	NA	-0.75	-6.64	-0.56	1.92e-9	Height;
THYM	cis	rs8077889	0.956	rs17742347	chr17:41846468	A/G	cg26893861	chr17:41843967	DUSP3	-1.08	-9.82	-0.71	4.05e-16	Triglycerides;
THYM	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.36	-0.48	5.71e-7	Mean corpuscular volume;
THYM	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg09517075	chr8:22133004	PIWIL2	0.64	5.94	0.52	4.64e-8	Hypertriglyceridemia;
THYM	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg12310025	chr6:25882481	NA	-0.84	-6.8	-0.57	9.29e-10	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg02782426	chr3:40428986	ENTPD3	0.56	5.02	0.46	2.41e-6	Renal cell carcinoma;
THYM	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg07636037	chr3:49044803	WDR6	-0.79	-5.62	-0.5	1.88e-7	Menarche (age at onset);
THYM	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg13390004	chr1:15929781	NA	0.62	4.72	0.44	8.11e-6	Systolic blood pressure;
THYM	trans	rs4650994	0.525	rs2493860	chr1:178541492	A/G	cg05059571	chr16:84539110	KIAA1609	-0.92	-10.85	-0.74	2.56e-18	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs9880211	1.000	rs13071220	chr3:136314119	T/C	cg21827317	chr3:136751795	NA	-0.69	-4.67	-0.43	1e-5	Body mass index;Height;
THYM	cis	rs6570726	0.935	rs386823	chr6:145841365	C/T	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg01256987	chr12:42539512	GXYLT1	-0.68	-4.89	-0.45	4.02e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
THYM	cis	rs9565309	0.579	rs76391359	chr13:77582708	C/G	cg13866767	chr13:78470850	EDNRB	1.06	4.81	0.44	5.76e-6	Morning vs. evening chronotype;
THYM	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.26	0.47	8.97e-7	Lung cancer in ever smokers;
THYM	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14159672	chr1:205819179	PM20D1	1.05	11.61	0.77	6.45e-20	Menarche (age at onset);
THYM	cis	rs17407555	0.657	rs10489076	chr4:10270848	T/C	cg00071950	chr4:10020882	SLC2A9	0.59	5.53	0.49	2.81e-7	Schizophrenia (age at onset);
THYM	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg04842962	chr6:43655489	MRPS18A	1.27	8.78	0.67	6.69e-14	IgG glycosylation;
THYM	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs600550	0.618	rs1443250	chr11:60102790	G/A	cg05040360	chr11:60102449	MS4A6E	0.48	4.67	0.43	9.74e-6	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs17407555	0.683	rs6823180	chr4:10275831	C/T	cg00071950	chr4:10020882	SLC2A9	0.56	5.15	0.47	1.4e-6	Schizophrenia (age at onset);
THYM	cis	rs4780401	0.755	rs7194034	chr16:11770777	A/G	cg01061890	chr16:11836724	TXNDC11	-0.61	-4.71	-0.43	8.55e-6	Rheumatoid arthritis;
THYM	cis	rs10751667	0.961	rs6421967	chr11:983966	T/C	ch.11.42038R	chr11:967971	AP2A2	0.6	4.85	0.45	4.76e-6	Alzheimer's disease (late onset);
THYM	cis	rs2625529	0.556	rs1552134	chr15:72232898	T/A	cg16672083	chr15:72433130	SENP8	0.49	4.45	0.42	2.31e-5	Red blood cell count;
THYM	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg14517863	chr17:44321492	NA	0.41	4.66	0.43	1.05e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4400599	1.000	rs4400599	chr1:154127100	A/G	cg05139571	chr1:154127138	NUP210L	0.54	4.62	0.43	1.21e-5	Platelet distribution width;
THYM	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg13695892	chr22:41940480	POLR3H	-0.72	-6.71	-0.57	1.39e-9	Vitiligo;
THYM	cis	rs17511627	0.808	rs9512140	chr13:26743703	A/T	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11614913	0.509	rs12300425	chr12:54395082	G/T	cg07791427	chr12:54402704	HOXC8	-0.52	-4.61	-0.43	1.25e-5	Waist circumference adjusted for body mass index;
THYM	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs7119	0.671	rs10152850	chr15:77904426	G/A	cg10437265	chr15:77819839	NA	-0.57	-5.69	-0.5	1.38e-7	Type 2 diabetes;
THYM	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg20007245	chr22:24372913	LOC391322	0.78	7.17	0.59	1.63e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg13683864	chr3:40499215	RPL14	0.79	7.53	0.61	2.93e-11	Renal cell carcinoma;
THYM	cis	rs988913	0.629	rs34685175	chr6:54866737	G/C	cg04690482	chr6:54711388	FAM83B	0.52	5.56	0.5	2.5e-7	Menarche (age at onset);
THYM	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg01616529	chr11:638424	DRD4	-0.78	-5.81	-0.51	8.27e-8	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs1728785	0.818	rs1170430	chr16:68604954	T/C	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.39e-6	Ulcerative colitis;
THYM	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.97	-5.47	-0.49	3.64e-7	Red cell distribution width;
THYM	cis	rs1878931	0.507	rs67218524	chr16:3403057	G/T	cg00484396	chr16:3507460	NAT15	0.46	4.53	0.42	1.73e-5	Body mass index (adult);
THYM	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.76	6.74	0.57	1.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.0	8.03	0.64	2.61e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg17105886	chr17:28927953	LRRC37B2	1.25	6.76	0.57	1.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg06521331	chr12:34319734	NA	-1.04	-10.13	-0.72	8.85e-17	Morning vs. evening chronotype;
THYM	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg03929089	chr4:120376271	NA	1.03	8.55	0.66	2.06e-13	Coronary artery disease;
THYM	cis	rs7107174	0.892	rs2512529	chr11:77977351	C/T	cg02023728	chr11:77925099	USP35	0.64	5.41	0.49	4.72e-7	Testicular germ cell tumor;
THYM	cis	rs6728642	0.808	rs114192053	chr2:97871906	G/A	cg26665480	chr2:98280029	ACTR1B	-1.04	-4.77	-0.44	6.53e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg06521331	chr12:34319734	NA	0.79	5.95	0.52	4.56e-8	Morning vs. evening chronotype;
THYM	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg25358565	chr5:93447407	FAM172A	1.36	10.94	0.75	1.62e-18	Diabetic retinopathy;
THYM	cis	rs4786125	0.588	rs1473516	chr16:6923077	C/T	cg03623568	chr16:6915990	A2BP1	-1.01	-9.86	-0.71	3.22e-16	Heart rate variability traits (SDNN);
THYM	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg27535305	chr1:53392650	SCP2	0.38	4.55	0.42	1.6e-5	Monocyte count;
THYM	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg07747251	chr5:1868357	NA	0.68	5.86	0.52	6.67e-8	Cardiovascular disease risk factors;
THYM	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg13114125	chr14:105738426	BRF1	-0.73	-5.72	-0.51	1.22e-7	Platelet count;
THYM	cis	rs3820068	0.581	rs6429762	chr1:15945595	A/C	cg27534772	chr1:16042836	PLEKHM2	0.54	5.99	0.52	3.81e-8	Systolic blood pressure;
THYM	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg22431228	chr1:16359049	CLCNKA	-0.52	-4.69	-0.43	9.13e-6	Dilated cardiomyopathy;
THYM	cis	rs78761021	0.867	rs17681708	chr17:9792872	T/C	cg26853458	chr17:9805074	RCVRN	0.52	4.65	0.43	1.08e-5	Type 2 diabetes;
THYM	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg00717180	chr2:96193071	NA	-0.72	-7.45	-0.61	4.21e-11	HDL cholesterol;
THYM	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg24733560	chr20:60626293	TAF4	0.58	5.84	0.51	7.31e-8	Body mass index;
THYM	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg23649088	chr2:200775458	C2orf69	0.81	6.14	0.53	1.88e-8	Schizophrenia;
THYM	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg00339695	chr16:24857497	SLC5A11	0.48	4.79	0.44	6.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2041895	0.509	rs10861674	chr12:107304037	A/G	cg26297688	chr12:107349093	C12orf23	-0.48	-4.66	-0.43	1.03e-5	Glaucoma (low intraocular pressure);
THYM	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs924712	0.522	rs12194012	chr6:54709851	C/T	cg19716238	chr6:54711378	FAM83B	0.47	4.51	0.42	1.87e-5	Breast cancer;
THYM	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg04317338	chr11:64019027	PLCB3	-0.85	-5.84	-0.51	7.3900000000000007e-08	Mean platelet volume;
THYM	cis	rs7100689	0.577	rs2185427	chr10:82056667	G/T	cg09936400	chr10:82049201	MAT1A	-0.47	-4.93	-0.45	3.5e-6	Post bronchodilator FEV1;
THYM	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg22841779	chr14:105766346	BRF1	-0.46	-5.68	-0.5	1.46e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7213347	0.610	rs8077194	chr17:2119475	A/G	cg16513277	chr17:2031491	SMG6	-0.64	-4.64	-0.43	1.13e-5	Total body bone mineral density;
THYM	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg01528321	chr10:82214614	TSPAN14	-0.81	-6.13	-0.53	2.04e-8	Post bronchodilator FEV1;
THYM	cis	rs7296418	0.619	rs7139321	chr12:123719528	T/G	cg00376283	chr12:123451042	ABCB9	0.78	6.18	0.54	1.62e-8	Platelet count;
THYM	cis	rs55823223	0.504	rs56098714	chr17:73860303	T/C	cg08125733	chr17:73851984	WBP2	0.84	5.44	0.49	4.13e-7	Psoriasis;
THYM	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg09359103	chr1:154839909	KCNN3	-0.69	-8.43	-0.65	3.66e-13	Prostate cancer;
THYM	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg06481639	chr22:41940642	POLR3H	-0.75	-5.22	-0.47	1.06e-6	Vitiligo;
THYM	cis	rs12579753	0.917	rs7313521	chr12:82205656	G/A	cg21231944	chr12:82153410	PPFIA2	-0.66	-5.01	-0.46	2.51e-6	Resting heart rate;
THYM	cis	rs2505998	1.000	rs2435362	chr10:43578779	A/C	cg06632098	chr10:43605906	RET	-1.06	-9.44	-0.7	2.63e-15	Hirschsprung disease;
THYM	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg02478829	chr6:26598070	ABT1	-0.35	-4.67	-0.43	9.79e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.68	6.04	0.53	2.94e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg14643075	chr5:176755449	NA	-0.48	-4.62	-0.43	1.2e-5	Hemoglobin concentration;Hematocrit;
THYM	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg08742575	chr21:47604166	C21orf56	0.76	5.81	0.51	8.3e-8	Testicular germ cell tumor;
THYM	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg25036284	chr2:26402008	FAM59B	-0.81	-5.18	-0.47	1.24e-6	Gut microbiome composition (summer);
THYM	cis	rs28647808	1.000	rs4962145	chr9:136275188	A/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg06634786	chr22:41940651	POLR3H	0.73	5.33	0.48	6.69e-7	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg24642844	chr7:1081250	C7orf50	-1.18	-5.51	-0.49	3.04e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs778371	0.697	rs4973564	chr2:233718440	A/G	cg08000102	chr2:233561755	GIGYF2	-0.86	-7.83	-0.63	6.99e-12	Schizophrenia;
THYM	cis	rs2898681	0.614	rs962416	chr4:53695657	G/T	cg00338735	chr4:53728038	RASL11B	-0.61	-5.76	-0.51	1.02e-7	Optic nerve measurement (cup area);
THYM	cis	rs13064411	0.735	rs6438158	chr3:113217290	C/T	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	5.94	0.52	4.66e-8	Bone mineral density;
THYM	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg00012203	chr2:219082015	ARPC2	-0.86	-8.51	-0.66	2.52e-13	Colorectal cancer;
THYM	cis	rs7104764	1.000	rs1533825	chr11:214163	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	-1.13	-10.07	-0.72	1.17e-16	Menarche (age at onset);
THYM	cis	rs3809566	0.963	rs3809565	chr15:63333619	A/G	cg00520135	chr15:63333846	TPM1	-0.57	-4.94	-0.45	3.3e-6	Platelet count;
THYM	cis	rs2502731	0.539	rs3003615	chr9:130997892	C/T	cg09976142	chr9:130955436	CIZ1	0.48	4.77	0.44	6.62e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs9972944	0.756	rs7222229	chr17:63765025	T/G	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs4523957	0.583	rs2641438	chr17:2017786	C/G	cg16513277	chr17:2031491	SMG6	-0.96	-8.72	-0.67	9.17e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03517284	chr6:25882590	NA	-0.96	-7.88	-0.63	5.39e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg15448220	chr1:150897856	SETDB1	0.88	7.27	0.6	1.02e-10	Tonsillectomy;
THYM	trans	rs4650994	1.000	rs10798616	chr1:178515642	G/C	cg05059571	chr16:84539110	KIAA1609	-0.75	-7.95	-0.63	3.83e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs6988636	0.901	rs62521825	chr8:124185786	C/A	cg23067535	chr8:124195133	FAM83A	-1.1	-5.77	-0.51	9.8e-8	Urinary uromodulin levels;
THYM	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs3768617	0.510	rs10911249	chr1:183080690	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.06	0.68	1.73e-14	Chronic sinus infection;
THYM	cis	rs7200543	1.000	rs4985124	chr16:15125441	A/C	cg01933576	chr16:15083564	PDXDC1	-0.86	-6.41	-0.55	5.54e-9	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs7719624	1.000	rs2107331	chr5:135377349	A/C	cg12897067	chr5:135418308	NA	-0.6	-4.9	-0.45	3.92e-6	Response to cytidine analogues (gemcitabine);
THYM	trans	rs208520	0.661	rs207111	chr6:66792513	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.66	-0.62	1.53e-11	Exhaled nitric oxide output;
THYM	cis	rs2282300	0.739	rs10835647	chr11:30313268	A/G	cg22891988	chr11:30607959	MPPED2	-0.71	-4.53	-0.42	1.72e-5	Morning vs. evening chronotype;
THYM	cis	rs6570726	0.791	rs414297	chr6:145887556	C/T	cg13319975	chr6:146136371	FBXO30	-0.66	-5.35	-0.48	6.11e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1335645	1.000	rs1335645	chr1:111684276	A/G	cg00321911	chr1:111669324	DRAM2	-1.13	-5.52	-0.49	2.9e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs995000	0.931	rs638714	chr1:62906489	G/T	cg06896770	chr1:63153194	DOCK7	0.92	7.38	0.6	6.01e-11	Triglyceride levels;
THYM	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg00684032	chr4:1343700	KIAA1530	0.55	4.76	0.44	7.03e-6	Obesity-related traits;
THYM	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs2290159	0.800	rs59821954	chr3:12687613	T/C	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs4919694	0.901	rs12264456	chr10:104830634	C/T	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs7119	0.604	rs907383	chr15:77870646	A/G	cg10437265	chr15:77819839	NA	-0.67	-6.52	-0.56	3.4e-9	Type 2 diabetes;
THYM	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	1.02	9.11	0.68	1.31e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7769051	0.522	rs9493449	chr6:133126179	T/A	cg22852734	chr6:133119734	C6orf192	1.45	6.1	0.53	2.32e-8	Type 2 diabetes nephropathy;
THYM	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg13683864	chr3:40499215	RPL14	-0.87	-8.43	-0.65	3.64e-13	Renal cell carcinoma;
THYM	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg25918947	chr17:41365094	TMEM106A	-0.59	-4.92	-0.45	3.66e-6	Menopause (age at onset);
THYM	cis	rs1403694	0.695	rs10937266	chr3:186433075	G/A	cg12454167	chr3:186435060	KNG1	0.5	6.72	0.57	1.35e-9	Blood protein levels;
THYM	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.94e-6	Breast cancer;
THYM	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs55728055	0.661	rs16989278	chr22:31957167	A/G	cg01338084	chr22:32026380	PISD	1.47	5.89	0.52	5.9e-8	Age-related hearing impairment;
THYM	cis	rs9581857	0.579	rs75024088	chr13:27970105	G/T	cg22138327	chr13:27999177	GTF3A	1.02	5.82	0.51	7.8e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg21773646	chr17:80085082	CCDC57	0.32	4.54	0.42	1.66e-5	Life satisfaction;
THYM	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg11941060	chr3:133502564	NA	-0.81	-6.78	-0.57	1e-9	Iron status biomarkers;
THYM	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg18252515	chr7:66147081	NA	-0.67	-5.08	-0.46	1.86e-6	Aortic root size;
THYM	cis	rs7011507	0.594	rs56308602	chr8:49350516	C/T	cg08774009	chr8:49309094	NA	-0.6	-4.71	-0.44	8.47e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs2276314	1.000	rs62101367	chr18:33550884	C/T	cg19628046	chr18:33552617	C18orf21	0.77	5.47	0.49	3.68e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.64	-4.6	-0.43	1.32e-5	Body mass index (adult);
THYM	cis	rs10929159	0.928	rs1349731	chr2:236924047	C/T	cg14895183	chr2:236924282	AGAP1	-0.53	-4.5	-0.42	1.95e-5	Parkinson's disease;
THYM	cis	rs870825	0.616	rs745656	chr4:185637523	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs6547741	1.000	rs6547741	chr2:27855924	G/A	cg27432699	chr2:27873401	GPN1	0.76	6.81	0.57	8.65e-10	Oral cavity cancer;
THYM	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2276498	0.751	rs6127061	chr20:52636607	G/T	cg23682609	chr20:52687365	BCAS1	0.59	5.03	0.46	2.29e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg24531977	chr5:56204891	C5orf35	-0.63	-4.82	-0.44	5.45e-6	Coronary artery disease;
THYM	cis	rs1467026	0.606	rs9814180	chr3:12818386	A/G	cg05775895	chr3:12838266	CAND2	1.06	10.5	0.73	1.39e-17	P wave duration;
THYM	cis	rs11031096	0.711	rs17283923	chr11:4173841	C/T	cg18678763	chr11:4115507	RRM1	-0.39	-4.65	-0.43	1.09e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9902453	0.874	rs11653805	chr17:28378276	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.22	-0.54	1.3e-8	Coffee consumption (cups per day);
THYM	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	8.9	0.67	3.71e-14	Cognitive test performance;
THYM	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg08999081	chr20:33150536	PIGU	0.8	7.37	0.6	6.23e-11	Coronary artery disease;
THYM	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg15921436	chr17:44337874	NA	0.91	6.69	0.57	1.56e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6032067	0.929	rs8126178	chr20:43822581	A/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.6	-5.78	-0.51	9.42e-8	Blood protein levels;
THYM	trans	rs7794364	0.538	rs10233018	chr7:117523709	A/G	cg21837391	chr1:1159412	SDF4	0.94	8.03	0.64	2.55e-12	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs728616	0.867	rs1054054	chr10:81682728	C/T	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs16866061	1.000	rs17480230	chr2:225399864	G/A	cg22455342	chr2:225449267	CUL3	0.68	4.9	0.45	3.87e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg27129171	chr3:47204927	SETD2	-0.8	-7.67	-0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs2213920	0.679	rs6415819	chr9:118212492	A/C	cg13918206	chr9:118159781	DEC1	0.81	4.67	0.43	9.95e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs12908161	0.515	rs12907646	chr15:85403496	G/A	cg12863693	chr15:85201151	NMB	0.54	4.52	0.42	1.79e-5	Schizophrenia;
THYM	cis	rs12149862	1.000	rs9941002	chr16:69502639	A/G	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs7131987	0.845	rs2042511	chr12:29408780	C/T	cg09582351	chr12:29534625	ERGIC2	-0.48	-4.59	-0.43	1.36e-5	QT interval;
THYM	cis	rs9910055	0.550	rs113844752	chr17:42297631	C/A	cg13607699	chr17:42295918	UBTF	0.9	8.72	0.67	8.8e-14	Total body bone mineral density;
THYM	cis	rs7084402	0.935	rs10826202	chr10:60359091	C/T	cg27040468	chr10:60456715	BICC1	-0.54	-4.5	-0.42	1.92e-5	Refractive error;
THYM	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg22875332	chr1:76189707	ACADM	0.88	9.09	0.68	1.44e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs11671005	0.735	rs11667723	chr19:58927489	A/G	cg18639983	chr19:58920768	ZNF584	0.59	5.0	0.46	2.63e-6	Mean platelet volume;
THYM	cis	rs7940866	0.804	rs3910266	chr11:130814272	A/C	cg05962950	chr11:130786565	SNX19	0.73	5.75	0.51	1.07e-7	Schizophrenia;
THYM	cis	rs6570726	0.967	rs450973	chr6:145863065	C/A	cg23711669	chr6:146136114	FBXO30	0.78	7.34	0.6	7.2e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2806561	1.000	rs2806561	chr1:23504795	C/T	cg12483005	chr1:23474871	LUZP1	-0.56	-5.94	-0.52	4.68e-8	Height;
THYM	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg27446573	chr6:127587934	RNF146	1.04	9.87	0.71	3.12e-16	Breast cancer;
THYM	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg18402987	chr7:1209562	NA	1.04	6.25	0.54	1.16e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs586688	1.000	rs589855	chr1:201631649	C/A	cg12048341	chr1:201712730	NAV1	-0.8	-4.61	-0.43	1.26e-5	Obesity-related traits;
THYM	cis	rs4731207	0.698	rs2286173	chr7:124465951	A/C	cg05285228	chr7:124571219	POT1	0.68	5.29	0.48	7.98e-7	Cutaneous malignant melanoma;
THYM	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg24209194	chr3:40518798	ZNF619	0.64	5.15	0.47	1.42e-6	Renal cell carcinoma;
THYM	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg14820908	chr5:178986412	RUFY1	0.64	6.89	0.58	6.17e-10	Lung cancer;
THYM	cis	rs9534288	0.699	rs1467665	chr13:46662919	C/T	cg15192986	chr13:46630673	CPB2	-0.65	-4.6	-0.43	1.28e-5	Blood protein levels;
THYM	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg13147721	chr7:65941812	NA	-0.96	-6.01	-0.52	3.45e-8	Diabetic kidney disease;
THYM	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg05973401	chr12:123451056	ABCB9	0.68	4.55	0.42	1.58e-5	Neutrophil percentage of white cells;
THYM	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg26566898	chr11:117069891	TAGLN	-0.41	-5.22	-0.47	1.06e-6	Blood protein levels;
THYM	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs3820068	0.608	rs12740492	chr1:16048951	A/T	cg05660106	chr1:15850417	CASP9	0.73	5.83	0.51	7.63e-8	Systolic blood pressure;
THYM	cis	rs6866344	0.598	rs11742176	chr5:178147931	C/T	cg03877680	chr5:178157825	ZNF354A	0.76	5.19	0.47	1.17e-6	Neutrophil percentage of white cells;
THYM	cis	rs7189233	0.911	rs72801854	chr16:53517242	G/A	cg02965178	chr16:53538660	AKTIP	-0.58	-4.61	-0.43	1.26e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2456568	0.900	rs877340	chr11:93689292	A/T	cg17595323	chr11:93583763	C11orf90	-0.54	-5.22	-0.47	1.03e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs651907	1.000	rs651907	chr3:101600724	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.52	4.51	0.42	1.86e-5	Colorectal cancer;
THYM	cis	rs2742234	0.541	rs11238490	chr10:43747598	G/A	cg06632098	chr10:43605906	RET	0.74	4.86	0.45	4.54e-6	Hirschsprung disease;
THYM	cis	rs4713118	0.869	rs9461405	chr6:27719375	G/T	cg12963246	chr6:28129442	ZNF389	0.64	4.86	0.45	4.62e-6	Parkinson's disease;
THYM	cis	rs4660261	0.545	rs803682	chr1:44362623	G/A	cg13246856	chr1:44399776	ARTN	0.5	5.07	0.46	1.95e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4243830	0.737	rs11122083	chr1:6593532	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.05	-5.78	-0.51	9.39e-8	Body mass index;
THYM	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-5.78	-0.51	9.67e-8	Systemic lupus erythematosus;
THYM	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.77	6.9	0.58	5.68e-10	Hip circumference adjusted for BMI;
THYM	cis	rs621559	0.636	rs1760672	chr1:43678677	A/G	cg13246856	chr1:44399776	ARTN	-0.55	-4.58	-0.43	1.4e-5	Telomere length;
THYM	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs2997447	0.761	rs55815920	chr1:26457662	A/C	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg02915803	chr1:1606292	LOC728661;CDK11B	0.62	5.1	0.46	1.73e-6	Body mass index;
THYM	cis	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg13789015	chr9:136890014	NCRNA00094	0.84	7.07	0.59	2.6e-10	Platelet distribution width;
THYM	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg05890377	chr2:74357713	NA	0.87	6.29	0.54	9.67e-9	Gestational age at birth (maternal effect);
THYM	cis	rs9326248	0.520	rs1446105	chr11:116798544	C/T	cg20608306	chr11:116969690	SIK3	0.63	7.94	0.63	3.94e-12	Blood protein levels;
THYM	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6032067	0.602	rs2741523	chr20:43920446	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.54	-5.46	-0.49	3.79e-7	Blood protein levels;
THYM	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg17063962	chr7:91808500	NA	-1.08	-11.41	-0.76	1.71e-19	Breast cancer;
THYM	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg00922110	chr4:57842668	C4orf14	-0.44	-5.13	-0.47	1.56e-6	Response to bleomycin (chromatid breaks);
THYM	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg02018176	chr4:1364513	KIAA1530	-0.8	-7.57	-0.61	2.41e-11	Obesity-related traits;
THYM	cis	rs7582180	0.614	rs10193204	chr2:101004540	A/G	cg14675211	chr2:100938903	LONRF2	-0.65	-6.27	-0.54	1.08e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg11266682	chr4:10021025	SLC2A9	0.74	12.06	0.78	7.11e-21	Bone mineral density;
THYM	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg26384229	chr12:38710491	ALG10B	1.0	7.56	0.61	2.54e-11	Bladder cancer;
THYM	cis	rs4866334	1.000	rs77052976	chr5:18453061	A/T	cg02002538	chr5:17811409	NA	-1.09	-4.54	-0.42	1.67e-5	IgG glycosylation;
THYM	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11141652	chr22:24348549	GSTTP1	-0.67	-6.51	-0.56	3.46e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg08125733	chr17:73851984	WBP2	0.8	5.7	0.5	1.35e-7	Psoriasis;
THYM	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs7084402	0.935	rs10763559	chr10:60347410	C/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.72	-0.51	1.25e-7	Refractive error;
THYM	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.7	-6.35	-0.55	7.43e-9	Personality dimensions;
THYM	cis	rs9866391	0.607	rs6764769	chr3:141100280	A/G	cg13411656	chr3:141121016	ZBTB38	-0.35	-5.14	-0.47	1.46e-6	Myopia;
THYM	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg13683864	chr3:40499215	RPL14	-0.87	-8.19	-0.64	1.2e-12	Renal cell carcinoma;
THYM	cis	rs2046867	0.908	rs11928067	chr3:72796340	T/C	cg25664220	chr3:72788482	NA	-0.86	-6.56	-0.56	2.76e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs28595532	0.920	rs116108618	chr4:119763585	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	4.84	0.44	4.97e-6	Menarche (age at onset);
THYM	cis	rs939574	1.000	rs9989854	chr2:220086280	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.2	-5.46	-0.49	3.84e-7	Platelet distribution width;
THYM	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg10518543	chr12:38710700	ALG10B	-0.57	-4.61	-0.43	1.24e-5	Bladder cancer;
THYM	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg00981070	chr1:2046702	PRKCZ	0.47	5.21	0.47	1.1e-6	Height;
THYM	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs35883536	0.647	rs10875317	chr1:101045438	G/T	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg17063962	chr7:91808500	NA	1.1	12.12	0.78	5.59e-21	Breast cancer;
THYM	cis	rs2734839	0.964	rs7122246	chr11:113304457	G/A	cg14159747	chr11:113255604	NA	0.32	6.22	0.54	1.34e-8	Information processing speed;
THYM	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg00908189	chr16:619842	PIGQ	1.05	9.25	0.69	6.62e-15	Height;
THYM	cis	rs679087	1.000	rs302317	chr12:29921443	G/A	cg14258853	chr12:29935411	TMTC1	-0.65	-5.86	-0.52	6.51e-8	Schizophrenia;
THYM	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.96	-8.65	-0.66	1.29e-13	Chronic sinus infection;
THYM	cis	rs9326248	0.769	rs499910	chr11:116763034	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.67	4.74	0.44	7.44e-6	Blood protein levels;
THYM	cis	rs7940866	0.801	rs2113929	chr11:130835974	G/A	cg05962950	chr11:130786565	SNX19	0.71	5.6	0.5	2.11e-7	Schizophrenia;
THYM	cis	rs12519773	0.555	rs2578490	chr5:92389236	C/T	cg18783429	chr5:92414398	NA	0.49	4.54	0.42	1.63e-5	Migraine;
THYM	cis	rs2898681	0.874	rs4864691	chr4:53755972	C/T	cg00338735	chr4:53728038	RASL11B	0.59	5.19	0.47	1.2e-6	Optic nerve measurement (cup area);
THYM	cis	rs7000551	0.751	rs2443505	chr8:22375341	G/A	cg12081754	chr8:22256438	SLC39A14	0.63	5.71	0.51	1.27e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9517302	0.847	rs9517297	chr13:99094961	A/C	cg22223119	chr13:99095684	FARP1	-0.95	-7.41	-0.61	5.13e-11	Obesity-related traits;
THYM	cis	rs2495707	0.602	rs75205635	chr10:102416299	G/T	cg00272971	chr10:102419564	NA	-0.56	-5.98	-0.52	3.85e-8	Body mass index;
THYM	cis	rs13185784	0.662	rs35759987	chr5:179679980	G/T	cg23248424	chr5:179741104	GFPT2	0.72	4.76	0.44	6.87e-6	TRAIL levels;
THYM	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg17143192	chr8:8559678	CLDN23	0.68	5.22	0.47	1.03e-6	Mood instability;
THYM	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg07636037	chr3:49044803	WDR6	0.95	10.01	0.72	1.59e-16	Parkinson's disease;
THYM	cis	rs12049351	0.665	rs11809370	chr1:229587133	A/G	cg11742688	chr1:229674241	ABCB10	-0.55	-4.66	-0.43	1.03e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg15242686	chr22:24348715	GSTTP1	0.72	7.59	0.61	2.19e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg01570182	chr17:44337453	NA	0.91	9.94	0.71	2.22e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs3862260	0.509	rs3795663	chr1:120165187	G/A	cg16322792	chr1:120165303	ZNF697	0.92	11.5	0.76	1.09e-19	Systemic lupus erythematosus;
THYM	cis	rs459571	0.959	rs465535	chr9:136910905	C/T	cg13789015	chr9:136890014	NCRNA00094	0.78	6.65	0.56	1.88e-9	Platelet distribution width;
THYM	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg27284194	chr4:1044797	NA	0.61	4.6	0.43	1.29e-5	Recombination rate (females);
THYM	cis	rs4654899	0.865	rs1472831	chr1:21435940	C/T	cg01072550	chr1:21505969	NA	-0.75	-6.6	-0.56	2.29e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs12586317	0.620	rs28404080	chr14:35539418	G/T	cg05294307	chr14:35346193	BAZ1A	-0.85	-5.67	-0.5	1.52e-7	Psoriasis;
THYM	cis	rs13064411	0.660	rs11916690	chr3:113012343	A/C	cg18753928	chr3:113234510	CCDC52	-0.81	-7.16	-0.59	1.71e-10	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg24531977	chr5:56204891	C5orf35	-1.0	-8.23	-0.65	9.77e-13	Initial pursuit acceleration;
THYM	cis	rs2742234	0.554	rs1254963	chr10:43696086	C/T	cg06632098	chr10:43605906	RET	0.79	5.1	0.46	1.73e-6	Hirschsprung disease;
THYM	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg14784868	chr12:69753453	YEATS4	0.69	5.16	0.47	1.38e-6	Response to diuretic therapy;
THYM	cis	rs7221773	0.568	rs4795480	chr17:27296269	A/G	cg18170879	chr17:27169527	C17orf63	0.61	4.55	0.42	1.56e-5	Mean corpuscular volume;
THYM	cis	rs62103177	0.535	rs62101568	chr18:77934671	G/A	cg07235805	chr18:78004237	PARD6G	0.51	6.34	0.55	7.69e-9	Opioid sensitivity;
THYM	cis	rs11118844	0.744	rs4623704	chr1:221953846	G/A	cg04222084	chr1:221915650	DUSP10	-1.04	-5.26	-0.47	8.95e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs4731207	0.698	rs10250202	chr7:124465509	A/C	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs72627123	0.867	rs8019192	chr14:74471267	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg26031613	chr14:104095156	KLC1	0.79	5.22	0.47	1.06e-6	Body mass index;
THYM	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg03396347	chr1:1875803	NA	-0.67	-6.72	-0.57	1.34e-9	Body mass index;
THYM	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs2658782	1.000	rs2658782	chr11:93166731	T/G	cg16424440	chr11:93231842	C11orf75	-0.74	-4.69	-0.43	9.19e-6	Pulmonary function decline;
THYM	cis	rs2882667	0.690	rs1651358	chr5:138081007	A/G	cg09476006	chr5:138032270	NA	-0.55	-4.46	-0.42	2.26e-5	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg25918947	chr17:41365094	TMEM106A	-0.6	-4.81	-0.44	5.75e-6	Menopause (age at onset);
THYM	cis	rs9807989	0.507	rs6758936	chr2:102991369	A/G	cg03938978	chr2:103052716	IL18RAP	-0.75	-9.6	-0.7	1.17e-15	Asthma;
THYM	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg06387496	chr7:2775674	GNA12	-0.43	-4.49	-0.42	2.04e-5	Height;
THYM	cis	rs977987	0.806	rs4888386	chr16:75389740	A/G	cg03315344	chr16:75512273	CHST6	0.74	6.05	0.53	2.9e-8	Dupuytren's disease;
THYM	cis	rs921968	0.613	rs2303565	chr2:219545309	T/C	cg02176678	chr2:219576539	TTLL4	-0.55	-5.46	-0.49	3.79e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs861020	0.630	rs599649	chr1:210003402	T/C	cg05527609	chr1:210001259	C1orf107	0.85	6.81	0.57	8.74e-10	Orofacial clefts;
THYM	cis	rs2456568	0.802	rs1395386	chr11:93639331	A/G	cg17347335	chr11:93583973	C11orf90	0.48	4.58	0.43	1.39e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs741677	0.929	rs741678	chr17:464291	T/C	cg06217071	chr17:408420	NA	0.6	5.6	0.5	2.1e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
THYM	cis	rs752010	0.714	rs10890144	chr1:42085397	G/T	cg06885757	chr1:42089581	HIVEP3	0.52	6.35	0.55	7.25e-9	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs72781680	0.752	rs72796130	chr2:23919740	T/C	cg08917208	chr2:24149416	ATAD2B	1.19	5.46	0.49	3.73e-7	Lymphocyte counts;
THYM	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg11189052	chr15:85197271	WDR73	-0.67	-5.5	-0.49	3.13e-7	Schizophrenia;
THYM	cis	rs7666738	0.819	rs13139560	chr4:99081188	C/T	cg10515332	chr4:99064459	C4orf37	0.69	4.98	0.45	2.86e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs865483	0.646	rs1034686	chr17:35899141	T/A	cg06716730	chr17:35851459	DUSP14	0.35	6.19	0.54	1.51e-8	Monocyte count;
THYM	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg06582575	chr6:163149167	PACRG;PARK2	1.11	7.46	0.61	3.98e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs960902	0.747	rs13412538	chr2:37724623	T/C	cg25341268	chr2:37734390	NA	0.56	4.81	0.44	5.73e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg26031613	chr14:104095156	KLC1	-0.67	-4.49	-0.42	2.04e-5	Body mass index;
THYM	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg08916839	chr5:415575	AHRR	1.13	6.82	0.57	8.25e-10	Fat distribution (HIV);
THYM	cis	rs4523957	0.890	rs216222	chr17:2155701	T/A	cg16513277	chr17:2031491	SMG6	0.8	7.64	0.62	1.69e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg23281280	chr6:28129359	ZNF389	0.61	4.94	0.45	3.3e-6	Depression;
THYM	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg12935359	chr14:103987150	CKB	0.59	5.96	0.52	4.2e-8	Body mass index;
THYM	cis	rs96067	0.711	rs272827	chr1:36627191	C/T	cg24686825	chr1:36642396	MAP7D1	0.82	6.9	0.58	5.66e-10	Corneal structure;
THYM	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	9.71	0.71	6.96e-16	Platelet count;
THYM	cis	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg09085632	chr11:111637200	PPP2R1B	1.16	11.93	0.77	1.35e-20	Primary sclerosing cholangitis;
THYM	cis	rs7084402	0.967	rs10826198	chr10:60274182	C/T	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg05215272	chr17:6899095	ALOX12	0.63	9.01	0.68	2.16e-14	Tonsillectomy;
THYM	cis	rs10501293	0.746	rs7105687	chr11:43035922	C/T	cg03447554	chr11:43094025	NA	0.61	4.51	0.42	1.83e-5	Cognitive performance;
THYM	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg26116260	chr4:7069785	GRPEL1	1.01	7.85	0.63	6.1e-12	Monocyte percentage of white cells;
THYM	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Body mass index;
THYM	cis	rs4930103	0.904	rs59121562	chr11:2025034	A/T	cg06197492	chr11:2016605	H19	0.6	5.36	0.48	5.73e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs6500395	1.000	rs11644518	chr16:48616789	A/G	cg04672837	chr16:48644449	N4BP1	0.51	4.98	0.45	2.85e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg03433033	chr1:76189801	ACADM	-0.66	-6.32	-0.54	8.39e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.09e-8	Systolic blood pressure;
THYM	cis	rs3015497	0.789	rs3015496	chr14:51114051	T/C	cg04730355	chr14:51134070	SAV1	-0.53	-4.7	-0.43	8.68e-6	Mean platelet volume;
THYM	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg09877947	chr5:131593287	PDLIM4	-0.66	-5.62	-0.5	1.92e-7	Acylcarnitine levels;
THYM	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg14820908	chr5:178986412	RUFY1	0.5	4.75	0.44	7.26e-6	Lung cancer;
THYM	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.54	0.42	1.62e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1609391	0.543	rs7651085	chr3:136625339	C/G	cg15507776	chr3:136538369	TMEM22	0.64	4.9	0.45	4.02e-6	Neuroticism;
THYM	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.55	-5.23	-0.47	1e-6	Lymphocyte counts;
THYM	cis	rs1403694	0.966	rs1648715	chr3:186439618	A/G	cg12454167	chr3:186435060	KNG1	0.43	5.82	0.51	8.09e-8	Blood protein levels;
THYM	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg09703963	chr11:616879	IRF7;MUPCDH	-0.64	-5.53	-0.49	2.78e-7	Systemic lupus erythematosus;
THYM	cis	rs3924048	0.574	rs3923904	chr1:12616535	T/C	cg00291366	chr1:12616550	NA	0.38	5.86	0.52	6.62e-8	Optic cup area;
THYM	cis	rs8051149	0.652	rs9926829	chr16:87883089	A/G	cg16773814	chr16:87644704	JPH3	0.48	4.46	0.42	2.28e-5	Blood metabolite levels;
THYM	cis	rs3741151	0.773	rs7950375	chr11:73281345	G/A	cg12959048	chr11:73096162	RELT	-0.52	-4.62	-0.43	1.21e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs941408	1.000	rs1624295	chr19:2792034	G/A	cg06609049	chr19:2785107	THOP1	0.77	6.23	0.54	1.25e-8	Total cholesterol levels;
THYM	cis	rs951188	0.688	rs57128972	chr2:150407832	G/C	cg17961725	chr2:150454027	NA	-0.85	-4.59	-0.43	1.35e-5	Daytime sleep phenotypes;
THYM	cis	rs13177918	0.750	rs59354956	chr5:149822020	G/A	cg14059543	chr5:149831962	NA	-0.92	-6.96	-0.58	4.39e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg16482183	chr6:26056742	HIST1H1C	0.96	5.97	0.52	4.07e-8	Iron status biomarkers;
THYM	cis	rs61776719	0.500	rs11210866	chr1:38449565	T/C	cg17077180	chr1:38461687	NA	0.43	4.89	0.45	4.18e-6	Coronary artery disease;
THYM	cis	rs2806561	1.000	rs2806563	chr1:23506625	C/T	cg19743168	chr1:23544995	NA	-0.59	-5.78	-0.51	9.4e-8	Height;
THYM	cis	rs11030122	0.702	rs1013351	chr11:3952303	A/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.59	-0.43	1.36e-5	Mean platelet volume;Platelet distribution width;
THYM	cis	rs10911232	0.520	rs10797831	chr1:183036816	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs6906287	0.647	rs6569020	chr6:118795522	C/T	cg21191810	chr6:118973309	C6orf204	0.57	5.69	0.5	1.4e-7	Electrocardiographic conduction measures;
THYM	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg11327659	chr7:150037044	RARRES2	0.42	4.97	0.45	2.94e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg18876405	chr7:65276391	NA	0.6	5.32	0.48	6.97e-7	Aortic root size;
THYM	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg16797656	chr11:68205561	LRP5	0.42	4.46	0.42	2.27e-5	Total body bone mineral density;
THYM	cis	rs36051895	0.522	rs12341844	chr9:5177872	C/T	cg02405213	chr9:5042618	JAK2	-1.02	-11.4	-0.76	1.75e-19	Pediatric autoimmune diseases;
THYM	cis	rs4731207	0.672	rs10249081	chr7:124468519	T/G	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs9549260	0.640	rs4943796	chr13:41196016	C/T	cg21288729	chr13:41239152	FOXO1	0.69	5.26	0.47	8.95e-7	Red blood cell count;
THYM	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg03676636	chr4:99064102	C4orf37	0.39	5.68	0.5	1.47e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs500891	0.525	rs6454320	chr6:84050814	C/T	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs1021993	0.553	rs1857966	chr1:209561715	C/T	cg06155620	chr1:209527581	NA	-0.52	-4.67	-0.43	1.01e-5	Gut microbiome composition (winter);
THYM	cis	rs2637266	0.756	rs846609	chr10:78551718	A/G	cg18941641	chr10:78392320	NA	0.72	5.69	0.5	1.4e-7	Pulmonary function;
THYM	cis	rs6138458	1.000	rs227616	chr20:24908811	T/C	cg06937882	chr20:24974362	C20orf3	-0.47	-4.48	-0.42	2.08e-5	Blood protein levels;
THYM	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs4455778	0.580	rs7777309	chr7:49085524	C/T	cg26309511	chr7:48887640	NA	0.68	5.94	0.52	4.63e-8	Lung cancer in never smokers;
THYM	cis	rs611744	0.967	rs645241	chr8:109190963	C/T	cg21045802	chr8:109455806	TTC35	0.59	5.32	0.48	7e-7	Dupuytren's disease;
THYM	cis	rs10788264	0.544	rs911786	chr10:124017583	C/G	cg09507567	chr10:124027408	NA	0.5	4.8	0.44	5.86e-6	Total body bone mineral density;
THYM	cis	rs1775715	0.707	rs2799024	chr10:32166922	A/G	cg04359828	chr10:32216031	ARHGAP12	0.39	5.13	0.47	1.52e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs1982963	0.613	rs2749885	chr14:52516567	T/G	cg05884192	chr14:52515736	NID2	-0.5	-5.12	-0.46	1.63e-6	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs457717	0.798	rs6881371	chr5:75922669	A/G	cg00415993	chr5:75919188	F2RL2;IQGAP2	-0.31	-4.55	-0.42	1.58e-5	Hearing impairment;
THYM	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	8.52	0.66	2.36e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12472274	0.941	rs4663861	chr2:239105203	C/T	cg17459225	chr2:239074497	NA	0.77	5.57	0.5	2.39e-7	Phospholipid levels (plasma);
THYM	cis	rs735396	1.000	rs1169311	chr12:121440731	C/T	cg02403541	chr12:121454288	C12orf43	0.59	4.73	0.44	7.87e-6	N-glycan levels;
THYM	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg22875332	chr1:76189707	ACADM	0.88	9.09	0.68	1.44e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg07424592	chr7:64974309	NA	-0.99	-5.15	-0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg00645579	chr11:617140	IRF7;MUPCDH	-0.47	-6.04	-0.53	3.05e-8	Systemic lupus erythematosus;
THYM	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg06481639	chr22:41940642	POLR3H	-0.61	-4.68	-0.43	9.49e-6	Vitiligo;
THYM	cis	rs11608355	0.618	rs11066368	chr12:109790342	C/T	cg10504392	chr12:110044639	NA	0.52	4.76	0.44	7.06e-6	Neuroticism;
THYM	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg22166914	chr1:53195759	ZYG11B	0.82	8.61	0.66	1.55e-13	Monocyte count;
THYM	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg22907277	chr7:1156413	C7orf50	0.87	8.76	0.67	7.42e-14	Longevity;Endometriosis;
THYM	cis	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg21775007	chr8:11205619	TDH	0.64	5.24	0.47	9.49e-7	Retinal vascular caliber;
THYM	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs490234	0.841	rs829311	chr9:128394623	C/T	cg14078157	chr9:128172775	NA	-0.65	-5.36	-0.48	5.85e-7	Mean arterial pressure;
THYM	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg26408565	chr15:76604113	ETFA	0.5	4.49	0.42	2.01e-5	Blood metabolite levels;
THYM	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg13319975	chr6:146136371	FBXO30	-0.63	-5.32	-0.48	6.83e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg12000587	chr17:30186630	C17orf79	-0.4	-4.56	-0.42	1.53e-5	Hip circumference adjusted for BMI;
THYM	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg22875332	chr1:76189707	ACADM	0.89	12.06	0.78	7.38e-21	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.49	0.49	3.33e-7	Platelet count;
THYM	cis	rs17401966	0.838	rs1556917	chr1:10400990	G/T	cg19773385	chr1:10388646	KIF1B	-0.59	-4.82	-0.44	5.39e-6	Hepatocellular carcinoma;
THYM	cis	rs9880211	0.898	rs73230099	chr3:136552627	A/G	cg21827317	chr3:136751795	NA	-0.72	-4.75	-0.44	7.08e-6	Body mass index;Height;
THYM	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg18825531	chr11:62321136	NA	-0.43	-4.79	-0.44	6.26e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.69	-4.62	-0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs6138458	0.620	rs2151462	chr20:24911823	T/C	cg06937882	chr20:24974362	C20orf3	-0.47	-4.54	-0.42	1.66e-5	Blood protein levels;
THYM	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg16006841	chr5:176797999	RGS14	0.52	6.19	0.54	1.55e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs3793683	0.858	rs1571145	chr10:134583672	C/G	cg18305652	chr10:134549665	INPP5A	-0.64	-5.73	-0.51	1.17e-7	Migraine;
THYM	cis	rs786425	0.711	rs67516712	chr12:124201524	G/A	cg15249119	chr12:124971054	NCOR2	-0.49	-4.47	-0.42	2.2e-5	Pubertal anthropometrics;
THYM	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg13390004	chr1:15929781	NA	0.63	4.79	0.44	6.2e-6	Systolic blood pressure;
THYM	trans	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg22358067	chr17:16797159	NA	-1.11	-6.97	-0.58	4.21e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs2637266	0.714	rs1965156	chr10:78450559	G/A	cg18941641	chr10:78392320	NA	0.73	5.85	0.51	7.02e-8	Pulmonary function;
THYM	cis	rs12579753	0.879	rs7131927	chr12:82166313	T/C	cg21231944	chr12:82153410	PPFIA2	-0.63	-4.72	-0.44	7.99e-6	Resting heart rate;
THYM	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg24846343	chr22:24311635	DDTL	0.44	5.56	0.5	2.43e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9644630	0.932	rs4922048	chr8:19360814	A/G	cg01280390	chr8:19363452	CSGALNACT1	0.76	8.13	0.64	1.58e-12	Oropharynx cancer;
THYM	cis	rs3020333	0.875	rs3020331	chr6:152008780	C/T	cg22157087	chr6:152012887	ESR1	0.43	4.64	0.43	1.11e-5	Total body bone mineral density;
THYM	cis	rs728616	0.867	rs117139504	chr10:81734207	C/A	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg16989719	chr2:238392110	NA	-0.65	-5.9	-0.52	5.62e-8	Prostate cancer;
THYM	cis	rs10992471	0.630	rs10453241	chr9:95198887	C/A	cg14631576	chr9:95140430	CENPP	-0.82	-8.14	-0.64	1.56e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7809950	0.678	rs17153981	chr7:106922106	A/G	cg23024343	chr7:107201750	COG5	-1.0	-8.43	-0.65	3.79e-13	Coronary artery disease;
THYM	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06873352	chr17:61820015	STRADA	0.56	5.58	0.5	2.22e-7	Height;
THYM	cis	rs892961	0.932	rs7208336	chr17:75412932	T/C	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs10248839	0.518	rs1317741	chr7:29711149	T/C	cg19413766	chr7:29689036	LOC646762	-0.81	-5.56	-0.5	2.48e-7	Facial emotion recognition (angry faces);
THYM	cis	rs7814319	0.700	rs3808385	chr8:97273513	C/T	cg20787634	chr8:97240163	UQCRB	-0.74	-6.78	-0.57	1e-9	Lung function (FVC);
THYM	cis	rs112998813	0.571	rs7328349	chr13:114930401	G/A	cg02694521	chr13:114055881	NA	0.58	4.45	0.42	2.31e-5	Nodular sclerosis Hodgkin lymphoma;
THYM	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.51	0.81	7.55e-24	Height;
THYM	cis	rs9314614	0.789	rs2978887	chr8:6710879	C/T	cg27319216	chr8:6693540	XKR5	-0.6	-6.2	-0.54	1.44e-8	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg24257776	chr3:47051546	LOC100129354	0.4	4.58	0.43	1.39e-5	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs734999	0.549	rs60733400	chr1:2516781	G/A	cg04866029	chr1:2707161	NA	0.43	4.47	0.42	2.13e-5	Ulcerative colitis;
THYM	cis	rs4737010	0.536	rs6474365	chr8:41662940	G/T	cg08923054	chr8:41654455	ANK1	0.84	5.19	0.47	1.2e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
THYM	cis	rs612683	0.826	rs7556246	chr1:100828914	A/G	cg09408571	chr1:101003634	GPR88	0.42	4.48	0.42	2.1e-5	Breast cancer;
THYM	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.52	-5.16	-0.47	1.36e-6	Schizophrenia;
THYM	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg01341218	chr17:43662625	NA	1.15	9.87	0.71	3.19e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg14196790	chr5:131705035	SLC22A5	-0.54	-5.08	-0.46	1.88e-6	Blood metabolite levels;
THYM	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg24375607	chr4:120327624	NA	0.62	4.81	0.44	5.59e-6	Corneal astigmatism;
THYM	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg10518543	chr12:38710700	ALG10B	-0.59	-4.97	-0.45	3.01e-6	Morning vs. evening chronotype;
THYM	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg23750338	chr8:142222470	SLC45A4	0.52	4.87	0.45	4.48e-6	Immature fraction of reticulocytes;
THYM	cis	rs4638749	0.677	rs4676186	chr2:108842640	T/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs870825	0.616	rs56232457	chr4:185628153	T/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs4713118	0.869	rs9348775	chr6:27695329	C/T	cg08968635	chr6:28129556	ZNF389	0.64	4.72	0.44	8.14e-6	Parkinson's disease;
THYM	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs2859741	0.546	rs3845491	chr1:37497521	C/T	cg09363841	chr1:37513479	NA	-0.68	-5.36	-0.48	5.82e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs2976388	1.000	rs1045574	chr8:143763958	C/T	cg13446199	chr8:143762866	PSCA	0.51	6.42	0.55	5.46e-9	Urinary tract infection frequency;
THYM	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg06850241	chr22:41845214	NA	-0.54	-4.68	-0.43	9.37e-6	Vitiligo;
THYM	cis	rs2073300	0.609	rs6137948	chr20:23416845	G/A	cg12062639	chr20:23401060	NAPB	1.09	5.69	0.5	1.4e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7481584	0.517	rs80872	chr11:3049984	G/T	cg03159660	chr11:2078197	NA	0.62	4.6	0.43	1.3e-5	Calcium levels;
THYM	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs939658	0.626	rs11631406	chr15:79445789	C/T	cg17916960	chr15:79447300	NA	-0.65	-7.22	-0.6	1.26e-10	Refractive error;
THYM	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg03517284	chr6:25882590	NA	-0.67	-4.47	-0.42	2.14e-5	Height;
THYM	cis	rs35995292	1.000	rs35995292	chr7:38913017	T/G	cg19166347	chr7:37955598	SFRP4	0.57	4.55	0.42	1.58e-5	Subjective well-being (multi-trait analysis);
THYM	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg26418147	chr1:205743515	RAB7L1	-0.56	-4.94	-0.45	3.38e-6	Menarche (age at onset);
THYM	cis	rs2806561	0.929	rs627304	chr1:23537555	A/G	cg12483005	chr1:23474871	LUZP1	0.53	5.38	0.48	5.4e-7	Height;
THYM	cis	rs9560113	1.000	rs4773386	chr13:112180896	C/G	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06850241	chr22:41845214	NA	-0.58	-5.18	-0.47	1.22e-6	Vitiligo;
THYM	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs9880211	0.613	rs13079205	chr3:135800693	A/G	cg21827317	chr3:136751795	NA	-0.71	-5.08	-0.46	1.86e-6	Body mass index;Height;
THYM	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-4.49	-0.42	2.04e-5	Hemoglobin concentration;
THYM	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg23758822	chr17:41437982	NA	1.22	11.98	0.78	1.07e-20	Menopause (age at onset);
THYM	cis	rs870825	0.860	rs72703518	chr4:185602109	T/C	cg04058563	chr4:185651563	MLF1IP	1.05	7.96	0.63	3.6e-12	Blood protein levels;
THYM	cis	rs3741151	0.773	rs57354084	chr11:73139376	A/T	cg12959048	chr11:73096162	RELT	-0.53	-5.08	-0.46	1.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg01819863	chr10:32635814	EPC1	1.04	6.64	0.56	1.9e-9	Sexual dysfunction (female);
THYM	cis	rs3741151	1.000	rs76764824	chr11:73073580	C/T	cg17517138	chr11:73019481	ARHGEF17	1.0	5.89	0.52	5.75e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2637266	0.935	rs7909808	chr10:78392318	A/G	cg18941641	chr10:78392320	NA	0.81	6.95	0.58	4.51e-10	Pulmonary function;
THYM	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg03264133	chr6:25882463	NA	-0.64	-4.87	-0.45	4.53e-6	Height;
THYM	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22133161	chr19:49891603	CCDC155	0.85	5.95	0.52	4.37e-8	Multiple sclerosis;
THYM	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg08999081	chr20:33150536	PIGU	0.77	6.95	0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg05335186	chr13:53173507	NA	-0.37	-4.79	-0.44	6.11e-6	Lewy body disease;
THYM	cis	rs7980687	0.506	rs1611973	chr12:123622731	C/G	cg00376283	chr12:123451042	ABCB9	0.88	7.46	0.61	4.16e-11	Height;Educational attainment;Head circumference (infant);
THYM	cis	rs216026	0.689	rs216051	chr12:2766899	C/A	cg19945202	chr12:2788847	CACNA1C	0.69	4.6	0.43	1.33e-5	Fractional exhaled nitric oxide (childhood);
THYM	trans	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	Neuroticism;
THYM	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg24209194	chr3:40518798	ZNF619	0.63	5.06	0.46	2.04e-6	Renal cell carcinoma;
THYM	cis	rs2505998	0.833	rs1864405	chr10:43604148	A/C	cg06632098	chr10:43605906	RET	-1.1	-10.64	-0.74	7.21e-18	Hirschsprung disease;
THYM	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg06808227	chr14:105710500	BRF1	-1.05	-9.15	-0.68	1.07e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9549260	0.651	rs9549251	chr13:41228650	A/G	cg21288729	chr13:41239152	FOXO1	0.73	5.82	0.51	7.84e-8	Red blood cell count;
THYM	cis	rs4866334	1.000	rs77699507	chr5:18481057	A/G	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs6430585	0.702	rs2304601	chr2:136528034	C/A	cg04750100	chr2:136595281	LCT	0.53	4.86	0.45	4.59e-6	Corneal structure;
THYM	cis	rs7027203	0.828	rs4344139	chr9:96600298	T/C	cg14598338	chr9:96623480	NA	-0.49	-5.22	-0.47	1.07e-6	DNA methylation (variation);
THYM	cis	rs8078723	0.714	rs3785550	chr17:38149727	C/T	cg17467752	chr17:38218738	THRA	-0.8	-6.53	-0.56	3.28e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg06521331	chr12:34319734	NA	-0.74	-5.8	-0.51	8.51e-8	Morning vs. evening chronotype;
THYM	cis	rs7592578	0.508	rs62180987	chr2:191267173	A/G	cg11845111	chr2:191398756	TMEM194B	-0.85	-6.37	-0.55	6.74e-9	Diastolic blood pressure;
THYM	cis	rs7584330	0.554	rs6705908	chr2:238433965	A/G	cg08992911	chr2:238395768	MLPH	0.57	4.58	0.43	1.39e-5	Prostate cancer;
THYM	cis	rs1729407	0.814	rs2542051	chr11:116697738	A/C	cg08985259	chr11:116699649	APOC3	0.58	4.8	0.44	5.8e-6	Apolipoprotein A-IV levels;
THYM	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.57	5.32	0.48	6.76e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg05754148	chr16:3507555	NAT15	0.66	6.73	0.57	1.29e-9	Tuberculosis;
THYM	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg13246856	chr1:44399776	ARTN	0.48	5.07	0.46	1.93e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7818345	0.569	rs4631483	chr8:19357923	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.48	4.67	0.43	9.8e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg09307838	chr4:120376055	NA	0.65	4.77	0.44	6.72e-6	Corneal astigmatism;
THYM	cis	rs1163251	0.837	rs2764886	chr1:120241771	C/T	cg19096424	chr1:120255104	PHGDH	0.67	4.94	0.45	3.29e-6	Blood metabolite levels;
THYM	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg24450063	chr1:156163899	SLC25A44	1.21	15.52	0.85	8.47e-28	Testicular germ cell tumor;
THYM	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.35	0.48	6.04e-7	Tonsillectomy;
THYM	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	7.32	0.6	7.96e-11	Platelet count;
THYM	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg10950924	chr17:47092072	IGF2BP1	0.62	7.23	0.6	1.2e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg17063962	chr7:91808500	NA	-1.1	-12.47	-0.79	1.01e-21	Breast cancer;
THYM	cis	rs4731207	0.698	rs10271687	chr7:124493731	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs34526934	0.608	rs2301301	chr2:177032267	T/C	cg26754761	chr2:177040938	NA	-0.74	-6.37	-0.55	6.7e-9	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg09184832	chr6:79620586	NA	-0.58	-4.53	-0.42	1.73e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3768617	0.510	rs10797835	chr1:183072908	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.76	0.44	6.83e-6	Fuchs's corneal dystrophy;
THYM	cis	rs8067545	0.641	rs203462	chr17:19812541	T/C	cg20830565	chr17:20408647	MGC102966	-0.53	-4.82	-0.44	5.37e-6	Schizophrenia;
THYM	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg22907277	chr7:1156413	C7orf50	0.68	4.49	0.42	2.01e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01341218	chr17:43662625	NA	-1.07	-9.27	-0.69	5.9e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-5.16	-0.47	1.35e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11671005	0.504	rs3794964	chr19:59070916	T/C	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.53	-4.66	-0.43	1.01e-5	Mean platelet volume;
THYM	cis	rs3020333	1.000	rs3020333	chr6:152010254	A/G	cg22157087	chr6:152012887	ESR1	0.57	6.74	0.57	1.23e-9	Total body bone mineral density;
THYM	cis	rs2658782	0.704	rs2605614	chr11:93232745	A/G	cg15737290	chr11:93063684	CCDC67	0.98	7.13	0.59	1.93e-10	Pulmonary function decline;
THYM	cis	rs9674544	0.556	rs1390154	chr17:47071483	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.49	-6.14	-0.53	1.92e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs4849845	0.777	rs3931841	chr2:121041314	A/G	cg03575764	chr2:121493832	NA	-0.69	-5.08	-0.46	1.89e-6	Mean platelet volume;
THYM	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg20891283	chr12:69753455	YEATS4	1.06	10.24	0.72	5.15e-17	Blood protein levels;
THYM	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg17775962	chr7:1200435	ZFAND2A	0.42	5.16	0.47	1.32e-6	Longevity;Endometriosis;
THYM	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.02	-0.58	3.26e-10	Mood instability;
THYM	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.57	4.85	0.45	4.8e-6	Blood metabolite levels;
THYM	cis	rs28595532	0.920	rs55758547	chr4:119769475	T/C	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs748404	0.586	rs2584700	chr15:43685332	A/G	cg12861797	chr15:43585817	TGM7	0.46	4.84	0.45	4.93e-6	Lung cancer;
THYM	cis	rs654950	0.841	rs2810549	chr1:41991761	C/T	cg06885757	chr1:42089581	HIVEP3	-0.47	-5.62	-0.5	1.92e-7	Airway imaging phenotypes;
THYM	cis	rs2694917	0.680	rs1043011	chr12:56865040	G/T	cg03677924	chr12:56849618	MIP	-0.57	-4.47	-0.42	2.17e-5	Blood metabolite ratios;
THYM	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg14829155	chr15:31115871	NA	-0.76	-6.47	-0.55	4.17e-9	Huntington's disease progression;
THYM	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg23989207	chr17:80870107	TBCD	-0.63	-5.35	-0.48	6.17e-7	Glycated hemoglobin levels;
THYM	cis	rs4077515	0.577	rs10870165	chr9:139316601	C/T	cg14115884	chr9:139300582	SDCCAG3	0.69	5.79	0.51	9.01e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg11663144	chr21:46675770	NA	-0.7	-9.58	-0.7	1.3e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs754466	0.580	rs2579178	chr10:79529215	A/G	cg17075019	chr10:79541650	NA	0.68	5.74	0.51	1.14e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg09263875	chr16:632152	PIGQ	0.71	6.15	0.53	1.85e-8	Height;
THYM	cis	rs887829	0.569	rs2008595	chr2:234637192	C/T	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.52	-0.42	1.78e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs6906287	0.647	rs4027880	chr6:118734134	A/T	cg21191810	chr6:118973309	C6orf204	0.55	5.54	0.49	2.68e-7	Electrocardiographic conduction measures;
THYM	cis	rs17152411	1.000	rs12573033	chr10:126607803	T/G	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg00990874	chr7:1149470	C7orf50	-0.69	-5.17	-0.47	1.29e-6	Bronchopulmonary dysplasia;
THYM	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg04111992	chr7:158790115	NA	0.59	4.94	0.45	3.35e-6	Facial morphology (factor 20);
THYM	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg24675056	chr1:15929824	NA	0.73	5.86	0.52	6.71e-8	Systolic blood pressure;
THYM	cis	rs56104184	0.830	rs73061617	chr19:49350984	G/A	cg16594139	chr19:49340574	PLEKHA4;HSD17B14	0.97	4.65	0.43	1.07e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs924712	0.521	rs4712073	chr6:54673227	A/G	cg19716238	chr6:54711378	FAM83B	-0.47	-4.47	-0.42	2.14e-5	Breast cancer;
THYM	cis	rs1691799	0.867	rs1168347	chr12:66757303	T/C	cg16791601	chr12:66731901	HELB	-0.74	-6.85	-0.57	7.3e-10	White blood cell count (basophil);
THYM	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1691799	0.899	rs903590	chr12:66745777	C/G	cg16791601	chr12:66731901	HELB	-0.76	-7.14	-0.59	1.86e-10	White blood cell count (basophil);
THYM	cis	rs635808	0.500	rs1964808	chr6:167172602	C/T	cg17732216	chr6:167178280	RPS6KA2	0.59	4.76	0.44	7.04e-6	Dental caries;
THYM	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg16797656	chr11:68205561	LRP5	0.45	4.77	0.44	6.58e-6	Total body bone mineral density;
THYM	cis	rs7078219	1.000	rs7081330	chr10:101274465	A/G	cg07044859	chr10:101282883	NA	-0.49	-5.27	-0.48	8.57e-7	Dental caries;
THYM	cis	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg02751453	chr18:77725136	HSBP1L1	0.55	4.52	0.42	1.77e-5	Opioid sensitivity;
THYM	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg18105134	chr13:113819100	PROZ	-1.02	-9.28	-0.69	5.58e-15	Platelet distribution width;
THYM	cis	rs7084402	0.935	rs10763559	chr10:60347410	C/T	cg07615347	chr10:60278583	BICC1	0.54	5.06	0.46	2.04e-6	Refractive error;
THYM	cis	rs6957923	0.655	rs13241000	chr7:23588135	A/G	cg20265043	chr7:23510089	IGF2BP3	0.51	5.58	0.5	2.28e-7	Height;
THYM	cis	rs4886920	0.862	rs35020526	chr15:78137862	G/T	cg10461261	chr15:78109450	NA	-0.47	-4.5	-0.42	1.96e-5	Neuroticism;
THYM	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg08807101	chr21:30365312	RNF160	0.91	7.57	0.61	2.36e-11	Dental caries;
THYM	cis	rs72781680	1.000	rs61739076	chr2:24149439	G/A	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.57	-6.13	-0.53	1.97e-8	Crohn's disease;
THYM	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg04234412	chr22:24373322	LOC391322	-0.77	-5.81	-0.51	8.24e-8	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7772486	0.764	rs2247211	chr6:146216379	G/A	cg13319975	chr6:146136371	FBXO30	-0.76	-6.48	-0.55	4.09e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg13736514	chr6:26305472	NA	-0.65	-6.63	-0.56	2.01e-9	Educational attainment;
THYM	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg05335186	chr13:53173507	NA	-0.5	-7.02	-0.58	3.22e-10	Lewy body disease;
THYM	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs804292	0.800	rs8191589	chr8:11634194	T/A	cg26752888	chr8:11627280	NEIL2	1.15	8.05	0.64	2.38e-12	Alcohol dependence;Nicotine use;
THYM	cis	rs17666538	0.792	rs73178875	chr8:674289	A/G	cg23958373	chr8:599963	NA	-0.96	-4.54	-0.42	1.66e-5	IgG glycosylation;
THYM	cis	rs6570726	0.764	rs9403733	chr6:145912311	A/C	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs977987	0.624	rs59867374	chr16:75432682	G/A	cg03315344	chr16:75512273	CHST6	0.73	6.14	0.53	1.88e-8	Dupuytren's disease;
THYM	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.94	7.1	0.59	2.21e-10	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg10047753	chr17:41438598	NA	1.15	10.54	0.73	1.15e-17	Menopause (age at onset);
THYM	cis	rs6722750	0.783	rs4671550	chr2:64389314	T/A	cg22352474	chr2:64371530	PELI1	0.74	6.51	0.56	3.49e-9	Neuroticism;
THYM	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg13319975	chr6:146136371	FBXO30	0.67	5.5	0.49	3.15e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7814319	0.674	rs2292835	chr8:97243720	G/A	cg20787634	chr8:97240163	UQCRB	-0.73	-7.16	-0.59	1.72e-10	Lung function (FVC);
THYM	cis	rs7246657	0.653	rs10406612	chr19:37716611	C/T	cg23950597	chr19:37808831	NA	-0.83	-5.0	-0.46	2.57e-6	Coronary artery calcification;
THYM	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11644478	chr21:40555479	PSMG1	0.98	7.72	0.62	1.15e-11	Cognitive function;
THYM	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg07606381	chr6:8435919	SLC35B3	-0.61	-4.45	-0.42	2.31e-5	Motion sickness;
THYM	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg25817165	chr18:72167213	CNDP2	-0.97	-10.17	-0.72	7.3e-17	Refractive error;
THYM	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs904251	0.864	rs2797801	chr6:37487161	A/G	cg01843034	chr6:37503916	NA	-0.69	-5.25	-0.47	9.14e-7	Cognitive performance;
THYM	cis	rs6689125	1	rs6689125	chr1:171736037	G/A	cg20598894	chr1:171756153	METTL13	-0.66	-4.58	-0.43	1.39e-5	Platelet distribution width;
THYM	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.94	0.45	3.37e-6	Prudent dietary pattern;
THYM	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg11941060	chr3:133502564	NA	0.73	6.17	0.54	1.63e-8	Iron status biomarkers;
THYM	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.56	-4.6	-0.43	1.32e-5	Hip circumference adjusted for BMI;
THYM	cis	rs12540874	0.698	rs3823674	chr7:50571996	C/T	cg00647317	chr7:50633725	DDC	0.32	4.65	0.43	1.06e-5	Systemic sclerosis;
THYM	cis	rs4642101	1.000	rs7650482	chr3:12841804	A/G	cg05775895	chr3:12838266	CAND2	0.79	6.18	0.54	1.6e-8	QRS complex (12-leadsum);
THYM	cis	rs4499344	0.664	rs7258278	chr19:33099523	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.88	7.48	0.61	3.65e-11	Mean platelet volume;
THYM	cis	rs877282	0.898	rs11253352	chr10:766598	C/A	cg10556349	chr10:835070	NA	-0.82	-5.62	-0.5	1.89e-7	Uric acid levels;
THYM	cis	rs2456568	0.802	rs1108910	chr11:93629677	C/T	cg17347335	chr11:93583973	C11orf90	0.48	4.58	0.43	1.39e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7127900	0.583	rs67379609	chr11:2233630	C/T	cg25635251	chr11:2234043	NA	0.67	5.0	0.46	2.6e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg10802521	chr3:52805072	NEK4	0.73	6.43	0.55	5.15e-9	Bipolar disorder;
THYM	cis	rs28595532	0.920	rs114210107	chr4:119734491	G/A	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg13319975	chr6:146136371	FBXO30	-0.66	-5.63	-0.5	1.85e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg24675658	chr1:53192096	ZYG11B	-0.66	-5.23	-0.47	1.01e-6	Monocyte count;
THYM	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08704250	chr15:31115839	NA	-0.51	-6.06	-0.53	2.68e-8	Huntington's disease progression;
THYM	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg26721908	chr21:47610096	LSS	-0.75	-5.43	-0.49	4.35e-7	Testicular germ cell tumor;
THYM	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg21798802	chr22:38057573	PDXP	0.47	5.36	0.48	5.79e-7	Fat distribution (HIV);
THYM	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg09359103	chr1:154839909	KCNN3	-0.79	-8.95	-0.68	2.92e-14	Prostate cancer;
THYM	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg07212818	chr11:638076	DRD4	-0.77	-5.92	-0.52	5.09e-8	Systemic lupus erythematosus;
THYM	cis	rs42648	0.748	rs10225744	chr7:89946003	T/C	cg03688058	chr7:89840708	STEAP2	-0.55	-4.49	-0.42	2e-5	Homocysteine levels;
THYM	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg23711669	chr6:146136114	FBXO30	0.88	8.72	0.67	9.02e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg05043794	chr9:111880884	C9orf5	-0.43	-6.21	-0.54	1.39e-8	Menarche (age at onset);
THYM	cis	rs11039798	0.588	rs7479642	chr11:48553808	G/T	cg24672777	chr11:48374446	OR4C45	-0.98	-6.31	-0.54	8.72e-9	Axial length;
THYM	cis	rs17102423	0.731	rs10143198	chr14:65555471	C/T	cg11161011	chr14:65562177	MAX	-0.63	-5.46	-0.49	3.78e-7	Obesity-related traits;
THYM	cis	rs6815814	0.851	rs17582921	chr4:38892649	T/C	cg06935464	chr4:38784597	TLR10	0.7	4.84	0.44	5.09e-6	Breast cancer;
THYM	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg26384229	chr12:38710491	ALG10B	0.99	7.7	0.62	1.31e-11	Bladder cancer;
THYM	cis	rs7429990	0.864	rs6777081	chr3:48155569	T/C	cg02219026	chr3:48282209	ZNF589	0.62	4.64	0.43	1.12e-5	Educational attainment (years of education);
THYM	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21582582	chr3:182698605	DCUN1D1	0.82	7.16	0.59	1.68e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg24692254	chr21:30365293	RNF160	-0.65	-4.84	-0.45	4.94e-6	Cognitive test performance;
THYM	cis	rs13082711	0.516	rs13084067	chr3:27358935	A/T	cg02860705	chr3:27208620	NA	0.76	5.84	0.51	7.17e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs4866334	1.000	rs79543647	chr5:18488484	G/A	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg18252515	chr7:66147081	NA	0.71	5.51	0.49	3.07e-7	Aortic root size;
THYM	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7089973	0.966	rs12775180	chr10:116639754	T/C	cg23260525	chr10:116636907	FAM160B1	0.58	5.21	0.47	1.1e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs2404602	0.735	rs11857327	chr15:76764263	G/C	cg23625390	chr15:77176239	SCAPER	-0.71	-4.87	-0.45	4.37e-6	Blood metabolite levels;
THYM	cis	rs11096990	0.634	rs746678	chr4:39280655	A/G	cg24403649	chr4:39172243	NA	-0.67	-5.84	-0.51	7.33e-8	Cognitive function;
THYM	cis	rs2281845	0.859	rs4915216	chr1:201077469	T/G	cg17810781	chr1:201082982	CACNA1S	0.62	6.48	0.55	4.03e-9	Permanent tooth development;
THYM	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg27534772	chr1:16042836	PLEKHM2	0.56	6.24	0.54	1.23e-8	Systolic blood pressure;
THYM	cis	rs10193935	0.901	rs13429697	chr2:42529818	C/T	cg27598129	chr2:42591480	NA	-0.75	-4.61	-0.43	1.25e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg04218760	chr10:45406644	TMEM72	-0.69	-6.47	-0.55	4.15e-9	Mean corpuscular volume;
THYM	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-5.89	-0.52	5.92e-8	Morning vs. evening chronotype;
THYM	cis	rs7107174	1.000	rs2512544	chr11:77986371	A/T	cg19901956	chr11:77921274	USP35	-0.68	-5.25	-0.47	9.31e-7	Testicular germ cell tumor;
THYM	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.46e-16	Prudent dietary pattern;
THYM	cis	rs9796	0.870	rs4244584	chr15:41259523	A/G	cg18705301	chr15:41695430	NDUFAF1	0.59	5.0	0.46	2.59e-6	Menopause (age at onset);
THYM	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg13854012	chr2:162103682	NA	-0.65	-5.39	-0.48	5.19e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs7084402	1.000	rs4113952	chr10:60268599	A/G	cg09696939	chr10:60272079	BICC1	-0.44	-5.08	-0.46	1.91e-6	Refractive error;
THYM	cis	rs12817549	0.754	rs4144501	chr12:94156587	G/A	cg19571390	chr12:94157676	CRADD	0.54	4.55	0.42	1.57e-5	Hip circumference adjusted for BMI;
THYM	cis	rs72627123	0.656	rs117145347	chr14:74564164	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.29	7.08	0.59	2.46e-10	Morning vs. evening chronotype;
THYM	cis	rs7107174	0.901	rs2450137	chr11:77925233	C/G	cg02023728	chr11:77925099	USP35	0.69	6.55	0.56	2.9e-9	Testicular germ cell tumor;
THYM	cis	rs870825	0.616	rs1401361	chr4:185643742	G/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs6570726	1.000	rs436066	chr6:145847127	C/T	cg23711669	chr6:146136114	FBXO30	0.9	8.61	0.66	1.56e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8032315	0.965	rs4932373	chr15:91429287	A/C	cg04510874	chr15:91427884	FES	0.62	4.64	0.43	1.12e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10779751	1.000	rs7524202	chr1:11297762	T/C	cg08854313	chr1:11322531	MTOR	0.94	8.23	0.65	9.67e-13	Body mass index;
THYM	cis	rs6754311	0.731	rs12615624	chr2:136721603	A/G	cg07169764	chr2:136633963	MCM6	0.68	5.97	0.52	4.08e-8	Mosquito bite size;
THYM	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg19508488	chr2:152266495	RIF1	-0.76	-6.04	-0.53	2.99e-8	Lung cancer;
THYM	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg22117172	chr7:91764530	CYP51A1	0.39	4.52	0.42	1.8e-5	Breast cancer;
THYM	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.29	4.52	0.42	1.78e-5	Obesity-related traits;
THYM	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg05872129	chr22:39784769	NA	-0.85	-7.15	-0.59	1.81e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11644478	chr21:40555479	PSMG1	-0.76	-6.49	-0.55	3.85e-9	Cognitive function;
THYM	cis	rs6430585	0.528	rs16832205	chr2:136684632	G/A	cg23851026	chr2:136556271	LCT	0.77	6.81	0.57	8.95e-10	Corneal structure;
THYM	cis	rs17407555	0.657	rs4698001	chr4:10279413	A/T	cg00071950	chr4:10020882	SLC2A9	0.59	5.5	0.49	3.2e-7	Schizophrenia (age at onset);
THYM	cis	rs10540	0.730	rs34690033	chr11:492677	G/C	cg21784768	chr11:537496	LRRC56	-1.17	-5.82	-0.51	7.86e-8	Body mass index;
THYM	cis	rs2063714	0.532	rs2063713	chr6:157196299	G/T	cg23222435	chr6:157204239	ARID1B	-0.79	-6.74	-0.57	1.24e-9	Sitting height ratio;
THYM	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg23583168	chr7:148888333	NA	-1.02	-13.19	-0.8	3.43e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs17401966	1.000	rs4845934	chr1:10468946	G/A	cg19773385	chr1:10388646	KIF1B	-0.64	-4.89	-0.45	4.14e-6	Hepatocellular carcinoma;
THYM	cis	rs72843506	0.656	rs73984559	chr17:19946516	C/A	cg12065943	chr17:19881925	AKAP10	-0.76	-4.58	-0.43	1.41e-5	Schizophrenia;
THYM	cis	rs11031096	0.621	rs11031159	chr11:4179695	T/G	cg18678763	chr11:4115507	RRM1	-0.39	-4.61	-0.43	1.27e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs6754311	0.593	rs55825471	chr2:136526981	T/A	cg07169764	chr2:136633963	MCM6	-0.67	-5.91	-0.52	5.34e-8	Mosquito bite size;
THYM	cis	rs4481887	0.741	rs6674078	chr1:248543026	G/A	cg17299007	chr1:248814626	OR2T27	0.43	4.58	0.43	1.41e-5	Common traits (Other);
THYM	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.79	6.4	0.55	5.83e-9	Blood protein levels;
THYM	cis	rs9905704	0.624	rs4932691	chr17:57094617	T/C	cg12560992	chr17:57184187	TRIM37	-0.68	-5.31	-0.48	7.04e-7	Testicular germ cell tumor;
THYM	cis	rs11096990	0.634	rs7564	chr4:39287322	C/T	cg24403649	chr4:39172243	NA	-0.66	-5.7	-0.51	1.32e-7	Cognitive function;
THYM	cis	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg10856724	chr12:34555212	NA	-0.88	-8.25	-0.65	8.84e-13	Morning vs. evening chronotype;
THYM	cis	rs2493137	0.507	rs1078499	chr1:230849096	A/G	cg24474852	chr1:230850050	AGT	-0.51	-5.04	-0.46	2.23e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs665401	0.965	rs1741663	chr6:117260779	G/A	cg20376953	chr6:117187980	NA	-0.55	-4.49	-0.42	1.99e-5	Neutrophil percentage of granulocytes;
THYM	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-7.24	-0.6	1.15e-10	Schizophrenia;
THYM	cis	rs9633835	0.707	rs4757142	chr11:13325695	C/T	cg04367197	chr11:13300320	ARNTL	0.44	4.45	0.42	2.31e-5	Body mass index;
THYM	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs2069036	0.951	rs4748246	chr10:16118857	A/G	cg26633223	chr10:15133461	NA	-0.69	-4.9	-0.45	4e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs2730245	0.527	rs62476464	chr7:158698063	C/T	cg11984989	chr7:158649758	WDR60	1.01	8.5	0.66	2.65e-13	Height;
THYM	cis	rs3796352	1.000	rs7625448	chr3:53120766	C/A	cg07884673	chr3:53033167	SFMBT1	0.93	4.63	0.43	1.18e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs919433	0.679	rs10931787	chr2:198520615	A/G	cg00792783	chr2:198669748	PLCL1	0.82	5.44	0.49	4.16e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	5.42	0.49	4.47e-7	Schizophrenia;
THYM	cis	rs28374715	0.662	rs113913466	chr15:41483100	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.02	-8.4	-0.65	4.27e-13	Ulcerative colitis;
THYM	cis	rs7172809	0.573	rs74027549	chr15:77524761	A/G	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg05768032	chr16:30646687	NA	0.55	5.56	0.5	2.46e-7	Multiple myeloma;
THYM	cis	rs72781680	1.000	rs72781658	chr2:24220141	A/G	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg04518342	chr5:131593106	PDLIM4	0.55	6.55	0.56	2.9e-9	Acylcarnitine levels;
THYM	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg09354556	chr3:47051341	NA	0.46	4.71	0.44	8.28e-6	Colorectal cancer;
THYM	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg26818010	chr10:134567672	INPP5A	-0.63	-5.42	-0.49	4.42e-7	Gait speed in old age;
THYM	cis	rs2302729	0.860	rs6489375	chr12:2777768	A/G	cg19945202	chr12:2788847	CACNA1C	-0.89	-6.02	-0.53	3.26e-8	Sleep quality;
THYM	cis	rs9302065	0.681	rs59108692	chr13:95962424	C/A	cg26751094	chr13:95954534	ABCC4	-0.45	-4.99	-0.46	2.71e-6	Blood metabolite levels;
THYM	cis	rs11166927	0.548	rs4736099	chr8:140828745	T/C	cg16909799	chr8:140841666	TRAPPC9	-0.83	-7.82	-0.63	7.28e-12	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.92	0.45	3.58e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2070677	1.000	rs1410897	chr10:135349537	G/A	cg20169779	chr10:135381914	SYCE1	0.81	5.79	0.51	8.91e-8	Gout;
THYM	cis	rs2034088	0.833	rs4968120	chr17:431364	T/G	cg13332499	chr17:408570	NA	0.57	4.59	0.43	1.36e-5	Hip circumference adjusted for BMI;
THYM	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg03351412	chr1:154909251	PMVK	0.7	5.38	0.48	5.4e-7	Prostate cancer;
THYM	cis	rs665401	0.899	rs434499	chr6:117213614	T/C	cg20376953	chr6:117187980	NA	0.61	4.83	0.44	5.25e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg25358565	chr5:93447407	FAM172A	1.37	10.93	0.75	1.76e-18	Diabetic retinopathy;
THYM	cis	rs2404602	0.647	rs10851889	chr15:77023336	C/T	cg23625390	chr15:77176239	SCAPER	-0.86	-6.08	-0.53	2.47e-8	Blood metabolite levels;
THYM	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.59	-0.5	2.2e-7	Menopause (age at onset);
THYM	cis	rs75059851	0.756	rs11223661	chr11:133851412	G/T	cg14047540	chr11:133829660	NA	-1.09	-7.23	-0.6	1.22e-10	Schizophrenia;
THYM	cis	rs12802200	0.535	rs12290412	chr11:569230	T/C	cg03909863	chr11:638404	DRD4	-0.67	-4.79	-0.44	6.2e-6	Systemic lupus erythematosus;
THYM	cis	rs34638657	0.540	rs2967384	chr16:82219223	A/T	cg07307142	chr16:82071433	HSD17B2	-0.59	-4.68	-0.43	9.51e-6	Lung adenocarcinoma;
THYM	cis	rs17255340	0.601	rs1144182	chr6:84023090	A/T	cg08257003	chr6:84140564	ME1	0.57	4.6	0.43	1.3e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg15445000	chr17:37608096	MED1	0.44	5.1	0.46	1.73e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11644478	chr21:40555479	PSMG1	-0.54	-4.53	-0.42	1.72e-5	Menarche (age at onset);
THYM	cis	rs870825	0.929	rs871254	chr4:185589226	G/C	cg04058563	chr4:185651563	MLF1IP	0.99	6.83	0.57	8.04e-10	Blood protein levels;
THYM	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg27129171	chr3:47204927	SETD2	-0.69	-6.65	-0.56	1.82e-9	Colorectal cancer;
THYM	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.0	0.63	3.07e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs728616	0.867	rs3088308	chr10:81697868	A/T	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs7631605	0.905	rs58693636	chr3:37102623	C/T	cg21328643	chr3:37258149	NA	-0.47	-4.45	-0.42	2.32e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs4986811	0.852	rs72893517	chr11:32451921	G/C	cg13301003	chr11:32449254	WT1	0.64	4.91	0.45	3.72e-6	Rubella-specific interleukin-6 secretion;
THYM	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg14004847	chr7:1930337	MAD1L1	-0.71	-5.45	-0.49	3.91e-7	Schizophrenia;
THYM	cis	rs877282	0.583	rs10904562	chr10:819058	T/C	cg10556349	chr10:835070	NA	-0.84	-5.48	-0.49	3.43e-7	Uric acid levels;
THYM	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg24308560	chr3:49941425	MST1R	-0.76	-6.34	-0.55	7.57e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg21773646	chr17:80085082	CCDC57	0.32	4.5	0.42	1.93e-5	Life satisfaction;
THYM	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg11266682	chr4:10021025	SLC2A9	0.74	12.07	0.78	6.92e-21	Bone mineral density;
THYM	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg03806693	chr22:41940476	POLR3H	-1.19	-10.87	-0.74	2.29e-18	Vitiligo;
THYM	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg17173187	chr15:85201210	NMB	0.56	5.55	0.49	2.61e-7	Schizophrenia;
THYM	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg03676636	chr4:99064102	C4orf37	0.5	7.65	0.62	1.6e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10463554	0.927	rs34800	chr5:102426503	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg06636001	chr8:8085503	FLJ10661	0.72	6.31	0.54	8.88e-9	Mood instability;
THYM	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg22535103	chr8:58192502	C8orf71	-0.95	-6.0	-0.52	3.51e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2239785	0.959	rs129423	chr22:36657329	A/G	cg15716373	chr22:36655542	APOL1	-0.42	-5.31	-0.48	7.13e-7	Glomerulosclerosis;
THYM	cis	rs7836436	0.686	rs61519992	chr8:120954517	A/C	cg05020510	chr8:120428057	NOV	1.04	5.18	0.47	1.24e-6	HIV-1 viral setpoint;
THYM	cis	rs9790314	0.934	rs462413	chr3:161101587	T/C	cg04691961	chr3:161091175	C3orf57	-0.59	-5.19	-0.47	1.19e-6	Morning vs. evening chronotype;
THYM	cis	rs288326	0.561	rs17703779	chr2:183895919	C/T	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg10523679	chr1:76189770	ACADM	0.9	7.35	0.6	7.04e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg11905131	chr22:24372483	LOC391322	-0.93	-10.22	-0.72	5.59e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4523957	0.928	rs8077545	chr17:2184555	A/G	cg16513277	chr17:2031491	SMG6	-0.79	-7.41	-0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg17143192	chr8:8559678	CLDN23	0.62	4.73	0.44	7.76e-6	Neuroticism;
THYM	cis	rs981844	0.712	rs4469056	chr4:154745796	A/T	cg09973105	chr4:154681532	RNF175	-0.52	-4.98	-0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs950880	0.710	rs17027037	chr2:102994884	A/G	cg03938978	chr2:103052716	IL18RAP	-0.5	-4.46	-0.42	2.24e-5	Serum protein levels (sST2);
THYM	cis	rs10463554	0.963	rs28301	chr5:102441482	A/G	cg23492399	chr5:102201601	PAM	-0.69	-5.04	-0.46	2.26e-6	Parkinson's disease;
THYM	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg13010199	chr12:38710504	ALG10B	0.65	4.55	0.42	1.58e-5	Bladder cancer;
THYM	cis	rs2456568	0.543	rs4144616	chr11:93621900	A/G	cg17595323	chr11:93583763	C11orf90	-0.51	-5.13	-0.47	1.53e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7772486	0.790	rs6926657	chr6:146255794	G/A	cg13319975	chr6:146136371	FBXO30	0.73	6.11	0.53	2.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg09436375	chr6:42928200	GNMT	-0.44	-5.76	-0.51	1.02e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg00484396	chr16:3507460	NAT15	0.75	10.45	0.73	1.8e-17	Tuberculosis;
THYM	cis	rs4589258	0.504	rs7113349	chr11:90386899	A/G	cg26138821	chr11:89956704	CHORDC1	0.62	4.49	0.42	1.98e-5	Intelligence (multi-trait analysis);
THYM	cis	rs35164067	1.000	rs11879191	chr19:10512911	G/A	cg01466491	chr19:10523363	NA	-0.65	-5.03	-0.46	2.28e-6	Inflammatory bowel disease;
THYM	cis	rs2282300	0.653	rs67745574	chr11:30234839	C/T	cg06241208	chr11:30344200	C11orf46	-0.74	-5.38	-0.48	5.44e-7	Morning vs. evening chronotype;
THYM	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.0	0.46	2.58e-6	Bipolar disorder;
THYM	cis	rs6838801	0.521	rs17322529	chr4:77560811	A/G	cg01477861	chr4:77609841	SHROOM3	-0.47	-4.94	-0.45	3.35e-6	Cleft lip with or without cleft palate;
THYM	cis	rs7107174	0.892	rs2512519	chr11:77953015	C/T	cg19901956	chr11:77921274	USP35	-0.81	-6.12	-0.53	2.12e-8	Testicular germ cell tumor;
THYM	cis	rs1270639	0.722	rs6950817	chr7:157439636	A/G	cg13357408	chr7:157437802	PTPRN2	0.45	4.51	0.42	1.82e-5	Colorectal cancer;
THYM	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2073300	1.000	rs6048834	chr20:23462213	C/T	cg12062639	chr20:23401060	NAPB	0.96	4.84	0.45	4.95e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg26031613	chr14:104095156	KLC1	0.97	7.49	0.61	3.49e-11	Body mass index;
THYM	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.94	-0.52	4.64e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs11225247	0.881	rs11225235	chr11:102247361	G/A	cg06323957	chr11:102217781	BIRC2	1.07	4.8	0.44	5.87e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs7119038	0.865	rs4936443	chr11:118740864	C/T	cg19308663	chr11:118741387	NA	-0.59	-5.67	-0.5	1.5e-7	Sjögren's syndrome;
THYM	cis	rs988913	0.706	rs9349748	chr6:54932002	T/C	cg18532076	chr6:54711417	FAM83B	0.49	4.62	0.43	1.18e-5	Menarche (age at onset);
THYM	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg03295274	chr13:50190584	NA	0.68	5.16	0.47	1.37e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg14004847	chr7:1930337	MAD1L1	-0.68	-5.13	-0.47	1.56e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6906287	0.631	rs6920640	chr6:118694464	T/G	cg21191810	chr6:118973309	C6orf204	0.53	5.04	0.46	2.26e-6	Electrocardiographic conduction measures;
THYM	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs12474201	0.928	rs7594523	chr2:46935791	G/C	cg09399716	chr2:46890238	NA	-0.55	-4.87	-0.45	4.43e-6	Height;
THYM	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg04546413	chr19:29218101	NA	1.09	9.4	0.69	3.15e-15	Methadone dose in opioid dependence;
THYM	cis	rs4285028	0.699	rs1344279	chr3:121615679	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.79	-5.52	-0.49	2.94e-7	Multiple sclerosis;
THYM	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg27034606	chr17:28928453	LRRC37B2	0.76	5.06	0.46	2.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg05347473	chr6:146136440	FBXO30	0.55	4.5	0.42	1.93e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11031096	0.502	rs4910598	chr11:4101368	C/T	cg18678763	chr11:4115507	RRM1	-0.43	-5.58	-0.5	2.28e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs4936894	0.500	rs7931968	chr11:124134686	C/T	cg23571170	chr11:124180298	OR8D1	-0.52	-4.51	-0.42	1.87e-5	Aging (time to death);
THYM	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg25072359	chr17:41440525	NA	0.64	4.48	0.42	2.05e-5	Menopause (age at onset);
THYM	cis	rs67311347	0.577	rs11712626	chr3:40259927	G/A	cg09455208	chr3:40491958	NA	0.43	4.54	0.42	1.65e-5	Renal cell carcinoma;
THYM	cis	rs7836436	1.000	rs56833210	chr8:121019040	C/A	cg05020510	chr8:120428057	NOV	0.87	4.45	0.42	2.32e-5	HIV-1 viral setpoint;
THYM	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg10253484	chr15:75165896	SCAMP2	0.61	4.52	0.42	1.78e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs9788682	0.747	rs2656072	chr15:78744292	A/G	cg18825076	chr15:78729989	IREB2	-0.69	-5.51	-0.49	3.05e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg00278517	chr6:167070616	RPS6KA2	-0.34	-4.64	-0.43	1.13e-5	Crohn's disease;
THYM	cis	rs12282928	1.000	rs6485822	chr11:48292801	C/G	cg22827986	chr11:48284249	OR4X1	0.51	5.43	0.49	4.28e-7	Migraine - clinic-based;
THYM	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.08	-0.64	2.07e-12	Personality dimensions;
THYM	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg03517284	chr6:25882590	NA	0.74	6.0	0.52	3.51e-8	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg04025307	chr7:1156635	C7orf50	0.71	5.98	0.52	3.83e-8	Longevity;Endometriosis;
THYM	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg24375607	chr4:120327624	NA	0.68	5.5	0.49	3.15e-7	Corneal astigmatism;
THYM	cis	rs9796	0.870	rs4923890	chr15:41258990	T/C	cg18705301	chr15:41695430	NDUFAF1	0.6	5.09	0.46	1.84e-6	Menopause (age at onset);
THYM	cis	rs11031096	0.711	rs12270809	chr11:4206537	G/A	cg18678763	chr11:4115507	RRM1	-0.41	-4.79	-0.44	6.14e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg03060546	chr3:49711283	APEH	-0.68	-5.25	-0.47	9.2e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs11642862	0.901	rs112190455	chr16:30971437	C/T	cg01070095	chr16:30968205	SETD1A	0.73	4.79	0.44	6.24e-6	Tonsillectomy;
THYM	cis	rs1957429	0.901	rs60979440	chr14:65390231	A/G	cg23373153	chr14:65346875	NA	-1.04	-6.49	-0.55	3.87e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs11650494	0.908	rs57390430	chr17:47374886	G/A	cg08112188	chr17:47440006	ZNF652	1.05	4.51	0.42	1.83e-5	Prostate cancer;
THYM	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg04248312	chr19:17393744	ANKLE1	-0.96	-12.68	-0.79	3.82e-22	Systemic lupus erythematosus;
THYM	cis	rs7216064	1.000	rs8081517	chr17:65845697	A/T	cg12091567	chr17:66097778	LOC651250	-0.71	-4.76	-0.44	6.86e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9467160	0.581	rs2760144	chr6:24479197	A/G	cg00346970	chr6:24499591	ALDH5A1	0.34	4.62	0.43	1.21e-5	Liver enzyme levels;
THYM	cis	rs34779708	0.966	rs1148245	chr10:35511894	C/T	cg03585969	chr10:35415529	CREM	0.64	4.72	0.44	7.96e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4866334	1.000	rs77653879	chr5:18449396	A/G	cg04591469	chr5:17810299	NA	-1.12	-4.54	-0.42	1.65e-5	IgG glycosylation;
THYM	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg16325326	chr1:53192061	ZYG11B	0.8	7.44	0.61	4.39e-11	Monocyte count;
THYM	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg09338302	chr7:1325757	NA	0.48	4.55	0.42	1.6e-5	Bipolar disorder;
THYM	cis	rs62070183	0.882	rs62070187	chr17:31190724	A/G	cg02981443	chr17:31254875	TMEM98	-0.52	-4.61	-0.43	1.25e-5	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs7809615	0.901	rs10808111	chr7:99070884	T/A	cg12290671	chr7:99195819	NA	-0.99	-4.83	-0.44	5.27e-6	Blood metabolite ratios;
THYM	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg03929089	chr4:120376271	NA	0.98	10.3	0.73	3.77e-17	Coronary artery disease;
THYM	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.75	-0.67	7.74e-14	Mean corpuscular volume;
THYM	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs2625529	1.000	rs2625529	chr15:72118777	C/G	cg16672083	chr15:72433130	SENP8	0.57	4.94	0.45	3.29e-6	Red blood cell count;
THYM	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg23131131	chr22:24373011	LOC391322	0.81	8.24	0.65	9.57e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs17449243	1.000	rs17449243	chr1:21174429	C/T	cg01072550	chr1:21505969	NA	0.85	5.45	0.49	3.89e-7	Subjective well-being;
THYM	cis	rs2552220	0.967	rs13255236	chr8:6009712	G/A	cg06481462	chr8:7005678	NA	0.51	5.21	0.47	1.08e-6	Interleukin-8 levels;
THYM	cis	rs7219021	0.669	rs35584414	chr17:47022727	C/G	cg09029085	chr17:47094198	IGF2BP1	0.38	5.12	0.46	1.62e-6	Schizophrenia or bipolar disorder;
THYM	cis	rs13315871	0.858	rs4075404	chr3:58411419	C/T	cg00563845	chr3:58318305	PXK	0.53	4.67	0.43	9.78e-6	Cholesterol, total;
THYM	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg06970220	chr1:156163860	SLC25A44	0.72	5.59	0.5	2.18e-7	Testicular germ cell tumor;
THYM	cis	rs35883536	0.647	rs2809790	chr1:101040461	C/T	cg06223162	chr1:101003688	GPR88	0.83	7.06	0.59	2.67e-10	Monocyte count;
THYM	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.56	0.81	6.23e-24	Height;
THYM	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs89107	0.576	rs72952771	chr6:118883817	C/T	cg21191810	chr6:118973309	C6orf204	0.51	5.1	0.46	1.71e-6	Cardiac structure and function;
THYM	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg27494647	chr7:150038898	RARRES2	0.43	5.42	0.49	4.44e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11225247	0.536	rs11605915	chr11:102237187	C/T	cg11690896	chr11:102217788	BIRC2	1.12	5.18	0.47	1.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs1883415	0.648	rs72834958	chr6:24506317	G/C	cg00346970	chr6:24499591	ALDH5A1	0.48	6.11	0.53	2.17e-8	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg24818145	chr4:99064322	C4orf37	0.92	5.8	0.51	8.75e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg11871910	chr12:69753446	YEATS4	1.03	9.32	0.69	4.63e-15	Blood protein levels;
THYM	cis	rs2710642	0.678	rs11125946	chr2:63298150	C/T	cg17519650	chr2:63277830	OTX1	-0.7	-4.9	-0.45	3.86e-6	LDL cholesterol levels;LDL cholesterol;
THYM	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg06064525	chr11:970664	AP2A2	0.36	6.98	0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg20486651	chr6:167070296	RPS6KA2	-0.51	-4.88	-0.45	4.3e-6	Crohn's disease;
THYM	cis	rs17102423	0.806	rs2411994	chr14:65590537	A/G	cg11161011	chr14:65562177	MAX	0.7	6.44	0.55	4.88e-9	Obesity-related traits;
THYM	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg10518543	chr12:38710700	ALG10B	-0.56	-4.5	-0.42	1.92e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg11235152	chr1:67600687	NA	-0.59	-5.1	-0.46	1.77e-6	Psoriasis;
THYM	cis	rs12681288	0.823	rs2701905	chr8:1003482	T/C	cg04918696	chr8:1004106	NA	-0.41	-4.63	-0.43	1.15e-5	Schizophrenia;
THYM	cis	rs2219968	1.000	rs6473084	chr8:78972524	T/C	cg00738934	chr8:78996279	NA	0.92	10.06	0.72	1.2e-16	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg06979684	chr11:27677125	BDNF;BDNFOS	-1.27	-6.91	-0.58	5.6e-10	Pulmonary function decline;
THYM	cis	rs501916	0.634	rs603569	chr15:48058929	G/A	cg20869673	chr15:48010124	SEMA6D	0.64	4.63	0.43	1.14e-5	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.6	8.36	0.65	5.17e-13	Monocyte percentage of white cells;
THYM	cis	rs12280210	0.557	rs12284696	chr11:116879519	A/G	cg20608306	chr11:116969690	SIK3	-0.82	-5.6	-0.5	2.03e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg27170947	chr2:26402098	FAM59B	-0.82	-6.64	-0.56	1.98e-9	Gut microbiome composition (summer);
THYM	cis	rs9364687	0.554	rs35442073	chr6:163930181	C/A	cg01639524	chr6:163818125	NA	0.47	4.57	0.42	1.49e-5	Body mass index;
THYM	cis	rs10779751	1.000	rs1064261	chr1:11288758	C/T	cg08854313	chr1:11322531	MTOR	0.92	7.76	0.62	9.52e-12	Body mass index;
THYM	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.52e-10	Prudent dietary pattern;
THYM	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2346160	0.899	rs206972	chr6:167689552	C/T	cg21686812	chr6:168078911	NA	-0.5	-4.6	-0.43	1.28e-5	Parental extreme longevity (95 years and older);
THYM	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg06917634	chr15:78832804	PSMA4	-0.82	-7.24	-0.6	1.17e-10	Sudden cardiac arrest;
THYM	cis	rs2439831	0.681	rs999047	chr15:43688916	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	6.89	0.58	5.93e-10	Lung cancer in ever smokers;
THYM	cis	rs995000	0.931	rs1167996	chr1:62927797	T/G	cg06896770	chr1:63153194	DOCK7	-0.92	-7.56	-0.61	2.53e-11	Triglyceride levels;
THYM	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg06636001	chr8:8085503	FLJ10661	0.76	6.69	0.57	1.51e-9	Red cell distribution width;
THYM	cis	rs13102973	0.965	rs4629509	chr4:135872410	C/T	cg14419869	chr4:135874104	NA	-0.82	-7.94	-0.63	4.06e-12	Subjective well-being;
THYM	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg27170947	chr2:26402098	FAM59B	-0.58	-4.89	-0.45	4.18e-6	Gut microbiome composition (summer);
THYM	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg24257776	chr3:47051546	LOC100129354	0.41	4.78	0.44	6.38e-6	Colorectal cancer;
THYM	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg11764359	chr7:65958608	NA	0.87	7.45	0.61	4.16e-11	Aortic root size;
THYM	cis	rs2479106	0.637	rs16927007	chr9:126714710	T/C	cg16191174	chr9:126692580	DENND1A	0.71	4.54	0.42	1.68e-5	Polycystic ovary syndrome;
THYM	cis	rs7681440	0.606	rs2583981	chr4:90752582	A/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs67981189	0.546	rs2810075	chr14:71375080	G/C	cg15910301	chr14:71632612	NA	-0.52	-4.49	-0.42	1.96e-5	Schizophrenia;
THYM	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11039798	0.588	rs6485869	chr11:48576903	G/T	cg24672777	chr11:48374446	OR4C45	-0.93	-6.01	-0.52	3.39e-8	Axial length;
THYM	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg26418147	chr1:205743515	RAB7L1	-0.54	-4.69	-0.43	9.32e-6	Menarche (age at onset);
THYM	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg11764359	chr7:65958608	NA	0.87	7.45	0.61	4.16e-11	Aortic root size;
THYM	cis	rs7166081	0.738	rs2286664	chr15:67701495	A/G	cg24579218	chr15:68104479	NA	-0.71	-7.0	-0.58	3.53e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs4803480	1.000	rs11882144	chr19:42072602	G/A	cg09848080	chr19:41642064	NA	0.64	4.6	0.43	1.3e-5	Schizophrenia;
THYM	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs1061377	1.000	rs9990742	chr4:39121414	G/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs6089829	0.888	rs4809467	chr20:61671688	A/G	cg08564027	chr20:61660810	NA	0.96	10.36	0.73	2.87e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9359856	0.872	rs9344948	chr6:90308226	T/G	cg13799429	chr6:90582589	CASP8AP2	0.46	4.46	0.42	2.29e-5	Bipolar disorder;
THYM	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg10645314	chr2:3704589	ALLC	-1.2	-8.58	-0.66	1.81e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.8e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2730245	0.527	rs2657362	chr7:158685095	A/G	cg01219135	chr7:158766336	NA	0.56	4.49	0.42	2.01e-5	Height;
THYM	cis	rs35883536	0.647	rs17411209	chr1:101046734	A/G	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg06618935	chr21:46677482	NA	-0.98	-9.58	-0.7	1.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4285028	0.948	rs34837785	chr3:121657776	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs9399401	0.890	rs7755109	chr6:142750392	C/T	cg04461802	chr6:142623433	GPR126	-0.46	-4.6	-0.43	1.3e-5	Chronic obstructive pulmonary disease;
THYM	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs360798	0.711	rs11900596	chr2:62904669	G/A	cg00752480	chr2:62680940	NA	-0.25	-4.49	-0.42	2e-5	Coronary artery disease;
THYM	trans	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.69	-9.03	-0.68	1.91e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.55	-0.56	2.92e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9302065	0.681	rs9524902	chr13:95963518	C/T	cg26751094	chr13:95954534	ABCC4	-0.45	-5.0	-0.46	2.66e-6	Blood metabolite levels;
THYM	cis	rs12257961	0.579	rs2352776	chr10:15370036	C/T	cg10616319	chr10:15468812	NA	0.64	4.9	0.45	3.94e-6	Selective IgA deficiency;
THYM	cis	rs11608355	1.000	rs9669684	chr12:109860644	C/T	cg10504392	chr12:110044639	NA	0.67	6.21	0.54	1.41e-8	Neuroticism;
THYM	cis	rs6060960	0.537	rs6089103	chr20:30464919	G/T	cg08478871	chr20:30606493	C20orf160	0.74	4.62	0.43	1.22e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.48	-0.73	1.54e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg15962314	chr1:44399869	ARTN	0.51	4.64	0.43	1.13e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs17125944	0.506	rs1998776	chr14:53355590	T/A	cg00686598	chr14:53173677	PSMC6	-1.01	-4.55	-0.42	1.56e-5	Alzheimer's disease (late onset);
THYM	cis	rs11771526	1.000	rs11770367	chr7:32354319	C/T	cg27532318	chr7:32358331	NA	0.96	5.74	0.51	1.13e-7	Body mass index;
THYM	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg04398451	chr17:18023971	MYO15A	-0.77	-7.04	-0.59	3.02e-10	Total body bone mineral density;
THYM	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs7000551	0.715	rs2443502	chr8:22340499	G/A	cg12081754	chr8:22256438	SLC39A14	0.65	5.55	0.49	2.63e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs66887589	0.870	rs2389875	chr4:120557014	G/T	cg13609457	chr4:120235615	NA	-0.48	-5.01	-0.46	2.46e-6	Diastolic blood pressure;
THYM	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs28595532	0.925	rs115651057	chr4:119486708	A/G	cg14228332	chr4:119757509	SEC24D	1.09	4.5	0.42	1.94e-5	Cannabis dependence symptom count;
THYM	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-4.65	-0.43	1.07e-5	Gut microbiome composition (summer);
THYM	cis	rs7178572	1.000	rs12904938	chr15:77721225	A/G	cg22256960	chr15:77711686	NA	-0.94	-7.93	-0.63	4.23e-12	Type 2 diabetes;
THYM	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg01368799	chr11:117014884	PAFAH1B2	0.77	6.26	0.54	1.1e-8	Blood protein levels;
THYM	cis	rs10411161	0.702	rs79180893	chr19:52395615	A/G	cg25361850	chr19:52391789	ZNF577	0.74	4.96	0.45	3.14e-6	Breast cancer;
THYM	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg14972814	chr11:95582409	MTMR2	-0.65	-5.11	-0.46	1.67e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg00898013	chr13:113819073	PROZ	-0.87	-8.8	-0.67	6.16e-14	Platelet distribution width;
THYM	cis	rs7226229	1.000	rs2127093	chr17:20919703	C/A	cg21263980	chr17:20946333	USP22	0.66	4.77	0.44	6.55e-6	Blood trace element (Se levels);
THYM	cis	rs7078219	0.576	rs989979	chr10:101322423	C/G	cg17888390	chr10:101282816	NA	-0.5	-4.98	-0.45	2.89e-6	Dental caries;
THYM	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg14008862	chr17:28927542	LRRC37B2	0.94	5.08	0.46	1.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7177699	0.550	rs4468572	chr15:79124475	C/T	cg00540400	chr15:79124168	NA	-0.64	-6.96	-0.58	4.42e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs4737010	0.501	rs12548116	chr8:41645074	A/G	cg08923054	chr8:41654455	ANK1	0.76	4.57	0.42	1.47e-5	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
THYM	cis	rs6995541	0.529	rs6992366	chr8:10689561	T/C	cg13457217	chr8:10683266	MIR1322;PINX1	-0.67	-5.02	-0.46	2.39e-6	Triglyceride levels;
THYM	cis	rs10499694	0.933	rs11575334	chr7:50597301	G/A	cg18232548	chr7:50535776	DDC	-0.6	-4.79	-0.44	6.02e-6	Body mass index;
THYM	cis	rs7809615	0.901	rs10226310	chr7:99118320	G/A	cg12290671	chr7:99195819	NA	-0.99	-4.83	-0.44	5.27e-6	Blood metabolite ratios;
THYM	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg05043794	chr9:111880884	C9orf5	-0.44	-6.39	-0.55	6.03e-9	Menarche (age at onset);
THYM	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg22907277	chr7:1156413	C7orf50	0.88	7.74	0.62	1.08e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg15744692	chr15:45671195	LOC145663;GATM	0.44	4.47	0.42	2.18e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.59	-4.53	-0.42	1.71e-5	Breast cancer;
THYM	cis	rs57994353	0.796	rs13283788	chr9:139384521	T/G	cg14115884	chr9:139300582	SDCCAG3	0.71	4.89	0.45	4.14e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs28493229	0.748	rs10426415	chr19:41183590	A/G	cg21869046	chr19:41225005	ITPKC	0.59	5.58	0.5	2.29e-7	Kawasaki disease;
THYM	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11644478	chr21:40555479	PSMG1	0.99	5.71	0.51	1.26e-7	Cognitive function;
THYM	cis	rs72827839	0.894	rs112306902	chr17:46191032	C/T	cg23391107	chr17:45924227	SP6	0.83	5.6	0.5	2.08e-7	Ease of getting up in the morning;
THYM	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.56	-7.53	-0.61	2.87e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs7264396	0.573	rs58355182	chr20:34075687	T/G	cg26038318	chr20:34205095	SPAG4	0.53	4.47	0.42	2.15e-5	Total cholesterol levels;
THYM	cis	rs3849570	1.000	rs9817181	chr3:81827765	A/C	cg07356753	chr3:81810745	GBE1	-0.91	-7.45	-0.61	4.23e-11	Waist circumference;Body mass index;
THYM	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg10589385	chr1:150898437	SETDB1	0.66	5.58	0.5	2.27e-7	Tonsillectomy;
THYM	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.7	5.26	0.47	8.95e-7	Tonsillectomy;
THYM	cis	rs2456568	0.525	rs6483269	chr11:93620428	C/T	cg17347335	chr11:93583973	C11orf90	0.57	5.94	0.52	4.6e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg09085632	chr11:111637200	PPP2R1B	1.19	12.69	0.79	3.69e-22	Primary sclerosing cholangitis;
THYM	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg26314531	chr2:26401878	FAM59B	-0.76	-5.02	-0.46	2.37e-6	Gut microbiome composition (summer);
THYM	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg12863693	chr15:85201151	NMB	0.62	5.57	0.5	2.41e-7	Schizophrenia;
THYM	cis	rs131777	0.545	rs131759	chr22:51015481	G/A	cg00983520	chr22:51017067	CPT1B;CHKB-CPT1B	0.33	4.76	0.44	7.01e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs8038465	0.615	rs4075802	chr15:73963239	A/G	cg15420318	chr15:73925796	NPTN	0.6	5.17	0.47	1.29e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs17407555	0.821	rs80278615	chr4:10143666	G/A	cg00071950	chr4:10020882	SLC2A9	-0.76	-5.68	-0.5	1.45e-7	Schizophrenia (age at onset);
THYM	cis	rs7511006	1.000	rs7290710	chr22:50677454	C/T	cg11077631	chr22:50617003	PANX2	-0.48	-5.21	-0.47	1.08e-6	Obesity-related traits;
THYM	cis	rs6500395	0.962	rs989070	chr16:48602243	G/A	cg04672837	chr16:48644449	N4BP1	0.48	4.64	0.43	1.11e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg16898833	chr6:26189333	HIST1H4D	1.3	4.47	0.42	2.14e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg04398451	chr17:18023971	MYO15A	0.74	6.43	0.55	5.19e-9	Total body bone mineral density;
THYM	cis	rs548181	0.668	rs579661	chr11:125474766	A/G	cg03464685	chr11:125439445	EI24	1.41	8.24	0.65	9.25e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2302777	0.507	rs9889711	chr17:38108292	A/T	cg26162295	chr17:38119207	GSDMA	-0.42	-5.05	-0.46	2.09e-6	Multiple myeloma (hyperdiploidy);
THYM	trans	rs4650994	0.967	rs6681043	chr1:178525957	A/G	cg05059571	chr16:84539110	KIAA1609	-0.75	-8.15	-0.64	1.43e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs7746082	0.627	rs7769470	chr6:106487292	G/A	cg02270332	chr6:106475062	NA	-0.63	-6.01	-0.52	3.46e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	7.35	0.6	6.91e-11	Platelet count;
THYM	cis	rs10799590	1.000	rs12132665	chr1:224832815	C/A	cg01808320	chr1:224927238	CNIH3	-0.57	-5.01	-0.46	2.54e-6	Opioid dependence;
THYM	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4595586	0.545	rs7958118	chr12:39376685	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.91	-7.97	-0.63	3.5e-12	Menarche (age at onset);
THYM	cis	rs782590	0.967	rs4672054	chr2:55773093	C/A	cg03859395	chr2:55845619	SMEK2	0.67	6.14	0.53	1.91e-8	Metabolic syndrome;
THYM	cis	rs3771570	1.000	rs73020143	chr2:242261240	T/A	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs4430311	0.723	rs11585986	chr1:243792591	G/C	cg25706552	chr1:244017396	NA	-0.54	-4.47	-0.42	2.2e-5	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg11366901	chr6:160182831	ACAT2	1.02	8.91	0.67	3.49e-14	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4474465	0.850	rs7938816	chr11:78266227	T/C	cg19901956	chr11:77921274	USP35	0.7	5.0	0.46	2.66e-6	Alzheimer's disease (survival time);
THYM	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3135718	1.000	rs2162540	chr10:123352136	C/T	cg15049101	chr10:123353889	FGFR2	-0.58	-4.96	-0.45	3.03e-6	Estrogen receptor status in breast cancer;
THYM	cis	rs7216064	1.000	rs9913471	chr17:65874495	C/T	cg12091567	chr17:66097778	LOC651250	-0.69	-4.65	-0.43	1.05e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.76	0.44	7.04e-6	Bipolar disorder;
THYM	cis	rs7020830	0.894	rs28766572	chr9:37093872	G/T	cg14294708	chr9:37120828	ZCCHC7	1.2	14.98	0.84	9.36e-27	Schizophrenia;
THYM	trans	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs8048589	0.558	rs35208076	chr16:12228169	C/T	cg01990910	chr16:12207648	SNX29	-0.44	-5.01	-0.46	2.52e-6	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg16325326	chr1:53192061	ZYG11B	-0.73	-7.1	-0.59	2.23e-10	Monocyte count;
THYM	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6840360	0.582	rs2724553	chr4:152321881	T/C	cg17479576	chr4:152424074	FAM160A1	-0.64	-4.72	-0.44	8.19e-6	Intelligence (multi-trait analysis);
THYM	cis	rs57994353	0.897	rs72775772	chr9:139356738	C/T	cg14115884	chr9:139300582	SDCCAG3	0.73	5.44	0.49	4.2e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.57	4.95	0.45	3.15e-6	Hip circumference adjusted for BMI;
THYM	cis	rs747334	0.818	rs3981165	chr10:92704909	C/T	cg07620928	chr10:92689909	NA	0.53	4.85	0.45	4.76e-6	Fibroblast growth factor basic levels;
THYM	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg02136620	chr5:178986620	RUFY1	0.58	5.74	0.51	1.15e-7	Lung cancer;
THYM	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg19507638	chr5:93509721	C5orf36	-0.68	-4.57	-0.42	1.49e-5	Diabetic retinopathy;
THYM	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg10560079	chr2:191398806	TMEM194B	-0.94	-7.79	-0.62	8.48e-12	Diastolic blood pressure;
THYM	cis	rs11771526	0.901	rs10252755	chr7:32304676	G/A	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs17152411	1.000	rs733401	chr10:126594158	A/T	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg16342193	chr10:102329863	NA	-0.48	-4.87	-0.45	4.52e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7980799	0.649	rs11052736	chr12:33669583	T/C	cg06521331	chr12:34319734	NA	-0.67	-4.64	-0.43	1.11e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg21385522	chr1:16154831	NA	-1.31	-14.68	-0.83	3.56e-26	Dilated cardiomyopathy;
THYM	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg08704250	chr15:31115839	NA	-0.54	-6.18	-0.54	1.57e-8	Huntington's disease progression;
THYM	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg02734326	chr4:10020555	SLC2A9	-0.71	-6.2	-0.54	1.44e-8	Bone mineral density;
THYM	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg06917634	chr15:78832804	PSMA4	-0.68	-4.63	-0.43	1.14e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs988913	0.678	rs4490665	chr6:54990817	C/T	cg18532076	chr6:54711417	FAM83B	0.49	4.54	0.42	1.64e-5	Menarche (age at onset);
THYM	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs977987	0.806	rs35683383	chr16:75479277	G/T	cg03315344	chr16:75512273	CHST6	0.74	5.92	0.52	5.07e-8	Dupuytren's disease;
THYM	cis	rs990171	0.913	rs1403554	chr2:103083453	G/A	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.1	-0.46	1.74e-6	Lymphocyte counts;
THYM	cis	rs11264213	0.901	rs661233	chr1:36364716	A/G	cg27506609	chr1:36549197	TEKT2	0.93	4.87	0.45	4.47e-6	Schizophrenia;
THYM	cis	rs3741151	0.773	rs74881062	chr11:73245769	G/A	cg17517138	chr11:73019481	ARHGEF17	0.9	4.71	0.43	8.56e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg07424592	chr7:64974309	NA	1.03	5.4	0.48	4.94e-7	Diabetic kidney disease;
THYM	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Gout;
THYM	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14240646	chr10:27532245	ACBD5	-0.91	-6.8	-0.57	9.17e-10	Breast cancer;
THYM	cis	rs74417235	0.639	rs7443642	chr5:154053450	A/G	cg25588787	chr5:154027256	NA	-0.9	-4.6	-0.43	1.32e-5	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs3087591	0.960	rs9807077	chr17:29634457	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.63	-5.33	-0.48	6.51e-7	Hip circumference;
THYM	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg16325326	chr1:53192061	ZYG11B	0.69	5.73	0.51	1.18e-7	Monocyte count;
THYM	cis	rs1448094	0.512	rs6539927	chr12:86244486	T/C	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.94	6.08	0.53	2.45e-8	Platelet count;
THYM	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg02527881	chr3:46936655	PTH1R	-0.68	-6.97	-0.58	4.19e-10	Colorectal cancer;
THYM	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg15557168	chr22:42548783	NA	-0.59	-4.61	-0.43	1.25e-5	Schizophrenia;
THYM	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg06636001	chr8:8085503	FLJ10661	0.62	5.37	0.48	5.48e-7	Mood instability;
THYM	cis	rs7100689	0.646	rs11202724	chr10:82136190	T/C	cg01528321	chr10:82214614	TSPAN14	0.79	6.01	0.52	3.47e-8	Post bronchodilator FEV1;
THYM	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19346786	chr7:2764209	NA	-0.78	-7.06	-0.59	2.68e-10	Height;
THYM	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	7.49	0.61	3.58e-11	Smoking behavior;
THYM	cis	rs4499344	0.633	rs259256	chr19:33151802	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.17	0.59	1.58e-10	Mean platelet volume;
THYM	cis	rs13279522	0.536	rs7843077	chr8:67036573	A/G	cg20171999	chr8:67343066	NA	0.47	4.69	0.43	9.22e-6	Coronary heart disease event reduction (statin therapy interaction);
THYM	cis	rs8067545	0.604	rs55705283	chr17:20027138	G/A	cg13482628	chr17:19912719	NA	0.53	4.57	0.42	1.46e-5	Schizophrenia;
THYM	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg21394778	chr1:3037102	PRDM16	0.46	4.47	0.42	2.12e-5	Height;
THYM	cis	rs868036	1.000	rs8037262	chr15:68108572	C/T	cg24579218	chr15:68104479	NA	-0.65	-6.54	-0.56	3.12e-9	Restless legs syndrome;
THYM	cis	rs28374715	0.681	rs7168307	chr15:41620534	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.12	-12.97	-0.8	9.4e-23	Ulcerative colitis;
THYM	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg00744431	chr10:134226547	PWWP2B	-0.6	-4.74	-0.44	7.41e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs4242434	0.927	rs35952885	chr8:22491622	T/G	cg11461670	chr8:22454935	PDLIM2	-0.4	-6.71	-0.57	1.37e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg00012203	chr2:219082015	ARPC2	-0.64	-5.28	-0.48	8.18e-7	Colorectal cancer;
THYM	cis	rs611744	0.967	rs678387	chr8:109242730	G/C	cg21045802	chr8:109455806	TTC35	0.57	4.97	0.45	2.98e-6	Dupuytren's disease;
THYM	cis	rs883565	0.655	rs6768957	chr3:39100094	G/A	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	5.0	0.46	2.59e-6	Handedness;
THYM	cis	rs9807841	0.538	rs714307	chr19:10835405	C/T	cg17848348	chr19:10766748	ILF3	-0.61	-5.04	-0.46	2.2e-6	Inflammatory skin disease;
THYM	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg22907277	chr7:1156413	C7orf50	0.8	5.1	0.46	1.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs58688157	0.626	rs7941198	chr11:571681	A/G	cg14433983	chr11:636460	DRD4	-0.62	-4.47	-0.42	2.13e-5	Systemic lupus erythematosus;
THYM	cis	rs988913	0.918	rs7739399	chr6:54855538	C/T	cg19716238	chr6:54711378	FAM83B	0.49	4.87	0.45	4.48e-6	Menarche (age at onset);
THYM	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs2219968	0.700	rs10088166	chr8:78867175	T/C	cg00738934	chr8:78996279	NA	-0.78	-7.47	-0.61	3.92e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg27490568	chr2:178487706	NA	0.61	5.63	0.5	1.82e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs868036	0.681	rs4548812	chr15:68060552	G/A	cg24579218	chr15:68104479	NA	-0.81	-8.27	-0.65	8.2e-13	Restless legs syndrome;
THYM	cis	rs35934224	0.891	rs13054713	chr22:19867914	C/A	cg11182965	chr22:19864308	TXNRD2	-0.93	-7.29	-0.6	9.33e-11	Glaucoma (primary open-angle);
THYM	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	5.18	0.47	1.25e-6	Height;
THYM	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg01570182	chr17:44337453	NA	-0.84	-9.31	-0.69	5.04e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4474465	1.000	rs11237511	chr11:78173606	C/T	cg19901956	chr11:77921274	USP35	-0.59	-4.48	-0.42	2.08e-5	Alzheimer's disease (survival time);
THYM	cis	rs7586879	1.000	rs7608185	chr2:25115432	G/C	cg01884057	chr2:25150051	NA	0.63	6.3	0.54	9.31e-9	Body mass index;
THYM	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg12667521	chr19:29218732	NA	0.9	8.23	0.65	9.85e-13	Methadone dose in opioid dependence;
THYM	cis	rs8028313	0.630	rs7169086	chr15:67934454	C/T	cg24579218	chr15:68104479	NA	-0.72	-6.41	-0.55	5.61e-9	Obesity;
THYM	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	5.75	0.51	1.1e-7	Height;
THYM	cis	rs3741798	1.000	rs61922045	chr12:12494394	A/C	cg08615371	chr12:12503544	MANSC1	0.88	5.13	0.47	1.53e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6906287	0.647	rs973944	chr6:118850956	T/G	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.12e-7	Electrocardiographic conduction measures;
THYM	cis	rs4862307	0.514	rs62340075	chr4:185014889	C/G	cg06737308	chr4:185021514	ENPP6	0.84	8.2	0.64	1.15e-12	Serum dimethylarginine levels (asymmetric/symetric ratio);
THYM	cis	rs61931739	0.929	rs1844524	chr12:34094709	A/T	cg10856724	chr12:34555212	NA	0.6	5.28	0.48	8.22e-7	Morning vs. evening chronotype;
THYM	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.71	5.71	0.51	1.27e-7	Blood metabolite levels;
THYM	cis	rs9807989	0.507	rs6734762	chr2:103062926	C/T	cg03938978	chr2:103052716	IL18RAP	0.75	9.74	0.71	6.06e-16	Asthma;
THYM	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06481639	chr22:41940642	POLR3H	-0.8	-5.33	-0.48	6.56e-7	Vitiligo;
THYM	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg00484396	chr16:3507460	NAT15	-0.62	-5.38	-0.48	5.46e-7	Tuberculosis;
THYM	cis	rs752010	0.967	rs4083593	chr1:42099583	A/G	cg04490934	chr1:41978749	HIVEP3	-0.56	-4.49	-0.42	2e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs236352	0.557	rs9368966	chr6:36825430	A/G	cg03410223	chr6:36853544	C6orf89	0.68	5.36	0.48	5.9e-7	Heart rate;
THYM	cis	rs1922291	0.546	rs3771187	chr2:102840358	A/G	cg13315345	chr2:102803985	IL1RL2	0.61	7.0	0.58	3.67e-10	Blood protein levels;
THYM	cis	rs3820068	0.608	rs7519899	chr1:16045579	A/G	cg27534772	chr1:16042836	PLEKHM2	0.47	4.84	0.44	5.12e-6	Systolic blood pressure;
THYM	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.69	5.65	0.5	1.65e-7	Renal function-related traits (BUN);
THYM	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg27572855	chr1:25598939	RHD	0.69	5.26	0.48	8.8e-7	Erythrocyte sedimentation rate;
THYM	cis	rs6754311	0.593	rs1438305	chr2:136502792	C/G	cg23851026	chr2:136556271	LCT	-0.57	-5.96	-0.52	4.29e-8	Mosquito bite size;
THYM	cis	rs9486719	1.000	rs12205655	chr6:96891733	T/A	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg00012203	chr2:219082015	ARPC2	0.85	7.65	0.62	1.64e-11	Colorectal cancer;
THYM	cis	rs3741151	0.687	rs7933355	chr11:73236817	G/C	cg17517138	chr11:73019481	ARHGEF17	0.9	4.73	0.44	7.74e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7851660	0.527	rs7870795	chr9:100574120	A/G	cg13688889	chr9:100608707	NA	-0.95	-8.51	-0.66	2.45e-13	Strep throat;
THYM	cis	rs3862030	0.720	rs7342070	chr10:104223628	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.63	-5.09	-0.46	1.83e-6	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs3118914	0.694	rs3118905	chr13:51105334	G/A	cg17056618	chr13:50216117	NA	-0.69	-4.55	-0.42	1.6e-5	Height;
THYM	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg24642844	chr7:1081250	C7orf50	-1.17	-5.84	-0.51	7.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg10661904	chr17:79619235	PDE6G	-0.57	-5.19	-0.47	1.2e-6	Eye color traits;
THYM	cis	rs763014	0.833	rs4984891	chr16:622234	T/A	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs9807989	0.524	rs6759479	chr2:103040047	A/C	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg14008862	chr17:28927542	LRRC37B2	0.85	4.6	0.43	1.33e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs919433	0.783	rs2565165	chr2:198233575	T/G	cg00792783	chr2:198669748	PLCL1	0.78	5.6	0.5	2.12e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs990171	1.000	rs10469840	chr2:103093243	T/C	cg13897122	chr2:103039542	IL18RAP	-0.41	-4.93	-0.45	3.49e-6	Lymphocyte counts;
THYM	cis	rs1451375	0.698	rs1813214	chr7:50637525	A/G	cg18232548	chr7:50535776	DDC	0.69	5.35	0.48	6.03e-7	Malaria;
THYM	cis	rs11645898	0.810	rs72787060	chr16:72105371	T/C	cg14768367	chr16:72042858	DHODH	-0.8	-5.8	-0.51	8.51e-8	Blood protein levels;
THYM	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.63	4.48	0.42	2.05e-5	Gut microbiome composition (summer);
THYM	cis	rs8135828	0.770	rs5763300	chr22:29927704	T/C	cg16189954	chr22:29138267	HSCB;CHEK2	0.76	4.72	0.44	8.2e-6	Lipid traits;
THYM	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg12863693	chr15:85201151	NMB	0.63	5.63	0.5	1.8e-7	Schizophrenia;
THYM	cis	rs71403859	0.730	rs17347255	chr16:71587225	C/T	cg08717414	chr16:71523259	ZNF19	-1.19	-6.31	-0.54	8.83e-9	Post bronchodilator FEV1;
THYM	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg02725872	chr8:58115012	NA	-1.11	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs611744	0.647	rs633901	chr8:109242981	G/T	cg21045802	chr8:109455806	TTC35	0.65	5.91	0.52	5.3e-8	Dupuytren's disease;
THYM	cis	rs13102973	1.000	rs11722746	chr4:135850567	A/T	cg14419869	chr4:135874104	NA	0.9	8.46	0.66	3.24e-13	Subjective well-being;
THYM	cis	rs16866061	1.000	rs72974238	chr2:225432470	C/A	cg12698349	chr2:225449008	CUL3	1.15	10.36	0.73	2.8e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg01299579	chr2:10830716	NOL10	0.5	4.72	0.44	8.26e-6	Prostate cancer;
THYM	cis	rs2806561	0.715	rs10753550	chr1:23322471	C/G	cg08872493	chr1:23521417	HTR1D	-0.39	-4.55	-0.42	1.61e-5	Height;
THYM	cis	rs2932538	0.883	rs6701351	chr1:113139196	G/A	cg22162597	chr1:113214053	CAPZA1	0.63	5.21	0.47	1.08e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs4474465	0.920	rs7396701	chr11:78202699	A/C	cg19901956	chr11:77921274	USP35	0.67	4.92	0.45	3.59e-6	Alzheimer's disease (survival time);
THYM	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg22709100	chr7:91322751	NA	0.63	4.86	0.45	4.55e-6	Breast cancer;
THYM	cis	rs728616	0.867	rs12413715	chr10:81687360	G/T	cg05935833	chr10:81318306	SFTPA2	-0.77	-4.66	-0.43	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9902453	0.765	rs12601647	chr17:28164953	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	6.53	0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs6570726	0.526	rs4895674	chr6:145735860	T/G	cg13319975	chr6:146136371	FBXO30	0.6	4.54	0.42	1.67e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1385374	0.858	rs34888374	chr12:129296536	G/A	cg04043695	chr12:129287642	SLC15A4	-0.8	-4.83	-0.44	5.3e-6	Systemic lupus erythematosus;
THYM	cis	rs2562456	0.755	rs2914646	chr19:21637161	A/C	cg21751540	chr19:21541537	ZNF738	0.83	5.52	0.49	2.91e-7	Pain;
THYM	cis	rs11779988	0.545	rs208762	chr8:17806734	G/A	cg01800426	chr8:17659068	MTUS1	-0.74	-5.29	-0.48	7.7e-7	Breast cancer;
THYM	cis	rs9470366	0.527	rs4711456	chr6:36632482	C/T	cg11920449	chr6:36645608	CDKN1A	0.66	5.63	0.5	1.84e-7	QRS duration;
THYM	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg27129171	chr3:47204927	SETD2	0.69	6.61	0.56	2.22e-9	Colorectal cancer;
THYM	cis	rs8192282	0.739	rs6687112	chr1:154497146	C/T	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs4731207	0.596	rs2402756	chr7:124579782	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.29	4.45	0.42	2.3e-5	Obesity-related traits;
THYM	cis	rs9633835	0.594	rs34369393	chr11:13289344	A/G	cg13286116	chr11:13302098	ARNTL	0.74	8.55	0.66	2.02e-13	Body mass index;
THYM	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs1003719	1.000	rs2154536	chr21:38492147	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.72	5.19	0.47	1.18e-6	Eye color traits;
THYM	cis	rs28595532	1.000	rs56225646	chr4:119651217	T/C	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg03676636	chr4:99064102	C4orf37	0.42	6.16	0.53	1.78e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg07460842	chr6:66804631	NA	-0.91	-6.41	-0.55	5.65e-9	Exhaled nitric oxide output;
THYM	cis	rs2334880	0.641	rs12325234	chr16:71459628	A/T	cg06353428	chr16:71660113	MARVELD3	-1.18	-6.03	-0.53	3.18e-8	Malaria;
THYM	cis	rs73198271	0.681	rs11987924	chr8:8649972	T/C	cg06636001	chr8:8085503	FLJ10661	-0.7	-4.77	-0.44	6.56e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	8.9	0.67	3.71e-14	Cognitive test performance;
THYM	cis	rs3011225	0.683	rs4660753	chr1:44321044	G/A	cg13246856	chr1:44399776	ARTN	0.48	4.95	0.45	3.27e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs9814567	0.727	rs4437193	chr3:134352344	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-7.37	-0.6	6.34e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs10857712	0.904	rs7918164	chr10:135223323	G/A	cg19904058	chr10:135279010	LOC619207	-0.51	-4.79	-0.44	6.24e-6	Systemic lupus erythematosus;
THYM	cis	rs17024684	1.000	rs17024739	chr3:3058876	A/G	cg22818988	chr3:3168509	TRNT1	-1.01	-4.51	-0.42	1.82e-5	Brain connectivity;
THYM	cis	rs1728785	1.000	rs1170439	chr16:68608511	T/C	cg02972257	chr16:68554789	NA	-0.76	-4.69	-0.43	9.2e-6	Ulcerative colitis;
THYM	cis	rs1062746	0.771	rs9308348	chr16:87371941	G/A	cg27365499	chr16:87376795	FBXO31	0.59	6.52	0.56	3.3e-9	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs10751667	1.000	rs6597965	chr11:964476	A/G	cg01483505	chr11:975446	AP2A2	0.64	5.05	0.46	2.17e-6	Alzheimer's disease (late onset);
THYM	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg03806693	chr22:41940476	POLR3H	1.23	8.12	0.64	1.71e-12	Vitiligo;
THYM	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg02825527	chr7:2087843	MAD1L1	-0.76	-5.08	-0.46	1.88e-6	Bipolar disorder;
THYM	cis	rs7586879	0.521	rs7597332	chr2:25075675	A/G	cg27107076	chr2:25050844	ADCY3	-0.31	-4.9	-0.45	3.91e-6	Body mass index;
THYM	cis	rs7192750	0.562	rs9921412	chr16:71988106	C/T	cg06353428	chr16:71660113	MARVELD3	0.72	5.4	0.48	4.87e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg18681998	chr4:17616180	MED28	0.86	7.79	0.62	8.27e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs863345	0.604	rs1342952	chr1:158464430	C/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs9807989	0.524	rs2110662	chr2:103020139	A/T	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.14	0.47	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4808199	0.948	rs1859287	chr19:19422187	T/C	cg03709012	chr19:19516395	GATAD2A	1.11	6.5	0.55	3.72e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs25645	0.502	rs7223318	chr17:38108553	G/C	cg24910161	chr17:38119198	GSDMA	-0.58	-6.31	-0.54	8.93e-9	Myeloid white cell count;
THYM	cis	rs2806561	0.894	rs1738475	chr1:23536891	C/G	cg19743168	chr1:23544995	NA	0.68	7.55	0.61	2.67e-11	Height;
THYM	cis	rs2273669	0.667	rs12196143	chr6:109302372	C/T	cg17117243	chr6:109341365	SESN1	-0.84	-4.94	-0.45	3.41e-6	Prostate cancer;
THYM	cis	rs425535	0.757	rs1594230	chr4:74841385	T/C	cg07868155	chr4:74864709	CXCL5	0.65	4.95	0.45	3.24e-6	Blood protein levels;
THYM	cis	rs7404928	0.707	rs3785388	chr16:23960889	A/G	cg26685404	chr16:23957272	PRKCB	0.61	6.99	0.58	3.79e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-4.6	-0.43	1.29e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1371867	0.775	rs6511	chr8:101252680	T/C	cg00191853	chr8:101177733	SPAG1	0.55	5.08	0.46	1.91e-6	Atrioventricular conduction;
THYM	cis	rs2276314	1.000	rs16967317	chr18:33573400	A/G	cg05985134	chr18:33552581	C18orf21	0.67	4.73	0.44	7.86e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs1007190	0.881	rs34854300	chr17:42969013	T/C	cg15406952	chr17:42872593	NA	0.8	5.57	0.5	2.34e-7	DNA methylation (variation);
THYM	cis	rs7980687	0.506	rs1611973	chr12:123622731	C/G	cg05973401	chr12:123451056	ABCB9	0.63	4.66	0.43	1.02e-5	Height;Educational attainment;Head circumference (infant);
THYM	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg03676636	chr4:99064102	C4orf37	0.45	6.68	0.57	1.57e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg20007245	chr22:24372913	LOC391322	-0.69	-6.11	-0.53	2.16e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06634786	chr22:41940651	POLR3H	-0.76	-5.54	-0.49	2.73e-7	Vitiligo;
THYM	cis	rs79149102	0.579	rs6495146	chr15:75367630	A/T	cg17294928	chr15:75287854	SCAMP5	-0.86	-4.73	-0.44	7.75e-6	Lung cancer;
THYM	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.57	4.49	0.42	2.01e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12681287	0.571	rs13254675	chr8:87353594	C/T	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs61931739	0.534	rs1852222	chr12:34008665	C/A	cg10856724	chr12:34555212	NA	-0.76	-6.77	-0.57	1.08e-9	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg17554472	chr22:41940697	POLR3H	0.69	4.54	0.42	1.63e-5	Vitiligo;
THYM	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg02551604	chr5:131831745	NA	-0.74	-5.52	-0.49	2.94e-7	Asthma (sex interaction);
THYM	cis	rs6918586	0.616	rs198836	chr6:26113616	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.59	-0.61	2.14e-11	Schizophrenia;
THYM	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg16188243	chr19:2783719	SGTA	0.67	4.63	0.43	1.15e-5	Total cholesterol levels;
THYM	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21582582	chr3:182698605	DCUN1D1	0.82	7.28	0.6	9.5e-11	Intelligence (multi-trait analysis);
THYM	cis	rs2820651	1.000	rs2820651	chr10:1471765	A/C	cg27404824	chr10:1454848	ADARB2	-0.85	-4.69	-0.43	9.23e-6	Migraine with aura;
THYM	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg15744005	chr10:104629667	AS3MT	-0.78	-7.33	-0.6	7.48e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2295359	1.000	rs10889661	chr1:67625309	T/A	cg11235152	chr1:67600687	NA	0.56	4.5	0.42	1.94e-5	Psoriasis;
THYM	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.88	-0.58	6.43e-10	Eye color traits;
THYM	cis	rs11018874	0.532	rs11018867	chr11:89862345	C/T	cg23743573	chr11:89867420	NAALAD2	0.77	4.77	0.44	6.74e-6	White blood cell types;
THYM	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg00852783	chr1:26633632	UBXN11	-0.81	-8.17	-0.64	1.32e-12	Obesity-related traits;
THYM	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg06634786	chr22:41940651	POLR3H	-0.57	-4.57	-0.42	1.47e-5	Neuroticism;
THYM	cis	rs9543976	1.000	rs7339146	chr13:76173719	G/A	cg01531495	chr13:76123901	UCHL3	-0.74	-5.04	-0.46	2.24e-6	Diabetic retinopathy;
THYM	cis	rs12983728	0.505	rs35511051	chr19:58665817	C/A	cg07378217	chr19:58662286	ZNF329	-0.75	-4.85	-0.45	4.79e-6	Cholesterol, total;
THYM	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs988913	0.957	rs9367597	chr6:54784652	C/T	cg04690482	chr6:54711388	FAM83B	0.48	5.2	0.47	1.13e-6	Menarche (age at onset);
THYM	cis	rs7626444	0.628	rs1684464	chr3:196485514	A/C	cg12930392	chr3:196481615	PAK2	0.4	4.97	0.45	2.97e-6	Monocyte count;
THYM	cis	rs907683	0.570	rs3755056	chr2:220281016	T/A	cg15015639	chr2:220282977	DES	0.42	5.98	0.52	3.93e-8	Resting heart rate;
THYM	cis	rs4713118	0.869	rs7776351	chr6:27726731	A/G	cg08968635	chr6:28129556	ZNF389	-0.72	-5.69	-0.5	1.4e-7	Parkinson's disease;
THYM	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14893161	chr1:205819251	PM20D1	0.86	8.5	0.66	2.61e-13	Menarche (age at onset);
THYM	cis	rs7429990	0.965	rs4599334	chr3:48066400	A/C	cg02219026	chr3:48282209	ZNF589	0.6	4.51	0.42	1.86e-5	Educational attainment (years of education);
THYM	cis	rs7757969	1.000	rs9481189	chr6:112113938	T/C	cg08601457	chr6:112115117	FYN	0.42	4.79	0.44	6.23e-6	Schizophrenia;
THYM	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg06636001	chr8:8085503	FLJ10661	0.71	6.27	0.54	1.07e-8	Mood instability;
THYM	cis	rs1372520	0.684	rs1837891	chr4:90736131	C/G	cg01966878	chr4:90757139	SNCA	0.63	4.91	0.45	3.72e-6	Neuroticism;
THYM	cis	rs859767	0.737	rs2280219	chr2:135351764	A/G	cg12500956	chr2:135428796	TMEM163	-0.49	-5.0	-0.46	2.66e-6	Neuroticism;
THYM	cis	rs17604090	0.818	rs28390296	chr7:29687091	C/T	cg19413766	chr7:29689036	LOC646762	-0.93	-5.09	-0.46	1.77e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg16586182	chr3:47516702	SCAP	0.63	5.6	0.5	2.12e-7	Colorectal cancer;
THYM	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg26354017	chr1:205819088	PM20D1	-0.73	-5.87	-0.52	6.34e-8	Menarche (age at onset);
THYM	cis	rs4072705	0.934	rs4838194	chr9:127342815	T/C	cg13476313	chr9:127244764	NR5A1	0.32	4.84	0.44	5.02e-6	Menarche (age at onset);
THYM	cis	rs2050392	0.517	rs160017	chr10:30772894	A/G	cg25182066	chr10:30743637	MAP3K8	-0.53	-4.67	-0.43	1.01e-5	Inflammatory bowel disease;
THYM	cis	rs11645898	0.745	rs55824906	chr16:72064905	A/G	cg03805757	chr16:71968109	PKD1L3	-0.72	-5.25	-0.47	9.38e-7	Blood protein levels;
THYM	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg06728252	chr6:26598149	ABT1	-0.43	-5.09	-0.46	1.79e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg06219351	chr7:158114137	PTPRN2	0.71	6.5	0.55	3.68e-9	Calcium levels;
THYM	cis	rs898549	1.000	rs10899956	chr10:44466480	C/T	cg08683644	chr10:44853092	NA	0.44	4.45	0.42	2.33e-5	Obesity-related traits;
THYM	cis	rs901683	0.850	rs80174235	chr10:46091818	G/C	cg18240400	chr10:46168597	ANUBL1	0.69	5.04	0.46	2.26e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg22907277	chr7:1156413	C7orf50	0.8	4.85	0.45	4.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs57920188	0.640	rs4378174	chr1:4080885	C/T	cg20703997	chr1:4087676	NA	0.92	6.4	0.55	5.98e-9	Interleukin-17 levels;
THYM	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.01	-5.45	-0.49	4.03e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg02696790	chr15:75250997	RPP25	0.5	4.47	0.42	2.16e-5	Breast cancer;
THYM	cis	rs4731207	0.698	rs6956638	chr7:124530115	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9914544	0.545	rs2305064	chr17:18770733	G/A	cg26378065	chr17:18585709	ZNF286B	0.59	4.5	0.42	1.9e-5	Educational attainment (years of education);
THYM	cis	rs7523273	0.606	rs2796283	chr1:207978732	C/T	cg22525895	chr1:207977042	MIR29B2	-0.95	-9.82	-0.71	4.02e-16	Schizophrenia;
THYM	trans	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg15997130	chr1:24165203	NA	0.77	6.87	0.58	6.65e-10	Immature fraction of reticulocytes;
THYM	cis	rs72781680	0.848	rs56371415	chr2:23932603	C/G	cg08917208	chr2:24149416	ATAD2B	1.1	4.81	0.44	5.71e-6	Lymphocyte counts;
THYM	cis	rs6684428	1.000	rs10888948	chr1:56382722	G/A	cg11651538	chr1:56320950	NA	-0.61	-4.68	-0.43	9.38e-6	Airflow obstruction;
THYM	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg26384229	chr12:38710491	ALG10B	0.73	5.4	0.48	5.01e-7	Morning vs. evening chronotype;
THYM	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg20295408	chr7:1910781	MAD1L1	-0.65	-4.85	-0.45	4.9e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg13447684	chr7:1895903	MAD1L1	0.58	4.86	0.45	4.72e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg12573674	chr2:1569213	NA	-1.16	-8.07	-0.64	2.18e-12	IgG glycosylation;
THYM	cis	rs57994353	0.897	rs36101132	chr9:139367566	G/A	cg14115884	chr9:139300582	SDCCAG3	0.69	5.08	0.46	1.91e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg21775007	chr8:11205619	TDH	0.63	4.97	0.45	2.91e-6	Retinal vascular caliber;
THYM	cis	rs7917772	0.582	rs10786687	chr10:104336994	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg03188948	chr7:1209495	NA	0.79	5.95	0.52	4.42e-8	Longevity;Endometriosis;
THYM	cis	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg06636001	chr8:8085503	FLJ10661	0.55	4.56	0.42	1.51e-5	Joint mobility (Beighton score);
THYM	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg11663144	chr21:46675770	NA	-0.5	-6.08	-0.53	2.55e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7586879	0.681	rs6545800	chr2:25118885	A/G	cg15423357	chr2:25149977	NA	-0.68	-7.53	-0.61	2.9e-11	Body mass index;
THYM	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg10047753	chr17:41438598	NA	0.97	7.99	0.63	3.21e-12	Menopause (age at onset);
THYM	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg00129232	chr17:37814104	STARD3	-0.74	-4.99	-0.46	2.76e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg07537917	chr2:241836409	C2orf54	-0.21	-4.72	-0.44	8.01e-6	Urinary metabolites;
THYM	cis	rs36051895	0.632	rs7040922	chr9:5174829	A/G	cg02405213	chr9:5042618	JAK2	0.95	10.0	0.72	1.63e-16	Pediatric autoimmune diseases;
THYM	cis	rs2456568	0.548	rs4402256	chr11:93660803	T/C	cg17595323	chr11:93583763	C11orf90	-0.52	-5.54	-0.49	2.68e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg13114125	chr14:105738426	BRF1	-0.73	-5.72	-0.51	1.22e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg01097406	chr16:89675127	NA	0.6	5.52	0.49	2.92e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs240764	0.645	rs240152	chr6:101067489	G/C	cg21058520	chr6:100914733	NA	-0.58	-4.89	-0.45	4.16e-6	Neuroticism;
THYM	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2273669	0.667	rs12206423	chr6:109353216	C/T	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg24006582	chr15:45444508	DUOX1	-0.83	-7.16	-0.59	1.7e-10	Uric acid levels;
THYM	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg04155289	chr7:94953770	PON1	-0.62	-5.87	-0.52	6.3e-8	Paraoxonase activity;
THYM	cis	rs7833986	1.000	rs13281873	chr8:57101799	C/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	4.78	0.44	6.48e-6	Height;
THYM	cis	rs4474465	0.850	rs4387376	chr11:78257662	T/C	cg19901956	chr11:77921274	USP35	0.61	4.64	0.43	1.1e-5	Alzheimer's disease (survival time);
THYM	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg11494091	chr17:61959527	GH2	0.7	6.46	0.55	4.55e-9	Height;
THYM	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-5.33	-0.48	6.7e-7	Hemoglobin concentration;
THYM	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg03605463	chr16:89740564	NA	0.91	6.88	0.58	6.2e-10	Vitiligo;
THYM	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg08017756	chr2:100939284	LONRF2	0.73	7.46	0.61	4.08e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7219021	0.705	rs2270576	chr17:47007963	C/T	cg09029085	chr17:47094198	IGF2BP1	0.33	4.48	0.42	2.04e-5	Schizophrenia or bipolar disorder;
THYM	cis	rs35934224	0.504	rs11704009	chr22:19840123	A/G	cg11182965	chr22:19864308	TXNRD2	-0.68	-5.03	-0.46	2.29e-6	Glaucoma (primary open-angle);
THYM	cis	rs7523273	0.586	rs2796276	chr1:207951513	G/A	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	cis	rs87938	0.863	rs4437116	chr3:41161343	C/T	cg02247160	chr3:41243829	CTNNB1	-0.34	-4.56	-0.42	1.54e-5	Bone mineral density (hip);
THYM	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22133161	chr19:49891603	CCDC155	0.82	5.5	0.49	3.2e-7	Multiple sclerosis;
THYM	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg21427119	chr20:30132790	HM13	-0.82	-5.61	-0.5	2.01e-7	Mean corpuscular hemoglobin;
THYM	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg15556689	chr8:8085844	FLJ10661	0.74	6.2	0.54	1.48e-8	Mood instability;
THYM	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg04455712	chr21:45112962	RRP1B	0.57	5.37	0.48	5.68e-7	Mean corpuscular volume;
THYM	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg05457628	chr5:178986728	RUFY1	0.64	6.01	0.52	3.43e-8	Lung cancer;
THYM	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg14972814	chr11:95582409	MTMR2	-0.72	-6.57	-0.56	2.67e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg27034606	chr17:28928453	LRRC37B2	0.84	5.44	0.49	4.05e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7084921	0.608	rs11596883	chr10:101861622	T/C	cg11344164	chr10:101878520	NA	-0.61	-5.17	-0.47	1.28e-6	Bone mineral density;
THYM	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	5.6	0.5	2.07e-7	Obesity-related traits;
THYM	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg12564285	chr5:131593104	PDLIM4	0.44	4.54	0.42	1.68e-5	Blood metabolite levels;
THYM	cis	rs9972944	0.729	rs7209787	chr17:63769896	G/C	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs9515201	0.884	rs11838776	chr13:111040681	G/A	cg15455643	chr13:111040242	COL4A2	0.53	5.94	0.52	4.68e-8	White matter hyperintensity burden;
THYM	cis	rs7507204	0.680	rs12975645	chr19:3419132	A/G	cg08380311	chr19:3435252	NFIC	0.86	7.01	0.58	3.44e-10	Height;
THYM	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8114671	0.562	rs2378292	chr20:33485178	T/C	cg08999081	chr20:33150536	PIGU	0.63	5.21	0.47	1.09e-6	Height;
THYM	trans	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	Neuroticism;
THYM	cis	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg00852783	chr1:26633632	UBXN11	-0.73	-5.6	-0.5	2.04e-7	Obesity-related traits;
THYM	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg00631329	chr6:26305371	NA	-0.61	-7.54	-0.61	2.76e-11	Educational attainment;
THYM	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-4.69	-0.43	9.24e-6	Total body bone mineral density;
THYM	cis	rs6570726	0.846	rs439035	chr6:145887990	G/C	cg23711669	chr6:146136114	FBXO30	0.85	7.9	0.63	4.99e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs956237	0.966	rs9992744	chr4:109049719	A/G	cg15700776	chr4:108852048	CYP2U1	0.57	4.62	0.43	1.22e-5	Systemic lupus erythematosus;
THYM	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg20295408	chr7:1910781	MAD1L1	-0.73	-5.53	-0.49	2.78e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs4482178	0.850	rs1753742	chr13:86261388	G/A	cg25308322	chr13:86268291	NA	0.68	4.75	0.44	7.32e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg03929089	chr4:120376271	NA	-1.01	-8.43	-0.65	3.69e-13	Coronary artery disease;
THYM	cis	rs10924970	0.935	rs12731746	chr1:235392546	T/C	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs394563	0.775	rs412894	chr6:149781175	G/A	cg26849637	chr6:150530249	PPP1R14C	-0.43	-4.79	-0.44	6.23e-6	Dupuytren's disease;
THYM	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg11266682	chr4:10021025	SLC2A9	0.74	12.07	0.78	6.92e-21	Bone mineral density;
THYM	cis	rs11563648	0.553	rs1419423	chr7:127018215	C/T	cg23081781	chr7:127225937	GCC1	-0.34	-4.64	-0.43	1.14e-5	Resting heart rate;
THYM	trans	rs71327718	1	rs71327718	chr3:125592857	C/G	cg07211511	chr3:129823064	LOC729375	-1.32	-8.47	-0.66	3.1e-13	Metabolite levels (HVA/5-HIAA ratio);
THYM	cis	rs11089937	0.616	rs12484496	chr22:22534686	A/C	cg06866756	chr22:22471216	NA	0.43	4.77	0.44	6.77e-6	Periodontitis (PAL4Q3);
THYM	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg00786635	chr1:25594202	NA	0.86	6.91	0.58	5.59e-10	Erythrocyte sedimentation rate;
THYM	cis	rs7809950	0.862	rs2299421	chr7:106946195	C/G	cg23024343	chr7:107201750	COG5	-0.7	-5.89	-0.52	5.79e-8	Coronary artery disease;
THYM	cis	rs12928939	0.517	rs17358402	chr16:71967927	C/T	cg03805757	chr16:71968109	PKD1L3	-1.09	-11.04	-0.75	1.02e-18	Post bronchodilator FEV1;
THYM	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg26924012	chr15:45694286	SPATA5L1	1.01	8.95	0.68	2.83e-14	Homoarginine levels;
THYM	cis	rs7524258	0.868	rs8179413	chr1:7267729	T/G	cg07173049	chr1:7289937	CAMTA1	0.77	5.84	0.51	7.14e-8	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Body mass index;
THYM	cis	rs8062405	0.755	rs62034355	chr16:28581038	G/C	cg09046979	chr16:28333134	SBK1	-0.53	-4.47	-0.42	2.18e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs78062588	1.000	rs73001420	chr1:154586759	C/G	cg13098855	chr1:153588927	S100A14	0.58	4.67	0.43	1e-5	Lung cancer;
THYM	cis	rs8133932	0.906	rs75900404	chr21:47105155	G/A	cg20357416	chr21:47294739	PCBP3	0.86	4.94	0.45	3.33e-6	Schizophrenia;
THYM	cis	rs11031096	0.563	rs12281849	chr11:4224832	C/T	cg08557956	chr11:4115526	RRM1	-0.61	-4.93	-0.45	3.46e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.1	0.46	1.72e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg18301423	chr5:131593218	PDLIM4	0.52	4.65	0.43	1.08e-5	Breast cancer;
THYM	cis	rs1729407	0.706	rs595049	chr11:116699445	C/A	cg08985259	chr11:116699649	APOC3	-0.62	-5.24	-0.47	9.59e-7	Apolipoprotein A-IV levels;
THYM	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg20283391	chr11:68216788	NA	-0.74	-5.6	-0.5	2.1e-7	Total body bone mineral density;
THYM	cis	rs11096990	0.593	rs7662880	chr4:39285224	C/T	cg24403649	chr4:39172243	NA	-0.66	-5.7	-0.51	1.32e-7	Cognitive function;
THYM	cis	rs7772486	0.805	rs4896831	chr6:145959481	T/C	cg13319975	chr6:146136371	FBXO30	-0.65	-5.35	-0.48	6.13e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg18105134	chr13:113819100	PROZ	-0.98	-9.11	-0.68	1.32e-14	Platelet distribution width;
THYM	cis	rs3960554	0.808	rs61303167	chr7:75671175	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-4.47	-0.42	2.18e-5	Eotaxin levels;
THYM	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg11494091	chr17:61959527	GH2	1.08	16.72	0.86	4.66e-30	Prudent dietary pattern;
THYM	cis	rs2811415	0.597	rs9858267	chr3:127786551	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs6754311	0.597	rs6760329	chr2:136544752	A/G	cg04750100	chr2:136595281	LCT	-0.51	-5.24	-0.47	9.53e-7	Mosquito bite size;
THYM	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs34375054	1.000	rs34375054	chr12:125665896	A/T	cg25124228	chr12:125621409	AACS	-0.63	-4.91	-0.45	3.77e-6	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs240764	0.658	rs1336244	chr6:101197953	C/T	cg21058520	chr6:100914733	NA	0.56	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg11764359	chr7:65958608	NA	-0.63	-4.89	-0.45	4.17e-6	Aortic root size;
THYM	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg04398451	chr17:18023971	MYO15A	0.89	7.89	0.63	5.03e-12	Total body bone mineral density;
THYM	cis	rs7192380	1.000	rs11647110	chr16:69589363	G/A	cg09409435	chr16:70099608	PDXDC2	0.59	4.6	0.43	1.31e-5	Sjögren's syndrome;
THYM	cis	rs6032067	0.929	rs2143944	chr20:43819370	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs2637266	1.000	rs12784382	chr10:78378348	G/T	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg01831904	chr17:28903510	LRRC37B2	-1.13	-5.5	-0.49	3.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2455799	0.502	rs2470532	chr3:15696909	A/C	cg16303742	chr3:15540471	COLQ	0.52	5.31	0.48	7.09e-7	Mean platelet volume;
THYM	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.58	-0.5	2.3e-7	Obesity-related traits;
THYM	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg06481639	chr22:41940642	POLR3H	0.79	5.52	0.49	2.89e-7	Vitiligo;
THYM	cis	rs7814319	0.933	rs13261690	chr8:97238661	C/A	cg20787634	chr8:97240163	UQCRB	-0.78	-9.51	-0.7	1.84e-15	Lung function (FVC);
THYM	cis	rs394563	0.775	rs420430	chr6:149785539	T/G	cg26849637	chr6:150530249	PPP1R14C	-0.43	-4.76	-0.44	6.79e-6	Dupuytren's disease;
THYM	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg26516362	chr5:178986906	RUFY1	0.4	4.56	0.42	1.51e-5	Lung cancer;
THYM	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg03690763	chr11:133734501	NA	-0.61	-4.73	-0.44	7.77e-6	Childhood ear infection;
THYM	cis	rs7786808	0.508	rs896765	chr7:158182809	G/A	cg01191920	chr7:158217561	PTPRN2	0.81	7.98	0.63	3.31e-12	Obesity-related traits;
THYM	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.94	6.12	0.53	2.08e-8	Smoking behavior;
THYM	cis	rs3087591	0.919	rs2012581	chr17:29560800	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.61	-5.18	-0.47	1.23e-6	Hip circumference;
THYM	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.37	5.21	0.47	1.11e-6	Obesity-related traits;
THYM	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg03388043	chr17:80084554	CCDC57	-0.66	-5.66	-0.5	1.61e-7	Life satisfaction;
THYM	cis	rs57590327	0.503	rs1464790	chr3:81852923	A/T	cg07356753	chr3:81810745	GBE1	0.83	6.17	0.54	1.64e-8	Extraversion;
THYM	cis	rs728616	0.867	rs12412226	chr10:81735288	C/T	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg15605315	chr1:45957053	TESK2	0.79	6.68	0.57	1.61e-9	High light scatter reticulocyte count;
THYM	cis	rs926938	0.584	rs1286561	chr1:115375428	T/C	cg12756093	chr1:115239321	AMPD1	-0.63	-5.08	-0.46	1.88e-6	Autism;
THYM	cis	rs11969893	0.737	rs1856131	chr6:101407104	C/G	cg12253828	chr6:101329408	ASCC3	1.08	6.2	0.54	1.43e-8	Economic and political preferences (immigration/crime);
THYM	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg00631329	chr6:26305371	NA	-0.65	-7.75	-0.62	1e-11	Educational attainment;
THYM	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg06481639	chr22:41940642	POLR3H	-0.75	-5.22	-0.47	1.06e-6	Vitiligo;
THYM	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg13390004	chr1:15929781	NA	0.59	4.57	0.42	1.47e-5	Systolic blood pressure;
THYM	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	7.72	0.62	1.16e-11	Cognitive test performance;
THYM	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs3960554	0.733	rs59170362	chr7:75629267	G/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.6	-5.09	-0.46	1.8e-6	Eotaxin levels;
THYM	cis	rs7616559	0.849	rs922865	chr3:156777954	G/C	cg15697575	chr3:156784781	NA	0.42	5.45	0.49	4e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs752010	0.967	rs2038978	chr1:42094719	A/G	cg22486000	chr1:42919398	ZMYND12	-0.44	-5.12	-0.47	1.58e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs8070740	1.000	rs8070740	chr17:5331896	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.69	5.32	0.48	6.84e-7	Menopause (age at onset);
THYM	cis	rs9326248	0.559	rs482371	chr11:116752163	T/C	cg20608306	chr11:116969690	SIK3	0.62	7.38	0.6	5.92e-11	Blood protein levels;
THYM	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14159672	chr1:205819179	PM20D1	0.97	10.33	0.73	3.31e-17	Menarche (age at onset);
THYM	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg05283184	chr6:79620031	NA	-0.94	-9.21	-0.69	7.9e-15	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg13736514	chr6:26305472	NA	-0.58	-7.15	-0.59	1.74e-10	Educational attainment;
THYM	cis	rs9581857	0.685	rs9579084	chr13:28028201	A/G	cg22138327	chr13:27999177	GTF3A	-0.8	-4.49	-0.42	1.96e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs67311347	0.544	rs7652439	chr3:40349948	G/T	cg24209194	chr3:40518798	ZNF619	0.56	4.61	0.43	1.24e-5	Renal cell carcinoma;
THYM	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg05294307	chr14:35346193	BAZ1A	-0.89	-7.29	-0.6	9.28e-11	Psoriasis;
THYM	cis	rs9921192	0.967	rs233956	chr16:4332858	C/T	cg00021532	chr16:4324280	TFAP4	0.87	7.61	0.62	2.02e-11	Prostate-specific antigen levels;
THYM	cis	rs860818	0.744	rs1728319	chr7:23231199	C/T	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs6684428	0.706	rs12138137	chr1:56325176	C/T	cg11651538	chr1:56320950	NA	-0.63	-4.97	-0.45	2.91e-6	Airflow obstruction;
THYM	cis	rs2160908	0.694	rs229519	chr22:37578579	C/T	cg26999345	chr22:37584441	C1QTNF6	-0.38	-4.52	-0.42	1.76e-5	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7814319	0.966	rs10095443	chr8:97269738	C/T	cg20787634	chr8:97240163	UQCRB	-0.79	-9.21	-0.69	8.24e-15	Lung function (FVC);
THYM	cis	rs6500395	1.000	rs8052196	chr16:48691644	C/T	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9563576	0.778	rs9563574	chr13:58656599	T/C	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.6	4.5	0.42	1.9e-5	Body mass index;
THYM	cis	rs35934224	0.783	rs45465601	chr22:19868678	T/C	cg11182965	chr22:19864308	TXNRD2	-0.95	-7.13	-0.59	1.98e-10	Glaucoma (primary open-angle);
THYM	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg11764359	chr7:65958608	NA	-0.82	-6.56	-0.56	2.81e-9	Aortic root size;
THYM	cis	rs10463554	0.963	rs62364874	chr5:102392179	T/C	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs28595532	0.920	rs114639588	chr4:119736176	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs888194	0.934	rs3742015	chr12:110017125	T/C	cg11367159	chr12:110044531	NA	0.5	4.73	0.44	7.86e-6	Neuroticism;
THYM	cis	rs2276314	0.762	rs3826600	chr18:33609053	A/G	cg05985134	chr18:33552581	C18orf21	0.66	4.84	0.44	5.02e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs10832963	0.658	rs1972960	chr11:18613336	G/A	cg09201001	chr11:18656081	SPTY2D1	0.76	5.5	0.49	3.24e-7	Breast cancer;
THYM	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg03474202	chr17:45855739	NA	-0.76	-6.7	-0.57	1.45e-9	IgG glycosylation;
THYM	cis	rs8078723	0.668	rs3907022	chr17:38134889	T/C	cg17467752	chr17:38218738	THRA	0.75	5.63	0.5	1.85e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs6430585	0.528	rs7606267	chr2:136668123	T/C	cg07169764	chr2:136633963	MCM6	1.24	14.04	0.82	6.77e-25	Corneal structure;
THYM	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs34638657	0.872	rs11859599	chr16:82182832	C/G	cg19807685	chr16:82068980	HSD17B2	-0.61	-4.62	-0.43	1.21e-5	Lung adenocarcinoma;
THYM	cis	rs1122401	0.515	rs2564983	chr5:53864440	C/T	cg04014864	chr5:54603544	SKIV2L2;DHX29	0.78	5.1	0.46	1.74e-6	Smoking initiation;
THYM	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg09367891	chr1:107599246	PRMT6	-0.7	-5.02	-0.46	2.42e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6860806	0.661	rs4705929	chr5:131584178	G/T	cg18758796	chr5:131593413	PDLIM4	0.63	6.11	0.53	2.19e-8	Breast cancer;
THYM	cis	rs714027	0.511	rs131274	chr22:30153864	G/A	cg27665648	chr22:30112403	NA	0.5	4.45	0.42	2.3e-5	Lymphocyte counts;
THYM	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg08017756	chr2:100939284	LONRF2	-0.75	-7.56	-0.61	2.54e-11	Intelligence (multi-trait analysis);
THYM	cis	rs4589258	0.966	rs2213093	chr11:90487576	C/T	cg26138821	chr11:89956704	CHORDC1	-0.69	-5.52	-0.49	3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1371867	0.875	rs1619759	chr8:101337560	T/C	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs8038465	0.550	rs11072431	chr15:73987642	T/A	cg15420318	chr15:73925796	NPTN	0.63	5.47	0.49	3.6e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg00898013	chr13:113819073	PROZ	0.88	8.98	0.68	2.52e-14	Platelet distribution width;
THYM	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs854765	0.583	rs6502627	chr17:17849671	C/T	cg16928487	chr17:17741425	SREBF1	-0.56	-5.54	-0.49	2.67e-7	Total body bone mineral density;
THYM	cis	rs4938330	0.512	rs4938327	chr11:116906728	T/C	cg20608306	chr11:116969690	SIK3	-0.49	-5.34	-0.48	6.24e-7	Blood protein levels;
THYM	cis	rs13102973	0.965	rs7656631	chr4:135869921	C/T	cg14419869	chr4:135874104	NA	-0.82	-7.94	-0.63	4.06e-12	Subjective well-being;
THYM	cis	rs1270639	0.778	rs2906933	chr7:157450749	T/A	cg13357408	chr7:157437802	PTPRN2	0.47	5.01	0.46	2.48e-6	Colorectal cancer;
THYM	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs12291225	0.679	rs10832240	chr11:14304744	C/T	cg19336497	chr11:14380999	RRAS2	-0.82	-9.66	-0.7	8.92e-16	Sense of smell;
THYM	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg20891283	chr12:69753455	YEATS4	1.09	12.1	0.78	5.96e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2447097	0.935	rs2447095	chr17:2293420	A/G	cg27406664	chr17:2294951	MNT	0.62	5.96	0.52	4.28e-8	Autism spectrum disorder;
THYM	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg21984481	chr17:79567631	NPLOC4	0.6	6.86	0.58	7.04e-10	Eye color traits;
THYM	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg10047753	chr17:41438598	NA	1.15	10.64	0.74	6.98e-18	Menopause (age at onset);
THYM	cis	rs35883536	0.528	rs1577511	chr1:101030859	G/A	cg06223162	chr1:101003688	GPR88	0.86	7.07	0.59	2.63e-10	Monocyte count;
THYM	cis	rs516946	1.000	rs10109812	chr8:41524899	A/G	cg19441908	chr8:41529140	ANK1	0.62	4.9	0.45	3.87e-6	Type 2 diabetes;
THYM	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg00310523	chr12:86230176	RASSF9	0.53	4.77	0.44	6.65e-6	Major depressive disorder;
THYM	cis	rs3892630	0.824	rs34425841	chr19:33231619	C/T	cg22928329	chr19:33183273	NUDT19	-0.73	-5.08	-0.46	1.91e-6	Red blood cell traits;
THYM	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg05313129	chr8:58192883	C8orf71	-0.78	-4.61	-0.43	1.23e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs6495122	0.501	rs8039755	chr15:75337426	T/C	cg02696790	chr15:75250997	RPP25	-0.48	-4.8	-0.44	5.83e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs6586111	1.000	rs7071672	chr10:82375965	C/G	cg03086067	chr10:82368399	SH2D4B	-0.56	-7.16	-0.59	1.68e-10	Capecitabine sensitivity;
THYM	cis	rs911119	1.000	rs13038305	chr20:23610262	C/T	cg16589663	chr20:23618590	CST3	0.77	4.71	0.44	8.31e-6	Chronic kidney disease;
THYM	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg07599136	chr5:415885	AHRR	0.93	5.17	0.47	1.29e-6	Fat distribution (HIV);
THYM	cis	rs7247513	0.856	rs2162863	chr19:12699777	G/T	cg01871581	chr19:12707946	ZNF490	-0.88	-9.08	-0.68	1.54e-14	Bipolar disorder;
THYM	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg24308560	chr3:49941425	MST1R	-0.61	-4.54	-0.42	1.65e-5	Body mass index;
THYM	cis	rs6840360	0.615	rs4696268	chr4:152464723	G/A	cg22705602	chr4:152727874	NA	-0.71	-7.94	-0.63	4.03e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7072216	0.691	rs3829853	chr10:100171174	A/G	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs985746	0.614	rs2164779	chr4:36818080	A/G	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg07936489	chr17:37558343	FBXL20	-0.85	-5.64	-0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08704250	chr15:31115839	NA	-0.54	-6.18	-0.54	1.59e-8	Huntington's disease progression;
THYM	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs3791556	0.501	rs3791533	chr2:240100616	G/A	cg03281426	chr2:240109471	HDAC4	0.48	4.52	0.42	1.78e-5	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg03929089	chr4:120376271	NA	-1.03	-12.43	-0.79	1.26e-21	Height;
THYM	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg03806693	chr22:41940476	POLR3H	-1.11	-8.99	-0.68	2.33e-14	Vitiligo;
THYM	cis	rs7828089	0.624	rs7001171	chr8:22270040	T/G	cg12081754	chr8:22256438	SLC39A14	0.87	8.14	0.64	1.49e-12	Verbal declarative memory;
THYM	cis	rs8070740	1.000	rs8076900	chr17:5327927	C/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.71	5.6	0.5	2.03e-7	Menopause (age at onset);
THYM	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg05872129	chr22:39784769	NA	-0.98	-8.25	-0.65	8.99e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg23851026	chr2:136556271	LCT	0.5	4.69	0.43	9.14e-6	Mosquito bite size;
THYM	cis	rs749052	0.831	rs115560780	chr2:232799677	C/T	cg22331108	chr2:232478452	NA	-0.96	-4.47	-0.42	2.14e-5	Height;
THYM	cis	rs7772486	0.686	rs9386131	chr6:146121608	G/A	cg13319975	chr6:146136371	FBXO30	-0.65	-5.35	-0.48	6.03e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg06618935	chr21:46677482	NA	-0.96	-9.16	-0.68	1.02e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs854765	0.565	rs854768	chr17:18018806	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.59	5.09	0.46	1.8e-6	Total body bone mineral density;
THYM	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg03188948	chr7:1209495	NA	1.12	6.44	0.55	4.78e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg05294307	chr14:35346193	BAZ1A	-0.93	-6.68	-0.57	1.64e-9	Psoriasis;
THYM	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/A	cg00383909	chr3:49044727	WDR6	1.05	5.99	0.52	3.79e-8	Parkinson's disease;
THYM	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg04398451	chr17:18023971	MYO15A	-0.73	-6.34	-0.55	7.78e-9	Total body bone mineral density;
THYM	cis	rs4072705	1.000	rs10818987	chr9:127520729	T/C	cg01786973	chr9:127249749	NR5A1	0.34	4.53	0.42	1.74e-5	Menarche (age at onset);
THYM	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg06656553	chr16:89960601	TCF25	-0.88	-5.16	-0.47	1.32e-6	Skin colour saturation;
THYM	cis	rs17608059	0.566	rs59795106	chr17:13912057	A/T	cg11395062	chr17:14139857	CDRT15	0.72	5.52	0.49	2.92e-7	Temperament;
THYM	cis	rs240764	0.817	rs11155596	chr6:101152631	C/T	cg21058520	chr6:100914733	NA	0.57	5.0	0.46	2.61e-6	Neuroticism;
THYM	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.9	7.92	0.63	4.34e-12	Monocyte percentage of white cells;
THYM	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg24818145	chr4:99064322	C4orf37	0.76	6.06	0.53	2.7e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg09060608	chr5:178986726	RUFY1	-0.6	-6.67	-0.56	1.7e-9	Lung cancer;
THYM	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg03709012	chr19:19516395	GATAD2A	-0.66	-4.63	-0.43	1.16e-5	Tonsillectomy;
THYM	cis	rs909002	0.800	rs4949454	chr1:32099041	A/G	cg13919466	chr1:32135498	COL16A1	0.5	5.02	0.46	2.38e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.58	4.97	0.45	2.98e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg13114125	chr14:105738426	BRF1	-0.71	-5.48	-0.49	3.45e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg05043794	chr9:111880884	C9orf5	-0.35	-4.93	-0.45	3.42e-6	Menarche (age at onset);
THYM	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg27532560	chr4:187881888	NA	0.95	11.87	0.77	1.81e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2354432	0.556	rs7525622	chr1:146774116	G/A	cg25205988	chr1:146714368	CHD1L	-1.03	-5.4	-0.48	5.01e-7	Mitochondrial DNA levels;
THYM	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg04546413	chr19:29218101	NA	1.09	9.44	0.7	2.56e-15	Methadone dose in opioid dependence;
THYM	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg08431931	chr22:42394659	WBP2NL	0.64	4.83	0.44	5.32e-6	Birth weight;
THYM	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg10047753	chr17:41438598	NA	1.19	11.33	0.76	2.52e-19	Menopause (age at onset);
THYM	cis	rs7177699	0.534	rs4387568	chr15:79109514	C/G	cg15571903	chr15:79123663	NA	-0.61	-6.86	-0.58	7.06e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg27446573	chr6:127587934	RNF146	1.02	9.5	0.7	1.93e-15	Breast cancer;
THYM	trans	rs4650994	0.525	rs2224811	chr1:178544323	C/T	cg05059571	chr16:84539110	KIAA1609	0.92	10.85	0.74	2.56e-18	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg02187348	chr16:89574699	SPG7	0.78	6.11	0.53	2.19e-8	Multiple myeloma (IgH translocation);
THYM	cis	rs6570726	0.791	rs4332001	chr6:145934841	T/C	cg13319975	chr6:146136371	FBXO30	-0.67	-5.34	-0.48	6.43e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg05340658	chr4:99064831	C4orf37	0.54	4.5	0.42	1.96e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10466239	0.892	rs17153534	chr10:43848651	C/A	cg12352960	chr10:43428578	NA	-0.96	-4.63	-0.43	1.17e-5	Telomere length;
THYM	cis	rs8070740	0.786	rs980407	chr17:5338818	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.72	5.7	0.5	1.34e-7	Menopause (age at onset);
THYM	cis	rs12200560	0.505	rs211166	chr6:97068598	T/C	cg06623918	chr6:96969491	KIAA0776	0.76	5.77	0.51	9.9e-8	Coronary heart disease;
THYM	cis	rs4595586	0.505	rs6580897	chr12:39372254	A/G	cg13010199	chr12:38710504	ALG10B	0.64	4.93	0.45	3.49e-6	Morning vs. evening chronotype;
THYM	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-4.84	-0.44	5.08e-6	Hemoglobin concentration;
THYM	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg02187348	chr16:89574699	SPG7	0.67	5.06	0.46	2.07e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg26597838	chr10:835615	NA	1.21	8.65	0.66	1.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg01884057	chr2:25150051	NA	-0.66	-6.8	-0.57	9.15e-10	Body mass index;
THYM	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	trans	rs7794364	0.658	rs6965740	chr7:117514840	A/C	cg21837391	chr1:1159412	SDF4	0.92	7.57	0.61	2.39e-11	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg12560992	chr17:57184187	TRIM37	-0.92	-8.68	-0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs8031584	1.000	rs11638409	chr15:31288190	A/C	cg08704250	chr15:31115839	NA	-0.55	-6.5	-0.56	3.63e-9	Huntington's disease progression;
THYM	cis	rs7828089	0.646	rs4872490	chr8:22280805	T/C	cg13512537	chr8:22265999	SLC39A14	-0.68	-5.38	-0.48	5.24e-7	Verbal declarative memory;
THYM	cis	rs911263	0.961	rs7148416	chr14:68747868	A/T	cg18825221	chr14:68749962	RAD51L1	0.61	6.86	0.58	6.96e-10	Primary biliary cholangitis;
THYM	cis	rs6089829	0.888	rs4809471	chr20:61684287	G/A	cg08564027	chr20:61660810	NA	0.96	10.52	0.73	1.27e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6570726	0.935	rs436212	chr6:145849400	G/A	cg23711669	chr6:146136114	FBXO30	0.9	9.23	0.69	7.15e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs910187	0.678	rs6018328	chr20:45813180	T/C	cg27589058	chr20:45804311	EYA2	-0.59	-5.07	-0.46	1.95e-6	Migraine;
THYM	cis	rs1003719	0.788	rs4816560	chr21:38487561	G/T	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs7192750	0.535	rs152826	chr16:72126180	A/G	cg06353428	chr16:71660113	MARVELD3	1.17	4.58	0.43	1.42e-5	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg14004847	chr7:1930337	MAD1L1	-0.68	-5.12	-0.46	1.61e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs3820068	0.705	rs16851727	chr1:15857918	C/T	cg05660106	chr1:15850417	CASP9	1.11	9.62	0.7	1.09e-15	Systolic blood pressure;
THYM	cis	rs6998277	0.830	rs6981007	chr8:103598257	G/C	cg10187029	chr8:103597600	NA	0.51	4.49	0.42	2.03e-5	Migraine;
THYM	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs17102423	0.559	rs4899160	chr14:65481212	C/T	cg12032228	chr14:64854572	MTHFD1	-0.72	-4.61	-0.43	1.24e-5	Obesity-related traits;
THYM	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg20503657	chr10:835505	NA	1.22	7.86	0.63	5.84e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs7582180	0.764	rs1967341	chr2:100924559	T/C	cg21926883	chr2:100939477	LONRF2	-0.61	-5.52	-0.49	2.91e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7082209	0.528	rs12412586	chr10:44851778	C/T	cg08683644	chr10:44853092	NA	-0.72	-4.48	-0.42	2.09e-5	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
THYM	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11890956	chr21:40555474	PSMG1	-0.68	-6.42	-0.55	5.42e-9	Menarche (age at onset);
THYM	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg04234412	chr22:24373322	LOC391322	0.93	9.27	0.69	6.01e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4930776	0.932	rs444834	chr12:5756795	T/G	cg02086166	chr12:5775618	ANO2	0.62	6.27	0.54	1.04e-8	Plasma clusterin levels;
THYM	cis	rs11186	0.591	rs72904412	chr2:189930354	T/C	cg11041835	chr2:189156425	GULP1	0.78	4.69	0.43	9.21e-6	Parkinson's disease;
THYM	cis	rs6539288	0.630	rs3759316	chr12:107370210	A/C	cg26297688	chr12:107349093	C12orf23	-0.46	-5.12	-0.47	1.58e-6	Total body bone mineral density;
THYM	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9902453	1.000	rs4795525	chr17:28388487	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs13102973	0.627	rs4435796	chr4:135883487	T/C	cg14419869	chr4:135874104	NA	0.85	7.05	0.59	2.84e-10	Subjective well-being;
THYM	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg03806693	chr22:41940476	POLR3H	-1.05	-8.83	-0.67	5.26e-14	Vitiligo;
THYM	cis	rs34779708	0.966	rs7070427	chr10:35485689	A/T	cg03585969	chr10:35415529	CREM	0.64	4.53	0.42	1.7e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg11301795	chr4:187892539	NA	-1.12	-16.69	-0.86	5.4e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg25319279	chr11:5960081	NA	-0.65	-5.51	-0.49	3.04e-7	DNA methylation (variation);
THYM	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg04944784	chr2:26401820	FAM59B	-1.08	-8.57	-0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs9992101	0.645	rs17238882	chr4:77289800	G/A	cg20311846	chr4:77356250	SHROOM3	-0.53	-5.69	-0.5	1.43e-7	Creatinine levels;
THYM	cis	rs6127978	0.702	rs1015985	chr20:55809956	C/T	cg15851418	chr20:55835831	BMP7	0.67	4.66	0.43	1.03e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs7107174	1.000	rs1942352	chr11:77970563	T/G	cg02023728	chr11:77925099	USP35	0.66	5.86	0.52	6.59e-8	Testicular germ cell tumor;
THYM	cis	rs2832077	0.943	rs2832091	chr21:30162855	C/T	cg24692254	chr21:30365293	RNF160	-0.8	-4.84	-0.44	5.02e-6	Cognitive test performance;
THYM	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg24692254	chr21:30365293	RNF160	0.88	7.74	0.62	1.08e-11	Dental caries;
THYM	cis	rs17401966	1.000	rs4348727	chr1:10265606	G/A	cg20482658	chr1:10539492	PEX14	0.37	4.5	0.42	1.89e-5	Hepatocellular carcinoma;
THYM	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg00645731	chr22:42541494	CYP2D7P1	0.68	5.84	0.51	7.34e-8	Birth weight;
THYM	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg16031515	chr1:205743344	RAB7L1	-0.69	-7.18	-0.59	1.51e-10	Menarche (age at onset);
THYM	cis	rs2067615	0.524	rs754184	chr12:107117521	A/G	cg15890332	chr12:107067104	RFX4	0.44	5.03	0.46	2.29e-6	Heart rate;
THYM	cis	rs79149102	0.579	rs6495140	chr15:75306041	T/C	cg17294928	chr15:75287854	SCAMP5	-1.06	-5.68	-0.5	1.49e-7	Lung cancer;
THYM	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg03388043	chr17:80084554	CCDC57	0.69	5.87	0.52	6.36e-8	Life satisfaction;
THYM	cis	rs7119	0.717	rs62009071	chr15:77817886	C/G	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.14	-0.64	1.54e-12	Mean corpuscular volume;
THYM	cis	rs7529073	0.815	rs1431982	chr1:214149061	T/G	cg24083324	chr1:214162604	PROX1	-0.6	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg08999081	chr20:33150536	PIGU	0.76	6.7	0.57	1.47e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs9948	1.000	rs6576987	chr2:97512059	G/A	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.83	-0.44	5.18e-6	Erectile dysfunction and prostate cancer treatment;
THYM	cis	rs662064	0.925	rs669701	chr1:10544725	A/G	cg20482658	chr1:10539492	PEX14	-0.47	-6.06	-0.53	2.71e-8	Asthma;
THYM	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00908189	chr16:619842	PIGQ	1.06	9.31	0.69	4.98e-15	Height;
THYM	cis	rs7809950	1.000	rs2712200	chr7:107142435	G/T	cg23024343	chr7:107201750	COG5	-0.91	-8.24	-0.65	9.37e-13	Coronary artery disease;
THYM	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.29	0.6	9.07e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs3017493	0.786	rs74344478	chr11:70681107	G/A	cg19942459	chr11:70508110	SHANK2	1.26	7.35	0.6	6.88e-11	Renal transplant outcome;
THYM	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7404928	0.557	rs8051700	chr16:23944712	A/G	cg26685404	chr16:23957272	PRKCB	0.58	6.53	0.56	3.16e-9	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs11209185	0.509	rs9326077	chr1:68452192	A/G	cg22082780	chr1:68452167	NA	0.69	9.4	0.69	3.22e-15	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg16989719	chr2:238392110	NA	-0.64	-5.83	-0.51	7.72e-8	Prostate cancer;
THYM	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg04476341	chr5:669733	TPPP	0.47	4.78	0.44	6.31e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg20891283	chr12:69753455	YEATS4	-1.09	-12.03	-0.78	8.44e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs57920188	0.535	rs10915664	chr1:4093700	G/A	cg20703997	chr1:4087676	NA	0.82	5.44	0.49	4.1e-7	Interleukin-17 levels;
THYM	cis	rs4243830	0.677	rs1556035	chr1:6579607	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.03	-6.18	-0.54	1.61e-8	Body mass index;
THYM	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg06481639	chr22:41940642	POLR3H	0.68	5.01	0.46	2.52e-6	Vitiligo;
THYM	cis	rs17253792	0.822	rs112238223	chr14:56056144	C/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.27	5.46	0.49	3.78e-7	Obesity-related traits;
THYM	cis	rs1797885	0.763	rs299649	chr3:12538719	T/C	cg05467012	chr3:12595696	NA	0.54	4.65	0.43	1.08e-5	Immature fraction of reticulocytes;
THYM	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs73198271	0.740	rs10094270	chr8:8646633	G/A	cg06636001	chr8:8085503	FLJ10661	-0.76	-5.06	-0.46	2.01e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg08807101	chr21:30365312	RNF160	-0.81	-6.03	-0.53	3.09e-8	Dental caries;
THYM	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs4523957	0.928	rs216190	chr17:2187457	C/T	cg16513277	chr17:2031491	SMG6	0.79	7.41	0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg00071950	chr4:10020882	SLC2A9	0.54	4.73	0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs76878669	0.538	rs1546358	chr11:66175261	G/C	cg18002602	chr11:66138449	SLC29A2	0.47	4.82	0.44	5.45e-6	Educational attainment (years of education);
THYM	cis	rs7404928	0.579	rs1858871	chr16:23923506	A/G	cg26685404	chr16:23957272	PRKCB	-0.62	-7.03	-0.58	3.18e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs10929159	0.928	rs6431418	chr2:236919559	C/T	cg14895183	chr2:236924282	AGAP1	0.52	4.49	0.42	2.04e-5	Parkinson's disease;
THYM	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg26769984	chr7:1090371	C7orf50	0.82	5.2	0.47	1.14e-6	Bronchopulmonary dysplasia;
THYM	cis	rs3820068	0.506	rs17448966	chr1:15990983	T/G	cg13390004	chr1:15929781	NA	0.66	5.0	0.46	2.6e-6	Systolic blood pressure;
THYM	cis	rs1981331	1.000	rs79694455	chr21:47983979	C/T	cg23283320	chr21:48055893	PRMT2	1.19	5.86	0.52	6.6e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg12031863	chr16:4587854	C16orf5	-0.44	-4.66	-0.43	1.04e-5	Schizophrenia;
THYM	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg10047753	chr17:41438598	NA	1.02	8.95	0.68	2.87e-14	Menopause (age at onset);
THYM	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg19077165	chr18:44547161	KATNAL2	0.6	7.36	0.6	6.67e-11	Personality dimensions;
THYM	cis	rs6430585	0.583	rs12472293	chr2:136648077	T/C	cg07169764	chr2:136633963	MCM6	1.24	13.95	0.82	1.01e-24	Corneal structure;
THYM	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs1642645	0.831	rs10736422	chr1:42480320	C/T	cg06092502	chr1:42611687	NA	0.61	4.74	0.44	7.58e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg09184832	chr6:79620586	NA	-0.56	-4.46	-0.42	2.24e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7626444	0.584	rs11711813	chr3:196467338	C/T	cg12930392	chr3:196481615	PAK2	0.42	5.19	0.47	1.18e-6	Monocyte count;
THYM	cis	rs28595532	1.000	rs28600971	chr4:119712728	G/T	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs7719624	1.000	rs2282791	chr5:135377730	T/G	cg12897067	chr5:135418308	NA	0.61	5.06	0.46	2.04e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs6032067	0.641	rs34919068	chr20:43755830	C/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.67	-5.92	-0.52	5.17e-8	Blood protein levels;
THYM	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg06074448	chr4:187884817	NA	0.93	10.67	0.74	6.26e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg06112835	chr11:68658793	MRPL21	0.45	6.39	0.55	6.21e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.51	5.06	0.46	2.07e-6	Schizophrenia;
THYM	cis	rs9314614	0.789	rs2980950	chr8:6712807	C/G	cg27319216	chr8:6693540	XKR5	-0.54	-5.71	-0.51	1.3e-7	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs7119	0.931	rs62009087	chr15:77833064	C/T	cg10437265	chr15:77819839	NA	0.71	6.6	0.56	2.37e-9	Type 2 diabetes;
THYM	cis	rs2976388	1.000	rs2976398	chr8:143764879	G/C	cg06565975	chr8:143823917	SLURP1	-0.45	-5.16	-0.47	1.38e-6	Urinary tract infection frequency;
THYM	cis	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg06521331	chr12:34319734	NA	-0.72	-4.99	-0.46	2.68e-6	Resting heart rate;
THYM	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg07169764	chr2:136633963	MCM6	-0.68	-6.23	-0.54	1.25e-8	Mosquito bite size;
THYM	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg11266682	chr4:10021025	SLC2A9	-0.62	-7.75	-0.62	1e-11	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6918586	0.594	rs198842	chr6:26111448	C/T	cg03264133	chr6:25882463	NA	0.64	4.94	0.45	3.41e-6	Schizophrenia;
THYM	cis	rs7688540	0.511	rs61794991	chr4:198207	A/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.91	5.56	0.5	2.45e-7	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg06618935	chr21:46677482	NA	0.95	9.26	0.69	6.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs35883536	1.000	rs1832121	chr1:101159476	A/G	cg06223162	chr1:101003688	GPR88	0.67	5.12	0.46	1.62e-6	Monocyte count;
THYM	cis	rs2816062	0.786	rs2816038	chr1:18880525	C/T	cg18795169	chr1:18902165	NA	-0.94	-10.8	-0.74	3.3e-18	Urate levels in lean individuals;
THYM	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.0	-7.33	-0.6	7.48e-11	Schizophrenia;
THYM	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg20387954	chr3:183756860	HTR3D	0.59	4.85	0.45	4.87e-6	Anterior chamber depth;
THYM	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg10803722	chr21:46713166	LOC642852	-0.38	-4.95	-0.45	3.16e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs59698941	0.882	rs67414627	chr5:132258165	A/G	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg10661904	chr17:79619235	PDE6G	-0.65	-6.31	-0.54	8.81e-9	Eye color traits;
THYM	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8033133	0.881	rs4344720	chr15:25324141	C/T	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.8	-5.82	-0.51	8.1e-8	Blood osmolality (transformed sodium);
THYM	cis	rs7100689	0.784	rs10749578	chr10:82139115	A/G	cg01528321	chr10:82214614	TSPAN14	-0.96	-7.28	-0.6	9.52e-11	Post bronchodilator FEV1;
THYM	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg08045932	chr20:61659980	NA	0.94	10.48	0.73	1.56e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg06808227	chr14:105710500	BRF1	-1.02	-8.64	-0.66	1.33e-13	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg08885076	chr2:99613938	TSGA10	-0.45	-4.53	-0.42	1.7e-5	Fear of minor pain;
THYM	cis	rs11039798	0.920	rs8186465	chr11:48796771	T/C	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs2777491	0.957	rs3743038	chr15:41694743	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.14	-13.05	-0.8	6.53e-23	Ulcerative colitis;
THYM	cis	rs12681287	0.640	rs7816629	chr8:87350788	A/T	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs2932538	0.922	rs12048528	chr1:113210534	A/C	cg22162597	chr1:113214053	CAPZA1	-0.65	-5.08	-0.46	1.91e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs13418717	1.000	rs13418717	chr2:127662897	A/T	cg25501666	chr2:127640322	NA	-1.49	-6.53	-0.56	3.21e-9	Heart failure;
THYM	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg26384229	chr12:38710491	ALG10B	1.05	10.43	0.73	1.96e-17	Heart rate;
THYM	cis	rs9807841	0.643	rs4435370	chr19:10774623	G/A	cg17848348	chr19:10766748	ILF3	-0.87	-7.74	-0.62	1.06e-11	Inflammatory skin disease;
THYM	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg09307838	chr4:120376055	NA	0.77	5.56	0.5	2.5e-7	Corneal astigmatism;
THYM	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg11461670	chr8:22454935	PDLIM2	-0.34	-6.23	-0.54	1.25e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3126085	0.935	rs6587651	chr1:152193121	G/T	cg26020982	chr1:152196106	HRNR	0.38	5.14	0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.01	-9.8	-0.71	4.35e-16	Primary sclerosing cholangitis;
THYM	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg10505658	chr17:80084571	CCDC57	-0.74	-8.13	-0.64	1.59e-12	Life satisfaction;
THYM	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg08999081	chr20:33150536	PIGU	0.73	6.56	0.56	2.86e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs7809615	0.901	rs11761528	chr7:99118801	C/T	cg12290671	chr7:99195819	NA	-0.99	-4.83	-0.44	5.27e-6	Blood metabolite ratios;
THYM	cis	rs4589258	0.898	rs1792593	chr11:90427629	T/A	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7833986	0.501	rs72651502	chr8:56875533	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.54	5.9	0.52	5.61e-8	Height;
THYM	cis	rs6956675	0.958	rs7779974	chr7:62576724	T/C	cg27518014	chr7:62859535	LOC100287834	0.65	5.05	0.46	2.15e-6	Obesity-related traits;
THYM	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg06027949	chr8:82754900	SNX16	-0.64	-5.35	-0.48	6.18e-7	Diastolic blood pressure;
THYM	cis	rs6754311	0.638	rs1011361	chr2:136553639	G/A	cg07169764	chr2:136633963	MCM6	-0.67	-5.91	-0.52	5.28e-8	Mosquito bite size;
THYM	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg11812906	chr14:75593930	NEK9	0.75	6.77	0.57	1.07e-9	Coronary artery disease;
THYM	cis	rs7772486	0.686	rs857882	chr6:145969716	T/G	cg23711669	chr6:146136114	FBXO30	-0.96	-10.03	-0.72	1.41e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28595532	0.925	rs10000445	chr4:119485311	C/T	cg11846333	chr4:119757529	SEC24D	1.37	4.91	0.45	3.85e-6	Cannabis dependence symptom count;
THYM	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg12560992	chr17:57184187	TRIM37	-0.91	-8.44	-0.65	3.49e-13	Intelligence (multi-trait analysis);
THYM	cis	rs12714314	0.830	rs12612812	chr2:1962131	A/C	cg05313794	chr2:1845466	MYT1L	-0.49	-4.46	-0.42	2.21e-5	Type 2 diabetes (age of onset);
THYM	cis	rs6570726	0.791	rs11155433	chr6:145907831	A/G	cg23711669	chr6:146136114	FBXO30	-0.95	-10.09	-0.72	1.07e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg23803603	chr1:2058230	PRKCZ	0.59	4.56	0.42	1.52e-5	Height;
THYM	cis	rs73086581	1.000	rs6052196	chr20:3945824	T/C	cg02187196	chr20:3869020	PANK2	0.5	5.62	0.5	1.92e-7	Response to antidepressants in depression;
THYM	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg15704280	chr7:45808275	SEPT13	1.0	7.71	0.62	1.23e-11	Coronary artery disease;
THYM	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg02782426	chr3:40428986	ENTPD3	0.53	4.66	0.43	1.04e-5	Renal cell carcinoma;
THYM	cis	rs3785574	1.000	rs3785574	chr17:61763185	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	10.19	0.72	6.4e-17	Height;
THYM	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg05025164	chr4:1340916	KIAA1530	0.91	7.1	0.59	2.21e-10	Longevity;
THYM	cis	rs6473252	0.966	rs10957986	chr8:81814779	C/T	cg08595989	chr8:81827712	NA	-0.41	-4.54	-0.42	1.65e-5	Breast cancer;
THYM	cis	rs7818345	0.595	rs58551730	chr8:19316627	T/A	cg01280390	chr8:19363452	CSGALNACT1	0.51	4.74	0.44	7.56e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs2734839	0.964	rs12363125	chr11:113285916	C/T	cg14159747	chr11:113255604	NA	0.31	6.32	0.54	8.63e-9	Information processing speed;
THYM	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg25208724	chr1:156163844	SLC25A44	0.94	9.47	0.7	2.21e-15	Testicular germ cell tumor;
THYM	cis	rs78579285	0.544	rs4782321	chr16:88780175	G/A	cg00973732	chr16:88803885	FAM38A	-0.88	-4.56	-0.42	1.51e-5	Joint mobility (Beighton score);
THYM	cis	rs548181	0.736	rs540436	chr11:125512619	A/G	cg03464685	chr11:125439445	EI24	1.21	7.39	0.6	5.67e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs17433780	0.523	rs6701673	chr1:89525812	C/G	cg09516651	chr1:89888402	LOC400759	1.02	10.26	0.72	4.66e-17	Carotid intima media thickness;
THYM	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg17264618	chr3:40429014	ENTPD3	0.54	5.31	0.48	7.33e-7	Renal cell carcinoma;
THYM	cis	rs28595532	0.920	rs17325017	chr4:119774607	A/G	cg21605333	chr4:119757512	SEC24D	1.67	6.17	0.53	1.69e-8	Cannabis dependence symptom count;
THYM	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg11764359	chr7:65958608	NA	0.63	4.92	0.45	3.66e-6	Aortic root size;
THYM	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.75	-5.87	-0.52	6.4e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4654899	0.758	rs1609558	chr1:21525228	C/T	cg01072550	chr1:21505969	NA	0.75	7.11	0.59	2.14e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs3806843	0.966	rs3806844	chr5:140206263	A/T	cg19875535	chr5:140030758	IK	0.58	4.47	0.42	2.16e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg01264106	chr22:38071602	LGALS1	0.37	4.7	0.43	8.94e-6	Fat distribution (HIV);
THYM	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg16049864	chr8:95962084	TP53INP1	0.79	6.06	0.53	2.68e-8	Type 2 diabetes;
THYM	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg14019146	chr3:50243930	SLC38A3	-0.55	-4.6	-0.43	1.3e-5	Body mass index;
THYM	cis	rs2834081	0.536	rs11702285	chr21:34474294	G/A	cg10915739	chr21:34405733	NA	0.51	5.11	0.46	1.63e-6	Sum eosinophil basophil counts;
THYM	cis	rs11711311	0.747	rs7638378	chr3:113343630	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.54	-4.49	-0.42	1.99e-5	IgG glycosylation;
THYM	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg06600287	chr1:53387719	ECHDC2	-0.35	-5.32	-0.48	6.82e-7	Monocyte count;
THYM	trans	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.12	7.82	0.63	7.17e-12	Exhaled nitric oxide output;
THYM	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs526231	0.615	rs26818	chr5:102529719	T/C	cg23492399	chr5:102201601	PAM	-0.71	-5.33	-0.48	6.54e-7	Primary biliary cholangitis;
THYM	cis	rs9543976	1.000	rs73223968	chr13:76141721	C/A	cg01531495	chr13:76123901	UCHL3	-0.75	-4.68	-0.43	9.4e-6	Diabetic retinopathy;
THYM	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg00012203	chr2:219082015	ARPC2	0.69	5.87	0.52	6.36e-8	Colorectal cancer;
THYM	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg20290983	chr6:43655470	MRPS18A	-1.18	-7.85	-0.63	6.13e-12	IgG glycosylation;
THYM	cis	rs4363385	0.818	rs4284210	chr1:152985711	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.76	-0.44	6.94e-6	Inflammatory skin disease;
THYM	cis	rs2354432	0.607	rs59689207	chr1:146722484	G/A	cg25205988	chr1:146714368	CHD1L	-1.04	-5.54	-0.49	2.67e-7	Mitochondrial DNA levels;
THYM	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg08847533	chr14:75593920	NEK9	-0.99	-10.52	-0.73	1.27e-17	Height;
THYM	cis	rs877282	1.000	rs11253367	chr10:773389	G/A	cg10556349	chr10:835070	NA	-0.75	-5.17	-0.47	1.31e-6	Uric acid levels;
THYM	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg18132916	chr6:79620363	NA	-0.62	-5.33	-0.48	6.59e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7588746	0.571	rs4673891	chr2:201156362	C/G	cg23649088	chr2:200775458	C2orf69	-0.68	-4.65	-0.43	1.08e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg08736216	chr1:53307985	ZYG11A	-0.58	-5.29	-0.48	7.85e-7	Monocyte count;
THYM	cis	rs13102973	0.863	rs13103492	chr4:135907685	A/C	cg14419869	chr4:135874104	NA	0.82	6.86	0.58	7.03e-10	Subjective well-being;
THYM	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg10589385	chr1:150898437	SETDB1	-0.64	-5.26	-0.48	8.81e-7	Melanoma;
THYM	cis	rs500891	0.525	rs1170484	chr6:84038522	A/G	cg08257003	chr6:84140564	ME1	0.56	4.47	0.42	2.19e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs335206	1.000	rs335205	chr5:122504682	A/C	cg16368670	chr5:122501738	PRDM6	-0.56	-4.55	-0.42	1.56e-5	QRS duration;
THYM	cis	rs9462846	0.725	rs9471969	chr6:42906384	G/T	cg21280719	chr6:42927975	GNMT	-0.49	-5.21	-0.47	1.08e-6	Blood protein levels;
THYM	cis	rs12280210	0.557	rs7112937	chr11:116880456	T/C	cg20608306	chr11:116969690	SIK3	-0.71	-5.22	-0.47	1.04e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4654899	0.865	rs10916910	chr1:21283192	G/T	cg01072550	chr1:21505969	NA	-0.75	-6.6	-0.56	2.29e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs9902453	0.808	rs10445400	chr17:28183059	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	4.82	0.44	5.44e-6	Coffee consumption (cups per day);
THYM	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg13695892	chr22:41940480	POLR3H	0.89	6.37	0.55	6.58e-9	Cannabis dependence symptom count;
THYM	cis	rs13006833	0.668	rs291447	chr2:191177005	A/C	cg27211696	chr2:191398769	TMEM194B	0.56	4.47	0.42	2.19e-5	Urinary metabolites;
THYM	cis	rs71403859	0.502	rs35394108	chr16:71540639	T/C	cg08717414	chr16:71523259	ZNF19	-1.42	-7.35	-0.6	6.98e-11	Post bronchodilator FEV1;
THYM	cis	rs960902	0.592	rs10865125	chr2:37737883	T/G	cg25341268	chr2:37734390	NA	-0.7	-6.49	-0.55	3.92e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs4474465	1.000	rs4944200	chr11:78166930	C/A	cg02023728	chr11:77925099	USP35	0.52	4.54	0.42	1.67e-5	Alzheimer's disease (survival time);
THYM	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg19774624	chr17:42201019	HDAC5	-0.75	-6.6	-0.56	2.38e-9	Total body bone mineral density;
THYM	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg20486651	chr6:167070296	RPS6KA2	-0.48	-4.79	-0.44	6.1e-6	Crohn's disease;
THYM	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg08885076	chr2:99613938	TSGA10	-0.57	-5.63	-0.5	1.81e-7	Chronic sinus infection;
THYM	cis	rs6429082	0.521	rs291390	chr1:235649678	T/C	cg26050004	chr1:235667680	B3GALNT2	0.91	8.53	0.66	2.22e-13	Adiposity;
THYM	cis	rs4803468	1.000	rs2241709	chr19:41912250	C/T	cg09537434	chr19:41945824	ATP5SL	-1.15	-11.44	-0.76	1.44e-19	Height;
THYM	cis	rs61931739	0.559	rs4385974	chr12:34313128	G/C	cg10856724	chr12:34555212	NA	-0.62	-5.55	-0.49	2.62e-7	Morning vs. evening chronotype;
THYM	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.97	-7.62	-0.62	1.88e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg04362960	chr10:104952993	NT5C2	0.6	5.11	0.46	1.66e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg13695892	chr22:41940480	POLR3H	-0.97	-7.51	-0.61	3.25e-11	Vitiligo;
THYM	cis	rs2273669	0.667	rs2356575	chr6:109367255	T/C	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.71	6.36	0.55	6.89e-9	Personality dimensions;
THYM	cis	rs1497406	0.744	rs4537547	chr1:16510798	C/T	cg20430773	chr1:16534157	ARHGEF19	-0.5	-5.47	-0.49	3.67e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg24675056	chr1:15929824	NA	0.74	5.93	0.52	4.95e-8	Systolic blood pressure;
THYM	cis	rs4951018	0.526	rs6693913	chr1:205654061	G/C	cg14159672	chr1:205819179	PM20D1	-0.64	-5.07	-0.46	1.96e-6	Prostate-specific antigen levels;
THYM	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.29e-7	Corneal astigmatism;
THYM	cis	rs56161922	1.000	rs56161922	chr1:207809833	G/A	cg09557387	chr1:207818395	CR1L	1.15	5.29	0.48	7.69e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.37	-0.48	5.56e-7	Mean corpuscular volume;
THYM	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg24672777	chr11:48374446	OR4C45	0.66	4.59	0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs939574	0.818	rs6744146	chr2:220070597	T/A	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.2	-5.46	-0.49	3.84e-7	Platelet distribution width;
THYM	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg22105103	chr4:187893119	NA	0.92	10.09	0.72	1.04e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg06636001	chr8:8085503	FLJ10661	0.78	6.8	0.57	9.2e-10	Red cell distribution width;
THYM	cis	rs3204270	0.759	rs8066217	chr17:79672615	C/G	cg09996840	chr17:79680718	SLC25A10	-0.59	-4.46	-0.42	2.24e-5	Dental caries;
THYM	cis	rs10782582	0.593	rs11163915	chr1:76130199	C/T	cg22875332	chr1:76189707	ACADM	-0.54	-5.07	-0.46	1.96e-6	Daytime sleep phenotypes;
THYM	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg03676636	chr4:99064102	C4orf37	0.5	7.59	0.61	2.14e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7843479	0.601	rs3824338	chr8:21864540	A/C	cg17168535	chr8:21777572	XPO7	0.78	6.76	0.57	1.1e-9	Mean corpuscular volume;
THYM	cis	rs6429082	0.783	rs291385	chr1:235646613	T/C	cg26050004	chr1:235667680	B3GALNT2	0.74	6.18	0.54	1.6e-8	Adiposity;
THYM	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg07599136	chr5:415885	AHRR	1.05	6.03	0.53	3.18e-8	Fat distribution (HIV);
THYM	cis	rs7264396	0.790	rs6060519	chr20:34217383	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-5.66	-0.5	1.58e-7	Total cholesterol levels;
THYM	cis	rs7546094	1.000	rs2932536	chr1:113202417	G/A	cg22162597	chr1:113214053	CAPZA1	-0.48	-4.9	-0.45	3.87e-6	Platelet distribution width;
THYM	cis	rs12216545	0.765	rs2373809	chr7:150249465	A/C	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.79	6.97	0.58	4.11e-10	Tonsillectomy;
THYM	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg23131131	chr22:24373011	LOC391322	-0.7	-6.45	-0.55	4.69e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg26384229	chr12:38710491	ALG10B	-0.75	-5.99	-0.52	3.8e-8	Morning vs. evening chronotype;
THYM	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg01119278	chr6:110721349	DDO	-0.55	-6.31	-0.54	8.81e-9	Platelet distribution width;
THYM	cis	rs1065656	0.581	rs344353	chr16:1846636	C/G	cg14074117	chr16:1909714	C16orf73	0.64	4.78	0.44	6.32e-6	Insulin-like growth factors;
THYM	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg17747265	chr1:1875780	NA	-0.8	-9.28	-0.69	5.65e-15	Body mass index;
THYM	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs6138458	1.000	rs227629	chr20:24913551	G/T	cg26195577	chr20:24973756	C20orf3	1.11	10.52	0.73	1.29e-17	Blood protein levels;
THYM	cis	rs8067545	1.000	rs8071730	chr17:19932731	C/T	cg20830565	chr17:20408647	MGC102966	-0.51	-4.68	-0.43	9.51e-6	Schizophrenia;
THYM	trans	rs10962692	0.530	rs10962656	chr9:16877788	G/A	cg03221025	chr16:88955224	CBFA2T3	0.74	7.08	0.59	2.43e-10	Ovarian cancer in BRCA2 mutation carriers;Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;
THYM	cis	rs12310956	0.510	rs7302434	chr12:33886819	G/A	cg10856724	chr12:34555212	NA	-0.65	-5.89	-0.52	5.95e-8	Morning vs. evening chronotype;
THYM	cis	rs1639906	0.893	rs13233298	chr7:2227707	C/T	cg19897017	chr7:2163380	MAD1L1	0.5	4.53	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs6496667	0.779	rs7175440	chr15:90949403	C/T	cg22089800	chr15:90895588	ZNF774	0.74	4.78	0.44	6.28e-6	Rheumatoid arthritis;
THYM	cis	rs4731207	0.561	rs6975148	chr7:124686508	A/G	cg05285228	chr7:124571219	POT1	-0.65	-5.0	-0.46	2.64e-6	Cutaneous malignant melanoma;
THYM	cis	rs11096990	0.819	rs4974991	chr4:39194767	T/A	cg24403649	chr4:39172243	NA	-0.62	-5.17	-0.47	1.31e-6	Cognitive function;
THYM	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg07570687	chr10:102243282	WNT8B	0.76	6.94	0.58	4.69e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs17401966	1.000	rs11121552	chr1:10435324	C/A	cg19773385	chr1:10388646	KIF1B	-0.64	-4.63	-0.43	1.16e-5	Hepatocellular carcinoma;
THYM	cis	rs7586879	0.616	rs6545813	chr2:25131287	C/T	cg15423357	chr2:25149977	NA	0.7	7.76	0.62	9.56e-12	Body mass index;
THYM	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.68	-4.87	-0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs7152530	0.571	rs17096600	chr14:98638244	T/C	cg05180522	chr14:98101740	NA	-0.59	-4.7	-0.43	8.79e-6	Staphylococcus aureus infection;
THYM	cis	rs1550582	1.000	rs76091740	chr8:135514419	C/T	cg17885191	chr8:135476712	NA	0.75	4.8	0.44	5.81e-6	Educational attainment;
THYM	cis	rs7107174	1.000	rs2244508	chr11:77948515	T/A	cg19901956	chr11:77921274	USP35	-0.81	-6.12	-0.53	2.05e-8	Testicular germ cell tumor;
THYM	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6761276	0.674	rs3811056	chr2:113831183	T/C	cg12858261	chr2:113808755	IL1F8	0.54	4.47	0.42	2.16e-5	Protein quantitative trait loci;
THYM	cis	rs2034088	0.931	rs7217763	chr17:421437	A/G	cg06217071	chr17:408420	NA	0.76	7.66	0.62	1.58e-11	Hip circumference adjusted for BMI;
THYM	cis	rs2898681	0.581	rs730247	chr4:53680696	T/G	cg21521518	chr4:53727714	RASL11B	0.47	5.33	0.48	6.52e-7	Optic nerve measurement (cup area);
THYM	cis	rs35164067	1.000	rs11085730	chr19:10497976	G/A	cg01466491	chr19:10523363	NA	-0.63	-4.57	-0.42	1.48e-5	Inflammatory bowel disease;
THYM	cis	rs58530613	0.792	rs77173582	chr4:124756520	C/T	cg11268546	chr4:124983615	NA	0.76	4.61	0.43	1.26e-5	Platelet count;
THYM	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	9.56	0.7	1.47e-15	Platelet count;
THYM	cis	rs1568889	1.000	rs11604085	chr11:28141002	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.66e-6	Bipolar disorder;
THYM	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg06636001	chr8:8085503	FLJ10661	-0.63	-5.36	-0.48	5.76e-7	Joint mobility (Beighton score);
THYM	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.59	4.5	0.42	1.91e-5	Tonsillectomy;
THYM	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	trans	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.12	-13.73	-0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4769475	1.000	rs7320397	chr13:26730629	G/A	cg13319468	chr13:27597730	NA	-0.6	-4.65	-0.43	1.06e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	6.3	0.54	9.15e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg23173402	chr1:227635558	NA	0.82	6.42	0.55	5.47e-9	Major depressive disorder;
THYM	cis	rs9543976	0.614	rs9573577	chr13:76103789	C/T	cg01531495	chr13:76123901	UCHL3	-0.87	-4.75	-0.44	7.21e-6	Diabetic retinopathy;
THYM	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.81	-4.97	-0.45	2.91e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs6570726	0.791	rs405206	chr6:145836873	C/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.44	-0.49	4.16e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg24375607	chr4:120327624	NA	0.59	4.68	0.43	9.43e-6	Corneal astigmatism;
THYM	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg10523679	chr1:76189770	ACADM	-0.84	-6.64	-0.56	1.96e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4731207	0.596	rs4406330	chr7:124641491	T/C	cg05285228	chr7:124571219	POT1	-0.71	-5.45	-0.49	3.91e-7	Cutaneous malignant melanoma;
THYM	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg06808227	chr14:105710500	BRF1	-1.08	-9.65	-0.7	9.45e-16	Mean platelet volume;Platelet distribution width;
THYM	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg09060608	chr5:178986726	RUFY1	0.59	6.66	0.56	1.79e-9	Lung cancer;
THYM	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg19748678	chr4:122722346	EXOSC9	0.75	5.39	0.48	5.03e-7	Type 2 diabetes;
THYM	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg24955955	chr5:415729	AHRR	1.02	5.69	0.5	1.39e-7	Fat distribution (HIV);
THYM	cis	rs6992848	0.791	rs11166957	chr8:141177468	G/A	cg22504031	chr8:141147661	TRAPPC9	0.61	4.69	0.43	9.21e-6	Response to amphetamines;
THYM	cis	rs2241210	0.550	rs7486178	chr12:109980266	G/A	cg08884029	chr12:110012500	MVK;MMAB	-0.58	-4.56	-0.42	1.52e-5	HDL cholesterol levels;
THYM	cis	rs6746082	0.570	rs61671081	chr2:25761103	A/C	cg23192403	chr2:25781496	DTNB	-0.44	-6.01	-0.52	3.38e-8	Multiple myeloma;
THYM	cis	rs240110	0.548	rs12190574	chr6:101173842	T/G	cg21058520	chr6:100914733	NA	0.6	5.26	0.47	8.93e-7	Neuroticism;
THYM	cis	rs742614	0.533	rs2747536	chr20:32404128	C/G	cg06304546	chr20:32448765	NA	-0.92	-9.43	-0.7	2.71e-15	Stearic acid (18:0) levels;
THYM	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg08773314	chr2:239334832	ASB1	0.65	9.86	0.71	3.36e-16	Multiple system atrophy;
THYM	cis	rs600806	0.850	rs4970752	chr1:109930852	C/T	cg23616212	chr1:109941201	SORT1	-0.5	-4.65	-0.43	1.06e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3741151	1.000	rs3741151	chr11:73020846	G/T	cg12959048	chr11:73096162	RELT	-0.5	-4.78	-0.44	6.38e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg20744362	chr22:50050164	C22orf34	0.77	6.97	0.58	4.25e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs35849525	0.776	rs7615318	chr3:49987475	C/T	cg14019146	chr3:50243930	SLC38A3	-0.59	-4.56	-0.42	1.55e-5	Intelligence (multi-trait analysis);
THYM	cis	rs11997175	1.000	rs6468203	chr8:33749572	T/A	ch.8.33884649F	chr8:33765107	NA	0.64	4.97	0.45	2.93e-6	Body mass index;
THYM	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg17509989	chr5:176798049	RGS14	-0.69	-6.23	-0.54	1.29e-8	Urate levels in lean individuals;
THYM	cis	rs4363385	0.553	rs41263664	chr1:152974063	G/A	cg13444842	chr1:152974279	SPRR3	-0.64	-4.86	-0.45	4.7e-6	Inflammatory skin disease;
THYM	cis	rs4866334	0.867	rs76734676	chr5:18487735	G/T	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg15921436	chr17:44337874	NA	-0.91	-6.85	-0.58	7.19e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg02820040	chr2:241836501	C2orf54	0.3	5.66	0.5	1.58e-7	Urinary metabolites;
THYM	cis	rs4589258	0.788	rs2097169	chr11:90479424	G/T	cg26138821	chr11:89956704	CHORDC1	-0.58	-4.66	-0.43	1.05e-5	Intelligence (multi-trait analysis);
THYM	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg22590775	chr19:49891494	CCDC155	0.81	6.74	0.57	1.22e-9	Multiple sclerosis;
THYM	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg01069141	chr11:67398826	TBX10;NUDT8	-0.47	-5.04	-0.46	2.2e-6	Mean corpuscular volume;
THYM	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg18305652	chr10:134549665	INPP5A	0.85	7.89	0.63	5.01e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs13256369	1.000	rs4841016	chr8:8572561	C/T	cg18904891	chr8:8559673	CLDN23	0.68	5.08	0.46	1.89e-6	Obesity-related traits;
THYM	cis	rs1670533	1.000	rs2014318	chr4:1068778	C/T	cg27284194	chr4:1044797	NA	-0.61	-4.6	-0.43	1.29e-5	Recombination rate (females);
THYM	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03517284	chr6:25882590	NA	-1.01	-8.88	-0.67	4.05e-14	Intelligence (multi-trait analysis);
THYM	cis	rs10982256	0.782	rs1324631	chr9:117254731	G/C	cg15903421	chr9:117267460	DFNB31	-0.56	-5.43	-0.49	4.39e-7	Bipolar disorder;
THYM	cis	rs7107770	1.000	rs67012209	chr11:125106395	G/A	cg07747661	chr11:125106135	PKNOX2	-0.91	-5.2	-0.47	1.16e-6	Photic sneeze reflex;
THYM	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.32	-9.88	-0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs7937890	0.874	rs6486191	chr11:14403739	G/A	cg19336497	chr11:14380999	RRAS2	-0.5	-5.39	-0.48	5.07e-7	Mitochondrial DNA levels;
THYM	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.71	5.46	0.49	3.74e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg24578937	chr1:2090814	PRKCZ	-0.79	-8.56	-0.66	1.95e-13	Height;
THYM	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg21138405	chr5:131827807	IRF1	-0.84	-9.6	-0.7	1.21e-15	Asthma (sex interaction);
THYM	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.46	0.42	2.26e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg17757837	chr7:157058334	UBE3C	0.64	5.09	0.46	1.79e-6	Body mass index;
THYM	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg15451548	chr1:2144873	NA	-0.47	-4.61	-0.43	1.26e-5	Height;
THYM	cis	rs7084402	0.967	rs1658447	chr10:60313174	G/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg26384229	chr12:38710491	ALG10B	1.05	10.43	0.73	1.96e-17	Heart rate;
THYM	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg00898013	chr13:113819073	PROZ	-1.03	-10.22	-0.72	5.73e-17	Platelet distribution width;
THYM	cis	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg09307838	chr4:120376055	NA	0.78	5.89	0.52	5.7e-8	Corneal astigmatism;
THYM	cis	rs4606347	0.789	rs79471423	chr1:66165565	G/T	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg03760483	chr17:6899297	ALOX12	0.7	9.53	0.7	1.65e-15	Tonsillectomy;
THYM	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg12935359	chr14:103987150	CKB	-0.65	-6.4	-0.55	5.78e-9	Body mass index;
THYM	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg02753203	chr1:228287806	NA	-0.61	-5.28	-0.48	8.19e-7	Diastolic blood pressure;
THYM	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg07636037	chr3:49044803	WDR6	0.96	9.89	0.71	2.83e-16	Parkinson's disease;
THYM	cis	rs112591243	0.655	rs7510435	chr21:48059798	G/A	cg26904215	chr21:47823096	PCNT	-1.0	-4.6	-0.43	1.3e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	10.29	0.73	4e-17	Chronic sinus infection;
THYM	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg13683864	chr3:40499215	RPL14	-0.91	-8.79	-0.67	6.47e-14	Renal cell carcinoma;
THYM	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6032067	0.641	rs34602589	chr20:43768734	T/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.73	-7.71	-0.62	1.23e-11	Blood protein levels;
THYM	cis	rs9814567	0.806	rs6806810	chr3:134323522	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.09e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs700651	0.821	rs771005	chr2:198675948	C/T	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Intracranial aneurysm;
THYM	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs9435341	0.965	rs61798468	chr1:107569316	T/G	cg00944433	chr1:107599041	PRMT6	-0.42	-4.96	-0.45	3.08e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs72781680	1.000	rs115861480	chr2:24129464	T/A	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs7107174	0.892	rs11237477	chr11:78095069	A/T	cg19901956	chr11:77921274	USP35	-0.65	-5.34	-0.48	6.41e-7	Testicular germ cell tumor;
THYM	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.75e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg24257776	chr3:47051546	LOC100129354	0.38	4.51	0.42	1.85e-5	Colorectal cancer;
THYM	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg02478829	chr6:26598070	ABT1	-0.33	-4.46	-0.42	2.27e-5	Intelligence (multi-trait analysis);
THYM	cis	rs870825	0.860	rs72703526	chr4:185605676	A/T	cg04058563	chr4:185651563	MLF1IP	1.0	7.42	0.61	4.93e-11	Blood protein levels;
THYM	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg08213375	chr14:104286397	PPP1R13B	0.43	5.28	0.48	8.03e-7	Schizophrenia;
THYM	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg20887711	chr4:1340912	KIAA1530	0.62	4.73	0.44	7.79e-6	Obesity-related traits;
THYM	cis	rs8192282	0.739	rs6697115	chr1:154499947	C/T	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg20887711	chr4:1340912	KIAA1530	0.69	6.2	0.54	1.43e-8	Longevity;
THYM	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg00944433	chr1:107599041	PRMT6	-0.38	-4.58	-0.43	1.39e-5	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs9486719	0.857	rs1157316	chr6:96869710	G/A	cg18709589	chr6:96969512	KIAA0776	0.68	4.66	0.43	1.04e-5	Migraine;Coronary artery disease;
THYM	cis	rs4713118	0.869	rs6902689	chr6:27709441	C/T	cg08968635	chr6:28129556	ZNF389	0.62	4.59	0.43	1.37e-5	Parkinson's disease;
THYM	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg20486651	chr6:167070296	RPS6KA2	0.5	4.76	0.44	7.01e-6	Crohn's disease;
THYM	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg03388025	chr16:89894329	SPIRE2	0.56	4.9	0.45	3.93e-6	Vitiligo;
THYM	cis	rs2456568	0.802	rs7101791	chr11:93638998	A/G	cg17347335	chr11:93583973	C11orf90	-0.48	-4.58	-0.43	1.39e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.58	4.97	0.45	2.98e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg26721908	chr21:47610096	LSS	0.75	5.43	0.49	4.35e-7	Testicular germ cell tumor;
THYM	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.55	0.49	2.56e-7	Tonsillectomy;
THYM	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-6.56	-0.56	2.84e-9	Colorectal cancer;
THYM	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06850241	chr22:41845214	NA	0.59	5.16	0.47	1.37e-6	Vitiligo;
THYM	trans	rs2270927	0.510	rs35966882	chr5:75577716	A/G	cg13563193	chr19:33072644	PDCD5	1.51	6.84	0.57	7.67e-10	Mean corpuscular volume;
THYM	cis	rs6087771	0.781	rs6089067	chr20:30358894	G/C	cg13852791	chr20:30311386	BCL2L1	0.89	8.22	0.64	1.01e-12	Subcortical brain region volumes;Putamen volume;
THYM	cis	rs713587	0.624	rs1550110	chr2:25124563	T/C	cg27107076	chr2:25050844	ADCY3	-0.29	-4.64	-0.43	1.1e-5	Body mass index in non-asthmatics;
THYM	cis	rs4242434	0.672	rs7830206	chr8:22485375	C/T	cg03733263	chr8:22462867	KIAA1967	1.03	9.86	0.71	3.36e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs870825	0.616	rs4437295	chr4:185643336	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg27129171	chr3:47204927	SETD2	-0.78	-7.49	-0.61	3.57e-11	Colorectal cancer;
THYM	cis	rs2404602	0.684	rs28895952	chr15:76856776	A/G	cg23625390	chr15:77176239	SCAPER	-0.9	-6.37	-0.55	6.74e-9	Blood metabolite levels;
THYM	trans	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11089937	0.857	rs5750578	chr22:22490837	A/G	cg21401457	chr22:22472743	NA	0.63	5.46	0.49	3.82e-7	Periodontitis (PAL4Q3);
THYM	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg01528321	chr10:82214614	TSPAN14	0.66	5.16	0.47	1.35e-6	Post bronchodilator FEV1;
THYM	cis	rs9902453	1.000	rs62070270	chr17:28263980	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	5.03	0.46	2.27e-6	Coffee consumption (cups per day);
THYM	cis	rs7246657	0.943	rs1015848	chr19:37945274	A/C	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg10856724	chr12:34555212	NA	-1.02	-9.32	-0.69	4.7e-15	Morning vs. evening chronotype;
THYM	trans	rs4749080	0.607	rs2000255	chr10:26467070	G/A	cg00192819	chr18:76486611	NA	1.01	7.06	0.59	2.68e-10	Obesity-related traits;
THYM	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg14820908	chr5:178986412	RUFY1	0.67	7.4	0.6	5.5e-11	Lung cancer;
THYM	cis	rs7909074	0.831	rs7903412	chr10:45382361	C/T	cg04218760	chr10:45406644	TMEM72	-0.63	-5.63	-0.5	1.86e-7	Mean corpuscular volume;
THYM	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg23711669	chr6:146136114	FBXO30	0.9	8.82	0.67	5.37e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg06064525	chr11:970664	AP2A2	-0.38	-7.42	-0.61	4.81e-11	Alzheimer's disease (late onset);
THYM	cis	rs6759004	1	rs6759004	chr2:202004676	C/T	cg08474651	chr2:201729683	CLK1	0.36	4.55	0.42	1.58e-5	Triptolide cytotoxicity;
THYM	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg13175981	chr1:150552382	MCL1	0.7	4.99	0.46	2.72e-6	Tonsillectomy;
THYM	cis	rs8028313	0.731	rs6494678	chr15:67946247	C/T	cg24579218	chr15:68104479	NA	-0.68	-6.32	-0.54	8.31e-9	Obesity;
THYM	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs1863824	0.502	rs11202058	chr10:88282611	G/A	cg06895675	chr10:88137553	NA	0.55	4.78	0.44	6.49e-6	Schizophrenia;
THYM	cis	rs9527	0.590	rs12415199	chr10:104895536	T/C	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg23583168	chr7:148888333	NA	-1.02	-14.09	-0.82	5.29e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg04317338	chr11:64019027	PLCB3	0.87	6.09	0.53	2.33e-8	Mean platelet volume;
THYM	cis	rs3126085	0.935	rs12760382	chr1:152260287	G/T	cg10321714	chr1:152280068	FLG	-0.7	-5.11	-0.46	1.67e-6	Atopic dermatitis;
THYM	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs986417	0.792	rs4901990	chr14:61015474	C/T	cg27398547	chr14:60952738	C14orf39	-1.18	-5.7	-0.5	1.33e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs7551222	0.752	rs4951400	chr1:204534571	C/G	cg20240347	chr1:204465584	NA	-0.54	-4.91	-0.45	3.81e-6	Schizophrenia;
THYM	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs924712	0.844	rs1472679	chr6:54735122	C/T	cg19716238	chr6:54711378	FAM83B	0.45	4.6	0.43	1.29e-5	Breast cancer;
THYM	cis	rs3760047	0.609	rs2541639	chr16:205035	C/T	cg25425005	chr16:202905	HBZ	-0.77	-5.78	-0.51	9.51e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs113835537	0.529	rs11227511	chr11:66281244	A/C	cg24851651	chr11:66362959	CCS	0.7	4.77	0.44	6.72e-6	Airway imaging phenotypes;
THYM	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg24308560	chr3:49941425	MST1R	0.63	4.78	0.44	6.37e-6	Body mass index;
THYM	cis	rs990171	0.913	rs2241117	chr2:103003043	T/C	cg13897122	chr2:103039542	IL18RAP	-0.39	-4.79	-0.44	6.08e-6	Lymphocyte counts;
THYM	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.88	9.94	0.71	2.24e-16	Prudent dietary pattern;
THYM	cis	rs7523273	0.925	rs12132780	chr1:207999605	C/T	cg22525895	chr1:207977042	MIR29B2	-0.83	-7.9	-0.63	4.95e-12	Schizophrenia;
THYM	cis	rs7000551	0.715	rs2469745	chr8:22343464	C/T	cg12081754	chr8:22256438	SLC39A14	0.62	5.38	0.48	5.3e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs6987853	0.563	rs2923408	chr8:42451526	A/G	cg09913449	chr8:42400586	C8orf40	0.62	5.57	0.5	2.39e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11089937	0.857	rs5750580	chr22:22491864	A/T	cg06866756	chr22:22471216	NA	-0.4	-4.46	-0.42	2.22e-5	Periodontitis (PAL4Q3);
THYM	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.72	6.79	0.57	9.58e-10	Lymphocyte counts;
THYM	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg01699819	chr7:1052092	C7orf50	-0.87	-7.92	-0.63	4.5e-12	Bronchopulmonary dysplasia;
THYM	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg12963246	chr6:28129442	ZNF389	0.72	6.12	0.53	2.05e-8	Depression;
THYM	cis	rs57920188	0.535	rs58051771	chr1:4092146	T/C	cg08764037	chr1:3634867	TP73	-0.44	-4.68	-0.43	9.63e-6	Interleukin-17 levels;
THYM	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg23187316	chr7:1099788	C7orf50	0.59	4.52	0.42	1.76e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg02527881	chr3:46936655	PTH1R	-0.69	-7.14	-0.59	1.9e-10	Colorectal cancer;
THYM	cis	rs939574	1.000	rs45488900	chr2:220116509	G/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.32	5.96	0.52	4.29e-8	Platelet distribution width;
THYM	cis	rs9302635	0.513	rs8044555	chr16:72152755	T/C	cg23815491	chr16:72088622	HP	0.77	5.95	0.52	4.37e-8	Blood protein levels;
THYM	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.03	10.73	0.74	4.6e-18	Cognitive ability;
THYM	cis	rs4280164	0.551	rs3212243	chr14:24810370	T/C	cg18846074	chr14:24801073	ADCY4	-0.56	-4.53	-0.42	1.71e-5	Parent of origin effect on language impairment (paternal);
THYM	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.47	-0.49	3.59e-7	Mean corpuscular volume;
THYM	cis	rs2276314	0.857	rs28791905	chr18:33602213	G/A	cg05985134	chr18:33552581	C18orf21	0.67	4.98	0.45	2.88e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs9486719	0.948	rs11152970	chr6:96909077	A/G	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg17127132	chr2:85788382	GGCX	0.66	5.41	0.49	4.75e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs11048434	0.736	rs7957321	chr12:9120154	C/T	cg13575925	chr12:9217583	LOC144571	0.53	4.94	0.45	3.31e-6	Sjögren's syndrome;
THYM	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs9814567	0.929	rs9838834	chr3:134207077	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-8.12	-0.64	1.71e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2139634	0.965	rs60986461	chr3:46548046	C/T	cg02332537	chr3:46540019	RTP3	0.48	4.9	0.45	3.89e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-4.88	-0.45	4.26e-6	Hemoglobin concentration;
THYM	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs4919694	1.000	rs7083328	chr10:104769268	G/A	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg01699819	chr7:1052092	C7orf50	-0.84	-7.05	-0.59	2.91e-10	Bronchopulmonary dysplasia;
THYM	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg10518543	chr12:38710700	ALG10B	-0.59	-4.67	-0.43	9.89e-6	Bladder cancer;
THYM	cis	rs11190604	0.767	rs10883489	chr10:102194532	T/C	cg07570687	chr10:102243282	WNT8B	0.85	8.46	0.66	3.16e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs12711979	0.692	rs6751947	chr2:3820739	G/A	cg17052675	chr2:3827356	NA	-0.48	-5.19	-0.47	1.19e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg21773646	chr17:80085082	CCDC57	0.31	4.49	0.42	2.02e-5	Life satisfaction;
THYM	cis	rs868036	0.756	rs2241421	chr15:68082825	G/A	cg24579218	chr15:68104479	NA	-0.65	-6.51	-0.56	3.59e-9	Restless legs syndrome;
THYM	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg12311346	chr5:56204834	C5orf35	-0.81	-5.9	-0.52	5.54e-8	Initial pursuit acceleration;
THYM	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg20007245	chr22:24372913	LOC391322	-0.76	-7.76	-0.62	9.61e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg24874828	chr4:187887005	NA	-0.76	-8.24	-0.65	9.29e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg19442545	chr10:75533431	FUT11	-0.66	-7.01	-0.58	3.4e-10	Inflammatory bowel disease;
THYM	cis	rs886126	0.950	rs2078851	chr12:111690579	C/T	cg10833066	chr12:111807467	FAM109A	-0.48	-5.93	-0.52	4.87e-8	Coronary heart disease;
THYM	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg08645402	chr16:4508243	NA	-0.77	-6.45	-0.55	4.62e-9	Schizophrenia;
THYM	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg10523679	chr1:76189770	ACADM	0.9	9.47	0.7	2.2e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg10802521	chr3:52805072	NEK4	-0.71	-5.96	-0.52	4.22e-8	Bipolar disorder;
THYM	cis	rs7607369	0.791	rs12468043	chr2:219354197	C/A	cg02176678	chr2:219576539	TTLL4	0.73	7.09	0.59	2.4e-10	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs8006682	0.541	rs10483815	chr14:69088991	A/T	cg02299497	chr14:69095570	NA	0.59	4.53	0.42	1.72e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs28595532	0.920	rs116047800	chr4:119773569	G/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs1788820	0.917	rs1788819	chr18:21100504	G/A	cg14672496	chr18:21087552	C18orf8	0.77	6.12	0.53	2.09e-8	Body mass index;
THYM	cis	rs4474465	0.850	rs7117513	chr11:78206418	T/G	cg19901956	chr11:77921274	USP35	0.65	4.8	0.44	5.97e-6	Alzheimer's disease (survival time);
THYM	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9361491	0.608	rs7767636	chr6:79446056	G/A	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs115683389	chr4:119735557	T/G	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs6430585	0.528	rs78274583	chr2:136734569	C/T	cg07169764	chr2:136633963	MCM6	1.19	11.38	0.76	1.91e-19	Corneal structure;
THYM	cis	rs9807989	0.507	rs4851004	chr2:103009537	A/G	cg03938978	chr2:103052716	IL18RAP	-0.75	-9.6	-0.7	1.17e-15	Asthma;
THYM	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg22189786	chr22:42395067	WBP2NL	0.52	5.22	0.47	1.04e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg10253484	chr15:75165896	SCAMP2	-0.66	-4.54	-0.42	1.64e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs7119	0.717	rs12902896	chr15:77809150	G/T	cg10437265	chr15:77819839	NA	-0.79	-8.2	-0.64	1.12e-12	Type 2 diabetes;
THYM	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg17063962	chr7:91808500	NA	1.04	8.5	0.66	2.58e-13	Breast cancer;
THYM	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg24818145	chr4:99064322	C4orf37	0.74	5.93	0.52	4.8e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7580658	0.963	rs867304	chr2:128078488	G/A	cg10021288	chr2:128175891	PROC	-0.78	-6.82	-0.57	8.26e-10	Protein C levels;
THYM	cis	rs2985684	0.947	rs1952013	chr14:50087357	C/G	cg02151108	chr14:50098012	C14orf104	-0.68	-5.42	-0.49	4.54e-7	Carotid intima media thickness;
THYM	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg25811766	chr13:21894605	NA	-0.77	-4.99	-0.46	2.77e-6	White matter hyperintensity burden;
THYM	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg25703541	chr22:24373054	LOC391322	0.9	11.69	0.77	4.37e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9296092	0.560	rs3846853	chr6:33528194	C/G	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs13232179	1.000	rs12672761	chr7:151118604	C/G	cg05714773	chr7:150493706	TMEM176B	-0.66	-4.66	-0.43	1.02e-5	Coronary heart disease;
THYM	cis	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg08133631	chr1:26527909	CATSPER4	-0.59	-4.94	-0.45	3.38e-6	Obesity-related traits;
THYM	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg26441486	chr22:50317300	CRELD2	0.43	6.57	0.56	2.71e-9	Schizophrenia;
THYM	cis	rs7975161	0.630	rs4129598	chr12:104620638	T/C	cg25273343	chr12:104657179	TXNRD1	-0.78	-5.35	-0.48	6.15e-7	Toenail selenium levels;
THYM	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg11247378	chr22:39784982	NA	-1.06	-10.14	-0.72	8.24e-17	Post bronchodilator FEV1;
THYM	trans	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs9326248	0.539	rs518181	chr11:116772787	C/A	cg20608306	chr11:116969690	SIK3	0.57	6.55	0.56	2.91e-9	Blood protein levels;
THYM	cis	rs9790314	0.723	rs12631850	chr3:160883062	C/T	cg03342759	chr3:160939853	NMD3	0.66	5.18	0.47	1.23e-6	Morning vs. evening chronotype;
THYM	cis	rs6032067	1.000	rs6017519	chr20:43854677	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.71	-7.53	-0.61	2.95e-11	Blood protein levels;
THYM	cis	rs7804356	0.834	rs2106905	chr7:26766851	T/C	cg24979288	chr7:27242424	NA	0.62	4.48	0.42	2.09e-5	Type 1 diabetes;
THYM	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.64	0.43	1.12e-5	Obesity-related traits;
THYM	cis	rs11190604	0.806	rs11190510	chr10:102157175	G/A	cg07570687	chr10:102243282	WNT8B	0.81	7.65	0.62	1.63e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs11096990	0.634	rs2062229	chr4:39286766	A/C	cg24403649	chr4:39172243	NA	0.66	5.7	0.51	1.32e-7	Cognitive function;
THYM	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9807841	0.617	rs892087	chr19:10794793	C/T	cg17848348	chr19:10766748	ILF3	-0.63	-4.97	-0.45	2.96e-6	Inflammatory skin disease;
THYM	cis	rs7465272	1.000	rs7017842	chr8:143685116	G/A	cg01509843	chr8:143695822	ARC	0.74	4.9	0.45	3.97e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs28595532	0.920	rs17257039	chr4:119603703	G/A	cg14228332	chr4:119757509	SEC24D	1.35	4.52	0.42	1.81e-5	Cannabis dependence symptom count;
THYM	cis	rs2455799	0.613	rs11712323	chr3:15891360	T/C	cg16303742	chr3:15540471	COLQ	-0.56	-5.87	-0.52	6.41e-8	Mean platelet volume;
THYM	cis	rs61990749	0.597	rs9788540	chr14:78132172	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	-1.15	-7.89	-0.63	5.15e-12	Fibroblast growth factor basic levels;
THYM	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg12463550	chr7:65579703	CRCP	0.56	4.55	0.42	1.57e-5	Aortic root size;
THYM	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.97	8.79	0.67	6.29e-14	Chronic sinus infection;
THYM	cis	rs9296092	0.538	rs62407567	chr6:33537213	A/G	cg13560919	chr6:33536144	NA	-0.92	-8.14	-0.64	1.51e-12	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03647317	chr4:187891568	NA	-0.83	-9.2	-0.69	8.27e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg11871910	chr12:69753446	YEATS4	0.72	5.78	0.51	9.67e-8	Response to diuretic therapy;
THYM	cis	rs7264396	0.790	rs6060519	chr20:34217383	G/A	cg26038318	chr20:34205095	SPAG4	0.65	5.35	0.48	6.1e-7	Total cholesterol levels;
THYM	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg07493874	chr5:1342172	CLPTM1L	0.74	6.77	0.57	1.04e-9	Lung cancer;
THYM	cis	rs7731657	0.537	rs10478953	chr5:130185380	A/C	cg08523029	chr5:130500466	HINT1	0.75	5.3	0.48	7.59e-7	Fasting plasma glucose;
THYM	cis	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg03597347	chr6:28058909	ZSCAN12L1	0.79	4.53	0.42	1.74e-5	Depression;
THYM	cis	rs5758659	0.679	rs134870	chr22:42652317	T/C	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-4.63	-0.43	1.15e-5	Cognitive function;
THYM	cis	rs1461503	0.966	rs4936764	chr11:122844492	G/A	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs757081	0.506	rs11529609	chr11:17063790	G/A	cg23530266	chr11:16132747	SOX6	0.54	4.45	0.42	2.36e-5	Systolic blood pressure;
THYM	cis	rs4731207	0.698	rs12538333	chr7:124508357	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg19747945	chr6:42946146	PEX6	-0.33	-4.82	-0.44	5.43e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03407747	chr17:6899364	ALOX12	0.79	10.15	0.72	7.75e-17	Tonsillectomy;
THYM	cis	rs4654899	0.865	rs12410467	chr1:21356055	G/A	cg01072550	chr1:21505969	NA	-0.75	-6.63	-0.56	2.02e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg00898013	chr13:113819073	PROZ	-0.89	-9.2	-0.69	8.65e-15	Platelet distribution width;
THYM	cis	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs750460	1.000	rs12905253	chr15:74232437	G/A	cg01349856	chr15:74220517	LOXL1	-0.62	-4.56	-0.42	1.51e-5	Height;
THYM	cis	rs4642101	0.765	rs3901665	chr3:12824610	C/A	cg05775895	chr3:12838266	CAND2	0.77	6.91	0.58	5.5e-10	QRS complex (12-leadsum);
THYM	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg13683864	chr3:40499215	RPL14	0.97	10.3	0.73	3.76e-17	Renal cell carcinoma;
THYM	cis	rs2120243	0.539	rs2305622	chr3:157122504	C/T	cg24825693	chr3:157122686	VEPH1	-0.47	-4.52	-0.42	1.8e-5	Hepatocellular carcinoma in hepatitis B infection;
THYM	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs6570726	0.935	rs384519	chr6:145846017	C/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.78	-0.51	9.29e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9560113	0.843	rs9555808	chr13:112181284	A/T	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs12908161	0.960	rs11633450	chr15:85307287	C/T	cg12863693	chr15:85201151	NMB	0.58	4.89	0.45	4.15e-6	Schizophrenia;
THYM	cis	rs4722585	0.533	rs2158359	chr7:26193309	A/C	cg07876897	chr7:26191696	NFE2L3	-0.55	-4.55	-0.42	1.59e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs854765	0.583	rs4257260	chr17:17857003	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.58	0.56	2.61e-9	Total body bone mineral density;
THYM	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg12386194	chr3:101231763	SENP7	0.95	7.53	0.61	2.92e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13315871	1.000	rs35621601	chr3:58323174	A/G	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs6570726	0.818	rs399516	chr6:145810849	C/A	cg13319975	chr6:146136371	FBXO30	-0.72	-6.1	-0.53	2.28e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg00339695	chr16:24857497	SLC5A11	0.68	6.43	0.55	5.15e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg05872129	chr22:39784769	NA	-0.91	-7.78	-0.62	8.79e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg12963246	chr6:28129442	ZNF389	0.72	6.12	0.53	2.05e-8	Depression;
THYM	cis	rs675209	0.601	rs12203597	chr6:7085512	G/A	cg24899545	chr6:7112846	RREB1	-0.52	-5.02	-0.46	2.41e-6	Urate levels;
THYM	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg10523679	chr1:76189770	ACADM	0.86	9.18	0.69	9.2e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7107174	1.000	rs11237469	chr11:78072875	A/T	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg10792982	chr14:105748885	BRF1	0.68	6.85	0.57	7.46e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9560113	1.000	rs4773383	chr13:112177764	C/T	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg08773314	chr2:239334832	ASB1	-0.64	-9.92	-0.71	2.51e-16	Multiple system atrophy;
THYM	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.48	-4.63	-0.43	1.14e-5	Crohn's disease;
THYM	cis	rs9296092	0.517	rs3912041	chr6:33521271	T/C	cg13560919	chr6:33536144	NA	-0.94	-9.31	-0.69	4.9e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs62070183	0.938	rs9303654	chr17:31036765	G/A	cg23177095	chr17:30873196	MYO1D	0.65	5.19	0.47	1.18e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs4363385	0.791	rs512198	chr1:153006245	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.59	-0.43	1.36e-5	Inflammatory skin disease;
THYM	cis	rs7681423	0.951	rs6050	chr4:155507590	C/T	cg20735720	chr4:155535218	FGG	0.61	4.55	0.42	1.55e-5	Fibrinogen;
THYM	cis	rs8102476	0.846	rs11083450	chr19:38754239	T/C	cg08196968	chr19:38746749	PPP1R14A	-0.47	-5.68	-0.5	1.46e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg21235903	chr8:38864411	ADAM9	0.89	7.08	0.59	2.51e-10	Energy expenditure (24h);
THYM	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg00129232	chr17:37814104	STARD3	0.7	4.79	0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg19746536	chr19:49375674	PPP1R15A	0.79	4.46	0.42	2.28e-5	Red cell distribution width;
THYM	cis	rs6575793	1.000	rs8006543	chr14:101033420	C/T	cg13673514	chr14:101035818	BEGAIN	-0.51	-4.93	-0.45	3.55e-6	Menarche (age at onset);
THYM	cis	rs7224737	1.000	rs1869365	chr17:40293865	T/C	cg20291162	chr17:40259547	DHX58	-0.73	-6.9	-0.58	5.87e-10	Fibrinogen levels;
THYM	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg07936489	chr17:37558343	FBXL20	-0.83	-5.84	-0.51	7.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg06532163	chr17:45867833	NA	0.65	6.61	0.56	2.24e-9	IgG glycosylation;
THYM	cis	rs9399401	0.884	rs7763064	chr6:142797289	C/T	cg04461802	chr6:142623433	GPR126	0.45	4.56	0.42	1.53e-5	Chronic obstructive pulmonary disease;
THYM	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg20290983	chr6:43655470	MRPS18A	-1.41	-15.15	-0.84	4.38e-27	IgG glycosylation;
THYM	cis	rs2282300	0.739	rs7942129	chr11:30224692	G/A	cg06241208	chr11:30344200	C11orf46	-0.77	-5.69	-0.5	1.38e-7	Morning vs. evening chronotype;
THYM	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg25072359	chr17:41440525	NA	0.65	4.56	0.42	1.5e-5	Menopause (age at onset);
THYM	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg06481639	chr22:41940642	POLR3H	0.79	5.52	0.49	2.89e-7	Vitiligo;
THYM	cis	rs9814567	0.806	rs4074522	chr3:134325626	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	7.55	0.61	2.7e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg00310523	chr12:86230176	RASSF9	0.52	4.63	0.43	1.15e-5	Major depressive disorder;
THYM	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	4.96	0.45	3.08e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7246657	0.943	rs7252099	chr19:37933780	G/A	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs6842047	0.611	rs12186257	chr4:187183498	G/C	cg23442198	chr4:187126114	CYP4V2	0.97	4.45	0.42	2.32e-5	Blood protein levels;
THYM	cis	rs17001868	0.568	rs9611311	chr22:40733951	T/C	cg07138101	chr22:40742427	ADSL	0.82	4.85	0.45	4.8e-6	Mammographic density (dense area);
THYM	cis	rs240764	0.531	rs1070990	chr6:101264412	T/A	cg21058520	chr6:100914733	NA	-0.6	-5.32	-0.48	6.98e-7	Neuroticism;
THYM	cis	rs3925075	1.000	rs4411512	chr16:31347445	C/T	cg02846316	chr16:31340340	ITGAM	0.58	6.08	0.53	2.44e-8	IgA nephropathy;
THYM	cis	rs1978968	0.700	rs10854521	chr22:18482600	C/T	cg01550578	chr22:18484421	MICAL3	0.62	4.67	0.43	9.77e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.65	0.5	1.64e-7	Tonsillectomy;
THYM	cis	rs752010	0.655	rs10890145	chr1:42086290	A/G	cg06885757	chr1:42089581	HIVEP3	0.6	7.65	0.62	1.61e-11	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs6541297	0.887	rs4846906	chr1:230284257	C/A	cg05784532	chr1:230284198	GALNT2	0.84	5.2	0.47	1.13e-6	Coronary artery disease;
THYM	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg16989719	chr2:238392110	NA	-0.66	-5.38	-0.48	5.29e-7	Prostate cancer;
THYM	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg16586182	chr3:47516702	SCAP	0.64	5.42	0.49	4.43e-7	Colorectal cancer;
THYM	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03517284	chr6:25882590	NA	-0.77	-6.14	-0.53	1.91e-8	Blood metabolite levels;
THYM	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg02038168	chr22:39784481	NA	-0.68	-5.58	-0.5	2.3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6429082	0.818	rs291340	chr1:235674379	C/T	cg26050004	chr1:235667680	B3GALNT2	0.74	5.91	0.52	5.24e-8	Adiposity;
THYM	cis	rs2071518	1.000	rs72684286	chr8:120401169	T/A	cg15718811	chr8:120427810	NOV	0.5	4.64	0.43	1.13e-5	Pulse pressure;Blood pressure;
THYM	cis	rs4731207	0.596	rs6466965	chr7:124579726	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs9905704	0.918	rs430973	chr17:56709206	T/G	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.74e-6	Testicular germ cell tumor;
THYM	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.65	0.56	1.84e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg27446573	chr6:127587934	RNF146	1.02	9.5	0.7	1.93e-15	Breast cancer;
THYM	trans	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs149313	0.560	rs151904	chr5:96066652	C/T	cg11214001	chr5:96078430	CAST	-0.64	-4.84	-0.44	5.02e-6	Blood protein levels;
THYM	cis	rs669446	0.561	rs639929	chr1:44083874	A/G	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg05660106	chr1:15850417	CASP9	0.73	5.92	0.52	5.14e-8	Systolic blood pressure;
THYM	cis	rs3820068	0.603	rs7516453	chr1:15972558	C/G	cg24675056	chr1:15929824	NA	0.78	5.84	0.51	7.24e-8	Systolic blood pressure;
THYM	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg03983476	chr2:10830698	NOL10	-0.61	-5.87	-0.52	6.3e-8	Prostate cancer;
THYM	cis	rs804280	0.525	rs809203	chr8:11619504	T/A	cg12395012	chr8:11607386	GATA4	-0.66	-5.27	-0.48	8.63e-7	Myopia (pathological);
THYM	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.54	-5.21	-0.47	1.1e-6	Schizophrenia;
THYM	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg13939156	chr17:80058883	NA	-0.37	-4.88	-0.45	4.32e-6	Life satisfaction;
THYM	cis	rs4776059	0.958	rs933860	chr15:52965468	T/C	cg22715398	chr15:52968154	KIAA1370	-0.58	-4.63	-0.43	1.16e-5	Schizophrenia;
THYM	cis	rs10886503	0.777	rs7919216	chr10:121265635	C/T	cg13260278	chr10:121265587	RGS10	-0.74	-6.51	-0.56	3.55e-9	Obstetric antiphospholipid syndrome;
THYM	cis	rs62229266	0.647	rs59397717	chr21:37451725	C/T	cg12218747	chr21:37451666	NA	-0.71	-6.86	-0.58	7.1e-10	Mitral valve prolapse;
THYM	cis	rs2898681	0.770	rs62336795	chr4:53737772	G/A	cg00791764	chr4:53727839	RASL11B	0.46	5.93	0.52	4.83e-8	Optic nerve measurement (cup area);
THYM	cis	rs2991971	0.810	rs12119202	chr1:45925931	A/T	cg15605315	chr1:45957053	TESK2	-0.66	-5.32	-0.48	6.85e-7	High light scatter reticulocyte count;
THYM	cis	rs9790314	0.967	rs9821201	chr3:160996155	G/C	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.16	-8.66	-0.66	1.18e-13	Platelet count;
THYM	cis	rs2204008	0.807	rs10880234	chr12:38318353	C/T	cg26384229	chr12:38710491	ALG10B	0.92	7.03	0.58	3.18e-10	Bladder cancer;
THYM	cis	rs7107174	1.000	rs2511175	chr11:77975081	A/G	cg02023728	chr11:77925099	USP35	0.65	5.83	0.51	7.52e-8	Testicular germ cell tumor;
THYM	cis	rs3204270	0.714	rs7503307	chr17:79674929	C/G	cg09996840	chr17:79680718	SLC25A10	-0.59	-4.46	-0.42	2.24e-5	Dental caries;
THYM	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.61	-4.83	-0.44	5.3e-6	Longevity;Endometriosis;
THYM	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg19875535	chr5:140030758	IK	0.57	4.47	0.42	2.16e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg10505658	chr17:80084571	CCDC57	-0.69	-7.95	-0.63	3.85e-12	Life satisfaction;
THYM	cis	rs2456568	0.548	rs10466334	chr11:93663512	A/G	cg17595323	chr11:93583763	C11orf90	-0.51	-5.46	-0.49	3.83e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg19770292	chr5:1868693	NA	0.54	4.97	0.45	2.95e-6	Cardiovascular disease risk factors;
THYM	cis	rs11563648	0.517	rs2269729	chr7:127032663	A/T	cg23081781	chr7:127225937	GCC1	-0.34	-4.65	-0.43	1.07e-5	Resting heart rate;
THYM	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.53	0.56	3.27e-9	Total body bone mineral density;
THYM	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg23583168	chr7:148888333	NA	-0.94	-10.32	-0.73	3.47e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.68	-5.06	-0.46	2.08e-6	Colorectal cancer;
THYM	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-4.6	-0.43	1.32e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.77	0.44	6.55e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7757969	1.000	rs28566870	chr6:112118932	T/C	cg08601457	chr6:112115117	FYN	0.51	4.58	0.43	1.39e-5	Schizophrenia;
THYM	cis	rs4363385	0.818	rs11205167	chr1:152989727	T/G	cg13444842	chr1:152974279	SPRR3	-0.61	-5.08	-0.46	1.86e-6	Inflammatory skin disease;
THYM	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg23711669	chr6:146136114	FBXO30	0.85	8.06	0.64	2.21e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4930103	0.935	rs11042167	chr11:2020901	G/A	cg06197492	chr11:2016605	H19	0.63	5.47	0.49	3.57e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg05707623	chr12:122985044	ZCCHC8	0.71	4.74	0.44	7.5e-6	Body mass index;
THYM	cis	rs912057	0.671	rs1294434	chr6:6745377	G/A	cg06612196	chr6:6737390	NA	0.7	11.63	0.77	5.88e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg02527881	chr3:46936655	PTH1R	0.59	5.63	0.5	1.86e-7	Colorectal cancer;
THYM	cis	rs3796352	0.881	rs34238610	chr3:53026480	A/T	cg04865290	chr3:52927548	TMEM110	-0.96	-5.01	-0.46	2.52e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg08132940	chr7:1081526	C7orf50	-1.16	-6.65	-0.56	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9902453	1.000	rs4350617	chr17:28423088	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.76	0.44	6.86e-6	Coffee consumption (cups per day);
THYM	cis	rs6860806	0.507	rs270615	chr5:131641573	G/C	cg04518342	chr5:131593106	PDLIM4	0.42	4.54	0.42	1.64e-5	Breast cancer;
THYM	cis	rs1021993	0.620	rs17014326	chr1:209515285	T/G	cg24997231	chr1:209527535	NA	-0.59	-5.35	-0.48	6.15e-7	Gut microbiome composition (winter);
THYM	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg13607699	chr17:42295918	UBTF	0.66	5.44	0.49	4.13e-7	Total body bone mineral density;
THYM	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg00376283	chr12:123451042	ABCB9	0.94	7.77	0.62	9.18e-12	Platelet count;
THYM	cis	rs34638657	0.500	rs1056675	chr16:82181934	T/C	cg07307142	chr16:82071433	HSD17B2	-0.84	-6.93	-0.58	5.07e-10	Lung adenocarcinoma;
THYM	cis	rs9790314	1.000	rs336570	chr3:161072054	A/G	cg04691961	chr3:161091175	C3orf57	0.61	5.29	0.48	7.88e-7	Morning vs. evening chronotype;
THYM	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg23758822	chr17:41437982	NA	1.16	11.05	0.75	9.86e-19	Menopause (age at onset);
THYM	cis	rs4731207	0.596	rs7799712	chr7:124649717	G/C	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs752010	0.644	rs6700390	chr1:42112554	A/G	cg06885757	chr1:42089581	HIVEP3	0.62	8.26	0.65	8.59e-13	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg10150615	chr22:24372951	LOC391322	-0.71	-5.63	-0.5	1.83e-7	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs9563576	0.778	rs1326537	chr13:58607871	T/C	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs9422860	0.666	rs12784516	chr10:127071580	G/A	cg01247788	chr10:126281564	LHPP	1.1	4.65	0.43	1.06e-5	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.16	9.07	0.68	1.58e-14	Cognitive test performance;
THYM	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg11941060	chr3:133502564	NA	-0.73	-6.42	-0.55	5.44e-9	Iron status biomarkers;
THYM	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg13010199	chr12:38710504	ALG10B	0.6	4.52	0.42	1.8e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg11266682	chr4:10021025	SLC2A9	0.74	10.8	0.74	3.21e-18	Bone mineral density;
THYM	cis	rs17443541	0.507	rs1823490	chr2:200463516	C/T	cg03741458	chr2:200468445	NA	-0.75	-5.77	-0.51	9.74e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7481584	0.624	rs449164	chr11:3053454	C/T	cg03159660	chr11:2078197	NA	0.62	4.6	0.43	1.3e-5	Calcium levels;
THYM	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg27129171	chr3:47204927	SETD2	0.7	6.7	0.57	1.44e-9	Colorectal cancer;
THYM	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	4.96	0.45	3.07e-6	Hip circumference adjusted for BMI;
THYM	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg27494647	chr7:150038898	RARRES2	0.47	5.82	0.51	7.95e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg14004847	chr7:1930337	MAD1L1	-0.68	-5.12	-0.46	1.61e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs112591243	0.685	rs2839362	chr21:48024626	G/A	cg26904215	chr21:47823096	PCNT	-0.98	-4.51	-0.42	1.89e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs7937682	0.793	rs4581484	chr11:111415822	G/A	cg09085632	chr11:111637200	PPP2R1B	0.77	6.25	0.54	1.15e-8	Primary sclerosing cholangitis;
THYM	cis	rs11771526	0.686	rs28399034	chr7:32272898	A/G	cg27532318	chr7:32358331	NA	0.76	5.44	0.49	4.16e-7	Body mass index;
THYM	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg00981070	chr1:2046702	PRKCZ	-0.5	-5.66	-0.5	1.59e-7	Height;
THYM	cis	rs1346	0.501	rs10750762	chr11:65368305	A/G	cg27068330	chr11:65405492	SIPA1	0.72	4.7	0.43	8.7e-6	Vertical cup-disc ratio;Optic cup area;
THYM	trans	rs10962692	0.608	rs10962648	chr9:16868958	G/C	cg03221025	chr16:88955224	CBFA2T3	0.75	7.2	0.59	1.37e-10	Ovarian cancer in BRCA2 mutation carriers;Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;
THYM	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	5.56	0.5	2.46e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg18876405	chr7:65276391	NA	0.57	4.73	0.44	7.67e-6	Aortic root size;
THYM	cis	rs9900497	0.604	rs12949049	chr17:19653310	A/G	cg22552966	chr17:19620595	SLC47A2	0.71	5.72	0.51	1.22e-7	Response to paliperidone in schizophrenia (CGI-S score);
THYM	cis	rs12935418	0.579	rs2123627	chr16:81021816	C/A	cg16651780	chr16:81037892	C16orf61	-0.86	-6.55	-0.56	3e-9	Mean corpuscular volume;
THYM	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg14456004	chr13:21872349	NA	-1.24	-10.0	-0.72	1.63e-16	White matter hyperintensity burden;
THYM	cis	rs1395	1.000	rs1659685	chr2:27420690	C/T	cg23587288	chr2:27483067	SLC30A3	0.58	5.09	0.46	1.78e-6	Blood metabolite levels;
THYM	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.8	6.52	0.56	3.41e-9	Blood protein levels;
THYM	cis	rs2859741	0.528	rs59729868	chr1:37493710	G/A	cg09363841	chr1:37513479	NA	-0.66	-5.21	-0.47	1.1e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs10095849	0.576	rs4733917	chr8:39476978	T/C	cg22755526	chr8:38854673	TM2D2;ADAM9	-0.62	-4.61	-0.43	1.24e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7772486	0.686	rs1292334	chr6:145968288	A/G	cg23711669	chr6:146136114	FBXO30	0.98	10.25	0.72	4.8e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg08807101	chr21:30365312	RNF160	0.95	7.83	0.63	6.81e-12	Dental caries;
THYM	cis	rs7487075	0.780	rs12296120	chr12:46737591	G/A	cg17501823	chr12:47219793	SLC38A4	0.49	4.63	0.43	1.18e-5	Itch intensity from mosquito bite;
THYM	trans	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg07393940	chr7:158741817	NA	-1.14	-9.25	-0.69	6.69e-15	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg26384229	chr12:38710491	ALG10B	-0.75	-6.31	-0.54	8.68e-9	Morning vs. evening chronotype;
THYM	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.96	6.44	0.55	4.96e-9	Platelet count;
THYM	cis	rs1994135	0.617	rs1384590	chr12:33734271	C/T	cg06521331	chr12:34319734	NA	-0.67	-4.65	-0.43	1.06e-5	Resting heart rate;
THYM	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.56	-10.9	-0.75	2.04e-18	Hemostatic factors and hematological phenotypes;
THYM	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg04267008	chr7:1944627	MAD1L1	0.59	4.79	0.44	6.16e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7584330	0.554	rs10183995	chr2:238433307	G/A	cg08992911	chr2:238395768	MLPH	0.88	5.73	0.51	1.17e-7	Prostate cancer;
THYM	cis	rs295140	0.507	rs4673814	chr2:201108133	G/A	cg23649088	chr2:200775458	C2orf69	-0.63	-5.59	-0.5	2.16e-7	QT interval;
THYM	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg02782426	chr3:40428986	ENTPD3	-0.52	-4.48	-0.42	2.07e-5	Renal cell carcinoma;
THYM	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg17264618	chr3:40429014	ENTPD3	0.52	4.86	0.45	4.57e-6	Renal cell carcinoma;
THYM	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12756686	chr19:29218302	NA	0.98	8.66	0.66	1.2e-13	Methadone dose in opioid dependence;
THYM	cis	rs13064411	0.696	rs7613546	chr3:113228019	G/A	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs4557020	0.904	rs7578287	chr2:54711229	T/C	cg11007406	chr2:54682859	SPTBN1	-0.35	-4.48	-0.42	2.08e-5	Myopia (pathological);
THYM	cis	rs1747683	0.966	rs3802583	chr10:13380084	A/G	cg00142036	chr10:13388442	SEPHS1	-0.29	-5.17	-0.47	1.32e-6	IgG glycosylation;
THYM	cis	rs4927850	1.000	rs4927848	chr3:195738406	A/G	cg12923728	chr3:195709715	SDHAP1	-0.79	-6.31	-0.54	8.86e-9	Pancreatic cancer;
THYM	cis	rs11696501	0.688	rs6104247	chr20:44244938	C/T	cg11783356	chr20:44313418	WFDC10B	-0.66	-4.52	-0.42	1.77e-5	Brain structure;
THYM	cis	rs12579753	0.872	rs11519752	chr12:82207300	A/G	cg21231944	chr12:82153410	PPFIA2	-0.68	-5.2	-0.47	1.15e-6	Resting heart rate;
THYM	cis	rs8018808	0.935	rs4223	chr14:77893276	A/G	cg20045696	chr14:77926864	AHSA1	-0.51	-4.6	-0.43	1.29e-5	Myeloid white cell count;
THYM	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	5.65	0.5	1.67e-7	Lung cancer in ever smokers;
THYM	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg07414643	chr4:187882934	NA	0.57	4.95	0.45	3.16e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg02269571	chr22:50332266	NA	-1.07	-5.81	-0.51	8.2e-8	Schizophrenia;
THYM	cis	rs1385374	0.858	rs10773578	chr12:129290026	G/C	cg04043695	chr12:129287642	SLC15A4	-0.8	-4.83	-0.44	5.3e-6	Systemic lupus erythematosus;
THYM	cis	rs12142240	0.698	rs112068407	chr1:46822291	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg25072359	chr17:41440525	NA	0.77	5.74	0.51	1.15e-7	Menopause (age at onset);
THYM	cis	rs17511627	0.673	rs4770936	chr13:26744293	A/G	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs988913	0.957	rs12525787	chr6:54789072	C/T	cg19716238	chr6:54711378	FAM83B	0.51	5.02	0.46	2.4e-6	Menarche (age at onset);
THYM	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg22875332	chr1:76189707	ACADM	-0.86	-9.51	-0.7	1.85e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg11812906	chr14:75593930	NEK9	-0.8	-7.19	-0.59	1.48e-10	Height;
THYM	cis	rs9796	0.866	rs516156	chr15:41381257	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.58	-4.73	-0.44	7.81e-6	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg07606381	chr6:8435919	SLC35B3	-0.62	-4.66	-0.43	1.04e-5	Motion sickness;
THYM	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg09074113	chr2:20870087	GDF7	0.66	6.61	0.56	2.28e-9	Abdominal aortic aneurysm;
THYM	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg06600287	chr1:53387719	ECHDC2	-0.29	-4.69	-0.43	9.17e-6	Monocyte count;
THYM	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg22875332	chr1:76189707	ACADM	0.88	11.22	0.75	4.31e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs910187	0.605	rs8124995	chr20:45811788	G/T	cg27589058	chr20:45804311	EYA2	-0.59	-5.04	-0.46	2.22e-6	Migraine;
THYM	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg15693483	chr7:1102177	C7orf50	0.39	4.64	0.43	1.12e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg02187348	chr16:89574699	SPG7	0.75	6.51	0.56	3.47e-9	Multiple myeloma (IgH translocation);
THYM	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg03929089	chr4:120376271	NA	-0.94	-9.83	-0.71	3.79e-16	Coronary artery disease;
THYM	cis	rs1691799	0.899	rs1168305	chr12:66738714	A/G	cg16791601	chr12:66731901	HELB	-0.76	-7.14	-0.59	1.9e-10	White blood cell count (basophil);
THYM	cis	rs8030485	0.536	rs1915724	chr15:79441027	A/G	cg17916960	chr15:79447300	NA	0.66	7.33	0.6	7.7e-11	Left ventricle wall thickness;
THYM	cis	rs67311347	0.544	rs2278929	chr3:40351008	C/G	cg13683864	chr3:40499215	RPL14	0.7	6.44	0.55	4.9e-9	Renal cell carcinoma;
THYM	cis	rs6840360	0.571	rs4696102	chr4:152529658	C/T	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg24803719	chr17:45855879	NA	-0.58	-6.04	-0.53	2.97e-8	IgG glycosylation;
THYM	cis	rs28595532	0.920	rs114963870	chr4:119758099	T/C	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs7695732	0.528	rs11097206	chr4:89912645	T/A	cg17769793	chr4:89976368	FAM13A	-0.49	-5.2	-0.47	1.17e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7317940	1.000	rs73225395	chr13:78007474	T/A	cg02481778	chr13:77460607	KCTD12	-0.8	-5.33	-0.48	6.52e-7	Age of smoking initiation;
THYM	trans	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg18335740	chr13:41363409	SLC25A15	0.73	7.51	0.61	3.14e-11	Lewy body disease;
THYM	cis	rs2229238	0.911	rs73020232	chr1:154482669	C/T	cg21262032	chr1:154437693	IL6R	-0.6	-5.3	-0.48	7.51e-7	Coronary heart disease;
THYM	cis	rs6596100	0.538	rs67519234	chr5:132199359	C/A	cg02081065	chr5:132209139	LEAP2	-0.95	-6.14	-0.53	1.87e-8	Breast cancer;
THYM	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03517284	chr6:25882590	NA	-0.97	-7.93	-0.63	4.14e-12	Intelligence (multi-trait analysis);
THYM	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg10760299	chr15:45669010	GATM	0.87	6.61	0.56	2.21e-9	Homoarginine levels;
THYM	cis	rs9677476	0.774	rs1973016	chr2:232117513	C/G	cg07929768	chr2:232055508	NA	0.64	6.24	0.54	1.19e-8	Food antigen IgG levels;
THYM	cis	rs988913	0.706	rs6908568	chr6:54881564	C/G	cg18532076	chr6:54711417	FAM83B	0.5	4.61	0.43	1.27e-5	Menarche (age at onset);
THYM	trans	rs75518195	0.590	rs62302817	chr4:64733697	A/T	cg14706739	chr8:21916355	EPB49	0.75	7.28	0.6	9.73e-11	Triptolide cytotoxicity;
THYM	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg21926883	chr2:100939477	LONRF2	-0.63	-5.8	-0.51	8.76e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg08000102	chr2:233561755	GIGYF2	0.68	6.11	0.53	2.16e-8	Coronary artery disease;
THYM	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg11245990	chr11:68621969	NA	0.52	6.78	0.57	1e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.49	-0.66	2.78e-13	Mean corpuscular volume;
THYM	cis	rs12540874	0.698	rs13234331	chr7:50560314	G/T	cg18232548	chr7:50535776	DDC	-0.9	-8.47	-0.66	3.08e-13	Systemic sclerosis;
THYM	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg12935359	chr14:103987150	CKB	-0.64	-6.43	-0.55	5.14e-9	Body mass index;
THYM	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg26441486	chr22:50317300	CRELD2	0.43	6.57	0.56	2.71e-9	Schizophrenia;
THYM	cis	rs6500395	0.962	rs9936883	chr16:48676443	G/A	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg18357526	chr6:26021779	HIST1H4A	0.76	6.64	0.56	1.96e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7192380	0.965	rs7205551	chr16:69605968	G/A	cg09409435	chr16:70099608	PDXDC2	0.63	4.68	0.43	9.52e-6	Sjögren's syndrome;
THYM	cis	rs6570726	0.935	rs424263	chr6:145840073	A/C	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs899997	1.000	rs2017091	chr15:79032744	G/A	cg04896959	chr15:78267971	NA	0.89	7.17	0.59	1.64e-10	Coronary artery disease or large artery stroke;
THYM	cis	rs1163251	0.902	rs511059	chr1:120217081	G/T	cg19096424	chr1:120255104	PHGDH	0.66	5.06	0.46	2.07e-6	Blood metabolite levels;
THYM	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg26384229	chr12:38710491	ALG10B	-0.73	-5.99	-0.52	3.77e-8	Morning vs. evening chronotype;
THYM	cis	rs11771526	0.892	rs62457540	chr7:32372199	A/G	cg27511599	chr7:32358540	NA	0.75	5.02	0.46	2.42e-6	Body mass index;
THYM	cis	rs977987	0.800	rs11645329	chr16:75336679	C/G	cg03315344	chr16:75512273	CHST6	0.83	6.67	0.56	1.66e-9	Dupuytren's disease;
THYM	cis	rs17818399	1.000	rs17818399	chr2:46826026	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.68	4.83	0.44	5.26e-6	Height;
THYM	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Body mass index;
THYM	cis	rs9443189	0.570	rs523465	chr6:76330434	G/C	cg01950844	chr6:76311363	SENP6	1.05	6.66	0.56	1.73e-9	Prostate cancer;
THYM	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg06481639	chr22:41940642	POLR3H	0.75	5.04	0.46	2.26e-6	Vitiligo;
THYM	cis	rs7078219	0.505	rs10883371	chr10:101292455	G/T	cg04972745	chr10:101287846	NA	-0.52	-4.98	-0.45	2.85e-6	Dental caries;
THYM	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs7772486	0.790	rs2256998	chr6:146207657	A/C	cg13319975	chr6:146136371	FBXO30	-0.74	-6.33	-0.54	7.91e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg23978390	chr7:1156363	C7orf50	0.67	5.05	0.46	2.13e-6	Longevity;Endometriosis;
THYM	cis	rs10503871	0.526	rs6982204	chr8:30483988	G/A	cg12158488	chr8:31336998	NA	-0.4	-4.48	-0.42	2.09e-5	Metabolite levels  (X-11787);
THYM	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg13695892	chr22:41940480	POLR3H	0.92	7.27	0.6	9.83e-11	Vitiligo;
THYM	cis	rs4631830	0.720	rs4935573	chr10:51504385	A/G	cg10326726	chr10:51549505	MSMB	0.5	4.99	0.46	2.68e-6	Prostate-specific antigen levels;
THYM	cis	rs4595586	0.545	rs2388179	chr12:39364036	T/A	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs870825	0.616	rs67409049	chr4:185623989	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs684232	0.602	rs384628	chr17:554912	G/A	cg15660573	chr17:549704	VPS53	-1.0	-11.2	-0.75	4.65e-19	Prostate cancer;
THYM	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg00071950	chr4:10020882	SLC2A9	-0.63	-5.91	-0.52	5.44e-8	Bone mineral density;
THYM	cis	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg21775007	chr8:11205619	TDH	0.66	5.35	0.48	5.98e-7	Retinal vascular caliber;
THYM	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.95	-9.44	-0.7	2.59e-15	Chronic sinus infection;
THYM	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	7.38	0.6	6.08e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg01831904	chr17:28903510	LRRC37B2	-1.04	-5.05	-0.46	2.17e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12444261	0.890	rs12446730	chr16:11751015	A/G	cg09662852	chr16:11707685	NA	-0.45	-4.46	-0.42	2.21e-5	QT interval;
THYM	cis	rs13256369	0.950	rs13270006	chr8:8574197	C/A	cg18904891	chr8:8559673	CLDN23	0.68	5.08	0.46	1.89e-6	Obesity-related traits;
THYM	cis	rs9807841	0.592	rs10415961	chr19:10759981	G/C	cg16900796	chr19:10755136	SLC44A2	0.34	5.55	0.49	2.63e-7	Inflammatory skin disease;
THYM	cis	rs1065852	0.503	rs9620006	chr22:42399547	T/A	cg01059385	chr22:42394853	WBP2NL	0.57	4.66	0.43	1.04e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg20283391	chr11:68216788	NA	-0.62	-4.61	-0.43	1.27e-5	Total body bone mineral density;
THYM	cis	rs5769765	0.837	rs7284417	chr22:50314346	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	5.14	0.47	1.45e-6	Schizophrenia;
THYM	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs59698941	0.943	rs4705873	chr5:132267167	G/A	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg13918804	chr1:2043761	PRKCZ	-0.82	-7.43	-0.61	4.76e-11	Height;
THYM	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg06623918	chr6:96969491	KIAA0776	-1.08	-10.64	-0.74	7.29e-18	Headache;
THYM	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.57	4.82	0.44	5.49e-6	Blood metabolite levels;
THYM	cis	rs7107174	0.901	rs1046780	chr11:77926769	A/G	cg02023728	chr11:77925099	USP35	0.68	6.37	0.55	6.62e-9	Testicular germ cell tumor;
THYM	cis	rs11711311	1.000	rs9288984	chr3:113525956	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.63	-5.49	-0.49	3.27e-7	IgG glycosylation;
THYM	cis	rs6570726	0.846	rs6919684	chr6:145883801	A/G	cg23711669	chr6:146136114	FBXO30	0.86	8.19	0.64	1.22e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs765787	0.530	rs2554455	chr15:45521304	T/C	cg24006582	chr15:45444508	DUOX1	-0.79	-6.67	-0.56	1.71e-9	Uric acid levels;
THYM	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg11752832	chr7:134001865	SLC35B4	0.76	5.72	0.51	1.24e-7	Mean platelet volume;
THYM	cis	rs11760633	0.672	rs6460870	chr7:1843200	C/G	cg23422044	chr7:1970798	MAD1L1	-0.68	-5.07	-0.46	1.99e-6	Coronary artery disease;
THYM	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg15556689	chr8:8085844	FLJ10661	0.84	7.73	0.62	1.1e-11	Mood instability;
THYM	cis	rs6430585	0.583	rs11886852	chr2:136589379	G/A	cg20242066	chr2:136595261	LCT	0.54	5.88	0.52	6.14e-8	Corneal structure;
THYM	cis	rs2898681	0.642	rs11538878	chr4:53728524	T/C	cg00812761	chr4:53799391	SCFD2	-0.54	-4.98	-0.45	2.86e-6	Optic nerve measurement (cup area);
THYM	cis	rs4731207	0.564	rs10270051	chr7:124649393	T/C	cg05285228	chr7:124571219	POT1	-0.72	-5.53	-0.49	2.81e-7	Cutaneous malignant melanoma;
THYM	cis	rs7578361	0.918	rs114604846	chr2:150380008	C/T	cg17961725	chr2:150454027	NA	-0.77	-5.72	-0.51	1.25e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs950776	0.745	rs36045869	chr15:78929498	C/T	cg06917634	chr15:78832804	PSMA4	0.65	4.77	0.44	6.62e-6	Sudden cardiac arrest;
THYM	cis	rs11605275	0.681	rs74841319	chr11:20027707	A/T	cg14835545	chr11:20032148	NAV2	-1.29	-6.34	-0.55	7.74e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs11250464	0.804	rs11250463	chr10:1406228	T/C	cg08668359	chr10:1443807	ADARB2	0.58	5.37	0.48	5.57e-7	Radiation response;
THYM	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.57	4.81	0.44	5.69e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs9790314	1.000	rs1993891	chr3:161047467	A/G	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg03929089	chr4:120376271	NA	-0.84	-8.56	-0.66	1.97e-13	Height;
THYM	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg09307838	chr4:120376055	NA	-0.69	-5.23	-0.47	1.01e-6	Corneal astigmatism;
THYM	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06481639	chr22:41940642	POLR3H	0.87	5.95	0.52	4.49e-8	Vitiligo;
THYM	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2239547	0.562	rs35380116	chr3:52979178	A/G	cg11645453	chr3:52864694	ITIH4	-0.28	-4.67	-0.43	1e-5	Schizophrenia;
THYM	cis	rs289828	0.579	rs56335263	chr2:152148131	T/A	cg05960677	chr2:152117363	RBM43	0.75	7.25	0.6	1.1e-10	Blood protein levels;
THYM	cis	rs870825	0.929	rs72689262	chr4:185590950	C/G	cg04058563	chr4:185651563	MLF1IP	0.96	6.73	0.57	1.26e-9	Blood protein levels;
THYM	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8068544	0.818	rs78333491	chr17:40163138	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.47	-7.45	-0.61	4.22e-11	Reticulocyte fraction of red cells;Reticulocyte count;
THYM	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.72	5.73	0.51	1.19e-7	Blood metabolite levels;
THYM	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.68	6.04	0.53	2.94e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.7	6.62	0.56	2.17e-9	Lymphocyte counts;
THYM	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	8.7	0.67	9.84e-14	Chronic sinus infection;
THYM	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg25703541	chr22:24373054	LOC391322	-0.72	-5.79	-0.51	9e-8	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs3849570	0.695	rs1851930	chr3:81895318	T/G	cg07356753	chr3:81810745	GBE1	-0.77	-5.78	-0.51	9.51e-8	Waist circumference;Body mass index;
THYM	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs12931267	0.561	rs34395984	chr16:89659511	C/T	cg07984980	chr16:89898383	SPIRE2	1.52	5.41	0.49	4.72e-7	Skin sensitivity to sun;Freckling;Hair color;
THYM	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-6.65	-0.56	1.84e-9	Chronic sinus infection;
THYM	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.58	0.43	1.41e-5	Bipolar disorder;
THYM	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.26	-9.1	-0.68	1.4e-14	Gut microbiome composition (summer);
THYM	cis	rs4455778	0.500	rs10224270	chr7:49041354	T/C	cg26309511	chr7:48887640	NA	0.63	5.47	0.49	3.67e-7	Lung cancer in never smokers;
THYM	cis	rs4285028	0.948	rs35902163	chr3:121649526	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs9534288	0.699	rs2296642	chr13:46656669	A/G	cg15192986	chr13:46630673	CPB2	-0.65	-4.54	-0.42	1.66e-5	Blood protein levels;
THYM	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg00278517	chr6:167070616	RPS6KA2	-0.35	-4.58	-0.42	1.44e-5	Crohn's disease;
THYM	cis	rs2732480	0.500	rs2450991	chr12:48651621	A/G	cg21466736	chr12:48725269	NA	-0.53	-4.91	-0.45	3.78e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs10896135	0.526	rs12795774	chr11:66381517	T/C	cg24851651	chr11:66362959	CCS	-0.85	-6.92	-0.58	5.14e-10	Bipolar disorder;
THYM	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg02820040	chr2:241836501	C2orf54	-0.33	-6.58	-0.56	2.59e-9	Urinary metabolites;
THYM	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-6.2	-0.54	1.47e-8	Total body bone mineral density;
THYM	cis	rs11671005	0.779	rs3794970	chr19:58986260	C/T	cg02808233	chr19:58920810	ZNF584	-0.58	-4.53	-0.42	1.68e-5	Mean platelet volume;
THYM	cis	rs7927592	0.913	rs12283755	chr11:68371658	A/G	cg20283391	chr11:68216788	NA	-0.79	-5.88	-0.52	6.21e-8	Total body bone mineral density;
THYM	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs4919687	0.550	rs7904252	chr10:104456725	A/C	cg18761893	chr10:103892519	PPRC1	-0.62	-4.75	-0.44	7.24e-6	Colorectal cancer;
THYM	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg23791538	chr6:167370224	RNASET2	-0.72	-5.66	-0.5	1.58e-7	Crohn's disease;
THYM	trans	rs11175492	1.000	rs11175489	chr12:65034641	C/T	cg12514734	chr12:3216258	TSPAN9	1.59	7.44	0.61	4.38e-11	Platelet count;
THYM	cis	rs6596100	0.538	rs72799458	chr5:132188063	C/T	cg02081065	chr5:132209139	LEAP2	-0.95	-6.14	-0.53	1.87e-8	Breast cancer;
THYM	cis	rs500891	0.525	rs12697921	chr6:84071913	G/C	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs7246657	0.714	rs12972195	chr19:37752505	T/C	cg22634378	chr19:37742834	NA	0.61	4.99	0.46	2.7e-6	Coronary artery calcification;
THYM	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg05802129	chr4:122689817	NA	-0.57	-4.47	-0.42	2.17e-5	Type 2 diabetes;
THYM	cis	rs1891275	0.509	rs34190234	chr10:93443074	A/C	cg07889827	chr10:93443413	NA	-0.47	-4.55	-0.42	1.57e-5	Intelligence (multi-trait analysis);
THYM	cis	rs11690935	0.885	rs10202823	chr2:172780132	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.71	-5.03	-0.46	2.27e-6	Schizophrenia;
THYM	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg10687131	chr2:20871002	GDF7	-0.72	-5.24	-0.47	9.68e-7	Abdominal aortic aneurysm;
THYM	cis	rs5753037	0.809	rs713657	chr22:30211876	A/G	cg27665648	chr22:30112403	NA	0.5	4.52	0.42	1.76e-5	Type 1 diabetes;
THYM	cis	rs7474896	0.561	rs2474603	chr10:38445682	C/T	cg13531842	chr10:38383804	ZNF37A	-0.73	-4.47	-0.42	2.2e-5	Obesity (extreme);
THYM	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg06618935	chr21:46677482	NA	-0.98	-9.57	-0.7	1.4e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg07636037	chr3:49044803	WDR6	0.85	7.6	0.62	2.06e-11	Parkinson's disease;
THYM	cis	rs4595586	0.545	rs4411311	chr12:39363612	C/G	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs7264396	0.836	rs4911183	chr20:34181553	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	0.61	4.79	0.44	6.08e-6	Total cholesterol levels;
THYM	cis	rs3741151	1.000	rs7949364	chr11:73041077	A/G	cg12959048	chr11:73096162	RELT	-0.46	-4.81	-0.44	5.69e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs208520	0.661	rs851466	chr6:66840476	A/G	cg07460842	chr6:66804631	NA	-0.96	-6.88	-0.58	6.25e-10	Exhaled nitric oxide output;
THYM	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14893161	chr1:205819251	PM20D1	0.9	9.23	0.69	7.34e-15	Menarche (age at onset);
THYM	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg00080972	chr5:178986291	RUFY1	-0.62	-8.7	-0.67	9.77e-14	Lung cancer;
THYM	cis	rs763014	0.838	rs4984670	chr16:641044	A/G	cg07343612	chr16:622815	PIGQ	-1.15	-12.09	-0.78	6.29e-21	Height;
THYM	cis	rs12754538	0.648	rs12028926	chr1:8818438	C/G	cg06159269	chr1:8767347	RERE	0.22	4.63	0.43	1.14e-5	Subjective well-being;
THYM	cis	rs6424115	1.000	rs12031592	chr1:24127864	A/C	cg15997130	chr1:24165203	NA	0.79	7.16	0.59	1.72e-10	Immature fraction of reticulocytes;
THYM	cis	rs9902453	0.866	rs4795529	chr17:28443549	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.67	0.56	1.69e-9	Coffee consumption (cups per day);
THYM	cis	rs11767557	0.938	rs10808026	chr7:143099133	C/A	cg05908241	chr7:143109367	NA	-0.65	-6.47	-0.55	4.33e-9	Alzheimer's disease (late onset);
THYM	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs977987	0.806	rs4888425	chr16:75476363	T/C	cg03315344	chr16:75512273	CHST6	0.74	5.92	0.52	5.07e-8	Dupuytren's disease;
THYM	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg03476357	chr21:30257390	N6AMT1	-0.61	-4.73	-0.44	7.84e-6	Dental caries;
THYM	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.5	-4.59	-0.43	1.35e-5	Rheumatoid arthritis;
THYM	cis	rs9880211	0.898	rs35304385	chr3:136386253	T/C	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg01579765	chr21:45077557	HSF2BP	0.47	7.1	0.59	2.21e-10	Mean corpuscular volume;
THYM	cis	rs7578361	0.918	rs115416348	chr2:150379954	A/G	cg17961725	chr2:150454027	NA	-0.77	-5.72	-0.51	1.25e-7	Acute lymphoblastic leukemia (childhood);
THYM	trans	rs10118776	0.677	rs13285109	chr9:6197408	A/G	cg02532923	chr16:89110004	NA	1.01	7.85	0.63	6.11e-12	Small cell lung carcinoma;
THYM	cis	rs11657217	0.677	rs8067469	chr17:77698322	G/A	cg06901238	chr17:77706717	ENPP7	0.79	8.08	0.64	2.08e-12	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
THYM	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg10792982	chr14:105748885	BRF1	0.76	7.95	0.63	3.92e-12	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7224737	1.000	rs739636	chr17:40281063	T/G	cg20291162	chr17:40259547	DHX58	-0.74	-6.93	-0.58	4.97e-10	Fibrinogen levels;
THYM	cis	rs1003719	0.680	rs7276569	chr21:38578207	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-4.53	-0.42	1.72e-5	Eye color traits;
THYM	cis	rs6665290	0.904	rs12409428	chr1:227189969	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.8	-6.0	-0.52	3.6e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg05738196	chr6:26577821	NA	0.81	7.99	0.63	3.09e-12	Intelligence (multi-trait analysis);
THYM	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.52	-6.64	-0.56	1.91e-9	Monocyte percentage of white cells;
THYM	cis	rs9894429	0.604	rs9912071	chr17:79609654	G/A	cg10661904	chr17:79619235	PDE6G	-0.57	-4.94	-0.45	3.37e-6	Eye color traits;
THYM	cis	rs6901250	0.851	rs6938235	chr6:117147946	G/T	cg12892004	chr6:117198278	RFX6	0.7	6.85	0.57	7.3e-10	C-reactive protein levels;
THYM	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg25036284	chr2:26402008	FAM59B	0.8	5.36	0.48	5.72e-7	Mean corpuscular hemoglobin;
THYM	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-5.33	-0.48	6.7e-7	Hemoglobin concentration;
THYM	cis	rs12142240	0.959	rs12137934	chr1:46728913	A/G	cg00530320	chr1:46809349	NSUN4	0.86	5.58	0.5	2.26e-7	Menopause (age at onset);
THYM	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg00074818	chr8:8560427	CLDN23	0.58	5.4	0.48	4.91e-7	Obesity-related traits;
THYM	trans	rs7952251	0.812	rs7105119	chr11:112427367	C/T	cg14154186	chr1:204970430	NFASC	-0.71	-7.14	-0.59	1.86e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.87	-4.64	-0.43	1.11e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg18402987	chr7:1209562	NA	0.72	5.18	0.47	1.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg25072359	chr17:41440525	NA	0.65	4.56	0.42	1.5e-5	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs79815064	0.850	rs75352297	chr3:46345151	T/C	cg20674725	chr3:47020919	NBEAL2	0.7	4.48	0.42	2.09e-5	Macrophage inflammatory protein 1b levels;
THYM	cis	rs854765	0.647	rs2955365	chr17:18023897	G/A	cg04398451	chr17:18023971	MYO15A	-0.96	-10.41	-0.73	2.25e-17	Total body bone mineral density;
THYM	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg03474202	chr17:45855739	NA	-0.74	-6.48	-0.55	4.1e-9	IgG glycosylation;
THYM	cis	rs752010	0.714	rs6658500	chr1:42088344	A/G	cg06885757	chr1:42089581	HIVEP3	-0.6	-7.65	-0.62	1.61e-11	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg02551604	chr5:131831745	NA	-1.01	-5.44	-0.49	4.05e-7	Asthma (sex interaction);
THYM	cis	rs6570726	0.791	rs365747	chr6:145866784	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-4.98	-0.45	2.87e-6	Obesity-related traits;
THYM	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg17911788	chr17:44343683	NA	0.71	6.76	0.57	1.09e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs526231	0.543	rs183752	chr5:102507812	T/C	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Primary biliary cholangitis;
THYM	cis	rs4866334	1.000	rs75023127	chr5:18487706	A/G	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs7833986	0.501	rs72653957	chr8:56990048	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	6.82	0.57	8.29e-10	Height;
THYM	cis	rs9527	0.590	rs10883834	chr10:104881402	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs2204008	0.682	rs10880321	chr12:38370110	C/G	cg26384229	chr12:38710491	ALG10B	-0.9	-7.09	-0.59	2.38e-10	Bladder cancer;
THYM	cis	rs4731207	0.596	rs7806530	chr7:124659884	C/T	cg05285228	chr7:124571219	POT1	0.69	5.25	0.47	9.35e-7	Cutaneous malignant melanoma;
THYM	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.74	-7.03	-0.59	3.08e-10	Personality dimensions;
THYM	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg12698349	chr2:225449008	CUL3	0.73	5.48	0.49	3.54e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs3960554	0.808	rs59882870	chr7:75638421	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.6	-5.03	-0.46	2.3e-6	Eotaxin levels;
THYM	cis	rs854765	0.624	rs12946746	chr17:17741669	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-5.66	-0.5	1.6e-7	Total body bone mineral density;
THYM	cis	rs554111	0.656	rs6685914	chr1:21362378	G/A	cg00373020	chr1:21041521	KIF17	-0.53	-4.46	-0.42	2.26e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs7020830	0.931	rs1388978	chr9:37144062	G/T	cg14294708	chr9:37120828	ZCCHC7	1.27	14.22	0.82	2.93e-25	Schizophrenia;
THYM	cis	rs4243830	0.850	rs2412309	chr1:6603151	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.11	-7.56	-0.61	2.57e-11	Body mass index;
THYM	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg26566898	chr11:117069891	TAGLN	0.4	5.1	0.46	1.76e-6	Blood protein levels;
THYM	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg22709100	chr7:91322751	NA	-0.62	-4.96	-0.45	3.05e-6	Breast cancer;
THYM	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg01831904	chr17:28903510	LRRC37B2	-1.13	-5.5	-0.49	3.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.76	5.48	0.49	3.44e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg23352942	chr3:46931381	PTH1R	-0.76	-7.41	-0.61	5.18e-11	Birth weight;
THYM	cis	rs4509693	0.882	rs7911997	chr10:102492380	A/G	cg24127310	chr10:102502104	NA	1.17	8.69	0.67	1.05e-13	Alzheimer's disease;
THYM	cis	rs1843834	1.000	rs4624372	chr2:225553128	A/G	cg22455342	chr2:225449267	CUL3	0.6	4.62	0.43	1.23e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs11252926	0.831	rs816570	chr10:680475	C/T	cg14018140	chr10:458528	DIP2C	0.55	5.21	0.47	1.09e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs34375054	0.526	rs117431213	chr12:125675271	C/G	cg25124228	chr12:125621409	AACS	-0.76	-5.79	-0.51	9.05e-8	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg13683864	chr3:40499215	RPL14	-0.88	-8.56	-0.66	1.96e-13	Renal cell carcinoma;
THYM	cis	rs1395	0.961	rs4665963	chr2:27528692	T/C	cg23587288	chr2:27483067	SLC30A3	-0.61	-5.16	-0.47	1.37e-6	Blood metabolite levels;
THYM	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg00271210	chr6:167070053	RPS6KA2	-0.73	-8.15	-0.64	1.44e-12	Crohn's disease;
THYM	trans	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg18335740	chr13:41363409	SLC25A15	0.74	8.2	0.64	1.13e-12	Lewy body disease;
THYM	cis	rs8016982	0.657	rs11625861	chr14:81735001	C/T	cg21807262	chr14:81713016	NA	0.53	5.01	0.46	2.56e-6	Schizophrenia;
THYM	cis	rs12188164	1.000	rs12188678	chr5:428231	T/C	cg14137381	chr5:502291	SLC9A3	-0.62	-4.57	-0.42	1.45e-5	Cystic fibrosis severity;
THYM	cis	rs4242434	0.646	rs6988593	chr8:22527440	A/G	cg03733263	chr8:22462867	KIAA1967	-0.98	-9.99	-0.72	1.73e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.0	9.81	0.71	4.11e-16	Colorectal cancer;
THYM	cis	rs2777491	1.000	rs7167729	chr15:41721042	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.12	-12.75	-0.79	2.77e-22	Ulcerative colitis;
THYM	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg10661904	chr17:79619235	PDE6G	0.53	4.74	0.44	7.56e-6	Eye color traits;
THYM	cis	rs476633	0.708	rs8030657	chr15:41444979	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.69	-5.4	-0.48	4.82e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7818345	0.613	rs13261732	chr8:19330215	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.46	4.62	0.43	1.22e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg09936400	chr10:82049201	MAT1A	0.43	4.54	0.42	1.64e-5	Post bronchodilator FEV1;
THYM	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg26031613	chr14:104095156	KLC1	0.79	5.22	0.47	1.06e-6	Body mass index;
THYM	cis	rs9807989	1.000	rs9807989	chr2:102971200	T/C	cg03938978	chr2:103052716	IL18RAP	0.63	6.46	0.55	4.36e-9	Asthma;
THYM	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg07936489	chr17:37558343	FBXL20	0.79	5.7	0.5	1.37e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg01448562	chr3:133502909	NA	-0.59	-4.7	-0.43	8.78e-6	Ankle injury;
THYM	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg09455208	chr3:40491958	NA	-0.43	-4.48	-0.42	2.06e-5	Renal cell carcinoma;
THYM	cis	rs7020830	0.858	rs7856690	chr9:37127545	A/T	cg14294708	chr9:37120828	ZCCHC7	1.23	12.74	0.79	2.79e-22	Schizophrenia;
THYM	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg08807101	chr21:30365312	RNF160	0.95	8.18	0.64	1.24e-12	Dental caries;
THYM	cis	rs59698941	0.943	rs79586717	chr5:132251790	T/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs11771526	1.000	rs17351142	chr7:32339843	T/G	cg13207630	chr7:32358064	NA	1.0	6.04	0.53	2.92e-8	Body mass index;
THYM	cis	rs2227564	0.620	rs3812637	chr10:75568846	C/T	cg00564723	chr10:75632066	CAMK2G	-0.5	-4.48	-0.42	2.1e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs901683	1.000	rs17157919	chr10:46044092	A/C	cg18240400	chr10:46168597	ANUBL1	-0.72	-4.93	-0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs9549367	0.789	rs9549698	chr13:113877701	A/G	cg18105134	chr13:113819100	PROZ	-1.0	-9.03	-0.68	1.92e-14	Platelet distribution width;
THYM	cis	rs28374715	0.578	rs7165914	chr15:41632451	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.78	-0.83	2.3e-26	Ulcerative colitis;
THYM	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg13319975	chr6:146136371	FBXO30	-0.63	-5.18	-0.47	1.24e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.0	-5.11	-0.46	1.65e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs728616	0.717	rs12412999	chr10:82008141	C/T	cg18148530	chr10:81370782	SFTPA1	0.76	4.97	0.45	2.96e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg06108461	chr20:60628389	TAF4	-1.03	-8.14	-0.64	1.49e-12	Body mass index;
THYM	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg03433033	chr1:76189801	ACADM	0.74	8.88	0.67	4.14e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg08859206	chr1:53392774	SCP2	0.51	5.4	0.48	4.94e-7	Monocyte count;
THYM	cis	rs2039659	0.719	rs4542551	chr13:86284155	A/G	cg25308322	chr13:86268291	NA	0.58	4.8	0.44	5.79e-6	Blood osmolality (transformed sodium);
THYM	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg22841779	chr14:105766346	BRF1	-0.46	-5.64	-0.5	1.74e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.32	9.94	0.71	2.24e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17739794	0.677	rs17739674	chr8:801584	G/T	cg20652464	chr8:752313	NA	-0.55	-4.49	-0.42	2.03e-5	Clozapine-induced cytotoxicity;
THYM	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg22683308	chr4:1340831	KIAA1530	-0.63	-4.52	-0.42	1.78e-5	Obesity-related traits;
THYM	cis	rs614226	0.748	rs78714658	chr12:121009944	G/A	cg01236616	chr12:121019343	POP5	-1.28	-9.66	-0.7	8.63e-16	Type 1 diabetes nephropathy;
THYM	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06481639	chr22:41940642	POLR3H	-0.8	-5.39	-0.48	5.08e-7	Vitiligo;
THYM	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg05347473	chr6:146136440	FBXO30	0.59	4.83	0.44	5.33e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg00339695	chr16:24857497	SLC5A11	0.47	4.7	0.43	8.71e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg22875332	chr1:76189707	ACADM	-0.87	-10.77	-0.74	3.75e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs11166927	1.000	rs11778622	chr8:140805582	A/G	cg16909799	chr8:140841666	TRAPPC9	0.64	5.7	0.5	1.34e-7	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs67072384	0.818	rs2291292	chr11:72467013	C/T	cg01380194	chr11:72452482	ARAP1	-0.81	-4.57	-0.42	1.49e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs1904096	0.506	rs17021463	chr4:95224812	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.54	-4.73	-0.44	7.71e-6	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg10515332	chr4:99064459	C4orf37	0.57	4.5	0.42	1.9e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg23989207	chr17:80870107	TBCD	0.62	5.24	0.47	9.74e-7	Glycated hemoglobin levels;
THYM	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg24209194	chr3:40518798	ZNF619	0.55	4.45	0.42	2.36e-5	Renal cell carcinoma;
THYM	cis	rs12681287	0.752	rs4288357	chr8:87251833	C/T	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs3772130	0.923	rs13434284	chr3:121482842	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs9972944	0.756	rs4791132	chr17:63769124	T/C	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs12208915	0.848	rs9352654	chr6:79500281	A/G	cg05283184	chr6:79620031	NA	0.78	5.04	0.46	2.22e-6	Left atrial antero-posterior diameter;
THYM	cis	rs7731657	0.509	rs9327583	chr5:130333614	T/A	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs7255436	0.965	rs11666233	chr19:8452045	G/T	cg10174797	chr19:8464628	RAB11B	0.43	5.19	0.47	1.21e-6	HDL cholesterol;
THYM	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg24675658	chr1:53192096	ZYG11B	-0.67	-5.48	-0.49	3.53e-7	Monocyte count;
THYM	cis	rs8033133	0.514	rs2732024	chr15:25297385	A/G	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.59	-4.56	-0.42	1.54e-5	Blood osmolality (transformed sodium);
THYM	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg03476357	chr21:30257390	N6AMT1	0.6	4.57	0.42	1.46e-5	Dental caries;
THYM	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg17063962	chr7:91808500	NA	-1.11	-11.18	-0.75	5.1e-19	Breast cancer;
THYM	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11890956	chr21:40555474	PSMG1	1.16	12.76	0.79	2.54e-22	Cognitive function;
THYM	cis	rs9972944	0.622	rs1895033	chr17:63777493	A/C	cg07283582	chr17:63770753	CCDC46	0.68	5.54	0.49	2.69e-7	Total body bone mineral density;
THYM	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg03188948	chr7:1209495	NA	1.04	6.09	0.53	2.41e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs78456975	0.739	rs11891867	chr2:1517894	C/T	cg12573674	chr2:1569213	NA	-1.23	-5.91	-0.52	5.35e-8	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2518683	0.628	rs174760	chr22:29700536	C/G	cg10230314	chr22:30552801	HORMAD2	-0.57	-4.48	-0.42	2.12e-5	Platelet count;
THYM	cis	rs6842047	1.000	rs10471184	chr4:187122904	C/T	cg02012338	chr4:187126139	CYP4V2	-0.99	-4.75	-0.44	7.1e-6	Blood protein levels;
THYM	cis	rs12446552	1.000	rs12446552	chr16:11720066	A/G	cg09662852	chr16:11707685	NA	-0.56	-5.59	-0.5	2.2e-7	Colorectal or endometrial cancer;
THYM	trans	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs10457678	0.564	rs2327901	chr6:139110033	T/C	cg05131254	chr6:138188363	TNFAIP3	0.63	4.45	0.42	2.33e-5	Colorectal or endometrial cancer;
THYM	cis	rs11771526	0.901	rs1530823	chr7:32311420	G/T	cg13207630	chr7:32358064	NA	-0.8	-5.05	-0.46	2.11e-6	Body mass index;
THYM	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg16325326	chr1:53192061	ZYG11B	0.81	7.52	0.61	3.05e-11	Monocyte count;
THYM	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg27490568	chr2:178487706	NA	0.64	5.74	0.51	1.12e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9302065	0.565	rs2993585	chr13:95961966	G/A	cg24476569	chr13:95954382	ABCC4	-0.79	-8.08	-0.64	2.05e-12	Blood metabolite levels;
THYM	trans	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7258015	0.865	rs1058154	chr19:10446897	C/A	cg01466491	chr19:10523363	NA	0.65	5.14	0.47	1.47e-6	Systemic lupus erythematosus or rheumatoid arthritis;
THYM	cis	rs9296092	0.560	rs9469505	chr6:33527348	A/G	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg03676636	chr4:99064102	C4orf37	0.43	6.32	0.54	8.55e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2554380	0.943	rs2585038	chr15:84337258	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.65	-5.11	-0.46	1.68e-6	Height;
THYM	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg02018176	chr4:1364513	KIAA1530	0.55	4.58	0.42	1.44e-5	Obesity-related traits;
THYM	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg26149184	chr10:133730230	NA	0.78	4.74	0.44	7.39e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg20290983	chr6:43655470	MRPS18A	1.44	16.17	0.86	4.93e-29	IgG glycosylation;
THYM	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg06028605	chr16:24865363	SLC5A11	-0.65	-5.07	-0.46	1.95e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7589342	0.899	rs879900	chr2:106494347	A/G	cg14210321	chr2:106509881	NCK2	-0.76	-5.84	-0.51	7.27e-8	Addiction;
THYM	cis	rs9788682	0.747	rs6495308	chr15:78907656	A/G	cg18825076	chr15:78729989	IREB2	0.6	5.0	0.46	2.58e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg03959625	chr15:84868606	LOC388152	0.47	4.47	0.42	2.2e-5	Schizophrenia;
THYM	cis	rs9840225	0.745	rs1499644	chr3:25235503	T/C	cg03152121	chr3:26146913	NA	-0.71	-4.46	-0.42	2.28e-5	PR interval in Tripanosoma cruzi seropositivity;
THYM	cis	rs6840360	0.642	rs7680013	chr4:152409477	A/C	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg00256281	chr22:41985642	PMM1	0.64	4.98	0.46	2.78e-6	Vitiligo;
THYM	cis	rs17401966	0.931	rs12137880	chr1:10388620	T/C	cg19773385	chr1:10388646	KIF1B	-0.6	-4.7	-0.43	8.88e-6	Hepatocellular carcinoma;
THYM	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg17143192	chr8:8559678	CLDN23	0.68	5.28	0.48	8.06e-7	Mood instability;
THYM	cis	rs2625529	0.668	rs12591313	chr15:72556746	T/C	cg16672083	chr15:72433130	SENP8	-0.54	-4.85	-0.45	4.88e-6	Red blood cell count;
THYM	trans	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg05926928	chr17:57297772	GDPD1	1.26	10.02	0.72	1.5e-16	Opioid sensitivity;
THYM	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg06238570	chr21:40685208	BRWD1	0.9	6.55	0.56	2.92e-9	Cognitive function;
THYM	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg18681998	chr4:17616180	MED28	0.85	7.68	0.62	1.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9677476	0.818	rs62197333	chr2:232085049	G/C	cg27665808	chr2:232055229	NA	0.56	4.59	0.43	1.33e-5	Food antigen IgG levels;
THYM	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg04398451	chr17:18023971	MYO15A	0.8	7.75	0.62	1.03e-11	Total body bone mineral density;
THYM	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg20744362	chr22:50050164	C22orf34	0.84	8.55	0.66	2.06e-13	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs289828	0.542	rs6723298	chr2:152159504	G/A	cg05960677	chr2:152117363	RBM43	0.68	6.36	0.55	6.97e-9	Blood protein levels;
THYM	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg06634786	chr22:41940651	POLR3H	-0.69	-5.53	-0.49	2.84e-7	Vitiligo;
THYM	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg08470875	chr2:26401718	FAM59B	0.73	4.51	0.42	1.84e-5	Gut microbiome composition (summer);
THYM	cis	rs59112743	0.510	rs2743548	chr6:15583824	A/C	cg10111214	chr6:14815676	NA	0.74	4.84	0.44	5.08e-6	Multiple keratinocyte cancers;
THYM	cis	rs6062788	0.617	rs71325425	chr20:61706114	G/A	cg17296441	chr20:62284078	STMN3	0.61	4.45	0.42	2.35e-5	Body mass index;
THYM	cis	rs8133932	0.701	rs2183599	chr21:47288873	C/G	cg20357416	chr21:47294739	PCBP3	-0.84	-5.2	-0.47	1.12e-6	Schizophrenia;
THYM	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg06558623	chr16:89946397	TCF25	1.34	5.65	0.5	1.67e-7	Skin colour saturation;
THYM	cis	rs35883536	0.588	rs12568329	chr1:101104588	A/G	cg06223162	chr1:101003688	GPR88	-0.62	-5.52	-0.49	2.96e-7	Monocyte count;
THYM	cis	rs34779708	0.931	rs34954932	chr10:35410807	G/T	cg03585969	chr10:35415529	CREM	0.66	4.76	0.44	6.85e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg02487422	chr3:49467188	NICN1	0.63	4.7	0.43	8.73e-6	Resting heart rate;
THYM	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg27414909	chr4:1201492	LOC100130872;LOC100130872-SPON2	0.59	4.59	0.43	1.34e-5	Longevity;
THYM	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg17554472	chr22:41940697	POLR3H	0.67	4.73	0.44	7.66e-6	Vitiligo;
THYM	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.77	-5.05	-0.46	2.13e-6	Mean platelet volume;
THYM	cis	rs57920188	0.535	rs10915658	chr1:4092921	T/C	cg08764037	chr1:3634867	TP73	-0.45	-4.68	-0.43	9.66e-6	Interleukin-17 levels;
THYM	cis	rs8016982	0.674	rs11850714	chr14:81662993	C/G	cg01989461	chr14:81687754	GTF2A1	0.86	7.64	0.62	1.67e-11	Schizophrenia;
THYM	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs7572733	0.534	rs1607374	chr2:198800440	A/G	cg00792783	chr2:198669748	PLCL1	0.84	6.0	0.52	3.51e-8	Dermatomyositis;
THYM	cis	rs3741151	0.773	rs57354084	chr11:73139376	A/T	cg17517138	chr11:73019481	ARHGEF17	0.94	5.48	0.49	3.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs3812049	0.784	rs3749748	chr5:127350549	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.71	-5.13	-0.47	1.55e-6	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg21775007	chr8:11205619	TDH	-0.69	-5.44	-0.49	4.07e-7	Retinal vascular caliber;
THYM	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg06623918	chr6:96969491	KIAA0776	-1.09	-10.31	-0.73	3.58e-17	Headache;
THYM	cis	rs7570971	0.792	rs56369224	chr2:136328890	A/T	cg07169764	chr2:136633963	MCM6	0.71	5.23	0.47	1.02e-6	Blood metabolite levels;Body mass index;Cholesterol, total;
THYM	cis	rs477692	0.625	rs4751104	chr10:131405358	G/A	cg05714579	chr10:131428358	MGMT	-0.77	-6.71	-0.57	1.38e-9	Response to temozolomide;
THYM	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg12310025	chr6:25882481	NA	0.72	5.86	0.52	6.59e-8	Blood metabolite levels;
THYM	cis	rs36051895	0.659	rs59668095	chr9:5043688	C/G	cg02405213	chr9:5042618	JAK2	-1.03	-10.88	-0.74	2.16e-18	Pediatric autoimmune diseases;
THYM	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg00339695	chr16:24857497	SLC5A11	-0.68	-6.18	-0.54	1.6e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg12826209	chr6:26865740	GUSBL1	0.94	5.02	0.46	2.37e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2430386	1.000	rs2430386	chr2:63178111	C/T	cg17519650	chr2:63277830	OTX1	0.68	5.35	0.48	6.14e-7	Prostate cancer;
THYM	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs9876781	0.900	rs1037773	chr3:48467902	C/T	cg06066452	chr3:48470258	PLXNB1	0.27	4.77	0.44	6.64e-6	Longevity;
THYM	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.51	-4.73	-0.44	7.86e-6	Crohn's disease;
THYM	cis	rs9649213	0.593	rs13246725	chr7:97914898	C/G	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9677476	0.821	rs6731682	chr2:232106245	G/C	cg07929768	chr2:232055508	NA	0.59	6.06	0.53	2.68e-8	Food antigen IgG levels;
THYM	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9814567	1.000	rs3932818	chr3:134206069	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-8.12	-0.64	1.71e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7727544	0.557	rs2897096	chr5:131486284	A/G	cg16205897	chr5:131564050	P4HA2	-0.45	-4.51	-0.42	1.83e-5	Blood metabolite levels;
THYM	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg13147721	chr7:65941812	NA	-0.71	-4.45	-0.42	2.33e-5	Diabetic kidney disease;
THYM	cis	rs459571	0.916	rs109536	chr9:136889987	G/C	cg13789015	chr9:136890014	NCRNA00094	0.84	7.24	0.6	1.16e-10	Platelet distribution width;
THYM	cis	rs8106542	0.906	rs3087969	chr19:10738639	C/T	cg17848348	chr19:10766748	ILF3	-0.81	-6.67	-0.56	1.7e-9	Platelet distribution width;
THYM	cis	rs7224737	1.000	rs8070446	chr17:40285879	G/A	cg20291162	chr17:40259547	DHX58	-0.7	-6.47	-0.55	4.18e-9	Fibrinogen levels;
THYM	cis	rs7809950	0.773	rs2237668	chr7:107050209	A/G	cg23024343	chr7:107201750	COG5	-0.97	-7.67	-0.62	1.5e-11	Coronary artery disease;
THYM	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs3796352	0.527	rs11716506	chr3:52944328	C/T	cg04865290	chr3:52927548	TMEM110	-0.8	-5.14	-0.47	1.47e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg26924012	chr15:45694286	SPATA5L1	1.05	9.37	0.69	3.68e-15	Homoarginine levels;
THYM	cis	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg07460842	chr6:66804631	NA	0.92	5.5	0.49	3.15e-7	Exhaled nitric oxide levels;
THYM	cis	rs877282	0.853	rs11595507	chr10:756703	C/T	cg10556349	chr10:835070	NA	-0.69	-4.49	-0.42	2.03e-5	Uric acid levels;
THYM	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs1255143	0.764	rs2799395	chr10:130055731	A/C	cg09953287	chr10:130009413	NA	0.58	4.55	0.42	1.56e-5	Interleukin-16 levels;
THYM	trans	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg07393940	chr7:158741817	NA	-1.14	-9.25	-0.69	6.69e-15	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs16912285	0.748	rs58504811	chr11:24252020	T/G	ch.11.24196551F	chr11:24239977	NA	0.91	5.3	0.48	7.44e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.56	4.79	0.44	6.05e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	cis	rs55728055	0.661	rs62237772	chr22:31964975	A/C	cg10537193	chr22:32026975	PISD	-0.68	-4.66	-0.43	1.03e-5	Age-related hearing impairment;
THYM	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg07636037	chr3:49044803	WDR6	0.75	5.24	0.47	9.51e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.65	-4.75	-0.44	7.21e-6	Response to fenofibrate (adiponectin levels);
THYM	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.7	-5.33	-0.48	6.74e-7	Response to bleomycin (chromatid breaks);
THYM	cis	rs1981331	0.609	rs76691528	chr21:48027823	T/C	cg17243659	chr21:48055224	PRMT2	1.24	5.31	0.48	7.32e-7	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-4.57	-0.42	1.49e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs8067545	0.750	rs4925077	chr17:19982276	C/T	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.63e-6	Schizophrenia;
THYM	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg27572855	chr1:25598939	RHD	0.65	4.93	0.45	3.43e-6	Erythrocyte sedimentation rate;
THYM	cis	rs10189230	0.834	rs10932914	chr2:222362999	C/A	cg14652038	chr2:222343519	EPHA4	0.59	4.79	0.44	6.17e-6	Urate levels in lean individuals;
THYM	cis	rs7241530	0.610	rs7239844	chr18:75893127	A/G	cg01960089	chr18:76674210	NA	0.54	4.81	0.44	5.61e-6	Educational attainment (years of education);
THYM	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg14129053	chr2:1895732	MYT1L	1.13	4.49	0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg18811423	chr2:55921094	PNPT1	-0.62	-5.82	-0.51	8.06e-8	Metabolic syndrome;
THYM	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg09307838	chr4:120376055	NA	0.78	5.62	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs3809566	1.000	rs4774471	chr15:63332645	A/T	cg00520135	chr15:63333846	TPM1	0.6	5.18	0.47	1.24e-6	Platelet count;
THYM	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg02527881	chr3:46936655	PTH1R	-0.69	-7.11	-0.59	2.11e-10	Colorectal cancer;
THYM	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg07606381	chr6:8435919	SLC35B3	0.63	4.71	0.43	8.51e-6	Motion sickness;
THYM	cis	rs12765878	0.967	rs10883941	chr10:105650782	C/T	cg11005552	chr10:105648138	OBFC1	0.87	11.39	0.76	1.84e-19	Coronary artery disease;
THYM	cis	rs684232	0.602	rs448465	chr17:559888	A/T	cg15660573	chr17:549704	VPS53	-0.96	-10.81	-0.74	3.17e-18	Prostate cancer;
THYM	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg01073479	chr16:3509474	NAT15	0.57	4.83	0.44	5.33e-6	Tuberculosis;
THYM	cis	rs8077889	1.000	rs59044152	chr17:41888747	A/G	cg26893861	chr17:41843967	DUSP3	1.09	10.05	0.72	1.3e-16	Triglycerides;
THYM	cis	rs7809950	0.678	rs982447	chr7:106973534	T/C	cg23024343	chr7:107201750	COG5	-1.0	-8.47	-0.66	3.05e-13	Coronary artery disease;
THYM	cis	rs4891159	0.756	rs55763305	chr18:74161249	G/C	cg24786174	chr18:74118243	ZNF516	-0.71	-7.97	-0.63	3.49e-12	Longevity;
THYM	cis	rs9992101	0.838	rs28418670	chr4:77371434	G/C	cg20311846	chr4:77356250	SHROOM3	-0.58	-5.26	-0.47	8.92e-7	Creatinine levels;
THYM	cis	rs2933343	0.729	rs6767104	chr3:128648117	G/T	cg11901034	chr3:128598214	ACAD9	0.68	5.36	0.48	5.9e-7	IgG glycosylation;
THYM	cis	rs735539	1.000	rs2290143	chr13:21280363	A/G	cg02792322	chr13:21280448	IL17D	0.67	4.95	0.45	3.17e-6	Dental caries;
THYM	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg08017756	chr2:100939284	LONRF2	-0.69	-7.09	-0.59	2.35e-10	Intelligence (multi-trait analysis);
THYM	cis	rs637571	0.607	rs575479	chr11:65690300	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.69	5.3	0.48	7.57e-7	Eosinophil percentage of white cells;
THYM	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs2267137	0.835	rs2267133	chr22:29765382	A/T	cg26480862	chr22:28839667	TTC28	0.45	4.46	0.42	2.25e-5	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs28595532	0.920	rs6818519	chr4:119787820	G/T	cg11846333	chr4:119757529	SEC24D	1.33	4.92	0.45	3.56e-6	Cannabis dependence symptom count;
THYM	cis	rs6701037	0.681	rs13374887	chr1:175131962	A/T	cg00958927	chr1:175162553	KIAA0040	0.33	4.48	0.42	2.06e-5	Alcohol dependence;
THYM	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg07424592	chr7:64974309	NA	1.12	5.24	0.47	9.64e-7	Diabetic kidney disease;
THYM	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs57920188	0.535	rs10915659	chr1:4092949	G/A	cg08764037	chr1:3634867	TP73	-0.45	-4.68	-0.43	9.66e-6	Interleukin-17 levels;
THYM	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg11597832	chr14:105993747	TMEM121	-0.53	-4.74	-0.44	7.53e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg14820908	chr5:178986412	RUFY1	0.65	6.5	0.56	3.62e-9	Lung cancer;
THYM	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.56	4.88	0.45	4.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg22508957	chr16:3507546	NAT15	-0.7	-7.05	-0.59	2.91e-10	Tuberculosis;
THYM	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg00684032	chr4:1343700	KIAA1530	0.61	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg03517284	chr6:25882590	NA	0.71	5.59	0.5	2.14e-7	Schizophrenia;
THYM	cis	rs2285947	0.967	rs2285944	chr7:21582964	A/T	cg04471919	chr7:21584483	DNAH11	0.45	4.47	0.42	2.16e-5	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
THYM	cis	rs2276498	0.751	rs71323984	chr20:52658295	G/A	cg23682609	chr20:52687365	BCAS1	0.56	4.55	0.42	1.6e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg02018176	chr4:1364513	KIAA1530	0.57	4.81	0.44	5.61e-6	Obesity-related traits;
THYM	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.88	8.57	0.66	1.84e-13	Menarche (age at onset);
THYM	cis	rs7589728	0.563	rs75606549	chr2:88466069	T/C	cg04511125	chr2:88470314	THNSL2	0.66	4.62	0.43	1.21e-5	Plasma clusterin levels;
THYM	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.8	8.45	0.65	3.38e-13	Lymphocyte counts;
THYM	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs4731207	0.596	rs12537431	chr7:124586556	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs11096990	0.855	rs2711989	chr4:39152036	A/G	cg24403649	chr4:39172243	NA	-0.62	-5.3	-0.48	7.5e-7	Cognitive function;
THYM	cis	rs4664308	0.837	rs56172865	chr2:160967333	C/T	cg03641300	chr2:160917029	PLA2R1	-0.71	-6.41	-0.55	5.48e-9	Idiopathic membranous nephropathy;
THYM	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg11335335	chr11:637885	DRD4	-0.63	-5.11	-0.46	1.64e-6	Systemic lupus erythematosus;
THYM	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg20744362	chr22:50050164	C22orf34	0.78	6.76	0.57	1.09e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg06558623	chr16:89946397	TCF25	1.33	5.62	0.5	1.94e-7	Skin colour saturation;
THYM	cis	rs2286885	1.000	rs1537989	chr9:129241824	C/T	cg14294646	chr9:129243551	FAM125B	-0.67	-6.41	-0.55	5.49e-9	Intraocular pressure;
THYM	cis	rs922692	1.000	rs11638372	chr15:78983559	A/G	cg15571903	chr15:79123663	NA	0.56	5.05	0.46	2.09e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg12564285	chr5:131593104	PDLIM4	0.44	4.69	0.43	9.21e-6	Breast cancer;
THYM	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg22907277	chr7:1156413	C7orf50	0.9	9.4	0.69	3.18e-15	Longevity;Endometriosis;
THYM	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg07636037	chr3:49044803	WDR6	0.97	9.82	0.71	4.1e-16	Parkinson's disease;
THYM	cis	rs1580019	0.961	rs4320456	chr7:32496003	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.59	0.56	2.42e-9	Cognitive ability;
THYM	cis	rs2456568	0.802	rs10765638	chr11:93636171	A/T	cg17595323	chr11:93583763	C11orf90	-0.58	-6.09	-0.53	2.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs40363	1.000	rs37771	chr16:3512866	G/T	cg22508957	chr16:3507546	NAT15	0.71	7.74	0.62	1.07e-11	Tuberculosis;
THYM	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg16797656	chr11:68205561	LRP5	0.52	6.08	0.53	2.47e-8	Total body bone mineral density;
THYM	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs854765	0.693	rs12936037	chr17:17777245	A/G	cg04398451	chr17:18023971	MYO15A	0.86	8.53	0.66	2.3e-13	Total body bone mineral density;
THYM	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs12477602	0.938	rs13024221	chr2:203058233	A/G	cg10634136	chr2:202901470	FZD7	0.63	4.5	0.42	1.89e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.66	-0.43	1.05e-5	Morning vs. evening chronotype;
THYM	cis	rs950776	0.714	rs3743073	chr15:78909539	G/T	cg06917634	chr15:78832804	PSMA4	-0.76	-6.43	-0.55	5.16e-9	Sudden cardiac arrest;
THYM	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg06784218	chr1:46089804	CCDC17	-0.31	-4.56	-0.42	1.51e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6686842	1.000	rs12134073	chr1:41689283	C/A	cg03387723	chr1:41708464	SCMH1	-0.43	-5.16	-0.47	1.37e-6	Height;
THYM	cis	rs11008222	0.935	rs11008223	chr10:31043077	G/A	cg00941203	chr10:31016591	NA	-0.35	-4.94	-0.45	3.39e-6	Congenital left-sided heart lesions (maternal effect);
THYM	cis	rs1018836	0.608	rs10094978	chr8:91509054	C/T	cg16814680	chr8:91681699	NA	-0.76	-6.27	-0.54	1.06e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg21862992	chr11:68658383	NA	0.23	4.51	0.42	1.86e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg07061783	chr6:25882402	NA	-0.88	-7.69	-0.62	1.32e-11	Intelligence (multi-trait analysis);
THYM	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg12373951	chr3:133503437	NA	0.56	6.17	0.53	1.69e-8	Iron status biomarkers;
THYM	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg18761221	chr20:60518478	NA	-0.7	-5.43	-0.49	4.34e-7	Obesity-related traits;
THYM	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg15451548	chr1:2144873	NA	-0.47	-4.54	-0.42	1.64e-5	Height;
THYM	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.67	8.57	0.66	1.83e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs7578361	0.959	rs11680630	chr2:150433128	C/G	cg17961725	chr2:150454027	NA	0.75	6.19	0.54	1.54e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	11.87	0.77	1.82e-20	Chronic sinus infection;
THYM	cis	rs13323323	0.652	rs9825080	chr3:44251270	C/T	cg16615211	chr3:44902933	MIR564;TMEM42	0.54	4.48	0.42	2.1e-5	IgG glycosylation;
THYM	cis	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg06521331	chr12:34319734	NA	0.84	6.44	0.55	4.78e-9	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7917772	0.582	rs12784963	chr10:104336986	G/A	cg00122347	chr10:104236741	TMEM180	0.42	6.22	0.54	1.34e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2456568	0.802	rs11020586	chr11:93638547	G/A	cg17347335	chr11:93583973	C11orf90	-0.48	-4.58	-0.43	1.39e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs72827839	0.779	rs57583172	chr17:46481963	G/A	cg23391107	chr17:45924227	SP6	0.86	5.55	0.5	2.54e-7	Ease of getting up in the morning;
THYM	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg05552183	chr6:42928497	GNMT	-0.7	-5.61	-0.5	2e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	trans	rs4650994	0.525	rs4993304	chr1:178535144	A/G	cg05059571	chr16:84539110	KIAA1609	-0.92	-10.85	-0.74	2.56e-18	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg24147428	chr11:65409760	SIPA1	-0.59	-4.56	-0.42	1.55e-5	Blood pressure (age interaction);
THYM	cis	rs317689	0.690	rs317646	chr12:69657145	A/G	cg20891283	chr12:69753455	YEATS4	-0.62	-4.48	-0.42	2.1e-5	Response to diuretic therapy;
THYM	cis	rs1448094	0.511	rs17279464	chr12:86164473	C/T	cg02569458	chr12:86230093	RASSF9	0.69	5.77	0.51	9.84e-8	Major depressive disorder;
THYM	cis	rs3017493	0.786	rs12295625	chr11:70671860	A/G	cg19942459	chr11:70508110	SHANK2	-1.16	-7.15	-0.59	1.8e-10	Renal transplant outcome;
THYM	cis	rs8018808	0.935	rs17824316	chr14:77930407	G/A	cg20045696	chr14:77926864	AHSA1	0.5	4.54	0.42	1.63e-5	Myeloid white cell count;
THYM	cis	rs2070488	1.000	rs13074160	chr3:38455650	G/T	cg24069376	chr3:38537580	EXOG	0.66	6.49	0.55	3.91e-9	Electrocardiographic conduction measures;
THYM	cis	rs9296092	0.517	rs62405949	chr6:33522800	G/A	cg13560919	chr6:33536144	NA	-0.94	-9.31	-0.69	4.9e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs4076764	0.846	rs12036398	chr1:163422204	C/T	cg06092702	chr1:163392909	NA	0.56	4.68	0.43	9.49e-6	Motion sickness;
THYM	cis	rs10484885	0.757	rs12215741	chr6:90154845	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.72	-5.87	-0.52	6.43e-8	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs11657217	0.638	rs4313839	chr17:77698619	C/T	cg06901238	chr17:77706717	ENPP7	-0.78	-7.77	-0.62	9.02e-12	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
THYM	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg26384229	chr12:38710491	ALG10B	0.73	5.35	0.48	6.04e-7	Morning vs. evening chronotype;
THYM	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg11247378	chr22:39784982	NA	-0.97	-10.29	-0.73	4.06e-17	Intelligence (multi-trait analysis);
THYM	cis	rs10463554	0.927	rs34825	chr5:102439318	T/C	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Parkinson's disease;
THYM	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.53	-4.92	-0.45	3.65e-6	Lymphocyte counts;
THYM	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg12292205	chr6:26970375	C6orf41	0.66	5.29	0.48	7.67e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6430585	0.702	rs746857	chr2:136554890	G/A	cg07169764	chr2:136633963	MCM6	-1.19	-12.55	-0.79	7.05e-22	Corneal structure;
THYM	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs6047844	0.750	rs6113509	chr20:22077352	G/A	cg16502866	chr20:23015624	SSTR4	-0.58	-4.48	-0.42	2.07e-5	Male-pattern baldness;
THYM	cis	rs901683	1.000	rs9422441	chr10:46048053	A/G	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7833986	0.501	rs72653959	chr8:56996516	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	6.82	0.57	8.29e-10	Height;
THYM	cis	rs6860806	0.507	rs270614	chr5:131640813	G/A	cg12564285	chr5:131593104	PDLIM4	0.46	5.01	0.46	2.49e-6	Breast cancer;
THYM	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg10360139	chr7:1886902	MAD1L1	0.63	5.52	0.49	2.9e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs265548	0.510	rs28415068	chr19:17910582	T/A	cg16744531	chr19:17905626	B3GNT3	0.58	6.06	0.53	2.75e-8	Tumor biomarkers;
THYM	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg05457628	chr5:178986728	RUFY1	0.64	6.53	0.56	3.29e-9	Lung cancer;
THYM	cis	rs790123	0.965	rs2133850	chr3:122381696	C/T	cg15604389	chr3:122379662	NA	0.6	5.47	0.49	3.62e-7	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs1499972	0.941	rs6769144	chr3:117624517	C/T	cg07612923	chr3:117604196	NA	1.19	5.0	0.46	2.66e-6	Schizophrenia;
THYM	cis	rs7084402	0.934	rs1593673	chr10:60294170	C/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.65e-7	Refractive error;
THYM	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg09877947	chr5:131593287	PDLIM4	0.61	5.08	0.46	1.86e-6	Acylcarnitine levels;
THYM	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg11366901	chr6:160182831	ACAT2	0.97	8.07	0.64	2.14e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2688608	0.530	rs71507081	chr10:75493136	G/A	cg19442545	chr10:75533431	FUT11	-0.51	-5.22	-0.47	1.03e-6	Inflammatory bowel disease;
THYM	cis	rs12410462	1.000	rs75637482	chr1:227622944	A/T	cg23173402	chr1:227635558	NA	0.68	6.15	0.53	1.79e-8	Major depressive disorder;
THYM	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	5.83	0.51	7.49e-8	Schizophrenia;
THYM	cis	rs12530845	0.623	rs76485854	chr7:135352668	T/C	cg19897172	chr7:135347071	PL-5283	-0.66	-5.51	-0.49	3.11e-7	Red blood cell traits;
THYM	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg27490568	chr2:178487706	NA	0.6	5.22	0.47	1.05e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg04518342	chr5:131593106	PDLIM4	0.49	5.26	0.47	8.91e-7	Acylcarnitine levels;
THYM	cis	rs7264396	0.563	rs2425088	chr20:34303902	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.69	-0.43	9.19e-6	Total cholesterol levels;
THYM	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg27129171	chr3:47204927	SETD2	-0.63	-5.12	-0.46	1.62e-6	Birth weight;
THYM	cis	rs8067545	0.636	rs11204300	chr17:20195438	C/T	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs924712	0.574	rs9370328	chr6:54680686	C/T	cg18532076	chr6:54711417	FAM83B	-0.51	-4.63	-0.43	1.17e-5	Breast cancer;
THYM	cis	rs6686842	1.000	rs11209718	chr1:41688938	C/T	cg03387723	chr1:41708464	SCMH1	-0.43	-5.05	-0.46	2.14e-6	Height;
THYM	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg23422044	chr7:1970798	MAD1L1	-0.77	-4.68	-0.43	9.38e-6	Neuroticism;
THYM	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs500891	0.525	rs1170341	chr6:84033239	A/C	cg21688264	chr6:84418724	SNAP91	0.79	5.09	0.46	1.83e-6	Platelet-derived growth factor BB levels;
THYM	cis	rs7107174	0.901	rs2450137	chr11:77925233	C/G	cg19901956	chr11:77921274	USP35	-0.71	-5.63	-0.5	1.8e-7	Testicular germ cell tumor;
THYM	cis	rs12216545	0.662	rs6972770	chr7:150240784	A/G	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7098100	0.748	rs10828252	chr10:21856475	G/T	cg04231319	chr10:21824447	MLLT10	-0.33	-4.46	-0.42	2.22e-5	Breast cancer;
THYM	cis	rs7084402	0.967	rs7921371	chr10:60330531	G/C	cg07615347	chr10:60278583	BICC1	-0.54	-5.08	-0.46	1.91e-6	Refractive error;
THYM	cis	rs1371867	0.817	rs1660314	chr8:101332953	C/T	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs11214589	0.719	rs4438071	chr11:113231614	C/T	cg14159747	chr11:113255604	NA	0.31	6.03	0.53	3.09e-8	Neuroticism;
THYM	cis	rs12579753	1.000	rs11115015	chr12:82174543	T/C	cg21231944	chr12:82153410	PPFIA2	-0.69	-5.26	-0.47	8.95e-7	Resting heart rate;
THYM	cis	rs6032067	0.777	rs56191952	chr20:43802487	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.93	-0.58	5.03e-10	Blood protein levels;
THYM	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg16325326	chr1:53192061	ZYG11B	-0.99	-11.45	-0.76	1.41e-19	Monocyte count;
THYM	cis	rs6430585	0.528	rs16832417	chr2:136744678	C/T	cg04750100	chr2:136595281	LCT	0.56	4.94	0.45	3.41e-6	Corneal structure;
THYM	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg10518543	chr12:38710700	ALG10B	0.59	4.97	0.45	3e-6	Morning vs. evening chronotype;
THYM	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg25703541	chr22:24373054	LOC391322	-1.01	-14.15	-0.82	3.93e-25	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg26597838	chr10:835615	NA	1.04	5.81	0.51	8.38e-8	Eosinophil percentage of granulocytes;
THYM	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg19746536	chr19:49375674	PPP1R15A	0.81	4.6	0.43	1.33e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03576123	chr11:487126	PTDSS2	-1.18	-5.77	-0.51	9.85e-8	Body mass index;
THYM	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg12031863	chr16:4587854	C16orf5	-0.47	-5.01	-0.46	2.48e-6	Schizophrenia;
THYM	cis	rs13065560	0.594	rs4234133	chr3:38888021	T/C	cg15678707	chr3:39149194	GORASP1;TTC21A	0.57	4.54	0.42	1.64e-5	Interleukin-18 levels;
THYM	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg03676636	chr4:99064102	C4orf37	0.45	6.69	0.57	1.51e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs988913	1.000	rs9370343	chr6:54820676	G/A	cg19716238	chr6:54711378	FAM83B	0.48	4.95	0.45	3.15e-6	Menarche (age at onset);
THYM	cis	rs10489202	0.913	rs380753	chr1:168035273	G/T	cg24449463	chr1:168025552	DCAF6	-0.77	-6.58	-0.56	2.52e-9	Schizophrenia;
THYM	cis	rs985746	0.614	rs2164778	chr4:36802605	C/A	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs2806561	0.734	rs10799788	chr1:23356864	G/A	cg12483005	chr1:23474871	LUZP1	0.54	5.49	0.49	3.4e-7	Height;
THYM	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg06713675	chr4:122721982	EXOSC9	0.59	5.52	0.49	2.89e-7	Type 2 diabetes;
THYM	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg18230493	chr5:56204884	C5orf35	0.62	4.7	0.43	8.66e-6	Initial pursuit acceleration;
THYM	cis	rs4880487	0.888	rs10794730	chr10:1247022	C/T	cg03183215	chr10:1252341	ADARB2	-0.99	-7.3	-0.6	8.86e-11	Migraine;
THYM	cis	rs1061377	0.965	rs10018622	chr4:39135564	G/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs10887741	0.532	rs791884	chr10:89410076	T/C	cg13926569	chr10:89418898	PAPSS2	-0.62	-5.89	-0.52	5.75e-8	Exercise (leisure time);
THYM	cis	rs754466	1.000	rs754466	chr10:79680434	A/T	cg17075019	chr10:79541650	NA	-0.61	-4.65	-0.43	1.08e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1915146	0.546	rs2454055	chr10:126859832	T/C	cg05090351	chr10:126851162	NA	0.66	7.15	0.59	1.79e-10	Menarche (age at onset);
THYM	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg22907277	chr7:1156413	C7orf50	0.8	4.85	0.45	4.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg06850241	chr22:41845214	NA	0.53	4.56	0.42	1.54e-5	Vitiligo;
THYM	cis	rs2281845	0.929	rs10920121	chr1:201079718	C/T	cg17810781	chr1:201082982	CACNA1S	0.66	7.09	0.59	2.4e-10	Permanent tooth development;
THYM	cis	rs985746	0.568	rs7665310	chr4:36821319	G/T	cg04301614	chr4:37585993	C4orf19	0.56	4.55	0.42	1.58e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg12560992	chr17:57184187	TRIM37	0.92	8.53	0.66	2.29e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg14228332	chr4:119757509	SEC24D	1.36	5.21	0.47	1.12e-6	Cannabis dependence symptom count;
THYM	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.82	-6.47	-0.55	4.26e-9	IgG glycosylation;
THYM	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs9378357	0.850	rs9392474	chr6:3293731	G/A	cg10513992	chr6:3293720	SLC22A23	-0.88	-4.49	-0.42	2.02e-5	Obesity-related traits;
THYM	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg19748678	chr4:122722346	EXOSC9	0.68	4.77	0.44	6.6e-6	Type 2 diabetes;
THYM	cis	rs6754311	0.550	rs3213889	chr2:136511575	A/G	cg07169764	chr2:136633963	MCM6	-0.67	-5.92	-0.52	5.11e-8	Mosquito bite size;
THYM	cis	rs2235642	0.964	rs2745181	chr16:1577056	A/G	cg07639376	chr16:1584516	IFT140;TMEM204	-0.5	-4.46	-0.42	2.21e-5	Coronary artery disease;
THYM	cis	rs7582180	0.790	rs13020451	chr2:100927131	T/G	cg21926883	chr2:100939477	LONRF2	-0.61	-5.52	-0.49	2.91e-7	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	5.23	0.47	1e-6	Obesity-related traits;
THYM	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg13695892	chr22:41940480	POLR3H	-0.88	-6.16	-0.53	1.73e-8	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg04455712	chr21:45112962	RRP1B	0.53	4.82	0.44	5.37e-6	Mean corpuscular volume;
THYM	cis	rs6840360	0.904	rs73862064	chr4:152503100	T/A	cg17479576	chr4:152424074	FAM160A1	-0.64	-4.81	-0.44	5.66e-6	Intelligence (multi-trait analysis);
THYM	cis	rs78062588	1.000	rs73001420	chr1:154586759	C/G	cg03138446	chr1:153746880	SLC27A3	1.19	4.64	0.43	1.1e-5	Lung cancer;
THYM	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.04	8.99	0.68	2.42e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg00981070	chr1:2046702	PRKCZ	0.47	5.21	0.47	1.1e-6	Height;
THYM	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg24375607	chr4:120327624	NA	-0.68	-5.44	-0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg11861562	chr11:117069780	TAGLN	-0.33	-4.76	-0.44	6.88e-6	Blood protein levels;
THYM	cis	rs1894633	0.574	rs10489286	chr1:172312919	A/G	cg13446689	chr1:172328377	DNM3	-0.51	-4.74	-0.44	7.43e-6	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs8025790	0.508	rs4776370	chr15:67904511	T/C	cg24579218	chr15:68104479	NA	-0.73	-6.66	-0.56	1.76e-9	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg03060546	chr3:49711283	APEH	-0.67	-5.08	-0.46	1.85e-6	Educational attainment (college completion);
THYM	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	trans	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg10856724	chr12:34555212	NA	-0.86	-7.58	-0.61	2.27e-11	Bladder cancer;
THYM	cis	rs9296092	0.538	rs112113649	chr6:33524529	A/G	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg07169764	chr2:136633963	MCM6	-0.64	-5.91	-0.52	5.45e-8	Mosquito bite size;
THYM	cis	rs72829446	0.530	rs11869899	chr17:7407915	C/T	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs887829	0.570	rs6736743	chr2:234595950	G/A	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.59	-0.43	1.36e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg04043695	chr12:129287642	SLC15A4	0.61	5.07	0.46	1.98e-6	Systemic lupus erythematosus;
THYM	cis	rs858239	0.633	rs858300	chr7:23244631	A/G	cg18081818	chr7:23246105	NA	-0.6	-5.43	-0.49	4.39e-7	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7731657	0.537	rs971700	chr5:130361575	T/G	cg08523029	chr5:130500466	HINT1	-0.81	-5.6	-0.5	2.04e-7	Fasting plasma glucose;
THYM	cis	rs6815814	0.904	rs67712706	chr4:38820616	A/G	cg14665413	chr4:38859728	TLR6	-0.39	-4.55	-0.42	1.6e-5	Breast cancer;
THYM	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg26384229	chr12:38710491	ALG10B	0.73	5.4	0.48	5.01e-7	Morning vs. evening chronotype;
THYM	cis	rs11838776	0.586	rs750598	chr13:111028978	C/T	cg05272587	chr13:111038400	COL4A2	-0.54	-4.73	-0.44	7.65e-6	Coronary artery disease;
THYM	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg05368731	chr17:41323189	NBR1	-1.2	-10.93	-0.75	1.72e-18	Menopause (age at onset);
THYM	cis	rs6674176	0.542	rs2906468	chr1:44319007	A/G	cg15962314	chr1:44399869	ARTN	0.49	4.68	0.43	9.61e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs6840360	0.967	rs6832562	chr4:152602798	A/G	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs67981189	0.570	rs67188216	chr14:71509324	T/A	cg15910301	chr14:71632612	NA	0.56	4.88	0.45	4.23e-6	Schizophrenia;
THYM	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg03476357	chr21:30257390	N6AMT1	-0.61	-4.59	-0.43	1.38e-5	Dental caries;
THYM	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg11764359	chr7:65958608	NA	-0.74	-6.15	-0.53	1.85e-8	Aortic root size;
THYM	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11644478	chr21:40555479	PSMG1	1.0	7.89	0.63	5.24e-12	Cognitive function;
THYM	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg01751800	chr4:77820391	ANKRD56	0.55	4.56	0.42	1.51e-5	Emphysema distribution in smoking;
THYM	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg26022315	chr17:47021804	SNF8	0.51	4.87	0.45	4.44e-6	Type 2 diabetes;
THYM	cis	rs988913	0.768	rs9396003	chr6:54741853	A/G	cg18532076	chr6:54711417	FAM83B	0.51	4.78	0.44	6.31e-6	Menarche (age at onset);
THYM	cis	rs2456568	0.867	rs2462744	chr11:93682913	G/A	cg26875233	chr11:93583750	C11orf90	-0.5	-4.88	-0.45	4.28e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs12928939	0.518	rs12445564	chr16:71943309	C/T	cg03805757	chr16:71968109	PKD1L3	-1.06	-9.92	-0.71	2.48e-16	Post bronchodilator FEV1;
THYM	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg09307838	chr4:120376055	NA	0.62	4.73	0.44	7.88e-6	Corneal astigmatism;
THYM	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs1784581	0.802	rs9458430	chr6:162426517	G/T	cg17173639	chr6:162384350	PARK2	-0.79	-7.76	-0.62	9.45e-12	Itch intensity from mosquito bite;
THYM	cis	rs17209837	0.607	rs4148813	chr7:87092376	A/G	cg04996195	chr7:87105398	ABCB4	0.63	4.79	0.44	6.03e-6	Gallbladder cancer;
THYM	cis	rs11608355	0.810	rs2217971	chr12:109857666	G/C	cg11367159	chr12:110044531	NA	0.6	5.17	0.47	1.31e-6	Neuroticism;
THYM	cis	rs10779751	0.922	rs2746637	chr1:11275588	A/G	cg08854313	chr1:11322531	MTOR	0.9	7.65	0.62	1.61e-11	Body mass index;
THYM	cis	rs10457678	0.564	rs7751745	chr6:139109125	A/G	cg05131254	chr6:138188363	TNFAIP3	0.63	4.45	0.42	2.33e-5	Colorectal or endometrial cancer;
THYM	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg02527881	chr3:46936655	PTH1R	0.52	4.99	0.46	2.77e-6	Colorectal cancer;
THYM	cis	rs10871290	0.801	rs3851726	chr16:74471644	G/C	cg01733217	chr16:74700730	RFWD3	-0.66	-5.72	-0.51	1.23e-7	Breast cancer;
THYM	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg12310025	chr6:25882481	NA	-0.69	-5.47	-0.49	3.69e-7	Blood metabolite levels;
THYM	cis	rs4866334	0.867	rs6452353	chr5:18482116	C/T	cg18608440	chr5:17519013	NA	-1.07	-4.95	-0.45	3.24e-6	IgG glycosylation;
THYM	trans	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg13615516	chr5:77269221	NA	0.84	7.68	0.62	1.4e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs514406	0.597	rs1241980	chr1:53286013	A/G	cg25767906	chr1:53392781	SCP2	0.69	5.82	0.51	8.07e-8	Monocyte count;
THYM	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs12530845	1.000	rs12530845	chr7:135329978	T/C	cg23117316	chr7:135346802	PL-5283	-0.66	-5.88	-0.52	6.21e-8	Red blood cell traits;
THYM	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg22852734	chr6:133119734	C6orf192	-1.32	-8.71	-0.67	9.24e-14	Type 2 diabetes nephropathy;
THYM	cis	rs17511627	0.808	rs7984239	chr13:26742786	A/G	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg03929089	chr4:120376271	NA	-0.98	-12.23	-0.78	3.3e-21	Coronary artery disease;
THYM	cis	rs2562152	0.706	rs216598	chr16:108585	T/C	cg02949481	chr16:131562	MPG	0.82	5.25	0.47	9.24e-7	Glioblastoma;
THYM	cis	rs1568889	1.000	rs12797712	chr11:28290890	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	4.52	0.42	1.75e-5	Bipolar disorder;
THYM	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg18305652	chr10:134549665	INPP5A	0.75	5.92	0.52	5.16e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg08968635	chr6:28129556	ZNF389	-0.61	-4.59	-0.43	1.35e-5	Parkinson's disease;
THYM	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg00074818	chr8:8560427	CLDN23	0.53	4.76	0.44	6.82e-6	Obesity-related traits;
THYM	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.7	-6.4	-0.55	5.74e-9	Personality dimensions;
THYM	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg18105134	chr13:113819100	PROZ	-0.98	-9.05	-0.68	1.79e-14	Platelet distribution width;
THYM	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2505998	0.833	rs1864403	chr10:43604950	C/T	cg06632098	chr10:43605906	RET	1.1	10.64	0.74	7.21e-18	Hirschsprung disease;
THYM	cis	rs6598955	0.543	rs17163720	chr1:26549399	A/G	cg04990556	chr1:26633338	UBXN11	-0.96	-6.06	-0.53	2.7e-8	Obesity-related traits;
THYM	cis	rs2456568	0.867	rs10501810	chr11:93666589	C/G	cg17595323	chr11:93583763	C11orf90	-0.56	-5.55	-0.49	2.56e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs983545	0.800	rs6783752	chr3:16966387	G/A	cg24159436	chr3:16974681	PLCL2	0.32	4.92	0.45	3.67e-6	Blood protein levels;
THYM	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg05731713	chr7:157510257	PTPRN2	0.54	5.33	0.48	6.68e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs4731207	0.698	rs6963177	chr7:124444604	T/A	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg02493798	chr17:6899577	ALOX12	-0.63	-8.36	-0.65	5.32e-13	Tonsillectomy;
THYM	cis	rs995000	0.931	rs637723	chr1:62906728	C/T	cg06896770	chr1:63153194	DOCK7	0.91	7.48	0.61	3.73e-11	Triglyceride levels;
THYM	cis	rs6748734	0.625	rs7355583	chr2:241821707	T/C	cg15164180	chr2:241846931	NA	-0.33	-4.54	-0.42	1.66e-5	Urinary metabolites;
THYM	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg00012203	chr2:219082015	ARPC2	0.65	5.63	0.5	1.86e-7	Colorectal cancer;
THYM	cis	rs7683537	0.887	rs7678412	chr4:185648611	T/C	cg04058563	chr4:185651563	MLF1IP	1.08	9.83	0.71	3.88e-16	Systemic lupus erythematosus;
THYM	cis	rs9658691	0.607	rs12411483	chr10:90780910	G/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.88	-5.87	-0.52	6.48e-8	Mosquito bite size;
THYM	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs990171	1.000	rs3860444	chr2:103007623	A/G	cg13897122	chr2:103039542	IL18RAP	-0.39	-4.79	-0.44	6.08e-6	Lymphocyte counts;
THYM	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg12311346	chr5:56204834	C5orf35	0.89	6.28	0.54	1.03e-8	Initial pursuit acceleration;
THYM	trans	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg05926928	chr17:57297772	GDPD1	1.26	10.02	0.72	1.5e-16	Opioid sensitivity;
THYM	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg14416269	chr4:6271139	WFS1	0.54	5.33	0.48	6.51e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs1499972	0.941	rs62264762	chr3:117634443	C/A	cg07612923	chr3:117604196	NA	1.29	5.37	0.48	5.63e-7	Schizophrenia;
THYM	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg00814883	chr7:100076585	TSC22D4	-0.94	-6.33	-0.54	7.91e-9	Platelet count;
THYM	cis	rs4718428	1.000	rs4718421	chr7:66350300	C/T	cg12165864	chr7:66369176	NA	-0.72	-5.46	-0.49	3.73e-7	Corneal structure;
THYM	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg16325326	chr1:53192061	ZYG11B	0.98	10.84	0.74	2.68e-18	Monocyte count;
THYM	trans	rs2136093	0.600	rs1981302	chr1:90908547	T/C	cg19688584	chr6:167529678	CCR6	0.5	7.06	0.59	2.66e-10	Response to antidepressants;
THYM	cis	rs9443645	0.509	rs12176511	chr6:79565721	G/A	cg05283184	chr6:79620031	NA	0.69	6.12	0.53	2.06e-8	Intelligence (multi-trait analysis);
THYM	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg22664400	chr11:66445111	RBM4B	-0.66	-4.47	-0.42	2.14e-5	Crohn's disease;
THYM	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg23851026	chr2:136556271	LCT	0.54	5.79	0.51	9.16e-8	Mosquito bite size;
THYM	cis	rs6840360	1.000	rs6823194	chr4:152604543	T/C	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg17145862	chr1:211918768	LPGAT1	0.9	8.99	0.68	2.44e-14	Leprosy;
THYM	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg05973401	chr12:123451056	ABCB9	0.68	4.55	0.42	1.58e-5	Neutrophil percentage of white cells;
THYM	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs10504073	0.669	rs4493917	chr8:50015846	C/T	cg00325661	chr8:49890786	NA	0.92	8.49	0.66	2.72e-13	Blood metabolite ratios;
THYM	cis	rs4733781	1.000	rs12680942	chr8:131264033	A/G	cg16277922	chr8:131349729	ASAP1	0.65	4.53	0.42	1.74e-5	Tuberculosis;
THYM	cis	rs6430585	0.527	rs62168833	chr2:136449254	G/A	cg07169764	chr2:136633963	MCM6	1.03	9.12	0.68	1.26e-14	Corneal structure;
THYM	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs10819861	0.645	rs10819815	chr9:98854722	G/A	cg14508093	chr9:98862825	NA	-0.23	-4.47	-0.42	2.17e-5	Electrocardiographic traits;
THYM	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg26384229	chr12:38710491	ALG10B	-0.73	-6.01	-0.52	3.42e-8	Morning vs. evening chronotype;
THYM	cis	rs7432375	0.641	rs835649	chr3:136671890	G/A	cg21827317	chr3:136751795	NA	0.62	5.32	0.48	7.01e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs925255	0.776	rs2279990	chr2:28636740	C/T	cg24044560	chr2:28636791	FOSL2	0.5	5.21	0.47	1.08e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7173743	0.525	rs8027870	chr15:79134045	A/G	cg15571903	chr15:79123663	NA	0.47	4.65	0.43	1.07e-5	Coronary artery disease;
THYM	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs3892630	0.757	rs8109823	chr19:33183316	A/G	cg02283691	chr19:33182526	NUDT19	-0.41	-4.9	-0.45	3.97e-6	Red blood cell traits;
THYM	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg09307838	chr4:120376055	NA	0.73	5.19	0.47	1.21e-6	Corneal astigmatism;
THYM	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg00981070	chr1:2046702	PRKCZ	-0.45	-5.73	-0.51	1.17e-7	Height;
THYM	cis	rs9905704	0.647	rs2108435	chr17:57102133	T/C	cg12560992	chr17:57184187	TRIM37	-0.71	-5.86	-0.52	6.52e-8	Testicular germ cell tumor;
THYM	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg01699819	chr7:1052092	C7orf50	-0.82	-6.87	-0.58	6.68e-10	Bronchopulmonary dysplasia;
THYM	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg11663144	chr21:46675770	NA	-0.71	-9.92	-0.71	2.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7107174	0.892	rs4944196	chr11:78008731	G/A	cg19901956	chr11:77921274	USP35	-0.69	-5.3	-0.48	7.42e-7	Testicular germ cell tumor;
THYM	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg06582575	chr6:163149167	PACRG;PARK2	1.08	7.64	0.62	1.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17006441	0.834	rs7626717	chr3:69845194	A/G	cg18496212	chr3:69797108	MITF	0.7	7.17	0.59	1.64e-10	Hemoglobin concentration;
THYM	cis	rs6921919	0.583	rs2041230	chr6:28365515	A/G	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.5	-0.42	1.89e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg09307838	chr4:120376055	NA	0.78	5.64	0.5	1.76e-7	Corneal astigmatism;
THYM	cis	rs8133932	0.621	rs1124309	chr21:47328767	C/A	cg20357416	chr21:47294739	PCBP3	-0.81	-4.93	-0.45	3.54e-6	Schizophrenia;
THYM	cis	rs7404928	0.651	rs9924831	chr16:23940738	T/C	cg26685404	chr16:23957272	PRKCB	0.61	7.0	0.58	3.53e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs67311347	0.910	rs13089215	chr3:40495894	T/C	cg13683864	chr3:40499215	RPL14	0.92	9.3	0.69	5.13e-15	Renal cell carcinoma;
THYM	cis	rs6980334	0.906	rs10264658	chr7:137779000	T/C	cg11874123	chr7:137028198	PTN	0.67	5.24	0.47	9.68e-7	Blood metabolite ratios;
THYM	cis	rs4589258	0.788	rs2105797	chr11:90478581	G/A	cg26138821	chr11:89956704	CHORDC1	-0.58	-4.66	-0.43	1.05e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg06064525	chr11:970664	AP2A2	0.36	7.05	0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.7	5.33	0.48	6.5e-7	Tonsillectomy;
THYM	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.29	-0.48	7.96e-7	Hemoglobin concentration;
THYM	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg19761014	chr17:28927070	LRRC37B2	0.89	4.93	0.45	3.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg03676636	chr4:99064102	C4orf37	0.5	7.65	0.62	1.6e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.44	5.29	0.48	7.96e-7	Monocyte percentage of white cells;
THYM	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg03806693	chr22:41940476	POLR3H	-0.78	-6.81	-0.57	8.72e-10	Neuroticism;
THYM	cis	rs10411161	0.579	rs59305384	chr19:52387064	A/G	cg25361850	chr19:52391789	ZNF577	0.75	5.28	0.48	8.02e-7	Breast cancer;
THYM	cis	rs289828	1.000	rs6715393	chr2:152140908	A/G	cg05960677	chr2:152117363	RBM43	0.59	5.54	0.49	2.73e-7	Blood protein levels;
THYM	cis	rs7528419	0.895	rs599839	chr1:109822166	A/G	cg00908766	chr1:109817496	CELSR2	-0.77	-6.26	-0.54	1.09e-8	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
THYM	cis	rs7771547	0.519	rs4713972	chr6:36371316	C/A	cg07856975	chr6:36356162	ETV7	0.65	5.5	0.49	3.13e-7	Platelet distribution width;
THYM	cis	rs7952251	0.528	rs11602446	chr11:112422841	C/T	cg13591377	chr11:112037102	TEX12	0.86	4.67	0.43	9.88e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7843479	0.582	rs11779655	chr8:21794041	A/G	cg17168535	chr8:21777572	XPO7	-0.96	-8.96	-0.68	2.81e-14	Mean corpuscular volume;
THYM	cis	rs6459804	0.935	rs72505543	chr7:157508867	G/A	cg15733309	chr7:157513707	PTPRN2	0.56	5.98	0.52	3.95e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs7189233	0.955	rs7184800	chr16:53509131	G/A	cg02965178	chr16:53538660	AKTIP	-0.59	-4.68	-0.43	9.61e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2242194	0.550	rs6682611	chr1:154997674	T/A	cg12436631	chr1:155007014	DCST1;DCST2	0.86	8.45	0.66	3.33e-13	Schizophrenia;
THYM	cis	rs4363385	0.626	rs1108410	chr1:153005662	T/C	cg13444842	chr1:152974279	SPRR3	-0.59	-4.66	-0.43	1.01e-5	Inflammatory skin disease;
THYM	cis	rs12500482	0.935	rs12644638	chr4:2413461	C/T	cg26605046	chr4:2439731	NA	-0.49	-4.5	-0.42	1.94e-5	Cognitive function;
THYM	cis	rs3903072	0.528	rs7928652	chr11:65580228	A/C	cg00576331	chr11:65640516	EFEMP2	-0.61	-4.49	-0.42	2e-5	Breast cancer;
THYM	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.63	5.08	0.46	1.87e-6	Blood protein levels;
THYM	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.5	-4.96	-0.45	3.07e-6	Crohn's disease;
THYM	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg11941060	chr3:133502564	NA	-0.73	-6.25	-0.54	1.18e-8	Iron status biomarkers;
THYM	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg11266682	chr4:10021025	SLC2A9	-0.52	-6.81	-0.57	8.66e-10	Bone mineral density;
THYM	cis	rs2398893	0.920	rs35886839	chr9:96738232	G/A	cg14459158	chr9:96720562	NA	0.53	4.65	0.43	1.06e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg14972814	chr11:95582409	MTMR2	-0.73	-6.62	-0.56	2.17e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs61931739	0.929	rs10844740	chr12:34067930	C/T	cg10856724	chr12:34555212	NA	0.6	5.33	0.48	6.65e-7	Morning vs. evening chronotype;
THYM	cis	rs6032067	0.929	rs8126178	chr20:43822581	A/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.44	-5.26	-0.47	8.92e-7	Blood protein levels;
THYM	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.14	-0.64	1.51e-12	Personality dimensions;
THYM	cis	rs728616	0.867	rs61860420	chr10:81739379	G/A	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg08772003	chr10:104629869	AS3MT	-0.55	-4.88	-0.45	4.23e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg06634786	chr22:41940651	POLR3H	-0.7	-5.1	-0.46	1.73e-6	Vitiligo;
THYM	cis	rs3087591	0.853	rs2953003	chr17:29502731	T/C	cg24425628	chr17:29625626	OMG;NF1	0.65	5.69	0.5	1.38e-7	Hip circumference;
THYM	cis	rs2278491	0.557	rs12675093	chr8:117798198	C/T	cg23513447	chr8:117778558	UTP23	0.62	4.51	0.42	1.84e-5	Body mass index;
THYM	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg15445000	chr17:37608096	MED1	0.41	5.04	0.46	2.26e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg24642844	chr7:1081250	C7orf50	-1.29	-8.3	-0.65	7.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	5.37	0.48	5.69e-7	Obesity-related traits;
THYM	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg22709100	chr7:91322751	NA	0.61	4.86	0.45	4.66e-6	Breast cancer;
THYM	cis	rs2249694	0.919	rs10857768	chr10:135402703	A/G	cg20169779	chr10:135381914	SYCE1	-0.53	-4.45	-0.42	2.34e-5	Obesity-related traits;
THYM	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.96	8.0	0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs735396	1.000	rs1169306	chr12:121438311	C/T	cg02403541	chr12:121454288	C12orf43	0.59	4.73	0.44	7.87e-6	N-glycan levels;
THYM	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.37	-0.48	5.64e-7	Total cholesterol levels;
THYM	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg22117172	chr7:91764530	CYP51A1	0.37	4.84	0.44	5.01e-6	Breast cancer;
THYM	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.77	7.29	0.6	8.94e-11	Lymphocyte counts;
THYM	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg27286337	chr10:134555280	INPP5A	0.85	6.36	0.55	6.91e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs4654899	0.643	rs1408409	chr1:21089781	T/C	cg01072550	chr1:21505969	NA	-0.62	-5.66	-0.5	1.62e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	7.2	0.59	1.38e-10	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg15247329	chr7:2764246	NA	-0.69	-5.71	-0.51	1.28e-7	Height;
THYM	cis	rs2718058	0.519	rs2598047	chr7:37888488	G/T	cg15028436	chr7:37888078	TXNDC3	0.71	4.66	0.43	1.03e-5	Alzheimer's disease (late onset);
THYM	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06850241	chr22:41845214	NA	-0.6	-5.39	-0.48	5.12e-7	Vitiligo;
THYM	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg03929089	chr4:120376271	NA	-0.99	-12.81	-0.8	2.07e-22	Height;
THYM	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg18681998	chr4:17616180	MED28	0.85	7.68	0.62	1.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs11771526	0.901	rs11771230	chr7:32315546	C/T	cg27532318	chr7:32358331	NA	-0.77	-5.06	-0.46	2.03e-6	Body mass index;
THYM	cis	rs988913	0.914	rs9396006	chr6:54787888	G/A	cg18532076	chr6:54711417	FAM83B	0.52	4.79	0.44	6.11e-6	Menarche (age at onset);
THYM	cis	rs7487075	0.780	rs12296120	chr12:46737591	G/A	cg21428710	chr12:47219797	SLC38A4	0.49	4.72	0.44	8.11e-6	Itch intensity from mosquito bite;
THYM	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg00071950	chr4:10020882	SLC2A9	0.86	8.92	0.68	3.37e-14	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs885814	0.839	rs4415532	chr1:21882070	C/T	cg14781605	chr1:21864896	ALPL	-0.64	-4.83	-0.44	5.23e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg20007245	chr22:24372913	LOC391322	0.82	6.47	0.55	4.2e-9	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg13010199	chr12:38710504	ALG10B	0.72	5.8	0.51	8.82e-8	Heart rate;
THYM	cis	rs931812	0.557	rs4734498	chr8:101946548	T/G	cg04962480	chr8:101962118	YWHAZ	-0.37	-5.69	-0.5	1.39e-7	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg14196790	chr5:131705035	SLC22A5	-0.67	-6.69	-0.57	1.55e-9	Blood metabolite levels;
THYM	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg23428387	chr22:49814324	NA	-0.59	-6.13	-0.53	2.01e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs72829446	0.530	rs7210292	chr17:7380305	G/T	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs12142240	0.698	rs6667861	chr1:46815749	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg10856724	chr12:34555212	NA	-0.92	-9.27	-0.69	6.02e-15	Morning vs. evening chronotype;
THYM	cis	rs61612642	0.523	rs59004693	chr6:42157392	G/A	cg01092361	chr6:42185687	MRPS10	0.98	6.0	0.52	3.6e-8	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.42	4.58	0.43	1.43e-5	Hemoglobin concentration;
THYM	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs617791	0.678	rs551659	chr11:65749645	C/T	cg17712092	chr4:129076599	LARP1B	0.92	7.26	0.6	1.07e-10	Breast cancer;
THYM	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg11266682	chr4:10021025	SLC2A9	0.72	11.65	0.77	5.23e-20	Bone mineral density;
THYM	cis	rs4631830	0.600	rs11004324	chr10:51496623	G/T	cg10326726	chr10:51549505	MSMB	-0.56	-5.54	-0.49	2.67e-7	Prostate-specific antigen levels;
THYM	cis	rs477692	0.583	rs2008387	chr10:131448764	C/T	cg05714579	chr10:131428358	MGMT	-0.96	-10.18	-0.72	6.87e-17	Response to temozolomide;
THYM	cis	rs9302690	0.744	rs62037113	chr16:57451388	A/T	cg27017172	chr16:57497170	POLR2C	0.82	4.88	0.45	4.29e-6	Blood protein levels;
THYM	cis	rs7107174	0.892	rs2510038	chr11:77966034	C/T	cg19901956	chr11:77921274	USP35	-0.75	-5.82	-0.51	7.9e-8	Testicular germ cell tumor;
THYM	cis	rs916888	0.647	rs199519	chr17:44853924	G/A	cg17911788	chr17:44343683	NA	0.49	4.72	0.44	8e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9302065	1.000	rs9302065	chr13:95971016	C/T	cg24476569	chr13:95954382	ABCC4	0.57	5.18	0.47	1.27e-6	Blood metabolite levels;
THYM	cis	rs1050631	0.564	rs559289	chr18:33752890	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.64	5.0	0.46	2.61e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg03909863	chr11:638404	DRD4	-0.66	-4.71	-0.44	8.41e-6	Systemic lupus erythematosus;
THYM	cis	rs137603	0.966	rs137585	chr22:39683444	G/A	cg24268161	chr22:39747459	SYNGR1	0.56	4.91	0.45	3.72e-6	Primary biliary cholangitis;
THYM	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-5.18	-0.47	1.24e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs76878669	0.583	rs8187658	chr11:66134085	C/T	cg18002602	chr11:66138449	SLC29A2	-0.63	-4.87	-0.45	4.51e-6	Educational attainment (years of education);
THYM	cis	rs2574704	0.532	rs2616553	chr3:11664812	T/C	cg07643000	chr3:11666825	VGLL4	-0.52	-5.09	-0.46	1.83e-6	Body mass index;
THYM	cis	rs9992101	0.744	rs2870238	chr4:77373079	C/T	cg20311846	chr4:77356250	SHROOM3	-0.54	-4.97	-0.45	2.93e-6	Creatinine levels;
THYM	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg15556689	chr8:8085844	FLJ10661	0.71	6.02	0.53	3.31e-8	Mood instability;
THYM	cis	rs4589258	0.737	rs1792612	chr11:90430422	G/C	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg19693284	chr19:2783607	SGTA	0.8	5.83	0.51	7.71e-8	Total cholesterol levels;
THYM	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg18876405	chr7:65276391	NA	-0.59	-4.86	-0.45	4.57e-6	Aortic root size;
THYM	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06873352	chr17:61820015	STRADA	0.8	9.74	0.71	5.98e-16	Prudent dietary pattern;
THYM	cis	rs611744	0.647	rs628206	chr8:109247873	A/G	cg21045802	chr8:109455806	TTC35	0.65	5.91	0.52	5.3e-8	Dupuytren's disease;
THYM	cis	rs28595532	1.000	rs55634130	chr4:119655093	C/T	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg18252515	chr7:66147081	NA	-1.45	-8.59	-0.66	1.72e-13	Diabetic kidney disease;
THYM	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg23982607	chr1:1823379	GNB1	-0.91	-9.58	-0.7	1.29e-15	Body mass index;
THYM	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg24069376	chr3:38537580	EXOG	0.69	6.79	0.57	9.87e-10	Electrocardiographic conduction measures;
THYM	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06873352	chr17:61820015	STRADA	0.56	5.63	0.5	1.84e-7	Height;
THYM	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg21252483	chr19:49399788	TULP2	-0.69	-4.75	-0.44	7.17e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	trans	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg25214090	chr10:38739885	LOC399744	0.97	8.35	0.65	5.49e-13	Corneal astigmatism;
THYM	cis	rs17739794	0.517	rs28362022	chr8:794120	G/A	cg07178994	chr8:816998	NA	0.76	7.6	0.61	2.11e-11	Clozapine-induced cytotoxicity;
THYM	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg16558253	chr16:72132732	DHX38	-0.59	-5.05	-0.46	2.17e-6	Fibrinogen levels;
THYM	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.7	0.71	7.32e-16	Colorectal cancer;
THYM	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg11871910	chr12:69753446	YEATS4	1.06	9.77	0.71	5.12e-16	Blood protein levels;
THYM	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs3741151	0.656	rs10501411	chr11:73292085	A/C	cg12959048	chr11:73096162	RELT	-0.52	-4.58	-0.43	1.43e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs1345301	0.935	rs11691721	chr2:102876679	G/A	cg03938978	chr2:103052716	IL18RAP	-0.62	-6.09	-0.53	2.36e-8	Waist circumference;
THYM	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg08847533	chr14:75593920	NEK9	-1.02	-11.28	-0.76	3.21e-19	Height;
THYM	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg03806693	chr22:41940476	POLR3H	-0.87	-7.21	-0.59	1.35e-10	Vitiligo;
THYM	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg00757033	chr12:89920650	WDR51B	0.77	11.72	0.77	3.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2276314	1.000	rs4799835	chr18:33571268	G/A	cg19628046	chr18:33552617	C18orf21	0.81	5.6	0.5	2.11e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7107174	1.000	rs11602622	chr11:78010830	A/G	cg19901956	chr11:77921274	USP35	-0.67	-5.21	-0.47	1.08e-6	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg13010199	chr12:38710504	ALG10B	0.71	5.49	0.49	3.34e-7	Heart rate;
THYM	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg13695892	chr22:41940480	POLR3H	0.91	6.04	0.53	3e-8	Vitiligo;
THYM	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg11941060	chr3:133502564	NA	-0.73	-6.23	-0.54	1.24e-8	Iron status biomarkers;
THYM	cis	rs11574514	1.000	rs1113232	chr16:67879827	C/A	cg09738193	chr16:67926317	PSKH1	-0.9	-4.61	-0.43	1.28e-5	Crohn's disease;
THYM	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg17105886	chr17:28927953	LRRC37B2	1.21	7.24	0.6	1.14e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4654899	0.571	rs34530426	chr1:21085204	C/T	cg01072550	chr1:21505969	NA	-0.62	-5.66	-0.5	1.62e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg20891283	chr12:69753455	YEATS4	0.62	4.48	0.42	2.1e-5	Response to diuretic therapy;
THYM	cis	rs7781977	0.575	rs7782210	chr7:50348745	A/G	cg01139861	chr7:50343298	IKZF1	0.55	5.16	0.47	1.34e-6	IgG glycosylation;
THYM	cis	rs652260	0.967	rs520802	chr19:7915451	A/C	cg15974673	chr19:7926970	EVI5L	-0.54	-5.15	-0.47	1.39e-6	Menarche (age at onset);
THYM	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg03929089	chr4:120376271	NA	1.02	8.78	0.67	6.68e-14	Coronary artery disease;
THYM	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-4.93	-0.45	3.48e-6	Hemoglobin concentration;
THYM	cis	rs10463554	0.963	rs11242485	chr5:102382034	G/A	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs11809207	0.859	rs61776644	chr1:26505548	T/C	cg03844060	chr1:26490628	NA	0.74	5.54	0.49	2.69e-7	Height;
THYM	cis	rs7119	0.717	rs34194537	chr15:77795761	G/A	cg10437265	chr15:77819839	NA	0.63	5.52	0.49	2.9e-7	Type 2 diabetes;
THYM	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg23791538	chr6:167370224	RNASET2	0.74	5.92	0.52	5.06e-8	Crohn's disease;
THYM	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg18876405	chr7:65276391	NA	-0.58	-4.99	-0.46	2.78e-6	Aortic root size;
THYM	cis	rs10493773	0.566	rs11161659	chr1:86183967	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.59	-9.23	-0.69	7.42e-15	Urate levels in overweight individuals;
THYM	cis	rs62244186	0.659	rs9855433	chr3:44468065	C/A	cg16615211	chr3:44902933	MIR564;TMEM42	0.48	4.64	0.43	1.13e-5	Depressive symptoms;
THYM	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg10518543	chr12:38710700	ALG10B	-0.57	-4.58	-0.43	1.42e-5	Morning vs. evening chronotype;
THYM	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg20486651	chr6:167070296	RPS6KA2	-0.51	-4.83	-0.44	5.26e-6	Crohn's disease;
THYM	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg03806693	chr22:41940476	POLR3H	1.03	9.17	0.69	9.96e-15	Vitiligo;
THYM	cis	rs6138458	0.961	rs11700073	chr20:24975215	C/G	cg06937882	chr20:24974362	C20orf3	-0.46	-4.58	-0.43	1.43e-5	Blood protein levels;
THYM	cis	rs13279522	0.536	rs13266516	chr8:67011471	C/T	cg20171999	chr8:67343066	NA	-0.46	-4.6	-0.43	1.3e-5	Coronary heart disease event reduction (statin therapy interaction);
THYM	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg22907277	chr7:1156413	C7orf50	0.87	8.76	0.67	7.42e-14	Longevity;Endometriosis;
THYM	cis	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg17294928	chr15:75287854	SCAMP5	0.96	5.13	0.47	1.52e-6	Lung cancer;
THYM	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg01059385	chr22:42394853	WBP2NL	-0.57	-4.65	-0.43	1.06e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs2637266	1.000	rs7475686	chr10:78358761	T/C	cg18941641	chr10:78392320	NA	0.8	6.94	0.58	4.82e-10	Pulmonary function;
THYM	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg06873352	chr17:61820015	STRADA	0.81	9.83	0.71	3.85e-16	Prudent dietary pattern;
THYM	cis	rs4499344	0.730	rs417823	chr19:33104561	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.88	7.57	0.61	2.44e-11	Mean platelet volume;
THYM	cis	rs1728785	1.000	rs889561	chr16:68605741	G/A	cg02972257	chr16:68554789	NA	-0.76	-4.9	-0.45	3.93e-6	Ulcerative colitis;
THYM	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Gout;
THYM	cis	rs2075230	0.705	rs2543555	chr17:7548785	A/C	cg27413385	chr17:7515425	FXR2	-0.35	-5.06	-0.46	2.06e-6	Hormone measurements;
THYM	cis	rs6495122	0.699	rs1378940	chr15:75083494	C/A	cg14664628	chr15:75095509	CSK	-0.81	-6.38	-0.55	6.5e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs1062746	0.771	rs10514621	chr16:87369578	G/T	cg27119004	chr16:87376851	FBXO31	0.46	4.68	0.43	9.57e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs10779751	1.000	rs1205592	chr1:11305663	C/T	cg08854313	chr1:11322531	MTOR	0.91	7.32	0.6	8.09e-11	Body mass index;
THYM	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9902453	0.765	rs2264303	chr17:28055348	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs11645898	0.935	rs72787078	chr16:72158493	C/T	cg03805757	chr16:71968109	PKD1L3	-0.73	-5.29	-0.48	7.84e-7	Blood protein levels;
THYM	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg23260525	chr10:116636907	FAM160B1	0.52	5.19	0.47	1.19e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06850241	chr22:41845214	NA	-0.59	-5.36	-0.48	5.85e-7	Vitiligo;
THYM	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	4.82	0.44	5.5e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9790314	0.747	rs9990242	chr3:160838461	T/C	cg04691961	chr3:161091175	C3orf57	-0.61	-4.71	-0.44	8.33e-6	Morning vs. evening chronotype;
THYM	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg07648498	chr16:89883185	FANCA	0.61	4.58	0.43	1.41e-5	Vitiligo;
THYM	cis	rs711830	1.000	rs6433571	chr2:177039578	G/T	cg13092806	chr2:177043255	NA	0.59	4.75	0.44	7.22e-6	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg26441486	chr22:50317300	CRELD2	0.49	5.36	0.48	5.93e-7	Schizophrenia;
THYM	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg19774624	chr17:42201019	HDAC5	-0.85	-8.23	-0.65	9.73e-13	Total body bone mineral density;
THYM	cis	rs11577318	0.579	rs11548246	chr1:26697166	G/A	cg19677267	chr1:26645161	CD52;UBXN11	0.54	6.0	0.52	3.63e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg12560992	chr17:57184187	TRIM37	0.91	8.22	0.64	1.05e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg14675211	chr2:100938903	LONRF2	0.77	8.32	0.65	6.49e-13	Intelligence (multi-trait analysis);
THYM	cis	rs1697139	0.583	rs11739587	chr5:66540481	A/C	cg11553311	chr5:66541588	NA	-0.72	-7.71	-0.62	1.21e-11	Breast cancer;
THYM	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg01017244	chr2:74357527	NA	1.08	9.62	0.7	1.09e-15	Gestational age at birth (maternal effect);
THYM	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg14675211	chr2:100938903	LONRF2	0.77	8.39	0.65	4.51e-13	Intelligence (multi-trait analysis);
THYM	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	4.83	0.44	5.14e-6	Menarche (age at onset);
THYM	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	7.92	0.63	4.35e-12	Lung cancer in ever smokers;
THYM	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg15693483	chr7:1102177	C7orf50	0.47	5.9	0.52	5.65e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg10862848	chr6:42927986	GNMT	0.54	7.06	0.59	2.75e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg24812749	chr6:127587940	RNF146	0.91	6.16	0.53	1.76e-8	Breast cancer;
THYM	cis	rs8049040	0.524	rs891125	chr16:71431621	C/T	cg08717414	chr16:71523259	ZNF19	-0.73	-4.46	-0.42	2.25e-5	Blood protein levels;
THYM	cis	rs9302065	0.529	rs2993582	chr13:95958181	G/T	cg26751094	chr13:95954534	ABCC4	-0.5	-5.69	-0.5	1.42e-7	Blood metabolite levels;
THYM	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg07532245	chr17:28927093	LRRC37B2	0.71	4.48	0.42	2.04e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg11764359	chr7:65958608	NA	0.86	7.24	0.6	1.17e-10	Aortic root size;
THYM	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg22105103	chr4:187893119	NA	0.89	9.04	0.68	1.84e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg02569458	chr12:86230093	RASSF9	0.62	5.34	0.48	6.31e-7	Major depressive disorder;
THYM	cis	rs3126085	0.560	rs12031363	chr1:152350645	G/A	cg10321714	chr1:152280068	FLG	-0.69	-4.84	-0.44	5.1e-6	Atopic dermatitis;
THYM	cis	rs4660306	0.677	rs1006215	chr1:45909945	T/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.64	4.55	0.42	1.61e-5	Homocysteine levels;
THYM	cis	rs7705042	0.686	rs6873747	chr5:141542155	T/A	cg07392085	chr5:141489673	NDFIP1	-0.65	-4.67	-0.43	9.91e-6	Asthma;
THYM	cis	rs960902	0.818	rs2192942	chr2:37731493	C/T	cg25341268	chr2:37734390	NA	-0.62	-5.13	-0.47	1.54e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg12893697	chr11:970389	AP2A2	-0.31	-5.04	-0.46	2.19e-6	Alzheimer's disease (late onset);
THYM	cis	rs4262150	0.883	rs72802853	chr5:152218058	C/T	cg06854687	chr5:151642065	NA	0.66	4.6	0.43	1.3e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs981844	0.683	rs1105496	chr4:154756755	T/C	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs939658	1.000	rs8031504	chr15:79458589	G/T	cg17916960	chr15:79447300	NA	0.78	9.46	0.7	2.37e-15	Refractive error;
THYM	cis	rs6866344	0.570	rs6896799	chr5:178147014	G/C	cg10224037	chr5:178157518	ZNF354A	1.03	8.58	0.66	1.76e-13	Neutrophil percentage of white cells;
THYM	cis	rs669446	0.533	rs3791042	chr1:44219275	T/C	cg12599982	chr1:44399894	ARTN	0.52	4.74	0.44	7.55e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg19761014	chr17:28927070	LRRC37B2	0.83	4.89	0.45	4.07e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2742417	0.603	rs2673075	chr3:45778288	C/A	cg04837898	chr3:45731254	SACM1L	-0.72	-5.02	-0.46	2.4e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	trans	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg25214090	chr10:38739885	LOC399744	0.93	7.92	0.63	4.43e-12	Corneal astigmatism;
THYM	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg16405210	chr4:1374714	KIAA1530	-0.61	-4.63	-0.43	1.15e-5	Obesity-related traits;
THYM	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg01073479	chr16:3509474	NAT15	0.54	5.23	0.47	1e-6	Tuberculosis;
THYM	cis	rs4769475	0.957	rs7327409	chr13:26730668	A/G	cg13319468	chr13:27597730	NA	-0.64	-4.84	-0.45	4.93e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs1886644	1.000	rs1886644	chr1:85350658	A/C	cg08479277	chr1:85350632	LPAR3	0.53	5.41	0.49	4.69e-7	Glucose homeostasis traits;
THYM	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg06636001	chr8:8085503	FLJ10661	0.71	6.27	0.54	1.04e-8	Mood instability;
THYM	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg06221963	chr1:154839813	KCNN3	-0.74	-8.01	-0.63	2.9e-12	Prostate cancer;
THYM	cis	rs148387471	1	rs148387471	chr3:127057551	ATAG/A	cg27326032	chr3:127006922	NA	-0.83	-4.94	-0.45	3.28e-6	Interleukin-10 levels;Interleukin-13 levels;
THYM	cis	rs758324	0.687	rs246353	chr5:131507072	A/G	cg16205897	chr5:131564050	P4HA2	0.61	4.99	0.46	2.74e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg18681998	chr4:17616180	MED28	0.79	7.15	0.59	1.77e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg20007245	chr22:24372913	LOC391322	0.75	6.78	0.57	1.03e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11585357	0.947	rs6684387	chr1:17611519	T/C	cg08277548	chr1:17600880	PADI3	0.87	5.92	0.52	5.07e-8	Hair shape;
THYM	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg05347473	chr6:146136440	FBXO30	0.77	6.53	0.56	3.19e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs877282	0.583	rs10904564	chr10:819459	C/G	cg10556349	chr10:835070	NA	-0.84	-5.48	-0.49	3.43e-7	Uric acid levels;
THYM	cis	rs950880	0.710	rs4851583	chr2:103060300	T/C	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.71	-0.44	8.33e-6	Serum protein levels (sST2);
THYM	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg00639195	chr15:79103007	ADAMTS7	-0.79	-6.17	-0.53	1.66e-8	Coronary artery disease or large artery stroke;
THYM	cis	rs889398	0.771	rs1500337	chr16:69901884	C/T	cg09409435	chr16:70099608	PDXDC2	-0.66	-5.25	-0.47	9.17e-7	Body mass index;
THYM	cis	rs11690935	0.632	rs1607254	chr2:172626552	A/G	cg13550731	chr2:172543902	DYNC1I2	0.63	4.95	0.45	3.19e-6	Schizophrenia;
THYM	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg11764359	chr7:65958608	NA	0.64	5.08	0.46	1.88e-6	Aortic root size;
THYM	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg21028142	chr17:79581711	NPLOC4	0.49	4.82	0.44	5.34e-6	Eye color traits;
THYM	cis	rs7572733	0.534	rs700674	chr2:198693703	C/T	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg16615211	chr3:44902933	MIR564;TMEM42	0.57	6.12	0.53	2.04e-8	Depressive symptoms;
THYM	cis	rs35264875	0.898	rs56140802	chr11:68861631	G/A	cg01993067	chr11:68851601	TPCN2	1.0	5.27	0.48	8.46e-7	Blond vs. brown hair color;
THYM	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg24675658	chr1:53192096	ZYG11B	-0.77	-6.93	-0.58	5.04e-10	Monocyte count;
THYM	cis	rs6032067	1.000	rs34685021	chr20:43888042	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.61	-5.92	-0.52	5e-8	Blood protein levels;
THYM	cis	rs10203711	1.000	rs4994756	chr2:239567125	T/C	cg14580085	chr2:239553406	NA	0.68	6.18	0.54	1.6e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1278352	0.798	rs1298425	chr10:127774612	C/T	cg08295661	chr10:127769903	ADAM12	-0.55	-5.64	-0.5	1.71e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28647808	0.786	rs28590601	chr9:136256224	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg17509989	chr5:176798049	RGS14	0.91	10.03	0.72	1.46e-16	Urinary electrolytes (magnesium/calcium ratio);
THYM	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.61	-0.43	1.27e-5	Type 2 diabetes;
THYM	cis	rs4642101	0.793	rs6799179	chr3:12829095	A/C	cg11882607	chr3:12858926	CAND2	-0.4	-4.52	-0.42	1.76e-5	QRS complex (12-leadsum);
THYM	cis	rs2806561	0.780	rs12409321	chr1:23398065	C/T	cg12483005	chr1:23474871	LUZP1	-0.51	-4.69	-0.43	9.25e-6	Height;
THYM	cis	rs12579753	0.917	rs2401003	chr12:82215192	G/A	cg21231944	chr12:82153410	PPFIA2	-0.7	-5.38	-0.48	5.24e-7	Resting heart rate;
THYM	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg12310025	chr6:25882481	NA	-0.69	-5.47	-0.49	3.69e-7	Blood metabolite levels;
THYM	cis	rs300703	0.872	rs12233077	chr2:120949	T/A	cg21211680	chr2:198530	NA	-1.39	-6.19	-0.54	1.54e-8	Blood protein levels;
THYM	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg00640147	chr17:61958756	GH2	-0.43	-4.56	-0.42	1.54e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg22841779	chr14:105766346	BRF1	-0.51	-6.58	-0.56	2.6e-9	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4737010	0.501	rs2111805	chr8:41643457	G/C	cg08923054	chr8:41654455	ANK1	0.76	4.57	0.42	1.47e-5	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
THYM	cis	rs4662750	0.583	rs2244880	chr2:128386644	G/C	cg16944093	chr2:128422120	LIMS2	-0.4	-4.59	-0.43	1.35e-5	Renal cell carcinoma;
THYM	cis	rs1003719	0.788	rs8133549	chr21:38447489	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs240764	0.687	rs239209	chr6:101140977	T/C	cg21058520	chr6:100914733	NA	-0.55	-4.7	-0.43	8.96e-6	Neuroticism;
THYM	cis	rs7586879	0.598	rs6545806	chr2:25124348	G/A	cg27107076	chr2:25050844	ADCY3	-0.29	-4.72	-0.44	8.01e-6	Body mass index;
THYM	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg18477163	chr1:228402036	OBSCN	-0.47	-5.2	-0.47	1.14e-6	Diastolic blood pressure;
THYM	cis	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.59	-0.43	1.37e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9500256	1.000	rs9500256	chr6:58308955	C/T	cg17976157	chr6:58263193	GUSBL2	-0.63	-5.05	-0.46	2.15e-6	Eosinophilic esophagitis (pediatric);
THYM	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.63	0.5	1.81e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs17818399	0.547	rs4952831	chr2:46761181	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.66	4.58	0.43	1.38e-5	Height;
THYM	cis	rs888194	0.677	rs2164743	chr12:109875163	C/T	cg10504392	chr12:110044639	NA	0.6	5.49	0.49	3.28e-7	Neuroticism;
THYM	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg03609598	chr5:56110824	MAP3K1	-0.67	-4.69	-0.43	9.21e-6	Coronary artery disease;
THYM	cis	rs68170813	0.523	rs4730241	chr7:107057361	G/A	cg00661777	chr7:106511741	PIK3CG	-0.66	-4.49	-0.42	2.03e-5	Coronary artery disease;
THYM	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg08213375	chr14:104286397	PPP1R13B	0.54	6.53	0.56	3.2e-9	Schizophrenia;
THYM	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg23428387	chr22:49814324	NA	-0.62	-6.42	-0.55	5.36e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg16928487	chr17:17741425	SREBF1	-0.56	-5.57	-0.5	2.37e-7	Total body bone mineral density;
THYM	cis	rs4363385	0.643	rs12734348	chr1:152924650	A/G	cg07796016	chr1:152779584	LCE1C	-0.62	-4.95	-0.45	3.16e-6	Inflammatory skin disease;
THYM	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.53	0.49	2.84e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg15962314	chr1:44399869	ARTN	-0.51	-4.64	-0.43	1.13e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03576123	chr11:487126	PTDSS2	1.16	5.56	0.5	2.43e-7	Body mass index;
THYM	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg08645402	chr16:4508243	NA	0.7	6.19	0.54	1.51e-8	Schizophrenia;
THYM	cis	rs9902453	0.904	rs11654983	chr17:28370042	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.22	-0.54	1.3e-8	Coffee consumption (cups per day);
THYM	cis	rs7107174	1.000	rs2512532	chr11:77968641	T/C	cg19901956	chr11:77921274	USP35	-0.73	-5.6	-0.5	2.04e-7	Testicular germ cell tumor;
THYM	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg13147721	chr7:65941812	NA	-1.1	-7.08	-0.59	2.45e-10	Diabetic kidney disease;
THYM	cis	rs910187	0.597	rs2073172	chr20:45809176	A/G	cg27589058	chr20:45804311	EYA2	-0.62	-5.26	-0.47	9.03e-7	Migraine;
THYM	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg12310025	chr6:25882481	NA	-0.73	-6.01	-0.52	3.41e-8	Blood metabolite levels;
THYM	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.66	-5.17	-0.47	1.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs17401966	0.931	rs2276100	chr1:10394536	C/G	cg19773385	chr1:10388646	KIF1B	-0.6	-4.7	-0.43	8.88e-6	Hepatocellular carcinoma;
THYM	cis	rs877282	0.898	rs71489279	chr10:760510	T/C	cg10556349	chr10:835070	NA	-0.78	-5.06	-0.46	2.06e-6	Uric acid levels;
THYM	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg14784868	chr12:69753453	YEATS4	0.59	4.54	0.42	1.64e-5	Blood protein levels;
THYM	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs12049351	0.832	rs28798529	chr1:229671614	G/A	cg11742688	chr1:229674241	ABCB10	-0.56	-4.51	-0.42	1.88e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs6578985	0.520	rs7924316	chr11:2173447	G/T	cg21019522	chr11:2920789	SLC22A18;SLC22A18AS	0.46	4.6	0.43	1.29e-5	Femoral neck bone geometry and menarche (age at onset);
THYM	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs3096299	0.934	rs9927904	chr16:89462847	G/A	cg02187348	chr16:89574699	SPG7	0.68	4.97	0.45	2.94e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg26566898	chr11:117069891	TAGLN	0.39	4.85	0.45	4.84e-6	Blood protein levels;
THYM	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg02773041	chr1:40204384	PPIE	0.77	6.01	0.52	3.46e-8	Blood protein levels;
THYM	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg06558623	chr16:89946397	TCF25	1.39	6.78	0.57	1.03e-9	Skin colour saturation;
THYM	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.62	-4.74	-0.44	7.35e-6	Lung cancer in ever smokers;
THYM	cis	rs13102973	0.965	rs4640720	chr4:135850050	G/T	cg14419869	chr4:135874104	NA	0.9	8.46	0.66	3.24e-13	Subjective well-being;
THYM	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg09338302	chr7:1325757	NA	0.48	4.51	0.42	1.86e-5	Bipolar disorder;
THYM	cis	rs2131877	0.871	rs62290352	chr3:194864191	G/A	cg21937377	chr3:194868750	C3orf21	0.4	4.74	0.44	7.47e-6	Non-small cell lung cancer;
THYM	cis	rs7408868	1.000	rs7254269	chr19:15277429	A/T	cg14696996	chr19:15285081	NOTCH3	-0.98	-5.61	-0.5	2.02e-7	Pulse pressure;
THYM	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg23803603	chr1:2058230	PRKCZ	-0.61	-5.54	-0.49	2.67e-7	Height;
THYM	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs11771526	1.000	rs11770367	chr7:32354319	C/T	cg27511599	chr7:32358540	NA	0.77	5.13	0.47	1.51e-6	Body mass index;
THYM	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg15536230	chr21:44985092	HSF2BP	-0.42	-5.03	-0.46	2.3e-6	Mean corpuscular volume;
THYM	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs67072384	0.901	rs67288233	chr11:72458361	G/A	cg01380194	chr11:72452482	ARAP1	-0.95	-4.99	-0.46	2.7e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs17401966	0.838	rs4333852	chr1:10387704	A/T	cg19773385	chr1:10388646	KIF1B	0.57	4.58	0.43	1.4e-5	Hepatocellular carcinoma;
THYM	cis	rs4731207	0.596	rs10275296	chr7:124681292	T/A	cg05285228	chr7:124571219	POT1	-0.65	-4.98	-0.45	2.9e-6	Cutaneous malignant melanoma;
THYM	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs58873874	0.737	rs79339674	chr5:156891326	G/A	cg08916508	chr5:156566250	MED7	-1.17	-4.52	-0.42	1.8e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg21138405	chr5:131827807	IRF1	0.84	9.58	0.7	1.31e-15	Asthma (sex interaction);
THYM	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg03264133	chr6:25882463	NA	0.65	5.06	0.46	2e-6	Schizophrenia;
THYM	cis	rs28595532	0.920	rs114414928	chr4:119728188	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg06873352	chr17:61820015	STRADA	0.8	9.97	0.72	1.92e-16	Prudent dietary pattern;
THYM	cis	rs7020830	1.000	rs7020830	chr9:37085184	A/T	cg14294708	chr9:37120828	ZCCHC7	1.24	15.16	0.84	4.26e-27	Schizophrenia;
THYM	cis	rs907683	0.584	rs12991025	chr2:220284779	C/T	cg15015639	chr2:220282977	DES	0.38	4.96	0.45	3.06e-6	Resting heart rate;
THYM	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1971762	0.527	rs1683151	chr12:53946219	C/G	cg16917193	chr12:54089295	NA	-0.73	-6.51	-0.56	3.46e-9	Height;
THYM	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.73	-6.27	-0.54	1.05e-8	Intelligence (multi-trait analysis);
THYM	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg22189786	chr22:42395067	WBP2NL	0.57	4.86	0.45	4.65e-6	Birth weight;
THYM	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg06064525	chr11:970664	AP2A2	-0.38	-7.23	-0.6	1.21e-10	Alzheimer's disease (late onset);
THYM	cis	rs8038465	0.622	rs56712926	chr15:73886849	G/T	cg15420318	chr15:73925796	NPTN	0.62	5.3	0.48	7.64e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg16240275	chr20:61666158	NCRNA00029	0.33	4.46	0.42	2.23e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs17122693	0.786	rs72679588	chr14:51092687	A/C	cg04730355	chr14:51134070	SAV1	0.91	4.95	0.45	3.19e-6	Cognitive performance;
THYM	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg26597838	chr10:835615	NA	1.52	11.37	0.76	2.05e-19	Eosinophil percentage of granulocytes;
THYM	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.92	5.02	0.46	2.41e-6	Initial pursuit acceleration;
THYM	cis	rs11603020	0.851	rs10896631	chr11:57381263	T/C	cg19752551	chr11:57585705	CTNND1	-0.6	-5.02	-0.46	2.42e-6	Blood protein levels;
THYM	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs9902453	0.780	rs3115093	chr17:28039755	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	6.2	0.54	1.44e-8	Coffee consumption (cups per day);
THYM	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg12031863	chr16:4587854	C16orf5	0.46	4.96	0.45	3.09e-6	Schizophrenia;
THYM	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg10518543	chr12:38710700	ALG10B	-0.59	-4.74	-0.44	7.53e-6	Morning vs. evening chronotype;
THYM	cis	rs8051149	0.688	rs55776570	chr16:87869516	C/G	cg01412419	chr16:87856264	NA	0.71	5.32	0.48	6.75e-7	Blood metabolite levels;
THYM	cis	rs11671005	0.779	rs11670125	chr19:58987390	G/T	cg02808233	chr19:58920810	ZNF584	0.57	4.51	0.42	1.89e-5	Mean platelet volume;
THYM	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg08999081	chr20:33150536	PIGU	-0.77	-6.95	-0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs2075230	0.705	rs1641531	chr17:7546791	C/G	cg27413385	chr17:7515425	FXR2	-0.35	-5.06	-0.46	2.06e-6	Hormone measurements;
THYM	cis	rs6732160	0.525	rs2303907	chr2:73470497	T/C	cg24220031	chr2:73402428	NA	-0.8	-9.63	-0.7	1e-15	Intelligence (multi-trait analysis);
THYM	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg16049864	chr8:95962084	TP53INP1	-0.68	-6.02	-0.53	3.25e-8	Type 2 diabetes;
THYM	cis	rs240764	0.817	rs239201	chr6:101123993	T/A	cg21058520	chr6:100914733	NA	-0.57	-4.99	-0.46	2.77e-6	Neuroticism;
THYM	cis	rs6570726	0.720	rs412623	chr6:145883257	C/A	cg13319975	chr6:146136371	FBXO30	-0.66	-5.36	-0.48	5.7e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg05768032	chr16:30646687	NA	0.54	5.51	0.49	3.04e-7	Multiple myeloma;
THYM	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg12310025	chr6:25882481	NA	-0.94	-8.46	-0.66	3.24e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7107174	0.892	rs2512548	chr11:77962116	A/G	cg02023728	chr11:77925099	USP35	0.68	6.12	0.53	2.12e-8	Testicular germ cell tumor;
THYM	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg21475434	chr5:93447410	FAM172A	-0.71	-4.51	-0.42	1.83e-5	Diabetic retinopathy;
THYM	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg27588902	chr6:42928151	GNMT	-0.56	-5.74	-0.51	1.13e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4660306	0.848	rs1088099	chr1:45946654	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.68	5.43	0.49	4.25e-7	Homocysteine levels;
THYM	cis	rs8078723	1.000	rs4794824	chr17:38179290	G/A	cg17467752	chr17:38218738	THRA	0.81	6.48	0.55	4.13e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg11317459	chr13:21872234	NA	1.22	10.68	0.74	5.83e-18	White matter hyperintensity burden;
THYM	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg10515332	chr4:99064459	C4orf37	0.57	4.54	0.42	1.63e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg11764359	chr7:65958608	NA	0.87	7.45	0.61	4.16e-11	Aortic root size;
THYM	cis	rs11574514	1.000	rs118106500	chr16:67931383	C/T	cg09738193	chr16:67926317	PSKH1	-0.91	-4.66	-0.43	1.01e-5	Crohn's disease;
THYM	cis	rs7072216	0.727	rs7915108	chr10:100164441	T/C	cg03852570	chr10:100175106	PYROXD2	0.37	4.97	0.45	2.91e-6	Metabolite levels;
THYM	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg06636001	chr8:8085503	FLJ10661	-0.84	-7.92	-0.63	4.43e-12	Joint mobility (Beighton score);
THYM	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg00271210	chr6:167070053	RPS6KA2	0.5	5.08	0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs35934224	0.769	rs76802530	chr22:19853406	T/C	cg11182965	chr22:19864308	TXNRD2	-0.8	-4.82	-0.44	5.49e-6	Glaucoma (primary open-angle);
THYM	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.85	-5.32	-0.48	6.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg07636037	chr3:49044803	WDR6	0.93	9.74	0.71	5.83e-16	Parkinson's disease;
THYM	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg27129171	chr3:47204927	SETD2	-0.78	-7.49	-0.61	3.57e-11	Colorectal cancer;
THYM	cis	rs6840360	0.533	rs1397683	chr4:152715916	T/C	cg22705602	chr4:152727874	NA	0.76	9.95	0.71	2.12e-16	Intelligence (multi-trait analysis);
THYM	cis	rs34638657	0.732	rs11859473	chr16:82201072	T/C	cg09439754	chr16:82129088	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	trans	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg07393940	chr7:158741817	NA	-1.07	-8.11	-0.64	1.81e-12	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs1061377	1.000	rs1061377	chr4:39124750	C/A	cg24403649	chr4:39172243	NA	0.59	4.78	0.44	6.29e-6	Uric acid levels;
THYM	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2625529	0.503	rs7162299	chr15:72414065	A/G	cg16672083	chr15:72433130	SENP8	0.49	4.52	0.42	1.76e-5	Red blood cell count;
THYM	cis	rs854765	0.624	rs11657130	chr17:17733826	T/C	cg16928487	chr17:17741425	SREBF1	0.55	5.12	0.47	1.56e-6	Total body bone mineral density;
THYM	cis	rs6988636	1.000	rs57902736	chr8:124189893	G/A	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9399401	0.921	rs9403387	chr6:142773210	G/T	cg04461802	chr6:142623433	GPR126	0.49	4.88	0.45	4.29e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg13010199	chr12:38710504	ALG10B	0.71	5.62	0.5	1.86e-7	Heart rate;
THYM	cis	rs13315871	0.929	rs13101057	chr3:58291467	A/G	cg12435725	chr3:58293450	RPP14	-0.53	-5.57	-0.5	2.32e-7	Cholesterol, total;
THYM	cis	rs137603	0.966	rs470079	chr22:39708333	T/C	cg24268161	chr22:39747459	SYNGR1	0.57	4.96	0.45	3.02e-6	Primary biliary cholangitis;
THYM	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-6.17	-0.53	1.69e-8	Mood instability;
THYM	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg17747265	chr1:1875780	NA	-0.8	-9.28	-0.69	5.67e-15	Body mass index;
THYM	cis	rs1957429	0.808	rs2357866	chr14:65336517	C/T	cg23373153	chr14:65346875	NA	1.01	5.19	0.47	1.19e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs4654899	0.758	rs6702331	chr1:21516107	A/T	cg01072550	chr1:21505969	NA	-0.76	-7.36	-0.6	6.4e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg12756686	chr19:29218302	NA	0.6	4.76	0.44	6.9e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs10411161	0.702	rs7250193	chr19:52385520	C/T	cg25361850	chr19:52391789	ZNF577	-0.71	-5.08	-0.46	1.85e-6	Breast cancer;
THYM	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	9.51	0.7	1.8e-15	Platelet count;
THYM	cis	rs6032067	0.538	rs17331776	chr20:43744754	G/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.65	-5.65	-0.5	1.67e-7	Blood protein levels;
THYM	cis	rs7588746	0.868	rs12104649	chr2:201128832	C/T	cg17644776	chr2:200775616	C2orf69	-0.8	-5.18	-0.47	1.26e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	trans	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17712092	chr4:129076599	LARP1B	0.92	7.66	0.62	1.56e-11	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg15744005	chr10:104629667	AS3MT	-0.86	-8.31	-0.65	6.58e-13	Arsenic metabolism;
THYM	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg02187348	chr16:89574699	SPG7	0.79	6.5	0.55	3.66e-9	Multiple myeloma (IgH translocation);
THYM	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg10515332	chr4:99064459	C4orf37	0.62	4.91	0.45	3.84e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2730245	0.527	rs924910	chr7:158672272	C/T	cg24397884	chr7:158709396	WDR60	0.55	5.36	0.48	5.79e-7	Height;
THYM	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8067545	0.611	rs2703807	chr17:20109189	C/T	cg13482628	chr17:19912719	NA	-0.55	-4.49	-0.42	1.99e-5	Schizophrenia;
THYM	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs870825	0.860	rs56180712	chr4:185600223	A/G	cg04058563	chr4:185651563	MLF1IP	1.05	7.96	0.63	3.6e-12	Blood protein levels;
THYM	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg26528311	chr1:38462546	FHL3	0.53	5.08	0.46	1.88e-6	Coronary artery disease;
THYM	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg06808227	chr14:105710500	BRF1	-1.02	-8.87	-0.67	4.38e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7264396	0.528	rs6058370	chr20:34518592	C/T	cg26038318	chr20:34205095	SPAG4	0.64	5.02	0.46	2.44e-6	Total cholesterol levels;
THYM	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg02725872	chr8:58115012	NA	-1.11	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs9905704	0.918	rs369184	chr17:56709086	C/T	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.74e-6	Testicular germ cell tumor;
THYM	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg25767906	chr1:53392781	SCP2	0.52	5.19	0.47	1.19e-6	Monocyte count;
THYM	cis	rs11563648	0.553	rs1894721	chr7:126958246	T/C	cg23081781	chr7:127225937	GCC1	-0.35	-4.79	-0.44	6.03e-6	Resting heart rate;
THYM	cis	rs2035647	0.537	rs3857868	chr7:137797764	T/A	cg11874123	chr7:137028198	PTN	0.65	4.92	0.45	3.68e-6	Blood metabolite levels;
THYM	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg27279351	chr12:120934652	DYNLL1	0.9	7.94	0.63	4e-12	High light scatter reticulocyte count;
THYM	cis	rs308403	0.600	rs13135445	chr4:123664457	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.69	4.63	0.43	1.16e-5	Blood protein levels;
THYM	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4713118	0.869	rs7773070	chr6:27728827	T/C	cg23161317	chr6:28129485	ZNF389	0.73	4.87	0.45	4.5e-6	Parkinson's disease;
THYM	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.47	0.49	3.6e-7	Tonsillectomy;
THYM	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg13393036	chr8:95962371	TP53INP1	-0.49	-4.98	-0.46	2.81e-6	Type 2 diabetes;
THYM	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs11771526	0.786	rs11768318	chr7:32372965	T/G	cg13207630	chr7:32358064	NA	1.06	6.2	0.54	1.44e-8	Body mass index;
THYM	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg11764359	chr7:65958608	NA	-0.69	-4.67	-0.43	9.75e-6	Aortic root size;
THYM	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg23815491	chr16:72088622	HP	0.81	6.46	0.55	4.54e-9	Fibrinogen levels;
THYM	cis	rs7607369	0.719	rs7567622	chr2:219624549	A/T	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs600806	0.888	rs3768497	chr1:109866230	T/C	cg02175308	chr1:109941060	SORT1	-0.54	-4.71	-0.43	8.55e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10186029	0.680	rs13007271	chr2:213937767	G/C	cg08319019	chr2:214017104	IKZF2	0.83	6.86	0.58	6.99e-10	Systemic sclerosis;
THYM	cis	rs9921222	0.597	rs7193109	chr16:413523	T/G	cg00101154	chr16:420108	MRPL28	-0.35	-4.57	-0.42	1.45e-5	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs8014204	0.804	rs2241274	chr14:75251331	G/A	cg06637938	chr14:75390232	RPS6KL1	0.56	5.49	0.49	3.27e-7	Caffeine consumption;
THYM	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg18904891	chr8:8559673	CLDN23	0.68	5.08	0.46	1.89e-6	Obesity-related traits;
THYM	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.82	0.44	5.35e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs12752838	0.777	rs11590606	chr1:8917669	C/T	cg06972019	chr1:8937448	ENO1	-0.88	-10.25	-0.72	4.95e-17	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs11614913	0.509	rs12300425	chr12:54395082	G/T	cg25285794	chr12:54402699	HOXC8	-0.52	-4.63	-0.43	1.17e-5	Waist circumference adjusted for body mass index;
THYM	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg15921436	chr17:44337874	NA	-0.91	-6.85	-0.58	7.19e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg10360139	chr7:1886902	MAD1L1	-0.82	-7.11	-0.59	2.16e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg12000587	chr17:30186630	C17orf79	0.47	6.92	0.58	5.19e-10	Hip circumference adjusted for BMI;
THYM	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.02	-0.46	2.38e-6	Life satisfaction;
THYM	cis	rs8180040	0.800	rs2088135	chr3:47280018	T/C	cg27129171	chr3:47204927	SETD2	-0.75	-7.08	-0.59	2.48e-10	Colorectal cancer;
THYM	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg12826209	chr6:26865740	GUSBL1	0.84	4.58	0.43	1.42e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.74	5.66	0.5	1.58e-7	Eosinophil percentage of white cells;
THYM	cis	rs3862030	0.720	rs12569526	chr10:104237007	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-5.91	-0.52	5.34e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg17911788	chr17:44343683	NA	-0.75	-7.05	-0.59	2.81e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg24531977	chr5:56204891	C5orf35	-0.93	-7.44	-0.61	4.48e-11	Initial pursuit acceleration;
THYM	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg09029085	chr17:47094198	IGF2BP1	0.49	6.98	0.58	4.02e-10	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg18252515	chr7:66147081	NA	0.63	4.54	0.42	1.65e-5	Aortic root size;
THYM	cis	rs11785693	0.862	rs1156861	chr8:4984434	G/C	cg26367366	chr8:4980734	NA	1.21	6.11	0.53	2.2e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs2041895	0.509	rs2024518	chr12:107296902	G/A	cg13944111	chr12:107296891	NA	0.65	5.1	0.46	1.74e-6	Glaucoma (low intraocular pressure);
THYM	cis	rs10751667	0.580	rs7395515	chr11:1005160	C/T	cg20248691	chr11:532330	HRAS	-0.45	-4.54	-0.42	1.64e-5	Alzheimer's disease (late onset);
THYM	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg12863693	chr15:85201151	NMB	0.65	5.67	0.5	1.56e-7	Schizophrenia;
THYM	cis	rs4638749	0.677	rs12475343	chr2:108851373	T/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg16006841	chr5:176797999	RGS14	0.5	5.96	0.52	4.35e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs2625529	0.824	rs12901886	chr15:72408069	G/A	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs7107174	1.000	rs12270434	chr11:78103300	G/A	cg02023728	chr11:77925099	USP35	0.63	6.11	0.53	2.23e-8	Testicular germ cell tumor;
THYM	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	8.23	0.65	9.9e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg11764359	chr7:65958608	NA	0.66	4.59	0.43	1.38e-5	Aortic root size;
THYM	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11890956	chr21:40555474	PSMG1	-0.9	-9.57	-0.7	1.4e-15	Cognitive function;
THYM	cis	rs6495367	0.898	rs2049176	chr15:79392548	A/C	cg17916960	chr15:79447300	NA	0.61	6.97	0.58	4.07e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs10426930	0.671	rs57900491	chr19:4995295	A/T	cg25246084	chr19:4971487	KDM4B	-0.51	-5.19	-0.47	1.17e-6	Monocyte percentage of white cells;
THYM	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg00757033	chr12:89920650	WDR51B	0.74	11.72	0.77	3.71e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7408868	1.000	rs7250232	chr19:15277199	C/T	cg14696996	chr19:15285081	NOTCH3	0.96	5.18	0.47	1.23e-6	Pulse pressure;
THYM	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg18681998	chr4:17616180	MED28	-0.79	-6.66	-0.56	1.81e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs459571	0.959	rs455381	chr9:136905577	C/A	cg13789015	chr9:136890014	NCRNA00094	0.82	7.14	0.59	1.84e-10	Platelet distribution width;
THYM	cis	rs10089	0.953	rs6595807	chr5:127531603	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.92	5.71	0.51	1.29e-7	Ileal carcinoids;
THYM	cis	rs7772486	0.719	rs4391282	chr6:146276780	A/T	cg23711669	chr6:146136114	FBXO30	-0.9	-8.74	-0.67	8.26e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg06582575	chr6:163149167	PACRG;PARK2	1.08	7.64	0.62	1.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1065852	0.526	rs9623489	chr22:42397026	A/G	cg01059385	chr22:42394853	WBP2NL	0.57	4.66	0.43	1.04e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs28595532	0.920	rs115576008	chr4:119736967	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg20203395	chr5:56204925	C5orf35	-0.66	-4.49	-0.42	2.02e-5	Type 2 diabetes;
THYM	cis	rs10487112	1.000	rs6980322	chr7:90068214	C/T	cg26521402	chr7:89842741	STEAP2	0.51	4.55	0.42	1.6e-5	Perceived unattractiveness to mosquitoes;
THYM	cis	rs13082711	0.595	rs1445114	chr3:27345489	C/A	cg02860705	chr3:27208620	NA	0.95	7.15	0.59	1.74e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs6754311	0.773	rs309179	chr2:136613780	G/A	cg20242066	chr2:136595261	LCT	-0.6	-7.1	-0.59	2.23e-10	Mosquito bite size;
THYM	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg14345882	chr6:26364793	BTN3A2	-0.59	-5.43	-0.49	4.31e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9583531	0.657	rs7318291	chr13:111352460	C/T	cg24331049	chr13:111365604	ING1	-0.65	-5.39	-0.48	5.15e-7	Coronary artery disease;
THYM	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg26924012	chr15:45694286	SPATA5L1	0.65	4.75	0.44	7.21e-6	Response to fenofibrate (adiponectin levels);
THYM	cis	rs13185784	0.703	rs6894217	chr5:179667806	G/A	cg02891314	chr5:179741120	GFPT2	0.67	4.5	0.42	1.89e-5	TRAIL levels;
THYM	cis	rs986417	0.901	rs1989477	chr14:61024867	T/C	cg27398547	chr14:60952738	C14orf39	0.98	4.73	0.44	7.84e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs4919694	1.000	rs4917382	chr10:104838510	G/A	cg04362960	chr10:104952993	NT5C2	1.14	7.07	0.59	2.65e-10	Arsenic metabolism;
THYM	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg18105134	chr13:113819100	PROZ	1.02	9.35	0.69	4.08e-15	Platelet distribution width;
THYM	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg18876405	chr7:65276391	NA	0.73	6.87	0.58	6.52e-10	Calcium levels;
THYM	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg14186256	chr22:23484241	RTDR1	0.96	9.57	0.7	1.38e-15	Bone mineral density;
THYM	cis	rs1061377	1.000	rs1982009	chr4:39124873	C/T	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs9906944	0.707	rs4794020	chr17:47111399	C/T	cg11673840	chr17:47092156	IGF2BP1	-0.54	-5.48	-0.49	3.55e-7	Intelligence (multi-trait analysis);Body fat percentage;
THYM	trans	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg07211511	chr3:129823064	LOC729375	-1.26	-8.96	-0.68	2.75e-14	Blood pressure (smoking interaction);
THYM	cis	rs448720	0.811	rs4776382	chr15:68179651	C/T	cg24579218	chr15:68104479	NA	-0.56	-4.95	-0.45	3.15e-6	Cognitive performance;
THYM	trans	rs3960554	0.808	rs78587454	chr7:75688672	G/A	cg19862616	chr7:65841803	NCRNA00174	0.93	6.95	0.58	4.6e-10	Eotaxin levels;
THYM	cis	rs4595586	0.525	rs12825567	chr12:39386621	C/T	cg13010199	chr12:38710504	ALG10B	0.61	4.65	0.43	1.05e-5	Morning vs. evening chronotype;
THYM	cis	rs8018808	0.846	rs11624990	chr14:77943616	C/T	cg20045696	chr14:77926864	AHSA1	0.5	4.67	0.43	9.73e-6	Myeloid white cell count;
THYM	trans	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	Myopia (pathological);
THYM	cis	rs3087591	0.960	rs9896041	chr17:29571326	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.68	-5.95	-0.52	4.46e-8	Hip circumference;
THYM	cis	rs3825942	0.900	rs8041642	chr15:74225106	G/A	cg23484268	chr15:74220776	LOXL1	0.49	4.74	0.44	7.52e-6	Glaucoma (exfoliation);
THYM	cis	rs1878931	0.507	rs67218524	chr16:3403057	G/T	cg21433313	chr16:3507492	NAT15	0.53	4.46	0.42	2.27e-5	Body mass index (adult);
THYM	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs950394	0.708	rs4851691	chr2:104992757	G/A	cg20302975	chr2:105468274	NA	-0.67	-4.62	-0.43	1.23e-5	Schizophrenia;
THYM	cis	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg07460842	chr6:66804631	NA	0.92	5.5	0.49	3.15e-7	Exhaled nitric oxide levels;
THYM	cis	rs9790314	0.747	rs9820825	chr3:160848155	A/G	cg04691961	chr3:161091175	C3orf57	-0.66	-5.23	-0.47	9.96e-7	Morning vs. evening chronotype;
THYM	cis	rs7089973	0.872	rs17092497	chr10:116612628	G/A	cg23260525	chr10:116636907	FAM160B1	0.51	4.59	0.43	1.38e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg14018140	chr10:458528	DIP2C	-0.54	-6.12	-0.53	2.13e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06634786	chr22:41940651	POLR3H	0.76	5.67	0.5	1.53e-7	Vitiligo;
THYM	cis	rs7592578	0.825	rs12477369	chr2:191455624	G/T	cg10560079	chr2:191398806	TMEM194B	0.94	6.92	0.58	5.37e-10	Diastolic blood pressure;
THYM	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02475777	chr4:1388615	CRIPAK	0.66	4.81	0.44	5.68e-6	Longevity;
THYM	cis	rs28476539	0.531	rs13114939	chr4:83540696	A/G	cg10249074	chr4:83542146	C4orf11	-0.71	-5.64	-0.5	1.72e-7	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg02527881	chr3:46936655	PTH1R	-0.6	-6.01	-0.52	3.48e-8	Colorectal cancer;
THYM	cis	rs3820068	0.608	rs6668919	chr1:16049893	A/G	cg27534772	chr1:16042836	PLEKHM2	-0.49	-5.1	-0.46	1.73e-6	Systolic blood pressure;
THYM	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg07022442	chr13:21864356	NA	0.74	4.97	0.45	3.01e-6	White matter hyperintensity burden;
THYM	cis	rs8133932	0.636	rs2014421	chr21:47278308	A/G	cg08707771	chr21:46690014	POFUT2	-0.73	-4.54	-0.42	1.65e-5	Schizophrenia;
THYM	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg14784868	chr12:69753453	YEATS4	1.13	12.26	0.78	2.8e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs12893597	0.715	rs74639969	chr14:76832150	A/G	cg20290672	chr14:76816747	NA	-0.71	-5.69	-0.5	1.39e-7	Maximal oxygen uptake response;
THYM	cis	rs7507204	0.723	rs12982194	chr19:3411947	G/A	cg08380311	chr19:3435252	NFIC	0.93	7.61	0.62	1.96e-11	Height;
THYM	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg12011299	chr4:100065546	ADH4	0.86	8.22	0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg22105103	chr4:187893119	NA	0.89	9.4	0.69	3.23e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2495707	0.624	rs2489008	chr10:102422934	C/T	cg03943218	chr10:102419600	NA	-0.63	-6.76	-0.57	1.09e-9	Body mass index;
THYM	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg05802129	chr4:122689817	NA	-0.6	-4.98	-0.45	2.87e-6	Type 2 diabetes;
THYM	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg08999081	chr20:33150536	PIGU	-0.75	-6.53	-0.56	3.16e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs12282928	1.000	rs4980423	chr11:48258607	C/G	cg22827986	chr11:48284249	OR4X1	0.53	5.5	0.49	3.18e-7	Migraine - clinic-based;
THYM	cis	rs921968	0.643	rs833083	chr2:219336959	A/T	cg02176678	chr2:219576539	TTLL4	-0.64	-6.08	-0.53	2.49e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-5.83	-0.51	7.7e-8	Total cholesterol levels;
THYM	cis	rs6430585	0.583	rs61253125	chr2:136618178	T/C	cg07169764	chr2:136633963	MCM6	1.24	13.85	0.82	1.58e-24	Corneal structure;
THYM	cis	rs17744026	0.649	rs948160	chr11:123685730	A/G	cg00079598	chr11:123676903	OR6M1	-0.52	-4.79	-0.44	6.14e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg22166914	chr1:53195759	ZYG11B	-0.72	-6.06	-0.53	2.78e-8	Monocyte count;
THYM	cis	rs6430585	0.591	rs309170	chr2:136672775	C/T	cg20242066	chr2:136595261	LCT	0.53	5.57	0.5	2.37e-7	Corneal structure;
THYM	cis	rs6840360	0.642	rs2709815	chr4:152363772	T/C	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.02	-0.53	3.26e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs490234	0.702	rs13284551	chr9:128411969	C/T	cg14078157	chr9:128172775	NA	-0.7	-5.29	-0.48	7.66e-7	Mean arterial pressure;
THYM	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg20295408	chr7:1910781	MAD1L1	-0.59	-4.66	-0.43	1.04e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs11577318	0.528	rs11247935	chr1:26698622	G/C	cg00852783	chr1:26633632	UBXN11	-0.66	-4.51	-0.42	1.87e-5	Granulocyte percentage of myeloid white cells;
THYM	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg05872129	chr22:39784769	NA	-0.89	-5.49	-0.49	3.35e-7	IgG glycosylation;
THYM	cis	rs7681440	0.583	rs2736988	chr4:90776345	C/T	cg06632027	chr4:90757378	SNCA	-0.66	-5.29	-0.48	7.91e-7	Dementia with Lewy bodies;
THYM	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.69	-5.13	-0.47	1.56e-6	Colorectal cancer;
THYM	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03517284	chr6:25882590	NA	-1.03	-9.5	-0.7	1.96e-15	Intelligence (multi-trait analysis);
THYM	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg24250549	chr1:154909240	PMVK	-0.63	-4.88	-0.45	4.2e-6	Prostate cancer;
THYM	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg11984989	chr7:158649758	WDR60	1.1	14.89	0.84	1.41e-26	Height;
THYM	cis	rs11771526	0.901	rs62457473	chr7:32306990	G/A	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs986417	1.000	rs8021348	chr14:60952777	G/T	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg06970220	chr1:156163860	SLC25A44	0.74	5.67	0.5	1.53e-7	Testicular germ cell tumor;
THYM	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg27572855	chr1:25598939	RHD	0.69	5.34	0.48	6.29e-7	Erythrocyte sedimentation rate;
THYM	cis	rs7177699	0.557	rs9806363	chr15:79110302	A/G	cg00540400	chr15:79124168	NA	-0.65	-6.99	-0.58	3.81e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs13064411	0.696	rs1486894	chr3:113211513	G/A	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs9814567	0.929	rs13088413	chr3:134309977	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.84	8.54	0.66	2.19e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg10515332	chr4:99064459	C4orf37	0.71	5.67	0.5	1.51e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3091242	0.866	rs11249249	chr1:25758134	A/G	cg10117171	chr1:25599238	RHD	-0.72	-5.46	-0.49	3.8e-7	Erythrocyte sedimentation rate;
THYM	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.76	-0.51	1.03e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs490234	0.841	rs536861	chr9:128313444	A/C	cg14078157	chr9:128172775	NA	0.67	5.28	0.48	8.02e-7	Mean arterial pressure;
THYM	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22496380	chr5:211416	CCDC127	-1.39	-8.13	-0.64	1.62e-12	Breast cancer;
THYM	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg17845761	chr1:175162550	KIAA0040	0.38	4.81	0.44	5.73e-6	Alcohol dependence;
THYM	cis	rs6768930	0.509	rs266846	chr3:57778634	C/G	cg07735586	chr3:57945651	NA	-0.33	-5.05	-0.46	2.15e-6	Obesity-related traits;
THYM	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg23791538	chr6:167370224	RNASET2	0.77	6.12	0.53	2.1e-8	Crohn's disease;
THYM	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg06728252	chr6:26598149	ABT1	-0.43	-5.11	-0.46	1.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7542375	0.534	rs34179415	chr1:221044204	A/G	cg16008148	chr1:221062819	NA	0.45	4.58	0.43	1.41e-5	Obesity-related traits;
THYM	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg27129171	chr3:47204927	SETD2	0.69	6.63	0.56	2.04e-9	Colorectal cancer;
THYM	cis	rs72792324	0.655	rs6896353	chr5:140757036	A/G	cg00808170	chr5:140807787	PCDHGA4;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB8P;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	-0.78	-4.61	-0.43	1.27e-5	Mean platelet volume;
THYM	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03647317	chr4:187891568	NA	-0.83	-9.53	-0.7	1.69e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs67981189	0.896	rs17108822	chr14:71445906	C/T	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg27129171	chr3:47204927	SETD2	0.8	7.67	0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg15445000	chr17:37608096	MED1	0.44	5.07	0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7264396	0.563	rs73902913	chr20:34432784	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-4.57	-0.42	1.45e-5	Total cholesterol levels;
THYM	cis	rs2976388	1.000	rs2976388	chr8:143760256	G/A	cg06565975	chr8:143823917	SLURP1	-0.53	-5.69	-0.5	1.41e-7	Urinary tract infection frequency;
THYM	cis	rs7666738	0.606	rs3846447	chr4:99099907	G/A	cg24818145	chr4:99064322	C4orf37	0.64	5.0	0.46	2.65e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6733011	0.578	rs6714243	chr2:99510039	A/G	cg08885076	chr2:99613938	TSGA10	-0.45	-4.48	-0.42	2.1e-5	Bipolar disorder;
THYM	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg14895029	chr7:2775587	GNA12	-0.62	-4.47	-0.42	2.13e-5	Height;
THYM	cis	rs7940866	0.834	rs10791108	chr11:130849354	T/A	cg05962950	chr11:130786565	SNX19	0.75	5.79	0.51	9.16e-8	Schizophrenia;
THYM	cis	rs1065656	0.591	rs2235648	chr16:1836796	C/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	0.4	4.92	0.45	3.61e-6	Insulin-like growth factors;
THYM	cis	rs9768139	0.634	rs11762383	chr7:158113889	C/T	cg06219351	chr7:158114137	PTPRN2	-0.8	-8.22	-0.64	1.05e-12	Calcium levels;
THYM	cis	rs11779988	0.545	rs439374	chr8:17786818	C/T	cg01800426	chr8:17659068	MTUS1	-0.76	-5.32	-0.48	6.88e-7	Breast cancer;
THYM	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg15242686	chr22:24348715	GSTTP1	-0.57	-5.29	-0.48	7.84e-7	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8133932	0.701	rs7279887	chr21:47301148	T/C	cg20357416	chr21:47294739	PCBP3	-0.89	-5.87	-0.52	6.3e-8	Schizophrenia;
THYM	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg23505145	chr19:12996616	KLF1	-1.06	-10.43	-0.73	2.02e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3008870	0.755	rs2815374	chr1:67507387	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.76	6.27	0.54	1.07e-8	Lymphocyte percentage of white cells;
THYM	cis	rs4589258	1.000	rs4589258	chr11:90471234	A/T	cg26138821	chr11:89956704	CHORDC1	-0.69	-5.52	-0.49	3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7072216	0.727	rs3750603	chr10:100175536	A/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs763014	0.931	rs56048717	chr16:634867	A/G	cg09263875	chr16:632152	PIGQ	0.73	6.29	0.54	9.69e-9	Height;
THYM	cis	rs7172809	0.573	rs60761381	chr15:77533844	G/C	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs62151617	0.527	rs11680093	chr2:70810066	C/T	cg04871472	chr2:70268913	NA	0.43	4.55	0.42	1.59e-5	Hair shape;
THYM	cis	rs6882716	0.591	rs10044607	chr5:10806058	G/A	cg14521931	chr5:10832172	NA	-0.74	-6.36	-0.55	6.96e-9	Alcohol consumption (maxi-drinks);
THYM	cis	rs11771526	0.901	rs10239582	chr7:32298116	T/A	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg06634786	chr22:41940651	POLR3H	-0.58	-4.86	-0.45	4.63e-6	Vitiligo;
THYM	cis	rs4523957	0.651	rs4790315	chr17:2070529	T/C	cg16513277	chr17:2031491	SMG6	-0.96	-8.75	-0.67	7.8500000000000006e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7177699	0.557	rs9920968	chr15:79118747	G/A	cg00540400	chr15:79124168	NA	0.63	6.89	0.58	6.04e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs10231759	0.617	rs13223879	chr7:150502868	G/A	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.63	4.78	0.44	6.34e-6	Height;
THYM	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg26545918	chr15:68124484	LBXCOR1	0.56	4.95	0.45	3.17e-6	Restless legs syndrome;
THYM	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg14456004	chr13:21872349	NA	-1.25	-10.18	-0.72	6.85e-17	White matter hyperintensity burden;
THYM	cis	rs10085978	0.781	rs13280419	chr8:143225596	G/A	cg26550068	chr8:142613273	NA	0.36	5.08	0.46	1.89e-6	Mosquito bite size;
THYM	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg12826209	chr6:26865740	GUSBL1	1.05	6.62	0.56	2.09e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9486719	0.857	rs3798293	chr6:97033370	A/G	cg06623918	chr6:96969491	KIAA0776	-0.76	-4.83	-0.44	5.29e-6	Migraine;Coronary artery disease;
THYM	cis	rs863345	0.604	rs2051450	chr1:158464062	A/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs3008870	1.000	rs2182143	chr1:67378936	T/C	cg02640540	chr1:67518911	SLC35D1	0.64	4.6	0.43	1.33e-5	Lymphocyte percentage of white cells;
THYM	cis	rs6674176	0.660	rs6801	chr1:44396646	C/G	cg12908607	chr1:44402522	ARTN	0.59	4.96	0.45	3.12e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg06481639	chr22:41940642	POLR3H	0.73	4.68	0.43	9.66e-6	Cannabis dependence symptom count;
THYM	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	5.39	0.48	5.05e-7	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg18252515	chr7:66147081	NA	-0.62	-4.62	-0.43	1.18e-5	Aortic root size;
THYM	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg13902645	chr11:5959945	NA	-0.55	-4.89	-0.45	4.02e-6	DNA methylation (variation);
THYM	cis	rs1823778	0.609	rs4891389	chr18:67705131	A/T	cg13164537	chr18:67624071	CD226	1.11	4.47	0.42	2.14e-5	Mean platelet volume;
THYM	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.4	0.48	4.9e-7	Melanoma;
THYM	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs2085601	0.503	rs2670630	chr4:89971342	C/T	cg17769793	chr4:89976368	FAM13A	-0.59	-6.62	-0.56	2.17e-9	Hair greying;
THYM	trans	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg19862616	chr7:65841803	NCRNA00174	1.02	11.27	0.76	3.27e-19	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6032067	0.929	rs17333555	chr20:43809761	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg26441486	chr22:50317300	CRELD2	0.38	5.58	0.5	2.27e-7	Schizophrenia;
THYM	cis	rs1448094	0.556	rs11610627	chr12:86167752	C/T	cg02569458	chr12:86230093	RASSF9	0.62	5.34	0.48	6.31e-7	Major depressive disorder;
THYM	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg03433033	chr1:76189801	ACADM	-0.51	-5.31	-0.48	7.2e-7	Daytime sleep phenotypes;
THYM	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg02478829	chr6:26598070	ABT1	-0.35	-4.57	-0.42	1.49e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg08000102	chr2:233561755	GIGYF2	-0.53	-4.66	-0.43	1.04e-5	Coronary artery disease;
THYM	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg02820040	chr2:241836501	C2orf54	-0.29	-5.96	-0.52	4.26e-8	Urinary metabolites;
THYM	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs36051895	0.632	rs11793886	chr9:5125469	A/G	cg02405213	chr9:5042618	JAK2	-1.02	-11.18	-0.75	5.05e-19	Pediatric autoimmune diseases;
THYM	cis	rs9816226	0.793	rs869400	chr3:185826740	T/G	cg00760338	chr3:185826511	ETV5	0.79	4.91	0.45	3.81e-6	Obesity;Body mass index;
THYM	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg18404041	chr3:52824283	ITIH1	-0.44	-4.46	-0.42	2.24e-5	Bipolar disorder;
THYM	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg05368731	chr17:41323189	NBR1	1.19	10.44	0.73	1.89e-17	Menopause (age at onset);
THYM	cis	rs12500482	0.509	rs1203784	chr4:2427108	T/C	cg26605046	chr4:2439731	NA	-0.68	-6.44	-0.55	4.97e-9	Cognitive function;
THYM	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.71	5.11	0.46	1.63e-6	Schizophrenia;
THYM	cis	rs72792324	0.655	rs28694549	chr5:140748146	A/G	cg21929183	chr5:140807225	PCDHGA4;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB8P;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	-0.89	-4.6	-0.43	1.31e-5	Mean platelet volume;
THYM	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg21475434	chr5:93447410	FAM172A	0.83	5.31	0.48	7.13e-7	Diabetic retinopathy;
THYM	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs7027203	1.000	rs7856374	chr9:96529791	G/A	cg14598338	chr9:96623480	NA	0.45	4.81	0.44	5.72e-6	DNA methylation (variation);
THYM	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg24397884	chr7:158709396	WDR60	-0.42	-4.94	-0.45	3.29e-6	Height;
THYM	cis	rs6598955	0.671	rs10159433	chr1:26618370	A/G	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.86	0.45	4.66e-6	Obesity-related traits;
THYM	cis	rs7103648	0.553	rs12803857	chr11:47890172	G/A	cg20307385	chr11:47447363	PSMC3	0.75	5.45	0.49	3.97e-7	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.65	0.5	1.64e-7	Tonsillectomy;
THYM	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg20283391	chr11:68216788	NA	-0.6	-4.72	-0.44	8.09e-6	Total body bone mineral density;
THYM	cis	rs1692580	0.840	rs262679	chr1:2169792	C/T	cg24578937	chr1:2090814	PRKCZ	0.51	5.06	0.46	2.06e-6	Coronary artery disease;
THYM	cis	rs9318086	0.648	rs78881146	chr13:24468704	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.56	4.61	0.43	1.27e-5	Myopia (pathological);
THYM	cis	rs67460515	0.500	rs9822435	chr3:160748068	A/T	cg12349858	chr3:160822545	B3GALNT1	0.61	4.95	0.45	3.16e-6	Parkinson's disease;
THYM	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.8	5.95	0.52	4.49e-8	Height;
THYM	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg01097406	chr16:89675127	NA	-0.58	-4.78	-0.44	6.3e-6	Vitiligo;
THYM	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg09469691	chr10:81107165	PPIF	0.71	5.54	0.49	2.72e-7	Height;
THYM	cis	rs4499344	0.623	rs259278	chr19:33161126	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	1.12	9.2	0.69	8.55e-15	Mean platelet volume;
THYM	cis	rs10089	1.000	rs2409109	chr5:127461471	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs6840360	0.550	rs6853955	chr4:152510806	G/A	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	trans	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs514406	0.505	rs374849	chr1:53185631	G/A	cg24675658	chr1:53192096	ZYG11B	-0.8	-7.2	-0.59	1.43e-10	Monocyte count;
THYM	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.8	-5.63	-0.5	1.82e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg14779329	chr11:130786720	SNX19	0.52	5.43	0.49	4.41e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs28595532	0.920	rs17323034	chr4:119606518	G/A	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs346785	0.610	rs347674	chr17:74278548	C/G	cg09812376	chr17:74270190	QRICH2	-0.78	-11.46	-0.76	1.31e-19	White matter hyperintensities in ischemic stroke;
THYM	cis	rs10887741	0.966	rs1980647	chr10:89422287	A/G	cg13926569	chr10:89418898	PAPSS2	0.59	6.32	0.54	8.43e-9	Exercise (leisure time);
THYM	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg24692254	chr21:30365293	RNF160	-1.06	-9.37	-0.69	3.74e-15	Dental caries;
THYM	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg23758822	chr17:41437982	NA	1.16	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs11085466	1.000	rs73552468	chr19:21772097	G/A	cg23004160	chr19:21646329	NA	-0.65	-4.7	-0.43	8.62e-6	Colorectal or endometrial cancer;
THYM	cis	rs7584330	0.554	rs10190935	chr2:238435482	G/A	cg08992911	chr2:238395768	MLPH	0.89	5.81	0.51	8.24e-8	Prostate cancer;
THYM	cis	rs10929159	0.928	rs6749436	chr2:236919992	A/G	cg20128773	chr2:236923534	AGAP1	0.36	4.75	0.44	7.13e-6	Parkinson's disease;
THYM	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg10589385	chr1:150898437	SETDB1	0.62	5.08	0.46	1.9e-6	Melanoma;
THYM	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg15448220	chr1:150897856	SETDB1	-0.9	-7.66	-0.62	1.56e-11	Melanoma;
THYM	cis	rs2050392	0.517	rs160017	chr10:30772894	A/G	cg02070205	chr10:30722105	MAP3K8	-0.59	-4.89	-0.45	4.03e-6	Inflammatory bowel disease;
THYM	cis	rs4731207	0.698	rs4731216	chr7:124466512	T/G	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7772486	0.806	rs4075695	chr6:146250959	A/G	cg23711669	chr6:146136114	FBXO30	-0.87	-8.4	-0.65	4.29e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg15448220	chr1:150897856	SETDB1	0.89	7.36	0.6	6.64e-11	Melanoma;
THYM	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg10164272	chr16:89456328	ANKRD11	0.58	4.46	0.42	2.27e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-7.02	-0.58	3.26e-10	Monocyte percentage of white cells;
THYM	cis	rs4975616	0.869	rs31490	chr5:1344458	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.79	-6.73	-0.57	1.25e-9	Lung cancer;
THYM	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs10832963	1.000	rs7943121	chr11:18656062	G/C	cg09201001	chr11:18656081	SPTY2D1	1.05	9.37	0.69	3.67e-15	Breast cancer;
THYM	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg17279839	chr7:150038598	RARRES2	0.54	4.7	0.43	8.67e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs754466	0.580	rs2579177	chr10:79529245	C/T	cg17075019	chr10:79541650	NA	-0.68	-5.74	-0.51	1.14e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs74338693	1.000	rs74338693	chr2:166813725	C/G	cg23808213	chr2:166948291	NA	-0.44	-4.45	-0.42	2.33e-5	Schizophrenia;
THYM	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg09877947	chr5:131593287	PDLIM4	0.58	4.82	0.44	5.38e-6	Blood metabolite levels;
THYM	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	4.55	0.42	1.57e-5	Bipolar disorder;
THYM	cis	rs7267979	0.966	rs6037103	chr20:25369095	A/G	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	7.12	0.59	2.09e-10	Cognitive test performance;
THYM	cis	rs9430161	0.611	rs2095920	chr1:11033457	T/A	cg02454025	chr1:11042201	C1orf127	0.91	10.49	0.73	1.51e-17	Ewing sarcoma;
THYM	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg00012203	chr2:219082015	ARPC2	0.65	5.63	0.5	1.86e-7	Colorectal cancer;
THYM	cis	rs929596	0.563	rs1105880	chr2:234601965	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.82	-7.06	-0.59	2.67e-10	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg20203395	chr5:56204925	C5orf35	0.67	4.58	0.42	1.44e-5	Initial pursuit acceleration;
THYM	cis	rs9914988	0.887	rs4795456	chr17:27072463	G/A	cg20469991	chr17:27169893	C17orf63	-0.8	-4.87	-0.45	4.48e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs4919694	0.711	rs113361908	chr10:104978126	T/C	cg04362960	chr10:104952993	NT5C2	1.08	6.44	0.55	4.96e-9	Arsenic metabolism;
THYM	cis	rs420259	0.510	rs12921516	chr16:23521403	T/G	cg00143387	chr16:23521605	GGA2	-0.82	-5.73	-0.51	1.19e-7	Bipolar disorder;
THYM	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg21926883	chr2:100939477	LONRF2	-0.55	-4.99	-0.46	2.74e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg17063962	chr7:91808500	NA	1.16	11.68	0.77	4.61e-20	Breast cancer;
THYM	cis	rs7927771	0.524	rs12362318	chr11:47682671	T/C	cg20307385	chr11:47447363	PSMC3	0.61	4.68	0.43	9.62e-6	Subjective well-being;
THYM	cis	rs2276314	0.857	rs62101376	chr18:33582955	T/C	cg05985134	chr18:33552581	C18orf21	0.69	4.84	0.44	5.07e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs1784581	0.588	rs9295178	chr6:162419226	T/A	cg17173639	chr6:162384350	PARK2	0.81	7.48	0.61	3.75e-11	Itch intensity from mosquito bite;
THYM	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg06784218	chr1:46089804	CCDC17	-0.29	-4.5	-0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs10203711	1.000	rs7590907	chr2:239550312	T/C	cg14580085	chr2:239553406	NA	0.59	4.85	0.45	4.81e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2404602	0.735	rs2454450	chr15:76831236	G/A	cg23625390	chr15:77176239	SCAPER	-0.7	-5.05	-0.46	2.15e-6	Blood metabolite levels;
THYM	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	5.42	0.49	4.47e-7	Schizophrenia;
THYM	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg12219531	chr12:120966889	COQ5	0.8	6.47	0.55	4.2e-9	High light scatter reticulocyte count;
THYM	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs58749629	1.000	rs58749629	chr20:44571317	G/A	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.57	-5.32	-0.48	6.81e-7	Abdominal aortic aneurysm;
THYM	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg01264106	chr22:38071602	LGALS1	0.36	4.55	0.42	1.56e-5	Fat distribution (HIV);
THYM	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.16	-0.47	1.37e-6	Mood instability;
THYM	cis	rs761746	0.705	rs2092905	chr22:31966274	T/C	cg01338084	chr22:32026380	PISD	-0.64	-5.53	-0.49	2.82e-7	Intelligence;
THYM	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg10023613	chr17:42248099	ASB16	0.28	4.64	0.43	1.11e-5	Bone mineral density (hip);Bone mineral density;
THYM	trans	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs9467711	0.559	rs9393727	chr6:26500011	C/G	cg12826209	chr6:26865740	GUSBL1	0.9	4.96	0.45	3.09e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg27394845	chr17:28928406	LRRC37B2	-0.97	-4.85	-0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2862064	1.000	rs905211	chr5:156447218	A/T	cg12943317	chr5:156479607	HAVCR1	-0.83	-5.15	-0.47	1.4e-6	Platelet count;
THYM	cis	rs736801	0.504	rs2070721	chr5:131825842	T/G	cg00255919	chr5:131827918	IRF1	0.52	6.68	0.57	1.59e-9	Breast cancer;Mosquito bite size;
THYM	cis	rs4731207	0.596	rs1481329	chr7:124631334	A/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs10911232	0.507	rs4652766	chr1:182994336	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs7106204	0.620	rs12805125	chr11:24258967	A/T	ch.11.24196551F	chr11:24239977	NA	-0.93	-5.71	-0.51	1.3e-7	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg14643075	chr5:176755449	NA	-0.48	-4.48	-0.42	2.11e-5	Hemoglobin concentration;Hematocrit;
THYM	cis	rs12935418	0.616	rs13336629	chr16:81005806	C/T	cg16651780	chr16:81037892	C16orf61	0.76	5.4	0.48	4.86e-7	Mean corpuscular volume;
THYM	cis	rs4072705	1.000	rs4836981	chr9:127340145	T/C	cg13476313	chr9:127244764	NR5A1	0.3	4.66	0.43	1.02e-5	Menarche (age at onset);
THYM	cis	rs919433	0.680	rs7605813	chr2:198375329	C/G	cg00792783	chr2:198669748	PLCL1	0.83	5.73	0.51	1.18e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg05754148	chr16:3507555	NAT15	0.88	7.96	0.63	3.57e-12	Tuberculosis;
THYM	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs714027	0.837	rs713875	chr22:30592487	C/G	cg11564601	chr22:30592435	NA	-0.31	-5.58	-0.5	2.23e-7	Lymphocyte counts;
THYM	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg13695892	chr22:41940480	POLR3H	-0.87	-6.35	-0.55	7.28e-9	Vitiligo;
THYM	cis	rs4891159	0.548	rs617823	chr18:74120233	A/G	cg24786174	chr18:74118243	ZNF516	0.98	13.84	0.82	1.65e-24	Longevity;
THYM	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.85	-7.05	-0.59	2.87e-10	Systemic lupus erythematosus;
THYM	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg12119029	chr16:89752879	CDK10	0.41	4.51	0.42	1.86e-5	Vitiligo;
THYM	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg13609457	chr4:120235615	NA	0.51	4.8	0.44	5.83e-6	Corneal astigmatism;
THYM	cis	rs4631830	0.683	rs10763193	chr10:51504938	G/A	cg10326726	chr10:51549505	MSMB	0.5	4.99	0.46	2.68e-6	Prostate-specific antigen levels;
THYM	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg22875332	chr1:76189707	ACADM	0.88	11.22	0.75	4.31e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg08999081	chr20:33150536	PIGU	0.59	5.03	0.46	2.29e-6	Coronary artery disease;
THYM	cis	rs7818345	0.967	rs4549789	chr8:19284015	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.53	0.42	1.73e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs78761021	0.867	rs77902029	chr17:9791780	T/A	cg26853458	chr17:9805074	RCVRN	0.52	4.65	0.43	1.08e-5	Type 2 diabetes;
THYM	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.83	0.67	5.15e-14	Colorectal cancer;
THYM	cis	rs13256369	0.851	rs13271698	chr8:8567539	C/A	cg18904891	chr8:8559673	CLDN23	0.67	4.97	0.45	3e-6	Obesity-related traits;
THYM	cis	rs4604732	0.588	rs7552461	chr1:247628644	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.69	4.8	0.44	5.99e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs36051895	0.632	rs7850425	chr9:5170645	G/T	cg02405213	chr9:5042618	JAK2	-0.98	-9.63	-0.7	9.99e-16	Pediatric autoimmune diseases;
THYM	cis	rs7546094	1.000	rs1001494	chr1:113110619	T/C	cg22162597	chr1:113214053	CAPZA1	0.45	4.62	0.43	1.21e-5	Platelet distribution width;
THYM	cis	rs986417	0.901	rs12886086	chr14:61042091	A/G	cg27398547	chr14:60952738	C14orf39	1.21	6.17	0.53	1.69e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2916260	0.736	rs9369201	chr6:40387037	T/C	cg08415973	chr6:40346114	TDRG1	0.72	4.69	0.43	8.99e-6	Incident coronary heart disease;
THYM	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg22166914	chr1:53195759	ZYG11B	0.77	7.32	0.6	8.1e-11	Monocyte count;
THYM	cis	rs9876781	1.000	rs9809843	chr3:48434398	T/C	cg06066452	chr3:48470258	PLXNB1	0.26	4.88	0.45	4.26e-6	Longevity;
THYM	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg06873352	chr17:61820015	STRADA	-0.79	-9.97	-0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs11677370	0.561	rs11687254	chr2:3830906	C/T	cg17052675	chr2:3827356	NA	-0.66	-6.48	-0.55	4.03e-9	Type 2 diabetes;
THYM	cis	rs2108225	0.900	rs2395930	chr7:107451677	T/C	cg18560240	chr7:107437656	SLC26A3	-0.79	-5.65	-0.5	1.68e-7	Ulcerative colitis;
THYM	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg00383909	chr3:49044727	WDR6	1.33	6.25	0.54	1.18e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4638749	0.627	rs6542753	chr2:108815852	T/A	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12643440	0.538	rs2314599	chr4:17139624	A/G	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs9522267	0.535	rs914036	chr13:112235542	G/A	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs995000	0.868	rs1007205	chr1:62936912	T/C	cg06896770	chr1:63153194	DOCK7	-0.92	-7.56	-0.61	2.53e-11	Triglyceride levels;
THYM	cis	rs526231	0.697	rs253759	chr5:102615675	G/A	cg23492399	chr5:102201601	PAM	-0.65	-4.52	-0.42	1.8e-5	Primary biliary cholangitis;
THYM	cis	rs985746	0.568	rs9999315	chr4:36801871	A/G	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg16797656	chr11:68205561	LRP5	0.48	4.98	0.46	2.79e-6	Total body bone mineral density;
THYM	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg09990169	chr2:241835740	C2orf54	-0.36	-5.85	-0.51	6.97e-8	Urinary metabolites;
THYM	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg10792982	chr14:105748885	BRF1	0.73	7.55	0.61	2.66e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg26513180	chr16:89883248	FANCA	-0.51	-4.6	-0.43	1.3e-5	Vitiligo;
THYM	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg24846343	chr22:24311635	DDTL	0.45	5.71	0.51	1.28e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs920590	0.758	rs1817836	chr8:19664852	T/C	cg01411142	chr8:19674711	INTS10	0.64	4.85	0.45	4.81e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg16006841	chr5:176797999	RGS14	0.49	5.78	0.51	9.61e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	4.79	0.44	6.04e-6	Menarche (age at onset);
THYM	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6539288	0.933	rs10778513	chr12:107302183	A/G	cg26297688	chr12:107349093	C12orf23	-0.44	-4.57	-0.42	1.49e-5	Total body bone mineral density;
THYM	cis	rs28595532	0.925	rs115651057	chr4:119486708	A/G	cg21605333	chr4:119757512	SEC24D	1.26	5.37	0.48	5.6e-7	Cannabis dependence symptom count;
THYM	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg03684893	chr10:554711	DIP2C	0.76	6.63	0.56	1.99e-9	Psychosis in Alzheimer's disease;
THYM	cis	rs2050392	0.829	rs306589	chr10:30723831	A/G	cg02070205	chr10:30722105	MAP3K8	-0.53	-4.54	-0.42	1.62e-5	Inflammatory bowel disease;
THYM	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg09354556	chr3:47051341	NA	0.44	4.57	0.42	1.46e-5	Colorectal cancer;
THYM	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg24020549	chr11:64937741	SPDYC	-0.46	-4.45	-0.42	2.34e-5	Eosinophil percentage of white cells;
THYM	cis	rs6586111	1.000	rs7073089	chr10:82371045	C/G	cg03086067	chr10:82368399	SH2D4B	-0.55	-6.93	-0.58	4.93e-10	Capecitabine sensitivity;
THYM	cis	rs2879627	0.560	rs2154281	chr10:53677635	A/G	cg08751451	chr10:53287690	PRKG1	-0.71	-4.66	-0.43	1.04e-5	Coronary artery disease;
THYM	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg00339695	chr16:24857497	SLC5A11	-0.68	-6.18	-0.54	1.6e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4889855	0.530	rs78012645	chr17:78550939	C/T	cg16591659	chr17:78472290	NA	0.45	5.14	0.47	1.46e-6	Fractional excretion of uric acid;
THYM	cis	rs1401999	0.932	rs4148557	chr3:183733784	A/G	cg01324343	chr3:183735012	ABCC5	0.85	11.53	0.76	9.24e-20	Anterior chamber depth;
THYM	cis	rs7523273	0.565	rs2104303	chr1:207886684	C/T	cg22525895	chr1:207977042	MIR29B2	-0.54	-5.08	-0.46	1.85e-6	Schizophrenia;
THYM	trans	rs8073060	0.559	rs72829925	chr17:34049778	C/A	cg19694781	chr19:47549865	TMEM160	1.02	8.69	0.67	1.01e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs4631830	0.720	rs12412140	chr10:51503977	T/C	cg10326726	chr10:51549505	MSMB	0.53	5.31	0.48	7.2e-7	Prostate-specific antigen levels;
THYM	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg11861562	chr11:117069780	TAGLN	0.33	4.76	0.44	6.86e-6	Blood protein levels;
THYM	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg01264106	chr22:38071602	LGALS1	0.4	5.13	0.47	1.54e-6	Fat distribution (HIV);
THYM	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg12386194	chr3:101231763	SENP7	0.96	7.52	0.61	3.12e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg18252515	chr7:66147081	NA	1.37	8.05	0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.47	-4.64	-0.43	1.11e-5	Crohn's disease;
THYM	cis	rs6060717	0.654	rs6060686	chr20:34512606	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.66	-4.72	-0.44	8.08e-6	Hip circumference adjusted for BMI;
THYM	cis	rs3806843	0.868	rs2531345	chr5:140126781	T/G	cg19875535	chr5:140030758	IK	-0.58	-4.52	-0.42	1.76e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22857025	chr5:266934	NA	-1.37	-8.88	-0.67	4.08e-14	Breast cancer;
THYM	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg13114125	chr14:105738426	BRF1	-0.77	-6.19	-0.54	1.53e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg12011299	chr4:100065546	ADH4	-0.92	-9.6	-0.7	1.18e-15	Alcohol dependence;
THYM	cis	rs3820068	0.603	rs1980607	chr1:15975237	A/G	cg27534772	chr1:16042836	PLEKHM2	0.55	6.04	0.53	3.01e-8	Systolic blood pressure;
THYM	cis	rs2219968	1.000	rs13248763	chr8:78975616	G/A	cg00738934	chr8:78996279	NA	0.92	10.06	0.72	1.2e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1448094	0.512	rs7133591	chr12:86239752	G/C	cg00310523	chr12:86230176	RASSF9	0.53	4.79	0.44	6.05e-6	Major depressive disorder;
THYM	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17127169	1.000	rs11208558	chr1:65425824	T/C	cg12075498	chr1:65428216	JAK1	0.4	5.0	0.46	2.64e-6	Sitting height ratio;
THYM	cis	rs7651039	0.619	rs7640807	chr3:15685137	A/G	cg16303742	chr3:15540471	COLQ	0.7	6.77	0.57	1.07e-9	Coronary heart disease;
THYM	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19346786	chr7:2764209	NA	-0.77	-6.83	-0.57	7.85e-10	Height;
THYM	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg08213375	chr14:104286397	PPP1R13B	0.45	4.81	0.44	5.59e-6	Reticulocyte count;
THYM	cis	rs2294693	0.730	rs9369248	chr6:40959664	G/T	cg14418226	chr6:40996092	UNC5CL	-0.72	-5.86	-0.52	6.74e-8	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs17826219	0.585	rs8064302	chr17:28724938	G/A	cg27034606	chr17:28928453	LRRC37B2	-0.78	-4.51	-0.42	1.84e-5	Body mass index;
THYM	cis	rs887829	0.570	rs10445704	chr2:234600274	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.79	-6.88	-0.58	6.26e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs1747683	0.677	rs1095368	chr10:13355131	T/C	cg25835351	chr10:13388524	SEPHS1	0.35	6.04	0.53	2.95e-8	IgG glycosylation;
THYM	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg22105103	chr4:187893119	NA	0.92	10.09	0.72	1.04e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7586879	0.681	rs28836469	chr2:25117215	A/G	cg27107076	chr2:25050844	ADCY3	-0.29	-4.66	-0.43	1.04e-5	Body mass index;
THYM	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs79349575	0.721	rs3744608	chr17:46993233	C/G	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs12148329	0.545	rs12916634	chr15:81025131	A/G	cg01654770	chr15:80543586	NA	-0.89	-4.6	-0.43	1.31e-5	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs7100689	0.516	rs10788546	chr10:82034854	T/C	cg09936400	chr10:82049201	MAT1A	0.45	5.01	0.46	2.49e-6	Post bronchodilator FEV1;
THYM	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg08017756	chr2:100939284	LONRF2	-0.75	-7.56	-0.61	2.54e-11	Intelligence (multi-trait analysis);
THYM	cis	rs12257961	0.521	rs7899540	chr10:15382782	G/A	cg10616319	chr10:15468812	NA	0.64	5.39	0.48	5.16e-7	Selective IgA deficiency;
THYM	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-4.71	-0.44	8.39e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg11764359	chr7:65958608	NA	-0.66	-4.56	-0.42	1.54e-5	Aortic root size;
THYM	cis	rs240764	0.635	rs7773043	chr6:100921115	G/A	cg21058520	chr6:100914733	NA	0.56	4.82	0.44	5.44e-6	Neuroticism;
THYM	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg03806693	chr22:41940476	POLR3H	1.04	7.62	0.62	1.86e-11	Cannabis dependence symptom count;
THYM	cis	rs11112613	0.775	rs7299470	chr12:105961773	G/A	cg03607813	chr12:105948248	NA	0.95	7.59	0.61	2.17e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg00898013	chr13:113819073	PROZ	-1.06	-9.78	-0.71	4.93e-16	Platelet distribution width;
THYM	cis	rs6901250	0.851	rs339324	chr6:117195024	C/T	cg12892004	chr6:117198278	RFX6	-0.7	-6.78	-0.57	9.91e-10	C-reactive protein levels;
THYM	cis	rs6539288	0.933	rs10861673	chr12:107300071	A/G	cg26297688	chr12:107349093	C12orf23	-0.44	-4.57	-0.42	1.49e-5	Total body bone mineral density;
THYM	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.71	6.04	0.53	3.04e-8	Calcium levels;
THYM	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg14972814	chr11:95582409	MTMR2	-0.71	-6.61	-0.56	2.19e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6964587	0.626	rs4422709	chr7:91510968	A/G	cg17063962	chr7:91808500	NA	-0.99	-8.38	-0.65	4.64e-13	Breast cancer;
THYM	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg20007245	chr22:24372913	LOC391322	-0.76	-7.81	-0.63	7.56e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.78	-0.44	6.31e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7107770	1.000	rs7104532	chr11:125100272	G/A	cg07747661	chr11:125106135	PKNOX2	-0.85	-5.12	-0.47	1.59e-6	Photic sneeze reflex;
THYM	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.86	-0.45	4.62e-6	Eye color traits;
THYM	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs1775715	0.737	rs2799017	chr10:32203460	A/G	cg04359828	chr10:32216031	ARHGAP12	0.39	5.14	0.47	1.45e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg08807101	chr21:30365312	RNF160	-0.8	-6.25	-0.54	1.15e-8	Dental caries;
THYM	trans	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg19862616	chr7:65841803	NCRNA00174	1.13	13.2	0.8	3.22e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs8114671	0.836	rs17404569	chr20:33674077	A/C	cg08999081	chr20:33150536	PIGU	-0.56	-4.83	-0.44	5.18e-6	Height;
THYM	cis	rs3771570	0.901	rs3821285	chr2:242421314	A/G	cg21155796	chr2:242212141	HDLBP	-1.02	-6.27	-0.54	1.06e-8	Prostate cancer;
THYM	cis	rs7631605	0.870	rs9839105	chr3:37262286	A/G	cg21328643	chr3:37258149	NA	-0.51	-4.88	-0.45	4.18e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs2518683	0.561	rs1894414	chr22:29702654	C/A	cg10230314	chr22:30552801	HORMAD2	0.57	4.48	0.42	2.12e-5	Platelet count;
THYM	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03576123	chr11:487126	PTDSS2	-1.24	-5.21	-0.47	1.1e-6	Body mass index;
THYM	cis	rs59698941	0.843	rs61541414	chr5:132226106	G/A	cg02081065	chr5:132209139	LEAP2	-0.82	-5.54	-0.49	2.73e-7	Apolipoprotein A-IV levels;
THYM	cis	rs67460515	0.892	rs35100811	chr3:161084046	A/C	cg03342759	chr3:160939853	NMD3	-0.9	-7.93	-0.63	4.25e-12	Parkinson's disease;
THYM	cis	rs4792901	0.959	rs55955027	chr17:41621156	T/A	cg21940313	chr17:41620911	ETV4	-0.52	-5.51	-0.49	3.08e-7	Dupuytren's disease;
THYM	trans	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17712092	chr4:129076599	LARP1B	-0.9	-7.35	-0.6	7.02e-11	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs6429082	0.811	rs291348	chr1:235667690	A/G	cg26050004	chr1:235667680	B3GALNT2	1.01	10.26	0.73	4.5e-17	Adiposity;
THYM	cis	rs986417	0.892	rs11622577	chr14:60814981	A/T	cg27398547	chr14:60952738	C14orf39	-1.26	-6.29	-0.54	9.47e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs6500395	0.926	rs7192297	chr16:48670421	G/A	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg00898013	chr13:113819073	PROZ	-0.89	-9.29	-0.69	5.34e-15	Platelet distribution width;
THYM	cis	rs11726022	0.927	rs35519779	chr4:188173766	T/C	cg09690449	chr4:187998952	NA	-0.51	-5.15	-0.47	1.41e-6	Systolic blood pressure (cigarette smoking interaction);
THYM	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.53	4.87	0.45	4.42e-6	Lymphocyte counts;
THYM	cis	rs7100689	0.622	rs1890890	chr10:82090643	A/T	cg01528321	chr10:82214614	TSPAN14	0.84	6.43	0.55	5.13e-9	Post bronchodilator FEV1;
THYM	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg18681998	chr4:17616180	MED28	0.98	9.9	0.71	2.68e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs960902	0.869	rs6735123	chr2:37735864	C/G	cg25341268	chr2:37734390	NA	-0.63	-5.37	-0.48	5.58e-7	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg01073479	chr16:3509474	NAT15	-0.54	-5.35	-0.48	6.1e-7	Tuberculosis;
THYM	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg02891314	chr5:179741120	GFPT2	-0.91	-7.29	-0.6	9.3e-11	Height;
THYM	cis	rs28595532	0.920	rs116062544	chr4:119735548	G/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg04772025	chr11:68637568	NA	0.6	6.22	0.54	1.35e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2133450	0.712	rs1546238	chr3:7366551	T/C	cg19930620	chr3:7340148	GRM7	-0.48	-4.49	-0.42	1.98e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg15448220	chr1:150897856	SETDB1	0.89	7.43	0.61	4.68e-11	Tonsillectomy;
THYM	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg12179176	chr11:130786555	SNX19	-0.86	-8.13	-0.64	1.61e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs3110496	0.685	rs550818	chr17:27901975	A/G	cg04498198	chr17:27899966	TP53I13	-0.56	-6.09	-0.53	2.38e-8	Height;
THYM	cis	rs868036	0.958	rs4261478	chr15:68074084	G/A	cg24579218	chr15:68104479	NA	-0.66	-6.8	-0.57	9.36e-10	Restless legs syndrome;
THYM	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg14829155	chr15:31115871	NA	-0.6	-5.08	-0.46	1.89e-6	Huntington's disease progression;
THYM	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.61	4.87	0.45	4.43e-6	Aortic root size;
THYM	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg10518543	chr12:38710700	ALG10B	0.57	4.67	0.43	1e-5	Heart rate;
THYM	cis	rs1065852	0.526	rs9623489	chr22:42397026	A/G	cg08431931	chr22:42394659	WBP2NL	0.74	6.08	0.53	2.48e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.22	9.08	0.68	1.54e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg17480646	chr11:65405466	SIPA1	-0.94	-8.85	-0.67	4.72e-14	Acne (severe);
THYM	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg09455208	chr3:40491958	NA	-0.43	-4.48	-0.42	2.06e-5	Renal cell carcinoma;
THYM	cis	rs78579285	0.544	rs4782320	chr16:88779865	G/A	cg00973732	chr16:88803885	FAM38A	-0.88	-4.56	-0.42	1.51e-5	Joint mobility (Beighton score);
THYM	cis	rs11645898	0.504	rs79169855	chr16:71950201	A/G	cg03805757	chr16:71968109	PKD1L3	-0.85	-6.42	-0.55	5.43e-9	Blood protein levels;
THYM	cis	rs6732160	0.564	rs7605716	chr2:73376250	G/A	cg24220031	chr2:73402428	NA	-0.71	-5.79	-0.51	8.94e-8	Intelligence (multi-trait analysis);
THYM	cis	rs986417	1.000	rs1951114	chr14:60922005	C/G	cg27398547	chr14:60952738	C14orf39	-1.15	-5.91	-0.52	5.37e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg00981070	chr1:2046702	PRKCZ	0.48	5.33	0.48	6.68e-7	Height;
THYM	cis	rs9563576	0.825	rs35576707	chr13:58556077	C/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs8081692	1	rs8081692	chr17:38154595	A/G	cg17467752	chr17:38218738	THRA	0.87	7.22	0.59	1.3e-10	Neutrophil count;
THYM	cis	rs7078219	0.686	rs12412214	chr10:101276256	G/A	cg23904955	chr10:101282759	NA	-0.41	-4.89	-0.45	4.15e-6	Dental caries;
THYM	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.63	4.46	0.42	2.28e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg07460842	chr6:66804631	NA	-0.95	-6.81	-0.57	8.9e-10	Exhaled nitric oxide output;
THYM	cis	rs3087591	0.960	rs1013947	chr17:29530362	C/T	cg24425628	chr17:29625626	OMG;NF1	0.66	5.79	0.51	9.11e-8	Hip circumference;
THYM	cis	rs6084875	0.812	rs2050369	chr20:4719493	C/T	cg19614321	chr20:4804581	RASSF2	0.45	4.53	0.42	1.7e-5	Systemic lupus erythematosus;
THYM	cis	rs2237898	0.585	rs12577753	chr11:2877468	G/A	cg12614029	chr11:2160564	INS-IGF2;IGF2AS;IGF2	-1.21	-4.48	-0.42	2.05e-5	Mosquito bite size;
THYM	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg17063962	chr7:91808500	NA	1.12	11.99	0.78	1.02e-20	Breast cancer;
THYM	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg20387954	chr3:183756860	HTR3D	0.58	4.73	0.44	7.72e-6	Anterior chamber depth;
THYM	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.55	-0.73	1.12e-17	Primary sclerosing cholangitis;
THYM	cis	rs10857712	0.551	rs12252576	chr10:135227244	T/C	cg00491522	chr10:135256596	NA	0.64	5.3	0.48	7.63e-7	Systemic lupus erythematosus;
THYM	cis	rs9311676	0.609	rs62258080	chr3:58367493	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.58	0.43	1.41e-5	Systemic lupus erythematosus;
THYM	cis	rs6876348	0.516	rs258004	chr5:128319330	T/G	cg25555059	chr5:128301488	SLC27A6	-0.45	-4.62	-0.43	1.21e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6032067	0.714	rs16989820	chr20:43837659	G/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.61	-5.89	-0.52	5.91e-8	Blood protein levels;
THYM	cis	rs10504073	0.584	rs11778863	chr8:49954893	C/T	cg00325661	chr8:49890786	NA	1.07	10.28	0.73	4.26e-17	Blood metabolite ratios;
THYM	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg14983838	chr19:29218262	NA	1.08	9.53	0.7	1.66e-15	Methadone dose in opioid dependence;
THYM	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.54	-5.26	-0.48	8.75e-7	Crohn's disease;
THYM	cis	rs11048434	0.612	rs7299653	chr12:9058993	A/T	cg13575925	chr12:9217583	LOC144571	0.53	4.77	0.44	6.64e-6	Sjögren's syndrome;
THYM	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg03676636	chr4:99064102	C4orf37	0.38	5.41	0.49	4.62e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9807841	0.670	rs8099926	chr19:10778647	A/G	cg16900796	chr19:10755136	SLC44A2	0.33	5.08	0.46	1.88e-6	Inflammatory skin disease;
THYM	cis	rs897984	0.684	rs6950	chr16:30995669	T/C	cg06892815	chr16:30991727	SETD1A	0.51	4.52	0.42	1.79e-5	Dementia with Lewy bodies;
THYM	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.85	0.45	4.9100000000000004e-06	Bipolar disorder;
THYM	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg04063615	chr12:132293388	NA	-0.49	-4.62	-0.43	1.21e-5	Migraine;
THYM	cis	rs72627123	0.867	rs58102735	chr14:74467531	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs4660531	1.000	rs61774746	chr1:41838561	T/G	cg01193554	chr1:41846683	NA	-0.35	-4.58	-0.42	1.44e-5	Bipolar disorder;
THYM	cis	rs11771526	0.901	rs11767773	chr7:32272342	T/G	cg13207630	chr7:32358064	NA	0.74	4.98	0.46	2.8e-6	Body mass index;
THYM	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs3784262	0.528	rs34556514	chr15:58333769	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.65	-5.04	-0.46	2.24e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
THYM	cis	rs761746	0.960	rs4820983	chr22:31929654	C/T	cg01338084	chr22:32026380	PISD	-0.57	-4.94	-0.45	3.28e-6	Intelligence;
THYM	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg16342193	chr10:102329863	NA	-0.6	-6.21	-0.54	1.41e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1568889	0.838	rs11030230	chr11:28174631	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs7084402	0.935	rs10826202	chr10:60359091	C/T	cg07615347	chr10:60278583	BICC1	0.55	5.12	0.47	1.59e-6	Refractive error;
THYM	cis	rs4731207	0.591	rs9691875	chr7:124675705	A/T	cg05285228	chr7:124571219	POT1	-0.63	-4.74	-0.44	7.37e-6	Cutaneous malignant melanoma;
THYM	cis	rs10883723	0.962	rs10883726	chr10:104236276	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.48	0.61	3.66e-11	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg24818145	chr4:99064322	C4orf37	0.9	7.36	0.6	6.5e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4690686	1.000	rs4690686	chr4:177242959	C/T	cg17059388	chr4:177262070	NA	0.41	5.38	0.48	5.31e-7	Essential tremor;
THYM	cis	rs7927592	0.913	rs11228292	chr11:68379772	C/T	cg20283391	chr11:68216788	NA	-0.71	-5.2	-0.47	1.12e-6	Total body bone mineral density;
THYM	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg01236616	chr12:121019343	POP5	1.31	10.38	0.73	2.57e-17	Type 1 diabetes nephropathy;
THYM	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg11941060	chr3:133502564	NA	-0.7	-5.7	-0.5	1.36e-7	Iron status biomarkers;
THYM	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4769475	0.957	rs9507673	chr13:26727444	C/T	cg13319468	chr13:27597730	NA	-0.65	-5.26	-0.47	9.03e-7	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg21280719	chr6:42927975	GNMT	-0.44	-4.75	-0.44	7.25e-6	Blood protein levels;
THYM	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg06221963	chr1:154839813	KCNN3	-0.73	-8.77	-0.67	7.12e-14	Prostate cancer;
THYM	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg22875332	chr1:76189707	ACADM	-0.94	-7.27	-0.6	1e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs13006833	0.739	rs291429	chr2:191197941	G/A	cg21644426	chr2:191273491	MFSD6	0.66	4.64	0.43	1.11e-5	Urinary metabolites;
THYM	cis	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg01386294	chr6:25732093	NA	0.89	4.51	0.42	1.84e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg11211951	chr8:145729740	GPT	-0.56	-5.24	-0.47	9.81e-7	Age at first birth;
THYM	cis	rs3020333	0.755	rs1293935	chr6:152017958	C/G	cg22157087	chr6:152012887	ESR1	0.55	6.73	0.57	1.25e-9	Total body bone mineral density;
THYM	cis	rs2273669	0.667	rs4527738	chr6:109309150	T/C	cg17117243	chr6:109341365	SESN1	-0.84	-4.94	-0.45	3.41e-6	Prostate cancer;
THYM	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg02725872	chr8:58115012	NA	-1.15	-7.43	-0.61	4.64e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg07414643	chr4:187882934	NA	-0.57	-4.95	-0.45	3.16e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1505368	0.567	rs2054617	chr2:213355890	T/C	cg16329650	chr2:213403929	ERBB4	0.64	5.52	0.49	2.96e-7	Symmetrical dimethylarginine levels;
THYM	cis	rs6867032	0.527	rs13190594	chr5:2012474	T/C	cg26168224	chr5:2018326	NA	1.08	9.44	0.7	2.61e-15	Gut microbiome composition (winter);
THYM	cis	rs6918586	0.636	rs198816	chr6:26127184	C/T	cg07061783	chr6:25882402	NA	0.57	4.48	0.42	2.07e-5	Schizophrenia;
THYM	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.7	0.71	7.32e-16	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg25214090	chr10:38739885	LOC399744	0.94	7.93	0.63	4.26e-12	Corneal astigmatism;
THYM	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	5.78	0.51	9.49e-8	Height;
THYM	cis	rs2991971	0.747	rs2492841	chr1:45894891	G/T	cg15605315	chr1:45957053	TESK2	-0.63	-5.17	-0.47	1.3e-6	High light scatter reticulocyte count;
THYM	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg27170947	chr2:26402098	FAM59B	0.82	6.57	0.56	2.7e-9	Gut microbiome composition (summer);
THYM	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg08645402	chr16:4508243	NA	-0.61	-5.12	-0.47	1.59e-6	Schizophrenia;
THYM	cis	rs2404602	0.735	rs11857015	chr15:76649390	T/C	cg23625390	chr15:77176239	SCAPER	-0.73	-5.21	-0.47	1.1e-6	Blood metabolite levels;
THYM	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg06636001	chr8:8085503	FLJ10661	-0.63	-5.36	-0.48	5.76e-7	Joint mobility (Beighton score);
THYM	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs2073300	1.000	rs6132628	chr20:23446734	G/A	cg12062639	chr20:23401060	NAPB	1.32	6.2	0.54	1.42e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg13609457	chr4:120235615	NA	0.59	5.22	0.47	1.04e-6	Corneal astigmatism;
THYM	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg22875332	chr1:76189707	ACADM	-0.87	-10.76	-0.74	3.98e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7772486	0.686	rs1337841	chr6:146059487	A/G	cg13319975	chr6:146136371	FBXO30	0.65	5.22	0.47	1.05e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.87	-4.64	-0.43	1.11e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg22709100	chr7:91322751	NA	-0.59	-4.77	-0.44	6.76e-6	Breast cancer;
THYM	cis	rs250677	0.522	rs6872172	chr5:148359529	G/C	cg18129178	chr5:148520854	ABLIM3	0.72	5.4	0.48	4.94e-7	Breast cancer;
THYM	cis	rs7631605	0.935	rs4678945	chr3:37239324	G/C	cg21328643	chr3:37258149	NA	-0.52	-4.95	-0.45	3.25e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg22907277	chr7:1156413	C7orf50	0.8	4.85	0.45	4.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6815814	0.950	rs73236615	chr4:38786869	G/T	cg06935464	chr4:38784597	TLR10	0.75	4.99	0.46	2.75e-6	Breast cancer;
THYM	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	5.79	0.51	9.1e-8	Monocyte percentage of white cells;
THYM	cis	rs7584330	0.554	rs111512641	chr2:238429538	G/A	cg08992911	chr2:238395768	MLPH	0.92	5.79	0.51	9.04e-8	Prostate cancer;
THYM	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.9	0.45	4.01e-6	Gut microbiome composition (summer);
THYM	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg08736216	chr1:53307985	ZYG11A	-0.6	-5.46	-0.49	3.79e-7	Monocyte count;
THYM	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs12496230	0.953	rs13096599	chr3:66848809	T/C	cg23477460	chr3:66848765	NA	1.26	7.6	0.61	2.11e-11	Type 2 diabetes;
THYM	cis	rs9905704	0.846	rs372648	chr17:56736785	A/C	cg12560992	chr17:57184187	TRIM37	0.65	4.51	0.42	1.89e-5	Testicular germ cell tumor;
THYM	cis	rs28374715	0.578	rs17730888	chr15:41637547	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.93	-0.84	1.18e-26	Ulcerative colitis;
THYM	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.43	0.7	2.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3772130	0.961	rs11716984	chr3:121362407	A/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.75	4.62	0.43	1.18e-5	Cognitive performance;
THYM	cis	rs6980334	0.911	rs2120846	chr7:137773291	T/G	cg22979093	chr7:137028410	PTN	0.57	4.48	0.42	2.09e-5	Blood metabolite ratios;
THYM	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.69	4.84	0.44	4.99e-6	Lung cancer in ever smokers;
THYM	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.3	-0.48	7.34e-7	Monocyte percentage of white cells;
THYM	cis	rs4595586	0.505	rs76485055	chr12:39358294	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs259282	0.574	rs4805780	chr19:33114406	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.62	4.84	0.44	4.95e-6	Schizophrenia;
THYM	cis	rs7119	0.604	rs2458035	chr15:77862806	G/A	cg27398640	chr15:77910606	LINGO1	0.62	7.12	0.59	2.05e-10	Type 2 diabetes;
THYM	cis	rs9992101	0.589	rs7675217	chr4:77413142	G/C	cg27417997	chr4:77356416	SHROOM3	-0.37	-4.46	-0.42	2.22e-5	Creatinine levels;
THYM	cis	rs2361718	0.522	rs11867921	chr17:78121170	G/T	cg09238746	chr17:78121135	EIF4A3	-1.23	-11.36	-0.76	2.1e-19	Yeast infection;
THYM	cis	rs4455778	0.580	rs5009336	chr7:49116299	A/G	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs4654899	0.861	rs10916876	chr1:21169996	T/C	cg01072550	chr1:21505969	NA	0.7	6.42	0.55	5.34e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg11461670	chr8:22454935	PDLIM2	-0.36	-6.52	-0.56	3.3e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg11812906	chr14:75593930	NEK9	-0.86	-8.02	-0.64	2.74e-12	Height;
THYM	cis	rs3810291	0.928	rs55731973	chr19:47616377	G/T	cg12068280	chr19:46804528	HIF3A	-0.42	-4.63	-0.43	1.15e-5	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);BMI in smokers;Hip circumference;Body mass index;Body mass index in physically active individuals;
THYM	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg06728252	chr6:26598149	ABT1	-0.44	-5.07	-0.46	1.95e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	trans	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg10856724	chr12:34555212	NA	-0.95	-8.42	-0.65	3.89e-13	Bladder cancer;
THYM	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-7.88	-0.63	5.3e-12	Chronic sinus infection;
THYM	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1286150	0.627	rs73328524	chr14:91496078	C/G	cg02136132	chr14:90527891	KCNK13	-0.66	-4.52	-0.42	1.8e-5	Total body bone mineral density;
THYM	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg24733560	chr20:60626293	TAF4	0.62	6.35	0.55	7.48e-9	Body mass index;
THYM	cis	rs728616	0.510	rs61860860	chr10:81758572	G/A	cg27452691	chr10:81370291	SFTPA1	0.66	4.5	0.42	1.92e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs10487112	1.000	rs11764237	chr7:90059248	C/T	cg26521402	chr7:89842741	STEAP2	0.51	4.55	0.42	1.6e-5	Perceived unattractiveness to mosquitoes;
THYM	cis	rs662064	0.748	rs2026792	chr1:10594790	A/G	cg20482658	chr1:10539492	PEX14	0.5	6.32	0.54	8.53e-9	Asthma;
THYM	cis	rs6840360	0.615	rs6836249	chr4:152465829	T/G	cg17479576	chr4:152424074	FAM160A1	-0.85	-6.4	-0.55	5.9e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg15744005	chr10:104629667	AS3MT	-0.8	-7.6	-0.61	2.08e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs11096990	0.964	rs9998591	chr4:39242111	C/A	cg24403649	chr4:39172243	NA	0.68	6.0	0.52	3.56e-8	Cognitive function;
THYM	cis	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg10856724	chr12:34555212	NA	-0.91	-9.35	-0.69	4.1e-15	Morning vs. evening chronotype;
THYM	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.22e-16	Bone mineral density;
THYM	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg26384229	chr12:38710491	ALG10B	-0.64	-4.84	-0.44	5.01e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6121246	0.559	rs6058462	chr20:30367674	C/T	cg13852791	chr20:30311386	BCL2L1	0.87	8.17	0.64	1.31e-12	Mean corpuscular hemoglobin;
THYM	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg16405210	chr4:1374714	KIAA1530	-0.69	-5.62	-0.5	1.92e-7	Longevity;
THYM	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6964587	0.692	rs12536220	chr7:91805595	T/G	cg17063962	chr7:91808500	NA	0.98	8.49	0.66	2.78e-13	Breast cancer;
THYM	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.94	7.84	0.63	6.55e-12	Lymphocyte percentage of white cells;
THYM	cis	rs13315871	1.000	rs3196769	chr3:58409361	A/T	cg12435725	chr3:58293450	RPP14	-0.46	-4.93	-0.45	3.54e-6	Cholesterol, total;
THYM	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg12908607	chr1:44402522	ARTN	-0.56	-4.87	-0.45	4.53e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs854765	0.693	rs12941039	chr17:17765655	C/T	cg04398451	chr17:18023971	MYO15A	0.85	8.53	0.66	2.26e-13	Total body bone mineral density;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg03587235	chr6:136682949	MAP7	-0.95	-7.3	-0.6	8.75e-11	Depressive symptoms;
THYM	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg07341220	chr16:1583899	IFT140;TMEM204	-0.61	-5.01	-0.46	2.53e-6	Coronary artery disease;
THYM	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.93	9.71	0.71	6.8e-16	Intelligence (multi-trait analysis);
THYM	cis	rs76662990	0.666	rs7734383	chr5:73937854	A/T	cg13275603	chr5:73927487	ENC1	-0.78	-4.52	-0.42	1.81e-5	Residual cognition;
THYM	cis	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg12935359	chr14:103987150	CKB	0.48	5.37	0.48	5.52e-7	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg08859206	chr1:53392774	SCP2	-0.66	-7.4	-0.6	5.39e-11	Monocyte count;
THYM	cis	rs1642645	0.831	rs768613	chr1:42485263	T/C	cg06092502	chr1:42611687	NA	0.61	4.74	0.44	7.58e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg01341218	chr17:43662625	NA	-1.07	-9.27	-0.69	5.9e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg19729930	chr2:74357872	NA	1.29	12.85	0.8	1.71e-22	Gestational age at birth (maternal effect);
THYM	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.14	-0.64	1.54e-12	Mean corpuscular volume;
THYM	cis	rs55871839	0.684	rs7829715	chr8:59803836	C/T	cg07426533	chr8:59803705	TOX	0.61	6.08	0.53	2.55e-8	Pneumonia;
THYM	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg04398451	chr17:18023971	MYO15A	0.95	10.61	0.74	8.23e-18	Total body bone mineral density;
THYM	cis	rs41005	0.967	rs1974696	chr2:8115782	A/G	cg03155496	chr2:8117019	LOC339788	0.99	9.35	0.69	3.98e-15	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs11696501	0.688	rs59196188	chr20:44278868	C/T	cg11783356	chr20:44313418	WFDC10B	-0.71	-4.91	-0.45	3.76e-6	Brain structure;
THYM	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg12756686	chr19:29218302	NA	0.81	5.83	0.51	7.53e-8	Methadone dose in opioid dependence;
THYM	cis	rs12643440	0.538	rs16894433	chr4:17143112	A/C	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs6964587	0.626	rs1011372	chr7:91509867	T/C	cg22709100	chr7:91322751	NA	-0.64	-4.72	-0.44	8.02e-6	Breast cancer;
THYM	cis	rs7926906	1.000	rs7952309	chr11:90526114	A/G	cg26138821	chr11:89956704	CHORDC1	-0.51	-4.56	-0.42	1.52e-5	Intelligence (multi-trait analysis);
THYM	trans	rs2340727	1.000	rs2340727	chr1:161946727	C/T	cg21574204	chr6:28048958	ZNF165	1.26	6.85	0.57	7.36e-10	White blood cell count;Hematology traits;
THYM	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg04025307	chr7:1156635	C7orf50	0.87	8.92	0.68	3.28e-14	Longevity;Endometriosis;
THYM	cis	rs4819852	0.958	rs756653	chr22:19976845	G/A	cg07821417	chr22:19972146	ARVCF	0.49	5.82	0.51	7.96e-8	Pulse pressure;
THYM	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs988913	1.000	rs9370343	chr6:54820676	G/A	cg04690482	chr6:54711388	FAM83B	0.47	5.23	0.47	1.03e-6	Menarche (age at onset);
THYM	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg22467129	chr15:76604101	ETFA	-0.54	-5.32	-0.48	6.8e-7	Blood metabolite levels;
THYM	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg06623918	chr6:96969491	KIAA0776	-1.06	-10.38	-0.73	2.56e-17	Headache;
THYM	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg19610905	chr11:61596333	FADS2	-0.63	-4.91	-0.45	3.86e-6	Trans fatty acid levels;
THYM	cis	rs7178572	0.889	rs7170877	chr15:77832019	C/G	cg22256960	chr15:77711686	NA	-0.96	-7.99	-0.63	3.15e-12	Type 2 diabetes;
THYM	cis	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg10856724	chr12:34555212	NA	-1.06	-10.08	-0.72	1.1e-16	Morning vs. evening chronotype;
THYM	cis	rs68170813	0.523	rs75999022	chr7:107017135	C/T	cg00661777	chr7:106511741	PIK3CG	-0.68	-4.71	-0.44	8.28e-6	Coronary artery disease;
THYM	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg24812749	chr6:127587940	RNF146	0.79	5.99	0.52	3.76e-8	Breast cancer;
THYM	cis	rs7326068	0.610	rs8000601	chr13:21339384	G/A	cg27499820	chr13:21296301	IL17D	0.61	4.5	0.42	1.91e-5	Schizophrenia, bipolar disorder and depression (combined);
THYM	cis	rs7084402	0.902	rs1649016	chr10:60288540	T/A	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs6499255	0.903	rs1800566	chr16:69745145	C/T	cg06765324	chr16:70207801	CLEC18C	0.53	4.61	0.43	1.27e-5	IgE levels;
THYM	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg15744005	chr10:104629667	AS3MT	-0.83	-7.67	-0.62	1.47e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs11118844	0.793	rs10218652	chr1:221947406	T/C	cg04222084	chr1:221915650	DUSP10	-1.04	-5.24	-0.47	9.72e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs76662990	0.610	rs6867790	chr5:73929650	G/A	cg13275603	chr5:73927487	ENC1	-0.78	-4.52	-0.42	1.81e-5	Residual cognition;
THYM	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.87	-6.63	-0.56	2e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg19418458	chr7:158789849	NA	-0.65	-5.82	-0.51	7.93e-8	Facial morphology (factor 20);
THYM	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg18512352	chr11:47633146	NA	-0.53	-6.36	-0.55	7.07e-9	Subjective well-being;
THYM	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg00757033	chr12:89920650	WDR51B	0.69	9.73	0.71	6.1e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg15445000	chr17:37608096	MED1	0.41	5.04	0.46	2.26e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	8.85	0.67	4.81e-14	Chronic sinus infection;
THYM	cis	rs289828	0.579	rs13007728	chr2:152158552	C/G	cg05960677	chr2:152117363	RBM43	0.7	6.7	0.57	1.49e-9	Blood protein levels;
THYM	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18876405	chr7:65276391	NA	0.56	4.63	0.43	1.18e-5	Aortic root size;
THYM	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg08968635	chr6:28129556	ZNF389	0.66	5.19	0.47	1.21e-6	Depression;
THYM	cis	rs4638749	0.677	rs10190865	chr2:108843624	T/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg14798641	chr3:49314920	USP4;C3orf62	-0.69	-4.69	-0.43	9.23e-6	Cognitive function;
THYM	cis	rs4907240	0.735	rs1122238	chr2:97186917	C/T	cg18419276	chr2:96971862	SNRNP200	-0.42	-5.09	-0.46	1.83e-6	Event-related brain oscillations;
THYM	cis	rs7258465	1.000	rs28572537	chr19:18552208	C/T	cg04166595	chr19:18636596	NA	0.62	4.7	0.43	8.77e-6	Breast cancer;
THYM	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg00786635	chr1:25594202	NA	0.88	6.85	0.58	7.14e-10	Erythrocyte sedimentation rate;
THYM	cis	rs8133932	0.736	rs4818804	chr21:47282631	T/C	cg20357416	chr21:47294739	PCBP3	-0.9	-5.92	-0.52	5.01e-8	Schizophrenia;
THYM	cis	rs7809950	0.954	rs2894466	chr7:107242909	G/A	cg23024343	chr7:107201750	COG5	0.92	7.65	0.62	1.63e-11	Coronary artery disease;
THYM	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg06636001	chr8:8085503	FLJ10661	0.71	6.27	0.54	1.04e-8	Mood instability;
THYM	cis	rs7119	0.689	rs12907630	chr15:77812906	G/T	cg10437265	chr15:77819839	NA	0.77	7.76	0.62	9.39e-12	Type 2 diabetes;
THYM	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg25182066	chr10:30743637	MAP3K8	-0.57	-5.08	-0.46	1.88e-6	Inflammatory bowel disease;
THYM	cis	rs289828	0.868	rs289832	chr2:152134405	G/C	cg05960677	chr2:152117363	RBM43	0.62	6.33	0.54	7.94e-9	Blood protein levels;
THYM	cis	rs7633857	0.512	rs1868109	chr3:160682500	G/A	cg03342759	chr3:160939853	NMD3	-0.67	-5.25	-0.47	9.26e-7	Educational attainment (years of education);
THYM	cis	rs36051895	0.659	rs7862042	chr9:5268139	G/A	cg02405213	chr9:5042618	JAK2	-0.98	-8.5	-0.66	2.65e-13	Pediatric autoimmune diseases;
THYM	cis	rs9787249	0.957	rs7548120	chr1:40204424	A/T	cg19912559	chr1:40204330	PPIE	0.63	4.67	0.43	9.98e-6	Blood protein levels;
THYM	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg14004847	chr7:1930337	MAD1L1	-0.66	-5.39	-0.48	5.1e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs13315871	0.929	rs13322156	chr3:58287620	C/T	cg00563845	chr3:58318305	PXK	0.59	5.03	0.46	2.29e-6	Cholesterol, total;
THYM	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.07	0.46	1.93e-6	Prudent dietary pattern;
THYM	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg18252515	chr7:66147081	NA	-0.63	-4.76	-0.44	7.01e-6	Aortic root size;
THYM	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg15962314	chr1:44399869	ARTN	0.55	5.38	0.48	5.38e-7	Intelligence (multi-trait analysis);
THYM	cis	rs78761021	0.720	rs874307	chr17:9798074	C/G	cg26853458	chr17:9805074	RCVRN	0.53	4.46	0.42	2.24e-5	Type 2 diabetes;
THYM	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.75	-0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg27490568	chr2:178487706	NA	-0.57	-5.17	-0.47	1.32e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs6840360	0.550	rs62327349	chr4:152627230	G/C	cg17479576	chr4:152424074	FAM160A1	-0.75	-4.85	-0.45	4.81e-6	Intelligence (multi-trait analysis);
THYM	cis	rs17534004	1.000	rs35858501	chr13:31472120	C/T	cg13251181	chr13:31481184	C13orf33	0.55	4.52	0.42	1.77e-5	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg23161317	chr6:28129485	ZNF389	0.94	7.32	0.6	8.03e-11	Depression;
THYM	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg04518342	chr5:131593106	PDLIM4	-0.54	-5.84	-0.51	7.31e-8	Acylcarnitine levels;
THYM	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg25319279	chr11:5960081	NA	-0.61	-5.28	-0.48	8.08e-7	DNA methylation (variation);
THYM	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.83	0.44	5.29e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs644799	0.511	rs11021301	chr11:95485145	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	5.88	0.52	6.21e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg25918947	chr17:41365094	TMEM106A	-0.56	-4.62	-0.43	1.22e-5	Menopause (age at onset);
THYM	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg24503407	chr1:205819492	PM20D1	1.09	11.47	0.76	1.26e-19	Menarche (age at onset);
THYM	cis	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg01364799	chr7:75623366	TMEM120A	-0.65	-4.76	-0.44	7e-6	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs3126085	0.935	rs2184951	chr1:152273168	T/G	cg10321714	chr1:152280068	FLG	-0.7	-5.11	-0.46	1.68e-6	Atopic dermatitis;
THYM	cis	rs1669338	0.588	rs3804783	chr3:3184442	C/T	cg16797762	chr3:3221439	CRBN	-0.97	-5.15	-0.47	1.41e-6	White matter integrity;
THYM	trans	rs1920324	0.622	rs75910759	chr3:103901237	G/A	cg01901466	chr14:93388880	CHGA	0.65	6.91	0.58	5.4e-10	Colorectal cancer;
THYM	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg17105886	chr17:28927953	LRRC37B2	1.13	6.42	0.55	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11112613	1.000	rs11112613	chr12:106003786	A/G	cg03607813	chr12:105948248	NA	0.92	5.53	0.49	2.8e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs62070183	0.808	rs79957065	chr17:31142749	C/T	cg02981443	chr17:31254875	TMEM98	-0.52	-4.72	-0.44	8.04e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg00191853	chr8:101177733	SPAG1	-0.56	-5.59	-0.5	2.15e-7	Atrioventricular conduction;
THYM	cis	rs9814567	1.000	rs10804632	chr3:134294501	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.43	-0.65	3.72e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06481639	chr22:41940642	POLR3H	-0.84	-5.96	-0.52	4.28e-8	Vitiligo;
THYM	cis	rs7772486	0.754	rs697054	chr6:146003770	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-5.01	-0.46	2.55e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10203711	1.000	rs12692239	chr2:239553947	T/C	cg14580085	chr2:239553406	NA	0.71	6.63	0.56	1.99e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs977987	0.806	rs4888411	chr16:75443183	T/A	cg03315344	chr16:75512273	CHST6	0.77	6.29	0.54	9.48e-9	Dupuytren's disease;
THYM	cis	rs4242434	0.889	rs11785755	chr8:22453223	C/A	cg11461670	chr8:22454935	PDLIM2	-0.41	-7.0	-0.58	3.64e-10	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	trans	rs4650994	0.625	rs6681348	chr1:178526271	A/C	cg05059571	chr16:84539110	KIAA1609	-0.75	-8.15	-0.64	1.43e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs9393692	0.620	rs9393697	chr6:26293841	C/T	cg13736514	chr6:26305472	NA	-0.47	-4.87	-0.45	4.39e-6	Educational attainment;
THYM	cis	rs7267979	0.966	rs2261790	chr20:25262789	T/C	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1011018	0.955	rs4132077	chr7:139420225	T/C	cg06079564	chr7:139468310	HIPK2	-0.73	-5.52	-0.49	2.93e-7	Systolic blood pressure;
THYM	cis	rs7219021	0.739	rs1800632	chr17:46970509	G/A	cg09029085	chr17:47094198	IGF2BP1	0.38	5.05	0.46	2.14e-6	Schizophrenia or bipolar disorder;
THYM	cis	rs1357245	0.533	rs9867168	chr3:27097776	C/T	cg03895047	chr3:27114861	NA	0.49	4.58	0.43	1.42e-5	Breast cancer;
THYM	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.57	4.49	0.42	2.01e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11555872	0.500	rs7290135	chr22:43921973	G/A	cg19629120	chr22:43924705	EFCAB6	-0.56	-4.64	-0.43	1.14e-5	Itch intensity from mosquito bite adjusted by bite size;Itch intensity from mosquito bite;
THYM	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg05754148	chr16:3507555	NAT15	0.71	7.17	0.59	1.6e-10	Tuberculosis;
THYM	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg26384229	chr12:38710491	ALG10B	-0.74	-5.7	-0.5	1.37e-7	Morning vs. evening chronotype;
THYM	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg02070205	chr10:30722105	MAP3K8	0.63	5.51	0.49	3.07e-7	Inflammatory bowel disease;
THYM	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg03517284	chr6:25882590	NA	0.65	5.32	0.48	7.02e-7	Blood metabolite levels;
THYM	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg27535305	chr1:53392650	SCP2	-0.47	-5.25	-0.47	9.15e-7	Monocyte count;
THYM	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg14829155	chr15:31115871	NA	-0.54	-4.7	-0.43	8.71e-6	Huntington's disease progression;
THYM	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7264396	0.790	rs2425160	chr20:34425968	A/G	cg26038318	chr20:34205095	SPAG4	0.6	4.7	0.43	8.69e-6	Total cholesterol levels;
THYM	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg06558623	chr16:89946397	TCF25	-0.91	-5.01	-0.46	2.53e-6	Skin colour saturation;
THYM	cis	rs77372450	0.551	rs10515752	chr5:157072377	G/A	cg00312553	chr5:157098553	C5orf52	-0.65	-4.63	-0.43	1.16e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs7236492	0.748	rs78531995	chr18:77198370	C/T	cg15644404	chr18:77186268	NFATC1	-1.05	-4.96	-0.45	3.04e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4766566	0.694	rs3847952	chr12:111746678	T/G	cg10833066	chr12:111807467	FAM109A	0.64	8.93	0.68	3.16e-14	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
THYM	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs9309473	0.519	rs12618600	chr2:73890682	T/C	cg19565262	chr2:73869966	NAT8	0.56	4.68	0.43	9.48e-6	Metabolite levels;
THYM	cis	rs10193935	0.901	rs222469	chr2:42640235	T/C	cg27598129	chr2:42591480	NA	-0.72	-4.47	-0.42	2.2e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg15744005	chr10:104629667	AS3MT	-0.85	-8.32	-0.65	6.26e-13	Arsenic metabolism;
THYM	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg18825531	chr11:62321136	NA	-0.46	-5.32	-0.48	6.94e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs870825	0.616	rs28463742	chr4:185611005	G/A	cg04058563	chr4:185651563	MLF1IP	1.05	9.13	0.68	1.2e-14	Blood protein levels;
THYM	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg03433033	chr1:76189801	ACADM	0.77	10.09	0.72	1.07e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7103648	0.966	rs1377416	chr11:47416746	C/T	cg20307385	chr11:47447363	PSMC3	0.94	8.51	0.66	2.49e-13	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs7119	0.604	rs2667783	chr15:77862529	G/A	cg27398640	chr15:77910606	LINGO1	0.62	7.12	0.59	2.05e-10	Type 2 diabetes;
THYM	cis	rs7432375	0.901	rs11919030	chr3:136348599	G/A	cg12473912	chr3:136751656	NA	0.63	5.41	0.49	4.69e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg08000102	chr2:233561755	GIGYF2	-0.68	-6.11	-0.53	2.16e-8	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg08994789	chr17:28903642	LRRC37B2	1.01	5.94	0.52	4.62e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs155076	1.000	rs567166	chr13:21837519	T/C	cg07022442	chr13:21864356	NA	0.71	4.66	0.43	1.03e-5	White matter hyperintensity burden;
THYM	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg03235661	chr20:60525775	NA	-0.58	-4.97	-0.45	2.95e-6	Obesity-related traits;
THYM	cis	rs4460079	0.531	rs7695515	chr4:114846404	C/T	cg02060584	chr4:113970739	ANK2	0.59	4.93	0.45	3.48e-6	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs4077515	0.577	rs3812584	chr9:139312719	C/T	cg14115884	chr9:139300582	SDCCAG3	-0.67	-5.88	-0.52	6.14e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg18032289	chr17:61959525	GH2	-0.49	-4.76	-0.44	7e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs1981331	0.609	rs57896262	chr21:48028188	C/T	cg23283320	chr21:48055893	PRMT2	1.45	7.93	0.63	4.15e-12	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg00339695	chr16:24857497	SLC5A11	0.48	4.79	0.44	6.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg06074448	chr4:187884817	NA	1.01	13.54	0.81	6.7e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28374715	0.681	rs7165396	chr15:41586947	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.56	-0.83	6.14e-26	Ulcerative colitis;
THYM	cis	rs16866061	1.000	rs10498163	chr2:225434445	A/G	cg22455342	chr2:225449267	CUL3	0.66	4.73	0.44	7.81e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs2439831	0.867	rs3213991	chr15:43670280	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs9906944	0.707	rs9912906	chr17:47104432	A/T	cg09029085	chr17:47094198	IGF2BP1	0.47	6.53	0.56	3.17e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg13443165	chr9:33130375	B4GALT1	-0.87	-7.97	-0.63	3.46e-12	IgG glycosylation;
THYM	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.81	-0.63	7.44e-12	Chronic sinus infection;
THYM	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg14582100	chr15:45693742	SPATA5L1	0.61	4.9	0.45	3.98e-6	Homoarginine levels;
THYM	cis	rs6964587	0.692	rs418	chr7:91583334	C/T	cg17063962	chr7:91808500	NA	-1.03	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs2688608	0.592	rs13013	chr10:75562161	C/A	cg23231163	chr10:75533350	FUT11	-0.43	-6.18	-0.54	1.57e-8	Inflammatory bowel disease;
THYM	trans	rs877282	0.945	rs10904556	chr10:789429	A/G	cg22713356	chr15:30763199	NA	1.4	11.86	0.77	1.9e-20	Uric acid levels;
THYM	cis	rs2282300	0.739	rs1717775	chr11:30350254	T/G	cg09906309	chr11:30344399	C11orf46	-0.73	-5.37	-0.48	5.47e-7	Morning vs. evening chronotype;
THYM	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg08017756	chr2:100939284	LONRF2	-0.75	-7.8	-0.62	7.89e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7646501	0.677	rs6795140	chr3:24061129	C/G	cg21910673	chr3:24143257	LOC152024	0.51	4.6	0.43	1.33e-5	Cognitive ability;Intelligence;
THYM	cis	rs1978968	0.717	rs1072405	chr22:18406068	A/C	cg01550578	chr22:18484421	MICAL3	0.61	4.61	0.43	1.27e-5	Presence of antiphospholipid antibodies;
THYM	cis	rs2919009	0.607	rs2303951	chr10:122714081	G/A	cg26518861	chr10:122708898	NA	-0.64	-4.59	-0.43	1.35e-5	Obesity-related traits;
THYM	cis	rs6570726	0.764	rs9403726	chr6:145901686	G/T	cg13319975	chr6:146136371	FBXO30	-0.65	-5.14	-0.47	1.48e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9543976	0.623	rs7982517	chr13:76162039	A/G	cg01531495	chr13:76123901	UCHL3	0.69	4.83	0.44	5.21e-6	Diabetic retinopathy;
THYM	cis	rs921968	0.643	rs589967	chr2:219445165	T/C	cg02176678	chr2:219576539	TTLL4	0.67	6.66	0.56	1.78e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg25811766	chr13:21894605	NA	0.73	5.96	0.52	4.22e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs11039798	0.925	rs6485831	chr11:48455031	A/T	cg24672777	chr11:48374446	OR4C45	-1.16	-7.24	-0.6	1.16e-10	Axial length;
THYM	cis	rs7772486	0.905	rs9373486	chr6:146446024	C/G	cg13319975	chr6:146136371	FBXO30	0.63	5.19	0.47	1.19e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1160297	0.634	rs10179810	chr2:53096145	T/A	cg07782112	chr2:53107842	NA	0.79	6.37	0.55	6.61e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs7940866	0.740	rs7131121	chr11:130806424	A/G	cg23692386	chr11:131799662	NTM	0.44	4.48	0.42	2.07e-5	Schizophrenia;
THYM	cis	rs11676348	0.846	rs11677534	chr2:219007060	T/C	cg06547715	chr2:218990976	CXCR2	0.49	5.13	0.47	1.54e-6	Ulcerative colitis;
THYM	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg22875332	chr1:76189707	ACADM	-0.73	-6.49	-0.55	3.89e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.32	-9.88	-0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg06634786	chr22:41940651	POLR3H	0.7	5.26	0.47	8.85e-7	Vitiligo;
THYM	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.61e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2075230	0.542	rs2955616	chr17:7544084	A/G	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.73	-0.44	7.7e-6	Hormone measurements;
THYM	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg07936489	chr17:37558343	FBXL20	-0.79	-5.7	-0.5	1.37e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg05368731	chr17:41323189	NBR1	-1.05	-9.14	-0.68	1.14e-14	Menopause (age at onset);
THYM	cis	rs4148689	1.000	rs3808186	chr7:117162954	A/G	cg17204129	chr7:117119601	CFTR	-0.69	-5.07	-0.46	1.98e-6	Gout;
THYM	cis	rs1018836	0.886	rs4734246	chr8:91569028	A/C	cg16814680	chr8:91681699	NA	-0.78	-6.45	-0.55	4.73e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg05973401	chr12:123451056	ABCB9	-0.69	-4.59	-0.43	1.36e-5	Neutrophil percentage of white cells;
THYM	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs293526	0.918	rs293522	chr6:83651741	G/A	cg23278060	chr6:83777448	DOPEY1	0.62	4.64	0.43	1.12e-5	Crohn's disease;
THYM	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs3791406	1.000	rs3791412	chr2:240031088	A/G	cg05758467	chr2:240035894	HDAC4	-0.44	-4.51	-0.42	1.84e-5	Skin aging (microtopography measurement);
THYM	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs7412746	0.611	rs12410869	chr1:150856153	G/T	cg15448220	chr1:150897856	SETDB1	0.88	7.08	0.59	2.43e-10	Melanoma;
THYM	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg26384229	chr12:38710491	ALG10B	-0.87	-8.86	-0.67	4.62e-14	Heart rate;
THYM	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	5.73	0.51	1.18e-7	Blood metabolite levels;
THYM	cis	rs40363	0.767	rs1003330	chr16:3541039	A/G	cg22508957	chr16:3507546	NAT15	-0.73	-6.54	-0.56	3.05e-9	Tuberculosis;
THYM	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	5.09	0.46	1.8e-6	Menarche (age at onset);
THYM	cis	rs1747683	0.932	rs1005089	chr10:13387295	G/A	cg00142036	chr10:13388442	SEPHS1	-0.29	-5.17	-0.47	1.27e-6	IgG glycosylation;
THYM	cis	rs4750440	0.585	rs4748069	chr10:14031188	A/G	cg27542038	chr10:14027202	FRMD4A	-0.56	-4.45	-0.42	2.31e-5	Adiponectin levels;
THYM	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg09455208	chr3:40491958	NA	0.46	4.92	0.45	3.65e-6	Renal cell carcinoma;
THYM	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.89	0.52	5.88e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs8060598	0.834	rs8061960	chr16:50761434	C/T	cg05261686	chr16:50743296	NOD2	0.37	4.56	0.42	1.52e-5	Leprosy;
THYM	cis	rs7220711	0.676	rs12600549	chr17:41776686	A/G	cg26893861	chr17:41843967	DUSP3	0.59	5.02	0.46	2.4e-6	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg24690094	chr11:67383802	NA	-0.7	-4.69	-0.43	9.17e-6	Mean corpuscular volume;
THYM	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg22875332	chr1:76189707	ACADM	0.87	10.83	0.74	2.76e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2439831	0.702	rs3784275	chr15:44091386	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	5.29	0.48	7.79e-7	Lung cancer in ever smokers;
THYM	cis	rs17471911	0.541	rs2805364	chr10:100926599	A/G	cg20566587	chr10:101492029	COX15;CUTC	0.79	4.86	0.45	4.67e-6	Neuroticism;
THYM	cis	rs9914578	1.000	rs62067978	chr17:2013058	G/A	cg16513277	chr17:2031491	SMG6	-0.7	-4.59	-0.43	1.38e-5	Body mass index;
THYM	cis	rs13315871	1.000	rs13320620	chr3:58408845	A/G	cg00563845	chr3:58318305	PXK	0.53	4.67	0.43	9.78e-6	Cholesterol, total;
THYM	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg04398451	chr17:18023971	MYO15A	-0.76	-6.88	-0.58	6.39e-10	Total body bone mineral density;
THYM	cis	rs4243830	0.850	rs1064835	chr1:6585539	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.78	4.48	0.42	2.09e-5	Body mass index;
THYM	cis	rs2080501	0.628	rs1344530	chr16:49665122	T/C	cg03087880	chr16:49666012	ZNF423	0.69	8.38	0.65	4.77e-13	IgG glycosylation;
THYM	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg20387954	chr3:183756860	HTR3D	0.56	4.64	0.43	1.11e-5	Anterior chamber depth;
THYM	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg03609598	chr5:56110824	MAP3K1	-0.89	-6.07	-0.53	2.63e-8	Initial pursuit acceleration;
THYM	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg11494091	chr17:61959527	GH2	-0.81	-7.6	-0.61	2.1e-11	Height;
THYM	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg19318889	chr4:1322082	MAEA	0.69	5.99	0.52	3.78e-8	Longevity;
THYM	cis	rs55728055	0.661	rs41302569	chr22:32046953	C/A	cg01338084	chr22:32026380	PISD	1.46	5.82	0.51	7.82e-8	Age-related hearing impairment;
THYM	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg11247378	chr22:39784982	NA	-1.02	-13.32	-0.81	1.82e-23	Intelligence (multi-trait analysis);
THYM	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg22655196	chr4:3374909	RGS12	0.58	6.85	0.58	7.15e-10	Serum sulfate level;
THYM	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg06453172	chr10:134556979	INPP5A	-0.67	-4.84	-0.44	5.1e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs2810114	1.000	rs2810114	chr14:71395604	C/A	cg15910301	chr14:71632612	NA	-0.56	-4.88	-0.45	4.23e-6	Alcohol dependence;
THYM	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg03929089	chr4:120376271	NA	-1.0	-7.14	-0.59	1.82e-10	Coronary artery disease;
THYM	cis	rs55728055	0.661	rs41302569	chr22:32046953	C/A	cg10537193	chr22:32026975	PISD	-0.93	-5.79	-0.51	9.16e-8	Age-related hearing impairment;
THYM	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg03909863	chr11:638404	DRD4	-0.76	-5.61	-0.5	1.99e-7	Systemic lupus erythematosus;
THYM	cis	rs4243830	0.737	rs925745	chr1:6615690	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.05	-6.85	-0.57	7.43e-10	Body mass index;
THYM	cis	rs11608355	0.618	rs4486687	chr12:109790741	T/A	cg11367159	chr12:110044531	NA	0.51	4.67	0.43	9.96e-6	Neuroticism;
THYM	cis	rs8013055	0.846	rs12717698	chr14:105979015	G/A	cg23356831	chr14:105996513	TMEM121	0.6	6.31	0.54	9.02e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs6669072	0.565	rs10922929	chr1:91279306	A/G	cg08895590	chr1:91227319	NA	0.4	4.56	0.42	1.53e-5	Cognitive function;
THYM	cis	rs883565	0.682	rs7623850	chr3:39053311	C/T	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	5.0	0.46	2.59e-6	Handedness;
THYM	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg24692254	chr21:30365293	RNF160	-1.07	-9.88	-0.71	2.92e-16	Dental caries;
THYM	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg23161317	chr6:28129485	ZNF389	0.67	5.37	0.48	5.68e-7	Cardiac Troponin-T levels;
THYM	cis	rs6448317	0.906	rs4053966	chr4:24901466	A/G	cg22968281	chr4:24586266	DHX15	0.7	5.2	0.47	1.15e-6	Heschl's gyrus morphology;
THYM	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9649213	0.555	rs7785612	chr7:97933867	T/A	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.46	0.42	2.27e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7586879	0.575	rs6706316	chr2:25128351	C/G	cg15423357	chr2:25149977	NA	0.7	7.76	0.62	9.56e-12	Body mass index;
THYM	trans	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg10856724	chr12:34555212	NA	-1.02	-9.32	-0.69	4.7e-15	Morning vs. evening chronotype;
THYM	cis	rs6918586	0.658	rs198843	chr6:26110314	A/T	cg03517284	chr6:25882590	NA	0.71	5.57	0.5	2.4e-7	Schizophrenia;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg20102585	chr18:29769532	MEP1B	-0.92	-6.88	-0.58	6.23e-10	Depressive symptoms;
THYM	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.16	-5.63	-0.5	1.85e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg07211511	chr3:129823064	LOC729375	-1.23	-9.83	-0.71	3.75e-16	Blood pressure (smoking interaction);
THYM	cis	rs4786125	0.512	rs55818804	chr16:6930199	T/C	cg03623568	chr16:6915990	A2BP1	-1.03	-8.74	-0.67	8.05e-14	Heart rate variability traits (SDNN);
THYM	cis	rs4595586	0.525	rs4450203	chr12:39381493	T/G	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs7598759	0.527	rs7571691	chr2:232369401	C/T	cg19187155	chr2:232395269	NMUR1	0.84	7.56	0.61	2.57e-11	Noise-induced hearing loss;
THYM	cis	rs7312774	0.748	rs1861745	chr12:107301642	C/T	cg16260113	chr12:107380972	MTERFD3	0.97	4.77	0.44	6.58e-6	Severe influenza A (H1N1) infection;
THYM	cis	rs9420	0.961	rs77993055	chr11:57522840	C/T	cg19752551	chr11:57585705	CTNND1	-0.73	-8.02	-0.64	2.79e-12	Schizophrenia;
THYM	cis	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg13609457	chr4:120235615	NA	0.6	5.39	0.48	5.15e-7	Corneal astigmatism;
THYM	cis	rs66887589	0.777	rs10015883	chr4:120268146	A/G	cg13609457	chr4:120235615	NA	0.49	4.95	0.45	3.17e-6	Diastolic blood pressure;
THYM	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg11461670	chr8:22454935	PDLIM2	-0.34	-6.23	-0.54	1.25e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs11031096	0.678	rs11031219	chr11:4197578	G/A	cg18678763	chr11:4115507	RRM1	-0.42	-4.95	-0.45	3.17e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs860818	1.000	rs858234	chr7:23240815	A/C	cg05407003	chr7:23246146	NA	1.27	4.72	0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg03188948	chr7:1209495	NA	0.68	4.73	0.44	7.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7578361	0.918	rs4494703	chr2:150377475	T/C	cg17961725	chr2:150454027	NA	-0.79	-6.02	-0.53	3.33e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11644478	chr21:40555479	PSMG1	-0.79	-6.75	-0.57	1.17e-9	Cognitive function;
THYM	cis	rs10208940	0.614	rs13413959	chr2:68834727	T/C	cg09157127	chr2:69201416	GKN1	0.93	4.78	0.44	6.3e-6	Urate levels in lean individuals;
THYM	cis	rs4148883	0.675	rs10015824	chr4:100074544	C/G	cg12011299	chr4:100065546	ADH4	0.66	5.65	0.5	1.65e-7	Alcohol dependence;
THYM	cis	rs988913	0.957	rs2397177	chr6:54834133	A/G	cg04690482	chr6:54711388	FAM83B	0.46	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg26566898	chr11:117069891	TAGLN	0.39	4.96	0.45	3.13e-6	Blood protein levels;
THYM	cis	rs714027	0.515	rs2412972	chr22:30519825	T/A	cg27665648	chr22:30112403	NA	-0.52	-4.73	-0.44	7.79e-6	Lymphocyte counts;
THYM	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14240646	chr10:27532245	ACBD5	-0.82	-4.7	-0.43	8.74e-6	Breast cancer;
THYM	cis	rs11969893	0.737	rs9498439	chr6:101404768	A/T	cg12253828	chr6:101329408	ASCC3	1.08	6.2	0.54	1.43e-8	Economic and political preferences (immigration/crime);
THYM	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg11266682	chr4:10021025	SLC2A9	0.68	9.68	0.7	7.95e-16	Bone mineral density;
THYM	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg05855489	chr10:104503620	C10orf26	-0.58	-4.55	-0.42	1.59e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg24209194	chr3:40518798	ZNF619	0.56	4.6	0.43	1.32e-5	Renal cell carcinoma;
THYM	cis	rs6032067	0.777	rs13038275	chr20:43780988	A/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.41	-0.65	4.05e-13	Blood protein levels;
THYM	cis	rs67981189	0.806	rs2810107	chr14:71421057	T/G	cg15910301	chr14:71632612	NA	-0.5	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22857025	chr5:266934	NA	-1.43	-9.54	-0.7	1.58e-15	Breast cancer;
THYM	cis	rs988913	1.000	rs9396011	chr6:54836739	C/T	cg04690482	chr6:54711388	FAM83B	0.46	5.17	0.47	1.31e-6	Menarche (age at onset);
THYM	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg05962950	chr11:130786565	SNX19	0.96	9.68	0.7	7.81e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10819861	0.645	rs10760765	chr9:98861229	C/T	cg14508093	chr9:98862825	NA	-0.25	-4.54	-0.42	1.65e-5	Electrocardiographic traits;
THYM	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9359856	0.510	rs2768936	chr6:90441851	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.84	-8.26	-0.65	8.31e-13	Bipolar disorder;
THYM	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg12826209	chr6:26865740	GUSBL1	1.04	6.68	0.57	1.63e-9	Intelligence (multi-trait analysis);
THYM	cis	rs10189230	0.904	rs1864462	chr2:222343823	G/C	cg14652038	chr2:222343519	EPHA4	0.54	4.53	0.42	1.7e-5	Urate levels in lean individuals;
THYM	cis	rs1483890	0.723	rs6549208	chr3:69412134	T/G	cg22125112	chr3:69402811	FRMD4B	0.54	6.85	0.58	7.21e-10	Resting heart rate;
THYM	cis	rs1483890	0.962	rs1483891	chr3:69410416	G/C	cg22125112	chr3:69402811	FRMD4B	0.45	5.8	0.51	8.82e-8	Resting heart rate;
THYM	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.77	-5.38	-0.48	5.28e-7	Body mass index;
THYM	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg17366294	chr4:99064904	C4orf37	-0.58	-6.98	-0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.49	-4.94	-0.45	3.39e-6	Depressive symptoms;
THYM	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17511627	0.808	rs7985629	chr13:26746396	C/T	cg13319468	chr13:27597730	NA	-0.68	-5.38	-0.48	5.34e-7	Alzheimer's disease;
THYM	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg24578937	chr1:2090814	PRKCZ	0.55	5.35	0.48	6.12e-7	Height;
THYM	cis	rs6964587	0.692	rs2027950	chr7:91863700	C/G	cg17063962	chr7:91808500	NA	-0.98	-8.49	-0.66	2.78e-13	Breast cancer;
THYM	trans	rs11242675	0.633	rs13219495	chr6:1321446	C/G	cg05315417	chr18:44237019	LOXHD1	0.68	6.91	0.58	5.63e-10	Breast cancer;
THYM	cis	rs7465272	1.000	rs13258638	chr8:143683582	C/T	cg01509843	chr8:143695822	ARC	0.72	4.85	0.45	4.73e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg20891558	chr2:74357851	NA	1.26	12.07	0.78	6.84e-21	Gestational age at birth (maternal effect);
THYM	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg23958373	chr8:599963	NA	1.03	4.67	0.43	9.89e-6	IgG glycosylation;
THYM	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.84e-8	Systolic blood pressure;
THYM	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg09826364	chr7:158789723	NA	0.52	4.6	0.43	1.3e-5	Facial morphology (factor 20);
THYM	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg02953382	chr22:24373134	LOC391322	-0.7	-6.47	-0.55	4.24e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.87	-5.75	-0.51	1.1e-7	Schizophrenia;
THYM	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg14196790	chr5:131705035	SLC22A5	0.55	5.05	0.46	2.15e-6	Blood metabolite levels;
THYM	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg06112835	chr11:68658793	MRPL21	-0.41	-5.8	-0.51	8.84e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6438424	0.967	rs9790189	chr3:117583647	T/A	cg07190778	chr3:117604296	NA	-0.4	-5.56	-0.5	2.51e-7	Menarche (age at onset);
THYM	cis	rs4664308	0.618	rs17830904	chr2:160891688	C/T	cg03641300	chr2:160917029	PLA2R1	0.66	5.79	0.51	9.16e-8	Idiopathic membranous nephropathy;
THYM	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg06784218	chr1:46089804	CCDC17	-0.31	-4.86	-0.45	4.61e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg24818145	chr4:99064322	C4orf37	0.65	5.1	0.46	1.72e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg00981070	chr1:2046702	PRKCZ	-0.46	-5.72	-0.51	1.24e-7	Height;
THYM	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg08439880	chr3:133502540	NA	0.7	5.85	0.51	7.06e-8	Iron status biomarkers;
THYM	cis	rs6424115	0.729	rs586173	chr1:24055718	A/G	cg15997130	chr1:24165203	NA	-0.65	-5.21	-0.47	1.07e-6	Immature fraction of reticulocytes;
THYM	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg21427119	chr20:30132790	HM13	-0.71	-4.72	-0.44	8.04e-6	Mean corpuscular hemoglobin;
THYM	cis	rs9534288	0.797	rs9526127	chr13:46571744	A/G	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg24675658	chr1:53192096	ZYG11B	0.79	6.31	0.54	8.97e-9	Monocyte count;
THYM	cis	rs2070488	1.000	rs13079757	chr3:38491444	C/T	cg24069376	chr3:38537580	EXOG	0.68	6.73	0.57	1.26e-9	Electrocardiographic conduction measures;
THYM	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg18105134	chr13:113819100	PROZ	-0.95	-8.47	-0.66	3.03e-13	Platelet distribution width;
THYM	cis	rs40363	0.951	rs250632	chr16:3523047	C/T	cg05754148	chr16:3507555	NAT15	0.89	8.08	0.64	2.02e-12	Tuberculosis;
THYM	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg13609457	chr4:120235615	NA	0.58	5.33	0.48	6.55e-7	Corneal astigmatism;
THYM	trans	rs75518195	0.500	rs62301956	chr4:64683858	G/A	cg14706739	chr8:21916355	EPB49	0.75	7.37	0.6	6.34e-11	Triptolide cytotoxicity;
THYM	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs1775715	0.644	rs2799022	chr10:32137198	C/T	cg04359828	chr10:32216031	ARHGAP12	0.38	4.82	0.44	5.48e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg27446573	chr6:127587934	RNF146	0.98	9.21	0.69	8.26e-15	Breast cancer;
THYM	cis	rs7084402	0.529	rs7912116	chr10:60335389	G/C	cg09696939	chr10:60272079	BICC1	-0.49	-5.7	-0.5	1.35e-7	Refractive error;
THYM	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.88	9.94	0.71	2.24e-16	Prudent dietary pattern;
THYM	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg20291162	chr17:40259547	DHX58	-0.69	-6.44	-0.55	4.96e-9	Fibrinogen levels;
THYM	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg00484396	chr16:3507460	NAT15	0.49	4.72	0.44	8.23e-6	Body mass index (adult);
THYM	cis	rs924712	0.596	rs2816810	chr6:54771137	A/C	cg04690482	chr6:54711388	FAM83B	0.46	5.41	0.49	4.78e-7	Breast cancer;
THYM	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg13397359	chr6:42928475	GNMT	0.57	4.9	0.45	3.9e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs10896609	0.550	rs2003065	chr11:57116707	A/T	cg15971518	chr11:57159174	PRG2	-0.62	-4.79	-0.44	6.21e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs17253792	0.822	rs79291233	chr14:56065302	G/C	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg03929089	chr4:120376271	NA	-1.03	-12.43	-0.79	1.26e-21	Height;
THYM	cis	rs6956675	0.915	rs7787116	chr7:62654060	G/A	cg27518014	chr7:62859535	LOC100287834	0.59	4.8	0.44	5.95e-6	Obesity-related traits;
THYM	cis	rs34638657	0.673	rs11645286	chr16:82201898	C/A	cg09894383	chr16:82067445	HSD17B2	-0.46	-5.32	-0.48	6.9e-7	Lung adenocarcinoma;
THYM	cis	rs55728055	0.661	rs62237763	chr22:31947392	C/G	cg01338084	chr22:32026380	PISD	1.47	5.89	0.52	5.9e-8	Age-related hearing impairment;
THYM	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg21475434	chr5:93447410	FAM172A	0.89	5.48	0.49	3.56e-7	Diabetic retinopathy;
THYM	cis	rs6700896	0.832	rs11208693	chr1:66108063	C/T	cg04111102	chr1:66153794	NA	0.55	5.23	0.47	9.89e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs600550	0.528	rs7108307	chr11:59844861	G/T	cg02771260	chr11:59836817	MS4A3	0.73	5.51	0.49	3.11e-7	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs2797160	1.000	rs1777226	chr6:126017691	C/A	cg16306078	chr6:126000798	NA	0.52	5.19	0.47	1.19e-6	Endometrial cancer;
THYM	cis	rs9560113	1.000	rs9555812	chr13:112181535	A/G	cg10483660	chr13:112241077	NA	0.55	5.02	0.46	2.43e-6	Menarche (age at onset);
THYM	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg17328964	chr8:145687451	CYHR1	0.82	7.25	0.6	1.12e-10	Age at first birth;
THYM	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.67	6.02	0.53	3.23e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg02725872	chr8:58115012	NA	-0.78	-4.84	-0.44	4.95e-6	Developmental language disorder (linguistic errors);
THYM	trans	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg15655154	chr3:113604241	GRAMD1C	-0.89	-7.24	-0.6	1.16e-10	Diastolic blood pressure;
THYM	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg01579765	chr21:45077557	HSF2BP	0.51	8.41	0.65	4.08e-13	Mean corpuscular volume;
THYM	cis	rs863345	0.604	rs7512592	chr1:158489945	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs2574704	0.816	rs2442777	chr3:11652331	G/A	cg07643000	chr3:11666825	VGLL4	0.39	4.64	0.43	1.1e-5	Body mass index;
THYM	cis	rs7216064	0.953	rs4791300	chr17:65930772	A/G	cg12091567	chr17:66097778	LOC651250	-0.73	-5.18	-0.47	1.25e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs9296092	0.517	rs7743178	chr6:33470462	G/A	cg13560919	chr6:33536144	NA	-0.84	-6.92	-0.58	5.15e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs6032067	0.632	rs62208389	chr20:43794783	A/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs9290065	0.519	rs956447	chr3:160668917	G/C	cg03342759	chr3:160939853	NMD3	-0.68	-5.35	-0.48	6.14e-7	Kawasaki disease;
THYM	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg17372223	chr3:52568218	NT5DC2	0.31	4.58	0.43	1.42e-5	Bipolar disorder;
THYM	cis	rs7192750	0.586	rs2335713	chr16:71904291	T/C	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs3181245	0.641	rs3756821	chr6:24646821	C/T	cg16906346	chr6:24646782	KIAA0319	-0.67	-5.74	-0.51	1.12e-7	Colorectal or endometrial cancer;
THYM	cis	rs4638749	0.677	rs10185270	chr2:108838692	A/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg08916839	chr5:415575	AHRR	1.14	6.87	0.58	6.77e-10	Fat distribution (HIV);
THYM	cis	rs985746	0.568	rs4833160	chr4:36799786	G/C	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg16926213	chr1:1841314	NA	0.54	5.64	0.5	1.73e-7	Body mass index;
THYM	cis	rs2777491	1.000	rs316613	chr15:41747598	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.11	-12.45	-0.79	1.12e-21	Ulcerative colitis;
THYM	cis	rs7107770	1.000	rs34140247	chr11:125092360	G/A	cg07747661	chr11:125106135	PKNOX2	-0.88	-5.18	-0.47	1.26e-6	Photic sneeze reflex;
THYM	cis	rs34779708	0.966	rs878264	chr10:35440581	T/C	cg03585969	chr10:35415529	CREM	0.66	4.76	0.44	6.85e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg25817165	chr18:72167213	CNDP2	-0.94	-7.91	-0.63	4.61e-12	Refractive error;
THYM	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.92	-6.03	-0.53	3.11e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg17775962	chr7:1200435	ZFAND2A	0.4	4.65	0.43	1.08e-5	Longevity;Endometriosis;
THYM	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg00339695	chr16:24857497	SLC5A11	-0.49	-4.85	-0.45	4.73e-6	Intelligence (multi-trait analysis);
THYM	cis	rs42648	0.748	rs10225744	chr7:89946003	T/C	cg25739043	chr7:89950458	NA	-0.51	-4.5	-0.42	1.94e-5	Homocysteine levels;
THYM	cis	rs6987853	0.602	rs2974337	chr8:42390873	C/T	cg09913449	chr8:42400586	C8orf40	0.75	6.66	0.56	1.8e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg00686598	chr14:53173677	PSMC6	1.38	6.88	0.58	6.42e-10	Alzheimer's disease (late onset);
THYM	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.28	-4.69	-0.43	8.96e-6	Obesity-related traits;
THYM	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg02275930	chr1:2372054	NA	-1.05	-9.39	-0.69	3.37e-15	Non-obstructive azoospermia;
THYM	cis	rs735539	1.000	rs6490605	chr13:21285009	C/T	cg02792322	chr13:21280448	IL17D	-0.69	-4.98	-0.45	2.84e-6	Dental caries;
THYM	cis	rs208520	0.586	rs208442	chr6:66900618	T/A	cg07460842	chr6:66804631	NA	-0.71	-4.69	-0.43	9.28e-6	Exhaled nitric oxide output;
THYM	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg02527881	chr3:46936655	PTH1R	-0.64	-6.0	-0.52	3.59e-8	Colorectal cancer;
THYM	cis	rs7599312	0.534	rs6435711	chr2:213410065	G/A	cg16329650	chr2:213403929	ERBB4	1.05	12.68	0.79	3.71e-22	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg10334053	chr1:2078117	PRKCZ	-0.45	-4.8	-0.44	5.83e-6	Height;
THYM	cis	rs71403859	0.502	rs34380814	chr16:71488175	C/T	cg08717414	chr16:71523259	ZNF19	-0.83	-4.56	-0.42	1.54e-5	Post bronchodilator FEV1;
THYM	cis	rs662064	0.852	rs616402	chr1:10566272	C/T	cg20482658	chr1:10539492	PEX14	0.47	5.75	0.51	1.07e-7	Asthma;
THYM	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg05043794	chr9:111880884	C9orf5	-0.36	-4.99	-0.46	2.71e-6	Menarche (age at onset);
THYM	cis	rs9324022	0.626	rs10873520	chr14:101175967	G/A	cg18089426	chr14:101175970	NA	0.77	5.4	0.48	4.98e-7	Plateletcrit;
THYM	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg01341218	chr17:43662625	NA	1.15	9.87	0.71	3.19e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4845570	1.000	rs6673002	chr1:151743275	G/T	cg18019451	chr1:151746047	TDRKH	0.73	4.49	0.42	1.98e-5	Coronary artery disease;
THYM	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg06108461	chr20:60628389	TAF4	-0.84	-7.06	-0.59	2.77e-10	Body mass index;
THYM	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg11301795	chr4:187892539	NA	1.07	15.97	0.85	1.21e-28	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg18131467	chr2:239335373	ASB1	-1.1	-11.05	-0.75	9.8e-19	Multiple system atrophy;
THYM	cis	rs2108225	0.714	rs929394	chr7:107437252	C/T	cg18560240	chr7:107437656	SLC26A3	-1.05	-8.04	-0.64	2.49e-12	Ulcerative colitis;
THYM	cis	rs4819852	1.000	rs7285377	chr22:19987202	G/T	cg07821417	chr22:19972146	ARVCF	0.47	5.36	0.48	5.84e-7	Pulse pressure;
THYM	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	4.47	0.42	2.13e-5	Alzheimer's disease;
THYM	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg06558623	chr16:89946397	TCF25	1.48	7.79	0.62	8.19e-12	Skin colour saturation;
THYM	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg17775962	chr7:1200435	ZFAND2A	0.43	5.16	0.47	1.34e-6	Longevity;Endometriosis;
THYM	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg21926883	chr2:100939477	LONRF2	-0.65	-6.02	-0.53	3.24e-8	Intelligence (multi-trait analysis);
THYM	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg20290983	chr6:43655470	MRPS18A	1.44	16.17	0.86	4.93e-29	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	7.8	0.62	8.02e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs16866061	0.962	rs16825685	chr2:225434256	C/G	cg22455342	chr2:225449267	CUL3	0.66	4.73	0.44	7.81e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs539096	0.692	rs6686238	chr1:44210253	C/G	cg12599982	chr1:44399894	ARTN	0.52	4.74	0.44	7.55e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg14196790	chr5:131705035	SLC22A5	0.6	5.76	0.51	1.02e-7	Blood metabolite levels;
THYM	cis	rs11039798	0.620	rs10838833	chr11:48238880	C/T	cg24672777	chr11:48374446	OR4C45	-1.14	-6.78	-0.57	1e-9	Axial length;
THYM	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg02569458	chr12:86230093	RASSF9	0.62	5.34	0.48	6.31e-7	Major depressive disorder;
THYM	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg26384229	chr12:38710491	ALG10B	0.97	7.89	0.63	5.19e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs7809950	0.678	rs7788330	chr7:106985648	G/T	cg23024343	chr7:107201750	COG5	-1.0	-8.5	-0.66	2.7e-13	Coronary artery disease;
THYM	cis	rs17006441	0.898	rs9858495	chr3:69874018	A/G	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs6815814	1.000	rs11722836	chr4:38811529	T/A	cg06935464	chr4:38784597	TLR10	0.72	4.71	0.44	8.42e-6	Breast cancer;
THYM	cis	rs12142240	0.698	rs67276232	chr1:46825484	T/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs6598955	0.671	rs41285347	chr1:26644399	C/T	cg20415053	chr1:26527928	CATSPER4	-0.58	-4.71	-0.43	8.58e-6	Obesity-related traits;
THYM	cis	rs17152411	1.000	rs10901843	chr10:126638020	A/G	cg07906193	chr10:126599966	NA	0.68	4.65	0.43	1.08e-5	Height;
THYM	cis	rs346785	0.692	rs6501883	chr17:74289908	A/G	cg09812376	chr17:74270190	QRICH2	-0.49	-4.9	-0.45	3.92e-6	White matter hyperintensities in ischemic stroke;
THYM	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg11366901	chr6:160182831	ACAT2	1.01	8.95	0.68	2.91e-14	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7894051	1.000	rs7897693	chr10:135200478	G/A	cg07511014	chr10:135191624	PAOX	-0.63	-4.65	-0.43	1.05e-5	Lifespan;
THYM	cis	rs10484885	0.793	rs1465954	chr6:90475013	G/A	cg13799429	chr6:90582589	CASP8AP2	0.84	8.26	0.65	8.31e-13	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs7192750	0.586	rs4788449	chr16:71931219	G/A	cg06353428	chr16:71660113	MARVELD3	0.76	5.6	0.5	2.04e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs4722585	0.513	rs11760917	chr7:26208025	A/G	cg07876897	chr7:26191696	NFE2L3	0.6	4.76	0.44	6.85e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs189798	1.000	rs189798	chr8:8990577	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-4.77	-0.44	6.62e-6	Myopia (pathological);
THYM	cis	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.78	0.44	6.43e-6	Body mass index;
THYM	cis	rs12519773	0.526	rs4242240	chr5:92517203	A/G	cg18783429	chr5:92414398	NA	0.5	4.91	0.45	3.72e-6	Migraine;
THYM	cis	rs13082711	0.911	rs6789539	chr3:27444076	T/A	cg02860705	chr3:27208620	NA	0.69	4.99	0.46	2.75e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg13447684	chr7:1895903	MAD1L1	0.54	4.54	0.42	1.62e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg03733263	chr8:22462867	KIAA1967	1.16	14.05	0.82	6.31e-25	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1843834	1.000	rs1565072	chr2:225545245	C/T	cg22455342	chr2:225449267	CUL3	-0.63	-4.85	-0.45	4.9100000000000004e-06	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg21775007	chr8:11205619	TDH	0.68	5.27	0.48	8.47e-7	Retinal vascular caliber;
THYM	cis	rs742614	0.533	rs6120395	chr20:32451693	A/G	cg06304546	chr20:32448765	NA	-1.01	-10.34	-0.73	3.17e-17	Stearic acid (18:0) levels;
THYM	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg22907277	chr7:1156413	C7orf50	0.87	7.58	0.61	2.31e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs760805	0.965	rs4648883	chr1:25261203	T/C	cg22509179	chr1:25234806	RUNX3	-0.73	-6.72	-0.57	1.34e-9	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg24578937	chr1:2090814	PRKCZ	0.81	8.54	0.66	2.22e-13	Height;
THYM	cis	rs1747683	0.966	rs3781085	chr10:13370958	G/T	cg25835351	chr10:13388524	SEPHS1	-0.33	-5.5	-0.49	3.21e-7	IgG glycosylation;
THYM	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg12564285	chr5:131593104	PDLIM4	0.6	7.19	0.59	1.48e-10	Acylcarnitine levels;
THYM	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg16240275	chr20:61666158	NCRNA00029	0.33	4.46	0.42	2.23e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg06634786	chr22:41940651	POLR3H	0.62	4.81	0.44	5.64e-6	Vitiligo;
THYM	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg18200150	chr17:30822561	MYO1D	0.72	6.23	0.54	1.26e-8	Schizophrenia;
THYM	cis	rs912057	0.671	rs1294435	chr6:6745455	G/A	cg06612196	chr6:6737390	NA	0.7	11.42	0.76	1.61e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs1178127	0.611	rs12535294	chr7:18818397	A/G	cg13420273	chr7:18810212	HDAC9	0.58	5.19	0.47	1.18e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs2692947	0.832	rs2438978	chr2:96679740	G/C	cg22654517	chr2:96458247	NA	0.68	4.87	0.45	4.36e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs11096990	0.964	rs35494908	chr4:39254194	A/C	cg24403649	chr4:39172243	NA	-0.67	-5.68	-0.5	1.5e-7	Cognitive function;
THYM	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg00684032	chr4:1343700	KIAA1530	0.59	4.87	0.45	4.41e-6	Obesity-related traits;
THYM	cis	rs7772486	0.875	rs864390	chr6:146315035	G/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.72	-0.51	1.25e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1062746	0.711	rs2303763	chr16:87376605	C/T	cg02258303	chr16:87377426	FBXO31	0.54	5.01	0.46	2.51e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs6840360	0.692	rs1838043	chr4:152411462	T/C	cg17479576	chr4:152424074	FAM160A1	-0.65	-4.92	-0.45	3.58e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4460079	0.556	rs28667209	chr4:114840102	C/T	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs7127900	0.904	rs7123180	chr11:2232272	A/G	cg25635251	chr11:2234043	NA	0.74	4.71	0.44	8.43e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs863345	0.604	rs12064489	chr1:158499449	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs12620999	0.887	rs10929214	chr2:238037436	C/G	cg15976283	chr2:238042351	NA	0.6	4.49	0.42	2e-5	Systemic lupus erythematosus;
THYM	cis	rs61774743	0.681	rs10889959	chr1:41849735	T/C	cg19619003	chr1:41846758	NA	-0.28	-6.03	-0.53	3.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4790312	0.935	rs3744274	chr17:1990959	G/T	cg20777128	chr17:1945076	DPH1;OVCA2	-0.48	-4.68	-0.43	9.35e-6	Left atrial antero-posterior diameter;
THYM	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg27284194	chr4:1044797	NA	-0.64	-4.87	-0.45	4.42e-6	Recombination rate (females);
THYM	cis	rs11726022	0.927	rs13122364	chr4:188167396	T/C	cg09690449	chr4:187998952	NA	-0.51	-5.15	-0.47	1.41e-6	Systolic blood pressure (cigarette smoking interaction);
THYM	trans	rs8073060	0.586	rs225286	chr17:33930458	G/A	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs6754311	0.551	rs9287442	chr2:136522710	A/G	cg07169764	chr2:136633963	MCM6	-0.67	-5.82	-0.51	7.78e-8	Mosquito bite size;
THYM	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg17264618	chr3:40429014	ENTPD3	0.5	4.81	0.44	5.73e-6	Renal cell carcinoma;
THYM	cis	rs11608355	1.000	rs10774692	chr12:109862324	G/T	cg11367159	chr12:110044531	NA	0.66	6.29	0.54	9.83e-9	Neuroticism;
THYM	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg16850897	chr7:100343110	ZAN	-0.73	-5.41	-0.49	4.62e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11997175	0.846	rs34860600	chr8:33761566	C/A	ch.8.33884649F	chr8:33765107	NA	0.73	6.08	0.53	2.53e-8	Body mass index;
THYM	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg06784218	chr1:46089804	CCDC17	-0.34	-5.03	-0.46	2.28e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg26031613	chr14:104095156	KLC1	0.75	5.11	0.46	1.63e-6	Body mass index;
THYM	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg19077165	chr18:44547161	KATNAL2	0.51	5.93	0.52	4.94e-8	Personality dimensions;
THYM	cis	rs2333194	0.875	rs7140876	chr14:73792938	A/G	cg09844916	chr14:74004424	HEATR4;ACOT1	0.57	4.55	0.42	1.56e-5	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs55728055	0.661	rs16989620	chr22:31839244	G/A	cg01338084	chr22:32026380	PISD	1.35	4.93	0.45	3.5e-6	Age-related hearing impairment;
THYM	cis	rs988913	0.629	rs34685175	chr6:54866737	G/C	cg19716238	chr6:54711378	FAM83B	0.52	5.04	0.46	2.18e-6	Menarche (age at onset);
THYM	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg23482746	chr15:76478102	C15orf27	-0.38	-4.55	-0.42	1.61e-5	Blood metabolite levels;
THYM	trans	rs2136093	0.600	rs10922862	chr1:90912379	T/A	cg19688584	chr6:167529678	CCR6	0.5	7.06	0.59	2.66e-10	Response to antidepressants;
THYM	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg24675658	chr1:53192096	ZYG11B	-0.77	-6.92	-0.58	5.37e-10	Monocyte count;
THYM	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg26384229	chr12:38710491	ALG10B	0.99	7.56	0.61	2.56e-11	Morning vs. evening chronotype;
THYM	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg22709100	chr7:91322751	NA	0.71	5.56	0.5	2.48e-7	Breast cancer;
THYM	cis	rs10089	0.953	rs114881127	chr5:127369661	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.97	6.65	0.56	1.82e-9	Ileal carcinoids;
THYM	cis	rs9913156	0.670	rs7219606	chr17:4561928	T/C	cg19197139	chr17:4613644	ARRB2	0.78	4.92	0.45	3.63e-6	Lymphocyte counts;
THYM	cis	rs6138458	0.961	rs227625	chr20:24911618	T/C	cg06937882	chr20:24974362	C20orf3	-0.47	-4.54	-0.42	1.66e-5	Blood protein levels;
THYM	cis	rs12765878	1.000	rs1980653	chr10:105654164	A/G	cg11005552	chr10:105648138	OBFC1	0.87	11.39	0.76	1.84e-19	Coronary artery disease;
THYM	cis	rs2637266	0.967	rs12246430	chr10:78352879	C/T	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs12478665	1	rs12478665	chr2:210123032	C/T	cg09336323	chr2:210074276	NA	0.79	5.27	0.48	8.52e-7	Hippocampal volume;
THYM	cis	rs800586	0.912	rs2694033	chr8:116810032	G/A	cg04656070	chr8:116661063	TRPS1	0.48	4.95	0.45	3.24e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg22852734	chr6:133119734	C6orf192	1.28	8.61	0.66	1.55e-13	Type 2 diabetes nephropathy;
THYM	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs2249694	1.000	rs2249694	chr10:135352153	A/G	cg20169779	chr10:135381914	SYCE1	0.57	4.53	0.42	1.71e-5	Obesity-related traits;
THYM	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg18404041	chr3:52824283	ITIH1	-0.47	-4.53	-0.42	1.7e-5	Bipolar disorder;
THYM	cis	rs713587	0.521	rs6545766	chr2:25077856	C/T	cg15423357	chr2:25149977	NA	0.6	5.4	0.48	4.82e-7	Body mass index in non-asthmatics;
THYM	cis	rs11650494	0.908	rs73340399	chr17:47372743	G/C	cg08112188	chr17:47440006	ZNF652	1.05	4.51	0.42	1.83e-5	Prostate cancer;
THYM	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg24308560	chr3:49941425	MST1R	0.59	4.46	0.42	2.26e-5	Body mass index;
THYM	cis	rs3020333	0.875	rs2941740	chr6:152009638	A/G	cg22157087	chr6:152012887	ESR1	0.44	4.8	0.44	5.85e-6	Total body bone mineral density;
THYM	cis	rs11563648	0.535	rs1946108	chr7:127050778	T/C	cg23081781	chr7:127225937	GCC1	-0.33	-4.52	-0.42	1.78e-5	Resting heart rate;
THYM	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03647317	chr4:187891568	NA	-0.83	-9.1	-0.68	1.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg24818145	chr4:99064322	C4orf37	0.68	5.33	0.48	6.55e-7	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs3008870	0.959	rs3008852	chr1:67383416	G/A	cg02640540	chr1:67518911	SLC35D1	0.64	4.6	0.43	1.33e-5	Lymphocyte percentage of white cells;
THYM	cis	rs2625529	0.556	rs55679065	chr15:72433395	C/T	cg16672083	chr15:72433130	SENP8	0.5	4.62	0.43	1.19e-5	Red blood cell count;
THYM	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg12311346	chr5:56204834	C5orf35	-0.77	-5.59	-0.5	2.18e-7	Initial pursuit acceleration;
THYM	cis	rs9324022	0.929	rs12888043	chr14:101170436	A/G	cg18089426	chr14:101175970	NA	-0.8	-5.11	-0.46	1.63e-6	Plateletcrit;
THYM	cis	rs4746818	0.901	rs7914719	chr10:70903832	T/C	cg11621586	chr10:70884670	VPS26A	1.28	11.0	0.75	1.26e-18	Left atrial antero-posterior diameter;
THYM	cis	rs9296092	0.538	rs62407564	chr6:33534010	C/T	cg13560919	chr6:33536144	NA	-0.94	-9.17	-0.69	9.74e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.53	-0.56	3.16e-9	Personality dimensions;
THYM	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg24692254	chr21:30365293	RNF160	1.03	10.07	0.72	1.17e-16	Dental caries;
THYM	cis	rs12935418	0.672	rs12446304	chr16:81046335	C/G	cg16651780	chr16:81037892	C16orf61	0.88	6.46	0.55	4.35e-9	Mean corpuscular volume;
THYM	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg12334488	chr2:20871173	GDF7	-0.65	-5.7	-0.5	1.34e-7	Abdominal aortic aneurysm;
THYM	cis	rs6430585	0.583	rs6728946	chr2:136635343	C/G	cg20242066	chr2:136595261	LCT	0.51	4.89	0.45	4.06e-6	Corneal structure;
THYM	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-4.74	-0.44	7.42e-6	Joint mobility (Beighton score);
THYM	cis	rs3820068	0.705	rs4646063	chr1:15829813	G/A	cg05660106	chr1:15850417	CASP9	1.08	9.21	0.69	8.15e-15	Systolic blood pressure;
THYM	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg05973401	chr12:123451056	ABCB9	0.65	4.73	0.44	7.83e-6	Platelet count;
THYM	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg09436375	chr6:42928200	GNMT	-0.41	-5.56	-0.5	2.46e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1981331	1.000	rs77587985	chr21:47993897	A/G	cg23283320	chr21:48055893	PRMT2	1.24	6.23	0.54	1.27e-8	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg23815491	chr16:72088622	HP	0.92	8.05	0.64	2.34e-12	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
THYM	cis	rs6009824	0.579	rs34296882	chr22:50098333	C/T	cg22070880	chr22:50098194	NA	0.65	4.59	0.43	1.36e-5	Natriuretic peptide levels;
THYM	cis	rs983545	0.800	rs4685400	chr3:16947451	C/T	cg24159436	chr3:16974681	PLCL2	0.31	4.6	0.43	1.29e-5	Blood protein levels;
THYM	cis	rs62045849	0.557	rs9938463	chr16:89183772	A/G	cg06035645	chr16:89190857	ACSF3	-0.88	-5.55	-0.5	2.53e-7	Red blood cell count;
THYM	cis	rs6686842	1.000	rs6663565	chr1:41563688	C/T	cg03387723	chr1:41708464	SCMH1	0.44	5.11	0.46	1.65e-6	Height;
THYM	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs7084402	0.934	rs1593673	chr10:60294170	C/T	cg07615347	chr10:60278583	BICC1	0.56	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs7104764	1.000	rs10902112	chr11:244106	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs4908768	0.657	rs3938719	chr1:8804997	A/G	cg06972019	chr1:8937448	ENO1	-0.55	-4.5	-0.42	1.89e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
THYM	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs56079296	0.642	rs12657394	chr5:121308199	C/T	cg05256605	chr5:121412184	LOX	0.62	4.75	0.44	7.16e-6	Coronary artery disease;
THYM	cis	rs79149102	0.579	rs74023908	chr15:75310710	T/C	cg17294928	chr15:75287854	SCAMP5	-0.98	-5.33	-0.48	6.65e-7	Lung cancer;
THYM	cis	rs792448	0.603	rs4951588	chr1:212500433	C/T	ch.1.4129519F	chr1:212238115	DTL	-0.57	-4.47	-0.42	2.19e-5	White blood cell count (basophil);
THYM	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg21475434	chr5:93447410	FAM172A	-0.7	-4.49	-0.42	1.98e-5	Diabetic retinopathy;
THYM	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg23711669	chr6:146136114	FBXO30	-0.98	-10.47	-0.73	1.68e-17	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs61931739	0.534	rs2625897	chr12:34064295	G/A	cg10856724	chr12:34555212	NA	-0.79	-7.41	-0.61	5.14e-11	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.52	0.56	3.42e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg16414030	chr3:133502952	NA	-0.84	-8.47	-0.66	3.08e-13	Iron status biomarkers;
THYM	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg26695010	chr11:65641043	EFEMP2	0.65	4.9	0.45	3.87e-6	Eosinophil percentage of white cells;
THYM	cis	rs8070624	0.543	rs4299203	chr17:17878159	T/G	cg04398451	chr17:18023971	MYO15A	-0.93	-8.84	-0.67	4.97e-14	Total body bone mineral density;
THYM	cis	rs4731207	0.596	rs10275346	chr7:124610346	T/C	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg02734326	chr4:10020555	SLC2A9	-0.64	-5.35	-0.48	5.97e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6032067	0.929	rs13039083	chr20:43878838	T/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.67	-7.02	-0.58	3.36e-10	Blood protein levels;
THYM	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.16	-5.63	-0.5	1.85e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg09436375	chr6:42928200	GNMT	-0.42	-5.32	-0.48	6.83e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	5.89	0.52	5.84e-8	Rheumatoid arthritis;
THYM	cis	rs9633835	0.524	rs12786955	chr11:13280635	G/C	cg13286116	chr11:13302098	ARNTL	-0.75	-8.3	-0.65	7.01e-13	Body mass index;
THYM	cis	rs6840360	0.571	rs875667	chr4:152525477	G/A	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6598955	0.612	rs12738188	chr1:26548029	G/C	cg00852783	chr1:26633632	UBXN11	0.84	8.54	0.66	2.17e-13	Obesity-related traits;
THYM	cis	rs2652822	0.525	rs35594365	chr15:63520154	T/C	cg09251291	chr15:63483946	RAB8B	0.5	4.55	0.42	1.56e-5	Metabolic traits;
THYM	cis	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.56	-0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg27490568	chr2:178487706	NA	0.58	5.26	0.48	8.72e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg07424592	chr7:64974309	NA	1.08	5.73	0.51	1.2e-7	Diabetic kidney disease;
THYM	cis	rs6882076	1.000	rs4704825	chr5:156382308	A/G	cg12943317	chr5:156479607	HAVCR1	-0.69	-5.84	-0.51	7.37e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs986417	1.000	rs1254270	chr14:60843134	G/T	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	trans	rs9929218	0.529	rs2296404	chr16:68729525	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.07	13.15	0.8	4.04e-23	Colorectal cancer;
THYM	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg26022315	chr17:47021804	SNF8	0.51	4.87	0.45	4.44e-6	Type 2 diabetes;
THYM	cis	rs823143	0.549	rs1094647	chr1:205655378	G/A	cg14893161	chr1:205819251	PM20D1	0.82	7.8	0.62	7.91e-12	Monocyte percentage of white cells;
THYM	cis	rs9880211	1.000	rs9828088	chr3:136247790	C/T	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs478304	0.593	rs2236682	chr11:65480090	G/T	cg17480646	chr11:65405466	SIPA1	-0.88	-7.85	-0.63	6.19e-12	Acne (severe);
THYM	cis	rs79149102	0.579	rs7181942	chr15:75300623	G/C	cg17294928	chr15:75287854	SCAMP5	-1.06	-5.68	-0.5	1.49e-7	Lung cancer;
THYM	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs7226229	1.000	rs7215369	chr17:20916856	G/A	cg21263980	chr17:20946333	USP22	0.67	5.02	0.46	2.38e-6	Blood trace element (Se levels);
THYM	cis	rs12188164	0.747	rs12188321	chr5:428418	C/G	cg00049323	chr5:472564	LOC25845	-0.41	-4.84	-0.44	4.96e-6	Cystic fibrosis severity;
THYM	cis	rs9467711	0.651	rs35402046	chr6:26099472	G/A	cg01386294	chr6:25732093	NA	0.9	4.88	0.45	4.34e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4642101	0.737	rs4299468	chr3:12825559	G/A	cg05775895	chr3:12838266	CAND2	0.77	6.91	0.58	5.5e-10	QRS complex (12-leadsum);
THYM	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.72	-0.44	8.14e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2066819	1.000	rs78121408	chr12:56684798	C/T	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs714027	0.605	rs1989870	chr22:30472254	A/G	cg27665648	chr22:30112403	NA	0.52	4.73	0.44	7.79e-6	Lymphocyte counts;
THYM	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.12	-0.72	9.13e-17	Primary sclerosing cholangitis;
THYM	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg17143192	chr8:8559678	CLDN23	0.87	6.53	0.56	3.24e-9	Obesity-related traits;
THYM	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg22105103	chr4:187893119	NA	0.92	10.09	0.72	1.04e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17473412	0.926	rs115796963	chr5:122654779	A/G	cg18093572	chr5:122598329	NA	0.55	4.53	0.42	1.7e-5	Total body bone mineral density;
THYM	cis	rs990171	1.000	rs6746271	chr2:103052995	G/C	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.17	-0.47	1.27e-6	Lymphocyte counts;
THYM	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg17863274	chr19:49399704	TULP2	-0.95	-5.5	-0.49	3.26e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg02734326	chr4:10020555	SLC2A9	0.76	6.89	0.58	6.16e-10	Bone mineral density;
THYM	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg23281280	chr6:28129359	ZNF389	0.61	4.88	0.45	4.21e-6	Depression;
THYM	cis	rs13326165	0.585	rs6783652	chr3:52323344	G/A	cg08438690	chr3:52279403	PPM1M	-0.88	-5.21	-0.47	1.1e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs7107174	0.792	rs2888465	chr11:77945807	T/C	cg19901956	chr11:77921274	USP35	-0.78	-5.89	-0.52	5.74e-8	Testicular germ cell tumor;
THYM	cis	rs1160297	0.609	rs4525730	chr2:53097497	C/T	cg07782112	chr2:53107842	NA	0.79	6.37	0.55	6.61e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs886126	1.000	rs4766451	chr12:111670682	G/T	cg10833066	chr12:111807467	FAM109A	0.46	5.67	0.5	1.52e-7	Coronary heart disease;
THYM	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg01097406	chr16:89675127	NA	0.84	7.57	0.61	2.36e-11	Vitiligo;
THYM	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-4.88	-0.45	4.26e-6	Chronic sinus infection;
THYM	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg10224037	chr5:178157518	ZNF354A	0.96	7.71	0.62	1.24e-11	Neutrophil percentage of white cells;
THYM	cis	rs2835345	0.563	rs12483690	chr21:37823563	A/G	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs3942852	0.868	rs7118226	chr11:48106267	T/G	cg25800328	chr11:47736132	AGBL2	-0.5	-4.7	-0.43	8.62e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs3892630	0.588	rs8106748	chr19:33282797	G/A	cg22928329	chr19:33183273	NUDT19	-0.67	-5.26	-0.47	8.89e-7	Red blood cell traits;
THYM	cis	rs1971762	0.527	rs4019971	chr12:53978715	A/G	cg16917193	chr12:54089295	NA	0.69	6.31	0.54	8.67e-9	Height;
THYM	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg27446573	chr6:127587934	RNF146	-1.1	-9.47	-0.7	2.26e-15	Breast cancer;
THYM	cis	rs7127900	0.561	rs7125026	chr11:2233617	C/T	cg25635251	chr11:2234043	NA	0.67	5.0	0.46	2.6e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs6570726	0.577	rs867056	chr6:145784805	A/C	cg05347473	chr6:146136440	FBXO30	-0.77	-6.76	-0.57	1.1e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg07690219	chr3:49449608	TCTA;RHOA	0.69	4.62	0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg24531977	chr5:56204891	C5orf35	0.64	4.87	0.45	4.46e-6	Coronary artery disease;
THYM	cis	rs2294693	0.898	rs6458195	chr6:40972498	A/T	cg21128951	chr6:40996213	UNC5CL	-0.56	-4.6	-0.43	1.31e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg27087555	chr16:88793112	FAM38A	-1.5	-11.17	-0.75	5.36e-19	Plateletcrit;
THYM	cis	rs977987	0.806	rs11862684	chr16:75461746	T/G	cg03315344	chr16:75512273	CHST6	0.76	6.17	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg13695892	chr22:41940480	POLR3H	0.87	6.33	0.54	8.03e-9	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg08470875	chr2:26401718	FAM59B	-0.72	-4.46	-0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg11266682	chr4:10021025	SLC2A9	0.73	10.48	0.73	1.58e-17	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	7.63	0.62	1.78e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs8067545	1.000	rs8065337	chr17:19941879	C/A	cg13482628	chr17:19912719	NA	0.57	4.73	0.44	7.7e-6	Schizophrenia;
THYM	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg21138405	chr5:131827807	IRF1	-0.84	-9.29	-0.69	5.56e-15	Asthma (sex interaction);
THYM	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg01819863	chr10:32635814	EPC1	1.04	6.64	0.56	1.9e-9	Sexual dysfunction (female);
THYM	cis	rs10899021	0.920	rs11236181	chr11:74345823	A/C	cg25880958	chr11:74394337	NA	-0.77	-4.66	-0.43	1.04e-5	Response to metformin (IC50);
THYM	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg05340658	chr4:99064831	C4orf37	0.54	4.51	0.42	1.83e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg08847533	chr14:75593920	NEK9	0.97	10.6	0.74	8.61e-18	Height;
THYM	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg06238570	chr21:40685208	BRWD1	-0.96	-9.14	-0.68	1.13e-14	Cognitive function;
THYM	cis	rs6087990	0.899	rs1333469	chr20:31361249	C/T	cg13636640	chr20:31349939	DNMT3B	0.92	9.55	0.7	1.48e-15	Ulcerative colitis;
THYM	cis	rs41005	1.000	rs13402078	chr2:8113107	C/T	cg03155496	chr2:8117019	LOC339788	-0.99	-9.37	-0.69	3.69e-15	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs7127900	1.000	rs6579000	chr11:2232042	C/T	cg25635251	chr11:2234043	NA	0.74	4.71	0.44	8.43e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs8050907	0.744	rs17137053	chr16:4524155	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.58	0.43	1.38e-5	Obesity-related traits;
THYM	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg08508325	chr11:3079039	CARS	-0.49	-6.29	-0.54	9.77e-9	Longevity;
THYM	cis	rs17102423	0.755	rs11625045	chr14:65549089	C/T	cg11161011	chr14:65562177	MAX	-0.83	-6.62	-0.56	2.13e-9	Obesity-related traits;
THYM	cis	rs9914988	0.943	rs9890377	chr17:27111111	A/G	cg20469991	chr17:27169893	C17orf63	-0.77	-4.59	-0.43	1.33e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs2346160	0.867	rs206975	chr6:167690356	A/G	cg21686812	chr6:168078911	NA	-0.5	-4.5	-0.42	1.93e-5	Parental extreme longevity (95 years and older);
THYM	cis	rs7226229	0.904	rs34550408	chr17:20940649	T/C	cg21263980	chr17:20946333	USP22	0.64	4.72	0.44	8.12e-6	Blood trace element (Se levels);
THYM	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg19346786	chr7:2764209	NA	-0.72	-6.08	-0.53	2.46e-8	Height;
THYM	cis	rs7909791	0.632	rs3752948	chr10:105670762	G/A	cg24587175	chr10:105670608	OBFC1	0.76	7.41	0.61	5.2e-11	White matter hyperintensity burden;
THYM	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg18709589	chr6:96969512	KIAA0776	0.66	4.87	0.45	4.51e-6	Headache;
THYM	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg17554472	chr22:41940697	POLR3H	0.7	4.97	0.45	2.97e-6	Vitiligo;
THYM	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg07937631	chr13:79184529	NA	-0.66	-4.94	-0.45	3.35e-6	Large artery stroke;
THYM	cis	rs7584330	0.504	rs11890307	chr2:238434705	A/G	cg14458575	chr2:238380390	NA	0.81	4.86	0.45	4.63e-6	Prostate cancer;
THYM	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg13918804	chr1:2043761	PRKCZ	-0.6	-5.2	-0.47	1.15e-6	Height;
THYM	cis	rs6939532	0.522	rs13218591	chr6:26376832	T/C	cg14345882	chr6:26364793	BTN3A2	0.39	5.2	0.47	1.14e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg00898013	chr13:113819073	PROZ	0.86	8.72	0.67	9e-14	Platelet distribution width;
THYM	cis	rs3771570	1.000	rs56363214	chr2:242227157	A/G	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22496380	chr5:211416	CCDC127	-1.4	-8.15	-0.64	1.44e-12	Breast cancer;
THYM	cis	rs3862260	0.509	rs3795662	chr1:120165135	G/T	cg16322792	chr1:120165303	ZNF697	0.92	11.5	0.76	1.09e-19	Systemic lupus erythematosus;
THYM	cis	rs1878931	0.580	rs3848355	chr16:3407489	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.94	8.78	0.67	6.76e-14	Body mass index (adult);
THYM	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg19875535	chr5:140030758	IK	-0.63	-5.59	-0.5	2.16e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs3892630	0.612	rs10413282	chr19:33182751	A/G	cg22928329	chr19:33183273	NUDT19	-0.66	-5.39	-0.48	5.08e-7	Red blood cell traits;
THYM	cis	rs7246967	0.611	rs73022711	chr19:22875404	G/A	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg04362960	chr10:104952993	NT5C2	0.58	4.82	0.44	5.34e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	trans	rs4866334	1.000	rs77052976	chr5:18453061	A/T	cg08675002	chr5:90437527	GPR98	-1.55	-7.42	-0.61	4.85e-11	IgG glycosylation;
THYM	cis	rs6840360	0.517	rs4399967	chr4:152729312	T/A	cg22705602	chr4:152727874	NA	0.8	11.0	0.75	1.22e-18	Intelligence (multi-trait analysis);
THYM	cis	rs3791556	0.842	rs55840142	chr2:240106884	G/A	cg03281426	chr2:240109471	HDAC4	0.57	5.56	0.5	2.46e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	7.17	0.59	1.64e-10	Smoking behavior;
THYM	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26314531	chr2:26401878	FAM59B	-0.76	-4.99	-0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg07936489	chr17:37558343	FBXL20	-0.76	-5.25	-0.47	9.27e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7084921	0.608	rs11596211	chr10:101840119	T/A	cg11344164	chr10:101878520	NA	-0.55	-4.76	-0.44	6.9e-6	Bone mineral density;
THYM	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg17264618	chr3:40429014	ENTPD3	0.53	5.06	0.46	2.05e-6	Renal cell carcinoma;
THYM	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs854765	0.583	rs8065563	chr17:17782404	A/G	cg16928487	chr17:17741425	SREBF1	-0.57	-5.35	-0.48	6.05e-7	Total body bone mineral density;
THYM	cis	rs6754311	0.593	rs10195620	chr2:136495619	A/T	cg07169764	chr2:136633963	MCM6	-0.66	-5.7	-0.5	1.37e-7	Mosquito bite size;
THYM	cis	rs2806561	0.754	rs10917337	chr1:23300723	G/A	cg19743168	chr1:23544995	NA	-0.59	-5.53	-0.49	2.81e-7	Height;
THYM	cis	rs12200560	0.505	rs211176	chr6:97073821	G/A	cg06623918	chr6:96969491	KIAA0776	0.76	5.87	0.52	6.31e-8	Coronary heart disease;
THYM	cis	rs2282300	0.739	rs35883696	chr11:30246407	A/C	cg09906309	chr11:30344399	C11orf46	-0.72	-5.34	-0.48	6.24e-7	Morning vs. evening chronotype;
THYM	cis	rs7851660	0.933	rs1867277	chr9:100615914	A/G	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs6598541	0.963	rs4966024	chr15:99295570	C/T	cg13297560	chr15:99320054	IGF1R	0.45	4.56	0.42	1.52e-5	Urate levels;
THYM	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg11494091	chr17:61959527	GH2	0.96	13.8	0.82	1.99e-24	Prudent dietary pattern;
THYM	cis	rs4606347	0.789	rs61780865	chr1:66162613	T/C	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg20744362	chr22:50050164	C22orf34	0.69	6.33	0.54	7.96e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7089973	0.934	rs68085797	chr10:116632130	A/T	cg23260525	chr10:116636907	FAM160B1	0.6	5.44	0.49	4.09e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9972944	0.651	rs9897920	chr17:63832286	C/T	cg07283582	chr17:63770753	CCDC46	-0.63	-4.9	-0.45	3.94e-6	Total body bone mineral density;
THYM	cis	rs4713118	0.824	rs2179095	chr6:27750858	A/G	cg08968635	chr6:28129556	ZNF389	-0.66	-5.21	-0.47	1.07e-6	Parkinson's disease;
THYM	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.22	9.75	0.71	5.57e-16	Platelet count;
THYM	cis	rs791888	0.929	rs791887	chr10:89411554	A/G	cg13926569	chr10:89418898	PAPSS2	-0.72	-8.03	-0.64	2.59e-12	Magnesium levels;
THYM	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs16866061	1.000	rs72974263	chr2:225447371	C/T	cg12698349	chr2:225449008	CUL3	1.14	10.47	0.73	1.64e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs7968440	0.933	rs2684889	chr12:51079874	A/G	cg20014596	chr12:50898483	DIP2B	0.56	4.55	0.42	1.57e-5	Fibrinogen;
THYM	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg13393036	chr8:95962371	TP53INP1	-0.46	-4.61	-0.43	1.25e-5	Type 2 diabetes;
THYM	cis	rs56322409	0.561	rs1053905	chr10:97366364	A/G	cg00110277	chr10:97668174	C10orf131	0.58	4.91	0.45	3.72e-6	Blood metabolite levels;
THYM	cis	rs2281845	0.859	rs1325312	chr1:201079021	A/G	cg22815214	chr1:201083145	CACNA1S	0.75	7.38	0.6	5.9e-11	Permanent tooth development;
THYM	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg13695892	chr22:41940480	POLR3H	0.85	6.98	0.58	3.94e-10	Vitiligo;
THYM	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg06074448	chr4:187884817	NA	-1.02	-13.05	-0.8	6.55e-23	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs946836	0.562	rs11211632	chr1:48406460	C/T	cg18376692	chr1:48452465	NA	0.5	4.97	0.45	2.94e-6	White matter integrity;
THYM	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg03909863	chr11:638404	DRD4	-0.86	-5.99	-0.52	3.66e-8	Systemic lupus erythematosus;
THYM	cis	rs2294693	0.945	rs10947944	chr6:41004657	T/C	cg14418226	chr6:40996092	UNC5CL	0.73	5.75	0.51	1.09e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg15704280	chr7:45808275	SEPT13	-1.02	-11.33	-0.76	2.47e-19	Coronary artery disease;
THYM	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg05043794	chr9:111880884	C9orf5	-0.43	-6.21	-0.54	1.39e-8	Menarche (age at onset);
THYM	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg11245990	chr11:68621969	NA	0.56	7.1	0.59	2.22e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg14983838	chr19:29218262	NA	0.83	5.48	0.49	3.46e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg08085267	chr17:45401833	C17orf57	-0.6	-4.68	-0.43	9.36e-6	Glaucoma (primary open-angle);
THYM	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs4148883	0.689	rs1154415	chr4:99999033	T/C	cg12011299	chr4:100065546	ADH4	0.65	5.8	0.51	8.75e-8	Alcohol dependence;
THYM	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.7	5.65	0.5	1.68e-7	Menarche (age at onset);
THYM	cis	rs2859741	0.647	rs548661	chr1:37479392	T/G	cg09363841	chr1:37513479	NA	-0.63	-4.68	-0.43	9.44e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs36051895	0.695	rs11794708	chr9:5023441	G/A	cg02405213	chr9:5042618	JAK2	-1.02	-10.4	-0.73	2.31e-17	Pediatric autoimmune diseases;
THYM	cis	rs11249608	0.548	rs62393076	chr5:178450646	C/G	cg01312482	chr5:178451176	ZNF879	-0.75	-6.21	-0.54	1.37e-8	Pubertal anthropometrics;
THYM	cis	rs12681287	0.511	rs7839601	chr8:87503839	G/C	cg27223183	chr8:87520930	FAM82B	-0.71	-5.46	-0.49	3.8e-7	Caudate activity during reward;
THYM	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg07679836	chr6:33548423	BAK1	0.48	6.18	0.54	1.61e-8	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
THYM	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg00376283	chr12:123451042	ABCB9	0.91	7.77	0.62	8.95e-12	Platelet count;
THYM	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg09549813	chr16:4587862	C16orf5	-0.54	-5.72	-0.51	1.21e-7	Schizophrenia;
THYM	cis	rs10463554	0.892	rs158401	chr5:102415468	A/G	cg23492399	chr5:102201601	PAM	-0.69	-5.17	-0.47	1.27e-6	Parkinson's disease;
THYM	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.56	-5.48	-0.49	3.54e-7	Crohn's disease;
THYM	cis	rs9435341	0.965	rs3108680	chr1:107572997	T/C	cg00944433	chr1:107599041	PRMT6	-0.38	-4.55	-0.42	1.6e-5	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs861020	0.606	rs2184919	chr1:210000015	C/T	cg05527609	chr1:210001259	C1orf107	-0.85	-6.86	-0.58	6.96e-10	Orofacial clefts;
THYM	cis	rs7512552	0.839	rs834236	chr1:150362968	C/T	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs34638657	0.872	rs7192444	chr16:82180338	C/G	cg19807685	chr16:82068980	HSD17B2	0.59	4.6	0.43	1.31e-5	Lung adenocarcinoma;
THYM	cis	rs7772486	0.817	rs2748491	chr6:146327759	T/C	cg05347473	chr6:146136440	FBXO30	0.57	4.52	0.42	1.77e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12282928	1.000	rs7107408	chr11:48291558	T/A	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs2085601	0.542	rs938266	chr4:89991395	C/T	cg17769793	chr4:89976368	FAM13A	-0.59	-6.86	-0.58	6.96e-10	Hair greying;
THYM	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs10992471	1.000	rs10992471	chr9:95559505	A/G	cg14631576	chr9:95140430	CENPP	0.66	5.82	0.51	7.88e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg23758822	chr17:41437982	NA	1.28	13.46	0.81	9.79e-24	Menopause (age at onset);
THYM	cis	rs17125944	0.615	rs7146915	chr14:53316039	C/T	cg00686598	chr14:53173677	PSMC6	-0.98	-4.74	-0.44	7.58e-6	Alzheimer's disease (late onset);
THYM	cis	rs2066819	1.000	rs76430365	chr12:56699993	A/C	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg21280719	chr6:42927975	GNMT	0.53	6.95	0.58	4.64e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9905704	0.918	rs9891129	chr17:56630474	T/C	cg12560992	chr17:57184187	TRIM37	-0.68	-4.73	-0.44	7.7e-6	Testicular germ cell tumor;
THYM	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.53	5.74	0.51	1.14e-7	Mean corpuscular volume;
THYM	cis	rs4731207	0.698	rs10255209	chr7:124554927	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg11663144	chr21:46675770	NA	0.63	8.05	0.64	2.38e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg02269571	chr22:50332266	NA	-1.16	-6.15	-0.53	1.81e-8	Mean platelet volume;
THYM	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg22709100	chr7:91322751	NA	0.6	4.74	0.44	7.58e-6	Breast cancer;
THYM	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg06481639	chr22:41940642	POLR3H	0.8	5.56	0.5	2.48e-7	Vitiligo;
THYM	cis	rs2456568	0.564	rs4608039	chr11:93624799	C/G	cg09189538	chr11:93579666	C11orf90	0.57	5.28	0.48	8.03e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg13695892	chr22:41940480	POLR3H	0.95	7.5	0.61	3.34e-11	Vitiligo;
THYM	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg03709012	chr19:19516395	GATAD2A	-0.74	-5.8	-0.51	8.48e-8	Tonsillectomy;
THYM	cis	rs9287719	0.674	rs6432130	chr2:10821557	T/C	cg02196655	chr2:10830764	NOL10	0.49	4.99	0.46	2.77e-6	Prostate cancer;
THYM	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg18758796	chr5:131593413	PDLIM4	-0.5	-4.77	-0.44	6.69e-6	Breast cancer;
THYM	cis	rs790123	0.842	rs2668339	chr3:122392433	G/C	cg15604389	chr3:122379662	NA	0.52	4.8	0.44	5.82e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs7546094	1.000	rs6691932	chr1:113144263	T/C	cg22162597	chr1:113214053	CAPZA1	0.48	4.91	0.45	3.81e-6	Platelet distribution width;
THYM	cis	rs2806561	0.704	rs588387	chr1:23523689	A/G	cg19743168	chr1:23544995	NA	0.62	6.31	0.54	8.74e-9	Height;
THYM	cis	rs2274459	0.908	rs34472165	chr6:33750031	A/G	cg06253072	chr6:33679850	C6orf125	0.52	4.65	0.43	1.07e-5	Obesity (extreme);
THYM	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg17074396	chr22:49843754	NA	-0.4	-4.62	-0.43	1.22e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06634786	chr22:41940651	POLR3H	-0.77	-5.78	-0.51	9.34e-8	Vitiligo;
THYM	cis	rs478304	0.651	rs948494	chr11:65552118	G/A	cg17480646	chr11:65405466	SIPA1	-0.94	-8.85	-0.67	4.72e-14	Acne (severe);
THYM	cis	rs1003719	0.751	rs7280371	chr21:38450008	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	8.1	0.64	1.86e-12	Monocyte percentage of white cells;
THYM	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg17054759	chr22:49844102	NA	-0.53	-4.64	-0.43	1.13e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs35125029	0.540	rs9973511	chr2:144254140	A/G	cg17056048	chr2:144271431	ARHGAP15	-0.54	-5.17	-0.47	1.31e-6	Morning vs. evening chronotype;
THYM	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg13609457	chr4:120235615	NA	0.5	4.76	0.44	6.95e-6	Corneal astigmatism;
THYM	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg09549813	chr16:4587862	C16orf5	-0.53	-5.22	-0.47	1.06e-6	Schizophrenia;
THYM	cis	rs6964587	0.610	rs6950682	chr7:91464218	G/T	cg22709100	chr7:91322751	NA	0.63	4.63	0.43	1.18e-5	Breast cancer;
THYM	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg05660106	chr1:15850417	CASP9	0.76	6.27	0.54	1.06e-8	Systolic blood pressure;
THYM	cis	rs10411161	0.702	rs10402630	chr19:52384570	G/A	cg25361850	chr19:52391789	ZNF577	0.71	4.99	0.46	2.69e-6	Breast cancer;
THYM	cis	rs367615	0.704	rs60538082	chr5:108829101	A/G	cg17395555	chr5:108820864	NA	0.76	9.36	0.69	3.82e-15	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg02038168	chr22:39784481	NA	-0.6	-4.99	-0.46	2.77e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2903698	0.585	rs7662152	chr4:76363040	G/A	cg03209871	chr4:76438412	RCHY1;THAP6	0.44	5.09	0.46	1.83e-6	Prion diseases;
THYM	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg06636551	chr8:101224915	SPAG1	-0.67	-6.53	-0.56	3.26e-9	Atrioventricular conduction;
THYM	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg02753203	chr1:228287806	NA	0.76	6.55	0.56	2.91e-9	Diastolic blood pressure;
THYM	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	4.59	0.43	1.35e-5	Aortic root size;
THYM	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs56775891	1.000	rs56775891	chr18:77575613	C/T	cg25357022	chr18:77495084	CTDP1	-0.68	-4.54	-0.42	1.66e-5	Schizophrenia;
THYM	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg26384229	chr12:38710491	ALG10B	0.7	5.28	0.48	8.04e-7	Heart rate;
THYM	trans	rs11175492	0.920	rs11175499	chr12:65041494	G/A	cg12514734	chr12:3216258	TSPAN9	1.59	7.44	0.61	4.38e-11	Platelet count;
THYM	cis	rs3820068	0.580	rs61169376	chr1:16003832	A/G	cg27534772	chr1:16042836	PLEKHM2	0.54	5.91	0.52	5.23e-8	Systolic blood pressure;
THYM	cis	rs11771526	0.901	rs62456038	chr7:32288663	G/A	cg13207630	chr7:32358064	NA	0.84	5.28	0.48	8.15e-7	Body mass index;
THYM	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg10792982	chr14:105748885	BRF1	-0.72	-7.35	-0.6	6.8e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11170631	0.504	rs10128880	chr12:53927783	T/C	cg16917193	chr12:54089295	NA	0.7	6.18	0.54	1.6e-8	Height;
THYM	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg12863693	chr15:85201151	NMB	0.62	5.57	0.5	2.41e-7	Schizophrenia;
THYM	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	6.15	0.53	1.83e-8	Platelet count;
THYM	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03452623	chr4:187889614	NA	-1.15	-17.53	-0.87	1.58e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7614311	0.681	rs73117083	chr3:63948455	G/C	cg22134162	chr3:63841271	THOC7	-0.56	-6.75	-0.57	1.18e-9	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	19.0	0.89	4.01e-34	Chronic sinus infection;
THYM	cis	rs10752881	1.000	rs10911185	chr1:182971747	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.62	5.03	0.46	2.29e-6	Colorectal cancer;
THYM	cis	rs807669	0.525	rs2073740	chr22:19196112	A/C	cg02655711	chr22:19163373	SLC25A1	-0.58	-6.28	-0.54	1.01e-8	Metabolite levels;
THYM	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs4930776	1.000	rs10774351	chr12:5767119	G/A	cg02086166	chr12:5775618	ANO2	-0.58	-5.71	-0.51	1.3e-7	Plasma clusterin levels;
THYM	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg27129171	chr3:47204927	SETD2	0.77	7.65	0.62	1.67e-11	Colorectal cancer;
THYM	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg18681998	chr4:17616180	MED28	0.82	6.96	0.58	4.31e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9970807	0.688	rs6670090	chr1:56932594	G/A	cg11959316	chr1:57001742	PPAP2B	-0.63	-4.88	-0.45	4.29e-6	Myocardial infarction;Coronary artery disease;
THYM	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg21028142	chr17:79581711	NPLOC4	-0.61	-6.22	-0.54	1.33e-8	Eye color traits;
THYM	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg18681998	chr4:17616180	MED28	0.85	7.64	0.62	1.72e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs10979	1.000	rs9321923	chr6:143897206	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs11677370	0.574	rs11686118	chr2:3854938	C/T	cg07307994	chr2:3828216	NA	-0.68	-4.47	-0.42	2.2e-5	Type 2 diabetes;
THYM	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg00376283	chr12:123451042	ABCB9	0.94	7.65	0.62	1.62e-11	Platelet count;
THYM	cis	rs34734847	1.000	rs56179458	chr12:121157535	G/A	cg21892295	chr12:121157589	UNC119B	-0.66	-7.5	-0.61	3.43e-11	Mean corpuscular volume;
THYM	cis	rs4930776	1.000	rs4619228	chr12:5766236	A/G	cg02086166	chr12:5775618	ANO2	-0.58	-5.71	-0.51	1.3e-7	Plasma clusterin levels;
THYM	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.65	-4.7	-0.43	8.92e-6	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs34526934	0.566	rs9141	chr2:177037970	T/C	cg14324370	chr2:177042789	NA	-0.7	-5.88	-0.52	5.98e-8	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs7582180	0.675	rs4851313	chr2:101029002	A/G	cg08017756	chr2:100939284	LONRF2	0.68	6.87	0.58	6.73e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg26031613	chr14:104095156	KLC1	0.7	4.57	0.42	1.47e-5	Body mass index;
THYM	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg20203395	chr5:56204925	C5orf35	-0.65	-4.53	-0.42	1.68e-5	Initial pursuit acceleration;
THYM	cis	rs2075230	0.705	rs2543554	chr17:7548028	C/T	cg27413385	chr17:7515425	FXR2	-0.35	-4.92	-0.45	3.63e-6	Hormone measurements;
THYM	cis	rs10504073	0.584	rs11784268	chr8:49956339	T/G	cg00325661	chr8:49890786	NA	1.07	10.28	0.73	4.26e-17	Blood metabolite ratios;
THYM	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg08999081	chr20:33150536	PIGU	0.8	7.83	0.63	6.81e-12	Coronary artery disease;
THYM	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg02018176	chr4:1364513	KIAA1530	0.5	4.57	0.42	1.48e-5	Obesity-related traits;
THYM	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg14829155	chr15:31115871	NA	-0.58	-5.13	-0.47	1.51e-6	Huntington's disease progression;
THYM	cis	rs7107174	1.000	rs10899470	chr11:78020052	C/T	cg19901956	chr11:77921274	USP35	-0.69	-5.3	-0.48	7.42e-7	Testicular germ cell tumor;
THYM	cis	rs2742234	0.590	rs1254960	chr10:43699657	C/T	cg06632098	chr10:43605906	RET	0.79	5.1	0.46	1.73e-6	Hirschsprung disease;
THYM	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg24209194	chr3:40518798	ZNF619	-0.69	-5.98	-0.52	3.94e-8	Renal cell carcinoma;
THYM	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg20503657	chr10:835505	NA	-1.17	-8.29	-0.65	7.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs289828	1.000	rs387297	chr2:152130045	C/G	cg05960677	chr2:152117363	RBM43	0.59	5.63	0.5	1.84e-7	Blood protein levels;
THYM	cis	rs988913	0.957	rs9475100	chr6:54840233	C/T	cg18532076	chr6:54711417	FAM83B	0.52	4.95	0.45	3.25e-6	Menarche (age at onset);
THYM	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg07424592	chr7:64974309	NA	-1.04	-5.27	-0.48	8.52e-7	Diabetic kidney disease;
THYM	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg08439880	chr3:133502540	NA	0.69	5.49	0.49	3.29e-7	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg04362960	chr10:104952993	NT5C2	0.6	5.11	0.46	1.66e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	8.57	0.66	1.88e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9796	0.562	rs3959554	chr15:41443924	A/G	cg21153102	chr15:41252147	NA	0.67	5.56	0.5	2.43e-7	Menopause (age at onset);
THYM	cis	rs16857609	0.564	rs13406698	chr2:218283085	A/G	cg15335768	chr2:218268053	DIRC3	-0.51	-7.33	-0.6	7.45e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	cis	rs673253	0.662	rs61769642	chr1:44051630	G/A	cg24466421	chr1:44070974	PTPRF	-0.6	-5.3	-0.48	7.53e-7	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.67	-0.56	1.7e-9	Chronic sinus infection;
THYM	cis	rs2213920	0.679	rs4978638	chr9:118232778	G/C	cg13918206	chr9:118159781	DEC1	0.8	4.53	0.42	1.74e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg17178900	chr1:205818956	PM20D1	0.97	10.25	0.72	4.73e-17	Menarche (age at onset);
THYM	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg12386194	chr3:101231763	SENP7	0.94	7.54	0.61	2.81e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg22875332	chr1:76189707	ACADM	0.87	11.1	0.75	7.71e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs10929159	0.928	rs6749436	chr2:236919992	A/G	cg14895183	chr2:236924282	AGAP1	0.54	4.67	0.43	9.81e-6	Parkinson's disease;
THYM	cis	rs4888262	0.526	rs8062959	chr16:74627628	T/C	cg01733217	chr16:74700730	RFWD3	0.82	8.54	0.66	2.2e-13	Testicular germ cell tumor;
THYM	cis	rs12950390	0.512	rs56254413	chr17:45857545	G/T	cg03474202	chr17:45855739	NA	-0.71	-4.78	-0.44	6.29e-6	IgG glycosylation;
THYM	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg07570687	chr10:102243282	WNT8B	0.74	6.43	0.55	5.18e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7224737	1.000	rs739636	chr17:40281063	T/G	cg00647820	chr17:40259828	DHX58	-0.68	-5.06	-0.46	2.03e-6	Fibrinogen levels;
THYM	cis	rs13064411	0.660	rs3829889	chr3:113015464	G/A	cg18753928	chr3:113234510	CCDC52	-0.85	-7.39	-0.6	5.59e-11	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs554111	0.656	rs12021529	chr1:21306161	C/T	cg00373020	chr1:21041521	KIF17	0.53	4.57	0.42	1.47e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs73086581	0.838	rs11906481	chr20:4028706	C/T	cg02187196	chr20:3869020	PANK2	0.46	5.15	0.47	1.39e-6	Response to antidepressants in depression;
THYM	cis	rs4930103	0.904	rs59121562	chr11:2025034	A/T	cg03175030	chr11:2018143	H19;MIR675	-0.45	-4.86	-0.45	4.62e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs7681440	0.543	rs2736997	chr4:90754557	G/A	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg13695892	chr22:41940480	POLR3H	0.86	6.33	0.54	8.08e-9	Vitiligo;
THYM	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs2859741	0.528	rs6686296	chr1:37489380	G/T	cg09363841	chr1:37513479	NA	0.66	5.21	0.47	1.1e-6	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs6570726	0.935	rs395948	chr6:145820185	G/A	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6939532	0.761	rs3799378	chr6:26404374	C/T	cg14345882	chr6:26364793	BTN3A2	-0.4	-4.64	-0.43	1.13e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg04025307	chr7:1156635	C7orf50	0.63	5.82	0.51	8.1e-8	Longevity;Endometriosis;
THYM	cis	rs113835537	0.529	rs57207756	chr11:66270360	C/T	cg10315249	chr11:66235081	PELI3	0.42	4.53	0.42	1.69e-5	Airway imaging phenotypes;
THYM	cis	rs2903698	0.565	rs13103482	chr4:76444183	A/G	cg03209871	chr4:76438412	RCHY1;THAP6	0.39	4.59	0.43	1.33e-5	Prion diseases;
THYM	cis	rs4930776	0.966	rs862395	chr12:5769537	G/A	cg02086166	chr12:5775618	ANO2	0.57	5.51	0.49	3.1e-7	Plasma clusterin levels;
THYM	cis	rs10788264	0.621	rs9633733	chr10:124056546	A/G	cg09507567	chr10:124027408	NA	-0.47	-4.58	-0.43	1.39e-5	Total body bone mineral density;
THYM	cis	rs7084402	0.905	rs1896244	chr10:60276182	A/G	cg09696939	chr10:60272079	BICC1	0.47	5.47	0.49	3.63e-7	Refractive error;
THYM	cis	rs28374715	0.733	rs9568	chr15:41573612	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.08	-10.98	-0.75	1.37e-18	Ulcerative colitis;
THYM	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg24874828	chr4:187887005	NA	-0.72	-7.22	-0.6	1.26e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg07570687	chr10:102243282	WNT8B	0.84	8.13	0.64	1.59e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg19761014	chr17:28927070	LRRC37B2	0.8	4.73	0.44	7.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg18252515	chr7:66147081	NA	-0.88	-6.71	-0.57	1.4e-9	Corneal structure;
THYM	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg14004847	chr7:1930337	MAD1L1	-0.65	-5.29	-0.48	7.86e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7809950	0.861	rs2701682	chr7:107295835	G/A	cg23024343	chr7:107201750	COG5	0.95	7.84	0.63	6.64e-12	Coronary artery disease;
THYM	cis	rs6546324	0.625	rs4671813	chr2:67841835	A/T	cg18237512	chr2:67827392	NA	-0.8	-4.77	-0.44	6.69e-6	Endometriosis;
THYM	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs2898681	0.770	rs10032190	chr4:53734940	C/A	cg00812761	chr4:53799391	SCFD2	-0.5	-4.47	-0.42	2.19e-5	Optic nerve measurement (cup area);
THYM	cis	rs2109514	1.000	rs3919515	chr7:116151784	C/G	cg12739419	chr7:116140593	CAV2	0.48	4.65	0.43	1.07e-5	Prevalent atrial fibrillation;
THYM	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg17063962	chr7:91808500	NA	1.12	12.78	0.8	2.4e-22	Breast cancer;
THYM	cis	rs4285028	0.699	rs1574115	chr3:121469225	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.79	-5.64	-0.5	1.78e-7	Multiple sclerosis;
THYM	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg06238570	chr21:40685208	BRWD1	0.87	6.38	0.55	6.56e-9	Cognitive function;
THYM	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg09085632	chr11:111637200	PPP2R1B	1.22	14.87	0.84	1.51e-26	Primary sclerosing cholangitis;
THYM	cis	rs1371867	0.846	rs1660347	chr8:101314980	G/A	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs2279817	0.863	rs6586569	chr1:18027377	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.74	4.64	0.43	1.13e-5	Neuroticism;
THYM	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg00376283	chr12:123451042	ABCB9	0.77	5.12	0.47	1.59e-6	Neutrophil percentage of white cells;
THYM	cis	rs4273100	0.541	rs7501702	chr17:19293727	C/T	cg25447019	chr17:19030144	GRAPL	0.75	5.9	0.52	5.57e-8	Schizophrenia;
THYM	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg24209194	chr3:40518798	ZNF619	-0.65	-5.45	-0.49	4.01e-7	Renal cell carcinoma;
THYM	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7809950	1.000	rs2520268	chr7:107191161	T/A	cg23024343	chr7:107201750	COG5	-0.96	-8.71	-0.67	9.41e-14	Coronary artery disease;
THYM	cis	rs3862030	0.720	rs3740415	chr10:104232716	G/A	cg00122347	chr10:104236741	TMEM180	0.48	7.03	0.59	3.09e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg05754148	chr16:3507555	NAT15	0.92	8.27	0.65	8.27e-13	Tuberculosis;
THYM	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.97	8.9	0.67	3.72e-14	Chronic sinus infection;
THYM	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg13695892	chr22:41940480	POLR3H	-1.03	-8.34	-0.65	5.73e-13	Vitiligo;
THYM	cis	rs7192750	0.586	rs8051038	chr16:71870700	G/A	cg06353428	chr16:71660113	MARVELD3	0.76	5.51	0.49	3.1e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg17063962	chr7:91808500	NA	1.14	11.07	0.75	8.88e-19	Breast cancer;
THYM	cis	rs853679	1.000	rs10456362	chr6:28221816	A/G	cg12963246	chr6:28129442	ZNF389	-0.67	-4.72	-0.44	8.12e-6	Depression;
THYM	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg27535305	chr1:53392650	SCP2	-0.54	-6.17	-0.53	1.67e-8	Monocyte count;
THYM	cis	rs679087	0.640	rs79708380	chr12:29909457	G/A	cg14258853	chr12:29935411	TMTC1	-0.58	-4.71	-0.43	8.52e-6	Schizophrenia;
THYM	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg08704250	chr15:31115839	NA	-0.54	-6.18	-0.54	1.57e-8	Huntington's disease progression;
THYM	cis	rs921968	0.541	rs2241527	chr2:219537224	A/G	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs79349575	0.778	rs12950328	chr17:46967061	C/T	cg26022315	chr17:47021804	SNF8	0.5	4.64	0.43	1.11e-5	Type 2 diabetes;
THYM	cis	rs939574	1.000	rs6712442	chr2:220117333	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.23	-5.59	-0.5	2.13e-7	Platelet distribution width;
THYM	cis	rs6893300	0.524	rs62404348	chr5:179146026	G/A	cg14593053	chr5:179126677	CANX	0.62	4.75	0.44	7.1e-6	Resting heart rate;
THYM	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.77	5.81	0.51	8.38e-8	Cognitive test performance;
THYM	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg18230493	chr5:56204884	C5orf35	-0.9	-6.6	-0.56	2.34e-9	Initial pursuit acceleration;
THYM	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg19747945	chr6:42946146	PEX6	-0.33	-4.9	-0.45	4e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs8050907	0.590	rs10500325	chr16:4553192	A/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.25	4.93	0.45	3.48e-6	Obesity-related traits;
THYM	cis	rs3126085	0.935	rs3120661	chr1:152294402	A/G	cg26020982	chr1:152196106	HRNR	-0.35	-4.96	-0.45	3.02e-6	Atopic dermatitis;
THYM	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg09021430	chr5:549028	NA	-0.7	-4.45	-0.42	2.34e-5	Lung disease severity in cystic fibrosis;
THYM	cis	rs931812	0.895	rs4734493	chr8:101902169	C/T	cg07239293	chr8:101170671	SPAG1	-0.68	-4.49	-0.42	2e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg21775007	chr8:11205619	TDH	-0.64	-4.85	-0.45	4.88e-6	Retinal vascular caliber;
THYM	cis	rs747334	0.777	rs10881870	chr10:92718286	G/T	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs2637266	0.739	rs2395404	chr10:78380513	G/T	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.18e-11	Pulmonary function;
THYM	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg07936489	chr17:37558343	FBXL20	0.85	5.64	0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg17063962	chr7:91808500	NA	-1.1	-12.47	-0.79	1.01e-21	Breast cancer;
THYM	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg22841779	chr14:105766346	BRF1	-0.48	-6.0	-0.52	3.55e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs3820068	0.626	rs11580170	chr1:15909744	C/T	cg05660106	chr1:15850417	CASP9	0.92	7.26	0.6	1.08e-10	Systolic blood pressure;
THYM	cis	rs4866334	1.000	rs77766662	chr5:18485586	A/C	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs55871839	0.536	rs10091451	chr8:59814953	A/T	cg07426533	chr8:59803705	TOX	-0.59	-5.67	-0.5	1.54e-7	Pneumonia;
THYM	cis	rs7246967	0.608	rs370734	chr19:23012586	C/G	cg05241461	chr19:22816980	ZNF492	0.54	4.53	0.42	1.74e-5	Bronchopulmonary dysplasia;
THYM	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg19774624	chr17:42201019	HDAC5	0.68	5.79	0.51	9.03e-8	Total body bone mineral density;
THYM	cis	rs8048589	0.898	rs11648235	chr16:12181079	C/T	cg02910054	chr16:12241554	SNX29	0.72	5.87	0.52	6.29e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21582582	chr3:182698605	DCUN1D1	0.81	7.13	0.59	1.93e-10	Intelligence (multi-trait analysis);
THYM	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.71	-5.05	-0.46	2.14e-6	Body mass index;
THYM	cis	rs2294693	0.580	rs4711653	chr6:40942996	T/C	cg21128951	chr6:40996213	UNC5CL	0.64	4.59	0.43	1.37e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs3126085	0.866	rs3126067	chr1:152276889	A/G	cg26020982	chr1:152196106	HRNR	-0.35	-4.79	-0.44	6.13e-6	Atopic dermatitis;
THYM	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg23750338	chr8:142222470	SLC45A4	0.52	4.87	0.45	4.48e-6	Immature fraction of reticulocytes;
THYM	cis	rs9500256	0.966	rs1322446	chr6:58311950	C/T	cg17976157	chr6:58263193	GUSBL2	-0.63	-5.05	-0.46	2.15e-6	Eosinophilic esophagitis (pediatric);
THYM	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg06028605	chr16:24865363	SLC5A11	-0.55	-5.15	-0.47	1.41e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.59	-4.47	-0.42	2.18e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs17331151	0.505	rs35371456	chr3:52563462	C/T	cg17372223	chr3:52568218	NT5DC2	0.61	4.96	0.45	3.02e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs892961	0.932	rs7223768	chr17:75410521	G/A	cg05865280	chr17:75406074	SEPT9	0.5	8.21	0.64	1.1e-12	Airflow obstruction;
THYM	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg26314531	chr2:26401878	FAM59B	-0.74	-5.05	-0.46	2.1e-6	Gut microbiome composition (summer);
THYM	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg18252515	chr7:66147081	NA	-0.69	-5.46	-0.49	3.79e-7	Aortic root size;
THYM	cis	rs9914544	0.545	rs12942794	chr17:18767217	A/C	cg26378065	chr17:18585709	ZNF286B	0.6	4.71	0.43	8.56e-6	Educational attainment (years of education);
THYM	cis	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg00495681	chr13:53174319	NA	-0.73	-6.69	-0.57	1.57e-9	Lewy body disease;
THYM	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg26818010	chr10:134567672	INPP5A	-0.83	-6.8	-0.57	9.14e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg13319975	chr6:146136371	FBXO30	0.65	5.22	0.47	1.05e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg10360139	chr7:1886902	MAD1L1	-0.61	-5.17	-0.47	1.3e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6087990	0.735	rs6058883	chr20:31365719	C/T	cg13636640	chr20:31349939	DNMT3B	-0.9	-9.2	-0.69	8.4e-15	Ulcerative colitis;
THYM	cis	rs7607369	0.526	rs4674322	chr2:219513782	C/T	cg02176678	chr2:219576539	TTLL4	0.67	4.84	0.45	4.93e-6	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.35	-0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg08132940	chr7:1081526	C7orf50	-0.77	-5.38	-0.48	5.35e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs4731207	0.698	rs13228116	chr7:124480506	A/G	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7107174	0.786	rs2450134	chr11:77925778	A/G	cg02023728	chr11:77925099	USP35	0.67	6.24	0.54	1.22e-8	Testicular germ cell tumor;
THYM	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.97	8.79	0.67	6.29e-14	Chronic sinus infection;
THYM	cis	rs1018836	0.923	rs10956748	chr8:91621537	T/A	cg16814680	chr8:91681699	NA	-0.85	-7.17	-0.59	1.59e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.93	6.61	0.56	2.22e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs877282	0.898	rs12354872	chr10:763362	G/A	cg10556349	chr10:835070	NA	-0.78	-5.06	-0.46	2.06e-6	Uric acid levels;
THYM	cis	rs28595532	0.920	rs114581578	chr4:119756404	C/T	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs17433780	0.808	rs1074541	chr1:89509499	A/G	cg09516651	chr1:89888402	LOC400759	0.97	8.07	0.64	2.12e-12	Carotid intima media thickness;
THYM	cis	rs4803468	1.000	rs2304242	chr19:41944616	G/T	cg09537434	chr19:41945824	ATP5SL	1.02	8.94	0.68	3.1e-14	Height;
THYM	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg15691649	chr6:25882328	NA	-0.83	-6.27	-0.54	1.04e-8	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.28	6.37	0.55	6.77e-9	Obesity-related traits;
THYM	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg13319975	chr6:146136371	FBXO30	-0.72	-6.02	-0.53	3.33e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.09	-0.46	1.83e-6	Life satisfaction;
THYM	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg10334053	chr1:2078117	PRKCZ	-0.5	-5.01	-0.46	2.48e-6	Height;
THYM	cis	rs6930083	0.510	rs4713994	chr6:36621533	A/G	cg08179530	chr6:36648295	CDKN1A	-0.84	-5.86	-0.52	6.58e-8	Coronary artery disease;
THYM	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg03388043	chr17:80084554	CCDC57	-0.66	-5.66	-0.5	1.61e-7	Life satisfaction;
THYM	cis	rs1351164	0.947	rs57004880	chr2:218272581	A/C	cg15335768	chr2:218268053	DIRC3	-0.41	-5.61	-0.5	2e-7	Height;
THYM	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg14186256	chr22:23484241	RTDR1	0.96	9.56	0.7	1.46e-15	Bone mineral density;
THYM	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg02574844	chr11:5959923	NA	-0.53	-4.67	-0.43	9.86e-6	DNA methylation (variation);
THYM	cis	rs4919694	1.000	rs12253284	chr10:104665145	G/C	cg04362960	chr10:104952993	NT5C2	1.06	6.61	0.56	2.24e-9	Arsenic metabolism;
THYM	cis	rs6435161	0.919	rs7566220	chr2:203594559	A/G	cg18429434	chr2:203499731	FAM117B	-0.79	-5.3	-0.48	7.37e-7	Total cholesterol levels;
THYM	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11048434	0.761	rs1805723	chr12:9142297	T/C	cg26114124	chr12:9217669	LOC144571	0.47	4.73	0.44	7.93e-6	Sjögren's syndrome;
THYM	cis	rs7705042	0.865	rs4912805	chr5:141493685	A/G	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.57	-0.5	2.4e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg03609598	chr5:56110824	MAP3K1	-0.67	-4.7	-0.43	8.63e-6	Coronary artery disease;
THYM	cis	rs9467711	0.591	rs35902160	chr6:26128538	C/G	cg01386294	chr6:25732093	NA	0.91	4.83	0.44	5.33e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6988636	1.000	rs28624331	chr8:124190768	G/A	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs12458462	0.851	rs3859317	chr18:77443093	A/C	cg11879182	chr18:77439856	CTDP1	0.81	7.86	0.63	6.03e-12	Monocyte count;
THYM	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.929	rs17424474	chr20:43804797	C/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg15744005	chr10:104629667	AS3MT	-0.8	-7.57	-0.61	2.4e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg07606381	chr6:8435919	SLC35B3	0.62	4.64	0.43	1.13e-5	Motion sickness;
THYM	trans	rs4650994	1.000	rs4650995	chr1:178517316	C/T	cg05059571	chr16:84539110	KIAA1609	-0.75	-7.95	-0.63	3.83e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg26116260	chr4:7069785	GRPEL1	1.11	9.86	0.71	3.33e-16	Monocyte percentage of white cells;
THYM	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2235649	0.663	rs113908028	chr16:1848915	G/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.93	-0.45	3.45e-6	Blood metabolite levels;
THYM	cis	rs4589258	1.000	rs4615986	chr11:90502456	G/A	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.74	-0.44	7.39e-6	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs11711311	0.736	rs2278941	chr3:113350508	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.04	-0.46	2.21e-6	IgG glycosylation;
THYM	cis	rs6430585	1.000	rs73958618	chr2:136500475	A/G	cg20242066	chr2:136595261	LCT	0.51	5.19	0.47	1.2e-6	Corneal structure;
THYM	cis	rs2219968	0.923	rs7822053	chr8:78979111	A/G	cg00738934	chr8:78996279	NA	0.84	9.0	0.68	2.25e-14	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg06636001	chr8:8085503	FLJ10661	0.7	5.97	0.52	4e-8	Joint mobility (Beighton score);
THYM	cis	rs56775891	0.959	rs11663602	chr18:77578191	G/T	cg26740109	chr18:77585428	NA	-0.71	-5.45	-0.49	4e-7	Schizophrenia;
THYM	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg23583168	chr7:148888333	NA	-1.02	-14.09	-0.82	5.29e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg02825527	chr7:2087843	MAD1L1	-0.75	-4.96	-0.45	3.1e-6	Bipolar disorder;
THYM	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs240764	0.658	rs4571568	chr6:101223955	T/A	cg21058520	chr6:100914733	NA	0.6	5.29	0.48	7.79e-7	Neuroticism;
THYM	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs490234	0.676	rs4838263	chr9:128225199	G/A	cg14078157	chr9:128172775	NA	-0.79	-6.43	-0.55	5.01e-9	Mean arterial pressure;
THYM	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg04976154	chr16:1532411	NA	-0.3	-4.87	-0.45	4.43e-6	Blood protein levels;
THYM	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg03517284	chr6:25882590	NA	0.71	5.64	0.5	1.75e-7	Schizophrenia;
THYM	cis	rs7927771	0.524	rs10838746	chr11:47706291	A/G	cg20307385	chr11:47447363	PSMC3	0.6	4.51	0.42	1.87e-5	Subjective well-being;
THYM	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg21475434	chr5:93447410	FAM172A	-0.93	-5.76	-0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs4595586	0.525	rs12818844	chr12:39423806	A/G	cg26384229	chr12:38710491	ALG10B	0.72	5.48	0.49	3.52e-7	Morning vs. evening chronotype;
THYM	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg20999797	chr1:1681921	NA	0.49	5.41	0.48	4.8e-7	Body mass index;
THYM	cis	rs3772130	0.962	rs6791046	chr3:121394707	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.77	4.71	0.44	8.33e-6	Cognitive performance;
THYM	cis	rs1172149	0.559	rs17417252	chr1:205216110	A/G	cg17889831	chr1:205181581	DSTYK	0.43	4.83	0.44	5.25e-6	Platelet distribution width;
THYM	cis	rs7211079	0.879	rs72852522	chr17:78131490	C/T	cg09238746	chr17:78121135	EIF4A3	-0.78	-4.91	-0.45	3.81e-6	Myocardial infarction;
THYM	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4766566	0.704	rs10849931	chr12:111753808	T/C	cg10833066	chr12:111807467	FAM109A	0.66	8.24	0.65	9.52e-13	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
THYM	cis	rs9399401	0.601	rs171891	chr6:142850612	G/A	cg04461802	chr6:142623433	GPR126	0.59	5.18	0.47	1.24e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs4072705	0.967	rs6478677	chr9:127422179	C/G	cg13476313	chr9:127244764	NR5A1	0.32	4.75	0.44	7.27e-6	Menarche (age at onset);
THYM	cis	rs2249694	0.960	rs6537613	chr10:135412414	T/G	cg20169779	chr10:135381914	SYCE1	-0.55	-4.5	-0.42	1.91e-5	Obesity-related traits;
THYM	cis	rs13177918	0.677	rs4541646	chr5:149822918	G/A	cg14059543	chr5:149831962	NA	-1.0	-7.6	-0.61	2.11e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs11771526	0.901	rs7357136	chr7:32302338	G/T	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg22683308	chr4:1340831	KIAA1530	-0.64	-5.07	-0.46	1.99e-6	Longevity;
THYM	cis	rs4595586	0.545	rs12813151	chr12:39363405	C/G	cg26384229	chr12:38710491	ALG10B	-0.7	-5.29	-0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs3825942	1.000	rs8034017	chr15:74222043	A/G	cg23484268	chr15:74220776	LOXL1	0.49	4.71	0.43	8.5e-6	Glaucoma (exfoliation);
THYM	cis	rs60695258	0.572	rs375795	chr4:87972465	C/T	cg10685359	chr4:87814065	C4orf36	-0.46	-5.76	-0.51	1.04e-7	Hematocrit;
THYM	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg02466173	chr16:30829666	NA	-0.55	-4.67	-0.43	9.76e-6	Dementia with Lewy bodies;
THYM	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg02038168	chr22:39784481	NA	0.7	5.67	0.5	1.51e-7	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg13395646	chr4:1353034	KIAA1530	0.59	5.31	0.48	7.33e-7	Obesity-related traits;
THYM	cis	rs9814567	0.762	rs13070654	chr3:134219348	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.71	6.01	0.53	3.37e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg04455712	chr21:45112962	RRP1B	0.51	4.72	0.44	8.23e-6	Mean corpuscular volume;
THYM	cis	rs2708977	0.932	rs12329128	chr2:97284917	G/A	cg01950434	chr2:97203154	ARID5A	0.6	4.83	0.44	5.32e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs728616	0.867	rs17883671	chr10:81695193	C/T	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6570726	0.967	rs373704	chr6:145860618	C/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.8	-0.51	8.64e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1371867	0.875	rs7830342	chr8:101327738	T/A	cg00191853	chr8:101177733	SPAG1	-0.51	-5.03	-0.46	2.29e-6	Atrioventricular conduction;
THYM	cis	rs790123	0.842	rs2650957	chr3:122396097	C/G	cg17380795	chr3:122379686	NA	0.55	4.95	0.45	3.22e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg02176678	chr2:219576539	TTLL4	0.7	7.0	0.58	3.61e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9677476	0.779	rs7569597	chr2:232102754	G/A	cg07929768	chr2:232055508	NA	0.59	5.02	0.46	2.45e-6	Food antigen IgG levels;
THYM	cis	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg09307838	chr4:120376055	NA	0.78	5.89	0.52	5.7e-8	Corneal astigmatism;
THYM	cis	rs34779708	0.966	rs4934537	chr10:35441512	C/T	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs11025559	0.773	rs16906274	chr11:20470142	T/C	cg19653624	chr11:20408972	PRMT3	-0.75	-5.13	-0.47	1.56e-6	Pursuit maintenance gain;
THYM	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg04248312	chr19:17393744	ANKLE1	-0.96	-12.68	-0.79	3.82e-22	Systemic lupus erythematosus;
THYM	cis	rs9902453	0.808	rs8069669	chr17:28239502	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	6.41	0.55	5.47e-9	Coffee consumption (cups per day);
THYM	cis	rs4930776	0.966	rs440737	chr12:5769385	G/C	cg02086166	chr12:5775618	ANO2	0.57	5.51	0.49	3.1e-7	Plasma clusterin levels;
THYM	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2913737	0.563	rs2963669	chr5:175923354	A/G	cg27658698	chr5:175955578	RNF44	-0.6	-4.69	-0.43	9.27e-6	Obesity-related traits;
THYM	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg15921436	chr17:44337874	NA	0.91	6.52	0.56	3.43e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7524258	0.868	rs4908448	chr1:7269283	A/G	cg07173049	chr1:7289937	CAMTA1	-0.57	-4.83	-0.44	5.13e-6	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg14972814	chr11:95582409	MTMR2	-0.58	-5.31	-0.48	7.17e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	4.63	0.43	1.14e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs17401966	0.931	rs1555849	chr1:10400602	G/T	cg19773385	chr1:10388646	KIF1B	0.6	4.7	0.43	8.88e-6	Hepatocellular carcinoma;
THYM	cis	rs1395	0.778	rs60631624	chr2:27497815	T/G	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.3	-0.48	7.55e-7	Blood metabolite levels;
THYM	cis	rs354225	0.544	rs4641979	chr2:54811917	G/A	cg23486701	chr2:54789491	SPTBN1	0.36	4.96	0.45	3.11e-6	Schizophrenia;
THYM	cis	rs3126085	0.560	rs12568784	chr1:152323132	G/T	cg10321714	chr1:152280068	FLG	-0.77	-5.31	-0.48	7.2e-7	Atopic dermatitis;
THYM	cis	rs829883	0.714	rs249847	chr12:98867716	C/T	cg25150519	chr12:98850993	NA	0.51	5.07	0.46	1.97e-6	Colorectal adenoma (advanced);
THYM	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.01	-9.8	-0.71	4.35e-16	Primary sclerosing cholangitis;
THYM	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg18301423	chr5:131593218	PDLIM4	0.52	4.91	0.45	3.79e-6	Acylcarnitine levels;
THYM	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg27535305	chr1:53392650	SCP2	-0.49	-5.46	-0.49	3.82e-7	Monocyte count;
THYM	cis	rs6754311	0.517	rs1469995	chr2:136542559	G/A	cg20242066	chr2:136595261	LCT	0.54	5.48	0.49	3.49e-7	Mosquito bite size;
THYM	cis	rs56309584	0.673	rs11658322	chr17:8171329	T/C	cg08322244	chr17:8066669	VAMP2	-0.57	-5.21	-0.47	1.08e-6	Initial pursuit acceleration;
THYM	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.8	-0.44	5.86e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs12893597	0.659	rs12588179	chr14:76846138	C/A	cg20290672	chr14:76816747	NA	-0.56	-4.65	-0.43	1.06e-5	Maximal oxygen uptake response;
THYM	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Body mass index;
THYM	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg23711669	chr6:146136114	FBXO30	0.96	9.87	0.71	3.12e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg08901578	chr4:187885870	NA	-0.63	-5.79	-0.51	8.9e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg06808227	chr14:105710500	BRF1	-1.03	-8.98	-0.68	2.5e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs240764	0.817	rs12193960	chr6:101150326	C/T	cg21058520	chr6:100914733	NA	0.58	5.22	0.47	1.04e-6	Neuroticism;
THYM	cis	rs9902453	0.817	rs55758314	chr17:28173978	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.66	0.43	1.03e-5	Coffee consumption (cups per day);
THYM	cis	rs9326248	0.769	rs499910	chr11:116763034	G/A	cg20608306	chr11:116969690	SIK3	0.56	5.7	0.5	1.34e-7	Blood protein levels;
THYM	cis	rs654950	0.934	rs641974	chr1:42002137	G/A	cg06885757	chr1:42089581	HIVEP3	-0.56	-7.36	-0.6	6.66e-11	Airway imaging phenotypes;
THYM	cis	rs1728785	0.901	rs1728787	chr16:68593042	G/C	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs10889850	0.675	rs1268441	chr1:70211123	A/G	cg01711146	chr1:70671364	SFRS11;LRRC40	0.76	4.45	0.42	2.35e-5	Body mass index;
THYM	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11209185	0.602	rs1926285	chr1:68446191	A/T	cg22082780	chr1:68452167	NA	0.49	5.74	0.51	1.14e-7	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6430585	0.528	rs114760827	chr2:136661110	G/A	cg20242066	chr2:136595261	LCT	0.56	5.17	0.47	1.28e-6	Corneal structure;
THYM	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03517284	chr6:25882590	NA	1.0	9.27	0.69	5.96e-15	Blood metabolite levels;
THYM	cis	rs2404602	0.735	rs11635463	chr15:76762986	C/T	cg23625390	chr15:77176239	SCAPER	-0.71	-4.87	-0.45	4.37e-6	Blood metabolite levels;
THYM	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs7267979	1.000	rs6050566	chr20:25351071	G/A	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4919694	1.000	rs17727391	chr10:104836101	C/A	cg04362960	chr10:104952993	NT5C2	1.14	7.07	0.59	2.65e-10	Arsenic metabolism;
THYM	cis	rs67311347	0.544	rs4974047	chr3:40339653	G/T	cg13683864	chr3:40499215	RPL14	-0.79	-7.44	-0.61	4.43e-11	Renal cell carcinoma;
THYM	cis	rs7100689	0.577	rs10749551	chr10:82054001	A/C	cg09936400	chr10:82049201	MAT1A	0.49	5.05	0.46	2.16e-6	Post bronchodilator FEV1;
THYM	cis	rs7177699	0.525	rs7402376	chr15:79113570	A/G	cg15571903	chr15:79123663	NA	-0.58	-6.53	-0.56	3.26e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg11266682	chr4:10021025	SLC2A9	0.74	12.07	0.78	6.92e-21	Bone mineral density;
THYM	cis	rs870825	0.860	rs60022249	chr4:185600772	T/C	cg04058563	chr4:185651563	MLF1IP	1.0	7.42	0.61	4.93e-11	Blood protein levels;
THYM	cis	rs28374715	0.662	rs72737792	chr15:41515589	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.01	-8.29	-0.65	7.22e-13	Ulcerative colitis;
THYM	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	8.89	0.67	3.88e-14	Chronic sinus infection;
THYM	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg09184832	chr6:79620586	NA	-0.59	-4.72	-0.44	8.17e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg03605463	chr16:89740564	NA	0.81	6.81	0.57	8.64e-10	Vitiligo;
THYM	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-5.02	-0.46	2.44e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9534288	0.797	rs9534287	chr13:46603926	A/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1497406	0.744	rs4233540	chr1:16507384	A/G	cg03887218	chr1:16534349	ARHGEF19	-0.48	-4.78	-0.44	6.38e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg05890377	chr2:74357713	NA	1.07	10.55	0.73	1.13e-17	Gestational age at birth (maternal effect);
THYM	cis	rs7617773	0.780	rs36121690	chr3:48345511	C/T	cg02219026	chr3:48282209	ZNF589	-0.64	-4.58	-0.43	1.39e-5	Coronary artery disease;
THYM	cis	rs7193541	0.684	rs9929496	chr16:74668473	G/A	cg01733217	chr16:74700730	RFWD3	1.0	11.86	0.77	1.93e-20	Multiple myeloma;
THYM	cis	rs420259	0.516	rs11074561	chr16:23495695	C/T	cg00143387	chr16:23521605	GGA2	-0.65	-4.46	-0.42	2.26e-5	Bipolar disorder;
THYM	cis	rs1003719	0.715	rs2835659	chr21:38567902	C/T	cg01329690	chr21:38580129	DSCR9	-0.36	-5.0	-0.46	2.67e-6	Eye color traits;
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg18430553	chr17:78795541	RPTOR	-0.94	-7.38	-0.6	5.96e-11	Energy expenditure (24h);
THYM	cis	rs7119	0.717	rs12912386	chr15:77817640	T/C	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.55	-5.23	-0.47	1e-6	Lymphocyte counts;
THYM	cis	rs28595532	0.920	rs115090549	chr4:119753554	T/C	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.69	-7.42	-0.61	4.85e-11	Crohn's disease;
THYM	cis	rs6575793	1.000	rs7141087	chr14:101036052	T/C	cg13521842	chr14:101036202	BEGAIN	-0.51	-4.59	-0.43	1.33e-5	Menarche (age at onset);
THYM	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg17372223	chr3:52568218	NT5DC2	0.36	5.57	0.5	2.35e-7	Electroencephalogram traits;
THYM	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.86	-0.45	4.62e-6	Eye color traits;
THYM	cis	rs6499255	0.951	rs3743673	chr16:69711311	A/T	cg00738113	chr16:70207722	CLEC18C	-0.46	-4.59	-0.43	1.35e-5	IgE levels;
THYM	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg04518342	chr5:131593106	PDLIM4	0.58	6.48	0.55	3.98e-9	Acylcarnitine levels;
THYM	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg12963246	chr6:28129442	ZNF389	0.76	6.07	0.53	2.67e-8	Parkinson's disease;
THYM	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg22664400	chr11:66445111	RBM4B	0.66	4.47	0.42	2.14e-5	Crohn's disease;
THYM	cis	rs7264396	0.561	rs6058388	chr20:34571846	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-4.67	-0.43	1e-5	Total cholesterol levels;
THYM	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg17757837	chr7:157058334	UBE3C	-0.93	-9.0	-0.68	2.28e-14	Body mass index;
THYM	cis	rs3826795	0.569	rs11671360	chr19:46795171	T/C	cg15229275	chr19:46800054	HIF3A	0.93	5.64	0.5	1.77e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.32	9.94	0.71	2.24e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs790123	0.581	rs2877628	chr3:122352678	A/G	cg17380795	chr3:122379686	NA	0.56	5.16	0.47	1.35e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2286885	0.965	rs4837091	chr9:129244928	A/G	cg14319473	chr9:129242481	FAM125B	0.65	4.91	0.45	3.78e-6	Intraocular pressure;
THYM	cis	rs9928842	0.882	rs8048956	chr16:75254966	C/G	cg09066997	chr16:75300724	BCAR1	-0.74	-4.81	-0.44	5.73e-6	Alcoholic chronic pancreatitis;
THYM	cis	rs6430585	0.528	rs309152	chr2:136657252	C/T	cg20242066	chr2:136595261	LCT	-0.5	-5.26	-0.47	8.85e-7	Corneal structure;
THYM	cis	rs7226229	0.797	rs961004	chr17:20878744	G/A	cg21263980	chr17:20946333	USP22	-0.72	-4.97	-0.45	2.99e-6	Blood trace element (Se levels);
THYM	cis	rs10924970	0.967	rs12030186	chr1:235397477	G/A	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg05962950	chr11:130786565	SNX19	0.84	7.27	0.6	9.89e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs921968	0.565	rs6436082	chr2:219639430	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg04398451	chr17:18023971	MYO15A	-0.96	-9.97	-0.72	1.87e-16	Total body bone mineral density;
THYM	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg26314531	chr2:26401878	FAM59B	0.78	5.13	0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg17264618	chr3:40429014	ENTPD3	-0.53	-5.08	-0.46	1.86e-6	Renal cell carcinoma;
THYM	cis	rs3741151	0.773	rs7945825	chr11:73287140	G/C	cg17517138	chr11:73019481	ARHGEF17	0.9	4.71	0.43	8.56e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.67	-8.64	-0.66	1.3e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg11764359	chr7:65958608	NA	-0.67	-4.77	-0.44	6.52e-6	Aortic root size;
THYM	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs11148252	0.633	rs9535888	chr13:52733206	C/G	cg00495681	chr13:53174319	NA	0.66	5.54	0.49	2.75e-7	Lewy body disease;
THYM	cis	rs4731207	0.596	rs6948283	chr7:124679523	T/C	cg05285228	chr7:124571219	POT1	-0.65	-4.98	-0.45	2.9e-6	Cutaneous malignant melanoma;
THYM	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg17366294	chr4:99064904	C4orf37	0.6	7.21	0.59	1.3100000000000001e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs524281	0.773	rs11227447	chr11:66048280	G/C	cg00563793	chr11:65837595	PACS1	0.79	4.66	0.43	1.03e-5	Electroencephalogram traits;
THYM	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg25566285	chr7:158114605	PTPRN2	-0.84	-10.37	-0.73	2.73e-17	Calcium levels;
THYM	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg08975724	chr8:8085496	FLJ10661	0.73	5.83	0.51	7.73e-8	Mood instability;
THYM	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs7772486	0.743	rs9376955	chr6:145949404	T/A	cg13319975	chr6:146136371	FBXO30	-0.65	-5.35	-0.48	6.13e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg00129232	chr17:37814104	STARD3	-0.76	-5.25	-0.47	9.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs7188697	0.646	rs7184114	chr16:58585369	C/A	cg26666090	chr16:58549219	SETD6	0.4	4.7	0.43	8.71e-6	QT interval;
THYM	cis	rs736408	0.812	rs9881468	chr3:52828628	C/T	cg10802521	chr3:52805072	NEK4	-0.71	-5.84	-0.51	7.4e-8	Bipolar disorder;
THYM	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg18681998	chr4:17616180	MED28	0.85	7.68	0.62	1.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs259282	0.605	rs66489063	chr19:33108959	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.72	5.96	0.52	4.22e-8	Schizophrenia;
THYM	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg03388043	chr17:80084554	CCDC57	0.69	5.98	0.52	3.85e-8	Life satisfaction;
THYM	cis	rs7513165	0.935	rs12097666	chr1:204162212	A/G	cg04791601	chr1:204159016	NA	0.4	5.2	0.47	1.15e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
THYM	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.68	6.04	0.53	2.94e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg24920358	chr1:40204285	PPIE	0.6	5.57	0.5	2.39e-7	Blood protein levels;
THYM	cis	rs7851660	0.594	rs28703314	chr9:100660145	A/T	cg13688889	chr9:100608707	NA	-0.72	-4.89	-0.45	4.12e-6	Strep throat;
THYM	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.31	0.6	8.34e-11	Obesity-related traits;
THYM	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11644478	chr21:40555479	PSMG1	-0.82	-7.29	-0.6	9.29e-11	Cognitive function;
THYM	trans	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4589258	0.713	rs12795930	chr11:90403032	A/G	cg26138821	chr11:89956704	CHORDC1	0.55	4.62	0.43	1.22e-5	Intelligence (multi-trait analysis);
THYM	cis	rs273218	1.000	rs273217	chr5:53380938	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.93	8.07	0.64	2.18e-12	Migraine;
THYM	cis	rs12216545	0.765	rs1851434	chr7:150229453	A/G	cg08960815	chr7:150264767	GIMAP4	0.88	8.24	0.65	9.15e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg26031613	chr14:104095156	KLC1	-0.68	-4.59	-0.43	1.37e-5	Body mass index;
THYM	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg18681998	chr4:17616180	MED28	0.85	7.68	0.62	1.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.704	rs35009666	chr20:43786020	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg08132940	chr7:1081526	C7orf50	-1.14	-6.99	-0.58	3.87e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.75	-0.67	7.74e-14	Mean corpuscular volume;
THYM	cis	rs11711311	0.747	rs11928494	chr3:113343219	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.53	-4.5	-0.42	1.95e-5	IgG glycosylation;
THYM	cis	rs7106204	0.534	rs78879754	chr11:24279312	G/A	ch.11.24196551F	chr11:24239977	NA	0.92	4.75	0.44	7.06e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs12540874	0.670	rs3887826	chr7:50544961	G/A	cg18232548	chr7:50535776	DDC	-0.9	-8.51	-0.66	2.5e-13	Systemic sclerosis;
THYM	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg27129171	chr3:47204927	SETD2	-0.72	-5.96	-0.52	4.3e-8	Birth weight;
THYM	cis	rs7828089	0.646	rs10094778	chr8:22285490	A/G	cg13512537	chr8:22265999	SLC39A14	-0.7	-5.46	-0.49	3.72e-7	Verbal declarative memory;
THYM	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs7107174	0.892	rs10793310	chr11:78099014	T/G	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs8103278	1.000	rs35302007	chr19:46219145	G/C	cg14061069	chr19:46274453	DMPK	-0.54	-5.27	-0.48	8.37e-7	Coronary artery disease;
THYM	cis	rs36051895	0.695	rs62541532	chr9:5017384	C/A	cg02405213	chr9:5042618	JAK2	-1.02	-10.21	-0.72	6.02e-17	Pediatric autoimmune diseases;
THYM	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg05335186	chr13:53173507	NA	-0.54	-6.29	-0.54	9.76e-9	Lewy body disease;
THYM	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03264133	chr6:25882463	NA	0.71	5.78	0.51	9.53e-8	Blood metabolite levels;
THYM	cis	rs800586	0.522	rs2737250	chr8:116661874	A/G	cg04656070	chr8:116661063	TRPS1	-0.54	-6.14	-0.53	1.94e-8	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7590720	1.000	rs7592663	chr2:216894978	T/C	cg25588852	chr2:216877276	MREG	-0.54	-4.49	-0.42	1.97e-5	Alcohol dependence;
THYM	cis	rs929596	0.755	rs4148325	chr2:234673309	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.9	-7.78	-0.62	8.93e-12	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs1003719	0.788	rs1155785	chr21:38447939	A/G	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg10589385	chr1:150898437	SETDB1	0.57	4.55	0.42	1.56e-5	Melanoma;
THYM	cis	rs1568889	0.838	rs11030206	chr11:28099747	C/T	cg15688670	chr11:27723190	BDNF	-0.63	-4.51	-0.42	1.84e-5	Bipolar disorder;
THYM	cis	rs4363385	0.747	rs2879488	chr1:152975241	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.53	-0.42	1.74e-5	Inflammatory skin disease;
THYM	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg02931644	chr1:25747376	RHCE	0.62	4.83	0.44	5.24e-6	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.2	7.9	0.63	4.86e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4662945	0.688	rs876890	chr2:130195492	A/T	cg05903289	chr2:130345205	NA	-0.59	-5.69	-0.5	1.38e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs6842047	0.611	rs12186257	chr4:187183498	G/C	cg09526685	chr4:187126073	CYP4V2	1.15	5.7	0.5	1.34e-7	Blood protein levels;
THYM	cis	rs87938	0.830	rs58183061	chr3:41175322	G/T	cg02247160	chr3:41243829	CTNNB1	-0.34	-4.51	-0.42	1.88e-5	Bone mineral density (hip);
THYM	cis	rs7104764	1.000	rs6598065	chr11:243211	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg22709100	chr7:91322751	NA	0.62	4.85	0.45	4.77e-6	Breast cancer;
THYM	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg10360139	chr7:1886902	MAD1L1	-0.59	-5.31	-0.48	7.19e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs3781426	0.960	rs10901852	chr10:126728522	G/C	cg04494136	chr10:126703576	CTBP2	-0.4	-5.35	-0.48	6.19e-7	Height;
THYM	cis	rs7917772	0.546	rs10883743	chr10:104338389	T/C	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs870825	0.616	rs28497285	chr4:185629169	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg17279839	chr7:150038598	RARRES2	0.56	5.45	0.49	3.92e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs1847202	0.826	rs13063441	chr3:72952400	A/G	cg25664220	chr3:72788482	NA	-0.64	-4.79	-0.44	6.14e-6	Motion sickness;
THYM	cis	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg08133631	chr1:26527909	CATSPER4	-0.55	-4.47	-0.42	2.17e-5	Obesity-related traits;
THYM	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg18681998	chr4:17616180	MED28	1.28	8.41	0.65	4.03e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6138458	1.000	rs227630	chr20:24913584	A/G	cg06937882	chr20:24974362	C20orf3	-0.47	-4.54	-0.42	1.66e-5	Blood protein levels;
THYM	cis	rs778371	0.723	rs2592104	chr2:233645970	G/A	cg08000102	chr2:233561755	GIGYF2	0.78	6.89	0.58	6.03e-10	Schizophrenia;
THYM	cis	rs981844	1.000	rs2606332	chr4:154655372	G/A	cg09973105	chr4:154681532	RNF175	-0.63	-5.18	-0.47	1.23e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg11812906	chr14:75593930	NEK9	-0.83	-7.35	-0.6	6.73e-11	Height;
THYM	cis	rs6992820	0.967	rs6996402	chr8:56752230	G/C	cg06880721	chr8:56792545	LYN	-0.69	-5.75	-0.51	1.07e-7	Mean platelet volume;
THYM	cis	rs4713118	0.869	rs10214440	chr6:27702440	A/C	cg08968635	chr6:28129556	ZNF389	0.62	4.59	0.43	1.37e-5	Parkinson's disease;
THYM	cis	rs7246657	0.943	rs1015848	chr19:37945274	A/C	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs6032067	0.704	rs2223901	chr20:43789924	C/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4731207	0.698	rs4377885	chr7:124533680	A/G	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg12311346	chr5:56204834	C5orf35	-0.82	-5.96	-0.52	4.2e-8	Initial pursuit acceleration;
THYM	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg06074448	chr4:187884817	NA	1.02	13.02	0.8	7.66e-23	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.73	-4.82	-0.44	5.35e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	trans	rs3960554	0.808	rs3779419	chr7:75695081	G/A	cg19862616	chr7:65841803	NCRNA00174	0.96	7.46	0.61	4.09e-11	Eotaxin levels;
THYM	cis	rs2456568	0.802	rs1395387	chr11:93639307	A/T	cg17347335	chr11:93583973	C11orf90	-0.48	-4.6	-0.43	1.28e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs67311347	0.568	rs9864544	chr3:40336204	T/C	cg24209194	chr3:40518798	ZNF619	0.55	4.6	0.43	1.29e-5	Renal cell carcinoma;
THYM	cis	rs13102973	0.899	rs13104539	chr4:135904385	G/A	cg14419869	chr4:135874104	NA	0.82	6.86	0.58	7.03e-10	Subjective well-being;
THYM	cis	rs6087990	0.806	rs4911108	chr20:31375311	A/G	cg13636640	chr20:31349939	DNMT3B	0.94	10.13	0.72	8.58e-17	Ulcerative colitis;
THYM	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg21784768	chr11:537496	LRRC56	-1.16	-5.78	-0.51	9.66e-8	Body mass index;
THYM	cis	rs9486719	0.947	rs2499801	chr6:96854594	G/A	cg18709589	chr6:96969512	KIAA0776	0.76	4.88	0.45	4.23e-6	Migraine;Coronary artery disease;
THYM	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg11861562	chr11:117069780	TAGLN	-0.32	-4.58	-0.43	1.42e-5	Blood protein levels;
THYM	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg27211696	chr2:191398769	TMEM194B	-0.67	-5.23	-0.47	9.98e-7	Diastolic blood pressure;
THYM	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg03476357	chr21:30257390	N6AMT1	-0.59	-4.6	-0.43	1.31e-5	Dental caries;
THYM	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg00255919	chr5:131827918	IRF1	0.45	5.17	0.47	1.29e-6	Asthma (sex interaction);
THYM	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs28595532	0.844	rs115411027	chr4:119490685	T/C	cg14228332	chr4:119757509	SEC24D	1.38	4.98	0.45	2.89e-6	Cannabis dependence symptom count;
THYM	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.86	-5.95	-0.52	4.55e-8	Body mass index;
THYM	cis	rs2749592	0.588	rs2504144	chr10:38383525	C/T	cg25427524	chr10:38739819	LOC399744	-0.7	-5.84	-0.51	7.36e-8	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg17372223	chr3:52568218	NT5DC2	0.39	6.34	0.55	7.54e-9	Hemoglobin concentration;
THYM	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.79	6.89	0.58	6.16e-10	Tonsillectomy;
THYM	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Body mass index;
THYM	cis	rs4975709	0.798	rs4975757	chr5:1882579	G/A	cg19770292	chr5:1868693	NA	0.5	4.53	0.42	1.69e-5	Cardiovascular disease risk factors;
THYM	cis	rs9902453	0.933	rs60694493	chr17:28473256	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	4.6	0.43	1.33e-5	Coffee consumption (cups per day);
THYM	cis	rs11771526	0.901	rs7357161	chr7:32302475	A/C	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg13319975	chr6:146136371	FBXO30	0.62	5.21	0.47	1.11e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg23187316	chr7:1099788	C7orf50	0.59	4.52	0.42	1.76e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9650657	0.615	rs7818181	chr8:10696515	C/T	cg12981288	chr8:11183844	MTMR9	-0.48	-4.51	-0.42	1.84e-5	Neuroticism;
THYM	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg07167872	chr1:205819463	PM20D1	0.61	4.67	0.43	1.01e-5	Parkinson's disease;
THYM	cis	rs4986172	0.690	rs11657325	chr17:43242694	C/T	cg27395066	chr17:43221220	ACBD4	0.71	5.84	0.51	7.42e-8	Height;
THYM	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg05802129	chr4:122689817	NA	-0.57	-4.47	-0.42	2.17e-5	Type 2 diabetes;
THYM	cis	rs9880211	1.000	rs9841529	chr3:136137283	A/C	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs7084402	0.902	rs4245599	chr10:60365755	A/G	cg27040468	chr10:60456715	BICC1	-0.55	-4.5	-0.42	1.94e-5	Refractive error;
THYM	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg10018233	chr7:150070692	REPIN1	0.37	5.32	0.48	6.97e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs728616	0.867	rs56365235	chr10:81894739	C/T	cg27452691	chr10:81370291	SFTPA1	0.88	5.73	0.51	1.16e-7	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg04156016	chr5:1868137	NA	0.5	4.63	0.43	1.17e-5	Cardiovascular disease risk factors;
THYM	trans	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg25214090	chr10:38739885	LOC399744	-0.94	-8.25	-0.65	9.14e-13	Corneal astigmatism;
THYM	cis	rs17854409	1.000	rs66634465	chr20:61482306	C/T	cg05147244	chr20:61493195	TCFL5	1.03	6.31	0.54	8.76e-9	Obesity-related traits;
THYM	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.51	-4.79	-0.44	6.24e-6	Lymphocyte counts;
THYM	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.74	5.68	0.5	1.49e-7	Eosinophil percentage of white cells;
THYM	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg23711669	chr6:146136114	FBXO30	0.85	7.55	0.61	2.62e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg14983838	chr19:29218262	NA	0.94	6.73	0.57	1.26e-9	Methadone dose in opioid dependence;
THYM	cis	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg18512352	chr11:47633146	NA	-0.38	-4.52	-0.42	1.75e-5	HDL cholesterol;
THYM	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg06634786	chr22:41940651	POLR3H	0.72	5.24	0.47	9.51e-7	Vitiligo;
THYM	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg09085632	chr11:111637200	PPP2R1B	1.03	10.3	0.73	3.8e-17	Primary sclerosing cholangitis;
THYM	cis	rs2916260	0.800	rs75727982	chr6:40389639	C/T	cg08415973	chr6:40346114	TDRG1	0.75	4.71	0.43	8.6e-6	Incident coronary heart disease;
THYM	cis	rs112998813	0.571	rs12584203	chr13:114926296	G/A	cg26703057	chr13:114071457	NA	0.76	4.48	0.42	2.06e-5	Nodular sclerosis Hodgkin lymphoma;
THYM	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg26384229	chr12:38710491	ALG10B	1.02	10.24	0.72	4.98e-17	Heart rate;
THYM	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg00898013	chr13:113819073	PROZ	-1.02	-10.0	-0.72	1.62e-16	Platelet distribution width;
THYM	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg27572855	chr1:25598939	RHD	0.7	5.36	0.48	5.88e-7	Erythrocyte sedimentation rate;
THYM	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg04025307	chr7:1156635	C7orf50	0.82	8.33	0.65	5.94e-13	Longevity;Endometriosis;
THYM	cis	rs17001868	0.568	rs9611316	chr22:40737027	A/G	cg07138101	chr22:40742427	ADSL	0.94	5.71	0.51	1.3e-7	Mammographic density (dense area);
THYM	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg02734326	chr4:10020555	SLC2A9	0.76	6.44	0.55	4.94e-9	Bone mineral density;
THYM	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg21658235	chr8:22456391	C8orf58	0.5	5.06	0.46	2.04e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg09703963	chr11:616879	IRF7;MUPCDH	-0.64	-5.53	-0.49	2.78e-7	Systemic lupus erythematosus;
THYM	cis	rs4654899	0.680	rs11805006	chr1:21249603	C/T	cg01072550	chr1:21505969	NA	-0.72	-6.75	-0.57	1.17e-9	Superior frontal gyrus grey matter volume;
THYM	trans	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.84	0.51	7.19e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg07507251	chr3:52567010	NT5DC2	0.42	4.97	0.45	2.99e-6	Hemoglobin concentration;
THYM	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg05025164	chr4:1340916	KIAA1530	0.91	7.13	0.59	1.99e-10	Longevity;
THYM	cis	rs17209837	0.607	rs11561963	chr7:87116550	T/A	cg04996195	chr7:87105398	ABCB4	0.64	4.68	0.43	9.48e-6	Gallbladder cancer;
THYM	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg13695892	chr22:41940480	POLR3H	-0.62	-4.99	-0.46	2.77e-6	Vitiligo;
THYM	cis	rs6500602	0.653	rs4786487	chr16:4440397	C/G	cg08645402	chr16:4508243	NA	-0.65	-5.33	-0.48	6.63e-7	Schizophrenia;
THYM	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.57	4.65	0.43	1.06e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs1267303	0.675	rs1267309	chr1:46987342	G/A	cg25110126	chr1:46999211	NA	-0.68	-5.3	-0.48	7.63e-7	Monobrow;
THYM	cis	rs1062753	0.922	rs9611712	chr22:42410993	T/C	cg22189786	chr22:42395067	WBP2NL	0.54	5.55	0.49	2.6e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg18512352	chr11:47633146	NA	0.51	6.44	0.55	4.85e-9	Subjective well-being;
THYM	cis	rs9527	0.615	rs1556960	chr10:104726673	A/G	cg04362960	chr10:104952993	NT5C2	0.63	4.76	0.44	6.9e-6	Arsenic metabolism;
THYM	cis	rs4642101	0.561	rs4560285	chr3:12809066	G/A	cg05775895	chr3:12838266	CAND2	0.6	4.62	0.43	1.23e-5	QRS complex (12-leadsum);
THYM	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg08645402	chr16:4508243	NA	0.73	6.61	0.56	2.2e-9	Schizophrenia;
THYM	cis	rs11764116	0.506	rs12531908	chr7:18838616	C/T	cg13420273	chr7:18810212	HDAC9	-0.57	-4.95	-0.45	3.26e-6	Ulcerative colitis;
THYM	cis	rs7226229	0.950	rs4985957	chr17:20906257	A/G	cg21263980	chr17:20946333	USP22	0.63	4.63	0.43	1.15e-5	Blood trace element (Se levels);
THYM	cis	rs7584330	0.554	rs74001399	chr2:238445440	G/A	cg14458575	chr2:238380390	NA	0.74	4.59	0.43	1.34e-5	Prostate cancer;
THYM	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg26408565	chr15:76604113	ETFA	-0.55	-4.77	-0.44	6.55e-6	Blood metabolite levels;
THYM	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg06636001	chr8:8085503	FLJ10661	-0.64	-5.4	-0.48	4.86e-7	Joint mobility (Beighton score);
THYM	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs4595586	0.545	rs12809206	chr12:39388748	A/C	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.05e-5	Morning vs. evening chronotype;
THYM	cis	rs554111	0.656	rs3121071	chr1:21128420	C/T	cg01072550	chr1:21505969	NA	0.55	4.88	0.45	4.24e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-5.21	-0.47	1.1e-6	Monocyte percentage of white cells;
THYM	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg00647820	chr17:40259828	DHX58	-0.6	-4.53	-0.42	1.72e-5	Fibrinogen levels;
THYM	cis	rs986417	0.818	rs8014133	chr14:61104738	A/G	cg27398547	chr14:60952738	C14orf39	0.94	5.21	0.47	1.07e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs889398	0.967	rs7359336	chr16:69733460	G/A	cg09409435	chr16:70099608	PDXDC2	0.59	4.54	0.42	1.66e-5	Body mass index;
THYM	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg23815491	chr16:72088622	HP	0.66	5.05	0.46	2.17e-6	Fibrinogen levels;
THYM	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg14983838	chr19:29218262	NA	0.76	5.75	0.51	1.08e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs8050907	0.744	rs79997896	chr16:4582512	G/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.25	5.11	0.46	1.66e-6	Obesity-related traits;
THYM	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg06238570	chr21:40685208	BRWD1	-0.97	-9.38	-0.69	3.44e-15	Cognitive function;
THYM	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg05802129	chr4:122689817	NA	-0.62	-4.87	-0.45	4.49e-6	Type 2 diabetes;
THYM	cis	rs6430585	0.702	rs2015532	chr2:136555525	G/T	cg04750100	chr2:136595281	LCT	-0.5	-4.74	-0.44	7.35e-6	Corneal structure;
THYM	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs921968	0.541	rs2710246	chr2:219533894	C/T	cg02176678	chr2:219576539	TTLL4	0.7	7.24	0.6	1.14e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg17074396	chr22:49843754	NA	-0.39	-4.61	-0.43	1.27e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs782590	0.537	rs7575170	chr2:55886780	C/T	cg18811423	chr2:55921094	PNPT1	-0.58	-4.98	-0.45	2.86e-6	Metabolic syndrome;
THYM	cis	rs7084402	0.967	rs1658452	chr10:60311114	A/T	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg00757033	chr12:89920650	WDR51B	0.75	12.04	0.78	7.96e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg07870213	chr5:140052090	DND1	-0.69	-8.1	-0.64	1.86e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg18811423	chr2:55921094	PNPT1	0.79	7.61	0.62	1.97e-11	Metabolic syndrome;
THYM	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg12031863	chr16:4587854	C16orf5	-0.46	-4.7	-0.43	8.86e-6	Schizophrenia;
THYM	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg06636001	chr8:8085503	FLJ10661	0.76	6.61	0.56	2.23e-9	Red cell distribution width;
THYM	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs79349575	0.783	rs1994970	chr17:47014127	C/T	cg26022315	chr17:47021804	SNF8	-0.5	-4.71	-0.44	8.36e-6	Type 2 diabetes;
THYM	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg15691649	chr6:25882328	NA	-0.72	-5.14	-0.47	1.49e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4919687	0.550	rs12761195	chr10:104465374	T/C	cg05855489	chr10:104503620	C10orf26	0.68	5.35	0.48	5.95e-7	Colorectal cancer;
THYM	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg03806693	chr22:41940476	POLR3H	1.03	9.17	0.69	9.96e-15	Vitiligo;
THYM	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg10523679	chr1:76189770	ACADM	0.9	9.53	0.7	1.67e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg02734326	chr4:10020555	SLC2A9	-0.64	-5.07	-0.46	1.98e-6	Bone mineral density;
THYM	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg24308560	chr3:49941425	MST1R	-0.76	-6.34	-0.55	7.57e-9	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg04025307	chr7:1156635	C7orf50	0.64	6.09	0.53	2.39e-8	Longevity;Endometriosis;
THYM	cis	rs72828912	0.665	rs9348631	chr6:24072212	G/A	cg26336265	chr6:25042955	NA	-0.87	-5.53	-0.49	2.85e-7	Squamous cell lung carcinoma;
THYM	cis	rs10779751	0.960	rs4845988	chr1:11319587	A/G	cg08854313	chr1:11322531	MTOR	1.04	10.2	0.72	6.24e-17	Body mass index;
THYM	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.46e-7	Heart rate;
THYM	cis	rs17739794	0.517	rs6559193	chr8:775451	C/T	cg07178994	chr8:816998	NA	-0.77	-7.3	-0.6	8.77e-11	Clozapine-induced cytotoxicity;
THYM	cis	rs11096990	0.964	rs11096987	chr4:39259190	A/G	cg24403649	chr4:39172243	NA	-0.69	-5.86	-0.52	6.54e-8	Cognitive function;
THYM	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg04315214	chr1:2043799	PRKCZ	-0.58	-4.54	-0.42	1.67e-5	Height;
THYM	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg02781088	chr2:113192302	RGPD8;RGPD5	0.86	4.67	0.43	1.01e-5	Yeast infection;
THYM	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg16049864	chr8:95962084	TP53INP1	-0.82	-7.42	-0.61	4.99e-11	Type 2 diabetes;
THYM	cis	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg10518543	chr12:38710700	ALG10B	-0.58	-4.54	-0.42	1.65e-5	Morning vs. evening chronotype;
THYM	cis	rs1978968	0.956	rs4992882	chr22:18445021	T/G	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs10504073	0.584	rs55908480	chr8:49923431	G/A	cg00325661	chr8:49890786	NA	1.02	10.3	0.73	3.73e-17	Blood metabolite ratios;
THYM	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg27129171	chr3:47204927	SETD2	0.74	7.2	0.59	1.42e-10	Colorectal cancer;
THYM	cis	rs11608355	0.810	rs2217972	chr12:109857612	C/T	cg10504392	chr12:110044639	NA	0.61	5.2	0.47	1.16e-6	Neuroticism;
THYM	cis	rs981844	0.712	rs55656103	chr4:154757478	T/C	cg09973105	chr4:154681532	RNF175	-0.66	-6.27	-0.54	1.04e-8	Response to statins (LDL cholesterol change);
THYM	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg00640147	chr17:61958756	GH2	-0.44	-4.68	-0.43	9.69e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg10523679	chr1:76189770	ACADM	-0.56	-4.61	-0.43	1.27e-5	Daytime sleep phenotypes;
THYM	cis	rs17608059	1.000	rs17608059	chr17:13910549	C/T	cg11395062	chr17:14139857	CDRT15	0.69	6.07	0.53	2.62e-8	Temperament;
THYM	cis	rs78761021	0.867	rs17743194	chr17:9788251	A/G	cg26853458	chr17:9805074	RCVRN	-0.51	-4.47	-0.42	2.13e-5	Type 2 diabetes;
THYM	cis	rs3892630	0.824	rs2287884	chr19:33321447	A/G	cg22980127	chr19:33182716	NUDT19	1.18	9.77	0.71	5.1e-16	Red blood cell traits;
THYM	trans	rs4650994	1.000	rs10913570	chr1:178523126	A/C	cg05059571	chr16:84539110	KIAA1609	-0.76	-8.2	-0.64	1.15e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs72829446	0.530	rs111259369	chr17:7383082	C/T	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg17330251	chr7:94953956	PON1	-0.72	-6.28	-0.54	1e-8	Paraoxonase activity;
THYM	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg10518543	chr12:38710700	ALG10B	-0.57	-4.54	-0.42	1.67e-5	Morning vs. evening chronotype;
THYM	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	cis	rs1003719	0.788	rs9977602	chr21:38450650	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs7011507	0.594	rs72639032	chr8:49356398	T/C	cg08774009	chr8:49309094	NA	-0.62	-4.92	-0.45	3.67e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs240764	0.781	rs239227	chr6:101107089	C/G	cg21058520	chr6:100914733	NA	-0.57	-5.03	-0.46	2.29e-6	Neuroticism;
THYM	cis	rs1971762	0.523	rs3852562	chr12:54085750	T/C	cg16917193	chr12:54089295	NA	0.96	9.59	0.7	1.24e-15	Height;
THYM	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg06728252	chr6:26598149	ABT1	-0.44	-5.15	-0.47	1.43e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8028313	0.630	rs4776373	chr15:67960523	G/A	cg24579218	chr15:68104479	NA	-0.71	-6.42	-0.55	5.31e-9	Obesity;
THYM	cis	rs7267979	1.000	rs11087521	chr20:25440648	G/A	cg08601574	chr20:25228251	PYGB	0.57	4.55	0.42	1.6e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs12765878	1.000	rs11191843	chr10:105648651	G/C	cg11005552	chr10:105648138	OBFC1	0.86	11.19	0.75	4.77e-19	Coronary artery disease;
THYM	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	12.98	0.8	9.2e-23	Height;
THYM	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg03433033	chr1:76189801	ACADM	-0.5	-5.08	-0.46	1.85e-6	Daytime sleep phenotypes;
THYM	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg00271210	chr6:167070053	RPS6KA2	-0.71	-7.66	-0.62	1.54e-11	Crohn's disease;
THYM	cis	rs1403694	1.000	rs1656911	chr3:186439373	T/C	cg12454167	chr3:186435060	KNG1	0.43	5.82	0.51	8.09e-8	Blood protein levels;
THYM	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg12408189	chr10:30722286	MAP3K8	-0.56	-4.6	-0.43	1.3e-5	Inflammatory bowel disease;
THYM	cis	rs2456568	0.933	rs1518577	chr11:93674907	C/T	cg26875233	chr11:93583750	C11orf90	-0.5	-4.88	-0.45	4.2e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs3796352	1.000	rs13091844	chr3:53010271	C/T	cg24530246	chr3:53118167	NA	-0.81	-4.62	-0.43	1.23e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg23231163	chr10:75533350	FUT11	0.43	6.2	0.54	1.49e-8	Inflammatory bowel disease;
THYM	cis	rs9733	0.596	rs7418501	chr1:150711896	A/T	cg10589385	chr1:150898437	SETDB1	0.65	5.62	0.5	1.88e-7	Tonsillectomy;
THYM	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg25918947	chr17:41365094	TMEM106A	-0.63	-5.18	-0.47	1.25e-6	Menopause (age at onset);
THYM	cis	rs397020	0.904	rs203547	chr20:1195245	T/A	cg03932398	chr20:1206703	RAD21L1	0.79	7.25	0.6	1.12e-10	Multiple sclerosis;
THYM	cis	rs61774743	0.521	rs60144015	chr1:41845246	C/A	cg08462924	chr1:41848221	NA	0.81	9.25	0.69	6.48e-15	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg07362569	chr17:61921086	SMARCD2	-0.58	-4.72	-0.44	8.16e-6	Prudent dietary pattern;
THYM	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg00277334	chr10:82204260	NA	-0.53	-5.41	-0.49	4.75e-7	Post bronchodilator FEV1;
THYM	cis	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg21110456	chr7:2059412	MAD1L1	-0.43	-4.51	-0.42	1.89e-5	Neuroticism;
THYM	cis	rs42648	0.935	rs42624	chr7:89957541	C/G	cg25739043	chr7:89950458	NA	-0.56	-4.8	-0.44	5.82e-6	Homocysteine levels;
THYM	cis	rs7512552	0.773	rs3737240	chr1:150483355	C/T	cg15654264	chr1:150340011	RPRD2	0.42	4.6	0.43	1.28e-5	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg18876405	chr7:65276391	NA	0.76	7.19	0.59	1.45e-10	Aortic root size;
THYM	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs616402	0.527	rs2274985	chr1:10573867	G/A	cg20482658	chr1:10539492	PEX14	-0.36	-5.41	-0.49	4.74e-7	Breast size;
THYM	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.27	0.69	5.96e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs8016982	0.674	rs2288499	chr14:81660997	C/T	cg01989461	chr14:81687754	GTF2A1	0.86	7.64	0.62	1.67e-11	Schizophrenia;
THYM	cis	rs950880	0.710	rs3771177	chr2:102955860	G/T	cg03938978	chr2:103052716	IL18RAP	-0.53	-4.64	-0.43	1.1e-5	Serum protein levels (sST2);
THYM	cis	rs6121246	0.512	rs6058384	chr20:30276409	A/T	cg13852791	chr20:30311386	BCL2L1	1.03	10.0	0.72	1.65e-16	Mean corpuscular hemoglobin;
THYM	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg24675658	chr1:53192096	ZYG11B	-0.66	-5.22	-0.47	1.04e-6	Monocyte count;
THYM	cis	rs2115536	1.000	rs11637477	chr15:80193295	C/T	cg00225070	chr15:80189496	MTHFS	0.64	5.63	0.5	1.86e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs4243830	0.737	rs11122088	chr1:6603677	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.06	-6.24	-0.54	1.21e-8	Body mass index;
THYM	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg24733560	chr20:60626293	TAF4	0.66	7.29	0.6	9.19e-11	Body mass index;
THYM	trans	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17712092	chr4:129076599	LARP1B	0.92	7.74	0.62	1.04e-11	Eosinophil percentage of white cells;
THYM	cis	rs7429990	0.932	rs11720151	chr3:48140634	G/A	cg02219026	chr3:48282209	ZNF589	0.59	4.55	0.42	1.6e-5	Educational attainment (years of education);
THYM	cis	rs490234	0.756	rs2416963	chr9:128241414	C/T	cg14078157	chr9:128172775	NA	-0.66	-5.11	-0.46	1.64e-6	Mean arterial pressure;
THYM	cis	rs990171	1.000	rs11677107	chr2:103057087	C/A	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.08	-0.46	1.87e-6	Lymphocyte counts;
THYM	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg24675056	chr1:15929824	NA	0.73	5.84	0.51	7.21e-8	Systolic blood pressure;
THYM	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg08975724	chr8:8085496	FLJ10661	-0.63	-4.91	-0.45	3.79e-6	Mood instability;
THYM	cis	rs2806561	0.664	rs4620508	chr1:23307438	C/T	cg12483005	chr1:23474871	LUZP1	0.51	4.96	0.45	3.05e-6	Height;
THYM	cis	rs7705042	0.865	rs4912622	chr5:141490587	A/G	cg07392085	chr5:141489673	NDFIP1	-0.54	-4.57	-0.42	1.47e-5	Asthma;
THYM	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.67	5.17	0.47	1.32e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg12573674	chr2:1569213	NA	-1.22	-4.82	-0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	trans	rs4262150	0.883	rs72804789	chr5:152322621	C/T	cg08281791	chr5:76607845	PDE8B	0.87	7.03	0.58	3.17e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs7084402	0.935	rs1632584	chr10:60282078	T/C	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.69	-7.42	-0.61	4.85e-11	Crohn's disease;
THYM	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs6840360	0.550	rs6535806	chr4:152483906	G/A	cg22705602	chr4:152727874	NA	-0.77	-8.64	-0.66	1.36e-13	Intelligence (multi-trait analysis);
THYM	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg12863693	chr15:85201151	NMB	0.63	5.49	0.49	3.38e-7	Schizophrenia;
THYM	cis	rs526231	0.547	rs72783895	chr5:102287496	C/A	cg23492399	chr5:102201601	PAM	-0.67	-4.85	-0.45	4.9e-6	Primary biliary cholangitis;
THYM	cis	rs11089937	0.651	rs1543779	chr22:22548492	C/T	cg21401457	chr22:22472743	NA	-0.54	-4.63	-0.43	1.14e-5	Periodontitis (PAL4Q3);
THYM	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg06028605	chr16:24865363	SLC5A11	-0.58	-5.69	-0.5	1.42e-7	Intelligence (multi-trait analysis);
THYM	cis	rs888194	0.934	rs12314392	chr12:110010866	A/G	cg11367159	chr12:110044531	NA	0.5	4.73	0.44	7.86e-6	Neuroticism;
THYM	cis	rs6570726	0.875	rs373313	chr6:145857791	T/C	cg13319975	chr6:146136371	FBXO30	-0.66	-5.63	-0.5	1.85e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4930103	0.935	rs4930110	chr11:2026701	G/C	cg18511798	chr11:2018149	H19;MIR675	-0.57	-5.56	-0.5	2.45e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg20503657	chr10:835505	NA	1.42	9.74	0.71	5.83e-16	Eosinophil percentage of granulocytes;
THYM	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg27394845	chr17:28928406	LRRC37B2	0.91	4.58	0.42	1.44e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7945718	0.967	rs2241857	chr11:12815831	C/T	cg25843174	chr11:12811716	TEAD1	-0.45	-4.53	-0.42	1.72e-5	Educational attainment (years of education);
THYM	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs9790314	0.875	rs7615592	chr3:160981548	A/C	cg03342759	chr3:160939853	NMD3	-0.8	-6.99	-0.58	3.71e-10	Morning vs. evening chronotype;
THYM	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg01819863	chr10:32635814	EPC1	1.04	6.64	0.56	1.9e-9	Sexual dysfunction (female);
THYM	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg18252515	chr7:66147081	NA	-0.88	-6.73	-0.57	1.26e-9	Corneal structure;
THYM	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg13770153	chr20:60521292	NA	-0.73	-4.73	-0.44	7.76e-6	Body mass index;
THYM	cis	rs67981189	0.821	rs61990419	chr14:71536287	G/T	cg15910301	chr14:71632612	NA	0.51	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg10792982	chr14:105748885	BRF1	0.69	6.89	0.58	6.08e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg13695892	chr22:41940480	POLR3H	0.85	6.69	0.57	1.53e-9	Vitiligo;
THYM	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg27534772	chr1:16042836	PLEKHM2	0.55	6.09	0.53	2.38e-8	Systolic blood pressure;
THYM	cis	rs7669967	0.557	rs13114936	chr4:156062755	C/T	cg17641028	chr4:156585641	NA	0.55	4.89	0.45	4.17e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg14517863	chr17:44321492	NA	0.46	5.11	0.46	1.69e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs950394	0.767	rs6543249	chr2:104990646	T/C	cg20302975	chr2:105468274	NA	-0.66	-4.53	-0.42	1.69e-5	Schizophrenia;
THYM	cis	rs11608355	0.552	rs2304549	chr12:109794875	A/G	cg10504392	chr12:110044639	NA	0.54	4.91	0.45	3.73e-6	Neuroticism;
THYM	cis	rs877282	0.853	rs7069720	chr10:754487	A/G	cg10556349	chr10:835070	NA	-0.69	-4.49	-0.42	2.03e-5	Uric acid levels;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg26615232	chr1:216561886	USH2A	-0.94	-7.1	-0.59	2.25e-10	Depressive symptoms;
THYM	cis	rs600806	0.850	rs1880670	chr1:109941133	C/T	cg23616212	chr1:109941201	SORT1	-0.5	-4.65	-0.43	1.06e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg10515332	chr4:99064459	C4orf37	-0.61	-4.94	-0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8030485	0.756	rs2102999	chr15:79410710	C/T	cg17916960	chr15:79447300	NA	-0.55	-5.71	-0.51	1.29e-7	Left ventricle wall thickness;
THYM	cis	rs9902453	0.904	rs9897794	chr17:28296327	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.11	0.53	2.21e-8	Coffee consumption (cups per day);
THYM	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg23649088	chr2:200775458	C2orf69	0.79	6.17	0.54	1.63e-8	Osteoporosis;
THYM	cis	rs67981189	0.896	rs8016506	chr14:71506317	C/T	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.61e-20	Menopause (age at onset);
THYM	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.79	-6.78	-0.57	1.01e-9	Lung cancer;
THYM	cis	rs7582180	0.726	rs2871340	chr2:100884117	A/C	cg21926883	chr2:100939477	LONRF2	0.57	5.1	0.46	1.76e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6964587	0.740	rs2020360	chr7:91439506	G/C	cg17063962	chr7:91808500	NA	1.16	11.45	0.76	1.36e-19	Breast cancer;
THYM	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg15693483	chr7:1102177	C7orf50	0.54	6.26	0.54	1.1e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1415259	0.609	rs4582765	chr1:162090349	C/T	cg26663636	chr1:162337134	NOS1AP	0.57	4.6	0.43	1.31e-5	Electrocardiographic traits;
THYM	cis	rs9970807	0.901	rs56170783	chr1:57016131	A/C	cg11959316	chr1:57001742	PPAP2B	0.81	5.68	0.5	1.46e-7	Myocardial infarction;Coronary artery disease;
THYM	cis	rs3204270	0.639	rs7215738	chr17:79659847	C/T	cg13117272	chr17:79681052	SLC25A10	-0.79	-4.98	-0.46	2.79e-6	Dental caries;
THYM	cis	rs2658782	0.901	rs11601056	chr11:93229161	C/T	cg15737290	chr11:93063684	CCDC67	-1.05	-6.48	-0.55	4.1e-9	Pulmonary function decline;
THYM	cis	rs7677751	1.000	rs73252946	chr4:55125992	G/A	cg17187183	chr4:55093834	PDGFRA	0.78	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs4425211	0.777	rs28576724	chr3:36959899	T/C	cg21328643	chr3:37258149	NA	-0.48	-4.62	-0.43	1.2e-5	Iris color (L* coordinate);
THYM	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg02478829	chr6:26598070	ABT1	-0.35	-4.67	-0.43	9.79e-6	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs4722166	0.568	rs1880241	chr7:22759469	A/G	cg05472934	chr7:22766657	IL6	0.62	5.06	0.46	2.08e-6	Lung cancer;
THYM	cis	rs13082711	0.911	rs7640929	chr3:27513944	C/A	cg02860705	chr3:27208620	NA	0.72	5.15	0.47	1.39e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg03929089	chr4:120376271	NA	-1.01	-13.68	-0.81	3.47e-24	Height;
THYM	cis	rs2702888	0.563	rs2741064	chr8:6760152	C/T	cg03082247	chr8:6756796	NA	0.59	4.67	0.43	9.93e-6	Blood pressure;
THYM	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg15691649	chr6:25882328	NA	-0.69	-5.42	-0.49	4.55e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.22	-0.47	1.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg00071950	chr4:10020882	SLC2A9	-0.55	-4.78	-0.44	6.41e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg19875535	chr5:140030758	IK	-0.6	-4.75	-0.44	7.26e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs12496230	0.953	rs4856960	chr3:66843301	T/C	cg04995300	chr3:66848608	NA	1.11	6.64	0.56	1.91e-9	Type 2 diabetes;
THYM	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg05425664	chr17:57184151	TRIM37	-0.61	-4.93	-0.45	3.42e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6480314	0.831	rs17538164	chr10:69975677	C/G	cg27159792	chr10:69524182	NA	-0.74	-4.75	-0.44	7.33e-6	Optic nerve measurement (disc area);
THYM	trans	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	Myopia (pathological);
THYM	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg04155289	chr7:94953770	PON1	-0.68	-6.46	-0.55	4.5e-9	Paraoxonase activity;
THYM	cis	rs4665630	0.522	rs114382704	chr2:23951810	G/T	cg12449528	chr2:24233341	MFSD2B	1.03	4.49	0.42	2.04e-5	Hypertension;
THYM	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg26929925	chr5:138714136	SLC23A1	-0.57	-4.97	-0.45	2.98e-6	Esophageal squamous cell carcinoma;
THYM	cis	rs669446	0.558	rs594293	chr1:44109199	A/G	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg18758796	chr5:131593413	PDLIM4	0.5	4.8	0.44	5.79e-6	Breast cancer;
THYM	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg05283184	chr6:79620031	NA	-0.91	-8.67	-0.66	1.17e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg10661904	chr17:79619235	PDE6G	-0.57	-5.3	-0.48	7.65e-7	Eye color traits;
THYM	cis	rs7580658	0.895	rs4662580	chr2:128102806	C/A	cg10021288	chr2:128175891	PROC	-0.74	-6.4	-0.55	5.94e-9	Protein C levels;
THYM	cis	rs611744	0.967	rs677288	chr8:109177539	T/C	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg24503407	chr1:205819492	PM20D1	0.84	7.6	0.61	2.1e-11	Monocyte percentage of white cells;
THYM	cis	rs6546324	0.625	rs4260227	chr2:67843537	G/A	cg18237512	chr2:67827392	NA	-0.8	-4.77	-0.44	6.69e-6	Endometriosis;
THYM	cis	rs9790314	1.000	rs1382426	chr3:161045933	G/A	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.26	0.69	6.31e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1883415	0.648	rs2817224	chr6:24507010	A/G	cg00346970	chr6:24499591	ALDH5A1	0.48	6.11	0.53	2.17e-8	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1018836	0.923	rs2105967	chr8:91587522	A/G	cg16814680	chr8:91681699	NA	-0.75	-6.29	-0.54	9.55e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg22764044	chr5:178986830	RUFY1	-0.53	-5.42	-0.49	4.53e-7	Lung cancer;
THYM	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg24006582	chr15:45444508	DUOX1	0.77	6.04	0.53	3.05e-8	Uric acid levels;
THYM	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs12137294	0.829	rs1172154	chr1:205220639	T/G	cg17889831	chr1:205181581	DSTYK	-0.41	-5.09	-0.46	1.82e-6	Red cell distribution width;
THYM	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg13319975	chr6:146136371	FBXO30	-0.66	-5.45	-0.49	3.93e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs11563648	0.573	rs7803031	chr7:126952552	C/G	cg08586737	chr7:127225949	GCC1	-0.34	-4.59	-0.43	1.36e-5	Resting heart rate;
THYM	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg02782426	chr3:40428986	ENTPD3	0.51	4.5	0.42	1.95e-5	Renal cell carcinoma;
THYM	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg24733560	chr20:60626293	TAF4	0.6	6.32	0.54	8.56e-9	Body mass index;
THYM	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg10360139	chr7:1886902	MAD1L1	0.61	4.88	0.45	4.3e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs10872587	0.657	rs11155459	chr6:146578751	A/G	cg23711669	chr6:146136114	FBXO30	-0.62	-4.63	-0.43	1.15e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2573210	0.645	rs1881492	chr2:233406998	A/C	cg20371266	chr2:233390781	CHRND	-0.52	-5.72	-0.51	1.21e-7	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs11229030	0.893	rs2584859	chr11:57207447	A/G	cg00522883	chr11:57194120	SLC43A3	0.61	4.71	0.44	8.48e-6	Crohn's disease;
THYM	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg18758796	chr5:131593413	PDLIM4	-0.5	-4.72	-0.44	8.15e-6	Breast cancer;
THYM	cis	rs2066819	1.000	rs116535779	chr12:56739261	A/G	cg26714650	chr12:56694279	CS	-1.21	-7.0	-0.58	3.57e-10	Psoriasis vulgaris;
THYM	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg03433033	chr1:76189801	ACADM	-0.5	-5.14	-0.47	1.46e-6	Daytime sleep phenotypes;
THYM	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg17757837	chr7:157058334	UBE3C	0.65	5.24	0.47	9.83e-7	Body mass index;
THYM	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	4.59	0.43	1.35e-5	Schizophrenia;
THYM	cis	rs12956009	0.583	rs1115360	chr18:44894550	C/G	cg19077165	chr18:44547161	KATNAL2	-0.49	-4.7	-0.43	8.81e-6	Educational attainment (years of education);
THYM	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg00129232	chr17:37814104	STARD3	-0.71	-4.78	-0.44	6.41e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs367615	0.512	rs246104	chr5:108700982	A/C	cg17395555	chr5:108820864	NA	-0.54	-6.37	-0.55	6.76e-9	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs778371	0.647	rs974321	chr2:233638351	G/A	cg08000102	chr2:233561755	GIGYF2	0.79	6.96	0.58	4.28e-10	Schizophrenia;
THYM	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg09354556	chr3:47051341	NA	0.47	4.8	0.44	5.93e-6	Colorectal cancer;
THYM	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg07636037	chr3:49044803	WDR6	0.92	9.4	0.69	3.13e-15	Parkinson's disease;
THYM	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs6430585	0.640	rs3816155	chr2:136552526	A/C	cg07169764	chr2:136633963	MCM6	-1.19	-13.21	-0.8	3.09e-23	Corneal structure;
THYM	cis	rs673253	0.556	rs35290231	chr1:44103033	G/A	cg24466421	chr1:44070974	PTPRF	-0.59	-5.09	-0.46	1.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6689305	0.505	rs1493617	chr1:100270735	C/A	cg15728779	chr1:99729504	LPPR4	0.41	4.66	0.43	1.02e-5	White matter integrity (bipolar disorder risk interaction);
THYM	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg17105886	chr17:28927953	LRRC37B2	1.24	7.45	0.61	4.35e-11	Body mass index;
THYM	cis	rs6918586	0.658	rs13161	chr6:26114702	C/T	cg12310025	chr6:25882481	NA	0.68	5.49	0.49	3.3e-7	Schizophrenia;
THYM	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg07343612	chr16:622815	PIGQ	-1.0	-9.77	-0.71	5.17e-16	Height;
THYM	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg06784218	chr1:46089804	CCDC17	-0.32	-4.83	-0.44	5.25e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg23730037	chr7:158596552	ESYT2	-0.49	-5.0	-0.46	2.66e-6	Height;
THYM	cis	rs73086581	0.945	rs6052222	chr20:3972793	G/A	cg02187196	chr20:3869020	PANK2	0.5	5.62	0.5	1.92e-7	Response to antidepressants in depression;
THYM	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg22166914	chr1:53195759	ZYG11B	-0.77	-8.25	-0.65	8.84e-13	Monocyte count;
THYM	cis	rs6700896	0.897	rs11208696	chr1:66121781	T/G	cg04111102	chr1:66153794	NA	0.56	5.25	0.47	9.2e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4866334	1.000	rs80012640	chr5:18455247	C/T	cg24599790	chr5:18972260	NA	-1.14	-4.67	-0.43	9.77e-6	IgG glycosylation;
THYM	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03576123	chr11:487126	PTDSS2	-1.24	-5.21	-0.47	1.1e-6	Body mass index;
THYM	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg04287289	chr16:89883240	FANCA	0.63	5.71	0.51	1.26e-7	Vitiligo;
THYM	cis	rs829880	0.570	rs844205	chr12:98846053	A/G	cg25150519	chr12:98850993	NA	0.69	5.95	0.52	4.52e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg26384229	chr12:38710491	ALG10B	-0.89	-7.49	-0.61	3.48e-11	Bladder cancer;
THYM	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg12031863	chr16:4587854	C16orf5	-0.45	-4.97	-0.45	2.93e-6	Schizophrenia;
THYM	cis	rs2276314	1.000	rs8086395	chr18:33564592	C/G	cg19628046	chr18:33552617	C18orf21	0.77	5.47	0.49	3.68e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7909074	0.898	rs10793565	chr10:45388231	G/C	cg04218760	chr10:45406644	TMEM72	-0.7	-6.49	-0.55	3.91e-9	Mean corpuscular volume;
THYM	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg19508488	chr2:152266495	RIF1	0.78	7.05	0.59	2.89e-10	Lung cancer;
THYM	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4919694	1.000	rs12245343	chr10:104774050	A/G	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs9462846	0.688	rs116255295	chr6:42906241	G/A	cg21280719	chr6:42927975	GNMT	-0.42	-4.54	-0.42	1.65e-5	Blood protein levels;
THYM	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg26597838	chr10:835615	NA	1.42	9.79	0.71	4.66e-16	Eosinophil percentage of granulocytes;
THYM	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg26384229	chr12:38710491	ALG10B	0.95	7.31	0.6	8.45e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.37	0.55	6.61e-9	Tonsillectomy;
THYM	cis	rs9831754	0.906	rs6782626	chr3:78406178	T/C	cg06138941	chr3:78371609	NA	-0.63	-4.48	-0.42	2.11e-5	Calcium levels;
THYM	cis	rs9527	0.641	rs4919684	chr10:104587024	A/G	cg04362960	chr10:104952993	NT5C2	0.63	4.93	0.45	3.44e-6	Arsenic metabolism;
THYM	cis	rs7851660	0.775	rs7034336	chr9:100661100	C/T	cg13688889	chr9:100608707	NA	-0.79	-5.71	-0.51	1.28e-7	Strep throat;
THYM	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg10515332	chr4:99064459	C4orf37	-0.64	-4.99	-0.46	2.7e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg12826209	chr6:26865740	GUSBL1	1.04	6.68	0.57	1.63e-9	Intelligence (multi-trait analysis);
THYM	cis	rs5769765	0.874	rs11703411	chr22:50258751	G/A	cg26441486	chr22:50317300	CRELD2	-0.42	-6.36	-0.55	7.09e-9	Schizophrenia;
THYM	cis	rs7584330	0.780	rs2292884	chr2:238443226	A/G	cg14458575	chr2:238380390	NA	0.81	6.42	0.55	5.28e-9	Prostate cancer;
THYM	cis	rs11148252	0.514	rs3818422	chr13:52719214	C/T	cg00495681	chr13:53174319	NA	-0.68	-5.95	-0.52	4.54e-8	Lewy body disease;
THYM	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg24308560	chr3:49941425	MST1R	0.8	6.83	0.57	8.05e-10	Intelligence (multi-trait analysis);
THYM	cis	rs3820068	0.580	rs61169376	chr1:16003832	A/G	cg13390004	chr1:15929781	NA	0.64	4.8	0.44	5.83e-6	Systolic blood pressure;
THYM	cis	rs3916	0.911	rs12829722	chr12:121155622	C/T	cg21892295	chr12:121157589	UNC119B	-0.52	-4.99	-0.46	2.76e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs1642645	0.831	rs7529102	chr1:42493322	T/C	cg22816091	chr1:42611670	NA	0.62	5.52	0.49	2.99e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26314531	chr2:26401878	FAM59B	0.76	5.02	0.46	2.37e-6	Gut microbiome composition (summer);
THYM	cis	rs12950390	0.512	rs11651000	chr17:45835278	G/A	cg06532163	chr17:45867833	NA	0.58	4.49	0.42	2e-5	IgG glycosylation;
THYM	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg26545918	chr15:68124484	LBXCOR1	0.54	4.55	0.42	1.57e-5	Restless legs syndrome;
THYM	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs2976388	0.507	rs1036385	chr8:143842901	T/C	cg17252645	chr8:143867129	LY6D	0.56	5.51	0.49	3.03e-7	Urinary tract infection frequency;
THYM	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg15445000	chr17:37608096	MED1	0.44	5.07	0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg14004847	chr7:1930337	MAD1L1	-0.64	-5.43	-0.49	4.27e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs6430585	0.528	rs309133	chr2:136751842	A/C	cg07169764	chr2:136633963	MCM6	1.0	9.76	0.71	5.42e-16	Corneal structure;
THYM	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg09737314	chr17:6899359	ALOX12	0.8	10.3	0.73	3.84e-17	Tonsillectomy;
THYM	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg05707623	chr12:122985044	ZCCHC8	0.75	5.41	0.49	4.72e-7	Body mass index;
THYM	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06481639	chr22:41940642	POLR3H	-0.83	-5.84	-0.51	7.23e-8	Vitiligo;
THYM	cis	rs3768617	0.565	rs3768626	chr1:183078462	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg10856724	chr12:34555212	NA	-0.88	-8.64	-0.66	1.33e-13	Morning vs. evening chronotype;
THYM	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg15448220	chr1:150897856	SETDB1	0.88	7.31	0.6	8.31e-11	Melanoma;
THYM	cis	rs8067545	0.611	rs2158472	chr17:20171524	C/T	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg08968635	chr6:28129556	ZNF389	0.71	5.58	0.5	2.28e-7	Parkinson's disease;
THYM	cis	rs67311347	0.594	rs12629111	chr3:40285351	T/C	cg13683864	chr3:40499215	RPL14	-0.59	-4.79	-0.44	6.08e-6	Renal cell carcinoma;
THYM	cis	rs66691851	0.504	rs863930	chr3:135949737	T/G	cg21827317	chr3:136751795	NA	0.64	5.99	0.52	3.69e-8	Neuroticism;Schizophrenia;
THYM	cis	rs4833103	0.542	rs7664687	chr4:38825597	C/G	cg06935464	chr4:38784597	TLR10	0.61	4.48	0.42	2.08e-5	Diabetes in response to antihypertensive drug treatment (treatment strategy interaction);
THYM	cis	rs9677476	0.779	rs10173555	chr2:232108769	C/G	cg07929768	chr2:232055508	NA	0.6	5.15	0.47	1.43e-6	Food antigen IgG levels;
THYM	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg12310025	chr6:25882481	NA	-0.69	-5.58	-0.5	2.3e-7	Blood metabolite levels;
THYM	cis	rs13256369	0.851	rs11249889	chr8:8564992	G/T	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs11577318	0.853	rs11247913	chr1:26648551	G/C	cg19677267	chr1:26645161	CD52;UBXN11	-0.49	-6.38	-0.55	6.56e-9	Granulocyte percentage of myeloid white cells;
THYM	cis	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg10856724	chr12:34555212	NA	-0.74	-5.54	-0.49	2.74e-7	Resting heart rate;
THYM	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Gout;
THYM	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg18252515	chr7:66147081	NA	1.43	8.54	0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs6539288	0.865	rs2888893	chr12:107338631	C/T	cg26297688	chr12:107349093	C12orf23	-0.47	-4.94	-0.45	3.36e-6	Total body bone mineral density;
THYM	cis	rs9790314	1.000	rs4273380	chr3:160950314	A/G	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs7771547	0.573	rs546272	chr6:36398562	G/A	cg07856975	chr6:36356162	ETV7	0.51	4.77	0.44	6.61e-6	Platelet distribution width;
THYM	cis	rs13082711	0.911	rs13089870	chr3:27447626	C/T	cg02860705	chr3:27208620	NA	0.69	4.99	0.46	2.75e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs36051895	0.664	rs11793659	chr9:5109707	A/G	cg02405213	chr9:5042618	JAK2	-1.03	-11.29	-0.76	3.01e-19	Pediatric autoimmune diseases;
THYM	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg20387954	chr3:183756860	HTR3D	0.56	4.64	0.43	1.11e-5	Anterior chamber depth;
THYM	cis	rs6840360	0.555	rs4554052	chr4:152726610	T/C	cg22705602	chr4:152727874	NA	0.76	9.95	0.71	2.12e-16	Intelligence (multi-trait analysis);
THYM	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg05043794	chr9:111880884	C9orf5	-0.36	-5.01	-0.46	2.48e-6	Menarche (age at onset);
THYM	cis	rs7814319	0.933	rs7827095	chr8:97239126	C/T	cg20787634	chr8:97240163	UQCRB	0.75	8.9	0.67	3.7e-14	Lung function (FVC);
THYM	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg19774624	chr17:42201019	HDAC5	-0.82	-7.98	-0.63	3.31e-12	Total body bone mineral density;
THYM	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg14019146	chr3:50243930	SLC38A3	0.54	4.56	0.42	1.53e-5	Body mass index;
THYM	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg04944784	chr2:26401820	FAM59B	-1.08	-8.57	-0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	5.92	0.52	5.18e-8	Obesity-related traits;
THYM	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg27532560	chr4:187881888	NA	-0.95	-11.68	-0.77	4.63e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg08000102	chr2:233561755	GIGYF2	0.69	6.09	0.53	2.35e-8	Coronary artery disease;
THYM	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg23711669	chr6:146136114	FBXO30	0.93	9.69	0.7	7.64e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10992471	0.528	rs1924243	chr9:95224847	C/T	cg14631576	chr9:95140430	CENPP	-0.84	-8.02	-0.64	2.69e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg08000102	chr2:233561755	GIGYF2	-0.54	-4.75	-0.44	7.12e-6	Coronary artery disease;
THYM	cis	rs10927875	0.691	rs2017583	chr1:16350028	A/G	cg21385522	chr1:16154831	NA	0.74	5.44	0.49	4.13e-7	Dilated cardiomyopathy;
THYM	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg03929089	chr4:120376271	NA	-0.97	-7.74	-0.62	1.06e-11	Coronary artery disease;
THYM	cis	rs6163	0.588	rs3818708	chr10:104503584	C/T	cg15744005	chr10:104629667	AS3MT	-0.79	-7.65	-0.62	1.66e-11	Waist circumference;Hip circumference;
THYM	cis	rs6430585	0.583	rs76097170	chr2:136593498	C/T	cg04750100	chr2:136595281	LCT	0.61	6.28	0.54	9.94e-9	Corneal structure;
THYM	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg10803722	chr21:46713166	LOC642852	-0.39	-5.05	-0.46	2.14e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg10047753	chr17:41438598	NA	1.19	11.15	0.75	5.97e-19	Menopause (age at onset);
THYM	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg00814883	chr7:100076585	TSC22D4	-0.95	-6.36	-0.55	6.93e-9	Platelet count;
THYM	cis	rs8077889	1.000	rs4793035	chr17:41887753	C/T	cg26893861	chr17:41843967	DUSP3	1.09	10.05	0.72	1.3e-16	Triglycerides;
THYM	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg08999081	chr20:33150536	PIGU	0.8	7.1	0.59	2.21e-10	Coronary artery disease;
THYM	cis	rs7119	0.634	rs11635634	chr15:77863412	T/C	cg10437265	chr15:77819839	NA	-0.64	-6.5	-0.55	3.67e-9	Type 2 diabetes;
THYM	cis	rs11739663	0.574	rs67276442	chr5:583918	T/C	cg16624210	chr5:671434	TPPP	0.68	6.71	0.57	1.37e-9	Ulcerative colitis;
THYM	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg12311346	chr5:56204834	C5orf35	0.87	5.9	0.52	5.58e-8	Initial pursuit acceleration;
THYM	cis	rs17401966	1.000	rs7530167	chr1:10453374	A/G	cg19773385	chr1:10388646	KIF1B	-0.63	-4.84	-0.44	5e-6	Hepatocellular carcinoma;
THYM	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.22e-7	Corneal astigmatism;
THYM	cis	rs10089	0.951	rs1864923	chr5:127420843	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg17074396	chr22:49843754	NA	-0.39	-4.52	-0.42	1.76e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4654899	1.000	rs7537072	chr1:21434533	T/C	cg01072550	chr1:21505969	NA	-0.74	-6.82	-0.57	8.58e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs4077515	0.870	rs10781510	chr9:139279173	G/A	cg14115884	chr9:139300582	SDCCAG3	0.73	6.9	0.58	5.79e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs834811	0.829	rs6980107	chr7:135900757	C/T	cg01726295	chr7:135938950	NA	-0.68	-6.06	-0.53	2.68e-8	Post-traumatic stress disorder;
THYM	cis	rs80319144	1.000	rs76714700	chr2:159265263	T/G	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs3087591	0.919	rs2952993	chr17:29539998	G/A	cg24425628	chr17:29625626	OMG;NF1	0.67	5.36	0.48	5.77e-7	Hip circumference;
THYM	cis	rs863345	0.604	rs7533071	chr1:158504479	T/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.33e-5	Alzheimer's disease;
THYM	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg06636001	chr8:8085503	FLJ10661	0.74	6.52	0.56	3.45e-9	Mood instability;
THYM	cis	rs757110	0.745	rs10734252	chr11:17404839	G/A	cg15432903	chr11:17409602	KCNJ11	0.58	6.59	0.56	2.43e-9	Type 2 diabetes;
THYM	trans	rs9929218	0.551	rs6499193	chr16:68727069	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.08	13.44	0.81	1.06e-23	Colorectal cancer;
THYM	cis	rs67072384	1.000	rs11235577	chr11:72451380	C/T	cg01380194	chr11:72452482	ARAP1	-0.97	-5.26	-0.47	8.93e-7	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs6089829	0.851	rs10854168	chr20:61669550	A/G	cg08564027	chr20:61660810	NA	0.97	10.38	0.73	2.61e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg27286337	chr10:134555280	INPP5A	0.96	7.9	0.63	4.94e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg02887458	chr19:19495540	GATAD2A	-0.44	-5.16	-0.47	1.33e-6	Bipolar disorder;
THYM	cis	rs6952808	0.626	rs57633152	chr7:2042547	C/G	cg14004847	chr7:1930337	MAD1L1	-0.68	-5.13	-0.47	1.54e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9443645	0.527	rs9359360	chr6:79702796	C/T	cg05283184	chr6:79620031	NA	-0.6	-4.67	-0.43	9.86e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1865721	0.771	rs7235563	chr18:73139335	C/G	cg26385618	chr18:73139727	C18orf62	-0.65	-4.88	-0.45	4.33e-6	Intelligence;
THYM	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7584330	0.554	rs7573177	chr2:238444467	C/T	cg08992911	chr2:238395768	MLPH	-0.69	-4.48	-0.42	2.08e-5	Prostate cancer;
THYM	cis	rs72627123	0.867	rs17093884	chr14:74482039	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.86	4.91	0.45	3.77e-6	Morning vs. evening chronotype;
THYM	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg14675211	chr2:100938903	LONRF2	0.77	8.39	0.65	4.51e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9807841	0.544	rs10407692	chr19:10770783	A/G	cg17848348	chr19:10766748	ILF3	-0.76	-6.17	-0.53	1.68e-8	Inflammatory skin disease;
THYM	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg09537434	chr19:41945824	ATP5SL	-1.09	-10.28	-0.73	4.16e-17	Height;
THYM	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs7267979	1.000	rs6050599	chr20:25400240	T/C	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7760949	0.889	rs9396272	chr6:13938080	C/T	cg27413430	chr6:13925136	RNF182	-0.53	-4.64	-0.43	1.11e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6840360	0.615	rs10021407	chr4:152465002	A/G	cg17479576	chr4:152424074	FAM160A1	-0.83	-6.46	-0.55	4.43e-9	Intelligence (multi-trait analysis);
THYM	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg14433983	chr11:636460	DRD4	-0.63	-4.51	-0.42	1.85e-5	Systemic lupus erythematosus;
THYM	cis	rs11711311	1.000	rs12636577	chr3:113497507	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.17	-0.47	1.3e-6	IgG glycosylation;
THYM	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg07936489	chr17:37558343	FBXL20	0.83	5.69	0.5	1.41e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg14581129	chr12:53358946	NA	-0.97	-7.08	-0.59	2.51e-10	Prostate cancer;
THYM	cis	rs6838801	0.823	rs28583649	chr4:77591712	T/A	cg01477861	chr4:77609841	SHROOM3	0.47	4.75	0.44	7.11e-6	Cleft lip with or without cleft palate;
THYM	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03517284	chr6:25882590	NA	-0.76	-5.98	-0.52	3.87e-8	Blood metabolite levels;
THYM	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg15693483	chr7:1102177	C7orf50	0.54	6.37	0.55	6.72e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.62	-4.84	-0.45	4.94e-6	Blood metabolite levels;
THYM	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg13175981	chr1:150552382	MCL1	0.78	5.79	0.51	8.88e-8	Tonsillectomy;
THYM	cis	rs3924048	0.559	rs6541037	chr1:12626155	A/G	cg00291366	chr1:12616550	NA	0.34	5.07	0.46	1.93e-6	Optic cup area;
THYM	cis	rs7586879	0.662	rs2384059	chr2:25100338	C/T	cg01884057	chr2:25150051	NA	0.71	7.53	0.61	2.89e-11	Body mass index;
THYM	cis	rs6743226	0.840	rs6747036	chr2:242227054	T/C	cg10021735	chr2:242295487	FARP2	0.63	4.49	0.42	1.98e-5	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg07061783	chr6:25882402	NA	0.72	5.75	0.51	1.06e-7	Intelligence (multi-trait analysis);
THYM	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg14159672	chr1:205819179	PM20D1	0.59	4.68	0.43	9.53e-6	Parkinson's disease;
THYM	cis	rs11186	0.556	rs72906384	chr2:189966491	A/C	cg11041835	chr2:189156425	GULP1	0.8	4.58	0.43	1.41e-5	Parkinson's disease;
THYM	cis	rs6684428	1.000	rs12070494	chr1:56348904	C/T	cg11651538	chr1:56320950	NA	-0.58	-4.54	-0.42	1.63e-5	Airflow obstruction;
THYM	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg11166453	chr1:247681781	NA	0.69	5.38	0.48	5.45e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs17006441	0.774	rs6768731	chr3:69845572	C/G	cg18496212	chr3:69797108	MITF	0.69	7.12	0.59	2.02e-10	Hemoglobin concentration;
THYM	cis	rs2455799	0.613	rs2455813	chr3:15735051	C/G	cg16303742	chr3:15540471	COLQ	-0.55	-5.98	-0.52	3.85e-8	Mean platelet volume;
THYM	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg07636037	chr3:49044803	WDR6	0.74	5.15	0.47	1.38e-6	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg11965913	chr1:205819406	PM20D1	1.13	14.13	0.82	4.5e-25	Menarche (age at onset);
THYM	cis	rs10504073	0.647	rs2292399	chr8:49987230	A/G	cg00325661	chr8:49890786	NA	0.93	8.79	0.67	6.32e-14	Blood metabolite ratios;
THYM	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg01304814	chr3:48885189	PRKAR2A	0.96	4.86	0.45	4.55e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg06009448	chr7:1102226	C7orf50	0.53	5.55	0.49	2.6e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.74	-6.76	-0.57	1.13e-9	Personality dimensions;
THYM	cis	rs2456568	0.741	rs2102332	chr11:93635281	G/T	cg17347335	chr11:93583973	C11orf90	-0.48	-4.58	-0.43	1.39e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs4936891	0.599	rs729775	chr11:123910401	C/A	cg22125253	chr11:123886957	OR10G4	-0.53	-4.55	-0.42	1.57e-5	Male fertility;
THYM	cis	rs9828933	0.832	rs2292662	chr3:63897215	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.72	-4.87	-0.45	4.52e-6	Type 2 diabetes;
THYM	cis	rs1823778	0.618	rs1583438	chr18:67700180	G/A	cg13164537	chr18:67624071	CD226	1.15	4.8	0.44	5.83e-6	Mean platelet volume;
THYM	cis	rs763014	0.500	rs11865749	chr16:717971	C/G	cg05638439	chr16:711235	WDR90	-0.76	-8.38	-0.65	4.8e-13	Height;
THYM	cis	rs2997447	0.688	rs3008431	chr1:26371281	A/G	cg19633962	chr1:26362018	EXTL1	-0.75	-4.87	-0.45	4.4e-6	QRS complex (12-leadsum);
THYM	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg15536230	chr21:44985092	HSF2BP	-0.42	-4.84	-0.44	5.02e-6	Mean corpuscular volume;
THYM	cis	rs60871478	0.628	rs73038185	chr7:845206	A/G	cg10248100	chr7:872053	UNC84A	0.74	4.85	0.45	4.86e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg00012203	chr2:219082015	ARPC2	-0.64	-5.2	-0.47	1.15e-6	Colorectal cancer;
THYM	cis	rs35110281	0.607	rs8131020	chr21:44981063	C/A	cg01579765	chr21:45077557	HSF2BP	-0.45	-6.8	-0.57	9.24e-10	Mean corpuscular volume;
THYM	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	8.69	0.67	1.04e-13	Cognitive test performance;
THYM	cis	rs11255615	1	rs11255615	chr10:8324889	C/T	cg24202448	chr10:7568106	NA	-0.95	-4.84	-0.45	4.93e-6	Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule);
THYM	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg22852734	chr6:133119734	C6orf192	1.23	7.73	0.62	1.1e-11	Type 2 diabetes nephropathy;
THYM	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg08999081	chr20:33150536	PIGU	-0.55	-4.84	-0.44	5.05e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs59698941	0.943	rs72799498	chr5:132291157	G/A	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs2075230	0.705	rs1641540	chr17:7545187	C/T	cg10509001	chr17:7553872	ATP1B2	-0.56	-4.52	-0.42	1.79e-5	Hormone measurements;
THYM	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg06481639	chr22:41940642	POLR3H	-0.73	-5.08	-0.46	1.91e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg23815491	chr16:72088622	HP	0.78	6.13	0.53	1.98e-8	Fibrinogen levels;
THYM	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg27490568	chr2:178487706	NA	0.58	5.35	0.48	6.11e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7940866	0.834	rs10791108	chr11:130849354	T/A	cg23692386	chr11:131799662	NTM	0.51	5.35	0.48	6.1e-7	Schizophrenia;
THYM	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg27129171	chr3:47204927	SETD2	-0.72	-6.87	-0.58	6.72e-10	Colorectal cancer;
THYM	cis	rs11249608	0.548	rs10516150	chr5:178459169	G/C	cg01312482	chr5:178451176	ZNF879	-0.76	-6.3	-0.54	9.29e-9	Pubertal anthropometrics;
THYM	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg15445000	chr17:37608096	MED1	0.44	5.07	0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg27170947	chr2:26402098	FAM59B	-0.61	-5.04	-0.46	2.25e-6	Gut microbiome composition (summer);
THYM	cis	rs12643440	0.538	rs62296684	chr4:17137455	A/T	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs13242816	0.881	rs13235183	chr7:116140149	G/T	cg16553024	chr7:116138462	CAV2	-1.09	-4.82	-0.44	5.51e-6	P wave duration;
THYM	cis	rs56309584	0.599	rs117347460	chr17:8097171	C/T	cg08322244	chr17:8066669	VAMP2	-0.53	-4.64	-0.43	1.1e-5	Initial pursuit acceleration;
THYM	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg23205692	chr1:25664452	TMEM50A	0.8	6.27	0.54	1.07e-8	Erythrocyte sedimentation rate;
THYM	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg13147721	chr7:65941812	NA	0.73	4.58	0.43	1.42e-5	Diabetic kidney disease;
THYM	cis	rs13394619	0.875	rs9287734	chr2:11724475	A/G	cg07314298	chr2:11723111	GREB1	-0.62	-6.09	-0.53	2.36e-8	Endometriosis;
THYM	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg27144592	chr16:783916	NARFL	0.46	5.01	0.46	2.54e-6	Height;
THYM	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11890956	chr21:40555474	PSMG1	-0.68	-6.42	-0.55	5.42e-9	Menarche (age at onset);
THYM	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	5.56	0.5	2.42e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7432375	0.966	rs7618871	chr3:136400420	G/T	cg21827317	chr3:136751795	NA	-0.57	-4.87	-0.45	4.42e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs988913	0.813	rs7741915	chr6:54755871	C/T	cg18532076	chr6:54711417	FAM83B	0.49	5.07	0.46	1.99e-6	Menarche (age at onset);
THYM	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4589258	1.000	rs4462299	chr11:90483274	A/T	cg26138821	chr11:89956704	CHORDC1	-0.68	-5.64	-0.5	1.73e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.538	rs6017488	chr20:43731022	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.54	-5.82	-0.51	7.84e-8	Blood protein levels;
THYM	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg13393036	chr8:95962371	TP53INP1	-0.48	-4.72	-0.44	8.22e-6	Type 2 diabetes;
THYM	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg19507638	chr5:93509721	C5orf36	-0.68	-4.57	-0.42	1.49e-5	Diabetic retinopathy;
THYM	cis	rs11943027	0.703	rs2381288	chr4:38827637	G/A	cg06935464	chr4:38784597	TLR10	0.61	4.5	0.42	1.9e-5	Alcohol dependence;
THYM	cis	rs946836	0.562	rs1361443	chr1:48391668	C/T	cg07202054	chr1:48452740	NA	-0.44	-4.59	-0.43	1.34e-5	White matter integrity;
THYM	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg00255919	chr5:131827918	IRF1	0.5	6.24	0.54	1.21e-8	Breast cancer;Mosquito bite size;
THYM	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07167872	chr1:205819463	PM20D1	1.15	12.6	0.79	5.61e-22	Menarche (age at onset);
THYM	cis	rs7107174	1.000	rs58235466	chr11:78030886	T/C	cg19901956	chr11:77921274	USP35	-0.66	-5.05	-0.46	2.13e-6	Testicular germ cell tumor;
THYM	cis	rs2658782	0.951	rs117384439	chr11:93111478	T/G	cg15737290	chr11:93063684	CCDC67	-0.98	-7.67	-0.62	1.51e-11	Pulmonary function decline;
THYM	cis	rs4481887	1.000	rs10888351	chr1:248451608	G/A	cg00666640	chr1:248458726	OR2T12	0.56	4.53	0.42	1.69e-5	Common traits (Other);
THYM	cis	rs288326	0.561	rs75139715	chr2:183890660	T/A	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2562456	0.833	rs516519	chr19:21481532	C/G	cg21751540	chr19:21541537	ZNF738	0.72	4.72	0.44	8.17e-6	Pain;
THYM	cis	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg21775007	chr8:11205619	TDH	0.68	5.83	0.51	7.57e-8	Retinal vascular caliber;
THYM	trans	rs8073060	0.505	rs225276	chr17:33973034	T/C	cg19694781	chr19:47549865	TMEM160	-0.95	-7.8	-0.62	7.8e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs79149102	0.579	rs7181942	chr15:75300623	G/C	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.99	-0.75	1.26e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg00376283	chr12:123451042	ABCB9	0.72	4.94	0.45	3.36e-6	Neutrophil percentage of white cells;
THYM	cis	rs4638749	0.677	rs2219081	chr2:108844350	T/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg05025164	chr4:1340916	KIAA1530	0.71	5.32	0.48	6.9e-7	Longevity;
THYM	cis	rs2289328	0.943	rs3803359	chr15:40662748	A/G	cg13931752	chr15:40660718	DISP2	-0.64	-5.23	-0.47	1.03e-6	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
THYM	cis	rs807669	0.772	rs809901	chr22:19228736	C/T	cg02655711	chr22:19163373	SLC25A1	0.64	7.22	0.59	1.3e-10	Metabolite levels;
THYM	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg06634786	chr22:41940651	POLR3H	-0.72	-6.01	-0.52	3.39e-8	Vitiligo;
THYM	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs72781680	0.898	rs56413706	chr2:24086961	G/A	cg08917208	chr2:24149416	ATAD2B	1.11	4.97	0.45	2.9e-6	Lymphocyte counts;
THYM	cis	rs71403859	0.502	rs7195767	chr16:71464943	A/G	cg08717414	chr16:71523259	ZNF19	-1.27	-5.7	-0.5	1.34e-7	Post bronchodilator FEV1;
THYM	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg03609598	chr5:56110824	MAP3K1	0.67	4.69	0.43	9.21e-6	Coronary artery disease;
THYM	cis	rs7193541	0.640	rs4072222	chr16:74706736	A/C	cg01733217	chr16:74700730	RFWD3	1.01	12.44	0.79	1.18e-21	Multiple myeloma;
THYM	cis	rs7264396	0.887	rs2236165	chr20:34096725	A/G	cg26038318	chr20:34205095	SPAG4	0.53	4.47	0.42	2.15e-5	Total cholesterol levels;
THYM	cis	rs7616559	0.512	rs2046270	chr3:156730764	A/T	cg15697575	chr3:156784781	NA	0.36	5.11	0.46	1.64e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs860818	1.000	rs858250	chr7:23218560	C/A	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg05738196	chr6:26577821	NA	0.97	9.6	0.7	1.17e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4792901	0.694	rs9907819	chr17:41602865	T/C	cg21940313	chr17:41620911	ETV4	-0.53	-5.03	-0.46	2.28e-6	Dupuytren's disease;
THYM	cis	rs921943	0.554	rs163132	chr5:78285921	A/G	cg11541897	chr5:78281793	ARSB	0.54	5.09	0.46	1.78e-6	Blood and toenail selenium levels;Blood trace element (Se levels);
THYM	cis	rs3092073	0.617	rs3746513	chr20:44594228	G/A	cg04940435	chr20:44420291	WFDC3;DNTTIP1	-0.48	-5.05	-0.46	2.16e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg08132940	chr7:1081526	C7orf50	-1.26	-7.56	-0.61	2.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10982256	0.789	rs2296262	chr9:117265406	C/T	cg15903421	chr9:117267460	DFNB31	-0.55	-5.21	-0.47	1.1e-6	Bipolar disorder;
THYM	cis	rs10479542	0.766	rs2411380	chr5:178973780	T/C	cg14820908	chr5:178986412	RUFY1	-0.53	-4.99	-0.46	2.68e-6	Lung cancer;
THYM	cis	rs6543140	0.964	rs2080288	chr2:103022166	G/A	cg03938978	chr2:103052716	IL18RAP	0.61	6.13	0.53	1.96e-8	Blood protein levels;
THYM	cis	rs12042938	0.579	rs980394	chr1:231779507	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.71	-4.98	-0.45	2.86e-6	Neuranatomic and neurocognitive phenotypes;
THYM	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg24675056	chr1:15929824	NA	0.73	5.86	0.52	6.71e-8	Systolic blood pressure;
THYM	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg13683864	chr3:40499215	RPL14	-1.05	-11.57	-0.76	7.71e-20	Renal cell carcinoma;
THYM	cis	rs17401966	1.000	rs3753037	chr1:10355834	C/T	cg20482658	chr1:10539492	PEX14	0.39	4.77	0.44	6.54e-6	Hepatocellular carcinoma;
THYM	cis	rs7084921	0.608	rs12780510	chr10:101865881	T/C	cg11344164	chr10:101878520	NA	-0.55	-4.74	-0.44	7.56e-6	Bone mineral density;
THYM	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg08847533	chr14:75593920	NEK9	-1.03	-11.28	-0.76	3.11e-19	Height;
THYM	cis	rs4072705	1.000	rs6478680	chr9:127458468	G/A	cg01786973	chr9:127249749	NR5A1	0.37	4.89	0.45	4.02e-6	Menarche (age at onset);
THYM	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg11247378	chr22:39784982	NA	-1.02	-13.44	-0.81	1.05e-23	Intelligence (multi-trait analysis);
THYM	cis	rs748404	0.690	rs2244981	chr15:43752751	T/C	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs4273100	0.646	rs4924990	chr17:19294824	G/T	cg18093559	chr17:18951025	GRAP	0.72	4.54	0.42	1.68e-5	Schizophrenia;
THYM	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg12386194	chr3:101231763	SENP7	0.69	5.21	0.47	1.1e-6	Colorectal cancer;
THYM	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.59	-7.32	-0.6	7.84e-11	Longevity;Endometriosis;
THYM	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg15445000	chr17:37608096	MED1	0.44	5.07	0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7084402	0.967	rs1649072	chr10:60298112	G/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.64	-0.5	1.72e-7	Refractive error;
THYM	cis	rs4499344	0.658	rs10415040	chr19:33052706	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.72	-4.9	-0.45	3.95e-6	Mean platelet volume;
THYM	cis	rs9796	0.621	rs2578655	chr15:41462809	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.6	-4.84	-0.44	5.05e-6	Menopause (age at onset);
THYM	cis	rs6032067	0.641	rs34602589	chr20:43768734	T/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.67	-5.94	-0.52	4.77e-8	Blood protein levels;
THYM	cis	rs8067545	0.611	rs1373146	chr17:20206675	G/A	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	trans	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg25214090	chr10:38739885	LOC399744	0.93	7.96	0.63	3.69e-12	Corneal astigmatism;
THYM	cis	rs6598541	0.821	rs62024526	chr15:99281188	C/T	cg13297560	chr15:99320054	IGF1R	-0.53	-4.89	-0.45	4.13e-6	Urate levels;
THYM	cis	rs2070677	1.000	rs2070677	chr10:135351174	A/T	cg20169779	chr10:135381914	SYCE1	-0.76	-5.51	-0.49	3.08e-7	Gout;
THYM	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg10047753	chr17:41438598	NA	1.15	10.32	0.73	3.45e-17	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg24375607	chr4:120327624	NA	0.62	5.11	0.46	1.7e-6	Corneal astigmatism;
THYM	cis	rs2012796	0.704	rs57670850	chr14:81841577	C/T	cg02996355	chr14:81879375	NA	0.83	6.35	0.55	7.2e-9	Night sleep phenotypes;
THYM	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.78	-5.08	-0.46	1.9e-6	Diabetic retinopathy;
THYM	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3857067	0.806	rs6857967	chr4:95112303	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.48	-0.42	2.07e-5	QT interval;
THYM	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg27284194	chr4:1044797	NA	0.66	5.03	0.46	2.33e-6	Recombination rate (females);
THYM	cis	rs669446	0.562	rs4660259	chr1:44194534	A/G	cg15962314	chr1:44399869	ARTN	0.47	5.18	0.47	1.22e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg22907277	chr7:1156413	C7orf50	0.78	6.56	0.56	2.87e-9	Longevity;Endometriosis;
THYM	cis	rs9527	0.590	rs2148200	chr10:104879847	C/A	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg03709012	chr19:19516395	GATAD2A	0.73	5.59	0.5	2.16e-7	Tonsillectomy;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg18126572	chr7:43909213	MRPS24	-1.29	-6.92	-0.58	5.35e-10	Pulmonary function decline;
THYM	cis	rs6570726	0.935	rs385185	chr6:145814992	A/G	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6087990	0.568	rs853854	chr20:31420757	T/A	cg13636640	chr20:31349939	DNMT3B	0.66	6.42	0.55	5.26e-9	Ulcerative colitis;
THYM	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg04476341	chr5:669733	TPPP	-0.49	-4.94	-0.45	3.3e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs8008002	1.000	rs8018744	chr14:75867306	C/T	cg17335494	chr14:75077385	LTBP2	0.47	4.49	0.42	2.01e-5	Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg07936489	chr17:37558343	FBXL20	-0.79	-5.7	-0.5	1.37e-7	Urinary metabolites;
THYM	cis	rs870825	0.616	rs28416641	chr4:185617999	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg00129232	chr17:37814104	STARD3	-0.77	-5.27	-0.48	8.58e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg23682913	chr1:2080710	PRKCZ	-0.54	-4.69	-0.43	9.1e-6	Height;
THYM	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg17366294	chr4:99064904	C4orf37	-0.57	-6.49	-0.55	3.79e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3820068	0.705	rs2042369	chr1:15843244	A/G	cg05660106	chr1:15850417	CASP9	-1.1	-9.92	-0.71	2.48e-16	Systolic blood pressure;
THYM	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg25767906	chr1:53392781	SCP2	-0.58	-5.84	-0.51	7.3e-8	Monocyte count;
THYM	cis	rs3136739	0.867	rs7829991	chr8:42103322	A/G	cg12091331	chr8:42065314	PLAT	0.63	4.78	0.44	6.37e-6	Plasma plasminogen activator levels;
THYM	cis	rs950880	0.710	rs3821204	chr2:102960281	C/G	cg03938978	chr2:103052716	IL18RAP	-0.52	-4.51	-0.42	1.83e-5	Serum protein levels (sST2);
THYM	cis	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg13683864	chr3:40499215	RPL14	-0.84	-7.85	-0.63	6.28e-12	Renal cell carcinoma;
THYM	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg14972814	chr11:95582409	MTMR2	-0.7	-6.48	-0.55	4.11e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1865721	0.771	rs7231277	chr18:73136724	A/G	cg26385618	chr18:73139727	C18orf62	-0.68	-5.12	-0.47	1.57e-6	Intelligence;
THYM	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg14019146	chr3:50243930	SLC38A3	0.85	7.32	0.6	8.02e-11	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg16325326	chr1:53192061	ZYG11B	-0.82	-8.46	-0.66	3.1400000000000003e-13	Monocyte count;
THYM	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg13609457	chr4:120235615	NA	0.6	5.35	0.48	5.99e-7	Corneal astigmatism;
THYM	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg13609457	chr4:120235615	NA	0.6	5.34	0.48	6.23e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12476592	0.516	rs11883730	chr2:63592230	A/C	cg17519650	chr2:63277830	OTX1	0.72	4.99	0.46	2.76e-6	Childhood ear infection;
THYM	cis	rs10463554	0.963	rs34381	chr5:102396556	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg11812906	chr14:75593930	NEK9	-0.86	-8.02	-0.64	2.74e-12	Height;
THYM	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg10802521	chr3:52805072	NEK4	-0.72	-6.12	-0.53	2.09e-8	Bipolar disorder;
THYM	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Body mass index;
THYM	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21582582	chr3:182698605	DCUN1D1	0.8	7.0	0.58	3.67e-10	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	0.544	rs13097602	chr3:40339247	T/C	cg13683864	chr3:40499215	RPL14	0.74	6.98	0.58	3.9e-10	Renal cell carcinoma;
THYM	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg13683864	chr3:40499215	RPL14	-0.85	-8.09	-0.64	1.91e-12	Renal cell carcinoma;
THYM	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg22079354	chr11:130786696	SNX19	0.52	4.58	0.43	1.39e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg11752832	chr7:134001865	SLC35B4	0.74	5.65	0.5	1.69e-7	Mean platelet volume;
THYM	cis	rs7084402	0.934	rs1649051	chr10:60321997	A/G	cg07615347	chr10:60278583	BICC1	0.55	5.07	0.46	1.92e-6	Refractive error;
THYM	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.12	-0.72	9.21e-17	Primary sclerosing cholangitis;
THYM	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg11317459	chr13:21872234	NA	-1.21	-9.22	-0.69	7.83e-15	White matter hyperintensity burden;
THYM	cis	rs6840360	0.615	rs1561917	chr4:152479233	G/A	cg22705602	chr4:152727874	NA	-0.71	-7.43	-0.61	4.71e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7572733	0.534	rs771009	chr2:198691082	A/G	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs7264396	0.790	rs6058283	chr20:34216276	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-5.65	-0.5	1.67e-7	Total cholesterol levels;
THYM	cis	rs11771526	0.901	rs17161123	chr7:32305426	G/A	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs35883536	0.545	rs56674564	chr1:101097718	T/C	cg06223162	chr1:101003688	GPR88	0.58	5.16	0.47	1.34e-6	Monocyte count;
THYM	trans	rs9951602	0.512	rs56009939	chr18:76644497	T/G	cg02800362	chr5:177631904	HNRNPAB	1.11	8.66	0.66	1.21e-13	Obesity-related traits;
THYM	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg06108461	chr20:60628389	TAF4	-1.01	-7.04	-0.59	2.94e-10	Body mass index;
THYM	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg18681998	chr4:17616180	MED28	0.95	9.51	0.7	1.88e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg05901451	chr6:126070800	HEY2	0.61	5.01	0.46	2.5e-6	Endometrial cancer;
THYM	cis	rs2404602	0.647	rs3812909	chr15:77176200	A/T	cg23625390	chr15:77176239	SCAPER	-0.82	-5.85	-0.51	6.95e-8	Blood metabolite levels;
THYM	cis	rs526231	0.511	rs10434792	chr5:102389602	G/C	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Primary biliary cholangitis;
THYM	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg20387954	chr3:183756860	HTR3D	0.58	4.73	0.44	7.72e-6	Anterior chamber depth;
THYM	cis	rs6754311	0.593	rs10928542	chr2:136410299	G/A	cg20242066	chr2:136595261	LCT	0.55	6.04	0.53	3.05e-8	Mosquito bite size;
THYM	cis	rs11264213	0.901	rs649152	chr1:36438649	T/G	cg27506609	chr1:36549197	TEKT2	0.92	4.83	0.44	5.3e-6	Schizophrenia;
THYM	cis	rs12410462	1.000	rs12407171	chr1:227642282	G/A	cg23173402	chr1:227635558	NA	0.67	5.97	0.52	4.02e-8	Major depressive disorder;
THYM	cis	rs11563648	0.553	rs10249166	chr7:127016155	G/C	cg23081781	chr7:127225937	GCC1	-0.37	-5.12	-0.46	1.61e-6	Resting heart rate;
THYM	cis	rs7740797	0.818	rs9397747	chr6:155106151	G/T	cg02865717	chr6:155053990	RBM16	-0.46	-4.64	-0.43	1.11e-5	Colorectal or endometrial cancer;
THYM	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg10802521	chr3:52805072	NEK4	-0.71	-6.18	-0.54	1.57e-8	Bipolar disorder;
THYM	cis	rs12142240	0.698	rs55670684	chr1:46835139	C/T	cg00530320	chr1:46809349	NSUN4	0.8	5.5	0.49	3.16e-7	Menopause (age at onset);
THYM	cis	rs6430585	0.583	rs4988145	chr2:136632300	A/C	cg07169764	chr2:136633963	MCM6	1.25	14.11	0.82	4.87e-25	Corneal structure;
THYM	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.64	-4.96	-0.45	3.1e-6	Tonsillectomy;
THYM	cis	rs55637147	0.671	rs10896610	chr11:57119602	G/A	cg15971518	chr11:57159174	PRG2	-0.65	-5.07	-0.46	1.98e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs2074585	0.560	rs1973537	chr15:91062901	T/C	cg22089800	chr15:90895588	ZNF774	-0.66	-4.79	-0.44	6.21e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
THYM	cis	rs7107174	1.000	rs10793311	chr11:78104399	G/C	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg07341220	chr16:1583899	IFT140;TMEM204	-0.66	-5.41	-0.49	4.64e-7	Coronary artery disease;
THYM	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.89	0.52	5.88e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7100689	0.646	rs1953972	chr10:82145666	A/G	cg01528321	chr10:82214614	TSPAN14	0.89	6.73	0.57	1.26e-9	Post bronchodilator FEV1;
THYM	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg03806693	chr22:41940476	POLR3H	1.08	8.43	0.65	3.63e-13	Vitiligo;
THYM	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs17818399	0.926	rs13033177	chr2:46831062	C/A	cg02822958	chr2:46747628	ATP6V1E2	0.63	4.5	0.42	1.93e-5	Height;
THYM	cis	rs2219968	0.962	rs2368508	chr8:78951278	T/C	cg00738934	chr8:78996279	NA	0.8	8.43	0.65	3.79e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	5.75	0.51	1.08e-7	Blood metabolite levels;
THYM	cis	rs6901250	0.744	rs636872	chr6:117087944	C/T	cg12892004	chr6:117198278	RFX6	0.76	7.36	0.6	6.5e-11	C-reactive protein levels;
THYM	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg02725872	chr8:58115012	NA	-0.98	-7.38	-0.6	5.95e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg14008862	chr17:28927542	LRRC37B2	0.92	4.79	0.44	6.05e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7818345	0.967	rs4391454	chr8:19275653	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.53	0.42	1.7e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	7.56	0.61	2.49e-11	Platelet count;
THYM	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg05707623	chr12:122985044	ZCCHC8	0.75	5.1	0.46	1.7e-6	Body mass index;
THYM	cis	rs72828912	0.831	rs2176933	chr6:24094140	A/G	cg26336265	chr6:25042955	NA	0.74	5.59	0.5	2.2e-7	Squamous cell lung carcinoma;
THYM	cis	rs675209	0.576	rs11243143	chr6:7120457	G/A	cg24899545	chr6:7112846	RREB1	-0.47	-4.87	-0.45	4.38e-6	Urate levels;
THYM	cis	rs75920871	0.528	rs11216255	chr11:116929995	A/G	cg20608306	chr11:116969690	SIK3	-0.54	-6.01	-0.52	3.45e-8	Subjective well-being;
THYM	cis	rs854765	0.964	rs12943202	chr17:17994332	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-4.86	-0.45	4.66e-6	Total body bone mineral density;
THYM	cis	rs4986172	0.539	rs3744760	chr17:43195981	C/T	cg24180402	chr17:43221464	ACBD4	-0.56	-4.77	-0.44	6.68e-6	Height;
THYM	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg18538332	chr22:24372958	LOC391322	-0.91	-10.86	-0.74	2.46e-18	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.96	8.0	0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs2455799	0.573	rs2470539	chr3:15717844	C/T	cg16303742	chr3:15540471	COLQ	-0.55	-5.63	-0.5	1.81e-7	Mean platelet volume;
THYM	cis	rs2504916	0.784	rs2457561	chr6:160755810	C/T	cg19643109	chr6:160697625	NA	-0.66	-5.09	-0.46	1.82e-6	Response to hepatitis C treatment;
THYM	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.47	-0.49	3.59e-7	Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769765	0.657	rs8136116	chr22:50256886	T/A	cg08270630	chr22:50330655	NA	0.72	4.68	0.43	9.6e-6	Schizophrenia;
THYM	cis	rs901683	0.702	rs76831684	chr10:46116032	C/T	cg18240400	chr10:46168597	ANUBL1	0.68	4.67	0.43	9.88e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.01	8.08	0.64	2.07e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs988913	1.000	rs9349740	chr6:54825708	A/C	cg04690482	chr6:54711388	FAM83B	0.46	5.17	0.47	1.31e-6	Menarche (age at onset);
THYM	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs1729951	0.546	rs12054218	chr3:136677496	C/G	cg12473912	chr3:136751656	NA	0.63	5.13	0.47	1.55e-6	Neuroticism;
THYM	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4803468	1.000	rs2569754	chr19:41936734	A/G	cg09537434	chr19:41945824	ATP5SL	-1.02	-8.91	-0.67	3.46e-14	Height;
THYM	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg18132916	chr6:79620363	NA	-0.6	-4.99	-0.46	2.72e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.72	4.65	0.43	1.07e-5	Lymphocyte percentage of white cells;
THYM	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg11335335	chr11:637885	DRD4	-0.73	-6.17	-0.53	1.65e-8	Systemic lupus erythematosus;
THYM	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg09455208	chr3:40491958	NA	0.45	4.55	0.42	1.59e-5	Renal cell carcinoma;
THYM	cis	rs9810089	0.708	rs711977	chr3:136227387	G/A	cg12473912	chr3:136751656	NA	0.57	4.78	0.44	6.44e-6	Gestational age at birth (child effect);
THYM	cis	rs7909074	1.000	rs4948925	chr10:45392455	C/T	cg05187965	chr10:45406764	TMEM72	-0.56	-5.5	-0.49	3.16e-7	Mean corpuscular volume;
THYM	cis	rs2292884	0.505	rs78063959	chr2:238428961	G/A	cg08992911	chr2:238395768	MLPH	0.92	5.79	0.51	9.04e-8	Prostate cancer;
THYM	cis	rs295140	0.546	rs842830	chr2:201131124	C/T	cg03447810	chr2:200324230	SATB2	-0.62	-4.69	-0.43	9.04e-6	QT interval;
THYM	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg08885076	chr2:99613938	TSGA10	0.63	6.0	0.52	3.64e-8	Chronic sinus infection;
THYM	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2108622	0.727	rs7254940	chr19:15984508	C/T	cg13772218	chr19:15982569	NA	0.5	4.48	0.42	2.06e-5	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4900538	0.963	rs1190553	chr14:102915331	G/T	cg18135206	chr14:102964638	TECPR2	-0.98	-8.26	-0.65	8.63e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2285947	1.000	rs10229224	chr7:21583921	G/A	cg04471919	chr7:21584483	DNAH11	0.45	4.46	0.42	2.29e-5	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
THYM	cis	rs3092073	0.617	rs3893276	chr20:44591089	G/C	cg04940435	chr20:44420291	WFDC3;DNTTIP1	-0.48	-5.1	-0.46	1.74e-6	Intelligence (multi-trait analysis);
THYM	cis	rs17604090	0.938	rs68072609	chr7:29682467	C/T	cg19413766	chr7:29689036	LOC646762	-0.93	-4.98	-0.46	2.8e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs7107174	1.000	rs2511170	chr11:77980582	A/G	cg02023728	chr11:77925099	USP35	0.64	5.85	0.51	7.04e-8	Testicular germ cell tumor;
THYM	cis	rs7614311	0.596	rs2888013	chr3:64005226	A/G	cg22134162	chr3:63841271	THOC7	-0.37	-4.56	-0.42	1.52e-5	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs7688540	0.771	rs11730202	chr4:210096	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.72	4.88	0.45	4.35e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs1018836	0.923	rs9694450	chr8:91618292	G/A	cg16814680	chr8:91681699	NA	-0.85	-7.26	-0.6	1.08e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.35	-0.48	6.13e-7	Monocyte percentage of white cells;
THYM	cis	rs1729951	0.575	rs75976	chr3:136700455	G/A	cg21827317	chr3:136751795	NA	0.72	6.55	0.56	2.93e-9	Neuroticism;
THYM	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg00071950	chr4:10020882	SLC2A9	0.81	8.73	0.67	8.54e-14	Bone mineral density;
THYM	cis	rs79387448	0.745	rs1159509	chr2:103169073	T/A	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg08017756	chr2:100939284	LONRF2	-0.72	-7.35	-0.6	6.77e-11	Intelligence (multi-trait analysis);
THYM	cis	rs35110281	0.641	rs4818861	chr21:45123807	A/G	cg04455712	chr21:45112962	RRP1B	0.56	4.98	0.46	2.79e-6	Mean corpuscular volume;
THYM	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg06636001	chr8:8085503	FLJ10661	0.63	5.84	0.51	7.24e-8	Joint mobility (Beighton score);
THYM	cis	rs4631830	0.869	rs7896437	chr10:51529593	A/C	cg10326726	chr10:51549505	MSMB	-0.6	-5.96	-0.52	4.35e-8	Prostate-specific antigen levels;
THYM	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg17830980	chr10:43048298	ZNF37B	-1.02	-10.36	-0.73	2.81e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg06521331	chr12:34319734	NA	-1.02	-10.3	-0.73	3.78e-17	Morning vs. evening chronotype;
THYM	trans	rs3960554	0.569	rs10954750	chr7:75664921	C/G	cg19862616	chr7:65841803	NCRNA00174	-0.98	-8.74	-0.67	8.18e-14	Eotaxin levels;
THYM	cis	rs11039798	0.588	rs10838970	chr11:48606267	G/T	cg24672777	chr11:48374446	OR4C45	-0.93	-6.01	-0.52	3.39e-8	Axial length;
THYM	cis	rs10158481	0.713	rs28487940	chr1:25475026	T/G	cg09264742	chr1:25757510	TMEM57	-0.65	-4.6	-0.43	1.28e-5	Urate levels in obese individuals;
THYM	trans	rs629535	0.862	rs598548	chr8:70032438	C/T	cg21567404	chr3:27674614	NA	1.12	10.86	0.74	2.44e-18	Dupuytren's disease;
THYM	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg02493740	chr2:85810744	VAMP5	-0.64	-5.05	-0.46	2.12e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2625529	0.652	rs8040216	chr15:72255249	C/T	cg16672083	chr15:72433130	SENP8	0.49	4.49	0.42	1.97e-5	Red blood cell count;
THYM	cis	rs2458413	0.563	rs2458422	chr8:105332817	C/T	cg13045555	chr8:105342365	NA	-0.33	-6.42	-0.55	5.44e-9	Paget's disease;
THYM	cis	rs2658782	0.639	rs2100552	chr11:93182249	G/A	cg15737290	chr11:93063684	CCDC67	0.74	5.73	0.51	1.16e-7	Pulmonary function decline;
THYM	cis	rs11671005	0.693	rs11668821	chr19:58955813	G/A	cg02808233	chr19:58920810	ZNF584	0.57	4.77	0.44	6.77e-6	Mean platelet volume;
THYM	cis	rs1214752	0.874	rs4714680	chr6:43371565	G/T	cg09674015	chr6:43045187	PTK7	-0.52	-4.59	-0.43	1.37e-5	Coronary artery disease;
THYM	cis	rs240764	0.658	rs12194255	chr6:101168439	G/A	cg21058520	chr6:100914733	NA	0.56	4.73	0.44	7.94e-6	Neuroticism;
THYM	cis	rs2041895	0.509	rs1838445	chr12:107314585	T/A	cg26297688	chr12:107349093	C12orf23	-0.48	-4.73	-0.44	7.65e-6	Glaucoma (low intraocular pressure);
THYM	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.65	-4.72	-0.44	8.09e-6	Colorectal cancer;
THYM	cis	rs7940866	0.834	rs10894298	chr11:130840571	C/A	cg23692386	chr11:131799662	NTM	0.48	5.08	0.46	1.91e-6	Schizophrenia;
THYM	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg08772003	chr10:104629869	AS3MT	0.68	6.44	0.55	4.77e-9	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg13010199	chr12:38710504	ALG10B	0.64	4.61	0.43	1.25e-5	Morning vs. evening chronotype;
THYM	cis	rs8102476	0.846	rs11083450	chr19:38754239	T/C	cg14131526	chr19:38747285	PPP1R14A	-0.58	-5.41	-0.49	4.61e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg09549813	chr16:4587862	C16orf5	-0.59	-6.65	-0.56	1.84e-9	Schizophrenia;
THYM	cis	rs4907240	0.961	rs6759099	chr2:97267260	G/C	cg01950434	chr2:97203154	ARID5A	-0.57	-4.81	-0.44	5.71e-6	Event-related brain oscillations;
THYM	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg03188948	chr7:1209495	NA	0.68	4.73	0.44	7.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9902453	1.000	rs62070312	chr17:28438877	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.76	0.44	6.86e-6	Coffee consumption (cups per day);
THYM	cis	rs12711979	0.509	rs10187740	chr2:3823965	A/G	cg17052675	chr2:3827356	NA	0.88	14.17	0.82	3.59e-25	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7213347	0.555	rs2760751	chr17:2028106	A/G	cg16513277	chr17:2031491	SMG6	-0.63	-4.56	-0.42	1.52e-5	Total body bone mineral density;
THYM	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg13877915	chr19:58951672	ZNF132	0.94	9.4	0.69	3.24e-15	Uric acid clearance;
THYM	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs7267979	1.000	rs11087520	chr20:25436827	C/T	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg11247378	chr22:39784982	NA	-1.01	-9.67	-0.7	8.58e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs10979	1.000	rs9390110	chr6:143893413	A/G	cg25407410	chr6:143891975	LOC285740	-0.63	-5.18	-0.47	1.26e-6	Hypospadias;
THYM	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg10047753	chr17:41438598	NA	1.19	11.15	0.75	5.97e-19	Menopause (age at onset);
THYM	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10911232	0.507	rs4652762	chr1:182993960	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs2811415	0.627	rs1042911	chr3:127789594	T/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg03806693	chr22:41940476	POLR3H	1.24	10.61	0.74	8.15e-18	Vitiligo;
THYM	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg07424592	chr7:64974309	NA	1.1	5.08	0.46	1.87e-6	Diabetic kidney disease;
THYM	cis	rs3126085	0.935	rs7531094	chr1:152176850	A/G	cg10321714	chr1:152280068	FLG	0.68	5.07	0.46	1.98e-6	Atopic dermatitis;
THYM	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg05347473	chr6:146136440	FBXO30	-0.6	-4.85	-0.45	4.83e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2455799	0.573	rs2062824	chr3:15757901	T/C	cg16303742	chr3:15540471	COLQ	-0.58	-6.1	-0.53	2.29e-8	Mean platelet volume;
THYM	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.7	0.71	7.32e-16	Colorectal cancer;
THYM	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg11764359	chr7:65958608	NA	0.78	6.31	0.54	8.68e-9	Aortic root size;
THYM	cis	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05901451	chr6:126070800	HEY2	0.58	4.69	0.43	9.1e-6	Endometrial cancer;
THYM	cis	rs7809950	0.817	rs2237678	chr7:107203265	T/G	cg23024343	chr7:107201750	COG5	-1.05	-9.25	-0.69	6.47e-15	Coronary artery disease;
THYM	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.7	-0.5	1.33e-7	Prostate cancer;
THYM	cis	rs7731657	0.537	rs13355837	chr5:130360537	C/T	cg08523029	chr5:130500466	HINT1	-0.85	-5.98	-0.52	3.88e-8	Fasting plasma glucose;
THYM	cis	rs8028313	0.630	rs12438118	chr15:67951150	A/C	cg26545918	chr15:68124484	LBXCOR1	-0.55	-4.79	-0.44	6.11e-6	Obesity;
THYM	cis	rs4595586	0.545	rs9668716	chr12:39378833	G/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs12282928	0.959	rs1827502	chr11:48265966	G/A	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg12165864	chr7:66369176	NA	0.67	5.26	0.47	8.99e-7	Aortic root size;
THYM	cis	rs6901004	0.803	rs354545	chr6:111531412	G/A	cg15721981	chr6:111408429	SLC16A10	-0.53	-4.46	-0.42	2.25e-5	Blood metabolite levels;
THYM	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg09035930	chr12:129282057	SLC15A4	0.85	10.44	0.73	1.93e-17	Systemic lupus erythematosus;
THYM	trans	rs1974653	0.672	rs11703058	chr22:20075048	G/A	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.54	-4.48	-0.42	2.07e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1499972	0.938	rs864199	chr3:117755612	T/C	cg07612923	chr3:117604196	NA	-1.5	-5.16	-0.47	1.38e-6	Schizophrenia;
THYM	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg01831904	chr17:28903510	LRRC37B2	-1.0	-5.11	-0.46	1.65e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg05294307	chr14:35346193	BAZ1A	-0.85	-5.67	-0.5	1.52e-7	Psoriasis;
THYM	cis	rs76878669	0.561	rs12794121	chr11:66126169	G/T	cg18002602	chr11:66138449	SLC29A2	0.49	4.98	0.45	2.86e-6	Educational attainment (years of education);
THYM	trans	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs6840360	0.606	rs2724550	chr4:152358986	C/T	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4589258	1.000	rs4437994	chr11:90457515	C/G	cg26138821	chr11:89956704	CHORDC1	-0.68	-5.64	-0.5	1.73e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg07930552	chr6:133119739	C6orf192	0.96	5.5	0.49	3.14e-7	Type 2 diabetes nephropathy;
THYM	cis	rs4891159	0.790	rs56077581	chr18:74116865	T/G	cg24786174	chr18:74118243	ZNF516	-0.87	-9.75	-0.71	5.54e-16	Longevity;
THYM	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg24450063	chr1:156163899	SLC25A44	1.06	12.58	0.79	6.23e-22	Testicular germ cell tumor;
THYM	cis	rs2070488	1.000	rs762317	chr3:38497659	A/G	cg24069376	chr3:38537580	EXOG	0.68	6.73	0.57	1.26e-9	Electrocardiographic conduction measures;
THYM	cis	rs11089937	0.651	rs928894	chr22:22540272	T/C	cg21401457	chr22:22472743	NA	0.56	4.75	0.44	7.31e-6	Periodontitis (PAL4Q3);
THYM	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.39	6.02	0.53	3.28e-8	Obesity-related traits;
THYM	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg00074818	chr8:8560427	CLDN23	0.57	5.13	0.47	1.55e-6	Obesity-related traits;
THYM	cis	rs34602589	0.535	rs7346579	chr20:43844722	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.69	-6.28	-0.54	1.02e-8	Parental longevity (mother's age at death);
THYM	cis	rs240764	0.658	rs11155635	chr6:101199367	C/T	cg21058520	chr6:100914733	NA	0.56	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs763014	0.865	rs2071979	chr16:624114	A/G	cg00908189	chr16:619842	PIGQ	1.02	9.27	0.69	6.03e-15	Height;
THYM	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg08999081	chr20:33150536	PIGU	0.62	5.27	0.48	8.56e-7	Coronary artery disease;
THYM	cis	rs7578361	1.000	rs6724414	chr2:150431354	G/A	cg17961725	chr2:150454027	NA	0.71	6.03	0.53	3.1e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg22203890	chr5:980708	NA	0.63	4.81	0.44	5.72e-6	Cystic fibrosis severity;
THYM	cis	rs4077515	0.935	rs3088081	chr9:139270149	A/G	cg14115884	chr9:139300582	SDCCAG3	0.76	8.18	0.64	1.28e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg16989719	chr2:238392110	NA	-0.6	-5.82	-0.51	8.08e-8	Prostate cancer;
THYM	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg20891283	chr12:69753455	YEATS4	0.62	4.48	0.42	2.1e-5	Response to diuretic therapy;
THYM	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg04267008	chr7:1944627	MAD1L1	-0.7	-5.84	-0.51	7.3e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg08859206	chr1:53392774	SCP2	0.51	5.7	0.51	1.32e-7	Monocyte count;
THYM	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg13319975	chr6:146136371	FBXO30	-0.65	-5.33	-0.48	6.73e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg00129232	chr17:37814104	STARD3	-0.88	-6.92	-0.58	5.26e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs2404602	0.735	rs2280306	chr15:76652258	C/G	cg23625390	chr15:77176239	SCAPER	-0.65	-4.7	-0.43	8.68e-6	Blood metabolite levels;
THYM	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs11645898	0.745	rs55824906	chr16:72064905	A/G	cg14768367	chr16:72042858	DHODH	-0.81	-5.89	-0.52	5.95e-8	Blood protein levels;
THYM	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg11494091	chr17:61959527	GH2	0.68	6.25	0.54	1.14e-8	Height;
THYM	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2295359	0.892	rs12401432	chr1:67656931	C/G	cg11235152	chr1:67600687	NA	0.69	5.69	0.5	1.37e-7	Psoriasis;
THYM	cis	rs490234	0.616	rs2841325	chr9:128163620	C/G	cg14078157	chr9:128172775	NA	0.85	6.93	0.58	4.91e-10	Mean arterial pressure;
THYM	cis	rs6570726	0.791	rs6913727	chr6:145899826	A/G	cg05347473	chr6:146136440	FBXO30	0.58	4.53	0.42	1.7e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs921968	0.541	rs3770216	chr2:219443717	A/G	cg02176678	chr2:219576539	TTLL4	-0.72	-7.15	-0.59	1.75e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs17030434	0.813	rs11732480	chr4:154665733	C/A	cg14289246	chr4:154710475	SFRP2	-0.9	-5.85	-0.51	6.89e-8	Electrocardiographic conduction measures;
THYM	cis	rs600806	0.850	rs4970729	chr1:109979202	G/A	cg23032129	chr1:109941072	SORT1	-0.57	-4.82	-0.44	5.54e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4631830	0.896	rs7088225	chr10:51522120	T/C	cg10326726	chr10:51549505	MSMB	0.53	5.35	0.48	6.07e-7	Prostate-specific antigen levels;
THYM	cis	rs9554348	0.541	rs61966896	chr13:96943689	A/G	cg25169784	chr13:96706045	UGGT2	0.85	4.66	0.43	1.03e-5	Schizophrenia;
THYM	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg05347473	chr6:146136440	FBXO30	-0.82	-7.32	-0.6	7.82e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs72792324	0.655	rs10051438	chr5:140757325	A/T	cg21929183	chr5:140807225	PCDHGA4;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB8P;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	-0.84	-4.5	-0.42	1.96e-5	Mean platelet volume;
THYM	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg11266682	chr4:10021025	SLC2A9	0.74	10.8	0.74	3.21e-18	Bone mineral density;
THYM	cis	rs1278352	0.767	rs1278357	chr10:127774231	A/G	cg08295661	chr10:127769903	ADAM12	-0.55	-5.64	-0.5	1.71e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg06481639	chr22:41940642	POLR3H	-0.69	-5.1	-0.46	1.73e-6	Vitiligo;
THYM	cis	rs17001868	0.568	rs55769635	chr22:40790101	G/A	cg07138101	chr22:40742427	ADSL	0.91	5.57	0.5	2.39e-7	Mammographic density (dense area);
THYM	cis	rs7592578	0.639	rs13417431	chr2:191293055	A/G	cg27211696	chr2:191398769	TMEM194B	-0.61	-4.56	-0.42	1.55e-5	Diastolic blood pressure;
THYM	cis	rs6918586	1.000	rs198806	chr6:26133616	A/G	cg03517284	chr6:25882590	NA	0.61	4.6	0.43	1.31e-5	Schizophrenia;
THYM	cis	rs17174870	0.955	rs77290039	chr2:112741106	G/A	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs735396	0.532	rs1169296	chr12:121428407	A/G	cg02403541	chr12:121454288	C12orf43	0.8	7.49	0.61	3.48e-11	N-glycan levels;
THYM	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg11984989	chr7:158649758	WDR60	1.14	13.86	0.82	1.53e-24	Height;
THYM	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg05872129	chr22:39784769	NA	-0.98	-8.25	-0.65	8.99e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.81	5.34	0.48	6.27e-7	Platelet count;
THYM	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg03433033	chr1:76189801	ACADM	-0.74	-8.5	-0.66	2.69e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4523957	0.890	rs9908888	chr17:2102453	G/C	cg16513277	chr17:2031491	SMG6	-0.8	-7.87	-0.63	5.67e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs72829446	0.530	rs8075007	chr17:7374507	A/T	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg03859395	chr2:55845619	SMEK2	0.67	6.02	0.53	3.3e-8	Metabolic syndrome;
THYM	cis	rs2845885	0.744	rs3802932	chr11:63988045	G/A	cg15432711	chr11:63952213	STIP1	0.61	4.85	0.45	4.9e-6	Body mass index;
THYM	cis	rs709400	0.663	rs72710714	chr14:103981849	T/G	cg26031613	chr14:104095156	KLC1	0.74	4.6	0.43	1.28e-5	Body mass index;
THYM	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg24642844	chr7:1081250	C7orf50	-1.29	-8.31	-0.65	6.62e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg13683864	chr3:40499215	RPL14	-1.01	-10.37	-0.73	2.73e-17	Renal cell carcinoma;
THYM	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg06636001	chr8:8085503	FLJ10661	-0.74	-7.06	-0.59	2.73e-10	Triglycerides;
THYM	cis	rs526231	0.543	rs32851	chr5:102468671	A/G	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.49e-6	Primary biliary cholangitis;
THYM	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg14186256	chr22:23484241	RTDR1	0.95	9.24	0.69	7.12e-15	Bone mineral density;
THYM	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1371867	0.846	rs1660348	chr8:101315248	A/G	cg00191853	chr8:101177733	SPAG1	-0.51	-5.03	-0.46	2.29e-6	Atrioventricular conduction;
THYM	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg08048268	chr3:133502702	NA	0.65	5.14	0.47	1.49e-6	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs9644630	0.897	rs4921654	chr8:19359974	G/T	cg01280390	chr8:19363452	CSGALNACT1	-0.81	-8.83	-0.67	5.35e-14	Oropharynx cancer;
THYM	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg18252515	chr7:66147081	NA	-1.62	-8.8	-0.67	5.99e-14	Diabetic kidney disease;
THYM	cis	rs2970992	0.764	rs4850948	chr2:101324333	C/T	cg01042948	chr2:101319752	NA	-0.63	-6.38	-0.55	6.33e-9	Educational attainment;
THYM	cis	rs2294693	0.945	rs9394755	chr6:41006680	C/T	cg14418226	chr6:40996092	UNC5CL	-0.68	-5.62	-0.5	1.9e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs9311676	0.656	rs7642652	chr3:58373667	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg08772003	chr10:104629869	AS3MT	-0.57	-4.92	-0.45	3.56e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg07460842	chr6:66804631	NA	0.97	6.01	0.52	3.49e-8	Exhaled nitric oxide levels;
THYM	cis	rs55883249	1.000	rs62119392	chr2:9714033	G/C	cg23886495	chr2:9695866	ADAM17	0.85	5.28	0.48	8.25e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs425277	0.583	rs3128334	chr1:2038662	G/A	cg10334053	chr1:2078117	PRKCZ	-0.5	-5.06	-0.46	2.04e-6	Height;
THYM	cis	rs2625529	0.652	rs2899775	chr15:72268354	C/T	cg16672083	chr15:72433130	SENP8	0.49	4.48	0.42	2.09e-5	Red blood cell count;
THYM	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07157834	chr1:205819609	PM20D1	0.89	9.0	0.68	2.28e-14	Menarche (age at onset);
THYM	cis	rs2070488	0.861	rs1858740	chr3:38438372	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.8	6.07	0.53	2.55e-8	Electrocardiographic conduction measures;
THYM	cis	rs1457451	0.748	rs7593455	chr2:65851312	A/G	cg16240816	chr2:65861662	NA	0.59	5.68	0.5	1.46e-7	Iron status biomarkers;
THYM	cis	rs986417	0.818	rs1010051	chr14:61002988	G/C	cg27398547	chr14:60952738	C14orf39	1.12	6.0	0.52	3.61e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs782590	0.902	rs3762513	chr2:55762957	C/T	cg03859395	chr2:55845619	SMEK2	0.66	6.08	0.53	2.51e-8	Metabolic syndrome;
THYM	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg00999904	chr2:3704751	ALLC	-0.73	-4.99	-0.46	2.75e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs9905704	0.846	rs302878	chr17:56762964	G/A	cg12560992	chr17:57184187	TRIM37	0.64	4.46	0.42	2.28e-5	Testicular germ cell tumor;
THYM	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs6430585	0.528	rs499483	chr2:136652524	G/A	cg07169764	chr2:136633963	MCM6	1.06	8.93	0.68	3.17e-14	Corneal structure;
THYM	cis	rs7119038	0.818	rs1048024	chr11:118618776	A/T	cg19308663	chr11:118741387	NA	0.57	5.33	0.48	6.51e-7	Sjögren's syndrome;
THYM	cis	rs55728055	0.661	rs62237791	chr22:31973124	A/G	cg01338084	chr22:32026380	PISD	1.39	6.92	0.58	5.23e-10	Age-related hearing impairment;
THYM	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg19761014	chr17:28927070	LRRC37B2	0.89	4.93	0.45	3.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg27490568	chr2:178487706	NA	0.63	6.08	0.53	2.49e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9361491	0.608	rs1180825	chr6:79433850	G/T	cg04547799	chr6:79944526	HMGN3	-0.66	-4.88	-0.45	4.34e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6754311	0.731	rs13404551	chr2:136721995	T/C	cg20242066	chr2:136595261	LCT	0.55	6.52	0.56	3.43e-9	Mosquito bite size;
THYM	cis	rs7572733	0.534	rs700681	chr2:198711502	C/A	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs2888875	0.519	rs17031112	chr2:43832300	A/T	cg22033476	chr2:43532275	THADA	-0.41	-4.57	-0.42	1.44e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs854765	0.551	rs6502626	chr17:17849450	C/T	cg16928487	chr17:17741425	SREBF1	-0.56	-5.45	-0.49	3.91e-7	Total body bone mineral density;
THYM	cis	rs1451375	0.617	rs10276473	chr7:50612997	A/C	cg18232548	chr7:50535776	DDC	-0.65	-4.78	-0.44	6.34e-6	Malaria;
THYM	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.19	-9.36	-0.69	3.85e-15	Platelet count;
THYM	cis	rs56079296	0.778	rs3805442	chr5:121404880	A/T	cg05256605	chr5:121412184	LOX	0.58	4.51	0.42	1.83e-5	Coronary artery disease;
THYM	trans	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg10856724	chr12:34555212	NA	-0.9	-8.53	-0.66	2.28e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4911259	0.552	rs13038881	chr20:31468113	T/C	cg13636640	chr20:31349939	DNMT3B	-0.6	-5.87	-0.52	6.41e-8	Inflammatory bowel disease;
THYM	cis	rs73198271	0.700	rs10090152	chr8:8652104	C/A	cg06636001	chr8:8085503	FLJ10661	-0.68	-4.63	-0.43	1.14e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs863345	0.604	rs2051451	chr1:158464265	A/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs35883536	0.647	rs2647325	chr1:101040195	T/C	cg09408571	chr1:101003634	GPR88	0.51	5.56	0.5	2.44e-7	Monocyte count;
THYM	cis	rs10208940	0.541	rs72901932	chr2:68748321	G/A	cg09157127	chr2:69201416	GKN1	0.85	4.6	0.43	1.32e-5	Urate levels in lean individuals;
THYM	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6918586	1.000	rs6918586	chr6:26097384	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	5.28	0.48	8.02e-7	Schizophrenia;
THYM	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg14186256	chr22:23484241	RTDR1	-0.96	-9.43	-0.7	2.71e-15	Bone mineral density;
THYM	cis	rs9790314	0.875	rs462514	chr3:161092809	C/T	cg03342759	chr3:160939853	NMD3	-0.73	-6.33	-0.54	7.93e-9	Morning vs. evening chronotype;
THYM	cis	rs6901250	0.610	rs9400964	chr6:117144808	G/T	cg12892004	chr6:117198278	RFX6	0.56	4.57	0.42	1.49e-5	C-reactive protein levels;
THYM	cis	rs7224737	1.000	rs9912088	chr17:40288278	T/C	cg02228675	chr17:40259724	DHX58	-0.66	-5.49	-0.49	3.28e-7	Fibrinogen levels;
THYM	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg04398451	chr17:18023971	MYO15A	0.91	7.98	0.63	3.27e-12	Total body bone mineral density;
THYM	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg25427524	chr10:38739819	LOC399744	-0.7	-6.38	-0.55	6.44e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg14458575	chr2:238380390	NA	0.9	7.53	0.61	2.94e-11	Prostate cancer;
THYM	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06634786	chr22:41940651	POLR3H	0.8	6.18	0.54	1.56e-8	Vitiligo;
THYM	cis	rs12291225	0.546	rs12795545	chr11:14355564	G/A	cg19336497	chr11:14380999	RRAS2	-0.91	-13.71	-0.82	3.02e-24	Sense of smell;
THYM	cis	rs9611565	0.506	rs2024566	chr22:41697338	A/G	cg03806693	chr22:41940476	POLR3H	-0.84	-7.2	-0.59	1.37e-10	Vitiligo;
THYM	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67460515	0.563	rs73023235	chr3:160864123	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-4.72	-0.44	8.07e-6	Parkinson's disease;
THYM	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.727	rs6941429	chr6:145952283	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs478304	0.903	rs495961	chr11:65540886	C/T	cg17480646	chr11:65405466	SIPA1	0.7	6.13	0.53	2e-8	Acne (severe);
THYM	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.14	-0.64	1.54e-12	Mean corpuscular volume;
THYM	cis	rs9972944	0.756	rs6416949	chr17:63767219	A/T	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs12620999	1.000	rs4558538	chr2:238055975	C/T	cg15976283	chr2:238042351	NA	0.65	5.14	0.47	1.45e-6	Systemic lupus erythematosus;
THYM	cis	rs514406	0.929	rs12145105	chr1:53340564	T/C	cg16325326	chr1:53192061	ZYG11B	0.83	7.91	0.63	4.68e-12	Monocyte count;
THYM	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg23711669	chr6:146136114	FBXO30	-0.84	-7.64	-0.62	1.73e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg17330251	chr7:94953956	PON1	-0.84	-7.9	-0.63	4.81e-12	Paraoxonase activity;
THYM	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg06850241	chr22:41845214	NA	0.5	4.45	0.42	2.34e-5	Vitiligo;
THYM	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg27168131	chr21:44088823	PDE9A	-0.48	-4.71	-0.44	8.32e-6	Mean corpuscular volume;
THYM	cis	rs5985	0.659	rs55963140	chr6:6317606	T/C	cg22185065	chr6:6318785	F13A1	0.78	5.74	0.51	1.15e-7	End-stage coagulation;
THYM	cis	rs6531656	0.553	rs4833077	chr4:38646376	T/A	cg24279243	chr4:38676559	KLF3	0.66	6.13	0.53	2.01e-8	Lymphocyte counts;
THYM	cis	rs7731657	0.537	rs2107334	chr5:130292773	T/C	cg08523029	chr5:130500466	HINT1	-0.76	-5.21	-0.47	1.11e-6	Fasting plasma glucose;
THYM	cis	rs17331151	0.505	rs7644763	chr3:52546487	C/T	cg17372223	chr3:52568218	NT5DC2	-0.61	-4.96	-0.45	3.02e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg00645579	chr11:617140	IRF7;MUPCDH	-0.42	-4.81	-0.44	5.56e-6	Systemic lupus erythematosus;
THYM	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg07884673	chr3:53033167	SFMBT1	1.25	6.34	0.55	7.83e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg05896524	chr21:47604654	C21orf56	0.81	5.37	0.48	5.61e-7	Testicular germ cell tumor;
THYM	cis	rs1981331	0.609	rs7283588	chr21:48059038	T/C	cg17243659	chr21:48055224	PRMT2	1.28	5.62	0.5	1.94e-7	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg09260853	chr1:2094483	PRKCZ	0.51	4.82	0.44	5.42e-6	Height;
THYM	cis	rs7178572	0.568	rs1389436	chr15:77665848	G/T	cg22256960	chr15:77711686	NA	-1.05	-8.4	-0.65	4.29e-13	Type 2 diabetes;
THYM	cis	rs7078219	0.505	rs7077040	chr10:101281014	C/G	cg07044859	chr10:101282883	NA	-0.41	-4.62	-0.43	1.22e-5	Dental caries;
THYM	cis	rs9790314	0.812	rs2004862	chr3:161135638	C/T	cg03342759	chr3:160939853	NMD3	-0.57	-4.91	-0.45	3.84e-6	Morning vs. evening chronotype;
THYM	cis	rs561341	0.528	rs11650908	chr17:30195425	T/C	cg12000587	chr17:30186630	C17orf79	0.4	6.01	0.52	3.42e-8	Hip circumference adjusted for BMI;
THYM	cis	rs679087	1.000	rs672107	chr12:29917266	T/A	cg14258853	chr12:29935411	TMTC1	-0.67	-6.12	-0.53	2.12e-8	Schizophrenia;
THYM	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg04944784	chr2:26401820	FAM59B	-0.66	-5.0	-0.46	2.6e-6	Gut microbiome composition (summer);
THYM	cis	rs2319125	0.683	rs7215312	chr17:64050394	A/T	cg04446870	chr17:64440273	PRKCA	0.5	4.48	0.42	2.12e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.46	-5.73	-0.51	1.19e-7	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs7953249	0.656	rs2243616	chr12:121406370	G/T	cg14101638	chr12:121416612	HNF1A	-0.46	-4.73	-0.44	7.91e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs4654899	0.680	rs3125160	chr1:21127803	G/C	cg01072550	chr1:21505969	NA	0.72	7.02	0.58	3.26e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs61931739	0.534	rs2636072	chr12:34062386	C/T	cg06521331	chr12:34319734	NA	-0.95	-9.13	-0.68	1.19e-14	Morning vs. evening chronotype;
THYM	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg05872129	chr22:39784769	NA	1.06	11.19	0.75	4.76e-19	Intelligence (multi-trait analysis);
THYM	cis	rs4481887	1.000	rs6697735	chr1:248465315	G/C	cg00666640	chr1:248458726	OR2T12	0.58	4.72	0.44	8.11e-6	Common traits (Other);
THYM	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg10150615	chr22:24372951	LOC391322	-1.01	-11.7	-0.77	4.18e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4523957	0.579	rs903160	chr17:2091765	C/T	cg16513277	chr17:2031491	SMG6	-0.94	-8.17	-0.64	1.34e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg18876405	chr7:65276391	NA	-0.55	-4.73	-0.44	7.84e-6	Aortic root size;
THYM	cis	rs62244186	0.608	rs2888390	chr3:44511405	G/A	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.46	-4.93	-0.45	3.49e-6	Depressive symptoms;
THYM	cis	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg13443165	chr9:33130375	B4GALT1	-0.87	-7.97	-0.63	3.46e-12	IgG glycosylation;
THYM	cis	rs72627123	0.737	rs2240632	chr14:74371166	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs4660531	1.000	rs61774746	chr1:41838561	T/G	cg08462924	chr1:41848221	NA	0.63	5.88	0.52	5.96e-8	Bipolar disorder;
THYM	cis	rs912057	0.671	rs1294420	chr6:6742752	C/T	cg06612196	chr6:6737390	NA	0.71	11.9	0.77	1.57e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg16624210	chr5:671434	TPPP	0.8	5.87	0.52	6.23e-8	Lung disease severity in cystic fibrosis;
THYM	cis	rs11098499	0.657	rs10434028	chr4:120294464	T/G	cg13609457	chr4:120235615	NA	0.53	4.89	0.45	4.12e-6	Corneal astigmatism;
THYM	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg23205692	chr1:25664452	TMEM50A	-0.84	-6.38	-0.55	6.28e-9	Erythrocyte sedimentation rate;
THYM	cis	rs524023	0.957	rs893007	chr11:64365668	C/A	cg19131476	chr11:64387923	NRXN2	-0.39	-5.64	-0.5	1.75e-7	Urate levels in obese individuals;
THYM	cis	rs2085601	0.509	rs1458558	chr4:89887620	C/T	cg17769793	chr4:89976368	FAM13A	-0.4	-4.92	-0.45	3.67e-6	Hair greying;
THYM	trans	rs11186	0.556	rs72906375	chr2:189965175	T/C	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg07570687	chr10:102243282	WNT8B	0.84	8.13	0.64	1.59e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs10504073	0.647	rs4873314	chr8:50011656	A/C	cg00325661	chr8:49890786	NA	0.9	8.16	0.64	1.38e-12	Blood metabolite ratios;
THYM	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg06713675	chr4:122721982	EXOSC9	-0.86	-9.81	-0.71	4.29e-16	Type 2 diabetes;
THYM	cis	rs7084402	0.902	rs4245599	chr10:60365755	A/G	cg09696939	chr10:60272079	BICC1	-0.48	-5.67	-0.5	1.51e-7	Refractive error;
THYM	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg03467027	chr4:99064603	C4orf37	0.59	4.5	0.42	1.92e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11186	0.504	rs72906305	chr2:189955346	T/C	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs2346160	0.899	rs206980	chr6:167691798	A/G	cg21686812	chr6:168078911	NA	0.54	4.77	0.44	6.54e-6	Parental extreme longevity (95 years and older);
THYM	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg11764359	chr7:65958608	NA	0.85	7.32	0.6	8.03e-11	Aortic root size;
THYM	cis	rs12496230	1.000	rs12496230	chr3:66829908	A/G	cg17646820	chr3:66848679	NA	0.82	5.06	0.46	2.06e-6	Type 2 diabetes;
THYM	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg20573242	chr4:122745356	CCNA2	0.62	4.54	0.42	1.62e-5	Type 2 diabetes;
THYM	cis	rs36051895	0.664	rs17425819	chr9:5114773	C/T	cg02405213	chr9:5042618	JAK2	-1.02	-11.42	-0.76	1.56e-19	Pediatric autoimmune diseases;
THYM	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.95	6.61	0.56	2.2e-9	Schizophrenia;
THYM	cis	rs4363385	0.510	rs6677674	chr1:153037601	A/G	cg06563695	chr1:153756334	NA	-0.6	-4.57	-0.42	1.47e-5	Inflammatory skin disease;
THYM	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg26038318	chr20:34205095	SPAG4	0.63	5.16	0.47	1.36e-6	Total cholesterol levels;
THYM	cis	rs4654899	0.897	rs6679753	chr1:21066634	G/C	cg01072550	chr1:21505969	NA	-0.61	-5.27	-0.48	8.41e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13082711	0.596	rs683503	chr3:27348094	C/T	cg02860705	chr3:27208620	NA	0.75	5.75	0.51	1.1e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.77	7.55	0.61	2.63e-11	Lymphocyte counts;
THYM	cis	rs12122100	0.774	rs12723253	chr1:146523303	C/T	cg03526459	chr1:146549940	NA	-0.69	-4.71	-0.44	8.28e-6	HIV-1 control;
THYM	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg03806693	chr22:41940476	POLR3H	1.1	8.83	0.67	5.2e-14	Vitiligo;
THYM	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg26597838	chr10:835615	NA	1.23	8.88	0.67	4.1e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs2456568	0.709	rs12806128	chr11:93634972	C/T	cg17595323	chr11:93583763	C11orf90	0.55	6.11	0.53	2.2e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2976388	1.000	rs2920282	chr8:143757763	T/C	cg06565975	chr8:143823917	SLURP1	-0.44	-4.94	-0.45	3.37e-6	Urinary tract infection frequency;
THYM	cis	rs7786877	0.680	rs12532878	chr7:100212254	G/A	cg04499151	chr7:100231278	TFR2	0.62	4.64	0.43	1.13e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg10856724	chr12:34555212	NA	-0.89	-8.35	-0.65	5.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.38	0.55	6.27e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg02725872	chr8:58115012	NA	1.14	7.59	0.61	2.17e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg25072359	chr17:41440525	NA	0.65	4.55	0.42	1.57e-5	Menopause (age at onset);
THYM	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.76	-4.93	-0.45	3.47e-6	Mean platelet volume;
THYM	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18876405	chr7:65276391	NA	-0.54	-4.46	-0.42	2.25e-5	Aortic root size;
THYM	cis	rs986417	0.818	rs1950315	chr14:61000031	A/C	cg27398547	chr14:60952738	C14orf39	1.12	6.0	0.52	3.61e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs55871839	0.559	rs2326268	chr8:59841217	C/T	cg07426533	chr8:59803705	TOX	0.62	5.11	0.46	1.63e-6	Pneumonia;
THYM	cis	rs73416724	0.925	rs2651201	chr6:43293366	G/A	cg26312998	chr6:43337775	ZNF318	-0.99	-4.93	-0.45	3.47e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	4.93	0.45	3.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg11296937	chr11:64084966	PRDX5;TRMT112	-0.97	-7.01	-0.58	3.51e-10	Depressive symptoms;
THYM	cis	rs72627123	1.000	rs17093141	chr14:74326903	G/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs12496230	0.953	rs4856960	chr3:66843301	T/C	cg17646820	chr3:66848679	NA	0.85	4.86	0.45	4.68e-6	Type 2 diabetes;
THYM	cis	rs7224737	1.000	rs2285657	chr17:40272594	C/A	cg20291162	chr17:40259547	DHX58	-0.68	-6.22	-0.54	1.32e-8	Fibrinogen levels;
THYM	cis	rs72827839	0.793	rs72823527	chr17:46098810	G/T	cg23391107	chr17:45924227	SP6	0.79	5.34	0.48	6.28e-7	Ease of getting up in the morning;
THYM	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg11301795	chr4:187892539	NA	-1.09	-16.54	-0.86	1.01e-29	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7078219	1.000	rs61872688	chr10:101273546	G/A	cg17888390	chr10:101282816	NA	-0.5	-4.78	-0.44	6.28e-6	Dental caries;
THYM	cis	rs9393692	0.620	rs9366650	chr6:26335997	G/A	cg00631329	chr6:26305371	NA	-0.45	-4.53	-0.42	1.72e-5	Educational attainment;
THYM	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg06634786	chr22:41940651	POLR3H	0.68	5.52	0.49	2.93e-7	Vitiligo;
THYM	cis	rs6964587	0.839	rs17731846	chr7:91440342	A/G	cg22709100	chr7:91322751	NA	0.66	4.98	0.46	2.83e-6	Breast cancer;
THYM	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg24642844	chr7:1081250	C7orf50	-0.74	-5.18	-0.47	1.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.93	5.98	0.52	3.95e-8	Smoking behavior;
THYM	cis	rs6032067	0.673	rs13039345	chr20:43895932	G/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.62	-6.03	-0.53	3.18e-8	Blood protein levels;
THYM	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg18538332	chr22:24372958	LOC391322	-0.92	-11.37	-0.76	1.99e-19	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	4.5	0.42	1.94e-5	Colorectal cancer;
THYM	cis	rs6500395	1.000	rs12598514	chr16:48689319	T/C	cg04672837	chr16:48644449	N4BP1	-0.48	-4.72	-0.44	8.24e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs59698941	0.891	rs72799497	chr5:132291148	T/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg08883853	chr7:1026168	CYP2W1	-0.45	-4.99	-0.46	2.69e-6	Longevity;Endometriosis;
THYM	cis	rs2456568	0.802	rs8181578	chr11:93637442	G/A	cg17595323	chr11:93583763	C11orf90	-0.58	-6.09	-0.53	2.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs9790314	0.632	rs62280333	chr3:160689060	G/A	cg04691961	chr3:161091175	C3orf57	0.58	4.63	0.43	1.15e-5	Morning vs. evening chronotype;
THYM	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg13390004	chr1:15929781	NA	0.61	4.63	0.43	1.15e-5	Systolic blood pressure;
THYM	cis	rs7246657	0.943	rs7252325	chr19:37930645	A/G	cg23950597	chr19:37808831	NA	-0.73	-4.84	-0.44	5.09e-6	Coronary artery calcification;
THYM	cis	rs6547741	1.000	rs6749052	chr2:27772879	A/T	cg27432699	chr2:27873401	GPN1	0.68	5.97	0.52	4.17e-8	Oral cavity cancer;
THYM	cis	rs131777	0.708	rs131749	chr22:51024624	C/T	cg00083937	chr22:51039805	MAPK8IP2	-0.59	-5.2	-0.47	1.15e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs3768617	0.510	rs7414273	chr1:183075017	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs1933112	0.966	rs4656605	chr1:168525897	A/T	cg17186328	chr1:168545835	XCL1	-0.58	-4.73	-0.44	7.66e-6	Blood protein levels;
THYM	cis	rs6669072	0.869	rs7526803	chr1:91235725	A/G	cg08895590	chr1:91227319	NA	0.44	4.99	0.46	2.74e-6	Cognitive function;
THYM	cis	rs10911232	0.507	rs3934578	chr1:183027216	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.57	4.65	0.43	1.06e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs3087591	1.000	rs4795579	chr17:29458682	T/C	cg24425628	chr17:29625626	OMG;NF1	0.65	5.52	0.49	2.96e-7	Hip circumference;
THYM	cis	rs17539620	0.624	rs62432736	chr6:154834401	A/G	cg20019720	chr6:154832845	CNKSR3	0.48	4.85	0.45	4.82e-6	Lipoprotein (a) levels;
THYM	cis	rs9296092	0.538	rs9461882	chr6:33520221	A/C	cg13560919	chr6:33536144	NA	-0.94	-9.31	-0.69	4.9e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs2294693	0.947	rs9349176	chr6:40989525	C/T	cg21128951	chr6:40996213	UNC5CL	0.61	4.95	0.45	3.24e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs2282300	0.739	rs1933343	chr11:30310992	T/C	cg25418670	chr11:30344373	C11orf46	0.82	6.97	0.58	4.25e-10	Morning vs. evening chronotype;
THYM	cis	rs9611519	0.857	rs4820434	chr22:41637119	G/T	cg03806693	chr22:41940476	POLR3H	-0.82	-6.6	-0.56	2.39e-9	Neuroticism;
THYM	cis	rs17818399	0.962	rs2122715	chr2:46845849	A/G	cg09399716	chr2:46890238	NA	-0.5	-4.53	-0.42	1.73e-5	Height;
THYM	cis	rs939574	1.000	rs7574937	chr2:220099331	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.31	5.97	0.52	4e-8	Platelet distribution width;
THYM	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg21862992	chr11:68658383	NA	-0.23	-4.51	-0.42	1.86e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs2903698	0.585	rs7657576	chr4:76429385	C/A	cg03209871	chr4:76438412	RCHY1;THAP6	0.4	4.7	0.43	8.84e-6	Prion diseases;
THYM	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg04756594	chr16:24857601	SLC5A11	-0.76	-5.51	-0.49	3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg16006841	chr5:176797999	RGS14	-0.7	-9.65	-0.7	9.31e-16	Hemoglobin concentration;Hematocrit;
THYM	cis	rs858239	0.508	rs2390754	chr7:23190494	A/G	cg09755872	chr7:23245557	NA	-0.5	-4.71	-0.43	8.55e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs6570726	0.738	rs6925594	chr6:145898454	T/C	cg05347473	chr6:146136440	FBXO30	0.58	4.53	0.42	1.7e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4731207	0.596	rs1531718	chr7:124644777	T/A	cg05285228	chr7:124571219	POT1	-0.7	-5.34	-0.48	6.36e-7	Cutaneous malignant melanoma;
THYM	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs901683	1.000	rs12764693	chr10:46023327	A/G	cg18240400	chr10:46168597	ANUBL1	0.8	5.19	0.47	1.19e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg17211192	chr8:82754475	SNX16	-0.88	-7.0	-0.58	3.55e-10	Diastolic blood pressure;
THYM	cis	rs9814567	1.000	rs6766897	chr3:134191303	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.76	-7.43	-0.61	4.74e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg04731861	chr2:219085781	ARPC2	0.53	4.9	0.45	4.01e-6	Colorectal cancer;
THYM	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	1.02	9.11	0.68	1.31e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg04414720	chr1:150670196	GOLPH3L	-0.62	-4.58	-0.43	1.41e-5	Tonsillectomy;
THYM	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg26384229	chr12:38710491	ALG10B	0.92	7.27	0.6	9.91e-11	Bladder cancer;
THYM	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg02380750	chr20:61661411	NA	0.63	6.18	0.54	1.59e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.11e-8	Systolic blood pressure;
THYM	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.25	-4.74	-0.44	7.58e-6	Obesity-related traits;
THYM	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg17863274	chr19:49399704	TULP2	-0.93	-5.69	-0.5	1.43e-7	Red cell distribution width;
THYM	cis	rs11771526	1.000	rs62457533	chr7:32355334	G/A	cg27532318	chr7:32358331	NA	0.96	5.74	0.51	1.13e-7	Body mass index;
THYM	cis	rs7705042	0.865	rs4385236	chr5:141513396	G/A	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg10802521	chr3:52805072	NEK4	-0.73	-6.43	-0.55	5.15e-9	Bipolar disorder;
THYM	cis	rs59698941	0.943	rs67843388	chr5:132288007	C/T	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs7084402	0.902	rs1593670	chr10:60300766	C/G	cg07615347	chr10:60278583	BICC1	0.57	5.36	0.48	5.86e-7	Refractive error;
THYM	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg02187348	chr16:89574699	SPG7	0.61	4.49	0.42	2e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs7524258	0.868	rs4908607	chr1:7269323	A/G	cg07173049	chr1:7289937	CAMTA1	0.61	4.9	0.45	3.95e-6	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs240764	0.853	rs10457809	chr6:100984400	C/T	cg21058520	chr6:100914733	NA	0.58	5.08	0.46	1.91e-6	Neuroticism;
THYM	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg22907277	chr7:1156413	C7orf50	0.8	4.85	0.45	4.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs12488721	1	rs12488721	chr3:135992645	T/C	cg12473912	chr3:136751656	NA	0.61	5.12	0.47	1.6e-6	Neuroticism;
THYM	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg09307838	chr4:120376055	NA	0.68	4.92	0.45	3.61e-6	Corneal astigmatism;
THYM	cis	rs11190604	0.767	rs10883481	chr10:102165021	G/A	cg07570687	chr10:102243282	WNT8B	0.81	7.68	0.62	1.44e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs3741151	0.892	rs2027760	chr11:73036481	G/A	cg12959048	chr11:73096162	RELT	-0.43	-4.54	-0.42	1.62e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg15448220	chr1:150897856	SETDB1	0.85	7.1	0.59	2.25e-10	Tonsillectomy;
THYM	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg23851026	chr2:136556271	LCT	-0.56	-6.04	-0.53	2.93e-8	Mosquito bite size;
THYM	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg27572855	chr1:25598939	RHD	-0.67	-5.06	-0.46	2.06e-6	Erythrocyte sedimentation rate;
THYM	cis	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.56	-0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4891159	0.790	rs10514217	chr18:74144939	A/G	cg24786174	chr18:74118243	ZNF516	-0.75	-6.41	-0.55	5.61e-9	Longevity;
THYM	cis	rs55728055	0.661	rs62237857	chr22:32039311	G/A	cg01338084	chr22:32026380	PISD	1.47	7.24	0.6	1.16e-10	Age-related hearing impairment;
THYM	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg10803722	chr21:46713166	LOC642852	-0.51	-5.77	-0.51	1.01e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg08430604	chr3:44902960	MIR564;TMEM42	0.53	4.93	0.45	3.55e-6	Depressive symptoms;
THYM	cis	rs476633	0.691	rs6492997	chr15:41541171	G/A	cg21153102	chr15:41252147	NA	0.55	4.58	0.43	1.42e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs17253792	0.545	rs17745459	chr14:56008549	T/A	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs1461503	0.511	rs4129007	chr11:122811812	T/C	cg27398637	chr11:122830231	C11orf63	-0.64	-5.76	-0.51	1.05e-7	Menarche (age at onset);
THYM	cis	rs6598955	0.724	rs4659420	chr1:26614333	G/A	cg04990556	chr1:26633338	UBXN11	-0.89	-8.52	-0.66	2.34e-13	Obesity-related traits;
THYM	cis	rs8050907	0.744	rs9935505	chr16:4586906	C/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.4	5.34	0.48	6.45e-7	Obesity-related traits;
THYM	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg10360139	chr7:1886902	MAD1L1	-0.6	-5.21	-0.47	1.1e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg08048268	chr3:133502702	NA	-0.62	-5.27	-0.48	8.52e-7	Iron status biomarkers;
THYM	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg03806693	chr22:41940476	POLR3H	1.1	8.94	0.68	3.12e-14	Vitiligo;
THYM	trans	rs2289577	0.764	rs17513200	chr6:90635116	T/C	cg22698489	chr1:159893696	TAGLN2	1.24	6.91	0.58	5.5e-10	Cognitive performance;
THYM	cis	rs9549260	0.709	rs2721072	chr13:41144919	G/A	cg21288729	chr13:41239152	FOXO1	0.73	5.63	0.5	1.82e-7	Red blood cell count;
THYM	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-8.52	-0.66	2.33e-13	Schizophrenia;
THYM	cis	rs9318086	0.648	rs7331047	chr13:24467342	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.61	5.16	0.47	1.33e-6	Myopia (pathological);
THYM	cis	rs11225247	0.881	rs12277594	chr11:102257415	A/C	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs6992820	0.967	rs7013663	chr8:56654839	C/T	cg06880721	chr8:56792545	LYN	-0.64	-5.17	-0.47	1.3e-6	Mean platelet volume;
THYM	trans	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.94	-8.97	-0.68	2.64e-14	Brugada syndrome;
THYM	cis	rs10269006	0.727	rs10259419	chr7:94367767	A/G	cg00347863	chr7:94220697	SGCE	0.53	4.56	0.42	1.51e-5	Breast cancer;
THYM	cis	rs1957429	0.708	rs73279839	chr14:65353834	T/C	cg23373153	chr14:65346875	NA	-1.34	-5.68	-0.5	1.5e-7	Pediatric areal bone mineral density (radius);
THYM	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs7131987	0.718	rs7976961	chr12:29463088	C/T	cg09582351	chr12:29534625	ERGIC2	-0.58	-5.08	-0.46	1.87e-6	QT interval;
THYM	cis	rs17253792	0.822	rs78386830	chr14:56069224	G/A	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs4713118	0.786	rs200502	chr6:27788062	C/T	cg12963246	chr6:28129442	ZNF389	0.57	5.45	0.49	3.99e-7	Parkinson's disease;
THYM	cis	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs12188164	0.812	rs10072668	chr5:422752	T/C	cg16294152	chr5:418696	AHRR	-0.63	-5.53	-0.49	2.83e-7	Cystic fibrosis severity;
THYM	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.77	-6.22	-0.54	1.31e-8	Intelligence (multi-trait analysis);
THYM	cis	rs10489202	0.608	rs6659593	chr1:168072152	A/T	cg24449463	chr1:168025552	DCAF6	-0.76	-7.54	-0.61	2.83e-11	Schizophrenia;
THYM	cis	rs3540	0.533	rs12916560	chr15:91056259	A/C	cg22089800	chr15:90895588	ZNF774	-0.7	-5.23	-0.47	1.02e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg16342193	chr10:102329863	NA	0.5	5.14	0.47	1.46e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg12310025	chr6:25882481	NA	0.94	8.66	0.66	1.23e-13	Blood metabolite levels;
THYM	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg19506201	chr17:79936561	ASPSCR1	-0.51	-4.53	-0.42	1.73e-5	Glycated hemoglobin levels;
THYM	cis	rs72627509	0.904	rs58408429	chr4:57769824	T/C	cg26694713	chr4:57773883	REST	0.75	4.83	0.44	5.13e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs524281	0.773	rs10791862	chr11:66013664	T/C	cg00563793	chr11:65837595	PACS1	0.79	4.71	0.43	8.53e-6	Electroencephalogram traits;
THYM	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg09184832	chr6:79620586	NA	-0.56	-4.46	-0.42	2.24e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3198697	1.000	rs3198697	chr16:15129940	C/T	cg03263237	chr16:15227611	NA	-0.58	-4.73	-0.44	7.89e-6	Triglycerides;
THYM	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.27	5.57	0.5	2.39e-7	Obesity-related traits;
THYM	cis	rs11645898	0.935	rs4788611	chr16:72175256	A/G	cg03805757	chr16:71968109	PKD1L3	-0.73	-5.37	-0.48	5.49e-7	Blood protein levels;
THYM	cis	rs11078597	0.731	rs2070863	chr17:1648502	C/T	cg18436246	chr17:1640651	WDR81	0.65	4.6	0.43	1.29e-5	Serum albumin level;
THYM	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs9790314	0.846	rs6791213	chr3:161033721	A/G	cg03342759	chr3:160939853	NMD3	-0.95	-9.47	-0.7	2.2e-15	Morning vs. evening chronotype;
THYM	cis	rs597539	0.545	rs3794027	chr11:68697336	T/C	cg11245990	chr11:68621969	NA	0.56	7.06	0.59	2.68e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1863824	0.625	rs10887598	chr10:88166160	T/A	cg06895675	chr10:88137553	NA	0.56	5.09	0.46	1.79e-6	Schizophrenia;
THYM	cis	rs17744121	0.584	rs73192185	chr21:30495194	C/G	cg24692254	chr21:30365293	RNF160	0.93	4.47	0.42	2.18e-5	Visceral fat;
THYM	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg16325326	chr1:53192061	ZYG11B	-0.82	-7.77	-0.62	9e-12	Monocyte count;
THYM	cis	rs924712	0.844	rs1472679	chr6:54735122	C/T	cg04690482	chr6:54711388	FAM83B	0.46	5.08	0.46	1.91e-6	Breast cancer;
THYM	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4389656	0.767	rs274704	chr5:6728340	A/G	cg10857441	chr5:6722123	POLS	-0.44	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg10295955	chr4:187884368	NA	-1.16	-16.24	-0.86	3.64e-29	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.65	5.23	0.47	1.02e-6	Chronic sinus infection;
THYM	cis	rs3204270	0.516	rs62077189	chr17:79673088	G/A	cg09996840	chr17:79680718	SLC25A10	-0.62	-4.78	-0.44	6.5e-6	Dental caries;
THYM	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg21926612	chr6:163149169	PACRG;PARK2	1.22	9.05	0.68	1.73e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs35260072	1	rs35260072	chr5:131630852	A/C	cg18758796	chr5:131593413	PDLIM4	0.51	4.62	0.43	1.19e-5	Itch intensity from mosquito bite;
THYM	cis	rs4808199	0.948	rs2301671	chr19:19466269	C/T	cg03709012	chr19:19516395	GATAD2A	1.05	5.98	0.52	3.95e-8	Nonalcoholic fatty liver disease;
THYM	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg23260525	chr10:116636907	FAM160B1	0.52	5.09	0.46	1.78e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs892961	0.965	rs2411111	chr17:75402540	A/T	cg05865280	chr17:75406074	SEPT9	0.51	8.62	0.66	1.44e-13	Airflow obstruction;
THYM	cis	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg05335186	chr13:53173507	NA	-0.49	-6.33	-0.54	7.91e-9	Lewy body disease;
THYM	cis	rs240764	0.612	rs9386154	chr6:100923704	G/C	cg21058520	chr6:100914733	NA	0.57	4.7	0.43	8.76e-6	Neuroticism;
THYM	cis	rs10751667	0.961	rs7480178	chr11:927108	T/C	cg01483505	chr11:975446	AP2A2	0.63	4.73	0.44	7.87e-6	Alzheimer's disease (late onset);
THYM	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs4650994	1.000	rs4077194	chr1:178533832	A/C	cg05059571	chr16:84539110	KIAA1609	0.75	8.07	0.64	2.18e-12	HDL cholesterol levels;HDL cholesterol;
THYM	trans	rs877282	0.945	rs11253397	chr10:789774	A/G	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg08885076	chr2:99613938	TSGA10	-0.57	-5.66	-0.5	1.6e-7	Chronic sinus infection;
THYM	cis	rs7772486	0.701	rs697056	chr6:146003897	C/T	cg13319975	chr6:146136371	FBXO30	0.63	5.17	0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28595532	0.920	rs56042726	chr4:119751777	T/A	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg04750100	chr2:136595281	LCT	-0.55	-6.28	-0.54	1.01e-8	Mosquito bite size;
THYM	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.72	-6.67	-0.56	1.69e-9	Personality dimensions;
THYM	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg04317338	chr11:64019027	PLCB3	0.86	5.89	0.52	5.78e-8	Mean platelet volume;
THYM	cis	rs289828	0.560	rs10203366	chr2:152156258	A/C	cg05960677	chr2:152117363	RBM43	0.7	6.56	0.56	2.79e-9	Blood protein levels;
THYM	cis	rs1629083	0.967	rs73024606	chr11:118120366	G/C	cg25155064	chr11:118100782	MPZL3	-0.57	-5.03	-0.46	2.34e-6	Lung cancer;
THYM	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg10248100	chr7:872053	UNC84A	0.74	4.99	0.46	2.75e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg13918804	chr1:2043761	PRKCZ	0.77	7.3	0.6	8.54e-11	Height;
THYM	cis	rs889398	0.683	rs8047682	chr16:69913446	G/A	cg09409435	chr16:70099608	PDXDC2	0.66	5.26	0.47	8.89e-7	Body mass index;
THYM	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg03709012	chr19:19516395	GATAD2A	0.76	6.05	0.53	2.87e-8	Tonsillectomy;
THYM	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg01448562	chr3:133502909	NA	-0.66	-4.85	-0.45	4.74e-6	Iron status biomarkers;
THYM	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.75	4.62	0.43	1.2e-5	Gut microbiome composition (summer);
THYM	cis	rs1298062	0.790	rs1274597	chr19:50973259	T/C	cg11430371	chr19:50961752	MYBPC2	0.44	4.48	0.42	2.05e-5	Age of smoking initiation;
THYM	cis	rs11809207	1.000	rs34587428	chr1:26522392	C/T	cg03844060	chr1:26490628	NA	0.68	4.87	0.45	4.36e-6	Height;
THYM	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Body mass index;
THYM	cis	rs7944735	0.567	rs77684932	chr11:48024893	A/G	cg24672777	chr11:48374446	OR4C45	-0.93	-4.71	-0.44	8.48e-6	Intraocular pressure;
THYM	cis	rs6701037	0.714	rs2285219	chr1:175130983	A/T	cg00958927	chr1:175162553	KIAA0040	-0.33	-4.48	-0.42	2.06e-5	Alcohol dependence;
THYM	cis	rs4663969	0.541	rs11902131	chr2:234594269	C/T	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.59	-0.43	1.36e-5	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs55728055	0.661	rs12160763	chr22:31794754	A/G	cg01338084	chr22:32026380	PISD	1.35	4.93	0.45	3.5e-6	Age-related hearing impairment;
THYM	cis	rs6163	0.727	rs284862	chr10:104572081	C/T	cg04362960	chr10:104952993	NT5C2	-0.63	-5.42	-0.49	4.52e-7	Waist circumference;Hip circumference;
THYM	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12478296	0.748	rs10185596	chr2:243001029	C/A	cg06360820	chr2:242988706	NA	-0.91	-5.79	-0.51	9.26e-8	Obesity-related traits;
THYM	cis	rs988913	0.768	rs9396003	chr6:54741853	A/G	cg04690482	chr6:54711388	FAM83B	0.44	4.58	0.43	1.4e-5	Menarche (age at onset);
THYM	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg20503657	chr10:835505	NA	1.14	7.96	0.63	3.64e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg04362960	chr10:104952993	NT5C2	0.58	4.8	0.44	5.78e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4747241	0.962	rs8316	chr10:74035297	C/T	cg07828833	chr10:74069493	NA	0.54	4.55	0.42	1.57e-5	Heschl's gyrus morphology;
THYM	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg21194808	chr1:2205498	SKI	-0.33	-4.49	-0.42	2.03e-5	Height;
THYM	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg22166914	chr1:53195759	ZYG11B	0.7	5.9	0.52	5.69e-8	Monocyte count;
THYM	cis	rs10186029	0.676	rs10497991	chr2:213968775	G/A	cg08319019	chr2:214017104	IKZF2	0.9	7.44	0.61	4.49e-11	Systemic sclerosis;
THYM	cis	rs4731207	0.698	rs1468377	chr7:124458599	A/G	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs2456568	0.775	rs1607404	chr11:93660449	C/G	cg17595323	chr11:93583763	C11orf90	-0.58	-5.75	-0.51	1.06e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs6980334	0.871	rs4732285	chr7:137754127	A/T	cg11874123	chr7:137028198	PTN	0.61	4.67	0.43	9.88e-6	Blood metabolite ratios;
THYM	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.71	5.31	0.48	7.11e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg07507251	chr3:52567010	NT5DC2	0.46	4.63	0.43	1.17e-5	Bipolar disorder;
THYM	cis	rs11077998	0.967	rs7350963	chr17:80491067	G/A	cg10255544	chr17:80519551	FOXK2	0.5	4.46	0.42	2.21e-5	Reticulocyte fraction of red cells;
THYM	cis	rs61931739	0.583	rs1873010	chr12:33756375	T/C	cg06521331	chr12:34319734	NA	-0.6	-4.45	-0.42	2.36e-5	Morning vs. evening chronotype;
THYM	cis	rs5769765	0.862	rs138897	chr22:50231067	T/C	cg26441486	chr22:50317300	CRELD2	0.44	6.87	0.58	6.59e-10	Schizophrenia;
THYM	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg03159660	chr11:2078197	NA	-0.65	-5.04	-0.46	2.24e-6	Type 2 diabetes;
THYM	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg03806693	chr22:41940476	POLR3H	-0.9	-8.29	-0.65	7.32e-13	Vitiligo;
THYM	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	4.75	0.44	7.17e-6	Schizophrenia;
THYM	cis	rs2213920	0.680	rs7863450	chr9:118242611	G/C	cg13918206	chr9:118159781	DEC1	0.84	4.63	0.43	1.17e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs16917546	1.000	rs10995260	chr10:64410580	G/A	cg03961010	chr10:64397487	ZNF365	-0.81	-6.71	-0.57	1.38e-9	Basal cell carcinoma;
THYM	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg06481639	chr22:41940642	POLR3H	-0.75	-5.78	-0.51	9.62e-8	Vitiligo;
THYM	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.71	0.44	8.48e-6	Prudent dietary pattern;
THYM	cis	rs34638657	0.872	rs8051436	chr16:82171979	G/C	cg07307142	chr16:82071433	HSD17B2	-0.95	-7.67	-0.62	1.51e-11	Lung adenocarcinoma;
THYM	cis	rs977987	0.931	rs7195161	chr16:75495572	T/C	cg03315344	chr16:75512273	CHST6	0.73	5.69	0.5	1.39e-7	Dupuytren's disease;
THYM	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg26384229	chr12:38710491	ALG10B	0.95	7.57	0.61	2.35e-11	Bladder cancer;
THYM	cis	rs2835345	0.563	rs60511692	chr21:37826389	G/T	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs742614	0.533	rs6059499	chr20:32447920	C/T	cg06304546	chr20:32448765	NA	1.0	10.8	0.74	3.31e-18	Stearic acid (18:0) levels;
THYM	cis	rs11574514	1.000	rs77335546	chr16:67868394	C/T	cg09738193	chr16:67926317	PSKH1	-0.91	-4.48	-0.42	2.1e-5	Crohn's disease;
THYM	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg03060546	chr3:49711283	APEH	-0.65	-4.91	-0.45	3.82e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg04034577	chr2:241836375	C2orf54	-0.49	-8.8	-0.67	6.02e-14	Urinary metabolites;
THYM	cis	rs3092073	0.617	rs17448680	chr20:44594726	T/C	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.5	-5.2	-0.47	1.12e-6	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.66	4.83	0.44	5.32e-6	Aortic root size;
THYM	cis	rs4808199	0.947	rs10401193	chr19:19591066	A/G	cg03709012	chr19:19516395	GATAD2A	1.19	7.25	0.6	1.12e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs61990749	0.597	rs2032781	chr14:78214875	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.04	0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs28374715	0.532	rs11854632	chr15:41682094	A/G	cg18705301	chr15:41695430	NDUFAF1	1.24	14.78	0.83	2.3e-26	Ulcerative colitis;
THYM	cis	rs988913	1.000	rs6926997	chr6:54817326	C/G	cg19716238	chr6:54711378	FAM83B	0.49	5.05	0.46	2.1e-6	Menarche (age at onset);
THYM	cis	rs7084402	0.967	rs1649077	chr10:60293906	A/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.65e-7	Refractive error;
THYM	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg05294307	chr14:35346193	BAZ1A	-0.86	-5.7	-0.51	1.33e-7	Psoriasis;
THYM	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg10334053	chr1:2078117	PRKCZ	-0.45	-4.74	-0.44	7.58e-6	Height;
THYM	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	cg12893697	chr11:970389	AP2A2	-0.31	-5.05	-0.46	2.13e-6	Alzheimer's disease (late onset);
THYM	cis	rs10411161	0.702	rs7251571	chr19:52389057	A/G	cg25361850	chr19:52391789	ZNF577	0.73	5.18	0.47	1.24e-6	Breast cancer;
THYM	cis	rs3768617	0.510	rs3765521	chr1:183077615	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg23161317	chr6:28129485	ZNF389	0.85	6.33	0.54	8.19e-9	Depression;
THYM	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg14972814	chr11:95582409	MTMR2	-0.78	-6.52	-0.56	3.3e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg18876405	chr7:65276391	NA	-0.55	-4.68	-0.43	9.66e-6	Calcium levels;
THYM	cis	rs10501293	0.746	rs7929118	chr11:43029294	C/T	cg03447554	chr11:43094025	NA	0.61	4.51	0.42	1.83e-5	Cognitive performance;
THYM	cis	rs7809950	1.000	rs17154077	chr7:107077941	C/T	cg23024343	chr7:107201750	COG5	0.9	8.07	0.64	2.19e-12	Coronary artery disease;
THYM	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg21926883	chr2:100939477	LONRF2	-0.65	-6.02	-0.53	3.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs490234	0.812	rs4838286	chr9:128460057	G/A	cg14078157	chr9:128172775	NA	-0.66	-5.01	-0.46	2.48e-6	Mean arterial pressure;
THYM	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg01097406	chr16:89675127	NA	-0.64	-5.28	-0.48	8.13e-7	Vitiligo;
THYM	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs12200560	0.505	rs211173	chr6:97070804	C/T	cg06623918	chr6:96969491	KIAA0776	0.76	5.81	0.51	8.28e-8	Coronary heart disease;
THYM	cis	rs10463554	0.963	rs34772	chr5:102450512	C/A	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Parkinson's disease;
THYM	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg10047753	chr17:41438598	NA	1.19	11.38	0.76	1.91e-19	Menopause (age at onset);
THYM	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.09	-7.74	-0.62	1.06e-11	Platelet count;
THYM	cis	rs900145	0.773	rs11022751	chr11:13307613	T/C	cg13286116	chr11:13302098	ARNTL	0.61	4.82	0.44	5.39e-6	Menarche (age at onset);
THYM	cis	rs3126085	0.935	rs10888467	chr1:152171707	C/T	cg10321714	chr1:152280068	FLG	0.68	5.07	0.46	1.98e-6	Atopic dermatitis;
THYM	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	9.67	0.7	8.34e-16	Platelet count;
THYM	cis	rs919433	0.750	rs788012	chr2:198229856	A/T	cg00792783	chr2:198669748	PLCL1	0.78	5.62	0.5	1.89e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs1445130	1.000	rs12619250	chr2:18834944	G/A	cg21927971	chr2:17837235	VSNL1	0.71	4.46	0.42	2.24e-5	Bulimia nervosa;
THYM	cis	rs10208940	0.614	rs35597853	chr2:68832417	T/C	cg09157127	chr2:69201416	GKN1	0.93	4.78	0.44	6.3e-6	Urate levels in lean individuals;
THYM	cis	rs7524258	0.903	rs4908609	chr1:7292910	G/A	cg07173049	chr1:7289937	CAMTA1	0.82	6.34	0.55	7.82e-9	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg09359103	chr1:154839909	KCNN3	-0.73	-9.27	-0.69	5.9e-15	Prostate cancer;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg13411962	chr8:28243934	ZNF395	-1.3	-7.28	-0.6	9.78e-11	Pulmonary function decline;
THYM	cis	rs6763768	0.578	rs13090627	chr3:53406425	C/T	cg16894138	chr3:53270350	TKT	0.72	5.5	0.49	3.2e-7	Bacterial meningitis;
THYM	cis	rs12148488	0.966	rs1867149	chr15:75339993	C/T	cg02696790	chr15:75250997	RPP25	-0.48	-4.8	-0.44	5.83e-6	Caffeine consumption;
THYM	cis	rs7412746	0.611	rs2256355	chr1:150811794	A/G	cg15448220	chr1:150897856	SETDB1	0.83	6.83	0.57	8.08e-10	Melanoma;
THYM	cis	rs72627509	0.857	rs781658	chr4:57779567	G/A	cg26694713	chr4:57773883	REST	0.76	4.85	0.45	4.78e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs8114671	0.836	rs6060140	chr20:33566507	G/A	cg08999081	chr20:33150536	PIGU	0.57	4.95	0.45	3.25e-6	Height;
THYM	cis	rs11948739	0.610	rs4235799	chr5:130232830	A/T	cg08523029	chr5:130500466	HINT1	-0.81	-5.75	-0.51	1.06e-7	Pediatric bone mineral content (hip);
THYM	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg21252483	chr19:49399788	TULP2	-0.87	-6.06	-0.53	2.77e-8	Red cell distribution width;
THYM	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg24733560	chr20:60626293	TAF4	0.56	5.76	0.51	1.02e-7	Body mass index;
THYM	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg08975724	chr8:8085496	FLJ10661	0.71	5.8	0.51	8.79e-8	Mood instability;
THYM	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg21028142	chr17:79581711	NPLOC4	-0.61	-6.22	-0.54	1.33e-8	Eye color traits;
THYM	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg10053473	chr17:62856997	LRRC37A3	0.92	7.34	0.6	7.17e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs7809950	0.953	rs2520263	chr7:107179119	T/C	cg23024343	chr7:107201750	COG5	-0.94	-8.59	-0.66	1.7e-13	Coronary artery disease;
THYM	trans	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	trans	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg21984481	chr17:79567631	NPLOC4	0.46	4.87	0.45	4.45e-6	Eye color traits;
THYM	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg02487422	chr3:49467188	NICN1	0.63	4.82	0.44	5.48e-6	Resting heart rate;
THYM	cis	rs2073300	1.000	rs115730610	chr20:23442621	G/A	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg09354556	chr3:47051341	NA	0.44	4.55	0.42	1.62e-5	Colorectal cancer;
THYM	cis	rs2932538	0.961	rs2932529	chr1:113193364	G/A	cg22162597	chr1:113214053	CAPZA1	-0.63	-4.96	-0.45	3.13e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs13082711	0.911	rs7640957	chr3:27514015	C/A	cg02860705	chr3:27208620	NA	0.72	5.06	0.46	2.01e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs4072705	0.585	rs7852843	chr9:127233823	C/T	cg01786973	chr9:127249749	NR5A1	-0.4	-5.1	-0.46	1.75e-6	Menarche (age at onset);
THYM	cis	rs6429082	0.702	rs7532018	chr1:235706290	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.63	-4.47	-0.42	2.2e-5	Adiposity;
THYM	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg05855489	chr10:104503620	C10orf26	0.56	4.49	0.42	1.99e-5	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg26038318	chr20:34205095	SPAG4	0.58	4.58	0.43	1.43e-5	Total cholesterol levels;
THYM	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	trans	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.77	-8.03	-0.64	2.55e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg04398451	chr17:18023971	MYO15A	0.9	9.71	0.71	6.98e-16	Total body bone mineral density;
THYM	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.67e-7	Corneal astigmatism;
THYM	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.67	0.62	1.48e-11	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.22e-7	Corneal astigmatism;
THYM	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg03404566	chr17:6899310	ALOX12	0.76	9.68	0.7	8.08e-16	Tonsillectomy;
THYM	cis	rs1747683	0.605	rs2275129	chr10:13378181	C/G	cg25835351	chr10:13388524	SEPHS1	-0.28	-4.8	-0.44	5.87e-6	IgG glycosylation;
THYM	cis	rs688187	0.843	rs12980275	chr19:39731783	A/G	cg16476317	chr19:39737804	NA	0.41	4.92	0.45	3.69e-6	Mucinous ovarian carcinoma;
THYM	cis	rs9788721	0.836	rs2568494	chr15:78740964	G/A	cg18825076	chr15:78729989	IREB2	-0.66	-6.33	-0.54	8.02e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs1385374	0.858	rs959989	chr12:129292708	A/T	cg04043695	chr12:129287642	SLC15A4	-0.8	-4.83	-0.44	5.3e-6	Systemic lupus erythematosus;
THYM	cis	rs3791406	1.000	rs3791406	chr2:240030484	A/G	cg14550559	chr2:240039617	HDAC4	0.6	5.44	0.49	4.11e-7	Skin aging (microtopography measurement);
THYM	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg24846680	chr1:228362309	C1orf69	0.59	4.78	0.44	6.29e-6	Diastolic blood pressure;
THYM	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg23958373	chr8:599963	NA	1.03	4.72	0.44	7.98e-6	IgG glycosylation;
THYM	cis	rs11997175	1.000	rs6468201	chr8:33746854	G/C	ch.8.33884649F	chr8:33765107	NA	0.64	4.97	0.45	2.93e-6	Body mass index;
THYM	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg13880726	chr7:1868755	MAD1L1	0.69	4.64	0.43	1.09e-5	Bipolar disorder;
THYM	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg03188948	chr7:1209495	NA	0.9	7.34	0.6	7.37e-11	Longevity;Endometriosis;
THYM	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14159672	chr1:205819179	PM20D1	0.97	10.05	0.72	1.32e-16	Menarche (age at onset);
THYM	cis	rs6987853	0.933	rs2923434	chr8:42422307	A/G	cg09913449	chr8:42400586	C8orf40	0.87	8.22	0.64	1.02e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg11375102	chr16:1583810	IFT140;TMEM204	-0.55	-4.68	-0.43	9.35e-6	Coronary artery disease;
THYM	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	trans	rs2562456	1.000	rs2562456	chr19:21666210	A/G	cg22241504	chr17:3539680	CTNS;SHPK	-0.85	-6.85	-0.57	7.27e-10	Pain;
THYM	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs938554	0.578	rs7663032	chr4:9993838	C/T	cg26689780	chr4:10079554	WDR1	-0.4	-4.69	-0.43	8.96e-6	Blood metabolite levels;
THYM	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg07936489	chr17:37558343	FBXL20	0.83	5.77	0.51	1e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs34638657	0.872	rs2967350	chr16:82196130	T/C	cg09439754	chr16:82129088	HSD17B2	-0.58	-5.13	-0.47	1.51e-6	Lung adenocarcinoma;
THYM	cis	rs4780401	0.755	rs8049633	chr16:11768810	T/C	cg01061890	chr16:11836724	TXNDC11	-0.61	-4.71	-0.43	8.55e-6	Rheumatoid arthritis;
THYM	cis	rs1729951	0.575	rs10935213	chr3:136693459	A/G	cg12473912	chr3:136751656	NA	0.63	5.13	0.47	1.55e-6	Neuroticism;
THYM	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg12419862	chr22:24373484	LOC391322	-0.76	-7.2	-0.59	1.37e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs748404	0.631	rs3809482	chr15:43661802	T/C	cg12861797	chr15:43585817	TGM7	0.45	4.65	0.43	1.08e-5	Lung cancer;
THYM	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg10802521	chr3:52805072	NEK4	-0.75	-7.03	-0.58	3.15e-10	Electroencephalogram traits;
THYM	cis	rs7267979	1.000	rs4815406	chr20:25341316	C/G	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9534288	0.664	rs1926446	chr13:46629995	A/C	cg15192986	chr13:46630673	CPB2	0.68	5.12	0.47	1.59e-6	Blood protein levels;
THYM	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg23992470	chr4:843637	GAK	1.11	5.18	0.47	1.23e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11648796	0.765	rs2003832	chr16:769538	G/A	cg09263875	chr16:632152	PIGQ	0.67	5.31	0.48	7.14e-7	Height;
THYM	cis	rs4940575	0.786	rs8088100	chr18:60840079	G/T	cg20947866	chr18:61143580	SERPINB5	0.9	5.34	0.48	6.28e-7	Breast cancer;
THYM	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg14004847	chr7:1930337	MAD1L1	-0.65	-5.29	-0.48	7.86e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs4919687	0.550	rs12780827	chr10:104467954	T/C	cg18761893	chr10:103892519	PPRC1	0.61	4.61	0.43	1.25e-5	Colorectal cancer;
THYM	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg05717871	chr11:638507	DRD4	-0.64	-5.11	-0.46	1.69e-6	Systemic lupus erythematosus;
THYM	cis	rs11186	0.556	rs72908324	chr2:189973464	C/T	cg11041835	chr2:189156425	GULP1	0.8	4.52	0.42	1.79e-5	Parkinson's disease;
THYM	cis	rs17152411	0.895	rs61872121	chr10:126586795	T/C	cg07906193	chr10:126599966	NA	0.68	4.65	0.43	1.08e-5	Height;
THYM	cis	rs6893807	0.697	rs27774	chr5:87959033	G/A	cg02225085	chr5:87975992	LOC645323	-0.6	-4.53	-0.42	1.72e-5	Body mass index;
THYM	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg14798641	chr3:49314920	USP4;C3orf62	-0.66	-4.63	-0.43	1.17e-5	Cognitive function;
THYM	cis	rs951366	0.553	rs10900522	chr1:205684067	T/C	cg26354017	chr1:205819088	PM20D1	-0.68	-5.19	-0.47	1.19e-6	Menarche (age at onset);
THYM	cis	rs4891159	0.790	rs72975929	chr18:74144630	G/C	cg24786174	chr18:74118243	ZNF516	-0.87	-9.85	-0.71	3.47e-16	Longevity;
THYM	cis	rs7584330	0.554	rs77956735	chr2:238399130	C/T	cg08992911	chr2:238395768	MLPH	1.1	6.36	0.55	7.01e-9	Prostate cancer;
THYM	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	8.22	0.64	1.02e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg01448562	chr3:133502909	NA	-0.82	-6.84	-0.57	7.51e-10	Iron status biomarkers;
THYM	cis	rs2688608	0.592	rs12253482	chr10:75496130	G/A	cg15838173	chr10:75533400	FUT11	-0.59	-5.99	-0.52	3.66e-8	Inflammatory bowel disease;
THYM	cis	rs1942	1.000	rs1942	chr15:41774423	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.7	-5.64	-0.5	1.76e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs67981189	0.896	rs221922	chr14:71585113	T/C	cg15910301	chr14:71632612	NA	-0.5	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.55	-5.64	-0.5	1.72e-7	Crohn's disease;
THYM	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg01557791	chr16:72042693	DHODH	0.64	5.33	0.48	6.58e-7	Prostate cancer;
THYM	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.73	5.73	0.51	1.16e-7	Tonsillectomy;
THYM	cis	rs10895275	0.961	rs11225165	chr11:102084574	C/T	cg24447756	chr11:102105824	NA	0.53	4.53	0.42	1.69e-5	Migraine;
THYM	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg00024416	chr22:24240387	NA	-0.69	-8.09	-0.64	1.91e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs236907	0.812	rs35249022	chr1:171760767	A/G	cg20598894	chr1:171756153	METTL13	-0.74	-5.59	-0.5	2.16e-7	Mean platelet volume;
THYM	cis	rs792448	0.603	rs12024665	chr1:212499895	C/T	ch.1.4129519F	chr1:212238115	DTL	-0.57	-4.47	-0.42	2.19e-5	White blood cell count (basophil);
THYM	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg12863693	chr15:85201151	NMB	0.63	5.56	0.5	2.43e-7	Schizophrenia;
THYM	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg15605315	chr1:45957053	TESK2	0.78	6.58	0.56	2.6e-9	High light scatter reticulocyte count;
THYM	cis	rs2346177	0.580	rs1530628	chr2:46670941	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.61	4.94	0.45	3.41e-6	HDL cholesterol;
THYM	cis	rs7119	0.717	rs8033067	chr15:77825495	G/T	cg10437265	chr15:77819839	NA	0.75	7.41	0.6	5.28e-11	Type 2 diabetes;
THYM	cis	rs7172809	0.573	rs7182221	chr15:77589535	C/T	cg22256960	chr15:77711686	NA	0.67	4.98	0.45	2.9e-6	Glucose homeostasis traits;
THYM	cis	rs7769051	0.711	rs9493436	chr6:133088275	T/C	cg07930552	chr6:133119739	C6orf192	0.96	5.35	0.48	6.18e-7	Type 2 diabetes nephropathy;
THYM	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg05754148	chr16:3507555	NAT15	0.88	7.16	0.59	1.69e-10	Tuberculosis;
THYM	cis	rs453301	0.564	rs28649568	chr8:8959671	T/G	cg06636001	chr8:8085503	FLJ10661	-0.64	-5.28	-0.48	8.09e-7	Joint mobility (Beighton score);
THYM	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg23187316	chr7:1099788	C7orf50	0.61	5.27	0.48	8.69e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7572733	0.534	rs7572123	chr2:198769637	A/G	cg05783139	chr2:198650985	BOLL	0.62	4.89	0.45	4.15e-6	Dermatomyositis;
THYM	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg08999081	chr20:33150536	PIGU	0.73	6.69	0.57	1.57e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg03476357	chr21:30257390	N6AMT1	-0.59	-4.6	-0.43	1.31e-5	Dental caries;
THYM	cis	rs863345	0.604	rs1342954	chr1:158464548	C/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs10771511	1	rs10771511	chr12:29437217	T/C	cg09582351	chr12:29534625	ERGIC2	-0.47	-4.86	-0.45	4.66e-6	Platelet distribution width;
THYM	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11644478	chr21:40555479	PSMG1	0.99	5.71	0.51	1.26e-7	Cognitive function;
THYM	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg19052272	chr2:3704530	ALLC	-0.67	-5.0	-0.46	2.62e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg06611532	chr13:114900021	NA	0.64	7.19	0.59	1.51e-10	Schizophrenia;
THYM	cis	rs5758659	0.729	rs134866	chr22:42650663	C/T	cg00645731	chr22:42541494	CYP2D7P1	-0.4	-4.72	-0.44	8e-6	Cognitive function;
THYM	trans	rs877282	1.000	rs11253369	chr10:773610	C/G	cg22713356	chr15:30763199	NA	1.21	9.71	0.71	6.98e-16	Uric acid levels;
THYM	cis	rs2625529	0.590	rs2607090	chr15:72496011	C/A	cg16672083	chr15:72433130	SENP8	-0.53	-4.75	-0.44	7.13e-6	Red blood cell count;
THYM	cis	rs611744	0.967	rs596245	chr8:109240822	G/A	cg21045802	chr8:109455806	TTC35	0.59	5.26	0.47	8.86e-7	Dupuytren's disease;
THYM	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg00300879	chr1:26503847	CNKSR1	0.41	5.45	0.49	3.97e-7	Height;
THYM	cis	rs920590	0.758	rs7010174	chr8:19661930	G/C	cg01411142	chr8:19674711	INTS10	0.63	4.79	0.44	6.06e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg07936489	chr17:37558343	FBXL20	0.82	5.69	0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg14458575	chr2:238380390	NA	-0.99	-7.81	-0.63	7.47e-12	Prostate cancer;
THYM	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.77	7.29	0.6	8.94e-11	Lymphocyte counts;
THYM	cis	rs9581943	0.967	rs7999100	chr13:28477401	C/A	cg16302790	chr13:28498334	PDX1	0.52	4.73	0.44	7.69e-6	Pancreatic cancer;
THYM	cis	rs2777491	0.707	rs1757456	chr15:41793494	A/T	cg18705301	chr15:41695430	NDUFAF1	-1.05	-11.06	-0.75	8.96e-19	Ulcerative colitis;
THYM	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg21252483	chr19:49399788	TULP2	-0.95	-7.2	-0.59	1.41e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7172809	0.573	rs58792939	chr15:77548113	C/G	cg22256960	chr15:77711686	NA	-0.65	-4.86	-0.45	4.71e-6	Glucose homeostasis traits;
THYM	cis	rs7705502	0.890	rs6885658	chr5:173307137	C/T	cg18693985	chr5:173351052	CPEB4	-0.79	-5.61	-0.5	1.97e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-6.28	-0.54	9.97e-9	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg10515332	chr4:99064459	C4orf37	0.6	4.74	0.44	7.59e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg00981070	chr1:2046702	PRKCZ	-0.4	-4.96	-0.45	3.1e-6	Height;
THYM	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg12310025	chr6:25882481	NA	-0.87	-7.78	-0.62	8.56e-12	Intelligence (multi-trait analysis);
THYM	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs4654899	0.802	rs4654724	chr1:21177210	C/T	cg01072550	chr1:21505969	NA	-0.68	-5.93	-0.52	4.82e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg25072359	chr17:41440525	NA	0.78	4.93	0.45	3.44e-6	Menopause (age at onset);
THYM	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.8e-7	Monocyte count;
THYM	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg02825527	chr7:2087843	MAD1L1	-0.77	-5.17	-0.47	1.29e-6	Bipolar disorder;
THYM	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	ch.11.42038R	chr11:967971	AP2A2	0.56	4.47	0.42	2.13e-5	Alzheimer's disease (late onset);
THYM	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.91	-7.97	-0.63	3.5e-12	Menarche (age at onset);
THYM	cis	rs10463554	0.856	rs26427	chr5:102366783	A/C	cg23492399	chr5:102201601	PAM	0.66	4.76	0.44	7e-6	Parkinson's disease;
THYM	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14240646	chr10:27532245	ACBD5	0.99	5.49	0.49	3.3e-7	Breast cancer;
THYM	cis	rs2625529	0.824	rs12592364	chr15:72284647	C/A	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg12310025	chr6:25882481	NA	0.83	6.83	0.57	8.11e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9470366	0.509	rs4713996	chr6:36629714	C/T	cg11920449	chr6:36645608	CDKN1A	0.66	5.58	0.5	2.26e-7	QRS duration;
THYM	cis	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg12963246	chr6:28129442	ZNF389	0.92	6.2	0.54	1.47e-8	Depression;
THYM	cis	rs6089584	0.821	rs4925332	chr20:60604639	C/T	cg13770153	chr20:60521292	NA	-0.7	-4.9	-0.45	3.99e-6	Body mass index;
THYM	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg02187348	chr16:89574699	SPG7	0.64	4.95	0.45	3.22e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg11764359	chr7:65958608	NA	0.86	7.24	0.6	1.17e-10	Aortic root size;
THYM	cis	rs4631830	0.900	rs7920517	chr10:51532621	G/A	cg16070123	chr10:51489643	NA	-0.52	-4.68	-0.43	9.37e-6	Prostate-specific antigen levels;
THYM	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg24209194	chr3:40518798	ZNF619	-0.73	-6.31	-0.54	8.87e-9	Renal cell carcinoma;
THYM	cis	rs3796352	1.000	rs13091844	chr3:53010271	C/T	cg04865290	chr3:52927548	TMEM110	-0.89	-4.65	-0.43	1.08e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs9549260	0.755	rs2701869	chr13:41157372	G/A	cg21288729	chr13:41239152	FOXO1	0.66	5.22	0.47	1.06e-6	Red blood cell count;
THYM	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg13319975	chr6:146136371	FBXO30	-0.66	-5.36	-0.48	5.73e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg18538332	chr22:24372958	LOC391322	-0.98	-11.95	-0.77	1.26e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs35883536	0.566	rs12566440	chr1:101095202	A/G	cg09408571	chr1:101003634	GPR88	0.43	5.16	0.47	1.34e-6	Monocyte count;
THYM	cis	rs6032067	0.852	rs6032046	chr20:43823679	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs4638749	1.000	rs2123694	chr2:108857505	A/G	cg25838818	chr2:108905173	SULT1C2	-0.6	-6.13	-0.53	1.97e-8	Blood pressure;
THYM	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg03188948	chr7:1209495	NA	0.9	5.02	0.46	2.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3204270	0.714	rs7189	chr17:79668897	C/T	cg13117272	chr17:79681052	SLC25A10	-0.76	-4.76	-0.44	6.85e-6	Dental caries;
THYM	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.38	0.55	6.56e-9	Platelet count;
THYM	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg18230493	chr5:56204884	C5orf35	-0.64	-4.86	-0.45	4.56e-6	Initial pursuit acceleration;
THYM	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg10248100	chr7:872053	UNC84A	0.74	4.99	0.46	2.75e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs9633835	0.894	rs11022762	chr11:13335926	A/G	cg13286116	chr11:13302098	ARNTL	-0.64	-6.62	-0.56	2.18e-9	Body mass index;
THYM	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06873352	chr17:61820015	STRADA	0.78	9.87	0.71	3.13e-16	Prudent dietary pattern;
THYM	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11645898	0.935	rs4788615	chr16:72192372	G/A	cg03805757	chr16:71968109	PKD1L3	-0.7	-5.14	-0.47	1.47e-6	Blood protein levels;
THYM	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg08470875	chr2:26401718	FAM59B	-0.72	-4.46	-0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs57561814	0.510	rs2066992	chr7:22768249	G/T	cg01770232	chr7:22766155	IL6	0.96	4.7	0.43	8.78e-6	Tonsillectomy;
THYM	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg26384229	chr12:38710491	ALG10B	0.6	4.56	0.42	1.54e-5	Heart rate;
THYM	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg26513180	chr16:89883248	FANCA	0.52	4.64	0.43	1.12e-5	Vitiligo;
THYM	cis	rs145308728	1	rs145308728	chr15:91000156	GTA/G	cg22089800	chr15:90895588	ZNF774	0.7	4.57	0.42	1.47e-5	Lymphocyte percentage of white cells;
THYM	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg24324837	chr19:49891574	CCDC155	0.66	6.33	0.54	8.23e-9	Multiple sclerosis;
THYM	cis	rs752010	0.714	rs10890144	chr1:42085397	G/T	cg22486000	chr1:42919398	ZMYND12	-0.4	-4.7	-0.43	8.95e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs2456568	0.867	rs2456569	chr11:93691393	C/A	cg26875233	chr11:93583750	C11orf90	-0.48	-4.73	-0.44	7.87e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7809950	1.000	rs2712201	chr7:107145564	T/C	cg23024343	chr7:107201750	COG5	-0.93	-8.3	-0.65	7.11e-13	Coronary artery disease;
THYM	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg04362960	chr10:104952993	NT5C2	0.68	4.7	0.43	8.91e-6	Arsenic metabolism;
THYM	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg04398451	chr17:18023971	MYO15A	0.95	10.61	0.74	8.23e-18	Total body bone mineral density;
THYM	cis	rs7592578	0.771	rs12052514	chr2:191378170	C/T	cg10560079	chr2:191398806	TMEM194B	-0.95	-7.86	-0.63	5.88e-12	Diastolic blood pressure;
THYM	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs897984	0.553	rs2125293	chr16:30863875	T/C	cg03418659	chr16:31128414	MYST1	0.64	4.68	0.43	9.46e-6	Dementia with Lewy bodies;
THYM	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg23711669	chr6:146136114	FBXO30	0.97	10.4	0.73	2.29e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg03684893	chr10:554711	DIP2C	-0.69	-5.44	-0.49	4.18e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs4631830	0.965	rs7070301	chr10:51543070	T/G	cg16070123	chr10:51489643	NA	-0.52	-4.63	-0.43	1.15e-5	Prostate-specific antigen levels;
THYM	cis	rs9972944	0.729	rs7502798	chr17:63781615	C/T	cg07283582	chr17:63770753	CCDC46	0.65	5.22	0.47	1.07e-6	Total body bone mineral density;
THYM	cis	rs2046867	0.862	rs57396880	chr3:72844785	G/A	cg25664220	chr3:72788482	NA	-0.91	-7.16	-0.59	1.72e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg24692254	chr21:30365293	RNF160	-0.95	-8.3	-0.65	7.11e-13	Dental caries;
THYM	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg26384229	chr12:38710491	ALG10B	-0.64	-4.62	-0.43	1.19e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1609391	0.543	rs1347209	chr3:136626697	G/T	cg15507776	chr3:136538369	TMEM22	0.64	4.9	0.45	4.02e-6	Neuroticism;
THYM	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-5.41	-0.49	4.61e-7	Vitiligo;
THYM	cis	rs7940866	0.834	rs7939417	chr11:130853832	T/A	cg05962950	chr11:130786565	SNX19	0.75	5.79	0.51	9.16e-8	Schizophrenia;
THYM	cis	rs34375054	0.738	rs10846834	chr12:125625570	A/G	cg25124228	chr12:125621409	AACS	-0.78	-6.62	-0.56	2.14e-9	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs10873998	0.523	rs12128499	chr1:79271822	A/T	cg17415326	chr1:79350918	NA	-0.44	-4.98	-0.46	2.8e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7043114	0.525	rs7020874	chr9:95112560	G/A	cg14631576	chr9:95140430	CENPP	-0.86	-9.03	-0.68	1.97e-14	Height;
THYM	cis	rs76662990	0.610	rs73113474	chr5:73942900	A/G	cg13275603	chr5:73927487	ENC1	-0.77	-4.63	-0.43	1.17e-5	Residual cognition;
THYM	cis	rs57221529	0.655	rs72704791	chr5:547896	A/G	cg16447950	chr5:562315	NA	-0.63	-4.48	-0.42	2.07e-5	Lung disease severity in cystic fibrosis;
THYM	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs8028313	0.630	rs28418298	chr15:67935745	C/T	cg24579218	chr15:68104479	NA	-0.7	-6.43	-0.55	5.04e-9	Obesity;
THYM	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg11279151	chr3:101281821	RG9MTD1	-1.05	-8.75	-0.67	7.65e-14	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg00757033	chr12:89920650	WDR51B	0.77	11.72	0.77	3.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs1374313	1.000	rs1374313	chr2:120145655	A/G	cg18093372	chr2:119607603	NA	-0.45	-4.5	-0.42	1.95e-5	Obesity-related traits;
THYM	cis	rs752010	0.967	rs6703597	chr1:42097904	C/T	cg22486000	chr1:42919398	ZMYND12	-0.41	-4.62	-0.43	1.21e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs17094448	0.557	rs117276277	chr14:74497463	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	4.87	0.45	4.38e-6	Blood protein levels;
THYM	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs700651	0.754	rs1518367	chr2:198807015	T/A	cg00792783	chr2:198669748	PLCL1	0.79	5.46	0.49	3.78e-7	Intracranial aneurysm;
THYM	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg23887609	chr12:130822674	PIWIL1	-0.61	-4.59	-0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg09359103	chr1:154839909	KCNN3	-0.86	-12.2	-0.78	3.76e-21	Prostate cancer;
THYM	cis	rs11085466	1.000	rs75211977	chr19:21760201	G/A	cg23026602	chr19:21646605	NA	-0.66	-4.84	-0.45	4.94e-6	Colorectal or endometrial cancer;
THYM	cis	rs28647808	1.000	rs35348753	chr9:136270070	A/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg03929089	chr4:120376271	NA	1.05	9.84	0.71	3.7e-16	Coronary artery disease;
THYM	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs739401	0.619	rs10766480	chr11:2961325	G/A	cg08508325	chr11:3079039	CARS	-0.52	-6.16	-0.53	1.78e-8	Longevity;
THYM	cis	rs13631	0.894	rs7856589	chr9:140003921	A/G	cg03717367	chr9:139980219	LOC100289341;MAN1B1	-0.52	-4.61	-0.43	1.24e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.98	7.8	0.62	8.01e-12	Age-related macular degeneration (geographic atrophy);
THYM	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg15704280	chr7:45808275	SEPT13	-0.94	-7.13	-0.59	2e-10	Coronary artery disease;
THYM	cis	rs4499344	0.730	rs10410888	chr19:33103328	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.61	0.62	2.02e-11	Mean platelet volume;
THYM	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg09307838	chr4:120376055	NA	0.7	5.24	0.47	9.74e-7	Corneal astigmatism;
THYM	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg22117172	chr7:91764530	CYP51A1	0.37	4.6	0.43	1.32e-5	Breast cancer;
THYM	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.71	5.63	0.5	1.8e-7	Tonsillectomy;
THYM	cis	rs35883536	0.528	rs1414414	chr1:101028907	T/C	cg06223162	chr1:101003688	GPR88	0.96	8.44	0.65	3.52e-13	Monocyte count;
THYM	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg23791538	chr6:167370224	RNASET2	-0.61	-4.81	-0.44	5.66e-6	Crohn's disease;
THYM	cis	rs1461503	1.000	rs1461499	chr11:122843987	C/A	cg27398637	chr11:122830231	C11orf63	-0.62	-5.64	-0.5	1.77e-7	Menarche (age at onset);
THYM	cis	rs7567389	0.719	rs1504135	chr2:128003251	C/T	cg09760422	chr2:128146352	NA	-0.53	-5.65	-0.5	1.7e-7	Self-rated health;
THYM	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg09877947	chr5:131593287	PDLIM4	0.65	5.62	0.5	1.87e-7	Blood metabolite levels;
THYM	cis	rs10887741	0.966	rs2255683	chr10:89419910	A/G	cg13926569	chr10:89418898	PAPSS2	-0.6	-6.15	-0.53	1.82e-8	Exercise (leisure time);
THYM	cis	rs7103648	0.897	rs35032070	chr11:47408592	G/A	cg20307385	chr11:47447363	PSMC3	0.84	6.78	0.57	1.02e-9	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg19748678	chr4:122722346	EXOSC9	0.76	5.41	0.49	4.78e-7	Type 2 diabetes;
THYM	cis	rs3809566	0.963	rs12148057	chr15:63331509	A/T	cg00520135	chr15:63333846	TPM1	-0.6	-5.18	-0.47	1.24e-6	Platelet count;
THYM	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.68	-5.93	-0.52	4.8e-8	Total body bone mineral density;
THYM	cis	rs7851660	0.809	rs10984253	chr9:100664474	A/G	cg13688889	chr9:100608707	NA	-0.79	-5.75	-0.51	1.06e-7	Strep throat;
THYM	cis	rs10744422	0.748	rs2292138	chr12:123339712	A/G	cg25930673	chr12:123319894	HIP1R	-0.86	-4.84	-0.44	5.09e-6	Schizophrenia;
THYM	cis	rs7119	0.717	rs12902912	chr15:77809170	A/G	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs921968	0.541	rs3845835	chr2:219342284	T/C	cg02176678	chr2:219576539	TTLL4	-0.73	-7.24	-0.6	1.18e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs35660623	0.850	rs2898246	chr8:10656291	A/C	cg12395012	chr8:11607386	GATA4	0.96	5.25	0.47	9.42e-7	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs56341938	0.935	rs11711205	chr3:168733394	G/A	cg09107232	chr3:169491072	MYNN	0.54	4.58	0.43	1.42e-5	Lung function (FEV1/FVC);
THYM	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.8	4.46	0.42	2.26e-5	Initial pursuit acceleration;
THYM	cis	rs17253792	0.822	rs79024594	chr14:56092997	T/G	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.12	8.84	0.67	5.07e-14	Cognitive test performance;
THYM	trans	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg10856724	chr12:34555212	NA	-1.02	-9.32	-0.69	4.7e-15	Morning vs. evening chronotype;
THYM	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg08859206	chr1:53392774	SCP2	-0.5	-5.23	-0.47	1e-6	Monocyte count;
THYM	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg00129232	chr17:37814104	STARD3	0.76	5.25	0.47	9.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg11009520	chr8:12052164	FAM86B1	0.6	4.79	0.44	6.02e-6	Morning vs. evening chronotype;
THYM	cis	rs10924970	0.967	rs10925270	chr1:235425875	C/T	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs1864585	0.806	rs73209932	chr8:10718700	T/C	cg11824826	chr8:9953022	MSRA	0.71	4.58	0.43	1.39e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
THYM	cis	rs1005224	0.520	rs6574249	chr14:76087152	A/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.62	-4.63	-0.43	1.16e-5	Large artery stroke;
THYM	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg13609457	chr4:120235615	NA	0.55	5.0	0.46	2.59e-6	Corneal astigmatism;
THYM	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg11812906	chr14:75593930	NEK9	-0.87	-7.93	-0.63	4.14e-12	Height;
THYM	cis	rs904251	0.797	rs1757177	chr6:37486370	C/T	cg25019722	chr6:37503610	NA	-0.63	-5.52	-0.49	2.9e-7	Cognitive performance;
THYM	cis	rs4808199	1.000	rs60321073	chr19:19499598	A/G	cg03709012	chr19:19516395	GATAD2A	1.19	7.25	0.6	1.12e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs939658	0.805	rs11631590	chr15:79446199	C/T	cg17916960	chr15:79447300	NA	-0.73	-8.41	-0.65	4.06e-13	Refractive error;
THYM	cis	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg06521331	chr12:34319734	NA	-0.86	-6.28	-0.54	1.01e-8	Morning vs. evening chronotype;
THYM	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-7.0	-0.58	3.54e-10	Monocyte percentage of white cells;
THYM	cis	rs4523957	0.820	rs2224770	chr17:2205923	T/C	cg16513277	chr17:2031491	SMG6	0.79	7.24	0.6	1.16e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg06883089	chr1:45254480	BEST4	0.6	4.46	0.42	2.27e-5	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg03929089	chr4:120376271	NA	-0.99	-12.81	-0.8	2.07e-22	Height;
THYM	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-1.07	-13.04	-0.8	6.91e-23	Height;
THYM	cis	rs1030420	1.000	rs10957375	chr8:67355484	C/T	cg06195829	chr8:66753750	PDE7A	-0.79	-4.53	-0.42	1.69e-5	Blood metabolite levels;
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg27402713	chr2:130831550	POTEF	0.88	6.96	0.58	4.27e-10	Energy expenditure (24h);
THYM	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1642645	0.831	rs11210563	chr1:42494633	G/T	cg22816091	chr1:42611670	NA	0.62	5.52	0.49	2.99e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.75	-6.43	-0.55	5.15e-9	Intelligence (multi-trait analysis);
THYM	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs7512552	0.839	rs1097070	chr1:150332955	A/T	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	cg01483505	chr11:975446	AP2A2	0.64	4.94	0.45	3.35e-6	Alzheimer's disease (late onset);
THYM	cis	rs1371867	0.839	rs1660313	chr8:101332712	G/A	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg15704280	chr7:45808275	SEPT13	1.02	8.31	0.65	6.7e-13	Coronary artery disease;
THYM	cis	rs12478296	1.000	rs56387669	chr2:243043889	T/C	cg06360820	chr2:242988706	NA	-0.95	-5.75	-0.51	1.08e-7	Obesity-related traits;
THYM	cis	rs10911251	0.546	rs944971	chr1:183112505	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.66	0.43	1.02e-5	Colorectal cancer;
THYM	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22968622	chr17:43663579	NA	0.81	6.94	0.58	4.78e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs859767	0.741	rs1467194	chr2:135430621	A/G	cg12500956	chr2:135428796	TMEM163	-0.51	-5.31	-0.48	7.1e-7	Neuroticism;
THYM	cis	rs17539620	0.624	rs7770107	chr6:154836862	A/G	cg20019720	chr6:154832845	CNKSR3	0.47	4.79	0.44	6.17e-6	Lipoprotein (a) levels;
THYM	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg08704250	chr15:31115839	NA	-0.54	-6.24	-0.54	1.23e-8	Huntington's disease progression;
THYM	cis	rs9468199	0.510	rs72851161	chr6:28071123	A/G	cg08851530	chr6:28072375	NA	1.15	4.46	0.42	2.28e-5	Parkinson's disease;
THYM	cis	rs2276314	0.802	rs9963714	chr18:33592056	T/C	cg19628046	chr18:33552617	C18orf21	0.75	5.33	0.48	6.55e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs9560113	1.000	rs11620313	chr13:112179363	G/A	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs1538970	0.816	rs4633317	chr1:45985157	T/C	cg05343316	chr1:45956843	TESK2	0.82	5.17	0.47	1.28e-6	Platelet count;
THYM	cis	rs61931739	0.817	rs10743842	chr12:34306859	C/T	cg06521331	chr12:34319734	NA	-0.65	-5.56	-0.5	2.46e-7	Morning vs. evening chronotype;
THYM	cis	rs4849845	0.760	rs55877687	chr2:121013675	A/G	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg02153584	chr22:29168773	CCDC117	0.67	5.17	0.47	1.29e-6	Lymphocyte counts;
THYM	cis	rs61931739	0.817	rs10772143	chr12:34230651	T/G	cg06521331	chr12:34319734	NA	-0.64	-5.37	-0.48	5.62e-7	Morning vs. evening chronotype;
THYM	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg11764359	chr7:65958608	NA	-0.84	-7.04	-0.59	2.94e-10	Aortic root size;
THYM	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06634786	chr22:41940651	POLR3H	-0.79	-6.08	-0.53	2.5e-8	Vitiligo;
THYM	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.22	-0.47	1.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg14004847	chr7:1930337	MAD1L1	-0.69	-5.55	-0.49	2.57e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs314370	0.521	rs314308	chr7:100420878	C/T	cg10426581	chr7:100472382	SRRT	0.48	4.55	0.42	1.61e-5	Resting heart rate;
THYM	cis	rs3771570	1.000	rs73004382	chr2:242382192	C/T	cg21155796	chr2:242212141	HDLBP	1.25	6.07	0.53	2.57e-8	Prostate cancer;
THYM	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg24675658	chr1:53192096	ZYG11B	0.78	7.02	0.58	3.33e-10	Monocyte count;
THYM	cis	rs427394	0.664	rs274697	chr5:6731477	A/C	cg10857441	chr5:6722123	POLS	-0.69	-8.08	-0.64	2.05e-12	Menopause (age at onset);
THYM	cis	rs7582403	0.807	rs1234429	chr2:148817799	A/G	cg23727674	chr2:148602993	ACVR2A	0.58	4.79	0.44	6.24e-6	Neuroticism;
THYM	cis	rs4474465	1.000	rs10899511	chr11:78170923	T/A	cg19901956	chr11:77921274	USP35	-0.6	-4.55	-0.42	1.56e-5	Alzheimer's disease (survival time);
THYM	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg13010199	chr12:38710504	ALG10B	0.64	4.61	0.43	1.25e-5	Morning vs. evening chronotype;
THYM	cis	rs4478037	0.822	rs9865342	chr3:33118631	G/A	cg19404215	chr3:33155277	CRTAP	1.07	6.99	0.58	3.76e-10	Major depressive disorder;
THYM	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg21475434	chr5:93447410	FAM172A	0.71	4.51	0.42	1.83e-5	Diabetic retinopathy;
THYM	cis	rs968451	0.951	rs12627838	chr22:39733521	A/G	cg24268161	chr22:39747459	SYNGR1	-0.66	-4.49	-0.42	2.02e-5	Primary biliary cholangitis;
THYM	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg08999081	chr20:33150536	PIGU	-0.57	-4.95	-0.45	3.25e-6	Height;
THYM	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg01073479	chr16:3509474	NAT15	0.54	5.23	0.47	1e-6	Tuberculosis;
THYM	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg03676636	chr4:99064102	C4orf37	0.42	6.05	0.53	2.83e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.93	-4.66	-0.43	1.05e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12956009	0.518	rs4574017	chr18:44891703	A/T	cg19077165	chr18:44547161	KATNAL2	-0.51	-4.93	-0.45	3.51e-6	Educational attainment (years of education);
THYM	cis	rs7246657	0.943	rs7408563	chr19:37808585	G/C	cg22634378	chr19:37742834	NA	0.68	5.67	0.5	1.55e-7	Coronary artery calcification;
THYM	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg13390004	chr1:15929781	NA	0.62	4.72	0.44	8.11e-6	Systolic blood pressure;
THYM	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg19346786	chr7:2764209	NA	-0.71	-5.98	-0.52	3.92e-8	Height;
THYM	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg08048268	chr3:133502702	NA	-0.7	-5.78	-0.51	9.47e-8	Iron status biomarkers;
THYM	cis	rs11603020	0.904	rs11606677	chr11:57383377	G/A	cg19752551	chr11:57585705	CTNND1	-0.6	-5.02	-0.46	2.42e-6	Blood protein levels;
THYM	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg23422044	chr7:1970798	MAD1L1	-0.77	-4.63	-0.43	1.16e-5	Neuroticism;
THYM	cis	rs977987	0.778	rs35214308	chr16:75476088	C/T	cg03315344	chr16:75512273	CHST6	0.74	5.92	0.52	5.07e-8	Dupuytren's disease;
THYM	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.79e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs4919044	0.866	rs835265	chr10:94786259	A/G	cg05127821	chr10:94822908	CYP26C1	-1.32	-7.25	-0.6	1.12e-10	Coronary artery disease;
THYM	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg26769984	chr7:1090371	C7orf50	0.77	5.18	0.47	1.25e-6	Bronchopulmonary dysplasia;
THYM	cis	rs17125944	0.615	rs7150808	chr14:53304871	C/T	cg00686598	chr14:53173677	PSMC6	-1.1	-5.22	-0.47	1.06e-6	Alzheimer's disease (late onset);
THYM	cis	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-5.52	-0.49	2.92e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11890956	chr21:40555474	PSMG1	-0.63	-5.73	-0.51	1.2e-7	Menarche (age at onset);
THYM	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg10911889	chr6:126070802	HEY2	0.58	4.62	0.43	1.22e-5	Brugada syndrome;
THYM	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg26408565	chr15:76604113	ETFA	-0.52	-4.51	-0.42	1.84e-5	Blood metabolite levels;
THYM	trans	rs1974653	0.672	rs113307754	chr22:20089271	A/G	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg26441486	chr22:50317300	CRELD2	-0.42	-6.45	-0.55	4.58e-9	Schizophrenia;
THYM	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg11764359	chr7:65958608	NA	-0.82	-6.45	-0.55	4.58e-9	Aortic root size;
THYM	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg22105103	chr4:187893119	NA	-0.88	-8.99	-0.68	2.37e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg24675658	chr1:53192096	ZYG11B	-0.59	-4.74	-0.44	7.39e-6	Monocyte count;
THYM	cis	rs2859741	1.000	rs4653239	chr1:37509872	C/G	cg09363841	chr1:37513479	NA	0.74	6.92	0.58	5.2e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs7429990	0.965	rs4296617	chr3:48068308	T/C	cg02219026	chr3:48282209	ZNF589	0.63	4.62	0.43	1.18e-5	Educational attainment (years of education);
THYM	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg18758796	chr5:131593413	PDLIM4	0.51	4.71	0.44	8.43e-6	Breast cancer;
THYM	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg03909863	chr11:638404	DRD4	-0.66	-4.66	-0.43	1.04e-5	Systemic lupus erythematosus;
THYM	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg02953382	chr22:24373134	LOC391322	0.69	6.22	0.54	1.3e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs59107033	0.559	rs60088212	chr3:123105548	G/A	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Lymphocyte counts;
THYM	cis	rs9788721	0.836	rs2656065	chr15:78750549	G/A	cg18825076	chr15:78729989	IREB2	-0.67	-6.57	-0.56	2.7e-9	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg03909863	chr11:638404	DRD4	-0.76	-6.04	-0.53	2.95e-8	Systemic lupus erythematosus;
THYM	cis	rs7831492	0.564	rs57596574	chr8:41609843	G/A	cg17182837	chr8:41585554	ANK1	-0.59	-5.25	-0.47	9.17e-7	Colorectal cancer;
THYM	cis	rs875971	0.964	rs697969	chr7:65558478	C/A	cg18876405	chr7:65276391	NA	-0.65	-5.53	-0.49	2.85e-7	Aortic root size;
THYM	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg10360139	chr7:1886902	MAD1L1	-0.83	-7.39	-0.6	5.8e-11	Bipolar disorder and schizophrenia;
THYM	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg02353165	chr6:42928485	GNMT	1.05	11.95	0.77	1.25e-20	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs28595532	0.764	rs56359736	chr4:119769689	G/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg17105886	chr17:28927953	LRRC37B2	1.25	6.76	0.57	1.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.39	6.98	0.58	3.9e-10	Obesity-related traits;
THYM	cis	rs2650000	0.798	rs2701175	chr12:121391671	C/A	cg02403541	chr12:121454288	C12orf43	-0.72	-6.68	-0.57	1.63e-9	Metabolic traits;LDL cholesterol;
THYM	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg06697600	chr4:7070879	GRPEL1	0.55	4.92	0.45	3.69e-6	Monocyte percentage of white cells;
THYM	cis	rs2976388	1.000	rs2717562	chr8:143776668	T/C	cg13446199	chr8:143762866	PSCA	0.5	6.27	0.54	1.06e-8	Urinary tract infection frequency;
THYM	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg16586182	chr3:47516702	SCAP	0.6	5.12	0.47	1.6e-6	Colorectal cancer;
THYM	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg09455208	chr3:40491958	NA	0.45	4.65	0.43	1.06e-5	Renal cell carcinoma;
THYM	cis	rs8078723	0.866	rs3935280	chr17:38189055	A/G	cg17467752	chr17:38218738	THRA	-0.84	-7.04	-0.59	3.01e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11890956	chr21:40555474	PSMG1	-0.9	-9.57	-0.7	1.4e-15	Cognitive function;
THYM	cis	rs10463554	0.892	rs59292735	chr5:102382751	T/C	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs11112613	0.775	rs61200462	chr12:105969271	G/A	cg03607813	chr12:105948248	NA	0.92	6.66	0.56	1.73e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs854765	0.547	rs2955383	chr17:17941364	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.44	0.55	4.82e-9	Total body bone mineral density;
THYM	cis	rs514406	0.893	rs6588446	chr1:53425260	G/A	cg08736216	chr1:53307985	ZYG11A	0.6	5.46	0.49	3.73e-7	Monocyte count;
THYM	cis	rs7084402	0.935	rs7474570	chr10:60343085	C/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.65	-0.5	1.67e-7	Refractive error;
THYM	cis	rs7107174	0.748	rs7105835	chr11:78075725	T/C	cg02023728	chr11:77925099	USP35	0.65	6.35	0.55	7.45e-9	Testicular germ cell tumor;
THYM	cis	rs2229238	0.911	rs73023346	chr1:154512077	C/T	cg21262032	chr1:154437693	IL6R	-0.64	-5.79	-0.51	8.9e-8	Coronary heart disease;
THYM	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg06917634	chr15:78832804	PSMA4	0.96	8.76	0.67	7.4e-14	Sudden cardiac arrest;
THYM	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg11663144	chr21:46675770	NA	-0.68	-9.57	-0.7	1.4e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7107174	0.892	rs10899490	chr11:78105879	C/T	cg19901956	chr11:77921274	USP35	-0.65	-5.34	-0.48	6.41e-7	Testicular germ cell tumor;
THYM	trans	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs11039798	0.588	rs3924476	chr11:48581733	T/C	cg24672777	chr11:48374446	OR4C45	-0.93	-6.01	-0.52	3.39e-8	Axial length;
THYM	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg24531977	chr5:56204891	C5orf35	0.72	5.87	0.52	6.25e-8	Initial pursuit acceleration;
THYM	cis	rs6568490	0.556	rs2354094	chr6:108090339	T/C	cg03500965	chr6:108145777	SCML4	0.4	4.75	0.44	7.2e-6	Lymphocyte counts;
THYM	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg24818145	chr4:99064322	C4orf37	0.73	5.74	0.51	1.13e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11039798	0.623	rs588700	chr11:48449889	T/C	cg24672777	chr11:48374446	OR4C45	0.93	5.92	0.52	5.2e-8	Axial length;
THYM	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg25072359	chr17:41440525	NA	0.74	5.37	0.48	5.47e-7	Menopause (age at onset);
THYM	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg20891283	chr12:69753455	YEATS4	0.73	6.17	0.54	1.64e-8	Response to diuretic therapy;
THYM	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg00852783	chr1:26633632	UBXN11	0.86	8.81	0.67	5.74e-14	Obesity-related traits;
THYM	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-4.94	-0.45	3.29e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4595586	0.545	rs11615634	chr12:39364704	A/C	cg26384229	chr12:38710491	ALG10B	0.69	5.35	0.48	6.11e-7	Morning vs. evening chronotype;
THYM	cis	rs595982	0.517	rs4801779	chr19:49406651	T/G	cg21252483	chr19:49399788	TULP2	-0.68	-6.8	-0.57	9.39e-10	Red cell distribution width;
THYM	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg13147721	chr7:65941812	NA	-0.74	-4.73	-0.44	7.94e-6	Diabetic kidney disease;
THYM	cis	rs2455799	0.552	rs1472697	chr3:15750268	G/A	cg16303742	chr3:15540471	COLQ	-0.55	-5.73	-0.51	1.19e-7	Mean platelet volume;
THYM	cis	rs11756438	0.571	rs2046951	chr6:119021888	T/C	cg21191810	chr6:118973309	C6orf204	0.6	6.2	0.54	1.43e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs12478296	1.000	rs60533128	chr2:243028088	A/G	cg06360820	chr2:242988706	NA	-1.19	-7.22	-0.6	1.3e-10	Obesity-related traits;
THYM	cis	rs921968	0.584	rs2305833	chr2:219305404	G/C	cg02176678	chr2:219576539	TTLL4	0.65	6.25	0.54	1.18e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg00129232	chr17:37814104	STARD3	-0.7	-4.93	-0.45	3.42e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs6598955	0.543	rs3795689	chr1:26560366	C/G	cg04990556	chr1:26633338	UBXN11	0.9	5.88	0.52	6.03e-8	Obesity-related traits;
THYM	cis	rs4589258	1.000	rs2187536	chr11:90463275	C/T	cg26138821	chr11:89956704	CHORDC1	0.71	5.7	0.5	1.37e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg05973401	chr12:123451056	ABCB9	0.66	4.82	0.44	5.41e-6	Platelet count;
THYM	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg03433033	chr1:76189801	ACADM	0.76	8.16	0.64	1.4e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.95	-9.92	-0.71	2.43e-16	Birth weight;
THYM	cis	rs34912216	0.542	rs12701398	chr7:4129330	G/T	cg26550874	chr7:4183528	SDK1	0.6	4.46	0.42	2.22e-5	Motion sickness;
THYM	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg26513180	chr16:89883248	FANCA	-0.68	-6.58	-0.56	2.61e-9	Vitiligo;
THYM	cis	rs13256369	0.802	rs12681925	chr8:8561649	G/A	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg27490568	chr2:178487706	NA	0.63	5.77	0.51	1e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg14582100	chr15:45693742	SPATA5L1	0.6	4.77	0.44	6.64e-6	Homoarginine levels;
THYM	cis	rs8031584	0.958	rs61997076	chr15:31216225	C/T	cg08704250	chr15:31115839	NA	-0.55	-6.04	-0.53	2.94e-8	Huntington's disease progression;
THYM	trans	rs4650994	0.544	rs2811306	chr1:178599248	C/G	cg05059571	chr16:84539110	KIAA1609	0.9	10.05	0.72	1.26e-16	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg12311346	chr5:56204834	C5orf35	0.85	6.07	0.53	2.65e-8	Initial pursuit acceleration;
THYM	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-1.1	-12.21	-0.78	3.61e-21	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.866	rs1007137	chr20:43816593	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.29	-0.48	7.93e-7	Blood protein levels;
THYM	cis	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg00291366	chr1:12616550	NA	0.39	6.08	0.53	2.55e-8	Optic cup area;
THYM	cis	rs9581857	0.579	rs76578450	chr13:27982656	C/A	cg22138327	chr13:27999177	GTF3A	1.04	6.13	0.53	1.97e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg10057126	chr4:77819792	ANKRD56	0.59	4.75	0.44	7.21e-6	Emphysema distribution in smoking;
THYM	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs6964587	0.621	rs38799	chr7:92045139	C/T	cg17063962	chr7:91808500	NA	-0.82	-6.86	-0.58	6.88e-10	Breast cancer;
THYM	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg13683864	chr3:40499215	RPL14	-0.91	-8.82	-0.67	5.51e-14	Renal cell carcinoma;
THYM	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg04111992	chr7:158790115	NA	-0.56	-5.02	-0.46	2.45e-6	Facial morphology (factor 20);
THYM	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.53	0.49	2.83e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg25214090	chr10:38739885	LOC399744	-0.9	-7.53	-0.61	2.84e-11	Corneal astigmatism;
THYM	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg19346786	chr7:2764209	NA	-0.6	-5.13	-0.47	1.52e-6	Height;
THYM	cis	rs7769051	0.711	rs7758531	chr6:133085302	T/C	cg22852734	chr6:133119734	C6orf192	1.25	7.58	0.61	2.3e-11	Type 2 diabetes nephropathy;
THYM	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs13082711	0.871	rs34209332	chr3:27434061	A/T	cg02860705	chr3:27208620	NA	0.67	4.7	0.43	8.96e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg04455712	chr21:45112962	RRP1B	0.54	5.0	0.46	2.61e-6	Mean corpuscular volume;
THYM	cis	rs4720575	1.000	rs1859522	chr7:47096901	G/A	cg00036614	chr7:47093842	NA	-0.65	-5.67	-0.5	1.51e-7	Angiotensin-converting enzyme inhibitor intolerance;
THYM	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg15448220	chr1:150897856	SETDB1	0.9	7.49	0.61	3.57e-11	Melanoma;
THYM	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg11494091	chr17:61959527	GH2	-1.09	-17.19	-0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg21427119	chr20:30132790	HM13	-0.74	-4.76	-0.44	7.03e-6	Mean corpuscular hemoglobin;
THYM	cis	rs1568889	0.938	rs7128045	chr11:28190180	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.55e-6	Bipolar disorder;
THYM	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg00484396	chr16:3507460	NAT15	0.48	4.5	0.42	1.9e-5	Body mass index (adult);
THYM	cis	rs7106204	0.514	rs7126508	chr11:24255147	G/A	ch.11.24196551F	chr11:24239977	NA	1.02	7.07	0.59	2.58e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg05896524	chr21:47604654	C21orf56	-0.72	-4.72	-0.44	8e-6	Testicular germ cell tumor;
THYM	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg20966754	chr17:47091339	IGF2BP1	-0.59	-7.3	-0.6	8.66e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg04398451	chr17:18023971	MYO15A	-0.74	-6.76	-0.57	1.11e-9	Total body bone mineral density;
THYM	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg26441486	chr22:50317300	CRELD2	0.45	7.97	0.63	3.43e-12	Schizophrenia;
THYM	cis	rs57920188	0.535	rs12129515	chr1:4094101	G/A	cg08764037	chr1:3634867	TP73	-0.45	-4.68	-0.43	9.66e-6	Interleukin-17 levels;
THYM	cis	rs763014	0.865	rs8909	chr16:633851	T/C	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg14456004	chr13:21872349	NA	1.21	9.0	0.68	2.32e-14	White matter hyperintensity burden;
THYM	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.15	-0.59	1.77e-10	Triglycerides;
THYM	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg00684032	chr4:1343700	KIAA1530	0.55	4.9	0.45	3.98e-6	Longevity;
THYM	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg08999081	chr20:33150536	PIGU	0.78	7.16	0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg06640241	chr16:89574553	SPG7	-0.74	-6.43	-0.55	5.16e-9	Multiple myeloma (IgH translocation);
THYM	cis	rs4285028	0.699	rs2689290	chr3:121585146	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-5.48	-0.49	3.54e-7	Multiple sclerosis;
THYM	cis	rs7107174	0.901	rs2512522	chr11:77925855	G/C	cg19901956	chr11:77921274	USP35	-0.73	-5.77	-0.51	9.81e-8	Testicular germ cell tumor;
THYM	cis	rs1457451	0.646	rs12622045	chr2:65855872	A/G	cg16240816	chr2:65861662	NA	0.58	6.28	0.54	1.01e-8	Iron status biomarkers;
THYM	cis	rs3925075	1.000	rs4506917	chr16:31347350	T/G	cg02846316	chr16:31340340	ITGAM	0.58	6.08	0.53	2.44e-8	IgA nephropathy;
THYM	cis	rs7100689	0.598	rs2342815	chr10:82086532	T/C	cg01528321	chr10:82214614	TSPAN14	0.84	6.43	0.55	5.15e-9	Post bronchodilator FEV1;
THYM	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs7614311	0.689	rs2276863	chr3:63849043	C/A	cg22134162	chr3:63841271	THOC7	-0.68	-8.51	-0.66	2.56e-13	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg08773314	chr2:239334832	ASB1	0.64	9.92	0.71	2.51e-16	Multiple system atrophy;
THYM	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg12292205	chr6:26970375	C6orf41	-0.55	-4.63	-0.43	1.17e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11948739	0.610	rs6863693	chr5:130217998	A/G	cg08523029	chr5:130500466	HINT1	-0.82	-5.8	-0.51	8.7e-8	Pediatric bone mineral content (hip);
THYM	cis	rs4601821	0.789	rs7123797	chr11:113262571	A/G	cg14159747	chr11:113255604	NA	0.24	4.51	0.42	1.86e-5	Alcoholic chronic pancreatitis;
THYM	cis	rs2404602	0.647	rs11631394	chr15:76973209	G/T	cg23625390	chr15:77176239	SCAPER	-0.82	-5.85	-0.51	6.95e-8	Blood metabolite levels;
THYM	cis	rs9788682	0.792	rs35031105	chr15:78772806	C/T	cg18825076	chr15:78729989	IREB2	0.7	5.57	0.5	2.39e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg25918947	chr17:41365094	TMEM106A	-0.69	-5.83	-0.51	7.6e-8	Menopause (age at onset);
THYM	cis	rs1018836	0.828	rs756568	chr8:91557038	G/C	cg16814680	chr8:91681699	NA	-0.9	-7.85	-0.63	6.31e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg13607699	chr17:42295918	UBTF	0.66	5.44	0.49	4.13e-7	Total body bone mineral density;
THYM	cis	rs5995756	0.627	rs3788568	chr22:40011273	G/T	cg21377881	chr22:40064566	CACNA1I	-0.54	-4.56	-0.42	1.52e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6964587	0.626	rs10225241	chr7:91524940	A/G	cg17063962	chr7:91808500	NA	-1.01	-9.05	-0.68	1.74e-14	Breast cancer;
THYM	cis	rs4654899	0.897	rs59537090	chr1:21498737	C/T	cg01072550	chr1:21505969	NA	-0.74	-6.63	-0.56	2.02e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg04518342	chr5:131593106	PDLIM4	0.52	6.04	0.53	2.96e-8	Acylcarnitine levels;
THYM	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs7776786	0.934	rs17349342	chr7:18815473	A/C	cg13420273	chr7:18810212	HDAC9	0.79	8.91	0.67	3.47e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2717559	0.522	rs2585158	chr8:143875832	C/T	cg03405983	chr8:143858548	LYNX1	0.55	6.03	0.53	3.17e-8	Urinary tract infection frequency;
THYM	trans	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg10856724	chr12:34555212	NA	-0.88	-7.57	-0.61	2.39e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs611744	0.967	rs671139	chr8:109191260	C/T	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs7089973	0.872	rs7923295	chr10:116625159	C/G	cg08188268	chr10:116634841	FAM160B1	0.31	5.14	0.47	1.5e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg26149184	chr10:133730230	NA	0.77	4.65	0.43	1.07e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs4285028	0.747	rs11916169	chr3:121403211	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.84	-7.2	-0.59	1.37e-10	Multiple sclerosis;
THYM	cis	rs2282300	0.956	rs1717779	chr11:30376698	A/T	cg25418670	chr11:30344373	C11orf46	-0.74	-5.84	-0.51	7.14e-8	Morning vs. evening chronotype;
THYM	cis	rs11167764	0.895	rs7734160	chr5:141473144	G/T	cg23435118	chr5:141488016	NDFIP1	-0.53	-4.51	-0.42	1.85e-5	Crohn's disease;
THYM	cis	rs17776563	0.887	rs72763812	chr15:89135461	G/A	cg01779732	chr15:90015521	RHCG	0.46	4.53	0.42	1.71e-5	Thyroid hormone levels;
THYM	cis	rs988913	0.768	rs1115159	chr6:54753541	T/C	cg18532076	chr6:54711417	FAM83B	0.46	4.69	0.43	8.99e-6	Menarche (age at onset);
THYM	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg11317459	chr13:21872234	NA	1.23	10.6	0.74	8.56e-18	White matter hyperintensity burden;
THYM	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg19774624	chr17:42201019	HDAC5	-0.76	-7.12	-0.59	2.05e-10	Total body bone mineral density;
THYM	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs1466662	0.641	rs34927139	chr4:155305491	C/T	cg05574313	chr4:155338166	DCHS2	0.73	5.27	0.48	8.6e-7	Alzheimer's disease (age of onset);
THYM	cis	rs9875589	0.509	rs4684174	chr3:14048375	C/T	cg03204825	chr3:13978759	TPRXL	-0.51	-4.46	-0.42	2.26e-5	Ovarian reserve;
THYM	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg12288994	chr5:1860383	NA	0.84	6.96	0.58	4.45e-10	Cardiovascular disease risk factors;
THYM	cis	rs7582180	0.817	rs1437967	chr2:100929072	C/G	cg21926883	chr2:100939477	LONRF2	-0.66	-6.01	-0.52	3.43e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg07424592	chr7:64974309	NA	1.08	4.86	0.45	4.67e-6	Diabetic kidney disease;
THYM	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg26149184	chr10:133730230	NA	0.77	4.65	0.43	1.07e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg18758796	chr5:131593413	PDLIM4	-0.5	-4.72	-0.44	8.15e-6	Breast cancer;
THYM	cis	rs4285028	0.747	rs9850439	chr3:121393075	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.84	-7.2	-0.59	1.37e-10	Multiple sclerosis;
THYM	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg23803603	chr1:2058230	PRKCZ	0.63	5.37	0.48	5.58e-7	Height;
THYM	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06634786	chr22:41940651	POLR3H	0.63	4.92	0.45	3.62e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs654950	0.875	rs881719	chr1:41991427	C/T	cg13396354	chr1:41153348	NA	0.44	4.56	0.42	1.5e-5	Airway imaging phenotypes;
THYM	cis	rs9733	0.544	rs2867302	chr1:150653650	T/C	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg08994789	chr17:28903642	LRRC37B2	-1.09	-5.32	-0.48	6.76e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs71403859	0.685	rs12444890	chr16:71636026	G/A	cg08717414	chr16:71523259	ZNF19	-1.1	-5.69	-0.5	1.38e-7	Post bronchodilator FEV1;
THYM	cis	rs2219968	0.740	rs4478563	chr8:78919823	A/G	cg00738934	chr8:78996279	NA	0.67	6.13	0.53	1.95e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1483890	0.662	rs6780513	chr3:69405494	G/A	cg22125112	chr3:69402811	FRMD4B	0.57	7.19	0.59	1.44e-10	Resting heart rate;
THYM	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg06636001	chr8:8085503	FLJ10661	-0.7	-6.17	-0.53	1.7e-8	Mood instability;
THYM	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg13010199	chr12:38710504	ALG10B	0.64	4.61	0.43	1.25e-5	Morning vs. evening chronotype;
THYM	trans	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg22709100	chr7:91322751	NA	0.61	4.82	0.44	5.38e-6	Breast cancer;
THYM	cis	rs34375054	0.624	rs12826658	chr12:125680237	A/G	cg25124228	chr12:125621409	AACS	-0.65	-4.69	-0.43	9.18e-6	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs7809950	0.678	rs7803151	chr7:106934246	G/A	cg23024343	chr7:107201750	COG5	-1.0	-8.43	-0.65	3.79e-13	Coronary artery disease;
THYM	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.67	9.16	0.68	1.04e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2862064	0.872	rs1393209	chr5:156477540	G/A	cg12943317	chr5:156479607	HAVCR1	-0.84	-5.23	-0.47	9.88e-7	Platelet count;
THYM	cis	rs7113850	0.541	rs78652241	chr11:24234956	A/T	ch.11.24196551F	chr11:24239977	NA	0.87	4.66	0.43	1.04e-5	Bone fracture in osteoporosis;
THYM	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg10360139	chr7:1886902	MAD1L1	-0.83	-7.47	-0.61	3.95e-11	Bipolar disorder and schizophrenia;
THYM	cis	rs9649465	1.000	rs10228367	chr7:123370903	C/T	cg15443791	chr7:124364398	NA	0.58	4.81	0.44	5.62e-6	Migraine;
THYM	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6693295	0.536	rs12118406	chr1:246230312	G/A	cg11798871	chr1:246315928	SMYD3	-0.78	-4.72	-0.44	8.16e-6	Migraine - clinic-based;Migraine with aura;
THYM	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	trans	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg10856724	chr12:34555212	NA	-0.88	-7.89	-0.63	5.22e-12	Bladder cancer;
THYM	cis	rs2235649	0.833	rs9922139	chr16:1848329	G/T	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs3126085	1.000	rs3120662	chr1:152302865	G/T	cg26020982	chr1:152196106	HRNR	-0.36	-4.95	-0.45	3.19e-6	Atopic dermatitis;
THYM	cis	rs58950470	0.849	rs7122657	chr11:65378028	C/T	cg27068330	chr11:65405492	SIPA1	0.62	4.58	0.42	1.44e-5	Schizophrenia;
THYM	cis	rs7973719	0.868	rs6486910	chr12:7356479	G/A	cg07052231	chr12:7363540	PEX5	0.61	5.26	0.48	8.71e-7	IgG glycosylation;
THYM	cis	rs2463822	1.000	rs118049526	chr11:62107508	C/T	cg06239285	chr11:62104954	ASRGL1	-1.4	-6.65	-0.56	1.86e-9	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6456042	0.756	rs2197450	chr6:166585112	C/T	cg11088901	chr6:166572345	T	-0.57	-5.42	-0.49	4.48e-7	Asthma;
THYM	cis	rs611744	0.647	rs6981420	chr8:109266694	T/G	cg21045802	chr8:109455806	TTC35	0.62	5.38	0.48	5.32e-7	Dupuytren's disease;
THYM	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.59	-0.5	2.15e-7	Menopause (age at onset);
THYM	cis	rs5769707	0.592	rs6009783	chr22:50011001	C/G	cg17054759	chr22:49844102	NA	-0.52	-4.56	-0.42	1.54e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg23791538	chr6:167370224	RNASET2	-0.58	-4.53	-0.42	1.72e-5	Crohn's disease;
THYM	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg13695892	chr22:41940480	POLR3H	0.94	7.07	0.59	2.59e-10	Vitiligo;
THYM	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.47	5.81	0.51	8.27e-8	Monocyte percentage of white cells;
THYM	cis	rs10992471	0.756	rs1121979	chr9:95140218	G/A	cg14631576	chr9:95140430	CENPP	-0.95	-10.73	-0.74	4.66e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6456042	0.893	rs3127424	chr6:166539090	A/G	cg11088901	chr6:166572345	T	-0.52	-4.9	-0.45	3.93e-6	Asthma;
THYM	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg18876405	chr7:65276391	NA	-0.55	-4.73	-0.44	7.84e-6	Aortic root size;
THYM	cis	rs7572733	0.534	rs4550664	chr2:198691405	C/T	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg18252515	chr7:66147081	NA	-0.66	-4.85	-0.45	4.8e-6	Aortic root size;
THYM	cis	rs682331	0.588	rs861577	chr1:184725621	T/G	cg16716196	chr1:184195068	NA	-0.59	-4.54	-0.42	1.65e-5	Obesity-related traits;
THYM	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg23281280	chr6:28129359	ZNF389	0.64	4.97	0.45	2.98e-6	Parkinson's disease;
THYM	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.76	-5.28	-0.48	8.31e-7	Body mass index;
THYM	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg09359103	chr1:154839909	KCNN3	0.69	8.67	0.66	1.16e-13	Prostate cancer;
THYM	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs6840360	1.000	rs6845944	chr4:152604520	C/T	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg26384229	chr12:38710491	ALG10B	0.99	7.69	0.62	1.35e-11	Bladder cancer;
THYM	cis	rs9866391	0.607	rs4683606	chr3:141110074	A/G	cg13411656	chr3:141121016	ZBTB38	-0.35	-5.23	-0.47	9.9e-7	Myopia;
THYM	cis	rs828999	0.703	rs11185287	chr1:108698605	A/T	cg24323958	chr1:108741884	SLC25A24	0.52	4.98	0.45	2.84e-6	Monocyte percentage of white cells;
THYM	cis	rs9788721	0.806	rs4887056	chr15:78734585	A/G	cg18825076	chr15:78729989	IREB2	-0.66	-6.19	-0.54	1.54e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs61931739	1.000	rs61931739	chr12:34089973	C/T	cg10856724	chr12:34555212	NA	0.61	4.98	0.46	2.8e-6	Morning vs. evening chronotype;
THYM	cis	rs11031096	0.678	rs12222136	chr11:4180148	T/C	cg22027985	chr11:4115532	RRM1	-0.5	-4.6	-0.43	1.3e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg01579765	chr21:45077557	HSF2BP	0.51	7.85	0.63	6.2e-12	Mean corpuscular volume;
THYM	cis	rs28595532	1.000	rs73842212	chr4:119638122	A/G	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg27532560	chr4:187881888	NA	-0.95	-11.68	-0.77	4.63e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03264133	chr6:25882463	NA	-0.69	-5.32	-0.48	7.03e-7	Blood metabolite levels;
THYM	cis	rs1784581	0.651	rs3016568	chr6:162388158	G/A	cg17173639	chr6:162384350	PARK2	-0.84	-7.88	-0.63	5.43e-12	Itch intensity from mosquito bite;
THYM	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg24531977	chr5:56204891	C5orf35	-1.01	-8.29	-0.65	7.47e-13	Initial pursuit acceleration;
THYM	cis	rs67072384	1.000	rs66628852	chr11:72454260	C/A	cg01380194	chr11:72452482	ARAP1	-0.97	-5.26	-0.47	8.93e-7	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg10047753	chr17:41438598	NA	0.98	6.34	0.55	7.72e-9	Menopause (age at onset);
THYM	cis	rs1983170	1.000	rs12563578	chr1:91993702	T/C	cg04676771	chr1:91176081	NA	0.68	4.85	0.45	4.84e-6	Eosinophil percentage of white cells;
THYM	cis	rs11771526	0.681	rs79578813	chr7:32308867	G/T	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs7000551	0.663	rs11778831	chr8:22335088	C/T	cg12081754	chr8:22256438	SLC39A14	0.62	5.53	0.49	2.79e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg15557168	chr22:42548783	NA	-0.59	-4.61	-0.43	1.25e-5	Schizophrenia;
THYM	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22857025	chr5:266934	NA	-1.54	-10.5	-0.73	1.41e-17	Breast cancer;
THYM	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg15962314	chr1:44399869	ARTN	0.55	5.35	0.48	6.12e-7	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg19761014	chr17:28927070	LRRC37B2	0.76	4.73	0.44	7.7e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs611744	0.647	rs2597658	chr8:109256014	C/T	cg21045802	chr8:109455806	TTC35	0.66	5.74	0.51	1.13e-7	Dupuytren's disease;
THYM	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg16414030	chr3:133502952	NA	-0.87	-8.51	-0.66	2.56e-13	Iron status biomarkers;
THYM	cis	rs904251	0.797	rs1757177	chr6:37486370	C/T	cg01843034	chr6:37503916	NA	-0.67	-5.3	-0.48	7.51e-7	Cognitive performance;
THYM	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.73	-4.82	-0.44	5.35e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.61	4.82	0.44	5.41e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11608355	0.597	rs2304548	chr12:109795166	T/G	cg11367159	chr12:110044531	NA	0.53	4.93	0.45	3.46e-6	Neuroticism;
THYM	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg23682913	chr1:2080710	PRKCZ	-0.64	-5.14	-0.47	1.44e-6	Height;
THYM	cis	rs911119	1.000	rs1064039	chr20:23618427	C/T	cg16589663	chr20:23618590	CST3	0.76	4.69	0.43	9.26e-6	Chronic kidney disease;
THYM	cis	rs28795989	0.795	rs4696779	chr4:7919375	T/C	cg00251875	chr4:7801337	AFAP1	-0.6	-4.73	-0.44	7.86e-6	Intraocular pressure;
THYM	cis	rs17006441	0.899	rs62251034	chr3:69868072	A/G	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs6543140	0.964	rs13383602	chr2:103085962	C/T	cg03938978	chr2:103052716	IL18RAP	0.6	5.78	0.51	9.35e-8	Blood protein levels;
THYM	cis	rs9826463	0.582	rs11719737	chr3:142164017	A/G	cg20824294	chr3:142316082	PLS1	0.71	4.97	0.45	2.98e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs3112255	0.567	rs2942884	chr2:101323578	C/T	cg01042948	chr2:101319752	NA	0.61	6.02	0.53	3.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4642101	0.737	rs6767504	chr3:12826667	C/T	cg05775895	chr3:12838266	CAND2	0.77	6.9	0.58	5.69e-10	QRS complex (12-leadsum);
THYM	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg26566898	chr11:117069891	TAGLN	0.4	5.16	0.47	1.36e-6	Blood protein levels;
THYM	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg01017244	chr2:74357527	NA	0.99	8.6	0.66	1.61e-13	Gestational age at birth (maternal effect);
THYM	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg10523679	chr1:76189770	ACADM	-0.55	-4.67	-0.43	9.97e-6	Daytime sleep phenotypes;
THYM	cis	rs7465272	1.000	rs7835613	chr8:143682428	C/T	cg10104451	chr8:143696006	ARC	-0.79	-5.52	-0.49	2.92e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg02018176	chr4:1364513	KIAA1530	0.6	4.69	0.43	9.22e-6	Obesity-related traits;
THYM	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg23231163	chr10:75533350	FUT11	-0.41	-5.9	-0.52	5.54e-8	Inflammatory bowel disease;
THYM	cis	rs7584330	0.554	rs729389	chr2:238425118	G/A	cg14458575	chr2:238380390	NA	0.79	4.65	0.43	1.06e-5	Prostate cancer;
THYM	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg13581527	chr7:1708566	NA	-0.69	-4.88	-0.45	4.32e-6	Multiple sclerosis;
THYM	cis	rs4731207	0.596	rs10226659	chr7:124609868	A/C	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs2625529	0.617	rs11630170	chr15:72448451	C/T	cg16672083	chr15:72433130	SENP8	0.5	4.57	0.42	1.48e-5	Red blood cell count;
THYM	cis	rs4481887	0.927	rs10888340	chr1:248440381	C/T	cg00666640	chr1:248458726	OR2T12	0.56	4.75	0.44	7.28e-6	Common traits (Other);
THYM	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.8	0.51	8.67e-8	Hip circumference adjusted for BMI;
THYM	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg04476341	chr5:669733	TPPP	0.61	4.52	0.42	1.8e-5	Obesity-related traits;
THYM	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg09455208	chr3:40491958	NA	-0.48	-5.12	-0.46	1.61e-6	Renal cell carcinoma;
THYM	cis	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg06636001	chr8:8085503	FLJ10661	-0.63	-5.18	-0.47	1.22e-6	Recombination measurement;
THYM	cis	rs17174870	0.955	rs6712080	chr2:112777441	C/T	cg17354880	chr2:112658759	MERTK	-0.59	-4.47	-0.42	2.13e-5	Multiple sclerosis;
THYM	cis	rs360798	0.532	rs12713468	chr2:62983213	G/A	cg17519650	chr2:63277830	OTX1	-0.68	-4.57	-0.42	1.44e-5	Coronary artery disease;
THYM	cis	rs11089937	0.616	rs743520	chr22:22532639	A/C	cg06866756	chr22:22471216	NA	-0.43	-4.66	-0.43	1.02e-5	Periodontitis (PAL4Q3);
THYM	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	5.28	0.48	8.32e-7	Schizophrenia;
THYM	cis	rs6430585	0.528	rs309142	chr2:136715324	T/C	cg23851026	chr2:136556271	LCT	0.69	7.27	0.6	1.02e-10	Corneal structure;
THYM	cis	rs596169	0.649	rs11118187	chr1:219156010	G/A	cg19270308	chr1:218458869	RRP15	-1.24	-4.52	-0.42	1.81e-5	Intraocular pressure;
THYM	cis	rs13102973	0.899	rs7438900	chr4:135909921	T/A	cg14419869	chr4:135874104	NA	0.82	6.86	0.58	7.03e-10	Subjective well-being;
THYM	cis	rs4474465	1.000	rs4945282	chr11:78188795	G/A	cg19901956	chr11:77921274	USP35	-0.62	-4.52	-0.42	1.81e-5	Alzheimer's disease (survival time);
THYM	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	6.57	0.56	2.66e-9	Total body bone mineral density;
THYM	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg23205692	chr1:25664452	TMEM50A	0.79	6.3	0.54	9.43e-9	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs28595532	0.764	rs116158926	chr4:119730572	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs714031	0.730	rs5757766	chr22:40069490	T/C	cg21377881	chr22:40064566	CACNA1I	-0.55	-4.95	-0.45	3.16e-6	Schizophrenia;
THYM	cis	rs7762018	0.607	rs80267898	chr6:170040306	G/A	cg19338460	chr6:170058176	WDR27	-1.06	-6.21	-0.54	1.39e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg04455712	chr21:45112962	RRP1B	0.51	4.76	0.44	6.94e-6	Mean corpuscular volume;
THYM	cis	rs6047844	0.569	rs1415799	chr20:22131194	A/G	cg16502866	chr20:23015624	SSTR4	0.57	4.75	0.44	7.33e-6	Male-pattern baldness;
THYM	cis	rs977987	0.843	rs2059256	chr16:75395835	G/T	cg03315344	chr16:75512273	CHST6	0.74	6.25	0.54	1.14e-8	Dupuytren's disease;
THYM	cis	rs863345	0.604	rs12034004	chr1:158463885	A/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg11211951	chr8:145729740	GPT	0.57	5.42	0.49	4.49e-7	Age at first birth;
THYM	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.73	5.57	0.5	2.36e-7	Tonsillectomy;
THYM	cis	rs62435770	1.000	rs17788472	chr6:169482877	C/T	cg07652237	chr6:170125491	PHF10	0.55	4.82	0.44	5.38e-6	Loneliness;
THYM	cis	rs11690935	0.589	rs2271758	chr2:172701157	T/G	cg13550731	chr2:172543902	DYNC1I2	0.61	4.65	0.43	1.07e-5	Schizophrenia;
THYM	cis	rs7193541	0.684	rs7201320	chr16:74694058	T/G	cg01733217	chr16:74700730	RFWD3	0.98	11.64	0.77	5.6e-20	Multiple myeloma;
THYM	cis	rs78761021	0.685	rs62064483	chr17:9796862	C/T	cg26853458	chr17:9805074	RCVRN	0.53	4.46	0.42	2.24e-5	Type 2 diabetes;
THYM	cis	rs921968	0.565	rs755112	chr2:219606052	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg01097406	chr16:89675127	NA	-0.6	-4.92	-0.45	3.56e-6	Vitiligo;
THYM	cis	rs2448490	0.642	rs535111	chr11:65485337	A/G	cg27068330	chr11:65405492	SIPA1	0.76	6.19	0.54	1.51e-8	Platelet count;
THYM	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg24578937	chr1:2090814	PRKCZ	0.59	5.88	0.52	6.22e-8	Height;
THYM	cis	rs4455778	0.580	rs4607559	chr7:49121902	G/A	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg23428387	chr22:49814324	NA	-0.5	-4.76	-0.44	6.94e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	trans	rs4866334	1.000	rs77766662	chr5:18485586	A/C	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.44	6.67	0.56	1.66e-9	Obesity-related traits;
THYM	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-6.67	-0.56	1.69e-9	Alzheimer's disease (late onset);
THYM	cis	rs995000	0.931	rs746735	chr1:63113511	C/A	cg06896770	chr1:63153194	DOCK7	-0.92	-7.54	-0.61	2.71e-11	Triglyceride levels;
THYM	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg25767906	chr1:53392781	SCP2	-0.52	-5.07	-0.46	1.93e-6	Monocyte count;
THYM	cis	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg08133631	chr1:26527909	CATSPER4	-0.59	-4.94	-0.45	3.38e-6	Obesity-related traits;
THYM	cis	rs7250872	0.647	rs2304613	chr19:1817943	G/C	cg18850929	chr19:1828978	REXO1	0.59	5.04	0.46	2.26e-6	Bipolar disorder;
THYM	cis	rs6558174	0.630	rs6558176	chr8:22522502	C/T	cg03733263	chr8:22462867	KIAA1967	-0.67	-4.96	-0.45	3.05e-6	Breast cancer;
THYM	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs2354432	1.000	rs11239944	chr1:146691015	C/T	cg25205988	chr1:146714368	CHD1L	0.9	6.21	0.54	1.42e-8	Mitochondrial DNA levels;
THYM	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg11789530	chr4:8429930	ACOX3	-0.74	-5.99	-0.52	3.74e-8	Response to antineoplastic agents;
THYM	cis	rs11723261	0.546	rs4315728	chr4:141021	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.86	5.68	0.5	1.48e-7	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.7	-5.72	-0.51	1.25e-7	Blood metabolite levels;
THYM	cis	rs4478037	0.822	rs3924695	chr3:33122085	C/T	cg19404215	chr3:33155277	CRTAP	0.96	6.49	0.55	3.83e-9	Major depressive disorder;
THYM	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg00080972	chr5:178986291	RUFY1	0.51	5.65	0.5	1.7e-7	Lung cancer;
THYM	cis	rs6456042	1.000	rs6456040	chr6:166534636	T/C	cg11088901	chr6:166572345	T	-0.51	-4.82	-0.44	5.5e-6	Asthma;
THYM	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg23982607	chr1:1823379	GNB1	0.73	6.68	0.57	1.6e-9	Body mass index;
THYM	cis	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.98	0.45	2.85e-6	Obesity-related traits;
THYM	cis	rs4917300	0.647	rs4917223	chr8:143115548	C/T	cg25363559	chr8:143086065	NA	-0.53	-4.66	-0.43	1.03e-5	Amyotrophic lateral sclerosis;
THYM	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg02782426	chr3:40428986	ENTPD3	0.56	4.95	0.45	3.21e-6	Renal cell carcinoma;
THYM	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg26314531	chr2:26401878	FAM59B	-0.76	-5.02	-0.46	2.37e-6	Gut microbiome composition (summer);
THYM	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	cis	rs3136739	0.717	rs60117685	chr8:42091477	A/G	cg12091331	chr8:42065314	PLAT	-0.81	-5.8	-0.51	8.65e-8	Plasma plasminogen activator levels;
THYM	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	4.98	0.46	2.8e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg15445000	chr17:37608096	MED1	-0.44	-5.07	-0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg26566898	chr11:117069891	TAGLN	-0.4	-5.1	-0.46	1.7e-6	Blood protein levels;
THYM	cis	rs9640161	0.830	rs1051764	chr7:150070663	T/C	cg10018233	chr7:150070692	REPIN1	0.47	7.94	0.63	4.08e-12	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4466137	0.953	rs7735476	chr5:83015140	G/C	cg16102102	chr5:83017553	HAPLN1	-1.11	-11.0	-0.75	1.21e-18	Prostate cancer;
THYM	cis	rs2732480	0.967	rs2732469	chr12:48712932	T/A	cg21466736	chr12:48725269	NA	-0.56	-5.43	-0.49	4.26e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs596169	0.655	rs11118195	chr1:219175366	C/T	cg19270308	chr1:218458869	RRP15	-1.24	-4.52	-0.42	1.81e-5	Intraocular pressure;
THYM	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs3784262	0.528	rs6493979	chr15:58338052	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.65	-5.04	-0.46	2.24e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
THYM	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg08305652	chr11:111469057	NA	0.53	4.58	0.43	1.41e-5	Primary sclerosing cholangitis;
THYM	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.57	-4.88	-0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg02487422	chr3:49467188	NICN1	0.63	4.82	0.44	5.48e-6	Resting heart rate;
THYM	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg11752832	chr7:134001865	SLC35B4	0.74	5.65	0.5	1.69e-7	Mean platelet volume;
THYM	cis	rs1021993	0.672	rs906353	chr1:209467522	A/G	cg24997231	chr1:209527535	NA	0.51	4.6	0.43	1.3e-5	Gut microbiome composition (winter);
THYM	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs4919694	0.901	rs10509763	chr10:104776391	G/A	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg07636037	chr3:49044803	WDR6	0.83	6.0	0.52	3.56e-8	Menarche (age at onset);
THYM	cis	rs3741151	1.000	rs76887714	chr11:73045500	C/T	cg12959048	chr11:73096162	RELT	-0.46	-4.81	-0.44	5.69e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs6669072	1.000	rs10922923	chr1:91248029	A/T	cg08895590	chr1:91227319	NA	-0.52	-5.89	-0.52	5.71e-8	Cognitive function;
THYM	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg18252515	chr7:66147081	NA	1.42	8.42	0.65	3.83e-13	Diabetic kidney disease;
THYM	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg25358565	chr5:93447407	FAM172A	1.32	11.28	0.76	3.22e-19	Diabetic retinopathy;
THYM	cis	rs3126085	0.935	rs6666382	chr1:152217226	C/G	cg10321714	chr1:152280068	FLG	-0.67	-4.66	-0.43	1.03e-5	Atopic dermatitis;
THYM	cis	rs910187	0.678	rs6066229	chr20:45815341	A/G	cg27589058	chr20:45804311	EYA2	0.68	6.16	0.53	1.76e-8	Migraine;
THYM	cis	rs2554380	0.843	rs7182216	chr15:84422506	C/G	cg14598478	chr15:84363061	ADAMTSL3	0.62	4.87	0.45	4.36e-6	Height;
THYM	cis	rs7719624	0.967	rs2282790	chr5:135363875	A/G	cg15329133	chr5:135467951	SMAD5;SMAD5OS	0.55	4.71	0.44	8.39e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs35110281	0.592	rs10211901	chr21:45122573	G/A	cg04455712	chr21:45112962	RRP1B	0.54	5.3	0.48	7.55e-7	Mean corpuscular volume;
THYM	cis	rs3849570	0.925	rs2873054	chr3:81888255	A/C	cg07356753	chr3:81810745	GBE1	-0.84	-6.22	-0.54	1.35e-8	Waist circumference;Body mass index;
THYM	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg10862848	chr6:42927986	GNMT	-0.51	-6.85	-0.57	7.42e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2932538	0.922	rs17438324	chr1:113100573	C/T	cg22162597	chr1:113214053	CAPZA1	0.66	5.21	0.47	1.09e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg22535103	chr8:58192502	C8orf71	-0.93	-4.56	-0.42	1.52e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.21	-8.44	-0.65	3.49e-13	Gut microbiome composition (summer);
THYM	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	4.53	0.42	1.74e-5	Obesity-related traits;
THYM	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.73	-0.51	1.18e-7	Bipolar disorder and schizophrenia;
THYM	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg17830980	chr10:43048298	ZNF37B	-1.02	-10.36	-0.73	2.81e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7523273	0.526	rs2745980	chr1:208018367	A/C	cg22525895	chr1:207977042	MIR29B2	0.87	9.27	0.69	6.04e-15	Schizophrenia;
THYM	cis	rs2742234	0.541	rs1059484	chr10:43679800	T/G	cg06632098	chr10:43605906	RET	-0.79	-5.1	-0.46	1.73e-6	Hirschsprung disease;
THYM	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg18641463	chr7:2144579	MAD1L1	0.61	4.47	0.42	2.2e-5	Height;
THYM	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg05182265	chr7:156933206	UBE3C	-0.68	-9.23	-0.69	7.17e-15	Body mass index;
THYM	cis	rs9677476	0.689	rs55748426	chr2:232054897	G/C	cg07929768	chr2:232055508	NA	0.64	6.45	0.55	4.73e-9	Food antigen IgG levels;
THYM	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg26818010	chr10:134567672	INPP5A	-0.82	-6.62	-0.56	2.15e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs28595532	0.764	rs116788606	chr4:119748849	G/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg15592062	chr6:167189543	RPS6KA2	-0.58	-5.88	-0.52	6.01e-8	Crohn's disease;
THYM	cis	rs2195525	0.572	rs3814754	chr11:119217957	C/T	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.44	4.92	0.45	3.64e-6	Urate levels;
THYM	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg24399712	chr22:39784796	NA	-0.88	-10.08	-0.72	1.14e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-7.84	-0.63	6.55e-12	Lymphocyte percentage of white cells;
THYM	cis	rs11771526	0.901	rs13438711	chr7:32297310	G/A	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs1349547	0.510	rs3852339	chr8:39497011	C/T	cg01911981	chr8:39380341	ADAM3A	-0.53	-4.87	-0.45	4.51e-6	HIV-1 susceptibility;
THYM	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg10802521	chr3:52805072	NEK4	-0.8	-7.53	-0.61	2.92e-11	Bipolar disorder;
THYM	cis	rs10992471	0.729	rs2181585	chr9:95551830	G/A	cg14631576	chr9:95140430	CENPP	-0.85	-7.31	-0.6	8.31e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs35883536	0.528	rs1542837	chr1:101029768	T/C	cg09408571	chr1:101003634	GPR88	0.57	6.19	0.54	1.49e-8	Monocyte count;
THYM	cis	rs12478296	0.685	rs67829386	chr2:242992276	T/A	cg06360820	chr2:242988706	NA	-1.15	-8.25	-0.65	9.01e-13	Obesity-related traits;
THYM	cis	rs1023500	1.000	rs9620001	chr22:42330229	T/C	cg19448990	chr22:41842841	TOB2	-0.74	-4.65	-0.43	1.05e-5	Schizophrenia;
THYM	cis	rs977987	0.800	rs12922951	chr16:75355096	C/G	cg03315344	chr16:75512273	CHST6	0.83	6.82	0.57	8.49e-10	Dupuytren's disease;
THYM	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.18	8.91	0.67	3.51e-14	Cognitive test performance;
THYM	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12310956	0.515	rs11052934	chr12:33970381	T/C	cg06521331	chr12:34319734	NA	-0.88	-8.26	-0.65	8.51e-13	Morning vs. evening chronotype;
THYM	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg06387496	chr7:2775674	GNA12	-0.43	-4.47	-0.42	2.2e-5	Height;
THYM	cis	rs4940575	0.679	rs55825601	chr18:60835819	C/T	cg25271770	chr18:61057090	VPS4B	0.77	4.61	0.43	1.24e-5	Breast cancer;
THYM	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg22841779	chr14:105766346	BRF1	-0.47	-5.81	-0.51	8.18e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg07936489	chr17:37558343	FBXL20	-0.83	-5.69	-0.5	1.41e-7	Glomerular filtration rate (creatinine);
THYM	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg22433210	chr17:43662623	NA	-1.05	-8.08	-0.64	2e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg12863693	chr15:85201151	NMB	0.63	5.5	0.49	3.17e-7	Schizophrenia;
THYM	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg19318889	chr4:1322082	MAEA	0.67	5.75	0.51	1.06e-7	Longevity;
THYM	cis	rs4474465	1.000	rs952605	chr11:78200427	A/T	cg19901956	chr11:77921274	USP35	-0.65	-4.8	-0.44	5.97e-6	Alzheimer's disease (survival time);
THYM	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg14584255	chr6:163149320	PACRG;PARK2	0.71	6.25	0.54	1.16e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg16486109	chr11:613632	IRF7	0.47	5.59	0.5	2.19e-7	Systemic lupus erythematosus;
THYM	cis	rs4262150	0.883	rs72802883	chr5:152246607	A/C	cg06854687	chr5:151642065	NA	0.64	4.46	0.42	2.27e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg00256281	chr22:41985642	PMM1	0.56	4.62	0.43	1.19e-5	Vitiligo;
THYM	cis	rs4417704	0.551	rs10173220	chr2:241896909	G/A	cg15164180	chr2:241846931	NA	-0.37	-4.58	-0.43	1.41e-5	Joint mobility (Beighton score);
THYM	cis	rs12122100	0.651	rs12737860	chr1:146546343	G/T	cg03526459	chr1:146549940	NA	-0.66	-4.49	-0.42	1.97e-5	HIV-1 control;
THYM	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.75	7.26	0.6	1.06e-10	Lymphocyte counts;
THYM	cis	rs526231	0.511	rs55741939	chr5:102372688	T/C	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Primary biliary cholangitis;
THYM	cis	rs35883536	0.588	rs114540631	chr1:101101249	A/G	cg09408571	chr1:101003634	GPR88	0.4	4.9	0.45	3.88e-6	Monocyte count;
THYM	cis	rs4474465	0.790	rs7481910	chr11:78264202	G/C	cg19901956	chr11:77921274	USP35	0.65	4.78	0.44	6.37e-6	Alzheimer's disease (survival time);
THYM	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg22508957	chr16:3507546	NAT15	-0.41	-4.53	-0.42	1.71e-5	Body mass index (adult);
THYM	cis	rs11997175	0.624	rs17701219	chr8:33728795	T/A	ch.8.33884649F	chr8:33765107	NA	0.68	5.1	0.46	1.76e-6	Body mass index;
THYM	cis	rs3126085	0.935	rs4845736	chr1:152175551	G/A	cg26020982	chr1:152196106	HRNR	0.34	4.52	0.42	1.76e-5	Atopic dermatitis;
THYM	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.67	4.76	0.44	6.93e-6	Aortic root size;
THYM	cis	rs116095464	1.000	rs6863730	chr5:325003	G/T	cg22857025	chr5:266934	NA	-1.37	-4.79	-0.44	6.17e-6	Breast cancer;
THYM	cis	rs7107770	1.000	rs6590139	chr11:125093850	G/A	cg04164023	chr11:125106101	PKNOX2	-0.8	-4.65	-0.43	1.05e-5	Photic sneeze reflex;
THYM	cis	rs3750965	1.000	rs7950657	chr11:68834831	G/A	cg01403660	chr11:68851641	TPCN2	0.74	5.89	0.52	5.83e-8	Hair color;
THYM	cis	rs986417	0.901	rs7159628	chr14:61010688	A/C	cg27398547	chr14:60952738	C14orf39	1.0	5.05	0.46	2.14e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs425277	0.917	rs78609670	chr1:2045886	G/T	cg00981070	chr1:2046702	PRKCZ	0.46	4.85	0.45	4.9e-6	Height;
THYM	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg27170947	chr2:26402098	FAM59B	-0.6	-5.02	-0.46	2.43e-6	Gut microbiome composition (summer);
THYM	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg22496380	chr5:211416	CCDC127	-1.34	-7.45	-0.61	4.31e-11	Breast cancer;
THYM	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.55	-4.72	-0.44	8.2e-6	Coronary artery disease;
THYM	cis	rs6088590	0.748	rs6142206	chr20:33212055	G/A	cg08999081	chr20:33150536	PIGU	0.69	6.12	0.53	2.12e-8	Coronary artery disease;
THYM	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg18806716	chr10:30721971	MAP3K8	-0.53	-5.31	-0.48	7.18e-7	Inflammatory bowel disease;
THYM	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg26597838	chr10:835615	NA	0.99	5.41	0.49	4.77e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs7572733	0.555	rs1435569	chr2:198718667	G/C	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.63	4.46	0.42	2.25e-5	Aortic root size;
THYM	cis	rs4886920	0.672	rs11072680	chr15:78130580	C/G	cg10461261	chr15:78109450	NA	0.46	4.57	0.42	1.44e-5	Neuroticism;
THYM	cis	rs3741151	0.881	rs73542929	chr11:73094539	G/T	cg17517138	chr11:73019481	ARHGEF17	0.99	5.79	0.51	9.03e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg13447684	chr7:1895903	MAD1L1	0.49	4.45	0.42	2.33e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs17708984	0.606	rs3786576	chr19:16193337	G/T	cg13618979	chr19:16186840	TPM4	0.36	4.78	0.44	6.48e-6	Platelet count;Platelet distribution width;
THYM	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg12179176	chr11:130786555	SNX19	0.84	7.93	0.63	4.27e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	trans	rs17001239	0.850	rs12482056	chr21:26957749	A/C	cg20081244	chr17:79859945	NPB	0.7	6.94	0.58	4.7e-10	Cognitive performance;
THYM	cis	rs12310956	0.515	rs1405031	chr12:33958931	A/C	cg10856724	chr12:34555212	NA	-0.72	-6.62	-0.56	2.14e-9	Morning vs. evening chronotype;
THYM	cis	rs977987	0.778	rs4888413	chr16:75443223	C/A	cg03315344	chr16:75512273	CHST6	0.77	6.29	0.54	9.48e-9	Dupuytren's disease;
THYM	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg18876405	chr7:65276391	NA	-0.57	-4.85	-0.45	4.83e-6	Aortic root size;
THYM	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.69	6.36	0.55	7.1e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg20891283	chr12:69753455	YEATS4	1.06	10.24	0.72	5.15e-17	Blood protein levels;
THYM	cis	rs7586673	0.857	rs16845580	chr2:161920884	T/C	cg22496339	chr2:162101262	NA	0.59	4.67	0.43	1e-5	Intelligence (multi-trait analysis);
THYM	cis	rs901683	1.000	rs78913745	chr10:46019911	A/T	cg18240400	chr10:46168597	ANUBL1	0.8	5.19	0.47	1.19e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg17644776	chr2:200775616	C2orf69	0.77	5.4	0.48	5.01e-7	Schizophrenia;
THYM	trans	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg00828689	chr3:196697064	PIGZ	0.97	6.96	0.58	4.29e-10	Lung adenocarcinoma;
THYM	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg07212818	chr11:638076	DRD4	-0.77	-5.92	-0.52	5.09e-8	Systemic lupus erythematosus;
THYM	cis	rs8133932	0.859	rs74681567	chr21:47054985	T/C	cg20357416	chr21:47294739	PCBP3	0.77	4.74	0.44	7.63e-6	Schizophrenia;
THYM	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9905704	0.918	rs581903	chr17:56719197	C/T	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.74e-6	Testicular germ cell tumor;
THYM	cis	rs1050631	0.592	rs1539823	chr18:33736261	T/C	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.58	4.56	0.42	1.54e-5	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs7267979	0.933	rs2424708	chr20:25281398	C/T	cg08601574	chr20:25228251	PYGB	0.57	4.51	0.42	1.87e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7098100	0.634	rs2666768	chr10:22201558	C/G	cg04231319	chr10:21824447	MLLT10	0.31	4.54	0.42	1.63e-5	Breast cancer;
THYM	cis	rs4731207	0.596	rs6957525	chr7:124656377	T/C	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs7213347	0.678	rs11658797	chr17:2088969	T/G	cg16513277	chr17:2031491	SMG6	-0.64	-4.65	-0.43	1.08e-5	Total body bone mineral density;
THYM	cis	rs7572733	0.515	rs6724526	chr2:198858401	A/G	cg00792783	chr2:198669748	PLCL1	0.82	5.63	0.5	1.79e-7	Dermatomyositis;
THYM	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg23482746	chr15:76478102	C15orf27	-0.44	-4.49	-0.42	2.01e-5	Blood metabolite levels;
THYM	cis	rs1005224	0.889	rs9323617	chr14:76158638	A/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.71	-5.83	-0.51	7.54e-8	Large artery stroke;
THYM	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.65e-6	Aortic root size;
THYM	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg06532163	chr17:45867833	NA	0.66	6.75	0.57	1.17e-9	IgG glycosylation;
THYM	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg25036284	chr2:26402008	FAM59B	0.8	5.36	0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg18477163	chr1:228402036	OBSCN	-0.45	-4.79	-0.44	6.18e-6	Diastolic blood pressure;
THYM	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg08901578	chr4:187885870	NA	-0.64	-5.9	-0.52	5.5e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.58	0.5	2.29e-7	Rheumatoid arthritis;
THYM	cis	rs3126085	0.935	rs2338430	chr1:152214420	C/T	cg10321714	chr1:152280068	FLG	-0.65	-4.73	-0.44	7.85e-6	Atopic dermatitis;
THYM	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06850241	chr22:41845214	NA	-0.57	-5.06	-0.46	2.01e-6	Vitiligo;
THYM	cis	rs2294693	0.891	rs4714421	chr6:40992837	C/T	cg14418226	chr6:40996092	UNC5CL	0.68	5.96	0.52	4.3e-8	Gastric cancer;Non-cardia gastric cancer;
THYM	trans	rs877282	0.898	rs11253346	chr10:765313	A/G	cg22713356	chr15:30763199	NA	1.36	10.13	0.72	8.77e-17	Uric acid levels;
THYM	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs9467160	0.501	rs1772257	chr6:24441214	C/T	cg20631270	chr6:24437470	GPLD1	-0.57	-4.84	-0.45	4.94e-6	Liver enzyme levels;
THYM	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg14634687	chr17:47094252	IGF2BP1	0.31	4.64	0.43	1.09e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg11663144	chr21:46675770	NA	-0.7	-9.65	-0.7	9.43e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7772486	0.790	rs9497435	chr6:146265340	C/A	cg23711669	chr6:146136114	FBXO30	-0.9	-8.72	-0.67	9.04e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg11654118	chr11:1945648	TNNT3	0.21	4.5	0.42	1.92e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs1451375	0.756	rs11761683	chr7:50542879	C/T	cg18232548	chr7:50535776	DDC	-0.77	-6.84	-0.57	7.61e-10	Malaria;
THYM	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg03806693	chr22:41940476	POLR3H	1.08	8.25	0.65	8.98e-13	Vitiligo;
THYM	cis	rs2976388	0.609	rs2585150	chr8:143792669	C/T	cg06565975	chr8:143823917	SLURP1	0.47	5.22	0.47	1.06e-6	Urinary tract infection frequency;
THYM	cis	rs4919087	0.810	rs10736115	chr10:99031685	A/G	cg19453742	chr10:98862320	SLIT1	-0.64	-5.14	-0.47	1.45e-6	Monocyte count;
THYM	trans	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg10856724	chr12:34555212	NA	0.89	8.05	0.64	2.41e-12	Bladder cancer;
THYM	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg23708337	chr7:1209742	NA	0.74	5.28	0.48	8.28e-7	Longevity;Endometriosis;
THYM	cis	rs6906287	0.531	rs56344535	chr6:119011263	T/C	cg21191810	chr6:118973309	C6orf204	0.56	5.26	0.47	8.93e-7	Electrocardiographic conduction measures;
THYM	cis	rs10411161	0.702	rs8113768	chr19:52383938	C/T	cg25361850	chr19:52391789	ZNF577	0.71	4.99	0.46	2.69e-6	Breast cancer;
THYM	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg24846343	chr22:24311635	DDTL	0.49	6.88	0.58	6.34e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9790314	0.747	rs1841526	chr3:160834682	A/G	cg04691961	chr3:161091175	C3orf57	-0.61	-4.71	-0.44	8.33e-6	Morning vs. evening chronotype;
THYM	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg02269571	chr22:50332266	NA	-0.71	-4.91	-0.45	3.78e-6	Schizophrenia;
THYM	cis	rs7264396	0.676	rs6060730	chr20:34558503	G/A	cg26038318	chr20:34205095	SPAG4	0.59	4.81	0.44	5.6e-6	Total cholesterol levels;
THYM	cis	rs7078219	0.524	rs6584277	chr10:101278055	A/G	cg23904955	chr10:101282759	NA	-0.42	-5.46	-0.49	3.74e-7	Dental caries;
THYM	cis	rs12620999	0.774	rs7584900	chr2:237957112	T/G	cg15976283	chr2:238042351	NA	-0.62	-4.8	-0.44	5.81e-6	Systemic lupus erythematosus;
THYM	cis	rs714027	1.000	rs4823075	chr22:30519152	T/C	cg11564601	chr22:30592435	NA	-0.3	-5.45	-0.49	3.98e-7	Lymphocyte counts;
THYM	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg18876405	chr7:65276391	NA	0.63	5.53	0.49	2.83e-7	Aortic root size;
THYM	cis	rs8063160	0.867	rs77381714	chr16:90078022	T/C	cg07984980	chr16:89898383	SPIRE2	1.35	5.55	0.49	2.62e-7	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs789852	1.000	rs789850	chr3:194325496	T/C	cg18000598	chr3:194342907	TMEM44	-1.19	-6.77	-0.57	1.05e-9	QT interval;
THYM	cis	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg06521331	chr12:34319734	NA	-0.94	-9.09	-0.68	1.48e-14	Morning vs. evening chronotype;
THYM	cis	rs4766566	0.590	rs3809283	chr12:111707754	A/T	cg10833066	chr12:111807467	FAM109A	0.45	4.7	0.43	8.62e-6	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
THYM	cis	rs8067545	0.611	rs2189709	chr17:20083226	T/A	cg13482628	chr17:19912719	NA	-0.53	-4.46	-0.42	2.29e-5	Schizophrenia;
THYM	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg07636037	chr3:49044803	WDR6	0.98	10.05	0.72	1.28e-16	Parkinson's disease;
THYM	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg10803722	chr21:46713166	LOC642852	-0.41	-5.11	-0.46	1.69e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6918586	0.658	rs198813	chr6:26128226	C/T	cg12310025	chr6:25882481	NA	0.68	5.56	0.5	2.47e-7	Schizophrenia;
THYM	cis	rs55728055	0.661	rs9621295	chr22:32007153	G/A	cg01338084	chr22:32026380	PISD	1.13	4.95	0.45	3.19e-6	Age-related hearing impairment;
THYM	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.67	5.81	0.51	8.24e-8	Height;
THYM	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.72	5.62	0.5	1.87e-7	Total cholesterol levels;
THYM	cis	rs4654899	0.931	rs2275468	chr1:21220375	T/G	cg01072550	chr1:21505969	NA	0.71	6.48	0.55	4.12e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs2239785	0.958	rs136162	chr22:36657474	A/G	cg15716373	chr22:36655542	APOL1	-0.4	-4.46	-0.42	2.23e-5	Glomerulosclerosis;
THYM	cis	rs4606347	0.789	rs80314161	chr1:66166733	C/T	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg06970220	chr1:156163860	SLC25A44	0.74	5.67	0.5	1.53e-7	Testicular germ cell tumor;
THYM	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg10150615	chr22:24372951	LOC391322	-1.01	-11.7	-0.77	4.18e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6980334	0.817	rs3805360	chr7:137794589	G/A	cg18769353	chr7:137028617	PTN	0.64	5.06	0.46	2.01e-6	Blood metabolite ratios;
THYM	cis	rs761746	0.705	rs5994415	chr22:32004588	G/A	cg10537193	chr22:32026975	PISD	-0.35	-4.89	-0.45	4.05e-6	Intelligence;
THYM	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg08132940	chr7:1081526	C7orf50	-0.77	-5.21	-0.47	1.1e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs987710	0.568	rs987708	chr22:22512081	G/A	cg21401457	chr22:22472743	NA	0.92	4.5	0.42	1.91e-5	Iron status biomarkers;Iron deficiency;
THYM	cis	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg24672777	chr11:48374446	OR4C45	0.73	4.6	0.43	1.28e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs236352	0.538	rs1150784	chr6:36863884	C/A	cg03410223	chr6:36853544	C6orf89	0.69	5.78	0.51	9.6e-8	Heart rate;
THYM	cis	rs2072499	0.868	rs2758600	chr1:156195205	C/T	cg24450063	chr1:156163899	SLC25A44	1.15	13.63	0.81	4.43e-24	Testicular germ cell tumor;
THYM	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg23711669	chr6:146136114	FBXO30	0.94	9.59	0.7	1.23e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6840360	0.615	rs12503677	chr4:152610543	A/G	cg22705602	chr4:152727874	NA	-0.79	-10.66	-0.74	6.62e-18	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg13695892	chr22:41940480	POLR3H	0.94	7.71	0.62	1.24e-11	Vitiligo;
THYM	cis	rs2070488	0.965	rs3762791	chr3:38568828	T/C	cg24069376	chr3:38537580	EXOG	-0.65	-6.4	-0.55	5.87e-9	Electrocardiographic conduction measures;
THYM	cis	rs4455778	0.561	rs6977535	chr7:49001350	C/T	cg26309511	chr7:48887640	NA	0.53	4.62	0.43	1.18e-5	Lung cancer in never smokers;
THYM	cis	rs3917265	0.510	rs11883987	chr2:102761240	C/T	cg13315345	chr2:102803985	IL1RL2	0.56	6.48	0.55	4.02e-9	Atopic dermatitis;
THYM	cis	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg06521331	chr12:34319734	NA	-0.73	-5.69	-0.5	1.38e-7	Morning vs. evening chronotype;
THYM	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.71	-0.57	1.43e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg24060327	chr5:131705240	SLC22A5	0.71	5.41	0.49	4.66e-7	Blood metabolite levels;
THYM	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg05738196	chr6:26577821	NA	0.63	5.11	0.46	1.68e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1823778	0.609	rs4891381	chr18:67595449	C/T	cg12929678	chr18:67624393	CD226	-1.5	-4.66	-0.43	1.02e-5	Mean platelet volume;
THYM	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.82	7.53	0.61	2.9100000000000002e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs561341	0.700	rs886223	chr17:30229877	G/T	cg13647721	chr17:30228624	UTP6	0.71	4.52	0.42	1.76e-5	Hip circumference adjusted for BMI;
THYM	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	18.27	0.88	7.47e-33	Chronic sinus infection;
THYM	cis	rs9517302	0.615	rs9517306	chr13:99097962	T/C	cg22223119	chr13:99095684	FARP1	-0.97	-7.09	-0.59	2.31e-10	Obesity-related traits;
THYM	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs2303759	0.830	rs7257053	chr19:49894456	C/G	cg24324837	chr19:49891574	CCDC155	0.66	6.6	0.56	2.3e-9	Multiple sclerosis;
THYM	cis	rs9921222	0.597	rs7193109	chr16:413523	T/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.39	6.2	0.54	1.48e-8	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg25358565	chr5:93447407	FAM172A	1.34	10.59	0.74	9.3e-18	Diabetic retinopathy;
THYM	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06873352	chr17:61820015	STRADA	0.53	5.18	0.47	1.24e-6	Height;
THYM	cis	rs28595532	0.841	rs114965278	chr4:119743694	T/A	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs10186029	0.548	rs4673728	chr2:214001997	C/G	cg08319019	chr2:214017104	IKZF2	0.78	6.14	0.53	1.95e-8	Systemic sclerosis;
THYM	cis	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg08968635	chr6:28129556	ZNF389	0.47	4.53	0.42	1.69e-5	Depression;
THYM	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg26721908	chr21:47610096	LSS	0.96	7.37	0.6	6.3e-11	Testicular germ cell tumor;
THYM	cis	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg05335186	chr13:53173507	NA	-0.49	-6.23	-0.54	1.28e-8	Lewy body disease;
THYM	cis	rs11645898	0.687	rs56129242	chr16:72098260	C/G	cg14768367	chr16:72042858	DHODH	-0.64	-4.78	-0.44	6.4e-6	Blood protein levels;
THYM	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg06453172	chr10:134556979	INPP5A	-0.71	-5.15	-0.47	1.41e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg01528321	chr10:82214614	TSPAN14	0.66	5.29	0.48	7.92e-7	Post bronchodilator FEV1;
THYM	cis	rs2797160	1.000	rs1832980	chr6:125997444	T/G	cg16306078	chr6:126000798	NA	-0.54	-5.51	-0.49	3.05e-7	Endometrial cancer;
THYM	cis	rs1933112	1.000	rs10918925	chr1:168525247	C/T	cg00154920	chr1:168513310	XCL2	0.54	5.3	0.48	7.59e-7	Blood protein levels;
THYM	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg18681998	chr4:17616180	MED28	0.99	10.18	0.72	6.74e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs12200560	0.505	rs211183	chr6:97074723	G/T	cg06623918	chr6:96969491	KIAA0776	-0.72	-5.26	-0.47	8.98e-7	Coronary heart disease;
THYM	cis	rs3744028	0.532	rs9903200	chr17:73839498	G/A	cg12407791	chr17:73824354	UNC13D	-0.54	-5.66	-0.5	1.63e-7	White matter hyperintensity burden;
THYM	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg03929089	chr4:120376271	NA	-1.03	-12.43	-0.79	1.26e-21	Height;
THYM	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg19610905	chr11:61596333	FADS2	-0.56	-4.5	-0.42	1.92e-5	Bipolar disorder;
THYM	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg24642844	chr7:1081250	C7orf50	-1.29	-8.3	-0.65	7.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg05457628	chr5:178986728	RUFY1	0.61	6.09	0.53	2.34e-8	Lung cancer;
THYM	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg12560992	chr17:57184187	TRIM37	0.93	8.88	0.67	4.06e-14	Intelligence (multi-trait analysis);
THYM	cis	rs10927875	0.722	rs9442216	chr1:16353400	T/C	cg22431228	chr1:16359049	CLCNKA	-0.48	-4.65	-0.43	1.07e-5	Dilated cardiomyopathy;
THYM	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg03929089	chr4:120376271	NA	-0.98	-11.99	-0.78	1.01e-20	Height;
THYM	cis	rs4919044	0.545	rs9420603	chr10:94777490	T/C	cg05127821	chr10:94822908	CYP26C1	-1.31	-6.9	-0.58	5.75e-10	Coronary artery disease;
THYM	cis	rs6840360	0.642	rs2709833	chr4:152377622	A/G	cg17479576	chr4:152424074	FAM160A1	-0.68	-5.17	-0.47	1.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg17426766	chr1:2046864	PRKCZ	-0.43	-4.97	-0.45	2.9e-6	Height;
THYM	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg24549020	chr5:56110836	MAP3K1	0.7	4.48	0.42	2.05e-5	Initial pursuit acceleration;
THYM	cis	rs17253792	0.822	rs8009608	chr14:56062590	C/T	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	trans	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg10856724	chr12:34555212	NA	-0.89	-8.35	-0.65	5.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9527	0.569	rs10786730	chr10:104724200	G/A	cg15744005	chr10:104629667	AS3MT	-0.61	-4.54	-0.42	1.65e-5	Arsenic metabolism;
THYM	cis	rs2710247	1	rs2710247	chr2:219467508	A/G	cg02176678	chr2:219576539	TTLL4	0.63	6.07	0.53	2.56e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11085466	1.000	rs75211977	chr19:21760201	G/A	cg23004160	chr19:21646329	NA	-0.65	-4.7	-0.43	8.62e-6	Colorectal or endometrial cancer;
THYM	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg18252515	chr7:66147081	NA	1.48	8.83	0.67	5.35e-14	Diabetic kidney disease;
THYM	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg12963246	chr6:28129442	ZNF389	0.65	4.95	0.45	3.26e-6	Parkinson's disease;
THYM	cis	rs2862064	0.649	rs1995377	chr5:156436679	T/A	cg12943317	chr5:156479607	HAVCR1	-0.86	-5.28	-0.48	8.3e-7	Platelet count;
THYM	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg08968635	chr6:28129556	ZNF389	0.71	5.58	0.5	2.28e-7	Parkinson's disease;
THYM	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg11366901	chr6:160182831	ACAT2	1.0	8.3	0.65	7.06e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs17433780	0.808	rs7541867	chr1:89513537	G/A	cg09516651	chr1:89888402	LOC400759	0.97	8.07	0.64	2.12e-12	Carotid intima media thickness;
THYM	cis	rs1569019	0.915	rs1569020	chr12:131574485	A/C	cg25772418	chr12:131519998	GPR133	-0.56	-4.62	-0.43	1.23e-5	Height;
THYM	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg15691649	chr6:25882328	NA	-0.62	-4.48	-0.42	2.07e-5	Intelligence (multi-trait analysis);
THYM	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.63	-4.51	-0.42	1.88e-5	Colorectal cancer;
THYM	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg23708337	chr7:1209742	NA	0.73	5.28	0.48	8e-7	Longevity;Endometriosis;
THYM	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg08999081	chr20:33150536	PIGU	-0.78	-7.16	-0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs2290159	0.800	rs5746214	chr3:12644753	A/G	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs56079296	0.929	rs4495212	chr5:121272917	G/C	cg01191064	chr5:121408893	LOX	-0.67	-4.47	-0.42	2.18e-5	Coronary artery disease;
THYM	cis	rs3773445	0.740	rs1730220	chr3:25618368	C/G	cg02315353	chr3:25825455	NGLY1	0.54	4.59	0.43	1.36e-5	Airway responsiveness in chronic obstructive pulmonary disease;
THYM	cis	rs1957429	0.808	rs1957436	chr14:65348207	T/G	cg23373153	chr14:65346875	NA	1.07	6.45	0.55	4.75e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs12291225	0.679	rs1043237	chr11:14289053	A/T	cg05501817	chr11:14380813	RRAS2	-0.75	-5.77	-0.51	9.76e-8	Sense of smell;
THYM	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg26314531	chr2:26401878	FAM59B	-0.74	-4.6	-0.43	1.33e-5	Gut microbiome composition (summer);
THYM	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg23583168	chr7:148888333	NA	-1.0	-14.72	-0.83	2.98e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs4589258	0.737	rs2155070	chr11:90417432	T/C	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2219968	1.000	rs4639505	chr8:78971658	A/G	cg00738934	chr8:78996279	NA	0.91	9.74	0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1178101	0.526	rs177080	chr7:18741007	G/A	cg12093519	chr7:19146441	NA	0.59	4.54	0.42	1.62e-5	Monobrow;
THYM	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg18876405	chr7:65276391	NA	0.59	4.78	0.44	6.46e-6	Aortic root size;
THYM	cis	rs2820651	0.614	rs114139266	chr10:1489054	C/T	cg13720710	chr10:1452970	ADARB2	0.79	4.99	0.46	2.72e-6	Migraine with aura;
THYM	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg23711669	chr6:146136114	FBXO30	0.85	8.06	0.64	2.25e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4595586	0.545	rs12809206	chr12:39388748	A/C	cg26384229	chr12:38710491	ALG10B	0.69	5.19	0.47	1.18e-6	Morning vs. evening chronotype;
THYM	cis	rs72717009	0.825	rs11810143	chr1:161480649	A/G	cg23840854	chr1:161414152	NA	-0.98	-5.15	-0.47	1.42e-6	Rheumatoid arthritis;
THYM	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg06873352	chr17:61820015	STRADA	0.8	10.33	0.73	3.28e-17	Prudent dietary pattern;
THYM	cis	rs12367572	0.930	rs10880695	chr12:45233261	T/C	cg03114573	chr12:45410052	DBX2	-0.59	-5.53	-0.49	2.82e-7	Gut microbiome composition (summer);
THYM	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg06623918	chr6:96969491	KIAA0776	1.09	9.89	0.71	2.89e-16	Headache;
THYM	cis	rs4638749	0.677	rs7581595	chr2:108847885	A/G	cg25838818	chr2:108905173	SULT1C2	-0.52	-5.29	-0.48	7.87e-7	Blood pressure;
THYM	cis	rs7681440	0.606	rs2583971	chr4:90747207	C/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs990171	1.000	rs2058622	chr2:102985424	A/G	cg13897122	chr2:103039542	IL18RAP	-0.4	-4.76	-0.44	6.87e-6	Lymphocyte counts;
THYM	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4460079	0.531	rs11727340	chr4:114849133	G/A	cg02060584	chr4:113970739	ANK2	-0.59	-4.86	-0.45	4.58e-6	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs12594515	1.000	rs7172161	chr15:45990780	A/G	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs74664507	0.527	rs4961501	chr9:16851678	T/G	cg13173848	chr9:16870893	BNC2	0.73	5.15	0.47	1.44e-6	Squamous cell carcinoma;
THYM	cis	rs1322639	0.614	rs6900964	chr6:169566763	A/G	cg04662567	chr6:169592167	NA	-0.73	-5.74	-0.51	1.13e-7	Pulse pressure;
THYM	cis	rs11711311	1.000	rs9828449	chr3:113518602	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.17	-0.47	1.3e-6	IgG glycosylation;
THYM	cis	rs988913	1.000	rs6902422	chr6:54811210	C/T	cg19716238	chr6:54711378	FAM83B	-0.52	-5.38	-0.48	5.42e-7	Menarche (age at onset);
THYM	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg23758822	chr17:41437982	NA	1.23	13.14	0.8	4.25e-23	Menopause (age at onset);
THYM	cis	rs7635838	0.617	rs347590	chr3:11289561	G/A	cg00170343	chr3:11313890	ATG7	0.65	5.08	0.46	1.92e-6	HDL cholesterol;
THYM	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7631605	0.934	rs7628444	chr3:37263592	C/G	cg21328643	chr3:37258149	NA	-0.53	-5.15	-0.47	1.39e-6	Cerebrospinal P-tau181p levels;
THYM	trans	rs208520	0.690	rs207114	chr6:66791703	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.04	-7.55	-0.61	2.69e-11	Exhaled nitric oxide output;
THYM	cis	rs3750965	1.000	rs3750965	chr11:68840160	A/G	cg06818126	chr11:68850279	TPCN2	-0.69	-4.77	-0.44	6.76e-6	Hair color;
THYM	cis	rs2898681	0.581	rs28618986	chr4:53677902	G/C	cg00338735	chr4:53728038	RASL11B	0.59	5.31	0.48	7.09e-7	Optic nerve measurement (cup area);
THYM	cis	rs74705753	1.000	rs74705753	chr22:42201517	A/G	cg03806693	chr22:41940476	POLR3H	-1.28	-5.39	-0.48	5.02e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	4.94	0.45	3.3e-6	Menarche (age at onset);
THYM	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg23758822	chr17:41437982	NA	1.16	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs12118280	0.581	rs545593	chr1:108720242	G/A	cg24323958	chr1:108741884	SLC25A24	0.67	4.72	0.44	7.98e-6	Myeloid white cell count;
THYM	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg14820908	chr5:178986412	RUFY1	-0.55	-5.68	-0.5	1.46e-7	Lung cancer;
THYM	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg20887711	chr4:1340912	KIAA1530	0.99	9.48	0.7	2.1e-15	Longevity;
THYM	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.36	0.69	3.89e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7631605	0.905	rs11714667	chr3:37222360	G/A	cg21328643	chr3:37258149	NA	-0.51	-4.87	-0.45	4.36e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg24812749	chr6:127587940	RNF146	0.96	7.77	0.62	9.12e-12	Breast cancer;
THYM	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs1699337	0.930	rs1373641	chr3:12402474	C/T	cg05467012	chr3:12595696	NA	-0.55	-4.56	-0.42	1.51e-5	Cholesterol, total;
THYM	cis	rs9549260	0.577	rs6563841	chr13:41239178	A/C	cg21288729	chr13:41239152	FOXO1	0.73	5.77	0.51	9.87e-8	Red blood cell count;
THYM	cis	rs9902453	0.900	rs56195309	chr17:28453753	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	4.6	0.43	1.33e-5	Coffee consumption (cups per day);
THYM	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.47	-0.49	3.59e-7	Mean corpuscular volume;
THYM	cis	rs17598306	0.935	rs2894086	chr7:96584416	A/G	cg26766885	chr7:96220185	NA	0.62	5.13	0.47	1.56e-6	Radiation response;
THYM	cis	rs2734839	0.964	rs2734838	chr11:113286501	A/G	cg14159747	chr11:113255604	NA	0.31	6.32	0.54	8.63e-9	Information processing speed;
THYM	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg16586182	chr3:47516702	SCAP	-0.65	-5.77	-0.51	1.01e-7	Colorectal cancer;
THYM	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-5.4	-0.48	4.89e-7	Chronic sinus infection;
THYM	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.48	0.42	2.07e-5	Motion sickness;
THYM	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg06636001	chr8:8085503	FLJ10661	0.52	4.51	0.42	1.82e-5	Joint mobility (Beighton score);
THYM	cis	rs17152411	0.793	rs7085829	chr10:126587142	A/G	cg07906193	chr10:126599966	NA	0.68	4.65	0.43	1.08e-5	Height;
THYM	cis	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg06521331	chr12:34319734	NA	-0.72	-4.99	-0.46	2.68e-6	Resting heart rate;
THYM	cis	rs7762018	0.607	rs61740334	chr6:170047902	T/A	cg19338460	chr6:170058176	WDR27	-1.07	-6.25	-0.54	1.15e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs17268829	0.671	rs2301646	chr7:94146975	T/G	cg00347863	chr7:94220697	SGCE	0.59	4.56	0.42	1.51e-5	Breast cancer;
THYM	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg04455712	chr21:45112962	RRP1B	-0.5	-4.62	-0.43	1.22e-5	Mean corpuscular volume;
THYM	cis	rs6546324	0.625	rs2861703	chr2:67861053	T/C	cg18237512	chr2:67827392	NA	-0.81	-4.98	-0.46	2.83e-6	Endometriosis;
THYM	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg01238044	chr22:24384105	GSTT1	-0.53	-4.79	-0.44	6.21e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4953404	0.590	rs4952838	chr2:46885225	C/T	cg09399716	chr2:46890238	NA	0.48	4.5	0.42	1.9e-5	Pulse pressure (alcohol consumption interaction);
THYM	cis	rs13315871	1.000	rs36037390	chr3:58321954	C/T	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs4243830	0.850	rs4908904	chr1:6580250	A/G	cg04093404	chr1:6614507	TAS1R1;NOL9	0.78	4.47	0.42	2.15e-5	Body mass index;
THYM	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg23649088	chr2:200775458	C2orf69	-0.77	-6.4	-0.55	5.84e-9	LDL cholesterol to HDL cholesterol ratio;
THYM	cis	rs12935418	0.673	rs2549888	chr16:81062030	G/T	cg16651780	chr16:81037892	C16orf61	-0.76	-5.63	-0.5	1.79e-7	Mean corpuscular volume;
THYM	cis	rs34638657	0.872	rs2967352	chr16:82196676	T/C	cg09439754	chr16:82129088	HSD17B2	-0.6	-5.26	-0.48	8.71e-7	Lung adenocarcinoma;
THYM	trans	rs10958605	0.761	rs2925035	chr8:40045822	A/G	cg02560310	chr20:60578131	TAF4	0.73	6.87	0.58	6.63e-10	Parkinson's disease (motor and cognition);
THYM	trans	rs11960314	0.717	rs883848	chr5:170070942	A/C	cg24723421	chr2:216283142	FN1	1.0	7.03	0.58	3.16e-10	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs7127900	0.950	rs6579003	chr11:2232310	A/C	cg25635251	chr11:2234043	NA	0.74	4.71	0.44	8.43e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs9814567	0.752	rs9848254	chr3:134330374	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7578361	0.918	rs4592816	chr2:150377624	A/G	cg17961725	chr2:150454027	NA	-0.79	-6.02	-0.53	3.33e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs12549902	0.932	rs6981607	chr8:41508168	A/C	cg00448191	chr8:41504890	NKX6-3	0.31	4.59	0.43	1.36e-5	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
THYM	cis	rs6032067	0.673	rs4522674	chr20:43893276	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.64	-6.47	-0.55	4.19e-9	Blood protein levels;
THYM	cis	rs7100689	0.646	rs1934693	chr10:82125650	T/C	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg17202724	chr17:61916730	SMARCD2	-0.47	-4.66	-0.43	1.01e-5	Prudent dietary pattern;
THYM	cis	rs6867032	0.834	rs10043083	chr5:1995687	C/G	cg26168224	chr5:2018326	NA	-1.11	-10.85	-0.74	2.53e-18	Gut microbiome composition (winter);
THYM	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4604732	0.536	rs12090434	chr1:247659286	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.73	4.96	0.45	3.09e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs7942486	0.895	rs1481881	chr11:13269536	T/C	cg13286116	chr11:13302098	ARNTL	-0.72	-8.03	-0.64	2.61e-12	Neuroticism;
THYM	cis	rs6964587	0.626	rs10243083	chr7:91552530	G/A	cg17063962	chr7:91808500	NA	-1.02	-9.26	-0.69	6.44e-15	Breast cancer;
THYM	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4481887	0.610	rs28763387	chr1:248559244	T/C	cg00666640	chr1:248458726	OR2T12	0.54	4.62	0.43	1.22e-5	Common traits (Other);
THYM	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs72627123	0.867	rs58894370	chr14:74485382	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg14829155	chr15:31115871	NA	-0.55	-5.04	-0.46	2.26e-6	Huntington's disease progression;
THYM	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg06108461	chr20:60628389	TAF4	-1.0	-8.03	-0.64	2.61e-12	Body mass index;
THYM	cis	rs4866334	1.000	rs76836105	chr5:18467089	T/G	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg07747251	chr5:1868357	NA	0.68	5.78	0.51	9.55e-8	Cardiovascular disease risk factors;
THYM	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg10911889	chr6:126070802	HEY2	0.55	4.49	0.42	1.97e-5	Brugada syndrome;
THYM	cis	rs13126513	0.708	rs1057613	chr4:100504985	G/A	cg05468953	chr4:100565104	NA	0.65	6.05	0.53	2.81e-8	Metabolite levels (MHPG);
THYM	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.75	-0.67	7.74e-14	Mean corpuscular volume;
THYM	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg19623624	chr10:135278901	LOC619207	-0.61	-4.89	-0.45	4.04e-6	Systemic lupus erythematosus;
THYM	cis	rs2637266	0.686	rs1660915	chr10:78525318	T/A	cg18941641	chr10:78392320	NA	0.73	5.84	0.51	7.29e-8	Pulmonary function;
THYM	cis	rs782590	0.967	rs782592	chr2:55843875	T/A	cg18811423	chr2:55921094	PNPT1	0.68	6.23	0.54	1.27e-8	Metabolic syndrome;
THYM	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg17173187	chr15:85201210	NMB	0.56	5.48	0.49	3.49e-7	Schizophrenia;
THYM	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs900145	0.773	rs11022749	chr11:13307366	A/G	cg13286116	chr11:13302098	ARNTL	0.61	4.82	0.44	5.39e-6	Menarche (age at onset);
THYM	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg06219351	chr7:158114137	PTPRN2	-0.74	-7.14	-0.59	1.86e-10	Calcium levels;
THYM	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg24375607	chr4:120327624	NA	0.66	5.12	0.46	1.6e-6	Corneal astigmatism;
THYM	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08109568	chr15:31115862	NA	0.76	6.82	0.57	8.54e-10	Huntington's disease progression;
THYM	cis	rs13232179	1.000	rs1860463	chr7:151119332	C/T	cg05714773	chr7:150493706	TMEM176B	0.63	4.54	0.42	1.66e-5	Coronary heart disease;
THYM	cis	rs886144	0.807	rs11858387	chr15:91729887	A/C	cg10978402	chr15:90931990	IQGAP1	-0.59	-4.57	-0.42	1.46e-5	Metabolite levels;
THYM	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg21028142	chr17:79581711	NPLOC4	-0.64	-6.74	-0.57	1.23e-9	Eye color traits;
THYM	cis	rs3741151	0.773	rs73542952	chr11:73108556	A/G	cg12959048	chr11:73096162	RELT	-0.53	-5.08	-0.46	1.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg18681998	chr4:17616180	MED28	0.85	7.68	0.62	1.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg22535103	chr8:58192502	C8orf71	-0.93	-4.66	-0.43	1.02e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs2282300	0.739	rs3858428	chr11:30296550	T/C	cg06241208	chr11:30344200	C11orf46	0.78	5.65	0.5	1.67e-7	Morning vs. evening chronotype;
THYM	cis	rs7941600	0.786	rs956517	chr11:9201995	C/G	cg21110646	chr11:9336536	TMEM41B	0.95	5.83	0.51	7.61e-8	Coronary artery disease;
THYM	cis	rs1670533	0.929	rs6599280	chr4:1063818	A/G	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.55	-4.59	-0.43	1.36e-5	Renal function-related traits (BUN);
THYM	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg13683864	chr3:40499215	RPL14	1.07	12.42	0.79	1.31e-21	Renal cell carcinoma;
THYM	cis	rs7078219	0.505	rs10883367	chr10:101287990	A/G	cg04972745	chr10:101287846	NA	-0.51	-4.84	-0.44	5.09e-6	Dental caries;
THYM	cis	rs2219968	0.525	rs7016237	chr8:78870943	C/A	cg00738934	chr8:78996279	NA	0.63	5.04	0.46	2.21e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg24642439	chr20:33292090	TP53INP2	0.59	4.48	0.42	2.09e-5	Coronary artery disease;
THYM	cis	rs1371867	0.641	rs1788209	chr8:101337056	C/T	cg06636551	chr8:101224915	SPAG1	-0.64	-6.54	-0.56	3.03e-9	Atrioventricular conduction;
THYM	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs6519955	0.866	rs9626920	chr22:46428993	A/G	cg00147172	chr22:46423604	NA	-0.24	-4.64	-0.43	1.09e-5	Dupuytren's disease;
THYM	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg08305652	chr11:111469057	NA	-0.53	-4.6	-0.43	1.29e-5	Primary sclerosing cholangitis;
THYM	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg05347473	chr6:146136440	FBXO30	0.58	4.74	0.44	7.64e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10924970	0.967	rs7512798	chr1:235356425	C/A	cg26050004	chr1:235667680	B3GALNT2	0.6	4.47	0.42	2.12e-5	Asthma;
THYM	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg18681998	chr4:17616180	MED28	0.91	8.58	0.66	1.75e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7264396	0.790	rs4519606	chr20:34324648	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-5.9	-0.52	5.6e-8	Total cholesterol levels;
THYM	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg07936489	chr17:37558343	FBXL20	0.82	5.69	0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg22709100	chr7:91322751	NA	-0.74	-5.77	-0.51	9.91e-8	Breast cancer;
THYM	cis	rs9814567	1.000	rs6785027	chr3:134211649	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.85	8.64	0.66	1.3e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2295359	0.892	rs12029362	chr1:67624231	G/A	cg11235152	chr1:67600687	NA	0.7	5.84	0.51	7.41e-8	Psoriasis;
THYM	cis	rs2997447	0.706	rs17184898	chr1:26447870	A/T	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg24874828	chr4:187887005	NA	-0.72	-7.44	-0.61	4.48e-11	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg10856724	chr12:34555212	NA	-1.01	-9.23	-0.69	7.34e-15	Bladder cancer;
THYM	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg00631329	chr6:26305371	NA	-0.63	-7.46	-0.61	3.99e-11	Educational attainment;
THYM	cis	rs6456042	0.965	rs1900056	chr6:166545910	A/G	cg11088901	chr6:166572345	T	-0.52	-4.9	-0.45	3.89e-6	Asthma;
THYM	cis	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg23807559	chr17:71189217	COG1	-1.07	-5.28	-0.48	8.27e-7	Pulmonary function decline;
THYM	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg18512352	chr11:47633146	NA	0.5	6.42	0.55	5.46e-9	Subjective well-being;
THYM	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7799006	0.606	rs4721527	chr7:2306655	G/A	cg08027265	chr7:2291960	NA	-0.42	-5.04	-0.46	2.25e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.97	-8.08	-0.64	2e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg02725872	chr8:58115012	NA	-0.91	-6.92	-0.58	5.22e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs9929218	0.529	rs8060790	chr16:68729112	A/G	cg01251360	chr16:68772225	CDH1	-0.29	-4.45	-0.42	2.36e-5	Colorectal cancer;
THYM	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg01236616	chr12:121019343	POP5	1.31	10.38	0.73	2.57e-17	Type 1 diabetes nephropathy;
THYM	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg03676636	chr4:99064102	C4orf37	0.43	6.56	0.56	2.83e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs34375054	0.752	rs12582808	chr12:125661459	G/T	cg25124228	chr12:125621409	AACS	-0.68	-4.85	-0.45	4.81e-6	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs3819817	0.550	rs7961492	chr12:96356749	A/G	cg26410635	chr12:96350720	AMDHD1	0.53	5.02	0.46	2.38e-6	Vitamin D levels;
THYM	cis	rs9326248	0.581	rs4938331	chr11:116930682	C/A	cg20608306	chr11:116969690	SIK3	0.64	7.97	0.63	3.42e-12	Blood protein levels;
THYM	cis	rs113835537	0.597	rs3737525	chr11:66306355	A/G	cg24851651	chr11:66362959	CCS	0.72	4.88	0.45	4.35e-6	Airway imaging phenotypes;
THYM	cis	rs870825	0.616	rs57086463	chr4:185639525	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs8041943	0.643	rs4779128	chr15:79919955	G/T	cg20511832	chr15:78934280	CHRNB4	0.43	4.89	0.45	4.09e-6	Bone mineral density (spine) and age at menarche;
THYM	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg26031613	chr14:104095156	KLC1	0.78	5.2	0.47	1.14e-6	Body mass index;
THYM	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.7	6.96	0.58	4.31e-10	Lymphocyte counts;
THYM	cis	rs11642862	0.892	rs117326446	chr16:30980128	A/T	cg01070095	chr16:30968205	SETD1A	0.73	4.65	0.43	1.05e-5	Tonsillectomy;
THYM	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg26354017	chr1:205819088	PM20D1	-0.73	-5.87	-0.52	6.34e-8	Menarche (age at onset);
THYM	cis	rs11645898	0.748	rs72787042	chr16:72067522	A/G	cg03805757	chr16:71968109	PKD1L3	-0.72	-5.25	-0.47	9.38e-7	Blood protein levels;
THYM	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg15557168	chr22:42548783	NA	0.58	4.68	0.43	9.66e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg05025164	chr4:1340916	KIAA1530	-0.7	-5.4	-0.48	4.85e-7	Obesity-related traits;
THYM	cis	rs2503875	1.000	rs2460538	chr10:43813446	A/G	cg23563014	chr10:44789077	NA	0.47	4.45	0.42	2.31e-5	Multiple sclerosis;
THYM	cis	rs75372982	1	rs75372982	chr19:33081333	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.78	-5.63	-0.5	1.81e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.69	-8.91	-0.67	3.51e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg27034606	chr17:28928453	LRRC37B2	0.76	5.06	0.46	2.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs28595532	0.920	rs114094671	chr4:119753540	G/A	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg08999081	chr20:33150536	PIGU	0.59	5.04	0.46	2.2e-6	Coronary artery disease;
THYM	cis	rs1878931	0.582	rs27231	chr16:3434966	C/T	cg00484396	chr16:3507460	NAT15	-0.47	-4.53	-0.42	1.74e-5	Body mass index (adult);
THYM	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7851660	0.967	rs7049054	chr9:100599969	T/G	cg13688889	chr9:100608707	NA	-0.83	-7.31	-0.6	8.28e-11	Strep throat;
THYM	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg03909863	chr11:638404	DRD4	-0.82	-5.84	-0.51	7.29e-8	Systemic lupus erythematosus;
THYM	cis	rs12142240	0.698	rs56063031	chr1:46825433	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs9486719	1.000	rs28623445	chr6:96899116	G/T	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg06600287	chr1:53387719	ECHDC2	-0.29	-4.69	-0.43	9.17e-6	Monocyte count;
THYM	cis	rs208520	0.955	rs208538	chr6:66964492	C/G	cg07460842	chr6:66804631	NA	-0.78	-5.07	-0.46	1.96e-6	Exhaled nitric oxide output;
THYM	cis	rs7826238	0.517	rs35144760	chr8:8361723	A/G	cg06636001	chr8:8085503	FLJ10661	-0.65	-5.09	-0.46	1.8e-6	Systolic blood pressure;
THYM	cis	rs6700896	0.931	rs79050868	chr1:66120916	G/A	cg04111102	chr1:66153794	NA	0.56	5.25	0.47	9.2e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.77	5.5	0.49	3.24e-7	Smoking behavior;
THYM	cis	rs240764	0.817	rs151573	chr6:101086333	T/C	cg21058520	chr6:100914733	NA	-0.57	-5.06	-0.46	2.04e-6	Neuroticism;
THYM	cis	rs1018836	0.828	rs7014967	chr8:91557843	G/T	cg16814680	chr8:91681699	NA	-0.9	-7.85	-0.63	6.31e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs2290159	0.800	rs5746193	chr3:12658601	C/T	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs1629083	0.935	rs1540191	chr11:118090432	G/A	cg25155064	chr11:118100782	MPZL3	-0.57	-5.04	-0.46	2.21e-6	Lung cancer;
THYM	cis	rs7705502	1.000	rs56197583	chr5:173336792	G/A	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs4589258	0.788	rs7126992	chr11:90478383	A/C	cg26138821	chr11:89956704	CHORDC1	-0.58	-4.66	-0.43	1.05e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg20476274	chr7:133979776	SLC35B4	0.67	4.62	0.43	1.22e-5	Mean platelet volume;
THYM	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg10523679	chr1:76189770	ACADM	0.92	10.35	0.73	2.94e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9394438	0.628	rs4714079	chr6:37544439	C/T	cg00985040	chr6:37553208	NA	-0.43	-4.64	-0.43	1.11e-5	IgG glycosylation;
THYM	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22496380	chr5:211416	CCDC127	-1.28	-7.77	-0.62	9.06e-12	Breast cancer;
THYM	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg02527881	chr3:46936655	PTH1R	0.54	5.21	0.47	1.1e-6	Colorectal cancer;
THYM	cis	rs1729951	0.575	rs361237	chr3:136702414	A/G	cg21827317	chr3:136751795	NA	0.72	6.5	0.55	3.69e-9	Neuroticism;
THYM	cis	rs9644630	0.804	rs11783263	chr8:19371674	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.78	7.4	0.6	5.45e-11	Oropharynx cancer;
THYM	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.64	-11.72	-0.77	3.65e-20	Hemostatic factors and hematological phenotypes;
THYM	cis	rs72712511	0.571	rs7698436	chr4:140767410	T/C	cg15010390	chr4:140216957	NDUFC1	0.66	4.84	0.45	4.94e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg07424592	chr7:64974309	NA	1.08	5.73	0.51	1.2e-7	Diabetic kidney disease;
THYM	cis	rs6009824	0.836	rs6009821	chr22:50085697	C/T	cg22070880	chr22:50098194	NA	0.65	4.6	0.43	1.3e-5	Natriuretic peptide levels;
THYM	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg06728252	chr6:26598149	ABT1	-0.43	-5.08	-0.46	1.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg27490568	chr2:178487706	NA	0.77	6.39	0.55	6.12e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg23840854	chr1:161414152	NA	-1.03	-5.72	-0.51	1.23e-7	Rheumatoid arthritis;
THYM	cis	rs7187994	0.848	rs3751759	chr16:84778222	G/A	cg07647771	chr16:84786436	USP10	-0.55	-5.06	-0.46	2.03e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs8016982	0.651	rs1885601	chr14:81641210	C/T	cg01989461	chr14:81687754	GTF2A1	0.79	6.61	0.56	2.22e-9	Schizophrenia;
THYM	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg08994789	chr17:28903642	LRRC37B2	1.03	5.24	0.47	9.83e-7	Body mass index;
THYM	cis	rs3126085	0.935	rs2291770	chr1:152179792	G/C	cg26020982	chr1:152196106	HRNR	0.35	4.57	0.42	1.45e-5	Atopic dermatitis;
THYM	cis	rs6032067	0.852	rs17424613	chr20:43806441	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs11785693	0.862	rs7009771	chr8:4990189	C/T	cg26367366	chr8:4980734	NA	0.94	4.74	0.44	7.42e-6	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs1568657	1.000	rs1568657	chr15:83726179	A/G	cg02750322	chr15:83673816	C15orf40	0.72	4.49	0.42	2.03e-5	Kawasaki disease;
THYM	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9527	0.641	rs34130454	chr10:104903638	A/G	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	4.54	0.42	1.66e-5	Hip circumference adjusted for BMI;
THYM	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.11	10.32	0.73	3.51e-17	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg23758822	chr17:41437982	NA	1.17	11.04	0.75	1.02e-18	Menopause (age at onset);
THYM	cis	rs921968	0.565	rs586194	chr2:219610433	A/G	cg02176678	chr2:219576539	TTLL4	-0.48	-4.73	-0.44	7.94e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg26418147	chr1:205743515	RAB7L1	-0.53	-4.59	-0.43	1.34e-5	Menarche (age at onset);
THYM	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg18105134	chr13:113819100	PROZ	0.96	8.96	0.68	2.73e-14	Platelet distribution width;
THYM	cis	rs2070488	0.932	rs4678604	chr3:38444273	G/A	cg24069376	chr3:38537580	EXOG	0.64	6.35	0.55	7.32e-9	Electrocardiographic conduction measures;
THYM	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg22920501	chr2:26401640	FAM59B	0.73	5.2	0.47	1.15e-6	Gut microbiome composition (summer);
THYM	cis	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.98	0.45	2.85e-6	Obesity-related traits;
THYM	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.72	0.51	1.25e-7	Rheumatoid arthritis;
THYM	cis	rs2279817	1.000	rs2279815	chr1:18022066	G/T	cg21791023	chr1:18019539	ARHGEF10L	0.82	5.24	0.47	9.52e-7	Neuroticism;
THYM	trans	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg25214090	chr10:38739885	LOC399744	0.83	7.11	0.59	2.14e-10	Corneal astigmatism;
THYM	cis	rs11048434	0.736	rs11048195	chr12:9105923	A/G	cg04155231	chr12:9217510	LOC144571	0.47	4.47	0.42	2.14e-5	Sjögren's syndrome;
THYM	cis	rs941408	1.000	rs941407	chr19:2812153	A/G	cg19693284	chr19:2783607	SGTA	0.65	4.97	0.45	2.92e-6	Total cholesterol levels;
THYM	cis	rs7578361	0.838	rs12467943	chr2:150357428	C/T	cg17961725	chr2:150454027	NA	0.72	5.25	0.47	9.22e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg03433033	chr1:76189801	ACADM	0.7	6.15	0.53	1.86e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs34638657	0.789	rs2303264	chr16:82203711	G/T	cg19807685	chr16:82068980	HSD17B2	-0.56	-4.61	-0.43	1.24e-5	Lung adenocarcinoma;
THYM	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg27129171	chr3:47204927	SETD2	-0.81	-8.14	-0.64	1.5e-12	Colorectal cancer;
THYM	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10823500	0.748	rs2394668	chr10:71943951	G/A	cg02100629	chr10:71892760	AIFM2	-0.37	-4.48	-0.42	2.1e-5	Blood protein levels;
THYM	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg17796960	chr10:135278976	LOC619207	-0.59	-4.87	-0.45	4.38e-6	Systemic lupus erythematosus;
THYM	cis	rs8077889	1.000	rs8077889	chr17:41878166	G/T	cg26893861	chr17:41843967	DUSP3	-0.99	-9.23	-0.69	7.23e-15	Triglycerides;
THYM	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg13866156	chr1:1669148	SLC35E2	-0.71	-7.14	-0.59	1.86e-10	Body mass index;
THYM	cis	rs9522267	0.535	rs9515452	chr13:112234553	A/G	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg08305652	chr11:111469057	NA	0.53	4.54	0.42	1.62e-5	Primary sclerosing cholangitis;
THYM	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12801636	0.512	rs12420618	chr11:65412974	C/G	cg19646538	chr11:65837255	PACS1	-0.47	-4.47	-0.42	2.14e-5	Coronary artery disease;HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg24209194	chr3:40518798	ZNF619	0.67	5.51	0.49	3.13e-7	Renal cell carcinoma;
THYM	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg16031515	chr1:205743344	RAB7L1	-0.69	-7.01	-0.58	3.39e-10	Menarche (age at onset);
THYM	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs2862064	1.000	rs905211	chr5:156447218	A/T	cg06200339	chr5:157079404	SOX30	0.56	4.46	0.42	2.28e-5	Platelet count;
THYM	cis	rs6728642	0.908	rs13400545	chr2:97871626	A/G	cg26665480	chr2:98280029	ACTR1B	-0.84	-4.81	-0.44	5.61e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg00898013	chr13:113819073	PROZ	-0.88	-8.96	-0.68	2.83e-14	Platelet distribution width;
THYM	cis	rs7584330	0.554	rs76605518	chr2:238425992	G/A	cg14458575	chr2:238380390	NA	0.79	4.65	0.43	1.06e-5	Prostate cancer;
THYM	cis	rs4273100	0.541	rs973649	chr17:19292068	A/G	cg25447019	chr17:19030144	GRAPL	0.75	5.86	0.52	6.62e-8	Schizophrenia;
THYM	cis	rs2811415	0.597	rs11706281	chr3:127803922	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs16854884	0.632	rs1466941	chr3:143670131	A/G	cg05063096	chr3:143689810	C3orf58	0.68	4.61	0.43	1.24e-5	Economic and political preferences (feminism/equality);
THYM	cis	rs1451375	0.741	rs55738142	chr7:50632326	T/C	cg18232548	chr7:50535776	DDC	0.68	5.24	0.47	9.76e-7	Malaria;
THYM	cis	rs11711311	0.955	rs1048892	chr3:113464859	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.26	-0.47	9.01e-7	IgG glycosylation;
THYM	cis	rs3733631	0.557	rs12646809	chr4:104699489	C/G	cg24090629	chr4:104641072	TACR3	-0.93	-5.1	-0.46	1.74e-6	Menarche (age at onset);
THYM	cis	rs6754311	0.509	rs12616520	chr2:136516748	A/T	cg07169764	chr2:136633963	MCM6	-0.67	-5.82	-0.51	7.78e-8	Mosquito bite size;
THYM	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg11335335	chr11:637885	DRD4	-0.63	-5.11	-0.46	1.64e-6	Systemic lupus erythematosus;
THYM	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3015497	0.753	rs12881776	chr14:51136330	T/G	cg04730355	chr14:51134070	SAV1	-0.51	-4.48	-0.42	2.08e-5	Mean platelet volume;
THYM	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg06713675	chr4:122721982	EXOSC9	-0.88	-9.96	-0.71	1.96e-16	Type 2 diabetes;
THYM	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14159672	chr1:205819179	PM20D1	0.95	9.42	0.69	2.91e-15	Menarche (age at onset);
THYM	cis	rs4343996	0.727	rs12537528	chr7:3375910	A/G	cg21248987	chr7:3385318	SDK1	0.37	4.47	0.42	2.14e-5	Motion sickness;
THYM	cis	rs7980799	0.653	rs11052722	chr12:33626530	G/A	cg06521331	chr12:34319734	NA	0.68	4.96	0.45	3.14e-6	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg06221963	chr1:154839813	KCNN3	-0.73	-8.77	-0.67	7.12e-14	Prostate cancer;
THYM	cis	rs7523273	0.554	rs2761434	chr1:207917499	C/T	cg22525895	chr1:207977042	MIR29B2	-0.68	-4.71	-0.44	8.36e-6	Schizophrenia;
THYM	cis	rs9549260	0.755	rs2721044	chr13:41162225	C/T	cg21288729	chr13:41239152	FOXO1	0.73	5.63	0.5	1.82e-7	Red blood cell count;
THYM	cis	rs929596	0.793	rs13009407	chr2:234652347	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.91	-6.74	-0.57	1.25e-9	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs6427356	0.513	rs2004706	chr1:157143490	C/T	cg27547283	chr1:156698502	C1orf66;ISG20L2	-0.58	-4.49	-0.42	2.02e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs6163	0.588	rs10786706	chr10:104500659	C/T	cg05855489	chr10:104503620	C10orf26	0.85	8.19	0.64	1.2e-12	Waist circumference;Hip circumference;
THYM	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg25767906	chr1:53392781	SCP2	-0.58	-5.85	-0.51	7.09e-8	Monocyte count;
THYM	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg07636037	chr3:49044803	WDR6	0.95	9.61	0.7	1.15e-15	Parkinson's disease;
THYM	cis	rs1003719	0.713	rs2835594	chr21:38466064	G/A	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.71	-7.66	-0.62	1.54e-11	Crohn's disease;
THYM	cis	rs4363385	0.747	rs4323653	chr1:152983359	T/G	cg13444842	chr1:152974279	SPRR3	-0.58	-4.71	-0.44	8.32e-6	Inflammatory skin disease;
THYM	cis	rs11195062	0.766	rs7922679	chr10:112014428	T/G	cg00817464	chr10:111662876	XPNPEP1	-0.47	-4.81	-0.44	5.74e-6	Multiple myeloma;
THYM	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg08000102	chr2:233561755	GIGYF2	-0.68	-6.11	-0.53	2.16e-8	Coronary artery disease;
THYM	cis	rs9611519	0.964	rs5995992	chr22:41487218	T/C	cg03806693	chr22:41940476	POLR3H	-0.85	-6.46	-0.55	4.44e-9	Neuroticism;
THYM	cis	rs7824557	0.614	rs2060456	chr8:11213363	C/T	cg21775007	chr8:11205619	TDH	0.69	6.04	0.53	2.96e-8	Retinal vascular caliber;
THYM	cis	rs288326	0.561	rs7595898	chr2:183819892	C/A	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs4563143	0.704	rs16961809	chr19:29226299	C/T	cg12756686	chr19:29218302	NA	0.83	6.5	0.55	3.73e-9	Methadone dose in opioid dependence;
THYM	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg24846343	chr22:24311635	DDTL	0.41	4.93	0.45	3.45e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.38	0.6	5.91e-11	Morning vs. evening chronotype;
THYM	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg07648498	chr16:89883185	FANCA	0.66	4.89	0.45	4.06e-6	Vitiligo;
THYM	cis	rs7688540	0.771	rs10021364	chr4:310691	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	-0.72	-4.79	-0.44	6.21e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs2124499	0.967	rs12330631	chr3:123089834	C/T	cg04890266	chr3:123102914	ADCY5	0.65	5.33	0.48	6.48e-7	Body mass index;
THYM	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg11984989	chr7:158649758	WDR60	1.17	15.57	0.85	6.93e-28	Height;
THYM	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg10802521	chr3:52805072	NEK4	-0.7	-5.94	-0.52	4.64e-8	Bipolar disorder;
THYM	cis	rs6988636	0.710	rs73339626	chr8:124142757	A/G	cg23067535	chr8:124195133	FAM83A	-0.99	-4.82	-0.44	5.52e-6	Urinary uromodulin levels;
THYM	cis	rs2777491	0.574	rs72739644	chr15:41719706	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.21	-13.52	-0.81	7.22e-24	Ulcerative colitis;
THYM	cis	rs42648	0.935	rs42627	chr7:89961876	C/T	cg25739043	chr7:89950458	NA	-0.55	-4.64	-0.43	1.12e-5	Homocysteine levels;
THYM	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg23711669	chr6:146136114	FBXO30	-0.93	-9.43	-0.7	2.71e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg16898833	chr6:26189333	HIST1H4D	1.44	5.52	0.49	2.98e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4285028	0.948	rs34181646	chr3:121705373	T/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-5.08	-0.46	1.87e-6	Multiple sclerosis;
THYM	cis	rs6988636	1.000	rs13259806	chr8:124190103	A/T	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs4924590	0.531	rs12913835	chr15:42227869	C/T	cg20935245	chr15:42234343	EHD4	0.4	4.53	0.42	1.73e-5	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
THYM	cis	rs4595586	0.525	rs7968458	chr12:39377139	C/A	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs9563576	0.778	rs4886039	chr13:58501075	A/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.63	4.68	0.43	9.55e-6	Body mass index;
THYM	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg20242066	chr2:136595261	LCT	-0.6	-7.44	-0.61	4.51e-11	Mosquito bite size;
THYM	cis	rs887829	0.588	rs7556676	chr2:234658250	A/G	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.57	-4.45	-0.42	2.3e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs1267303	0.642	rs6670699	chr1:46997270	C/T	cg25110126	chr1:46999211	NA	0.77	6.12	0.53	2.1e-8	Monobrow;
THYM	cis	rs877282	0.898	rs11253340	chr10:764786	G/T	cg10556349	chr10:835070	NA	-0.78	-5.06	-0.46	2.06e-6	Uric acid levels;
THYM	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg09307838	chr4:120376055	NA	0.78	5.7	0.5	1.35e-7	Corneal astigmatism;
THYM	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg23352942	chr3:46931381	PTH1R	-0.57	-5.08	-0.46	1.91e-6	Birth weight;
THYM	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg14675211	chr2:100938903	LONRF2	0.78	8.49	0.66	2.78e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg14008862	chr17:28927542	LRRC37B2	0.88	4.55	0.42	1.57e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg22166914	chr1:53195759	ZYG11B	0.82	7.82	0.63	7.16e-12	Monocyte count;
THYM	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg20966754	chr17:47091339	IGF2BP1	-0.62	-7.89	-0.63	5.16e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs56104184	0.887	rs55869333	chr19:49342145	T/G	cg16594139	chr19:49340574	PLEKHA4;HSD17B14	1.03	6.41	0.55	5.59e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs9733	0.596	rs6686525	chr1:150635811	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.61	4.47	0.42	2.19e-5	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg06728252	chr6:26598149	ABT1	-0.43	-5.11	-0.46	1.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg20242066	chr2:136595261	LCT	0.57	6.98	0.58	3.99e-10	Mosquito bite size;
THYM	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg25566285	chr7:158114605	PTPRN2	0.89	10.32	0.73	3.44e-17	Calcium levels;
THYM	cis	rs7100689	0.580	rs2168721	chr10:82208192	A/G	cg01528321	chr10:82214614	TSPAN14	0.74	5.81	0.51	8.22e-8	Post bronchodilator FEV1;
THYM	cis	rs61776719	0.520	rs12569027	chr1:38449163	C/T	cg17077180	chr1:38461687	NA	0.43	4.89	0.45	4.18e-6	Coronary artery disease;
THYM	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg13395646	chr4:1353034	KIAA1530	0.6	5.41	0.49	4.79e-7	Obesity-related traits;
THYM	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg00129232	chr17:37814104	STARD3	0.69	4.51	0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs7772486	0.790	rs6570723	chr6:146151230	A/T	cg13319975	chr6:146136371	FBXO30	-0.69	-5.65	-0.5	1.7e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.69	-5.54	-0.49	2.69e-7	Menarche (age at onset);
THYM	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg06238570	chr21:40685208	BRWD1	-0.96	-8.92	-0.68	3.35e-14	Cognitive function;
THYM	cis	rs9361491	0.684	rs961680	chr6:79460619	T/A	cg04547799	chr6:79944526	HMGN3	-0.64	-4.54	-0.42	1.64e-5	Intelligence (multi-trait analysis);
THYM	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg14829155	chr15:31115871	NA	-0.58	-5.13	-0.47	1.51e-6	Huntington's disease progression;
THYM	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg09263875	chr16:632152	PIGQ	0.73	6.29	0.54	9.69e-9	Height;
THYM	cis	rs2295499	0.643	rs35424748	chr4:2669054	T/C	cg14003022	chr4:3043019	NA	0.52	4.61	0.43	1.24e-5	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg17063962	chr7:91808500	NA	1.16	13.11	0.8	4.9e-23	Breast cancer;
THYM	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg02527881	chr3:46936655	PTH1R	-0.6	-6.01	-0.52	3.48e-8	Colorectal cancer;
THYM	cis	rs9653442	0.712	rs7582731	chr2:100686486	T/C	cg07810366	chr2:100720526	AFF3	-0.37	-5.54	-0.49	2.71e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs1797081	0.840	rs10904820	chr10:16848473	A/G	cg23933602	chr10:16859644	RSU1	0.85	8.88	0.67	4.16e-14	Platelet distribution width;
THYM	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg00271210	chr6:167070053	RPS6KA2	0.7	7.41	0.61	5.11e-11	Crohn's disease;
THYM	cis	rs9633835	0.594	rs4146385	chr11:13291931	T/A	cg13286116	chr11:13302098	ARNTL	-0.75	-8.79	-0.67	6.29e-14	Body mass index;
THYM	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs981844	0.712	rs10014763	chr4:154739140	C/T	cg09973105	chr4:154681532	RNF175	-0.52	-4.98	-0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg05802129	chr4:122689817	NA	-0.59	-4.65	-0.43	1.07e-5	Type 2 diabetes;
THYM	cis	rs10911232	0.507	rs4651138	chr1:183001312	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs7633857	0.512	rs2376477	chr3:160700699	G/T	cg03342759	chr3:160939853	NMD3	-0.67	-5.25	-0.47	9.11e-7	Educational attainment (years of education);
THYM	cis	rs986417	1.000	rs1272688	chr14:60920718	T/C	cg27398547	chr14:60952738	C14orf39	-1.25	-6.51	-0.56	3.59e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03452623	chr4:187889614	NA	-1.17	-20.2	-0.9	3.72e-36	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs868036	1.000	rs6494694	chr15:68057142	A/C	cg24579218	chr15:68104479	NA	0.65	6.25	0.54	1.16e-8	Restless legs syndrome;
THYM	cis	rs3087591	0.879	rs59015798	chr17:29580882	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.69	-5.36	-0.48	5.72e-7	Hip circumference;
THYM	cis	rs11563648	0.553	rs10252640	chr7:126956492	G/A	cg23081781	chr7:127225937	GCC1	-0.36	-4.88	-0.45	4.31e-6	Resting heart rate;
THYM	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg18252515	chr7:66147081	NA	0.64	4.56	0.42	1.55e-5	Aortic root size;
THYM	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg17264618	chr3:40429014	ENTPD3	0.51	5.06	0.46	2.03e-6	Renal cell carcinoma;
THYM	cis	rs2820651	0.614	rs78492247	chr10:1488937	G/C	cg13720710	chr10:1452970	ADARB2	0.72	4.71	0.43	8.6e-6	Migraine with aura;
THYM	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg14008862	chr17:28927542	LRRC37B2	0.89	4.57	0.42	1.49e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg23482746	chr15:76478102	C15orf27	-0.4	-4.58	-0.43	1.41e-5	Blood metabolite levels;
THYM	cis	rs208520	0.690	rs207114	chr6:66791703	C/T	cg07460842	chr6:66804631	NA	-1.05	-7.79	-0.62	8.12e-12	Exhaled nitric oxide output;
THYM	cis	rs7178572	1.000	rs965480	chr15:77781926	A/G	cg22256960	chr15:77711686	NA	-0.93	-7.89	-0.63	5.04e-12	Type 2 diabetes;
THYM	cis	rs13082711	0.911	rs7625337	chr3:27516853	G/T	cg02860705	chr3:27208620	NA	0.72	5.15	0.47	1.39e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs2888674	1.000	rs717658	chr7:150503637	A/T	cg10409299	chr7:150498843	TMEM176B;TMEM176A	0.48	4.63	0.43	1.15e-5	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
THYM	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg22535103	chr8:58192502	C8orf71	-1.03	-6.35	-0.55	7.45e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs427394	1.000	rs274672	chr5:6744176	G/A	cg10857441	chr5:6722123	POLS	-0.66	-8.01	-0.63	2.86e-12	Menopause (age at onset);
THYM	cis	rs7582180	0.903	rs7557977	chr2:100897573	G/A	cg14675211	chr2:100938903	LONRF2	0.64	5.43	0.49	4.28e-7	Intelligence (multi-trait analysis);
THYM	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg14972814	chr11:95582409	MTMR2	-0.58	-5.3	-0.48	7.56e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9563576	0.778	rs11148425	chr13:58657674	A/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.6	4.5	0.42	1.9e-5	Body mass index;
THYM	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs6541297	0.653	rs4846917	chr1:230299222	T/C	cg20703242	chr1:230279135	GALNT2	0.81	5.3	0.48	7.46e-7	Coronary artery disease;
THYM	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.94	8.4	0.65	4.38e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2806561	0.577	rs488438	chr1:23498999	T/A	cg19743168	chr1:23544995	NA	0.58	5.92	0.52	5.07e-8	Height;
THYM	cis	rs9902453	0.967	rs61240589	chr17:28449035	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	4.6	0.43	1.33e-5	Coffee consumption (cups per day);
THYM	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06481639	chr22:41940642	POLR3H	-0.66	-4.85	-0.45	4.89e-6	Vitiligo;
THYM	cis	rs478304	0.654	rs7115734	chr11:65458964	G/A	cg17480646	chr11:65405466	SIPA1	-0.97	-8.99	-0.68	2.44e-14	Acne (severe);
THYM	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg08975724	chr8:8085496	FLJ10661	0.63	5.04	0.46	2.19e-6	Systolic blood pressure;
THYM	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs7084402	0.902	rs10763557	chr10:60341515	C/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.72	-0.51	1.25e-7	Refractive error;
THYM	cis	rs4638749	0.677	rs10174695	chr2:108842164	G/A	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs16866061	1.000	rs10498163	chr2:225434445	A/G	cg12698349	chr2:225449008	CUL3	1.15	10.44	0.73	1.91e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	trans	rs8002861	0.967	rs7994883	chr13:44478805	A/G	cg17145862	chr1:211918768	LPGAT1	-0.99	-11.5	-0.76	1.06e-19	Leprosy;
THYM	cis	rs2976388	0.625	rs2257840	chr8:143809193	C/T	cg06565975	chr8:143823917	SLURP1	0.49	5.46	0.49	3.72e-7	Urinary tract infection frequency;
THYM	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg02527881	chr3:46936655	PTH1R	0.6	5.74	0.51	1.12e-7	Colorectal cancer;
THYM	cis	rs2282300	0.739	rs1765139	chr11:30353725	T/C	cg06241208	chr11:30344200	C11orf46	-0.84	-6.46	-0.55	4.36e-9	Morning vs. evening chronotype;
THYM	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg24154853	chr7:158122151	PTPRN2	0.56	5.04	0.46	2.25e-6	Calcium levels;
THYM	cis	rs868036	0.681	rs1026737	chr15:68107072	A/C	cg24579218	chr15:68104479	NA	-0.82	-8.85	-0.67	4.77e-14	Restless legs syndrome;
THYM	cis	rs9527	0.615	rs11191485	chr10:104729816	G/C	cg04362960	chr10:104952993	NT5C2	0.63	4.76	0.44	6.9e-6	Arsenic metabolism;
THYM	trans	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg25214090	chr10:38739885	LOC399744	0.92	8.08	0.64	2e-12	Corneal astigmatism;
THYM	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg15448220	chr1:150897856	SETDB1	0.89	7.59	0.61	2.17e-11	Melanoma;
THYM	cis	rs1095368	0.622	rs36108296	chr10:13388644	G/C	cg25835351	chr10:13388524	SEPHS1	-0.28	-4.89	-0.45	4.14e-6	IgG glycosylation;
THYM	cis	rs10911232	0.524	rs4652773	chr1:183054827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg14893161	chr1:205819251	PM20D1	-0.68	-6.35	-0.55	7.5e-9	Menarche (age at onset);
THYM	cis	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg06521331	chr12:34319734	NA	-1.03	-10.3	-0.73	3.74e-17	Morning vs. evening chronotype;
THYM	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg00639195	chr15:79103007	ADAMTS7	-0.84	-6.04	-0.53	2.99e-8	Coronary artery disease or large artery stroke;
THYM	cis	rs11997175	0.583	rs4386938	chr8:33673156	A/G	ch.8.33884649F	chr8:33765107	NA	0.66	4.88	0.45	4.24e-6	Body mass index;
THYM	cis	rs7119	0.717	rs12904254	chr15:77802585	C/A	cg10437265	chr15:77819839	NA	0.78	7.67	0.62	1.49e-11	Type 2 diabetes;
THYM	cis	rs854765	0.624	rs4925119	chr17:17742904	A/G	cg04398451	chr17:18023971	MYO15A	0.71	6.05	0.53	2.88e-8	Total body bone mineral density;
THYM	cis	rs965469	0.603	rs6051849	chr20:3404860	C/G	cg25506879	chr20:3388711	C20orf194	-0.69	-5.53	-0.49	2.86e-7	IFN-related cytopenia;
THYM	cis	rs7567389	0.889	rs1504136	chr2:127977118	T/C	cg09760422	chr2:128146352	NA	-0.49	-5.97	-0.52	4.06e-8	Self-rated health;
THYM	cis	rs17604090	0.816	rs10248839	chr7:29697253	T/C	cg19413766	chr7:29689036	LOC646762	-1.04	-5.82	-0.51	7.9e-8	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg02574844	chr11:5959923	NA	-0.52	-4.85	-0.45	4.78e-6	DNA methylation (variation);
THYM	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg24803719	chr17:45855879	NA	-0.6	-6.33	-0.54	7.96e-9	IgG glycosylation;
THYM	cis	rs818427	0.710	rs1966477	chr5:112172786	G/T	cg04614008	chr5:112630677	MCC	-0.63	-4.46	-0.42	2.29e-5	Total body bone mineral density;
THYM	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg08859206	chr1:53392774	SCP2	-0.64	-7.43	-0.61	4.61e-11	Monocyte count;
THYM	cis	rs4455778	0.580	rs34005483	chr7:49094307	A/G	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg03929089	chr4:120376271	NA	-0.95	-10.79	-0.74	3.5e-18	Height;
THYM	cis	rs6032067	0.641	rs17332243	chr20:43756071	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.72	-7.65	-0.62	1.63e-11	Blood protein levels;
THYM	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg27532560	chr4:187881888	NA	0.92	11.22	0.76	4.13e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1018836	0.631	rs9987133	chr8:91470730	T/C	cg16814680	chr8:91681699	NA	-0.69	-5.58	-0.5	2.3e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs1697139	0.583	rs11960733	chr5:66538715	C/T	cg11553311	chr5:66541588	NA	0.71	7.31	0.6	8.42e-11	Breast cancer;
THYM	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs61990749	0.597	rs10142722	chr14:78275549	A/T	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.04	0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs1335645	0.570	rs2165145	chr1:111625213	C/T	cg00321911	chr1:111669324	DRAM2	-1.38	-7.97	-0.63	3.51e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg13695892	chr22:41940480	POLR3H	0.9	7.31	0.6	8.34e-11	Vitiligo;
THYM	cis	rs7572263	0.874	rs9646836	chr2:209055610	C/A	cg23998903	chr2:209048830	C2orf80	0.44	5.66	0.5	1.62e-7	Glioma;Non-glioblastoma glioma;
THYM	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg17757837	chr7:157058334	UBE3C	0.66	5.29	0.48	7.81e-7	Body mass index;
THYM	cis	rs12935418	0.616	rs9936366	chr16:81045262	A/G	cg16651780	chr16:81037892	C16orf61	0.87	6.38	0.55	6.35e-9	Mean corpuscular volume;
THYM	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06873352	chr17:61820015	STRADA	0.79	9.84	0.71	3.66e-16	Prudent dietary pattern;
THYM	cis	rs28785552	0.897	rs34244888	chr19:53242228	T/A	cg10871876	chr19:53194124	ZNF83	0.81	6.86	0.58	6.83e-10	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs611744	0.967	rs673854	chr8:109191838	G/A	cg21045802	chr8:109455806	TTC35	0.62	5.48	0.49	3.49e-7	Dupuytren's disease;
THYM	cis	rs928736	0.557	rs2834083	chr21:34436973	A/G	cg00274965	chr21:34405681	NA	0.56	6.31	0.54	8.77e-9	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg13010199	chr12:38710504	ALG10B	0.72	5.92	0.52	5.01e-8	Heart rate;
THYM	cis	rs7681440	0.583	rs2583958	chr4:90720365	T/C	cg06632027	chr4:90757378	SNCA	-0.66	-5.19	-0.47	1.18e-6	Dementia with Lewy bodies;
THYM	cis	rs4400599	1.000	rs3001363	chr1:154125067	C/T	cg05139571	chr1:154127138	NUP210L	-0.54	-4.54	-0.42	1.62e-5	Platelet distribution width;
THYM	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-5.4	-0.48	4.89e-7	Chronic sinus infection;
THYM	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-1.01	-12.98	-0.8	9.27e-23	Chronic sinus infection;
THYM	cis	rs4144027	0.869	rs55924227	chr14:104361350	G/C	cg08213375	chr14:104286397	PPP1R13B	0.42	4.46	0.42	2.24e-5	Blood metabolite levels;
THYM	cis	rs7172809	0.615	rs16968900	chr15:77826911	A/G	cg22256960	chr15:77711686	NA	-0.66	-4.85	-0.45	4.86e-6	Glucose homeostasis traits;
THYM	cis	rs12348691	0.503	rs4743138	chr9:100614296	C/T	cg13688889	chr9:100608707	NA	0.9	6.12	0.53	2.06e-8	Alopecia areata;
THYM	cis	rs7408868	1.000	rs2074622	chr19:15277620	G/C	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs7326068	0.610	rs9552265	chr13:21311695	C/T	cg27499820	chr13:21296301	IL17D	0.61	4.46	0.42	2.21e-5	Schizophrenia, bipolar disorder and depression (combined);
THYM	cis	rs9549367	0.804	rs9549704	chr13:113885187	T/C	cg00898013	chr13:113819073	PROZ	-0.92	-8.8	-0.67	6.06e-14	Platelet distribution width;
THYM	cis	rs7246657	0.943	rs4802766	chr19:37981933	T/C	cg22634378	chr19:37742834	NA	0.66	5.49	0.49	3.29e-7	Coronary artery calcification;
THYM	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg04398451	chr17:18023971	MYO15A	-0.97	-10.23	-0.72	5.37e-17	Total body bone mineral density;
THYM	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg24503407	chr1:205819492	PM20D1	1.13	11.9	0.77	1.6e-20	Menarche (age at onset);
THYM	cis	rs763014	0.833	rs4984891	chr16:622234	T/A	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs3892630	0.824	rs12976069	chr19:33280084	G/A	cg22928329	chr19:33183273	NUDT19	-0.72	-5.32	-0.48	6.99e-7	Red blood cell traits;
THYM	cis	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13636640	chr20:31349939	DNMT3B	0.92	9.68	0.7	7.87e-16	Ulcerative colitis;
THYM	trans	rs8073060	0.586	rs6505484	chr17:33993152	G/A	cg19694781	chr19:47549865	TMEM160	-1.01	-8.48	-0.66	2.89e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs2859741	1.000	rs1773575	chr1:37505129	T/C	cg09363841	chr1:37513479	NA	-0.74	-6.92	-0.58	5.2e-10	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg16405210	chr4:1374714	KIAA1530	-0.75	-6.61	-0.56	2.22e-9	Longevity;
THYM	cis	rs35883536	1.000	rs12566507	chr1:101089679	T/A	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs8077889	0.672	rs1230400	chr17:41845451	G/A	cg26893861	chr17:41843967	DUSP3	-1.12	-14.93	-0.84	1.15e-26	Triglycerides;
THYM	cis	rs36051895	0.623	rs28872016	chr9:5253558	T/G	cg02405213	chr9:5042618	JAK2	-0.93	-9.62	-0.7	1.07e-15	Pediatric autoimmune diseases;
THYM	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg09877947	chr5:131593287	PDLIM4	0.61	5.08	0.46	1.86e-6	Acylcarnitine levels;
THYM	cis	rs12594515	1.000	rs56412446	chr15:45996424	A/G	cg01629716	chr15:45996671	NA	0.53	5.27	0.48	8.45e-7	Waist circumference;Weight;
THYM	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg13699009	chr12:122356056	WDR66	0.49	4.53	0.42	1.74e-5	Mean corpuscular volume;
THYM	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25951256	chr10:38645740	HSD17B7P2	-0.54	-4.73	-0.44	7.66e-6	Breast cancer;
THYM	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg06582575	chr6:163149167	PACRG;PARK2	1.08	7.64	0.62	1.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7843479	0.931	rs1031883	chr8:21788936	G/A	cg17168535	chr8:21777572	XPO7	0.82	5.87	0.52	6.41e-8	Mean corpuscular volume;
THYM	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg13114125	chr14:105738426	BRF1	-0.75	-6.02	-0.53	3.27e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs804280	0.662	rs7826055	chr8:11611723	G/C	cg02840367	chr8:11660030	FDFT1	0.68	4.72	0.44	8.21e-6	Myopia (pathological);
THYM	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs12950390	0.512	rs72831681	chr17:45847174	C/G	cg03474202	chr17:45855739	NA	-0.72	-4.87	-0.45	4.42e-6	IgG glycosylation;
THYM	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs524023	0.914	rs2277311	chr11:64387932	G/A	cg19131476	chr11:64387923	NRXN2	-0.39	-5.54	-0.49	2.7e-7	Urate levels in obese individuals;
THYM	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.08	8.96	0.68	2.75e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11696501	0.637	rs6104298	chr20:44327774	A/G	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	cis	rs9649465	1.000	rs2052128	chr7:123380405	T/A	cg15443791	chr7:124364398	NA	0.58	4.81	0.44	5.62e-6	Migraine;
THYM	cis	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg10856724	chr12:34555212	NA	-0.91	-8.9	-0.67	3.68e-14	Morning vs. evening chronotype;
THYM	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs986417	1.000	rs1950904	chr14:60964954	G/C	cg27398547	chr14:60952738	C14orf39	1.25	6.45	0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs7106204	0.748	rs2403888	chr11:24208071	C/G	ch.11.24196551F	chr11:24239977	NA	-0.98	-7.1	-0.59	2.22e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg06634786	chr22:41940651	POLR3H	-0.68	-5.5	-0.49	3.22e-7	Vitiligo;
THYM	cis	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg23161317	chr6:28129485	ZNF389	1.07	6.53	0.56	3.23e-9	Depression;
THYM	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	7.5	0.61	3.29e-11	Platelet count;
THYM	cis	rs9826463	0.702	rs73228758	chr3:142320559	A/G	cg20824294	chr3:142316082	PLS1	0.64	4.62	0.43	1.2e-5	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs6032067	0.641	rs13042991	chr20:43767178	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.47	-5.31	-0.48	7.26e-7	Blood protein levels;
THYM	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg14893161	chr1:205819251	PM20D1	-0.62	-5.23	-0.47	1.03e-6	Prostate-specific antigen levels;
THYM	cis	rs12347191	0.500	rs907580	chr9:100622597	T/C	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Orofacial clefts;
THYM	cis	rs73198271	0.740	rs10098636	chr8:8647324	C/T	cg15556689	chr8:8085844	FLJ10661	-0.73	-4.58	-0.43	1.39e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg13902645	chr11:5959945	NA	0.57	5.08	0.46	1.91e-6	DNA methylation (variation);
THYM	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg18252515	chr7:66147081	NA	-0.66	-4.85	-0.45	4.8e-6	Aortic root size;
THYM	cis	rs11723261	0.582	rs116471062	chr4:163522	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.84	5.97	0.52	4.01e-8	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg08645402	chr16:4508243	NA	0.77	6.52	0.56	3.44e-9	Schizophrenia;
THYM	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg11764359	chr7:65958608	NA	-0.7	-5.5	-0.49	3.18e-7	Aortic root size;
THYM	cis	rs1499972	0.941	rs62264763	chr3:117637305	G/A	cg07612923	chr3:117604196	NA	1.19	5.0	0.46	2.66e-6	Schizophrenia;
THYM	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg22655196	chr4:3374909	RGS12	0.66	8.31	0.65	6.56e-13	Serum sulfate level;
THYM	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg24375607	chr4:120327624	NA	-0.61	-4.84	-0.44	4.98e-6	Corneal astigmatism;
THYM	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg01579765	chr21:45077557	HSF2BP	-0.47	-7.46	-0.61	4.06e-11	Mean corpuscular volume;
THYM	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg16586182	chr3:47516702	SCAP	-0.67	-5.61	-0.5	1.99e-7	Colorectal cancer;
THYM	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg01579765	chr21:45077557	HSF2BP	-0.54	-8.68	-0.67	1.06e-13	Mean corpuscular volume;
THYM	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg11764359	chr7:65958608	NA	0.69	4.68	0.43	9.69e-6	Aortic root size;
THYM	cis	rs7267979	0.744	rs6050463	chr20:25208990	G/A	cg03522245	chr20:25566470	NINL	0.66	4.98	0.45	2.89e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7589342	0.929	rs1465640	chr2:106439103	C/T	cg14210321	chr2:106509881	NCK2	-0.72	-5.15	-0.47	1.4e-6	Addiction;
THYM	cis	rs6531656	0.898	rs337615	chr4:38679064	G/C	cg24279243	chr4:38676559	KLF3	0.87	6.11	0.53	2.2e-8	Lymphocyte counts;
THYM	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.94	-0.52	4.64e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs4786125	0.626	rs6500859	chr16:6914358	A/T	cg03623568	chr16:6915990	A2BP1	-0.99	-9.87	-0.71	3.12e-16	Heart rate variability traits (SDNN);
THYM	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08109568	chr15:31115862	NA	-0.76	-6.77	-0.57	1.05e-9	Huntington's disease progression;
THYM	cis	rs7584330	0.697	rs60278044	chr2:238357118	A/G	cg14458575	chr2:238380390	NA	0.92	7.24	0.6	1.18e-10	Prostate cancer;
THYM	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg24308560	chr3:49941425	MST1R	0.79	6.77	0.57	1.06e-9	Intelligence (multi-trait analysis);
THYM	cis	rs4901869	0.864	rs12891575	chr14:59334342	T/A	cg02291164	chr14:59296302	NA	0.79	7.56	0.61	2.51e-11	Panic disorder;
THYM	cis	rs7172809	0.599	rs17471753	chr15:77763809	C/T	cg22256960	chr15:77711686	NA	-0.61	-4.47	-0.42	2.18e-5	Glucose homeostasis traits;
THYM	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg01448562	chr3:133502909	NA	-0.83	-7.15	-0.59	1.82e-10	Iron status biomarkers;
THYM	cis	rs17604090	0.526	rs10260080	chr7:29757941	T/G	cg20541039	chr7:29606985	NA	-0.89	-4.74	-0.44	7.49e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs662064	0.603	rs12065251	chr1:10522289	C/T	cg20482658	chr1:10539492	PEX14	0.47	5.26	0.48	8.75e-7	Asthma;
THYM	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg08975724	chr8:8085496	FLJ10661	0.61	4.79	0.44	6.18e-6	Systolic blood pressure;
THYM	cis	rs9378357	0.558	rs9378356	chr6:3291336	A/G	cg08754725	chr6:3293098	SLC22A23	0.78	5.3	0.48	7.4e-7	Obesity-related traits;
THYM	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.78	-6.0	-0.52	3.56e-8	Eosinophil percentage of white cells;
THYM	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg11494091	chr17:61959527	GH2	0.69	6.32	0.54	8.45e-9	Height;
THYM	cis	rs12368653	0.545	rs2277324	chr12:58013175	G/A	cg12615879	chr12:58013172	SLC26A10	0.7	7.21	0.59	1.32e-10	Multiple sclerosis;
THYM	cis	rs9431487	0.760	rs2244633	chr1:219006208	G/A	cg13962170	chr1:218691051	NA	0.55	4.81	0.44	5.63e-6	Gut microbiome composition (summer);
THYM	cis	rs611744	0.870	rs685358	chr8:109161413	T/C	cg21045802	chr8:109455806	TTC35	0.67	6.47	0.55	4.27e-9	Dupuytren's disease;
THYM	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg16230307	chr14:35515116	FAM177A1	0.85	5.53	0.49	2.84e-7	Psoriasis;
THYM	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.59	4.98	0.46	2.81e-6	Hemoglobin concentration;
THYM	cis	rs2033711	0.902	rs4801589	chr19:58953398	C/G	cg13877915	chr19:58951672	ZNF132	0.91	8.64	0.66	1.34e-13	Uric acid clearance;
THYM	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg17143192	chr8:8559678	CLDN23	-0.83	-7.05	-0.59	2.82e-10	Obesity-related traits;
THYM	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg20295408	chr7:1910781	MAD1L1	-0.65	-5.21	-0.47	1.11e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg16414030	chr3:133502952	NA	-0.84	-8.47	-0.66	3.08e-13	Iron status biomarkers;
THYM	cis	rs7572733	0.555	rs6729473	chr2:198763928	G/A	cg05783139	chr2:198650985	BOLL	0.62	4.89	0.45	4.15e-6	Dermatomyositis;
THYM	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4786125	0.636	rs11644404	chr16:6904030	C/A	cg03623568	chr16:6915990	A2BP1	-1.01	-9.88	-0.71	2.98e-16	Heart rate variability traits (SDNN);
THYM	cis	rs6430585	0.640	rs58301703	chr2:136532225	G/A	cg04750100	chr2:136595281	LCT	0.53	4.86	0.45	4.59e-6	Corneal structure;
THYM	cis	rs7100689	0.646	rs11202751	chr10:82147802	G/A	cg01528321	chr10:82214614	TSPAN14	0.89	6.73	0.57	1.26e-9	Post bronchodilator FEV1;
THYM	cis	rs728616	0.867	rs61860043	chr10:81946398	G/A	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7833986	0.534	rs2667972	chr8:56906661	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	6.4	0.55	5.76e-9	Height;
THYM	cis	rs4930776	1.000	rs251781	chr12:5772269	G/C	cg02086166	chr12:5775618	ANO2	0.6	6.11	0.53	2.2e-8	Plasma clusterin levels;
THYM	cis	rs950880	0.593	rs887972	chr2:103040945	G/A	cg03938978	chr2:103052716	IL18RAP	-0.56	-5.02	-0.46	2.43e-6	Serum protein levels (sST2);
THYM	trans	rs8073060	0.586	rs17638867	chr17:34052513	C/T	cg19694781	chr19:47549865	TMEM160	0.9	7.6	0.61	2.05e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs2970992	0.764	rs2090012	chr2:101330582	T/C	cg01042948	chr2:101319752	NA	0.6	5.89	0.52	5.76e-8	Educational attainment;
THYM	cis	rs7106204	0.514	rs12282611	chr11:24271352	A/C	ch.11.24196551F	chr11:24239977	NA	1.0	6.96	0.58	4.4e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs17511627	0.808	rs7983335	chr13:26742287	A/G	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs9649213	0.593	rs6969731	chr7:97924571	T/G	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.6e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4731207	0.698	rs10261610	chr7:124450577	G/A	cg05285228	chr7:124571219	POT1	0.66	5.24	0.47	9.66e-7	Cutaneous malignant melanoma;
THYM	cis	rs56104184	0.830	rs17272658	chr19:49355405	C/T	cg16594139	chr19:49340574	PLEKHA4;HSD17B14	0.98	4.73	0.44	7.75e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7474896	0.507	rs2474555	chr10:38465220	G/C	cg25427524	chr10:38739819	LOC399744	-0.74	-4.74	-0.44	7.42e-6	Obesity (extreme);
THYM	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg25767906	chr1:53392781	SCP2	-0.52	-5.29	-0.48	7.7300000000000005e-07	Monocyte count;
THYM	cis	rs2165738	1.000	rs2165738	chr2:24692809	C/G	cg27107076	chr2:25050844	ADCY3	0.3	4.65	0.43	1.08e-5	Type 1 diabetes;
THYM	cis	rs9790314	0.902	rs9863590	chr3:161116445	T/C	cg03342759	chr3:160939853	NMD3	-0.77	-6.89	-0.58	5.91e-10	Morning vs. evening chronotype;
THYM	cis	rs7011507	0.594	rs907176	chr8:49357729	T/C	cg08774009	chr8:49309094	NA	-0.62	-4.92	-0.45	3.67e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs7909074	0.714	rs10900129	chr10:45398609	G/C	cg04218760	chr10:45406644	TMEM72	-0.6	-5.32	-0.48	6.94e-7	Mean corpuscular volume;
THYM	cis	rs3781426	0.882	rs10901854	chr10:126733643	T/C	cg04494136	chr10:126703576	CTBP2	-0.35	-4.74	-0.44	7.56e-6	Height;
THYM	cis	rs2124969	0.548	rs7586751	chr2:160958145	T/C	cg03641300	chr2:160917029	PLA2R1	-0.65	-4.58	-0.43	1.38e-5	Waist circumference adjusted for body mass index;
THYM	cis	rs73193808	1.000	rs73193819	chr21:30544657	T/C	cg06824297	chr21:30391795	RWDD2B	-0.69	-4.47	-0.42	2.14e-5	Coronary artery disease;
THYM	cis	rs7586879	0.639	rs13407913	chr2:25097644	A/G	cg01884057	chr2:25150051	NA	0.7	7.27	0.6	1.01e-10	Body mass index;
THYM	cis	rs10231759	0.617	rs11982701	chr7:150512156	G/T	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.66	4.97	0.45	3e-6	Height;
THYM	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg24531977	chr5:56204891	C5orf35	-0.69	-5.33	-0.48	6.72e-7	Coronary artery disease;
THYM	cis	rs654950	0.841	rs676383	chr1:41993753	C/T	cg13396354	chr1:41153348	NA	0.44	4.53	0.42	1.73e-5	Airway imaging phenotypes;
THYM	cis	rs7084402	0.967	rs1427198	chr10:60274970	T/G	cg26159090	chr10:60474252	BICC1;LOC728640	-0.43	-4.45	-0.42	2.3e-5	Refractive error;
THYM	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs295140	0.566	rs295141	chr2:201163556	C/T	cg14106933	chr2:201194453	SPATS2L	0.42	4.51	0.42	1.86e-5	QT interval;
THYM	cis	rs752010	0.644	rs7541348	chr1:42113215	T/G	cg06885757	chr1:42089581	HIVEP3	0.61	8.21	0.64	1.09e-12	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg17644776	chr2:200775616	C2orf69	0.81	5.51	0.49	3.09e-7	Schizophrenia;
THYM	cis	rs7246657	0.943	rs12981532	chr19:37889280	G/A	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs11792861	0.591	rs2275641	chr9:111696389	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.81	7.05	0.59	2.88e-10	Menarche (age at onset);
THYM	cis	rs34638657	0.702	rs62044259	chr16:82199523	A/T	cg09439754	chr16:82129088	HSD17B2	-0.51	-5.13	-0.47	1.52e-6	Lung adenocarcinoma;
THYM	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs1395	0.961	rs4665965	chr2:27536380	C/T	cg23587288	chr2:27483067	SLC30A3	0.6	5.0	0.46	2.59e-6	Blood metabolite levels;
THYM	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg22907277	chr7:1156413	C7orf50	0.86	5.31	0.48	7.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs887829	0.570	rs12623271	chr2:234599941	C/G	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.54	-4.57	-0.42	1.45e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs2303759	0.874	rs8108669	chr19:49845895	C/T	cg22307029	chr19:49891270	CCDC155	0.79	7.13	0.59	1.97e-10	Multiple sclerosis;
THYM	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg09537434	chr19:41945824	ATP5SL	1.09	10.65	0.74	6.94e-18	Height;
THYM	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg27490568	chr2:178487706	NA	0.57	5.59	0.5	2.15e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2985684	0.948	rs2883437	chr14:50031666	A/G	cg02151108	chr14:50098012	C14orf104	-0.74	-6.06	-0.53	2.74e-8	Carotid intima media thickness;
THYM	cis	rs763014	0.898	rs62030902	chr16:638264	C/G	cg09263875	chr16:632152	PIGQ	0.73	5.95	0.52	4.44e-8	Height;
THYM	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-5.12	-0.47	1.59e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs4474465	0.920	rs7944485	chr11:78225261	T/C	cg19901956	chr11:77921274	USP35	0.7	5.15	0.47	1.43e-6	Alzheimer's disease (survival time);
THYM	cis	rs9549260	0.539	rs4943813	chr13:41338134	G/C	cg21288729	chr13:41239152	FOXO1	0.7	5.27	0.48	8.56e-7	Red blood cell count;
THYM	cis	rs9527	0.590	rs10883836	chr10:104891198	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs6500395	1.000	rs7198773	chr16:48606091	T/C	cg04672837	chr16:48644449	N4BP1	0.54	5.5	0.49	3.25e-7	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg06028808	chr11:68637592	NA	0.71	7.67	0.62	1.5e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg18904891	chr8:8559673	CLDN23	0.67	4.97	0.45	3e-6	Obesity-related traits;
THYM	cis	rs1729951	0.575	rs2163896	chr3:136691177	G/A	cg12473912	chr3:136751656	NA	0.63	5.13	0.47	1.55e-6	Neuroticism;
THYM	trans	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs7322722	0.945	rs10400634	chr13:77761210	G/A	cg04565255	chr13:77565759	CLN5	-0.44	-4.49	-0.42	2.03e-5	Preeclampsia;
THYM	cis	rs11608355	0.846	rs4766471	chr12:109853462	G/A	cg10504392	chr12:110044639	NA	0.6	5.08	0.46	1.89e-6	Neuroticism;
THYM	cis	rs6430585	0.583	rs111837148	chr2:136612036	G/A	cg07169764	chr2:136633963	MCM6	1.24	13.85	0.82	1.58e-24	Corneal structure;
THYM	cis	rs1387259	0.859	rs2054905	chr12:48687951	A/G	cg21466736	chr12:48725269	NA	-0.54	-5.02	-0.46	2.44e-6	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg00255919	chr5:131827918	IRF1	-0.46	-5.0	-0.46	2.62e-6	Asthma (sex interaction);
THYM	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	6.54	0.56	3.08e-9	Obesity-related traits;
THYM	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg05564831	chr3:52568323	NT5DC2	0.48	5.06	0.46	2.02e-6	Electroencephalogram traits;
THYM	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg02725872	chr8:58115012	NA	-1.14	-7.59	-0.61	2.17e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs7084402	0.967	rs1649034	chr10:60279324	G/A	cg07615347	chr10:60278583	BICC1	-0.56	-5.15	-0.47	1.4e-6	Refractive error;
THYM	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg20607798	chr8:58055168	NA	0.83	4.68	0.43	9.53e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg07460842	chr6:66804631	NA	-0.87	-5.96	-0.52	4.3e-8	Exhaled nitric oxide output;
THYM	cis	rs709400	0.663	rs11626787	chr14:103991749	A/G	cg26031613	chr14:104095156	KLC1	0.74	4.62	0.43	1.19e-5	Body mass index;
THYM	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg14004847	chr7:1930337	MAD1L1	-0.64	-5.11	-0.46	1.67e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg11941060	chr3:133502564	NA	-0.72	-6.24	-0.54	1.24e-8	Iron status biomarkers;
THYM	cis	rs2286885	1.000	rs1537987	chr9:129242112	T/C	cg14319473	chr9:129242481	FAM125B	0.66	5.01	0.46	2.52e-6	Intraocular pressure;
THYM	cis	rs9649213	0.613	rs6961129	chr7:97975542	T/G	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs67072384	1.000	rs11235579	chr11:72453095	A/G	cg01380194	chr11:72452482	ARAP1	-0.97	-5.26	-0.47	8.93e-7	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs9970807	0.901	rs56348932	chr1:56988551	A/C	cg11959316	chr1:57001742	PPAP2B	0.8	5.84	0.51	7.12e-8	Myocardial infarction;Coronary artery disease;
THYM	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg18252515	chr7:66147081	NA	-0.62	-4.55	-0.42	1.59e-5	Aortic root size;
THYM	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg09469691	chr10:81107165	PPIF	0.72	5.56	0.5	2.43e-7	Height;
THYM	cis	rs2505675	0.887	rs2505676	chr6:2355375	C/G	cg01959516	chr6:2449276	NA	-0.64	-5.33	-0.48	6.66e-7	Tuberculosis;
THYM	cis	rs912057	1.000	rs1294407	chr6:6738103	C/G	cg13809441	chr6:6737631	NA	0.43	4.76	0.44	6.95e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs6723226	0.650	rs6729952	chr2:32764922	T/C	cg02381751	chr2:32503542	YIPF4	0.56	4.47	0.42	2.19e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg23711669	chr6:146136114	FBXO30	0.86	8.54	0.66	2.14e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9644630	0.804	rs11779939	chr8:19327487	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.71	7.04	0.59	2.94e-10	Oropharynx cancer;
THYM	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-5.36	-0.48	5.89e-7	Vitiligo;
THYM	cis	rs36051895	0.659	rs7859390	chr9:5062473	A/T	cg02405213	chr9:5042618	JAK2	-1.01	-11.38	-0.76	1.96e-19	Pediatric autoimmune diseases;
THYM	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1421898	0.625	rs10476256	chr5:157942780	C/T	cg06698293	chr5:158690540	UBLCP1	-0.97	-4.6	-0.43	1.28e-5	Inflammatory skin disease;
THYM	cis	rs7084402	0.905	rs1896244	chr10:60276182	A/G	cg07615347	chr10:60278583	BICC1	-0.56	-5.15	-0.47	1.4e-6	Refractive error;
THYM	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg26384229	chr12:38710491	ALG10B	-0.9	-7.35	-0.6	6.77e-11	Morning vs. evening chronotype;
THYM	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg12311346	chr5:56204834	C5orf35	-0.82	-6.04	-0.53	3.01e-8	Initial pursuit acceleration;
THYM	cis	rs8016982	0.633	rs7141288	chr14:81710232	C/A	cg21807262	chr14:81713016	NA	-0.59	-5.61	-0.5	2.03e-7	Schizophrenia;
THYM	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg07936489	chr17:37558343	FBXL20	-0.79	-5.7	-0.5	1.37e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs1198430	1.000	rs1198432	chr1:23756155	C/T	cg27447006	chr1:23763279	ASAP3	-0.83	-4.45	-0.42	2.29e-5	Total cholesterol levels;
THYM	cis	rs13326165	0.585	rs10460962	chr3:52343679	C/T	cg08438690	chr3:52279403	PPM1M	-0.8	-4.69	-0.43	9.03e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg19770292	chr5:1868693	NA	0.54	5.0	0.46	2.63e-6	Cardiovascular disease risk factors;
THYM	cis	rs4788570	0.578	rs7204992	chr16:71658444	G/A	cg06353428	chr16:71660113	MARVELD3	1.37	9.59	0.7	1.22e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg24209194	chr3:40518798	ZNF619	0.58	4.78	0.44	6.34e-6	Renal cell carcinoma;
THYM	cis	rs72827839	1.000	rs1472966	chr17:46430145	A/G	cg23391107	chr17:45924227	SP6	0.76	4.58	0.43	1.39e-5	Ease of getting up in the morning;
THYM	cis	rs6500395	1.000	rs7197732	chr16:48575878	G/A	cg04672837	chr16:48644449	N4BP1	0.47	4.46	0.42	2.23e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.96	7.01	0.58	3.39e-10	Smoking behavior;
THYM	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03576123	chr11:487126	PTDSS2	-1.52	-7.48	-0.61	3.64e-11	Body mass index;
THYM	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs10752881	0.935	rs10911235	chr1:183053746	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Colorectal cancer;
THYM	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg23173402	chr1:227635558	NA	0.68	6.07	0.53	2.59e-8	Major depressive disorder;
THYM	cis	rs1497406	0.744	rs6677710	chr1:16507618	A/G	cg20430773	chr1:16534157	ARHGEF19	0.47	5.17	0.47	1.32e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12667521	chr19:29218732	NA	0.89	8.17	0.64	1.34e-12	Methadone dose in opioid dependence;
THYM	cis	rs8180040	0.903	rs12487736	chr3:47459679	C/T	cg02527881	chr3:46936655	PTH1R	-0.62	-6.14	-0.53	1.9e-8	Colorectal cancer;
THYM	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg03188948	chr7:1209495	NA	0.91	5.04	0.46	2.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	11.87	0.77	1.78e-20	Chronic sinus infection;
THYM	cis	rs782590	0.935	rs6739513	chr2:55749902	G/A	cg03859395	chr2:55845619	SMEK2	0.66	6.08	0.53	2.51e-8	Metabolic syndrome;
THYM	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg26384229	chr12:38710491	ALG10B	0.99	7.62	0.62	1.85e-11	Bladder cancer;
THYM	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18402987	chr7:1209562	NA	0.77	5.88	0.52	6.22e-8	Longevity;Endometriosis;
THYM	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.59	-4.87	-0.45	4.53e-6	Bipolar disorder;
THYM	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.15e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7927592	0.546	rs599083	chr11:68192346	T/G	cg16797656	chr11:68205561	LRP5	0.54	6.19	0.54	1.52e-8	Total body bone mineral density;
THYM	cis	rs6960043	0.782	rs1558317	chr7:15065564	T/A	cg19272540	chr7:15055459	NA	-0.42	-4.67	-0.43	9.72e-6	Type 2 diabetes;
THYM	cis	rs4481887	0.741	rs7540715	chr1:248544206	C/T	cg00666640	chr1:248458726	OR2T12	0.55	4.73	0.44	7.65e-6	Common traits (Other);
THYM	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg10018233	chr7:150070692	REPIN1	-0.37	-5.34	-0.48	6.26e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs17125944	0.686	rs4450307	chr14:53334783	G/A	cg00686598	chr14:53173677	PSMC6	-1.08	-4.83	-0.44	5.23e-6	Alzheimer's disease (late onset);
THYM	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg24530246	chr3:53118167	NA	-0.77	-4.64	-0.43	1.1e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg03806693	chr22:41940476	POLR3H	0.98	8.1	0.64	1.84e-12	Vitiligo;
THYM	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg26384229	chr12:38710491	ALG10B	0.99	7.62	0.62	1.85e-11	Bladder cancer;
THYM	cis	rs6456042	1.000	rs6924688	chr6:166534443	T/G	cg11088901	chr6:166572345	T	-0.51	-4.78	-0.44	6.47e-6	Asthma;
THYM	cis	rs9640161	0.830	rs1051764	chr7:150070663	T/C	cg11327659	chr7:150037044	RARRES2	0.37	4.52	0.42	1.8e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs3126085	0.825	rs7535078	chr1:152222915	T/C	cg10321714	chr1:152280068	FLG	0.68	4.99	0.46	2.72e-6	Atopic dermatitis;
THYM	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	4.54	0.42	1.66e-5	Hip circumference adjusted for BMI;
THYM	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs2777491	0.668	rs2026946	chr15:41789704	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.04	-10.74	-0.74	4.42e-18	Ulcerative colitis;
THYM	cis	rs7107174	1.000	rs4627115	chr11:78007873	T/G	cg02023728	chr11:77925099	USP35	0.65	5.83	0.51	7.52e-8	Testicular germ cell tumor;
THYM	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg26384229	chr12:38710491	ALG10B	1.07	11.6	0.77	6.77e-20	Heart rate;
THYM	cis	rs72772090	0.539	rs11750464	chr5:96113031	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.77	4.63	0.43	1.17e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6840360	0.571	rs17275577	chr4:152519899	G/A	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg06558623	chr16:89946397	TCF25	1.39	6.26	0.54	1.09e-8	Skin colour saturation;
THYM	cis	rs7523273	0.925	rs6540443	chr1:208002010	T/A	cg22525895	chr1:207977042	MIR29B2	-0.83	-7.9	-0.63	4.95e-12	Schizophrenia;
THYM	cis	rs936229	0.784	rs12906946	chr15:75153140	A/G	cg14664628	chr15:75095509	CSK	-0.75	-5.77	-0.51	9.79e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs9768139	0.683	rs72505558	chr7:158113215	A/G	cg06219351	chr7:158114137	PTPRN2	-0.79	-8.18	-0.64	1.27e-12	Calcium levels;
THYM	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs2239547	0.618	rs2071041	chr3:52864693	T/G	cg11645453	chr3:52864694	ITIH4	0.3	4.53	0.42	1.73e-5	Schizophrenia;
THYM	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg11757124	chr7:157526947	PTPRN2	-0.65	-5.19	-0.47	1.21e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg09165964	chr15:75287851	SCAMP5	1.04	5.9	0.52	5.63e-8	Lung cancer;
THYM	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg12935359	chr14:103987150	CKB	-0.64	-6.25	-0.54	1.15e-8	Body mass index;
THYM	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs9826463	0.582	rs7633870	chr3:142118914	A/G	cg20824294	chr3:142316082	PLS1	0.77	5.31	0.48	7.08e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg00484396	chr16:3507460	NAT15	0.71	9.1	0.68	1.41e-14	Tuberculosis;
THYM	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.67	5.84	0.51	7.4e-8	Lung disease severity in cystic fibrosis;
THYM	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg18876405	chr7:65276391	NA	-0.56	-4.84	-0.44	5.06e-6	Calcium levels;
THYM	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg10253484	chr15:75165896	SCAMP2	0.68	4.56	0.42	1.5e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg22433210	chr17:43662623	NA	1.12	8.59	0.66	1.69e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs17253792	0.545	rs35230683	chr14:56012493	G/T	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-5.63	-0.5	1.84e-7	Chronic sinus infection;
THYM	cis	rs9611519	1.000	rs3818003	chr22:41609690	C/T	cg03806693	chr22:41940476	POLR3H	-0.74	-5.74	-0.51	1.12e-7	Neuroticism;
THYM	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg17143192	chr8:8559678	CLDN23	0.91	6.72	0.57	1.33e-9	Obesity-related traits;
THYM	cis	rs925255	0.776	rs2279990	chr2:28636740	C/T	cg01273330	chr2:28605224	NA	-0.59	-5.29	-0.48	7.75e-7	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg15556689	chr8:8085844	FLJ10661	-0.71	-5.84	-0.51	7.3900000000000007e-08	Mood instability;
THYM	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	4.51	0.42	1.83e-5	Calcium levels;
THYM	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg21984481	chr17:79567631	NPLOC4	0.61	6.88	0.58	6.43e-10	Eye color traits;
THYM	trans	rs2075230	0.642	rs1641528	chr17:7548320	A/G	cg04140212	chr2:85829138	TMEM150A	-0.58	-6.85	-0.57	7.26e-10	Hormone measurements;
THYM	cis	rs778371	0.649	rs283465	chr2:233666787	G/A	cg08000102	chr2:233561755	GIGYF2	0.73	5.98	0.52	3.92e-8	Schizophrenia;
THYM	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs6032067	0.714	rs3761194	chr20:43885935	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.59	-6.61	-0.56	2.25e-9	Blood protein levels;
THYM	cis	rs4919044	0.756	rs2478239	chr10:94806370	A/T	cg05127821	chr10:94822908	CYP26C1	-1.23	-6.66	-0.56	1.76e-9	Coronary artery disease;
THYM	cis	rs6032067	0.929	rs17424723	chr20:43814520	G/T	cg16667508	chr20:43936853	MATN4;RBPJL	0.79	8.45	0.65	3.42e-13	Blood protein levels;
THYM	cis	rs17122693	1.000	rs35014209	chr14:51054598	A/G	cg04730355	chr14:51134070	SAV1	1.03	5.3	0.48	7.62e-7	Cognitive performance;
THYM	cis	rs112591243	0.655	rs7510435	chr21:48059798	G/A	cg26697654	chr21:47851941	PCNT	0.83	4.58	0.43	1.39e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs17209837	0.607	rs4148810	chr7:87102251	C/T	cg04996195	chr7:87105398	ABCB4	0.63	4.84	0.44	5.09e-6	Gallbladder cancer;
THYM	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg16325326	chr1:53192061	ZYG11B	0.82	7.77	0.62	9e-12	Monocyte count;
THYM	cis	rs4660531	1.000	rs4660531	chr1:41839822	G/T	cg08462924	chr1:41848221	NA	0.63	5.9	0.52	5.61e-8	Bipolar disorder;
THYM	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg04447362	chr2:237654635	NA	0.48	4.49	0.42	2.03e-5	Prostate cancer;
THYM	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg16558253	chr16:72132732	DHX38	-0.66	-5.88	-0.52	6.13e-8	Fibrinogen levels;
THYM	cis	rs7122937	0.906	rs2074239	chr11:2485092	C/T	cg27115973	chr11:2481206	KCNQ1	0.62	6.22	0.54	1.3e-8	QT interval;
THYM	cis	rs586688	1.000	rs635979	chr1:201637811	C/T	cg07139329	chr1:201708558	NAV1	0.46	4.59	0.43	1.33e-5	Obesity-related traits;
THYM	cis	rs4930103	0.935	rs4930098	chr11:2020955	G/C	cg18511798	chr11:2018149	H19;MIR675	-0.57	-5.57	-0.5	2.39e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs2898681	0.837	rs2017237	chr4:53748515	A/G	cg00338735	chr4:53728038	RASL11B	0.57	5.14	0.47	1.47e-6	Optic nerve measurement (cup area);
THYM	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg20891283	chr12:69753455	YEATS4	0.72	5.57	0.5	2.34e-7	Response to diuretic therapy;
THYM	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg10803722	chr21:46713166	LOC642852	-0.41	-5.33	-0.48	6.47e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs137603	0.602	rs137654	chr22:39732413	C/T	cg24268161	chr22:39747459	SYNGR1	0.64	5.36	0.48	5.79e-7	Primary biliary cholangitis;
THYM	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg24678163	chr13:52769951	THSD1P	0.48	4.62	0.43	1.2e-5	Lewy body disease;
THYM	cis	rs533123	0.816	rs569356	chr1:29136686	A/G	cg08366446	chr1:29138936	OPRD1	-0.99	-4.74	-0.44	7.43e-6	Schizophrenia;
THYM	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg02524346	chr8:600233	NA	0.96	4.56	0.42	1.53e-5	IgG glycosylation;
THYM	cis	rs924712	0.677	rs239796	chr6:54802593	A/G	cg04690482	chr6:54711388	FAM83B	0.45	5.39	0.48	5.07e-7	Breast cancer;
THYM	trans	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg26384229	chr12:38710491	ALG10B	0.89	6.9	0.58	5.73e-10	Morning vs. evening chronotype;
THYM	cis	rs1823778	0.609	rs892767	chr18:67699093	C/T	cg13164537	chr18:67624071	CD226	1.11	4.94	0.45	3.28e-6	Mean platelet volume;
THYM	cis	rs977987	0.836	rs4888376	chr16:75322573	T/C	cg03315344	chr16:75512273	CHST6	0.83	6.98	0.58	4.01e-10	Dupuytren's disease;
THYM	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg22467129	chr15:76604101	ETFA	0.54	5.03	0.46	2.31e-6	Blood metabolite levels;
THYM	cis	rs4845875	0.513	rs198397	chr1:11883332	A/G	cg24844545	chr1:11908347	NPPA	-0.49	-4.87	-0.45	4.49e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs9916302	0.706	rs12950186	chr17:37393395	A/C	cg07936489	chr17:37558343	FBXL20	-0.79	-5.08	-0.46	1.92e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg13319975	chr6:146136371	FBXO30	-0.64	-5.24	-0.47	9.69e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg16558253	chr16:72132732	DHX38	-0.66	-6.01	-0.52	3.42e-8	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
THYM	cis	rs919433	0.680	rs2244271	chr2:198286581	C/T	cg05783139	chr2:198650985	BOLL	0.63	4.93	0.45	3.48e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4595586	0.545	rs7970307	chr12:39380760	A/C	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs346785	1.000	rs164106	chr17:74290566	C/A	cg09812376	chr17:74270190	QRICH2	-0.6	-6.9	-0.58	5.65e-10	White matter hyperintensities in ischemic stroke;
THYM	cis	rs13326165	0.585	rs6445385	chr3:52345459	A/G	cg08438690	chr3:52279403	PPM1M	-0.81	-4.74	-0.44	7.37e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs4924935	1.000	rs35341640	chr17:18818228	G/A	cg26378065	chr17:18585709	ZNF286B	-0.72	-5.3	-0.48	7.42e-7	Pancreatic cancer;
THYM	cis	rs1933112	1.000	rs2179500	chr1:168515827	A/G	cg00154920	chr1:168513310	XCL2	-0.5	-4.97	-0.45	2.97e-6	Blood protein levels;
THYM	cis	rs9959145	0.778	rs2186906	chr18:12572195	G/C	cg14160804	chr18:12703040	PSMG2;CEP76	-0.9	-4.47	-0.42	2.15e-5	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg26031613	chr14:104095156	KLC1	1.21	12.73	0.79	3.03e-22	Body mass index;
THYM	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg06221963	chr1:154839813	KCNN3	-0.77	-9.84	-0.71	3.56e-16	Prostate cancer;
THYM	cis	rs7084402	0.870	rs1896245	chr10:60276083	T/G	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	trans	rs8002861	0.875	rs12872943	chr13:44410553	G/A	cg17145862	chr1:211918768	LPGAT1	-0.85	-7.77	-0.62	9e-12	Leprosy;
THYM	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs3091242	0.728	rs706845	chr1:25730713	G/A	cg23205692	chr1:25664452	TMEM50A	0.84	6.41	0.55	5.63e-9	Erythrocyte sedimentation rate;
THYM	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg05425664	chr17:57184151	TRIM37	-0.58	-4.6	-0.43	1.31e-5	Intelligence (multi-trait analysis);
THYM	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg07167872	chr1:205819463	PM20D1	0.6	4.49	0.42	1.98e-5	Parkinson's disease;
THYM	cis	rs62244186	0.627	rs12386385	chr3:44457540	A/G	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.51	-5.11	-0.46	1.65e-6	Depressive symptoms;
THYM	cis	rs6450176	1.000	rs3776717	chr5:53298762	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.14	-0.53	1.94e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs9403317	0.700	rs55971403	chr6:141909478	C/T	cg15052665	chr6:141804349	NA	0.76	5.75	0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6430585	0.591	rs4585083	chr2:136486342	C/T	cg23851026	chr2:136556271	LCT	0.68	5.8	0.51	8.81e-8	Corneal structure;
THYM	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg04546413	chr19:29218101	NA	0.69	4.48	0.42	2.11e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	6.28	0.54	9.92e-9	Coronary artery disease;
THYM	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg11317459	chr13:21872234	NA	1.15	7.91	0.63	4.7e-12	White matter hyperintensity burden;
THYM	cis	rs2639990	1.000	rs1702831	chr18:72897368	C/A	cg18449964	chr18:72917101	ZADH2	1.29	6.2	0.54	1.48e-8	Vascular endothelial growth factor levels;
THYM	cis	rs2742234	0.518	rs1254967	chr10:43690391	G/A	cg06632098	chr10:43605906	RET	0.8	5.02	0.46	2.43e-6	Hirschsprung disease;
THYM	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7216064	0.953	rs4790981	chr17:65921834	A/G	cg12091567	chr17:66097778	LOC651250	-0.73	-5.18	-0.47	1.25e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6138458	1.000	rs6114984	chr20:24976610	A/G	cg06937882	chr20:24974362	C20orf3	-0.46	-4.64	-0.43	1.11e-5	Blood protein levels;
THYM	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.88	-7.81	-0.63	7.42e-12	Menarche (age at onset);
THYM	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg08885076	chr2:99613938	TSGA10	-0.69	-6.07	-0.53	2.66e-8	Chronic sinus infection;
THYM	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg23187316	chr7:1099788	C7orf50	0.58	4.45	0.42	2.32e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg10911889	chr6:126070802	HEY2	0.58	4.73	0.44	7.76e-6	Brugada syndrome;
THYM	cis	rs1629083	0.967	rs56356019	chr11:118114893	A/G	cg25155064	chr11:118100782	MPZL3	-0.57	-5.03	-0.46	2.34e-6	Lung cancer;
THYM	cis	rs11031096	0.678	rs1442727	chr11:4188188	G/T	cg18678763	chr11:4115507	RRM1	0.4	4.71	0.44	8.28e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg03609598	chr5:56110824	MAP3K1	-0.73	-4.69	-0.43	9.1e-6	Initial pursuit acceleration;
THYM	cis	rs17006441	0.932	rs56056340	chr3:69869008	T/C	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg10802521	chr3:52805072	NEK4	-0.8	-7.53	-0.61	2.92e-11	Bipolar disorder;
THYM	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg00990874	chr7:1149470	C7orf50	-0.7	-5.23	-0.47	1.03e-6	Bronchopulmonary dysplasia;
THYM	cis	rs10411161	0.702	rs7251929	chr19:52389258	C/T	cg25361850	chr19:52391789	ZNF577	0.74	5.18	0.47	1.22e-6	Breast cancer;
THYM	cis	rs6032067	0.516	rs6032087	chr20:43902305	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.59	-5.8	-0.51	8.72e-8	Blood protein levels;
THYM	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg12000587	chr17:30186630	C17orf79	0.48	6.98	0.58	4.04e-10	Hip circumference adjusted for BMI;
THYM	cis	rs72627123	0.867	rs11159040	chr14:74328799	G/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg05043794	chr9:111880884	C9orf5	-0.43	-6.21	-0.54	1.39e-8	Menarche (age at onset);
THYM	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg14004847	chr7:1930337	MAD1L1	0.67	5.38	0.48	5.35e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7512552	0.839	rs11587116	chr1:150451898	A/T	cg15654264	chr1:150340011	RPRD2	0.45	5.32	0.48	7.01e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs17597773	0.638	rs7530176	chr1:220989382	G/A	cg16008148	chr1:221062819	NA	0.41	4.54	0.42	1.62e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs977987	0.778	rs7203157	chr16:75417920	T/C	cg03315344	chr16:75512273	CHST6	0.73	6.17	0.53	1.66e-8	Dupuytren's disease;
THYM	cis	rs4805272	0.539	rs1422212	chr19:29330191	T/A	cg14983838	chr19:29218262	NA	0.84	5.48	0.49	3.49e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg11009520	chr8:12052164	FAM86B1	0.65	5.37	0.48	5.53e-7	Morning vs. evening chronotype;
THYM	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg23583168	chr7:148888333	NA	-1.02	-13.36	-0.81	1.58e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs73198271	0.813	rs56007835	chr8:8610026	G/A	cg06636001	chr8:8085503	FLJ10661	-0.84	-5.88	-0.52	6.15e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg03929089	chr4:120376271	NA	0.96	10.27	0.73	4.46e-17	Coronary artery disease;
THYM	cis	rs1467026	0.563	rs58674721	chr3:12811233	G/A	cg05775895	chr3:12838266	CAND2	0.87	7.21	0.59	1.34e-10	P wave duration;
THYM	cis	rs7843479	0.601	rs10101881	chr8:21830158	A/G	cg17168535	chr8:21777572	XPO7	0.83	6.98	0.58	4.01e-10	Mean corpuscular volume;
THYM	cis	rs7830933	0.868	rs6981261	chr8:23596063	C/T	cg04349084	chr8:23602677	NA	0.6	6.44	0.55	4.86e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs9796	0.870	rs11854472	chr15:41357687	G/A	cg21153102	chr15:41252147	NA	0.68	6.31	0.54	8.68e-9	Menopause (age at onset);
THYM	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.58	-0.5	2.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6456042	0.965	rs3099294	chr6:166530992	T/C	cg11088901	chr6:166572345	T	-0.52	-4.9	-0.45	3.9e-6	Asthma;
THYM	cis	rs8133932	0.520	rs380120	chr21:47364511	C/A	cg20357416	chr21:47294739	PCBP3	0.74	4.59	0.43	1.36e-5	Schizophrenia;
THYM	cis	rs28595532	0.920	rs115738062	chr4:119725490	C/T	cg14228332	chr4:119757509	SEC24D	1.36	5.21	0.47	1.12e-6	Cannabis dependence symptom count;
THYM	cis	rs9543976	0.614	rs4885308	chr13:76106493	G/C	cg01531495	chr13:76123901	UCHL3	-0.94	-5.26	-0.47	8.92e-7	Diabetic retinopathy;
THYM	cis	rs864643	0.812	rs7618019	chr3:39580111	T/A	cg20142358	chr3:39093977	WDR48	-0.69	-4.7	-0.43	8.94e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	6.67	0.56	1.66e-9	Prudent dietary pattern;
THYM	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg15445000	chr17:37608096	MED1	0.44	5.07	0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7027203	0.828	rs10761288	chr9:96609363	C/T	cg13679303	chr9:96623674	NA	-0.54	-5.6	-0.5	2.06e-7	DNA methylation (variation);
THYM	cis	rs10463554	0.963	rs154355	chr5:102498881	G/T	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.54e-6	Parkinson's disease;
THYM	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg16060761	chr17:80687452	NA	-0.65	-5.27	-0.48	8.4e-7	Glycated hemoglobin levels;
THYM	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg23803603	chr1:2058230	PRKCZ	-0.59	-5.04	-0.46	2.25e-6	Height;
THYM	cis	rs7119038	0.818	rs11826521	chr11:118610549	G/T	cg19308663	chr11:118741387	NA	0.56	5.21	0.47	1.09e-6	Sjögren's syndrome;
THYM	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.6	-0.5	2.08e-7	Type 2 diabetes;
THYM	cis	rs9534288	0.699	rs7139571	chr13:46662584	G/A	cg15192986	chr13:46630673	CPB2	-0.67	-4.69	-0.43	9.31e-6	Blood protein levels;
THYM	cis	rs72781680	0.898	rs72786276	chr2:24062566	G/A	cg08917208	chr2:24149416	ATAD2B	1.11	4.97	0.45	2.9e-6	Lymphocyte counts;
THYM	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	6.31	0.54	8.69e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs8070740	0.579	rs28429022	chr17:5354471	A/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.57	5.17	0.47	1.27e-6	Menopause (age at onset);
THYM	cis	rs10411161	0.702	rs7247017	chr19:52391769	T/C	cg25361850	chr19:52391789	ZNF577	0.72	4.87	0.45	4.42e-6	Breast cancer;
THYM	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg04944784	chr2:26401820	FAM59B	-1.05	-8.18	-0.64	1.23e-12	Gut microbiome composition (summer);
THYM	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.96	-8.51	-0.66	2.54e-13	Urate levels;
THYM	cis	rs9560113	1.000	rs9555810	chr13:112181437	C/G	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs995000	0.931	rs642845	chr1:62908235	T/C	cg06896770	chr1:63153194	DOCK7	0.91	7.48	0.61	3.73e-11	Triglyceride levels;
THYM	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg11266682	chr4:10021025	SLC2A9	-0.62	-7.75	-0.62	1e-11	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs34602589	0.535	rs7346579	chr20:43844722	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.71	-7.45	-0.61	4.34e-11	Parental longevity (mother's age at death);
THYM	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg25767906	chr1:53392781	SCP2	0.51	5.13	0.47	1.5e-6	Monocyte count;
THYM	cis	rs28595532	1.000	rs115965820	chr4:119586485	G/A	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs6450176	1.000	rs7736354	chr5:53297591	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.81	-6.03	-0.53	3.17e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg09359103	chr1:154839909	KCNN3	0.83	11.46	0.76	1.3e-19	Prostate cancer;
THYM	trans	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg26043149	chr18:55253948	FECH	1.21	11.52	0.76	9.63e-20	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg08736216	chr1:53307985	ZYG11A	-0.6	-5.56	-0.5	2.5e-7	Monocyte count;
THYM	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7582180	0.726	rs4438499	chr2:100876789	A/G	cg14675211	chr2:100938903	LONRF2	-0.53	-4.79	-0.44	6.1e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7631605	0.935	rs3733030	chr3:37170717	T/C	cg21328643	chr3:37258149	NA	-0.48	-4.49	-0.42	2.02e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs2625529	0.526	rs8032222	chr15:72479178	C/G	cg16672083	chr15:72433130	SENP8	0.5	4.56	0.42	1.55e-5	Red blood cell count;
THYM	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg26879891	chr1:152191343	HRNR	-0.56	-4.96	-0.45	3.07e-6	Inflammatory skin disease;
THYM	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg06108461	chr20:60628389	TAF4	-0.87	-7.25	-0.6	1.1e-10	Body mass index;
THYM	cis	rs3126085	0.935	rs11204947	chr1:152218257	G/T	cg26020982	chr1:152196106	HRNR	-0.35	-4.53	-0.42	1.69e-5	Atopic dermatitis;
THYM	cis	rs7192750	0.586	rs8057124	chr16:71972409	T/C	cg06353428	chr16:71660113	MARVELD3	0.72	5.13	0.47	1.5e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs12579753	0.956	rs35278765	chr12:82173126	T/C	cg21231944	chr12:82153410	PPFIA2	-0.68	-5.16	-0.47	1.36e-6	Resting heart rate;
THYM	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.5	-0.49	3.18e-7	Obesity-related traits;
THYM	trans	rs7615952	0.575	rs35949599	chr3:125544202	G/A	cg07211511	chr3:129823064	LOC729375	-0.92	-7.14	-0.59	1.85e-10	Blood pressure (smoking interaction);
THYM	cis	rs11225247	0.772	rs61895376	chr11:102227892	A/G	cg11690896	chr11:102217788	BIRC2	1.12	5.18	0.47	1.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs198426	0.506	rs11230766	chr11:61426582	A/T	cg23976388	chr11:61510081	DAGLA	-0.52	-4.99	-0.46	2.7e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
THYM	cis	rs791888	0.728	rs2255682	chr10:89419873	C/G	cg10377144	chr10:89419177	PAPSS2	-0.41	-6.58	-0.56	2.53e-9	Magnesium levels;
THYM	cis	rs7584330	0.740	rs13418586	chr2:238445593	A/G	cg16989719	chr2:238392110	NA	-0.48	-4.79	-0.44	6.23e-6	Prostate cancer;
THYM	cis	rs9818758	0.882	rs74926817	chr3:49378833	C/G	cg00383909	chr3:49044727	WDR6	0.77	5.05	0.46	2.16e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs990171	0.913	rs6729638	chr2:102996022	C/T	cg13897122	chr2:103039542	IL18RAP	-0.39	-4.79	-0.44	6.08e-6	Lymphocyte counts;
THYM	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	-0.62	-5.26	-0.48	8.71e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg11663144	chr21:46675770	NA	0.68	8.1	0.64	1.89e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.62	0.43	1.23e-5	Obesity-related traits;
THYM	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg27034606	chr17:28928453	LRRC37B2	0.76	5.06	0.46	2.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6754311	0.551	rs2304599	chr2:136528004	C/G	cg07169764	chr2:136633963	MCM6	-0.71	-6.02	-0.53	3.2e-8	Mosquito bite size;
THYM	cis	rs1160297	0.609	rs12713231	chr2:53105695	C/G	cg07782112	chr2:53107842	NA	0.75	6.06	0.53	2.78e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg12826209	chr6:26865740	GUSBL1	0.84	6.07	0.53	2.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4773144	1.000	rs4773144	chr13:110960712	A/G	cg02050376	chr13:109984684	NA	0.24	4.69	0.43	9.11e-6	Coronary artery disease;Coronary heart disease;
THYM	cis	rs1395	0.778	rs1439767	chr2:27389634	A/G	cg23587288	chr2:27483067	SLC30A3	-0.6	-5.25	-0.47	9.17e-7	Blood metabolite levels;
THYM	cis	rs10929159	0.928	rs7565059	chr2:236926347	A/G	cg14895183	chr2:236924282	AGAP1	0.55	4.71	0.43	8.58e-6	Parkinson's disease;
THYM	cis	rs654950	1.000	rs600401	chr1:41984658	C/T	cg06885757	chr1:42089581	HIVEP3	0.53	6.98	0.58	4.02e-10	Airway imaging phenotypes;
THYM	trans	rs10962692	0.569	rs62541922	chr9:16870182	T/C	cg03221025	chr16:88955224	CBFA2T3	0.75	7.2	0.59	1.37e-10	Ovarian cancer in BRCA2 mutation carriers;Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;
THYM	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg13695892	chr22:41940480	POLR3H	0.85	6.16	0.53	1.72e-8	Vitiligo;
THYM	cis	rs12519773	0.597	rs4308464	chr5:92468867	G/C	cg18783429	chr5:92414398	NA	0.49	4.84	0.44	4.99e-6	Migraine;
THYM	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg27129171	chr3:47204927	SETD2	0.81	7.95	0.63	3.9e-12	Colorectal cancer;
THYM	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg16624210	chr5:671434	TPPP	0.68	4.86	0.45	4.65e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs7618501	0.521	rs3774759	chr3:49939120	G/T	cg14019146	chr3:50243930	SLC38A3	-0.61	-5.14	-0.47	1.45e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8032315	1.000	rs2071410	chr15:91420940	C/G	cg04510874	chr15:91427884	FES	0.61	4.57	0.42	1.44e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7100689	0.753	rs4934125	chr10:82147466	T/C	cg01528321	chr10:82214614	TSPAN14	0.99	7.52	0.61	3.07e-11	Post bronchodilator FEV1;
THYM	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.43	0.61	4.69e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs988913	1.000	rs6922438	chr6:54841383	A/C	cg04690482	chr6:54711388	FAM83B	0.46	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	cis	rs3087591	0.960	rs2952998	chr17:29418412	T/C	cg24425628	chr17:29625626	OMG;NF1	0.65	5.59	0.5	2.16e-7	Hip circumference;
THYM	cis	rs2976388	1.000	rs2920297	chr8:143763083	A/G	cg06565975	chr8:143823917	SLURP1	-0.45	-5.23	-0.47	9.95e-7	Urinary tract infection frequency;
THYM	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	5.53	0.49	2.86e-7	Tonsillectomy;
THYM	cis	rs2219968	0.962	rs6995342	chr8:78951749	A/T	cg00738934	chr8:78996279	NA	0.8	8.43	0.65	3.79e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9790314	0.967	rs9821201	chr3:160996155	G/C	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs7084402	0.935	rs12248958	chr10:60278255	G/A	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs2070433	0.559	rs11089057	chr21:47721228	T/A	cg12379764	chr21:47803548	PCNT	0.98	5.58	0.5	2.24e-7	Lymphocyte counts;
THYM	cis	rs34638657	0.872	rs7192444	chr16:82180338	C/G	cg09894383	chr16:82067445	HSD17B2	0.53	5.45	0.49	3.95e-7	Lung adenocarcinoma;
THYM	cis	rs9303280	0.559	rs4795408	chr17:38107627	G/A	cg24910161	chr17:38119198	GSDMA	-0.55	-6.86	-0.58	6.96e-10	Self-reported allergy;
THYM	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg02887458	chr19:19495540	GATAD2A	-0.49	-5.38	-0.48	5.37e-7	Bipolar disorder;
THYM	cis	rs11792861	0.591	rs2275641	chr9:111696389	G/C	cg05043794	chr9:111880884	C9orf5	-0.34	-4.74	-0.44	7.54e-6	Menarche (age at onset);
THYM	cis	rs67460515	0.563	rs4521287	chr3:160812752	C/T	cg03342759	chr3:160939853	NMD3	-0.62	-4.65	-0.43	1.07e-5	Parkinson's disease;
THYM	cis	rs4478037	0.818	rs17522946	chr3:33138777	A/G	cg19404215	chr3:33155277	CRTAP	0.97	6.66	0.56	1.74e-9	Major depressive disorder;
THYM	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg08470875	chr2:26401718	FAM59B	0.74	4.59	0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs969413	0.535	rs8077394	chr17:79258787	A/G	cg15215033	chr17:79258732	SLC38A10	0.39	4.8	0.44	5.84e-6	Frontotemporal dementia;
THYM	cis	rs7100689	0.646	rs10749573	chr10:82136839	T/A	cg01528321	chr10:82214614	TSPAN14	0.79	6.01	0.52	3.47e-8	Post bronchodilator FEV1;
THYM	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg25767906	chr1:53392781	SCP2	-0.58	-5.87	-0.52	6.47e-8	Monocyte count;
THYM	cis	rs2625529	0.618	rs6494992	chr15:72420750	G/C	cg16672083	chr15:72433130	SENP8	0.5	4.54	0.42	1.65e-5	Red blood cell count;
THYM	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.65	-4.7	-0.43	8.92e-6	Colorectal cancer;
THYM	cis	rs9649213	0.614	rs3944111	chr7:98005766	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.68	-5.75	-0.51	1.08e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs7084402	0.967	rs1649025	chr10:60281584	C/G	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs2067615	0.560	rs4964485	chr12:107121952	A/G	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs791888	0.858	rs1555434	chr10:89419143	G/C	cg10377144	chr10:89419177	PAPSS2	-0.43	-7.45	-0.61	4.31e-11	Magnesium levels;
THYM	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg13175981	chr1:150552382	MCL1	0.78	5.82	0.51	7.84e-8	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
THYM	cis	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg07460842	chr6:66804631	NA	0.94	5.94	0.52	4.75e-8	Exhaled nitric oxide levels;
THYM	cis	rs89107	0.576	rs11967375	chr6:118823975	A/G	cg21191810	chr6:118973309	C6orf204	0.52	5.14	0.47	1.46e-6	Cardiac structure and function;
THYM	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.72	0.51	1.23e-7	Lung cancer in ever smokers;
THYM	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg13147721	chr7:65941812	NA	0.73	4.58	0.43	1.42e-5	Diabetic kidney disease;
THYM	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.9	-7.42	-0.61	4.94e-11	Chronic sinus infection;
THYM	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06873352	chr17:61820015	STRADA	0.75	8.77	0.67	7.17e-14	Prudent dietary pattern;
THYM	cis	rs13315871	1.000	rs11708590	chr3:58336635	A/G	cg00563845	chr3:58318305	PXK	-0.55	-4.84	-0.45	4.93e-6	Cholesterol, total;
THYM	cis	rs10992471	0.603	rs7872610	chr9:95299137	G/C	cg14631576	chr9:95140430	CENPP	-0.97	-8.65	-0.66	1.29e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7649443	0.758	rs34305944	chr3:197015418	C/A	cg20744464	chr3:196756875	MFI2	0.62	4.56	0.42	1.53e-5	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs2439831	1.000	rs2584726	chr15:43715382	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg18904891	chr8:8559673	CLDN23	-0.57	-4.86	-0.45	4.71e-6	Mood instability;
THYM	cis	rs9515201	0.627	rs952359	chr13:111026734	G/A	cg05272587	chr13:111038400	COL4A2	-0.53	-4.63	-0.43	1.17e-5	White matter hyperintensity burden;
THYM	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg06850241	chr22:41845214	NA	0.54	4.6	0.43	1.33e-5	Vitiligo;
THYM	cis	rs28595532	0.920	rs115500312	chr4:119752551	G/A	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg21657705	chr17:61574500	ACE	0.43	4.65	0.43	1.06e-5	Prudent dietary pattern;
THYM	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg22681709	chr2:178499509	PDE11A	-0.54	-4.77	-0.44	6.57e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg12963246	chr6:28129442	ZNF389	0.56	5.05	0.46	2.12e-6	Cardiac Troponin-T levels;
THYM	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg18876405	chr7:65276391	NA	0.57	4.73	0.44	7.67e-6	Aortic root size;
THYM	cis	rs925255	0.810	rs1396733	chr2:28642747	A/C	cg01273330	chr2:28605224	NA	0.53	5.11	0.46	1.66e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7772486	0.817	rs12198065	chr6:146385286	G/C	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs72829446	0.556	rs9907042	chr17:7402985	A/G	cg02795151	chr17:7402630	POLR2A	-0.54	-5.58	-0.5	2.23e-7	Androgen levels;
THYM	cis	rs1395	0.744	rs1122227	chr2:27544285	C/T	cg23587288	chr2:27483067	SLC30A3	-0.6	-5.04	-0.46	2.25e-6	Blood metabolite levels;
THYM	cis	rs7582180	0.903	rs13031712	chr2:100896512	G/A	cg14675211	chr2:100938903	LONRF2	0.64	5.43	0.49	4.28e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7804356	0.798	rs727448	chr7:26787426	T/C	cg24979288	chr7:27242424	NA	0.62	4.46	0.42	2.26e-5	Type 1 diabetes;
THYM	cis	rs28595532	0.920	rs17259284	chr4:119779298	T/C	cg14228332	chr4:119757509	SEC24D	1.59	5.76	0.51	1.02e-7	Cannabis dependence symptom count;
THYM	cis	rs57994353	0.667	rs11145930	chr9:139304016	C/T	cg14115884	chr9:139300582	SDCCAG3	0.56	4.47	0.42	2.2e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg18305652	chr10:134549665	INPP5A	0.86	7.82	0.63	7.22e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg12031863	chr16:4587854	C16orf5	-0.46	-5.09	-0.46	1.77e-6	Schizophrenia;
THYM	trans	rs10962692	0.608	rs10962649	chr9:16873535	C/T	cg03221025	chr16:88955224	CBFA2T3	0.75	7.2	0.59	1.37e-10	Ovarian cancer in BRCA2 mutation carriers;Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;
THYM	cis	rs28595532	0.764	rs115986119	chr4:119767785	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs1802575	0.935	rs10199082	chr2:56040099	T/C	cg22104478	chr2:55845289	SMEK2	0.96	4.53	0.42	1.71e-5	Childhood ear infection;
THYM	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg05738196	chr6:26577821	NA	0.57	4.7	0.43	8.72e-6	Schizophrenia;
THYM	cis	rs790123	1.000	rs790125	chr3:122388464	A/G	cg15604389	chr3:122379662	NA	0.56	4.97	0.45	2.96e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs4363385	0.747	rs4845507	chr1:152968414	T/G	cg13444842	chr1:152974279	SPRR3	-0.57	-4.51	-0.42	1.88e-5	Inflammatory skin disease;
THYM	cis	rs9677476	0.863	rs2006780	chr2:232066704	T/G	cg07929768	chr2:232055508	NA	0.61	6.17	0.54	1.63e-8	Food antigen IgG levels;
THYM	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg21784768	chr11:537496	LRRC56	-1.37	-6.17	-0.53	1.7e-8	Body mass index;
THYM	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg05182265	chr7:156933206	UBE3C	-0.69	-9.34	-0.69	4.32e-15	Body mass index;
THYM	cis	rs11756438	0.572	rs2798328	chr6:119005378	C/T	cg21191810	chr6:118973309	C6orf204	0.56	5.47	0.49	3.57e-7	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs79387448	0.655	rs77763678	chr2:102916749	G/A	cg09003973	chr2:102972529	NA	1.25	6.26	0.54	1.12e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs2070488	0.965	rs9829192	chr3:38569463	G/T	cg24069376	chr3:38537580	EXOG	-0.64	-6.19	-0.54	1.54e-8	Electrocardiographic conduction measures;
THYM	cis	rs11645898	0.504	rs79489472	chr16:71870359	C/T	cg03805757	chr16:71968109	PKD1L3	-0.85	-6.36	-0.55	6.87e-9	Blood protein levels;
THYM	cis	rs146009840	1	rs146009840	chr15:78906177	A/T	cg04882995	chr15:78912658	CHRNA3	0.54	4.55	0.42	1.61e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg22907277	chr7:1156413	C7orf50	0.77	4.62	0.43	1.18e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs611744	0.967	rs677330	chr8:109177572	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs6138458	0.701	rs6138474	chr20:25012427	T/A	cg26195577	chr20:24973756	C20orf3	0.75	6.04	0.53	2.94e-8	Blood protein levels;
THYM	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg17366294	chr4:99064904	C4orf37	0.6	7.47	0.61	3.94e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.6	-0.5	2.08e-7	Type 2 diabetes;
THYM	cis	rs9790314	0.686	rs2306061	chr3:160787502	C/T	cg04691961	chr3:161091175	C3orf57	-0.61	-4.7	-0.43	8.63e-6	Morning vs. evening chronotype;
THYM	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg05234568	chr11:5960015	NA	-0.62	-4.97	-0.45	2.95e-6	DNA methylation (variation);
THYM	cis	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs7772486	0.754	rs1415747	chr6:146077249	A/G	cg23711669	chr6:146136114	FBXO30	0.96	10.51	0.73	1.35e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg10802521	chr3:52805072	NEK4	-0.72	-5.99	-0.52	3.74e-8	Bipolar disorder;
THYM	cis	rs62070183	0.938	rs17183176	chr17:31054125	T/C	cg02981443	chr17:31254875	TMEM98	-0.54	-4.81	-0.44	5.69e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg09877947	chr5:131593287	PDLIM4	0.65	5.63	0.5	1.86e-7	Blood metabolite levels;
THYM	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg00256281	chr22:41985642	PMM1	-0.63	-5.17	-0.47	1.29e-6	Vitiligo;
THYM	cis	rs220324	0.688	rs2012103	chr21:43561369	A/G	cg09727148	chr21:43560719	UMODL1	0.82	9.94	0.71	2.25e-16	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.87	-0.45	4.45e-6	Eye color traits;
THYM	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg18876405	chr7:65276391	NA	-0.64	-5.54	-0.49	2.68e-7	Aortic root size;
THYM	cis	rs6450176	1.000	rs6876198	chr5:53303595	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.14	-0.53	1.94e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs11214589	0.747	rs10891536	chr11:113209428	C/G	cg14159747	chr11:113255604	NA	0.29	5.7	0.5	1.37e-7	Neuroticism;
THYM	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg06634786	chr22:41940651	POLR3H	-0.66	-4.76	-0.44	6.97e-6	Vitiligo;
THYM	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.43	-0.49	4.24e-7	Mean corpuscular volume;
THYM	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg08048268	chr3:133502702	NA	-0.61	-4.76	-0.44	6.79e-6	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg11245990	chr11:68621969	NA	0.56	7.2	0.59	1.38e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg08859206	chr1:53392774	SCP2	-0.51	-5.32	-0.48	6.88e-7	Monocyte count;
THYM	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.52e-7	Heart rate;
THYM	cis	rs995000	0.899	rs1168031	chr1:62967987	C/T	cg06896770	chr1:63153194	DOCK7	-0.91	-7.48	-0.61	3.62e-11	Triglyceride levels;
THYM	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg13289132	chr10:30722225	MAP3K8	-0.61	-5.04	-0.46	2.21e-6	Inflammatory bowel disease;
THYM	cis	rs11676855	0.893	rs6431329	chr2:235934338	C/T	cg14917874	chr2:235941519	SH3BP4	0.6	5.44	0.49	4.13e-7	Dialysis-related mortality;
THYM	cis	rs7084402	0.967	rs1346302	chr10:60267137	G/A	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs73206853	0.841	rs55741511	chr12:110880613	G/T	cg24010859	chr12:110868153	NA	0.61	4.45	0.42	2.33e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
THYM	cis	rs7119	0.679	rs34075648	chr15:77847802	G/C	cg10437265	chr15:77819839	NA	0.68	6.22	0.54	1.33e-8	Type 2 diabetes;
THYM	cis	rs17826219	0.585	rs8064302	chr17:28724938	G/A	cg17105886	chr17:28927953	LRRC37B2	-1.11	-4.91	-0.45	3.75e-6	Body mass index;
THYM	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg22875332	chr1:76189707	ACADM	0.82	7.41	0.61	5.21e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9733	0.596	rs12085275	chr1:150650265	T/C	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg13902645	chr11:5959945	NA	0.55	4.85	0.45	4.84e-6	DNA methylation (variation);
THYM	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg25072359	chr17:41440525	NA	0.64	4.46	0.42	2.28e-5	Menopause (age at onset);
THYM	cis	rs11711311	1.000	rs12637066	chr3:113527574	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.59	-5.13	-0.47	1.52e-6	IgG glycosylation;
THYM	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg16989719	chr2:238392110	NA	-0.66	-5.38	-0.48	5.29e-7	Prostate cancer;
THYM	cis	rs9921192	0.967	rs3747571	chr16:4323983	A/G	cg00021532	chr16:4324280	TFAP4	0.87	7.89	0.63	5.09e-12	Prostate-specific antigen levels;
THYM	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.37	-0.48	5.64e-7	Total cholesterol levels;
THYM	cis	rs910187	0.571	rs6512428	chr20:45807822	T/C	cg27589058	chr20:45804311	EYA2	-0.68	-6.03	-0.53	3.15e-8	Migraine;
THYM	cis	rs9902453	0.791	rs9904051	chr17:28244122	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	5.39	0.48	5.11e-7	Coffee consumption (cups per day);
THYM	cis	rs289828	0.538	rs9287956	chr2:152154006	C/T	cg05960677	chr2:152117363	RBM43	0.71	6.61	0.56	2.24e-9	Blood protein levels;
THYM	cis	rs9595908	0.865	rs743760	chr13:33071127	C/G	cg12383807	chr13:33924137	NA	0.52	4.46	0.42	2.21e-5	Body mass index;
THYM	cis	rs4589258	1.000	rs4423148	chr11:90496453	T/A	cg26138821	chr11:89956704	CHORDC1	-0.58	-4.7	-0.43	8.8e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs3106136	0.546	rs7685121	chr4:95175682	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.2	-0.47	1.14e-6	Capecitabine sensitivity;
THYM	cis	rs7172809	0.599	rs12324795	chr15:77739786	T/C	cg10437265	chr15:77819839	NA	-0.5	-4.57	-0.42	1.47e-5	Glucose homeostasis traits;
THYM	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg11494091	chr17:61959527	GH2	1.08	16.72	0.86	4.66e-30	Prudent dietary pattern;
THYM	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg04315214	chr1:2043799	PRKCZ	0.68	5.67	0.5	1.54e-7	Height;
THYM	cis	rs7917772	0.582	rs10786698	chr10:104378750	G/A	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1499972	0.878	rs1093463	chr3:117744762	C/T	cg07612923	chr3:117604196	NA	-1.5	-5.16	-0.47	1.38e-6	Schizophrenia;
THYM	cis	rs9816226	0.590	rs869401	chr3:185826546	G/A	cg00760338	chr3:185826511	ETV5	0.88	7.62	0.62	1.86e-11	Obesity;Body mass index;
THYM	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg18402987	chr7:1209562	NA	1.15	7.17	0.59	1.6e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4820539	0.934	rs3788351	chr22:23469181	T/C	cg14186256	chr22:23484241	RTDR1	0.92	8.58	0.66	1.79e-13	Bone mineral density;
THYM	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg06618935	chr21:46677482	NA	-0.95	-8.15	-0.64	1.45e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg18132916	chr6:79620363	NA	-0.55	-4.78	-0.44	6.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.86	-0.45	4.62e-6	Eye color traits;
THYM	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg04414720	chr1:150670196	GOLPH3L	0.62	4.71	0.44	8.35e-6	Tonsillectomy;
THYM	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg10523679	chr1:76189770	ACADM	0.93	7.09	0.59	2.37e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg21827317	chr3:136751795	NA	0.97	12.62	0.79	5.13e-22	Schizophrenia;
THYM	cis	rs911263	0.961	rs2104047	chr14:68754417	T/C	cg18825221	chr14:68749962	RAD51L1	0.58	6.44	0.55	4.93e-9	Primary biliary cholangitis;
THYM	cis	rs1696756	0.816	rs2650242	chr17:77827360	A/T	cg00646381	chr17:77835854	NA	0.39	4.6	0.43	1.3e-5	Glucocorticoid-induced osteonecrosis (age 10 years and older);
THYM	cis	rs2795502	0.564	rs11239840	chr10:43439353	C/T	cg08461752	chr10:43522343	NA	-0.76	-4.62	-0.43	1.2e-5	Blood protein levels;
THYM	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg10523679	chr1:76189770	ACADM	-0.57	-4.81	-0.44	5.56e-6	Daytime sleep phenotypes;
THYM	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg02869364	chr7:1081709	C7orf50	0.44	5.1	0.46	1.73e-6	Longevity;Endometriosis;
THYM	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg06009448	chr7:1102226	C7orf50	0.53	5.55	0.49	2.6e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10744422	1.000	rs936083	chr12:123338964	A/G	cg25930673	chr12:123319894	HIP1R	-0.86	-4.84	-0.44	5.09e-6	Schizophrenia;
THYM	trans	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg10856724	chr12:34555212	NA	-0.87	-7.75	-0.62	9.89e-12	Morning vs. evening chronotype;
THYM	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg22166914	chr1:53195759	ZYG11B	0.9	10.44	0.73	1.91e-17	Monocyte count;
THYM	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg03806693	chr22:41940476	POLR3H	0.95	7.85	0.63	6.34e-12	Vitiligo;
THYM	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg10792982	chr14:105748885	BRF1	0.72	7.48	0.61	3.62e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg19770292	chr5:1868693	NA	0.54	4.95	0.45	3.26e-6	Cardiovascular disease risk factors;
THYM	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg09307838	chr4:120376055	NA	0.7	5.08	0.46	1.85e-6	Corneal astigmatism;
THYM	cis	rs1371867	0.817	rs1788185	chr8:101335529	T/C	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg12386194	chr3:101231763	SENP7	0.97	7.83	0.63	6.87e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg27446573	chr6:127587934	RNF146	0.59	4.47	0.42	2.19e-5	Breast cancer;
THYM	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg05043794	chr9:111880884	C9orf5	-0.43	-6.35	-0.55	7.29e-9	Menarche (age at onset);
THYM	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg21475434	chr5:93447410	FAM172A	0.71	4.51	0.42	1.83e-5	Diabetic retinopathy;
THYM	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg17054759	chr22:49844102	NA	-0.48	-4.49	-0.42	2e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs1178127	0.542	rs10950704	chr7:18836179	A/G	cg13420273	chr7:18810212	HDAC9	-0.61	-5.28	-0.48	8.17e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg12310025	chr6:25882481	NA	-0.66	-5.04	-0.46	2.22e-6	Height;
THYM	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg27034606	chr17:28928453	LRRC37B2	0.82	5.25	0.47	9.11e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8192282	0.739	rs4575077	chr1:154495011	C/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg07511668	chr11:68622177	NA	0.43	4.56	0.42	1.52e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg23791538	chr6:167370224	RNASET2	0.74	5.92	0.52	5.06e-8	Crohn's disease;
THYM	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17174870	0.955	rs78116208	chr2:112769801	C/T	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs7216064	0.953	rs58141639	chr17:65864902	C/T	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.87	-9.14	-0.68	1.12e-14	Schizophrenia;
THYM	cis	rs13082711	0.911	rs11717669	chr3:27458484	C/T	cg02860705	chr3:27208620	NA	0.83	5.64	0.5	1.72e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg18132916	chr6:79620363	NA	-0.55	-4.78	-0.44	6.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg18105134	chr13:113819100	PROZ	-0.98	-9.05	-0.68	1.79e-14	Platelet distribution width;
THYM	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-5.76	-0.51	1.03e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs8141529	0.719	rs132561	chr22:29351179	C/T	cg02153584	chr22:29168773	CCDC117	-0.62	-4.67	-0.43	9.96e-6	Lymphocyte counts;
THYM	cis	rs56104184	0.887	rs16982311	chr19:49342188	C/T	cg21252483	chr19:49399788	TULP2	-0.68	-4.73	-0.44	7.8e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2742234	0.590	rs2435337	chr10:43661836	G/C	cg06632098	chr10:43605906	RET	-0.79	-5.1	-0.46	1.73e-6	Hirschsprung disease;
THYM	cis	rs7428	0.545	rs4832163	chr2:85541083	T/C	cg24342717	chr2:85555507	TGOLN2	-0.74	-6.59	-0.56	2.43e-9	Ear protrusion;
THYM	cis	rs7100689	0.784	rs10887838	chr10:82161380	G/A	cg03086067	chr10:82368399	SH2D4B	-0.48	-4.55	-0.42	1.58e-5	Post bronchodilator FEV1;
THYM	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg03909863	chr11:638404	DRD4	-0.76	-6.04	-0.53	2.95e-8	Systemic lupus erythematosus;
THYM	cis	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg18512352	chr11:47633146	NA	-0.38	-4.52	-0.42	1.75e-5	HDL cholesterol;
THYM	cis	rs9359856	0.623	rs1179906	chr6:90323624	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.78	-7.61	-0.62	1.99e-11	Bipolar disorder;
THYM	cis	rs12149862	1.000	rs12102486	chr16:69464474	C/T	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs7394190	0.748	rs4746147	chr10:75527708	A/G	cg07699608	chr10:75541558	CHCHD1	0.91	4.93	0.45	3.49e-6	Incident atrial fibrillation;
THYM	cis	rs7119	0.634	rs11635634	chr15:77863412	T/C	cg27398640	chr15:77910606	LINGO1	0.62	7.21	0.59	1.33e-10	Type 2 diabetes;
THYM	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.53	-4.47	-0.42	2.13e-5	Height;
THYM	cis	rs17102423	0.588	rs7150646	chr14:65540463	G/T	cg11161011	chr14:65562177	MAX	-0.7	-5.74	-0.51	1.12e-7	Obesity-related traits;
THYM	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs73198271	0.681	rs11987924	chr8:8649972	T/C	cg15556689	chr8:8085844	FLJ10661	-0.74	-4.91	-0.45	3.75e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs293526	0.879	rs2770675	chr6:83705017	G/A	cg23278060	chr6:83777448	DOPEY1	0.61	4.46	0.42	2.24e-5	Crohn's disease;
THYM	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.75	-0.44	7.21e-6	Mean corpuscular volume;
THYM	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg12560992	chr17:57184187	TRIM37	-0.76	-6.41	-0.55	5.54e-9	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg13609457	chr4:120235615	NA	-0.56	-5.24	-0.47	9.65e-7	Corneal astigmatism;
THYM	cis	rs1642645	0.915	rs10890177	chr1:42506381	T/C	cg10197057	chr1:42612518	NA	0.45	4.84	0.44	4.96e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs899997	0.862	rs12912524	chr15:78952756	G/A	cg00639195	chr15:79103007	ADAMTS7	-0.76	-5.09	-0.46	1.81e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12923728	chr3:195709715	SDHAP1	-0.78	-6.29	-0.54	9.85e-9	Pancreatic cancer;
THYM	cis	rs6430585	0.528	rs895285	chr2:136710554	A/G	cg04750100	chr2:136595281	LCT	0.56	4.94	0.45	3.41e-6	Corneal structure;
THYM	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg06850241	chr22:41845214	NA	0.54	4.68	0.43	9.37e-6	Vitiligo;
THYM	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	4.7	0.43	8.72e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg09184832	chr6:79620586	NA	-0.58	-4.53	-0.42	1.68e-5	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg24675658	chr1:53192096	ZYG11B	-0.65	-5.24	-0.47	9.68e-7	Monocyte count;
THYM	cis	rs8048589	1.000	rs13336687	chr16:12187065	C/T	cg02910054	chr16:12241554	SNX29	0.69	5.7	0.5	1.36e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs6840360	1.000	rs6839074	chr4:152603357	A/G	cg22705602	chr4:152727874	NA	0.63	6.81	0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs13315871	0.929	rs13322000	chr3:58286929	G/A	cg12435725	chr3:58293450	RPP14	-0.53	-5.57	-0.5	2.32e-7	Cholesterol, total;
THYM	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs2038823	1.000	rs11618119	chr13:96946102	A/G	cg25169784	chr13:96706045	UGGT2	0.81	4.49	0.42	1.99e-5	Diabetic retinopathy;
THYM	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22455342	chr2:225449267	CUL3	-1.01	-8.22	-0.64	1.04e-12	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs62070183	0.808	rs76373015	chr17:31142041	C/A	cg02981443	chr17:31254875	TMEM98	-0.52	-4.72	-0.44	8.04e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs7119038	0.774	rs7945144	chr11:118608716	A/G	cg19308663	chr11:118741387	NA	0.46	4.61	0.43	1.24e-5	Sjögren's syndrome;
THYM	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg15164180	chr2:241846931	NA	-0.37	-4.96	-0.45	3.07e-6	Urinary metabolites;
THYM	trans	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg10856724	chr12:34555212	NA	-1.01	-8.89	-0.67	3.83e-14	Bladder cancer;
THYM	cis	rs4589258	1.000	rs9651551	chr11:90502896	C/T	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.93	-0.45	3.5e-6	Intelligence (multi-trait analysis);
THYM	cis	rs56104184	0.775	rs73061689	chr19:49397214	C/T	cg21252483	chr19:49399788	TULP2	-0.91	-6.15	-0.53	1.83e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg26752003	chr8:145688521	CYHR1	-0.59	-4.86	-0.45	4.65e-6	Age at first birth;
THYM	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg11764359	chr7:65958608	NA	-0.65	-4.98	-0.45	2.84e-6	Aortic root size;
THYM	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg04654363	chr8:8581213	NA	-0.48	-4.62	-0.43	1.22e-5	Obesity-related traits;
THYM	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg00376283	chr12:123451042	ABCB9	-0.62	-4.53	-0.42	1.72e-5	Neutrophil percentage of white cells;
THYM	cis	rs6032067	0.636	rs6104092	chr20:43906730	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	0.62	5.74	0.51	1.14e-7	Blood protein levels;
THYM	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	10.77	0.74	3.77e-18	Chronic sinus infection;
THYM	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.65	4.84	0.45	4.95e-6	Lung cancer in ever smokers;
THYM	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg25811766	chr13:21894605	NA	-0.76	-4.92	-0.45	3.62e-6	White matter hyperintensity burden;
THYM	cis	rs1062746	0.528	rs12149622	chr16:87340235	A/G	cg02258303	chr16:87377426	FBXO31	-0.62	-4.94	-0.45	3.33e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs12765878	1.000	rs2902639	chr10:105658588	G/C	cg11005552	chr10:105648138	OBFC1	0.86	10.28	0.73	4.24e-17	Coronary artery disease;
THYM	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg18252515	chr7:66147081	NA	-1.6	-8.8	-0.67	6.03e-14	Diabetic kidney disease;
THYM	cis	rs7551222	0.752	rs4951389	chr1:204475834	G/T	cg20240347	chr1:204465584	NA	-0.55	-5.02	-0.46	2.41e-6	Schizophrenia;
THYM	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg21862992	chr11:68658383	NA	0.23	4.49	0.42	2.03e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs10823500	0.640	rs7077538	chr10:71993094	T/G	cg02100629	chr10:71892760	AIFM2	-0.42	-4.89	-0.45	4.07e-6	Blood protein levels;
THYM	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg05802129	chr4:122689817	NA	-0.59	-4.63	-0.43	1.15e-5	Type 2 diabetes;
THYM	trans	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs920590	0.717	rs62496675	chr8:19635733	A/T	cg01411142	chr8:19674711	INTS10	0.73	5.62	0.5	1.89e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs12291225	0.675	rs10219255	chr11:14257960	A/T	cg19336497	chr11:14380999	RRAS2	-0.51	-5.07	-0.46	1.98e-6	Sense of smell;
THYM	cis	rs1965732	0.522	rs34086816	chr2:3718985	A/G	cg25251562	chr2:3704773	ALLC	-0.55	-4.47	-0.42	2.18e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs28647808	1.000	rs2051680	chr9:136222789	A/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.11	-4.86	-0.45	4.64e-6	Blood protein levels;
THYM	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.54	0.73	1.14e-17	Prudent dietary pattern;
THYM	cis	rs2404602	0.622	rs1567671	chr15:77209200	C/G	cg23625390	chr15:77176239	SCAPER	-0.84	-5.64	-0.5	1.73e-7	Blood metabolite levels;
THYM	cis	rs761746	0.960	rs4820982	chr22:31929480	T/C	cg10537193	chr22:32026975	PISD	0.36	4.88	0.45	4.27e-6	Intelligence;
THYM	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg08859206	chr1:53392774	SCP2	-0.8	-8.96	-0.68	2.73e-14	Monocyte count;
THYM	cis	rs28595532	0.841	rs115725150	chr4:119768647	T/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs10197940	0.550	rs77233070	chr2:152416477	G/A	cg06191203	chr2:152266755	RIF1	-0.74	-4.64	-0.43	1.11e-5	Lung cancer;
THYM	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg16342193	chr10:102329863	NA	-0.52	-5.29	-0.48	7.79e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1922291	0.546	rs2310241	chr2:102841949	A/C	cg13315345	chr2:102803985	IL1RL2	0.63	7.14	0.59	1.89e-10	Blood protein levels;
THYM	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg16031515	chr1:205743344	RAB7L1	-0.7	-7.37	-0.6	6.11e-11	Menarche (age at onset);
THYM	cis	rs2116941	1.000	rs7250265	chr19:10339818	G/C	cg01850179	chr19:10340795	S1PR2	-0.66	-8.99	-0.68	2.35e-14	Pulse pressure;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg25038926	chr2:111556206	ACOXL	-0.97	-6.89	-0.58	5.93e-10	Depressive symptoms;
THYM	cis	rs28595532	0.844	rs115573749	chr4:119756848	T/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs2806561	0.765	rs9426692	chr1:23508426	C/T	cg12483005	chr1:23474871	LUZP1	0.59	6.31	0.54	9.03e-9	Height;
THYM	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg02734326	chr4:10020555	SLC2A9	-0.58	-4.76	-0.44	6.81e-6	Bone mineral density;
THYM	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg23711669	chr6:146136114	FBXO30	-0.97	-10.14	-0.72	8.1e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9902453	0.833	rs7216631	chr17:28495112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	6.58	0.56	2.55e-9	Coffee consumption (cups per day);
THYM	cis	rs3819817	0.575	rs4762654	chr12:96357577	G/A	cg26410635	chr12:96350720	AMDHD1	0.53	5.03	0.46	2.36e-6	Vitamin D levels;
THYM	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg15704280	chr7:45808275	SEPT13	-0.97	-11.09	-0.75	7.8e-19	Coronary artery disease;
THYM	cis	rs950881	0.562	rs11692335	chr2:103077893	C/T	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Allergy;
THYM	cis	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg09307838	chr4:120376055	NA	0.73	5.51	0.49	3.11e-7	Corneal astigmatism;
THYM	cis	rs921665	0.749	rs4477952	chr2:3201249	G/A	cg16434511	chr2:3151078	NA	-0.82	-5.28	-0.48	8.03e-7	World class endurance athleticism;
THYM	cis	rs1784581	0.802	rs6455787	chr6:162411378	G/A	cg17173639	chr6:162384350	PARK2	0.8	8.01	0.64	2.8e-12	Itch intensity from mosquito bite;
THYM	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg26354017	chr1:205819088	PM20D1	0.89	8.7	0.67	1.01e-13	Menarche (age at onset);
THYM	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg24692254	chr21:30365293	RNF160	1.0	8.82	0.67	5.61e-14	Dental caries;
THYM	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17253792	0.822	rs17832365	chr14:56153531	C/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs4631830	0.812	rs11593361	chr10:51539156	A/G	cg10326726	chr10:51549505	MSMB	-0.58	-5.85	-0.51	6.98e-8	Prostate-specific antigen levels;
THYM	cis	rs4731207	0.505	rs7791488	chr7:124578268	A/G	cg05285228	chr7:124571219	POT1	-0.65	-4.88	-0.45	4.3e-6	Cutaneous malignant melanoma;
THYM	cis	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs7592578	0.766	rs62181052	chr2:191387858	A/G	cg10560079	chr2:191398806	TMEM194B	-0.94	-6.86	-0.58	7.11e-10	Diastolic blood pressure;
THYM	cis	rs6499255	0.951	rs10500551	chr16:69666970	C/T	cg00738113	chr16:70207722	CLEC18C	-0.44	-4.57	-0.42	1.45e-5	IgE levels;
THYM	cis	rs9790314	0.875	rs459515	chr3:161092351	T/C	cg03342759	chr3:160939853	NMD3	-0.73	-6.32	-0.54	8.42e-9	Morning vs. evening chronotype;
THYM	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg12292205	chr6:26970375	C6orf41	0.63	5.11	0.46	1.65e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2282300	0.739	rs1765139	chr11:30353725	T/C	cg22891988	chr11:30607959	MPPED2	-0.7	-4.56	-0.42	1.54e-5	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3741151	0.572	rs12290623	chr11:73121872	C/G	cg17517138	chr11:73019481	ARHGEF17	0.75	4.72	0.44	8.17e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9515201	0.787	rs9521734	chr13:111037289	A/T	cg15455643	chr13:111040242	COL4A2	0.51	5.71	0.51	1.28e-7	White matter hyperintensity burden;
THYM	trans	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg07393940	chr7:158741817	NA	1.1	8.37	0.65	4.87e-13	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6531656	0.605	rs337613	chr4:38678818	G/A	cg24279243	chr4:38676559	KLF3	0.85	7.61	0.62	2e-11	Lymphocyte counts;
THYM	cis	rs6424115	0.790	rs72874118	chr1:24177800	A/G	cg15997130	chr1:24165203	NA	-0.72	-5.97	-0.52	4.17e-8	Immature fraction of reticulocytes;
THYM	cis	rs72627123	0.867	rs72627118	chr14:74355285	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg06026331	chr20:60912101	LAMA5	-0.74	-5.76	-0.51	1.01e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs6876348	0.516	rs257905	chr5:128317797	A/G	cg02841155	chr5:128301328	SLC27A6	-0.5	-4.89	-0.45	4.18e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg24874828	chr4:187887005	NA	0.76	8.24	0.65	9.29e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	6.13	0.53	1.95e-8	Total body bone mineral density;
THYM	cis	rs7187994	0.848	rs16974560	chr16:84788425	A/G	cg07647771	chr16:84786436	USP10	-0.55	-5.05	-0.46	2.15e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.51	5.32	0.48	6.93e-7	Schizophrenia;
THYM	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.55	0.42	1.57e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg18032289	chr17:61959525	GH2	-0.49	-4.7	-0.43	8.9e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg12373951	chr3:133503437	NA	0.54	5.89	0.52	5.82e-8	Iron status biomarkers;
THYM	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg17077180	chr1:38461687	NA	0.56	6.81	0.57	8.72e-10	Coronary artery disease;
THYM	cis	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg04504001	chr16:74340046	PSMD7	0.57	5.27	0.48	8.59e-7	Energy expenditure (24h);
THYM	cis	rs17767294	0.708	rs72851138	chr6:28042654	C/T	cg08851530	chr6:28072375	NA	1.15	4.46	0.42	2.28e-5	Parkinson's disease;
THYM	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg00631329	chr6:26305371	NA	-0.61	-7.35	-0.6	6.77e-11	Educational attainment;
THYM	cis	rs2292884	0.505	rs77856818	chr2:238402830	G/A	cg08992911	chr2:238395768	MLPH	1.11	6.48	0.55	4.07e-9	Prostate cancer;
THYM	cis	rs9814567	1.000	rs9289471	chr3:134230811	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.87	-9.06	-0.68	1.72e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg16405210	chr4:1374714	KIAA1530	-0.57	-4.62	-0.43	1.19e-5	Longevity;
THYM	cis	rs800586	0.796	rs2694027	chr8:116723398	T/G	cg04656070	chr8:116661063	TRPS1	0.47	5.04	0.46	2.26e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.9	0.63	4.79e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	4.53	0.42	1.74e-5	Bipolar disorder;
THYM	cis	rs548181	0.536	rs503288	chr11:125461787	C/T	cg03464685	chr11:125439445	EI24	-0.85	-6.45	-0.55	4.58e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs12042938	0.507	rs1765778	chr1:231732356	G/A	cg04892437	chr1:231737901	TSNAX-DISC1	-0.48	-4.59	-0.43	1.36e-5	Neuranatomic and neurocognitive phenotypes;
THYM	cis	rs7617773	0.743	rs71323397	chr3:48374874	A/G	cg02219026	chr3:48282209	ZNF589	-0.71	-4.97	-0.45	3.01e-6	Coronary artery disease;
THYM	cis	rs7010267	0.623	rs13254554	chr8:120010805	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.62	4.96	0.45	3.05e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs4930103	0.935	rs2071095	chr11:2020627	C/A	cg18511798	chr11:2018149	H19;MIR675	-0.57	-5.57	-0.5	2.39e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs9677476	0.818	rs62197333	chr2:232085049	G/C	cg07929768	chr2:232055508	NA	0.61	6.23	0.54	1.27e-8	Food antigen IgG levels;
THYM	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg15557168	chr22:42548783	NA	-0.61	-4.75	-0.44	7.12e-6	Schizophrenia;
THYM	cis	rs6840360	0.904	rs6825241	chr4:152543783	C/A	cg17479576	chr4:152424074	FAM160A1	-0.65	-4.91	-0.45	3.72e-6	Intelligence (multi-trait analysis);
THYM	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg03709012	chr19:19516395	GATAD2A	-0.75	-5.67	-0.5	1.56e-7	Tonsillectomy;
THYM	cis	rs9644630	0.930	rs6586840	chr8:19365832	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.82	-8.65	-0.66	1.29e-13	Oropharynx cancer;
THYM	cis	rs67311347	0.544	rs9868700	chr3:40345408	G/A	cg13683864	chr3:40499215	RPL14	-0.79	-7.48	-0.61	3.69e-11	Renal cell carcinoma;
THYM	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg03732007	chr1:2071316	PRKCZ	0.5	4.51	0.42	1.89e-5	Height;
THYM	cis	rs6840360	0.901	rs1561915	chr4:152479724	G/A	cg22705602	chr4:152727874	NA	-0.45	-4.6	-0.43	1.31e-5	Intelligence (multi-trait analysis);
THYM	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg18811423	chr2:55921094	PNPT1	0.77	7.34	0.6	7.35e-11	Metabolic syndrome;
THYM	cis	rs11249608	0.510	rs6861539	chr5:178452307	A/G	cg01312482	chr5:178451176	ZNF879	-0.76	-6.3	-0.54	9.29e-9	Pubertal anthropometrics;
THYM	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg27535305	chr1:53392650	SCP2	0.4	4.66	0.43	1.02e-5	Monocyte count;
THYM	cis	rs1215050	0.740	rs700739	chr4:99022546	A/G	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.57	-4.69	-0.43	9.01e-6	Homoarginine levels;
THYM	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg11984989	chr7:158649758	WDR60	1.17	15.57	0.85	6.93e-28	Height;
THYM	cis	rs76798021	0.810	rs11709171	chr3:53669904	A/C	cg21503701	chr3:53781065	CACNA1D	-0.63	-4.68	-0.43	9.35e-6	Lung function (FEV1/FVC);
THYM	cis	rs7731657	0.567	rs6888236	chr5:130215911	A/G	cg08523029	chr5:130500466	HINT1	-0.82	-5.8	-0.51	8.7e-8	Fasting plasma glucose;
THYM	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg16624210	chr5:671434	TPPP	-0.64	-6.62	-0.56	2.15e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs6138458	0.620	rs2151462	chr20:24911823	T/C	cg26195577	chr20:24973756	C20orf3	1.11	10.52	0.73	1.29e-17	Blood protein levels;
THYM	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg10518543	chr12:38710700	ALG10B	-0.57	-4.49	-0.42	2.04e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1011018	0.955	rs10952510	chr7:139431350	A/T	cg06079564	chr7:139468310	HIPK2	-0.73	-5.54	-0.49	2.65e-7	Systolic blood pressure;
THYM	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg25427524	chr10:38739819	LOC399744	-0.65	-5.7	-0.5	1.34e-7	Extrinsic epigenetic age acceleration;
THYM	cis	rs7084402	0.967	rs1658423	chr10:60331627	T/G	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg12560992	chr17:57184187	TRIM37	0.73	6.2	0.54	1.43e-8	Intelligence (multi-trait analysis);
THYM	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg03605463	chr16:89740564	NA	0.58	4.51	0.42	1.83e-5	Hemoglobin concentration;
THYM	cis	rs12532960	0.731	rs12532964	chr7:42378833	A/G	cg23473276	chr7:42834405	NA	0.99	4.65	0.43	1.08e-5	Inflammatory biomarkers;
THYM	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg16558253	chr16:72132732	DHX38	-0.61	-5.58	-0.5	2.28e-7	Fibrinogen levels;
THYM	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg11845111	chr2:191398756	TMEM194B	-0.96	-8.42	-0.65	3.87e-13	Pulse pressure;
THYM	cis	rs9543976	0.623	rs7317250	chr13:76167141	C/T	cg01531495	chr13:76123901	UCHL3	0.66	4.8	0.44	5.85e-6	Diabetic retinopathy;
THYM	cis	rs11227306	0.934	rs7940691	chr11:65640906	C/T	cg00576331	chr11:65640516	EFEMP2	0.71	5.48	0.49	3.49e-7	DNA methylation (variation);
THYM	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg26408565	chr15:76604113	ETFA	-0.55	-4.77	-0.44	6.55e-6	Blood metabolite levels;
THYM	cis	rs13126513	0.872	rs1072626	chr4:100407267	A/G	cg05468953	chr4:100565104	NA	0.61	5.43	0.49	4.38e-7	Metabolite levels (MHPG);
THYM	cis	rs6723226	0.766	rs398290	chr2:32503526	T/C	cg02381751	chr2:32503542	YIPF4	0.67	5.54	0.49	2.72e-7	Intelligence (multi-trait analysis);
THYM	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Body mass index;
THYM	cis	rs4343996	0.521	rs10237577	chr7:3424305	C/A	cg21248987	chr7:3385318	SDK1	0.39	4.99	0.46	2.68e-6	Motion sickness;
THYM	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg06808227	chr14:105710500	BRF1	-1.08	-9.65	-0.7	9.45e-16	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9807989	0.507	rs1035129	chr2:103019785	T/C	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	6.25	0.54	1.16e-8	Smoking behavior;
THYM	trans	rs9929218	0.551	rs2281850	chr16:68718750	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.16	-16.53	-0.86	1.06e-29	Colorectal cancer;
THYM	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.7	4.66	0.43	1.04e-5	Menarche (age at onset);
THYM	cis	rs17174870	0.955	rs76852916	chr2:112701291	G/C	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg13385794	chr1:248469461	NA	0.67	4.61	0.43	1.24e-5	Common traits (Other);
THYM	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg05182265	chr7:156933206	UBE3C	0.7	9.62	0.7	1.06e-15	Body mass index;
THYM	cis	rs6430585	0.591	rs309118	chr2:136746224	G/C	cg23851026	chr2:136556271	LCT	0.7	7.3	0.6	8.77e-11	Corneal structure;
THYM	cis	rs1215050	0.740	rs783936	chr4:98928628	G/T	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs12579753	1.000	rs12366580	chr12:82222784	G/A	cg07988820	chr12:82153109	PPFIA2	-0.73	-4.61	-0.43	1.23e-5	Resting heart rate;
THYM	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg18876405	chr7:65276391	NA	-0.57	-4.92	-0.45	3.56e-6	Aortic root size;
THYM	cis	rs791888	0.929	rs791887	chr10:89411554	A/G	cg10377144	chr10:89419177	PAPSS2	-0.4	-6.14	-0.53	1.92e-8	Magnesium levels;
THYM	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg12564285	chr5:131593104	PDLIM4	-0.43	-4.66	-0.43	1.04e-5	Breast cancer;
THYM	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg21773646	chr17:80085082	CCDC57	0.36	4.98	0.45	2.87e-6	Life satisfaction;
THYM	cis	rs7267979	0.966	rs8123949	chr20:25388133	C/T	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4455778	0.580	rs6970665	chr7:49124091	T/A	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg01073479	chr16:3509474	NAT15	-0.57	-5.45	-0.49	3.92e-7	Tuberculosis;
THYM	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg08508325	chr11:3079039	CARS	-0.52	-6.31	-0.54	8.88e-9	Longevity;
THYM	cis	rs1483890	0.605	rs1843045	chr3:69413121	C/T	cg22125112	chr3:69402811	FRMD4B	0.38	4.91	0.45	3.81e-6	Resting heart rate;
THYM	cis	rs6089829	0.888	rs4809467	chr20:61671688	A/G	cg03213289	chr20:61660250	NA	0.98	10.61	0.74	8.36e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg21475434	chr5:93447410	FAM172A	0.92	5.95	0.52	4.54e-8	Diabetic retinopathy;
THYM	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg12667521	chr19:29218732	NA	0.86	7.18	0.59	1.56e-10	Methadone dose in opioid dependence;
THYM	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs500891	0.525	rs2023241	chr6:84051460	G/A	cg08257003	chr6:84140564	ME1	0.58	4.66	0.43	1.01e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs4470825	0.837	rs474075	chr6:83897565	C/T	cg02405813	chr6:83072522	TPBG	-0.58	-4.45	-0.42	2.35e-5	Schizophrenia;
THYM	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg10518543	chr12:38710700	ALG10B	-0.56	-4.48	-0.42	2.07e-5	Morning vs. evening chronotype;
THYM	cis	rs6570726	0.934	rs430003	chr6:145819506	C/T	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg12288994	chr5:1860383	NA	0.62	4.76	0.44	6.91e-6	Cardiovascular disease risk factors;
THYM	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg05973401	chr12:123451056	ABCB9	0.62	4.5	0.42	1.93e-5	Neutrophil percentage of white cells;
THYM	cis	rs3768617	0.528	rs6686682	chr1:183080539	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs2658782	0.724	rs2248020	chr11:93259965	A/C	cg15737290	chr11:93063684	CCDC67	0.9	6.56	0.56	2.76e-9	Pulmonary function decline;
THYM	cis	rs13006833	0.739	rs291470	chr2:191189558	T/A	cg11845111	chr2:191398756	TMEM194B	0.66	4.71	0.43	8.54e-6	Urinary metabolites;
THYM	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg13390004	chr1:15929781	NA	0.64	4.85	0.45	4.88e-6	Systolic blood pressure;
THYM	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg21194808	chr1:2205498	SKI	-0.33	-4.6	-0.43	1.3e-5	Height;
THYM	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg23583168	chr7:148888333	NA	-1.04	-13.86	-0.82	1.49e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs2286885	1.000	rs2286885	chr9:129246487	A/C	cg14294646	chr9:129243551	FAM125B	-0.62	-5.68	-0.5	1.48e-7	Intraocular pressure;
THYM	cis	rs887829	0.569	rs6431628	chr2:234647478	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.69	-5.37	-0.48	5.61e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg18240062	chr17:79603768	NPLOC4	0.74	6.52	0.56	3.45e-9	Eye color traits;
THYM	cis	rs10823500	0.777	rs10999196	chr10:71982305	T/C	cg25502086	chr10:71892093	AIFM2	-0.56	-5.08	-0.46	1.87e-6	Blood protein levels;
THYM	cis	rs1878931	0.582	rs9921152	chr16:3421199	A/G	cg21433313	chr16:3507492	NAT15	-0.59	-4.99	-0.46	2.75e-6	Body mass index (adult);
THYM	cis	rs2273669	0.667	rs16822	chr6:109307710	G/A	cg17117243	chr6:109341365	SESN1	-0.84	-4.94	-0.45	3.41e-6	Prostate cancer;
THYM	cis	rs12579753	1.000	rs11613196	chr12:82173251	A/T	cg07988820	chr12:82153109	PPFIA2	0.78	4.97	0.45	2.92e-6	Resting heart rate;
THYM	cis	rs3768617	0.510	rs3768620	chr1:183092237	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg26131816	chr17:42072204	PYY	0.52	4.5	0.42	1.96e-5	Menopause (age at onset);
THYM	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.0	0.63	2.98e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg03161606	chr19:29218774	NA	0.87	7.71	0.62	1.23e-11	Methadone dose in opioid dependence;
THYM	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg07343612	chr16:622815	PIGQ	-1.08	-11.34	-0.76	2.36e-19	Height;
THYM	cis	rs870825	0.860	rs62339895	chr4:185598681	A/G	cg04058563	chr4:185651563	MLF1IP	-0.87	-6.49	-0.55	3.89e-9	Blood protein levels;
THYM	cis	rs12155623	0.803	rs7011862	chr8:49817333	C/G	cg00325661	chr8:49890786	NA	0.65	4.6	0.43	1.32e-5	Sudden cardiac arrest;
THYM	cis	rs28476539	0.567	rs7669516	chr4:83563116	A/C	cg10249074	chr4:83542146	C4orf11	-0.66	-5.27	-0.48	8.48e-7	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg25358565	chr5:93447407	FAM172A	1.31	11.12	0.75	6.98e-19	Diabetic retinopathy;
THYM	cis	rs728616	0.867	rs723193	chr10:81708155	G/T	cg05935833	chr10:81318306	SFTPA2	-0.75	-4.98	-0.45	2.85e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg10856724	chr12:34555212	NA	-0.92	-9.27	-0.69	6.02e-15	Morning vs. evening chronotype;
THYM	cis	rs9362426	1.000	rs9294377	chr6:88084839	G/A	cg10393598	chr6:87862264	NA	-0.61	-4.83	-0.44	5.13e-6	Depressive episodes in bipolar disorder;
THYM	cis	rs1568889	1.000	rs33937991	chr11:28045260	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	4.49	0.42	2.03e-5	Bipolar disorder;
THYM	cis	rs293526	0.959	rs9449566	chr6:83683838	A/G	cg23278060	chr6:83777448	DOPEY1	-0.63	-4.67	-0.43	9.71e-6	Crohn's disease;
THYM	cis	rs9796	0.870	rs28479904	chr15:41268305	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.57	-4.54	-0.42	1.65e-5	Menopause (age at onset);
THYM	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg18512352	chr11:47633146	NA	-0.53	-6.43	-0.55	5.09e-9	Subjective well-being;
THYM	cis	rs7100689	0.725	rs10736340	chr10:82061071	C/T	cg01528321	chr10:82214614	TSPAN14	1.02	7.78	0.62	8.75e-12	Post bronchodilator FEV1;
THYM	cis	rs3845702	0.736	rs2367990	chr2:180843126	C/T	cg01881094	chr2:180872142	CWC22	-0.89	-5.34	-0.48	6.22e-7	Schizophrenia;
THYM	trans	rs4940575	0.679	rs17070779	chr18:60835738	C/T	cg08454546	chr15:59731340	FAM81A	-1.03	-6.96	-0.58	4.42e-10	Breast cancer;
THYM	cis	rs4919694	1.000	rs78893207	chr10:104796138	T/C	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs754466	0.580	rs1058198	chr10:79566632	G/A	cg17075019	chr10:79541650	NA	-0.63	-5.06	-0.46	2.01e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7843479	0.562	rs4872191	chr8:21824547	A/G	cg17168535	chr8:21777572	XPO7	0.92	8.65	0.66	1.26e-13	Mean corpuscular volume;
THYM	cis	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg10518543	chr12:38710700	ALG10B	-0.57	-4.57	-0.42	1.47e-5	Morning vs. evening chronotype;
THYM	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg10792982	chr14:105748885	BRF1	0.74	7.66	0.62	1.56e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs10463554	0.963	rs26262	chr5:102545163	T/G	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Parkinson's disease;
THYM	cis	rs2046867	0.818	rs62249861	chr3:72867779	A/G	cg25664220	chr3:72788482	NA	-0.95	-7.97	-0.63	3.52e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg02869364	chr7:1081709	C7orf50	-0.6	-4.97	-0.45	3e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg03929089	chr4:120376271	NA	-0.94	-10.63	-0.74	7.58e-18	Height;
THYM	cis	rs7412746	0.611	rs7532045	chr1:150821847	G/A	cg10589385	chr1:150898437	SETDB1	0.59	4.91	0.45	3.83e-6	Melanoma;
THYM	cis	rs3096299	0.781	rs3102381	chr16:89409720	G/C	cg06640241	chr16:89574553	SPG7	0.6	4.46	0.42	2.26e-5	Multiple myeloma (IgH translocation);
THYM	trans	rs10462794	0.789	rs7719895	chr5:4490338	C/T	cg13433994	chr3:23958502	NKIRAS1;RPL15	1.22	6.99	0.58	3.75e-10	DNA methylation (variation);
THYM	cis	rs6840360	0.571	rs62327278	chr4:152558790	G/C	cg17479576	chr4:152424074	FAM160A1	-0.82	-5.76	-0.51	1.05e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7107770	1.000	rs61912987	chr11:125107553	C/T	cg07747661	chr11:125106135	PKNOX2	-0.92	-5.28	-0.48	8.31e-7	Photic sneeze reflex;
THYM	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg06481639	chr22:41940642	POLR3H	-0.64	-4.64	-0.43	1.13e-5	Neuroticism;
THYM	cis	rs877282	0.629	rs78997110	chr10:764388	A/G	cg10556349	chr10:835070	NA	-0.85	-5.53	-0.49	2.82e-7	Uric acid levels;
THYM	cis	rs7586879	0.796	rs36071142	chr2:25080570	C/T	cg01884057	chr2:25150051	NA	0.51	4.73	0.44	7.92e-6	Body mass index;
THYM	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg13010199	chr12:38710504	ALG10B	0.76	6.07	0.53	2.59e-8	Heart rate;
THYM	cis	rs425277	0.917	rs78395918	chr1:2045876	G/A	cg23682913	chr1:2080710	PRKCZ	0.59	4.55	0.42	1.6e-5	Height;
THYM	cis	rs12310956	0.532	rs1589902	chr12:33989289	G/A	cg10856724	chr12:34555212	NA	-0.75	-6.8	-0.57	9.1e-10	Morning vs. evening chronotype;
THYM	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg01742263	chr5:138714339	SLC23A1	-0.57	-4.63	-0.43	1.17e-5	Esophageal squamous cell carcinoma;
THYM	cis	rs3791406	0.929	rs3828202	chr2:240030122	A/G	cg05758467	chr2:240035894	HDAC4	-0.44	-4.51	-0.42	1.84e-5	Skin aging (microtopography measurement);
THYM	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg00981070	chr1:2046702	PRKCZ	0.48	5.29	0.48	7.9e-7	Height;
THYM	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4343996	0.935	rs10276190	chr7:3348663	C/T	cg21248987	chr7:3385318	SDK1	0.41	4.95	0.45	3.17e-6	Motion sickness;
THYM	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg17264618	chr3:40429014	ENTPD3	0.49	4.78	0.44	6.38e-6	Renal cell carcinoma;
THYM	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-5.93	-0.52	4.95e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs11089937	0.616	rs713624	chr22:22535144	A/G	cg06866756	chr22:22471216	NA	-0.43	-4.68	-0.43	9.54e-6	Periodontitis (PAL4Q3);
THYM	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg05962950	chr11:130786565	SNX19	0.92	8.84	0.67	4.9e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-5.81	-0.51	8.27e-8	Total cholesterol levels;
THYM	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg09455208	chr3:40491958	NA	-0.45	-4.84	-0.45	4.95e-6	Renal cell carcinoma;
THYM	cis	rs9646944	0.501	rs10174323	chr2:103012781	C/A	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	cis	rs1448094	0.511	rs10506923	chr12:86152595	C/T	cg00310523	chr12:86230176	RASSF9	-0.57	-4.83	-0.44	5.15e-6	Major depressive disorder;
THYM	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg03929089	chr4:120376271	NA	0.97	10.74	0.74	4.47e-18	Coronary artery disease;
THYM	cis	rs9515201	0.859	rs9521732	chr13:111033821	G/T	cg05272587	chr13:111038400	COL4A2	-0.75	-6.51	-0.56	3.57e-9	White matter hyperintensity burden;
THYM	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg03388025	chr16:89894329	SPIRE2	0.55	4.68	0.43	9.68e-6	Vitiligo;
THYM	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg01577475	chr2:114033581	PAX8;LOC440839	0.51	4.9	0.45	3.89e-6	Lymphocyte counts;
THYM	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1018836	0.886	rs10956750	chr8:91621704	G/C	cg16814680	chr8:91681699	NA	-0.85	-7.17	-0.59	1.59e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg02527881	chr3:46936655	PTH1R	-0.63	-6.29	-0.54	9.52e-9	Colorectal cancer;
THYM	cis	rs500891	0.504	rs1145897	chr6:84040440	C/T	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs8077889	0.869	rs11713	chr17:41845824	A/G	cg26893861	chr17:41843967	DUSP3	-0.98	-8.39	-0.65	4.58e-13	Triglycerides;
THYM	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg23583168	chr7:148888333	NA	1.0	12.68	0.79	3.85e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg11502198	chr6:26597334	ABT1	0.61	5.15	0.47	1.39e-6	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs728616	0.867	rs61860042	chr10:81946238	G/A	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs807029	0.577	rs701835	chr10:102762127	A/G	cg14905631	chr10:102746534	C10orf2;MRPL43	0.37	4.97	0.45	2.92e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs2039659	0.719	rs1764968	chr13:86257543	G/C	cg25308322	chr13:86268291	NA	0.68	5.83	0.51	7.46e-8	Blood osmolality (transformed sodium);
THYM	cis	rs10089	1.000	rs73337363	chr5:127483597	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.02	7.11	0.59	2.11e-10	Ileal carcinoids;
THYM	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg05802129	chr4:122689817	NA	-0.57	-4.47	-0.42	2.17e-5	Type 2 diabetes;
THYM	cis	rs4788570	0.697	rs4788559	chr16:71848959	T/C	cg06353428	chr16:71660113	MARVELD3	1.43	8.62	0.66	1.49e-13	Intelligence (multi-trait analysis);
THYM	cis	rs12893668	0.703	rs4906335	chr14:104021141	C/A	cg08213375	chr14:104286397	PPP1R13B	0.42	4.63	0.43	1.18e-5	Reticulocyte count;
THYM	cis	rs3741798	1.000	rs61922025	chr12:12486263	G/A	cg08615371	chr12:12503544	MANSC1	0.88	4.89	0.45	4.17e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg03433033	chr1:76189801	ACADM	0.74	8.87	0.67	4.31e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg00256281	chr22:41985642	PMM1	-0.58	-4.83	-0.44	5.14e-6	Vitiligo;
THYM	cis	rs1784581	0.588	rs7752870	chr6:162422510	T/C	cg17173639	chr6:162384350	PARK2	0.81	7.48	0.61	3.75e-11	Itch intensity from mosquito bite;
THYM	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg18402987	chr7:1209562	NA	1.16	7.29	0.6	9.12e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.21	0.47	1.11e-6	Obesity-related traits;
THYM	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg08847533	chr14:75593920	NEK9	-0.92	-9.94	-0.71	2.22e-16	Height;
THYM	cis	rs1747683	0.966	rs647253	chr10:13363242	T/C	cg25835351	chr10:13388524	SEPHS1	0.33	5.5	0.49	3.22e-7	IgG glycosylation;
THYM	cis	rs9807989	0.507	rs10439410	chr2:102990788	A/C	cg03938978	chr2:103052716	IL18RAP	-0.75	-9.6	-0.7	1.17e-15	Asthma;
THYM	cis	rs112998813	0.571	rs9590395	chr13:114927224	C/G	cg26703057	chr13:114071457	NA	0.77	4.59	0.43	1.35e-5	Nodular sclerosis Hodgkin lymphoma;
THYM	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg17747265	chr1:1875780	NA	0.75	8.2	0.64	1.14e-12	Body mass index;
THYM	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6496667	0.533	rs2074583	chr15:91009192	T/C	cg22089800	chr15:90895588	ZNF774	0.68	5.07	0.46	1.94e-6	Rheumatoid arthritis;
THYM	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg17644776	chr2:200775616	C2orf69	0.84	5.72	0.51	1.24e-7	Schizophrenia;
THYM	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg04731861	chr2:219085781	ARPC2	-0.5	-4.75	-0.44	7.29e-6	Colorectal cancer;
THYM	cis	rs2354432	0.607	rs4314933	chr1:146821386	T/C	cg25205988	chr1:146714368	CHD1L	1.01	5.52	0.49	2.91e-7	Mitochondrial DNA levels;
THYM	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03452623	chr4:187889614	NA	-1.19	-19.33	-0.89	1.1e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6430585	0.528	rs309172	chr2:136674028	A/G	cg20242066	chr2:136595261	LCT	0.54	5.71	0.51	1.29e-7	Corneal structure;
THYM	cis	rs10744422	1.000	rs2292135	chr12:123334075	G/A	cg25930673	chr12:123319894	HIP1R	-0.86	-4.84	-0.44	5.09e-6	Schizophrenia;
THYM	cis	rs12310956	0.532	rs7967627	chr12:33974669	G/T	cg06521331	chr12:34319734	NA	-0.92	-8.57	-0.66	1.89e-13	Morning vs. evening chronotype;
THYM	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg27129171	chr3:47204927	SETD2	-0.72	-6.38	-0.55	6.51e-9	Colorectal cancer;
THYM	cis	rs7264396	0.790	rs3746410	chr20:34190870	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.62	-5.07	-0.46	1.93e-6	Total cholesterol levels;
THYM	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	4.75	0.44	7.12e-6	Obesity-related traits;
THYM	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg09455208	chr3:40491958	NA	-0.44	-4.59	-0.43	1.35e-5	Renal cell carcinoma;
THYM	cis	rs853679	0.574	rs1233705	chr6:28166447	C/G	cg23281280	chr6:28129359	ZNF389	0.55	4.83	0.44	5.12e-6	Depression;
THYM	cis	rs1065852	0.526	rs56234624	chr22:42388826	A/G	cg01059385	chr22:42394853	WBP2NL	0.57	4.66	0.43	1.04e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs2637266	1.000	rs12260492	chr10:78365242	C/A	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs9326248	0.581	rs10892053	chr11:116857003	C/T	cg20608306	chr11:116969690	SIK3	0.63	7.93	0.63	4.29e-12	Blood protein levels;
THYM	cis	rs490234	0.812	rs7875713	chr9:128268903	G/T	cg14078157	chr9:128172775	NA	-0.7	-5.59	-0.5	2.17e-7	Mean arterial pressure;
THYM	cis	rs9828933	0.766	rs864975	chr3:63885615	T/C	cg16258503	chr3:63850278	ATXN7;THOC7	0.91	5.39	0.48	5.21e-7	Type 2 diabetes;
THYM	cis	rs612683	0.602	rs2030048	chr1:101006577	C/T	cg09408571	chr1:101003634	GPR88	-0.56	-6.91	-0.58	5.61e-10	Breast cancer;
THYM	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg06108461	chr20:60628389	TAF4	-0.8	-6.51	-0.56	3.54e-9	Body mass index;
THYM	cis	rs13064411	0.696	rs1386336	chr3:113144153	C/T	cg18753928	chr3:113234510	CCDC52	-0.91	-8.22	-0.64	1.04e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs3960554	0.800	rs112463197	chr7:75622912	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-4.49	-0.42	2e-5	Eotaxin levels;
THYM	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg00677455	chr12:58241039	CTDSP2	0.73	5.16	0.47	1.34e-6	Multiple sclerosis;
THYM	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg24209194	chr3:40518798	ZNF619	0.55	4.48	0.42	2.1e-5	Renal cell carcinoma;
THYM	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg17757837	chr7:157058334	UBE3C	0.66	5.29	0.48	7.81e-7	Body mass index;
THYM	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg24578937	chr1:2090814	PRKCZ	0.55	5.39	0.48	5.14e-7	Height;
THYM	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg12893428	chr3:195717962	SDHAP1	0.51	4.57	0.42	1.49e-5	Pancreatic cancer;
THYM	cis	rs9807841	0.670	rs2738042	chr19:10790143	C/G	cg16900796	chr19:10755136	SLC44A2	0.32	4.87	0.45	4.5e-6	Inflammatory skin disease;
THYM	cis	rs713587	0.563	rs2384057	chr2:25100167	C/G	cg01884057	chr2:25150051	NA	0.65	6.22	0.54	1.31e-8	Body mass index in non-asthmatics;
THYM	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg10661904	chr17:79619235	PDE6G	-0.66	-6.41	-0.55	5.55e-9	Eye color traits;
THYM	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg24531977	chr5:56204891	C5orf35	1.02	8.53	0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg04398451	chr17:18023971	MYO15A	0.9	9.71	0.71	6.98e-16	Total body bone mineral density;
THYM	cis	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg07460842	chr6:66804631	NA	-0.75	-4.88	-0.45	4.28e-6	Exhaled nitric oxide output;
THYM	cis	rs11969893	0.649	rs1321204	chr6:101468591	A/G	cg12253828	chr6:101329408	ASCC3	0.91	5.13	0.47	1.53e-6	Economic and political preferences (immigration/crime);
THYM	cis	rs10788264	0.504	rs4751886	chr10:124020396	T/C	cg09507567	chr10:124027408	NA	0.53	5.44	0.49	4.11e-7	Total body bone mineral density;
THYM	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg03388043	chr17:80084554	CCDC57	-0.7	-5.7	-0.5	1.34e-7	Life satisfaction;
THYM	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg02569458	chr12:86230093	RASSF9	0.64	5.35	0.48	6.04e-7	Major depressive disorder;
THYM	cis	rs7769051	0.711	rs7738071	chr6:133085116	G/A	cg22852734	chr6:133119734	C6orf192	1.27	7.34	0.6	7.22e-11	Type 2 diabetes nephropathy;
THYM	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg16624210	chr5:671434	TPPP	0.74	6.34	0.54	7.87e-9	Obesity-related traits;
THYM	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg08807101	chr21:30365312	RNF160	0.94	8.08	0.64	2.08e-12	Dental caries;
THYM	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg24692254	chr21:30365293	RNF160	-0.99	-9.28	-0.69	5.71e-15	Dental caries;
THYM	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs9875589	0.509	rs2733556	chr3:14100172	A/T	cg03204825	chr3:13978759	TPRXL	-0.53	-4.54	-0.42	1.67e-5	Ovarian reserve;
THYM	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs1775715	0.870	rs7912121	chr10:32228995	T/G	cg04359828	chr10:32216031	ARHGAP12	0.4	5.16	0.47	1.37e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	trans	rs877282	0.853	rs11253332	chr10:755262	G/C	cg22713356	chr15:30763199	NA	1.27	9.37	0.69	3.62e-15	Uric acid levels;
THYM	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7731657	0.537	rs6595983	chr5:130335755	A/G	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12756686	chr19:29218302	NA	0.98	8.72	0.67	9.12e-14	Methadone dose in opioid dependence;
THYM	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg06558623	chr16:89946397	TCF25	1.34	5.65	0.5	1.67e-7	Skin colour saturation;
THYM	cis	rs2916260	0.800	rs56049942	chr6:40392989	C/T	cg08415973	chr6:40346114	TDRG1	0.75	4.71	0.43	8.6e-6	Incident coronary heart disease;
THYM	cis	rs929596	0.583	rs77070100	chr2:234587847	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.73	-5.77	-0.51	9.75e-8	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs34638657	0.732	rs12595971	chr16:82200309	T/C	cg09439754	chr16:82129088	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	cis	rs55702914	0.837	rs2195507	chr2:198172336	T/C	cg00792783	chr2:198669748	PLCL1	-0.63	-4.84	-0.44	5.11e-6	Major depression and alcohol dependence;
THYM	cis	rs740474	0.831	rs10477148	chr5:140989242	C/T	cg24137543	chr5:140893634	NA	0.51	5.99	0.52	3.8e-8	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7909074	0.966	rs879074	chr10:45400053	G/A	cg05187965	chr10:45406764	TMEM72	-0.49	-4.62	-0.43	1.19e-5	Mean corpuscular volume;
THYM	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11644478	chr21:40555479	PSMG1	1.09	9.51	0.7	1.85e-15	Cognitive function;
THYM	cis	rs11711311	1.000	rs9827682	chr3:113450251	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.59	-5.19	-0.47	1.2e-6	IgG glycosylation;
THYM	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.64	-4.89	-0.45	4.1e-6	Multiple sclerosis;
THYM	cis	rs200810	0.653	rs10457310	chr6:97983877	C/T	cg17774634	chr6:97730494	C6orf167;MIR548H3	0.93	5.57	0.5	2.32e-7	Body mass index;
THYM	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg23260525	chr10:116636907	FAM160B1	0.52	5.19	0.47	1.19e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9649465	0.967	rs1506642	chr7:123390058	A/G	cg15443791	chr7:124364398	NA	0.59	4.85	0.45	4.82e-6	Migraine;
THYM	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg01448562	chr3:133502909	NA	-0.83	-7.15	-0.59	1.82e-10	Iron status biomarkers;
THYM	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg03684893	chr10:554711	DIP2C	-0.7	-6.27	-0.54	1.07e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.56	-0.66	1.96e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs901683	1.000	rs901683	chr10:45966422	C/T	cg18240400	chr10:46168597	ANUBL1	0.71	4.71	0.44	8.33e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	6.3	0.54	9.15e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg07022442	chr13:21864356	NA	0.72	4.78	0.44	6.49e-6	White matter hyperintensity burden;
THYM	cis	rs9646944	0.501	rs13030642	chr2:103091585	C/A	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg04944784	chr2:26401820	FAM59B	-1.03	-8.04	-0.64	2.46e-12	Gut microbiome composition (summer);
THYM	cis	rs6430585	0.640	rs58301703	chr2:136532225	G/A	cg07169764	chr2:136633963	MCM6	1.22	13.28	0.81	2.23e-23	Corneal structure;
THYM	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs4845875	0.600	rs11805138	chr1:11833159	T/C	cg14194983	chr1:11908298	NPPA	0.53	4.81	0.44	5.68e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs2131877	0.830	rs62290347	chr3:194852620	A/G	cg21937377	chr3:194868750	C3orf21	0.42	4.89	0.45	4.03e-6	Non-small cell lung cancer;
THYM	cis	rs9972944	0.729	rs6504351	chr17:63765275	C/T	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs9527	0.615	rs4919682	chr10:104584330	C/T	cg04362960	chr10:104952993	NT5C2	0.62	4.55	0.42	1.62e-5	Arsenic metabolism;
THYM	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	6.01	0.52	3.39e-8	Mean corpuscular hemoglobin;
THYM	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg14768367	chr16:72042858	DHODH	0.68	5.29	0.48	7.98e-7	Fibrinogen levels;
THYM	cis	rs9399401	0.626	rs1928528	chr6:142779109	T/G	cg03128060	chr6:142623767	GPR126	0.7	9.01	0.68	2.19e-14	Chronic obstructive pulmonary disease;
THYM	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg26149184	chr10:133730230	NA	0.77	4.65	0.43	1.07e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs89107	0.550	rs11758454	chr6:118848799	A/C	cg21191810	chr6:118973309	C6orf204	0.51	5.11	0.46	1.67e-6	Cardiac structure and function;
THYM	cis	rs6754311	0.593	rs7608045	chr2:136413359	T/C	cg04750100	chr2:136595281	LCT	0.56	5.89	0.52	5.87e-8	Mosquito bite size;
THYM	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg18904891	chr8:8559673	CLDN23	0.68	5.08	0.46	1.89e-6	Obesity-related traits;
THYM	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs7224737	1.000	rs2285657	chr17:40272594	C/A	cg00647820	chr17:40259828	DHX58	-0.61	-4.56	-0.42	1.51e-5	Fibrinogen levels;
THYM	cis	rs9563576	0.518	rs4884285	chr13:58311469	A/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	-0.63	-4.89	-0.45	4.04e-6	Body mass index;
THYM	cis	rs11186	0.556	rs59488585	chr2:189966807	T/G	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	cis	rs2456568	0.508	rs1607403	chr11:93660514	A/G	cg26875233	chr11:93583750	C11orf90	-0.56	-6.24	-0.54	1.22e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs1351592	0.891	rs2128323	chr2:213384298	T/G	cg17842354	chr2:214149035	SPAG16	-0.85	-4.54	-0.42	1.62e-5	Polycystic ovary syndrome;
THYM	cis	rs4243830	0.579	rs10779794	chr1:6612651	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.09	-7.38	-0.6	5.96e-11	Body mass index;
THYM	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	5.88	0.52	6.15e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs17323877	chr4:119671188	A/G	cg21605333	chr4:119757512	SEC24D	1.34	4.79	0.44	6.06e-6	Cannabis dependence symptom count;
THYM	trans	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs2282300	0.739	rs34224414	chr11:30251041	T/G	cg25418670	chr11:30344373	C11orf46	-0.81	-6.87	-0.58	6.66e-10	Morning vs. evening chronotype;
THYM	cis	rs7312774	0.881	rs12320167	chr12:107310167	G/A	cg16260113	chr12:107380972	MTERFD3	0.97	5.63	0.5	1.84e-7	Severe influenza A (H1N1) infection;
THYM	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg13397359	chr6:42928475	GNMT	0.58	5.07	0.46	1.98e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	trans	rs9296092	0.517	rs7743178	chr6:33470462	G/A	cg00929798	chr10:135150139	CALY	0.69	6.91	0.58	5.61e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs8067545	1.000	rs7218708	chr17:19926836	A/G	cg13482628	chr17:19912719	NA	0.59	4.74	0.44	7.38e-6	Schizophrenia;
THYM	cis	rs10463554	0.927	rs34795	chr5:102424420	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg22535103	chr8:58192502	C8orf71	-0.85	-4.77	-0.44	6.68e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs12704876	0.530	rs2177675	chr7:96342253	A/T	cg03808172	chr7:96339361	SHFM1	0.72	5.3	0.48	7.38e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg02153584	chr22:29168773	CCDC117	0.61	4.76	0.44	6.94e-6	Lymphocyte counts;
THYM	cis	rs863345	0.604	rs975118	chr1:158511445	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs6939532	0.522	rs9358933	chr6:26363688	C/T	cg14345882	chr6:26364793	BTN3A2	0.4	5.07	0.46	2e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7181230	1.000	rs7181230	chr15:40360741	A/G	cg20592017	chr15:40364740	NA	0.6	5.46	0.49	3.78e-7	Dehydroepiandrosterone sulphate levels;
THYM	cis	rs11096990	0.600	rs6835337	chr4:39282809	T/A	cg24403649	chr4:39172243	NA	-0.68	-5.9	-0.52	5.51e-8	Cognitive function;
THYM	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg16586182	chr3:47516702	SCAP	-0.67	-5.62	-0.5	1.9e-7	Colorectal cancer;
THYM	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.02	-5.33	-0.48	6.6e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9361491	0.608	rs7751066	chr6:79443088	A/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg06634786	chr22:41940651	POLR3H	0.73	5.33	0.48	6.69e-7	Cannabis dependence symptom count;
THYM	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg25554036	chr4:6271136	WFS1	0.51	4.61	0.43	1.27e-5	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs11997175	0.600	rs4739590	chr8:33802686	A/G	ch.8.33884649F	chr8:33765107	NA	0.64	4.92	0.45	3.57e-6	Body mass index;
THYM	cis	rs2075230	0.850	rs6503039	chr17:7470060	A/G	cg10509001	chr17:7553872	ATP1B2	0.58	4.62	0.43	1.21e-5	Hormone measurements;
THYM	cis	rs477692	0.583	rs2008387	chr10:131448764	C/T	cg06209143	chr10:131448811	MGMT	-0.63	-5.21	-0.47	1.11e-6	Response to temozolomide;
THYM	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg23711669	chr6:146136114	FBXO30	-0.98	-10.65	-0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg00074818	chr8:8560427	CLDN23	0.58	5.4	0.48	4.91e-7	Obesity-related traits;
THYM	cis	rs2274459	1.000	rs877187	chr6:33706211	A/G	cg06253072	chr6:33679850	C6orf125	-0.52	-5.27	-0.48	8.41e-7	Obesity (extreme);
THYM	cis	rs919433	0.680	rs1116734	chr2:198365043	C/G	cg00792783	chr2:198669748	PLCL1	0.86	6.09	0.53	2.38e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs790123	1.000	rs790117	chr3:122380888	C/T	cg15604389	chr3:122379662	NA	0.6	5.52	0.49	2.91e-7	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs870825	0.616	rs28607131	chr4:185651617	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs9807841	0.592	rs10407349	chr19:10758453	G/A	cg16900796	chr19:10755136	SLC44A2	0.34	5.55	0.49	2.63e-7	Inflammatory skin disease;
THYM	cis	rs11048434	0.736	rs1805724	chr12:9104609	T/C	cg04155231	chr12:9217510	LOC144571	0.47	4.47	0.42	2.14e-5	Sjögren's syndrome;
THYM	cis	rs73086581	0.947	rs73084531	chr20:3878429	G/A	cg02187196	chr20:3869020	PANK2	0.4	4.74	0.44	7.39e-6	Response to antidepressants in depression;
THYM	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg05802129	chr4:122689817	NA	-0.59	-4.65	-0.43	1.08e-5	Type 2 diabetes;
THYM	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg25214090	chr10:38739885	LOC399744	0.91	7.65	0.62	1.67e-11	Corneal astigmatism;
THYM	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg22431228	chr1:16359049	CLCNKA	-0.53	-5.13	-0.47	1.51e-6	Dilated cardiomyopathy;
THYM	cis	rs7551222	0.752	rs12032733	chr1:204481209	G/A	cg20240347	chr1:204465584	NA	-0.51	-4.54	-0.42	1.64e-5	Schizophrenia;
THYM	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg24818145	chr4:99064322	C4orf37	0.67	5.01	0.46	2.53e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11771526	0.901	rs17161124	chr7:32307324	A/T	cg27532318	chr7:32358331	NA	-0.72	-4.78	-0.44	6.45e-6	Body mass index;
THYM	cis	rs7567389	0.677	rs4662720	chr2:128076607	T/C	cg06038358	chr2:128176007	PROC	-0.43	-4.53	-0.42	1.7e-5	Self-rated health;
THYM	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs919433	0.679	rs6757669	chr2:198530355	C/T	cg05783139	chr2:198650985	BOLL	0.66	4.98	0.46	2.78e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg04896959	chr15:78267971	NA	0.87	8.1	0.64	1.85e-12	Coronary artery disease or large artery stroke;
THYM	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg24846343	chr22:24311635	DDTL	0.44	5.49	0.49	3.35e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg25208724	chr1:156163844	SLC25A44	1.12	12.78	0.8	2.33e-22	Testicular germ cell tumor;
THYM	cis	rs3818285	0.679	rs612155	chr10:111630731	C/G	cg00817464	chr10:111662876	XPNPEP1	0.48	5.16	0.47	1.34e-6	Superior crus of antihelix expression;
THYM	cis	rs11645898	0.935	rs72787077	chr16:72156674	C/T	cg14768367	chr16:72042858	DHODH	-0.76	-5.49	-0.49	3.35e-7	Blood protein levels;
THYM	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.7	0.51	1.32e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12282928	0.917	rs9651621	chr11:48340048	G/C	cg22827986	chr11:48284249	OR4X1	0.53	5.59	0.5	2.21e-7	Migraine - clinic-based;
THYM	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg03676636	chr4:99064102	C4orf37	0.45	6.84	0.57	7.76e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg10589385	chr1:150898437	SETDB1	0.65	5.4	0.48	4.83e-7	Melanoma;
THYM	cis	rs919433	0.647	rs6741205	chr2:198525997	G/C	cg05783139	chr2:198650985	BOLL	0.66	4.98	0.46	2.78e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg18876405	chr7:65276391	NA	-0.55	-4.57	-0.42	1.49e-5	Aortic root size;
THYM	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg13390004	chr1:15929781	NA	0.59	4.57	0.42	1.47e-5	Systolic blood pressure;
THYM	cis	rs3540	0.553	rs8042861	chr15:90977333	G/T	cg22089800	chr15:90895588	ZNF774	0.75	5.96	0.52	4.35e-8	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs9902453	0.726	rs3110494	chr17:27976597	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.29	0.54	9.75e-9	Coffee consumption (cups per day);
THYM	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26314531	chr2:26401878	FAM59B	-0.77	-5.03	-0.46	2.27e-6	Gut microbiome composition (summer);
THYM	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg08109568	chr15:31115862	NA	-0.55	-5.5	-0.49	3.24e-7	Huntington's disease progression;
THYM	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg27432699	chr2:27873401	GPN1	0.61	5.31	0.48	7.28e-7	Oral cavity cancer;
THYM	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg07936489	chr17:37558343	FBXL20	-0.67	-4.62	-0.43	1.22e-5	Asthma;
THYM	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg19746536	chr19:49375674	PPP1R15A	0.81	4.47	0.42	2.12e-5	Red cell distribution width;
THYM	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg05552183	chr6:42928497	GNMT	0.7	5.57	0.5	2.36e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs17030434	0.834	rs6535958	chr4:154760834	C/G	cg14289246	chr4:154710475	SFRP2	0.67	4.87	0.45	4.49e-6	Electrocardiographic conduction measures;
THYM	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.95	6.09	0.53	2.36e-8	Platelet count;
THYM	cis	rs8068544	0.818	rs75771390	chr17:40194054	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.47	-7.47	-0.61	3.88e-11	Reticulocyte fraction of red cells;Reticulocyte count;
THYM	cis	rs17174870	0.955	rs1400324	chr2:112681220	C/A	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs10929159	0.928	rs3738994	chr2:236918539	T/C	cg20128773	chr2:236923534	AGAP1	0.36	4.75	0.44	7.23e-6	Parkinson's disease;
THYM	cis	rs7824557	0.614	rs17741537	chr8:11213092	A/G	cg21775007	chr8:11205619	TDH	0.7	6.19	0.54	1.51e-8	Retinal vascular caliber;
THYM	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.97	9.35	0.69	4.11e-15	Cognitive ability;
THYM	cis	rs2976388	0.625	rs2717600	chr8:143813988	A/G	cg06565975	chr8:143823917	SLURP1	-0.43	-4.68	-0.43	9.36e-6	Urinary tract infection frequency;
THYM	cis	rs7599312	0.553	rs6710653	chr2:213404893	A/G	cg16329650	chr2:213403929	ERBB4	1.04	12.32	0.78	2.07e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg06808227	chr14:105710500	BRF1	-1.02	-8.99	-0.68	2.39e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg23035555	chr19:3500370	DOHH	-0.78	-4.49	-0.42	2.03e-5	Total cholesterol levels;
THYM	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg16325326	chr1:53192061	ZYG11B	0.81	7.52	0.61	3.05e-11	Monocyte count;
THYM	cis	rs36051895	0.623	rs4358852	chr9:5251238	C/T	cg02405213	chr9:5042618	JAK2	-0.93	-9.64	-0.7	9.49e-16	Pediatric autoimmune diseases;
THYM	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs12893597	0.704	rs34065247	chr14:76834029	A/C	cg20290672	chr14:76816747	NA	-0.71	-5.73	-0.51	1.17e-7	Maximal oxygen uptake response;
THYM	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg14517863	chr17:44321492	NA	-0.44	-5.0	-0.46	2.59e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg08885076	chr2:99613938	TSGA10	0.69	6.47	0.55	4.31e-9	Chronic sinus infection;
THYM	cis	rs454510	0.826	rs347903	chr1:120192431	C/T	cg16322792	chr1:120165303	ZNF697	0.59	5.09	0.46	1.79e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
THYM	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg24818145	chr4:99064322	C4orf37	0.88	7.12	0.59	2.09e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7200543	1.000	rs34614532	chr16:15132908	T/C	cg01933576	chr16:15083564	PDXDC1	-0.99	-8.04	-0.64	2.48e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs9325144	0.723	rs11169519	chr12:39177441	G/A	cg26384229	chr12:38710491	ALG10B	-0.6	-4.62	-0.43	1.18e-5	Morning vs. evening chronotype;
THYM	cis	rs6570726	0.791	rs379040	chr6:145889035	T/C	cg23711669	chr6:146136114	FBXO30	0.91	8.94	0.68	3.02e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs4808199	0.947	rs10404728	chr19:19595014	C/T	cg03709012	chr19:19516395	GATAD2A	1.19	7.25	0.6	1.12e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs754466	0.606	rs11002309	chr10:79594931	C/T	cg17075019	chr10:79541650	NA	-0.72	-5.95	-0.52	4.38e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg13736514	chr6:26305472	NA	-0.6	-7.45	-0.61	4.23e-11	Educational attainment;
THYM	cis	rs7582180	0.739	rs10195793	chr2:100925803	A/G	cg21926883	chr2:100939477	LONRF2	-0.61	-5.52	-0.49	2.91e-7	Intelligence (multi-trait analysis);
THYM	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11890956	chr21:40555474	PSMG1	-1.17	-12.72	-0.79	3.2e-22	Cognitive function;
THYM	cis	rs988913	1.000	rs1503142	chr6:54818948	C/T	cg04690482	chr6:54711388	FAM83B	0.47	5.33	0.48	6.64e-7	Menarche (age at onset);
THYM	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	5.08	0.46	1.86e-6	Obesity-related traits;
THYM	cis	rs1957429	0.901	rs7143661	chr14:65378981	G/A	cg23373153	chr14:65346875	NA	1.04	6.49	0.55	3.87e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg06728252	chr6:26598149	ABT1	-0.44	-5.24	-0.47	9.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg26038318	chr20:34205095	SPAG4	0.64	5.27	0.48	8.62e-7	Total cholesterol levels;
THYM	cis	rs28374715	0.532	rs316607	chr15:41772693	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.15	-12.85	-0.8	1.71e-22	Ulcerative colitis;
THYM	cis	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg06623918	chr6:96969491	KIAA0776	-0.92	-7.36	-0.6	6.71e-11	Headache;
THYM	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.96	-8.0	-0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg13695892	chr22:41940480	POLR3H	-0.94	-7.28	-0.6	9.75e-11	Vitiligo;
THYM	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg11764359	chr7:65958608	NA	-0.82	-6.45	-0.55	4.58e-9	Aortic root size;
THYM	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg23260525	chr10:116636907	FAM160B1	0.52	5.19	0.47	1.19e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg13683864	chr3:40499215	RPL14	-1.06	-11.61	-0.77	6.25e-20	Renal cell carcinoma;
THYM	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg27490568	chr2:178487706	NA	0.56	5.1	0.46	1.77e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg06238570	chr21:40685208	BRWD1	0.9	6.63	0.56	2.05e-9	Cognitive function;
THYM	cis	rs2066819	1.000	rs79718165	chr12:56644251	C/T	cg26714650	chr12:56694279	CS	-1.27	-6.32	-0.54	8.6e-9	Psoriasis vulgaris;
THYM	cis	rs6429082	0.755	rs291371	chr1:235693105	C/G	cg26050004	chr1:235667680	B3GALNT2	0.76	6.94	0.58	4.86e-10	Adiposity;
THYM	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.06	0.46	2.05e-6	Obesity-related traits;
THYM	cis	rs8192282	0.584	rs6427724	chr1:154502499	T/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg06238570	chr21:40685208	BRWD1	-0.69	-6.08	-0.53	2.47e-8	Menarche (age at onset);
THYM	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg05802129	chr4:122689817	NA	-0.59	-4.65	-0.43	1.08e-5	Type 2 diabetes;
THYM	cis	rs611744	0.604	rs13248461	chr8:109285833	C/T	cg21045802	chr8:109455806	TTC35	0.7	6.18	0.54	1.63e-8	Dupuytren's disease;
THYM	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs2625529	0.652	rs3759820	chr15:72300031	A/C	cg16672083	chr15:72433130	SENP8	0.49	4.45	0.42	2.32e-5	Red blood cell count;
THYM	cis	rs611744	0.647	rs7015513	chr8:109262570	A/C	cg21045802	chr8:109455806	TTC35	0.66	5.9	0.52	5.68e-8	Dupuytren's disease;
THYM	cis	rs6918586	0.565	rs13196986	chr6:26090452	T/C	cg03264133	chr6:25882463	NA	-0.69	-4.65	-0.43	1.08e-5	Schizophrenia;
THYM	cis	rs7412746	0.587	rs11204722	chr1:150730184	A/C	cg15448220	chr1:150897856	SETDB1	-0.85	-6.94	-0.58	4.85e-10	Melanoma;
THYM	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg26384229	chr12:38710491	ALG10B	1.04	9.99	0.72	1.71e-16	Heart rate;
THYM	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg03281154	chr5:1086625	SLC12A7	0.63	5.0	0.46	2.66e-6	Cystic fibrosis severity;
THYM	cis	rs7428	0.502	rs3184781	chr2:85549527	T/C	cg24342717	chr2:85555507	TGOLN2	-0.77	-6.63	-0.56	2.06e-9	Ear protrusion;
THYM	cis	rs35995292	0.963	rs2893567	chr7:38902934	A/G	cg19166347	chr7:37955598	SFRP4	0.56	4.47	0.42	2.18e-5	Subjective well-being (multi-trait analysis);
THYM	cis	rs901683	0.850	rs12765244	chr10:46032041	A/T	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs6665290	0.904	rs2297418	chr1:227192579	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg09184832	chr6:79620586	NA	-0.59	-4.84	-0.44	4.99e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4285028	0.948	rs13067270	chr3:121673901	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg19016782	chr12:123741754	C12orf65	-0.7	-4.59	-0.43	1.35e-5	Neutrophil percentage of white cells;
THYM	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg20503657	chr10:835505	NA	1.14	7.96	0.63	3.64e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs8073060	0.963	rs11080353	chr17:33871281	C/T	cg07895132	chr17:33825172	SLFN12L	0.61	5.6	0.5	2.08e-7	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs10186029	0.676	rs1025820	chr2:213933778	T/G	cg08319019	chr2:214017104	IKZF2	0.92	7.8	0.62	7.85e-12	Systemic sclerosis;
THYM	cis	rs600806	0.815	rs4970758	chr1:109979617	A/G	cg23616212	chr1:109941201	SORT1	-0.48	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs911119	1.000	rs6114209	chr20:23622266	G/C	cg16589663	chr20:23618590	CST3	0.76	4.49	0.42	1.98e-5	Chronic kidney disease;
THYM	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg09354556	chr3:47051341	NA	0.46	4.71	0.44	8.3e-6	Colorectal cancer;
THYM	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg15448220	chr1:150897856	SETDB1	-0.86	-6.94	-0.58	4.73e-10	Melanoma;
THYM	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg22907277	chr7:1156413	C7orf50	0.82	4.98	0.46	2.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs5417	0.780	rs222849	chr17:7185861	T/C	cg14660024	chr17:7154518	C17orf81;DULLARD	0.8	6.25	0.54	1.13e-8	Diastolic blood pressure;
THYM	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg16049864	chr8:95962084	TP53INP1	-0.77	-7.02	-0.58	3.27e-10	Type 2 diabetes;
THYM	cis	rs11642862	0.901	rs77604316	chr16:30921487	G/A	cg01070095	chr16:30968205	SETD1A	0.74	4.79	0.44	6.12e-6	Tonsillectomy;
THYM	cis	rs10457678	0.564	rs3763186	chr6:139106722	C/A	cg05131254	chr6:138188363	TNFAIP3	0.63	4.45	0.42	2.33e-5	Colorectal or endometrial cancer;
THYM	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg15744005	chr10:104629667	AS3MT	-0.76	-7.03	-0.58	3.13e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2069036	1.000	rs7911698	chr10:16094300	A/G	cg26633223	chr10:15133461	NA	-0.66	-4.63	-0.43	1.16e-5	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6430585	0.583	rs11886852	chr2:136589379	G/A	cg07169764	chr2:136633963	MCM6	1.08	12.45	0.79	1.14e-21	Corneal structure;
THYM	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg04398451	chr17:18023971	MYO15A	0.88	7.51	0.61	3.23e-11	Total body bone mineral density;
THYM	cis	rs8114671	0.562	rs6088647	chr20:33505997	T/C	cg08999081	chr20:33150536	PIGU	0.63	5.21	0.47	1.09e-6	Height;
THYM	cis	rs6480314	0.636	rs7914274	chr10:70000057	T/C	cg27159792	chr10:69524182	NA	0.81	4.89	0.45	4.06e-6	Optic nerve measurement (disc area);
THYM	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg02463440	chr8:22132932	PIWIL2	0.58	5.04	0.46	2.26e-6	Hypertriglyceridemia;
THYM	cis	rs4660306	1.000	rs7536557	chr1:45992114	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.56	-4.48	-0.42	2.11e-5	Homocysteine levels;
THYM	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg16586182	chr3:47516702	SCAP	-0.61	-5.25	-0.47	9.2e-7	Colorectal cancer;
THYM	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg13902645	chr11:5959945	NA	0.51	4.49	0.42	1.97e-5	DNA methylation (variation);
THYM	cis	rs4242434	0.819	rs6999893	chr8:22465427	T/C	cg01710189	chr8:22454888	PDLIM2	-0.5	-5.7	-0.5	1.34e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg10047753	chr17:41438598	NA	1.15	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs16825455	1.000	rs16825455	chr1:21837755	A/G	cg13963528	chr1:22612141	NA	-0.74	-4.53	-0.42	1.71e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs);
THYM	cis	rs58785573	1.000	rs58785573	chr4:38653773	A/T	cg24279243	chr4:38676559	KLF3	0.46	4.73	0.44	7.68e-6	Lymphocyte percentage of white cells;
THYM	cis	rs2295499	0.715	rs2282766	chr4:2658327	G/A	cg17924901	chr4:3475233	DOK7	0.23	4.86	0.45	4.55e-6	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs870825	0.616	rs28444118	chr4:185621692	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg25427524	chr10:38739819	LOC399744	-0.67	-6.25	-0.54	1.16e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11574514	1.000	rs28655136	chr16:68001447	T/C	cg04582263	chr16:67973788	LCAT	1.12	5.04	0.46	2.26e-6	Crohn's disease;
THYM	cis	rs10929159	0.928	rs2123511	chr2:236923187	C/T	cg20128773	chr2:236923534	AGAP1	0.35	4.66	0.43	1.01e-5	Parkinson's disease;
THYM	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg04287289	chr16:89883240	FANCA	0.65	5.87	0.52	6.49e-8	Vitiligo;
THYM	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg25838465	chr1:92012736	NA	-0.91	-9.25	-0.69	6.55e-15	Breast cancer;
THYM	cis	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg15556689	chr8:8085844	FLJ10661	0.74	5.97	0.52	4.09e-8	Red cell distribution width;
THYM	cis	rs4690686	0.500	rs17062797	chr4:177262063	G/A	cg17059388	chr4:177262070	NA	0.48	6.73	0.57	1.29e-9	Essential tremor;
THYM	cis	rs8070740	0.786	rs34878464	chr17:5327251	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.66	5.29	0.48	7.77e-7	Menopause (age at onset);
THYM	cis	rs56775891	1.000	rs4799088	chr18:77573548	A/G	cg26740109	chr18:77585428	NA	-0.66	-4.72	-0.44	8.26e-6	Schizophrenia;
THYM	cis	rs4654899	0.865	rs12130841	chr1:21067051	C/T	cg01072550	chr1:21505969	NA	-0.61	-5.27	-0.48	8.41e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs6435161	1.000	rs72927001	chr2:203530332	T/C	cg18429434	chr2:203499731	FAM117B	-0.76	-5.01	-0.46	2.49e-6	Total cholesterol levels;
THYM	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg21475434	chr5:93447410	FAM172A	0.96	6.08	0.53	2.55e-8	Diabetic retinopathy;
THYM	cis	rs17443541	0.507	rs12622777	chr2:200465331	G/A	cg03741458	chr2:200468445	NA	-0.8	-6.04	-0.53	3.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg16342193	chr10:102329863	NA	-0.52	-5.29	-0.48	7.74e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.67	-5.26	-0.47	8.97e-7	Lung cancer in ever smokers;
THYM	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg06636001	chr8:8085503	FLJ10661	0.69	6.07	0.53	2.63e-8	Mood instability;
THYM	cis	rs6032067	0.673	rs2301366	chr20:43836173	T/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.64	-7.37	-0.6	6.28e-11	Blood protein levels;
THYM	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg02734326	chr4:10020555	SLC2A9	0.77	7.16	0.59	1.73e-10	Bone mineral density;
THYM	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg03388043	chr17:80084554	CCDC57	0.69	5.87	0.52	6.36e-8	Life satisfaction;
THYM	cis	rs7177699	0.557	rs4380028	chr15:79111093	C/T	cg15571903	chr15:79123663	NA	-0.59	-6.78	-0.57	9.9e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs4866334	1.000	rs77743777	chr5:18488452	G/A	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs6840360	0.837	rs13138986	chr4:152719310	T/C	cg22705602	chr4:152727874	NA	0.57	6.21	0.54	1.39e-8	Intelligence (multi-trait analysis);
THYM	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg06917634	chr15:78832804	PSMA4	-0.88	-8.37	-0.65	4.86e-13	Sudden cardiac arrest;
THYM	cis	rs1278352	0.728	rs2126742	chr10:127774515	C/T	cg08295661	chr10:127769903	ADAM12	0.55	5.64	0.5	1.71e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg03709012	chr19:19516395	GATAD2A	-0.75	-5.85	-0.51	7.06e-8	Tonsillectomy;
THYM	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.44	5.47	0.49	3.61e-7	Monocyte percentage of white cells;
THYM	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg12386194	chr3:101231763	SENP7	0.69	5.15	0.47	1.41e-6	Colorectal cancer;
THYM	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06850241	chr22:41845214	NA	0.59	4.76	0.44	7e-6	Vitiligo;
THYM	cis	rs6450176	1.000	rs6886510	chr5:53303127	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.82	6.14	0.53	1.94e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg00024416	chr22:24240387	NA	0.55	5.52	0.49	2.93e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1994135	0.617	rs2200155	chr12:33734935	G/A	cg10856724	chr12:34555212	NA	-0.72	-5.57	-0.5	2.4e-7	Resting heart rate;
THYM	cis	rs2997447	0.706	rs61776622	chr1:26469035	A/G	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs13256369	1.000	rs12545771	chr8:8567977	C/G	cg17143192	chr8:8559678	CLDN23	0.91	6.74	0.57	1.2e-9	Obesity-related traits;
THYM	cis	rs2073300	0.609	rs6137941	chr20:23400848	G/A	cg12062639	chr20:23401060	NAPB	1.1	5.73	0.51	1.16e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg06623918	chr6:96969491	KIAA0776	-1.05	-9.75	-0.71	5.73e-16	Headache;
THYM	cis	rs10895275	0.961	rs1820455	chr11:102092366	A/T	cg24447756	chr11:102105824	NA	0.54	4.74	0.44	7.37e-6	Migraine;
THYM	cis	rs865483	0.895	rs4795203	chr17:35828972	T/C	cg06716730	chr17:35851459	DUSP14	0.43	7.08	0.59	2.49e-10	Monocyte count;
THYM	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs921665	0.831	rs80283188	chr2:3199209	T/C	cg16434511	chr2:3151078	NA	1.13	6.04	0.53	2.97e-8	World class endurance athleticism;
THYM	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg06611532	chr13:114900021	NA	0.63	7.04	0.59	2.98e-10	Schizophrenia;
THYM	cis	rs2213920	0.619	rs7857548	chr9:118199365	C/T	cg13918206	chr9:118159781	DEC1	0.86	4.9	0.45	3.86e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs7584330	0.666	rs72620819	chr2:238354982	C/T	cg16989719	chr2:238392110	NA	-0.63	-4.88	-0.45	4.29e-6	Prostate cancer;
THYM	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg06634786	chr22:41940651	POLR3H	0.72	5.25	0.47	9.13e-7	Cannabis dependence symptom count;
THYM	cis	rs6964587	0.839	rs13229273	chr7:91444472	G/A	cg17063962	chr7:91808500	NA	1.15	11.08	0.75	8.21e-19	Breast cancer;
THYM	cis	rs2985684	0.846	rs10150624	chr14:50051565	A/G	cg02151108	chr14:50098012	C14orf104	-0.69	-5.7	-0.5	1.34e-7	Carotid intima media thickness;
THYM	cis	rs8103278	1.000	rs8108864	chr19:46301671	G/A	cg14061069	chr19:46274453	DMPK	-0.58	-5.72	-0.51	1.21e-7	Coronary artery disease;
THYM	cis	rs4713118	0.869	rs9461400	chr6:27700559	A/G	cg12963246	chr6:28129442	ZNF389	0.64	4.86	0.45	4.62e-6	Parkinson's disease;
THYM	cis	rs4731207	0.698	rs6960504	chr7:124530314	A/G	cg05285228	chr7:124571219	POT1	-0.64	-4.82	-0.44	5.49e-6	Cutaneous malignant melanoma;
THYM	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.88	-10.46	-0.73	1.73e-17	Chronic sinus infection;
THYM	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs950169	0.960	rs12905475	chr15:84800495	G/A	cg24253500	chr15:84953950	NA	0.59	4.72	0.44	8.07e-6	Schizophrenia;
THYM	cis	rs6450176	0.638	rs56220547	chr5:53287952	A/G	ch.5.1024479R	chr5:53302184	ARL15	-1.2	-10.72	-0.74	4.78e-18	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs6531656	0.578	rs7686818	chr4:38682612	A/G	cg24279243	chr4:38676559	KLF3	0.83	7.47	0.61	3.85e-11	Lymphocyte counts;
THYM	cis	rs4690686	0.769	rs11133146	chr4:177278878	C/T	cg17059388	chr4:177262070	NA	-0.39	-5.93	-0.52	4.89e-8	Essential tremor;
THYM	cis	rs13326165	0.502	rs73091166	chr3:52397539	C/T	cg08438690	chr3:52279403	PPM1M	-0.84	-4.6	-0.43	1.32e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs13256369	0.951	rs13260947	chr8:8565883	A/G	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs3768617	0.510	rs2296292	chr1:183086757	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs7260598	0.535	rs13343732	chr19:24111281	A/G	cg15526094	chr19:24182596	NA	-0.63	-5.09	-0.46	1.82e-6	Response to taxane treatment (placlitaxel);
THYM	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg00958927	chr1:175162553	KIAA0040	0.36	4.92	0.45	3.66e-6	Alcohol dependence;
THYM	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.3	-0.48	7.55e-7	Blood metabolite levels;
THYM	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.38	0.48	5.3e-7	Tonsillectomy;
THYM	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg12407791	chr17:73824354	UNC13D	-0.45	-5.18	-0.47	1.22e-6	White matter hyperintensity burden;
THYM	cis	rs9948	0.867	rs62152860	chr2:97516818	C/A	cg01990225	chr2:97406019	LMAN2L	-0.98	-4.46	-0.42	2.26e-5	Erectile dysfunction and prostate cancer treatment;
THYM	cis	rs6840360	0.967	rs6535817	chr4:152641941	G/C	cg22705602	chr4:152727874	NA	-0.6	-6.39	-0.55	6.07e-9	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg22974920	chr21:40686053	BRWD1	0.59	4.5	0.42	1.95e-5	Cognitive function;
THYM	cis	rs10744422	1.000	rs10847869	chr12:123328359	C/G	cg25930673	chr12:123319894	HIP1R	-0.88	-5.15	-0.47	1.43e-6	Schizophrenia;
THYM	cis	rs478304	0.654	rs10896035	chr11:65461160	G/A	cg17480646	chr11:65405466	SIPA1	-0.97	-8.99	-0.68	2.44e-14	Acne (severe);
THYM	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg07022442	chr13:21864356	NA	-0.64	-4.47	-0.42	2.2e-5	White matter hyperintensity burden;
THYM	cis	rs4842666	0.831	rs11105378	chr12:90090741	C/T	cg00757033	chr12:89920650	WDR51B	0.47	4.57	0.42	1.49e-5	Blood pressure;
THYM	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.66	4.63	0.43	1.18e-5	Aortic root size;
THYM	cis	rs9790314	0.905	rs6789388	chr3:160970437	G/A	cg03342759	chr3:160939853	NMD3	-0.81	-7.28	-0.6	9.51e-11	Morning vs. evening chronotype;
THYM	cis	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg01528321	chr10:82214614	TSPAN14	0.82	6.22	0.54	1.34e-8	Post bronchodilator FEV1;
THYM	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg02734326	chr4:10020555	SLC2A9	0.77	7.16	0.59	1.73e-10	Bone mineral density;
THYM	cis	rs7712401	0.517	rs10066188	chr5:122364030	C/T	cg19808643	chr5:122110361	SNX2	-0.61	-5.22	-0.47	1.04e-6	Mean platelet volume;
THYM	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg21028142	chr17:79581711	NPLOC4	-0.61	-6.22	-0.54	1.32e-8	Eye color traits;
THYM	cis	rs36051895	0.632	rs10815171	chr9:5172567	G/A	cg02405213	chr9:5042618	JAK2	-1.0	-10.52	-0.73	1.28e-17	Pediatric autoimmune diseases;
THYM	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg24250549	chr1:154909240	PMVK	0.77	5.9	0.52	5.58e-8	Prostate cancer;
THYM	cis	rs10992471	0.528	rs10117627	chr9:95203953	G/A	cg14631576	chr9:95140430	CENPP	-0.84	-8.02	-0.64	2.69e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6598955	0.670	rs6676619	chr1:26539035	T/G	cg00852783	chr1:26633632	UBXN11	0.82	7.73	0.62	1.12e-11	Obesity-related traits;
THYM	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg11752832	chr7:134001865	SLC35B4	0.76	5.72	0.51	1.24e-7	Mean platelet volume;
THYM	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.55	-0.73	1.12e-17	Primary sclerosing cholangitis;
THYM	cis	rs7107174	0.681	rs10793301	chr11:78020913	G/T	cg02023728	chr11:77925099	USP35	0.65	5.83	0.51	7.52e-8	Testicular germ cell tumor;
THYM	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg15445000	chr17:37608096	MED1	-0.44	-5.07	-0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg10523679	chr1:76189770	ACADM	-0.84	-6.64	-0.56	1.96e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg10018233	chr7:150070692	REPIN1	0.43	5.87	0.52	6.26e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4654899	0.931	rs6661116	chr1:21337155	C/G	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.26e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg17757837	chr7:157058334	UBE3C	-0.66	-5.32	-0.48	6.85e-7	Body mass index;
THYM	cis	rs76878669	0.561	rs4930363	chr11:66169676	C/T	cg18002602	chr11:66138449	SLC29A2	0.47	4.93	0.45	3.5e-6	Educational attainment (years of education);
THYM	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg11494091	chr17:61959527	GH2	1.05	16.37	0.86	2.08e-29	Prudent dietary pattern;
THYM	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg16586182	chr3:47516702	SCAP	0.64	5.62	0.5	1.93e-7	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg10515332	chr4:99064459	C4orf37	0.57	4.56	0.42	1.54e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3862030	0.720	rs11593971	chr10:104234090	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-5.91	-0.52	5.34e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg01017244	chr2:74357527	NA	-1.09	-8.72	-0.67	9.05e-14	Gestational age at birth (maternal effect);
THYM	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.5	-0.49	3.18e-7	Obesity-related traits;
THYM	cis	rs6732160	0.588	rs2043101	chr2:73374050	A/G	cg24220031	chr2:73402428	NA	-0.71	-5.79	-0.51	8.94e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg05985134	chr18:33552581	C18orf21	-0.69	-4.86	-0.45	4.62e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs6032067	0.538	rs13041506	chr20:43739655	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.6	-6.1	-0.53	2.24e-8	Blood protein levels;
THYM	cis	rs2456568	0.803	rs10831142	chr11:93640781	A/G	cg17595323	chr11:93583763	C11orf90	0.6	6.33	0.54	8.23e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg00012203	chr2:219082015	ARPC2	-0.77	-6.63	-0.56	2.03e-9	Colorectal cancer;
THYM	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg03115019	chr17:80708279	FN3K	0.64	4.49	0.42	2.02e-5	Glycated hemoglobin levels;
THYM	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg11663144	chr21:46675770	NA	-0.72	-10.48	-0.73	1.54e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg23187316	chr7:1099788	C7orf50	0.45	4.89	0.45	4.09e-6	Longevity;Endometriosis;
THYM	cis	rs12935418	0.616	rs2549853	chr16:81026455	G/A	cg16651780	chr16:81037892	C16orf61	-0.84	-6.56	-0.56	2.82e-9	Mean corpuscular volume;
THYM	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg04944784	chr2:26401820	FAM59B	1.09	8.74	0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs12476592	0.602	rs262515	chr2:63891194	G/T	cg17519650	chr2:63277830	OTX1	-0.72	-4.68	-0.43	9.38e-6	Childhood ear infection;
THYM	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg23978390	chr7:1156363	C7orf50	0.62	4.56	0.42	1.51e-5	Longevity;Endometriosis;
THYM	cis	rs35883536	0.528	rs1577511	chr1:101030859	G/A	cg09408571	chr1:101003634	GPR88	0.56	5.96	0.52	4.27e-8	Monocyte count;
THYM	cis	rs3911569	0.511	rs565902	chr11:95076066	G/A	cg08427067	chr11:95015466	NA	-0.76	-4.58	-0.43	1.39e-5	Alzheimer disease and age of onset;
THYM	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4523957	0.583	rs2760737	chr17:2024647	C/T	cg16513277	chr17:2031491	SMG6	-0.96	-8.72	-0.67	9.17e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs986417	0.748	rs10133403	chr14:60945298	C/T	cg27398547	chr14:60952738	C14orf39	1.13	6.34	0.55	7.62e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs9880211	1.000	rs12695645	chr3:135990881	A/T	cg21827317	chr3:136751795	NA	-0.66	-4.46	-0.42	2.22e-5	Body mass index;Height;
THYM	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.55	-5.74	-0.51	1.15e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs9972944	0.756	rs8077164	chr17:63764645	C/T	cg07283582	chr17:63770753	CCDC46	-0.66	-4.97	-0.45	2.96e-6	Total body bone mineral density;
THYM	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg26924012	chr15:45694286	SPATA5L1	1.03	9.11	0.68	1.29e-14	Homoarginine levels;
THYM	cis	rs2811415	0.597	rs10934839	chr3:127745539	T/C	cg05377949	chr3:127951287	EEFSEC	0.37	4.57	0.42	1.45e-5	Lung function (FEV1/FVC);
THYM	cis	rs3781426	0.662	rs3781412	chr10:126715154	A/G	cg01213599	chr10:126704259	CTBP2	-0.32	-4.57	-0.42	1.48e-5	Height;
THYM	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.63	4.61	0.43	1.24e-5	Renal function-related traits (BUN);
THYM	cis	rs7926906	0.713	rs7952437	chr11:90526222	C/T	cg26138821	chr11:89956704	CHORDC1	0.53	4.72	0.44	8.08e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.68	9.11	0.68	1.34e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg04063615	chr12:132293388	NA	-0.58	-4.91	-0.45	3.79e-6	Migraine;
THYM	cis	rs4589258	0.737	rs1792599	chr11:90442240	C/T	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11723261	0.582	rs6830247	chr4:150683	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.84	5.97	0.52	4.01e-8	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14442939	chr10:27389572	ANKRD26	0.86	4.61	0.43	1.25e-5	Breast cancer;
THYM	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg12257156	chr7:158823799	VIPR2	0.67	5.96	0.52	4.29e-8	Facial morphology (factor 20);
THYM	cis	rs7246967	0.608	rs428613	chr19:23009919	C/G	cg05241461	chr19:22816980	ZNF492	0.54	4.53	0.42	1.74e-5	Bronchopulmonary dysplasia;
THYM	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg00129232	chr17:37814104	STARD3	0.71	4.8	0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	trans	rs62103177	0.789	rs7242289	chr18:77603291	C/T	cg05926928	chr17:57297772	GDPD1	1.19	9.0	0.68	2.28e-14	Opioid sensitivity;
THYM	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.12	8.17	0.64	1.29e-12	Platelet count;
THYM	cis	rs6032067	0.929	rs6017511	chr20:43833132	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs5769707	0.632	rs135871	chr22:50008969	A/G	cg20744362	chr22:50050164	C22orf34	0.8	7.01	0.58	3.38e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg06656553	chr16:89960601	TCF25	-0.84	-4.82	-0.44	5.5e-6	Skin colour saturation;
THYM	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg26850624	chr5:429559	AHRR	-0.71	-5.23	-0.47	1.02e-6	Cystic fibrosis severity;
THYM	cis	rs2239547	0.522	rs2581815	chr3:52982159	C/G	cg11645453	chr3:52864694	ITIH4	0.27	4.56	0.42	1.51e-5	Schizophrenia;
THYM	cis	rs75920871	0.623	rs17120244	chr11:116919511	C/T	cg20608306	chr11:116969690	SIK3	-0.49	-4.68	-0.43	9.62e-6	Subjective well-being;
THYM	cis	rs4845875	0.600	rs11805138	chr1:11833159	T/C	cg24844545	chr1:11908347	NPPA	0.59	4.89	0.45	4.12e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg14820908	chr5:178986412	RUFY1	0.63	6.28	0.54	9.9e-9	Lung cancer;
THYM	cis	rs2273669	0.667	rs7766248	chr6:109347262	C/T	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg18352616	chr4:3374830	RGS12	0.77	8.8	0.67	6.14e-14	Serum sulfate level;
THYM	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7567389	0.677	rs72845976	chr2:128086440	T/A	cg09760422	chr2:128146352	NA	0.4	4.52	0.42	1.8e-5	Self-rated health;
THYM	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.66	4.64	0.43	1.13e-5	Tonsillectomy;
THYM	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg12935359	chr14:103987150	CKB	0.61	6.14	0.53	1.93e-8	Body mass index;
THYM	cis	rs2290159	0.800	rs9809947	chr3:12655944	T/C	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7589728	0.514	rs12465706	chr2:88467459	C/A	cg04511125	chr2:88470314	THNSL2	0.66	4.62	0.43	1.21e-5	Plasma clusterin levels;
THYM	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg08645402	chr16:4508243	NA	0.76	6.61	0.56	2.28e-9	Schizophrenia;
THYM	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg00277334	chr10:82204260	NA	-0.83	-10.18	-0.72	6.99e-17	Post bronchodilator FEV1;
THYM	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.61e-20	Menopause (age at onset);
THYM	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.66	-4.63	-0.43	1.18e-5	Aortic root size;
THYM	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg23583168	chr7:148888333	NA	-1.1	-16.73	-0.86	4.47e-30	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs34638657	0.827	rs11641736	chr16:82206279	G/A	cg09894383	chr16:82067445	HSD17B2	-0.5	-4.83	-0.44	5.31e-6	Lung adenocarcinoma;
THYM	cis	rs11096990	0.855	rs2566176	chr4:39155993	A/G	cg24403649	chr4:39172243	NA	-0.6	-5.09	-0.46	1.77e-6	Cognitive function;
THYM	cis	rs28595532	0.920	rs115076001	chr4:119764346	T/G	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs4866334	1.000	rs76836105	chr5:18467089	T/G	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs4242434	0.672	rs3758042	chr8:22486951	T/C	cg21658235	chr8:22456391	C8orf58	0.45	4.57	0.42	1.48e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs12549902	0.966	rs4317621	chr8:41516581	A/G	cg21772509	chr8:41503840	NKX6-3	0.65	6.07	0.53	2.58e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
THYM	cis	rs4660306	0.961	rs937290	chr1:45961955	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.43	-0.49	4.37e-7	Homocysteine levels;
THYM	cis	rs7312774	0.618	rs73385161	chr12:107300164	G/A	cg16260113	chr12:107380972	MTERFD3	1.05	5.57	0.5	2.4e-7	Severe influenza A (H1N1) infection;
THYM	cis	rs2050392	0.517	rs160018	chr10:30772703	T/C	cg25182066	chr10:30743637	MAP3K8	-0.55	-4.71	-0.44	8.47e-6	Inflammatory bowel disease;
THYM	cis	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg10856724	chr12:34555212	NA	1.03	10.43	0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs10463554	0.927	rs34776	chr5:102451794	C/G	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Parkinson's disease;
THYM	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg25036284	chr2:26402008	FAM59B	0.8	5.36	0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs7762018	0.556	rs75659875	chr6:170054800	A/C	cg19338460	chr6:170058176	WDR27	-1.06	-6.51	-0.56	3.48e-9	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs7267979	0.816	rs8115257	chr20:25207931	A/G	cg08601574	chr20:25228251	PYGB	0.63	4.93	0.45	3.49e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4523957	0.890	rs12941621	chr17:2194852	C/T	cg16513277	chr17:2031491	SMG6	0.78	7.45	0.61	4.34e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg02640540	chr1:67518911	SLC35D1	0.65	4.83	0.44	5.32e-6	Lymphocyte percentage of white cells;
THYM	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg17294928	chr15:75287854	SCAMP5	-0.94	-7.94	-0.63	4.01e-12	Blood trace element (Zn levels);
THYM	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg12179176	chr11:130786555	SNX19	0.95	9.69	0.71	7.59e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7317940	1.000	rs7317940	chr13:78021218	G/A	cg02481778	chr13:77460607	KCTD12	-0.7	-4.69	-0.43	9e-6	Age of smoking initiation;
THYM	cis	rs2239547	0.522	rs6770957	chr3:52995416	T/C	cg11645453	chr3:52864694	ITIH4	0.29	4.48	0.42	2.06e-5	Schizophrenia;
THYM	cis	rs870825	0.616	rs2310108	chr4:185639475	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs1160297	0.585	rs12614959	chr2:53090302	T/C	cg07782112	chr2:53107842	NA	0.76	6.26	0.54	1.09e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs17102423	0.755	rs4902358	chr14:65542477	A/G	cg11161011	chr14:65562177	MAX	-0.85	-6.83	-0.57	8.06e-10	Obesity-related traits;
THYM	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs977987	0.843	rs4146810	chr16:75415831	A/G	cg03315344	chr16:75512273	CHST6	0.69	6.09	0.53	2.36e-8	Dupuytren's disease;
THYM	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg04025307	chr7:1156635	C7orf50	0.5	4.71	0.44	8.46e-6	Longevity;Endometriosis;
THYM	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg00677455	chr12:58241039	CTDSP2	0.75	5.59	0.5	2.19e-7	Multiple sclerosis;
THYM	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg24812749	chr6:127587940	RNF146	0.97	7.72	0.62	1.14e-11	Breast cancer;
THYM	cis	rs2455799	0.613	rs6772879	chr3:15741793	G/A	cg16303742	chr3:15540471	COLQ	-0.54	-5.87	-0.52	6.41e-8	Mean platelet volume;
THYM	cis	rs1569175	1.000	rs281777	chr2:200839613	T/C	cg23649088	chr2:200775458	C2orf69	-0.76	-4.57	-0.42	1.47e-5	Response to treatment for acute lymphoblastic leukemia;
THYM	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02475777	chr4:1388615	CRIPAK	0.71	5.18	0.47	1.27e-6	Longevity;
THYM	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg13609457	chr4:120235615	NA	0.5	4.76	0.44	6.95e-6	Corneal astigmatism;
THYM	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.13	-8.4	-0.65	4.32e-13	Platelet count;
THYM	cis	rs791888	0.965	rs791877	chr10:89406863	A/G	cg10377144	chr10:89419177	PAPSS2	0.38	5.97	0.52	4.1e-8	Magnesium levels;
THYM	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg06634786	chr22:41940651	POLR3H	0.71	5.04	0.46	2.19e-6	Vitiligo;
THYM	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.53	-4.97	-0.45	3.01e-6	Lymphocyte counts;
THYM	cis	rs16866061	1.000	rs4674916	chr2:225365635	C/A	cg12698349	chr2:225449008	CUL3	1.14	10.45	0.73	1.77e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.64	0.43	1.12e-5	Obesity-related traits;
THYM	cis	rs7626444	0.625	rs843541	chr3:196475750	A/G	cg12930392	chr3:196481615	PAK2	0.4	4.92	0.45	3.58e-6	Monocyte count;
THYM	cis	rs939658	0.567	rs11631829	chr15:79446529	C/T	cg17916960	chr15:79447300	NA	-0.64	-7.0	-0.58	3.57e-10	Refractive error;
THYM	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg07570687	chr10:102243282	WNT8B	0.75	6.59	0.56	2.4e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs995000	0.931	rs1168020	chr1:63009956	C/T	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg04362960	chr10:104952993	NT5C2	0.6	4.86	0.45	4.62e-6	Arsenic metabolism;
THYM	cis	rs12282928	0.959	rs713325	chr11:48285301	A/G	cg22827986	chr11:48284249	OR4X1	-0.53	-5.5	-0.49	3.18e-7	Migraine - clinic-based;
THYM	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg03609598	chr5:56110824	MAP3K1	-0.89	-6.07	-0.53	2.63e-8	Initial pursuit acceleration;
THYM	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg10515332	chr4:99064459	C4orf37	0.71	5.67	0.5	1.51e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2730245	0.527	rs842700	chr7:158697565	G/A	cg24397884	chr7:158709396	WDR60	0.54	5.26	0.47	8.87e-7	Height;
THYM	cis	rs16912285	0.591	rs12796137	chr11:24364459	T/G	ch.11.24196551F	chr11:24239977	NA	0.84	5.9	0.52	5.47e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2219968	1.000	rs12056577	chr8:78961915	A/C	cg00738934	chr8:78996279	NA	0.91	9.75	0.71	5.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg17105886	chr17:28927953	LRRC37B2	-1.18	-6.06	-0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6669072	0.647	rs1335727	chr1:91238652	C/T	cg08895590	chr1:91227319	NA	-0.65	-8.25	-0.65	9.1e-13	Cognitive function;
THYM	cis	rs7980799	0.682	rs10844611	chr12:33603544	T/C	cg06521331	chr12:34319734	NA	0.67	4.62	0.43	1.22e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs2046867	0.862	rs75638790	chr3:72830502	C/T	cg25664220	chr3:72788482	NA	-0.95	-7.22	-0.6	1.28e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs11190604	1.000	rs11190601	chr10:102296730	A/G	cg16342193	chr10:102329863	NA	-0.52	-5.08	-0.46	1.85e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg11764359	chr7:65958608	NA	0.78	6.09	0.53	2.34e-8	Aortic root size;
THYM	cis	rs490234	0.841	rs950534	chr9:128225881	C/G	cg14078157	chr9:128172775	NA	-0.62	-4.72	-0.44	8.18e-6	Mean arterial pressure;
THYM	cis	rs8049040	0.609	rs11866859	chr16:71478888	G/A	cg08717414	chr16:71523259	ZNF19	-0.79	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs4919694	1.000	rs4917988	chr10:104752830	T/G	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg10224037	chr5:178157518	ZNF354A	1.0	8.0	0.63	2.99e-12	Neutrophil percentage of white cells;
THYM	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg12564285	chr5:131593104	PDLIM4	0.6	7.19	0.59	1.48e-10	Acylcarnitine levels;
THYM	cis	rs4930103	0.935	rs2075745	chr11:2018336	A/T	cg18511798	chr11:2018149	H19;MIR675	-0.57	-5.57	-0.5	2.39e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg11327659	chr7:150037044	RARRES2	0.4	4.63	0.43	1.15e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg18709589	chr6:96969512	KIAA0776	-0.58	-4.69	-0.43	9.22e-6	Headache;
THYM	cis	rs911555	0.723	rs4906320	chr14:103876925	T/C	cg12935359	chr14:103987150	CKB	0.52	5.96	0.52	4.19e-8	Intelligence (multi-trait analysis);
THYM	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.68	5.09	0.46	1.79e-6	Tonsillectomy;
THYM	cis	rs7631605	0.935	rs6550455	chr3:37147358	T/C	cg21328643	chr3:37258149	NA	-0.47	-4.51	-0.42	1.87e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs2505998	0.833	rs2251674	chr10:43605392	A/G	cg06632098	chr10:43605906	RET	1.1	11.1	0.75	7.65e-19	Hirschsprung disease;
THYM	cis	rs17253792	0.822	rs28409547	chr14:56047826	C/T	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg23428387	chr22:49814324	NA	-0.58	-6.08	-0.53	2.52e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2637266	0.935	rs6480822	chr10:78354092	A/C	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22455342	chr2:225449267	CUL3	0.97	9.01	0.68	2.14e-14	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs1160297	0.609	rs6715847	chr2:53097378	T/G	cg07782112	chr2:53107842	NA	0.77	6.13	0.53	2.03e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.16	-0.75	5.56e-19	Primary sclerosing cholangitis;
THYM	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg14784868	chr12:69753453	YEATS4	0.77	6.32	0.54	8.57e-9	Blood protein levels;
THYM	cis	rs4509693	1.000	rs4244340	chr10:102499268	G/C	cg15234845	chr10:102496500	NA	0.65	4.6	0.43	1.3e-5	Alzheimer's disease;
THYM	cis	rs10463554	0.526	rs114525197	chr5:102443045	T/C	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.49e-6	Parkinson's disease;
THYM	cis	rs7572733	0.534	rs1401091	chr2:198790423	T/G	cg00792783	chr2:198669748	PLCL1	-0.84	-6.0	-0.52	3.54e-8	Dermatomyositis;
THYM	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.59	-0.43	1.34e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs9914988	1.000	rs9914988	chr17:27183104	G/A	cg20469991	chr17:27169893	C17orf63	0.78	5.04	0.46	2.22e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs2731664	0.792	rs2544809	chr5:176885499	T/C	cg14098951	chr5:176875120	PRR7	0.57	5.02	0.46	2.45e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4148689	0.951	rs4148687	chr7:117134634	G/A	cg17204129	chr7:117119601	CFTR	-0.59	-4.7	-0.43	8.83e-6	Gout;
THYM	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg03806693	chr22:41940476	POLR3H	0.97	8.04	0.64	2.5e-12	Vitiligo;
THYM	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg07157834	chr1:205819609	PM20D1	-0.6	-5.35	-0.48	6.11e-7	Menarche (age at onset);
THYM	cis	rs7914558	0.505	rs12260436	chr10:104741114	A/C	cg15744005	chr10:104629667	AS3MT	-0.82	-6.29	-0.54	9.74e-9	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs73086581	1.000	rs6037708	chr20:3961253	C/G	cg02187196	chr20:3869020	PANK2	0.5	5.62	0.5	1.92e-7	Response to antidepressants in depression;
THYM	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg15556689	chr8:8085844	FLJ10661	-0.59	-4.61	-0.43	1.26e-5	Joint mobility (Beighton score);
THYM	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs6032067	0.929	rs17424723	chr20:43814520	G/T	cg20256260	chr20:43936981	MATN4;RBPJL	0.78	7.04	0.59	2.96e-10	Blood protein levels;
THYM	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.58	4.58	0.43	1.42e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1823778	0.609	rs12955117	chr18:67628430	T/C	cg13164537	chr18:67624071	CD226	1.16	4.76	0.44	6.79e-6	Mean platelet volume;
THYM	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg06766960	chr11:133703094	NA	-0.53	-5.25	-0.47	9.26e-7	Childhood ear infection;
THYM	cis	rs6025261	0.761	rs3848695	chr20:55513254	C/T	cg04763273	chr20:55502381	NA	0.54	4.45	0.42	2.34e-5	Verbal memory performance (delayed recall level);
THYM	cis	rs2066819	1.000	rs41423244	chr12:56693520	A/C	cg26714650	chr12:56694279	CS	1.35	7.01	0.58	3.41e-10	Psoriasis vulgaris;
THYM	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg04842962	chr6:43655489	MRPS18A	1.41	15.7	0.85	3.85e-28	IgG glycosylation;
THYM	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg27129171	chr3:47204927	SETD2	0.7	6.69	0.57	1.57e-9	Colorectal cancer;
THYM	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg08017756	chr2:100939284	LONRF2	-0.74	-7.3	-0.6	8.73e-11	Intelligence (multi-trait analysis);
THYM	cis	rs3771570	1.000	rs73002147	chr2:242302934	T/C	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs1451375	0.652	rs7803788	chr7:50625898	A/G	cg14593290	chr7:50529359	DDC	-0.54	-4.56	-0.42	1.55e-5	Malaria;
THYM	cis	rs10927875	0.596	rs1806990	chr1:16129377	G/A	cg21385522	chr1:16154831	NA	-1.32	-13.48	-0.81	9e-24	Dilated cardiomyopathy;
THYM	cis	rs1747683	0.528	rs1983830	chr10:13363636	A/G	cg25835351	chr10:13388524	SEPHS1	-0.32	-5.76	-0.51	1.05e-7	IgG glycosylation;
THYM	cis	rs28595532	0.920	rs56303276	chr4:119723514	C/T	cg11846333	chr4:119757529	SEC24D	1.46	5.09	0.46	1.83e-6	Cannabis dependence symptom count;
THYM	cis	rs4460079	0.531	rs13111878	chr4:114840202	A/G	cg02060584	chr4:113970739	ANK2	-0.56	-4.58	-0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg02820040	chr2:241836501	C2orf54	-0.29	-5.96	-0.52	4.26e-8	Urinary metabolites;
THYM	trans	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg10856724	chr12:34555212	NA	-0.82	-7.07	-0.59	2.55e-10	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs8017423	0.900	rs7141887	chr14:90705364	G/T	cg04239629	chr14:90701769	NA	-0.62	-4.52	-0.42	1.81e-5	Mortality in heart failure;
THYM	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs6500395	0.962	rs1564980	chr16:48651377	A/T	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7106204	0.609	rs11824883	chr11:24284952	G/A	ch.11.24196551F	chr11:24239977	NA	0.95	5.86	0.52	6.58e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs2456568	0.802	rs1395387	chr11:93639307	A/T	cg17595323	chr11:93583763	C11orf90	-0.59	-6.24	-0.54	1.21e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg19346786	chr7:2764209	NA	-0.58	-4.98	-0.45	2.86e-6	Height;
THYM	cis	rs4523957	0.583	rs8067895	chr17:2030234	G/A	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs61931739	0.890	rs1197560	chr12:34121447	G/C	cg10856724	chr12:34555212	NA	-0.6	-5.27	-0.48	8.62e-7	Morning vs. evening chronotype;
THYM	cis	rs77140172	0.677	rs77860352	chr4:89627774	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	1.38	5.66	0.5	1.6e-7	Post bronchodilator FEV1;
THYM	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	5.03	0.46	2.34e-6	Hip circumference adjusted for BMI;
THYM	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg14798641	chr3:49314920	USP4;C3orf62	-0.69	-4.69	-0.43	9.23e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg22875332	chr1:76189707	ACADM	0.89	12.06	0.78	7.38e-21	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7909074	1.000	rs10751361	chr10:45398186	C/A	cg04218760	chr10:45406644	TMEM72	-0.65	-5.85	-0.51	6.91e-8	Mean corpuscular volume;
THYM	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg00278517	chr6:167070616	RPS6KA2	-0.35	-4.58	-0.42	1.44e-5	Crohn's disease;
THYM	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg03733263	chr8:22462867	KIAA1967	1.01	11.35	0.76	2.25e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg07362569	chr17:61921086	SMARCD2	0.71	6.06	0.53	2.71e-8	Prudent dietary pattern;
THYM	cis	rs3820068	0.608	rs12740492	chr1:16048951	A/T	cg27534772	chr1:16042836	PLEKHM2	0.49	5.06	0.46	2.01e-6	Systolic blood pressure;
THYM	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.41	-4.47	-0.42	2.2e-5	Hemoglobin concentration;
THYM	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg10760299	chr15:45669010	GATM	-0.73	-5.12	-0.46	1.6e-6	Homoarginine levels;
THYM	cis	rs677665	0.537	rs12121476	chr1:9335327	C/G	cg03265564	chr1:9748971	PIK3CD	0.25	4.71	0.43	8.54e-6	Eosinophil percentage of white cells;
THYM	cis	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg17143192	chr8:8559678	CLDN23	-0.61	-4.91	-0.45	3.82e-6	Mood instability;
THYM	cis	rs868036	1.000	rs1026734	chr15:68100950	T/C	cg24579218	chr15:68104479	NA	-0.65	-6.51	-0.56	3.59e-9	Restless legs syndrome;
THYM	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg06481639	chr22:41940642	POLR3H	-0.6	-4.8	-0.44	6e-6	Neuroticism;
THYM	cis	rs11809207	0.523	rs2783706	chr1:26504697	A/G	cg00147160	chr1:26503991	CNKSR1	0.53	7.17	0.59	1.65e-10	Height;
THYM	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.33e-5	Retinal vascular caliber;
THYM	cis	rs2075230	0.705	rs11078702	chr17:7543508	T/G	cg27413385	chr17:7515425	FXR2	-0.36	-5.1	-0.46	1.74e-6	Hormone measurements;
THYM	cis	rs4523957	0.748	rs12603592	chr17:2119818	A/T	cg16513277	chr17:2031491	SMG6	-0.77	-7.51	-0.61	3.16e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg15704280	chr7:45808275	SEPT13	-0.77	-6.87	-0.58	6.53e-10	Coronary artery disease;
THYM	cis	rs11225247	0.772	rs11501343	chr11:102227214	A/C	cg11690896	chr11:102217788	BIRC2	1.12	5.18	0.47	1.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs128738	0.500	rs28667882	chr5:131568113	C/G	cg22598563	chr5:131563921	P4HA2	0.57	4.91	0.45	3.77e-6	Giant cell arteritis;
THYM	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg01699819	chr7:1052092	C7orf50	0.84	7.66	0.62	1.59e-11	Bronchopulmonary dysplasia;
THYM	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg17054759	chr22:49844102	NA	-0.51	-4.83	-0.44	5.14e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg12935359	chr14:103987150	CKB	-0.63	-6.45	-0.55	4.63e-9	Body mass index;
THYM	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg25237894	chr2:233734115	C2orf82	-0.35	-4.96	-0.45	3.12e-6	Coronary artery disease;
THYM	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg03188948	chr7:1209495	NA	0.9	5.02	0.46	2.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7727544	0.547	rs10076758	chr5:131524299	A/G	cg16205897	chr5:131564050	P4HA2	-0.45	-4.51	-0.42	1.83e-5	Blood metabolite levels;
THYM	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg18132916	chr6:79620363	NA	-0.54	-4.79	-0.44	6.11e-6	Intelligence (multi-trait analysis);
THYM	trans	rs4650994	0.544	rs10798613	chr1:178500022	C/T	cg05059571	chr16:84539110	KIAA1609	-0.95	-11.25	-0.76	3.55e-19	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.71	5.5	0.49	3.14e-7	Tonsillectomy;
THYM	cis	rs6988636	1.000	rs11993411	chr8:124180537	T/C	cg23067535	chr8:124195133	FAM83A	-1.04	-5.51	-0.49	3.04e-7	Urinary uromodulin levels;
THYM	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg26441486	chr22:50317300	CRELD2	0.44	7.45	0.61	4.35e-11	Schizophrenia;
THYM	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg09035930	chr12:129282057	SLC15A4	0.84	10.33	0.73	3.29e-17	Systemic lupus erythematosus;
THYM	cis	rs7523273	0.546	rs2796261	chr1:207888760	C/T	cg22525895	chr1:207977042	MIR29B2	-0.53	-5.04	-0.46	2.19e-6	Schizophrenia;
THYM	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg03351412	chr1:154909251	PMVK	0.7	5.35	0.48	6.1e-7	Prostate cancer;
THYM	cis	rs11225247	0.685	rs12273698	chr11:102234776	A/G	cg11690896	chr11:102217788	BIRC2	1.12	5.18	0.47	1.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs13064411	0.518	rs7637618	chr3:113176122	G/A	cg18753928	chr3:113234510	CCDC52	-0.78	-7.16	-0.59	1.68e-10	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	4.79	0.44	6.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs854765	0.583	rs8078105	chr17:17853782	T/C	cg16928487	chr17:17741425	SREBF1	-0.55	-5.47	-0.49	3.62e-7	Total body bone mineral density;
THYM	cis	rs7975161	0.753	rs7972034	chr12:104640881	G/T	cg25273343	chr12:104657179	TXNRD1	-0.77	-4.57	-0.42	1.48e-5	Toenail selenium levels;
THYM	cis	rs28785552	0.554	rs11084178	chr19:53212361	C/T	cg10871876	chr19:53194124	ZNF83	0.65	5.11	0.46	1.69e-6	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	5.57	0.5	2.36e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs36051895	0.632	rs9657576	chr9:5183028	T/G	cg02405213	chr9:5042618	JAK2	-1.01	-11.19	-0.75	4.95e-19	Pediatric autoimmune diseases;
THYM	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs4731207	0.698	rs4728012	chr7:124481798	C/T	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs4619206	1	rs4619206	chr12:1002857	T/C	cg06357748	chr12:1025529	RAD52	0.41	4.68	0.43	9.64e-6	Lung cancer in ever smokers;
THYM	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg00376283	chr12:123451042	ABCB9	0.72	4.88	0.45	4.24e-6	Neutrophil percentage of white cells;
THYM	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg10802700	chr17:80790467	TBCD;ZNF750	0.58	4.66	0.43	1.05e-5	Breast cancer;
THYM	cis	rs9814567	1.000	rs6801596	chr3:134252114	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-8.41	-0.65	4e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs865483	0.929	rs9906140	chr17:35857151	A/G	cg06716730	chr17:35851459	DUSP14	-0.41	-6.88	-0.58	6.38e-10	Monocyte count;
THYM	cis	rs75920871	0.588	rs4548653	chr11:116903316	G/A	cg20608306	chr11:116969690	SIK3	-0.49	-5.34	-0.48	6.24e-7	Subjective well-being;
THYM	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg00376283	chr12:123451042	ABCB9	0.71	4.87	0.45	4.45e-6	Neutrophil percentage of white cells;
THYM	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13732083	chr21:47605072	C21orf56	0.71	4.99	0.46	2.78e-6	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg03476357	chr21:30257390	N6AMT1	-0.61	-4.72	-0.44	8.17e-6	Dental caries;
THYM	cis	rs2836633	0.929	rs62217517	chr21:40033177	T/A	cg12884169	chr21:40033163	ERG	0.68	8.52	0.66	2.33e-13	Coronary artery disease;
THYM	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg08772003	chr10:104629869	AS3MT	-0.53	-4.54	-0.42	1.64e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.84	-5.77	-0.51	1e-7	Body mass index;
THYM	cis	rs8067545	0.611	rs2703776	chr17:20137709	C/A	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs2964802	0.505	rs1438714	chr5:10811422	G/A	cg14521931	chr5:10832172	NA	-0.6	-5.04	-0.46	2.2e-6	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs1978968	1.000	rs1110662	chr22:18444908	G/A	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Body mass index;
THYM	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	4.95	0.45	3.17e-6	Motion sickness;
THYM	cis	rs6867032	1.000	rs4413568	chr5:2016894	A/G	cg26168224	chr5:2018326	NA	1.34	16.84	0.87	2.78e-30	Gut microbiome composition (winter);
THYM	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg22974920	chr21:40686053	BRWD1	-0.67	-5.36	-0.48	5.87e-7	Cognitive function;
THYM	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg03433033	chr1:76189801	ACADM	-0.64	-5.96	-0.52	4.23e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg00129232	chr17:37814104	STARD3	0.78	5.43	0.49	4.27e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7152530	0.520	rs12100628	chr14:98635483	T/C	cg05180522	chr14:98101740	NA	-0.61	-4.74	-0.44	7.57e-6	Staphylococcus aureus infection;
THYM	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg17644776	chr2:200775616	C2orf69	0.77	5.4	0.48	5.01e-7	Schizophrenia;
THYM	cis	rs4631830	0.863	rs4554834	chr10:51530146	A/C	cg10326726	chr10:51549505	MSMB	-0.55	-5.57	-0.5	2.32e-7	Prostate-specific antigen levels;
THYM	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg07955315	chr12:132687729	GALNT9	0.48	5.04	0.46	2.26e-6	Anti-saccade response;
THYM	cis	rs2034088	0.833	rs9748016	chr17:410451	G/T	cg06217071	chr17:408420	NA	0.84	9.03	0.68	1.92e-14	Hip circumference adjusted for BMI;
THYM	cis	rs7584330	0.518	rs74478860	chr2:238437364	C/G	cg08992911	chr2:238395768	MLPH	1.11	6.57	0.56	2.65e-9	Prostate cancer;
THYM	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg11764359	chr7:65958608	NA	-0.64	-4.84	-0.44	5.08e-6	Aortic root size;
THYM	cis	rs919433	0.679	rs6757669	chr2:198530355	C/T	cg00792783	chr2:198669748	PLCL1	0.82	5.44	0.49	4.16e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg12963246	chr6:28129442	ZNF389	0.77	6.4	0.55	5.74e-9	Parkinson's disease;
THYM	cis	rs7011507	0.648	rs6471752	chr8:49309167	C/T	cg08774009	chr8:49309094	NA	-0.71	-6.32	-0.54	8.45e-9	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs13102973	0.899	rs4546304	chr4:135902382	G/A	cg14419869	chr4:135874104	NA	0.82	6.86	0.58	7.03e-10	Subjective well-being;
THYM	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg15704280	chr7:45808275	SEPT13	-0.82	-8.08	-0.64	2.08e-12	Height;
THYM	cis	rs9296092	0.560	rs9469500	chr6:33526196	C/T	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03264133	chr6:25882463	NA	-0.73	-5.82	-0.51	7.95e-8	Blood metabolite levels;
THYM	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg02527881	chr3:46936655	PTH1R	-0.69	-5.38	-0.48	5.32e-7	Birth weight;
THYM	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg25811766	chr13:21894605	NA	-0.77	-4.91	-0.45	3.82e-6	White matter hyperintensity burden;
THYM	cis	rs995000	0.899	rs1167998	chr1:62931632	C/A	cg06896770	chr1:63153194	DOCK7	-0.89	-7.35	-0.6	7.03e-11	Triglyceride levels;
THYM	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg18538332	chr22:24372958	LOC391322	-0.91	-7.13	-0.59	1.96e-10	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7512552	0.839	rs6662108	chr1:150420541	G/T	cg15654264	chr1:150340011	RPRD2	0.44	5.12	0.47	1.58e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2024714	0.835	rs2427220	chr20:60218702	C/A	cg11922086	chr20:60783424	NA	0.87	4.54	0.42	1.63e-5	Longevity;
THYM	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12530845	0.943	rs60858457	chr7:135336918	T/C	cg23117316	chr7:135346802	PL-5283	-0.67	-5.92	-0.52	5.05e-8	Red blood cell traits;
THYM	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg10253484	chr15:75165896	SCAMP2	-0.75	-5.4	-0.48	4.81e-7	Airflow obstruction;
THYM	cis	rs7000551	0.671	rs59370752	chr8:22288889	A/C	cg12081754	chr8:22256438	SLC39A14	1.04	9.02	0.68	2.08e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg01097406	chr16:89675127	NA	-0.62	-5.04	-0.46	2.23e-6	Vitiligo;
THYM	cis	rs79149102	0.579	rs76900720	chr15:75348895	A/T	cg09165964	chr15:75287851	SCAMP5	-0.93	-4.93	-0.45	3.52e-6	Lung cancer;
THYM	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg00990874	chr7:1149470	C7orf50	-0.61	-4.59	-0.43	1.34e-5	Bronchopulmonary dysplasia;
THYM	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg03676636	chr4:99064102	C4orf37	0.41	5.67	0.5	1.56e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs757081	0.634	rs17472942	chr11:17094702	A/G	cg15432903	chr11:17409602	KCNJ11	-0.5	-4.71	-0.44	8.4e-6	Systolic blood pressure;
THYM	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg26028573	chr6:26043587	HIST1H2BB	0.52	4.59	0.43	1.35e-5	Blood metabolite levels;
THYM	cis	rs7131987	0.903	rs918873	chr12:29390501	G/T	cg09582351	chr12:29534625	ERGIC2	-0.49	-4.66	-0.43	1.01e-5	QT interval;
THYM	cis	rs2932538	0.961	rs6690292	chr1:113188419	C/T	cg22162597	chr1:113214053	CAPZA1	-0.63	-5.21	-0.47	1.08e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg12031863	chr16:4587854	C16orf5	-0.42	-4.6	-0.43	1.28e-5	Schizophrenia;
THYM	cis	rs66691851	0.504	rs863930	chr3:135949737	T/G	cg12473912	chr3:136751656	NA	0.7	6.49	0.55	3.95e-9	Neuroticism;Schizophrenia;
THYM	cis	rs11048434	0.518	rs7311509	chr12:9179034	A/G	cg26114124	chr12:9217669	LOC144571	0.51	4.5	0.42	1.94e-5	Sjögren's syndrome;
THYM	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg23982607	chr1:1823379	GNB1	0.72	6.44	0.55	4.96e-9	Body mass index;
THYM	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg06766960	chr11:133703094	NA	-0.61	-5.42	-0.49	4.41e-7	Childhood ear infection;
THYM	cis	rs28595532	0.920	rs56046676	chr4:119766733	A/G	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg23758822	chr17:41437982	NA	1.22	13.81	0.82	1.89e-24	Menopause (age at onset);
THYM	cis	rs7084402	0.967	rs11815274	chr10:60328891	A/G	cg09696939	chr10:60272079	BICC1	0.46	5.53	0.49	2.75e-7	Refractive error;
THYM	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg07061783	chr6:25882402	NA	-0.8	-6.68	-0.57	1.64e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg07537917	chr2:241836409	C2orf54	-0.26	-6.35	-0.55	7.26e-9	Urinary metabolites;
THYM	cis	rs8112449	0.894	rs34681319	chr19:10517696	G/A	cg01466491	chr19:10523363	NA	-0.66	-6.3	-0.54	9.36e-9	Multiple sclerosis;Gastritis;
THYM	cis	rs490234	0.651	rs13301073	chr9:128284378	G/A	cg14078157	chr9:128172775	NA	-0.76	-6.24	-0.54	1.23e-8	Mean arterial pressure;
THYM	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg17509989	chr5:176798049	RGS14	-0.65	-5.63	-0.5	1.81e-7	Urate levels in lean individuals;
THYM	cis	rs6032067	1.000	rs35284867	chr20:43845836	A/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.37	-0.48	5.67e-7	Blood protein levels;
THYM	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg06108461	chr20:60628389	TAF4	-1.1	-9.2	-0.69	8.33e-15	Body mass index;
THYM	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg16188243	chr19:2783719	SGTA	0.69	4.81	0.44	5.67e-6	Total cholesterol levels;
THYM	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.27	-5.73	-0.51	1.2e-7	Obesity-related traits;
THYM	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg04865290	chr3:52927548	TMEM110	-0.88	-4.55	-0.42	1.59e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.78	-6.97	-0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs28595532	1.000	rs115706377	chr4:119628481	G/A	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg05738196	chr6:26577821	NA	-0.68	-5.54	-0.49	2.74e-7	Intelligence (multi-trait analysis);
THYM	cis	rs17253792	0.822	rs78261053	chr14:56061784	C/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs7953508	0.506	rs10859532	chr12:93960917	G/C	cg18151635	chr12:93972918	NA	-0.87	-6.12	-0.53	2.07e-8	Pubertal anthropometrics;
THYM	cis	rs7616559	1.000	rs7616559	chr3:156728610	A/G	cg15697575	chr3:156784781	NA	-0.41	-5.36	-0.48	5.92e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg16230307	chr14:35515116	FAM177A1	0.83	5.34	0.48	6.36e-7	Psoriasis;
THYM	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg13395646	chr4:1353034	KIAA1530	-0.55	-4.6	-0.43	1.29e-5	Longevity;
THYM	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs3096299	0.583	rs2965949	chr16:89520452	A/G	cg06640241	chr16:89574553	SPG7	0.85	5.88	0.52	6.17e-8	Multiple myeloma (IgH translocation);
THYM	cis	rs7769051	0.522	rs6930703	chr6:133111266	C/T	cg07930552	chr6:133119739	C6orf192	1.14	4.51	0.42	1.82e-5	Type 2 diabetes nephropathy;
THYM	cis	rs17443541	0.507	rs6753800	chr2:200462959	G/C	cg01795955	chr2:200468626	NA	-0.72	-5.0	-0.46	2.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg25237894	chr2:233734115	C2orf82	-0.36	-5.15	-0.47	1.42e-6	Coronary artery disease;
THYM	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg10911889	chr6:126070802	HEY2	0.57	4.54	0.42	1.64e-5	Brugada syndrome;
THYM	cis	rs526231	0.511	rs6881612	chr5:102377013	C/T	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Primary biliary cholangitis;
THYM	cis	rs2294693	1.000	rs2294693	chr6:41005502	T/C	cg14418226	chr6:40996092	UNC5CL	0.7	6.02	0.53	3.22e-8	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs9972944	0.657	rs9904302	chr17:63758238	A/G	cg07283582	chr17:63770753	CCDC46	-0.66	-5.1	-0.46	1.73e-6	Total body bone mineral density;
THYM	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg18681998	chr4:17616180	MED28	-0.96	-9.54	-0.7	1.56e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg09035930	chr12:129282057	SLC15A4	-0.6	-5.45	-0.49	3.99e-7	Systemic lupus erythematosus;
THYM	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg09990169	chr2:241835740	C2orf54	-0.31	-5.15	-0.47	1.43e-6	Urinary metabolites;
THYM	cis	rs61990749	0.597	rs1978416	chr14:78227901	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.02	0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	trans	rs11186	0.556	rs59488585	chr2:189966807	T/G	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	cis	rs939574	1.000	rs2293078	chr2:220100683	C/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.32	5.96	0.52	4.29e-8	Platelet distribution width;
THYM	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg15445000	chr17:37608096	MED1	0.44	5.07	0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9972944	0.729	rs10083872	chr17:63773474	A/G	cg07283582	chr17:63770753	CCDC46	0.68	5.54	0.49	2.69e-7	Total body bone mineral density;
THYM	cis	rs3812831	0.695	rs913526	chr13:114928946	G/C	cg06611532	chr13:114900021	NA	0.66	7.29	0.6	9.16e-11	Schizophrenia;
THYM	cis	rs7599312	0.517	rs10192988	chr2:213407782	T/G	cg16329650	chr2:213403929	ERBB4	1.04	12.32	0.78	2.07e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg20469991	chr17:27169893	C17orf63	-0.79	-4.79	-0.44	6.18e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs11583043	0.918	rs11582211	chr1:101416871	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.62	4.52	0.42	1.77e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg03396347	chr1:1875803	NA	-0.7	-7.27	-0.6	1.03e-10	Body mass index;
THYM	cis	rs870825	0.932	rs2696059	chr4:185575127	A/T	cg04058563	chr4:185651563	MLF1IP	-0.86	-6.12	-0.53	2.07e-8	Blood protein levels;
THYM	cis	rs1050631	0.564	rs1785934	chr18:33718326	A/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.28	0.48	8.32e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs977987	0.836	rs7200053	chr16:75474618	C/T	cg03315344	chr16:75512273	CHST6	0.74	5.92	0.52	5.07e-8	Dupuytren's disease;
THYM	cis	rs2303759	0.914	rs2288481	chr19:49878196	G/A	cg22590775	chr19:49891494	CCDC155	0.84	6.49	0.55	3.85e-9	Multiple sclerosis;
THYM	cis	rs854765	0.583	rs11078404	chr17:17820487	A/T	cg04398451	chr17:18023971	MYO15A	-0.76	-6.93	-0.58	4.99e-10	Total body bone mineral density;
THYM	trans	rs9929218	0.508	rs1559366	chr16:68799611	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.93	9.61	0.7	1.14e-15	Colorectal cancer;
THYM	cis	rs12208915	0.731	rs9448581	chr6:79553378	A/G	cg05283184	chr6:79620031	NA	-0.62	-4.7	-0.43	8.74e-6	Left atrial antero-posterior diameter;
THYM	cis	rs490234	0.588	rs34983978	chr9:128169170	G/A	cg13590414	chr9:128173245	NA	-0.58	-4.72	-0.44	8.26e-6	Mean arterial pressure;
THYM	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg05294307	chr14:35346193	BAZ1A	-0.88	-6.16	-0.53	1.74e-8	Psoriasis;
THYM	cis	rs9435341	0.965	rs1762485	chr1:107625056	C/T	cg00944433	chr1:107599041	PRMT6	0.43	5.3	0.48	7.5e-7	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg24531977	chr5:56204891	C5orf35	0.72	5.77	0.51	9.7e-8	Initial pursuit acceleration;
THYM	cis	rs1829883	0.931	rs7720138	chr5:98879849	G/C	cg08333243	chr5:99726346	NA	0.54	4.96	0.45	3.12e-6	Hemostatic factors and hematological phenotypes;
THYM	cis	rs6032067	0.641	rs34638860	chr20:43765839	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.7	-7.59	-0.61	2.14e-11	Blood protein levels;
THYM	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs986417	1.000	rs10143118	chr14:61066043	G/A	cg27398547	chr14:60952738	C14orf39	1.16	6.36	0.55	7.03e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs8028313	0.731	rs13380201	chr15:67973665	A/G	cg24579218	chr15:68104479	NA	-0.72	-6.74	-0.57	1.19e-9	Obesity;
THYM	cis	rs34638657	0.500	rs1056675	chr16:82181934	T/C	cg09439754	chr16:82129088	HSD17B2	-0.51	-4.78	-0.44	6.51e-6	Lung adenocarcinoma;
THYM	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg20203395	chr5:56204925	C5orf35	-0.67	-4.58	-0.42	1.44e-5	Type 2 diabetes;
THYM	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg19748678	chr4:122722346	EXOSC9	0.73	5.15	0.47	1.42e-6	Type 2 diabetes;
THYM	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg22709100	chr7:91322751	NA	0.66	4.59	0.43	1.34e-5	Breast cancer;
THYM	cis	rs775227	0.574	rs13064411	chr3:113046640	A/G	cg18753928	chr3:113234510	CCDC52	-0.75	-5.04	-0.46	2.23e-6	Dental caries;
THYM	cis	rs11645898	0.810	rs72787085	chr16:72182564	C/T	cg03805757	chr16:71968109	PKD1L3	-0.73	-5.37	-0.48	5.49e-7	Blood protein levels;
THYM	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.67	-6.9	-0.58	5.78e-10	Crohn's disease;
THYM	cis	rs2806561	0.704	rs2746560	chr1:23526279	G/A	cg19743168	chr1:23544995	NA	0.65	6.86	0.58	7.01e-10	Height;
THYM	cis	rs8067545	0.934	rs34848191	chr17:19918626	G/T	cg13482628	chr17:19912719	NA	0.56	4.54	0.42	1.67e-5	Schizophrenia;
THYM	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg10334053	chr1:2078117	PRKCZ	-0.47	-4.96	-0.45	3.11e-6	Height;
THYM	cis	rs2219968	0.525	rs4406385	chr8:78876684	G/A	cg00738934	chr8:78996279	NA	0.61	4.93	0.45	3.5e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8028313	0.504	rs338364	chr15:68173921	A/G	cg24579218	chr15:68104479	NA	-0.68	-6.43	-0.55	5.07e-9	Obesity;
THYM	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs10887741	0.690	rs12772633	chr10:89442492	G/A	cg13926569	chr10:89418898	PAPSS2	0.64	6.84	0.57	7.69e-10	Exercise (leisure time);
THYM	cis	rs8067545	0.611	rs2526476	chr17:20134289	C/T	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs7553864	0.605	rs7531038	chr1:87605049	C/G	cg17420885	chr1:87600446	LOC339524	-0.85	-7.63	-0.62	1.8e-11	Smoking behavior;
THYM	cis	rs7247513	0.964	rs12979795	chr19:12717847	C/T	cg01871581	chr19:12707946	ZNF490	0.86	9.44	0.7	2.63e-15	Bipolar disorder;
THYM	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg23711669	chr6:146136114	FBXO30	0.96	9.87	0.71	3.12e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7043114	0.525	rs6479419	chr9:95110002	T/C	cg14631576	chr9:95140430	CENPP	-0.86	-9.03	-0.68	1.97e-14	Height;
THYM	trans	rs629535	0.725	rs639127	chr8:70073251	A/G	cg21567404	chr3:27674614	NA	1.08	10.14	0.72	8.19e-17	Dupuytren's disease;
THYM	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7582180	0.764	rs13006224	chr2:100917109	C/T	cg14675211	chr2:100938903	LONRF2	0.76	8.1	0.64	1.84e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7948975	1	rs7948975	chr11:90424638	T/C	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Educational attainment (years of education);
THYM	cis	rs2985684	0.789	rs1957979	chr14:50063332	A/G	cg02151108	chr14:50098012	C14orf104	-0.71	-5.49	-0.49	3.4e-7	Carotid intima media thickness;
THYM	cis	rs2070677	0.627	rs2987797	chr10:135379934	G/A	cg20169779	chr10:135381914	SYCE1	0.87	6.56	0.56	2.85e-9	Gout;
THYM	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg13918804	chr1:2043761	PRKCZ	-0.81	-7.45	-0.61	4.35e-11	Height;
THYM	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg16405210	chr4:1374714	KIAA1530	-1.04	-9.44	-0.7	2.66e-15	Longevity;
THYM	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg23231163	chr10:75533350	FUT11	-0.49	-7.06	-0.59	2.76e-10	Inflammatory bowel disease;
THYM	cis	rs10779751	1.000	rs2024627	chr1:11298790	T/C	cg08854313	chr1:11322531	MTOR	0.94	8.23	0.65	9.67e-13	Body mass index;
THYM	cis	rs6500395	0.925	rs6500396	chr16:48625458	A/T	cg04672837	chr16:48644449	N4BP1	0.51	4.98	0.45	2.85e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg04315214	chr1:2043799	PRKCZ	0.55	4.58	0.43	1.41e-5	Height;
THYM	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg01097406	chr16:89675127	NA	0.61	5.53	0.49	2.76e-7	Hemoglobin concentration;
THYM	cis	rs4731207	0.646	rs7783781	chr7:124454413	T/G	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs4654899	0.965	rs7512116	chr1:21501095	C/A	cg01072550	chr1:21505969	NA	-0.74	-6.63	-0.56	2.02e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg27490568	chr2:178487706	NA	0.57	5.35	0.48	6.07e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs595982	0.546	rs12461075	chr19:49399821	G/A	cg19746536	chr19:49375674	PPP1R15A	0.97	9.26	0.69	6.24e-15	Red cell distribution width;
THYM	cis	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg05182265	chr7:156933206	UBE3C	-0.69	-9.32	-0.69	4.58e-15	Body mass index;
THYM	cis	rs4148087	0.932	rs2032259	chr21:43621473	G/C	cg09727148	chr21:43560719	UMODL1	0.54	4.5	0.42	1.9e-5	Eating disorder in bipolar disorder;
THYM	cis	rs4731207	0.596	rs1871775	chr7:124674652	G/T	cg05285228	chr7:124571219	POT1	-0.65	-4.98	-0.45	2.9e-6	Cutaneous malignant melanoma;
THYM	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg27534772	chr1:16042836	PLEKHM2	0.56	6.31	0.54	8.77e-9	Systolic blood pressure;
THYM	cis	rs11186	0.556	rs56080628	chr2:189958076	G/T	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs10463554	0.890	rs26428	chr5:102366484	C/T	cg23492399	chr5:102201601	PAM	0.64	4.81	0.44	5.71e-6	Parkinson's disease;
THYM	cis	rs2522056	1.000	rs2106854	chr5:131769174	C/T	cg24060327	chr5:131705240	SLC22A5	0.7	4.53	0.42	1.74e-5	Lymphocyte counts;Fibrinogen;
THYM	cis	rs35264875	1.000	rs7940235	chr11:68820121	C/T	cg01993067	chr11:68851601	TPCN2	1.04	5.08	0.46	1.87e-6	Blond vs. brown hair color;
THYM	cis	rs2050392	1.000	rs2480280	chr10:30696092	A/G	cg02070205	chr10:30722105	MAP3K8	-0.52	-4.65	-0.43	1.07e-5	Inflammatory bowel disease;
THYM	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg18132916	chr6:79620363	NA	-0.56	-4.95	-0.45	3.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg00645579	chr11:617140	IRF7;MUPCDH	-0.52	-6.57	-0.56	2.68e-9	Systemic lupus erythematosus;
THYM	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg14416269	chr4:6271139	WFS1	0.54	5.62	0.5	1.93e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7246657	0.943	rs10404602	chr19:37825633	A/T	cg22634378	chr19:37742834	NA	0.68	5.67	0.5	1.55e-7	Coronary artery calcification;
THYM	cis	rs885814	0.673	rs1767429	chr1:21889340	A/G	cg14781605	chr1:21864896	ALPL	-0.63	-4.53	-0.42	1.71e-5	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs2692947	0.832	rs4907212	chr2:96410048	T/A	cg22654517	chr2:96458247	NA	0.58	4.59	0.43	1.36e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg06636001	chr8:8085503	FLJ10661	-0.62	-5.28	-0.48	8.27e-7	Joint mobility (Beighton score);
THYM	cis	rs1729951	0.575	rs747843	chr3:136703130	G/C	cg12473912	chr3:136751656	NA	0.62	5.03	0.46	2.34e-6	Neuroticism;
THYM	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	7.59	0.61	2.23e-11	Smoking behavior;
THYM	cis	rs684232	0.602	rs4968057	chr17:517521	T/A	cg15660573	chr17:549704	VPS53	-1.02	-11.2	-0.75	4.53e-19	Prostate cancer;
THYM	cis	rs2069036	0.951	rs11253760	chr10:16109238	T/C	cg26633223	chr10:15133461	NA	0.71	5.04	0.46	2.2e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs11031096	0.655	rs56172516	chr11:4182004	G/T	cg22027985	chr11:4115532	RRM1	-0.5	-4.6	-0.43	1.3e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs6430585	0.640	rs6716070	chr2:136544651	G/T	cg07169764	chr2:136633963	MCM6	-1.19	-13.32	-0.81	1.84e-23	Corneal structure;
THYM	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg00278517	chr6:167070616	RPS6KA2	-0.35	-4.58	-0.42	1.44e-5	Crohn's disease;
THYM	cis	rs57994353	0.897	rs72775778	chr9:139381128	G/A	cg14115884	chr9:139300582	SDCCAG3	0.68	4.7	0.43	8.9e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.85	-6.21	-0.54	1.38e-8	Multiple sclerosis;
THYM	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg10760299	chr15:45669010	GATM	-0.72	-4.98	-0.46	2.83e-6	Homoarginine levels;
THYM	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg06636001	chr8:8085503	FLJ10661	0.72	6.66	0.56	1.76e-9	Joint mobility (Beighton score);
THYM	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs986417	1.000	rs1018531	chr14:60970844	C/T	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg23815491	chr16:72088622	HP	0.68	5.23	0.47	1.01e-6	Fibrinogen levels;
THYM	cis	rs4888262	0.526	rs6564142	chr16:74590047	T/C	cg01733217	chr16:74700730	RFWD3	0.8	8.28	0.65	7.82e-13	Testicular germ cell tumor;
THYM	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg26384229	chr12:38710491	ALG10B	-0.83	-8.3	-0.65	6.83e-13	Heart rate;
THYM	cis	rs791888	0.858	rs2180968	chr10:89418730	A/C	cg13926569	chr10:89418898	PAPSS2	0.75	9.27	0.69	6.04e-15	Magnesium levels;
THYM	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg24503407	chr1:205819492	PM20D1	0.95	9.15	0.68	1.08e-14	Menarche (age at onset);
THYM	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg23682913	chr1:2080710	PRKCZ	-0.57	-5.35	-0.48	6.05e-7	Height;
THYM	cis	rs4654899	0.758	rs6688147	chr1:21335894	A/G	cg01072550	chr1:21505969	NA	-0.76	-7.43	-0.61	4.71e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg16322792	chr1:120165303	ZNF697	0.92	11.5	0.76	1.09e-19	Systemic lupus erythematosus;
THYM	cis	rs7084402	0.902	rs1658417	chr10:60333039	T/C	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg06028808	chr11:68637592	NA	0.62	6.5	0.55	3.73e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg08773314	chr2:239334832	ASB1	0.64	9.5	0.7	1.94e-15	Multiple system atrophy;
THYM	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg14664628	chr15:75095509	CSK	-0.66	-4.93	-0.45	3.43e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg02493798	chr17:6899577	ALOX12	-0.65	-7.94	-0.63	4.12e-12	Tonsillectomy;
THYM	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.12	7.31	0.6	8.35e-11	Platelet count;
THYM	cis	rs28595532	0.920	rs55985953	chr4:119764971	T/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg24675658	chr1:53192096	ZYG11B	0.61	4.93	0.45	3.52e-6	Monocyte count;
THYM	trans	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg15556689	chr8:8085844	FLJ10661	0.7	6.06	0.53	2.7e-8	Mood instability;
THYM	cis	rs2932538	0.961	rs2932539	chr1:113215786	A/G	cg22162597	chr1:113214053	CAPZA1	-0.65	-5.08	-0.46	1.91e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs10158481	0.759	rs9438863	chr1:25487864	A/T	cg09264742	chr1:25757510	TMEM57	-0.63	-4.52	-0.42	1.78e-5	Urate levels in obese individuals;
THYM	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg00376283	chr12:123451042	ABCB9	0.72	4.94	0.45	3.36e-6	Neutrophil percentage of white cells;
THYM	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.5	0.73	1.4e-17	Prudent dietary pattern;
THYM	cis	rs1728785	1.000	rs7202306	chr16:68587684	G/A	cg02972257	chr16:68554789	NA	-0.76	-4.63	-0.43	1.14e-5	Ulcerative colitis;
THYM	cis	rs7523273	1.000	rs12410786	chr1:207976205	T/A	cg22525895	chr1:207977042	MIR29B2	-0.85	-8.13	-0.64	1.62e-12	Schizophrenia;
THYM	cis	rs3784262	0.528	rs10518961	chr15:58334345	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.65	-5.04	-0.46	2.24e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
THYM	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg24209194	chr3:40518798	ZNF619	0.63	5.02	0.46	2.46e-6	Renal cell carcinoma;
THYM	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg12165864	chr7:66369176	NA	-0.64	-4.97	-0.45	2.97e-6	Aortic root size;
THYM	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg18252515	chr7:66147081	NA	0.66	4.87	0.45	4.38e-6	Aortic root size;
THYM	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg16325326	chr1:53192061	ZYG11B	0.8	7.54	0.61	2.79e-11	Monocyte count;
THYM	cis	rs748404	0.631	rs6493084	chr15:43647627	A/G	cg12861797	chr15:43585817	TGM7	0.44	4.67	0.43	9.79e-6	Lung cancer;
THYM	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg13866156	chr1:1669148	SLC35E2	-0.73	-7.29	-0.6	9.23e-11	Body mass index;
THYM	cis	rs1215050	0.740	rs1084784	chr4:98961711	T/G	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg03859395	chr2:55845619	SMEK2	0.58	5.06	0.46	2.02e-6	Metabolic syndrome;
THYM	cis	rs7584330	0.554	rs6760913	chr2:238400702	C/T	cg14458575	chr2:238380390	NA	0.86	4.48	0.42	2.11e-5	Prostate cancer;
THYM	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg00256281	chr22:41985642	PMM1	-0.57	-4.76	-0.44	7.03e-6	Vitiligo;
THYM	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg22974920	chr21:40686053	BRWD1	-0.63	-4.97	-0.45	2.98e-6	Cognitive function;
THYM	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg11871910	chr12:69753446	YEATS4	0.85	7.03	0.59	3.09e-10	Blood protein levels;
THYM	cis	rs28595532	0.920	rs115214765	chr4:119728167	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs36051895	0.664	rs10974963	chr9:5101305	G/A	cg02405213	chr9:5042618	JAK2	-1.0	-10.94	-0.75	1.67e-18	Pediatric autoimmune diseases;
THYM	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg12935359	chr14:103987150	CKB	-0.58	-5.66	-0.5	1.61e-7	Body mass index;
THYM	cis	rs10095849	0.608	rs72641297	chr8:39472233	C/T	cg01911981	chr8:39380341	ADAM3A	-0.59	-5.05	-0.46	2.13e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg03929089	chr4:120376271	NA	-0.98	-11.74	-0.77	3.42e-20	Coronary artery disease;
THYM	cis	rs6987853	0.966	rs1947297	chr8:42453023	A/G	cg09913449	chr8:42400586	C8orf40	0.84	7.87	0.63	5.79e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7725337	1.000	rs984399	chr5:88381894	G/A	cg11280525	chr5:87955695	LOC645323	-0.4	-4.52	-0.42	1.78e-5	Total body bone mineral density;
THYM	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs4843185	0.516	rs374029	chr16:85725953	G/A	cg26571870	chr16:85723150	GINS2	-0.41	-4.65	-0.43	1.07e-5	Platelet distribution width;
THYM	trans	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg25214090	chr10:38739885	LOC399744	0.96	8.21	0.64	1.11e-12	Corneal astigmatism;
THYM	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg23711669	chr6:146136114	FBXO30	0.84	8.52	0.66	2.44e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1403694	0.695	rs1050274	chr3:186435370	G/A	cg12454167	chr3:186435060	KNG1	0.53	7.54	0.61	2.83e-11	Blood protein levels;
THYM	cis	rs3750965	1.000	rs1466222	chr11:68832848	G/A	cg01403660	chr11:68851641	TPCN2	0.74	5.89	0.52	5.83e-8	Hair color;
THYM	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg12419862	chr22:24373484	LOC391322	0.71	6.32	0.54	8.51e-9	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg20891283	chr12:69753455	YEATS4	1.06	10.24	0.72	5.15e-17	Blood protein levels;
THYM	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	-0.45	-8.8	-0.67	6.09e-14	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs854765	0.647	rs1008136	chr17:18027142	C/G	cg04398451	chr17:18023971	MYO15A	-1.0	-11.09	-0.75	7.9e-19	Total body bone mineral density;
THYM	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg00339695	chr16:24857497	SLC5A11	0.7	6.56	0.56	2.75e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6484504	0.576	rs208072	chr11:31141288	A/G	cg26647111	chr11:31128758	NA	0.59	4.58	0.43	1.38e-5	Red blood cell count;
THYM	cis	rs9902453	0.845	rs10853135	chr17:28188675	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.61	0.43	1.27e-5	Coffee consumption (cups per day);
THYM	cis	rs7809950	0.678	rs2237660	chr7:106862963	T/A	cg23024343	chr7:107201750	COG5	-1.0	-8.43	-0.65	3.79e-13	Coronary artery disease;
THYM	cis	rs2219968	0.525	rs1552434	chr8:78879528	A/G	cg00738934	chr8:78996279	NA	0.61	4.95	0.45	3.21e-6	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg20290983	chr6:43655470	MRPS18A	-1.23	-6.95	-0.58	4.51e-10	IgG glycosylation;
THYM	cis	rs1448094	0.580	rs11615323	chr12:86282171	T/C	cg02569458	chr12:86230093	RASSF9	0.58	5.04	0.46	2.26e-6	Major depressive disorder;
THYM	cis	rs11792861	0.525	rs2417975	chr9:111860185	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	5.08	0.46	1.85e-6	Menarche (age at onset);
THYM	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg06598544	chr20:61472147	COL9A3	-1.11	-7.41	-0.61	5.05e-11	Obesity-related traits;
THYM	cis	rs78540526	1.000	rs78540526	chr11:69331418	C/T	cg08353955	chr11:69289746	NA	-1.18	-4.57	-0.42	1.47e-5	Breast cancer;
THYM	trans	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs1389724	0.686	rs11102159	chr1:111324727	A/G	cg25283465	chr1:111323341	NA	-0.58	-4.73	-0.44	7.75e-6	Schizophrenia;
THYM	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg20573242	chr4:122745356	CCNA2	0.62	4.57	0.42	1.47e-5	Type 2 diabetes;
THYM	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg27129171	chr3:47204927	SETD2	0.77	7.65	0.62	1.67e-11	Colorectal cancer;
THYM	cis	rs11715566	0.515	rs11713893	chr3:117606479	A/G	cg07190778	chr3:117604296	NA	0.42	5.72	0.51	1.23e-7	Menarche (age at onset);
THYM	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.48	-0.55	4.1e-9	Personality dimensions;
THYM	trans	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	Neuroticism;
THYM	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg23758822	chr17:41437982	NA	1.16	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.76	-0.44	7.03e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs67981189	0.529	rs2810097	chr14:71434114	C/T	cg15910301	chr14:71632612	NA	-0.54	-4.8	-0.44	5.87e-6	Schizophrenia;
THYM	cis	rs10504073	0.647	rs11785310	chr8:50025035	G/A	cg00325661	chr8:49890786	NA	0.92	8.49	0.66	2.72e-13	Blood metabolite ratios;
THYM	cis	rs41005	0.597	rs34452414	chr2:8101593	C/T	cg03155496	chr2:8117019	LOC339788	-0.76	-5.25	-0.47	9.08e-7	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs273218	1.000	rs156385	chr5:53370749	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.86	7.32	0.6	7.88e-11	Migraine;
THYM	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg20744362	chr22:50050164	C22orf34	0.84	8.55	0.66	2.06e-13	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg18681998	chr4:17616180	MED28	0.79	6.77	0.57	1.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs28595532	0.920	rs114792862	chr4:119759938	G/A	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg03684893	chr10:554711	DIP2C	0.75	5.53	0.49	2.82e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg04546413	chr19:29218101	NA	0.98	6.85	0.58	7.15e-10	Methadone dose in opioid dependence;
THYM	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1345301	1.000	rs11686567	chr2:102876609	A/G	cg03938978	chr2:103052716	IL18RAP	-0.62	-6.09	-0.53	2.36e-8	Waist circumference;
THYM	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg26384229	chr12:38710491	ALG10B	-0.87	-8.84	-0.67	4.86e-14	Heart rate;
THYM	cis	rs7177699	0.526	rs7165733	chr15:79123505	G/A	cg15571903	chr15:79123663	NA	0.58	6.56	0.56	2.77e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg02478829	chr6:26598070	ABT1	-0.4	-5.09	-0.46	1.79e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6554196	0.525	rs12499367	chr4:55505911	C/T	cg18836493	chr4:55524333	KIT	-0.54	-4.58	-0.42	1.43e-5	Monocyte count;
THYM	cis	rs713587	0.967	rs10182458	chr2:25150641	A/G	cg15423357	chr2:25149977	NA	0.69	7.82	0.63	7.12e-12	Body mass index in non-asthmatics;
THYM	cis	rs2404602	0.647	rs11637096	chr15:76931102	T/C	cg23625390	chr15:77176239	SCAPER	-0.9	-6.46	-0.55	4.52e-9	Blood metabolite levels;
THYM	cis	rs7084402	1.000	rs1427204	chr10:60267640	A/C	cg09696939	chr10:60272079	BICC1	0.47	5.42	0.49	4.46e-7	Refractive error;
THYM	cis	rs977987	0.806	rs7204984	chr16:75475520	G/C	cg03315344	chr16:75512273	CHST6	0.74	5.92	0.52	5.07e-8	Dupuytren's disease;
THYM	cis	rs11585357	0.895	rs34324150	chr1:17632464	C/G	cg08277548	chr1:17600880	PADI3	-0.88	-5.22	-0.47	1.05e-6	Hair shape;
THYM	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg09263875	chr16:632152	PIGQ	0.73	6.29	0.54	9.69e-9	Height;
THYM	cis	rs765787	0.530	rs2899378	chr15:45537584	C/T	cg25801113	chr15:45476975	SHF	-0.39	-4.57	-0.42	1.48e-5	Uric acid levels;
THYM	cis	rs8192282	0.739	rs4474240	chr1:154457855	A/C	cg07911225	chr1:154474108	TDRD10;SHE	-0.61	-4.79	-0.44	6.2e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg24375607	chr4:120327624	NA	0.6	5.06	0.46	2.04e-6	Corneal astigmatism;
THYM	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg19052272	chr2:3704530	ALLC	-0.68	-5.08	-0.46	1.92e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs4919669	0.582	rs4919649	chr10:104272336	T/C	cg00122347	chr10:104236741	TMEM180	-0.59	-4.8	-0.44	5.93e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
THYM	cis	rs6987853	0.787	rs2974314	chr8:42457043	C/T	cg09913449	chr8:42400586	C8orf40	0.95	9.53	0.7	1.64e-15	Mean corpuscular hemoglobin concentration;
THYM	cis	rs763014	0.802	rs4262946	chr16:632138	C/T	cg09263875	chr16:632152	PIGQ	0.73	5.95	0.52	4.44e-8	Height;
THYM	cis	rs7681423	0.906	rs56010410	chr4:155502869	T/C	cg20735720	chr4:155535218	FGG	-0.69	-5.18	-0.47	1.23e-6	Fibrinogen;
THYM	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg02038168	chr22:39784481	NA	-0.67	-5.43	-0.49	4.32e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg21280719	chr6:42927975	GNMT	-0.51	-6.84	-0.57	7.67e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg23583168	chr7:148888333	NA	-1.02	-13.36	-0.81	1.58e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs17376456	0.597	rs11135401	chr5:93365716	G/A	cg25358565	chr5:93447407	FAM172A	-0.9	-6.68	-0.57	1.58e-9	Diabetic retinopathy;
THYM	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg08994789	chr17:28903642	LRRC37B2	1.09	6.3	0.54	9.14e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg04043695	chr12:129287642	SLC15A4	0.64	5.26	0.47	9.04e-7	Systemic lupus erythematosus;
THYM	cis	rs2072499	0.767	rs3001789	chr1:156197614	T/G	cg06970220	chr1:156163860	SLC25A44	0.71	5.8	0.51	8.5e-8	Testicular germ cell tumor;
THYM	cis	rs11030122	0.702	rs4910868	chr11:3980224	A/C	cg18678763	chr11:4115507	RRM1	-0.44	-5.59	-0.5	2.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg15744005	chr10:104629667	AS3MT	-0.78	-5.66	-0.5	1.58e-7	Arsenic metabolism;
THYM	cis	rs1448094	0.512	rs7302741	chr12:86237127	C/T	cg02569458	chr12:86230093	RASSF9	0.63	5.56	0.5	2.51e-7	Major depressive disorder;
THYM	cis	rs7119	0.679	rs12909808	chr15:77816944	A/G	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs12765878	1.000	rs2273698	chr10:105649158	G/A	cg11005552	chr10:105648138	OBFC1	0.86	11.19	0.75	4.77e-19	Coronary artery disease;
THYM	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14159672	chr1:205819179	PM20D1	0.96	10.04	0.72	1.33e-16	Menarche (age at onset);
THYM	cis	rs7731657	0.537	rs4706002	chr5:130373830	C/T	cg08523029	chr5:130500466	HINT1	-0.85	-5.98	-0.52	3.88e-8	Fasting plasma glucose;
THYM	cis	rs4072705	0.615	rs4838189	chr9:127248926	C/A	cg01786973	chr9:127249749	NR5A1	0.38	4.86	0.45	4.59e-6	Menarche (age at onset);
THYM	cis	rs7107770	1.000	rs66970478	chr11:125106048	C/G	cg07747661	chr11:125106135	PKNOX2	-0.92	-5.28	-0.48	8.31e-7	Photic sneeze reflex;
THYM	cis	rs9534288	0.797	rs2404727	chr13:46581697	T/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.32	-4.51	-0.42	1.84e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7107174	1.000	rs2510051	chr11:77981171	A/C	cg19901956	chr11:77921274	USP35	-0.68	-5.26	-0.48	8.74e-7	Testicular germ cell tumor;
THYM	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg07636037	chr3:49044803	WDR6	0.92	7.92	0.63	4.52e-12	Menarche (age at onset);
THYM	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg04772025	chr11:68637568	NA	0.65	6.76	0.57	1.1e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg19346786	chr7:2764209	NA	0.69	5.8	0.51	8.63e-8	Height;
THYM	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg10518543	chr12:38710700	ALG10B	-0.56	-4.57	-0.42	1.49e-5	Morning vs. evening chronotype;
THYM	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg03859395	chr2:55845619	SMEK2	0.7	6.23	0.54	1.28e-8	Metabolic syndrome;
THYM	cis	rs34638657	0.872	rs2967352	chr16:82196676	T/C	cg07307142	chr16:82071433	HSD17B2	-1.0	-7.94	-0.63	4.09e-12	Lung adenocarcinoma;
THYM	cis	rs988913	0.958	rs1503140	chr6:54810766	A/G	cg04690482	chr6:54711388	FAM83B	0.48	5.36	0.48	5.77e-7	Menarche (age at onset);
THYM	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22496380	chr5:211416	CCDC127	-1.33	-7.99	-0.63	3.21e-12	Breast cancer;
THYM	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg19077165	chr18:44547161	KATNAL2	0.48	5.88	0.52	6.14e-8	Personality dimensions;
THYM	cis	rs28595532	1.000	rs114912871	chr4:119697004	G/C	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs4930776	0.897	rs377447	chr12:5762782	A/G	cg02086166	chr12:5775618	ANO2	0.61	6.07	0.53	2.57e-8	Plasma clusterin levels;
THYM	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9515201	0.627	rs9521730	chr13:111031180	C/T	cg15455643	chr13:111040242	COL4A2	0.52	6.34	0.55	7.58e-9	White matter hyperintensity burden;
THYM	cis	rs7084402	0.967	rs1649022	chr10:60285867	A/G	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg02018176	chr4:1364513	KIAA1530	0.99	9.76	0.71	5.32e-16	Longevity;
THYM	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg02569458	chr12:86230093	RASSF9	0.62	5.13	0.47	1.56e-6	Major depressive disorder;
THYM	cis	rs11574514	1.000	rs116908316	chr16:67804955	C/T	cg09738193	chr16:67926317	PSKH1	-0.9	-4.61	-0.43	1.28e-5	Crohn's disease;
THYM	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg27588902	chr6:42928151	GNMT	-0.56	-5.6	-0.5	2.08e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7224737	1.000	rs2240010	chr17:40278081	T/A	cg02228675	chr17:40259724	DHX58	-0.66	-5.49	-0.49	3.28e-7	Fibrinogen levels;
THYM	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg20482658	chr1:10539492	PEX14	0.33	4.84	0.45	4.93e-6	Prostate cancer;
THYM	cis	rs12701220	0.842	rs10236293	chr7:1032637	G/A	cg26769984	chr7:1090371	C7orf50	0.8	5.09	0.46	1.79e-6	Bronchopulmonary dysplasia;
THYM	cis	rs28595532	0.920	rs56342843	chr4:119765070	G/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg03609598	chr5:56110824	MAP3K1	-0.85	-5.83	-0.51	7.62e-8	Initial pursuit acceleration;
THYM	cis	rs4919694	1.000	rs12268849	chr10:104737682	G/A	cg04362960	chr10:104952993	NT5C2	1.06	6.61	0.56	2.24e-9	Arsenic metabolism;
THYM	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg15693483	chr7:1102177	C7orf50	0.46	5.71	0.51	1.27e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6495122	0.699	rs3784789	chr15:75082552	C/G	cg14664628	chr15:75095509	CSK	-0.81	-6.38	-0.55	6.5e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs3825932	0.961	rs10400877	chr15:79234378	A/T	cg25744700	chr15:79237217	CTSH	0.47	4.46	0.42	2.22e-5	Type 1 diabetes;
THYM	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.17	-0.47	1.28e-6	Joint mobility (Beighton score);
THYM	cis	rs6815814	0.950	rs5743789	chr4:38833173	A/T	cg02016764	chr4:38805732	TLR1	-0.51	-5.08	-0.46	1.85e-6	Breast cancer;
THYM	cis	rs4455778	0.580	rs4917032	chr7:49111505	T/G	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06873352	chr17:61820015	STRADA	0.57	5.68	0.5	1.46e-7	Height;
THYM	cis	rs478304	0.514	rs75601653	chr11:65483370	C/G	cg17480646	chr11:65405466	SIPA1	-0.91	-8.21	-0.64	1.08e-12	Acne (severe);
THYM	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs1642645	0.793	rs4660211	chr1:42484294	T/C	cg06092502	chr1:42611687	NA	0.61	4.74	0.44	7.58e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg16586182	chr3:47516702	SCAP	-0.57	-4.93	-0.45	3.45e-6	Colorectal cancer;
THYM	trans	rs7615952	0.688	rs4422259	chr3:125545831	C/T	cg07211511	chr3:129823064	LOC729375	-0.91	-7.61	-0.62	1.97e-11	Blood pressure (smoking interaction);
THYM	cis	rs6531209	0.851	rs973129	chr2:20332942	A/G	cg24416238	chr2:20211868	MATN3	-0.65	-5.57	-0.5	2.38e-7	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs6763768	0.705	rs312483	chr3:53524051	A/G	cg05923681	chr3:52580707	PBRM1	-0.68	-4.46	-0.42	2.25e-5	Bacterial meningitis;
THYM	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg12165864	chr7:66369176	NA	0.65	4.91	0.45	3.75e-6	Aortic root size;
THYM	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg13695892	chr22:41940480	POLR3H	-1.03	-7.97	-0.63	3.55e-12	Vitiligo;
THYM	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19346786	chr7:2764209	NA	-0.75	-6.49	-0.55	3.94e-9	Height;
THYM	cis	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs17767294	0.708	rs72851168	chr6:28080008	C/T	cg08851530	chr6:28072375	NA	1.15	4.46	0.42	2.28e-5	Parkinson's disease;
THYM	cis	rs10214930	1.000	rs6462051	chr7:27844661	C/T	cg04422003	chr7:28448295	CREB5	-0.62	-4.62	-0.43	1.19e-5	Hypospadias;
THYM	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg06873352	chr17:61820015	STRADA	-0.59	-6.66	-0.56	1.75e-9	Prudent dietary pattern;
THYM	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg15556689	chr8:8085844	FLJ10661	0.62	4.84	0.44	5.03e-6	Parkinson's disease;
THYM	cis	rs8050907	1.000	rs13335998	chr16:4651921	G/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.57	0.42	1.47e-5	Obesity-related traits;
THYM	cis	rs9938149	0.706	rs7498700	chr16:88320620	T/C	cg05067156	chr16:88591451	ZFPM1	-0.43	-4.52	-0.42	1.81e-5	Corneal structure;Central corneal thickness;
THYM	cis	rs8013055	0.846	rs12717698	chr14:105979015	G/A	cg11597832	chr14:105993747	TMEM121	-0.52	-4.66	-0.43	1.01e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs9790314	1.000	rs2218803	chr3:161047973	T/G	cg04691961	chr3:161091175	C3orf57	-0.57	-4.73	-0.44	7.7e-6	Morning vs. evening chronotype;
THYM	trans	rs480407	0.824	rs13023011	chr2:161726469	A/G	cg06548410	chr19:1997657	BTBD2	-0.73	-6.88	-0.58	6.29e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.87	0.45	4.53e-6	Bipolar disorder;
THYM	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg12560992	chr17:57184187	TRIM37	0.89	8.01	0.63	2.88e-12	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.27	5.46	0.49	3.88e-7	Obesity-related traits;
THYM	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.58	-0.43	1.39e-5	Fear of minor pain;
THYM	cis	rs76662990	0.764	rs6895845	chr5:73899431	A/G	cg13275603	chr5:73927487	ENC1	0.79	4.97	0.45	2.95e-6	Residual cognition;
THYM	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg17173187	chr15:85201210	NMB	0.57	5.63	0.5	1.79e-7	Schizophrenia;
THYM	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-5.08	-0.46	1.91e-6	Gut microbiome composition (summer);
THYM	cis	rs6430585	0.583	rs2322813	chr2:136582809	A/G	cg20242066	chr2:136595261	LCT	0.47	4.45	0.42	2.33e-5	Corneal structure;
THYM	cis	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg13609457	chr4:120235615	NA	0.53	4.91	0.45	3.79e-6	Corneal astigmatism;
THYM	cis	rs2997447	0.761	rs79778025	chr1:26449337	A/G	cg03844060	chr1:26490628	NA	0.75	5.23	0.47	9.92e-7	QRS complex (12-leadsum);
THYM	cis	rs3768617	0.510	rs6666259	chr1:183102855	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.92	0.45	3.58e-6	Fuchs's corneal dystrophy;
THYM	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg20607798	chr8:58055168	NA	0.88	4.63	0.43	1.16e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg05717871	chr11:638507	DRD4	-0.69	-6.03	-0.53	3.1e-8	Systemic lupus erythematosus;
THYM	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.47	-4.76	-0.44	7.02e-6	Crohn's disease;
THYM	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg18681998	chr4:17616180	MED28	0.84	7.05	0.59	2.85e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg24308560	chr3:49941425	MST1R	0.64	5.53	0.49	2.79e-7	Body mass index;
THYM	cis	rs7115242	0.800	rs493134	chr11:116833679	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.86	4.7	0.43	8.89e-6	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
THYM	cis	rs1922291	0.546	rs12473710	chr2:102840979	T/C	cg13315345	chr2:102803985	IL1RL2	0.63	7.15	0.59	1.77e-10	Blood protein levels;
THYM	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs977987	0.872	rs3743609	chr16:75467021	G/C	cg03315344	chr16:75512273	CHST6	0.73	5.95	0.52	4.52e-8	Dupuytren's disease;
THYM	cis	rs9646944	0.501	rs10181785	chr2:103025274	C/T	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg13918804	chr1:2043761	PRKCZ	-0.61	-4.62	-0.43	1.19e-5	Height;
THYM	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06481639	chr22:41940642	POLR3H	-0.8	-5.48	-0.49	3.52e-7	Vitiligo;
THYM	cis	rs6427356	0.513	rs78347184	chr1:157147650	G/T	cg27547283	chr1:156698502	C1orf66;ISG20L2	-0.59	-4.58	-0.43	1.4e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4072705	1.000	rs13283284	chr9:127516177	T/C	cg13476313	chr9:127244764	NR5A1	0.31	4.7	0.43	8.82e-6	Menarche (age at onset);
THYM	cis	rs1878931	0.582	rs40633	chr16:3425325	A/G	cg22508957	chr16:3507546	NAT15	0.48	4.95	0.45	3.17e-6	Body mass index (adult);
THYM	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-14.05	-0.82	6.23e-25	Height;
THYM	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg01341218	chr17:43662625	NA	1.13	9.58	0.7	1.32e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs752010	0.631	rs4660549	chr1:42088102	A/G	cg06885757	chr1:42089581	HIVEP3	0.77	11.38	0.76	1.91e-19	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs921665	0.517	rs75547222	chr2:3160476	A/T	cg16434511	chr2:3151078	NA	1.15	5.37	0.48	5.68e-7	World class endurance athleticism;
THYM	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg24692254	chr21:30365293	RNF160	-0.85	-7.06	-0.59	2.74e-10	Dental caries;
THYM	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg25237894	chr2:233734115	C2orf82	-0.36	-5.1	-0.46	1.77e-6	Coronary artery disease;
THYM	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg10505658	chr17:80084571	CCDC57	0.66	7.04	0.59	2.96e-10	Life satisfaction;
THYM	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg00744431	chr10:134226547	PWWP2B	0.5	4.45	0.42	2.34e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs34779708	0.966	rs4294520	chr10:35422506	C/T	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.82e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg13395646	chr4:1353034	KIAA1530	-0.56	-5.35	-0.48	6.16e-7	Obesity-related traits;
THYM	cis	rs896322	0.920	rs3851286	chr1:205153517	C/T	cg21643547	chr1:205240462	TMCC2	-0.82	-4.47	-0.42	2.19e-5	Mean platelet volume;
THYM	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg15445000	chr17:37608096	MED1	0.41	5.04	0.46	2.26e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg11764359	chr7:65958608	NA	-0.82	-6.45	-0.55	4.58e-9	Aortic root size;
THYM	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-7.56	-0.61	2.52e-11	Chronic sinus infection;
THYM	cis	rs11225247	1.000	rs78847320	chr11:102301890	G/A	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg14784868	chr12:69753453	YEATS4	1.12	10.87	0.74	2.32e-18	Blood protein levels;
THYM	cis	rs7578361	0.959	rs4297844	chr2:150400108	A/C	cg17961725	chr2:150454027	NA	-0.74	-5.91	-0.52	5.37e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs2637266	0.935	rs2579771	chr10:78407544	A/G	cg18941641	chr10:78392320	NA	0.77	6.59	0.56	2.41e-9	Pulmonary function;
THYM	cis	rs684232	0.602	rs331008	chr17:544617	C/T	cg15660573	chr17:549704	VPS53	-1.0	-11.2	-0.75	4.65e-19	Prostate cancer;
THYM	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg20891283	chr12:69753455	YEATS4	1.09	12.05	0.78	7.75e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg12564285	chr5:131593104	PDLIM4	0.55	5.83	0.51	7.73e-8	Blood metabolite levels;
THYM	cis	rs11031096	0.503	rs10835604	chr11:4109709	A/T	cg22027985	chr11:4115532	RRM1	-0.47	-4.6	-0.43	1.3e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg24324837	chr19:49891574	CCDC155	-0.52	-4.7	-0.43	8.78e-6	Multiple sclerosis;
THYM	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.65e-6	Aortic root size;
THYM	cis	rs711830	1.000	rs1318778	chr2:177037831	C/G	cg13092806	chr2:177043255	NA	0.59	4.75	0.44	7.22e-6	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs7106204	0.609	rs35037636	chr11:24299533	C/G	ch.11.24196551F	chr11:24239977	NA	0.99	6.11	0.53	2.16e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg18230493	chr5:56204884	C5orf35	-0.89	-6.53	-0.56	3.25e-9	Initial pursuit acceleration;
THYM	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg20387954	chr3:183756860	HTR3D	0.54	5.21	0.47	1.09e-6	Anterior chamber depth;
THYM	cis	rs10929159	0.928	rs6431419	chr2:236919669	C/A	cg20128773	chr2:236923534	AGAP1	0.35	4.62	0.43	1.23e-5	Parkinson's disease;
THYM	cis	rs11083475	0.607	rs6508816	chr19:39267783	G/A	cg07403899	chr19:39283540	NA	-0.57	-4.57	-0.42	1.44e-5	Heart rate;
THYM	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg15448220	chr1:150897856	SETDB1	-0.87	-7.75	-0.62	1.01e-11	Melanoma;
THYM	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg12923728	chr3:195709715	SDHAP1	-0.78	-6.36	-0.55	7.14e-9	Pancreatic cancer;
THYM	cis	rs9660180	0.934	rs34849348	chr1:1762757	C/T	cg03396347	chr1:1875803	NA	-0.67	-6.86	-0.58	6.87e-10	Body mass index;
THYM	cis	rs2188554	0.785	rs7789741	chr7:117206941	T/G	cg21212505	chr7:117228958	CFTR	-0.61	-4.73	-0.44	7.65e-6	Esophageal adenocarcinoma;
THYM	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-5.91	-0.52	5.34e-8	Total cholesterol levels;
THYM	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg06917634	chr15:78832804	PSMA4	0.96	8.76	0.67	7.4e-14	Sudden cardiac arrest;
THYM	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1784581	0.894	rs1790000	chr6:162388707	A/G	cg17173639	chr6:162384350	PARK2	0.95	9.63	0.7	1.03e-15	Itch intensity from mosquito bite;
THYM	cis	rs854037	1.000	rs854037	chr5:57091783	A/G	cg08523694	chr5:57076192	NA	0.58	4.48	0.42	2.11e-5	Birth weight;
THYM	cis	rs12532214	0.592	rs112075085	chr7:3172047	A/T	cg19214707	chr7:3157722	NA	-0.84	-5.03	-0.46	2.28e-6	Itch intensity from mosquito bite;
THYM	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg18252515	chr7:66147081	NA	0.63	4.71	0.44	8.44e-6	Aortic root size;
THYM	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.61	-7.87	-0.63	5.57e-12	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs791590	1.000	rs2246031	chr10:6092210	A/G	cg17191567	chr10:6178319	NA	-0.74	-5.11	-0.46	1.69e-6	Soluble interleukin-2 receptor subunit alpha;
THYM	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg04398451	chr17:18023971	MYO15A	-0.76	-6.96	-0.58	4.39e-10	Total body bone mineral density;
THYM	cis	rs7119	0.717	rs34981488	chr15:77723403	T/G	cg10437265	chr15:77819839	NA	0.61	5.36	0.48	5.77e-7	Type 2 diabetes;
THYM	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg20608306	chr11:116969690	SIK3	0.51	5.51	0.49	3.05e-7	Blood protein levels;
THYM	cis	rs11645898	1.000	rs72791117	chr16:72217385	T/C	cg14768367	chr16:72042858	DHODH	-0.68	-4.99	-0.46	2.76e-6	Blood protein levels;
THYM	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg16615211	chr3:44902933	MIR564;TMEM42	0.46	4.52	0.42	1.77e-5	Depressive symptoms;
THYM	cis	rs13102973	0.640	rs6857995	chr4:135834193	G/A	cg14419869	chr4:135874104	NA	0.7	5.72	0.51	1.26e-7	Subjective well-being;
THYM	cis	rs10489202	1.000	rs7520232	chr1:168011995	T/C	cg24449463	chr1:168025552	DCAF6	-0.8	-6.3	-0.54	9.45e-9	Schizophrenia;
THYM	cis	rs12110303	1	rs12110303	chr5:90662839	G/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.78	4.97	0.45	2.91e-6	Breast cancer;
THYM	cis	rs1933112	1.000	rs1933112	chr1:168521417	A/G	cg17186328	chr1:168545835	XCL1	-0.54	-4.55	-0.42	1.58e-5	Blood protein levels;
THYM	cis	rs67478160	0.619	rs10083367	chr14:104314183	C/G	cg08213375	chr14:104286397	PPP1R13B	-0.57	-6.86	-0.58	7.08e-10	Schizophrenia;
THYM	cis	rs36051895	0.553	rs12338854	chr9:5057568	G/C	cg02405213	chr9:5042618	JAK2	-1.03	-11.49	-0.76	1.15e-19	Pediatric autoimmune diseases;
THYM	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg10505658	chr17:80084571	CCDC57	0.7	8.07	0.64	2.18e-12	Life satisfaction;
THYM	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg11245990	chr11:68621969	NA	0.57	7.46	0.61	4.06e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2273669	0.665	rs66543278	chr6:109396926	C/T	cg17117243	chr6:109341365	SESN1	-0.78	-4.77	-0.44	6.52e-6	Prostate cancer;
THYM	cis	rs2346177	0.580	rs7565770	chr2:46683683	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.59	4.66	0.43	1.01e-5	HDL cholesterol;
THYM	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg17105886	chr17:28927953	LRRC37B2	1.31	7.85	0.63	6.35e-12	Body mass index;
THYM	cis	rs4654899	0.931	rs7543140	chr1:21180250	G/A	cg01072550	chr1:21505969	NA	0.69	6.37	0.55	6.58e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg00271210	chr6:167070053	RPS6KA2	-0.69	-7.42	-0.61	4.85e-11	Crohn's disease;
THYM	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg04025307	chr7:1156635	C7orf50	0.78	6.62	0.56	2.1e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	5.46	0.49	3.85e-7	Lung cancer in ever smokers;
THYM	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg25918947	chr17:41365094	TMEM106A	-0.57	-4.8	-0.44	5.92e-6	Menopause (age at onset);
THYM	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-6.17	-0.53	1.7e-8	Chronic sinus infection;
THYM	cis	rs1775715	0.674	rs2778670	chr10:32161676	G/A	cg04359828	chr10:32216031	ARHGAP12	0.39	5.03	0.46	2.32e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg12179176	chr11:130786555	SNX19	0.86	8.07	0.64	2.12e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.09e-8	Systolic blood pressure;
THYM	cis	rs1371867	0.817	rs1660315	chr8:101332956	G/A	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg22875332	chr1:76189707	ACADM	0.88	9.09	0.68	1.44e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg08885076	chr2:99613938	TSGA10	-0.46	-4.63	-0.43	1.16e-5	Bipolar disorder;
THYM	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg07570687	chr10:102243282	WNT8B	0.75	6.74	0.57	1.21e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg24675658	chr1:53192096	ZYG11B	-0.78	-7.04	-0.59	3.02e-10	Monocyte count;
THYM	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg20283391	chr11:68216788	NA	-0.63	-4.96	-0.45	3.03e-6	Total body bone mineral density;
THYM	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.59	-6.31	-0.54	8.65e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs1113500	0.748	rs1781048	chr1:108555050	A/T	cg06207961	chr1:108661230	NA	0.6	4.95	0.45	3.24e-6	Growth-regulated protein alpha levels;
THYM	cis	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg10856724	chr12:34555212	NA	-0.92	-9.1	-0.68	1.41e-14	Morning vs. evening chronotype;
THYM	cis	rs988913	0.793	rs9370333	chr6:54738246	A/G	cg04690482	chr6:54711388	FAM83B	0.47	4.85	0.45	4.89e-6	Menarche (age at onset);
THYM	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg24209194	chr3:40518798	ZNF619	-0.58	-4.78	-0.44	6.32e-6	Renal cell carcinoma;
THYM	cis	rs7582180	0.638	rs7581011	chr2:100954659	A/G	cg21926883	chr2:100939477	LONRF2	0.68	6.42	0.55	5.32e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg00071950	chr4:10020882	SLC2A9	-0.75	-7.53	-0.61	2.88e-11	Bone mineral density;
THYM	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs2295359	0.892	rs10889657	chr1:67615487	A/G	cg11235152	chr1:67600687	NA	0.69	5.83	0.51	7.49e-8	Psoriasis;
THYM	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.5	-4.93	-0.45	3.5e-6	Crohn's disease;
THYM	cis	rs6032067	0.759	rs118190342	chr20:43843130	A/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.61	-5.89	-0.52	5.91e-8	Blood protein levels;
THYM	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg08498830	chr11:832797	CD151	-0.62	-4.51	-0.42	1.82e-5	Mean platelet volume;
THYM	cis	rs1129187	0.748	rs9471968	chr6:42905235	A/G	cg10862848	chr6:42927986	GNMT	-0.51	-6.7	-0.57	1.5e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9420	0.925	rs488769	chr11:57450720	A/C	cg19752551	chr11:57585705	CTNND1	-0.67	-7.85	-0.63	6.23e-12	Schizophrenia;
THYM	cis	rs28595532	0.920	rs115240535	chr4:119745395	G/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs11809207	0.523	rs12565756	chr1:26498196	G/T	cg26412358	chr1:26503933	CNKSR1	0.35	4.77	0.44	6.56e-6	Height;
THYM	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg08736216	chr1:53307985	ZYG11A	-0.59	-5.36	-0.48	5.83e-7	Monocyte count;
THYM	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs56161922	0.730	rs74231794	chr1:207850717	G/A	cg09557387	chr1:207818395	CR1L	1.13	5.05	0.46	2.11e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg24846680	chr1:228362309	C1orf69	0.52	4.71	0.43	8.6e-6	Diastolic blood pressure;
THYM	cis	rs71403859	0.502	rs17280181	chr16:71523514	C/T	cg08717414	chr16:71523259	ZNF19	-1.45	-7.43	-0.61	4.75e-11	Post bronchodilator FEV1;
THYM	cis	rs7772486	0.790	rs2485632	chr6:146193228	A/G	cg23711669	chr6:146136114	FBXO30	0.92	9.28	0.69	5.66e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11671005	0.504	rs3794963	chr19:59071051	C/G	cg04170623	chr19:59071414	UBE2M;LOC100131691	0.53	4.66	0.43	1.01e-5	Mean platelet volume;
THYM	cis	rs34779708	0.931	rs72789690	chr10:35382817	T/C	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg17173187	chr15:85201210	NMB	0.56	5.66	0.5	1.6e-7	Schizophrenia;
THYM	cis	rs1843834	0.755	rs10197382	chr2:225574650	T/C	cg22455342	chr2:225449267	CUL3	0.57	4.47	0.42	2.14e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg26384229	chr12:38710491	ALG10B	-0.71	-5.89	-0.52	5.95e-8	Morning vs. evening chronotype;
THYM	cis	rs7772486	0.727	rs12190966	chr6:146146820	T/G	cg23711669	chr6:146136114	FBXO30	0.92	9.0	0.68	2.32e-14	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs11186	0.591	rs7420319	chr2:189960257	A/G	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.49e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg05872129	chr22:39784769	NA	-0.97	-10.24	-0.72	5.2e-17	Intelligence (multi-trait analysis);
THYM	cis	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg16068833	chr1:26644515	UBXN11;CD52	0.26	4.5	0.42	1.9e-5	Obesity-related traits;
THYM	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg14019146	chr3:50243930	SLC38A3	-0.55	-4.6	-0.43	1.3e-5	Body mass index;
THYM	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg12935359	chr14:103987150	CKB	0.45	5.61	0.5	2e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11890956	chr21:40555474	PSMG1	1.08	10.56	0.73	1.05e-17	Cognitive function;
THYM	cis	rs2637266	0.934	rs2395408	chr10:78380929	G/A	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs600806	0.815	rs3768495	chr1:109935325	C/T	cg16988986	chr1:109941118	SORT1	-0.43	-4.56	-0.42	1.5e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7836436	1.000	rs59096952	chr8:121019539	G/A	cg05020510	chr8:120428057	NOV	0.93	4.85	0.45	4.73e-6	HIV-1 viral setpoint;
THYM	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg24733560	chr20:60626293	TAF4	0.51	4.56	0.42	1.51e-5	Body mass index;
THYM	cis	rs1029738	0.615	rs3757447	chr7:22894735	A/T	cg04907244	chr7:22894795	SNORD93	-0.39	-4.97	-0.45	2.93e-6	Fibrinogen levels;
THYM	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg12011299	chr4:100065546	ADH4	0.99	12.58	0.79	6.08e-22	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs9914544	0.564	rs11868500	chr17:18770254	A/G	cg26378065	chr17:18585709	ZNF286B	0.59	4.5	0.42	1.9e-5	Educational attainment (years of education);
THYM	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg08859206	chr1:53392774	SCP2	-0.66	-7.63	-0.62	1.77e-11	Monocyte count;
THYM	cis	rs59698941	0.943	rs66480446	chr5:132274793	T/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs7089973	0.872	rs11818114	chr10:116634878	G/C	cg23260525	chr10:116636907	FAM160B1	0.52	4.66	0.43	1.02e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs28595532	0.920	rs56117870	chr4:119766583	T/C	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg18131467	chr2:239335373	ASB1	1.08	10.28	0.73	4.19e-17	Multiple system atrophy;
THYM	cis	rs2736345	0.742	rs4840568	chr8:11351019	G/A	cg21281001	chr8:11725306	CTSB	0.62	4.53	0.42	1.7e-5	Sjögren's syndrome;Systemic lupus erythematosus;
THYM	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg18876405	chr7:65276391	NA	0.6	5.3	0.48	7.4e-7	Aortic root size;
THYM	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg14008862	chr17:28927542	LRRC37B2	-0.89	-4.76	-0.44	6.78e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9644630	0.897	rs17128525	chr8:19364006	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.8	-8.18	-0.64	1.24e-12	Oropharynx cancer;
THYM	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg06636001	chr8:8085503	FLJ10661	-0.69	-5.85	-0.51	7.02e-8	Mood instability;
THYM	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg24503407	chr1:205819492	PM20D1	1.15	12.13	0.78	5.17e-21	Menarche (age at onset);
THYM	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg08125733	chr17:73851984	WBP2	1.35	6.56	0.56	2.83e-9	Psoriasis;
THYM	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg12011299	chr4:100065546	ADH4	0.94	9.78	0.71	4.9e-16	Alcohol dependence;
THYM	cis	rs2303759	0.918	rs1054770	chr19:49878115	G/A	cg22307029	chr19:49891270	CCDC155	0.81	7.2	0.59	1.42e-10	Multiple sclerosis;
THYM	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg02527881	chr3:46936655	PTH1R	0.61	5.71	0.51	1.28e-7	Colorectal cancer;
THYM	cis	rs10895275	0.961	rs10895278	chr11:102095335	T/C	cg24447756	chr11:102105824	NA	0.53	4.73	0.44	7.69e-6	Migraine;
THYM	cis	rs10779751	0.734	rs1034528	chr1:11249132	G/C	cg08854313	chr1:11322531	MTOR	-0.68	-5.59	-0.5	2.21e-7	Body mass index;
THYM	cis	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.85	7.62	0.62	1.88e-11	Cognitive ability;
THYM	cis	rs7177699	0.557	rs10083696	chr15:79124016	G/A	cg00540400	chr15:79124168	NA	-0.64	-6.85	-0.58	7.18e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs11603020	0.950	rs28362950	chr11:57371918	G/A	cg19752551	chr11:57585705	CTNND1	-0.6	-4.97	-0.45	3e-6	Blood protein levels;
THYM	cis	rs9467160	0.581	rs2817246	chr6:24472336	C/T	cg00346970	chr6:24499591	ALDH5A1	0.35	4.69	0.43	9.25e-6	Liver enzyme levels;
THYM	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.22e-16	Bone mineral density;
THYM	cis	rs1994135	0.647	rs66542958	chr12:33695385	T/G	cg06521331	chr12:34319734	NA	-0.72	-4.99	-0.46	2.68e-6	Resting heart rate;
THYM	cis	rs10193935	0.901	rs72798529	chr2:42537471	C/T	cg27598129	chr2:42591480	NA	-0.76	-4.61	-0.43	1.23e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1451375	0.959	rs1451373	chr7:50622606	A/G	cg18232548	chr7:50535776	DDC	0.73	5.57	0.5	2.35e-7	Malaria;
THYM	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1784581	0.588	rs10945792	chr6:162423484	C/T	cg17173639	chr6:162384350	PARK2	0.81	7.48	0.61	3.75e-11	Itch intensity from mosquito bite;
THYM	cis	rs6473252	0.966	rs2084088	chr8:81811905	C/A	cg08595989	chr8:81827712	NA	-0.41	-4.54	-0.42	1.65e-5	Breast cancer;
THYM	cis	rs9916302	0.821	rs11078916	chr17:37746307	T/C	cg07936489	chr17:37558343	FBXL20	-0.86	-5.89	-0.52	5.87e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs61931739	0.517	rs1843737	chr12:34015305	A/G	cg06521331	chr12:34319734	NA	-0.9	-8.61	-0.66	1.5e-13	Morning vs. evening chronotype;
THYM	cis	rs9420	0.922	rs35808061	chr11:57547000	T/C	cg19752551	chr11:57585705	CTNND1	-0.73	-7.98	-0.63	3.28e-12	Schizophrenia;
THYM	cis	rs6570726	0.791	rs9390336	chr6:145896823	A/T	cg13319975	chr6:146136371	FBXO30	-0.63	-5.02	-0.46	2.43e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg11845111	chr2:191398756	TMEM194B	-0.96	-7.22	-0.6	1.26e-10	Diastolic blood pressure;
THYM	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.72	-5.56	-0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs758324	0.680	rs154732	chr5:131471874	C/G	cg16205897	chr5:131564050	P4HA2	0.54	4.76	0.44	6.9e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs9443645	0.507	rs9352633	chr6:79462623	C/G	cg05283184	chr6:79620031	NA	-0.61	-4.89	-0.45	4.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs2361718	0.631	rs2289539	chr17:78152119	T/C	cg09238746	chr17:78121135	EIF4A3	-1.01	-8.67	-0.66	1.16e-13	Yeast infection;
THYM	cis	rs4563143	0.675	rs17498203	chr19:29279734	G/T	cg03161606	chr19:29218774	NA	0.85	7.12	0.59	2.02e-10	Methadone dose in opioid dependence;
THYM	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.7	6.53	0.56	3.28e-9	Total body bone mineral density;
THYM	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg00981070	chr1:2046702	PRKCZ	-0.44	-5.4	-0.48	4.93e-7	Height;
THYM	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.65e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg19327006	chr6:143084770	HIVEP2	-0.91	-6.88	-0.58	6.38e-10	Depressive symptoms;
THYM	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg03806693	chr22:41940476	POLR3H	1.11	8.99	0.68	2.33e-14	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg24675658	chr1:53192096	ZYG11B	-0.8	-7.2	-0.59	1.43e-10	Monocyte count;
THYM	cis	rs4242434	0.927	rs13271626	chr8:22467760	C/G	cg14690197	chr8:22456421	C8orf58	0.48	4.68	0.43	9.65e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs4988958	0.565	rs6760621	chr2:102999952	T/C	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma (childhood onset);
THYM	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg13609457	chr4:120235615	NA	-0.58	-5.29	-0.48	7.89e-7	Corneal astigmatism;
THYM	cis	rs7107174	0.901	rs10899500	chr11:78125246	A/G	cg19901956	chr11:77921274	USP35	-0.7	-4.85	-0.45	4.73e-6	Testicular germ cell tumor;
THYM	cis	rs4072980	0.545	rs11210870	chr1:38449910	T/C	cg04673462	chr1:38461896	NA	-0.43	-5.51	-0.49	3.08e-7	Coronary artery disease;
THYM	cis	rs9825379	0.643	rs6810158	chr3:141148231	T/C	cg13411656	chr3:141121016	ZBTB38	-0.49	-4.61	-0.43	1.24e-5	Height;
THYM	cis	rs2227564	0.830	rs2633322	chr10:75693932	T/C	cg00564723	chr10:75632066	CAMK2G	-0.5	-4.64	-0.43	1.12e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs1729407	0.647	rs2727791	chr11:116684562	C/G	cg03742763	chr11:116700049	APOC3	-0.33	-4.75	-0.44	7.26e-6	Apolipoprotein A-IV levels;
THYM	cis	rs6980334	0.798	rs10280394	chr7:137767201	C/A	cg06915773	chr7:137028165	PTN	0.6	4.8	0.44	5.89e-6	Blood metabolite ratios;
THYM	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg00898013	chr13:113819073	PROZ	-0.87	-8.78	-0.67	6.82e-14	Platelet distribution width;
THYM	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg14458575	chr2:238380390	NA	0.92	7.87	0.63	5.56e-12	Prostate cancer;
THYM	cis	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg22948669	chr1:198089801	NA	-0.71	-5.43	-0.49	4.28e-7	Depressive symptoms;
THYM	cis	rs7255436	0.965	rs28729307	chr19:8452742	A/G	cg10174797	chr19:8464628	RAB11B	0.43	5.19	0.47	1.18e-6	HDL cholesterol;
THYM	cis	rs1003719	0.788	rs2156076	chr21:38452634	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.69	5.0	0.46	2.58e-6	Eye color traits;
THYM	cis	rs6565180	0.962	rs6565182	chr16:30374381	C/T	cg10017167	chr16:30683065	NA	0.41	4.46	0.42	2.22e-5	Tonsillectomy;
THYM	cis	rs7106204	1.000	rs35876423	chr11:24214859	G/T	ch.11.24196551F	chr11:24239977	NA	0.91	5.63	0.5	1.85e-7	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.7	5.63	0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs6687430	0.532	rs67488812	chr1:10614804	A/G	cg20482658	chr1:10539492	PEX14	0.5	6.32	0.54	8.53e-9	Hand grip strength;
THYM	cis	rs4638749	1.000	rs12477202	chr2:108867112	G/A	cg25838818	chr2:108905173	SULT1C2	-0.63	-6.3	-0.54	9.3e-9	Blood pressure;
THYM	cis	rs4974559	0.790	rs28712208	chr4:1316695	A/T	cg16185996	chr4:1008614	FGFRL1	-0.43	-4.53	-0.42	1.7e-5	Systolic blood pressure;
THYM	trans	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs7172809	0.599	rs2012756	chr15:77745301	G/C	cg22256960	chr15:77711686	NA	-0.61	-4.47	-0.42	2.18e-5	Glucose homeostasis traits;
THYM	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg13695892	chr22:41940480	POLR3H	0.85	6.16	0.53	1.72e-8	Vitiligo;
THYM	trans	rs7224296	0.709	rs199518	chr17:44854580	A/C	cg01341218	chr17:43662625	NA	-0.82	-6.99	-0.58	3.87e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9902453	1.000	rs9890205	chr17:28382704	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs11574514	0.661	rs9972635	chr16:67682580	T/C	cg04582263	chr16:67973788	LCAT	0.97	4.63	0.43	1.17e-5	Crohn's disease;
THYM	cis	rs2133450	0.712	rs17697928	chr3:7367771	A/G	cg19930620	chr3:7340148	GRM7	-0.48	-4.49	-0.42	1.98e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg06028808	chr11:68637592	NA	0.71	7.61	0.62	1.99e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg06009448	chr7:1102226	C7orf50	0.52	5.44	0.49	4.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6860806	0.507	rs270614	chr5:131640813	G/A	cg18758796	chr5:131593413	PDLIM4	0.54	5.1	0.46	1.73e-6	Breast cancer;
THYM	cis	rs921968	0.643	rs526134	chr2:219402371	G/A	cg02176678	chr2:219576539	TTLL4	0.68	6.71	0.57	1.42e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs59698941	0.943	rs67074969	chr5:132251063	T/A	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs17331151	0.585	rs36012032	chr3:52814709	C/A	cg17372223	chr3:52568218	NT5DC2	0.6	5.13	0.47	1.56e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs17407555	0.955	rs10489074	chr4:10272605	C/A	cg11266682	chr4:10021025	SLC2A9	-0.44	-4.45	-0.42	2.3e-5	Schizophrenia (age at onset);
THYM	cis	rs7523273	0.606	rs859705	chr1:207959665	A/G	cg22525895	chr1:207977042	MIR29B2	0.97	10.43	0.73	1.98e-17	Schizophrenia;
THYM	cis	rs2456568	0.548	rs10501809	chr11:93666263	C/G	cg26875233	chr11:93583750	C11orf90	-0.52	-5.79	-0.51	8.93e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg00129232	chr17:37814104	STARD3	-0.83	-5.93	-0.52	4.91e-8	Asthma;
THYM	cis	rs9527	0.615	rs10883781	chr10:104581130	A/G	cg04362960	chr10:104952993	NT5C2	0.66	5.24	0.47	9.74e-7	Arsenic metabolism;
THYM	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg16322792	chr1:120165303	ZNF697	0.92	11.5	0.76	1.09e-19	Systemic lupus erythematosus;
THYM	cis	rs72829446	0.530	rs56078345	chr17:7394341	T/C	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs6815814	0.808	rs7673348	chr4:38845198	G/A	cg14665413	chr4:38859728	TLR6	-0.37	-4.68	-0.43	9.66e-6	Breast cancer;
THYM	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg25811766	chr13:21894605	NA	0.73	5.95	0.52	4.49e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs17331151	0.512	rs9637477	chr3:52891426	G/C	cg07884673	chr3:53033167	SFMBT1	-0.71	-4.67	-0.43	9.95e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2734839	0.964	rs11214605	chr11:113300601	C/T	cg14159747	chr11:113255604	NA	0.32	6.48	0.55	4.01e-9	Information processing speed;
THYM	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg18252515	chr7:66147081	NA	-1.37	-8.05	-0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.32e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg15556689	chr8:8085844	FLJ10661	0.7	5.84	0.51	7.11e-8	Mood instability;
THYM	cis	rs4148087	1.000	rs1117640	chr21:43625274	T/G	cg09727148	chr21:43560719	UMODL1	0.56	4.59	0.43	1.33e-5	Eating disorder in bipolar disorder;
THYM	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg13683864	chr3:40499215	RPL14	1.07	12.42	0.79	1.31e-21	Renal cell carcinoma;
THYM	cis	rs9364687	0.664	rs2294709	chr6:163907241	T/C	cg01639524	chr6:163818125	NA	0.49	4.9	0.45	3.87e-6	Body mass index;
THYM	cis	rs11677370	0.603	rs10164826	chr2:3849951	G/C	cg17052675	chr2:3827356	NA	-0.71	-6.57	-0.56	2.7e-9	Type 2 diabetes;
THYM	cis	rs11690935	1.000	rs312918	chr2:172569587	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.85	-6.25	-0.54	1.15e-8	Schizophrenia;
THYM	cis	rs6835098	1.000	rs6826412	chr4:174109622	C/T	cg08422745	chr4:174089978	GALNT7	-1.0	-8.37	-0.65	5e-13	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs36051895	0.632	rs12337480	chr9:5134567	T/A	cg02405213	chr9:5042618	JAK2	-1.03	-11.39	-0.76	1.84e-19	Pediatric autoimmune diseases;
THYM	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06873352	chr17:61820015	STRADA	0.78	9.87	0.71	3.13e-16	Prudent dietary pattern;
THYM	cis	rs13064411	0.518	rs2399480	chr3:113228599	T/C	cg18753928	chr3:113234510	CCDC52	-0.84	-7.87	-0.63	5.58e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs9595908	0.965	rs7991314	chr13:33126074	T/C	cg12383807	chr13:33924137	NA	-0.57	-5.0	-0.46	2.58e-6	Body mass index;
THYM	cis	rs9875589	0.509	rs56071023	chr3:14075920	A/G	cg03204825	chr3:13978759	TPRXL	-0.54	-4.67	-0.43	9.89e-6	Ovarian reserve;
THYM	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg00278517	chr6:167070616	RPS6KA2	-0.33	-4.52	-0.42	1.79e-5	Crohn's disease;
THYM	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg23422044	chr7:1970798	MAD1L1	0.79	5.24	0.47	9.83e-7	Bipolar disorder;
THYM	cis	rs12282928	0.918	rs1503186	chr11:48244307	A/G	cg22827986	chr11:48284249	OR4X1	-0.51	-5.43	-0.49	4.28e-7	Migraine - clinic-based;
THYM	cis	rs10751667	0.580	rs7396041	chr11:1001607	G/A	cg20946044	chr11:1010712	AP2A2	-0.58	-4.88	-0.45	4.22e-6	Alzheimer's disease (late onset);
THYM	cis	rs9902453	0.730	rs4583306	chr17:28538715	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-4.76	-0.44	6.85e-6	Coffee consumption (cups per day);
THYM	cis	rs514406	0.893	rs10888759	chr1:53433274	A/G	cg24675658	chr1:53192096	ZYG11B	0.61	4.9	0.45	3.86e-6	Monocyte count;
THYM	cis	rs7429990	0.965	rs1013431	chr3:48029118	A/C	cg02219026	chr3:48282209	ZNF589	0.6	4.5	0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.68	6.04	0.53	2.94e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg27279351	chr12:120934652	DYNLL1	0.96	8.75	0.67	7.6e-14	High light scatter reticulocyte count;
THYM	cis	rs2637266	0.600	rs10824427	chr10:78344387	A/G	cg18941641	chr10:78392320	NA	-0.67	-4.59	-0.43	1.37e-5	Pulmonary function;
THYM	cis	rs10484885	0.588	rs9344947	chr6:90304789	A/G	cg13799429	chr6:90582589	CASP8AP2	0.76	6.9	0.58	5.9e-10	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs7940866	0.770	rs10750456	chr11:130819634	A/G	cg05962950	chr11:130786565	SNX19	0.75	5.94	0.52	4.74e-8	Schizophrenia;
THYM	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg10452248	chr16:89456354	ANKRD11	0.65	4.71	0.44	8.29e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06850241	chr22:41845214	NA	-0.58	-5.19	-0.47	1.18e-6	Vitiligo;
THYM	cis	rs4076764	0.801	rs12046142	chr1:163375247	G/A	cg24596788	chr1:163392923	NA	-0.73	-6.2	-0.54	1.45e-8	Motion sickness;
THYM	cis	rs9356181	0.900	rs381500	chr6:164478388	C/A	cg21271420	chr6:164527436	NA	0.41	4.74	0.44	7.38e-6	Mean corpuscular volume;
THYM	cis	rs12310956	0.532	rs10844719	chr12:33987714	A/G	cg10856724	chr12:34555212	NA	-0.75	-6.8	-0.57	9.1e-10	Morning vs. evening chronotype;
THYM	cis	rs11247915	0.600	rs3795686	chr1:26582091	G/A	cg00852783	chr1:26633632	UBXN11	0.77	6.08	0.53	2.48e-8	Obesity-related traits;
THYM	trans	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg19862616	chr7:65841803	NCRNA00174	1.12	13.73	0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg04455712	chr21:45112962	RRP1B	0.5	4.47	0.42	2.13e-5	Mean corpuscular volume;
THYM	cis	rs3772130	0.962	rs9841595	chr3:121483326	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs7772486	0.654	rs1011597	chr6:146075672	A/C	cg13319975	chr6:146136371	FBXO30	0.65	5.22	0.47	1.05e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11574514	1.000	rs1107767	chr16:68020063	C/G	cg04582263	chr16:67973788	LCAT	1.12	5.04	0.46	2.26e-6	Crohn's disease;
THYM	cis	rs12935418	0.672	rs11150334	chr16:81042542	A/T	cg16651780	chr16:81037892	C16orf61	0.84	6.38	0.55	6.34e-9	Mean corpuscular volume;
THYM	cis	rs71403859	1.000	rs71403859	chr16:71640207	C/T	cg08717414	chr16:71523259	ZNF19	-1.11	-5.78	-0.51	9.62e-8	Post bronchodilator FEV1;
THYM	cis	rs8133932	0.598	rs753092	chr21:47293521	C/A	cg08707771	chr21:46690014	POFUT2	-0.79	-4.63	-0.43	1.15e-5	Schizophrenia;
THYM	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg22307297	chr20:60903441	LAMA5	-0.53	-4.64	-0.43	1.12e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg08645402	chr16:4508243	NA	0.72	6.33	0.54	7.93e-9	Schizophrenia;
THYM	cis	rs526231	0.543	rs62362884	chr5:102567455	G/A	cg23492399	chr5:102201601	PAM	-0.68	-5.11	-0.46	1.64e-6	Primary biliary cholangitis;
THYM	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	6.38	0.55	6.44e-9	Smoking behavior;
THYM	cis	rs3791406	1.000	rs3791406	chr2:240030484	A/G	cg27074582	chr2:240114406	HDAC4	0.44	4.5	0.42	1.96e-5	Skin aging (microtopography measurement);
THYM	cis	rs4638749	0.677	rs2219081	chr2:108844350	T/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg22189786	chr22:42395067	WBP2NL	0.48	4.51	0.42	1.85e-5	Birth weight;
THYM	cis	rs4718428	0.705	rs4718430	chr7:66432024	G/T	cg26963428	chr7:66367121	NA	-0.63	-4.85	-0.45	4.78e-6	Corneal structure;
THYM	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg18904891	chr8:8559673	CLDN23	0.67	4.97	0.45	3e-6	Obesity-related traits;
THYM	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg03188948	chr7:1209495	NA	0.93	5.56	0.5	2.47e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7192750	0.586	rs2335710	chr16:71923181	C/G	cg06353428	chr16:71660113	MARVELD3	-0.71	-5.01	-0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg08999081	chr20:33150536	PIGU	-0.57	-4.95	-0.45	3.25e-6	Height;
THYM	cis	rs960902	0.764	rs1113496	chr2:37732855	T/C	cg25341268	chr2:37734390	NA	-0.61	-5.17	-0.47	1.3e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs11031096	0.617	rs12288918	chr11:4191466	G/T	cg08557956	chr11:4115526	RRM1	-0.59	-5.44	-0.49	4.19e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4654899	0.802	rs935918	chr1:21145660	C/T	cg01072550	chr1:21505969	NA	-0.7	-6.35	-0.55	7.4e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg16405210	chr4:1374714	KIAA1530	-1.1	-10.49	-0.73	1.47e-17	Longevity;
THYM	cis	rs988913	0.957	rs1503146	chr6:54759495	G/T	cg04690482	chr6:54711388	FAM83B	0.45	4.84	0.44	5.08e-6	Menarche (age at onset);
THYM	cis	rs6701037	0.681	rs2285220	chr1:175130773	T/A	cg00958927	chr1:175162553	KIAA0040	-0.33	-4.48	-0.42	2.06e-5	Alcohol dependence;
THYM	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg07157834	chr1:205819609	PM20D1	-0.59	-4.54	-0.42	1.62e-5	Menarche (age at onset);
THYM	cis	rs28595532	0.920	rs10004184	chr4:119486801	G/T	cg14228332	chr4:119757509	SEC24D	1.38	4.99	0.46	2.77e-6	Cannabis dependence symptom count;
THYM	trans	rs8002861	0.905	rs12875052	chr13:44449368	G/C	cg17145862	chr1:211918768	LPGAT1	-0.97	-9.31	-0.69	4.82e-15	Leprosy;
THYM	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg24450063	chr1:156163899	SLC25A44	1.21	15.52	0.85	8.47e-28	Testicular germ cell tumor;
THYM	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.26	9.15	0.68	1.11e-14	Platelet count;
THYM	cis	rs6988636	1.000	rs4282551	chr8:124185916	G/A	cg26140120	chr8:124219575	FAM83A	0.87	4.81	0.44	5.77e-6	Urinary uromodulin levels;
THYM	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg24209194	chr3:40518798	ZNF619	0.63	5.06	0.46	2.04e-6	Renal cell carcinoma;
THYM	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg02696790	chr15:75250997	RPP25	0.49	4.71	0.44	8.48e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.88	-8.01	-0.63	2.88e-12	Menarche (age at onset);
THYM	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg18230493	chr5:56204884	C5orf35	-0.89	-6.53	-0.56	3.25e-9	Type 2 diabetes;
THYM	cis	rs36051895	0.664	rs10121077	chr9:5098411	G/A	cg02405213	chr9:5042618	JAK2	-1.01	-11.42	-0.76	1.59e-19	Pediatric autoimmune diseases;
THYM	cis	rs4747241	0.593	rs10740401	chr10:74066397	T/G	cg07828833	chr10:74069493	NA	0.59	5.02	0.46	2.43e-6	Heschl's gyrus morphology;
THYM	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg15962314	chr1:44399869	ARTN	0.51	4.78	0.44	6.34e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs2130392	1.000	rs3796689	chr4:185649866	C/A	cg04058563	chr4:185651563	MLF1IP	0.63	6.19	0.54	1.5e-8	Kawasaki disease;
THYM	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg26513180	chr16:89883248	FANCA	0.73	7.46	0.61	4.06e-11	Vitiligo;
THYM	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg17644776	chr2:200775616	C2orf69	0.81	5.96	0.52	4.18e-8	Osteoporosis;
THYM	cis	rs3892630	0.588	rs2112917	chr19:33317543	C/T	cg22928329	chr19:33183273	NUDT19	-0.67	-5.31	-0.48	7.05e-7	Red blood cell traits;
THYM	cis	rs17102423	0.963	rs35002541	chr14:65598704	G/A	cg11161011	chr14:65562177	MAX	-0.69	-6.21	-0.54	1.4e-8	Obesity-related traits;
THYM	cis	rs1421898	0.625	rs17702921	chr5:157970985	T/C	cg06698293	chr5:158690540	UBLCP1	-0.97	-4.6	-0.43	1.28e-5	Inflammatory skin disease;
THYM	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg25554036	chr4:6271136	WFS1	-0.56	-5.32	-0.48	7.04e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs10411161	0.702	rs7256926	chr19:52391988	A/G	cg25361850	chr19:52391789	ZNF577	0.72	4.87	0.45	4.42e-6	Breast cancer;
THYM	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg16586182	chr3:47516702	SCAP	-0.62	-5.28	-0.48	8.32e-7	Colorectal cancer;
THYM	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg18252515	chr7:66147081	NA	1.48	8.83	0.67	5.15e-14	Diabetic kidney disease;
THYM	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs10193935	0.792	rs7559001	chr2:42474301	C/T	cg27598129	chr2:42591480	NA	-0.79	-5.07	-0.46	1.96e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2885056	0.699	rs34275421	chr19:10644812	T/A	cg04833646	chr19:10679720	CDKN2D	1.07	9.15	0.68	1.08e-14	Red cell distribution width;
THYM	cis	rs752010	0.967	rs2038978	chr1:42094719	A/G	cg06885757	chr1:42089581	HIVEP3	0.41	4.54	0.42	1.65e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg05335186	chr13:53173507	NA	0.44	5.27	0.48	8.46e-7	Lewy body disease;
THYM	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg15962314	chr1:44399869	ARTN	0.53	4.58	0.43	1.41e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22857025	chr5:266934	NA	-1.43	-9.3	-0.69	5.28e-15	Breast cancer;
THYM	cis	rs7584330	0.554	rs2325838	chr2:238386515	C/A	cg14458575	chr2:238380390	NA	0.93	4.8	0.44	5.8e-6	Prostate cancer;
THYM	cis	rs13287066	0.967	rs7022679	chr9:96172790	A/T	cg13460858	chr9:96720652	NA	-0.55	-4.56	-0.42	1.51e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7107174	1.000	rs2511180	chr11:77937255	A/G	cg02023728	chr11:77925099	USP35	0.67	6.27	0.54	1.08e-8	Testicular germ cell tumor;
THYM	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg10802521	chr3:52805072	NEK4	-0.71	-6.18	-0.54	1.57e-8	Bipolar disorder;
THYM	cis	rs2562456	0.833	rs8106025	chr19:21634724	A/C	cg21751540	chr19:21541537	ZNF738	0.75	4.92	0.45	3.68e-6	Pain;
THYM	cis	rs13102973	0.864	rs7435952	chr4:135900983	C/T	cg14419869	chr4:135874104	NA	0.82	6.86	0.58	7.03e-10	Subjective well-being;
THYM	cis	rs6930083	0.737	rs13196885	chr6:36632688	C/T	cg11920449	chr6:36645608	CDKN1A	0.76	6.4	0.55	5.88e-9	Coronary artery disease;
THYM	cis	rs3733589	1.000	rs6850167	chr4:10164653	T/C	cg17095147	chr4:10101400	WDR1	-1.19	-5.0	-0.46	2.64e-6	Renal overload gout;
THYM	cis	rs7580658	0.614	rs2896888	chr2:127965811	A/C	cg10021288	chr2:128175891	PROC	-0.6	-5.29	-0.48	7.67e-7	Protein C levels;
THYM	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg12000587	chr17:30186630	C17orf79	0.39	4.48	0.42	2.1e-5	Hip circumference adjusted for BMI;
THYM	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg14018140	chr10:458528	DIP2C	-0.63	-6.49	-0.55	3.81e-9	Psychosis in Alzheimer's disease;
THYM	cis	rs12579753	1.000	rs17748942	chr12:82170478	G/A	cg21231944	chr12:82153410	PPFIA2	-0.69	-5.26	-0.47	8.95e-7	Resting heart rate;
THYM	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg03909863	chr11:638404	DRD4	-0.76	-6.04	-0.53	2.95e-8	Systemic lupus erythematosus;
THYM	cis	rs192264	0.614	rs379452	chr16:65976506	A/G	cg02795155	chr16:66785218	DYNC1LI2	0.58	4.68	0.43	9.41e-6	Subjective well-being;
THYM	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg00129232	chr17:37814104	STARD3	0.7	4.79	0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg13010199	chr12:38710504	ALG10B	0.71	5.91	0.52	5.24e-8	Heart rate;
THYM	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg10792982	chr14:105748885	BRF1	0.7	7.07	0.59	2.55e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1801251	0.727	rs283482	chr2:233646920	A/T	cg08000102	chr2:233561755	GIGYF2	0.64	5.63	0.5	1.84e-7	Coronary artery disease;
THYM	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg23758822	chr17:41437982	NA	1.16	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg26354017	chr1:205819088	PM20D1	0.93	9.29	0.69	5.52e-15	Menarche (age at onset);
THYM	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg12935359	chr14:103987150	CKB	-0.62	-6.48	-0.55	3.97e-9	Body mass index;
THYM	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.06	9.59	0.7	1.27e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs8078723	1.000	rs4795416	chr17:38158133	C/T	cg17467752	chr17:38218738	THRA	0.87	7.22	0.59	1.3e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13732083	chr21:47605072	C21orf56	-0.68	-4.82	-0.44	5.46e-6	Testicular germ cell tumor;
THYM	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg07169764	chr2:136633963	MCM6	-0.71	-6.29	-0.54	9.76e-9	Mosquito bite size;
THYM	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg04267008	chr7:1944627	MAD1L1	-0.57	-5.09	-0.46	1.83e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg27446573	chr6:127587934	RNF146	1.06	10.33	0.73	3.24e-17	Breast cancer;
THYM	cis	rs1050631	0.592	rs1789527	chr18:33712229	C/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.32	0.48	6.94e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs11118844	0.744	rs10863655	chr1:221952515	A/G	cg04222084	chr1:221915650	DUSP10	-0.95	-4.72	-0.44	8.22e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs10214930	1.000	rs2074580	chr7:27833853	A/G	cg04422003	chr7:28448295	CREB5	-0.62	-4.62	-0.43	1.19e-5	Hypospadias;
THYM	cis	rs7106204	0.748	rs6484031	chr11:24237115	A/C	ch.11.24196551F	chr11:24239977	NA	1.0	7.01	0.58	3.4e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg18230493	chr5:56204884	C5orf35	-0.91	-6.74	-0.57	1.23e-9	Initial pursuit acceleration;
THYM	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11890956	chr21:40555474	PSMG1	-0.66	-6.44	-0.55	4.92e-9	Menarche (age at onset);
THYM	cis	rs11792861	0.926	rs10512391	chr9:111809530	A/G	cg05043794	chr9:111880884	C9orf5	-0.36	-5.23	-0.47	1e-6	Menarche (age at onset);
THYM	cis	rs897984	0.553	rs2125293	chr16:30863875	T/C	cg05768032	chr16:30646687	NA	-0.47	-4.61	-0.43	1.28e-5	Dementia with Lewy bodies;
THYM	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.33e-5	Retinal vascular caliber;
THYM	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg23815491	chr16:72088622	HP	0.68	5.25	0.47	9.17e-7	Fibrinogen levels;
THYM	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.91	8.17	0.64	1.29e-12	Monocyte percentage of white cells;
THYM	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg10661904	chr17:79619235	PDE6G	-0.57	-5.3	-0.48	7.61e-7	Eye color traits;
THYM	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.54	-5.06	-0.46	2.06e-6	Crohn's disease;
THYM	cis	rs6980334	1.000	rs7795946	chr7:137785091	A/G	cg26979473	chr7:137028389	PTN	0.61	4.5	0.42	1.92e-5	Blood metabolite ratios;
THYM	cis	rs17030434	0.784	rs6835960	chr4:154650460	G/A	cg14289246	chr4:154710475	SFRP2	-0.74	-5.29	-0.48	7.96e-7	Electrocardiographic conduction measures;
THYM	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7107174	1.000	rs2450128	chr11:77940075	G/A	cg19901956	chr11:77921274	USP35	-0.66	-5.27	-0.48	8.5e-7	Testicular germ cell tumor;
THYM	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs10781543	0.817	rs1128874	chr9:139323424	T/C	cg14115884	chr9:139300582	SDCCAG3	0.68	6.05	0.53	2.82e-8	Monocyte percentage of white cells;
THYM	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg18252515	chr7:66147081	NA	-0.88	-6.73	-0.57	1.26e-9	Corneal structure;
THYM	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg06108461	chr20:60628389	TAF4	-1.01	-7.85	-0.63	6.17e-12	Body mass index;
THYM	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg11663144	chr21:46675770	NA	-0.7	-9.8	-0.71	4.38e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2278491	0.557	rs12675074	chr8:117798038	G/T	cg23513447	chr8:117778558	UTP23	0.62	4.51	0.42	1.84e-5	Body mass index;
THYM	cis	rs886126	1.000	rs10774616	chr12:111662885	G/T	cg10833066	chr12:111807467	FAM109A	0.45	5.44	0.49	4.15e-7	Coronary heart disease;
THYM	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg26769984	chr7:1090371	C7orf50	0.78	5.27	0.48	8.58e-7	Bronchopulmonary dysplasia;
THYM	trans	rs10962692	0.608	rs10962642	chr9:16857292	G/T	cg03221025	chr16:88955224	CBFA2T3	0.76	7.39	0.6	5.8e-11	Ovarian cancer in BRCA2 mutation carriers;Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;
THYM	cis	rs951188	0.744	rs10497045	chr2:150345870	A/G	cg17961725	chr2:150454027	NA	0.94	4.79	0.44	6.22e-6	Daytime sleep phenotypes;
THYM	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg16926213	chr1:1841314	NA	0.54	5.64	0.5	1.73e-7	Body mass index;
THYM	cis	rs7107174	1.000	rs2511168	chr11:77965081	T/G	cg02023728	chr11:77925099	USP35	0.68	6.03	0.53	3.06e-8	Testicular germ cell tumor;
THYM	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg09359103	chr1:154839909	KCNN3	-0.84	-12.12	-0.78	5.54e-21	Prostate cancer;
THYM	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg11327659	chr7:150037044	RARRES2	0.44	5.15	0.47	1.38e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs12134040	0.646	rs61835532	chr1:236511729	T/G	cg22129571	chr1:236215502	NID1	-0.57	-4.5	-0.42	1.93e-5	Urate levels (BMI interaction);
THYM	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg00677455	chr12:58241039	CTDSP2	0.76	6.02	0.53	3.26e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.683	rs13042431	chr20:43781253	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.49	-0.49	3.31e-7	Blood protein levels;
THYM	cis	rs9905704	0.918	rs302868	chr17:56752123	C/T	cg12560992	chr17:57184187	TRIM37	0.67	4.68	0.43	9.59e-6	Testicular germ cell tumor;
THYM	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg00071950	chr4:10020882	SLC2A9	0.85	9.57	0.7	1.4e-15	Bone mineral density;
THYM	cis	rs2505998	0.843	rs2506008	chr10:43580224	C/A	cg06632098	chr10:43605906	RET	-1.04	-9.58	-0.7	1.33e-15	Hirschsprung disease;
THYM	cis	rs6815814	0.950	rs73236615	chr4:38786869	G/T	cg02016764	chr4:38805732	TLR1	-0.55	-5.29	-0.48	7.82e-7	Breast cancer;
THYM	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg18904891	chr8:8559673	CLDN23	0.72	5.4	0.48	4.83e-7	Obesity-related traits;
THYM	cis	rs2075230	0.642	rs1641513	chr17:7554242	T/C	cg10509001	chr17:7553872	ATP1B2	-0.61	-4.81	-0.44	5.56e-6	Hormone measurements;
THYM	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg13319975	chr6:146136371	FBXO30	-0.7	-5.72	-0.51	1.23e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs883565	0.655	rs6777651	chr3:39143599	G/C	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	4.98	0.46	2.82e-6	Handedness;
THYM	cis	rs7221773	0.568	rs8076554	chr17:27249972	A/C	cg18170879	chr17:27169527	C17orf63	0.6	4.5	0.42	1.95e-5	Mean corpuscular volume;
THYM	cis	rs427394	0.582	rs274661	chr5:6704848	C/T	cg10857441	chr5:6722123	POLS	-0.7	-7.46	-0.61	3.98e-11	Menopause (age at onset);
THYM	cis	rs7084402	0.935	rs12248958	chr10:60278255	G/A	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs11756438	0.683	rs4945624	chr6:119017155	G/T	cg21191810	chr6:118973309	C6orf204	0.57	5.35	0.48	5.96e-7	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs1728785	1.000	rs864741	chr16:68576577	C/T	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg00484396	chr16:3507460	NAT15	0.75	10.45	0.73	1.8e-17	Tuberculosis;
THYM	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg15448220	chr1:150897856	SETDB1	0.86	7.21	0.59	1.33e-10	Tonsillectomy;
THYM	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg02018176	chr4:1364513	KIAA1530	0.56	4.57	0.42	1.46e-5	Obesity-related traits;
THYM	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg19077165	chr18:44547161	KATNAL2	-0.67	-8.66	-0.66	1.19e-13	Personality dimensions;
THYM	cis	rs73219805	0.793	rs3808573	chr8:26196633	A/T	cg22461835	chr8:26723365	ADRA1A	-0.57	-4.94	-0.45	3.31e-6	Schizophrenia;
THYM	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg13607699	chr17:42295918	UBTF	0.59	4.86	0.45	4.58e-6	Total body bone mineral density;
THYM	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg04025307	chr7:1156635	C7orf50	0.77	6.65	0.56	1.86e-9	Longevity;Endometriosis;
THYM	cis	rs1728785	1.000	rs1645979	chr16:68603660	G/T	cg02972257	chr16:68554789	NA	-0.76	-4.9	-0.45	3.93e-6	Ulcerative colitis;
THYM	cis	rs2898681	0.581	rs730246	chr4:53680719	T/C	cg00791764	chr4:53727839	RASL11B	0.44	5.46	0.49	3.81e-7	Optic nerve measurement (cup area);
THYM	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	4.56	0.42	1.54e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg23161317	chr6:28129485	ZNF389	0.85	6.33	0.54	8.19e-9	Depression;
THYM	cis	rs9796	0.553	rs7171437	chr15:41315168	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.67	-5.72	-0.51	1.25e-7	Menopause (age at onset);
THYM	cis	rs7398996	1	rs7398996	chr12:53659448	C/T	cg16917193	chr12:54089295	NA	0.57	4.48	0.42	2.07e-5	Total body bone mineral density (age 45-60);
THYM	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	4.55	0.42	1.61e-5	Bipolar disorder;
THYM	cis	rs4919687	0.550	rs12783444	chr10:104480659	G/A	cg15744005	chr10:104629667	AS3MT	-0.59	-4.67	-0.43	9.79e-6	Colorectal cancer;
THYM	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg04520793	chr17:42248056	ASB16	0.33	4.56	0.42	1.55e-5	Total body bone mineral density;
THYM	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg06634786	chr22:41940651	POLR3H	0.73	5.57	0.5	2.37e-7	Vitiligo;
THYM	cis	rs6980334	0.817	rs10954603	chr7:137794021	A/G	cg18769353	chr7:137028617	PTN	0.64	5.06	0.46	2.01e-6	Blood metabolite ratios;
THYM	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg20283391	chr11:68216788	NA	-0.74	-5.43	-0.49	4.25e-7	Total body bone mineral density;
THYM	cis	rs1267303	0.675	rs7519040	chr1:46986641	A/G	cg16387850	chr1:46982889	NA	-0.44	-5.6	-0.5	2.05e-7	Monobrow;
THYM	cis	rs10504073	0.647	rs341807	chr8:50032676	C/T	cg00325661	chr8:49890786	NA	0.78	7.03	0.59	3.11e-10	Blood metabolite ratios;
THYM	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg16928487	chr17:17741425	SREBF1	-0.56	-5.44	-0.49	4.09e-7	Total body bone mineral density;
THYM	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg15921436	chr17:44337874	NA	0.97	6.92	0.58	5.14e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4951018	0.526	rs4245718	chr1:205652472	G/A	cg14159672	chr1:205819179	PM20D1	-0.65	-5.16	-0.47	1.32e-6	Prostate-specific antigen levels;
THYM	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg00801512	chr17:28996047	NA	0.79	5.25	0.47	9.24e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4866334	0.867	rs78519816	chr5:18463568	G/A	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg08859206	chr1:53392774	SCP2	0.51	5.7	0.51	1.32e-7	Monocyte count;
THYM	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22857025	chr5:266934	NA	-1.5	-9.71	-0.71	6.9e-16	Breast cancer;
THYM	cis	rs7264396	0.563	rs2425114	chr20:34322346	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Total cholesterol levels;
THYM	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg23428387	chr22:49814324	NA	-0.5	-4.77	-0.44	6.53e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9653442	0.675	rs961788	chr2:100641459	T/C	cg07810366	chr2:100720526	AFF3	-0.42	-5.89	-0.52	5.95e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	5.54	0.49	2.69e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6584283	0.846	rs7917446	chr10:101286207	T/C	cg23904955	chr10:101282759	NA	-0.38	-4.84	-0.44	5.03e-6	Ulcerative colitis;
THYM	cis	rs6032067	0.704	rs62208390	chr20:43794844	A/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs10170846	0.626	rs9288575	chr2:223495133	A/C	cg25565276	chr2:223520875	FARSB	1.16	8.72	0.67	9.05e-14	Schizophrenia (inflammation and infection response interaction);
THYM	cis	rs8192282	0.739	rs7513603	chr1:154481158	T/C	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs2295359	0.824	rs12060309	chr1:67604219	T/C	cg11235152	chr1:67600687	NA	0.78	6.88	0.58	6.21e-10	Psoriasis;
THYM	trans	rs8073060	0.533	rs178736	chr17:33928158	G/T	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg03806693	chr22:41940476	POLR3H	-1.22	-10.52	-0.73	1.3e-17	Vitiligo;
THYM	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg17063962	chr7:91808500	NA	1.16	13.12	0.8	4.77e-23	Breast cancer;
THYM	cis	rs6956675	0.915	rs10232119	chr7:62638227	C/T	cg27518014	chr7:62859535	LOC100287834	0.65	4.98	0.46	2.83e-6	Obesity-related traits;
THYM	cis	rs7412746	0.611	rs3768018	chr1:150723747	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.32	0.48	7.02e-7	Melanoma;
THYM	cis	rs3126085	1.000	rs12405278	chr1:152282267	G/A	cg10321714	chr1:152280068	FLG	-0.76	-5.68	-0.5	1.47e-7	Atopic dermatitis;
THYM	cis	rs73086581	0.838	rs11907416	chr20:4005619	G/C	cg02187196	chr20:3869020	PANK2	0.48	5.19	0.47	1.21e-6	Response to antidepressants in depression;
THYM	cis	rs7824557	0.638	rs4413734	chr8:11212778	C/T	cg21775007	chr8:11205619	TDH	0.65	5.64	0.5	1.72e-7	Retinal vascular caliber;
THYM	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg07606381	chr6:8435919	SLC35B3	0.63	4.76	0.44	6.93e-6	Motion sickness;
THYM	cis	rs6430585	0.591	rs1374330	chr2:136420908	A/C	cg07169764	chr2:136633963	MCM6	1.15	10.74	0.74	4.37e-18	Corneal structure;
THYM	cis	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg08133631	chr1:26527909	CATSPER4	-0.59	-4.94	-0.45	3.38e-6	Obesity-related traits;
THYM	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.72	7.0	0.58	3.56e-10	Lymphocyte counts;
THYM	cis	rs1451375	0.617	rs745043	chr7:50543955	T/G	cg18232548	chr7:50535776	DDC	-0.68	-5.06	-0.46	2.02e-6	Malaria;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg27400772	chr19:38715064	DPF1	1.26	6.98	0.58	4.04e-10	Pulmonary function decline;
THYM	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg20295408	chr7:1910781	MAD1L1	-0.67	-5.04	-0.46	2.27e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg20744362	chr22:50050164	C22orf34	0.79	6.87	0.58	6.74e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs28595532	0.920	rs28797314	chr4:119783044	A/G	cg11846333	chr4:119757529	SEC24D	1.39	5.31	0.48	7.04e-7	Cannabis dependence symptom count;
THYM	cis	rs988913	0.706	rs7761336	chr6:54734602	A/T	cg04690482	chr6:54711388	FAM83B	0.46	4.93	0.45	3.5e-6	Menarche (age at onset);
THYM	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.66	4.87	0.45	4.49e-6	Aortic root size;
THYM	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-11.43	-0.76	1.48e-19	Height;
THYM	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg22664400	chr11:66445111	RBM4B	-0.66	-4.47	-0.42	2.14e-5	Crohn's disease;
THYM	cis	rs12681287	0.752	rs12679266	chr8:87258833	T/C	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.96	6.22	0.54	1.34e-8	Smoking behavior;
THYM	cis	rs2455799	0.613	rs4685264	chr3:15858347	G/A	cg16303742	chr3:15540471	COLQ	-0.56	-5.88	-0.52	6.13e-8	Mean platelet volume;
THYM	trans	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs8112211	0.954	rs7252835	chr19:38832946	G/A	cg09474229	chr19:39360330	RINL	-0.52	-4.72	-0.44	8.22e-6	Blood protein levels;
THYM	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs4474465	1.000	rs7102316	chr11:78149365	C/T	cg19901956	chr11:77921274	USP35	-0.66	-4.91	-0.45	3.71e-6	Alzheimer's disease (survival time);
THYM	cis	rs72792324	1.000	rs73265834	chr5:140741673	G/C	cg21929183	chr5:140807225	PCDHGA4;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB8P;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	-0.89	-4.6	-0.43	1.31e-5	Mean platelet volume;
THYM	cis	rs6570726	0.791	rs4896820	chr6:145894957	T/C	cg23711669	chr6:146136114	FBXO30	0.87	8.07	0.64	2.16e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg22709100	chr7:91322751	NA	-0.6	-4.8	-0.44	5.84e-6	Breast cancer;
THYM	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg18402987	chr7:1209562	NA	0.6	4.56	0.42	1.51e-5	Longevity;Endometriosis;
THYM	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg06873352	chr17:61820015	STRADA	-0.67	-8.3	-0.65	6.93e-13	Prudent dietary pattern;
THYM	cis	rs2463822	0.858	rs2513037	chr11:62084822	A/T	cg06239285	chr11:62104954	ASRGL1	-1.32	-7.26	-0.6	1.05e-10	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs995000	0.931	rs630144	chr1:62918864	A/G	cg06896770	chr1:63153194	DOCK7	0.91	7.48	0.61	3.73e-11	Triglyceride levels;
THYM	cis	rs4713118	0.868	rs10484401	chr6:27746590	A/T	cg23161317	chr6:28129485	ZNF389	-0.73	-4.56	-0.42	1.55e-5	Parkinson's disease;
THYM	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg09165964	chr15:75287851	SCAMP5	-1.0	-9.02	-0.68	2.08e-14	Blood trace element (Zn levels);
THYM	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg02187348	chr16:89574699	SPG7	0.79	6.71	0.57	1.4e-9	Multiple myeloma (IgH translocation);
THYM	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg17426766	chr1:2046864	PRKCZ	-0.41	-4.81	-0.44	5.67e-6	Height;
THYM	cis	rs61931739	0.517	rs1843735	chr12:34047389	C/G	cg06521331	chr12:34319734	NA	-0.93	-8.67	-0.66	1.15e-13	Morning vs. evening chronotype;
THYM	cis	rs13223928	0.621	rs4722440	chr7:3155901	C/T	cg19214707	chr7:3157722	NA	0.85	7.16	0.59	1.73e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs34421088	0.585	rs6992190	chr8:11596549	A/C	cg12395012	chr8:11607386	GATA4	0.65	5.4	0.48	4.88e-7	Neuroticism;
THYM	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg27284194	chr4:1044797	NA	0.62	4.73	0.44	7.81e-6	Recombination rate (females);
THYM	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg23958373	chr8:599963	NA	0.89	4.57	0.42	1.44e-5	IgG glycosylation;
THYM	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06634786	chr22:41940651	POLR3H	0.9	6.28	0.54	1e-8	Vitiligo;
THYM	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg13683864	chr3:40499215	RPL14	1.05	11.64	0.77	5.54e-20	Renal cell carcinoma;
THYM	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg08772003	chr10:104629869	AS3MT	-0.6	-5.54	-0.49	2.68e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs763014	0.865	rs4006748	chr16:632225	T/C	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg08885076	chr2:99613938	TSGA10	-0.66	-6.08	-0.53	2.47e-8	Chronic sinus infection;
THYM	cis	rs56104184	0.668	rs73063523	chr19:49408943	T/C	cg17863274	chr19:49399704	TULP2	-1.02	-6.56	-0.56	2.8e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06873352	chr17:61820015	STRADA	0.78	10.07	0.72	1.19e-16	Prudent dietary pattern;
THYM	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs4930776	1.000	rs11063799	chr12:5766512	G/A	cg02086166	chr12:5775618	ANO2	-0.58	-5.71	-0.51	1.3e-7	Plasma clusterin levels;
THYM	cis	rs2290159	0.948	rs11711270	chr3:12639596	C/T	cg05467012	chr3:12595696	NA	0.65	4.53	0.42	1.7e-5	Cholesterol, total;
THYM	cis	rs13315871	0.790	rs13066409	chr3:58428444	A/G	cg00563845	chr3:58318305	PXK	0.53	4.67	0.43	9.78e-6	Cholesterol, total;
THYM	cis	rs28595532	0.920	rs115675321	chr4:119742153	A/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg24250549	chr1:154909240	PMVK	0.8	6.38	0.55	6.48e-9	Prostate cancer;
THYM	cis	rs2445762	0.559	rs4774585	chr15:51616480	G/A	cg00184732	chr15:51633821	GLDN	0.59	4.48	0.42	2.05e-5	Hormone measurements;
THYM	cis	rs6099847	0.636	rs56391812	chr20:56503868	C/G	cg03401480	chr20:57087179	APCDD1L	0.79	4.66	0.43	1.05e-5	Obesity-related traits;
THYM	trans	rs11722228	0.508	rs9732	chr4:10076658	T/C	cg26043149	chr18:55253948	FECH	1.13	10.72	0.74	4.93e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs10095849	0.576	rs13260129	chr8:39477848	A/C	cg22755526	chr8:38854673	TM2D2;ADAM9	-0.62	-4.61	-0.43	1.24e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs12367572	0.965	rs7979717	chr12:45242272	A/T	cg03114573	chr12:45410052	DBX2	-0.54	-5.1	-0.46	1.77e-6	Gut microbiome composition (summer);
THYM	cis	rs6496667	1.000	rs7177486	chr15:90897109	G/A	cg22089800	chr15:90895588	ZNF774	0.84	4.96	0.45	3.04e-6	Rheumatoid arthritis;
THYM	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg08859206	chr1:53392774	SCP2	-0.65	-7.33	-0.6	7.72e-11	Monocyte count;
THYM	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg27535305	chr1:53392650	SCP2	-0.4	-4.58	-0.42	1.44e-5	Monocyte count;
THYM	cis	rs10149470	0.549	rs9652403	chr14:104036024	G/C	cg24130564	chr14:104152367	KLC1	-0.6	-5.0	-0.46	2.59e-6	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
THYM	cis	rs8025790	0.508	rs12905371	chr15:67845930	C/T	cg24579218	chr15:68104479	NA	-0.67	-6.1	-0.53	2.3e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg07169764	chr2:136633963	MCM6	0.74	6.18	0.54	1.62e-8	Mosquito bite size;
THYM	cis	rs7107174	0.901	rs10899497	chr11:78124534	T/C	cg19901956	chr11:77921274	USP35	-0.65	-5.22	-0.47	1.05e-6	Testicular germ cell tumor;
THYM	cis	rs1448094	0.511	rs6539921	chr12:86164163	G/A	cg00310523	chr12:86230176	RASSF9	0.61	5.31	0.48	7.29e-7	Major depressive disorder;
THYM	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg10047753	chr17:41438598	NA	1.17	10.44	0.73	1.89e-17	Menopause (age at onset);
THYM	cis	rs7226229	1.000	rs8064435	chr17:20917782	A/G	cg21263980	chr17:20946333	USP22	0.63	4.67	0.43	9.97e-6	Blood trace element (Se levels);
THYM	cis	rs2346160	0.867	rs412495	chr6:167688940	C/G	cg21686812	chr6:168078911	NA	0.5	4.6	0.43	1.28e-5	Parental extreme longevity (95 years and older);
THYM	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-5.1	-0.46	1.7e-6	Hemoglobin concentration;
THYM	cis	rs7586879	0.681	rs28836469	chr2:25117215	A/G	cg15423357	chr2:25149977	NA	0.68	7.53	0.61	2.9e-11	Body mass index;
THYM	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.64	4.91	0.45	3.81e-6	Multiple sclerosis;
THYM	cis	rs941408	1.000	rs941410	chr19:2787329	G/A	cg06609049	chr19:2785107	THOP1	0.85	7.03	0.58	3.14e-10	Total cholesterol levels;
THYM	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg00645579	chr11:617140	IRF7;MUPCDH	-0.46	-5.23	-0.47	9.99e-7	Systemic lupus erythematosus and Systemic sclerosis;
THYM	trans	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Bladder cancer;
THYM	cis	rs6496667	0.510	rs16944405	chr15:90975517	A/G	cg22089800	chr15:90895588	ZNF774	0.69	5.07	0.46	1.93e-6	Rheumatoid arthritis;
THYM	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg05973401	chr12:123451056	ABCB9	0.7	4.52	0.42	1.81e-5	Neutrophil percentage of white cells;
THYM	cis	rs4474465	0.920	rs10899529	chr11:78207848	T/C	cg19901956	chr11:77921274	USP35	0.65	4.8	0.44	5.97e-6	Alzheimer's disease (survival time);
THYM	cis	rs425277	1.000	rs262670	chr1:2082458	C/T	cg24578937	chr1:2090814	PRKCZ	0.81	8.54	0.66	2.22e-13	Height;
THYM	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17253792	0.822	rs10135426	chr14:56054644	A/G	cg01858014	chr14:56050164	KTN1	-1.17	-4.89	-0.45	4.1e-6	Putamen volume;
THYM	cis	rs7927771	0.839	rs7124681	chr11:47529947	C/A	cg18512352	chr11:47633146	NA	-0.46	-5.5	-0.49	3.15e-7	Subjective well-being;
THYM	cis	rs8077889	0.672	rs15359	chr17:41843979	C/G	cg26893861	chr17:41843967	DUSP3	-1.18	-20.46	-0.9	1.39e-36	Triglycerides;
THYM	cis	rs7915131	1.000	rs10219104	chr10:64420972	C/A	cg03961010	chr10:64397487	ZNF365	-0.72	-5.31	-0.48	7.05e-7	Schizophrenia;
THYM	cis	rs1728785	0.818	rs1728772	chr16:68584526	C/T	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs79387448	0.576	rs11902044	chr2:102972534	C/T	cg09003973	chr2:102972529	NA	1.38	7.38	0.6	5.96e-11	Gut microbiota (bacterial taxa);
THYM	cis	rs28785552	0.897	rs10424736	chr19:53239176	G/A	cg10871876	chr19:53194124	ZNF83	0.82	6.89	0.58	5.93e-10	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs4237845	0.680	rs10877033	chr12:58283731	T/C	cg22764591	chr12:58329936	NA	1.01	8.09	0.64	1.99e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7107174	1.000	rs731600	chr11:77963133	A/G	cg02023728	chr11:77925099	USP35	0.71	6.54	0.56	3.14e-9	Testicular germ cell tumor;
THYM	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.76	8.44	0.65	3.53e-13	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg09184832	chr6:79620586	NA	-0.56	-4.46	-0.42	2.24e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg22325292	chr17:80708367	FN3K	0.62	4.48	0.42	2.09e-5	Glycated hemoglobin levels;
THYM	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg07936489	chr17:37558343	FBXL20	-0.77	-5.03	-0.46	2.28e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7584330	0.554	rs77180399	chr2:238442951	G/A	cg08992911	chr2:238395768	MLPH	1.11	6.57	0.56	2.65e-9	Prostate cancer;
THYM	cis	rs9361491	0.608	rs9352629	chr6:79461880	T/A	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg03433033	chr1:76189801	ACADM	-0.51	-5.31	-0.48	7.2e-7	Daytime sleep phenotypes;
THYM	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg16325326	chr1:53192061	ZYG11B	0.8	7.44	0.61	4.48e-11	Monocyte count;
THYM	cis	rs1784581	0.588	rs9295179	chr6:162420546	G/A	cg17173639	chr6:162384350	PARK2	0.81	7.48	0.61	3.75e-11	Itch intensity from mosquito bite;
THYM	cis	rs35264875	1.000	rs72928636	chr11:68848386	C/T	cg01993067	chr11:68851601	TPCN2	1.0	5.3	0.48	7.4e-7	Blond vs. brown hair color;
THYM	cis	rs17401966	0.867	rs12403443	chr1:10423988	A/G	cg19773385	chr1:10388646	KIF1B	-0.63	-4.64	-0.43	1.11e-5	Hepatocellular carcinoma;
THYM	cis	rs12142240	0.698	rs4372193	chr1:46853233	G/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs13082711	0.911	rs57992391	chr3:27511567	A/C	cg02860705	chr3:27208620	NA	0.72	5.15	0.47	1.39e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs1061377	1.000	rs1897137	chr4:39133007	G/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.76	-0.44	6.98e-6	Crohn's disease;
THYM	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	6.98	0.58	3.88e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Gout;
THYM	cis	rs12049351	0.665	rs3767325	chr1:229590046	C/T	cg11742688	chr1:229674241	ABCB10	-0.55	-4.66	-0.43	1.03e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs2797160	1.000	rs6933471	chr6:126017029	T/G	cg16306078	chr6:126000798	NA	0.54	5.56	0.5	2.5e-7	Endometrial cancer;
THYM	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg06092702	chr1:163392909	NA	-0.61	-5.35	-0.48	5.97e-7	Motion sickness;
THYM	cis	rs2395909	1	rs2395909	chr7:107292663	G/A	cg23024343	chr7:107201750	COG5	0.64	5.28	0.48	8.13e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs800586	0.912	rs2694035	chr8:116794593	C/G	cg04656070	chr8:116661063	TRPS1	-0.48	-4.95	-0.45	3.24e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs11039798	0.688	rs10839007	chr11:48703442	A/C	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs11645898	0.935	rs4788605	chr16:72154682	G/T	cg14768367	chr16:72042858	DHODH	-0.73	-5.18	-0.47	1.23e-6	Blood protein levels;
THYM	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11890956	chr21:40555474	PSMG1	0.66	6.38	0.55	6.51e-9	Menarche (age at onset);
THYM	cis	rs6840360	0.582	rs4473638	chr4:152322146	C/T	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.22	-0.47	1.05e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg23982607	chr1:1823379	GNB1	-0.57	-4.82	-0.44	5.37e-6	Body mass index;
THYM	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg00147160	chr1:26503991	CNKSR1	0.53	7.17	0.59	1.65e-10	Height;
THYM	cis	rs4523957	0.620	rs1565764	chr17:2074303	G/A	cg16513277	chr17:2031491	SMG6	-1.02	-9.98	-0.72	1.78e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6882076	1.000	rs1501908	chr5:156398169	C/G	cg12943317	chr5:156479607	HAVCR1	0.72	5.94	0.52	4.63e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs3892630	0.878	rs1559177	chr19:33210646	A/G	cg02283691	chr19:33182526	NUDT19	-0.4	-4.82	-0.44	5.36e-6	Red blood cell traits;
THYM	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg14798641	chr3:49314920	USP4;C3orf62	-0.69	-4.69	-0.43	9.23e-6	Cognitive function;
THYM	trans	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg20587970	chr11:113659929	NA	-1.28	-9.17	-0.69	9.76e-15	Hip circumference adjusted for BMI;
THYM	cis	rs56104184	0.775	rs73061695	chr19:49399988	T/C	cg17863274	chr19:49399704	TULP2	-1.01	-6.47	-0.55	4.29e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg27129171	chr3:47204927	SETD2	0.8	7.93	0.63	4.18e-12	Colorectal cancer;
THYM	cis	rs2836633	0.929	rs4143428	chr21:40030582	G/T	cg05519781	chr21:40033154	ERG	0.75	7.28	0.6	9.39e-11	Coronary artery disease;
THYM	cis	rs7412746	0.586	rs2864882	chr1:150883037	C/T	cg15448220	chr1:150897856	SETDB1	0.86	6.94	0.58	4.73e-10	Melanoma;
THYM	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.17	0.64	1.34e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs8060598	0.804	rs2357791	chr16:50764836	G/A	cg05261686	chr16:50743296	NOD2	0.37	4.65	0.43	1.06e-5	Leprosy;
THYM	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg05313129	chr8:58192883	C8orf71	-0.75	-4.59	-0.43	1.34e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs7078219	0.965	rs11190141	chr10:101292390	C/T	cg17888390	chr10:101282816	NA	-0.52	-4.98	-0.46	2.81e-6	Dental caries;
THYM	cis	rs9948	1.000	rs62152794	chr2:97485110	T/C	cg01990225	chr2:97406019	LMAN2L	-0.9	-4.52	-0.42	1.81e-5	Erectile dysfunction and prostate cancer treatment;
THYM	cis	rs1018836	0.608	rs6992512	chr8:91477936	C/A	cg16814680	chr8:91681699	NA	-0.71	-5.57	-0.5	2.39e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs1371867	0.817	rs1660315	chr8:101332956	G/A	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	4.71	0.44	8.46e-6	Coronary artery disease;
THYM	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg13609457	chr4:120235615	NA	-0.59	-5.25	-0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg17063962	chr7:91808500	NA	-1.08	-11.41	-0.76	1.71e-19	Breast cancer;
THYM	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs12282928	1.000	rs4436574	chr11:48334788	G/A	cg22827986	chr11:48284249	OR4X1	0.53	5.59	0.5	2.21e-7	Migraine - clinic-based;
THYM	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg11812906	chr14:75593930	NEK9	-0.87	-8.2	-0.64	1.16e-12	Height;
THYM	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.71	5.11	0.46	1.63e-6	Height;
THYM	cis	rs11648796	0.879	rs12448432	chr16:778820	G/A	cg16899442	chr16:776458	CCDC78;HAGHL	0.45	4.94	0.45	3.35e-6	Height;
THYM	cis	rs7772486	0.754	rs702319	chr6:146006117	T/C	cg13319975	chr6:146136371	FBXO30	0.66	5.2	0.47	1.13e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg24812749	chr6:127587940	RNF146	0.97	7.72	0.62	1.14e-11	Breast cancer;
THYM	cis	rs9527	0.615	rs36045108	chr10:104697929	G/A	cg15744005	chr10:104629667	AS3MT	-0.6	-4.58	-0.42	1.43e-5	Arsenic metabolism;
THYM	cis	rs3135718	0.967	rs1219642	chr10:123348389	T/C	cg15049101	chr10:123353889	FGFR2	0.58	5.07	0.46	1.95e-6	Estrogen receptor status in breast cancer;
THYM	cis	rs3803170	0.513	rs11065884	chr12:111818701	A/G	cg10833066	chr12:111807467	FAM109A	0.43	4.45	0.42	2.3e-5	Mean corpuscular hemoglobin;
THYM	cis	rs96067	0.740	rs10752586	chr1:36614713	C/G	cg24686825	chr1:36642396	MAP7D1	-0.68	-4.71	-0.44	8.32e-6	Corneal structure;
THYM	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg26513180	chr16:89883248	FANCA	0.71	7.25	0.6	1.1e-10	Vitiligo;
THYM	cis	rs6480314	0.636	rs61854792	chr10:70003659	T/C	cg27159792	chr10:69524182	NA	0.81	4.89	0.45	4.06e-6	Optic nerve measurement (disc area);
THYM	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.71	7.89	0.63	5.19e-12	Eosinophil percentage of white cells;
THYM	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.12	-0.47	1.58e-6	Primary biliary cholangitis;
THYM	cis	rs6429082	0.818	rs704706	chr1:235614378	G/A	cg26050004	chr1:235667680	B3GALNT2	0.73	6.04	0.53	3.03e-8	Adiposity;
THYM	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg26384229	chr12:38710491	ALG10B	-0.89	-9.06	-0.68	1.67e-14	Heart rate;
THYM	cis	rs883115	0.846	rs6665204	chr1:224814765	T/C	cg01808320	chr1:224927238	CNIH3	-0.55	-4.53	-0.42	1.7e-5	Cancer;
THYM	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg10360139	chr7:1886902	MAD1L1	-0.54	-4.9	-0.45	3.87e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9515201	0.748	rs9583489	chr13:111032833	C/T	cg06243866	chr13:111019493	COL4A2	-0.77	-7.19	-0.59	1.46e-10	White matter hyperintensity burden;
THYM	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg25036284	chr2:26402008	FAM59B	-0.74	-4.87	-0.45	4.39e-6	Gut microbiome composition (summer);
THYM	cis	rs35660623	0.850	rs6993632	chr8:10669906	A/G	cg12395012	chr8:11607386	GATA4	-0.96	-5.3	-0.48	7.48e-7	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	6.93	0.58	5.11e-10	Smoking behavior;
THYM	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg03388043	chr17:80084554	CCDC57	-0.64	-5.44	-0.49	4.08e-7	Life satisfaction;
THYM	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg07679836	chr6:33548423	BAK1	0.49	6.33	0.54	8.22e-9	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
THYM	cis	rs10992471	0.528	rs1924244	chr9:95224952	A/G	cg14631576	chr9:95140430	CENPP	-0.84	-8.02	-0.64	2.69e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs10992471	0.518	rs4743876	chr9:95512216	C/G	cg14631576	chr9:95140430	CENPP	-0.94	-7.51	-0.61	3.22e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg08885076	chr2:99613938	TSGA10	0.57	5.28	0.48	8.05e-7	Chronic sinus infection;
THYM	cis	rs9677476	0.863	rs10181630	chr2:232091757	C/T	cg23338755	chr2:231921595	PSMD1	0.66	4.96	0.45	3.1e-6	Food antigen IgG levels;
THYM	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg03388043	chr17:80084554	CCDC57	0.69	5.87	0.52	6.36e-8	Life satisfaction;
THYM	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg03806693	chr22:41940476	POLR3H	0.98	9.32	0.69	4.62e-15	Vitiligo;
THYM	cis	rs41005	0.597	rs62104919	chr2:8101999	C/T	cg03155496	chr2:8117019	LOC339788	-0.76	-5.25	-0.47	9.09e-7	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs7769051	0.522	rs6934155	chr6:133124021	C/T	cg22852734	chr6:133119734	C6orf192	1.45	6.1	0.53	2.32e-8	Type 2 diabetes nephropathy;
THYM	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-8.52	-0.66	2.33e-13	Schizophrenia;
THYM	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg21159260	chr5:475889	SLC9A3	0.42	4.46	0.42	2.28e-5	Obesity-related traits;
THYM	trans	rs4650994	1.000	rs10913571	chr1:178526648	A/T	cg05059571	chr16:84539110	KIAA1609	-0.75	-8.15	-0.64	1.43e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs981844	1.000	rs17298985	chr4:154664261	C/T	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs2440129	0.611	rs434473	chr17:6904934	A/G	cg09737314	chr17:6899359	ALOX12	-0.8	-9.35	-0.69	4.15e-15	Tonsillectomy;
THYM	cis	rs686320	1.000	rs3132770	chr11:65251317	G/A	cg21144158	chr11:65211084	MIR612	0.65	4.7	0.43	8.95e-6	Hip circumference adjusted for BMI;
THYM	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg06115741	chr20:33292138	TP53INP2	0.72	4.83	0.44	5.29e-6	Coronary artery disease;
THYM	cis	rs7011507	0.662	rs55914945	chr8:49342959	C/T	cg08774009	chr8:49309094	NA	-0.63	-4.91	-0.45	3.71e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs7264396	0.563	rs2066066	chr20:34329359	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Total cholesterol levels;
THYM	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg18252515	chr7:66147081	NA	-1.39	-8.32	-0.65	6.35e-13	Diabetic kidney disease;
THYM	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg01236616	chr12:121019343	POP5	-1.31	-10.73	-0.74	4.51e-18	Type 1 diabetes nephropathy;
THYM	cis	rs7177699	0.557	rs6495333	chr15:79113215	G/A	cg15571903	chr15:79123663	NA	0.57	6.57	0.56	2.71e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs4733781	0.814	rs62524640	chr8:131144746	C/A	cg16277922	chr8:131349729	ASAP1	0.61	4.7	0.43	8.82e-6	Tuberculosis;
THYM	cis	rs4866334	1.000	rs79543647	chr5:18488484	G/A	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs12476592	0.571	rs2592386	chr2:63894064	A/G	cg17519650	chr2:63277830	OTX1	-0.72	-4.68	-0.43	9.38e-6	Childhood ear infection;
THYM	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.94	6.13	0.53	1.96e-8	Platelet count;
THYM	cis	rs3008870	1.000	rs2755240	chr1:67477339	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.93	7.76	0.62	9.52e-12	Lymphocyte percentage of white cells;
THYM	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg07884673	chr3:53033167	SFMBT1	1.25	6.34	0.55	7.83e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg10164272	chr16:89456328	ANKRD11	0.63	4.74	0.44	7.4e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg13695892	chr22:41940480	POLR3H	0.88	7.43	0.61	4.72e-11	Vitiligo;
THYM	cis	rs4866334	1.000	rs78003303	chr5:18479948	A/G	cg18608440	chr5:17519013	NA	1.07	4.52	0.42	1.8e-5	IgG glycosylation;
THYM	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.66	-4.46	-0.42	2.25e-5	Body mass index (adult);
THYM	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg24874828	chr4:187887005	NA	0.73	7.58	0.61	2.27e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg18904891	chr8:8559673	CLDN23	-0.57	-4.65	-0.43	1.07e-5	Neuroticism;
THYM	cis	rs490234	0.841	rs513568	chr9:128411854	G/A	cg14078157	chr9:128172775	NA	-0.59	-4.58	-0.43	1.43e-5	Mean arterial pressure;
THYM	cis	rs6840360	0.554	rs10222838	chr4:152690099	T/C	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.835	rs34774430	chr17:80181919	T/C	cg03388043	chr17:80084554	CCDC57	-0.71	-5.89	-0.52	5.84e-8	Life satisfaction;
THYM	cis	rs55871839	0.708	rs13263261	chr8:59814688	T/G	cg07426533	chr8:59803705	TOX	-0.69	-7.22	-0.6	1.27e-10	Pneumonia;
THYM	cis	rs7009516	0.819	rs12542012	chr8:24223031	C/T	cg01759110	chr8:24241694	ADAMDEC1	0.54	4.78	0.44	6.49e-6	Hair greying;
THYM	cis	rs9470366	0.527	rs733590	chr6:36645203	A/G	cg24425727	chr6:36645648	CDKN1A	-0.74	-6.94	-0.58	4.81e-10	QRS duration;
THYM	cis	rs71403859	0.730	rs12923781	chr16:71653464	G/A	cg08717414	chr16:71523259	ZNF19	-0.93	-4.84	-0.44	5.12e-6	Post bronchodilator FEV1;
THYM	cis	rs10089	0.953	rs13358455	chr5:127365786	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.97	6.65	0.56	1.82e-9	Ileal carcinoids;
THYM	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.65	-5.35	-0.48	6.09e-7	Monocyte percentage of white cells;
THYM	trans	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg10856724	chr12:34555212	NA	-0.97	-7.16	-0.59	1.7e-10	Bladder cancer;
THYM	cis	rs2734839	0.964	rs12798900	chr11:113298996	G/T	cg14159747	chr11:113255604	NA	0.32	6.48	0.55	4.03e-9	Information processing speed;
THYM	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg19761014	chr17:28927070	LRRC37B2	0.76	4.73	0.44	7.7e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11577318	0.579	rs10794532	chr1:26694260	T/C	cg16664472	chr1:26644822	UBXN11;CD52	0.33	4.69	0.43	9e-6	Granulocyte percentage of myeloid white cells;
THYM	cis	rs7840202	0.524	rs10955287	chr8:103420005	A/T	cg09990700	chr8:103251014	RRM2B	-1.0	-4.67	-0.43	9.79e-6	Rate of cognitive decline in mild cognitive impairment (time interaction);Gestational age at birth in labor-initiated deliveries (child effect);
THYM	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg19912559	chr1:40204330	PPIE	-0.64	-4.92	-0.45	3.61e-6	Blood protein levels;
THYM	cis	rs651907	0.541	rs2925325	chr3:101630668	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	4.78	0.44	6.43e-6	Colorectal cancer;
THYM	cis	rs17030434	0.784	rs72617459	chr4:154661686	T/C	cg14289246	chr4:154710475	SFRP2	-0.69	-5.4	-0.48	4.96e-7	Electrocardiographic conduction measures;
THYM	cis	rs10208940	0.614	rs13385342	chr2:68749497	C/T	cg09157127	chr2:69201416	GKN1	0.84	4.54	0.42	1.66e-5	Urate levels in lean individuals;
THYM	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg24692254	chr21:30365293	RNF160	-0.85	-7.06	-0.59	2.74e-10	Dental caries;
THYM	cis	rs34638657	0.732	rs10514532	chr16:82200337	C/T	cg07307142	chr16:82071433	HSD17B2	0.92	8.53	0.66	2.3e-13	Lung adenocarcinoma;
THYM	cis	rs10231759	0.617	rs11982695	chr7:150512100	G/A	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.66	4.97	0.45	3e-6	Height;
THYM	cis	rs2463822	1.000	rs115395195	chr11:62100353	G/A	cg06239285	chr11:62104954	ASRGL1	-1.4	-6.7	-0.57	1.45e-9	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs35883536	0.935	rs12409832	chr1:101107725	A/G	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg07570687	chr10:102243282	WNT8B	0.77	6.86	0.58	7.1e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs8067545	0.611	rs733794	chr17:20157957	T/C	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg01699819	chr7:1052092	C7orf50	-0.7	-5.94	-0.52	4.62e-8	Bronchopulmonary dysplasia;
THYM	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.78	-5.09	-0.46	1.8e-6	Mean platelet volume;
THYM	cis	rs9814567	0.778	rs4955546	chr3:134334738	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.57	-0.61	2.38e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	trans	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg13615516	chr5:77269221	NA	0.86	8.01	0.63	2.88e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1178127	0.611	rs1989817	chr7:18829644	G/A	cg13420273	chr7:18810212	HDAC9	-0.62	-5.42	-0.49	4.6e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg24818145	chr4:99064322	C4orf37	0.9	7.36	0.6	6.5e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg07777115	chr5:623756	CEP72	-0.8	-4.78	-0.44	6.48e-6	Obesity-related traits;
THYM	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg00495681	chr13:53174319	NA	0.73	6.85	0.57	7.36e-10	Lewy body disease;
THYM	cis	rs9430161	0.611	rs34032547	chr1:11034374	C/G	cg02454025	chr1:11042201	C1orf127	0.91	10.49	0.73	1.51e-17	Ewing sarcoma;
THYM	cis	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg27068330	chr11:65405492	SIPA1	-0.68	-4.6	-0.43	1.32e-5	Breast cancer;
THYM	cis	rs6570726	0.935	rs407721	chr6:145871354	A/C	cg13319975	chr6:146136371	FBXO30	-0.66	-5.62	-0.5	1.89e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4262150	0.883	rs72802889	chr5:152254829	T/C	cg06854687	chr5:151642065	NA	0.64	4.46	0.42	2.27e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs595982	0.559	rs17206700	chr19:49361255	A/G	cg21252483	chr19:49399788	TULP2	-0.81	-5.67	-0.5	1.56e-7	Red cell distribution width;
THYM	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg02734326	chr4:10020555	SLC2A9	0.76	6.44	0.55	4.94e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg11247378	chr22:39784982	NA	-1.05	-14.1	-0.82	5.05e-25	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg05368731	chr17:41323189	NBR1	1.07	6.91	0.58	5.5e-10	Menopause (age at onset);
THYM	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.83	0.44	5.29e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs763014	0.898	rs916414	chr16:632073	C/T	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs17433780	0.504	rs7525985	chr1:89460948	C/T	cg10631373	chr1:89457642	RBMXL1;CCBL2	0.32	5.01	0.46	2.53e-6	Carotid intima media thickness;
THYM	cis	rs1451375	1.000	rs1451374	chr7:50622653	G/A	cg18232548	chr7:50535776	DDC	0.73	5.57	0.5	2.35e-7	Malaria;
THYM	cis	rs6570726	1.000	rs373778	chr6:145873252	C/T	cg23711669	chr6:146136114	FBXO30	0.83	8.07	0.64	2.16e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.11	-7.53	-0.61	2.93e-11	Schizophrenia;
THYM	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13315871	0.929	rs9854438	chr3:58277327	G/A	cg00563845	chr3:58318305	PXK	0.55	4.9	0.45	3.99e-6	Cholesterol, total;
THYM	cis	rs7769051	0.522	rs7759524	chr6:133109574	A/G	cg22852734	chr6:133119734	C6orf192	1.47	6.85	0.57	7.36e-10	Type 2 diabetes nephropathy;
THYM	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg18681998	chr4:17616180	MED28	0.94	8.61	0.66	1.51e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg03806693	chr22:41940476	POLR3H	1.04	7.62	0.62	1.86e-11	Vitiligo;
THYM	cis	rs2637266	1.000	rs17384253	chr10:78342391	A/G	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs1286150	0.628	rs11849825	chr14:91493114	T/G	cg02136132	chr14:90527891	KCNK13	-0.66	-4.52	-0.42	1.8e-5	Total body bone mineral density;
THYM	cis	rs4642101	0.561	rs7641959	chr3:12810755	G/C	cg05775895	chr3:12838266	CAND2	0.74	5.96	0.52	4.25e-8	QRS complex (12-leadsum);
THYM	cis	rs11771526	0.792	rs10249413	chr7:32304259	G/C	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg18105134	chr13:113819100	PROZ	-1.0	-9.11	-0.68	1.32e-14	Platelet distribution width;
THYM	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg11266682	chr4:10021025	SLC2A9	0.73	12.79	0.8	2.25e-22	Bone mineral density;
THYM	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg04362960	chr10:104952993	NT5C2	0.58	4.68	0.43	9.68e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2625529	0.824	rs12899485	chr15:72143215	A/G	cg16672083	chr15:72433130	SENP8	0.55	4.96	0.45	3.02e-6	Red blood cell count;
THYM	cis	rs74461473	0.567	rs1076904	chr3:50652469	A/G	cg12257692	chr3:49977190	RBM6	-0.87	-4.5	-0.42	1.9e-5	Conotruncal heart defects (maternal effects);
THYM	cis	rs7940866	0.774	rs12420126	chr11:130834811	C/T	cg05962950	chr11:130786565	SNX19	0.74	5.85	0.51	7.07e-8	Schizophrenia;
THYM	cis	rs2836974	0.604	rs914156	chr21:40717478	C/A	cg11644478	chr21:40555479	PSMG1	0.68	4.92	0.45	3.63e-6	Cognitive function;
THYM	cis	rs9361491	0.608	rs9352620	chr6:79443547	T/G	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg20307385	chr11:47447363	PSMC3	0.56	4.47	0.42	2.16e-5	Subjective well-being;
THYM	cis	rs4820539	0.966	rs2283803	chr22:23454881	G/A	cg21100191	chr22:23484243	RTDR1	0.71	6.33	0.54	8.23e-9	Bone mineral density;
THYM	cis	rs7264396	0.563	rs2425109	chr20:34316218	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Total cholesterol levels;
THYM	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg09436375	chr6:42928200	GNMT	-0.43	-5.62	-0.5	1.9e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.75e-6	Aortic root size;
THYM	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	5.31	0.48	7.32e-7	Obesity-related traits;
THYM	cis	rs4455778	0.543	rs7808690	chr7:49065751	A/C	cg26309511	chr7:48887640	NA	0.69	6.04	0.53	2.94e-8	Lung cancer in never smokers;
THYM	cis	rs2229238	0.911	rs6674171	chr1:154491683	A/G	cg21262032	chr1:154437693	IL6R	-0.6	-5.39	-0.48	5.21e-7	Coronary heart disease;
THYM	cis	rs4242434	0.927	rs57594397	chr8:22475657	T/C	cg21658235	chr8:22456391	C8orf58	0.58	5.39	0.48	5.02e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6032067	0.527	rs6017490	chr20:43736369	C/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.59	-6.26	-0.54	1.11e-8	Blood protein levels;
THYM	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg02887458	chr19:19495540	GATAD2A	0.47	5.3	0.48	7.47e-7	Bipolar disorder;
THYM	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs2219968	0.683	rs7010860	chr8:78907284	C/T	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg18758796	chr5:131593413	PDLIM4	-0.5	-4.72	-0.44	8.15e-6	Blood metabolite levels;
THYM	cis	rs3771570	0.901	rs62190410	chr2:242410621	C/T	cg21155796	chr2:242212141	HDLBP	1.2	6.25	0.54	1.15e-8	Prostate cancer;
THYM	trans	rs8187707	0.655	rs55957832	chr10:101686509	C/G	cg07700925	chr10:129540267	NA	1.07	7.24	0.6	1.15e-10	Carboplatin disposition in epthelial ovarian cancer;
THYM	cis	rs4280164	0.551	rs12436194	chr14:24804859	C/T	cg22990158	chr14:24802150	ADCY4	0.6	5.05	0.46	2.16e-6	Parent of origin effect on language impairment (paternal);
THYM	trans	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg20587970	chr11:113659929	NA	-1.37	-8.96	-0.68	2.79e-14	Hip circumference adjusted for BMI;
THYM	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg25237894	chr2:233734115	C2orf82	-0.36	-5.15	-0.47	1.42e-6	Coronary artery disease;
THYM	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs8067545	1.000	rs2108980	chr17:19920518	G/A	cg20830565	chr17:20408647	MGC102966	-0.5	-4.67	-0.43	9.81e-6	Schizophrenia;
THYM	cis	rs9560113	0.573	rs9560133	chr13:112240013	C/A	cg10483660	chr13:112241077	NA	0.66	7.9	0.63	4.87e-12	Menarche (age at onset);
THYM	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12756686	chr19:29218302	NA	0.88	7.05	0.59	2.83e-10	Methadone dose in opioid dependence;
THYM	cis	rs4343996	0.542	rs6969267	chr7:3435750	T/C	cg21248987	chr7:3385318	SDK1	0.4	5.18	0.47	1.25e-6	Motion sickness;
THYM	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg17345569	chr6:42928274	GNMT	-0.46	-4.52	-0.42	1.77e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg02820040	chr2:241836501	C2orf54	-0.33	-6.58	-0.56	2.59e-9	Urinary metabolites;
THYM	cis	rs501916	0.833	rs59184310	chr15:48050205	A/T	cg20869673	chr15:48010124	SEMA6D	0.7	5.19	0.47	1.17e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs1003719	0.715	rs2835675	chr21:38582815	G/A	cg01329690	chr21:38580129	DSCR9	-0.4	-5.56	-0.5	2.45e-7	Eye color traits;
THYM	cis	rs2976388	1.000	rs2976396	chr8:143764001	A/G	cg13446199	chr8:143762866	PSCA	-0.51	-6.42	-0.55	5.46e-9	Urinary tract infection frequency;
THYM	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg23161317	chr6:28129485	ZNF389	0.94	7.03	0.58	3.18e-10	Parkinson's disease;
THYM	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg22431228	chr1:16359049	CLCNKA	-0.53	-5.13	-0.47	1.51e-6	Dilated cardiomyopathy;
THYM	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	4.82	0.44	5.5e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7568458	0.870	rs1562323	chr2:85809711	T/C	cg17127132	chr2:85788382	GGCX	0.61	4.68	0.43	9.69e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.71	-5.81	-0.51	8.35e-8	Menarche (age at onset);
THYM	cis	rs2070488	0.965	rs2154778	chr3:38553639	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-6.35	-0.55	7.49e-9	Electrocardiographic conduction measures;
THYM	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg10150615	chr22:24372951	LOC391322	-0.97	-12.36	-0.79	1.72e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1448094	0.511	rs17279133	chr12:86162353	G/A	cg02569458	chr12:86230093	RASSF9	0.69	5.77	0.51	9.84e-8	Major depressive disorder;
THYM	cis	rs9527	0.590	rs11191572	chr10:104893137	A/G	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs2404602	0.735	rs4886798	chr15:76673226	A/G	cg23625390	chr15:77176239	SCAPER	0.66	4.73	0.44	7.83e-6	Blood metabolite levels;
THYM	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.68	8.72	0.67	9.16e-14	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.46	-4.92	-0.45	3.63e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
THYM	cis	rs1994135	0.669	rs10844629	chr12:33697096	T/A	cg06521331	chr12:34319734	NA	-0.66	-4.94	-0.45	3.29e-6	Resting heart rate;
THYM	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg15704280	chr7:45808275	SEPT13	-1.01	-11.27	-0.76	3.31e-19	Coronary artery disease;
THYM	cis	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg10856724	chr12:34555212	NA	-0.92	-9.27	-0.69	6.02e-15	Morning vs. evening chronotype;
THYM	cis	rs9311676	0.656	rs12496906	chr3:58390490	A/C	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs3892630	0.620	rs10413279	chr19:33182746	A/G	cg22980127	chr19:33182716	NUDT19	1.16	11.8	0.77	2.51e-20	Red blood cell traits;
THYM	cis	rs8102476	0.905	rs7250689	chr19:38753625	C/T	cg14131526	chr19:38747285	PPP1R14A	0.58	5.41	0.49	4.61e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2275731	0.505	rs7910712	chr10:16479256	T/C	cg00316341	chr10:16898311	CUBN	0.35	4.77	0.44	6.68e-6	Bone fracture in osteoporosis;
THYM	cis	rs7599312	0.586	rs7565257	chr2:213388276	G/A	cg16329650	chr2:213403929	ERBB4	0.62	4.72	0.44	8e-6	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs8048589	0.660	rs11075054	chr16:12216295	C/A	cg02910054	chr16:12241554	SNX29	0.8	6.12	0.53	2.08e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs7084402	0.935	rs10740731	chr10:60348886	G/A	cg27040468	chr10:60456715	BICC1	-0.54	-4.49	-0.42	1.98e-5	Refractive error;
THYM	cis	rs6032067	0.929	rs17424723	chr20:43814520	G/T	cg27176129	chr20:43937155	MATN4;RBPJL	0.49	5.19	0.47	1.19e-6	Blood protein levels;
THYM	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11948739	0.537	rs12518203	chr5:130233745	G/A	cg08523029	chr5:130500466	HINT1	-0.77	-5.2	-0.47	1.13e-6	Pediatric bone mineral content (hip);
THYM	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg12165864	chr7:66369176	NA	-0.65	-5.08	-0.46	1.89e-6	Aortic root size;
THYM	cis	rs7953508	0.711	rs3825198	chr12:93977465	T/A	cg13201927	chr12:93977447	NA	0.65	4.6	0.43	1.28e-5	Pubertal anthropometrics;
THYM	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg04654363	chr8:8581213	NA	-0.48	-4.62	-0.43	1.22e-5	Obesity-related traits;
THYM	cis	rs4481887	1.000	rs10888356	chr1:248465044	C/T	cg13385794	chr1:248469461	NA	-0.67	-4.62	-0.43	1.22e-5	Common traits (Other);
THYM	cis	rs2731664	0.792	rs335420	chr5:176898619	C/T	cg14098951	chr5:176875120	PRR7	-0.52	-4.57	-0.42	1.47e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	cg01483505	chr11:975446	AP2A2	0.66	5.33	0.48	6.69e-7	Alzheimer's disease (late onset);
THYM	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg05342682	chr7:94953680	PON1	0.55	5.99	0.52	3.66e-8	Paraoxonase activity;
THYM	cis	rs7772486	0.875	rs2748490	chr6:146329681	G/T	cg13319975	chr6:146136371	FBXO30	-0.72	-6.03	-0.53	3.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12310956	0.510	rs4931758	chr12:33871870	C/T	cg10856724	chr12:34555212	NA	-0.64	-5.82	-0.51	7.77e-8	Morning vs. evening chronotype;
THYM	cis	rs6032067	0.543	rs13045693	chr20:43911817	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.4	-4.77	-0.44	6.69e-6	Blood protein levels;
THYM	cis	rs7264396	0.887	rs6120951	chr20:34045191	G/A	cg26038318	chr20:34205095	SPAG4	0.53	4.47	0.42	2.15e-5	Total cholesterol levels;
THYM	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg18402987	chr7:1209562	NA	0.7	5.25	0.47	9.41e-7	Longevity;Endometriosis;
THYM	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg11764359	chr7:65958608	NA	0.76	6.16	0.53	1.73e-8	Aortic root size;
THYM	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg17691542	chr6:26056736	HIST1H1C	0.92	5.44	0.49	4.08e-7	Iron status biomarkers;
THYM	cis	rs11690935	0.959	rs6433314	chr2:172660971	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.81	-5.87	-0.52	6.34e-8	Schizophrenia;
THYM	cis	rs554111	0.571	rs4537519	chr1:21461370	T/C	cg00373020	chr1:21041521	KIF17	-0.57	-4.85	-0.45	4.77e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs6882716	1.000	rs4702730	chr5:10799879	T/A	cg14521931	chr5:10832172	NA	-0.71	-5.62	-0.5	1.89e-7	Alcohol consumption (maxi-drinks);
THYM	cis	rs11648796	0.717	rs10682	chr16:767430	C/G	cg03287339	chr16:711135	WDR90	-0.53	-4.5	-0.42	1.9e-5	Height;
THYM	cis	rs10887741	1.000	rs10887741	chr10:89443310	A/G	cg13926569	chr10:89418898	PAPSS2	0.56	5.53	0.49	2.78e-7	Exercise (leisure time);
THYM	cis	rs7394190	0.748	rs16930909	chr10:75561582	T/C	cg07699608	chr10:75541558	CHCHD1	0.9	4.83	0.44	5.17e-6	Incident atrial fibrillation;
THYM	cis	rs1046896	0.628	rs12452314	chr17:80723362	A/G	cg02398342	chr17:80708632	TBCD;FN3K	0.68	5.15	0.47	1.38e-6	Glycated hemoglobin levels;
THYM	cis	rs9658691	0.920	rs72809352	chr10:90742624	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.92	-5.2	-0.47	1.12e-6	Mosquito bite size;
THYM	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg05313129	chr8:58192883	C8orf71	-0.81	-4.87	-0.45	4.48e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg23422044	chr7:1970798	MAD1L1	-0.76	-5.29	-0.48	7.67e-7	Bipolar disorder;
THYM	cis	rs2354432	0.546	rs11240030	chr1:146882616	G/A	cg25205988	chr1:146714368	CHD1L	0.95	4.7	0.43	8.68e-6	Mitochondrial DNA levels;
THYM	cis	rs9928842	1.000	rs9928842	chr16:75242867	T/C	cg09066997	chr16:75300724	BCAR1	0.78	5.0	0.46	2.65e-6	Alcoholic chronic pancreatitis;
THYM	cis	rs7043114	0.507	rs6479420	chr9:95116406	T/C	cg14631576	chr9:95140430	CENPP	-0.87	-9.07	-0.68	1.62e-14	Height;
THYM	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg05754148	chr16:3507555	NAT15	0.92	8.27	0.65	8.27e-13	Tuberculosis;
THYM	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg02869364	chr7:1081709	C7orf50	-0.61	-4.91	-0.45	3.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs6032067	1.000	rs6032067	chr20:43864809	G/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs11785693	0.909	rs62489556	chr8:4968149	G/A	cg26367366	chr8:4980734	NA	1.16	5.47	0.49	3.64e-7	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs16828019	0.704	rs34660906	chr1:41551968	C/T	cg16989117	chr1:40781907	COL9A2	0.96	4.71	0.44	8.49e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14442939	chr10:27389572	ANKRD26	0.86	4.61	0.43	1.25e-5	Breast cancer;
THYM	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg03929089	chr4:120376271	NA	-0.93	-7.63	-0.62	1.83e-11	Coronary artery disease;
THYM	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg02734326	chr4:10020555	SLC2A9	-0.58	-4.75	-0.44	7.28e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg27394845	chr17:28928406	LRRC37B2	0.98	4.82	0.44	5.45e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17511627	0.755	rs4770937	chr13:26744401	T/C	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg13695892	chr22:41940480	POLR3H	0.82	6.05	0.53	2.92e-8	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs8018808	0.967	rs176766	chr14:77865367	G/A	cg20045696	chr14:77926864	AHSA1	0.53	4.73	0.44	7.91e-6	Myeloid white cell count;
THYM	cis	rs11760633	0.607	rs7777233	chr7:1831671	C/T	cg23422044	chr7:1970798	MAD1L1	-0.65	-4.68	-0.43	9.58e-6	Coronary artery disease;
THYM	cis	rs4746818	0.793	rs2008541	chr10:70860599	A/G	cg11621586	chr10:70884670	VPS26A	0.86	5.1	0.46	1.7e-6	Left atrial antero-posterior diameter;
THYM	cis	rs2625529	0.504	rs11072349	chr15:72464471	T/C	cg16672083	chr15:72433130	SENP8	0.51	4.62	0.43	1.22e-5	Red blood cell count;
THYM	cis	rs6728642	0.908	rs6576996	chr2:97623312	T/C	cg26665480	chr2:98280029	ACTR1B	-0.8	-4.5	-0.42	1.95e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg15242686	chr22:24348715	GSTTP1	0.57	5.81	0.51	8.47e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.44	7.34	0.6	7.07e-11	Obesity-related traits;
THYM	cis	rs9787249	0.957	rs12074147	chr1:40203722	T/C	cg24920358	chr1:40204285	PPIE	0.56	4.89	0.45	4.14e-6	Blood protein levels;
THYM	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21659725	chr3:3221576	CRBN	0.9	10.01	0.72	1.55e-16	Intelligence (multi-trait analysis);
THYM	cis	rs4595586	0.545	rs1303887	chr12:39366523	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs1843834	0.823	rs2129610	chr2:225505345	G/A	cg22455342	chr2:225449267	CUL3	0.7	5.06	0.46	2.05e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9443189	0.526	rs775060	chr6:76373567	G/A	cg01950844	chr6:76311363	SENP6	-1.05	-6.66	-0.56	1.73e-9	Prostate cancer;
THYM	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg11366901	chr6:160182831	ACAT2	1.05	9.6	0.7	1.18e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs870825	0.616	rs7694899	chr4:185625390	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.69	0.71	7.45e-16	Blood protein levels;
THYM	cis	rs13418717	1.000	rs10496658	chr2:127663497	C/T	cg25501666	chr2:127640322	NA	1.36	6.36	0.55	7e-9	Heart failure;
THYM	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg09307838	chr4:120376055	NA	0.72	4.97	0.45	3.01e-6	Corneal astigmatism;
THYM	cis	rs6430585	0.583	rs7561565	chr2:136640787	A/C	cg04750100	chr2:136595281	LCT	0.52	4.87	0.45	4.45e-6	Corneal structure;
THYM	cis	rs7187994	0.848	rs16974535	chr16:84783473	G/A	cg07647771	chr16:84786436	USP10	-0.55	-5.06	-0.46	2.03e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg08999081	chr20:33150536	PIGU	0.79	7.48	0.61	3.72e-11	Coronary artery disease;
THYM	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg08885076	chr2:99613938	TSGA10	-0.66	-6.08	-0.53	2.47e-8	Chronic sinus infection;
THYM	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg10852096	chr15:79043040	NA	-0.63	-4.84	-0.44	4.99e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs36051895	0.625	rs11792531	chr9:5152203	T/C	cg02405213	chr9:5042618	JAK2	-1.09	-10.97	-0.75	1.41e-18	Pediatric autoimmune diseases;
THYM	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg05335186	chr13:53173507	NA	-0.54	-6.32	-0.54	8.41e-9	Lewy body disease;
THYM	cis	rs11626933	0.959	rs2149649	chr14:90774974	A/G	cg14092571	chr14:90743983	NA	0.82	8.75	0.67	7.66e-14	Gut microbiota (bacterial taxa);
THYM	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg12893697	chr11:970389	AP2A2	-0.33	-5.47	-0.49	3.71e-7	Alzheimer's disease (late onset);
THYM	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg17294928	chr15:75287854	SCAMP5	-0.68	-4.61	-0.43	1.24e-5	Blood trace element (Zn levels);
THYM	cis	rs2080501	0.540	rs7184732	chr16:49685986	C/T	cg05126388	chr16:49670144	ZNF423	-0.81	-9.75	-0.71	5.61e-16	IgG glycosylation;
THYM	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs447921	0.724	rs346803	chr17:74381567	G/A	cg17201438	chr17:74438067	UBE2O	-0.81	-5.89	-0.52	5.72e-8	Mitochondrial DNA levels;
THYM	cis	rs1863824	0.625	rs2018507	chr10:88163251	A/G	cg06895675	chr10:88137553	NA	-0.56	-5.09	-0.46	1.79e-6	Schizophrenia;
THYM	cis	rs13064411	0.696	rs6438156	chr3:113206929	C/A	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg12564285	chr5:131593104	PDLIM4	0.52	5.85	0.51	6.96e-8	Blood metabolite levels;
THYM	cis	rs300703	0.654	rs435733	chr2:121222	A/G	cg21211680	chr2:198530	NA	-1.33	-7.55	-0.61	2.66e-11	Blood protein levels;
THYM	cis	rs988913	0.678	rs4712096	chr6:54978214	C/G	cg18532076	chr6:54711417	FAM83B	0.49	4.51	0.42	1.83e-5	Menarche (age at onset);
THYM	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg03909863	chr11:638404	DRD4	-0.66	-4.71	-0.44	8.41e-6	Systemic lupus erythematosus;
THYM	cis	rs7705502	1.000	rs17696147	chr5:173373143	T/C	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs10121009	0.591	rs10814221	chr9:35291473	T/C	cg15271616	chr9:35490515	RUSC2	0.74	5.0	0.46	2.63e-6	Parkinson's disease;
THYM	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs870825	0.860	rs61165411	chr4:185604461	G/A	cg04058563	chr4:185651563	MLF1IP	1.05	7.96	0.63	3.6e-12	Blood protein levels;
THYM	cis	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg19677267	chr1:26645161	CD52;UBXN11	0.55	5.18	0.47	1.22e-6	Obesity-related traits;
THYM	cis	rs1005224	1.000	rs1005224	chr14:76173860	A/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.69	-5.53	-0.49	2.77e-7	Large artery stroke;
THYM	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg10589385	chr1:150898437	SETDB1	0.62	5.08	0.46	1.9e-6	Melanoma;
THYM	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.52	-5.8	-0.51	8.5e-8	Schizophrenia;
THYM	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.66	-4.63	-0.43	1.18e-5	Aortic root size;
THYM	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg18252515	chr7:66147081	NA	-1.44	-8.51	-0.66	2.48e-13	Diabetic kidney disease;
THYM	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg24549020	chr5:56110836	MAP3K1	0.71	4.63	0.43	1.15e-5	Initial pursuit acceleration;
THYM	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg05283184	chr6:79620031	NA	-0.9	-9.12	-0.68	1.28e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.68	-4.57	-0.42	1.44e-5	Menarche (age at onset);
THYM	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg19077165	chr18:44547161	KATNAL2	0.51	5.99	0.52	3.73e-8	Personality dimensions;
THYM	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg03060546	chr3:49711283	APEH	0.75	6.15	0.53	1.8e-8	Resting heart rate;
THYM	cis	rs11148252	0.711	rs61957304	chr13:52798423	G/A	cg05335186	chr13:53173507	NA	-0.48	-6.7	-0.57	1.49e-9	Lewy body disease;
THYM	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03647317	chr4:187891568	NA	-0.85	-9.13	-0.68	1.17e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Body mass index;
THYM	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg09537434	chr19:41945824	ATP5SL	-1.06	-9.52	-0.7	1.74e-15	Height;
THYM	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg07169764	chr2:136633963	MCM6	-0.71	-6.05	-0.53	2.81e-8	Mosquito bite size;
THYM	cis	rs7705502	1.000	rs17694791	chr5:173326891	C/T	cg18693985	chr5:173351052	CPEB4	-0.78	-5.64	-0.5	1.71e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg08999081	chr20:33150536	PIGU	0.76	6.67	0.57	1.65e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs3960554	0.741	rs28446604	chr7:75662518	C/T	cg17325771	chr7:75508891	RHBDD2	-0.39	-4.49	-0.42	1.97e-5	Eotaxin levels;
THYM	trans	rs1500251	1.000	rs58349538	chr5:98575433	T/C	cg10622019	chr1:4221485	NA	0.59	6.98	0.58	3.91e-10	Periodontitis (Mean PAL);
THYM	cis	rs924712	0.677	rs239850	chr6:54761282	C/G	cg04690482	chr6:54711388	FAM83B	0.44	5.06	0.46	2.01e-6	Breast cancer;
THYM	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg13695892	chr22:41940480	POLR3H	-0.98	-7.65	-0.62	1.61e-11	Vitiligo;
THYM	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10779751	1.000	rs11121698	chr1:11267283	C/T	cg08854313	chr1:11322531	MTOR	1.01	9.78	0.71	4.97e-16	Body mass index;
THYM	cis	rs9650657	0.615	rs12541110	chr8:10695125	A/T	cg12981288	chr8:11183844	MTMR9	-0.5	-4.71	-0.44	8.34e-6	Neuroticism;
THYM	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg10505658	chr17:80084571	CCDC57	0.7	8.07	0.64	2.18e-12	Life satisfaction;
THYM	cis	rs4919087	0.892	rs2065861	chr10:99004608	C/T	cg19453742	chr10:98862320	SLIT1	-0.63	-4.76	-0.44	6.83e-6	Monocyte count;
THYM	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs7582180	0.764	rs4851293	chr2:100925106	A/T	cg21926883	chr2:100939477	LONRF2	-0.61	-5.52	-0.49	2.91e-7	Intelligence (multi-trait analysis);
THYM	cis	rs367615	0.918	rs4576198	chr5:108867350	T/G	cg17395555	chr5:108820864	NA	0.53	4.8	0.44	5.95e-6	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs1986734	0.576	rs12503749	chr4:77418383	T/C	cg20311846	chr4:77356250	SHROOM3	-0.43	-4.66	-0.43	1.01e-5	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
THYM	cis	rs6541297	0.941	rs6690424	chr1:230278892	C/T	cg20703242	chr1:230279135	GALNT2	0.92	6.26	0.54	1.13e-8	Coronary artery disease;
THYM	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg24209194	chr3:40518798	ZNF619	0.64	5.06	0.46	2.03e-6	Renal cell carcinoma;
THYM	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs2464469	0.654	rs4646570	chr15:58343146	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.64	-4.86	-0.45	4.71e-6	Barrett's esophagus  or Esophageal adenocarcinoma;
THYM	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg01236616	chr12:121019343	POP5	1.31	10.38	0.73	2.57e-17	Type 1 diabetes nephropathy;
THYM	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7589342	0.831	rs10169998	chr2:106452253	A/G	cg14210321	chr2:106509881	NCK2	-0.75	-5.36	-0.48	5.72e-7	Addiction;
THYM	cis	rs7937682	0.924	rs564601	chr11:111594077	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.12	-10.75	-0.74	4.11e-18	Primary sclerosing cholangitis;
THYM	cis	rs2235573	0.657	rs4821731	chr22:38445214	C/A	cg19171272	chr22:38449367	NA	-0.5	-5.19	-0.47	1.18e-6	Glioblastoma;Glioma;
THYM	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs56341938	0.935	rs1544659	chr3:168741912	A/T	cg09107232	chr3:169491072	MYNN	0.54	4.58	0.43	1.42e-5	Lung function (FEV1/FVC);
THYM	cis	rs72827839	0.779	rs72827858	chr17:46474361	A/G	cg23391107	chr17:45924227	SP6	0.86	5.55	0.5	2.54e-7	Ease of getting up in the morning;
THYM	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.56	-0.5	2.45e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13177918	0.677	rs3900644	chr5:149822922	T/A	cg14059543	chr5:149831962	NA	-1.0	-7.6	-0.61	2.11e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg15704280	chr7:45808275	SEPT13	-1.06	-15.41	-0.85	1.38e-27	Height;
THYM	cis	rs2658782	1.000	rs2605582	chr11:93163799	C/T	cg15737290	chr11:93063684	CCDC67	1.05	7.97	0.63	3.42e-12	Pulmonary function decline;
THYM	cis	rs1829883	0.835	rs10068675	chr5:98890617	C/G	cg08333243	chr5:99726346	NA	-0.52	-4.55	-0.42	1.62e-5	Hemostatic factors and hematological phenotypes;
THYM	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg06784218	chr1:46089804	CCDC17	-0.3	-4.64	-0.43	1.1e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg08498830	chr11:832797	CD151	-0.62	-4.51	-0.42	1.82e-5	Mean platelet volume;
THYM	cis	rs2882877	0.706	rs11685197	chr2:190412377	G/A	cg10752008	chr2:190445175	SLC40A1	0.73	5.88	0.52	5.96e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg01831904	chr17:28903510	LRRC37B2	-1.13	-5.5	-0.49	3.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg16524936	chr4:1340807	KIAA1530	-0.66	-5.29	-0.48	7.87e-7	Longevity;
THYM	cis	rs478304	0.654	rs7115734	chr11:65458964	G/A	cg27068330	chr11:65405492	SIPA1	-1.03	-10.31	-0.73	3.55e-17	Acne (severe);
THYM	cis	rs1933112	1.000	rs1933110	chr1:168523455	A/G	cg17186328	chr1:168545835	XCL1	-0.55	-4.59	-0.43	1.37e-5	Blood protein levels;
THYM	cis	rs17102423	0.594	rs1124752	chr14:65567515	G/T	cg11161011	chr14:65562177	MAX	-0.69	-5.58	-0.5	2.31e-7	Obesity-related traits;
THYM	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs6430585	0.528	rs16832205	chr2:136684632	G/A	cg07169764	chr2:136633963	MCM6	1.18	10.98	0.75	1.39e-18	Corneal structure;
THYM	cis	rs7772486	0.790	rs9403749	chr6:146162239	A/G	cg13319975	chr6:146136371	FBXO30	-0.64	-5.27	-0.48	8.44e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg19748678	chr4:122722346	EXOSC9	0.73	5.15	0.47	1.42e-6	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg17366294	chr4:99064904	C4orf37	0.54	6.26	0.54	1.11e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.67	-8.64	-0.66	1.3e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs758324	0.732	rs156046	chr5:131492723	C/A	cg16205897	chr5:131564050	P4HA2	0.52	4.6	0.43	1.29e-5	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg13902645	chr11:5959945	NA	-0.55	-4.82	-0.44	5.5e-6	DNA methylation (variation);
THYM	cis	rs7894051	1.000	rs2185746	chr10:135195332	A/G	cg12428399	chr10:135191333	PAOX	-1.0	-4.61	-0.43	1.27e-5	Lifespan;
THYM	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	-0.76	-5.91	-0.52	5.41e-8	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg02527881	chr3:46936655	PTH1R	-0.61	-5.7	-0.51	1.33e-7	Colorectal cancer;
THYM	cis	rs12711979	0.509	rs10191674	chr2:3827891	C/T	cg17052675	chr2:3827356	NA	-0.92	-16.76	-0.86	3.97e-30	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg24060327	chr5:131705240	SLC22A5	-0.81	-6.71	-0.57	1.4e-9	Breast cancer;
THYM	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg00383909	chr3:49044727	WDR6	1.05	5.99	0.52	3.79e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs863345	0.604	rs1578762	chr1:158497440	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs4919687	0.550	rs7904252	chr10:104456725	A/C	cg04362960	chr10:104952993	NT5C2	-0.61	-4.92	-0.45	3.65e-6	Colorectal cancer;
THYM	cis	rs9361491	0.608	rs9350773	chr6:79456705	A/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg13319975	chr6:146136371	FBXO30	-0.64	-5.19	-0.47	1.18e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg14019146	chr3:50243930	SLC38A3	-0.61	-5.17	-0.47	1.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6809651	0.524	rs6444105	chr3:185811301	C/T	cg00760338	chr3:185826511	ETV5	-0.89	-7.0	-0.58	3.55e-10	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
THYM	cis	rs28785552	0.897	rs7259466	chr19:53239369	G/A	cg22067481	chr19:53234126	ZNF611	-0.99	-10.33	-0.73	3.31e-17	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg12310025	chr6:25882481	NA	-0.73	-6.01	-0.52	3.41e-8	Blood metabolite levels;
THYM	cis	rs7567389	0.600	rs11679414	chr2:128151003	G/A	cg09760422	chr2:128146352	NA	0.4	4.71	0.44	8.47e-6	Self-rated health;
THYM	cis	rs747334	0.715	rs2027108	chr10:92747353	C/T	cg07620928	chr10:92689909	NA	-0.55	-4.94	-0.45	3.36e-6	Fibroblast growth factor basic levels;
THYM	cis	rs10927875	0.518	rs1763597	chr1:16343297	C/T	cg21385522	chr1:16154831	NA	0.65	4.65	0.43	1.08e-5	Dilated cardiomyopathy;
THYM	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg18681998	chr4:17616180	MED28	0.81	6.87	0.58	6.5e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg13607699	chr17:42295918	UBTF	-0.66	-5.59	-0.5	2.16e-7	Total body bone mineral density;
THYM	cis	rs13102973	0.965	rs4864244	chr4:135866959	A/G	cg14419869	chr4:135874104	NA	0.82	7.94	0.63	4.06e-12	Subjective well-being;
THYM	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg22753661	chr15:79092743	ADAMTS7	0.73	4.7	0.43	8.87e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs7572733	0.555	rs13395030	chr2:198750806	A/G	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs2219968	0.683	rs35877710	chr8:78899041	T/C	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg16850897	chr7:100343110	ZAN	-0.71	-5.37	-0.48	5.67e-7	Other erythrocyte phenotypes;
THYM	cis	rs4638749	0.906	rs34974921	chr2:108860253	A/G	cg06795125	chr2:108905320	SULT1C2	-0.42	-5.48	-0.49	3.42e-7	Blood pressure;
THYM	cis	rs67981189	0.896	rs17108925	chr14:71499727	A/G	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg11965913	chr1:205819406	PM20D1	-0.61	-4.84	-0.44	5.08e-6	Menarche (age at onset);
THYM	cis	rs240764	0.507	rs9390682	chr6:101219119	T/C	cg21058520	chr6:100914733	NA	-0.58	-4.54	-0.42	1.66e-5	Neuroticism;
THYM	cis	rs7572733	0.534	rs4850813	chr2:198775982	C/T	cg05783139	chr2:198650985	BOLL	-0.62	-4.89	-0.45	4.15e-6	Dermatomyositis;
THYM	cis	rs7927771	0.524	rs7942074	chr11:47720509	T/C	cg20307385	chr11:47447363	PSMC3	0.6	4.49	0.42	2.02e-5	Subjective well-being;
THYM	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg08873628	chr1:175162347	KIAA0040	0.51	4.59	0.43	1.34e-5	Alcohol dependence;
THYM	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg24020549	chr11:64937741	SPDYC	-0.46	-4.45	-0.42	2.29e-5	Eosinophil percentage of white cells;
THYM	cis	rs920590	0.918	rs11777075	chr8:19655666	G/A	cg01411142	chr8:19674711	INTS10	0.6	4.53	0.42	1.71e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1018836	0.828	rs1858673	chr8:91551526	C/A	cg16814680	chr8:91681699	NA	-0.87	-7.41	-0.61	5.15e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9921222	0.500	rs11648673	chr16:377794	G/A	cg16579431	chr16:433439	TMEM8A;LOC100134368	0.71	5.65	0.5	1.69e-7	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg08213375	chr14:104286397	PPP1R13B	0.52	6.25	0.54	1.18e-8	Schizophrenia;
THYM	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg20283391	chr11:68216788	NA	-0.69	-5.14	-0.47	1.49e-6	Total body bone mineral density;
THYM	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.8e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	6.66	0.56	1.74e-9	Lung cancer in ever smokers;
THYM	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	4.51	0.42	1.82e-5	Aortic root size;
THYM	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg17775962	chr7:1200435	ZFAND2A	0.42	4.92	0.45	3.59e-6	Longevity;Endometriosis;
THYM	cis	rs665401	0.692	rs339314	chr6:117182678	C/T	cg20376953	chr6:117187980	NA	0.61	4.89	0.45	4.05e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg10047753	chr17:41438598	NA	1.18	11.26	0.76	3.4e-19	Menopause (age at onset);
THYM	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg10856724	chr12:34555212	NA	-0.78	-6.99	-0.58	3.83e-10	Morning vs. evening chronotype;
THYM	cis	rs2280018	0.581	rs7404524	chr16:15129158	A/G	cg27102117	chr16:15229624	NA	0.65	5.02	0.46	2.45e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
THYM	cis	rs2294693	0.891	rs4714420	chr6:40992799	T/C	cg14418226	chr6:40996092	UNC5CL	0.68	5.96	0.52	4.3e-8	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs4589258	0.933	rs7102601	chr11:90396378	T/C	cg26138821	chr11:89956704	CHORDC1	0.71	6.0	0.52	3.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs72829446	0.530	rs2301609	chr17:7399866	G/A	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg00277334	chr10:82204260	NA	-0.83	-10.18	-0.72	6.99e-17	Post bronchodilator FEV1;
THYM	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg26354017	chr1:205819088	PM20D1	-0.78	-7.23	-0.6	1.21e-10	Monocyte percentage of white cells;
THYM	cis	rs6479527	0.625	rs1933667	chr9:96744109	G/C	cg14459158	chr9:96720562	NA	0.5	5.68	0.5	1.44e-7	Esophageal adenocarcinoma;
THYM	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg00074818	chr8:8560427	CLDN23	0.58	5.4	0.48	4.91e-7	Obesity-related traits;
THYM	cis	rs1079204	1.000	rs1567869	chr2:219126735	C/T	cg05728596	chr2:219128475	GPBAR1	-1.38	-6.94	-0.58	4.68e-10	Smooth-surface caries;
THYM	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg02640540	chr1:67518911	SLC35D1	0.67	5.1	0.46	1.74e-6	Lymphocyte percentage of white cells;
THYM	cis	rs2046867	0.818	rs62249863	chr3:72868666	G/C	cg25664220	chr3:72788482	NA	-0.95	-7.95	-0.63	3.75e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs2040771	0.774	rs9604935	chr22:19211665	C/T	cg02655711	chr22:19163373	SLC25A1	0.55	5.81	0.51	8.39e-8	Metabolite levels (small molecules and protein measures);
THYM	cis	rs6430585	0.583	rs7581814	chr2:136641593	C/G	cg20242066	chr2:136595261	LCT	-0.51	-4.89	-0.45	4.06e-6	Corneal structure;
THYM	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg25703541	chr22:24373054	LOC391322	-0.88	-9.55	-0.7	1.49e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg23583168	chr7:148888333	NA	-1.02	-12.95	-0.8	1.06e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs514406	0.698	rs11206055	chr1:53436632	A/T	cg22166914	chr1:53195759	ZYG11B	-0.63	-5.44	-0.49	4.16e-7	Monocyte count;
THYM	cis	rs4731207	0.596	rs10231818	chr7:124574184	G/A	cg05285228	chr7:124571219	POT1	-0.69	-5.25	-0.47	9.35e-7	Cutaneous malignant melanoma;
THYM	cis	rs2803122	0.846	rs10738535	chr9:19299362	T/C	cg19584733	chr9:19298547	DENND4C	-0.6	-5.17	-0.47	1.3e-6	Pulse pressure;
THYM	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg23131131	chr22:24373011	LOC391322	0.81	7.73	0.62	1.11e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs861020	0.630	rs628445	chr1:210004953	C/T	cg05527609	chr1:210001259	C1orf107	0.85	6.82	0.57	8.53e-10	Orofacial clefts;
THYM	cis	rs2455799	0.613	rs1532767	chr3:15733600	A/T	cg16303742	chr3:15540471	COLQ	-0.54	-5.87	-0.52	6.41e-8	Mean platelet volume;
THYM	cis	rs73198271	0.601	rs11997731	chr8:8649848	C/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-4.77	-0.44	6.56e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg00495681	chr13:53174319	NA	0.82	8.6	0.66	1.61e-13	Lewy body disease;
THYM	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg08736216	chr1:53307985	ZYG11A	-0.56	-5.16	-0.47	1.35e-6	Monocyte count;
THYM	cis	rs1003719	0.679	rs1133001	chr21:38512956	A/G	cg01329690	chr21:38580129	DSCR9	-0.37	-5.09	-0.46	1.83e-6	Eye color traits;
THYM	cis	rs7084921	0.608	rs2862948	chr10:101864173	A/G	cg11344164	chr10:101878520	NA	-0.58	-4.98	-0.45	2.86e-6	Bone mineral density;
THYM	cis	rs34421088	0.624	rs13278982	chr8:11589033	G/A	cg12395012	chr8:11607386	GATA4	-0.68	-5.27	-0.48	8.47e-7	Neuroticism;
THYM	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg07061783	chr6:25882402	NA	0.84	7.37	0.6	6.13e-11	Blood metabolite levels;
THYM	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Electroencephalogram traits;
THYM	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.78	0.51	9.35e-8	Obesity-related traits;
THYM	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg21427119	chr20:30132790	HM13	-0.86	-5.96	-0.52	4.2e-8	Mean corpuscular hemoglobin;
THYM	cis	rs916888	0.779	rs199526	chr17:44847707	C/G	cg01570182	chr17:44337453	NA	-0.71	-7.71	-0.62	1.21e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9534288	0.797	rs9534276	chr13:46574317	T/G	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg05657792	chr17:6899758	ALOX12	0.49	4.87	0.45	4.51e-6	Tonsillectomy;
THYM	cis	rs1278352	0.660	rs1278342	chr10:127770794	A/C	cg08295661	chr10:127769903	ADAM12	-0.54	-5.39	-0.48	5.1e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs6430585	0.528	rs309158	chr2:136680534	A/G	cg23851026	chr2:136556271	LCT	0.69	7.1	0.59	2.26e-10	Corneal structure;
THYM	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg00958927	chr1:175162553	KIAA0040	0.36	4.92	0.45	3.66e-6	Alcohol dependence;
THYM	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.61	-4.71	-0.44	8.43e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6596100	0.538	rs113848378	chr5:132192372	T/C	cg02081065	chr5:132209139	LEAP2	-0.95	-6.14	-0.53	1.87e-8	Breast cancer;
THYM	cis	rs834811	0.831	rs1097147	chr7:135880446	C/T	cg01726295	chr7:135938950	NA	0.61	5.09	0.46	1.79e-6	Post-traumatic stress disorder;
THYM	cis	rs10170846	0.800	rs10180462	chr2:223526385	C/T	cg25565276	chr2:223520875	FARSB	0.61	4.9	0.45	3.94e-6	Schizophrenia (inflammation and infection response interaction);
THYM	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg00814883	chr7:100076585	TSC22D4	-0.97	-6.52	-0.56	3.42e-9	Platelet count;
THYM	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.87	-6.71	-0.57	1.43e-9	Electrocardiographic conduction measures;
THYM	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg26736099	chr17:61989275	CSHL1	0.28	4.55	0.42	1.61e-5	Prudent dietary pattern;
THYM	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg13918804	chr1:2043761	PRKCZ	0.87	8.94	0.68	3e-14	Height;
THYM	cis	rs3027234	0.724	rs11651453	chr17:8103695	A/G	cg08322244	chr17:8066669	VAMP2	-0.54	-4.82	-0.44	5.52e-6	Telomere length;
THYM	cis	rs7246657	0.653	rs10402050	chr19:37688958	A/T	cg23950597	chr19:37808831	NA	-0.83	-5.0	-0.46	2.57e-6	Coronary artery calcification;
THYM	cis	rs2067615	0.524	rs10778500	chr12:107074410	T/A	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	cis	rs7107174	1.000	rs2510055	chr11:77961912	C/T	cg19901956	chr11:77921274	USP35	-0.76	-5.83	-0.51	7.53e-8	Testicular germ cell tumor;
THYM	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.45	-5.52	-0.49	2.93e-7	Schizophrenia;
THYM	cis	rs28595532	0.920	rs114966881	chr4:119761078	C/G	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	10.73	0.74	4.66e-18	Chronic sinus infection;
THYM	cis	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg06521331	chr12:34319734	NA	0.83	6.39	0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs5758659	0.716	rs5758661	chr22:42624445	A/C	cg00645731	chr22:42541494	CYP2D7P1	-0.41	-4.77	-0.44	6.73e-6	Cognitive function;
THYM	cis	rs7224737	0.750	rs13380830	chr17:40297658	C/G	cg20291162	chr17:40259547	DHX58	-0.67	-5.0	-0.46	2.65e-6	Fibrinogen levels;
THYM	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg09904177	chr6:26538194	HMGN4	0.54	4.57	0.42	1.47e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1062746	0.771	rs12447487	chr16:87377036	C/T	cg27119004	chr16:87376851	FBXO31	-0.48	-4.71	-0.43	8.5e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs7567389	0.677	rs72845976	chr2:128086440	T/A	cg06038358	chr2:128176007	PROC	0.43	4.53	0.42	1.7e-5	Self-rated health;
THYM	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Body mass index;
THYM	cis	rs4660306	0.884	rs7543076	chr1:45964238	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.43	-0.49	4.37e-7	Homocysteine levels;
THYM	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg06623918	chr6:96969491	KIAA0776	-1.09	-10.31	-0.73	3.58e-17	Headache;
THYM	cis	rs11726022	0.927	rs34224534	chr4:188173875	G/A	cg09690449	chr4:187998952	NA	-0.51	-5.15	-0.47	1.41e-6	Systolic blood pressure (cigarette smoking interaction);
THYM	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg06636001	chr8:8085503	FLJ10661	0.77	7.09	0.59	2.36e-10	Mood instability;
THYM	cis	rs11190604	0.767	rs10509743	chr10:102190406	C/T	cg07570687	chr10:102243282	WNT8B	0.81	7.78	0.62	8.93e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg10518543	chr12:38710700	ALG10B	-0.54	-4.52	-0.42	1.79e-5	Morning vs. evening chronotype;
THYM	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg03264133	chr6:25882463	NA	0.67	5.16	0.47	1.38e-6	Height;
THYM	cis	rs6032067	0.929	rs13043296	chr20:43805688	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs11031096	0.782	rs11031110	chr11:4162652	G/C	cg18678763	chr11:4115507	RRM1	-0.47	-6.57	-0.56	2.7e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9527	0.590	rs2182348	chr10:104872684	A/G	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg02527881	chr3:46936655	PTH1R	-0.69	-7.1	-0.59	2.23e-10	Colorectal cancer;
THYM	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2862064	1.000	rs9313400	chr5:156433341	A/G	cg12943317	chr5:156479607	HAVCR1	-0.86	-5.28	-0.48	8.3e-7	Platelet count;
THYM	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg20503657	chr10:835505	NA	1.15	8.03	0.64	2.58e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.68	5.26	0.47	9e-7	Eosinophil percentage of white cells;
THYM	cis	rs9534288	0.797	rs992631	chr13:46591989	A/G	cg15192986	chr13:46630673	CPB2	0.62	4.72	0.44	8.2e-6	Blood protein levels;
THYM	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg13010199	chr12:38710504	ALG10B	0.78	6.16	0.53	1.75e-8	Heart rate;
THYM	cis	rs11031096	0.711	rs17283923	chr11:4173841	C/T	cg08557956	chr11:4115526	RRM1	-0.53	-4.8	-0.44	5.78e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7267979	1.000	rs2257432	chr20:25271086	T/C	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1892700	0.853	rs62227710	chr21:34954170	A/G	cg24865779	chr21:34775042	IFNGR2	0.46	4.45	0.42	2.35e-5	Educational attainment;
THYM	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg19748678	chr4:122722346	EXOSC9	0.64	4.54	0.42	1.64e-5	Type 2 diabetes;
THYM	cis	rs72717009	0.825	rs7515174	chr1:161476949	C/G	cg23840854	chr1:161414152	NA	-1.03	-5.5	-0.49	3.16e-7	Rheumatoid arthritis;
THYM	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.67	6.01	0.52	3.42e-8	Calcium levels;
THYM	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs6748734	0.548	rs12618707	chr2:241874559	T/C	cg15164180	chr2:241846931	NA	0.39	4.98	0.45	2.85e-6	Urinary metabolites;
THYM	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg17480646	chr11:65405466	SIPA1	0.97	9.19	0.69	9.05e-15	Acne (severe);
THYM	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg14159672	chr1:205819179	PM20D1	0.77	6.68	0.57	1.59e-9	Menarche (age at onset);
THYM	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg00012203	chr2:219082015	ARPC2	-0.83	-7.86	-0.63	5.87e-12	Colorectal cancer;
THYM	cis	rs9543976	0.623	rs7986566	chr13:76197931	C/T	cg01531495	chr13:76123901	UCHL3	0.65	4.77	0.44	6.59e-6	Diabetic retinopathy;
THYM	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg10856724	chr12:34555212	NA	-0.87	-7.7	-0.62	1.3e-11	Morning vs. evening chronotype;
THYM	cis	rs12282928	0.959	rs2870509	chr11:48284109	T/C	cg22827986	chr11:48284249	OR4X1	-0.53	-5.5	-0.49	3.18e-7	Migraine - clinic-based;
THYM	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg09549813	chr16:4587862	C16orf5	-0.59	-6.65	-0.56	1.84e-9	Schizophrenia;
THYM	cis	rs941408	0.890	rs1640269	chr19:2793194	A/C	cg06609049	chr19:2785107	THOP1	0.66	5.46	0.49	3.81e-7	Total cholesterol levels;
THYM	cis	rs16973500	1.000	rs16973500	chr16:71965196	C/T	cg04311557	chr16:71523289	ZNF19	-0.59	-5.0	-0.46	2.58e-6	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs5985	0.659	rs55963140	chr6:6317606	T/C	cg16530177	chr6:6320324	F13A1	0.7	5.83	0.51	7.44e-8	End-stage coagulation;
THYM	cis	rs6701037	0.566	rs13373754	chr1:175139275	C/A	cg08873628	chr1:175162347	KIAA0040	0.51	4.65	0.43	1.09e-5	Alcohol dependence;
THYM	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg14019146	chr3:50243930	SLC38A3	0.54	4.56	0.42	1.53e-5	Body mass index;
THYM	cis	rs11605275	0.901	rs76234355	chr11:20037463	G/C	cg14835545	chr11:20032148	NAV2	-1.52	-6.26	-0.54	1.13e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs11696501	0.694	rs4812943	chr20:44260966	G/C	cg11783356	chr20:44313418	WFDC10B	-0.69	-4.76	-0.44	6.98e-6	Brain structure;
THYM	cis	rs665401	1.000	rs2750417	chr6:117259191	C/T	cg20376953	chr6:117187980	NA	-0.55	-4.49	-0.42	1.99e-5	Neutrophil percentage of granulocytes;
THYM	cis	rs12519773	0.717	rs66496757	chr5:92488062	A/G	cg18783429	chr5:92414398	NA	0.54	5.11	0.46	1.68e-6	Migraine;
THYM	cis	rs11773103	0.500	rs1089469	chr7:86952675	C/G	cg25477497	chr7:87228808	ABCB1	-0.45	-4.77	-0.44	6.53e-6	Bipolar disorder or major depressive disorder (combined);
THYM	cis	rs13102973	0.682	rs11938038	chr4:135894258	T/C	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	10.36	0.73	2.81e-17	Chronic sinus infection;
THYM	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg06108461	chr20:60628389	TAF4	-1.06	-9.1	-0.68	1.39e-14	Body mass index;
THYM	cis	rs2404602	0.735	rs11857327	chr15:76764263	G/C	cg23482746	chr15:76478102	C15orf27	0.47	4.46	0.42	2.27e-5	Blood metabolite levels;
THYM	cis	rs6430585	0.528	rs309172	chr2:136674028	A/G	cg07169764	chr2:136633963	MCM6	1.02	10.37	0.73	2.74e-17	Corneal structure;
THYM	cis	rs12282928	0.959	rs11039637	chr11:48306980	C/T	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs55665837	0.922	rs12287212	chr11:14449861	C/A	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg11266682	chr4:10021025	SLC2A9	0.71	11.15	0.75	5.95e-19	Bone mineral density;
THYM	cis	rs34779708	0.931	rs11010067	chr10:35295431	C/G	cg03585969	chr10:35415529	CREM	-0.63	-4.66	-0.43	1.01e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs2820651	0.614	rs76389357	chr10:1482550	C/T	cg13720710	chr10:1452970	ADARB2	0.77	4.83	0.44	5.17e-6	Migraine with aura;
THYM	cis	rs9972944	0.756	rs6416948	chr17:63767131	T/G	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg03159660	chr11:2078197	NA	-0.65	-5.04	-0.46	2.24e-6	Type 2 diabetes;
THYM	cis	rs9906944	0.703	rs940088	chr17:47145848	T/C	cg14634687	chr17:47094252	IGF2BP1	0.31	4.77	0.44	6.72e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	trans	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg13683864	chr3:40499215	RPL14	-1.08	-12.04	-0.78	7.87e-21	Renal cell carcinoma;
THYM	cis	rs478304	0.654	rs7934036	chr11:65451020	G/T	cg17480646	chr11:65405466	SIPA1	-0.97	-8.99	-0.68	2.44e-14	Acne (severe);
THYM	cis	rs7107174	1.000	rs12277648	chr11:78054336	C/T	cg02023728	chr11:77925099	USP35	0.62	6.0	0.52	3.51e-8	Testicular germ cell tumor;
THYM	cis	rs6047844	0.750	rs1883751	chr20:22080540	A/G	cg16502866	chr20:23015624	SSTR4	0.58	4.45	0.42	2.31e-5	Male-pattern baldness;
THYM	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg07884673	chr3:53033167	SFMBT1	1.17	5.88	0.52	6.13e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7072216	0.763	rs2274244	chr10:100175218	A/G	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg11752832	chr7:134001865	SLC35B4	0.72	5.43	0.49	4.28e-7	Mean platelet volume;
THYM	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	6.9	0.58	5.83e-10	Platelet count;
THYM	cis	rs7027203	0.717	rs7869328	chr9:96588782	A/G	cg13679303	chr9:96623674	NA	-0.5	-5.08	-0.46	1.89e-6	DNA methylation (variation);
THYM	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg13683864	chr3:40499215	RPL14	-1.03	-11.13	-0.75	6.57e-19	Renal cell carcinoma;
THYM	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg18904891	chr8:8559673	CLDN23	0.57	4.87	0.45	4.46e-6	Mood instability;
THYM	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22857025	chr5:266934	NA	-1.59	-10.2	-0.72	6.04e-17	Breast cancer;
THYM	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg05182265	chr7:156933206	UBE3C	-0.7	-9.53	-0.7	1.66e-15	Body mass index;
THYM	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg00999904	chr2:3704751	ALLC	-0.73	-4.99	-0.46	2.75e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg22841779	chr14:105766346	BRF1	-0.47	-5.84	-0.51	7.22e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs10238623	0.926	rs4506107	chr7:28806495	A/G	cg04979876	chr7:28109361	JAZF1	-0.54	-4.52	-0.42	1.77e-5	Anxiety in major depressive disorder;
THYM	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg25072359	chr17:41440525	NA	0.64	4.48	0.42	2.05e-5	Menopause (age at onset);
THYM	cis	rs7100689	0.599	rs946892	chr10:82127551	C/T	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg27125505	chr17:43679177	LOC644172	0.77	6.97	0.58	4.25e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg26384229	chr12:38710491	ALG10B	-0.68	-5.25	-0.47	9.12e-7	Morning vs. evening chronotype;
THYM	cis	rs35934224	0.783	rs34675706	chr22:19847618	G/A	cg11182965	chr22:19864308	TXNRD2	-0.68	-5.74	-0.51	1.11e-7	Glaucoma (primary open-angle);
THYM	cis	rs7772486	0.875	rs2748482	chr6:146336532	T/C	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-5.4	-0.48	4.89e-7	Chronic sinus infection;
THYM	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg26924012	chr15:45694286	SPATA5L1	0.96	8.07	0.64	2.14e-12	Homoarginine levels;
THYM	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.3	-0.65	6.94e-13	Smoking initiation;
THYM	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg12560992	chr17:57184187	TRIM37	-0.93	-8.81	-0.67	5.86e-14	Intelligence (multi-trait analysis);
THYM	cis	rs1198430	0.683	rs7551124	chr1:23785760	C/T	cg19827787	chr1:23763612	ASAP3	0.66	5.08	0.46	1.92e-6	Total cholesterol levels;
THYM	trans	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06850241	chr22:41845214	NA	0.59	5.16	0.47	1.37e-6	Vitiligo;
THYM	cis	rs7000551	0.751	rs2469775	chr8:22373238	T/C	cg12081754	chr8:22256438	SLC39A14	0.63	5.71	0.51	1.27e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	5.55	0.49	2.63e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.92	0.45	3.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs2050392	0.630	rs303426	chr10:30740379	A/G	cg13289132	chr10:30722225	MAP3K8	0.57	4.56	0.42	1.54e-5	Inflammatory bowel disease;
THYM	cis	rs72828912	0.831	rs2176934	chr6:24094194	A/T	cg26336265	chr6:25042955	NA	0.69	5.51	0.49	3e-7	Squamous cell lung carcinoma;
THYM	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg23583168	chr7:148888333	NA	-1.0	-13.2	-0.8	3.29e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg26384229	chr12:38710491	ALG10B	1.01	7.83	0.63	6.96e-12	Heart rate;
THYM	cis	rs1483890	1.000	rs1483890	chr3:69410725	A/G	cg22125112	chr3:69402811	FRMD4B	0.47	6.11	0.53	2.19e-8	Resting heart rate;
THYM	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-6.31	-0.54	8.74e-9	Chronic sinus infection;
THYM	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg09455208	chr3:40491958	NA	-0.47	-4.83	-0.44	5.3e-6	Renal cell carcinoma;
THYM	cis	rs8016982	0.633	rs55822231	chr14:81708677	C/T	cg21807262	chr14:81713016	NA	-0.56	-5.15	-0.47	1.39e-6	Schizophrenia;
THYM	cis	rs6089584	0.627	rs6089303	chr20:60565797	G/A	cg24733560	chr20:60626293	TAF4	0.59	5.82	0.51	8.03e-8	Body mass index;
THYM	cis	rs9875589	0.509	rs11927267	chr3:14073992	T/G	cg03204825	chr3:13978759	TPRXL	-0.54	-4.67	-0.43	1.01e-5	Ovarian reserve;
THYM	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg26818010	chr10:134567672	INPP5A	-0.92	-7.52	-0.61	3.1e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7131987	0.650	rs7973786	chr12:29462744	C/T	cg09582351	chr12:29534625	ERGIC2	-0.6	-5.2	-0.47	1.12e-6	QT interval;
THYM	cis	rs863345	0.604	rs1894038	chr1:158455947	T/C	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg03929089	chr4:120376271	NA	-0.94	-10.74	-0.74	4.27e-18	Coronary artery disease;
THYM	cis	rs11264213	0.591	rs274755	chr1:36544237	T/C	cg27506609	chr1:36549197	TEKT2	-1.25	-4.67	-0.43	1e-5	Schizophrenia;
THYM	cis	rs1983170	1.000	rs483532	chr1:91980447	A/G	cg25838465	chr1:92012736	NA	-0.66	-4.48	-0.42	2.09e-5	Eosinophil percentage of white cells;
THYM	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg09307838	chr4:120376055	NA	0.68	4.93	0.45	3.43e-6	Corneal astigmatism;
THYM	cis	rs2916260	0.932	rs892367	chr6:40369612	C/T	cg08415973	chr6:40346114	TDRG1	0.75	4.51	0.42	1.83e-5	Incident coronary heart disease;
THYM	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.73	-4.46	-0.42	2.21e-5	Diabetic retinopathy;
THYM	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11644478	chr21:40555479	PSMG1	1.09	9.34	0.69	4.28e-15	Cognitive function;
THYM	cis	rs11031096	0.678	rs61899754	chr11:4201312	A/T	cg08557956	chr11:4115526	RRM1	-0.57	-5.17	-0.47	1.27e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11644478	chr21:40555479	PSMG1	-0.76	-6.49	-0.55	3.85e-9	Cognitive function;
THYM	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	0.9	7.11	0.59	2.16e-10	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2495707	0.647	rs1541266	chr10:102421292	C/T	cg03943218	chr10:102419600	NA	-0.62	-6.68	-0.57	1.58e-9	Body mass index;
THYM	cis	rs17443541	0.507	rs4675702	chr2:200453139	C/G	cg01795955	chr2:200468626	NA	-0.66	-4.45	-0.42	2.35e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.698	rs28409696	chr7:124562515	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg08883853	chr7:1026168	CYP2W1	0.45	4.99	0.46	2.68e-6	Longevity;Endometriosis;
THYM	cis	rs7666738	0.785	rs11097614	chr4:99092175	G/C	cg18180107	chr4:99064573	C4orf37	0.58	4.47	0.42	2.16e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg07061783	chr6:25882402	NA	0.57	4.48	0.42	2.07e-5	Schizophrenia;
THYM	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg17775962	chr7:1200435	ZFAND2A	0.47	5.49	0.49	3.39e-7	Longevity;Endometriosis;
THYM	cis	rs1994135	0.715	rs11052742	chr12:33692290	A/C	cg10856724	chr12:34555212	NA	-0.63	-4.95	-0.45	3.23e-6	Resting heart rate;
THYM	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg06636001	chr8:8085503	FLJ10661	0.7	5.72	0.51	1.22e-7	Neuroticism;
THYM	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg16342193	chr10:102329863	NA	-0.57	-5.92	-0.52	5.11e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg22764044	chr5:178986830	RUFY1	0.52	5.41	0.49	4.7e-7	Lung cancer;
THYM	cis	rs1922291	0.528	rs34778121	chr2:102841567	C/T	cg13315345	chr2:102803985	IL1RL2	0.62	7.15	0.59	1.81e-10	Blood protein levels;
THYM	cis	rs74181299	0.712	rs2241161	chr2:65290842	A/C	cg20592124	chr2:65290738	CEP68	-0.43	-4.94	-0.45	3.38e-6	Pulse pressure;
THYM	cis	rs1550582	1.000	rs7822348	chr8:135542483	C/G	cg17885191	chr8:135476712	NA	0.75	4.69	0.43	9.23e-6	Educational attainment;
THYM	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05901451	chr6:126070800	HEY2	-0.95	-9.49	-0.7	2e-15	Brugada syndrome;
THYM	cis	rs883115	0.846	rs1566388	chr1:224795474	A/T	cg21444086	chr1:224821584	CNIH3	-0.45	-4.53	-0.42	1.74e-5	Cancer;
THYM	cis	rs10744422	1.000	rs10744434	chr12:123368419	T/A	cg25930673	chr12:123319894	HIP1R	-0.9	-5.14	-0.47	1.47e-6	Schizophrenia;
THYM	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg23205692	chr1:25664452	TMEM50A	0.83	6.37	0.55	6.66e-9	Erythrocyte sedimentation rate;
THYM	cis	rs11030122	0.661	rs12290747	chr11:3939650	T/C	cg18678763	chr11:4115507	RRM1	-0.44	-5.59	-0.5	2.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg05373962	chr22:49881684	NA	-0.64	-6.22	-0.54	1.31e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs3820068	0.608	rs58140482	chr1:16043979	A/G	cg05660106	chr1:15850417	CASP9	0.72	5.59	0.5	2.2e-7	Systolic blood pressure;
THYM	cis	rs1978968	1.000	rs1076543	chr22:18446490	T/C	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs2969070	0.831	rs7799266	chr7:2506595	G/A	cg25507518	chr7:2405875	EIF3B	-0.47	-4.62	-0.43	1.21e-5	Diastolic blood pressure;
THYM	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg08736216	chr1:53307985	ZYG11A	-0.57	-5.29	-0.48	7.83e-7	Monocyte count;
THYM	cis	rs56161922	0.908	rs78159416	chr1:207820375	C/A	cg09557387	chr1:207818395	CR1L	1.15	5.27	0.48	8.55e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg08847533	chr14:75593920	NEK9	-1.0	-10.24	-0.72	5.17e-17	Height;
THYM	cis	rs17030434	0.906	rs11099901	chr4:154671468	T/A	cg14289246	chr4:154710475	SFRP2	-0.91	-5.95	-0.52	4.5e-8	Electrocardiographic conduction measures;
THYM	cis	rs4363385	0.693	rs418550	chr1:153048045	A/T	cg13444842	chr1:152974279	SPRR3	-0.62	-5.08	-0.46	1.87e-6	Inflammatory skin disease;
THYM	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.61	5.25	0.47	9.38e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg06636001	chr8:8085503	FLJ10661	0.67	5.71	0.51	1.3e-7	Mood instability;
THYM	cis	rs1018836	0.923	rs4734269	chr8:91635474	G/C	cg16814680	chr8:91681699	NA	-0.84	-6.98	-0.58	4.03e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg27494647	chr7:150038898	RARRES2	-0.43	-5.42	-0.49	4.44e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs17253792	0.822	rs77420254	chr14:56069646	C/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs12044355	0.516	rs2356383	chr1:231742973	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.87	-8.18	-0.64	1.28e-12	Alzheimer's disease;
THYM	cis	rs1994135	0.692	rs7297538	chr12:33693438	T/C	cg06521331	chr12:34319734	NA	-0.72	-4.99	-0.46	2.68e-6	Resting heart rate;
THYM	cis	rs2554380	0.843	rs2098904	chr15:84406255	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.57	-4.5	-0.42	1.91e-5	Height;
THYM	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg13289132	chr10:30722225	MAP3K8	-0.57	-4.84	-0.44	5.02e-6	Inflammatory bowel disease;
THYM	cis	rs12519773	1.000	rs995620	chr5:92452676	A/C	cg18783429	chr5:92414398	NA	0.48	4.55	0.42	1.59e-5	Migraine;
THYM	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.68	-5.28	-0.48	8.12e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg04772025	chr11:68637568	NA	-0.63	-6.58	-0.56	2.59e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg07157834	chr1:205819609	PM20D1	-0.62	-4.77	-0.44	6.69e-6	Menarche (age at onset);
THYM	cis	rs6543140	0.964	rs4851589	chr2:103077145	A/G	cg03938978	chr2:103052716	IL18RAP	0.57	5.73	0.51	1.17e-7	Blood protein levels;
THYM	cis	rs4499344	0.696	rs398990	chr19:33104244	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.61	0.62	2.02e-11	Mean platelet volume;
THYM	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg05234568	chr11:5960015	NA	-0.57	-4.57	-0.42	1.49e-5	DNA methylation (variation);
THYM	cis	rs6459804	0.787	rs78566714	chr7:157508951	G/A	cg15733309	chr7:157513707	PTPRN2	0.58	6.21	0.54	1.38e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs9810089	0.934	rs684195	chr3:135993599	A/C	cg21827317	chr3:136751795	NA	0.54	4.47	0.42	2.18e-5	Gestational age at birth (child effect);
THYM	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7364180	0.582	rs139568	chr22:42210985	C/T	cg06481639	chr22:41940642	POLR3H	0.63	4.95	0.45	3.2e-6	Alzheimer's disease biomarkers;
THYM	cis	rs7119	0.717	rs8032405	chr15:77825344	A/G	cg10437265	chr15:77819839	NA	0.74	7.2	0.59	1.41e-10	Type 2 diabetes;
THYM	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs7772486	0.727	rs10223508	chr6:146285205	C/T	cg13319975	chr6:146136371	FBXO30	0.75	6.25	0.54	1.17e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg24154853	chr7:158122151	PTPRN2	0.55	4.82	0.44	5.35e-6	Calcium levels;
THYM	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg00071950	chr4:10020882	SLC2A9	-0.53	-4.67	-0.43	9.99e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7106204	0.513	rs7131144	chr11:24249486	A/G	ch.11.24196551F	chr11:24239977	NA	0.99	7.01	0.58	3.42e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs1346	0.552	rs10896022	chr11:65366610	C/A	cg27068330	chr11:65405492	SIPA1	0.7	4.54	0.42	1.67e-5	Vertical cup-disc ratio;Optic cup area;
THYM	cis	rs7107174	1.000	rs2256051	chr11:77920457	G/A	cg19901956	chr11:77921274	USP35	-0.68	-5.44	-0.49	4.19e-7	Testicular germ cell tumor;
THYM	cis	rs4917300	0.605	rs7820768	chr8:143110823	C/T	cg26003909	chr8:143102224	NA	-0.32	-4.64	-0.43	1.12e-5	Amyotrophic lateral sclerosis;
THYM	cis	rs6430585	0.528	rs6750549	chr2:136707480	A/G	cg04750100	chr2:136595281	LCT	0.53	5.07	0.46	1.95e-6	Corneal structure;
THYM	cis	rs35883536	0.967	rs4908091	chr1:101138171	G/A	cg06223162	chr1:101003688	GPR88	0.67	5.2	0.47	1.14e-6	Monocyte count;
THYM	cis	rs868036	1.000	rs4776376	chr15:68093435	G/A	cg24579218	chr15:68104479	NA	-0.65	-6.51	-0.56	3.59e-9	Restless legs syndrome;
THYM	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg08431931	chr22:42394659	WBP2NL	0.7	4.97	0.45	2.96e-6	Birth weight;
THYM	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg24642844	chr7:1081250	C7orf50	-1.25	-8.11	-0.64	1.79e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9527	0.545	rs12247514	chr10:104958066	C/A	cg15744005	chr10:104629667	AS3MT	-0.6	-4.45	-0.42	2.33e-5	Arsenic metabolism;
THYM	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.96	-8.0	-0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg03264133	chr6:25882463	NA	-0.89	-8.01	-0.63	2.84e-12	Intelligence (multi-trait analysis);
THYM	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg10053473	chr17:62856997	LRRC37A3	0.82	7.15	0.59	1.8e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg07414643	chr4:187882934	NA	0.67	5.92	0.52	5.16e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7177699	0.526	rs7166764	chr15:79123509	T/G	cg00540400	chr15:79124168	NA	0.63	6.74	0.57	1.23e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	trans	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg25214090	chr10:38739885	LOC399744	0.97	8.0	0.63	2.96e-12	Corneal astigmatism;
THYM	cis	rs2354432	1.000	rs2120003	chr1:146690635	A/G	cg25205988	chr1:146714368	CHD1L	1.1	6.8	0.57	9.03e-10	Mitochondrial DNA levels;
THYM	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg18538332	chr22:24372958	LOC391322	-1.01	-11.72	-0.77	3.68e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4919694	1.000	rs17787717	chr10:104695699	T/G	cg15744005	chr10:104629667	AS3MT	-0.85	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03404566	chr17:6899310	ALOX12	0.75	9.63	0.7	1.03e-15	Tonsillectomy;
THYM	cis	rs346785	0.692	rs7225131	chr17:74290097	T/A	cg09812376	chr17:74270190	QRICH2	-0.49	-4.9	-0.45	3.92e-6	White matter hyperintensities in ischemic stroke;
THYM	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg03060546	chr3:49711283	APEH	0.75	6.11	0.53	2.16e-8	Resting heart rate;
THYM	cis	rs7208859	0.614	rs7216394	chr17:28825756	T/C	cg17105886	chr17:28927953	LRRC37B2	-1.06	-4.85	-0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7799006	0.691	rs10447541	chr7:2301578	T/G	cg08027265	chr7:2291960	NA	-0.44	-5.27	-0.48	8.41e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2012796	0.785	rs61986593	chr14:81840659	G/A	cg02996355	chr14:81879375	NA	0.83	6.35	0.55	7.2e-9	Night sleep phenotypes;
THYM	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg16586182	chr3:47516702	SCAP	-0.63	-5.52	-0.49	2.96e-7	Colorectal cancer;
THYM	cis	rs6473252	0.966	rs12546179	chr8:81814084	G/C	cg08595989	chr8:81827712	NA	-0.41	-4.54	-0.42	1.65e-5	Breast cancer;
THYM	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs34526934	0.608	rs34720456	chr2:177027292	G/A	cg26754761	chr2:177040938	NA	-0.72	-6.16	-0.53	1.72e-8	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs1298062	0.790	rs1274604	chr19:50969325	A/G	cg11430371	chr19:50961752	MYBPC2	0.47	4.64	0.43	1.13e-5	Age of smoking initiation;
THYM	cis	rs3771317	0.941	rs2286895	chr2:191535698	G/A	cg17118478	chr2:191543902	NAB1	-0.59	-4.5	-0.42	1.9e-5	Primary biliary cholangitis;
THYM	cis	rs61931739	0.658	rs10772149	chr12:34285498	A/G	cg06521331	chr12:34319734	NA	-0.64	-5.18	-0.47	1.22e-6	Morning vs. evening chronotype;
THYM	cis	rs8102476	0.905	rs7250689	chr19:38753625	C/T	cg08052629	chr19:38746615	PPP1R14A	0.48	6.02	0.53	3.24e-8	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg02018176	chr4:1364513	KIAA1530	0.95	8.91	0.67	3.61e-14	Longevity;
THYM	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg23791538	chr6:167370224	RNASET2	-0.61	-4.62	-0.43	1.22e-5	Crohn's disease;
THYM	cis	rs4638749	0.677	rs10208945	chr2:108838593	G/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs7771547	0.642	rs595954	chr6:36464834	C/G	cg07856975	chr6:36356162	ETV7	0.58	5.58	0.5	2.24e-7	Platelet distribution width;
THYM	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg07685180	chr8:600429	NA	-0.94	-4.55	-0.42	1.57e-5	IgG glycosylation;
THYM	cis	rs4919087	0.926	rs945189	chr10:99091766	C/G	cg19453742	chr10:98862320	SLIT1	-0.58	-4.79	-0.44	6.03e-6	Monocyte count;
THYM	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs11096990	0.679	rs6531707	chr4:39297684	T/C	cg24403649	chr4:39172243	NA	-0.64	-5.48	-0.49	3.43e-7	Cognitive function;
THYM	cis	rs863345	0.604	rs2317969	chr1:158491753	A/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs6992848	0.791	rs34121671	chr8:141167664	G/A	cg22504031	chr8:141147661	TRAPPC9	0.64	4.95	0.45	3.19e-6	Response to amphetamines;
THYM	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg10360139	chr7:1886902	MAD1L1	-0.86	-7.83	-0.63	6.99e-12	Bipolar disorder and schizophrenia;
THYM	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg25427524	chr10:38739819	LOC399744	-0.64	-5.87	-0.52	6.38e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4242434	0.927	rs57594397	chr8:22475657	T/C	cg03733263	chr8:22462867	KIAA1967	1.17	11.85	0.77	1.99e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9314614	0.933	rs2741098	chr8:6690276	C/T	cg16580759	chr8:6693379	XKR5	0.44	4.57	0.42	1.47e-5	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs42648	0.837	rs4728879	chr7:89924237	T/G	cg25739043	chr7:89950458	NA	-0.52	-4.47	-0.42	2.2e-5	Homocysteine levels;
THYM	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg21252483	chr19:49399788	TULP2	-0.95	-7.2	-0.59	1.41e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg20999797	chr1:1681921	NA	0.5	5.51	0.49	3.08e-7	Body mass index;
THYM	cis	rs1215050	0.740	rs1214994	chr4:99035577	C/T	cg17366294	chr4:99064904	C4orf37	0.41	4.55	0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg14507445	chr22:49886340	NA	-0.51	-4.56	-0.42	1.54e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg13695892	chr22:41940480	POLR3H	-0.86	-5.96	-0.52	4.19e-8	Vitiligo;
THYM	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg10117171	chr1:25599238	RHD	-0.65	-4.76	-0.44	6.89e-6	Erythrocyte sedimentation rate;
THYM	cis	rs17854409	0.764	rs3761301	chr20:61494021	C/T	cg06598544	chr20:61472147	COL9A3	-1.11	-4.57	-0.42	1.48e-5	Obesity-related traits;
THYM	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg01579765	chr21:45077557	HSF2BP	0.53	8.63	0.66	1.37e-13	Mean corpuscular volume;
THYM	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg26384229	chr12:38710491	ALG10B	-0.87	-8.5	-0.66	2.59e-13	Heart rate;
THYM	cis	rs61931739	0.534	rs1352207	chr12:34036862	C/T	cg06521331	chr12:34319734	NA	0.95	9.08	0.68	1.53e-14	Morning vs. evening chronotype;
THYM	cis	rs6032067	0.777	rs2868236	chr20:43794070	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	trans	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg10856724	chr12:34555212	NA	-1.01	-9.23	-0.69	7.34e-15	Bladder cancer;
THYM	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg13319975	chr6:146136371	FBXO30	0.63	5.17	0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.47	-4.79	-0.44	6.1e-6	Longevity;Endometriosis;
THYM	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg18105134	chr13:113819100	PROZ	-0.95	-8.7	-0.67	1e-13	Platelet distribution width;
THYM	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg16325326	chr1:53192061	ZYG11B	0.81	7.53	0.61	2.93e-11	Monocyte count;
THYM	cis	rs6988636	0.892	rs58116120	chr8:124191776	T/G	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs6121246	0.542	rs75694362	chr20:30450708	T/C	cg09796376	chr20:30640595	HCK	0.85	4.51	0.42	1.83e-5	Mean corpuscular hemoglobin;
THYM	cis	rs4819852	0.958	rs2238787	chr22:19976406	G/A	cg07821417	chr22:19972146	ARVCF	0.49	5.82	0.51	7.96e-8	Pulse pressure;
THYM	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs2811415	0.597	rs1007232	chr3:127801896	C/A	cg05377949	chr3:127951287	EEFSEC	0.37	4.53	0.42	1.7e-5	Lung function (FEV1/FVC);
THYM	cis	rs7777677	0.925	rs4726547	chr7:142370582	C/T	cg21785750	chr7:142428317	NA	0.68	5.94	0.52	4.71e-8	Alcoholic chronic pancreatitis;
THYM	cis	rs55823223	0.648	rs11869977	chr17:73857382	C/G	cg08125733	chr17:73851984	WBP2	1.22	8.17	0.64	1.3e-12	Psoriasis;
THYM	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg21475434	chr5:93447410	FAM172A	0.95	6.03	0.53	3.16e-8	Diabetic retinopathy;
THYM	cis	rs4646404	0.509	rs4646365	chr17:17467783	C/T	cg11245205	chr17:17398264	RASD1	-0.42	-4.82	-0.44	5.38e-6	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
THYM	cis	rs79349575	0.783	rs4294857	chr17:46983391	G/A	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg07424592	chr7:64974309	NA	1.1	5.08	0.46	1.87e-6	Diabetic kidney disease;
THYM	cis	rs6138458	1.000	rs11906373	chr20:24938832	A/G	cg06937882	chr20:24974362	C20orf3	-0.47	-4.45	-0.42	2.31e-5	Blood protein levels;
THYM	cis	rs62158800	0.568	rs62161312	chr2:108346567	C/T	cg27431625	chr2:107679531	NA	1.04	4.9	0.45	3.87e-6	Facial morphology (factor 22);
THYM	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	8.54	0.66	2.17e-13	Cognitive test performance;
THYM	cis	rs4713118	0.581	rs200504	chr6:27785820	T/C	cg08968635	chr6:28129556	ZNF389	0.67	4.68	0.43	9.38e-6	Parkinson's disease;
THYM	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg08470875	chr2:26401718	FAM59B	0.74	4.59	0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg13880726	chr7:1868755	MAD1L1	-0.7	-4.71	-0.43	8.6e-6	Bipolar disorder;
THYM	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg03929089	chr4:120376271	NA	-0.75	-7.09	-0.59	2.41e-10	Coronary artery disease;
THYM	cis	rs61931739	0.817	rs10743841	chr12:34252870	T/C	cg10856724	chr12:34555212	NA	-0.62	-5.72	-0.51	1.24e-7	Morning vs. evening chronotype;
THYM	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg13607699	chr17:42295918	UBTF	0.65	5.52	0.49	2.97e-7	Total body bone mineral density;
THYM	cis	rs300703	0.872	rs428697	chr2:213302	G/A	cg21211680	chr2:198530	NA	1.18	6.0	0.52	3.52e-8	Blood protein levels;
THYM	cis	rs9361491	0.608	rs4706736	chr6:79475476	A/T	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.88e-5	Intelligence (multi-trait analysis);
THYM	cis	rs11009175	0.615	rs6481820	chr10:33299937	C/T	cg00146027	chr10:33299147	NA	-0.68	-5.13	-0.47	1.55e-6	Depression (quantitative trait);
THYM	cis	rs9790314	0.663	rs1599379	chr3:160860665	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-4.6	-0.43	1.31e-5	Morning vs. evening chronotype;
THYM	cis	rs6866344	0.697	rs17184281	chr5:178127563	G/A	cg10224037	chr5:178157518	ZNF354A	1.01	7.91	0.63	4.74e-12	Neutrophil percentage of white cells;
THYM	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg05182265	chr7:156933206	UBE3C	-0.69	-9.38	-0.69	3.46e-15	Body mass index;
THYM	cis	rs28595532	0.764	rs116158926	chr4:119730572	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs6733011	0.578	rs1878585	chr2:99501698	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.7	-0.43	8.62e-6	Bipolar disorder;
THYM	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg25036284	chr2:26402008	FAM59B	-0.74	-4.87	-0.45	4.39e-6	Gut microbiome composition (summer);
THYM	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg00376283	chr12:123451042	ABCB9	0.93	7.83	0.63	7e-12	Platelet count;
THYM	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.62	0.43	1.23e-5	Obesity-related traits;
THYM	cis	rs72827839	1.000	rs72827876	chr17:46523974	A/G	cg23391107	chr17:45924227	SP6	0.76	4.58	0.43	1.39e-5	Ease of getting up in the morning;
THYM	cis	rs7617773	0.747	rs34076262	chr3:48370416	C/T	cg02219026	chr3:48282209	ZNF589	-0.68	-4.77	-0.44	6.56e-6	Coronary artery disease;
THYM	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	4.93	0.45	3.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs490234	0.966	rs534214	chr9:128369224	A/G	cg14078157	chr9:128172775	NA	-0.6	-4.73	-0.44	7.87e-6	Mean arterial pressure;
THYM	cis	rs7635838	0.684	rs2594968	chr3:11352442	T/C	cg00170343	chr3:11313890	ATG7	0.57	4.56	0.42	1.51e-5	HDL cholesterol;
THYM	cis	rs11690935	0.959	rs6709156	chr2:172591944	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.85	-6.26	-0.54	1.09e-8	Schizophrenia;
THYM	cis	rs56104184	0.887	rs16982311	chr19:49342188	C/T	cg26267310	chr19:49340593	PLEKHA4;HSD17B14	0.94	6.06	0.53	2.71e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs9217	0.513	rs7216801	chr17:7386811	A/T	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Height;
THYM	cis	rs9479482	0.967	rs34006533	chr6:150350574	C/A	cg25797454	chr6:150327115	RAET1K	0.43	4.47	0.42	2.18e-5	Alopecia areata;
THYM	cis	rs7191700	0.644	rs12149160	chr16:11439303	G/T	cg00044050	chr16:11439710	C16orf75	-0.9	-7.77	-0.62	9.1e-12	Multiple sclerosis;
THYM	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg08439880	chr3:133502540	NA	-0.79	-6.65	-0.56	1.89e-9	Iron status biomarkers;
THYM	cis	rs737337	0.623	rs3810308	chr19:11333596	T/C	cg00586551	chr19:11347513	LOC55908;DOCK6	0.66	4.7	0.43	8.89e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg02931644	chr1:25747376	RHCE	0.62	4.83	0.44	5.24e-6	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	trans	rs10802346	0.545	rs1770003	chr1:246408356	A/G	cg22732515	chr19:44031385	ETHE1	1.03	8.56	0.66	1.99e-13	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg00074818	chr8:8560427	CLDN23	0.58	5.4	0.48	4.91e-7	Obesity-related traits;
THYM	cis	rs7943203	0.524	rs373759	chr11:108220657	C/T	cg04873221	chr11:107992290	ACAT1	-0.7	-4.6	-0.43	1.28e-5	Red blood cell count;Mean corpuscular volume;
THYM	cis	rs2836633	0.965	rs2836621	chr21:40054149	C/T	cg05519781	chr21:40033154	ERG	0.69	6.57	0.56	2.64e-9	Coronary artery disease;
THYM	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg22433210	chr17:43662623	NA	-1.02	-8.09	-0.64	1.97e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7681440	0.583	rs2619367	chr4:90767095	A/C	cg06632027	chr4:90757378	SNCA	-0.66	-5.29	-0.48	7.91e-7	Dementia with Lewy bodies;
THYM	cis	rs12091564	1	rs12091564	chr1:145395604	C/T	cg08057159	chr1:145507538	RBM8A	-1.03	-4.59	-0.43	1.38e-5	Coronary heart disease (SNP X SNP interaction);
THYM	cis	rs596169	0.764	rs659302	chr1:219112335	T/A	cg19270308	chr1:218458869	RRP15	1.24	4.52	0.42	1.81e-5	Intraocular pressure;
THYM	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs34779708	0.966	rs4934730	chr10:35415555	A/G	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs3755605	0.864	rs1987540	chr3:169772725	C/G	cg18444028	chr3:169782040	GPR160	0.56	4.62	0.43	1.19e-5	Testicular germ cell tumor;
THYM	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg05294307	chr14:35346193	BAZ1A	-0.85	-5.73	-0.51	1.17e-7	Psoriasis;
THYM	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.18	9.42	0.7	2.82e-15	Cognitive test performance;
THYM	cis	rs870825	0.655	rs35397385	chr4:185639095	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-7.47	-0.61	3.89e-11	Chronic sinus infection;
THYM	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg10360139	chr7:1886902	MAD1L1	-0.59	-5.09	-0.46	1.81e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs611744	0.870	rs633794	chr8:109174702	A/G	cg21045802	chr8:109455806	TTC35	0.7	6.79	0.57	9.74e-10	Dupuytren's disease;
THYM	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg16102102	chr5:83017553	HAPLN1	-0.96	-8.29	-0.65	7.26e-13	Prostate cancer;
THYM	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg02187348	chr16:89574699	SPG7	0.74	5.65	0.5	1.7e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	5.93	0.52	4.95e-8	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs1994135	0.565	rs11052767	chr12:33731194	A/G	cg06521331	chr12:34319734	NA	-0.66	-4.86	-0.45	4.61e-6	Resting heart rate;
THYM	cis	rs4378999	0.660	rs11928733	chr3:50833438	C/T	cg27233566	chr3:49894142	TRAIP	0.77	4.47	0.42	2.16e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg06191203	chr2:152266755	RIF1	-0.71	-4.71	-0.43	8.5e-6	Lung cancer;
THYM	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg22920501	chr2:26401640	FAM59B	0.71	5.0	0.46	2.57e-6	Gut microbiome composition (summer);
THYM	cis	rs6918586	0.658	rs198838	chr6:26113340	C/T	cg03517284	chr6:25882590	NA	-0.66	-5.1	-0.46	1.72e-6	Schizophrenia;
THYM	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg02734326	chr4:10020555	SLC2A9	0.76	7.25	0.6	1.13e-10	Bone mineral density;
THYM	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg06027949	chr8:82754900	SNX16	-0.64	-5.35	-0.48	6.18e-7	Diastolic blood pressure;
THYM	cis	rs10883723	0.962	rs1056738	chr10:104236481	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.48	0.61	3.66e-11	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs901683	1.000	rs75595592	chr10:46039930	A/G	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg15445000	chr17:37608096	MED1	-0.44	-5.19	-0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	9.38	0.69	3.49e-15	Chronic sinus infection;
THYM	cis	rs11190604	0.767	rs10883491	chr10:102196071	G/T	cg16342193	chr10:102329863	NA	-0.51	-5.29	-0.48	7.96e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg23260525	chr10:116636907	FAM160B1	0.49	5.02	0.46	2.38e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6866344	0.570	rs1132338	chr5:178139442	T/G	cg10224037	chr5:178157518	ZNF354A	0.95	7.74	0.62	1.07e-11	Neutrophil percentage of white cells;
THYM	cis	rs9314614	0.872	rs2951865	chr8:6708924	A/C	cg27319216	chr8:6693540	XKR5	-0.6	-6.38	-0.55	6.53e-9	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg14018140	chr10:458528	DIP2C	0.56	6.26	0.54	1.09e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg00684032	chr4:1343700	KIAA1530	-0.63	-5.4	-0.48	4.93e-7	Obesity-related traits;
THYM	cis	rs11690935	0.959	rs10166005	chr2:172607294	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.85	-6.26	-0.54	1.09e-8	Schizophrenia;
THYM	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13732083	chr21:47605072	C21orf56	0.71	4.99	0.46	2.78e-6	Testicular germ cell tumor;
THYM	cis	rs9828933	0.766	rs3774725	chr3:63974258	T/G	cg16258503	chr3:63850278	ATXN7;THOC7	-0.85	-5.5	-0.49	3.16e-7	Type 2 diabetes;
THYM	cis	rs863345	0.564	rs7540999	chr1:158504570	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs995000	0.965	rs1570694	chr1:63103217	A/G	cg06896770	chr1:63153194	DOCK7	0.98	8.18	0.64	1.26e-12	Triglyceride levels;
THYM	cis	rs1580019	0.961	rs11765387	chr7:32494790	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.59	0.56	2.42e-9	Cognitive ability;
THYM	cis	rs988913	0.957	rs9475100	chr6:54840233	C/T	cg04690482	chr6:54711388	FAM83B	0.49	5.28	0.48	8.01e-7	Menarche (age at onset);
THYM	cis	rs7836436	0.686	rs7010457	chr8:120955012	A/G	cg05020510	chr8:120428057	NOV	1.04	5.18	0.47	1.24e-6	HIV-1 viral setpoint;
THYM	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg06074448	chr4:187884817	NA	-1.0	-13.48	-0.81	8.89e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs919433	0.617	rs10931793	chr2:198577585	G/A	cg00792783	chr2:198669748	PLCL1	-0.77	-5.4	-0.48	4.91e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg10589385	chr1:150898437	SETDB1	0.62	5.08	0.46	1.9e-6	Melanoma;
THYM	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg27490568	chr2:178487706	NA	0.64	5.11	0.46	1.64e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.86	6.61	0.56	2.23e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg04287289	chr16:89883240	FANCA	0.58	5.52	0.49	2.97e-7	Vitiligo;
THYM	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg08859206	chr1:53392774	SCP2	0.47	4.84	0.44	5.09e-6	Monocyte count;
THYM	cis	rs12889267	0.722	rs2319626	chr14:21565149	G/C	cg02988727	chr14:21567520	ZNF219;C14orf176	0.53	5.09	0.46	1.79e-6	Hematocrit;Resting heart rate;
THYM	cis	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg10856724	chr12:34555212	NA	-0.79	-7.41	-0.61	5.14e-11	Morning vs. evening chronotype;
THYM	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg01017244	chr2:74357527	NA	1.11	10.15	0.72	7.73e-17	Gestational age at birth (maternal effect);
THYM	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs10924970	0.967	rs2382616	chr1:235454237	C/T	cg26050004	chr1:235667680	B3GALNT2	0.6	4.5	0.42	1.92e-5	Asthma;
THYM	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.99	7.61	0.62	2e-11	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs933688	1.000	rs1541674	chr5:90660447	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	8.23	0.64	1e-12	Smoking behavior;
THYM	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08109568	chr15:31115862	NA	-0.58	-5.81	-0.51	8.18e-8	Huntington's disease progression;
THYM	cis	rs2976388	0.578	rs13263987	chr8:143827387	A/C	cg06565975	chr8:143823917	SLURP1	-0.73	-8.35	-0.65	5.53e-13	Urinary tract infection frequency;
THYM	cis	rs1032971	0.639	rs34026098	chr17:64935197	C/T	cg26743024	chr17:64960282	CACNG4	0.47	4.65	0.43	1.07e-5	Pursuit maintenance gain;
THYM	cis	rs7084921	0.520	rs2902377	chr10:101876770	G/A	cg11344164	chr10:101878520	NA	-0.59	-5.68	-0.5	1.46e-7	Bone mineral density;
THYM	cis	rs4950928	0.712	rs7518666	chr1:203163590	C/T	cg14085262	chr1:203155938	CHI3L1	-0.79	-5.42	-0.49	4.56e-7	YKL-40 levels;
THYM	cis	rs12134245	0.742	rs17501381	chr1:92003919	A/G	cg25838465	chr1:92012736	NA	-0.9	-8.55	-0.66	2.09e-13	Breast cancer;
THYM	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg08994789	chr17:28903642	LRRC37B2	-1.1	-5.46	-0.49	3.79e-7	Body mass index;
THYM	cis	rs2219968	1.000	rs11783780	chr8:78971571	A/T	cg00738934	chr8:78996279	NA	0.91	9.74	0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.76	-6.4	-0.55	5.74e-9	Tonsillectomy;
THYM	cis	rs11153147	0.655	rs117298489	chr6:109432996	T/G	cg17117243	chr6:109341365	SESN1	-0.92	-5.47	-0.49	3.63e-7	Mean corpuscular volume;
THYM	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg10523679	chr1:76189770	ACADM	-0.83	-6.52	-0.56	3.44e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs12310956	0.510	rs10743832	chr12:33884146	A/C	cg06521331	chr12:34319734	NA	-0.57	-4.61	-0.43	1.26e-5	Morning vs. evening chronotype;
THYM	cis	rs2276314	1.000	rs4799835	chr18:33571268	G/A	cg05985134	chr18:33552581	C18orf21	0.72	5.01	0.46	2.47e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs2282300	0.739	rs7952339	chr11:30327344	C/T	cg09906309	chr11:30344399	C11orf46	0.72	5.54	0.49	2.73e-7	Morning vs. evening chronotype;
THYM	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-5.1	-0.46	1.75e-6	Gut microbiome composition (summer);
THYM	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg19761014	chr17:28927070	LRRC37B2	0.71	4.52	0.42	1.77e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs899997	0.862	rs8043123	chr15:78973393	C/T	cg04896959	chr15:78267971	NA	-0.82	-6.43	-0.55	5.22e-9	Coronary artery disease or large artery stroke;
THYM	cis	rs10896135	0.526	rs12795774	chr11:66381517	T/C	cg15964523	chr11:66469143	SPTBN2	0.87	7.11	0.59	2.2e-10	Bipolar disorder;
THYM	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg16624210	chr5:671434	TPPP	0.76	5.54	0.49	2.71e-7	Obesity-related traits;
THYM	cis	rs1558375	0.679	rs31676	chr7:87069880	T/C	cg04996195	chr7:87105398	ABCB4	-0.59	-4.53	-0.42	1.73e-5	Gallbladder cancer;
THYM	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	4.54	0.42	1.67e-5	Alzheimer's disease;
THYM	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg24375607	chr4:120327624	NA	0.64	4.74	0.44	7.41e-6	Corneal astigmatism;
THYM	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg02788857	chr8:22132959	PIWIL2	0.58	5.54	0.49	2.7e-7	Hypertriglyceridemia;
THYM	cis	rs7677751	0.806	rs1800810	chr4:55094031	C/G	cg17187183	chr4:55093834	PDGFRA	0.74	5.5	0.49	3.14e-7	Corneal astigmatism;
THYM	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg16342193	chr10:102329863	NA	-0.59	-6.2	-0.54	1.48e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg25811766	chr13:21894605	NA	0.69	5.55	0.49	2.63e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03452623	chr4:187889614	NA	-1.17	-20.04	-0.9	6.92e-36	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg09307838	chr4:120376055	NA	0.78	5.89	0.52	5.7e-8	Corneal astigmatism;
THYM	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03404566	chr17:6899310	ALOX12	0.74	9.36	0.69	3.78e-15	Tonsillectomy;
THYM	cis	rs8038465	0.592	rs1542579	chr15:73935897	A/G	cg15420318	chr15:73925796	NPTN	0.61	5.25	0.47	9.1e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg18904891	chr8:8559673	CLDN23	0.58	4.69	0.43	8.98e-6	Joint mobility (Beighton score);
THYM	cis	rs7216064	0.953	rs62086044	chr17:65970837	G/T	cg12091567	chr17:66097778	LOC651250	-0.72	-4.88	-0.45	4.35e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs3015497	0.763	rs2934689	chr14:51118327	A/C	cg04730355	chr14:51134070	SAV1	-0.53	-4.7	-0.43	8.68e-6	Mean platelet volume;
THYM	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg06618935	chr21:46677482	NA	-0.97	-8.09	-0.64	1.92e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs28595532	0.920	rs115372254	chr4:119771735	T/C	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs6866344	0.568	rs4626352	chr5:178096777	G/A	cg10224037	chr5:178157518	ZNF354A	0.82	5.5	0.49	3.26e-7	Neutrophil percentage of white cells;
THYM	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg24060327	chr5:131705240	SLC22A5	0.73	5.47	0.49	3.61e-7	Blood metabolite levels;
THYM	cis	rs5771069	0.933	rs137845	chr22:50439430	A/G	cg08241514	chr22:50438769	IL17REL	-0.41	-4.65	-0.43	1.05e-5	Ulcerative colitis;
THYM	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg06784218	chr1:46089804	CCDC17	0.3	4.82	0.44	5.43e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg00640147	chr17:61958756	GH2	0.42	4.48	0.42	2.08e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg20486651	chr6:167070296	RPS6KA2	-0.46	-4.51	-0.42	1.82e-5	Crohn's disease;
THYM	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg13695892	chr22:41940480	POLR3H	0.89	6.37	0.55	6.58e-9	Vitiligo;
THYM	cis	rs11112613	0.818	rs117644588	chr12:106022040	G/C	cg03607813	chr12:105948248	NA	1.09	6.18	0.54	1.6e-8	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs11112613	0.713	rs73184082	chr12:105951748	T/C	cg03607813	chr12:105948248	NA	0.99	8.21	0.64	1.08e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs916888	0.647	rs199523	chr17:44848517	C/A	cg15921436	chr17:44337874	NA	-0.74	-6.03	-0.53	3.13e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1497406	0.744	rs4661718	chr1:16505908	C/T	cg03887218	chr1:16534349	ARHGEF19	0.47	4.46	0.42	2.29e-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1153858	0.723	rs11855527	chr15:45606685	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.9	-7.0	-0.58	3.65e-10	Homoarginine levels;
THYM	cis	rs6450176	0.909	rs255755	chr5:53307772	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-6.52	-0.56	3.3e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs3862030	0.594	rs7923675	chr10:104235809	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.7	0.57	1.45e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg16615211	chr3:44902933	MIR564;TMEM42	0.5	5.26	0.48	8.81e-7	Depressive symptoms;
THYM	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg27490568	chr2:178487706	NA	0.61	5.93	0.52	4.82e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg13770153	chr20:60521292	NA	-0.68	-4.74	-0.44	7.36e-6	Body mass index;
THYM	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg17830980	chr10:43048298	ZNF37B	-1.01	-10.1	-0.72	1.02e-16	Extrinsic epigenetic age acceleration;
THYM	cis	rs4654899	0.965	rs4654898	chr1:21376383	T/C	cg01072550	chr1:21505969	NA	-0.7	-6.4	-0.55	5.98e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs11096990	0.964	rs7687651	chr4:39244692	A/G	cg24403649	chr4:39172243	NA	-0.67	-5.68	-0.5	1.5e-7	Cognitive function;
THYM	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg07511668	chr11:68622177	NA	0.44	4.63	0.43	1.16e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg06634786	chr22:41940651	POLR3H	-0.7	-4.92	-0.45	3.59e-6	Vitiligo;
THYM	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg13390004	chr1:15929781	NA	0.61	4.63	0.43	1.15e-5	Systolic blood pressure;
THYM	cis	rs7084921	0.608	rs11597390	chr10:101861435	A/G	cg11344164	chr10:101878520	NA	0.6	5.15	0.47	1.41e-6	Bone mineral density;
THYM	cis	rs11039798	1.000	rs12281162	chr11:48650491	T/C	cg24672777	chr11:48374446	OR4C45	-1.1	-6.54	-0.56	3.01e-9	Axial length;
THYM	cis	rs4803468	0.904	rs60781668	chr19:41944842	A/T	cg09537434	chr19:41945824	ATP5SL	1.09	10.16	0.72	7.58e-17	Height;
THYM	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg25703541	chr22:24373054	LOC391322	-0.76	-5.87	-0.52	6.5e-8	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs4474465	0.915	rs7123060	chr11:78208634	A/G	cg19901956	chr11:77921274	USP35	0.65	4.8	0.44	5.97e-6	Alzheimer's disease (survival time);
THYM	cis	rs8038465	0.615	rs11072430	chr15:73981701	A/G	cg15420318	chr15:73925796	NPTN	-0.6	-5.19	-0.47	1.17e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg03709012	chr19:19516395	GATAD2A	-0.74	-5.8	-0.51	8.48e-8	Tonsillectomy;
THYM	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg21028142	chr17:79581711	NPLOC4	-0.61	-6.2	-0.54	1.42e-8	Eye color traits;
THYM	cis	rs13006833	0.668	rs291453	chr2:191160196	G/A	cg27211696	chr2:191398769	TMEM194B	0.56	4.46	0.42	2.28e-5	Urinary metabolites;
THYM	cis	rs10208940	0.614	rs10180387	chr2:68823896	G/T	cg09157127	chr2:69201416	GKN1	0.89	4.71	0.43	8.61e-6	Urate levels in lean individuals;
THYM	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7177699	0.550	rs4468572	chr15:79124475	C/T	cg15571903	chr15:79123663	NA	-0.56	-6.4	-0.55	5.8e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs2688608	0.620	rs11000767	chr10:75516626	G/T	cg19442545	chr10:75533431	FUT11	-0.63	-6.78	-0.57	1.01e-9	Inflammatory bowel disease;
THYM	cis	rs6430585	0.583	rs3769013	chr2:136556182	C/T	cg07169764	chr2:136633963	MCM6	1.15	13.2	0.8	3.3e-23	Corneal structure;
THYM	cis	rs7119	0.651	rs12904200	chr15:77845902	C/G	cg27398640	chr15:77910606	LINGO1	-0.61	-6.05	-0.53	2.92e-8	Type 2 diabetes;
THYM	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg13609457	chr4:120235615	NA	0.59	5.19	0.47	1.2e-6	Corneal astigmatism;
THYM	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg25767906	chr1:53392781	SCP2	-0.56	-5.2	-0.47	1.13e-6	Monocyte count;
THYM	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg09455208	chr3:40491958	NA	-0.45	-4.49	-0.42	2.03e-5	Renal cell carcinoma;
THYM	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg18132916	chr6:79620363	NA	0.58	5.27	0.48	8.5e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg20486651	chr6:167070296	RPS6KA2	0.5	4.79	0.44	6.18e-6	Crohn's disease;
THYM	cis	rs537626	0.667	rs625668	chr11:69308369	G/A	cg08353955	chr11:69289746	NA	-0.98	-4.75	-0.44	7.26e-6	Breast cancer (early onset);
THYM	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg03806693	chr22:41940476	POLR3H	-0.86	-8.43	-0.65	3.65e-13	Vitiligo;
THYM	cis	rs6584283	0.875	rs10748783	chr10:101285872	C/A	cg07044859	chr10:101282883	NA	-0.39	-4.52	-0.42	1.8e-5	Ulcerative colitis;
THYM	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg05368731	chr17:41323189	NBR1	1.2	10.93	0.75	1.72e-18	Menopause (age at onset);
THYM	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg08835221	chr22:38071607	LGALS1	0.35	4.88	0.45	4.34e-6	Fat distribution (HIV);
THYM	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg16778714	chr17:28903809	LRRC37B2	-0.69	-4.75	-0.44	7.3e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg02527881	chr3:46936655	PTH1R	0.66	6.61	0.56	2.18e-9	Colorectal cancer;
THYM	cis	rs10872587	0.657	rs11155459	chr6:146578751	A/G	cg05347473	chr6:146136440	FBXO30	-0.65	-4.77	-0.44	6.63e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs870825	0.655	rs1527870	chr4:185616631	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs4474465	0.920	rs7947824	chr11:78223731	C/G	cg19901956	chr11:77921274	USP35	0.7	5.2	0.47	1.12e-6	Alzheimer's disease (survival time);
THYM	cis	rs11166927	0.967	rs12680346	chr8:140814379	C/T	cg16909799	chr8:140841666	TRAPPC9	0.64	5.82	0.51	7.92e-8	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs7220711	1.000	rs8072333	chr17:41793893	C/T	cg26893861	chr17:41843967	DUSP3	0.67	5.79	0.51	8.98e-8	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs10411161	0.702	rs16983196	chr19:52384779	C/A	cg25361850	chr19:52391789	ZNF577	0.71	4.99	0.46	2.69e-6	Breast cancer;
THYM	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg12863693	chr15:85201151	NMB	0.53	4.82	0.44	5.45e-6	Schizophrenia;
THYM	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs6840360	0.593	rs4696106	chr4:152606818	A/G	cg22705602	chr4:152727874	NA	-0.81	-10.87	-0.74	2.32e-18	Intelligence (multi-trait analysis);
THYM	cis	rs10751667	1.000	rs10751667	chr11:941941	A/T	cg01483505	chr11:975446	AP2A2	0.63	4.76	0.44	7e-6	Alzheimer's disease (late onset);
THYM	cis	rs9486719	1.000	rs34236778	chr6:96884556	C/A	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg06808227	chr14:105710500	BRF1	-1.03	-8.81	-0.67	5.76e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7172809	0.897	rs74026933	chr15:77826969	A/C	cg22256960	chr15:77711686	NA	-0.67	-4.61	-0.43	1.27e-5	Glucose homeostasis traits;
THYM	cis	rs4523957	0.928	rs216206	chr17:2196088	C/T	cg16513277	chr17:2031491	SMG6	0.79	7.37	0.6	6.32e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs13064411	0.696	rs6787026	chr3:113162117	A/G	cg10517650	chr3:113235015	CCDC52	-0.57	-4.75	-0.44	7.26e-6	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7772486	0.790	rs7753092	chr6:146248863	C/T	cg23711669	chr6:146136114	FBXO30	-0.97	-10.07	-0.72	1.15e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10501293	0.746	rs7944338	chr11:43015799	A/G	cg03447554	chr11:43094025	NA	0.6	4.46	0.42	2.21e-5	Cognitive performance;
THYM	cis	rs2637266	0.935	rs2583052	chr10:78403288	C/G	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg18252515	chr7:66147081	NA	0.66	4.81	0.44	5.74e-6	Aortic root size;
THYM	cis	rs2836633	0.895	rs2212606	chr21:40044940	A/C	cg05519781	chr21:40033154	ERG	0.72	6.6	0.56	2.3e-9	Coronary artery disease;
THYM	cis	rs2463822	1.000	rs7481995	chr11:62129312	G/C	cg06239285	chr11:62104954	ASRGL1	1.44	7.7	0.62	1.3e-11	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg22709100	chr7:91322751	NA	0.68	5.07	0.46	1.97e-6	Breast cancer;
THYM	cis	rs1728785	0.892	rs4783562	chr16:68562963	A/G	cg02972257	chr16:68554789	NA	-0.77	-4.86	-0.45	4.68e-6	Ulcerative colitis;
THYM	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg01097406	chr16:89675127	NA	0.84	7.57	0.61	2.36e-11	Vitiligo;
THYM	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.68	0.5	1.46e-7	Height;
THYM	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg17644776	chr2:200775616	C2orf69	0.92	7.74	0.62	1.05e-11	Osteoporosis;
THYM	cis	rs3136516	0.537	rs2291444	chr11:47179143	C/T	cg00724111	chr11:47209415	PACSIN3	-0.38	-4.73	-0.44	7.73e-6	Venous thromboembolism;
THYM	cis	rs4936891	0.520	rs61908590	chr11:123869811	A/C	cg22125253	chr11:123886957	OR10G4	-0.57	-4.94	-0.45	3.35e-6	Male fertility;
THYM	cis	rs1499972	0.824	rs705219	chr3:117702270	T/A	cg07612923	chr3:117604196	NA	-1.37	-5.16	-0.47	1.34e-6	Schizophrenia;
THYM	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7580658	0.637	rs9636235	chr2:127981551	C/T	cg09152259	chr2:128156114	NA	-0.36	-4.7	-0.43	8.84e-6	Protein C levels;
THYM	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg09549813	chr16:4587862	C16orf5	-0.5	-5.67	-0.5	1.53e-7	Schizophrenia;
THYM	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg15448220	chr1:150897856	SETDB1	0.85	6.98	0.58	3.88e-10	Tonsillectomy;
THYM	cis	rs427394	0.632	rs2279656	chr5:6737576	G/A	cg10857441	chr5:6722123	POLS	-0.71	-7.51	-0.61	3.17e-11	Menopause (age at onset);
THYM	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg06565975	chr8:143823917	SLURP1	-0.7	-8.31	-0.65	6.72e-13	Urinary tract infection frequency;
THYM	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg15445000	chr17:37608096	MED1	-0.44	-5.19	-0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs17826219	0.562	rs719600	chr17:28731262	G/A	cg27034606	chr17:28928453	LRRC37B2	-0.77	-4.5	-0.42	1.96e-5	Body mass index;
THYM	cis	rs4606347	0.872	rs76257047	chr1:66096931	C/T	cg04111102	chr1:66153794	NA	0.59	4.54	0.42	1.67e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg08508325	chr11:3079039	CARS	-0.52	-6.62	-0.56	2.08e-9	Longevity;
THYM	cis	rs7173743	0.756	rs8032842	chr15:79125849	G/A	cg15571903	chr15:79123663	NA	0.56	6.26	0.54	1.12e-8	Coronary artery disease;
THYM	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg24642844	chr7:1081250	C7orf50	-0.74	-5.18	-0.47	1.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs56079296	0.642	rs2914610	chr5:121314168	A/G	cg05256605	chr5:121412184	LOX	-0.61	-4.63	-0.43	1.15e-5	Coronary artery disease;
THYM	cis	rs4845570	0.920	rs1521185	chr1:151764049	A/G	cg07092448	chr1:151763213	TDRKH	1.17	8.57	0.66	1.86e-13	Coronary artery disease;
THYM	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg00129232	chr17:37814104	STARD3	0.87	7.23	0.6	1.23e-10	Asthma;
THYM	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg15704280	chr7:45808275	SEPT13	-1.0	-8.07	-0.64	2.18e-12	Height;
THYM	cis	rs7631605	0.819	rs1392748	chr3:37265313	T/C	cg21328643	chr3:37258149	NA	-0.58	-5.57	-0.5	2.39e-7	Cerebrospinal P-tau181p levels;
THYM	cis	rs714027	0.585	rs41168	chr22:30418161	A/C	cg27665648	chr22:30112403	NA	-0.51	-4.55	-0.42	1.6e-5	Lymphocyte counts;
THYM	cis	rs1747683	0.702	rs2254252	chr10:13363822	C/T	cg00142036	chr10:13388442	SEPHS1	0.32	6.24	0.54	1.2e-8	IgG glycosylation;
THYM	cis	rs7089973	0.872	rs41284358	chr10:116622339	A/G	cg23260525	chr10:116636907	FAM160B1	0.52	4.72	0.44	8.04e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9902453	0.765	rs2729440	chr17:28106874	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs7582180	0.614	rs10193204	chr2:101004540	A/G	cg21926883	chr2:100939477	LONRF2	0.66	6.11	0.53	2.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs977987	0.778	rs4243112	chr16:75321031	T/C	cg03315344	chr16:75512273	CHST6	0.83	6.93	0.58	5e-10	Dupuytren's disease;
THYM	cis	rs700651	0.821	rs770661	chr2:198725444	A/G	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Intracranial aneurysm;
THYM	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg24209194	chr3:40518798	ZNF619	0.62	4.86	0.45	4.54e-6	Renal cell carcinoma;
THYM	cis	rs4460079	0.531	rs4266345	chr4:114847473	T/C	cg02060584	chr4:113970739	ANK2	0.59	4.93	0.45	3.48e-6	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs3741151	1.000	rs75007932	chr11:73080336	G/A	cg12959048	chr11:73096162	RELT	-0.53	-5.13	-0.47	1.52e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg18230493	chr5:56204884	C5orf35	-0.92	-6.99	-0.58	3.72e-10	Initial pursuit acceleration;
THYM	cis	rs7584330	0.518	rs6715245	chr2:238445803	C/T	cg14458575	chr2:238380390	NA	1.03	6.01	0.52	3.38e-8	Prostate cancer;
THYM	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg03676636	chr4:99064102	C4orf37	0.42	6.16	0.53	1.75e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg18681998	chr4:17616180	MED28	0.88	8.04	0.64	2.47e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.8	-0.44	6.01e-6	Mean corpuscular volume;
THYM	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21659725	chr3:3221576	CRBN	-0.88	-9.81	-0.71	4.18e-16	Intelligence (multi-trait analysis);
THYM	cis	rs11169225	0.724	rs7305290	chr12:50341465	A/G	cg04450003	chr12:50355995	AQP5	0.67	5.37	0.48	5.47e-7	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs8078723	0.668	rs3859192	chr17:38128648	C/T	cg17467752	chr17:38218738	THRA	0.73	5.48	0.49	3.47e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs1978968	0.912	rs1110666	chr22:18457720	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	0.51	4.5	0.42	1.93e-5	Presence of antiphospholipid antibodies;
THYM	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg06623918	chr6:96969491	KIAA0776	-1.05	-10.59	-0.74	9.01e-18	Headache;
THYM	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.68	0.5	1.45e-7	Height;
THYM	cis	rs17253792	0.822	rs76164147	chr14:56140369	T/C	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg12408189	chr10:30722286	MAP3K8	-0.56	-4.82	-0.44	5.38e-6	Inflammatory bowel disease;
THYM	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg22535103	chr8:58192502	C8orf71	-0.86	-4.82	-0.44	5.4e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs58873874	0.737	rs76634949	chr5:156890399	C/T	cg08916508	chr5:156566250	MED7	-1.17	-4.52	-0.42	1.8e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs4908768	0.555	rs4908777	chr1:8804237	A/G	cg06972019	chr1:8937448	ENO1	-0.6	-4.52	-0.42	1.77e-5	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1559088	0.947	rs10403238	chr19:33552405	A/G	cg03563238	chr19:33554763	RHPN2	-0.5	-4.48	-0.42	2.04e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg27286337	chr10:134555280	INPP5A	0.93	6.97	0.58	4.19e-10	Migraine;
THYM	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs586688	0.582	rs550365	chr1:201665278	A/G	cg14168733	chr1:201708718	NAV1	-0.6	-5.49	-0.49	3.3e-7	Obesity-related traits;
THYM	cis	rs11078597	0.731	rs4989024	chr17:1639719	A/G	cg18436246	chr17:1640651	WDR81	0.63	4.48	0.42	2.04e-5	Serum albumin level;
THYM	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg11494091	chr17:61959527	GH2	0.7	6.46	0.55	4.55e-9	Height;
THYM	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11890956	chr21:40555474	PSMG1	-0.9	-9.61	-0.7	1.12e-15	Cognitive function;
THYM	cis	rs4363385	0.667	rs6675352	chr1:152936749	A/G	cg07796016	chr1:152779584	LCE1C	-0.58	-4.65	-0.43	1.05e-5	Inflammatory skin disease;
THYM	trans	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	trans	rs3960554	0.808	rs2286829	chr7:75677739	G/A	cg19862616	chr7:65841803	NCRNA00174	0.95	7.23	0.6	1.21e-10	Eotaxin levels;
THYM	cis	rs13064411	0.542	rs7650671	chr3:113201216	C/T	cg18753928	chr3:113234510	CCDC52	-0.78	-7.16	-0.59	1.68e-10	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg27535305	chr1:53392650	SCP2	-0.54	-6.29	-0.54	9.77e-9	Monocyte count;
THYM	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg13147721	chr7:65941812	NA	-1.0	-6.2	-0.54	1.47e-8	Diabetic kidney disease;
THYM	trans	rs8073060	0.660	rs58266733	chr17:34003812	A/T	cg19694781	chr19:47549865	TMEM160	-1.02	-8.69	-0.67	1.01e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs9329289	0.510	rs10903785	chr10:2550063	C/T	cg07014206	chr10:2547000	NA	-0.59	-5.42	-0.49	4.45e-7	Age-related hearing impairment;
THYM	cis	rs9420	0.528	rs11229077	chr11:57399072	A/G	cg19752551	chr11:57585705	CTNND1	0.58	5.17	0.47	1.3e-6	Schizophrenia;
THYM	cis	rs6121246	0.865	rs77130187	chr20:30269060	G/A	cg13852791	chr20:30311386	BCL2L1	0.94	6.82	0.57	8.4e-10	Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg10515332	chr4:99064459	C4orf37	-0.61	-4.94	-0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs308403	0.509	rs309376	chr4:123680191	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.97	8.95	0.68	2.9e-14	Blood protein levels;
THYM	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg13877915	chr19:58951672	ZNF132	0.94	9.38	0.69	3.42e-15	Uric acid clearance;
THYM	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg14583973	chr4:3374767	RGS12	0.69	6.75	0.57	1.19e-9	Serum sulfate level;
THYM	cis	rs2562456	0.837	rs62110205	chr19:21760071	A/G	cg21751540	chr19:21541537	ZNF738	-0.74	-5.17	-0.47	1.31e-6	Pain;
THYM	cis	rs7894051	1.000	rs7899476	chr10:135197214	A/G	cg07511014	chr10:135191624	PAOX	0.65	4.5	0.42	1.89e-5	Lifespan;
THYM	cis	rs13424612	0.839	rs6437355	chr2:240905550	G/C	cg01812947	chr2:240904978	NDUFA10	0.56	4.59	0.43	1.35e-5	Odorant perception (isobutyraldehyde);
THYM	trans	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg11812906	chr14:75593930	NEK9	0.84	7.79	0.62	8.24e-12	Height;
THYM	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg08736216	chr1:53307985	ZYG11A	-0.59	-5.43	-0.49	4.3e-7	Monocyte count;
THYM	cis	rs36051895	0.554	rs7856773	chr9:5204705	T/C	cg02405213	chr9:5042618	JAK2	-0.9	-9.02	-0.68	2.02e-14	Pediatric autoimmune diseases;
THYM	cis	rs13102973	0.965	rs9998499	chr4:135869362	G/A	cg14419869	chr4:135874104	NA	-0.82	-7.99	-0.63	3.12e-12	Subjective well-being;
THYM	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg03295274	chr13:50190584	NA	0.69	5.26	0.47	8.98e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-5.77	-0.51	9.69e-8	Gut microbiome composition (summer);
THYM	cis	rs36051895	0.632	rs10815165	chr9:5149138	T/C	cg02405213	chr9:5042618	JAK2	-1.04	-11.14	-0.75	6.36e-19	Pediatric autoimmune diseases;
THYM	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs11771526	0.681	rs79578813	chr7:32308867	G/T	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs3771570	1.000	rs17386695	chr2:242379751	A/G	cg21155796	chr2:242212141	HDLBP	-1.25	-6.07	-0.53	2.57e-8	Prostate cancer;
THYM	cis	rs17818399	0.749	rs13000560	chr2:46790997	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.73	4.88	0.45	4.29e-6	Height;
THYM	cis	rs3849570	0.883	rs28435942	chr3:81679692	C/T	cg07356753	chr3:81810745	GBE1	-0.83	-6.11	-0.53	2.19e-8	Waist circumference;Body mass index;
THYM	cis	rs654950	0.875	rs4660544	chr1:41996871	T/C	cg06885757	chr1:42089581	HIVEP3	-0.44	-5.26	-0.47	9e-7	Airway imaging phenotypes;
THYM	cis	rs524023	0.957	rs528211	chr11:64351721	C/T	cg19131476	chr11:64387923	NRXN2	0.32	4.57	0.42	1.48e-5	Urate levels in obese individuals;
THYM	cis	rs11577318	0.853	rs7537477	chr1:26618829	C/T	cg19677267	chr1:26645161	CD52;UBXN11	-0.45	-5.83	-0.51	7.66e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs4730250	0.708	rs4730242	chr7:107057373	G/C	cg00661777	chr7:106511741	PIK3CG	-0.67	-4.59	-0.43	1.36e-5	Osteoarthritis;
THYM	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2832077	1.000	rs2832077	chr21:30141021	G/A	cg24692254	chr21:30365293	RNF160	-0.84	-5.22	-0.47	1.04e-6	Cognitive test performance;
THYM	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	trans	rs877282	0.853	rs7092805	chr10:756246	G/A	cg22713356	chr15:30763199	NA	1.26	8.94	0.68	3.06e-14	Uric acid levels;
THYM	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg17264618	chr3:40429014	ENTPD3	0.47	4.48	0.42	2.1e-5	Renal cell carcinoma;
THYM	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg24154853	chr7:158122151	PTPRN2	-0.53	-4.91	-0.45	3.78e-6	Calcium levels;
THYM	cis	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg10856724	chr12:34555212	NA	-0.95	-9.37	-0.69	3.71e-15	Morning vs. evening chronotype;
THYM	cis	rs2229238	0.955	rs4072391	chr1:154438880	A/G	cg21262032	chr1:154437693	IL6R	0.58	5.22	0.47	1.06e-6	Coronary heart disease;
THYM	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg21773646	chr17:80085082	CCDC57	-0.34	-4.91	-0.45	3.72e-6	Life satisfaction;
THYM	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.95	7.89	0.63	5.17e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg17173187	chr15:85201210	NMB	0.56	5.51	0.49	3e-7	Schizophrenia;
THYM	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.92	7.55	0.61	2.6e-11	Lymphocyte percentage of white cells;
THYM	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg21433313	chr16:3507492	NAT15	0.59	4.96	0.45	3.03e-6	Body mass index (adult);
THYM	cis	rs4474465	1.000	rs7928933	chr11:78193921	T/C	cg19901956	chr11:77921274	USP35	-0.63	-4.69	-0.43	9.19e-6	Alzheimer's disease (survival time);
THYM	cis	rs11696501	0.688	rs6073854	chr20:44309605	A/G	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs926938	0.765	rs2268701	chr1:115233046	C/T	cg12756093	chr1:115239321	AMPD1	-0.82	-6.31	-0.54	8.78e-9	Autism;
THYM	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg21773646	chr17:80085082	CCDC57	0.32	4.5	0.42	1.93e-5	Life satisfaction;
THYM	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg04181038	chr4:183730758	NA	1.02	8.45	0.66	3.35e-13	Pediatric autoimmune diseases;
THYM	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg12935359	chr14:103987150	CKB	-0.66	-6.48	-0.55	3.99e-9	Body mass index;
THYM	cis	rs2072510	0.593	rs2540493	chr12:96415842	A/C	cg18817487	chr12:96390143	HAL	0.45	5.47	0.49	3.61e-7	Metabolite levels (small molecules and protein measures);
THYM	cis	rs4638749	0.501	rs6708539	chr2:108745042	C/A	cg25838818	chr2:108905173	SULT1C2	-0.49	-4.88	-0.45	4.3e-6	Blood pressure;
THYM	cis	rs1461503	0.934	rs11605693	chr11:122837037	T/C	cg27398637	chr11:122830231	C11orf63	-0.6	-5.06	-0.46	2.06e-6	Menarche (age at onset);
THYM	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg24209194	chr3:40518798	ZNF619	0.55	4.45	0.42	2.34e-5	Renal cell carcinoma;
THYM	cis	rs10744422	0.528	rs6489245	chr12:123360151	G/A	cg25930673	chr12:123319894	HIP1R	-0.85	-4.94	-0.45	3.38e-6	Schizophrenia;
THYM	cis	rs2241584	0.967	rs6867318	chr5:175949233	A/G	cg27658698	chr5:175955578	RNF44	0.43	5.16	0.47	1.36e-6	Menopause (age at onset);
THYM	cis	rs9807989	0.839	rs10204837	chr2:102977730	C/A	cg03938978	chr2:103052716	IL18RAP	0.63	6.55	0.56	2.99e-9	Asthma;
THYM	cis	rs4731207	0.596	rs1531715	chr7:124638207	G/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg15556689	chr8:8085844	FLJ10661	-0.66	-5.21	-0.47	1.09e-6	Mood instability;
THYM	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.2	8.02	0.64	2.74e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg14019146	chr3:50243930	SLC38A3	0.6	5.11	0.46	1.67e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11690935	0.959	rs10204502	chr2:172588866	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-6.5	-0.55	3.76e-9	Schizophrenia;
THYM	cis	rs7511006	1.000	rs5771109	chr22:50678571	T/C	cg11077631	chr22:50617003	PANX2	-0.53	-5.77	-0.51	9.99e-8	Obesity-related traits;
THYM	cis	rs6430585	0.528	rs111682961	chr2:136653848	C/T	cg20242066	chr2:136595261	LCT	0.56	5.16	0.47	1.38e-6	Corneal structure;
THYM	cis	rs8067545	0.611	rs2703803	chr17:20107069	G/T	cg20830565	chr17:20408647	MGC102966	0.49	4.48	0.42	2.05e-5	Schizophrenia;
THYM	cis	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg02317251	chr4:10116515	WDR1	-0.53	-4.73	-0.44	7.92e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs7927771	0.507	rs7119517	chr11:47675316	T/C	cg20307385	chr11:47447363	PSMC3	0.6	4.58	0.43	1.41e-5	Subjective well-being;
THYM	cis	rs870825	0.721	rs72703528	chr4:185607311	A/G	cg04058563	chr4:185651563	MLF1IP	1.05	7.96	0.63	3.6e-12	Blood protein levels;
THYM	cis	rs7267979	1.000	rs6050555	chr20:25328543	A/G	cg08601574	chr20:25228251	PYGB	-0.58	-4.6	-0.43	1.32e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg03433033	chr1:76189801	ACADM	-0.78	-10.37	-0.73	2.69e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs354225	0.513	rs10187338	chr2:54806611	A/G	cg23486701	chr2:54789491	SPTBN1	0.36	4.77	0.44	6.58e-6	Schizophrenia;
THYM	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg02734326	chr4:10020555	SLC2A9	0.76	7.25	0.6	1.13e-10	Bone mineral density;
THYM	cis	rs2439831	1.000	rs565007	chr15:43716641	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs806215	0.950	rs2073561	chr7:127227769	G/C	cg08586737	chr7:127225949	GCC1	-0.4	-4.65	-0.43	1.05e-5	Type 2 diabetes;
THYM	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg14074117	chr16:1909714	C16orf73	-0.7	-4.45	-0.42	2.3e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs7011507	0.700	rs6989759	chr8:49296878	A/T	cg08774009	chr8:49309094	NA	-0.7	-5.45	-0.49	3.96e-7	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs6430585	0.527	rs1900306	chr2:136416533	G/A	cg23851026	chr2:136556271	LCT	0.65	5.55	0.49	2.59e-7	Corneal structure;
THYM	cis	rs9364687	0.639	rs4709722	chr6:163969279	A/G	cg01639524	chr6:163818125	NA	0.49	4.87	0.45	4.48e-6	Body mass index;
THYM	cis	rs17443541	0.564	rs1450570	chr2:200442061	G/T	cg03741458	chr2:200468445	NA	0.77	5.51	0.49	3.03e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.29e-7	Corneal astigmatism;
THYM	cis	rs977987	0.806	rs4888416	chr16:75449176	C/G	cg03315344	chr16:75512273	CHST6	0.76	6.16	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs7258015	1.000	rs3176767	chr19:10449751	A/C	cg01466491	chr19:10523363	NA	0.67	5.33	0.48	6.56e-7	Systemic lupus erythematosus or rheumatoid arthritis;
THYM	cis	rs2625529	0.617	rs2929509	chr15:72239272	T/C	cg16672083	chr15:72433130	SENP8	0.49	4.47	0.42	2.17e-5	Red blood cell count;
THYM	cis	rs73198271	0.599	rs10103169	chr8:8650698	T/A	cg15556689	chr8:8085844	FLJ10661	-0.74	-4.91	-0.45	3.75e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4072705	1.000	rs2067791	chr9:127438294	C/T	cg13476313	chr9:127244764	NR5A1	0.34	5.46	0.49	3.83e-7	Menarche (age at onset);
THYM	cis	rs55728055	0.661	rs16989617	chr22:31839151	T/C	cg01338084	chr22:32026380	PISD	1.35	4.93	0.45	3.5e-6	Age-related hearing impairment;
THYM	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs733592	0.524	rs10875744	chr12:48498440	G/C	cg21466736	chr12:48725269	NA	-0.45	-4.85	-0.45	4.83e-6	Plateletcrit;
THYM	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.98	5.42	0.49	4.56e-7	Initial pursuit acceleration;
THYM	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg14416269	chr4:6271139	WFS1	0.54	5.62	0.5	1.93e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs8048589	1.000	rs13336687	chr16:12187065	C/T	cg01990910	chr16:12207648	SNX29	-0.45	-5.12	-0.47	1.56e-6	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg11871910	chr12:69753446	YEATS4	1.06	9.8	0.71	4.32e-16	Blood protein levels;
THYM	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg06108461	chr20:60628389	TAF4	-0.99	-7.54	-0.61	2.73e-11	Body mass index;
THYM	trans	rs4262150	0.883	rs4958587	chr5:152251201	T/C	cg08281791	chr5:76607845	PDE8B	0.92	6.91	0.58	5.62e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs1912528	0.783	rs769661	chr4:140869936	C/T	cg11128457	chr4:140864437	MAML3	0.48	5.03	0.46	2.35e-6	Educational attainment (years of education);
THYM	cis	rs11108495	1.000	rs11108495	chr12:96807917	A/G	cg26037974	chr12:96640840	ELK3	-0.55	-4.49	-0.42	1.97e-5	Weight;
THYM	cis	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg26384229	chr12:38710491	ALG10B	-0.74	-5.81	-0.51	8.33e-8	Bladder cancer;
THYM	cis	rs2073300	1.000	rs6114144	chr20:23462022	A/T	cg12062639	chr20:23401060	NAPB	0.96	4.84	0.45	4.95e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs12130333	0.761	rs12092541	chr1:62917913	G/A	cg06896770	chr1:63153194	DOCK7	0.97	4.6	0.43	1.3e-5	Triglycerides;
THYM	cis	rs6500395	0.926	rs11645193	chr16:48594229	C/T	cg04672837	chr16:48644449	N4BP1	0.48	4.58	0.43	1.39e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6840360	0.642	rs2034061	chr4:152420756	C/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-5.65	-0.5	1.7e-7	Intelligence (multi-trait analysis);
THYM	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg11245990	chr11:68621969	NA	0.57	7.34	0.6	7.24e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg02527881	chr3:46936655	PTH1R	-0.67	-6.75	-0.57	1.18e-9	Colorectal cancer;
THYM	cis	rs3820068	0.608	rs7516683	chr1:16020502	A/G	cg27534772	chr1:16042836	PLEKHM2	-0.54	-5.65	-0.5	1.64e-7	Systolic blood pressure;
THYM	cis	rs12478296	1.000	rs12474070	chr2:243039738	C/T	cg06360820	chr2:242988706	NA	-0.87	-5.4	-0.48	4.88e-7	Obesity-related traits;
THYM	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg22117172	chr7:91764530	CYP51A1	0.35	4.46	0.42	2.27e-5	Breast cancer;
THYM	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Body mass index;
THYM	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg09462578	chr12:12878428	APOLD1	-0.9	-5.44	-0.49	4.07e-7	Systemic lupus erythematosus;
THYM	cis	rs240764	0.528	rs964223	chr6:101250982	T/A	cg21058520	chr6:100914733	NA	-0.58	-4.54	-0.42	1.62e-5	Neuroticism;
THYM	cis	rs11039798	0.511	rs2047812	chr11:48162042	A/G	cg24672777	chr11:48374446	OR4C45	0.8	4.68	0.43	9.48e-6	Axial length;
THYM	cis	rs6570726	0.935	rs454614	chr6:145832633	C/T	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg14582100	chr15:45693742	SPATA5L1	0.6	4.77	0.44	6.64e-6	Homoarginine levels;
THYM	cis	rs13070279	0.582	rs34586454	chr3:71799897	C/G	cg19388776	chr3:71835112	PROK2	0.88	5.16	0.47	1.34e-6	Monocyte count;
THYM	cis	rs7107174	1.000	rs12277648	chr11:78054336	C/T	cg19901956	chr11:77921274	USP35	-0.65	-5.37	-0.48	5.66e-7	Testicular germ cell tumor;
THYM	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg03467027	chr4:99064603	C4orf37	0.59	4.5	0.42	1.92e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.57	-6.16	-0.53	1.74e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg11752832	chr7:134001865	SLC35B4	0.73	5.51	0.49	3.06e-7	Mean platelet volume;
THYM	cis	rs1322639	0.806	rs1322640	chr6:169586887	T/C	cg03254818	chr6:169586852	NA	-0.78	-5.74	-0.51	1.15e-7	Pulse pressure;
THYM	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg07511668	chr11:68622177	NA	0.44	4.63	0.43	1.16e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6840360	0.615	rs2120098	chr4:152457180	T/A	cg17479576	chr4:152424074	FAM160A1	-0.84	-6.36	-0.55	6.92e-9	Intelligence (multi-trait analysis);
THYM	cis	rs595982	0.559	rs4802516	chr19:49366170	T/C	cg21252483	chr19:49399788	TULP2	-0.86	-6.06	-0.53	2.76e-8	Red cell distribution width;
THYM	cis	rs7626444	0.565	rs7613010	chr3:196490221	G/T	cg12930392	chr3:196481615	PAK2	0.41	5.04	0.46	2.18e-6	Monocyte count;
THYM	cis	rs7000551	0.725	rs2461483	chr8:22386479	C/T	cg12081754	chr8:22256438	SLC39A14	0.65	5.65	0.5	1.67e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg23649088	chr2:200775458	C2orf69	0.83	6.97	0.58	4.07e-10	Osteoporosis;
THYM	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	7.35	0.6	6.91e-11	Platelet count;
THYM	cis	rs34734847	1.000	rs3752531	chr12:121157851	A/G	cg21892295	chr12:121157589	UNC119B	-0.66	-7.5	-0.61	3.43e-11	Mean corpuscular volume;
THYM	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg00071950	chr4:10020882	SLC2A9	0.86	10.33	0.73	3.3e-17	Bone mineral density;
THYM	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg18132916	chr6:79620363	NA	-0.55	-4.84	-0.44	4.98e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4866334	1.000	rs76306109	chr5:18481141	A/C	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	trans	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg05043794	chr9:111880884	C9orf5	0.36	5.05	0.46	2.12e-6	Menarche (age at onset);
THYM	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg23711669	chr6:146136114	FBXO30	0.93	9.04	0.68	1.9e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4474465	1.000	rs10793319	chr11:78217237	G/A	cg19901956	chr11:77921274	USP35	0.66	4.84	0.44	4.99e-6	Alzheimer's disease (survival time);
THYM	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg03929089	chr4:120376271	NA	-1.01	-13.71	-0.82	3.1e-24	Height;
THYM	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg03467027	chr4:99064603	C4orf37	0.59	4.5	0.42	1.92e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4851254	0.660	rs114552491	chr2:100709533	C/T	cg22139774	chr2:100720529	AFF3	-0.4	-4.57	-0.42	1.46e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6539288	0.677	rs10778518	chr12:107343950	C/T	cg26297688	chr12:107349093	C12orf23	0.5	6.02	0.53	3.22e-8	Total body bone mineral density;
THYM	cis	rs7177699	0.557	rs7403714	chr15:79118650	C/T	cg00540400	chr15:79124168	NA	-0.64	-6.76	-0.57	1.09e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.55	0.42	1.57e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2070488	0.965	rs9877282	chr3:38541452	A/G	cg24069376	chr3:38537580	EXOG	-0.69	-6.79	-0.57	9.87e-10	Electrocardiographic conduction measures;
THYM	cis	rs36051895	0.664	rs28378223	chr9:5113087	C/G	cg02405213	chr9:5042618	JAK2	-1.0	-11.01	-0.75	1.17e-18	Pediatric autoimmune diseases;
THYM	cis	rs6047844	0.593	rs6113524	chr20:22094192	T/A	cg16502866	chr20:23015624	SSTR4	-0.58	-4.61	-0.43	1.25e-5	Male-pattern baldness;
THYM	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg23583168	chr7:148888333	NA	1.0	13.59	0.81	5.1900000000000004e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg09354556	chr3:47051341	NA	0.46	4.71	0.44	8.28e-6	Colorectal cancer;
THYM	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	9.43	0.7	2.7e-15	Platelet count;
THYM	cis	rs4792901	0.765	rs35557239	chr17:41548275	A/C	cg21940313	chr17:41620911	ETV4	-0.51	-4.95	-0.45	3.19e-6	Dupuytren's disease;
THYM	trans	rs877282	1.000	rs34257857	chr10:772993	C/A	cg22713356	chr15:30763199	NA	1.26	10.12	0.72	9.24e-17	Uric acid levels;
THYM	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg10518543	chr12:38710700	ALG10B	0.57	4.58	0.43	1.4e-5	Morning vs. evening chronotype;
THYM	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs4654899	0.802	rs115818417	chr1:21200411	C/T	cg01072550	chr1:21505969	NA	-0.69	-5.99	-0.52	3.78e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg26384229	chr12:38710491	ALG10B	0.68	5.16	0.47	1.35e-6	Morning vs. evening chronotype;
THYM	cis	rs425535	0.817	rs442155	chr4:74851232	A/G	cg07868155	chr4:74864709	CXCL5	-0.67	-5.22	-0.47	1.04e-6	Blood protein levels;
THYM	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg17366294	chr4:99064904	C4orf37	0.53	5.9	0.52	5.67e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs822354	1.000	rs866601	chr3:186479009	A/G	cg23249140	chr3:186560453	ADIPOQ	-0.5	-4.91	-0.45	3.75e-6	Adiponectin levels;
THYM	cis	rs61931739	0.500	rs7134491	chr12:34443072	C/T	cg06521331	chr12:34319734	NA	-0.73	-4.78	-0.44	6.31e-6	Morning vs. evening chronotype;
THYM	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg24675658	chr1:53192096	ZYG11B	-0.7	-5.6	-0.5	2.04e-7	Monocyte count;
THYM	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg04546413	chr19:29218101	NA	1.06	8.75	0.67	7.75e-14	Methadone dose in opioid dependence;
THYM	cis	rs2219968	0.525	rs7823969	chr8:78879106	G/A	cg00738934	chr8:78996279	NA	0.61	4.95	0.45	3.21e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs800586	0.500	rs727581	chr8:116650491	T/C	cg04656070	chr8:116661063	TRPS1	-0.52	-5.72	-0.51	1.21e-7	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2456568	0.771	rs2102333	chr11:93634749	G/A	cg26875233	chr11:93583750	C11orf90	-0.53	-5.53	-0.49	2.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs17253792	0.545	rs34719936	chr14:56015134	G/A	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg06784218	chr1:46089804	CCDC17	0.3	4.75	0.44	7.14e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg22535103	chr8:58192502	C8orf71	-0.93	-4.56	-0.42	1.52e-5	Developmental language disorder (linguistic errors);
THYM	trans	rs28595532	0.623	rs11932674	chr4:119306807	A/C	cg26518628	chr1:97050305	NA	-1.1	-8.54	-0.66	2.15e-13	Cannabis dependence symptom count;
THYM	cis	rs2242116	0.743	rs11719795	chr3:46951935	T/C	cg27129171	chr3:47204927	SETD2	0.7	5.99	0.52	3.7e-8	Birth weight;
THYM	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg00981070	chr1:2046702	PRKCZ	0.39	4.92	0.45	3.62e-6	Height;
THYM	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg20503657	chr10:835505	NA	1.17	8.3	0.65	7.12e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs10751667	0.600	rs11246376	chr11:999622	C/T	cg20946044	chr11:1010712	AP2A2	-0.58	-4.88	-0.45	4.22e-6	Alzheimer's disease (late onset);
THYM	cis	rs12216545	0.765	rs2888666	chr7:150252350	G/A	cg08960815	chr7:150264767	GIMAP4	-0.87	-7.96	-0.63	3.61e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs12282928	0.837	rs10742851	chr11:48534771	A/G	cg22827986	chr11:48284249	OR4X1	-0.54	-5.56	-0.5	2.47e-7	Migraine - clinic-based;
THYM	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg13918804	chr1:2043761	PRKCZ	-0.62	-4.68	-0.43	9.63e-6	Height;
THYM	cis	rs6009824	0.891	rs6009820	chr22:50085456	C/T	cg22070880	chr22:50098194	NA	0.65	4.7	0.43	8.94e-6	Natriuretic peptide levels;
THYM	cis	rs13315871	0.790	rs28502788	chr3:58296208	A/T	cg12435725	chr3:58293450	RPP14	-0.5	-5.35	-0.48	6.13e-7	Cholesterol, total;
THYM	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg08772003	chr10:104629869	AS3MT	-0.57	-4.92	-0.45	3.69e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.66	-4.71	-0.43	8.55e-6	Age at first birth;
THYM	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg26384229	chr12:38710491	ALG10B	0.71	5.52	0.49	2.92e-7	Morning vs. evening chronotype;
THYM	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3017493	0.786	rs112552548	chr11:70675096	G/A	cg03578926	chr11:70508032	SHANK2	0.86	5.12	0.46	1.6e-6	Renal transplant outcome;
THYM	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg17063962	chr7:91808500	NA	-1.12	-12.68	-0.79	3.85e-22	Breast cancer;
THYM	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg25251562	chr2:3704773	ALLC	-1.34	-10.0	-0.72	1.67e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs554111	0.656	rs17450813	chr1:21264308	T/C	cg00373020	chr1:21041521	KIF17	-0.55	-4.65	-0.43	1.06e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs2046867	0.862	rs6805234	chr3:72829869	A/G	cg25664220	chr3:72788482	NA	-0.78	-5.91	-0.52	5.36e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg17105886	chr17:28927953	LRRC37B2	1.21	7.24	0.6	1.14e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6542838	0.641	rs7565510	chr2:99494833	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-4.47	-0.42	2.14e-5	Fear of minor pain;
THYM	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12667521	chr19:29218732	NA	0.76	6.22	0.54	1.36e-8	Methadone dose in opioid dependence;
THYM	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg08742575	chr21:47604166	C21orf56	-0.69	-5.58	-0.5	2.27e-7	Testicular germ cell tumor;
THYM	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg21138405	chr5:131827807	IRF1	-0.85	-9.31	-0.69	4.86e-15	Asthma (sex interaction);
THYM	cis	rs11048434	0.761	rs12827055	chr12:9130861	G/T	cg04155231	chr12:9217510	LOC144571	0.48	4.59	0.43	1.34e-5	Sjögren's syndrome;
THYM	cis	rs6424115	1.000	rs7515969	chr1:24158398	G/A	cg15997130	chr1:24165203	NA	-0.78	-6.79	-0.57	9.49e-10	Immature fraction of reticulocytes;
THYM	cis	rs6754311	0.593	rs11679508	chr2:136474098	A/T	cg07169764	chr2:136633963	MCM6	-0.71	-5.75	-0.51	1.06e-7	Mosquito bite size;
THYM	cis	rs2637266	1.000	rs2395390	chr10:78357734	C/G	cg18941641	chr10:78392320	NA	0.81	7.03	0.58	3.17e-10	Pulmonary function;
THYM	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg10589385	chr1:150898437	SETDB1	0.64	5.38	0.48	5.29e-7	Tonsillectomy;
THYM	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg10047753	chr17:41438598	NA	1.21	11.66	0.77	5.04e-20	Menopause (age at onset);
THYM	cis	rs1883415	0.727	rs2760116	chr6:24504238	C/T	cg00346970	chr6:24499591	ALDH5A1	0.42	5.64	0.5	1.73e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1971762	0.563	rs7975862	chr12:54078427	A/C	cg16917193	chr12:54089295	NA	-0.9	-9.22	-0.69	7.82e-15	Height;
THYM	cis	rs72712511	0.571	rs10020932	chr4:140763270	C/G	cg15010390	chr4:140216957	NDUFC1	0.66	4.84	0.45	4.94e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2625529	0.617	rs2957365	chr15:72348106	C/T	cg16672083	chr15:72433130	SENP8	0.49	4.52	0.42	1.76e-5	Red blood cell count;
THYM	cis	rs12912251	1.000	rs12901215	chr15:38992893	G/A	cg08274633	chr15:38988533	C15orf53	-0.23	-4.72	-0.44	8.03e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
THYM	cis	rs13418717	0.793	rs6733255	chr2:127662386	C/T	cg25501666	chr2:127640322	NA	-1.26	-6.6	-0.56	2.37e-9	Heart failure;
THYM	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.06	9.44	0.7	2.63e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg10760299	chr15:45669010	GATM	0.85	6.57	0.56	2.69e-9	Homoarginine levels;
THYM	cis	rs500891	0.525	rs1170483	chr6:84038253	G/C	cg21688264	chr6:84418724	SNAP91	0.74	4.51	0.42	1.87e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs11112613	0.818	rs2374507	chr12:106009570	A/C	cg03607813	chr12:105948248	NA	0.97	5.3	0.48	7.57e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg23682913	chr1:2080710	PRKCZ	-0.61	-5.17	-0.47	1.28e-6	Height;
THYM	cis	rs7568458	0.905	rs6714709	chr2:85756375	C/G	cg17127132	chr2:85788382	GGCX	0.64	5.22	0.47	1.07e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs66823261	0.778	rs2906332	chr8:194943	C/T	cg27532244	chr8:182981	ZNF596;RPL23AP53	-0.81	-4.87	-0.45	4.51e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs17030434	0.654	rs28640133	chr4:154645926	T/A	cg14289246	chr4:154710475	SFRP2	-0.67	-4.71	-0.44	8.48e-6	Electrocardiographic conduction measures;
THYM	cis	rs1061377	1.000	rs7664078	chr4:39118203	A/T	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs7078219	0.965	rs10883358	chr10:101273857	C/T	cg23904955	chr10:101282759	NA	-0.44	-5.25	-0.47	9.32e-7	Dental caries;
THYM	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs870825	0.860	rs60523653	chr4:185604676	T/C	cg04058563	chr4:185651563	MLF1IP	1.0	7.42	0.61	4.93e-11	Blood protein levels;
THYM	cis	rs990171	1.000	rs917997	chr2:103070568	T/C	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.13	-0.47	1.5e-6	Lymphocyte counts;
THYM	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg14129053	chr2:1895732	MYT1L	-1.13	-4.49	-0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg10802521	chr3:52805072	NEK4	-0.75	-7.07	-0.59	2.65e-10	Bipolar disorder;
THYM	cis	rs9649213	0.574	rs3801251	chr7:98027618	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7552404	0.628	rs4949686	chr1:76473299	G/C	cg10523679	chr1:76189770	ACADM	0.85	6.09	0.53	2.41e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg10856724	chr12:34555212	NA	-0.83	-7.32	-0.6	7.93e-11	Morning vs. evening chronotype;
THYM	cis	rs10769966	0.515	rs2568069	chr11:8977707	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.57	5.49	0.49	3.29e-7	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs300703	0.719	rs385909	chr2:199678	A/G	cg21211680	chr2:198530	NA	1.15	6.94	0.58	4.7e-10	Blood protein levels;
THYM	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg14137381	chr5:502291	SLC9A3	-0.67	-4.68	-0.43	9.62e-6	Cystic fibrosis severity;
THYM	cis	rs72627123	1.000	rs72627129	chr14:74374805	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg12963246	chr6:28129442	ZNF389	0.81	6.75	0.57	1.19e-9	Parkinson's disease;
THYM	cis	rs747334	0.846	rs10881871	chr10:92722412	G/A	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg05425664	chr17:57184151	TRIM37	0.56	4.49	0.42	1.97e-5	Intelligence (multi-trait analysis);
THYM	cis	rs12935418	0.504	rs1549288	chr16:81060761	C/T	cg16651780	chr16:81037892	C16orf61	0.6	4.87	0.45	4.51e-6	Mean corpuscular volume;
THYM	trans	rs11186	0.556	rs72906307	chr2:189955684	G/C	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs11249608	0.636	rs13359572	chr5:178449276	T/C	cg01312482	chr5:178451176	ZNF879	-0.68	-5.27	-0.48	8.43e-7	Pubertal anthropometrics;
THYM	cis	rs9467711	0.659	rs36014129	chr6:25884519	G/A	cg16898833	chr6:26189333	HIST1H4D	1.33	4.6	0.43	1.32e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11031096	0.711	rs10767882	chr11:4205841	G/A	cg22027985	chr11:4115532	RRM1	-0.53	-4.91	-0.45	3.77e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs11018874	0.532	rs11018867	chr11:89862345	C/T	cg14505434	chr11:89522851	NA	0.66	4.69	0.43	9.03e-6	White blood cell types;
THYM	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg26384229	chr12:38710491	ALG10B	1.1	11.24	0.76	3.88e-19	Heart rate;
THYM	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg01416388	chr22:39784598	NA	-0.94	-9.28	-0.69	5.64e-15	Intelligence (multi-trait analysis);
THYM	cis	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg13443165	chr9:33130375	B4GALT1	-0.87	-7.99	-0.63	3.23e-12	IgG glycosylation;
THYM	cis	rs741677	0.663	rs405203	chr17:491009	A/G	cg15660573	chr17:549704	VPS53	0.71	5.56	0.5	2.52e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
THYM	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg15744005	chr10:104629667	AS3MT	-0.8	-7.36	-0.6	6.45e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4242434	0.787	rs1545837	chr8:22477807	T/C	cg14690197	chr8:22456421	C8orf58	0.54	4.69	0.43	8.98e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6593803	0.765	rs6701830	chr1:147170542	G/T	cg06627043	chr1:147838662	NA	-0.51	-4.94	-0.45	3.28e-6	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
THYM	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	5.51	0.49	3.1e-7	Tonsillectomy;
THYM	cis	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg08133631	chr1:26527909	CATSPER4	-0.59	-4.94	-0.45	3.38e-6	Obesity-related traits;
THYM	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg01819863	chr10:32635814	EPC1	1.04	6.58	0.56	2.51e-9	Sexual dysfunction (female);
THYM	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg21433313	chr16:3507492	NAT15	0.54	4.73	0.44	7.71e-6	Body mass index (adult);
THYM	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg06784218	chr1:46089804	CCDC17	0.3	4.63	0.43	1.18e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg25319279	chr11:5960081	NA	0.64	5.51	0.49	3.11e-7	DNA methylation (variation);
THYM	cis	rs713587	0.525	rs11675457	chr2:25079770	C/T	cg01884057	chr2:25150051	NA	0.64	6.06	0.53	2.73e-8	Body mass index in non-asthmatics;
THYM	cis	rs6732160	0.588	rs62151795	chr2:73376840	G/A	cg24220031	chr2:73402428	NA	-0.71	-5.79	-0.51	8.94e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs17443541	0.507	rs7562008	chr2:200454560	A/G	cg03741458	chr2:200468445	NA	-0.78	-5.63	-0.5	1.84e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3755605	0.802	rs2160901	chr3:169752951	C/T	cg18444028	chr3:169782040	GPR160	0.57	4.63	0.43	1.16e-5	Testicular germ cell tumor;
THYM	cis	rs2637266	0.626	rs846603	chr10:78570793	A/G	cg18941641	chr10:78392320	NA	-0.69	-5.37	-0.48	5.49e-7	Pulmonary function;
THYM	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg08901578	chr4:187885870	NA	-0.7	-6.86	-0.58	7.1e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2456568	0.709	rs7942444	chr11:93637160	G/A	cg26875233	chr11:93583750	C11orf90	0.52	5.78	0.51	9.42e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg10792982	chr14:105748885	BRF1	0.7	6.95	0.58	4.6e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs877529	0.683	rs139379	chr22:39525791	A/T	cg02523424	chr22:39548724	CBX7	-0.52	-4.54	-0.42	1.66e-5	Multiple myeloma;
THYM	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg05472934	chr7:22766657	IL6	-0.9	-7.24	-0.6	1.16e-10	Lung cancer;
THYM	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs4731207	0.564	rs10279816	chr7:124581580	T/C	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	trans	rs9951602	0.512	rs7240758	chr18:76650677	T/C	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs2932538	0.961	rs4838960	chr1:113163632	G/T	cg22162597	chr1:113214053	CAPZA1	-0.63	-5.21	-0.47	1.08e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs28647808	0.881	rs4246171	chr9:136264731	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs4660306	0.961	rs3748643	chr1:45965703	G/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.43	-0.49	4.37e-7	Homocysteine levels;
THYM	cis	rs4523957	0.583	rs2760741	chr17:2020443	C/T	cg16513277	chr17:2031491	SMG6	-0.96	-8.72	-0.67	9.17e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4363385	0.818	rs441229	chr1:153015059	A/C	cg13444842	chr1:152974279	SPRR3	-0.59	-4.81	-0.44	5.61e-6	Inflammatory skin disease;
THYM	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs7119	0.604	rs2271397	chr15:77907775	T/C	cg10437265	chr15:77819839	NA	-0.5	-4.99	-0.46	2.78e-6	Type 2 diabetes;
THYM	cis	rs1508086	0.641	rs13262826	chr8:57827380	C/T	cg13208732	chr8:57124347	CHCHD7;PLAG1	-0.7	-4.66	-0.43	1.05e-5	Hand grip strength;
THYM	cis	rs9534288	0.797	rs7328081	chr13:46611695	T/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs926938	0.618	rs6693491	chr1:115371061	A/G	cg12756093	chr1:115239321	AMPD1	-0.6	-4.91	-0.45	3.72e-6	Autism;
THYM	cis	rs7586879	1.000	rs1865687	chr2:25112885	G/A	cg01884057	chr2:25150051	NA	0.63	6.3	0.54	9.31e-9	Body mass index;
THYM	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg00129232	chr17:37814104	STARD3	-0.88	-6.68	-0.57	1.61e-9	Asthma;
THYM	cis	rs28595532	0.920	rs115706007	chr4:119733638	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg24803719	chr17:45855879	NA	0.6	6.26	0.54	1.08e-8	IgG glycosylation;
THYM	cis	rs2403083	0.584	rs4150942	chr8:86115686	G/A	cg13721134	chr8:86350390	CA3	0.47	4.61	0.43	1.27e-5	Plasma amyloid beta peptide concentrations (ABx-40);
THYM	cis	rs4074961	0.527	rs10908356	chr1:38038388	G/A	cg17933807	chr1:38061675	GNL2	1.09	14.67	0.83	3.78e-26	Axial length;
THYM	cis	rs3106136	0.527	rs2632411	chr4:95149434	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.57	-4.99	-0.46	2.73e-6	Capecitabine sensitivity;
THYM	cis	rs17030434	0.954	rs79908936	chr4:154749305	C/T	cg14289246	chr4:154710475	SFRP2	-0.87	-5.86	-0.52	6.66e-8	Electrocardiographic conduction measures;
THYM	cis	rs4792901	0.802	rs9893137	chr17:41590928	C/T	cg21940313	chr17:41620911	ETV4	-0.53	-5.03	-0.46	2.28e-6	Dupuytren's disease;
THYM	cis	rs61008539	0.741	rs11767322	chr7:867405	A/G	cg15782153	chr7:917662	C7orf20	0.51	5.2	0.47	1.13e-6	Perceived unattractiveness to mosquitoes;
THYM	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg17554472	chr22:41940697	POLR3H	-0.66	-4.6	-0.43	1.31e-5	Vitiligo;
THYM	cis	rs2085601	0.542	rs1533291	chr4:89964456	C/T	cg17769793	chr4:89976368	FAM13A	-0.59	-6.86	-0.58	6.96e-10	Hair greying;
THYM	cis	rs4792901	0.765	rs3809751	chr17:41559785	A/G	cg21940313	chr17:41620911	ETV4	-0.53	-5.03	-0.46	2.28e-6	Dupuytren's disease;
THYM	cis	rs11948739	0.610	rs6883635	chr5:130304613	C/T	cg08523029	chr5:130500466	HINT1	0.78	5.58	0.5	2.26e-7	Pediatric bone mineral content (hip);
THYM	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg13147721	chr7:65941812	NA	-0.73	-4.58	-0.43	1.42e-5	Diabetic kidney disease;
THYM	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg13683864	chr3:40499215	RPL14	-1.05	-11.77	-0.77	2.9e-20	Renal cell carcinoma;
THYM	cis	rs921968	0.565	rs7599365	chr2:219620566	G/A	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs763014	0.833	rs3743904	chr16:632767	A/G	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs2562456	0.917	rs2681376	chr19:21715525	T/G	cg21751540	chr19:21541537	ZNF738	0.65	4.48	0.42	2.12e-5	Pain;
THYM	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.12	7.7	0.62	1.28e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2404602	0.735	rs1607015	chr15:76702429	C/T	cg23625390	chr15:77176239	SCAPER	-0.68	-4.75	-0.44	7.34e-6	Blood metabolite levels;
THYM	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs6430585	0.528	rs309142	chr2:136715324	T/C	cg04750100	chr2:136595281	LCT	0.53	5.67	0.5	1.53e-7	Corneal structure;
THYM	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg02221750	chr19:17393354	ANKLE1	-0.95	-8.56	-0.66	1.95e-13	Systemic lupus erythematosus;
THYM	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10463554	0.963	rs26253	chr5:102556967	T/C	cg23492399	chr5:102201601	PAM	-0.68	-5.29	-0.48	7.85e-7	Parkinson's disease;
THYM	cis	rs1691799	0.799	rs10784525	chr12:66772766	G/A	cg16791601	chr12:66731901	HELB	-0.77	-7.16	-0.59	1.66e-10	White blood cell count (basophil);
THYM	cis	rs988913	0.706	rs10755776	chr6:54938402	A/C	cg18532076	chr6:54711417	FAM83B	0.49	4.67	0.43	9.72e-6	Menarche (age at onset);
THYM	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg02527881	chr3:46936655	PTH1R	-0.61	-5.7	-0.51	1.33e-7	Colorectal cancer;
THYM	cis	rs2294693	0.541	rs11756247	chr6:40944111	A/G	cg21128951	chr6:40996213	UNC5CL	0.64	4.59	0.43	1.37e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg23281280	chr6:28129359	ZNF389	0.61	4.74	0.44	7.58e-6	Parkinson's disease;
THYM	cis	rs2073300	1.000	rs6048811	chr20:23446719	G/C	cg12062639	chr20:23401060	NAPB	1.32	6.15	0.53	1.81e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg18876405	chr7:65276391	NA	0.64	5.57	0.5	2.33e-7	Aortic root size;
THYM	cis	rs791888	1.000	rs2762521	chr10:89414923	T/A	cg10377144	chr10:89419177	PAPSS2	-0.4	-6.5	-0.55	3.68e-9	Magnesium levels;
THYM	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg03929089	chr4:120376271	NA	-1.01	-13.71	-0.82	3.1e-24	Height;
THYM	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg12311346	chr5:56204834	C5orf35	-0.83	-6.19	-0.54	1.52e-8	Initial pursuit acceleration;
THYM	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-5.53	-0.49	2.8e-7	Morning vs. evening chronotype;
THYM	cis	rs9790314	0.846	rs1478568	chr3:161014276	C/T	cg03342759	chr3:160939853	NMD3	-0.94	-8.6	-0.66	1.59e-13	Morning vs. evening chronotype;
THYM	cis	rs919433	0.680	rs7605813	chr2:198375329	C/G	cg05783139	chr2:198650985	BOLL	0.62	4.82	0.44	5.36e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg13683864	chr3:40499215	RPL14	0.88	8.71	0.67	9.58e-14	Renal cell carcinoma;
THYM	cis	rs4824093	0.610	rs13340054	chr22:50311726	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.01	-4.62	-0.43	1.19e-5	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs28595532	0.920	rs116305850	chr4:119779892	A/G	cg21605333	chr4:119757512	SEC24D	1.61	6.06	0.53	2.69e-8	Cannabis dependence symptom count;
THYM	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg18681998	chr4:17616180	MED28	0.79	6.7	0.57	1.49e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6032067	0.777	rs73907811	chr20:43801395	T/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.41	-0.65	4.05e-13	Blood protein levels;
THYM	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg12011299	chr4:100065546	ADH4	0.81	8.21	0.64	1.1e-12	Alcohol dependence;
THYM	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs950776	0.667	rs57728226	chr15:78929350	G/C	cg06917634	chr15:78832804	PSMA4	0.65	4.77	0.44	6.62e-6	Sudden cardiac arrest;
THYM	cis	rs2832191	0.967	rs2251377	chr21:30530599	T/C	cg08807101	chr21:30365312	RNF160	0.73	5.51	0.49	3.1e-7	Dental caries;
THYM	cis	rs8006385	0.764	rs3814827	chr14:93535197	G/A	cg24044707	chr14:94291526	NA	0.47	4.64	0.43	1.13e-5	Platelet count;
THYM	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg26384229	chr12:38710491	ALG10B	-0.71	-6.55	-0.56	2.88e-9	Heart rate;
THYM	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11563648	0.553	rs6467123	chr7:127015459	A/G	cg23081781	chr7:127225937	GCC1	-0.35	-4.78	-0.44	6.41e-6	Resting heart rate;
THYM	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg10047753	chr17:41438598	NA	1.21	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg27588902	chr6:42928151	GNMT	-0.53	-5.1	-0.46	1.7e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs860818	1.000	rs858297	chr7:23244961	C/G	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs12216545	0.737	rs4339548	chr7:150229315	G/T	cg08960815	chr7:150264767	GIMAP4	-0.89	-8.27	-0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg22841779	chr14:105766346	BRF1	-0.46	-5.72	-0.51	1.25e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs28595532	0.920	rs115853212	chr4:119765354	C/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-5.45	-0.49	4.04e-7	Gut microbiome composition (summer);
THYM	cis	rs7769051	0.711	rs9493436	chr6:133088275	T/C	cg22852734	chr6:133119734	C6orf192	1.27	7.83	0.63	6.83e-12	Type 2 diabetes nephropathy;
THYM	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg08847533	chr14:75593920	NEK9	-0.99	-10.35	-0.73	2.98e-17	Height;
THYM	cis	rs3750965	0.919	rs12280942	chr11:68859683	A/G	cg06818126	chr11:68850279	TPCN2	0.65	4.58	0.43	1.41e-5	Hair color;
THYM	cis	rs1395	0.778	rs17005956	chr2:27451099	C/T	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.52	-0.49	2.95e-7	Blood metabolite levels;
THYM	trans	rs8073060	0.544	rs7210966	chr17:33986334	G/C	cg19694781	chr19:47549865	TMEM160	-1.06	-9.08	-0.68	1.54e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg25566285	chr7:158114605	PTPRN2	0.89	10.22	0.72	5.47e-17	Calcium levels;
THYM	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg20290983	chr6:43655470	MRPS18A	1.44	15.94	0.85	1.35e-28	IgG glycosylation;
THYM	cis	rs3772130	0.923	rs34865234	chr3:121560995	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.81	5.08	0.46	1.89e-6	Cognitive performance;
THYM	cis	rs2732480	0.557	rs2732454	chr12:48719677	T/C	cg21466736	chr12:48725269	NA	-0.54	-4.97	-0.45	2.95e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg24675658	chr1:53192096	ZYG11B	0.57	4.7	0.43	8.7e-6	Monocyte count;
THYM	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.88	5.64	0.5	1.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4731207	0.672	rs3213667	chr7:124480869	T/C	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	trans	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg13615516	chr5:77269221	NA	0.83	7.44	0.61	4.57e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7561149	0.902	rs3769858	chr2:179667806	C/T	cg12089249	chr2:179345200	MIR548N;PLEKHA3	0.65	4.49	0.42	2.02e-5	QT interval;
THYM	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg09549813	chr16:4587862	C16orf5	-0.57	-6.41	-0.55	5.48e-9	Schizophrenia;
THYM	cis	rs2219968	0.525	rs6989539	chr8:78873431	A/T	cg00738934	chr8:78996279	NA	0.61	4.93	0.45	3.5e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2412459	0.635	rs518802	chr15:40254613	G/T	cg16127683	chr15:40268777	EIF2AK4	0.53	4.63	0.43	1.16e-5	Response to haloperidol in psychosis;
THYM	cis	rs2066819	0.901	rs773665	chr12:56717466	C/T	cg26714650	chr12:56694279	CS	1.34	7.72	0.62	1.17e-11	Psoriasis vulgaris;
THYM	cis	rs7404928	0.579	rs12933794	chr16:23934299	C/G	cg26685404	chr16:23957272	PRKCB	-0.58	-6.53	-0.56	3.16e-9	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs4474465	0.790	rs4944206	chr11:78263127	T/C	cg19901956	chr11:77921274	USP35	0.61	4.64	0.43	1.1e-5	Alzheimer's disease (survival time);
THYM	cis	rs35123781	0.696	rs356433	chr5:139071193	C/T	cg10513866	chr5:139070639	NA	0.53	4.54	0.42	1.62e-5	Schizophrenia;
THYM	trans	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg10856724	chr12:34555212	NA	0.79	6.92	0.58	5.22e-10	Morning vs. evening chronotype;
THYM	trans	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs3020333	0.721	rs1293936	chr6:152017691	T/G	cg22157087	chr6:152012887	ESR1	0.53	6.19	0.54	1.55e-8	Total body bone mineral density;
THYM	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg22508957	chr16:3507546	NAT15	-0.49	-5.17	-0.47	1.28e-6	Body mass index (adult);
THYM	cis	rs4563143	0.663	rs10417671	chr19:29235335	T/C	cg12667521	chr19:29218732	NA	0.79	6.66	0.56	1.73e-9	Methadone dose in opioid dependence;
THYM	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg03407747	chr17:6899364	ALOX12	0.79	10.32	0.73	3.36e-17	Tonsillectomy;
THYM	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg24733560	chr20:60626293	TAF4	0.62	6.64	0.56	1.96e-9	Body mass index;
THYM	cis	rs12509991	0.582	rs4834088	chr4:127039606	G/T	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs747334	0.659	rs9664170	chr10:92692047	T/A	cg07620928	chr10:92689909	NA	0.54	5.04	0.46	2.17e-6	Fibroblast growth factor basic levels;
THYM	cis	rs1160297	0.609	rs10168840	chr2:53084498	A/G	cg07782112	chr2:53107842	NA	0.76	6.2	0.54	1.47e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg05368731	chr17:41323189	NBR1	1.25	11.64	0.77	5.42e-20	Menopause (age at onset);
THYM	cis	rs960902	0.747	rs7593333	chr2:37725712	A/G	cg25341268	chr2:37734390	NA	0.56	4.72	0.44	8.06e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg00255919	chr5:131827918	IRF1	-0.45	-5.04	-0.46	2.26e-6	Asthma (sex interaction);
THYM	cis	rs732765	0.644	rs2268613	chr14:75408500	G/A	cg15890469	chr14:75408846	PGF	0.67	4.61	0.43	1.26e-5	Non-small cell lung cancer;
THYM	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06850241	chr22:41845214	NA	-0.58	-5.19	-0.47	1.18e-6	Vitiligo;
THYM	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.76	-0.44	6.96e-6	Type 2 diabetes;
THYM	cis	rs4430311	0.723	rs12144546	chr1:243883877	T/G	cg25706552	chr1:244017396	NA	-0.55	-4.68	-0.43	9.36e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg06623918	chr6:96969491	KIAA0776	1.09	10.37	0.73	2.65e-17	Headache;
THYM	cis	rs3820068	0.608	rs12091644	chr1:16044945	G/A	cg27534772	chr1:16042836	PLEKHM2	0.51	5.25	0.47	9.14e-7	Systolic blood pressure;
THYM	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg20295408	chr7:1910781	MAD1L1	-0.61	-4.85	-0.45	4.75e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6430585	0.583	rs4988145	chr2:136632300	A/C	cg20242066	chr2:136595261	LCT	0.52	4.95	0.45	3.2e-6	Corneal structure;
THYM	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs10857712	0.851	rs56153177	chr10:135216975	G/A	cg19904058	chr10:135279010	LOC619207	-0.56	-5.39	-0.48	5.19e-7	Systemic lupus erythematosus;
THYM	cis	rs67072384	0.892	rs72964172	chr11:72436436	G/A	cg01380194	chr11:72452482	ARAP1	-0.83	-4.59	-0.43	1.35e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs13102973	0.867	rs11722699	chr4:135907871	G/T	cg14419869	chr4:135874104	NA	0.82	6.89	0.58	6.03e-10	Subjective well-being;
THYM	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg18252515	chr7:66147081	NA	1.37	8.05	0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs9788682	0.748	rs569207	chr15:78873119	A/G	cg18825076	chr15:78729989	IREB2	-0.6	-4.89	-0.45	4.18e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs889398	0.967	rs244417	chr16:69663519	T/C	cg09409435	chr16:70099608	PDXDC2	-0.63	-4.92	-0.45	3.64e-6	Body mass index;
THYM	cis	rs912057	0.901	rs744056	chr6:6733540	A/G	cg06612196	chr6:6737390	NA	0.62	7.57	0.61	2.38e-11	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs2742234	0.590	rs2505557	chr10:43666016	C/T	cg06632098	chr10:43605906	RET	-0.8	-5.02	-0.46	2.43e-6	Hirschsprung disease;
THYM	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg05738196	chr6:26577821	NA	0.79	7.01	0.58	3.44e-10	Intelligence (multi-trait analysis);
THYM	cis	rs750460	0.844	rs28617339	chr15:74223571	T/C	cg23484268	chr15:74220776	LOXL1	0.42	4.61	0.43	1.24e-5	Height;
THYM	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg05768032	chr16:30646687	NA	0.56	5.65	0.5	1.65e-7	Multiple myeloma;
THYM	cis	rs2273669	0.667	rs11153154	chr6:109357324	G/T	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs4455778	0.538	rs6583514	chr7:49123556	T/C	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs17125944	0.686	rs7144029	chr14:53333616	G/T	cg00686598	chr14:53173677	PSMC6	-1.08	-4.83	-0.44	5.23e-6	Alzheimer's disease (late onset);
THYM	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6988636	0.710	rs62521805	chr8:124159200	C/T	cg23067535	chr8:124195133	FAM83A	-0.99	-4.82	-0.44	5.52e-6	Urinary uromodulin levels;
THYM	cis	rs13102973	0.965	rs28826933	chr4:135876644	T/A	cg14419869	chr4:135874104	NA	-0.82	-7.97	-0.63	3.53e-12	Subjective well-being;
THYM	cis	rs10911251	0.546	rs12034436	chr1:183114797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.64	0.43	1.11e-5	Colorectal cancer;
THYM	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg14972814	chr11:95582409	MTMR2	-0.56	-5.03	-0.46	2.31e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9560113	0.580	rs9560116	chr13:112193731	G/A	cg14154082	chr13:112174009	NA	0.53	4.61	0.43	1.27e-5	Menarche (age at onset);
THYM	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg06009448	chr7:1102226	C7orf50	0.48	5.01	0.46	2.55e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4940575	0.786	rs8088100	chr18:60840079	G/T	cg25271770	chr18:61057090	VPS4B	0.82	4.92	0.45	3.69e-6	Breast cancer;
THYM	trans	rs9951602	0.512	rs8089247	chr18:76651467	C/A	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs950881	0.932	rs72823646	chr2:102954213	G/A	cg20060108	chr2:102954350	IL1RL1	0.85	4.68	0.43	9.48e-6	Allergy;
THYM	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg10802521	chr3:52805072	NEK4	-0.73	-6.21	-0.54	1.42e-8	Bipolar disorder;
THYM	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06850241	chr22:41845214	NA	0.49	4.62	0.43	1.21e-5	Vitiligo;
THYM	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg17264618	chr3:40429014	ENTPD3	0.54	5.19	0.47	1.17e-6	Renal cell carcinoma;
THYM	cis	rs9534288	0.797	rs9534283	chr13:46589256	C/A	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	7.91	0.63	4.71e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.16	9.2	0.69	8.54e-15	Cognitive test performance;
THYM	cis	rs9876781	1.000	rs6794875	chr3:48455626	A/G	cg06066452	chr3:48470258	PLXNB1	0.27	4.79	0.44	6.02e-6	Longevity;
THYM	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg13683864	chr3:40499215	RPL14	-1.05	-11.49	-0.76	1.13e-19	Renal cell carcinoma;
THYM	cis	rs4499344	0.921	rs752718	chr19:33086262	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.77	-5.45	-0.49	3.92e-7	Mean platelet volume;
THYM	cis	rs3135724	0.951	rs17102287	chr10:123350191	T/C	cg15049101	chr10:123353889	FGFR2	0.73	4.68	0.43	9.62e-6	Estrogen receptor status in HER2 negative breast cancer;
THYM	cis	rs2188554	0.740	rs213944	chr7:117190066	C/T	cg25509184	chr7:117119382	CFTR	0.55	4.7	0.43	8.65e-6	Esophageal adenocarcinoma;
THYM	cis	rs9486719	1.000	rs12208449	chr6:96903253	A/G	cg18709589	chr6:96969512	KIAA0776	0.68	4.55	0.42	1.58e-5	Migraine;Coronary artery disease;
THYM	cis	rs6500395	0.962	rs9937623	chr16:48571590	A/T	cg04672837	chr16:48644449	N4BP1	-0.47	-4.46	-0.42	2.23e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs6430585	0.583	rs2839740	chr2:136648883	G/T	cg04750100	chr2:136595281	LCT	0.56	4.96	0.45	3.13e-6	Corneal structure;
THYM	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg02574844	chr11:5959923	NA	-0.51	-4.46	-0.42	2.27e-5	DNA methylation (variation);
THYM	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	5.49	0.49	3.37e-7	Platelet count;
THYM	cis	rs9796	0.621	rs9972349	chr15:41491656	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.59	-4.83	-0.44	5.13e-6	Menopause (age at onset);
THYM	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg16680214	chr1:154839983	KCNN3	-0.51	-5.67	-0.5	1.51e-7	Prostate cancer;
THYM	cis	rs7106204	0.748	rs11027755	chr11:24203857	C/T	ch.11.24196551F	chr11:24239977	NA	0.97	6.93	0.58	5.07e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg07167872	chr1:205819463	PM20D1	-0.66	-5.57	-0.5	2.4e-7	Menarche (age at onset);
THYM	cis	rs9549367	0.789	rs35569628	chr13:113872712	T/C	cg18105134	chr13:113819100	PROZ	-0.99	-9.17	-0.69	9.65e-15	Platelet distribution width;
THYM	cis	rs7264396	0.563	rs2425089	chr20:34304036	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.69	-0.43	9.19e-6	Total cholesterol levels;
THYM	cis	rs4866334	1.000	rs74720949	chr5:18503571	T/C	cg24599790	chr5:18972260	NA	-1.15	-4.67	-0.43	9.77e-6	IgG glycosylation;
THYM	cis	rs9790314	0.846	rs12495310	chr3:160970956	T/A	cg03342759	chr3:160939853	NMD3	-0.95	-9.47	-0.7	2.2e-15	Morning vs. evening chronotype;
THYM	cis	rs490234	0.729	rs10819050	chr9:128237178	G/T	cg14078157	chr9:128172775	NA	-0.69	-5.35	-0.48	6.13e-7	Mean arterial pressure;
THYM	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.68	5.33	0.48	6.56e-7	Tonsillectomy;
THYM	cis	rs420259	0.516	rs2106458	chr16:23531431	G/A	cg00143387	chr16:23521605	GGA2	-0.72	-5.18	-0.47	1.26e-6	Bipolar disorder;
THYM	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06634786	chr22:41940651	POLR3H	-0.77	-5.74	-0.51	1.14e-7	Vitiligo;
THYM	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg19016782	chr12:123741754	C12orf65	-0.7	-4.59	-0.43	1.35e-5	Neutrophil percentage of white cells;
THYM	cis	rs1747683	0.932	rs10752297	chr10:13375906	T/C	cg00142036	chr10:13388442	SEPHS1	-0.28	-4.99	-0.46	2.75e-6	IgG glycosylation;
THYM	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg23711669	chr6:146136114	FBXO30	0.93	9.09	0.68	1.46e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.02	6.88	0.58	6.27e-10	Smoking behavior;
THYM	cis	rs9970807	0.636	rs10888971	chr1:56932261	T/C	cg11959316	chr1:57001742	PPAP2B	-0.63	-4.88	-0.45	4.29e-6	Myocardial infarction;Coronary artery disease;
THYM	cis	rs7681440	0.583	rs2583988	chr4:90760828	C/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.33	-0.48	6.7e-7	Dementia with Lewy bodies;
THYM	cis	rs2279817	1.000	rs905389	chr1:18021406	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.78	5.09	0.46	1.77e-6	Neuroticism;
THYM	trans	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Bladder cancer;
THYM	cis	rs2463822	0.614	rs117699706	chr11:62161659	T/C	cg06239285	chr11:62104954	ASRGL1	-1.4	-6.65	-0.56	1.86e-9	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4808199	0.895	rs8105984	chr19:19374068	T/C	cg03709012	chr19:19516395	GATAD2A	1.18	6.78	0.57	1.03e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs10089	0.953	rs758179	chr5:127354424	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.94	6.29	0.54	9.62e-9	Ileal carcinoids;
THYM	cis	rs11225247	1.000	rs11547916	chr11:102267820	C/T	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg19729930	chr2:74357872	NA	1.28	12.98	0.8	9.16e-23	Gestational age at birth (maternal effect);
THYM	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.68	-5.66	-0.5	1.6e-7	Renal function-related traits (BUN);
THYM	cis	rs6430585	0.583	rs78364332	chr2:136640101	T/C	cg23851026	chr2:136556271	LCT	0.8	7.65	0.62	1.64e-11	Corneal structure;
THYM	cis	rs763014	0.898	rs2384978	chr16:625384	T/C	cg09263875	chr16:632152	PIGQ	0.69	5.85	0.51	7.08e-8	Height;
THYM	trans	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17712092	chr4:129076599	LARP1B	0.92	7.76	0.62	9.49e-12	Eosinophil percentage of white cells;
THYM	cis	rs7200543	0.848	rs62039480	chr16:15137450	G/A	cg01933576	chr16:15083564	PDXDC1	-0.98	-8.5	-0.66	2.66e-13	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs9393777	0.720	rs56401801	chr6:27301512	T/A	cg23161317	chr6:28129485	ZNF389	1.17	4.61	0.43	1.25e-5	Intelligence (multi-trait analysis);
THYM	cis	rs34912216	0.580	rs12701399	chr7:4131943	C/A	cg03141780	chr7:4150753	SDK1	0.68	5.17	0.47	1.29e-6	Motion sickness;
THYM	trans	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg25214090	chr10:38739885	LOC399744	0.87	7.35	0.6	6.89e-11	Corneal astigmatism;
THYM	cis	rs2439831	0.850	rs28413881	chr15:44174099	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	4.76	0.44	7.06e-6	Lung cancer in ever smokers;
THYM	cis	rs2668423	1.000	rs2526136	chr19:1368398	A/G	cg02639931	chr19:1387894	NDUFS7	-0.51	-6.02	-0.53	3.25e-8	Nonalcoholic fatty liver disease;
THYM	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg03476357	chr21:30257390	N6AMT1	-0.68	-5.09	-0.46	1.78e-6	Cognitive test performance;
THYM	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg05662444	chr5:154026397	NA	0.55	4.83	0.44	5.29e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs11771526	0.901	rs62457470	chr7:32303516	A/G	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs2404602	0.735	rs11635463	chr15:76762986	C/T	cg23482746	chr15:76478102	C15orf27	0.47	4.46	0.42	2.27e-5	Blood metabolite levels;
THYM	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg10334053	chr1:2078117	PRKCZ	-0.48	-4.99	-0.46	2.76e-6	Height;
THYM	cis	rs2273669	0.504	rs77373614	chr6:109418075	T/C	cg17117243	chr6:109341365	SESN1	-0.92	-5.47	-0.49	3.63e-7	Prostate cancer;
THYM	cis	rs12681287	0.608	rs13272148	chr8:87481853	T/C	cg27223183	chr8:87520930	FAM82B	-0.67	-5.05	-0.46	2.17e-6	Caudate activity during reward;
THYM	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.5	-0.73	1.45e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06481639	chr22:41940642	POLR3H	-0.8	-5.39	-0.48	5.08e-7	Vitiligo;
THYM	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.64	-0.5	1.73e-7	Menopause (age at onset);
THYM	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg09307838	chr4:120376055	NA	-0.7	-4.74	-0.44	7.55e-6	Corneal astigmatism;
THYM	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg20283391	chr11:68216788	NA	-0.68	-5.11	-0.46	1.69e-6	Total body bone mineral density;
THYM	cis	rs9326248	0.516	rs6589577	chr11:116749977	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.92	5.08	0.46	1.85e-6	Blood protein levels;
THYM	cis	rs3126085	0.825	rs11204938	chr1:152193990	A/G	cg26020982	chr1:152196106	HRNR	0.38	5.14	0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg00852783	chr1:26633632	UBXN11	0.68	5.61	0.5	1.97e-7	Granulocyte percentage of myeloid white cells;
THYM	cis	rs1129187	0.748	rs6458312	chr6:42904274	G/T	cg21280719	chr6:42927975	GNMT	-0.51	-6.73	-0.57	1.28e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2219968	0.887	rs67368685	chr8:78966267	A/G	cg00738934	chr8:78996279	NA	0.91	9.74	0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg03188948	chr7:1209495	NA	0.92	5.37	0.48	5.63e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1922291	0.752	rs10167431	chr2:102852802	T/C	cg13315345	chr2:102803985	IL1RL2	0.62	6.75	0.57	1.15e-9	Blood protein levels;
THYM	cis	rs6531656	0.796	rs337609	chr4:38662059	A/C	cg24279243	chr4:38676559	KLF3	0.81	5.49	0.49	3.3e-7	Lymphocyte counts;
THYM	cis	rs7100689	0.646	rs7081889	chr10:82165427	C/A	cg01528321	chr10:82214614	TSPAN14	0.92	7.68	0.62	1.42e-11	Post bronchodilator FEV1;
THYM	cis	rs9660180	0.868	rs12567685	chr1:1806647	T/C	cg23982607	chr1:1823379	GNB1	-0.92	-9.7	-0.71	7.17e-16	Body mass index;
THYM	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg05973401	chr12:123451056	ABCB9	0.68	4.55	0.42	1.58e-5	Neutrophil percentage of white cells;
THYM	cis	rs926938	0.560	rs360610	chr1:115393915	T/C	cg12756093	chr1:115239321	AMPD1	0.59	4.67	0.43	9.8e-6	Autism;
THYM	cis	rs857228	1.000	rs857228	chr14:98670158	G/T	cg13130031	chr14:99584939	NA	-0.34	-4.58	-0.43	1.41e-5	Sexual dysfunction (SSRI/SNRI-related);
THYM	cis	rs10489202	0.908	rs6692861	chr1:168079553	G/C	cg24449463	chr1:168025552	DCAF6	-0.71	-5.34	-0.48	6.46e-7	Schizophrenia;
THYM	cis	rs7166081	0.738	rs28399271	chr15:67710011	G/A	cg24579218	chr15:68104479	NA	-0.7	-6.68	-0.57	1.59e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs6700896	0.966	rs4655557	chr1:66080787	T/C	cg04111102	chr1:66153794	NA	0.49	4.49	0.42	2.02e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg10856724	chr12:34555212	NA	-0.89	-8.35	-0.65	5.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6995541	0.529	rs11776674	chr8:10689632	G/A	cg13457217	chr8:10683266	MIR1322;PINX1	-0.67	-5.02	-0.46	2.39e-6	Triglyceride levels;
THYM	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg25358565	chr5:93447407	FAM172A	1.39	9.8	0.71	4.44e-16	Diabetic retinopathy;
THYM	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.66	-5.48	-0.49	3.42e-7	Blood metabolite levels;
THYM	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg11752832	chr7:134001865	SLC35B4	0.68	4.93	0.45	3.53e-6	Mean platelet volume;
THYM	cis	rs490234	0.841	rs10123054	chr9:128452054	C/T	cg14078157	chr9:128172775	NA	-0.63	-4.92	-0.45	3.64e-6	Mean arterial pressure;
THYM	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg26384229	chr12:38710491	ALG10B	0.73	5.4	0.48	5.01e-7	Morning vs. evening chronotype;
THYM	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg24530246	chr3:53118167	NA	-0.82	-4.7	-0.43	8.91e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg09737314	chr17:6899359	ALOX12	-0.81	-10.91	-0.75	1.91e-18	Tonsillectomy;
THYM	cis	rs2811415	0.597	rs10934845	chr3:127763859	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs35123781	0.502	rs195674	chr5:138927219	G/A	cg08720517	chr5:138729919	LOC389333	0.56	4.64	0.43	1.13e-5	Schizophrenia;
THYM	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs9527	0.590	rs12355120	chr10:104852166	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs7828089	0.967	rs7828414	chr8:22264585	T/C	cg13512537	chr8:22265999	SLC39A14	-0.61	-5.13	-0.47	1.55e-6	Verbal declarative memory;
THYM	cis	rs9733	0.544	rs72700902	chr1:150633347	C/T	cg10589385	chr1:150898437	SETDB1	0.66	5.58	0.5	2.27e-7	Tonsillectomy;
THYM	cis	rs921665	0.749	rs921664	chr2:3174585	C/T	cg16434511	chr2:3151078	NA	-0.85	-5.0	-0.46	2.63e-6	World class endurance athleticism;
THYM	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg10862848	chr6:42927986	GNMT	-0.56	-7.39	-0.6	5.62e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1885364	1.000	rs1885364	chr22:28094845	A/G	cg17187762	chr22:28070120	NA	0.39	4.67	0.43	9.73e-6	Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion);
THYM	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg27034606	chr17:28928453	LRRC37B2	0.81	5.38	0.48	5.32e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs28785552	0.765	rs28850924	chr19:53234323	T/G	cg10871876	chr19:53194124	ZNF83	0.8	6.81	0.57	8.66e-10	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.88	-8.43	-0.65	3.69e-13	Lung cancer;
THYM	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg11789530	chr4:8429930	ACOX3	-0.7	-5.43	-0.49	4.36e-7	Response to antineoplastic agents;
THYM	cis	rs12612325	1.000	rs12621139	chr2:119632724	G/A	cg03693553	chr2:120130028	DBI	0.57	4.47	0.42	2.13e-5	Total body bone mineral density;
THYM	cis	rs1062746	0.557	rs35441225	chr16:87335498	C/A	cg27119004	chr16:87376851	FBXO31	0.5	4.75	0.44	7.29e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs1403694	0.695	rs3821815	chr3:186434262	A/G	cg12454167	chr3:186435060	KNG1	0.51	7.05	0.59	2.86e-10	Blood protein levels;
THYM	cis	rs3820068	0.608	rs7552400	chr1:16035892	A/G	cg27534772	chr1:16042836	PLEKHM2	0.51	5.25	0.47	9.14e-7	Systolic blood pressure;
THYM	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg17063962	chr7:91808500	NA	1.16	13.11	0.8	4.9e-23	Breast cancer;
THYM	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03452623	chr4:187889614	NA	-1.19	-19.33	-0.89	1.1e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4654899	0.680	rs12407731	chr1:21254789	C/T	cg01072550	chr1:21505969	NA	-0.72	-6.75	-0.57	1.17e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs7772486	0.875	rs2777477	chr6:146305491	A/G	cg23711669	chr6:146136114	FBXO30	0.89	8.8	0.67	5.96e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg21475434	chr5:93447410	FAM172A	0.85	5.45	0.49	3.89e-7	Diabetic retinopathy;
THYM	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs4919694	0.572	rs12255989	chr10:104867206	C/T	cg04362960	chr10:104952993	NT5C2	0.97	6.41	0.55	5.51e-9	Arsenic metabolism;
THYM	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg17294928	chr15:75287854	SCAMP5	-0.98	-5.33	-0.48	6.65e-7	Lung cancer;
THYM	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg08305652	chr11:111469057	NA	-0.53	-4.6	-0.43	1.29e-5	Primary sclerosing cholangitis;
THYM	cis	rs12149862	1.000	rs7184131	chr16:69470711	G/A	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg14784868	chr12:69753453	YEATS4	1.13	12.35	0.79	1.8e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg02038168	chr22:39784481	NA	-0.57	-4.45	-0.42	2.36e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4455778	0.580	rs4357241	chr7:49089468	A/G	cg26309511	chr7:48887640	NA	0.68	5.94	0.52	4.63e-8	Lung cancer in never smokers;
THYM	cis	rs4378999	0.528	rs4485709	chr3:50776497	G/T	cg27233566	chr3:49894142	TRAIP	0.77	4.47	0.42	2.16e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs1403694	0.966	rs9869244	chr3:186437554	A/T	cg12454167	chr3:186435060	KNG1	0.45	6.0	0.52	3.58e-8	Blood protein levels;
THYM	cis	rs1986734	0.560	rs4859683	chr4:77419073	C/T	cg20311846	chr4:77356250	SHROOM3	-0.41	-4.55	-0.42	1.6e-5	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
THYM	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg01699819	chr7:1052092	C7orf50	-0.78	-6.76	-0.57	1.09e-9	Bronchopulmonary dysplasia;
THYM	cis	rs977987	0.778	rs4887821	chr16:75398574	G/A	cg03315344	chr16:75512273	CHST6	0.74	6.13	0.53	2.02e-8	Dupuytren's disease;
THYM	cis	rs12594515	1.000	rs8031128	chr15:45988528	C/G	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs4280164	0.551	rs882726	chr14:24797997	C/A	cg22990158	chr14:24802150	ADCY4	0.59	5.09	0.46	1.82e-6	Parent of origin effect on language impairment (paternal);
THYM	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg04398451	chr17:18023971	MYO15A	-0.9	-8.4	-0.65	4.31e-13	Total body bone mineral density;
THYM	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	cis	rs5771069	0.896	rs137862	chr22:50446550	C/A	cg27467552	chr22:50353597	PIM3	-0.44	-4.67	-0.43	9.85e-6	Ulcerative colitis;
THYM	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.7	6.48	0.55	4.13e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs9419702	0.639	rs9419624	chr10:133534822	G/A	cg23460707	chr10:133558971	NA	0.44	4.55	0.42	1.58e-5	Survival in rectal cancer;
THYM	cis	rs9810089	0.903	rs10935185	chr3:136290529	C/G	cg12473912	chr3:136751656	NA	0.62	5.22	0.47	1.05e-6	Gestational age at birth (child effect);
THYM	cis	rs12935418	0.616	rs2549863	chr16:81029367	C/G	cg16651780	chr16:81037892	C16orf61	-0.81	-6.26	-0.54	1.09e-8	Mean corpuscular volume;
THYM	cis	rs4792901	0.802	rs58141510	chr17:41586475	C/T	cg21940313	chr17:41620911	ETV4	-0.54	-5.13	-0.47	1.5e-6	Dupuytren's disease;
THYM	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg10760299	chr15:45669010	GATM	0.76	5.72	0.51	1.23e-7	Homoarginine levels;
THYM	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg17480646	chr11:65405466	SIPA1	-0.92	-8.37	-0.65	4.97e-13	Acne (severe);
THYM	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg00814883	chr7:100076585	TSC22D4	-0.92	-5.72	-0.51	1.25e-7	Platelet count;
THYM	cis	rs7043114	0.507	rs10992291	chr9:95033009	T/C	cg14631576	chr9:95140430	CENPP	-0.85	-9.0	-0.68	2.26e-14	Height;
THYM	cis	rs6450176	0.830	rs7718193	chr5:53291591	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-6.6	-0.56	2.31e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs6032067	0.929	rs36032462	chr20:43873088	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.71	-7.45	-0.61	4.33e-11	Blood protein levels;
THYM	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.25	-10.36	-0.73	2.75e-17	Platelet count;
THYM	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg16586182	chr3:47516702	SCAP	0.65	5.53	0.49	2.84e-7	Colorectal cancer;
THYM	cis	rs782590	0.818	rs2627765	chr2:55883317	G/T	cg18811423	chr2:55921094	PNPT1	0.72	6.66	0.56	1.75e-9	Metabolic syndrome;
THYM	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg18301423	chr5:131593218	PDLIM4	0.5	4.7	0.43	8.95e-6	Acylcarnitine levels;
THYM	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs240764	0.717	rs6916468	chr6:101160325	G/C	cg21058520	chr6:100914733	NA	0.57	4.92	0.45	3.69e-6	Neuroticism;
THYM	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg05457628	chr5:178986728	RUFY1	0.55	5.12	0.46	1.61e-6	Lung cancer;
THYM	cis	rs3849570	1.000	rs9818006	chr3:81828230	A/C	cg07356753	chr3:81810745	GBE1	-0.74	-5.42	-0.49	4.57e-7	Waist circumference;Body mass index;
THYM	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg12310025	chr6:25882481	NA	-0.91	-8.33	-0.65	5.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg14500267	chr11:67383377	NA	-0.77	-6.47	-0.55	4.33e-9	Mean corpuscular volume;
THYM	cis	rs4237845	0.773	rs6650218	chr12:58289078	T/A	cg22764591	chr12:58329936	NA	1.0	8.13	0.64	1.62e-12	Intelligence (multi-trait analysis);
THYM	cis	rs335206	1.000	rs335201	chr5:122509649	G/A	cg16368670	chr5:122501738	PRDM6	-0.56	-4.55	-0.42	1.56e-5	QRS duration;
THYM	cis	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg13789015	chr9:136890014	NCRNA00094	0.85	7.29	0.6	9.11e-11	Platelet distribution width;
THYM	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg24399712	chr22:39784796	NA	-0.93	-10.65	-0.74	6.66e-18	Intelligence (multi-trait analysis);
THYM	cis	rs921968	0.541	rs3770214	chr2:219508988	C/T	cg02176678	chr2:219576539	TTLL4	-0.72	-7.2	-0.59	1.42e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs2404602	0.735	rs62028423	chr15:76754514	G/A	cg23482746	chr15:76478102	C15orf27	0.43	4.45	0.42	2.36e-5	Blood metabolite levels;
THYM	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg04267008	chr7:1944627	MAD1L1	-0.61	-4.94	-0.45	3.29e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs35934224	0.710	rs73381839	chr22:19850397	G/A	cg11182965	chr22:19864308	TXNRD2	-0.76	-4.67	-0.43	9.79e-6	Glaucoma (primary open-angle);
THYM	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg00684032	chr4:1343700	KIAA1530	-0.66	-5.62	-0.5	1.9e-7	Obesity-related traits;
THYM	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg15556689	chr8:8085844	FLJ10661	0.58	4.56	0.42	1.5e-5	Mood instability;
THYM	cis	rs4072705	0.586	rs7869042	chr9:127246751	C/T	cg13476313	chr9:127244764	NR5A1	-0.39	-5.96	-0.52	4.23e-8	Menarche (age at onset);
THYM	cis	rs4604732	0.588	rs4356092	chr1:247632668	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.75	4.98	0.46	2.83e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg23583168	chr7:148888333	NA	-1.04	-13.45	-0.81	1.02e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg27446573	chr6:127587934	RNF146	-0.7	-6.15	-0.53	1.81e-8	Breast cancer;
THYM	cis	rs3806843	0.966	rs3806842	chr5:140212676	C/T	cg19875535	chr5:140030758	IK	0.64	5.07	0.46	1.96e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg04267008	chr7:1944627	MAD1L1	0.63	5.56	0.5	2.51e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs6840360	1.000	rs749982	chr4:152601353	A/G	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs921968	0.613	rs2710251	chr2:219543433	T/C	cg02176678	chr2:219576539	TTLL4	-0.5	-5.01	-0.46	2.48e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	6.08	0.53	2.46e-8	Schizophrenia;
THYM	cis	rs1670533	1.000	rs1670533	chr4:1078187	G/A	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs7085104	0.513	rs619824	chr10:104581288	G/T	cg08772003	chr10:104629869	AS3MT	-0.66	-6.29	-0.54	9.68e-9	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg13695892	chr22:41940480	POLR3H	0.87	6.35	0.55	7.28e-9	Vitiligo;
THYM	cis	rs2455799	0.613	rs11713820	chr3:15866590	A/G	cg16303742	chr3:15540471	COLQ	0.54	5.78	0.51	9.67e-8	Mean platelet volume;
THYM	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs72627123	0.867	rs74395411	chr14:74478584	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.86	4.91	0.45	3.77e-6	Morning vs. evening chronotype;
THYM	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.91	6.21	0.54	1.38e-8	Schizophrenia;
THYM	cis	rs4654899	0.680	rs10799670	chr1:21179445	T/C	cg01072550	chr1:21505969	NA	0.71	6.83	0.57	8.01e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs17741873	0.614	rs74617374	chr10:75690059	G/T	cg02947784	chr10:75434997	AGAP5	-0.66	-4.45	-0.42	2.32e-5	Paclitaxel disposition in epithelial ovarian cancer;
THYM	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg03733263	chr8:22462867	KIAA1967	-0.94	-9.63	-0.7	1e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs346785	0.692	rs9900514	chr17:74285595	T/C	cg09812376	chr17:74270190	QRICH2	-0.5	-5.2	-0.47	1.14e-6	White matter hyperintensities in ischemic stroke;
THYM	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg16414030	chr3:133502952	NA	-0.92	-8.98	-0.68	2.53e-14	Iron status biomarkers;
THYM	cis	rs4481887	0.962	rs10788770	chr1:248457474	T/G	cg13385794	chr1:248469461	NA	0.68	4.62	0.43	1.22e-5	Common traits (Other);
THYM	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg06618935	chr21:46677482	NA	-0.97	-8.09	-0.64	1.92e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg18538332	chr22:24372958	LOC391322	0.85	8.82	0.67	5.36e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs34779708	0.931	rs7897457	chr10:35386040	A/G	cg03585969	chr10:35415529	CREM	0.66	4.76	0.44	6.85e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg24154853	chr7:158122151	PTPRN2	0.58	5.18	0.47	1.25e-6	Calcium levels;
THYM	cis	rs67981189	0.519	rs2526853	chr14:71415952	G/A	cg15910301	chr14:71632612	NA	-0.55	-4.53	-0.42	1.7e-5	Schizophrenia;
THYM	cis	rs28595532	0.920	rs115271785	chr4:119735748	A/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg19774624	chr17:42201019	HDAC5	0.7	5.83	0.51	7.43e-8	Total body bone mineral density;
THYM	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs6964587	0.585	rs10266481	chr7:91554338	T/C	cg17063962	chr7:91808500	NA	-1.02	-9.26	-0.69	6.44e-15	Breast cancer;
THYM	cis	rs9933309	1.000	rs9933309	chr16:88844932	A/G	cg02610723	chr16:88850534	FAM38A	0.69	4.9	0.45	3.94e-6	Glycated hemoglobin levels;
THYM	cis	rs36051895	0.623	rs1575283	chr9:5238588	C/T	cg02405213	chr9:5042618	JAK2	-0.9	-9.05	-0.68	1.75e-14	Pediatric autoimmune diseases;
THYM	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12681287	0.640	rs67123356	chr8:87453992	A/C	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs2832077	0.506	rs10222093	chr21:30163518	T/C	cg24692254	chr21:30365293	RNF160	-0.88	-6.37	-0.55	6.78e-9	Cognitive test performance;
THYM	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg01017244	chr2:74357527	NA	1.15	9.41	0.69	3.01e-15	Gestational age at birth (maternal effect);
THYM	cis	rs870825	0.616	rs35533356	chr4:185639134	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.69	0.71	7.45e-16	Blood protein levels;
THYM	cis	rs9914544	0.545	rs8069826	chr17:18765490	G/T	cg26378065	chr17:18585709	ZNF286B	0.6	4.71	0.43	8.56e-6	Educational attainment (years of education);
THYM	cis	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.96	0.45	3.04e-6	Obesity-related traits;
THYM	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg13010199	chr12:38710504	ALG10B	-0.56	-4.84	-0.44	4.96e-6	Heart rate;
THYM	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg05283184	chr6:79620031	NA	-0.94	-9.25	-0.69	6.67e-15	Intelligence (multi-trait analysis);
THYM	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.77	-7.17	-0.59	1.6e-10	Personality dimensions;
THYM	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg10150615	chr22:24372951	LOC391322	-0.76	-7.34	-0.6	7.25e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg04398451	chr17:18023971	MYO15A	-0.99	-11.32	-0.76	2.63e-19	Total body bone mineral density;
THYM	cis	rs10871290	0.650	rs12600126	chr16:74489732	A/T	cg01733217	chr16:74700730	RFWD3	-0.59	-4.99	-0.46	2.72e-6	Breast cancer;
THYM	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.52	-5.97	-0.52	4.04e-8	Insulin-like growth factors;
THYM	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg25036284	chr2:26402008	FAM59B	0.74	4.87	0.45	4.39e-6	Gut microbiome composition (summer);
THYM	cis	rs9549260	0.564	rs4943804	chr13:41269994	A/G	cg21288729	chr13:41239152	FOXO1	0.65	4.91	0.45	3.83e-6	Red blood cell count;
THYM	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg01097406	chr16:89675127	NA	0.57	4.68	0.43	9.47e-6	Vitiligo;
THYM	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg07570687	chr10:102243282	WNT8B	-0.76	-6.52	-0.56	3.32e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg06850241	chr22:41845214	NA	0.54	4.68	0.43	9.37e-6	Vitiligo;
THYM	cis	rs13223928	0.651	rs4722435	chr7:3152962	C/T	cg19214707	chr7:3157722	NA	0.85	7.2	0.59	1.42e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs4766566	0.609	rs933305	chr12:111738287	G/A	cg10833066	chr12:111807467	FAM109A	0.61	7.56	0.61	2.5e-11	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
THYM	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg13114125	chr14:105738426	BRF1	-0.74	-5.72	-0.51	1.22e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg13246856	chr1:44399776	ARTN	0.51	5.05	0.46	2.16e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg15556689	chr8:8085844	FLJ10661	-0.65	-5.76	-0.51	1.04e-7	Mood instability;
THYM	cis	rs1483890	0.723	rs900669	chr3:69406802	T/A	cg22125112	chr3:69402811	FRMD4B	0.57	7.19	0.59	1.44e-10	Resting heart rate;
THYM	cis	rs1061377	1.000	rs10018049	chr4:39117401	C/T	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs4919694	0.901	rs113541728	chr10:104716771	A/T	cg04362960	chr10:104952993	NT5C2	1.14	6.92	0.58	5.36e-10	Arsenic metabolism;
THYM	cis	rs35883536	0.605	rs2133118	chr1:101034337	C/T	cg06223162	chr1:101003688	GPR88	-0.88	-7.53	-0.61	2.92e-11	Monocyte count;
THYM	cis	rs9296092	0.560	rs3846854	chr6:33528466	T/C	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03264133	chr6:25882463	NA	-0.69	-5.32	-0.48	7.03e-7	Blood metabolite levels;
THYM	trans	rs75518195	0.543	rs62301914	chr4:64664861	G/A	cg14706739	chr8:21916355	EPB49	0.76	7.56	0.61	2.58e-11	Triptolide cytotoxicity;
THYM	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg13447684	chr7:1895903	MAD1L1	-0.56	-5.11	-0.46	1.68e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4655537	0.500	rs4655586	chr1:66187803	G/A	cg04111102	chr1:66153794	NA	0.52	4.59	0.43	1.36e-5	Blood protein levels;
THYM	cis	rs6502050	0.835	rs8064935	chr17:80180178	T/C	cg10505658	chr17:80084571	CCDC57	-0.67	-7.39	-0.6	5.75e-11	Life satisfaction;
THYM	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg00484396	chr16:3507460	NAT15	0.5	4.9	0.45	3.97e-6	Body mass index (adult);
THYM	cis	rs2073300	1.000	rs114718317	chr20:23442620	T/C	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs17407555	0.738	rs73212870	chr4:10111798	C/G	cg11266682	chr4:10021025	SLC2A9	-0.57	-6.12	-0.53	2.06e-8	Schizophrenia (age at onset);
THYM	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg08017756	chr2:100939284	LONRF2	-0.74	-7.57	-0.61	2.34e-11	Intelligence (multi-trait analysis);
THYM	cis	rs941408	1.000	rs941410	chr19:2787329	G/A	cg13078421	chr19:2624622	GNG7	0.61	4.64	0.43	1.11e-5	Total cholesterol levels;
THYM	cis	rs7614311	0.636	rs66818634	chr3:63913222	G/A	cg22134162	chr3:63841271	THOC7	-0.55	-6.24	-0.54	1.23e-8	Lung function (FVC);Lung function (FEV1);
THYM	trans	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg19862616	chr7:65841803	NCRNA00174	-0.99	-10.35	-0.73	3.02e-17	Coffee consumption;Coffee consumption (cups per day);
THYM	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg06609049	chr19:2785107	THOP1	1.2	12.48	0.79	9.64e-22	Total cholesterol levels;
THYM	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg26516362	chr5:178986906	RUFY1	0.4	4.95	0.45	3.23e-6	Lung cancer;
THYM	cis	rs12257961	0.521	rs10796279	chr10:15375400	A/T	cg10616319	chr10:15468812	NA	-0.66	-5.33	-0.48	6.53e-7	Selective IgA deficiency;
THYM	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg08132940	chr7:1081526	C7orf50	-1.15	-6.58	-0.56	2.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg13012494	chr21:47604986	C21orf56	0.63	4.68	0.43	9.59e-6	Testicular germ cell tumor;
THYM	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg08807101	chr21:30365312	RNF160	-0.79	-5.93	-0.52	4.97e-8	Dental caries;
THYM	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg08498830	chr11:832797	CD151	-0.62	-4.55	-0.42	1.57e-5	Mean platelet volume;
THYM	cis	rs986417	0.818	rs7144656	chr14:61032909	A/G	cg27398547	chr14:60952738	C14orf39	1.25	6.45	0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs9649213	0.593	rs3801254	chr7:98010811	G/A	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12620999	0.941	rs4408676	chr2:238085280	C/T	cg23555395	chr2:238036564	NA	-0.61	-4.85	-0.45	4.87e-6	Systemic lupus erythematosus;
THYM	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg07570687	chr10:102243282	WNT8B	0.76	6.9	0.58	5.82e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2282032	0.527	rs8004573	chr14:90765743	C/T	cg14092571	chr14:90743983	NA	0.64	6.32	0.54	8.28e-9	Longevity;
THYM	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs4700695	0.719	rs27085	chr5:65435063	C/T	cg21114390	chr5:65439923	SFRS12	0.78	4.63	0.43	1.15e-5	Facial morphology (factor 19);
THYM	cis	rs6964587	0.692	rs17672805	chr7:91573466	A/G	cg22709100	chr7:91322751	NA	-0.63	-4.67	-0.43	1e-5	Breast cancer;
THYM	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg05872129	chr22:39784769	NA	-1.03	-11.26	-0.76	3.53e-19	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg06600287	chr1:53387719	ECHDC2	-0.31	-5.11	-0.46	1.68e-6	Monocyte count;
THYM	cis	rs2072499	0.833	rs2758605	chr1:156200445	G/C	cg25208724	chr1:156163844	SLC25A44	0.97	9.94	0.71	2.21e-16	Testicular germ cell tumor;
THYM	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	6.27	0.54	1.08e-8	Obesity-related traits;
THYM	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg17054759	chr22:49844102	NA	-0.52	-4.72	-0.44	8.24e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6496667	1.000	rs58436485	chr15:90900633	G/A	cg22089800	chr15:90895588	ZNF774	0.84	4.92	0.45	3.68e-6	Rheumatoid arthritis;
THYM	cis	rs10493773	0.748	rs12758511	chr1:86165987	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.48	-6.24	-0.54	1.19e-8	Urate levels in overweight individuals;
THYM	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg14196790	chr5:131705035	SLC22A5	-0.55	-4.93	-0.45	3.55e-6	Blood metabolite levels;
THYM	cis	rs78456975	0.689	rs10194040	chr2:1543293	T/G	cg12573674	chr2:1569213	NA	-1.39	-6.82	-0.57	8.45e-10	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs10832963	0.594	rs1550869	chr11:18613498	G/T	cg09201001	chr11:18656081	SPTY2D1	0.79	5.6	0.5	2.12e-7	Breast cancer;
THYM	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs6032067	0.714	rs35770435	chr20:43788804	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.51	-0.49	3.1e-7	Blood protein levels;
THYM	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg01448562	chr3:133502909	NA	0.79	6.82	0.57	8.35e-10	Iron status biomarkers;
THYM	cis	rs72781680	0.821	rs72790304	chr2:24108557	G/A	cg10599693	chr2:24300242	SF3B14	0.83	4.56	0.42	1.5e-5	Lymphocyte counts;
THYM	cis	rs6964587	0.692	rs418	chr7:91583334	C/T	cg22709100	chr7:91322751	NA	-0.63	-4.66	-0.43	1.04e-5	Breast cancer;
THYM	cis	rs28374715	0.532	rs28584379	chr15:41670408	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.2	-13.34	-0.81	1.7e-23	Ulcerative colitis;
THYM	cis	rs1620921	0.756	rs783163	chr6:161182401	A/T	cg01280913	chr6:161186852	NA	-0.51	-4.65	-0.43	1.06e-5	Lipoprotein (a) - cholesterol levels;
THYM	cis	rs686320	1.000	rs1787666	chr11:65249089	A/C	cg19332572	chr11:65321591	LTBP3	0.93	6.05	0.53	2.88e-8	Hip circumference adjusted for BMI;
THYM	cis	rs910187	0.678	rs1046659	chr20:45817068	G/A	cg27589058	chr20:45804311	EYA2	-0.6	-5.31	-0.48	7.28e-7	Migraine;
THYM	cis	rs420259	0.516	rs9302410	chr16:23511372	C/T	cg00143387	chr16:23521605	GGA2	-0.74	-5.31	-0.48	7.21e-7	Bipolar disorder;
THYM	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.96	-6.76	-0.57	1.12e-9	Schizophrenia;
THYM	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.51	-4.79	-0.44	6.24e-6	Lymphocyte counts;
THYM	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg06558623	chr16:89946397	TCF25	1.5	8.19	0.64	1.22e-12	Skin colour saturation;
THYM	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.33e-5	Retinal vascular caliber;
THYM	cis	rs17006441	0.932	rs35896616	chr3:69868189	A/G	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs72827839	0.689	rs72833468	chr17:45949338	T/C	cg23391107	chr17:45924227	SP6	0.79	5.01	0.46	2.47e-6	Ease of getting up in the morning;
THYM	cis	rs300703	1.000	rs300703	chr2:239416	C/T	cg21211680	chr2:198530	NA	1.33	5.61	0.5	1.97e-7	Blood protein levels;
THYM	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg13695892	chr22:41940480	POLR3H	-0.99	-7.48	-0.61	3.62e-11	Vitiligo;
THYM	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg06532163	chr17:45867833	NA	0.66	6.75	0.57	1.17e-9	IgG glycosylation;
THYM	cis	rs12134245	0.776	rs13447464	chr1:91968278	G/A	cg02896835	chr1:92012615	NA	-0.59	-4.97	-0.45	2.98e-6	Breast cancer;
THYM	cis	rs2133450	0.712	rs9867566	chr3:7368673	C/T	cg19930620	chr3:7340148	GRM7	-0.49	-4.53	-0.42	1.72e-5	Early response to risperidone in schizophrenia;
THYM	trans	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs12711979	0.509	rs12711972	chr2:3823786	T/C	cg17052675	chr2:3827356	NA	-0.88	-13.79	-0.82	2.09e-24	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs6539288	0.901	rs4964193	chr12:107321748	C/T	cg26297688	chr12:107349093	C12orf23	-0.47	-4.93	-0.45	3.42e-6	Total body bone mineral density;
THYM	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg07362569	chr17:61921086	SMARCD2	0.64	5.95	0.52	4.43e-8	Prudent dietary pattern;
THYM	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg21784768	chr11:537496	LRRC56	-1.07	-5.36	-0.48	5.7e-7	Body mass index;
THYM	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg19746536	chr19:49375674	PPP1R15A	0.81	4.59	0.43	1.34e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.95	0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-5.61	-0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg22467129	chr15:76604101	ETFA	-0.56	-5.27	-0.48	8.62e-7	Blood metabolite levels;
THYM	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg18904891	chr8:8559673	CLDN23	0.6	4.99	0.46	2.75e-6	Mood instability;
THYM	cis	rs1448094	0.511	rs17345272	chr12:86165334	A/C	cg00310523	chr12:86230176	RASSF9	0.61	5.31	0.48	7.29e-7	Major depressive disorder;
THYM	cis	rs58722170	0.659	rs55852308	chr1:38078630	A/T	cg17933807	chr1:38061675	GNL2	-0.9	-6.91	-0.58	5.62e-10	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg17294928	chr15:75287854	SCAMP5	-0.99	-9.14	-0.68	1.15e-14	Blood trace element (Zn levels);
THYM	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs11039798	1.000	rs12280020	chr11:48618844	G/C	cg24672777	chr11:48374446	OR4C45	-1.14	-6.95	-0.58	4.55e-10	Axial length;
THYM	cis	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg01528321	chr10:82214614	TSPAN14	1.02	7.84	0.63	6.52e-12	Post bronchodilator FEV1;
THYM	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.69	8.77	0.67	6.85e-14	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs4638749	1.000	rs1466212	chr2:108856532	G/A	cg06795125	chr2:108905320	SULT1C2	-0.41	-5.38	-0.48	5.42e-7	Blood pressure;
THYM	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg18252515	chr7:66147081	NA	-0.68	-5.02	-0.46	2.39e-6	Aortic root size;
THYM	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg15247329	chr7:2764246	NA	-0.71	-5.95	-0.52	4.37e-8	Height;
THYM	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg27588902	chr6:42928151	GNMT	-0.56	-5.77	-0.51	1.01e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1443512	0.947	rs894739	chr12:54346869	T/C	cg15261861	chr12:54132255	NA	-0.47	-4.54	-0.42	1.64e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11890956	chr21:40555474	PSMG1	0.97	11.03	0.75	1.05e-18	Cognitive function;
THYM	cis	rs12368653	0.666	rs701007	chr12:58113416	C/A	cg12615879	chr12:58013172	SLC26A10	0.54	5.35	0.48	6.04e-7	Multiple sclerosis;
THYM	cis	rs7824557	0.614	rs10503421	chr8:11221313	C/T	cg21775007	chr8:11205619	TDH	0.74	6.02	0.53	3.24e-8	Retinal vascular caliber;
THYM	cis	rs28595532	0.764	rs115986119	chr4:119767785	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	7.73	0.62	1.1e-11	Smoking behavior;
THYM	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg07936489	chr17:37558343	FBXL20	-0.66	-4.54	-0.42	1.62e-5	Asthma;
THYM	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs6424115	0.931	rs2473377	chr1:24148260	T/C	cg15997130	chr1:24165203	NA	0.77	7.11	0.59	2.15e-10	Immature fraction of reticulocytes;
THYM	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg22535103	chr8:58192502	C8orf71	-0.96	-5.89	-0.52	5.76e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs270601	0.866	rs460271	chr5:131630062	C/G	cg04518342	chr5:131593106	PDLIM4	0.45	4.68	0.43	9.69e-6	Acylcarnitine levels;
THYM	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg00339695	chr16:24857497	SLC5A11	-0.47	-4.66	-0.43	1.02e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6570726	0.791	rs9322029	chr6:145906683	A/G	cg23711669	chr6:146136114	FBXO30	0.96	9.87	0.71	3.12e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg12863693	chr15:85201151	NMB	0.63	5.63	0.5	1.8e-7	Schizophrenia;
THYM	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg04025307	chr7:1156635	C7orf50	0.76	4.73	0.44	7.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg16230307	chr14:35515116	FAM177A1	0.83	5.29	0.48	7.72e-7	Psoriasis;
THYM	cis	rs4481887	0.741	rs6682957	chr1:248535639	T/G	cg17299007	chr1:248814626	OR2T27	0.42	4.52	0.42	1.81e-5	Common traits (Other);
THYM	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg05234568	chr11:5960015	NA	-0.59	-4.75	-0.44	7.28e-6	DNA methylation (variation);
THYM	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11644478	chr21:40555479	PSMG1	1.11	9.99	0.72	1.76e-16	Cognitive function;
THYM	cis	rs4731207	0.564	rs12531844	chr7:124603900	C/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs6430585	0.528	rs3098102	chr2:136654833	C/T	cg07169764	chr2:136633963	MCM6	0.96	9.1	0.68	1.36e-14	Corneal structure;
THYM	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg27170947	chr2:26402098	FAM59B	-0.58	-4.88	-0.45	4.35e-6	Gut microbiome composition (summer);
THYM	cis	rs240764	0.658	rs10872634	chr6:101199579	C/T	cg21058520	chr6:100914733	NA	0.6	5.29	0.48	7.79e-7	Neuroticism;
THYM	cis	rs2730245	0.527	rs2527202	chr7:158738849	T/C	cg24397884	chr7:158709396	WDR60	-0.56	-4.89	-0.45	4.13e-6	Height;
THYM	cis	rs4343996	0.626	rs57952815	chr7:3395417	T/A	cg21248987	chr7:3385318	SDK1	-0.4	-5.14	-0.47	1.44e-6	Motion sickness;
THYM	cis	rs4930776	0.966	rs1860953	chr12:5765529	C/A	cg02086166	chr12:5775618	ANO2	-0.58	-5.71	-0.51	1.3e-7	Plasma clusterin levels;
THYM	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg07371521	chr5:154026371	NA	0.57	5.45	0.49	3.96e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg12981288	chr8:11183844	MTMR9	-0.47	-4.65	-0.43	1.09e-5	Retinal vascular caliber;
THYM	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg16342193	chr10:102329863	NA	0.5	5.1	0.46	1.72e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs728616	0.867	rs41298231	chr10:81682461	C/T	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9361491	0.657	rs7382016	chr6:79455781	A/T	cg04547799	chr6:79944526	HMGN3	0.66	4.58	0.43	1.41e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs62070183	0.938	rs17183176	chr17:31054125	T/C	cg23177095	chr17:30873196	MYO1D	0.66	5.14	0.47	1.48e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg10360139	chr7:1886902	MAD1L1	-0.78	-6.77	-0.57	1.08e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg10505658	chr17:80084571	CCDC57	-0.7	-7.94	-0.63	4.12e-12	Life satisfaction;
THYM	cis	rs10743315	0.557	rs117033327	chr12:19373040	G/T	cg02471346	chr12:19282374	PLEKHA5	1.17	4.83	0.44	5.31e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg22166914	chr1:53195759	ZYG11B	0.91	10.7	0.74	5.4e-18	Monocyte count;
THYM	cis	rs7429990	0.965	rs62260764	chr3:47990500	G/C	cg17215036	chr3:48129188	MAP4	0.66	4.54	0.42	1.68e-5	Educational attainment (years of education);
THYM	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg04756594	chr16:24857601	SLC5A11	0.76	5.51	0.49	3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg18681998	chr4:17616180	MED28	0.98	9.91	0.71	2.55e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg19016782	chr12:123741754	C12orf65	0.69	4.5	0.42	1.94e-5	Neutrophil percentage of white cells;
THYM	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg00495681	chr13:53174319	NA	0.63	5.75	0.51	1.07e-7	Lewy body disease;
THYM	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg27394845	chr17:28928406	LRRC37B2	0.98	4.83	0.44	5.31e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg02931644	chr1:25747376	RHCE	0.59	4.53	0.42	1.73e-5	Erythrocyte sedimentation rate;
THYM	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg22433210	chr17:43662623	NA	-1.05	-8.08	-0.64	2e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11048434	0.723	rs2080116	chr12:9138183	A/G	cg14913610	chr12:9142341	KLRG1	-0.29	-4.48	-0.42	2.11e-5	Sjögren's syndrome;
THYM	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg27490568	chr2:178487706	NA	0.59	5.91	0.52	5.43e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4237845	0.816	rs61935769	chr12:58294344	G/A	cg22764591	chr12:58329936	NA	0.84	5.67	0.5	1.53e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg21775007	chr8:11205619	TDH	0.67	5.45	0.49	4.01e-7	Retinal vascular caliber;
THYM	cis	rs6840360	0.593	rs2175409	chr4:152701656	A/G	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs6430585	0.941	rs12469551	chr2:136510012	T/G	cg07169764	chr2:136633963	MCM6	-0.93	-8.04	-0.64	2.51e-12	Corneal structure;
THYM	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg08508325	chr11:3079039	CARS	-0.49	-6.0	-0.52	3.61e-8	Longevity;
THYM	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg08132940	chr7:1081526	C7orf50	-1.16	-6.65	-0.56	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3847687	1.000	rs11061303	chr12:131526322	A/G	cg13586425	chr12:131519906	GPR133	-0.33	-5.3	-0.48	7.43e-7	Longevity;
THYM	cis	rs4481887	0.741	rs6421453	chr1:248533285	A/G	cg00666640	chr1:248458726	OR2T12	0.55	4.74	0.44	7.59e-6	Common traits (Other);
THYM	cis	rs7719624	0.840	rs916951	chr5:135384443	A/G	cg15329133	chr5:135467951	SMAD5;SMAD5OS	-0.58	-5.17	-0.47	1.3e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs870825	0.929	rs10003354	chr4:185589782	G/A	cg04058563	chr4:185651563	MLF1IP	0.96	6.66	0.56	1.78e-9	Blood protein levels;
THYM	cis	rs13070279	0.655	rs35281203	chr3:71801535	G/A	cg19388776	chr3:71835112	PROK2	0.91	5.28	0.48	8.32e-7	Monocyte count;
THYM	cis	rs7106204	0.514	rs2099889	chr11:24255971	A/G	ch.11.24196551F	chr11:24239977	NA	1.0	6.88	0.58	6.32e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs6456156	0.773	rs6456159	chr6:167529272	T/A	cg09487078	chr6:167525398	CCR6	-0.44	-4.92	-0.45	3.63e-6	Primary biliary cholangitis;
THYM	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg22166914	chr1:53195759	ZYG11B	0.91	10.77	0.74	3.71e-18	Monocyte count;
THYM	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg09703963	chr11:616879	IRF7;MUPCDH	-0.64	-5.53	-0.49	2.78e-7	Systemic lupus erythematosus;
THYM	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg04025307	chr7:1156635	C7orf50	0.68	6.49	0.55	3.96e-9	Longevity;Endometriosis;
THYM	cis	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.24	9.45	0.7	2.46e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7191439	0.789	rs4598894	chr16:88776141	G/A	cg27087555	chr16:88793112	FAM38A	-1.33	-7.66	-0.62	1.59e-11	Plateletcrit;
THYM	cis	rs6502050	0.835	rs12450154	chr17:80182672	G/A	cg03388043	chr17:80084554	CCDC57	-0.71	-5.89	-0.52	5.84e-8	Life satisfaction;
THYM	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs4455778	0.538	rs67216951	chr7:49088028	C/T	cg26309511	chr7:48887640	NA	0.68	5.94	0.52	4.63e-8	Lung cancer in never smokers;
THYM	cis	rs10911232	0.507	rs10911195	chr1:182993438	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	trans	rs10043228	1.000	rs12520594	chr5:115621597	C/T	cg12255298	chr19:3976193	EEF2	1.06	6.99	0.58	3.8e-10	Asthma or chronic obstructive pulmonary disease;
THYM	cis	rs931127	0.505	rs746429	chr11:65417434	G/A	cg27068330	chr11:65405492	SIPA1	-1.06	-11.49	-0.76	1.16e-19	Systemic lupus erythematosus;
THYM	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg25566285	chr7:158114605	PTPRN2	0.86	9.77	0.71	5.03e-16	Calcium levels;
THYM	cis	rs79149102	0.579	rs78664321	chr15:75339575	G/A	cg09165964	chr15:75287851	SCAMP5	-1.01	-5.02	-0.46	2.37e-6	Lung cancer;
THYM	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg17063962	chr7:91808500	NA	-1.14	-11.55	-0.76	8.51e-20	Breast cancer;
THYM	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg19774624	chr17:42201019	HDAC5	0.72	6.35	0.55	7.19e-9	Total body bone mineral density;
THYM	cis	rs7631605	0.875	rs55898028	chr3:37248337	A/G	cg21328643	chr3:37258149	NA	-0.52	-4.95	-0.45	3.25e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg10505658	chr17:80084571	CCDC57	-0.74	-8.32	-0.65	6.42e-13	Life satisfaction;
THYM	cis	rs4478037	0.822	rs9863331	chr3:33123235	G/T	cg19404215	chr3:33155277	CRTAP	0.96	6.51	0.56	3.58e-9	Major depressive disorder;
THYM	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg24692254	chr21:30365293	RNF160	1.06	9.93	0.71	2.29e-16	Dental caries;
THYM	cis	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg10856724	chr12:34555212	NA	-0.92	-8.73	-0.67	8.35e-14	Morning vs. evening chronotype;
THYM	cis	rs28595532	0.920	rs115530096	chr4:119760512	T/G	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg11764359	chr7:65958608	NA	-0.67	-4.65	-0.43	1.08e-5	Aortic root size;
THYM	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-4.54	-0.42	1.63e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	4.54	0.42	1.66e-5	Hip circumference adjusted for BMI;
THYM	cis	rs58873874	0.737	rs11466807	chr5:156914928	A/G	cg08916508	chr5:156566250	MED7	-1.31	-4.98	-0.45	2.84e-6	Bipolar disorder (body mass index interaction);
THYM	trans	rs1997103	1.000	rs9649857	chr7:55411777	C/T	cg20935933	chr6:143382018	AIG1	0.86	6.91	0.58	5.41e-10	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg14779329	chr11:130786720	SNX19	0.53	5.57	0.5	2.34e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	9.9	0.71	2.7e-16	Platelet count;
THYM	cis	rs7191700	0.836	rs28502009	chr16:11426541	G/A	cg00044050	chr16:11439710	C16orf75	0.67	4.56	0.42	1.53e-5	Multiple sclerosis;
THYM	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg19077165	chr18:44547161	KATNAL2	0.5	5.84	0.51	7.15e-8	Personality dimensions;
THYM	cis	rs562638	0.591	rs251906	chr19:39826838	C/G	cg11865883	chr19:39971137	TIMM50	0.67	4.69	0.43	9.05e-6	Obesity-related traits;
THYM	cis	rs2404602	0.735	rs4886798	chr15:76673226	A/G	cg23482746	chr15:76478102	C15orf27	-0.49	-4.93	-0.45	3.43e-6	Blood metabolite levels;
THYM	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg10523679	chr1:76189770	ACADM	0.87	8.11	0.64	1.77e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs295140	0.605	rs296818	chr2:201176944	C/T	cg14106933	chr2:201194453	SPATS2L	-0.42	-4.49	-0.42	2e-5	QT interval;
THYM	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg10018233	chr7:150070692	REPIN1	-0.37	-5.34	-0.48	6.26e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg00786635	chr1:25594202	NA	0.88	6.97	0.58	4.22e-10	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2073300	0.609	rs74809795	chr20:23372383	A/C	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.99	12.2	0.78	3.73e-21	Chronic sinus infection;
THYM	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.77	-6.42	-0.55	5.37e-9	Intelligence (multi-trait analysis);
THYM	cis	rs11018874	0.597	rs10765243	chr11:89855118	C/G	cg05041596	chr11:89867385	NAALAD2	0.74	4.55	0.42	1.57e-5	White blood cell types;
THYM	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg12310025	chr6:25882481	NA	-0.69	-5.47	-0.49	3.69e-7	Blood metabolite levels;
THYM	cis	rs612683	0.524	rs479269	chr1:100887616	A/G	cg06223162	chr1:101003688	GPR88	0.76	6.59	0.56	2.44e-9	Breast cancer;
THYM	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-11.3	-0.76	2.81e-19	Height;
THYM	cis	rs7119	0.717	rs16968835	chr15:77734261	G/A	cg10437265	chr15:77819839	NA	0.56	4.99	0.46	2.78e-6	Type 2 diabetes;
THYM	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg17480646	chr11:65405466	SIPA1	-0.94	-8.68	-0.67	1.07e-13	Acne (severe);
THYM	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11644478	chr21:40555479	PSMG1	1.11	9.99	0.72	1.76e-16	Cognitive function;
THYM	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg04317338	chr11:64019027	PLCB3	0.95	6.56	0.56	2.8e-9	Mean platelet volume;
THYM	cis	rs7772486	0.846	rs1474871	chr6:146406294	G/A	cg05347473	chr6:146136440	FBXO30	0.6	4.81	0.44	5.67e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7177699	0.557	rs12898292	chr15:79112603	A/G	cg00540400	chr15:79124168	NA	0.62	6.51	0.56	3.49e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3847687	0.966	rs3847689	chr12:131525534	T/G	cg13586425	chr12:131519906	GPR133	-0.32	-5.18	-0.47	1.26e-6	Longevity;
THYM	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.55	0.42	1.57e-5	Body mass index;
THYM	cis	rs7705502	1.000	rs966544	chr5:173350405	A/G	cg18693985	chr5:173351052	CPEB4	-0.76	-5.47	-0.49	3.57e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2463822	1.000	rs72921501	chr11:62115622	A/T	cg06239285	chr11:62104954	ASRGL1	-1.43	-6.9	-0.58	5.87e-10	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg03467027	chr4:99064603	C4orf37	0.59	4.5	0.42	1.92e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10045504	0.743	rs57488025	chr5:38757173	T/C	cg07423205	chr5:37834672	GDNF	-0.49	-4.95	-0.45	3.21e-6	Night sleep phenotypes;
THYM	cis	rs1538970	0.816	rs868351	chr1:46009818	G/T	cg05343316	chr1:45956843	TESK2	0.81	5.33	0.48	6.71e-7	Platelet count;
THYM	cis	rs9828933	1.000	rs1060897	chr3:63997872	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.79	5.2	0.47	1.13e-6	Type 2 diabetes;
THYM	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg05754148	chr16:3507555	NAT15	-0.78	-6.2	-0.54	1.47e-8	Tuberculosis;
THYM	cis	rs7681440	0.583	rs2583987	chr4:90760221	A/C	cg06632027	chr4:90757378	SNCA	-0.67	-5.33	-0.48	6.7e-7	Dementia with Lewy bodies;
THYM	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.96e-6	Resting heart rate;
THYM	cis	rs7940866	0.804	rs10894289	chr11:130808685	C/T	cg05962950	chr11:130786565	SNX19	0.72	5.52	0.49	2.99e-7	Schizophrenia;
THYM	cis	rs2463822	1.000	rs1881534	chr11:62085083	A/G	cg06239285	chr11:62104954	ASRGL1	1.38	7.23	0.6	1.21e-10	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7107174	0.901	rs11237487	chr11:78126754	G/C	cg02023728	chr11:77925099	USP35	0.54	4.56	0.42	1.55e-5	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg02527881	chr3:46936655	PTH1R	0.57	5.22	0.47	1.04e-6	Colorectal cancer;
THYM	cis	rs4481887	0.708	rs6696691	chr1:248539720	T/C	cg17299007	chr1:248814626	OR2T27	0.42	4.55	0.42	1.62e-5	Common traits (Other);
THYM	cis	rs2637266	0.783	rs846585	chr10:78494466	T/G	cg18941641	chr10:78392320	NA	0.75	6.01	0.53	3.35e-8	Pulmonary function;
THYM	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg06238570	chr21:40685208	BRWD1	-0.71	-5.99	-0.52	3.75e-8	Menarche (age at onset);
THYM	cis	rs9905704	0.846	rs302861	chr17:56697040	G/C	cg12560992	chr17:57184187	TRIM37	0.65	4.51	0.42	1.89e-5	Testicular germ cell tumor;
THYM	cis	rs10752881	1.000	rs12133714	chr1:182988252	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Colorectal cancer;
THYM	cis	rs9515201	0.859	rs9521732	chr13:111033821	G/T	cg06243866	chr13:111019493	COL4A2	-0.94	-8.91	-0.67	3.46e-14	White matter hyperintensity burden;
THYM	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg08305652	chr11:111469057	NA	-0.53	-4.51	-0.42	1.87e-5	Primary sclerosing cholangitis;
THYM	cis	rs2361718	0.501	rs11869566	chr17:78143248	T/C	cg09238746	chr17:78121135	EIF4A3	-1.11	-10.44	-0.73	1.87e-17	Yeast infection;
THYM	cis	rs6840360	0.573	rs4696250	chr4:152266321	T/C	cg22705602	chr4:152727874	NA	-0.49	-4.73	-0.44	7.88e-6	Intelligence (multi-trait analysis);
THYM	cis	rs34638657	0.872	rs2967326	chr16:82188246	A/G	cg09439754	chr16:82129088	HSD17B2	-0.6	-5.24	-0.47	9.81e-7	Lung adenocarcinoma;
THYM	cis	rs3126085	0.935	rs3126043	chr1:152256030	C/G	cg10321714	chr1:152280068	FLG	0.67	5.14	0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs2997447	0.846	rs61775430	chr1:26411109	G/A	cg03844060	chr1:26490628	NA	0.67	4.61	0.43	1.26e-5	QRS complex (12-leadsum);
THYM	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg02891314	chr5:179741120	GFPT2	-0.91	-7.29	-0.6	9.3e-11	Height;
THYM	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg06115741	chr20:33292138	TP53INP2	0.72	4.87	0.45	4.48e-6	Coronary artery disease;
THYM	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg26446133	chr18:72167187	CNDP2	-1.02	-7.49	-0.61	3.5e-11	Refractive error;
THYM	cis	rs13256369	0.802	rs13280101	chr8:8562773	G/A	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs11779988	0.545	rs208752	chr8:17774258	A/G	cg01800426	chr8:17659068	MTUS1	-0.72	-4.96	-0.45	3.04e-6	Breast cancer;
THYM	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg24846343	chr22:24311635	DDTL	0.44	5.32	0.48	6.75e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9646944	0.501	rs2293223	chr2:103035468	C/T	cg01241218	chr2:102972058	NA	0.76	4.93	0.45	3.43e-6	Blood protein levels;
THYM	cis	rs2066819	1.000	rs2371494	chr12:56728000	G/A	cg26714650	chr12:56694279	CS	-1.34	-7.72	-0.62	1.17e-11	Psoriasis vulgaris;
THYM	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg03517284	chr6:25882590	NA	0.71	5.64	0.5	1.75e-7	Schizophrenia;
THYM	cis	rs36051895	0.632	rs1590803	chr9:5177533	T/C	cg02405213	chr9:5042618	JAK2	-1.0	-10.98	-0.75	1.39e-18	Pediatric autoimmune diseases;
THYM	cis	rs9565309	0.579	rs9573976	chr13:77582519	C/T	cg13866767	chr13:78470850	EDNRB	1.06	4.81	0.44	5.76e-6	Morning vs. evening chronotype;
THYM	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg23803603	chr1:2058230	PRKCZ	-0.67	-5.62	-0.5	1.88e-7	Height;
THYM	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg14018140	chr10:458528	DIP2C	-0.61	-7.25	-0.6	1.13e-10	Psychosis in Alzheimer's disease;
THYM	cis	rs34638657	0.872	rs6420436	chr16:82186719	C/G	cg09439754	chr16:82129088	HSD17B2	-0.59	-5.16	-0.47	1.36e-6	Lung adenocarcinoma;
THYM	cis	rs9549260	0.564	rs6563844	chr13:41298190	T/C	cg21288729	chr13:41239152	FOXO1	0.65	4.83	0.44	5.26e-6	Red blood cell count;
THYM	cis	rs921968	0.541	rs6720403	chr2:219294258	A/C	cg02176678	chr2:219576539	TTLL4	-0.76	-7.74	-0.62	1.07e-11	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg03647317	chr4:187891568	NA	0.76	7.59	0.61	2.13e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2997447	0.706	rs17184877	chr1:26443908	A/T	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	trans	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg14517863	chr17:44321492	NA	-0.41	-4.76	-0.44	6.97e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg02187348	chr16:89574699	SPG7	0.77	6.35	0.55	7.28e-9	Multiple myeloma (IgH translocation);
THYM	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg13395646	chr4:1353034	KIAA1530	-0.55	-4.6	-0.43	1.29e-5	Longevity;
THYM	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg05182265	chr7:156933206	UBE3C	-0.69	-9.32	-0.69	4.58e-15	Body mass index;
THYM	cis	rs9311676	0.632	rs62259779	chr3:58425692	C/G	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.71	-7.66	-0.62	1.54e-11	Crohn's disease;
THYM	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg21926883	chr2:100939477	LONRF2	-0.65	-5.96	-0.52	4.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	4.79	0.44	6.04e-6	Menarche (age at onset);
THYM	cis	rs8044868	0.586	rs7199261	chr16:72082788	A/G	cg16558253	chr16:72132732	DHX38	-0.55	-4.67	-0.43	1e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs752010	0.715	rs4083592	chr1:42099522	A/G	cg06885757	chr1:42089581	HIVEP3	0.75	10.32	0.73	3.46e-17	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg05962950	chr11:130786565	SNX19	0.7	5.57	0.5	2.41e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg07492924	chr16:433825	LOC100134368	0.46	5.05	0.46	2.12e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9309473	0.500	rs10865398	chr2:73741497	A/C	cg19565262	chr2:73869966	NAT8	0.53	4.67	0.43	9.89e-6	Metabolite levels;
THYM	cis	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg06521331	chr12:34319734	NA	-1.04	-10.33	-0.73	3.22e-17	Morning vs. evening chronotype;
THYM	cis	rs11648796	0.765	rs3829492	chr16:781633	G/A	cg05638439	chr16:711235	WDR90	-0.62	-5.21	-0.47	1.1e-6	Height;
THYM	cis	rs7216064	1.000	rs4790908	chr17:65852907	T/G	cg12091567	chr17:66097778	LOC651250	-0.71	-4.76	-0.44	6.86e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg20387954	chr3:183756860	HTR3D	0.56	4.64	0.43	1.11e-5	Anterior chamber depth;
THYM	trans	rs877282	0.898	rs12356709	chr10:763365	A/G	cg22713356	chr15:30763199	NA	1.36	10.13	0.72	8.77e-17	Uric acid levels;
THYM	cis	rs7000551	0.725	rs4871998	chr8:22308150	A/T	cg12081754	chr8:22256438	SLC39A14	0.64	5.19	0.47	1.19e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg17796960	chr10:135278976	LOC619207	-0.59	-4.87	-0.45	4.38e-6	Systemic lupus erythematosus;
THYM	cis	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg09307838	chr4:120376055	NA	0.7	5.27	0.48	8.48e-7	Corneal astigmatism;
THYM	cis	rs4733770	0.581	rs12550366	chr8:131136047	A/T	cg16277922	chr8:131349729	ASAP1	0.64	5.99	0.52	3.7e-8	Schizophrenia;
THYM	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg03060546	chr3:49711283	APEH	-0.7	-5.87	-0.52	6.46e-8	Educational attainment;
THYM	cis	rs9534288	0.797	rs7998854	chr13:46592174	C/A	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg12963246	chr6:28129442	ZNF389	0.51	4.53	0.42	1.72e-5	Parkinson's disease;
THYM	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.59	-7.32	-0.6	7.84e-11	Longevity;Endometriosis;
THYM	cis	rs8018808	0.935	rs1061629	chr14:77926011	A/G	cg20045696	chr14:77926864	AHSA1	-0.53	-4.65	-0.43	1.07e-5	Myeloid white cell count;
THYM	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.34	0.48	6.29e-7	Height;
THYM	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg04455712	chr21:45112962	RRP1B	0.51	4.72	0.44	8.23e-6	Mean corpuscular volume;
THYM	cis	rs10911232	0.507	rs11582514	chr1:182992161	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs921968	0.545	rs2433738	chr2:219551036	T/A	cg02176678	chr2:219576539	TTLL4	-0.55	-5.46	-0.49	3.79e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg09260853	chr1:2094483	PRKCZ	-0.44	-4.56	-0.42	1.55e-5	Height;
THYM	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg20283391	chr11:68216788	NA	-0.71	-5.27	-0.48	8.44e-7	Total body bone mineral density;
THYM	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg17554472	chr22:41940697	POLR3H	0.7	4.76	0.44	7.04e-6	Vitiligo;
THYM	trans	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg10856724	chr12:34555212	NA	-0.88	-7.57	-0.61	2.39e-11	Bladder cancer;
THYM	cis	rs4589258	0.762	rs1792595	chr11:90446148	C/T	cg26138821	chr11:89956704	CHORDC1	0.57	4.7	0.43	8.65e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg02375289	chr11:725873	EPS8L2	0.62	5.34	0.48	6.41e-7	Breast cancer;
THYM	cis	rs2839186	0.565	rs2839183	chr21:47687144	G/A	cg12379764	chr21:47803548	PCNT	0.91	6.21	0.54	1.4e-8	Testicular germ cell tumor;
THYM	cis	rs995000	0.965	rs4587594	chr1:63133930	G/A	cg06896770	chr1:63153194	DOCK7	1.0	7.85	0.63	6.33e-12	Triglyceride levels;
THYM	cis	rs752010	0.967	rs10890153	chr1:42102060	C/A	cg22486000	chr1:42919398	ZMYND12	-0.41	-4.64	-0.43	1.12e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs863345	0.584	rs10908677	chr1:158506186	C/T	cg12129480	chr1:158549410	OR10X1	0.51	4.88	0.45	4.19e-6	Pneumococcal bacteremia;
THYM	cis	rs2250402	1.000	rs2250402	chr15:40322552	G/T	cg02374934	chr15:41228736	DLL4	-0.69	-4.71	-0.43	8.52e-6	Corneal curvature;
THYM	cis	rs17685	0.884	rs3823882	chr7:75631913	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.53	5.42	0.49	4.43e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg03859395	chr2:55845619	SMEK2	0.7	6.23	0.54	1.28e-8	Metabolic syndrome;
THYM	cis	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.1	-0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7084402	0.967	rs7091440	chr10:60271372	T/A	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs1971762	1.000	rs10876480	chr12:54066271	C/G	cg16917193	chr12:54089295	NA	0.57	4.45	0.42	2.33e-5	Height;
THYM	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg05872129	chr22:39784769	NA	-1.04	-10.32	-0.73	3.48e-17	Intelligence (multi-trait analysis);
THYM	cis	rs3771570	1.000	rs59496049	chr2:242260756	G/C	cg21155796	chr2:242212141	HDLBP	1.16	6.55	0.56	2.88e-9	Prostate cancer;
THYM	cis	rs55882075	0.722	rs10903245	chr5:179133608	T/C	cg14593053	chr5:179126677	CANX	0.62	4.61	0.43	1.23e-5	Monocyte percentage of white cells;
THYM	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg18850127	chr7:39170497	POU6F2	0.6	5.66	0.5	1.57e-7	IgG glycosylation;
THYM	cis	rs61931739	0.711	rs7968821	chr12:34318351	G/A	cg06521331	chr12:34319734	NA	-0.69	-5.79	-0.51	9.16e-8	Morning vs. evening chronotype;
THYM	cis	rs7909074	1.000	rs7909074	chr10:45395839	G/A	cg04218760	chr10:45406644	TMEM72	-0.69	-6.47	-0.55	4.15e-9	Mean corpuscular volume;
THYM	cis	rs28647808	1.000	rs2285481	chr9:136271744	A/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg06221963	chr1:154839813	KCNN3	0.8	9.66	0.7	8.82e-16	Prostate cancer;
THYM	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.12	8.13	0.64	1.64e-12	Cognitive test performance;
THYM	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg18755752	chr8:142205143	DENND3	0.79	7.75	0.62	9.92e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg26384229	chr12:38710491	ALG10B	0.94	7.9	0.63	4.92e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg21385522	chr1:16154831	NA	-0.84	-6.09	-0.53	2.35e-8	Dilated cardiomyopathy;
THYM	cis	rs1497406	0.744	rs12057175	chr1:16508375	A/G	cg20430773	chr1:16534157	ARHGEF19	0.5	5.47	0.49	3.67e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs920590	0.684	rs59259846	chr8:19669468	C/G	cg03894339	chr8:19674705	INTS10	0.59	4.46	0.42	2.21e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg08901578	chr4:187885870	NA	-0.63	-5.79	-0.51	8.9e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg21984481	chr17:79567631	NPLOC4	0.46	4.87	0.45	4.45e-6	Eye color traits;
THYM	cis	rs28595532	0.920	rs115271785	chr4:119735748	A/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs2073300	1.000	rs6132629	chr20:23451251	G/A	cg12062639	chr20:23401060	NAPB	1.2	5.64	0.5	1.73e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs4792901	0.877	rs34454760	chr17:41642246	A/G	cg21940313	chr17:41620911	ETV4	-0.46	-5.04	-0.46	2.22e-6	Dupuytren's disease;
THYM	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg07511668	chr11:68622177	NA	0.43	4.63	0.43	1.15e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6942756	1.000	rs2718084	chr7:128897342	T/C	cg02491457	chr7:128862824	NA	0.44	4.66	0.43	1.03e-5	White matter hyperintensity burden;
THYM	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-4.88	-0.45	4.31e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg13683864	chr3:40499215	RPL14	1.07	12.42	0.79	1.31e-21	Renal cell carcinoma;
THYM	trans	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg19862616	chr7:65841803	NCRNA00174	1.09	12.64	0.79	4.47e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7246657	1.000	rs10426297	chr19:37798373	A/G	cg22634378	chr19:37742834	NA	0.63	5.28	0.48	8.18e-7	Coronary artery calcification;
THYM	cis	rs1021993	0.672	rs2843173	chr1:209487041	A/G	cg24997231	chr1:209527535	NA	0.5	4.5	0.42	1.9e-5	Gut microbiome composition (winter);
THYM	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg12573674	chr2:1569213	NA	-1.16	-8.07	-0.64	2.18e-12	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs1448094	0.512	rs7957170	chr12:86243282	A/G	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs10479542	0.533	rs10464056	chr5:178972705	G/T	cg14820908	chr5:178986412	RUFY1	0.55	4.54	0.42	1.66e-5	Lung cancer;
THYM	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg27588902	chr6:42928151	GNMT	-0.55	-5.52	-0.49	2.97e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg02018176	chr4:1364513	KIAA1530	0.55	4.59	0.43	1.35e-5	Obesity-related traits;
THYM	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg25811766	chr13:21894605	NA	-0.81	-5.33	-0.48	6.67e-7	White matter hyperintensity burden;
THYM	trans	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05901451	chr6:126070800	HEY2	-0.68	-5.99	-0.52	3.69e-8	Brugada syndrome;
THYM	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg27129171	chr3:47204927	SETD2	0.69	6.18	0.54	1.57e-8	Colorectal cancer;
THYM	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg00640147	chr17:61958756	GH2	-0.43	-4.6	-0.43	1.3e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg15557168	chr22:42548783	NA	0.6	4.82	0.44	5.52e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg09877947	chr5:131593287	PDLIM4	0.62	5.57	0.5	2.37e-7	Blood metabolite levels;
THYM	cis	rs6032067	0.543	rs13045693	chr20:43911817	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.61	-7.01	-0.58	3.44e-10	Blood protein levels;
THYM	cis	rs2282300	0.739	rs1765133	chr11:30339400	C/T	cg09906309	chr11:30344399	C11orf46	-0.73	-5.37	-0.48	5.47e-7	Morning vs. evening chronotype;
THYM	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.02	8.91	0.67	3.55e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7103648	0.712	rs10838703	chr11:47422861	C/G	cg20307385	chr11:47447363	PSMC3	0.81	5.87	0.52	6.25e-8	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs1784581	0.588	rs7765624	chr6:162427462	C/A	cg17173639	chr6:162384350	PARK2	0.8	7.18	0.59	1.57e-10	Itch intensity from mosquito bite;
THYM	cis	rs9287719	0.753	rs2018512	chr2:10759279	T/G	cg03983476	chr2:10830698	NOL10	-0.58	-5.35	-0.48	6.15e-7	Prostate cancer;
THYM	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg15605315	chr1:45957053	TESK2	0.79	6.68	0.57	1.61e-9	High light scatter reticulocyte count;
THYM	cis	rs920590	0.758	rs7012358	chr8:19662498	C/T	cg01411142	chr8:19674711	INTS10	0.61	4.66	0.43	1.03e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs6084875	0.840	rs1999665	chr20:4720988	C/T	cg19614321	chr20:4804581	RASSF2	0.45	4.53	0.42	1.7e-5	Systemic lupus erythematosus;
THYM	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg24209194	chr3:40518798	ZNF619	0.57	4.61	0.43	1.28e-5	Renal cell carcinoma;
THYM	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg00080972	chr5:178986291	RUFY1	0.52	6.1	0.53	2.26e-8	Lung cancer;
THYM	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg02527881	chr3:46936655	PTH1R	-0.57	-5.41	-0.49	4.69e-7	Colorectal cancer;
THYM	cis	rs6496667	0.533	rs7173201	chr15:90991195	A/T	cg00425431	chr15:90792223	TTLL13	0.4	4.64	0.43	1.11e-5	Rheumatoid arthritis;
THYM	cis	rs59698941	0.943	rs67551921	chr5:132289033	G/A	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs28595532	0.920	rs116231457	chr4:119762396	A/C	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg23248424	chr5:179741104	GFPT2	-0.94	-6.97	-0.58	4.06e-10	Height;
THYM	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg24397884	chr7:158709396	WDR60	-0.42	-4.94	-0.45	3.29e-6	Height;
THYM	cis	rs143985986	1	rs143985986	chr3:58399886	TC/T	cg26110898	chr3:58419937	PDHB	0.44	4.63	0.43	1.17e-5	Hematocrit;
THYM	cis	rs3806843	0.838	rs2262567	chr5:140132134	T/A	cg19875535	chr5:140030758	IK	-0.58	-4.52	-0.42	1.76e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs4654899	1.000	rs7525438	chr1:21458217	G/A	cg01072550	chr1:21505969	NA	-0.74	-6.69	-0.57	1.54e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs4242434	0.892	rs71513892	chr8:22456517	C/G	cg01710189	chr8:22454888	PDLIM2	-0.56	-5.38	-0.48	5.31e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg20486651	chr6:167070296	RPS6KA2	0.49	4.56	0.42	1.54e-5	Crohn's disease;
THYM	cis	rs72627123	0.867	rs79250763	chr14:74491121	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	4.87	0.45	4.38e-6	Morning vs. evening chronotype;
THYM	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.92	6.9	0.58	5.69e-10	Blood protein levels;
THYM	cis	rs600550	0.519	rs7931525	chr11:60103826	G/A	cg05040360	chr11:60102449	MS4A6E	0.48	4.67	0.43	9.74e-6	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg27494647	chr7:150038898	RARRES2	0.4	4.59	0.43	1.35e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs9486719	1.000	rs11152969	chr6:96908712	A/C	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg06609049	chr19:2785107	THOP1	0.69	5.85	0.51	6.83e-8	Total cholesterol levels;
THYM	cis	rs17548007	0.932	rs17450322	chr12:103362187	C/T	cg27569040	chr12:103351855	ASCL1	-1.13	-4.63	-0.43	1.17e-5	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
THYM	cis	rs4474465	0.790	rs4492845	chr11:78260161	C/T	cg19901956	chr11:77921274	USP35	0.6	4.7	0.43	8.86e-6	Alzheimer's disease (survival time);
THYM	cis	rs9457247	0.534	rs9347170	chr6:167405187	C/T	cg00271210	chr6:167070053	RPS6KA2	0.48	4.72	0.44	8e-6	Crohn's disease;
THYM	trans	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg12256311	chr17:685750	GLOD4;RNMTL1	-1.01	-7.1	-0.59	2.3e-10	Lung adenocarcinoma;
THYM	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg17105886	chr17:28927953	LRRC37B2	1.35	7.01	0.58	3.52e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg23682913	chr1:2080710	PRKCZ	0.6	4.83	0.44	5.13e-6	Height;
THYM	cis	rs8133932	0.636	rs2014421	chr21:47278308	A/G	cg20357416	chr21:47294739	PCBP3	-0.9	-6.18	-0.54	1.58e-8	Schizophrenia;
THYM	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg08975724	chr8:8085496	FLJ10661	-0.7	-5.61	-0.5	1.95e-7	Mood instability;
THYM	cis	rs7640424	1.000	rs7640424	chr3:107820063	C/T	cg09227934	chr3:107805635	CD47	-0.73	-5.73	-0.51	1.19e-7	Body mass index;
THYM	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg02353165	chr6:42928485	GNMT	0.98	10.22	0.72	5.53e-17	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg16418258	chr15:42840397	LRRC57;HAUS2	-0.56	-4.5	-0.42	1.95e-5	Lung cancer;
THYM	cis	rs7236492	0.577	rs7236190	chr18:77198217	T/C	cg15644404	chr18:77186268	NFATC1	-0.76	-4.88	-0.45	4.2e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22307029	chr19:49891270	CCDC155	0.81	7.15	0.59	1.74e-10	Multiple sclerosis;
THYM	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg09455208	chr3:40491958	NA	0.47	4.72	0.44	8.26e-6	Renal cell carcinoma;
THYM	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg08999081	chr20:33150536	PIGU	-0.77	-6.95	-0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs7100689	0.646	rs11202725	chr10:82136276	A/G	cg01528321	chr10:82214614	TSPAN14	0.79	6.01	0.52	3.47e-8	Post bronchodilator FEV1;
THYM	cis	rs11585357	0.947	rs2977304	chr1:17611615	T/C	cg08277548	chr1:17600880	PADI3	0.87	5.92	0.52	5.07e-8	Hair shape;
THYM	cis	rs4148087	1.000	rs9977571	chr21:43624157	G/A	cg09727148	chr21:43560719	UMODL1	0.56	4.59	0.43	1.33e-5	Eating disorder in bipolar disorder;
THYM	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg17178900	chr1:205818956	PM20D1	-0.67	-5.58	-0.5	2.29e-7	Prostate-specific antigen levels;
THYM	cis	rs10503871	0.584	rs12550251	chr8:30454729	G/A	cg12158488	chr8:31336998	NA	-0.4	-4.46	-0.42	2.26e-5	Metabolite levels  (X-11787);
THYM	cis	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg10856724	chr12:34555212	NA	1.04	10.25	0.72	4.77e-17	Morning vs. evening chronotype;
THYM	cis	rs995000	0.931	rs10889330	chr1:62939466	G/C	cg06896770	chr1:63153194	DOCK7	0.91	7.77	0.62	9.14e-12	Triglyceride levels;
THYM	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg02527881	chr3:46936655	PTH1R	-0.65	-6.04	-0.53	3.02e-8	Colorectal cancer;
THYM	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg26721908	chr21:47610096	LSS	0.71	5.12	0.47	1.59e-6	Testicular germ cell tumor;
THYM	cis	rs10791323	0.571	rs4937839	chr11:133734177	T/C	cg03690763	chr11:133734501	NA	-0.64	-5.23	-0.47	1.01e-6	Childhood ear infection;
THYM	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg18876405	chr7:65276391	NA	0.58	4.83	0.44	5.18e-6	Aortic root size;
THYM	cis	rs7731657	0.537	rs3981875	chr5:130226055	G/C	cg08523029	chr5:130500466	HINT1	-0.79	-5.38	-0.48	5.4e-7	Fasting plasma glucose;
THYM	cis	rs11039798	0.511	rs7948129	chr11:48167828	G/A	cg24672777	chr11:48374446	OR4C45	0.8	4.68	0.43	9.48e-6	Axial length;
THYM	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg00310523	chr12:86230176	RASSF9	0.53	4.89	0.45	4.13e-6	Major depressive disorder;
THYM	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg27535305	chr1:53392650	SCP2	-0.4	-4.52	-0.42	1.78e-5	Monocyte count;
THYM	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg13918804	chr1:2043761	PRKCZ	0.62	4.83	0.44	5.32e-6	Height;
THYM	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.9	8.42	0.65	3.88e-13	Monocyte percentage of white cells;
THYM	cis	rs3772130	0.885	rs9816844	chr3:121496324	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs747334	0.846	rs11186398	chr10:92723864	A/G	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg13175981	chr1:150552382	MCL1	0.7	5.1	0.46	1.75e-6	Lymphocyte counts;
THYM	cis	rs36051895	0.632	rs12352285	chr9:5141476	C/G	cg02405213	chr9:5042618	JAK2	-1.03	-10.77	-0.74	3.84e-18	Pediatric autoimmune diseases;
THYM	cis	rs12216545	0.711	rs9632622	chr7:150233219	T/C	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs9796	0.866	rs2176998	chr15:41420807	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.56	-4.57	-0.42	1.45e-5	Menopause (age at onset);
THYM	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.42	4.47	0.42	2.18e-5	Hemoglobin concentration;
THYM	cis	rs9814567	0.752	rs13084192	chr3:134336095	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.76	7.23	0.6	1.24e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg06558623	chr16:89946397	TCF25	0.88	4.75	0.44	7.33e-6	Skin colour saturation;
THYM	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg04025307	chr7:1156635	C7orf50	0.52	4.51	0.42	1.88e-5	Longevity;Endometriosis;
THYM	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg01483505	chr11:975446	AP2A2	0.58	4.75	0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg08859206	chr1:53392774	SCP2	0.6	6.72	0.57	1.34e-9	Monocyte count;
THYM	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.66	5.56	0.5	2.48e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg06130144	chr11:64578348	MEN1	0.71	4.51	0.42	1.83e-5	Mean platelet volume;
THYM	cis	rs985746	0.568	rs1542017	chr4:36795855	A/G	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg23708337	chr7:1209742	NA	0.78	5.92	0.52	4.99e-8	Longevity;Endometriosis;
THYM	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg25767906	chr1:53392781	SCP2	-0.63	-6.25	-0.54	1.18e-8	Monocyte count;
THYM	cis	rs4792901	1.000	rs12149975	chr17:41660682	C/T	cg21940313	chr17:41620911	ETV4	0.5	5.42	0.49	4.55e-7	Dupuytren's disease;
THYM	cis	rs7104764	0.507	rs7111364	chr11:258542	G/C	cg18336825	chr11:236787	PSMD13;SIRT3	0.85	5.53	0.49	2.83e-7	Menarche (age at onset);
THYM	cis	rs7000551	0.689	rs10110254	chr8:22309551	G/T	cg12081754	chr8:22256438	SLC39A14	0.64	5.23	0.47	1.02e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9430161	0.579	rs79323519	chr1:11036050	T/C	cg27631724	chr1:11040367	C1orf127	0.63	5.35	0.48	6.13e-7	Ewing sarcoma;
THYM	cis	rs3820068	0.562	rs10927841	chr1:16045261	T/C	cg24675056	chr1:15929824	NA	0.75	5.67	0.5	1.53e-7	Systolic blood pressure;
THYM	cis	rs888194	0.898	rs10850379	chr12:110002777	A/G	cg11367159	chr12:110044531	NA	-0.57	-5.41	-0.49	4.68e-7	Neuroticism;
THYM	cis	rs12893597	0.821	rs12896434	chr14:76816746	C/T	cg20290672	chr14:76816747	NA	-0.75	-6.3	-0.54	9.09e-9	Maximal oxygen uptake response;
THYM	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.48	-4.62	-0.43	1.19e-5	Crohn's disease;
THYM	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg15704280	chr7:45808275	SEPT13	-1.04	-14.05	-0.82	6.23e-25	Height;
THYM	cis	rs2458413	0.586	rs2669453	chr8:105368930	C/A	cg21295575	chr8:105352067	TM7SF4	-0.31	-4.93	-0.45	3.55e-6	Paget's disease;
THYM	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg03474202	chr17:45855739	NA	-0.74	-6.5	-0.55	3.7e-9	IgG glycosylation;
THYM	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg03609598	chr5:56110824	MAP3K1	-0.91	-6.33	-0.54	8.19e-9	Initial pursuit acceleration;
THYM	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg00376283	chr12:123451042	ABCB9	0.93	7.83	0.63	7e-12	Platelet count;
THYM	cis	rs11771526	1.000	rs6462350	chr7:32342000	G/A	cg27532318	chr7:32358331	NA	0.91	5.34	0.48	6.45e-7	Body mass index;
THYM	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg11266682	chr4:10021025	SLC2A9	0.74	12.07	0.78	6.92e-21	Bone mineral density;
THYM	cis	rs240764	0.658	rs7746947	chr6:101188708	G/A	cg21058520	chr6:100914733	NA	0.56	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs34638657	0.833	rs7200628	chr16:82200747	C/T	cg09439754	chr16:82129088	HSD17B2	-0.57	-5.6	-0.5	2.06e-7	Lung adenocarcinoma;
THYM	trans	rs8073060	0.545	rs3859282	chr17:34006111	T/C	cg19694781	chr19:47549865	TMEM160	-1.02	-8.69	-0.67	1.01e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs9796	0.870	rs2412574	chr15:41259707	G/C	cg21153102	chr15:41252147	NA	0.73	6.88	0.58	6.27e-10	Menopause (age at onset);
THYM	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg26384229	chr12:38710491	ALG10B	-0.62	-4.57	-0.42	1.49e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs13418717	1.000	rs4452092	chr2:127655112	G/A	cg25501666	chr2:127640322	NA	1.64	6.58	0.56	2.51e-9	Heart failure;
THYM	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg20744362	chr22:50050164	C22orf34	0.71	6.51	0.56	3.47e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg16586182	chr3:47516702	SCAP	-0.62	-5.32	-0.48	6.98e-7	Colorectal cancer;
THYM	cis	rs7633857	0.512	rs733948	chr3:160652784	C/G	cg03342759	chr3:160939853	NMD3	-0.61	-4.73	-0.44	7.89e-6	Educational attainment (years of education);
THYM	cis	rs713587	0.934	rs6728219	chr2:25159172	T/C	cg15423357	chr2:25149977	NA	0.66	7.21	0.59	1.3100000000000001e-10	Body mass index in non-asthmatics;
THYM	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg20744362	chr22:50050164	C22orf34	0.83	8.13	0.64	1.63e-12	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs898549	1.000	rs66887775	chr10:44459605	C/T	cg08683644	chr10:44853092	NA	0.45	4.61	0.43	1.27e-5	Obesity-related traits;
THYM	cis	rs919433	0.617	rs700643	chr2:198601370	A/G	cg00792783	chr2:198669748	PLCL1	0.81	5.67	0.5	1.51e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7833986	1.000	rs72654002	chr8:57095939	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	4.98	0.45	2.84e-6	Height;
THYM	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg20821713	chr7:1055600	C7orf50	-0.43	-4.59	-0.43	1.36e-5	Bronchopulmonary dysplasia;
THYM	cis	rs1021993	0.597	rs2356722	chr1:209524734	A/G	cg24997231	chr1:209527535	NA	-0.6	-5.42	-0.49	4.43e-7	Gut microbiome composition (winter);
THYM	cis	rs28595532	0.920	rs114037572	chr4:119735609	T/G	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg05660106	chr1:15850417	CASP9	0.73	5.92	0.52	5.14e-8	Systolic blood pressure;
THYM	cis	rs1003719	0.715	rs1981432	chr21:38541356	G/A	cg01329690	chr21:38580129	DSCR9	-0.4	-5.64	-0.5	1.74e-7	Eye color traits;
THYM	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg06766960	chr11:133703094	NA	-0.52	-4.83	-0.44	5.25e-6	Childhood ear infection;
THYM	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.62	0.66	1.45e-13	Cognitive test performance;
THYM	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg06636001	chr8:8085503	FLJ10661	0.8	7.66	0.62	1.59e-11	Mood instability;
THYM	cis	rs13177918	0.677	rs13161417	chr5:149822500	G/C	cg14059543	chr5:149831962	NA	-1.0	-7.6	-0.61	2.11e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg19507638	chr5:93509721	C5orf36	0.68	4.57	0.42	1.49e-5	Diabetic retinopathy;
THYM	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs4523957	0.614	rs7219693	chr17:2061101	C/A	cg16513277	chr17:2031491	SMG6	-0.94	-8.42	-0.65	3.95e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg27490568	chr2:178487706	NA	0.62	5.84	0.51	7.15e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9816226	1.000	rs61587156	chr3:185831583	T/G	cg00760338	chr3:185826511	ETV5	-0.74	-4.56	-0.42	1.55e-5	Obesity;Body mass index;
THYM	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg09455208	chr3:40491958	NA	0.48	4.94	0.45	3.33e-6	Renal cell carcinoma;
THYM	cis	rs6570726	0.905	rs419575	chr6:145840174	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg03474202	chr17:45855739	NA	-0.76	-6.7	-0.57	1.45e-9	IgG glycosylation;
THYM	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.719	rs35184673	chr4:99050945	T/C	cg24818145	chr4:99064322	C4orf37	0.97	6.03	0.53	3.12e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11031096	0.655	rs10835695	chr11:4178962	G/T	cg08557956	chr11:4115526	RRM1	-0.52	-4.68	-0.43	9.36e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg02782426	chr3:40428986	ENTPD3	0.54	4.78	0.44	6.26e-6	Renal cell carcinoma;
THYM	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg02627403	chr17:73823769	UNC13D	-0.46	-4.85	-0.45	4.8e-6	White matter hyperintensity burden;
THYM	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg07636037	chr3:49044803	WDR6	0.96	9.68	0.7	8e-16	Parkinson's disease;
THYM	cis	rs9435341	0.860	rs12406721	chr1:107563243	G/T	cg00944433	chr1:107599041	PRMT6	-0.41	-4.6	-0.43	1.28e-5	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs67981189	0.865	rs2810117	chr14:71391025	T/C	cg15910301	chr14:71632612	NA	-0.5	-4.54	-0.42	1.66e-5	Schizophrenia;
THYM	cis	rs6732160	0.588	rs13407363	chr2:73372558	T/C	cg24220031	chr2:73402428	NA	-0.73	-6.05	-0.53	2.79e-8	Intelligence (multi-trait analysis);
THYM	cis	rs941408	0.515	rs56000942	chr19:2774104	G/C	cg06609049	chr19:2785107	THOP1	1.06	10.0	0.72	1.65e-16	Total cholesterol levels;
THYM	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg09165964	chr15:75287851	SCAMP5	-1.07	-10.9	-0.75	1.98e-18	Blood trace element (Zn levels);
THYM	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg18681998	chr4:17616180	MED28	0.93	9.4	0.69	3.1e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg04455712	chr21:45112962	RRP1B	0.51	4.63	0.43	1.16e-5	Mean corpuscular volume;
THYM	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg16230307	chr14:35515116	FAM177A1	0.78	5.05	0.46	2.17e-6	Psoriasis;
THYM	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg12560992	chr17:57184187	TRIM37	0.93	8.88	0.67	4.06e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.86	-7.67	-0.62	1.46e-11	Intelligence (multi-trait analysis);
THYM	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg18105134	chr13:113819100	PROZ	-1.16	-10.33	-0.73	3.27e-17	Platelet distribution width;
THYM	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg03388043	chr17:80084554	CCDC57	0.69	5.98	0.52	3.85e-8	Life satisfaction;
THYM	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.56	-6.14	-0.53	1.92e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg05717871	chr11:638507	DRD4	-0.62	-4.96	-0.45	3.11e-6	Systemic lupus erythematosus;
THYM	cis	rs9457247	0.534	rs9366078	chr6:167399512	A/G	cg15592062	chr6:167189543	RPS6KA2	0.52	5.32	0.48	6.84e-7	Crohn's disease;
THYM	cis	rs921968	0.643	rs832802	chr2:219386899	C/T	cg02176678	chr2:219576539	TTLL4	0.68	6.71	0.57	1.42e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg23711669	chr6:146136114	FBXO30	0.97	10.49	0.73	1.45e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7296418	0.922	rs1727293	chr12:123648032	C/T	cg05973401	chr12:123451056	ABCB9	0.65	4.72	0.44	8.04e-6	Platelet count;
THYM	cis	rs7264396	0.836	rs6058275	chr20:34186331	G/A	cg26038318	chr20:34205095	SPAG4	0.54	4.53	0.42	1.69e-5	Total cholesterol levels;
THYM	cis	rs7106204	0.514	rs10834307	chr11:24272516	G/A	ch.11.24196551F	chr11:24239977	NA	-1.0	-7.09	-0.59	2.34e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7894051	0.850	rs41310326	chr10:135182280	C/T	cg12428399	chr10:135191333	PAOX	1.2	4.47	0.42	2.17e-5	Lifespan;
THYM	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg04234412	chr22:24373322	LOC391322	0.98	12.22	0.78	3.35e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg13683864	chr3:40499215	RPL14	-0.76	-7.12	-0.59	2.03e-10	Renal cell carcinoma;
THYM	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg17366294	chr4:99064904	C4orf37	0.56	6.58	0.56	2.51e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8101881	0.576	rs7250662	chr19:33364092	T/G	cg16861209	chr19:33361127	SLC7A9	-0.5	-4.57	-0.42	1.44e-5	Blood metabolite levels;Urinary metabolites;Urinary metabolites (H-NMR features);
THYM	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg22875332	chr1:76189707	ACADM	0.88	11.22	0.75	4.31e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6430585	0.702	rs2304601	chr2:136528034	C/A	cg07169764	chr2:136633963	MCM6	1.22	13.28	0.81	2.23e-23	Corneal structure;
THYM	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg17178900	chr1:205818956	PM20D1	1.05	11.83	0.77	2.23e-20	Menarche (age at onset);
THYM	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg02725872	chr8:58115012	NA	-0.94	-7.12	-0.59	2.07e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs2069036	0.779	rs9988786	chr10:16075202	T/C	cg26633223	chr10:15133461	NA	0.62	4.66	0.43	1.03e-5	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg02887458	chr19:19495540	GATAD2A	-0.42	-5.08	-0.46	1.87e-6	Bipolar disorder;
THYM	cis	rs1003719	0.646	rs2032063	chr21:38576657	A/T	cg01329690	chr21:38580129	DSCR9	-0.36	-5.0	-0.46	2.67e-6	Eye color traits;
THYM	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.28	4.5	0.42	1.96e-5	Obesity-related traits;
THYM	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg08999081	chr20:33150536	PIGU	-0.75	-6.89	-0.58	5.99e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs2928148	0.522	rs11858278	chr15:41416276	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.88	-7.25	-0.6	1.12e-10	Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg16586182	chr3:47516702	SCAP	-0.67	-5.61	-0.5	1.99e-7	Colorectal cancer;
THYM	cis	rs6960043	0.875	rs2215382	chr7:15055010	C/G	cg19272540	chr7:15055459	NA	0.53	5.95	0.52	4.43e-8	Type 2 diabetes;
THYM	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg09035930	chr12:129282057	SLC15A4	-0.59	-5.24	-0.47	9.46e-7	Systemic lupus erythematosus;
THYM	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg16342193	chr10:102329863	NA	-0.53	-5.32	-0.48	6.84e-7	Palmitoleic acid (16:1n-7) levels;
THYM	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg15704280	chr7:45808275	SEPT13	1.02	11.52	0.76	9.66e-20	Coronary artery disease;
THYM	cis	rs34330	0.562	rs12229100	chr12:12865836	A/G	cg09462578	chr12:12878428	APOLD1	0.91	5.48	0.49	3.43e-7	Systemic lupus erythematosus;
THYM	cis	rs4660306	0.677	rs1691217	chr1:45900190	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.66	4.65	0.43	1.06e-5	Homocysteine levels;
THYM	cis	rs4788570	0.625	rs4788810	chr16:71621637	C/T	cg06353428	chr16:71660113	MARVELD3	-1.34	-7.64	-0.62	1.76e-11	Intelligence (multi-trait analysis);
THYM	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg00684032	chr4:1343700	KIAA1530	0.68	5.58	0.5	2.31e-7	Obesity-related traits;
THYM	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18252515	chr7:66147081	NA	0.64	4.69	0.43	9.21e-6	Aortic root size;
THYM	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg22875332	chr1:76189707	ACADM	0.86	10.01	0.72	1.6e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg06026331	chr20:60912101	LAMA5	0.84	6.34	0.55	7.83e-9	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs6988636	1.000	rs13260775	chr8:124190167	G/A	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs36051895	0.664	rs10115518	chr9:5094559	T/C	cg02405213	chr9:5042618	JAK2	-1.0	-10.94	-0.75	1.67e-18	Pediatric autoimmune diseases;
THYM	cis	rs2180341	0.513	rs12196828	chr6:127696864	C/T	cg27446573	chr6:127587934	RNF146	0.74	6.05	0.53	2.85e-8	Breast cancer;
THYM	cis	rs13017997	0.510	rs6751480	chr2:156874657	T/C	cg17654050	chr2:157184978	NR4A2	0.37	4.5	0.42	1.94e-5	Schizophrenia;
THYM	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4234284	0.556	rs13072737	chr3:126948835	C/T	cg27326032	chr3:127006922	NA	-0.82	-5.36	-0.48	5.73e-7	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
THYM	cis	rs8077889	1.000	rs113919636	chr17:41877740	A/C	cg26893861	chr17:41843967	DUSP3	0.98	8.64	0.66	1.31e-13	Triglycerides;
THYM	cis	rs7119	0.689	rs11630557	chr15:77820712	A/G	cg10437265	chr15:77819839	NA	0.77	7.68	0.62	1.44e-11	Type 2 diabetes;
THYM	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg10802521	chr3:52805072	NEK4	-0.72	-6.16	-0.53	1.77e-8	Bipolar disorder;
THYM	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg05347473	chr6:146136440	FBXO30	-0.8	-7.14	-0.59	1.85e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-5.28	-0.48	8.27e-7	Joint mobility (Beighton score);
THYM	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg04234412	chr22:24373322	LOC391322	-0.9	-9.0	-0.68	2.22e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs28595532	0.920	rs116146507	chr4:119749556	A/G	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg05234568	chr11:5960015	NA	-0.57	-4.53	-0.42	1.69e-5	DNA methylation (variation);
THYM	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg03806693	chr22:41940476	POLR3H	-1.21	-10.75	-0.74	4.11e-18	Vitiligo;
THYM	cis	rs854765	0.718	rs6502629	chr17:17869642	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	5.99	0.52	3.76e-8	Total body bone mineral density;
THYM	cis	rs3845702	0.736	rs12693214	chr2:180825685	G/A	cg01881094	chr2:180872142	CWC22	-0.89	-5.34	-0.48	6.22e-7	Schizophrenia;
THYM	cis	rs3862030	0.810	rs11593710	chr10:104328719	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-5.7	-0.5	1.33e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg27535305	chr1:53392650	SCP2	-0.54	-6.2	-0.54	1.48e-8	Monocyte count;
THYM	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg12863693	chr15:85201151	NMB	0.63	5.63	0.5	1.8e-7	Schizophrenia;
THYM	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg23649088	chr2:200775458	C2orf69	-0.74	-5.59	-0.5	2.17e-7	Schizophrenia;
THYM	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg24578937	chr1:2090814	PRKCZ	0.79	8.18	0.64	1.26e-12	Height;
THYM	trans	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.66	-0.62	1.53e-11	Exhaled nitric oxide output;
THYM	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg08885076	chr2:99613938	TSGA10	0.66	5.97	0.52	4.17e-8	Chronic sinus infection;
THYM	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg22431228	chr1:16359049	CLCNKA	-0.51	-4.97	-0.45	3e-6	Dilated cardiomyopathy;
THYM	cis	rs55702914	0.628	rs67657812	chr2:198387401	A/G	cg00792783	chr2:198669748	PLCL1	0.66	4.88	0.45	4.32e-6	Major depression and alcohol dependence;
THYM	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg05283184	chr6:79620031	NA	0.91	9.08	0.68	1.5e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7220711	0.902	rs4793019	chr17:41781160	A/C	cg26893861	chr17:41843967	DUSP3	-0.64	-5.42	-0.49	4.5e-7	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs7943203	0.925	rs11212666	chr11:108350451	A/T	cg04873221	chr11:107992290	ACAT1	-0.62	-4.51	-0.42	1.88e-5	Red blood cell count;Mean corpuscular volume;
THYM	cis	rs9796	0.866	rs2928148	chr15:41401550	G/A	cg18705301	chr15:41695430	NDUFAF1	0.6	4.89	0.45	4.12e-6	Menopause (age at onset);
THYM	cis	rs919433	0.653	rs700651	chr2:198631714	G/A	cg05783139	chr2:198650985	BOLL	0.6	4.65	0.43	1.06e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2637266	1.000	rs6480827	chr10:78356333	T/G	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs2340727	0.660	rs1962508	chr1:161945419	C/A	ch.1.159725313R	chr1:161458689	NA	-0.78	-5.32	-0.48	6.8e-7	White blood cell count;Hematology traits;
THYM	cis	rs4900538	0.855	rs762105	chr14:102830175	A/G	cg18135206	chr14:102964638	TECPR2	-0.81	-6.24	-0.54	1.2e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg00383909	chr3:49044727	WDR6	1.16	6.78	0.57	1.02e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg27490568	chr2:178487706	NA	0.61	5.63	0.5	1.82e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2811415	0.597	rs9814296	chr3:127732028	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg06108461	chr20:60628389	TAF4	-0.83	-7.04	-0.59	3.03e-10	Body mass index;
THYM	cis	rs9302635	0.513	rs7198572	chr16:72183220	G/A	cg23815491	chr16:72088622	HP	0.79	6.18	0.54	1.62e-8	Blood protein levels;
THYM	trans	rs6462411	0.818	rs2057921	chr7:3907788	C/T	cg14907788	chr19:2555976	GNG7	0.66	6.9	0.58	5.76e-10	Quantitative traits;
THYM	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg03433033	chr1:76189801	ACADM	0.76	8.16	0.64	1.4e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9560113	0.960	rs4773378	chr13:112174154	G/A	cg14154082	chr13:112174009	NA	0.86	8.0	0.63	2.95e-12	Menarche (age at onset);
THYM	cis	rs35883536	0.967	rs1855788	chr1:101118331	A/G	cg06223162	chr1:101003688	GPR88	0.62	4.74	0.44	7.46e-6	Monocyte count;
THYM	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg13683864	chr3:40499215	RPL14	-1.05	-11.49	-0.76	1.13e-19	Renal cell carcinoma;
THYM	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg24803719	chr17:45855879	NA	-0.6	-6.31	-0.54	8.89e-9	IgG glycosylation;
THYM	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg13010199	chr12:38710504	ALG10B	-0.59	-5.14	-0.47	1.46e-6	Heart rate;
THYM	cis	rs11731175	0.960	rs7435006	chr4:189858093	C/T	cg00431894	chr4:189871012	NA	-0.81	-6.19	-0.54	1.52e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg02734326	chr4:10020555	SLC2A9	-0.71	-6.2	-0.54	1.44e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2361710	0.704	rs12937349	chr17:78120320	G/C	cg09238746	chr17:78121135	EIF4A3	-0.78	-6.43	-0.55	5e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
THYM	cis	rs524281	0.731	rs476551	chr11:66006323	G/C	cg00563793	chr11:65837595	PACS1	0.77	4.62	0.43	1.19e-5	Electroencephalogram traits;
THYM	cis	rs9560113	0.509	rs4773390	chr13:112208904	G/A	cg10483660	chr13:112241077	NA	0.64	7.01	0.58	3.46e-10	Menarche (age at onset);
THYM	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.59	-11.2	-0.75	4.73e-19	Hemostatic factors and hematological phenotypes;
THYM	cis	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg12981288	chr8:11183844	MTMR9	-0.47	-4.65	-0.43	1.09e-5	Retinal vascular caliber;
THYM	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg10047753	chr17:41438598	NA	1.19	11.63	0.77	5.87e-20	Menopause (age at onset);
THYM	cis	rs12928939	0.517	rs10852507	chr16:71971900	G/A	cg03805757	chr16:71968109	PKD1L3	-1.1	-11.02	-0.75	1.11e-18	Post bronchodilator FEV1;
THYM	cis	rs7084402	0.967	rs1658462	chr10:60298284	A/C	cg07615347	chr10:60278583	BICC1	0.57	5.36	0.48	5.86e-7	Refractive error;
THYM	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg00129232	chr17:37814104	STARD3	-0.71	-4.8	-0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs1580019	0.961	rs6949851	chr7:32493807	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.76	6.82	0.57	8.42e-10	Cognitive ability;
THYM	cis	rs2303759	0.918	rs10405465	chr19:49869298	C/T	cg22133161	chr19:49891603	CCDC155	0.77	5.15	0.47	1.38e-6	Multiple sclerosis;
THYM	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg13147721	chr7:65941812	NA	0.73	4.58	0.43	1.42e-5	Diabetic kidney disease;
THYM	cis	rs7226229	0.950	rs3816664	chr17:20918834	T/C	cg21263980	chr17:20946333	USP22	0.67	5.02	0.46	2.38e-6	Blood trace element (Se levels);
THYM	cis	rs7084402	0.967	rs1649025	chr10:60281584	C/G	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs56104184	0.775	rs56349331	chr19:49403009	T/A	cg19746536	chr19:49375674	PPP1R15A	0.81	4.59	0.43	1.34e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg26022315	chr17:47021804	SNF8	0.51	4.87	0.45	4.44e-6	Type 2 diabetes;
THYM	cis	rs6541297	1.000	rs2144298	chr1:230280198	T/C	cg20703242	chr1:230279135	GALNT2	0.94	6.07	0.53	2.57e-8	Coronary artery disease;
THYM	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs7107174	1.000	rs2512542	chr11:77981780	G/A	cg19901956	chr11:77921274	USP35	-0.64	-4.97	-0.45	2.97e-6	Testicular germ cell tumor;
THYM	trans	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Bladder cancer;
THYM	cis	rs612683	0.602	rs12565245	chr1:101019326	T/G	cg06223162	chr1:101003688	GPR88	0.84	7.58	0.61	2.27e-11	Breast cancer;
THYM	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg22709100	chr7:91322751	NA	0.63	4.86	0.45	4.55e-6	Breast cancer;
THYM	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg10515332	chr4:99064459	C4orf37	0.57	4.54	0.42	1.68e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4950928	0.823	rs2494277	chr1:203168092	A/G	cg17014757	chr1:203156097	CHI3L1	-0.96	-5.81	-0.51	8.25e-8	YKL-40 levels;
THYM	cis	rs9814567	1.000	rs3846055	chr3:134203973	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-8.32	-0.65	6.32e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2637266	0.935	rs12414653	chr10:78394071	C/G	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7769051	0.522	rs11965927	chr6:133101353	T/C	cg07930552	chr6:133119739	C6orf192	1.24	5.07	0.46	1.97e-6	Type 2 diabetes nephropathy;
THYM	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs7666738	0.546	rs7699578	chr4:98838893	T/C	cg03676636	chr4:99064102	C4orf37	0.45	4.72	0.44	8.02e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg14004847	chr7:1930337	MAD1L1	-0.67	-5.14	-0.47	1.45e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6163	0.588	rs3818708	chr10:104503584	C/T	cg04362960	chr10:104952993	NT5C2	0.56	4.78	0.44	6.5e-6	Waist circumference;Hip circumference;
THYM	cis	rs960902	0.648	rs11124585	chr2:37711892	G/A	cg25341268	chr2:37734390	NA	0.57	4.53	0.42	1.69e-5	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg00191853	chr8:101177733	SPAG1	0.56	5.34	0.48	6.33e-7	Atrioventricular conduction;
THYM	cis	rs2806561	0.734	rs2235548	chr1:23394062	G/A	cg19743168	chr1:23544995	NA	0.48	4.69	0.43	9.07e-6	Height;
THYM	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg26384229	chr12:38710491	ALG10B	-0.89	-9.06	-0.68	1.67e-14	Heart rate;
THYM	cis	rs854765	0.686	rs8065497	chr17:17782649	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-5.83	-0.51	7.69e-8	Total body bone mineral density;
THYM	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg01831904	chr17:28903510	LRRC37B2	-1.02	-5.0	-0.46	2.64e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	4.81	0.44	5.69e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1457451	0.749	rs2024450	chr2:65868962	C/G	cg16240816	chr2:65861662	NA	-0.63	-6.56	-0.56	2.79e-9	Iron status biomarkers;
THYM	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08704250	chr15:31115839	NA	-0.64	-6.32	-0.54	8.3e-9	Huntington's disease progression;
THYM	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	9.55	0.7	1.49e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4654899	0.897	rs1021077	chr1:21106016	A/G	cg01072550	chr1:21505969	NA	-0.61	-5.27	-0.48	8.41e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg04455712	chr21:45112962	RRP1B	0.51	4.72	0.44	8.23e-6	Mean corpuscular volume;
THYM	cis	rs818427	0.684	rs465899	chr5:112177171	G/A	cg04614008	chr5:112630677	MCC	-0.64	-4.64	-0.43	1.12e-5	Total body bone mineral density;
THYM	cis	rs8133932	0.701	rs2839021	chr21:47280016	C/T	cg20357416	chr21:47294739	PCBP3	0.9	6.21	0.54	1.37e-8	Schizophrenia;
THYM	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg13607699	chr17:42295918	UBTF	0.91	9.47	0.7	2.26e-15	Total body bone mineral density;
THYM	cis	rs220324	0.688	rs9979344	chr21:43559926	C/T	cg09727148	chr21:43560719	UMODL1	0.84	10.06	0.72	1.26e-16	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.64	-5.4	-0.48	4.8e-7	Height;
THYM	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	6.37	0.55	6.76e-9	Total body bone mineral density;
THYM	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg18252515	chr7:66147081	NA	0.63	4.74	0.44	7.37e-6	Aortic root size;
THYM	cis	rs4836390	0.656	rs10072361	chr5:128017544	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	4.64	0.43	1.09e-5	Coronary artery disease;
THYM	cis	rs2075230	0.850	rs6503039	chr17:7470060	A/G	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	0.31	4.48	0.42	2.07e-5	Hormone measurements;
THYM	cis	rs586688	0.543	rs1267115	chr1:201676312	A/G	cg14168733	chr1:201708718	NAV1	-0.56	-5.11	-0.46	1.67e-6	Obesity-related traits;
THYM	cis	rs11650494	0.710	rs11654557	chr17:47390136	A/G	cg08112188	chr17:47440006	ZNF652	1.25	5.41	0.49	4.62e-7	Prostate cancer;
THYM	cis	rs8073060	0.855	rs12150450	chr17:33868896	A/T	cg07895132	chr17:33825172	SLFN12L	0.61	5.6	0.5	2.08e-7	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs2463822	0.687	rs118012228	chr11:62155914	G/A	cg06239285	chr11:62104954	ASRGL1	-1.4	-6.65	-0.56	1.86e-9	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2797160	1.000	rs1739349	chr6:126014984	G/C	cg16306078	chr6:126000798	NA	0.54	5.53	0.49	2.75e-7	Endometrial cancer;
THYM	cis	rs6424115	0.830	rs6672157	chr1:24198840	C/G	cg15997130	chr1:24165203	NA	0.74	6.35	0.55	7.22e-9	Immature fraction of reticulocytes;
THYM	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.48	-0.42	2.05e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs4654899	0.828	rs4654735	chr1:21432001	T/C	cg01072550	chr1:21505969	NA	-0.72	-6.3	-0.54	9.05e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs7688540	0.771	rs11722521	chr4:276765	A/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.68	4.82	0.44	5.43e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs870825	0.549	rs28579266	chr4:185627262	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg02478829	chr6:26598070	ABT1	-0.33	-4.46	-0.42	2.27e-5	Intelligence (multi-trait analysis);
THYM	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg01579765	chr21:45077557	HSF2BP	0.53	8.47	0.66	2.98e-13	Mean corpuscular volume;
THYM	cis	rs986417	1.000	rs9989167	chr14:60942374	T/C	cg27398547	chr14:60952738	C14orf39	1.13	6.34	0.55	7.62e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4732038	0.510	rs12671983	chr7:134273155	T/C	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.38	0.55	6.27e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg08645402	chr16:4508243	NA	0.78	7.72	0.62	1.19e-11	Schizophrenia;
THYM	cis	rs1401999	0.628	rs1520195	chr3:183736882	G/A	cg01324343	chr3:183735012	ABCC5	0.73	9.23	0.69	7.4e-15	Anterior chamber depth;
THYM	cis	rs8130944	0.866	rs1878070	chr21:44123705	A/G	cg04090347	chr21:44061597	NA	-0.56	-4.7	-0.43	8.83e-6	Perceived unattractiveness to mosquitoes;
THYM	cis	rs2732480	0.523	rs34286639	chr12:48629044	C/T	cg21466736	chr12:48725269	NA	-0.55	-5.02	-0.46	2.43e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs7567389	0.853	rs7585314	chr2:127962493	T/C	cg06038358	chr2:128176007	PROC	-0.46	-4.81	-0.44	5.76e-6	Self-rated health;
THYM	cis	rs1061377	1.000	rs9996285	chr4:39132176	A/G	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs2625529	0.713	rs12903980	chr15:72165549	C/T	cg16672083	chr15:72433130	SENP8	-0.51	-4.58	-0.43	1.39e-5	Red blood cell count;
THYM	cis	rs1007190	0.881	rs3744470	chr17:42983901	A/T	cg15406952	chr17:42872593	NA	0.8	5.57	0.5	2.34e-7	DNA methylation (variation);
THYM	cis	rs4481887	1.000	rs11204626	chr1:248458974	T/A	cg00666640	chr1:248458726	OR2T12	0.57	4.66	0.43	1.05e-5	Common traits (Other);
THYM	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg26131816	chr17:42072204	PYY	0.53	4.5	0.42	1.96e-5	Menopause (age at onset);
THYM	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg09469691	chr10:81107165	PPIF	0.71	5.51	0.49	3.09e-7	Height;
THYM	cis	rs977987	0.806	rs4146809	chr16:75415775	A/G	cg03315344	chr16:75512273	CHST6	-0.68	-5.88	-0.52	6.22e-8	Dupuytren's disease;
THYM	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg26384229	chr12:38710491	ALG10B	0.97	7.44	0.61	4.48e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs61931739	0.534	rs2087128	chr12:34000173	T/C	cg10856724	chr12:34555212	NA	-0.72	-6.49	-0.55	3.94e-9	Morning vs. evening chronotype;
THYM	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg16325326	chr1:53192061	ZYG11B	-0.95	-10.63	-0.74	7.38e-18	Monocyte count;
THYM	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg27129171	chr3:47204927	SETD2	-0.7	-6.73	-0.57	1.3e-9	Colorectal cancer;
THYM	cis	rs2762049	0.524	rs806344	chr13:50857421	A/G	cg01618923	chr13:49883335	CAB39L	-0.47	-4.66	-0.43	1.03e-5	Aortic root size;
THYM	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg01097406	chr16:89675127	NA	-0.55	-4.56	-0.42	1.52e-5	Vitiligo;
THYM	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg11812906	chr14:75593930	NEK9	-0.8	-7.19	-0.59	1.48e-10	Height;
THYM	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg16586182	chr3:47516702	SCAP	-0.62	-5.42	-0.49	4.52e-7	Colorectal cancer;
THYM	cis	rs9486719	1.000	rs12201449	chr6:96959382	C/T	cg18709589	chr6:96969512	KIAA0776	-0.73	-4.83	-0.44	5.28e-6	Migraine;Coronary artery disease;
THYM	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg26545918	chr15:68124484	LBXCOR1	0.55	5.08	0.46	1.87e-6	Obesity;
THYM	cis	rs12121840	0.790	rs10918212	chr1:165541677	A/G	cg19407955	chr1:165599744	MGST3	-0.65	-4.64	-0.43	1.12e-5	Interleukin-1-receptor antagonist levels;
THYM	cis	rs36051895	0.530	rs10115208	chr9:5229353	T/C	cg02405213	chr9:5042618	JAK2	-0.81	-7.68	-0.62	1.45e-11	Pediatric autoimmune diseases;
THYM	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg00376283	chr12:123451042	ABCB9	0.8	6.41	0.55	5.49e-9	Neutrophil percentage of white cells;
THYM	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg21475434	chr5:93447410	FAM172A	0.95	6.03	0.53	3.16e-8	Diabetic retinopathy;
THYM	cis	rs7599312	0.532	rs7564590	chr2:213387900	C/T	cg16329650	chr2:213403929	ERBB4	0.59	4.65	0.43	1.07e-5	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg03929089	chr4:120376271	NA	-0.98	-12.02	-0.78	9.02e-21	Height;
THYM	cis	rs6430585	0.528	rs7606267	chr2:136668123	T/C	cg20242066	chr2:136595261	LCT	0.51	4.9	0.45	3.9e-6	Corneal structure;
THYM	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06481639	chr22:41940642	POLR3H	0.82	5.77	0.51	9.74e-8	Vitiligo;
THYM	cis	rs9326248	0.559	rs10892064	chr11:116896553	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.67	5.33	0.48	6.64e-7	Blood protein levels;
THYM	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg06481639	chr22:41940642	POLR3H	0.73	5.29	0.48	7.78e-7	Vitiligo;
THYM	cis	rs7584330	0.554	rs11892169	chr2:238432809	G/A	cg14458575	chr2:238380390	NA	0.8	4.71	0.43	8.54e-6	Prostate cancer;
THYM	cis	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.56	-0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg08439880	chr3:133502540	NA	-0.73	-6.42	-0.55	5.46e-9	Iron status biomarkers;
THYM	cis	rs6430585	0.528	rs16832417	chr2:136744678	C/T	cg23851026	chr2:136556271	LCT	0.78	6.95	0.58	4.47e-10	Corneal structure;
THYM	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg13695892	chr22:41940480	POLR3H	0.86	7.06	0.59	2.77e-10	Vitiligo;
THYM	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg24154853	chr7:158122151	PTPRN2	0.55	4.82	0.44	5.35e-6	Calcium levels;
THYM	cis	rs76662990	0.610	rs6869778	chr5:73945433	A/G	cg13275603	chr5:73927487	ENC1	-0.77	-4.63	-0.43	1.17e-5	Residual cognition;
THYM	cis	rs9653442	0.835	rs1561230	chr2:100746642	C/T	cg07810366	chr2:100720526	AFF3	0.45	6.63	0.56	2.07e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08109568	chr15:31115862	NA	0.76	6.69	0.57	1.53e-9	Huntington's disease progression;
THYM	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.88	7.81	0.63	7.51e-12	Monocyte percentage of white cells;
THYM	cis	rs6882716	0.636	rs1470023	chr5:10800150	A/G	cg14521931	chr5:10832172	NA	-0.71	-6.05	-0.53	2.91e-8	Alcohol consumption (maxi-drinks);
THYM	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg17372223	chr3:52568218	NT5DC2	0.37	5.78	0.51	9.55e-8	Electroencephalogram traits;
THYM	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.87	7.63	0.62	1.8e-11	Intelligence (multi-trait analysis);
THYM	cis	rs40363	0.716	rs9926612	chr16:3540968	A/C	cg21433313	chr16:3507492	NAT15	-0.7	-4.68	-0.43	9.62e-6	Tuberculosis;
THYM	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg14829155	chr15:31115871	NA	-0.58	-5.15	-0.47	1.4e-6	Huntington's disease progression;
THYM	trans	rs8002861	0.869	rs7989857	chr13:44464090	C/T	cg17145862	chr1:211918768	LPGAT1	1.03	11.49	0.76	1.13e-19	Leprosy;
THYM	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg03159660	chr11:2078197	NA	-0.62	-4.5	-0.42	1.94e-5	Longevity;
THYM	cis	rs8133932	0.667	rs3788218	chr21:47287332	A/G	cg20357416	chr21:47294739	PCBP3	-0.84	-5.2	-0.47	1.12e-6	Schizophrenia;
THYM	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg26850624	chr5:429559	AHRR	-0.68	-5.61	-0.5	2.02e-7	Cystic fibrosis severity;
THYM	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs700651	0.752	rs7592556	chr2:198891021	G/A	cg00792783	chr2:198669748	PLCL1	0.82	5.63	0.5	1.79e-7	Intracranial aneurysm;
THYM	cis	rs9311676	0.656	rs11708895	chr3:58403042	T/C	cg26110898	chr3:58419937	PDHB	0.44	4.63	0.43	1.17e-5	Systemic lupus erythematosus;
THYM	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg06623918	chr6:96969491	KIAA0776	1.09	10.37	0.73	2.65e-17	Headache;
THYM	cis	rs10203711	0.966	rs10929288	chr2:239583146	A/G	cg14580085	chr2:239553406	NA	0.69	6.19	0.54	1.53e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg14779329	chr11:130786720	SNX19	0.47	4.94	0.45	3.41e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs807029	0.533	rs12571302	chr10:102742763	C/A	cg14905631	chr10:102746534	C10orf2;MRPL43	0.36	4.93	0.45	3.49e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7772486	0.720	rs6901888	chr6:146023144	A/G	cg13319975	chr6:146136371	FBXO30	0.63	5.17	0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.61	-11.06	-0.75	9.36e-19	Hemostatic factors and hematological phenotypes;
THYM	cis	rs2692947	0.644	rs1168976	chr2:96813480	G/A	cg23100626	chr2:96804247	ASTL	0.38	4.52	0.42	1.78e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg16615211	chr3:44902933	MIR564;TMEM42	0.46	4.52	0.42	1.77e-5	Depressive symptoms;
THYM	cis	rs11225247	1.000	rs11605066	chr11:102296688	T/C	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	6.59	0.56	2.39e-9	Schizophrenia;
THYM	cis	rs936229	0.626	rs3765066	chr15:75140854	G/A	cg14664628	chr15:75095509	CSK	-0.82	-6.0	-0.52	3.65e-8	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs6138458	1.000	rs11905625	chr20:24977065	A/C	cg26195577	chr20:24973756	C20orf3	1.09	11.01	0.75	1.16e-18	Blood protein levels;
THYM	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg05182265	chr7:156933206	UBE3C	0.7	9.62	0.7	1.06e-15	Body mass index;
THYM	cis	rs3791406	1.000	rs3791406	chr2:240030484	A/G	cg11903188	chr2:239195602	PER2	0.43	4.61	0.43	1.25e-5	Skin aging (microtopography measurement);
THYM	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg13695892	chr22:41940480	POLR3H	0.85	6.98	0.58	3.94e-10	Vitiligo;
THYM	cis	rs4664308	0.618	rs3749117	chr2:160885442	T/C	cg03641300	chr2:160917029	PLA2R1	-0.61	-5.14	-0.47	1.45e-6	Idiopathic membranous nephropathy;
THYM	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg16586182	chr3:47516702	SCAP	-0.64	-5.61	-0.5	2.03e-7	Colorectal cancer;
THYM	cis	rs713587	0.934	rs6728219	chr2:25159172	T/C	cg01884057	chr2:25150051	NA	0.67	7.0	0.58	3.58e-10	Body mass index in non-asthmatics;
THYM	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg15242686	chr22:24348715	GSTTP1	0.76	8.13	0.64	1.63e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg07870213	chr5:140052090	DND1	0.7	7.7	0.62	1.28e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs62064224	0.791	rs11656289	chr17:30761160	T/C	cg18200150	chr17:30822561	MYO1D	0.84	7.34	0.6	7.1e-11	Schizophrenia;
THYM	cis	rs236907	0.859	rs1801898	chr1:171765964	A/G	cg20598894	chr1:171756153	METTL13	-0.75	-5.43	-0.49	4.31e-7	Mean platelet volume;
THYM	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-4.96	-0.45	3.03e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs4343996	0.536	rs10258056	chr7:3414624	C/T	cg21248987	chr7:3385318	SDK1	0.4	4.89	0.45	4.12e-6	Motion sickness;
THYM	trans	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.8	-8.98	-0.68	2.53e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg09044154	chr16:88155775	NA	-0.75	-5.08	-0.46	1.87e-6	Menopause (age at onset);
THYM	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg18850127	chr7:39170497	POU6F2	0.54	5.03	0.46	2.3e-6	IgG glycosylation;
THYM	cis	rs8078723	0.510	rs11655264	chr17:38138995	G/C	cg17467752	chr17:38218738	THRA	-0.72	-5.52	-0.49	2.9e-7	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1499972	0.941	rs1093464	chr3:117726256	C/T	cg07612923	chr3:117604196	NA	-1.5	-5.16	-0.47	1.38e-6	Schizophrenia;
THYM	cis	rs6459804	0.787	rs78566714	chr7:157508951	G/A	cg05731713	chr7:157510257	PTPRN2	0.51	4.81	0.44	5.76e-6	Bipolar disorder and schizophrenia;
THYM	trans	rs293526	0.917	rs112390640	chr6:83636946	C/T	cg16504798	chr19:8643540	MYO1F	-0.45	-6.85	-0.57	7.39e-10	Crohn's disease;
THYM	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.87e-6	Resting heart rate;
THYM	cis	rs4792901	0.802	rs72833136	chr17:41599690	G/A	cg21940313	chr17:41620911	ETV4	-0.54	-5.13	-0.47	1.5e-6	Dupuytren's disease;
THYM	cis	rs6754311	0.689	rs192822	chr2:136682274	A/T	cg07169764	chr2:136633963	MCM6	0.66	5.5	0.49	3.19e-7	Mosquito bite size;
THYM	cis	rs12928939	0.815	rs7185575	chr16:71672569	A/G	cg02602352	chr16:70688171	IL34	0.43	5.05	0.46	2.09e-6	Post bronchodilator FEV1;
THYM	cis	rs13108904	0.604	rs13103860	chr4:1320120	G/A	cg13395646	chr4:1353034	KIAA1530	-0.68	-6.16	-0.53	1.73e-8	Obesity-related traits;
THYM	cis	rs6762477	0.505	rs17304079	chr3:50085153	A/G	cg14019146	chr3:50243930	SLC38A3	-0.59	-4.56	-0.42	1.55e-5	Menarche (age at onset);
THYM	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.72	-6.23	-0.54	1.28e-8	Chronic sinus infection;
THYM	cis	rs7264396	0.563	rs2425146	chr20:34355268	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-4.55	-0.42	1.56e-5	Total cholesterol levels;
THYM	cis	rs6988636	0.710	rs73339621	chr8:124138936	C/T	cg23067535	chr8:124195133	FAM83A	-0.99	-4.82	-0.44	5.52e-6	Urinary uromodulin levels;
THYM	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg01191920	chr7:158217561	PTPRN2	0.9	9.03	0.68	1.96e-14	Obesity-related traits;
THYM	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-6.53	-0.56	3.27e-9	Total body bone mineral density;
THYM	cis	rs11621135	0.567	rs757571	chr14:71660762	C/T	cg18506020	chr14:71758942	NA	-0.47	-4.5	-0.42	1.9e-5	Hair greying;
THYM	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg15704280	chr7:45808275	SEPT13	-0.99	-11.43	-0.76	1.48e-19	Height;
THYM	cis	rs4713118	0.629	rs203887	chr6:28021269	C/T	cg23161317	chr6:28129485	ZNF389	0.97	6.83	0.57	7.96e-10	Parkinson's disease;
THYM	cis	rs34638657	0.702	rs12599988	chr16:82200063	T/C	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.11	-0.64	1.73e-12	Lung adenocarcinoma;
THYM	cis	rs2219968	0.828	rs1486923	chr8:78883445	T/C	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs34638657	0.732	rs7205534	chr16:82201618	C/T	cg09439754	chr16:82129088	HSD17B2	-0.51	-5.04	-0.46	2.26e-6	Lung adenocarcinoma;
THYM	cis	rs6138458	1.000	rs227615	chr20:24908721	T/C	cg26195577	chr20:24973756	C20orf3	1.12	10.51	0.73	1.38e-17	Blood protein levels;
THYM	cis	rs3092073	0.617	rs3893276	chr20:44591089	G/C	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.49	-5.13	-0.47	1.52e-6	Intelligence (multi-trait analysis);
THYM	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg13918804	chr1:2043761	PRKCZ	-0.63	-4.77	-0.44	6.78e-6	Height;
THYM	cis	rs7572733	0.576	rs1865586	chr2:198758868	C/T	cg00792783	chr2:198669748	PLCL1	-0.84	-5.89	-0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs9479482	1.000	rs9478362	chr6:150340526	T/C	cg07578070	chr6:150326732	RAET1K	0.54	4.47	0.42	2.19e-5	Alopecia areata;
THYM	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg09165964	chr15:75287851	SCAMP5	-1.01	-5.72	-0.51	1.25e-7	Lung cancer;
THYM	cis	rs10931896	0.531	rs296801	chr2:201142812	C/T	cg17644776	chr2:200775616	C2orf69	0.66	5.38	0.48	5.41e-7	Systolic blood pressure;
THYM	cis	rs13065560	0.594	rs4336049	chr3:38922068	G/A	cg15678707	chr3:39149194	GORASP1;TTC21A	0.59	4.65	0.43	1.08e-5	Interleukin-18 levels;
THYM	cis	rs735539	0.521	rs9315905	chr13:21404969	A/G	cg02792322	chr13:21280448	IL17D	0.66	4.78	0.44	6.37e-6	Dental caries;
THYM	cis	rs3847687	0.546	rs12832254	chr12:131519388	T/C	cg25772418	chr12:131519998	GPR133	-0.36	-4.79	-0.44	6.17e-6	Longevity;
THYM	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg03351412	chr1:154909251	PMVK	0.73	5.58	0.5	2.3e-7	Prostate cancer;
THYM	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg10018233	chr7:150070692	REPIN1	0.38	5.42	0.49	4.46e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs887829	0.609	rs7597496	chr2:234630443	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.7	-5.61	-0.5	2e-7	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs1003719	0.680	rs2835621	chr21:38510616	G/A	cg01329690	chr21:38580129	DSCR9	-0.38	-5.21	-0.47	1.09e-6	Eye color traits;
THYM	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg00012203	chr2:219082015	ARPC2	0.84	7.98	0.63	3.38e-12	Colorectal cancer;
THYM	cis	rs13256369	0.851	rs13249700	chr8:8563637	C/T	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg02527881	chr3:46936655	PTH1R	-0.63	-6.29	-0.54	9.52e-9	Colorectal cancer;
THYM	cis	rs28374715	0.510	rs8034073	chr15:41545613	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.97	-7.74	-0.62	1.08e-11	Ulcerative colitis;
THYM	cis	rs116095464	1.000	rs56095714	chr5:311256	C/T	cg22857025	chr5:266934	NA	-1.59	-5.22	-0.47	1.06e-6	Breast cancer;
THYM	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg05368731	chr17:41323189	NBR1	1.25	11.1	0.75	7.44e-19	Menopause (age at onset);
THYM	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg03929089	chr4:120376271	NA	-1.03	-12.19	-0.78	3.85e-21	Height;
THYM	cis	rs889398	0.874	rs2917677	chr16:69750849	C/T	cg09409435	chr16:70099608	PDXDC2	-0.6	-4.62	-0.43	1.22e-5	Body mass index;
THYM	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg06481639	chr22:41940642	POLR3H	0.82	5.68	0.5	1.49e-7	Vitiligo;
THYM	cis	rs7267979	1.000	rs4813566	chr20:25386465	G/T	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs34638657	0.573	rs1364289	chr16:82224212	T/A	cg07307142	chr16:82071433	HSD17B2	-0.57	-4.8	-0.44	5.87e-6	Lung adenocarcinoma;
THYM	cis	rs11009175	0.725	rs11009183	chr10:33306309	A/C	cg00146027	chr10:33299147	NA	-0.73	-4.88	-0.45	4.29e-6	Depression (quantitative trait);
THYM	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg04673462	chr1:38461896	NA	-0.44	-5.41	-0.49	4.63e-7	Coronary artery disease;
THYM	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg16405210	chr4:1374714	KIAA1530	0.86	7.57	0.61	2.42e-11	Obesity-related traits;
THYM	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg24209194	chr3:40518798	ZNF619	-0.66	-5.61	-0.5	1.97e-7	Renal cell carcinoma;
THYM	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg14196790	chr5:131705035	SLC22A5	0.51	4.52	0.42	1.79e-5	Blood metabolite levels;
THYM	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg09455208	chr3:40491958	NA	-0.45	-4.79	-0.44	6.06e-6	Renal cell carcinoma;
THYM	cis	rs1800682	0.528	rs3903454	chr10:90743434	A/T	cg03111039	chr10:90751583	FAS;ACTA2	0.57	5.85	0.51	7.01e-8	Chronic lymphocytic leukemia;
THYM	cis	rs7172809	0.897	rs74026930	chr15:77825253	G/A	cg22256960	chr15:77711686	NA	-0.67	-4.61	-0.43	1.27e-5	Glucose homeostasis traits;
THYM	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg20887711	chr4:1340912	KIAA1530	0.68	5.74	0.51	1.11e-7	Longevity;
THYM	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg02478829	chr6:26598070	ABT1	-0.33	-4.46	-0.42	2.27e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7772486	0.558	rs9376965	chr6:146130055	G/A	cg13319975	chr6:146136371	FBXO30	-0.66	-5.42	-0.49	4.59e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2039659	0.719	rs1764953	chr13:86253145	C/A	cg25308322	chr13:86268291	NA	0.66	5.51	0.49	3.11e-7	Blood osmolality (transformed sodium);
THYM	cis	rs7122937	0.677	rs11022922	chr11:2479195	C/T	cg27115973	chr11:2481206	KCNQ1	0.6	6.41	0.55	5.71e-9	QT interval;
THYM	cis	rs68170813	0.562	rs17429825	chr7:107050731	C/T	cg00661777	chr7:106511741	PIK3CG	-0.66	-4.49	-0.42	2.03e-5	Coronary artery disease;
THYM	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs6754311	0.509	rs3820794	chr2:136505546	C/T	cg20242066	chr2:136595261	LCT	-0.51	-5.6	-0.5	2.06e-7	Mosquito bite size;
THYM	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg06400119	chr7:158046222	PTPRN2	0.57	5.13	0.47	1.51e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg03929089	chr4:120376271	NA	-0.94	-10.63	-0.74	7.58e-18	Height;
THYM	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg06640241	chr16:89574553	SPG7	0.89	8.17	0.64	1.34e-12	Multiple myeloma (IgH translocation);
THYM	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg23602478	chr1:26503979	CNKSR1	0.36	4.97	0.45	2.96e-6	Height;
THYM	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6754311	0.773	rs680428	chr2:136630757	A/G	cg20242066	chr2:136595261	LCT	-0.6	-7.1	-0.59	2.23e-10	Mosquito bite size;
THYM	cis	rs17152411	1.000	rs7083298	chr10:126590691	T/C	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg21231944	chr12:82153410	PPFIA2	-0.61	-4.45	-0.42	2.33e-5	Resting heart rate;
THYM	cis	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg12981288	chr8:11183844	MTMR9	-0.45	-4.48	-0.42	2.05e-5	Retinal vascular caliber;
THYM	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg03690763	chr11:133734501	NA	-0.6	-4.71	-0.43	8.51e-6	Childhood ear infection;
THYM	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg09455208	chr3:40491958	NA	-0.48	-4.89	-0.45	4.1e-6	Renal cell carcinoma;
THYM	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg06028808	chr11:68637592	NA	0.7	7.47	0.61	3.85e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg02493740	chr2:85810744	VAMP5	-0.64	-5.06	-0.46	2.06e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs12928939	0.769	rs1056303	chr16:71670066	C/T	cg02602352	chr16:70688171	IL34	0.42	4.9	0.45	3.86e-6	Post bronchodilator FEV1;
THYM	cis	rs11886999	0.680	rs997547	chr2:96859034	A/G	cg18419276	chr2:96971862	SNRNP200	-0.52	-4.74	-0.44	7.6e-6	Cardiac Troponin-T levels;
THYM	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg07362569	chr17:61921086	SMARCD2	-0.58	-5.23	-0.47	9.98e-7	Prudent dietary pattern;
THYM	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08109568	chr15:31115862	NA	0.76	6.69	0.57	1.53e-9	Huntington's disease progression;
THYM	cis	rs7762018	0.607	rs80106119	chr6:170048309	T/C	cg19338460	chr6:170058176	WDR27	-1.06	-6.21	-0.54	1.39e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg03676636	chr4:99064102	C4orf37	0.43	6.32	0.54	8.55e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9653442	0.648	rs11123805	chr2:100643464	A/G	cg22139774	chr2:100720529	AFF3	-0.33	-4.89	-0.45	4.07e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs240764	0.782	rs7748644	chr6:101166809	T/G	cg21058520	chr6:100914733	NA	0.56	4.73	0.44	7.94e-6	Neuroticism;
THYM	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.65	5.47	0.49	3.66e-7	Lung disease severity in cystic fibrosis;
THYM	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg24060327	chr5:131705240	SLC22A5	0.73	5.47	0.49	3.61e-7	Blood metabolite levels;
THYM	cis	rs13082711	0.911	rs2370995	chr3:27428216	C/T	cg02860705	chr3:27208620	NA	0.67	4.7	0.43	8.87e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg18404041	chr3:52824283	ITIH1	0.57	5.79	0.51	9.14e-8	Bipolar disorder;
THYM	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-4.57	-0.42	1.47e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.75	5.57	0.5	2.37e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg08859206	chr1:53392774	SCP2	-0.51	-5.32	-0.48	6.88e-7	Monocyte count;
THYM	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg10018233	chr7:150070692	REPIN1	0.45	7.69	0.62	1.34e-11	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs8067545	0.578	rs4925087	chr17:20024582	A/C	cg13482628	chr17:19912719	NA	0.55	4.7	0.43	8.82e-6	Schizophrenia;
THYM	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg06728252	chr6:26598149	ABT1	-0.43	-5.08	-0.46	1.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3135724	0.855	rs11200017	chr10:123339685	G/A	cg15049101	chr10:123353889	FGFR2	0.75	4.69	0.43	9.21e-6	Estrogen receptor status in HER2 negative breast cancer;
THYM	trans	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg10856724	chr12:34555212	NA	-1.01	-9.23	-0.69	7.34e-15	Bladder cancer;
THYM	cis	rs7107174	0.892	rs2512534	chr11:77970039	T/A	cg19901956	chr11:77921274	USP35	-0.76	-5.83	-0.51	7.53e-8	Testicular germ cell tumor;
THYM	cis	rs6867032	1.000	rs6867032	chr5:2015103	G/T	cg26168224	chr5:2018326	NA	-1.29	-15.53	-0.85	8.25e-28	Gut microbiome composition (winter);
THYM	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.37	-0.55	6.73e-9	Personality dimensions;
THYM	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg11494091	chr17:61959527	GH2	1.09	16.58	0.86	8.39e-30	Prudent dietary pattern;
THYM	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6032067	1.000	rs6032052	chr20:43829883	C/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.84	-5.79	-0.51	9.16e-8	Body mass index;
THYM	trans	rs629535	0.590	rs56200825	chr8:70123450	G/A	cg21567404	chr3:27674614	NA	-0.89	-7.13	-0.59	1.95e-10	Dupuytren's disease;
THYM	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg02773041	chr1:40204384	PPIE	0.77	5.99	0.52	3.8e-8	Blood protein levels;
THYM	cis	rs11716531	0.574	rs62256311	chr3:27271505	G/A	cg02860705	chr3:27208620	NA	0.77	5.99	0.52	3.81e-8	Diastolic blood pressure;
THYM	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2295499	0.833	rs1913448	chr4:2708814	G/A	cg26540191	chr4:3475093	DOK7	0.22	4.47	0.42	2.15e-5	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg24675658	chr1:53192096	ZYG11B	-0.75	-5.77	-0.51	9.84e-8	Monocyte count;
THYM	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg23422044	chr7:1970798	MAD1L1	-0.93	-6.39	-0.55	6.11e-9	Bipolar disorder;
THYM	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg09359103	chr1:154839909	KCNN3	-0.8	-10.4	-0.73	2.34e-17	Prostate cancer;
THYM	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs59698941	0.943	rs57550938	chr5:132248104	G/A	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs7107174	1.000	rs2248407	chr11:77937800	G/A	cg02023728	chr11:77925099	USP35	0.76	7.23	0.6	1.2e-10	Testicular germ cell tumor;
THYM	cis	rs7107174	1.000	rs10899485	chr11:78072383	C/T	cg19901956	chr11:77921274	USP35	0.67	5.46	0.49	3.82e-7	Testicular germ cell tumor;
THYM	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06481639	chr22:41940642	POLR3H	-0.84	-5.94	-0.52	4.61e-8	Vitiligo;
THYM	cis	rs921968	0.643	rs711186	chr2:219346102	A/G	cg02176678	chr2:219576539	TTLL4	-0.7	-7.14	-0.59	1.88e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7551222	0.663	rs1563828	chr1:204516577	A/G	cg20240347	chr1:204465584	NA	-0.55	-5.02	-0.46	2.41e-6	Schizophrenia;
THYM	cis	rs6450176	0.953	rs3776724	chr5:53292270	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-6.61	-0.56	2.22e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs568617	0.626	rs78028320	chr11:65582015	G/A	cg06054963	chr11:65657880	CCDC85B	-0.79	-4.61	-0.43	1.27e-5	Crohn's disease;
THYM	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg14895029	chr7:2775587	GNA12	-0.68	-4.91	-0.45	3.78e-6	Height;
THYM	cis	rs1728785	1.000	rs11648314	chr16:68596775	A/G	cg02972257	chr16:68554789	NA	-0.78	-5.02	-0.46	2.39e-6	Ulcerative colitis;
THYM	trans	rs11186	0.556	rs55977069	chr2:189964747	G/T	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg00639195	chr15:79103007	ADAMTS7	-0.8	-6.2	-0.54	1.43e-8	Coronary artery disease or large artery stroke;
THYM	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.02	-7.97	-0.63	3.45e-12	Schizophrenia;
THYM	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg11526020	chr17:80870163	TBCD	0.45	4.46	0.42	2.26e-5	Glycated hemoglobin levels;
THYM	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg07936489	chr17:37558343	FBXL20	0.71	5.26	0.47	9.02e-7	Asthma;
THYM	cis	rs9527	0.590	rs12414232	chr10:104914491	A/T	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs4660306	0.961	rs12082256	chr1:45951380	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.43	-0.49	4.37e-7	Homocysteine levels;
THYM	cis	rs4589258	0.762	rs4497368	chr11:90405970	C/G	cg26138821	chr11:89956704	CHORDC1	0.55	4.7	0.43	8.71e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg18850127	chr7:39170497	POU6F2	0.58	5.44	0.49	4.22e-7	IgG glycosylation;
THYM	cis	rs12134245	0.776	rs12125947	chr1:91990487	T/C	cg02896835	chr1:92012615	NA	-0.65	-5.77	-0.51	9.9e-8	Breast cancer;
THYM	cis	rs55728055	0.661	rs12165609	chr22:32036332	T/C	cg01338084	chr22:32026380	PISD	1.24	6.43	0.55	5.18e-9	Age-related hearing impairment;
THYM	cis	rs10208649	0.908	rs13387890	chr2:54266386	C/T	cg04546899	chr2:54196757	PSME4	0.68	4.73	0.44	7.94e-6	Body mass index;
THYM	cis	rs9677476	0.818	rs28678038	chr2:232063997	A/T	cg23338755	chr2:231921595	PSMD1	0.69	5.02	0.46	2.43e-6	Food antigen IgG levels;
THYM	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg05872129	chr22:39784769	NA	-0.99	-9.75	-0.71	5.63e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg25072359	chr17:41440525	NA	-0.6	-4.49	-0.42	2.01e-5	Menopause (age at onset);
THYM	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	5.42	0.49	4.46e-7	Age-related macular degeneration (geographic atrophy);
THYM	trans	rs2075230	0.705	rs1641519	chr17:7550166	C/A	cg04140212	chr2:85829138	TMEM150A	-0.57	-6.87	-0.58	6.7e-10	Hormone measurements;
THYM	cis	rs6669072	0.605	rs34304726	chr1:91257997	T/C	cg08895590	chr1:91227319	NA	-0.44	-5.12	-0.46	1.62e-6	Cognitive function;
THYM	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg24955955	chr5:415729	AHRR	1.13	6.55	0.56	2.9e-9	Fat distribution (HIV);
THYM	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg07884673	chr3:53033167	SFMBT1	1.25	6.34	0.55	7.83e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.54e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs524281	0.773	rs10791863	chr11:66027358	C/T	cg00563793	chr11:65837595	PACS1	0.79	4.71	0.43	8.53e-6	Electroencephalogram traits;
THYM	cis	rs7084402	0.967	rs1427197	chr10:60275150	A/G	cg09696939	chr10:60272079	BICC1	0.47	5.53	0.49	2.84e-7	Refractive error;
THYM	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.84	5.41	0.49	4.7e-7	Smoking behavior;
THYM	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg24060327	chr5:131705240	SLC22A5	-0.77	-6.55	-0.56	2.92e-9	Blood metabolite levels;
THYM	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg22189786	chr22:42395067	WBP2NL	0.56	5.05	0.46	2.12e-6	Birth weight;
THYM	cis	rs58688157	0.705	rs936468	chr11:607175	G/A	cg01616529	chr11:638424	DRD4	-0.74	-5.47	-0.49	3.59e-7	Systemic lupus erythematosus;
THYM	cis	rs4148087	0.673	rs8133852	chr21:43595552	C/A	cg09727148	chr21:43560719	UMODL1	0.63	4.96	0.45	3.05e-6	Eating disorder in bipolar disorder;
THYM	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg05738196	chr6:26577821	NA	0.86	8.72	0.67	9.13e-14	Intelligence (multi-trait analysis);
THYM	cis	rs12476592	0.602	rs262538	chr2:63908025	A/T	cg17519650	chr2:63277830	OTX1	0.74	4.71	0.43	8.61e-6	Childhood ear infection;
THYM	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg13609457	chr4:120235615	NA	0.58	5.33	0.48	6.55e-7	Corneal astigmatism;
THYM	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.68	-4.99	-0.46	2.68e-6	Colorectal cancer;
THYM	cis	rs10208649	0.901	rs6748686	chr2:54264618	G/T	cg04546899	chr2:54196757	PSME4	0.68	4.73	0.44	7.94e-6	Body mass index;
THYM	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs887829	0.570	rs12623271	chr2:234599941	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.79	-6.88	-0.58	6.26e-10	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs4654899	0.895	rs7515590	chr1:21216664	T/C	cg01072550	chr1:21505969	NA	0.71	6.46	0.55	4.51e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.78	-0.44	6.31e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg27490568	chr2:178487706	NA	0.66	5.8	0.51	8.78e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg15445000	chr17:37608096	MED1	0.44	5.22	0.47	1.07e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg02269571	chr22:50332266	NA	-0.64	-4.83	-0.44	5.14e-6	Schizophrenia;
THYM	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg13695892	chr22:41940480	POLR3H	0.98	7.49	0.61	3.58e-11	Vitiligo;
THYM	cis	rs754466	0.580	rs10430529	chr10:79582623	C/A	cg17075019	chr10:79541650	NA	-0.7	-5.73	-0.51	1.2e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6500395	1.000	rs7194570	chr16:48672986	A/G	cg04672837	chr16:48644449	N4BP1	-0.65	-5.23	-0.47	1e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg24642844	chr7:1081250	C7orf50	-1.28	-8.54	-0.66	2.16e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg16524733	chr11:117070046	TAGLN	-0.42	-4.69	-0.43	9.06e-6	Blood protein levels;
THYM	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg15556689	chr8:8085844	FLJ10661	0.7	6.03	0.53	3.07e-8	Neuroticism;
THYM	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg10911889	chr6:126070802	HEY2	0.59	4.73	0.44	7.77e-6	Brugada syndrome;
THYM	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg27211696	chr2:191398769	TMEM194B	-0.61	-4.53	-0.42	1.72e-5	Diastolic blood pressure;
THYM	cis	rs7799006	0.527	rs3779009	chr7:2203692	G/C	cg10360139	chr7:1886902	MAD1L1	-0.64	-4.89	-0.45	4.02e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg20415053	chr1:26527928	CATSPER4	-0.58	-4.71	-0.43	8.58e-6	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1003719	0.699	rs1015549	chr21:38448880	T/C	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs9527	0.590	rs10883820	chr10:104764661	A/C	cg04362960	chr10:104952993	NT5C2	-0.61	-4.61	-0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs675209	0.601	rs3904600	chr6:7109665	C/G	cg24899545	chr6:7112846	RREB1	-0.46	-4.64	-0.43	1.12e-5	Urate levels;
THYM	cis	rs2089162	1	rs2089162	chr15:78739763	A/G	cg18825076	chr15:78729989	IREB2	-0.66	-5.98	-0.52	3.83e-8	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs526231	0.511	rs10434793	chr5:102389815	A/T	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Primary biliary cholangitis;
THYM	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg06009448	chr7:1102226	C7orf50	0.53	5.59	0.5	2.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg17264618	chr3:40429014	ENTPD3	0.53	4.99	0.46	2.69e-6	Renal cell carcinoma;
THYM	cis	rs4606347	0.652	rs61780867	chr1:66162760	A/G	cg04111102	chr1:66153794	NA	0.6	4.47	0.42	2.14e-5	Cerebrospinal fluid biomarker levels;
THYM	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7586879	0.681	rs6545790	chr2:25109302	A/G	cg27107076	chr2:25050844	ADCY3	-0.28	-4.61	-0.43	1.25e-5	Body mass index;
THYM	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.61	4.82	0.44	5.41e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12928939	0.815	rs12446005	chr16:71655035	G/A	cg02602352	chr16:70688171	IL34	0.42	4.53	0.42	1.69e-5	Post bronchodilator FEV1;
THYM	cis	rs12149862	1.000	rs9929857	chr16:69471417	A/G	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg12165864	chr7:66369176	NA	-0.65	-5.08	-0.46	1.89e-6	Aortic root size;
THYM	cis	rs4924935	0.770	rs4924946	chr17:18846525	A/T	cg26378065	chr17:18585709	ZNF286B	-0.7	-5.76	-0.51	1.05e-7	Pancreatic cancer;
THYM	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14893161	chr1:205819251	PM20D1	0.93	9.86	0.71	3.34e-16	Menarche (age at onset);
THYM	cis	rs425535	0.697	rs416046	chr4:74857682	A/G	cg07868155	chr4:74864709	CXCL5	0.73	4.52	0.42	1.75e-5	Blood protein levels;
THYM	cis	rs13185784	0.667	rs4454029	chr5:179645325	C/T	cg23248424	chr5:179741104	GFPT2	0.72	4.83	0.44	5.29e-6	TRAIL levels;
THYM	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs6906287	0.669	rs6913012	chr6:118973137	G/A	cg01113488	chr6:119027122	NA	0.58	4.74	0.44	7.47e-6	Electrocardiographic conduction measures;
THYM	cis	rs1371867	0.846	rs1788167	chr8:101319996	C/T	cg00191853	chr8:101177733	SPAG1	-0.51	-5.03	-0.46	2.29e-6	Atrioventricular conduction;
THYM	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg05872129	chr22:39784769	NA	-0.99	-9.59	-0.7	1.25e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg17105886	chr17:28927953	LRRC37B2	1.32	6.56	0.56	2.79e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg07936489	chr17:37558343	FBXL20	0.83	5.84	0.51	7.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg26690334	chr16:1524521	CLCN7	0.43	5.48	0.49	3.47e-7	Bone mineral density;
THYM	cis	rs240764	0.612	rs2397974	chr6:100925828	C/T	cg21058520	chr6:100914733	NA	0.57	4.7	0.43	8.76e-6	Neuroticism;
THYM	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.22e-7	Corneal astigmatism;
THYM	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg17264618	chr3:40429014	ENTPD3	0.52	4.95	0.45	3.22e-6	Renal cell carcinoma;
THYM	cis	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg04369109	chr6:150039330	LATS1	-0.6	-4.57	-0.42	1.48e-5	Lung cancer;
THYM	cis	rs6906287	0.559	rs2798322	chr6:118991605	G/T	cg01113488	chr6:119027122	NA	0.6	5.06	0.46	2.05e-6	Electrocardiographic conduction measures;
THYM	cis	rs7000551	0.505	rs4872499	chr8:22293306	A/G	cg12081754	chr8:22256438	SLC39A14	-1.05	-8.49	-0.66	2.74e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg22852734	chr6:133119734	C6orf192	1.32	8.71	0.67	9.24e-14	Type 2 diabetes nephropathy;
THYM	cis	rs600806	0.821	rs1030522	chr1:109900707	C/G	cg23616212	chr1:109941201	SORT1	-0.5	-4.72	-0.44	8.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9302065	0.565	rs2992908	chr13:95960600	G/A	cg26751094	chr13:95954534	ABCC4	-0.49	-5.49	-0.49	3.39e-7	Blood metabolite levels;
THYM	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg14019146	chr3:50243930	SLC38A3	0.83	7.13	0.59	1.92e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg01483505	chr11:975446	AP2A2	0.56	4.59	0.43	1.36e-5	Alzheimer's disease (late onset);
THYM	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	4.61	0.43	1.24e-5	Prudent dietary pattern;
THYM	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	5.43	0.49	4.33e-7	Obesity-related traits;
THYM	trans	rs2136093	0.600	rs12126321	chr1:90909633	T/C	cg19688584	chr6:167529678	CCR6	0.5	7.06	0.59	2.66e-10	Response to antidepressants;
THYM	cis	rs2209875	0.549	rs3211707	chr9:91933134	G/C	cg13881405	chr9:92220388	GADD45G	-0.48	-4.93	-0.45	3.44e-6	Pelvic organ prolapse (moderate/severe);
THYM	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg16405210	chr4:1374714	KIAA1530	-1.11	-10.78	-0.74	3.66e-18	Longevity;
THYM	cis	rs2820651	0.614	rs116335204	chr10:1480569	A/G	cg02445968	chr10:1449028	ADARB2	-0.92	-4.76	-0.44	6.99e-6	Migraine with aura;
THYM	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg18305652	chr10:134549665	INPP5A	0.75	5.9	0.52	5.46e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg00495681	chr13:53174319	NA	0.76	7.02	0.58	3.26e-10	Lewy body disease;
THYM	cis	rs4474465	0.920	rs10751291	chr11:78217687	T/C	cg19901956	chr11:77921274	USP35	0.68	5.08	0.46	1.91e-6	Alzheimer's disease (survival time);
THYM	cis	rs11225247	1.000	rs78664789	chr11:102327287	A/T	cg06323957	chr11:102217781	BIRC2	1.09	4.49	0.42	2.01e-5	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs6430585	0.528	rs309166	chr2:136667487	C/T	cg20242066	chr2:136595261	LCT	0.53	5.57	0.5	2.37e-7	Corneal structure;
THYM	trans	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg13615516	chr5:77269221	NA	0.84	7.68	0.62	1.4e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1003719	0.713	rs2835594	chr21:38466064	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs904251	0.861	rs2776875	chr6:37486796	G/C	cg01843034	chr6:37503916	NA	-0.72	-5.7	-0.51	1.32e-7	Cognitive performance;
THYM	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg06766960	chr11:133703094	NA	-0.52	-4.83	-0.44	5.25e-6	Childhood ear infection;
THYM	cis	rs6918586	0.658	rs198822	chr6:26123539	G/C	cg03517284	chr6:25882590	NA	0.71	5.64	0.5	1.75e-7	Schizophrenia;
THYM	cis	rs1129187	0.702	rs2296805	chr6:42928758	T/G	cg10862848	chr6:42927986	GNMT	-0.53	-7.24	-0.6	1.18e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg24209194	chr3:40518798	ZNF619	0.67	5.5	0.49	3.2e-7	Renal cell carcinoma;
THYM	cis	rs11997175	0.624	rs7016783	chr8:33696831	A/G	ch.8.33884649F	chr8:33765107	NA	0.64	4.61	0.43	1.24e-5	Body mass index;
THYM	cis	rs36051895	0.589	rs6476947	chr9:5204279	A/G	cg02405213	chr9:5042618	JAK2	-0.9	-9.02	-0.68	2.02e-14	Pediatric autoimmune diseases;
THYM	cis	rs4919694	1.000	rs77505796	chr10:104647774	A/T	cg04362960	chr10:104952993	NT5C2	1.16	7.18	0.59	1.55e-10	Arsenic metabolism;
THYM	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg03060546	chr3:49711283	APEH	-0.75	-6.08	-0.53	2.48e-8	Resting heart rate;
THYM	cis	rs7152530	0.571	rs7145698	chr14:98638076	T/C	cg05180522	chr14:98101740	NA	-0.59	-4.72	-0.44	8.03e-6	Staphylococcus aureus infection;
THYM	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg02527881	chr3:46936655	PTH1R	0.84	8.34	0.65	5.7e-13	Birth weight;
THYM	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14240646	chr10:27532245	ACBD5	-0.88	-5.07	-0.46	1.98e-6	Breast cancer;
THYM	cis	rs17407555	0.560	rs73229842	chr4:10044524	C/T	cg11266682	chr4:10021025	SLC2A9	-0.58	-5.7	-0.5	1.33e-7	Schizophrenia (age at onset);
THYM	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.08	7.84	0.63	6.6e-12	Platelet count;
THYM	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg08132940	chr7:1081526	C7orf50	-1.29	-7.37	-0.6	6.29e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg03929089	chr4:120376271	NA	-0.94	-10.74	-0.74	4.27e-18	Coronary artery disease;
THYM	cis	rs6763768	0.606	rs11130365	chr3:53291478	C/T	cg16894138	chr3:53270350	TKT	0.75	5.44	0.49	4.11e-7	Bacterial meningitis;
THYM	cis	rs2797160	1.000	rs1739348	chr6:126014573	T/C	cg16306078	chr6:126000798	NA	0.54	5.53	0.49	2.75e-7	Endometrial cancer;
THYM	cis	rs78707713	0.560	rs17569412	chr10:71237536	C/A	cg08851181	chr10:71228077	TSPAN15	-0.8	-5.95	-0.52	4.46e-8	Venous thromboembolism;
THYM	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg00071950	chr4:10020882	SLC2A9	0.88	9.22	0.69	7.56e-15	Bone mineral density;
THYM	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg23711669	chr6:146136114	FBXO30	-0.93	-9.39	-0.69	3.39e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs61931739	0.513	rs4931760	chr12:33898361	T/C	cg10856724	chr12:34555212	NA	-0.65	-5.94	-0.52	4.7e-8	Morning vs. evening chronotype;
THYM	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg26031613	chr14:104095156	KLC1	0.73	4.81	0.44	5.73e-6	Body mass index;
THYM	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs478304	0.903	rs1151502	chr11:65503485	G/C	cg17480646	chr11:65405466	SIPA1	0.7	6.13	0.53	2e-8	Acne (severe);
THYM	cis	rs1163251	0.837	rs660073	chr1:120245173	T/C	cg19096424	chr1:120255104	PHGDH	0.67	4.94	0.45	3.29e-6	Blood metabolite levels;
THYM	cis	rs6547741	1.000	rs6737921	chr2:27839107	T/C	cg27432699	chr2:27873401	GPN1	0.72	6.28	0.54	1.01e-8	Oral cavity cancer;
THYM	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg27446573	chr6:127587934	RNF146	1.01	9.68	0.7	8.06e-16	Breast cancer;
THYM	cis	rs289828	0.519	rs6708382	chr2:152157904	A/T	cg05960677	chr2:152117363	RBM43	0.7	6.81	0.57	8.86e-10	Blood protein levels;
THYM	cis	rs2953174	0.507	rs34568097	chr2:241540989	A/G	cg27449114	chr2:241501342	DUSP28	0.62	4.75	0.44	7.3e-6	Bipolar disorder;
THYM	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg03709012	chr19:19516395	GATAD2A	-0.71	-5.13	-0.47	1.51e-6	Tonsillectomy;
THYM	cis	rs7704138	0.639	rs3915816	chr5:55017474	C/T	cg18456523	chr5:54516805	NA	-0.58	-4.55	-0.42	1.56e-5	Height;
THYM	cis	rs6586111	1.000	rs7067994	chr10:82373459	A/G	cg03086067	chr10:82368399	SH2D4B	-0.56	-7.16	-0.59	1.68e-10	Capecitabine sensitivity;
THYM	cis	rs11563648	0.553	rs4731358	chr7:127054787	A/T	cg23081781	chr7:127225937	GCC1	-0.34	-4.58	-0.43	1.41e-5	Resting heart rate;
THYM	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg06453172	chr10:134556979	INPP5A	-0.69	-4.96	-0.45	3.04e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-6.02	-0.53	3.27e-8	Prostate cancer;
THYM	cis	rs4595586	0.545	rs3911798	chr12:39389901	A/G	cg26384229	chr12:38710491	ALG10B	0.67	5.1	0.46	1.71e-6	Morning vs. evening chronotype;
THYM	cis	rs1784581	0.588	rs6455790	chr6:162418447	C/T	cg17173639	chr6:162384350	PARK2	-0.81	-7.48	-0.61	3.75e-11	Itch intensity from mosquito bite;
THYM	cis	rs899997	1.000	rs755998	chr15:79032469	C/T	cg04896959	chr15:78267971	NA	0.89	7.17	0.59	1.64e-10	Coronary artery disease or large artery stroke;
THYM	cis	rs1050631	0.536	rs1785928	chr18:33725931	A/G	cg23776217	chr18:34409391	KIAA1328;C18orf10	-0.6	-4.69	-0.43	9.09e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs2625529	0.556	rs11630611	chr15:72466312	C/T	cg16672083	chr15:72433130	SENP8	0.54	4.77	0.44	6.61e-6	Red blood cell count;
THYM	trans	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs4940575	0.679	rs55825601	chr18:60835819	C/T	cg24349668	chr18:61441546	SERPINB7	0.75	4.63	0.43	1.15e-5	Breast cancer;
THYM	cis	rs61931739	0.612	rs1906137	chr12:33939676	T/A	cg06521331	chr12:34319734	NA	-0.58	-4.77	-0.44	6.52e-6	Morning vs. evening chronotype;
THYM	cis	rs4481887	0.741	rs28616194	chr1:248531904	T/A	cg17299007	chr1:248814626	OR2T27	0.42	4.52	0.42	1.81e-5	Common traits (Other);
THYM	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg14972814	chr11:95582409	MTMR2	0.75	6.16	0.53	1.74e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs62103177	0.733	rs62103232	chr18:77635553	G/A	cg05926928	chr17:57297772	GDPD1	1.26	10.02	0.72	1.5e-16	Opioid sensitivity;
THYM	cis	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg12826209	chr6:26865740	GUSBL1	0.94	5.5	0.49	3.26e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg27129171	chr3:47204927	SETD2	0.8	7.67	0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs2742234	0.590	rs2075912	chr10:43622217	T/C	cg06632098	chr10:43605906	RET	-0.76	-4.83	-0.44	5.28e-6	Hirschsprung disease;
THYM	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg16615211	chr3:44902933	MIR564;TMEM42	0.5	5.36	0.48	5.91e-7	Depressive symptoms;
THYM	cis	rs9581943	1.000	rs2297316	chr13:28490211	G/A	cg16302790	chr13:28498334	PDX1	0.61	5.49	0.49	3.28e-7	Pancreatic cancer;
THYM	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg18681998	chr4:17616180	MED28	0.81	6.87	0.58	6.5e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9858542	0.537	rs9873994	chr3:49359943	T/C	cg00383909	chr3:49044727	WDR6	0.76	5.0	0.46	2.62e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs9527	0.614	rs11191589	chr10:104930382	T/C	cg04362960	chr10:104952993	NT5C2	0.65	5.04	0.46	2.18e-6	Arsenic metabolism;
THYM	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg26446133	chr18:72167187	CNDP2	-1.02	-10.4	-0.73	2.35e-17	Refractive error;
THYM	cis	rs3780378	0.875	rs7869668	chr9:5069837	G/A	cg02405213	chr9:5042618	JAK2	-0.74	-7.17	-0.59	1.59e-10	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs11030122	0.702	rs10767715	chr11:3951409	G/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.73	-0.51	1.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg13395646	chr4:1353034	KIAA1530	-0.69	-6.29	-0.54	9.78e-9	Obesity-related traits;
THYM	cis	rs17253792	0.598	rs12880362	chr14:56017929	G/C	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs220324	0.647	rs9981668	chr21:43559780	G/T	cg09727148	chr21:43560719	UMODL1	0.84	9.68	0.7	8.06e-16	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg22974920	chr21:40686053	BRWD1	-0.58	-4.49	-0.42	2e-5	Cognitive function;
THYM	cis	rs554111	0.656	rs17450813	chr1:21264308	T/C	cg01072550	chr1:21505969	NA	0.58	5.06	0.46	2.06e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs12257961	0.609	rs10906892	chr10:15389924	T/A	cg10616319	chr10:15468812	NA	-0.59	-5.01	-0.46	2.54e-6	Selective IgA deficiency;
THYM	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg08847533	chr14:75593920	NEK9	0.98	10.77	0.74	3.87e-18	Height;
THYM	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg03806693	chr22:41940476	POLR3H	1.19	10.49	0.73	1.46e-17	Vitiligo;
THYM	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.02	0.53	3.28e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs1479119	0.780	rs7971776	chr12:13500896	G/A	cg08467512	chr12:13044556	GPRC5A	0.61	4.57	0.42	1.49e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs7246967	0.541	rs16999009	chr19:22909658	A/G	cg05241461	chr19:22816980	ZNF492	-0.61	-4.82	-0.44	5.38e-6	Bronchopulmonary dysplasia;
THYM	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg13695892	chr22:41940480	POLR3H	0.84	6.25	0.54	1.16e-8	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs17604090	0.793	rs73687726	chr7:29688773	T/C	cg19413766	chr7:29689036	LOC646762	-0.91	-5.02	-0.46	2.37e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg24675658	chr1:53192096	ZYG11B	-0.73	-6.52	-0.56	3.31e-9	Monocyte count;
THYM	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg13683864	chr3:40499215	RPL14	-1.05	-12.08	-0.78	6.51e-21	Renal cell carcinoma;
THYM	cis	rs4746818	1.000	rs7901617	chr10:70904063	C/T	cg04149295	chr10:70884716	VPS26A	0.72	4.75	0.44	7.31e-6	Left atrial antero-posterior diameter;
THYM	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg10523679	chr1:76189770	ACADM	-0.55	-4.49	-0.42	1.99e-5	Daytime sleep phenotypes;
THYM	cis	rs6665290	0.904	rs11587443	chr1:227187896	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.13	-15.82	-0.85	2.26e-28	Myeloid white cell count;
THYM	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.38	-0.48	5.36e-7	Menopause (age at onset);
THYM	cis	rs34638657	0.872	rs6420435	chr16:82184201	A/C	cg09439754	chr16:82129088	HSD17B2	-0.6	-5.18	-0.47	1.27e-6	Lung adenocarcinoma;
THYM	cis	rs4731207	0.596	rs1026839	chr7:124672599	C/T	cg05285228	chr7:124571219	POT1	0.63	4.74	0.44	7.37e-6	Cutaneous malignant melanoma;
THYM	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2273669	0.667	rs11755471	chr6:109342169	T/C	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs72627123	0.867	rs74337992	chr14:74356053	T/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs28595532	0.920	rs56046676	chr4:119766733	A/G	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs61931739	0.929	rs2389272	chr12:34067771	T/C	cg06521331	chr12:34319734	NA	0.57	4.68	0.43	9.63e-6	Morning vs. evening chronotype;
THYM	cis	rs7119	0.717	rs12910594	chr15:77817103	G/A	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs939658	0.805	rs1915726	chr15:79420620	C/G	cg17916960	chr15:79447300	NA	-0.68	-7.85	-0.63	6.28e-12	Refractive error;
THYM	cis	rs870825	0.518	rs56034065	chr4:185655402	A/G	cg04058563	chr4:185651563	MLF1IP	1.09	7.62	0.62	1.92e-11	Blood protein levels;
THYM	cis	rs17152411	1.000	rs17152377	chr10:126592852	T/G	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs514406	0.505	rs431427	chr1:53179094	C/A	cg08859206	chr1:53392774	SCP2	-0.5	-5.23	-0.47	1e-6	Monocyte count;
THYM	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg18169835	chr10:134612155	NA	0.6	4.46	0.42	2.25e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs889398	0.771	rs3790080	chr16:69902139	A/G	cg09409435	chr16:70099608	PDXDC2	0.66	5.22	0.47	1.07e-6	Body mass index;
THYM	cis	rs2554380	0.783	rs2554385	chr15:84406587	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.57	-4.5	-0.42	1.91e-5	Height;
THYM	cis	rs1692120	0.545	rs1812458	chr11:61408449	C/T	cg19838087	chr11:61442541	NA	-0.51	-6.15	-0.53	1.81e-8	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
THYM	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg12011299	chr4:100065546	ADH4	0.75	7.3	0.6	8.58e-11	Alcohol dependence;
THYM	cis	rs7772486	0.875	rs2814866	chr6:146339414	C/A	cg23711669	chr6:146136114	FBXO30	0.9	8.82	0.67	5.37e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4474465	1.000	rs1567889	chr11:78147055	A/G	cg19901956	chr11:77921274	USP35	-0.66	-4.96	-0.45	3.14e-6	Alzheimer's disease (survival time);
THYM	cis	rs9733	0.543	rs72702558	chr1:150683251	G/A	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg06521331	chr12:34319734	NA	-1.02	-10.14	-0.72	8.47e-17	Morning vs. evening chronotype;
THYM	cis	rs55728055	1.000	rs16989427	chr22:32108475	C/T	cg10537193	chr22:32026975	PISD	-0.89	-5.26	-0.47	8.91e-7	Age-related hearing impairment;
THYM	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	4.79	0.44	6.04e-6	Menarche (age at onset);
THYM	cis	rs4788570	0.615	rs9888756	chr16:71740477	G/A	cg06353428	chr16:71660113	MARVELD3	1.3	8.83	0.67	5.33e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7940866	0.801	rs10894300	chr11:130845943	A/G	cg05962950	chr11:130786565	SNX19	0.75	5.78	0.51	9.52e-8	Schizophrenia;
THYM	cis	rs6732160	0.656	rs2043093	chr2:73407342	G/C	cg24220031	chr2:73402428	NA	-0.74	-8.56	-0.66	1.98e-13	Intelligence (multi-trait analysis);
THYM	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg22508957	chr16:3507546	NAT15	0.72	7.97	0.63	3.4e-12	Tuberculosis;
THYM	cis	rs3781426	1.000	rs11245469	chr10:126713807	C/T	cg04494136	chr10:126703576	CTBP2	-0.4	-5.57	-0.5	2.37e-7	Height;
THYM	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg04842962	chr6:43655489	MRPS18A	1.41	15.7	0.85	3.85e-28	IgG glycosylation;
THYM	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg15445000	chr17:37608096	MED1	-0.44	-5.07	-0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	trans	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Bladder cancer;
THYM	cis	rs1030420	1.000	rs7014273	chr8:67358694	A/G	cg06195829	chr8:66753750	PDE7A	-0.79	-4.53	-0.42	1.69e-5	Blood metabolite levels;
THYM	cis	rs362272	0.545	rs2749785	chr4:3325179	G/C	cg14583973	chr4:3374767	RGS12	0.7	6.79	0.57	9.59e-10	Serum sulfate level;
THYM	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.66	-0.5	1.63e-7	Menopause (age at onset);
THYM	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg22907277	chr7:1156413	C7orf50	0.79	4.84	0.44	5.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2404618	0.624	rs28439223	chr8:1476901	C/G	cg13402656	chr8:1511478	DLGAP2	-0.77	-7.13	-0.59	1.92e-10	Lung cancer;
THYM	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg02887458	chr19:19495540	GATAD2A	-0.45	-4.89	-0.45	4.05e-6	Bipolar disorder;
THYM	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg22508957	chr16:3507546	NAT15	-0.69	-9.19	-0.69	8.75e-15	Tuberculosis;
THYM	cis	rs7572733	0.555	rs1435569	chr2:198718667	G/C	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg00898013	chr13:113819073	PROZ	0.88	9.0	0.68	2.24e-14	Platelet distribution width;
THYM	cis	rs910187	0.605	rs6018320	chr20:45804412	A/G	cg27589058	chr20:45804311	EYA2	-0.68	-6.04	-0.53	3.03e-8	Migraine;
THYM	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02475777	chr4:1388615	CRIPAK	-0.67	-4.84	-0.44	5.11e-6	Longevity;
THYM	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg25554036	chr4:6271136	WFS1	0.5	4.54	0.42	1.62e-5	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs12530845	0.524	rs7795267	chr7:135308455	C/G	cg19897172	chr7:135347071	PL-5283	-0.52	-4.48	-0.42	2.1e-5	Red blood cell traits;
THYM	cis	rs8067545	0.611	rs757494	chr17:20150340	C/T	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs10886503	0.920	rs756279	chr10:121259879	G/A	cg13260278	chr10:121265587	RGS10	-0.66	-5.9	-0.52	5.57e-8	Obstetric antiphospholipid syndrome;
THYM	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg15445000	chr17:37608096	MED1	-0.44	-5.22	-0.47	1.07e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.76	6.74	0.57	1.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12282928	0.876	rs1158898	chr11:48273246	G/A	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs9788721	0.934	rs16969968	chr15:78882925	G/A	cg18825076	chr15:78729989	IREB2	-0.54	-4.81	-0.44	5.71e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08704250	chr15:31115839	NA	-0.54	-6.3	-0.54	9.31e-9	Huntington's disease progression;
THYM	cis	rs9790314	1.000	rs4597724	chr3:160963110	A/G	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs2658782	1.000	rs2605583	chr11:93164957	T/A	cg15737290	chr11:93063684	CCDC67	1.05	7.97	0.63	3.42e-12	Pulmonary function decline;
THYM	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg11764359	chr7:65958608	NA	0.85	7.0	0.58	3.62e-10	Aortic root size;
THYM	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg22166914	chr1:53195759	ZYG11B	0.77	7.6	0.62	2.04e-11	Monocyte count;
THYM	cis	rs10979	0.965	rs34373782	chr6:143888258	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs600806	0.815	rs4970754	chr1:109969721	A/G	cg23616212	chr1:109941201	SORT1	-0.48	-4.47	-0.42	2.17e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg00631329	chr6:26305371	NA	-0.63	-7.47	-0.61	3.86e-11	Educational attainment;
THYM	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg14779329	chr11:130786720	SNX19	0.56	6.17	0.54	1.63e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9914988	1.000	rs6803	chr17:27187789	C/T	cg20469991	chr17:27169893	C17orf63	0.8	5.05	0.46	2.11e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs4889855	0.530	rs4889872	chr17:78621306	G/A	cg16591659	chr17:78472290	NA	0.41	4.78	0.44	6.28e-6	Fractional excretion of uric acid;
THYM	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg10802521	chr3:52805072	NEK4	-0.6	-5.25	-0.47	9.11e-7	Bipolar disorder;
THYM	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.01	10.95	0.75	1.6e-18	Intelligence (multi-trait analysis);
THYM	cis	rs11209185	0.602	rs12034179	chr1:68433212	T/C	cg22082780	chr1:68452167	NA	-0.49	-5.74	-0.51	1.14e-7	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs16854884	0.632	rs4563409	chr3:143682122	T/G	cg05063096	chr3:143689810	C3orf58	0.74	4.94	0.45	3.38e-6	Economic and political preferences (feminism/equality);
THYM	cis	rs55788414	0.932	rs35424543	chr16:81181983	G/A	cg06400318	chr16:81190750	PKD1L2	-1.0	-5.23	-0.47	1.01e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs611744	0.604	rs6469170	chr8:109305277	T/C	cg21045802	chr8:109455806	TTC35	0.72	6.6	0.56	2.34e-9	Dupuytren's disease;
THYM	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg06728252	chr6:26598149	ABT1	-0.43	-5.08	-0.46	1.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg27211696	chr2:191398769	TMEM194B	0.68	5.23	0.47	1.01e-6	Diastolic blood pressure;
THYM	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg05347473	chr6:146136440	FBXO30	-0.56	-4.45	-0.42	2.34e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs892961	0.932	rs11657961	chr17:75405407	C/T	cg11351908	chr17:75402473	SEPT9	0.59	5.74	0.51	1.11e-7	Airflow obstruction;
THYM	cis	rs314370	0.951	rs12705095	chr7:100484381	T/G	cg08558340	chr7:100472263	SRRT	0.61	4.99	0.46	2.75e-6	Resting heart rate;
THYM	cis	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg07235805	chr18:78004237	PARD6G	-0.46	-5.19	-0.47	1.21e-6	Opioid sensitivity;
THYM	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg13695892	chr22:41940480	POLR3H	-0.87	-6.35	-0.55	7.28e-9	Vitiligo;
THYM	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg12379764	chr21:47803548	PCNT	-0.83	-5.37	-0.48	5.52e-7	Testicular germ cell tumor;
THYM	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs7542375	0.507	rs2784270	chr1:221094967	C/T	cg16008148	chr1:221062819	NA	-0.37	-5.55	-0.49	2.56e-7	Obesity-related traits;
THYM	cis	rs6906287	0.669	rs2356491	chr6:118806564	A/G	cg21191810	chr6:118973309	C6orf204	0.57	5.66	0.5	1.6e-7	Electrocardiographic conduction measures;
THYM	cis	rs1050631	0.564	rs8098627	chr18:33721636	T/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.28	0.48	8.32e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg22907277	chr7:1156413	C7orf50	0.83	4.87	0.45	4.37e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3087591	1.000	rs4541129	chr17:29442878	T/C	cg24425628	chr17:29625626	OMG;NF1	0.65	5.61	0.5	2e-7	Hip circumference;
THYM	cis	rs11225247	0.772	rs61895376	chr11:102227892	A/G	cg06323957	chr11:102217781	BIRC2	1.02	4.74	0.44	7.52e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg00898013	chr13:113819073	PROZ	-0.88	-9.0	-0.68	2.24e-14	Platelet distribution width;
THYM	cis	rs12935418	0.616	rs12444054	chr16:80964217	T/G	cg16651780	chr16:81037892	C16orf61	0.83	5.33	0.48	6.62e-7	Mean corpuscular volume;
THYM	cis	rs17641971	0.684	rs7005693	chr8:49987965	A/C	cg00325661	chr8:49890786	NA	0.6	4.79	0.44	6.24e-6	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500395	0.889	rs2080507	chr16:48688634	T/A	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.65	-6.0	-0.52	3.51e-8	Total body bone mineral density;
THYM	cis	rs7027203	0.717	rs7869328	chr9:96588782	A/G	cg14598338	chr9:96623480	NA	-0.48	-5.13	-0.47	1.54e-6	DNA methylation (variation);
THYM	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg10465839	chr16:1584050	IFT140;TMEM204	-0.64	-5.56	-0.5	2.51e-7	Coronary artery disease;
THYM	cis	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg12292205	chr6:26970375	C6orf41	-0.97	-4.68	-0.43	9.51e-6	Intelligence (multi-trait analysis);
THYM	cis	rs665401	0.965	rs1761880	chr6:117259777	C/A	cg20376953	chr6:117187980	NA	-0.55	-4.49	-0.42	1.99e-5	Neutrophil percentage of granulocytes;
THYM	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06873352	chr17:61820015	STRADA	0.56	5.63	0.5	1.84e-7	Height;
THYM	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg14019146	chr3:50243930	SLC38A3	-0.6	-5.08	-0.46	1.88e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10911232	0.507	rs10911222	chr1:183047363	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg19507638	chr5:93509721	C5orf36	-0.7	-4.71	-0.44	8.43e-6	Diabetic retinopathy;
THYM	cis	rs8030379	0.967	rs7182563	chr15:84548746	A/G	cg15564896	chr15:84287328	SH3GL3	0.57	4.77	0.44	6.57e-6	Waist circumference adjusted for body mass index;Waist circumference;
THYM	cis	rs7584330	0.518	rs7585975	chr2:238439089	G/A	cg08992911	chr2:238395768	MLPH	1.05	6.53	0.56	3.16e-9	Prostate cancer;
THYM	cis	rs8133932	0.667	rs760436	chr21:47278055	C/T	cg20357416	chr21:47294739	PCBP3	-0.77	-4.95	-0.45	3.2e-6	Schizophrenia;
THYM	cis	rs11122895	1.000	rs11122890	chr2:112467554	T/C	cg23262488	chr2:112468472	NA	0.67	9.57	0.7	1.36e-15	Allergic sensitization;
THYM	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg00256281	chr22:41985642	PMM1	-0.57	-4.76	-0.44	7.03e-6	Vitiligo;
THYM	cis	rs2976388	1.000	rs2976394	chr8:143763622	C/T	cg06565975	chr8:143823917	SLURP1	-0.45	-5.23	-0.47	9.95e-7	Urinary tract infection frequency;
THYM	cis	rs12765878	1.000	rs7100920	chr10:105640978	A/G	cg11005552	chr10:105648138	OBFC1	-0.81	-10.24	-0.72	5.18e-17	Coronary artery disease;
THYM	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg18641463	chr7:2144579	MAD1L1	0.62	4.51	0.42	1.82e-5	Height;
THYM	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs6430585	0.528	rs75753154	chr2:136665711	T/C	cg23851026	chr2:136556271	LCT	0.77	7.29	0.6	9.12e-11	Corneal structure;
THYM	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg06108461	chr20:60628389	TAF4	1.05	7.34	0.6	7.32e-11	Body mass index;
THYM	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg22535103	chr8:58192502	C8orf71	-0.96	-5.47	-0.49	3.7e-7	Developmental language disorder (linguistic errors);
THYM	trans	rs3960554	0.867	rs79359354	chr7:75702597	G/A	cg19862616	chr7:65841803	NCRNA00174	0.97	7.31	0.6	8.48e-11	Eotaxin levels;
THYM	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg25811766	chr13:21894605	NA	-0.78	-5.02	-0.46	2.38e-6	White matter hyperintensity burden;
THYM	cis	rs2108622	1.000	rs62107762	chr19:15982538	C/G	cg13772218	chr19:15982569	NA	0.61	5.48	0.49	3.5e-7	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs10501293	0.746	rs4578378	chr11:43031293	C/T	cg03447554	chr11:43094025	NA	0.61	4.51	0.42	1.83e-5	Cognitive performance;
THYM	cis	rs2798269	0.604	rs2185883	chr13:22157265	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.61	-4.55	-0.42	1.6e-5	PR segment;
THYM	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg11247378	chr22:39784982	NA	-1.02	-12.79	-0.8	2.28e-22	Intelligence (multi-trait analysis);
THYM	cis	rs11574514	1.000	rs13339239	chr16:67809401	C/T	cg04582263	chr16:67973788	LCAT	1.08	5.09	0.46	1.82e-6	Crohn's disease;
THYM	cis	rs13064411	0.696	rs1552432	chr3:113225660	G/C	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg18512352	chr11:47633146	NA	-0.54	-6.86	-0.58	6.99e-10	Subjective well-being;
THYM	cis	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-5.43	-0.49	4.23e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6430585	0.878	rs9677760	chr2:136538939	T/A	cg04750100	chr2:136595281	LCT	-0.53	-5.1	-0.46	1.71e-6	Corneal structure;
THYM	cis	rs7267979	0.966	rs2482948	chr20:25296499	T/C	cg08601574	chr20:25228251	PYGB	-0.57	-4.51	-0.42	1.87e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg23161317	chr6:28129485	ZNF389	0.71	5.59	0.5	2.21e-7	Cardiac Troponin-T levels;
THYM	cis	rs17253792	0.822	rs17253730	chr14:56157911	A/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs995000	0.931	rs116405518	chr1:63036807	G/A	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs3126085	0.935	rs7531094	chr1:152176850	A/G	cg26020982	chr1:152196106	HRNR	0.37	5.06	0.46	2.05e-6	Atopic dermatitis;
THYM	cis	rs2901656	0.544	rs6658843	chr1:172399082	G/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.55	5.41	0.49	4.66e-7	Red cell distribution width;Platelet distribution width;
THYM	cis	rs61990749	0.597	rs4903643	chr14:78254791	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	1.18	8.09	0.64	1.98e-12	Fibroblast growth factor basic levels;
THYM	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg03354898	chr7:1950403	MAD1L1	-0.5	-4.73	-0.44	7.75e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs11039798	0.623	rs6485879	chr11:48587984	G/T	cg24672777	chr11:48374446	OR4C45	-0.93	-6.01	-0.52	3.39e-8	Axial length;
THYM	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg03433033	chr1:76189801	ACADM	-0.51	-5.31	-0.48	7.2e-7	Daytime sleep phenotypes;
THYM	cis	rs3126085	1.000	rs11204971	chr1:152259078	A/G	cg10321714	chr1:152280068	FLG	-0.76	-5.68	-0.5	1.47e-7	Atopic dermatitis;
THYM	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg14500267	chr11:67383377	NA	0.83	6.73	0.57	1.28e-9	Mean corpuscular volume;
THYM	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg27490568	chr2:178487706	NA	-0.59	-5.36	-0.48	5.91e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg06623918	chr6:96969491	KIAA0776	-1.11	-10.02	-0.72	1.49e-16	Headache;
THYM	cis	rs7107174	1.000	rs2511169	chr11:77965321	T/C	cg02023728	chr11:77925099	USP35	0.71	6.54	0.56	3.14e-9	Testicular germ cell tumor;
THYM	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg14784868	chr12:69753453	YEATS4	0.83	7.22	0.6	1.28e-10	Response to diuretic therapy;
THYM	cis	rs2235649	0.833	rs55684627	chr16:1848817	G/A	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs7113850	0.541	rs76671714	chr11:24231278	C/G	ch.11.24196551F	chr11:24239977	NA	1.04	5.45	0.49	3.97e-7	Bone fracture in osteoporosis;
THYM	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-4.56	-0.42	1.55e-5	Alzheimer's disease;
THYM	cis	rs2195525	0.572	rs3814759	chr11:119217580	C/T	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.46	4.98	0.46	2.82e-6	Urate levels;
THYM	cis	rs17253792	0.822	rs74940664	chr14:56135065	A/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7226229	1.000	rs4462662	chr17:20961579	T/G	cg21263980	chr17:20946333	USP22	0.65	4.55	0.42	1.61e-5	Blood trace element (Se levels);
THYM	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg10760299	chr15:45669010	GATM	-0.87	-6.83	-0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs79149102	0.579	rs8031545	chr15:75290496	T/C	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	cis	rs12282928	0.959	rs11039640	chr11:48307236	G/A	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg12524338	chr4:183729343	NA	0.91	5.86	0.52	6.52e-8	Pediatric autoimmune diseases;
THYM	cis	rs7507204	0.906	rs62125968	chr19:3422261	G/A	cg08380311	chr19:3435252	NFIC	0.86	7.01	0.58	3.44e-10	Height;
THYM	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg09307838	chr4:120376055	NA	0.7	5.24	0.47	9.74e-7	Corneal astigmatism;
THYM	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs10782582	0.632	rs77099976	chr1:76240524	T/C	cg03433033	chr1:76189801	ACADM	-0.47	-4.51	-0.42	1.87e-5	Daytime sleep phenotypes;
THYM	cis	rs9403317	0.960	rs10872536	chr6:141849145	A/T	cg15052665	chr6:141804349	NA	0.86	8.78	0.67	6.72e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg13114125	chr14:105738426	BRF1	-0.72	-5.61	-0.5	2.01e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg27535305	chr1:53392650	SCP2	-0.41	-4.77	-0.44	6.58e-6	Monocyte count;
THYM	cis	rs2688608	0.560	rs10128354	chr10:75470045	T/C	cg15838173	chr10:75533400	FUT11	-0.59	-5.99	-0.52	3.66e-8	Inflammatory bowel disease;
THYM	cis	rs931127	0.719	rs11227259	chr11:65459404	T/C	cg27068330	chr11:65405492	SIPA1	-0.83	-7.52	-0.61	3.07e-11	Systemic lupus erythematosus;
THYM	cis	rs1457451	0.646	rs4671675	chr2:65861655	A/G	cg16240816	chr2:65861662	NA	0.71	9.25	0.69	6.73e-15	Iron status biomarkers;
THYM	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.92	-6.03	-0.53	3.11e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs2820651	1.000	rs79849781	chr10:1473961	A/C	cg02445968	chr10:1449028	ADARB2	-1.2	-6.24	-0.54	1.19e-8	Migraine with aura;
THYM	trans	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg20587970	chr11:113659929	NA	-1.24	-8.8	-0.67	6.09e-14	Hip circumference adjusted for BMI;
THYM	cis	rs6674176	0.628	rs4660759	chr1:44432500	C/G	cg13246856	chr1:44399776	ARTN	0.47	4.86	0.45	4.68e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs863345	0.604	rs10908673	chr1:158503908	T/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs863345	0.604	rs10908651	chr1:158451272	A/C	cg12129480	chr1:158549410	OR10X1	0.48	4.64	0.43	1.12e-5	Pneumococcal bacteremia;
THYM	cis	rs13315871	0.929	rs79813245	chr3:58318475	G/A	cg12435725	chr3:58293450	RPP14	-0.53	-5.51	-0.49	3.09e-7	Cholesterol, total;
THYM	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg17105886	chr17:28927953	LRRC37B2	1.22	7.38	0.6	5.85e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg04654363	chr8:8581213	NA	-0.48	-4.62	-0.43	1.22e-5	Obesity-related traits;
THYM	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg26384229	chr12:38710491	ALG10B	-0.72	-6.08	-0.53	2.53e-8	Morning vs. evening chronotype;
THYM	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg21862992	chr11:68658383	NA	0.23	4.49	0.42	2.02e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2289328	0.941	rs11636147	chr15:40721128	C/G	cg13931752	chr15:40660718	DISP2	0.7	5.17	0.47	1.31e-6	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
THYM	cis	rs34779708	1.000	rs34779708	chr10:35466185	T/G	cg03585969	chr10:35415529	CREM	0.68	4.86	0.45	4.64e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg19913688	chr11:428466	ANO9	-0.88	-4.53	-0.42	1.74e-5	Body mass index;
THYM	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg16405210	chr4:1374714	KIAA1530	-1.03	-9.38	-0.69	3.54e-15	Longevity;
THYM	cis	rs4343996	1.000	rs10238520	chr7:3341615	G/A	cg21248987	chr7:3385318	SDK1	0.4	4.84	0.44	5.08e-6	Motion sickness;
THYM	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.55	-4.69	-0.43	8.99e-6	Platelet count;
THYM	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.59	-11.2	-0.75	4.73e-19	Hemostatic factors and hematological phenotypes;
THYM	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg26850624	chr5:429559	AHRR	-0.72	-5.68	-0.5	1.45e-7	Cystic fibrosis severity;
THYM	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.49	-4.95	-0.45	3.22e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg00129232	chr17:37814104	STARD3	0.7	4.79	0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs8025790	0.508	rs28673019	chr15:67809823	T/A	cg24579218	chr15:68104479	NA	-0.68	-6.15	-0.53	1.86e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs4819143	0.517	rs1783076	chr21:47373586	C/T	cg20357416	chr21:47294739	PCBP3	0.79	4.94	0.45	3.38e-6	Insulin resistance/response;
THYM	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg01570182	chr17:44337453	NA	-0.63	-6.68	-0.57	1.61e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg06521331	chr12:34319734	NA	-0.73	-5.66	-0.5	1.59e-7	Morning vs. evening chronotype;
THYM	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg05043794	chr9:111880884	C9orf5	-0.41	-6.15	-0.53	1.8e-8	Menarche (age at onset);
THYM	cis	rs240764	0.658	rs12664626	chr6:101195720	A/G	cg21058520	chr6:100914733	NA	0.56	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs17321999	1.000	rs7604484	chr2:30491556	T/G	cg05247661	chr2:30472410	LBH	0.67	4.78	0.44	6.41e-6	Systemic lupus erythematosus;
THYM	cis	rs9992101	0.547	rs7675258	chr4:77413179	A/G	cg20311846	chr4:77356250	SHROOM3	0.45	4.68	0.43	9.35e-6	Creatinine levels;
THYM	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg24692254	chr21:30365293	RNF160	-0.99	-9.28	-0.69	5.71e-15	Dental caries;
THYM	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg19862616	chr7:65841803	NCRNA00174	1.12	13.73	0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg16342193	chr10:102329863	NA	-0.56	-5.69	-0.5	1.38e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs859767	0.924	rs842349	chr2:135342452	G/T	cg12500956	chr2:135428796	TMEM163	0.56	5.29	0.48	7.78e-7	Neuroticism;
THYM	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg11764359	chr7:65958608	NA	-0.88	-7.56	-0.61	2.55e-11	Aortic root size;
THYM	cis	rs1030420	0.948	rs73691543	chr8:67382075	A/C	cg06195829	chr8:66753750	PDE7A	-0.79	-4.51	-0.42	1.88e-5	Blood metabolite levels;
THYM	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg18681998	chr4:17616180	MED28	0.97	9.52	0.7	1.74e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs72627123	0.867	rs59421227	chr14:74350227	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs6840360	0.582	rs1372976	chr4:152451453	G/A	cg17479576	chr4:152424074	FAM160A1	-0.66	-5.0	-0.46	2.67e-6	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.18	0.64	1.26e-12	Corneal astigmatism;
THYM	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg04398451	chr17:18023971	MYO15A	-0.78	-6.53	-0.56	3.17e-9	Total body bone mineral density;
THYM	cis	rs6430585	0.528	rs111682961	chr2:136653848	C/T	cg04750100	chr2:136595281	LCT	0.56	4.96	0.45	3.13e-6	Corneal structure;
THYM	cis	rs13315871	0.654	rs11711261	chr3:58343696	C/A	cg12435725	chr3:58293450	RPP14	-0.38	-4.85	-0.45	4.75e-6	Cholesterol, total;
THYM	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.76	0.67	7.37e-14	Colorectal cancer;
THYM	cis	rs10203711	0.966	rs4663939	chr2:239569867	C/A	cg14580085	chr2:239553406	NA	0.68	6.18	0.54	1.6e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg25256661	chr17:7137939	DVL2	1.04	8.28	0.65	7.64e-13	Diastolic blood pressure;
THYM	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg14416269	chr4:6271139	WFS1	0.54	5.62	0.5	1.93e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg19774624	chr17:42201019	HDAC5	-0.66	-5.69	-0.5	1.39e-7	Total body bone mineral density;
THYM	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs3820068	0.608	rs12740492	chr1:16048951	A/T	cg13390004	chr1:15929781	NA	0.65	4.92	0.45	3.62e-6	Systolic blood pressure;
THYM	cis	rs8070624	0.543	rs7219320	chr17:17880877	A/G	cg16928487	chr17:17741425	SREBF1	-0.51	-4.63	-0.43	1.18e-5	Total body bone mineral density;
THYM	cis	rs6840360	0.642	rs1596290	chr4:152410540	G/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-5.65	-0.5	1.7e-7	Intelligence (multi-trait analysis);
THYM	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg16486109	chr11:613632	IRF7	0.47	5.59	0.5	2.19e-7	Systemic lupus erythematosus;
THYM	trans	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg00376283	chr12:123451042	ABCB9	0.71	4.75	0.44	7.32e-6	Neutrophil percentage of white cells;
THYM	trans	rs9929218	0.953	rs12920562	chr16:68737512	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-7.29	-0.6	9.13e-11	Colorectal cancer;
THYM	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg08470875	chr2:26401718	FAM59B	-0.77	-4.6	-0.43	1.29e-5	Gut microbiome composition (summer);
THYM	cis	rs2073300	1.000	rs6114137	chr20:23457264	G/A	cg12062639	chr20:23401060	NAPB	0.99	4.96	0.45	3.07e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7582180	0.677	rs2067783	chr2:100877370	T/C	cg08017756	chr2:100939284	LONRF2	-0.57	-4.92	-0.45	3.56e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.12	8.13	0.64	1.64e-12	Cognitive test performance;
THYM	cis	rs6754311	0.773	rs309178	chr2:136611624	C/T	cg07169764	chr2:136633963	MCM6	-0.72	-6.25	-0.54	1.18e-8	Mosquito bite size;
THYM	cis	rs36051895	0.695	rs10974915	chr9:5016818	A/G	cg02405213	chr9:5042618	JAK2	-1.02	-10.52	-0.73	1.27e-17	Pediatric autoimmune diseases;
THYM	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.61	-4.95	-0.45	3.16e-6	Chronic sinus infection;
THYM	cis	rs67385638	1.000	rs2855039	chr11:5271671	C/T	cg12559170	chr11:5275217	HBG2	0.87	8.64	0.66	1.35e-13	Hemoglobin levels;
THYM	cis	rs4866334	0.850	rs75708102	chr5:18489975	C/A	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs28647808	1.000	rs4962143	chr9:136275137	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg14008862	chr17:28927542	LRRC37B2	0.92	4.88	0.45	4.18e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs3126085	0.667	rs12747821	chr1:152240424	G/A	cg10321714	chr1:152280068	FLG	0.68	5.25	0.47	9.18e-7	Atopic dermatitis;
THYM	cis	rs9399401	0.667	rs6900233	chr6:142717283	C/G	cg04461802	chr6:142623433	GPR126	0.77	7.46	0.61	3.98e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs4638749	0.603	rs34153365	chr2:108846583	C/T	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg25918947	chr17:41365094	TMEM106A	-0.59	-4.88	-0.45	4.23e-6	Menopause (age at onset);
THYM	cis	rs7084402	0.967	rs1658442	chr10:60318897	G/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.47	-0.49	3.63e-7	Refractive error;
THYM	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg23187316	chr7:1099788	C7orf50	0.58	4.45	0.42	2.32e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg02734326	chr4:10020555	SLC2A9	-0.62	-4.74	-0.44	7.49e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg19077165	chr18:44547161	KATNAL2	0.56	6.98	0.58	3.96e-10	Personality dimensions;
THYM	cis	rs6032067	0.777	rs13037087	chr20:43834313	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs17122693	0.681	rs72679587	chr14:51092686	A/G	cg04730355	chr14:51134070	SAV1	0.91	4.95	0.45	3.19e-6	Cognitive performance;
THYM	cis	rs4478037	1.000	rs61433006	chr3:33162363	T/A	cg19404215	chr3:33155277	CRTAP	1.18	8.15	0.64	1.49e-12	Major depressive disorder;
THYM	cis	rs1061377	0.965	rs1046655	chr4:39127747	G/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs6557607	1.000	rs73672962	chr8:22867790	C/G	cg04259752	chr8:23262159	LOXL2	0.43	4.55	0.42	1.59e-5	Plasma trimethylamine N-oxide levels;
THYM	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg10224037	chr5:178157518	ZNF354A	0.94	7.71	0.62	1.2e-11	Neutrophil percentage of white cells;
THYM	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03264133	chr6:25882463	NA	0.72	5.71	0.51	1.29e-7	Blood metabolite levels;
THYM	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg17063962	chr7:91808500	NA	1.1	12.12	0.78	5.59e-21	Breast cancer;
THYM	cis	rs13256369	1.000	rs883648	chr8:8569521	A/G	cg17143192	chr8:8559678	CLDN23	0.91	6.74	0.57	1.2e-9	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8050907	0.744	rs11866840	chr16:4536354	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.22	4.58	0.43	1.43e-5	Obesity-related traits;
THYM	cis	rs6674176	0.628	rs3791116	chr1:44414156	T/A	cg15962314	chr1:44399869	ARTN	0.54	5.37	0.48	5.57e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs7487075	0.930	rs7308910	chr12:46838242	T/C	cg17501823	chr12:47219793	SLC38A4	0.46	4.54	0.42	1.67e-5	Itch intensity from mosquito bite;
THYM	cis	rs17818399	0.962	rs7565274	chr2:46841861	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.71	5.24	0.47	9.76e-7	Height;
THYM	cis	rs12291225	0.679	rs11023172	chr11:14295367	C/G	cg05501817	chr11:14380813	RRAS2	-0.75	-5.72	-0.51	1.24e-7	Sense of smell;
THYM	cis	rs870825	0.616	rs6552804	chr4:185637699	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs9534288	0.797	rs7982998	chr13:46601535	C/T	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs9361491	0.657	rs1180828	chr6:79435422	C/G	cg04547799	chr6:79944526	HMGN3	0.66	4.61	0.43	1.24e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg00074818	chr8:8560427	CLDN23	0.57	5.35	0.48	6e-7	Obesity-related traits;
THYM	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	5.3	0.48	7.48e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7809950	0.678	rs17154040	chr7:107005246	C/T	cg23024343	chr7:107201750	COG5	0.95	7.96	0.63	3.66e-12	Coronary artery disease;
THYM	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg17863274	chr19:49399704	TULP2	-1.0	-6.15	-0.53	1.85e-8	Red cell distribution width;
THYM	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.07	-0.82	5.85e-25	Height;
THYM	cis	rs12519773	0.525	rs57542119	chr5:92538853	T/C	cg18783429	chr5:92414398	NA	0.5	4.91	0.45	3.72e-6	Migraine;
THYM	cis	rs7107174	1.000	rs4134379	chr11:77992588	A/G	cg19901956	chr11:77921274	USP35	-0.69	-5.22	-0.47	1.03e-6	Testicular germ cell tumor;
THYM	cis	rs9543976	0.614	rs73223948	chr13:76098025	C/A	cg01531495	chr13:76123901	UCHL3	-0.87	-4.83	-0.44	5.32e-6	Diabetic retinopathy;
THYM	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg15744005	chr10:104629667	AS3MT	0.56	4.66	0.43	1.02e-5	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg00684032	chr4:1343700	KIAA1530	0.55	4.76	0.44	7.03e-6	Obesity-related traits;
THYM	cis	rs6665290	0.904	rs10916075	chr1:227184074	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.13	-15.82	-0.85	2.26e-28	Myeloid white cell count;
THYM	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs6995541	0.529	rs2292370	chr8:10690319	G/A	cg13457217	chr8:10683266	MIR1322;PINX1	-0.67	-5.02	-0.46	2.39e-6	Triglyceride levels;
THYM	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7181230	1.000	rs28620926	chr15:40357171	A/G	cg20592017	chr15:40364740	NA	0.62	5.57	0.5	2.36e-7	Dehydroepiandrosterone sulphate levels;
THYM	cis	rs16866061	1.000	rs12470077	chr2:225334971	T/C	cg22455342	chr2:225449267	CUL3	0.68	4.88	0.45	4.23e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg06238570	chr21:40685208	BRWD1	-0.96	-9.2	-0.69	8.43e-15	Cognitive function;
THYM	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs3126085	0.515	rs12033221	chr1:152356113	A/G	cg10321714	chr1:152280068	FLG	-0.69	-4.84	-0.44	5.1e-6	Atopic dermatitis;
THYM	cis	rs7666738	0.887	rs34509663	chr4:98982531	C/T	cg07917127	chr4:99064746	C4orf37	0.59	4.5	0.42	1.93e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg10047753	chr17:41438598	NA	1.23	11.75	0.77	3.23e-20	Menopause (age at onset);
THYM	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg10911889	chr6:126070802	HEY2	0.59	4.73	0.44	7.89e-6	Brugada syndrome;
THYM	cis	rs1448094	0.511	rs17279289	chr12:86162792	T/G	cg02569458	chr12:86230093	RASSF9	0.69	5.77	0.51	9.84e-8	Major depressive disorder;
THYM	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.87	-0.45	4.45e-6	Eye color traits;
THYM	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.8e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg01710189	chr8:22454888	PDLIM2	-0.48	-5.04	-0.46	2.19e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1190596	0.581	rs1190571	chr14:102634901	C/A	cg08231664	chr14:102516632	DYNC1H1	-0.4	-4.77	-0.44	6.6e-6	Behavioural disinhibition (generation interaction);
THYM	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg17747265	chr1:1875780	NA	-0.78	-8.95	-0.68	2.85e-14	Body mass index;
THYM	cis	rs34638657	0.732	rs12597534	chr16:82200276	G/T	cg09439754	chr16:82129088	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	cis	rs4866334	1.000	rs116309900	chr5:18430285	G/T	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs71403859	0.730	rs17356316	chr16:71746921	C/T	cg08717414	chr16:71523259	ZNF19	-0.92	-5.16	-0.47	1.32e-6	Post bronchodilator FEV1;
THYM	cis	rs6920965	0.545	rs614031	chr6:126165720	A/C	cg05901451	chr6:126070800	HEY2	-0.63	-5.3	-0.48	7.43e-7	High light scatter reticulocyte count;
THYM	cis	rs986417	0.818	rs12880313	chr14:60935504	T/C	cg27398547	chr14:60952738	C14orf39	1.21	6.17	0.53	1.69e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06850241	chr22:41845214	NA	-0.55	-4.82	-0.44	5.52e-6	Vitiligo;
THYM	cis	rs2073300	1.000	rs112057098	chr20:23448901	C/T	cg12062639	chr20:23401060	NAPB	1.2	5.64	0.5	1.73e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs4780401	0.609	rs4781142	chr16:11808806	T/C	cg01061890	chr16:11836724	TXNDC11	-0.66	-5.44	-0.49	4.13e-7	Rheumatoid arthritis;
THYM	cis	rs11030122	0.702	rs12223176	chr11:3982537	T/G	cg18678763	chr11:4115507	RRM1	-0.44	-5.59	-0.5	2.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs995000	0.931	rs11207970	chr1:62915473	C/T	cg06896770	chr1:63153194	DOCK7	0.99	8.18	0.64	1.26e-12	Triglyceride levels;
THYM	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg10515332	chr4:99064459	C4orf37	0.62	4.96	0.45	3.07e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6815814	0.950	rs11725779	chr4:38811668	G/A	cg06935464	chr4:38784597	TLR10	0.72	4.71	0.44	8.42e-6	Breast cancer;
THYM	cis	rs476633	0.691	rs2164996	chr15:41536624	A/G	cg21153102	chr15:41252147	NA	0.53	4.48	0.42	2.08e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg13175981	chr1:150552382	MCL1	0.7	4.99	0.46	2.72e-6	Tonsillectomy;
THYM	cis	rs7586879	0.681	rs28836469	chr2:25117215	A/G	cg01884057	chr2:25150051	NA	0.71	7.7	0.62	1.31e-11	Body mass index;
THYM	cis	rs7172677	1.000	rs8032208	chr15:75431245	A/G	cg09165964	chr15:75287851	SCAMP5	-0.63	-4.75	-0.44	7.24e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs2074585	0.802	rs2589940	chr15:90931363	C/T	cg22089800	chr15:90895588	ZNF774	0.69	5.4	0.48	5e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
THYM	cis	rs10949662	1.000	rs10949662	chr7:157534105	A/G	cg15733309	chr7:157513707	PTPRN2	-0.61	-6.41	-0.55	5.49e-9	Intelligence (multi-trait analysis);
THYM	cis	rs513349	1.000	rs513349	chr6:33541719	A/G	cg07679836	chr6:33548423	BAK1	0.34	4.76	0.44	6.86e-6	Platelet count;
THYM	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg13395646	chr4:1353034	KIAA1530	-0.61	-5.56	-0.5	2.42e-7	Obesity-related traits;
THYM	cis	rs6500395	0.962	rs9941275	chr16:48573428	A/G	cg04672837	chr16:48644449	N4BP1	0.49	4.74	0.44	7.38e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs36051895	0.664	rs10815157	chr9:5108771	C/G	cg02405213	chr9:5042618	JAK2	-0.99	-11.13	-0.75	6.48e-19	Pediatric autoimmune diseases;
THYM	cis	rs2252521	0.524	rs317745	chr7:29068114	T/C	cg24222995	chr7:28995786	TRIL	-0.62	-4.46	-0.42	2.28e-5	Cognitive performance;
THYM	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg07936489	chr17:37558343	FBXL20	0.82	5.69	0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg02725872	chr8:58115012	NA	-0.88	-6.55	-0.56	3e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7688540	0.723	rs61794999	chr4:232367	T/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.72	4.88	0.45	4.35e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs236907	0.859	rs2232813	chr1:171750577	T/C	cg20598894	chr1:171756153	METTL13	-0.74	-5.59	-0.5	2.16e-7	Mean platelet volume;
THYM	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg21427119	chr20:30132790	HM13	0.71	4.79	0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06850241	chr22:41845214	NA	0.59	5.16	0.47	1.37e-6	Vitiligo;
THYM	cis	rs6495122	0.662	rs12898997	chr15:75090349	C/T	cg14664628	chr15:75095509	CSK	-0.83	-6.52	-0.56	3.38e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg25358565	chr5:93447407	FAM172A	1.31	11.12	0.75	6.98e-19	Diabetic retinopathy;
THYM	cis	rs4788570	0.615	rs1423983	chr16:71701248	G/A	cg06353428	chr16:71660113	MARVELD3	1.28	8.72	0.67	8.76e-14	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9352866	0.841	rs1582154	chr6:81527455	G/A	cg08356243	chr6:80645827	ELOVL4	-0.45	-4.46	-0.42	2.23e-5	Antibody level in response to infection;
THYM	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9828933	0.678	rs704366	chr3:63871648	A/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.74	4.7	0.43	8.74e-6	Type 2 diabetes;
THYM	cis	rs9527	0.590	rs10786738	chr10:104869451	C/T	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg08132940	chr7:1081526	C7orf50	-1.17	-6.67	-0.56	1.7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs5417	0.780	rs222849	chr17:7185861	T/C	cg03186999	chr17:7165420	CLDN7	-0.56	-5.77	-0.51	9.95e-8	Diastolic blood pressure;
THYM	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg23422044	chr7:1970798	MAD1L1	-0.79	-5.24	-0.47	9.83e-7	Bipolar disorder;
THYM	cis	rs2811415	0.597	rs9844891	chr3:127743260	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.74	-7.03	-0.59	3.08e-10	Personality dimensions;
THYM	cis	rs2731664	0.756	rs4976695	chr5:176862963	T/A	cg14098951	chr5:176875120	PRR7	0.57	5.06	0.46	2.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg07936489	chr17:37558343	FBXL20	0.84	5.76	0.51	1.03e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg00129232	chr17:37814104	STARD3	0.7	4.93	0.45	3.42e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs80319144	1.000	rs77748196	chr2:159302112	C/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs8064299	0.597	rs6501737	chr17:72780830	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.88	-8.69	-0.67	1.06e-13	Monocyte count;
THYM	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg12407791	chr17:73824354	UNC13D	-0.41	-4.54	-0.42	1.67e-5	White matter hyperintensity burden;
THYM	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg09549813	chr16:4587862	C16orf5	-0.56	-6.5	-0.56	3.62e-9	Schizophrenia;
THYM	cis	rs2273669	0.667	rs11153148	chr6:109304084	C/T	cg17117243	chr6:109341365	SESN1	-0.85	-4.97	-0.45	2.94e-6	Prostate cancer;
THYM	cis	rs6812193	0.508	rs7676094	chr4:77412894	C/T	cg20311846	chr4:77356250	SHROOM3	-0.45	-4.72	-0.44	8.12e-6	Parkinson's disease;
THYM	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Body mass index;
THYM	cis	rs593982	0.920	rs1151500	chr11:65481166	T/C	cg08755490	chr11:65554678	OVOL1	1.29	4.66	0.43	1.03e-5	Atopic dermatitis;
THYM	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg19016782	chr12:123741754	C12orf65	-0.71	-4.66	-0.43	1.05e-5	Neutrophil percentage of white cells;
THYM	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs56104184	0.830	rs45589039	chr19:49355385	C/T	cg15549821	chr19:49342101	PLEKHA4	-1.19	-6.1	-0.53	2.33e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs6840360	1.000	rs12331037	chr4:152663971	G/A	cg22705602	chr4:152727874	NA	-0.58	-6.26	-0.54	1.1e-8	Intelligence (multi-trait analysis);
THYM	cis	rs73198271	0.641	rs34473848	chr8:8649837	C/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-4.77	-0.44	6.56e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs6429082	0.755	rs291367	chr1:235690800	G/A	cg26050004	chr1:235667680	B3GALNT2	0.78	7.09	0.59	2.34e-10	Adiposity;
THYM	trans	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg10856724	chr12:34555212	NA	-1.02	-9.35	-0.69	3.96e-15	Morning vs. evening chronotype;
THYM	cis	rs8050907	1.000	rs9922925	chr16:4624892	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.27	5.12	0.46	1.6e-6	Obesity-related traits;
THYM	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg12863693	chr15:85201151	NMB	0.54	4.54	0.42	1.67e-5	Schizophrenia;
THYM	cis	rs921968	0.565	rs12611632	chr2:219621258	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs12142240	0.698	rs17357628	chr1:46808462	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg01483505	chr11:975446	AP2A2	0.58	4.75	0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs4786125	0.879	rs11645781	chr16:6896128	C/T	cg03623568	chr16:6915990	A2BP1	0.72	5.7	0.5	1.36e-7	Heart rate variability traits (SDNN);
THYM	cis	rs4460079	0.531	rs12510815	chr4:114836649	C/T	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg20007245	chr22:24372913	LOC391322	-0.7	-6.16	-0.53	1.76e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs8028182	0.537	rs4371118	chr15:75898890	C/A	cg23097139	chr15:75918757	SNUPN	-0.48	-4.77	-0.44	6.67e-6	Sudden cardiac arrest;
THYM	cis	rs2404602	0.647	rs11852395	chr15:77087785	T/C	cg23625390	chr15:77176239	SCAPER	-0.87	-6.12	-0.53	2.05e-8	Blood metabolite levels;
THYM	cis	rs57590327	0.503	rs6802480	chr3:81906671	G/A	cg07356753	chr3:81810745	GBE1	-0.74	-5.43	-0.49	4.33e-7	Extraversion;
THYM	cis	rs3741151	0.686	rs1938777	chr11:73122340	A/G	cg12959048	chr11:73096162	RELT	-0.46	-4.93	-0.45	3.46e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9790314	1.000	rs4350933	chr3:160955879	G/T	cg03342759	chr3:160939853	NMD3	-0.76	-7.0	-0.58	3.68e-10	Morning vs. evening chronotype;
THYM	cis	rs16854884	0.632	rs10513234	chr3:143670957	A/G	cg05063096	chr3:143689810	C3orf58	-0.76	-5.13	-0.47	1.54e-6	Economic and political preferences (feminism/equality);
THYM	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg22105103	chr4:187893119	NA	0.89	9.4	0.69	3.23e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs807669	0.903	rs1780637	chr22:19178250	A/G	cg02655711	chr22:19163373	SLC25A1	0.97	11.57	0.76	7.63e-20	Metabolite levels;
THYM	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg10589385	chr1:150898437	SETDB1	0.63	5.27	0.48	8.58e-7	Melanoma;
THYM	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg02782426	chr3:40428986	ENTPD3	-0.51	-4.56	-0.42	1.55e-5	Renal cell carcinoma;
THYM	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07157834	chr1:205819609	PM20D1	-0.72	-6.56	-0.56	2.84e-9	Monocyte percentage of white cells;
THYM	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg05775895	chr3:12838266	CAND2	1.02	10.26	0.72	4.71e-17	QRS complex (12-leadsum);
THYM	cis	rs17739794	0.557	rs35185084	chr8:808721	C/G	cg07178994	chr8:816998	NA	0.47	4.57	0.42	1.46e-5	Clozapine-induced cytotoxicity;
THYM	cis	rs35883536	1.000	rs2065784	chr1:101096056	A/G	cg06223162	chr1:101003688	GPR88	-0.68	-5.29	-0.48	7.7300000000000005e-07	Monocyte count;
THYM	cis	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg05084668	chr3:125655381	ALG1L	-0.74	-4.68	-0.43	9.36e-6	Blood pressure (smoking interaction);
THYM	cis	rs2302729	0.727	rs10848684	chr12:2793478	G/A	cg19945202	chr12:2788847	CACNA1C	-0.9	-5.99	-0.52	3.81e-8	Sleep quality;
THYM	cis	rs7106204	0.609	rs72874176	chr11:24330205	C/T	ch.11.24196551F	chr11:24239977	NA	0.98	5.91	0.52	5.4e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg23161317	chr6:28129485	ZNF389	0.85	6.33	0.54	8.19e-9	Depression;
THYM	cis	rs1957429	0.614	rs117722345	chr14:65381464	C/G	cg23373153	chr14:65346875	NA	-1.25	-5.03	-0.46	2.29e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs892961	0.966	rs4386185	chr17:75400891	G/A	cg05865280	chr17:75406074	SEPT9	0.5	8.26	0.65	8.3e-13	Airflow obstruction;
THYM	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	4.54	0.42	1.66e-5	Hip circumference adjusted for BMI;
THYM	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg11301795	chr4:187892539	NA	-1.11	-19.07	-0.89	3.07e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.87	-6.47	-0.55	4.16e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2237234	1.000	rs2237234	chr6:26391394	G/A	cg12826209	chr6:26865740	GUSBL1	0.77	6.27	0.54	1.05e-8	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11690935	0.959	rs7608403	chr2:172646765	A/C	cg13550731	chr2:172543902	DYNC1I2	-0.8	-5.78	-0.51	9.45e-8	Schizophrenia;
THYM	cis	rs1371867	0.817	rs1788185	chr8:101335529	T/C	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs765787	0.530	rs12904331	chr15:45518293	C/T	cg24006582	chr15:45444508	DUOX1	0.81	6.51	0.56	3.6e-9	Uric acid levels;
THYM	cis	rs6570726	0.818	rs398812	chr6:145817271	T/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.72	-6.37	-0.55	6.63e-9	Lung cancer;
THYM	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg14159672	chr1:205819179	PM20D1	-0.73	-5.77	-0.51	9.83e-8	Menarche (age at onset);
THYM	cis	rs6430585	0.528	rs586964	chr2:136652491	G/A	cg20242066	chr2:136595261	LCT	0.55	5.17	0.47	1.31e-6	Corneal structure;
THYM	cis	rs4713118	0.513	rs149972	chr6:27983227	C/T	cg23161317	chr6:28129485	ZNF389	0.65	5.2	0.47	1.14e-6	Parkinson's disease;
THYM	cis	rs7572733	0.555	rs6745726	chr2:198934080	A/G	cg00792783	chr2:198669748	PLCL1	0.71	4.61	0.43	1.28e-5	Dermatomyositis;
THYM	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg13683864	chr3:40499215	RPL14	1.05	11.46	0.76	1.29e-19	Renal cell carcinoma;
THYM	cis	rs1348850	0.526	rs2293475	chr2:178407897	C/T	cg27490568	chr2:178487706	NA	-0.64	-5.24	-0.47	9.62e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2080501	0.601	rs12919799	chr16:49668955	C/T	cg05126388	chr16:49670144	ZNF423	-0.87	-12.53	-0.79	7.76e-22	IgG glycosylation;
THYM	cis	rs904251	0.861	rs1757180	chr6:37486145	T/C	cg01843034	chr6:37503916	NA	-0.7	-5.33	-0.48	6.47e-7	Cognitive performance;
THYM	cis	rs747334	0.846	rs76718710	chr10:92709697	A/G	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs9595908	0.965	rs7328733	chr13:33126737	A/C	cg12383807	chr13:33924137	NA	-0.57	-5.0	-0.46	2.58e-6	Body mass index;
THYM	cis	rs13253111	1.000	rs17411738	chr8:28060572	T/G	cg26534493	chr8:28060551	NA	-0.53	-4.78	-0.44	6.36e-6	Childhood body mass index;
THYM	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg13010199	chr12:38710504	ALG10B	0.64	4.73	0.44	7.88e-6	Bladder cancer;
THYM	cis	rs2235649	0.833	rs9922139	chr16:1848329	G/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28595532	0.920	rs114575045	chr4:119739794	A/G	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg17911788	chr17:44343683	NA	0.67	6.38	0.55	6.53e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7107174	0.901	rs1046780	chr11:77926769	A/G	cg19901956	chr11:77921274	USP35	-0.68	-5.35	-0.48	6.11e-7	Testicular germ cell tumor;
THYM	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg17644776	chr2:200775616	C2orf69	-0.71	-5.03	-0.46	2.3e-6	Schizophrenia;
THYM	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg18252515	chr7:66147081	NA	-0.67	-5.08	-0.46	1.86e-6	Aortic root size;
THYM	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs9470366	0.883	rs9462210	chr6:36628953	G/A	cg24425727	chr6:36645648	CDKN1A	-0.59	-4.77	-0.44	6.55e-6	QRS duration;
THYM	cis	rs654950	0.901	rs594656	chr1:41999873	C/T	cg06885757	chr1:42089581	HIVEP3	-0.58	-7.77	-0.62	9e-12	Airway imaging phenotypes;
THYM	cis	rs13326165	0.585	rs56352611	chr3:52338590	T/C	cg08438690	chr3:52279403	PPM1M	-0.74	-4.65	-0.43	1.07e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs3772130	0.583	rs7618041	chr3:121566481	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.86	7.17	0.59	1.63e-10	Cognitive performance;
THYM	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	5.44	0.49	4.09e-7	Obesity-related traits;
THYM	cis	rs1775715	0.737	rs2808072	chr10:32205504	A/T	cg04359828	chr10:32216031	ARHGAP12	0.39	4.83	0.44	5.32e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg22875332	chr1:76189707	ACADM	-0.54	-5.15	-0.47	1.42e-6	Daytime sleep phenotypes;
THYM	cis	rs12282928	0.959	rs11039633	chr11:48297665	A/C	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg15536230	chr21:44985092	HSF2BP	0.42	5.04	0.46	2.26e-6	Mean corpuscular volume;
THYM	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg10515332	chr4:99064459	C4orf37	0.62	4.99	0.46	2.78e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg15838173	chr10:75533400	FUT11	-0.59	-6.07	-0.53	2.56e-8	Inflammatory bowel disease;
THYM	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	6.88	0.58	6.35e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.64	0.43	1.1e-5	Obesity-related traits;
THYM	cis	rs9972944	0.651	rs7221371	chr17:63765174	C/A	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs919433	0.889	rs12472355	chr2:198205840	C/A	cg00792783	chr2:198669748	PLCL1	-0.71	-5.14	-0.47	1.46e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4262150	0.883	rs72802856	chr5:152218952	G/A	cg06854687	chr5:151642065	NA	0.66	4.6	0.43	1.3e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	5.02	0.46	2.39e-6	Menarche (age at onset);
THYM	cis	rs89107	0.575	rs11752928	chr6:118977768	C/G	cg21191810	chr6:118973309	C6orf204	0.57	5.95	0.52	4.46e-8	Cardiac structure and function;
THYM	cis	rs11651000	0.625	rs4794063	chr17:45804494	C/T	cg06532163	chr17:45867833	NA	0.53	5.08	0.46	1.89e-6	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7586879	0.964	rs11688665	chr2:25121168	G/T	cg15423357	chr2:25149977	NA	0.56	5.45	0.49	3.97e-7	Body mass index;
THYM	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg18105134	chr13:113819100	PROZ	-0.98	-9.05	-0.68	1.79e-14	Platelet distribution width;
THYM	cis	rs2637266	1.000	rs7080883	chr10:78361200	A/G	cg18941641	chr10:78392320	NA	0.72	6.33	0.54	8.03e-9	Pulmonary function;
THYM	cis	rs1003719	0.751	rs55740803	chr21:38542761	G/A	cg01329690	chr21:38580129	DSCR9	-0.36	-5.09	-0.46	1.81e-6	Eye color traits;
THYM	cis	rs13326165	0.585	rs724801	chr3:52488517	C/T	cg08438690	chr3:52279403	PPM1M	-0.85	-4.67	-0.43	9.89e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs7760949	0.889	rs9475807	chr6:13934597	T/C	cg11053062	chr6:13924544	RNF182	-0.48	-4.6	-0.43	1.28e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Body mass index;
THYM	cis	rs9880211	0.563	rs6793835	chr3:135819934	A/G	cg21827317	chr3:136751795	NA	0.71	5.16	0.47	1.33e-6	Body mass index;Height;
THYM	cis	rs12534701	1.000	rs13232266	chr7:154681363	A/T	cg24255201	chr7:154684926	DPP6	0.71	5.51	0.49	3.07e-7	Colorectal cancer (diet interaction);
THYM	cis	rs654950	0.875	rs881719	chr1:41991427	C/T	cg06885757	chr1:42089581	HIVEP3	-0.49	-6.01	-0.52	3.46e-8	Airway imaging phenotypes;
THYM	cis	rs11096990	0.634	rs7659894	chr4:39284435	G/A	cg24403649	chr4:39172243	NA	-0.65	-5.49	-0.49	3.4e-7	Cognitive function;
THYM	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg10047753	chr17:41438598	NA	0.93	6.13	0.53	1.96e-8	Menopause (age at onset);
THYM	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.27	9.69	0.7	7.64e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6456042	0.965	rs6920259	chr6:166534490	A/G	cg11088901	chr6:166572345	T	-0.51	-4.82	-0.44	5.5e-6	Asthma;
THYM	cis	rs4084127	1.000	rs4084128	chr11:69596342	C/T	cg14578030	chr11:69591383	FGF4	0.5	4.56	0.42	1.54e-5	Type 1 diabetes;
THYM	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg10523679	chr1:76189770	ACADM	-0.55	-4.67	-0.43	9.97e-6	Daytime sleep phenotypes;
THYM	cis	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs7084921	0.608	rs11592689	chr10:101865516	A/T	cg11344164	chr10:101878520	NA	-0.55	-4.69	-0.43	9.2e-6	Bone mineral density;
THYM	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg18512352	chr11:47633146	NA	-0.56	-7.3	-0.6	8.87e-11	Subjective well-being;
THYM	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg05660106	chr1:15850417	CASP9	0.74	6.04	0.53	2.93e-8	Systolic blood pressure;
THYM	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg08883853	chr7:1026168	CYP2W1	-0.45	-4.99	-0.46	2.68e-6	Longevity;Endometriosis;
THYM	trans	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg10856724	chr12:34555212	NA	-0.96	-8.66	-0.66	1.22e-13	Bladder cancer;
THYM	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg08132940	chr7:1081526	C7orf50	-1.15	-6.58	-0.56	2.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4750440	0.702	rs4748068	chr10:14030692	T/A	cg27542038	chr10:14027202	FRMD4A	-0.5	-4.45	-0.42	2.36e-5	Adiponectin levels;
THYM	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg27211696	chr2:191398769	TMEM194B	-0.78	-7.51	-0.61	3.13e-11	Pulse pressure;
THYM	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.49	4.62	0.43	1.22e-5	Birth weight;
THYM	cis	rs2273669	0.667	rs12195836	chr6:109357701	T/G	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs754466	1.000	rs12220902	chr10:79682918	C/T	cg17075019	chr10:79541650	NA	-0.61	-4.63	-0.43	1.16e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2562152	0.530	rs216604	chr16:112513	T/C	cg02949481	chr16:131562	MPG	0.78	4.89	0.45	4.12e-6	Glioblastoma;
THYM	cis	rs295140	1.000	rs13028959	chr2:201185919	C/A	cg04283868	chr2:201171347	SPATS2L	0.74	5.53	0.49	2.81e-7	QT interval;
THYM	cis	rs892961	1.000	rs1075457	chr17:75400737	A/G	cg05865280	chr17:75406074	SEPT9	-0.46	-7.89	-0.63	5.18e-12	Airflow obstruction;
THYM	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg15445000	chr17:37608096	MED1	-0.42	-5.07	-0.46	1.93e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4631830	0.695	rs11004584	chr10:51500088	G/T	cg10326726	chr10:51549505	MSMB	-0.58	-5.75	-0.51	1.1e-7	Prostate-specific antigen levels;
THYM	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg26818010	chr10:134567672	INPP5A	-0.93	-7.48	-0.61	3.71e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs919433	0.963	rs2043016	chr2:198146381	C/T	cg00792783	chr2:198669748	PLCL1	-0.65	-4.72	-0.44	8.18e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs79149102	0.579	rs12592477	chr15:75292699	C/T	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	cis	rs9457247	0.534	rs9355610	chr6:167383075	G/A	cg23791538	chr6:167370224	RNASET2	0.8	7.06	0.59	2.78e-10	Crohn's disease;
THYM	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg08017756	chr2:100939284	LONRF2	-0.73	-7.46	-0.61	4.08e-11	Intelligence (multi-trait analysis);
THYM	cis	rs899997	1.000	rs2017091	chr15:79032744	G/A	cg00639195	chr15:79103007	ADAMTS7	-0.81	-5.72	-0.51	1.24e-7	Coronary artery disease or large artery stroke;
THYM	cis	rs7107174	1.000	rs10899489	chr11:78095373	G/T	cg19901956	chr11:77921274	USP35	-0.64	-5.35	-0.48	6.06e-7	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.6	-5.35	-0.48	6.18e-7	Prudent dietary pattern;
THYM	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg23711669	chr6:146136114	FBXO30	-0.9	-8.72	-0.67	9.04e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg12292205	chr6:26970375	C6orf41	0.53	4.49	0.42	1.99e-5	Schizophrenia;
THYM	cis	rs3768617	0.510	rs12078729	chr1:183060072	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.76	0.44	6.83e-6	Fuchs's corneal dystrophy;
THYM	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-4.6	-0.43	1.32e-5	Mood instability;
THYM	cis	rs11250464	0.736	rs5015512	chr10:1411923	T/C	cg08668359	chr10:1443807	ADARB2	0.63	5.46	0.49	3.75e-7	Radiation response;
THYM	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg20608306	chr11:116969690	SIK3	-0.52	-5.64	-0.5	1.78e-7	Blood protein levels;
THYM	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg27446573	chr6:127587934	RNF146	0.74	5.97	0.52	4.01e-8	Breast cancer;
THYM	trans	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg26043149	chr18:55253948	FECH	1.16	10.82	0.74	2.98e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs7226229	0.904	rs2364329	chr17:20922925	G/C	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs921968	0.565	rs692049	chr2:219622778	G/A	cg02176678	chr2:219576539	TTLL4	-0.48	-4.73	-0.44	7.94e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg24818145	chr4:99064322	C4orf37	0.91	7.54	0.61	2.72e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7926906	0.713	rs10741376	chr11:90538099	C/T	cg26138821	chr11:89956704	CHORDC1	0.54	4.9	0.45	3.9e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11711311	1.000	rs891574	chr3:113537639	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.61	-5.14	-0.47	1.46e-6	IgG glycosylation;
THYM	cis	rs17407555	0.697	rs56079809	chr4:10102736	C/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-5.59	-0.5	2.2e-7	Schizophrenia (age at onset);
THYM	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg02953382	chr22:24373134	LOC391322	-0.79	-8.15	-0.64	1.48e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg25703541	chr22:24373054	LOC391322	-0.9	-11.68	-0.77	4.45e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg20283391	chr11:68216788	NA	-0.69	-5.14	-0.47	1.49e-6	Total body bone mineral density;
THYM	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg13695892	chr22:41940480	POLR3H	0.89	6.74	0.57	1.2e-9	Vitiligo;
THYM	cis	rs476633	0.708	rs8031159	chr15:41445199	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.69	-5.4	-0.48	4.82e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs240764	0.507	rs9404031	chr6:101211298	T/C	cg21058520	chr6:100914733	NA	-0.58	-4.54	-0.42	1.66e-5	Neuroticism;
THYM	cis	rs6930083	0.737	rs13196885	chr6:36632688	C/T	cg08179530	chr6:36648295	CDKN1A	-0.79	-5.93	-0.52	4.91e-8	Coronary artery disease;
THYM	cis	rs7402982	0.647	rs4966007	chr15:99200056	G/A	cg27438980	chr15:99195143	IGF1R	-0.51	-4.54	-0.42	1.66e-5	Birth weight;
THYM	cis	rs262150	0.501	rs1062610	chr7:158821175	C/T	cg04111992	chr7:158790115	NA	-0.57	-5.05	-0.46	2.12e-6	Facial morphology (factor 20);
THYM	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg08859206	chr1:53392774	SCP2	-0.77	-9.38	-0.69	3.55e-15	Monocyte count;
THYM	trans	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg24060327	chr5:131705240	SLC22A5	-0.83	-6.92	-0.58	5.2e-10	Breast cancer;
THYM	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg26384229	chr12:38710491	ALG10B	1.06	11.07	0.75	8.9e-19	Heart rate;
THYM	cis	rs12410462	0.551	rs2819516	chr1:227637092	A/G	cg22525281	chr1:228134933	WNT9A	-0.59	-4.84	-0.44	5.1e-6	Major depressive disorder;
THYM	trans	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg25214090	chr10:38739885	LOC399744	0.86	7.44	0.61	4.54e-11	Corneal astigmatism;
THYM	cis	rs4262150	0.883	rs72802887	chr5:152249082	A/G	cg06854687	chr5:151642065	NA	0.66	4.59	0.43	1.36e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs7412746	0.611	rs111905669	chr1:150777565	T/C	cg15448220	chr1:150897856	SETDB1	0.88	7.5	0.61	3.4e-11	Melanoma;
THYM	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg17775962	chr7:1200435	ZFAND2A	0.53	5.78	0.51	9.26e-8	Longevity;Endometriosis;
THYM	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg15133208	chr4:90757351	SNCA	-0.59	-4.85	-0.45	4.81e-6	Neuroticism;
THYM	cis	rs12310956	0.532	rs6488186	chr12:33974122	G/A	cg06521331	chr12:34319734	NA	-0.92	-8.57	-0.66	1.89e-13	Morning vs. evening chronotype;
THYM	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg00071950	chr4:10020882	SLC2A9	0.88	9.22	0.69	7.56e-15	Bone mineral density;
THYM	cis	rs944722	0.628	rs4795051	chr17:26079497	G/C	cg07704981	chr17:26127537	NOS2	-0.49	-4.49	-0.42	1.99e-5	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg24675658	chr1:53192096	ZYG11B	-0.59	-4.9	-0.45	3.96e-6	Monocyte count;
THYM	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs782590	0.721	rs782641	chr2:55929294	C/T	cg18811423	chr2:55921094	PNPT1	0.73	6.58	0.56	2.55e-9	Metabolic syndrome;
THYM	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg00376283	chr12:123451042	ABCB9	0.7	4.72	0.44	8.27e-6	Neutrophil percentage of white cells;
THYM	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg18876405	chr7:65276391	NA	0.57	4.73	0.44	7.67e-6	Aortic root size;
THYM	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.26	0.54	1.12e-8	Total body bone mineral density;
THYM	cis	rs57561814	0.510	rs1524107	chr7:22768219	C/T	cg01770232	chr7:22766155	IL6	0.96	4.7	0.43	8.78e-6	Tonsillectomy;
THYM	cis	rs2219968	1.000	rs33987699	chr8:78953437	A/C	cg00738934	chr8:78996279	NA	0.88	9.27	0.69	5.97e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg05234568	chr11:5960015	NA	-0.64	-5.17	-0.47	1.29e-6	DNA methylation (variation);
THYM	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg15448220	chr1:150897856	SETDB1	0.9	7.49	0.61	3.57e-11	Melanoma;
THYM	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4919694	0.901	rs79331374	chr10:104882913	G/A	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs1873147	0.861	rs2899687	chr15:63325548	C/T	cg12160578	chr15:63334699	TPM1	-0.61	-4.52	-0.42	1.8e-5	Orofacial clefts;
THYM	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-5.98	-0.52	3.86e-8	Prostate cancer;
THYM	cis	rs6686842	0.965	rs1472570	chr1:41714084	G/T	cg03387723	chr1:41708464	SCMH1	0.43	5.03	0.46	2.34e-6	Height;
THYM	cis	rs988913	0.662	rs11754240	chr6:54921499	T/G	cg04690482	chr6:54711388	FAM83B	0.46	4.71	0.44	8.41e-6	Menarche (age at onset);
THYM	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg09085632	chr11:111637200	PPP2R1B	1.15	10.89	0.75	2.07e-18	Primary sclerosing cholangitis;
THYM	cis	rs7219021	0.705	rs12939844	chr17:47025559	T/A	cg09029085	chr17:47094198	IGF2BP1	0.33	4.48	0.42	2.04e-5	Schizophrenia or bipolar disorder;
THYM	cis	rs6430585	0.646	rs12476116	chr2:136497199	A/G	cg23851026	chr2:136556271	LCT	0.67	5.79	0.51	8.9e-8	Corneal structure;
THYM	cis	rs6960043	0.818	rs10264063	chr7:15053193	G/C	cg19272540	chr7:15055459	NA	0.55	6.04	0.53	3.05e-8	Type 2 diabetes;
THYM	cis	rs1797885	0.628	rs116002	chr3:12578104	C/T	cg05467012	chr3:12595696	NA	-0.65	-5.23	-0.47	1.01e-6	Immature fraction of reticulocytes;
THYM	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg26384229	chr12:38710491	ALG10B	1.06	10.15	0.72	7.84e-17	Heart rate;
THYM	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg07690219	chr3:49449608	TCTA;RHOA	0.69	4.62	0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs946836	0.562	rs11211631	chr1:48383741	A/C	cg18376692	chr1:48452465	NA	-0.5	-4.97	-0.45	2.94e-6	White matter integrity;
THYM	cis	rs995000	0.931	rs2479464	chr1:63130991	G/A	cg06896770	chr1:63153194	DOCK7	-0.92	-7.45	-0.61	4.23e-11	Triglyceride levels;
THYM	cis	rs2333194	0.875	rs10220356	chr14:73809476	C/T	cg09844916	chr14:74004424	HEATR4;ACOT1	-0.58	-4.61	-0.43	1.28e-5	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg10760299	chr15:45669010	GATM	0.72	5.06	0.46	2.07e-6	Homoarginine levels;
THYM	cis	rs7208859	0.673	rs75142521	chr17:29240537	G/A	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11969893	0.850	rs9791284	chr6:101353886	G/A	cg12253828	chr6:101329408	ASCC3	1.22	7.07	0.59	2.55e-10	Economic and political preferences (immigration/crime);
THYM	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11644478	chr21:40555479	PSMG1	1.11	9.99	0.72	1.76e-16	Cognitive function;
THYM	cis	rs10819861	0.621	rs7025349	chr9:98847691	C/T	cg14508093	chr9:98862825	NA	0.24	4.63	0.43	1.14e-5	Electrocardiographic traits;
THYM	cis	rs611744	0.967	rs628340	chr8:109189425	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs4601821	0.895	rs7130431	chr11:113238223	A/C	cg14159747	chr11:113255604	NA	0.25	4.73	0.44	7.9e-6	Alcoholic chronic pancreatitis;
THYM	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg12179176	chr11:130786555	SNX19	0.83	6.89	0.58	6.06e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg14416269	chr4:6271139	WFS1	0.55	5.69	0.5	1.41e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs918629	1.000	rs3777167	chr5:95286017	A/G	cg16656078	chr5:95278638	ELL2	-0.6	-4.53	-0.42	1.71e-5	IgG glycosylation;
THYM	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	7.8	0.62	7.81e-12	Platelet count;
THYM	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg24812749	chr6:127587940	RNF146	0.92	7.35	0.6	6.98e-11	Breast cancer;
THYM	cis	rs61931739	0.927	rs1906135	chr12:34038103	C/A	cg06521331	chr12:34319734	NA	0.61	4.76	0.44	6.95e-6	Morning vs. evening chronotype;
THYM	cis	rs7084402	0.967	rs1658419	chr10:60332812	A/C	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs2075230	0.850	rs111633209	chr17:7476635	G/A	cg16696476	chr17:8191344	RANGRF;SLC25A35	0.29	4.64	0.43	1.09e-5	Hormone measurements;
THYM	cis	rs7599312	0.534	rs7607373	chr2:213409719	G/A	cg20637307	chr2:213403960	ERBB4	0.99	10.51	0.73	1.33e-17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4731207	0.596	rs7810299	chr7:124645104	A/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg13447684	chr7:1895903	MAD1L1	-0.55	-4.59	-0.43	1.35e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg08355456	chr11:67383691	NA	0.85	7.32	0.6	7.93e-11	Mean corpuscular volume;
THYM	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg22535103	chr8:58192502	C8orf71	-0.91	-5.93	-0.52	4.88e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.75	-5.5	-0.49	3.17e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg06532163	chr17:45867833	NA	0.63	6.32	0.54	8.4e-9	IgG glycosylation;
THYM	cis	rs2742417	0.603	rs2742371	chr3:45782763	G/A	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs4866334	1.000	rs76533277	chr5:18488162	G/A	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs1215050	0.765	rs783925	chr4:98969881	T/C	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9876781	1.000	rs13091785	chr3:48494098	C/T	cg06066452	chr3:48470258	PLXNB1	0.27	4.71	0.44	8.4e-6	Longevity;
THYM	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg07690219	chr3:49449608	TCTA;RHOA	0.7	4.71	0.43	8.57e-6	Menarche (age at onset);
THYM	trans	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg00339695	chr16:24857497	SLC5A11	-0.68	-6.41	-0.55	5.69e-9	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs114262028	chr4:119734877	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs9796	0.689	rs28409432	chr15:41447454	G/A	cg21153102	chr15:41252147	NA	0.6	5.05	0.46	2.09e-6	Menopause (age at onset);
THYM	cis	rs11671005	0.735	rs56290606	chr19:58919320	A/G	cg18639983	chr19:58920768	ZNF584	0.59	5.0	0.46	2.63e-6	Mean platelet volume;
THYM	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg03709012	chr19:19516395	GATAD2A	0.84	7.26	0.6	1.05e-10	Tonsillectomy;
THYM	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg17294928	chr15:75287854	SCAMP5	-0.72	-4.83	-0.44	5.3e-6	Blood trace element (Zn levels);
THYM	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg09201001	chr11:18656081	SPTY2D1	1.05	9.37	0.69	3.67e-15	Breast cancer;
THYM	cis	rs425277	0.500	rs908744	chr1:2038893	G/A	cg13918804	chr1:2043761	PRKCZ	0.77	7.29	0.6	9.18e-11	Height;
THYM	cis	rs9467160	0.651	rs7755403	chr6:24453447	C/G	cg00346970	chr6:24499591	ALDH5A1	0.31	4.55	0.42	1.59e-5	Liver enzyme levels;
THYM	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.77	-7.17	-0.59	1.64e-10	Personality dimensions;
THYM	cis	rs73086581	0.680	rs11908158	chr20:3936672	G/T	cg02187196	chr20:3869020	PANK2	0.5	5.52	0.49	2.96e-7	Response to antidepressants in depression;
THYM	cis	rs4595586	0.545	rs6580894	chr12:39371951	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg01416388	chr22:39784598	NA	0.77	5.98	0.52	3.84e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs9486719	0.656	rs6924957	chr6:96853579	G/T	cg06623918	chr6:96969491	KIAA0776	0.86	5.49	0.49	3.31e-7	Migraine;Coronary artery disease;
THYM	cis	rs8067545	0.967	rs4924801	chr17:19921070	T/C	cg20830565	chr17:20408647	MGC102966	-0.51	-4.69	-0.43	9.19e-6	Schizophrenia;
THYM	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11771526	0.792	rs17161105	chr7:32299187	T/C	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg06521331	chr12:34319734	NA	-1.03	-10.3	-0.73	3.74e-17	Morning vs. evening chronotype;
THYM	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg20007245	chr22:24372913	LOC391322	-0.77	-7.87	-0.63	5.6e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2273669	0.510	rs78596296	chr6:109374465	T/C	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.48e-7	Prostate cancer;
THYM	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs62435770	1.000	rs62434685	chr6:169510785	T/C	cg07652237	chr6:170125491	PHF10	0.5	4.49	0.42	1.97e-5	Loneliness;
THYM	cis	rs8067545	0.750	rs4925072	chr17:19956899	C/T	cg13482628	chr17:19912719	NA	-0.54	-4.57	-0.42	1.46e-5	Schizophrenia;
THYM	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7578361	0.918	rs10439269	chr2:150376781	C/G	cg17961725	chr2:150454027	NA	-0.77	-5.72	-0.51	1.25e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg06636001	chr8:8085503	FLJ10661	0.73	6.24	0.54	1.21e-8	Mood instability;
THYM	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15084286	chr11:17036142	PLEKHA7	0.97	8.68	0.66	1.1e-13	Coronary artery disease;
THYM	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs5758659	0.716	rs2143138	chr22:42618340	T/C	cg00645731	chr22:42541494	CYP2D7P1	-0.42	-5.0	-0.46	2.62e-6	Cognitive function;
THYM	cis	rs11825685	0.502	rs7929317	chr11:134607871	A/C	cg02395454	chr11:134605862	NA	-0.9	-7.66	-0.62	1.57e-11	IgG glycosylation;
THYM	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg05340658	chr4:99064831	C4orf37	0.54	4.5	0.42	1.96e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08045932	chr20:61659980	NA	0.94	11.22	0.75	4.28e-19	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs7578361	0.959	rs4667338	chr2:150407720	G/A	cg17961725	chr2:150454027	NA	0.74	5.91	0.52	5.37e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs595982	0.517	rs10404905	chr19:49406175	A/T	cg21252483	chr19:49399788	TULP2	0.68	6.8	0.57	9.39e-10	Red cell distribution width;
THYM	cis	rs6430585	0.583	rs78364332	chr2:136640101	T/C	cg07169764	chr2:136633963	MCM6	1.25	14.39	0.83	1.36e-25	Corneal structure;
THYM	cis	rs2903698	0.519	rs28877578	chr4:76424976	G/A	cg03209871	chr4:76438412	RCHY1;THAP6	0.41	4.72	0.44	8.14e-6	Prion diseases;
THYM	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg18681998	chr4:17616180	MED28	0.94	8.65	0.66	1.25e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs73198271	0.765	rs534103	chr8:8634069	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-4.96	-0.45	3.12e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs12310956	0.515	rs11052934	chr12:33970381	T/C	cg10856724	chr12:34555212	NA	-0.72	-6.65	-0.56	1.82e-9	Morning vs. evening chronotype;
THYM	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg18876405	chr7:65276391	NA	-0.64	-5.55	-0.49	2.58e-7	Aortic root size;
THYM	cis	rs1371867	0.846	rs1788191	chr8:101260844	C/T	cg06636551	chr8:101224915	SPAG1	0.64	6.0	0.52	3.63e-8	Atrioventricular conduction;
THYM	cis	rs2898681	1.000	rs4864690	chr4:53750771	T/A	cg21521518	chr4:53727714	RASL11B	0.51	5.6	0.5	2.06e-7	Optic nerve measurement (cup area);
THYM	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg07636037	chr3:49044803	WDR6	0.84	7.39	0.6	5.67e-11	Menarche (age at onset);
THYM	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg16414030	chr3:133502952	NA	-0.84	-8.51	-0.66	2.57e-13	Iron status biomarkers;
THYM	cis	rs9649213	0.574	rs62479853	chr7:97917158	G/T	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg24308560	chr3:49941425	MST1R	-0.76	-6.48	-0.55	4.1e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg17105886	chr17:28927953	LRRC37B2	1.32	6.56	0.56	2.79e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6570726	0.967	rs413880	chr6:145804822	G/A	cg23711669	chr6:146136114	FBXO30	0.76	7.02	0.58	3.36e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2204008	0.654	rs1290325	chr12:38152910	C/T	cg26384229	chr12:38710491	ALG10B	-0.73	-5.87	-0.52	6.29e-8	Bladder cancer;
THYM	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg16325326	chr1:53192061	ZYG11B	0.76	5.99	0.52	3.68e-8	Monocyte count;
THYM	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg11764359	chr7:65958608	NA	0.82	6.56	0.56	2.81e-9	Aortic root size;
THYM	cis	rs7614311	0.689	rs56329572	chr3:63846672	G/A	cg22134162	chr3:63841271	THOC7	-0.63	-7.34	-0.6	7.05e-11	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg07599136	chr5:415885	AHRR	0.93	5.17	0.47	1.29e-6	Fat distribution (HIV);
THYM	cis	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs11690935	0.959	rs7597387	chr2:172577116	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.83	-5.96	-0.52	4.27e-8	Schizophrenia;
THYM	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg17863274	chr19:49399704	TULP2	-0.92	-5.48	-0.49	3.47e-7	Red cell distribution width;
THYM	cis	rs11771526	0.901	rs41519845	chr7:32315443	A/T	cg27532318	chr7:32358331	NA	0.77	5.06	0.46	2.03e-6	Body mass index;
THYM	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg25767906	chr1:53392781	SCP2	-0.67	-6.28	-0.54	1e-8	Monocyte count;
THYM	cis	rs854765	0.647	rs854818	chr17:18022039	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.6	4.94	0.45	3.39e-6	Total body bone mineral density;
THYM	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg18641463	chr7:2144579	MAD1L1	0.61	4.52	0.42	1.78e-5	Height;
THYM	cis	rs17854409	1.000	rs66956644	chr20:61484499	T/C	cg06598544	chr20:61472147	COL9A3	-1.11	-7.41	-0.61	5.05e-11	Obesity-related traits;
THYM	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg04455712	chr21:45112962	RRP1B	-0.56	-5.13	-0.47	1.5e-6	Mean corpuscular volume;
THYM	cis	rs12282928	1.000	rs11039668	chr11:48326479	A/G	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg11752832	chr7:134001865	SLC35B4	0.71	4.83	0.44	5.26e-6	Mean platelet volume;
THYM	cis	rs6665290	0.904	rs1186	chr1:227177731	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg17911788	chr17:44343683	NA	-0.6	-6.03	-0.53	3.12e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs3112255	0.512	rs11123843	chr2:101338023	A/T	cg01042948	chr2:101319752	NA	0.5	4.96	0.45	3.13e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6598955	0.671	rs12088858	chr1:26643708	C/A	cg08133631	chr1:26527909	CATSPER4	-0.63	-5.22	-0.47	1.05e-6	Obesity-related traits;
THYM	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg05347473	chr6:146136440	FBXO30	0.58	4.53	0.42	1.7e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg12863693	chr15:85201151	NMB	0.63	5.49	0.49	3.38e-7	Schizophrenia;
THYM	cis	rs7809950	0.817	rs4727679	chr7:107085018	T/C	cg23024343	chr7:107201750	COG5	-1.02	-8.69	-0.67	1.02e-13	Coronary artery disease;
THYM	cis	rs6840360	0.571	rs62327278	chr4:152558790	G/C	cg22705602	chr4:152727874	NA	-0.81	-8.67	-0.66	1.16e-13	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg13609457	chr4:120235615	NA	0.54	4.98	0.45	2.87e-6	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3768617	0.510	rs3765522	chr1:183077618	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs11039131	0.629	rs67871383	chr11:47335838	T/C	cg20307385	chr11:47447363	PSMC3	-0.61	-4.61	-0.43	1.23e-5	Schizophrenia;
THYM	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.21	-0.47	1.11e-6	Hemoglobin concentration;
THYM	cis	rs9549260	0.591	rs9577108	chr13:41271764	G/A	cg21288729	chr13:41239152	FOXO1	0.66	4.9	0.45	3.96e-6	Red blood cell count;
THYM	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg22189786	chr22:42395067	WBP2NL	-0.52	-5.22	-0.47	1.04e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs2273669	0.665	rs17070147	chr6:109406223	G/A	cg17117243	chr6:109341365	SESN1	-0.86	-5.26	-0.47	9.04e-7	Prostate cancer;
THYM	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg22920501	chr2:26401640	FAM59B	0.77	5.88	0.52	6.04e-8	Gut microbiome composition (summer);
THYM	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs800586	0.628	rs2737265	chr8:116667634	A/G	cg04656070	chr8:116661063	TRPS1	-0.56	-5.72	-0.51	1.21e-7	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg05043794	chr9:111880884	C9orf5	-0.43	-6.21	-0.54	1.39e-8	Menarche (age at onset);
THYM	cis	rs240764	0.680	rs12209777	chr6:101156639	G/A	cg21058520	chr6:100914733	NA	0.56	4.73	0.44	7.92e-6	Neuroticism;
THYM	cis	rs8038465	0.638	rs8036954	chr15:73974282	T/C	cg15420318	chr15:73925796	NPTN	0.6	5.26	0.48	8.8e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1642645	0.831	rs348128	chr1:42488361	T/C	cg10197057	chr1:42612518	NA	0.47	5.14	0.47	1.47e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg08999081	chr20:33150536	PIGU	-0.55	-4.84	-0.44	5.05e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9560113	1.000	rs4773384	chr13:112177987	A/G	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg09307838	chr4:120376055	NA	-0.64	-4.7	-0.43	8.72e-6	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg02931644	chr1:25747376	RHCE	0.64	4.96	0.45	3.08e-6	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs600806	0.889	rs585545	chr1:109841662	A/T	cg23032129	chr1:109941072	SORT1	-0.54	-4.56	-0.42	1.51e-5	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs10992471	0.603	rs13301537	chr9:95229047	A/G	cg14631576	chr9:95140430	CENPP	-0.99	-9.94	-0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg11941060	chr3:133502564	NA	0.73	6.17	0.54	1.63e-8	Iron status biomarkers;
THYM	trans	rs629535	0.814	rs674429	chr8:70069942	G/A	cg21567404	chr3:27674614	NA	1.08	10.14	0.72	8.19e-17	Dupuytren's disease;
THYM	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03452623	chr4:187889614	NA	-1.19	-19.33	-0.89	1.1e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg06112835	chr11:68658793	MRPL21	0.43	6.08	0.53	2.48e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg23583168	chr7:148888333	NA	-0.93	-10.21	-0.72	5.88e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6988636	1.000	rs11993411	chr8:124180537	T/C	cg26140120	chr8:124219575	FAM83A	0.85	4.81	0.44	5.76e-6	Urinary uromodulin levels;
THYM	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg11663144	chr21:46675770	NA	-0.69	-9.27	-0.69	6.12e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg06092702	chr1:163392909	NA	-0.61	-5.39	-0.48	5.13e-7	Motion sickness;
THYM	cis	rs4631830	0.540	rs2843562	chr10:51496796	A/G	cg20129853	chr10:51489980	NA	0.35	4.91	0.45	3.71e-6	Prostate-specific antigen levels;
THYM	cis	rs11886999	0.638	rs73958180	chr2:96844103	A/T	cg18419276	chr2:96971862	SNRNP200	-0.52	-4.74	-0.44	7.6e-6	Cardiac Troponin-T levels;
THYM	cis	rs1568889	0.838	rs7943538	chr11:28288955	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg22907277	chr7:1156413	C7orf50	0.6	5.09	0.46	1.84e-6	Longevity;Endometriosis;
THYM	cis	rs17253792	0.822	rs75288952	chr14:56034010	C/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg00484396	chr16:3507460	NAT15	0.45	4.52	0.42	1.81e-5	Body mass index (adult);
THYM	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg22676075	chr6:135203613	NA	-0.73	-6.81	-0.57	8.94e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	trans	rs9929218	0.529	rs8060790	chr16:68729112	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.06	13.03	0.8	7.1e-23	Colorectal cancer;
THYM	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg13683864	chr3:40499215	RPL14	-0.84	-7.85	-0.63	6.28e-12	Renal cell carcinoma;
THYM	cis	rs11771526	1.000	rs10231440	chr7:32299435	C/A	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs12347191	0.500	rs907578	chr9:100622883	A/G	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Orofacial clefts;
THYM	cis	rs1864585	0.806	rs73209947	chr8:10749448	C/T	cg11824826	chr8:9953022	MSRA	0.64	4.55	0.42	1.61e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
THYM	cis	rs8133932	0.861	rs71324446	chr21:47231428	C/T	cg20357416	chr21:47294739	PCBP3	0.89	5.1	0.46	1.75e-6	Schizophrenia;
THYM	cis	rs8044868	0.521	rs7203821	chr16:72101165	T/C	cg06353428	chr16:71660113	MARVELD3	0.6	4.53	0.42	1.7e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg07362569	chr17:61921086	SMARCD2	-0.74	-6.62	-0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg18105134	chr13:113819100	PROZ	-1.2	-9.98	-0.72	1.85e-16	Platelet distribution width;
THYM	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg08847533	chr14:75593920	NEK9	0.97	10.19	0.72	6.35e-17	Height;
THYM	cis	rs4474465	0.920	rs12271198	chr11:78158943	G/A	cg19901956	chr11:77921274	USP35	-0.62	-4.63	-0.43	1.15e-5	Alzheimer's disease (survival time);
THYM	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg23758822	chr17:41437982	NA	1.22	11.95	0.77	1.26e-20	Menopause (age at onset);
THYM	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7582403	0.510	rs6430295	chr2:148897781	T/C	cg23727674	chr2:148602993	ACVR2A	0.63	4.64	0.43	1.13e-5	Neuroticism;
THYM	cis	rs4474465	1.000	rs7106080	chr11:78150592	G/A	cg02023728	chr11:77925099	USP35	0.53	4.65	0.43	1.08e-5	Alzheimer's disease (survival time);
THYM	cis	rs10752881	1.000	rs4420053	chr1:182976133	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-14.22	-0.82	2.89e-25	Height;
THYM	cis	rs2658782	0.789	rs3020076	chr11:93141058	C/T	cg15737290	chr11:93063684	CCDC67	0.9	7.07	0.59	2.57e-10	Pulmonary function decline;
THYM	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7553864	0.965	rs7539833	chr1:87613228	C/G	cg17420885	chr1:87600446	LOC339524	-0.76	-6.48	-0.55	4e-9	Smoking behavior;
THYM	cis	rs13215566	0.789	rs6930407	chr6:89905239	G/A	cg08400210	chr6:89908154	GABRR1	0.98	5.75	0.51	1.09e-7	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs1775715	0.870	rs1419168	chr10:32257332	A/C	cg04359828	chr10:32216031	ARHGAP12	0.39	4.9	0.45	3.96e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs7851660	0.809	rs1561961	chr9:100667599	C/T	cg13688889	chr9:100608707	NA	-0.77	-5.55	-0.49	2.56e-7	Strep throat;
THYM	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs28595532	0.920	rs115485705	chr4:119733286	G/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	cis	rs9633835	0.594	rs2219998	chr11:13292864	G/A	cg13286116	chr11:13302098	ARNTL	-0.75	-8.79	-0.67	6.29e-14	Body mass index;
THYM	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.81	-5.37	-0.48	5.66e-7	IgG glycosylation;
THYM	cis	rs12282928	1.000	rs10838840	chr11:48258010	C/A	cg22827986	chr11:48284249	OR4X1	0.51	5.43	0.49	4.28e-7	Migraine - clinic-based;
THYM	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.67	9.11	0.68	1.32e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg21475434	chr5:93447410	FAM172A	-1.0	-6.55	-0.56	2.89e-9	Diabetic retinopathy;
THYM	cis	rs7216064	1.000	rs55896768	chr17:65913358	T/C	cg12091567	chr17:66097778	LOC651250	-0.73	-5.18	-0.47	1.25e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs4363385	0.747	rs4319267	chr1:152972699	T/G	cg13444842	chr1:152974279	SPRR3	-0.6	-4.79	-0.44	6.16e-6	Inflammatory skin disease;
THYM	cis	rs7192750	0.586	rs4788570	chr16:71920144	G/A	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg12386194	chr3:101231763	SENP7	0.69	5.16	0.47	1.34e-6	Colorectal cancer;
THYM	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg12935359	chr14:103987150	CKB	-0.64	-6.25	-0.54	1.15e-8	Body mass index;
THYM	cis	rs6967414	0.786	rs7782227	chr7:6748594	T/C	cg09896999	chr7:6746977	ZNF12	-0.63	-4.85	-0.45	4.76e-6	Hematocrit;Hemoglobin concentration;
THYM	cis	rs3820068	0.608	rs12760450	chr1:16037282	G/A	cg05660106	chr1:15850417	CASP9	0.72	5.6	0.5	2.04e-7	Systolic blood pressure;
THYM	cis	rs10752881	1.000	rs10752887	chr1:182990834	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Colorectal cancer;
THYM	cis	rs7646881	1.000	rs7646881	chr3:158453279	C/A	cg19483011	chr3:158453295	NA	-0.77	-5.54	-0.49	2.65e-7	Tetralogy of Fallot;
THYM	trans	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg20587970	chr11:113659929	NA	-1.11	-7.25	-0.6	1.12e-10	Hip circumference adjusted for BMI;
THYM	cis	rs6840360	0.615	rs113052419	chr4:152473008	T/C	cg17479576	chr4:152424074	FAM160A1	-0.83	-6.46	-0.55	4.43e-9	Intelligence (multi-trait analysis);
THYM	cis	rs12681287	0.570	rs10956830	chr8:87430483	T/A	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs11574514	0.661	rs9940402	chr16:67830338	T/A	cg04582263	chr16:67973788	LCAT	1.03	4.91	0.45	3.76e-6	Crohn's disease;
THYM	cis	rs600806	0.850	rs10745355	chr1:109951711	T/C	cg02175308	chr1:109941060	SORT1	-0.56	-4.99	-0.46	2.76e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg15691649	chr6:25882328	NA	-0.74	-6.19	-0.54	1.51e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg14690197	chr8:22456421	C8orf58	0.52	4.58	0.43	1.4e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs889398	0.742	rs12446197	chr16:69854869	A/G	cg09409435	chr16:70099608	PDXDC2	-0.62	-4.89	-0.45	4.03e-6	Body mass index;
THYM	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs4509693	1.000	rs6584394	chr10:102497258	G/A	cg15234845	chr10:102496500	NA	0.65	4.6	0.43	1.3e-5	Alzheimer's disease;
THYM	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs6842789	0.510	rs35633695	chr4:124895105	G/A	cg01723706	chr4:124814442	LOC285419	0.75	4.7	0.43	8.94e-6	Neuroticism;
THYM	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg08847533	chr14:75593920	NEK9	-1.03	-11.28	-0.76	3.11e-19	Height;
THYM	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg01097406	chr16:89675127	NA	-0.64	-5.33	-0.48	6.54e-7	Vitiligo;
THYM	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg09549813	chr16:4587862	C16orf5	-0.6	-6.89	-0.58	5.94e-10	Schizophrenia;
THYM	cis	rs7267979	1.000	rs6115140	chr20:25285507	C/A	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs10752881	0.967	rs10911186	chr1:182972542	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.8	0.44	5.84e-6	Colorectal cancer;
THYM	cis	rs4750440	0.702	rs7917812	chr10:14030067	G/A	cg27542038	chr10:14027202	FRMD4A	-0.5	-4.45	-0.42	2.36e-5	Adiponectin levels;
THYM	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg26119090	chr2:26468346	HADHA;HADHB	0.77	4.62	0.43	1.21e-5	Gut microbiome composition (summer);
THYM	cis	rs4790333	0.571	rs2012068	chr17:2255351	C/T	cg02569219	chr17:2266849	SGSM2	0.7	6.19	0.54	1.49e-8	Proinsulin levels;
THYM	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg26314531	chr2:26401878	FAM59B	0.78	5.13	0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs7106204	0.702	rs11826172	chr11:24233998	G/A	ch.11.24196551F	chr11:24239977	NA	1.05	7.53	0.61	2.96e-11	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg21984481	chr17:79567631	NPLOC4	-0.6	-6.66	-0.56	1.74e-9	Eye color traits;
THYM	cis	rs7582180	0.627	rs4851312	chr2:101011241	G/A	cg14675211	chr2:100938903	LONRF2	0.6	5.73	0.51	1.18e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2625529	0.775	rs35673773	chr15:72399886	C/A	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg00290607	chr11:67383545	NA	-0.76	-5.05	-0.46	2.13e-6	Mean corpuscular volume;
THYM	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.49	5.7	0.5	1.35e-7	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg10360139	chr7:1886902	MAD1L1	-0.62	-5.37	-0.48	5.63e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs6547741	1.000	rs1972669	chr2:27767107	T/G	cg27432699	chr2:27873401	GPN1	0.68	5.97	0.52	4.17e-8	Oral cavity cancer;
THYM	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.33	10.11	0.72	9.63e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg13695892	chr22:41940480	POLR3H	0.85	6.98	0.58	3.94e-10	Cannabis dependence symptom count;
THYM	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg08645402	chr16:4508243	NA	0.68	5.49	0.49	3.4e-7	Schizophrenia;
THYM	cis	rs2070677	1.000	rs2515641	chr10:135351362	T/C	cg20169779	chr10:135381914	SYCE1	0.77	5.59	0.5	2.18e-7	Gout;
THYM	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg23131131	chr22:24373011	LOC391322	-0.8	-8.24	-0.65	9.33e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4788570	0.584	rs6499529	chr16:71715378	C/T	cg06353428	chr16:71660113	MARVELD3	1.28	8.72	0.67	8.76e-14	Intelligence (multi-trait analysis);
THYM	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg15704280	chr7:45808275	SEPT13	1.01	11.27	0.76	3.31e-19	Coronary artery disease;
THYM	cis	rs7582180	0.614	rs1530031	chr2:101009326	T/C	cg21926883	chr2:100939477	LONRF2	-0.66	-6.02	-0.53	3.23e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7586879	0.929	rs6545807	chr2:25124358	C/T	cg15423357	chr2:25149977	NA	0.57	5.6	0.5	2.09e-7	Body mass index;
THYM	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs4654899	0.629	rs2320590	chr1:21155195	C/T	cg01072550	chr1:21505969	NA	0.64	5.84	0.51	7.3e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs728616	0.867	rs61860034	chr10:81931848	C/T	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg17173187	chr15:85201210	NMB	0.56	5.57	0.5	2.38e-7	Schizophrenia;
THYM	cis	rs11096990	0.613	rs7690414	chr4:39212289	G/C	cg24403649	chr4:39172243	NA	0.6	5.16	0.47	1.35e-6	Cognitive function;
THYM	cis	rs4664308	1.000	rs56297666	chr2:160902023	G/C	cg03641300	chr2:160917029	PLA2R1	-0.72	-6.38	-0.55	6.34e-9	Idiopathic membranous nephropathy;
THYM	cis	rs2901656	0.677	rs2301455	chr1:172418268	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.58	5.84	0.51	7.22e-8	Red cell distribution width;Platelet distribution width;
THYM	cis	rs3925075	0.764	rs8044482	chr16:31345752	T/C	cg02846316	chr16:31340340	ITGAM	0.58	6.03	0.53	3.06e-8	IgA nephropathy;
THYM	cis	rs4654899	0.606	rs13376428	chr1:21120027	T/C	cg01072550	chr1:21505969	NA	-0.66	-6.02	-0.53	3.2e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs4606347	0.789	rs61780871	chr1:66164521	G/A	cg04111102	chr1:66153794	NA	0.67	5.35	0.48	6.08e-7	Cerebrospinal fluid biomarker levels;
THYM	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg22166914	chr1:53195759	ZYG11B	-0.77	-8.25	-0.65	8.81e-13	Monocyte count;
THYM	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg20607798	chr8:58055168	NA	0.9	4.85	0.45	4.86e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg09260853	chr1:2094483	PRKCZ	0.51	4.81	0.44	5.76e-6	Height;
THYM	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg08847533	chr14:75593920	NEK9	-0.93	-10.06	-0.72	1.22e-16	Height;
THYM	cis	rs367615	0.552	rs2963025	chr5:108733256	A/C	cg17395555	chr5:108820864	NA	-0.54	-6.77	-0.57	1.04e-9	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs1011018	0.955	rs1541481	chr7:139465277	C/T	cg06079564	chr7:139468310	HIPK2	-0.77	-5.98	-0.52	3.9e-8	Systolic blood pressure;
THYM	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg14895029	chr7:2775587	GNA12	-0.66	-4.71	-0.43	8.5e-6	Height;
THYM	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.66	4.72	0.44	8.03e-6	Aortic root size;
THYM	cis	rs7100689	0.646	rs10887808	chr10:82137367	G/A	cg01528321	chr10:82214614	TSPAN14	0.79	6.01	0.52	3.47e-8	Post bronchodilator FEV1;
THYM	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.57	4.65	0.43	1.06e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs11756438	0.546	rs9489497	chr6:118999636	T/C	cg21191810	chr6:118973309	C6orf204	0.56	5.65	0.5	1.7e-7	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs611744	0.805	rs453634	chr8:109135101	T/C	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.06e-6	Dupuytren's disease;
THYM	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs4077515	0.874	rs3812575	chr9:139293259	T/C	cg14115884	chr9:139300582	SDCCAG3	0.76	8.17	0.64	1.29e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4243830	0.850	rs6679649	chr1:6606608	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.2	8.46	0.66	3.19e-13	Body mass index;
THYM	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.16	-0.75	5.56e-19	Primary sclerosing cholangitis;
THYM	cis	rs9915657	0.933	rs17246133	chr17:70140485	A/G	cg09344028	chr17:70110421	NA	0.43	4.55	0.42	1.6e-5	Thyroid hormone levels;
THYM	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg26384229	chr12:38710491	ALG10B	-0.62	-4.57	-0.42	1.47e-5	Bladder cancer;
THYM	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg12893697	chr11:970389	AP2A2	-0.31	-5.21	-0.47	1.08e-6	Alzheimer's disease (late onset);
THYM	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg12408189	chr10:30722286	MAP3K8	-0.52	-4.49	-0.42	2.01e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs7589342	0.929	rs12053259	chr2:106428720	G/A	cg14210321	chr2:106509881	NCK2	-0.72	-5.12	-0.46	1.62e-6	Addiction;
THYM	cis	rs4455778	0.580	rs6974104	chr7:49126777	C/G	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg02574844	chr11:5959923	NA	-0.53	-4.66	-0.43	1.03e-5	DNA methylation (variation);
THYM	cis	rs4242434	0.889	rs11785755	chr8:22453223	C/A	cg14690197	chr8:22456421	C8orf58	0.58	5.27	0.48	8.62e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg23583168	chr7:148888333	NA	-1.06	-13.95	-0.82	1.01e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs11225247	1.000	rs78270346	chr11:102290831	A/G	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs9420	0.816	rs674094	chr11:57665336	A/C	cg19752551	chr11:57585705	CTNND1	0.75	7.76	0.62	9.8e-12	Schizophrenia;
THYM	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg21475434	chr5:93447410	FAM172A	0.85	5.41	0.49	4.61e-7	Diabetic retinopathy;
THYM	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg11245990	chr11:68621969	NA	0.57	7.2	0.59	1.41e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.47	0.55	4.29e-9	Total body bone mineral density;
THYM	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg10515332	chr4:99064459	C4orf37	0.6	4.75	0.44	7.27e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg02734326	chr4:10020555	SLC2A9	-0.6	-4.85	-0.45	4.9100000000000004e-06	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1756650	0.571	rs1957438	chr14:87930070	G/C	cg10325478	chr14:88793021	KCNK10	-0.64	-4.73	-0.44	7.85e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
THYM	cis	rs245880	0.740	rs245890	chr7:29190720	T/C	cg17163760	chr7:29186267	CPVL	-0.59	-4.94	-0.45	3.3e-6	Warfarin maintenance dose;
THYM	cis	rs62158800	0.568	rs2083401	chr2:108370337	G/A	cg09155462	chr2:109189131	NA	1.11	4.51	0.42	1.86e-5	Facial morphology (factor 22);
THYM	cis	rs12039431	0.706	rs61605574	chr1:37973943	G/A	cg17933807	chr1:38061675	GNL2	-0.75	-5.54	-0.49	2.73e-7	Epithelial ovarian cancer;
THYM	cis	rs76662990	1.000	rs7732552	chr5:73851137	G/A	cg01264639	chr5:73839484	NA	1.1	4.72	0.44	8.17e-6	Residual cognition;
THYM	cis	rs8030485	0.536	rs12595749	chr15:79432359	A/G	cg17916960	chr15:79447300	NA	0.65	7.48	0.61	3.61e-11	Left ventricle wall thickness;
THYM	cis	rs889398	0.774	rs6499263	chr16:69890149	T/C	cg09409435	chr16:70099608	PDXDC2	0.63	4.92	0.45	3.63e-6	Body mass index;
THYM	cis	rs12208915	0.848	rs12209635	chr6:79532215	C/T	cg05283184	chr6:79620031	NA	0.75	4.89	0.45	4.06e-6	Left atrial antero-posterior diameter;
THYM	cis	rs611744	0.647	rs9969614	chr8:109260581	A/G	cg21045802	chr8:109455806	TTC35	0.64	5.71	0.51	1.28e-7	Dupuytren's disease;
THYM	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg26384229	chr12:38710491	ALG10B	-0.79	-7.74	-0.62	1.08e-11	Heart rate;
THYM	cis	rs1699337	0.770	rs709156	chr3:12461615	G/A	cg05467012	chr3:12595696	NA	0.55	4.49	0.42	1.99e-5	Cholesterol, total;
THYM	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs10269006	0.634	rs6465431	chr7:94374906	T/C	cg00347863	chr7:94220697	SGCE	0.53	4.52	0.42	1.76e-5	Breast cancer;
THYM	cis	rs593982	0.925	rs603509	chr11:65507605	C/T	cg08755490	chr11:65554678	OVOL1	-1.36	-8.73	-0.67	8.51e-14	Atopic dermatitis;
THYM	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg06453172	chr10:134556979	INPP5A	-0.61	-4.54	-0.42	1.64e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg09455208	chr3:40491958	NA	0.45	4.63	0.43	1.17e-5	Renal cell carcinoma;
THYM	cis	rs7580658	0.963	rs12463451	chr2:128053883	C/T	cg10021288	chr2:128175891	PROC	-0.78	-6.82	-0.57	8.26e-10	Protein C levels;
THYM	cis	rs6987853	0.787	rs2974309	chr8:42426961	G/A	cg09913449	chr8:42400586	C8orf40	1.07	12.64	0.79	4.53e-22	Mean corpuscular hemoglobin concentration;
THYM	cis	rs10095849	0.576	rs1584683	chr8:39483679	G/C	cg01911981	chr8:39380341	ADAM3A	-0.59	-5.01	-0.46	2.47e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2625529	0.526	rs10851850	chr15:72486509	A/G	cg16672083	chr15:72433130	SENP8	0.52	4.7	0.43	8.9e-6	Red blood cell count;
THYM	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg08704250	chr15:31115839	NA	0.68	7.56	0.61	2.47e-11	Huntington's disease progression;
THYM	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1994135	0.617	rs2200155	chr12:33734935	G/A	cg06521331	chr12:34319734	NA	-0.67	-4.65	-0.43	1.06e-5	Resting heart rate;
THYM	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg03295274	chr13:50190584	NA	0.69	5.25	0.47	9.22e-7	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06636551	chr8:101224915	SPAG1	0.9	11.05	0.75	9.79e-19	Atrioventricular conduction;
THYM	cis	rs34286592	1.000	rs34286592	chr16:29820480	C/T	cg04633683	chr16:29837056	MVP	0.57	4.58	0.43	1.4e-5	Multiple sclerosis;
THYM	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg15691649	chr6:25882328	NA	-0.74	-6.19	-0.54	1.51e-8	Intelligence (multi-trait analysis);
THYM	cis	rs3768617	0.510	rs4651139	chr1:183091963	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg19875535	chr5:140030758	IK	0.61	4.82	0.44	5.53e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs4936891	0.543	rs7102719	chr11:123877757	G/A	cg22125253	chr11:123886957	OR10G4	-0.58	-4.91	-0.45	3.83e-6	Male fertility;
THYM	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg11764359	chr7:65958608	NA	-0.63	-4.88	-0.45	4.26e-6	Aortic root size;
THYM	cis	rs722599	0.847	rs2058919	chr14:75310812	C/G	cg18090894	chr14:75227656	NA	0.51	4.49	0.42	1.98e-5	IgG glycosylation;
THYM	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg27129171	chr3:47204927	SETD2	-0.69	-6.62	-0.56	2.18e-9	Colorectal cancer;
THYM	cis	rs2070677	0.799	rs11101854	chr10:135394430	G/A	cg20169779	chr10:135381914	SYCE1	-0.78	-6.01	-0.52	3.43e-8	Gout;
THYM	cis	rs9972944	0.756	rs6504343	chr17:63755458	C/T	cg07283582	chr17:63770753	CCDC46	-0.62	-4.8	-0.44	5.79e-6	Total body bone mineral density;
THYM	cis	rs4718428	0.705	rs2901311	chr7:66415069	T/C	cg12165864	chr7:66369176	NA	-0.76	-5.35	-0.48	6.02e-7	Corneal structure;
THYM	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1829883	1.000	rs2511973	chr5:98807871	T/A	cg08333243	chr5:99726346	NA	-0.57	-5.48	-0.49	3.51e-7	Hemostatic factors and hematological phenotypes;
THYM	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg02353165	chr6:42928485	GNMT	0.87	8.06	0.64	2.21e-12	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7616559	0.820	rs1482859	chr3:156754666	T/A	cg15697575	chr3:156784781	NA	0.41	5.3	0.48	7.61e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg12011299	chr4:100065546	ADH4	0.85	8.12	0.64	1.67e-12	Alcohol dependence;
THYM	cis	rs10992471	0.603	rs10761160	chr9:95208701	A/T	cg14631576	chr9:95140430	CENPP	-0.99	-9.94	-0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	trans	rs629535	0.862	rs662725	chr8:70029616	C/T	cg21567404	chr3:27674614	NA	1.12	10.86	0.74	2.44e-18	Dupuytren's disease;
THYM	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg22907277	chr7:1156413	C7orf50	0.66	5.93	0.52	4.86e-8	Longevity;Endometriosis;
THYM	cis	rs4849845	0.889	rs7605557	chr2:121032732	G/A	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg10803722	chr21:46713166	LOC642852	-0.42	-5.57	-0.5	2.4e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg17366294	chr4:99064904	C4orf37	0.54	6.31	0.54	8.73e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	4.98	0.45	2.88e-6	Schizophrenia;
THYM	cis	rs7705502	0.780	rs55959485	chr5:173297051	A/G	cg18693985	chr5:173351052	CPEB4	-0.79	-5.72	-0.51	1.24e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs2976388	1.000	rs2976394	chr8:143763622	C/T	cg13446199	chr8:143762866	PSCA	0.51	6.42	0.55	5.46e-9	Urinary tract infection frequency;
THYM	cis	rs4474465	0.850	rs7122676	chr11:78268525	A/G	cg19901956	chr11:77921274	USP35	0.64	4.67	0.43	9.78e-6	Alzheimer's disease (survival time);
THYM	cis	rs28595532	0.841	rs115907265	chr4:119730593	G/A	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs7119	0.717	rs12911854	chr15:77817288	T/C	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg04267008	chr7:1944627	MAD1L1	0.5	4.48	0.42	2.08e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs586688	0.625	rs567337	chr1:201652979	G/A	cg14168733	chr1:201708718	NAV1	-0.58	-5.43	-0.49	4.29e-7	Obesity-related traits;
THYM	cis	rs11190604	0.943	rs113791644	chr10:102324330	T/G	cg16342193	chr10:102329863	NA	-0.59	-6.01	-0.53	3.36e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs55665837	1.000	rs12287715	chr11:14444575	G/A	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg26513180	chr16:89883248	FANCA	0.72	7.38	0.6	5.86e-11	Vitiligo;
THYM	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs28595532	0.925	rs28627331	chr4:119665345	T/C	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg12667521	chr19:29218732	NA	0.73	5.42	0.49	4.53e-7	Methadone dose in opioid dependence;
THYM	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg05340658	chr4:99064831	C4orf37	0.54	4.53	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12791968	1.000	rs1552300	chr11:45002594	G/A	cg11846598	chr11:44996168	LOC221122	-0.9	-7.55	-0.61	2.63e-11	Inhibitory control;
THYM	cis	rs3885907	0.626	rs9315049	chr13:31330981	A/C	cg19953038	chr13:31306303	NA	0.64	4.88	0.45	4.25e-6	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
THYM	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg10505658	chr17:80084571	CCDC57	-0.69	-7.95	-0.63	3.85e-12	Life satisfaction;
THYM	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg14784868	chr12:69753453	YEATS4	1.13	12.26	0.78	2.8e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs931127	0.617	rs10896027	chr11:65420760	C/G	cg27068330	chr11:65405492	SIPA1	0.75	5.89	0.52	5.89e-8	Systemic lupus erythematosus;
THYM	cis	rs208520	1.000	rs208521	chr6:66953625	C/T	cg07460842	chr6:66804631	NA	-0.85	-5.48	-0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs6754311	0.551	rs2304599	chr2:136528004	C/G	cg23851026	chr2:136556271	LCT	-0.61	-6.01	-0.53	3.36e-8	Mosquito bite size;
THYM	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-7.9	-0.63	4.93e-12	Chronic sinus infection;
THYM	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg27532560	chr4:187881888	NA	-0.96	-11.95	-0.77	1.24e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg06970220	chr1:156163860	SLC25A44	0.68	5.62	0.5	1.88e-7	Testicular germ cell tumor;
THYM	cis	rs36051895	0.587	rs11999802	chr9:5189773	T/G	cg02405213	chr9:5042618	JAK2	-0.88	-8.98	-0.68	2.49e-14	Pediatric autoimmune diseases;
THYM	cis	rs7809950	1.000	rs2520249	chr7:107146748	A/G	cg23024343	chr7:107201750	COG5	-0.93	-8.44	-0.65	3.55e-13	Coronary artery disease;
THYM	cis	rs986417	1.000	rs2350900	chr14:60938681	T/A	cg27398547	chr14:60952738	C14orf39	1.15	6.5	0.56	3.62e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs1003719	0.715	rs8129942	chr21:38552070	A/G	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg07212818	chr11:638076	DRD4	-0.76	-5.51	-0.49	3.05e-7	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs919433	0.679	rs7564924	chr2:198513877	C/T	cg00792783	chr2:198669748	PLCL1	0.76	4.91	0.45	3.81e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg08411435	chr17:37784024	PPP1R1B	-0.32	-4.48	-0.42	2.08e-5	Asthma;
THYM	cis	rs7705502	0.709	rs6869803	chr5:173298825	C/T	cg18693985	chr5:173351052	CPEB4	-0.79	-5.72	-0.51	1.24e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg05335186	chr13:53173507	NA	-0.49	-6.23	-0.54	1.28e-8	Lewy body disease;
THYM	cis	rs858239	0.932	rs858275	chr7:23294144	T/C	cg05407003	chr7:23246146	NA	-0.56	-4.46	-0.42	2.26e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg26384229	chr12:38710491	ALG10B	0.72	5.57	0.5	2.33e-7	Morning vs. evening chronotype;
THYM	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg24733560	chr20:60626293	TAF4	0.51	4.58	0.43	1.41e-5	Body mass index;
THYM	cis	rs9921192	1.000	rs233950	chr16:4327397	A/G	cg00021532	chr16:4324280	TFAP4	0.87	7.86	0.63	5.91e-12	Prostate-specific antigen levels;
THYM	cis	rs6032067	0.641	rs6017495	chr20:43756955	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.64	-5.8	-0.51	8.81e-8	Blood protein levels;
THYM	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.61	5.0	0.46	2.57e-6	Bipolar disorder;
THYM	cis	rs600806	0.850	rs4970846	chr1:109946095	A/C	cg02175308	chr1:109941060	SORT1	-0.57	-5.09	-0.46	1.78e-6	Intelligence (multi-trait analysis);
THYM	cis	rs539096	0.872	rs674725	chr1:44061795	C/T	cg00143623	chr1:44495758	SLC6A9	0.7	5.47	0.49	3.7e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7100689	0.622	rs4933378	chr10:82147057	T/C	cg01528321	chr10:82214614	TSPAN14	0.89	6.73	0.57	1.26e-9	Post bronchodilator FEV1;
THYM	cis	rs6877440	1.000	rs11948554	chr5:109056642	A/G	cg17395555	chr5:108820864	NA	0.55	4.65	0.43	1.09e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs17534004	1.000	rs35858501	chr13:31472120	C/T	cg00367615	chr13:31480979	C13orf33	0.66	4.76	0.44	7.05e-6	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg06656553	chr16:89960601	TCF25	0.76	4.51	0.42	1.88e-5	Skin colour saturation;
THYM	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg27588902	chr6:42928151	GNMT	-0.56	-5.6	-0.5	2.08e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs728616	0.867	rs12412226	chr10:81735288	C/T	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs1499972	0.941	rs56077465	chr3:117540517	C/T	cg07612923	chr3:117604196	NA	1.3	5.34	0.48	6.23e-7	Schizophrenia;
THYM	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg22709100	chr7:91322751	NA	-0.6	-4.8	-0.44	5.84e-6	Breast cancer;
THYM	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg08999081	chr20:33150536	PIGU	-0.57	-4.95	-0.45	3.25e-6	Height;
THYM	cis	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg12981288	chr8:11183844	MTMR9	-0.47	-4.65	-0.43	1.09e-5	Retinal vascular caliber;
THYM	cis	rs67981189	0.896	rs2158997	chr14:71497794	C/G	cg15910301	chr14:71632612	NA	-0.5	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	cis	rs6918586	1.000	rs198811	chr6:26128446	A/G	cg15691649	chr6:25882328	NA	-0.59	-4.47	-0.42	2.17e-5	Schizophrenia;
THYM	cis	rs9796	0.689	rs692511	chr15:41446252	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.62	-4.92	-0.45	3.61e-6	Menopause (age at onset);
THYM	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg06074448	chr4:187884817	NA	-1.04	-13.69	-0.81	3.39e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg09359103	chr1:154839909	KCNN3	-0.81	-10.3	-0.73	3.79e-17	Prostate cancer;
THYM	cis	rs12532214	1.000	rs12532214	chr7:3169890	C/G	cg19214707	chr7:3157722	NA	-0.86	-5.97	-0.52	4.12e-8	Itch intensity from mosquito bite;
THYM	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg25767906	chr1:53392781	SCP2	0.72	6.48	0.55	4.15e-9	Monocyte count;
THYM	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.58	0.43	1.41e-5	Bipolar disorder;
THYM	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.12	8.13	0.64	1.64e-12	Cognitive test performance;
THYM	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11644478	chr21:40555479	PSMG1	-0.76	-6.51	-0.56	3.49e-9	Cognitive function;
THYM	cis	rs6570726	0.935	rs585292	chr6:145862228	T/C	cg23711669	chr6:146136114	FBXO30	0.91	9.57	0.7	1.4e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg09184832	chr6:79620586	NA	-0.58	-4.53	-0.42	1.73e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg10523679	chr1:76189770	ACADM	-0.85	-7.95	-0.63	3.77e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7267979	1.000	rs6037095	chr20:25335687	A/G	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg14196790	chr5:131705035	SLC22A5	0.56	4.92	0.45	3.69e-6	Blood metabolite levels;
THYM	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg05973401	chr12:123451056	ABCB9	0.71	4.82	0.44	5.46e-6	Neutrophil percentage of white cells;
THYM	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg20387954	chr3:183756860	HTR3D	0.58	4.81	0.44	5.56e-6	Anterior chamber depth;
THYM	cis	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs6598955	0.671	rs17163868	chr1:26648381	A/G	cg08133631	chr1:26527909	CATSPER4	0.58	4.69	0.43	8.98e-6	Obesity-related traits;
THYM	cis	rs11645898	0.935	rs72787094	chr16:72192613	C/A	cg03805757	chr16:71968109	PKD1L3	-0.7	-5.14	-0.47	1.47e-6	Blood protein levels;
THYM	cis	rs66887589	0.934	rs7672519	chr4:120544112	C/T	cg13609457	chr4:120235615	NA	-0.47	-4.95	-0.45	3.27e-6	Diastolic blood pressure;
THYM	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg15733309	chr7:157513707	PTPRN2	0.57	6.36	0.55	6.99e-9	Bipolar disorder and schizophrenia;
THYM	trans	rs8073060	0.586	rs7213804	chr17:34010931	T/G	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg06521331	chr12:34319734	NA	-1.01	-11.07	-0.75	8.95e-19	Morning vs. evening chronotype;
THYM	cis	rs3791406	1.000	rs3791406	chr2:240030484	A/G	cg20627572	chr2:239991813	HDAC4	0.46	4.48	0.42	2.08e-5	Skin aging (microtopography measurement);
THYM	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06634786	chr22:41940651	POLR3H	0.8	6.18	0.54	1.56e-8	Vitiligo;
THYM	cis	rs7580658	0.637	rs3902960	chr2:127988242	G/C	cg10021288	chr2:128175891	PROC	-0.65	-5.79	-0.51	8.9e-8	Protein C levels;
THYM	cis	rs4595586	0.525	rs4768531	chr12:39417754	T/A	cg13010199	chr12:38710504	ALG10B	0.65	4.5	0.42	1.96e-5	Morning vs. evening chronotype;
THYM	cis	rs7681440	0.560	rs1442147	chr4:90748738	C/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-5.98	-0.52	3.88e-8	Chronic sinus infection;
THYM	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg25358565	chr5:93447407	FAM172A	1.39	9.77	0.71	5.02e-16	Diabetic retinopathy;
THYM	cis	rs4481887	0.741	rs4360554	chr1:248553206	C/T	cg00666640	chr1:248458726	OR2T12	0.54	4.62	0.43	1.22e-5	Common traits (Other);
THYM	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs854765	0.583	rs4341796	chr17:17839024	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.34	0.55	7.83e-9	Total body bone mineral density;
THYM	cis	rs6918586	0.658	rs198840	chr6:26112164	T/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.59	-0.61	2.21e-11	Schizophrenia;
THYM	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1642645	0.793	rs4660211	chr1:42484294	T/C	cg22816091	chr1:42611670	NA	0.62	5.52	0.49	2.99e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg06728252	chr6:26598149	ABT1	-0.44	-5.07	-0.46	1.95e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11652874	0.772	rs1490932	chr17:31979407	T/C	cg07860833	chr17:31537624	ACCN1	0.87	4.64	0.43	1.11e-5	Severe gingival inflammation;
THYM	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg04267008	chr7:1944627	MAD1L1	-0.65	-5.65	-0.5	1.64e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg02696790	chr15:75250997	RPP25	0.49	4.71	0.44	8.48e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs7677751	0.806	rs17084051	chr4:55087581	C/A	cg17187183	chr4:55093834	PDGFRA	0.71	5.49	0.49	3.35e-7	Corneal astigmatism;
THYM	cis	rs7610301	1.000	rs60911065	chr3:46642237	C/T	cg22951056	chr3:46887651	NA	-0.77	-4.83	-0.44	5.13e-6	Blood protein levels;
THYM	cis	rs10899021	0.790	rs12280434	chr11:74332827	C/T	cg25880958	chr11:74394337	NA	-0.72	-4.72	-0.44	7.99e-6	Response to metformin (IC50);
THYM	cis	rs921968	0.643	rs4674321	chr2:219511368	G/A	cg02176678	chr2:219576539	TTLL4	0.61	5.86	0.52	6.61e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg15744005	chr10:104629667	AS3MT	-0.86	-8.2	-0.64	1.16e-12	Arsenic metabolism;
THYM	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg10661904	chr17:79619235	PDE6G	-0.64	-6.37	-0.55	6.62e-9	Eye color traits;
THYM	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg09455208	chr3:40491958	NA	0.5	5.24	0.47	9.76e-7	Renal cell carcinoma;
THYM	cis	rs6032067	0.929	rs45461302	chr20:43805274	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.6	-0.56	2.34e-9	Blood protein levels;
THYM	cis	rs17534004	1.000	rs12870594	chr13:31462909	T/C	cg00367615	chr13:31480979	C13orf33	0.65	4.68	0.43	9.69e-6	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg18032289	chr17:61959525	GH2	0.46	4.48	0.42	2.1e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg25072359	chr17:41440525	NA	0.72	5.26	0.47	8.95e-7	Menopause (age at onset);
THYM	cis	rs7980799	0.682	rs1351682	chr12:33598775	G/A	cg06521331	chr12:34319734	NA	0.66	4.61	0.43	1.24e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs9549260	0.785	rs2253001	chr13:41145330	A/T	cg21288729	chr13:41239152	FOXO1	0.71	5.48	0.49	3.55e-7	Red blood cell count;
THYM	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg14784868	chr12:69753453	YEATS4	1.06	9.75	0.71	5.58e-16	Blood protein levels;
THYM	cis	rs868036	0.958	rs3784709	chr15:68072275	C/T	cg24579218	chr15:68104479	NA	-0.66	-6.69	-0.57	1.57e-9	Restless legs syndrome;
THYM	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.88	7.81	0.63	7.51e-12	Monocyte percentage of white cells;
THYM	cis	rs1550582	0.548	rs7828645	chr8:135497385	A/G	cg17885191	chr8:135476712	NA	-1.12	-9.07	-0.68	1.62e-14	Educational attainment;
THYM	cis	rs941408	1.000	rs1640266	chr19:2787832	T/G	cg17333051	chr19:2783644	SGTA	0.61	5.52	0.49	2.95e-7	Total cholesterol levels;
THYM	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg27170947	chr2:26402098	FAM59B	0.82	5.91	0.52	5.43e-8	Gut microbiome composition (summer);
THYM	cis	rs6840360	0.571	rs4696273	chr4:152528477	G/A	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg16928487	chr17:17741425	SREBF1	-0.56	-5.57	-0.5	2.37e-7	Total body bone mineral density;
THYM	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg25427524	chr10:38739819	LOC399744	0.65	6.14	0.53	1.87e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs2836633	0.929	rs62217518	chr21:40033189	T/G	cg12884169	chr21:40033163	ERG	0.68	8.52	0.66	2.33e-13	Coronary artery disease;
THYM	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg25703541	chr22:24373054	LOC391322	0.85	9.25	0.69	6.76e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg03517284	chr6:25882590	NA	-0.67	-4.47	-0.42	2.14e-5	Height;
THYM	cis	rs7009516	0.669	rs12674766	chr8:24241732	C/T	cg01759110	chr8:24241694	ADAMDEC1	-0.54	-5.04	-0.46	2.18e-6	Hair greying;
THYM	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg11764359	chr7:65958608	NA	0.65	5.07	0.46	1.96e-6	Aortic root size;
THYM	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.32	-9.95	-0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs6558530	0.863	rs4595147	chr8:1703569	G/T	cg09410841	chr8:1729607	CLN8	0.68	4.98	0.46	2.79e-6	Systolic blood pressure;
THYM	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg14829155	chr15:31115871	NA	0.75	6.38	0.55	6.46e-9	Huntington's disease progression;
THYM	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg04234412	chr22:24373322	LOC391322	0.94	7.89	0.63	5.23e-12	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs1580019	0.885	rs4460270	chr7:32496450	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.59	0.56	2.42e-9	Cognitive ability;
THYM	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26314531	chr2:26401878	FAM59B	-0.78	-5.13	-0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg22920501	chr2:26401640	FAM59B	-1.07	-9.54	-0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs2085601	0.542	rs35006100	chr4:89983742	C/G	cg17769793	chr4:89976368	FAM13A	0.59	6.62	0.56	2.17e-9	Hair greying;
THYM	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg24531977	chr5:56204891	C5orf35	-0.64	-4.87	-0.45	4.46e-6	Coronary artery disease;
THYM	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg01699819	chr7:1052092	C7orf50	-0.87	-7.92	-0.63	4.5e-12	Bronchopulmonary dysplasia;
THYM	cis	rs4595586	0.505	rs6580897	chr12:39372254	A/G	cg26384229	chr12:38710491	ALG10B	0.7	5.39	0.48	5.22e-7	Morning vs. evening chronotype;
THYM	cis	rs8060598	0.745	rs17312836	chr16:50741462	A/C	cg05261686	chr16:50743296	NOD2	0.39	4.76	0.44	6.78e-6	Leprosy;
THYM	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs7901056	0.840	rs3006810	chr10:26724697	C/T	cg23318538	chr10:26883079	C10orf50	-0.34	-4.46	-0.42	2.21e-5	Lymphocyte counts;
THYM	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg02569458	chr12:86230093	RASSF9	-0.66	-5.63	-0.5	1.84e-7	Major depressive disorder;
THYM	cis	rs9902453	0.817	rs7217961	chr17:28403112	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-6.08	-0.53	2.47e-8	Coffee consumption (cups per day);
THYM	cis	rs61931739	0.635	rs1486884	chr12:33908876	A/T	cg10856724	chr12:34555212	NA	0.62	5.61	0.5	2e-7	Morning vs. evening chronotype;
THYM	cis	rs2073300	0.609	rs2295238	chr20:23387946	C/G	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg08704250	chr15:31115839	NA	0.47	5.54	0.49	2.68e-7	Huntington's disease progression;
THYM	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06634786	chr22:41940651	POLR3H	0.84	6.24	0.54	1.21e-8	Vitiligo;
THYM	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.77	0.51	1.01e-7	Hip circumference adjusted for BMI;
THYM	cis	rs7511006	1.000	rs7511006	chr22:50676259	T/C	cg11077631	chr22:50617003	PANX2	-0.48	-5.21	-0.47	1.08e-6	Obesity-related traits;
THYM	cis	rs1994135	0.617	rs10844644	chr12:33735871	A/G	cg06521331	chr12:34319734	NA	-0.68	-4.74	-0.44	7.43e-6	Resting heart rate;
THYM	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg22508957	chr16:3507546	NAT15	0.64	9.04	0.68	1.85e-14	Tuberculosis;
THYM	cis	rs7119	0.667	rs4886889	chr15:77902347	T/C	cg27398640	chr15:77910606	LINGO1	0.68	8.73	0.67	8.58e-14	Type 2 diabetes;
THYM	cis	rs13126513	0.510	rs10516445	chr4:100524679	C/G	cg05468953	chr4:100565104	NA	0.66	6.38	0.55	6.47e-9	Metabolite levels (MHPG);
THYM	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg24642844	chr7:1081250	C7orf50	-0.71	-4.87	-0.45	4.43e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg10360139	chr7:1886902	MAD1L1	-0.66	-5.62	-0.5	1.88e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs939658	0.805	rs35230534	chr15:79441093	T/C	cg17916960	chr15:79447300	NA	-0.73	-8.58	-0.66	1.81e-13	Refractive error;
THYM	cis	rs829883	0.664	rs249833	chr12:98832189	T/C	cg25150519	chr12:98850993	NA	0.53	5.22	0.47	1.05e-6	Colorectal adenoma (advanced);
THYM	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg18252515	chr7:66147081	NA	-1.65	-9.03	-0.68	1.94e-14	Diabetic kidney disease;
THYM	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg27170947	chr2:26402098	FAM59B	-0.54	-4.62	-0.43	1.22e-5	Gut microbiome composition (summer);
THYM	cis	rs6674176	0.542	rs803675	chr1:44353237	G/A	cg15962314	chr1:44399869	ARTN	0.53	4.99	0.46	2.71e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg02018176	chr4:1364513	KIAA1530	0.5	4.58	0.43	1.42e-5	Obesity-related traits;
THYM	cis	rs600806	0.815	rs10858097	chr1:109967324	C/A	cg02175308	chr1:109941060	SORT1	-0.57	-5.08	-0.46	1.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg08772003	chr10:104629869	AS3MT	-0.67	-5.92	-0.52	5.2100000000000003e-08	Arsenic metabolism;
THYM	cis	rs10095849	0.608	rs10108019	chr8:39439518	T/C	cg01911981	chr8:39380341	ADAM3A	-0.62	-5.13	-0.47	1.51e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs1448094	0.512	rs7970081	chr12:86243392	G/T	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs11966931	1.000	rs17589215	chr6:108147664	C/T	cg25323841	chr6:108444506	NA	0.67	4.65	0.43	1.07e-5	Neutrophil percentage of white cells;
THYM	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg05283184	chr6:79620031	NA	-1.01	-9.47	-0.7	2.22e-15	Intelligence (multi-trait analysis);
THYM	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg11812906	chr14:75593930	NEK9	0.8	7.24	0.6	1.15e-10	Height;
THYM	cis	rs12137294	0.669	rs1177720	chr1:205234428	C/T	cg17889831	chr1:205181581	DSTYK	-0.4	-4.92	-0.45	3.57e-6	Red cell distribution width;
THYM	cis	rs4363385	0.818	rs11205175	chr1:153001296	A/C	cg13444842	chr1:152974279	SPRR3	-0.59	-4.81	-0.44	5.61e-6	Inflammatory skin disease;
THYM	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg07936489	chr17:37558343	FBXL20	-0.69	-4.79	-0.44	6.22e-6	Asthma;
THYM	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.55	-4.72	-0.44	8.2e-6	Coronary artery disease;
THYM	cis	rs11645898	1.000	rs72791117	chr16:72217385	T/C	cg03805757	chr16:71968109	PKD1L3	-0.68	-5.19	-0.47	1.18e-6	Blood protein levels;
THYM	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06634786	chr22:41940651	POLR3H	-0.66	-5.29	-0.48	7.97e-7	Vitiligo;
THYM	cis	rs3947	1.000	rs1736084	chr8:11703657	C/T	cg26752888	chr8:11627280	NEIL2	-0.72	-4.66	-0.43	1.05e-5	Blood protein levels;
THYM	cis	rs1986734	0.597	rs4859684	chr4:77419107	C/T	cg20311846	chr4:77356250	SHROOM3	-0.43	-4.66	-0.43	1.01e-5	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
THYM	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg07820996	chr16:1026944	NA	-0.55	-4.47	-0.42	2.15e-5	Blood protein levels;
THYM	cis	rs2229238	0.911	rs7556449	chr1:154505886	C/T	cg21262032	chr1:154437693	IL6R	0.63	5.65	0.5	1.68e-7	Coronary heart disease;
THYM	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg22709100	chr7:91322751	NA	-0.6	-4.8	-0.44	5.84e-6	Breast cancer;
THYM	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg03929089	chr4:120376271	NA	-0.93	-8.5	-0.66	2.69e-13	Coronary artery disease;
THYM	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg00383909	chr3:49044727	WDR6	1.12	6.62	0.56	2.13e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs73072330	0.643	rs56298666	chr3:47667218	A/G	cg09665691	chr3:47563885	NA	1.44	5.12	0.47	1.58e-6	Stem cell growth factor beta levels;
THYM	cis	rs1499972	0.887	rs9842435	chr3:117517339	A/G	cg07612923	chr3:117604196	NA	-1.31	-5.35	-0.48	6.02e-7	Schizophrenia;
THYM	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg03433033	chr1:76189801	ACADM	0.75	8.57	0.66	1.9e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs12282928	1.000	rs10769345	chr11:48335164	C/G	cg22827986	chr11:48284249	OR4X1	0.53	5.59	0.5	2.21e-7	Migraine - clinic-based;
THYM	cis	rs11167764	0.945	rs6878397	chr5:141474012	A/G	cg23435118	chr5:141488016	NDFIP1	-0.53	-4.51	-0.42	1.85e-5	Crohn's disease;
THYM	cis	rs12620999	0.938	rs4575672	chr2:238070572	T/C	cg23555395	chr2:238036564	NA	-0.61	-4.85	-0.45	4.87e-6	Systemic lupus erythematosus;
THYM	cis	rs4664308	0.967	rs17241792	chr2:160915205	C/T	cg03641300	chr2:160917029	PLA2R1	-0.76	-6.89	-0.58	6.12e-10	Idiopathic membranous nephropathy;
THYM	cis	rs2806561	0.780	rs4655142	chr1:23333728	T/C	cg08872493	chr1:23521417	HTR1D	-0.37	-4.53	-0.42	1.74e-5	Height;
THYM	cis	rs4851254	0.660	rs4851244	chr2:100671449	C/T	cg22139774	chr2:100720529	AFF3	0.41	4.69	0.43	9.07e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg06112835	chr11:68658793	MRPL21	0.45	6.37	0.55	6.61e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.73	0.44	7.82e-6	Obesity-related traits;
THYM	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg14582100	chr15:45693742	SPATA5L1	0.56	4.63	0.43	1.17e-5	Homoarginine levels;
THYM	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg17202724	chr17:61916730	SMARCD2	-0.46	-4.64	-0.43	1.13e-5	Prudent dietary pattern;
THYM	cis	rs2862064	0.932	rs1995378	chr5:156421132	G/A	cg12943317	chr5:156479607	HAVCR1	-0.87	-5.18	-0.47	1.26e-6	Platelet count;
THYM	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg27631724	chr1:11040367	C1orf127	0.62	5.49	0.49	3.4e-7	Ewing sarcoma;
THYM	cis	rs6121246	0.511	rs879982	chr20:30398510	A/G	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs7616559	0.849	rs2321459	chr3:156762886	T/C	cg15697575	chr3:156784781	NA	0.42	5.37	0.48	5.54e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs2073300	0.609	rs6137915	chr20:23358509	A/G	cg12062639	chr20:23401060	NAPB	-1.1	-5.73	-0.51	1.16e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs60180747	0.865	rs11639073	chr15:66600097	C/A	cg08479319	chr15:66648941	TIPIN	0.66	4.48	0.42	2.05e-5	Testicular germ cell tumor;
THYM	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg17063962	chr7:91808500	NA	1.17	11.48	0.76	1.17e-19	Breast cancer;
THYM	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg21926883	chr2:100939477	LONRF2	-0.64	-5.85	-0.51	6.82e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs1466662	0.677	rs1388070	chr4:155300938	A/G	cg05574313	chr4:155338166	DCHS2	0.63	4.55	0.42	1.56e-5	Alzheimer's disease (age of onset);
THYM	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg12310025	chr6:25882481	NA	-1.07	-10.47	-0.73	1.6e-17	Uric acid levels;
THYM	cis	rs714027	1.000	rs2412973	chr22:30529631	C/A	cg11564601	chr22:30592435	NA	-0.3	-5.45	-0.49	3.98e-7	Lymphocyte counts;
THYM	cis	rs7187994	0.848	rs12448489	chr16:84774022	G/A	cg07647771	chr16:84786436	USP10	-0.57	-5.0	-0.46	2.57e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs36051895	0.623	rs11506293	chr9:5257430	A/G	cg02405213	chr9:5042618	JAK2	-0.97	-9.39	-0.69	3.31e-15	Pediatric autoimmune diseases;
THYM	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06634786	chr22:41940651	POLR3H	-0.82	-6.14	-0.53	1.93e-8	Vitiligo;
THYM	cis	rs6430585	0.528	rs721765	chr2:136748779	C/A	cg07169764	chr2:136633963	MCM6	1.19	11.38	0.76	1.91e-19	Corneal structure;
THYM	cis	rs7267979	1.000	rs6132835	chr20:25434667	A/G	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7616559	0.512	rs9818874	chr3:156730141	G/A	cg15697575	chr3:156784781	NA	0.36	5.11	0.46	1.64e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs985746	0.527	rs12512618	chr4:36796439	C/G	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs2109514	1.000	rs6466579	chr7:116151155	T/C	cg12739419	chr7:116140593	CAV2	-0.48	-4.65	-0.43	1.07e-5	Prevalent atrial fibrillation;
THYM	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22857025	chr5:266934	NA	-1.57	-9.68	-0.7	8.05e-16	Breast cancer;
THYM	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg26031613	chr14:104095156	KLC1	1.23	12.6	0.79	5.44e-22	Body mass index;
THYM	cis	rs4455778	0.580	rs4275185	chr7:49114615	C/G	cg26309511	chr7:48887640	NA	0.62	5.72	0.51	1.25e-7	Lung cancer in never smokers;
THYM	cis	rs2235642	0.859	rs9927529	chr16:1619488	C/T	cg00463982	chr16:1583984	IFT140;TMEM204	-0.54	-4.52	-0.42	1.76e-5	Coronary artery disease;
THYM	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg06092702	chr1:163392909	NA	0.55	4.54	0.42	1.63e-5	Motion sickness;
THYM	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg07648498	chr16:89883185	FANCA	0.63	4.72	0.44	7.96e-6	Vitiligo;
THYM	cis	rs59698941	0.943	rs73271090	chr5:132313550	G/A	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	trans	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg10856724	chr12:34555212	NA	-1.02	-9.32	-0.69	4.7e-15	Morning vs. evening chronotype;
THYM	cis	rs5758511	0.680	rs5758662	chr22:42628088	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.5	4.61	0.43	1.27e-5	Birth weight;
THYM	cis	rs763014	0.865	rs62030874	chr16:632233	T/C	cg00908189	chr16:619842	PIGQ	1.03	9.28	0.69	5.74e-15	Height;
THYM	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg18352616	chr4:3374830	RGS12	0.77	8.69	0.67	1.05e-13	Serum sulfate level;
THYM	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg23428387	chr22:49814324	NA	0.56	5.98	0.52	3.87e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs919433	0.679	rs1902249	chr2:198521356	T/C	cg00792783	chr2:198669748	PLCL1	0.82	5.44	0.49	4.16e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4481887	1.000	rs4579792	chr1:248463742	C/T	cg13385794	chr1:248469461	NA	-0.65	-4.49	-0.42	1.97e-5	Common traits (Other);
THYM	cis	rs11969893	0.655	rs67724651	chr6:101417004	T/G	cg12253828	chr6:101329408	ASCC3	1.23	6.93	0.58	5.09e-10	Economic and political preferences (immigration/crime);
THYM	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-5.78	-0.51	9.67e-8	Systemic lupus erythematosus;
THYM	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.86	-7.69	-0.62	1.36e-11	Intelligence (multi-trait analysis);
THYM	cis	rs728616	0.717	rs61860016	chr10:81915889	G/C	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.87	-0.45	4.41e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg15704280	chr7:45808275	SEPT13	-1.02	-11.33	-0.76	2.47e-19	Coronary artery disease;
THYM	cis	rs2820651	0.614	rs80334103	chr10:1489460	T/C	cg13720710	chr10:1452970	ADARB2	0.79	4.99	0.46	2.72e-6	Migraine with aura;
THYM	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg13695892	chr22:41940480	POLR3H	-0.98	-7.65	-0.62	1.61e-11	Vitiligo;
THYM	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg01416388	chr22:39784598	NA	-0.75	-5.91	-0.52	5.4e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs12200782	0.505	rs1535275	chr6:26520767	G/C	cg12826209	chr6:26865740	GUSBL1	0.69	4.55	0.42	1.61e-5	Small cell lung carcinoma;
THYM	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg13609457	chr4:120235615	NA	0.61	5.47	0.49	3.57e-7	Corneal astigmatism;
THYM	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg22974920	chr21:40686053	BRWD1	0.6	4.75	0.44	7.15e-6	Cognitive function;
THYM	cis	rs4866334	1.000	rs114489248	chr5:18478969	C/A	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs9788721	0.836	rs17405217	chr15:78731149	C/T	cg18825076	chr15:78729989	IREB2	-0.68	-6.14	-0.53	1.88e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.738	rs9485039	chr6:146319387	C/T	cg23711669	chr6:146136114	FBXO30	0.99	10.16	0.72	7.58e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11225247	1.000	rs79991976	chr11:102321434	T/C	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs10911232	0.507	rs10797833	chr1:183044067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs2067615	0.524	rs9804754	chr12:107083031	G/A	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	cis	rs7927771	0.524	rs4539273	chr11:47694699	C/T	cg18512352	chr11:47633146	NA	-0.41	-4.51	-0.42	1.85e-5	Subjective well-being;
THYM	cis	rs61931739	0.817	rs592857	chr12:34197673	T/G	cg10856724	chr12:34555212	NA	-0.62	-5.55	-0.49	2.62e-7	Morning vs. evening chronotype;
THYM	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg22535103	chr8:58192502	C8orf71	-0.98	-4.87	-0.45	4.49e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7980799	0.682	rs7138529	chr12:33634855	T/C	cg10856724	chr12:34555212	NA	0.62	4.58	0.43	1.39e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs3780378	1.000	rs10117591	chr9:5094539	G/A	cg02405213	chr9:5042618	JAK2	-0.62	-5.64	-0.5	1.75e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs2236918	0.687	rs2797601	chr1:242029249	C/G	cg21919602	chr1:242011447	EXO1	-0.6	-4.45	-0.42	2.35e-5	Menopause (age at onset);
THYM	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.67	0.43	9.95e-6	Bipolar disorder;
THYM	cis	rs67072384	1.000	rs12271961	chr11:72453596	G/A	cg01380194	chr11:72452482	ARAP1	-0.97	-5.26	-0.47	8.93e-7	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg27279351	chr12:120934652	DYNLL1	0.93	8.22	0.64	1.02e-12	High light scatter reticulocyte count;
THYM	cis	rs7100689	0.784	rs11202699	chr10:82131453	A/G	cg01528321	chr10:82214614	TSPAN14	0.96	7.25	0.6	1.12e-10	Post bronchodilator FEV1;
THYM	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg07424592	chr7:64974309	NA	-0.99	-5.15	-0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs7224314	1.000	rs62084080	chr17:65387014	C/T	cg01507342	chr17:65387096	PITPNC1	-0.91	-10.3	-0.73	3.76e-17	Diisocyanate-induced asthma;
THYM	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg26384229	chr12:38710491	ALG10B	-1.01	-9.42	-0.69	2.88e-15	Heart rate;
THYM	cis	rs6722750	0.818	rs13411753	chr2:64394417	A/G	cg22352474	chr2:64371530	PELI1	0.72	6.15	0.53	1.78e-8	Neuroticism;
THYM	cis	rs877282	0.786	rs11253392	chr10:788768	G/A	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs7172809	0.643	rs75159723	chr15:77841841	A/G	cg22256960	chr15:77711686	NA	-0.74	-5.36	-0.48	5.73e-7	Glucose homeostasis traits;
THYM	cis	rs308447	0.576	rs7673491	chr4:123710875	A/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.85	6.86	0.58	7.03e-10	Perceived unattractiveness to mosquitoes;
THYM	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg21644426	chr2:191273491	MFSD6	0.76	6.12	0.53	2.08e-8	Pulse pressure;
THYM	cis	rs778371	0.676	rs921055	chr2:233697337	A/C	cg08000102	chr2:233561755	GIGYF2	-0.79	-6.96	-0.58	4.28e-10	Schizophrenia;
THYM	cis	rs7246657	0.943	rs10417503	chr19:37842735	T/C	cg22634378	chr19:37742834	NA	0.68	5.67	0.5	1.55e-7	Coronary artery calcification;
THYM	cis	rs6546324	0.625	rs6752799	chr2:67858503	G/A	cg18237512	chr2:67827392	NA	-0.79	-4.75	-0.44	7.23e-6	Endometriosis;
THYM	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg13877915	chr19:58951672	ZNF132	0.9	8.63	0.66	1.38e-13	Uric acid clearance;
THYM	cis	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs4986172	0.726	rs12051846	chr17:43226887	A/G	cg24180402	chr17:43221464	ACBD4	0.61	5.02	0.46	2.39e-6	Height;
THYM	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg10523679	chr1:76189770	ACADM	0.91	9.7	0.71	7.37e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs12711979	0.509	rs10192699	chr2:3824297	A/G	cg17052675	chr2:3827356	NA	-0.88	-13.79	-0.82	2.09e-24	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs9527	0.545	rs7915816	chr10:104881750	A/G	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg17211192	chr8:82754475	SNX16	-0.8	-6.99	-0.58	3.78e-10	Diastolic blood pressure;
THYM	cis	rs2046867	0.818	rs11928620	chr3:72863209	A/C	cg25664220	chr3:72788482	NA	-0.93	-7.47	-0.61	3.83e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs3126085	1.000	rs72696963	chr1:152181189	T/C	cg10321714	chr1:152280068	FLG	-0.75	-5.5	-0.49	3.22e-7	Atopic dermatitis;
THYM	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs35995292	0.927	rs4720308	chr7:38914285	A/C	cg19166347	chr7:37955598	SFRP4	0.57	4.55	0.42	1.58e-5	Subjective well-being (multi-trait analysis);
THYM	cis	rs2219968	0.756	rs10504661	chr8:78846469	T/G	cg00738934	chr8:78996279	NA	-0.78	-7.47	-0.61	3.92e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg11247378	chr22:39784982	NA	-1.05	-13.82	-0.82	1.87e-24	Intelligence (multi-trait analysis);
THYM	cis	rs7193541	0.646	rs4888267	chr16:74687906	A/G	cg01733217	chr16:74700730	RFWD3	0.99	11.67	0.77	4.7e-20	Multiple myeloma;
THYM	cis	rs10463554	0.963	rs6596530	chr5:102371440	C/G	cg23492399	chr5:102201601	PAM	-0.67	-5.18	-0.47	1.26e-6	Parkinson's disease;
THYM	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs6570726	0.935	rs442254	chr6:145849118	T/C	cg23711669	chr6:146136114	FBXO30	0.9	9.23	0.69	7.15e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4606347	0.789	rs17407384	chr1:66167038	A/G	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg09060608	chr5:178986726	RUFY1	0.54	5.66	0.5	1.59e-7	Lung cancer;
THYM	cis	rs8017423	0.935	rs8012299	chr14:90715822	G/T	cg04239629	chr14:90701769	NA	-0.62	-4.52	-0.42	1.81e-5	Mortality in heart failure;
THYM	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg16524733	chr11:117070046	TAGLN	-0.42	-4.64	-0.43	1.12e-5	Blood protein levels;
THYM	cis	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg00495681	chr13:53174319	NA	0.73	6.84	0.57	7.7e-10	Lewy body disease;
THYM	cis	rs5769707	0.681	rs4622843	chr22:50036916	T/G	cg20744362	chr22:50050164	C22orf34	0.77	7.04	0.59	2.98e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.59	-0.43	1.37e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2120243	0.504	rs1824058	chr3:157124780	C/A	cg24825693	chr3:157122686	VEPH1	-0.47	-4.49	-0.42	2.03e-5	Hepatocellular carcinoma in hepatitis B infection;
THYM	cis	rs7404928	0.651	rs3785391	chr16:23956629	A/G	cg26685404	chr16:23957272	PRKCB	0.68	8.12	0.64	1.7e-12	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs10256972	0.706	rs7784559	chr7:1002973	A/G	cg07930192	chr7:1003750	NA	0.87	7.69	0.62	1.35e-11	Longevity;Endometriosis;
THYM	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.07	7.5	0.61	3.29e-11	Platelet count;
THYM	cis	rs28595532	0.920	rs115484560	chr4:119756781	T/G	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs4788815	0.562	rs12926041	chr16:71978645	G/C	cg06353428	chr16:71660113	MARVELD3	0.77	5.72	0.51	1.21e-7	Metabolite levels;
THYM	cis	rs1451375	0.617	rs7790758	chr7:50561544	G/A	cg18232548	chr7:50535776	DDC	-0.68	-5.19	-0.47	1.21e-6	Malaria;
THYM	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.9	7.28	0.6	9.61e-11	Lymphocyte percentage of white cells;
THYM	cis	rs2302612	0.528	rs17026825	chr2:102836665	A/T	cg13315345	chr2:102803985	IL1RL2	0.68	4.58	0.43	1.4e-5	Serum protein levels (sST2);
THYM	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg10505658	chr17:80084571	CCDC57	-0.72	-7.71	-0.62	1.22e-11	Life satisfaction;
THYM	cis	rs7312774	0.748	rs7966019	chr12:107297502	G/T	cg16260113	chr12:107380972	MTERFD3	1.05	5.57	0.5	2.4e-7	Severe influenza A (H1N1) infection;
THYM	cis	rs10739663	0.520	rs3122937	chr9:128154808	A/G	cg14078157	chr9:128172775	NA	-0.91	-7.95	-0.63	3.88e-12	Resting heart rate;
THYM	cis	rs1298062	0.757	rs1673039	chr19:50977957	C/T	cg11430371	chr19:50961752	MYBPC2	0.46	4.52	0.42	1.77e-5	Age of smoking initiation;
THYM	cis	rs2282300	0.739	rs7926465	chr11:30333016	C/T	cg25418670	chr11:30344373	C11orf46	0.82	6.98	0.58	3.93e-10	Morning vs. evening chronotype;
THYM	cis	rs17152411	1.000	rs7097282	chr10:126593492	T/C	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs7187994	0.848	rs12934432	chr16:84770913	T/A	cg07647771	chr16:84786436	USP10	-0.57	-4.73	-0.44	7.95e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs1003719	0.788	rs2006941	chr21:38467616	C/A	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs2137111	0.579	rs116951852	chr15:77721319	A/T	cg10437265	chr15:77819839	NA	-0.5	-4.56	-0.42	1.5e-5	Anticoagulant levels;
THYM	trans	rs1997103	1.000	rs6953509	chr7:55412179	G/A	cg20935933	chr6:143382018	AIG1	0.86	6.91	0.58	5.41e-10	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs67981189	0.656	rs2810113	chr14:71395770	C/T	cg15910301	chr14:71632612	NA	-0.5	-4.49	-0.42	1.98e-5	Schizophrenia;
THYM	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.14	8.16	0.64	1.38e-12	Cognitive test performance;
THYM	cis	rs4866334	1.000	rs79543647	chr5:18488484	G/A	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06850241	chr22:41845214	NA	0.58	5.11	0.46	1.63e-6	Vitiligo;
THYM	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs4819143	0.517	rs454268	chr21:47373114	G/A	cg20357416	chr21:47294739	PCBP3	0.79	4.94	0.45	3.38e-6	Insulin resistance/response;
THYM	cis	rs12765878	0.812	rs2984132	chr10:105657892	T/C	cg11005552	chr10:105648138	OBFC1	-0.62	-5.93	-0.52	4.78e-8	Coronary artery disease;
THYM	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg15242686	chr22:24348715	GSTTP1	0.51	4.47	0.42	2.14e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg08999081	chr20:33150536	PIGU	0.8	7.37	0.6	6.23e-11	Coronary artery disease;
THYM	cis	rs4727027	0.704	rs12704083	chr7:148909759	G/A	cg23583168	chr7:148888333	NA	-1.07	-15.64	-0.85	5e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs10208940	0.614	rs28597751	chr2:68822903	A/G	cg09157127	chr2:69201416	GKN1	0.89	4.71	0.43	8.61e-6	Urate levels in lean individuals;
THYM	cis	rs9902453	0.933	rs7224199	chr17:28523726	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.83	0.44	5.26e-6	Coffee consumption (cups per day);
THYM	cis	rs2811415	0.597	rs67763343	chr3:127803163	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11644478	chr21:40555479	PSMG1	-0.8	-6.91	-0.58	5.38e-10	Cognitive function;
THYM	cis	rs7772486	0.875	rs7761033	chr6:146356106	C/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs586688	0.625	rs688122	chr1:201653344	T/C	cg14168733	chr1:201708718	NAV1	-0.61	-5.6	-0.5	2.1e-7	Obesity-related traits;
THYM	cis	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg18512352	chr11:47633146	NA	-0.38	-4.52	-0.42	1.75e-5	HDL cholesterol;
THYM	cis	rs4523957	0.651	rs9895342	chr17:2081647	T/C	cg16513277	chr17:2031491	SMG6	-0.95	-8.69	-0.67	1.05e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg16680214	chr1:154839983	KCNN3	-0.39	-4.63	-0.43	1.15e-5	Prostate cancer;
THYM	trans	rs1974653	0.672	rs9606254	chr22:20100409	C/T	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs6815814	0.898	rs115807384	chr4:38851585	A/C	cg06935464	chr4:38784597	TLR10	0.76	4.7	0.43	8.87e-6	Breast cancer;
THYM	cis	rs76662990	0.610	rs10079609	chr5:73918616	A/G	cg13275603	chr5:73927487	ENC1	-0.79	-4.55	-0.42	1.57e-5	Residual cognition;
THYM	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg03929089	chr4:120376271	NA	0.9	8.74	0.67	8e-14	Coronary artery disease;
THYM	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-4.76	-0.44	6.82e-6	Gut microbiome composition (summer);
THYM	cis	rs868036	0.718	rs28399056	chr15:68116010	C/A	cg26545918	chr15:68124484	LBXCOR1	0.5	4.45	0.42	2.31e-5	Restless legs syndrome;
THYM	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg09021430	chr5:549028	NA	0.62	5.94	0.52	4.57e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs17253792	0.822	rs76267907	chr14:56066969	C/A	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.69	-5.16	-0.47	1.36e-6	Tonsillectomy;
THYM	cis	rs600806	0.850	rs10776807	chr1:109956156	A/G	cg23032129	chr1:109941072	SORT1	0.6	5.25	0.47	9.41e-7	Intelligence (multi-trait analysis);
THYM	cis	rs12586317	0.545	rs58342373	chr14:35395269	T/C	cg16230307	chr14:35515116	FAM177A1	0.72	5.02	0.46	2.41e-6	Psoriasis;
THYM	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg00484396	chr16:3507460	NAT15	-0.49	-4.98	-0.46	2.8e-6	Body mass index (adult);
THYM	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg16342193	chr10:102329863	NA	-0.52	-5.29	-0.48	7.74e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7359257	1.000	rs11071951	chr15:67694766	C/T	cg24579218	chr15:68104479	NA	0.55	4.77	0.44	6.55e-6	Menarche (age at onset);
THYM	cis	rs12282928	1.000	rs2134554	chr11:48262351	C/T	cg22827986	chr11:48284249	OR4X1	-0.53	-5.39	-0.48	5.06e-7	Migraine - clinic-based;
THYM	cis	rs1003719	0.788	rs2835574	chr21:38455324	C/A	cg01329690	chr21:38580129	DSCR9	0.39	5.25	0.47	9.23e-7	Eye color traits;
THYM	cis	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg07460842	chr6:66804631	NA	-0.91	-6.25	-0.54	1.14e-8	Exhaled nitric oxide output;
THYM	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs713587	0.525	rs1541984	chr2:25082414	G/A	cg01884057	chr2:25150051	NA	0.64	5.98	0.52	3.82e-8	Body mass index in non-asthmatics;
THYM	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg25703541	chr22:24373054	LOC391322	-0.87	-8.81	-0.67	5.77e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6598163	0.517	rs12366296	chr12:132296824	C/G	cg00078996	chr12:132293329	NA	0.6	5.88	0.52	6.05e-8	Migraine;
THYM	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg03609598	chr5:56110824	MAP3K1	-0.82	-5.57	-0.5	2.35e-7	Initial pursuit acceleration;
THYM	cis	rs9814567	1.000	rs4498009	chr3:134198008	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.65	-0.62	1.62e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10095849	0.554	rs7838204	chr8:39405858	A/G	cg01911981	chr8:39380341	ADAM3A	0.56	4.77	0.44	6.54e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs12413816	0.517	rs4750400	chr10:13765923	A/G	cg16485048	chr10:13749193	FRMD4A	0.47	4.58	0.43	1.43e-5	Red cell distribution width;
THYM	cis	rs4430311	0.756	rs2953329	chr1:244025999	A/G	cg25706552	chr1:244017396	NA	0.58	5.0	0.46	2.59e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs13064411	0.696	rs1486894	chr3:113211513	G/A	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg14784868	chr12:69753453	YEATS4	0.9	7.77	0.62	9.35e-12	Response to diuretic therapy;
THYM	cis	rs2340727	0.660	rs1962509	chr1:161945467	C/G	ch.1.159725313R	chr1:161458689	NA	-0.78	-5.32	-0.48	6.8e-7	White blood cell count;Hematology traits;
THYM	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg14004847	chr7:1930337	MAD1L1	-0.65	-5.03	-0.46	2.3e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4363385	0.818	rs12029168	chr1:152987993	G/A	cg13444842	chr1:152974279	SPRR3	-0.61	-5.08	-0.46	1.86e-6	Inflammatory skin disease;
THYM	cis	rs4266144	0.544	rs7340627	chr3:156832393	A/G	cg16248515	chr3:156840234	NA	-0.58	-5.39	-0.48	5.15e-7	Coronary artery disease;
THYM	cis	rs4589258	0.788	rs10830565	chr11:90460817	C/T	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.72	-0.44	7.95e-6	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs115046587	chr4:119779604	T/C	cg14228332	chr4:119757509	SEC24D	1.59	5.76	0.51	1.02e-7	Cannabis dependence symptom count;
THYM	cis	rs916888	0.647	rs199524	chr17:44848438	G/T	cg17911788	chr17:44343683	NA	0.54	5.33	0.48	6.72e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs6430585	0.583	rs12475516	chr2:136560761	C/G	cg23851026	chr2:136556271	LCT	0.7	7.49	0.61	3.45e-11	Corneal structure;
THYM	cis	rs904251	0.861	rs914349	chr6:37484715	A/C	cg25019722	chr6:37503610	NA	-0.65	-4.97	-0.45	2.9e-6	Cognitive performance;
THYM	cis	rs6032067	0.632	rs35361894	chr20:43794403	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs6032067	0.641	rs13042991	chr20:43767178	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.7	-7.59	-0.61	2.14e-11	Blood protein levels;
THYM	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.5	0.49	3.18e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg27490568	chr2:178487706	NA	0.62	5.7	0.5	1.35e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg19875535	chr5:140030758	IK	-0.63	-5.69	-0.5	1.43e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17685	0.753	rs869804	chr7:75688954	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.1	-0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg17644776	chr2:200775616	C2orf69	0.8	4.82	0.44	5.52e-6	Schizophrenia;
THYM	cis	rs9560113	1.000	rs4771757	chr13:112176379	G/T	cg10483660	chr13:112241077	NA	0.53	4.76	0.44	6.81e-6	Menarche (age at onset);
THYM	cis	rs2832077	1.000	rs12329875	chr21:30137796	C/T	cg24692254	chr21:30365293	RNF160	-0.84	-5.22	-0.47	1.04e-6	Cognitive test performance;
THYM	cis	rs1557488	0.566	rs1946076	chr11:126673586	C/T	cg03950493	chr11:126582183	KIRREL3	0.39	4.66	0.43	1.05e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg13607699	chr17:42295918	UBTF	0.66	5.44	0.49	4.13e-7	Total body bone mineral density;
THYM	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs75059851	1.000	rs3758927	chr11:133829644	C/G	cg14047540	chr11:133829660	NA	1.17	8.14	0.64	1.53e-12	Schizophrenia;
THYM	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.69	-5.16	-0.47	1.36e-6	Tonsillectomy;
THYM	cis	rs6782029	0.517	rs11128563	chr3:11678101	T/C	cg07643000	chr3:11666825	VGLL4	-0.47	-5.13	-0.47	1.51e-6	Anorexia nervosa;
THYM	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg09323728	chr8:95962352	TP53INP1	-0.47	-4.65	-0.43	1.08e-5	Type 2 diabetes;
THYM	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg14972814	chr11:95582409	MTMR2	-0.68	-5.39	-0.48	5.02e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11890956	chr21:40555474	PSMG1	-0.66	-6.44	-0.55	4.92e-9	Menarche (age at onset);
THYM	cis	rs4523957	0.928	rs170044	chr17:2197502	C/G	cg16513277	chr17:2031491	SMG6	-0.78	-7.38	-0.6	6.02e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg15704280	chr7:45808275	SEPT13	-1.03	-12.98	-0.8	9.03e-23	Coronary artery disease;
THYM	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg23260525	chr10:116636907	FAM160B1	0.53	5.33	0.48	6.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs4343996	0.934	rs4495320	chr7:3369936	G/A	cg21248987	chr7:3385318	SDK1	-0.4	-4.8	-0.44	5.79e-6	Motion sickness;
THYM	cis	rs7119	0.717	rs12904348	chr15:77815738	G/C	cg27398640	chr15:77910606	LINGO1	-0.57	-5.76	-0.51	1.03e-7	Type 2 diabetes;
THYM	cis	rs4660456	0.597	rs7518568	chr1:41174180	C/G	cg11417323	chr1:41160271	NFYC	0.42	4.69	0.43	9.05e-6	Platelet count;
THYM	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg20503657	chr10:835505	NA	0.94	5.16	0.47	1.33e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg06968155	chr5:131705112	SLC22A5	-0.59	-4.61	-0.43	1.23e-5	Blood metabolite levels;
THYM	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.29	9.73	0.71	6.33e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg03517284	chr6:25882590	NA	-0.68	-4.49	-0.42	1.98e-5	Height;
THYM	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg18681998	chr4:17616180	MED28	1.01	10.48	0.73	1.53e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6988636	1.000	rs57902736	chr8:124189893	G/A	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs4654899	0.965	rs17418249	chr1:21390582	C/T	cg01072550	chr1:21505969	NA	-0.71	-6.29	-0.54	9.47e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg03388025	chr16:89894329	SPIRE2	0.55	4.76	0.44	7e-6	Vitiligo;
THYM	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg11965913	chr1:205819406	PM20D1	-0.61	-4.84	-0.44	5.08e-6	Menarche (age at onset);
THYM	cis	rs12791968	0.659	rs12808379	chr11:45009273	C/G	cg11846598	chr11:44996168	LOC221122	-0.79	-5.84	-0.51	7.17e-8	Inhibitory control;
THYM	cis	rs59698941	0.550	rs11748737	chr5:132201070	C/T	cg27099455	chr5:132201840	GDF9;UQCRQ	0.53	4.61	0.43	1.26e-5	Apolipoprotein A-IV levels;
THYM	cis	rs485842	1.000	rs477612	chr11:96026835	C/T	cg23866687	chr11:96026956	MAML2	0.45	6.36	0.55	6.98e-9	Corneal astigmatism;
THYM	cis	rs8033133	0.560	rs12441340	chr15:25323964	G/T	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.64	-4.7	-0.43	8.67e-6	Blood osmolality (transformed sodium);
THYM	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11048434	0.736	rs1805724	chr12:9104609	T/C	cg13575925	chr12:9217583	LOC144571	0.52	4.97	0.45	2.96e-6	Sjögren's syndrome;
THYM	cis	rs7107174	1.000	rs2511175	chr11:77975081	A/G	cg19901956	chr11:77921274	USP35	-0.69	-5.3	-0.48	7.42e-7	Testicular germ cell tumor;
THYM	cis	rs1018836	0.923	rs34126139	chr8:91572045	T/G	cg16814680	chr8:91681699	NA	-0.75	-6.17	-0.53	1.69e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.77	0.51	1.01e-7	Rheumatoid arthritis;
THYM	cis	rs4731207	0.565	rs1904972	chr7:124669687	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.09	-0.46	1.78e-6	Cutaneous malignant melanoma;
THYM	cis	rs2130392	0.926	rs1107907	chr4:185620108	G/T	cg04058563	chr4:185651563	MLF1IP	0.61	6.13	0.53	1.98e-8	Kawasaki disease;
THYM	cis	rs17253792	0.822	rs75897560	chr14:56090965	C/T	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs57920188	0.585	rs6696138	chr1:4073575	G/A	cg20703997	chr1:4087676	NA	1.05	7.6	0.61	2.11e-11	Interleukin-17 levels;
THYM	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs3760982	0.585	rs67773424	chr19:44293994	G/A	cg11993925	chr19:44307056	LYPD5	0.64	5.0	0.46	2.64e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg18681998	chr4:17616180	MED28	0.85	7.68	0.62	1.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs611744	0.967	rs598022	chr8:109187759	C/T	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs965469	0.895	rs6051844	chr20:3402674	G/T	cg25506879	chr20:3388711	C20orf194	0.79	5.05	0.46	2.16e-6	IFN-related cytopenia;
THYM	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg27211696	chr2:191398769	TMEM194B	-0.83	-8.06	-0.64	2.24e-12	Pulse pressure;
THYM	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg26038318	chr20:34205095	SPAG4	0.59	4.65	0.43	1.08e-5	Total cholesterol levels;
THYM	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.14	-0.64	1.54e-12	Mean corpuscular volume;
THYM	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	5.59	0.5	2.16e-7	Monocyte percentage of white cells;
THYM	cis	rs2281845	0.826	rs4915484	chr1:201076917	C/G	cg17810781	chr1:201082982	CACNA1S	0.53	5.36	0.48	5.78e-7	Permanent tooth development;
THYM	cis	rs56104184	0.830	rs28556985	chr19:49351149	C/T	cg16594139	chr19:49340574	PLEKHA4;HSD17B14	1.04	5.75	0.51	1.07e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7100689	0.622	rs1417221	chr10:82100428	G/A	cg01528321	chr10:82214614	TSPAN14	0.84	6.43	0.55	5.15e-9	Post bronchodilator FEV1;
THYM	cis	rs9359856	0.913	rs9362665	chr6:90309844	C/T	cg13799429	chr6:90582589	CASP8AP2	0.48	4.69	0.43	9.31e-6	Bipolar disorder;
THYM	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg23187316	chr7:1099788	C7orf50	0.59	4.49	0.42	2.01e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4951011	0.706	rs4364935	chr1:203759009	C/T	cg24343524	chr1:203763352	ZC3H11A	0.71	6.05	0.53	2.9e-8	Breast cancer;
THYM	cis	rs7209460	0.556	rs2316513	chr17:1988377	A/T	cg15816464	chr17:2026533	SMG6	0.39	4.73	0.44	7.69e-6	Coronary artery disease;Total body bone mineral density;
THYM	cis	rs7943358	0.955	rs1466553	chr11:15726208	C/G	cg11966998	chr11:15692519	NA	-0.46	-4.6	-0.43	1.32e-5	Gut microbiome composition (summer);
THYM	cis	rs9633835	0.832	rs4757144	chr11:13331226	C/T	cg13286116	chr11:13302098	ARNTL	-0.67	-7.07	-0.59	2.58e-10	Body mass index;
THYM	cis	rs1005224	0.853	rs9323616	chr14:76151697	T/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.71	-5.83	-0.51	7.54e-8	Large artery stroke;
THYM	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.49	0.49	3.33e-7	Platelet count;
THYM	cis	rs9646944	0.531	rs17027029	chr2:102990648	G/C	cg01241218	chr2:102972058	NA	0.82	5.35	0.48	6.02e-7	Blood protein levels;
THYM	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg26384229	chr12:38710491	ALG10B	-0.74	-5.8	-0.51	8.85e-8	Bladder cancer;
THYM	cis	rs13256369	0.851	rs13267036	chr8:8566685	G/A	cg18904891	chr8:8559673	CLDN23	0.68	5.03	0.46	2.35e-6	Obesity-related traits;
THYM	cis	rs7809950	0.817	rs62483725	chr7:107201575	G/A	cg23024343	chr7:107201750	COG5	-1.05	-9.25	-0.69	6.47e-15	Coronary artery disease;
THYM	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.14	0.59	1.83e-10	Obesity-related traits;
THYM	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg23815491	chr16:72088622	HP	0.78	6.13	0.53	1.98e-8	Fibrinogen levels;
THYM	cis	rs13064411	0.696	rs9836396	chr3:113184282	T/C	cg10517650	chr3:113235015	CCDC52	-0.56	-4.99	-0.46	2.74e-6	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7705502	0.644	rs6882088	chr5:173294176	A/G	cg18693985	chr5:173351052	CPEB4	-0.79	-5.72	-0.51	1.24e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs4533251	0.607	rs4439725	chr15:97247494	A/G	cg14021153	chr15:96884532	NA	0.53	4.49	0.42	2e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs6748734	0.625	rs4312489	chr2:241821068	T/A	cg02820040	chr2:241836501	C2orf54	-0.24	-4.5	-0.42	1.94e-5	Urinary metabolites;
THYM	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg09367891	chr1:107599246	PRMT6	0.72	5.16	0.47	1.32e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs9399401	0.667	rs7757571	chr6:142702589	A/C	cg04461802	chr6:142623433	GPR126	0.77	7.46	0.61	3.98e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs3820068	0.608	rs7519899	chr1:16045579	A/G	cg13390004	chr1:15929781	NA	0.64	4.86	0.45	4.68e-6	Systolic blood pressure;
THYM	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1878931	0.543	rs17612463	chr16:3420479	G/C	cg00484396	chr16:3507460	NAT15	-0.48	-4.62	-0.43	1.2e-5	Body mass index (adult);
THYM	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg15445000	chr17:37608096	MED1	0.41	4.97	0.45	2.96e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs11009175	0.615	rs6481817	chr10:33299247	C/T	cg00146027	chr10:33299147	NA	-0.68	-5.13	-0.47	1.55e-6	Depression (quantitative trait);
THYM	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg24060327	chr5:131705240	SLC22A5	-0.81	-6.71	-0.57	1.4e-9	Breast cancer;
THYM	cis	rs62064224	0.703	rs4287613	chr17:30827688	C/T	cg18200150	chr17:30822561	MYO1D	0.85	8.21	0.64	1.08e-12	Schizophrenia;
THYM	cis	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg17333051	chr19:2783644	SGTA	0.61	5.6	0.5	2.08e-7	Total cholesterol levels;
THYM	cis	rs3796352	0.527	rs11714793	chr3:52924930	A/G	cg24530246	chr3:53118167	NA	-0.66	-4.59	-0.43	1.36e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg03433033	chr1:76189801	ACADM	0.77	9.42	0.69	2.92e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9296092	0.538	rs9469488	chr6:33517117	G/T	cg13560919	chr6:33536144	NA	-0.94	-9.16	-0.68	1.03e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs7804356	0.822	rs6971397	chr7:26782564	C/T	cg24979288	chr7:27242424	NA	0.62	4.46	0.42	2.26e-5	Type 1 diabetes;
THYM	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg15693483	chr7:1102177	C7orf50	0.54	6.26	0.54	1.1e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg25703541	chr22:24373054	LOC391322	-0.87	-9.37	-0.69	3.65e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4262150	0.883	rs12652844	chr5:152315418	T/C	cg06854687	chr5:151642065	NA	0.68	4.82	0.44	5.34e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17401966	1.000	rs4846210	chr1:10322153	A/G	cg20482658	chr1:10539492	PEX14	0.39	4.66	0.43	1.04e-5	Hepatocellular carcinoma;
THYM	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	6.01	0.53	3.35e-8	Hip circumference adjusted for BMI;
THYM	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs4148689	1.000	rs10487369	chr7:117174804	T/A	cg17204129	chr7:117119601	CFTR	-0.66	-5.07	-0.46	1.96e-6	Gout;
THYM	cis	rs2806561	0.929	rs6669568	chr1:23540469	G/A	cg12483005	chr1:23474871	LUZP1	-0.54	-5.48	-0.49	3.54e-7	Height;
THYM	cis	rs9399401	0.710	rs12197866	chr6:142706063	C/T	cg03128060	chr6:142623767	GPR126	0.7	9.47	0.7	2.29e-15	Chronic obstructive pulmonary disease;
THYM	cis	rs4851266	0.898	rs12614880	chr2:100849341	A/G	cg14675211	chr2:100938903	LONRF2	0.64	5.04	0.46	2.19e-6	Educational attainment;
THYM	cis	rs9296092	0.517	rs11752179	chr6:33534713	G/T	cg13560919	chr6:33536144	NA	-0.93	-9.1	-0.68	1.38e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs4243830	0.850	rs7536908	chr1:6607814	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.06	-6.84	-0.57	7.66e-10	Body mass index;
THYM	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.19	0.54	1.52e-8	Coronary artery disease;
THYM	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.67	-5.18	-0.47	1.22e-6	Tonsillectomy;
THYM	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg05294307	chr14:35346193	BAZ1A	-0.83	-5.54	-0.49	2.64e-7	Psoriasis;
THYM	cis	rs7814319	0.870	rs2292836	chr8:97239613	A/C	cg20787634	chr8:97240163	UQCRB	-0.78	-9.51	-0.7	1.84e-15	Lung function (FVC);
THYM	cis	rs1065852	0.526	rs2413663	chr22:42402399	T/A	cg01059385	chr22:42394853	WBP2NL	0.57	4.66	0.43	1.04e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs36051895	0.658	rs12346093	chr9:5021140	T/A	cg02405213	chr9:5042618	JAK2	-1.02	-10.36	-0.73	2.83e-17	Pediatric autoimmune diseases;
THYM	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg23682913	chr1:2080710	PRKCZ	0.57	4.91	0.45	3.79e-6	Height;
THYM	cis	rs3862030	0.720	rs3740415	chr10:104232716	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.71	-5.96	-0.52	4.3e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs899997	1.000	rs12904489	chr15:79033925	T/A	cg04896959	chr15:78267971	NA	0.91	7.28	0.6	9.49e-11	Coronary artery disease or large artery stroke;
THYM	cis	rs62045844	0.510	rs7201122	chr16:89167140	G/C	cg06035645	chr16:89190857	ACSF3	-0.82	-4.94	-0.45	3.4e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg23711669	chr6:146136114	FBXO30	-0.98	-10.55	-0.73	1.11e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs920590	0.758	rs1826420	chr8:19664878	G/T	cg01411142	chr8:19674711	INTS10	0.64	4.85	0.45	4.81e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg06481639	chr22:41940642	POLR3H	-0.82	-5.68	-0.5	1.49e-7	Vitiligo;
THYM	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.75	-6.14	-0.53	1.92e-8	Blood metabolite levels;
THYM	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg03433033	chr1:76189801	ACADM	0.76	8.16	0.64	1.4e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1007190	0.881	rs6503406	chr17:42937105	C/T	cg15406952	chr17:42872593	NA	0.8	5.57	0.5	2.34e-7	DNA methylation (variation);
THYM	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg09184832	chr6:79620586	NA	-0.58	-4.53	-0.42	1.73e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg03433033	chr1:76189801	ACADM	0.78	10.75	0.74	4.24e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs10203711	1.000	rs4994753	chr2:239567253	T/C	cg14580085	chr2:239553406	NA	0.68	6.18	0.54	1.6e-8	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs877282	0.685	rs56234340	chr10:781339	A/G	cg22713356	chr15:30763199	NA	1.29	11.03	0.75	1.04e-18	Uric acid levels;
THYM	cis	rs9378357	0.510	rs4286820	chr6:3281392	C/T	cg08754725	chr6:3293098	SLC22A23	0.66	4.85	0.45	4.87e-6	Obesity-related traits;
THYM	cis	rs8041943	0.634	rs10519268	chr15:79924428	G/A	cg20511832	chr15:78934280	CHRNB4	0.42	4.82	0.44	5.4e-6	Bone mineral density (spine) and age at menarche;
THYM	cis	rs360798	0.532	rs7573756	chr2:62990637	G/A	cg17519650	chr2:63277830	OTX1	-0.68	-4.57	-0.42	1.44e-5	Coronary artery disease;
THYM	cis	rs12410462	0.502	rs78101727	chr1:227732069	C/T	cg23173402	chr1:227635558	NA	0.88	6.46	0.55	4.39e-9	Major depressive disorder;
THYM	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg23260525	chr10:116636907	FAM160B1	0.53	5.44	0.49	4.17e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.15	-5.7	-0.5	1.37e-7	Schizophrenia;
THYM	cis	rs892961	0.899	rs66749226	chr17:75412826	G/A	cg05865280	chr17:75406074	SEPT9	0.48	8.22	0.64	1.06e-12	Airflow obstruction;
THYM	cis	rs9527	0.641	rs10786732	chr10:104762535	T/C	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg09367891	chr1:107599246	PRMT6	0.7	4.7	0.43	8.81e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg07936489	chr17:37558343	FBXL20	0.82	5.61	0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2046867	0.862	rs62251656	chr3:72827393	T/C	cg25664220	chr3:72788482	NA	-0.87	-6.62	-0.56	2.14e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs981844	0.775	rs17371468	chr4:154759826	G/C	cg09973105	chr4:154681532	RNF175	-0.62	-5.1	-0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg03188948	chr7:1209495	NA	0.92	5.2	0.47	1.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs735396	1.000	rs1169313	chr12:121442670	C/T	cg02403541	chr12:121454288	C12orf43	-0.58	-4.71	-0.44	8.36e-6	N-glycan levels;
THYM	cis	rs7582180	0.764	rs13006224	chr2:100917109	C/T	cg21926883	chr2:100939477	LONRF2	-0.62	-5.64	-0.5	1.75e-7	Intelligence (multi-trait analysis);
THYM	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg03709012	chr19:19516395	GATAD2A	0.85	7.08	0.59	2.49e-10	Tonsillectomy;
THYM	cis	rs4950928	0.823	rs2486065	chr1:203167871	A/G	cg17014757	chr1:203156097	CHI3L1	-0.98	-5.5	-0.49	3.13e-7	YKL-40 levels;
THYM	cis	rs17818399	0.890	rs34544165	chr2:46836906	A/G	cg09399716	chr2:46890238	NA	-0.53	-4.86	-0.45	4.67e-6	Height;
THYM	cis	rs4654899	0.897	rs10799668	chr1:21169385	T/C	cg01072550	chr1:21505969	NA	0.7	6.44	0.55	4.8e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs62158800	0.568	rs62161312	chr2:108346567	C/T	cg10013287	chr2:108537568	NA	1.2	5.61	0.5	1.97e-7	Facial morphology (factor 22);
THYM	cis	rs10927875	0.726	rs1763603	chr1:16339809	T/C	cg22431228	chr1:16359049	CLCNKA	-0.52	-4.98	-0.45	2.86e-6	Dilated cardiomyopathy;
THYM	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg24531977	chr5:56204891	C5orf35	-0.69	-5.33	-0.48	6.72e-7	Coronary artery disease;
THYM	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	5.51	0.49	3.1e-7	Schizophrenia;
THYM	cis	rs7677751	0.806	rs60806423	chr4:55086816	C/T	cg17187183	chr4:55093834	PDGFRA	0.72	5.59	0.5	2.19e-7	Corneal astigmatism;
THYM	cis	rs6964587	0.839	rs13246743	chr7:91453945	G/T	cg17063962	chr7:91808500	NA	1.15	11.08	0.75	8.21e-19	Breast cancer;
THYM	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg23682913	chr1:2080710	PRKCZ	-0.6	-4.79	-0.44	6.06e-6	Height;
THYM	cis	rs67311347	0.544	rs6787516	chr3:40355616	C/T	cg13683864	chr3:40499215	RPL14	-0.71	-6.29	-0.54	9.68e-9	Renal cell carcinoma;
THYM	cis	rs835154	0.817	rs835157	chr5:14874533	T/C	cg11792786	chr5:14870083	ANKH	-0.45	-4.83	-0.44	5.27e-6	Blood metabolite levels;
THYM	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.28	6.37	0.55	6.77e-9	Obesity-related traits;
THYM	cis	rs1403694	0.515	rs1656925	chr3:186449123	T/C	cg12454167	chr3:186435060	KNG1	0.44	5.89	0.52	5.76e-8	Blood protein levels;
THYM	cis	rs7584330	0.554	rs7598559	chr2:238435398	A/G	cg14458575	chr2:238380390	NA	-0.81	-4.86	-0.45	4.63e-6	Prostate cancer;
THYM	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.93	-7.16	-0.59	1.73e-10	Multiple sclerosis;
THYM	cis	rs8070740	0.898	rs8074617	chr17:5323989	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.72	6.03	0.53	3.15e-8	Menopause (age at onset);
THYM	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg03929089	chr4:120376271	NA	-1.03	-8.74	-0.67	8.32e-14	Coronary artery disease;
THYM	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg20295408	chr7:1910781	MAD1L1	-0.69	-5.0	-0.46	2.59e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6882076	1.000	rs12517431	chr5:156392248	C/T	cg12943317	chr5:156479607	HAVCR1	-0.72	-5.96	-0.52	4.36e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs3892630	0.824	rs34748593	chr19:33240447	T/C	cg22980127	chr19:33182716	NUDT19	1.14	9.23	0.69	7.47e-15	Red blood cell traits;
THYM	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06634786	chr22:41940651	POLR3H	0.84	6.24	0.54	1.21e-8	Vitiligo;
THYM	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg11366901	chr6:160182831	ACAT2	1.09	10.12	0.72	9.06e-17	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9972944	0.902	rs10512503	chr17:63772066	G/A	cg07283582	chr17:63770753	CCDC46	0.67	5.41	0.49	4.74e-7	Total body bone mineral density;
THYM	cis	rs13102973	0.899	rs4479760	chr4:135867474	T/C	cg14419869	chr4:135874104	NA	0.88	8.62	0.66	1.45e-13	Subjective well-being;
THYM	cis	rs739496	0.542	rs7399113	chr12:111792848	G/A	cg10833066	chr12:111807467	FAM109A	0.52	5.92	0.52	5e-8	Platelet count;
THYM	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8180040	0.800	rs11920354	chr3:47262246	C/A	cg27129171	chr3:47204927	SETD2	-0.74	-7.05	-0.59	2.85e-10	Colorectal cancer;
THYM	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.96e-6	Resting heart rate;
THYM	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06850241	chr22:41845214	NA	-0.61	-5.46	-0.49	3.73e-7	Vitiligo;
THYM	cis	rs17407555	0.821	rs4292329	chr4:10144459	C/G	cg00071950	chr4:10020882	SLC2A9	-0.76	-5.68	-0.5	1.45e-7	Schizophrenia (age at onset);
THYM	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-11.3	-0.76	2.81e-19	Height;
THYM	cis	rs2227564	0.649	rs2688626	chr10:75611090	G/A	cg00564723	chr10:75632066	CAMK2G	-0.52	-5.19	-0.47	1.19e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs921968	0.529	rs6729341	chr2:219611434	T/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg12963246	chr6:28129442	ZNF389	0.54	4.77	0.44	6.6e-6	Parkinson's disease;
THYM	cis	rs1267303	0.798	rs1267304	chr1:46990426	C/T	cg25110126	chr1:46999211	NA	-0.82	-6.23	-0.54	1.24e-8	Monobrow;
THYM	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg15556689	chr8:8085844	FLJ10661	0.66	5.2	0.47	1.15e-6	Joint mobility (Beighton score);
THYM	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg06917634	chr15:78832804	PSMA4	-0.91	-7.9	-0.63	4.85e-12	Sudden cardiac arrest;
THYM	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg19418458	chr7:158789849	NA	-0.62	-5.83	-0.51	7.66e-8	Facial morphology (factor 20);
THYM	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg26441486	chr22:50317300	CRELD2	0.45	7.6	0.62	2.04e-11	Schizophrenia;
THYM	cis	rs28647808	1.000	rs28690644	chr9:136269669	A/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs4851254	0.660	rs60697219	chr2:100699507	G/A	cg22139774	chr2:100720529	AFF3	-0.41	-4.69	-0.43	9.07e-6	Intelligence (multi-trait analysis);
THYM	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg11526020	chr17:80870163	TBCD	0.44	4.55	0.42	1.57e-5	Breast cancer;
THYM	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg11764359	chr7:65958608	NA	0.7	4.79	0.44	6.21e-6	Aortic root size;
THYM	cis	rs12310956	0.510	rs7301767	chr12:33886529	A/T	cg10856724	chr12:34555212	NA	-0.64	-5.78	-0.51	9.56e-8	Morning vs. evening chronotype;
THYM	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg23791538	chr6:167370224	RNASET2	-0.75	-5.86	-0.51	6.8e-8	Crohn's disease;
THYM	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg04772025	chr11:68637568	NA	0.6	6.22	0.54	1.35e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2898681	0.581	rs730246	chr4:53680719	T/C	cg00338735	chr4:53728038	RASL11B	0.6	5.56	0.5	2.5e-7	Optic nerve measurement (cup area);
THYM	cis	rs10911232	0.507	rs10797820	chr1:183011366	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg00990874	chr7:1149470	C7orf50	-0.61	-4.64	-0.43	1.12e-5	Bronchopulmonary dysplasia;
THYM	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	6.49	0.55	3.94e-9	Obesity-related traits;
THYM	cis	rs7705502	1.000	rs747472	chr5:173353514	T/C	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg02734326	chr4:10020555	SLC2A9	0.76	6.89	0.58	6.16e-10	Bone mineral density;
THYM	cis	rs16917546	1.000	rs12768538	chr10:64406358	C/G	cg03961010	chr10:64397487	ZNF365	0.79	6.57	0.56	2.64e-9	Basal cell carcinoma;
THYM	cis	rs9790314	0.934	rs461638	chr3:161103166	A/G	cg04691961	chr3:161091175	C3orf57	-0.57	-4.93	-0.45	3.55e-6	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	5.92	0.52	5.15e-8	Total body bone mineral density;
THYM	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg08847533	chr14:75593920	NEK9	0.97	10.6	0.74	8.61e-18	Height;
THYM	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg04546413	chr19:29218101	NA	0.71	4.45	0.42	2.34e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg25358565	chr5:93447407	FAM172A	-0.97	-7.06	-0.59	2.76e-10	Diabetic retinopathy;
THYM	cis	rs6840360	0.617	rs2724564	chr4:152349962	G/T	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg10018233	chr7:150070692	REPIN1	-0.5	-7.76	-0.62	9.42e-12	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg09455208	chr3:40491958	NA	0.5	5.2	0.47	1.13e-6	Renal cell carcinoma;
THYM	cis	rs12530845	0.623	rs7798256	chr7:135344211	C/A	cg23117316	chr7:135346802	PL-5283	-0.77	-5.88	-0.52	6.18e-8	Red blood cell traits;
THYM	cis	rs9393692	0.620	rs6930616	chr6:26331969	A/G	cg13736514	chr6:26305472	NA	-0.46	-4.7	-0.43	8.63e-6	Educational attainment;
THYM	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2506889	0.553	rs7548453	chr1:10589836	A/G	cg20482658	chr1:10539492	PEX14	-0.37	-5.94	-0.52	4.75e-8	Breast cancer;
THYM	trans	rs9929218	0.520	rs1078621	chr16:68778996	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.97	10.51	0.73	1.32e-17	Colorectal cancer;
THYM	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg07936489	chr17:37558343	FBXL20	0.85	5.64	0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs4072980	0.545	rs7519947	chr1:38447725	T/C	cg04673462	chr1:38461896	NA	-0.43	-5.35	-0.48	6.2e-7	Coronary artery disease;
THYM	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg22079354	chr11:130786696	SNX19	0.53	4.85	0.45	4.9100000000000004e-06	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7122539	0.506	rs11227625	chr11:66684151	T/G	cg04006266	chr11:66300458	BBS1	0.44	4.97	0.45	3e-6	HIV-1 susceptibility;
THYM	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12516959	chr21:47718080	NA	-0.48	-6.03	-0.53	3.18e-8	Testicular germ cell tumor;
THYM	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-4.46	-0.42	2.21e-5	Monocyte percentage of white cells;
THYM	cis	rs977987	0.806	rs12933281	chr16:75483064	T/G	cg03315344	chr16:75512273	CHST6	0.72	5.72	0.51	1.21e-7	Dupuytren's disease;
THYM	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg02018176	chr4:1364513	KIAA1530	0.56	4.95	0.45	3.19e-6	Obesity-related traits;
THYM	cis	rs9906944	0.641	rs11655587	chr17:47140794	C/T	cg14634687	chr17:47094252	IGF2BP1	0.28	4.5	0.42	1.9e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7189233	0.910	rs3809634	chr16:53538157	A/G	cg02965178	chr16:53538660	AKTIP	-0.65	-5.5	-0.49	3.25e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7000551	0.779	rs2443507	chr8:22373231	G/A	cg12081754	chr8:22256438	SLC39A14	0.63	5.71	0.51	1.27e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7578361	0.885	rs7571890	chr2:150419893	T/C	cg17961725	chr2:150454027	NA	0.71	6.01	0.52	3.43e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs28595532	0.920	rs115085630	chr4:119741765	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs4919087	0.962	rs10748694	chr10:99056190	A/T	cg19453742	chr10:98862320	SLIT1	-0.65	-5.02	-0.46	2.36e-6	Monocyte count;
THYM	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg18402987	chr7:1209562	NA	0.61	4.7	0.43	8.83e-6	Longevity;Endometriosis;
THYM	cis	rs854765	0.623	rs9893690	chr17:17753846	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.66	-5.87	-0.52	6.43e-8	Total body bone mineral density;
THYM	cis	rs9303401	0.573	rs67378767	chr17:57194237	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.14	8.32	0.65	6.27e-13	Cognitive test performance;
THYM	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg07362569	chr17:61921086	SMARCD2	0.73	6.43	0.55	5.01e-9	Prudent dietary pattern;
THYM	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-9.8	-0.71	4.48e-16	Height;
THYM	cis	rs7582180	0.663	rs4850929	chr2:100990707	A/C	cg21926883	chr2:100939477	LONRF2	-0.65	-6.1	-0.53	2.25e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1878931	0.535	rs7188903	chr16:3412861	A/G	cg00484396	chr16:3507460	NAT15	-0.47	-4.56	-0.42	1.55e-5	Body mass index (adult);
THYM	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	6.36	0.55	6.96e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg10760299	chr15:45669010	GATM	-0.81	-6.61	-0.56	2.25e-9	Homoarginine levels;
THYM	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg09307838	chr4:120376055	NA	0.68	4.93	0.45	3.47e-6	Corneal astigmatism;
THYM	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg11861562	chr11:117069780	TAGLN	0.31	4.5	0.42	1.91e-5	Blood protein levels;
THYM	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg08885076	chr2:99613938	TSGA10	0.52	5.04	0.46	2.24e-6	Chronic sinus infection;
THYM	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg23281280	chr6:28129359	ZNF389	0.66	5.09	0.46	1.78e-6	Depression;
THYM	cis	rs6087990	0.735	rs4911261	chr20:31391360	A/G	cg13636640	chr20:31349939	DNMT3B	0.9	9.45	0.7	2.46e-15	Ulcerative colitis;
THYM	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg22508957	chr16:3507546	NAT15	0.48	4.85	0.45	4.74e-6	Body mass index (adult);
THYM	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.9	-0.45	4.01e-6	Monocyte count;
THYM	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg25072359	chr17:41440525	NA	0.72	5.37	0.48	5.5e-7	Menopause (age at onset);
THYM	cis	rs2797160	1.000	rs77678056	chr6:126019738	A/G	cg16306078	chr6:126000798	NA	0.54	5.45	0.49	3.94e-7	Endometrial cancer;
THYM	cis	rs17818399	0.633	rs2242033	chr2:46842410	A/G	cg09399716	chr2:46890238	NA	-0.46	-4.6	-0.43	1.28e-5	Height;
THYM	cis	rs13126513	0.642	rs2851025	chr4:100437553	C/T	cg05468953	chr4:100565104	NA	0.68	5.75	0.51	1.06e-7	Metabolite levels (MHPG);
THYM	cis	rs4930776	0.900	rs398270	chr12:5759790	C/T	cg02086166	chr12:5775618	ANO2	0.61	6.07	0.53	2.57e-8	Plasma clusterin levels;
THYM	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg00255919	chr5:131827918	IRF1	0.47	5.21	0.47	1.1e-6	Asthma (sex interaction);
THYM	cis	rs17001868	0.568	rs9607701	chr22:40739116	A/G	cg07138101	chr22:40742427	ADSL	0.94	5.71	0.51	1.3e-7	Mammographic density (dense area);
THYM	cis	rs2219968	0.962	rs6473079	chr8:78928787	A/G	cg00738934	chr8:78996279	NA	0.8	8.65	0.66	1.27e-13	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg22433210	chr17:43662623	NA	-1.05	-8.08	-0.64	2e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg06808227	chr14:105710500	BRF1	-1.03	-8.94	-0.68	3.05e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4595586	0.525	rs3914597	chr12:39388693	G/A	cg26384229	chr12:38710491	ALG10B	0.69	5.19	0.47	1.18e-6	Morning vs. evening chronotype;
THYM	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg26736099	chr17:61989275	CSHL1	0.29	4.72	0.44	8.2e-6	Prudent dietary pattern;
THYM	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg22166914	chr1:53195759	ZYG11B	0.91	10.68	0.74	5.96e-18	Monocyte count;
THYM	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs73086581	1.000	rs56324992	chr20:3978153	C/A	cg02187196	chr20:3869020	PANK2	0.49	5.42	0.49	4.48e-7	Response to antidepressants in depression;
THYM	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg06600287	chr1:53387719	ECHDC2	-0.35	-5.71	-0.51	1.31e-7	Monocyte count;
THYM	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35883536	1.000	rs1610387	chr1:101123943	T/G	cg06223162	chr1:101003688	GPR88	0.66	4.9	0.45	3.94e-6	Monocyte count;
THYM	cis	rs8063160	0.533	rs58656226	chr16:89745091	T/G	cg07984980	chr16:89898383	SPIRE2	1.33	5.49	0.49	3.33e-7	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg13319975	chr6:146136371	FBXO30	-0.69	-5.76	-0.51	1.02e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.93	-0.45	3.52e-6	Monocyte count;
THYM	trans	rs8073060	0.586	rs225300	chr17:33922428	C/T	cg19694781	chr19:47549865	TMEM160	-0.98	-8.52	-0.66	2.45e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs3126085	0.877	rs12133847	chr1:152170101	T/G	cg26020982	chr1:152196106	HRNR	0.34	4.52	0.42	1.76e-5	Atopic dermatitis;
THYM	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg01579765	chr21:45077557	HSF2BP	-0.5	-7.57	-0.61	2.41e-11	Mean corpuscular volume;
THYM	cis	rs11690935	0.632	rs12998411	chr2:172530707	G/C	cg13550731	chr2:172543902	DYNC1I2	0.61	4.79	0.44	6.05e-6	Schizophrenia;
THYM	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs7772486	0.754	rs1055212	chr6:146058315	A/T	cg23711669	chr6:146136114	FBXO30	-0.98	-10.55	-0.73	1.11e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11650494	0.808	rs76366926	chr17:47396628	T/C	cg08112188	chr17:47440006	ZNF652	1.25	5.41	0.49	4.62e-7	Prostate cancer;
THYM	cis	rs828999	0.688	rs10218769	chr1:108713244	T/C	cg24323958	chr1:108741884	SLC25A24	0.57	5.61	0.5	1.97e-7	Monocyte percentage of white cells;
THYM	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg06850241	chr22:41845214	NA	-0.53	-4.68	-0.43	9.67e-6	Vitiligo;
THYM	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg19875535	chr5:140030758	IK	0.58	4.54	0.42	1.63e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs8073060	0.586	rs9649	chr17:34050934	C/T	cg19694781	chr19:47549865	TMEM160	1.01	8.58	0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	trans	rs637571	0.607	rs589253	chr11:65693080	G/A	cg17712092	chr4:129076599	LARP1B	1.03	9.83	0.71	3.74e-16	Eosinophil percentage of white cells;
THYM	cis	rs9831754	1.000	rs9822043	chr3:78352113	T/C	cg06138941	chr3:78371609	NA	-0.66	-4.5	-0.42	1.95e-5	Calcium levels;
THYM	cis	rs870825	0.616	rs7683799	chr4:185632164	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.69	0.71	7.45e-16	Blood protein levels;
THYM	cis	rs250585	0.736	rs465193	chr16:23596983	A/G	cg00143387	chr16:23521605	GGA2	0.76	5.6	0.5	2.1e-7	Egg allergy;
THYM	cis	rs240764	0.817	rs11155606	chr6:101163915	T/C	cg21058520	chr6:100914733	NA	0.58	5.22	0.47	1.06e-6	Neuroticism;
THYM	cis	rs28785552	0.966	rs7247272	chr19:53236331	C/T	cg10871876	chr19:53194124	ZNF83	-0.82	-6.97	-0.58	4.11e-10	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg26441486	chr22:50317300	CRELD2	0.43	6.27	0.54	1.07e-8	Schizophrenia;
THYM	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.52	-5.92	-0.52	5.05e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs13315871	1.000	rs13076951	chr3:58436703	C/T	cg00563845	chr3:58318305	PXK	0.53	4.67	0.43	9.78e-6	Cholesterol, total;
THYM	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06634786	chr22:41940651	POLR3H	0.76	5.89	0.52	5.77e-8	Vitiligo;
THYM	cis	rs6596100	0.538	rs4705972	chr5:132179237	T/A	cg02081065	chr5:132209139	LEAP2	-0.96	-6.11	-0.53	2.22e-8	Breast cancer;
THYM	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg01416388	chr22:39784598	NA	-0.87	-6.83	-0.57	8.07e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.66	-5.26	-0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs16976116	0.951	rs9300	chr15:55489065	G/A	cg11288833	chr15:55489084	RSL24D1	0.69	4.49	0.42	2e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3126085	1.000	rs1858482	chr1:152306921	A/G	cg10321714	chr1:152280068	FLG	0.72	5.44	0.49	4.14e-7	Atopic dermatitis;
THYM	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg23505145	chr19:12996616	KLF1	1.0	10.12	0.72	9.12e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs990171	1.000	rs12712145	chr2:103008710	T/C	cg13897122	chr2:103039542	IL18RAP	-0.39	-4.79	-0.44	6.08e-6	Lymphocyte counts;
THYM	cis	rs11760633	0.607	rs11761457	chr7:1829228	C/T	cg23422044	chr7:1970798	MAD1L1	-0.63	-4.63	-0.43	1.14e-5	Coronary artery disease;
THYM	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg13683864	chr3:40499215	RPL14	-1.06	-11.92	-0.77	1.4e-20	Renal cell carcinoma;
THYM	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg00981070	chr1:2046702	PRKCZ	0.43	5.2	0.47	1.16e-6	Height;
THYM	cis	rs950880	0.710	rs56043441	chr2:103087383	C/T	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.74	-0.44	7.54e-6	Serum protein levels (sST2);
THYM	cis	rs62070183	0.882	rs17183295	chr17:31078272	C/T	cg02981443	chr17:31254875	TMEM98	-0.54	-4.87	-0.45	4.46e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg15693483	chr7:1102177	C7orf50	0.54	6.29	0.54	9.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg05347473	chr6:146136440	FBXO30	0.61	4.86	0.45	4.65e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6701037	0.566	rs4344281	chr1:175135376	C/T	cg17845761	chr1:175162550	KIAA0040	0.37	4.77	0.44	6.72e-6	Alcohol dependence;
THYM	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg15704280	chr7:45808275	SEPT13	-1.04	-14.05	-0.82	6.23e-25	Height;
THYM	cis	rs76935404	0.811	rs8100418	chr19:41414363	A/T	cg19493303	chr19:41414353	NA	0.56	5.05	0.46	2.16e-6	nicotine metabolite ratio in current smokers;
THYM	cis	rs593982	0.920	rs488170	chr11:65481544	T/C	cg08755490	chr11:65554678	OVOL1	1.29	4.66	0.43	1.03e-5	Atopic dermatitis;
THYM	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg03929089	chr4:120376271	NA	-1.01	-13.5	-0.81	8.23e-24	Height;
THYM	cis	rs3808502	0.527	rs56177149	chr8:11247298	G/A	cg21775007	chr8:11205619	TDH	0.63	5.0	0.46	2.59e-6	Neuroticism;
THYM	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.59	-0.5	2.15e-7	Menopause (age at onset);
THYM	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg11764359	chr7:65958608	NA	0.79	6.53	0.56	3.2e-9	Aortic root size;
THYM	cis	rs2281845	0.929	rs6413915	chr1:201091041	A/C	cg17810781	chr1:201082982	CACNA1S	-0.72	-7.7	-0.62	1.29e-11	Permanent tooth development;
THYM	cis	rs7809950	0.678	rs12670688	chr7:106821016	A/G	cg23024343	chr7:107201750	COG5	0.99	8.39	0.65	4.58e-13	Coronary artery disease;
THYM	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg00024416	chr22:24240387	NA	-0.71	-7.55	-0.61	2.67e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg05896524	chr21:47604654	C21orf56	-0.74	-5.2	-0.47	1.16e-6	Testicular germ cell tumor;
THYM	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-6.03	-0.53	3.09e-8	Joint mobility (Beighton score);
THYM	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg21100191	chr22:23484243	RTDR1	0.73	6.5	0.55	3.66e-9	Bone mineral density;
THYM	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg04248312	chr19:17393744	ANKLE1	-0.96	-12.86	-0.8	1.58e-22	Systemic lupus erythematosus;
THYM	cis	rs28595532	1.000	rs116030177	chr4:119650768	T/C	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs3087591	0.960	rs757384	chr17:29596135	C/T	cg24425628	chr17:29625626	OMG;NF1	0.68	5.88	0.52	6.13e-8	Hip circumference;
THYM	cis	rs7705502	0.641	rs7731717	chr5:173281685	T/C	cg18693985	chr5:173351052	CPEB4	-0.7	-4.89	-0.45	4.06e-6	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg26031613	chr14:104095156	KLC1	-0.67	-4.49	-0.42	2.04e-5	Body mass index;
THYM	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg24578937	chr1:2090814	PRKCZ	-0.56	-5.65	-0.5	1.67e-7	Height;
THYM	trans	rs1973993	0.567	rs2800433	chr1:96998126	T/A	cg10631902	chr5:14652156	NA	0.64	7.02	0.58	3.34e-10	Weight;
THYM	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2033711	0.622	rs975947	chr19:58898193	C/T	cg13877915	chr19:58951672	ZNF132	0.54	4.46	0.42	2.23e-5	Uric acid clearance;
THYM	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg09323728	chr8:95962352	TP53INP1	-0.45	-4.67	-0.43	9.99e-6	Type 2 diabetes;
THYM	cis	rs490234	0.812	rs13286111	chr9:128429951	A/T	cg14078157	chr9:128172775	NA	-0.66	-5.01	-0.46	2.48e-6	Mean arterial pressure;
THYM	cis	rs7589728	0.563	rs12479338	chr2:88444513	C/T	cg04511125	chr2:88470314	THNSL2	0.66	4.62	0.43	1.21e-5	Plasma clusterin levels;
THYM	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg17063962	chr7:91808500	NA	0.96	7.5	0.61	3.38e-11	Breast cancer;
THYM	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs447921	0.813	rs34234366	chr17:74398510	C/A	cg17201438	chr17:74438067	UBE2O	0.81	5.85	0.51	6.9e-8	Mitochondrial DNA levels;
THYM	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.27	-0.65	8.15e-13	Mean corpuscular volume;
THYM	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	-0.72	-5.19	-0.47	1.21e-6	Prostate cancer;
THYM	cis	rs9527	0.545	rs7915816	chr10:104881750	A/G	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs6541297	1.000	rs6541297	chr1:230283506	G/A	cg20703242	chr1:230279135	GALNT2	0.94	6.24	0.54	1.2e-8	Coronary artery disease;
THYM	cis	rs1978968	1.000	rs2099942	chr22:18438314	A/C	cg01550578	chr22:18484421	MICAL3	0.69	5.26	0.47	8.93e-7	Presence of antiphospholipid antibodies;
THYM	cis	rs28595532	0.841	rs115851302	chr4:119776504	C/T	cg21605333	chr4:119757512	SEC24D	1.67	6.17	0.53	1.69e-8	Cannabis dependence symptom count;
THYM	cis	rs6754311	0.593	rs1446584	chr2:136419961	C/T	cg23851026	chr2:136556271	LCT	-0.59	-5.62	-0.5	1.91e-7	Mosquito bite size;
THYM	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg04156016	chr5:1868137	NA	0.52	5.03	0.46	2.27e-6	Cardiovascular disease risk factors;
THYM	cis	rs7043114	0.525	rs10116241	chr9:95240546	T/C	cg14631576	chr9:95140430	CENPP	-0.82	-8.18	-0.64	1.27e-12	Height;
THYM	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg02734326	chr4:10020555	SLC2A9	0.77	6.88	0.58	6.26e-10	Bone mineral density;
THYM	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg02389323	chr16:88786976	FAM38A	0.93	5.75	0.51	1.07e-7	Plateletcrit;
THYM	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg14186256	chr22:23484241	RTDR1	0.96	9.43	0.7	2.76e-15	Bone mineral density;
THYM	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs1483890	0.962	rs1483891	chr3:69410416	G/C	cg08872313	chr3:69292290	FRMD4B	-0.33	-4.46	-0.42	2.23e-5	Resting heart rate;
THYM	cis	rs79387448	0.745	rs59694233	chr2:103116521	G/A	cg09003973	chr2:102972529	NA	0.78	4.85	0.45	4.84e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs899997	1.000	rs12899201	chr15:79033534	G/A	cg10852096	chr15:79043040	NA	-0.63	-4.46	-0.42	2.27e-5	Coronary artery disease or large artery stroke;
THYM	cis	rs995000	0.931	rs597078	chr1:62917857	G/A	cg06896770	chr1:63153194	DOCK7	0.91	7.48	0.61	3.73e-11	Triglyceride levels;
THYM	cis	rs6840360	0.571	rs28608620	chr4:152504791	C/T	cg17479576	chr4:152424074	FAM160A1	-0.79	-5.81	-0.51	8.22e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4077515	0.874	rs10781505	chr9:139271355	C/T	cg14115884	chr9:139300582	SDCCAG3	-0.76	-8.19	-0.64	1.21e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs586688	0.625	rs609396	chr1:201655233	C/T	cg14168733	chr1:201708718	NAV1	-0.6	-5.55	-0.49	2.61e-7	Obesity-related traits;
THYM	cis	rs9790314	0.690	rs4679930	chr3:160842875	C/G	cg03342759	chr3:160939853	NMD3	-0.6	-4.47	-0.42	2.18e-5	Morning vs. evening chronotype;
THYM	cis	rs11030122	0.702	rs10767715	chr11:3951409	G/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.59	-0.43	1.36e-5	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.68	0.5	1.45e-7	Height;
THYM	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.78	-4.47	-0.42	2.15e-5	Body mass index;
THYM	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11644478	chr21:40555479	PSMG1	0.99	7.85	0.63	6.25e-12	Cognitive function;
THYM	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg18806716	chr10:30721971	MAP3K8	0.52	5.22	0.47	1.07e-6	Inflammatory bowel disease;
THYM	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg03806693	chr22:41940476	POLR3H	-1.11	-8.99	-0.68	2.33e-14	Vitiligo;
THYM	cis	rs55665837	1.000	rs11023214	chr11:14436259	G/C	cg19336497	chr11:14380999	RRAS2	-0.64	-6.95	-0.58	4.63e-10	Vitamin D levels;
THYM	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.93	7.88	0.63	5.28e-12	Multiple sclerosis;
THYM	cis	rs56104184	0.830	rs17272658	chr19:49355405	C/T	cg15549821	chr19:49342101	PLEKHA4	-1.19	-6.1	-0.53	2.33e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs3796352	1.000	rs7645611	chr3:53125297	G/C	cg07884673	chr3:53033167	SFMBT1	0.93	4.65	0.43	1.09e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs3892630	0.588	rs1976501	chr19:33208155	C/T	cg22928329	chr19:33183273	NUDT19	-0.68	-5.31	-0.48	7.19e-7	Red blood cell traits;
THYM	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg00271210	chr6:167070053	RPS6KA2	-0.49	-5.05	-0.46	2.09e-6	Primary biliary cholangitis;
THYM	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg22166914	chr1:53195759	ZYG11B	0.78	7.28	0.6	9.69e-11	Monocyte count;
THYM	cis	rs7107174	1.000	rs11237460	chr11:78056274	G/A	cg19901956	chr11:77921274	USP35	-0.64	-5.3	-0.48	7.43e-7	Testicular germ cell tumor;
THYM	cis	rs72949976	0.646	rs1441169	chr2:214033530	A/G	cg08319019	chr2:214017104	IKZF2	0.63	4.94	0.45	3.29e-6	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg16778714	chr17:28903809	LRRC37B2	-0.76	-4.49	-0.42	2.03e-5	Body mass index;
THYM	cis	rs6840360	1.000	rs1105535	chr4:152605170	A/G	cg22705602	chr4:152727874	NA	-0.59	-6.33	-0.54	8.23e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg23989207	chr17:80870107	TBCD	0.62	5.24	0.47	9.74e-7	Glycated hemoglobin levels;
THYM	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg04455712	chr21:45112962	RRP1B	0.51	4.72	0.44	8.23e-6	Mean corpuscular volume;
THYM	cis	rs10463554	0.963	rs26821	chr5:102520400	A/C	cg23492399	chr5:102201601	PAM	-0.7	-5.16	-0.47	1.34e-6	Parkinson's disease;
THYM	cis	rs3126085	0.560	rs2525	chr1:152339064	A/G	cg10321714	chr1:152280068	FLG	-0.7	-5.19	-0.47	1.19e-6	Atopic dermatitis;
THYM	cis	rs9649213	0.593	rs56286037	chr7:98019522	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg07092213	chr7:1199455	ZFAND2A	-0.59	-4.6	-0.43	1.33e-5	Longevity;Endometriosis;
THYM	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.57	-4.62	-0.43	1.2e-5	Coronary artery disease;
THYM	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg06766960	chr11:133703094	NA	-0.49	-4.58	-0.43	1.42e-5	Childhood ear infection;
THYM	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg13695892	chr22:41940480	POLR3H	-0.84	-6.46	-0.55	4.45e-9	Vitiligo;
THYM	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg14779329	chr11:130786720	SNX19	0.49	5.07	0.46	1.98e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2777491	0.915	rs7178634	chr15:41634587	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.14	-12.89	-0.8	1.38e-22	Ulcerative colitis;
THYM	cis	rs9287719	0.746	rs6742448	chr2:10759126	G/A	cg03983476	chr2:10830698	NOL10	-0.58	-5.35	-0.48	6.15e-7	Prostate cancer;
THYM	cis	rs2456568	0.709	rs1546400	chr11:93639203	G/A	cg17595323	chr11:93583763	C11orf90	0.55	6.11	0.53	2.2e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7172809	0.548	rs79036117	chr15:77474832	G/A	cg22256960	chr15:77711686	NA	-0.65	-4.83	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg24675658	chr1:53192096	ZYG11B	-0.75	-5.75	-0.51	1.08e-7	Monocyte count;
THYM	trans	rs8073060	0.586	rs8074800	chr17:33979148	A/G	cg19694781	chr19:47549865	TMEM160	1.06	9.33	0.69	4.53e-15	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs4345220	0.553	rs4860999	chr4:41649717	G/C	cg15232654	chr4:41643107	LIMCH1	0.44	4.8	0.44	5.95e-6	Migraine with aura;
THYM	cis	rs76693355	0.850	rs61898345	chr11:120188964	A/C	cg09120934	chr11:120187999	POU2F3	-0.38	-4.57	-0.42	1.47e-5	Intraocular pressure;
THYM	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg25072359	chr17:41440525	NA	0.66	4.67	0.43	9.85e-6	Menopause (age at onset);
THYM	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg23887609	chr12:130822674	PIWIL1	-0.61	-4.59	-0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs13315871	0.929	rs1047335	chr3:58280942	A/G	cg12435725	chr3:58293450	RPP14	-0.48	-5.2	-0.47	1.16e-6	Cholesterol, total;
THYM	cis	rs6840360	0.550	rs6836343	chr4:152497564	A/G	cg22705602	chr4:152727874	NA	-0.77	-8.64	-0.66	1.36e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6009824	0.891	rs11090995	chr22:50085210	G/A	cg22070880	chr22:50098194	NA	0.67	4.75	0.44	7.1e-6	Natriuretic peptide levels;
THYM	cis	rs72712511	0.571	rs11100306	chr4:140767698	T/C	cg15010390	chr4:140216957	NDUFC1	0.63	4.78	0.44	6.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg11764359	chr7:65958608	NA	-0.81	-6.42	-0.55	5.45e-9	Aortic root size;
THYM	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg08508325	chr11:3079039	CARS	-0.53	-6.57	-0.56	2.64e-9	Longevity;
THYM	cis	rs912057	0.932	rs1294404	chr6:6735022	G/A	cg06612196	chr6:6737390	NA	0.66	8.63	0.66	1.43e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs9372253	0.678	rs6568644	chr6:110707820	C/T	cg00083206	chr6:110721305	DDO	-0.49	-5.41	-0.49	4.77e-7	Platelet distribution width;
THYM	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg17911788	chr17:44343683	NA	-0.75	-7.05	-0.59	2.81e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9790314	0.871	rs336561	chr3:161125305	C/T	cg03342759	chr3:160939853	NMD3	-0.81	-7.63	-0.62	1.78e-11	Morning vs. evening chronotype;
THYM	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg06191203	chr2:152266755	RIF1	0.75	4.59	0.43	1.34e-5	Lung cancer;
THYM	cis	rs6032067	0.929	rs36032462	chr20:43873088	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.72	-6.57	-0.56	2.73e-9	Blood protein levels;
THYM	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.53	-4.99	-0.46	2.68e-6	Lymphocyte counts;
THYM	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg21773646	chr17:80085082	CCDC57	-0.34	-4.91	-0.45	3.76e-6	Life satisfaction;
THYM	cis	rs61931739	0.890	rs1705750	chr12:34142648	C/T	cg06521331	chr12:34319734	NA	-0.7	-5.67	-0.5	1.52e-7	Morning vs. evening chronotype;
THYM	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs9790314	0.540	rs35462273	chr3:160991877	C/T	cg03342759	chr3:160939853	NMD3	-0.91	-7.79	-0.62	8.5e-12	Morning vs. evening chronotype;
THYM	cis	rs2294693	0.679	rs12200923	chr6:40970092	T/G	cg21128951	chr6:40996213	UNC5CL	0.62	4.56	0.42	1.55e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs2303759	0.709	rs2278405	chr19:49812403	A/C	cg22590775	chr19:49891494	CCDC155	-0.61	-4.73	-0.44	7.7e-6	Multiple sclerosis;
THYM	cis	rs7020830	0.830	rs12554976	chr9:37244505	G/T	cg14294708	chr9:37120828	ZCCHC7	1.21	14.14	0.82	4.17e-25	Schizophrenia;
THYM	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6563842	0.563	rs9603786	chr13:41316364	G/A	cg21288729	chr13:41239152	FOXO1	0.68	5.14	0.47	1.49e-6	Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
THYM	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.61	4.67	0.43	9.91e-6	Glycated hemoglobin levels;
THYM	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg08213375	chr14:104286397	PPP1R13B	0.46	4.85	0.45	4.9e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs2688608	0.592	rs3849967	chr10:75483366	C/T	cg19442545	chr10:75533431	FUT11	-0.51	-5.22	-0.47	1.03e-6	Inflammatory bowel disease;
THYM	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg18512352	chr11:47633146	NA	-0.52	-6.14	-0.53	1.92e-8	Subjective well-being;
THYM	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg00256281	chr22:41985642	PMM1	0.63	4.83	0.44	5.25e-6	Vitiligo;
THYM	cis	rs951366	0.531	rs12030754	chr1:205678043	G/C	cg16031515	chr1:205743344	RAB7L1	0.54	4.59	0.43	1.37e-5	Menarche (age at onset);
THYM	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg04990556	chr1:26633338	UBXN11	-0.89	-8.52	-0.66	2.34e-13	Obesity-related traits;
THYM	cis	rs7089973	0.872	rs7072364	chr10:116620840	G/A	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.14	-0.47	1.5e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9807989	0.507	rs7605284	chr2:103044175	T/G	cg03938978	chr2:103052716	IL18RAP	0.75	9.8	0.71	4.43e-16	Asthma;
THYM	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg09021430	chr5:549028	NA	-0.74	-5.51	-0.49	3.07e-7	Obesity-related traits;
THYM	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg11905131	chr22:24372483	LOC391322	-0.89	-9.33	-0.69	4.41e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11096990	0.593	rs4580660	chr4:39153836	G/A	cg24403649	chr4:39172243	NA	0.61	5.19	0.47	1.21e-6	Cognitive function;
THYM	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg00990874	chr7:1149470	C7orf50	-0.63	-4.66	-0.43	1.01e-5	Bronchopulmonary dysplasia;
THYM	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg24818145	chr4:99064322	C4orf37	0.73	5.87	0.52	6.3e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs899997	1.000	rs8030090	chr15:79034260	A/G	cg04896959	chr15:78267971	NA	0.91	7.28	0.6	9.49e-11	Coronary artery disease or large artery stroke;
THYM	cis	rs4731207	0.596	rs7778875	chr7:124645446	G/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg11062466	chr8:58055876	NA	1.1	8.74	0.67	8.25e-14	Developmental language disorder (linguistic errors);
THYM	cis	rs6430585	0.591	rs12475553	chr2:136483355	G/T	cg07169764	chr2:136633963	MCM6	1.14	10.58	0.74	9.78e-18	Corneal structure;
THYM	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg08736216	chr1:53307985	ZYG11A	0.59	5.51	0.49	3.12e-7	Monocyte count;
THYM	cis	rs8067545	0.641	rs1479129	chr17:19845769	A/G	cg20830565	chr17:20408647	MGC102966	-0.53	-4.84	-0.44	4.99e-6	Schizophrenia;
THYM	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs995000	0.931	rs10889331	chr1:62943007	G/T	cg06896770	chr1:63153194	DOCK7	-0.91	-7.58	-0.61	2.33e-11	Triglyceride levels;
THYM	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg10360139	chr7:1886902	MAD1L1	-0.58	-4.63	-0.43	1.15e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs7551222	0.752	rs12741351	chr1:204528256	G/A	cg20240347	chr1:204465584	NA	-0.54	-4.91	-0.45	3.81e-6	Schizophrenia;
THYM	cis	rs4792901	0.765	rs9894019	chr17:41565505	T/G	cg21940313	chr17:41620911	ETV4	-0.55	-5.32	-0.48	6.8e-7	Dupuytren's disease;
THYM	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg07636037	chr3:49044803	WDR6	0.84	7.39	0.6	5.67e-11	Menarche (age at onset);
THYM	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg03188948	chr7:1209495	NA	0.59	4.57	0.42	1.48e-5	Longevity;Endometriosis;
THYM	cis	rs10924970	0.934	rs10802572	chr1:235426121	A/T	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs10789491	1.000	rs10749863	chr1:47174328	C/T	cg15501359	chr1:47185051	KIAA0494	1.08	7.67	0.62	1.48e-11	Response to hepatitis C treatment;
THYM	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg27279351	chr12:120934652	DYNLL1	0.92	8.22	0.64	1.04e-12	High light scatter reticulocyte count;
THYM	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg21028142	chr17:79581711	NPLOC4	0.52	5.13	0.47	1.52e-6	Eye color traits;
THYM	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12509991	0.582	rs970726	chr4:127048559	C/T	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs113835537	0.529	rs17496250	chr11:66270774	C/G	cg10315249	chr11:66235081	PELI3	0.42	4.53	0.42	1.69e-5	Airway imaging phenotypes;
THYM	cis	rs7408868	1.000	rs7249525	chr19:15277309	G/A	cg14696996	chr19:15285081	NOTCH3	0.96	5.37	0.48	5.61e-7	Pulse pressure;
THYM	cis	rs13191362	0.507	rs7772787	chr6:163190981	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.75	5.84	0.51	7.35e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg02527881	chr3:46936655	PTH1R	-0.6	-6.01	-0.52	3.48e-8	Colorectal cancer;
THYM	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg13010199	chr12:38710504	ALG10B	0.73	5.82	0.51	7.99e-8	Heart rate;
THYM	cis	rs2075230	0.642	rs1641524	chr17:7549645	T/G	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.28	-4.62	-0.43	1.21e-5	Hormone measurements;
THYM	cis	rs7236492	0.683	rs79747802	chr18:77198964	C/T	cg15644404	chr18:77186268	NFATC1	-1.05	-4.96	-0.45	3.04e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs13256369	0.755	rs12680167	chr8:8562467	A/G	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs870825	0.616	rs28608669	chr4:185632890	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.69	0.71	7.45e-16	Blood protein levels;
THYM	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-5.94	-0.52	4.69e-8	Longevity;Endometriosis;
THYM	cis	rs9399401	0.667	rs11759653	chr6:142720354	G/A	cg03128060	chr6:142623767	GPR126	0.7	9.47	0.7	2.29e-15	Chronic obstructive pulmonary disease;
THYM	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs7546094	1.000	rs7546094	chr1:113154400	C/T	cg22162597	chr1:113214053	CAPZA1	0.48	4.91	0.45	3.81e-6	Platelet distribution width;
THYM	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg21028142	chr17:79581711	NPLOC4	0.62	6.13	0.53	1.96e-8	Eye color traits;
THYM	cis	rs9814567	0.712	rs9838621	chr3:134332319	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7127900	0.950	rs7395734	chr11:2231694	C/T	cg25635251	chr11:2234043	NA	0.74	4.71	0.44	8.43e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs7551222	0.721	rs4951402	chr1:204539122	C/T	cg20240347	chr1:204465584	NA	-0.54	-4.91	-0.45	3.81e-6	Schizophrenia;
THYM	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg06766960	chr11:133703094	NA	-0.61	-5.42	-0.49	4.41e-7	Childhood ear infection;
THYM	cis	rs7567389	0.504	rs1568278	chr2:128190195	G/A	cg09760422	chr2:128146352	NA	0.38	4.56	0.42	1.54e-5	Self-rated health;
THYM	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.73	5.66	0.5	1.6e-7	Tonsillectomy;
THYM	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg14345882	chr6:26364793	BTN3A2	0.62	5.6	0.5	2.06e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg12560992	chr17:57184187	TRIM37	0.91	8.51	0.66	2.54e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2663905	0.706	rs7162859	chr15:81360038	C/T	cg09888468	chr15:81410853	NA	0.75	5.62	0.5	1.92e-7	QT interval (drug interaction);
THYM	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg05373962	chr22:49881684	NA	-0.67	-6.83	-0.57	7.99e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4664308	0.618	rs6722275	chr2:160893260	C/T	cg03641300	chr2:160917029	PLA2R1	-0.65	-5.47	-0.49	3.58e-7	Idiopathic membranous nephropathy;
THYM	cis	rs12049351	0.612	rs4925491	chr1:229608289	T/C	cg11742688	chr1:229674241	ABCB10	-0.54	-4.57	-0.42	1.46e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.59	0.5	2.21e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2455799	0.613	rs2470536	chr3:15715156	G/C	cg16303742	chr3:15540471	COLQ	-0.55	-5.63	-0.5	1.81e-7	Mean platelet volume;
THYM	cis	rs10231759	0.583	rs55649631	chr7:150512828	A/C	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.65	5.06	0.46	2.06e-6	Height;
THYM	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg19077165	chr18:44547161	KATNAL2	0.51	5.93	0.52	4.94e-8	Personality dimensions;
THYM	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs654950	0.806	rs7550496	chr1:42043834	G/A	cg06885757	chr1:42089581	HIVEP3	0.59	7.86	0.63	5.84e-12	Airway imaging phenotypes;
THYM	cis	rs2806561	0.765	rs1738469	chr1:23511407	G/C	cg19743168	chr1:23544995	NA	0.55	5.59	0.5	2.18e-7	Height;
THYM	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg23711669	chr6:146136114	FBXO30	0.77	7.14	0.59	1.87e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4595586	0.545	rs12819186	chr12:39356912	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs9527	0.569	rs10883801	chr10:104677887	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-5.01	-0.46	2.51e-6	Arsenic metabolism;
THYM	cis	rs6570726	0.791	rs443628	chr6:145883484	T/C	cg23711669	chr6:146136114	FBXO30	0.96	10.2	0.72	6.08e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28795989	0.761	rs1320075	chr4:7903244	C/A	cg00251875	chr4:7801337	AFAP1	0.59	4.74	0.44	7.35e-6	Intraocular pressure;
THYM	cis	rs2075230	0.588	rs1641537	chr17:7545721	T/C	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.74	-0.44	7.55e-6	Hormone measurements;
THYM	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg18850127	chr7:39170497	POU6F2	0.58	5.42	0.49	4.57e-7	IgG glycosylation;
THYM	cis	rs765787	0.530	rs12904265	chr15:45526713	C/T	cg25801113	chr15:45476975	SHF	-0.39	-4.57	-0.42	1.48e-5	Uric acid levels;
THYM	cis	rs9560113	0.843	rs9555808	chr13:112181284	A/T	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.96	5.28	0.48	8.27e-7	Initial pursuit acceleration;
THYM	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg08296037	chr16:1584118	IFT140;TMEM204	-0.61	-5.18	-0.47	1.24e-6	Coronary artery disease;
THYM	cis	rs2652834	0.861	rs4774472	chr15:63353760	C/A	cg05507819	chr15:63340323	TPM1	0.74	4.51	0.42	1.84e-5	HDL cholesterol;
THYM	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2637266	0.967	rs2579760	chr10:78321768	A/C	cg18941641	chr10:78392320	NA	0.8	6.9	0.58	5.69e-10	Pulmonary function;
THYM	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.68	4.93	0.45	3.45e-6	Aortic root size;
THYM	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.5	0.42	1.93e-5	Motion sickness;
THYM	cis	rs61931739	0.963	rs12307606	chr12:34016365	C/T	cg10856724	chr12:34555212	NA	0.58	4.99	0.46	2.75e-6	Morning vs. evening chronotype;
THYM	cis	rs2803122	0.905	rs10123360	chr9:19303662	A/G	cg19584733	chr9:19298547	DENND4C	-0.53	-4.47	-0.42	2.18e-5	Pulse pressure;
THYM	cis	rs1061377	1.000	rs13109200	chr4:39126016	A/G	cg24403649	chr4:39172243	NA	0.59	4.78	0.44	6.29e-6	Uric acid levels;
THYM	cis	rs7851660	0.809	rs12006522	chr9:100652711	G/C	cg13688889	chr9:100608707	NA	-0.78	-5.67	-0.5	1.53e-7	Strep throat;
THYM	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg07777115	chr5:623756	CEP72	-0.8	-4.78	-0.44	6.48e-6	Obesity-related traits;
THYM	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.45	0.81	1.03e-23	Height;
THYM	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.66	-5.65	-0.5	1.68e-7	Blood metabolite levels;
THYM	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg24006582	chr15:45444508	DUOX1	-0.82	-7.14	-0.59	1.86e-10	Uric acid levels;
THYM	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs924712	0.844	rs7765721	chr6:54734941	C/A	cg04690482	chr6:54711388	FAM83B	-0.46	-5.08	-0.46	1.86e-6	Breast cancer;
THYM	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs12534701	1.000	rs3807297	chr7:154682304	G/A	cg24255201	chr7:154684926	DPP6	0.78	6.07	0.53	2.66e-8	Colorectal cancer (diet interaction);
THYM	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.43	-5.37	-0.48	5.67e-7	Monocyte percentage of white cells;
THYM	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg24675658	chr1:53192096	ZYG11B	0.61	4.9	0.45	3.86e-6	Monocyte count;
THYM	cis	rs1483890	0.723	rs1843046	chr3:69410614	C/A	cg22125112	chr3:69402811	FRMD4B	0.54	6.85	0.58	7.21e-10	Resting heart rate;
THYM	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs6763768	1.000	rs6763768	chr3:53537879	C/T	cg06098138	chr3:53912235	ACTR8	-0.54	-4.75	-0.44	7.21e-6	Bacterial meningitis;
THYM	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg18252515	chr7:66147081	NA	-0.67	-5.08	-0.46	1.86e-6	Aortic root size;
THYM	cis	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs7100689	0.646	rs1934692	chr10:82125734	C/A	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs4786125	0.920	rs6500849	chr16:6895246	C/T	cg03623568	chr16:6915990	A2BP1	-0.78	-6.28	-0.54	1.02e-8	Heart rate variability traits (SDNN);
THYM	cis	rs2288884	0.767	rs58329304	chr19:52535172	A/G	cg05974498	chr19:52599256	ZNF841	0.35	4.51	0.42	1.85e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs9467603	1.000	rs13201341	chr6:25822661	C/T	cg16898833	chr6:26189333	HIST1H4D	1.33	4.6	0.43	1.32e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg12560992	chr17:57184187	TRIM37	0.89	8.01	0.63	2.88e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg05283184	chr6:79620031	NA	-0.91	-8.87	-0.67	4.37e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.37	4.61	0.43	1.25e-5	Schizophrenia;
THYM	cis	rs7487075	0.754	rs10880962	chr12:46773444	C/G	cg22049899	chr12:47219821	SLC38A4	0.48	4.75	0.44	7.28e-6	Itch intensity from mosquito bite;
THYM	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg19729930	chr2:74357872	NA	1.26	11.15	0.75	5.87e-19	Gestational age at birth (maternal effect);
THYM	cis	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg23231163	chr10:75533350	FUT11	-0.41	-5.84	-0.51	7.41e-8	Inflammatory bowel disease;
THYM	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg26384229	chr12:38710491	ALG10B	0.99	7.63	0.62	1.81e-11	Morning vs. evening chronotype;
THYM	cis	rs868036	0.718	rs2241420	chr15:68082816	G/A	cg24579218	chr15:68104479	NA	-0.82	-8.85	-0.67	4.77e-14	Restless legs syndrome;
THYM	cis	rs7189233	0.955	rs17800727	chr16:53481010	A/G	cg02965178	chr16:53538660	AKTIP	-0.6	-4.59	-0.43	1.37e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7584330	0.868	rs7569197	chr2:238383073	A/G	cg14458575	chr2:238380390	NA	0.97	7.95	0.63	3.92e-12	Prostate cancer;
THYM	cis	rs7084402	0.935	rs1593675	chr10:60291694	G/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs1728785	1.000	rs1170431	chr16:68605639	T/C	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.39e-6	Ulcerative colitis;
THYM	cis	rs4654899	0.931	rs3767241	chr1:21166144	C/T	cg01072550	chr1:21505969	NA	0.69	6.35	0.55	7.21e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs9992101	1.000	rs9992101	chr4:77360431	A/G	cg20311846	chr4:77356250	SHROOM3	0.65	6.56	0.56	2.75e-9	Creatinine levels;
THYM	cis	rs775227	0.574	rs2018912	chr3:113060140	A/G	cg18753928	chr3:113234510	CCDC52	-0.76	-5.24	-0.47	9.81e-7	Dental caries;
THYM	cis	rs669446	0.562	rs11210907	chr1:44191759	C/T	cg12599982	chr1:44399894	ARTN	0.53	4.85	0.45	4.75e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs62435770	1.000	rs62433599	chr6:169523563	A/C	cg07652237	chr6:170125491	PHF10	0.55	4.94	0.45	3.29e-6	Loneliness;
THYM	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg09359103	chr1:154839909	KCNN3	-0.73	-9.27	-0.69	5.9e-15	Prostate cancer;
THYM	cis	rs3750965	0.806	rs7107680	chr11:68859894	C/T	cg01403660	chr11:68851641	TPCN2	0.72	5.75	0.51	1.07e-7	Hair color;
THYM	cis	rs3892630	0.878	rs11878394	chr19:33205844	G/C	cg22980127	chr19:33182716	NUDT19	1.12	9.08	0.68	1.55e-14	Red blood cell traits;
THYM	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg20503657	chr10:835505	NA	1.17	8.29	0.65	7.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg21784768	chr11:537496	LRRC56	-1.05	-4.84	-0.44	5.04e-6	Body mass index;
THYM	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg15704280	chr7:45808275	SEPT13	-1.07	-15.24	-0.84	2.93e-27	Height;
THYM	cis	rs17006441	0.932	rs62253173	chr3:69897070	C/T	cg18496212	chr3:69797108	MITF	0.68	6.85	0.57	7.35e-10	Hemoglobin concentration;
THYM	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.8	6.52	0.56	3.41e-9	Blood protein levels;
THYM	cis	rs17174870	0.955	rs55799805	chr2:112766319	T/C	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg17554472	chr22:41940697	POLR3H	0.73	5.15	0.47	1.39e-6	Vitiligo;
THYM	cis	rs12216545	0.765	rs2272092	chr7:150264645	C/T	cg08960815	chr7:150264767	GIMAP4	-0.89	-8.27	-0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs870825	0.616	rs79884757	chr4:185621454	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs2303759	0.676	rs7248378	chr19:49908144	C/A	cg22590775	chr19:49891494	CCDC155	0.62	5.2	0.47	1.15e-6	Multiple sclerosis;
THYM	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs5417	0.775	rs222852	chr17:7140606	A/G	cg25256661	chr17:7137939	DVL2	0.77	5.87	0.52	6.29e-8	Diastolic blood pressure;
THYM	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.83	-7.18	-0.59	1.56e-10	Chronic sinus infection;
THYM	cis	rs236907	0.814	rs2232825	chr1:171763549	C/T	cg20598894	chr1:171756153	METTL13	-0.68	-5.05	-0.46	2.16e-6	Mean platelet volume;
THYM	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg11764359	chr7:65958608	NA	-0.81	-6.42	-0.55	5.45e-9	Aortic root size;
THYM	cis	rs11153147	0.655	rs11962337	chr6:109496081	C/T	cg17117243	chr6:109341365	SESN1	-0.82	-4.8	-0.44	5.98e-6	Mean corpuscular volume;
THYM	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	trans	rs11722228	0.508	rs3822246	chr4:10094698	G/A	cg26043149	chr18:55253948	FECH	1.16	10.82	0.74	2.98e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs6424115	0.760	rs2999566	chr1:24051124	A/G	cg15997130	chr1:24165203	NA	0.66	5.4	0.48	4.82e-7	Immature fraction of reticulocytes;
THYM	cis	rs72627123	0.867	rs17094107	chr14:74406382	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs12519773	0.501	rs4293897	chr5:92500822	T/G	cg18783429	chr5:92414398	NA	0.53	5.37	0.48	5.63e-7	Migraine;
THYM	cis	rs2075230	0.850	rs75853747	chr17:7476706	C/T	cg10509001	chr17:7553872	ATP1B2	0.59	4.69	0.43	9e-6	Hormone measurements;
THYM	cis	rs7216064	0.906	rs8074644	chr17:65878217	G/C	cg12091567	chr17:66097778	LOC651250	-0.69	-4.65	-0.43	1.05e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs6840360	0.642	rs2053566	chr4:152445831	A/C	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg21237687	chr17:6899380	ALOX12	0.74	9.07	0.68	1.61e-14	Tonsillectomy;
THYM	cis	rs12519773	0.534	rs2453763	chr5:92376460	T/A	cg18783429	chr5:92414398	NA	-0.49	-4.52	-0.42	1.78e-5	Migraine;
THYM	cis	rs7772486	0.790	rs6917135	chr6:146152426	T/C	cg23711669	chr6:146136114	FBXO30	0.92	9.0	0.68	2.32e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg19913688	chr11:428466	ANO9	-0.86	-4.53	-0.42	1.69e-5	Body mass index;
THYM	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg09877947	chr5:131593287	PDLIM4	0.65	5.39	0.48	5.1e-7	Blood metabolite levels;
THYM	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg06618935	chr21:46677482	NA	-0.94	-8.98	-0.68	2.47e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2913737	0.563	rs2913898	chr5:175905303	T/C	cg27658698	chr5:175955578	RNF44	0.59	4.63	0.43	1.18e-5	Obesity-related traits;
THYM	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg10802521	chr3:52805072	NEK4	-0.79	-7.47	-0.61	3.96e-11	Bipolar disorder;
THYM	cis	rs7829975	0.774	rs11249893	chr8:8700851	C/T	cg17143192	chr8:8559678	CLDN23	0.59	4.63	0.43	1.16e-5	Mood instability;
THYM	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06634786	chr22:41940651	POLR3H	-0.71	-5.12	-0.47	1.57e-6	Vitiligo;
THYM	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg09242541	chr1:10490025	APITD1	0.26	4.86	0.45	4.6e-6	Prostate cancer;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg00138451	chr17:5318662	NUP88	-0.98	-6.87	-0.58	6.53e-10	Depressive symptoms;
THYM	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg24130564	chr14:104152367	KLC1	0.63	5.75	0.51	1.06e-7	Intelligence (multi-trait analysis);
THYM	cis	rs13253111	0.967	rs7821358	chr8:28060690	A/G	cg26534493	chr8:28060551	NA	-0.52	-4.6	-0.43	1.28e-5	Childhood body mass index;
THYM	cis	rs7580658	0.963	rs12052483	chr2:128136820	T/G	cg10021288	chr2:128175891	PROC	-0.83	-7.11	-0.59	2.19e-10	Protein C levels;
THYM	cis	rs9296092	0.538	rs78061112	chr6:33526587	T/G	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs919433	0.783	rs788014	chr2:198228997	G/A	cg00792783	chr2:198669748	PLCL1	0.78	5.62	0.5	1.89e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4792901	0.802	rs9907507	chr17:41587045	T/G	cg21940313	chr17:41620911	ETV4	-0.53	-5.03	-0.46	2.28e-6	Dupuytren's disease;
THYM	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg06238570	chr21:40685208	BRWD1	0.91	6.77	0.57	1.08e-9	Cognitive function;
THYM	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg20476274	chr7:133979776	SLC35B4	0.68	4.55	0.42	1.58e-5	Mean platelet volume;
THYM	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg23791538	chr6:167370224	RNASET2	0.77	6.12	0.53	2.1e-8	Crohn's disease;
THYM	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.75	-5.93	-0.52	4.78e-8	Blood protein levels;
THYM	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs10206020	0.921	rs6605278	chr2:1547230	C/T	cg12573674	chr2:1569213	NA	-1.35	-8.52	-0.66	2.42e-13	IgG glycosylation;
THYM	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg18681998	chr4:17616180	MED28	0.63	5.22	0.47	1.04e-6	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7167736	1.000	rs7167736	chr15:101206638	T/G	cg03479535	chr15:100889701	FLJ42289	0.53	4.51	0.42	1.83e-5	Chin dimples;
THYM	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg26441486	chr22:50317300	CRELD2	0.43	6.27	0.54	1.07e-8	Schizophrenia;
THYM	trans	rs877282	0.891	rs11253393	chr10:788824	G/T	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg02187348	chr16:89574699	SPG7	-0.71	-5.05	-0.46	2.15e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs2663905	0.706	rs2683260	chr15:81385552	A/C	cg27419860	chr15:81426477	C15orf26	-0.78	-5.71	-0.51	1.29e-7	QT interval (drug interaction);
THYM	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	7.14	0.59	1.88e-10	Platelet count;
THYM	cis	rs13168506	0.552	rs889010	chr5:135572910	C/A	cg15329133	chr5:135467951	SMAD5;SMAD5OS	0.51	4.49	0.42	2.02e-5	Stroke;
THYM	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg13010199	chr12:38710504	ALG10B	0.65	4.84	0.44	4.99e-6	Morning vs. evening chronotype;
THYM	cis	rs1011018	0.955	rs28656273	chr7:139467676	T/C	cg06079564	chr7:139468310	HIPK2	-0.77	-5.98	-0.52	3.9e-8	Systolic blood pressure;
THYM	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg27490568	chr2:178487706	NA	-0.59	-5.63	-0.5	1.83e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4919044	0.808	rs9419765	chr10:94798171	C/T	cg05127821	chr10:94822908	CYP26C1	-1.23	-6.66	-0.56	1.76e-9	Coronary artery disease;
THYM	cis	rs9810089	0.802	rs10935182	chr3:136137422	G/A	cg12473912	chr3:136751656	NA	0.57	4.85	0.45	4.81e-6	Gestational age at birth (child effect);
THYM	cis	rs9583531	0.600	rs9521909	chr13:111362170	A/G	cg24331049	chr13:111365604	ING1	0.72	6.04	0.53	2.96e-8	Coronary artery disease;
THYM	cis	rs12540874	0.670	rs3887826	chr7:50544961	G/A	cg00647317	chr7:50633725	DDC	0.33	5.01	0.46	2.47e-6	Systemic sclerosis;
THYM	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg18876405	chr7:65276391	NA	0.67	5.93	0.52	4.98e-8	Aortic root size;
THYM	cis	rs1374313	0.872	rs6721734	chr2:120149587	T/G	cg18093372	chr2:119607603	NA	-0.46	-4.65	-0.43	1.07e-5	Obesity-related traits;
THYM	cis	rs4866334	1.000	rs76883636	chr5:18488763	G/T	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg08645402	chr16:4508243	NA	-0.69	-6.0	-0.52	3.58e-8	Schizophrenia;
THYM	cis	rs259964	0.692	rs259975	chr20:57809838	T/C	cg09005679	chr20:57875326	EDN3	-0.39	-4.66	-0.43	1.03e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03517284	chr6:25882590	NA	-0.99	-9.66	-0.7	8.77e-16	Intelligence (multi-trait analysis);
THYM	cis	rs1950500	0.565	rs3181248	chr14:24808168	G/A	cg22990158	chr14:24802150	ADCY4	-0.51	-5.42	-0.49	4.44e-7	Height;
THYM	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs11157436	0.918	rs3811285	chr14:22623255	G/A	cg26433554	chr14:23315189	MMP14	0.44	4.61	0.43	1.24e-5	Neurocognitive impairment in HIV-1 infection (continuous);
THYM	cis	rs77688320	0.517	rs2270315	chr2:202317265	C/A	cg06686451	chr2:201350984	NA	-0.59	-4.46	-0.42	2.28e-5	Breast cancer;
THYM	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg01475377	chr6:109611718	NA	-0.59	-5.07	-0.46	1.94e-6	Reticulocyte fraction of red cells;
THYM	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg24910161	chr17:38119198	GSDMA	0.46	4.7	0.43	8.72e-6	Self-reported allergy;
THYM	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs763014	0.898	rs12917944	chr16:622565	A/G	cg00908189	chr16:619842	PIGQ	1.03	9.46	0.7	2.34e-15	Height;
THYM	cis	rs4845459	0.967	rs4845450	chr1:152591200	T/C	cg27206522	chr1:152595629	LCE3A	-0.51	-4.54	-0.42	1.66e-5	Psoriasis;
THYM	cis	rs4638749	0.627	rs4676185	chr2:108841908	G/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg02725872	chr8:58115012	NA	-0.88	-6.24	-0.54	1.24e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs10231759	0.617	rs4463336	chr7:150513582	A/G	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.66	4.97	0.45	3e-6	Height;
THYM	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg12031863	chr16:4587854	C16orf5	0.45	5.1	0.46	1.76e-6	Schizophrenia;
THYM	cis	rs6430585	0.591	rs77096272	chr2:136663605	C/A	cg04750100	chr2:136595281	LCT	0.56	4.96	0.45	3.03e-6	Corneal structure;
THYM	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg03388025	chr16:89894329	SPIRE2	0.53	4.49	0.42	1.99e-5	Vitiligo;
THYM	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg02503808	chr4:7069936	GRPEL1	0.84	5.79	0.51	9.03e-8	Monocyte percentage of white cells;
THYM	cis	rs6500395	1.000	rs1558815	chr16:48704869	C/A	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg26384229	chr12:38710491	ALG10B	0.96	7.77	0.62	8.98e-12	Bladder cancer;
THYM	cis	rs2806561	0.734	rs11578046	chr1:23425139	G/A	cg19743168	chr1:23544995	NA	0.5	4.89	0.45	4.05e-6	Height;
THYM	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg14835575	chr10:16859367	RSU1	0.72	5.12	0.47	1.57e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
THYM	cis	rs921968	0.541	rs2556391	chr2:219556346	T/C	cg02176678	chr2:219576539	TTLL4	-0.73	-7.23	-0.6	1.2e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7772486	0.597	rs6912351	chr6:146264071	T/C	cg05347473	chr6:146136440	FBXO30	-0.82	-7.32	-0.6	7.82e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7084921	0.552	rs11594333	chr10:101880700	A/G	cg11344164	chr10:101878520	NA	0.6	5.73	0.51	1.2e-7	Bone mineral density;
THYM	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg24733560	chr20:60626293	TAF4	0.51	4.56	0.42	1.51e-5	Body mass index;
THYM	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg05973401	chr12:123451056	ABCB9	0.71	4.82	0.44	5.46e-6	Neutrophil percentage of white cells;
THYM	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg07212818	chr11:638076	DRD4	-0.79	-6.69	-0.57	1.57e-9	Systemic lupus erythematosus;
THYM	cis	rs61931739	0.817	rs10772144	chr12:34242463	A/C	cg10856724	chr12:34555212	NA	-0.62	-5.55	-0.49	2.62e-7	Morning vs. evening chronotype;
THYM	cis	rs3087591	0.960	rs4435317	chr17:29436512	G/C	cg24425628	chr17:29625626	OMG;NF1	0.64	5.54	0.49	2.68e-7	Hip circumference;
THYM	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg27129171	chr3:47204927	SETD2	0.67	6.43	0.55	5.04e-9	Colorectal cancer;
THYM	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg13683864	chr3:40499215	RPL14	-0.85	-8.03	-0.64	2.57e-12	Renal cell carcinoma;
THYM	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg14779329	chr11:130786720	SNX19	0.55	5.83	0.51	7.58e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg27490568	chr2:178487706	NA	0.61	5.37	0.48	5.68e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1445130	1.000	rs12619250	chr2:18834944	G/A	cg26077359	chr2:19280274	NA	0.78	4.53	0.42	1.71e-5	Bulimia nervosa;
THYM	cis	rs28476539	0.640	rs72658996	chr4:83552364	C/T	cg10249074	chr4:83542146	C4orf11	-0.64	-5.06	-0.46	2.05e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs4780401	0.609	rs16958588	chr16:11819330	G/A	cg01061890	chr16:11836724	TXNDC11	-0.66	-5.44	-0.49	4.22e-7	Rheumatoid arthritis;
THYM	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg05768032	chr16:30646687	NA	0.55	5.55	0.49	2.56e-7	Multiple myeloma;
THYM	cis	rs28595532	0.920	rs116697254	chr4:119733603	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs995000	0.826	rs7555577	chr1:63034363	A/C	cg06896770	chr1:63153194	DOCK7	-0.89	-6.92	-0.58	5.26e-10	Triglyceride levels;
THYM	cis	rs240764	0.612	rs241819	chr6:100910798	G/A	cg21058520	chr6:100914733	NA	0.64	5.61	0.5	2.02e-7	Neuroticism;
THYM	cis	rs7107770	0.739	rs12793744	chr11:125079871	G/T	cg04164023	chr11:125106101	PKNOX2	-0.71	-4.6	-0.43	1.3e-5	Photic sneeze reflex;
THYM	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg23682913	chr1:2080710	PRKCZ	0.57	4.91	0.45	3.79e-6	Height;
THYM	cis	rs4589258	0.933	rs726125	chr11:90443299	C/G	cg26138821	chr11:89956704	CHORDC1	0.7	5.9	0.52	5.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2637266	0.716	rs2579734	chr10:78441306	A/G	cg18941641	chr10:78392320	NA	0.76	6.39	0.55	6.21e-9	Pulmonary function;
THYM	cis	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg10856724	chr12:34555212	NA	-0.88	-8.26	-0.65	8.47e-13	Morning vs. evening chronotype;
THYM	cis	rs2502731	0.584	rs3003578	chr9:130994179	C/T	cg13642260	chr9:130955380	CIZ1	0.66	5.19	0.47	1.18e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs912057	0.609	rs1294431	chr6:6745003	G/C	cg06612196	chr6:6737390	NA	0.71	11.9	0.77	1.57e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs751728	0.664	rs943475	chr6:33749978	C/T	cg16492833	chr6:33679775	C6orf125	-0.37	-4.69	-0.43	8.96e-6	Crohn's disease;
THYM	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2933343	0.621	rs728838	chr3:128589013	A/G	cg11901034	chr3:128598214	ACAD9	-0.7	-5.68	-0.5	1.47e-7	IgG glycosylation;
THYM	cis	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg09307838	chr4:120376055	NA	0.73	5.49	0.49	3.37e-7	Corneal astigmatism;
THYM	cis	rs7590720	1.000	rs7559031	chr2:216902583	A/G	cg12620499	chr2:216877984	MREG	0.83	5.71	0.51	1.29e-7	Alcohol dependence;
THYM	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg00256281	chr22:41985642	PMM1	0.64	5.02	0.46	2.42e-6	Vitiligo;
THYM	cis	rs9807841	0.592	rs11085743	chr19:10759442	G/A	cg16900796	chr19:10755136	SLC44A2	0.38	6.2	0.54	1.47e-8	Inflammatory skin disease;
THYM	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg17366294	chr4:99064904	C4orf37	0.53	5.9	0.52	5.67e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs308403	0.533	rs309377	chr4:123676353	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.98	8.86	0.67	4.45e-14	Blood protein levels;
THYM	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg17063962	chr7:91808500	NA	1.08	11.02	0.75	1.1e-18	Breast cancer;
THYM	cis	rs2235649	0.833	rs9929185	chr16:1852070	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs9876781	1.000	rs7636044	chr3:48484560	A/G	cg06066452	chr3:48470258	PLXNB1	0.27	4.85	0.45	4.87e-6	Longevity;
THYM	cis	rs4243830	0.850	rs908273	chr1:6588604	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.06	-6.9	-0.58	5.79e-10	Body mass index;
THYM	cis	rs977987	0.843	rs35737321	chr16:75439185	A/T	cg03315344	chr16:75512273	CHST6	0.77	6.43	0.55	5.19e-9	Dupuytren's disease;
THYM	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg07636037	chr3:49044803	WDR6	0.97	10.07	0.72	1.15e-16	Parkinson's disease;
THYM	cis	rs950881	0.932	rs72823621	chr2:102925435	C/T	cg20060108	chr2:102954350	IL1RL1	0.81	4.47	0.42	2.14e-5	Allergy;
THYM	cis	rs4563143	0.514	rs73029079	chr19:29294903	A/G	cg14983838	chr19:29218262	NA	0.95	6.79	0.57	9.81e-10	Methadone dose in opioid dependence;
THYM	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg12165864	chr7:66369176	NA	-0.67	-5.26	-0.47	8.99e-7	Aortic root size;
THYM	cis	rs5167	0.504	rs4803781	chr19:45459671	C/T	cg09555818	chr19:45449301	APOC2	0.67	7.38	0.6	6.04e-11	Blood protein levels;
THYM	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg22974920	chr21:40686053	BRWD1	0.58	4.46	0.42	2.29e-5	Cognitive function;
THYM	cis	rs6496667	0.557	rs2526002	chr15:90965655	C/T	cg22089800	chr15:90895588	ZNF774	0.66	4.86	0.45	4.64e-6	Rheumatoid arthritis;
THYM	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs1448094	0.527	rs1900700	chr12:86232166	C/T	cg02569458	chr12:86230093	RASSF9	0.64	5.51	0.49	3.11e-7	Major depressive disorder;
THYM	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg21775007	chr8:11205619	TDH	-0.73	-5.68	-0.5	1.49e-7	Retinal vascular caliber;
THYM	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.74	5.8	0.51	8.83e-8	Total cholesterol levels;
THYM	cis	rs198426	0.813	rs12805732	chr11:61448384	G/A	cg19838087	chr11:61442541	NA	0.57	5.69	0.5	1.42e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
THYM	cis	rs9527	0.590	rs4917992	chr10:104786313	G/A	cg04362960	chr10:104952993	NT5C2	0.59	4.47	0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs2235649	0.753	rs4316755	chr16:1849916	T/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.85	-0.45	4.89e-6	Blood metabolite levels;
THYM	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4234284	0.556	rs4679147	chr3:126955702	C/T	cg27326032	chr3:127006922	NA	-0.82	-5.36	-0.48	5.73e-7	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
THYM	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg00744431	chr10:134226547	PWWP2B	-0.6	-4.67	-0.43	1e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg10856724	chr12:34555212	NA	0.79	6.9	0.58	5.77e-10	Bladder cancer;
THYM	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg14458575	chr2:238380390	NA	-1.09	-8.79	-0.67	6.36e-14	Prostate cancer;
THYM	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg02782426	chr3:40428986	ENTPD3	0.54	4.79	0.44	6.02e-6	Renal cell carcinoma;
THYM	cis	rs7127900	1.000	rs7109474	chr11:2233219	G/A	cg25635251	chr11:2234043	NA	0.74	4.71	0.44	8.43e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs600806	0.888	rs10858084	chr1:109882250	T/A	cg23032129	chr1:109941072	SORT1	-0.57	-4.84	-0.44	5.11e-6	Intelligence (multi-trait analysis);
THYM	cis	rs250677	0.522	rs56309414	chr5:148376026	C/G	cg18129178	chr5:148520854	ABLIM3	-0.71	-5.31	-0.48	7.05e-7	Breast cancer;
THYM	cis	rs7570971	1.000	rs1375131	chr2:135954797	T/C	cg07169764	chr2:136633963	MCM6	0.69	4.71	0.43	8.54e-6	Blood metabolite levels;Body mass index;Cholesterol, total;
THYM	cis	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg07460842	chr6:66804631	NA	0.79	5.18	0.47	1.25e-6	Exhaled nitric oxide output;
THYM	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg27446573	chr6:127587934	RNF146	1.01	9.68	0.7	8.06e-16	Breast cancer;
THYM	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6840360	0.615	rs6858483	chr4:152465509	C/T	cg17479576	chr4:152424074	FAM160A1	-0.85	-6.4	-0.55	5.9e-9	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg07362569	chr17:61921086	SMARCD2	0.76	6.88	0.58	6.45e-10	Prudent dietary pattern;
THYM	cis	rs12620999	1.000	rs4377286	chr2:238069686	C/T	cg23555395	chr2:238036564	NA	-0.61	-4.85	-0.45	4.87e-6	Systemic lupus erythematosus;
THYM	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg02228675	chr17:40259724	DHX58	-0.66	-5.49	-0.49	3.28e-7	Fibrinogen levels;
THYM	cis	rs7089973	0.836	rs1966384	chr10:116627910	G/T	cg08188268	chr10:116634841	FAM160B1	-0.3	-4.68	-0.43	9.49e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs10899021	0.790	rs59958321	chr11:74354614	G/A	cg25880958	chr11:74394337	NA	-0.69	-4.45	-0.42	2.35e-5	Response to metformin (IC50);
THYM	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg08859206	chr1:53392774	SCP2	-0.5	-5.16	-0.47	1.34e-6	Monocyte count;
THYM	cis	rs7772486	0.790	rs1133832	chr6:146205604	C/T	cg23711669	chr6:146136114	FBXO30	-0.88	-8.52	-0.66	2.41e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3862030	0.720	rs7342070	chr10:104223628	T/C	cg00122347	chr10:104236741	TMEM180	0.47	7.02	0.58	3.36e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg00383909	chr3:49044727	WDR6	1.12	6.66	0.56	1.75e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs17443541	0.507	rs12613262	chr2:200465327	T/C	cg01795955	chr2:200468626	NA	-0.72	-5.0	-0.46	2.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7980799	0.682	rs7303356	chr12:33633599	C/G	cg06521331	chr12:34319734	NA	0.68	4.94	0.45	3.29e-6	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg24209194	chr3:40518798	ZNF619	-0.62	-5.15	-0.47	1.4e-6	Renal cell carcinoma;
THYM	cis	rs9788682	0.624	rs518425	chr15:78883813	A/G	cg18825076	chr15:78729989	IREB2	0.53	4.57	0.42	1.49e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg24503407	chr1:205819492	PM20D1	-0.6	-4.67	-0.43	9.85e-6	Prostate-specific antigen levels;
THYM	trans	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg07211511	chr3:129823064	LOC729375	-1.27	-9.98	-0.72	1.79e-16	Blood pressure (smoking interaction);
THYM	cis	rs4638749	0.677	rs13414687	chr2:108806245	A/G	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs2070488	0.965	rs2126534	chr3:38445165	T/G	cg24069376	chr3:38537580	EXOG	0.64	6.35	0.55	7.43e-9	Electrocardiographic conduction measures;
THYM	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg12310025	chr6:25882481	NA	-0.73	-6.01	-0.52	3.41e-8	Blood metabolite levels;
THYM	cis	rs9303029	0.800	rs9896620	chr17:80411207	C/G	cg21720206	chr17:80877845	TBCD	0.77	4.78	0.44	6.45e-6	Protein quantitative trait loci;
THYM	cis	rs10208940	0.764	rs13410556	chr2:68749322	A/G	cg21663668	chr2:69393377	ANTXR1	0.87	4.58	0.43	1.41e-5	Urate levels in lean individuals;
THYM	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg10803722	chr21:46713166	LOC642852	0.51	6.42	0.55	5.23e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7267979	0.903	rs6132819	chr20:25218618	C/G	cg08601574	chr20:25228251	PYGB	0.6	4.73	0.44	7.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg15691649	chr6:25882328	NA	-0.73	-6.18	-0.54	1.58e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12410462	1.000	rs75198003	chr1:227623853	C/A	cg04117972	chr1:227635322	NA	0.71	4.8	0.44	5.85e-6	Major depressive disorder;
THYM	cis	rs6543140	0.964	rs10169192	chr2:103072211	A/G	cg03938978	chr2:103052716	IL18RAP	0.58	5.84	0.51	7.16e-8	Blood protein levels;
THYM	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs911555	0.723	rs56227024	chr14:103861706	A/G	cg12935359	chr14:103987150	CKB	0.53	6.24	0.54	1.22e-8	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg17264618	chr3:40429014	ENTPD3	-0.5	-4.54	-0.42	1.67e-5	Renal cell carcinoma;
THYM	cis	rs61990749	0.597	rs10136053	chr14:78155205	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-1.17	-8.02	-0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg05025164	chr4:1340916	KIAA1530	0.93	7.43	0.61	4.75e-11	Longevity;
THYM	cis	rs2562456	0.876	rs11085467	chr19:21751843	A/G	cg21751540	chr19:21541537	ZNF738	-0.68	-4.74	-0.44	7.36e-6	Pain;
THYM	cis	rs988913	0.813	rs4712082	chr6:54771019	G/A	cg04690482	chr6:54711388	FAM83B	0.5	5.4	0.48	4.85e-7	Menarche (age at onset);
THYM	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg05234568	chr11:5960015	NA	-0.57	-5.03	-0.46	2.33e-6	DNA methylation (variation);
THYM	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.76	-0.51	1.03e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs12935418	0.552	rs2113196	chr16:81025490	A/C	cg16651780	chr16:81037892	C16orf61	-0.84	-6.56	-0.56	2.82e-9	Mean corpuscular volume;
THYM	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg06623918	chr6:96969491	KIAA0776	1.09	9.82	0.71	3.91e-16	Headache;
THYM	cis	rs9616064	0.506	rs2073275	chr22:47070432	G/C	cg05621596	chr22:47072043	GRAMD4	-0.55	-4.67	-0.43	9.85e-6	Urate levels in obese individuals;
THYM	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg10360139	chr7:1886902	MAD1L1	-0.6	-5.13	-0.47	1.51e-6	Bipolar disorder and schizophrenia;
THYM	trans	rs8002861	0.935	rs7318147	chr13:44445153	C/G	cg17145862	chr1:211918768	LPGAT1	-0.95	-9.69	-0.71	7.49e-16	Leprosy;
THYM	cis	rs11031096	0.727	rs2268168	chr11:4142069	C/T	cg08557956	chr11:4115526	RRM1	-0.5	-4.9	-0.45	3.94e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs13102973	0.863	rs11099307	chr4:135908104	T/C	cg14419869	chr4:135874104	NA	0.82	6.83	0.57	7.94e-10	Subjective well-being;
THYM	cis	rs6032067	1.000	rs6032059	chr20:43852443	A/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.41	-0.55	5.57e-9	Blood protein levels;
THYM	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.65	-4.72	-0.44	8.12e-6	Colorectal cancer;
THYM	cis	rs10779751	1.000	rs7544489	chr1:11299511	A/G	cg08854313	chr1:11322531	MTOR	-1.05	-10.24	-0.72	5.04e-17	Body mass index;
THYM	cis	rs9527	0.622	rs12779263	chr10:104886533	G/T	cg04362960	chr10:104952993	NT5C2	0.62	4.52	0.42	1.76e-5	Arsenic metabolism;
THYM	cis	rs28595532	0.844	rs80188901	chr4:119500014	C/T	cg21605333	chr4:119757512	SEC24D	1.41	4.74	0.44	7.63e-6	Cannabis dependence symptom count;
THYM	cis	rs1448094	0.512	rs7313278	chr12:86250263	C/T	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06850241	chr22:41845214	NA	-0.56	-4.84	-0.44	5.08e-6	Vitiligo;
THYM	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg13114125	chr14:105738426	BRF1	-0.74	-5.88	-0.52	6.07e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg21784768	chr11:537496	LRRC56	-1.07	-5.36	-0.48	5.7e-7	Body mass index;
THYM	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.45	0.55	4.74e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs807669	0.544	rs2040771	chr22:19161935	C/T	cg02655711	chr22:19163373	SLC25A1	0.62	7.03	0.59	3.11e-10	Metabolite levels;
THYM	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg01324343	chr3:183735012	ABCC5	0.9	13.08	0.8	5.7e-23	Anterior chamber depth;
THYM	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg04731861	chr2:219085781	ARPC2	-0.48	-4.53	-0.42	1.74e-5	Colorectal cancer;
THYM	cis	rs58799304	0.588	rs11590832	chr1:156079306	C/T	cg15685922	chr1:156045208	MEX3A	-0.45	-4.55	-0.42	1.59e-5	Ischemic stroke;
THYM	cis	rs6032067	0.929	rs11699850	chr20:43809049	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	trans	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.12	-13.73	-0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg06028808	chr11:68637592	NA	0.65	6.7	0.57	1.44e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2334880	0.713	rs4788828	chr16:71724090	C/A	cg06353428	chr16:71660113	MARVELD3	1.29	9.01	0.68	2.12e-14	Malaria;
THYM	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg11764359	chr7:65958608	NA	-0.65	-4.97	-0.45	2.95e-6	Aortic root size;
THYM	cis	rs7119	0.717	rs12911963	chr15:77807175	G/C	cg27398640	chr15:77910606	LINGO1	-0.52	-5.21	-0.47	1.12e-6	Type 2 diabetes;
THYM	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs748404	0.587	rs9920879	chr15:43639770	A/G	cg12861797	chr15:43585817	TGM7	0.44	4.67	0.43	9.79e-6	Lung cancer;
THYM	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg06917634	chr15:78832804	PSMA4	-0.83	-6.84	-0.57	7.67e-10	Sudden cardiac arrest;
THYM	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg27398817	chr8:82754497	SNX16	0.71	6.05	0.53	2.89e-8	Diastolic blood pressure;
THYM	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs1448094	0.544	rs56330110	chr12:86166666	A/G	cg02569458	chr12:86230093	RASSF9	0.61	5.46	0.49	3.84e-7	Major depressive disorder;
THYM	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg24803719	chr17:45855879	NA	-0.6	-6.3	-0.54	9.35e-9	IgG glycosylation;
THYM	cis	rs6032067	1.000	rs2233896	chr20:43850400	C/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.71	-7.53	-0.61	2.95e-11	Blood protein levels;
THYM	cis	rs9906944	0.545	rs2088140	chr17:47094599	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.62	-7.1	-0.59	2.31e-10	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	6.1	0.53	2.24e-8	Schizophrenia;
THYM	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg07936489	chr17:37558343	FBXL20	-0.75	-4.74	-0.44	7.6e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs1799949	0.832	rs2070835	chr17:41174025	A/C	cg25918947	chr17:41365094	TMEM106A	-0.61	-4.93	-0.45	3.55e-6	Menopause (age at onset);
THYM	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg22166914	chr1:53195759	ZYG11B	0.64	5.48	0.49	3.54e-7	Monocyte count;
THYM	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg15592062	chr6:167189543	RPS6KA2	0.59	6.16	0.53	1.73e-8	Crohn's disease;
THYM	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg06418219	chr1:154948305	SHC1;CKS1B	0.72	5.49	0.49	3.31e-7	Prostate cancer;
THYM	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg14634687	chr17:47094252	IGF2BP1	0.31	4.82	0.44	5.38e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7781557	1.000	rs10487284	chr7:102470275	G/A	cg06322601	chr7:102330635	NA	0.63	4.72	0.44	8.21e-6	Colorectal adenoma (advanced);
THYM	cis	rs2235649	0.798	rs4100646	chr16:1850446	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.52	-4.48	-0.42	2.05e-5	Blood metabolite levels;
THYM	cis	rs7267979	1.000	rs6050631	chr20:25431749	C/T	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg00101154	chr16:420108	MRPL28	-0.34	-4.67	-0.43	1e-5	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg10802521	chr3:52805072	NEK4	-0.81	-7.3	-0.6	8.53e-11	Bipolar disorder;
THYM	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg08999081	chr20:33150536	PIGU	-0.6	-5.14	-0.47	1.45e-6	Height;
THYM	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg15704280	chr7:45808275	SEPT13	1.01	11.04	0.75	1.03e-18	Coronary artery disease;
THYM	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg17173187	chr15:85201210	NMB	0.54	5.39	0.48	5.09e-7	Schizophrenia;
THYM	cis	rs2668423	0.502	rs2074898	chr19:1391361	A/G	cg02639931	chr19:1387894	NDUFS7	-0.58	-9.36	-0.69	3.85e-15	Nonalcoholic fatty liver disease;
THYM	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg10360139	chr7:1886902	MAD1L1	-0.63	-5.56	-0.5	2.49e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs11756438	0.683	rs72962906	chr6:119008305	C/T	cg21191810	chr6:118973309	C6orf204	0.52	4.88	0.45	4.35e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	4.82	0.44	5.38e-6	Obesity-related traits;
THYM	cis	rs4595586	0.566	rs7135104	chr12:39411086	C/T	cg26384229	chr12:38710491	ALG10B	0.56	4.46	0.42	2.27e-5	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7107174	1.000	rs11603112	chr11:78073491	G/A	cg19901956	chr11:77921274	USP35	-0.65	-5.37	-0.48	5.66e-7	Testicular germ cell tumor;
THYM	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg18876405	chr7:65276391	NA	0.61	5.2	0.47	1.13e-6	Aortic root size;
THYM	cis	rs7072216	0.763	rs8181292	chr10:100175477	A/G	cg03852570	chr10:100175106	PYROXD2	0.38	5.03	0.46	2.35e-6	Metabolite levels;
THYM	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg08885076	chr2:99613938	TSGA10	0.52	5.04	0.46	2.24e-6	Chronic sinus infection;
THYM	cis	rs9914988	0.943	rs9908881	chr17:27100924	T/A	cg20469991	chr17:27169893	C17orf63	-0.78	-4.64	-0.43	1.11e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.72	6.79	0.57	9.58e-10	Lymphocyte counts;
THYM	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs7953508	0.711	rs10492321	chr12:93980088	T/A	cg13201927	chr12:93977447	NA	0.73	5.2	0.47	1.15e-6	Pubertal anthropometrics;
THYM	cis	rs10751667	0.961	rs6597951	chr11:991530	C/T	cg01483505	chr11:975446	AP2A2	0.64	4.94	0.45	3.35e-6	Alzheimer's disease (late onset);
THYM	cis	rs4242434	0.819	rs751680	chr8:22475627	G/A	cg03733263	chr8:22462867	KIAA1967	0.99	11.18	0.75	5.03e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03517284	chr6:25882590	NA	0.74	5.83	0.51	7.58e-8	Blood metabolite levels;
THYM	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs4919044	0.674	rs115089490	chr10:94793496	G/C	cg05127821	chr10:94822908	CYP26C1	-1.21	-6.19	-0.54	1.54e-8	Coronary artery disease;
THYM	cis	rs9355610	0.927	rs2757041	chr6:167370532	C/G	cg15592062	chr6:167189543	RPS6KA2	0.51	5.21	0.47	1.11e-6	Graves' disease;
THYM	cis	rs16866061	0.962	rs16825685	chr2:225434256	C/G	cg12698349	chr2:225449008	CUL3	1.15	10.44	0.73	1.91e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs887829	0.570	rs6753569	chr2:234595817	A/C	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.59	-0.43	1.36e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg22105103	chr4:187893119	NA	0.91	9.58	0.7	1.34e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10979	0.965	rs9496674	chr6:143886106	G/T	cg25407410	chr6:143891975	LOC285740	-0.63	-5.46	-0.49	3.76e-7	Hypospadias;
THYM	cis	rs11690462	0.534	rs7571808	chr2:26572068	G/T	cg11525280	chr2:26624667	C2orf39	-0.53	-5.38	-0.48	5.27e-7	Coronary artery disease;
THYM	cis	rs7100689	0.622	rs7090351	chr10:82142047	T/G	cg01528321	chr10:82214614	TSPAN14	0.78	5.93	0.52	4.97e-8	Post bronchodilator FEV1;
THYM	cis	rs34779708	0.931	rs2490663	chr10:35329735	A/G	cg03585969	chr10:35415529	CREM	-0.62	-4.45	-0.42	2.31e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs73086581	1.000	rs17287822	chr20:3978536	C/T	cg02187196	chr20:3869020	PANK2	0.46	5.27	0.48	8.46e-7	Response to antidepressants in depression;
THYM	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7523273	0.606	rs2796263	chr1:207915978	T/C	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	cis	rs4866334	1.000	rs75534671	chr5:18487744	G/A	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg15556689	chr8:8085844	FLJ10661	0.68	5.38	0.48	5.44e-7	Red cell distribution width;
THYM	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg06481639	chr22:41940642	POLR3H	-0.76	-5.29	-0.48	7.85e-7	Vitiligo;
THYM	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.84e-8	Systolic blood pressure;
THYM	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg22105103	chr4:187893119	NA	0.92	10.13	0.72	8.89e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs78472555	1.000	rs11247124	chr15:100265725	C/T	cg18869061	chr15:100272053	LYSMD4	-0.77	-4.53	-0.42	1.74e-5	Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs7219021	0.550	rs35929648	chr17:47002543	A/G	cg09029085	chr17:47094198	IGF2BP1	-0.37	-5.21	-0.47	1.08e-6	Schizophrenia or bipolar disorder;
THYM	cis	rs12586317	0.552	rs78139839	chr14:35789347	C/T	cg07166546	chr14:35805898	NA	-0.22	-5.26	-0.47	8.91e-7	Psoriasis;
THYM	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg16579431	chr16:433439	TMEM8A;LOC100134368	0.63	5.14	0.47	1.48e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2458413	0.521	rs2458427	chr8:105339594	G/T	cg04554929	chr8:105342491	NA	-0.5	-7.61	-0.62	2e-11	Paget's disease;
THYM	cis	rs35934224	0.714	rs75224199	chr22:19851164	G/A	cg11182965	chr22:19864308	TXNRD2	-0.8	-4.82	-0.44	5.49e-6	Glaucoma (primary open-angle);
THYM	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg21385522	chr1:16154831	NA	0.73	5.37	0.48	5.58e-7	Dilated cardiomyopathy;
THYM	cis	rs7513165	0.932	rs11240694	chr1:204157973	C/T	cg04791601	chr1:204159016	NA	0.39	4.78	0.44	6.31e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
THYM	cis	rs2721195	0.781	rs10110962	chr8:145780323	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.78	6.08	0.53	2.49e-8	Age at first birth;
THYM	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg26384229	chr12:38710491	ALG10B	-0.9	-7.35	-0.6	6.77e-11	Bladder cancer;
THYM	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.75	-5.09	-0.46	1.82e-6	Body mass index;
THYM	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg26597838	chr10:835615	NA	1.08	7.25	0.6	1.1e-10	Eosinophil percentage of granulocytes;
THYM	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.27	10.84	0.74	2.66e-18	Platelet count;
THYM	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg14416269	chr4:6271139	WFS1	0.54	5.62	0.5	1.93e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg15009913	chr1:2287741	MORN1	-0.49	-4.7	-0.43	8.92e-6	Body mass index;
THYM	cis	rs1160297	0.576	rs6746666	chr2:53089346	C/T	cg07782112	chr2:53107842	NA	0.73	5.9	0.52	5.45e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs7578361	0.918	rs967697	chr2:150336210	C/T	cg17961725	chr2:150454027	NA	-0.77	-5.69	-0.5	1.43e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9733	0.596	rs11582840	chr1:150688487	A/G	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg09877947	chr5:131593287	PDLIM4	0.58	4.63	0.43	1.15e-5	Blood metabolite levels;
THYM	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg02825527	chr7:2087843	MAD1L1	-0.83	-5.04	-0.46	2.24e-6	Neuroticism;
THYM	cis	rs10899021	0.790	rs11236180	chr11:74342928	A/G	cg25880958	chr11:74394337	NA	-0.72	-4.72	-0.44	7.99e-6	Response to metformin (IC50);
THYM	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-11.43	-0.76	1.48e-19	Height;
THYM	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.24	9.45	0.7	2.46e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs79565040	1	rs79565040	chr1:8917398	T/TTA	cg10211414	chr1:8875053	RERE	-0.66	-6.3	-0.54	9.13e-9	White blood cell count (basophil);
THYM	cis	rs1983170	1.000	rs1983170	chr1:91986482	G/A	cg04676771	chr1:91176081	NA	0.68	4.85	0.45	4.84e-6	Eosinophil percentage of white cells;
THYM	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg12310025	chr6:25882481	NA	-0.74	-6.06	-0.53	2.71e-8	Blood metabolite levels;
THYM	cis	rs7187994	0.895	rs12933276	chr16:84770867	C/T	cg07647771	chr16:84786436	USP10	-0.57	-4.73	-0.44	7.95e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs10206020	0.836	rs10202105	chr2:1553301	C/T	cg12573674	chr2:1569213	NA	-1.35	-8.97	-0.68	2.67e-14	IgG glycosylation;
THYM	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg02018176	chr4:1364513	KIAA1530	-0.81	-7.69	-0.62	1.37e-11	Obesity-related traits;
THYM	cis	rs11711311	0.747	rs11928590	chr3:113343478	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.54	-4.49	-0.42	1.99e-5	IgG glycosylation;
THYM	cis	rs4886920	0.605	rs12912080	chr15:78126758	T/C	cg10461261	chr15:78109450	NA	0.46	4.46	0.42	2.25e-5	Neuroticism;
THYM	cis	rs4720575	1.000	rs4507670	chr7:47097526	C/T	cg00036614	chr7:47093842	NA	-0.6	-5.28	-0.48	8.3e-7	Angiotensin-converting enzyme inhibitor intolerance;
THYM	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg18538332	chr22:24372958	LOC391322	-1.05	-13.88	-0.82	1.4e-24	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg26924012	chr15:45694286	SPATA5L1	1.02	9.33	0.69	4.4e-15	Homoarginine levels;
THYM	cis	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	0.929	rs2280550	chr7:1976556	G/A	cg10360139	chr7:1886902	MAD1L1	-0.59	-4.76	-0.44	6.82e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg04025307	chr7:1156635	C7orf50	0.87	8.37	0.65	5e-13	Longevity;Endometriosis;
THYM	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg07424592	chr7:64974309	NA	1.08	5.73	0.51	1.2e-7	Diabetic kidney disease;
THYM	cis	rs1003719	0.646	rs7276711	chr21:38578189	G/A	cg01329690	chr21:38580129	DSCR9	-0.36	-5.0	-0.46	2.67e-6	Eye color traits;
THYM	cis	rs669446	0.562	rs6429636	chr1:44183540	G/T	cg15962314	chr1:44399869	ARTN	0.43	4.58	0.43	1.42e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg06238570	chr21:40685208	BRWD1	0.92	6.87	0.58	6.76e-10	Cognitive function;
THYM	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg18825531	chr11:62321136	NA	-0.42	-4.8	-0.44	5.78e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg10515332	chr4:99064459	C4orf37	0.59	4.68	0.43	9.33e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.7	5.63	0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg12560992	chr17:57184187	TRIM37	0.93	8.88	0.67	4.06e-14	Intelligence (multi-trait analysis);
THYM	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg00339695	chr16:24857497	SLC5A11	0.68	6.47	0.55	4.23e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22455342	chr2:225449267	CUL3	0.97	9.01	0.68	2.12e-14	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs6546324	0.625	rs1430792	chr2:67864744	A/C	cg18237512	chr2:67827392	NA	-0.82	-5.05	-0.46	2.11e-6	Endometriosis;
THYM	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg09338302	chr7:1325757	NA	0.48	4.5	0.42	1.96e-5	Bipolar disorder;
THYM	cis	rs1336149	0.529	rs1750811	chr1:157038021	T/A	cg12604331	chr1:156906485	ARHGEF11;MIR765	-0.55	-4.57	-0.42	1.45e-5	Chin dimples;
THYM	cis	rs11792861	0.566	rs6477687	chr9:111837791	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.6	-5.08	-0.46	1.85e-6	Menarche (age at onset);
THYM	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Body mass index;
THYM	cis	rs2364543	0.624	rs61774752	chr1:41847024	T/C	cg19619003	chr1:41846758	NA	-0.28	-5.83	-0.51	7.63e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg05738196	chr6:26577821	NA	-0.66	-5.16	-0.47	1.33e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg06074448	chr4:187884817	NA	-1.02	-12.98	-0.8	9.26e-23	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12817549	0.685	rs4761525	chr12:94147763	T/G	cg19571390	chr12:94157676	CRADD	0.57	4.72	0.44	8.16e-6	Hip circumference adjusted for BMI;
THYM	cis	rs11599315	0.507	rs12218307	chr10:1341914	G/A	cg09624528	chr10:1369823	ADARB2	0.77	6.14	0.53	1.87e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	trans	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.12	8.09	0.64	1.9e-12	Exhaled nitric oxide output;
THYM	cis	rs10186029	0.708	rs4672673	chr2:213981463	A/G	cg08319019	chr2:214017104	IKZF2	0.8	6.51	0.56	3.56e-9	Systemic sclerosis;
THYM	cis	rs2797160	1.000	rs1832938	chr6:125988964	G/C	cg16306078	chr6:126000798	NA	-0.54	-5.6	-0.5	2.08e-7	Endometrial cancer;
THYM	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg08999081	chr20:33150536	PIGU	0.59	5.24	0.47	9.7e-7	Height;
THYM	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg19774624	chr17:42201019	HDAC5	0.83	8.07	0.64	2.15e-12	Total body bone mineral density;
THYM	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg13683864	chr3:40499215	RPL14	0.68	5.96	0.52	4.35e-8	Renal cell carcinoma;
THYM	cis	rs2625529	0.762	rs1384007	chr15:72229534	T/C	cg16672083	chr15:72433130	SENP8	-0.56	-5.03	-0.46	2.35e-6	Red blood cell count;
THYM	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg01751800	chr4:77820391	ANKRD56	0.56	4.63	0.43	1.15e-5	Emphysema distribution in smoking;
THYM	cis	rs6430585	0.583	rs79176913	chr2:136638113	C/A	cg04750100	chr2:136595281	LCT	0.56	5.26	0.47	8.94e-7	Corneal structure;
THYM	cis	rs3106136	0.546	rs2632417	chr4:95137542	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.06	-0.46	2.08e-6	Capecitabine sensitivity;
THYM	cis	rs6547741	0.967	rs4665995	chr2:27813827	T/G	cg27432699	chr2:27873401	GPN1	0.68	5.97	0.52	4.14e-8	Oral cavity cancer;
THYM	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg13390004	chr1:15929781	NA	0.62	4.72	0.44	8.11e-6	Systolic blood pressure;
THYM	cis	rs2637266	0.597	rs2583065	chr10:78555915	A/G	cg18941641	chr10:78392320	NA	0.74	5.85	0.51	6.96e-8	Pulmonary function;
THYM	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg18512352	chr11:47633146	NA	-0.52	-6.14	-0.53	1.92e-8	Subjective well-being;
THYM	cis	rs36051895	0.659	rs10283730	chr9:5073289	G/A	cg02405213	chr9:5042618	JAK2	-1.03	-11.11	-0.75	7.02e-19	Pediatric autoimmune diseases;
THYM	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg10802521	chr3:52805072	NEK4	-0.57	-4.81	-0.44	5.67e-6	Electroencephalogram traits;
THYM	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg00631329	chr6:26305371	NA	-0.74	-7.75	-0.62	9.96e-12	Educational attainment;
THYM	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg16049864	chr8:95962084	TP53INP1	0.77	6.45	0.55	4.62e-9	Type 2 diabetes;
THYM	cis	rs9796	0.870	rs2412572	chr15:41264426	G/C	cg18705301	chr15:41695430	NDUFAF1	0.55	4.57	0.42	1.44e-5	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3741151	1.000	rs74749711	chr11:73052839	A/T	cg12959048	chr11:73096162	RELT	-0.46	-4.88	-0.45	4.2e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7246967	0.673	rs407989	chr19:22991586	C/G	cg05241461	chr19:22816980	ZNF492	-0.63	-4.97	-0.45	3e-6	Bronchopulmonary dysplasia;
THYM	cis	rs10887741	0.646	rs1358864	chr10:89426630	A/C	cg13926569	chr10:89418898	PAPSS2	0.63	7.28	0.6	9.67e-11	Exercise (leisure time);
THYM	cis	rs2932538	0.922	rs7522110	chr1:113072914	A/C	cg22162597	chr1:113214053	CAPZA1	0.6	4.82	0.44	5.52e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	6.03	0.53	3.08e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12496230	0.951	rs34954762	chr3:66853890	A/G	cg23477460	chr3:66848765	NA	1.26	8.4	0.65	4.28e-13	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg20503657	chr10:835505	NA	1.37	9.33	0.69	4.52e-15	Eosinophil percentage of granulocytes;
THYM	cis	rs72827839	0.846	rs74992250	chr17:46272986	G/C	cg23391107	chr17:45924227	SP6	0.83	5.6	0.5	2.06e-7	Ease of getting up in the morning;
THYM	cis	rs13082711	0.911	rs4973769	chr3:27425746	T/C	cg02860705	chr3:27208620	NA	0.67	4.7	0.43	8.87e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs988913	0.706	rs34563989	chr6:54945469	G/A	cg18532076	chr6:54711417	FAM83B	0.49	4.51	0.42	1.83e-5	Menarche (age at onset);
THYM	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs6732160	0.613	rs58317144	chr2:73388153	C/T	cg24220031	chr2:73402428	NA	-0.73	-5.81	-0.51	8.47e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7578361	1.000	rs6756528	chr2:150395893	C/T	cg17961725	chr2:150454027	NA	0.61	5.16	0.47	1.35e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg18200150	chr17:30822561	MYO1D	0.79	6.82	0.57	8.57e-10	Schizophrenia;
THYM	cis	rs713587	0.563	rs10865315	chr2:25100738	C/A	cg01884057	chr2:25150051	NA	0.64	6.17	0.53	1.66e-8	Body mass index in non-asthmatics;
THYM	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg02753203	chr1:228287806	NA	0.97	8.27	0.65	8.11e-13	Diastolic blood pressure;
THYM	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg09455208	chr3:40491958	NA	0.46	4.87	0.45	4.42e-6	Renal cell carcinoma;
THYM	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg07460842	chr6:66804631	NA	0.93	5.61	0.5	1.96e-7	Exhaled nitric oxide levels;
THYM	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg21014159	chr11:117668035	DSCAML1	0.72	5.11	0.46	1.68e-6	Myopia;
THYM	cis	rs12216545	0.737	rs1916010	chr7:150234051	A/G	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg11494091	chr17:61959527	GH2	0.7	6.46	0.55	4.55e-9	Height;
THYM	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg03433033	chr1:76189801	ACADM	0.78	9.51	0.7	1.87e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs986417	1.000	rs8015462	chr14:61046687	G/A	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg22974920	chr21:40686053	BRWD1	-0.58	-4.49	-0.42	2e-5	Cognitive function;
THYM	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22857025	chr5:266934	NA	-1.59	-9.89	-0.71	2.8e-16	Breast cancer;
THYM	cis	rs3820068	0.705	rs57440988	chr1:15879034	T/C	cg05660106	chr1:15850417	CASP9	1.16	10.06	0.72	1.25e-16	Systolic blood pressure;
THYM	cis	rs4148883	0.628	rs34195655	chr4:100073795	C/T	cg12011299	chr4:100065546	ADH4	0.66	5.65	0.5	1.65e-7	Alcohol dependence;
THYM	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg10792982	chr14:105748885	BRF1	0.68	6.8	0.57	9.14e-10	Platelet count;
THYM	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg04267008	chr7:1944627	MAD1L1	-0.55	-4.49	-0.42	2.03e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs4638749	0.501	rs1872594	chr2:108746813	T/C	cg25838818	chr2:108905173	SULT1C2	-0.52	-4.89	-0.45	4.13e-6	Blood pressure;
THYM	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg14690197	chr8:22456421	C8orf58	0.49	4.84	0.44	5.07e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg12311346	chr5:56204834	C5orf35	0.61	4.67	0.43	9.99e-6	Initial pursuit acceleration;
THYM	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.71	5.66	0.5	1.59e-7	Tonsillectomy;
THYM	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg06521331	chr12:34319734	NA	-0.95	-9.11	-0.68	1.31e-14	Morning vs. evening chronotype;
THYM	cis	rs9364687	0.639	rs2321703	chr6:163957736	A/T	cg01639524	chr6:163818125	NA	0.46	4.5	0.42	1.89e-5	Body mass index;
THYM	cis	rs1488864	0.655	rs1844188	chr11:6346572	A/G	cg12755421	chr11:6342214	PRKCDBP	-0.52	-4.52	-0.42	1.78e-5	Smooth-surface caries;
THYM	cis	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg06521331	chr12:34319734	NA	-1.03	-10.3	-0.73	3.74e-17	Morning vs. evening chronotype;
THYM	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg26384229	chr12:38710491	ALG10B	-0.71	-5.53	-0.49	2.8e-7	Morning vs. evening chronotype;
THYM	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.59	-4.77	-0.44	6.69e-6	Response to bleomycin (chromatid breaks);
THYM	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg06377222	chr21:46677750	NA	-0.5	-4.53	-0.42	1.74e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg22681709	chr2:178499509	PDE11A	-0.55	-5.61	-0.5	2.01e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs765787	0.530	rs28526629	chr15:45540462	C/T	cg24006582	chr15:45444508	DUOX1	-0.84	-7.23	-0.6	1.23e-10	Uric acid levels;
THYM	cis	rs2625529	0.938	rs8747	chr15:72115541	C/A	cg16672083	chr15:72433130	SENP8	-0.56	-4.74	-0.44	7.62e-6	Red blood cell count;
THYM	cis	rs4499344	0.657	rs259238	chr19:33140381	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	6.33	0.54	7.93e-9	Mean platelet volume;
THYM	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg09359103	chr1:154839909	KCNN3	-0.83	-11.05	-0.75	9.7e-19	Prostate cancer;
THYM	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg08017756	chr2:100939284	LONRF2	-0.73	-7.53	-0.61	2.88e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12446552	0.695	rs113962704	chr16:11717832	T/A	cg09662852	chr16:11707685	NA	-0.64	-6.04	-0.53	3e-8	Colorectal or endometrial cancer;
THYM	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	5.13	0.47	1.5e-6	Obesity-related traits;
THYM	cis	rs6960043	0.782	rs4721401	chr7:15064896	T/G	cg19272540	chr7:15055459	NA	-0.44	-4.87	-0.45	4.36e-6	Type 2 diabetes;
THYM	cis	rs514406	0.627	rs485128	chr1:53344583	T/C	cg08736216	chr1:53307985	ZYG11A	-0.62	-5.56	-0.5	2.49e-7	Monocyte count;
THYM	cis	rs12579753	0.913	rs17749243	chr12:82178079	A/C	cg07988820	chr12:82153109	PPFIA2	-0.78	-4.92	-0.45	3.61e-6	Resting heart rate;
THYM	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.73	-7.2	-0.59	1.4e-10	Lymphocyte counts;
THYM	cis	rs4363385	0.818	rs574649	chr1:153008471	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg20387954	chr3:183756860	HTR3D	0.58	4.81	0.44	5.56e-6	Anterior chamber depth;
THYM	cis	rs7937890	0.869	rs2915404	chr11:14404825	A/G	cg19336497	chr11:14380999	RRAS2	-0.48	-5.1	-0.46	1.76e-6	Mitochondrial DNA levels;
THYM	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg14196790	chr5:131705035	SLC22A5	0.55	5.04	0.46	2.21e-6	Blood metabolite levels;
THYM	cis	rs7781977	0.920	rs62447179	chr7:50339609	G/A	cg01139861	chr7:50343298	IKZF1	0.71	6.89	0.58	5.97e-10	IgG glycosylation;
THYM	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.43	0.7	2.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7507204	0.530	rs4807469	chr19:3443382	G/C	cg08380311	chr19:3435252	NFIC	1.14	14.73	0.83	2.87e-26	Height;
THYM	cis	rs2463822	1.000	rs72921498	chr11:62113090	C/T	cg06239285	chr11:62104954	ASRGL1	-1.42	-7.37	-0.6	6.25e-11	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg08645402	chr16:4508243	NA	0.63	5.1	0.46	1.74e-6	Schizophrenia;
THYM	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.27	6.27	0.54	1.04e-8	Obesity-related traits;
THYM	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg24692254	chr21:30365293	RNF160	0.64	4.82	0.44	5.48e-6	Cognitive test performance;
THYM	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg02527881	chr3:46936655	PTH1R	-0.66	-6.44	-0.55	4.86e-9	Colorectal cancer;
THYM	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg11673840	chr17:47092156	IGF2BP1	-0.5	-5.02	-0.46	2.38e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7567389	0.510	rs6755028	chr2:128195442	G/A	cg09760422	chr2:128146352	NA	-0.45	-5.91	-0.52	5.23e-8	Self-rated health;
THYM	cis	rs11756438	0.572	rs2638552	chr6:118999412	C/T	cg21191810	chr6:118973309	C6orf204	0.56	5.65	0.5	1.7e-7	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg26384229	chr12:38710491	ALG10B	-1.05	-10.43	-0.73	1.96e-17	Heart rate;
THYM	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.73	-0.44	7.7e-6	Crohn's disease;
THYM	cis	rs11723261	0.582	rs3747693	chr4:124375	T/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.85	5.95	0.52	4.45e-8	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs1065852	0.526	rs4822079	chr22:42394612	G/C	cg22189786	chr22:42395067	WBP2NL	0.53	5.39	0.48	5.22e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg26384229	chr12:38710491	ALG10B	1.0	7.56	0.61	2.54e-11	Bladder cancer;
THYM	cis	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.58	-0.43	1.39e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg13443165	chr9:33130375	B4GALT1	-0.87	-7.99	-0.63	3.23e-12	IgG glycosylation;
THYM	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg27534772	chr1:16042836	PLEKHM2	-0.55	-6.15	-0.53	1.82e-8	Systolic blood pressure;
THYM	cis	rs4891159	0.790	rs11150953	chr18:74145491	G/A	cg24786174	chr18:74118243	ZNF516	-0.87	-9.72	-0.71	6.43e-16	Longevity;
THYM	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	7.64	0.62	1.73e-11	Smoking behavior;
THYM	cis	rs752010	0.806	rs4457567	chr1:42091407	C/T	cg06885757	chr1:42089581	HIVEP3	0.55	6.52	0.56	3.4e-9	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.55	-5.61	-0.5	2.01e-7	Crohn's disease;
THYM	cis	rs9393692	0.620	rs6908402	chr6:26293014	A/T	cg00631329	chr6:26305371	NA	-0.47	-4.82	-0.44	5.46e-6	Educational attainment;
THYM	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg21475434	chr5:93447410	FAM172A	0.86	5.57	0.5	2.35e-7	Diabetic retinopathy;
THYM	cis	rs79349575	0.783	rs62075818	chr17:46982327	T/A	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg00383909	chr3:49044727	WDR6	1.14	6.76	0.57	1.13e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs9549260	0.755	rs58919811	chr13:41226485	A/C	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs265548	0.608	rs36690	chr19:17910483	C/T	cg16744531	chr19:17905626	B3GNT3	0.58	6.08	0.53	2.52e-8	Tumor biomarkers;
THYM	cis	rs12935418	0.583	rs12446698	chr16:80964421	G/A	cg16651780	chr16:81037892	C16orf61	0.82	5.2	0.47	1.13e-6	Mean corpuscular volume;
THYM	cis	rs9902453	0.933	rs7216494	chr17:28502651	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.83	0.44	5.26e-6	Coffee consumption (cups per day);
THYM	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg23583168	chr7:148888333	NA	-1.0	-13.2	-0.8	3.29e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg10523679	chr1:76189770	ACADM	0.89	8.45	0.65	3.39e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg02725872	chr8:58115012	NA	-0.81	-5.05	-0.46	2.12e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg06558623	chr16:89946397	TCF25	1.5	6.54	0.56	3.14e-9	Skin colour saturation;
THYM	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs4481887	0.741	rs6587462	chr1:248539094	C/T	cg00666640	chr1:248458726	OR2T12	-0.55	-4.71	-0.44	8.41e-6	Common traits (Other);
THYM	cis	rs2730245	0.527	rs1188971	chr7:158664463	G/T	cg11984989	chr7:158649758	WDR60	1.01	8.5	0.66	2.65e-13	Height;
THYM	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.65	4.79	0.44	6.09e-6	Glycated hemoglobin levels;
THYM	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg04282206	chr17:62833786	PLEKHM1P	-0.83	-8.06	-0.64	2.23e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4363385	0.818	rs378010	chr1:153007987	A/G	cg13444842	chr1:152974279	SPRR3	-0.59	-4.81	-0.44	5.61e-6	Inflammatory skin disease;
THYM	cis	rs1347297	0.526	rs2276617	chr2:179250397	A/G	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.6	-4.63	-0.43	1.16e-5	Alzheimer disease and age of onset;
THYM	cis	rs2859741	0.967	rs522481	chr1:37488337	C/T	cg09363841	chr1:37513479	NA	-0.7	-6.58	-0.56	2.52e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.63	-5.54	-0.49	2.68e-7	Hip circumference adjusted for BMI;
THYM	cis	rs933688	0.941	rs11948056	chr5:90680468	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.81	5.3	0.48	7.56e-7	Smoking behavior;
THYM	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg10018233	chr7:150070692	REPIN1	0.45	7.72	0.62	1.16e-11	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg15247329	chr7:2764246	NA	-0.7	-5.92	-0.52	5.06e-8	Height;
THYM	cis	rs4851266	0.898	rs10496346	chr2:100853267	A/G	cg08017756	chr2:100939284	LONRF2	0.56	4.45	0.42	2.31e-5	Educational attainment;
THYM	cis	rs2456568	0.802	rs11020585	chr11:93638493	A/C	cg17347335	chr11:93583973	C11orf90	0.46	4.5	0.42	1.95e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2797160	0.967	rs1343120	chr6:125992810	A/G	cg16306078	chr6:126000798	NA	-0.54	-5.61	-0.5	2.02e-7	Endometrial cancer;
THYM	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg11764359	chr7:65958608	NA	0.67	4.77	0.44	6.52e-6	Aortic root size;
THYM	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg27394845	chr17:28928406	LRRC37B2	-0.92	-4.58	-0.43	1.39e-5	Body mass index;
THYM	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg22655196	chr4:3374909	RGS12	-0.61	-7.41	-0.61	5.15e-11	Serum sulfate level;
THYM	cis	rs868036	0.681	rs4776977	chr15:68108219	C/T	cg24579218	chr15:68104479	NA	-0.83	-8.84	-0.67	5e-14	Restless legs syndrome;
THYM	cis	rs7809615	0.748	rs35183025	chr7:99030782	A/T	cg12290671	chr7:99195819	NA	-0.99	-4.83	-0.44	5.27e-6	Blood metabolite ratios;
THYM	cis	rs59112743	0.510	rs9476836	chr6:15527312	G/T	cg10111214	chr6:14815676	NA	0.75	5.05	0.46	2.17e-6	Multiple keratinocyte cancers;
THYM	cis	rs1448094	0.511	rs7968059	chr12:86163606	A/G	cg00310523	chr12:86230176	RASSF9	0.61	5.31	0.48	7.29e-7	Major depressive disorder;
THYM	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg13147721	chr7:65941812	NA	-0.67	-5.34	-0.48	6.23e-7	Diabetic kidney disease;
THYM	cis	rs6531656	0.663	rs337619	chr4:38621542	T/G	cg24279243	chr4:38676559	KLF3	0.81	6.99	0.58	3.82e-10	Lymphocyte counts;
THYM	cis	rs9796	0.689	rs6492983	chr15:41436049	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.62	-4.92	-0.45	3.62e-6	Menopause (age at onset);
THYM	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg07414643	chr4:187882934	NA	0.67	5.95	0.52	4.52e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg21385522	chr1:16154831	NA	0.85	6.01	0.52	3.38e-8	Dilated cardiomyopathy;
THYM	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg11871910	chr12:69753446	YEATS4	1.06	9.8	0.71	4.32e-16	Blood protein levels;
THYM	cis	rs11096990	0.634	rs3733287	chr4:39217352	A/G	cg24403649	chr4:39172243	NA	0.6	5.16	0.47	1.35e-6	Cognitive function;
THYM	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg10523679	chr1:76189770	ACADM	-0.81	-6.39	-0.55	6.24e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.68	-5.28	-0.48	8.12e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs3812831	0.654	rs6560933	chr13:114937294	A/G	cg06611532	chr13:114900021	NA	-0.58	-6.37	-0.55	6.68e-9	Schizophrenia;
THYM	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg06558623	chr16:89946397	TCF25	1.33	5.65	0.5	1.64e-7	Skin colour saturation;
THYM	cis	rs854765	0.624	rs12938501	chr17:17737258	A/C	cg04398451	chr17:18023971	MYO15A	0.76	6.62	0.56	2.12e-9	Total body bone mineral density;
THYM	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg10505658	chr17:80084571	CCDC57	0.68	7.46	0.61	4.14e-11	Life satisfaction;
THYM	cis	rs6570726	0.870	rs370653	chr6:145823642	G/A	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6918586	0.615	rs198841	chr6:26111671	G/T	cg07061783	chr6:25882402	NA	0.58	4.57	0.42	1.46e-5	Schizophrenia;
THYM	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.37	0.55	6.72e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg26384229	chr12:38710491	ALG10B	-0.74	-5.69	-0.5	1.42e-7	Bladder cancer;
THYM	trans	rs59551326	0.517	rs11087946	chr21:26592951	C/T	cg17452615	chr12:122019080	KDM2B	-0.8	-6.84	-0.57	7.67e-10	Alcohol dependence;
THYM	cis	rs4866334	1.000	rs79246642	chr5:18442878	C/T	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg07424592	chr7:64974309	NA	1.09	5.01	0.46	2.55e-6	Diabetic kidney disease;
THYM	cis	rs7010267	0.935	rs4319131	chr8:119947651	A/G	cg17171407	chr8:119960777	TNFRSF11B	-0.59	-4.79	-0.44	6.12e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.77	7.29	0.6	8.94e-11	Lymphocyte counts;
THYM	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg06634786	chr22:41940651	POLR3H	0.66	5.15	0.47	1.39e-6	Vitiligo;
THYM	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.7	4.75	0.44	7.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs748404	0.660	rs2467741	chr15:43742626	T/C	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs6840360	0.667	rs4266275	chr4:152348064	A/G	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.3	-0.48	7.43e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg00376283	chr12:123451042	ABCB9	-0.75	-5.22	-0.47	1.05e-6	Neutrophil percentage of white cells;
THYM	cis	rs362296	0.511	rs2857861	chr4:3323767	C/T	cg22655196	chr4:3374909	RGS12	0.44	5.21	0.47	1.1e-6	Parental longevity (mother's age at death);
THYM	cis	rs7843479	1.000	rs2054711	chr8:21818060	A/G	cg17168535	chr8:21777572	XPO7	0.73	5.25	0.47	9.34e-7	Mean corpuscular volume;
THYM	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg24578937	chr1:2090814	PRKCZ	0.75	7.56	0.61	2.54e-11	Height;
THYM	cis	rs2797160	1.000	rs2211418	chr6:125995503	G/A	cg16306078	chr6:126000798	NA	-0.52	-5.25	-0.47	9.07e-7	Endometrial cancer;
THYM	cis	rs5985	0.659	rs3024323	chr6:6317960	A/G	cg16530177	chr6:6320324	F13A1	0.7	5.83	0.51	7.44e-8	End-stage coagulation;
THYM	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg14784868	chr12:69753453	YEATS4	1.13	12.26	0.78	2.8e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg05283184	chr6:79620031	NA	-0.94	-9.25	-0.69	6.49e-15	Intelligence (multi-trait analysis);
THYM	cis	rs3096299	0.754	rs3096320	chr16:89403057	C/A	cg02627286	chr16:89590583	SPG7	0.5	4.48	0.42	2.07e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs36051895	0.632	rs2381213	chr9:5168871	A/G	cg02405213	chr9:5042618	JAK2	1.04	9.96	0.71	2.03e-16	Pediatric autoimmune diseases;
THYM	cis	rs9677476	0.863	rs4637098	chr2:232075528	C/T	cg07929768	chr2:232055508	NA	0.62	6.41	0.55	5.63e-9	Food antigen IgG levels;
THYM	cis	rs897984	0.762	rs8062719	chr16:31002664	A/G	cg06892815	chr16:30991727	SETD1A	0.5	4.64	0.43	1.12e-5	Dementia with Lewy bodies;
THYM	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg22117172	chr7:91764530	CYP51A1	0.35	4.46	0.42	2.27e-5	Breast cancer;
THYM	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg00271210	chr6:167070053	RPS6KA2	-0.5	-4.93	-0.45	3.5e-6	Crohn's disease;
THYM	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg18876405	chr7:65276391	NA	-0.58	-4.99	-0.46	2.78e-6	Aortic root size;
THYM	cis	rs2688608	1.000	rs2688610	chr10:75654931	A/G	cg15838173	chr10:75533400	FUT11	0.42	4.56	0.42	1.51e-5	Inflammatory bowel disease;
THYM	cis	rs9549260	0.755	rs2755214	chr13:41149345	T/G	cg21288729	chr13:41239152	FOXO1	0.73	5.63	0.5	1.82e-7	Red blood cell count;
THYM	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg08736216	chr1:53307985	ZYG11A	-0.56	-5.21	-0.47	1.07e-6	Monocyte count;
THYM	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg03213289	chr20:61660250	NA	-0.85	-8.83	-0.67	5.23e-14	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6499129	0.571	rs13339140	chr16:67213923	C/T	cg26912222	chr16:68000829	SLC12A4	0.93	4.86	0.45	4.55e-6	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg18758796	chr5:131593413	PDLIM4	0.49	4.66	0.43	1.03e-5	Blood metabolite levels;
THYM	cis	rs7426056	0.530	rs1181389	chr2:204574890	T/C	cg13651908	chr2:204570033	CD28	-0.7	-5.33	-0.48	6.55e-7	Primary sclerosing cholangitis;
THYM	cis	rs1299926	1.000	rs1299926	chr16:8871081	A/T	cg08365638	chr16:9212442	C16orf72	0.95	4.61	0.43	1.27e-5	Anger;
THYM	cis	rs4851254	0.660	rs1821830	chr2:100680279	C/T	cg22139774	chr2:100720529	AFF3	-0.41	-4.69	-0.43	9.07e-6	Intelligence (multi-trait analysis);
THYM	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs131777	0.545	rs131759	chr22:51015481	G/A	cg00083937	chr22:51039805	MAPK8IP2	0.62	5.54	0.49	2.73e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs28829049	0.565	rs2182197	chr1:19369527	C/T	cg22333259	chr1:19394757	NA	0.48	4.99	0.46	2.78e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg02317251	chr4:10116515	WDR1	-0.56	-4.95	-0.45	3.23e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs2273669	0.667	rs75942063	chr6:109352545	G/A	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg26038318	chr20:34205095	SPAG4	0.59	4.7	0.43	8.69e-6	Total cholesterol levels;
THYM	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs9880211	0.904	rs9857833	chr3:136404467	T/C	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.77	6.67	0.56	1.67e-9	Menarche (age at onset);
THYM	cis	rs17598306	1.000	rs17598306	chr7:96581811	A/G	cg13449377	chr7:96631089	DLX6AS	-0.76	-4.78	-0.44	6.38e-6	Radiation response;
THYM	cis	rs870825	0.616	rs7659101	chr4:185632158	C/T	cg04058563	chr4:185651563	MLF1IP	1.06	9.68	0.7	7.89e-16	Blood protein levels;
THYM	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.49	4.57	0.42	1.44e-5	Lymphocyte counts;
THYM	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.64	-6.72	-0.57	1.33e-9	Longevity;Endometriosis;
THYM	cis	rs6032067	0.673	rs2301366	chr20:43836173	T/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.61	-5.89	-0.52	5.91e-8	Blood protein levels;
THYM	cis	rs4767234	1.000	rs7967272	chr12:114644733	T/G	cg13131185	chr12:113914611	NA	-0.47	-4.54	-0.42	1.64e-5	Airflow obstruction;
THYM	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg01073479	chr16:3509474	NAT15	0.63	5.26	0.48	8.71e-7	Tuberculosis;
THYM	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg23583168	chr7:148888333	NA	-1.0	-13.46	-0.81	9.53e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1451375	0.755	rs6969081	chr7:50624505	A/T	cg18232548	chr7:50535776	DDC	0.67	5.18	0.47	1.22e-6	Malaria;
THYM	cis	rs7404928	0.678	rs6497703	chr16:23921464	G/A	cg26685404	chr16:23957272	PRKCB	0.67	7.58	0.61	2.26e-11	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs7572733	0.534	rs7604700	chr2:198718630	A/G	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs9399401	0.667	rs11155242	chr6:142691549	A/C	cg03128060	chr6:142623767	GPR126	0.7	9.41	0.69	2.99e-15	Chronic obstructive pulmonary disease;
THYM	trans	rs10462794	0.789	rs7719895	chr5:4490338	C/T	cg10044466	chr11:10328911	ADM	-1.18	-6.92	-0.58	5.33e-10	DNA methylation (variation);
THYM	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg13319975	chr6:146136371	FBXO30	-0.65	-5.35	-0.48	6.03e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4604732	0.578	rs7525209	chr1:247627404	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	4.54	0.42	1.64e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg00278517	chr6:167070616	RPS6KA2	-0.35	-4.81	-0.44	5.7e-6	Crohn's disease;
THYM	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg09264619	chr17:80180166	NA	-0.54	-4.54	-0.42	1.66e-5	Life satisfaction;
THYM	cis	rs1021993	0.672	rs2843167	chr1:209512897	A/T	cg06155620	chr1:209527581	NA	-0.51	-4.53	-0.42	1.72e-5	Gut microbiome composition (winter);
THYM	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg09035930	chr12:129282057	SLC15A4	0.59	5.33	0.48	6.66e-7	Systemic lupus erythematosus;
THYM	cis	rs600806	0.815	rs10858089	chr1:109926828	T/C	cg23616212	chr1:109941201	SORT1	-0.5	-4.65	-0.43	1.06e-5	Intelligence (multi-trait analysis);
THYM	trans	rs9747201	1.000	rs57405744	chr17:80177465	A/G	cg07393940	chr7:158741817	NA	1.1	8.4	0.65	4.38e-13	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs11671005	0.651	rs55716128	chr19:59048754	C/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.59	-4.62	-0.43	1.19e-5	Mean platelet volume;
THYM	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-5.97	-0.52	4.14e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg11189052	chr15:85197271	WDR73	-0.68	-5.36	-0.48	5.73e-7	P wave terminal force;
THYM	cis	rs72627123	0.867	rs17094076	chr14:74400492	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg26384229	chr12:38710491	ALG10B	-0.61	-4.54	-0.42	1.62e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs490234	0.676	rs13293034	chr9:128256951	C/T	cg14078157	chr9:128172775	NA	-0.76	-6.42	-0.55	5.35e-9	Mean arterial pressure;
THYM	cis	rs9790314	0.645	rs10936224	chr3:160902531	G/A	cg03342759	chr3:160939853	NMD3	-0.77	-6.33	-0.54	7.98e-9	Morning vs. evening chronotype;
THYM	cis	rs7172809	0.599	rs17471753	chr15:77763809	C/T	cg10437265	chr15:77819839	NA	-0.5	-4.57	-0.42	1.47e-5	Glucose homeostasis traits;
THYM	cis	rs300703	0.719	rs385272	chr2:206704	A/G	cg21211680	chr2:198530	NA	-1.15	-7.0	-0.58	3.62e-10	Blood protein levels;
THYM	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg02887458	chr19:19495540	GATAD2A	-0.42	-5.08	-0.46	1.87e-6	Bipolar disorder;
THYM	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg10661904	chr17:79619235	PDE6G	-0.65	-6.24	-0.54	1.19e-8	Eye color traits;
THYM	cis	rs11771526	0.892	rs76035550	chr7:32371359	G/A	cg27532318	chr7:32358331	NA	0.95	5.63	0.5	1.85e-7	Body mass index;
THYM	cis	rs7584330	0.666	rs72620816	chr2:238353604	C/T	cg16989719	chr2:238392110	NA	-0.64	-4.94	-0.45	3.3e-6	Prostate cancer;
THYM	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg09549813	chr16:4587862	C16orf5	0.59	6.65	0.56	1.84e-9	Schizophrenia;
THYM	cis	rs7918232	0.943	rs4747584	chr10:27373333	G/A	cg14442939	chr10:27389572	ANKRD26	0.79	4.47	0.42	2.13e-5	Breast cancer;
THYM	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg02734326	chr4:10020555	SLC2A9	0.6	5.02	0.46	2.43e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11563648	0.553	rs6979232	chr7:127016217	T/A	cg08586737	chr7:127225949	GCC1	-0.33	-4.56	-0.42	1.5e-5	Resting heart rate;
THYM	cis	rs144658219	1	rs144658219	chr7:80296965	G/GTACTTGAT	cg21369886	chr7:80305251	CD36	-0.61	-6.18	-0.54	1.6e-8	Red blood cell count;
THYM	cis	rs9790314	1.000	rs9850455	chr3:161017192	G/A	cg04691961	chr3:161091175	C3orf57	-0.53	-4.55	-0.42	1.56e-5	Morning vs. evening chronotype;
THYM	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg21798802	chr22:38057573	PDXP	0.47	5.37	0.48	5.51e-7	Fat distribution (HIV);
THYM	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.58	-4.72	-0.44	8.14e-6	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs912057	1.000	rs1294414	chr6:6740366	A/G	cg06612196	chr6:6737390	NA	0.69	9.89	0.71	2.89e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.76	4.9	0.45	3.98e-6	Smoking behavior;
THYM	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg22920501	chr2:26401640	FAM59B	-1.05	-9.27	-0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs8133932	0.701	rs2183599	chr21:47288873	C/G	cg08707771	chr21:46690014	POFUT2	-0.76	-4.45	-0.42	2.29e-5	Schizophrenia;
THYM	cis	rs9287719	0.674	rs759399	chr2:10796883	T/C	cg02196655	chr2:10830764	NOL10	0.51	5.1	0.46	1.71e-6	Prostate cancer;
THYM	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-6.65	-0.56	1.84e-9	Chronic sinus infection;
THYM	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg27211696	chr2:191398769	TMEM194B	0.83	8.34	0.65	5.78e-13	Pulse pressure;
THYM	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg12935359	chr14:103987150	CKB	-0.63	-6.62	-0.56	2.09e-9	Body mass index;
THYM	cis	rs490234	0.651	rs13291556	chr9:128240922	T/C	cg14078157	chr9:128172775	NA	-0.77	-6.24	-0.54	1.2e-8	Mean arterial pressure;
THYM	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.14	0.47	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7772486	0.875	rs2814872	chr6:146310234	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.66	-0.5	1.62e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2562456	0.917	rs10420016	chr19:21688602	C/G	cg21751540	chr19:21541537	ZNF738	0.7	4.89	0.45	4.11e-6	Pain;
THYM	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg11245990	chr11:68621969	NA	0.44	4.79	0.44	6.12e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg17178900	chr1:205818956	PM20D1	0.97	10.11	0.72	9.5e-17	Menarche (age at onset);
THYM	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg16624210	chr5:671434	TPPP	0.76	5.61	0.5	2.03e-7	Obesity-related traits;
THYM	cis	rs72772090	0.539	rs72773922	chr5:96116660	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs3733631	1.000	rs28650409	chr4:104628577	C/T	cg24090629	chr4:104641072	TACR3	-0.86	-5.41	-0.49	4.62e-7	Menarche (age at onset);
THYM	cis	rs10492096	0.947	rs11559082	chr12:6602367	C/T	cg13857086	chr12:6580257	VAMP1	0.87	5.27	0.48	8.47e-7	Hip geometry;
THYM	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg06481639	chr22:41940642	POLR3H	-0.74	-4.85	-0.45	4.81e-6	Vitiligo;
THYM	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg27588902	chr6:42928151	GNMT	-0.5	-4.88	-0.45	4.3e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4523957	0.620	rs8070272	chr17:2063117	A/G	cg16513277	chr17:2031491	SMG6	-0.93	-8.54	-0.66	2.22e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7589342	0.894	rs6736932	chr2:106444854	A/G	cg14210321	chr2:106509881	NCK2	-0.72	-5.15	-0.47	1.4e-6	Addiction;
THYM	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1387259	0.929	rs11168460	chr12:48597365	A/G	cg21466736	chr12:48725269	NA	-0.54	-4.88	-0.45	4.33e-6	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	trans	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg07211511	chr3:129823064	LOC729375	-0.91	-7.27	-0.6	1.03e-10	Blood pressure (smoking interaction);
THYM	cis	rs4455778	1.000	rs4455778	chr7:49119500	G/T	cg26309511	chr7:48887640	NA	0.51	4.46	0.42	2.25e-5	Lung cancer in never smokers;
THYM	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg00383909	chr3:49044727	WDR6	1.12	6.62	0.56	2.13e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg07075026	chr17:47091521	IGF2BP1	-0.54	-6.25	-0.54	1.15e-8	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06634786	chr22:41940651	POLR3H	0.84	6.24	0.54	1.21e-8	Vitiligo;
THYM	cis	rs739496	0.515	rs66480035	chr12:112052651	T/C	cg10833066	chr12:111807467	FAM109A	0.52	5.97	0.52	4.05e-8	Platelet count;
THYM	cis	rs7940866	0.834	rs2324315	chr11:130839772	C/G	cg05962950	chr11:130786565	SNX19	0.73	5.79	0.51	8.99e-8	Schizophrenia;
THYM	cis	rs4242434	0.927	rs2272718	chr8:22457388	G/A	cg01710189	chr8:22454888	PDLIM2	-0.56	-5.22	-0.47	1.07e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg26354017	chr1:205819088	PM20D1	0.58	4.63	0.43	1.18e-5	Parkinson's disease;
THYM	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13012494	chr21:47604986	C21orf56	0.75	5.19	0.47	1.18e-6	Testicular germ cell tumor;
THYM	cis	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg07460842	chr6:66804631	NA	-1.1	-7.73	-0.62	1.09e-11	Exhaled nitric oxide output;
THYM	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.22	0.64	1.03e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg09021430	chr5:549028	NA	-0.71	-5.31	-0.48	7.21e-7	Obesity-related traits;
THYM	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg10802521	chr3:52805072	NEK4	-0.79	-7.47	-0.61	3.96e-11	Electroencephalogram traits;
THYM	cis	rs6674176	0.597	rs3762422	chr1:44400532	T/A	cg15962314	chr1:44399869	ARTN	0.51	4.75	0.44	7.14e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs7172809	0.573	rs17468413	chr15:77544510	T/A	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.51	4.7	0.43	8.85e-6	Birth weight;
THYM	cis	rs611744	0.658	rs2443774	chr8:109064957	T/C	cg21045802	chr8:109455806	TTC35	0.59	5.11	0.46	1.68e-6	Dupuytren's disease;
THYM	cis	rs12410462	0.681	rs113316536	chr1:227547033	T/G	cg04117972	chr1:227635322	NA	0.77	4.7	0.43	8.68e-6	Major depressive disorder;
THYM	trans	rs877282	0.945	rs12782447	chr10:771870	C/T	cg22713356	chr15:30763199	NA	1.39	11.36	0.76	2.09e-19	Uric acid levels;
THYM	cis	rs10979	1.000	rs12738	chr6:143890049	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs7084402	0.967	rs7921207	chr10:60270235	G/T	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs11031096	0.678	rs2044135	chr11:4187233	G/A	cg08557956	chr11:4115526	RRM1	-0.55	-4.97	-0.45	2.9e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03576123	chr11:487126	PTDSS2	-1.24	-5.21	-0.47	1.1e-6	Body mass index;
THYM	cis	rs6988636	1.000	rs4377946	chr8:124185887	T/C	cg23067535	chr8:124195133	FAM83A	-1.1	-5.77	-0.51	9.8e-8	Urinary uromodulin levels;
THYM	cis	rs2276498	0.751	rs6123345	chr20:52640597	A/G	cg23682609	chr20:52687365	BCAS1	0.56	4.57	0.42	1.45e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs4568518	0.535	rs6975848	chr7:18061241	G/A	cg00911873	chr7:18067463	PRPS1L1	-0.6	-4.85	-0.45	4.81e-6	Measles;
THYM	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg03388043	chr17:80084554	CCDC57	0.69	5.87	0.52	6.36e-8	Life satisfaction;
THYM	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs11760633	0.615	rs11767667	chr7:1840557	C/T	cg23422044	chr7:1970798	MAD1L1	-0.63	-4.48	-0.42	2.12e-5	Coronary artery disease;
THYM	cis	rs2702888	0.512	rs2738153	chr8:6751900	T/G	cg03082247	chr8:6756796	NA	-0.56	-4.77	-0.44	6.69e-6	Blood pressure;
THYM	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg07936489	chr17:37558343	FBXL20	-0.79	-5.36	-0.48	5.79e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7584330	0.554	rs10176035	chr2:238433449	T/C	cg14458575	chr2:238380390	NA	0.82	4.89	0.45	4.16e-6	Prostate cancer;
THYM	cis	rs11025559	0.796	rs10833317	chr11:20412277	A/T	cg19653624	chr11:20408972	PRMT3	-0.68	-4.7	-0.43	8.91e-6	Pursuit maintenance gain;
THYM	cis	rs2050392	1.000	rs2183176	chr10:30698544	C/T	cg02070205	chr10:30722105	MAP3K8	0.51	4.53	0.42	1.74e-5	Inflammatory bowel disease;
THYM	cis	rs501916	0.833	rs3809486	chr15:48051549	G/T	cg20869673	chr15:48010124	SEMA6D	0.71	5.33	0.48	6.59e-7	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.27	-0.48	8.61e-7	Hemoglobin concentration;
THYM	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg07414643	chr4:187882934	NA	0.67	5.92	0.52	5.16e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs10463554	0.927	rs257315	chr5:102421429	C/A	cg23492399	chr5:102201601	PAM	-0.69	-5.17	-0.47	1.27e-6	Parkinson's disease;
THYM	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg06002616	chr8:101225028	SPAG1	-0.46	-4.75	-0.44	7.33e-6	Atrioventricular conduction;
THYM	cis	rs2115536	0.720	rs12916091	chr15:80222572	T/G	cg00225070	chr15:80189496	MTHFS	0.58	4.75	0.44	7.34e-6	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs1065852	0.526	rs7290655	chr22:42390225	C/G	cg08431931	chr22:42394659	WBP2NL	0.74	6.08	0.53	2.48e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs1211375	0.563	rs1203980	chr16:264642	C/T	cg17291625	chr16:236080	NA	0.61	5.21	0.47	1.11e-6	Hematology traits;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9470366	0.527	rs4711456	chr6:36632482	C/T	cg08179530	chr6:36648295	CDKN1A	-0.61	-4.5	-0.42	1.9e-5	QRS duration;
THYM	cis	rs57244997	0.685	rs2226770	chr6:162447251	C/T	cg17173639	chr6:162384350	PARK2	0.77	4.85	0.45	4.9e-6	Mosquito bite size;
THYM	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg10253484	chr15:75165896	SCAMP2	-0.62	-4.46	-0.42	2.24e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs1178127	0.611	rs2588597	chr7:18817610	A/G	cg13420273	chr7:18810212	HDAC9	0.55	4.95	0.45	3.24e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs61931739	0.635	rs1525895	chr12:33966496	A/G	cg06521331	chr12:34319734	NA	-0.56	-4.7	-0.43	8.67e-6	Morning vs. evening chronotype;
THYM	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg10117171	chr1:25599238	RHD	0.68	4.87	0.45	4.52e-6	Erythrocyte sedimentation rate;
THYM	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg04918696	chr8:1004106	NA	-0.45	-4.9	-0.45	3.88e-6	Schizophrenia;
THYM	cis	rs11634944	0.716	rs2052723	chr15:25237892	T/A	cg10601234	chr15:25523666	NA	-0.53	-4.94	-0.45	3.34e-6	Interleukin-8 levels;
THYM	cis	rs858239	0.699	rs1881200	chr7:23201637	T/C	cg18081818	chr7:23246105	NA	0.6	5.44	0.49	4.13e-7	Cerebrospinal fluid biomarker levels;
THYM	cis	rs10779751	0.960	rs4845857	chr1:11285680	T/C	cg08854313	chr1:11322531	MTOR	0.95	8.37	0.65	4.95e-13	Body mass index;
THYM	cis	rs1451375	1.000	rs2329340	chr7:50620229	C/T	cg18232548	chr7:50535776	DDC	0.73	5.66	0.5	1.57e-7	Malaria;
THYM	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg13390004	chr1:15929781	NA	0.62	4.72	0.44	8.11e-6	Systolic blood pressure;
THYM	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg00256281	chr22:41985642	PMM1	-0.57	-4.69	-0.43	9.08e-6	Vitiligo;
THYM	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg08885076	chr2:99613938	TSGA10	-0.51	-4.95	-0.45	3.2e-6	Chronic sinus infection;
THYM	cis	rs6032067	0.683	rs34508373	chr20:43788087	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.67	-7.93	-0.63	4.13e-12	Blood protein levels;
THYM	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg07606381	chr6:8435919	SLC35B3	0.63	4.64	0.43	1.11e-5	Motion sickness;
THYM	cis	rs1278352	0.894	rs898322	chr10:127771723	C/T	cg08295661	chr10:127769903	ADAM12	-0.43	-4.77	-0.44	6.76e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs2658782	0.789	rs1456238	chr11:93117370	G/C	cg15737290	chr11:93063684	CCDC67	0.88	6.82	0.57	8.23e-10	Pulmonary function decline;
THYM	cis	rs3820068	0.581	rs68052904	chr1:15916714	T/C	cg27534772	chr1:16042836	PLEKHM2	0.55	6.08	0.53	2.52e-8	Systolic blood pressure;
THYM	cis	rs4654899	0.932	rs10916943	chr1:21472429	T/C	cg01072550	chr1:21505969	NA	0.74	6.82	0.57	8.58e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs7582180	0.638	rs9973536	chr2:100942243	C/T	cg08017756	chr2:100939284	LONRF2	-0.74	-7.88	-0.63	5.29e-12	Intelligence (multi-trait analysis);
THYM	cis	rs961764	0.935	rs569691	chr6:117473648	C/T	cg13016975	chr6:117150798	GPRC6A	0.37	4.59	0.43	1.33e-5	Height;
THYM	cis	rs7172809	0.524	rs4886852	chr15:77417173	A/T	cg22256960	chr15:77711686	NA	-0.64	-4.76	-0.44	6.83e-6	Glucose homeostasis traits;
THYM	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg10505658	chr17:80084571	CCDC57	0.66	7.04	0.59	3.01e-10	Life satisfaction;
THYM	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.88	8.14	0.64	1.5e-12	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg24818145	chr4:99064322	C4orf37	0.72	5.66	0.5	1.62e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg23711669	chr6:146136114	FBXO30	0.93	9.04	0.68	1.9e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4866334	1.000	rs78447918	chr5:18488634	T/A	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs25645	0.502	rs7209742	chr17:38108708	A/G	cg26162295	chr17:38119207	GSDMA	-0.42	-5.05	-0.46	2.09e-6	Myeloid white cell count;
THYM	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg16031515	chr1:205743344	RAB7L1	-0.72	-7.65	-0.62	1.59e-11	Menarche (age at onset);
THYM	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg27588902	chr6:42928151	GNMT	-0.59	-5.89	-0.52	5.79e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs4654899	0.865	rs61779075	chr1:21417027	T/C	cg01072550	chr1:21505969	NA	-0.75	-6.6	-0.56	2.29e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs4803480	0.935	rs1476769	chr19:42084277	C/G	cg09848080	chr19:41642064	NA	0.62	4.49	0.42	1.99e-5	Schizophrenia;
THYM	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg03188948	chr7:1209495	NA	0.74	5.9	0.52	5.62e-8	Longevity;Endometriosis;
THYM	cis	rs9733	0.519	rs12095002	chr1:150649249	G/A	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg15921436	chr17:44337874	NA	-0.77	-6.19	-0.54	1.55e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.55	4.49	0.42	2e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs61931739	0.817	rs1705772	chr12:34174756	G/A	cg06521331	chr12:34319734	NA	-0.67	-5.63	-0.5	1.81e-7	Morning vs. evening chronotype;
THYM	cis	rs11209185	0.509	rs9436357	chr1:68452488	C/T	cg22082780	chr1:68452167	NA	0.69	9.4	0.69	3.22e-15	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg18681998	chr4:17616180	MED28	-0.98	-9.6	-0.7	1.19e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11644478	chr21:40555479	PSMG1	-1.11	-10.07	-0.72	1.16e-16	Cognitive function;
THYM	cis	rs3764563	1.000	rs2283603	chr19:15731128	T/C	cg20725493	chr19:15740067	CYP4F8	-1.02	-4.62	-0.43	1.2e-5	Inflammatory biomarkers;
THYM	cis	rs7572733	0.534	rs4850815	chr2:198786167	G/T	cg00792783	chr2:198669748	PLCL1	-0.84	-6.0	-0.52	3.54e-8	Dermatomyositis;
THYM	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg02527881	chr3:46936655	PTH1R	-0.65	-6.4	-0.55	5.78e-9	Colorectal cancer;
THYM	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26314531	chr2:26401878	FAM59B	-0.76	-5.02	-0.46	2.37e-6	Gut microbiome composition (summer);
THYM	cis	rs72827839	0.846	rs72823599	chr17:46132424	C/G	cg23391107	chr17:45924227	SP6	0.83	5.6	0.5	2.08e-7	Ease of getting up in the morning;
THYM	cis	rs9583531	0.657	rs7337126	chr13:111376788	A/G	cg24331049	chr13:111365604	ING1	0.63	5.12	0.47	1.57e-6	Coronary artery disease;
THYM	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.32	0.69	4.64e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	4.57	0.42	1.49e-5	Mood instability;
THYM	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg22105103	chr4:187893119	NA	0.96	10.31	0.73	3.64e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9902453	0.808	rs12452288	chr17:28235220	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.65	0.43	1.07e-5	Coffee consumption (cups per day);
THYM	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg11812906	chr14:75593930	NEK9	-0.87	-7.94	-0.63	4.03e-12	Height;
THYM	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg07936489	chr17:37558343	FBXL20	-0.87	-5.78	-0.51	9.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg08305652	chr11:111469057	NA	-0.54	-4.62	-0.43	1.21e-5	Primary sclerosing cholangitis;
THYM	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg00898013	chr13:113819073	PROZ	-0.88	-8.96	-0.68	2.83e-14	Platelet distribution width;
THYM	cis	rs427394	0.659	rs274674	chr5:6755460	C/T	cg10857441	chr5:6722123	POLS	-0.72	-7.89	-0.63	5.24e-12	Menopause (age at onset);
THYM	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg07424592	chr7:64974309	NA	-1.04	-5.27	-0.48	8.52e-7	Diabetic kidney disease;
THYM	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg19318889	chr4:1322082	MAEA	-0.52	-4.54	-0.42	1.65e-5	Obesity-related traits;
THYM	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg22841779	chr14:105766346	BRF1	-0.47	-5.81	-0.51	8.18e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11190604	0.767	rs10883490	chr10:102194775	C/T	cg07570687	chr10:102243282	WNT8B	0.81	7.78	0.62	8.93e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs651907	0.640	rs1091664	chr3:101618690	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	6.16	0.53	1.78e-8	Colorectal cancer;
THYM	cis	rs11785693	0.862	rs62491189	chr8:4991309	T/C	cg26367366	chr8:4980734	NA	1.21	5.9	0.52	5.46e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8064299	0.655	rs2305214	chr17:72768970	G/A	cg21922841	chr17:72744131	SLC9A3R1	0.35	4.84	0.45	4.93e-6	Monocyte count;
THYM	cis	rs9457247	0.602	rs17615336	chr6:167506734	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.52	-4.85	-0.45	4.78e-6	Crohn's disease;
THYM	cis	rs9522267	0.737	rs7330902	chr13:112227599	C/T	cg10483660	chr13:112241077	NA	-0.62	-6.72	-0.57	1.33e-9	Hepatitis;
THYM	cis	rs7216064	1.000	rs9912770	chr17:65868233	C/T	cg12091567	chr17:66097778	LOC651250	-0.71	-4.76	-0.44	6.86e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs995000	0.859	rs9436661	chr1:62904575	T/G	cg06896770	chr1:63153194	DOCK7	0.92	7.12	0.59	2.07e-10	Triglyceride levels;
THYM	cis	rs954108	0.809	rs1792022	chr13:29367967	A/G	cg11788234	chr13:29393811	NA	-0.58	-4.55	-0.42	1.59e-5	Obesity-related traits;
THYM	cis	rs5769707	0.521	rs739244	chr22:50060158	A/G	cg23428387	chr22:49814324	NA	-0.52	-5.26	-0.48	8.82e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10158481	0.759	rs9438890	chr1:25477449	A/T	cg09264742	chr1:25757510	TMEM57	-0.69	-5.1	-0.46	1.77e-6	Urate levels in obese individuals;
THYM	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08564027	chr20:61660810	NA	0.92	10.22	0.72	5.6e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs651907	1.000	rs665211	chr3:101600028	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.52	4.57	0.42	1.49e-5	Colorectal cancer;
THYM	cis	rs8014204	0.566	rs752857	chr14:75130944	C/T	cg06637938	chr14:75390232	RPS6KL1	0.59	5.21	0.47	1.08e-6	Caffeine consumption;
THYM	cis	rs7941600	0.786	rs12286943	chr11:9183753	A/T	cg21110646	chr11:9336536	TMEM41B	-0.89	-4.72	-0.44	8.08e-6	Coronary artery disease;
THYM	cis	rs6531209	0.926	rs7563386	chr2:20338795	C/T	cg24416238	chr2:20211868	MATN3	-0.64	-5.01	-0.46	2.5e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs6669072	0.739	rs3843305	chr1:91243376	G/A	cg08895590	chr1:91227319	NA	-0.65	-7.84	-0.63	6.67e-12	Cognitive function;
THYM	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg26038318	chr20:34205095	SPAG4	-0.65	-5.3	-0.48	7.66e-7	Total cholesterol levels;
THYM	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg06130144	chr11:64578348	MEN1	0.88	5.37	0.48	5.64e-7	Mean platelet volume;
THYM	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg01191920	chr7:158217561	PTPRN2	-0.83	-7.89	-0.63	5.2e-12	Obesity-related traits;
THYM	cis	rs3540	0.512	rs3862433	chr15:91076028	G/A	cg00487526	chr15:90818384	NA	0.59	4.51	0.42	1.82e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs526231	0.543	rs34765	chr5:102506864	G/C	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Primary biliary cholangitis;
THYM	cis	rs28785552	0.554	rs11084183	chr19:53213517	T/C	cg22067481	chr19:53234126	ZNF611	-0.98	-9.54	-0.7	1.56e-15	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06634786	chr22:41940651	POLR3H	-0.8	-6.21	-0.54	1.37e-8	Vitiligo;
THYM	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg24812749	chr6:127587940	RNF146	0.92	7.38	0.6	5.93e-11	Breast cancer;
THYM	cis	rs2070677	0.935	rs11101869	chr10:135400631	C/T	cg20169779	chr10:135381914	SYCE1	-0.78	-6.01	-0.52	3.43e-8	Gout;
THYM	cis	rs10214930	1.000	rs6970578	chr7:27844038	C/T	cg04422003	chr7:28448295	CREB5	-0.62	-4.62	-0.43	1.19e-5	Hypospadias;
THYM	cis	rs995000	0.931	rs638305	chr1:62906537	G/T	cg06896770	chr1:63153194	DOCK7	0.91	7.48	0.61	3.73e-11	Triglyceride levels;
THYM	cis	rs7078219	0.897	rs10883360	chr10:101281158	C/G	cg07044859	chr10:101282883	NA	-0.49	-5.19	-0.47	1.21e-6	Dental caries;
THYM	cis	rs4455778	0.536	rs38771	chr7:48940564	C/A	cg26309511	chr7:48887640	NA	0.64	6.18	0.54	1.58e-8	Lung cancer in never smokers;
THYM	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg03433033	chr1:76189801	ACADM	-0.52	-5.44	-0.49	4.21e-7	Daytime sleep phenotypes;
THYM	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg20302533	chr7:39170763	POU6F2	0.65	4.78	0.44	6.27e-6	IgG glycosylation;
THYM	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg14008862	chr17:28927542	LRRC37B2	0.92	4.53	0.42	1.72e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1003719	0.788	rs9981226	chr21:38452127	C/T	cg01329690	chr21:38580129	DSCR9	0.39	5.25	0.47	9.23e-7	Eye color traits;
THYM	cis	rs3017493	0.786	rs78344725	chr11:70687830	G/A	cg04110224	chr11:70508463	SHANK2	0.9	4.46	0.42	2.23e-5	Renal transplant outcome;
THYM	cis	rs1003719	0.762	rs11701556	chr21:38455153	A/G	cg01329690	chr21:38580129	DSCR9	0.39	5.25	0.47	9.23e-7	Eye color traits;
THYM	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg21475434	chr5:93447410	FAM172A	0.91	4.99	0.46	2.76e-6	Diabetic retinopathy;
THYM	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg05738196	chr6:26577821	NA	0.95	9.89	0.71	2.78e-16	Intelligence (multi-trait analysis);
THYM	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg20151795	chr6:28129481	ZNF389	0.75	4.59	0.43	1.36e-5	Parkinson's disease;
THYM	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg24818145	chr4:99064322	C4orf37	0.78	6.25	0.54	1.15e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg00147160	chr1:26503991	CNKSR1	0.51	6.72	0.57	1.35e-9	Height;
THYM	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg06618935	chr21:46677482	NA	-0.97	-9.08	-0.68	1.51e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg02551604	chr5:131831745	NA	0.84	6.68	0.57	1.59e-9	Asthma (sex interaction);
THYM	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg19196401	chr6:110721138	DDO	-0.6	-6.92	-0.58	5.26e-10	Platelet distribution width;
THYM	cis	rs240764	0.658	rs10872628	chr6:101176349	A/G	cg21058520	chr6:100914733	NA	0.62	5.45	0.49	3.89e-7	Neuroticism;
THYM	cis	rs900145	0.814	rs4414197	chr11:13306311	A/C	cg13286116	chr11:13302098	ARNTL	-0.64	-4.92	-0.45	3.67e-6	Menarche (age at onset);
THYM	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg01017244	chr2:74357527	NA	1.08	9.62	0.7	1.09e-15	Gestational age at birth (maternal effect);
THYM	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.34	-0.65	5.7e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg21385522	chr1:16154831	NA	-0.74	-5.71	-0.51	1.3e-7	Dilated cardiomyopathy;
THYM	cis	rs12190007	0.846	rs9505962	chr6:169726667	A/G	cg16388071	chr6:169726476	NA	0.55	4.77	0.44	6.77e-6	Obesity-related traits;
THYM	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg26149184	chr10:133730230	NA	0.77	4.65	0.43	1.07e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg24910161	chr17:38119198	GSDMA	0.42	4.45	0.42	2.31e-5	Self-reported allergy;
THYM	cis	rs900145	0.773	rs4146388	chr11:13306605	C/T	cg13286116	chr11:13302098	ARNTL	0.59	4.46	0.42	2.24e-5	Menarche (age at onset);
THYM	cis	rs4731207	0.655	rs7808203	chr7:124502136	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs67311347	0.577	rs11712626	chr3:40259927	G/A	cg13683864	chr3:40499215	RPL14	-0.69	-6.02	-0.53	3.23e-8	Renal cell carcinoma;
THYM	cis	rs11039798	0.920	rs11040015	chr11:48783130	G/T	cg24672777	chr11:48374446	OR4C45	-1.08	-6.41	-0.55	5.59e-9	Axial length;
THYM	cis	rs7524258	0.778	rs12028181	chr1:7315085	C/T	cg07173049	chr1:7289937	CAMTA1	-0.73	-5.61	-0.5	1.98e-7	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs7828089	0.582	rs3817445	chr8:22266054	G/T	cg13512537	chr8:22265999	SLC39A14	-0.67	-5.57	-0.5	2.39e-7	Verbal declarative memory;
THYM	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.04	-5.01	-0.46	2.49e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg17366294	chr4:99064904	C4orf37	0.48	5.41	0.49	4.69e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg05362011	chr13:21860987	NA	-0.56	-4.52	-0.42	1.8e-5	White matter hyperintensity burden;
THYM	cis	rs1018836	0.923	rs13259842	chr8:91550819	A/G	cg16814680	chr8:91681699	NA	-0.84	-7.59	-0.61	2.21e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg15592062	chr6:167189543	RPS6KA2	0.59	6.0	0.52	3.56e-8	Crohn's disease;
THYM	cis	rs4660261	0.526	rs2906458	chr1:44336389	A/G	cg13246856	chr1:44399776	ARTN	-0.49	-4.89	-0.45	4.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs919433	0.679	rs7564924	chr2:198513877	C/T	cg05783139	chr2:198650985	BOLL	0.68	5.14	0.47	1.5e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg23583168	chr7:148888333	NA	-1.03	-13.7	-0.81	3.25e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg20283391	chr11:68216788	NA	-0.73	-5.4	-0.48	4.96e-7	Total body bone mineral density;
THYM	cis	rs12540874	0.759	rs12718572	chr7:50573325	C/T	cg18232548	chr7:50535776	DDC	-0.81	-6.36	-0.55	6.95e-9	Systemic sclerosis;
THYM	cis	rs3126085	0.560	rs941935	chr1:152339488	A/G	cg10321714	chr1:152280068	FLG	-0.7	-5.19	-0.47	1.19e-6	Atopic dermatitis;
THYM	cis	rs747334	0.846	rs10785978	chr10:92706044	A/G	cg07620928	chr10:92689909	NA	-0.55	-4.88	-0.45	4.3e-6	Fibroblast growth factor basic levels;
THYM	cis	rs72717009	0.825	rs61802846	chr1:161473873	A/C	cg23840854	chr1:161414152	NA	-1.03	-5.5	-0.49	3.16e-7	Rheumatoid arthritis;
THYM	cis	rs7172677	1.000	rs72730601	chr15:75421720	A/T	cg09165964	chr15:75287851	SCAMP5	0.6	4.45	0.42	2.33e-5	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs72627123	1.000	rs72627124	chr14:74369128	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs2273669	0.504	rs1539596	chr6:109408428	C/G	cg17117243	chr6:109341365	SESN1	-0.92	-5.47	-0.49	3.63e-7	Prostate cancer;
THYM	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22509189	chr2:225307070	NA	-0.87	-7.39	-0.6	5.67e-11	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg04362960	chr10:104952993	NT5C2	0.64	4.89	0.45	4.17e-6	Arsenic metabolism;
THYM	cis	rs8103278	1.000	rs7252126	chr19:46302374	T/A	cg14061069	chr19:46274453	DMPK	-0.58	-5.72	-0.51	1.21e-7	Coronary artery disease;
THYM	cis	rs2276314	0.857	rs7237599	chr18:33639396	T/C	cg05985134	chr18:33552581	C18orf21	0.66	4.84	0.44	5.02e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7582180	0.739	rs10195793	chr2:100925803	A/G	cg14675211	chr2:100938903	LONRF2	0.76	8.22	0.64	1.01e-12	Intelligence (multi-trait analysis);
THYM	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg08430604	chr3:44902960	MIR564;TMEM42	0.53	5.05	0.46	2.09e-6	Depressive symptoms;
THYM	cis	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg07460842	chr6:66804631	NA	0.95	5.67	0.5	1.53e-7	Exhaled nitric oxide levels;
THYM	cis	rs2075230	0.642	rs1641535	chr17:7546133	T/C	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.74	-0.44	7.55e-6	Hormone measurements;
THYM	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg11494091	chr17:61959527	GH2	0.7	6.38	0.55	6.38e-9	Height;
THYM	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9905704	0.918	rs11656666	chr17:56929840	A/G	cg12560992	chr17:57184187	TRIM37	0.68	4.72	0.44	8.17e-6	Testicular germ cell tumor;
THYM	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg06634786	chr22:41940651	POLR3H	-0.66	-4.8	-0.44	5.78e-6	Vitiligo;
THYM	cis	rs4786125	0.804	rs7205797	chr16:6895384	C/A	cg03623568	chr16:6915990	A2BP1	-0.76	-6.05	-0.53	2.91e-8	Heart rate variability traits (SDNN);
THYM	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg12311346	chr5:56204834	C5orf35	-0.81	-5.9	-0.52	5.54e-8	Initial pursuit acceleration;
THYM	cis	rs757110	0.803	rs7928810	chr11:17372443	G/T	cg15432903	chr11:17409602	KCNJ11	0.59	6.42	0.55	5.34e-9	Type 2 diabetes;
THYM	cis	rs72848980	0.512	rs3781362	chr10:105375601	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.56	5.12	0.47	1.6e-6	White matter hyperintensity burden;
THYM	cis	rs11771526	0.901	rs62457468	chr7:32301341	C/T	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs1808579	0.935	rs1623060	chr18:21143183	C/T	cg14672496	chr18:21087552	C18orf8	0.53	4.92	0.45	3.61e-6	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
THYM	cis	rs28595532	0.920	rs56291421	chr4:119732294	G/A	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs7524258	0.868	rs916393	chr1:7272250	T/C	cg07173049	chr1:7289937	CAMTA1	0.63	5.02	0.46	2.4e-6	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs3764563	0.660	rs8107923	chr19:15737899	A/T	cg20725493	chr19:15740067	CYP4F8	-1.02	-4.62	-0.43	1.2e-5	Inflammatory biomarkers;
THYM	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg02887458	chr19:19495540	GATAD2A	-0.45	-4.89	-0.45	4.05e-6	Bipolar disorder;
THYM	cis	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05901451	chr6:126070800	HEY2	-0.84	-8.41	-0.65	4.02e-13	Brugada syndrome;
THYM	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg24530246	chr3:53118167	NA	-0.83	-4.78	-0.44	6.39e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg11266682	chr4:10021025	SLC2A9	0.64	8.95	0.68	2.97e-14	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.17	-0.47	1.28e-6	Joint mobility (Beighton score);
THYM	cis	rs11771526	0.901	rs10264511	chr7:32304170	T/C	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs3106136	0.510	rs28838299	chr4:95215887	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.53	-4.55	-0.42	1.59e-5	Capecitabine sensitivity;
THYM	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg11764359	chr7:65958608	NA	-0.74	-6.15	-0.53	1.85e-8	Aortic root size;
THYM	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	10.61	0.74	8.08e-18	Platelet count;
THYM	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg15556689	chr8:8085844	FLJ10661	0.62	4.99	0.46	2.68e-6	Mood instability;
THYM	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg06221963	chr1:154839813	KCNN3	-0.73	-8.77	-0.67	7.12e-14	Prostate cancer;
THYM	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-4.57	-0.42	1.49e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10489202	1.000	rs2272911	chr1:167936302	C/T	cg24449463	chr1:168025552	DCAF6	-0.85	-6.66	-0.56	1.81e-9	Schizophrenia;
THYM	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg19507638	chr5:93509721	C5orf36	-0.67	-4.48	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28595532	0.920	rs115860482	chr4:119759546	A/G	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg22875332	chr1:76189707	ACADM	0.79	7.03	0.59	3.08e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg26384229	chr12:38710491	ALG10B	0.9	7.32	0.6	7.85e-11	Bladder cancer;
THYM	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs7616559	0.962	rs9875244	chr3:156721597	G/A	cg15697575	chr3:156784781	NA	0.4	4.99	0.46	2.78e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg06028808	chr11:68637592	NA	0.71	7.73	0.62	1.13e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7129727	1	rs7129727	chr11:57484660	G/A	cg19752551	chr11:57585705	CTNND1	-0.66	-7.73	-0.62	1.11e-11	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	7.12	0.59	2.09e-10	Cognitive test performance;
THYM	cis	rs1639906	0.895	rs62443039	chr7:2209354	C/T	cg19897017	chr7:2163380	MAD1L1	-0.51	-4.78	-0.44	6.42e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg26963428	chr7:66367121	NA	-0.57	-4.57	-0.42	1.48e-5	Corneal structure;
THYM	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg10523679	chr1:76189770	ACADM	0.89	8.51	0.66	2.52e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7772486	0.875	rs7766595	chr6:146364507	A/T	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28785552	0.554	rs10424921	chr19:53211087	T/C	cg22067481	chr19:53234126	ZNF611	-0.86	-8.16	-0.64	1.4e-12	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs2456568	0.867	rs1827931	chr11:93663170	T/C	cg17595323	chr11:93583763	C11orf90	-0.56	-5.55	-0.5	2.55e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2798269	0.564	rs1967778	chr13:22164868	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.63	-4.66	-0.43	1.01e-5	PR segment;
THYM	cis	rs6499129	1.000	rs8063771	chr16:67506115	C/T	cg03615565	chr16:67572595	FAM65A	0.47	4.57	0.42	1.47e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6840360	1.000	rs751012	chr4:152602247	A/C	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	trans	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.24	14.66	0.83	3.9e-26	Exhaled nitric oxide output;
THYM	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg07930552	chr6:133119739	C6orf192	0.96	5.5	0.49	3.14e-7	Type 2 diabetes nephropathy;
THYM	cis	rs7267979	1.000	rs422844	chr20:25445591	T/C	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg26384229	chr12:38710491	ALG10B	0.97	7.44	0.61	4.48e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4940575	0.679	rs17070779	chr18:60835738	C/T	cg20947866	chr18:61143580	SERPINB5	-0.87	-5.15	-0.47	1.38e-6	Breast cancer;
THYM	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg10360139	chr7:1886902	MAD1L1	-0.59	-4.96	-0.45	3.09e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs10203711	0.901	rs907101	chr2:239564458	T/A	cg14580085	chr2:239553406	NA	0.68	6.07	0.53	2.58e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1278352	0.660	rs1152656	chr10:127759821	A/G	cg08295661	chr10:127769903	ADAM12	-0.53	-5.19	-0.47	1.21e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs4481887	0.927	rs10788765	chr1:248445642	A/G	cg00666640	chr1:248458726	OR2T12	-0.52	-4.5	-0.42	1.91e-5	Common traits (Other);
THYM	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg12310025	chr6:25882481	NA	-0.91	-8.87	-0.67	4.22e-14	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.58	0.56	2.61e-9	Total body bone mineral density;
THYM	cis	rs55871839	0.533	rs1015794	chr8:59838228	C/T	cg07426533	chr8:59803705	TOX	0.62	5.11	0.46	1.63e-6	Pneumonia;
THYM	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg12560992	chr17:57184187	TRIM37	-0.92	-8.41	-0.65	4.15e-13	Intelligence (multi-trait analysis);
THYM	cis	rs1158570	0.814	rs7839523	chr8:131281826	G/T	cg16277922	chr8:131349729	ASAP1	0.65	5.67	0.5	1.51e-7	Platelet count;
THYM	cis	rs4866334	1.000	rs79459190	chr5:18504469	T/G	cg02002538	chr5:17811409	NA	-1.1	-4.55	-0.42	1.61e-5	IgG glycosylation;
THYM	cis	rs9534288	0.742	rs7337140	chr13:46641481	C/T	cg15192986	chr13:46630673	CPB2	0.64	4.61	0.43	1.24e-5	Blood protein levels;
THYM	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg03676636	chr4:99064102	C4orf37	0.42	6.16	0.53	1.78e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4792901	0.759	rs34409913	chr17:41564293	T/G	cg21940313	chr17:41620911	ETV4	-0.51	-5.2	-0.47	1.12e-6	Dupuytren's disease;
THYM	cis	rs6032067	1.000	rs6032060	chr20:43852454	A/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.5	-0.49	3.14e-7	Blood protein levels;
THYM	cis	rs34783982	0.881	rs8032849	chr15:89495166	C/T	cg26213453	chr15:89455860	MFGE8	0.5	4.65	0.43	1.06e-5	Squamous cell lung carcinoma;
THYM	cis	rs17174870	0.955	rs55792453	chr2:112778389	C/T	cg17354880	chr2:112658759	MERTK	-0.6	-4.58	-0.43	1.41e-5	Multiple sclerosis;
THYM	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg14675211	chr2:100938903	LONRF2	0.75	7.93	0.63	4.32e-12	Intelligence (multi-trait analysis);
THYM	cis	rs1160297	0.576	rs12713233	chr2:53116767	T/A	cg07782112	chr2:53107842	NA	0.76	6.58	0.56	2.52e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs6785206	0.667	rs2253125	chr3:128329793	T/C	cg16766828	chr3:128327626	NA	-0.57	-5.57	-0.5	2.32e-7	Lymphocyte percentage of white cells;
THYM	cis	rs2131877	0.830	rs1874104	chr3:194845226	A/C	cg21937377	chr3:194868750	C3orf21	-0.4	-4.48	-0.42	2.08e-5	Non-small cell lung cancer;
THYM	cis	rs9543976	1.000	rs1535724	chr13:76183273	G/C	cg01531495	chr13:76123901	UCHL3	0.75	5.05	0.46	2.1e-6	Diabetic retinopathy;
THYM	cis	rs10911232	0.507	rs10797814	chr1:182990929	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs4792901	0.918	rs76798487	chr17:41633391	A/G	cg21940313	chr17:41620911	ETV4	-0.49	-5.11	-0.46	1.7e-6	Dupuytren's disease;
THYM	cis	rs2295359	0.824	rs4655679	chr1:67599657	A/G	cg11235152	chr1:67600687	NA	-0.7	-6.0	-0.52	3.61e-8	Psoriasis;
THYM	cis	rs7551222	0.752	rs4252687	chr1:204497335	G/C	cg20240347	chr1:204465584	NA	-0.51	-4.54	-0.42	1.64e-5	Schizophrenia;
THYM	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.77	-0.44	6.61e-6	Eye color traits;
THYM	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs2237457	0.525	rs2329488	chr7:50706071	C/T	cg08586669	chr7:50727761	GRB10	-0.3	-4.92	-0.45	3.61e-6	Schizophrenia (treatment resistant);
THYM	cis	rs3017493	0.786	rs12295625	chr11:70671860	A/G	cg21202716	chr11:70508022	SHANK2	-0.95	-4.92	-0.45	3.63e-6	Renal transplant outcome;
THYM	cis	rs6918586	0.658	rs198826	chr6:26121153	A/G	cg12310025	chr6:25882481	NA	-0.57	-4.57	-0.42	1.46e-5	Schizophrenia;
THYM	cis	rs910316	0.503	rs4903273	chr14:75441795	G/A	cg11812906	chr14:75593930	NEK9	-0.68	-5.81	-0.51	8.29e-8	Height;
THYM	cis	rs7178572	0.889	rs7177055	chr15:77832762	A/G	cg22256960	chr15:77711686	NA	0.97	8.05	0.64	2.32e-12	Type 2 diabetes;
THYM	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.94	0.45	3.37e-6	Prudent dietary pattern;
THYM	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.91	-6.52	-0.56	3.31e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs67460515	0.563	rs73023235	chr3:160864123	G/A	cg12349858	chr3:160822545	B3GALNT1	0.57	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs6840360	0.571	rs12648420	chr4:152543434	G/C	cg17479576	chr4:152424074	FAM160A1	-0.8	-5.65	-0.5	1.68e-7	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs853679	1.000	rs1936365	chr6:28268452	C/G	cg23161317	chr6:28129485	ZNF389	-0.76	-4.88	-0.45	4.26e-6	Depression;
THYM	cis	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.49	-4.84	-0.44	5.09e-6	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg10047753	chr17:41438598	NA	1.17	10.89	0.75	2.11e-18	Menopause (age at onset);
THYM	cis	rs17641971	0.645	rs10504073	chr8:50024944	C/T	cg00325661	chr8:49890786	NA	0.58	4.48	0.42	2.04e-5	Blood metabolite levels;
THYM	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg04731861	chr2:219085781	ARPC2	-0.54	-5.23	-0.47	1.02e-6	Colorectal cancer;
THYM	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-9.0	-0.68	2.22e-14	Chronic sinus infection;
THYM	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg06640241	chr16:89574553	SPG7	0.92	8.2	0.64	1.12e-12	Multiple myeloma (IgH translocation);
THYM	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg25358565	chr5:93447407	FAM172A	1.32	11.28	0.76	3.22e-19	Diabetic retinopathy;
THYM	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg13390004	chr1:15929781	NA	0.63	4.79	0.44	6.2e-6	Systolic blood pressure;
THYM	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg26384229	chr12:38710491	ALG10B	1.05	10.39	0.73	2.4e-17	Heart rate;
THYM	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs854765	0.583	rs12452219	chr17:17829423	C/T	cg16928487	chr17:17741425	SREBF1	-0.54	-5.21	-0.47	1.08e-6	Total body bone mineral density;
THYM	cis	rs6570726	0.791	rs422099	chr6:145806936	C/T	cg23711669	chr6:146136114	FBXO30	0.96	9.68	0.7	7.83e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2730245	0.527	rs842700	chr7:158697565	G/A	cg11984989	chr7:158649758	WDR60	1.01	8.46	0.66	3.26e-13	Height;
THYM	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg23682913	chr1:2080710	PRKCZ	-0.52	-4.53	-0.42	1.71e-5	Height;
THYM	cis	rs5758511	0.689	rs62240864	chr22:42563889	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.59	4.45	0.42	2.36e-5	Birth weight;
THYM	cis	rs919433	0.653	rs700651	chr2:198631714	G/A	cg00792783	chr2:198669748	PLCL1	0.81	5.65	0.5	1.68e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs790123	0.965	rs2133850	chr3:122381696	C/T	cg17380795	chr3:122379686	NA	0.59	5.41	0.49	4.78e-7	Response to angiotensin II receptor blocker therapy;
THYM	trans	rs75715012	0.850	rs17305505	chr11:21609484	A/G	cg22317004	chr11:1360335	NA	-0.84	-6.84	-0.57	7.67e-10	Chronic periodontitis (mean interproximal clinical attachment level);
THYM	cis	rs7119	0.689	rs11630926	chr15:77819582	T/C	cg27398640	chr15:77910606	LINGO1	-0.52	-4.88	-0.45	4.2e-6	Type 2 diabetes;
THYM	cis	rs1878931	0.582	rs9635562	chr16:3416689	G/A	cg00484396	chr16:3507460	NAT15	-0.47	-4.47	-0.42	2.14e-5	Body mass index (adult);
THYM	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg24209194	chr3:40518798	ZNF619	0.55	4.58	0.43	1.43e-5	Renal cell carcinoma;
THYM	cis	rs12310956	0.532	rs10772114	chr12:33853970	G/A	cg10856724	chr12:34555212	NA	-0.62	-5.59	-0.5	2.18e-7	Morning vs. evening chronotype;
THYM	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg08431931	chr22:42394659	WBP2NL	0.69	4.59	0.43	1.34e-5	Birth weight;
THYM	cis	rs55728055	0.661	rs16989278	chr22:31957167	A/G	cg10537193	chr22:32026975	PISD	-0.92	-5.68	-0.5	1.45e-7	Age-related hearing impairment;
THYM	cis	rs1003719	0.788	rs4817845	chr21:38447132	T/C	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs3772130	0.603	rs10470410	chr3:121434977	G/T	cg20356878	chr3:121714668	ILDR1	0.63	4.89	0.45	4.07e-6	Cognitive performance;
THYM	cis	rs2012796	0.743	rs12435764	chr14:81836866	A/C	cg02996355	chr14:81879375	NA	0.83	6.38	0.55	6.55e-9	Night sleep phenotypes;
THYM	cis	rs7572733	0.534	rs700680	chr2:198707950	A/T	cg05783139	chr2:198650985	BOLL	-0.59	-4.58	-0.43	1.41e-5	Dermatomyositis;
THYM	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg00071950	chr4:10020882	SLC2A9	0.79	8.52	0.66	2.44e-13	Bone mineral density;
THYM	cis	rs684232	0.644	rs870183	chr17:599811	A/G	cg15660573	chr17:549704	VPS53	-0.77	-6.81	-0.57	8.99e-10	Prostate cancer;
THYM	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs7772486	0.597	rs1970306	chr6:146154543	A/G	cg23711669	chr6:146136114	FBXO30	0.85	7.99	0.63	3.12e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg03806693	chr22:41940476	POLR3H	1.09	9.5	0.7	1.96e-15	Vitiligo;
THYM	cis	rs1883415	0.552	rs2328824	chr6:24507761	G/A	cg00346970	chr6:24499591	ALDH5A1	-0.4	-6.44	-0.55	4.96e-9	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2806561	1.000	rs654585	chr1:23514714	T/C	cg08872493	chr1:23521417	HTR1D	0.37	4.5	0.42	1.9e-5	Height;
THYM	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.75	-4.96	-0.45	3.07e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg24733560	chr20:60626293	TAF4	0.52	4.69	0.43	9.24e-6	Body mass index;
THYM	cis	rs1034435	0.755	rs5768679	chr22:48892847	T/G	cg05992904	chr22:48892994	FAM19A5	-0.81	-8.89	-0.67	3.91e-14	Late-onset Alzheimer's disease;
THYM	cis	rs12134245	0.776	rs13447464	chr1:91968278	G/A	cg25838465	chr1:92012736	NA	-0.85	-7.58	-0.61	2.33e-11	Breast cancer;
THYM	cis	rs9326248	0.530	rs4604928	chr11:117044203	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.95	5.34	0.48	6.34e-7	Blood protein levels;
THYM	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg00339695	chr16:24857497	SLC5A11	0.47	4.7	0.43	8.71e-6	Intelligence (multi-trait analysis);
THYM	cis	rs861020	0.630	rs655712	chr1:210006437	G/A	cg05527609	chr1:210001259	C1orf107	0.85	6.82	0.57	8.53e-10	Orofacial clefts;
THYM	cis	rs34779708	0.966	rs11010122	chr10:35493518	A/C	cg03585969	chr10:35415529	CREM	0.63	4.47	0.42	2.15e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	9.37	0.69	3.63e-15	Platelet count;
THYM	cis	rs17209837	0.527	rs4148824	chr7:87075362	A/G	cg04996195	chr7:87105398	ABCB4	0.63	4.52	0.42	1.76e-5	Gallbladder cancer;
THYM	cis	rs77372450	0.551	rs11739924	chr5:157070236	C/A	cg00312553	chr5:157098553	C5orf52	-0.65	-4.63	-0.43	1.16e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.91	0.45	3.85e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7940866	0.874	rs10791113	chr11:130873165	A/G	cg23692386	chr11:131799662	NTM	0.46	4.9	0.45	4e-6	Schizophrenia;
THYM	cis	rs981844	0.714	rs6822142	chr4:154683524	C/T	cg09973105	chr4:154681532	RNF175	0.54	4.98	0.45	2.88e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg13852791	chr20:30311386	BCL2L1	0.74	5.35	0.48	6.15e-7	Mean corpuscular hemoglobin;
THYM	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg02018176	chr4:1364513	KIAA1530	0.74	6.99	0.58	3.86e-10	Longevity;
THYM	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg07636037	chr3:49044803	WDR6	0.82	5.76	0.51	1.03e-7	Menarche (age at onset);
THYM	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg03929089	chr4:120376271	NA	-0.99	-12.81	-0.8	2.07e-22	Height;
THYM	cis	rs11025559	0.773	rs10833334	chr11:20498640	T/C	cg19653624	chr11:20408972	PRMT3	-0.75	-5.18	-0.47	1.22e-6	Pursuit maintenance gain;
THYM	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg03929089	chr4:120376271	NA	-0.99	-12.81	-0.8	2.07e-22	Height;
THYM	cis	rs11771526	0.901	rs10252303	chr7:32304438	C/T	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg05660106	chr1:15850417	CASP9	0.74	6.04	0.53	2.93e-8	Systolic blood pressure;
THYM	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11264213	0.901	rs11263830	chr1:36345798	C/T	cg27506609	chr1:36549197	TEKT2	0.92	4.83	0.44	5.3e-6	Schizophrenia;
THYM	cis	rs6906287	0.669	rs12208253	chr6:118925097	G/C	cg21191810	chr6:118973309	C6orf204	0.57	5.73	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg04476341	chr5:669733	TPPP	-0.49	-4.92	-0.45	3.62e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs35100037	0.803	rs17211886	chr5:128652100	T/C	cg05211662	chr5:128795605	ADAMTS19	-0.85	-4.46	-0.42	2.22e-5	Ankle injury;
THYM	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.89	0.52	5.88e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs10962692	0.608	rs10962645	chr9:16863543	A/C	cg03221025	chr16:88955224	CBFA2T3	0.75	7.2	0.59	1.37e-10	Ovarian cancer in BRCA2 mutation carriers;Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;
THYM	cis	rs9649213	0.593	rs7807555	chr7:97957517	G/A	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.6e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7927771	0.542	rs11039336	chr11:47706141	A/G	cg18512352	chr11:47633146	NA	-0.41	-4.47	-0.42	2.17e-5	Subjective well-being;
THYM	cis	rs889398	0.677	rs68161338	chr16:69823778	T/G	cg09409435	chr16:70099608	PDXDC2	-0.6	-4.55	-0.42	1.57e-5	Body mass index;
THYM	cis	rs11249608	0.548	rs7707587	chr5:178462590	G/C	cg01312482	chr5:178451176	ZNF879	-0.76	-6.3	-0.54	9.29e-9	Pubertal anthropometrics;
THYM	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23221052	chr5:179740743	GFPT2	-0.9	-6.84	-0.57	7.63e-10	Height;
THYM	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg00647820	chr17:40259828	DHX58	-0.62	-4.65	-0.43	1.06e-5	Fibrinogen levels;
THYM	cis	rs4654899	1.000	rs6426668	chr1:21396596	T/C	cg01072550	chr1:21505969	NA	-0.71	-6.29	-0.54	9.47e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06481639	chr22:41940642	POLR3H	-0.64	-4.81	-0.44	5.78e-6	Vitiligo;
THYM	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg04287289	chr16:89883240	FANCA	0.63	5.71	0.51	1.3e-7	Vitiligo;
THYM	cis	rs6496667	0.533	rs7173201	chr15:90991195	A/T	cg22089800	chr15:90895588	ZNF774	0.65	4.73	0.44	7.89e-6	Rheumatoid arthritis;
THYM	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg27284194	chr4:1044797	NA	0.64	4.87	0.45	4.47e-6	Recombination rate (females);
THYM	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg08835221	chr22:38071607	LGALS1	0.35	4.88	0.45	4.34e-6	Fat distribution (HIV);
THYM	cis	rs7084402	0.967	rs1658432	chr10:60329069	C/G	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg22681709	chr2:178499509	PDE11A	-0.61	-5.51	-0.49	3.11e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg14196790	chr5:131705035	SLC22A5	0.55	5.04	0.46	2.21e-6	Blood metabolite levels;
THYM	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg27534772	chr1:16042836	PLEKHM2	0.53	5.9	0.52	5.65e-8	Systolic blood pressure;
THYM	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg21775007	chr8:11205619	TDH	-0.68	-5.27	-0.48	8.47e-7	Neuroticism;
THYM	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg26516362	chr5:178986906	RUFY1	-0.38	-4.75	-0.44	7.09e-6	Lung cancer;
THYM	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg02353165	chr6:42928485	GNMT	-0.78	-6.85	-0.57	7.4e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7246967	0.551	rs3925175	chr19:22880958	G/A	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03576123	chr11:487126	PTDSS2	-1.3	-6.61	-0.56	2.21e-9	Body mass index;
THYM	cis	rs4604732	0.588	rs7549495	chr1:247627806	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.69	4.8	0.44	5.99e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg11189052	chr15:85197271	WDR73	-0.64	-4.83	-0.44	5.29e-6	P wave terminal force;
THYM	cis	rs4638749	0.677	rs10189396	chr2:108829637	A/G	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs61931739	0.857	rs419112	chr12:34130528	A/G	cg06521331	chr12:34319734	NA	-0.6	-4.86	-0.45	4.71e-6	Morning vs. evening chronotype;
THYM	cis	rs10992471	0.651	rs7043984	chr9:95529408	C/T	cg14631576	chr9:95140430	CENPP	-0.94	-8.39	-0.65	4.43e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg27129171	chr3:47204927	SETD2	-0.7	-6.73	-0.57	1.3e-9	Colorectal cancer;
THYM	cis	rs13401104	0.587	rs62190974	chr2:237145263	C/T	cg19324714	chr2:237145437	ASB18	0.63	4.68	0.43	9.6e-6	Educational attainment;
THYM	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg03806693	chr22:41940476	POLR3H	1.1	8.83	0.67	5.2e-14	Cannabis dependence symptom count;
THYM	cis	rs1021993	0.868	rs6685498	chr1:209530832	G/A	cg24997231	chr1:209527535	NA	-0.59	-4.59	-0.43	1.36e-5	Gut microbiome composition (winter);
THYM	cis	rs6840360	0.642	rs2709828	chr4:152355268	C/T	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4363385	0.525	rs11205138	chr1:152890568	G/A	cg07796016	chr1:152779584	LCE1C	-0.73	-5.92	-0.52	5.03e-8	Inflammatory skin disease;
THYM	cis	rs17826219	0.733	rs7221691	chr17:28723619	C/T	cg17105886	chr17:28927953	LRRC37B2	-1.11	-4.91	-0.45	3.78e-6	Body mass index;
THYM	cis	rs7705502	0.962	rs72812847	chr5:173377817	G/A	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs12208915	0.848	rs12203336	chr6:79518315	G/T	cg05283184	chr6:79620031	NA	0.73	4.77	0.44	6.59e-6	Left atrial antero-posterior diameter;
THYM	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg03806693	chr22:41940476	POLR3H	-0.86	-8.51	-0.66	2.47e-13	Vitiligo;
THYM	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg24503407	chr1:205819492	PM20D1	0.9	8.28	0.65	7.83e-13	Menarche (age at onset);
THYM	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg00271210	chr6:167070053	RPS6KA2	0.69	7.42	0.61	4.85e-11	Crohn's disease;
THYM	cis	rs240764	0.817	rs239245	chr6:101090377	C/A	cg21058520	chr6:100914733	NA	-0.57	-5.06	-0.46	2.04e-6	Neuroticism;
THYM	cis	rs11645898	0.748	rs72791120	chr16:72224583	G/T	cg03805757	chr16:71968109	PKD1L3	-0.73	-5.61	-0.5	2e-7	Blood protein levels;
THYM	cis	rs2229238	0.866	rs112231452	chr1:154504900	G/A	cg21262032	chr1:154437693	IL6R	-0.59	-5.15	-0.47	1.43e-6	Coronary heart disease;
THYM	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg18032289	chr17:61959525	GH2	-0.5	-4.84	-0.44	5.07e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs7219021	0.705	rs1962412	chr17:46970259	T/C	cg09029085	chr17:47094198	IGF2BP1	-0.35	-4.67	-0.43	9.73e-6	Schizophrenia or bipolar disorder;
THYM	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg22907277	chr7:1156413	C7orf50	0.73	4.56	0.42	1.55e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs684232	0.602	rs10521107	chr17:511156	G/A	cg15660573	chr17:549704	VPS53	-1.02	-11.2	-0.75	4.53e-19	Prostate cancer;
THYM	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg15592062	chr6:167189543	RPS6KA2	0.59	6.1	0.53	2.29e-8	Lung cancer;
THYM	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg22907277	chr7:1156413	C7orf50	0.87	7.48	0.61	3.63e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6690583	0.697	rs4907126	chr1:85523453	C/T	cg22153463	chr1:85462885	MCOLN2	0.72	4.9	0.45	3.91e-6	Serum sulfate level;
THYM	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg18230493	chr5:56204884	C5orf35	-0.87	-6.5	-0.55	3.77e-9	Initial pursuit acceleration;
THYM	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9790314	0.560	rs1450521	chr3:161091237	C/A	cg03342759	chr3:160939853	NMD3	-0.71	-5.99	-0.52	3.81e-8	Morning vs. evening chronotype;
THYM	cis	rs7432375	0.566	rs835636	chr3:136674500	A/C	cg21827317	chr3:136751795	NA	0.56	4.68	0.43	9.56e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	trans	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg10856724	chr12:34555212	NA	-0.84	-7.18	-0.59	1.53e-10	Bladder cancer;
THYM	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg00071950	chr4:10020882	SLC2A9	0.75	7.53	0.61	2.88e-11	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7546094	0.935	rs3013439	chr1:113200671	T/G	cg22162597	chr1:113214053	CAPZA1	-0.48	-4.9	-0.45	3.87e-6	Platelet distribution width;
THYM	cis	rs2354432	0.607	rs7553584	chr1:146693429	A/G	cg25205988	chr1:146714368	CHD1L	-1.1	-4.92	-0.45	3.66e-6	Mitochondrial DNA levels;
THYM	cis	rs7719624	0.510	rs2548977	chr5:135463769	C/T	cg15329133	chr5:135467951	SMAD5;SMAD5OS	0.58	4.83	0.44	5.14e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs36051895	0.632	rs7030853	chr9:5179002	C/T	cg02405213	chr9:5042618	JAK2	-0.99	-10.81	-0.74	3.1e-18	Pediatric autoimmune diseases;
THYM	cis	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg10856724	chr12:34555212	NA	-0.91	-9.08	-0.68	1.57e-14	Morning vs. evening chronotype;
THYM	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg17830980	chr10:43048298	ZNF37B	-1.1	-11.0	-0.75	1.23e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs2067615	0.579	rs10861663	chr12:107183589	G/A	cg15890332	chr12:107067104	RFX4	0.48	5.49	0.49	3.34e-7	Heart rate;
THYM	cis	rs2985684	1.000	rs3007030	chr14:50086563	C/T	cg02151108	chr14:50098012	C14orf104	-0.68	-5.64	-0.5	1.74e-7	Carotid intima media thickness;
THYM	cis	rs2463822	0.669	rs72919484	chr11:62043430	T/C	cg06239285	chr11:62104954	ASRGL1	-1.24	-5.95	-0.52	4.51e-8	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs10857712	0.851	rs7913420	chr10:135213854	C/T	cg17796960	chr10:135278976	LOC619207	-0.59	-5.06	-0.46	2.07e-6	Systemic lupus erythematosus;
THYM	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	5.77	0.51	1.01e-7	Platelet count;
THYM	cis	rs3087591	0.920	rs4795592	chr17:29612620	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.64	-5.44	-0.49	4.06e-7	Hip circumference;
THYM	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg21028142	chr17:79581711	NPLOC4	0.65	6.66	0.56	1.75e-9	Eye color traits;
THYM	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg26721908	chr21:47610096	LSS	-0.73	-5.23	-0.47	1.02e-6	Testicular germ cell tumor;
THYM	cis	rs17125944	0.615	rs12589020	chr14:53312002	C/T	cg00686598	chr14:53173677	PSMC6	1.06	4.81	0.44	5.56e-6	Alzheimer's disease (late onset);
THYM	cis	rs1642645	0.915	rs10890176	chr1:42503950	A/C	cg10197057	chr1:42612518	NA	0.45	4.84	0.44	5.05e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg01181863	chr3:195395398	SDHAP2	-0.62	-4.79	-0.44	6.2e-6	Pancreatic cancer;
THYM	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg24675658	chr1:53192096	ZYG11B	0.56	4.62	0.43	1.21e-5	Monocyte count;
THYM	cis	rs9563576	0.643	rs9563560	chr13:58508597	C/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.63	4.68	0.43	9.55e-6	Body mass index;
THYM	cis	rs3774749	0.565	rs6800021	chr3:50190346	G/A	cg14019146	chr3:50243930	SLC38A3	-0.63	-5.45	-0.49	3.97e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg05043794	chr9:111880884	C9orf5	-0.41	-6.04	-0.53	2.95e-8	Menarche (age at onset);
THYM	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg27129171	chr3:47204927	SETD2	0.71	6.66	0.56	1.81e-9	Colorectal cancer;
THYM	cis	rs7719624	0.870	rs3792900	chr5:135393754	A/G	cg15329133	chr5:135467951	SMAD5;SMAD5OS	0.57	5.03	0.46	2.31e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs3125734	0.633	rs7088891	chr10:64034019	G/T	cg09941381	chr10:64027924	RTKN2	-0.58	-4.75	-0.44	7.19e-6	Rheumatoid arthritis;
THYM	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg21194808	chr1:2205498	SKI	-0.33	-4.6	-0.43	1.3e-5	Height;
THYM	cis	rs11085466	0.615	rs76695906	chr19:21766710	G/A	cg23026602	chr19:21646605	NA	-0.67	-4.98	-0.46	2.79e-6	Colorectal or endometrial cancer;
THYM	cis	rs2227564	0.678	rs2242257	chr10:75597605	A/G	cg00564723	chr10:75632066	CAMK2G	0.57	5.75	0.51	1.08e-7	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs28476539	0.567	rs6812648	chr4:83564536	C/T	cg10249074	chr4:83542146	C4orf11	-0.66	-5.27	-0.48	8.48e-7	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	trans	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg10856724	chr12:34555212	NA	-0.99	-8.65	-0.66	1.26e-13	Bladder cancer;
THYM	cis	rs9902453	0.740	rs2729446	chr17:28102499	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.73	0.57	1.29e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7927771	0.524	rs10838739	chr11:47672743	A/G	cg20307385	chr11:47447363	PSMC3	-0.6	-4.55	-0.42	1.58e-5	Subjective well-being;
THYM	cis	rs6988636	1.000	rs7002332	chr8:124185442	G/C	cg22384356	chr8:124195192	FAM83A	-0.86	-5.15	-0.47	1.41e-6	Urinary uromodulin levels;
THYM	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg02696790	chr15:75250997	RPP25	-0.49	-5.02	-0.46	2.38e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs709400	1.000	rs6593	chr14:104163282	G/A	cg26031613	chr14:104095156	KLC1	1.23	12.52	0.79	7.95e-22	Body mass index;
THYM	cis	rs57920188	0.535	rs4520388	chr1:4092671	T/G	cg08764037	chr1:3634867	TP73	-0.44	-4.68	-0.43	9.33e-6	Interleukin-17 levels;
THYM	cis	rs67072384	1.000	rs67072384	chr11:72450724	C/T	cg01380194	chr11:72452482	ARAP1	-0.93	-5.07	-0.46	1.98e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs4888262	0.508	rs7189123	chr16:74540097	C/A	cg01733217	chr16:74700730	RFWD3	0.8	8.28	0.65	7.82e-13	Testicular germ cell tumor;
THYM	cis	rs34375054	0.526	rs34764657	chr12:125679639	A/G	cg25124228	chr12:125621409	AACS	-0.76	-5.7	-0.5	1.35e-7	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs6450176	0.857	rs1541680	chr5:53304725	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.14	-0.53	1.94e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs7851660	0.809	rs7866436	chr9:100650096	G/A	cg13688889	chr9:100608707	NA	-0.74	-5.43	-0.49	4.25e-7	Strep throat;
THYM	cis	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg06521331	chr12:34319734	NA	-0.94	-8.59	-0.66	1.66e-13	Morning vs. evening chronotype;
THYM	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg15704280	chr7:45808275	SEPT13	1.01	7.86	0.63	5.81e-12	Coronary artery disease;
THYM	cis	rs6840360	0.615	rs4696094	chr4:152465501	C/T	cg17479576	chr4:152424074	FAM160A1	-0.89	-6.74	-0.57	1.22e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs7100689	0.580	rs2168721	chr10:82208192	A/G	cg00277334	chr10:82204260	NA	-0.65	-6.38	-0.55	6.34e-9	Post bronchodilator FEV1;
THYM	cis	rs11048434	0.761	rs2377675	chr12:9124765	C/T	cg26114124	chr12:9217669	LOC144571	0.46	4.57	0.42	1.44e-5	Sjögren's syndrome;
THYM	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg23583168	chr7:148888333	NA	-1.03	-13.7	-0.81	3.25e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs568617	0.626	rs78028320	chr11:65582015	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	-0.81	-4.47	-0.42	2.19e-5	Crohn's disease;
THYM	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg26441486	chr22:50317300	CRELD2	0.43	6.57	0.56	2.71e-9	Schizophrenia;
THYM	cis	rs13102973	0.863	rs13129178	chr4:135858219	A/C	cg14419869	chr4:135874104	NA	0.9	8.82	0.67	5.39e-14	Subjective well-being;
THYM	cis	rs9296092	0.517	rs62405895	chr6:33471969	G/T	cg13560919	chr6:33536144	NA	-0.83	-6.89	-0.58	6.04e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.12	-0.47	1.58e-6	Total cholesterol levels;
THYM	cis	rs2398893	0.920	rs55947603	chr9:96739765	C/G	cg14459158	chr9:96720562	NA	0.53	4.65	0.43	1.06e-5	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2976388	1.000	rs2585179	chr8:143774193	G/A	cg13446199	chr8:143762866	PSCA	0.5	6.28	0.54	1.03e-8	Urinary tract infection frequency;
THYM	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg03433033	chr1:76189801	ACADM	0.77	10.21	0.72	6.01e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg08807101	chr21:30365312	RNF160	-0.64	-4.71	-0.44	8.31e-6	Dental caries;
THYM	cis	rs6490294	0.529	rs7137386	chr12:112283914	T/G	cg10833066	chr12:111807467	FAM109A	0.49	5.44	0.49	4.17e-7	Mean platelet volume;
THYM	cis	rs6840360	0.901	rs1443094	chr4:152456724	C/T	cg17479576	chr4:152424074	FAM160A1	-0.64	-4.98	-0.45	2.85e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10751667	0.961	rs6597971	chr11:928598	T/A	cg01483505	chr11:975446	AP2A2	0.66	5.12	0.46	1.6e-6	Alzheimer's disease (late onset);
THYM	cis	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg07460842	chr6:66804631	NA	0.81	4.87	0.45	4.52e-6	Exhaled nitric oxide output;
THYM	cis	rs6531656	0.663	rs6531654	chr4:38626282	T/C	cg24279243	chr4:38676559	KLF3	0.81	6.99	0.58	3.82e-10	Lymphocyte counts;
THYM	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg08000102	chr2:233561755	GIGYF2	0.69	6.09	0.53	2.35e-8	Coronary artery disease;
THYM	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg13877915	chr19:58951672	ZNF132	0.95	9.52	0.7	1.76e-15	Uric acid clearance;
THYM	cis	rs12142240	0.698	rs1135459	chr1:46815930	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs214467	0.524	rs740346	chr7:111177544	A/C	cg02729030	chr7:110879415	IMMP2L	-0.52	-4.45	-0.42	2.31e-5	Schizophrenia;
THYM	cis	rs9653442	0.835	rs7565967	chr2:100744683	G/T	cg22139774	chr2:100720529	AFF3	-0.38	-6.06	-0.53	2.69e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs4466137	0.904	rs6887104	chr5:83003535	G/A	cg16102102	chr5:83017553	HAPLN1	-1.11	-11.03	-0.75	1.07e-18	Prostate cancer;
THYM	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg23791538	chr6:167370224	RNASET2	0.74	5.92	0.52	5.06e-8	Crohn's disease;
THYM	cis	rs654128	0.640	rs170951	chr6:117220071	T/C	cg12892004	chr6:117198278	RFX6	-0.72	-5.66	-0.5	1.61e-7	Telomere length;
THYM	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg22974920	chr21:40686053	BRWD1	-0.58	-4.58	-0.43	1.4e-5	Cognitive function;
THYM	cis	rs4747241	0.739	rs11596698	chr10:74069445	C/G	cg07828833	chr10:74069493	NA	0.57	4.75	0.44	7.07e-6	Heschl's gyrus morphology;
THYM	cis	rs28595532	0.920	rs116146507	chr4:119749556	A/G	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.63	-4.48	-0.42	2.05e-5	Gut microbiome composition (summer);
THYM	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg00129232	chr17:37814104	STARD3	-0.69	-4.45	-0.42	2.32e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg10589385	chr1:150898437	SETDB1	0.62	5.26	0.47	8.86e-7	Tonsillectomy;
THYM	cis	rs11771526	0.892	rs62457539	chr7:32364604	G/A	cg27511599	chr7:32358540	NA	0.75	5.02	0.46	2.42e-6	Body mass index;
THYM	cis	rs514406	0.505	rs395169	chr1:53174071	G/A	cg22166914	chr1:53195759	ZYG11B	0.9	10.56	0.73	1.04e-17	Monocyte count;
THYM	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg07532245	chr17:28927093	LRRC37B2	0.62	4.48	0.42	2.05e-5	Body mass index;
THYM	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg01341218	chr17:43662625	NA	0.87	7.55	0.61	2.7e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12711979	0.509	rs10195488	chr2:3824135	T/C	cg17052675	chr2:3827356	NA	-0.88	-13.79	-0.82	2.09e-24	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs6669072	0.605	rs11586930	chr1:91255296	T/G	cg08895590	chr1:91227319	NA	-0.46	-5.26	-0.47	8.92e-7	Cognitive function;
THYM	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg07959070	chr22:50026188	C22orf34	-0.28	-4.96	-0.45	3.12e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg17279839	chr7:150038598	RARRES2	0.56	5.43	0.49	4.4e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg18105134	chr13:113819100	PROZ	-1.2	-7.72	-0.62	1.17e-11	Platelet distribution width;
THYM	cis	rs2278491	0.557	rs4876679	chr8:117763873	A/G	cg23513447	chr8:117778558	UTP23	-0.75	-5.36	-0.48	5.9e-7	Body mass index;
THYM	cis	rs61931739	1.000	rs12311881	chr12:34036100	A/G	cg06521331	chr12:34319734	NA	0.61	4.76	0.44	6.95e-6	Morning vs. evening chronotype;
THYM	cis	rs79149102	0.579	rs73436579	chr15:75294514	C/T	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.57	-5.57	-0.5	2.41e-7	Lymphocyte counts;
THYM	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg03806693	chr22:41940476	POLR3H	1.21	10.48	0.73	1.56e-17	Vitiligo;
THYM	cis	rs919433	0.589	rs7601800	chr2:198395099	T/C	cg00792783	chr2:198669748	PLCL1	0.86	6.08	0.53	2.49e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs1401999	0.510	rs3749438	chr3:183705184	G/A	cg01324343	chr3:183735012	ABCC5	0.52	5.31	0.48	7.11e-7	Anterior chamber depth;
THYM	cis	rs35934224	0.724	rs35374520	chr22:19851149	A/G	cg11182965	chr22:19864308	TXNRD2	-0.72	-5.82	-0.51	7.88e-8	Glaucoma (primary open-angle);
THYM	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-4.75	-0.44	7.13e-6	Type 2 diabetes;
THYM	cis	rs4589258	0.737	rs7121155	chr11:90418203	T/C	cg26138821	chr11:89956704	CHORDC1	0.56	4.68	0.43	9.36e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg05043794	chr9:111880884	C9orf5	-0.43	-6.21	-0.54	1.39e-8	Menarche (age at onset);
THYM	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg15556689	chr8:8085844	FLJ10661	0.6	4.65	0.43	1.08e-5	Mood instability;
THYM	cis	rs7119038	0.865	rs10892299	chr11:118726843	C/T	cg19308663	chr11:118741387	NA	0.57	5.5	0.49	3.2e-7	Sjögren's syndrome;
THYM	cis	rs2742234	0.590	rs2257767	chr10:43657811	T/G	cg06632098	chr10:43605906	RET	-0.8	-5.02	-0.46	2.43e-6	Hirschsprung disease;
THYM	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Gout;
THYM	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13223928	0.651	rs4722426	chr7:3150697	C/T	cg19214707	chr7:3157722	NA	0.85	7.17	0.59	1.59e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	7.35	0.6	6.91e-11	Platelet count;
THYM	cis	rs898549	0.520	rs1873757	chr10:44539016	G/A	cg27599783	chr10:45480162	RASSF4	0.5	4.57	0.42	1.47e-5	Obesity-related traits;
THYM	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg25767906	chr1:53392781	SCP2	-0.53	-5.2	-0.47	1.13e-6	Monocyte count;
THYM	cis	rs4631830	0.657	rs2611502	chr10:51500301	A/G	cg10326726	chr10:51549505	MSMB	-0.6	-5.93	-0.52	4.82e-8	Prostate-specific antigen levels;
THYM	cis	rs7669967	0.595	rs1902493	chr4:156054699	A/G	cg17641028	chr4:156585641	NA	-0.57	-5.13	-0.47	1.53e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg08132940	chr7:1081526	C7orf50	-1.15	-6.58	-0.56	2.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6980334	0.679	rs2306847	chr7:137798593	A/T	cg22979093	chr7:137028410	PTN	0.64	5.01	0.46	2.51e-6	Blood metabolite ratios;
THYM	cis	rs13108904	0.521	rs11247998	chr4:1363602	T/C	cg13395646	chr4:1353034	KIAA1530	-0.74	-7.16	-0.59	1.71e-10	Obesity-related traits;
THYM	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg08645402	chr16:4508243	NA	0.67	5.77	0.51	1.01e-7	Schizophrenia;
THYM	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg05552183	chr6:42928497	GNMT	0.66	5.13	0.47	1.54e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg27572855	chr1:25598939	RHD	0.7	5.54	0.49	2.66e-7	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.72	5.72	0.51	1.21e-7	Blood metabolite levels;
THYM	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Body mass index;
THYM	cis	rs11031096	0.782	rs2284450	chr11:4149214	A/T	cg18678763	chr11:4115507	RRM1	-0.47	-6.57	-0.56	2.7e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs1003719	0.680	rs7275984	chr21:38505696	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-4.75	-0.44	7.3e-6	Eye color traits;
THYM	cis	rs7975161	0.572	rs7132418	chr12:104603591	C/A	cg25273343	chr12:104657179	TXNRD1	-0.76	-5.22	-0.47	1.07e-6	Toenail selenium levels;
THYM	cis	rs11225247	0.772	rs10219215	chr11:102238237	C/T	cg11690896	chr11:102217788	BIRC2	1.12	5.18	0.47	1.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs2806561	1.000	rs2746553	chr1:23493246	T/C	cg12483005	chr1:23474871	LUZP1	0.55	5.68	0.5	1.46e-7	Height;
THYM	cis	rs28374715	0.532	rs28463309	chr15:41666716	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.78	-0.83	2.3e-26	Ulcerative colitis;
THYM	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7529073	0.815	rs1431984	chr1:214148628	A/G	cg24083324	chr1:214162604	PROX1	-0.6	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs7267979	0.966	rs2263204	chr20:25377688	A/T	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1160297	0.609	rs10203699	chr2:53105568	A/G	cg07782112	chr2:53107842	NA	0.78	6.41	0.55	5.67e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs7980799	0.682	rs10161491	chr12:33623806	T/C	cg10856724	chr12:34555212	NA	0.62	4.58	0.43	1.39e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg06108461	chr20:60628389	TAF4	-1.04	-8.47	-0.66	3.05e-13	Body mass index;
THYM	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg12826209	chr6:26865740	GUSBL1	0.76	5.61	0.5	1.99e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2554380	0.843	rs2562783	chr15:84387926	G/C	cg14598478	chr15:84363061	ADAMTSL3	-0.65	-5.23	-0.47	1.02e-6	Height;
THYM	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg07343612	chr16:622815	PIGQ	-1.08	-10.52	-0.73	1.27e-17	Height;
THYM	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg17294928	chr15:75287854	SCAMP5	0.96	8.06	0.64	2.24e-12	Blood trace element (Zn levels);
THYM	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg15605315	chr1:45957053	TESK2	0.78	6.78	0.57	9.97e-10	High light scatter reticulocyte count;
THYM	cis	rs7772486	0.875	rs1412081	chr6:146409733	A/G	cg05347473	chr6:146136440	FBXO30	0.57	4.59	0.43	1.36e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	5.26	0.47	9.02e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs28595532	0.920	rs17258050	chr4:119672019	G/A	cg14228332	chr4:119757509	SEC24D	1.35	4.52	0.42	1.81e-5	Cannabis dependence symptom count;
THYM	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg02527881	chr3:46936655	PTH1R	0.57	5.4	0.48	4.99e-7	Colorectal cancer;
THYM	cis	rs7078219	1.000	rs7081330	chr10:101274465	A/G	cg23904955	chr10:101282759	NA	-0.45	-5.38	-0.48	5.42e-7	Dental caries;
THYM	cis	rs7084402	0.967	rs1658425	chr10:60331547	G/C	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	trans	rs480407	0.857	rs270962	chr2:161688053	G/T	cg06548410	chr19:1997657	BTBD2	0.7	6.87	0.58	6.79e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs9549260	0.755	rs8001443	chr13:41216646	C/T	cg21288729	chr13:41239152	FOXO1	-0.73	-5.82	-0.51	7.84e-8	Red blood cell count;
THYM	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg11461670	chr8:22454935	PDLIM2	-0.37	-6.62	-0.56	2.1e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg11764359	chr7:65958608	NA	0.8	6.58	0.56	2.51e-9	Aortic root size;
THYM	cis	rs17826219	0.562	rs719600	chr17:28731262	G/A	cg17105886	chr17:28927953	LRRC37B2	-1.13	-4.99	-0.46	2.77e-6	Body mass index;
THYM	cis	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg02825527	chr7:2087843	MAD1L1	-0.7	-4.55	-0.42	1.58e-5	Bipolar disorder;
THYM	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg02527881	chr3:46936655	PTH1R	0.6	5.51	0.49	3.04e-7	Colorectal cancer;
THYM	cis	rs920590	0.684	rs7461774	chr8:19666645	G/A	cg01411142	chr8:19674711	INTS10	0.7	5.4	0.48	4.95e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg22535103	chr8:58192502	C8orf71	-0.93	-5.25	-0.47	9.15e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs2898681	0.837	rs2017237	chr4:53748515	A/G	cg21521518	chr4:53727714	RASL11B	0.46	5.22	0.47	1.05e-6	Optic nerve measurement (cup area);
THYM	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.26	0.47	8.97e-7	Lung cancer in ever smokers;
THYM	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.88	5.64	0.5	1.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4481887	0.741	rs28444488	chr1:248531776	C/A	cg00666640	chr1:248458726	OR2T12	0.55	4.74	0.44	7.59e-6	Common traits (Other);
THYM	cis	rs7633857	0.537	rs1580253	chr3:160767150	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-4.49	-0.42	2.02e-5	Educational attainment (years of education);
THYM	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg03396347	chr1:1875803	NA	-0.67	-6.86	-0.58	6.84e-10	Body mass index;
THYM	cis	rs7651039	1.000	rs7651039	chr3:15648004	C/T	cg16303742	chr3:15540471	COLQ	-0.55	-5.29	-0.48	7.88e-7	Coronary heart disease;
THYM	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg06636001	chr8:8085503	FLJ10661	-0.75	-6.6	-0.56	2.34e-9	Mood instability;
THYM	cis	rs34599045	0.522	rs71517761	chr1:152901128	T/A	cg07796016	chr1:152779584	LCE1C	-1.14	-4.47	-0.42	2.18e-5	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg04944784	chr2:26401820	FAM59B	1.05	8.18	0.64	1.23e-12	Gut microbiome composition (summer);
THYM	cis	rs12887734	0.603	rs3212038	chr14:104178186	A/G	cg08213375	chr14:104286397	PPP1R13B	0.44	4.77	0.44	6.54e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg08968635	chr6:28129556	ZNF389	0.6	4.58	0.43	1.4e-5	Parkinson's disease;
THYM	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg00383909	chr3:49044727	WDR6	1.18	6.7	0.57	1.46e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs7107174	1.000	rs1893448	chr11:77969180	G/A	cg19901956	chr11:77921274	USP35	-0.71	-5.46	-0.49	3.75e-7	Testicular germ cell tumor;
THYM	cis	rs807669	0.802	rs762528	chr22:19166680	A/G	cg02655711	chr22:19163373	SLC25A1	0.98	11.9	0.77	1.58e-20	Metabolite levels;
THYM	cis	rs4589258	0.737	rs1792608	chr11:90432928	A/T	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4460079	0.531	rs7663612	chr4:114835882	C/G	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg12981288	chr8:11183844	MTMR9	-0.46	-4.68	-0.43	9.49e-6	Retinal vascular caliber;
THYM	cis	rs2425143	0.512	rs2425126	chr20:34331730	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Blood protein levels;
THYM	cis	rs7584330	0.652	rs7607231	chr2:238372896	T/C	cg14458575	chr2:238380390	NA	0.92	7.7	0.62	1.31e-11	Prostate cancer;
THYM	cis	rs3126085	0.935	rs1496046	chr1:152184534	C/G	cg10321714	chr1:152280068	FLG	0.78	5.71	0.51	1.28e-7	Atopic dermatitis;
THYM	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg04750100	chr2:136595281	LCT	0.53	6.42	0.55	5.41e-9	Mosquito bite size;
THYM	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.59	-7.33	-0.6	7.55e-11	Longevity;Endometriosis;
THYM	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg13695892	chr22:41940480	POLR3H	0.91	6.69	0.57	1.5e-9	Vitiligo;
THYM	cis	rs7191439	0.858	rs2340973	chr16:88773396	G/A	cg04602696	chr16:88846723	FAM38A	-0.66	-4.79	-0.44	6.17e-6	Plateletcrit;
THYM	cis	rs2836974	0.931	rs2989330	chr21:40716209	A/G	cg11644478	chr21:40555479	PSMG1	0.92	6.45	0.55	4.62e-9	Cognitive function;
THYM	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg05043794	chr9:111880884	C9orf5	0.35	4.93	0.45	3.42e-6	Menarche (age at onset);
THYM	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11644478	chr21:40555479	PSMG1	1.08	9.3	0.69	5.18e-15	Cognitive function;
THYM	cis	rs7524258	0.900	rs6577425	chr1:7306338	G/T	cg07173049	chr1:7289937	CAMTA1	0.7	5.7	0.51	1.32e-7	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg09021430	chr5:549028	NA	-0.76	-6.05	-0.53	2.91e-8	Obesity-related traits;
THYM	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg07570687	chr10:102243282	WNT8B	0.84	8.13	0.64	1.59e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg25817165	chr18:72167213	CNDP2	-0.97	-10.17	-0.72	7.3e-17	Refractive error;
THYM	cis	rs7107174	0.901	rs10899496	chr11:78123831	A/G	cg02023728	chr11:77925099	USP35	0.62	6.32	0.54	8.55e-9	Testicular germ cell tumor;
THYM	cis	rs6121246	0.529	rs7261354	chr20:30202414	T/C	cg13852791	chr20:30311386	BCL2L1	0.74	5.41	0.48	4.8e-7	Mean corpuscular hemoglobin;
THYM	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-4.81	-0.44	5.66e-6	Crohn's disease;
THYM	cis	rs4343996	0.536	rs10228055	chr7:3414750	G/A	cg21248987	chr7:3385318	SDK1	0.4	4.91	0.45	3.72e-6	Motion sickness;
THYM	cis	rs9486719	1.000	rs10457159	chr6:96993139	G/A	cg18709589	chr6:96969512	KIAA0776	-0.68	-4.71	-0.44	8.44e-6	Migraine;Coronary artery disease;
THYM	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg13695892	chr22:41940480	POLR3H	-0.97	-7.35	-0.6	6.72e-11	Vitiligo;
THYM	cis	rs7404928	0.536	rs195995	chr16:23954399	A/G	cg26685404	chr16:23957272	PRKCB	-0.58	-6.55	-0.56	2.95e-9	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg05090351	chr10:126851162	NA	-0.74	-8.83	-0.67	5.14e-14	Menarche (age at onset);
THYM	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	5.03	0.46	2.33e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.68	-5.76	-0.51	1.02e-7	Renal function-related traits (BUN);
THYM	cis	rs17253792	0.822	rs79022053	chr14:56071721	A/G	cg01858014	chr14:56050164	KTN1	-1.22	-5.13	-0.47	1.52e-6	Putamen volume;
THYM	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg27490568	chr2:178487706	NA	0.57	5.31	0.48	7.2e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9787249	1.000	rs9787249	chr1:40212878	G/A	cg24920358	chr1:40204285	PPIE	0.6	5.57	0.5	2.39e-7	Blood protein levels;
THYM	cis	rs854765	0.624	rs12946746	chr17:17741669	T/C	cg04398451	chr17:18023971	MYO15A	0.84	7.62	0.62	1.84e-11	Total body bone mineral density;
THYM	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	4.97	0.45	3.01e-6	Height;
THYM	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg22981736	chr15:31284413	MTMR10	-0.57	-4.77	-0.44	6.64e-6	Huntington's disease progression;
THYM	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg05552183	chr6:42928497	GNMT	0.69	5.39	0.48	5.08e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.67	5.0	0.46	2.64e-6	Tonsillectomy;
THYM	cis	rs889398	0.741	rs6499269	chr16:69908918	T/C	cg09409435	chr16:70099608	PDXDC2	0.66	5.25	0.47	9.4e-7	Body mass index;
THYM	cis	rs1011018	0.955	rs6464214	chr7:139454165	A/G	cg06079564	chr7:139468310	HIPK2	-0.77	-6.04	-0.53	3.05e-8	Systolic blood pressure;
THYM	cis	rs7671261	0.540	rs4325981	chr4:90024321	G/A	cg17769793	chr4:89976368	FAM13A	0.42	4.52	0.42	1.79e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.74	-6.47	-0.55	4.2e-9	Chronic sinus infection;
THYM	cis	rs7584330	0.738	rs4402703	chr2:238374957	T/A	cg16989719	chr2:238392110	NA	-0.62	-5.9	-0.52	5.46e-8	Prostate cancer;
THYM	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg04772025	chr11:68637568	NA	0.63	6.58	0.56	2.59e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6684428	0.706	rs11206673	chr1:56326340	C/T	cg11651538	chr1:56320950	NA	0.63	4.97	0.45	2.91e-6	Airflow obstruction;
THYM	cis	rs800586	0.957	rs813889	chr8:116798852	C/T	cg04656070	chr8:116661063	TRPS1	0.48	4.95	0.45	3.24e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs854765	0.663	rs3183702	chr17:17747289	A/G	cg16928487	chr17:17741425	SREBF1	0.54	5.16	0.47	1.34e-6	Total body bone mineral density;
THYM	cis	rs28795989	0.896	rs7655918	chr4:7889301	A/G	cg12728606	chr4:7903970	AFAP1	0.43	4.59	0.43	1.34e-5	Intraocular pressure;
THYM	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg17063962	chr7:91808500	NA	1.15	11.92	0.77	1.43e-20	Breast cancer;
THYM	cis	rs9291683	0.679	rs2278122	chr4:10096241	T/A	cg00071950	chr4:10020882	SLC2A9	-0.7	-7.55	-0.61	2.6e-11	Bone mineral density;
THYM	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg14779329	chr11:130786720	SNX19	0.52	5.7	0.51	1.32e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs807669	0.807	rs712948	chr22:19206499	A/G	cg02655711	chr22:19163373	SLC25A1	0.92	10.1	0.72	1.02e-16	Metabolite levels;
THYM	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg08470875	chr2:26401718	FAM59B	-0.72	-4.46	-0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg19592336	chr6:28129416	ZNF389	-0.69	-4.61	-0.43	1.27e-5	Depression;
THYM	cis	rs10484885	0.824	rs28372875	chr6:90529343	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.87	-7.73	-0.62	1.13e-11	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg15733309	chr7:157513707	PTPRN2	0.57	6.36	0.55	6.99e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	6.08	0.53	2.46e-8	Schizophrenia;
THYM	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg06481639	chr22:41940642	POLR3H	-0.82	-5.68	-0.5	1.49e-7	Vitiligo;
THYM	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg00012203	chr2:219082015	ARPC2	0.87	8.3	0.65	6.88e-13	Colorectal cancer;
THYM	cis	rs2120019	0.608	rs8042558	chr15:75320433	G/T	cg09165964	chr15:75287851	SCAMP5	-1.05	-11.01	-0.75	1.16e-18	Blood trace element (Zn levels);
THYM	cis	rs6500395	0.962	rs2101372	chr16:48627306	G/A	cg04672837	chr16:48644449	N4BP1	0.48	4.64	0.43	1.13e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.26	-9.1	-0.68	1.4e-14	Gut microbiome composition (summer);
THYM	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg20283391	chr11:68216788	NA	-0.68	-5.11	-0.46	1.69e-6	Total body bone mineral density;
THYM	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg16325326	chr1:53192061	ZYG11B	0.98	11.37	0.76	2.04e-19	Monocyte count;
THYM	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg05347473	chr6:146136440	FBXO30	0.57	4.59	0.43	1.38e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7246657	0.943	rs10407084	chr19:37907792	T/C	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-5.33	-0.48	6.7e-7	Hemoglobin concentration;
THYM	cis	rs1448094	0.511	rs7139088	chr12:86147878	T/C	cg02569458	chr12:86230093	RASSF9	-0.66	-5.63	-0.5	1.84e-7	Major depressive disorder;
THYM	cis	rs11997175	0.624	rs4526317	chr8:33682936	T/A	ch.8.33884649F	chr8:33765107	NA	0.66	5.03	0.46	2.33e-6	Body mass index;
THYM	cis	rs11760633	0.526	rs10950371	chr7:1825304	T/C	cg27050990	chr7:2629313	IQCE	0.66	4.83	0.44	5.2e-6	Coronary artery disease;
THYM	cis	rs1843834	0.931	rs10170573	chr2:225552916	A/G	cg22455342	chr2:225449267	CUL3	0.6	4.62	0.43	1.23e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs1336900	0.513	rs56253522	chr1:150614869	C/A	cg04414720	chr1:150670196	GOLPH3L	0.64	4.78	0.44	6.49e-6	Blood protein levels;
THYM	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg06623918	chr6:96969491	KIAA0776	-1.05	-9.75	-0.71	5.73e-16	Headache;
THYM	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg07022442	chr13:21864356	NA	0.72	4.76	0.44	6.91e-6	White matter hyperintensity burden;
THYM	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08704250	chr15:31115839	NA	0.69	8.65	0.66	1.27e-13	Huntington's disease progression;
THYM	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg09455208	chr3:40491958	NA	0.5	5.15	0.47	1.39e-6	Renal cell carcinoma;
THYM	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg27532560	chr4:187881888	NA	-0.96	-11.41	-0.76	1.68e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7572733	0.534	rs4850813	chr2:198775982	C/T	cg00792783	chr2:198669748	PLCL1	-0.84	-5.97	-0.52	4.15e-8	Dermatomyositis;
THYM	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg19770292	chr5:1868693	NA	0.54	4.97	0.45	2.95e-6	Cardiovascular disease risk factors;
THYM	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2455799	0.634	rs62243670	chr3:15918990	C/T	cg16303742	chr3:15540471	COLQ	-0.57	-5.76	-0.51	1.04e-7	Mean platelet volume;
THYM	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg01073479	chr16:3509474	NAT15	-0.51	-4.94	-0.45	3.32e-6	Tuberculosis;
THYM	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg11663144	chr21:46675770	NA	-0.71	-9.92	-0.71	2.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg09260853	chr1:2094483	PRKCZ	-0.44	-4.65	-0.43	1.07e-5	Height;
THYM	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4666002	0.789	rs6727388	chr2:27932587	A/G	cg27432699	chr2:27873401	GPN1	0.62	4.71	0.43	8.52e-6	Phospholipid levels (plasma);
THYM	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg02640540	chr1:67518911	SLC35D1	0.64	4.68	0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-5.13	-0.47	1.55e-6	Lymphocyte counts;
THYM	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg17105886	chr17:28927953	LRRC37B2	1.13	6.42	0.55	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4930103	0.874	rs80047492	chr11:2025032	A/T	cg03175030	chr11:2018143	H19;MIR675	-0.45	-4.86	-0.45	4.62e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg08000102	chr2:233561755	GIGYF2	-0.83	-7.26	-0.6	1.05e-10	Coronary artery disease;
THYM	cis	rs1949733	0.959	rs2688242	chr4:8429943	T/G	cg11789530	chr4:8429930	ACOX3	0.74	5.48	0.49	3.49e-7	Response to antineoplastic agents;
THYM	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg11764359	chr7:65958608	NA	0.67	4.75	0.44	7.31e-6	Aortic root size;
THYM	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg04520793	chr17:42248056	ASB16	-0.31	-4.99	-0.46	2.69e-6	Bone mineral density (hip);Bone mineral density;
THYM	cis	rs7589342	0.839	rs12997003	chr2:106436413	C/T	cg14210321	chr2:106509881	NCK2	-0.69	-4.86	-0.45	4.58e-6	Addiction;
THYM	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg11905131	chr22:24372483	LOC391322	-0.97	-11.96	-0.78	1.19e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.65	-11.76	-0.77	3.01e-20	Hemostatic factors and hematological phenotypes;
THYM	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg02018176	chr4:1364513	KIAA1530	0.7	6.27	0.54	1.08e-8	Longevity;
THYM	cis	rs12216545	0.765	rs2140140	chr7:150249354	C/T	cg00323915	chr7:150264987	GIMAP4	-0.51	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs1505368	0.567	rs2054617	chr2:213355890	T/C	cg20637307	chr2:213403960	ERBB4	0.58	4.61	0.43	1.26e-5	Symmetrical dimethylarginine levels;
THYM	cis	rs7809950	1.000	rs2520269	chr7:107191327	T/C	cg23024343	chr7:107201750	COG5	-0.93	-8.58	-0.66	1.74e-13	Coronary artery disease;
THYM	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs17443541	0.507	rs12613262	chr2:200465327	T/C	cg03741458	chr2:200468445	NA	-0.8	-6.04	-0.53	3.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg00277334	chr10:82204260	NA	-0.55	-5.91	-0.52	5.22e-8	Post bronchodilator FEV1;
THYM	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg10661904	chr17:79619235	PDE6G	-0.57	-5.3	-0.48	7.61e-7	Eye color traits;
THYM	cis	rs4363385	0.818	rs11205174	chr1:153001230	C/T	cg13444842	chr1:152974279	SPRR3	0.58	4.6	0.43	1.32e-5	Inflammatory skin disease;
THYM	cis	rs72627123	0.656	rs4646864	chr14:74526703	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.29	7.08	0.59	2.46e-10	Morning vs. evening chronotype;
THYM	cis	rs6499255	0.951	rs10852457	chr16:69607853	C/T	cg00738113	chr16:70207722	CLEC18C	-0.43	-4.5	-0.42	1.93e-5	IgE levels;
THYM	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg11494091	chr17:61959527	GH2	1.07	16.52	0.86	1.13e-29	Prudent dietary pattern;
THYM	cis	rs636291	0.517	rs55935829	chr1:10540926	A/T	cg20482658	chr1:10539492	PEX14	-0.33	-4.89	-0.45	4.18e-6	Prostate cancer;
THYM	cis	rs7084402	0.967	rs1658495	chr10:60280153	C/A	cg09696939	chr10:60272079	BICC1	0.47	5.47	0.49	3.63e-7	Refractive error;
THYM	cis	rs12681288	0.523	rs111782857	chr8:962486	T/C	cg08648136	chr8:956695	NA	0.56	4.92	0.45	3.57e-6	Schizophrenia;
THYM	cis	rs3820068	0.608	rs12092485	chr1:16048038	A/G	cg05660106	chr1:15850417	CASP9	0.73	5.79	0.51	8.96e-8	Systolic blood pressure;
THYM	cis	rs7572733	0.515	rs12619300	chr2:198786490	A/C	cg00792783	chr2:198669748	PLCL1	-0.84	-6.0	-0.52	3.54e-8	Dermatomyositis;
THYM	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg13736514	chr6:26305472	NA	-0.62	-7.54	-0.61	2.81e-11	Educational attainment;
THYM	cis	rs7247513	0.930	rs35275129	chr19:12716493	G/A	cg01871581	chr19:12707946	ZNF490	-0.93	-10.97	-0.75	1.45e-18	Bipolar disorder;
THYM	cis	rs6163	0.588	rs3818708	chr10:104503584	C/T	cg08772003	chr10:104629869	AS3MT	-0.51	-4.53	-0.42	1.69e-5	Waist circumference;Hip circumference;
THYM	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg14983838	chr19:29218262	NA	-0.82	-5.62	-0.5	1.88e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	5.43	0.49	4.24e-7	Obesity-related traits;
THYM	trans	rs4650994	1.000	rs4354501	chr1:178524596	T/C	cg05059571	chr16:84539110	KIAA1609	-0.75	-8.15	-0.64	1.43e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	trans	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs9470366	0.816	rs1321310	chr6:36623124	C/T	cg24425727	chr6:36645648	CDKN1A	0.56	4.59	0.43	1.34e-5	QRS duration;
THYM	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg02527881	chr3:46936655	PTH1R	-0.63	-6.19	-0.54	1.52e-8	Colorectal cancer;
THYM	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg02493740	chr2:85810744	VAMP5	-0.63	-4.98	-0.46	2.8e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs11077998	0.967	rs7502945	chr17:80495039	T/C	cg10255544	chr17:80519551	FOXK2	0.51	4.48	0.42	2.05e-5	Reticulocyte fraction of red cells;
THYM	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg18252515	chr7:66147081	NA	0.67	5.24	0.47	9.7e-7	Aortic root size;
THYM	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	4.94	0.45	3.4e-6	Height;
THYM	cis	rs2811415	0.597	rs6801215	chr3:127762336	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-4.87	-0.45	4.47e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg24818145	chr4:99064322	C4orf37	0.72	5.7	0.51	1.33e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7524258	0.868	rs2412153	chr1:7272412	C/T	cg07173049	chr1:7289937	CAMTA1	0.63	5.02	0.46	2.4e-6	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg02734326	chr4:10020555	SLC2A9	0.76	7.25	0.6	1.13e-10	Bone mineral density;
THYM	cis	rs12410462	1.000	rs6672162	chr1:227632335	G/A	cg23173402	chr1:227635558	NA	0.68	6.15	0.53	1.79e-8	Major depressive disorder;
THYM	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg12935359	chr14:103987150	CKB	0.67	6.33	0.54	8.22e-9	Bone mineral density;
THYM	cis	rs7107770	0.739	rs12788937	chr11:125082221	G/A	cg04164023	chr11:125106101	PKNOX2	-0.71	-4.55	-0.42	1.56e-5	Photic sneeze reflex;
THYM	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg11752832	chr7:134001865	SLC35B4	0.76	5.57	0.5	2.34e-7	Mean platelet volume;
THYM	cis	rs981844	0.712	rs1037648	chr4:154737877	T/C	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs514406	0.893	rs1242317	chr1:53414766	T/C	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.9	-0.45	3.86e-6	Monocyte count;
THYM	cis	rs11048434	0.736	rs11048190	chr12:9104939	C/T	cg04155231	chr12:9217510	LOC144571	0.47	4.47	0.42	2.14e-5	Sjögren's syndrome;
THYM	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg18305652	chr10:134549665	INPP5A	0.8	6.56	0.56	2.83e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs4589258	0.737	rs1783800	chr11:90445471	C/T	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2712184	0.756	rs2712161	chr2:217662384	G/A	cg05032264	chr2:217675019	NA	-0.54	-4.46	-0.42	2.22e-5	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs11039571	0.588	rs61917001	chr11:48233667	G/C	cg24672777	chr11:48374446	OR4C45	-0.99	-6.22	-0.54	1.34e-8	D-dimer levels;
THYM	cis	rs911119	0.954	rs35966482	chr20:23620716	G/T	cg16589663	chr20:23618590	CST3	0.78	4.83	0.44	5.31e-6	Chronic kidney disease;
THYM	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg20608306	chr11:116969690	SIK3	0.52	6.75	0.57	1.16e-9	Blood protein levels;
THYM	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg06238570	chr21:40685208	BRWD1	-0.96	-9.14	-0.68	1.13e-14	Cognitive function;
THYM	cis	rs11225247	1.000	rs12269847	chr11:102269743	G/C	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	trans	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg05926928	chr17:57297772	GDPD1	1.2	9.3	0.69	5.26e-15	Opioid sensitivity;
THYM	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg07570687	chr10:102243282	WNT8B	0.75	6.53	0.56	3.24e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg23958373	chr8:599963	NA	0.92	4.6	0.43	1.3e-5	IgG glycosylation;
THYM	cis	rs1371867	0.846	rs1660328	chr8:101303450	A/G	cg00191853	chr8:101177733	SPAG1	-0.5	-5.01	-0.46	2.54e-6	Atrioventricular conduction;
THYM	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg10589385	chr1:150898437	SETDB1	0.62	5.26	0.47	8.86e-7	Tonsillectomy;
THYM	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg12179176	chr11:130786555	SNX19	0.94	9.9	0.71	2.71e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg25382214	chr1:3105252	PRDM16	0.52	4.5	0.42	1.9e-5	Migraine;
THYM	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg13393036	chr8:95962371	TP53INP1	-0.47	-4.9	-0.45	3.95e-6	Type 2 diabetes;
THYM	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.23	-0.47	9.94e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12188164	0.965	rs72717415	chr5:430059	G/A	cg26850624	chr5:429559	AHRR	-0.69	-5.39	-0.48	5.09e-7	Cystic fibrosis severity;
THYM	cis	rs28493229	0.708	rs78900506	chr19:41160096	T/C	cg21869046	chr19:41225005	ITPKC	0.52	4.57	0.42	1.46e-5	Kawasaki disease;
THYM	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	5.43	0.49	4.33e-7	Obesity-related traits;
THYM	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg08109568	chr15:31115862	NA	-0.63	-5.95	-0.52	4.43e-8	Huntington's disease progression;
THYM	cis	rs6032067	0.641	rs74174934	chr20:43761331	T/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.67	-5.94	-0.52	4.77e-8	Blood protein levels;
THYM	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg06634786	chr22:41940651	POLR3H	0.66	5.15	0.47	1.39e-6	Vitiligo;
THYM	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg06784218	chr1:46089804	CCDC17	-0.32	-4.82	-0.44	5.41e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6964587	0.755	rs13229505	chr7:91444679	G/T	cg22709100	chr7:91322751	NA	0.69	5.11	0.46	1.68e-6	Breast cancer;
THYM	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg26131816	chr17:42072204	PYY	0.54	4.68	0.43	9.6e-6	Menopause (age at onset);
THYM	cis	rs7119	0.637	rs2667775	chr15:77864802	T/G	cg10437265	chr15:77819839	NA	-0.7	-7.1	-0.59	2.28e-10	Type 2 diabetes;
THYM	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg21385522	chr1:16154831	NA	0.69	4.75	0.44	7.18e-6	Systolic blood pressure;
THYM	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg09263875	chr16:632152	PIGQ	0.7	5.71	0.51	1.27e-7	Height;
THYM	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg10862848	chr6:42927986	GNMT	-0.51	-6.83	-0.57	8.14e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs67311347	0.544	rs60329764	chr3:40334621	C/T	cg24209194	chr3:40518798	ZNF619	-0.58	-4.92	-0.45	3.64e-6	Renal cell carcinoma;
THYM	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg23711669	chr6:146136114	FBXO30	0.93	9.39	0.69	3.39e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4285028	0.747	rs1128163	chr3:121350573	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.83	-6.75	-0.57	1.16e-9	Multiple sclerosis;
THYM	cis	rs1728785	1.000	rs1749791	chr16:68572347	C/T	cg02972257	chr16:68554789	NA	-0.75	-4.62	-0.43	1.22e-5	Ulcerative colitis;
THYM	cis	rs116095464	1.000	rs908116	chr5:317119	A/T	cg22857025	chr5:266934	NA	-1.37	-4.98	-0.46	2.8e-6	Breast cancer;
THYM	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg22875332	chr1:76189707	ACADM	0.88	11.22	0.75	4.31e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs13256369	1.000	rs873063	chr8:8572447	A/G	cg00074818	chr8:8560427	CLDN23	0.53	4.76	0.44	6.82e-6	Obesity-related traits;
THYM	cis	rs10489202	0.535	rs12736786	chr1:167988283	C/G	cg24449463	chr1:168025552	DCAF6	-0.89	-9.21	-0.69	7.91e-15	Schizophrenia;
THYM	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg16405210	chr4:1374714	KIAA1530	-0.7	-5.77	-0.51	9.71e-8	Longevity;
THYM	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg00191853	chr8:101177733	SPAG1	-0.56	-5.59	-0.5	2.15e-7	Atrioventricular conduction;
THYM	cis	rs1883415	0.549	rs34265697	chr6:24507706	C/T	cg00346970	chr6:24499591	ALDH5A1	0.48	6.11	0.53	2.17e-8	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6754311	0.773	rs188680	chr2:136630989	A/G	cg20242066	chr2:136595261	LCT	-0.6	-7.1	-0.59	2.23e-10	Mosquito bite size;
THYM	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg18477163	chr1:228402036	OBSCN	0.59	6.68	0.57	1.61e-9	Diastolic blood pressure;
THYM	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs34779708	0.966	rs4934734	chr10:35434373	T/C	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs728616	0.614	rs1885552	chr10:81712092	C/G	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7100689	0.524	rs7902460	chr10:82199263	T/A	cg00277334	chr10:82204260	NA	-0.55	-5.62	-0.5	1.88e-7	Post bronchodilator FEV1;
THYM	cis	rs56079296	0.929	rs73795207	chr5:121357759	A/C	cg05256605	chr5:121412184	LOX	0.59	4.47	0.42	2.18e-5	Coronary artery disease;
THYM	cis	rs10489525	0.583	rs6691374	chr1:115642818	T/C	cg01522456	chr1:115632236	TSPAN2	0.81	5.34	0.48	6.37e-7	Autism;
THYM	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg16579431	chr16:433439	TMEM8A;LOC100134368	0.63	5.24	0.47	9.75e-7	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs2742417	0.603	rs2742449	chr3:45764544	T/C	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs1178127	0.648	rs2519746	chr7:18817369	T/C	cg13420273	chr7:18810212	HDAC9	0.57	5.16	0.47	1.34e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg04156016	chr5:1868137	NA	0.49	4.6	0.43	1.31e-5	Cardiovascular disease risk factors;
THYM	cis	rs7584330	0.554	rs112402109	chr2:238429058	A/G	cg08992911	chr2:238395768	MLPH	0.92	5.79	0.51	9.04e-8	Prostate cancer;
THYM	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg10505658	chr17:80084571	CCDC57	0.7	8.07	0.64	2.12e-12	Life satisfaction;
THYM	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.07	12.65	0.79	4.44e-22	Height;
THYM	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg18252515	chr7:66147081	NA	-0.67	-5.08	-0.46	1.86e-6	Aortic root size;
THYM	cis	rs3204270	0.639	rs6565620	chr17:79658100	C/T	cg13117272	chr17:79681052	SLC25A10	-0.77	-4.84	-0.44	4.98e-6	Dental caries;
THYM	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs6496667	0.865	rs7171617	chr15:90904858	G/A	cg22089800	chr15:90895588	ZNF774	0.69	4.52	0.42	1.79e-5	Rheumatoid arthritis;
THYM	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg14972814	chr11:95582409	MTMR2	-0.58	-5.2	-0.47	1.14e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1978968	0.957	rs2053601	chr22:18448605	G/C	cg01550578	chr22:18484421	MICAL3	0.69	5.21	0.47	1.1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs7828089	0.819	rs4872488	chr8:22257012	G/A	cg13512537	chr8:22265999	SLC39A14	-0.57	-4.71	-0.44	8.37e-6	Verbal declarative memory;
THYM	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg05368731	chr17:41323189	NBR1	1.26	11.54	0.76	9.06e-20	Menopause (age at onset);
THYM	cis	rs4660261	0.526	rs3094954	chr1:44320919	C/T	cg15962314	chr1:44399869	ARTN	0.53	5.39	0.48	5.01e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg06481639	chr22:41940642	POLR3H	0.84	5.82	0.51	7.87e-8	Vitiligo;
THYM	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg00080972	chr5:178986291	RUFY1	-0.62	-8.7	-0.67	1.01e-13	Lung cancer;
THYM	cis	rs782590	0.748	rs782634	chr2:55897700	T/C	cg03859395	chr2:55845619	SMEK2	0.56	4.79	0.44	6.08e-6	Metabolic syndrome;
THYM	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg22105103	chr4:187893119	NA	-0.94	-9.94	-0.71	2.25e-16	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs4650994	0.935	rs12039531	chr1:178515612	G/A	cg05059571	chr16:84539110	KIAA1609	-0.75	-7.95	-0.63	3.83e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs2249694	0.537	rs9418988	chr10:135327632	C/T	cg20169779	chr10:135381914	SYCE1	0.64	4.76	0.44	6.79e-6	Obesity-related traits;
THYM	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.5	4.67	0.43	1.01e-5	Lymphocyte counts;
THYM	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg24812749	chr6:127587940	RNF146	0.98	7.86	0.63	5.91e-12	Breast cancer;
THYM	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.94	6.37	0.55	6.72e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg10505658	chr17:80084571	CCDC57	-0.72	-7.86	-0.63	5.81e-12	Life satisfaction;
THYM	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs8018808	0.967	rs10133896	chr14:77853806	C/T	cg20045696	chr14:77926864	AHSA1	-0.53	-4.74	-0.44	7.5e-6	Myeloid white cell count;
THYM	cis	rs2282300	0.696	rs1222214	chr11:30347695	C/G	cg09906309	chr11:30344399	C11orf46	-0.73	-5.37	-0.48	5.47e-7	Morning vs. evening chronotype;
THYM	cis	rs7692976	0.503	rs9991904	chr4:110922579	A/G	cg06981781	chr4:110842888	EGF	-0.39	-4.67	-0.43	9.85e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs586688	1.000	rs522869	chr1:201638600	A/G	cg07139329	chr1:201708558	NAV1	0.5	4.82	0.44	5.37e-6	Obesity-related traits;
THYM	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg07414643	chr4:187882934	NA	-0.64	-5.75	-0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2299587	0.560	rs3913556	chr8:17781401	A/G	cg01800426	chr8:17659068	MTUS1	-0.68	-5.18	-0.47	1.22e-6	Economic and political preferences;
THYM	cis	rs2456568	0.802	rs1574515	chr11:93629643	T/C	cg17347335	chr11:93583973	C11orf90	-0.48	-4.58	-0.43	1.39e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs9644630	0.932	rs4273861	chr8:19352703	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.71	7.06	0.59	2.78e-10	Oropharynx cancer;
THYM	cis	rs1018836	0.632	rs7017630	chr8:91482604	A/G	cg16814680	chr8:91681699	NA	-0.79	-6.63	-0.56	2.07e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-4.73	-0.44	7.71e-6	Mood instability;
THYM	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg12292205	chr6:26970375	C6orf41	-0.67	-5.6	-0.5	2.07e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs17689437	0.813	rs11075691	chr16:68665255	C/T	cg26468152	chr16:69355012	VPS4A	-0.66	-4.75	-0.44	7.34e-6	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
THYM	cis	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg06521331	chr12:34319734	NA	0.75	5.63	0.5	1.81e-7	Morning vs. evening chronotype;
THYM	cis	rs700651	0.821	rs4850812	chr2:198743655	G/T	cg00792783	chr2:198669748	PLCL1	-0.84	-5.89	-0.52	5.8e-8	Intracranial aneurysm;
THYM	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg17509989	chr5:176798049	RGS14	-0.66	-5.8	-0.51	8.71e-8	Urate levels in lean individuals;
THYM	cis	rs10931896	0.531	rs295117	chr2:201146828	C/T	cg23649088	chr2:200775458	C2orf69	0.66	5.66	0.5	1.61e-7	Systolic blood pressure;
THYM	cis	rs10208940	0.614	rs12713651	chr2:68835090	G/A	cg09157127	chr2:69201416	GKN1	0.93	4.78	0.44	6.3e-6	Urate levels in lean individuals;
THYM	cis	rs3820068	0.608	rs12091326	chr1:16048005	A/G	cg27534772	chr1:16042836	PLEKHM2	0.48	4.99	0.46	2.71e-6	Systolic blood pressure;
THYM	cis	rs669446	0.558	rs6429631	chr1:44113441	T/C	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg00376283	chr12:123451042	ABCB9	0.67	5.17	0.47	1.31e-6	Height;Educational attainment;Head circumference (infant);
THYM	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg06027949	chr8:82754900	SNX16	-0.76	-6.3	-0.54	9.34e-9	Diastolic blood pressure;
THYM	cis	rs713587	0.563	rs1529897	chr2:25086827	T/G	cg01884057	chr2:25150051	NA	0.66	6.37	0.55	6.75e-9	Body mass index in non-asthmatics;
THYM	cis	rs6906287	0.647	rs13217710	chr6:118843601	A/G	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg01364799	chr7:75623366	TMEM120A	-0.65	-4.78	-0.44	6.41e-6	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.53	-4.87	-0.45	4.42e-6	Lymphocyte counts;
THYM	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg23682913	chr1:2080710	PRKCZ	-0.59	-5.28	-0.48	8.17e-7	Height;
THYM	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7586879	0.639	rs6545776	chr2:25099357	A/C	cg27107076	chr2:25050844	ADCY3	-0.3	-4.82	-0.44	5.38e-6	Body mass index;
THYM	cis	rs4363385	0.818	rs382292	chr1:153006641	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs4343996	0.603	rs4722722	chr7:3398176	T/A	cg21248987	chr7:3385318	SDK1	-0.41	-5.32	-0.48	6.99e-7	Motion sickness;
THYM	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg02380750	chr20:61661411	NA	-0.64	-6.26	-0.54	1.13e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.81	-0.63	7.44e-12	Chronic sinus infection;
THYM	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg00256281	chr22:41985642	PMM1	0.6	5.13	0.47	1.53e-6	Vitiligo;
THYM	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg12463550	chr7:65579703	CRCP	-0.57	-4.76	-0.44	7.01e-6	Aortic root size;
THYM	cis	rs2229238	0.911	rs4639752	chr1:154508974	T/A	cg21262032	chr1:154437693	IL6R	-0.63	-5.65	-0.5	1.68e-7	Coronary heart disease;
THYM	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg11366901	chr6:160182831	ACAT2	1.08	9.54	0.7	1.56e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7187994	0.551	rs8050719	chr16:84780468	G/A	cg26765084	chr16:85018922	ZDHHC7	-0.48	-4.93	-0.45	3.46e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg04025307	chr7:1156635	C7orf50	0.72	4.46	0.42	2.27e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg11266682	chr4:10021025	SLC2A9	0.55	6.81	0.57	8.63e-10	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs3892630	0.824	rs35700505	chr19:33325006	C/T	cg22980127	chr19:33182716	NUDT19	1.19	9.82	0.71	3.96e-16	Red blood cell traits;
THYM	cis	rs28795989	0.828	rs34701321	chr4:7889792	T/G	cg12728606	chr4:7903970	AFAP1	0.43	4.59	0.43	1.34e-5	Intraocular pressure;
THYM	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg09165964	chr15:75287851	SCAMP5	-0.98	-8.83	-0.67	5.29e-14	Blood trace element (Zn levels);
THYM	trans	rs8073060	0.586	rs225278	chr17:33974170	C/T	cg19694781	chr19:47549865	TMEM160	-1.0	-8.52	-0.66	2.41e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs888194	1.000	rs888194	chr12:109986918	C/G	cg10504392	chr12:110044639	NA	0.58	5.27	0.48	8.6e-7	Neuroticism;
THYM	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg13447684	chr7:1895903	MAD1L1	0.49	4.45	0.42	2.33e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs7107174	0.892	rs12284390	chr11:78103902	C/A	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.39e-10	Prudent dietary pattern;
THYM	cis	rs889398	0.933	rs244418	chr16:69622762	G/A	cg09409435	chr16:70099608	PDXDC2	-0.63	-4.92	-0.45	3.64e-6	Body mass index;
THYM	cis	rs72949976	0.734	rs62189579	chr2:214016984	T/A	cg08319019	chr2:214017104	IKZF2	-0.72	-5.5	-0.49	3.25e-7	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06850241	chr22:41845214	NA	-0.63	-5.46	-0.49	3.86e-7	Vitiligo;
THYM	cis	rs12142240	0.698	rs7525309	chr1:46809025	G/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg02887458	chr19:19495540	GATAD2A	0.47	5.3	0.48	7.47e-7	Bipolar disorder;
THYM	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg03188948	chr7:1209495	NA	0.9	5.02	0.46	2.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs240764	0.717	rs239215	chr6:101147426	A/G	cg21058520	chr6:100914733	NA	-0.54	-4.59	-0.43	1.34e-5	Neuroticism;
THYM	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg22907277	chr7:1156413	C7orf50	0.84	7.05	0.59	2.81e-10	Longevity;Endometriosis;
THYM	cis	rs10493773	0.609	rs3753789	chr1:86174814	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.59	-9.23	-0.69	7.42e-15	Urate levels in overweight individuals;
THYM	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1878931	0.624	rs28089	chr16:3446937	G/A	cg00484396	chr16:3507460	NAT15	0.55	5.3	0.48	7.61e-7	Body mass index (adult);
THYM	trans	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg19748678	chr4:122722346	EXOSC9	0.72	5.11	0.46	1.68e-6	Type 2 diabetes;
THYM	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg05754148	chr16:3507555	NAT15	-0.61	-5.77	-0.51	9.83e-8	Tuberculosis;
THYM	cis	rs8192282	0.739	rs6427720	chr1:154501756	G/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg22709100	chr7:91322751	NA	0.61	4.73	0.44	7.65e-6	Breast cancer;
THYM	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs3755605	1.000	rs67666682	chr3:169757762	G/A	cg18444028	chr3:169782040	GPR160	0.59	4.73	0.44	7.89e-6	Testicular germ cell tumor;
THYM	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg05283184	chr6:79620031	NA	-0.91	-8.88	-0.67	4.11e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg18477163	chr1:228402036	OBSCN	0.57	6.22	0.54	1.36e-8	Diastolic blood pressure;
THYM	trans	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs2404602	0.575	rs11072611	chr15:76947983	A/G	cg23625390	chr15:77176239	SCAPER	0.88	5.59	0.5	2.12e-7	Blood metabolite levels;
THYM	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg06481639	chr22:41940642	POLR3H	-0.73	-5.55	-0.49	2.56e-7	Vitiligo;
THYM	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.76	-7.15	-0.59	1.79e-10	Personality dimensions;
THYM	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg11301795	chr4:187892539	NA	-1.11	-18.94	-0.89	5.16e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12928939	0.774	rs7192860	chr16:71643622	G/A	cg02602352	chr16:70688171	IL34	0.41	4.46	0.42	2.26e-5	Post bronchodilator FEV1;
THYM	cis	rs6450176	1.000	rs58369491	chr5:53297295	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.81	-6.03	-0.53	3.17e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs34065801	0.632	rs1104539	chr13:36515298	C/T	cg14522731	chr13:37393990	RFXAP	0.51	4.5	0.42	1.92e-5	Breast size;
THYM	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs6500602	1.000	rs11648292	chr16:4462897	C/A	cg08645402	chr16:4508243	NA	0.63	5.45	0.49	3.89e-7	Schizophrenia;
THYM	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg14643075	chr5:176755449	NA	0.48	4.48	0.42	2.11e-5	Hemoglobin concentration;Hematocrit;
THYM	cis	rs2692947	0.864	rs2579518	chr2:96675259	G/A	cg23100626	chr2:96804247	ASTL	0.34	4.47	0.42	2.18e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs2625529	0.652	rs8030815	chr15:72403001	T/C	cg16672083	chr15:72433130	SENP8	0.5	4.53	0.42	1.69e-5	Red blood cell count;
THYM	cis	rs1055129	0.655	rs3744006	chr17:73838816	G/A	cg02627403	chr17:73823769	UNC13D	-0.45	-4.59	-0.43	1.38e-5	White matter hyperintensity burden;
THYM	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg20007245	chr22:24372913	LOC391322	0.77	6.1	0.53	2.3e-8	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7582180	0.764	rs12712075	chr2:100924129	T/C	cg14675211	chr2:100938903	LONRF2	0.76	8.22	0.64	1.01e-12	Intelligence (multi-trait analysis);
THYM	cis	rs6448317	1.000	rs13105803	chr4:24940002	A/G	cg22968281	chr4:24586266	DHX15	0.71	4.99	0.46	2.71e-6	Heschl's gyrus morphology;
THYM	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	4.96	0.45	3.07e-6	Hip circumference adjusted for BMI;
THYM	cis	rs36051895	0.589	rs7869015	chr9:5199750	C/T	cg02405213	chr9:5042618	JAK2	-0.91	-9.45	-0.7	2.51e-15	Pediatric autoimmune diseases;
THYM	cis	rs9905704	0.918	rs302867	chr17:56752819	C/T	cg12560992	chr17:57184187	TRIM37	-0.66	-4.58	-0.43	1.43e-5	Testicular germ cell tumor;
THYM	cis	rs6424115	0.800	rs6665733	chr1:24200158	T/C	cg15997130	chr1:24165203	NA	0.76	6.39	0.55	6.14e-9	Immature fraction of reticulocytes;
THYM	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03576123	chr11:487126	PTDSS2	-1.24	-5.21	-0.47	1.1e-6	Body mass index;
THYM	cis	rs899997	0.906	rs62010552	chr15:78987686	T/C	cg22753661	chr15:79092743	ADAMTS7	-0.67	-4.51	-0.42	1.83e-5	Coronary artery disease or large artery stroke;
THYM	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg04414720	chr1:150670196	GOLPH3L	-0.64	-4.84	-0.44	5e-6	Tonsillectomy;
THYM	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.73	5.66	0.5	1.6e-7	Tonsillectomy;
THYM	cis	rs950776	0.752	rs62010328	chr15:78894971	C/T	cg06917634	chr15:78832804	PSMA4	0.88	7.13	0.59	1.98e-10	Sudden cardiac arrest;
THYM	cis	rs2737265	0.723	rs2142333	chr8:116659458	C/T	cg04656070	chr8:116661063	TRPS1	-0.56	-6.48	-0.55	4.03e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;
THYM	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg21427119	chr20:30132790	HM13	-0.69	-4.62	-0.43	1.23e-5	Mean corpuscular hemoglobin;
THYM	trans	rs9296092	0.517	rs62405895	chr6:33471969	G/T	cg00929798	chr10:135150139	CALY	0.7	7.02	0.58	3.26e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs11785693	0.862	rs11774126	chr8:4979583	A/C	cg26367366	chr8:4980734	NA	1.22	5.99	0.52	3.74e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs13418717	0.793	rs13398472	chr2:127622469	G/A	cg25501666	chr2:127640322	NA	1.61	6.31	0.54	8.81e-9	Heart failure;
THYM	cis	rs7589728	0.514	rs74426843	chr2:88459388	C/T	cg04511125	chr2:88470314	THNSL2	0.66	4.62	0.43	1.21e-5	Plasma clusterin levels;
THYM	trans	rs9929218	0.508	rs6499194	chr16:68744100	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.07	13.2	0.8	3.3e-23	Colorectal cancer;
THYM	trans	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg05926928	chr17:57297772	GDPD1	1.25	9.97	0.72	1.88e-16	Opioid sensitivity;
THYM	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg22683308	chr4:1340831	KIAA1530	-0.63	-4.55	-0.42	1.57e-5	Obesity-related traits;
THYM	cis	rs17102423	0.594	rs1953232	chr14:65570386	A/C	cg11161011	chr14:65562177	MAX	0.7	5.67	0.5	1.53e-7	Obesity-related traits;
THYM	cis	rs4919694	0.808	rs112574306	chr10:104971159	C/T	cg04362960	chr10:104952993	NT5C2	1.07	6.08	0.53	2.45e-8	Arsenic metabolism;
THYM	cis	rs4866334	1.000	rs77052976	chr5:18453061	A/T	cg18608440	chr5:17519013	NA	1.16	5.19	0.47	1.17e-6	IgG glycosylation;
THYM	cis	rs8101881	0.510	rs2287876	chr19:33360652	A/T	cg16861209	chr19:33361127	SLC7A9	-0.53	-4.87	-0.45	4.44e-6	Blood metabolite levels;Urinary metabolites;Urinary metabolites (H-NMR features);
THYM	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg03929089	chr4:120376271	NA	-1.03	-12.43	-0.79	1.26e-21	Height;
THYM	cis	rs9296092	0.521	rs6929165	chr6:33515958	T/G	cg13560919	chr6:33536144	NA	-0.9	-8.4	-0.65	4.24e-13	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs2075230	0.642	rs1613071	chr17:7551229	A/G	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.28	-4.62	-0.43	1.21e-5	Hormone measurements;
THYM	cis	rs3862260	0.509	rs10923879	chr1:120163831	A/G	cg16322792	chr1:120165303	ZNF697	0.92	11.5	0.76	1.09e-19	Systemic lupus erythematosus;
THYM	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg11663144	chr21:46675770	NA	-0.71	-10.09	-0.72	1.08e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs58873874	0.737	rs75022277	chr5:156881962	T/C	cg08916508	chr5:156566250	MED7	-1.29	-4.86	-0.45	4.57e-6	Bipolar disorder (body mass index interaction);
THYM	cis	rs1371867	0.810	rs1692004	chr8:101247320	T/C	cg00191853	chr8:101177733	SPAG1	0.55	5.14	0.47	1.5e-6	Atrioventricular conduction;
THYM	cis	rs8067545	0.586	rs11657161	chr17:20180715	A/G	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	trans	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg17830980	chr10:43048298	ZNF37B	0.99	8.54	0.66	2.15e-13	Extrinsic epigenetic age acceleration;
THYM	cis	rs6570726	0.935	rs398060	chr6:145841515	C/T	cg13319975	chr6:146136371	FBXO30	0.64	5.39	0.48	5.13e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6032067	0.632	rs35632684	chr20:43802889	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.41	-0.65	4.05e-13	Blood protein levels;
THYM	cis	rs28595532	0.920	rs55640619	chr4:119761999	C/T	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs4731207	0.724	rs6968693	chr7:124549976	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7020830	0.931	rs3802422	chr9:37097172	G/A	cg14294708	chr9:37120828	ZCCHC7	1.22	15.71	0.85	3.64e-28	Schizophrenia;
THYM	cis	rs7528419	0.927	rs660240	chr1:109817838	T/C	cg00908766	chr1:109817496	CELSR2	0.88	7.02	0.58	3.31e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
THYM	cis	rs4887067	1	rs4887067	chr15:78886947	G/A	cg18825076	chr15:78729989	IREB2	-0.54	-4.77	-0.44	6.53e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg11245990	chr11:68621969	NA	0.57	7.2	0.59	1.41e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs3087591	0.922	rs2905805	chr17:29502856	C/A	cg24425628	chr17:29625626	OMG;NF1	0.65	5.69	0.5	1.38e-7	Hip circumference;
THYM	cis	rs7614311	0.681	rs57766205	chr3:63895303	G/C	cg22134162	chr3:63841271	THOC7	-0.58	-7.17	-0.59	1.58e-10	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs67981189	0.529	rs17108808	chr14:71441552	T/C	cg15910301	chr14:71632612	NA	0.56	4.88	0.45	4.23e-6	Schizophrenia;
THYM	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg11764359	chr7:65958608	NA	-0.88	-7.56	-0.61	2.55e-11	Aortic root size;
THYM	cis	rs17253792	0.822	rs2147114	chr14:56077118	C/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs524023	0.914	rs555456	chr11:64418259	T/C	cg19131476	chr11:64387923	NRXN2	-0.39	-5.54	-0.49	2.7e-7	Urate levels in obese individuals;
THYM	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg24812749	chr6:127587940	RNF146	0.97	7.72	0.62	1.14e-11	Breast cancer;
THYM	cis	rs2455799	0.613	rs2345736	chr3:15824860	T/G	cg16303742	chr3:15540471	COLQ	-0.52	-5.69	-0.5	1.41e-7	Mean platelet volume;
THYM	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.44	4.8	0.44	5.92e-6	Hemoglobin concentration;
THYM	cis	rs7172809	0.599	rs17381821	chr15:77403477	T/A	cg22256960	chr15:77711686	NA	-0.64	-4.76	-0.44	6.94e-6	Glucose homeostasis traits;
THYM	cis	rs6430585	0.583	rs111837148	chr2:136612036	G/A	cg04750100	chr2:136595281	LCT	0.57	5.29	0.48	7.86e-7	Corneal structure;
THYM	cis	rs7107174	1.000	rs2512535	chr11:77971468	C/T	cg19901956	chr11:77921274	USP35	-0.71	-5.46	-0.49	3.75e-7	Testicular germ cell tumor;
THYM	cis	rs9457247	0.638	rs239933	chr6:167413230	A/G	cg00278517	chr6:167070616	RPS6KA2	-0.34	-4.67	-0.43	9.76e-6	Crohn's disease;
THYM	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg00024416	chr22:24240387	NA	0.77	8.37	0.65	5.01e-13	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg19847130	chr8:10466454	RP1L1	0.5	4.55	0.42	1.61e-5	Neuroticism;
THYM	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg17143192	chr8:8559678	CLDN23	0.89	6.45	0.55	4.55e-9	Obesity-related traits;
THYM	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7216064	0.861	rs62084252	chr17:65879578	G/C	cg12091567	chr17:66097778	LOC651250	-0.69	-4.65	-0.43	1.05e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs12134245	0.747	rs11164929	chr1:92012836	G/C	cg25838465	chr1:92012736	NA	-0.91	-8.85	-0.67	4.68e-14	Breast cancer;
THYM	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg18806716	chr10:30721971	MAP3K8	0.52	5.44	0.49	4.1e-7	Inflammatory bowel disease;
THYM	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg23758822	chr17:41437982	NA	1.21	11.55	0.76	8.59e-20	Menopause (age at onset);
THYM	cis	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg21775007	chr8:11205619	TDH	-0.68	-5.27	-0.48	8.47e-7	Retinal vascular caliber;
THYM	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg05373962	chr22:49881684	NA	-0.66	-5.95	-0.52	4.37e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg09307838	chr4:120376055	NA	0.68	5.08	0.46	1.89e-6	Corneal astigmatism;
THYM	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg16325326	chr1:53192061	ZYG11B	-0.83	-8.65	-0.66	1.28e-13	Monocyte count;
THYM	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg04842962	chr6:43655489	MRPS18A	1.27	9.24	0.69	7.05e-15	IgG glycosylation;
THYM	trans	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg07621104	chr11:117668040	DSCAML1	0.81	6.39	0.55	6e-9	Myopia;
THYM	trans	rs4940575	0.679	rs60803287	chr18:60830184	A/C	cg01781374	chr5:110777659	CAMK4	0.99	6.99	0.58	3.7e-10	Breast cancer;
THYM	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg07424592	chr7:64974309	NA	1.05	4.76	0.44	6.92e-6	Diabetic kidney disease;
THYM	cis	rs9915657	0.595	rs10438697	chr17:70055734	A/G	cg06234051	chr17:70120541	SOX9	0.63	5.44	0.49	4.05e-7	Thyroid hormone levels;
THYM	cis	rs40363	0.645	rs37774	chr16:3512695	T/C	cg21433313	chr16:3507492	NAT15	0.86	9.41	0.69	2.96e-15	Tuberculosis;
THYM	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.76	-6.06	-0.53	2.77e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4866334	1.000	rs80007833	chr5:18489203	G/T	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg14186256	chr22:23484241	RTDR1	-0.96	-9.57	-0.7	1.38e-15	Bone mineral density;
THYM	cis	rs1451375	0.617	rs2329366	chr7:50544966	G/A	cg18232548	chr7:50535776	DDC	-0.66	-5.02	-0.46	2.41e-6	Malaria;
THYM	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs4803468	1.000	rs284648	chr19:41926790	T/C	cg09537434	chr19:41945824	ATP5SL	-1.05	-9.33	-0.69	4.53e-15	Height;
THYM	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.33	0.48	6.74e-7	Height;
THYM	cis	rs919433	0.750	rs788010	chr2:198230949	T/C	cg05783139	chr2:198650985	BOLL	0.56	4.5	0.42	1.96e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg00484396	chr16:3507460	NAT15	0.55	5.47	0.49	3.67e-7	Body mass index (adult);
THYM	cis	rs3771570	1.000	rs62186411	chr2:242236667	A/C	cg21155796	chr2:242212141	HDLBP	1.28	6.14	0.53	1.92e-8	Prostate cancer;
THYM	cis	rs7106204	0.748	rs12273426	chr11:24212058	T/C	ch.11.24196551F	chr11:24239977	NA	0.99	7.0	0.58	3.64e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs17376456	0.597	rs10866760	chr5:93338335	G/A	cg25358565	chr5:93447407	FAM172A	-0.82	-6.03	-0.53	3.14e-8	Diabetic retinopathy;
THYM	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg14779329	chr11:130786720	SNX19	0.54	5.88	0.52	6.2e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11771526	0.792	rs11770580	chr7:32305009	T/C	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg18105134	chr13:113819100	PROZ	-0.98	-9.11	-0.68	1.32e-14	Platelet distribution width;
THYM	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg11952622	chr19:58962976	ZNF324B	0.7	5.29	0.48	7.93e-7	Mean platelet volume;
THYM	cis	rs131777	0.577	rs5770928	chr22:51029091	G/C	cg00083937	chr22:51039805	MAPK8IP2	0.57	4.85	0.45	4.73e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2458413	0.500	rs2458415	chr8:105351998	A/C	cg21295575	chr8:105352067	TM7SF4	-0.37	-5.34	-0.48	6.2e-7	Paget's disease;
THYM	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg22981736	chr15:31284413	MTMR10	-0.57	-4.79	-0.44	6.14e-6	Huntington's disease progression;
THYM	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg12310025	chr6:25882481	NA	0.92	8.2	0.64	1.12e-12	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	0.931	rs2989330	chr21:40716209	A/G	cg11890956	chr21:40555474	PSMG1	0.98	7.86	0.63	6.03e-12	Cognitive function;
THYM	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12667521	chr19:29218732	NA	0.79	6.66	0.56	1.73e-9	Methadone dose in opioid dependence;
THYM	cis	rs427394	0.802	rs274720	chr5:6719933	A/G	cg10857441	chr5:6722123	POLS	-0.72	-8.87	-0.67	4.28e-14	Menopause (age at onset);
THYM	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg06600287	chr1:53387719	ECHDC2	-0.34	-5.4	-0.48	4.88e-7	Monocyte count;
THYM	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	trans	rs629535	0.821	rs650267	chr8:70029160	C/T	cg21567404	chr3:27674614	NA	1.12	10.86	0.74	2.44e-18	Dupuytren's disease;
THYM	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg17757837	chr7:157058334	UBE3C	-0.93	-9.0	-0.68	2.28e-14	Body mass index;
THYM	trans	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs9733	0.596	rs12403255	chr1:150660412	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs57994353	0.861	rs3812591	chr9:139341612	C/T	cg14115884	chr9:139300582	SDCCAG3	-0.64	-4.48	-0.42	2.08e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs7599312	0.586	rs7571561	chr2:213386267	T/C	cg16329650	chr2:213403929	ERBB4	0.62	4.85	0.45	4.75e-6	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9828933	0.516	rs704371	chr3:63867528	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	0.75	5.57	0.5	2.37e-7	Type 2 diabetes;
THYM	cis	rs4499344	0.730	rs259279	chr19:33161274	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-1.08	-9.42	-0.7	2.84e-15	Mean platelet volume;
THYM	cis	rs5769765	0.862	rs138897	chr22:50231067	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.93	-6.37	-0.55	6.65e-9	Schizophrenia;
THYM	cis	rs4727027	0.704	rs4727031	chr7:148908305	T/C	cg23583168	chr7:148888333	NA	-1.05	-14.79	-0.84	2.17e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs902774	0.515	rs2363635	chr12:53354622	T/C	cg16329197	chr12:53359506	NA	-0.61	-5.02	-0.46	2.43e-6	Prostate cancer;
THYM	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg18681998	chr4:17616180	MED28	0.81	6.85	0.58	7.23e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs11648796	0.959	rs9928077	chr16:784765	C/T	cg05638439	chr16:711235	WDR90	-0.6	-4.98	-0.45	2.86e-6	Height;
THYM	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg22907277	chr7:1156413	C7orf50	0.7	6.45	0.55	4.68e-9	Longevity;Endometriosis;
THYM	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg18681998	chr4:17616180	MED28	0.85	7.68	0.62	1.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg15704280	chr7:45808275	SEPT13	-1.02	-13.33	-0.81	1.74e-23	Coronary artery disease;
THYM	cis	rs11186	0.556	rs7419543	chr2:189967433	T/C	cg11041835	chr2:189156425	GULP1	0.8	4.58	0.43	1.41e-5	Parkinson's disease;
THYM	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg26384229	chr12:38710491	ALG10B	-0.74	-6.24	-0.54	1.22e-8	Morning vs. evening chronotype;
THYM	cis	rs9581857	0.579	rs77509251	chr13:27959981	G/A	cg22138327	chr13:27999177	GTF3A	0.98	5.44	0.49	4.21e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs9420	0.925	rs10896636	chr11:57448032	C/G	cg19752551	chr11:57585705	CTNND1	-0.72	-7.89	-0.63	5.25e-12	Schizophrenia;
THYM	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg18402987	chr7:1209562	NA	0.9	5.38	0.48	5.39e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg11663144	chr21:46675770	NA	-0.71	-9.28	-0.69	5.77e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg17178900	chr1:205818956	PM20D1	0.92	8.92	0.67	3.42e-14	Menarche (age at onset);
THYM	cis	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg09307838	chr4:120376055	NA	0.6	4.55	0.42	1.59e-5	Diastolic blood pressure;
THYM	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.61	0.56	2.21e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg17063962	chr7:91808500	NA	1.16	13.12	0.8	4.77e-23	Breast cancer;
THYM	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs4642101	0.640	rs7629354	chr3:12827746	T/G	cg05775895	chr3:12838266	CAND2	0.9	7.78	0.62	8.86e-12	QRS complex (12-leadsum);
THYM	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.75	-8.98	-0.68	2.49e-14	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs11690935	0.959	rs67204065	chr2:172672624	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.77	-5.55	-0.49	2.62e-7	Schizophrenia;
THYM	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg24530246	chr3:53118167	NA	-0.85	-4.82	-0.44	5.52e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2447097	0.935	rs2447094	chr17:2294048	A/C	cg27406664	chr17:2294951	MNT	0.63	5.91	0.52	5.34e-8	Autism spectrum disorder;
THYM	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg02221750	chr19:17393354	ANKLE1	-0.95	-8.88	-0.67	4.11e-14	Systemic lupus erythematosus;
THYM	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg24874828	chr4:187887005	NA	-0.68	-6.91	-0.58	5.4e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7089973	0.872	rs3180654	chr10:116615045	T/C	cg23260525	chr10:116636907	FAM160B1	0.51	4.57	0.42	1.49e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.57	4.65	0.43	1.06e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7524258	0.903	rs4908449	chr1:7292700	T/C	cg07173049	chr1:7289937	CAMTA1	0.82	6.34	0.55	7.82e-9	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs7772486	0.875	rs13198450	chr6:146370524	C/A	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs59043219	1	rs59043219	chr1:209970610	G/A	cg22029157	chr1:209979665	IRF6	0.8	8.97	0.68	2.58e-14	Crohn's disease;Inflammatory bowel disease;Alzheimer's disease (APOE e4 interaction);
THYM	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg09184832	chr6:79620586	NA	-0.57	-4.65	-0.43	1.09e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg00376283	chr12:123451042	ABCB9	0.68	5.22	0.47	1.04e-6	Neutrophil percentage of white cells;
THYM	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg06064525	chr11:970664	AP2A2	-0.35	-6.68	-0.57	1.63e-9	Alzheimer's disease (late onset);
THYM	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg08411435	chr17:37784024	PPP1R1B	-0.32	-4.53	-0.42	1.74e-5	Asthma;
THYM	cis	rs9311676	0.656	rs11718352	chr3:58401480	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs7084402	0.967	rs1658479	chr10:60289398	C/A	cg09696939	chr10:60272079	BICC1	-0.45	-5.14	-0.47	1.47e-6	Refractive error;
THYM	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg22105103	chr4:187893119	NA	0.95	10.29	0.73	3.97e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg15921436	chr17:44337874	NA	-0.96	-7.05	-0.59	2.8e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6427356	0.513	rs2001762	chr1:157143423	A/C	cg27547283	chr1:156698502	C1orf66;ISG20L2	-0.58	-4.49	-0.42	2.02e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg13944838	chr5:179740914	GFPT2	-0.82	-6.38	-0.55	6.42e-9	Height;
THYM	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11890956	chr21:40555474	PSMG1	-0.69	-6.69	-0.57	1.54e-9	Menarche (age at onset);
THYM	cis	rs4919694	1.000	rs11191473	chr10:104710710	C/G	cg15744005	chr10:104629667	AS3MT	-0.85	-4.67	-0.43	9.96e-6	Arsenic metabolism;
THYM	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg12893697	chr11:970389	AP2A2	-0.32	-5.35	-0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs61931739	0.513	rs10844698	chr12:33890158	C/T	cg10856724	chr12:34555212	NA	-0.65	-5.93	-0.52	4.87e-8	Morning vs. evening chronotype;
THYM	cis	rs733592	0.504	rs2261608	chr12:48721634	A/T	cg21466736	chr12:48725269	NA	-0.47	-5.13	-0.47	1.55e-6	Plateletcrit;
THYM	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg05481257	chr2:20870211	GDF7	0.64	5.93	0.52	4.82e-8	Abdominal aortic aneurysm;
THYM	cis	rs6906287	0.647	rs12197337	chr6:118884092	C/T	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg22508957	chr16:3507546	NAT15	-0.41	-4.53	-0.42	1.71e-5	Body mass index (adult);
THYM	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	7.57	0.61	2.37e-11	Platelet count;
THYM	cis	rs669446	0.562	rs4660260	chr1:44195353	A/G	cg12599982	chr1:44399894	ARTN	0.53	4.87	0.45	4.39e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-7.9	-0.63	4.93e-12	Chronic sinus infection;
THYM	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg00129232	chr17:37814104	STARD3	-0.71	-4.8	-0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4642101	0.561	rs9812144	chr3:12805910	G/A	cg11882607	chr3:12858926	CAND2	-0.45	-5.09	-0.46	1.84e-6	QRS complex (12-leadsum);
THYM	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs7200543	1.000	rs6498541	chr16:15140657	A/G	cg01933576	chr16:15083564	PDXDC1	-0.94	-7.82	-0.63	7.27e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg15744005	chr10:104629667	AS3MT	-0.88	-8.48	-0.66	2.97e-13	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg00814883	chr7:100076585	TSC22D4	-1.01	-6.78	-0.57	1.01e-9	Platelet count;
THYM	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg02869364	chr7:1081709	C7orf50	-0.58	-5.15	-0.47	1.43e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4746818	1.000	rs4746818	chr10:70884687	G/T	cg04149295	chr10:70884716	VPS26A	0.84	5.96	0.52	4.22e-8	Left atrial antero-posterior diameter;
THYM	cis	rs7551222	0.752	rs4245736	chr1:204486205	G/C	cg20240347	chr1:204465584	NA	-0.51	-4.54	-0.42	1.64e-5	Schizophrenia;
THYM	cis	rs7432375	0.804	rs6764567	chr3:136425514	A/C	cg12473912	chr3:136751656	NA	-0.62	-5.27	-0.48	8.44e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg04750100	chr2:136595281	LCT	-0.56	-6.13	-0.53	1.97e-8	Mosquito bite size;
THYM	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg21644426	chr2:191273491	MFSD6	0.65	4.5	0.42	1.94e-5	Diastolic blood pressure;
THYM	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg06873352	chr17:61820015	STRADA	0.69	8.81	0.67	5.84e-14	Prudent dietary pattern;
THYM	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1451375	0.657	rs7802148	chr7:50648284	T/C	cg18232548	chr7:50535776	DDC	0.69	5.35	0.48	6.03e-7	Malaria;
THYM	cis	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg09307838	chr4:120376055	NA	-0.74	-5.8	-0.51	8.52e-8	Corneal astigmatism;
THYM	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg16928487	chr17:17741425	SREBF1	-0.48	-4.49	-0.42	2.03e-5	Total body bone mineral density;
THYM	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.56	-0.5	2.5e-7	Menopause (age at onset);
THYM	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg21226059	chr5:178986404	RUFY1	0.61	6.79	0.57	9.44e-10	Lung cancer;
THYM	cis	rs747334	0.846	rs7093432	chr10:92714640	T/C	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	12.13	0.78	5.13e-21	Chronic sinus infection;
THYM	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg24733560	chr20:60626293	TAF4	0.62	6.55	0.56	2.89e-9	Body mass index;
THYM	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08109568	chr15:31115862	NA	-0.76	-6.77	-0.57	1.05e-9	Huntington's disease progression;
THYM	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.71	-5.68	-0.5	1.47e-7	Blood protein levels;
THYM	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.85	5.5	0.49	3.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs40363	0.868	rs37772	chr16:3512843	A/G	cg22508957	chr16:3507546	NAT15	0.61	7.42	0.61	4.94e-11	Tuberculosis;
THYM	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg09455208	chr3:40491958	NA	-0.46	-4.66	-0.43	1.03e-5	Renal cell carcinoma;
THYM	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg27398817	chr8:82754497	SNX16	-0.83	-6.57	-0.56	2.65e-9	Diastolic blood pressure;
THYM	cis	rs6840360	0.571	rs72728182	chr4:152487027	T/C	cg22705602	chr4:152727874	NA	-0.77	-8.05	-0.64	2.4e-12	Intelligence (multi-trait analysis);
THYM	cis	rs804292	1.000	rs804292	chr8:11643915	C/T	cg26752888	chr8:11627280	NEIL2	-0.98	-7.49	-0.61	3.6e-11	Alcohol dependence;Nicotine use;
THYM	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.92	-10.65	-0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs2455799	0.613	rs4467435	chr3:15791671	A/G	cg16303742	chr3:15540471	COLQ	-0.56	-5.73	-0.51	1.18e-7	Mean platelet volume;
THYM	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg17554472	chr22:41940697	POLR3H	0.73	5.15	0.47	1.39e-6	Vitiligo;
THYM	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2245368	0.523	rs67814714	chr7:76517422	T/C	cg15770687	chr7:76625569	PMS2L11	0.83	5.37	0.48	5.66e-7	Body mass index in physically inactive individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6665290	0.835	rs11578479	chr1:227210888	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.12	-14.94	-0.84	1.14e-26	Myeloid white cell count;
THYM	cis	rs2398893	0.960	rs11792744	chr9:96742661	C/T	cg14459158	chr9:96720562	NA	0.53	4.7	0.43	8.85e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1483890	0.638	rs1564756	chr3:69402489	T/G	cg22125112	chr3:69402811	FRMD4B	-0.55	-6.81	-0.57	8.87e-10	Resting heart rate;
THYM	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg01324343	chr3:183735012	ABCC5	0.88	13.13	0.8	4.58e-23	Anterior chamber depth;
THYM	cis	rs2072732	0.861	rs12034794	chr1:2937551	T/G	cg08733933	chr1:2954429	NA	-0.61	-4.6	-0.43	1.3e-5	Plateletcrit;
THYM	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03647317	chr4:187891568	NA	-0.82	-8.81	-0.67	5.87e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.91	5.89	0.52	5.81e-8	Platelet count;
THYM	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-4.81	-0.44	5.66e-6	Crohn's disease;
THYM	trans	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg18335740	chr13:41363409	SLC25A15	0.77	8.31	0.65	6.76e-13	Lewy body disease;
THYM	cis	rs7267979	0.932	rs4280527	chr20:25544014	A/G	cg03522245	chr20:25566470	NINL	0.59	4.51	0.42	1.84e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg05084668	chr3:125655381	ALG1L	-0.71	-4.61	-0.43	1.23e-5	Blood pressure (smoking interaction);
THYM	cis	rs9527	0.590	rs1926029	chr10:104855670	C/T	cg04362960	chr10:104952993	NT5C2	0.59	4.52	0.42	1.81e-5	Arsenic metabolism;
THYM	cis	rs9361491	0.657	rs7766318	chr6:79451515	A/C	cg04547799	chr6:79944526	HMGN3	-0.66	-4.58	-0.43	1.41e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.5	0.7	1.9e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg23161317	chr6:28129485	ZNF389	0.8	4.76	0.44	6.96e-6	Depression;
THYM	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs7584099	0.563	rs3820716	chr2:148680260	G/A	cg23727674	chr2:148602993	ACVR2A	0.55	4.53	0.42	1.69e-5	Response to statin therapy;
THYM	cis	rs2806561	0.765	rs1997866	chr1:23512524	A/G	cg12483005	chr1:23474871	LUZP1	0.59	6.3	0.54	9.23e-9	Height;
THYM	cis	rs7772486	0.790	rs1854900	chr6:146331382	G/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg03709012	chr19:19516395	GATAD2A	0.76	6.05	0.53	2.87e-8	Tonsillectomy;
THYM	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs72828912	0.731	rs9356925	chr6:24058402	A/C	cg19882886	chr6:25043046	NA	-0.86	-4.47	-0.42	2.14e-5	Squamous cell lung carcinoma;
THYM	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03264133	chr6:25882463	NA	-0.67	-5.21	-0.47	1.1e-6	Blood metabolite levels;
THYM	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg12310025	chr6:25882481	NA	-0.69	-5.47	-0.49	3.69e-7	Blood metabolite levels;
THYM	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.56	5.35	0.48	6.13e-7	Lymphocyte counts;
THYM	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg10018233	chr7:150070692	REPIN1	0.5	7.69	0.62	1.32e-11	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg10295955	chr4:187884368	NA	-1.22	-17.54	-0.87	1.51e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg14349672	chr11:133703707	NA	-0.54	-4.74	-0.44	7.5e-6	Childhood ear infection;
THYM	cis	rs7119	0.717	rs12917314	chr15:77818285	T/C	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg16342193	chr10:102329863	NA	-0.59	-6.2	-0.54	1.48e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg08645402	chr16:4508243	NA	0.6	5.11	0.46	1.64e-6	Schizophrenia;
THYM	cis	rs1915146	0.656	rs10794201	chr10:126846531	C/T	cg05090351	chr10:126851162	NA	0.53	5.51	0.49	3.05e-7	Menarche (age at onset);
THYM	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg23803603	chr1:2058230	PRKCZ	-0.55	-4.68	-0.43	9.58e-6	Height;
THYM	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg20295408	chr7:1910781	MAD1L1	-0.62	-4.88	-0.45	4.21e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2290159	0.800	rs60953453	chr3:12654921	C/A	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	trans	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs6785206	0.803	rs2712380	chr3:128338661	A/C	cg16766828	chr3:128327626	NA	-0.75	-7.34	-0.6	7.04e-11	Lymphocyte percentage of white cells;
THYM	cis	rs6906287	0.647	rs34479834	chr6:118826244	T/A	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs7191439	0.626	rs8059794	chr16:88787388	C/T	cg27087555	chr16:88793112	FAM38A	-1.5	-10.7	-0.74	5.25e-18	Plateletcrit;
THYM	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg20503657	chr10:835505	NA	1.17	8.29	0.65	7.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs748404	0.631	rs8042688	chr15:43638525	G/A	cg12861797	chr15:43585817	TGM7	0.44	4.67	0.43	9.79e-6	Lung cancer;
THYM	cis	rs539096	0.692	rs6669157	chr1:44216876	T/C	cg12599982	chr1:44399894	ARTN	0.52	4.75	0.44	7.2e-6	Intelligence (multi-trait analysis);
THYM	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22857025	chr5:266934	NA	-1.59	-10.2	-0.72	6.04e-17	Breast cancer;
THYM	cis	rs7772486	0.774	rs2247571	chr6:146219533	T/A	cg23711669	chr6:146136114	FBXO30	0.79	7.25	0.6	1.13e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg24375607	chr4:120327624	NA	0.68	5.31	0.48	7.26e-7	Corneal astigmatism;
THYM	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs977987	0.778	rs12445726	chr16:75465575	C/T	cg03315344	chr16:75512273	CHST6	0.73	5.83	0.51	7.5e-8	Dupuytren's disease;
THYM	cis	rs2229238	0.911	rs7551873	chr1:154505857	A/G	cg21262032	chr1:154437693	IL6R	0.6	5.37	0.48	5.68e-7	Coronary heart disease;
THYM	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg25072359	chr17:41440525	NA	0.65	4.5	0.42	1.9e-5	Menopause (age at onset);
THYM	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg13114125	chr14:105738426	BRF1	-0.75	-5.87	-0.52	6.23e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7909791	0.549	rs11191820	chr10:105594855	A/G	cg24587175	chr10:105670608	OBFC1	0.59	5.91	0.52	5.23e-8	White matter hyperintensity burden;
THYM	cis	rs2888674	1.000	rs1006581	chr7:150511923	A/G	cg10409299	chr7:150498843	TMEM176B;TMEM176A	-0.48	-4.63	-0.43	1.16e-5	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
THYM	trans	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg07393940	chr7:158741817	NA	-1.14	-9.25	-0.69	6.69e-15	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg16586182	chr3:47516702	SCAP	-0.67	-5.61	-0.5	1.99e-7	Colorectal cancer;
THYM	cis	rs758324	0.732	rs45511	chr5:131439161	C/T	cg16205897	chr5:131564050	P4HA2	0.57	4.86	0.45	4.58e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg17143192	chr8:8559678	CLDN23	0.91	6.74	0.57	1.2e-9	Obesity-related traits;
THYM	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg24375607	chr4:120327624	NA	0.59	4.93	0.45	3.52e-6	Corneal astigmatism;
THYM	cis	rs147499554	1	rs147499554	chr15:78900650	C/T	cg18825076	chr15:78729989	IREB2	-0.55	-5.04	-0.46	2.26e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs17253792	0.545	rs12894368	chr14:56025178	C/A	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs72828912	0.665	rs11756314	chr6:24074700	C/A	cg19882886	chr6:25043046	NA	-0.88	-4.58	-0.43	1.42e-5	Squamous cell lung carcinoma;
THYM	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.81	-0.63	7.44e-12	Chronic sinus infection;
THYM	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg16624210	chr5:671434	TPPP	0.76	5.61	0.5	2.03e-7	Obesity-related traits;
THYM	cis	rs6099847	0.629	rs73915162	chr20:56490073	G/A	cg03401480	chr20:57087179	APCDD1L	0.84	4.58	0.43	1.42e-5	Obesity-related traits;
THYM	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg12386194	chr3:101231763	SENP7	0.95	7.47	0.61	3.85e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7804356	0.834	rs10281261	chr7:26789472	T/C	cg24979288	chr7:27242424	NA	0.62	4.46	0.42	2.26e-5	Type 1 diabetes;
THYM	cis	rs7772486	0.875	rs7739371	chr6:146424353	C/G	cg13319975	chr6:146136371	FBXO30	-0.61	-4.96	-0.45	3.05e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10779751	0.770	rs2791643	chr1:11207269	C/T	cg08854313	chr1:11322531	MTOR	0.77	6.2	0.54	1.44e-8	Body mass index;
THYM	cis	rs6840360	0.571	rs1473305	chr4:152511721	T/G	cg17479576	chr4:152424074	FAM160A1	-0.8	-5.65	-0.5	1.68e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg00129232	chr17:37814104	STARD3	0.73	4.98	0.45	2.87e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1985732	1	rs1985732	chr6:26376161	A/G	cg14345882	chr6:26364793	BTN3A2	0.39	5.09	0.46	1.82e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs4631830	0.747	rs745180	chr10:51504493	A/C	cg10326726	chr10:51549505	MSMB	0.53	5.28	0.48	8.03e-7	Prostate-specific antigen levels;
THYM	cis	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs1003719	0.680	rs1034357	chr21:38571482	G/C	cg01329690	chr21:38580129	DSCR9	-0.36	-5.0	-0.46	2.67e-6	Eye color traits;
THYM	cis	rs459571	0.920	rs417142	chr9:136891370	G/T	cg13789015	chr9:136890014	NCRNA00094	0.83	7.23	0.6	1.25e-10	Platelet distribution width;
THYM	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg08975724	chr8:8085496	FLJ10661	0.72	5.57	0.5	2.37e-7	Mood instability;
THYM	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2213920	0.749	rs6478172	chr9:118251281	C/T	cg13918206	chr9:118159781	DEC1	0.84	4.63	0.43	1.17e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg11526020	chr17:80870163	TBCD	-0.44	-4.56	-0.42	1.53e-5	Breast cancer;
THYM	cis	rs3126085	0.935	rs3126046	chr1:152256925	G/A	cg26020982	chr1:152196106	HRNR	-0.35	-4.95	-0.45	3.26e-6	Atopic dermatitis;
THYM	cis	rs3087591	0.762	rs7502029	chr17:29590791	T/A	cg24425628	chr17:29625626	OMG;NF1	0.64	5.46	0.49	3.8e-7	Hip circumference;
THYM	cis	rs3540	0.557	rs11634314	chr15:91042066	A/C	cg22089800	chr15:90895588	ZNF774	-0.68	-5.22	-0.47	1.05e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg10589385	chr1:150898437	SETDB1	0.63	5.31	0.48	7.19e-7	Melanoma;
THYM	cis	rs921968	0.509	rs72963905	chr2:219547027	T/G	cg02176678	chr2:219576539	TTLL4	-0.73	-7.22	-0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.15	-0.47	1.4e-6	Total cholesterol levels;
THYM	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg05738196	chr6:26577821	NA	0.95	9.89	0.71	2.78e-16	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg03188948	chr7:1209495	NA	0.61	4.65	0.43	1.09e-5	Longevity;Endometriosis;
THYM	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg20891283	chr12:69753455	YEATS4	0.73	6.0	0.52	3.51e-8	Blood protein levels;
THYM	cis	rs3087591	0.960	rs12603885	chr17:29466722	C/T	cg24425628	chr17:29625626	OMG;NF1	0.58	5.03	0.46	2.32e-6	Hip circumference;
THYM	cis	rs193541	0.509	rs6899195	chr5:122141459	G/A	cg19808643	chr5:122110361	SNX2	-0.57	-4.68	-0.43	9.41e-6	Glucose homeostasis traits;
THYM	cis	rs13223928	0.605	rs10951052	chr7:3155301	A/G	cg19214707	chr7:3157722	NA	-0.91	-7.01	-0.58	3.37e-10	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg09455208	chr3:40491958	NA	-0.45	-4.55	-0.42	1.59e-5	Renal cell carcinoma;
THYM	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg18252515	chr7:66147081	NA	0.6	4.52	0.42	1.76e-5	Aortic root size;
THYM	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg24818145	chr4:99064322	C4orf37	0.7	5.51	0.49	3.09e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg05962950	chr11:130786565	SNX19	0.94	8.84	0.67	4.93e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg01191920	chr7:158217561	PTPRN2	-1.0	-11.0	-0.75	1.25e-18	Obesity-related traits;
THYM	cis	rs684232	0.688	rs2657633	chr17:600502	C/T	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.39	-4.71	-0.43	8.55e-6	Prostate cancer;
THYM	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg19077165	chr18:44547161	KATNAL2	-0.66	-8.3	-0.65	7.02e-13	Personality dimensions;
THYM	cis	rs986417	0.606	rs7156375	chr14:61110627	G/A	cg27398547	chr14:60952738	C14orf39	0.94	5.21	0.47	1.07e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg00071950	chr4:10020882	SLC2A9	-0.68	-6.46	-0.55	4.41e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4631830	0.863	rs2843550	chr10:51521452	C/T	cg10326726	chr10:51549505	MSMB	-0.59	-5.86	-0.52	6.68e-8	Prostate-specific antigen levels;
THYM	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.68	-4.46	-0.42	2.22e-5	Menarche (age at onset);
THYM	cis	rs28829049	0.597	rs34219832	chr1:19502432	C/T	cg13387374	chr1:19411106	UBR4	0.65	4.86	0.45	4.71e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs270601	0.866	rs460271	chr5:131630062	C/G	cg12564285	chr5:131593104	PDLIM4	0.5	5.22	0.47	1.05e-6	Acylcarnitine levels;
THYM	cis	rs6987853	0.688	rs2923433	chr8:42418723	T/C	cg09913449	chr8:42400586	C8orf40	1.07	11.34	0.76	2.34e-19	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg13147721	chr7:65941812	NA	0.74	4.67	0.43	9.98e-6	Diabetic kidney disease;
THYM	cis	rs12188164	0.897	rs55932239	chr5:423906	G/A	cg26850624	chr5:429559	AHRR	-0.7	-5.5	-0.49	3.15e-7	Cystic fibrosis severity;
THYM	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg26384229	chr12:38710491	ALG10B	0.66	5.19	0.47	1.2e-6	Morning vs. evening chronotype;
THYM	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.86	0.74	2.46e-18	Chronic sinus infection;
THYM	cis	rs9646944	0.501	rs3771161	chr2:103003961	C/A	cg01241218	chr2:102972058	NA	0.81	5.28	0.48	8.09e-7	Blood protein levels;
THYM	cis	rs981844	0.890	rs55917677	chr4:154701051	C/T	cg09973105	chr4:154681532	RNF175	-0.67	-5.54	-0.49	2.68e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg21926883	chr2:100939477	LONRF2	-0.69	-6.37	-0.55	6.63e-9	Intelligence (multi-trait analysis);
THYM	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg23161317	chr6:28129485	ZNF389	0.94	7.03	0.58	3.18e-10	Parkinson's disease;
THYM	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg22764044	chr5:178986830	RUFY1	0.49	4.96	0.45	3.1e-6	Lung cancer;
THYM	cis	rs7666738	0.688	rs35739409	chr4:98576934	C/T	cg24818145	chr4:99064322	C4orf37	0.84	4.93	0.45	3.52e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg20887711	chr4:1340912	KIAA1530	-0.59	-4.62	-0.43	1.22e-5	Obesity-related traits;
THYM	cis	rs12530845	1.000	rs12540325	chr7:135334111	T/C	cg23117316	chr7:135346802	PL-5283	-0.66	-5.88	-0.52	6.21e-8	Red blood cell traits;
THYM	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg24069376	chr3:38537580	EXOG	0.68	6.73	0.57	1.26e-9	Electrocardiographic conduction measures;
THYM	cis	rs13102973	0.899	rs10213137	chr4:135900543	T/C	cg14419869	chr4:135874104	NA	-0.78	-6.5	-0.55	3.76e-9	Subjective well-being;
THYM	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg25427524	chr10:38739819	LOC399744	-0.65	-6.16	-0.53	1.75e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs13326165	0.585	rs11713914	chr3:52379110	C/T	cg08438690	chr3:52279403	PPM1M	-0.86	-5.24	-0.47	9.72e-7	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg10802521	chr3:52805072	NEK4	0.75	6.51	0.56	3.56e-9	Bipolar disorder;
THYM	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs7542375	0.683	rs11118626	chr1:221108912	C/G	cg16008148	chr1:221062819	NA	0.46	5.3	0.48	7.5e-7	Obesity-related traits;
THYM	cis	rs10411161	0.752	rs10404812	chr19:52400691	T/C	cg25361850	chr19:52391789	ZNF577	0.71	4.69	0.43	8.97e-6	Breast cancer;
THYM	cis	rs4746818	0.818	rs10823302	chr10:70895418	G/T	cg04149295	chr10:70884716	VPS26A	0.84	5.92	0.52	5.05e-8	Left atrial antero-posterior diameter;
THYM	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg13393036	chr8:95962371	TP53INP1	-0.49	-4.98	-0.46	2.81e-6	Type 2 diabetes;
THYM	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.58	0.56	2.61e-9	Total body bone mineral density;
THYM	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg06108461	chr20:60628389	TAF4	-1.04	-8.21	-0.64	1.1e-12	Body mass index;
THYM	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg19774624	chr17:42201019	HDAC5	-0.85	-8.23	-0.65	9.73e-13	Total body bone mineral density;
THYM	cis	rs6840360	0.967	rs10049728	chr4:152672121	C/G	cg22705602	chr4:152727874	NA	-0.58	-6.26	-0.54	1.1e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7592578	0.537	rs62180982	chr2:191264485	G/T	cg11845111	chr2:191398756	TMEM194B	-0.86	-5.91	-0.52	5.34e-8	Diastolic blood pressure;
THYM	cis	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg17366294	chr4:99064904	C4orf37	0.59	7.05	0.59	2.84e-10	Colonoscopy-negative controls vs population controls;
THYM	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg00129232	chr17:37814104	STARD3	-0.87	-7.23	-0.6	1.23e-10	Asthma;
THYM	cis	rs7447927	0.950	rs13153461	chr5:138852369	G/A	cg08720517	chr5:138729919	LOC389333	-0.61	-5.1	-0.46	1.76e-6	Esophageal squamous cell carcinoma;
THYM	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.64	-5.53	-0.49	2.78e-7	Systemic lupus erythematosus;
THYM	cis	rs28595532	0.841	rs115918392	chr4:119610356	T/A	cg14228332	chr4:119757509	SEC24D	1.35	4.52	0.42	1.81e-5	Cannabis dependence symptom count;
THYM	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg12179176	chr11:130786555	SNX19	0.78	6.73	0.57	1.27e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs921968	0.613	rs6436066	chr2:219578361	T/G	cg02176678	chr2:219576539	TTLL4	-0.53	-5.11	-0.46	1.69e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	5.18	0.47	1.23e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	trans	rs629535	0.767	rs62513418	chr8:70114376	G/T	cg21567404	chr3:27674614	NA	-1.06	-9.7	-0.71	7.22e-16	Dupuytren's disease;
THYM	cis	rs7771547	0.642	rs629560	chr6:36511391	A/G	cg07856975	chr6:36356162	ETV7	0.52	4.98	0.46	2.8e-6	Platelet distribution width;
THYM	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs514406	0.929	rs12354395	chr1:53327663	A/G	cg22166914	chr1:53195759	ZYG11B	0.8	8.04	0.64	2.5e-12	Monocyte count;
THYM	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg14129053	chr2:1895732	MYT1L	1.16	4.47	0.42	2.2e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs28476539	0.568	rs7691204	chr4:83553993	A/T	cg10249074	chr4:83542146	C4orf11	-0.64	-5.06	-0.46	2.03e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs921968	0.608	rs7598056	chr2:219352511	A/C	cg02176678	chr2:219576539	TTLL4	0.68	6.56	0.56	2.74e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4788570	0.578	rs4788553	chr16:71780277	T/G	cg06353428	chr16:71660113	MARVELD3	1.39	9.52	0.7	1.78e-15	Intelligence (multi-trait analysis);
THYM	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg07424592	chr7:64974309	NA	1.08	5.7	0.51	1.32e-7	Diabetic kidney disease;
THYM	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06873352	chr17:61820015	STRADA	0.76	9.49	0.7	2.07e-15	Prudent dietary pattern;
THYM	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.56	-4.53	-0.42	1.74e-5	Bipolar disorder;
THYM	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg15693483	chr7:1102177	C7orf50	0.52	4.91	0.45	3.82e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7942486	0.895	rs11825506	chr11:13269937	A/G	cg13286116	chr11:13302098	ARNTL	-0.72	-8.03	-0.64	2.61e-12	Neuroticism;
THYM	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg13683864	chr3:40499215	RPL14	1.08	12.78	0.8	2.33e-22	Renal cell carcinoma;
THYM	cis	rs470093	0.932	rs5764317	chr22:44209288	G/T	cg09142166	chr22:44276013	PNPLA5	-0.57	-5.56	-0.5	2.5e-7	Staphylococcus aureus infection;
THYM	cis	rs1003719	0.715	rs2835659	chr21:38567902	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-4.53	-0.42	1.72e-5	Eye color traits;
THYM	cis	rs7267979	1.000	rs2258879	chr20:25279213	T/C	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs478304	0.651	rs7110576	chr11:65512057	T/G	cg17480646	chr11:65405466	SIPA1	-0.94	-8.68	-0.67	1.07e-13	Acne (severe);
THYM	cis	rs7432375	0.901	rs6802702	chr3:136489563	G/A	cg21827317	chr3:136751795	NA	-0.58	-4.76	-0.44	6.95e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg08000102	chr2:233561755	GIGYF2	-0.56	-4.98	-0.46	2.8e-6	Coronary artery disease;
THYM	cis	rs981844	0.961	rs56148270	chr4:154660874	C/T	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg17264618	chr3:40429014	ENTPD3	0.49	4.64	0.43	1.1e-5	Renal cell carcinoma;
THYM	cis	rs76878669	0.561	rs11823140	chr11:66098322	G/T	cg15964523	chr11:66469143	SPTBN2	-0.68	-4.86	-0.45	4.7e-6	Educational attainment (years of education);
THYM	cis	rs7772486	0.624	rs6930154	chr6:146025662	C/T	cg23711669	chr6:146136114	FBXO30	-0.91	-8.87	-0.67	4.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13064411	0.627	rs9825827	chr3:113182231	T/C	cg10517650	chr3:113235015	CCDC52	-0.56	-4.99	-0.46	2.74e-6	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg04772025	chr11:68637568	NA	0.62	6.61	0.56	2.21e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg25918947	chr17:41365094	TMEM106A	0.65	5.4	0.48	4.99e-7	Menopause (age at onset);
THYM	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg18876405	chr7:65276391	NA	0.57	4.83	0.44	5.27e-6	Aortic root size;
THYM	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg22590775	chr19:49891494	CCDC155	0.87	5.81	0.51	8.43e-8	Multiple sclerosis;
THYM	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg20891558	chr2:74357851	NA	1.19	11.11	0.75	7.28e-19	Gestational age at birth (maternal effect);
THYM	cis	rs12681287	0.547	rs7461366	chr8:87511685	C/T	cg27223183	chr8:87520930	FAM82B	-0.71	-5.46	-0.49	3.8e-7	Caudate activity during reward;
THYM	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg16624210	chr5:671434	TPPP	0.63	5.95	0.52	4.37e-8	Obesity-related traits;
THYM	cis	rs240764	0.658	rs35168784	chr6:101183499	C/T	cg21058520	chr6:100914733	NA	0.6	5.32	0.48	6.98e-7	Neuroticism;
THYM	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-5.21	-0.47	1.07e-6	Gut microbiome composition (summer);
THYM	cis	rs986417	1.000	rs4243618	chr14:61067022	T/C	cg27398547	chr14:60952738	C14orf39	1.3	6.11	0.53	2.15e-8	Gut microbiota (bacterial taxa);
THYM	trans	rs208520	0.661	rs207079	chr6:66770462	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.12	-7.56	-0.61	2.5e-11	Exhaled nitric oxide output;
THYM	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg23711669	chr6:146136114	FBXO30	0.93	9.71	0.71	6.86e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg11494091	chr17:61959527	GH2	0.68	6.3	0.54	9.16e-9	Height;
THYM	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg11366901	chr6:160182831	ACAT2	1.1	10.29	0.73	4.02e-17	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg16482183	chr6:26056742	HIST1H1C	0.82	5.32	0.48	6.78e-7	Iron status biomarkers;
THYM	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg23711669	chr6:146136114	FBXO30	0.96	9.81	0.71	4.28e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1978968	1.000	rs13053667	chr22:18443404	G/A	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs8050907	0.744	rs74403649	chr16:4575804	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.13	4.76	0.44	6.97e-6	Obesity-related traits;
THYM	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg05368731	chr17:41323189	NBR1	1.21	10.98	0.75	1.38e-18	Menopause (age at onset);
THYM	cis	rs7131987	0.903	rs6487796	chr12:29422764	A/G	cg09582351	chr12:29534625	ERGIC2	-0.48	-4.59	-0.43	1.35e-5	QT interval;
THYM	cis	rs13102973	1.000	rs13112665	chr4:135898581	C/A	cg14419869	chr4:135874104	NA	0.89	8.45	0.66	3.35e-13	Subjective well-being;
THYM	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg04772025	chr11:68637568	NA	-0.66	-6.99	-0.58	3.79e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg11366901	chr6:160182831	ACAT2	1.1	10.1	0.72	1.02e-16	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs36051895	0.659	rs72701605	chr9:5062056	G/A	cg02405213	chr9:5042618	JAK2	-1.01	-11.2	-0.75	4.73e-19	Pediatric autoimmune diseases;
THYM	cis	rs8180040	0.903	rs2276853	chr3:47282303	G/A	cg27129171	chr3:47204927	SETD2	0.75	7.26	0.6	1.07e-10	Colorectal cancer;
THYM	cis	rs7312774	0.748	rs7295619	chr12:107316934	T/A	cg16260113	chr12:107380972	MTERFD3	0.96	5.17	0.47	1.32e-6	Severe influenza A (H1N1) infection;
THYM	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	5.07	0.46	1.92e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg06636001	chr8:8085503	FLJ10661	0.58	4.46	0.42	2.22e-5	Obesity-related traits;
THYM	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg06784218	chr1:46089804	CCDC17	-0.32	-4.82	-0.44	5.41e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg06009448	chr7:1102226	C7orf50	0.53	5.55	0.49	2.6e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg07393940	chr7:158741817	NA	-1.09	-7.77	-0.62	9.14e-12	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs420259	0.516	rs9931842	chr16:23524558	T/A	cg00143387	chr16:23521605	GGA2	-0.72	-5.18	-0.47	1.26e-6	Bipolar disorder;
THYM	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs4262150	0.883	rs4437425	chr5:152238341	G/A	cg06854687	chr5:151642065	NA	0.64	4.46	0.42	2.27e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs314370	0.951	rs12705092	chr7:100473550	G/A	cg08558340	chr7:100472263	SRRT	0.61	4.99	0.46	2.75e-6	Resting heart rate;
THYM	cis	rs1639906	0.507	rs1004643	chr7:2185324	G/C	cg19897017	chr7:2163380	MAD1L1	-0.62	-6.74	-0.57	1.21e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4730276	0.674	rs7777259	chr7:107560651	G/T	cg23293999	chr7:106826042	HBP1	-0.6	-4.91	-0.45	3.8e-6	Ulcerative colitis;
THYM	cis	rs236352	0.576	rs6914008	chr6:36853037	T/A	cg03410223	chr6:36853544	C6orf89	0.69	5.44	0.49	4.22e-7	Heart rate;
THYM	cis	rs17030434	1.000	rs79094565	chr4:154718997	T/C	cg14289246	chr4:154710475	SFRP2	-0.76	-5.24	-0.47	9.79e-7	Electrocardiographic conduction measures;
THYM	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.72	4.65	0.43	1.07e-5	Lymphocyte percentage of white cells;
THYM	cis	rs1983170	0.799	rs2063055	chr1:92020835	G/T	cg02896835	chr1:92012615	NA	0.59	4.54	0.42	1.68e-5	Eosinophil percentage of white cells;
THYM	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg06481639	chr22:41940642	POLR3H	0.72	4.68	0.43	9.65e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg17330251	chr7:94953956	PON1	0.85	7.66	0.62	1.54e-11	Paraoxonase activity;
THYM	cis	rs892961	0.777	rs747483	chr17:75412091	C/T	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg07371521	chr5:154026371	NA	0.57	5.45	0.49	3.96e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg08133631	chr1:26527909	CATSPER4	-0.57	-4.69	-0.43	9.29e-6	Obesity-related traits;
THYM	cis	rs36051895	0.632	rs7038813	chr9:5177685	A/G	cg02405213	chr9:5042618	JAK2	-1.0	-10.98	-0.75	1.39e-18	Pediatric autoimmune diseases;
THYM	cis	rs981844	0.683	rs4696191	chr4:154740668	G/A	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs8103278	0.507	rs16939	chr19:46276056	C/A	cg14061069	chr19:46274453	DMPK	0.89	13.75	0.82	2.55e-24	Coronary artery disease;
THYM	cis	rs4803468	1.000	rs13344563	chr19:41945904	G/C	cg09537434	chr19:41945824	ATP5SL	1.1	10.47	0.73	1.63e-17	Height;
THYM	cis	rs77372450	0.551	rs11134891	chr5:157103373	G/A	cg00312553	chr5:157098553	C5orf52	-0.66	-4.7	-0.43	8.79e-6	Bipolar disorder (body mass index interaction);
THYM	cis	rs3796352	1.000	rs33999310	chr3:52883332	G/A	cg07884673	chr3:53033167	SFMBT1	0.93	4.81	0.44	5.63e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs10089	0.953	rs6875982	chr5:127529197	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.92	5.76	0.51	1.04e-7	Ileal carcinoids;
THYM	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg08645402	chr16:4508243	NA	0.66	5.52	0.49	2.97e-7	Schizophrenia;
THYM	cis	rs995000	0.931	rs583609	chr1:62916796	T/C	cg06896770	chr1:63153194	DOCK7	0.9	7.4	0.6	5.39e-11	Triglyceride levels;
THYM	cis	rs2663905	0.664	rs2460855	chr15:81361729	G/T	cg05624577	chr15:81411055	NA	-0.68	-5.23	-0.47	1e-6	QT interval (drug interaction);
THYM	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg13609457	chr4:120235615	NA	0.51	4.76	0.44	6.87e-6	Corneal astigmatism;
THYM	cis	rs1018836	0.886	rs10112242	chr8:91642631	G/C	cg16814680	chr8:91681699	NA	-0.99	-9.24	-0.69	7.07e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg26384229	chr12:38710491	ALG10B	1.04	10.36	0.73	2.75e-17	Heart rate;
THYM	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	6.53	0.56	3.28e-9	Schizophrenia;
THYM	cis	rs988913	1.000	rs7744592	chr6:54826345	A/G	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.74e-6	Menarche (age at onset);
THYM	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22857025	chr5:266934	NA	-1.51	-10.21	-0.72	5.8e-17	Breast cancer;
THYM	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg09469691	chr10:81107165	PPIF	0.71	5.81	0.51	8.23e-8	Height;
THYM	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg15448220	chr1:150897856	SETDB1	0.88	7.18	0.59	1.51e-10	Melanoma;
THYM	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22496380	chr5:211416	CCDC127	-1.33	-7.99	-0.63	3.21e-12	Breast cancer;
THYM	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg05182265	chr7:156933206	UBE3C	-0.69	-9.32	-0.69	4.58e-15	Body mass index;
THYM	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg02640540	chr1:67518911	SLC35D1	0.59	4.64	0.43	1.09e-5	Lymphocyte percentage of white cells;
THYM	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Parkinson's disease;
THYM	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs7200543	1.000	rs3803575	chr16:15138447	T/C	cg01933576	chr16:15083564	PDXDC1	-0.93	-7.77	-0.62	9.28e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs977987	0.778	rs4888409	chr16:75436231	A/T	cg03315344	chr16:75512273	CHST6	0.77	6.31	0.54	8.75e-9	Dupuytren's disease;
THYM	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg00376283	chr12:123451042	ABCB9	0.68	5.22	0.47	1.04e-6	Neutrophil percentage of white cells;
THYM	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	6.33	0.54	8.19e-9	Platelet count;
THYM	cis	rs4866334	1.000	rs116612534	chr5:18506467	C/A	cg04591469	chr5:17810299	NA	-1.14	-4.6	-0.43	1.28e-5	IgG glycosylation;
THYM	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg18402987	chr7:1209562	NA	0.84	5.18	0.47	1.22e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg21775007	chr8:11205619	TDH	-0.68	-5.27	-0.48	8.47e-7	Retinal vascular caliber;
THYM	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12756686	chr19:29218302	NA	0.98	8.72	0.67	9.12e-14	Methadone dose in opioid dependence;
THYM	cis	rs57927100	0.554	rs11868657	chr17:75335939	G/A	cg18271897	chr17:75316784	SEPT9	0.62	5.41	0.49	4.74e-7	Systolic blood pressure;
THYM	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg14129053	chr2:1895732	MYT1L	1.13	4.49	0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs34734847	1.000	rs56179458	chr12:121157535	G/A	cg10600917	chr12:121163489	ACADS	0.57	5.15	0.47	1.41e-6	Mean corpuscular volume;
THYM	cis	rs10501293	0.703	rs4755684	chr11:42988175	C/T	cg03447554	chr11:43094025	NA	0.63	4.67	0.43	9.76e-6	Cognitive performance;
THYM	cis	rs7582180	0.764	rs13006224	chr2:100917109	C/T	cg08017756	chr2:100939284	LONRF2	-0.72	-7.39	-0.6	5.65e-11	Intelligence (multi-trait analysis);
THYM	cis	rs17321999	0.904	rs13386353	chr2:30480756	A/G	cg05247661	chr2:30472410	LBH	0.62	4.47	0.42	2.16e-5	Systemic lupus erythematosus;
THYM	cis	rs514406	0.929	rs2607095	chr1:53325639	T/C	cg22166914	chr1:53195759	ZYG11B	0.8	8.04	0.64	2.5e-12	Monocyte count;
THYM	cis	rs28595532	0.920	rs56252481	chr4:119754023	C/T	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs4660306	1.000	rs4660306	chr1:45978675	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.66	5.33	0.48	6.57e-7	Homocysteine levels;
THYM	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg06634786	chr22:41940651	POLR3H	-0.6	-4.6	-0.43	1.32e-5	Vitiligo;
THYM	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs9287719	0.781	rs12472807	chr2:10781605	G/A	cg03983476	chr2:10830698	NOL10	-0.58	-5.24	-0.47	9.54e-7	Prostate cancer;
THYM	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.62	0.56	2.12e-9	Total body bone mineral density;
THYM	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg14517863	chr17:44321492	NA	-0.44	-5.0	-0.46	2.59e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9972944	0.756	rs1421032	chr17:63766368	A/C	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs7607369	0.566	rs55658481	chr2:219284215	G/A	cg02176678	chr2:219576539	TTLL4	-0.63	-5.47	-0.49	3.71e-7	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg09517075	chr8:22133004	PIWIL2	0.63	5.57	0.5	2.35e-7	Hypertriglyceridemia;
THYM	cis	rs1692580	0.840	rs696094	chr1:2169215	G/A	cg24578937	chr1:2090814	PRKCZ	0.51	5.24	0.47	9.85e-7	Coronary artery disease;
THYM	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs11112613	0.713	rs11112588	chr12:105943801	A/C	cg03607813	chr12:105948248	NA	1.07	9.36	0.69	3.87e-15	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.79e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs4974559	0.739	rs4333131	chr4:1323789	A/G	cg02980000	chr4:1222292	CTBP1	0.77	4.82	0.44	5.41e-6	Systolic blood pressure;
THYM	cis	rs72627123	0.867	rs59892091	chr14:74417609	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.82	4.65	0.43	1.08e-5	Morning vs. evening chronotype;
THYM	cis	rs6840360	0.571	rs11723395	chr4:152524191	G/A	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs17030434	0.911	rs17030490	chr4:154738340	C/T	cg14289246	chr4:154710475	SFRP2	-0.81	-5.51	-0.49	3.08e-7	Electrocardiographic conduction measures;
THYM	cis	rs2742540	0.503	rs982273	chr11:8906862	T/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.59	-4.99	-0.46	2.77e-6	Hematocrit;
THYM	cis	rs514406	0.825	rs12089511	chr1:53436427	A/T	cg06600287	chr1:53387719	ECHDC2	0.31	5.11	0.46	1.68e-6	Monocyte count;
THYM	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1823778	0.609	rs8085960	chr18:67647035	C/A	cg12929678	chr18:67624393	CD226	1.3	4.63	0.43	1.14e-5	Mean platelet volume;
THYM	cis	rs57244997	1.000	rs73026551	chr6:162393642	A/C	cg17173639	chr6:162384350	PARK2	-0.96	-5.56	-0.5	2.47e-7	Mosquito bite size;
THYM	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7267979	0.868	rs6107019	chr20:25233985	C/T	cg08601574	chr20:25228251	PYGB	0.59	4.68	0.43	9.42e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg11789530	chr4:8429930	ACOX3	0.74	5.99	0.52	3.74e-8	Response to antineoplastic agents;
THYM	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg12863693	chr15:85201151	NMB	0.55	4.53	0.42	1.71e-5	Schizophrenia;
THYM	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11651000	0.857	rs57171311	chr17:45826168	A/G	cg03474202	chr17:45855739	NA	-0.78	-6.66	-0.56	1.73e-9	IgG glycosylation;
THYM	cis	rs9611198	0.846	rs5757733	chr22:39968173	T/G	cg19570171	chr22:39239822	NPTXR	0.63	5.05	0.46	2.16e-6	Schizophrenia;
THYM	cis	rs7568458	0.870	rs6719046	chr2:85757371	G/A	cg17127132	chr2:85788382	GGCX	0.65	5.25	0.47	9.44e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg03351412	chr1:154909251	PMVK	-0.66	-5.3	-0.48	7.51e-7	Prostate cancer;
THYM	trans	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg10856724	chr12:34555212	NA	-0.78	-7.08	-0.59	2.48e-10	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4523957	0.583	rs2760738	chr17:2024600	A/G	cg16513277	chr17:2031491	SMG6	-0.96	-8.72	-0.67	9.17e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg24733560	chr20:60626293	TAF4	0.62	6.64	0.56	1.96e-9	Body mass index;
THYM	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg08975724	chr8:8085496	FLJ10661	0.6	4.88	0.45	4.26e-6	Mood instability;
THYM	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg20295408	chr7:1910781	MAD1L1	-0.65	-5.21	-0.47	1.12e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg11301795	chr4:187892539	NA	-1.11	-17.65	-0.88	9.45e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg10589385	chr1:150898437	SETDB1	0.66	5.58	0.5	2.27e-7	Tonsillectomy;
THYM	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	4.79	0.44	6.19e-6	Height;
THYM	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg04455712	chr21:45112962	RRP1B	0.58	5.58	0.5	2.3e-7	Mean corpuscular volume;
THYM	cis	rs3026101	0.624	rs7426	chr17:5288983	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.55	4.87	0.45	4.46e-6	Body mass index;
THYM	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg15733309	chr7:157513707	PTPRN2	0.57	6.33	0.54	8.08e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg24209194	chr3:40518798	ZNF619	0.55	4.48	0.42	2.1e-5	Renal cell carcinoma;
THYM	cis	rs7255436	0.965	rs7351098	chr19:8451671	G/C	cg10174797	chr19:8464628	RAB11B	0.43	5.19	0.47	1.21e-6	HDL cholesterol;
THYM	cis	rs2668423	0.922	rs266805	chr19:1376723	C/T	cg02639931	chr19:1387894	NDUFS7	-0.48	-5.72	-0.51	1.21e-7	Nonalcoholic fatty liver disease;
THYM	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg22709100	chr7:91322751	NA	0.63	4.86	0.45	4.55e-6	Breast cancer;
THYM	cis	rs36051895	0.632	rs10115962	chr9:5140841	T/C	cg02405213	chr9:5042618	JAK2	-1.01	-10.2	-0.72	6.29e-17	Pediatric autoimmune diseases;
THYM	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13732083	chr21:47605072	C21orf56	-0.71	-4.99	-0.46	2.78e-6	Testicular germ cell tumor;
THYM	cis	rs2085601	0.542	rs13143981	chr4:89989715	A/G	cg17769793	chr4:89976368	FAM13A	0.59	6.62	0.56	2.17e-9	Hair greying;
THYM	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2456568	0.835	rs7936182	chr11:93665532	T/A	cg17595323	chr11:93583763	C11orf90	-0.56	-5.55	-0.5	2.55e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs4866334	1.000	rs80033831	chr5:18481972	A/G	cg18608440	chr5:17519013	NA	1.07	4.52	0.42	1.79e-5	IgG glycosylation;
THYM	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg15445000	chr17:37608096	MED1	0.4	4.64	0.43	1.13e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg12310025	chr6:25882481	NA	-0.83	-6.72	-0.57	1.36e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg02869364	chr7:1081709	C7orf50	-0.75	-4.54	-0.42	1.63e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg02953382	chr22:24373134	LOC391322	-0.7	-6.16	-0.53	1.74e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs12466960	0.846	rs6753827	chr2:28578285	C/G	cg11535839	chr2:28582676	NA	0.6	4.8	0.44	5.99e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg08305652	chr11:111469057	NA	0.53	4.58	0.43	1.41e-5	Primary sclerosing cholangitis;
THYM	cis	rs2811415	0.597	rs9850779	chr3:127744518	G/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg27129171	chr3:47204927	SETD2	-0.83	-8.26	-0.65	8.65e-13	Colorectal cancer;
THYM	cis	rs6964587	0.626	rs7807765	chr7:91531974	C/A	cg22709100	chr7:91322751	NA	-0.63	-4.71	-0.43	8.57e-6	Breast cancer;
THYM	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg02734326	chr4:10020555	SLC2A9	0.76	6.89	0.58	6.09e-10	Bone mineral density;
THYM	cis	rs1971762	0.583	rs7979659	chr12:54086579	A/G	cg16917193	chr12:54089295	NA	0.96	9.59	0.7	1.24e-15	Height;
THYM	cis	rs2075230	0.705	rs2543554	chr17:7548028	C/T	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	-0.31	-4.55	-0.42	1.61e-5	Hormone measurements;
THYM	cis	rs686320	1.000	rs3132770	chr11:65251317	G/A	cg23743554	chr11:65321226	LTBP3	0.73	4.46	0.42	2.21e-5	Hip circumference adjusted for BMI;
THYM	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg07212818	chr11:638076	DRD4	-0.77	-5.92	-0.52	5.09e-8	Systemic lupus erythematosus;
THYM	cis	rs6539288	0.589	rs1037013	chr12:107219308	A/G	cg15890332	chr12:107067104	RFX4	0.43	4.9	0.45	3.94e-6	Total body bone mineral density;
THYM	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs12681287	0.570	rs4961188	chr8:87383033	T/C	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs6840360	0.550	rs4696269	chr4:152481704	T/A	cg17479576	chr4:152424074	FAM160A1	-0.82	-5.82	-0.51	7.78e-8	Intelligence (multi-trait analysis);
THYM	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03576123	chr11:487126	PTDSS2	-1.43	-6.84	-0.57	7.5e-10	Body mass index;
THYM	cis	rs977102	0.556	rs4856847	chr3:67357071	C/T	cg06096184	chr3:66549732	LRIG1	0.66	4.6	0.43	1.32e-5	Response to amphetamines;
THYM	cis	rs4378999	0.660	rs7639301	chr3:50837991	C/G	cg27233566	chr3:49894142	TRAIP	0.77	4.47	0.42	2.16e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg00024416	chr22:24240387	NA	-0.63	-7.01	-0.58	3.5e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-5.17	-0.47	1.29e-6	Hemoglobin concentration;
THYM	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.66	5.82	0.51	7.79e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.76	-0.44	6.88e-6	Crohn's disease;
THYM	cis	rs4888262	0.526	rs13330282	chr16:74572373	C/T	cg01733217	chr16:74700730	RFWD3	0.8	8.45	0.66	3.35e-13	Testicular germ cell tumor;
THYM	cis	rs1030877	1.000	rs2576743	chr2:105901337	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.59	5.07	0.46	1.93e-6	Obesity-related traits;
THYM	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg03467027	chr4:99064603	C4orf37	0.59	4.45	0.42	2.35e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7426056	0.671	rs3116496	chr2:204594512	T/C	cg07930752	chr2:204569955	CD28	-0.72	-5.05	-0.46	2.17e-6	Primary sclerosing cholangitis;
THYM	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg13695892	chr22:41940480	POLR3H	-0.99	-7.44	-0.61	4.51e-11	Vitiligo;
THYM	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.57	-0.42	1.47e-5	Morning vs. evening chronotype;
THYM	cis	rs919433	0.713	rs11900232	chr2:198466273	T/C	cg00792783	chr2:198669748	PLCL1	0.81	5.63	0.5	1.83e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.06	6.7	0.57	1.45e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4866334	1.000	rs75378321	chr5:18402051	C/T	cg18608440	chr5:17519013	NA	1.19	4.97	0.45	2.93e-6	IgG glycosylation;
THYM	cis	rs7246657	0.943	rs4801803	chr19:37966923	A/G	cg22634378	chr19:37742834	NA	-0.66	-5.5	-0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs7119	0.700	rs4886883	chr15:77888924	C/T	cg10437265	chr15:77819839	NA	0.61	5.97	0.52	4.04e-8	Type 2 diabetes;
THYM	cis	rs2816062	0.775	rs2816046	chr1:18893708	A/G	cg18795169	chr1:18902165	NA	-0.95	-11.27	-0.76	3.3e-19	Urate levels in lean individuals;
THYM	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg22907277	chr7:1156413	C7orf50	0.82	4.98	0.46	2.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg10523679	chr1:76189770	ACADM	0.9	9.47	0.7	2.2e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6430585	0.591	rs77096272	chr2:136663605	C/A	cg20242066	chr2:136595261	LCT	0.56	5.17	0.47	1.28e-6	Corneal structure;
THYM	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg08132940	chr7:1081526	C7orf50	-1.16	-6.65	-0.56	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8070740	0.838	rs1050390	chr17:5336058	G/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.7	5.16	0.47	1.34e-6	Menopause (age at onset);
THYM	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg14018140	chr10:458528	DIP2C	-0.59	-6.99	-0.58	3.83e-10	Psychosis in Alzheimer's disease;
THYM	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg23260525	chr10:116636907	FAM160B1	0.53	5.59	0.5	2.2e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg13695892	chr22:41940480	POLR3H	0.85	6.98	0.58	3.94e-10	Vitiligo;
THYM	cis	rs1113500	0.580	rs1781058	chr1:108564059	C/G	cg06207961	chr1:108661230	NA	0.62	5.3	0.48	7.52e-7	Growth-regulated protein alpha levels;
THYM	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg12031863	chr16:4587854	C16orf5	-0.43	-4.51	-0.42	1.87e-5	Schizophrenia;
THYM	cis	rs4747241	0.771	rs7075993	chr10:74054590	C/G	cg07828833	chr10:74069493	NA	0.58	4.88	0.45	4.29e-6	Heschl's gyrus morphology;
THYM	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg17264618	chr3:40429014	ENTPD3	-0.52	-5.03	-0.46	2.29e-6	Renal cell carcinoma;
THYM	cis	rs500891	0.525	rs1361784	chr6:84090690	A/T	cg08257003	chr6:84140564	ME1	0.58	4.66	0.43	1.01e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg19901468	chr14:105411992	AHNAK2	-0.81	-6.57	-0.56	2.64e-9	Rheumatoid arthritis;
THYM	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg08847533	chr14:75593920	NEK9	-1.01	-11.32	-0.76	2.63e-19	Height;
THYM	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg04455712	chr21:45112962	RRP1B	0.54	5.04	0.46	2.22e-6	Mean corpuscular volume;
THYM	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03452623	chr4:187889614	NA	-1.17	-20.2	-0.9	3.72e-36	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9814567	0.762	rs13079012	chr3:134247706	A/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.4	4.49	0.42	1.99e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs986417	0.901	rs1950313	chr14:60997782	A/G	cg27398547	chr14:60952738	C14orf39	1.25	6.45	0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs713587	0.525	rs1541984	chr2:25082414	G/A	cg15423357	chr2:25149977	NA	0.61	5.86	0.52	6.72e-8	Body mass index in non-asthmatics;
THYM	cis	rs155076	1.000	rs566364	chr13:21837583	T/C	cg25811766	chr13:21894605	NA	-0.75	-4.75	-0.44	7.29e-6	White matter hyperintensity burden;
THYM	cis	rs6570726	0.935	rs382910	chr6:145865941	G/A	cg13319975	chr6:146136371	FBXO30	-0.67	-5.89	-0.52	5.9e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9311676	0.609	rs6770113	chr3:58379297	C/A	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg09549813	chr16:4587862	C16orf5	-0.5	-5.4	-0.48	4.94e-7	Schizophrenia;
THYM	cis	rs669446	0.562	rs6429636	chr1:44183540	G/T	cg12599982	chr1:44399894	ARTN	0.53	4.85	0.45	4.75e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg06064525	chr11:970664	AP2A2	-0.35	-6.67	-0.56	1.69e-9	Alzheimer's disease (late onset);
THYM	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg02524346	chr8:600233	NA	0.92	4.6	0.43	1.3e-5	IgG glycosylation;
THYM	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.07	7.53	0.61	2.93e-11	Smoking behavior;
THYM	cis	rs2294693	0.945	rs742494	chr6:41007835	A/T	cg14418226	chr6:40996092	UNC5CL	0.75	6.13	0.53	1.97e-8	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg06634786	chr22:41940651	POLR3H	0.71	5.15	0.47	1.4e-6	Vitiligo;
THYM	cis	rs858239	0.539	rs6461694	chr7:23187779	G/A	cg09755872	chr7:23245557	NA	-0.5	-4.71	-0.43	8.55e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg13695892	chr22:41940480	POLR3H	0.89	6.37	0.55	6.58e-9	Vitiligo;
THYM	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg25319279	chr11:5960081	NA	0.64	5.66	0.5	1.6e-7	DNA methylation (variation);
THYM	cis	rs2903698	0.585	rs9994735	chr4:76363477	C/A	cg03209871	chr4:76438412	RCHY1;THAP6	0.44	5.09	0.46	1.83e-6	Prion diseases;
THYM	cis	rs870825	0.616	rs4610378	chr4:185624220	C/T	cg04058563	chr4:185651563	MLF1IP	-1.07	-9.69	-0.71	7.45e-16	Blood protein levels;
THYM	cis	rs149313	0.560	rs151904	chr5:96066652	C/T	cg24982541	chr5:96078678	CAST	-0.51	-5.72	-0.51	1.24e-7	Blood protein levels;
THYM	cis	rs1371867	0.846	rs1660348	chr8:101315248	A/G	cg06636551	chr8:101224915	SPAG1	-0.63	-6.33	-0.54	8.05e-9	Atrioventricular conduction;
THYM	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg04025307	chr7:1156635	C7orf50	-0.8	-7.99	-0.63	3.18e-12	Longevity;Endometriosis;
THYM	cis	rs4363385	0.755	rs1933382	chr1:153003295	G/T	cg13444842	chr1:152974279	SPRR3	0.55	4.49	0.42	1.96e-5	Inflammatory skin disease;
THYM	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg12560992	chr17:57184187	TRIM37	-0.8	-6.77	-0.57	1.07e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9581857	0.579	rs118061689	chr13:27974499	A/T	cg22138327	chr13:27999177	GTF3A	1.02	5.82	0.51	7.8e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg24818145	chr4:99064322	C4orf37	0.74	5.93	0.52	4.8e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2456568	0.900	rs2456559	chr11:93668858	A/T	cg17595323	chr11:93583763	C11orf90	-0.51	-4.95	-0.45	3.17e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs1994135	0.692	rs1579909	chr12:33694780	T/C	cg10856724	chr12:34555212	NA	-0.63	-4.91	-0.45	3.84e-6	Resting heart rate;
THYM	cis	rs11640436	0.565	rs2162957	chr16:77297193	C/T	cg06128999	chr16:77247126	NA	-0.44	-5.73	-0.51	1.2e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs4851254	0.660	rs17023468	chr2:100694091	A/G	cg22139774	chr2:100720529	AFF3	-0.41	-4.69	-0.43	9.07e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7705502	0.855	rs17763083	chr5:173351488	C/T	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg25036284	chr2:26402008	FAM59B	-0.8	-5.36	-0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs2354432	0.505	rs7551766	chr1:146858964	A/G	cg25205988	chr1:146714368	CHD1L	-1.04	-4.75	-0.44	7.28e-6	Mitochondrial DNA levels;
THYM	cis	rs12282928	1.000	rs1503169	chr11:48271287	C/T	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs4919044	1.000	rs17108043	chr10:94770697	A/G	cg05127821	chr10:94822908	CYP26C1	1.21	6.17	0.54	1.64e-8	Coronary artery disease;
THYM	cis	rs11190604	0.790	rs11190535	chr10:102197441	A/T	cg07570687	chr10:102243282	WNT8B	0.85	8.39	0.65	4.57e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs8017423	0.967	rs12896540	chr14:90729392	T/C	cg04374321	chr14:90722782	PSMC1	-0.63	-4.45	-0.42	2.34e-5	Mortality in heart failure;
THYM	cis	rs7107174	0.681	rs10793301	chr11:78020913	G/T	cg19901956	chr11:77921274	USP35	-0.69	-5.3	-0.48	7.42e-7	Testicular germ cell tumor;
THYM	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-5.59	-0.5	2.15e-7	Monocyte percentage of white cells;
THYM	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg21433313	chr16:3507492	NAT15	-0.51	-4.53	-0.42	1.7e-5	Body mass index (adult);
THYM	cis	rs7666738	0.830	rs10009206	chr4:99056900	A/C	cg10515332	chr4:99064459	C4orf37	-0.64	-5.07	-0.46	1.96e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1994135	0.586	rs7308214	chr12:33713834	T/A	cg06521331	chr12:34319734	NA	-0.7	-4.9	-0.45	3.91e-6	Resting heart rate;
THYM	cis	rs7089973	0.872	rs34064819	chr10:116621154	C/A	cg23260525	chr10:116636907	FAM160B1	0.52	4.72	0.44	8.04e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg24678163	chr13:52769951	THSD1P	-0.49	-4.76	-0.44	6.89e-6	Lewy body disease;
THYM	trans	rs2754412	1	rs2754412	chr10:38627834	A/G	cg17830980	chr10:43048298	ZNF37B	-0.89	-7.63	-0.62	1.76e-11	Breast cancer;
THYM	cis	rs17598306	1.000	rs73402670	chr7:96580336	A/G	cg23184042	chr7:96615519	DLX6AS	0.61	4.76	0.44	6.82e-6	Radiation response;
THYM	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg03859395	chr2:55845619	SMEK2	0.61	5.47	0.49	3.72e-7	Metabolic syndrome;
THYM	cis	rs910187	0.641	rs6018327	chr20:45813126	C/T	cg27589058	chr20:45804311	EYA2	-0.59	-5.07	-0.46	1.95e-6	Migraine;
THYM	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg18132916	chr6:79620363	NA	-0.58	-5.27	-0.48	8.5e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2237457	0.525	rs2108352	chr7:50705481	T/C	cg08586669	chr7:50727761	GRB10	-0.3	-4.92	-0.45	3.61e-6	Schizophrenia (treatment resistant);
THYM	cis	rs9403317	0.538	rs9403331	chr6:142000123	A/C	cg15052665	chr6:141804349	NA	0.74	5.38	0.48	5.31e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Blood metabolite levels;
THYM	cis	rs6430585	0.528	rs12474975	chr2:136702118	A/T	cg04750100	chr2:136595281	LCT	0.56	4.94	0.45	3.41e-6	Corneal structure;
THYM	cis	rs6032067	0.640	rs13043809	chr20:43753220	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.69	-5.99	-0.52	3.76e-8	Blood protein levels;
THYM	cis	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg07460842	chr6:66804631	NA	1.1	8.21	0.64	1.08e-12	Exhaled nitric oxide output;
THYM	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg23260525	chr10:116636907	FAM160B1	0.53	5.33	0.48	6.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg19761014	chr17:28927070	LRRC37B2	0.78	4.99	0.46	2.76e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7408868	0.831	rs1548555	chr19:15278057	A/G	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4499344	0.622	rs10401677	chr19:33061120	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.73	4.87	0.45	4.47e-6	Mean platelet volume;
THYM	cis	rs13256369	0.851	rs13258283	chr8:8563630	T/C	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs995000	0.931	rs1168036	chr1:62962734	A/G	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs4481887	1.000	rs4244176	chr1:248468231	G/A	cg13385794	chr1:248469461	NA	0.65	4.66	0.43	1.04e-5	Common traits (Other);
THYM	cis	rs55823223	0.648	rs11867560	chr17:73857206	A/G	cg09253696	chr17:73873529	TRIM47	-0.69	-4.7	-0.43	8.72e-6	Psoriasis;
THYM	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg11494091	chr17:61959527	GH2	1.06	16.85	0.87	2.73e-30	Prudent dietary pattern;
THYM	cis	rs7851660	0.967	rs3758249	chr9:100614140	T/C	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs9902453	0.967	rs9913074	chr17:28481199	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.83	0.44	5.26e-6	Coffee consumption (cups per day);
THYM	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg10248100	chr7:872053	UNC84A	0.74	4.99	0.46	2.75e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs514406	0.893	rs10888759	chr1:53433274	A/G	cg25767906	chr1:53392781	SCP2	0.58	5.84	0.51	7.3e-8	Monocyte count;
THYM	cis	rs9486719	1.000	rs2273622	chr6:97058567	A/G	cg18709589	chr6:96969512	KIAA0776	-0.69	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03760483	chr17:6899297	ALOX12	0.68	9.14	0.68	1.16e-14	Tonsillectomy;
THYM	cis	rs10411161	0.752	rs4584941	chr19:52392141	C/T	cg25361850	chr19:52391789	ZNF577	0.77	4.86	0.45	4.72e-6	Breast cancer;
THYM	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	5.51	0.49	3.1e-7	Schizophrenia;
THYM	cis	rs2963155	0.590	rs258757	chr5:142620736	A/G	cg17617527	chr5:142782415	NR3C1	-1.17	-6.16	-0.53	1.75e-8	Breast cancer;
THYM	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg04234412	chr22:24373322	LOC391322	-0.9	-8.8	-0.67	6.11e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg03806693	chr22:41940476	POLR3H	-0.79	-6.13	-0.53	1.95e-8	Neuroticism;
THYM	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg05347473	chr6:146136440	FBXO30	0.79	6.93	0.58	5.03e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6980334	0.817	rs11982192	chr7:137795842	G/T	cg22979093	chr7:137028410	PTN	0.62	4.95	0.45	3.19e-6	Blood metabolite ratios;
THYM	cis	rs9790314	0.521	rs60625846	chr3:161084525	G/T	cg03342759	chr3:160939853	NMD3	-0.71	-5.99	-0.52	3.81e-8	Morning vs. evening chronotype;
THYM	cis	rs7772486	0.754	rs10872580	chr6:146140281	C/T	cg23711669	chr6:146136114	FBXO30	-0.94	-9.95	-0.71	2.1e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg18252515	chr7:66147081	NA	-1.56	-8.47	-0.66	3e-13	Diabetic kidney disease;
THYM	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg27494647	chr7:150038898	RARRES2	0.48	6.0	0.52	3.53e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs36051895	0.589	rs11790596	chr9:5198335	T/C	cg02405213	chr9:5042618	JAK2	-0.92	-9.47	-0.7	2.26e-15	Pediatric autoimmune diseases;
THYM	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg10117171	chr1:25599238	RHD	-0.75	-5.56	-0.5	2.44e-7	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs2235642	0.533	rs17135391	chr16:1605606	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.54	-5.41	-0.49	4.67e-7	Coronary artery disease;
THYM	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg25358565	chr5:93447407	FAM172A	1.37	10.94	0.75	1.67e-18	Diabetic retinopathy;
THYM	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg10802521	chr3:52805072	NEK4	-0.72	-6.07	-0.53	2.55e-8	Bipolar disorder;
THYM	cis	rs12122100	0.507	rs1925343	chr1:146505535	A/T	cg22671717	chr1:146548657	NA	-0.51	-5.02	-0.46	2.38e-6	HIV-1 control;
THYM	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg17143192	chr8:8559678	CLDN23	0.91	6.72	0.57	1.33e-9	Obesity-related traits;
THYM	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg07061783	chr6:25882402	NA	0.82	6.9	0.58	5.84e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.17	11.49	0.76	1.16e-19	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs10256972	0.552	rs6953538	chr7:1196974	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.56	-5.59	-0.5	2.21e-7	Longevity;Endometriosis;
THYM	cis	rs4731207	0.596	rs28817916	chr7:124588550	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs11650494	0.908	rs73324308	chr17:47405338	T/G	cg08112188	chr17:47440006	ZNF652	1.05	4.51	0.42	1.83e-5	Prostate cancer;
THYM	cis	rs3741798	1.000	rs17375328	chr12:12485292	T/C	cg08615371	chr12:12503544	MANSC1	0.88	4.9	0.45	3.92e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs600806	0.850	rs10745354	chr1:109931908	C/T	cg23616212	chr1:109941201	SORT1	-0.5	-4.65	-0.43	1.06e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4866334	0.764	rs10042816	chr5:18483053	C/A	cg18608440	chr5:17519013	NA	-1.07	-4.95	-0.45	3.24e-6	IgG glycosylation;
THYM	cis	rs9549367	0.659	rs9549703	chr13:113885094	T/TTAG	cg00898013	chr13:113819073	PROZ	-0.97	-9.01	-0.68	2.2e-14	Platelet distribution width;
THYM	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg20203395	chr5:56204925	C5orf35	-0.67	-4.58	-0.42	1.44e-5	Initial pursuit acceleration;
THYM	cis	rs2637266	0.749	rs4979830	chr10:78457484	C/T	cg18941641	chr10:78392320	NA	0.81	6.55	0.56	2.92e-9	Pulmonary function;
THYM	cis	rs9296092	0.517	rs76662639	chr6:33508476	G/A	cg13560919	chr6:33536144	NA	-0.89	-7.62	-0.62	1.86e-11	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs526231	0.543	rs34801	chr5:102426513	T/A	cg23492399	chr5:102201601	PAM	-0.67	-4.96	-0.45	3.05e-6	Primary biliary cholangitis;
THYM	cis	rs897984	0.683	rs8046001	chr16:30833321	C/T	cg02466173	chr16:30829666	NA	-0.55	-4.73	-0.44	7.89e-6	Dementia with Lewy bodies;
THYM	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg17105886	chr17:28927953	LRRC37B2	1.29	6.49	0.55	3.84e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg22117172	chr7:91764530	CYP51A1	0.39	4.93	0.45	3.5e-6	Breast cancer;
THYM	cis	rs4595586	0.525	rs7970652	chr12:39374873	T/C	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg10589385	chr1:150898437	SETDB1	0.63	5.17	0.47	1.28e-6	Melanoma;
THYM	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg19729930	chr2:74357872	NA	1.25	12.52	0.79	8.21e-22	Gestational age at birth (maternal effect);
THYM	cis	rs17253792	0.822	rs75995456	chr14:56073194	A/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs2747539	0.588	rs6088305	chr20:32389066	C/A	cg06304546	chr20:32448765	NA	-0.68	-4.63	-0.43	1.16e-5	Dysphagia;
THYM	cis	rs3540	0.512	rs3862434	chr15:91080387	C/T	cg22089800	chr15:90895588	ZNF774	0.67	5.1	0.46	1.72e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs4808199	0.947	rs751858	chr19:19602821	G/C	cg03709012	chr19:19516395	GATAD2A	1.18	7.11	0.59	2.16e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs9902453	0.845	rs12601963	chr17:28246358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.65	0.43	1.07e-5	Coffee consumption (cups per day);
THYM	cis	rs6430585	0.583	rs3087343	chr2:136622543	T/G	cg20242066	chr2:136595261	LCT	0.51	4.87	0.45	4.44e-6	Corneal structure;
THYM	cis	rs4780401	0.609	rs9924522	chr16:11816852	C/A	cg01061890	chr16:11836724	TXNDC11	-0.66	-5.44	-0.49	4.22e-7	Rheumatoid arthritis;
THYM	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg16325326	chr1:53192061	ZYG11B	-0.98	-11.09	-0.75	7.79e-19	Monocyte count;
THYM	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.53	0.56	3.27e-9	Total body bone mineral density;
THYM	cis	rs9486719	0.857	rs4346856	chr6:96880270	C/T	cg18709589	chr6:96969512	KIAA0776	0.64	4.56	0.42	1.5e-5	Migraine;Coronary artery disease;
THYM	trans	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17712092	chr4:129076599	LARP1B	0.92	7.74	0.62	1.07e-11	Eosinophil percentage of white cells;
THYM	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.77	-5.1	-0.46	1.7e-6	Body mass index;
THYM	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.79	-7.16	-0.59	1.67e-10	Lung cancer in ever smokers;
THYM	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg11789530	chr4:8429930	ACOX3	-0.7	-5.71	-0.51	1.28e-7	Response to antineoplastic agents;
THYM	cis	rs1018836	0.828	rs9297871	chr8:91572731	G/A	cg16814680	chr8:91681699	NA	-0.89	-7.57	-0.61	2.37e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs28595532	0.920	rs55806110	chr4:119742583	A/G	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg05025164	chr4:1340916	KIAA1530	0.95	7.73	0.62	1.13e-11	Longevity;
THYM	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.52	0.49	2.99e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs72627123	0.867	rs73303135	chr14:74495090	C/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.86	4.91	0.45	3.77e-6	Morning vs. evening chronotype;
THYM	cis	rs4285028	0.948	rs79103597	chr3:121667629	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.85	6.71	0.57	1.39e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	6.38	0.55	6.45e-9	Smoking behavior;
THYM	cis	rs1775715	0.835	rs1419169	chr10:32257204	C/G	cg04359828	chr10:32216031	ARHGAP12	0.41	5.21	0.47	1.11e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg18681998	chr4:17616180	MED28	0.97	9.8	0.71	4.41e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9905704	0.918	rs68139131	chr17:56717249	A/G	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.74e-6	Testicular germ cell tumor;
THYM	cis	rs2913737	0.563	rs2913900	chr5:175924367	A/T	cg27658698	chr5:175955578	RNF44	0.59	4.63	0.43	1.15e-5	Obesity-related traits;
THYM	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg14019146	chr3:50243930	SLC38A3	-0.56	-4.68	-0.43	9.51e-6	Body mass index;
THYM	cis	rs8041943	0.643	rs2902952	chr15:79909729	T/C	cg03800648	chr15:79044299	NA	-0.63	-4.5	-0.42	1.93e-5	Bone mineral density (spine) and age at menarche;
THYM	cis	rs35883536	0.647	rs1855630	chr1:101039979	C/G	cg09408571	chr1:101003634	GPR88	-0.48	-5.18	-0.47	1.24e-6	Monocyte count;
THYM	cis	rs9677476	0.818	rs6749936	chr2:232055684	C/T	cg20307347	chr2:231734563	ITM2C	-0.53	-4.47	-0.42	2.16e-5	Food antigen IgG levels;
THYM	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg13683864	chr3:40499215	RPL14	-1.02	-10.56	-0.73	1.06e-17	Renal cell carcinoma;
THYM	cis	rs11577318	0.528	rs11247935	chr1:26698622	G/C	cg19677267	chr1:26645161	CD52;UBXN11	0.51	5.62	0.5	1.88e-7	Granulocyte percentage of myeloid white cells;
THYM	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg17063962	chr7:91808500	NA	1.1	12.12	0.78	5.59e-21	Breast cancer;
THYM	cis	rs7193541	0.684	rs7191665	chr16:74688948	T/G	cg01733217	chr16:74700730	RFWD3	0.99	11.67	0.77	4.7e-20	Multiple myeloma;
THYM	cis	rs892961	0.932	rs11650011	chr17:75412334	A/G	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg13010199	chr12:38710504	ALG10B	-0.62	-5.41	-0.49	4.72e-7	Heart rate;
THYM	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg15247329	chr7:2764246	NA	-0.72	-6.01	-0.52	3.49e-8	Height;
THYM	cis	rs7084402	0.967	rs1649065	chr10:60306386	T/G	cg07615347	chr10:60278583	BICC1	0.56	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs12200560	0.505	rs59296768	chr6:97075535	C/T	cg06623918	chr6:96969491	KIAA0776	0.78	6.03	0.53	3.13e-8	Coronary heart disease;
THYM	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs9858542	0.537	rs67882627	chr3:49380441	A/T	cg00383909	chr3:49044727	WDR6	0.77	5.05	0.46	2.16e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs425277	1.000	rs436045	chr1:2071556	A/G	cg23803603	chr1:2058230	PRKCZ	-0.59	-4.56	-0.42	1.5e-5	Height;
THYM	cis	rs4664308	1.000	rs17831251	chr2:160914156	C/T	cg03641300	chr2:160917029	PLA2R1	-0.76	-6.89	-0.58	6.12e-10	Idiopathic membranous nephropathy;
THYM	cis	rs877282	0.838	rs11253374	chr10:774961	C/T	cg10556349	chr10:835070	NA	-0.79	-5.55	-0.49	2.62e-7	Uric acid levels;
THYM	cis	rs11690935	0.550	rs6730085	chr2:172864845	C/A	cg13550731	chr2:172543902	DYNC1I2	0.58	4.57	0.42	1.49e-5	Schizophrenia;
THYM	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg09455208	chr3:40491958	NA	0.46	4.85	0.45	4.87e-6	Renal cell carcinoma;
THYM	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg10117171	chr1:25599238	RHD	-0.75	-5.56	-0.5	2.44e-7	Erythrocyte sedimentation rate;
THYM	cis	rs9563576	0.778	rs9569791	chr13:58552308	A/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.67	0.43	9.99e-6	Obesity-related traits;
THYM	cis	rs8051149	0.688	rs12444670	chr16:87870312	C/T	cg08401758	chr16:87887443	SLC7A5	0.49	4.57	0.42	1.45e-5	Blood metabolite levels;
THYM	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg21784768	chr11:537496	LRRC56	-1.37	-6.17	-0.53	1.7e-8	Body mass index;
THYM	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.25	-4.91	-0.45	3.72e-6	Obesity-related traits;
THYM	cis	rs835154	1.000	rs835154	chr5:14876569	A/G	cg14843632	chr5:14870594	ANKH	-0.72	-7.23	-0.6	1.23e-10	Blood metabolite levels;
THYM	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg03433033	chr1:76189801	ACADM	-0.5	-5.29	-0.48	7.94e-7	Daytime sleep phenotypes;
THYM	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg22431228	chr1:16359049	CLCNKA	-0.57	-5.35	-0.48	5.97e-7	Systolic blood pressure;
THYM	cis	rs13315871	1.000	rs13076951	chr3:58436703	C/T	cg12435725	chr3:58293450	RPP14	-0.46	-4.93	-0.45	3.54e-6	Cholesterol, total;
THYM	cis	rs7551222	0.716	rs12041075	chr1:204492153	C/G	cg20240347	chr1:204465584	NA	-0.51	-4.54	-0.42	1.64e-5	Schizophrenia;
THYM	cis	rs17433780	0.504	rs6428494	chr1:89472196	C/T	cg09516651	chr1:89888402	LOC400759	0.7	5.41	0.49	4.64e-7	Carotid intima media thickness;
THYM	cis	rs3771570	1.000	rs17386555	chr2:242371825	G/A	cg21155796	chr2:242212141	HDLBP	1.25	6.04	0.53	2.95e-8	Prostate cancer;
THYM	cis	rs2688608	0.647	rs2461863	chr10:75680236	C/T	cg02947784	chr10:75434997	AGAP5	0.51	4.83	0.44	5.29e-6	Inflammatory bowel disease;
THYM	cis	rs4638749	0.677	rs12712017	chr2:108843556	C/T	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs75059851	1.000	rs73036062	chr11:133828187	G/A	cg14047540	chr11:133829660	NA	-1.15	-7.96	-0.63	3.61e-12	Schizophrenia;
THYM	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg18681998	chr4:17616180	MED28	-1.02	-9.82	-0.71	3.98e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg06850241	chr22:41845214	NA	0.53	4.72	0.44	8.08e-6	Vitiligo;
THYM	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	10.77	0.74	3.77e-18	Chronic sinus infection;
THYM	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg13695892	chr22:41940480	POLR3H	-0.96	-7.29	-0.6	8.97e-11	Vitiligo;
THYM	cis	rs2862064	0.872	rs2902132	chr5:156445525	C/T	cg12943317	chr5:156479607	HAVCR1	-0.86	-5.28	-0.48	8.3e-7	Platelet count;
THYM	trans	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17712092	chr4:129076599	LARP1B	0.92	7.66	0.62	1.56e-11	Eosinophil percentage of white cells;
THYM	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs34638657	0.797	rs7203990	chr16:82185320	A/G	cg09439754	chr16:82129088	HSD17B2	-0.61	-5.3	-0.48	7.58e-7	Lung adenocarcinoma;
THYM	cis	rs12142240	0.659	rs111723629	chr1:46853361	G/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg06238570	chr21:40685208	BRWD1	-0.96	-9.16	-0.68	1.02e-14	Cognitive function;
THYM	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg08736216	chr1:53307985	ZYG11A	-0.62	-5.47	-0.49	3.63e-7	Monocyte count;
THYM	cis	rs7187994	0.848	rs8044948	chr16:84749734	A/T	cg07647771	chr16:84786436	USP10	-0.53	-4.88	-0.45	4.22e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	trans	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg07393940	chr7:158741817	NA	1.11	8.12	0.64	1.69e-12	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs12369179	0.737	rs116896792	chr12:122948907	T/C	cg18578876	chr12:123200353	GPR109B	-1.3	-6.04	-0.53	3e-8	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
THYM	cis	rs12478296	1.000	rs56136197	chr2:243043877	T/C	cg06360820	chr2:242988706	NA	-0.91	-5.52	-0.49	2.97e-7	Obesity-related traits;
THYM	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg12483005	chr1:23474871	LUZP1	-0.57	-5.82	-0.51	7.79e-8	Height;
THYM	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg00757033	chr12:89920650	WDR51B	0.75	12.04	0.78	7.96e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7107174	0.901	rs11237487	chr11:78126754	G/C	cg19901956	chr11:77921274	USP35	-0.71	-5.4	-0.48	4.99e-7	Testicular germ cell tumor;
THYM	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg13736514	chr6:26305472	NA	-0.6	-7.33	-0.6	7.46e-11	Educational attainment;
THYM	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg05295671	chr13:79234353	RNF219	0.85	5.71	0.51	1.27e-7	Large artery stroke;
THYM	cis	rs868036	0.718	rs8025790	chr15:68076399	G/T	cg24579218	chr15:68104479	NA	-0.82	-9.12	-0.68	1.26e-14	Restless legs syndrome;
THYM	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg16926213	chr1:1841314	NA	0.55	5.8	0.51	8.77e-8	Body mass index;
THYM	cis	rs7107174	1.000	rs10899481	chr11:78058721	A/T	cg19901956	chr11:77921274	USP35	0.63	5.18	0.47	1.26e-6	Testicular germ cell tumor;
THYM	cis	rs7618501	0.521	rs7615206	chr3:49937505	T/C	cg14019146	chr3:50243930	SLC38A3	-0.61	-5.14	-0.47	1.45e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11651000	0.625	rs11079786	chr17:45805916	A/G	cg03474202	chr17:45855739	NA	0.68	5.75	0.51	1.09e-7	IgG glycosylation;
THYM	cis	rs4363385	0.818	rs532773	chr1:153011750	T/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.57	-0.42	1.47e-5	Inflammatory skin disease;
THYM	cis	rs6547741	1.000	rs6750943	chr2:27777904	T/G	cg27432699	chr2:27873401	GPN1	0.68	5.97	0.52	4.06e-8	Oral cavity cancer;
THYM	cis	rs2835345	0.563	rs4378885	chr21:37824911	G/T	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs4660261	0.526	rs2485997	chr1:44345841	G/C	cg13246856	chr1:44399776	ARTN	0.51	5.26	0.47	8.99e-7	Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg21394778	chr1:3037102	PRDM16	0.46	4.47	0.42	2.12e-5	Height;
THYM	cis	rs4792901	0.959	rs12603797	chr17:41630813	A/G	cg21940313	chr17:41620911	ETV4	-0.52	-5.51	-0.49	3.08e-7	Dupuytren's disease;
THYM	cis	rs3008870	1.000	rs3008848	chr1:67379284	C/T	cg02640540	chr1:67518911	SLC35D1	0.64	4.6	0.43	1.33e-5	Lymphocyte percentage of white cells;
THYM	cis	rs7106204	0.534	rs77470639	chr11:24250082	C/T	ch.11.24196551F	chr11:24239977	NA	0.96	4.95	0.45	3.18e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs711830	0.965	rs2072590	chr2:177042633	A/C	cg26754761	chr2:177040938	NA	-0.56	-4.89	-0.45	4.04e-6	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg26384229	chr12:38710491	ALG10B	0.98	7.51	0.61	3.24e-11	Morning vs. evening chronotype;
THYM	cis	rs12291225	0.679	rs11605531	chr11:14291594	A/G	cg05501817	chr11:14380813	RRAS2	-0.75	-5.72	-0.51	1.24e-7	Sense of smell;
THYM	cis	rs365132	1.000	rs2055619	chr5:176415964	A/G	cg17809377	chr5:176326619	HK3	-0.3	-4.55	-0.42	1.59e-5	Menarche and menopause (age at onset);Menopause (age at onset);
THYM	cis	rs7512552	0.809	rs828783	chr1:150376977	C/T	cg15654264	chr1:150340011	RPRD2	0.45	5.2	0.47	1.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.87	-6.47	-0.55	4.16e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17443541	0.507	rs4675719	chr2:200472364	C/T	cg01795955	chr2:200468626	NA	-0.71	-4.69	-0.43	9.29e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9549260	0.755	rs7328677	chr13:41229905	A/G	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg27170947	chr2:26402098	FAM59B	-0.8	-6.37	-0.55	6.74e-9	Gut microbiome composition (summer);
THYM	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg25358565	chr5:93447407	FAM172A	-0.87	-6.53	-0.56	3.27e-9	Diabetic retinopathy;
THYM	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg03676636	chr4:99064102	C4orf37	0.43	6.32	0.54	8.55e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg24675658	chr1:53192096	ZYG11B	-0.65	-5.24	-0.47	9.68e-7	Monocyte count;
THYM	cis	rs6032067	0.683	rs6032029	chr20:43786064	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.67	-7.93	-0.63	4.13e-12	Blood protein levels;
THYM	cis	rs17685	0.712	rs869805	chr7:75688596	C/T	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.56	-0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs11771526	0.901	rs10244622	chr7:32302960	C/T	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg26597838	chr10:835615	NA	0.85	5.15	0.47	1.38e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs17818399	0.926	rs1824050	chr2:46839477	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.63	4.59	0.43	1.37e-5	Height;
THYM	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg12386194	chr3:101231763	SENP7	0.94	7.31	0.6	8.41e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.49	-4.66	-0.43	1.03e-5	Crohn's disease;
THYM	cis	rs490234	0.783	rs28729336	chr9:128405488	T/G	cg14078157	chr9:128172775	NA	-0.66	-5.05	-0.46	2.12e-6	Mean arterial pressure;
THYM	cis	rs10489202	0.632	rs413168	chr1:168005789	C/G	cg24449463	chr1:168025552	DCAF6	-0.9	-9.11	-0.68	1.3e-14	Schizophrenia;
THYM	cis	rs10743315	0.778	rs965861	chr12:19360719	A/G	cg02471346	chr12:19282374	PLEKHA5	-0.81	-5.03	-0.46	2.28e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs1448094	0.511	rs17279338	chr12:86162874	G/A	cg02569458	chr12:86230093	RASSF9	0.69	5.77	0.51	9.84e-8	Major depressive disorder;
THYM	cis	rs9807841	0.568	rs1560708	chr19:10749236	T/C	cg16900796	chr19:10755136	SLC44A2	0.4	6.39	0.55	6.18e-9	Inflammatory skin disease;
THYM	cis	rs11608355	0.846	rs12581637	chr12:109855429	G/A	cg11367159	chr12:110044531	NA	0.6	5.17	0.47	1.31e-6	Neuroticism;
THYM	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2273669	0.588	rs2145767	chr6:109296185	C/T	cg17117243	chr6:109341365	SESN1	-0.86	-4.9	-0.45	3.88e-6	Prostate cancer;
THYM	cis	rs4378999	0.660	rs9825535	chr3:50772664	C/T	cg27233566	chr3:49894142	TRAIP	0.77	4.47	0.42	2.16e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs7771547	0.573	rs9470278	chr6:36399239	G/A	cg07856975	chr6:36356162	ETV7	-0.52	-4.72	-0.44	8.26e-6	Platelet distribution width;
THYM	cis	rs71403859	0.803	rs10500562	chr16:71627731	A/C	cg08717414	chr16:71523259	ZNF19	-1.12	-5.92	-0.52	5.02e-8	Post bronchodilator FEV1;
THYM	cis	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg12000587	chr17:30186630	C17orf79	0.5	7.03	0.59	3.11e-10	Hip circumference adjusted for BMI;
THYM	cis	rs7772486	0.754	rs6570708	chr6:145989428	C/T	cg23711669	chr6:146136114	FBXO30	-0.96	-10.16	-0.72	7.44e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4148689	0.951	rs1896888	chr7:117190598	T/C	cg17204129	chr7:117119601	CFTR	-0.57	-4.47	-0.42	2.2e-5	Gout;
THYM	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg07424592	chr7:64974309	NA	-0.99	-5.15	-0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg15445000	chr17:37608096	MED1	-0.44	-5.1	-0.46	1.73e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs4474465	0.915	rs12273367	chr11:78173835	A/T	cg19901956	chr11:77921274	USP35	-0.6	-4.55	-0.42	1.56e-5	Alzheimer's disease (survival time);
THYM	cis	rs67311347	0.544	rs7652439	chr3:40349948	G/T	cg13683864	chr3:40499215	RPL14	-0.78	-7.19	-0.59	1.44e-10	Renal cell carcinoma;
THYM	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg12386194	chr3:101231763	SENP7	0.66	5.0	0.46	2.59e-6	Colorectal cancer;
THYM	cis	rs3781426	0.924	rs4962724	chr10:126733319	A/G	cg04494136	chr10:126703576	CTBP2	-0.37	-5.0	-0.46	2.66e-6	Height;
THYM	cis	rs1728785	1.000	rs12918865	chr16:68566546	G/A	cg02972257	chr16:68554789	NA	-0.75	-4.57	-0.42	1.47e-5	Ulcerative colitis;
THYM	cis	rs514406	0.698	rs11206055	chr1:53436632	A/T	cg08859206	chr1:53392774	SCP2	0.77	9.38	0.69	3.55e-15	Monocyte count;
THYM	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg12573674	chr2:1569213	NA	-1.22	-4.82	-0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs4951011	0.882	rs6593945	chr1:203762306	C/T	cg24343524	chr1:203763352	ZC3H11A	0.65	5.78	0.51	9.32e-8	Breast cancer;
THYM	cis	rs1691799	0.899	rs1168358	chr12:66748664	A/G	cg16791601	chr12:66731901	HELB	-0.75	-7.08	-0.59	2.51e-10	White blood cell count (basophil);
THYM	cis	rs889398	0.771	rs1566454	chr16:69900083	C/T	cg09409435	chr16:70099608	PDXDC2	0.66	5.25	0.47	9.17e-7	Body mass index;
THYM	cis	rs6032067	0.759	rs118190342	chr20:43843130	A/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.37	-0.48	5.59e-7	Blood protein levels;
THYM	cis	rs7695732	0.572	rs1903007	chr4:89892072	G/A	cg17769793	chr4:89976368	FAM13A	-0.5	-5.57	-0.5	2.36e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs1691799	0.899	rs1168320	chr12:66744849	C/T	cg16791601	chr12:66731901	HELB	-0.75	-7.25	-0.6	1.08e-10	White blood cell count (basophil);
THYM	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg10803722	chr21:46713166	LOC642852	0.4	5.19	0.47	1.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9959145	1.000	rs1592641	chr18:12647240	A/G	cg14160804	chr18:12703040	PSMG2;CEP76	0.88	4.49	0.42	2e-5	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs7089973	0.872	rs60820172	chr10:116625891	C/T	cg23260525	chr10:116636907	FAM160B1	0.52	4.72	0.44	8.04e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg13147721	chr7:65941812	NA	-0.94	-5.74	-0.51	1.13e-7	Diabetic kidney disease;
THYM	cis	rs7551222	0.752	rs16853865	chr1:204465659	A/G	cg20240347	chr1:204465584	NA	-0.51	-4.54	-0.42	1.64e-5	Schizophrenia;
THYM	cis	rs12282928	1.000	rs10838858	chr11:48301755	C/T	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs11048434	0.736	rs12821842	chr12:9108984	G/A	cg13575925	chr12:9217583	LOC144571	0.52	4.97	0.45	2.96e-6	Sjögren's syndrome;
THYM	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg02018176	chr4:1364513	KIAA1530	0.58	4.57	0.42	1.46e-5	Obesity-related traits;
THYM	cis	rs7084402	0.967	rs1658490	chr10:60281616	G/A	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs79387448	0.701	rs11465584	chr2:102982629	G/A	cg09003973	chr2:102972529	NA	1.38	7.38	0.6	5.96e-11	Gut microbiota (bacterial taxa);
THYM	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.15	-0.47	1.4e-6	Total cholesterol levels;
THYM	cis	rs7809950	1.000	rs2057837	chr7:107222725	C/G	cg23024343	chr7:107201750	COG5	0.9	8.06	0.64	2.24e-12	Coronary artery disease;
THYM	cis	rs868036	0.681	rs4776375	chr15:68085555	G/A	cg24579218	chr15:68104479	NA	-0.82	-8.85	-0.67	4.77e-14	Restless legs syndrome;
THYM	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg26031613	chr14:104095156	KLC1	1.09	9.89	0.71	2.9e-16	Body mass index;
THYM	cis	rs1163251	0.902	rs639216	chr1:120217414	C/T	cg19096424	chr1:120255104	PHGDH	0.67	5.25	0.47	9.26e-7	Blood metabolite levels;
THYM	cis	rs7705042	0.828	rs11750521	chr5:141500704	T/C	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg26384229	chr12:38710491	ALG10B	-0.82	-8.17	-0.64	1.32e-12	Heart rate;
THYM	cis	rs4731207	0.596	rs10244797	chr7:124571684	C/T	cg05285228	chr7:124571219	POT1	-0.62	-4.65	-0.43	1.07e-5	Cutaneous malignant melanoma;
THYM	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg14196790	chr5:131705035	SLC22A5	0.59	5.62	0.5	1.94e-7	Blood metabolite levels;
THYM	cis	rs9943465	0.688	rs2449896	chr10:132066752	T/C	cg02700606	chr10:131763134	EBF3	0.7	4.48	0.42	2.09e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg06618935	chr21:46677482	NA	0.99	9.3	0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg00071950	chr4:10020882	SLC2A9	0.87	9.09	0.68	1.45e-14	Bone mineral density;
THYM	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg22920501	chr2:26401640	FAM59B	-1.05	-9.3	-0.69	5.07e-15	Gut microbiome composition (summer);
THYM	cis	rs2273669	0.915	rs6935782	chr6:109289881	A/G	cg17117243	chr6:109341365	SESN1	-0.78	-4.63	-0.43	1.14e-5	Prostate cancer;
THYM	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg06850241	chr22:41845214	NA	-0.54	-4.68	-0.43	9.37e-6	Vitiligo;
THYM	cis	rs7394190	0.630	rs4746150	chr10:75565935	A/G	cg07699608	chr10:75541558	CHCHD1	0.89	4.7	0.43	8.88e-6	Incident atrial fibrillation;
THYM	cis	rs1075232	1.000	rs16956838	chr15:31819695	C/G	cg01030201	chr15:31746330	NA	-1.17	-4.57	-0.42	1.45e-5	Survival in colorectal cancer (non-distant metastatic);
THYM	cis	rs7772486	0.597	rs9386136	chr6:146158300	A/T	cg23711669	chr6:146136114	FBXO30	0.85	7.99	0.63	3.12e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6570726	1.000	rs404229	chr6:145868200	G/A	cg23711669	chr6:146136114	FBXO30	0.83	8.07	0.64	2.16e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg08901578	chr4:187885870	NA	-0.63	-5.79	-0.51	8.9e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.81	-7.53	-0.61	2.96e-11	Personality dimensions;
THYM	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.71	-7.61	-0.62	1.99e-11	Prudent dietary pattern;
THYM	cis	rs614226	0.688	rs75111771	chr12:121009943	T/C	cg01236616	chr12:121019343	POP5	-1.28	-9.66	-0.7	8.63e-16	Type 1 diabetes nephropathy;
THYM	trans	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg10856724	chr12:34555212	NA	-0.8	-7.08	-0.59	2.49e-10	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg24642844	chr7:1081250	C7orf50	-1.29	-8.43	-0.65	3.79e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg06028808	chr11:68637592	NA	0.68	7.24	0.6	1.18e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs72848980	0.512	rs61151381	chr10:105370496	C/G	cg00126946	chr10:105363258	SH3PXD2A	0.52	4.77	0.44	6.71e-6	White matter hyperintensity burden;
THYM	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg20607798	chr8:58055168	NA	0.88	4.63	0.43	1.16e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14893161	chr1:205819251	PM20D1	-0.94	-10.23	-0.72	5.42e-17	Menarche (age at onset);
THYM	cis	rs7822232	0.908	rs56057523	chr8:145134153	G/C	cg12091641	chr8:145180933	NA	-1.02	-4.88	-0.45	4.35e-6	Blood metabolite levels;
THYM	cis	rs1691799	0.867	rs1168348	chr12:66757168	G/A	cg16791601	chr12:66731901	HELB	-0.73	-6.86	-0.58	6.96e-10	White blood cell count (basophil);
THYM	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg15997130	chr1:24165203	NA	0.78	7.14	0.59	1.88e-10	Immature fraction of reticulocytes;
THYM	cis	rs1003719	0.762	rs4399800	chr21:38489478	G/T	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg03929089	chr4:120376271	NA	-1.02	-12.29	-0.78	2.4e-21	Height;
THYM	cis	rs7084921	0.608	rs12779818	chr10:101866118	G/A	cg11344164	chr10:101878520	NA	-0.55	-4.74	-0.44	7.56e-6	Bone mineral density;
THYM	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs12579753	1.000	rs7975863	chr12:82227288	C/T	cg21231944	chr12:82153410	PPFIA2	-0.65	-4.83	-0.44	5.17e-6	Resting heart rate;
THYM	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg24846680	chr1:228362309	C1orf69	0.53	4.93	0.45	3.54e-6	Diastolic blood pressure;
THYM	cis	rs4631830	0.683	rs11004409	chr10:51498019	G/C	cg10326726	chr10:51549505	MSMB	0.53	5.15	0.47	1.38e-6	Prostate-specific antigen levels;
THYM	cis	rs1878931	0.535	rs7188903	chr16:3412861	A/G	cg22508957	chr16:3507546	NAT15	-0.49	-5.17	-0.47	1.28e-6	Body mass index (adult);
THYM	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.78	0.51	9.35e-8	Obesity-related traits;
THYM	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.08	8.84	0.67	4.98e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs56104184	0.723	rs73063522	chr19:49408358	C/G	cg17863274	chr19:49399704	TULP2	-1.02	-6.56	-0.56	2.8e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg17345569	chr6:42928274	GNMT	-0.46	-4.52	-0.42	1.77e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg14018140	chr10:458528	DIP2C	0.61	7.14	0.59	1.86e-10	Psychosis in Alzheimer's disease;
THYM	cis	rs6840360	0.967	rs7667197	chr4:152613952	G/A	cg22705602	chr4:152727874	NA	-0.6	-6.38	-0.55	6.53e-9	Intelligence (multi-trait analysis);
THYM	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg25319279	chr11:5960081	NA	0.53	4.45	0.42	2.31e-5	DNA methylation (variation);
THYM	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	5.92	0.52	5.15e-8	Total body bone mineral density;
THYM	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg15744005	chr10:104629667	AS3MT	-0.86	-8.65	-0.66	1.26e-13	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg23758822	chr17:41437982	NA	1.16	11.05	0.75	9.86e-19	Menopause (age at onset);
THYM	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg00576331	chr11:65640516	EFEMP2	0.68	4.58	0.43	1.42e-5	Crohn's disease;
THYM	cis	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg12193833	chr17:30244370	NA	-0.7	-4.82	-0.44	5.41e-6	Hip circumference adjusted for BMI;
THYM	cis	rs12472274	0.646	rs11677736	chr2:239087198	A/T	cg17459225	chr2:239074497	NA	0.74	5.17	0.47	1.3e-6	Phospholipid levels (plasma);
THYM	cis	rs9906944	1.000	rs9906944	chr17:47091420	C/T	cg09029085	chr17:47094198	IGF2BP1	0.45	6.45	0.55	4.74e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs1215050	0.740	rs783932	chr4:98973936	C/G	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg03806693	chr22:41940476	POLR3H	0.95	7.85	0.63	6.34e-12	Vitiligo;
THYM	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.87	-8.55	-0.66	2.03e-13	Lung cancer;
THYM	cis	rs800586	0.956	rs1065805	chr8:116803130	C/T	cg04656070	chr8:116661063	TRPS1	0.49	4.7	0.43	8.9e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs12282928	1.000	rs2870510	chr11:48321334	G/A	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.58	-0.43	1.4e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4662945	0.525	rs10174479	chr2:130296287	A/C	cg05903289	chr2:130345205	NA	-0.55	-5.1	-0.46	1.72e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs4930103	0.682	rs217714	chr11:2011512	C/T	cg18511798	chr11:2018149	H19;MIR675	-0.63	-6.25	-0.54	1.16e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11644478	chr21:40555479	PSMG1	-0.81	-7.24	-0.6	1.14e-10	Cognitive function;
THYM	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.1	7.58	0.61	2.26e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	7.13	0.59	1.97e-10	Prudent dietary pattern;
THYM	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.67	-4.49	-0.42	1.98e-5	Menarche (age at onset);
THYM	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg13147721	chr7:65941812	NA	0.73	4.58	0.43	1.42e-5	Diabetic kidney disease;
THYM	cis	rs7926906	0.817	rs7941948	chr11:90527549	C/T	cg26138821	chr11:89956704	CHORDC1	-0.51	-4.57	-0.42	1.48e-5	Intelligence (multi-trait analysis);
THYM	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Body mass index;
THYM	cis	rs1957429	0.808	rs1957428	chr14:65354058	T/C	cg23373153	chr14:65346875	NA	1.06	6.31	0.54	8.93e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs2273669	0.667	rs76201299	chr6:109344975	T/G	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-7.37	-0.6	6.27e-11	Chronic sinus infection;
THYM	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg15704280	chr7:45808275	SEPT13	1.01	8.51	0.66	2.52e-13	Coronary artery disease;
THYM	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg06600287	chr1:53387719	ECHDC2	-0.33	-5.12	-0.46	1.6e-6	Monocyte count;
THYM	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08109568	chr15:31115862	NA	-0.63	-5.99	-0.52	3.8e-8	Huntington's disease progression;
THYM	cis	rs2456568	0.741	rs9633811	chr11:93628327	A/G	cg26875233	chr11:93583750	C11orf90	0.54	5.84	0.51	7.11e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg17426766	chr1:2046864	PRKCZ	-0.41	-4.81	-0.44	5.67e-6	Height;
THYM	cis	rs10411161	0.702	rs10423835	chr19:52387322	A/G	cg25361850	chr19:52391789	ZNF577	0.73	5.09	0.46	1.84e-6	Breast cancer;
THYM	cis	rs78579285	0.545	rs113385327	chr16:88785242	A/C	cg00973732	chr16:88803885	FAM38A	-0.88	-4.56	-0.42	1.51e-5	Joint mobility (Beighton score);
THYM	cis	rs6430585	0.941	rs10496737	chr2:136540083	A/G	cg23851026	chr2:136556271	LCT	0.64	5.85	0.51	6.99e-8	Corneal structure;
THYM	cis	rs17122693	0.748	rs7159861	chr14:51144660	C/T	cg04730355	chr14:51134070	SAV1	-0.98	-6.05	-0.53	2.9e-8	Cognitive performance;
THYM	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs3772130	0.962	rs9812228	chr3:121495682	C/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs1113500	0.614	rs12565953	chr1:108607087	C/T	cg06207961	chr1:108661230	NA	0.69	5.03	0.46	2.27e-6	Growth-regulated protein alpha levels;
THYM	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg02018176	chr4:1364513	KIAA1530	0.53	4.46	0.42	2.27e-5	Obesity-related traits;
THYM	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg01073479	chr16:3509474	NAT15	-0.57	-5.34	-0.48	6.3e-7	Tuberculosis;
THYM	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg08132940	chr7:1081526	C7orf50	-1.26	-7.56	-0.61	2.5e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg20887711	chr4:1340912	KIAA1530	0.97	9.02	0.68	2.07e-14	Longevity;
THYM	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg02734326	chr4:10020555	SLC2A9	0.78	6.67	0.56	1.68e-9	Bone mineral density;
THYM	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg27394845	chr17:28928406	LRRC37B2	0.97	4.55	0.42	1.57e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg07131210	chr7:1025825	CYP2W1	-0.82	-4.61	-0.43	1.27e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7089973	0.872	rs36036948	chr10:116631649	A/G	cg23260525	chr10:116636907	FAM160B1	0.52	4.66	0.43	1.02e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7551222	0.752	rs2369244	chr1:204515299	C/G	cg20240347	chr1:204465584	NA	0.55	4.91	0.45	3.84e-6	Schizophrenia;
THYM	cis	rs6593803	0.622	rs11583679	chr1:147167893	A/G	cg06627043	chr1:147838662	NA	-0.47	-4.46	-0.42	2.23e-5	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
THYM	cis	rs12643440	0.538	rs10939707	chr4:17146776	G/T	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs654950	1.000	rs646228	chr1:41986066	A/C	cg06885757	chr1:42089581	HIVEP3	0.58	7.74	0.62	1.05e-11	Airway imaging phenotypes;
THYM	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg17279839	chr7:150038598	RARRES2	0.56	5.0	0.46	2.62e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg03709012	chr19:19516395	GATAD2A	-0.82	-6.79	-0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg26441486	chr22:50317300	CRELD2	0.45	6.37	0.55	6.76e-9	Schizophrenia;
THYM	cis	rs6570726	0.935	rs449377	chr6:145852437	C/G	cg23711669	chr6:146136114	FBXO30	0.9	9.4	0.69	3.15e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8013055	0.846	rs10139744	chr14:105974696	G/A	cg23356831	chr14:105996513	TMEM121	0.59	5.84	0.51	7.27e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg13695892	chr22:41940480	POLR3H	0.95	7.43	0.61	4.77e-11	Vitiligo;
THYM	cis	rs12282928	1.000	rs7481393	chr11:48302735	C/T	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs7705042	0.865	rs2338821	chr5:141509433	A/G	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs1065656	0.571	rs2745170	chr16:1835231	G/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	0.38	4.62	0.43	1.19e-5	Insulin-like growth factors;
THYM	cis	rs2456568	0.805	rs2032400	chr11:93676937	G/A	cg17595323	chr11:93583763	C11orf90	-0.54	-5.22	-0.47	1.04e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs42648	0.935	rs42621	chr7:89956484	A/G	cg25739043	chr7:89950458	NA	-0.56	-4.8	-0.44	5.82e-6	Homocysteine levels;
THYM	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg10802521	chr3:52805072	NEK4	-0.57	-4.87	-0.45	4.47e-6	Electroencephalogram traits;
THYM	cis	rs2747539	0.702	rs13043926	chr20:32420456	C/G	cg06304546	chr20:32448765	NA	-0.68	-4.76	-0.44	7.03e-6	Dysphagia;
THYM	cis	rs10411161	0.702	rs6509591	chr19:52391940	A/T	cg25361850	chr19:52391789	ZNF577	0.73	5.01	0.46	2.56e-6	Breast cancer;
THYM	cis	rs6541297	0.793	rs6692319	chr1:230284375	C/T	cg20703242	chr1:230279135	GALNT2	0.96	6.36	0.55	6.87e-9	Coronary artery disease;
THYM	cis	rs6750795	0.870	rs6754952	chr2:232381245	G/T	cg19187155	chr2:232395269	NMUR1	-0.97	-9.49	-0.7	2e-15	Height;
THYM	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg13319975	chr6:146136371	FBXO30	-0.65	-5.32	-0.48	7.02e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7078219	0.523	rs10883366	chr10:101287785	G/A	cg04972745	chr10:101287846	NA	-0.51	-4.84	-0.44	5.09e-6	Dental caries;
THYM	cis	rs11048434	0.736	rs35870866	chr12:9129091	C/A	cg26114124	chr12:9217669	LOC144571	0.46	4.57	0.42	1.44e-5	Sjögren's syndrome;
THYM	cis	rs295137	0.798	rs295142	chr2:201211716	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-5.02	-0.46	2.39e-6	Asthma (bronchodilator response);
THYM	cis	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg07460842	chr6:66804631	NA	0.92	5.5	0.49	3.15e-7	Exhaled nitric oxide levels;
THYM	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg18252515	chr7:66147081	NA	-0.61	-4.5	-0.42	1.9e-5	Aortic root size;
THYM	cis	rs17685	0.712	rs869805	chr7:75688596	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.1	-0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg17644776	chr2:200775616	C2orf69	-0.8	-4.82	-0.44	5.52e-6	Schizophrenia;
THYM	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg08975724	chr8:8085496	FLJ10661	-0.68	-5.43	-0.49	4.3e-7	Mood instability;
THYM	cis	rs6867032	1.000	rs4975794	chr5:2015330	A/G	cg26168224	chr5:2018326	NA	-1.29	-15.53	-0.85	8.25e-28	Gut microbiome composition (winter);
THYM	cis	rs6598955	0.671	rs7551557	chr1:26596614	G/A	cg08133631	chr1:26527909	CATSPER4	-0.57	-4.64	-0.43	1.1e-5	Obesity-related traits;
THYM	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg08901578	chr4:187885870	NA	-0.63	-5.88	-0.52	6.15e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10791323	0.604	rs2723615	chr11:133704567	C/T	cg06766960	chr11:133703094	NA	-0.57	-5.25	-0.47	9.26e-7	Childhood ear infection;
THYM	cis	rs60695258	0.550	rs388401	chr4:87974415	C/G	cg10685359	chr4:87814065	C4orf36	0.46	5.77	0.51	9.77e-8	Hematocrit;
THYM	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7246657	0.943	rs3745765	chr19:37854235	G/T	cg22634378	chr19:37742834	NA	0.65	5.34	0.48	6.2e-7	Coronary artery calcification;
THYM	cis	rs2932538	1.000	rs2932538	chr1:113216543	A/G	cg22162597	chr1:113214053	CAPZA1	-0.65	-5.08	-0.46	1.91e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg21361702	chr7:150065534	REPIN1	0.67	4.93	0.45	3.53e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg21658235	chr8:22456391	C8orf58	0.52	5.15	0.47	1.42e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	5.53	0.49	2.78e-7	Height;
THYM	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg11301795	chr4:187892539	NA	-1.11	-17.65	-0.88	9.45e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs868036	1.000	rs1471460	chr15:68089299	G/A	cg24579218	chr15:68104479	NA	-0.65	-6.51	-0.56	3.59e-9	Restless legs syndrome;
THYM	cis	rs1150668	0.799	rs853684	chr6:28294550	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.65	-5.06	-0.46	2.06e-6	Pubertal anthropometrics;
THYM	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg06636001	chr8:8085503	FLJ10661	0.72	6.31	0.54	8.75e-9	Mood instability;
THYM	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg25358565	chr5:93447407	FAM172A	0.98	7.16	0.59	1.71e-10	Diabetic retinopathy;
THYM	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.25	5.54	0.49	2.65e-7	Obesity-related traits;
THYM	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg01119278	chr6:110721349	DDO	-0.6	-6.57	-0.56	2.72e-9	Platelet distribution width;
THYM	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3096299	0.685	rs2911244	chr16:89521860	A/G	cg02187348	chr16:89574699	SPG7	0.74	6.15	0.53	1.86e-8	Multiple myeloma (IgH translocation);
THYM	cis	rs12220238	0.908	rs11000937	chr10:75998785	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.85	4.58	0.43	1.41e-5	Soluble interleukin-2 receptor subunit alpha;
THYM	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg23231163	chr10:75533350	FUT11	-0.44	-6.23	-0.54	1.29e-8	Inflammatory bowel disease;
THYM	cis	rs4713118	0.616	rs9348789	chr6:28025486	C/T	cg12963246	chr6:28129442	ZNF389	0.77	6.4	0.55	5.74e-9	Parkinson's disease;
THYM	cis	rs55728055	0.661	rs9619217	chr22:32043611	A/G	cg10537193	chr22:32026975	PISD	-0.61	-4.57	-0.42	1.47e-5	Age-related hearing impairment;
THYM	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.74	-5.75	-0.51	1.08e-7	Tonsillectomy;
THYM	cis	rs9677476	0.863	rs58067379	chr2:232088295	A/T	cg20307347	chr2:231734563	ITM2C	-0.51	-4.56	-0.42	1.54e-5	Food antigen IgG levels;
THYM	cis	rs7705502	0.780	rs111991836	chr5:173299577	A/C	cg18693985	chr5:173351052	CPEB4	-0.79	-5.72	-0.51	1.24e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs34779708	0.966	rs35146199	chr10:35460939	T/C	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg18132916	chr6:79620363	NA	-0.6	-5.35	-0.48	6.15e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10743315	0.557	rs74478800	chr12:19367517	A/T	cg02471346	chr12:19282374	PLEKHA5	1.09	4.55	0.42	1.58e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06634786	chr22:41940651	POLR3H	0.8	6.18	0.54	1.56e-8	Vitiligo;
THYM	cis	rs6598955	0.670	rs10794525	chr1:26537193	C/A	cg00852783	chr1:26633632	UBXN11	0.82	7.73	0.62	1.12e-11	Obesity-related traits;
THYM	cis	rs346785	0.551	rs347677	chr17:74274596	C/T	cg10318678	chr17:74308979	PRPSAP1	-0.5	-4.59	-0.43	1.34e-5	White matter hyperintensities in ischemic stroke;
THYM	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg02953382	chr22:24373134	LOC391322	-0.72	-5.22	-0.47	1.06e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-5.05	-0.46	2.12e-6	Lymphocyte counts;
THYM	cis	rs10886503	0.777	rs4751734	chr10:121264927	T/C	cg13260278	chr10:121265587	RGS10	-0.73	-6.55	-0.56	2.95e-9	Obstetric antiphospholipid syndrome;
THYM	cis	rs28595532	1.000	rs11931194	chr4:119631160	C/T	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	trans	rs1023500	1.000	rs3752591	chr22:42339516	A/G	cg07080231	chr15:101300217	NA	-0.84	-6.89	-0.58	6.06e-10	Schizophrenia;
THYM	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs9810089	0.934	rs1279949	chr3:135996870	T/A	cg12473912	chr3:136751656	NA	0.61	5.13	0.47	1.5e-6	Gestational age at birth (child effect);
THYM	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs478304	0.651	rs11227281	chr11:65496558	T/C	cg17480646	chr11:65405466	SIPA1	-0.94	-8.68	-0.67	1.07e-13	Acne (severe);
THYM	cis	rs2302729	0.578	rs2302728	chr12:2774668	A/C	cg19945202	chr12:2788847	CACNA1C	0.7	5.93	0.52	4.78e-8	Sleep quality;
THYM	cis	rs4242434	0.672	rs7830206	chr8:22485375	C/T	cg21658235	chr8:22456391	C8orf58	0.5	4.78	0.44	6.41e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7246967	0.673	rs3853650	chr19:22880490	A/G	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg04546413	chr19:29218101	NA	1.07	8.46	0.66	3.27e-13	Methadone dose in opioid dependence;
THYM	cis	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg07460842	chr6:66804631	NA	-0.96	-6.71	-0.57	1.42e-9	Exhaled nitric oxide output;
THYM	cis	rs9611519	0.964	rs5995992	chr22:41487218	T/C	cg06481639	chr22:41940642	POLR3H	-0.74	-5.42	-0.49	4.5e-7	Neuroticism;
THYM	cis	rs12594515	1.000	rs8039622	chr15:45986431	A/G	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs10186029	0.524	rs10932471	chr2:214009667	G/A	cg08319019	chr2:214017104	IKZF2	0.77	5.82	0.51	7.91e-8	Systemic sclerosis;
THYM	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs939658	0.935	rs12903747	chr15:79449627	A/C	cg17916960	chr15:79447300	NA	0.72	8.61	0.66	1.51e-13	Refractive error;
THYM	cis	rs295140	0.506	rs4673855	chr2:201136143	A/G	cg23649088	chr2:200775458	C2orf69	-0.66	-5.55	-0.49	2.56e-7	QT interval;
THYM	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg16558253	chr16:72132732	DHX38	-0.66	-5.88	-0.52	6.13e-8	Fibrinogen levels;
THYM	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06481639	chr22:41940642	POLR3H	0.87	5.95	0.52	4.49e-8	Vitiligo;
THYM	cis	rs7809950	0.954	rs2712193	chr7:107125885	A/C	cg23024343	chr7:107201750	COG5	-0.92	-8.21	-0.64	1.06e-12	Coronary artery disease;
THYM	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg01699819	chr7:1052092	C7orf50	-0.87	-7.92	-0.63	4.5e-12	Bronchopulmonary dysplasia;
THYM	cis	rs4595586	0.545	rs12812959	chr12:39371197	T/C	cg26384229	chr12:38710491	ALG10B	0.72	5.3	0.48	7.57e-7	Morning vs. evening chronotype;
THYM	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg13607699	chr17:42295918	UBTF	0.59	4.86	0.45	4.58e-6	Total body bone mineral density;
THYM	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg13010199	chr12:38710504	ALG10B	-0.6	-4.46	-0.42	2.29e-5	Bladder cancer;
THYM	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11890956	chr21:40555474	PSMG1	-1.11	-11.39	-0.76	1.81e-19	Cognitive function;
THYM	cis	rs9527	0.615	rs11191401	chr10:104573403	A/G	cg04362960	chr10:104952993	NT5C2	0.66	5.23	0.47	1.02e-6	Arsenic metabolism;
THYM	cis	rs8192282	0.739	rs4131514	chr1:154500089	A/G	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg02869364	chr7:1081709	C7orf50	-0.45	-5.03	-0.46	2.3e-6	Longevity;Endometriosis;
THYM	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03517284	chr6:25882590	NA	-0.74	-5.89	-0.52	5.89e-8	Blood metabolite levels;
THYM	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg15691649	chr6:25882328	NA	-0.64	-4.58	-0.43	1.41e-5	Intelligence (multi-trait analysis);
THYM	cis	rs11696845	0.626	rs4810439	chr20:43377870	C/G	cg25301532	chr20:43378953	KCNK15	-0.62	-5.08	-0.46	1.88e-6	Obesity-related traits;
THYM	cis	rs28595532	0.920	rs115838006	chr4:119754356	T/C	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.78	-5.09	-0.46	1.8e-6	Mean platelet volume;
THYM	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg11764359	chr7:65958608	NA	0.87	7.45	0.61	4.16e-11	Aortic root size;
THYM	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg05043794	chr9:111880884	C9orf5	-0.4	-6.12	-0.53	2.13e-8	Menarche (age at onset);
THYM	trans	rs12544026	0.515	rs579607	chr8:102870341	T/C	cg06633066	chr19:7735510	NA	-0.77	-6.87	-0.58	6.69e-10	Major depression and alcohol dependence;
THYM	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg23791538	chr6:167370224	RNASET2	-0.58	-4.53	-0.42	1.72e-5	Crohn's disease;
THYM	cis	rs7523273	0.568	rs61821293	chr1:208007277	T/G	cg22525895	chr1:207977042	MIR29B2	-0.77	-5.05	-0.46	2.09e-6	Schizophrenia;
THYM	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg25566285	chr7:158114605	PTPRN2	-0.88	-10.98	-0.75	1.37e-18	Calcium levels;
THYM	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22496380	chr5:211416	CCDC127	-1.37	-7.61	-0.62	1.95e-11	Breast cancer;
THYM	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg06965744	chr5:177196865	FAM153A	0.59	5.09	0.46	1.79e-6	Methadone dose in opioid dependence;
THYM	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.78	6.29	0.54	9.87e-9	Lymphocyte percentage of white cells;
THYM	cis	rs4866334	0.867	rs78519816	chr5:18463568	G/A	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg14186256	chr22:23484241	RTDR1	0.97	9.16	0.68	1.01e-14	Bone mineral density;
THYM	cis	rs9653442	0.866	rs11123811	chr2:100760172	T/C	cg22139774	chr2:100720529	AFF3	-0.35	-5.66	-0.5	1.57e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs2072499	0.966	rs2244144	chr1:156184598	G/A	cg06970220	chr1:156163860	SLC25A44	0.73	5.66	0.5	1.62e-7	Testicular germ cell tumor;
THYM	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs790123	0.692	rs790129	chr3:122385170	C/T	cg15604389	chr3:122379662	NA	-0.59	-4.86	-0.45	4.62e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs9467773	0.626	rs6936006	chr6:26350565	A/G	cg14345882	chr6:26364793	BTN3A2	0.36	4.85	0.45	4.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4974559	0.790	rs6850727	chr4:1323273	G/C	cg16185996	chr4:1008614	FGFRL1	-0.42	-4.5	-0.42	1.93e-5	Systolic blood pressure;
THYM	cis	rs1728785	0.688	rs698729	chr16:68624205	G/C	cg02972257	chr16:68554789	NA	-0.71	-4.59	-0.43	1.37e-5	Ulcerative colitis;
THYM	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22590775	chr19:49891494	CCDC155	0.63	4.8	0.44	5.89e-6	Multiple sclerosis;
THYM	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs728616	0.867	rs12413715	chr10:81687360	G/T	cg27452691	chr10:81370291	SFTPA1	0.85	4.55	0.42	1.61e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg13147721	chr7:65941812	NA	-0.94	-5.74	-0.51	1.13e-7	Diabetic kidney disease;
THYM	cis	rs259282	0.605	rs3760939	chr19:33106911	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.6	5.04	0.46	2.2e-6	Schizophrenia;
THYM	cis	rs67981189	0.752	rs2332477	chr14:71403311	T/C	cg15910301	chr14:71632612	NA	-0.5	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	cis	rs9653442	0.835	rs11885529	chr2:100746935	A/G	cg07810366	chr2:100720526	AFF3	-0.45	-6.79	-0.57	9.8e-10	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg15693483	chr7:1102177	C7orf50	0.54	6.29	0.54	9.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs293526	0.959	rs293529	chr6:83646411	T/A	cg23278060	chr6:83777448	DOPEY1	0.61	4.49	0.42	2.02e-5	Crohn's disease;
THYM	cis	rs9581943	0.967	rs9554197	chr13:28476978	C/T	cg16302790	chr13:28498334	PDX1	0.52	4.73	0.44	7.69e-6	Pancreatic cancer;
THYM	cis	rs12532960	0.749	rs73691818	chr7:42364963	C/T	cg23473276	chr7:42834405	NA	0.87	4.77	0.44	6.71e-6	Inflammatory biomarkers;
THYM	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-11.56	-0.76	8.27e-20	Height;
THYM	cis	rs2806561	0.929	rs6660880	chr1:23540302	T/C	cg08872493	chr1:23521417	HTR1D	-0.37	-4.61	-0.43	1.27e-5	Height;
THYM	cis	rs4919694	1.000	rs17727391	chr10:104836101	C/A	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs11585357	0.895	rs4625336	chr1:17630964	G/T	cg08277548	chr1:17600880	PADI3	-0.81	-5.02	-0.46	2.4e-6	Hair shape;
THYM	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg10295955	chr4:187884368	NA	-1.19	-17.25	-0.87	5.06e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10929159	0.964	rs3754659	chr2:236950634	C/T	cg20128773	chr2:236923534	AGAP1	-0.35	-4.61	-0.43	1.24e-5	Parkinson's disease;
THYM	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg03188948	chr7:1209495	NA	0.68	4.69	0.43	9.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg00290607	chr11:67383545	NA	-0.71	-4.9	-0.45	3.88e-6	Mean corpuscular volume;
THYM	cis	rs10992471	0.603	rs10820974	chr9:95211876	T/C	cg14631576	chr9:95140430	CENPP	-0.84	-8.02	-0.64	2.69e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg10295955	chr4:187884368	NA	-1.22	-17.54	-0.87	1.51e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1113500	0.897	rs55980437	chr1:108639498	G/A	cg06207961	chr1:108661230	NA	0.64	5.09	0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg26384229	chr12:38710491	ALG10B	-0.96	-7.77	-0.62	8.98e-12	Bladder cancer;
THYM	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg13397359	chr6:42928475	GNMT	-0.61	-5.49	-0.49	3.39e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg13695892	chr22:41940480	POLR3H	-0.91	-6.72	-0.57	1.34e-9	Vitiligo;
THYM	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg23188684	chr11:67383651	NA	0.68	5.99	0.52	3.7e-8	Mean corpuscular volume;
THYM	cis	rs9796	0.689	rs11855797	chr15:41434679	C/T	cg21153102	chr15:41252147	NA	0.6	4.93	0.45	3.43e-6	Menopause (age at onset);
THYM	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg16586182	chr3:47516702	SCAP	0.64	5.62	0.5	1.93e-7	Colorectal cancer;
THYM	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg18681998	chr4:17616180	MED28	0.79	6.79	0.57	9.51e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.67	-0.62	1.5e-11	Personality dimensions;
THYM	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg02527881	chr3:46936655	PTH1R	-0.62	-5.89	-0.52	5.9e-8	Colorectal cancer;
THYM	cis	rs79387448	0.638	rs6741230	chr2:103069631	C/T	cg09003973	chr2:102972529	NA	1.24	7.3	0.6	8.69e-11	Gut microbiota (bacterial taxa);
THYM	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs7772486	0.754	rs9386134	chr6:146145508	G/A	cg23711669	chr6:146136114	FBXO30	0.98	10.58	0.74	9.59e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	trans	rs7618501	1.000	rs2247036	chr3:49882349	C/T	cg21659725	chr3:3221576	CRBN	0.88	9.57	0.7	1.35e-15	Intelligence (multi-trait analysis);
THYM	cis	rs600806	0.815	rs10858088	chr1:109923586	C/T	cg02175308	chr1:109941060	SORT1	-0.6	-5.3	-0.48	7.58e-7	Intelligence (multi-trait analysis);
THYM	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg23281280	chr6:28129359	ZNF389	0.66	5.09	0.46	1.78e-6	Depression;
THYM	trans	rs9951602	0.512	rs73494176	chr18:76644895	T/C	cg02800362	chr5:177631904	HNRNPAB	1.12	8.77	0.67	6.87e-14	Obesity-related traits;
THYM	cis	rs6473252	0.584	rs12542283	chr8:81820942	A/G	cg08595989	chr8:81827712	NA	-0.5	-5.44	-0.49	4.12e-7	Breast cancer;
THYM	cis	rs911119	1.000	rs6036476	chr20:23610308	C/G	cg16589663	chr20:23618590	CST3	0.77	4.71	0.44	8.31e-6	Chronic kidney disease;
THYM	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg24257776	chr3:47051546	LOC100129354	0.41	4.73	0.44	7.73e-6	Colorectal cancer;
THYM	cis	rs8180040	0.903	rs2276854	chr3:47276968	C/T	cg27129171	chr3:47204927	SETD2	0.75	7.27	0.6	9.95e-11	Colorectal cancer;
THYM	cis	rs28595532	0.920	rs56227053	chr4:119772460	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs2811415	0.597	rs9820563	chr3:127780871	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs56104184	0.830	rs28556985	chr19:49351149	C/T	cg17863274	chr19:49399704	TULP2	-0.8	-4.46	-0.42	2.22e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg13609457	chr4:120235615	NA	0.65	5.14	0.47	1.45e-6	Corneal astigmatism;
THYM	cis	rs7412746	0.553	rs59337856	chr1:150746406	G/T	cg10589385	chr1:150898437	SETDB1	0.64	5.25	0.47	9.11e-7	Melanoma;
THYM	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg26031613	chr14:104095156	KLC1	1.2	12.48	0.79	9.64e-22	Body mass index;
THYM	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg00717180	chr2:96193071	NA	-0.65	-6.88	-0.58	6.46e-10	Height;
THYM	cis	rs6987853	0.583	rs2974311	chr8:42455166	G/A	cg09913449	chr8:42400586	C8orf40	0.64	5.63	0.5	1.82e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg05738196	chr6:26577821	NA	0.84	8.48	0.66	2.87e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg02887458	chr19:19495540	GATAD2A	-0.44	-5.19	-0.47	1.17e-6	Bipolar disorder;
THYM	cis	rs7582180	0.663	rs4850930	chr2:100990955	T/C	cg21926883	chr2:100939477	LONRF2	-0.65	-6.1	-0.53	2.25e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg13446199	chr8:143762866	PSCA	-0.41	-4.53	-0.42	1.7e-5	Urinary tract infection frequency;
THYM	cis	rs67460515	0.563	rs11922959	chr3:160828871	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-4.7	-0.43	8.93e-6	Parkinson's disease;
THYM	cis	rs4888262	0.508	rs4887779	chr16:74647795	A/G	cg01733217	chr16:74700730	RFWD3	-0.78	-7.86	-0.63	5.93e-12	Testicular germ cell tumor;
THYM	cis	rs10870270	0.917	rs11146417	chr10:133791034	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.83	-5.81	-0.51	8.14e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.53	0.56	3.27e-9	Total body bone mineral density;
THYM	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg06618935	chr21:46677482	NA	0.92	6.72	0.57	1.33e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7940866	0.903	rs1820353	chr11:130870765	A/G	cg23692386	chr11:131799662	NTM	0.43	4.69	0.43	9.27e-6	Schizophrenia;
THYM	cis	rs10089	0.953	rs3805615	chr5:127519049	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.93	6.03	0.53	3.15e-8	Ileal carcinoids;
THYM	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs6500395	1.000	rs11076578	chr16:48714520	C/G	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.94	6.5	0.55	3.77e-9	Schizophrenia;
THYM	cis	rs7010267	0.744	rs2062377	chr8:120007420	T/A	cg17171407	chr8:119960777	TNFRSF11B	0.58	4.7	0.43	8.71e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg27129171	chr3:47204927	SETD2	0.73	5.33	0.48	6.62e-7	Birth weight;
THYM	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.76	0.44	7.04e-6	Bipolar disorder;
THYM	cis	rs11048434	0.736	rs1476911	chr12:9090859	C/T	cg13575925	chr12:9217583	LOC144571	0.53	4.94	0.45	3.31e-6	Sjögren's syndrome;
THYM	cis	rs4363385	0.667	rs454186	chr1:153049149	C/T	cg13444842	chr1:152974279	SPRR3	-0.61	-5.02	-0.46	2.45e-6	Inflammatory skin disease;
THYM	cis	rs17744026	0.586	rs75444328	chr11:123720105	T/C	cg00079598	chr11:123676903	OR6M1	-0.48	-4.49	-0.42	1.98e-5	IgE levels in asthmatics (D.p. specific);
THYM	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg03929089	chr4:120376271	NA	0.97	10.35	0.73	2.89e-17	Coronary artery disease;
THYM	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs11190604	0.666	rs7084768	chr10:102200497	T/C	cg16342193	chr10:102329863	NA	0.49	4.98	0.46	2.81e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs28595532	0.920	rs116305850	chr4:119779892	A/G	cg11846333	chr4:119757529	SEC24D	1.36	4.83	0.44	5.31e-6	Cannabis dependence symptom count;
THYM	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg01751800	chr4:77820391	ANKRD56	0.55	4.59	0.43	1.36e-5	Emphysema distribution in smoking;
THYM	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg07936489	chr17:37558343	FBXL20	0.86	6.01	0.52	3.4e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs2562456	0.793	rs2562474	chr19:21646282	A/C	cg21751540	chr19:21541537	ZNF738	0.72	4.7	0.43	8.88e-6	Pain;
THYM	cis	rs28595532	0.841	rs114768988	chr4:119744451	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs912057	0.632	rs1294432	chr6:6745027	C/T	cg13809441	chr6:6737631	NA	0.44	5.32	0.48	6.97e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs17253792	0.731	rs74829671	chr14:56112759	G/C	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg22753661	chr15:79092743	ADAMTS7	-0.78	-5.35	-0.48	6.1e-7	Diastolic blood pressure;
THYM	cis	rs2296887	0.841	rs7913281	chr10:104010142	A/G	cg26089160	chr10:104170217	PSD	-0.62	-4.66	-0.43	1.01e-5	Parkinson's disease;
THYM	cis	rs919433	0.680	rs788023	chr2:198283305	T/C	cg05783139	chr2:198650985	BOLL	0.63	4.93	0.45	3.48e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9814567	0.752	rs9846111	chr3:134335034	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.57	-0.61	2.38e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2139634	0.965	rs11719033	chr3:46529063	G/C	cg02332537	chr3:46540019	RTP3	0.45	4.61	0.43	1.26e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg22974920	chr21:40686053	BRWD1	-0.57	-4.48	-0.42	2.04e-5	Cognitive function;
THYM	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg24006582	chr15:45444508	DUOX1	0.77	6.04	0.53	3.05e-8	Uric acid levels;
THYM	cis	rs4076764	0.914	rs7536270	chr1:163377379	T/C	cg24596788	chr1:163392923	NA	-0.8	-7.45	-0.61	4.17e-11	Motion sickness;
THYM	cis	rs6840360	0.901	rs1561915	chr4:152479724	G/A	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.53	-0.49	2.76e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg13443165	chr9:33130375	B4GALT1	-0.87	-7.99	-0.63	3.23e-12	IgG glycosylation;
THYM	cis	rs4246215	1	rs4246215	chr11:61564299	G/T	cg19610905	chr11:61596333	FADS2	-0.61	-5.31	-0.48	7.16e-7	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);Platelet count;Inflammatory bowel disease;Trans fatty acid levels;Crohn's disease;Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);Red blood cell fatty acid levels;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
THYM	cis	rs7084402	1.000	rs7095501	chr10:60271940	T/C	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs7809950	0.817	rs2712230	chr7:107294151	G/A	cg23024343	chr7:107201750	COG5	0.83	6.74	0.57	1.19e-9	Coronary artery disease;
THYM	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg01579765	chr21:45077557	HSF2BP	0.52	8.63	0.66	1.38e-13	Mean corpuscular volume;
THYM	cis	rs1007190	0.881	rs11079378	chr17:42957462	A/G	cg15406952	chr17:42872593	NA	0.8	5.57	0.5	2.34e-7	DNA methylation (variation);
THYM	cis	rs17125944	0.686	rs73304351	chr14:53375140	G/A	cg00686598	chr14:53173677	PSMC6	1.1	4.92	0.45	3.69e-6	Alzheimer's disease (late onset);
THYM	cis	rs7578361	0.851	rs4500908	chr2:150427516	C/T	cg17961725	chr2:150454027	NA	0.71	6.03	0.53	3.1e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs137603	0.966	rs137616	chr22:39703883	A/G	cg24268161	chr22:39747459	SYNGR1	0.54	4.76	0.44	7.04e-6	Primary biliary cholangitis;
THYM	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg11663144	chr21:46675770	NA	-0.68	-7.92	-0.63	4.48e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs7264396	0.563	rs2425084	chr20:34301871	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.75	-0.44	7.2e-6	Total cholesterol levels;
THYM	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg02782426	chr3:40428986	ENTPD3	-0.51	-4.54	-0.42	1.67e-5	Renal cell carcinoma;
THYM	cis	rs6975557	0.922	rs7807783	chr7:107979091	G/T	cg23543795	chr7:107965081	NRCAM	-0.63	-5.69	-0.5	1.42e-7	Femoral neck bone geometry and menarche (age at onset);
THYM	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg11673840	chr17:47092156	IGF2BP1	-0.61	-7.87	-0.63	5.52e-12	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2549003	0.811	rs10035166	chr5:131823927	C/T	cg21138405	chr5:131827807	IRF1	-0.73	-5.3	-0.48	7.59e-7	Asthma (sex interaction);
THYM	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg18230493	chr5:56204884	C5orf35	-0.89	-6.53	-0.56	3.25e-9	Initial pursuit acceleration;
THYM	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg00129232	chr17:37814104	STARD3	0.76	5.25	0.47	9.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs977987	0.843	rs10514396	chr16:75422903	T/C	cg03315344	chr16:75512273	CHST6	0.73	6.29	0.54	9.83e-9	Dupuytren's disease;
THYM	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg18105134	chr13:113819100	PROZ	-0.98	-9.0	-0.68	2.28e-14	Platelet distribution width;
THYM	cis	rs6032067	0.538	rs13041506	chr20:43739655	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.54	-4.74	-0.44	7.44e-6	Blood protein levels;
THYM	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg14433983	chr11:636460	DRD4	-0.67	-4.53	-0.42	1.74e-5	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg13397359	chr6:42928475	GNMT	0.61	5.44	0.49	4.07e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg17063962	chr7:91808500	NA	1.08	11.35	0.76	2.25e-19	Breast cancer;
THYM	cis	rs3771570	0.892	rs59715783	chr2:242366262	C/T	cg21155796	chr2:242212141	HDLBP	1.25	6.07	0.53	2.57e-8	Prostate cancer;
THYM	cis	rs9361491	0.608	rs1588087	chr6:79475917	A/T	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.88e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg02475374	chr8:10988117	XKR6	0.63	4.73	0.44	7.78e-6	Triglycerides;
THYM	cis	rs807669	0.903	rs807667	chr22:19161327	A/G	cg02655711	chr22:19163373	SLC25A1	-0.98	-11.86	-0.77	1.93e-20	Metabolite levels;
THYM	cis	rs2811415	0.597	rs9839092	chr3:127742108	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs4343996	0.536	rs10228046	chr7:3414735	G/A	cg21248987	chr7:3385318	SDK1	0.4	4.91	0.45	3.72e-6	Motion sickness;
THYM	cis	rs9807841	0.592	rs1053007	chr19:10754400	A/G	cg17848348	chr19:10766748	ILF3	-0.74	-6.11	-0.53	2.14e-8	Inflammatory skin disease;
THYM	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs9326248	0.559	rs12808524	chr11:116890993	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.67	5.34	0.48	6.36e-7	Blood protein levels;
THYM	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg17554472	chr22:41940697	POLR3H	0.7	4.97	0.45	2.97e-6	Vitiligo;
THYM	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg12386194	chr3:101231763	SENP7	0.65	4.91	0.45	3.75e-6	Colorectal cancer;
THYM	cis	rs8067545	1.000	rs4925065	chr17:19914546	C/T	cg13482628	chr17:19912719	NA	0.57	4.8	0.44	5.98e-6	Schizophrenia;
THYM	cis	rs4243830	0.850	rs7552196	chr1:6590502	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.08	-7.12	-0.59	2.02e-10	Body mass index;
THYM	cis	rs8112449	0.822	rs4804133	chr19:10550932	T/A	cg01466491	chr19:10523363	NA	-0.62	-5.9	-0.52	5.56e-8	Multiple sclerosis;Gastritis;
THYM	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg15704280	chr7:45808275	SEPT13	-0.98	-11.44	-0.76	1.43e-19	Coronary artery disease;
THYM	cis	rs5995756	0.666	rs3788566	chr22:40006024	G/T	cg21377881	chr22:40064566	CACNA1I	-0.56	-4.74	-0.44	7.47e-6	Autism spectrum disorder or schizophrenia;
THYM	trans	rs4262150	0.883	rs72802887	chr5:152249082	A/G	cg08281791	chr5:76607845	PDE8B	0.93	6.87	0.58	6.5e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg10523679	chr1:76189770	ACADM	0.92	10.35	0.73	2.94e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg00898013	chr13:113819073	PROZ	0.83	8.57	0.66	1.86e-13	Platelet distribution width;
THYM	cis	rs10206020	0.921	rs4072986	chr2:1547734	C/G	cg12573674	chr2:1569213	NA	-1.35	-8.52	-0.66	2.42e-13	IgG glycosylation;
THYM	cis	rs7193541	0.684	rs9923145	chr16:74686166	G/A	cg01733217	chr16:74700730	RFWD3	0.99	11.69	0.77	4.4e-20	Multiple myeloma;
THYM	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg02018176	chr4:1364513	KIAA1530	-0.81	-7.68	-0.62	1.41e-11	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg10515332	chr4:99064459	C4orf37	0.61	5.02	0.46	2.46e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg17328964	chr8:145687451	CYHR1	-0.68	-6.08	-0.53	2.52e-8	Age at first birth;
THYM	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg14416269	chr4:6271139	WFS1	0.55	5.69	0.5	1.41e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg21475434	chr5:93447410	FAM172A	0.95	6.03	0.53	3.16e-8	Diabetic retinopathy;
THYM	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg07511668	chr11:68622177	NA	0.43	4.56	0.42	1.52e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6430585	0.697	rs7607174	chr2:136513670	T/A	cg04750100	chr2:136595281	LCT	0.53	4.86	0.45	4.59e-6	Corneal structure;
THYM	cis	rs1728785	0.901	rs11642189	chr16:68583990	G/A	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg19077165	chr18:44547161	KATNAL2	-0.6	-7.62	-0.62	1.87e-11	Personality dimensions;
THYM	cis	rs669446	0.561	rs516790	chr1:44081712	G/T	cg00143623	chr1:44495758	SLC6A9	-0.6	-4.65	-0.43	1.07e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg24375607	chr4:120327624	NA	-0.68	-5.44	-0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg18252515	chr7:66147081	NA	0.6	4.52	0.42	1.76e-5	Aortic root size;
THYM	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg06789500	chr7:2109450	MAD1L1	-0.65	-4.46	-0.42	2.24e-5	Bipolar disorder;
THYM	cis	rs9914544	1.000	rs9916245	chr17:18766825	C/G	cg26378065	chr17:18585709	ZNF286B	0.61	5.02	0.46	2.38e-6	Educational attainment (years of education);
THYM	cis	rs1371867	0.875	rs1788176	chr8:101332112	A/G	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs1728785	0.892	rs1170427	chr16:68603852	G/T	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.39e-6	Ulcerative colitis;
THYM	cis	rs2806561	0.929	rs6694445	chr1:23540428	A/G	cg08872493	chr1:23521417	HTR1D	0.37	4.61	0.43	1.27e-5	Height;
THYM	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg15556689	chr8:8085844	FLJ10661	0.57	4.62	0.43	1.23e-5	Mood instability;
THYM	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08109568	chr15:31115862	NA	-0.78	-6.95	-0.58	4.56e-10	Huntington's disease progression;
THYM	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.38	0.55	6.27e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg17063962	chr7:91808500	NA	1.16	13.12	0.8	4.77e-23	Breast cancer;
THYM	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg03582285	chr17:40700314	NA	-0.66	-6.64	-0.56	1.97e-9	Colorectal or endometrial cancer;
THYM	cis	rs9677476	0.818	rs9973675	chr2:232095484	G/A	cg23338755	chr2:231921595	PSMD1	0.69	4.94	0.45	3.31e-6	Food antigen IgG levels;
THYM	cis	rs4072705	0.967	rs10217141	chr9:127403935	C/T	cg13476313	chr9:127244764	NR5A1	0.31	4.88	0.45	4.28e-6	Menarche (age at onset);
THYM	cis	rs6754311	0.608	rs3739020	chr2:136602491	T/G	cg04750100	chr2:136595281	LCT	0.52	5.29	0.48	7.9e-7	Mosquito bite size;
THYM	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.72	0.51	1.23e-7	Lung cancer in ever smokers;
THYM	cis	rs346785	0.666	rs379503	chr17:74308358	A/C	cg04798684	chr17:74309056	PRPSAP1	-0.51	-4.59	-0.43	1.33e-5	White matter hyperintensities in ischemic stroke;
THYM	cis	rs6121246	0.559	rs6060922	chr20:30333909	C/T	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9311676	0.656	rs55692656	chr3:58383174	A/T	cg26110898	chr3:58419937	PDHB	0.44	4.85	0.45	4.74e-6	Systemic lupus erythematosus;
THYM	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.8	-0.51	8.64e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg14784868	chr12:69753453	YEATS4	0.9	7.77	0.62	9.35e-12	Response to diuretic therapy;
THYM	cis	rs6921919	0.583	rs6907950	chr6:28370246	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.5	-0.42	1.89e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg20295408	chr7:1910781	MAD1L1	-0.62	-4.45	-0.42	2.36e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs2133450	0.526	rs12492754	chr3:7346656	A/G	cg19930620	chr3:7340148	GRM7	-0.51	-5.42	-0.49	4.58e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs988913	0.706	rs13208701	chr6:54880468	T/A	cg18532076	chr6:54711417	FAM83B	0.5	4.65	0.43	1.08e-5	Menarche (age at onset);
THYM	cis	rs28595532	0.920	rs116717907	chr4:119762568	A/G	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg03735888	chr19:58951602	ZNF132	0.78	6.61	0.56	2.22e-9	Mean platelet volume;
THYM	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg24209194	chr3:40518798	ZNF619	0.65	5.32	0.48	6.75e-7	Renal cell carcinoma;
THYM	cis	rs1461503	0.934	rs7107560	chr11:122845380	T/C	cg27398637	chr11:122830231	C11orf63	-0.71	-6.64	-0.56	1.97e-9	Menarche (age at onset);
THYM	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg04362960	chr10:104952993	NT5C2	0.58	4.66	0.43	1.04e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg05368731	chr17:41323189	NBR1	1.25	11.51	0.76	1.04e-19	Menopause (age at onset);
THYM	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg07648498	chr16:89883185	FANCA	0.66	4.89	0.45	4.06e-6	Vitiligo;
THYM	cis	rs36051895	0.659	rs7025540	chr9:5043152	T/C	cg02405213	chr9:5042618	JAK2	-1.06	-11.14	-0.75	6.33e-19	Pediatric autoimmune diseases;
THYM	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg00376283	chr12:123451042	ABCB9	0.86	6.89	0.58	6.19e-10	Platelet count;
THYM	cis	rs10979	0.931	rs9484771	chr6:143896897	T/A	cg25407410	chr6:143891975	LOC285740	-0.59	-4.95	-0.45	3.15e-6	Hypospadias;
THYM	cis	rs11690935	1.000	rs11678984	chr2:172535848	T/G	cg13550731	chr2:172543902	DYNC1I2	0.87	6.48	0.55	4.04e-9	Schizophrenia;
THYM	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs990171	1.000	rs990171	chr2:103086770	A/C	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.1	-0.46	1.74e-6	Lymphocyte counts;
THYM	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg16797656	chr11:68205561	LRP5	0.46	4.96	0.45	3.09e-6	Total body bone mineral density;
THYM	cis	rs2439831	0.681	rs28653441	chr15:43677262	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.68	4.7	0.43	8.71e-6	Lung cancer in ever smokers;
THYM	cis	rs595982	0.517	rs4801779	chr19:49406651	T/G	cg19746536	chr19:49375674	PPP1R15A	0.99	9.63	0.7	1.03e-15	Red cell distribution width;
THYM	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.74	-0.67	7.93e-14	Mean corpuscular volume;
THYM	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg13010199	chr12:38710504	ALG10B	-0.72	-5.86	-0.52	6.64e-8	Heart rate;
THYM	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg01699819	chr7:1052092	C7orf50	-0.6	-5.02	-0.46	2.43e-6	Bronchopulmonary dysplasia;
THYM	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg23649088	chr2:200775458	C2orf69	-0.75	-5.65	-0.5	1.64e-7	Schizophrenia;
THYM	cis	rs1691799	0.867	rs1168339	chr12:66759236	T/G	cg16791601	chr12:66731901	HELB	-0.72	-6.82	-0.57	8.35e-10	White blood cell count (basophil);
THYM	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	5.07	0.46	1.92e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg19077165	chr18:44547161	KATNAL2	-0.62	-7.82	-0.63	7.04e-12	Personality dimensions;
THYM	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02018176	chr4:1364513	KIAA1530	-0.92	-8.94	-0.68	3.06e-14	Longevity;
THYM	cis	rs3733631	1.000	rs10014175	chr4:104659515	T/A	cg24090629	chr4:104641072	TACR3	-0.83	-5.14	-0.47	1.44e-6	Menarche (age at onset);
THYM	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.77	0.51	1.01e-7	Rheumatoid arthritis;
THYM	cis	rs12530845	0.623	rs73721681	chr7:135361917	A/G	cg19897172	chr7:135347071	PL-5283	-0.66	-5.51	-0.49	3.11e-7	Red blood cell traits;
THYM	cis	rs56775891	1.000	rs6650631	chr18:77566535	G/C	cg25357022	chr18:77495084	CTDP1	-0.65	-4.61	-0.43	1.25e-5	Schizophrenia;
THYM	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.58	4.95	0.45	3.25e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6087990	1.000	rs6087990	chr20:31349908	T/C	cg13636640	chr20:31349939	DNMT3B	0.97	11.49	0.76	1.14e-19	Ulcerative colitis;
THYM	cis	rs6956675	0.915	rs1608134	chr7:62653607	A/C	cg08930214	chr7:62859557	LOC100287834	0.62	5.03	0.46	2.33e-6	Obesity-related traits;
THYM	cis	rs13082711	0.554	rs10514679	chr3:27412591	A/G	cg02860705	chr3:27208620	NA	0.84	5.92	0.52	5.18e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs8014204	0.935	rs4903267	chr14:75360419	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.58	-5.63	-0.5	1.84e-7	Caffeine consumption;
THYM	cis	rs6693295	0.536	rs2788013	chr1:246241892	C/T	cg11798871	chr1:246315928	SMYD3	-0.75	-4.63	-0.43	1.16e-5	Migraine - clinic-based;Migraine with aura;
THYM	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg20295408	chr7:1910781	MAD1L1	-0.58	-4.63	-0.43	1.14e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24549020	chr5:56110836	MAP3K1	0.72	4.66	0.43	1.02e-5	Initial pursuit acceleration;
THYM	cis	rs4148087	1.000	rs2168344	chr21:43621496	C/G	cg09727148	chr21:43560719	UMODL1	0.56	4.59	0.43	1.33e-5	Eating disorder in bipolar disorder;
THYM	cis	rs478304	0.654	rs1074155	chr11:65458197	C/T	cg17480646	chr11:65405466	SIPA1	0.97	8.62	0.66	1.46e-13	Acne (severe);
THYM	cis	rs7626444	0.563	rs2686598	chr3:196487719	C/T	cg12930392	chr3:196481615	PAK2	0.4	4.97	0.45	2.97e-6	Monocyte count;
THYM	cis	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.76	0.44	7.03e-6	Obesity-related traits;
THYM	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg15744005	chr10:104629667	AS3MT	-0.83	-7.75	-0.62	9.94e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4866334	1.000	rs79107423	chr5:18501522	A/G	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.84e-7	IgG glycosylation;
THYM	cis	rs6500395	0.962	rs7199625	chr16:48650217	G/C	cg04672837	chr16:48644449	N4BP1	0.48	4.59	0.43	1.35e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2811415	0.531	rs9839861	chr3:127742405	G/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.67	0.43	1e-5	Lung function (FEV1/FVC);
THYM	cis	rs67072384	0.901	rs11235585	chr11:72476007	G/A	cg01380194	chr11:72452482	ARAP1	-0.84	-4.67	-0.43	9.94e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs79057730	0.684	rs6955004	chr7:790792	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.89	4.92	0.45	3.62e-6	Initial pursuit acceleration;
THYM	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg23161317	chr6:28129485	ZNF389	1.0	7.99	0.63	3.23e-12	Depression;
THYM	cis	rs34368983	0.681	rs11013249	chr10:23308000	G/C	cg17782713	chr10:22613360	BMI1	0.96	4.71	0.44	8.42e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6733011	0.628	rs1983352	chr2:99454227	A/G	cg08885076	chr2:99613938	TSGA10	-0.46	-4.45	-0.42	2.31e-5	Bipolar disorder;
THYM	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg12564285	chr5:131593104	PDLIM4	-0.43	-4.66	-0.43	1.04e-5	Breast cancer;
THYM	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.78	0.51	9.58e-8	Hip circumference adjusted for BMI;
THYM	cis	rs447921	0.817	rs11077823	chr17:74456001	C/T	cg17201438	chr17:74438067	UBE2O	0.66	4.8	0.44	5.82e-6	Mitochondrial DNA levels;
THYM	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg03453431	chr7:157225567	NA	-0.59	-5.31	-0.48	7.07e-7	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.97	10.51	0.73	1.32e-17	Intelligence (multi-trait analysis);
THYM	cis	rs11608355	0.618	rs7958220	chr12:109830980	T/C	cg11367159	chr12:110044531	NA	0.53	4.79	0.44	6.16e-6	Neuroticism;
THYM	cis	rs34375054	0.660	rs12303416	chr12:125593358	C/T	cg25124228	chr12:125621409	AACS	-0.78	-6.04	-0.53	3.02e-8	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs8180040	0.903	rs7636423	chr3:47309134	C/G	cg27129171	chr3:47204927	SETD2	0.77	7.25	0.6	1.11e-10	Colorectal cancer;
THYM	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg06784218	chr1:46089804	CCDC17	-0.32	-4.73	-0.44	7.83e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19346786	chr7:2764209	NA	-0.82	-7.44	-0.61	4.58e-11	Height;
THYM	cis	rs6840360	0.532	rs4235221	chr4:152511193	C/T	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg00129232	chr17:37814104	STARD3	-0.82	-5.84	-0.51	7.4e-8	Asthma;
THYM	cis	rs3857067	0.806	rs28408270	chr4:95114572	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg22974920	chr21:40686053	BRWD1	-0.63	-4.97	-0.45	2.98e-6	Cognitive function;
THYM	cis	rs889398	0.967	rs2032912	chr16:69568303	G/T	cg09409435	chr16:70099608	PDXDC2	-0.61	-4.45	-0.42	2.34e-5	Body mass index;
THYM	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg17644776	chr2:200775616	C2orf69	0.74	5.24	0.47	9.63e-7	Schizophrenia;
THYM	cis	rs6032067	0.777	rs13038342	chr20:43800232	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.52	-5.89	-0.52	5.76e-8	Blood protein levels;
THYM	cis	rs9443645	0.507	rs1876389	chr6:79481932	A/T	cg04547799	chr6:79944526	HMGN3	-0.69	-5.03	-0.46	2.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6586163	0.527	rs3740286	chr10:90751340	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.55	5.32	0.48	7.01e-7	Chronic lymphocytic leukemia;
THYM	cis	rs2932538	0.922	rs7527076	chr1:113150481	G/A	cg22162597	chr1:113214053	CAPZA1	0.65	5.32	0.48	6.9e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg13683864	chr3:40499215	RPL14	-0.85	-7.88	-0.63	5.41e-12	Renal cell carcinoma;
THYM	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg09417038	chr21:47716443	C21orf57	0.7	6.36	0.55	6.93e-9	Testicular germ cell tumor;
THYM	cis	rs6960043	0.967	rs6978885	chr7:15053307	G/A	cg19272540	chr7:15055459	NA	-0.48	-5.86	-0.52	6.75e-8	Type 2 diabetes;
THYM	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08704250	chr15:31115839	NA	-0.69	-7.64	-0.62	1.7e-11	Huntington's disease progression;
THYM	cis	rs3916	0.955	rs12828810	chr12:121152017	T/G	cg21892295	chr12:121157589	UNC119B	-0.53	-5.18	-0.47	1.25e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg00129232	chr17:37814104	STARD3	0.73	4.98	0.45	2.87e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs10744422	1.000	rs3817094	chr12:123332032	T/C	cg25930673	chr12:123319894	HIP1R	-0.86	-4.84	-0.44	5.09e-6	Schizophrenia;
THYM	cis	rs7941600	0.708	rs11042290	chr11:9357059	G/A	cg19415743	chr11:9336845	TMEM41B	1.07	5.33	0.48	6.52e-7	Coronary artery disease;
THYM	cis	rs11122272	0.525	rs61835222	chr1:231537917	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-5.32	-0.48	6.84e-7	Hemoglobin concentration;
THYM	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg04025307	chr7:1156635	C7orf50	0.68	6.47	0.55	4.25e-9	Longevity;Endometriosis;
THYM	cis	rs9646944	0.501	rs17027246	chr2:103080055	C/G	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg07424592	chr7:64974309	NA	1.09	5.01	0.46	2.55e-6	Diabetic kidney disease;
THYM	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg17063962	chr7:91808500	NA	1.1	12.1	0.78	6.01e-21	Breast cancer;
THYM	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6772849	0.768	rs9820741	chr3:128416080	G/A	cg23732725	chr3:128766093	NA	-0.5	-4.5	-0.42	1.94e-5	Monocyte percentage of white cells;Monocyte count;
THYM	cis	rs11792861	0.591	rs2282206	chr9:111746267	A/G	cg05043794	chr9:111880884	C9orf5	-0.36	-5.0	-0.46	2.59e-6	Menarche (age at onset);
THYM	cis	rs7264396	0.563	rs2425138	chr20:34345710	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-4.59	-0.43	1.34e-5	Total cholesterol levels;
THYM	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg11366901	chr6:160182831	ACAT2	1.08	9.54	0.7	1.56e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2085601	0.542	rs2464513	chr4:89945728	T/C	cg17769793	chr4:89976368	FAM13A	-0.53	-5.83	-0.51	7.75e-8	Hair greying;
THYM	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg09307838	chr4:120376055	NA	-0.77	-5.63	-0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg18131467	chr2:239335373	ASB1	1.1	11.05	0.75	9.8e-19	Multiple system atrophy;
THYM	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg20891283	chr12:69753455	YEATS4	0.62	4.48	0.42	2.1e-5	Response to diuretic therapy;
THYM	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg24733560	chr20:60626293	TAF4	0.51	4.58	0.43	1.41e-5	Body mass index;
THYM	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg01324343	chr3:183735012	ABCC5	0.64	8.63	0.66	1.42e-13	Anterior chamber depth;
THYM	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.03	-7.08	-0.59	2.43e-10	Platelet count;
THYM	cis	rs9300255	0.770	rs7980687	chr12:123822711	G/A	cg05973401	chr12:123451056	ABCB9	-0.74	-4.57	-0.42	1.49e-5	Neutrophil percentage of white cells;
THYM	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4930103	1.000	rs4929983	chr11:2024579	C/T	cg06197492	chr11:2016605	H19	0.63	5.79	0.51	8.89e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Body mass index;
THYM	cis	rs7828089	0.646	rs4872490	chr8:22280805	T/C	cg12081754	chr8:22256438	SLC39A14	0.8	7.16	0.59	1.73e-10	Verbal declarative memory;
THYM	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22496380	chr5:211416	CCDC127	-1.33	-7.99	-0.63	3.21e-12	Breast cancer;
THYM	cis	rs13177918	0.677	rs13171800	chr5:149824355	G/A	cg14059543	chr5:149831962	NA	-1.01	-7.71	-0.62	1.21e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9972944	0.627	rs28845012	chr17:63760891	G/A	cg07283582	chr17:63770753	CCDC46	-0.64	-4.91	-0.45	3.77e-6	Total body bone mineral density;
THYM	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg18512352	chr11:47633146	NA	0.51	6.11	0.53	2.21e-8	Subjective well-being;
THYM	cis	rs7465272	1.000	rs13259747	chr8:143683567	A/C	cg10104451	chr8:143696006	ARC	-0.78	-5.42	-0.49	4.45e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg08999081	chr20:33150536	PIGU	0.59	5.12	0.47	1.59e-6	Coronary artery disease;
THYM	cis	rs939658	0.683	rs8024572	chr15:79465600	A/G	cg17916960	chr15:79447300	NA	0.69	8.08	0.64	2e-12	Refractive error;
THYM	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg11764359	chr7:65958608	NA	-0.87	-7.44	-0.61	4.39e-11	Aortic root size;
THYM	cis	rs7572733	0.534	rs700662	chr2:198668751	T/C	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg22166914	chr1:53195759	ZYG11B	0.63	5.43	0.49	4.4e-7	Monocyte count;
THYM	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs72949976	0.864	rs10176806	chr2:214022596	T/G	cg08319019	chr2:214017104	IKZF2	-0.77	-6.17	-0.53	1.66e-8	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg02317251	chr4:10116515	WDR1	-0.56	-4.95	-0.45	3.23e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs2302612	0.528	rs3771184	chr2:102842952	G/A	cg13315345	chr2:102803985	IL1RL2	0.72	4.88	0.45	4.28e-6	Serum protein levels (sST2);
THYM	cis	rs2075230	0.705	rs1641520	chr17:7550157	T/A	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	-0.3	-4.46	-0.42	2.28e-5	Hormone measurements;
THYM	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg24308560	chr3:49941425	MST1R	-0.76	-6.34	-0.55	7.57e-9	Intelligence (multi-trait analysis);
THYM	cis	rs12478296	0.901	rs59191623	chr2:243028595	G/A	cg06360820	chr2:242988706	NA	-0.93	-6.19	-0.54	1.54e-8	Obesity-related traits;
THYM	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg25208724	chr1:156163844	SLC25A44	1.13	12.94	0.8	1.09e-22	Testicular germ cell tumor;
THYM	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg08431931	chr22:42394659	WBP2NL	0.72	5.11	0.46	1.68e-6	Birth weight;
THYM	cis	rs7404928	0.651	rs8055831	chr16:23950185	C/T	cg26685404	chr16:23957272	PRKCB	-0.6	-6.95	-0.58	4.57e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs752010	0.574	rs6671999	chr1:42120416	G/A	cg06885757	chr1:42089581	HIVEP3	0.45	5.0	0.46	2.61e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs7836436	1.000	rs58821811	chr8:121019608	C/T	cg05020510	chr8:120428057	NOV	0.93	4.85	0.45	4.73e-6	HIV-1 viral setpoint;
THYM	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg22974920	chr21:40686053	BRWD1	0.6	4.63	0.43	1.15e-5	Cognitive function;
THYM	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg14675211	chr2:100938903	LONRF2	0.74	7.33	0.6	7.71e-11	Intelligence (multi-trait analysis);
THYM	cis	rs10492096	1.000	rs10492096	chr12:6580582	A/G	cg13857086	chr12:6580257	VAMP1	0.9	5.49	0.49	3.34e-7	Hip geometry;
THYM	cis	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.47	-0.42	2.16e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7107174	0.688	rs11237490	chr11:78135229	C/T	cg19901956	chr11:77921274	USP35	-0.73	-5.61	-0.5	2.02e-7	Testicular germ cell tumor;
THYM	cis	rs3206736	0.548	rs2021177	chr7:35020188	T/C	cg13068698	chr7:35078082	DPY19L1	0.47	4.54	0.42	1.66e-5	Diastolic blood pressure;
THYM	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg02734326	chr4:10020555	SLC2A9	-0.61	-5.09	-0.46	1.8e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-5.83	-0.51	7.7e-8	Total cholesterol levels;
THYM	cis	rs986417	0.818	rs767603	chr14:61098683	T/C	cg27398547	chr14:60952738	C14orf39	1.04	5.74	0.51	1.14e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs782590	0.902	rs4672052	chr2:55732018	A/C	cg03859395	chr2:55845619	SMEK2	0.63	5.68	0.5	1.47e-7	Metabolic syndrome;
THYM	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs10089	0.953	rs1012851	chr5:127360241	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.96	6.36	0.55	7.05e-9	Ileal carcinoids;
THYM	cis	rs4731207	0.596	rs6466973	chr7:124605426	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg13736514	chr6:26305472	NA	-0.61	-7.59	-0.61	2.21e-11	Educational attainment;
THYM	cis	rs12126655	0.529	rs7517496	chr1:108393995	T/C	cg12211867	chr1:108023441	NTNG1	0.35	4.51	0.42	1.88e-5	Plasma thyroid-stimulating hormone levels;
THYM	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.77	-6.25	-0.54	1.14e-8	Chronic sinus infection;
THYM	trans	rs11722228	0.594	rs10939663	chr4:10032516	T/G	cg26043149	chr18:55253948	FECH	1.14	9.86	0.71	3.36e-16	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.63	-4.98	-0.46	2.82e-6	Blood metabolite levels;
THYM	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs2237457	0.543	rs2108348	chr7:50703282	T/G	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.48e-6	Schizophrenia (treatment resistant);
THYM	cis	rs28476539	0.567	rs6813051	chr4:83564715	G/C	cg10249074	chr4:83542146	C4orf11	-0.66	-5.27	-0.48	8.48e-7	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs526231	0.697	rs253754	chr5:102631962	T/C	cg23492399	chr5:102201601	PAM	-0.6	-4.53	-0.42	1.74e-5	Primary biliary cholangitis;
THYM	cis	rs7224314	1.000	rs62085808	chr17:65357692	G/A	cg01507342	chr17:65387096	PITPNC1	-0.8	-7.95	-0.63	3.83e-12	Diisocyanate-induced asthma;
THYM	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg26031613	chr14:104095156	KLC1	1.04	9.64	0.7	9.51e-16	Body mass index;
THYM	cis	rs11671005	0.610	rs11669345	chr19:59062259	C/T	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.62	-5.03	-0.46	2.29e-6	Mean platelet volume;
THYM	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs7084402	0.967	rs1649084	chr10:60292117	T/A	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs11039798	0.764	rs7294013	chr11:48762416	G/A	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.97	6.83	0.57	8.03e-10	Schizophrenia;
THYM	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg10023613	chr17:42248099	ASB16	0.27	4.49	0.42	2e-5	Bone mineral density (hip);Bone mineral density;
THYM	cis	rs35100037	0.803	rs28415191	chr5:128612415	A/C	cg05211662	chr5:128795605	ADAMTS19	-0.85	-5.05	-0.46	2.11e-6	Ankle injury;
THYM	cis	rs3134353	0.541	rs3134380	chr8:101943319	G/A	cg04962480	chr8:101962118	YWHAZ	-0.38	-5.83	-0.51	7.54e-8	Body mass index;
THYM	cis	rs11608355	0.545	rs61941585	chr12:109905222	C/T	cg11367159	chr12:110044531	NA	0.6	4.54	0.42	1.66e-5	Neuroticism;
THYM	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg12564285	chr5:131593104	PDLIM4	0.43	4.76	0.44	6.88e-6	Breast cancer;
THYM	cis	rs7512552	0.780	rs55823828	chr1:150467296	G/C	cg15654264	chr1:150340011	RPRD2	0.45	5.2	0.47	1.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	18.96	0.89	4.77e-34	Chronic sinus infection;
THYM	cis	rs1050631	0.592	rs1789548	chr18:33724296	G/A	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.58	4.56	0.42	1.54e-5	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg07694864	chr17:40700509	NA	-0.72	-6.83	-0.57	7.88e-10	Colorectal or endometrial cancer;
THYM	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg06074448	chr4:187884817	NA	-1.02	-13.05	-0.8	6.55e-23	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg03877680	chr5:178157825	ZNF354A	0.73	4.97	0.45	2.93e-6	Neutrophil percentage of white cells;
THYM	cis	rs59698941	0.943	rs56927472	chr5:132226038	T/A	cg02081065	chr5:132209139	LEAP2	-0.85	-5.74	-0.51	1.14e-7	Apolipoprotein A-IV levels;
THYM	cis	rs28595532	1.000	rs115706377	chr4:119628481	G/A	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg01264106	chr22:38071602	LGALS1	-0.42	-5.07	-0.46	1.98e-6	Fat distribution (HIV);
THYM	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg10803722	chr21:46713166	LOC642852	-0.38	-4.75	-0.44	7.19e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9790314	0.663	rs13098884	chr3:160687386	A/G	cg04691961	chr3:161091175	C3orf57	0.58	4.63	0.43	1.15e-5	Morning vs. evening chronotype;
THYM	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg00383909	chr3:49044727	WDR6	1.12	6.62	0.56	2.13e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs7071206	0.947	rs716255	chr10:79419679	A/T	cg07817648	chr10:79422355	NA	-0.94	-7.17	-0.59	1.59e-10	Bone mineral density;
THYM	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg05890377	chr2:74357713	NA	1.09	10.22	0.72	5.55e-17	Gestational age at birth (maternal effect);
THYM	cis	rs9914544	0.545	rs4510081	chr17:18798846	A/C	cg26378065	chr17:18585709	ZNF286B	0.59	4.77	0.44	6.6e-6	Educational attainment (years of education);
THYM	cis	rs6754311	0.593	rs10202489	chr2:136494186	G/A	cg04750100	chr2:136595281	LCT	-0.58	-6.34	-0.55	7.66e-9	Mosquito bite size;
THYM	cis	rs7404928	0.535	rs195997	chr16:23954990	C/T	cg26685404	chr16:23957272	PRKCB	-0.63	-7.24	-0.6	1.16e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs8050907	1.000	rs111344533	chr16:4654144	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.57	0.42	1.47e-5	Obesity-related traits;
THYM	cis	rs735396	1.000	rs1169309	chr12:121439192	G/T	cg02403541	chr12:121454288	C12orf43	0.59	4.73	0.44	7.87e-6	N-glycan levels;
THYM	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg03806693	chr22:41940476	POLR3H	-1.01	-9.37	-0.69	3.69e-15	Vitiligo;
THYM	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg20283391	chr11:68216788	NA	-0.57	-4.49	-0.42	2.03e-5	Total body bone mineral density;
THYM	cis	rs662064	0.852	rs2483677	chr1:10580891	C/T	cg20482658	chr1:10539492	PEX14	0.45	5.61	0.5	2e-7	Asthma;
THYM	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg24642844	chr7:1081250	C7orf50	-0.71	-4.99	-0.46	2.69e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8114671	0.836	rs745849	chr20:33572178	G/A	cg08999081	chr20:33150536	PIGU	-0.55	-4.85	-0.45	4.82e-6	Height;
THYM	cis	rs1692580	0.870	rs263532	chr1:2164116	T/C	cg21194808	chr1:2205498	SKI	0.32	4.74	0.44	7.35e-6	Coronary artery disease;
THYM	cis	rs7178572	0.568	rs28524916	chr15:77599002	T/A	cg22256960	chr15:77711686	NA	1.01	8.22	0.64	1.05e-12	Type 2 diabetes;
THYM	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.9	9.05	0.68	1.76e-14	Menarche (age at onset);
THYM	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg02734326	chr4:10020555	SLC2A9	-0.64	-5.71	-0.51	1.3e-7	Bone mineral density;
THYM	cis	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.16	-0.53	1.78e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg06271696	chr7:157225062	NA	-0.6	-4.5	-0.42	1.91e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs72627123	1.000	rs7148538	chr14:74392342	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg02398342	chr17:80708632	TBCD;FN3K	0.64	4.68	0.43	9.55e-6	Glycated hemoglobin levels;
THYM	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg07636037	chr3:49044803	WDR6	0.83	5.02	0.46	2.43e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs1559088	0.546	rs11881543	chr19:33559372	T/G	cg03563238	chr19:33554763	RHPN2	-0.55	-4.69	-0.43	8.98e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg07460842	chr6:66804631	NA	-0.97	-7.04	-0.59	3.03e-10	Exhaled nitric oxide output;
THYM	cis	rs420259	0.516	rs2040573	chr16:23529732	C/T	cg00143387	chr16:23521605	GGA2	-0.72	-5.18	-0.47	1.26e-6	Bipolar disorder;
THYM	cis	rs7089973	0.836	rs12765350	chr10:116635305	G/A	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.05	-0.46	2.15e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs800586	0.595	rs2737246	chr8:116659578	G/C	cg04656070	chr8:116661063	TRPS1	-0.56	-5.61	-0.5	1.97e-7	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs728616	0.702	rs78734698	chr10:81756449	G/A	cg18148530	chr10:81370782	SFTPA1	0.77	4.91	0.45	3.79e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.51	7.29	0.6	8.98e-11	Monocyte percentage of white cells;
THYM	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg08847533	chr14:75593920	NEK9	-0.96	-10.3	-0.73	3.86e-17	Height;
THYM	cis	rs9826463	0.582	rs11707154	chr3:142077131	A/T	cg20824294	chr3:142316082	PLS1	0.79	5.22	0.47	1.04e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs72717009	0.825	rs12722986	chr1:161465420	A/G	cg23840854	chr1:161414152	NA	-1.03	-5.72	-0.51	1.23e-7	Rheumatoid arthritis;
THYM	cis	rs988913	0.813	rs7741915	chr6:54755871	C/T	cg19716238	chr6:54711378	FAM83B	0.48	5.3	0.48	7.59e-7	Menarche (age at onset);
THYM	cis	rs2066819	1.000	rs117779516	chr12:56750872	G/C	cg26714650	chr12:56694279	CS	-1.42	-6.47	-0.55	4.28e-9	Psoriasis vulgaris;
THYM	cis	rs7953508	0.711	rs3825198	chr12:93977465	T/A	cg18151635	chr12:93972918	NA	-0.71	-5.07	-0.46	1.99e-6	Pubertal anthropometrics;
THYM	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03264133	chr6:25882463	NA	-0.7	-5.49	-0.49	3.3e-7	Blood metabolite levels;
THYM	cis	rs9788682	0.747	rs7177514	chr15:78907406	C/G	cg18825076	chr15:78729989	IREB2	0.6	4.78	0.44	6.34e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14893161	chr1:205819251	PM20D1	0.93	9.81	0.71	4.29e-16	Menarche (age at onset);
THYM	cis	rs7772486	0.846	rs866473	chr6:146353414	A/C	cg23711669	chr6:146136114	FBXO30	0.94	9.59	0.7	1.25e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg20891283	chr12:69753455	YEATS4	0.65	4.74	0.44	7.43e-6	Response to diuretic therapy;
THYM	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg14196790	chr5:131705035	SLC22A5	-0.51	-4.62	-0.43	1.21e-5	Blood metabolite levels;
THYM	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg19875535	chr5:140030758	IK	0.58	4.46	0.42	2.21e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs4961252	0.505	rs6990155	chr8:142098977	C/T	cg09914555	chr8:142094789	NA	0.54	5.0	0.46	2.66e-6	Isovolumetric relaxation time;Response to interferon beta therapy;
THYM	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg14582100	chr15:45693742	SPATA5L1	-0.68	-5.82	-0.51	8.01e-8	Homoarginine levels;
THYM	cis	rs11190604	0.652	rs76629555	chr10:102191417	T/C	cg16342193	chr10:102329863	NA	-0.5	-5.17	-0.47	1.29e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7072216	0.763	rs7911036	chr10:100167015	A/T	cg26618903	chr10:100175079	PYROXD2	-0.48	-4.6	-0.43	1.33e-5	Metabolite levels;
THYM	cis	rs7819412	0.545	rs11781155	chr8:10917560	C/T	cg16664915	chr8:10907788	XKR6	-0.58	-4.81	-0.44	5.74e-6	Triglycerides;
THYM	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg09549813	chr16:4587862	C16orf5	-0.48	-5.3	-0.48	7.4e-7	Schizophrenia;
THYM	cis	rs2777491	0.957	rs16971798	chr15:41657144	A/T	cg18705301	chr15:41695430	NDUFAF1	1.02	10.62	0.74	7.95e-18	Ulcerative colitis;
THYM	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	5.15	0.47	1.43e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs995000	0.931	rs10789117	chr1:63072265	A/C	cg06896770	chr1:63153194	DOCK7	0.92	7.57	0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs2637266	0.597	rs846615	chr10:78548489	A/G	cg18941641	chr10:78392320	NA	-0.74	-5.81	-0.51	8.27e-8	Pulmonary function;
THYM	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg08305652	chr11:111469057	NA	0.53	4.58	0.43	1.41e-5	Primary sclerosing cholangitis;
THYM	cis	rs12478296	0.685	rs35577962	chr2:242993575	A/G	cg06360820	chr2:242988706	NA	-1.15	-8.21	-0.64	1.08e-12	Obesity-related traits;
THYM	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1784581	1.000	rs1784582	chr6:162400712	A/G	cg17173639	chr6:162384350	PARK2	-0.94	-8.8	-0.67	6.05e-14	Itch intensity from mosquito bite;
THYM	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg27494647	chr7:150038898	RARRES2	0.43	5.42	0.49	4.44e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs4824093	0.610	rs74371371	chr22:50314074	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.03	-4.99	-0.46	2.68e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg09877947	chr5:131593287	PDLIM4	0.73	6.88	0.58	6.31e-10	Acylcarnitine levels;
THYM	cis	rs2070488	1.000	rs13089394	chr3:38446309	C/A	cg24069376	chr3:38537580	EXOG	0.64	6.35	0.55	7.43e-9	Electrocardiographic conduction measures;
THYM	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg27087555	chr16:88793112	FAM38A	-1.5	-11.17	-0.75	5.36e-19	Plateletcrit;
THYM	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg12386194	chr3:101231763	SENP7	0.69	5.16	0.47	1.34e-6	Colorectal cancer;
THYM	cis	rs2455799	0.613	rs13071730	chr3:15891035	C/T	cg16303742	chr3:15540471	COLQ	-0.56	-5.87	-0.52	6.41e-8	Mean platelet volume;
THYM	cis	rs7106204	0.748	rs7946633	chr11:24237411	C/T	ch.11.24196551F	chr11:24239977	NA	1.0	7.01	0.58	3.4e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs58722170	0.610	rs55884510	chr1:38068943	G/A	cg17933807	chr1:38061675	GNL2	-0.9	-6.86	-0.58	7.09e-10	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs6087990	0.735	rs910083	chr20:31378690	A/C	cg13636640	chr20:31349939	DNMT3B	0.93	10.23	0.72	5.37e-17	Ulcerative colitis;
THYM	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg22764044	chr5:178986830	RUFY1	-0.53	-5.4	-0.48	4.95e-7	Lung cancer;
THYM	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs986417	0.901	rs1955694	chr14:61020617	G/T	cg27398547	chr14:60952738	C14orf39	1.0	5.86	0.52	6.52e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs2915864	1.000	rs2906073	chr5:141576807	T/G	cg00542992	chr5:141595654	NA	0.62	4.65	0.43	1.06e-5	Facial morphology (factor 20);
THYM	cis	rs7943358	0.910	rs3959891	chr11:15713976	C/A	cg11966998	chr11:15692519	NA	-0.48	-4.6	-0.43	1.3e-5	Gut microbiome composition (summer);
THYM	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	12.13	0.78	5.13e-21	Chronic sinus infection;
THYM	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg00990874	chr7:1149470	C7orf50	0.61	4.82	0.44	5.35e-6	Bronchopulmonary dysplasia;
THYM	cis	rs8112449	1.000	rs17697965	chr19:10519410	A/C	cg01466491	chr19:10523363	NA	0.67	6.62	0.56	2.11e-9	Multiple sclerosis;Gastritis;
THYM	cis	rs9361491	0.608	rs2321775	chr6:79478790	C/T	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.88e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg15445000	chr17:37608096	MED1	0.44	5.22	0.47	1.07e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg22307297	chr20:60903441	LAMA5	-0.54	-4.76	-0.44	6.8e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs61931739	0.635	rs1405025	chr12:33908491	C/T	cg10856724	chr12:34555212	NA	-0.63	-5.9	-0.52	5.54e-8	Morning vs. evening chronotype;
THYM	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg03929089	chr4:120376271	NA	-1.01	-13.68	-0.81	3.47e-24	Height;
THYM	cis	rs5770917	1.000	rs2073604	chr22:51008925	G/A	cg06530441	chr22:51016950	CPT1B;CHKB-CPT1B	-0.97	-4.65	-0.43	1.06e-5	Narcolepsy;
THYM	cis	rs2552220	1.000	rs13264807	chr8:6007408	G/T	cg06481462	chr8:7005678	NA	0.46	4.91	0.45	3.71e-6	Interleukin-8 levels;
THYM	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg21926883	chr2:100939477	LONRF2	-0.58	-4.99	-0.46	2.76e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7512552	0.803	rs13294	chr1:150484987	G/A	cg15654264	chr1:150340011	RPRD2	0.46	5.41	0.49	4.73e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7247513	0.930	rs1864082	chr19:12707904	T/C	cg01871581	chr19:12707946	ZNF490	-0.87	-9.36	-0.69	3.84e-15	Bipolar disorder;
THYM	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs2195525	0.572	rs12421814	chr11:119220839	G/A	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.43	4.83	0.44	5.19e-6	Urate levels;
THYM	cis	rs7592578	0.771	rs12053190	chr2:191383348	A/G	cg21644426	chr2:191273491	MFSD6	-0.64	-4.51	-0.42	1.88e-5	Diastolic blood pressure;
THYM	cis	rs2898681	0.567	rs77657787	chr4:53729981	G/A	cg00791764	chr4:53727839	RASL11B	0.65	6.4	0.55	5.74e-9	Optic nerve measurement (cup area);
THYM	cis	rs1568889	1.000	rs61236373	chr11:28212720	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.55e-6	Bipolar disorder;
THYM	cis	rs4499344	0.556	rs259230	chr19:33133865	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.93	6.54	0.56	3.01e-9	Mean platelet volume;
THYM	cis	rs9583531	0.574	rs7319459	chr13:111352408	T/C	cg24331049	chr13:111365604	ING1	-0.72	-6.03	-0.53	3.15e-8	Coronary artery disease;
THYM	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg23758822	chr17:41437982	NA	1.22	11.98	0.78	1.07e-20	Menopause (age at onset);
THYM	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.12	9.06	0.68	1.73e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11190604	0.767	rs12360395	chr10:102194074	A/T	cg16342193	chr10:102329863	NA	-0.5	-5.17	-0.47	1.29e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs17744026	0.682	rs76647391	chr11:123683085	T/C	cg00079598	chr11:123676903	OR6M1	-0.52	-4.79	-0.44	6.14e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs13082711	0.954	rs34348584	chr3:27532704	T/C	cg02860705	chr3:27208620	NA	0.83	5.61	0.5	2e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg04362960	chr10:104952993	NT5C2	0.63	4.47	0.42	2.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9515201	0.818	rs9521733	chr13:111034542	C/T	cg15455643	chr13:111040242	COL4A2	-0.49	-5.58	-0.5	2.3e-7	White matter hyperintensity burden;
THYM	cis	rs17030434	0.769	rs11727144	chr4:154645181	G/C	cg14289246	chr4:154710475	SFRP2	-0.77	-5.07	-0.46	1.95e-6	Electrocardiographic conduction measures;
THYM	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg03806693	chr22:41940476	POLR3H	-0.79	-6.16	-0.53	1.73e-8	Vitiligo;
THYM	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg13010199	chr12:38710504	ALG10B	0.71	5.77	0.51	9.75e-8	Heart rate;
THYM	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg06027949	chr8:82754900	SNX16	0.64	5.35	0.48	6.18e-7	Diastolic blood pressure;
THYM	cis	rs4262150	0.883	rs12654450	chr5:152238850	T/C	cg06854687	chr5:151642065	NA	0.64	4.46	0.42	2.27e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs8064299	0.655	rs734232	chr17:72765731	C/T	cg21922841	chr17:72744131	SLC9A3R1	0.35	4.71	0.43	8.51e-6	Monocyte count;
THYM	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg23978390	chr7:1156363	C7orf50	0.68	4.75	0.44	7.34e-6	Longevity;Endometriosis;
THYM	cis	rs7524258	0.867	rs35399313	chr1:7277293	T/C	cg19809453	chr1:6508028	ESPN	-0.57	-4.46	-0.42	2.21e-5	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs6840360	0.593	rs1366907	chr4:152682749	T/C	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.27	9.78	0.71	4.84e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg11845111	chr2:191398756	TMEM194B	-1.0	-7.65	-0.62	1.66e-11	Diastolic blood pressure;
THYM	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs3785574	0.650	rs7406102	chr17:62004749	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.9	-9.17	-0.69	1e-14	Height;
THYM	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.73	0.44	7.76e-6	Bipolar disorder;
THYM	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg11327659	chr7:150037044	RARRES2	-0.43	-5.27	-0.48	8.39e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg00376283	chr12:123451042	ABCB9	0.71	4.75	0.44	7.32e-6	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs870825	0.616	rs6844588	chr4:185644517	T/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs8114671	0.901	rs6119581	chr20:33773689	T/A	cg08999081	chr20:33150536	PIGU	0.53	4.77	0.44	6.63e-6	Height;
THYM	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18402987	chr7:1209562	NA	0.76	5.88	0.52	6.2e-8	Longevity;Endometriosis;
THYM	cis	rs2219968	1.000	rs4541901	chr8:78971715	G/A	cg00738934	chr8:78996279	NA	0.88	9.31	0.69	5.05e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs654950	0.875	rs633297	chr1:41985453	A/C	cg13396354	chr1:41153348	NA	-0.44	-4.64	-0.43	1.12e-5	Airway imaging phenotypes;
THYM	cis	rs2290159	0.800	rs57884385	chr3:12673551	G/C	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs13326165	0.543	rs77020200	chr3:52312976	C/T	cg08438690	chr3:52279403	PPM1M	-0.88	-5.21	-0.47	1.1e-6	HDL cholesterol;HDL cholesterol levels;
THYM	trans	rs11186	0.591	rs55765720	chr2:189964970	T/A	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg03690763	chr11:133734501	NA	-0.62	-5.21	-0.47	1.11e-6	Childhood ear infection;
THYM	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg27572855	chr1:25598939	RHD	0.65	4.93	0.45	3.43e-6	Erythrocyte sedimentation rate;
THYM	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	4.89	0.45	4.1e-6	Hip circumference adjusted for BMI;
THYM	cis	rs288326	0.561	rs80252162	chr2:183717105	G/A	cg09997497	chr2:183902928	NCKAP1	1.09	5.06	0.46	2.03e-6	Blood protein levels;
THYM	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6992820	0.899	rs10435638	chr8:56754115	C/T	cg06880721	chr8:56792545	LYN	-0.65	-5.25	-0.47	9.24e-7	Mean platelet volume;
THYM	cis	rs757110	0.770	rs11024271	chr11:17395540	T/C	cg15432903	chr11:17409602	KCNJ11	0.58	6.28	0.54	1.01e-8	Type 2 diabetes;
THYM	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg00645579	chr11:617140	IRF7;MUPCDH	-0.53	-6.0	-0.52	3.64e-8	Systemic lupus erythematosus;
THYM	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg24596788	chr1:163392923	NA	0.77	7.43	0.61	4.68e-11	Motion sickness;
THYM	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg02753203	chr1:228287806	NA	-0.61	-5.15	-0.47	1.4e-6	Diastolic blood pressure;
THYM	cis	rs2282300	0.739	rs3858428	chr11:30296550	T/C	cg25418670	chr11:30344373	C11orf46	0.82	6.97	0.58	4.25e-10	Morning vs. evening chronotype;
THYM	cis	rs7580658	0.864	rs3088374	chr2:128062048	T/C	cg10021288	chr2:128175891	PROC	-0.79	-6.82	-0.57	8.33e-10	Protein C levels;
THYM	cis	rs2066819	1.000	rs2629447	chr12:56700809	G/A	cg26714650	chr12:56694279	CS	1.26	7.39	0.6	5.59e-11	Psoriasis vulgaris;
THYM	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg06917634	chr15:78832804	PSMA4	0.96	8.76	0.67	7.4e-14	Sudden cardiac arrest;
THYM	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	trans	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg13615516	chr5:77269221	NA	0.86	8.01	0.63	2.88e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7772486	0.790	rs9791313	chr6:146266172	T/C	cg13319975	chr6:146136371	FBXO30	0.75	6.26	0.54	1.11e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11186	0.556	rs7424001	chr2:189960570	G/C	cg11041835	chr2:189156425	GULP1	0.83	5.05	0.46	2.14e-6	Parkinson's disease;
THYM	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-7.02	-0.58	3.26e-10	Monocyte percentage of white cells;
THYM	cis	rs2658782	0.666	rs2925361	chr11:93098823	G/A	cg15737290	chr11:93063684	CCDC67	0.9	7.11	0.59	2.15e-10	Pulmonary function decline;
THYM	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	7.48	0.61	3.72e-11	Platelet count;
THYM	cis	rs7078219	0.743	rs11190133	chr10:101278725	C/T	cg17888390	chr10:101282816	NA	-0.5	-4.84	-0.44	4.98e-6	Dental caries;
THYM	cis	rs131777	0.708	rs131749	chr22:51024624	C/T	cg25309564	chr22:51001381	C22orf41	-0.59	-4.68	-0.43	9.59e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg22307297	chr20:60903441	LAMA5	0.53	4.59	0.43	1.38e-5	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg12379764	chr21:47803548	PCNT	-0.73	-4.79	-0.44	6.2e-6	Testicular germ cell tumor;
THYM	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg10802521	chr3:52805072	NEK4	0.68	5.65	0.5	1.69e-7	Bipolar disorder;
THYM	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg18252515	chr7:66147081	NA	0.66	5.09	0.46	1.84e-6	Aortic root size;
THYM	cis	rs1864400	0.696	rs2742239	chr10:43621712	A/G	cg06632098	chr10:43605906	RET	-0.76	-4.83	-0.44	5.28e-6	Hirschsprung disease;
THYM	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg14780466	chr2:20870812	GDF7	-0.81	-6.77	-0.57	1.05e-9	Abdominal aortic aneurysm;
THYM	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg08885076	chr2:99613938	TSGA10	-0.67	-6.33	-0.54	8.19e-9	Chronic sinus infection;
THYM	cis	rs13394619	0.775	rs10165819	chr2:11722102	A/T	cg07314298	chr2:11723111	GREB1	-0.61	-5.85	-0.51	7.03e-8	Endometriosis;
THYM	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg26384229	chr12:38710491	ALG10B	0.99	7.94	0.63	3.99e-12	Bladder cancer;
THYM	cis	rs6424115	0.800	rs2229581	chr1:24201094	G/C	cg15997130	chr1:24165203	NA	0.76	6.39	0.55	6.14e-9	Immature fraction of reticulocytes;
THYM	cis	rs2050392	0.965	rs2265371	chr10:30690840	C/T	cg02070205	chr10:30722105	MAP3K8	-0.53	-4.69	-0.43	9.07e-6	Inflammatory bowel disease;
THYM	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg03433033	chr1:76189801	ACADM	-0.5	-5.08	-0.46	1.88e-6	Daytime sleep phenotypes;
THYM	cis	rs7432375	0.933	rs6791142	chr3:136377377	C/T	cg21827317	chr3:136751795	NA	0.59	5.05	0.46	2.11e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs6918586	0.658	rs198813	chr6:26128226	C/T	cg03264133	chr6:25882463	NA	0.65	5.06	0.46	2e-6	Schizophrenia;
THYM	cis	rs7894051	0.850	rs114753168	chr10:135182737	A/G	cg12428399	chr10:135191333	PAOX	1.2	4.47	0.42	2.17e-5	Lifespan;
THYM	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg00686598	chr14:53173677	PSMC6	-1.19	-6.13	-0.53	2e-8	Alzheimer's disease (late onset);
THYM	cis	rs9733	0.596	rs34140753	chr1:150642583	T/C	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg10505658	chr17:80084571	CCDC57	-0.69	-7.95	-0.63	3.85e-12	Life satisfaction;
THYM	cis	rs2227564	0.678	rs2242256	chr10:75597546	C/G	cg00564723	chr10:75632066	CAMK2G	0.57	5.75	0.51	1.08e-7	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4481887	0.676	rs946761	chr1:248521032	T/C	cg00666640	chr1:248458726	OR2T12	0.55	4.79	0.44	6.14e-6	Common traits (Other);
THYM	cis	rs700651	0.821	rs700690	chr2:198727626	A/G	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Intracranial aneurysm;
THYM	cis	rs7000551	0.621	rs4872496	chr8:22289288	G/A	cg12081754	chr8:22256438	SLC39A14	1.03	8.83	0.67	5.27e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs354225	0.584	rs6706263	chr2:54815240	C/T	cg23486701	chr2:54789491	SPTBN1	0.35	4.68	0.43	9.65e-6	Schizophrenia;
THYM	cis	rs4805272	0.582	rs11083652	chr19:29231569	G/C	cg14983838	chr19:29218262	NA	-0.62	-4.89	-0.45	4.13e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs3087591	1.000	rs3087591	chr17:29630970	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.7	-5.55	-0.49	2.55e-7	Hip circumference;
THYM	cis	rs17253792	0.555	rs17683626	chr14:56041112	G/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.78	-0.44	6.31e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs2274459	1.000	rs3793080	chr6:33767803	A/G	cg06253072	chr6:33679850	C6orf125	-0.54	-5.29	-0.48	7.72e-7	Obesity (extreme);
THYM	cis	rs11864453	0.793	rs7197869	chr16:72079352	G/C	cg16558253	chr16:72132732	DHX38	-0.6	-5.52	-0.49	2.92e-7	Fibrinogen levels;
THYM	cis	rs2239547	0.522	rs9831409	chr3:52985711	A/T	cg11645453	chr3:52864694	ITIH4	-0.29	-4.68	-0.43	9.49e-6	Schizophrenia;
THYM	cis	rs17401966	0.858	rs61778404	chr1:10432879	A/G	cg19773385	chr1:10388646	KIF1B	-0.6	-4.7	-0.43	8.64e-6	Hepatocellular carcinoma;
THYM	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03264133	chr6:25882463	NA	-0.87	-7.84	-0.63	6.38e-12	Intelligence (multi-trait analysis);
THYM	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg12031863	chr16:4587854	C16orf5	-0.44	-4.95	-0.45	3.24e-6	Schizophrenia;
THYM	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs6163	0.508	rs11191381	chr10:104493444	C/T	cg04362960	chr10:104952993	NT5C2	0.68	5.45	0.49	4.01e-7	Waist circumference;Hip circumference;
THYM	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.64e-20	Menopause (age at onset);
THYM	cis	rs6430585	0.528	rs12476127	chr2:136763242	A/G	cg23851026	chr2:136556271	LCT	0.76	7.47	0.61	3.81e-11	Corneal structure;
THYM	cis	rs977987	0.778	rs12930452	chr16:75462055	A/G	cg03315344	chr16:75512273	CHST6	0.76	6.17	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs9913156	0.748	rs56124631	chr17:4561378	A/G	cg19197139	chr17:4613644	ARRB2	0.78	4.92	0.45	3.63e-6	Lymphocyte counts;
THYM	cis	rs877282	0.891	rs34652870	chr10:772218	T/C	cg10556349	chr10:835070	NA	-0.77	-5.28	-0.48	8.04e-7	Uric acid levels;
THYM	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg11663144	chr21:46675770	NA	-0.71	-9.92	-0.71	2.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.15	-8.43	-0.65	3.75e-13	Schizophrenia;
THYM	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg22709100	chr7:91322751	NA	-0.6	-4.8	-0.44	5.84e-6	Breast cancer;
THYM	cis	rs13126513	0.768	rs6822162	chr4:100472583	A/G	cg05468953	chr4:100565104	NA	0.63	5.77	0.51	9.95e-8	Metabolite levels (MHPG);
THYM	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg00368973	chr17:30333964	NA	0.77	4.7	0.43	8.82e-6	Hip circumference adjusted for BMI;
THYM	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg02725872	chr8:58115012	NA	-0.84	-5.75	-0.51	1.06e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs2742417	0.603	rs2253979	chr3:45773320	A/G	cg04837898	chr3:45731254	SACM1L	-0.71	-4.97	-0.45	2.97e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg00495681	chr13:53174319	NA	0.87	8.71	0.67	9.4e-14	Lewy body disease;
THYM	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg21773646	chr17:80085082	CCDC57	0.31	4.49	0.42	2.02e-5	Life satisfaction;
THYM	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg12373951	chr3:133503437	NA	0.59	6.56	0.56	2.8e-9	Iron status biomarkers;
THYM	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg23803603	chr1:2058230	PRKCZ	0.59	4.55	0.42	1.59e-5	Height;
THYM	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg19318889	chr4:1322082	MAEA	-0.58	-4.92	-0.45	3.57e-6	Longevity;
THYM	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg17747265	chr1:1875780	NA	-0.8	-9.29	-0.69	5.55e-15	Body mass index;
THYM	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg21862992	chr11:68658383	NA	0.23	4.49	0.42	2.03e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7104764	0.917	rs6598067	chr11:243093	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs7084402	0.967	rs7087528	chr10:60301294	A/T	cg09696939	chr10:60272079	BICC1	0.47	5.64	0.5	1.72e-7	Refractive error;
THYM	cis	rs4786125	0.706	rs8062094	chr16:6902585	A/G	cg03623568	chr16:6915990	A2BP1	-0.96	-9.54	-0.7	1.61e-15	Heart rate variability traits (SDNN);
THYM	cis	rs10089	1.000	rs10060181	chr5:127475573	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg06917634	chr15:78832804	PSMA4	-0.87	-7.2	-0.59	1.37e-10	Sudden cardiac arrest;
THYM	cis	rs12049351	0.774	rs10449250	chr1:229640771	A/G	cg11742688	chr1:229674241	ABCB10	-0.54	-4.47	-0.42	2.14e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs17401966	1.000	rs12757820	chr1:10266671	A/T	cg20482658	chr1:10539492	PEX14	0.37	4.5	0.42	1.89e-5	Hepatocellular carcinoma;
THYM	cis	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg06521331	chr12:34319734	NA	-0.73	-5.46	-0.49	3.74e-7	Morning vs. evening chronotype;
THYM	cis	rs7582180	0.625	rs12612755	chr2:100906061	T/C	cg08017756	chr2:100939284	LONRF2	-0.64	-5.58	-0.5	2.23e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11563648	0.573	rs1419393	chr7:126945708	G/A	cg23081781	chr7:127225937	GCC1	-0.34	-4.69	-0.43	9.14e-6	Resting heart rate;
THYM	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.09	-7.74	-0.62	1.06e-11	Platelet count;
THYM	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg19418458	chr7:158789849	NA	-0.62	-5.83	-0.51	7.66e-8	Facial morphology (factor 20);
THYM	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-1.0	-9.19	-0.69	8.88e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.69	-5.92	-0.52	5.06e-8	Renal function-related traits (BUN);
THYM	cis	rs40363	0.767	rs1003330	chr16:3541039	A/G	cg21433313	chr16:3507492	NAT15	-0.7	-4.68	-0.43	9.62e-6	Tuberculosis;
THYM	cis	rs4523957	0.928	rs422632	chr17:2162049	G/A	cg16513277	chr17:2031491	SMG6	0.79	7.41	0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg04025307	chr7:1156635	C7orf50	0.72	4.46	0.42	2.27e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg14416269	chr4:6271139	WFS1	0.54	5.62	0.5	1.93e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs13177918	0.603	rs10447222	chr5:149832667	A/G	cg14059543	chr5:149831962	NA	-0.97	-8.21	-0.64	1.1e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs11039798	0.512	rs28453037	chr11:49006929	C/A	cg24672777	chr11:48374446	OR4C45	-0.93	-5.81	-0.51	8.44e-8	Axial length;
THYM	cis	rs8103278	0.507	rs3745802	chr19:46271177	G/T	cg02218324	chr19:46318439	RSPH6A	-0.35	-4.53	-0.42	1.71e-5	Coronary artery disease;
THYM	cis	rs2290159	0.948	rs11711270	chr3:12639596	C/T	cg23032965	chr3:12705835	RAF1	0.71	4.75	0.44	7.24e-6	Cholesterol, total;
THYM	cis	rs9527	0.569	rs10786730	chr10:104724200	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-4.61	-0.43	1.26e-5	Arsenic metabolism;
THYM	cis	rs10936602	0.527	rs7628572	chr3:169539649	T/A	cg17737146	chr3:169530037	LRRC34	0.5	4.75	0.44	7.09e-6	Renal cell carcinoma;
THYM	cis	rs73198271	0.740	rs10109886	chr8:8680558	G/A	cg15556689	chr8:8085844	FLJ10661	-0.74	-4.8	-0.44	5.85e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg23161317	chr6:28129485	ZNF389	0.67	5.33	0.48	6.55e-7	Parkinson's disease;
THYM	cis	rs4974559	0.594	rs59544360	chr4:1313575	G/T	cg02980000	chr4:1222292	CTBP1	0.78	5.11	0.46	1.68e-6	Systolic blood pressure;
THYM	cis	rs7582180	0.663	rs6542930	chr2:100944383	T/A	cg08017756	chr2:100939284	LONRF2	-0.74	-7.88	-0.63	5.29e-12	Intelligence (multi-trait analysis);
THYM	cis	rs6987853	0.787	rs12677427	chr8:42414226	T/A	cg09913449	chr8:42400586	C8orf40	1.09	12.37	0.79	1.63e-21	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7794273	0.788	rs6948023	chr7:18841289	C/T	cg13420273	chr7:18810212	HDAC9	0.57	4.51	0.42	1.83e-5	Night sleep phenotypes;
THYM	cis	rs17597773	0.527	rs2484699	chr1:221083752	C/T	cg16008148	chr1:221062819	NA	0.35	4.99	0.46	2.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg10803722	chr21:46713166	LOC642852	-0.43	-5.62	-0.5	1.9e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs11771526	0.901	rs2191000	chr7:32275098	C/A	cg13207630	chr7:32358064	NA	0.79	5.01	0.46	2.49e-6	Body mass index;
THYM	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg03209412	chr4:183728196	NA	0.66	5.98	0.52	3.88e-8	Pediatric autoimmune diseases;
THYM	cis	rs684232	0.666	rs838371	chr17:609275	T/C	cg15660573	chr17:549704	VPS53	-0.87	-8.15	-0.64	1.45e-12	Prostate cancer;
THYM	cis	rs931812	0.895	rs7831714	chr8:101913987	C/T	cg07585502	chr8:101912084	NA	-0.6	-4.64	-0.43	1.1e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs10799590	0.929	rs7544312	chr1:224833282	T/C	cg01808320	chr1:224927238	CNIH3	-0.57	-5.01	-0.46	2.54e-6	Opioid dependence;
THYM	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg13607699	chr17:42295918	UBTF	0.86	8.34	0.65	5.82e-13	Total body bone mineral density;
THYM	cis	rs748404	0.660	rs2439846	chr15:43740970	G/A	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg00271210	chr6:167070053	RPS6KA2	0.7	7.31	0.6	8.36e-11	Crohn's disease;
THYM	cis	rs4233567	0.722	rs10166361	chr2:144257825	C/T	cg17056048	chr2:144271431	ARHGAP15	-0.53	-5.24	-0.47	9.82e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg18305652	chr10:134549665	INPP5A	-0.66	-5.81	-0.51	8.21e-8	Migraine;
THYM	cis	rs6546324	0.539	rs4671192	chr2:67841855	A/G	cg18237512	chr2:67827392	NA	-0.8	-4.77	-0.44	6.69e-6	Endometriosis;
THYM	cis	rs9933309	1.000	rs9933309	chr16:88844932	A/G	cg04602696	chr16:88846723	FAM38A	-0.5	-4.72	-0.44	8.1e-6	Glycated hemoglobin levels;
THYM	cis	rs4243830	0.850	rs2063806	chr1:6610382	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.09	-7.38	-0.6	5.96e-11	Body mass index;
THYM	cis	rs2991971	0.810	rs6657237	chr1:45920108	A/T	cg15605315	chr1:45957053	TESK2	-0.67	-5.39	-0.48	5.01e-7	High light scatter reticulocyte count;
THYM	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg23682913	chr1:2080710	PRKCZ	-0.54	-4.69	-0.43	9.1e-6	Height;
THYM	cis	rs7267979	1.000	rs7267979	chr20:25298087	C/T	cg08601574	chr20:25228251	PYGB	0.59	4.81	0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs11030122	0.632	rs11030599	chr11:4031677	A/G	cg18678763	chr11:4115507	RRM1	-0.44	-5.8	-0.51	8.7e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg08885076	chr2:99613938	TSGA10	0.69	6.47	0.55	4.31e-9	Chronic sinus infection;
THYM	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs16866061	0.962	rs3845840	chr2:225359100	G/A	cg22455342	chr2:225449267	CUL3	0.68	4.88	0.45	4.23e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs9807989	0.773	rs5010059	chr2:102968826	C/G	cg03938978	chr2:103052716	IL18RAP	0.63	6.46	0.55	4.36e-9	Asthma;
THYM	cis	rs7100689	0.754	rs1934695	chr10:82125230	T/C	cg01528321	chr10:82214614	TSPAN14	0.97	7.39	0.6	5.79e-11	Post bronchodilator FEV1;
THYM	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg01119278	chr6:110721349	DDO	-0.58	-6.34	-0.55	7.83e-9	Platelet distribution width;
THYM	cis	rs76878669	0.561	rs4930362	chr11:66154360	T/C	cg14263139	chr11:66104018	RIN1	-0.36	-4.46	-0.42	2.29e-5	Educational attainment (years of education);
THYM	cis	rs7772486	0.686	rs1569540	chr6:146069112	A/G	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs55665837	1.000	rs10466412	chr11:14505189	A/T	cg19336497	chr11:14380999	RRAS2	-0.64	-7.04	-0.59	3e-10	Vitamin D levels;
THYM	cis	rs7216064	1.000	rs6504542	chr17:65836642	T/C	cg12091567	chr17:66097778	LOC651250	-0.71	-4.76	-0.44	6.86e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg18876405	chr7:65276391	NA	-0.63	-5.3	-0.48	7.36e-7	Aortic root size;
THYM	cis	rs9788682	0.748	rs667282	chr15:78863472	T/C	cg18825076	chr15:78729989	IREB2	0.6	4.86	0.45	4.66e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs16912285	0.688	rs59797575	chr11:24315536	A/T	ch.11.24196551F	chr11:24239977	NA	1.01	7.11	0.59	2.17e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs3010562	0.668	rs9457305	chr6:167760702	T/G	cg22772386	chr6:167763320	NA	-0.51	-5.18	-0.47	1.25e-6	Gut microbiome composition (summer and winter);
THYM	cis	rs2455799	0.613	rs1345157	chr3:15895581	C/G	cg16303742	chr3:15540471	COLQ	-0.56	-5.87	-0.52	6.41e-8	Mean platelet volume;
THYM	cis	rs9399401	0.925	rs9496374	chr6:142735221	G/C	cg04461802	chr6:142623433	GPR126	0.49	4.97	0.45	3e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.48	-0.73	1.54e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg14664628	chr15:75095509	CSK	-0.67	-4.92	-0.45	3.7e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs12681287	0.752	rs10104138	chr8:87247659	G/A	cg27223183	chr8:87520930	FAM82B	-0.6	-4.64	-0.43	1.1e-5	Caudate activity during reward;
THYM	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs17102423	0.731	rs1957949	chr14:65542607	C/T	cg11161011	chr14:65562177	MAX	-0.63	-5.59	-0.5	2.13e-7	Obesity-related traits;
THYM	cis	rs3772130	0.583	rs34051021	chr3:121433005	C/A	cg20356878	chr3:121714668	ILDR1	0.63	4.89	0.45	4.07e-6	Cognitive performance;
THYM	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg24250549	chr1:154909240	PMVK	0.79	6.82	0.57	8.33e-10	Prostate cancer;
THYM	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg06636551	chr8:101224915	SPAG1	-0.67	-6.52	-0.56	3.36e-9	Atrioventricular conduction;
THYM	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg18252515	chr7:66147081	NA	-1.44	-8.51	-0.66	2.48e-13	Diabetic kidney disease;
THYM	cis	rs6901004	0.596	rs411604	chr6:111565847	A/G	cg15721981	chr6:111408429	SLC16A10	-0.59	-4.53	-0.42	1.74e-5	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03264133	chr6:25882463	NA	-0.86	-7.12	-0.59	2.08e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg26168224	chr5:2018326	NA	0.88	6.45	0.55	4.57e-9	Gut microbiome composition (winter);
THYM	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg15744005	chr10:104629667	AS3MT	-0.83	-7.67	-0.62	1.47e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs892961	0.899	rs66749226	chr17:75412826	G/A	cg11351908	chr17:75402473	SEPT9	0.56	5.52	0.49	2.95e-7	Airflow obstruction;
THYM	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg26446133	chr18:72167187	CNDP2	-0.59	-4.91	-0.45	3.74e-6	Refractive error;
THYM	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg17264618	chr3:40429014	ENTPD3	-0.54	-5.32	-0.48	6.89e-7	Renal cell carcinoma;
THYM	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8133932	0.654	rs7280405	chr21:47275611	C/T	cg08707771	chr21:46690014	POFUT2	-0.73	-4.59	-0.43	1.37e-5	Schizophrenia;
THYM	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.69	-4.5	-0.42	1.95e-5	Menarche (age at onset);
THYM	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg22907277	chr7:1156413	C7orf50	0.83	5.1	0.46	1.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs4596713	0.507	rs2275428	chr9:71792582	A/T	cg16512924	chr15:28394682	HERC2	0.83	6.93	0.58	5.02e-10	Headache;
THYM	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg13147721	chr7:65941812	NA	-0.73	-4.58	-0.43	1.42e-5	Diabetic kidney disease;
THYM	trans	rs8002861	0.810	rs9533664	chr13:44440527	T/C	cg17145862	chr1:211918768	LPGAT1	0.94	9.74	0.71	6.04e-16	Leprosy;
THYM	cis	rs8067545	0.636	rs11204300	chr17:20195438	C/T	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg21427119	chr20:30132790	HM13	-0.96	-7.02	-0.58	3.34e-10	Mean corpuscular hemoglobin;
THYM	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Gout;
THYM	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg03806693	chr22:41940476	POLR3H	-0.81	-6.73	-0.57	1.27e-9	Neuroticism;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg06774797	chr6:132271971	CTGF	1.27	7.18	0.59	1.57e-10	Pulmonary function decline;
THYM	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.12	-0.47	1.58e-6	Total cholesterol levels;
THYM	trans	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg19346786	chr7:2764209	NA	-0.71	-5.97	-0.52	4.13e-8	Height;
THYM	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs7760949	0.889	rs9475806	chr6:13934527	A/G	cg27413430	chr6:13925136	RNF182	0.52	4.52	0.42	1.82e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs59698941	0.709	rs58237345	chr5:132266351	T/A	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs12791968	0.765	rs12794751	chr11:44998769	C/G	cg11846598	chr11:44996168	LOC221122	-0.81	-5.91	-0.52	5.28e-8	Inhibitory control;
THYM	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg10515332	chr4:99064459	C4orf37	0.67	5.33	0.48	6.48e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg05872129	chr22:39784769	NA	-0.87	-7.35	-0.6	6.76e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg11764359	chr7:65958608	NA	-0.7	-4.89	-0.45	4.09e-6	Aortic root size;
THYM	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg10518543	chr12:38710700	ALG10B	-0.58	-4.6	-0.43	1.3e-5	Morning vs. evening chronotype;
THYM	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.8	6.76	0.57	1.09e-9	Lymphocyte percentage of white cells;
THYM	cis	rs2820651	0.614	rs56385558	chr10:1490864	G/T	cg27404824	chr10:1454848	ADARB2	0.88	4.79	0.44	6.18e-6	Migraine with aura;
THYM	cis	rs10789491	1.000	rs10789491	chr1:47179310	A/G	cg15501359	chr1:47185051	KIAA0494	1.14	8.24	0.65	9.45e-13	Response to hepatitis C treatment;
THYM	cis	rs3017493	0.786	rs59579317	chr11:70684569	A/G	cg03578926	chr11:70508032	SHANK2	0.86	4.79	0.44	6.06e-6	Renal transplant outcome;
THYM	cis	rs8077889	0.917	rs8081646	chr17:41893360	T/C	cg26893861	chr17:41843967	DUSP3	1.09	10.2	0.72	6.31e-17	Triglycerides;
THYM	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg26924012	chr15:45694286	SPATA5L1	1.04	9.47	0.7	2.19e-15	Homoarginine levels;
THYM	cis	rs8033133	0.647	rs1124767	chr15:25326173	T/C	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.74	-5.97	-0.52	4.11e-8	Blood osmolality (transformed sodium);
THYM	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.52	-6.42	-0.55	5.41e-9	Bone mineral density;
THYM	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	trans	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg06636001	chr8:8085503	FLJ10661	-0.76	-6.9	-0.58	5.89e-10	Retinal vascular caliber;
THYM	cis	rs7107174	1.000	rs2510040	chr11:77944548	T/A	cg19901956	chr11:77921274	USP35	-0.81	-6.12	-0.53	2.05e-8	Testicular germ cell tumor;
THYM	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg24531977	chr5:56204891	C5orf35	0.65	4.93	0.45	3.51e-6	Coronary artery disease;
THYM	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg08772003	chr10:104629869	AS3MT	0.66	6.29	0.54	9.68e-9	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs752010	1.000	rs2077172	chr1:42093340	A/G	cg22486000	chr1:42919398	ZMYND12	-0.42	-4.95	-0.45	3.22e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.12	-7.77	-0.62	8.99e-12	Schizophrenia;
THYM	cis	rs2637266	1.000	rs1907305	chr10:78339512	C/G	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs9560113	0.508	rs2774425	chr13:112235077	A/G	cg10483660	chr13:112241077	NA	-0.68	-8.29	-0.65	7.35e-13	Menarche (age at onset);
THYM	cis	rs11089937	0.585	rs6001229	chr22:22542083	C/T	cg06866756	chr22:22471216	NA	0.48	5.33	0.48	6.49e-7	Periodontitis (PAL4Q3);
THYM	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg13683864	chr3:40499215	RPL14	-1.07	-12.25	-0.78	2.92e-21	Renal cell carcinoma;
THYM	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg08645402	chr16:4508243	NA	0.7	6.12	0.53	2.1e-8	Schizophrenia;
THYM	cis	rs7220711	0.680	rs1877633	chr17:41775043	C/T	cg26893861	chr17:41843967	DUSP3	0.68	6.07	0.53	2.62e-8	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg26384229	chr12:38710491	ALG10B	0.69	5.2	0.47	1.13e-6	Morning vs. evening chronotype;
THYM	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg05335186	chr13:53173507	NA	-0.47	-5.87	-0.52	6.38e-8	Lewy body disease;
THYM	cis	rs13064411	0.696	rs2399479	chr3:113227050	G/A	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs1065852	0.526	rs9623489	chr22:42397026	A/G	cg09667013	chr22:42394590	WBP2NL	0.54	4.8	0.44	5.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	trans	rs8073060	0.586	rs226084	chr17:34019582	T/A	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg00129232	chr17:37814104	STARD3	-0.71	-4.8	-0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2075230	0.705	rs1642795	chr17:7542591	C/T	cg27413385	chr17:7515425	FXR2	-0.36	-5.07	-0.46	1.95e-6	Hormone measurements;
THYM	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg06074448	chr4:187884817	NA	-1.0	-12.72	-0.79	3.11e-22	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg21100191	chr22:23484243	RTDR1	0.73	6.5	0.55	3.66e-9	Bone mineral density;
THYM	cis	rs4455778	0.538	rs6958308	chr7:49123900	C/T	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs854765	0.686	rs8065497	chr17:17782649	A/G	cg04398451	chr17:18023971	MYO15A	0.79	6.56	0.56	2.81e-9	Total body bone mineral density;
THYM	cis	rs7512552	0.768	rs7517441	chr1:150283643	A/T	cg15654264	chr1:150340011	RPRD2	-0.44	-5.19	-0.47	1.21e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg17830980	chr10:43048298	ZNF37B	1.04	10.47	0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs10791097	0.967	rs6590512	chr11:130717916	A/G	cg14779329	chr11:130786720	SNX19	-0.53	-5.59	-0.5	2.2e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg04317338	chr11:64019027	PLCB3	0.85	5.81	0.51	8.33e-8	Mean platelet volume;
THYM	cis	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-5.84	-0.51	7.42e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6728642	0.572	rs60621865	chr2:97598001	T/C	cg26665480	chr2:98280029	ACTR1B	-0.75	-5.01	-0.46	2.55e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg08772003	chr10:104629869	AS3MT	-0.57	-4.92	-0.45	3.56e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4606347	0.789	rs111558223	chr1:66164670	C/A	cg04111102	chr1:66153794	NA	0.67	5.35	0.48	6.08e-7	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg10911889	chr6:126070802	HEY2	0.57	4.75	0.44	7.22e-6	Brugada syndrome;
THYM	cis	rs6570726	0.791	rs9373463	chr6:145894762	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-4.99	-0.46	2.75e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2050392	0.687	rs608693	chr10:30734971	G/A	cg18806716	chr10:30721971	MAP3K8	-0.57	-5.42	-0.49	4.57e-7	Inflammatory bowel disease;
THYM	cis	rs7267979	0.744	rs6050464	chr20:25209299	C/A	cg08601574	chr20:25228251	PYGB	0.66	5.31	0.48	7.34e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg21775007	chr8:11205619	TDH	-0.68	-5.27	-0.48	8.47e-7	Retinal vascular caliber;
THYM	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	4.97	0.45	3e-6	Height;
THYM	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg18252515	chr7:66147081	NA	-0.67	-5.24	-0.47	9.51e-7	Aortic root size;
THYM	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg03060546	chr3:49711283	APEH	-0.73	-6.03	-0.53	3.14e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.86	7.86	0.63	5.89e-12	Cognitive ability;
THYM	cis	rs56322409	0.561	rs12778814	chr10:97367117	A/C	cg00110277	chr10:97668174	C10orf131	0.58	4.91	0.45	3.72e-6	Blood metabolite levels;
THYM	cis	rs4285028	0.948	rs1920290	chr3:121672305	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3791406	0.929	rs3828202	chr2:240030122	A/G	cg14550559	chr2:240039617	HDAC4	-0.6	-5.42	-0.49	4.58e-7	Skin aging (microtopography measurement);
THYM	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg01416388	chr22:39784598	NA	-0.89	-8.22	-0.64	1.01e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7107770	1.000	rs35054925	chr11:125106539	T/C	cg07747661	chr11:125106135	PKNOX2	-0.92	-5.19	-0.47	1.17e-6	Photic sneeze reflex;
THYM	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg19318889	chr4:1322082	MAEA	0.63	5.44	0.49	4.22e-7	Longevity;
THYM	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg16049864	chr8:95962084	TP53INP1	-0.86	-8.13	-0.64	1.62e-12	Type 2 diabetes;
THYM	cis	rs7771547	0.519	rs6917489	chr6:36368169	C/T	cg07856975	chr6:36356162	ETV7	0.62	5.44	0.49	4.16e-7	Platelet distribution width;
THYM	cis	rs921968	0.565	rs1078803	chr2:219606538	A/C	cg02176678	chr2:219576539	TTLL4	0.45	4.55	0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs62045849	0.557	rs3743982	chr16:89181139	T/G	cg06035645	chr16:89190857	ACSF3	-0.89	-5.52	-0.49	2.88e-7	Red blood cell count;
THYM	cis	rs11031096	0.503	rs10835604	chr11:4109709	A/T	cg18678763	chr11:4115507	RRM1	-0.44	-5.83	-0.51	7.44e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4589258	0.737	rs11019135	chr11:90407300	T/C	cg26138821	chr11:89956704	CHORDC1	0.56	4.68	0.43	9.36e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1395	1.000	rs1395	chr2:27424636	G/A	cg23587288	chr2:27483067	SLC30A3	0.58	5.09	0.46	1.78e-6	Blood metabolite levels;
THYM	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg26597838	chr10:835615	NA	1.23	8.88	0.67	4.1e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs7567389	0.677	rs7556675	chr2:128053747	C/T	cg09760422	chr2:128146352	NA	-0.4	-4.52	-0.42	1.8e-5	Self-rated health;
THYM	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	11.87	0.77	1.82e-20	Chronic sinus infection;
THYM	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg05025164	chr4:1340916	KIAA1530	-0.8	-6.2	-0.54	1.43e-8	Longevity;
THYM	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg23791538	chr6:167370224	RNASET2	-0.58	-4.53	-0.42	1.72e-5	Crohn's disease;
THYM	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg10802521	chr3:52805072	NEK4	-0.73	-6.43	-0.55	5.15e-9	Bipolar disorder;
THYM	cis	rs9916302	0.821	rs4795386	chr17:37746847	A/G	cg07936489	chr17:37558343	FBXL20	-0.87	-5.93	-0.52	4.95e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg18252515	chr7:66147081	NA	-1.61	-8.73	-0.67	8.74e-14	Diabetic kidney disease;
THYM	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg04772025	chr11:68637568	NA	0.62	6.55	0.56	2.96e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9658691	0.607	rs12415680	chr10:90780737	A/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.88	-5.87	-0.52	6.48e-8	Mosquito bite size;
THYM	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.28	-4.74	-0.44	7.35e-6	Obesity-related traits;
THYM	cis	rs4363385	0.818	rs4845522	chr1:153011099	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg13880726	chr7:1868755	MAD1L1	-0.68	-4.54	-0.42	1.64e-5	Bipolar disorder;
THYM	cis	rs6893300	0.524	rs6601073	chr5:179177271	A/G	cg14593053	chr5:179126677	CANX	-0.59	-4.64	-0.43	1.12e-5	Resting heart rate;
THYM	cis	rs7084402	0.967	rs1658421	chr10:60331928	A/T	cg07615347	chr10:60278583	BICC1	0.53	4.98	0.45	2.85e-6	Refractive error;
THYM	cis	rs4788570	0.615	rs7188675	chr16:71680002	C/T	cg06353428	chr16:71660113	MARVELD3	1.26	8.32	0.65	6.23e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11644478	chr21:40555479	PSMG1	-0.76	-6.49	-0.55	3.85e-9	Cognitive function;
THYM	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg09904177	chr6:26538194	HMGN4	0.53	4.47	0.42	2.16e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1011018	0.955	rs7790519	chr7:139446671	A/G	cg06079564	chr7:139468310	HIPK2	0.72	5.42	0.49	4.6e-7	Systolic blood pressure;
THYM	cis	rs7640424	0.620	rs34910554	chr3:107816733	C/T	cg09227934	chr3:107805635	CD47	-0.65	-4.99	-0.46	2.68e-6	Body mass index;
THYM	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg04944784	chr2:26401820	FAM59B	-1.05	-8.18	-0.64	1.23e-12	Gut microbiome composition (summer);
THYM	cis	rs2120243	0.539	rs6441126	chr3:157095016	C/T	cg24825693	chr3:157122686	VEPH1	-0.48	-4.48	-0.42	2.09e-5	Hepatocellular carcinoma in hepatitis B infection;
THYM	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg27631724	chr1:11040367	C1orf127	0.64	5.64	0.5	1.72e-7	Ewing sarcoma;
THYM	cis	rs1062746	0.528	rs891092	chr16:87338226	G/A	cg27365499	chr16:87376795	FBXO31	0.52	5.03	0.46	2.28e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs3796619	1.000	rs1466215	chr4:1072220	C/T	cg27284194	chr4:1044797	NA	0.53	4.95	0.45	3.22e-6	Recombination rate (males);
THYM	cis	rs4638749	0.906	rs34974921	chr2:108860253	A/G	cg25838818	chr2:108905173	SULT1C2	-0.61	-6.18	-0.54	1.6e-8	Blood pressure;
THYM	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg21926883	chr2:100939477	LONRF2	-0.65	-5.96	-0.52	4.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.91	5.01	0.46	2.51e-6	Initial pursuit acceleration;
THYM	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg06221963	chr1:154839813	KCNN3	-0.78	-9.74	-0.71	5.93e-16	Prostate cancer;
THYM	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs11249608	0.548	rs6867208	chr5:178455575	G/A	cg01312482	chr5:178451176	ZNF879	-0.76	-6.3	-0.54	9.29e-9	Pubertal anthropometrics;
THYM	cis	rs28595532	0.920	rs115437723	chr4:119741828	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.36	0.55	6.93e-9	Cannabis dependence symptom count;
THYM	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg07424592	chr7:64974309	NA	1.12	5.24	0.47	9.64e-7	Diabetic kidney disease;
THYM	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.52	0.49	2.99e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg18681998	chr4:17616180	MED28	0.81	7.22	0.6	1.29e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs1957429	0.614	rs75819890	chr14:65370321	T/G	cg23373153	chr14:65346875	NA	-1.25	-5.03	-0.46	2.29e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs2066819	1.000	rs74673257	chr12:56638077	T/C	cg26714650	chr12:56694279	CS	-1.27	-6.32	-0.54	8.6e-9	Psoriasis vulgaris;
THYM	cis	rs7267979	1.000	rs2258617	chr20:25274318	C/T	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6430585	0.583	rs2304371	chr2:136561557	A/G	cg20242066	chr2:136595261	LCT	0.43	4.52	0.42	1.8e-5	Corneal structure;
THYM	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg23708337	chr7:1209742	NA	0.73	5.28	0.48	8e-7	Longevity;Endometriosis;
THYM	cis	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg06521331	chr12:34319734	NA	0.88	6.46	0.55	4.41e-9	Morning vs. evening chronotype;
THYM	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg12963246	chr6:28129442	ZNF389	-0.87	-7.7	-0.62	1.29e-11	Depression;
THYM	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg13609457	chr4:120235615	NA	0.6	5.39	0.48	5.11e-7	Corneal astigmatism;
THYM	cis	rs4273100	0.512	rs2233072	chr17:19281828	T/G	cg25447019	chr17:19030144	GRAPL	0.75	5.86	0.52	6.62e-8	Schizophrenia;
THYM	cis	rs7575217	0.588	rs11675221	chr2:101670937	C/T	cg12594615	chr2:101643137	TBC1D8	0.59	4.77	0.44	6.63e-6	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg23758822	chr17:41437982	NA	1.06	7.46	0.61	4.13e-11	Menopause (age at onset);
THYM	cis	rs476633	0.708	rs111717706	chr15:41441162	C/T	cg21153102	chr15:41252147	NA	0.59	4.61	0.43	1.26e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs11989744	0.957	rs57291069	chr8:23570211	G/T	cg04349084	chr8:23602677	NA	0.5	5.21	0.47	1.09e-6	Waist-hip ratio;
THYM	cis	rs41005	0.967	rs6752776	chr2:8104594	A/G	cg03155496	chr2:8117019	LOC339788	0.98	8.94	0.68	3.04e-14	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg13609457	chr4:120235615	NA	-0.62	-5.42	-0.49	4.52e-7	Corneal astigmatism;
THYM	cis	rs981844	0.816	rs62325148	chr4:154727993	A/G	cg09973105	chr4:154681532	RNF175	-0.66	-5.45	-0.49	3.98e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs16866061	1.000	rs4674916	chr2:225365635	C/A	cg22455342	chr2:225449267	CUL3	0.67	4.84	0.44	4.98e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg27534772	chr1:16042836	PLEKHM2	0.53	5.9	0.52	5.65e-8	Systolic blood pressure;
THYM	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg13147721	chr7:65941812	NA	0.73	4.58	0.43	1.42e-5	Diabetic kidney disease;
THYM	cis	rs6960043	0.738	rs12538043	chr7:15058998	C/G	cg19272540	chr7:15055459	NA	0.5	5.24	0.47	9.58e-7	Type 2 diabetes;
THYM	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg07936489	chr17:37558343	FBXL20	-0.84	-5.58	-0.5	2.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs28595532	0.920	rs115982145	chr4:119605707	A/G	cg14228332	chr4:119757509	SEC24D	1.35	4.52	0.42	1.81e-5	Cannabis dependence symptom count;
THYM	cis	rs887829	0.570	rs10168333	chr2:234596988	C/T	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.57	-0.42	1.45e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg02070205	chr10:30722105	MAP3K8	-0.53	-4.52	-0.42	1.76e-5	Inflammatory bowel disease;
THYM	cis	rs2985684	0.948	rs11623263	chr14:50083295	A/G	cg02151108	chr14:50098012	C14orf104	-0.69	-5.74	-0.51	1.15e-7	Carotid intima media thickness;
THYM	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	6.55	0.56	2.93e-9	Obesity-related traits;
THYM	cis	rs6032067	0.929	rs6017503	chr20:43815103	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.73	-8.04	-0.64	2.47e-12	Blood protein levels;
THYM	cis	rs6964587	0.626	rs1011372	chr7:91509867	T/C	cg17063962	chr7:91808500	NA	-1.0	-8.65	-0.66	1.28e-13	Breast cancer;
THYM	cis	rs9788721	0.902	rs951266	chr15:78878541	C/T	cg18825076	chr15:78729989	IREB2	-0.53	-4.72	-0.44	8.07e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs10924970	0.967	rs10925192	chr1:235400826	T/C	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs9921192	1.000	rs2892165	chr16:4324293	A/T	cg00021532	chr16:4324280	TFAP4	0.87	7.89	0.63	5.09e-12	Prostate-specific antigen levels;
THYM	cis	rs59698941	0.882	rs4705977	chr5:132245114	C/A	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs854765	0.663	rs4925120	chr17:17754633	C/T	cg04398451	chr17:18023971	MYO15A	0.77	7.22	0.6	1.26e-10	Total body bone mineral density;
THYM	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg24578937	chr1:2090814	PRKCZ	-0.59	-6.23	-0.54	1.28e-8	Height;
THYM	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg02725872	chr8:58115012	NA	-1.09	-8.15	-0.64	1.43e-12	Developmental language disorder (linguistic errors);
THYM	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12756686	chr19:29218302	NA	0.98	8.72	0.67	9.12e-14	Methadone dose in opioid dependence;
THYM	cis	rs11078597	0.731	rs8077638	chr17:1640793	C/T	cg18436246	chr17:1640651	WDR81	0.65	4.6	0.43	1.29e-5	Serum albumin level;
THYM	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg00757033	chr12:89920650	WDR51B	0.77	11.72	0.77	3.74e-20	NT-proBNP levels in acute coronary syndrome;
THYM	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg09549813	chr16:4587862	C16orf5	-0.47	-5.13	-0.47	1.52e-6	Schizophrenia;
THYM	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg19774624	chr17:42201019	HDAC5	-0.62	-5.17	-0.47	1.28e-6	Total body bone mineral density;
THYM	cis	rs3206736	0.548	rs328891	chr7:35013517	C/T	cg13068698	chr7:35078082	DPY19L1	0.46	4.48	0.42	2.06e-5	Diastolic blood pressure;
THYM	cis	rs7107174	1.000	rs2511190	chr11:77988310	T/C	cg02023728	chr11:77925099	USP35	0.65	5.95	0.52	4.47e-8	Testicular germ cell tumor;
THYM	cis	rs490234	0.841	rs13285366	chr9:128375047	G/A	cg14078157	chr9:128172775	NA	-0.66	-5.15	-0.47	1.43e-6	Mean arterial pressure;
THYM	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg10164272	chr16:89456328	ANKRD11	-0.65	-4.45	-0.42	2.32e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg19318889	chr4:1322082	MAEA	-0.52	-4.53	-0.42	1.7e-5	Obesity-related traits;
THYM	cis	rs9926296	0.715	rs648548	chr16:89749436	C/G	cg03605463	chr16:89740564	NA	0.85	6.33	0.54	7.89e-9	Vitiligo;
THYM	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg12310025	chr6:25882481	NA	0.67	5.77	0.51	9.89e-8	Blood metabolite levels;
THYM	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06850241	chr22:41845214	NA	0.54	5.04	0.46	2.24e-6	Vitiligo;
THYM	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg07150166	chr2:30669952	LCLAT1	1.35	5.98	0.52	3.86e-8	Midgestational circulating levels of PBDEs (fetal genetic effect);
THYM	cis	rs367615	0.731	rs58241713	chr5:108853664	G/A	cg17395555	chr5:108820864	NA	0.7	8.49	0.66	2.82e-13	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg12016809	chr21:47604291	C21orf56	0.66	4.83	0.44	5.24e-6	Testicular germ cell tumor;
THYM	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	trans	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg25214090	chr10:38739885	LOC399744	0.83	7.11	0.59	2.14e-10	Corneal astigmatism;
THYM	cis	rs16866061	1.000	rs11688397	chr2:225393173	C/T	cg12698349	chr2:225449008	CUL3	1.14	10.45	0.73	1.77e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs6570726	0.967	rs373527	chr6:145801861	C/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.75	-0.51	1.07e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.68	0.5	1.45e-7	Height;
THYM	cis	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg14675211	chr2:100938903	LONRF2	0.77	8.5	0.66	2.68e-13	Intelligence (multi-trait analysis);
THYM	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg14820908	chr5:178986412	RUFY1	0.63	6.25	0.54	1.16e-8	Lung cancer;
THYM	cis	rs4654899	0.833	rs10916858	chr1:21086602	C/G	cg01072550	chr1:21505969	NA	-0.58	-5.05	-0.46	2.14e-6	Superior frontal gyrus grey matter volume;
THYM	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg12893697	chr11:970389	AP2A2	-0.31	-5.21	-0.47	1.1e-6	Alzheimer's disease (late onset);
THYM	cis	rs12711979	0.509	rs10195596	chr2:3824222	T/G	cg17052675	chr2:3827356	NA	-0.88	-13.79	-0.82	2.09e-24	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg23161317	chr6:28129485	ZNF389	0.71	5.59	0.5	2.21e-7	Cardiac Troponin-T levels;
THYM	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg17911788	chr17:44343683	NA	-0.68	-6.31	-0.54	8.89e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs919433	0.648	rs3097384	chr2:198278834	T/A	cg00792783	chr2:198669748	PLCL1	0.82	5.67	0.5	1.54e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs17030434	0.834	rs6843172	chr4:154760600	T/C	cg14289246	chr4:154710475	SFRP2	-0.69	-4.95	-0.45	3.24e-6	Electrocardiographic conduction measures;
THYM	cis	rs7584330	0.518	rs74003108	chr2:238448000	T/C	cg14458575	chr2:238380390	NA	0.82	4.53	0.42	1.73e-5	Prostate cancer;
THYM	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg25517755	chr10:38738941	LOC399744	0.76	6.94	0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs13006833	0.668	rs2664253	chr2:191148558	G/A	cg11845111	chr2:191398756	TMEM194B	0.65	4.48	0.42	2.09e-5	Urinary metabolites;
THYM	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg27129171	chr3:47204927	SETD2	0.74	7.2	0.59	1.42e-10	Colorectal cancer;
THYM	cis	rs12142240	0.659	rs17361873	chr1:46832686	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs17174870	0.955	rs55766181	chr2:112766304	G/C	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg18252515	chr7:66147081	NA	0.62	4.55	0.42	1.59e-5	Aortic root size;
THYM	cis	rs308403	0.509	rs9990804	chr4:123671984	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.97	8.19	0.64	1.18e-12	Blood protein levels;
THYM	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg05283184	chr6:79620031	NA	-0.9	-9.12	-0.68	1.24e-14	Intelligence (multi-trait analysis);
THYM	cis	rs1681630	0.545	rs12790666	chr11:47983477	G/A	cg18512352	chr11:47633146	NA	-0.37	-4.54	-0.42	1.62e-5	Height;
THYM	cis	rs10895275	0.510	rs1942683	chr11:102044647	C/T	cg24447756	chr11:102105824	NA	-0.51	-4.49	-0.42	2.04e-5	Migraine;
THYM	cis	rs4478037	0.822	rs4320035	chr3:33113697	C/G	cg19404215	chr3:33155277	CRTAP	-1.01	-6.52	-0.56	3.34e-9	Major depressive disorder;
THYM	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg10360139	chr7:1886902	MAD1L1	-0.75	-6.83	-0.57	7.86e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs981844	1.000	rs2251900	chr4:154654145	C/T	cg09973105	chr4:154681532	RNF175	-0.59	-4.89	-0.45	4.1e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs4455778	0.580	rs4560745	chr7:49115412	G/T	cg26309511	chr7:48887640	NA	0.64	5.72	0.51	1.23e-7	Lung cancer in never smokers;
THYM	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg16405210	chr4:1374714	KIAA1530	-0.62	-5.07	-0.46	2e-6	Longevity;
THYM	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg02869364	chr7:1081709	C7orf50	-0.4	-4.45	-0.42	2.32e-5	Longevity;Endometriosis;
THYM	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg05347473	chr6:146136440	FBXO30	0.77	6.53	0.56	3.19e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg21433558	chr17:40837037	CNTNAP1	0.76	6.91	0.58	5.41e-10	Colorectal or endometrial cancer;
THYM	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg18252515	chr7:66147081	NA	-1.45	-8.88	-0.67	4.01e-14	Diabetic kidney disease;
THYM	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs7465272	0.957	rs11994668	chr8:143687392	G/T	cg10104451	chr8:143696006	ARC	-0.8	-5.52	-0.49	2.92e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs28595532	0.764	rs56309519	chr4:119754158	C/T	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	trans	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.93	6.05	0.53	2.87e-8	Platelet count;
THYM	cis	rs7560272	0.723	rs1052161	chr2:73828538	A/G	cg19565262	chr2:73869966	NAT8	-0.59	-4.85	-0.45	4.8e-6	Schizophrenia;
THYM	cis	rs2281845	0.895	rs1325309	chr1:201079458	T/A	cg17810781	chr1:201082982	CACNA1S	0.66	7.1	0.59	2.29e-10	Permanent tooth development;
THYM	cis	rs7772486	0.875	rs6934467	chr6:146410529	G/T	cg05347473	chr6:146136440	FBXO30	0.61	4.95	0.45	3.24e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg26818010	chr10:134567672	INPP5A	-0.75	-6.03	-0.53	3.08e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs2797685	0.617	rs172933	chr1:7844680	T/C	cg06712362	chr1:7811235	CAMTA1	-0.67	-5.47	-0.49	3.68e-7	Crohn's disease;
THYM	cis	rs7009516	0.692	rs9650408	chr8:24240670	T/C	cg01759110	chr8:24241694	ADAMDEC1	-0.52	-4.91	-0.45	3.83e-6	Hair greying;
THYM	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg23583168	chr7:148888333	NA	-1.03	-13.88	-0.82	1.38e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs11252926	0.527	rs11252754	chr10:538637	G/A	cg14018140	chr10:458528	DIP2C	-0.47	-4.65	-0.43	1.07e-5	Psychosis in Alzheimer's disease;
THYM	cis	rs4372836	0.576	rs6547880	chr2:29018889	T/C	cg09522027	chr2:28974177	PPP1CB	-0.62	-4.78	-0.44	6.43e-6	Body mass index;
THYM	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg14768367	chr16:72042858	DHODH	0.65	4.98	0.46	2.83e-6	Fibrinogen levels;
THYM	cis	rs9399401	0.710	rs6900087	chr6:142717303	A/T	cg04461802	chr6:142623433	GPR126	0.77	7.46	0.61	3.98e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs10789491	0.953	rs1866770	chr1:47182468	G/T	cg15501359	chr1:47185051	KIAA0494	1.14	8.24	0.65	9.45e-13	Response to hepatitis C treatment;
THYM	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg06784218	chr1:46089804	CCDC17	0.3	4.82	0.44	5.43e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs10045504	1.000	rs10045504	chr5:38762288	A/C	cg07423205	chr5:37834672	GDNF	0.47	4.84	0.44	4.99e-6	Night sleep phenotypes;
THYM	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg24399712	chr22:39784796	NA	-0.88	-8.02	-0.64	2.7e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg19729930	chr2:74357872	NA	1.01	7.23	0.6	1.2e-10	Gestational age at birth (maternal effect);
THYM	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg17366294	chr4:99064904	C4orf37	0.57	6.68	0.57	1.63e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs977987	0.806	rs4888389	chr16:75395228	T/C	cg03315344	chr16:75512273	CHST6	0.73	6.16	0.53	1.73e-8	Dupuytren's disease;
THYM	cis	rs7084921	0.578	rs11592631	chr10:101878219	G/A	cg11344164	chr10:101878520	NA	-0.63	-5.62	-0.5	1.87e-7	Bone mineral density;
THYM	cis	rs4455778	0.580	rs4273799	chr7:49079809	T/C	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.87	-0.52	6.49e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg13525197	chr6:28411240	ZSCAN23	0.68	5.44	0.49	4.13e-7	Pubertal anthropometrics;
THYM	cis	rs11864453	0.793	rs7197453	chr16:72079127	G/C	cg16558253	chr16:72132732	DHX38	-0.6	-5.52	-0.49	2.92e-7	Fibrinogen levels;
THYM	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.82	7.51	0.61	3.23e-11	Schizophrenia;
THYM	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg25918947	chr17:41365094	TMEM106A	-0.57	-4.59	-0.43	1.33e-5	Menopause (age at onset);
THYM	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg15445000	chr17:37608096	MED1	0.44	5.22	0.47	1.07e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7107174	1.000	rs9651769	chr11:77996166	T/C	cg19901956	chr11:77921274	USP35	-0.71	-5.45	-0.49	3.89e-7	Testicular germ cell tumor;
THYM	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg12311346	chr5:56204834	C5orf35	-0.81	-5.9	-0.52	5.54e-8	Initial pursuit acceleration;
THYM	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg12560992	chr17:57184187	TRIM37	-0.84	-7.19	-0.59	1.47e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2276314	0.857	rs62101394	chr18:33592299	C/T	cg05985134	chr18:33552581	C18orf21	0.66	4.84	0.44	5.02e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs1922291	0.546	rs3771185	chr2:102840507	C/T	cg13315345	chr2:102803985	IL1RL2	-0.61	-7.0	-0.58	3.67e-10	Blood protein levels;
THYM	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg21926883	chr2:100939477	LONRF2	-0.67	-6.25	-0.54	1.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs7546094	1.000	rs2999155	chr1:113221658	G/A	cg22162597	chr1:113214053	CAPZA1	-0.47	-4.7	-0.43	8.7e-6	Platelet distribution width;
THYM	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg19196401	chr6:110721138	DDO	-0.62	-6.73	-0.57	1.3e-9	Platelet distribution width;
THYM	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg16586182	chr3:47516702	SCAP	-0.62	-5.32	-0.48	6.98e-7	Colorectal cancer;
THYM	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg26769984	chr7:1090371	C7orf50	0.83	5.6	0.5	2.04e-7	Bronchopulmonary dysplasia;
THYM	cis	rs67981189	0.574	rs2010713	chr14:71368735	T/G	cg15910301	chr14:71632612	NA	-0.53	-4.63	-0.43	1.14e-5	Schizophrenia;
THYM	cis	rs8180040	0.800	rs56250009	chr3:47279497	G/C	cg27129171	chr3:47204927	SETD2	-0.75	-7.08	-0.59	2.48e-10	Colorectal cancer;
THYM	cis	rs11648796	0.879	rs12448432	chr16:778820	G/A	cg20104307	chr16:778658	HAGHL	0.4	5.88	0.52	6.15e-8	Height;
THYM	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06873352	chr17:61820015	STRADA	0.8	9.98	0.72	1.85e-16	Prudent dietary pattern;
THYM	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg10802521	chr3:52805072	NEK4	0.71	5.92	0.52	5.19e-8	Bipolar disorder;
THYM	cis	rs72827839	0.793	rs72825512	chr17:46155069	C/T	cg23391107	chr17:45924227	SP6	0.83	5.6	0.5	2.08e-7	Ease of getting up in the morning;
THYM	cis	rs454510	0.816	rs347904	chr1:120177620	C/T	cg16322792	chr1:120165303	ZNF697	0.63	5.01	0.46	2.5e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
THYM	cis	rs4919694	1.000	rs10509760	chr10:104634107	A/G	cg04362960	chr10:104952993	NT5C2	1.14	7.07	0.59	2.65e-10	Arsenic metabolism;
THYM	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs6570726	0.791	rs9399558	chr6:145911730	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg09085632	chr11:111637200	PPP2R1B	1.21	12.78	0.8	2.36e-22	Primary sclerosing cholangitis;
THYM	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg22968622	chr17:43663579	NA	1.18	10.66	0.74	6.45e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs662064	0.962	rs6540933	chr1:10547263	C/T	cg20482658	chr1:10539492	PEX14	-0.48	-5.93	-0.52	4.82e-8	Asthma;
THYM	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg02825527	chr7:2087843	MAD1L1	-0.76	-5.08	-0.46	1.88e-6	Neuroticism;
THYM	cis	rs733592	0.507	rs7138917	chr12:48455255	G/A	cg21466736	chr12:48725269	NA	0.44	4.74	0.44	7.57e-6	Plateletcrit;
THYM	trans	rs1641537	0.568	rs1641515	chr17:7551950	C/A	cg04140212	chr2:85829138	TMEM150A	-0.58	-7.0	-0.58	3.6e-10	Sex hormone-binding globulin levels;
THYM	cis	rs12478296	0.901	rs7423119	chr2:243005488	T/A	cg06360820	chr2:242988706	NA	-0.92	-6.13	-0.53	1.98e-8	Obesity-related traits;
THYM	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg23422044	chr7:1970798	MAD1L1	-0.75	-4.56	-0.42	1.54e-5	Neuroticism;
THYM	cis	rs7757969	1.000	rs7752620	chr6:112138294	C/T	cg08601457	chr6:112115117	FYN	-0.41	-4.62	-0.43	1.19e-5	Schizophrenia;
THYM	cis	rs28595532	0.920	rs55794497	chr4:119764664	A/G	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg00071950	chr4:10020882	SLC2A9	0.88	9.07	0.68	1.59e-14	Bone mineral density;
THYM	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg06600287	chr1:53387719	ECHDC2	-0.29	-4.69	-0.43	9.17e-6	Monocyte count;
THYM	cis	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg10856724	chr12:34555212	NA	-0.88	-8.25	-0.65	8.84e-13	Morning vs. evening chronotype;
THYM	cis	rs7926906	1.000	rs1404524	chr11:90533647	T/G	cg26138821	chr11:89956704	CHORDC1	-0.57	-5.2	-0.47	1.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2404602	0.647	rs11072625	chr15:77084984	A/G	cg23625390	chr15:77176239	SCAPER	0.89	6.51	0.56	3.55e-9	Blood metabolite levels;
THYM	cis	rs1642645	0.793	rs4083557	chr1:42478177	C/T	cg22816091	chr1:42611670	NA	0.62	5.52	0.49	2.99e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs8028313	0.630	rs16951105	chr15:67965694	A/G	cg26545918	chr15:68124484	LBXCOR1	0.55	4.85	0.45	4.87e-6	Obesity;
THYM	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg00277334	chr10:82204260	NA	-0.52	-5.37	-0.48	5.53e-7	Post bronchodilator FEV1;
THYM	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg27170947	chr2:26402098	FAM59B	-0.56	-4.59	-0.43	1.36e-5	Gut microbiome composition (summer);
THYM	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg27534772	chr1:16042836	PLEKHM2	0.56	6.31	0.54	8.77e-9	Systolic blood pressure;
THYM	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg08847533	chr14:75593920	NEK9	-0.96	-10.31	-0.73	3.66e-17	Height;
THYM	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg20291162	chr17:40259547	DHX58	-0.7	-6.47	-0.55	4.18e-9	Fibrinogen levels;
THYM	cis	rs17153755	0.796	rs2645456	chr8:11615182	A/G	cg23916205	chr8:11614368	GATA4	-0.6	-4.83	-0.44	5.33e-6	Testicular germ cell tumor;
THYM	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg12863693	chr15:85201151	NMB	0.63	5.5	0.49	3.17e-7	Schizophrenia;
THYM	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg27535305	chr1:53392650	SCP2	0.66	7.27	0.6	9.92e-11	Monocyte count;
THYM	cis	rs933688	1.000	rs1363839	chr5:90671274	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.75	4.91	0.45	3.8e-6	Smoking behavior;
THYM	cis	rs10203711	0.933	rs2334025	chr2:239564114	A/G	cg14580085	chr2:239553406	NA	-0.52	-4.48	-0.42	2.12e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9326248	0.731	rs90192	chr11:117059347	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.73	5.08	0.46	1.87e-6	Blood protein levels;
THYM	cis	rs13380717	0.554	rs9932360	chr16:86923791	C/G	cg05661093	chr16:86825505	NA	-0.56	-4.97	-0.45	2.92e-6	Sepsis in extremely premature infants;
THYM	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg15592062	chr6:167189543	RPS6KA2	-0.49	-4.89	-0.45	4.04e-6	Crohn's disease;
THYM	cis	rs7213347	0.611	rs1231207	chr17:2125450	A/C	cg16513277	chr17:2031491	SMG6	-0.64	-4.75	-0.44	7.17e-6	Total body bone mineral density;
THYM	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg07870213	chr5:140052090	DND1	0.71	7.63	0.62	1.84e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9733	0.570	rs951281	chr1:150691122	A/C	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg06481639	chr22:41940642	POLR3H	-0.83	-6.19	-0.54	1.55e-8	Vitiligo;
THYM	cis	rs12310956	0.510	rs1825903	chr12:33870437	G/C	cg06521331	chr12:34319734	NA	-0.57	-4.58	-0.43	1.42e-5	Morning vs. evening chronotype;
THYM	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.94	0.75	1.62e-18	Diabetic retinopathy;
THYM	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.53	0.56	3.29e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg05335186	chr13:53173507	NA	0.45	5.31	0.48	7.15e-7	Lewy body disease;
THYM	cis	rs887829	0.570	rs10168155	chr2:234596836	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-6.51	-0.56	3.47e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs11168351	0.864	rs12228750	chr12:48496997	G/A	cg21466736	chr12:48725269	NA	0.49	4.85	0.45	4.81e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7106204	0.748	rs28656439	chr11:24207653	G/C	ch.11.24196551F	chr11:24239977	NA	0.95	6.84	0.57	7.8e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs6032067	0.683	rs6032029	chr20:43786064	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.49	-0.49	3.31e-7	Blood protein levels;
THYM	cis	rs12208915	0.848	rs7774691	chr6:79505798	C/G	cg05283184	chr6:79620031	NA	0.74	4.84	0.44	5.06e-6	Left atrial antero-posterior diameter;
THYM	cis	rs7020830	0.898	rs2790063	chr9:37287405	G/A	cg14294708	chr9:37120828	ZCCHC7	1.24	14.33	0.83	1.74e-25	Schizophrenia;
THYM	cis	rs6956675	1.000	rs10229492	chr7:62580546	G/A	cg08930214	chr7:62859557	LOC100287834	0.62	4.58	0.43	1.42e-5	Obesity-related traits;
THYM	cis	rs11153147	0.502	rs75772189	chr6:109416369	C/G	cg17117243	chr6:109341365	SESN1	-0.9	-5.31	-0.48	7.24e-7	Mean corpuscular volume;
THYM	cis	rs2637266	0.756	rs846621	chr10:78545171	G/T	cg18941641	chr10:78392320	NA	0.68	5.55	0.5	2.54e-7	Pulmonary function;
THYM	cis	rs4767364	1.000	rs7979545	chr12:112790648	T/C	cg10833066	chr12:111807467	FAM109A	0.44	4.84	0.45	4.92e-6	Oral cavity and pharyngeal cancer;
THYM	cis	rs72829446	0.530	rs8071847	chr17:7407327	A/G	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs995000	0.895	rs597076	chr1:62917865	T/A	cg06896770	chr1:63153194	DOCK7	0.91	7.48	0.61	3.73e-11	Triglyceride levels;
THYM	cis	rs2070488	1.000	rs13074025	chr3:38455704	C/A	cg24069376	chr3:38537580	EXOG	0.66	6.49	0.55	3.91e-9	Electrocardiographic conduction measures;
THYM	cis	rs981844	0.754	rs897608	chr4:154754960	C/T	cg09973105	chr4:154681532	RNF175	-0.52	-4.98	-0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg05182265	chr7:156933206	UBE3C	0.59	7.11	0.59	2.15e-10	Body mass index;
THYM	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	9.4	0.69	3.1e-15	Chronic sinus infection;
THYM	cis	rs12310956	0.510	rs10844693	chr12:33865197	A/G	cg06521331	chr12:34319734	NA	0.56	4.45	0.42	2.34e-5	Morning vs. evening chronotype;
THYM	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg03433033	chr1:76189801	ACADM	0.77	9.42	0.69	2.92e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg19875535	chr5:140030758	IK	-0.58	-4.53	-0.42	1.69e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7586879	0.593	rs11689543	chr2:25130440	A/T	cg01884057	chr2:25150051	NA	0.75	7.96	0.63	3.73e-12	Body mass index;
THYM	cis	rs9660180	0.839	rs12040826	chr1:1705287	A/C	cg13866156	chr1:1669148	SLC35E2	-0.72	-7.33	-0.6	7.57e-11	Body mass index;
THYM	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg11366901	chr6:160182831	ACAT2	1.06	9.39	0.69	3.35e-15	Age-related macular degeneration (geographic atrophy);
THYM	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg20587970	chr11:113659929	NA	-1.32	-8.66	-0.66	1.23e-13	Hip circumference adjusted for BMI;
THYM	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg11764359	chr7:65958608	NA	-0.62	-4.73	-0.44	7.94e-6	Aortic root size;
THYM	cis	rs4969178	0.600	rs4969183	chr17:76393372	A/G	cg05887092	chr17:76393375	PGS1	0.41	4.67	0.43	9.98e-6	HDL cholesterol levels;
THYM	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg25767906	chr1:53392781	SCP2	0.55	4.92	0.45	3.69e-6	Monocyte count;
THYM	cis	rs7267979	1.000	rs7343481	chr20:25300113	C/T	cg08601574	chr20:25228251	PYGB	-0.57	-4.59	-0.43	1.35e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06634786	chr22:41940651	POLR3H	-0.67	-5.64	-0.5	1.75e-7	Vitiligo;
THYM	cis	rs7631605	0.967	rs9832138	chr3:37175960	A/G	cg21328643	chr3:37258149	NA	-0.47	-4.46	-0.42	2.26e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg02869364	chr7:1081709	C7orf50	-0.6	-4.79	-0.44	6.08e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg04518342	chr5:131593106	PDLIM4	0.45	5.03	0.46	2.32e-6	Breast cancer;
THYM	cis	rs7107174	0.688	rs10899501	chr11:78131408	C/T	cg19901956	chr11:77921274	USP35	-0.71	-5.35	-0.48	6.07e-7	Testicular germ cell tumor;
THYM	cis	rs4919087	1.000	rs11189122	chr10:99072595	G/A	cg19453742	chr10:98862320	SLIT1	-0.63	-5.17	-0.47	1.31e-6	Monocyte count;
THYM	cis	rs12477602	0.938	rs13024221	chr2:203058233	A/G	cg03345454	chr2:202901428	FZD7	0.73	4.56	0.42	1.51e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg08835221	chr22:38071607	LGALS1	-0.4	-5.27	-0.48	8.53e-7	Fat distribution (HIV);
THYM	cis	rs140330585	1	rs140330585	chr15:78866445	G/A	cg04882995	chr15:78912658	CHRNA3	0.54	4.54	0.42	1.62e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs8078723	0.866	rs7502514	chr17:38188844	A/G	cg17467752	chr17:38218738	THRA	-0.86	-7.08	-0.59	2.52e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg15445000	chr17:37608096	MED1	0.44	5.07	0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs36051895	0.664	rs12340866	chr9:5094185	G/A	cg02405213	chr9:5042618	JAK2	-1.0	-10.94	-0.75	1.67e-18	Pediatric autoimmune diseases;
THYM	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg11245990	chr11:68621969	NA	0.53	6.77	0.57	1.04e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg13683864	chr3:40499215	RPL14	-0.83	-7.81	-0.63	7.51e-12	Renal cell carcinoma;
THYM	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg12165864	chr7:66369176	NA	-0.65	-5.08	-0.46	1.89e-6	Aortic root size;
THYM	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	13.53	0.81	7.07e-24	Height;
THYM	cis	rs9359856	0.636	rs9294440	chr6:90308666	C/G	cg13799429	chr6:90582589	CASP8AP2	0.75	6.81	0.57	9e-10	Bipolar disorder;
THYM	trans	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg07393940	chr7:158741817	NA	-1.0	-7.35	-0.6	6.86e-11	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg18252515	chr7:66147081	NA	-1.57	-8.55	-0.66	2.07e-13	Diabetic kidney disease;
THYM	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs68170813	0.599	rs12532514	chr7:107000952	C/T	cg00661777	chr7:106511741	PIK3CG	-0.68	-4.71	-0.44	8.28e-6	Coronary artery disease;
THYM	cis	rs2069036	0.855	rs9988721	chr10:16077478	C/G	cg26633223	chr10:15133461	NA	0.65	4.69	0.43	9.18e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg13683864	chr3:40499215	RPL14	0.9	8.18	0.64	1.25e-12	Renal cell carcinoma;
THYM	cis	rs10256972	0.642	rs6961424	chr7:1004113	T/C	cg02602264	chr7:1026310	CYP2W1	-0.54	-5.17	-0.47	1.29e-6	Longevity;Endometriosis;
THYM	cis	rs6815814	0.861	rs11936050	chr4:38789524	C/T	cg06935464	chr4:38784597	TLR10	0.73	5.34	0.48	6.27e-7	Breast cancer;
THYM	cis	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg18252515	chr7:66147081	NA	0.61	4.57	0.42	1.47e-5	Aortic root size;
THYM	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03647317	chr4:187891568	NA	0.82	8.62	0.66	1.49e-13	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg07393940	chr7:158741817	NA	-1.14	-9.25	-0.69	6.69e-15	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs888194	0.568	rs10850137	chr12:109874794	C/G	cg10504392	chr12:110044639	NA	0.53	4.45	0.42	2.33e-5	Neuroticism;
THYM	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg00129232	chr17:37814104	STARD3	0.76	5.25	0.47	9.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs137603	0.644	rs137620	chr22:39709776	T/C	cg24268161	chr22:39747459	SYNGR1	0.65	5.49	0.49	3.4e-7	Primary biliary cholangitis;
THYM	cis	rs4285028	0.731	rs2877561	chr3:121712051	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.77	5.37	0.48	5.67e-7	Multiple sclerosis;
THYM	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg09307838	chr4:120376055	NA	0.68	5.08	0.46	1.86e-6	Corneal astigmatism;
THYM	cis	rs6570726	0.935	rs388394	chr6:145852689	C/T	cg13319975	chr6:146136371	FBXO30	-0.69	-6.01	-0.53	3.36e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg18252515	chr7:66147081	NA	-1.44	-8.51	-0.66	2.48e-13	Diabetic kidney disease;
THYM	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.22	9.08	0.68	1.54e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg18477163	chr1:228402036	OBSCN	0.65	6.53	0.56	3.17e-9	Diastolic blood pressure;
THYM	cis	rs2797160	1.000	rs2747725	chr6:126012397	A/C	cg16306078	chr6:126000798	NA	0.56	5.6	0.5	2.1e-7	Endometrial cancer;
THYM	cis	rs6467136	0.765	rs11764631	chr7:127179493	G/A	cg08586737	chr7:127225949	GCC1	-0.33	-4.87	-0.45	4.45e-6	Type 2 diabetes;
THYM	cis	rs9790314	0.934	rs455386	chr3:161102495	A/T	cg04691961	chr3:161091175	C3orf57	-0.58	-4.97	-0.45	3e-6	Morning vs. evening chronotype;
THYM	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg05754148	chr16:3507555	NAT15	-0.87	-6.93	-0.58	4.92e-10	Tuberculosis;
THYM	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg26513180	chr16:89883248	FANCA	-0.72	-7.38	-0.6	5.86e-11	Vitiligo;
THYM	cis	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.33e-5	Retinal vascular caliber;
THYM	cis	rs12478296	0.901	rs6731775	chr2:242999443	T/C	cg06360820	chr2:242988706	NA	-1.0	-6.71	-0.57	1.4e-9	Obesity-related traits;
THYM	cis	rs9868809	0.772	rs9812200	chr3:48695667	A/G	cg00383909	chr3:49044727	WDR6	-0.88	-5.14	-0.47	1.46e-6	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4732038	0.510	rs4529385	chr7:134271270	C/T	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs6438424	0.521	rs10934427	chr3:117721983	T/C	cg07910724	chr3:117604411	NA	0.5	4.69	0.43	9.28e-6	Menarche (age at onset);
THYM	cis	rs11785693	0.909	rs62489558	chr8:4968620	G/A	cg26367366	chr8:4980734	NA	1.16	5.47	0.49	3.64e-7	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs2836633	0.929	rs2836610	chr21:40044502	C/T	cg05519781	chr21:40033154	ERG	0.75	7.16	0.59	1.7e-10	Coronary artery disease;
THYM	cis	rs711830	1.000	rs1318778	chr2:177037831	C/G	cg26754761	chr2:177040938	NA	-0.58	-5.03	-0.46	2.27e-6	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs2505998	0.833	rs2505535	chr10:43593043	A/G	cg06632098	chr10:43605906	RET	-1.1	-10.64	-0.74	7.21e-18	Hirschsprung disease;
THYM	trans	rs8073060	0.586	rs7212488	chr17:33993476	A/T	cg19694781	chr19:47549865	TMEM160	-1.06	-9.08	-0.68	1.54e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs6542838	0.641	rs6757098	chr2:99471399	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-4.46	-0.42	2.24e-5	Fear of minor pain;
THYM	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg08305652	chr11:111469057	NA	0.53	4.51	0.42	1.88e-5	Primary sclerosing cholangitis;
THYM	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg10802521	chr3:52805072	NEK4	-0.73	-6.43	-0.55	5.15e-9	Bipolar disorder;
THYM	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg12292205	chr6:26970375	C6orf41	0.57	4.78	0.44	6.44e-6	Autism spectrum disorder or schizophrenia;
THYM	trans	rs3960554	0.808	rs868555	chr7:75697418	G/A	cg19862616	chr7:65841803	NCRNA00174	0.93	6.95	0.58	4.6e-10	Eotaxin levels;
THYM	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg22907277	chr7:1156413	C7orf50	0.84	8.19	0.64	1.21e-12	Longevity;Endometriosis;
THYM	cis	rs6087990	0.965	rs742630	chr20:31350664	C/G	cg13636640	chr20:31349939	DNMT3B	0.93	9.85	0.71	3.45e-16	Ulcerative colitis;
THYM	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg26597838	chr10:835615	NA	1.08	7.25	0.6	1.1e-10	Eosinophil percentage of granulocytes;
THYM	trans	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs61931739	0.853	rs10844751	chr12:34099651	T/G	cg06521331	chr12:34319734	NA	0.6	4.85	0.45	4.86e-6	Morning vs. evening chronotype;
THYM	cis	rs10744422	1.000	rs7972447	chr12:123354545	C/G	cg25930673	chr12:123319894	HIP1R	-0.84	-4.88	-0.45	4.25e-6	Schizophrenia;
THYM	cis	rs11671005	0.569	rs73068335	chr19:59089308	C/G	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.61	-4.9	-0.45	3.97e-6	Mean platelet volume;
THYM	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.69	0.57	1.53e-9	Body mass index;
THYM	cis	rs1775715	0.737	rs2799000	chr10:32124894	C/T	cg04359828	chr10:32216031	ARHGAP12	0.36	4.76	0.44	6.9e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06634786	chr22:41940651	POLR3H	0.69	5.31	0.48	7.18e-7	Vitiligo;
THYM	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.34	-0.65	5.7e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs4595586	0.545	rs6580893	chr12:39371885	G/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs7586879	0.765	rs11683429	chr2:25120733	T/A	cg01884057	chr2:25150051	NA	0.52	4.59	0.43	1.37e-5	Body mass index;
THYM	cis	rs4792901	0.765	rs34778116	chr17:41539698	G/T	cg21940313	chr17:41620911	ETV4	-0.52	-5.04	-0.46	2.23e-6	Dupuytren's disease;
THYM	cis	rs10411161	0.702	rs8110531	chr19:52383510	C/T	cg25361850	chr19:52391789	ZNF577	0.72	4.96	0.45	3.09e-6	Breast cancer;
THYM	trans	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg07211511	chr3:129823064	LOC729375	-1.2	-9.65	-0.7	9.11e-16	Blood pressure (smoking interaction);
THYM	cis	rs4595586	0.545	rs12819186	chr12:39356912	C/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs7917772	0.582	rs4917978	chr10:104366353	C/T	cg00122347	chr10:104236741	TMEM180	0.41	5.81	0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs28595532	0.920	rs114168088	chr4:119772666	G/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs9549367	0.724	rs7985335	chr13:113869244	G/T	cg18105134	chr13:113819100	PROZ	0.96	9.12	0.68	1.24e-14	Platelet distribution width;
THYM	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg04025307	chr7:1156635	C7orf50	0.52	4.51	0.42	1.88e-5	Longevity;Endometriosis;
THYM	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.35	-4.7	-0.43	8.85e-6	Longevity;Endometriosis;
THYM	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg17366294	chr4:99064904	C4orf37	0.54	6.4	0.55	5.74e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg08048268	chr3:133502702	NA	0.64	5.34	0.48	6.41e-7	Iron status biomarkers;
THYM	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg18681998	chr4:17616180	MED28	0.79	7.12	0.59	2.03e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs728616	0.867	rs12415870	chr10:81949470	A/G	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg10802521	chr3:52805072	NEK4	-0.6	-5.1	-0.46	1.71e-6	Electroencephalogram traits;
THYM	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg01448562	chr3:133502909	NA	-0.83	-6.87	-0.58	6.75e-10	Iron status biomarkers;
THYM	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg10117171	chr1:25599238	RHD	-0.65	-4.72	-0.44	8.13e-6	Erythrocyte sedimentation rate;
THYM	cis	rs7107174	0.901	rs10899500	chr11:78125246	A/G	cg02023728	chr11:77925099	USP35	0.65	5.15	0.47	1.4e-6	Testicular germ cell tumor;
THYM	cis	rs6720763	0.945	rs11902653	chr2:167997478	G/A	cg10633051	chr2:168042982	XIRP2	-0.72	-5.15	-0.47	1.39e-6	Atopic dermatitis;
THYM	cis	rs478304	0.651	rs11604451	chr11:65551710	C/T	cg17480646	chr11:65405466	SIPA1	-0.94	-8.85	-0.67	4.72e-14	Acne (severe);
THYM	cis	rs12682352	0.652	rs3827806	chr8:8724276	C/T	cg18904891	chr8:8559673	CLDN23	0.6	5.02	0.46	2.37e-6	Neuroticism;
THYM	cis	rs7107174	1.000	rs2511187	chr11:77985849	T/A	cg19901956	chr11:77921274	USP35	-0.68	-5.25	-0.47	9.31e-7	Testicular germ cell tumor;
THYM	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg17328964	chr8:145687451	CYHR1	0.68	6.9	0.58	5.88e-10	Age at first birth;
THYM	cis	rs9902453	0.868	rs7212162	chr17:28321328	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	6.54	0.56	3.11e-9	Coffee consumption (cups per day);
THYM	cis	rs35883536	0.647	rs7524322	chr1:101047730	C/G	cg06223162	chr1:101003688	GPR88	0.86	7.45	0.61	4.18e-11	Monocyte count;
THYM	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg18825531	chr11:62321136	NA	-0.44	-5.1	-0.46	1.76e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12667521	chr19:29218732	NA	0.89	8.17	0.64	1.34e-12	Methadone dose in opioid dependence;
THYM	cis	rs472109	0.535	rs10118	chr11:9800601	G/A	cg06876053	chr11:9810051	SBF2	-0.6	-4.72	-0.44	7.99e-6	Coronary artery disease;
THYM	cis	rs7178572	1.000	rs34591043	chr15:77713586	A/G	cg22256960	chr15:77711686	NA	-0.94	-7.93	-0.63	4.23e-12	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs921665	0.831	rs921666	chr2:3192141	G/C	cg16434511	chr2:3151078	NA	-0.87	-5.46	-0.49	3.8e-7	World class endurance athleticism;
THYM	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-13.94	-0.82	1.07e-24	Height;
THYM	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg14349672	chr11:133703707	NA	-0.51	-4.69	-0.43	9.19e-6	Childhood ear infection;
THYM	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs6980334	1.000	rs6977075	chr7:137775867	C/T	cg03464514	chr7:137028442	PTN	-0.56	-4.67	-0.43	9.74e-6	Blood metabolite ratios;
THYM	trans	rs111612372	1	rs111612372	chr2:20433218	T/C	cg27368651	chr22:31829985	DRG1	-0.85	-9.32	-0.69	4.81e-15	Body mass index;
THYM	cis	rs6500596	0.570	rs8055628	chr16:4447477	G/A	cg08645402	chr16:4508243	NA	0.74	6.33	0.54	8e-9	Schizophrenia;
THYM	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg17426766	chr1:2046864	PRKCZ	0.37	4.54	0.42	1.62e-5	Height;
THYM	cis	rs8067545	0.611	rs2526465	chr17:20167611	T/C	cg20830565	chr17:20408647	MGC102966	0.48	4.45	0.42	2.31e-5	Schizophrenia;
THYM	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg24642844	chr7:1081250	C7orf50	-1.0	-6.09	-0.53	2.37e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.63	5.08	0.46	1.88e-6	Blood metabolite levels;
THYM	cis	rs59197085	0.636	rs61012549	chr7:128442897	G/A	cg00734629	chr7:128471146	FLNC	0.77	4.52	0.42	1.8e-5	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
THYM	cis	rs2862064	1.000	rs7706978	chr5:156432566	T/C	cg12943317	chr5:156479607	HAVCR1	-0.86	-5.28	-0.48	8.3e-7	Platelet count;
THYM	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg11663144	chr21:46675770	NA	-0.74	-10.57	-0.74	1e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg05342682	chr7:94953680	PON1	-0.55	-6.13	-0.53	1.97e-8	Paraoxonase activity;
THYM	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg11663144	chr21:46675770	NA	-0.69	-9.29	-0.69	5.39e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.34	-0.65	5.7e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg21226059	chr5:178986404	RUFY1	0.6	6.13	0.53	2.03e-8	Lung cancer;
THYM	cis	rs10457678	0.564	rs3763187	chr6:139106787	G/A	cg05131254	chr6:138188363	TNFAIP3	0.63	4.45	0.42	2.33e-5	Colorectal or endometrial cancer;
THYM	cis	rs10895275	0.625	rs61893575	chr11:102040103	G/A	cg24447756	chr11:102105824	NA	-0.51	-4.87	-0.45	4.51e-6	Migraine;
THYM	cis	rs11048434	0.761	rs12827055	chr12:9130861	G/T	cg13575925	chr12:9217583	LOC144571	0.53	5.0	0.46	2.59e-6	Sjögren's syndrome;
THYM	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.51	-4.79	-0.44	6.24e-6	Lymphocyte counts;
THYM	cis	rs6032067	0.929	rs6017513	chr20:43835232	A/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.81	-0.57	8.91e-10	Blood protein levels;
THYM	cis	rs3741798	1.000	rs61922027	chr12:12486444	C/T	cg08615371	chr12:12503544	MANSC1	0.88	4.89	0.45	4.17e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs1003719	0.680	rs1034357	chr21:38571482	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-4.53	-0.42	1.72e-5	Eye color traits;
THYM	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg07636037	chr3:49044803	WDR6	0.99	10.41	0.73	2.15e-17	Parkinson's disease;
THYM	trans	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg10856724	chr12:34555212	NA	-0.94	-8.13	-0.64	1.61e-12	Bladder cancer;
THYM	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg21427119	chr20:30132790	HM13	-0.73	-4.94	-0.45	3.41e-6	Mean corpuscular hemoglobin;
THYM	cis	rs35883536	0.647	rs2783702	chr1:101040836	G/A	cg09408571	chr1:101003634	GPR88	0.51	5.56	0.5	2.44e-7	Monocyte count;
THYM	cis	rs1003719	0.788	rs60447195	chr21:38448600	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs490234	0.841	rs7863341	chr9:128449085	A/G	cg14078157	chr9:128172775	NA	0.63	4.9	0.45	4e-6	Mean arterial pressure;
THYM	cis	rs981844	0.740	rs7653960	chr4:154697430	T/G	cg09973105	chr4:154681532	RNF175	0.54	5.05	0.46	2.17e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg17757837	chr7:157058334	UBE3C	0.66	5.29	0.48	7.81e-7	Body mass index;
THYM	cis	rs939574	1.000	rs1109866	chr2:220083279	C/T	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.2	-5.46	-0.49	3.84e-7	Platelet distribution width;
THYM	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-4.65	-0.43	1.07e-5	Gut microbiome composition (summer);
THYM	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg23262073	chr20:60523788	NA	0.88	6.06	0.53	2.73e-8	Obesity-related traits;
THYM	cis	rs12257961	0.579	rs6602837	chr10:15370901	A/G	cg10616319	chr10:15468812	NA	-0.72	-5.66	-0.5	1.59e-7	Selective IgA deficiency;
THYM	cis	rs12257961	0.576	rs4750630	chr10:15400183	C/T	cg10616319	chr10:15468812	NA	-0.54	-4.58	-0.43	1.41e-5	Selective IgA deficiency;
THYM	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs7404928	0.651	rs60561757	chr16:23915241	C/T	cg26685404	chr16:23957272	PRKCB	0.66	7.48	0.61	3.68e-11	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs7953508	0.506	rs768775	chr12:93968197	T/C	cg18151635	chr12:93972918	NA	-0.87	-6.12	-0.53	2.07e-8	Pubertal anthropometrics;
THYM	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.76	-0.51	1.05e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs6547741	1.000	rs1528404	chr2:27846603	C/T	cg27432699	chr2:27873401	GPN1	-0.73	-6.36	-0.55	7.06e-9	Oral cavity cancer;
THYM	cis	rs17174870	1.000	rs80088736	chr2:112674805	A/G	cg17354880	chr2:112658759	MERTK	-0.58	-4.48	-0.42	2.11e-5	Multiple sclerosis;
THYM	cis	rs28595532	0.920	rs115271785	chr4:119735748	A/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs7572733	0.651	rs55852341	chr2:198491180	C/T	cg00792783	chr2:198669748	PLCL1	0.63	4.63	0.43	1.15e-5	Dermatomyositis;
THYM	cis	rs3847687	0.565	rs10848271	chr12:131519703	C/G	cg25772418	chr12:131519998	GPR133	-0.35	-4.51	-0.42	1.89e-5	Longevity;
THYM	cis	rs13086611	1	rs13086611	chr3:49385417	A/T	cg19602139	chr3:49690254	BSN	0.56	4.5	0.42	1.95e-5	Educational attainment;
THYM	cis	rs988913	1.000	rs1503135	chr6:54841672	C/T	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.75e-6	Menarche (age at onset);
THYM	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500637	0.580	rs5013674	chr16:4932470	G/A	cg08329684	chr16:4932620	PPL	-0.34	-4.59	-0.43	1.35e-5	Cancer;
THYM	cis	rs2075165	0.901	rs7522860	chr1:156275281	C/T	cg20302342	chr1:156215951	PAQR6	0.47	4.85	0.45	4.78e-6	Tonsillectomy;
THYM	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg23989207	chr17:80870107	TBCD	0.61	5.13	0.47	1.54e-6	Glycated hemoglobin levels;
THYM	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.14	6.64	0.56	1.9e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg20887711	chr4:1340912	KIAA1530	0.71	6.6	0.56	2.38e-9	Longevity;
THYM	cis	rs8141529	0.692	rs2239828	chr22:29358802	C/T	cg02153584	chr22:29168773	CCDC117	-0.65	-4.91	-0.45	3.72e-6	Lymphocyte counts;
THYM	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9796	0.621	rs7170049	chr15:41484287	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.57	-4.62	-0.43	1.19e-5	Menopause (age at onset);
THYM	cis	rs4654899	0.772	rs12145203	chr1:21086127	C/T	cg01072550	chr1:21505969	NA	-0.64	-5.53	-0.49	2.79e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg04362960	chr10:104952993	NT5C2	0.63	4.47	0.42	2.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6032067	0.714	rs2071651	chr20:43853153	T/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.61	-5.97	-0.52	4.08e-8	Blood protein levels;
THYM	cis	rs8001976	0.517	rs1924794	chr13:48275412	A/G	cg08008141	chr13:48761357	NA	0.78	4.68	0.43	9.38e-6	Aging (time to event);
THYM	cis	rs6867032	0.687	rs4998338	chr5:2015910	A/G	cg26168224	chr5:2018326	NA	1.29	15.56	0.85	7.19e-28	Gut microbiome composition (winter);
THYM	cis	rs11585357	0.895	rs2977305	chr1:17613737	A/T	cg08277548	chr1:17600880	PADI3	0.89	5.38	0.48	5.23e-7	Hair shape;
THYM	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg14004847	chr7:1930337	MAD1L1	-0.68	-5.52	-0.49	2.95e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs9880211	0.718	rs35320690	chr3:135932494	C/T	cg21827317	chr3:136751795	NA	0.68	4.76	0.44	7e-6	Body mass index;Height;
THYM	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg16797656	chr11:68205561	LRP5	0.45	4.73	0.44	7.75e-6	Total body bone mineral density;
THYM	cis	rs2806561	0.808	rs12128178	chr1:23354814	C/T	cg12483005	chr1:23474871	LUZP1	-0.51	-4.63	-0.43	1.17e-5	Height;
THYM	cis	rs78456975	0.506	rs13384333	chr2:1555531	A/C	cg12573674	chr2:1569213	NA	-1.31	-8.63	-0.66	1.38e-13	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg18641463	chr7:2144579	MAD1L1	0.62	4.52	0.42	1.79e-5	Height;
THYM	cis	rs59698941	0.943	rs66480446	chr5:132274793	T/C	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg14517863	chr17:44321492	NA	0.47	5.22	0.47	1.04e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs35883536	0.647	rs11166485	chr1:101048805	G/C	cg06223162	chr1:101003688	GPR88	-0.79	-6.76	-0.57	1.13e-9	Monocyte count;
THYM	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg27129171	chr3:47204927	SETD2	0.79	7.46	0.61	4.01e-11	Colorectal cancer;
THYM	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9399401	0.677	rs11155241	chr6:142664439	T/A	cg04461802	chr6:142623433	GPR126	0.8	7.42	0.61	5e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs860818	1.000	rs1637214	chr7:23236842	C/T	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg11663144	chr21:46675770	NA	-0.7	-9.65	-0.7	9.43e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11048434	0.518	rs2377678	chr12:9174158	A/G	cg26114124	chr12:9217669	LOC144571	0.53	4.49	0.42	2.01e-5	Sjögren's syndrome;
THYM	cis	rs7772486	0.875	rs9373483	chr6:146364194	A/G	cg23711669	chr6:146136114	FBXO30	0.93	9.69	0.7	7.64e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg09990169	chr2:241835740	C2orf54	-0.31	-5.13	-0.47	1.53e-6	Urinary metabolites;
THYM	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg08999081	chr20:33150536	PIGU	-0.71	-6.12	-0.53	2.05e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs7582180	0.764	rs1967341	chr2:100924559	T/C	cg14675211	chr2:100938903	LONRF2	0.76	8.22	0.64	1.01e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	5.41	0.49	4.63e-7	Hip circumference adjusted for BMI;
THYM	cis	rs61931739	0.513	rs10772116	chr12:33897795	G/C	cg10856724	chr12:34555212	NA	-0.67	-5.95	-0.52	4.46e-8	Morning vs. evening chronotype;
THYM	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg20203395	chr5:56204925	C5orf35	-0.66	-4.62	-0.43	1.22e-5	Initial pursuit acceleration;
THYM	cis	rs7020830	0.931	rs7851239	chr9:37138672	A/G	cg14294708	chr9:37120828	ZCCHC7	-1.39	-13.14	-0.8	4.28e-23	Schizophrenia;
THYM	cis	rs78761021	0.688	rs55811931	chr17:9796537	G/A	cg26853458	chr17:9805074	RCVRN	0.53	4.46	0.42	2.24e-5	Type 2 diabetes;
THYM	cis	rs478304	0.934	rs506853	chr11:65521247	C/T	cg27068330	chr11:65405492	SIPA1	0.82	7.91	0.63	4.72e-12	Acne (severe);
THYM	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs9972944	0.756	rs7212901	chr17:63766499	T/C	cg07283582	chr17:63770753	CCDC46	-0.67	-5.07	-0.46	1.92e-6	Total body bone mineral density;
THYM	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg10518543	chr12:38710700	ALG10B	-0.56	-4.56	-0.42	1.5e-5	Morning vs. evening chronotype;
THYM	cis	rs6840360	0.550	rs7683134	chr4:152503362	A/C	cg17479576	chr4:152424074	FAM160A1	-0.82	-5.82	-0.51	7.78e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg24672777	chr11:48374446	OR4C45	0.67	4.65	0.43	1.06e-5	Coronary artery disease;
THYM	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	7.8	0.62	7.81e-12	Platelet count;
THYM	cis	rs13232179	0.920	rs12703136	chr7:151119280	C/T	cg01177956	chr7:150756509	SLC4A2;CDK5	-0.79	-4.48	-0.42	2.1e-5	Coronary heart disease;
THYM	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-11.38	-0.76	1.93e-19	Coronary artery disease;
THYM	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg10523679	chr1:76189770	ACADM	0.75	5.67	0.5	1.52e-7	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg04518342	chr5:131593106	PDLIM4	0.49	5.26	0.47	8.91e-7	Acylcarnitine levels;
THYM	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg04248312	chr19:17393744	ANKLE1	-0.98	-13.19	-0.8	3.47e-23	Systemic lupus erythematosus;
THYM	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg03433033	chr1:76189801	ACADM	0.74	9.95	0.71	2.14e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs548181	0.545	rs76179820	chr11:125616379	A/G	cg03464685	chr11:125439445	EI24	-1.32	-8.04	-0.64	2.53e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6906287	0.647	rs6569015	chr6:118686344	C/T	cg21191810	chr6:118973309	C6orf204	0.52	5.02	0.46	2.36e-6	Electrocardiographic conduction measures;
THYM	cis	rs7631605	0.875	rs2110194	chr3:37097087	C/T	cg21328643	chr3:37258149	NA	-0.49	-4.59	-0.43	1.33e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg26513180	chr16:89883248	FANCA	0.72	7.21	0.59	1.34e-10	Vitiligo;
THYM	cis	rs823143	0.549	rs1094647	chr1:205655378	G/A	cg17178900	chr1:205818956	PM20D1	0.85	7.91	0.63	4.62e-12	Monocyte percentage of white cells;
THYM	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.27	9.69	0.7	7.64e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2109514	0.902	rs717957	chr7:116113107	G/C	cg12739419	chr7:116140593	CAV2	-0.48	-4.92	-0.45	3.58e-6	Prevalent atrial fibrillation;
THYM	trans	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg10856724	chr12:34555212	NA	-0.88	-7.63	-0.62	1.84e-11	Bladder cancer;
THYM	cis	rs6701037	0.566	rs10489326	chr1:175134677	A/G	cg08873628	chr1:175162347	KIAA0040	0.51	4.65	0.43	1.09e-5	Alcohol dependence;
THYM	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg12386194	chr3:101231763	SENP7	0.96	7.53	0.61	2.97e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg11645453	chr3:52864694	ITIH4	0.29	4.67	0.43	9.71e-6	Schizophrenia;
THYM	cis	rs7267979	1.000	rs4815409	chr20:25346697	C/A	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg18357526	chr6:26021779	HIST1H4A	0.73	5.63	0.5	1.85e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7589342	0.862	rs6745887	chr2:106468039	G/A	cg14210321	chr2:106509881	NCK2	-0.75	-5.6	-0.5	2.09e-7	Addiction;
THYM	cis	rs9747347	1	rs9747347	chr17:79606820	T/C	cg18240062	chr17:79603768	NPLOC4	0.72	5.65	0.5	1.69e-7	Myopia;
THYM	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg06481639	chr22:41940642	POLR3H	0.8	5.56	0.5	2.48e-7	Vitiligo;
THYM	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg11764359	chr7:65958608	NA	0.66	4.69	0.43	8.98e-6	Aortic root size;
THYM	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg03517284	chr6:25882590	NA	0.71	5.64	0.5	1.75e-7	Schizophrenia;
THYM	cis	rs11711311	0.955	rs9881563	chr3:113414031	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.56	4.78	0.44	6.37e-6	IgG glycosylation;
THYM	cis	rs7119	0.651	rs12904823	chr15:77837662	G/A	cg27398640	chr15:77910606	LINGO1	-0.63	-6.57	-0.56	2.74e-9	Type 2 diabetes;
THYM	cis	rs1050631	0.592	rs483583	chr18:33759017	G/A	cg25426722	chr18:33708991	SLC39A6;ELP2	0.61	4.69	0.43	9.29e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg24955955	chr5:415729	AHRR	1.06	5.98	0.52	3.84e-8	Fat distribution (HIV);
THYM	cis	rs7084402	0.935	rs12264028	chr10:60278140	C/T	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg24678163	chr13:52769951	THSD1P	0.49	4.58	0.43	1.38e-5	Lewy body disease;
THYM	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.81	-5.74	-0.51	1.13e-7	Body mass index;
THYM	cis	rs4243830	0.850	rs908273	chr1:6588604	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.81	-4.48	-0.42	2.11e-5	Body mass index;
THYM	cis	rs929596	0.639	rs2070959	chr2:234602191	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.82	-6.44	-0.55	4.92e-9	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs2072499	0.833	rs2251847	chr1:156204047	G/A	cg24450063	chr1:156163899	SLC25A44	1.01	11.21	0.75	4.32e-19	Testicular germ cell tumor;
THYM	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg05738196	chr6:26577821	NA	0.63	5.11	0.46	1.68e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7020830	0.931	rs13295115	chr9:37157964	T/G	cg14294708	chr9:37120828	ZCCHC7	1.3	15.72	0.85	3.55e-28	Schizophrenia;
THYM	cis	rs754466	1.000	rs12220311	chr10:79681507	C/T	cg17075019	chr10:79541650	NA	-0.61	-4.53	-0.42	1.7e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs72960926	0.744	rs72964203	chr6:74858552	T/C	cg03266952	chr6:74778945	NA	-0.93	-5.26	-0.47	9.06e-7	Metabolite levels (MHPG);
THYM	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg26031613	chr14:104095156	KLC1	0.81	5.35	0.48	6.02e-7	Body mass index;
THYM	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg03213289	chr20:61660250	NA	0.9	9.38	0.69	3.48e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg22841779	chr14:105766346	BRF1	-0.48	-6.0	-0.52	3.55e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg07507251	chr3:52567010	NT5DC2	0.46	5.52	0.49	2.93e-7	Electroencephalogram traits;
THYM	cis	rs6964587	0.692	rs2027950	chr7:91863700	C/G	cg22709100	chr7:91322751	NA	-0.67	-5.07	-0.46	1.97e-6	Breast cancer;
THYM	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg22974920	chr21:40686053	BRWD1	-0.57	-4.48	-0.42	2.04e-5	Cognitive function;
THYM	cis	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg01364799	chr7:75623366	TMEM120A	-0.62	-4.46	-0.42	2.22e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs41311933	0.831	rs12685344	chr9:123764991	G/A	cg13567360	chr9:123745713	C5	-1.01	-5.42	-0.49	4.53e-7	Coronary artery disease;
THYM	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg15744005	chr10:104629667	AS3MT	-0.8	-7.6	-0.61	2.08e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1729951	0.575	rs1682356	chr3:136692037	T/C	cg21827317	chr3:136751795	NA	0.75	6.64	0.56	1.92e-9	Neuroticism;
THYM	cis	rs7429990	0.965	rs9814961	chr3:48017617	A/G	cg02219026	chr3:48282209	ZNF589	-0.6	-4.5	-0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg09549813	chr16:4587862	C16orf5	-0.57	-6.52	-0.56	3.39e-9	Schizophrenia;
THYM	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg14018140	chr10:458528	DIP2C	-0.57	-6.39	-0.55	6.18e-9	Psychosis in Alzheimer's disease;
THYM	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg03690763	chr11:133734501	NA	-0.65	-5.26	-0.48	8.76e-7	Childhood ear infection;
THYM	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg21926883	chr2:100939477	LONRF2	-0.6	-5.39	-0.48	5.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg08999081	chr20:33150536	PIGU	-0.78	-7.16	-0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg07362569	chr17:61921086	SMARCD2	0.72	6.4	0.55	5.96e-9	Prudent dietary pattern;
THYM	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	8.57	0.66	1.87e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9825379	0.643	rs78960151	chr3:141146944	C/G	cg13411656	chr3:141121016	ZBTB38	-0.56	-4.78	-0.44	6.47e-6	Height;
THYM	cis	rs514406	0.893	rs6661115	chr1:53426148	G/A	cg08859206	chr1:53392774	SCP2	0.68	7.66	0.62	1.55e-11	Monocyte count;
THYM	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14115884	chr9:139300582	SDCCAG3	-0.68	-6.16	-0.53	1.77e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.91	10.43	0.73	2.04e-17	Prudent dietary pattern;
THYM	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg14582100	chr15:45693742	SPATA5L1	-0.63	-5.27	-0.48	8.56e-7	Homoarginine levels;
THYM	cis	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg22709100	chr7:91322751	NA	-0.62	-4.9	-0.45	3.98e-6	Breast cancer;
THYM	cis	rs8067545	0.586	rs57837691	chr17:20203073	T/C	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs6964587	0.692	rs4729025	chr7:91847504	C/T	cg22709100	chr7:91322751	NA	0.67	5.07	0.46	1.97e-6	Breast cancer;
THYM	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg11366901	chr6:160182831	ACAT2	1.01	8.95	0.68	2.91e-14	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-5.02	-0.46	2.39e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs346785	0.692	rs2279057	chr17:74309425	A/G	cg09812376	chr17:74270190	QRICH2	-0.49	-5.42	-0.49	4.56e-7	White matter hyperintensities in ischemic stroke;
THYM	cis	rs55883249	0.957	rs16867083	chr2:9767441	C/T	cg23886495	chr2:9695866	ADAM17	-0.73	-4.59	-0.43	1.35e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs12460587	0.587	rs55899235	chr19:52603124	T/C	cg05974498	chr19:52599256	ZNF841	0.34	5.42	0.49	4.48e-7	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs6988636	1.000	rs6988636	chr8:124185970	A/G	cg26140120	chr8:124219575	FAM83A	0.87	4.81	0.44	5.77e-6	Urinary uromodulin levels;
THYM	cis	rs40363	0.671	rs4786425	chr16:3537650	A/G	cg01073479	chr16:3509474	NAT15	-0.68	-5.45	-0.49	4.02e-7	Tuberculosis;
THYM	cis	rs611744	0.967	rs584555	chr8:109218612	C/G	cg21045802	chr8:109455806	TTC35	0.58	5.1	0.46	1.74e-6	Dupuytren's disease;
THYM	cis	rs9326248	0.581	rs7120963	chr11:116830261	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.64	-5.1	-0.46	1.73e-6	Blood protein levels;
THYM	cis	rs6669072	0.647	rs2954561	chr1:91240853	G/A	cg08895590	chr1:91227319	NA	-0.68	-8.42	-0.65	3.81e-13	Cognitive function;
THYM	cis	rs1691799	0.863	rs1168291	chr12:66732488	T/C	cg16791601	chr12:66731901	HELB	-0.76	-7.23	-0.6	1.21e-10	White blood cell count (basophil);
THYM	cis	rs2742417	0.603	rs2742372	chr3:45783472	T/C	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg10803722	chr21:46713166	LOC642852	-0.5	-6.23	-0.54	1.26e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7940866	0.834	rs10894302	chr11:130861994	C/T	cg05962950	chr11:130786565	SNX19	0.73	5.6	0.5	2.1e-7	Schizophrenia;
THYM	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg00129232	chr17:37814104	STARD3	-1.01	-7.91	-0.63	4.55e-12	Asthma;
THYM	cis	rs950880	0.710	rs2270298	chr2:102992079	A/G	cg03938978	chr2:103052716	IL18RAP	-0.5	-4.46	-0.42	2.24e-5	Serum protein levels (sST2);
THYM	cis	rs2108225	0.900	rs4518594	chr7:107451060	G/C	cg18560240	chr7:107437656	SLC26A3	-0.87	-6.68	-0.57	1.62e-9	Ulcerative colitis;
THYM	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg23356831	chr14:105996513	TMEM121	0.58	6.17	0.54	1.64e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs514406	0.792	rs1242201	chr1:53344748	G/A	cg08859206	chr1:53392774	SCP2	-0.73	-8.5	-0.66	2.66e-13	Monocyte count;
THYM	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg26513180	chr16:89883248	FANCA	0.72	6.97	0.58	4.09e-10	Vitiligo;
THYM	cis	rs4589258	1.000	rs4400760	chr11:90494775	G/A	cg26138821	chr11:89956704	CHORDC1	-0.7	-5.64	-0.5	1.74e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4660306	0.961	rs4660864	chr1:45966582	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.65	-5.23	-0.47	1.01e-6	Homocysteine levels;
THYM	trans	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg19862616	chr7:65841803	NCRNA00174	1.13	13.2	0.8	3.22e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs669446	0.562	rs4660259	chr1:44194534	A/G	cg12599982	chr1:44399894	ARTN	0.53	4.87	0.45	4.39e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg10792982	chr14:105748885	BRF1	0.75	7.8	0.62	7.96e-12	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg13695892	chr22:41940480	POLR3H	-0.91	-7.25	-0.6	1.09e-10	Vitiligo;
THYM	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg10802521	chr3:52805072	NEK4	-0.8	-7.5	-0.61	3.34e-11	Electroencephalogram traits;
THYM	cis	rs4363385	0.647	rs56412380	chr1:153000705	T/C	cg13444842	chr1:152974279	SPRR3	-0.59	-4.64	-0.43	1.11e-5	Inflammatory skin disease;
THYM	cis	rs5417	0.788	rs2654185	chr17:7183362	G/T	cg15298719	chr17:7165255	CLDN7	0.33	4.77	0.44	6.77e-6	Diastolic blood pressure;
THYM	cis	rs1467026	0.584	rs9880453	chr3:12804060	C/T	cg05775895	chr3:12838266	CAND2	0.85	6.99	0.58	3.73e-10	P wave duration;
THYM	cis	rs4888262	0.526	rs12921903	chr16:74625575	C/T	cg01733217	chr16:74700730	RFWD3	0.82	8.54	0.66	2.2e-13	Testicular germ cell tumor;
THYM	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg18252515	chr7:66147081	NA	0.63	4.64	0.43	1.1e-5	Aortic root size;
THYM	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg10164272	chr16:89456328	ANKRD11	0.59	4.55	0.42	1.6e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs9543976	0.588	rs7324195	chr13:76192522	G/A	cg01531495	chr13:76123901	UCHL3	0.66	4.8	0.44	5.85e-6	Diabetic retinopathy;
THYM	cis	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.65e-6	Aortic root size;
THYM	cis	rs4268898	0.636	rs72803210	chr2:24615710	A/G	cg06627628	chr2:24431161	ITSN2	-0.74	-5.0	-0.46	2.61e-6	Asthma;
THYM	cis	rs17030434	0.784	rs67664355	chr4:154660229	A/G	cg14289246	chr4:154710475	SFRP2	-0.72	-5.68	-0.5	1.45e-7	Electrocardiographic conduction measures;
THYM	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg20503657	chr10:835505	NA	1.1	7.6	0.61	2.12e-11	Eosinophil percentage of granulocytes;
THYM	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06634786	chr22:41940651	POLR3H	-0.81	-5.88	-0.52	6.16e-8	Vitiligo;
THYM	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.5	-4.66	-0.43	1.04e-5	Lymphocyte counts;
THYM	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg10253484	chr15:75165896	SCAMP2	0.66	4.54	0.42	1.64e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg06221963	chr1:154839813	KCNN3	-0.77	-9.84	-0.71	3.56e-16	Prostate cancer;
THYM	cis	rs80319144	0.521	rs55873205	chr2:159311576	C/G	cg24986868	chr2:159312599	PKP4;CCDC148	0.52	4.99	0.46	2.77e-6	Restless legs syndrome;
THYM	cis	rs2692947	0.770	rs72823920	chr2:96430876	G/A	cg22654517	chr2:96458247	NA	0.74	5.38	0.48	5.33e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg12379764	chr21:47803548	PCNT	-0.8	-5.15	-0.47	1.38e-6	Testicular germ cell tumor;
THYM	cis	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-5.84	-0.51	7.42e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg18446336	chr7:2847575	GNA12	0.52	5.17	0.47	1.3e-6	Loneliness (linear analysis);
THYM	cis	rs9902453	0.845	rs2628165	chr17:28121166	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.74	0.44	7.62e-6	Coffee consumption (cups per day);
THYM	cis	rs700651	0.821	rs4850812	chr2:198743655	G/T	cg05783139	chr2:198650985	BOLL	-0.62	-4.84	-0.44	5.09e-6	Intracranial aneurysm;
THYM	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.78	-0.44	6.31e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3818717	0.507	rs12940675	chr17:17651214	C/T	cg04398451	chr17:18023971	MYO15A	0.64	5.3	0.48	7.41e-7	Lymphocyte counts;
THYM	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.16	9.2	0.69	8.54e-15	Cognitive test performance;
THYM	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg00599163	chr2:162100495	NA	0.57	4.48	0.42	2.09e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6547741	0.904	rs2384628	chr2:27774702	T/G	cg27432699	chr2:27873401	GPN1	0.64	5.55	0.5	2.53e-7	Oral cavity cancer;
THYM	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg22868518	chr11:507468	RNH1	-1.11	-4.58	-0.43	1.41e-5	Body mass index;
THYM	cis	rs12530845	0.945	rs59664351	chr7:135314717	C/A	cg23117316	chr7:135346802	PL-5283	-0.64	-5.62	-0.5	1.93e-7	Red blood cell traits;
THYM	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg06784218	chr1:46089804	CCDC17	-0.34	-5.03	-0.46	2.28e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9574309	0.586	rs1218307	chr13:79417832	A/G	cg20271865	chr13:80233183	NA	0.38	4.73	0.44	7.72e-6	IgG glycosylation;
THYM	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg10505658	chr17:80084571	CCDC57	-0.72	-7.83	-0.63	6.9e-12	Life satisfaction;
THYM	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg01528321	chr10:82214614	TSPAN14	0.96	7.48	0.61	3.7e-11	Post bronchodilator FEV1;
THYM	trans	rs877282	0.891	rs11253355	chr10:768367	C/G	cg22713356	chr15:30763199	NA	1.4	11.3	0.76	2.86e-19	Uric acid levels;
THYM	cis	rs4849845	0.889	rs1065518	chr2:121050989	T/A	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs11148252	0.634	rs1571189	chr13:52731004	A/T	cg00495681	chr13:53174319	NA	0.57	4.9	0.45	3.86e-6	Lewy body disease;
THYM	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg12935359	chr14:103987150	CKB	-0.65	-6.4	-0.55	5.78e-9	Body mass index;
THYM	cis	rs28595532	0.841	rs116452272	chr4:119770802	T/C	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs11087114	0.561	rs6079567	chr20:14780425	G/A	cg04470754	chr20:14904432	MACROD2	-0.71	-4.55	-0.42	1.6e-5	Common carotid intima-media thickness in HIV infection;
THYM	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg10515332	chr4:99064459	C4orf37	0.58	4.67	0.43	9.78e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1797885	0.714	rs299661	chr3:12554069	A/G	cg05467012	chr3:12595696	NA	0.54	4.64	0.43	1.1e-5	Immature fraction of reticulocytes;
THYM	cis	rs10203711	1.000	rs6711116	chr2:239596636	T/G	cg14580085	chr2:239553406	NA	0.66	5.88	0.52	5.96e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17604090	0.526	rs10260080	chr7:29757941	T/G	cg19413766	chr7:29689036	LOC646762	-0.96	-4.81	-0.44	5.74e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs9311676	0.609	rs55845662	chr3:58424899	A/C	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs7523273	0.597	rs2724374	chr1:207941191	G/T	cg22525895	chr1:207977042	MIR29B2	0.76	5.18	0.47	1.27e-6	Schizophrenia;
THYM	cis	rs9329289	0.550	rs11251294	chr10:2562328	C/T	cg15501526	chr10:2543763	NA	-0.61	-5.85	-0.51	6.97e-8	Age-related hearing impairment;
THYM	cis	rs4930776	0.966	rs862394	chr12:5769554	A/G	cg02086166	chr12:5775618	ANO2	0.57	5.51	0.49	3.1e-7	Plasma clusterin levels;
THYM	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg17366294	chr4:99064904	C4orf37	0.54	6.31	0.54	8.73e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs936229	0.911	rs6939	chr15:75136257	A/C	cg14664628	chr15:75095509	CSK	-1.04	-8.13	-0.64	1.61e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg09517075	chr8:22133004	PIWIL2	0.63	5.74	0.51	1.14e-7	Hypertriglyceridemia;
THYM	cis	rs4907240	0.925	rs11164109	chr2:97300833	T/A	cg18419276	chr2:96971862	SNRNP200	-0.4	-4.75	-0.44	7.2e-6	Event-related brain oscillations;
THYM	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg09549813	chr16:4587862	C16orf5	0.58	6.58	0.56	2.58e-9	Schizophrenia;
THYM	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs921968	0.541	rs58650092	chr2:219304851	C/A	cg02176678	chr2:219576539	TTLL4	-0.75	-7.66	-0.62	1.55e-11	Mean corpuscular hemoglobin concentration;
THYM	cis	rs714027	0.585	rs5752978	chr22:30300586	C/G	cg27665648	chr22:30112403	NA	0.53	4.7	0.43	8.92e-6	Lymphocyte counts;
THYM	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg16486109	chr11:613632	IRF7	0.47	5.59	0.5	2.19e-7	Systemic lupus erythematosus;
THYM	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg01416388	chr22:39784598	NA	-0.87	-6.8	-0.57	9.43e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs73198271	0.700	rs10103282	chr8:8650757	T/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-4.77	-0.44	6.56e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4474465	0.688	rs10899553	chr11:78265210	A/G	cg02023728	chr11:77925099	USP35	-0.53	-4.62	-0.43	1.21e-5	Alzheimer's disease (survival time);
THYM	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg24675056	chr1:15929824	NA	0.73	5.93	0.52	4.81e-8	Systolic blood pressure;
THYM	trans	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg08901578	chr4:187885870	NA	-0.65	-6.34	-0.55	7.77e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7113850	0.541	rs7935630	chr11:24222206	A/C	ch.11.24196551F	chr11:24239977	NA	0.92	4.89	0.45	4.04e-6	Bone fracture in osteoporosis;
THYM	cis	rs919433	0.684	rs55775495	chr2:198245965	C/T	cg00792783	chr2:198669748	PLCL1	0.78	5.39	0.48	5.11e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03264133	chr6:25882463	NA	-0.7	-5.51	-0.49	3.06e-7	Blood metabolite levels;
THYM	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.56	0.81	6.23e-24	Height;
THYM	cis	rs250585	0.736	rs499812	chr16:23410419	T/C	cg00143387	chr16:23521605	GGA2	0.74	5.25	0.47	9.16e-7	Egg allergy;
THYM	cis	rs6087771	0.714	rs6058259	chr20:30235302	A/G	cg13852791	chr20:30311386	BCL2L1	0.86	8.08	0.64	2.03e-12	Subcortical brain region volumes;Putamen volume;
THYM	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg16486109	chr11:613632	IRF7	0.52	5.33	0.48	6.51e-7	Systemic lupus erythematosus;
THYM	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg11366901	chr6:160182831	ACAT2	1.02	8.95	0.68	2.9e-14	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg26384229	chr12:38710491	ALG10B	0.98	7.51	0.61	3.24e-11	Morning vs. evening chronotype;
THYM	cis	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg06521331	chr12:34319734	NA	0.95	9.13	0.68	1.19e-14	Morning vs. evening chronotype;
THYM	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg11905131	chr22:24372483	LOC391322	-0.98	-12.81	-0.8	2.02e-22	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg05573699	chr3:52720067	GNL3;PBRM1	-0.54	-4.54	-0.42	1.67e-5	Bipolar disorder;
THYM	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg25566285	chr7:158114605	PTPRN2	0.89	10.22	0.72	5.47e-17	Calcium levels;
THYM	cis	rs4891159	0.790	rs9950025	chr18:74113596	C/G	cg24786174	chr18:74118243	ZNF516	0.87	9.75	0.71	5.54e-16	Longevity;
THYM	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg23708337	chr7:1209742	NA	0.63	4.54	0.42	1.63e-5	Longevity;Endometriosis;
THYM	cis	rs1728785	1.000	rs1170445	chr16:68573064	G/T	cg02972257	chr16:68554789	NA	-0.75	-4.62	-0.43	1.22e-5	Ulcerative colitis;
THYM	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-5.1	-0.46	1.74e-6	Lymphocyte counts;
THYM	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg26597838	chr10:835615	NA	1.21	8.74	0.67	7.95e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs2075230	0.778	rs114255812	chr17:7476549	T/C	cg10509001	chr17:7553872	ATP1B2	0.59	4.69	0.43	9e-6	Hormone measurements;
THYM	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg05660106	chr1:15850417	CASP9	0.75	6.05	0.53	2.87e-8	Systolic blood pressure;
THYM	cis	rs1011018	0.628	rs10224408	chr7:139415723	G/A	cg06079564	chr7:139468310	HIPK2	-0.75	-4.84	-0.44	5.09e-6	Systolic blood pressure;
THYM	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg02953382	chr22:24373134	LOC391322	-0.69	-6.22	-0.54	1.3e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3087591	0.960	rs1801052	chr17:29508775	C/T	cg24425628	chr17:29625626	OMG;NF1	0.66	5.79	0.51	9.11e-8	Hip circumference;
THYM	cis	rs28595532	0.920	rs17257945	chr4:119666465	T/A	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs4862307	0.514	rs7696176	chr4:185014390	A/G	cg06737308	chr4:185021514	ENPP6	0.79	7.83	0.63	6.84e-12	Serum dimethylarginine levels (asymmetric/symetric ratio);
THYM	trans	rs4650994	1.000	rs10913572	chr1:178526718	C/T	cg05059571	chr16:84539110	KIAA1609	-0.75	-8.15	-0.64	1.43e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs6960043	0.575	rs10224343	chr7:15032808	C/A	cg19272540	chr7:15055459	NA	-0.52	-5.92	-0.52	4.99e-8	Type 2 diabetes;
THYM	cis	rs34526934	0.566	rs62624470	chr2:177040907	C/T	cg26754761	chr2:177040938	NA	-0.73	-6.48	-0.55	3.98e-9	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs13040088	0.935	rs62200158	chr20:61557906	C/T	cg23096297	chr20:61557774	DIDO1	1.07	7.38	0.6	6.06e-11	Menopause (age at onset);
THYM	cis	rs7152530	0.545	rs7159827	chr14:98636968	C/A	cg05180522	chr14:98101740	NA	-0.62	-4.71	-0.44	8.33e-6	Staphylococcus aureus infection;
THYM	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg12419862	chr22:24373484	LOC391322	-0.86	-9.09	-0.68	1.44e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg12564285	chr5:131593104	PDLIM4	-0.43	-4.73	-0.44	7.77e-6	Breast cancer;
THYM	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg08885076	chr2:99613938	TSGA10	-0.64	-5.53	-0.49	2.86e-7	Chronic sinus infection;
THYM	cis	rs4732038	0.510	rs11976004	chr7:134272392	C/A	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg26516362	chr5:178986906	RUFY1	0.38	4.75	0.44	7.09e-6	Lung cancer;
THYM	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	7.27	0.6	1.01e-10	Platelet count;
THYM	cis	rs9902453	0.765	rs2874505	chr17:28037923	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.8	6.1	0.53	2.28e-8	Coffee consumption (cups per day);
THYM	cis	rs7119038	0.730	rs10790269	chr11:118729456	C/T	cg19308663	chr11:118741387	NA	-0.57	-5.5	-0.49	3.2e-7	Sjögren's syndrome;
THYM	cis	rs7695732	0.550	rs10006121	chr4:89901115	A/G	cg17769793	chr4:89976368	FAM13A	-0.49	-5.2	-0.47	1.17e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7772486	0.875	rs6909827	chr6:146365738	A/G	cg13319975	chr6:146136371	FBXO30	-0.72	-6.02	-0.53	3.33e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg11871910	chr12:69753446	YEATS4	0.69	5.6	0.5	2.04e-7	Blood protein levels;
THYM	cis	rs79057730	0.684	rs6955004	chr7:790792	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.96	4.85	0.45	4.81e-6	Initial pursuit acceleration;
THYM	cis	rs6840360	0.571	rs4696279	chr4:152560449	G/A	cg22705602	chr4:152727874	NA	-0.76	-7.92	-0.63	4.35e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4732038	0.565	rs706193	chr7:134269909	A/G	cg06906464	chr7:134288099	NA	-0.46	-4.61	-0.43	1.26e-5	Longevity;
THYM	cis	rs7731657	0.509	rs6595985	chr5:130339400	A/C	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs28647808	0.881	rs7029256	chr9:136263655	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs4919044	0.808	rs835275	chr10:94796683	T/C	cg05127821	chr10:94822908	CYP26C1	-1.23	-6.66	-0.56	1.76e-9	Coronary artery disease;
THYM	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg08213375	chr14:104286397	PPP1R13B	0.46	4.85	0.45	4.9e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg25918947	chr17:41365094	TMEM106A	-0.69	-5.63	-0.5	1.86e-7	Menopause (age at onset);
THYM	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg24642439	chr20:33292090	TP53INP2	0.59	4.69	0.43	9.31e-6	Coronary artery disease;
THYM	cis	rs763014	0.898	rs8060921	chr16:635988	C/A	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs939658	0.776	rs11631411	chr15:79445816	C/T	cg17916960	chr15:79447300	NA	-0.75	-8.85	-0.67	4.67e-14	Refractive error;
THYM	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-4.74	-0.44	7.42e-6	Joint mobility (Beighton score);
THYM	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg04455712	chr21:45112962	RRP1B	0.5	4.53	0.42	1.74e-5	Mean corpuscular volume;
THYM	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg06600287	chr1:53387719	ECHDC2	-0.29	-4.69	-0.43	9.17e-6	Monocyte count;
THYM	cis	rs1065852	0.526	rs1062753	chr22:42392811	G/A	cg08431931	chr22:42394659	WBP2NL	0.74	6.08	0.53	2.48e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2888674	0.527	rs10231759	chr7:150512172	A/G	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.57	4.55	0.42	1.56e-5	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
THYM	cis	rs2219968	0.923	rs35392911	chr8:78976979	C/A	cg00738934	chr8:78996279	NA	0.92	10.08	0.72	1.12e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1448094	0.512	rs10863086	chr12:86244225	G/A	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg22968622	chr17:43663579	NA	-1.1	-9.99	-0.72	1.7e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs977987	0.778	rs2113232	chr16:75391185	T/C	cg03315344	chr16:75512273	CHST6	0.75	6.28	0.54	1.02e-8	Dupuytren's disease;
THYM	cis	rs72627123	0.881	rs17094011	chr14:74392128	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs6763768	0.668	rs312475	chr3:53513354	A/G	cg16894138	chr3:53270350	TKT	0.69	5.06	0.46	2.05e-6	Bacterial meningitis;
THYM	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg00376283	chr12:123451042	ABCB9	0.72	4.94	0.45	3.36e-6	Neutrophil percentage of white cells;
THYM	cis	rs6430585	0.583	rs79176913	chr2:136638113	C/A	cg07169764	chr2:136633963	MCM6	1.25	14.39	0.83	1.36e-25	Corneal structure;
THYM	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg00071950	chr4:10020882	SLC2A9	0.75	7.49	0.61	3.45e-11	Bone mineral density;
THYM	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs4589258	0.737	rs1792611	chr11:90430498	T/A	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg17888033	chr8:143858414	LYNX1	-0.45	-5.16	-0.47	1.34e-6	Urinary tract infection frequency;
THYM	cis	rs611744	0.647	rs1584373	chr8:109263399	C/A	cg21045802	chr8:109455806	TTC35	0.63	5.66	0.5	1.62e-7	Dupuytren's disease;
THYM	cis	rs11771526	0.551	rs2392053	chr7:32259056	C/T	cg13207630	chr7:32358064	NA	-0.72	-4.95	-0.45	3.26e-6	Body mass index;
THYM	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg19507638	chr5:93509721	C5orf36	-0.68	-4.57	-0.42	1.49e-5	Diabetic retinopathy;
THYM	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg01324343	chr3:183735012	ABCC5	0.9	13.08	0.8	5.7e-23	Anterior chamber depth;
THYM	cis	rs4642101	0.511	rs9809596	chr3:12840513	C/G	cg05775895	chr3:12838266	CAND2	1.12	11.44	0.76	1.46e-19	QRS complex (12-leadsum);
THYM	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg10862848	chr6:42927986	GNMT	-0.52	-6.87	-0.58	6.64e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs904251	0.861	rs1757173	chr6:37486952	A/C	cg01843034	chr6:37503916	NA	-0.71	-5.61	-0.5	1.98e-7	Cognitive performance;
THYM	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg02953382	chr22:24373134	LOC391322	-0.71	-6.49	-0.55	3.93e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.71	-7.66	-0.62	1.54e-11	Crohn's disease;
THYM	cis	rs17401966	0.838	rs11121551	chr1:10435170	T/C	cg19773385	chr1:10388646	KIF1B	-0.59	-4.82	-0.44	5.39e-6	Hepatocellular carcinoma;
THYM	cis	rs11252926	0.565	rs4881308	chr10:484983	G/T	cg14018140	chr10:458528	DIP2C	-0.49	-4.94	-0.45	3.36e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.5	-0.42	1.9e-5	Morning vs. evening chronotype;
THYM	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Body mass index;
THYM	cis	rs901683	1.000	rs17451208	chr10:46051905	C/G	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs7560272	0.723	rs6743576	chr2:73814333	G/A	cg19565262	chr2:73869966	NAT8	-0.61	-5.0	-0.46	2.65e-6	Schizophrenia;
THYM	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg24675658	chr1:53192096	ZYG11B	-0.78	-6.53	-0.56	3.28e-9	Monocyte count;
THYM	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.83	-7.63	-0.62	1.78e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg26384229	chr12:38710491	ALG10B	1.0	7.56	0.61	2.54e-11	Bladder cancer;
THYM	cis	rs8063160	0.756	rs71396951	chr16:89726593	G/C	cg07984980	chr16:89898383	SPIRE2	1.49	6.02	0.53	3.3e-8	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg19507638	chr5:93509721	C5orf36	-0.65	-4.54	-0.42	1.63e-5	Diabetic retinopathy;
THYM	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.71	6.5	0.56	3.64e-9	Personality dimensions;
THYM	cis	rs2073145	0.779	rs13042465	chr20:56199319	G/T	cg00177431	chr20:56272862	PMEPA1	0.51	4.56	0.42	1.55e-5	Hippocampal atrophy;
THYM	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg23422044	chr7:1970798	MAD1L1	-0.77	-5.3	-0.48	7.56e-7	Bipolar disorder;
THYM	cis	rs34779708	0.966	rs12782948	chr10:35450607	G/A	cg03585969	chr10:35415529	CREM	0.66	4.76	0.44	6.85e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs10461617	0.541	rs7715822	chr5:56043600	G/T	cg03609598	chr5:56110824	MAP3K1	-0.89	-4.51	-0.42	1.88e-5	Type 2 diabetes;
THYM	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg24375607	chr4:120327624	NA	0.62	5.03	0.46	2.32e-6	Corneal astigmatism;
THYM	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7631605	1.000	rs2302507	chr3:37144535	C/A	cg21328643	chr3:37258149	NA	-0.47	-4.51	-0.42	1.87e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg03806693	chr22:41940476	POLR3H	-0.84	-6.41	-0.55	5.61e-9	Neuroticism;
THYM	cis	rs2456568	0.805	rs55784864	chr11:93682887	G/A	cg17595323	chr11:93583763	C11orf90	-0.54	-5.22	-0.47	1.04e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs4746818	0.793	rs2805913	chr10:70858062	A/G	cg11621586	chr10:70884670	VPS26A	1.02	7.45	0.61	4.31e-11	Left atrial antero-posterior diameter;
THYM	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs72828912	0.665	rs9393523	chr6:24067664	A/G	cg26336265	chr6:25042955	NA	-0.86	-5.43	-0.49	4.31e-7	Squamous cell lung carcinoma;
THYM	cis	rs7084402	0.967	rs7100474	chr10:60273121	T/C	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs7191439	0.858	rs6500489	chr16:88772046	T/C	cg02389323	chr16:88786976	FAM38A	1.0	5.55	0.49	2.55e-7	Plateletcrit;
THYM	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7937682	0.575	rs34558891	chr11:111737912	C/T	cg09085632	chr11:111637200	PPP2R1B	1.19	12.58	0.79	6.05e-22	Primary sclerosing cholangitis;
THYM	cis	rs58873874	0.737	rs79951742	chr5:156886713	A/G	cg08916508	chr5:156566250	MED7	-1.29	-4.86	-0.45	4.57e-6	Bipolar disorder (body mass index interaction);
THYM	cis	rs1214752	0.935	rs4714684	chr6:43396856	G/T	cg09674015	chr6:43045187	PTK7	0.5	4.66	0.43	1.02e-5	Coronary artery disease;
THYM	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg05182265	chr7:156933206	UBE3C	0.7	9.62	0.7	1.05e-15	Body mass index;
THYM	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs9359856	0.510	rs2768940	chr6:90436319	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.86	-8.59	-0.66	1.67e-13	Bipolar disorder;
THYM	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs10752881	1.000	rs4402094	chr1:182986441	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.79	0.44	6.13e-6	Colorectal cancer;
THYM	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg14349672	chr11:133703707	NA	-0.51	-4.69	-0.43	9.19e-6	Childhood ear infection;
THYM	cis	rs11030122	0.673	rs66596383	chr11:3979745	C/T	cg18678763	chr11:4115507	RRM1	-0.43	-5.4	-0.48	5.01e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg14324370	chr2:177042789	NA	-0.69	-5.82	-0.51	7.82e-8	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs6546324	0.625	rs2861681	chr2:67830139	A/G	cg18237512	chr2:67827392	NA	-0.78	-4.63	-0.43	1.16e-5	Endometriosis;
THYM	cis	rs3768617	0.510	rs12086466	chr1:183075778	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.58	-4.77	-0.44	6.72e-6	Fuchs's corneal dystrophy;
THYM	cis	rs478304	0.934	rs498354	chr11:65528213	A/G	cg17480646	chr11:65405466	SIPA1	0.7	6.27	0.54	1.07e-8	Acne (severe);
THYM	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.53	-4.92	-0.45	3.66e-6	Lymphocyte counts;
THYM	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg27170947	chr2:26402098	FAM59B	-0.78	-6.09	-0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1395	0.778	rs11126918	chr2:27438710	G/A	cg23587288	chr2:27483067	SLC30A3	-0.63	-5.55	-0.5	2.53e-7	Blood metabolite levels;
THYM	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.59	4.58	0.43	1.4e-5	Height;
THYM	cis	rs10752881	1.000	rs10797808	chr1:182979623	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg15744005	chr10:104629667	AS3MT	-0.78	-7.33	-0.6	7.48e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.21	8.51	0.66	2.47e-13	Cognitive test performance;
THYM	cis	rs7000551	0.619	rs2443506	chr8:22373383	T/C	cg12081754	chr8:22256438	SLC39A14	0.68	6.12	0.53	2.07e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs12681287	0.752	rs10092651	chr8:87247678	A/C	cg27223183	chr8:87520930	FAM82B	-0.6	-4.64	-0.43	1.1e-5	Caudate activity during reward;
THYM	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg24060327	chr5:131705240	SLC22A5	-0.81	-6.71	-0.57	1.4e-9	Breast cancer;
THYM	cis	rs9790314	0.543	rs1349352	chr3:161118486	C/T	cg03342759	chr3:160939853	NMD3	-0.84	-7.31	-0.6	8.38e-11	Morning vs. evening chronotype;
THYM	cis	rs2294693	0.945	rs9369252	chr6:40986028	C/T	cg14418226	chr6:40996092	UNC5CL	-0.66	-4.82	-0.44	5.45e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs6032067	0.632	rs35361894	chr20:43794403	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs740474	0.768	rs6880745	chr5:140981247	C/A	cg24137543	chr5:140893634	NA	0.51	6.08	0.53	2.5e-8	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs17253792	0.545	rs12894613	chr14:56016221	T/C	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg00801512	chr17:28996047	NA	-0.76	-4.9	-0.45	3.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4523957	0.855	rs9893573	chr17:2126003	A/G	cg16513277	chr17:2031491	SMG6	-0.81	-8.07	-0.64	2.15e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg27494647	chr7:150038898	RARRES2	0.4	4.59	0.43	1.35e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2898681	0.561	rs7699960	chr4:53735661	C/A	cg00791764	chr4:53727839	RASL11B	0.6	6.55	0.56	2.92e-9	Optic nerve measurement (cup area);
THYM	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg13736514	chr6:26305472	NA	-0.69	-7.02	-0.58	3.34e-10	Educational attainment;
THYM	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.57	4.92	0.45	3.66e-6	Hip circumference adjusted for BMI;
THYM	cis	rs684232	0.602	rs8064796	chr17:525937	A/C	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.39	-4.77	-0.44	6.73e-6	Prostate cancer;
THYM	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.93	10.4	0.73	2.32e-17	Prudent dietary pattern;
THYM	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.82	-5.88	-0.52	6.04e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13012494	chr21:47604986	C21orf56	-0.77	-5.47	-0.49	3.69e-7	Testicular germ cell tumor;
THYM	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.21	-9.54	-0.7	1.61e-15	Platelet count;
THYM	cis	rs1061377	1.000	rs7673299	chr4:39110758	G/A	cg24403649	chr4:39172243	NA	0.56	4.56	0.42	1.54e-5	Uric acid levels;
THYM	cis	rs2195525	0.572	rs883247	chr11:119217254	C/T	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.44	4.92	0.45	3.56e-6	Urate levels;
THYM	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg19875535	chr5:140030758	IK	0.63	5.69	0.5	1.43e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg06028605	chr16:24865363	SLC5A11	0.63	5.03	0.46	2.3e-6	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.635	rs7979207	chr12:33910566	C/T	cg06521331	chr12:34319734	NA	0.57	4.76	0.44	7e-6	Morning vs. evening chronotype;
THYM	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg21862992	chr11:68658383	NA	0.23	4.48	0.42	2.07e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs995000	0.931	rs1184547	chr1:63007228	G/A	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs36051895	0.623	rs7043634	chr9:5263146	G/A	cg02405213	chr9:5042618	JAK2	-0.94	-9.2	-0.69	8.64e-15	Pediatric autoimmune diseases;
THYM	cis	rs4242434	0.672	rs3758041	chr8:22486987	A/G	cg01710189	chr8:22454888	PDLIM2	-0.48	-5.12	-0.47	1.56e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg01324343	chr3:183735012	ABCC5	0.72	8.35	0.65	5.61e-13	Anterior chamber depth;
THYM	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg07636037	chr3:49044803	WDR6	1.0	10.78	0.74	3.59e-18	Parkinson's disease;
THYM	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.41	-0.65	4.08e-13	Mean corpuscular volume;
THYM	cis	rs12643440	0.538	rs4299576	chr4:17140108	G/A	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs17443541	0.507	rs2122535	chr2:200456289	G/A	cg03741458	chr2:200468445	NA	-0.8	-6.04	-0.53	3.03e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg10360139	chr7:1886902	MAD1L1	-0.58	-4.94	-0.45	3.35e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs11671005	0.735	rs3088284	chr19:58929427	G/A	cg18639983	chr19:58920768	ZNF584	0.61	5.02	0.46	2.37e-6	Mean platelet volume;
THYM	cis	rs9486719	1.000	rs2499809	chr6:96870110	C/T	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs921968	0.643	rs579610	chr2:219327582	C/A	cg02176678	chr2:219576539	TTLL4	0.68	6.71	0.57	1.42e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs362272	0.505	rs10155132	chr4:3369500	A/G	cg14583973	chr4:3374767	RGS12	0.66	6.18	0.54	1.59e-8	Serum sulfate level;
THYM	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg06873352	chr17:61820015	STRADA	-0.69	-8.83	-0.67	5.13e-14	Prudent dietary pattern;
THYM	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg10802521	chr3:52805072	NEK4	-0.68	-5.57	-0.5	2.36e-7	Bipolar disorder;
THYM	cis	rs28595532	0.920	rs114581578	chr4:119756404	C/T	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg13939156	chr17:80058883	NA	0.4	5.25	0.47	9.42e-7	Life satisfaction;
THYM	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg02527881	chr3:46936655	PTH1R	-0.61	-5.71	-0.51	1.28e-7	Colorectal cancer;
THYM	cis	rs7131987	0.650	rs7954871	chr12:29459732	G/A	cg09582351	chr12:29534625	ERGIC2	-0.6	-5.2	-0.47	1.12e-6	QT interval;
THYM	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg14582100	chr15:45693742	SPATA5L1	0.65	5.36	0.48	5.94e-7	Homoarginine levels;
THYM	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.68	5.07	0.46	1.95e-6	Tonsillectomy;
THYM	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg04944784	chr2:26401820	FAM59B	-1.05	-8.18	-0.64	1.23e-12	Gut microbiome composition (summer);
THYM	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg04546413	chr19:29218101	NA	0.71	4.45	0.42	2.34e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg24163568	chr5:669837	TPPP	-0.58	-5.41	-0.49	4.63e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs981844	0.816	rs62325151	chr4:154730595	A/G	cg09973105	chr4:154681532	RNF175	-0.66	-5.45	-0.49	3.98e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs228769	1.000	rs12937692	chr17:42256430	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	5.78	0.51	9.37e-8	Bone mineral density (hip);Bone mineral density (spine);
THYM	cis	rs7178572	0.633	rs7162637	chr15:77843365	A/G	cg22256960	chr15:77711686	NA	-0.77	-5.62	-0.5	1.87e-7	Type 2 diabetes;
THYM	cis	rs9733	0.596	rs3087960	chr1:150620569	C/G	cg04414720	chr1:150670196	GOLPH3L	0.66	5.06	0.46	2.06e-6	Tonsillectomy;
THYM	cis	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs1697139	0.528	rs7725332	chr5:66529458	T/C	cg11553311	chr5:66541588	NA	0.61	6.33	0.54	8.02e-9	Breast cancer;
THYM	cis	rs4343996	0.811	rs6462030	chr7:3392526	G/A	cg21248987	chr7:3385318	SDK1	-0.41	-5.06	-0.46	2.02e-6	Motion sickness;
THYM	cis	rs3772130	0.962	rs11707504	chr3:121496734	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06873352	chr17:61820015	STRADA	0.56	5.58	0.5	2.22e-7	Height;
THYM	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.7	-4.71	-0.43	8.57e-6	Menarche (age at onset);
THYM	cis	rs593982	0.920	rs1151501	chr11:65484883	A/G	cg08755490	chr11:65554678	OVOL1	1.29	4.66	0.43	1.03e-5	Atopic dermatitis;
THYM	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.67	5.27	0.48	8.43e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg08085267	chr17:45401833	C17orf57	-0.62	-4.9	-0.45	4.01e-6	Glaucoma (primary open-angle);
THYM	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg05738196	chr6:26577821	NA	0.95	9.89	0.71	2.78e-16	Intelligence (multi-trait analysis);
THYM	cis	rs921968	0.643	rs10187066	chr2:219514759	A/G	cg02176678	chr2:219576539	TTLL4	0.6	5.84	0.51	7.3e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg10760299	chr15:45669010	GATM	0.9	6.98	0.58	4.02e-10	Homoarginine levels;
THYM	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg08807101	chr21:30365312	RNF160	-0.73	-5.41	-0.49	4.65e-7	Dental caries;
THYM	cis	rs735539	0.521	rs2585902	chr13:21417636	A/C	cg02792322	chr13:21280448	IL17D	-0.66	-4.78	-0.44	6.37e-6	Dental caries;
THYM	cis	rs17255340	0.577	rs12192297	chr6:84070966	T/C	cg08257003	chr6:84140564	ME1	0.58	4.66	0.43	1.01e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs28595532	0.764	rs55913633	chr4:119747444	C/A	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.93	10.54	0.73	1.16e-17	Prudent dietary pattern;
THYM	cis	rs868036	1.000	rs6494696	chr15:68103206	C/G	cg24579218	chr15:68104479	NA	0.67	6.84	0.57	7.75e-10	Restless legs syndrome;
THYM	cis	rs9388451	0.505	rs6920965	chr6:126179111	G/A	cg05901451	chr6:126070800	HEY2	-0.67	-4.82	-0.44	5.41e-6	Brugada syndrome;
THYM	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg11597832	chr14:105993747	TMEM121	-0.5	-4.54	-0.42	1.66e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg16928487	chr17:17741425	SREBF1	-0.56	-5.54	-0.49	2.67e-7	Total body bone mineral density;
THYM	cis	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg11009520	chr8:12052164	FAM86B1	0.61	5.05	0.46	2.14e-6	Morning vs. evening chronotype;
THYM	cis	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg21775007	chr8:11205619	TDH	-0.6	-4.91	-0.45	3.82e-6	Retinal vascular caliber;
THYM	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg09549813	chr16:4587862	C16orf5	-0.58	-6.32	-0.54	8.61e-9	Schizophrenia;
THYM	cis	rs7359257	0.967	rs6494654	chr15:67681907	C/T	cg24579218	chr15:68104479	NA	-0.54	-4.62	-0.43	1.19e-5	Menarche (age at onset);
THYM	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg23332699	chr15:44069569	ELL3	0.72	4.61	0.43	1.23e-5	Lung cancer in ever smokers;
THYM	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg20503657	chr10:835505	NA	1.37	9.4	0.69	3.17e-15	Eosinophil percentage of granulocytes;
THYM	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg20486651	chr6:167070296	RPS6KA2	0.5	4.79	0.44	6.18e-6	Crohn's disease;
THYM	cis	rs17789174	0.523	rs35006889	chr16:85077196	C/T	cg09576074	chr16:84341327	WFDC1	0.39	4.45	0.42	2.36e-5	Dysphagia;
THYM	cis	rs4866334	1.000	rs76259459	chr5:18456963	A/T	cg24599790	chr5:18972260	NA	-1.14	-4.67	-0.43	9.77e-6	IgG glycosylation;
THYM	cis	rs4389656	0.857	rs2279657	chr5:6737571	A/G	cg10857441	chr5:6722123	POLS	-0.44	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs11030122	0.592	rs4910880	chr11:4084630	C/G	cg18678763	chr11:4115507	RRM1	-0.41	-5.33	-0.48	6.72e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.86	-5.67	-0.5	1.56e-7	Body mass index;
THYM	cis	rs4294134	0.832	rs35061496	chr7:135254269	T/C	cg08396481	chr7:135194601	CNOT4	-0.81	-4.58	-0.43	1.42e-5	Paget's disease;
THYM	cis	rs7580658	0.676	rs12465955	chr2:128007074	A/T	cg09152259	chr2:128156114	NA	-0.34	-4.5	-0.42	1.96e-5	Protein C levels;
THYM	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg26513180	chr16:89883248	FANCA	0.71	7.22	0.6	1.3e-10	Vitiligo;
THYM	trans	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg19862616	chr7:65841803	NCRNA00174	1.06	11.85	0.77	2e-20	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4474465	1.000	rs11237522	chr11:78209879	A/G	cg19901956	chr11:77921274	USP35	-0.66	-4.95	-0.45	3.22e-6	Alzheimer's disease (survival time);
THYM	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg23262073	chr20:60523788	NA	-0.9	-6.12	-0.53	2.06e-8	Obesity-related traits;
THYM	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg03859395	chr2:55845619	SMEK2	0.64	5.8	0.51	8.82e-8	Metabolic syndrome;
THYM	cis	rs35883536	0.647	rs2783693	chr1:101045040	C/T	cg09408571	chr1:101003634	GPR88	0.48	5.21	0.47	1.07e-6	Monocyte count;
THYM	cis	rs36051895	0.632	rs62543560	chr9:5175938	C/T	cg02405213	chr9:5042618	JAK2	-1.02	-10.66	-0.74	6.51e-18	Pediatric autoimmune diseases;
THYM	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg00271210	chr6:167070053	RPS6KA2	0.72	7.96	0.63	3.73e-12	Crohn's disease;
THYM	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.64	-8.65	-0.66	1.29e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.36	-0.48	5.86e-7	Alzheimer's disease (late onset);
THYM	cis	rs9302065	0.565	rs2993586	chr13:95962578	T/C	cg24476569	chr13:95954382	ABCC4	-0.79	-8.01	-0.63	2.85e-12	Blood metabolite levels;
THYM	cis	rs10193935	0.901	rs222464	chr2:42643889	C/T	cg27598129	chr2:42591480	NA	-0.72	-4.47	-0.42	2.2e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs490234	0.676	rs13299008	chr9:128213966	T/G	cg14078157	chr9:128172775	NA	-0.79	-6.47	-0.55	4.3e-9	Mean arterial pressure;
THYM	cis	rs9378357	0.850	rs6910086	chr6:3287118	T/C	cg10513992	chr6:3293720	SLC22A23	1.02	4.83	0.44	5.32e-6	Obesity-related traits;
THYM	cis	rs8070740	0.898	rs9895440	chr17:5325643	C/A	cg25236894	chr17:5323110	RPAIN;NUP88	0.72	6.03	0.53	3.15e-8	Menopause (age at onset);
THYM	cis	rs56104184	0.723	rs116909499	chr19:49407733	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.83	-4.61	-0.43	1.25e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2504916	0.784	rs2484241	chr6:160771618	G/A	cg19643109	chr6:160697625	NA	-0.67	-4.67	-0.43	9.81e-6	Response to hepatitis C treatment;
THYM	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg07936489	chr17:37558343	FBXL20	-0.82	-5.61	-0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg01238044	chr22:24384105	GSTT1	-0.53	-4.7	-0.43	8.83e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg00129232	chr17:37814104	STARD3	0.71	4.8	0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg12011299	chr4:100065546	ADH4	0.74	7.23	0.6	1.24e-10	Alcohol dependence;
THYM	cis	rs3892630	0.824	rs34425841	chr19:33231619	C/T	cg22980127	chr19:33182716	NUDT19	1.1	8.03	0.64	2.56e-12	Red blood cell traits;
THYM	cis	rs2085601	0.542	rs1708660	chr4:89956164	A/G	cg17769793	chr4:89976368	FAM13A	-0.53	-5.85	-0.51	7.01e-8	Hair greying;
THYM	cis	rs2070677	1.000	rs12263487	chr10:135403585	A/G	cg20169779	chr10:135381914	SYCE1	-1.07	-6.81	-0.57	8.99e-10	Gout;
THYM	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.47	0.49	3.57e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2730245	0.583	rs2788473	chr7:158649280	T/C	cg23730037	chr7:158596552	ESYT2	-0.45	-4.64	-0.43	1.1e-5	Height;
THYM	cis	rs5769765	0.908	rs4058453	chr22:50250297	T/C	cg08270630	chr22:50330655	NA	0.73	4.83	0.44	5.24e-6	Schizophrenia;
THYM	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg27572855	chr1:25598939	RHD	0.7	5.38	0.48	5.4e-7	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	6.93	0.58	5.06e-10	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs586688	0.582	rs1270536	chr1:201670876	A/G	cg14168733	chr1:201708718	NAV1	-0.59	-5.33	-0.48	6.58e-7	Obesity-related traits;
THYM	cis	rs6674176	0.628	rs3828146	chr1:44428715	C/T	cg13246856	chr1:44399776	ARTN	0.48	4.87	0.45	4.49e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs62070183	0.938	rs9898762	chr17:31038659	G/A	cg23177095	chr17:30873196	MYO1D	0.65	5.19	0.47	1.18e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg10802521	chr3:52805072	NEK4	-0.66	-6.1	-0.53	2.32e-8	Bipolar disorder;
THYM	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg18758796	chr5:131593413	PDLIM4	0.6	5.9	0.52	5.68e-8	Acylcarnitine levels;
THYM	cis	rs2668423	0.501	rs502121	chr19:1387299	T/C	cg02639931	chr19:1387894	NDUFS7	-0.58	-9.01	-0.68	2.11e-14	Nonalcoholic fatty liver disease;
THYM	cis	rs3008870	0.755	rs2065002	chr1:67487119	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.8	-6.74	-0.57	1.22e-9	Lymphocyte percentage of white cells;
THYM	cis	rs11771526	0.901	rs28631129	chr7:32305044	G/C	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs3087591	1.000	rs8068801	chr17:29570587	G/T	cg24425628	chr17:29625626	OMG;NF1	-0.68	-5.95	-0.52	4.46e-8	Hip circumference;
THYM	cis	rs2806561	0.796	rs1738467	chr1:23506521	C/T	cg12483005	chr1:23474871	LUZP1	0.59	6.3	0.54	9.22e-9	Height;
THYM	cis	rs524023	1.000	rs10792441	chr11:64360629	C/T	cg19131476	chr11:64387923	NRXN2	-0.36	-5.0	-0.46	2.61e-6	Urate levels in obese individuals;
THYM	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs7192380	0.964	rs8055756	chr16:69648653	A/G	cg09409435	chr16:70099608	PDXDC2	-0.62	-4.82	-0.44	5.35e-6	Sjögren's syndrome;
THYM	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg23187316	chr7:1099788	C7orf50	0.58	4.45	0.42	2.32e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs1003719	0.646	rs7276711	chr21:38578189	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-4.53	-0.42	1.72e-5	Eye color traits;
THYM	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs6430585	0.583	rs59243420	chr2:136584538	A/T	cg07169764	chr2:136633963	MCM6	1.21	14.22	0.82	2.97e-25	Corneal structure;
THYM	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg22496339	chr2:162101262	NA	0.73	5.82	0.51	7.83e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9913156	0.841	rs72824957	chr17:4590496	C/T	cg19197139	chr17:4613644	ARRB2	0.84	4.97	0.45	2.92e-6	Lymphocyte counts;
THYM	cis	rs6430585	0.702	rs1042712	chr2:136545844	C/G	cg23851026	chr2:136556271	LCT	-0.78	-7.36	-0.6	6.49e-11	Corneal structure;
THYM	cis	rs1003719	0.688	rs2000413	chr21:38539718	G/A	cg01329690	chr21:38580129	DSCR9	-0.36	-5.01	-0.46	2.54e-6	Eye color traits;
THYM	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg13114125	chr14:105738426	BRF1	0.72	5.68	0.5	1.49e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs12530845	0.673	rs4073627	chr7:135312572	A/G	cg19897172	chr7:135347071	PL-5283	0.51	4.76	0.44	6.99e-6	Red blood cell traits;
THYM	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.12	-0.47	1.58e-6	Primary biliary cholangitis;
THYM	cis	rs10979	1.000	rs12191231	chr6:143891114	A/C	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs2997447	0.802	rs72884792	chr1:26436688	G/C	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs7104764	0.917	rs7107362	chr11:244108	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg13902645	chr11:5959945	NA	-0.53	-4.62	-0.43	1.19e-5	DNA methylation (variation);
THYM	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.12e-15	Body mass index;
THYM	cis	rs6450176	1.000	rs7707547	chr5:53295737	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.84	-6.38	-0.55	6.53e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs8014204	0.901	rs2080087	chr14:75365062	C/T	cg06637938	chr14:75390232	RPS6KL1	0.59	5.71	0.51	1.3e-7	Caffeine consumption;
THYM	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg07061783	chr6:25882402	NA	0.8	6.75	0.57	1.15e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1451375	0.617	rs10271341	chr7:50591583	A/C	cg18232548	chr7:50535776	DDC	0.67	5.03	0.46	2.31e-6	Malaria;
THYM	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.65	-4.72	-0.44	8.09e-6	Colorectal cancer;
THYM	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg26384229	chr12:38710491	ALG10B	1.0	8.01	0.63	2.86e-12	Bladder cancer;
THYM	cis	rs12983728	0.572	rs59114323	chr19:58649994	C/T	cg07378217	chr19:58662286	ZNF329	-0.76	-5.01	-0.46	2.53e-6	Cholesterol, total;
THYM	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs12478296	1.000	rs6739247	chr2:243039189	C/A	cg06360820	chr2:242988706	NA	-0.87	-5.4	-0.48	4.88e-7	Obesity-related traits;
THYM	cis	rs56104184	0.775	rs73063505	chr19:49402765	T/C	cg17863274	chr19:49399704	TULP2	-1.01	-6.47	-0.55	4.29e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg21775007	chr8:11205619	TDH	0.74	6.67	0.57	1.65e-9	Retinal vascular caliber;
THYM	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg09021430	chr5:549028	NA	-0.73	-5.44	-0.49	4.18e-7	Obesity-related traits;
THYM	cis	rs4919687	0.550	rs7904396	chr10:104456838	C/T	cg18761893	chr10:103892519	PPRC1	0.61	4.71	0.43	8.5e-6	Colorectal cancer;
THYM	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.51	0.81	7.55e-24	Height;
THYM	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg15592062	chr6:167189543	RPS6KA2	0.58	5.8	0.51	8.65e-8	Crohn's disease;
THYM	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg07492924	chr16:433825	LOC100134368	0.48	5.25	0.47	9.1e-7	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs3106136	0.527	rs4235050	chr4:95157156	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.1	-0.46	1.7e-6	Capecitabine sensitivity;
THYM	cis	rs35934224	0.783	rs7284106	chr22:19857549	T/C	cg11182965	chr22:19864308	TXNRD2	-0.74	-6.03	-0.53	3.14e-8	Glaucoma (primary open-angle);
THYM	cis	rs7631605	0.967	rs4678949	chr3:37253277	C/T	cg21328643	chr3:37258149	NA	-0.57	-5.53	-0.49	2.79e-7	Cerebrospinal P-tau181p levels;
THYM	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.64	-0.5	1.73e-7	Menopause (age at onset);
THYM	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg10334053	chr1:2078117	PRKCZ	0.45	4.58	0.43	1.39e-5	Height;
THYM	cis	rs6430585	0.759	rs12467770	chr2:136536095	G/A	cg23851026	chr2:136556271	LCT	0.79	7.53	0.61	2.86e-11	Corneal structure;
THYM	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs7084402	0.935	rs1427195	chr10:60278967	T/C	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs4363385	0.510	rs12083211	chr1:153032131	A/T	cg13444842	chr1:152974279	SPRR3	0.63	5.14	0.47	1.48e-6	Inflammatory skin disease;
THYM	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg26384229	chr12:38710491	ALG10B	1.03	9.92	0.71	2.51e-16	Heart rate;
THYM	cis	rs9807989	0.507	rs4851572	chr2:103019031	G/A	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs1448094	0.556	rs11610789	chr12:86169541	A/G	cg00310523	chr12:86230176	RASSF9	0.56	4.94	0.45	3.29e-6	Major depressive disorder;
THYM	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21659725	chr3:3221576	CRBN	-0.88	-9.81	-0.71	4.18e-16	Intelligence (multi-trait analysis);
THYM	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg14416269	chr4:6271139	WFS1	0.55	5.69	0.5	1.41e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs113835537	0.529	rs11227503	chr11:66275242	G/C	cg24851651	chr11:66362959	CCS	0.7	4.82	0.44	5.46e-6	Airway imaging phenotypes;
THYM	cis	rs7119	0.637	rs12913005	chr15:77856571	T/A	cg10437265	chr15:77819839	NA	0.71	7.55	0.61	2.66e-11	Type 2 diabetes;
THYM	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg04455712	chr21:45112962	RRP1B	0.6	5.97	0.52	4.06e-8	Mean corpuscular volume;
THYM	cis	rs7072216	0.727	rs6584199	chr10:100169983	A/G	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs11645898	0.688	rs437638	chr16:72095452	C/T	cg14768367	chr16:72042858	DHODH	-0.78	-5.37	-0.48	5.63e-7	Blood protein levels;
THYM	cis	rs4363385	0.818	rs11205176	chr1:153002481	A/G	cg13444842	chr1:152974279	SPRR3	-0.59	-4.81	-0.44	5.61e-6	Inflammatory skin disease;
THYM	cis	rs2985684	0.894	rs7152110	chr14:50018218	T/C	cg02151108	chr14:50098012	C14orf104	-0.76	-6.46	-0.55	4.47e-9	Carotid intima media thickness;
THYM	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg00383909	chr3:49044727	WDR6	1.05	5.98	0.52	3.82e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg10047753	chr17:41438598	NA	1.18	11.26	0.76	3.4e-19	Menopause (age at onset);
THYM	cis	rs2882877	0.648	rs35078179	chr2:190391921	A/C	cg10752008	chr2:190445175	SLC40A1	0.72	6.14	0.53	1.9e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7122539	0.734	rs4930391	chr11:66645254	A/G	cg24851651	chr11:66362959	CCS	-0.63	-5.34	-0.48	6.22e-7	HIV-1 susceptibility;
THYM	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg02493798	chr17:6899577	ALOX12	0.64	8.4	0.65	4.32e-13	Tonsillectomy;
THYM	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg03404566	chr17:6899310	ALOX12	-0.75	-9.58	-0.7	1.33e-15	Tonsillectomy;
THYM	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg02353165	chr6:42928485	GNMT	0.85	8.12	0.64	1.72e-12	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg20387954	chr3:183756860	HTR3D	0.58	4.81	0.44	5.56e-6	Anterior chamber depth;
THYM	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg00666640	chr1:248458726	OR2T12	0.57	4.75	0.44	7.19e-6	Common traits (Other);
THYM	cis	rs7072216	0.763	rs2274246	chr10:100175060	C/T	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs1729951	0.575	rs16844326	chr3:136678385	G/C	cg21827317	chr3:136751795	NA	0.75	6.64	0.56	1.92e-9	Neuroticism;
THYM	cis	rs11771526	0.901	rs11760534	chr7:32262966	C/T	cg13207630	chr7:32358064	NA	0.8	5.02	0.46	2.37e-6	Body mass index;
THYM	cis	rs1775715	0.677	rs2491272	chr10:32186783	A/G	cg04359828	chr10:32216031	ARHGAP12	0.41	5.12	0.47	1.57e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs2279817	0.820	rs11203440	chr1:18026352	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.77	4.77	0.44	6.58e-6	Neuroticism;
THYM	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg25427524	chr10:38739819	LOC399744	-0.64	-5.99	-0.52	3.75e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs7940866	0.738	rs10894308	chr11:130891895	G/A	cg12179176	chr11:130786555	SNX19	0.69	5.62	0.5	1.89e-7	Schizophrenia;
THYM	cis	rs8180040	0.800	rs11921117	chr3:47294000	T/C	cg02527881	chr3:46936655	PTH1R	0.59	5.48	0.49	3.44e-7	Colorectal cancer;
THYM	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.7	-5.78	-0.51	9.52e-8	Lymphocyte counts;
THYM	cis	rs8048589	0.558	rs34565142	chr16:12231347	C/T	cg02910054	chr16:12241554	SNX29	0.73	6.48	0.55	3.97e-9	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs7404928	0.579	rs2188356	chr16:23931713	C/G	cg26685404	chr16:23957272	PRKCB	-0.58	-6.53	-0.56	3.16e-9	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs11608355	0.810	rs2217971	chr12:109857666	G/C	cg10504392	chr12:110044639	NA	0.61	5.2	0.47	1.16e-6	Neuroticism;
THYM	cis	rs500891	0.504	rs976065	chr6:84092514	C/T	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs9814567	0.752	rs4955468	chr3:134340850	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.56	-0.61	2.55e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs4792901	0.759	rs9915640	chr17:41603882	T/C	cg21940313	chr17:41620911	ETV4	-0.51	-5.2	-0.47	1.12e-6	Dupuytren's disease;
THYM	cis	rs6980334	1.000	rs7787591	chr7:137778203	C/T	cg18769353	chr7:137028617	PTN	0.63	5.06	0.46	2.01e-6	Blood metabolite ratios;
THYM	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg17366294	chr4:99064904	C4orf37	-0.58	-6.94	-0.58	4.82e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4746818	1.000	rs10762259	chr10:70890929	C/T	cg11621586	chr10:70884670	VPS26A	1.31	11.97	0.78	1.11e-20	Left atrial antero-posterior diameter;
THYM	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg10193763	chr2:225306901	NA	-0.52	-5.48	-0.49	3.41e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1524976	1.000	rs4688240	chr3:65522392	A/G	cg16238336	chr3:65465873	MAGI1	-0.84	-4.76	-0.44	6.84e-6	PR interval;
THYM	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2562456	0.833	rs2928211	chr19:21541297	A/G	cg21751540	chr19:21541537	ZNF738	0.74	4.83	0.44	5.26e-6	Pain;
THYM	cis	rs7666738	0.962	rs4699596	chr4:99012924	C/T	cg17366294	chr4:99064904	C4orf37	0.53	5.9	0.52	5.67e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7188445	0.614	rs62043313	chr16:79744134	T/G	cg10278394	chr16:79454280	NA	0.47	4.53	0.42	1.71e-5	Urate levels;
THYM	cis	rs58873874	0.737	rs11739062	chr5:156901701	G/T	cg08916508	chr5:156566250	MED7	-1.17	-4.52	-0.42	1.8e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs4769475	0.957	rs9512120	chr13:26720554	C/T	cg13319468	chr13:27597730	NA	-0.68	-5.56	-0.5	2.45e-7	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7258465	1.000	rs28572537	chr19:18552208	C/T	cg01380346	chr19:18557039	ELL	-0.49	-5.01	-0.46	2.53e-6	Breast cancer;
THYM	cis	rs3126085	0.825	rs116321073	chr1:152240413	A/T	cg26020982	chr1:152196106	HRNR	0.34	4.63	0.43	1.14e-5	Atopic dermatitis;
THYM	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg04944784	chr2:26401820	FAM59B	0.7	4.49	0.42	2.02e-5	Gut microbiome composition (summer);
THYM	cis	rs470093	0.932	rs470088	chr22:44240685	C/T	cg09142166	chr22:44276013	PNPLA5	-0.6	-5.77	-0.51	9.87e-8	Staphylococcus aureus infection;
THYM	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg20290983	chr6:43655470	MRPS18A	0.89	6.88	0.58	6.31e-10	IgG glycosylation;
THYM	cis	rs9790314	0.690	rs7633857	chr3:160844942	C/G	cg03342759	chr3:160939853	NMD3	-0.6	-4.47	-0.42	2.18e-5	Morning vs. evening chronotype;
THYM	cis	rs7216064	1.000	rs12602655	chr17:65909442	A/G	cg12091567	chr17:66097778	LOC651250	-0.69	-4.45	-0.42	2.31e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg11764359	chr7:65958608	NA	-0.75	-6.04	-0.53	2.97e-8	Aortic root size;
THYM	cis	rs7089973	0.872	rs11818115	chr10:116634891	G/A	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.05	-0.46	2.15e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg06640241	chr16:89574553	SPG7	0.95	9.01	0.68	2.14e-14	Multiple myeloma (IgH translocation);
THYM	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg11366901	chr6:160182831	ACAT2	-1.05	-9.6	-0.7	1.18e-15	Age-related macular degeneration (geographic atrophy);
THYM	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs7119038	0.865	rs4938573	chr11:118741842	C/T	cg19308663	chr11:118741387	NA	-0.59	-5.67	-0.5	1.5e-7	Sjögren's syndrome;
THYM	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2456568	0.835	rs8181533	chr11:93638614	C/T	cg17347335	chr11:93583973	C11orf90	-0.48	-4.58	-0.43	1.39e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs9522267	0.535	rs9522299	chr13:112236013	C/A	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs909002	0.849	rs871634	chr1:32093167	G/C	cg13919466	chr1:32135498	COL16A1	-0.49	-4.48	-0.42	2.1e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7119	0.717	rs12901732	chr15:77818933	G/T	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg00012203	chr2:219082015	ARPC2	0.87	8.52	0.66	2.38e-13	Colorectal cancer;
THYM	cis	rs12681288	0.550	rs4637864	chr8:959761	C/T	cg23354307	chr8:1885189	ARHGEF10	-0.54	-4.52	-0.42	1.79e-5	Schizophrenia;
THYM	cis	rs7258015	1.000	rs3176768	chr19:10449665	A/G	cg01466491	chr19:10523363	NA	-0.59	-4.72	-0.44	8.13e-6	Systemic lupus erythematosus or rheumatoid arthritis;
THYM	cis	rs28595532	0.920	rs115994609	chr4:119777273	G/A	cg21605333	chr4:119757512	SEC24D	1.67	6.17	0.53	1.69e-8	Cannabis dependence symptom count;
THYM	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs1775715	0.870	rs10827003	chr10:32266216	A/G	cg04359828	chr10:32216031	ARHGAP12	0.41	5.19	0.47	1.19e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.48	-4.8	-0.44	5.86e-6	Crohn's disease;
THYM	cis	rs2820651	0.614	rs76389357	chr10:1482550	C/T	cg27404824	chr10:1454848	ADARB2	0.87	4.74	0.44	7.61e-6	Migraine with aura;
THYM	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs2777491	0.874	rs28716108	chr15:41655523	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.07	-10.51	-0.73	1.34e-17	Ulcerative colitis;
THYM	cis	rs7246657	0.943	rs10406177	chr19:37907947	G/A	cg22634378	chr19:37742834	NA	0.62	5.18	0.47	1.22e-6	Coronary artery calcification;
THYM	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17453880	0.712	rs7733573	chr5:152048219	C/T	cg12297329	chr5:152029980	NA	-0.59	-4.48	-0.42	2.06e-5	Subjective well-being;
THYM	cis	rs1371867	0.846	rs1660324	chr8:101281271	C/T	cg06636551	chr8:101224915	SPAG1	-0.67	-6.52	-0.56	3.36e-9	Atrioventricular conduction;
THYM	cis	rs735539	1.000	rs6490604	chr13:21284828	A/G	cg02792322	chr13:21280448	IL17D	-0.63	-4.45	-0.42	2.29e-5	Dental caries;
THYM	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03517284	chr6:25882590	NA	-1.01	-9.24	-0.69	6.85e-15	Blood metabolite levels;
THYM	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg00898013	chr13:113819073	PROZ	1.0	7.64	0.62	1.73e-11	Platelet distribution width;
THYM	cis	rs17209837	0.607	rs10452936	chr7:87094306	C/A	cg04996195	chr7:87105398	ABCB4	0.63	4.84	0.44	5.09e-6	Gallbladder cancer;
THYM	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg13683864	chr3:40499215	RPL14	0.97	10.3	0.73	3.78e-17	Renal cell carcinoma;
THYM	cis	rs2675662	0.525	rs12264025	chr10:75494450	A/G	cg23231163	chr10:75533350	FUT11	-0.41	-5.9	-0.52	5.54e-8	Psoriasis vulgaris;Psoriasis;
THYM	cis	rs4713118	0.505	rs276371	chr6:27910708	A/T	cg09682330	chr6:28411287	ZSCAN23	-0.62	-5.46	-0.49	3.81e-7	Parkinson's disease;
THYM	cis	rs10752881	1.000	rs10797800	chr1:182969828	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.67	0.43	9.78e-6	Colorectal cancer;
THYM	cis	rs2455799	0.573	rs2654648	chr3:15775425	T/C	cg16303742	chr3:15540471	COLQ	-0.56	-5.73	-0.51	1.18e-7	Mean platelet volume;
THYM	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg12564285	chr5:131593104	PDLIM4	0.5	5.63	0.5	1.84e-7	Breast cancer;
THYM	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg04043695	chr12:129287642	SLC15A4	0.59	4.86	0.45	4.72e-6	Systemic lupus erythematosus;
THYM	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.68	5.08	0.46	1.89e-6	Tonsillectomy;
THYM	cis	rs4919694	1.000	rs12257941	chr10:104833161	C/T	cg04362960	chr10:104952993	NT5C2	1.14	7.07	0.59	2.65e-10	Arsenic metabolism;
THYM	cis	rs6956675	0.534	rs7780975	chr7:62652443	G/A	cg27518014	chr7:62859535	LOC100287834	0.53	4.59	0.43	1.33e-5	Obesity-related traits;
THYM	cis	rs4242434	0.819	rs720745	chr8:22471147	G/T	cg01710189	chr8:22454888	PDLIM2	-0.49	-5.47	-0.49	3.69e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs13326165	0.585	rs3210487	chr3:52293859	A/G	cg08438690	chr3:52279403	PPM1M	-0.85	-4.84	-0.44	4.98e-6	HDL cholesterol;HDL cholesterol levels;
THYM	trans	rs2136093	0.666	rs10922854	chr1:90860149	A/G	cg19688584	chr6:167529678	CCR6	0.5	6.97	0.58	4.23e-10	Response to antidepressants;
THYM	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs4148087	1.000	rs4148087	chr21:43622267	C/T	cg09727148	chr21:43560719	UMODL1	0.54	4.5	0.42	1.9e-5	Eating disorder in bipolar disorder;
THYM	cis	rs2820292	0.524	rs11803449	chr1:201788804	G/A	cg06775570	chr1:201857621	SHISA4	-0.44	-4.48	-0.42	2.06e-5	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
THYM	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.75	0.67	7.59e-14	Cognitive test performance;
THYM	cis	rs28374715	0.532	rs11854820	chr15:41676526	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.21	-13.52	-0.81	7.22e-24	Ulcerative colitis;
THYM	cis	rs7705502	0.890	rs72810974	chr5:173307505	G/T	cg18693985	chr5:173351052	CPEB4	-0.8	-5.74	-0.51	1.13e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg03605463	chr16:89740564	NA	-0.65	-4.75	-0.44	7.28e-6	Vitiligo;
THYM	cis	rs4737010	0.501	rs1579274	chr8:41658923	T/G	cg08923054	chr8:41654455	ANK1	0.82	5.03	0.46	2.31e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
THYM	cis	rs10781543	0.845	rs10735662	chr9:139327869	A/T	cg14115884	chr9:139300582	SDCCAG3	0.69	6.17	0.53	1.66e-8	Monocyte percentage of white cells;
THYM	cis	rs75059851	0.756	rs56241440	chr11:133840830	A/C	cg14047540	chr11:133829660	NA	-1.1	-7.34	-0.6	7.1e-11	Schizophrenia;
THYM	cis	rs6960043	0.818	rs2191348	chr7:15064255	G/T	cg19272540	chr7:15055459	NA	-0.42	-4.71	-0.44	8.42e-6	Type 2 diabetes;
THYM	cis	rs7107174	1.000	rs11237456	chr11:78040780	C/G	cg19901956	chr11:77921274	USP35	-0.65	-5.4	-0.48	5.01e-7	Testicular germ cell tumor;
THYM	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.24e-7	Corneal astigmatism;
THYM	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg06112835	chr11:68658793	MRPL21	-0.37	-4.68	-0.43	9.48e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6754311	0.550	rs3213889	chr2:136511575	A/G	cg04750100	chr2:136595281	LCT	-0.55	-6.28	-0.54	1.01e-8	Mosquito bite size;
THYM	cis	rs9644630	0.930	rs7005075	chr8:19367452	G/C	cg01280390	chr8:19363452	CSGALNACT1	-0.83	-9.12	-0.68	1.27e-14	Oropharynx cancer;
THYM	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg16989719	chr2:238392110	NA	-0.61	-5.0	-0.46	2.64e-6	Prostate cancer;
THYM	trans	rs4940575	0.679	rs55825601	chr18:60835819	C/T	cg08454546	chr15:59731340	FAM81A	1.03	6.96	0.58	4.42e-10	Breast cancer;
THYM	cis	rs6531656	0.626	rs5029114	chr4:38703005	C/T	cg24279243	chr4:38676559	KLF3	-0.83	-6.05	-0.53	2.9e-8	Lymphocyte counts;
THYM	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-4.56	-0.42	1.55e-5	Alzheimer's disease;
THYM	cis	rs4363385	0.510	rs11812015	chr1:153045584	G/T	cg13444842	chr1:152974279	SPRR3	-0.6	-4.74	-0.44	7.54e-6	Inflammatory skin disease;
THYM	cis	rs9905704	0.918	rs12952362	chr17:56900870	A/G	cg12560992	chr17:57184187	TRIM37	0.68	4.72	0.44	8.17e-6	Testicular germ cell tumor;
THYM	cis	rs4664308	0.967	rs34248629	chr2:160902497	C/T	cg03641300	chr2:160917029	PLA2R1	-0.75	-6.92	-0.58	5.23e-10	Idiopathic membranous nephropathy;
THYM	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs13315871	0.929	rs11130628	chr3:58315835	T/C	cg00563845	chr3:58318305	PXK	0.6	5.3	0.48	7.63e-7	Cholesterol, total;
THYM	cis	rs71537559	1	rs71537559	chr6:27309779	G/C	cg23161317	chr6:28129485	ZNF389	1.1	4.63	0.43	1.18e-5	Squamous cell lung carcinoma;
THYM	cis	rs7177699	0.557	rs7165902	chr15:79115872	T/G	cg15571903	chr15:79123663	NA	0.57	6.57	0.56	2.71e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg12698349	chr2:225449008	CUL3	0.73	5.47	0.49	3.64e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs6980334	0.817	rs10228704	chr7:137795206	T/C	cg18769353	chr7:137028617	PTN	0.64	5.06	0.46	2.01e-6	Blood metabolite ratios;
THYM	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.6	8.32	0.65	6.27e-13	Monocyte percentage of white cells;
THYM	cis	rs7178572	0.568	rs1493700	chr15:77629060	T/C	cg22256960	chr15:77711686	NA	-1.04	-8.25	-0.65	9.01e-13	Type 2 diabetes;
THYM	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg13918804	chr1:2043761	PRKCZ	0.88	8.76	0.67	7.5e-14	Height;
THYM	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.88	8.14	0.64	1.56e-12	Menarche (age at onset);
THYM	cis	rs11157436	0.874	rs35951144	chr14:22617926	G/C	cg26433554	chr14:23315189	MMP14	0.44	4.61	0.43	1.24e-5	Neurocognitive impairment in HIV-1 infection (continuous);
THYM	cis	rs12681287	0.640	rs61106663	chr8:87477081	G/C	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs2340727	0.524	rs9970947	chr1:161942636	G/A	ch.1.159725313R	chr1:161458689	NA	-0.79	-5.52	-0.49	2.98e-7	White blood cell count;Hematology traits;
THYM	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg10523679	chr1:76189770	ACADM	0.94	8.52	0.66	2.42e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs34638657	0.732	rs4889477	chr16:82201302	C/T	cg09439754	chr16:82129088	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	cis	rs2235642	0.533	rs2076436	chr16:1608082	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.48	-4.78	-0.44	6.46e-6	Coronary artery disease;
THYM	cis	rs3126085	0.935	rs12730241	chr1:152274016	G/A	cg10321714	chr1:152280068	FLG	-0.7	-5.11	-0.46	1.68e-6	Atopic dermatitis;
THYM	cis	rs7226229	1.000	rs4985820	chr17:20931660	G/T	cg21263980	chr17:20946333	USP22	0.66	4.76	0.44	7.01e-6	Blood trace element (Se levels);
THYM	cis	rs4343996	0.692	rs55848061	chr7:3454639	T/A	cg21248987	chr7:3385318	SDK1	0.4	4.89	0.45	4.14e-6	Motion sickness;
THYM	cis	rs7192750	0.586	rs8050488	chr16:71911470	C/T	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs7084402	0.967	rs1649023	chr10:60285820	C/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg23791538	chr6:167370224	RNASET2	0.79	6.3	0.54	9.05e-9	Crohn's disease;
THYM	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg01416388	chr22:39784598	NA	-0.91	-8.26	-0.65	8.64e-13	Intelligence (multi-trait analysis);
THYM	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg19346786	chr7:2764209	NA	-0.71	-5.98	-0.52	3.97e-8	Height;
THYM	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-5.73	-0.51	1.17e-7	Total body bone mineral density;
THYM	cis	rs2235649	0.798	rs78540053	chr16:1853275	G/A	cg03034668	chr16:1723424	CRAMP1L	-0.63	-5.45	-0.49	4.04e-7	Blood metabolite levels;
THYM	cis	rs2204008	0.529	rs1315350	chr12:38164282	C/A	cg26384229	chr12:38710491	ALG10B	-0.74	-5.69	-0.5	1.42e-7	Bladder cancer;
THYM	cis	rs9583531	0.600	rs2119479	chr13:111371181	A/C	cg24331049	chr13:111365604	ING1	0.71	5.77	0.51	9.67e-8	Coronary artery disease;
THYM	cis	rs2456568	0.802	rs7115629	chr11:93635477	G/A	cg17595323	chr11:93583763	C11orf90	-0.58	-6.09	-0.53	2.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs13064411	0.735	rs10511326	chr3:113216325	T/C	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs9788682	0.747	rs8042374	chr15:78908032	A/G	cg18825076	chr15:78729989	IREB2	0.62	5.16	0.47	1.36e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs7757969	1.000	rs7758660	chr6:112128947	T/C	cg08601457	chr6:112115117	FYN	0.42	4.79	0.44	6.23e-6	Schizophrenia;
THYM	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7267979	0.966	rs2482918	chr20:25412135	C/T	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs68170813	0.559	rs12537785	chr7:107050221	T/C	cg00661777	chr7:106511741	PIK3CG	-0.66	-4.49	-0.42	2.03e-5	Coronary artery disease;
THYM	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg07959070	chr22:50026188	C22orf34	-0.28	-4.73	-0.44	7.76e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.86	-0.45	4.62e-6	Eye color traits;
THYM	cis	rs7246657	0.941	rs67293224	chr19:37803248	C/T	cg22634378	chr19:37742834	NA	0.66	5.41	0.49	4.75e-7	Coronary artery calcification;
THYM	cis	rs7106204	0.514	rs2068454	chr11:24256166	C/G	ch.11.24196551F	chr11:24239977	NA	-0.93	-6.71	-0.57	1.37e-9	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg07636037	chr3:49044803	WDR6	0.92	7.94	0.63	4.07e-12	Menarche (age at onset);
THYM	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg26597838	chr10:835615	NA	1.04	5.81	0.51	8.38e-8	Eosinophil percentage of granulocytes;
THYM	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg13395646	chr4:1353034	KIAA1530	0.59	5.31	0.48	7.33e-7	Obesity-related traits;
THYM	cis	rs7719624	1.000	rs7719624	chr5:135377566	A/G	cg12897067	chr5:135418308	NA	-0.59	-4.86	-0.45	4.54e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg08999081	chr20:33150536	PIGU	-0.76	-6.81	-0.57	8.93e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs4731207	0.596	rs11981797	chr7:124579451	T/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs8041943	0.643	rs3848183	chr15:79923232	A/C	cg20511832	chr15:78934280	CHRNB4	0.41	4.72	0.44	8.08e-6	Bone mineral density (spine) and age at menarche;
THYM	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg10803722	chr21:46713166	LOC642852	-0.43	-5.45	-0.49	4.01e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg24672777	chr11:48374446	OR4C45	-0.99	-6.44	-0.55	4.78e-9	Axial length;
THYM	cis	rs600806	0.888	rs3879449	chr1:109904971	A/T	cg02175308	chr1:109941060	SORT1	-0.59	-5.13	-0.47	1.51e-6	Intelligence (multi-trait analysis);
THYM	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4243830	0.737	rs7552172	chr1:6612269	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.09	-7.38	-0.6	5.96e-11	Body mass index;
THYM	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03517284	chr6:25882590	NA	0.82	6.55	0.56	2.89e-9	Intelligence (multi-trait analysis);
THYM	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg00012203	chr2:219082015	ARPC2	0.79	7.37	0.6	6.13e-11	Colorectal cancer;
THYM	cis	rs10479542	0.766	rs2411380	chr5:178973780	T/C	cg00080972	chr5:178986291	RUFY1	-0.46	-4.98	-0.46	2.83e-6	Lung cancer;
THYM	cis	rs2115630	0.967	rs7171167	chr15:85239123	A/T	cg11189052	chr15:85197271	WDR73	-0.65	-5.09	-0.46	1.81e-6	P wave terminal force;
THYM	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg22189786	chr22:42395067	WBP2NL	0.57	5.17	0.47	1.27e-6	Birth weight;
THYM	cis	rs4731207	0.569	rs75791754	chr7:124464917	C/T	cg05285228	chr7:124571219	POT1	0.67	5.27	0.48	8.35e-7	Cutaneous malignant melanoma;
THYM	cis	rs8050907	0.744	rs13330134	chr16:4526923	T/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.3	5.2	0.47	1.16e-6	Obesity-related traits;
THYM	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg09060608	chr5:178986726	RUFY1	0.51	5.05	0.46	2.12e-6	Lung cancer;
THYM	cis	rs7727544	0.547	rs56083751	chr5:131664638	T/A	cg24060327	chr5:131705240	SLC22A5	-0.66	-4.84	-0.44	4.98e-6	Blood metabolite levels;
THYM	cis	rs61931739	0.857	rs419112	chr12:34130528	A/G	cg10856724	chr12:34555212	NA	-0.6	-5.29	-0.48	7.98e-7	Morning vs. evening chronotype;
THYM	cis	rs7692976	0.503	rs62325265	chr4:110923592	T/C	cg06981781	chr4:110842888	EGF	-0.39	-4.66	-0.43	1.04e-5	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg24642439	chr20:33292090	TP53INP2	0.68	5.14	0.47	1.47e-6	Coronary artery disease;
THYM	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	trans	rs8002861	0.810	rs2275252	chr13:44454374	A/C	cg17145862	chr1:211918768	LPGAT1	1.0	11.34	0.76	2.4e-19	Leprosy;
THYM	cis	rs28374715	0.578	rs13313520	chr15:41629127	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.78	-0.83	2.3e-26	Ulcerative colitis;
THYM	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg05340658	chr4:99064831	C4orf37	0.55	4.64	0.43	1.11e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs863345	0.565	rs6679056	chr1:158450314	A/G	cg12129480	chr1:158549410	OR10X1	-0.47	-4.45	-0.42	2.33e-5	Pneumococcal bacteremia;
THYM	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg13395646	chr4:1353034	KIAA1530	-0.59	-5.76	-0.51	1.04e-7	Longevity;
THYM	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg03806693	chr22:41940476	POLR3H	1.03	9.17	0.69	9.96e-15	Vitiligo;
THYM	cis	rs1728785	1.000	rs864742	chr16:68575309	T/C	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg08885076	chr2:99613938	TSGA10	-0.58	-5.61	-0.5	1.99e-7	Chronic sinus infection;
THYM	cis	rs11690935	0.550	rs62183784	chr2:172866696	A/G	cg13550731	chr2:172543902	DYNC1I2	0.56	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg17644776	chr2:200775616	C2orf69	0.77	5.4	0.48	5.01e-7	Schizophrenia;
THYM	cis	rs362272	0.545	rs2239725	chr4:3305739	C/T	cg14583973	chr4:3374767	RGS12	0.65	6.24	0.54	1.21e-8	Serum sulfate level;
THYM	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg19077165	chr18:44547161	KATNAL2	0.51	5.99	0.52	3.73e-8	Personality dimensions;
THYM	cis	rs6701037	0.566	rs1014555	chr1:175134249	C/T	cg17845761	chr1:175162550	KIAA0040	0.38	4.81	0.44	5.73e-6	Alcohol dependence;
THYM	cis	rs12291225	0.585	rs11023197	chr11:14380998	G/A	cg19336497	chr11:14380999	RRAS2	-0.91	-13.68	-0.81	3.58e-24	Sense of smell;
THYM	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg02176678	chr2:219576539	TTLL4	0.73	7.25	0.6	1.09e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-4.46	-0.42	2.27e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	trans	rs10802346	0.545	rs10802345	chr1:246372834	C/T	cg13514129	chr1:39547527	MACF1	1.03	10.76	0.74	3.93e-18	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4732038	0.528	rs1722903	chr7:134276281	T/G	cg06906464	chr7:134288099	NA	-0.46	-4.61	-0.43	1.26e-5	Longevity;
THYM	cis	rs6061231	0.675	rs755726	chr20:60962624	T/C	cg24112000	chr20:60950667	NA	-0.74	-6.95	-0.58	4.66e-10	Colorectal cancer;
THYM	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg12826209	chr6:26865740	GUSBL1	1.04	6.68	0.57	1.63e-9	Intelligence (multi-trait analysis);
THYM	trans	rs11186	0.630	rs55850163	chr2:189963786	C/T	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg17063962	chr7:91808500	NA	1.16	13.12	0.8	4.77e-23	Breast cancer;
THYM	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg27535305	chr1:53392650	SCP2	-0.4	-4.58	-0.42	1.44e-5	Monocyte count;
THYM	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg14829155	chr15:31115871	NA	-0.75	-6.3	-0.54	9.11e-9	Huntington's disease progression;
THYM	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg27170947	chr2:26402098	FAM59B	-0.82	-6.64	-0.56	1.93e-9	Gut microbiome composition (summer);
THYM	cis	rs9972944	0.729	rs1421033	chr17:63766714	A/C	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg15247329	chr7:2764246	NA	-0.68	-5.65	-0.5	1.66e-7	Height;
THYM	cis	rs28595532	0.920	rs116231457	chr4:119762396	A/C	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs1971762	0.545	rs7297461	chr12:54047178	A/T	cg16917193	chr12:54089295	NA	0.76	7.26	0.6	1.04e-10	Height;
THYM	cis	rs1865721	0.804	rs719179	chr18:73146396	A/G	cg26385618	chr18:73139727	C18orf62	-0.63	-4.56	-0.42	1.5e-5	Intelligence;
THYM	cis	rs7107174	1.000	rs2511158	chr11:77973980	C/T	cg02023728	chr11:77925099	USP35	0.69	6.19	0.54	1.55e-8	Testicular germ cell tumor;
THYM	cis	rs9900062	1.000	rs11871616	chr17:62737602	C/T	cg02598441	chr17:62777298	LOC146880	-0.93	-5.42	-0.49	4.58e-7	QT interval;
THYM	cis	rs13082711	0.522	rs514668	chr3:27330972	A/G	cg02860705	chr3:27208620	NA	0.65	5.09	0.46	1.79e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-5.19	-0.47	1.17e-6	Chronic sinus infection;
THYM	cis	rs735539	0.521	rs9550672	chr13:21428380	G/T	cg02792322	chr13:21280448	IL17D	-0.65	-4.68	-0.43	9.45e-6	Dental caries;
THYM	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg15242686	chr22:24348715	GSTTP1	0.56	5.13	0.47	1.55e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs425277	0.606	rs2460001	chr1:2111030	T/C	cg03732007	chr1:2071316	PRKCZ	0.51	4.93	0.45	3.54e-6	Height;
THYM	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg16342193	chr10:102329863	NA	-0.52	-5.29	-0.48	7.74e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.16	-5.63	-0.5	1.85e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8050907	0.744	rs9922933	chr16:4572602	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.24	4.89	0.45	4.14e-6	Obesity-related traits;
THYM	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14159672	chr1:205819179	PM20D1	0.83	8.32	0.65	6.2800000000000005e-13	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.86	0.45	4.64e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3741151	0.686	rs7125598	chr11:73160589	C/T	cg12959048	chr11:73096162	RELT	0.44	4.8	0.44	5.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg25208724	chr1:156163844	SLC25A44	1.13	12.36	0.79	1.7e-21	Testicular germ cell tumor;
THYM	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	4.47	0.42	2.13e-5	Alzheimer's disease;
THYM	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg03188948	chr7:1209495	NA	0.66	5.11	0.46	1.63e-6	Longevity;Endometriosis;
THYM	cis	rs611744	0.805	rs396149	chr8:109108740	A/C	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.05e-6	Dupuytren's disease;
THYM	cis	rs6840360	0.571	rs7664663	chr4:152508014	G/C	cg22705602	chr4:152727874	NA	-0.78	-8.16	-0.64	1.38e-12	Intelligence (multi-trait analysis);
THYM	cis	rs977987	0.806	rs766521	chr16:75424154	A/G	cg03315344	chr16:75512273	CHST6	-0.72	-5.8	-0.51	8.75e-8	Dupuytren's disease;
THYM	cis	rs739496	0.541	rs593226	chr12:111993886	A/G	cg10833066	chr12:111807467	FAM109A	0.51	5.76	0.51	1.05e-7	Platelet count;
THYM	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg10523679	chr1:76189770	ACADM	0.92	10.35	0.73	2.94e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7119	0.651	rs8041398	chr15:77839173	A/G	cg27398640	chr15:77910606	LINGO1	-0.63	-6.58	-0.56	2.58e-9	Type 2 diabetes;
THYM	cis	rs7106204	0.514	rs12291514	chr11:24360203	T/C	ch.11.24196551F	chr11:24239977	NA	0.84	5.9	0.52	5.47e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg22709100	chr7:91322751	NA	0.61	4.83	0.44	5.26e-6	Breast cancer;
THYM	cis	rs7772486	0.875	rs2224121	chr6:146343214	G/A	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg18352616	chr4:3374830	RGS12	0.76	8.61	0.66	1.54e-13	Serum sulfate level;
THYM	cis	rs2074585	0.708	rs2589939	chr15:90930875	C/T	cg22089800	chr15:90895588	ZNF774	0.69	5.4	0.48	5e-7	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
THYM	cis	rs736801	0.504	rs2070721	chr5:131825842	T/G	cg21138405	chr5:131827807	IRF1	0.71	7.79	0.62	8.37e-12	Breast cancer;Mosquito bite size;
THYM	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg08807101	chr21:30365312	RNF160	0.73	5.51	0.49	3.1e-7	Dental caries;
THYM	trans	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg10856724	chr12:34555212	NA	0.91	8.12	0.64	1.64e-12	Bladder cancer;
THYM	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg06009448	chr7:1102226	C7orf50	0.51	5.29	0.48	7.99e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9311676	0.656	rs6445977	chr3:58379560	T/C	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg19052272	chr2:3704530	ALLC	-1.13	-9.1	-0.68	1.41e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.53	-0.66	2.31e-13	Monocyte count;
THYM	cis	rs7592578	0.771	rs75579212	chr2:191376575	C/T	cg21644426	chr2:191273491	MFSD6	-0.65	-4.54	-0.42	1.62e-5	Diastolic blood pressure;
THYM	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg21280719	chr6:42927975	GNMT	-0.53	-7.26	-0.6	1.07e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg14582100	chr15:45693742	SPATA5L1	0.62	5.02	0.46	2.37e-6	Homoarginine levels;
THYM	cis	rs35110281	0.641	rs4818861	chr21:45123807	A/G	cg15536230	chr21:44985092	HSF2BP	-0.45	-5.27	-0.48	8.59e-7	Mean corpuscular volume;
THYM	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg06238570	chr21:40685208	BRWD1	0.91	6.77	0.57	1.08e-9	Cognitive function;
THYM	cis	rs7107174	1.000	rs2510049	chr11:77985459	G/T	cg02023728	chr11:77925099	USP35	0.65	5.83	0.51	7.52e-8	Testicular germ cell tumor;
THYM	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg26566898	chr11:117069891	TAGLN	0.4	5.16	0.47	1.36e-6	Blood protein levels;
THYM	cis	rs11997175	0.550	rs7464954	chr8:33832202	A/G	ch.8.33884649F	chr8:33765107	NA	0.7	5.4	0.48	5e-7	Body mass index;
THYM	cis	rs8013055	0.898	rs8004007	chr14:105971435	G/C	cg04429589	chr14:105992532	TMEM121	-0.46	-5.08	-0.46	1.87e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs3087591	0.821	rs12949024	chr17:29445086	A/T	cg24425628	chr17:29625626	OMG;NF1	0.64	5.29	0.48	7.71e-7	Hip circumference;
THYM	cis	rs2016266	0.855	rs1379610	chr12:53681683	A/G	cg16917193	chr12:54089295	NA	-0.58	-4.46	-0.42	2.23e-5	Bone mineral density (spine);Bone mineral density;
THYM	trans	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg10856724	chr12:34555212	NA	-1.01	-9.23	-0.69	7.34e-15	Bladder cancer;
THYM	trans	rs4866334	1.000	rs77523779	chr5:18486747	C/A	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg06028808	chr11:68637592	NA	0.65	6.8	0.57	9.29e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg14675211	chr2:100938903	LONRF2	0.77	8.39	0.65	4.51e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9914988	0.943	rs9303621	chr17:27161138	A/G	cg20469991	chr17:27169893	C17orf63	-0.76	-4.78	-0.44	6.27e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1003719	0.680	rs3992	chr21:38505969	G/A	cg01329690	chr21:38580129	DSCR9	-0.38	-5.21	-0.47	1.09e-6	Eye color traits;
THYM	cis	rs35883536	0.584	rs56112014	chr1:101037431	A/G	cg09408571	chr1:101003634	GPR88	-0.49	-5.09	-0.46	1.8e-6	Monocyte count;
THYM	cis	rs2562456	0.793	rs2650819	chr19:21638873	C/T	cg21751540	chr19:21541537	ZNF738	0.75	4.92	0.45	3.68e-6	Pain;
THYM	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Body mass index;
THYM	cis	rs7677751	0.806	rs7698425	chr4:55090656	C/T	cg17187183	chr4:55093834	PDGFRA	0.71	5.49	0.49	3.35e-7	Corneal astigmatism;
THYM	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg03517284	chr6:25882590	NA	-0.68	-4.52	-0.42	1.76e-5	Height;
THYM	cis	rs977987	0.806	rs6564252	chr16:75388940	C/T	cg03315344	chr16:75512273	CHST6	0.72	5.9	0.52	5.66e-8	Dupuytren's disease;
THYM	cis	rs988913	0.874	rs4712084	chr6:54861284	G/A	cg18532076	chr6:54711417	FAM83B	0.51	4.74	0.44	7.6e-6	Menarche (age at onset);
THYM	trans	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg10856724	chr12:34555212	NA	-0.93	-7.98	-0.63	3.29e-12	Bladder cancer;
THYM	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg26408565	chr15:76604113	ETFA	-0.55	-4.85	-0.45	4.73e-6	Blood metabolite levels;
THYM	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg07930552	chr6:133119739	C6orf192	-0.93	-5.14	-0.47	1.49e-6	Type 2 diabetes nephropathy;
THYM	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg16558253	chr16:72132732	DHX38	-0.63	-5.55	-0.49	2.6e-7	Fibrinogen levels;
THYM	trans	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs17122693	0.551	rs2934683	chr14:51058511	C/T	cg04730355	chr14:51134070	SAV1	1.02	7.1	0.59	2.29e-10	Cognitive performance;
THYM	cis	rs56104184	0.775	rs17272707	chr19:49404535	T/G	cg19746536	chr19:49375674	PPP1R15A	0.81	4.59	0.43	1.34e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.54	0.42	1.68e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg18825531	chr11:62321136	NA	-0.45	-5.09	-0.46	1.78e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs13082711	0.911	rs17682751	chr3:27497027	C/T	cg02860705	chr3:27208620	NA	-0.74	-5.3	-0.48	7.62e-7	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg08916839	chr5:415575	AHRR	1.14	6.87	0.58	6.77e-10	Fat distribution (HIV);
THYM	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg16342193	chr10:102329863	NA	-0.55	-5.59	-0.5	2.14e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4343996	0.902	rs9969270	chr7:3368974	C/T	cg21248987	chr7:3385318	SDK1	-0.41	-4.93	-0.45	3.5e-6	Motion sickness;
THYM	cis	rs6032067	0.929	rs34412950	chr20:43805132	C/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs6076065	0.723	rs7269627	chr20:23362727	A/T	cg11657817	chr20:23433608	CST11	0.31	4.57	0.42	1.48e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg03806693	chr22:41940476	POLR3H	-1.22	-10.58	-0.74	9.45e-18	Vitiligo;
THYM	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg14798641	chr3:49314920	USP4;C3orf62	-0.69	-4.69	-0.43	9.23e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-4.85	-0.45	4.9e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs10248619	0.505	rs886821	chr7:50743095	T/C	cg12248358	chr7:50534670	DDC	-0.99	-4.69	-0.43	9.29e-6	Fasting blood glucose;Fasting blood glucose (BMI interaction);
THYM	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg17863274	chr19:49399704	TULP2	-0.89	-4.65	-0.43	1.09e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg07917127	chr4:99064746	C4orf37	0.61	4.59	0.43	1.35e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg19847130	chr8:10466454	RP1L1	-0.51	-4.77	-0.44	6.77e-6	Neuroticism;
THYM	cis	rs7078219	1.000	rs11190130	chr10:101275206	C/T	cg17888390	chr10:101282816	NA	-0.51	-4.78	-0.44	6.3e-6	Dental caries;
THYM	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg22920501	chr2:26401640	FAM59B	1.07	9.54	0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs28595532	0.920	rs114724233	chr4:119754918	T/A	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs3741151	0.656	rs56884659	chr11:73252947	C/G	cg12959048	chr11:73096162	RELT	-0.52	-4.58	-0.43	1.43e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg13147721	chr7:65941812	NA	0.73	4.58	0.43	1.42e-5	Diabetic kidney disease;
THYM	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs7131987	0.868	rs11050151	chr12:29403008	T/A	cg09582351	chr12:29534625	ERGIC2	-0.46	-4.47	-0.42	2.19e-5	QT interval;
THYM	cis	rs367615	0.918	rs13173339	chr5:108871318	T/A	cg17395555	chr5:108820864	NA	0.55	4.95	0.45	3.25e-6	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs7616559	0.849	rs7627652	chr3:156773347	C/T	cg15697575	chr3:156784781	NA	0.42	5.37	0.48	5.54e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg24818145	chr4:99064322	C4orf37	0.7	5.43	0.49	4.24e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6570726	0.818	rs9390338	chr6:145908265	A/G	cg05347473	chr6:146136440	FBXO30	0.58	4.51	0.42	1.85e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17030434	1.000	rs952211	chr4:154717816	A/G	cg14289246	chr4:154710475	SFRP2	-0.8	-5.33	-0.48	6.7e-7	Electrocardiographic conduction measures;
THYM	cis	rs1978968	0.957	rs34486385	chr22:18444290	C/T	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs10095849	0.576	rs10090933	chr8:39441745	T/C	cg01911981	chr8:39380341	ADAM3A	-0.58	-4.91	-0.45	3.84e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs34526934	0.608	rs7606110	chr2:177028551	T/C	cg26754761	chr2:177040938	NA	-0.72	-6.16	-0.53	1.72e-8	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs6539288	0.677	rs1348566	chr12:107325648	C/T	cg26297688	chr12:107349093	C12orf23	-0.51	-6.04	-0.53	2.94e-8	Total body bone mineral density;
THYM	cis	rs75059851	0.756	rs11223649	chr11:133840471	T/C	cg14047540	chr11:133829660	NA	-1.1	-7.34	-0.6	7.1e-11	Schizophrenia;
THYM	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg09165964	chr15:75287851	SCAMP5	-0.83	-4.72	-0.44	8.12e-6	Blood trace element (Zn levels);
THYM	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg07606381	chr6:8435919	SLC35B3	0.63	4.71	0.43	8.51e-6	Motion sickness;
THYM	cis	rs11048434	0.723	rs2080117	chr12:9138341	C/T	cg04155231	chr12:9217510	LOC144571	0.5	4.86	0.45	4.7e-6	Sjögren's syndrome;
THYM	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs919433	0.588	rs11690163	chr2:198527507	A/T	cg00792783	chr2:198669748	PLCL1	0.82	5.44	0.49	4.16e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg03354898	chr7:1950403	MAD1L1	-0.51	-4.74	-0.44	7.37e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs3020333	0.846	rs3020335	chr6:152013223	G/T	cg22157087	chr6:152012887	ESR1	0.44	4.94	0.45	3.36e-6	Total body bone mineral density;
THYM	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2464469	0.526	rs2899612	chr15:58335867	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.65	-5.04	-0.46	2.24e-6	Barrett's esophagus  or Esophageal adenocarcinoma;
THYM	cis	rs892961	0.720	rs103458	chr17:75416031	A/G	cg05865280	chr17:75406074	SEPT9	0.5	8.39	0.65	4.57e-13	Airflow obstruction;
THYM	cis	rs6840360	0.615	rs58977077	chr4:152470239	T/G	cg17479576	chr4:152424074	FAM160A1	-0.83	-6.46	-0.55	4.43e-9	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg13609457	chr4:120235615	NA	0.56	5.12	0.46	1.62e-6	Corneal astigmatism;
THYM	cis	rs6748734	0.581	rs10207380	chr2:241860911	A/G	cg15164180	chr2:241846931	NA	-0.39	-4.59	-0.43	1.38e-5	Urinary metabolites;
THYM	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.99	-0.75	1.26e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs8050907	0.744	rs1362625	chr16:4526310	G/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.3	5.2	0.47	1.16e-6	Obesity-related traits;
THYM	cis	rs2552220	1.000	rs36071949	chr8:6006572	T/C	cg06481462	chr8:7005678	NA	0.47	4.77	0.44	6.77e-6	Interleukin-8 levels;
THYM	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.76	4.86	0.45	4.59e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg23730037	chr7:158596552	ESYT2	-0.51	-5.09	-0.46	1.8e-6	Height;
THYM	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11671005	0.735	rs34152946	chr19:58923263	C/T	cg18639983	chr19:58920768	ZNF584	0.59	5.0	0.46	2.63e-6	Mean platelet volume;
THYM	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg21226059	chr5:178986404	RUFY1	0.58	5.91	0.52	5.34e-8	Lung cancer;
THYM	cis	rs10463554	0.927	rs158245	chr5:102409505	G/T	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg06481639	chr22:41940642	POLR3H	0.72	4.68	0.43	9.65e-6	Vitiligo;
THYM	trans	rs1973993	0.691	rs6658131	chr1:96889314	C/T	cg10631902	chr5:14652156	NA	0.77	9.44	0.7	2.62e-15	Weight;
THYM	cis	rs765787	0.530	rs12592055	chr15:45514477	C/T	cg25801113	chr15:45476975	SHF	-0.39	-4.52	-0.42	1.79e-5	Uric acid levels;
THYM	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9905704	0.647	rs33922512	chr17:57114148	C/G	cg12560992	chr17:57184187	TRIM37	-0.69	-5.24	-0.47	9.62e-7	Testicular germ cell tumor;
THYM	cis	rs35306767	0.623	rs12354710	chr10:1114020	C/T	cg26597838	chr10:835615	NA	0.87	5.35	0.48	6.07e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs367615	0.704	rs17161885	chr5:108852642	A/G	cg17395555	chr5:108820864	NA	0.72	8.53	0.66	2.29e-13	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	6.34	0.55	7.78e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg22681709	chr2:178499509	PDE11A	-0.6	-5.78	-0.51	9.6e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs2294693	0.679	rs12200923	chr6:40970092	T/G	cg14418226	chr6:40996092	UNC5CL	0.71	5.57	0.5	2.41e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.75	0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg11879182	chr18:77439856	CTDP1	0.81	7.86	0.63	5.87e-12	Monocyte count;
THYM	cis	rs6598955	0.671	rs11247910	chr1:26645666	G/A	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.7	0.43	8.83e-6	Obesity-related traits;
THYM	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs4901869	0.966	rs4901870	chr14:59334221	A/T	cg02291164	chr14:59296302	NA	-0.81	-8.2	-0.64	1.13e-12	Panic disorder;
THYM	cis	rs7107174	1.000	rs2248407	chr11:77937800	G/A	cg19901956	chr11:77921274	USP35	-0.73	-5.61	-0.5	1.96e-7	Testicular germ cell tumor;
THYM	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs2334880	0.678	rs12918320	chr16:71463602	A/G	cg06353428	chr16:71660113	MARVELD3	-1.17	-5.98	-0.52	3.85e-8	Malaria;
THYM	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.74	8.11	0.64	1.79e-12	Eosinophil percentage of white cells;
THYM	cis	rs10516089	0.504	rs10068044	chr5:171139868	G/A	cg17535961	chr5:171094783	NA	0.41	4.47	0.42	2.18e-5	Venous thromboembolism (SNP x SNP interaction);
THYM	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg03929089	chr4:120376271	NA	-0.95	-7.21	-0.59	1.34e-10	Coronary artery disease;
THYM	cis	rs453301	0.653	rs2953806	chr8:8914124	C/T	cg18904891	chr8:8559673	CLDN23	0.62	4.81	0.44	5.7e-6	Joint mobility (Beighton score);
THYM	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg21028142	chr17:79581711	NPLOC4	0.51	5.01	0.46	2.47e-6	Eye color traits;
THYM	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg24818145	chr4:99064322	C4orf37	0.76	5.91	0.52	5.33e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg18681998	chr4:17616180	MED28	1.01	10.37	0.73	2.69e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg12031863	chr16:4587854	C16orf5	-0.45	-4.57	-0.42	1.49e-5	Schizophrenia;
THYM	cis	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg06521331	chr12:34319734	NA	-1.02	-10.14	-0.72	8.47e-17	Morning vs. evening chronotype;
THYM	cis	rs2806561	0.577	rs488438	chr1:23498999	T/A	cg12483005	chr1:23474871	LUZP1	0.56	5.89	0.52	5.88e-8	Height;
THYM	cis	rs988913	0.706	rs13208701	chr6:54880468	T/A	cg04690482	chr6:54711388	FAM83B	0.43	4.45	0.42	2.36e-5	Menarche (age at onset);
THYM	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.26	0.47	8.97e-7	Lung cancer in ever smokers;
THYM	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg26441486	chr22:50317300	CRELD2	-0.4	-6.33	-0.54	8.22e-9	Schizophrenia;
THYM	cis	rs600231	0.623	rs587080	chr11:65253800	A/C	cg17120908	chr11:65337727	SSSCA1	-0.62	-4.77	-0.44	6.53e-6	Bone mineral density;
THYM	cis	rs79387448	0.745	rs1989399	chr2:103166742	G/A	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs1005224	0.889	rs2059382	chr14:76158916	T/C	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.71	-5.83	-0.51	7.54e-8	Large artery stroke;
THYM	cis	rs1729951	0.575	rs16844326	chr3:136678385	G/C	cg12473912	chr3:136751656	NA	0.63	5.13	0.47	1.55e-6	Neuroticism;
THYM	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg02782426	chr3:40428986	ENTPD3	0.56	5.02	0.46	2.41e-6	Renal cell carcinoma;
THYM	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg09165964	chr15:75287851	SCAMP5	-1.07	-11.0	-0.75	1.2e-18	Blood trace element (Zn levels);
THYM	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg27129171	chr3:47204927	SETD2	0.64	5.35	0.48	5.97e-7	Birth weight;
THYM	cis	rs7927771	0.524	rs12362318	chr11:47682671	T/C	cg18512352	chr11:47633146	NA	0.41	4.55	0.42	1.61e-5	Subjective well-being;
THYM	cis	rs800586	0.957	rs800590	chr8:116812578	C/T	cg04656070	chr8:116661063	TRPS1	0.49	4.7	0.43	8.9e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg04731861	chr2:219085781	ARPC2	-0.5	-4.5	-0.42	1.93e-5	Colorectal cancer;
THYM	cis	rs2625529	0.712	rs2054601	chr15:72184968	T/C	cg16672083	chr15:72433130	SENP8	-0.51	-4.56	-0.42	1.52e-5	Red blood cell count;
THYM	cis	rs3818285	0.679	rs552419	chr10:111630883	G/T	cg00817464	chr10:111662876	XPNPEP1	0.48	5.03	0.46	2.35e-6	Superior crus of antihelix expression;
THYM	cis	rs9902453	0.967	rs12449783	chr17:28527653	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	4.58	0.42	1.44e-5	Coffee consumption (cups per day);
THYM	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.63	5.38	0.48	5.35e-7	Lung disease severity in cystic fibrosis;
THYM	cis	rs7084402	0.967	rs1593672	chr10:60294379	T/C	cg09696939	chr10:60272079	BICC1	-0.46	-5.47	-0.49	3.7e-7	Refractive error;
THYM	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.64	8.83	0.67	5.25e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.59	-5.2	-0.47	1.16e-6	Coronary artery disease;
THYM	cis	rs654950	0.792	rs625448	chr1:41988541	A/T	cg06885757	chr1:42089581	HIVEP3	0.4	4.47	0.42	2.19e-5	Airway imaging phenotypes;
THYM	cis	rs17407555	0.632	rs12510727	chr4:10271070	T/G	cg00071950	chr4:10020882	SLC2A9	0.59	5.53	0.49	2.81e-7	Schizophrenia (age at onset);
THYM	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.31e-5	Retinal vascular caliber;
THYM	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg12165864	chr7:66369176	NA	-0.61	-4.75	-0.44	7.14e-6	Aortic root size;
THYM	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg13114125	chr14:105738426	BRF1	0.7	5.45	0.49	4e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg02640540	chr1:67518911	SLC35D1	0.64	4.68	0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg04731861	chr2:219085781	ARPC2	-0.54	-5.0	-0.46	2.57e-6	Colorectal cancer;
THYM	cis	rs4148689	0.904	rs2402205	chr7:117146448	T/C	cg17204129	chr7:117119601	CFTR	-0.63	-4.92	-0.45	3.69e-6	Gout;
THYM	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg17063962	chr7:91808500	NA	-1.13	-12.56	-0.79	6.81e-22	Breast cancer;
THYM	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11731175	0.960	rs62342334	chr4:189858840	T/C	cg00431894	chr4:189871012	NA	-0.82	-6.24	-0.54	1.2e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs800586	0.788	rs800571	chr8:116732907	T/C	cg04656070	chr8:116661063	TRPS1	0.48	4.49	0.42	2.01e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg21226059	chr5:178986404	RUFY1	0.6	6.8	0.57	9.25e-10	Lung cancer;
THYM	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg02753203	chr1:228287806	NA	0.78	6.67	0.56	1.65e-9	Diastolic blood pressure;
THYM	cis	rs10992471	0.598	rs2398751	chr9:95206240	C/T	cg14631576	chr9:95140430	CENPP	0.65	5.66	0.5	1.61e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg04287289	chr16:89883240	FANCA	0.65	5.93	0.52	4.78e-8	Vitiligo;
THYM	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg02734326	chr4:10020555	SLC2A9	-0.6	-4.7	-0.43	8.84e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6867032	0.527	rs9312971	chr5:2012888	C/A	cg26168224	chr5:2018326	NA	1.07	9.19	0.69	9.08e-15	Gut microbiome composition (winter);
THYM	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg10802521	chr3:52805072	NEK4	-0.74	-6.34	-0.55	7.65e-9	Bipolar disorder;
THYM	cis	rs7681440	0.606	rs2737009	chr4:90746836	A/G	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs9992101	0.838	rs1398018	chr4:77372923	T/C	cg20311846	chr4:77356250	SHROOM3	-0.63	-5.62	-0.5	1.88e-7	Creatinine levels;
THYM	cis	rs733592	0.507	rs10747529	chr12:48473369	G/A	cg21466736	chr12:48725269	NA	0.46	4.96	0.45	3.09e-6	Plateletcrit;
THYM	cis	rs7119	0.717	rs12901338	chr15:77804900	T/A	cg10437265	chr15:77819839	NA	0.76	7.61	0.62	1.98e-11	Type 2 diabetes;
THYM	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg16486109	chr11:613632	IRF7	0.52	5.33	0.48	6.51e-7	Systemic lupus erythematosus;
THYM	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg06238570	chr21:40685208	BRWD1	-0.95	-8.85	-0.67	4.7e-14	Cognitive function;
THYM	cis	rs10208940	0.614	rs7572135	chr2:68806585	G/A	cg09157127	chr2:69201416	GKN1	0.81	4.82	0.44	5.34e-6	Urate levels in lean individuals;
THYM	cis	rs2404618	0.561	rs9918765	chr8:1484467	C/T	cg13402656	chr8:1511478	DLGAP2	-0.78	-7.0	-0.58	3.63e-10	Lung cancer;
THYM	cis	rs3796352	1.000	rs6445557	chr3:53083969	C/T	cg07884673	chr3:53033167	SFMBT1	-1.01	-5.88	-0.52	6.04e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg10518543	chr12:38710700	ALG10B	-0.56	-4.56	-0.42	1.52e-5	Morning vs. evening chronotype;
THYM	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg18252515	chr7:66147081	NA	-0.67	-4.93	-0.45	3.42e-6	Aortic root size;
THYM	cis	rs4363385	0.818	rs435633	chr1:153011811	A/G	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs7027203	0.790	rs10123836	chr9:96584109	G/T	cg13679303	chr9:96623674	NA	-0.47	-4.74	-0.44	7.5e-6	DNA methylation (variation);
THYM	cis	rs763014	0.865	rs2384977	chr16:625388	C/T	cg07343612	chr16:622815	PIGQ	-1.05	-10.74	-0.74	4.28e-18	Height;
THYM	cis	rs6732160	0.845	rs72807999	chr2:73391695	T/C	cg24220031	chr2:73402428	NA	-0.81	-8.6	-0.66	1.59e-13	Intelligence (multi-trait analysis);
THYM	cis	rs17253792	0.822	rs112418863	chr14:56114079	G/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg10803722	chr21:46713166	LOC642852	-0.43	-5.65	-0.5	1.71e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs236907	0.814	rs6695933	chr1:171774239	A/C	cg20598894	chr1:171756153	METTL13	-0.73	-4.92	-0.45	3.57e-6	Mean platelet volume;
THYM	cis	rs26232	0.520	rs26432	chr5:102365710	T/A	cg23492399	chr5:102201601	PAM	0.64	4.81	0.44	5.71e-6	Rheumatoid arthritis;
THYM	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg06634786	chr22:41940651	POLR3H	0.7	5.29	0.48	7.78e-7	Vitiligo;
THYM	cis	rs2948294	0.566	rs13274039	chr8:8111659	A/G	cg15556689	chr8:8085844	FLJ10661	0.68	5.49	0.49	3.28e-7	Red cell distribution width;
THYM	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg18681998	chr4:17616180	MED28	0.96	9.4	0.69	3.12e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2046867	0.818	rs17010204	chr3:72879099	G/A	cg25664220	chr3:72788482	NA	-0.85	-6.82	-0.57	8.44e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg25358565	chr5:93447407	FAM172A	-0.97	-7.06	-0.59	2.76e-10	Diabetic retinopathy;
THYM	cis	rs6987853	0.736	rs2923446	chr8:42404177	G/A	cg09913449	chr8:42400586	C8orf40	1.1	12.4	0.79	1.41e-21	Mean corpuscular hemoglobin concentration;
THYM	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg01570182	chr17:44337453	NA	-0.6	-6.4	-0.55	5.8e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14893161	chr1:205819251	PM20D1	0.94	10.0	0.72	1.61e-16	Menarche (age at onset);
THYM	cis	rs72772090	0.539	rs17481759	chr5:96114695	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4731207	0.596	rs10239507	chr7:124596785	T/C	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs13082711	0.595	rs4973762	chr3:27364789	A/T	cg02860705	chr3:27208620	NA	0.85	6.41	0.55	5.61e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg10360139	chr7:1886902	MAD1L1	-0.59	-4.53	-0.42	1.68e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg00256281	chr22:41985642	PMM1	0.57	4.7	0.43	8.96e-6	Vitiligo;
THYM	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg05738196	chr6:26577821	NA	0.98	9.43	0.7	2.73e-15	Intelligence (multi-trait analysis);
THYM	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg07061783	chr6:25882402	NA	0.57	4.48	0.42	2.07e-5	Schizophrenia;
THYM	cis	rs7004484	1.000	rs16904548	chr8:132926770	A/G	cg15420926	chr8:132929147	EFR3A	-0.48	-4.57	-0.42	1.49e-5	Survival in rectal cancer;
THYM	cis	rs11671005	0.735	rs11668789	chr19:58928309	C/T	cg18639983	chr19:58920768	ZNF584	0.61	5.02	0.46	2.37e-6	Mean platelet volume;
THYM	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg19052272	chr2:3704530	ALLC	-0.72	-5.51	-0.49	3.09e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs17030434	0.953	rs11099906	chr4:154691690	A/T	cg14289246	chr4:154710475	SFRP2	-0.83	-5.58	-0.5	2.24e-7	Electrocardiographic conduction measures;
THYM	cis	rs12681287	0.640	rs7461413	chr8:87470978	C/G	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs7584330	0.554	rs79020383	chr2:238425834	G/A	cg08992911	chr2:238395768	MLPH	0.85	5.39	0.48	5.19e-7	Prostate cancer;
THYM	cis	rs995000	0.931	rs11207996	chr1:63055470	G/A	cg06896770	chr1:63153194	DOCK7	1.0	8.17	0.64	1.31e-12	Triglyceride levels;
THYM	cis	rs995000	0.965	rs12047226	chr1:63105538	T/C	cg06896770	chr1:63153194	DOCK7	1.0	8.18	0.64	1.28e-12	Triglyceride levels;
THYM	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg06636001	chr8:8085503	FLJ10661	0.8	7.96	0.63	3.72e-12	Systolic blood pressure;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg26121294	chr12:96347746	AMDHD1	-0.97	-7.04	-0.59	2.99e-10	Depressive symptoms;
THYM	cis	rs9810089	0.706	rs521746	chr3:136103920	C/T	cg21827317	chr3:136751795	NA	-0.55	-4.73	-0.44	7.87e-6	Gestational age at birth (child effect);
THYM	cis	rs9649213	0.593	rs55825602	chr7:98013039	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7572733	0.534	rs771009	chr2:198691082	A/G	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg10755058	chr3:40428713	ENTPD3	0.52	4.53	0.42	1.74e-5	Renal cell carcinoma;
THYM	cis	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg07460842	chr6:66804631	NA	-1.24	-15.98	-0.85	1.13e-28	Exhaled nitric oxide output;
THYM	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.7	5.63	0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg21475434	chr5:93447410	FAM172A	0.83	5.31	0.48	7.13e-7	Diabetic retinopathy;
THYM	cis	rs800586	0.500	rs2737249	chr8:116661045	T/G	cg04656070	chr8:116661063	TRPS1	-0.56	-6.45	-0.55	4.62e-9	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2806561	1.000	rs654585	chr1:23514714	T/C	cg12483005	chr1:23474871	LUZP1	0.6	6.11	0.53	2.2e-8	Height;
THYM	cis	rs6570726	0.935	rs397418	chr6:145842362	C/T	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7241530	0.585	rs7233393	chr18:75888229	G/A	cg14642773	chr18:75888474	NA	0.66	4.5	0.42	1.91e-5	Educational attainment (years of education);
THYM	cis	rs11030122	0.702	rs10500590	chr11:3964724	T/C	cg18678763	chr11:4115507	RRM1	-0.44	-5.73	-0.51	1.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs922692	0.744	rs12903203	chr15:79084933	T/C	cg22753661	chr15:79092743	ADAMTS7	0.61	4.59	0.43	1.38e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs4862307	0.514	rs11736004	chr4:185013843	C/T	cg06737308	chr4:185021514	ENPP6	0.83	7.86	0.63	5.9e-12	Serum dimethylarginine levels (asymmetric/symetric ratio);
THYM	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg13695892	chr22:41940480	POLR3H	0.89	7.16	0.59	1.69e-10	Vitiligo;
THYM	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg11663144	chr21:46675770	NA	-0.71	-10.03	-0.72	1.42e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs912057	0.601	rs1294411	chr6:6739034	T/C	cg13809441	chr6:6737631	NA	0.52	6.83	0.57	7.96e-10	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs3772130	0.962	rs9856641	chr3:121566859	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.75	4.64	0.43	1.1e-5	Cognitive performance;
THYM	cis	rs7769051	0.522	rs7738256	chr6:133113066	C/G	cg07930552	chr6:133119739	C6orf192	1.21	5.29	0.48	7.84e-7	Type 2 diabetes nephropathy;
THYM	cis	rs11785693	0.862	rs11778367	chr8:4988398	T/C	cg26367366	chr8:4980734	NA	0.94	4.74	0.44	7.42e-6	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6032067	1.000	rs6032065	chr20:43855649	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.48	-0.49	3.54e-7	Blood protein levels;
THYM	cis	rs9790314	0.905	rs6774276	chr3:160941318	C/T	cg03342759	chr3:160939853	NMD3	-0.81	-7.28	-0.6	9.51e-11	Morning vs. evening chronotype;
THYM	cis	rs8067545	0.750	rs4924805	chr17:19997205	C/G	cg13482628	chr17:19912719	NA	0.56	4.7	0.43	8.78e-6	Schizophrenia;
THYM	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs6980334	0.911	rs2120846	chr7:137773291	T/G	cg18769353	chr7:137028617	PTN	0.62	4.87	0.45	4.39e-6	Blood metabolite ratios;
THYM	cis	rs11723261	0.564	rs61792258	chr4:137264	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.86	5.68	0.5	1.48e-7	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs9581857	0.516	rs57394995	chr13:27972025	A/C	cg22138327	chr13:27999177	GTF3A	0.71	4.65	0.43	1.06e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs346785	0.692	rs2279053	chr17:74287389	C/T	cg09812376	chr17:74270190	QRICH2	0.48	4.97	0.45	2.93e-6	White matter hyperintensities in ischemic stroke;
THYM	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg12560992	chr17:57184187	TRIM37	0.71	5.49	0.49	3.35e-7	Testicular germ cell tumor;
THYM	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs2235649	0.833	rs9926962	chr16:1851826	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.61	-5.44	-0.49	4.08e-7	Blood metabolite levels;
THYM	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs9682041	0.660	rs13089074	chr3:170113481	G/A	cg11886554	chr3:170076028	SKIL	1.0	4.56	0.42	1.54e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs6570726	1.000	rs444564	chr6:145859795	G/C	cg23711669	chr6:146136114	FBXO30	0.83	8.07	0.64	2.16e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7616559	0.962	rs4574238	chr3:156726263	A/T	cg15697575	chr3:156784781	NA	0.4	5.03	0.46	2.35e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg02527881	chr3:46936655	PTH1R	-0.65	-6.55	-0.56	2.97e-9	Colorectal cancer;
THYM	cis	rs2820651	0.614	rs56368317	chr10:1490983	G/A	cg02445968	chr10:1449028	ADARB2	-1.05	-5.33	-0.48	6.52e-7	Migraine with aura;
THYM	cis	rs9914988	0.559	rs1109024	chr17:27189971	C/T	cg20469991	chr17:27169893	C17orf63	0.8	5.05	0.46	2.13e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs2991971	1.000	rs2934859	chr1:46017836	C/T	cg15605315	chr1:45957053	TESK2	0.65	5.12	0.46	1.6e-6	High light scatter reticulocyte count;
THYM	cis	rs478304	0.934	rs574483	chr11:65515277	A/G	cg17480646	chr11:65405466	SIPA1	0.7	6.27	0.54	1.07e-8	Acne (severe);
THYM	cis	rs3026101	0.647	rs4790263	chr17:5307084	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.57	5.19	0.47	1.18e-6	Body mass index;
THYM	cis	rs7584330	0.704	rs7602387	chr2:238356795	A/G	cg16989719	chr2:238392110	NA	-0.6	-5.73	-0.51	1.18e-7	Prostate cancer;
THYM	cis	rs1499972	0.938	rs866001	chr3:117724023	G/A	cg07612923	chr3:117604196	NA	-1.5	-5.16	-0.47	1.38e-6	Schizophrenia;
THYM	cis	rs3015497	0.663	rs12434932	chr14:51157614	T/C	cg04730355	chr14:51134070	SAV1	-0.54	-4.62	-0.43	1.21e-5	Mean platelet volume;
THYM	trans	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Bladder cancer;
THYM	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg24549020	chr5:56110836	MAP3K1	-0.76	-4.59	-0.43	1.36e-5	Initial pursuit acceleration;
THYM	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg09307838	chr4:120376055	NA	0.77	5.56	0.5	2.5e-7	Corneal astigmatism;
THYM	cis	rs76662990	0.610	rs10071779	chr5:73918344	C/A	cg13275603	chr5:73927487	ENC1	-0.79	-4.55	-0.42	1.57e-5	Residual cognition;
THYM	cis	rs4606347	0.932	rs1938491	chr1:66118121	C/T	cg04111102	chr1:66153794	NA	0.6	4.53	0.42	1.7e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs981844	0.740	rs6815202	chr4:154682440	A/G	cg09973105	chr4:154681532	RNF175	0.54	4.98	0.45	2.88e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs9457247	0.534	rs2345568	chr6:167381804	A/G	cg00271210	chr6:167070053	RPS6KA2	0.47	4.53	0.42	1.7e-5	Crohn's disease;
THYM	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg11871910	chr12:69753446	YEATS4	0.64	4.65	0.43	1.06e-5	Response to diuretic therapy;
THYM	cis	rs885814	1.000	rs17455136	chr1:21862253	T/G	cg14781605	chr1:21864896	ALPL	-0.7	-5.27	-0.48	8.58e-7	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg12031863	chr16:4587854	C16orf5	-0.42	-4.54	-0.42	1.63e-5	Schizophrenia;
THYM	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg24846343	chr22:24311635	DDTL	0.45	5.71	0.51	1.28e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3924048	0.559	rs6541038	chr1:12626210	G/T	cg00291366	chr1:12616550	NA	0.34	5.07	0.46	1.93e-6	Optic cup area;
THYM	cis	rs6500395	0.963	rs6500405	chr16:48690486	C/T	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg12863693	chr15:85201151	NMB	0.65	5.95	0.52	4.55e-8	Schizophrenia;
THYM	cis	rs274567	0.711	rs404771	chr5:131635092	A/T	cg24060327	chr5:131705240	SLC22A5	-0.77	-6.08	-0.53	2.51e-8	Blood metabolite levels;
THYM	cis	rs2663905	0.605	rs2683235	chr15:81398791	A/G	cg25029264	chr15:81426347	C15orf26	-0.74	-4.51	-0.42	1.84e-5	QT interval (drug interaction);
THYM	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	4.54	0.42	1.66e-5	Hip circumference adjusted for BMI;
THYM	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2011503	0.941	rs10403273	chr19:19372968	C/G	cg02887458	chr19:19495540	GATAD2A	-0.43	-5.21	-0.47	1.1e-6	Bipolar disorder;
THYM	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg21433313	chr16:3507492	NAT15	-0.51	-4.53	-0.42	1.7e-5	Body mass index (adult);
THYM	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg12165864	chr7:66369176	NA	-0.63	-4.95	-0.45	3.27e-6	Aortic root size;
THYM	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg18681998	chr4:17616180	MED28	0.79	6.71	0.57	1.39e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6840360	0.642	rs11735957	chr4:152427506	G/A	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs4731207	0.698	rs3919896	chr7:124553007	A/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs4919044	0.808	rs12354891	chr10:94818438	T/A	cg05127821	chr10:94822908	CYP26C1	-1.24	-6.68	-0.57	1.64e-9	Coronary artery disease;
THYM	cis	rs6882076	0.925	rs1393207	chr5:156397540	T/A	cg12943317	chr5:156479607	HAVCR1	-0.72	-5.94	-0.52	4.63e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg06634786	chr22:41940651	POLR3H	-0.72	-5.26	-0.48	8.73e-7	Vitiligo;
THYM	cis	rs11148252	0.870	rs11148246	chr13:52797537	C/T	cg00495681	chr13:53174319	NA	0.77	6.95	0.58	4.59e-10	Lewy body disease;
THYM	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11696501	0.739	rs6032411	chr20:44286542	C/G	cg11783356	chr20:44313418	WFDC10B	-0.71	-4.91	-0.45	3.76e-6	Brain structure;
THYM	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg16482183	chr6:26056742	HIST1H1C	0.82	5.32	0.48	6.78e-7	Iron status biomarkers;
THYM	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg15704280	chr7:45808275	SEPT13	-0.96	-7.01	-0.58	3.46e-10	Coronary artery disease;
THYM	cis	rs6700896	0.900	rs7524581	chr1:66166499	T/C	cg04111102	chr1:66153794	NA	-0.63	-6.28	-0.54	1.02e-8	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs12765878	0.603	rs10883944	chr10:105651657	G/T	cg11005552	chr10:105648138	OBFC1	-0.53	-4.83	-0.44	5.27e-6	Coronary artery disease;
THYM	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs7592578	0.723	rs4371384	chr2:191430741	A/G	cg11845111	chr2:191398756	TMEM194B	1.01	8.01	0.63	2.87e-12	Diastolic blood pressure;
THYM	cis	rs1797081	0.967	rs780632	chr10:16861400	A/G	cg23933602	chr10:16859644	RSU1	-0.92	-10.93	-0.75	1.69e-18	Platelet distribution width;
THYM	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg27490568	chr2:178487706	NA	0.63	5.92	0.52	5.07e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg07424592	chr7:64974309	NA	1.1	5.08	0.46	1.87e-6	Diabetic kidney disease;
THYM	cis	rs7511006	1.000	rs5771109	chr22:50678571	T/C	cg16294310	chr22:50629110	TRABD	0.59	4.45	0.42	2.35e-5	Obesity-related traits;
THYM	cis	rs17401966	0.964	rs17400510	chr1:10290421	T/C	cg20482658	chr1:10539492	PEX14	0.37	4.5	0.42	1.91e-5	Hepatocellular carcinoma;
THYM	cis	rs2455799	0.613	rs7642876	chr3:15883094	A/G	cg16303742	chr3:15540471	COLQ	-0.55	-5.72	-0.51	1.25e-7	Mean platelet volume;
THYM	cis	rs8114671	0.967	rs34515766	chr20:33785221	C/G	cg08999081	chr20:33150536	PIGU	-0.53	-4.77	-0.44	6.63e-6	Height;
THYM	cis	rs7572733	0.534	rs734037	chr2:198749269	G/A	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg22166914	chr1:53195759	ZYG11B	0.66	5.71	0.51	1.31e-7	Monocyte count;
THYM	cis	rs34065801	0.538	rs1891671	chr13:36578153	C/T	cg10939960	chr13:36560980	DCLK1	-0.57	-4.6	-0.43	1.32e-5	Breast size;
THYM	cis	rs28595532	0.764	rs56309519	chr4:119754158	C/T	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg09904177	chr6:26538194	HMGN4	0.54	4.57	0.42	1.47e-5	Intelligence (multi-trait analysis);
THYM	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg08109568	chr15:31115862	NA	-0.55	-5.38	-0.48	5.41e-7	Huntington's disease progression;
THYM	trans	rs1973993	0.567	rs2800431	chr1:97000998	C/T	cg10631902	chr5:14652156	NA	0.64	7.02	0.58	3.34e-10	Weight;
THYM	cis	rs13126513	0.503	rs2637770	chr4:100595742	T/C	cg05468953	chr4:100565104	NA	0.66	6.1	0.53	2.25e-8	Metabolite levels (MHPG);
THYM	cis	rs28374715	0.662	rs16971558	chr15:41458619	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.0	-8.25	-0.65	8.84e-13	Ulcerative colitis;
THYM	cis	rs7635838	0.557	rs347615	chr3:11277284	T/A	cg00170343	chr3:11313890	ATG7	0.64	4.96	0.45	3.13e-6	HDL cholesterol;
THYM	cis	rs3741151	0.773	rs73548693	chr11:73286637	G/A	cg17517138	chr11:73019481	ARHGEF17	0.9	4.71	0.43	8.56e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7178572	0.889	rs11857450	chr15:77802791	C/G	cg22256960	chr15:77711686	NA	0.94	7.84	0.63	6.62e-12	Type 2 diabetes;
THYM	cis	rs7100689	0.622	rs7082093	chr10:82134954	T/G	cg01528321	chr10:82214614	TSPAN14	0.8	5.96	0.52	4.32e-8	Post bronchodilator FEV1;
THYM	cis	rs4664308	0.967	rs17831329	chr2:160915819	T/C	cg03641300	chr2:160917029	PLA2R1	-0.78	-6.97	-0.58	4.25e-10	Idiopathic membranous nephropathy;
THYM	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs40363	0.723	rs2379831	chr16:3538927	T/C	cg00484396	chr16:3507460	NAT15	-0.62	-5.38	-0.48	5.46e-7	Tuberculosis;
THYM	cis	rs67072384	1.000	rs72966113	chr11:72450970	C/T	cg01380194	chr11:72452482	ARAP1	-0.97	-5.26	-0.47	8.93e-7	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9733	0.596	rs72702570	chr1:150688196	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg18252515	chr7:66147081	NA	-1.65	-9.03	-0.68	1.94e-14	Diabetic kidney disease;
THYM	cis	rs506338	0.517	rs530252	chr11:64443465	T/C	cg19395706	chr11:64412079	NRXN2	0.34	4.51	0.42	1.86e-5	Body mass index;Urate levels;
THYM	cis	rs7523273	0.565	rs2025374	chr1:207887536	A/G	cg22525895	chr1:207977042	MIR29B2	-0.53	-5.05	-0.46	2.17e-6	Schizophrenia;
THYM	cis	rs748404	0.631	rs7167882	chr15:43678663	A/C	cg12861797	chr15:43585817	TGM7	0.44	4.58	0.43	1.42e-5	Lung cancer;
THYM	cis	rs713587	0.713	rs11682135	chr2:25205377	G/A	cg15423357	chr2:25149977	NA	-0.58	-5.94	-0.52	4.62e-8	Body mass index in non-asthmatics;
THYM	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6032067	0.777	rs2868236	chr20:43794070	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg19346786	chr7:2764209	NA	-0.69	-5.93	-0.52	4.86e-8	Height;
THYM	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg11764359	chr7:65958608	NA	0.88	7.53	0.61	2.88e-11	Aortic root size;
THYM	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.32	0.48	6.9e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7107174	1.000	rs2512544	chr11:77986371	A/T	cg02023728	chr11:77925099	USP35	0.65	5.95	0.52	4.47e-8	Testicular germ cell tumor;
THYM	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg24818145	chr4:99064322	C4orf37	0.75	5.9	0.52	5.53e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10269006	0.727	rs9641147	chr7:94368896	A/G	cg00347863	chr7:94220697	SGCE	0.54	4.68	0.43	9.57e-6	Breast cancer;
THYM	cis	rs17604090	0.529	rs2392128	chr7:29711139	A/G	cg19413766	chr7:29689036	LOC646762	0.81	5.64	0.5	1.77e-7	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs1021993	0.621	rs2246571	chr1:209469671	G/A	cg24997231	chr1:209527535	NA	0.5	4.55	0.42	1.57e-5	Gut microbiome composition (winter);
THYM	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg24450063	chr1:156163899	SLC25A44	0.99	11.01	0.75	1.16e-18	Testicular germ cell tumor;
THYM	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg05043794	chr9:111880884	C9orf5	-0.41	-6.15	-0.53	1.8e-8	Menarche (age at onset);
THYM	cis	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg05084668	chr3:125655381	ALG1L	-0.8	-4.62	-0.43	1.21e-5	Blood pressure (smoking interaction);
THYM	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg05962950	chr11:130786565	SNX19	0.86	7.44	0.61	4.51e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	trans	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10493773	0.775	rs11161649	chr1:86165446	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.48	-6.24	-0.54	1.19e-8	Urate levels in overweight individuals;
THYM	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg24308560	chr3:49941425	MST1R	-0.76	-6.31	-0.54	8.82e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg24642844	chr7:1081250	C7orf50	-1.28	-8.22	-0.64	1.06e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg00898013	chr13:113819073	PROZ	0.83	8.33	0.65	6.02e-13	Platelet distribution width;
THYM	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg24846343	chr22:24311635	DDTL	0.45	5.65	0.5	1.67e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg04476341	chr5:669733	TPPP	0.61	4.52	0.42	1.8e-5	Obesity-related traits;
THYM	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg10518543	chr12:38710700	ALG10B	-0.58	-4.6	-0.43	1.31e-5	Morning vs. evening chronotype;
THYM	cis	rs995000	0.965	rs12116574	chr1:63037837	C/T	cg06896770	chr1:63153194	DOCK7	1.0	8.17	0.64	1.31e-12	Triglyceride levels;
THYM	cis	rs7705502	0.855	rs56364564	chr5:173312730	C/T	cg18693985	chr5:173351052	CPEB4	-0.79	-5.67	-0.5	1.55e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs9443645	0.527	rs36128361	chr6:79684340	C/G	cg05283184	chr6:79620031	NA	-0.6	-4.67	-0.43	9.86e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3772130	0.923	rs28674947	chr3:121529421	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs2710642	0.564	rs7583570	chr2:62852926	C/T	cg17519650	chr2:63277830	OTX1	0.64	4.71	0.44	8.46e-6	LDL cholesterol levels;LDL cholesterol;
THYM	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs2552220	0.818	rs13252262	chr8:6006236	G/A	cg06481462	chr8:7005678	NA	0.45	4.77	0.44	6.58e-6	Interleukin-8 levels;
THYM	cis	rs11605275	1.000	rs78091560	chr11:20032279	G/A	cg14835545	chr11:20032148	NAV2	-1.38	-7.35	-0.6	7e-11	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs71403859	0.502	rs12927006	chr16:71549911	A/G	cg08717414	chr16:71523259	ZNF19	-1.41	-7.23	-0.6	1.22e-10	Post bronchodilator FEV1;
THYM	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4803468	0.967	rs4803461	chr19:41908871	G/A	cg09537434	chr19:41945824	ATP5SL	-1.17	-11.56	-0.76	7.92e-20	Height;
THYM	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg03733263	chr8:22462867	KIAA1967	1.11	13.42	0.81	1.19e-23	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7772486	0.875	rs11755334	chr6:146399297	T/C	cg05347473	chr6:146136440	FBXO30	0.57	4.59	0.43	1.36e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.09	-7.74	-0.62	1.06e-11	Platelet count;
THYM	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg14784868	chr12:69753453	YEATS4	0.8	6.2	0.54	1.44e-8	Response to diuretic therapy;
THYM	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.96e-6	Resting heart rate;
THYM	cis	rs8133932	0.906	rs77809339	chr21:47097331	G/A	cg20357416	chr21:47294739	PCBP3	0.86	4.94	0.45	3.33e-6	Schizophrenia;
THYM	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs9563576	0.709	rs9316965	chr13:58583296	A/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.75	0.44	7.12e-6	Body mass index;
THYM	cis	rs600806	0.854	rs11142	chr1:109897103	A/G	cg02175308	chr1:109941060	SORT1	-0.59	-5.18	-0.47	1.22e-6	Intelligence (multi-trait analysis);
THYM	cis	rs61905145	1	rs61905145	chr11:116718415	G/A	cg04087571	chr11:116723030	SIK3	-0.36	-4.55	-0.42	1.56e-5	Subjective well-being;
THYM	cis	rs1372520	0.684	rs10008964	chr4:90744721	G/A	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs9902453	0.845	rs62068583	chr17:28001482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.87	0.45	4.38e-6	Coffee consumption (cups per day);
THYM	cis	rs17407555	0.738	rs73212895	chr4:10121025	C/T	cg00071950	chr4:10020882	SLC2A9	-0.74	-5.16	-0.47	1.37e-6	Schizophrenia (age at onset);
THYM	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg18252515	chr7:66147081	NA	-1.45	-8.88	-0.67	4.01e-14	Diabetic kidney disease;
THYM	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg06873352	chr17:61820015	STRADA	0.75	9.27	0.69	6.15e-15	Prudent dietary pattern;
THYM	cis	rs59698941	0.943	rs12519955	chr5:132283095	G/A	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg13944838	chr5:179740914	GFPT2	-0.86	-6.69	-0.57	1.55e-9	Height;
THYM	trans	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg10856724	chr12:34555212	NA	-0.87	-7.41	-0.61	5.14e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	5.75	0.51	1.08e-7	Blood metabolite levels;
THYM	cis	rs60695258	0.550	rs4693798	chr4:87914288	G/C	cg10685359	chr4:87814065	C4orf36	0.45	5.78	0.51	9.52e-8	Hematocrit;
THYM	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg13695892	chr22:41940480	POLR3H	-0.99	-7.44	-0.61	4.51e-11	Vitiligo;
THYM	cis	rs3785574	1.000	rs3785574	chr17:61763185	T/C	cg11494091	chr17:61959527	GH2	0.74	6.33	0.54	8.16e-9	Height;
THYM	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg21773646	chr17:80085082	CCDC57	-0.34	-4.91	-0.45	3.76e-6	Life satisfaction;
THYM	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg26566898	chr11:117069891	TAGLN	0.39	4.97	0.45	2.92e-6	Blood protein levels;
THYM	cis	rs7084402	1.000	rs1863665	chr10:60266640	T/C	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg05294307	chr14:35346193	BAZ1A	-0.83	-5.45	-0.49	4e-7	Psoriasis;
THYM	cis	rs1559088	0.600	rs10423965	chr19:33600319	T/G	cg03563238	chr19:33554763	RHPN2	-0.54	-4.6	-0.43	1.32e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs7829975	0.774	rs11249893	chr8:8700851	C/T	cg06636001	chr8:8085503	FLJ10661	0.82	8.28	0.65	7.86e-13	Mood instability;
THYM	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg08645402	chr16:4508243	NA	0.67	5.58	0.5	2.25e-7	Schizophrenia;
THYM	cis	rs941408	0.515	rs759066	chr19:2775337	G/T	cg06609049	chr19:2785107	THOP1	1.14	10.42	0.73	2.09e-17	Total cholesterol levels;
THYM	cis	rs4595586	0.545	rs7310463	chr12:39368927	T/C	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs11249608	0.636	rs13361077	chr5:178449174	G/C	cg01312482	chr5:178451176	ZNF879	-0.68	-5.27	-0.48	8.43e-7	Pubertal anthropometrics;
THYM	cis	rs12149862	1.000	rs9929461	chr16:69478168	C/T	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg06009448	chr7:1102226	C7orf50	0.48	5.01	0.46	2.55e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10174077	0.687	rs4664491	chr2:152479986	C/T	cg06191203	chr2:152266755	RIF1	-0.75	-4.78	-0.44	6.35e-6	Squamous cell lung carcinoma;
THYM	cis	rs208520	1.000	rs208527	chr6:66957209	A/C	cg07460842	chr6:66804631	NA	-0.85	-5.48	-0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs75920871	0.588	rs1871756	chr11:116953645	G/A	cg20608306	chr11:116969690	SIK3	-0.52	-5.72	-0.51	1.2e-7	Subjective well-being;
THYM	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg22535103	chr8:58192502	C8orf71	-0.96	-5.47	-0.49	3.7e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs4803468	1.000	rs10422956	chr19:41901261	C/T	cg09537434	chr19:41945824	ATP5SL	-1.09	-9.95	-0.71	2.14e-16	Height;
THYM	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg12386194	chr3:101231763	SENP7	0.66	5.0	0.46	2.59e-6	Colorectal cancer;
THYM	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg08999081	chr20:33150536	PIGU	0.84	7.86	0.63	5.86e-12	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	5.7	0.5	1.37e-7	Schizophrenia;
THYM	cis	rs7914558	0.902	rs7092200	chr10:104844872	T/C	cg15744005	chr10:104629667	AS3MT	-0.79	-7.47	-0.61	3.94e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg19747945	chr6:42946146	PEX6	-0.34	-5.12	-0.46	1.61e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs870825	0.655	rs35764203	chr4:185639078	C/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs2276314	1.000	rs1789513	chr18:33545630	A/G	cg05985134	chr18:33552581	C18orf21	-0.66	-4.49	-0.42	2e-5	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs2303759	0.507	rs35042238	chr19:49872941	C/T	cg22307029	chr19:49891270	CCDC155	0.86	6.17	0.54	1.64e-8	Multiple sclerosis;
THYM	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg02524346	chr8:600233	NA	-1.01	-4.72	-0.44	8.12e-6	IgG glycosylation;
THYM	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9309473	0.607	rs58962779	chr2:73555801	T/C	cg20560298	chr2:73613845	ALMS1	-0.64	-4.45	-0.42	2.3e-5	Metabolite levels;
THYM	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg03806693	chr22:41940476	POLR3H	1.25	10.88	0.74	2.22e-18	Vitiligo;
THYM	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.59	4.45	0.42	2.35e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg10792982	chr14:105748885	BRF1	0.73	7.56	0.61	2.48e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg03517284	chr6:25882590	NA	-0.67	-4.92	-0.45	3.58e-6	Height;
THYM	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28595532	0.920	rs55806110	chr4:119742583	A/G	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs1040555	0.516	rs242547	chr20:31418581	T/C	cg13636640	chr20:31349939	DNMT3B	0.67	6.6	0.56	2.36e-9	Lymphocyte percentage of white cells;
THYM	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg04111992	chr7:158790115	NA	-0.59	-4.72	-0.44	8.04e-6	Facial morphology (factor 20);
THYM	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg24733560	chr20:60626293	TAF4	0.59	6.04	0.53	2.94e-8	Body mass index;
THYM	trans	rs9503551	0.710	rs9503537	chr6:3327407	A/G	cg17620335	chr10:51566824	NCOA4	-0.92	-6.9	-0.58	5.82e-10	Nicotine dependence;
THYM	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs112184198	0.915	rs2476967	chr10:102595299	T/A	cg03679755	chr10:101875035	NA	-0.81	-4.54	-0.42	1.68e-5	Systolic blood pressure;
THYM	cis	rs2455799	0.613	rs4685258	chr3:15792315	G/A	cg16303742	chr3:15540471	COLQ	-0.56	-5.73	-0.51	1.18e-7	Mean platelet volume;
THYM	cis	rs11039798	1.000	rs11039904	chr11:48682597	T/A	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs4662945	0.652	rs35707860	chr2:130200219	C/T	cg05903289	chr2:130345205	NA	-0.59	-5.69	-0.5	1.38e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.61	-0.43	1.24e-5	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg03806693	chr22:41940476	POLR3H	-1.02	-8.29	-0.65	7.26e-13	Vitiligo;
THYM	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg12573674	chr2:1569213	NA	-1.22	-4.82	-0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03576123	chr11:487126	PTDSS2	-1.3	-6.61	-0.56	2.21e-9	Body mass index;
THYM	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.9	7.81	0.63	7.43e-12	Multiple sclerosis;
THYM	cis	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg07460842	chr6:66804631	NA	0.92	5.5	0.49	3.15e-7	Exhaled nitric oxide levels;
THYM	cis	rs7119	0.689	rs11630557	chr15:77820712	A/G	cg27398640	chr15:77910606	LINGO1	-0.56	-5.72	-0.51	1.24e-7	Type 2 diabetes;
THYM	cis	rs41311933	0.831	rs79516694	chr9:123766526	A/C	cg13567360	chr9:123745713	C5	-0.91	-5.03	-0.46	2.34e-6	Coronary artery disease;
THYM	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg18357526	chr6:26021779	HIST1H4A	0.65	5.61	0.5	1.99e-7	Intelligence (multi-trait analysis);
THYM	cis	rs28374715	0.662	rs691907	chr15:41474657	C/G	cg18705301	chr15:41695430	NDUFAF1	1.04	8.82	0.67	5.6e-14	Ulcerative colitis;
THYM	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg13010199	chr12:38710504	ALG10B	-0.59	-5.14	-0.47	1.46e-6	Heart rate;
THYM	cis	rs7772486	0.790	rs2265919	chr6:146221753	A/G	cg13319975	chr6:146136371	FBXO30	-0.73	-6.11	-0.53	2.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg11673840	chr17:47092156	IGF2BP1	-0.68	-8.47	-0.66	2.99e-13	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg10661904	chr17:79619235	PDE6G	-0.57	-5.17	-0.47	1.32e-6	Eye color traits;
THYM	cis	rs11048434	0.736	rs12423746	chr12:9113002	G/T	cg13575925	chr12:9217583	LOC144571	0.52	4.97	0.45	2.96e-6	Sjögren's syndrome;
THYM	cis	rs6598955	0.671	rs11247909	chr1:26640135	G/A	cg20415053	chr1:26527928	CATSPER4	-0.58	-4.71	-0.43	8.58e-6	Obesity-related traits;
THYM	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg16928487	chr17:17741425	SREBF1	-0.55	-5.04	-0.46	2.21e-6	Total body bone mineral density;
THYM	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg07606381	chr6:8435919	SLC35B3	0.63	4.64	0.43	1.11e-5	Motion sickness;
THYM	cis	rs2371030	0.965	rs4672590	chr2:211575322	G/C	cg18417063	chr2:211583084	NA	-0.53	-4.57	-0.42	1.48e-5	Non-small cell lung cancer;
THYM	cis	rs56341938	0.935	rs10513654	chr3:168746668	T/C	cg09107232	chr3:169491072	MYNN	0.53	4.52	0.42	1.8e-5	Lung function (FEV1/FVC);
THYM	cis	rs2463822	0.925	rs1528730	chr11:62081181	A/C	cg06239285	chr11:62104954	ASRGL1	1.37	7.54	0.61	2.75e-11	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs12983728	0.732	rs34003091	chr19:58662254	T/C	cg07378217	chr19:58662286	ZNF329	-0.93	-5.55	-0.49	2.58e-7	Cholesterol, total;
THYM	cis	rs4919687	0.550	rs11191371	chr10:104459897	G/C	cg04362960	chr10:104952993	NT5C2	0.61	4.89	0.45	4.08e-6	Colorectal cancer;
THYM	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17006441	0.932	rs7634376	chr3:69844977	G/A	cg18496212	chr3:69797108	MITF	0.7	7.17	0.59	1.64e-10	Hemoglobin concentration;
THYM	cis	rs8050907	0.744	rs8063956	chr16:4531761	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.45	5.39	0.48	5.08e-7	Obesity-related traits;
THYM	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg13695892	chr22:41940480	POLR3H	0.89	7.47	0.61	3.97e-11	Vitiligo;
THYM	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7089973	0.836	rs7895551	chr10:116625481	C/T	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.14	-0.47	1.5e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs28795989	0.731	rs6857814	chr4:7916540	A/G	cg00251875	chr4:7801337	AFAP1	-0.6	-4.74	-0.44	7.53e-6	Intraocular pressure;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg21205803	chr2:211346899	CPS1	-0.94	-7.17	-0.59	1.62e-10	Depressive symptoms;
THYM	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg23711669	chr6:146136114	FBXO30	0.85	8.17	0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg14582100	chr15:45693742	SPATA5L1	0.55	4.72	0.44	8.16e-6	Homoarginine levels;
THYM	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg12288994	chr5:1860383	NA	0.86	7.08	0.59	2.44e-10	Cardiovascular disease risk factors;
THYM	cis	rs6831352	0.879	rs1984364	chr4:100070783	A/C	cg12011299	chr4:100065546	ADH4	-0.82	-7.62	-0.62	1.91e-11	Alcohol dependence;
THYM	cis	rs67460515	0.563	rs6794882	chr3:160851849	G/A	cg12349858	chr3:160822545	B3GALNT1	0.57	4.58	0.43	1.39e-5	Parkinson's disease;
THYM	cis	rs4731207	0.698	rs12537161	chr7:124538590	A/G	cg05285228	chr7:124571219	POT1	-0.66	-5.24	-0.47	9.46e-7	Cutaneous malignant melanoma;
THYM	cis	rs6750795	0.502	rs11685196	chr2:232381298	A/G	cg19187155	chr2:232395269	NMUR1	0.81	6.45	0.55	4.75e-9	Height;
THYM	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg20295408	chr7:1910781	MAD1L1	-0.61	-4.85	-0.45	4.75e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg11764359	chr7:65958608	NA	0.67	4.77	0.44	6.52e-6	Aortic root size;
THYM	cis	rs4363385	0.747	rs12048412	chr1:152977092	A/T	cg13444842	chr1:152974279	SPRR3	-0.59	-4.68	-0.43	9.41e-6	Inflammatory skin disease;
THYM	cis	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg21231944	chr12:82153410	PPFIA2	-0.64	-4.76	-0.44	7.01e-6	Resting heart rate;
THYM	cis	rs763014	0.898	rs2384978	chr16:625384	T/C	cg07343612	chr16:622815	PIGQ	-1.07	-11.06	-0.75	9.07e-19	Height;
THYM	cis	rs3796619	0.924	rs11940546	chr4:1072485	C/T	cg27284194	chr4:1044797	NA	0.53	4.95	0.45	3.22e-6	Recombination rate (males);
THYM	cis	rs354225	0.544	rs28581481	chr2:54812372	T/G	cg23486701	chr2:54789491	SPTBN1	0.36	4.83	0.44	5.13e-6	Schizophrenia;
THYM	cis	rs7107174	0.901	rs4944199	chr11:78122779	A/G	cg02023728	chr11:77925099	USP35	0.65	6.17	0.53	1.7e-8	Testicular germ cell tumor;
THYM	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg21361702	chr7:150065534	REPIN1	0.67	4.93	0.45	3.53e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs1457451	0.646	rs2045432	chr2:65863984	T/G	cg16240816	chr2:65861662	NA	0.68	8.18	0.64	1.25e-12	Iron status biomarkers;
THYM	cis	rs57920188	0.584	rs10915654	chr1:4091419	C/A	cg20703997	chr1:4087676	NA	0.94	6.32	0.54	8.36e-9	Interleukin-17 levels;
THYM	cis	rs3017493	0.786	rs78344725	chr11:70687830	G/A	cg14537332	chr11:70508113	SHANK2	1.16	7.34	0.6	7.14e-11	Renal transplant outcome;
THYM	cis	rs7592578	0.766	rs35818159	chr2:191409616	C/G	cg10560079	chr2:191398806	TMEM194B	-0.91	-6.57	-0.56	2.63e-9	Diastolic blood pressure;
THYM	cis	rs911555	0.662	rs4906322	chr14:103879032	A/G	cg12935359	chr14:103987150	CKB	0.48	5.4	0.48	4.97e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg02527881	chr3:46936655	PTH1R	0.81	8.03	0.64	2.61e-12	Birth weight;
THYM	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.53	-4.92	-0.45	3.67e-6	Lymphocyte counts;
THYM	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg26384229	chr12:38710491	ALG10B	1.07	10.43	0.73	2.04e-17	Heart rate;
THYM	cis	rs3862030	0.720	rs11191295	chr10:104231054	A/G	cg00122347	chr10:104236741	TMEM180	0.48	7.03	0.59	3.09e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs12620999	1.000	rs11689249	chr2:238083542	T/A	cg15976283	chr2:238042351	NA	0.62	4.86	0.45	4.69e-6	Systemic lupus erythematosus;
THYM	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg24503407	chr1:205819492	PM20D1	-0.84	-7.66	-0.62	1.56e-11	Monocyte percentage of white cells;
THYM	cis	rs17539620	0.624	rs62432735	chr6:154834055	T/C	cg20019720	chr6:154832845	CNKSR3	0.53	5.48	0.49	3.49e-7	Lipoprotein (a) levels;
THYM	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg21854286	chr17:40700858	NA	-0.67	-6.51	-0.56	3.57e-9	Colorectal or endometrial cancer;
THYM	cis	rs9527	0.568	rs1926036	chr10:104883812	C/T	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg18404041	chr3:52824283	ITIH1	-0.53	-5.23	-0.47	9.96e-7	Bipolar disorder;
THYM	cis	rs9303401	0.703	rs8072182	chr17:57211213	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.67	4.98	0.46	2.83e-6	Cognitive test performance;
THYM	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg13944838	chr5:179740914	GFPT2	-0.87	-6.28	-0.54	9.99e-9	Height;
THYM	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg00300879	chr1:26503847	CNKSR1	0.43	5.74	0.51	1.15e-7	Height;
THYM	cis	rs8064299	0.597	rs7210318	chr17:72783385	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.88	8.77	0.67	7.13e-14	Monocyte count;
THYM	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg10295955	chr4:187884368	NA	-1.22	-17.58	-0.87	1.28e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs72827839	0.846	rs72823530	chr17:46109371	G/A	cg23391107	chr17:45924227	SP6	0.8	5.49	0.49	3.4e-7	Ease of getting up in the morning;
THYM	cis	rs4363385	0.510	rs7532166	chr1:153046851	C/G	cg13444842	chr1:152974279	SPRR3	-0.6	-4.68	-0.43	9.48e-6	Inflammatory skin disease;
THYM	cis	rs28595532	0.920	rs114792862	chr4:119759938	G/A	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs7940866	0.774	rs2162059	chr11:130831224	C/T	cg23692386	chr11:131799662	NTM	0.44	4.59	0.43	1.37e-5	Schizophrenia;
THYM	cis	rs1451375	0.617	rs2329371	chr7:50615440	G/A	cg18232548	chr7:50535776	DDC	0.65	4.78	0.44	6.34e-6	Malaria;
THYM	cis	rs6687430	0.526	rs12120962	chr1:10609505	G/A	cg20482658	chr1:10539492	PEX14	-0.39	-5.36	-0.48	5.84e-7	Hand grip strength;
THYM	cis	rs7084921	0.521	rs6584345	chr10:101884909	C/A	cg11344164	chr10:101878520	NA	-0.6	-5.71	-0.51	1.26e-7	Bone mineral density;
THYM	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg20242066	chr2:136595261	LCT	0.54	6.85	0.57	7.31e-10	Mosquito bite size;
THYM	cis	rs7731657	0.537	rs1010208	chr5:130325939	T/C	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs9515203	0.596	rs9521731	chr13:111032699	C/G	cg26053697	chr13:111039873	COL4A2	0.73	4.88	0.45	4.34e-6	Coronary artery disease;
THYM	cis	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg17074396	chr22:49843754	NA	-0.39	-4.6	-0.43	1.29e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7772486	0.743	rs2092262	chr6:146037105	C/T	cg13319975	chr6:146136371	FBXO30	0.65	5.35	0.48	6.13e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs889398	0.869	rs862320	chr16:69651866	C/T	cg09409435	chr16:70099608	PDXDC2	-0.63	-4.92	-0.45	3.64e-6	Body mass index;
THYM	cis	rs977987	0.872	rs7206665	chr16:75475287	A/C	cg03315344	chr16:75512273	CHST6	0.73	5.98	0.52	3.87e-8	Dupuytren's disease;
THYM	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs1345301	0.518	rs1035131	chr2:102862641	A/C	cg03938978	chr2:103052716	IL18RAP	-0.51	-4.79	-0.44	6.13e-6	Waist circumference;
THYM	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7809950	0.953	rs3094383	chr7:107143164	G/A	cg23024343	chr7:107201750	COG5	-0.91	-8.24	-0.65	9.37e-13	Coronary artery disease;
THYM	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg06636001	chr8:8085503	FLJ10661	-0.75	-6.68	-0.57	1.58e-9	Joint mobility (Beighton score);
THYM	cis	rs67460515	0.892	rs73026976	chr3:160964271	G/A	cg03342759	chr3:160939853	NMD3	-0.93	-7.98	-0.63	3.34e-12	Parkinson's disease;
THYM	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg05872129	chr22:39784769	NA	-1.1	-12.04	-0.78	7.99e-21	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg01264106	chr22:38071602	LGALS1	0.4	4.79	0.44	6.04e-6	Fat distribution (HIV);
THYM	cis	rs11779988	0.545	rs398806	chr8:17786226	T/C	cg01800426	chr8:17659068	MTUS1	-0.76	-5.32	-0.48	6.94e-7	Breast cancer;
THYM	cis	rs3741151	0.773	rs17244616	chr11:73293112	C/T	cg17517138	chr11:73019481	ARHGEF17	0.9	4.71	0.43	8.56e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs79149102	0.579	rs9788648	chr15:75300284	A/G	cg17294928	chr15:75287854	SCAMP5	-1.06	-5.68	-0.5	1.49e-7	Lung cancer;
THYM	trans	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Bladder cancer;
THYM	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-6.58	-0.56	2.55e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9880211	0.562	rs13068210	chr3:135905546	T/G	cg21827317	chr3:136751795	NA	-0.73	-5.09	-0.46	1.78e-6	Body mass index;Height;
THYM	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg12386194	chr3:101231763	SENP7	0.66	5.0	0.46	2.59e-6	Colorectal cancer;
THYM	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg23422044	chr7:1970798	MAD1L1	-0.77	-5.3	-0.48	7.56e-7	Bipolar disorder;
THYM	cis	rs2241584	0.967	rs9313736	chr5:175948316	A/G	cg27658698	chr5:175955578	RNF44	0.52	5.9	0.52	5.5e-8	Menopause (age at onset);
THYM	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg27125505	chr17:43679177	LOC644172	0.77	6.97	0.58	4.25e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg22920501	chr2:26401640	FAM59B	-0.84	-7.52	-0.61	3.02e-11	Gut microbiome composition (summer);
THYM	cis	rs1018836	0.608	rs6982329	chr8:91467488	A/G	cg16814680	chr8:91681699	NA	-0.72	-5.82	-0.51	8.05e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg19912559	chr1:40204330	PPIE	0.64	4.87	0.45	4.45e-6	Blood protein levels;
THYM	cis	rs1829883	0.835	rs2511900	chr5:98775156	G/A	cg08333243	chr5:99726346	NA	-0.53	-4.49	-0.42	2.01e-5	Hemostatic factors and hematological phenotypes;
THYM	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg27068330	chr11:65405492	SIPA1	-0.81	-5.52	-0.49	2.95e-7	Breast cancer;
THYM	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.66	5.22	0.47	1.07e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2522056	1.000	rs7730247	chr5:131781288	A/C	cg24060327	chr5:131705240	SLC22A5	0.73	4.7	0.43	8.8e-6	Lymphocyte counts;Fibrinogen;
THYM	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.66	-5.38	-0.48	5.3e-7	Tonsillectomy;
THYM	cis	rs11690935	0.527	rs7586556	chr2:172901887	G/C	cg13550731	chr2:172543902	DYNC1I2	0.71	5.78	0.51	9.66e-8	Schizophrenia;
THYM	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg13010199	chr12:38710504	ALG10B	0.72	5.92	0.52	5.01e-8	Heart rate;
THYM	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg06598544	chr20:61472147	COL9A3	-1.12	-6.98	-0.58	3.91e-10	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg10515332	chr4:99064459	C4orf37	-0.61	-4.94	-0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.77	0.51	1.01e-7	Rheumatoid arthritis;
THYM	cis	rs9733	0.596	rs1136808	chr1:150702717	G/C	cg15448220	chr1:150897856	SETDB1	0.85	7.1	0.59	2.25e-10	Tonsillectomy;
THYM	cis	rs1129187	0.755	rs2296804	chr6:42931261	C/G	cg19747945	chr6:42946146	PEX6	-0.34	-5.08	-0.46	1.88e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs8014204	0.836	rs888413	chr14:75267396	C/T	cg06637938	chr14:75390232	RPS6KL1	0.52	5.07	0.46	1.96e-6	Caffeine consumption;
THYM	cis	rs10489202	0.513	rs4657731	chr1:168081255	C/T	cg24449463	chr1:168025552	DCAF6	-0.79	-7.54	-0.61	2.77e-11	Schizophrenia;
THYM	cis	rs11077998	0.844	rs1109123	chr17:80522391	T/C	cg10255544	chr17:80519551	FOXK2	0.5	4.45	0.42	2.3e-5	Reticulocyte fraction of red cells;
THYM	cis	rs7000551	0.689	rs12545909	chr8:22310052	A/G	cg12081754	chr8:22256438	SLC39A14	-0.63	-5.47	-0.49	3.57e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9420	0.890	rs547891	chr11:57499065	C/T	cg19752551	chr11:57585705	CTNND1	0.66	7.73	0.62	1.11e-11	Schizophrenia;
THYM	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.69	4.62	0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs7084402	0.935	rs10826202	chr10:60359091	C/T	cg09696939	chr10:60272079	BICC1	-0.48	-5.83	-0.51	7.57e-8	Refractive error;
THYM	cis	rs6840360	0.642	rs11099819	chr4:152430178	T/C	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs988913	1.000	rs9367600	chr6:54837977	T/C	cg04690482	chr6:54711388	FAM83B	0.46	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.53	0.56	3.27e-9	Total body bone mineral density;
THYM	cis	rs7267979	1.000	rs2259956	chr20:25282433	A/G	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs554111	0.634	rs10799673	chr1:21274671	T/G	cg01072550	chr1:21505969	NA	0.56	4.73	0.44	7.85e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs6570726	0.935	rs366621	chr6:145861275	A/G	cg23711669	chr6:146136114	FBXO30	0.84	8.52	0.66	2.44e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2075230	0.642	rs1642811	chr17:7549151	A/C	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.28	-4.62	-0.43	1.21e-5	Hormone measurements;
THYM	cis	rs4363385	0.720	rs6672735	chr1:152981086	A/G	cg13444842	chr1:152974279	SPRR3	-0.59	-4.68	-0.43	9.41e-6	Inflammatory skin disease;
THYM	cis	rs4363385	0.510	rs10888528	chr1:153050516	A/G	cg13444842	chr1:152974279	SPRR3	0.61	4.89	0.45	4.05e-6	Inflammatory skin disease;
THYM	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7927771	0.524	rs7107922	chr11:47669289	C/A	cg18512352	chr11:47633146	NA	0.41	4.59	0.43	1.34e-5	Subjective well-being;
THYM	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg20295408	chr7:1910781	MAD1L1	-0.67	-5.26	-0.48	8.76e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs12829704	0.561	rs3829307	chr12:21292206	A/T	cg12696586	chr12:21590942	PYROXD1	0.58	4.54	0.42	1.67e-5	Blood metabolite levels;
THYM	cis	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg09035930	chr12:129282057	SLC15A4	0.84	10.7	0.74	5.31e-18	Systemic lupus erythematosus;
THYM	cis	rs28595532	0.920	rs56291421	chr4:119732294	G/A	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs526231	0.543	rs34779	chr5:102452768	A/G	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.49e-6	Primary biliary cholangitis;
THYM	cis	rs490234	0.545	rs10117700	chr9:128250651	C/T	cg14078157	chr9:128172775	NA	-0.64	-5.1	-0.46	1.7e-6	Mean arterial pressure;
THYM	cis	rs1747683	0.966	rs10737070	chr10:13369846	C/T	cg25835351	chr10:13388524	SEPHS1	-0.35	-5.9	-0.52	5.49e-8	IgG glycosylation;
THYM	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.53	-4.86	-0.45	4.56e-6	Lymphocyte counts;
THYM	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg00271210	chr6:167070053	RPS6KA2	0.7	7.41	0.61	5.11e-11	Crohn's disease;
THYM	cis	rs11756438	0.572	rs2638545	chr6:119000203	G/C	cg21191810	chr6:118973309	C6orf204	0.56	5.65	0.5	1.7e-7	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg15133208	chr4:90757351	SNCA	-0.56	-4.66	-0.43	1.04e-5	Neuroticism;
THYM	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg25036284	chr2:26402008	FAM59B	0.72	4.71	0.43	8.59e-6	Gut microbiome composition (summer);
THYM	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs1003719	0.751	rs55992706	chr21:38542749	G/A	cg01329690	chr21:38580129	DSCR9	-0.36	-5.09	-0.46	1.81e-6	Eye color traits;
THYM	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg21028142	chr17:79581711	NPLOC4	0.64	6.74	0.57	1.23e-9	Eye color traits;
THYM	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg12560992	chr17:57184187	TRIM37	-0.73	-5.91	-0.52	5.28e-8	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.963	rs1817759	chr12:34101521	G/A	cg06521331	chr12:34319734	NA	0.63	4.77	0.44	6.74e-6	Morning vs. evening chronotype;
THYM	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg12419862	chr22:24373484	LOC391322	0.88	10.23	0.72	5.41e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs4845570	1.000	rs4845570	chr1:151759104	C/T	cg07092448	chr1:151763213	TDRKH	1.04	6.79	0.57	9.75e-10	Coronary artery disease;
THYM	cis	rs988913	0.957	rs9296771	chr6:54782274	T/A	cg18532076	chr6:54711417	FAM83B	0.52	4.83	0.44	5.13e-6	Menarche (age at onset);
THYM	cis	rs2354432	0.607	rs7523812	chr1:146673489	A/G	cg25205988	chr1:146714368	CHD1L	-1.1	-4.92	-0.45	3.66e-6	Mitochondrial DNA levels;
THYM	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.44	7.34	0.6	7.07e-11	Obesity-related traits;
THYM	cis	rs7631605	0.935	rs2885608	chr3:37176045	A/G	cg21328643	chr3:37258149	NA	-0.48	-4.61	-0.43	1.25e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs10992471	0.580	rs7020104	chr9:95416524	A/G	cg14631576	chr9:95140430	CENPP	-0.94	-7.64	-0.62	1.75e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs9938149	0.736	rs7501402	chr16:88320911	A/T	cg05067156	chr16:88591451	ZFPM1	-0.44	-4.78	-0.44	6.3e-6	Corneal structure;Central corneal thickness;
THYM	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs79387448	0.614	rs985523	chr2:102954376	G/A	cg09003973	chr2:102972529	NA	1.25	7.31	0.6	8.31e-11	Gut microbiota (bacterial taxa);
THYM	trans	rs9951602	0.512	rs9946115	chr18:76654531	A/C	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs10231759	0.583	rs35792015	chr7:150513841	A/G	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.66	4.97	0.45	3e-6	Height;
THYM	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.72	0.57	1.34e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1983170	0.935	rs578155	chr1:91976541	G/A	cg02896835	chr1:92012615	NA	-0.64	-4.67	-0.43	9.92e-6	Eosinophil percentage of white cells;
THYM	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.81	-0.63	7.44e-12	Chronic sinus infection;
THYM	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs7317940	1.000	rs17765211	chr13:78008374	A/G	cg02481778	chr13:77460607	KCTD12	-0.69	-4.69	-0.43	9.27e-6	Age of smoking initiation;
THYM	cis	rs4474465	1.000	rs12277701	chr11:78140726	A/T	cg19901956	chr11:77921274	USP35	-0.6	-4.5	-0.42	1.91e-5	Alzheimer's disease (survival time);
THYM	cis	rs9290065	0.519	rs2121721	chr3:160685788	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-4.45	-0.42	2.3e-5	Kawasaki disease;
THYM	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg05340658	chr4:99064831	C4orf37	-0.57	-4.83	-0.44	5.32e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg22166914	chr1:53195759	ZYG11B	0.9	10.74	0.74	4.39e-18	Monocyte count;
THYM	cis	rs34638657	0.872	rs2967355	chr16:82200103	G/T	cg09439754	chr16:82129088	HSD17B2	0.61	5.37	0.48	5.64e-7	Lung adenocarcinoma;
THYM	cis	rs4595586	0.545	rs1562729	chr12:39406179	T/G	cg26384229	chr12:38710491	ALG10B	0.67	5.14	0.47	1.49e-6	Morning vs. evening chronotype;
THYM	cis	rs1160297	0.576	rs12617374	chr2:53107105	C/T	cg07782112	chr2:53107842	NA	0.74	5.93	0.52	4.95e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg18105134	chr13:113819100	PROZ	-0.98	-9.0	-0.68	2.28e-14	Platelet distribution width;
THYM	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.71	5.37	0.48	5.49e-7	Tonsillectomy;
THYM	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg04234412	chr22:24373322	LOC391322	-0.67	-5.09	-0.46	1.8e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg02187348	chr16:89574699	SPG7	0.77	6.54	0.56	3.04e-9	Multiple myeloma (IgH translocation);
THYM	cis	rs7107174	1.000	rs2510032	chr11:77968631	G/C	cg19901956	chr11:77921274	USP35	-0.74	-5.69	-0.5	1.38e-7	Testicular germ cell tumor;
THYM	cis	rs13016963	0.546	rs10186527	chr2:202200575	C/T	cg12544106	chr2:202507780	ALS2CR4	-0.64	-4.78	-0.44	6.35e-6	Esophageal squamous cell carcinoma;Melanoma;
THYM	cis	rs7078219	0.505	rs7916751	chr10:101285650	T/A	cg17888390	chr10:101282816	NA	-0.45	-4.59	-0.43	1.35e-5	Dental caries;
THYM	cis	rs1021993	0.553	rs1857966	chr1:209561715	C/T	cg24997231	chr1:209527535	NA	-0.57	-5.17	-0.47	1.3e-6	Gut microbiome composition (winter);
THYM	cis	rs860818	1.000	rs858243	chr7:23224357	C/T	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg14983838	chr19:29218262	NA	1.09	9.77	0.71	5e-16	Methadone dose in opioid dependence;
THYM	cis	rs12200560	0.505	rs2015196	chr6:97075331	G/C	cg06623918	chr6:96969491	KIAA0776	0.78	6.03	0.53	3.13e-8	Coronary heart disease;
THYM	cis	rs9470366	0.545	rs2395655	chr6:36645696	C/T	cg08179530	chr6:36648295	CDKN1A	-0.8	-6.38	-0.55	6.34e-9	QRS duration;
THYM	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg12310025	chr6:25882481	NA	-0.73	-6.01	-0.52	3.41e-8	Blood metabolite levels;
THYM	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.98	4.89	0.45	4.07e-6	Initial pursuit acceleration;
THYM	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg26597838	chr10:835615	NA	1.23	8.88	0.67	4.1e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg13397359	chr6:42928475	GNMT	0.6	5.49	0.49	3.31e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg02734326	chr4:10020555	SLC2A9	0.6	5.11	0.46	1.69e-6	Bone mineral density;
THYM	cis	rs293526	1.000	rs293526	chr6:83648056	C/T	cg23278060	chr6:83777448	DOPEY1	0.62	4.49	0.42	1.98e-5	Crohn's disease;
THYM	cis	rs9810089	0.802	rs833861	chr3:136231067	T/A	cg21827317	chr3:136751795	NA	0.57	4.98	0.45	2.86e-6	Gestational age at birth (child effect);
THYM	cis	rs6496667	0.557	rs2601201	chr15:90958000	C/T	cg00425431	chr15:90792223	TTLL13	0.44	5.28	0.48	8.22e-7	Rheumatoid arthritis;
THYM	cis	rs7119	0.651	rs12902072	chr15:77848732	T/C	cg10437265	chr15:77819839	NA	0.71	6.44	0.55	4.77e-9	Type 2 diabetes;
THYM	cis	rs2898681	0.770	rs10032190	chr4:53734940	C/A	cg00791764	chr4:53727839	RASL11B	0.46	6.1	0.53	2.28e-8	Optic nerve measurement (cup area);
THYM	cis	rs4509693	0.843	rs4403743	chr10:102496740	A/C	cg15234845	chr10:102496500	NA	0.65	4.6	0.43	1.3e-5	Alzheimer's disease;
THYM	cis	rs9560113	0.960	rs953260	chr13:112173685	C/T	cg10483660	chr13:112241077	NA	0.53	4.73	0.44	7.8e-6	Menarche (age at onset);
THYM	cis	rs986417	0.818	rs2092722	chr14:61062890	T/A	cg27398547	chr14:60952738	C14orf39	0.93	5.06	0.46	2.07e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg18876405	chr7:65276391	NA	-0.61	-5.19	-0.47	1.2e-6	Aortic root size;
THYM	cis	rs56775891	1.000	rs4799088	chr18:77573548	A/G	cg13263691	chr18:77568018	NA	0.64	4.83	0.44	5.17e-6	Schizophrenia;
THYM	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg16342193	chr10:102329863	NA	-0.52	-5.29	-0.48	7.74e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs920590	0.758	rs2898491	chr8:19661883	C/T	cg01411142	chr8:19674711	INTS10	0.63	4.8	0.44	6e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs926938	0.765	rs12407408	chr1:115234275	A/G	cg12756093	chr1:115239321	AMPD1	0.83	6.41	0.55	5.54e-9	Autism;
THYM	cis	rs12188164	0.812	rs9313065	chr5:423426	T/C	cg16294152	chr5:418696	AHRR	-0.63	-5.53	-0.49	2.83e-7	Cystic fibrosis severity;
THYM	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs3825932	1.000	rs3825932	chr15:79235446	A/G	cg25744700	chr15:79237217	CTSH	0.48	4.55	0.42	1.61e-5	Type 1 diabetes;
THYM	cis	rs9309473	0.500	rs6546862	chr2:73860348	G/A	cg19565262	chr2:73869966	NAT8	0.53	4.51	0.42	1.88e-5	Metabolite levels;
THYM	cis	rs2806561	1.000	rs1208932	chr1:23429122	T/G	cg08872493	chr1:23521417	HTR1D	-0.39	-4.99	-0.46	2.76e-6	Height;
THYM	cis	rs72627123	0.867	rs61522544	chr14:74481953	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.86	4.91	0.45	3.77e-6	Morning vs. evening chronotype;
THYM	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg11317459	chr13:21872234	NA	1.19	9.7	0.71	7.22e-16	White matter hyperintensity burden;
THYM	cis	rs9611519	1.000	rs2273085	chr22:41615376	C/T	cg03806693	chr22:41940476	POLR3H	-0.74	-5.66	-0.5	1.58e-7	Neuroticism;
THYM	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg17211192	chr8:82754475	SNX16	0.91	7.3	0.6	8.57e-11	Diastolic blood pressure;
THYM	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg00074818	chr8:8560427	CLDN23	0.58	5.4	0.48	4.91e-7	Obesity-related traits;
THYM	cis	rs7769051	0.803	rs59740783	chr6:133231711	G/A	cg22852734	chr6:133119734	C6orf192	1.08	5.93	0.52	4.78e-8	Type 2 diabetes nephropathy;
THYM	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg08000102	chr2:233561755	GIGYF2	-0.79	-6.96	-0.58	4.36e-10	Coronary artery disease;
THYM	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs924712	0.844	rs973205	chr6:54729949	C/A	cg19716238	chr6:54711378	FAM83B	-0.45	-4.54	-0.42	1.64e-5	Breast cancer;
THYM	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg18876405	chr7:65276391	NA	-0.76	-7.17	-0.59	1.61e-10	Aortic root size;
THYM	cis	rs761746	0.739	rs5753714	chr22:31990930	G/T	cg10537193	chr22:32026975	PISD	0.38	5.17	0.47	1.27e-6	Intelligence;
THYM	cis	rs3126085	0.825	rs7535078	chr1:152222915	T/C	cg26020982	chr1:152196106	HRNR	0.37	4.98	0.45	2.89e-6	Atopic dermatitis;
THYM	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg04972856	chr6:88032051	C6orf162;GJB7	0.42	5.19	0.47	1.18e-6	Monocyte percentage of white cells;
THYM	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg09455208	chr3:40491958	NA	0.5	5.17	0.47	1.27e-6	Renal cell carcinoma;
THYM	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg05373962	chr22:49881684	NA	-0.67	-6.15	-0.53	1.82e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg13877915	chr19:58951672	ZNF132	0.9	8.63	0.66	1.38e-13	Uric acid clearance;
THYM	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	6.13	0.53	1.95e-8	Total body bone mineral density;
THYM	cis	rs1729951	0.575	rs361239	chr3:136701295	G/T	cg21827317	chr3:136751795	NA	0.74	6.65	0.56	1.84e-9	Neuroticism;
THYM	cis	rs593982	0.688	rs3897552	chr11:65560880	C/T	cg08755490	chr11:65554678	OVOL1	-1.35	-7.68	-0.62	1.42e-11	Atopic dermatitis;
THYM	cis	rs12474201	0.928	rs35825831	chr2:46932544	T/G	cg09399716	chr2:46890238	NA	-0.5	-4.47	-0.42	2.2e-5	Height;
THYM	cis	rs11249608	0.548	rs62393072	chr5:178450056	C/T	cg01312482	chr5:178451176	ZNF879	-0.75	-6.21	-0.54	1.37e-8	Pubertal anthropometrics;
THYM	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg21475434	chr5:93447410	FAM172A	0.96	6.1	0.53	2.29e-8	Diabetic retinopathy;
THYM	cis	rs9810089	0.527	rs590198	chr3:135953729	G/A	cg12473912	chr3:136751656	NA	0.7	6.49	0.55	3.95e-9	Gestational age at birth (child effect);
THYM	cis	rs9611565	0.525	rs1883827	chr22:41703579	A/G	cg06481639	chr22:41940642	POLR3H	-0.61	-4.7	-0.43	8.89e-6	Vitiligo;
THYM	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.84	-5.3	-0.48	7.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs75920871	0.528	rs11216245	chr11:116913202	C/T	cg20608306	chr11:116969690	SIK3	-0.52	-5.78	-0.51	9.38e-8	Subjective well-being;
THYM	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs4889855	0.614	rs7208670	chr17:78494220	T/G	cg16381019	chr17:79072495	BAIAP2	-0.57	-4.62	-0.43	1.18e-5	Fractional excretion of uric acid;
THYM	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg13852791	chr20:30311386	BCL2L1	0.87	6.96	0.58	4.36e-10	Mean corpuscular hemoglobin;
THYM	cis	rs11186	0.630	rs72906395	chr2:189967636	C/T	cg11041835	chr2:189156425	GULP1	0.82	4.87	0.45	4.45e-6	Parkinson's disease;
THYM	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg06640241	chr16:89574553	SPG7	-0.82	-5.64	-0.5	1.77e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs8044868	0.586	rs6499557	chr16:72082654	A/G	cg16558253	chr16:72132732	DHX38	-0.55	-4.67	-0.43	1e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg14416269	chr4:6271139	WFS1	-0.53	-5.45	-0.49	3.91e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg07460842	chr6:66804631	NA	-0.97	-6.96	-0.58	4.44e-10	Exhaled nitric oxide output;
THYM	cis	rs4589258	0.933	rs6483068	chr11:90399758	C/G	cg26834418	chr11:89957033	CHORDC1	0.5	4.48	0.42	2.06e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg01017244	chr2:74357527	NA	1.12	9.24	0.69	7.11e-15	Gestational age at birth (maternal effect);
THYM	cis	rs7901056	0.967	rs36120850	chr10:26718091	C/T	cg23318538	chr10:26883079	C10orf50	0.37	4.95	0.45	3.23e-6	Lymphocyte counts;
THYM	cis	rs34779708	0.966	rs12775799	chr10:35488264	C/T	cg03585969	chr10:35415529	CREM	0.63	4.47	0.42	2.15e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg08999081	chr20:33150536	PIGU	0.6	5.11	0.46	1.65e-6	Coronary artery disease;
THYM	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg04455712	chr21:45112962	RRP1B	0.54	5.04	0.46	2.22e-6	Mean corpuscular volume;
THYM	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.62	4.46	0.42	2.25e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg21280719	chr6:42927975	GNMT	-0.53	-7.16	-0.59	1.69e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2658782	0.906	rs2658791	chr11:93198983	T/C	cg15737290	chr11:93063684	CCDC67	0.99	7.07	0.59	2.61e-10	Pulmonary function decline;
THYM	cis	rs7106204	1.000	rs7106204	chr11:24236096	C/T	ch.11.24196551F	chr11:24239977	NA	-0.99	-6.07	-0.53	2.66e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7772486	0.727	rs10447449	chr6:146138707	A/G	cg23711669	chr6:146136114	FBXO30	0.92	9.0	0.68	2.32e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg06558623	chr16:89946397	TCF25	1.34	5.7	0.51	1.32e-7	Skin colour saturation;
THYM	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg02869364	chr7:1081709	C7orf50	-0.44	-5.04	-0.46	2.21e-6	Longevity;Endometriosis;
THYM	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.8	-7.22	-0.6	1.25e-10	Personality dimensions;
THYM	cis	rs6032067	0.929	rs6017503	chr20:43815103	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.58	-0.56	2.55e-9	Blood protein levels;
THYM	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg14004847	chr7:1930337	MAD1L1	-0.66	-5.16	-0.47	1.35e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg09307838	chr4:120376055	NA	0.76	5.72	0.51	1.21e-7	Corneal astigmatism;
THYM	cis	rs72829446	0.530	rs7217492	chr17:7396049	C/G	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg15242686	chr22:24348715	GSTTP1	0.55	4.94	0.45	3.4e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	trans	rs4262150	0.883	rs72804775	chr5:152303195	C/T	cg08281791	chr5:76607845	PDE8B	0.93	7.05	0.59	2.83e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2841277	0.720	rs11160827	chr14:105422228	C/T	cg14403583	chr14:105418241	AHNAK2	-0.7	-4.97	-0.45	3.01e-6	Rheumatoid arthritis;
THYM	cis	rs10095849	0.576	rs4584120	chr8:39447072	C/T	cg22755526	chr8:38854673	TM2D2;ADAM9	-0.63	-4.66	-0.43	1.04e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg19904058	chr10:135279010	LOC619207	-0.57	-5.32	-0.48	7.02e-7	Systemic lupus erythematosus;
THYM	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05901451	chr6:126070800	HEY2	-0.68	-5.92	-0.52	5.07e-8	Brugada syndrome;
THYM	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg13114125	chr14:105738426	BRF1	-0.74	-5.72	-0.51	1.22e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs2276314	0.512	rs8096189	chr18:33462372	A/T	cg19628046	chr18:33552617	C18orf21	0.65	4.93	0.45	3.42e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs782590	0.557	rs7592219	chr2:55887176	T/C	cg18811423	chr2:55921094	PNPT1	-0.58	-5.07	-0.46	1.99e-6	Metabolic syndrome;
THYM	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg03709012	chr19:19516395	GATAD2A	0.76	6.05	0.53	2.87e-8	Tonsillectomy;
THYM	cis	rs7772486	0.875	rs2777481	chr6:146310036	G/T	cg23711669	chr6:146136114	FBXO30	0.9	8.92	0.68	3.32e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg02012338	chr4:187126139	CYP4V2	0.97	4.59	0.43	1.36e-5	Blood protein levels;
THYM	cis	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs6496667	0.779	rs7168898	chr15:90943065	G/A	cg22089800	chr15:90895588	ZNF774	0.76	4.9	0.45	4.01e-6	Rheumatoid arthritis;
THYM	cis	rs4919044	0.808	rs835279	chr10:94809809	A/T	cg05127821	chr10:94822908	CYP26C1	-1.25	-6.78	-0.57	1.01e-9	Coronary artery disease;
THYM	cis	rs12579753	1.000	rs12811607	chr12:82233619	T/G	cg07988820	chr12:82153109	PPFIA2	-0.73	-4.53	-0.42	1.71e-5	Resting heart rate;
THYM	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs2688608	0.592	rs7080579	chr10:75504029	T/A	cg23231163	chr10:75533350	FUT11	-0.41	-5.9	-0.52	5.54e-8	Inflammatory bowel disease;
THYM	cis	rs7336332	0.598	rs1885989	chr13:28010117	G/A	cg22138327	chr13:27999177	GTF3A	0.62	4.62	0.43	1.21e-5	Weight;
THYM	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg10518543	chr12:38710700	ALG10B	-0.6	-5.06	-0.46	2.02e-6	Morning vs. evening chronotype;
THYM	cis	rs13006833	0.703	rs291427	chr2:191194059	C/T	cg11845111	chr2:191398756	TMEM194B	0.65	4.48	0.42	2.07e-5	Urinary metabolites;
THYM	cis	rs13326165	0.585	rs73088783	chr3:52305286	C/T	cg08438690	chr3:52279403	PPM1M	-0.74	-4.64	-0.43	1.12e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg26384229	chr12:38710491	ALG10B	-0.72	-5.73	-0.51	1.16e-7	Morning vs. evening chronotype;
THYM	cis	rs3138083	0.607	rs12376134	chr9:35643284	C/T	cg07116010	chr9:35646325	NA	0.89	8.89	0.67	3.92e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
THYM	cis	rs9361491	0.657	rs9352625	chr6:79454754	G/A	cg04547799	chr6:79944526	HMGN3	-0.66	-4.58	-0.43	1.41e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7582180	0.677	rs11694723	chr2:100878122	C/T	cg21926883	chr2:100939477	LONRF2	-0.56	-4.74	-0.44	7.54e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4481887	0.676	rs7527991	chr1:248527649	T/A	cg00666640	chr1:248458726	OR2T12	0.54	4.62	0.43	1.2e-5	Common traits (Other);
THYM	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg16230307	chr14:35515116	FAM177A1	0.74	4.62	0.43	1.21e-5	Psoriasis;
THYM	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	-0.74	-5.02	-0.46	2.42e-6	Renal function-related traits (BUN);
THYM	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.75	8.34	0.65	5.64e-13	Eosinophil percentage of white cells;
THYM	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg20503657	chr10:835505	NA	1.1	7.16	0.59	1.7e-10	Eosinophil percentage of granulocytes;
THYM	cis	rs34375054	0.624	rs12580033	chr12:125676083	A/T	cg25124228	chr12:125621409	AACS	-0.67	-4.87	-0.45	4.48e-6	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	6.3	0.54	9.17e-9	Platelet count;
THYM	cis	rs7772486	0.686	rs7739735	chr6:146123536	G/A	cg23711669	chr6:146136114	FBXO30	0.83	7.92	0.63	4.52e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg17105886	chr17:28927953	LRRC37B2	1.25	6.76	0.57	1.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4242434	0.927	rs13271626	chr8:22467760	C/G	cg03733263	chr8:22462867	KIAA1967	1.15	13.54	0.81	6.65e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1448094	0.511	rs17279240	chr12:86162550	A/T	cg00310523	chr12:86230176	RASSF9	0.61	5.31	0.48	7.29e-7	Major depressive disorder;
THYM	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4638749	0.501	rs2220261	chr2:108758885	G/A	cg25838818	chr2:108905173	SULT1C2	-0.52	-4.89	-0.45	4.13e-6	Blood pressure;
THYM	cis	rs4951018	0.526	rs6693913	chr1:205654061	G/C	cg07157834	chr1:205819609	PM20D1	-0.6	-4.77	-0.44	6.56e-6	Prostate-specific antigen levels;
THYM	cis	rs2456568	0.548	rs10466334	chr11:93663512	A/G	cg26875233	chr11:93583750	C11orf90	-0.52	-5.79	-0.51	8.93e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg24530246	chr3:53118167	NA	0.75	4.5	0.42	1.91e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs1499972	0.941	rs62263112	chr3:117615515	T/C	cg07612923	chr3:117604196	NA	1.19	5.0	0.46	2.66e-6	Schizophrenia;
THYM	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg11189052	chr15:85197271	WDR73	-0.69	-5.37	-0.48	5.55e-7	P wave terminal force;
THYM	cis	rs113835537	0.559	rs11227497	chr11:66269464	T/C	cg24851651	chr11:66362959	CCS	0.69	4.81	0.44	5.56e-6	Airway imaging phenotypes;
THYM	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg12219531	chr12:120966889	COQ5	0.83	6.85	0.58	7.22e-10	High light scatter reticulocyte count;
THYM	cis	rs6121246	0.609	rs6060983	chr20:30420924	T/C	cg13852791	chr20:30311386	BCL2L1	0.89	8.22	0.64	1.02e-12	Mean corpuscular hemoglobin;
THYM	cis	rs7264396	0.563	rs6058312	chr20:34324484	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Total cholesterol levels;
THYM	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.95	-4.51	-0.42	1.87e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg07211511	chr3:129823064	LOC729375	-1.32	-8.73	-0.67	8.5e-14	Blood pressure (smoking interaction);
THYM	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg00255919	chr5:131827918	IRF1	0.47	5.14	0.47	1.44e-6	Asthma (sex interaction);
THYM	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg07537917	chr2:241836409	C2orf54	-0.21	-4.79	-0.44	6.07e-6	Urinary metabolites;
THYM	cis	rs2732480	0.557	rs2732441	chr12:48723324	C/G	cg21466736	chr12:48725269	NA	-0.6	-5.36	-0.48	5.86e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11890956	chr21:40555474	PSMG1	-0.95	-10.67	-0.74	6.29e-18	Cognitive function;
THYM	cis	rs1729951	0.575	rs747842	chr3:136703121	A/C	cg12473912	chr3:136751656	NA	0.62	5.03	0.46	2.32e-6	Neuroticism;
THYM	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.86	0.74	2.46e-18	Chronic sinus infection;
THYM	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg04362960	chr10:104952993	NT5C2	0.6	5.11	0.46	1.66e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs11696501	0.694	rs6073827	chr20:44265556	T/C	cg11783356	chr20:44313418	WFDC10B	-0.66	-4.53	-0.42	1.72e-5	Brain structure;
THYM	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg15693483	chr7:1102177	C7orf50	0.54	6.26	0.54	1.1e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3819817	0.601	rs7963900	chr12:96353198	T/A	cg26410635	chr12:96350720	AMDHD1	0.53	5.02	0.46	2.38e-6	Vitamin D levels;
THYM	cis	rs4363385	0.507	rs6587710	chr1:152870716	A/G	cg07796016	chr1:152779584	LCE1C	-0.76	-6.31	-0.54	8.87e-9	Inflammatory skin disease;
THYM	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg09455208	chr3:40491958	NA	0.47	4.95	0.45	3.25e-6	Renal cell carcinoma;
THYM	cis	rs990171	1.000	rs7561487	chr2:103077894	A/G	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.13	-0.47	1.5e-6	Lymphocyte counts;
THYM	cis	rs6496667	1.000	rs16944254	chr15:90898527	C/T	cg22089800	chr15:90895588	ZNF774	0.71	4.71	0.43	8.55e-6	Rheumatoid arthritis;
THYM	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg16558253	chr16:72132732	DHX38	-0.58	-5.02	-0.46	2.46e-6	Fibrinogen levels;
THYM	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg13880726	chr7:1868755	MAD1L1	-0.72	-4.8	-0.44	5.78e-6	Bipolar disorder;
THYM	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.53	4.64	0.43	1.13e-5	Lymphocyte counts;
THYM	cis	rs4363385	0.747	rs4845332	chr1:152982632	C/T	cg13444842	chr1:152974279	SPRR3	-0.59	-4.68	-0.43	9.52e-6	Inflammatory skin disease;
THYM	cis	rs73787773	0.629	rs27982	chr5:111463837	C/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	0.98	5.77	0.51	9.75e-8	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs9646944	0.501	rs10210176	chr2:103079516	A/C	cg01241218	chr2:102972058	NA	-0.76	-4.94	-0.45	3.41e-6	Blood protein levels;
THYM	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg07414643	chr4:187882934	NA	0.61	5.31	0.48	7.17e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-4.81	-0.44	5.66e-6	Crohn's disease;
THYM	cis	rs7010267	0.740	rs7464496	chr8:119954842	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.55	4.49	0.42	1.98e-5	Total body bone mineral density (age 45-60);
THYM	cis	rs7772486	0.624	rs9485018	chr6:146025731	T/C	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg24642439	chr20:33292090	TP53INP2	0.6	4.58	0.43	1.39e-5	Coronary artery disease;
THYM	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg19774624	chr17:42201019	HDAC5	-0.77	-7.16	-0.59	1.73e-10	Total body bone mineral density;
THYM	cis	rs7100689	0.646	rs7089003	chr10:82124155	T/C	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg22166914	chr1:53195759	ZYG11B	0.77	7.6	0.62	2.04e-11	Monocyte count;
THYM	cis	rs28595532	0.920	rs116098781	chr4:119771613	G/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs17345786	0.520	rs1476123	chr3:101313413	C/G	cg12386194	chr3:101231763	SENP7	0.59	5.06	0.46	2.04e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg10760299	chr15:45669010	GATM	0.85	6.57	0.56	2.69e-9	Homoarginine levels;
THYM	cis	rs7220711	0.934	rs8079336	chr17:41782831	C/T	cg26893861	chr17:41843967	DUSP3	0.62	5.21	0.47	1.11e-6	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs758324	0.732	rs156059	chr5:131479631	G/A	cg16205897	chr5:131564050	P4HA2	0.59	4.86	0.45	4.64e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs7107174	0.892	rs2511167	chr11:77964698	C/T	cg19901956	chr11:77921274	USP35	-0.74	-5.74	-0.51	1.14e-7	Testicular germ cell tumor;
THYM	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg13393036	chr8:95962371	TP53INP1	0.45	4.77	0.44	6.65e-6	Type 2 diabetes;
THYM	cis	rs595982	0.559	rs73061632	chr19:49361663	G/A	cg21252483	chr19:49399788	TULP2	-0.81	-5.67	-0.5	1.56e-7	Red cell distribution width;
THYM	cis	rs722599	0.847	rs2058919	chr14:75310812	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.6	-5.54	-0.49	2.71e-7	IgG glycosylation;
THYM	cis	rs72772090	0.539	rs3335	chr5:96115070	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg21775007	chr8:11205619	TDH	0.65	5.21	0.47	1.08e-6	Retinal vascular caliber;
THYM	cis	rs12368653	0.789	rs2270777	chr12:58145156	C/T	cg12615879	chr12:58013172	SLC26A10	0.49	4.64	0.43	1.12e-5	Multiple sclerosis;
THYM	cis	rs13065560	0.594	rs4398365	chr3:38878804	C/G	cg15678707	chr3:39149194	GORASP1;TTC21A	0.59	4.72	0.44	7.99e-6	Interleukin-18 levels;
THYM	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg25566285	chr7:158114605	PTPRN2	0.89	10.22	0.72	5.47e-17	Calcium levels;
THYM	cis	rs35934224	0.769	rs117985725	chr22:19860852	T/C	cg11182965	chr22:19864308	TXNRD2	-0.88	-5.2	-0.47	1.14e-6	Glaucoma (primary open-angle);
THYM	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg02527881	chr3:46936655	PTH1R	-0.61	-5.7	-0.51	1.33e-7	Colorectal cancer;
THYM	cis	rs6570726	1.000	rs455109	chr6:145872665	C/T	cg23711669	chr6:146136114	FBXO30	0.83	8.07	0.64	2.16e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg16797656	chr11:68205561	LRP5	0.43	4.55	0.42	1.58e-5	Total body bone mineral density;
THYM	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg01341218	chr17:43662625	NA	1.15	9.87	0.71	3.19e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2219968	0.676	rs34077447	chr8:78839966	T/C	cg00738934	chr8:78996279	NA	-0.7	-6.22	-0.54	1.35e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs79387448	0.745	rs17027341	chr2:103136559	A/G	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2282300	0.739	rs34951229	chr11:30265166	C/G	cg06241208	chr11:30344200	C11orf46	-0.77	-5.59	-0.5	2.15e-7	Morning vs. evening chronotype;
THYM	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.25	-10.33	-0.73	3.19e-17	Platelet count;
THYM	cis	rs909002	0.962	rs7537646	chr1:32135495	G/A	cg13919466	chr1:32135498	COL16A1	-0.59	-5.97	-0.52	4.12e-8	Intelligence (multi-trait analysis);
THYM	cis	rs870825	0.549	rs7656993	chr4:185635159	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs2806561	0.765	rs1612905	chr1:23510023	G/T	cg19743168	chr1:23544995	NA	0.55	5.6	0.5	2.09e-7	Height;
THYM	cis	rs61990749	0.544	rs176979	chr14:78198072	A/C	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.02	0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg04315214	chr1:2043799	PRKCZ	0.66	5.58	0.5	2.23e-7	Height;
THYM	cis	rs56079296	1.000	rs56079296	chr5:121276797	A/G	cg01191064	chr5:121408893	LOX	-0.66	-4.5	-0.42	1.96e-5	Coronary artery disease;
THYM	cis	rs9611565	0.506	rs1984839	chr22:41685937	G/C	cg06481639	chr22:41940642	POLR3H	-0.64	-4.93	-0.45	3.46e-6	Vitiligo;
THYM	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg05283184	chr6:79620031	NA	-0.91	-8.88	-0.67	4.11e-14	Intelligence (multi-trait analysis);
THYM	cis	rs4790312	0.875	rs9303241	chr17:1978963	T/A	cg15816464	chr17:2026533	SMG6	0.37	4.75	0.44	7.2e-6	Left atrial antero-posterior diameter;
THYM	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs6448317	1.000	rs7698504	chr4:24939386	A/T	cg22968281	chr4:24586266	DHX15	0.7	4.79	0.44	6.02e-6	Heschl's gyrus morphology;
THYM	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs5758511	0.680	rs1107554	chr22:42667594	C/G	cg22189786	chr22:42395067	WBP2NL	0.53	4.88	0.45	4.22e-6	Birth weight;
THYM	cis	rs2811415	0.597	rs10934837	chr3:127726173	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11644478	chr21:40555479	PSMG1	1.11	9.99	0.72	1.76e-16	Cognitive function;
THYM	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12681287	0.640	rs7017706	chr8:87480890	C/T	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg14004847	chr7:1930337	MAD1L1	-0.63	-5.05	-0.46	2.16e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg24324837	chr19:49891574	CCDC155	0.66	6.52	0.56	3.39e-9	Multiple sclerosis;
THYM	cis	rs6519955	0.897	rs4073601	chr22:46434686	A/G	cg05468064	chr22:46423449	NA	0.46	6.45	0.55	4.69e-9	Dupuytren's disease;
THYM	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg03188948	chr7:1209495	NA	0.74	5.7	0.5	1.36e-7	Longevity;Endometriosis;
THYM	cis	rs936229	0.906	rs9210	chr15:75128501	T/C	cg14664628	chr15:75095509	CSK	-1.08	-8.39	-0.65	4.53e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.45	-5.4	-0.48	4.96e-7	Longevity;Endometriosis;
THYM	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg20712883	chr12:51590929	POU6F1	0.85	5.47	0.49	3.69e-7	Cisplatin-induced ototoxicity;
THYM	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg09033563	chr22:24373618	LOC391322	-0.52	-4.45	-0.42	2.32e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1371867	0.846	rs1692007	chr8:101268343	T/C	cg00191853	chr8:101177733	SPAG1	0.51	5.03	0.46	2.29e-6	Atrioventricular conduction;
THYM	cis	rs3796619	1.000	rs4974601	chr4:1095410	G/A	cg27284194	chr4:1044797	NA	0.53	4.88	0.45	4.21e-6	Recombination rate (males);
THYM	cis	rs9563576	0.518	rs9591829	chr13:58317864	A/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.66	5.11	0.46	1.65e-6	Body mass index;
THYM	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs420259	0.516	rs7190131	chr16:23502149	C/T	cg00143387	chr16:23521605	GGA2	-0.77	-5.51	-0.49	3.12e-7	Bipolar disorder;
THYM	cis	rs9826463	0.582	rs2291363	chr3:142116151	A/G	cg20824294	chr3:142316082	PLS1	0.8	5.46	0.49	3.74e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs7119	0.717	rs12898370	chr15:77808598	A/T	cg27398640	chr15:77910606	LINGO1	-0.57	-5.69	-0.5	1.4e-7	Type 2 diabetes;
THYM	cis	rs57920188	0.535	rs7412438	chr1:4095581	C/G	cg20703997	chr1:4087676	NA	0.85	5.69	0.5	1.41e-7	Interleukin-17 levels;
THYM	cis	rs1483890	0.642	rs6795775	chr3:69402801	C/T	cg22125112	chr3:69402811	FRMD4B	0.55	6.81	0.57	8.87e-10	Resting heart rate;
THYM	cis	rs9677476	0.863	rs58383275	chr2:232063946	T/C	cg23338755	chr2:231921595	PSMD1	0.69	5.02	0.46	2.43e-6	Food antigen IgG levels;
THYM	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg11764359	chr7:65958608	NA	0.63	4.83	0.44	5.13e-6	Aortic root size;
THYM	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11096990	0.892	rs11930865	chr4:39220331	T/C	cg24403649	chr4:39172243	NA	-0.66	-5.67	-0.5	1.51e-7	Cognitive function;
THYM	cis	rs4919694	0.901	rs12264456	chr10:104830634	C/T	cg04362960	chr10:104952993	NT5C2	1.14	7.07	0.59	2.65e-10	Arsenic metabolism;
THYM	cis	rs79149102	0.579	rs12591175	chr15:75356073	C/T	cg09165964	chr15:75287851	SCAMP5	-1.01	-5.72	-0.51	1.25e-7	Lung cancer;
THYM	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.72	-6.12	-0.53	2.09e-8	Coronary artery disease;
THYM	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg13695892	chr22:41940480	POLR3H	0.89	6.74	0.57	1.2e-9	Vitiligo;
THYM	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg15557168	chr22:42548783	NA	-0.6	-4.59	-0.43	1.33e-5	Schizophrenia;
THYM	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg04731861	chr2:219085781	ARPC2	0.55	5.26	0.47	8.86e-7	Colorectal cancer;
THYM	cis	rs4523957	0.579	rs2270478	chr17:2089848	G/A	cg16513277	chr17:2031491	SMG6	-0.97	-8.83	-0.67	5.35e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg17063962	chr7:91808500	NA	-1.1	-11.79	-0.77	2.64e-20	Breast cancer;
THYM	cis	rs9796	0.689	rs72737758	chr15:41449778	C/T	cg21153102	chr15:41252147	NA	0.64	5.3	0.48	7.5e-7	Menopause (age at onset);
THYM	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	13.05	0.8	6.7e-23	Chronic sinus infection;
THYM	cis	rs2273669	0.667	rs2273668	chr6:109323519	G/T	cg17117243	chr6:109341365	SESN1	-0.9	-5.38	-0.48	5.45e-7	Prostate cancer;
THYM	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg06766960	chr11:133703094	NA	-0.57	-5.41	-0.48	4.79e-7	Childhood ear infection;
THYM	cis	rs4343996	0.967	rs34735349	chr7:3344115	C/G	cg21248987	chr7:3385318	SDK1	0.41	4.95	0.45	3.17e-6	Motion sickness;
THYM	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg18252515	chr7:66147081	NA	-0.66	-5.01	-0.46	2.55e-6	Aortic root size;
THYM	cis	rs2717559	0.522	rs2585160	chr8:143875204	G/A	cg17888033	chr8:143858414	LYNX1	0.47	5.32	0.48	6.82e-7	Urinary tract infection frequency;
THYM	cis	rs2235649	0.833	rs7189070	chr16:1850813	G/A	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.68	-4.57	-0.42	1.44e-5	Menarche (age at onset);
THYM	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg10802521	chr3:52805072	NEK4	-0.71	-5.96	-0.52	4.22e-8	Bipolar disorder;
THYM	cis	rs739496	0.542	rs10849937	chr12:111792427	A/G	cg10833066	chr12:111807467	FAM109A	0.51	5.84	0.51	7.21e-8	Platelet count;
THYM	trans	rs877282	0.853	rs11595507	chr10:756703	C/T	cg22713356	chr15:30763199	NA	1.27	9.37	0.69	3.62e-15	Uric acid levels;
THYM	cis	rs259282	0.524	rs11878322	chr19:33122886	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.72	6.39	0.55	6.04e-9	Schizophrenia;
THYM	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.79	0.51	9.18e-8	Rheumatoid arthritis;
THYM	cis	rs9435341	0.896	rs1623927	chr1:107596120	T/C	cg00944433	chr1:107599041	PRMT6	0.43	5.42	0.49	4.42e-7	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg08807101	chr21:30365312	RNF160	-0.67	-4.87	-0.45	4.5e-6	Dental caries;
THYM	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg09436375	chr6:42928200	GNMT	-0.42	-5.48	-0.49	3.51e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg08847533	chr14:75593920	NEK9	-0.96	-10.3	-0.73	3.86e-17	Height;
THYM	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg27572855	chr1:25598939	RHD	-0.65	-4.93	-0.45	3.43e-6	Erythrocyte sedimentation rate;
THYM	cis	rs55728055	0.661	rs73158601	chr22:31790417	C/A	cg10537193	chr22:32026975	PISD	-0.91	-5.25	-0.47	9.24e-7	Age-related hearing impairment;
THYM	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg23131131	chr22:24373011	LOC391322	0.82	7.6	0.61	2.11e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg00814883	chr7:100076585	TSC22D4	-0.98	-6.62	-0.56	2.15e-9	Platelet count;
THYM	cis	rs7695732	0.550	rs11097207	chr4:89912705	A/C	cg17769793	chr4:89976368	FAM13A	-0.49	-5.2	-0.47	1.17e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg13319975	chr6:146136371	FBXO30	-0.66	-5.23	-0.47	9.87e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9807841	0.592	rs2742313	chr19:10799750	T/C	cg16900796	chr19:10755136	SLC44A2	0.4	6.18	0.54	1.61e-8	Inflammatory skin disease;
THYM	cis	rs2916260	0.800	rs75440451	chr6:40392597	C/G	cg08415973	chr6:40346114	TDRG1	0.76	4.77	0.44	6.74e-6	Incident coronary heart disease;
THYM	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg17063962	chr7:91808500	NA	-1.1	-12.09	-0.78	6.22e-21	Breast cancer;
THYM	cis	rs9902453	0.868	rs8066731	chr17:28523121	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	6.59	0.56	2.45e-9	Coffee consumption (cups per day);
THYM	cis	rs10819861	0.620	rs10819834	chr9:98857473	C/G	cg14508093	chr9:98862825	NA	-0.23	-4.47	-0.42	2.17e-5	Electrocardiographic traits;
THYM	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs713587	0.646	rs2384061	chr2:25135620	C/T	cg15423357	chr2:25149977	NA	0.59	5.82	0.51	7.88e-8	Body mass index in non-asthmatics;
THYM	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	trans	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg10856724	chr12:34555212	NA	-0.94	-8.22	-0.64	1.01e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg05962950	chr11:130786565	SNX19	0.9	8.16	0.64	1.41e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7681440	0.583	rs2583965	chr4:90740103	G/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs2070488	0.965	rs1870915	chr3:38494228	G/C	cg24069376	chr3:38537580	EXOG	0.66	6.8	0.57	9.12e-10	Electrocardiographic conduction measures;
THYM	cis	rs3733631	1.000	rs28688000	chr4:104620713	A/G	cg24090629	chr4:104641072	TACR3	-0.87	-5.51	-0.49	3.08e-7	Menarche (age at onset);
THYM	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg22852734	chr6:133119734	C6orf192	1.28	8.61	0.66	1.55e-13	Type 2 diabetes nephropathy;
THYM	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.47	0.49	3.63e-7	Electroencephalogram traits;
THYM	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg12179176	chr11:130786555	SNX19	-0.94	-9.63	-0.7	1.04e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7772486	0.846	rs2144478	chr6:146381445	A/G	cg23711669	chr6:146136114	FBXO30	0.9	8.82	0.67	5.37e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4595586	0.545	rs1356265	chr12:39403696	A/G	cg26384229	chr12:38710491	ALG10B	0.64	5.01	0.46	2.46e-6	Morning vs. evening chronotype;
THYM	cis	rs3752962	0.569	rs12451788	chr17:1941048	C/T	cg24156229	chr17:1948635	NA	0.61	5.14	0.47	1.48e-6	Itch intensity from mosquito bite;
THYM	cis	rs7089973	0.872	rs7075888	chr10:116627117	C/T	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.14	-0.47	1.5e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs6988636	1.000	rs58177772	chr8:124188067	T/C	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08704250	chr15:31115839	NA	0.68	7.28	0.6	9.45e-11	Huntington's disease progression;
THYM	cis	rs6867032	1.000	rs28392808	chr5:2013477	A/G	cg26168224	chr5:2018326	NA	1.28	15.48	0.85	1e-27	Gut microbiome composition (winter);
THYM	cis	rs11585357	0.895	rs72646798	chr1:17614422	C/T	cg08277548	chr1:17600880	PADI3	-0.9	-5.43	-0.49	4.38e-7	Hair shape;
THYM	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1395	0.848	rs6716850	chr2:27525350	G/A	cg23587288	chr2:27483067	SLC30A3	-0.57	-4.48	-0.42	2.04e-5	Blood metabolite levels;
THYM	cis	rs4455778	0.580	rs10257863	chr7:49092400	C/A	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg20891283	chr12:69753455	YEATS4	0.76	6.34	0.55	7.72e-9	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7131987	0.621	rs57803026	chr12:29497506	G/A	cg09582351	chr12:29534625	ERGIC2	-0.59	-5.13	-0.47	1.55e-6	QT interval;
THYM	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg10802521	chr3:52805072	NEK4	-0.57	-4.87	-0.45	4.47e-6	Electroencephalogram traits;
THYM	cis	rs7192380	0.893	rs12924052	chr16:69777246	T/C	cg09409435	chr16:70099608	PDXDC2	-0.63	-4.7	-0.43	8.92e-6	Sjögren's syndrome;
THYM	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs7582180	0.663	rs1114595	chr2:100960072	T/A	cg08017756	chr2:100939284	LONRF2	-0.72	-7.58	-0.61	2.31e-11	Intelligence (multi-trait analysis);
THYM	cis	rs17253792	0.822	rs76819679	chr14:56134672	C/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs1395	1.000	rs1275528	chr2:27430781	A/G	cg23587288	chr2:27483067	SLC30A3	0.58	5.09	0.46	1.78e-6	Blood metabolite levels;
THYM	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg07988820	chr12:82153109	PPFIA2	-0.83	-5.29	-0.48	7.71e-7	Resting heart rate;
THYM	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg08431931	chr22:42394659	WBP2NL	0.7	4.91	0.45	3.72e-6	Birth weight;
THYM	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.73	-0.44	7.7e-6	Crohn's disease;
THYM	cis	rs4072705	1.000	rs7874367	chr9:127377780	A/T	cg01786973	chr9:127249749	NR5A1	-0.37	-4.87	-0.45	4.41e-6	Menarche (age at onset);
THYM	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	-0.77	-6.69	-0.57	1.54e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs599083	0.530	rs546803	chr11:68186392	C/T	cg16797656	chr11:68205561	LRP5	-0.5	-5.46	-0.49	3.84e-7	Bone mineral density (spine);
THYM	cis	rs2816062	0.710	rs2816052	chr1:18895536	T/C	cg18795169	chr1:18902165	NA	-0.99	-12.14	-0.78	5.02e-21	Urate levels in lean individuals;
THYM	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg17554472	chr22:41940697	POLR3H	0.67	4.54	0.42	1.66e-5	Vitiligo;
THYM	cis	rs28595532	0.920	rs115841156	chr4:119740073	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs6430585	1.000	rs6430585	chr2:136506927	A/C	cg04750100	chr2:136595281	LCT	-0.52	-5.03	-0.46	2.28e-6	Corneal structure;
THYM	cis	rs2294693	0.947	rs6924722	chr6:41002195	C/T	cg14418226	chr6:40996092	UNC5CL	-0.7	-6.4	-0.55	5.96e-9	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	5.41	0.49	4.69e-7	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg25237894	chr2:233734115	C2orf82	-0.35	-4.88	-0.45	4.27e-6	Coronary artery disease;
THYM	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.77	0.51	1.01e-7	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs778371	0.697	rs2344613	chr2:233603065	C/G	cg08000102	chr2:233561755	GIGYF2	0.79	6.96	0.58	4.28e-10	Schizophrenia;
THYM	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg16586182	chr3:47516702	SCAP	0.68	5.66	0.5	1.58e-7	Colorectal cancer;
THYM	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22857025	chr5:266934	NA	-1.43	-9.54	-0.7	1.58e-15	Breast cancer;
THYM	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg07343612	chr16:622815	PIGQ	-1.08	-10.52	-0.73	1.27e-17	Height;
THYM	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs6424115	0.733	rs2502996	chr1:24199041	T/C	cg15997130	chr1:24165203	NA	0.74	6.35	0.55	7.22e-9	Immature fraction of reticulocytes;
THYM	cis	rs2290159	0.800	rs5746193	chr3:12658601	C/T	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.09	0.64	1.96e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.83	-5.75	-0.51	1.06e-7	Body mass index;
THYM	cis	rs28595532	0.920	rs10001115	chr4:119781867	A/C	cg14228332	chr4:119757509	SEC24D	1.36	5.22	0.47	1.07e-6	Cannabis dependence symptom count;
THYM	cis	rs8070128	0.600	rs8071238	chr17:17900990	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	6.09	0.53	2.42e-8	Total body bone mineral density;
THYM	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg13114125	chr14:105738426	BRF1	-0.75	-6.02	-0.53	3.27e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7584330	0.738	rs13398506	chr2:238374824	A/G	cg16989719	chr2:238392110	NA	-0.62	-5.9	-0.52	5.46e-8	Prostate cancer;
THYM	cis	rs7828089	0.935	rs896375	chr8:22262098	A/G	cg13512537	chr8:22265999	SLC39A14	-0.63	-5.29	-0.48	7.92e-7	Verbal declarative memory;
THYM	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg08885076	chr2:99613938	TSGA10	-0.46	-4.53	-0.42	1.71e-5	Fear of minor pain;
THYM	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg08885076	chr2:99613938	TSGA10	0.65	5.96	0.52	4.31e-8	Chronic sinus infection;
THYM	cis	rs6980334	0.871	rs1025967	chr7:137753091	T/C	cg18769353	chr7:137028617	PTN	0.58	4.58	0.43	1.39e-5	Blood metabolite ratios;
THYM	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg15605315	chr1:45957053	TESK2	0.79	6.68	0.57	1.61e-9	High light scatter reticulocyte count;
THYM	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs28595532	0.841	rs114465037	chr4:119778165	A/G	cg21605333	chr4:119757512	SEC24D	1.67	6.17	0.53	1.69e-8	Cannabis dependence symptom count;
THYM	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg22189786	chr22:42395067	WBP2NL	0.54	4.66	0.43	1.03e-5	Birth weight;
THYM	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.94	0.45	3.37e-6	Prudent dietary pattern;
THYM	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg24803719	chr17:45855879	NA	-0.6	-6.33	-0.54	7.96e-9	IgG glycosylation;
THYM	cis	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg06521331	chr12:34319734	NA	-0.84	-6.44	-0.55	4.78e-9	Morning vs. evening chronotype;
THYM	cis	rs4642101	0.561	rs7641959	chr3:12810755	G/C	cg11882607	chr3:12858926	CAND2	-0.46	-5.23	-0.47	1.01e-6	QRS complex (12-leadsum);
THYM	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg10248100	chr7:872053	UNC84A	0.74	4.99	0.46	2.75e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs995000	0.931	rs10889349	chr1:63081919	A/G	cg06896770	chr1:63153194	DOCK7	0.89	7.31	0.6	8.2e-11	Triglyceride levels;
THYM	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg06634786	chr22:41940651	POLR3H	-0.51	-4.5	-0.42	1.93e-5	Vitiligo;
THYM	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg19077165	chr18:44547161	KATNAL2	-0.44	-4.6	-0.43	1.31e-5	Educational attainment;
THYM	cis	rs7247513	0.859	rs35945052	chr19:12703230	G/A	cg01871581	chr19:12707946	ZNF490	-0.95	-11.49	-0.76	1.16e-19	Bipolar disorder;
THYM	cis	rs7809950	1.000	rs1544336	chr7:107082415	G/C	cg23024343	chr7:107201750	COG5	-0.91	-8.09	-0.64	1.92e-12	Coronary artery disease;
THYM	cis	rs236907	0.859	rs36080557	chr1:171764003	A/G	cg20598894	chr1:171756153	METTL13	-0.74	-5.59	-0.5	2.16e-7	Mean platelet volume;
THYM	cis	rs7267979	0.668	rs2387977	chr20:25599776	C/T	cg03522245	chr20:25566470	NINL	-0.61	-4.83	-0.44	5.23e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.56	-7.94	-0.63	3.93e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs789852	0.764	rs1705999	chr3:194316333	C/T	cg18000598	chr3:194342907	TMEM44	-1.11	-6.93	-0.58	4.95e-10	QT interval;
THYM	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg02018176	chr4:1364513	KIAA1530	0.73	6.98	0.58	3.95e-10	Longevity;
THYM	cis	rs7107174	1.000	rs7107174	chr11:77997936	C/T	cg19901956	chr11:77921274	USP35	-0.74	-5.57	-0.5	2.39e-7	Testicular germ cell tumor;
THYM	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.63	-4.6	-0.43	1.31e-5	Aortic root size;
THYM	cis	rs4474465	0.790	rs6592790	chr11:78262618	T/C	cg19901956	chr11:77921274	USP35	0.58	4.54	0.42	1.68e-5	Alzheimer's disease (survival time);
THYM	cis	rs599083	0.530	rs640569	chr11:68184820	A/G	cg16797656	chr11:68205561	LRP5	-0.47	-5.14	-0.47	1.49e-6	Bone mineral density (spine);
THYM	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1847202	0.859	rs4566476	chr3:72948995	G/C	cg25664220	chr3:72788482	NA	-0.64	-4.88	-0.45	4.2e-6	Motion sickness;
THYM	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg00383909	chr3:49044727	WDR6	1.21	7.52	0.61	3.1e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs3892630	0.824	rs12976069	chr19:33280084	G/A	cg22980127	chr19:33182716	NUDT19	1.13	9.09	0.68	1.45e-14	Red blood cell traits;
THYM	cis	rs11186	0.556	rs58289599	chr2:189964389	C/T	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	cis	rs11948739	0.539	rs10045319	chr5:130250710	G/A	cg08523029	chr5:130500466	HINT1	0.9	5.96	0.52	4.21e-8	Pediatric bone mineral content (hip);
THYM	cis	rs1670533	1.000	rs3816474	chr4:1050653	G/A	cg27284194	chr4:1044797	NA	0.69	4.86	0.45	4.64e-6	Recombination rate (females);
THYM	cis	rs921968	0.643	rs524902	chr2:219433357	A/C	cg02176678	chr2:219576539	TTLL4	0.64	6.08	0.53	2.49e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg02640540	chr1:67518911	SLC35D1	-0.64	-4.68	-0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg27211696	chr2:191398769	TMEM194B	-0.6	-4.5	-0.42	1.94e-5	Diastolic blood pressure;
THYM	cis	rs13256369	1.000	rs4840352	chr8:8573508	A/G	cg00074818	chr8:8560427	CLDN23	0.53	4.76	0.44	6.82e-6	Obesity-related traits;
THYM	cis	rs7404928	0.651	rs8055864	chr16:23950236	T/G	cg26685404	chr16:23957272	PRKCB	0.61	7.09	0.59	2.38e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg12963246	chr6:28129442	ZNF389	0.77	6.4	0.55	5.74e-9	Parkinson's disease;
THYM	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14893161	chr1:205819251	PM20D1	-0.82	-8.15	-0.64	1.44e-12	Monocyte percentage of white cells;
THYM	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg05182265	chr7:156933206	UBE3C	-0.7	-9.53	-0.7	1.66e-15	Body mass index;
THYM	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6723226	0.557	rs62136260	chr2:32575447	T/C	cg02381751	chr2:32503542	YIPF4	-0.55	-4.53	-0.42	1.72e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg23758822	chr17:41437982	NA	1.22	11.98	0.78	1.07e-20	Menopause (age at onset);
THYM	cis	rs56341938	0.935	rs62273763	chr3:168755964	G/A	cg09107232	chr3:169491072	MYNN	0.52	4.45	0.42	2.32e-5	Lung function (FEV1/FVC);
THYM	cis	rs10823500	0.674	rs7089860	chr10:71992848	C/G	cg02100629	chr10:71892760	AIFM2	-0.42	-4.92	-0.45	3.6e-6	Blood protein levels;
THYM	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg04731861	chr2:219085781	ARPC2	0.53	5.03	0.46	2.29e-6	Colorectal cancer;
THYM	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.54	4.67	0.43	9.75e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	0.75	6.1	0.53	2.33e-8	Age at first birth;
THYM	cis	rs6754311	0.593	rs2034276	chr2:136422171	A/T	cg07169764	chr2:136633963	MCM6	0.7	5.67	0.5	1.55e-7	Mosquito bite size;
THYM	cis	rs7851660	0.967	rs4743135	chr9:100599493	C/T	cg13688889	chr9:100608707	NA	-0.83	-7.31	-0.6	8.28e-11	Strep throat;
THYM	cis	rs12611088	0.600	rs2261316	chr19:44030998	A/G	cg18042043	chr19:44147545	NA	0.4	4.67	0.43	1e-5	Plasma amyloid beta peptide concentrations (ABx-42);
THYM	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg09260853	chr1:2094483	PRKCZ	-0.44	-4.56	-0.42	1.55e-5	Height;
THYM	cis	rs9828933	0.882	rs3816156	chr3:63999712	A/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.77	-4.71	-0.44	8.43e-6	Type 2 diabetes;
THYM	cis	rs55728055	0.661	rs9680589	chr22:31853484	G/A	cg01338084	chr22:32026380	PISD	1.35	4.92	0.45	3.69e-6	Age-related hearing impairment;
THYM	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg07169764	chr2:136633963	MCM6	-0.71	-6.29	-0.54	9.76e-9	Mosquito bite size;
THYM	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg01097406	chr16:89675127	NA	0.81	7.38	0.6	6.02e-11	Vitiligo;
THYM	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg18252515	chr7:66147081	NA	1.37	8.05	0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs67311347	0.544	rs12635762	chr3:40332759	C/T	cg24209194	chr3:40518798	ZNF619	-0.57	-4.8	-0.44	5.84e-6	Renal cell carcinoma;
THYM	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg11266682	chr4:10021025	SLC2A9	-0.52	-6.28	-0.54	1.03e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs17407555	0.779	rs4459989	chr4:10112602	C/T	cg11266682	chr4:10021025	SLC2A9	-0.57	-5.4	-0.48	4.89e-7	Schizophrenia (age at onset);
THYM	cis	rs4851266	0.898	rs13010010	chr2:100852734	C/T	cg08017756	chr2:100939284	LONRF2	-0.56	-4.45	-0.42	2.31e-5	Educational attainment;
THYM	cis	rs17443541	0.507	rs4675716	chr2:200463370	A/C	cg01795955	chr2:200468626	NA	0.72	5.0	0.46	2.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs877282	0.945	rs11253396	chr10:789754	C/T	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs554111	0.656	rs12567861	chr1:21395133	C/T	cg01072550	chr1:21505969	NA	0.56	4.77	0.44	6.55e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg12419862	chr22:24373484	LOC391322	-0.76	-7.23	-0.6	1.19e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg22907277	chr7:1156413	C7orf50	0.92	9.39	0.69	3.27e-15	Longevity;Endometriosis;
THYM	trans	rs9951602	0.573	rs78623099	chr18:76646228	G/T	cg02800362	chr5:177631904	HNRNPAB	1.14	9.05	0.68	1.76e-14	Obesity-related traits;
THYM	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg05660106	chr1:15850417	CASP9	0.76	6.17	0.54	1.63e-8	Systolic blood pressure;
THYM	cis	rs12681287	0.752	rs10435563	chr8:87266060	C/T	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs8112449	0.822	rs11670504	chr19:10546771	C/T	cg01466491	chr19:10523363	NA	0.6	5.51	0.49	3.08e-7	Multiple sclerosis;Gastritis;
THYM	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg18132916	chr6:79620363	NA	-0.59	-5.15	-0.47	1.41e-6	Intelligence (multi-trait analysis);
THYM	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg23803603	chr1:2058230	PRKCZ	0.6	4.69	0.43	9.29e-6	Height;
THYM	cis	rs28595532	0.920	rs114019902	chr4:119755564	G/A	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs10504073	0.647	rs62507245	chr8:50006939	A/T	cg00325661	chr8:49890786	NA	0.93	8.63	0.66	1.37e-13	Blood metabolite ratios;
THYM	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg27129171	chr3:47204927	SETD2	-0.78	-7.49	-0.61	3.57e-11	Colorectal cancer;
THYM	cis	rs1756650	0.543	rs1957440	chr14:87918728	C/T	cg10325478	chr14:88793021	KCNK10	-0.6	-4.54	-0.42	1.64e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
THYM	cis	rs72827839	0.841	rs16952265	chr17:46184883	G/A	cg23391107	chr17:45924227	SP6	0.83	5.6	0.5	2.08e-7	Ease of getting up in the morning;
THYM	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg09060608	chr5:178986726	RUFY1	0.6	6.67	0.56	1.7e-9	Lung cancer;
THYM	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg09455208	chr3:40491958	NA	0.46	4.67	0.43	9.9e-6	Renal cell carcinoma;
THYM	cis	rs2933343	0.679	rs789221	chr3:128591625	A/G	cg11901034	chr3:128598214	ACAD9	-0.7	-5.68	-0.5	1.47e-7	IgG glycosylation;
THYM	cis	rs71391092	1	rs71391092	chr16:74567075	C/G	cg01733217	chr16:74700730	RFWD3	-0.72	-4.69	-0.43	9.11e-6	Schizophrenia;
THYM	cis	rs919433	0.679	rs6741314	chr2:198526088	G/A	cg05783139	chr2:198650985	BOLL	0.66	4.98	0.46	2.78e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg00814883	chr7:100076585	TSC22D4	-0.95	-6.36	-0.55	6.93e-9	Platelet count;
THYM	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.57	4.49	0.42	2.01e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2236521	0.617	rs2236520	chr20:60892172	T/C	cg06026331	chr20:60912101	LAMA5	0.84	6.49	0.55	3.91e-9	Pelvic organ prolapse;
THYM	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	10.62	0.74	7.85e-18	Chronic sinus infection;
THYM	cis	rs2295499	0.643	rs35424748	chr4:2669054	T/C	cg17924901	chr4:3475233	DOK7	0.22	4.75	0.44	7.26e-6	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs3135718	1.000	rs2981582	chr10:123352317	A/G	cg15049101	chr10:123353889	FGFR2	-0.58	-5.0	-0.46	2.56e-6	Estrogen receptor status in breast cancer;
THYM	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg08508325	chr11:3079039	CARS	-0.49	-6.31	-0.54	8.74e-9	Type 2 diabetes;
THYM	cis	rs2798269	0.604	rs7325693	chr13:22163211	G/C	cg18095732	chr13:22033692	ZDHHC20	-0.62	-4.61	-0.43	1.26e-5	PR segment;
THYM	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg21926883	chr2:100939477	LONRF2	-0.55	-4.99	-0.46	2.74e-6	Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.958	rs262660	chr1:2086757	A/G	cg24578937	chr1:2090814	PRKCZ	0.81	8.54	0.66	2.22e-13	Height;
THYM	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg12573674	chr2:1569213	NA	-1.16	-8.21	-0.64	1.1e-12	IgG glycosylation;
THYM	cis	rs960902	0.710	rs2192943	chr2:37731460	A/C	cg25341268	chr2:37734390	NA	-0.66	-5.89	-0.52	5.81e-8	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg26384229	chr12:38710491	ALG10B	-0.71	-5.53	-0.49	2.8e-7	Morning vs. evening chronotype;
THYM	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg22875332	chr1:76189707	ACADM	0.87	10.83	0.74	2.76e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9658691	0.607	rs9325604	chr10:90775756	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.88	-5.87	-0.52	6.48e-8	Mosquito bite size;
THYM	cis	rs6032067	0.929	rs2233895	chr20:43850143	T/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.41	-0.55	5.57e-9	Blood protein levels;
THYM	cis	rs11809207	0.523	rs2783628	chr1:26501827	A/C	cg00147160	chr1:26503991	CNKSR1	0.53	7.17	0.59	1.65e-10	Height;
THYM	cis	rs763014	0.931	rs2071980	chr16:626346	A/C	cg09263875	chr16:632152	PIGQ	0.71	6.15	0.53	1.85e-8	Height;
THYM	cis	rs55871839	0.559	rs4738736	chr8:59836001	C/T	cg07426533	chr8:59803705	TOX	0.62	5.11	0.46	1.63e-6	Pneumonia;
THYM	cis	rs611744	0.967	rs613644	chr8:109188994	G/A	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs66887589	0.870	rs59590064	chr4:120539753	T/C	cg13609457	chr4:120235615	NA	-0.47	-4.95	-0.45	3.27e-6	Diastolic blood pressure;
THYM	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg09333631	chr3:44802604	KIF15;KIAA1143	0.39	4.53	0.42	1.71e-5	Depressive symptoms;
THYM	cis	rs9790314	0.905	rs6441370	chr3:160993754	C/T	cg04691961	chr3:161091175	C3orf57	-0.55	-4.53	-0.42	1.7e-5	Morning vs. evening chronotype;
THYM	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg16049864	chr8:95962084	TP53INP1	-0.69	-6.21	-0.54	1.41e-8	Type 2 diabetes;
THYM	cis	rs7927771	0.524	rs7107792	chr11:47669249	A/C	cg20307385	chr11:47447363	PSMC3	0.6	4.55	0.42	1.58e-5	Subjective well-being;
THYM	cis	rs4786125	0.512	rs55694271	chr16:6930378	G/A	cg03623568	chr16:6915990	A2BP1	-1.03	-8.74	-0.67	8.05e-14	Heart rate variability traits (SDNN);
THYM	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg14018140	chr10:458528	DIP2C	0.64	6.08	0.53	2.52e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs7582180	0.614	rs9973737	chr2:100942296	T/C	cg21926883	chr2:100939477	LONRF2	-0.64	-5.9	-0.52	5.54e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg26408565	chr15:76604113	ETFA	-0.53	-4.64	-0.43	1.13e-5	Blood metabolite levels;
THYM	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	8.01	0.64	2.84e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg25358565	chr5:93447407	FAM172A	0.96	6.78	0.57	1.01e-9	Diabetic retinopathy;
THYM	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8041943	0.595	rs11852378	chr15:79924769	T/A	cg20511832	chr15:78934280	CHRNB4	0.45	4.92	0.45	3.56e-6	Bone mineral density (spine) and age at menarche;
THYM	cis	rs2404602	0.647	rs11855296	chr15:77092962	C/T	cg23625390	chr15:77176239	SCAPER	-0.87	-6.12	-0.53	2.05e-8	Blood metabolite levels;
THYM	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg09359103	chr1:154839909	KCNN3	-0.83	-10.63	-0.74	7.67e-18	Prostate cancer;
THYM	cis	rs7428	0.847	rs1969260	chr2:85568810	C/T	cg24342717	chr2:85555507	TGOLN2	-0.57	-5.06	-0.46	2.04e-6	Ear protrusion;
THYM	cis	rs9326248	0.813	rs7115562	chr11:117020470	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.67	4.78	0.44	6.27e-6	Blood protein levels;
THYM	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.36	0.48	5.75e-7	Height;
THYM	trans	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6754311	0.510	rs1374329	chr2:136421323	A/G	cg23851026	chr2:136556271	LCT	0.6	5.67	0.5	1.51e-7	Mosquito bite size;
THYM	cis	rs4746818	1.000	rs9299502	chr10:70876934	C/T	cg11621586	chr10:70884670	VPS26A	1.24	10.33	0.73	3.28e-17	Left atrial antero-posterior diameter;
THYM	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg02725872	chr8:58115012	NA	-1.11	-8.56	-0.66	1.98e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs2806561	0.729	rs649664	chr1:23324263	C/T	cg19743168	chr1:23544995	NA	-0.59	-5.78	-0.51	9.53e-8	Height;
THYM	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg01699819	chr7:1052092	C7orf50	-0.79	-6.97	-0.58	4.24e-10	Bronchopulmonary dysplasia;
THYM	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg14349672	chr11:133703707	NA	-0.54	-4.83	-0.44	5.3e-6	Childhood ear infection;
THYM	cis	rs7119	0.717	rs12904254	chr15:77802585	C/A	cg27398640	chr15:77910606	LINGO1	-0.55	-5.4	-0.48	4.84e-7	Type 2 diabetes;
THYM	cis	rs12410462	0.581	rs75219436	chr1:227546617	C/T	cg23173402	chr1:227635558	NA	0.68	5.42	0.49	4.42e-7	Major depressive disorder;
THYM	cis	rs1448094	0.511	rs61930587	chr12:86158793	T/C	cg00310523	chr12:86230176	RASSF9	0.57	5.07	0.46	1.94e-6	Major depressive disorder;
THYM	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg27394845	chr17:28928406	LRRC37B2	0.97	4.55	0.42	1.57e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	8.7	0.67	9.84e-14	Chronic sinus infection;
THYM	cis	rs13064411	0.696	rs9839921	chr3:113199093	G/C	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg11764359	chr7:65958608	NA	-0.82	-6.6	-0.56	2.29e-9	Aortic root size;
THYM	cis	rs7481584	0.581	rs515481	chr11:3047184	A/G	cg03159660	chr11:2078197	NA	0.62	4.62	0.43	1.22e-5	Calcium levels;
THYM	cis	rs1499972	0.941	rs6807173	chr3:117642281	T/G	cg07612923	chr3:117604196	NA	1.19	5.0	0.46	2.66e-6	Schizophrenia;
THYM	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7084402	0.967	rs1614258	chr10:60308407	C/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.65e-7	Refractive error;
THYM	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg09462578	chr12:12878428	APOLD1	-1.11	-11.47	-0.76	1.24e-19	Lymphocyte counts;
THYM	cis	rs10871290	1.000	rs10871290	chr16:74472696	C/T	cg01733217	chr16:74700730	RFWD3	-0.6	-5.06	-0.46	2.04e-6	Breast cancer;
THYM	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg24812749	chr6:127587940	RNF146	0.98	7.94	0.63	4.04e-12	Breast cancer;
THYM	cis	rs10186029	0.509	rs6718004	chr2:213945280	A/T	cg08319019	chr2:214017104	IKZF2	0.75	5.2	0.47	1.15e-6	Systemic sclerosis;
THYM	cis	rs62435770	1.000	rs17184572	chr6:169489584	C/T	cg07652237	chr6:170125491	PHF10	0.52	4.57	0.42	1.46e-5	Loneliness;
THYM	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11890956	chr21:40555474	PSMG1	1.17	13.11	0.8	4.95e-23	Cognitive function;
THYM	cis	rs6430585	1.000	rs73958618	chr2:136500475	A/G	cg23851026	chr2:136556271	LCT	0.59	5.45	0.49	4.02e-7	Corneal structure;
THYM	cis	rs7626444	0.625	rs2948170	chr3:196492531	A/G	cg12930392	chr3:196481615	PAK2	0.41	5.01	0.46	2.53e-6	Monocyte count;
THYM	cis	rs7072216	0.763	rs733345	chr10:100164215	G/T	cg03852570	chr10:100175106	PYROXD2	0.37	4.78	0.44	6.49e-6	Metabolite levels;
THYM	cis	rs6570726	0.791	rs6902410	chr6:145905261	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-4.99	-0.46	2.75e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.88	5.64	0.5	1.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs427394	0.659	rs274717	chr5:6721067	C/T	cg10857441	chr5:6722123	POLS	0.7	7.48	0.61	3.78e-11	Menopause (age at onset);
THYM	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11890956	chr21:40555474	PSMG1	0.99	8.4	0.65	4.29e-13	Cognitive function;
THYM	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22857025	chr5:266934	NA	-1.57	-9.68	-0.7	8.05e-16	Breast cancer;
THYM	cis	rs10751667	1.000	rs6597972	chr11:928402	C/T	cg01483505	chr11:975446	AP2A2	0.63	4.97	0.45	2.96e-6	Alzheimer's disease (late onset);
THYM	cis	rs3087591	0.887	rs2905875	chr17:29541339	A/T	cg24425628	chr17:29625626	OMG;NF1	0.67	5.6	0.5	2.05e-7	Hip circumference;
THYM	cis	rs2281845	0.859	rs4915216	chr1:201077469	T/G	cg22815214	chr1:201083145	CACNA1S	0.72	6.82	0.57	8.32e-10	Permanent tooth development;
THYM	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg22841779	chr14:105766346	BRF1	-0.47	-5.74	-0.51	1.13e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg26354017	chr1:205819088	PM20D1	0.71	5.6	0.5	2.07e-7	Menarche (age at onset);
THYM	cis	rs7917772	0.582	rs7922780	chr10:104401203	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-4.6	-0.43	1.28e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs10744422	1.000	rs4759381	chr12:123348480	G/A	cg25930673	chr12:123319894	HIP1R	-0.89	-4.95	-0.45	3.25e-6	Schizophrenia;
THYM	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg04398451	chr17:18023971	MYO15A	-0.76	-6.96	-0.58	4.39e-10	Total body bone mineral density;
THYM	cis	rs11771526	0.686	rs77847042	chr7:32277207	A/G	cg13207630	chr7:32358064	NA	0.74	4.98	0.46	2.8e-6	Body mass index;
THYM	cis	rs4849845	0.849	rs3889224	chr2:121024419	A/G	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs4481887	0.741	rs6587458	chr1:248532290	T/A	cg17299007	chr1:248814626	OR2T27	0.42	4.52	0.42	1.81e-5	Common traits (Other);
THYM	cis	rs3126085	0.935	rs10888466	chr1:152166223	A/C	cg10321714	chr1:152280068	FLG	-0.68	-5.07	-0.46	1.98e-6	Atopic dermatitis;
THYM	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg22709100	chr7:91322751	NA	0.63	4.86	0.45	4.55e-6	Breast cancer;
THYM	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg20637307	chr2:213403960	ERBB4	1.04	11.18	0.75	5.22e-19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs28595532	0.920	rs114916728	chr4:119776886	G/A	cg14228332	chr4:119757509	SEC24D	1.59	5.76	0.51	1.02e-7	Cannabis dependence symptom count;
THYM	cis	rs2970992	0.764	rs2175792	chr2:101323275	T/C	cg01042948	chr2:101319752	NA	0.57	5.64	0.5	1.74e-7	Educational attainment;
THYM	cis	rs265548	0.646	rs36692	chr19:17906839	C/T	cg21960279	chr19:17905606	B3GNT3	0.61	5.76	0.51	1.01e-7	Tumor biomarkers;
THYM	cis	rs11264213	0.901	rs653417	chr1:36356842	G/T	cg27506609	chr1:36549197	TEKT2	0.92	4.83	0.44	5.3e-6	Schizophrenia;
THYM	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg22166914	chr1:53195759	ZYG11B	-0.95	-11.68	-0.77	4.54e-20	Monocyte count;
THYM	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg10360139	chr7:1886902	MAD1L1	-0.63	-5.46	-0.49	3.78e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs4900538	0.855	rs1209151	chr14:102893756	C/T	cg18135206	chr14:102964638	TECPR2	-0.82	-6.42	-0.55	5.42e-9	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg18811423	chr2:55921094	PNPT1	-0.58	-5.51	-0.49	3.08e-7	Metabolic syndrome;
THYM	cis	rs11031096	0.711	rs12270809	chr11:4206537	G/A	cg22027985	chr11:4115532	RRM1	-0.53	-4.9	-0.45	3.97e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs17253792	0.731	rs79483151	chr14:56048851	C/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs7589342	0.745	rs933793	chr2:106511846	C/T	cg14210321	chr2:106509881	NCK2	0.81	6.14	0.53	1.93e-8	Addiction;
THYM	cis	rs11225247	1.000	rs11605010	chr11:102266343	T/G	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs4780401	0.609	rs35902600	chr16:11800848	C/T	cg01061890	chr16:11836724	TXNDC11	-0.66	-5.44	-0.49	4.13e-7	Rheumatoid arthritis;
THYM	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg23187316	chr7:1099788	C7orf50	0.61	5.29	0.48	7.81e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4866334	1.000	rs1554786	chr5:18404421	T/C	cg24599790	chr5:18972260	NA	-1.18	-4.51	-0.42	1.84e-5	IgG glycosylation;
THYM	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs67072384	0.892	rs72966136	chr11:72456710	G/C	cg01380194	chr11:72452482	ARAP1	-0.94	-4.85	-0.45	4.79e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg21775007	chr8:11205619	TDH	-0.67	-4.86	-0.45	4.57e-6	Retinal vascular caliber;
THYM	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg11764359	chr7:65958608	NA	0.69	4.78	0.44	6.27e-6	Aortic root size;
THYM	cis	rs4523957	0.583	rs1565763	chr17:2055300	T/C	cg16513277	chr17:2031491	SMG6	-1.01	-9.62	-0.7	1.06e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.52	5.71	0.51	1.29e-7	Mean corpuscular volume;
THYM	cis	rs7264396	0.563	rs59064961	chr20:34307950	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.76	-0.44	6.84e-6	Total cholesterol levels;
THYM	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg26513180	chr16:89883248	FANCA	0.54	5.11	0.46	1.65e-6	Vitiligo;
THYM	cis	rs7828089	0.935	rs1568569	chr8:22249943	T/G	cg12081754	chr8:22256438	SLC39A14	0.66	5.68	0.5	1.48e-7	Verbal declarative memory;
THYM	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg26597838	chr10:835615	NA	0.99	5.51	0.49	3.13e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs7267979	1.000	rs2500446	chr20:25339664	C/T	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4242434	0.819	rs2291230	chr8:22463697	C/G	cg11461670	chr8:22454935	PDLIM2	-0.32	-6.32	-0.54	8.53e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs17407555	0.821	rs55851451	chr4:10139189	G/A	cg11266682	chr4:10021025	SLC2A9	-0.6	-5.79	-0.51	8.88e-8	Schizophrenia (age at onset);
THYM	cis	rs36051895	0.558	rs7038687	chr9:5134065	C/T	cg02405213	chr9:5042618	JAK2	1.03	11.71	0.77	3.98e-20	Pediatric autoimmune diseases;
THYM	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs2898681	0.519	rs73814886	chr4:53733251	C/T	cg21521518	chr4:53727714	RASL11B	0.49	4.51	0.42	1.82e-5	Optic nerve measurement (cup area);
THYM	cis	rs7017212	0.689	rs7842835	chr8:10016634	C/T	cg17371911	chr8:10683139	PINX1;MIR1322	-0.55	-4.49	-0.42	1.99e-5	Schizophrenia;
THYM	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg02725872	chr8:58115012	NA	-0.71	-5.22	-0.47	1.05e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg05283184	chr6:79620031	NA	-0.91	-8.85	-0.67	4.68e-14	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs56331118	chr4:119767054	G/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg14196790	chr5:131705035	SLC22A5	-0.55	-5.04	-0.46	2.21e-6	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1747683	0.585	rs10796058	chr10:13357286	C/T	cg25835351	chr10:13388524	SEPHS1	-0.28	-4.81	-0.44	5.58e-6	IgG glycosylation;
THYM	cis	rs11696501	0.688	rs6094192	chr20:44297796	G/A	cg11783356	chr20:44313418	WFDC10B	-0.69	-4.73	-0.44	7.72e-6	Brain structure;
THYM	cis	rs2637266	0.745	rs2579732	chr10:78442778	T/C	cg18941641	chr10:78392320	NA	0.77	6.54	0.56	3.02e-9	Pulmonary function;
THYM	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg10792982	chr14:105748885	BRF1	0.71	7.11	0.59	2.11e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg03517284	chr6:25882590	NA	-0.99	-9.74	-0.71	6.01e-16	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg11764359	chr7:65958608	NA	-0.85	-7.42	-0.61	5.02e-11	Aortic root size;
THYM	cis	rs10489202	1.000	rs12408205	chr1:167982332	A/G	cg24449463	chr1:168025552	DCAF6	-0.83	-6.51	-0.56	3.58e-9	Schizophrenia;
THYM	cis	rs2997447	0.846	rs3008414	chr1:26404747	G/A	cg03844060	chr1:26490628	NA	0.65	4.46	0.42	2.22e-5	QRS complex (12-leadsum);
THYM	cis	rs920590	0.527	rs79929516	chr8:19650050	G/C	cg01411142	chr8:19674711	INTS10	0.77	5.81	0.51	8.31e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs600231	0.690	rs1152619	chr11:65255589	C/A	cg17120908	chr11:65337727	SSSCA1	-0.71	-5.03	-0.46	2.27e-6	Bone mineral density;
THYM	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg17063962	chr7:91808500	NA	0.97	7.4	0.6	5.52e-11	Breast cancer;
THYM	cis	rs863345	0.565	rs59188837	chr1:158500636	C/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs7688540	0.771	rs74984113	chr4:250522	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.72	4.88	0.45	4.35e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs4631830	0.863	rs4486572	chr10:51531805	A/G	cg16070123	chr10:51489643	NA	-0.5	-4.48	-0.42	2.09e-5	Prostate-specific antigen levels;
THYM	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg08645402	chr16:4508243	NA	0.75	6.95	0.58	4.67e-10	Schizophrenia;
THYM	cis	rs28595532	0.920	rs114168088	chr4:119772666	G/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg03476357	chr21:30257390	N6AMT1	0.6	4.57	0.42	1.44e-5	Dental caries;
THYM	cis	rs10463554	0.553	rs72785712	chr5:102324397	A/G	cg23492399	chr5:102201601	PAM	-0.66	-5.15	-0.47	1.4e-6	Parkinson's disease;
THYM	cis	rs2710642	0.544	rs10204410	chr2:62829979	G/T	cg17519650	chr2:63277830	OTX1	0.63	4.68	0.43	9.38e-6	LDL cholesterol levels;LDL cholesterol;
THYM	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg21427119	chr20:30132790	HM13	-1.0	-7.38	-0.6	5.92e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs2797160	1.000	rs1935773	chr6:125996475	A/G	cg16306078	chr6:126000798	NA	-0.52	-5.17	-0.47	1.31e-6	Endometrial cancer;
THYM	cis	rs611744	0.901	rs2348801	chr8:109167337	C/T	cg21045802	chr8:109455806	TTC35	0.57	4.89	0.45	4.12e-6	Dupuytren's disease;
THYM	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4746818	0.711	rs2491024	chr10:70847084	T/C	cg11621586	chr10:70884670	VPS26A	0.9	6.56	0.56	2.85e-9	Left atrial antero-posterior diameter;
THYM	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg10523679	chr1:76189770	ACADM	-0.85	-7.39	-0.6	5.77e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.03	-6.98	-0.58	3.99e-10	Platelet count;
THYM	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg26850624	chr5:429559	AHRR	-0.72	-5.68	-0.5	1.45e-7	Cystic fibrosis severity;
THYM	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs4690686	0.538	rs4690687	chr4:177259635	A/G	cg17059388	chr4:177262070	NA	-0.45	-6.01	-0.52	3.49e-8	Essential tremor;
THYM	cis	rs6960043	0.818	rs2215383	chr7:15062983	T/C	cg19272540	chr7:15055459	NA	-0.42	-4.71	-0.44	8.42e-6	Type 2 diabetes;
THYM	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg05527609	chr1:210001259	C1orf107	1.08	9.03	0.68	1.93e-14	Orofacial clefts;
THYM	cis	rs11608355	0.846	rs60945232	chr12:109854401	A/G	cg11367159	chr12:110044531	NA	0.6	5.17	0.47	1.31e-6	Neuroticism;
THYM	cis	rs6089584	0.587	rs13041784	chr20:60561671	T/C	cg24733560	chr20:60626293	TAF4	0.61	6.21	0.54	1.41e-8	Body mass index;
THYM	cis	rs4589258	0.933	rs1792596	chr11:90443745	G/T	cg26138821	chr11:89956704	CHORDC1	0.7	5.9	0.52	5.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2976388	0.647	rs2244163	chr8:143784500	T/G	cg13446199	chr8:143762866	PSCA	-0.41	-4.53	-0.42	1.7e-5	Urinary tract infection frequency;
THYM	cis	rs7582180	0.701	rs4622752	chr2:100892018	A/G	cg08017756	chr2:100939284	LONRF2	0.59	5.35	0.48	6e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6987853	0.966	rs2923439	chr8:42429122	A/G	cg09913449	chr8:42400586	C8orf40	0.87	8.22	0.64	1.02e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg17264618	chr3:40429014	ENTPD3	0.52	5.17	0.47	1.32e-6	Renal cell carcinoma;
THYM	cis	rs889398	0.769	rs12927052	chr16:69857043	A/G	cg09409435	chr16:70099608	PDXDC2	-0.62	-4.91	-0.45	3.77e-6	Body mass index;
THYM	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg04156016	chr5:1868137	NA	0.55	5.37	0.48	5.49e-7	Cardiovascular disease risk factors;
THYM	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.27	10.28	0.73	4.18e-17	Platelet count;
THYM	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06634786	chr22:41940651	POLR3H	0.79	6.02	0.53	3.27e-8	Vitiligo;
THYM	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg26384229	chr12:38710491	ALG10B	-0.9	-7.35	-0.6	6.77e-11	Morning vs. evening chronotype;
THYM	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs1003719	0.751	rs10154032	chr21:38453459	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.71	5.03	0.46	2.32e-6	Eye color traits;
THYM	cis	rs13315871	0.929	rs76226186	chr3:58318499	C/T	cg00563845	chr3:58318305	PXK	0.59	5.02	0.46	2.37e-6	Cholesterol, total;
THYM	cis	rs1728785	1.000	rs698717	chr16:68560199	A/G	cg02972257	chr16:68554789	NA	-0.76	-4.76	-0.44	6.82e-6	Ulcerative colitis;
THYM	cis	rs67311347	0.544	rs9833640	chr3:40354941	T/A	cg13683864	chr3:40499215	RPL14	-0.71	-6.29	-0.54	9.68e-9	Renal cell carcinoma;
THYM	cis	rs7322722	1.000	rs7322722	chr13:77879376	G/A	cg04565255	chr13:77565759	CLN5	-0.46	-4.62	-0.43	1.2e-5	Preeclampsia;
THYM	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg13390004	chr1:15929781	NA	0.63	4.83	0.44	5.25e-6	Systolic blood pressure;
THYM	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg24675658	chr1:53192096	ZYG11B	-0.64	-5.3	-0.48	7.47e-7	Monocyte count;
THYM	cis	rs2404602	0.735	rs437131	chr15:76781051	C/T	cg23625390	chr15:77176239	SCAPER	0.59	4.5	0.42	1.89e-5	Blood metabolite levels;
THYM	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg22105103	chr4:187893119	NA	0.92	10.09	0.72	1.04e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3768617	0.510	rs2224933	chr1:183095765	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg06108461	chr20:60628389	TAF4	-0.84	-7.06	-0.59	2.77e-10	Body mass index;
THYM	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-1.05	-7.06	-0.59	2.74e-10	Cognitive test performance;
THYM	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4243830	0.737	rs11122091	chr1:6609559	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.08	-7.14	-0.59	1.83e-10	Body mass index;
THYM	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06481639	chr22:41940642	POLR3H	0.67	4.64	0.43	1.12e-5	Vitiligo;
THYM	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	10.29	0.73	3.95e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7004484	1.000	rs16904549	chr8:132927687	T/C	cg15420926	chr8:132929147	EFR3A	0.48	4.57	0.42	1.49e-5	Survival in rectal cancer;
THYM	cis	rs2011503	0.941	rs17751061	chr19:19413092	C/T	cg02887458	chr19:19495540	GATAD2A	-0.51	-5.63	-0.5	1.86e-7	Bipolar disorder;
THYM	cis	rs9534288	0.699	rs2146884	chr13:46660392	T/C	cg15192986	chr13:46630673	CPB2	-0.65	-4.54	-0.42	1.66e-5	Blood protein levels;
THYM	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.49	4.62	0.43	1.22e-5	Birth weight;
THYM	cis	rs887829	0.694	rs6749496	chr2:234624286	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.8	-6.72	-0.57	1.32e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs4654899	0.865	rs7532667	chr1:21438239	A/G	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.29e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg06238570	chr21:40685208	BRWD1	0.89	6.24	0.54	1.19e-8	Cognitive function;
THYM	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.67	0.66	1.16e-13	Lung cancer in ever smokers;
THYM	cis	rs514406	0.597	rs1241980	chr1:53286013	A/G	cg27535305	chr1:53392650	SCP2	0.7	7.7	0.62	1.3e-11	Monocyte count;
THYM	cis	rs6032067	0.683	rs34508373	chr20:43788087	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.49	-0.49	3.31e-7	Blood protein levels;
THYM	cis	rs10463554	0.963	rs72785733	chr5:102374192	T/A	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Parkinson's disease;
THYM	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg14820908	chr5:178986412	RUFY1	0.55	5.68	0.5	1.46e-7	Lung cancer;
THYM	cis	rs28595532	0.920	rs115673173	chr4:119755321	C/T	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs1691799	0.899	rs1168321	chr12:66744517	C/G	cg16791601	chr12:66731901	HELB	0.75	7.25	0.6	1.08e-10	White blood cell count (basophil);
THYM	cis	rs2404602	0.735	rs12906143	chr15:76709523	T/A	cg23625390	chr15:77176239	SCAPER	-0.68	-4.75	-0.44	7.34e-6	Blood metabolite levels;
THYM	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg03453431	chr7:157225567	NA	-0.65	-6.38	-0.55	6.38e-9	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.51e-15	Intelligence (multi-trait analysis);
THYM	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg00645579	chr11:617140	IRF7;MUPCDH	-0.52	-6.46	-0.55	4.44e-9	Systemic lupus erythematosus;
THYM	cis	rs4851266	0.702	rs11123820	chr2:100871186	A/G	cg14675211	chr2:100938903	LONRF2	0.66	5.48	0.49	3.48e-7	Educational attainment;
THYM	cis	rs2732480	0.538	rs1387259	chr12:48703522	C/T	cg21466736	chr12:48725269	NA	0.57	5.32	0.48	6.76e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs4595586	0.545	rs7972590	chr12:39376615	A/G	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs9733	0.519	rs2184833	chr1:150675483	C/T	cg15448220	chr1:150897856	SETDB1	0.88	7.27	0.6	1.02e-10	Tonsillectomy;
THYM	cis	rs28595532	0.920	rs114037572	chr4:119735609	T/G	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs7725337	0.965	rs1427968	chr5:88344778	C/G	cg11280525	chr5:87955695	LOC645323	-0.4	-4.49	-0.42	2.03e-5	Total body bone mineral density;
THYM	cis	rs2046867	0.862	rs6788139	chr3:72835630	A/G	cg25664220	chr3:72788482	NA	0.86	6.71	0.57	1.37e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs863345	0.604	rs11264984	chr1:158464990	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg19507638	chr5:93509721	C5orf36	-0.67	-4.48	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs6563943	0.892	rs8059833	chr16:83639311	C/T	cg01935413	chr16:83636749	CDH13	0.54	5.42	0.49	4.45e-7	Height;
THYM	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.56	-5.13	-0.47	1.51e-6	Type 2 diabetes;
THYM	cis	rs28595532	0.920	rs115085630	chr4:119741765	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg16414030	chr3:133502952	NA	0.6	4.76	0.44	6.96e-6	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg08859206	chr1:53392774	SCP2	0.6	6.92	0.58	5.22e-10	Monocyte count;
THYM	cis	rs1524976	1.000	rs62255273	chr3:65452827	C/A	cg16238336	chr3:65465873	MAGI1	-1.01	-6.33	-0.54	8.04e-9	PR interval;
THYM	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg15247329	chr7:2764246	NA	-0.64	-5.23	-0.47	9.86e-7	Height;
THYM	trans	rs9929218	0.551	rs3785134	chr16:68728938	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.06	13.03	0.8	7.1e-23	Colorectal cancer;
THYM	cis	rs7980799	0.653	rs1384598	chr12:33622899	T/A	cg10856724	chr12:34555212	NA	0.6	4.5	0.42	1.93e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs13102973	0.720	rs7687463	chr4:135885773	G/T	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg06558623	chr16:89946397	TCF25	1.36	6.6	0.56	2.33e-9	Skin colour saturation;
THYM	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg03079132	chr16:727212	RHBDL1	0.38	4.51	0.42	1.88e-5	Height;
THYM	cis	rs35123781	1.000	rs35123781	chr5:139065180	A/G	cg10513866	chr5:139070639	NA	0.47	4.69	0.43	9.13e-6	Schizophrenia;
THYM	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-15.26	-0.84	2.74e-27	Height;
THYM	cis	rs6570726	0.846	rs7762536	chr6:145923145	T/C	cg23711669	chr6:146136114	FBXO30	0.9	8.54	0.66	2.12e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28595532	0.920	rs114207133	chr4:119755140	T/C	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs10929159	0.928	rs34769167	chr2:236920442	A/G	cg14895183	chr2:236924282	AGAP1	0.52	4.51	0.42	1.88e-5	Parkinson's disease;
THYM	cis	rs10489202	0.683	rs4657730	chr1:168072738	A/T	cg24449463	chr1:168025552	DCAF6	-0.73	-6.33	-0.54	8.09e-9	Schizophrenia;
THYM	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg05347473	chr6:146136440	FBXO30	0.6	4.86	0.45	4.66e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7582180	0.845	rs11683088	chr2:100920667	C/T	cg14675211	chr2:100938903	LONRF2	0.67	6.48	0.55	4.1e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs7666738	0.752	rs35436270	chr4:99088280	G/A	cg10515332	chr4:99064459	C4orf37	0.66	4.85	0.45	4.73e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg02487422	chr3:49467188	NICN1	0.62	4.72	0.44	8.23e-6	Resting heart rate;
THYM	cis	rs501916	0.575	rs56345741	chr15:48065010	A/C	cg20869673	chr15:48010124	SEMA6D	0.63	4.49	0.42	1.99e-5	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs6840360	0.615	rs7669761	chr4:152609304	G/A	cg22705602	chr4:152727874	NA	-0.79	-10.66	-0.74	6.62e-18	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg23187316	chr7:1099788	C7orf50	0.6	4.62	0.43	1.19e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg25517755	chr10:38738941	LOC399744	-0.77	-7.48	-0.61	3.65e-11	Corneal astigmatism;
THYM	cis	rs2692947	0.740	rs4907280	chr2:96402126	A/G	cg23100626	chr2:96804247	ASTL	0.33	4.47	0.42	2.16e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg11366901	chr6:160182831	ACAT2	1.04	8.69	0.67	1.03e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg03709012	chr19:19516395	GATAD2A	-0.79	-6.39	-0.55	6.1e-9	Tonsillectomy;
THYM	cis	rs7523273	0.606	rs12401619	chr1:207976276	G/C	cg22525895	chr1:207977042	MIR29B2	-0.98	-10.5	-0.73	1.41e-17	Schizophrenia;
THYM	cis	rs3916	0.794	rs3021337	chr12:121163261	C/T	cg21892295	chr12:121157589	UNC119B	-0.57	-6.16	-0.53	1.75e-8	Urinary metabolites (H-NMR features);
THYM	cis	rs7010267	1.000	rs7010267	chr8:119946656	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.58	4.69	0.43	9.11e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg15247329	chr7:2764246	NA	-0.69	-5.76	-0.51	1.02e-7	Height;
THYM	cis	rs9876781	1.000	rs11130170	chr3:48449897	C/T	cg06066452	chr3:48470258	PLXNB1	0.27	4.89	0.45	4.08e-6	Longevity;
THYM	cis	rs9790314	0.580	rs10936227	chr3:161043869	A/C	cg03342759	chr3:160939853	NMD3	-0.67	-5.7	-0.5	1.34e-7	Morning vs. evening chronotype;
THYM	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs4838594	0.715	rs11101340	chr10:49682402	C/T	cg22796704	chr10:49673534	ARHGAP22	-0.31	-4.55	-0.42	1.61e-5	Daytime sleep phenotypes;
THYM	cis	rs6570726	0.818	rs412350	chr6:145852409	T/C	cg23711669	chr6:146136114	FBXO30	0.98	10.43	0.73	1.98e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2073300	1.000	rs79169006	chr20:23443535	A/T	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03264133	chr6:25882463	NA	-0.84	-6.46	-0.55	4.36e-9	Intelligence (multi-trait analysis);
THYM	cis	rs4474465	1.000	rs6592779	chr11:78197283	G/C	cg19901956	chr11:77921274	USP35	-0.7	-5.16	-0.47	1.35e-6	Alzheimer's disease (survival time);
THYM	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg27068330	chr11:65405492	SIPA1	-0.66	-4.47	-0.42	2.17e-5	Breast cancer;
THYM	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13082711	1.000	rs6791212	chr3:27507179	C/A	cg02860705	chr3:27208620	NA	0.72	5.06	0.46	2.01e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs2282300	0.739	rs10835647	chr11:30313268	A/G	cg09906309	chr11:30344399	C11orf46	-0.76	-5.61	-0.5	1.95e-7	Morning vs. evening chronotype;
THYM	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-7.03	-0.59	3.09e-10	Chronic sinus infection;
THYM	cis	rs6032067	0.641	rs62206437	chr20:43759316	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.41	-0.49	4.61e-7	Blood protein levels;
THYM	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06850241	chr22:41845214	NA	-0.6	-5.24	-0.47	9.66e-7	Vitiligo;
THYM	cis	rs6495367	0.872	rs7183818	chr15:79372413	A/G	cg17916960	chr15:79447300	NA	0.61	6.57	0.56	2.64e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7264396	0.635	rs2024854	chr20:34511189	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.16	-0.47	1.36e-6	Total cholesterol levels;
THYM	cis	rs6032067	0.632	rs35361894	chr20:43794403	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs7107174	1.000	rs10793304	chr11:78064907	A/G	cg02023728	chr11:77925099	USP35	0.6	5.77	0.51	9.96e-8	Testicular germ cell tumor;
THYM	cis	rs4842666	0.915	rs117742247	chr12:89991313	C/T	cg00757033	chr12:89920650	WDR51B	0.55	5.07	0.46	1.99e-6	Blood pressure;
THYM	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs892961	0.932	rs11658267	chr17:75411884	C/T	cg05865280	chr17:75406074	SEPT9	-0.48	-8.14	-0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs11122895	0.791	rs12373588	chr2:112466265	T/G	cg23262488	chr2:112468472	NA	0.47	5.33	0.48	6.64e-7	Allergic sensitization;
THYM	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg16506815	chr2:162101123	NA	0.59	4.46	0.42	2.29e-5	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg19507638	chr5:93509721	C5orf36	-0.7	-4.71	-0.44	8.43e-6	Diabetic retinopathy;
THYM	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg03806693	chr22:41940476	POLR3H	1.18	10.78	0.74	3.58e-18	Vitiligo;
THYM	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg00981070	chr1:2046702	PRKCZ	-0.47	-5.85	-0.51	6.95e-8	Height;
THYM	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg22709100	chr7:91322751	NA	0.71	5.51	0.49	3.04e-7	Breast cancer;
THYM	cis	rs6754311	0.773	rs309178	chr2:136611624	C/T	cg20242066	chr2:136595261	LCT	-0.6	-7.14	-0.59	1.83e-10	Mosquito bite size;
THYM	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg22852734	chr6:133119734	C6orf192	1.32	8.71	0.67	9.24e-14	Type 2 diabetes nephropathy;
THYM	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg10047753	chr17:41438598	NA	1.22	11.79	0.77	2.71e-20	Menopause (age at onset);
THYM	cis	rs2797160	0.967	rs2226158	chr6:125995467	C/T	cg16306078	chr6:126000798	NA	-0.47	-4.46	-0.42	2.23e-5	Endometrial cancer;
THYM	cis	rs3820068	0.580	rs12760698	chr1:16009814	G/A	cg05660106	chr1:15850417	CASP9	0.74	5.99	0.52	3.77e-8	Systolic blood pressure;
THYM	cis	rs4074961	0.669	rs4652964	chr1:38078300	A/G	cg17933807	chr1:38061675	GNL2	1.08	13.26	0.81	2.44e-23	Axial length;
THYM	cis	rs425535	0.757	rs2043537	chr4:74810456	G/C	cg07868155	chr4:74864709	CXCL5	0.63	4.47	0.42	2.15e-5	Blood protein levels;
THYM	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg26031613	chr14:104095156	KLC1	0.75	5.11	0.46	1.63e-6	Body mass index;
THYM	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg23161317	chr6:28129485	ZNF389	0.58	4.46	0.42	2.25e-5	Cardiac Troponin-T levels;
THYM	trans	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg17712092	chr4:129076599	LARP1B	-0.88	-7.05	-0.59	2.9e-10	Eosinophil percentage of white cells;
THYM	cis	rs35264875	1.000	rs72919428	chr11:68828949	C/T	cg01993067	chr11:68851601	TPCN2	1.0	4.68	0.43	9.62e-6	Blond vs. brown hair color;
THYM	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg00898013	chr13:113819073	PROZ	-0.83	-8.33	-0.65	6.02e-13	Platelet distribution width;
THYM	cis	rs72960926	0.744	rs2351778	chr6:74866814	T/G	cg03266952	chr6:74778945	NA	-0.83	-4.77	-0.44	6.58e-6	Metabolite levels (MHPG);
THYM	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.32	-0.48	7.02e-7	Monocyte percentage of white cells;
THYM	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.7	6.53	0.56	3.28e-9	Total body bone mineral density;
THYM	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.73	0.71	6.12e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12579753	1.000	rs11115047	chr12:82232773	C/G	cg21231944	chr12:82153410	PPFIA2	-0.66	-4.89	-0.45	4.15e-6	Resting heart rate;
THYM	cis	rs28795989	0.795	rs12641498	chr4:7917574	C/T	cg00251875	chr4:7801337	AFAP1	-0.62	-4.93	-0.45	3.51e-6	Intraocular pressure;
THYM	cis	rs2797160	1.000	rs4895798	chr6:126000162	A/G	cg16306078	chr6:126000798	NA	-0.54	-5.54	-0.49	2.66e-7	Endometrial cancer;
THYM	cis	rs8070624	0.543	rs8068175	chr17:17874486	C/T	cg04398451	chr17:18023971	MYO15A	-0.93	-8.84	-0.67	4.97e-14	Total body bone mineral density;
THYM	cis	rs9902453	0.845	rs58606097	chr17:28020379	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.85	0.45	4.84e-6	Coffee consumption (cups per day);
THYM	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg22709100	chr7:91322751	NA	0.7	5.21	0.47	1.09e-6	Breast cancer;
THYM	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg07343612	chr16:622815	PIGQ	-1.08	-11.34	-0.76	2.36e-19	Height;
THYM	cis	rs11997175	0.603	rs66828270	chr8:33790155	C/G	ch.8.33884649F	chr8:33765107	NA	0.69	5.29	0.48	7.98e-7	Body mass index;
THYM	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg18252515	chr7:66147081	NA	1.37	8.05	0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg05872129	chr22:39784769	NA	-1.04	-11.15	-0.75	5.9e-19	Intelligence (multi-trait analysis);
THYM	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg08999081	chr20:33150536	PIGU	-0.77	-6.95	-0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs9399401	0.710	rs7765770	chr6:142687305	C/T	cg04461802	chr6:142623433	GPR126	0.76	7.33	0.6	7.72e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg24209194	chr3:40518798	ZNF619	0.61	4.79	0.44	6.14e-6	Renal cell carcinoma;
THYM	cis	rs7200543	1.000	rs55727637	chr16:15145252	C/T	cg01933576	chr16:15083564	PDXDC1	-0.96	-8.11	-0.64	1.77e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg12963246	chr6:28129442	ZNF389	0.72	6.12	0.53	2.05e-8	Depression;
THYM	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.61	-4.96	-0.45	3.12e-6	Longevity;Endometriosis;
THYM	cis	rs36051895	0.623	rs62541543	chr9:5042082	G/A	cg02405213	chr9:5042618	JAK2	-1.03	-10.88	-0.74	2.16e-18	Pediatric autoimmune diseases;
THYM	cis	rs12472274	1.000	rs12472274	chr2:239095422	G/A	cg17459225	chr2:239074497	NA	0.77	5.58	0.5	2.23e-7	Phospholipid levels (plasma);
THYM	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg18512352	chr11:47633146	NA	-0.53	-6.56	-0.56	2.75e-9	Subjective well-being;
THYM	cis	rs854765	0.583	rs8065970	chr17:17858771	A/G	cg16928487	chr17:17741425	SREBF1	-0.55	-5.47	-0.49	3.62e-7	Total body bone mineral density;
THYM	cis	rs17006441	0.932	rs17638562	chr3:69880713	C/T	cg18496212	chr3:69797108	MITF	0.64	6.28	0.54	1e-8	Hemoglobin concentration;
THYM	cis	rs17598306	1.000	rs73402670	chr7:96580336	A/G	cg26766885	chr7:96220185	NA	0.62	5.13	0.47	1.56e-6	Radiation response;
THYM	cis	rs3796352	1.000	rs11706035	chr3:53011868	A/T	cg04865290	chr3:52927548	TMEM110	-0.89	-4.65	-0.43	1.08e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg03433033	chr1:76189801	ACADM	0.55	4.77	0.44	6.61e-6	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs946836	0.562	rs11578428	chr1:48411232	C/T	cg18376692	chr1:48452465	NA	-0.55	-5.66	-0.5	1.58e-7	White matter integrity;
THYM	cis	rs2085601	0.542	rs2704601	chr4:89980580	C/A	cg17769793	chr4:89976368	FAM13A	0.59	6.58	0.56	2.52e-9	Hair greying;
THYM	cis	rs7917772	0.604	rs4917977	chr10:104363119	C/T	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9359856	0.564	rs6914142	chr6:90398903	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.94	-7.55	-0.61	2.65e-11	Bipolar disorder;
THYM	cis	rs240764	0.658	rs705585	chr6:101262409	A/G	cg21058520	chr6:100914733	NA	-0.6	-5.32	-0.48	6.98e-7	Neuroticism;
THYM	cis	rs35883536	0.525	rs2647321	chr1:101032006	T/G	cg06223162	chr1:101003688	GPR88	0.88	7.71	0.62	1.21e-11	Monocyte count;
THYM	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.76	-6.88	-0.58	6.25e-10	Personality dimensions;
THYM	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg19318889	chr4:1322082	MAEA	0.69	5.99	0.52	3.8e-8	Longevity;
THYM	cis	rs2072510	0.569	rs7134860	chr12:96390358	C/A	cg18817487	chr12:96390143	HAL	0.47	5.71	0.51	1.31e-7	Metabolite levels (small molecules and protein measures);
THYM	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg05084668	chr3:125655381	ALG1L	-0.72	-4.78	-0.44	6.44e-6	Blood pressure (smoking interaction);
THYM	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22968622	chr17:43663579	NA	1.18	10.66	0.74	6.45e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs56390833	1	rs56390833	chr15:78877381	C/A	cg18825076	chr15:78729989	IREB2	-0.53	-4.74	-0.44	7.44e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs11048434	0.761	rs12828902	chr12:9132231	C/T	cg26114124	chr12:9217669	LOC144571	0.46	4.57	0.42	1.44e-5	Sjögren's syndrome;
THYM	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs4788815	0.533	rs12102548	chr16:71929763	C/G	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	Metabolite levels;
THYM	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg12165864	chr7:66369176	NA	0.65	5.06	0.46	2.07e-6	Aortic root size;
THYM	cis	rs2239547	0.562	rs2581810	chr3:52960859	C/T	cg11645453	chr3:52864694	ITIH4	-0.29	-4.68	-0.43	9.49e-6	Schizophrenia;
THYM	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs42648	0.777	rs4728878	chr7:89924232	T/G	cg25739043	chr7:89950458	NA	-0.53	-4.53	-0.42	1.72e-5	Homocysteine levels;
THYM	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg15592062	chr6:167189543	RPS6KA2	0.49	4.93	0.45	3.48e-6	Crohn's disease;
THYM	cis	rs7084402	0.967	rs1658467	chr10:60295316	A/G	cg07615347	chr10:60278583	BICC1	0.56	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg13175981	chr1:150552382	MCL1	0.7	4.99	0.46	2.72e-6	Tonsillectomy;
THYM	cis	rs17255340	0.577	rs6937273	chr6:84095513	A/G	cg08257003	chr6:84140564	ME1	0.56	4.51	0.42	1.88e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg02734326	chr4:10020555	SLC2A9	0.76	7.25	0.6	1.13e-10	Bone mineral density;
THYM	cis	rs1278769	0.735	rs12585036	chr13:113535741	C/T	cg17842918	chr13:113540400	ATP11A	-0.43	-4.46	-0.42	2.27e-5	Interstitial lung disease;
THYM	cis	rs9913156	0.696	rs72835620	chr17:4558128	G/A	cg19197139	chr17:4613644	ARRB2	0.83	5.0	0.46	2.63e-6	Lymphocyte counts;
THYM	cis	rs7107174	0.688	rs881361	chr11:78128047	C/G	cg19901956	chr11:77921274	USP35	-0.71	-5.35	-0.48	6.07e-7	Testicular germ cell tumor;
THYM	cis	rs11563648	0.573	rs6467116	chr7:126950053	G/A	cg23081781	chr7:127225937	GCC1	-0.36	-4.88	-0.45	4.31e-6	Resting heart rate;
THYM	cis	rs7119	0.700	rs60701760	chr15:77888152	G/A	cg27398640	chr15:77910606	LINGO1	0.65	7.96	0.63	3.74e-12	Type 2 diabetes;
THYM	cis	rs7834588	0.544	rs13277301	chr8:63816442	C/T	cg20602954	chr8:63776762	NKAIN3	-0.63	-5.23	-0.47	9.91e-7	Response to Vitamin E supplementation;
THYM	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg04362960	chr10:104952993	NT5C2	0.56	4.74	0.44	7.45e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2456568	0.564	rs6483270	chr11:93624380	C/T	cg17347335	chr11:93583973	C11orf90	-0.58	-6.18	-0.54	1.62e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-5.35	-0.48	5.99e-7	Hemoglobin concentration;
THYM	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.68	-5.11	-0.46	1.64e-6	Multiple sclerosis;
THYM	cis	rs4499344	0.805	rs116855540	chr19:33083830	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.77	-5.45	-0.49	3.92e-7	Mean platelet volume;
THYM	cis	rs13126513	0.671	rs13119384	chr4:100443782	T/C	cg05468953	chr4:100565104	NA	0.57	4.49	0.42	2e-5	Metabolite levels (MHPG);
THYM	cis	rs13064411	0.542	rs9877649	chr3:113226874	C/T	cg18753928	chr3:113234510	CCDC52	-0.84	-7.87	-0.63	5.58e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.6	-0.5	2.11e-7	Menopause (age at onset);
THYM	cis	rs10911232	0.507	rs4651137	chr1:182994300	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs6867032	0.527	rs13153217	chr5:2012788	G/T	cg26168224	chr5:2018326	NA	-0.87	-6.46	-0.55	4.53e-9	Gut microbiome composition (winter);
THYM	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03576123	chr11:487126	PTDSS2	-1.52	-7.48	-0.61	3.64e-11	Body mass index;
THYM	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg12011299	chr4:100065546	ADH4	0.92	9.15	0.68	1.07e-14	Alcohol dependence;
THYM	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg09436375	chr6:42928200	GNMT	-0.44	-5.71	-0.51	1.31e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg23711669	chr6:146136114	FBXO30	-0.85	-8.14	-0.64	1.52e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg27532560	chr4:187881888	NA	-0.96	-12.62	-0.79	5.09e-22	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg08754478	chr10:133766260	PPP2R2D	0.95	6.69	0.57	1.56e-9	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg18305652	chr10:134549665	INPP5A	-0.86	-7.82	-0.63	7.22e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.23	8.69	0.67	1.05e-13	Cognitive test performance;
THYM	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11890956	chr21:40555474	PSMG1	-0.66	-6.38	-0.55	6.51e-9	Menarche (age at onset);
THYM	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg17888033	chr8:143858414	LYNX1	-0.45	-5.14	-0.47	1.49e-6	Urinary tract infection frequency;
THYM	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg17775962	chr7:1200435	ZFAND2A	0.42	5.16	0.47	1.36e-6	Longevity;Endometriosis;
THYM	cis	rs9915657	0.870	rs12941066	chr17:70141226	C/T	cg06234051	chr17:70120541	SOX9	-0.63	-5.63	-0.5	1.78e-7	Thyroid hormone levels;
THYM	cis	rs2898681	0.528	rs73814883	chr4:53728054	G/C	cg00791764	chr4:53727839	RASL11B	0.66	6.6	0.56	2.3e-9	Optic nerve measurement (cup area);
THYM	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.53	-4.98	-0.45	2.85e-6	Lymphocyte counts;
THYM	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.88	-7.8	-0.62	7.93e-12	Menarche (age at onset);
THYM	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg16342193	chr10:102329863	NA	-0.49	-4.85	-0.45	4.73e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg03060546	chr3:49711283	APEH	0.77	6.37	0.55	6.65e-9	Resting heart rate;
THYM	cis	rs654950	0.806	rs10749832	chr1:42041806	C/T	cg06885757	chr1:42089581	HIVEP3	0.59	7.85	0.63	6.11e-12	Airway imaging phenotypes;
THYM	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs611744	0.905	rs421695	chr8:109117403	T/C	cg21045802	chr8:109455806	TTC35	0.59	5.16	0.47	1.34e-6	Dupuytren's disease;
THYM	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg03929089	chr4:120376271	NA	-1.01	-8.47	-0.66	3.05e-13	Height;
THYM	cis	rs4919694	1.000	rs58317752	chr10:104799267	T/A	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg08704250	chr15:31115839	NA	-0.49	-5.81	-0.51	8.17e-8	Huntington's disease progression;
THYM	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.87e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs34526934	0.608	rs728521	chr2:177031683	T/C	cg14324370	chr2:177042789	NA	-0.7	-5.97	-0.52	4.16e-8	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs478304	0.934	rs509206	chr11:65493807	C/T	cg27068330	chr11:65405492	SIPA1	0.87	8.29	0.65	7.42e-13	Acne (severe);
THYM	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg07414643	chr4:187882934	NA	0.67	5.92	0.52	5.16e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg22166914	chr1:53195759	ZYG11B	0.91	10.77	0.74	3.71e-18	Monocyte count;
THYM	cis	rs941873	0.900	rs4979862	chr10:81131599	G/A	cg09469691	chr10:81107165	PPIF	0.76	6.31	0.54	8.71e-9	Height;
THYM	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.66	-0.56	1.79e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4363385	0.747	rs2879489	chr1:152970465	A/G	cg13444842	chr1:152974279	SPRR3	-0.62	-4.87	-0.45	4.52e-6	Inflammatory skin disease;
THYM	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg16414030	chr3:133502952	NA	-0.67	-6.24	-0.54	1.23e-8	Ankle injury;
THYM	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2273669	0.667	rs17070136	chr6:109350550	T/C	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	cis	rs11122895	1.000	rs11122895	chr2:112470155	C/T	cg23262488	chr2:112468472	NA	0.67	9.57	0.7	1.36e-15	Allergic sensitization;
THYM	cis	rs6495122	0.630	rs12912343	chr15:75251041	C/G	cg02696790	chr15:75250997	RPP25	0.53	4.92	0.45	3.65e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs529866	0.519	rs4451969	chr16:11383519	A/G	cg00044050	chr16:11439710	C16orf75	-0.81	-5.74	-0.51	1.11e-7	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg27490568	chr2:178487706	NA	0.61	5.49	0.49	3.38e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1883415	0.534	rs2253794	chr6:24479642	C/A	cg20631270	chr6:24437470	GPLD1	0.53	4.46	0.42	2.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg13334819	chr7:99746414	C7orf59	-0.7	-4.77	-0.44	6.59e-6	Coronary artery disease;
THYM	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg11871910	chr12:69753446	YEATS4	0.7	5.7	0.51	1.32e-7	Blood protein levels;
THYM	cis	rs4523957	0.890	rs9900379	chr17:2101134	G/A	cg16513277	chr17:2031491	SMG6	-0.8	-7.67	-0.62	1.46e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs11640439	1.000	rs11640439	chr16:57303194	C/T	cg09403559	chr16:56334857	GNAO1	0.65	5.49	0.49	3.33e-7	Sleep duration;
THYM	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg05340658	chr4:99064831	C4orf37	0.54	4.52	0.42	1.78e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17331151	0.505	rs13086936	chr3:52659079	T/C	cg17372223	chr3:52568218	NT5DC2	0.58	4.61	0.43	1.23e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1971762	1.000	rs1971762	chr12:54058238	C/T	cg22997177	chr12:54070527	ATP5G2	-0.47	-4.97	-0.45	3e-6	Height;
THYM	cis	rs3741151	0.686	rs17851510	chr11:73106294	A/C	cg12959048	chr11:73096162	RELT	-0.46	-4.79	-0.44	6.18e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	5.57	0.5	2.36e-7	Eosinophil percentage of white cells;
THYM	cis	rs981844	0.712	rs1563461	chr4:154751913	C/T	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs9560113	1.000	rs9555805	chr13:112179765	C/T	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg01097406	chr16:89675127	NA	-0.62	-5.04	-0.46	2.23e-6	Vitiligo;
THYM	cis	rs4719841	0.662	rs6980357	chr7:25994009	A/G	cg24254488	chr7:25991654	NA	0.54	4.96	0.45	3.08e-6	Triglyceride levels;
THYM	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg18252515	chr7:66147081	NA	0.65	5.07	0.46	1.94e-6	Aortic root size;
THYM	cis	rs12579753	0.872	rs7956132	chr12:82178709	A/G	cg21231944	chr12:82153410	PPFIA2	-0.62	-4.61	-0.43	1.25e-5	Resting heart rate;
THYM	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg13695892	chr22:41940480	POLR3H	0.97	7.24	0.6	1.13e-10	Vitiligo;
THYM	cis	rs4642101	0.793	rs56082700	chr3:12833833	T/C	cg05775895	chr3:12838266	CAND2	0.81	7.01	0.58	3.41e-10	QRS complex (12-leadsum);
THYM	cis	rs923375	0.533	rs923376	chr17:3393086	A/G	cg02458198	chr17:3375211	SPATA22	0.58	4.91	0.45	3.73e-6	Myopia (pathological);
THYM	cis	rs4363385	0.747	rs4568784	chr1:152972694	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.53	-0.42	1.71e-5	Inflammatory skin disease;
THYM	cis	rs6840360	0.550	rs62327267	chr4:152518753	G/T	cg22705602	chr4:152727874	NA	-0.78	-8.73	-0.67	8.56e-14	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg13683864	chr3:40499215	RPL14	-0.92	-9.22	-0.69	7.64e-15	Renal cell carcinoma;
THYM	cis	rs8064299	0.597	rs9944506	chr17:72782726	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.88	8.62	0.66	1.43e-13	Monocyte count;
THYM	cis	rs7100689	0.890	rs7086627	chr10:82220597	C/T	cg01528321	chr10:82214614	TSPAN14	1.32	8.82	0.67	5.5e-14	Post bronchodilator FEV1;
THYM	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19346786	chr7:2764209	NA	-0.78	-6.96	-0.58	4.45e-10	Height;
THYM	cis	rs6840360	1.000	rs6535819	chr4:152651503	A/G	cg22705602	chr4:152727874	NA	-0.58	-6.41	-0.55	5.56e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg05973401	chr12:123451056	ABCB9	0.64	4.63	0.43	1.17e-5	Platelet count;
THYM	cis	rs6882076	1.000	rs7724832	chr5:156381370	C/T	cg12943317	chr5:156479607	HAVCR1	-0.71	-5.77	-0.51	9.71e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg23758822	chr17:41437982	NA	1.21	11.17	0.75	5.41e-19	Menopause (age at onset);
THYM	cis	rs427394	0.632	rs377137	chr5:6740468	T/G	cg10857441	chr5:6722123	POLS	-0.7	-7.53	-0.61	2.93e-11	Menopause (age at onset);
THYM	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg02696790	chr15:75250997	RPP25	-0.5	-5.23	-0.47	1e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg13695892	chr22:41940480	POLR3H	0.85	6.12	0.53	2.07e-8	Cannabis dependence symptom count;
THYM	cis	rs11085466	1.000	rs2292986	chr19:21776332	A/C	cg23026602	chr19:21646605	NA	0.64	4.8	0.44	5.78e-6	Colorectal or endometrial cancer;
THYM	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg04896959	chr15:78267971	NA	0.93	8.58	0.66	1.81e-13	Coronary artery disease or large artery stroke;
THYM	cis	rs4713118	0.824	rs742046	chr6:27739254	A/G	cg08968635	chr6:28129556	ZNF389	0.66	5.21	0.47	1.07e-6	Parkinson's disease;
THYM	cis	rs9790314	1.000	rs975323	chr3:161021322	A/G	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs586688	1.000	rs522869	chr1:201638600	A/G	cg14168733	chr1:201708718	NAV1	0.57	5.28	0.48	8.05e-7	Obesity-related traits;
THYM	cis	rs28595532	0.920	rs17324807	chr4:119770638	G/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.62	0.56	2.12e-9	Total body bone mineral density;
THYM	cis	rs9814567	0.896	rs7653807	chr3:134345724	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-8.47	-0.66	3e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs67981189	0.784	rs58984901	chr14:71551988	C/T	cg15910301	chr14:71632612	NA	0.51	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs4766566	0.576	rs7398343	chr12:111774068	A/C	cg10833066	chr12:111807467	FAM109A	0.62	7.99	0.63	3.21e-12	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
THYM	cis	rs9326248	0.569	rs10892082	chr11:117039325	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.95	5.34	0.48	6.34e-7	Blood protein levels;
THYM	cis	rs4808199	0.948	rs7259434	chr19:19428805	A/T	cg03709012	chr19:19516395	GATAD2A	1.11	6.5	0.55	3.72e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs3791406	0.963	rs3791408	chr2:240030591	C/T	cg20627572	chr2:239991813	HDAC4	-0.46	-4.49	-0.42	2.04e-5	Skin aging (microtopography measurement);
THYM	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs912057	0.585	rs1745341	chr6:6744990	T/C	cg06612196	chr6:6737390	NA	0.71	11.9	0.77	1.57e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs3087591	0.887	rs2905796	chr17:29537586	G/A	cg24425628	chr17:29625626	OMG;NF1	0.62	5.12	0.46	1.62e-6	Hip circumference;
THYM	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3862030	0.720	rs2025713	chr10:104230156	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.71	-5.96	-0.52	4.3e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs863345	0.604	rs10908665	chr1:158499889	T/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs293526	0.959	rs913577	chr6:83645062	C/T	cg23278060	chr6:83777448	DOPEY1	0.61	4.49	0.42	2.02e-5	Crohn's disease;
THYM	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg11905131	chr22:24372483	LOC391322	-0.92	-9.62	-0.7	1.06e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg25258033	chr6:167368657	RNASET2	-0.39	-4.53	-0.42	1.74e-5	Crohn's disease;
THYM	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg10047753	chr17:41438598	NA	1.16	10.76	0.74	3.96e-18	Menopause (age at onset);
THYM	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg10295955	chr4:187884368	NA	1.15	14.64	0.83	4.33e-26	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7100689	0.753	rs1856773	chr10:82060484	T/A	cg01528321	chr10:82214614	TSPAN14	1.02	7.78	0.62	8.75e-12	Post bronchodilator FEV1;
THYM	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs28595532	0.920	rs114796605	chr4:119744472	C/A	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs6547741	0.844	rs55826602	chr2:27863452	A/G	cg27432699	chr2:27873401	GPN1	-0.87	-7.73	-0.62	1.14e-11	Oral cavity cancer;
THYM	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg06713675	chr4:122721982	EXOSC9	-0.86	-9.81	-0.71	4.29e-16	Type 2 diabetes;
THYM	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg11764359	chr7:65958608	NA	-0.66	-5.06	-0.46	2.04e-6	Aortic root size;
THYM	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg24060327	chr5:131705240	SLC22A5	-0.83	-6.92	-0.58	5.2e-10	Breast cancer;
THYM	cis	rs4589258	0.737	rs7129072	chr11:90418608	A/C	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg16558253	chr16:72132732	DHX38	-0.58	-5.02	-0.46	2.46e-6	Fibrinogen levels;
THYM	cis	rs7107174	1.000	rs2510051	chr11:77981171	A/C	cg02023728	chr11:77925099	USP35	0.64	5.85	0.51	7.04e-8	Testicular germ cell tumor;
THYM	cis	rs17443541	0.564	rs1450570	chr2:200442061	G/T	cg01795955	chr2:200468626	NA	0.69	4.57	0.42	1.45e-5	Intelligence (multi-trait analysis);
THYM	cis	rs554111	0.656	rs3121071	chr1:21128420	C/T	cg00373020	chr1:21041521	KIF17	-0.51	-4.47	-0.42	2.13e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs2294693	0.541	rs11756247	chr6:40944111	A/G	cg14418226	chr6:40996092	UNC5CL	0.72	5.42	0.49	4.49e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs3806843	0.868	rs2531342	chr5:140130612	C/T	cg19875535	chr5:140030758	IK	-0.58	-4.55	-0.42	1.58e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs2235642	0.964	rs2745181	chr16:1577056	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.6	-4.99	-0.46	2.76e-6	Coronary artery disease;
THYM	cis	rs713587	0.967	rs713586	chr2:25158008	A/G	cg15423357	chr2:25149977	NA	0.67	7.42	0.61	5.04e-11	Body mass index in non-asthmatics;
THYM	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs35883536	0.566	rs12566440	chr1:101095202	A/G	cg06223162	chr1:101003688	GPR88	0.62	5.52	0.49	2.96e-7	Monocyte count;
THYM	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg17054759	chr22:49844102	NA	-0.53	-4.93	-0.45	3.54e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg16797656	chr11:68205561	LRP5	0.45	4.78	0.44	6.46e-6	Total body bone mineral density;
THYM	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg07755735	chr2:20870362	GDF7	0.69	6.15	0.53	1.85e-8	Abdominal aortic aneurysm;
THYM	cis	rs7772486	0.790	rs4075694	chr6:146251108	G/C	cg13319975	chr6:146136371	FBXO30	0.7	5.77	0.51	1.01e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg23583168	chr7:148888333	NA	-0.99	-12.74	-0.79	2.81e-22	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs9807989	0.839	rs3771166	chr2:102986222	G/A	cg03938978	chr2:103052716	IL18RAP	0.67	7.05	0.59	2.82e-10	Asthma;
THYM	cis	rs6500395	1.000	rs7195684	chr16:48710750	G/A	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs4866334	1.000	rs76259459	chr5:18456963	A/T	cg02002538	chr5:17811409	NA	-1.09	-4.54	-0.42	1.67e-5	IgG glycosylation;
THYM	cis	rs1580019	0.961	rs4460271	chr7:32496503	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.59	0.56	2.42e-9	Cognitive ability;
THYM	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.97	8.9	0.67	3.72e-14	Chronic sinus infection;
THYM	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg14798641	chr3:49314920	USP4;C3orf62	-0.66	-4.63	-0.43	1.14e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs4746818	0.818	rs7076011	chr10:70900430	T/C	cg04149295	chr10:70884716	VPS26A	0.78	5.27	0.48	8.48e-7	Left atrial antero-posterior diameter;
THYM	cis	rs6998277	0.830	rs6468836	chr8:103602630	A/G	cg10187029	chr8:103597600	NA	0.52	4.69	0.43	9.1e-6	Migraine;
THYM	cis	rs28595532	0.920	rs115994240	chr4:119744622	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs1403694	0.515	rs1648700	chr3:186449916	C/T	cg12454167	chr3:186435060	KNG1	-0.44	-5.89	-0.52	5.76e-8	Blood protein levels;
THYM	cis	rs2334880	0.610	rs8051767	chr16:71731720	C/T	cg06353428	chr16:71660113	MARVELD3	1.32	8.87	0.67	4.31e-14	Malaria;
THYM	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg00898013	chr13:113819073	PROZ	0.88	8.78	0.67	6.63e-14	Platelet distribution width;
THYM	cis	rs4372836	0.518	rs12472549	chr2:28992004	T/C	cg09522027	chr2:28974177	PPP1CB	-0.62	-4.79	-0.44	6.18e-6	Body mass index;
THYM	cis	rs4780401	0.728	rs8057398	chr16:11780629	G/T	cg01061890	chr16:11836724	TXNDC11	-0.62	-4.56	-0.42	1.5e-5	Rheumatoid arthritis;
THYM	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs2820651	0.614	rs56203704	chr10:1490143	G/A	cg13720710	chr10:1452970	ADARB2	0.8	5.06	0.46	2.05e-6	Migraine with aura;
THYM	cis	rs4845875	0.559	rs4846047	chr1:11843632	C/G	cg06193043	chr1:11908199	NPPA	0.6	5.13	0.47	1.53e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg18105134	chr13:113819100	PROZ	0.99	8.31	0.65	6.81e-13	Platelet distribution width;
THYM	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg06002616	chr8:101225028	SPAG1	0.45	4.5	0.42	1.93e-5	Atrioventricular conduction;
THYM	cis	rs6876348	0.928	rs10078631	chr5:128108183	G/A	cg25555059	chr5:128301488	SLC27A6	-0.45	-4.64	-0.43	1.12e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9563576	0.825	rs68160525	chr13:58555450	T/C	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs2070488	0.965	rs13093640	chr3:38487176	A/G	cg24069376	chr3:38537580	EXOG	0.68	6.73	0.57	1.26e-9	Electrocardiographic conduction measures;
THYM	cis	rs595982	0.501	rs112370206	chr19:49396623	C/T	cg21252483	chr19:49399788	TULP2	-0.65	-6.07	-0.53	2.62e-8	Red cell distribution width;
THYM	cis	rs2811415	0.597	rs56380765	chr3:127768878	C/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg04731861	chr2:219085781	ARPC2	0.54	5.05	0.46	2.09e-6	Colorectal cancer;
THYM	cis	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg01364799	chr7:75623366	TMEM120A	-0.64	-4.56	-0.42	1.52e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg24209194	chr3:40518798	ZNF619	0.59	4.74	0.44	7.35e-6	Renal cell carcinoma;
THYM	cis	rs6951245	0.542	rs28460147	chr7:1217192	G/A	cg15693483	chr7:1102177	C7orf50	0.54	5.39	0.48	5.19e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg02527881	chr3:46936655	PTH1R	0.52	4.99	0.46	2.77e-6	Colorectal cancer;
THYM	cis	rs4746818	0.892	rs12437	chr10:70864065	T/C	cg11621586	chr10:70884670	VPS26A	0.91	6.03	0.53	3.09e-8	Left atrial antero-posterior diameter;
THYM	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg25072359	chr17:41440525	NA	0.65	4.52	0.42	1.76e-5	Menopause (age at onset);
THYM	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg10803722	chr21:46713166	LOC642852	-0.41	-5.44	-0.49	4.18e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg17845761	chr1:175162550	KIAA0040	-0.36	-4.57	-0.42	1.45e-5	Alcohol dependence;
THYM	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4455778	0.580	rs7804423	chr7:49118270	A/G	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg06873352	chr17:61820015	STRADA	0.77	9.62	0.7	1.08e-15	Prudent dietary pattern;
THYM	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg23758822	chr17:41437982	NA	1.18	11.13	0.75	6.64e-19	Menopause (age at onset);
THYM	cis	rs4919694	1.000	rs112240253	chr10:104753726	C/T	cg04362960	chr10:104952993	NT5C2	1.14	6.92	0.58	5.38e-10	Arsenic metabolism;
THYM	cis	rs7523273	0.606	rs2488253	chr1:207938709	C/A	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	cis	rs922692	0.744	rs12903203	chr15:79084933	T/C	cg00540400	chr15:79124168	NA	-0.52	-4.49	-0.42	2.04e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg08859206	chr1:53392774	SCP2	-0.66	-7.55	-0.61	2.7e-11	Monocyte count;
THYM	cis	rs654950	0.806	rs1815257	chr1:42041479	A/C	cg06885757	chr1:42089581	HIVEP3	-0.58	-7.82	-0.63	7.37e-12	Airway imaging phenotypes;
THYM	cis	rs9653442	0.866	rs12712065	chr2:100761105	C/G	cg22139774	chr2:100720529	AFF3	-0.35	-5.7	-0.5	1.36e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs6840360	1.000	rs1355413	chr4:152633667	C/T	cg22705602	chr4:152727874	NA	-0.6	-6.39	-0.55	6.18e-9	Intelligence (multi-trait analysis);
THYM	cis	rs8014204	0.566	rs9441	chr14:75128425	G/A	cg06637938	chr14:75390232	RPS6KL1	0.59	5.26	0.47	8.96e-7	Caffeine consumption;
THYM	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg27588902	chr6:42928151	GNMT	-0.55	-5.52	-0.49	2.97e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg03433033	chr1:76189801	ACADM	0.77	10.21	0.72	6.01e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg12011299	chr4:100065546	ADH4	0.82	7.9	0.63	4.82e-12	Alcohol dependence;
THYM	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg17775962	chr7:1200435	ZFAND2A	0.42	5.16	0.47	1.32e-6	Longevity;Endometriosis;
THYM	cis	rs10887741	0.966	rs2077695	chr10:89435483	T/C	cg13926569	chr10:89418898	PAPSS2	0.6	6.18	0.54	1.56e-8	Exercise (leisure time);
THYM	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg16031515	chr1:205743344	RAB7L1	-0.74	-7.3	-0.6	8.61e-11	Menarche (age at onset);
THYM	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg24375607	chr4:120327624	NA	0.64	4.47	0.42	2.18e-5	Corneal astigmatism;
THYM	cis	rs6920965	0.507	rs12203025	chr6:126192034	C/T	cg10911889	chr6:126070802	HEY2	0.71	4.93	0.45	3.42e-6	High light scatter reticulocyte count;
THYM	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9297145	0.724	rs6958790	chr7:98774738	C/T	cg05967295	chr7:98741636	SMURF1	-0.83	-6.21	-0.54	1.41e-8	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs673253	0.686	rs6698389	chr1:44051574	A/G	cg24466421	chr1:44070974	PTPRF	-0.6	-5.34	-0.48	6.24e-7	Intelligence (multi-trait analysis);
THYM	cis	rs66887589	0.775	rs6843229	chr4:120424087	T/C	cg13609457	chr4:120235615	NA	0.47	4.86	0.45	4.57e-6	Diastolic blood pressure;
THYM	cis	rs4713118	0.869	rs9366700	chr6:27696951	C/T	cg12963246	chr6:28129442	ZNF389	0.64	4.86	0.45	4.62e-6	Parkinson's disease;
THYM	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.36	5.11	0.46	1.64e-6	Obesity-related traits;
THYM	cis	rs9650657	0.644	rs10091386	chr8:10696620	A/C	cg12981288	chr8:11183844	MTMR9	-0.48	-4.51	-0.42	1.84e-5	Neuroticism;
THYM	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg03929089	chr4:120376271	NA	-0.95	-10.79	-0.74	3.5e-18	Height;
THYM	cis	rs9486719	1.000	rs13207333	chr6:96882254	T/C	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs11756438	0.572	rs1771756	chr6:119018502	C/T	cg21191810	chr6:118973309	C6orf204	0.58	5.88	0.52	6.06e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs1747683	0.585	rs10752293	chr10:13357223	G/A	cg25835351	chr10:13388524	SEPHS1	-0.28	-4.81	-0.44	5.58e-6	IgG glycosylation;
THYM	cis	rs7772486	0.720	rs991507	chr6:146023609	G/A	cg23711669	chr6:146136114	FBXO30	-0.98	-10.65	-0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7731657	0.537	rs1120621	chr5:130340853	T/C	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs9905704	0.881	rs12942879	chr17:56861253	G/A	cg12560992	chr17:57184187	TRIM37	0.68	4.72	0.44	8.17e-6	Testicular germ cell tumor;
THYM	cis	rs500891	0.525	rs1539439	chr6:84078564	C/T	cg08257003	chr6:84140564	ME1	-0.56	-4.46	-0.42	2.25e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs886774	0.526	rs4266570	chr7:107500486	A/G	cg23293999	chr7:106826042	HBP1	-0.58	-4.64	-0.43	1.12e-5	Ulcerative colitis;
THYM	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.25	-5.11	-0.46	1.64e-6	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.74	5.42	0.49	4.51e-7	Height;
THYM	cis	rs7113850	0.541	rs76005477	chr11:24233322	G/A	ch.11.24196551F	chr11:24239977	NA	0.98	5.14	0.47	1.49e-6	Bone fracture in osteoporosis;
THYM	cis	rs754466	0.580	rs11002294	chr10:79540588	T/C	cg17075019	chr10:79541650	NA	-0.69	-5.73	-0.51	1.17e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs56341938	0.900	rs4955566	chr3:168750279	T/C	cg09107232	chr3:169491072	MYNN	0.52	4.45	0.42	2.32e-5	Lung function (FEV1/FVC);
THYM	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg06481639	chr22:41940642	POLR3H	0.74	4.85	0.45	4.81e-6	Vitiligo;
THYM	cis	rs7953508	0.506	rs3869308	chr12:93959918	A/G	cg18151635	chr12:93972918	NA	-0.87	-6.12	-0.53	2.07e-8	Pubertal anthropometrics;
THYM	cis	rs4242434	0.854	rs13258100	chr8:22451116	A/T	cg11461670	chr8:22454935	PDLIM2	-0.39	-6.57	-0.56	2.66e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs10744422	1.000	rs937766	chr12:123331094	G/T	cg25930673	chr12:123319894	HIP1R	-0.86	-4.84	-0.44	5.09e-6	Schizophrenia;
THYM	cis	rs854765	0.624	rs9902941	chr17:17733760	C/T	cg04398451	chr17:18023971	MYO15A	0.76	6.62	0.56	2.12e-9	Total body bone mineral density;
THYM	cis	rs6032067	0.673	rs36019441	chr20:43892401	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.42	-4.54	-0.42	1.67e-5	Blood protein levels;
THYM	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	6.93e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2456568	0.835	rs8181533	chr11:93638614	C/T	cg26875233	chr11:93583750	C11orf90	-0.53	-5.53	-0.49	2.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs4535497	0.525	rs4975639	chr5:1108250	A/G	cg00278107	chr5:1061253	SLC12A7	0.61	4.83	0.44	5.12e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs12310956	0.532	rs1852226	chr12:33962940	G/A	cg06521331	chr12:34319734	NA	-0.88	-8.26	-0.65	8.51e-13	Morning vs. evening chronotype;
THYM	cis	rs7586879	0.687	rs11892869	chr2:25096692	A/T	cg15423357	chr2:25149977	NA	0.66	7.01	0.58	3.49e-10	Body mass index;
THYM	cis	rs2273669	0.504	rs59358669	chr6:109500192	G/A	cg17117243	chr6:109341365	SESN1	-0.79	-4.7	-0.43	8.8e-6	Prostate cancer;
THYM	cis	rs4792901	0.765	rs9892162	chr17:41600800	T/C	cg21940313	chr17:41620911	ETV4	-0.53	-5.03	-0.46	2.28e-6	Dupuytren's disease;
THYM	cis	rs13082711	0.911	rs13075550	chr3:27427618	A/G	cg02860705	chr3:27208620	NA	0.67	4.72	0.44	8.23e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg18132916	chr6:79620363	NA	0.59	5.29	0.48	7.95e-7	Intelligence (multi-trait analysis);
THYM	cis	rs34526934	0.608	rs67508915	chr2:177032560	T/C	cg26754761	chr2:177040938	NA	-0.74	-6.37	-0.55	6.7e-9	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs4944092	1.000	rs7125695	chr11:75908131	A/G	cg04588336	chr11:75916460	WNT11	0.66	6.71	0.57	1.39e-9	PR interval;
THYM	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg04772025	chr11:68637568	NA	0.63	6.85	0.58	7.17e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg18240062	chr17:79603768	NPLOC4	0.73	6.55	0.56	2.9e-9	Eye color traits;
THYM	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.78	-0.44	6.31e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs9807989	0.708	rs6543124	chr2:102987459	T/A	cg09003973	chr2:102972529	NA	0.57	4.65	0.43	1.09e-5	Asthma;
THYM	cis	rs7172809	0.573	rs13379686	chr15:77436191	T/C	cg22256960	chr15:77711686	NA	-0.64	-4.76	-0.44	6.83e-6	Glucose homeostasis traits;
THYM	cis	rs2734839	0.964	rs2734831	chr11:113293596	G/T	cg14159747	chr11:113255604	NA	-0.31	-6.32	-0.54	8.63e-9	Information processing speed;
THYM	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs600806	0.850	rs10858086	chr1:109915075	C/A	cg02175308	chr1:109941060	SORT1	-0.56	-4.99	-0.46	2.76e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg26384229	chr12:38710491	ALG10B	0.69	5.32	0.48	6.98e-7	Morning vs. evening chronotype;
THYM	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg01097406	chr16:89675127	NA	-0.6	-5.07	-0.46	1.94e-6	Vitiligo;
THYM	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg15704280	chr7:45808275	SEPT13	0.99	7.95	0.63	3.79e-12	Coronary artery disease;
THYM	cis	rs2066819	0.892	rs112931321	chr12:56667894	C/T	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs7729447	0.776	rs17540155	chr5:32694033	C/T	cg16267343	chr5:32710456	NPR3	0.8	7.2	0.59	1.41e-10	Blood pressure;
THYM	cis	rs636291	0.517	rs2781233	chr1:10529194	T/C	cg05038881	chr1:10490043	APITD1	0.24	4.57	0.42	1.47e-5	Prostate cancer;
THYM	cis	rs11031096	0.678	rs10767872	chr11:4184239	T/G	cg22027985	chr11:4115532	RRM1	-0.52	-4.78	-0.44	6.29e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.52e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2070488	1.000	rs13072809	chr3:38468171	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	6.88	0.58	6.34e-10	Electrocardiographic conduction measures;
THYM	cis	rs8030485	0.571	rs939654	chr15:79415218	G/A	cg17916960	chr15:79447300	NA	0.6	5.97	0.52	4.02e-8	Left ventricle wall thickness;
THYM	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg03806693	chr22:41940476	POLR3H	1.03	9.13	0.68	1.19e-14	Vitiligo;
THYM	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg11764359	chr7:65958608	NA	-0.76	-6.22	-0.54	1.35e-8	Aortic root size;
THYM	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.8e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1994135	0.654	rs1384591	chr12:33734170	T/C	cg10856724	chr12:34555212	NA	-0.72	-5.57	-0.5	2.4e-7	Resting heart rate;
THYM	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg23356831	chr14:105996513	TMEM121	0.58	6.29	0.54	9.88e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg00080972	chr5:178986291	RUFY1	0.53	6.09	0.53	2.36e-8	Lung cancer;
THYM	cis	rs3768617	0.510	rs3768622	chr1:183090011	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	4.98	0.46	2.84e-6	Fuchs's corneal dystrophy;
THYM	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg07167872	chr1:205819463	PM20D1	0.91	8.35	0.65	5.47e-13	Monocyte percentage of white cells;
THYM	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7106204	0.534	rs75335266	chr11:24256395	G/T	ch.11.24196551F	chr11:24239977	NA	0.91	4.72	0.44	8.27e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7572733	0.534	rs700684	chr2:198713099	C/T	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.71	-4.75	-0.44	7.11e-6	Menarche (age at onset);
THYM	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg11764359	chr7:65958608	NA	0.8	6.38	0.55	6.55e-9	Aortic root size;
THYM	cis	rs9359856	0.564	rs56224741	chr6:90475231	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs6430585	0.528	rs309165	chr2:136667301	T/C	cg04750100	chr2:136595281	LCT	0.56	5.87	0.52	6.36e-8	Corneal structure;
THYM	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg06112835	chr11:68658793	MRPL21	0.44	6.53	0.56	3.28e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7772486	0.754	rs702318	chr6:146005873	G/T	cg23711669	chr6:146136114	FBXO30	-0.97	-9.96	-0.71	2.04e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg21475434	chr5:93447410	FAM172A	0.96	6.1	0.53	2.29e-8	Diabetic retinopathy;
THYM	cis	rs9522267	0.502	rs9522281	chr13:112222389	G/A	cg10483660	chr13:112241077	NA	-0.59	-6.61	-0.56	2.22e-9	Hepatitis;
THYM	cis	rs9644630	0.813	rs4922036	chr8:19328219	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.71	7.43	0.61	4.6e-11	Oropharynx cancer;
THYM	cis	rs2286885	0.965	rs10819167	chr9:129241716	T/A	cg14319473	chr9:129242481	FAM125B	0.66	5.01	0.46	2.52e-6	Intraocular pressure;
THYM	cis	rs80130819	0.642	rs4760607	chr12:48365265	A/C	cg24011408	chr12:48396354	COL2A1	-0.89	-4.56	-0.42	1.5e-5	Prostate cancer;
THYM	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs3820068	0.705	rs4646091	chr1:15822043	T/C	cg05660106	chr1:15850417	CASP9	1.13	10.23	0.72	5.39e-17	Systolic blood pressure;
THYM	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg23682913	chr1:2080710	PRKCZ	-0.54	-4.91	-0.45	3.77e-6	Height;
THYM	cis	rs911119	1.000	rs911119	chr20:23612737	C/T	cg16589663	chr20:23618590	CST3	-0.78	-4.77	-0.44	6.71e-6	Chronic kidney disease;
THYM	cis	rs2075230	0.850	rs9896688	chr17:7483915	A/T	cg10509001	chr17:7553872	ATP1B2	0.59	4.69	0.43	9e-6	Hormone measurements;
THYM	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg17911788	chr17:44343683	NA	-0.6	-6.03	-0.53	3.12e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs17401966	0.931	rs11121545	chr1:10411211	A/G	cg19773385	chr1:10388646	KIF1B	-0.6	-4.7	-0.43	8.88e-6	Hepatocellular carcinoma;
THYM	trans	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg10856724	chr12:34555212	NA	-0.94	-8.13	-0.64	1.61e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg06784218	chr1:46089804	CCDC17	-0.32	-4.75	-0.44	7.22e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs57920188	1.000	rs57920188	chr1:4087708	T/G	cg20703997	chr1:4087676	NA	0.74	5.09	0.46	1.8e-6	Interleukin-17 levels;
THYM	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg20744362	chr22:50050164	C22orf34	0.83	8.41	0.65	4.11e-13	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.79	5.19	0.47	1.2e-6	Smoking behavior;
THYM	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg07988820	chr12:82153109	PPFIA2	-0.82	-5.23	-0.47	9.93e-7	Resting heart rate;
THYM	cis	rs684232	0.666	rs366151	chr17:598311	A/C	cg15660573	chr17:549704	VPS53	-0.87	-8.15	-0.64	1.45e-12	Prostate cancer;
THYM	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg00786635	chr1:25594202	NA	0.87	7.02	0.58	3.24e-10	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs986417	1.000	rs6573312	chr14:60952536	G/T	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs501916	0.634	rs1561482	chr15:48069663	G/A	cg20869673	chr15:48010124	SEMA6D	0.63	4.49	0.42	1.99e-5	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	trans	rs8002861	0.967	rs7983109	chr13:44484351	C/A	cg17145862	chr1:211918768	LPGAT1	0.99	11.5	0.76	1.07e-19	Leprosy;
THYM	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg18252515	chr7:66147081	NA	0.63	4.47	0.42	2.13e-5	Aortic root size;
THYM	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg19875535	chr5:140030758	IK	-0.63	-5.54	-0.49	2.7e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg24675056	chr1:15929824	NA	0.73	5.89	0.52	5.95e-8	Systolic blood pressure;
THYM	cis	rs10484885	0.878	rs72921934	chr6:90579464	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.87	-7.73	-0.62	1.13e-11	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs2637266	0.935	rs7918777	chr10:78394375	A/G	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs12410462	0.681	rs115959512	chr1:227599578	T/C	cg04117972	chr1:227635322	NA	0.89	5.14	0.47	1.47e-6	Major depressive disorder;
THYM	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg07978099	chr16:83986941	OSGIN1	0.69	6.38	0.55	6.28e-9	Pursuit maintenance gain;
THYM	cis	rs6127978	0.702	rs6127981	chr20:55824149	G/T	cg15851418	chr20:55835831	BMP7	0.68	4.89	0.45	4.12e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs761746	0.960	rs5753686	chr22:31947948	G/A	cg10537193	chr22:32026975	PISD	-0.36	-4.8	-0.44	5.91e-6	Intelligence;
THYM	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg07606381	chr6:8435919	SLC35B3	-0.6	-4.47	-0.42	2.12e-5	Motion sickness;
THYM	cis	rs56104184	0.775	rs117016425	chr19:49400216	C/T	cg15549821	chr19:49342101	PLEKHA4	-0.82	-4.55	-0.42	1.56e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg12386194	chr3:101231763	SENP7	0.7	5.29	0.48	7.69e-7	Colorectal cancer;
THYM	cis	rs1421898	0.625	rs17624723	chr5:157969514	G/A	cg06698293	chr5:158690540	UBLCP1	-0.97	-4.6	-0.43	1.28e-5	Inflammatory skin disease;
THYM	cis	rs9814567	1.000	rs1498718	chr3:134205920	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-8.12	-0.64	1.71e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg18252515	chr7:66147081	NA	-0.87	-6.66	-0.56	1.74e-9	Corneal structure;
THYM	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.37	-0.48	5.64e-7	Total cholesterol levels;
THYM	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg05347473	chr6:146136440	FBXO30	0.58	4.64	0.43	1.1e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.75	7.26	0.6	1.05e-10	Lymphocyte counts;
THYM	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg03388025	chr16:89894329	SPIRE2	-0.55	-4.76	-0.44	7e-6	Vitiligo;
THYM	cis	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg23422044	chr7:1970798	MAD1L1	-0.95	-6.58	-0.56	2.51e-9	Bipolar disorder;
THYM	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg06917634	chr15:78832804	PSMA4	-0.91	-8.0	-0.63	3.05e-12	Sudden cardiac arrest;
THYM	cis	rs4455778	0.580	rs4244231	chr7:49103406	G/A	cg26309511	chr7:48887640	NA	0.68	5.94	0.52	4.63e-8	Lung cancer in never smokers;
THYM	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg16342193	chr10:102329863	NA	-0.53	-5.28	-0.48	8.1e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs35995292	1.000	rs56098802	chr7:38913730	T/C	cg19166347	chr7:37955598	SFRP4	0.57	4.55	0.42	1.58e-5	Subjective well-being (multi-trait analysis);
THYM	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg26116260	chr4:7069785	GRPEL1	1.08	10.21	0.72	5.88e-17	Monocyte percentage of white cells;
THYM	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg02527881	chr3:46936655	PTH1R	-0.65	-6.44	-0.55	4.94e-9	Colorectal cancer;
THYM	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg13683864	chr3:40499215	RPL14	-1.05	-11.11	-0.75	7.16e-19	Renal cell carcinoma;
THYM	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg06453172	chr10:134556979	INPP5A	-0.67	-4.84	-0.44	5.1e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs733592	0.507	rs56129148	chr12:48485530	T/C	cg21466736	chr12:48725269	NA	0.46	4.96	0.45	3.09e-6	Plateletcrit;
THYM	cis	rs13006833	0.739	rs291430	chr2:191198727	A/C	cg21644426	chr2:191273491	MFSD6	0.64	4.46	0.42	2.24e-5	Urinary metabolites;
THYM	cis	rs3126085	0.935	rs4845745	chr1:152185184	C/T	cg10321714	chr1:152280068	FLG	0.68	4.95	0.45	3.2e-6	Atopic dermatitis;
THYM	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg05754148	chr16:3507555	NAT15	0.58	4.87	0.45	4.45e-6	Body mass index (adult);
THYM	cis	rs4631830	0.965	rs7070301	chr10:51543070	T/G	cg10326726	chr10:51549505	MSMB	-0.58	-5.67	-0.5	1.56e-7	Prostate-specific antigen levels;
THYM	cis	rs7107174	0.901	rs2450133	chr11:77925759	A/C	cg19901956	chr11:77921274	USP35	-0.73	-5.77	-0.51	9.81e-8	Testicular germ cell tumor;
THYM	cis	rs4642101	0.535	rs55692304	chr3:12840057	C/T	cg05775895	chr3:12838266	CAND2	1.12	11.34	0.76	2.4e-19	QRS complex (12-leadsum);
THYM	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg06636001	chr8:8085503	FLJ10661	-0.75	-6.51	-0.56	3.61e-9	Mood instability;
THYM	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.92e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.44	7.31	0.6	8.19e-11	Obesity-related traits;
THYM	cis	rs7614311	0.636	rs17344090	chr3:64004101	T/C	cg22134162	chr3:63841271	THOC7	-0.5	-6.04	-0.53	2.93e-8	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs7408868	1.000	rs2074618	chr19:15276143	C/T	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs448720	0.840	rs399755	chr15:68161587	T/A	cg24579218	chr15:68104479	NA	0.69	6.14	0.53	1.93e-8	Cognitive performance;
THYM	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-4.45	-0.42	2.35e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4790333	1.000	rs4790333	chr17:2262703	A/G	cg02569219	chr17:2266849	SGSM2	-0.67	-6.18	-0.54	1.58e-8	Proinsulin levels;
THYM	cis	rs2070488	0.965	rs2366123	chr3:38493153	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	7.18	0.59	1.57e-10	Electrocardiographic conduction measures;
THYM	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg07570687	chr10:102243282	WNT8B	0.74	6.46	0.55	4.36e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg08772003	chr10:104629869	AS3MT	-0.57	-4.93	-0.45	3.43e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6754311	0.509	rs10188066	chr2:136539513	G/A	cg07169764	chr2:136633963	MCM6	-0.71	-6.02	-0.53	3.2e-8	Mosquito bite size;
THYM	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg13770153	chr20:60521292	NA	-0.64	-4.48	-0.42	2.05e-5	Body mass index;
THYM	cis	rs2456568	0.543	rs4144616	chr11:93621900	A/G	cg09189538	chr11:93579666	C11orf90	-0.57	-5.17	-0.47	1.28e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg24874828	chr4:187887005	NA	-0.73	-7.49	-0.61	3.59e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.17	-0.47	1.28e-6	Joint mobility (Beighton score);
THYM	trans	rs4650994	0.525	rs2493858	chr1:178541210	A/G	cg05059571	chr16:84539110	KIAA1609	-0.92	-10.85	-0.74	2.56e-18	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs2133450	0.679	rs28578967	chr3:7365088	G/A	cg19930620	chr3:7340148	GRM7	-0.48	-4.55	-0.42	1.61e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs800586	0.751	rs800535	chr8:116720390	T/G	cg04656070	chr8:116661063	TRPS1	0.47	5.08	0.46	1.88e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg25237894	chr2:233734115	C2orf82	-0.36	-5.15	-0.47	1.42e-6	Coronary artery disease;
THYM	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.86	-7.44	-0.61	4.57e-11	Uric acid levels;
THYM	cis	rs919433	0.889	rs787998	chr2:198216092	A/G	cg00792783	chr2:198669748	PLCL1	0.78	5.67	0.5	1.53e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs1371867	0.846	rs1660316	chr8:101333049	T/C	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg06238570	chr21:40685208	BRWD1	-0.72	-6.28	-0.54	9.9e-9	Menarche (age at onset);
THYM	cis	rs6835098	0.962	rs6851632	chr4:174109611	A/G	cg08422745	chr4:174089978	GALNT7	-1.0	-8.37	-0.65	5e-13	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg15440763	chr7:158190612	PTPRN2	0.48	4.46	0.42	2.29e-5	Obesity-related traits;
THYM	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg08773314	chr2:239334832	ASB1	0.64	9.92	0.71	2.51e-16	Multiple system atrophy;
THYM	cis	rs7084402	0.967	rs1623568	chr10:60320446	T/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.47	-0.49	3.63e-7	Refractive error;
THYM	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg18850127	chr7:39170497	POU6F2	0.6	5.66	0.5	1.57e-7	IgG glycosylation;
THYM	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg11905131	chr22:24372483	LOC391322	-0.63	-4.82	-0.44	5.54e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.66	5.8	0.51	8.69e-8	Electroencephalogram traits;
THYM	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg23791538	chr6:167370224	RNASET2	-0.59	-4.51	-0.42	1.82e-5	Crohn's disease;
THYM	cis	rs7072216	0.763	rs7914401	chr10:100163928	A/G	cg26618903	chr10:100175079	PYROXD2	-0.5	-4.76	-0.44	6.96e-6	Metabolite levels;
THYM	cis	rs1345301	0.552	rs1558626	chr2:102862070	T/A	cg03938978	chr2:103052716	IL18RAP	-0.5	-4.68	-0.43	9.59e-6	Waist circumference;
THYM	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23221052	chr5:179740743	GFPT2	-0.88	-7.06	-0.59	2.74e-10	Height;
THYM	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs675209	0.638	rs6912908	chr6:7080522	C/T	cg07207043	chr6:7051497	NA	-0.34	-5.28	-0.48	8.16e-7	Urate levels;
THYM	cis	rs2115630	0.754	rs12595321	chr15:85331269	G/A	cg11189052	chr15:85197271	WDR73	-0.6	-4.74	-0.44	7.45e-6	P wave terminal force;
THYM	cis	rs7246657	0.943	rs10414904	chr19:37830088	G/A	cg22634378	chr19:37742834	NA	0.65	5.34	0.48	6.2e-7	Coronary artery calcification;
THYM	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg26384229	chr12:38710491	ALG10B	1.05	10.44	0.73	1.86e-17	Heart rate;
THYM	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg13607699	chr17:42295918	UBTF	0.66	5.44	0.49	4.13e-7	Total body bone mineral density;
THYM	cis	rs11096990	0.855	rs56275407	chr4:39178844	T/G	cg24403649	chr4:39172243	NA	-0.66	-5.61	-0.5	1.99e-7	Cognitive function;
THYM	cis	rs12149862	1.000	rs7193341	chr16:69475620	G/A	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg06028605	chr16:24865363	SLC5A11	0.63	5.18	0.47	1.26e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs12611088	0.571	rs8110232	chr19:44027390	T/C	cg18042043	chr19:44147545	NA	-0.4	-4.71	-0.43	8.57e-6	Plasma amyloid beta peptide concentrations (ABx-42);
THYM	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg13390004	chr1:15929781	NA	0.62	4.72	0.44	8.11e-6	Systolic blood pressure;
THYM	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg27446573	chr6:127587934	RNF146	0.98	9.21	0.69	8.26e-15	Breast cancer;
THYM	cis	rs2637266	0.596	rs2579723	chr10:78246092	A/G	cg18941641	chr10:78392320	NA	0.6	4.63	0.43	1.18e-5	Pulmonary function;
THYM	trans	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg03676636	chr4:99064102	C4orf37	0.5	7.59	0.61	2.14e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13315871	1.000	rs13060489	chr3:58339287	G/A	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg00071950	chr4:10020882	SLC2A9	-0.79	-8.15	-0.64	1.42e-12	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17102423	0.760	rs2781375	chr14:65569597	A/G	cg11161011	chr14:65562177	MAX	-0.67	-5.73	-0.51	1.16e-7	Obesity-related traits;
THYM	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg10253484	chr15:75165896	SCAMP2	-0.66	-4.54	-0.42	1.64e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg08999081	chr20:33150536	PIGU	-0.73	-6.56	-0.56	2.86e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg01236616	chr12:121019343	POP5	1.31	10.38	0.73	2.57e-17	Type 1 diabetes nephropathy;
THYM	cis	rs4690686	0.500	rs7683662	chr4:177272004	A/T	cg17059388	chr4:177262070	NA	0.47	6.87	0.58	6.67e-10	Essential tremor;
THYM	cis	rs7953508	0.750	rs11107119	chr12:93983132	T/A	cg13201927	chr12:93977447	NA	0.73	5.2	0.47	1.15e-6	Pubertal anthropometrics;
THYM	cis	rs7000551	0.751	rs2100291	chr8:22374551	C/T	cg12081754	chr8:22256438	SLC39A14	0.63	5.71	0.51	1.27e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs67460515	0.563	rs35914913	chr3:160826561	A/G	cg12349858	chr3:160822545	B3GALNT1	0.57	4.63	0.43	1.17e-5	Parkinson's disease;
THYM	cis	rs9796	0.870	rs12910027	chr15:41283817	A/T	cg21153102	chr15:41252147	NA	-0.67	-5.95	-0.52	4.53e-8	Menopause (age at onset);
THYM	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.49	-5.0	-0.46	2.64e-6	Depressive symptoms;
THYM	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg18252515	chr7:66147081	NA	-0.66	-5.01	-0.46	2.55e-6	Aortic root size;
THYM	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.7	6.0	0.52	3.55e-8	Total body bone mineral density;
THYM	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.49	-0.42	2.04e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg18105134	chr13:113819100	PROZ	-0.99	-9.19	-0.69	8.83e-15	Platelet distribution width;
THYM	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-15.24	-0.84	2.93e-27	Height;
THYM	cis	rs1784581	0.802	rs2156747	chr6:162430000	C/G	cg17173639	chr6:162384350	PARK2	-0.79	-7.85	-0.63	6.28e-12	Itch intensity from mosquito bite;
THYM	cis	rs7236492	0.683	rs78250476	chr18:77198934	G/A	cg15644404	chr18:77186268	NFATC1	-1.05	-4.96	-0.45	3.04e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs13006833	0.668	rs291466	chr2:191184475	A/G	cg21644426	chr2:191273491	MFSD6	0.66	4.64	0.43	1.11e-5	Urinary metabolites;
THYM	cis	rs8067545	0.516	rs11869258	chr17:20206898	G/A	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs6032067	0.929	rs6017512	chr20:43835038	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.81	-0.57	8.91e-10	Blood protein levels;
THYM	cis	rs4737010	0.570	rs7823138	chr8:41644861	C/T	cg08923054	chr8:41654455	ANK1	-0.8	-4.89	-0.45	4.05e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
THYM	cis	rs2039659	0.719	rs1764951	chr13:86252900	T/C	cg25308322	chr13:86268291	NA	0.66	5.51	0.49	3.11e-7	Blood osmolality (transformed sodium);
THYM	cis	rs4575098	0.626	rs11265557	chr1:161106354	T/G	cg24329783	chr1:161160887	ADAMTS4	-0.61	-5.71	-0.51	1.27e-7	Monocyte percentage of white cells;
THYM	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg27490568	chr2:178487706	NA	0.62	5.81	0.51	8.38e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs6032067	0.641	rs35227660	chr20:43756697	C/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.47	-5.31	-0.48	7.26e-7	Blood protein levels;
THYM	cis	rs56104184	0.775	rs56317021	chr19:49395960	C/T	cg17863274	chr19:49399704	TULP2	-0.95	-5.5	-0.49	3.26e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7412746	0.611	rs66847267	chr1:150875173	C/A	cg10589385	chr1:150898437	SETDB1	0.57	4.55	0.42	1.56e-5	Melanoma;
THYM	cis	rs763014	0.898	rs8060585	chr16:635794	C/G	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg03806693	chr22:41940476	POLR3H	-1.23	-10.66	-0.74	6.4e-18	Vitiligo;
THYM	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg03806693	chr22:41940476	POLR3H	1.17	11.01	0.75	1.18e-18	Vitiligo;
THYM	cis	rs9515201	0.859	rs9521732	chr13:111033821	G/T	cg15455643	chr13:111040242	COL4A2	0.49	5.27	0.48	8.5e-7	White matter hyperintensity burden;
THYM	cis	rs7267979	0.834	rs6115100	chr20:25225938	C/A	cg08601574	chr20:25228251	PYGB	0.59	4.79	0.44	6.25e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1113500	0.933	rs745795	chr1:108629345	C/T	cg06207961	chr1:108661230	NA	0.66	5.17	0.47	1.28e-6	Growth-regulated protein alpha levels;
THYM	cis	rs514406	0.830	rs533935	chr1:53308807	T/C	cg22166914	chr1:53195759	ZYG11B	0.76	7.58	0.61	2.23e-11	Monocyte count;
THYM	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg05234568	chr11:5960015	NA	-0.61	-4.98	-0.45	2.88e-6	DNA methylation (variation);
THYM	cis	rs35264875	0.846	rs72930627	chr11:68867121	C/A	cg01993067	chr11:68851601	TPCN2	0.98	4.96	0.45	3.11e-6	Blond vs. brown hair color;
THYM	trans	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg19862616	chr7:65841803	NCRNA00174	1.11	12.51	0.79	8.39e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg03929089	chr4:120376271	NA	-0.95	-7.21	-0.59	1.34e-10	Coronary artery disease;
THYM	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-10.28	-0.73	4.14e-17	Coronary artery disease;
THYM	cis	rs2505998	0.912	rs2505994	chr10:43568887	C/T	cg06632098	chr10:43605906	RET	1.03	8.87	0.67	4.3e-14	Hirschsprung disease;
THYM	cis	rs4845875	0.600	rs4846040	chr1:11837048	C/G	cg06193043	chr1:11908199	NPPA	0.58	4.95	0.45	3.18e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs10946292	0.706	rs6920519	chr6:170426208	G/A	cg20675539	chr6:170408355	NA	0.77	4.61	0.43	1.25e-5	Obesity-related traits;
THYM	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg26384229	chr12:38710491	ALG10B	-0.83	-8.3	-0.65	6.83e-13	Heart rate;
THYM	cis	rs977987	0.866	rs17696831	chr16:75493298	C/G	cg03315344	chr16:75512273	CHST6	0.72	5.68	0.5	1.46e-7	Dupuytren's disease;
THYM	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs763014	0.931	rs62030903	chr16:638323	T/A	cg07343612	chr16:622815	PIGQ	-1.15	-12.09	-0.78	6.29e-21	Height;
THYM	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg19418458	chr7:158789849	NA	-0.67	-6.52	-0.56	3.3e-9	Facial morphology (factor 20);
THYM	cis	rs1018836	0.663	rs3950221	chr8:91478108	G/A	cg16814680	chr8:91681699	NA	-0.73	-6.18	-0.54	1.56e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9420	0.961	rs708228	chr11:57585662	C/T	cg19752551	chr11:57585705	CTNND1	-0.74	-8.02	-0.64	2.68e-12	Schizophrenia;
THYM	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	13.59	0.81	5.3e-24	Chronic sinus infection;
THYM	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg03647317	chr4:187891568	NA	-0.59	-5.58	-0.5	2.24e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12817211	0.502	rs34167640	chr12:50516991	T/C	cg06168149	chr12:50497778	GPD1	0.3	4.52	0.42	1.82e-5	Colorectal or endometrial cancer;
THYM	cis	rs2688608	0.839	rs2633310	chr10:75594050	G/T	cg15838173	chr10:75533400	FUT11	0.44	4.72	0.44	8.1e-6	Inflammatory bowel disease;
THYM	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg10518543	chr12:38710700	ALG10B	-0.59	-4.67	-0.43	9.89e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg23649088	chr2:200775458	C2orf69	0.76	5.75	0.51	1.1e-7	Schizophrenia;
THYM	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17006441	0.932	rs6549252	chr3:69845515	A/C	cg18496212	chr3:69797108	MITF	0.69	7.12	0.59	2.02e-10	Hemoglobin concentration;
THYM	cis	rs236907	0.859	rs3891278	chr1:171756248	A/C	cg20598894	chr1:171756153	METTL13	-0.74	-5.59	-0.5	2.16e-7	Mean platelet volume;
THYM	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg05738196	chr6:26577821	NA	-0.63	-5.12	-0.46	1.63e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7122539	0.646	rs543191	chr11:66583779	T/G	cg24851651	chr11:66362959	CCS	0.65	5.6	0.5	2.05e-7	HIV-1 susceptibility;
THYM	cis	rs12142240	0.698	rs56909107	chr1:46808224	A/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs9796	0.835	rs2927062	chr15:41302687	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.56	-4.57	-0.42	1.48e-5	Menopause (age at onset);
THYM	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg14196790	chr5:131705035	SLC22A5	0.55	5.03	0.46	2.34e-6	Blood metabolite levels;
THYM	cis	rs36051895	0.695	rs7045000	chr9:5015143	G/A	cg02405213	chr9:5042618	JAK2	-1.02	-10.67	-0.74	6.09e-18	Pediatric autoimmune diseases;
THYM	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs7211079	0.833	rs7220523	chr17:78127695	G/A	cg09238746	chr17:78121135	EIF4A3	-0.78	-4.88	-0.45	4.31e-6	Myocardial infarction;
THYM	cis	rs7568458	0.875	rs2044474	chr2:85758790	G/A	cg17127132	chr2:85788382	GGCX	0.65	5.25	0.47	9.44e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs40363	1.000	rs37773	chr16:3512834	G/A	cg22508957	chr16:3507546	NAT15	0.69	8.24	0.65	9.39e-13	Tuberculosis;
THYM	cis	rs2742540	0.524	rs2653562	chr11:8918160	A/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.6	-4.96	-0.45	3.1e-6	Hematocrit;
THYM	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	5.78	0.51	9.49e-8	Height;
THYM	cis	rs56341938	0.904	rs12495278	chr3:168755124	C/T	cg09107232	chr3:169491072	MYNN	0.52	4.45	0.42	2.32e-5	Lung function (FEV1/FVC);
THYM	cis	rs1018836	0.632	rs6988302	chr8:91477660	C/T	cg16814680	chr8:91681699	NA	-0.74	-6.16	-0.53	1.71e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs11696501	0.688	rs6073834	chr20:44279989	C/A	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.89	0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs3760982	0.585	rs8109478	chr19:44298256	C/T	cg11993925	chr19:44307056	LYPD5	0.64	5.02	0.46	2.4e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	trans	rs8002861	0.870	rs2121030	chr13:44444574	C/T	cg17145862	chr1:211918768	LPGAT1	-0.94	-9.74	-0.71	6.04e-16	Leprosy;
THYM	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg10150615	chr22:24372951	LOC391322	-0.95	-11.98	-0.78	1.08e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg06600287	chr1:53387719	ECHDC2	-0.38	-5.73	-0.51	1.17e-7	Monocyte count;
THYM	cis	rs1775715	0.870	rs1755085	chr10:32250931	T/C	cg04359828	chr10:32216031	ARHGAP12	0.41	5.19	0.47	1.19e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg07636037	chr3:49044803	WDR6	0.99	10.4	0.73	2.28e-17	Parkinson's disease;
THYM	cis	rs35883536	0.609	rs1577513	chr1:101044402	C/A	cg06223162	chr1:101003688	GPR88	0.82	6.93	0.58	5.03e-10	Monocyte count;
THYM	cis	rs9581943	0.967	rs11618581	chr13:28476911	C/T	cg16302790	chr13:28498334	PDX1	0.51	4.67	0.43	9.73e-6	Pancreatic cancer;
THYM	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg10911889	chr6:126070802	HEY2	0.59	4.72	0.44	8.23e-6	Brugada syndrome;
THYM	cis	rs3771570	1.000	rs3771564	chr2:242355701	G/A	cg21155796	chr2:242212141	HDLBP	1.25	6.07	0.53	2.57e-8	Prostate cancer;
THYM	cis	rs1801251	1.000	rs7592717	chr2:233577038	G/A	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs10463554	0.963	rs62362546	chr5:102351319	C/T	cg23492399	chr5:102201601	PAM	-0.67	-5.18	-0.47	1.26e-6	Parkinson's disease;
THYM	cis	rs1061377	0.513	rs2566162	chr4:39128073	A/G	cg24403649	chr4:39172243	NA	0.6	4.51	0.42	1.85e-5	Uric acid levels;
THYM	cis	rs870825	0.616	rs6833858	chr4:185639961	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg13010199	chr12:38710504	ALG10B	0.71	5.56	0.5	2.5e-7	Heart rate;
THYM	cis	rs3125734	0.633	rs1864836	chr10:64028538	C/G	cg09941381	chr10:64027924	RTKN2	-0.55	-4.51	-0.42	1.86e-5	Rheumatoid arthritis;
THYM	cis	rs208520	0.690	rs851465	chr6:66840293	G/A	cg07460842	chr6:66804631	NA	-0.96	-6.88	-0.58	6.25e-10	Exhaled nitric oxide output;
THYM	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg14019146	chr3:50243930	SLC38A3	0.54	4.56	0.42	1.53e-5	Body mass index;
THYM	cis	rs250585	0.736	rs40817	chr16:23422672	C/G	cg00143387	chr16:23521605	GGA2	0.74	5.25	0.47	9.16e-7	Egg allergy;
THYM	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.08	-7.42	-0.61	4.86e-11	Schizophrenia;
THYM	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg04025307	chr7:1156635	C7orf50	0.62	5.73	0.51	1.2e-7	Longevity;Endometriosis;
THYM	cis	rs713587	0.719	rs4665736	chr2:25187599	C/T	cg01884057	chr2:25150051	NA	-0.57	-5.61	-0.5	1.97e-7	Body mass index in non-asthmatics;
THYM	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg09323728	chr8:95962352	TP53INP1	-0.44	-4.5	-0.42	1.89e-5	Type 2 diabetes;
THYM	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg07022442	chr13:21864356	NA	0.72	4.78	0.44	6.49e-6	White matter hyperintensity burden;
THYM	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg19875535	chr5:140030758	IK	0.58	4.46	0.42	2.21e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs36051895	0.664	rs62543877	chr9:5093465	C/A	cg02405213	chr9:5042618	JAK2	-1.0	-10.94	-0.75	1.67e-18	Pediatric autoimmune diseases;
THYM	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.68	-4.99	-0.46	2.68e-6	Colorectal cancer;
THYM	cis	rs9810089	0.967	rs10935177	chr3:135851077	G/T	cg21827317	chr3:136751795	NA	-0.57	-4.92	-0.45	3.61e-6	Gestational age at birth (child effect);
THYM	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	4.96	0.45	3.05e-6	Motion sickness;
THYM	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	4.86	0.45	4.63e-6	Hip circumference adjusted for BMI;
THYM	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg24733560	chr20:60626293	TAF4	0.62	6.64	0.56	1.96e-9	Body mass index;
THYM	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg23958373	chr8:599963	NA	0.89	4.57	0.42	1.44e-5	IgG glycosylation;
THYM	cis	rs4664308	0.935	rs6731260	chr2:160977769	A/G	cg03641300	chr2:160917029	PLA2R1	-0.75	-6.87	-0.58	6.63e-10	Idiopathic membranous nephropathy;
THYM	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg08439880	chr3:133502540	NA	-0.72	-6.18	-0.54	1.59e-8	Iron status biomarkers;
THYM	cis	rs1160297	0.576	rs13002328	chr2:53085447	A/C	cg07782112	chr2:53107842	NA	0.76	6.36	0.55	6.99e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg22709100	chr7:91322751	NA	-0.62	-4.96	-0.45	3.05e-6	Breast cancer;
THYM	cis	rs11771526	0.892	rs11764802	chr7:32372978	C/T	cg27532318	chr7:32358331	NA	0.95	5.63	0.5	1.85e-7	Body mass index;
THYM	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg09704166	chr2:114031854	PAX8;LOC440839	0.68	5.91	0.52	5.35e-8	Lymphocyte counts;
THYM	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg24578937	chr1:2090814	PRKCZ	-0.56	-5.65	-0.5	1.67e-7	Height;
THYM	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg03433033	chr1:76189801	ACADM	-0.64	-5.88	-0.52	6.11e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg08017756	chr2:100939284	LONRF2	-0.76	-7.58	-0.61	2.25e-11	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg00852783	chr1:26633632	UBXN11	0.85	8.72	0.67	9.13e-14	Obesity-related traits;
THYM	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg04944784	chr2:26401820	FAM59B	-0.79	-6.18	-0.54	1.61e-8	Gut microbiome composition (summer);
THYM	cis	rs7804356	0.871	rs212848	chr7:26722155	G/T	cg24979288	chr7:27242424	NA	0.64	4.57	0.42	1.49e-5	Type 1 diabetes;
THYM	cis	rs754466	0.580	rs11002289	chr10:79532580	G/A	cg17075019	chr10:79541650	NA	-0.69	-5.73	-0.51	1.17e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg24531977	chr5:56204891	C5orf35	0.73	5.94	0.52	4.7e-8	Initial pursuit acceleration;
THYM	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg14972814	chr11:95582409	MTMR2	-0.72	-6.7	-0.57	1.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2915864	1.000	rs2906070	chr5:141579597	A/G	cg00542992	chr5:141595654	NA	0.62	4.65	0.43	1.06e-5	Facial morphology (factor 20);
THYM	cis	rs1448094	0.512	rs1900701	chr12:86236231	T/C	cg00310523	chr12:86230176	RASSF9	0.53	4.84	0.44	5.02e-6	Major depressive disorder;
THYM	cis	rs2299587	0.560	rs11987695	chr8:17781085	A/G	cg01800426	chr8:17659068	MTUS1	-0.7	-5.44	-0.49	4.11e-7	Economic and political preferences;
THYM	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg24874828	chr4:187887005	NA	-0.72	-7.22	-0.6	1.26e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6840360	0.571	rs7692700	chr4:152552797	C/T	cg17479576	chr4:152424074	FAM160A1	-0.83	-5.86	-0.52	6.62e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.04	8.6	0.66	1.64e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6430585	0.702	rs2304601	chr2:136528034	C/A	cg23851026	chr2:136556271	LCT	0.79	7.53	0.61	2.86e-11	Corneal structure;
THYM	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg01616529	chr11:638424	DRD4	-0.74	-5.68	-0.5	1.45e-7	Systemic lupus erythematosus;
THYM	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg16325326	chr1:53192061	ZYG11B	-0.75	-6.06	-0.53	2.72e-8	Monocyte count;
THYM	cis	rs6163	0.588	rs3818708	chr10:104503584	C/T	cg05855489	chr10:104503620	C10orf26	0.85	8.19	0.64	1.2e-12	Waist circumference;Hip circumference;
THYM	cis	rs7927771	0.524	rs10838739	chr11:47672743	A/G	cg18512352	chr11:47633146	NA	-0.41	-4.59	-0.43	1.34e-5	Subjective well-being;
THYM	cis	rs8028313	0.630	rs12438118	chr15:67951150	A/C	cg24579218	chr15:68104479	NA	0.7	6.35	0.55	7.47e-9	Obesity;
THYM	cis	rs79387448	0.745	rs17027496	chr2:103178223	T/A	cg09003973	chr2:102972529	NA	0.75	4.67	0.43	9.99e-6	Gut microbiota (bacterial taxa);
THYM	trans	rs3960554	0.610	rs11971800	chr7:75731608	C/T	cg19862616	chr7:65841803	NCRNA00174	0.97	7.23	0.6	1.21e-10	Eotaxin levels;
THYM	cis	rs12291225	0.679	rs4756786	chr11:14285900	C/A	cg19336497	chr11:14380999	RRAS2	-0.82	-9.58	-0.7	1.34e-15	Sense of smell;
THYM	cis	rs10887741	0.690	rs10509410	chr10:89440001	C/T	cg13926569	chr10:89418898	PAPSS2	0.61	6.54	0.56	3.07e-9	Exercise (leisure time);
THYM	cis	rs2073300	1.000	rs6114138	chr20:23457350	G/A	cg12062639	chr20:23401060	NAPB	0.99	4.96	0.45	3.07e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg09307838	chr4:120376055	NA	0.77	5.56	0.5	2.5e-7	Corneal astigmatism;
THYM	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg23583168	chr7:148888333	NA	-0.93	-9.97	-0.71	1.95e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.32	0.54	8.42e-9	Platelet count;
THYM	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg12011299	chr4:100065546	ADH4	0.75	7.3	0.6	8.58e-11	Alcohol dependence;
THYM	cis	rs8133932	0.701	rs3788228	chr21:47307669	G/A	cg20357416	chr21:47294739	PCBP3	-0.88	-5.7	-0.5	1.37e-7	Schizophrenia;
THYM	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg25036284	chr2:26402008	FAM59B	-0.77	-5.25	-0.47	9.37e-7	Gut microbiome composition (summer);
THYM	cis	rs6032067	0.925	rs62208424	chr20:43813341	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs4849845	0.889	rs4564775	chr2:121044454	T/C	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg26967526	chr14:35346199	BAZ1A	-0.81	-5.34	-0.48	6.45e-7	Psoriasis;
THYM	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg04362960	chr10:104952993	NT5C2	-0.6	-4.99	-0.46	2.7e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7246967	0.673	rs55684269	chr19:22924547	C/T	cg05241461	chr19:22816980	ZNF492	0.59	4.61	0.43	1.26e-5	Bronchopulmonary dysplasia;
THYM	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg26038318	chr20:34205095	SPAG4	0.59	4.68	0.43	9.62e-6	Total cholesterol levels;
THYM	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.62	8.68	0.67	1.09e-13	Monocyte percentage of white cells;
THYM	cis	rs7216064	1.000	rs9912084	chr17:65868035	A/C	cg12091567	chr17:66097778	LOC651250	-0.71	-4.76	-0.44	6.86e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs8114671	0.585	rs2236271	chr20:33523840	G/T	cg08999081	chr20:33150536	PIGU	-0.65	-5.42	-0.49	4.5e-7	Height;
THYM	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	6.05	0.53	2.89e-8	Obesity-related traits;
THYM	cis	rs3204270	0.759	rs62075725	chr17:79611510	A/G	cg18367735	chr17:79674897	NA	0.8	4.8	0.44	5.82e-6	Dental caries;
THYM	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg12963246	chr6:28129442	ZNF389	0.72	6.2	0.54	1.44e-8	Depression;
THYM	cis	rs7818345	0.569	rs4484715	chr8:19358296	T/G	cg01280390	chr8:19363452	CSGALNACT1	0.64	5.5	0.49	3.21e-7	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs5022636	0.507	rs2031797	chr1:151278505	A/G	cg17724175	chr1:150552817	MCL1	-0.39	-4.46	-0.42	2.28e-5	Gut microbiota (functional units);
THYM	cis	rs11671005	0.735	rs45617039	chr19:58951096	G/A	cg18639983	chr19:58920768	ZNF584	0.59	4.82	0.44	5.48e-6	Mean platelet volume;
THYM	cis	rs56079296	0.929	rs7715363	chr5:121283915	G/C	cg05256605	chr5:121412184	LOX	-0.61	-4.69	-0.43	9.18e-6	Coronary artery disease;
THYM	cis	rs4909189	1.000	rs11764065	chr7:158135974	T/C	cg15736062	chr7:158136485	PTPRN2	-0.63	-5.03	-0.46	2.34e-6	Response to amphetamines;
THYM	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.22	-0.47	1.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg15556689	chr8:8085844	FLJ10661	0.6	4.67	0.43	9.96e-6	Mood instability;
THYM	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg08807101	chr21:30365312	RNF160	0.72	5.52	0.49	2.99e-7	Dental caries;
THYM	cis	rs988913	1.000	rs6902245	chr6:54813006	C/A	cg04690482	chr6:54711388	FAM83B	0.48	5.36	0.48	5.77e-7	Menarche (age at onset);
THYM	cis	rs67311347	0.635	rs62261855	chr3:40294938	C/T	cg13683864	chr3:40499215	RPL14	-0.7	-6.2	-0.54	1.44e-8	Renal cell carcinoma;
THYM	cis	rs9926296	0.715	rs648548	chr16:89749436	C/G	cg01097406	chr16:89675127	NA	0.87	7.75	0.62	1.01e-11	Vitiligo;
THYM	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg12379764	chr21:47803548	PCNT	-0.83	-5.37	-0.48	5.52e-7	Testicular germ cell tumor;
THYM	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg01448562	chr3:133502909	NA	-0.84	-7.17	-0.59	1.59e-10	Iron status biomarkers;
THYM	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-5.12	-0.47	1.59e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg08885076	chr2:99613938	TSGA10	-0.61	-5.79	-0.51	9.26e-8	Chronic sinus infection;
THYM	cis	rs12282928	0.959	rs10769331	chr11:48249779	G/A	cg22827986	chr11:48284249	OR4X1	-0.52	-5.22	-0.47	1.06e-6	Migraine - clinic-based;
THYM	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg13393036	chr8:95962371	TP53INP1	-0.46	-4.63	-0.43	1.18e-5	Type 2 diabetes;
THYM	cis	rs2455826	0.500	rs2455852	chr3:15688688	C/T	cg13420985	chr3:16524424	RFTN1	0.47	5.0	0.46	2.64e-6	Inflammatory skin disease;
THYM	cis	rs10208940	0.614	rs10205865	chr2:68829676	A/G	cg09157127	chr2:69201416	GKN1	0.93	4.78	0.44	6.3e-6	Urate levels in lean individuals;
THYM	cis	rs1395	0.778	rs4665960	chr2:27467598	C/T	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.52	-0.49	2.95e-7	Blood metabolite levels;
THYM	cis	rs2777491	1.000	rs7168177	chr15:41715585	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.13	-12.73	-0.79	3.01e-22	Ulcerative colitis;
THYM	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11890956	chr21:40555474	PSMG1	-0.66	-6.44	-0.55	4.92e-9	Menarche (age at onset);
THYM	cis	rs6939532	0.522	rs9366652	chr6:26354219	C/G	cg14345882	chr6:26364793	BTN3A2	0.4	5.17	0.47	1.29e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg09035930	chr12:129282057	SLC15A4	0.85	10.29	0.73	3.94e-17	Systemic lupus erythematosus;
THYM	cis	rs16857609	0.564	rs1478581	chr2:218292652	C/T	cg15335768	chr2:218268053	DIRC3	-0.52	-7.45	-0.61	4.22e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	cis	rs9403317	0.600	rs9399375	chr6:141920702	A/T	cg15052665	chr6:141804349	NA	0.76	5.75	0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4523957	0.690	rs28505924	chr17:2088838	G/C	cg16513277	chr17:2031491	SMG6	-0.94	-8.81	-0.67	5.81e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-5.33	-0.48	6.7e-7	Hemoglobin concentration;
THYM	cis	rs17253792	0.822	rs45501402	chr14:56140115	C/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs2658782	0.901	rs2605611	chr11:93229319	T/G	cg15737290	chr11:93063684	CCDC67	1.05	7.36	0.6	6.42e-11	Pulmonary function decline;
THYM	cis	rs9527	0.830	rs10883790	chr10:104640955	A/C	cg15744005	chr10:104629667	AS3MT	-0.66	-4.82	-0.44	5.36e-6	Arsenic metabolism;
THYM	cis	rs7953249	0.564	rs1183910	chr12:121420807	G/A	cg14101638	chr12:121416612	HNF1A	0.5	5.1	0.46	1.76e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs6987853	0.787	rs2974351	chr8:42407047	A/T	cg09913449	chr8:42400586	C8orf40	1.1	12.33	0.78	1.96e-21	Mean corpuscular hemoglobin concentration;
THYM	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs4077515	0.839	rs10781518	chr9:139300547	C/T	cg14115884	chr9:139300582	SDCCAG3	-0.77	-8.37	-0.65	5.07e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg08645402	chr16:4508243	NA	0.71	6.45	0.55	4.69e-9	Schizophrenia;
THYM	cis	rs9563576	0.778	rs17054511	chr13:58499890	A/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	-0.62	-4.51	-0.42	1.84e-5	Body mass index;
THYM	cis	rs9876781	1.000	rs9812647	chr3:48448914	C/G	cg06066452	chr3:48470258	PLXNB1	-0.26	-4.64	-0.43	1.1e-5	Longevity;
THYM	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg19077165	chr18:44547161	KATNAL2	0.5	5.98	0.52	3.95e-8	Personality dimensions;
THYM	cis	rs1385374	1.000	rs1385374	chr12:129300694	C/T	cg04043695	chr12:129287642	SLC15A4	-0.8	-4.83	-0.44	5.3e-6	Systemic lupus erythematosus;
THYM	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-5.12	-0.47	1.59e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.68	6.04	0.53	2.94e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs28595532	0.920	rs116428408	chr4:119758514	G/C	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs6918586	0.658	rs198837	chr6:26113398	A/T	cg03264133	chr6:25882463	NA	-0.6	-4.58	-0.42	1.43e-5	Schizophrenia;
THYM	cis	rs7131987	0.650	rs10843382	chr12:29451721	G/A	cg09582351	chr12:29534625	ERGIC2	-0.53	-4.68	-0.43	9.37e-6	QT interval;
THYM	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs961764	1.000	rs961764	chr6:117522156	C/G	cg13016975	chr6:117150798	GPRC6A	0.37	4.45	0.42	2.33e-5	Height;
THYM	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg21773646	chr17:80085082	CCDC57	0.34	4.75	0.44	7.12e-6	Life satisfaction;
THYM	cis	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg21775007	chr8:11205619	TDH	-0.64	-5.05	-0.46	2.09e-6	Retinal vascular caliber;
THYM	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg13609457	chr4:120235615	NA	-0.59	-5.34	-0.48	6.31e-7	Corneal astigmatism;
THYM	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg12011299	chr4:100065546	ADH4	0.86	8.22	0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg26384229	chr12:38710491	ALG10B	1.02	8.22	0.64	1.05e-12	Bladder cancer;
THYM	cis	rs1065852	0.526	rs2097562	chr22:42389500	T/C	cg01059385	chr22:42394853	WBP2NL	0.57	4.66	0.43	1.04e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs4986811	1.000	rs11031779	chr11:32452888	C/T	cg13301003	chr11:32449254	WT1	0.64	4.91	0.45	3.72e-6	Rubella-specific interleukin-6 secretion;
THYM	cis	rs1847202	0.859	rs13090900	chr3:72946560	C/A	cg25664220	chr3:72788482	NA	-0.65	-4.85	-0.45	4.9e-6	Motion sickness;
THYM	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	7.12	0.59	2.09e-10	Cognitive test performance;
THYM	cis	rs7631605	0.905	rs9823617	chr3:37199350	A/T	cg21328643	chr3:37258149	NA	-0.54	-5.42	-0.49	4.46e-7	Cerebrospinal P-tau181p levels;
THYM	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23221052	chr5:179740743	GFPT2	0.88	7.06	0.59	2.74e-10	Height;
THYM	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg13147721	chr7:65941812	NA	0.73	4.58	0.43	1.42e-5	Diabetic kidney disease;
THYM	cis	rs854765	0.551	rs12600546	chr17:17867614	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.62	0.56	2.11e-9	Total body bone mineral density;
THYM	cis	rs34638657	0.646	rs72628279	chr16:82199664	A/C	cg07307142	chr16:82071433	HSD17B2	-0.86	-7.43	-0.61	4.69e-11	Lung adenocarcinoma;
THYM	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg01699819	chr7:1052092	C7orf50	-0.59	-4.95	-0.45	3.16e-6	Bronchopulmonary dysplasia;
THYM	cis	rs7568458	0.811	rs10175792	chr2:85761654	A/G	cg17127132	chr2:85788382	GGCX	0.72	6.21	0.54	1.42e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg12756686	chr19:29218302	NA	0.95	7.63	0.62	1.82e-11	Methadone dose in opioid dependence;
THYM	cis	rs10788972	0.586	rs13373789	chr1:54581869	A/G	cg13191808	chr1:55505327	PCSK9	0.51	4.52	0.42	1.8e-5	Parkinson disease and lewy body pathology;
THYM	cis	rs9457247	0.534	rs12055488	chr6:167379570	A/G	cg15592062	chr6:167189543	RPS6KA2	0.51	5.27	0.48	8.58e-7	Crohn's disease;
THYM	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.83	-5.25	-0.47	9.38e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs34638657	0.702	rs12599946	chr16:82199831	T/C	cg09439754	chr16:82129088	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.69	6.03	0.53	3.17e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17708984	0.606	rs3826723	chr19:16190802	G/A	cg13618979	chr19:16186840	TPM4	0.36	4.78	0.44	6.39e-6	Platelet count;Platelet distribution width;
THYM	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	-0.7	-6.1	-0.53	2.31e-8	Lymphocyte counts;
THYM	cis	rs8050907	0.744	rs78538387	chr16:4523167	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.3	5.2	0.47	1.16e-6	Obesity-related traits;
THYM	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg19507638	chr5:93509721	C5orf36	-0.67	-4.5	-0.42	1.95e-5	Diabetic retinopathy;
THYM	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg22841779	chr14:105766346	BRF1	-0.48	-6.0	-0.52	3.55e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs8077889	1.000	rs17675122	chr17:41886190	A/G	cg26893861	chr17:41843967	DUSP3	1.09	10.05	0.72	1.3e-16	Triglycerides;
THYM	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg25208724	chr1:156163844	SLC25A44	1.07	8.09	0.64	1.97e-12	Testicular germ cell tumor;
THYM	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06481639	chr22:41940642	POLR3H	-0.74	-5.03	-0.46	2.34e-6	Vitiligo;
THYM	cis	rs12444261	1.000	rs8063949	chr16:11736835	C/T	cg09662852	chr16:11707685	NA	-0.49	-4.63	-0.43	1.14e-5	QT interval;
THYM	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-5.13	-0.47	1.5e-6	Gut microbiome composition (summer);
THYM	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg08000102	chr2:233561755	GIGYF2	0.69	6.09	0.53	2.35e-8	Coronary artery disease;
THYM	cis	rs924712	0.844	rs931766	chr6:54726869	C/T	cg04690482	chr6:54711388	FAM83B	-0.45	-4.96	-0.45	3.09e-6	Breast cancer;
THYM	cis	rs9915657	1.000	rs9915657	chr17:70127536	T/C	cg09344028	chr17:70110421	NA	0.46	4.58	0.43	1.43e-5	Thyroid hormone levels;
THYM	cis	rs61931739	0.929	rs10844730	chr12:34026721	C/G	cg10856724	chr12:34555212	NA	0.61	5.31	0.48	7.28e-7	Morning vs. evening chronotype;
THYM	cis	rs2072510	0.569	rs7134975	chr12:96390420	C/A	cg18817487	chr12:96390143	HAL	0.47	5.71	0.51	1.31e-7	Metabolite levels (small molecules and protein measures);
THYM	cis	rs7084402	0.967	rs10826198	chr10:60274182	C/T	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs6754311	0.550	rs3213889	chr2:136511575	A/G	cg20242066	chr2:136595261	LCT	-0.57	-6.93	-0.58	4.9e-10	Mosquito bite size;
THYM	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg05373962	chr22:49881684	NA	-0.6	-5.52	-0.49	2.95e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg06850241	chr22:41845214	NA	0.53	4.45	0.42	2.34e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs9527	0.590	rs34104646	chr10:104896078	T/A	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs2073300	1.000	rs6137976	chr20:23463241	C/T	cg12062639	chr20:23401060	NAPB	1.32	6.2	0.54	1.42e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6838801	0.823	rs13139112	chr4:77584089	G/A	cg01477861	chr4:77609841	SHROOM3	0.47	4.68	0.43	9.56e-6	Cleft lip with or without cleft palate;
THYM	cis	rs5769707	0.616	rs6009786	chr22:50015145	A/G	cg07959070	chr22:50026188	C22orf34	-0.28	-4.88	-0.45	4.19e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.62	0.43	1.23e-5	Obesity-related traits;
THYM	trans	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg19862616	chr7:65841803	NCRNA00174	1.12	13.73	0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg04398451	chr17:18023971	MYO15A	-0.78	-7.09	-0.59	2.35e-10	Total body bone mineral density;
THYM	cis	rs1448094	0.533	rs7955135	chr12:86146350	G/A	cg00310523	chr12:86230176	RASSF9	-0.57	-5.07	-0.46	1.98e-6	Major depressive disorder;
THYM	cis	rs3087591	0.960	rs2269855	chr17:29482878	G/A	cg24425628	chr17:29625626	OMG;NF1	0.66	5.79	0.51	9.11e-8	Hip circumference;
THYM	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg00074818	chr8:8560427	CLDN23	0.61	5.63	0.5	1.86e-7	Obesity-related traits;
THYM	cis	rs1050631	0.564	rs559289	chr18:33752890	A/C	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.63	4.86	0.45	4.56e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs1005224	0.889	rs10132250	chr14:76124380	C/A	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.68	-5.5	-0.49	3.26e-7	Large artery stroke;
THYM	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg26384229	chr12:38710491	ALG10B	-0.91	-7.45	-0.61	4.34e-11	Bladder cancer;
THYM	cis	rs8180040	0.800	rs6768221	chr3:47296899	C/G	cg27129171	chr3:47204927	SETD2	-0.75	-7.08	-0.59	2.48e-10	Colorectal cancer;
THYM	cis	rs9534288	0.843	rs2094245	chr13:46602207	T/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs300703	0.935	rs300749	chr2:208143	G/T	cg21211680	chr2:198530	NA	1.1	5.76	0.51	1.05e-7	Blood protein levels;
THYM	cis	rs1499972	0.941	rs62266064	chr3:117546871	T/C	cg07612923	chr3:117604196	NA	1.39	5.65	0.5	1.7e-7	Schizophrenia;
THYM	cis	rs4690686	0.500	rs7667671	chr4:177275599	T/C	cg17059388	chr4:177262070	NA	0.49	6.87	0.58	6.62e-10	Essential tremor;
THYM	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg06074448	chr4:187884817	NA	-1.02	-13.05	-0.8	6.55e-23	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4523957	0.855	rs12603057	chr17:2112567	T/C	cg16513277	chr17:2031491	SMG6	-0.79	-7.76	-0.62	9.62e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2976388	1.000	rs2920295	chr8:143764937	A/G	cg06565975	chr8:143823917	SLURP1	-0.45	-5.16	-0.47	1.38e-6	Urinary tract infection frequency;
THYM	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg24803719	chr17:45855879	NA	0.6	6.26	0.54	1.08e-8	IgG glycosylation;
THYM	cis	rs6754311	0.551	rs9287442	chr2:136522710	A/G	cg20242066	chr2:136595261	LCT	-0.56	-6.86	-0.58	7.1e-10	Mosquito bite size;
THYM	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg09323728	chr8:95962352	TP53INP1	-0.45	-4.48	-0.42	2.12e-5	Type 2 diabetes;
THYM	cis	rs2046867	0.818	rs62249874	chr3:72911202	G/C	cg25664220	chr3:72788482	NA	-0.89	-7.11	-0.59	2.15e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs887829	0.570	rs13015720	chr2:234600999	G/A	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.54	-4.57	-0.42	1.45e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs155076	1.000	rs2783107	chr13:21837532	C/A	cg11317459	chr13:21872234	NA	-1.2	-8.92	-0.68	3.4e-14	White matter hyperintensity burden;
THYM	cis	rs9467603	0.920	rs34493019	chr6:25714959	A/G	cg16898833	chr6:26189333	HIST1H4D	1.33	4.6	0.43	1.32e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg05234568	chr11:5960015	NA	-0.62	-4.98	-0.46	2.81e-6	DNA methylation (variation);
THYM	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg23205692	chr1:25664452	TMEM50A	-0.83	-6.37	-0.55	6.66e-9	Erythrocyte sedimentation rate;
THYM	cis	rs28595532	0.920	rs56322132	chr4:119742496	T/A	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg14327541	chr9:86597173	RMI1	-0.89	-6.85	-0.57	7.18e-10	Depressive symptoms;
THYM	cis	rs4474465	1.000	rs57042969	chr11:78160120	C/T	cg19901956	chr11:77921274	USP35	-0.61	-4.52	-0.42	1.76e-5	Alzheimer's disease (survival time);
THYM	cis	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg19677267	chr1:26645161	CD52;UBXN11	0.49	4.49	0.42	2.04e-5	Obesity-related traits;
THYM	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg22875332	chr1:76189707	ACADM	0.81	7.35	0.6	6.8e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6438424	0.905	rs13090448	chr3:117574367	T/C	cg07190778	chr3:117604296	NA	-0.4	-5.61	-0.5	2e-7	Menarche (age at onset);
THYM	trans	rs4866334	0.557	rs116250256	chr5:18457657	A/T	cg08675002	chr5:90437527	GPR98	-1.55	-7.42	-0.61	4.85e-11	IgG glycosylation;
THYM	cis	rs9517302	0.512	rs9517305	chr13:99097910	G/C	cg22223119	chr13:99095684	FARP1	-0.96	-6.78	-0.57	9.9e-10	Obesity-related traits;
THYM	cis	rs7011507	0.700	rs72639005	chr8:49321961	T/C	cg08774009	chr8:49309094	NA	-0.62	-4.83	-0.44	5.19e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg13395646	chr4:1353034	KIAA1530	-0.61	-5.23	-0.47	1.02e-6	Obesity-related traits;
THYM	cis	rs7818345	0.640	rs13267801	chr8:19326834	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.63	5.45	0.49	3.88e-7	Language performance in older adults (adjusted for episodic memory);
THYM	trans	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs3820068	0.603	rs6695903	chr1:15985940	C/T	cg24675056	chr1:15929824	NA	0.76	6.25	0.54	1.14e-8	Systolic blood pressure;
THYM	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg23711669	chr6:146136114	FBXO30	0.98	10.58	0.74	9.59e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4343996	0.558	rs11771359	chr7:3412515	C/T	cg21248987	chr7:3385318	SDK1	0.4	4.94	0.45	3.32e-6	Motion sickness;
THYM	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg02487422	chr3:49467188	NICN1	0.63	4.82	0.44	5.48e-6	Resting heart rate;
THYM	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03264133	chr6:25882463	NA	-0.69	-5.32	-0.48	7.03e-7	Blood metabolite levels;
THYM	cis	rs10463554	0.963	rs34773	chr5:102450576	C/G	cg23492399	chr5:102201601	PAM	-0.7	-5.11	-0.46	1.69e-6	Parkinson's disease;
THYM	cis	rs10463554	1.000	rs17154893	chr5:102316606	G/A	cg23492399	chr5:102201601	PAM	-0.63	-4.94	-0.45	3.36e-6	Parkinson's disease;
THYM	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg06238570	chr21:40685208	BRWD1	0.84	5.79	0.51	9.09e-8	Cognitive function;
THYM	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg23682913	chr1:2080710	PRKCZ	0.6	4.83	0.44	5.13e-6	Height;
THYM	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11141652	chr22:24348549	GSTTP1	0.67	6.54	0.56	3.08e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9399401	0.816	rs9496392	chr6:142799327	T/G	cg04461802	chr6:142623433	GPR126	0.45	4.55	0.42	1.57e-5	Chronic obstructive pulmonary disease;
THYM	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg04398451	chr17:18023971	MYO15A	-0.92	-9.33	-0.69	4.39e-15	Total body bone mineral density;
THYM	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.75	5.92	0.52	5.12e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg13609457	chr4:120235615	NA	0.59	5.22	0.47	1.04e-6	Corneal astigmatism;
THYM	cis	rs57590327	0.555	rs3772909	chr3:81707264	T/C	cg07356753	chr3:81810745	GBE1	-0.83	-5.87	-0.52	6.26e-8	Extraversion;
THYM	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11890956	chr21:40555474	PSMG1	0.68	5.44	0.49	4.16e-7	Cognitive function;
THYM	cis	rs11048434	0.761	rs1805721	chr12:9147569	A/G	cg14913610	chr12:9142341	KLRG1	0.29	4.48	0.42	2.11e-5	Sjögren's syndrome;
THYM	cis	rs2046867	0.628	rs7356054	chr3:72912727	A/G	cg25664220	chr3:72788482	NA	-0.76	-6.37	-0.55	6.8e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs6732160	0.809	rs13387480	chr2:73371007	C/T	cg24220031	chr2:73402428	NA	-0.78	-8.4	-0.65	4.37e-13	Intelligence (multi-trait analysis);
THYM	cis	rs11690935	0.959	rs10207085	chr2:172585885	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.88	-6.5	-0.55	3.76e-9	Schizophrenia;
THYM	cis	rs7107174	0.892	rs10431155	chr11:78121978	T/C	cg19901956	chr11:77921274	USP35	-0.68	-5.45	-0.49	3.93e-7	Testicular germ cell tumor;
THYM	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs72627123	0.867	rs74635757	chr14:74489225	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.86	4.91	0.45	3.77e-6	Morning vs. evening chronotype;
THYM	cis	rs12765878	0.564	rs2073338	chr10:105642803	A/C	cg04688330	chr10:105451802	SH3PXD2A	0.4	4.97	0.45	2.92e-6	Coronary artery disease;
THYM	cis	rs28595532	0.920	rs115242199	chr4:119728652	A/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs293526	0.879	rs2783159	chr6:83634061	A/G	cg23278060	chr6:83777448	DOPEY1	0.61	4.49	0.42	2.02e-5	Crohn's disease;
THYM	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg11764359	chr7:65958608	NA	-0.74	-6.15	-0.53	1.85e-8	Aortic root size;
THYM	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg05313129	chr8:58192883	C8orf71	-0.75	-4.59	-0.43	1.34e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg02734326	chr4:10020555	SLC2A9	0.67	5.9	0.52	5.48e-8	Bone mineral density;
THYM	cis	rs4664308	0.870	rs2305818	chr2:161029218	G/A	cg03641300	chr2:160917029	PLA2R1	-0.74	-6.54	-0.56	3.03e-9	Idiopathic membranous nephropathy;
THYM	cis	rs7927771	0.524	rs754434	chr11:47814280	A/G	cg20307385	chr11:47447363	PSMC3	0.58	4.48	0.42	2.04e-5	Subjective well-being;
THYM	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg23711669	chr6:146136114	FBXO30	0.92	9.4	0.69	3.17e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	9.76	0.71	5.3e-16	Platelet count;
THYM	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs3916	0.794	rs3021337	chr12:121163261	C/T	cg10600917	chr12:121163489	ACADS	0.61	5.65	0.5	1.69e-7	Urinary metabolites (H-NMR features);
THYM	cis	rs3017493	0.685	rs78711146	chr11:70671687	G/A	cg21202716	chr11:70508022	SHANK2	1.01	4.89	0.45	4.05e-6	Renal transplant outcome;
THYM	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg23758822	chr17:41437982	NA	1.23	12.08	0.78	6.67e-21	Menopause (age at onset);
THYM	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg23422044	chr7:1970798	MAD1L1	-0.79	-5.24	-0.47	9.83e-7	Neuroticism;
THYM	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.55	0.42	1.57e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4474465	0.850	rs10793332	chr11:78270020	C/G	cg19901956	chr11:77921274	USP35	0.65	4.71	0.44	8.39e-6	Alzheimer's disease (survival time);
THYM	cis	rs2456568	0.802	rs10765640	chr11:93636462	C/T	cg17595323	chr11:93583763	C11orf90	-0.58	-6.09	-0.53	2.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs11563648	0.573	rs10270756	chr7:126948658	C/T	cg23081781	chr7:127225937	GCC1	0.35	4.79	0.44	6.03e-6	Resting heart rate;
THYM	cis	rs9581857	0.579	rs9581846	chr13:27987953	A/G	cg22138327	chr13:27999177	GTF3A	1.04	6.13	0.53	1.97e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg24531977	chr5:56204891	C5orf35	-0.98	-8.21	-0.64	1.08e-12	Initial pursuit acceleration;
THYM	cis	rs9296092	0.500	rs35150558	chr6:33519612	T/A	cg13560919	chr6:33536144	NA	-0.93	-8.89	-0.67	3.9e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs4523957	0.928	rs170045	chr17:2196905	A/G	cg16513277	chr17:2031491	SMG6	0.79	7.37	0.6	6.32e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs13256369	0.760	rs7816171	chr8:8575835	T/C	cg17143192	chr8:8559678	CLDN23	0.91	6.72	0.57	1.33e-9	Obesity-related traits;
THYM	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg25767906	chr1:53392781	SCP2	-0.47	-4.65	-0.43	1.06e-5	Monocyte count;
THYM	cis	rs7762018	0.607	rs78941587	chr6:170061157	G/C	cg19338460	chr6:170058176	WDR27	-1.04	-6.21	-0.54	1.42e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs6430585	0.528	rs3099429	chr2:136655582	T/A	cg07169764	chr2:136633963	MCM6	0.95	8.57	0.66	1.89e-13	Corneal structure;
THYM	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg14829155	chr15:31115871	NA	-0.57	-4.99	-0.46	2.76e-6	Huntington's disease progression;
THYM	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.68	-4.46	-0.42	2.22e-5	Menarche (age at onset);
THYM	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg05738196	chr6:26577821	NA	0.84	8.48	0.66	2.87e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg11764359	chr7:65958608	NA	0.62	4.73	0.44	7.94e-6	Aortic root size;
THYM	cis	rs11031096	0.589	rs935130	chr11:4213530	A/G	cg08557956	chr11:4115526	RRM1	-0.55	-4.71	-0.43	8.56e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg02569458	chr12:86230093	RASSF9	-0.66	-5.63	-0.5	1.84e-7	Major depressive disorder;
THYM	cis	rs10979	1.000	rs12211659	chr6:143898348	G/T	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs7220711	0.934	rs1983490	chr17:41782957	C/T	cg26893861	chr17:41843967	DUSP3	0.6	5.14	0.47	1.49e-6	Bone mineral density (spine);Bone mineral density (hip);
THYM	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg27490568	chr2:178487706	NA	0.61	5.6	0.5	2.12e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9970807	0.748	rs1815487	chr1:56939358	C/G	cg11959316	chr1:57001742	PPAP2B	-0.63	-4.82	-0.44	5.34e-6	Myocardial infarction;Coronary artery disease;
THYM	cis	rs11247915	0.600	rs72649360	chr1:26662904	C/T	cg00852783	chr1:26633632	UBXN11	0.73	5.98	0.52	3.97e-8	Obesity-related traits;
THYM	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.56	-0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs78761021	0.755	rs17743980	chr17:9793839	G/A	cg26853458	chr17:9805074	RCVRN	0.54	4.51	0.42	1.86e-5	Type 2 diabetes;
THYM	cis	rs10899021	0.920	rs12287097	chr11:74332664	A/G	cg25880958	chr11:74394337	NA	-0.77	-4.66	-0.43	1.04e-5	Response to metformin (IC50);
THYM	cis	rs4866334	1.000	rs114400023	chr5:18432893	T/C	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs73787773	0.629	rs6594564	chr5:111467814	C/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	0.9	4.87	0.45	4.48e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06850241	chr22:41845214	NA	0.57	5.09	0.46	1.82e-6	Vitiligo;
THYM	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7677751	0.767	rs6846502	chr4:55062090	T/C	cg17187183	chr4:55093834	PDGFRA	0.66	5.14	0.47	1.45e-6	Corneal astigmatism;
THYM	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg17178900	chr1:205818956	PM20D1	0.85	7.91	0.63	4.62e-12	Monocyte percentage of white cells;
THYM	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg05738196	chr6:26577821	NA	0.76	6.45	0.55	4.59e-9	Intelligence (multi-trait analysis);
THYM	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14893161	chr1:205819251	PM20D1	0.97	10.8	0.74	3.3e-18	Menarche (age at onset);
THYM	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg17554472	chr22:41940697	POLR3H	0.67	4.73	0.44	7.66e-6	Vitiligo;
THYM	cis	rs2067615	0.579	rs10861665	chr12:107193836	T/C	cg15890332	chr12:107067104	RFX4	0.48	5.63	0.5	1.81e-7	Heart rate;
THYM	trans	rs4650994	0.544	rs11579513	chr1:178496092	T/C	cg05059571	chr16:84539110	KIAA1609	-0.84	-9.68	-0.7	7.86e-16	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg14416269	chr4:6271139	WFS1	0.54	5.62	0.5	1.93e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs6840360	0.571	rs11932059	chr4:152524496	G/A	cg17479576	chr4:152424074	FAM160A1	-0.8	-5.65	-0.5	1.68e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4687717	0.717	rs13059189	chr3:53288475	G/A	cg16894138	chr3:53270350	TKT	0.84	6.21	0.54	1.38e-8	Blood metabolite levels;Blood metabolite ratios;
THYM	cis	rs10504073	0.647	rs4873098	chr8:50021041	T/C	cg00325661	chr8:49890786	NA	0.86	7.69	0.62	1.35e-11	Blood metabolite ratios;
THYM	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg04731861	chr2:219085781	ARPC2	-0.54	-5.0	-0.46	2.57e-6	Colorectal cancer;
THYM	cis	rs4845459	0.967	rs6701307	chr1:152590444	G/A	cg27206522	chr1:152595629	LCE3A	-0.51	-4.54	-0.42	1.66e-5	Psoriasis;
THYM	cis	rs7107174	1.000	rs72931690	chr11:78073192	G/A	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	ch.11.42038R	chr11:967971	AP2A2	0.59	4.73	0.44	7.79e-6	Alzheimer's disease (late onset);
THYM	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg16405210	chr4:1374714	KIAA1530	-0.61	-4.92	-0.45	3.65e-6	Longevity;
THYM	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg11335335	chr11:637885	DRD4	-0.66	-5.06	-0.46	2.02e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs6754311	0.551	rs10928545	chr2:136501840	A/G	cg07169764	chr2:136633963	MCM6	-0.68	-5.87	-0.52	6.5e-8	Mosquito bite size;
THYM	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg08847533	chr14:75593920	NEK9	-0.96	-10.93	-0.75	1.72e-18	Height;
THYM	cis	rs7107174	1.000	rs2510048	chr11:77987464	T/C	cg02023728	chr11:77925099	USP35	0.65	5.83	0.51	7.52e-8	Testicular germ cell tumor;
THYM	cis	rs17001868	0.568	rs909669	chr22:40742417	C/T	cg07138101	chr22:40742427	ADSL	0.96	5.82	0.51	8.03e-8	Mammographic density (dense area);
THYM	cis	rs4690686	0.500	rs12501181	chr4:177264851	G/A	cg17059388	chr4:177262070	NA	0.48	6.73	0.57	1.29e-9	Essential tremor;
THYM	cis	rs13082711	0.554	rs35840701	chr3:27334231	A/C	cg02860705	chr3:27208620	NA	0.95	7.19	0.59	1.47e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg06611532	chr13:114900021	NA	0.64	7.17	0.59	1.61e-10	Schizophrenia;
THYM	cis	rs11148252	0.634	rs4941727	chr13:52721067	A/G	cg05335186	chr13:53173507	NA	0.38	4.6	0.43	1.31e-5	Lewy body disease;
THYM	cis	rs7359257	1.000	rs55854539	chr15:67707832	G/C	cg24579218	chr15:68104479	NA	0.53	4.64	0.43	1.12e-5	Menarche (age at onset);
THYM	cis	rs2075230	0.850	rs78553499	chr17:7478498	G/A	cg16696476	chr17:8191344	RANGRF;SLC25A35	0.29	4.64	0.43	1.09e-5	Hormone measurements;
THYM	cis	rs34638657	0.872	rs6420436	chr16:82186719	C/G	cg19807685	chr16:82068980	HSD17B2	-0.66	-5.1	-0.46	1.77e-6	Lung adenocarcinoma;
THYM	cis	rs7772486	0.806	rs7740785	chr6:146171299	C/A	cg23711669	chr6:146136114	FBXO30	0.9	8.83	0.67	5.34e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9527	0.590	rs7067663	chr10:104883650	A/G	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs2639990	1.000	rs632157	chr18:72911548	G/A	cg11568697	chr18:72916393	ZADH2	1.24	5.45	0.49	3.98e-7	Vascular endothelial growth factor levels;
THYM	cis	rs9828933	0.766	rs704361	chr3:63883671	T/G	cg16258503	chr3:63850278	ATXN7;THOC7	0.85	5.22	0.47	1.07e-6	Type 2 diabetes;
THYM	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg15445000	chr17:37608096	MED1	0.44	5.1	0.46	1.72e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2806561	0.929	rs9426694	chr1:23539742	T/C	cg12483005	chr1:23474871	LUZP1	0.54	5.48	0.49	3.52e-7	Height;
THYM	cis	rs526231	0.543	rs7714539	chr5:102328878	G/A	cg23492399	chr5:102201601	PAM	-0.65	-5.1	-0.46	1.73e-6	Primary biliary cholangitis;
THYM	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg00376283	chr12:123451042	ABCB9	0.7	4.72	0.44	8.27e-6	Height;Educational attainment;Head circumference (infant);
THYM	cis	rs7849270	1.000	rs2541161	chr9:131884802	C/T	cg14069949	chr9:131965419	NA	-0.5	-4.52	-0.42	1.8e-5	Blood metabolite ratios;
THYM	cis	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg24308560	chr3:49941425	MST1R	-0.58	-4.66	-0.43	1.02e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1003719	0.680	rs2835664	chr21:38573429	G/A	cg01329690	chr21:38580129	DSCR9	-0.36	-5.0	-0.46	2.67e-6	Eye color traits;
THYM	cis	rs2637266	1.000	rs35991266	chr10:78378733	A/G	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.0	-10.08	-0.72	1.13e-16	Cognitive ability;
THYM	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg16586182	chr3:47516702	SCAP	0.65	5.61	0.5	1.99e-7	Colorectal cancer;
THYM	cis	rs4148689	0.904	rs10953847	chr7:117191819	T/C	cg17204129	chr7:117119601	CFTR	-0.59	-4.6	-0.43	1.32e-5	Gout;
THYM	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.82	-5.09	-0.46	1.82e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg10360139	chr7:1886902	MAD1L1	-0.57	-4.82	-0.44	5.45e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7584330	0.554	rs729389	chr2:238425118	G/A	cg08992911	chr2:238395768	MLPH	0.85	5.39	0.48	5.19e-7	Prostate cancer;
THYM	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg10802521	chr3:52805072	NEK4	-0.67	-6.17	-0.53	1.67e-8	Bipolar disorder;
THYM	cis	rs7178572	0.568	rs12913233	chr15:77543297	C/T	cg22256960	chr15:77711686	NA	-1.04	-8.57	-0.66	1.83e-13	Type 2 diabetes;
THYM	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs7224737	1.000	rs2285657	chr17:40272594	C/A	cg02228675	chr17:40259724	DHX58	-0.64	-5.21	-0.47	1.11e-6	Fibrinogen levels;
THYM	cis	rs9525927	0.625	rs4942300	chr13:44811032	G/A	cg06480998	chr13:44712834	NA	0.54	4.5	0.42	1.93e-5	Dupuytren's disease;
THYM	cis	rs9649213	0.593	rs6961438	chr7:98005849	T/C	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.88	9.94	0.71	2.24e-16	Prudent dietary pattern;
THYM	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.37	0.55	6.61e-9	Tonsillectomy;
THYM	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg24733560	chr20:60626293	TAF4	0.6	6.44	0.55	4.8e-9	Body mass index;
THYM	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1372520	0.684	rs2619356	chr4:90750844	C/T	cg01966878	chr4:90757139	SNCA	-0.6	-4.62	-0.43	1.19e-5	Neuroticism;
THYM	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg12311346	chr5:56204834	C5orf35	-0.81	-5.9	-0.52	5.54e-8	Type 2 diabetes;
THYM	cis	rs4690686	0.538	rs13120287	chr4:177260184	T/C	cg17059388	chr4:177262070	NA	0.45	6.01	0.52	3.49e-8	Essential tremor;
THYM	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg27532560	chr4:187881888	NA	-0.96	-11.3	-0.76	2.88e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs593982	1.000	rs118030231	chr11:65501905	G/A	cg08755490	chr11:65554678	OVOL1	-1.44	-7.91	-0.63	4.57e-12	Atopic dermatitis;
THYM	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg22920501	chr2:26401640	FAM59B	-0.83	-7.3	-0.6	8.69e-11	Gut microbiome composition (summer);
THYM	cis	rs10208940	0.541	rs13402396	chr2:68759580	C/G	cg09157127	chr2:69201416	GKN1	0.89	4.7	0.43	8.87e-6	Urate levels in lean individuals;
THYM	cis	rs34311866	0.808	rs62294491	chr4:969111	C/T	cg11017086	chr4:979022	SLC26A1	0.71	4.71	0.43	8.53e-6	Parkinson's disease;
THYM	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg01528321	chr10:82214614	TSPAN14	0.67	5.77	0.51	9.77e-8	Post bronchodilator FEV1;
THYM	cis	rs9325144	0.505	rs6582691	chr12:38806894	T/C	cg10518543	chr12:38710700	ALG10B	-0.5	-4.45	-0.42	2.33e-5	Morning vs. evening chronotype;
THYM	cis	rs1007190	0.881	rs9914884	chr17:42955589	T/C	cg15406952	chr17:42872593	NA	0.8	5.57	0.5	2.34e-7	DNA methylation (variation);
THYM	cis	rs2075230	0.705	rs1641539	chr17:7545578	T/C	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.74	-0.44	7.55e-6	Hormone measurements;
THYM	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg06027949	chr8:82754900	SNX16	0.64	5.35	0.48	6.18e-7	Diastolic blood pressure;
THYM	cis	rs892961	0.932	rs12452788	chr17:75406866	T/C	cg11351908	chr17:75402473	SEPT9	0.57	5.59	0.5	2.12e-7	Airflow obstruction;
THYM	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg12219531	chr12:120966889	COQ5	0.8	6.55	0.56	2.9e-9	High light scatter reticulocyte count;
THYM	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg18876405	chr7:65276391	NA	0.58	4.83	0.44	5.18e-6	Aortic root size;
THYM	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg26566898	chr11:117069891	TAGLN	0.41	5.1	0.46	1.72e-6	Blood protein levels;
THYM	cis	rs6121246	0.567	rs6060399	chr20:30220823	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	4.99	0.46	2.76e-6	Mean corpuscular hemoglobin;
THYM	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.38	0.55	6.56e-9	Platelet count;
THYM	cis	rs7833986	1.000	rs13273123	chr8:57100791	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	-0.5	-4.78	-0.44	6.48e-6	Height;
THYM	cis	rs6700896	0.897	rs28480230	chr1:66124075	C/T	cg04111102	chr1:66153794	NA	0.54	5.03	0.46	2.31e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9653442	1.000	rs7580200	chr2:100811903	G/T	cg07810366	chr2:100720526	AFF3	0.34	4.58	0.43	1.41e-5	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.635	rs1525895	chr12:33966496	A/G	cg10856724	chr12:34555212	NA	-0.64	-6.03	-0.53	3.15e-8	Morning vs. evening chronotype;
THYM	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	4.69	0.43	9e-6	Menarche (age at onset);
THYM	cis	rs7187994	0.848	rs12922556	chr16:84784290	C/T	cg07647771	chr16:84786436	USP10	0.53	4.93	0.45	3.43e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs58106596	0.605	rs58212470	chr2:232561579	C/T	cg18146074	chr2:232242955	NA	0.33	4.45	0.42	2.34e-5	White blood cell count;Lymphocyte counts;
THYM	cis	rs611744	0.507	rs2121900	chr8:109333542	T/C	cg21045802	chr8:109455806	TTC35	0.83	7.39	0.6	5.6e-11	Dupuytren's disease;
THYM	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg26384229	chr12:38710491	ALG10B	-0.82	-7.97	-0.63	3.51e-12	Heart rate;
THYM	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg24812749	chr6:127587940	RNF146	0.92	6.28	0.54	1.02e-8	Breast cancer;
THYM	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg00383909	chr3:49044727	WDR6	1.12	6.61	0.56	2.27e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22307029	chr19:49891270	CCDC155	0.81	7.28	0.6	9.38e-11	Multiple sclerosis;
THYM	cis	rs995000	0.899	rs1002687	chr1:62963737	G/A	cg06896770	chr1:63153194	DOCK7	-0.94	-7.73	-0.62	1.11e-11	Triglyceride levels;
THYM	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg05738196	chr6:26577821	NA	0.83	8.34	0.65	5.8e-13	Intelligence (multi-trait analysis);
THYM	cis	rs10484885	0.775	rs55926724	chr6:90417450	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.83	-8.18	-0.64	1.28e-12	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs6570726	0.557	rs403956	chr6:145829956	T/C	cg05347473	chr6:146136440	FBXO30	0.77	6.53	0.56	3.19e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs2637266	0.846	rs752006	chr10:78393136	G/T	cg18941641	chr10:78392320	NA	0.6	4.79	0.44	6.07e-6	Pulmonary function;
THYM	cis	rs6032067	0.714	rs35665166	chr20:43865006	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.36	-0.48	5.9e-7	Blood protein levels;
THYM	cis	rs28476539	0.567	rs17005974	chr4:83569061	C/T	cg10249074	chr4:83542146	C4orf11	0.66	5.27	0.48	8.48e-7	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07167872	chr1:205819463	PM20D1	0.99	9.9	0.71	2.71e-16	Menarche (age at onset);
THYM	cis	rs36051895	0.626	rs7870694	chr9:5100628	T/C	cg02405213	chr9:5042618	JAK2	-1.01	-11.42	-0.76	1.59e-19	Pediatric autoimmune diseases;
THYM	cis	rs17006441	0.898	rs62252216	chr3:69881906	T/C	cg18496212	chr3:69797108	MITF	0.65	6.36	0.55	7.15e-9	Hemoglobin concentration;
THYM	cis	rs360798	0.532	rs12994674	chr2:62996645	G/A	cg17519650	chr2:63277830	OTX1	-0.65	-4.63	-0.43	1.17e-5	Coronary artery disease;
THYM	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg18761221	chr20:60518478	NA	0.7	5.6	0.5	2.1e-7	Obesity-related traits;
THYM	cis	rs7106204	0.609	rs12804374	chr11:24338016	A/G	ch.11.24196551F	chr11:24239977	NA	0.95	6.05	0.53	2.84e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs8067545	1.000	rs4925066	chr17:19915292	A/G	cg13482628	chr17:19912719	NA	0.59	5.13	0.47	1.54e-6	Schizophrenia;
THYM	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg13607699	chr17:42295918	UBTF	0.66	5.44	0.49	4.13e-7	Total body bone mineral density;
THYM	cis	rs2354432	0.607	rs12402309	chr1:146721983	T/A	cg25205988	chr1:146714368	CHD1L	-1.04	-5.54	-0.49	2.67e-7	Mitochondrial DNA levels;
THYM	cis	rs42648	0.869	rs10234301	chr7:89918278	T/C	cg25739043	chr7:89950458	NA	-0.52	-4.47	-0.42	2.2e-5	Homocysteine levels;
THYM	cis	rs1336149	0.515	rs9426942	chr1:157038591	C/A	cg12604331	chr1:156906485	ARHGEF11;MIR765	-0.55	-4.57	-0.42	1.45e-5	Chin dimples;
THYM	cis	rs12530845	1.000	rs12540688	chr7:135329690	T/C	cg23117316	chr7:135346802	PL-5283	-0.66	-5.88	-0.52	6.21e-8	Red blood cell traits;
THYM	cis	rs12368653	1.000	rs12368653	chr12:58133256	A/G	cg22764591	chr12:58329936	NA	0.65	4.97	0.45	2.94e-6	Multiple sclerosis;
THYM	cis	rs8013055	0.846	rs35723046	chr14:105970548	C/T	cg23356831	chr14:105996513	TMEM121	0.56	5.76	0.51	1.02e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg01483505	chr11:975446	AP2A2	-0.56	-4.6	-0.43	1.33e-5	Alzheimer's disease (late onset);
THYM	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg00376283	chr12:123451042	ABCB9	0.72	4.88	0.45	4.24e-6	Neutrophil percentage of white cells;
THYM	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg16405210	chr4:1374714	KIAA1530	-0.69	-5.62	-0.5	1.92e-7	Longevity;
THYM	cis	rs12530845	0.945	rs76298187	chr7:135334534	A/G	cg23117316	chr7:135346802	PL-5283	-0.66	-5.88	-0.52	6.21e-8	Red blood cell traits;
THYM	cis	rs478304	0.718	rs61744384	chr11:65387378	T/A	cg27068330	chr11:65405492	SIPA1	-0.87	-8.11	-0.64	1.78e-12	Acne (severe);
THYM	cis	rs3126085	0.734	rs3120653	chr1:152284854	A/G	cg10321714	chr1:152280068	FLG	-0.67	-5.14	-0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06850241	chr22:41845214	NA	0.6	5.32	0.48	6.75e-7	Vitiligo;
THYM	cis	rs4849845	0.889	rs1370380	chr2:121014895	G/A	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.14	0.47	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs13064411	0.627	rs28710051	chr3:113143531	G/A	cg10517650	chr3:113235015	CCDC52	-0.6	-5.06	-0.46	2.06e-6	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg03188948	chr7:1209495	NA	0.68	4.69	0.43	9.28e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg13147721	chr7:65941812	NA	-0.94	-5.74	-0.51	1.13e-7	Diabetic kidney disease;
THYM	cis	rs17597773	0.606	rs11590084	chr1:221040401	C/T	cg16008148	chr1:221062819	NA	0.52	4.45	0.42	2.29e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4642101	0.765	rs9871991	chr3:12827525	C/A	cg05775895	chr3:12838266	CAND2	0.79	7.06	0.59	2.66e-10	QRS complex (12-leadsum);
THYM	cis	rs7582180	0.874	rs13031270	chr2:100896311	G/T	cg14675211	chr2:100938903	LONRF2	0.64	5.43	0.49	4.28e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4430311	0.688	rs4658590	chr1:243908796	A/T	cg25706552	chr1:244017396	NA	-0.56	-4.89	-0.45	4.15e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs4631830	0.863	rs2926494	chr10:51517356	T/C	cg16070123	chr10:51489643	NA	-0.5	-4.73	-0.44	7.92e-6	Prostate-specific antigen levels;
THYM	cis	rs863345	0.604	rs4373761	chr1:158464634	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs4788570	0.615	rs2032918	chr16:71703436	T/G	cg06353428	chr16:71660113	MARVELD3	1.37	9.56	0.7	1.47e-15	Intelligence (multi-trait analysis);
THYM	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg27286337	chr10:134555280	INPP5A	0.85	6.47	0.55	4.17e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7705042	0.793	rs10463348	chr5:141502035	G/T	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs2455799	0.613	rs4685269	chr3:15942354	A/G	cg16303742	chr3:15540471	COLQ	-0.52	-5.35	-0.48	6.19e-7	Mean platelet volume;
THYM	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22857025	chr5:266934	NA	-1.57	-9.68	-0.7	8.05e-16	Breast cancer;
THYM	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg17211192	chr8:82754475	SNX16	0.82	7.41	0.61	5.09e-11	Diastolic blood pressure;
THYM	cis	rs2302729	0.929	rs7306298	chr12:2777311	G/A	cg19945202	chr12:2788847	CACNA1C	-0.88	-5.75	-0.51	1.06e-7	Sleep quality;
THYM	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2456568	0.695	rs7942055	chr11:93691063	A/C	cg17595323	chr11:93583763	C11orf90	0.48	4.52	0.42	1.79e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs9858542	0.537	rs56038006	chr3:49362369	C/T	cg00383909	chr3:49044727	WDR6	0.76	5.0	0.46	2.62e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs4460079	0.531	rs11943585	chr4:114835701	G/A	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.48	0.42	2.07e-5	Motion sickness;
THYM	cis	rs9574309	0.644	rs9544892	chr13:79417762	G/T	cg20271865	chr13:80233183	NA	-0.4	-5.32	-0.48	6.91e-7	IgG glycosylation;
THYM	cis	rs7508	0.546	rs382752	chr8:17898383	A/G	cg01800426	chr8:17659068	MTUS1	0.7	4.98	0.45	2.9e-6	Atrial fibrillation;
THYM	cis	rs6541297	1.000	rs2352723	chr1:230291868	C/T	cg05784532	chr1:230284198	GALNT2	-0.82	-5.03	-0.46	2.3e-6	Coronary artery disease;
THYM	cis	rs13102973	0.899	rs13122646	chr4:135906123	T/C	cg14419869	chr4:135874104	NA	0.82	6.86	0.58	7.03e-10	Subjective well-being;
THYM	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg00898013	chr13:113819073	PROZ	-0.91	-7.78	-0.62	8.67e-12	Platelet distribution width;
THYM	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg11366901	chr6:160182831	ACAT2	1.16	7.54	0.61	2.79e-11	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg12863693	chr15:85201151	NMB	0.64	5.65	0.5	1.64e-7	Schizophrenia;
THYM	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg08999081	chr20:33150536	PIGU	0.68	5.89	0.52	5.72e-8	Coronary artery disease;
THYM	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg08280861	chr8:58055591	NA	0.84	4.49	0.42	2e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.09	0.53	2.43e-8	Coronary artery disease;
THYM	cis	rs1559088	1.000	rs2161225	chr19:33551899	C/T	cg03563238	chr19:33554763	RHPN2	-0.5	-4.48	-0.42	2.04e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs61931739	0.513	rs1608906	chr12:33894986	T/C	cg10856724	chr12:34555212	NA	-0.62	-5.52	-0.49	2.98e-7	Morning vs. evening chronotype;
THYM	cis	rs3741151	0.656	rs12290785	chr11:73259012	G/T	cg17517138	chr11:73019481	ARHGEF17	0.9	4.71	0.43	8.56e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7646881	1.000	rs61558956	chr3:158452655	T/A	cg19483011	chr3:158453295	NA	-0.69	-4.93	-0.45	3.45e-6	Tetralogy of Fallot;
THYM	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg15448220	chr1:150897856	SETDB1	0.83	6.84	0.57	7.67e-10	Melanoma;
THYM	trans	rs2244497	0.671	rs56011218	chr17:64510006	T/C	cg12905176	chr3:66027307	NA	-0.74	-7.07	-0.59	2.63e-10	Neuroticism;
THYM	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg26039829	chr8:22132926	PIWIL2	0.65	5.51	0.49	3.08e-7	Hypertriglyceridemia;
THYM	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg17911788	chr17:44343683	NA	-0.77	-7.15	-0.59	1.79e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg13319975	chr6:146136371	FBXO30	0.63	5.12	0.46	1.61e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7980799	0.682	rs1601006	chr12:33629519	C/T	cg06521331	chr12:34319734	NA	0.63	4.48	0.42	2.12e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs9796	0.621	rs1659228	chr15:41471978	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.58	-4.79	-0.44	6.07e-6	Menopause (age at onset);
THYM	cis	rs2879627	0.504	rs1892367	chr10:53674581	A/G	cg08751451	chr10:53287690	PRKG1	-0.65	-4.52	-0.42	1.8e-5	Coronary artery disease;
THYM	cis	rs1670533	1.000	rs13135215	chr4:1054364	A/G	cg27284194	chr4:1044797	NA	0.61	4.6	0.43	1.29e-5	Recombination rate (females);
THYM	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg23205692	chr1:25664452	TMEM50A	0.85	6.55	0.56	2.99e-9	Erythrocyte sedimentation rate;
THYM	cis	rs8006385	1.000	rs753728	chr14:93523060	G/A	ch.14.1513839R	chr14:93819181	KIAA1409	-0.91	-4.5	-0.42	1.94e-5	Platelet count;
THYM	cis	rs11190604	0.767	rs10883483	chr10:102174244	T/C	cg07570687	chr10:102243282	WNT8B	0.82	7.71	0.62	1.25e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs900145	0.859	rs2403662	chr11:13302822	A/G	cg13286116	chr11:13302098	ARNTL	-0.59	-4.47	-0.42	2.13e-5	Menarche (age at onset);
THYM	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2456568	0.548	rs10466335	chr11:93663820	G/C	cg26875233	chr11:93583750	C11orf90	-0.52	-5.79	-0.51	8.93e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs986417	1.000	rs1024223	chr14:60926119	C/T	cg27398547	chr14:60952738	C14orf39	1.15	5.91	0.52	5.37e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs2033711	0.870	rs6510152	chr19:58953319	C/T	cg13877915	chr19:58951672	ZNF132	0.91	8.41	0.65	4.07e-13	Uric acid clearance;
THYM	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg24060327	chr5:131705240	SLC22A5	-0.68	-5.2	-0.47	1.15e-6	Breast cancer;
THYM	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg14784868	chr12:69753453	YEATS4	0.89	7.73	0.62	1.13e-11	Cerebrospinal fluid biomarker levels;
THYM	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg09035930	chr12:129282057	SLC15A4	0.88	11.96	0.78	1.2e-20	Systemic lupus erythematosus;
THYM	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg22166914	chr1:53195759	ZYG11B	-0.68	-6.72	-0.57	1.31e-9	Monocyte count;
THYM	cis	rs1448094	0.512	rs11832992	chr12:86240790	T/C	cg00310523	chr12:86230176	RASSF9	0.53	4.79	0.44	6.05e-6	Major depressive disorder;
THYM	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg10802521	chr3:52805072	NEK4	-0.71	-5.96	-0.52	4.22e-8	Bipolar disorder;
THYM	cis	rs1499972	0.941	rs55864156	chr3:117664968	C/G	cg07612923	chr3:117604196	NA	1.41	5.43	0.49	4.28e-7	Schizophrenia;
THYM	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg17757837	chr7:157058334	UBE3C	0.66	5.29	0.48	7.68e-7	Body mass index;
THYM	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg15536230	chr21:44985092	HSF2BP	-0.45	-5.8	-0.51	8.81e-8	Mean corpuscular volume;
THYM	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	6.46	0.55	4.54e-9	Total body bone mineral density;
THYM	cis	rs6510489	1.000	rs17638216	chr19:35978458	G/A	cg15078284	chr19:36004994	DMKN	0.42	4.91	0.45	3.77e-6	Bipolar disorder;
THYM	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg22947322	chr17:47091978	IGF2BP1	-0.67	-6.9	-0.58	5.9e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs2282300	0.739	rs34951229	chr11:30265166	C/G	cg25418670	chr11:30344373	C11orf46	-0.81	-6.87	-0.58	6.66e-10	Morning vs. evening chronotype;
THYM	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg24578937	chr1:2090814	PRKCZ	0.75	7.56	0.61	2.54e-11	Height;
THYM	cis	rs12594515	1.000	rs6493176	chr15:45990026	A/G	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs2495707	0.532	rs2495709	chr10:102416833	C/T	cg07919443	chr10:102419409	NA	-0.61	-5.06	-0.46	2.05e-6	Body mass index;
THYM	cis	rs34330	0.562	rs12229100	chr12:12865836	A/G	cg04607235	chr12:12878440	APOLD1	0.95	5.71	0.51	1.29e-7	Systemic lupus erythematosus;
THYM	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg07010633	chr17:73824396	UNC13D	-0.43	-4.61	-0.43	1.28e-5	White matter hyperintensity burden;
THYM	cis	rs1915146	0.546	rs9422857	chr10:126861278	C/G	cg05090351	chr10:126851162	NA	0.66	7.15	0.59	1.79e-10	Menarche (age at onset);
THYM	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg06634786	chr22:41940651	POLR3H	0.64	4.97	0.45	2.91e-6	Cannabis dependence symptom count;
THYM	cis	rs2456568	0.803	rs10831142	chr11:93640781	A/G	cg17347335	chr11:93583973	C11orf90	0.48	4.63	0.43	1.18e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg11871910	chr12:69753446	YEATS4	1.01	9.83	0.71	3.8e-16	Cerebrospinal fluid biomarker levels;
THYM	cis	rs757110	0.770	rs11024268	chr11:17387982	A/G	cg15432903	chr11:17409602	KCNJ11	0.58	6.28	0.54	1.01e-8	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg04756594	chr16:24857601	SLC5A11	0.76	5.51	0.49	3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14159672	chr1:205819179	PM20D1	0.92	9.2	0.69	8.59e-15	Menarche (age at onset);
THYM	cis	rs17253792	0.822	rs78826571	chr14:56048906	G/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs7944735	0.578	rs7949985	chr11:48062449	C/T	cg24672777	chr11:48374446	OR4C45	-0.95	-5.2	-0.47	1.12e-6	Intraocular pressure;
THYM	cis	rs981844	1.000	rs10517579	chr4:154666321	T/C	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg10589385	chr1:150898437	SETDB1	0.6	4.76	0.44	6.8e-6	Melanoma;
THYM	cis	rs6733011	0.578	rs1581251	chr2:99500867	C/T	cg08885076	chr2:99613938	TSGA10	-0.45	-4.47	-0.42	2.15e-5	Bipolar disorder;
THYM	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg05872129	chr22:39784769	NA	-1.01	-10.65	-0.74	6.85e-18	Intelligence (multi-trait analysis);
THYM	cis	rs12478296	1.000	rs56162244	chr2:243018690	A/G	cg06360820	chr2:242988706	NA	-0.96	-6.27	-0.54	1.06e-8	Obesity-related traits;
THYM	cis	rs2997447	0.846	rs3008234	chr1:26405458	A/G	cg03844060	chr1:26490628	NA	0.67	4.53	0.42	1.73e-5	QRS complex (12-leadsum);
THYM	cis	rs921943	0.554	rs163132	chr5:78285921	A/G	cg17845680	chr5:78281827	ARSB	0.56	5.29	0.48	7.89e-7	Blood and toenail selenium levels;Blood trace element (Se levels);
THYM	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg17264618	chr3:40429014	ENTPD3	0.52	4.95	0.45	3.22e-6	Renal cell carcinoma;
THYM	cis	rs7173743	0.756	rs7169511	chr15:79128665	T/C	cg15571903	chr15:79123663	NA	0.54	6.2	0.54	1.48e-8	Coronary artery disease;
THYM	cis	rs4638749	0.677	rs6757761	chr2:108834842	T/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg19761014	chr17:28927070	LRRC37B2	0.73	4.46	0.42	2.21e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9913156	0.793	rs8074545	chr17:4567337	C/G	cg19197139	chr17:4613644	ARRB2	-0.85	-5.19	-0.47	1.21e-6	Lymphocyte counts;
THYM	cis	rs56104184	0.775	rs55737338	chr19:49403141	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.82	-4.55	-0.42	1.56e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs17122693	1.000	rs17122674	chr14:51066429	G/A	cg04730355	chr14:51134070	SAV1	1.01	5.39	0.48	5.15e-7	Cognitive performance;
THYM	cis	rs11048434	0.636	rs11047953	chr12:9064923	A/C	cg13575925	chr12:9217583	LOC144571	0.53	4.82	0.44	5.35e-6	Sjögren's syndrome;
THYM	cis	rs9902453	0.780	rs62068621	chr17:28170382	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.66	0.43	1.03e-5	Coffee consumption (cups per day);
THYM	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	7.57	0.61	2.37e-11	Platelet count;
THYM	cis	rs2652834	0.821	rs7174174	chr15:63372327	A/G	cg05507819	chr15:63340323	TPM1	-0.67	-4.55	-0.42	1.57e-5	HDL cholesterol;
THYM	cis	rs7084402	1.000	rs1863664	chr10:60266839	A/G	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs61774743	0.557	rs4660192	chr1:41842350	C/T	cg01193554	chr1:41846683	NA	-0.38	-5.31	-0.48	7.05e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg05738196	chr6:26577821	NA	0.72	5.75	0.51	1.06e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg01448562	chr3:133502909	NA	0.96	8.33	0.65	5.92e-13	Iron status biomarkers;
THYM	cis	rs9902453	1.000	rs7207021	chr17:28400516	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-4.62	-0.43	1.2e-5	Coffee consumption (cups per day);
THYM	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg19875535	chr5:140030758	IK	-0.63	-5.69	-0.5	1.43e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs6964587	0.839	rs62466809	chr7:91472801	A/G	cg22709100	chr7:91322751	NA	0.64	4.87	0.45	4.42e-6	Breast cancer;
THYM	cis	rs791888	0.965	rs791876	chr10:89406527	G/A	cg13926569	chr10:89418898	PAPSS2	-0.66	-7.15	-0.59	1.77e-10	Magnesium levels;
THYM	trans	rs3960554	0.808	rs59882870	chr7:75638421	G/A	cg19862616	chr7:65841803	NCRNA00174	0.97	7.28	0.6	9.48e-11	Eotaxin levels;
THYM	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg21984481	chr17:79567631	NPLOC4	-0.48	-5.04	-0.46	2.26e-6	Eye color traits;
THYM	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs75804782	0.522	rs11889150	chr2:239324542	A/G	cg18131467	chr2:239335373	ASB1	-0.82	-5.1	-0.46	1.7e-6	Morning vs. evening chronotype;Chronotype;
THYM	cis	rs36051895	0.732	rs7046736	chr9:5015732	C/A	cg02405213	chr9:5042618	JAK2	-0.88	-8.59	-0.66	1.7e-13	Pediatric autoimmune diseases;
THYM	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg10505658	chr17:80084571	CCDC57	-0.74	-8.13	-0.64	1.59e-12	Life satisfaction;
THYM	cis	rs2273669	0.667	rs11153153	chr6:109356104	A/T	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	cis	rs1003719	0.762	rs2835598	chr21:38466669	T/C	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4638749	0.677	rs17035849	chr2:108842593	G/T	cg06795125	chr2:108905320	SULT1C2	-0.36	-4.6	-0.43	1.32e-5	Blood pressure;
THYM	cis	rs1003719	0.645	rs8131944	chr21:38547215	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg26354017	chr1:205819088	PM20D1	-0.7	-5.51	-0.49	3.03e-7	Menarche (age at onset);
THYM	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	7.35	0.6	6.91e-11	Platelet count;
THYM	cis	rs11997175	0.624	rs17700425	chr8:33691467	T/G	ch.8.33884649F	chr8:33765107	NA	0.66	5.03	0.46	2.33e-6	Body mass index;
THYM	cis	rs12282928	1.000	rs1503183	chr11:48259296	C/T	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs1061377	1.000	rs3796511	chr4:39122206	G/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg10856724	chr12:34555212	NA	-0.83	-7.48	-0.61	3.64e-11	Morning vs. evening chronotype;
THYM	cis	rs6430585	0.583	rs73957037	chr2:136588031	C/A	cg20242066	chr2:136595261	LCT	0.53	5.86	0.52	6.68e-8	Corneal structure;
THYM	cis	rs4242434	0.819	rs7843128	chr8:22473465	T/C	cg01710189	chr8:22454888	PDLIM2	-0.45	-4.93	-0.45	3.51e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg12373951	chr3:133503437	NA	0.66	7.27	0.6	9.95e-11	Iron status biomarkers;
THYM	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.7	4.71	0.43	8.57e-6	Menarche (age at onset);
THYM	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg13918804	chr1:2043761	PRKCZ	-0.63	-4.69	-0.43	8.99e-6	Height;
THYM	cis	rs665401	1.000	rs678230	chr6:117257795	C/T	cg20376953	chr6:117187980	NA	0.55	4.49	0.42	1.99e-5	Neutrophil percentage of granulocytes;
THYM	cis	rs6738825	0.606	rs10931784	chr2:198405636	T/A	cg00792783	chr2:198669748	PLCL1	0.63	4.64	0.43	1.11e-5	Crohn's disease;
THYM	cis	rs6496667	0.557	rs2526002	chr15:90965655	C/T	cg00425431	chr15:90792223	TTLL13	0.41	4.81	0.44	5.72e-6	Rheumatoid arthritis;
THYM	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg02221750	chr19:17393354	ANKLE1	-0.94	-8.56	-0.66	1.92e-13	Systemic lupus erythematosus;
THYM	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg12935359	chr14:103987150	CKB	-0.42	-5.0	-0.46	2.67e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11186	0.630	rs10931391	chr2:189914387	A/G	cg11041835	chr2:189156425	GULP1	0.79	4.5	0.42	1.91e-5	Parkinson's disease;
THYM	cis	rs6570726	0.935	rs451349	chr6:145820894	A/G	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg06970220	chr1:156163860	SLC25A44	-0.72	-5.64	-0.5	1.73e-7	Testicular germ cell tumor;
THYM	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg10589385	chr1:150898437	SETDB1	0.62	5.08	0.46	1.9e-6	Melanoma;
THYM	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg21427119	chr20:30132790	HM13	-0.73	-4.94	-0.45	3.41e-6	Mean corpuscular hemoglobin;
THYM	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg10803722	chr21:46713166	LOC642852	-0.42	-5.58	-0.5	2.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg09904177	chr6:26538194	HMGN4	0.53	4.47	0.42	2.16e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9361491	0.608	rs9352631	chr6:79462197	A/G	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg07021052	chr2:20871279	NA	-0.66	-5.17	-0.47	1.27e-6	Abdominal aortic aneurysm;
THYM	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg12011299	chr4:100065546	ADH4	0.69	6.2	0.54	1.46e-8	Alcohol dependence;
THYM	cis	rs11096990	0.793	rs9997050	chr4:39302665	A/G	cg24403649	chr4:39172243	NA	-0.68	-5.12	-0.47	1.57e-6	Cognitive function;
THYM	cis	rs7729447	0.776	rs4867472	chr5:32693566	C/T	cg16267343	chr5:32710456	NPR3	0.79	7.16	0.59	1.69e-10	Blood pressure;
THYM	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg11141652	chr22:24348549	GSTTP1	0.63	6.35	0.55	7.23e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg14004847	chr7:1930337	MAD1L1	-0.65	-5.29	-0.48	7.86e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg15448220	chr1:150897856	SETDB1	0.86	6.94	0.58	4.73e-10	Melanoma;
THYM	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg01528321	chr10:82214614	TSPAN14	0.67	5.77	0.51	9.77e-8	Post bronchodilator FEV1;
THYM	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg00376283	chr12:123451042	ABCB9	0.73	5.03	0.46	2.29e-6	Neutrophil percentage of white cells;
THYM	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg00277334	chr10:82204260	NA	-0.83	-10.18	-0.72	6.99e-17	Post bronchodilator FEV1;
THYM	cis	rs6424115	0.830	rs6680132	chr1:24198804	T/C	cg15997130	chr1:24165203	NA	0.74	6.35	0.55	7.22e-9	Immature fraction of reticulocytes;
THYM	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg02038168	chr22:39784481	NA	0.66	5.75	0.51	1.07e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs9915657	0.870	rs4140903	chr17:70133771	C/T	cg09344028	chr17:70110421	NA	0.49	4.84	0.44	5.09e-6	Thyroid hormone levels;
THYM	cis	rs2455799	0.613	rs11920540	chr3:15854608	G/A	cg16303742	chr3:15540471	COLQ	-0.56	-5.88	-0.52	6.13e-8	Mean platelet volume;
THYM	cis	rs673253	0.686	rs596522	chr1:44066424	G/T	cg24466421	chr1:44070974	PTPRF	-0.55	-4.66	-0.43	1.04e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7122539	0.646	rs569818	chr11:66570749	G/A	cg24851651	chr11:66362959	CCS	0.65	5.6	0.5	2.05e-7	HIV-1 susceptibility;
THYM	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg03929089	chr4:120376271	NA	-0.95	-10.82	-0.74	2.97e-18	Height;
THYM	cis	rs73198271	0.740	rs10109886	chr8:8680558	G/A	cg06636001	chr8:8085503	FLJ10661	-0.69	-4.65	-0.43	1.06e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs1003719	0.715	rs2835613	chr21:38496883	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-4.61	-0.43	1.26e-5	Eye color traits;
THYM	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg06808227	chr14:105710500	BRF1	-1.05	-9.15	-0.68	1.07e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg13695892	chr22:41940480	POLR3H	-1.04	-8.51	-0.66	2.47e-13	Vitiligo;
THYM	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg07341220	chr16:1583899	IFT140;TMEM204	-0.57	-4.93	-0.45	3.51e-6	Coronary artery disease;
THYM	cis	rs6121246	0.559	rs6060950	chr20:30378031	T/C	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs2235642	0.507	rs2235643	chr16:1585115	A/G	cg19030554	chr16:1822289	NME3;MRPS34;EME2	0.54	5.53	0.49	2.78e-7	Coronary artery disease;
THYM	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.92	7.96	0.63	3.6e-12	Multiple sclerosis;
THYM	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg11663144	chr21:46675770	NA	-0.72	-10.48	-0.73	1.54e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg13390004	chr1:15929781	NA	0.62	4.72	0.44	8.11e-6	Systolic blood pressure;
THYM	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-4.85	-0.45	4.76e-6	Hemoglobin concentration;
THYM	cis	rs7107174	1.000	rs57738705	chr11:77994489	A/G	cg02023728	chr11:77925099	USP35	0.67	6.02	0.53	3.25e-8	Testicular germ cell tumor;
THYM	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg14583973	chr4:3374767	RGS12	0.71	6.99	0.58	3.86e-10	Serum sulfate level;
THYM	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg04772025	chr11:68637568	NA	0.66	6.9	0.58	5.88e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4509693	0.722	rs10883536	chr10:102489331	A/C	cg24127310	chr10:102502104	NA	1.17	8.61	0.66	1.53e-13	Alzheimer's disease;
THYM	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg11266682	chr4:10021025	SLC2A9	0.73	12.79	0.8	2.25e-22	Bone mineral density;
THYM	cis	rs13256369	0.802	rs4840350	chr8:8561442	A/G	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs3820068	0.608	rs12760450	chr1:16037282	G/A	cg27534772	chr1:16042836	PLEKHM2	0.5	5.18	0.47	1.26e-6	Systolic blood pressure;
THYM	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg07570687	chr10:102243282	WNT8B	0.85	8.1	0.64	1.89e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs644799	0.562	rs671320	chr11:95578780	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	5.97	0.52	4.03e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.81	-4.97	-0.45	2.91e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs4076764	0.515	rs4657268	chr1:163376507	A/T	cg06092702	chr1:163392909	NA	-0.57	-5.01	-0.46	2.54e-6	Motion sickness;
THYM	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg22907277	chr7:1156413	C7orf50	0.7	4.61	0.43	1.24e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg26354017	chr1:205819088	PM20D1	-0.71	-5.59	-0.5	2.15e-7	Menarche (age at onset);
THYM	cis	rs986417	1.000	rs1254303	chr14:60886301	A/G	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs9467160	0.520	rs9379660	chr6:24441635	C/G	cg20631270	chr6:24437470	GPLD1	0.57	4.84	0.45	4.94e-6	Liver enzyme levels;
THYM	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg24642844	chr7:1081250	C7orf50	-0.71	-4.87	-0.45	4.43e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.69	-5.16	-0.47	1.36e-6	Tonsillectomy;
THYM	cis	rs4788570	0.538	rs16973260	chr16:71534853	A/G	cg06353428	chr16:71660113	MARVELD3	1.01	5.04	0.46	2.2e-6	Intelligence (multi-trait analysis);
THYM	cis	rs526231	0.511	rs73179850	chr5:102348577	T/A	cg23492399	chr5:102201601	PAM	-0.71	-5.49	-0.49	3.37e-7	Primary biliary cholangitis;
THYM	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.07	-10.85	-0.74	2.51e-18	Primary sclerosing cholangitis;
THYM	cis	rs28595532	0.920	rs56302493	chr4:119772382	A/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs6032067	1.000	rs6032060	chr20:43852454	A/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.71	-7.53	-0.61	2.95e-11	Blood protein levels;
THYM	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7927771	0.524	rs3758655	chr11:47703943	T/C	cg18512352	chr11:47633146	NA	0.4	4.47	0.42	2.14e-5	Subjective well-being;
THYM	cis	rs2085601	0.542	rs1708678	chr4:89976467	A/G	cg17769793	chr4:89976368	FAM13A	-0.59	-6.62	-0.56	2.17e-9	Hair greying;
THYM	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg27490568	chr2:178487706	NA	0.64	6.33	0.54	8.08e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12756686	chr19:29218302	NA	0.98	8.72	0.67	9.12e-14	Methadone dose in opioid dependence;
THYM	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg08498830	chr11:832797	CD151	-0.65	-4.69	-0.43	9.02e-6	Mean platelet volume;
THYM	cis	rs79349575	0.783	rs62075839	chr17:46996434	G/C	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs8133932	0.608	rs382195	chr21:47339222	G/A	cg20357416	chr21:47294739	PCBP3	0.8	4.88	0.45	4.26e-6	Schizophrenia;
THYM	cis	rs8048589	0.615	rs34098770	chr16:12237812	G/A	cg02910054	chr16:12241554	SNX29	0.83	7.02	0.58	3.27e-10	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs1278352	0.767	rs1278358	chr10:127774691	T/C	cg08295661	chr10:127769903	ADAM12	-0.55	-5.64	-0.5	1.71e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg21028142	chr17:79581711	NPLOC4	0.61	6.22	0.54	1.32e-8	Eye color traits;
THYM	cis	rs240764	0.764	rs6910391	chr6:100925774	T/C	cg21058520	chr6:100914733	NA	0.54	4.76	0.44	6.81e-6	Neuroticism;
THYM	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9649465	0.935	rs1605285	chr7:123374412	A/G	cg15443791	chr7:124364398	NA	0.58	4.81	0.44	5.62e-6	Migraine;
THYM	cis	rs13315871	0.929	rs71311852	chr3:58298843	G/A	cg00563845	chr3:58318305	PXK	0.59	5.03	0.46	2.29e-6	Cholesterol, total;
THYM	cis	rs7872515	0.536	rs7864340	chr9:94777390	T/C	cg13922115	chr9:95397568	IPPK	0.88	4.46	0.42	2.25e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg24060327	chr5:131705240	SLC22A5	-0.68	-5.18	-0.47	1.23e-6	Breast cancer;
THYM	cis	rs2219968	0.962	rs10808824	chr8:78926741	G/A	cg00738934	chr8:78996279	NA	0.8	8.65	0.66	1.27e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg10661904	chr17:79619235	PDE6G	0.65	6.28	0.54	1.01e-8	Eye color traits;
THYM	cis	rs11676348	0.755	rs62183956	chr2:219046122	C/T	cg00012203	chr2:219082015	ARPC2	0.57	4.46	0.42	2.26e-5	Ulcerative colitis;
THYM	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg24818145	chr4:99064322	C4orf37	0.7	5.43	0.49	4.24e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg21159260	chr5:475889	SLC9A3	0.42	4.46	0.42	2.28e-5	Obesity-related traits;
THYM	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg10117171	chr1:25599238	RHD	-0.69	-5.08	-0.46	1.89e-6	Erythrocyte sedimentation rate;
THYM	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg08975724	chr8:8085496	FLJ10661	0.67	4.97	0.45	2.96e-6	Neuroticism;
THYM	cis	rs7267979	1.000	rs2500404	chr20:25359758	A/C	cg08601574	chr20:25228251	PYGB	-0.58	-4.71	-0.43	8.54e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg04455712	chr21:45112962	RRP1B	0.49	4.48	0.42	2.07e-5	Mean corpuscular volume;
THYM	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs9914988	0.619	rs9898529	chr17:27318861	A/T	cg26182037	chr17:27055700	NEK8	0.82	5.1	0.46	1.77e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg00129232	chr17:37814104	STARD3	0.75	5.4	0.48	4.93e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg12826209	chr6:26865740	GUSBL1	0.84	6.07	0.53	2.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7246657	0.943	rs1015849	chr19:37946180	G/A	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.06e-12	Height;
THYM	cis	rs7107174	0.901	rs10899493	chr11:78117534	T/C	cg02023728	chr11:77925099	USP35	0.59	5.49	0.49	3.4e-7	Testicular germ cell tumor;
THYM	cis	rs11711311	1.000	rs16861312	chr3:113492402	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.58	-5.06	-0.46	2.01e-6	IgG glycosylation;
THYM	cis	rs6456042	0.824	rs3127423	chr6:166539088	G/A	cg11088901	chr6:166572345	T	-0.52	-4.9	-0.45	3.93e-6	Asthma;
THYM	cis	rs3847687	1.000	rs11061290	chr12:131518747	C/T	cg13586425	chr12:131519906	GPR133	-0.29	-4.66	-0.43	1.05e-5	Longevity;
THYM	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg03806693	chr22:41940476	POLR3H	1.11	9.95	0.71	2.12e-16	Vitiligo;
THYM	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	9.51	0.7	1.85e-15	Platelet count;
THYM	cis	rs818427	0.669	rs2952615	chr5:112138888	G/C	cg04614008	chr5:112630677	MCC	-0.62	-4.5	-0.42	1.92e-5	Total body bone mineral density;
THYM	cis	rs1003719	0.762	rs11088381	chr21:38478429	G/A	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs877282	1.000	rs11253363	chr10:771891	A/G	cg10556349	chr10:835070	NA	-0.72	-5.2	-0.47	1.14e-6	Uric acid levels;
THYM	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg06636001	chr8:8085503	FLJ10661	0.65	5.77	0.51	9.85e-8	Mean corpuscular hemoglobin;
THYM	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg10117171	chr1:25599238	RHD	-0.67	-4.92	-0.45	3.62e-6	Erythrocyte sedimentation rate;
THYM	cis	rs1056053	0.514	rs3099269	chr6:166572242	T/A	cg11088901	chr6:166572345	T	-0.58	-5.22	-0.47	1.06e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg04025307	chr7:1156635	C7orf50	0.6	5.43	0.49	4.34e-7	Longevity;Endometriosis;
THYM	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.87	-0.45	4.47e-6	Body mass index;
THYM	cis	rs11651000	0.846	rs41321047	chr17:45813665	G/A	cg24803719	chr17:45855879	NA	-0.64	-5.14	-0.47	1.47e-6	IgG glycosylation;
THYM	cis	rs7106204	0.609	rs12276488	chr11:24250211	G/A	ch.11.24196551F	chr11:24239977	NA	1.01	6.28	0.54	1.02e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg22920501	chr2:26401640	FAM59B	-1.04	-9.12	-0.68	1.26e-14	Gut microbiome composition (summer);
THYM	cis	rs4722166	0.603	rs7801406	chr7:22788274	A/G	cg05472934	chr7:22766657	IL6	0.89	6.86	0.58	6.86e-10	Lung cancer;
THYM	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg27490568	chr2:178487706	NA	0.62	5.82	0.51	7.82e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg24250549	chr1:154909240	PMVK	-0.7	-5.56	-0.5	2.51e-7	Prostate cancer;
THYM	cis	rs2708977	1.000	rs2708977	chr2:97230074	G/A	cg01950434	chr2:97203154	ARID5A	-0.56	-4.95	-0.45	3.19e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg24450063	chr1:156163899	SLC25A44	-1.15	-14.9	-0.84	1.35e-26	Testicular germ cell tumor;
THYM	cis	rs36051895	0.664	rs884132	chr9:5114522	G/A	cg02405213	chr9:5042618	JAK2	-1.01	-11.38	-0.76	1.95e-19	Pediatric autoimmune diseases;
THYM	cis	rs10484885	0.757	rs12201016	chr6:90149275	C/T	cg13799429	chr6:90582589	CASP8AP2	0.73	6.04	0.53	2.95e-8	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs425277	1.000	rs262647	chr1:2095699	C/T	cg21394778	chr1:3037102	PRDM16	0.46	4.45	0.42	2.3e-5	Height;
THYM	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg08213375	chr14:104286397	PPP1R13B	0.49	5.99	0.52	3.73e-8	Schizophrenia;
THYM	cis	rs526231	0.511	rs58344084	chr5:102378212	C/T	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Primary biliary cholangitis;
THYM	cis	rs7178572	0.633	rs4886877	chr15:77838535	C/G	cg22256960	chr15:77711686	NA	-0.77	-5.95	-0.52	4.54e-8	Type 2 diabetes;
THYM	cis	rs7695732	0.595	rs1921683	chr4:89906034	A/G	cg17769793	chr4:89976368	FAM13A	-0.49	-5.4	-0.48	4.81e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs362272	0.524	rs3129334	chr4:3368526	T/C	cg22655196	chr4:3374909	RGS12	0.63	7.9	0.63	5e-12	Serum sulfate level;
THYM	cis	rs7917772	0.582	rs3936017	chr10:104354424	T/C	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6840360	0.967	rs10776524	chr4:152602585	G/A	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7777754	0.512	rs3757472	chr7:50537983	A/C	cg18232548	chr7:50535776	DDC	-0.92	-8.1	-0.64	1.85e-12	Response to zileuton treatment in asthma (FEV1 change interaction);
THYM	cis	rs113835537	0.529	rs2277302	chr11:66240882	T/C	cg24851651	chr11:66362959	CCS	0.62	4.48	0.42	2.09e-5	Airway imaging phenotypes;
THYM	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06634786	chr22:41940651	POLR3H	-0.68	-5.18	-0.47	1.26e-6	Vitiligo;
THYM	cis	rs293526	0.959	rs293489	chr6:83622687	A/T	cg23278060	chr6:83777448	DOPEY1	0.62	4.49	0.42	2.02e-5	Crohn's disease;
THYM	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs34638657	0.702	rs67612167	chr16:82199598	A/G	cg09439754	chr16:82129088	HSD17B2	-0.5	-4.94	-0.45	3.37e-6	Lung adenocarcinoma;
THYM	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.31	0.6	8.45e-11	Obesity-related traits;
THYM	cis	rs6674176	0.597	rs6671164	chr1:44403489	G/T	cg12908607	chr1:44402522	ARTN	-0.63	-5.16	-0.47	1.34e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs4731207	0.564	rs7794565	chr7:124648968	A/C	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05901451	chr6:126070800	HEY2	-0.92	-9.44	-0.7	2.6e-15	Brugada syndrome;
THYM	cis	rs2282300	0.739	rs1933342	chr11:30312825	C/T	cg25418670	chr11:30344373	C11orf46	0.82	6.98	0.58	3.93e-10	Morning vs. evening chronotype;
THYM	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.68	9.11	0.68	1.34e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg15921436	chr17:44337874	NA	0.74	5.89	0.52	5.77e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9640161	0.830	rs1051764	chr7:150070663	T/C	cg21361702	chr7:150065534	REPIN1	0.68	5.46	0.49	3.75e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs9633740	0.504	rs1993484	chr10:82222698	T/C	cg01528321	chr10:82214614	TSPAN14	1.12	6.13	0.53	2.03e-8	Post bronchodilator FEV1;
THYM	cis	rs10924970	0.967	rs11585350	chr1:235482739	A/G	cg26050004	chr1:235667680	B3GALNT2	0.59	4.48	0.42	2.06e-5	Asthma;
THYM	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg00376283	chr12:123451042	ABCB9	0.82	4.98	0.45	2.86e-6	Height;Educational attainment;Head circumference (infant);
THYM	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg20476274	chr7:133979776	SLC35B4	0.71	4.6	0.43	1.32e-5	Mean platelet volume;
THYM	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg07777115	chr5:623756	CEP72	-0.8	-4.78	-0.44	6.48e-6	Obesity-related traits;
THYM	cis	rs13315871	1.000	rs35542947	chr3:58323244	C/T	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs11838776	0.586	rs750598	chr13:111028978	C/T	cg15455643	chr13:111040242	COL4A2	0.5	6.17	0.53	1.65e-8	Coronary artery disease;
THYM	cis	rs7772486	0.875	rs2492855	chr6:146296926	A/G	cg23711669	chr6:146136114	FBXO30	0.89	8.81	0.67	5.64e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg06112835	chr11:68658793	MRPL21	0.43	6.08	0.53	2.48e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg03188948	chr7:1209495	NA	0.74	5.9	0.52	5.62e-8	Longevity;Endometriosis;
THYM	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg13395646	chr4:1353034	KIAA1530	-0.54	-4.83	-0.44	5.17e-6	Obesity-related traits;
THYM	cis	rs9302065	0.529	rs2993582	chr13:95958181	G/T	cg24476569	chr13:95954382	ABCC4	-0.78	-7.88	-0.63	5.41e-12	Blood metabolite levels;
THYM	cis	rs6032067	0.516	rs991049	chr20:43898139	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	0.4	4.74	0.44	7.53e-6	Blood protein levels;
THYM	cis	rs7590720	0.840	rs705648	chr2:216933792	C/T	cg12620499	chr2:216877984	MREG	0.71	4.84	0.44	4.98e-6	Alcohol dependence;
THYM	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs4660306	1.000	rs10736426	chr1:45984353	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.59	4.7	0.43	8.86e-6	Homocysteine levels;
THYM	cis	rs6598955	0.724	rs3924934	chr1:26644079	A/G	cg04990556	chr1:26633338	UBXN11	-0.87	-8.28	-0.65	7.66e-13	Obesity-related traits;
THYM	cis	rs7776786	0.603	rs12539715	chr7:18830320	G/A	cg13420273	chr7:18810212	HDAC9	-0.58	-5.16	-0.47	1.36e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg02527881	chr3:46936655	PTH1R	0.61	5.7	0.51	1.33e-7	Colorectal cancer;
THYM	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26314531	chr2:26401878	FAM59B	0.76	5.02	0.46	2.37e-6	Gut microbiome composition (summer);
THYM	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.68	-4.46	-0.42	2.22e-5	Menarche (age at onset);
THYM	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.81	6.04	0.53	3e-8	Cognitive test performance;
THYM	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3087591	0.960	rs2905793	chr17:29470072	C/T	cg24425628	chr17:29625626	OMG;NF1	0.65	5.61	0.5	2e-7	Hip circumference;
THYM	cis	rs13031619	0.607	rs13011199	chr2:3694994	A/G	cg10645314	chr2:3704589	ALLC	0.64	4.83	0.44	5.2e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs6430585	0.528	rs75753154	chr2:136665711	T/C	cg04750100	chr2:136595281	LCT	0.57	5.28	0.48	8.26e-7	Corneal structure;
THYM	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg13319975	chr6:146136371	FBXO30	0.75	6.26	0.54	1.11e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg06558623	chr16:89946397	TCF25	1.37	6.61	0.56	2.23e-9	Skin colour saturation;
THYM	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg18352616	chr4:3374830	RGS12	0.76	8.61	0.66	1.54e-13	Serum sulfate level;
THYM	cis	rs28595532	0.920	rs116791817	chr4:119763303	C/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs8070624	0.543	rs8068175	chr17:17874486	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	6.7	0.57	1.48e-9	Total body bone mineral density;
THYM	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.55	-0.42	1.59e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs192264	0.614	rs398834	chr16:65976282	T/C	cg02795155	chr16:66785218	DYNC1LI2	0.6	4.77	0.44	6.61e-6	Subjective well-being;
THYM	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg23982607	chr1:1823379	GNB1	-0.94	-9.59	-0.7	1.22e-15	Body mass index;
THYM	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.22	-8.8	-0.67	5.95e-14	Gut microbiome composition (summer);
THYM	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.16	9.01	0.68	2.12e-14	Cognitive test performance;
THYM	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg11764359	chr7:65958608	NA	0.82	6.56	0.56	2.81e-9	Aortic root size;
THYM	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg22709100	chr7:91322751	NA	0.68	5.42	0.49	4.59e-7	Breast cancer;
THYM	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg18758796	chr5:131593413	PDLIM4	0.5	4.72	0.44	8.15e-6	Breast cancer;
THYM	cis	rs3819817	0.575	rs3751265	chr12:96356060	G/A	cg26410635	chr12:96350720	AMDHD1	0.53	5.02	0.46	2.38e-6	Vitamin D levels;
THYM	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06481639	chr22:41940642	POLR3H	-0.86	-5.91	-0.52	5.28e-8	Vitiligo;
THYM	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg02782426	chr3:40428986	ENTPD3	-0.51	-4.56	-0.42	1.55e-5	Renal cell carcinoma;
THYM	cis	rs11577318	0.853	rs17645	chr1:26646730	A/G	cg19677267	chr1:26645161	CD52;UBXN11	-0.5	-6.66	-0.56	1.78e-9	Granulocyte percentage of myeloid white cells;
THYM	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.62	4.68	0.43	9.67e-6	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	5.37	0.48	5.55e-7	Mood instability;
THYM	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg16989719	chr2:238392110	NA	-0.64	-5.54	-0.49	2.73e-7	Prostate cancer;
THYM	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg10523679	chr1:76189770	ACADM	0.9	9.45	0.7	2.52e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1499972	0.941	rs55929115	chr3:117614158	T/A	cg07612923	chr3:117604196	NA	1.19	5.02	0.46	2.45e-6	Schizophrenia;
THYM	cis	rs4766566	0.590	rs4766567	chr12:111707556	G/A	cg10833066	chr12:111807467	FAM109A	0.45	4.7	0.43	8.62e-6	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
THYM	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6459804	1.000	rs73163880	chr7:157508755	C/T	cg11757124	chr7:157526947	PTPRN2	-0.66	-5.21	-0.47	1.11e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs13256369	0.851	rs13255061	chr8:8563834	G/A	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs7262634	1.000	rs7262634	chr20:45834279	T/C	cg18599129	chr20:45867857	ZMYND8	0.82	4.83	0.44	5.14e-6	Response to protease inhibitor treatment in hepatitis c (bilirubin toxicity);
THYM	cis	rs9486719	1.000	rs72931061	chr6:96880285	G/A	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs67981189	0.858	rs2526862	chr14:71409614	T/C	cg15910301	chr14:71632612	NA	-0.5	-4.52	-0.42	1.77e-5	Schizophrenia;
THYM	cis	rs7772486	0.875	rs2207785	chr6:146332784	T/G	cg05347473	chr6:146136440	FBXO30	0.57	4.54	0.42	1.66e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg25251562	chr2:3704773	ALLC	-0.81	-5.41	-0.49	4.62e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs1950626	0.750	rs34061904	chr14:101435974	A/G	cg11887864	chr14:101510502	MIR1185-2	0.54	4.52	0.42	1.75e-5	Pelvic organ prolapse (moderate/severe);
THYM	cis	rs2901656	1.000	rs6691993	chr1:172426998	T/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.47	4.76	0.44	7.01e-6	Red cell distribution width;Platelet distribution width;
THYM	cis	rs4919044	0.866	rs55661575	chr10:94825108	C/T	cg05127821	chr10:94822908	CYP26C1	-1.24	-6.68	-0.57	1.64e-9	Coronary artery disease;
THYM	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs752010	0.684	rs10789402	chr1:42084649	A/G	cg06885757	chr1:42089581	HIVEP3	0.6	7.65	0.62	1.61e-11	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg11764359	chr7:65958608	NA	-0.74	-6.15	-0.53	1.85e-8	Aortic root size;
THYM	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg03609598	chr5:56110824	MAP3K1	-0.85	-5.85	-0.51	6.86e-8	Initial pursuit acceleration;
THYM	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg00801512	chr17:28996047	NA	-0.76	-5.0	-0.46	2.65e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6995541	0.529	rs7004998	chr8:10689142	G/T	cg13457217	chr8:10683266	MIR1322;PINX1	-0.67	-5.02	-0.46	2.39e-6	Triglyceride levels;
THYM	cis	rs10186029	0.509	rs7603654	chr2:213944140	C/G	cg08319019	chr2:214017104	IKZF2	-0.67	-4.97	-0.45	2.96e-6	Systemic sclerosis;
THYM	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.8	-5.44	-0.49	4.14e-7	Body mass index;
THYM	cis	rs669446	0.561	rs568639	chr1:44086080	T/C	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg10360139	chr7:1886902	MAD1L1	-0.58	-4.61	-0.43	1.28e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs737337	0.623	rs4804155	chr19:11334295	C/G	cg00586551	chr19:11347513	LOC55908;DOCK6	0.73	5.85	0.51	7.04e-8	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs13315871	0.929	rs71311854	chr3:58319159	G/A	cg12435725	chr3:58293450	RPP14	-0.53	-5.51	-0.49	3.09e-7	Cholesterol, total;
THYM	cis	rs13315871	0.929	rs2056120	chr3:58309436	A/T	cg00563845	chr3:58318305	PXK	0.57	5.09	0.46	1.83e-6	Cholesterol, total;
THYM	cis	rs4638749	1.000	rs12472278	chr2:108873433	A/T	cg13968390	chr2:108904812	SULT1C2	0.53	4.64	0.43	1.13e-5	Blood pressure;
THYM	cis	rs6438424	1.000	rs6438424	chr3:117574822	A/C	cg07190778	chr3:117604296	NA	-0.4	-5.49	-0.49	3.4e-7	Menarche (age at onset);
THYM	cis	rs13326165	0.543	rs1769	chr3:52290550	A/G	cg08438690	chr3:52279403	PPM1M	-0.82	-4.74	-0.44	7.45e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs17030434	0.815	rs78638854	chr4:154648804	C/T	cg14289246	chr4:154710475	SFRP2	-0.81	-5.22	-0.47	1.05e-6	Electrocardiographic conduction measures;
THYM	trans	rs4866334	1.000	rs77653879	chr5:18449396	A/G	cg08675002	chr5:90437527	GPR98	-1.55	-7.42	-0.61	4.85e-11	IgG glycosylation;
THYM	cis	rs2963155	0.518	rs712189	chr5:142631258	C/T	cg17617527	chr5:142782415	NR3C1	1.2	6.6	0.56	2.37e-9	Breast cancer;
THYM	cis	rs7814319	0.966	rs10955069	chr8:97253788	C/T	cg20787634	chr8:97240163	UQCRB	-0.78	-9.49	-0.7	2.01e-15	Lung function (FVC);
THYM	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.0	-0.46	2.59e-6	Primary biliary cholangitis;
THYM	cis	rs7809950	0.678	rs77395658	chr7:107000651	G/A	cg23024343	chr7:107201750	COG5	-0.99	-8.39	-0.65	4.58e-13	Coronary artery disease;
THYM	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg06808227	chr14:105710500	BRF1	-1.02	-8.8	-0.67	6.1e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.2	-9.34	-0.69	4.26e-15	Platelet count;
THYM	cis	rs10782582	0.546	rs79652169	chr1:76233882	G/A	cg22875332	chr1:76189707	ACADM	-0.53	-4.69	-0.43	9.07e-6	Daytime sleep phenotypes;
THYM	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.71	-5.47	-0.49	3.63e-7	Total cholesterol levels;
THYM	cis	rs7599312	0.534	rs7607363	chr2:213402705	A/G	cg16329650	chr2:213403929	ERBB4	1.04	12.32	0.78	2.07e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7267979	0.932	rs446649	chr20:25467359	A/G	cg03522245	chr20:25566470	NINL	0.57	4.48	0.42	2.1e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg26441486	chr22:50317300	CRELD2	-0.31	-4.93	-0.45	3.42e-6	Schizophrenia;
THYM	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-13.18	-0.8	3.51e-23	Height;
THYM	cis	rs593982	0.858	rs663797	chr11:65552740	A/G	cg08755490	chr11:65554678	OVOL1	1.34	8.46	0.66	3.12e-13	Atopic dermatitis;
THYM	cis	rs1965732	0.504	rs13004799	chr2:3716456	G/A	cg25251562	chr2:3704773	ALLC	-0.58	-4.68	-0.43	9.36e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	trans	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg25214090	chr10:38739885	LOC399744	0.83	7.11	0.59	2.14e-10	Corneal astigmatism;
THYM	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg01579765	chr21:45077557	HSF2BP	0.53	8.44	0.65	3.47e-13	Mean corpuscular volume;
THYM	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg06558623	chr16:89946397	TCF25	0.9	4.7	0.43	8.81e-6	Interleukin-17 levels;
THYM	cis	rs12802200	0.535	rs12290412	chr11:569230	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.58	-4.5	-0.42	1.89e-5	Systemic lupus erythematosus;
THYM	cis	rs4285028	0.747	rs4048703	chr3:121374361	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.84	-7.2	-0.59	1.37e-10	Multiple sclerosis;
THYM	cis	rs6665290	0.904	rs1045287	chr1:227178962	C/T	cg10327440	chr1:227177885	CDC42BPA	1.14	16.31	0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs868036	0.718	rs28675295	chr15:68116400	C/A	cg26545918	chr15:68124484	LBXCOR1	0.5	4.45	0.42	2.31e-5	Restless legs syndrome;
THYM	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg18357526	chr6:26021779	HIST1H4A	0.61	4.81	0.44	5.75e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22590775	chr19:49891494	CCDC155	0.63	4.7	0.43	8.94e-6	Multiple sclerosis;
THYM	cis	rs6835098	1.000	rs9990666	chr4:174083150	G/T	cg08422745	chr4:174089978	GALNT7	-0.97	-8.28	-0.65	7.53e-13	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs9811920	0.638	rs793474	chr3:99544380	C/T	cg07805332	chr3:99536008	MIR548G;C3orf26	-0.42	-4.51	-0.42	1.85e-5	Axial length;
THYM	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs6032067	0.673	rs13042474	chr20:43893068	G/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.42	-4.54	-0.42	1.67e-5	Blood protein levels;
THYM	cis	rs6960043	1.000	rs6972333	chr7:15051643	G/A	cg19272540	chr7:15055459	NA	-0.53	-6.25	-0.54	1.15e-8	Type 2 diabetes;
THYM	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg11882607	chr3:12858926	CAND2	-0.4	-4.48	-0.42	2.09e-5	QRS complex (12-leadsum);
THYM	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs675209	0.512	rs2326878	chr6:7075094	C/A	cg07207043	chr6:7051497	NA	0.32	4.85	0.45	4.84e-6	Urate levels;
THYM	cis	rs6032067	0.641	rs6032006	chr20:43755053	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.47	-5.31	-0.48	7.26e-7	Blood protein levels;
THYM	cis	rs4731207	0.536	rs13307657	chr7:124600864	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs11671005	0.735	rs11878198	chr19:58920302	A/G	cg18639983	chr19:58920768	ZNF584	0.59	5.0	0.46	2.63e-6	Mean platelet volume;
THYM	cis	rs1048238	0.506	rs698890	chr1:16267371	C/G	cg21385522	chr1:16154831	NA	-0.68	-5.69	-0.5	1.39e-7	Systolic blood pressure;
THYM	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg05294307	chr14:35346193	BAZ1A	-0.89	-7.29	-0.6	9.28e-11	Psoriasis;
THYM	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg24596788	chr1:163392923	NA	-0.78	-7.19	-0.59	1.5e-10	Motion sickness;
THYM	cis	rs1799810	0.640	rs55998444	chr2:128119846	T/C	cg06038358	chr2:128176007	PROC	0.45	4.81	0.44	5.58e-6	Self-rated health;
THYM	cis	rs12802200	0.535	rs12290412	chr11:569230	T/C	cg16486109	chr11:613632	IRF7	0.49	5.42	0.49	4.56e-7	Systemic lupus erythematosus;
THYM	cis	rs1728785	0.901	rs11075688	chr16:68655924	A/G	cg02972257	chr16:68554789	NA	0.76	4.94	0.45	3.36e-6	Ulcerative colitis;
THYM	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg18876405	chr7:65276391	NA	0.71	6.58	0.56	2.57e-9	Aortic root size;
THYM	trans	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg18335740	chr13:41363409	SLC25A15	0.73	7.51	0.61	3.14e-11	Lewy body disease;
THYM	cis	rs9906944	0.933	rs12945020	chr17:47082775	G/A	cg11673840	chr17:47092156	IGF2BP1	-0.49	-4.78	-0.44	6.5e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg01831904	chr17:28903510	LRRC37B2	-1.02	-5.07	-0.46	1.98e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg11335335	chr11:637885	DRD4	-0.66	-5.14	-0.47	1.46e-6	Systemic lupus erythematosus;
THYM	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.96	6.22	0.54	1.34e-8	Smoking behavior;
THYM	cis	rs62070183	0.532	rs78021166	chr17:30975531	G/A	cg02981443	chr17:31254875	TMEM98	-0.52	-4.63	-0.43	1.15e-5	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg24450063	chr1:156163899	SLC25A44	-1.21	-15.42	-0.85	1.31e-27	Testicular germ cell tumor;
THYM	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg06618935	chr21:46677482	NA	-0.97	-9.48	-0.7	2.09e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4523957	0.583	rs2957926	chr17:2024030	C/T	cg16513277	chr17:2031491	SMG6	-0.96	-8.72	-0.67	9.17e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.44	0.61	4.38e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9633740	1.000	rs7922621	chr10:82251544	C/A	cg01528321	chr10:82214614	TSPAN14	0.94	4.5	0.42	1.9e-5	Post bronchodilator FEV1;
THYM	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg05347473	chr6:146136440	FBXO30	0.57	4.52	0.42	1.78e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs713587	0.967	rs713586	chr2:25158008	A/G	cg01884057	chr2:25150051	NA	0.66	6.97	0.58	4.11e-10	Body mass index in non-asthmatics;
THYM	cis	rs10905065	1.000	rs10905065	chr10:5769827	C/T	cg11519256	chr10:5708881	ASB13	0.49	4.85	0.45	4.79e-6	Menopause (age at onset);
THYM	cis	rs2235649	0.833	rs7189070	chr16:1850813	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	0.626	rs6972945	chr7:91549576	C/G	cg17063962	chr7:91808500	NA	-1.02	-9.26	-0.69	6.44e-15	Breast cancer;
THYM	cis	rs9527	0.590	rs12415199	chr10:104895536	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg11494091	chr17:61959527	GH2	1.03	16.67	0.86	5.85e-30	Prudent dietary pattern;
THYM	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg06558623	chr16:89946397	TCF25	0.98	5.43	0.49	4.39e-7	Skin colour saturation;
THYM	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg05660106	chr1:15850417	CASP9	0.76	6.27	0.54	1.06e-8	Systolic blood pressure;
THYM	cis	rs1448094	0.512	rs61930864	chr12:86246740	G/A	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg09197432	chr4:183729176	NA	0.83	5.18	0.47	1.22e-6	Pediatric autoimmune diseases;
THYM	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg09877947	chr5:131593287	PDLIM4	-0.55	-4.6	-0.43	1.31e-5	Blood metabolite levels;
THYM	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.83	0.57	8.15e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs208520	0.690	rs851458	chr6:66813279	T/G	cg07460842	chr6:66804631	NA	-1.06	-7.89	-0.63	5.14e-12	Exhaled nitric oxide output;
THYM	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg02931644	chr1:25747376	RHCE	0.58	4.46	0.42	2.28e-5	Erythrocyte sedimentation rate;
THYM	cis	rs1878931	0.520	rs2015640	chr16:3465018	G/C	cg00484396	chr16:3507460	NAT15	0.5	4.84	0.45	4.94e-6	Body mass index (adult);
THYM	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg08645402	chr16:4508243	NA	0.66	5.52	0.49	2.97e-7	Schizophrenia;
THYM	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs1395	0.744	rs72817536	chr2:27497548	A/G	cg23587288	chr2:27483067	SLC30A3	-0.59	-4.63	-0.43	1.16e-5	Blood metabolite levels;
THYM	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg05660106	chr1:15850417	CASP9	0.73	5.91	0.52	5.22e-8	Systolic blood pressure;
THYM	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg21854759	chr1:92012499	NA	-0.7	-5.58	-0.5	2.27e-7	Breast cancer;
THYM	cis	rs7599312	0.532	rs1531788	chr2:213394320	C/T	cg16329650	chr2:213403929	ERBB4	0.57	4.47	0.42	2.17e-5	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6032067	0.538	rs62206429	chr20:43730333	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.56	-4.9	-0.45	3.97e-6	Blood protein levels;
THYM	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg14675211	chr2:100938903	LONRF2	0.7	7.56	0.61	2.5e-11	Intelligence (multi-trait analysis);
THYM	cis	rs9479482	0.686	rs2010259	chr6:150385475	C/T	cg25797454	chr6:150327115	RAET1K	0.44	4.49	0.42	1.98e-5	Alopecia areata;
THYM	cis	rs6840360	0.615	rs58977077	chr4:152470239	T/G	cg22705602	chr4:152727874	NA	-0.71	-7.94	-0.63	4.03e-12	Intelligence (multi-trait analysis);
THYM	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg04455712	chr21:45112962	RRP1B	0.49	4.48	0.42	2.07e-5	Mean corpuscular volume;
THYM	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.54	-5.42	-0.49	4.43e-7	Crohn's disease;
THYM	cis	rs13256369	0.708	rs10903310	chr8:8589687	A/C	cg00074818	chr8:8560427	CLDN23	-0.58	-5.36	-0.48	5.71e-7	Obesity-related traits;
THYM	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg02269571	chr22:50332266	NA	-0.71	-4.91	-0.45	3.78e-6	Schizophrenia;
THYM	cis	rs6840360	0.642	rs4263379	chr4:152399131	G/A	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs55883249	1.000	rs62119428	chr2:9743332	T/C	cg23886495	chr2:9695866	ADAM17	0.83	5.36	0.48	5.85e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs2736337	0.532	rs6998387	chr8:11293458	C/T	cg11009520	chr8:12052164	FAM86B1	-0.58	-4.46	-0.42	2.26e-5	Rheumatoid arthritis;
THYM	cis	rs4936894	0.500	rs11219541	chr11:124130982	G/A	cg23571170	chr11:124180298	OR8D1	-0.51	-4.52	-0.42	1.8e-5	Aging (time to death);
THYM	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg27446573	chr6:127587934	RNF146	1.0	8.72	0.67	9.16e-14	Breast cancer;
THYM	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.38	0.55	6.52e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs4788570	0.584	rs8051968	chr16:71761978	C/A	cg06353428	chr16:71660113	MARVELD3	1.31	8.68	0.67	1.08e-13	Intelligence (multi-trait analysis);
THYM	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg04520793	chr17:42248056	ASB16	0.31	4.88	0.45	4.2e-6	Bone mineral density (hip);Bone mineral density;
THYM	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.56	-7.29	-0.6	9.26e-11	Monocyte percentage of white cells;
THYM	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg06064525	chr11:970664	AP2A2	-0.36	-6.98	-0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	cis	rs9902453	0.704	rs2628179	chr17:28071796	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-5.17	-0.47	1.31e-6	Coffee consumption (cups per day);
THYM	cis	rs208520	0.874	rs208491	chr6:66928459	C/G	cg07460842	chr6:66804631	NA	-0.86	-5.5	-0.49	3.15e-7	Exhaled nitric oxide output;
THYM	cis	rs995000	0.931	rs11207992	chr1:63041800	T/G	cg06896770	chr1:63153194	DOCK7	1.0	8.17	0.64	1.31e-12	Triglyceride levels;
THYM	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg24250549	chr1:154909240	PMVK	0.78	6.77	0.57	1.05e-9	Prostate cancer;
THYM	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg11882607	chr3:12858926	CAND2	-0.42	-4.65	-0.43	1.09e-5	QRS complex (12-leadsum);
THYM	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg18811423	chr2:55921094	PNPT1	0.75	7.07	0.59	2.6e-10	Metabolic syndrome;
THYM	cis	rs35934224	0.831	rs1044732	chr22:19863142	T/C	cg11182965	chr22:19864308	TXNRD2	-0.93	-7.14	-0.59	1.84e-10	Glaucoma (primary open-angle);
THYM	cis	rs7020830	0.894	rs13300951	chr9:37146627	A/G	cg14294708	chr9:37120828	ZCCHC7	1.34	18.37	0.88	4.93e-33	Schizophrenia;
THYM	cis	rs698813	0.674	rs6544752	chr2:44499049	G/A	cg04920474	chr2:44395004	PPM1B	0.56	4.46	0.42	2.23e-5	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
THYM	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg12893697	chr11:970389	AP2A2	-0.32	-5.35	-0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs28595532	0.920	rs114410095	chr4:119731110	G/A	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs2066819	1.000	rs79101914	chr12:56729739	A/G	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg10360139	chr7:1886902	MAD1L1	-0.61	-5.4	-0.48	4.86e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9649465	0.905	rs3757504	chr7:123391750	C/T	cg15443791	chr7:124364398	NA	0.56	4.63	0.43	1.16e-5	Migraine;
THYM	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06850241	chr22:41845214	NA	-0.59	-5.34	-0.48	6.24e-7	Vitiligo;
THYM	cis	rs1113500	0.933	rs10785834	chr1:108639101	A/C	cg06207961	chr1:108661230	NA	0.62	4.93	0.45	3.55e-6	Growth-regulated protein alpha levels;
THYM	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg06636001	chr8:8085503	FLJ10661	-0.62	-5.28	-0.48	8.27e-7	Joint mobility (Beighton score);
THYM	cis	rs9916302	0.752	rs676882	chr17:37433424	A/T	cg03321784	chr17:37729644	NA	-0.55	-4.51	-0.42	1.86e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg06532163	chr17:45867833	NA	-0.64	-6.45	-0.55	4.65e-9	IgG glycosylation;
THYM	cis	rs10911232	0.507	rs10752890	chr1:183021910	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs2282300	0.739	rs2225909	chr11:30329744	T/C	cg09906309	chr11:30344399	C11orf46	0.73	5.37	0.48	5.47e-7	Morning vs. evening chronotype;
THYM	cis	rs9393692	0.620	rs9358918	chr6:26286744	C/T	cg00631329	chr6:26305371	NA	-0.46	-4.71	-0.44	8.43e-6	Educational attainment;
THYM	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg16230307	chr14:35515116	FAM177A1	0.9	5.84	0.51	7.37e-8	Psoriasis;
THYM	cis	rs35883536	0.647	rs12043865	chr1:101042651	G/A	cg09408571	chr1:101003634	GPR88	-0.48	-5.2	-0.47	1.14e-6	Monocyte count;
THYM	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg11141652	chr22:24348549	GSTTP1	0.48	4.45	0.42	2.33e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg09467607	chr2:36825704	FEZ2	-0.46	-5.76	-0.51	1.02e-7	Height;
THYM	cis	rs13082711	0.953	rs35124294	chr3:27539526	A/G	cg02860705	chr3:27208620	NA	0.76	4.94	0.45	3.31e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs35883536	0.647	rs7524322	chr1:101047730	C/G	cg09408571	chr1:101003634	GPR88	0.5	5.48	0.49	3.51e-7	Monocyte count;
THYM	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg26028573	chr6:26043587	HIST1H2BB	0.53	4.55	0.42	1.6e-5	Blood metabolite levels;
THYM	cis	rs6815814	0.699	rs11730390	chr4:38881414	T/C	cg06935464	chr4:38784597	TLR10	0.74	4.61	0.43	1.23e-5	Breast cancer;
THYM	cis	rs2888875	0.632	rs6742108	chr2:43776853	T/C	cg22033476	chr2:43532275	THADA	-0.39	-4.49	-0.42	1.99e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs7106204	0.514	rs7123539	chr11:24272000	G/A	ch.11.24196551F	chr11:24239977	NA	-1.0	-6.96	-0.58	4.4e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg05299048	chr3:52828583	ITIH3	0.6	4.55	0.42	1.6e-5	Bipolar disorder;
THYM	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg24209194	chr3:40518798	ZNF619	0.63	5.06	0.46	2.04e-6	Renal cell carcinoma;
THYM	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg26441486	chr22:50317300	CRELD2	0.45	7.6	0.62	2.04e-11	Schizophrenia;
THYM	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.32	-9.88	-0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs9733	0.596	rs12072339	chr1:150686099	A/G	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg13695892	chr22:41940480	POLR3H	-0.99	-7.44	-0.61	4.51e-11	Vitiligo;
THYM	cis	rs17174870	0.955	rs17175331	chr2:112712870	C/T	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs2806561	0.765	rs641808	chr1:23514123	T/G	cg19743168	chr1:23544995	NA	0.55	5.64	0.5	1.74e-7	Height;
THYM	cis	rs66887589	0.967	rs59516282	chr4:120502016	G/A	cg13609457	chr4:120235615	NA	-0.47	-4.91	-0.45	3.74e-6	Diastolic blood pressure;
THYM	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg20283391	chr11:68216788	NA	-0.61	-4.88	-0.45	4.35e-6	Total body bone mineral density;
THYM	cis	rs7610301	1.000	rs35444533	chr3:46644257	C/T	cg22951056	chr3:46887651	NA	-0.8	-5.23	-0.47	1.01e-6	Blood protein levels;
THYM	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg25767906	chr1:53392781	SCP2	0.52	5.19	0.47	1.19e-6	Monocyte count;
THYM	cis	rs8032315	0.965	rs35346340	chr15:91427872	G/C	cg04510874	chr15:91427884	FES	0.66	4.93	0.45	3.5e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.87	0.45	4.53e-6	Bipolar disorder;
THYM	cis	rs490234	0.552	rs3122938	chr9:128157326	A/G	cg14078157	chr9:128172775	NA	0.91	7.95	0.63	3.88e-12	Mean arterial pressure;
THYM	cis	rs28476539	0.567	rs17005996	chr4:83570300	A/G	cg10249074	chr4:83542146	C4orf11	-0.66	-5.27	-0.48	8.48e-7	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs7649443	0.959	rs13072590	chr3:197011680	G/A	cg20744464	chr3:196756875	MFI2	0.62	4.56	0.42	1.53e-5	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg22974920	chr21:40686053	BRWD1	-0.6	-4.63	-0.43	1.15e-5	Cognitive function;
THYM	cis	rs11756438	0.572	rs2798326	chr6:119005226	C/T	cg21191810	chr6:118973309	C6orf204	0.59	6.06	0.53	2.78e-8	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	6.49	0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	5.92	0.52	5.15e-8	Total body bone mineral density;
THYM	cis	rs7917772	0.545	rs3934960	chr10:104355275	A/G	cg00122347	chr10:104236741	TMEM180	0.42	6.22	0.54	1.34e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7927771	0.524	rs10838732	chr11:47607940	C/G	cg18512352	chr11:47633146	NA	0.41	4.62	0.43	1.21e-5	Subjective well-being;
THYM	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg16524936	chr4:1340807	KIAA1530	-0.67	-5.19	-0.47	1.17e-6	Longevity;
THYM	cis	rs11605275	0.792	rs2568131	chr11:20046407	G/T	cg14835545	chr11:20032148	NAV2	1.13	5.62	0.5	1.87e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg00080972	chr5:178986291	RUFY1	-0.49	-5.82	-0.51	7.91e-8	Lung cancer;
THYM	cis	rs7394190	0.748	rs11541237	chr10:75530962	C/T	cg07699608	chr10:75541558	CHCHD1	0.91	4.93	0.45	3.49e-6	Incident atrial fibrillation;
THYM	cis	rs28595532	0.920	rs116091383	chr4:119635518	A/G	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs11690935	0.655	rs1028127	chr2:172530036	T/C	cg13550731	chr2:172543902	DYNC1I2	0.61	4.79	0.44	6.05e-6	Schizophrenia;
THYM	cis	rs10170846	0.893	rs11692810	chr2:223544096	A/C	cg25565276	chr2:223520875	FARSB	-0.65	-4.74	-0.44	7.58e-6	Schizophrenia (inflammation and infection response interaction);
THYM	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg02640540	chr1:67518911	SLC35D1	0.59	4.64	0.43	1.09e-5	Lymphocyte percentage of white cells;
THYM	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg23583168	chr7:148888333	NA	-0.99	-13.42	-0.81	1.17e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg23791538	chr6:167370224	RNASET2	0.74	5.92	0.52	5.06e-8	Crohn's disease;
THYM	cis	rs6754311	0.678	rs309181	chr2:136614813	C/G	cg23851026	chr2:136556271	LCT	-0.5	-4.76	-0.44	6.97e-6	Mosquito bite size;
THYM	cis	rs7131987	0.621	rs11050181	chr12:29467669	C/T	cg09582351	chr12:29534625	ERGIC2	-0.6	-5.2	-0.47	1.14e-6	QT interval;
THYM	cis	rs7173389	0.551	rs75952618	chr15:73676517	G/A	cg15851312	chr15:73076263	ADPGK	-0.85	-4.46	-0.42	2.2e-5	Resting heart rate;
THYM	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg18105134	chr13:113819100	PROZ	-0.98	-9.0	-0.68	2.28e-14	Platelet distribution width;
THYM	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg21644426	chr2:191273491	MFSD6	-0.64	-4.51	-0.42	1.88e-5	Diastolic blood pressure;
THYM	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.8	7.19	0.59	1.5e-10	Prudent dietary pattern;
THYM	cis	rs7828089	0.504	rs4872505	chr8:22337996	A/T	cg12081754	chr8:22256438	SLC39A14	0.64	5.77	0.51	1.01e-7	Verbal declarative memory;
THYM	cis	rs7584330	0.518	rs74003104	chr2:238446823	C/T	cg08992911	chr2:238395768	MLPH	0.9	5.47	0.49	3.65e-7	Prostate cancer;
THYM	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11644478	chr21:40555479	PSMG1	0.95	5.44	0.49	4.06e-7	Cognitive function;
THYM	cis	rs4849845	0.889	rs4091515	chr2:121043403	G/A	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs4746818	1.000	rs9299502	chr10:70876934	C/T	cg04149295	chr10:70884716	VPS26A	0.8	5.44	0.49	4.18e-7	Left atrial antero-posterior diameter;
THYM	cis	rs35883536	1.000	rs3861733	chr1:101111807	G/A	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg03929089	chr4:120376271	NA	-0.99	-12.83	-0.8	1.9e-22	Height;
THYM	cis	rs1021993	0.953	rs950890	chr1:209482817	A/C	cg06155620	chr1:209527581	NA	0.53	4.83	0.44	5.26e-6	Gut microbiome composition (winter);
THYM	cis	rs12142240	0.698	rs56049453	chr1:46835468	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7246657	1.000	rs7247672	chr19:37743928	A/G	cg22634378	chr19:37742834	NA	0.64	5.31	0.48	7.33e-7	Coronary artery calcification;
THYM	cis	rs4654899	0.733	rs10916907	chr1:21261088	A/C	cg01072550	chr1:21505969	NA	-0.75	-7.21	-0.59	1.34e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg11789530	chr4:8429930	ACOX3	-0.75	-6.02	-0.53	3.23e-8	Response to antineoplastic agents;
THYM	cis	rs7725337	0.929	rs3850654	chr5:88370560	C/T	cg11280525	chr5:87955695	LOC645323	-0.41	-4.64	-0.43	1.12e-5	Total body bone mineral density;
THYM	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs516946	1.000	rs516946	chr8:41519248	C/T	cg19441908	chr8:41529140	ANK1	0.63	4.82	0.44	5.41e-6	Type 2 diabetes;
THYM	cis	rs11249608	0.548	rs6859936	chr5:178451214	T/C	cg01312482	chr5:178451176	ZNF879	-0.76	-6.36	-0.55	7.14e-9	Pubertal anthropometrics;
THYM	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.78	-7.17	-0.59	1.61e-10	Personality dimensions;
THYM	cis	rs3017493	0.685	rs78711146	chr11:70671687	G/A	cg14537332	chr11:70508113	SHANK2	1.15	7.3	0.6	8.87e-11	Renal transplant outcome;
THYM	cis	rs4664308	1.000	rs6759836	chr2:160912802	C/T	cg03641300	chr2:160917029	PLA2R1	-0.76	-6.89	-0.58	6.12e-10	Idiopathic membranous nephropathy;
THYM	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.09e-8	Systolic blood pressure;
THYM	cis	rs7843479	0.965	rs9314269	chr8:21804989	A/G	cg17168535	chr8:21777572	XPO7	0.72	5.25	0.47	9.39e-7	Mean corpuscular volume;
THYM	cis	rs7586879	0.639	rs2384058	chr2:25100328	A/G	cg27107076	chr2:25050844	ADCY3	-0.28	-4.47	-0.42	2.16e-5	Body mass index;
THYM	cis	rs6906287	0.647	rs3890198	chr6:118706447	T/C	cg21191810	chr6:118973309	C6orf204	0.56	5.45	0.49	3.93e-7	Electrocardiographic conduction measures;
THYM	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg25918947	chr17:41365094	TMEM106A	0.56	4.62	0.43	1.22e-5	Menopause (age at onset);
THYM	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg08017756	chr2:100939284	LONRF2	-0.74	-7.61	-0.62	1.98e-11	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs1160297	0.575	rs10865272	chr2:53093447	C/T	cg07782112	chr2:53107842	NA	0.72	5.76	0.51	1.02e-7	Hemostatic factors and hematological phenotypes;
THYM	cis	rs8030485	0.536	rs4778918	chr15:79434040	T/C	cg17916960	chr15:79447300	NA	0.62	7.17	0.59	1.6e-10	Left ventricle wall thickness;
THYM	cis	rs7695732	0.595	rs10033484	chr4:89905472	A/G	cg17769793	chr4:89976368	FAM13A	-0.5	-5.63	-0.5	1.84e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs9826463	1.000	rs7647212	chr3:142322055	G/A	cg20824294	chr3:142316082	PLS1	0.64	4.66	0.43	1.01e-5	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs7772486	0.754	rs6570703	chr6:145957052	C/T	cg13319975	chr6:146136371	FBXO30	-0.67	-5.46	-0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6964587	0.692	rs6953256	chr7:91575417	C/T	cg22709100	chr7:91322751	NA	-0.63	-4.67	-0.43	1e-5	Breast cancer;
THYM	cis	rs9633835	0.524	rs4756763	chr11:13280556	G/A	cg13286116	chr11:13302098	ARNTL	-0.72	-8.02	-0.64	2.71e-12	Body mass index;
THYM	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2964802	0.505	rs6897847	chr5:10831632	T/C	cg14521931	chr5:10832172	NA	-0.67	-5.78	-0.51	9.47e-8	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs67460515	0.531	rs13315565	chr3:160754626	G/C	cg12349858	chr3:160822545	B3GALNT1	0.63	5.14	0.47	1.47e-6	Parkinson's disease;
THYM	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	10.0	0.72	1.67e-16	Platelet count;
THYM	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg26384229	chr12:38710491	ALG10B	0.95	7.55	0.61	2.7e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs8013055	0.796	rs4075105	chr14:106000231	C/T	cg11597832	chr14:105993747	TMEM121	-0.52	-4.52	-0.42	1.77e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg14779329	chr11:130786720	SNX19	0.56	6.33	0.54	7.96e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs12188164	0.965	rs56346498	chr5:423595	C/T	cg26850624	chr5:429559	AHRR	-0.7	-5.5	-0.49	3.15e-7	Cystic fibrosis severity;
THYM	cis	rs7828089	0.646	rs12679702	chr8:22282190	G/C	cg12081754	chr8:22256438	SLC39A14	0.82	7.22	0.6	1.3e-10	Verbal declarative memory;
THYM	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg00786635	chr1:25594202	NA	0.92	7.28	0.6	9.7e-11	Erythrocyte sedimentation rate;
THYM	cis	rs10992471	0.598	rs1175788	chr9:95117798	C/T	cg14631576	chr9:95140430	CENPP	-0.71	-6.41	-0.55	5.55e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs72627123	1.000	rs72627122	chr14:74368236	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg10018233	chr7:150070692	REPIN1	0.37	5.3	0.48	7.38e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg11941060	chr3:133502564	NA	0.73	6.33	0.54	8.21e-9	Iron status biomarkers;
THYM	cis	rs7084402	0.967	rs12242287	chr10:60278340	A/G	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.05e-6	Refractive error;
THYM	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg08000102	chr2:233561755	GIGYF2	-0.68	-5.97	-0.52	4.08e-8	Coronary artery disease;
THYM	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg02820040	chr2:241836501	C2orf54	-0.32	-6.4	-0.55	5.9e-9	Urinary metabolites;
THYM	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-5.53	-0.49	2.8e-7	Prostate cancer;
THYM	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg07507251	chr3:52567010	NT5DC2	0.45	5.39	0.48	5.02e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11645898	0.935	rs72787091	chr16:72190184	C/T	cg03805757	chr16:71968109	PKD1L3	-0.69	-5.1	-0.46	1.74e-6	Blood protein levels;
THYM	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg02269571	chr22:50332266	NA	-0.7	-4.91	-0.45	3.84e-6	Schizophrenia;
THYM	cis	rs7100689	0.646	rs7077854	chr10:82124070	C/T	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs786425	0.585	rs10744162	chr12:124243707	T/C	cg15249119	chr12:124971054	NCOR2	0.52	4.77	0.44	6.73e-6	Pubertal anthropometrics;
THYM	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg06108461	chr20:60628389	TAF4	-1.06	-9.1	-0.68	1.39e-14	Body mass index;
THYM	cis	rs6754311	0.593	rs4954280	chr2:136420690	C/T	cg23851026	chr2:136556271	LCT	-0.59	-5.74	-0.51	1.14e-7	Mosquito bite size;
THYM	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg08859206	chr1:53392774	SCP2	0.47	4.84	0.44	5.09e-6	Monocyte count;
THYM	cis	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs3857067	0.806	rs11943926	chr4:95136512	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.48	-0.42	2.07e-5	QT interval;
THYM	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg12379764	chr21:47803548	PCNT	-0.79	-5.07	-0.46	1.95e-6	Testicular germ cell tumor;
THYM	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg25427524	chr10:38739819	LOC399744	-0.73	-6.77	-0.57	1.04e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg17796960	chr10:135278976	LOC619207	-0.59	-4.87	-0.45	4.38e-6	Systemic lupus erythematosus;
THYM	cis	rs8180040	0.835	rs6780013	chr3:47452118	G/A	cg16586182	chr3:47516702	SCAP	0.67	5.63	0.5	1.79e-7	Colorectal cancer;
THYM	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg08132940	chr7:1081526	C7orf50	-1.16	-6.72	-0.57	1.36e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3916	0.911	rs34673751	chr12:121171891	G/A	cg21892295	chr12:121157589	UNC119B	-0.49	-4.68	-0.43	9.53e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs2898681	0.642	rs11538878	chr4:53728524	T/C	cg00791764	chr4:53727839	RASL11B	0.47	6.22	0.54	1.32e-8	Optic nerve measurement (cup area);
THYM	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg09035930	chr12:129282057	SLC15A4	0.85	10.29	0.73	3.94e-17	Systemic lupus erythematosus;
THYM	cis	rs904251	0.737	rs914347	chr6:37484970	A/C	cg25019722	chr6:37503610	NA	-0.64	-5.12	-0.47	1.59e-6	Cognitive performance;
THYM	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg23750338	chr8:142222470	SLC45A4	-0.52	-4.87	-0.45	4.48e-6	Immature fraction of reticulocytes;
THYM	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.61	-0.43	1.27e-5	Type 2 diabetes;
THYM	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.05	6.74	0.57	1.23e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs57994353	0.865	rs35857370	chr9:139354097	G/A	cg14115884	chr9:139300582	SDCCAG3	0.73	5.44	0.49	4.2e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg14779329	chr11:130786720	SNX19	0.55	6.05	0.53	2.89e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg17127132	chr2:85788382	GGCX	0.7	6.22	0.54	1.32e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	trans	rs3745567	0.688	rs2241394	chr19:6685230	C/G	cg11100804	chr5:140783173	PCDHGA4;PCDHGA6;PCDHGA1;PCDHGA8;PCDHGA5;PCDHGB1;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA9;PCDHGA7;PCDHGB2;PCDHGB5;PCDHGB3	0.82	7.09	0.59	2.33e-10	Complement C3 and C4 levels;
THYM	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs2717559	0.522	rs2585159	chr8:143875817	G/A	cg17252645	chr8:143867129	LY6D	0.82	10.09	0.72	1.08e-16	Urinary tract infection frequency;
THYM	cis	rs6844506	0.607	rs2136758	chr4:185226060	T/A	cg12654155	chr4:185238627	NA	-0.57	-4.61	-0.43	1.24e-5	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
THYM	cis	rs17125944	0.615	rs7146179	chr14:53298853	A/G	cg00686598	chr14:53173677	PSMC6	-1.01	-4.78	-0.44	6.39e-6	Alzheimer's disease (late onset);
THYM	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg21427119	chr20:30132790	HM13	-0.86	-6.07	-0.53	2.65e-8	Mean corpuscular hemoglobin;
THYM	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs9583531	0.689	rs9521913	chr13:111382058	C/T	cg24331049	chr13:111365604	ING1	-0.64	-5.42	-0.49	4.55e-7	Coronary artery disease;
THYM	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg22535103	chr8:58192502	C8orf71	-0.94	-5.62	-0.5	1.86e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs12530845	0.943	rs58577912	chr7:135329269	T/G	cg23117316	chr7:135346802	PL-5283	-0.67	-5.92	-0.52	5.05e-8	Red blood cell traits;
THYM	cis	rs6032067	0.561	rs2743317	chr20:43936931	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-5.89	-0.52	5.9e-8	Blood protein levels;
THYM	cis	rs12711979	0.765	rs7559461	chr2:3818623	G/A	cg17052675	chr2:3827356	NA	-0.49	-5.23	-0.47	9.93e-7	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg27490568	chr2:178487706	NA	0.57	4.96	0.45	3.05e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7429990	0.965	rs7430913	chr3:48032357	G/T	cg02219026	chr3:48282209	ZNF589	0.6	4.5	0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs2069036	0.953	rs4275520	chr10:16090779	G/A	cg26633223	chr10:15133461	NA	0.68	4.66	0.43	1.02e-5	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg00071950	chr4:10020882	SLC2A9	-0.69	-6.13	-0.53	2e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.61	-0.43	1.27e-5	Type 2 diabetes;
THYM	cis	rs11122272	0.735	rs2790873	chr1:231539685	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-5.32	-0.48	6.84e-7	Hemoglobin concentration;
THYM	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg14784868	chr12:69753453	YEATS4	1.13	12.26	0.78	2.8e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg00814883	chr7:100076585	TSC22D4	-1.0	-6.82	-0.57	8.43e-10	Platelet count;
THYM	cis	rs8063160	0.867	rs59574756	chr16:90067513	A/G	cg07984980	chr16:89898383	SPIRE2	1.26	5.07	0.46	1.92e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.61	5.43	0.49	4.25e-7	Personality dimensions;
THYM	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg15501526	chr10:2543763	NA	0.77	7.64	0.62	1.7e-11	Age-related hearing impairment;
THYM	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11645898	0.872	rs4788459	chr16:72153125	C/G	cg03805757	chr16:71968109	PKD1L3	-0.73	-5.41	-0.49	4.66e-7	Blood protein levels;
THYM	cis	rs807669	0.868	rs762529	chr22:19170205	C/G	cg02655711	chr22:19163373	SLC25A1	0.98	11.86	0.77	1.93e-20	Metabolite levels;
THYM	trans	rs2136093	0.600	rs1981302	chr1:90908547	T/C	cg21057494	chr3:45066971	CLEC3B	0.53	7.07	0.59	2.65e-10	Response to antidepressants;
THYM	cis	rs6450176	0.564	rs255759	chr5:53328549	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.94	-8.32	-0.65	6.26e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22307029	chr19:49891270	CCDC155	0.82	7.43	0.61	4.71e-11	Multiple sclerosis;
THYM	cis	rs988913	0.706	rs6910384	chr6:54743998	G/A	cg04690482	chr6:54711388	FAM83B	0.44	4.58	0.43	1.4e-5	Menarche (age at onset);
THYM	cis	rs933688	1.000	rs186717	chr5:90780467	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	7.1	0.59	2.24e-10	Smoking behavior;
THYM	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg22166914	chr1:53195759	ZYG11B	0.92	10.92	0.75	1.79e-18	Monocyte count;
THYM	cis	rs1113500	0.897	rs11185263	chr1:108639804	C/G	cg06207961	chr1:108661230	NA	0.64	5.16	0.47	1.36e-6	Growth-regulated protein alpha levels;
THYM	cis	rs448720	1.000	rs2219800	chr15:68208760	G/A	cg23793686	chr15:68133972	NA	-0.48	-4.46	-0.42	2.27e-5	Cognitive performance;
THYM	cis	rs9534288	0.797	rs2404729	chr13:46617368	C/T	cg15192986	chr13:46630673	CPB2	-0.66	-4.69	-0.43	8.98e-6	Blood protein levels;
THYM	cis	rs7590720	0.704	rs7603645	chr2:216876949	C/G	cg12620499	chr2:216877984	MREG	1.06	9.09	0.68	1.42e-14	Alcohol dependence;
THYM	cis	rs919433	0.519	rs700656	chr2:198653667	T/C	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg00191853	chr8:101177733	SPAG1	-0.56	-5.59	-0.5	2.15e-7	Atrioventricular conduction;
THYM	cis	rs995000	0.931	rs1690766	chr1:62987289	T/C	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg00958927	chr1:175162553	KIAA0040	0.35	4.88	0.45	4.32e-6	Diastolic blood pressure;
THYM	cis	rs7616559	0.530	rs7616314	chr3:156728530	C/G	cg15697575	chr3:156784781	NA	-0.34	-4.88	-0.45	4.27e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg10589385	chr1:150898437	SETDB1	0.62	5.08	0.46	1.9e-6	Melanoma;
THYM	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg11247378	chr22:39784982	NA	-1.02	-12.84	-0.8	1.82e-22	Intelligence (multi-trait analysis);
THYM	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg00129232	chr17:37814104	STARD3	-0.87	-7.23	-0.6	1.23e-10	Asthma;
THYM	cis	rs9565309	0.579	rs75065210	chr13:77588491	A/G	cg13866767	chr13:78470850	EDNRB	1.06	4.81	0.44	5.76e-6	Morning vs. evening chronotype;
THYM	trans	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg10856724	chr12:34555212	NA	-1.01	-9.21	-0.69	7.89e-15	Bladder cancer;
THYM	cis	rs2456568	0.741	rs2102332	chr11:93635281	G/T	cg26875233	chr11:93583750	C11orf90	-0.53	-5.53	-0.49	2.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs76935404	0.811	rs12150973	chr19:41434524	T/C	cg19493303	chr19:41414353	NA	0.56	5.13	0.47	1.53e-6	nicotine metabolite ratio in current smokers;
THYM	cis	rs2302612	0.528	rs3771188	chr2:102840348	T/C	cg13315345	chr2:102803985	IL1RL2	0.68	4.71	0.43	8.61e-6	Serum protein levels (sST2);
THYM	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg02782426	chr3:40428986	ENTPD3	-0.49	-4.56	-0.42	1.5e-5	Renal cell carcinoma;
THYM	trans	rs11175492	1.000	rs73321733	chr12:65039646	G/C	cg12514734	chr12:3216258	TSPAN9	1.59	7.44	0.61	4.38e-11	Platelet count;
THYM	cis	rs11658309	1	rs11658309	chr17:17762247	T/G	cg04398451	chr17:18023971	MYO15A	0.8	7.75	0.62	1.03e-11	Strep throat;
THYM	cis	rs990171	0.770	rs7562254	chr2:102924947	A/C	cg13897122	chr2:103039542	IL18RAP	-0.43	-5.1	-0.46	1.71e-6	Lymphocyte counts;
THYM	cis	rs4363385	0.714	rs4845329	chr1:152974454	G/C	cg13444842	chr1:152974279	SPRR3	-0.57	-4.53	-0.42	1.74e-5	Inflammatory skin disease;
THYM	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg06108461	chr20:60628389	TAF4	-0.82	-6.66	-0.56	1.74e-9	Body mass index;
THYM	cis	rs289828	0.519	rs34385951	chr2:152154208	A/G	cg05960677	chr2:152117363	RBM43	0.7	6.33	0.54	8e-9	Blood protein levels;
THYM	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg13147721	chr7:65941812	NA	0.59	4.48	0.42	2.08e-5	Diabetic kidney disease;
THYM	cis	rs977987	0.806	rs1544810	chr16:75411163	A/T	cg03315344	chr16:75512273	CHST6	0.72	6.09	0.53	2.34e-8	Dupuytren's disease;
THYM	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.69	5.23	0.47	1e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg08999081	chr20:33150536	PIGU	0.59	5.04	0.46	2.2e-6	Coronary artery disease;
THYM	cis	rs10501293	0.746	rs7114320	chr11:43013621	C/G	cg03447554	chr11:43094025	NA	-0.6	-4.46	-0.42	2.21e-5	Cognitive performance;
THYM	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.74	8.1	0.64	1.83e-12	Eosinophil percentage of white cells;
THYM	cis	rs9467711	0.651	rs34555420	chr6:26090270	G/T	cg16898833	chr6:26189333	HIST1H4D	1.33	4.61	0.43	1.24e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs792448	0.717	rs1389371	chr1:212410155	A/G	cg14523881	chr1:213164074	VASH2	0.61	4.88	0.45	4.31e-6	White blood cell count (basophil);
THYM	cis	rs7193541	0.965	rs7199068	chr16:74698263	C/G	cg01733217	chr16:74700730	RFWD3	0.84	8.29	0.65	7.24e-13	Multiple myeloma;
THYM	cis	rs67072384	0.892	rs7104664	chr11:72444450	C/T	cg01380194	chr11:72452482	ARAP1	-0.83	-4.7	-0.43	8.89e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.1	-0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs921968	0.643	rs508157	chr2:219435288	G/A	cg02176678	chr2:219576539	TTLL4	0.64	6.08	0.53	2.49e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg19052272	chr2:3704530	ALLC	-0.67	-5.0	-0.46	2.62e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.71	5.81	0.51	8.35e-8	Menarche (age at onset);
THYM	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg27446573	chr6:127587934	RNF146	1.02	9.5	0.7	1.93e-15	Breast cancer;
THYM	cis	rs9810089	0.814	rs864437	chr3:136119909	C/G	cg12473912	chr3:136751656	NA	0.64	5.39	0.48	5.15e-7	Gestational age at birth (child effect);
THYM	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs9682041	0.622	rs7640791	chr3:170155726	G/C	cg11886554	chr3:170076028	SKIL	1.08	4.58	0.43	1.39e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	trans	rs9951602	0.512	rs4799246	chr18:76653417	A/G	cg02800362	chr5:177631904	HNRNPAB	1.12	8.75	0.67	7.73e-14	Obesity-related traits;
THYM	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.8e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9807989	0.507	rs10203558	chr2:103027640	T/C	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs17401966	1.000	rs1339458	chr1:10328338	C/T	cg20482658	chr1:10539492	PEX14	0.38	4.54	0.42	1.67e-5	Hepatocellular carcinoma;
THYM	cis	rs7917772	0.510	rs2001389	chr10:104375258	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs28595532	0.764	rs115011450	chr4:119778171	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.08	0.46	1.92e-6	Cannabis dependence symptom count;
THYM	cis	rs368123	0.686	rs2774226	chr6:160700386	G/A	cg19643109	chr6:160697625	NA	-0.72	-7.74	-0.62	1.06e-11	Waist circumference;
THYM	cis	rs11771526	0.901	rs62457472	chr7:32306885	A/G	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs9905704	0.918	rs304282	chr17:56785571	T/C	cg12560992	chr17:57184187	TRIM37	0.67	4.68	0.43	9.59e-6	Testicular germ cell tumor;
THYM	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg02734326	chr4:10020555	SLC2A9	0.7	6.21	0.54	1.39e-8	Bone mineral density;
THYM	cis	rs6748734	0.625	rs4312489	chr2:241821068	T/A	cg09990169	chr2:241835740	C2orf54	-0.32	-5.16	-0.47	1.35e-6	Urinary metabolites;
THYM	cis	rs4866334	1.000	rs75533364	chr5:18453341	G/A	cg02002538	chr5:17811409	NA	-1.09	-4.54	-0.42	1.67e-5	IgG glycosylation;
THYM	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs2505998	0.833	rs2742244	chr10:43603592	G/C	cg06632098	chr10:43605906	RET	-1.11	-11.1	-0.75	7.48e-19	Hirschsprung disease;
THYM	cis	rs40363	0.645	rs37774	chr16:3512695	T/C	cg05754148	chr16:3507555	NAT15	0.74	7.14	0.59	1.86e-10	Tuberculosis;
THYM	cis	rs9388451	0.536	rs34725880	chr6:126155237	A/G	cg10911889	chr6:126070802	HEY2	0.63	4.8	0.44	5.85e-6	Brugada syndrome;
THYM	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg25072359	chr17:41440525	NA	0.66	4.53	0.42	1.7e-5	Menopause (age at onset);
THYM	cis	rs7084402	0.967	rs1649081	chr10:60292444	G/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs6840360	0.571	rs62327275	chr4:152548238	G/T	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs888194	0.568	rs10850141	chr12:109876128	C/T	cg10504392	chr12:110044639	NA	0.53	4.45	0.42	2.33e-5	Neuroticism;
THYM	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg02725872	chr8:58115012	NA	-0.97	-7.19	-0.59	1.48e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs2985684	0.948	rs6572592	chr14:50080871	G/A	cg02151108	chr14:50098012	C14orf104	-0.69	-5.74	-0.51	1.15e-7	Carotid intima media thickness;
THYM	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg12893697	chr11:970389	AP2A2	-0.32	-5.35	-0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg11189052	chr15:85197271	WDR73	-0.61	-4.75	-0.44	7.08e-6	P wave terminal force;
THYM	cis	rs11711311	1.000	rs2242108	chr3:113433903	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.27	-0.48	8.56e-7	IgG glycosylation;
THYM	cis	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg18898632	chr2:242989856	NA	-0.66	-4.46	-0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg01699819	chr7:1052092	C7orf50	-0.59	-5.02	-0.46	2.45e-6	Bronchopulmonary dysplasia;
THYM	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg09307838	chr4:120376055	NA	0.65	4.79	0.44	6.07e-6	Corneal astigmatism;
THYM	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg17644776	chr2:200775616	C2orf69	-0.72	-5.03	-0.46	2.33e-6	Schizophrenia;
THYM	cis	rs13102973	0.965	rs6853276	chr4:135881445	A/T	cg14419869	chr4:135874104	NA	0.89	8.63	0.66	1.39e-13	Subjective well-being;
THYM	cis	rs12049351	0.665	rs10916477	chr1:229576965	C/T	cg11742688	chr1:229674241	ABCB10	-0.54	-4.56	-0.42	1.54e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs13064411	0.696	rs13325046	chr3:113104444	C/T	cg18753928	chr3:113234510	CCDC52	-0.93	-8.32	-0.65	6.22e-13	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.63	4.56	0.42	1.55e-5	Multiple sclerosis;
THYM	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	4.55	0.42	1.57e-5	Bipolar disorder;
THYM	cis	rs2976388	0.647	rs2585154	chr8:143783485	C/T	cg13446199	chr8:143762866	PSCA	-0.43	-4.73	-0.44	7.84e-6	Urinary tract infection frequency;
THYM	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg06112835	chr11:68658793	MRPL21	0.47	6.78	0.57	1e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7940866	0.838	rs10750455	chr11:130800330	C/T	cg05962950	chr11:130786565	SNX19	0.84	7.07	0.59	2.6200000000000003e-10	Schizophrenia;
THYM	cis	rs939658	0.805	rs11634679	chr15:79432475	T/C	cg17916960	chr15:79447300	NA	-0.73	-8.47	-0.66	3.05e-13	Refractive error;
THYM	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg15428835	chr7:75027521	TRIM73;TRIM74	-0.78	-6.36	-0.55	6.96e-9	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4731207	0.698	rs727506	chr7:124462027	A/G	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00908189	chr16:619842	PIGQ	1.06	9.31	0.69	5e-15	Height;
THYM	cis	rs7246967	0.673	rs57736314	chr19:22880272	T/G	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg04267008	chr7:1944627	MAD1L1	-0.62	-5.48	-0.49	3.51e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg07917127	chr4:99064746	C4orf37	0.59	4.48	0.42	2.05e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11997175	0.583	rs12680811	chr8:33778426	A/C	ch.8.33884649F	chr8:33765107	NA	0.69	5.36	0.48	5.91e-7	Body mass index;
THYM	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg00495681	chr13:53174319	NA	0.73	7.22	0.6	1.25e-10	Lewy body disease;
THYM	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg18230493	chr5:56204884	C5orf35	-0.86	-4.79	-0.44	6.13e-6	Type 2 diabetes;
THYM	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg15921436	chr17:44337874	NA	0.78	6.3	0.54	9.05e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs757081	0.667	rs569780	chr11:17206745	C/T	cg07093617	chr11:18158918	MRGPRX3	-0.49	-4.61	-0.43	1.23e-5	Systolic blood pressure;
THYM	cis	rs11089937	0.651	rs1543779	chr22:22548492	C/T	cg06866756	chr22:22471216	NA	0.47	5.55	0.49	2.56e-7	Periodontitis (PAL4Q3);
THYM	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg05043794	chr9:111880884	C9orf5	-0.41	-6.15	-0.53	1.8e-8	Menarche (age at onset);
THYM	cis	rs887829	0.570	rs10203266	chr2:234596368	G/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-6.51	-0.56	3.47e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs988913	0.957	rs9382397	chr6:54782893	A/G	cg19716238	chr6:54711378	FAM83B	0.51	5.02	0.46	2.4e-6	Menarche (age at onset);
THYM	cis	rs6570726	0.791	rs414600	chr6:145879606	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2970992	0.741	rs10176355	chr2:101335078	G/A	cg01042948	chr2:101319752	NA	0.59	5.84	0.51	7.15e-8	Educational attainment;
THYM	cis	rs7529073	0.815	rs1431983	chr1:214148772	A/C	cg24083324	chr1:214162604	PROX1	0.6	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg06618935	chr21:46677482	NA	-0.99	-9.26	-0.69	6.42e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13012494	chr21:47604986	C21orf56	-0.75	-5.19	-0.47	1.18e-6	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg10856724	chr12:34555212	NA	0.8	7.4	0.6	5.4e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs17433780	0.860	rs61798916	chr1:89493957	G/A	cg09516651	chr1:89888402	LOC400759	0.96	7.66	0.62	1.58e-11	Carotid intima media thickness;
THYM	trans	rs2540647	0.706	rs2518804	chr22:18975504	A/C	cg19521646	chr19:15197788	OR1I1	1.02	6.88	0.58	6.37e-10	Blood metabolite ratios;
THYM	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg25588787	chr5:154027256	NA	0.9	4.6	0.43	1.32e-5	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg12310025	chr6:25882481	NA	0.71	5.91	0.52	5.36e-8	Blood metabolite levels;
THYM	cis	rs10895275	0.649	rs7104685	chr11:102087163	A/G	cg24447756	chr11:102105824	NA	0.47	4.75	0.44	7.27e-6	Migraine;
THYM	cis	rs67460515	0.892	rs11710489	chr3:161093332	G/A	cg03342759	chr3:160939853	NMD3	-0.9	-7.93	-0.63	4.25e-12	Parkinson's disease;
THYM	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg08901578	chr4:187885870	NA	-0.68	-6.63	-0.56	2.07e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10895275	0.924	rs12786272	chr11:102086363	C/T	cg24447756	chr11:102105824	NA	0.54	4.74	0.44	7.37e-6	Migraine;
THYM	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.09	-0.64	1.9e-12	Mean corpuscular volume;
THYM	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21582582	chr3:182698605	DCUN1D1	0.8	7.0	0.58	3.67e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.43	1.27e-5	Breast cancer;
THYM	cis	rs17818399	0.926	rs35350086	chr2:46834036	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.63	4.5	0.42	1.93e-5	Height;
THYM	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg09354556	chr3:47051341	NA	0.45	4.63	0.43	1.14e-5	Colorectal cancer;
THYM	cis	rs611744	0.905	rs610891	chr8:109161003	C/T	cg21045802	chr8:109455806	TTC35	-0.55	-4.8	-0.44	6e-6	Dupuytren's disease;
THYM	cis	rs9902453	0.904	rs4994353	chr17:28386280	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-4.62	-0.43	1.18e-5	Coffee consumption (cups per day);
THYM	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-1.0	-8.15	-0.64	1.44e-12	Schizophrenia;
THYM	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg10803722	chr21:46713166	LOC642852	-0.42	-5.57	-0.5	2.4e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs854765	0.583	rs62064156	chr17:17822480	C/T	cg16928487	chr17:17741425	SREBF1	-0.54	-5.21	-0.47	1.08e-6	Total body bone mineral density;
THYM	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg05425664	chr17:57184151	TRIM37	-0.61	-4.81	-0.44	5.61e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6987853	0.787	rs2923441	chr8:42429937	G/T	cg09913449	chr8:42400586	C8orf40	-1.06	-11.6	-0.77	6.75e-20	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4746818	1.000	rs10762259	chr10:70890929	C/T	cg04149295	chr10:70884716	VPS26A	0.84	5.92	0.52	5.05e-8	Left atrial antero-posterior diameter;
THYM	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg18105134	chr13:113819100	PROZ	-0.98	-9.05	-0.68	1.79e-14	Platelet distribution width;
THYM	cis	rs17006441	0.932	rs6781171	chr3:69845553	A/T	cg18496212	chr3:69797108	MITF	0.69	7.12	0.59	2.02e-10	Hemoglobin concentration;
THYM	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11644478	chr21:40555479	PSMG1	1.1	9.84	0.71	3.61e-16	Cognitive function;
THYM	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg03433033	chr1:76189801	ACADM	0.79	11.21	0.75	4.52e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4523957	0.651	rs898748	chr17:2085475	G/T	cg16513277	chr17:2031491	SMG6	-0.95	-8.69	-0.67	1.05e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	trans	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg10856724	chr12:34555212	NA	-0.94	-8.62	-0.66	1.47e-13	Bladder cancer;
THYM	cis	rs3768617	0.510	rs1413388	chr1:183096694	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.9	7.83	0.63	6.8e-12	Multiple sclerosis;
THYM	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg11211951	chr8:145729740	GPT	0.55	5.37	0.48	5.58e-7	Age at first birth;
THYM	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg07690219	chr3:49449608	TCTA;RHOA	0.69	4.62	0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	10.73	0.74	4.66e-18	Chronic sinus infection;
THYM	cis	rs10208940	0.614	rs35149981	chr2:68751584	G/T	cg09157127	chr2:69201416	GKN1	0.89	4.71	0.43	8.61e-6	Urate levels in lean individuals;
THYM	cis	rs9311676	0.656	rs56232415	chr3:58394850	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	trans	rs58106596	0.747	rs72994902	chr2:232585117	G/T	cg01370599	chr3:116745421	NA	0.96	7.02	0.58	3.32e-10	White blood cell count;Lymphocyte counts;
THYM	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg17173187	chr15:85201210	NMB	0.57	5.85	0.51	6.94e-8	Schizophrenia;
THYM	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg21100191	chr22:23484243	RTDR1	0.75	6.65	0.56	1.84e-9	Bone mineral density;
THYM	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22496380	chr5:211416	CCDC127	-1.28	-7.77	-0.62	9.06e-12	Breast cancer;
THYM	cis	rs2692947	0.644	rs2969491	chr2:96794982	C/T	cg23100626	chr2:96804247	ASTL	0.39	4.77	0.44	6.56e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs72949976	0.584	rs12471432	chr2:214022893	A/T	cg08319019	chr2:214017104	IKZF2	0.81	7.05	0.59	2.91e-10	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs61931739	0.513	rs1463634	chr12:33899621	A/G	cg10856724	chr12:34555212	NA	-0.67	-5.95	-0.52	4.46e-8	Morning vs. evening chronotype;
THYM	cis	rs4481887	1.000	rs7511706	chr1:248467360	G/A	cg13385794	chr1:248469461	NA	0.65	4.66	0.43	1.04e-5	Common traits (Other);
THYM	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03517284	chr6:25882590	NA	-0.78	-6.24	-0.54	1.22e-8	Blood metabolite levels;
THYM	cis	rs11214589	0.905	rs12804573	chr11:113241726	G/A	cg14159747	chr11:113255604	NA	0.36	7.77	0.62	9.29e-12	Neuroticism;
THYM	cis	rs11252926	0.661	rs7077209	chr10:484159	A/G	cg03684893	chr10:554711	DIP2C	0.71	5.85	0.51	6.98e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs72828912	0.665	rs9348631	chr6:24072212	G/A	cg19882886	chr6:25043046	NA	-0.88	-4.58	-0.43	1.42e-5	Squamous cell lung carcinoma;
THYM	cis	rs8112449	0.894	rs12611227	chr19:10501740	A/G	cg01466491	chr19:10523363	NA	-0.68	-6.21	-0.54	1.39e-8	Multiple sclerosis;Gastritis;
THYM	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg14004847	chr7:1930337	MAD1L1	-0.66	-4.87	-0.45	4.36e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7681440	0.583	rs2619373	chr4:90722433	G/A	cg06632027	chr4:90757378	SNCA	-0.66	-5.19	-0.47	1.18e-6	Dementia with Lewy bodies;
THYM	cis	rs7078219	0.543	rs10786556	chr10:101278324	C/T	cg07044859	chr10:101282883	NA	-0.43	-4.87	-0.45	4.44e-6	Dental caries;
THYM	cis	rs1728785	0.901	rs8050289	chr16:68566976	T/A	cg02972257	chr16:68554789	NA	-0.74	-4.54	-0.42	1.63e-5	Ulcerative colitis;
THYM	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.92	-0.58	5.35e-10	Corneal astigmatism;
THYM	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg01699819	chr7:1052092	C7orf50	-0.62	-5.76	-0.51	1.04e-7	Bronchopulmonary dysplasia;
THYM	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg12963246	chr6:28129442	ZNF389	0.53	4.71	0.44	8.3e-6	Parkinson's disease;
THYM	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg18252515	chr7:66147081	NA	-0.62	-4.55	-0.42	1.59e-5	Aortic root size;
THYM	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg04518342	chr5:131593106	PDLIM4	0.48	5.28	0.48	8.22e-7	Breast cancer;
THYM	cis	rs367615	0.704	rs72804385	chr5:108848143	T/C	cg17395555	chr5:108820864	NA	0.74	8.82	0.67	5.59e-14	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.43	-0.49	4.24e-7	Mean corpuscular volume;
THYM	trans	rs9951602	0.512	rs9946120	chr18:76654548	A/T	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg22907277	chr7:1156413	C7orf50	0.82	4.98	0.46	2.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg03806693	chr22:41940476	POLR3H	-1.1	-8.81	-0.67	5.87e-14	Vitiligo;
THYM	cis	rs3204270	0.639	rs8074225	chr17:79618270	G/A	cg18367735	chr17:79674897	NA	0.75	4.51	0.42	1.87e-5	Dental caries;
THYM	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg17366294	chr4:99064904	C4orf37	0.57	6.82	0.57	8.42e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7264396	0.580	rs2064511	chr20:34448810	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.67	4.85	0.45	4.83e-6	Total cholesterol levels;
THYM	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg08859206	chr1:53392774	SCP2	-0.48	-4.93	-0.45	3.44e-6	Monocyte count;
THYM	cis	rs965469	0.895	rs6051840	chr20:3391483	C/T	cg25506879	chr20:3388711	C20orf194	0.71	4.54	0.42	1.67e-5	IFN-related cytopenia;
THYM	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg22681709	chr2:178499509	PDE11A	-0.54	-4.77	-0.44	6.57e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1629083	0.870	rs12362596	chr11:118105473	G/C	cg25155064	chr11:118100782	MPZL3	-0.57	-4.97	-0.45	2.94e-6	Lung cancer;
THYM	cis	rs12413816	0.784	rs11258560	chr10:13770137	A/G	cg16485048	chr10:13749193	FRMD4A	0.48	4.71	0.43	8.54e-6	Red cell distribution width;
THYM	cis	rs34375054	0.933	rs34019704	chr12:125659567	C/G	cg25124228	chr12:125621409	AACS	-0.63	-4.89	-0.45	4.03e-6	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs8114671	0.839	rs6142290	chr20:33654672	A/C	cg08999081	chr20:33150536	PIGU	-0.56	-4.83	-0.44	5.18e-6	Height;
THYM	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg24399712	chr22:39784796	NA	-0.91	-8.23	-0.64	1e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs10256972	0.552	rs6953538	chr7:1196974	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.61	-4.89	-0.45	4.17e-6	Longevity;Endometriosis;
THYM	cis	rs10203711	1.000	rs6707795	chr2:239555580	T/C	cg14580085	chr2:239553406	NA	0.71	6.49	0.55	3.82e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg27490568	chr2:178487706	NA	0.56	5.11	0.46	1.64e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg22862634	chr11:62369728	EML3;MTA2	0.64	9.24	0.69	6.82e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4747241	0.562	rs9416018	chr10:74100642	G/A	cg07828833	chr10:74069493	NA	-0.61	-4.92	-0.45	3.56e-6	Heschl's gyrus morphology;
THYM	trans	rs480407	0.857	rs270970	chr2:161690668	A/C	cg06548410	chr19:1997657	BTBD2	0.71	6.92	0.58	5.23e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs11886999	0.680	rs6756208	chr2:96832699	T/C	cg10278162	chr2:97193688	NA	-0.73	-4.52	-0.42	1.75e-5	Cardiac Troponin-T levels;
THYM	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg16031515	chr1:205743344	RAB7L1	-0.73	-7.79	-0.62	8.2e-12	Menarche (age at onset);
THYM	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2034650	0.544	rs2289331	chr15:40699940	T/C	cg12699599	chr15:40643142	PHGR1	-0.6	-5.49	-0.49	3.3e-7	Interstitial lung disease;
THYM	cis	rs2334880	0.638	rs35166226	chr16:71443219	T/C	cg06353428	chr16:71660113	MARVELD3	-0.96	-5.1	-0.46	1.74e-6	Malaria;
THYM	cis	rs6032067	1.000	rs6017526	chr20:43871555	A/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.37	-0.48	5.52e-7	Blood protein levels;
THYM	cis	rs6763768	0.606	rs11130367	chr3:53293373	G/A	cg16894138	chr3:53270350	TKT	0.73	5.46	0.49	3.73e-7	Bacterial meningitis;
THYM	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg03433033	chr1:76189801	ACADM	0.77	9.17	0.69	9.63e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs7772486	0.686	rs1415744	chr6:146022531	C/T	cg13319975	chr6:146136371	FBXO30	-0.65	-5.22	-0.47	1.05e-6	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs7615952	0.608	rs35668111	chr3:125544635	C/T	cg07211511	chr3:129823064	LOC729375	-0.92	-7.28	-0.6	9.56e-11	Blood pressure (smoking interaction);
THYM	cis	rs9515201	0.627	rs952359	chr13:111026734	G/A	cg15455643	chr13:111040242	COL4A2	0.52	6.42	0.55	5.46e-9	White matter hyperintensity burden;
THYM	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg08901578	chr4:187885870	NA	0.67	6.44	0.55	4.82e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg04287289	chr16:89883240	FANCA	0.65	6.04	0.53	3.01e-8	Vitiligo;
THYM	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg02734326	chr4:10020555	SLC2A9	-0.62	-5.04	-0.46	2.21e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4731207	0.623	rs28807101	chr7:124598826	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg24060327	chr5:131705240	SLC22A5	-0.83	-6.92	-0.58	5.2e-10	Blood metabolite levels;
THYM	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg15704280	chr7:45808275	SEPT13	-1.09	-13.51	-0.81	7.82e-24	Height;
THYM	cis	rs12681287	0.640	rs7460342	chr8:87475137	C/T	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs11030122	0.702	rs2898947	chr11:3977572	G/A	cg22027985	chr11:4115532	RRM1	-0.48	-4.59	-0.43	1.36e-5	Mean platelet volume;Platelet distribution width;
THYM	cis	rs112908525	1	rs112908525	chr7:80305278	T/TGAGGGTTGA	cg21369886	chr7:80305251	CD36	-0.63	-6.84	-0.57	7.71e-10	Mean corpuscular volume;
THYM	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.61	7.95	0.63	3.85e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25427524	chr10:38739819	LOC399744	-0.73	-6.77	-0.57	1.04e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg14019146	chr3:50243930	SLC38A3	-0.6	-5.08	-0.46	1.88e-6	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg18252515	chr7:66147081	NA	0.66	4.87	0.45	4.38e-6	Aortic root size;
THYM	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg24324837	chr19:49891574	CCDC155	0.67	6.39	0.55	6.1e-9	Multiple sclerosis;
THYM	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg02953382	chr22:24373134	LOC391322	-0.72	-5.28	-0.48	8.3e-7	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs6076065	0.683	rs2424528	chr20:23361613	C/T	cg11657817	chr20:23433608	CST11	0.31	4.57	0.42	1.48e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg18512352	chr11:47633146	NA	0.48	5.85	0.51	6.84e-8	Subjective well-being;
THYM	cis	rs4474465	1.000	rs10899502	chr11:78141021	C/T	cg02023728	chr11:77925099	USP35	0.53	4.65	0.43	1.08e-5	Alzheimer's disease (survival time);
THYM	cis	rs3011225	0.710	rs3011222	chr1:44317545	C/T	cg15962314	chr1:44399869	ARTN	0.53	5.39	0.48	5.01e-7	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg06719487	chr1:10489962	APITD1	0.41	4.68	0.43	9.43e-6	Prostate cancer;
THYM	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg00071950	chr4:10020882	SLC2A9	-0.66	-5.9	-0.52	5.59e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6584283	0.875	rs1548962	chr10:101289735	C/G	cg04972745	chr10:101287846	NA	0.51	4.84	0.44	5.09e-6	Ulcerative colitis;
THYM	cis	rs2279817	1.000	rs2354290	chr1:18019861	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.75	4.73	0.44	7.76e-6	Neuroticism;
THYM	cis	rs899997	0.906	rs6495318	chr15:78992137	G/C	cg04896959	chr15:78267971	NA	-0.86	-7.9	-0.63	4.84e-12	Coronary artery disease or large artery stroke;
THYM	cis	rs7267979	0.966	rs2261795	chr20:25263136	T/C	cg08601574	chr20:25228251	PYGB	0.56	4.47	0.42	2.15e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs17321999	1.000	rs9309678	chr2:30487198	A/G	cg05247661	chr2:30472410	LBH	0.65	4.66	0.43	1.04e-5	Systemic lupus erythematosus;
THYM	cis	rs6500395	0.925	rs16946342	chr16:48668542	G/A	cg04672837	chr16:48644449	N4BP1	0.48	4.72	0.44	8.24e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg24675658	chr1:53192096	ZYG11B	-0.67	-5.33	-0.48	6.69e-7	Monocyte count;
THYM	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06481639	chr22:41940642	POLR3H	-0.66	-4.8	-0.44	5.83e-6	Vitiligo;
THYM	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.55	-0.73	1.12e-17	Primary sclerosing cholangitis;
THYM	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs981844	0.712	rs4434231	chr4:154746293	G/T	cg09973105	chr4:154681532	RNF175	0.51	4.85	0.45	4.82e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	9.67	0.7	8.34e-16	Platelet count;
THYM	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg26924012	chr15:45694286	SPATA5L1	0.66	4.86	0.45	4.69e-6	Response to fenofibrate (adiponectin levels);
THYM	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7614311	1.000	rs7646324	chr3:63808118	T/C	cg22134162	chr3:63841271	THOC7	-0.52	-6.48	-0.55	3.99e-9	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg26818010	chr10:134567672	INPP5A	-0.93	-7.48	-0.61	3.71e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs9992101	1.000	rs10023335	chr4:77358987	C/T	cg20311846	chr4:77356250	SHROOM3	0.66	6.67	0.56	1.72e-9	Creatinine levels;
THYM	cis	rs7909074	1.000	rs10900128	chr10:45393201	G/T	cg04218760	chr10:45406644	TMEM72	-0.67	-6.01	-0.52	3.42e-8	Mean corpuscular volume;
THYM	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg03676636	chr4:99064102	C4orf37	0.45	6.85	0.57	7.43e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4731207	0.844	rs4731208	chr7:124398196	T/C	cg05285228	chr7:124571219	POT1	0.71	5.65	0.5	1.64e-7	Cutaneous malignant melanoma;
THYM	cis	rs9399401	0.925	rs1040526	chr6:142735816	A/G	cg04461802	chr6:142623433	GPR126	0.49	4.97	0.45	3e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs892961	0.932	rs7216909	chr17:75405234	A/G	cg05865280	chr17:75406074	SEPT9	0.5	8.75	0.67	7.71e-14	Airflow obstruction;
THYM	cis	rs4242434	0.892	rs71513892	chr8:22456517	C/G	cg03733263	chr8:22462867	KIAA1967	1.16	11.74	0.77	3.36e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	5.04	0.46	2.19e-6	Hip circumference adjusted for BMI;
THYM	cis	rs4455778	0.559	rs6583511	chr7:49122876	G/A	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg13319975	chr6:146136371	FBXO30	-0.66	-5.63	-0.5	1.85e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg01448562	chr3:133502909	NA	-0.83	-6.92	-0.58	5.31e-10	Iron status biomarkers;
THYM	cis	rs9677476	0.863	rs57199832	chr2:232069083	T/G	cg23338755	chr2:231921595	PSMD1	0.66	4.8	0.44	5.79e-6	Food antigen IgG levels;
THYM	cis	rs7772486	0.686	rs857875	chr6:145980033	T/G	cg23711669	chr6:146136114	FBXO30	-0.91	-8.87	-0.67	4.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg18681998	chr4:17616180	MED28	0.96	9.08	0.68	1.56e-14	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg18681998	chr4:17616180	MED28	0.98	9.91	0.71	2.55e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7100689	0.577	rs4934038	chr10:82057334	C/A	cg01528321	chr10:82214614	TSPAN14	0.96	7.12	0.59	2.06e-10	Post bronchodilator FEV1;
THYM	cis	rs7772486	0.846	rs7755440	chr6:146375906	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg18876405	chr7:65276391	NA	0.76	7.17	0.59	1.61e-10	Aortic root size;
THYM	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	5.42	0.49	4.47e-7	Schizophrenia;
THYM	cis	rs7107174	1.000	rs10793297	chr11:78009660	T/C	cg19901956	chr11:77921274	USP35	-0.69	-5.3	-0.48	7.42e-7	Testicular germ cell tumor;
THYM	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg27572855	chr1:25598939	RHD	-0.65	-4.93	-0.45	3.43e-6	Erythrocyte sedimentation rate;
THYM	cis	rs17604090	0.793	rs17150667	chr7:29689338	G/T	cg19413766	chr7:29689036	LOC646762	-0.91	-5.02	-0.46	2.37e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9807841	0.592	rs3810154	chr19:10764914	G/A	cg17848348	chr19:10766748	ILF3	-0.76	-6.15	-0.53	1.85e-8	Inflammatory skin disease;
THYM	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.12	9.06	0.68	1.73e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs17473412	1.000	rs10519723	chr5:122711641	T/C	cg18093572	chr5:122598329	NA	0.55	4.7	0.43	8.94e-6	Total body bone mineral density;
THYM	cis	rs10463554	0.963	rs67068617	chr5:102375681	C/G	cg23492399	chr5:102201601	PAM	-0.67	-5.09	-0.46	1.77e-6	Parkinson's disease;
THYM	cis	rs66887589	0.774	rs9307477	chr4:120421809	G/A	cg13609457	chr4:120235615	NA	0.47	4.88	0.45	4.28e-6	Diastolic blood pressure;
THYM	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4363385	0.626	rs12062770	chr1:153062837	A/C	cg06563695	chr1:153756334	NA	-0.59	-4.93	-0.45	3.44e-6	Inflammatory skin disease;
THYM	cis	rs700651	0.786	rs58224025	chr2:198821988	G/A	cg00792783	chr2:198669748	PLCL1	0.82	5.75	0.51	1.08e-7	Intracranial aneurysm;
THYM	cis	rs55794721	0.543	rs1293260	chr1:25709104	C/G	cg09222892	chr1:25734099	RHCE	0.58	4.55	0.42	1.57e-5	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs11166927	1.000	rs11166927	chr8:140796420	T/C	cg16909799	chr8:140841666	TRAPPC9	0.59	4.96	0.45	3.13e-6	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs2562456	0.833	rs2968078	chr19:21641744	A/G	cg21751540	chr19:21541537	ZNF738	0.76	4.98	0.45	2.88e-6	Pain;
THYM	cis	rs12549902	1.000	rs12550613	chr8:41510260	G/C	cg21772509	chr8:41503840	NKX6-3	0.7	6.54	0.56	3.04e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
THYM	cis	rs8078723	0.966	rs7021	chr17:38153875	T/A	cg17467752	chr17:38218738	THRA	0.87	7.22	0.59	1.3e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs6584283	0.846	rs7917446	chr10:101286207	T/C	cg04972745	chr10:101287846	NA	-0.51	-4.76	-0.44	6.99e-6	Ulcerative colitis;
THYM	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg00256281	chr22:41985642	PMM1	0.63	4.74	0.44	7.41e-6	Vitiligo;
THYM	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22968622	chr17:43663579	NA	1.18	10.66	0.74	6.45e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6669072	0.527	rs34401202	chr1:91269160	A/G	cg08895590	chr1:91227319	NA	-0.39	-4.45	-0.42	2.32e-5	Cognitive function;
THYM	cis	rs240764	0.717	rs239236	chr6:101099217	A/G	cg21058520	chr6:100914733	NA	-0.58	-4.91	-0.45	3.73e-6	Neuroticism;
THYM	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg18681998	chr4:17616180	MED28	0.98	9.91	0.71	2.55e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg07959070	chr22:50026188	C22orf34	-0.28	-4.73	-0.44	7.7e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.65	-4.82	-0.44	5.34e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs2806561	0.606	rs10917335	chr1:23294136	A/G	cg19743168	chr1:23544995	NA	0.48	4.54	0.42	1.62e-5	Height;
THYM	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg06112835	chr11:68658793	MRPL21	0.46	6.53	0.56	3.28e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg08742575	chr21:47604166	C21orf56	-0.75	-5.65	-0.5	1.68e-7	Testicular germ cell tumor;
THYM	cis	rs11209185	0.623	rs6662264	chr1:68447276	C/T	cg22082780	chr1:68452167	NA	0.49	5.87	0.52	6.27e-8	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11890956	chr21:40555474	PSMG1	1.07	10.55	0.73	1.12e-17	Cognitive function;
THYM	cis	rs11231629	1	rs11231629	chr11:63648573	C/T	cg04850017	chr11:63683019	RCOR2	0.55	5.27	0.48	8.53e-7	Schizophrenia;
THYM	cis	rs10089	1.000	rs3805607	chr5:127477418	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.01	6.92	0.58	5.25e-10	Ileal carcinoids;
THYM	cis	rs897984	0.520	rs4889536	chr16:30871755	G/T	cg03418659	chr16:31128414	MYST1	0.64	4.68	0.43	9.46e-6	Dementia with Lewy bodies;
THYM	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg05313129	chr8:58192883	C8orf71	-0.85	-4.97	-0.45	2.93e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs28647808	0.881	rs71483207	chr9:136258698	A/G	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs11809207	1.000	rs41284333	chr1:26517267	A/G	cg03844060	chr1:26490628	NA	0.7	5.01	0.46	2.51e-6	Height;
THYM	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg17747265	chr1:1875780	NA	-0.79	-9.12	-0.68	1.24e-14	Body mass index;
THYM	cis	rs2888875	0.533	rs4146253	chr2:43711066	T/C	cg22033476	chr2:43532275	THADA	-0.4	-4.49	-0.42	1.98e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs7586879	0.964	rs4077679	chr2:25122852	T/C	cg15423357	chr2:25149977	NA	0.57	5.6	0.5	2.09e-7	Body mass index;
THYM	cis	rs2289328	0.823	rs71472433	chr15:40649609	A/C	cg13931752	chr15:40660718	DISP2	0.62	4.56	0.42	1.53e-5	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
THYM	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg09034736	chr1:150693464	HORMAD1	0.53	4.85	0.45	4.83e-6	Tonsillectomy;
THYM	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg14416269	chr4:6271139	WFS1	0.55	5.67	0.5	1.5e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg15556689	chr8:8085844	FLJ10661	0.65	5.28	0.48	8.12e-7	Mood instability;
THYM	cis	rs6665290	0.904	rs1343744	chr1:227183022	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.13	-15.45	-0.85	1.14e-27	Myeloid white cell count;
THYM	cis	rs59227481	1	rs59227481	chr12:110007993	A/G	cg08884029	chr12:110012500	MVK;MMAB	-0.58	-4.56	-0.42	1.51e-5	Age-related nuclear cataracts;
THYM	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg27446573	chr6:127587934	RNF146	0.74	6.53	0.56	3.27e-9	Breast cancer;
THYM	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg09549813	chr16:4587862	C16orf5	0.6	7.03	0.58	3.17e-10	Schizophrenia;
THYM	cis	rs308403	0.533	rs12644866	chr4:123667604	T/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.97	8.12	0.64	1.68e-12	Blood protein levels;
THYM	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs9902453	0.817	rs12051834	chr17:28192785	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.65	0.43	1.08e-5	Coffee consumption (cups per day);
THYM	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg25358565	chr5:93447407	FAM172A	1.39	10.21	0.72	5.75e-17	Diabetic retinopathy;
THYM	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg14456004	chr13:21872349	NA	-1.27	-10.82	-0.74	3.02e-18	White matter hyperintensity burden;
THYM	cis	rs7072216	0.763	rs10748729	chr10:100171371	G/C	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs12530845	1.000	rs6975251	chr7:135328689	C/G	cg23117316	chr7:135346802	PL-5283	-0.66	-5.88	-0.52	6.21e-8	Red blood cell traits;
THYM	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg16680214	chr1:154839983	KCNN3	-0.45	-5.03	-0.46	2.32e-6	Prostate cancer;
THYM	cis	rs4654899	0.865	rs10493006	chr1:21375904	G/A	cg01072550	chr1:21505969	NA	-0.71	-6.16	-0.53	1.76e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs9658691	0.607	rs3740281	chr10:90772150	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.88	-5.87	-0.52	6.48e-8	Mosquito bite size;
THYM	cis	rs7578361	1.000	rs13003409	chr2:150401169	C/T	cg17961725	chr2:150454027	NA	0.65	5.54	0.49	2.74e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs595982	0.661	rs606400	chr19:49371498	T/C	cg19746536	chr19:49375674	PPP1R15A	1.28	17.69	0.88	8.02e-32	Red cell distribution width;
THYM	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg03684893	chr10:554711	DIP2C	-0.7	-6.26	-0.54	1.09e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs11118844	0.843	rs12403995	chr1:221921377	C/A	cg04222084	chr1:221915650	DUSP10	-0.99	-5.28	-0.48	8.3e-7	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs17122693	1.000	rs72679576	chr14:51090881	G/A	cg04730355	chr14:51134070	SAV1	0.91	4.94	0.45	3.38e-6	Cognitive performance;
THYM	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03517284	chr6:25882590	NA	0.74	5.89	0.52	5.89e-8	Blood metabolite levels;
THYM	cis	rs8180040	0.800	rs62248905	chr3:47274082	A/G	cg27129171	chr3:47204927	SETD2	-0.75	-7.08	-0.59	2.48e-10	Colorectal cancer;
THYM	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg14004847	chr7:1930337	MAD1L1	-0.66	-4.87	-0.45	4.5e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs11997175	0.646	rs4593495	chr8:33692649	C/T	ch.8.33884649F	chr8:33765107	NA	0.66	4.99	0.46	2.67e-6	Body mass index;
THYM	cis	rs644799	0.562	rs671320	chr11:95578780	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.76	6.56	0.56	2.77e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg04772025	chr11:68637568	NA	0.61	6.33	0.54	8.18e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg07061783	chr6:25882402	NA	0.58	4.58	0.43	1.39e-5	Schizophrenia;
THYM	trans	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg06636001	chr8:8085503	FLJ10661	-0.75	-7.03	-0.58	3.18e-10	Retinal vascular caliber;
THYM	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.88	5.64	0.5	1.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.93	5.99	0.52	3.67e-8	Platelet count;
THYM	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs17001868	0.614	rs61467436	chr22:40736713	T/C	cg07138101	chr22:40742427	ADSL	0.94	5.71	0.51	1.3e-7	Mammographic density (dense area);
THYM	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4660306	1.000	rs2993259	chr1:46001550	T/C	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.64	-5.23	-0.47	9.98e-7	Homocysteine levels;
THYM	cis	rs6918586	0.594	rs198842	chr6:26111448	C/T	cg12310025	chr6:25882481	NA	0.68	5.49	0.49	3.36e-7	Schizophrenia;
THYM	cis	rs55883249	1.000	rs11676903	chr2:9763201	G/C	cg23886495	chr2:9695866	ADAM17	0.73	4.52	0.42	1.76e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-6.7	-0.57	1.48e-9	Total body bone mineral density;
THYM	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg20503657	chr10:835505	NA	1.37	9.33	0.69	4.52e-15	Eosinophil percentage of granulocytes;
THYM	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg01017244	chr2:74357527	NA	1.03	8.95	0.68	2.9e-14	Gestational age at birth (maternal effect);
THYM	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg08017756	chr2:100939284	LONRF2	-0.75	-7.78	-0.62	8.81e-12	Intelligence (multi-trait analysis);
THYM	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg12379764	chr21:47803548	PCNT	-0.72	-4.77	-0.44	6.71e-6	Testicular germ cell tumor;
THYM	cis	rs4746818	1.000	rs7476357	chr10:70935660	G/A	cg04149295	chr10:70884716	VPS26A	0.78	5.31	0.48	7.18e-7	Left atrial antero-posterior diameter;
THYM	cis	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg07460842	chr6:66804631	NA	1.1	8.21	0.64	1.08e-12	Exhaled nitric oxide output;
THYM	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg09682330	chr6:28411287	ZSCAN23	-0.5	-4.48	-0.42	2.06e-5	Pubertal anthropometrics;
THYM	cis	rs61931739	0.578	rs1482992	chr12:33599387	G/A	cg06521331	chr12:34319734	NA	0.61	4.54	0.42	1.65e-5	Morning vs. evening chronotype;
THYM	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg23131131	chr22:24373011	LOC391322	0.87	7.49	0.61	3.5e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs11031096	0.711	rs10835723	chr11:4207566	G/C	cg22027985	chr11:4115532	RRM1	-0.53	-4.74	-0.44	7.41e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg11494091	chr17:61959527	GH2	0.7	6.38	0.55	6.38e-9	Height;
THYM	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg03806693	chr22:41940476	POLR3H	-1.03	-8.5	-0.66	2.66e-13	Vitiligo;
THYM	cis	rs7127900	0.583	rs11043140	chr11:2233951	T/C	cg25635251	chr11:2234043	NA	0.71	5.42	0.49	4.51e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg07570687	chr10:102243282	WNT8B	0.76	6.9	0.58	5.82e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs17006441	0.932	rs13093918	chr3:69876430	A/G	cg18496212	chr3:69797108	MITF	0.67	6.66	0.56	1.77e-9	Hemoglobin concentration;
THYM	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg02018176	chr4:1364513	KIAA1530	0.73	6.49	0.55	3.95e-9	Longevity;
THYM	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.66	5.22	0.47	1.07e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4891159	0.548	rs660342	chr18:74130896	C/G	cg24786174	chr18:74118243	ZNF516	0.97	14.43	0.83	1.15e-25	Longevity;
THYM	trans	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg19862616	chr7:65841803	NCRNA00174	1.01	10.65	0.74	6.9e-18	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1065656	0.512	rs3751893	chr16:1842209	A/G	cg14074117	chr16:1909714	C16orf73	0.58	4.59	0.43	1.34e-5	Insulin-like growth factors;
THYM	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg18252515	chr7:66147081	NA	0.66	4.87	0.45	4.38e-6	Aortic root size;
THYM	cis	rs9399401	0.601	rs171891	chr6:142850612	G/A	cg03128060	chr6:142623767	GPR126	0.57	6.74	0.57	1.21e-9	Chronic obstructive pulmonary disease;
THYM	cis	rs9549260	0.755	rs7335520	chr13:41196407	C/T	cg21288729	chr13:41239152	FOXO1	0.67	5.2	0.47	1.13e-6	Red blood cell count;
THYM	cis	rs4907240	0.961	rs6749159	chr2:97267293	T/C	cg01950434	chr2:97203154	ARID5A	-0.57	-4.81	-0.44	5.71e-6	Event-related brain oscillations;
THYM	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg06718696	chr17:78121285	EIF4A3	1.02	7.38	0.6	5.95e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
THYM	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	5.61	0.5	1.96e-7	Tonsillectomy;
THYM	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs992157	0.932	rs10203039	chr2:219187367	T/C	cg00012203	chr2:219082015	ARPC2	0.68	6.05	0.53	2.92e-8	Colorectal cancer;
THYM	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs757081	0.667	rs12577525	chr11:17260116	G/A	cg07093617	chr11:18158918	MRGPRX3	-0.49	-4.61	-0.43	1.23e-5	Systolic blood pressure;
THYM	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.41	-6.4	-0.55	5.78e-9	Obesity-related traits;
THYM	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg03433033	chr1:76189801	ACADM	0.74	8.88	0.67	4.14e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs860818	1.000	rs1626853	chr7:23235342	C/T	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg06009448	chr7:1102226	C7orf50	0.53	5.55	0.49	2.6e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7072216	0.763	rs6584201	chr10:100170209	T/C	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs863345	0.625	rs4575081	chr1:158504837	C/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs1403694	1.000	rs2689197	chr3:186438346	C/T	cg12454167	chr3:186435060	KNG1	0.45	6.0	0.52	3.58e-8	Blood protein levels;
THYM	cis	rs4481887	0.962	rs10788770	chr1:248457474	T/G	cg00666640	chr1:248458726	OR2T12	0.57	4.61	0.43	1.24e-5	Common traits (Other);
THYM	cis	rs7829975	0.748	rs693109	chr8:8640172	C/A	cg15556689	chr8:8085844	FLJ10661	-0.63	-5.47	-0.49	3.58e-7	Mood instability;
THYM	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	5.38	0.48	5.34e-7	Height;
THYM	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	5.74	0.51	1.11e-7	Obesity-related traits;
THYM	cis	rs3772130	0.962	rs13065245	chr3:121566729	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.81	5.08	0.46	1.89e-6	Cognitive performance;
THYM	cis	rs514406	0.597	rs1241980	chr1:53286013	A/G	cg22166914	chr1:53195759	ZYG11B	-0.66	-4.82	-0.44	5.38e-6	Monocyte count;
THYM	cis	rs4705952	0.557	rs2548990	chr5:131861646	G/A	cg13566430	chr5:131992455	IL13	0.54	4.54	0.42	1.66e-5	C-reactive protein levels;
THYM	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.66e-11	Aortic root size;
THYM	cis	rs1335645	0.655	rs61808584	chr1:111632839	T/C	cg00321911	chr1:111669324	DRAM2	-1.14	-6.18	-0.54	1.57e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11627756	0.918	rs2403070	chr14:103093432	T/C	cg27124170	chr14:102829869	TECPR2;CINP	-0.67	-4.62	-0.43	1.19e-5	Mean platelet volume;
THYM	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	5.97	0.52	4.05e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg23161317	chr6:28129485	ZNF389	0.84	6.3	0.54	9.31e-9	Parkinson's disease;
THYM	cis	rs6430585	0.528	rs16832417	chr2:136744678	C/T	cg07169764	chr2:136633963	MCM6	1.19	11.38	0.76	1.91e-19	Corneal structure;
THYM	cis	rs17030434	0.953	rs76442373	chr4:154694783	G/A	cg14289246	chr4:154710475	SFRP2	-0.83	-5.58	-0.5	2.24e-7	Electrocardiographic conduction measures;
THYM	cis	rs7772486	0.754	rs9386132	chr6:146140751	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.56	-0.5	2.45e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg04315214	chr1:2043799	PRKCZ	0.58	4.54	0.42	1.67e-5	Height;
THYM	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg16926213	chr1:1841314	NA	0.55	5.8	0.51	8.77e-8	Body mass index;
THYM	cis	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg19847130	chr8:10466454	RP1L1	0.5	4.52	0.42	1.8e-5	Triglycerides;
THYM	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.73	-4.87	-0.45	4.36e-6	Body mass index;
THYM	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.66	8.96	0.68	2.76e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9534288	0.797	rs7331368	chr13:46609062	G/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs2456568	0.548	rs10501809	chr11:93666263	C/G	cg17595323	chr11:93583763	C11orf90	-0.51	-5.46	-0.49	3.83e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs11214589	0.905	rs10891539	chr11:113236492	G/C	cg14159747	chr11:113255604	NA	0.37	7.88	0.63	5.48e-12	Neuroticism;
THYM	cis	rs6430585	0.583	rs9636213	chr2:136589278	G/A	cg20242066	chr2:136595261	LCT	-0.53	-5.82	-0.51	7.77e-8	Corneal structure;
THYM	cis	rs17321999	1.000	rs72787721	chr2:30489411	C/T	cg05247661	chr2:30472410	LBH	0.69	4.67	0.43	9.98e-6	Systemic lupus erythematosus;
THYM	cis	rs1878931	0.582	rs9937267	chr16:3421073	C/T	cg22508957	chr16:3507546	NAT15	-0.49	-5.2	-0.47	1.13e-6	Body mass index (adult);
THYM	cis	rs7267979	1.000	rs2424700	chr20:25266513	A/G	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg06238570	chr21:40685208	BRWD1	0.87	4.7	0.43	8.78e-6	Cognitive function;
THYM	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs7107174	0.786	rs4945269	chr11:78047077	A/G	cg19901956	chr11:77921274	USP35	-0.65	-5.38	-0.48	5.38e-7	Testicular germ cell tumor;
THYM	cis	rs7746082	0.627	rs12201431	chr6:106496905	G/A	cg02270332	chr6:106475062	NA	-0.65	-5.95	-0.52	4.38e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg16624210	chr5:671434	TPPP	-0.63	-6.36	-0.55	7.19e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg13114125	chr14:105738426	BRF1	0.73	5.65	0.5	1.66e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs8014204	0.967	rs2359240	chr14:75328247	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.57	-5.33	-0.48	6.47e-7	Caffeine consumption;
THYM	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg13695892	chr22:41940480	POLR3H	0.83	6.07	0.53	2.67e-8	Vitiligo;
THYM	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg04518342	chr5:131593106	PDLIM4	0.48	5.29	0.48	7.92e-7	Breast cancer;
THYM	cis	rs7772486	0.686	rs4895684	chr6:146114023	A/C	cg23711669	chr6:146136114	FBXO30	-0.83	-7.92	-0.63	4.52e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs921968	0.643	rs586374	chr2:219383003	A/C	cg02176678	chr2:219576539	TTLL4	0.68	6.71	0.57	1.42e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg19418458	chr7:158789849	NA	0.65	5.82	0.51	7.97e-8	Facial morphology (factor 20);
THYM	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11644478	chr21:40555479	PSMG1	0.56	4.69	0.43	9.07e-6	Menarche (age at onset);
THYM	cis	rs3767633	0.800	rs6685369	chr1:161754834	T/C	cg27495845	chr1:161693088	FCRLB	-0.51	-4.69	-0.43	9.13e-6	IgG glycosylation;
THYM	cis	rs9649213	0.593	rs13246843	chr7:98002661	G/T	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4595586	0.679	rs7955725	chr12:39322903	C/T	cg13010199	chr12:38710504	ALG10B	0.56	4.54	0.42	1.67e-5	Morning vs. evening chronotype;
THYM	cis	rs4242434	0.747	rs6986550	chr8:22467870	T/A	cg11461670	chr8:22454935	PDLIM2	-0.32	-6.15	-0.53	1.79e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg19077165	chr18:44547161	KATNAL2	0.56	6.72	0.57	1.34e-9	Personality dimensions;
THYM	cis	rs4455778	0.580	rs4285433	chr7:49114185	A/G	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs62435770	1.000	rs62434682	chr6:169507558	A/G	cg07652237	chr6:170125491	PHF10	0.55	4.91	0.45	3.84e-6	Loneliness;
THYM	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7247513	0.892	rs1864081	chr19:12707978	G/A	cg01871581	chr19:12707946	ZNF490	-0.95	-11.42	-0.76	1.61e-19	Bipolar disorder;
THYM	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg04455712	chr21:45112962	RRP1B	0.5	4.62	0.43	1.21e-5	Mean corpuscular volume;
THYM	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg14675211	chr2:100938903	LONRF2	0.8	8.8	0.67	6.15e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg07061783	chr6:25882402	NA	-0.91	-8.01	-0.63	2.93e-12	Intelligence (multi-trait analysis);
THYM	cis	rs6570726	0.935	rs408768	chr6:145871735	A/G	cg23711669	chr6:146136114	FBXO30	0.91	9.57	0.7	1.4e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.56	-5.13	-0.47	1.51e-6	Type 2 diabetes;
THYM	cis	rs8102476	0.905	rs7250689	chr19:38753625	C/T	cg05778847	chr19:38746538	PPP1R14A	0.49	5.57	0.5	2.32e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2241584	0.666	rs2913896	chr5:175921461	A/G	cg27658698	chr5:175955578	RNF44	0.43	4.93	0.45	3.51e-6	Menopause (age at onset);
THYM	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.08	9.39	0.69	3.32e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs28595532	1.000	rs75497896	chr4:119636703	T/C	cg21605333	chr4:119757512	SEC24D	1.42	4.79	0.44	6.16e-6	Cannabis dependence symptom count;
THYM	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg18252515	chr7:66147081	NA	0.72	5.64	0.5	1.73e-7	Aortic root size;
THYM	cis	rs1568889	0.838	rs7125749	chr11:28154692	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg26769984	chr7:1090371	C7orf50	0.81	5.42	0.49	4.45e-7	Bronchopulmonary dysplasia;
THYM	cis	rs13215566	0.789	rs9444674	chr6:89906257	A/G	cg08400210	chr6:89908154	GABRR1	0.99	5.49	0.49	3.32e-7	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg09517075	chr8:22133004	PIWIL2	0.63	5.74	0.51	1.14e-7	Hypertriglyceridemia;
THYM	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg21984481	chr17:79567631	NPLOC4	-0.47	-4.95	-0.45	3.22e-6	Eye color traits;
THYM	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg17279839	chr7:150038598	RARRES2	0.56	5.26	0.47	8.96e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg16486109	chr11:613632	IRF7	0.49	5.44	0.49	4.08e-7	Systemic lupus erythematosus;
THYM	cis	rs1797885	0.510	rs2442820	chr3:12599196	G/C	cg05467012	chr3:12595696	NA	0.6	5.36	0.48	5.92e-7	Immature fraction of reticulocytes;
THYM	cis	rs17407555	0.821	rs55919137	chr4:10133803	C/A	cg11266682	chr4:10021025	SLC2A9	-0.58	-5.46	-0.49	3.72e-7	Schizophrenia (age at onset);
THYM	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg08847533	chr14:75593920	NEK9	-0.98	-10.02	-0.72	1.53e-16	Height;
THYM	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg05775895	chr3:12838266	CAND2	1.04	10.24	0.72	5.14e-17	QRS complex (12-leadsum);
THYM	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg19318889	chr4:1322082	MAEA	-0.51	-4.53	-0.42	1.73e-5	Obesity-related traits;
THYM	cis	rs8016982	0.633	rs4363794	chr14:81674327	C/A	cg01989461	chr14:81687754	GTF2A1	0.83	7.89	0.63	5.22e-12	Schizophrenia;
THYM	cis	rs11690935	1.000	rs35549875	chr2:172532392	A/G	cg13550731	chr2:172543902	DYNC1I2	0.85	6.15	0.53	1.8e-8	Schizophrenia;
THYM	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg26513180	chr16:89883248	FANCA	0.72	7.12	0.59	2.05e-10	Vitiligo;
THYM	cis	rs6435161	1.000	rs72926957	chr2:203487023	G/C	cg18429434	chr2:203499731	FAM117B	-0.68	-4.47	-0.42	2.14e-5	Total cholesterol levels;
THYM	cis	rs7255436	0.928	rs7250870	chr19:8453682	C/T	cg10174797	chr19:8464628	RAB11B	0.43	5.19	0.47	1.18e-6	HDL cholesterol;
THYM	cis	rs4595586	0.545	rs12819907	chr12:39356906	A/G	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg15556689	chr8:8085844	FLJ10661	0.73	6.08	0.53	2.45e-8	Mood instability;
THYM	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg06636001	chr8:8085503	FLJ10661	0.67	5.39	0.48	5.13e-7	Mood instability;
THYM	cis	rs7474896	0.616	rs1985260	chr10:38434090	C/T	cg25427524	chr10:38739819	LOC399744	-0.73	-4.61	-0.43	1.27e-5	Obesity (extreme);
THYM	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7172809	0.615	rs56097641	chr15:77810740	A/C	cg22256960	chr15:77711686	NA	-0.66	-4.8	-0.44	5.93e-6	Glucose homeostasis traits;
THYM	cis	rs9486719	1.000	rs4078038	chr6:96904366	A/G	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs1448094	0.621	rs10863090	chr12:86282211	C/T	cg02569458	chr12:86230093	RASSF9	0.52	4.73	0.44	7.8e-6	Major depressive disorder;
THYM	cis	rs1729951	0.575	rs12494558	chr3:136678781	C/G	cg21827317	chr3:136751795	NA	0.75	6.64	0.56	1.92e-9	Neuroticism;
THYM	cis	rs11031096	0.678	rs4606468	chr11:4183643	G/T	cg18678763	chr11:4115507	RRM1	-0.4	-4.73	-0.44	7.95e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs6570726	0.526	rs72994723	chr6:145722948	G/A	cg13319975	chr6:146136371	FBXO30	0.6	4.68	0.43	9.54e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg08048268	chr3:133502702	NA	-0.66	-5.71	-0.51	1.27e-7	Iron status biomarkers;
THYM	cis	rs308447	0.543	rs13130243	chr4:123708911	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.85	6.83	0.57	8.12e-10	Perceived unattractiveness to mosquitoes;
THYM	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg21475434	chr5:93447410	FAM172A	0.93	5.81	0.51	8.12e-8	Diabetic retinopathy;
THYM	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.94	7.19	0.59	1.45e-10	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4788570	0.538	rs72797713	chr16:71534208	G/A	cg06353428	chr16:71660113	MARVELD3	-1.01	-5.04	-0.46	2.2e-6	Intelligence (multi-trait analysis);
THYM	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg04455712	chr21:45112962	RRP1B	0.5	4.85	0.45	4.84e-6	Mean corpuscular volume;
THYM	cis	rs2637266	0.655	rs10824436	chr10:78457848	T/C	cg18941641	chr10:78392320	NA	0.75	6.16	0.53	1.77e-8	Pulmonary function;
THYM	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg04731861	chr2:219085781	ARPC2	-0.52	-4.74	-0.44	7.37e-6	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg17366294	chr4:99064904	C4orf37	0.57	6.82	0.57	8.42e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg10505658	chr17:80084571	CCDC57	0.7	8.07	0.64	2.18e-12	Life satisfaction;
THYM	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg23711669	chr6:146136114	FBXO30	0.86	8.06	0.64	2.28e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9560113	0.622	rs4773388	chr13:112195250	A/C	cg14154082	chr13:112174009	NA	0.52	4.46	0.42	2.27e-5	Menarche (age at onset);
THYM	cis	rs675209	0.591	rs9405325	chr6:7082633	C/T	cg07207043	chr6:7051497	NA	-0.32	-5.03	-0.46	2.29e-6	Urate levels;
THYM	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.76	-4.97	-0.45	3e-6	Mean platelet volume;
THYM	cis	rs6570726	0.764	rs4263604	chr6:145916697	A/G	cg23711669	chr6:146136114	FBXO30	0.95	9.91	0.71	2.53e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg01416388	chr22:39784598	NA	-0.95	-9.15	-0.68	1.11e-14	Intelligence (multi-trait analysis);
THYM	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg23422044	chr7:1970798	MAD1L1	-0.79	-5.21	-0.47	1.09e-6	Bipolar disorder;
THYM	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg27129171	chr3:47204927	SETD2	-0.82	-7.83	-0.63	6.81e-12	Colorectal cancer;
THYM	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs548181	0.736	rs540723	chr11:125489621	A/G	cg03464685	chr11:125439445	EI24	1.24	7.56	0.61	2.49e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg18240062	chr17:79603768	NPLOC4	0.74	6.52	0.56	3.45e-9	Eye color traits;
THYM	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg26752003	chr8:145688521	CYHR1	-0.89	-7.69	-0.62	1.33e-11	Age at first birth;
THYM	cis	rs6547741	0.743	rs7564625	chr2:27862397	C/T	cg27432699	chr2:27873401	GPN1	-0.87	-7.73	-0.62	1.14e-11	Oral cavity cancer;
THYM	cis	rs4792901	0.918	rs12603164	chr17:41618566	C/G	cg21940313	chr17:41620911	ETV4	-0.48	-5.17	-0.47	1.28e-6	Dupuytren's disease;
THYM	cis	rs9649213	0.593	rs3801263	chr7:97965016	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg24531977	chr5:56204891	C5orf35	0.72	5.83	0.51	7.64e-8	Initial pursuit acceleration;
THYM	cis	rs2072499	0.932	rs2736613	chr1:156196016	T/C	cg25208724	chr1:156163844	SLC25A44	1.12	12.22	0.78	3.41e-21	Testicular germ cell tumor;
THYM	cis	rs2085601	0.542	rs1795733	chr4:89976832	G/A	cg17769793	chr4:89976368	FAM13A	-0.59	-6.86	-0.58	6.96e-10	Hair greying;
THYM	cis	rs75804782	0.522	rs7561954	chr2:239318280	G/A	cg18131467	chr2:239335373	ASB1	-0.75	-4.58	-0.43	1.4e-5	Morning vs. evening chronotype;Chronotype;
THYM	cis	rs72828912	0.665	rs9393523	chr6:24067664	A/G	cg19882886	chr6:25043046	NA	-0.86	-4.47	-0.42	2.14e-5	Squamous cell lung carcinoma;
THYM	cis	rs6987853	0.787	rs2923413	chr8:42455308	A/G	cg09913449	chr8:42400586	C8orf40	0.95	9.53	0.7	1.64e-15	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4474465	0.850	rs7111004	chr11:78269961	G/A	cg19901956	chr11:77921274	USP35	0.67	4.88	0.45	4.19e-6	Alzheimer's disease (survival time);
THYM	cis	rs864643	0.738	rs34922979	chr3:39592425	G/A	cg20142358	chr3:39093977	WDR48	-0.64	-4.57	-0.42	1.49e-5	Attention deficit hyperactivity disorder;
THYM	cis	rs28595532	1.000	rs56000725	chr4:119637675	G/A	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs9443645	0.527	rs12196485	chr6:79556871	A/G	cg05283184	chr6:79620031	NA	-0.58	-4.53	-0.42	1.71e-5	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.547	rs12150369	chr17:17911014	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.58	0.56	2.61e-9	Total body bone mineral density;
THYM	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg16414030	chr3:133502952	NA	0.94	9.88	0.71	2.92e-16	Iron status biomarkers;
THYM	cis	rs3857067	0.806	rs6817795	chr4:95127716	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.48	-0.42	2.07e-5	QT interval;
THYM	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg04025307	chr7:1156635	C7orf50	0.68	6.47	0.55	4.25e-9	Longevity;Endometriosis;
THYM	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14240646	chr10:27532245	ACBD5	0.86	5.03	0.46	2.28e-6	Breast cancer;
THYM	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.75	-4.6	-0.43	1.29e-5	Diabetic retinopathy;
THYM	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg13852791	chr20:30311386	BCL2L1	0.75	5.99	0.52	3.74e-8	Mean corpuscular hemoglobin;
THYM	cis	rs870825	0.616	rs14969	chr4:185615764	C/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg18230493	chr5:56204884	C5orf35	0.65	4.93	0.45	3.47e-6	Initial pursuit acceleration;
THYM	cis	rs7084402	0.967	rs1649028	chr10:60280428	A/G	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs2455799	0.573	rs2470546	chr3:15733897	T/C	cg16303742	chr3:15540471	COLQ	-0.53	-5.9	-0.52	5.47e-8	Mean platelet volume;
THYM	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg26818010	chr10:134567672	INPP5A	-0.91	-7.12	-0.59	2.1e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7100689	0.646	rs1953971	chr10:82145647	G/C	cg01528321	chr10:82214614	TSPAN14	0.89	6.73	0.57	1.26e-9	Post bronchodilator FEV1;
THYM	cis	rs17122693	1.000	rs3759588	chr14:51062357	G/A	cg04730355	chr14:51134070	SAV1	0.99	5.42	0.49	4.44e-7	Cognitive performance;
THYM	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg17202724	chr17:61916730	SMARCD2	0.5	5.05	0.46	2.14e-6	Prudent dietary pattern;
THYM	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg15242686	chr22:24348715	GSTTP1	0.65	6.68	0.57	1.59e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1847202	0.859	rs13096870	chr3:72948172	G/A	cg25664220	chr3:72788482	NA	-0.64	-4.83	-0.44	5.23e-6	Motion sickness;
THYM	cis	rs4523957	0.928	rs216202	chr17:2197387	T/C	cg16513277	chr17:2031491	SMG6	0.77	7.16	0.59	1.73e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6842789	0.516	rs6842663	chr4:124935949	T/C	cg01723706	chr4:124814442	LOC285419	0.66	4.56	0.42	1.54e-5	Neuroticism;
THYM	cis	rs7772486	0.764	rs2265468	chr6:146218346	A/C	cg23711669	chr6:146136114	FBXO30	0.95	9.88	0.71	2.94e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.81	-7.03	-0.58	3.13e-10	Intelligence (multi-trait analysis);
THYM	cis	rs67981189	0.896	rs2526890	chr14:71430127	A/T	cg15910301	chr14:71632612	NA	-0.5	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg02782426	chr3:40428986	ENTPD3	-0.57	-5.2	-0.47	1.12e-6	Renal cell carcinoma;
THYM	cis	rs12216545	0.765	rs6464082	chr7:150260607	A/C	cg08960815	chr7:150264767	GIMAP4	-0.85	-7.68	-0.62	1.38e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg13695892	chr22:41940480	POLR3H	0.94	7.07	0.59	2.59e-10	Vitiligo;
THYM	cis	rs2688608	0.588	rs10128205	chr10:75469648	C/G	cg15838173	chr10:75533400	FUT11	-0.55	-5.37	-0.48	5.58e-7	Inflammatory bowel disease;
THYM	cis	rs4481887	1.000	rs4244172	chr1:248466838	A/G	cg13385794	chr1:248469461	NA	0.65	4.53	0.42	1.74e-5	Common traits (Other);
THYM	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg09085632	chr11:111637200	PPP2R1B	1.21	12.39	0.79	1.54e-21	Primary sclerosing cholangitis;
THYM	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg13607699	chr17:42295918	UBTF	0.62	4.83	0.44	5.31e-6	Total body bone mineral density;
THYM	cis	rs76878669	0.561	rs55998145	chr11:66152586	A/G	cg18002602	chr11:66138449	SLC29A2	0.5	5.02	0.46	2.38e-6	Educational attainment (years of education);
THYM	trans	rs4866334	1.000	rs75023127	chr5:18487706	A/G	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg07424592	chr7:64974309	NA	1.08	4.84	0.44	5.04e-6	Diabetic kidney disease;
THYM	cis	rs2219968	0.701	rs1994035	chr8:79003651	C/T	cg00738934	chr8:78996279	NA	-0.83	-8.01	-0.64	2.82e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12893597	0.715	rs34486942	chr14:76831530	G/A	cg20290672	chr14:76816747	NA	-0.71	-5.69	-0.5	1.39e-7	Maximal oxygen uptake response;
THYM	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg13010199	chr12:38710504	ALG10B	-0.6	-4.46	-0.42	2.29e-5	Bladder cancer;
THYM	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg14798641	chr3:49314920	USP4;C3orf62	-0.69	-4.69	-0.43	9.23e-6	Cognitive function;
THYM	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.56	0.56	2.79e-9	Total body bone mineral density;
THYM	cis	rs977987	0.843	rs28655617	chr16:75489642	G/A	cg03315344	chr16:75512273	CHST6	0.73	6.1	0.53	2.3e-8	Dupuytren's disease;
THYM	cis	rs2797160	1.000	rs1739377	chr6:126012236	T/C	cg16306078	chr6:126000798	NA	0.53	5.42	0.49	4.51e-7	Endometrial cancer;
THYM	cis	rs858239	0.633	rs858300	chr7:23244631	A/G	cg05407003	chr7:23246146	NA	-0.73	-6.39	-0.55	6e-9	Cerebrospinal fluid biomarker levels;
THYM	cis	rs1559088	1.000	rs1974783	chr19:33551507	C/G	cg03563238	chr19:33554763	RHPN2	-0.5	-4.48	-0.42	2.04e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.5	4.48	0.42	2.06e-5	Birth weight;
THYM	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg26384229	chr12:38710491	ALG10B	-0.97	-7.44	-0.61	4.48e-11	Bladder cancer;
THYM	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg04043695	chr12:129287642	SLC15A4	0.58	4.53	0.42	1.69e-5	Systemic lupus erythematosus;
THYM	cis	rs9810089	0.758	rs12492510	chr3:136151631	G/T	cg12473912	chr3:136751656	NA	0.62	5.27	0.48	8.44e-7	Gestational age at birth (child effect);
THYM	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg22709100	chr7:91322751	NA	-0.64	-4.96	-0.45	3.08e-6	Breast cancer;
THYM	cis	rs2658782	0.724	rs1869914	chr11:93112492	C/G	cg15737290	chr11:93063684	CCDC67	0.9	7.19	0.59	1.49e-10	Pulmonary function decline;
THYM	trans	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg07211511	chr3:129823064	LOC729375	-1.34	-9.22	-0.69	7.72e-15	Blood pressure (smoking interaction);
THYM	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg02782426	chr3:40428986	ENTPD3	-0.5	-4.48	-0.42	2.1e-5	Renal cell carcinoma;
THYM	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06481639	chr22:41940642	POLR3H	0.82	5.77	0.51	9.74e-8	Vitiligo;
THYM	cis	rs6089829	0.589	rs73921629	chr20:61676036	G/C	cg08045932	chr20:61659980	NA	-0.9	-7.53	-0.61	2.88e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.23	4.66	0.43	1.02e-5	Obesity-related traits;
THYM	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-5.36	-0.48	5.89e-7	Vitiligo;
THYM	cis	rs4654899	0.802	rs9651021	chr1:21222770	A/C	cg01072550	chr1:21505969	NA	-0.7	-6.26	-0.54	1.12e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg18876405	chr7:65276391	NA	0.56	4.73	0.44	7.72e-6	Aortic root size;
THYM	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.82	-7.16	-0.59	1.7e-10	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs938554	0.513	rs11943372	chr4:9999346	T/A	cg26689780	chr4:10079554	WDR1	-0.39	-4.46	-0.42	2.23e-5	Blood metabolite levels;
THYM	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg05182265	chr7:156933206	UBE3C	-0.64	-8.1	-0.64	1.81e-12	Body mass index;
THYM	cis	rs17372054	1.000	rs7074452	chr10:4793816	A/C	cg19993680	chr10:5576748	NA	0.56	4.6	0.43	1.29e-5	Major depressive disorder;
THYM	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg04772025	chr11:68637568	NA	0.61	6.23	0.54	1.26e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs79387448	0.655	rs3771167	chr2:102986188	A/G	cg09003973	chr2:102972529	NA	1.29	7.48	0.61	3.76e-11	Gut microbiota (bacterial taxa);
THYM	cis	rs58873874	1.000	rs11740562	chr5:156942285	C/T	cg08916508	chr5:156566250	MED7	1.3	5.32	0.48	7e-7	Bipolar disorder (body mass index interaction);
THYM	cis	rs198389	0.589	rs198391	chr1:11876417	C/T	cg24844545	chr1:11908347	NPPA	0.5	4.95	0.45	3.18e-6	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
THYM	cis	rs7580658	0.929	rs4150496	chr2:128029503	C/T	cg10021288	chr2:128175891	PROC	-0.78	-6.82	-0.57	8.26e-10	Protein C levels;
THYM	cis	rs9796	0.689	rs692511	chr15:41446252	A/C	cg21153102	chr15:41252147	NA	0.6	4.98	0.45	2.84e-6	Menopause (age at onset);
THYM	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	4.78	0.44	6.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs6496667	1.000	rs8042825	chr15:90897885	C/G	cg22089800	chr15:90895588	ZNF774	-0.74	-5.0	-0.46	2.65e-6	Rheumatoid arthritis;
THYM	cis	rs425277	0.606	rs2459984	chr1:2086312	A/G	cg00981070	chr1:2046702	PRKCZ	0.42	5.19	0.47	1.2e-6	Height;
THYM	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg18252515	chr7:66147081	NA	-0.88	-6.71	-0.57	1.4e-9	Corneal structure;
THYM	cis	rs1883415	0.591	rs10456305	chr6:24491341	C/T	cg00346970	chr6:24499591	ALDH5A1	-0.36	-5.34	-0.48	6.28e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3820068	0.562	rs10927841	chr1:16045261	T/C	cg13390004	chr1:15929781	NA	0.63	4.55	0.42	1.61e-5	Systolic blood pressure;
THYM	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg11375102	chr16:1583810	IFT140;TMEM204	-0.59	-4.98	-0.46	2.83e-6	Coronary artery disease;
THYM	cis	rs8133932	0.654	rs2839041	chr21:47322616	T/C	cg20357416	chr21:47294739	PCBP3	-0.81	-4.92	-0.45	3.56e-6	Schizophrenia;
THYM	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg02187348	chr16:89574699	SPG7	0.7	5.5	0.49	3.14e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.51	5.32	0.48	6.93e-7	Schizophrenia;
THYM	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg11494091	chr17:61959527	GH2	0.69	6.32	0.54	8.45e-9	Height;
THYM	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	10.01	0.72	1.59e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg13918804	chr1:2043761	PRKCZ	-0.61	-4.62	-0.43	1.19e-5	Height;
THYM	cis	rs12701220	0.762	rs10247470	chr7:1092512	C/G	cg00990874	chr7:1149470	C7orf50	-0.6	-4.61	-0.43	1.25e-5	Bronchopulmonary dysplasia;
THYM	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg14458575	chr2:238380390	NA	0.97	7.68	0.62	1.41e-11	Prostate cancer;
THYM	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg10523679	chr1:76189770	ACADM	0.88	8.37	0.65	5.04e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9583531	0.689	rs1061386	chr13:111373368	G/C	cg24331049	chr13:111365604	ING1	0.64	5.28	0.48	8e-7	Coronary artery disease;
THYM	cis	rs12478296	1.000	rs57603292	chr2:243028537	G/A	cg06360820	chr2:242988706	NA	-1.08	-6.69	-0.57	1.56e-9	Obesity-related traits;
THYM	cis	rs6591182	0.504	rs7130955	chr11:65372580	C/T	cg17480646	chr11:65405466	SIPA1	-0.84	-7.49	-0.61	3.54e-11	Non-alcoholic fatty liver disease histology (lobular);
THYM	cis	rs4687717	0.717	rs13101181	chr3:53288224	G/A	cg16894138	chr3:53270350	TKT	0.84	6.21	0.54	1.38e-8	Blood metabolite levels;Blood metabolite ratios;
THYM	cis	rs3768617	0.510	rs2093984	chr1:183094314	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	4.98	0.46	2.84e-6	Fuchs's corneal dystrophy;
THYM	cis	rs611744	0.583	rs1448148	chr8:109333074	T/A	cg21045802	chr8:109455806	TTC35	0.79	7.23	0.6	1.19e-10	Dupuytren's disease;
THYM	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg13609457	chr4:120235615	NA	0.6	5.39	0.48	5.11e-7	Corneal astigmatism;
THYM	cis	rs7084402	0.967	rs1582827	chr10:60297102	T/C	cg07615347	chr10:60278583	BICC1	0.56	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs4568518	0.535	rs3935149	chr7:18060929	G/A	cg00911873	chr7:18067463	PRPS1L1	-0.6	-4.85	-0.45	4.81e-6	Measles;
THYM	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg04362960	chr10:104952993	NT5C2	0.6	5.11	0.46	1.66e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7000551	0.751	rs2469768	chr8:22381362	G/A	cg12081754	chr8:22256438	SLC39A14	0.65	5.67	0.5	1.51e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs447921	0.861	rs17596582	chr17:74438120	A/T	cg17201438	chr17:74438067	UBE2O	-0.77	-5.46	-0.49	3.74e-7	Mitochondrial DNA levels;
THYM	cis	rs12142240	0.698	rs66516678	chr1:46810112	G/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs9733	0.628	rs7540874	chr1:150702663	A/C	cg10589385	chr1:150898437	SETDB1	0.62	5.26	0.47	8.86e-7	Tonsillectomy;
THYM	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg22535103	chr8:58192502	C8orf71	-0.86	-4.82	-0.44	5.4e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4243830	0.850	rs11122043	chr1:6580429	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.08	-7.53	-0.61	2.9100000000000002e-11	Body mass index;
THYM	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03647317	chr4:187891568	NA	0.84	9.32	0.69	4.68e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2901656	0.546	rs9425598	chr1:172371922	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.49	4.9	0.45	3.92e-6	Red cell distribution width;Platelet distribution width;
THYM	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg12311346	chr5:56204834	C5orf35	-0.59	-4.65	-0.43	1.08e-5	Type 2 diabetes;
THYM	cis	rs6450176	0.587	rs10471884	chr5:53344135	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.87	-7.49	-0.61	3.5e-11	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg23161317	chr6:28129485	ZNF389	0.85	6.33	0.54	8.19e-9	Depression;
THYM	trans	rs59551326	0.517	rs2829642	chr21:26582103	T/C	cg17452615	chr12:122019080	KDM2B	-0.8	-6.84	-0.57	7.67e-10	Alcohol dependence;
THYM	cis	rs7833986	1.000	rs34608229	chr8:57097017	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	4.78	0.44	6.48e-6	Height;
THYM	cis	rs1729951	0.545	rs1097288	chr3:136693721	C/T	cg12473912	chr3:136751656	NA	0.63	5.13	0.47	1.55e-6	Neuroticism;
THYM	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs2154427	0.872	rs76474418	chr21:34050113	A/G	cg21871883	chr21:34145043	C21orf49;C21orf66	1.0	5.26	0.47	8.92e-7	Bilirubin levels;
THYM	cis	rs12291225	0.679	rs11369	chr11:14288096	A/G	cg19336497	chr11:14380999	RRAS2	-0.82	-9.58	-0.7	1.34e-15	Sense of smell;
THYM	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg04398451	chr17:18023971	MYO15A	-0.92	-9.33	-0.69	4.39e-15	Total body bone mineral density;
THYM	cis	rs3820068	0.608	rs58140482	chr1:16043979	A/G	cg27534772	chr1:16042836	PLEKHM2	0.51	5.25	0.47	9.14e-7	Systolic blood pressure;
THYM	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg11247378	chr22:39784982	NA	-0.99	-11.25	-0.76	3.7e-19	Intelligence (multi-trait analysis);
THYM	cis	rs6754311	0.593	rs55825471	chr2:136526981	T/A	cg04750100	chr2:136595281	LCT	-0.56	-6.37	-0.55	6.59e-9	Mosquito bite size;
THYM	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.09e-8	Systolic blood pressure;
THYM	cis	rs9572053	0.550	rs9541667	chr13:69554033	T/C	cg16757992	chr13:69559194	NA	-0.61	-4.91	-0.45	3.8e-6	Subjective well-being;
THYM	cis	rs7078219	0.714	rs11190139	chr10:101288099	C/G	cg17888390	chr10:101282816	NA	-0.55	-5.29	-0.48	7.79e-7	Dental caries;
THYM	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg00463982	chr16:1583984	IFT140;TMEM204	-0.62	-5.29	-0.48	7.82e-7	Coronary artery disease;
THYM	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	9.42	0.69	2.88e-15	Chronic sinus infection;
THYM	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg12935359	chr14:103987150	CKB	-0.64	-6.43	-0.55	5.14e-9	Body mass index;
THYM	cis	rs3087591	0.960	rs11870097	chr17:29448097	C/T	cg24425628	chr17:29625626	OMG;NF1	0.64	5.45	0.49	3.96e-7	Hip circumference;
THYM	cis	rs924712	0.570	rs2134536	chr6:54857680	G/A	cg04690482	chr6:54711388	FAM83B	-0.49	-5.76	-0.51	1.05e-7	Breast cancer;
THYM	cis	rs7580658	0.963	rs2090574	chr2:128131391	C/A	cg10021288	chr2:128175891	PROC	-0.83	-7.08	-0.59	2.5e-10	Protein C levels;
THYM	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11608355	0.515	rs12833054	chr12:109890955	G/A	cg11367159	chr12:110044531	NA	0.62	4.74	0.44	7.42e-6	Neuroticism;
THYM	cis	rs6430585	0.941	rs7589832	chr2:136504101	A/C	cg04750100	chr2:136595281	LCT	0.53	5.13	0.47	1.55e-6	Corneal structure;
THYM	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6987853	0.814	rs2167338	chr8:42455079	A/G	cg09913449	chr8:42400586	C8orf40	0.95	9.52	0.7	1.8e-15	Mean corpuscular hemoglobin concentration;
THYM	cis	rs12310956	0.532	rs1525903	chr12:33964163	T/C	cg06521331	chr12:34319734	NA	-0.92	-8.57	-0.66	1.89e-13	Morning vs. evening chronotype;
THYM	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg09904177	chr6:26538194	HMGN4	0.53	4.48	0.42	2.09e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg19628046	chr18:33552617	C18orf21	0.77	5.47	0.49	3.68e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs4819852	0.958	rs2238786	chr22:19975444	A/G	cg07821417	chr22:19972146	ARVCF	0.49	5.82	0.51	7.96e-8	Pulse pressure;
THYM	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4788570	0.727	rs7204118	chr16:71833658	G/C	cg06353428	chr16:71660113	MARVELD3	1.41	8.53	0.66	2.29e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7267979	0.816	rs1044573	chr20:25206654	A/G	cg03522245	chr20:25566470	NINL	0.62	4.68	0.43	9.69e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.49	-0.42	2.04e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4888262	0.545	rs4888270	chr16:74698576	A/G	cg01733217	chr16:74700730	RFWD3	0.88	9.59	0.7	1.24e-15	Testicular germ cell tumor;
THYM	cis	rs17021463	0.902	rs11097413	chr4:95249286	C/T	cg11021082	chr4:95130006	SMARCAD1	0.54	4.7	0.43	8.78e-6	Testicular germ cell tumor;
THYM	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg24530246	chr3:53118167	NA	-0.83	-4.78	-0.44	6.39e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs4343996	0.934	rs6959232	chr7:3376530	A/G	cg21248987	chr7:3385318	SDK1	-0.4	-4.82	-0.44	5.49e-6	Motion sickness;
THYM	cis	rs2276314	1.000	rs9304153	chr18:33562150	T/C	cg05985134	chr18:33552581	C18orf21	0.72	5.0	0.46	2.6e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17209837	0.607	rs45478299	chr7:87111321	G/A	cg04996195	chr7:87105398	ABCB4	0.65	4.77	0.44	6.62e-6	Gallbladder cancer;
THYM	cis	rs337100	0.521	rs1644316	chr5:122531379	G/T	cg04547002	chr5:122551801	NA	0.6	4.52	0.42	1.8e-5	Pulse pressure;
THYM	trans	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.8	-8.98	-0.68	2.52e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4851266	0.898	rs10496346	chr2:100853267	A/G	cg14675211	chr2:100938903	LONRF2	-0.67	-5.59	-0.5	2.15e-7	Educational attainment;
THYM	cis	rs4654899	0.802	rs2290381	chr1:21213271	C/A	cg01072550	chr1:21505969	NA	-0.71	-6.36	-0.55	7.06e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg03188948	chr7:1209495	NA	0.91	7.19	0.59	1.48e-10	Longevity;Endometriosis;
THYM	cis	rs3781426	1.000	rs3781421	chr10:126709703	C/T	cg04494136	chr10:126703576	CTBP2	-0.37	-5.02	-0.46	2.37e-6	Height;
THYM	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg09323728	chr8:95962352	TP53INP1	0.45	4.67	0.43	9.99e-6	Type 2 diabetes;
THYM	cis	rs13315871	0.929	rs13080398	chr3:58300282	A/G	cg12435725	chr3:58293450	RPP14	-0.53	-5.57	-0.5	2.32e-7	Cholesterol, total;
THYM	cis	rs11588062	1.000	rs11588062	chr1:46779764	C/T	cg22112435	chr1:46664449	POMGNT1	-0.47	-4.89	-0.45	4.13e-6	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs2916260	0.932	rs77339485	chr6:40382512	A/G	cg08415973	chr6:40346114	TDRG1	0.76	4.64	0.43	1.1e-5	Incident coronary heart disease;
THYM	cis	rs9902453	0.934	rs4427857	chr17:28457989	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.84	6.58	0.56	2.55e-9	Coffee consumption (cups per day);
THYM	cis	rs2276314	0.857	rs3737474	chr18:33613595	T/C	cg05985134	chr18:33552581	C18orf21	0.69	4.88	0.45	4.22e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7582180	0.638	rs7581011	chr2:100954659	A/G	cg08017756	chr2:100939284	LONRF2	0.73	7.65	0.62	1.66e-11	Intelligence (multi-trait analysis);
THYM	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs2806561	1.000	rs2776819	chr1:23470116	A/T	cg19743168	chr1:23544995	NA	0.57	5.52	0.49	2.9e-7	Height;
THYM	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs736408	0.583	rs2302417	chr3:52814256	T/A	cg17372223	chr3:52568218	NT5DC2	0.31	4.6	0.43	1.31e-5	Bipolar disorder;
THYM	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg27034606	chr17:28928453	LRRC37B2	0.85	5.5	0.49	3.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7894051	1.000	rs10776675	chr10:135183094	C/A	cg12428399	chr10:135191333	PAOX	-0.97	-4.53	-0.42	1.7e-5	Lifespan;
THYM	cis	rs886126	0.627	rs4766561	chr12:111673244	C/T	cg10833066	chr12:111807467	FAM109A	0.49	5.26	0.47	8.98e-7	Coronary heart disease;
THYM	cis	rs7772486	0.790	rs9497431	chr6:146248177	T/C	cg13319975	chr6:146136371	FBXO30	0.7	5.8	0.51	8.55e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg02187348	chr16:89574699	SPG7	-0.72	-5.22	-0.47	1.05e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs453193	0.597	rs3111416	chr2:8452313	G/A	cg12167548	chr2:8464763	NA	0.42	4.53	0.42	1.72e-5	Granulocyte percentage of myeloid white cells;
THYM	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg13854012	chr2:162103682	NA	-0.61	-4.85	-0.45	4.81e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7100689	0.560	rs10887891	chr10:82207717	A/C	cg00277334	chr10:82204260	NA	-0.66	-6.63	-0.56	1.99e-9	Post bronchodilator FEV1;
THYM	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg11764359	chr7:65958608	NA	0.63	4.94	0.45	3.36e-6	Aortic root size;
THYM	cis	rs3816788	0.620	rs11783414	chr8:21773384	A/G	cg17168535	chr8:21777572	XPO7	-0.82	-6.77	-0.57	1.04e-9	Lung cancer in ever smokers;
THYM	cis	rs7829975	0.774	rs11249893	chr8:8700851	C/T	cg18904891	chr8:8559673	CLDN23	0.56	4.74	0.44	7.57e-6	Mood instability;
THYM	cis	rs9790314	1.000	rs1382426	chr3:161045933	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg07212818	chr11:638076	DRD4	-0.79	-6.69	-0.57	1.57e-9	Systemic lupus erythematosus;
THYM	cis	rs12348691	0.503	rs10983975	chr9:100614188	A/C	cg13688889	chr9:100608707	NA	-0.88	-5.99	-0.52	3.78e-8	Alopecia areata;
THYM	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22496380	chr5:211416	CCDC127	-1.29	-7.76	-0.62	9.7e-12	Breast cancer;
THYM	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg05043794	chr9:111880884	C9orf5	-0.43	-6.31	-0.54	8.79e-9	Menarche (age at onset);
THYM	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg20891283	chr12:69753455	YEATS4	1.09	12.03	0.78	8.44e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg05738196	chr6:26577821	NA	0.84	8.48	0.66	2.87e-13	Intelligence (multi-trait analysis);
THYM	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg14583973	chr4:3374767	RGS12	0.65	6.25	0.54	1.16e-8	Serum sulfate level;
THYM	cis	rs34638657	0.732	rs2967359	chr16:82202968	G/C	cg09894383	chr16:82067445	HSD17B2	-0.45	-4.95	-0.45	3.15e-6	Lung adenocarcinoma;
THYM	cis	rs9646944	0.501	rs2110736	chr2:103050855	T/C	cg01241218	chr2:102972058	NA	0.76	4.86	0.45	4.55e-6	Blood protein levels;
THYM	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg15133208	chr4:90757351	SNCA	-0.56	-4.66	-0.43	1.04e-5	Neuroticism;
THYM	cis	rs7089973	0.872	rs10490908	chr10:116616162	T/C	cg08188268	chr10:116634841	FAM160B1	-0.3	-4.93	-0.45	3.54e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs4901869	0.966	rs4901868	chr14:59333792	C/T	cg02291164	chr14:59296302	NA	-0.8	-8.12	-0.64	1.64e-12	Panic disorder;
THYM	trans	rs1974653	0.672	rs8139107	chr22:20093288	C/T	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs4664308	0.618	rs66484345	chr2:160894930	C/T	cg03641300	chr2:160917029	PLA2R1	-0.67	-5.65	-0.5	1.69e-7	Idiopathic membranous nephropathy;
THYM	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.56	-5.62	-0.5	1.92e-7	Crohn's disease;
THYM	cis	rs7264396	0.563	rs6060566	chr20:34288226	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.76	-0.44	6.84e-6	Total cholesterol levels;
THYM	cis	rs9646954	0.791	rs4851300	chr2:100958804	C/A	cg08017756	chr2:100939284	LONRF2	-0.55	-4.85	-0.45	4.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7715811	1.000	rs10050673	chr5:13761643	G/A	cg07548982	chr5:13769939	DNAH5	-0.5	-4.5	-0.42	1.95e-5	Subclinical atherosclerosis traits (other);
THYM	cis	rs8018808	0.935	rs958463	chr14:77886721	G/T	cg20045696	chr14:77926864	AHSA1	0.53	4.81	0.44	5.73e-6	Myeloid white cell count;
THYM	cis	rs4363657	0.943	rs73069021	chr12:21399955	G/A	cg14622193	chr12:21587445	NA	0.75	4.81	0.44	5.73e-6	Bilirubin levels;Blood metabolite levels;
THYM	cis	rs365132	0.934	rs6861925	chr5:176324729	C/G	cg17809377	chr5:176326619	HK3	-0.31	-4.75	-0.44	7.07e-6	Menarche and menopause (age at onset);Menopause (age at onset);
THYM	cis	rs9902453	1.000	rs4533340	chr17:28277951	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	4.69	0.43	9.31e-6	Coffee consumption (cups per day);
THYM	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7567389	0.637	rs4150421	chr2:128044930	A/G	cg09760422	chr2:128146352	NA	-0.4	-4.52	-0.42	1.8e-5	Self-rated health;
THYM	cis	rs2637266	0.600	rs2395430	chr10:78465471	G/A	cg18941641	chr10:78392320	NA	0.77	5.95	0.52	4.38e-8	Pulmonary function;
THYM	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg24733560	chr20:60626293	TAF4	0.51	4.45	0.42	2.31e-5	Body mass index;
THYM	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs854765	0.624	rs8078756	chr17:17744725	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-5.39	-0.48	5.17e-7	Total body bone mineral density;
THYM	cis	rs4481887	0.741	rs28444488	chr1:248531776	C/A	cg17299007	chr1:248814626	OR2T27	0.42	4.52	0.42	1.81e-5	Common traits (Other);
THYM	cis	rs4891159	0.790	rs8085133	chr18:74144083	A/C	cg24786174	chr18:74118243	ZNF516	-0.94	-12.32	-0.78	2.11e-21	Longevity;
THYM	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.71	-5.46	-0.49	3.73e-7	Tonsillectomy;
THYM	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg17178900	chr1:205818956	PM20D1	0.78	7.73	0.62	1.1e-11	Menarche (age at onset);
THYM	cis	rs28595532	0.844	rs55845920	chr4:119490085	C/T	cg11846333	chr4:119757529	SEC24D	1.36	4.83	0.44	5.23e-6	Cannabis dependence symptom count;
THYM	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg10505658	chr17:80084571	CCDC57	-0.69	-7.95	-0.63	3.85e-12	Life satisfaction;
THYM	cis	rs2717559	0.522	rs2572922	chr8:143871652	G/A	cg03405983	chr8:143858548	LYNX1	0.53	5.8	0.51	8.76e-8	Urinary tract infection frequency;
THYM	cis	rs6430585	0.697	rs7607174	chr2:136513670	T/A	cg07169764	chr2:136633963	MCM6	1.22	13.28	0.81	2.23e-23	Corneal structure;
THYM	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg21014159	chr11:117668035	DSCAML1	0.68	4.84	0.44	5e-6	Myopia;
THYM	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs887829	0.570	rs10168333	chr2:234596988	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-6.51	-0.56	3.47e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg06112835	chr11:68658793	MRPL21	0.45	6.39	0.55	6.18e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11644478	chr21:40555479	PSMG1	0.98	7.72	0.62	1.15e-11	Cognitive function;
THYM	cis	rs9611519	0.929	rs9611466	chr22:41426299	A/T	cg06481639	chr22:41940642	POLR3H	-0.6	-4.47	-0.42	2.16e-5	Neuroticism;
THYM	cis	rs854765	0.547	rs7223696	chr17:17915791	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.58	0.56	2.61e-9	Total body bone mineral density;
THYM	cis	rs4474465	1.000	rs2063727	chr11:78183882	T/A	cg19901956	chr11:77921274	USP35	-0.62	-4.66	-0.43	1.01e-5	Alzheimer's disease (survival time);
THYM	cis	rs698833	0.501	rs12473699	chr2:44507673	G/A	cg04920474	chr2:44395004	PPM1B	0.62	6.12	0.53	2.12e-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
THYM	cis	rs684232	0.602	rs2543775	chr17:557123	G/A	cg15660573	chr17:549704	VPS53	-0.99	-11.0	-0.75	1.22e-18	Prostate cancer;
THYM	cis	rs611744	0.868	rs612722	chr8:109194850	C/T	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg11764359	chr7:65958608	NA	0.84	7.06	0.59	2.72e-10	Aortic root size;
THYM	cis	rs4732038	0.510	rs68103559	chr7:134279556	C/T	cg06906464	chr7:134288099	NA	-0.56	-5.49	-0.49	3.31e-7	Longevity;
THYM	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.64	4.6	0.43	1.32e-5	Body mass index (adult);
THYM	cis	rs4970966	1.000	rs4970966	chr1:150584103	A/C	cg16565154	chr1:151129062	TNFAIP8L2	0.32	4.62	0.43	1.23e-5	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.69	-0.67	1.03e-13	Monocyte count;
THYM	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg12386194	chr3:101231763	SENP7	0.69	5.11	0.46	1.65e-6	Colorectal cancer;
THYM	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg11789530	chr4:8429930	ACOX3	0.74	5.99	0.52	3.74e-8	Response to antineoplastic agents;
THYM	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg05791153	chr7:19748676	TWISTNB	1.26	8.95	0.68	2.92e-14	Night sleep phenotypes;
THYM	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg26597838	chr10:835615	NA	-1.24	-9.02	-0.68	2.01e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg19418458	chr7:158789849	NA	-0.67	-6.55	-0.56	3e-9	Facial morphology (factor 20);
THYM	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs1629083	0.840	rs10790248	chr11:118125672	G/A	cg25155064	chr11:118100782	MPZL3	-0.57	-5.03	-0.46	2.34e-6	Lung cancer;
THYM	cis	rs2862064	1.000	rs1948759	chr5:156442657	C/T	cg12943317	chr5:156479607	HAVCR1	0.83	5.19	0.47	1.17e-6	Platelet count;
THYM	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg05754148	chr16:3507555	NAT15	0.72	6.82	0.57	8.39e-10	Tuberculosis;
THYM	cis	rs3087591	0.879	rs4795591	chr17:29612410	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.63	-5.38	-0.48	5.3e-7	Hip circumference;
THYM	cis	rs288326	0.561	rs74942055	chr2:183793653	A/G	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs17708984	0.606	rs3786574	chr19:16193617	T/C	cg13618979	chr19:16186840	TPM4	0.35	4.59	0.43	1.38e-5	Platelet count;Platelet distribution width;
THYM	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg15445000	chr17:37608096	MED1	0.44	5.1	0.46	1.72e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg03433033	chr1:76189801	ACADM	0.73	7.09	0.59	2.41e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg04317338	chr11:64019027	PLCB3	0.78	5.34	0.48	6.38e-7	Mean platelet volume;
THYM	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg09417038	chr21:47716443	C21orf57	0.6	5.08	0.46	1.85e-6	Testicular germ cell tumor;
THYM	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg04772025	chr11:68637568	NA	0.66	6.9	0.58	5.88e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg27170947	chr2:26402098	FAM59B	-0.8	-6.3	-0.54	9.35e-9	Gut microbiome composition (summer);
THYM	cis	rs4499344	0.633	rs166311	chr19:33161246	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.58	0.61	2.32e-11	Mean platelet volume;
THYM	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg00024416	chr22:24240387	NA	-0.71	-7.15	-0.59	1.76e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4927850	0.521	rs4927679	chr3:195658360	C/T	cg12923728	chr3:195709715	SDHAP1	0.59	5.13	0.47	1.53e-6	Pancreatic cancer;
THYM	cis	rs9554348	0.541	rs11617706	chr13:96987233	G/A	cg25169784	chr13:96706045	UGGT2	0.85	4.55	0.42	1.58e-5	Schizophrenia;
THYM	cis	rs1050631	0.564	rs8098627	chr18:33721636	T/G	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.6	4.69	0.43	9.09e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs6500395	1.000	rs1909765	chr16:48597358	A/G	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs17253792	0.822	rs75399477	chr14:56174413	T/C	cg01858014	chr14:56050164	KTN1	-1.18	-4.77	-0.44	6.75e-6	Putamen volume;
THYM	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	5.41	0.49	4.77e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2898681	0.874	rs59649036	chr4:53741175	T/C	cg21521518	chr4:53727714	RASL11B	0.46	5.2	0.47	1.15e-6	Optic nerve measurement (cup area);
THYM	cis	rs595982	0.559	rs17272680	chr19:49364511	A/G	cg15549821	chr19:49342101	PLEKHA4	0.96	5.51	0.49	3e-7	Red cell distribution width;
THYM	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg23711669	chr6:146136114	FBXO30	0.95	10.16	0.72	7.47e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg13609457	chr4:120235615	NA	0.64	5.55	0.49	2.56e-7	Educational attainment;
THYM	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg06728252	chr6:26598149	ABT1	-0.44	-5.23	-0.47	1.02e-6	Intelligence (multi-trait analysis);
THYM	cis	rs72717009	0.825	rs12722986	chr1:161465420	A/G	cg15358701	chr1:161410459	NA	-0.97	-5.37	-0.48	5.56e-7	Rheumatoid arthritis;
THYM	cis	rs6669072	1.000	rs3856228	chr1:91247029	T/G	cg08895590	chr1:91227319	NA	-0.54	-6.4	-0.55	5.78e-9	Cognitive function;
THYM	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg02931644	chr1:25747376	RHCE	0.58	4.51	0.42	1.83e-5	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs2070488	1.000	rs13074025	chr3:38455704	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	6.83	0.57	7.89e-10	Electrocardiographic conduction measures;
THYM	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06634786	chr22:41940651	POLR3H	0.79	5.9	0.52	5.57e-8	Vitiligo;
THYM	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg00376283	chr12:123451042	ABCB9	0.73	4.97	0.45	2.96e-6	Neutrophil percentage of white cells;
THYM	cis	rs28374715	0.662	rs28827035	chr15:41492290	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.02	-8.36	-0.65	5.28e-13	Ulcerative colitis;
THYM	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10493773	0.748	rs6576784	chr1:86149476	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.48	-6.24	-0.54	1.19e-8	Urate levels in overweight individuals;
THYM	cis	rs3772130	0.962	rs13433692	chr3:121484714	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg18402987	chr7:1209562	NA	0.67	5.08	0.46	1.84e-6	Longevity;Endometriosis;
THYM	cis	rs11190604	0.767	rs7076606	chr10:102192267	T/C	cg07570687	chr10:102243282	WNT8B	0.85	8.46	0.66	3.16e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs870825	0.616	rs6843185	chr4:185649878	A/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg08305652	chr11:111469057	NA	0.53	4.58	0.43	1.41e-5	Primary sclerosing cholangitis;
THYM	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21659725	chr3:3221576	CRBN	0.9	9.83	0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg21231944	chr12:82153410	PPFIA2	-0.64	-4.76	-0.44	7.01e-6	Resting heart rate;
THYM	cis	rs12681287	0.604	rs7017716	chr8:87429001	A/C	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs9325144	0.723	rs10161183	chr12:39182087	T/C	cg26384229	chr12:38710491	ALG10B	-0.6	-4.62	-0.43	1.18e-5	Morning vs. evening chronotype;
THYM	cis	rs2970992	0.764	rs925577	chr2:101324948	C/T	cg01042948	chr2:101319752	NA	-0.57	-5.45	-0.49	4.04e-7	Educational attainment;
THYM	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12216545	0.737	rs7788962	chr7:150227227	G/A	cg08960815	chr7:150264767	GIMAP4	-0.89	-8.27	-0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.88	9.61	0.7	1.12e-15	Prudent dietary pattern;
THYM	cis	rs59698941	0.550	rs11739194	chr5:132201230	T/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.53	4.61	0.43	1.26e-5	Apolipoprotein A-IV levels;
THYM	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg25208724	chr1:156163844	SLC25A44	1.11	12.2	0.78	3.68e-21	Testicular germ cell tumor;
THYM	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg11764359	chr7:65958608	NA	-0.81	-6.92	-0.58	5.2400000000000005e-10	Aortic root size;
THYM	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg27284194	chr4:1044797	NA	0.6	4.54	0.42	1.68e-5	Recombination rate (females);
THYM	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.65	5.32	0.48	6.93e-7	Hemoglobin concentration;
THYM	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg05738196	chr6:26577821	NA	-0.57	-4.55	-0.42	1.61e-5	Schizophrenia;
THYM	cis	rs10979	1.000	rs6570566	chr6:143899534	G/A	cg25407410	chr6:143891975	LOC285740	-0.6	-4.75	-0.44	7.32e-6	Hypospadias;
THYM	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg04414720	chr1:150670196	GOLPH3L	0.62	4.71	0.44	8.35e-6	Tonsillectomy;
THYM	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg22974920	chr21:40686053	BRWD1	-0.58	-4.49	-0.42	2e-5	Cognitive function;
THYM	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg25072359	chr17:41440525	NA	0.75	5.53	0.49	2.85e-7	Menopause (age at onset);
THYM	trans	rs9929218	0.559	rs11642362	chr16:68811307	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.94	9.79	0.71	4.69e-16	Colorectal cancer;
THYM	cis	rs6121246	0.559	rs6060915	chr20:30330306	A/G	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs2213920	0.749	rs4637918	chr9:118258247	G/T	cg13918206	chr9:118159781	DEC1	0.83	4.58	0.43	1.42e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg00645579	chr11:617140	IRF7;MUPCDH	-0.48	-5.74	-0.51	1.13e-7	Systemic lupus erythematosus;
THYM	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg08132940	chr7:1081526	C7orf50	-1.16	-6.65	-0.56	1.87e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg09462578	chr12:12878428	APOLD1	0.8	7.17	0.59	1.59e-10	Birth weight;
THYM	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	13.05	0.8	6.7e-23	Chronic sinus infection;
THYM	cis	rs12956009	0.518	rs3902716	chr18:44889441	G/A	cg19077165	chr18:44547161	KATNAL2	-0.52	-5.12	-0.47	1.57e-6	Educational attainment (years of education);
THYM	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.22	-0.47	1.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs7584330	0.784	rs1463795	chr2:238412392	C/G	cg14458575	chr2:238380390	NA	-0.88	-6.93	-0.58	5.07e-10	Prostate cancer;
THYM	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg12011299	chr4:100065546	ADH4	0.69	6.2	0.54	1.46e-8	Alcohol dependence;
THYM	cis	rs56161922	1.000	rs41274776	chr1:207812791	A/G	cg09557387	chr1:207818395	CR1L	1.14	5.23	0.47	9.96e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg23602478	chr1:26503979	CNKSR1	0.35	4.69	0.43	9.12e-6	Height;
THYM	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.98	-10.85	-0.74	2.52e-18	Chronic sinus infection;
THYM	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg02953382	chr22:24373134	LOC391322	-0.7	-6.16	-0.53	1.74e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg00383909	chr3:49044727	WDR6	1.19	7.36	0.6	6.4e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs501916	0.634	rs3803349	chr15:48064867	T/A	cg20869673	chr15:48010124	SEMA6D	0.63	4.49	0.42	1.99e-5	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs2273669	0.504	rs78662936	chr6:109449690	G/T	cg17117243	chr6:109341365	SESN1	-0.92	-5.47	-0.49	3.63e-7	Prostate cancer;
THYM	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs995000	0.929	rs12038768	chr1:63040728	G/T	cg06896770	chr1:63153194	DOCK7	1.0	8.17	0.64	1.31e-12	Triglyceride levels;
THYM	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg26384229	chr12:38710491	ALG10B	1.05	10.43	0.73	1.96e-17	Heart rate;
THYM	cis	rs72781680	0.752	rs72796116	chr2:23913769	C/T	cg08917208	chr2:24149416	ATAD2B	1.19	5.46	0.49	3.73e-7	Lymphocyte counts;
THYM	cis	rs72717009	0.825	rs6671753	chr1:161478708	G/A	cg23840854	chr1:161414152	NA	-1.02	-5.41	-0.49	4.61e-7	Rheumatoid arthritis;
THYM	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg02527881	chr3:46936655	PTH1R	-0.61	-5.71	-0.51	1.28e-7	Colorectal cancer;
THYM	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg14196790	chr5:131705035	SLC22A5	0.56	4.92	0.45	3.69e-6	Blood metabolite levels;
THYM	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	5.54	0.49	2.71e-7	Obesity-related traits;
THYM	cis	rs865483	1.000	rs865483	chr17:35851177	A/C	cg06716730	chr17:35851459	DUSP14	0.43	7.18	0.59	1.52e-10	Monocyte count;
THYM	cis	rs9826463	0.582	rs56370391	chr3:142084647	A/G	cg20824294	chr3:142316082	PLS1	0.76	5.28	0.48	8.31e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg26967526	chr14:35346199	BAZ1A	-0.8	-5.27	-0.48	8.47e-7	Psoriasis;
THYM	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg07414643	chr4:187882934	NA	0.67	5.95	0.52	4.52e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4631830	0.720	rs2843560	chr10:51512129	C/G	cg10326726	chr10:51549505	MSMB	0.52	5.18	0.47	1.23e-6	Prostate-specific antigen levels;
THYM	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.66	-5.09	-0.46	1.8e-6	Menarche (age at onset);
THYM	cis	rs13082711	0.911	rs73050094	chr3:27519552	T/A	cg02860705	chr3:27208620	NA	0.72	5.06	0.46	2.01e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.84e-8	Systolic blood pressure;
THYM	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg26038318	chr20:34205095	SPAG4	0.58	4.6	0.43	1.3e-5	Total cholesterol levels;
THYM	cis	rs2070488	0.931	rs7630012	chr3:38552250	A/G	cg24069376	chr3:38537580	EXOG	-0.65	-6.4	-0.55	5.87e-9	Electrocardiographic conduction measures;
THYM	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg12826209	chr6:26865740	GUSBL1	0.79	5.62	0.5	1.92e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg13852791	chr20:30311386	BCL2L1	0.67	4.76	0.44	7.04e-6	Mean corpuscular hemoglobin;
THYM	cis	rs6840360	0.582	rs2709827	chr4:152331252	G/C	cg17479576	chr4:152424074	FAM160A1	-0.74	-5.64	-0.5	1.73e-7	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg24675658	chr1:53192096	ZYG11B	-0.66	-5.22	-0.47	1.04e-6	Monocyte count;
THYM	cis	rs6754311	0.552	rs1030765	chr2:136553188	A/T	cg23851026	chr2:136556271	LCT	-0.56	-5.85	-0.51	6.84e-8	Mosquito bite size;
THYM	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg14004847	chr7:1930337	MAD1L1	-0.66	-5.38	-0.48	5.31e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7572733	0.514	rs770659	chr2:198669754	G/C	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg05283184	chr6:79620031	NA	-0.91	-8.84	-0.67	4.86e-14	Intelligence (multi-trait analysis);
THYM	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg08439880	chr3:133502540	NA	-0.73	-6.42	-0.55	5.46e-9	Iron status biomarkers;
THYM	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg09260853	chr1:2094483	PRKCZ	-0.46	-4.71	-0.43	8.57e-6	Height;
THYM	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg27034606	chr17:28928453	LRRC37B2	0.84	5.53	0.49	2.83e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4888378	0.535	rs9319483	chr16:75345791	T/C	cg07303275	chr16:75499416	TMEM170A	-0.62	-4.68	-0.43	9.33e-6	Coronary artery disease;
THYM	cis	rs10186029	0.582	rs12052695	chr2:214003559	G/T	cg08319019	chr2:214017104	IKZF2	0.78	6.14	0.53	1.95e-8	Systemic sclerosis;
THYM	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.81	-7.31	-0.6	8.33e-11	Chronic sinus infection;
THYM	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.38	5.34	0.48	6.28e-7	Obesity-related traits;
THYM	cis	rs4595586	0.525	rs7968566	chr12:39377200	C/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs10463554	0.963	rs34380	chr5:102396949	A/G	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs941408	1.000	rs941406	chr19:2803623	A/G	cg06609049	chr19:2785107	THOP1	0.68	5.81	0.51	8.19e-8	Total cholesterol levels;
THYM	cis	rs7772486	0.875	rs10457793	chr6:146415403	A/G	cg13319975	chr6:146136371	FBXO30	-0.61	-4.96	-0.45	3.05e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg26038318	chr20:34205095	SPAG4	0.65	5.33	0.48	6.57e-7	Total cholesterol levels;
THYM	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg25358565	chr5:93447407	FAM172A	-0.96	-6.78	-0.57	1.01e-9	Diabetic retinopathy;
THYM	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1003719	0.680	rs2835629	chr21:38521660	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.66	-4.72	-0.44	8.18e-6	Eye color traits;
THYM	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg09409435	chr16:70099608	PDXDC2	1.14	6.78	0.57	9.98e-10	Menarche (age at onset);
THYM	cis	rs7592578	0.679	rs62181018	chr2:191323295	C/T	cg10560079	chr2:191398806	TMEM194B	-0.85	-6.33	-0.54	8.22e-9	Diastolic blood pressure;
THYM	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg25036284	chr2:26402008	FAM59B	-0.78	-5.19	-0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg00071950	chr4:10020882	SLC2A9	0.88	9.22	0.69	7.56e-15	Bone mineral density;
THYM	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs8018808	1.000	rs4903577	chr14:77847258	C/T	cg20045696	chr14:77926864	AHSA1	-0.59	-5.38	-0.48	5.45e-7	Myeloid white cell count;
THYM	cis	rs78062588	1.000	rs73001418	chr1:154585594	T/A	cg03138446	chr1:153746880	SLC27A3	1.19	4.64	0.43	1.1e-5	Lung cancer;
THYM	cis	rs9787249	0.957	rs11809515	chr1:40205326	C/A	cg19912559	chr1:40204330	PPIE	0.64	4.89	0.45	4.06e-6	Blood protein levels;
THYM	cis	rs262150	0.625	rs117651953	chr7:158780563	G/A	cg23058037	chr7:158824108	VIPR2	0.5	4.58	0.43	1.4e-5	Facial morphology (factor 20);
THYM	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg06026331	chr20:60912101	LAMA5	-0.62	-4.9	-0.45	3.89e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg26446133	chr18:72167187	CNDP2	-0.99	-7.91	-0.63	4.64e-12	Refractive error;
THYM	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Parkinson's disease;
THYM	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.84	-7.08	-0.59	2.46e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg06238570	chr21:40685208	BRWD1	-0.96	-9.26	-0.69	6.43e-15	Cognitive function;
THYM	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg09165964	chr15:75287851	SCAMP5	-1.08	-10.64	-0.74	7.02e-18	Blood trace element (Zn levels);
THYM	cis	rs2147904	0.867	rs1408947	chr1:42364198	C/T	cg16685388	chr1:42384056	HIVEP3	0.56	4.65	0.43	1.05e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;
THYM	cis	rs1448094	0.511	rs34656916	chr12:86154658	G/C	cg00310523	chr12:86230176	RASSF9	0.53	4.6	0.43	1.32e-5	Major depressive disorder;
THYM	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs6138458	1.000	rs6707	chr20:24944166	C/T	cg26195577	chr20:24973756	C20orf3	1.11	10.36	0.73	2.84e-17	Blood protein levels;
THYM	cis	rs673253	0.686	rs3791139	chr1:44051771	T/C	cg24466421	chr1:44070974	PTPRF	-0.61	-5.43	-0.49	4.34e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg08835221	chr22:38071607	LGALS1	0.37	4.95	0.45	3.22e-6	Fat distribution (HIV);
THYM	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg25208724	chr1:156163844	SLC25A44	1.12	12.78	0.8	2.33e-22	Testicular germ cell tumor;
THYM	cis	rs13040088	1.000	rs6090155	chr20:61527378	G/A	cg23096297	chr20:61557774	DIDO1	1.07	7.4	0.6	5.37e-11	Menopause (age at onset);
THYM	cis	rs9915657	1.000	rs9915657	chr17:70127536	T/C	cg06234051	chr17:70120541	SOX9	-0.6	-5.26	-0.47	9.06e-7	Thyroid hormone levels;
THYM	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.79	0.51	9.18e-8	Rheumatoid arthritis;
THYM	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.3	-0.48	7.34e-7	Monocyte percentage of white cells;
THYM	cis	rs67460515	0.528	rs11915989	chr3:160902259	A/G	cg03342759	chr3:160939853	NMD3	-0.68	-5.11	-0.46	1.64e-6	Parkinson's disease;
THYM	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg07930552	chr6:133119739	C6orf192	0.98	5.87	0.52	6.38e-8	Type 2 diabetes nephropathy;
THYM	cis	rs9796	0.870	rs2925345	chr15:41311799	T/C	cg21153102	chr15:41252147	NA	-0.66	-5.91	-0.52	5.42e-8	Menopause (age at onset);
THYM	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg06481639	chr22:41940642	POLR3H	0.7	4.8	0.44	5.91e-6	Vitiligo;
THYM	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg26721908	chr21:47610096	LSS	-0.87	-6.27	-0.54	1.05e-8	Testicular germ cell tumor;
THYM	cis	rs9896052	0.649	rs6501797	chr17:73444312	G/A	cg27112972	chr17:74378252	NA	0.58	4.7	0.43	8.78e-6	Sight-threatening diabetic retinopathy in type 2 diabetes;
THYM	cis	rs11716531	0.574	rs7624067	chr3:27267853	G/A	cg02860705	chr3:27208620	NA	0.77	6.22	0.54	1.33e-8	Diastolic blood pressure;
THYM	cis	rs7463256	0.966	rs6557643	chr8:23097802	A/G	cg14349055	chr8:23104193	CHMP7	-1.02	-12.34	-0.78	1.89e-21	Attention deficit hyperactivity disorder;
THYM	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg19077165	chr18:44547161	KATNAL2	0.61	7.58	0.61	2.28e-11	Personality dimensions;
THYM	cis	rs7616559	0.849	rs10936057	chr3:156758657	A/G	cg15697575	chr3:156784781	NA	0.42	5.37	0.48	5.54e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg17554472	chr22:41940697	POLR3H	-0.69	-4.49	-0.42	1.99e-5	Vitiligo;
THYM	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg09307838	chr4:120376055	NA	0.71	5.07	0.46	1.98e-6	Corneal astigmatism;
THYM	cis	rs11190604	1.000	rs10883510	chr10:102297018	C/T	cg07570687	chr10:102243282	WNT8B	0.76	6.47	0.55	4.16e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg00639195	chr15:79103007	ADAMTS7	-0.74	-5.68	-0.5	1.49e-7	Coronary artery disease or large artery stroke;
THYM	cis	rs800586	0.788	rs800539	chr8:116725199	G/A	cg04656070	chr8:116661063	TRPS1	0.48	4.49	0.42	2.01e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg12179176	chr11:130786555	SNX19	0.78	6.73	0.57	1.27e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs910316	0.523	rs4026175	chr14:75502240	C/A	cg08847533	chr14:75593920	NEK9	0.9	8.12	0.64	1.7e-12	Height;
THYM	cis	rs13191362	0.507	rs2849534	chr6:163144657	T/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.84	-6.24	-0.54	1.21e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7264396	0.563	rs1970577	chr20:34336737	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Total cholesterol levels;
THYM	cis	rs7107174	1.000	rs2510041	chr11:77945284	G/A	cg19901956	chr11:77921274	USP35	-0.75	-5.64	-0.5	1.78e-7	Testicular germ cell tumor;
THYM	cis	rs9581857	0.579	rs79904593	chr13:27996893	G/A	cg22138327	chr13:27999177	GTF3A	1.05	6.1	0.53	2.31e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg25767906	chr1:53392781	SCP2	-0.58	-5.87	-0.52	6.47e-8	Monocyte count;
THYM	cis	rs7119	0.667	rs4886889	chr15:77902347	T/C	cg10437265	chr15:77819839	NA	-0.57	-5.64	-0.5	1.73e-7	Type 2 diabetes;
THYM	cis	rs2034088	0.930	rs2034089	chr17:433001	G/A	cg06217071	chr17:408420	NA	0.77	7.56	0.61	2.47e-11	Hip circumference adjusted for BMI;
THYM	cis	rs1878931	0.624	rs28089	chr16:3446937	G/A	cg05754148	chr16:3507555	NAT15	0.6	4.9	0.45	3.87e-6	Body mass index (adult);
THYM	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg08045932	chr20:61659980	NA	0.93	10.4	0.73	2.3e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg17911788	chr17:44343683	NA	-0.77	-7.15	-0.59	1.79e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs17277593	0.898	rs13290672	chr9:13959282	T/C	cg13736497	chr9:14323193	NA	-0.65	-4.53	-0.42	1.7e-5	Endometriosis;
THYM	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg22433210	chr17:43662623	NA	1.1	8.29	0.65	7.36e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs10927875	0.518	rs945416	chr1:16344402	G/A	cg21385522	chr1:16154831	NA	0.65	4.65	0.43	1.08e-5	Dilated cardiomyopathy;
THYM	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9644630	0.932	rs6991941	chr8:19352377	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.71	7.06	0.59	2.78e-10	Oropharynx cancer;
THYM	cis	rs55665837	1.000	rs10832264	chr11:14459982	T/A	cg19336497	chr11:14380999	RRAS2	-0.64	-7.04	-0.59	3e-10	Vitamin D levels;
THYM	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg12408189	chr10:30722286	MAP3K8	-0.63	-5.68	-0.5	1.48e-7	Inflammatory bowel disease;
THYM	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.9	0.63	4.79e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7944735	0.671	rs7106731	chr11:48003392	T/G	cg25800328	chr11:47736132	AGBL2	0.42	4.65	0.43	1.09e-5	Intraocular pressure;
THYM	cis	rs7408868	0.908	rs62113794	chr19:15277337	C/A	cg14696996	chr19:15285081	NOTCH3	0.96	5.19	0.47	1.21e-6	Pulse pressure;
THYM	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg09307838	chr4:120376055	NA	-0.73	-5.22	-0.47	1.03e-6	Corneal astigmatism;
THYM	cis	rs7567389	0.744	rs6430934	chr2:128000833	T/C	cg09760422	chr2:128146352	NA	-0.52	-6.31	-0.54	8.95e-9	Self-rated health;
THYM	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg09307838	chr4:120376055	NA	0.7	5.27	0.48	8.48e-7	Corneal astigmatism;
THYM	cis	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg07460842	chr6:66804631	NA	-0.84	-5.65	-0.5	1.68e-7	Exhaled nitric oxide output;
THYM	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.59	4.5	0.42	1.94e-5	Colorectal cancer;
THYM	cis	rs752010	1.000	rs4999015	chr1:42093547	G/A	cg06885757	chr1:42089581	HIVEP3	0.41	4.67	0.43	9.9e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg07936489	chr17:37558343	FBXL20	-0.73	-5.03	-0.46	2.32e-6	Asthma;
THYM	cis	rs3812049	0.784	rs2617617	chr5:127455008	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	5.28	0.48	8.32e-7	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg18402987	chr7:1209562	NA	1.21	7.47	0.61	3.93e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3892630	0.878	rs1061686	chr19:33204544	C/T	cg22980127	chr19:33182716	NUDT19	-1.12	-9.08	-0.68	1.55e-14	Red blood cell traits;
THYM	cis	rs4589258	0.737	rs2226919	chr11:90464441	A/G	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.93	-0.45	3.53e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg13607699	chr17:42295918	UBTF	0.6	5.03	0.46	2.33e-6	Total body bone mineral density;
THYM	cis	rs10779751	1.000	rs11121704	chr1:11293959	A/G	cg08854313	chr1:11322531	MTOR	-0.95	-7.54	-0.61	2.76e-11	Body mass index;
THYM	cis	rs12780046	0.656	rs5025590	chr10:100820860	C/T	cg20566587	chr10:101492029	COX15;CUTC	0.78	5.07	0.46	1.97e-6	Non-glioblastoma glioma;
THYM	cis	rs61008539	0.537	rs7793929	chr7:855076	A/T	cg15782153	chr7:917662	C7orf20	0.47	4.92	0.45	3.61e-6	Perceived unattractiveness to mosquitoes;
THYM	cis	rs514406	0.526	rs835608	chr1:53169758	T/A	cg27535305	chr1:53392650	SCP2	0.47	5.41	0.49	4.75e-7	Monocyte count;
THYM	cis	rs941873	0.868	rs1483733	chr10:81130036	A/G	cg09469691	chr10:81107165	PPIF	0.71	6.02	0.53	3.25e-8	Height;
THYM	cis	rs4499344	0.730	rs392332	chr19:33105743	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	6.97	0.58	4.16e-10	Mean platelet volume;
THYM	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg04315214	chr1:2043799	PRKCZ	0.59	4.56	0.42	1.55e-5	Height;
THYM	cis	rs3768617	0.510	rs3768621	chr1:183090057	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs7586879	0.559	rs13387729	chr2:25076126	A/G	cg15423357	chr2:25149977	NA	0.62	6.33	0.54	8.22e-9	Body mass index;
THYM	cis	rs514406	0.893	rs6682024	chr1:53439525	T/C	cg25767906	chr1:53392781	SCP2	0.57	5.69	0.5	1.39e-7	Monocyte count;
THYM	cis	rs4845570	1.000	rs4845356	chr1:151759223	T/A	cg07092448	chr1:151763213	TDRKH	1.04	6.79	0.57	9.75e-10	Coronary artery disease;
THYM	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg18404041	chr3:52824283	ITIH1	0.51	4.93	0.45	3.49e-6	Bipolar disorder;
THYM	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg12311346	chr5:56204834	C5orf35	-0.83	-6.15	-0.53	1.8e-8	Initial pursuit acceleration;
THYM	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg06112835	chr11:68658793	MRPL21	0.45	6.39	0.55	6.21e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6539288	0.933	rs1444583	chr12:107312846	C/G	cg26297688	chr12:107349093	C12orf23	0.47	4.89	0.45	4.15e-6	Total body bone mineral density;
THYM	cis	rs6988636	1.000	rs28670850	chr8:124189125	A/G	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg10515332	chr4:99064459	C4orf37	0.66	5.3	0.48	7.35e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2066819	1.000	rs77768890	chr12:56725121	A/G	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg11764359	chr7:65958608	NA	-0.62	-4.73	-0.44	7.94e-6	Aortic root size;
THYM	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.67	0.43	9.95e-6	Bipolar disorder;
THYM	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	5.72	0.51	1.24e-7	Rheumatoid arthritis;
THYM	cis	rs6570726	0.846	rs9399559	chr6:145945778	C/T	cg23711669	chr6:146136114	FBXO30	0.85	8.17	0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3780378	0.875	rs7861599	chr9:5067298	C/T	cg02405213	chr9:5042618	JAK2	-0.68	-6.32	-0.54	8.46e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs4474465	0.831	rs12287010	chr11:78161452	A/T	cg19901956	chr11:77921274	USP35	0.6	4.55	0.42	1.56e-5	Alzheimer's disease (survival time);
THYM	trans	rs480407	0.857	rs270963	chr2:161688281	C/A	cg06548410	chr19:1997657	BTBD2	0.7	6.87	0.58	6.79e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg09085632	chr11:111637200	PPP2R1B	0.95	8.68	0.67	1.1e-13	Primary sclerosing cholangitis;
THYM	cis	rs13102973	0.965	rs55967588	chr4:135860189	G/A	cg14419869	chr4:135874104	NA	0.89	8.76	0.67	7.5e-14	Subjective well-being;
THYM	cis	rs2070677	1.000	rs4301745	chr10:135421636	T/G	cg20169779	chr10:135381914	SYCE1	-0.75	-5.76	-0.51	1.03e-7	Gout;
THYM	cis	rs4589258	0.601	rs1792606	chr11:90435257	A/C	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs17453880	0.929	rs7715495	chr5:152048107	T/G	cg12297329	chr5:152029980	NA	-0.59	-4.48	-0.42	2.06e-5	Subjective well-being;
THYM	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.43e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs870825	0.616	rs57271221	chr4:185627198	C/T	cg04058563	chr4:185651563	MLF1IP	1.16	9.67	0.7	8.28e-16	Blood protein levels;
THYM	cis	rs9467711	0.591	rs68149500	chr6:26111271	C/T	cg01386294	chr6:25732093	NA	0.88	4.7	0.43	8.83e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs28785552	0.931	rs8113078	chr19:53239084	T/G	cg22067481	chr19:53234126	ZNF611	-1.02	-10.75	-0.74	4.15e-18	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06481639	chr22:41940642	POLR3H	0.83	5.86	0.52	6.65e-8	Vitiligo;
THYM	trans	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg10856724	chr12:34555212	NA	-1.02	-9.56	-0.7	1.47e-15	Bladder cancer;
THYM	cis	rs7575217	0.588	rs2278729	chr2:101668857	C/T	cg12594615	chr2:101643137	TBC1D8	0.56	4.51	0.42	1.82e-5	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs919433	0.617	rs2037590	chr2:198584775	T/A	cg00792783	chr2:198669748	PLCL1	-0.77	-5.4	-0.48	4.91e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs11077998	0.935	rs12185276	chr17:80498997	T/C	cg10255544	chr17:80519551	FOXK2	0.51	4.48	0.42	2.05e-5	Reticulocyte fraction of red cells;
THYM	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg24399712	chr22:39784796	NA	-0.77	-7.24	-0.6	1.17e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	trans	rs7952251	0.812	rs6589302	chr11:112424647	C/T	cg14154186	chr1:204970430	NFASC	-0.71	-7.14	-0.59	1.86e-10	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs10504073	0.584	rs56078938	chr8:49940342	A/C	cg00325661	chr8:49890786	NA	1.09	11.06	0.75	9.14e-19	Blood metabolite ratios;
THYM	cis	rs1729951	0.575	rs35289288	chr3:136680568	C/T	cg21827317	chr3:136751795	NA	0.75	6.64	0.56	1.92e-9	Neuroticism;
THYM	cis	rs2124499	0.837	rs9814758	chr3:123062657	T/G	cg04890266	chr3:123102914	ADCY5	0.65	4.84	0.44	5.12e-6	Body mass index;
THYM	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg12165864	chr7:66369176	NA	-0.81	-6.03	-0.53	3.07e-8	Corneal structure;
THYM	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg23428387	chr22:49814324	NA	-0.57	-5.9	-0.52	5.51e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg12473912	chr3:136751656	NA	0.84	8.76	0.67	7.39e-14	Schizophrenia;
THYM	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg15592062	chr6:167189543	RPS6KA2	0.59	6.16	0.53	1.73e-8	Crohn's disease;
THYM	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg11663144	chr21:46675770	NA	-0.64	-8.93	-0.68	3.19e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg03388043	chr17:80084554	CCDC57	-0.66	-5.66	-0.5	1.61e-7	Life satisfaction;
THYM	cis	rs2290159	0.752	rs3773349	chr3:12649732	T/C	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg12165864	chr7:66369176	NA	-0.63	-4.98	-0.45	2.86e-6	Aortic root size;
THYM	cis	rs3768617	0.510	rs12091137	chr1:183075732	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	5.05	0.46	2.15e-6	Fuchs's corneal dystrophy;
THYM	cis	rs7043114	0.525	rs6479416	chr9:95053871	G/T	cg14631576	chr9:95140430	CENPP	-0.85	-9.03	-0.68	1.99e-14	Height;
THYM	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg08885076	chr2:99613938	TSGA10	0.57	5.28	0.48	8.05e-7	Chronic sinus infection;
THYM	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg15744005	chr10:104629667	AS3MT	0.91	9.63	0.7	1.04e-15	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg17509989	chr5:176798049	RGS14	0.67	6.14	0.53	1.94e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs36051895	0.632	rs10974983	chr9:5149657	G/T	cg02405213	chr9:5042618	JAK2	-1.05	-11.06	-0.75	9.03e-19	Pediatric autoimmune diseases;
THYM	cis	rs1374313	0.843	rs6542528	chr2:120152453	A/C	cg18093372	chr2:119607603	NA	-0.46	-4.67	-0.43	9.9e-6	Obesity-related traits;
THYM	cis	rs1387259	0.931	rs11168474	chr12:48621384	A/C	cg21466736	chr12:48725269	NA	-0.53	-4.91	-0.45	3.85e-6	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg05347473	chr6:146136440	FBXO30	0.59	4.65	0.43	1.08e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs892961	0.932	rs35657663	chr17:75412482	T/C	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs7586879	0.616	rs916485	chr2:25082273	T/C	cg01884057	chr2:25150051	NA	0.69	6.94	0.58	4.77e-10	Body mass index;
THYM	cis	rs8133932	0.654	rs371587	chr21:47348512	G/A	cg20357416	chr21:47294739	PCBP3	0.8	4.88	0.45	4.26e-6	Schizophrenia;
THYM	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg13683864	chr3:40499215	RPL14	-0.9	-8.73	-0.67	8.59e-14	Renal cell carcinoma;
THYM	trans	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs9970334	0.596	rs709209	chr1:6278414	A/G	cg15892785	chr1:6309343	GPR153	-0.68	-5.88	-0.52	6.14e-8	Resting heart rate;
THYM	cis	rs883565	0.792	rs784490	chr3:39173530	C/T	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	4.49	0.42	1.97e-5	Handedness;
THYM	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg11905131	chr22:24372483	LOC391322	-0.77	-7.04	-0.59	3.05e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs870825	0.616	rs28459754	chr4:185636280	C/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs6674176	0.935	rs4314918	chr1:44377503	G/A	cg12908607	chr1:44402522	ARTN	-0.63	-5.14	-0.47	1.49e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs17470137	1.000	rs337101	chr5:122550646	C/T	cg04547002	chr5:122551801	NA	-0.66	-4.93	-0.45	3.42e-6	Aortic root size;
THYM	cis	rs7851660	0.844	rs6478445	chr9:100624299	A/G	cg13688889	chr9:100608707	NA	-0.77	-5.31	-0.48	7.25e-7	Strep throat;
THYM	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg18252515	chr7:66147081	NA	-1.48	-8.83	-0.67	5.23e-14	Diabetic kidney disease;
THYM	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.87e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-5.77	-0.51	9.69e-8	Gut microbiome composition (summer);
THYM	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg10518543	chr12:38710700	ALG10B	-0.58	-4.53	-0.42	1.68e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.64	-4.68	-0.43	9.45e-6	Aortic root size;
THYM	cis	rs6956675	0.915	rs1609795	chr7:62650531	T/C	cg08930214	chr7:62859557	LOC100287834	0.61	4.78	0.44	6.29e-6	Obesity-related traits;
THYM	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg03806693	chr22:41940476	POLR3H	-1.13	-9.15	-0.68	1.09e-14	Vitiligo;
THYM	cis	rs6596100	0.538	rs10491280	chr5:132196383	G/T	cg02081065	chr5:132209139	LEAP2	0.79	5.26	0.47	8.96e-7	Breast cancer;
THYM	cis	rs9403317	0.654	rs12175282	chr6:142002585	C/T	cg15052665	chr6:141804349	NA	0.74	5.38	0.48	5.31e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg20608306	chr11:116969690	SIK3	0.52	5.59	0.5	2.15e-7	Blood protein levels;
THYM	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs941408	1.000	rs941406	chr19:2803623	A/G	cg17333051	chr19:2783644	SGTA	0.53	4.81	0.44	5.65e-6	Total cholesterol levels;
THYM	trans	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Bladder cancer;
THYM	trans	rs7952251	0.812	rs6589303	chr11:112428108	T/C	cg14154186	chr1:204970430	NFASC	-0.73	-7.54	-0.61	2.79e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs3087591	0.960	rs10512433	chr17:29600564	T/C	cg24425628	chr17:29625626	OMG;NF1	0.65	5.7	0.5	1.36e-7	Hip circumference;
THYM	cis	rs9443189	0.570	rs6903124	chr6:76290079	A/C	cg01950844	chr6:76311363	SENP6	1.1	6.88	0.58	6.48e-10	Prostate cancer;
THYM	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg14983838	chr19:29218262	NA	1.13	9.44	0.7	2.55e-15	Methadone dose in opioid dependence;
THYM	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-4.6	-0.43	1.3e-5	Bladder cancer;
THYM	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.21	0.47	1.1e-6	Electroencephalogram traits;
THYM	cis	rs7159131	0.812	rs8021320	chr14:37028783	A/C	cg12051980	chr14:37117758	NA	0.45	4.73	0.44	7.89e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg05294307	chr14:35346193	BAZ1A	-0.93	-6.68	-0.57	1.64e-9	Psoriasis;
THYM	cis	rs728616	0.764	rs117833443	chr10:81738136	A/C	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg00684032	chr4:1343700	KIAA1530	0.62	5.54	0.49	2.69e-7	Obesity-related traits;
THYM	cis	rs1160297	0.609	rs10167421	chr2:53096163	G/C	cg07782112	chr2:53107842	NA	0.79	6.37	0.55	6.61e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs13418717	1.000	rs10203501	chr2:127642143	C/T	cg25501666	chr2:127640322	NA	1.68	7.27	0.6	9.85e-11	Heart failure;
THYM	cis	rs11577318	0.579	rs10794532	chr1:26694260	T/C	cg00852783	chr1:26633632	UBXN11	-0.66	-4.53	-0.42	1.7e-5	Granulocyte percentage of myeloid white cells;
THYM	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06873352	chr17:61820015	STRADA	0.67	7.63	0.62	1.82e-11	Prudent dietary pattern;
THYM	cis	rs7000551	0.527	rs12677619	chr8:22243326	G/A	cg12081754	chr8:22256438	SLC39A14	1.15	11.29	0.76	2.96e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg11245990	chr11:68621969	NA	-0.57	-7.46	-0.61	4.06e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs886774	0.507	rs12705424	chr7:107519723	A/G	cg23293999	chr7:106826042	HBP1	-0.59	-4.58	-0.42	1.43e-5	Ulcerative colitis;
THYM	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg06064525	chr11:970664	AP2A2	-0.35	-6.44	-0.55	4.84e-9	Alzheimer's disease (late onset);
THYM	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg10117171	chr1:25599238	RHD	-0.68	-4.87	-0.45	4.52e-6	Erythrocyte sedimentation rate;
THYM	cis	rs11039798	0.764	rs2089208	chr11:48899860	C/T	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs10218795	1	rs10218795	chr1:145416056	C/T	cg08057159	chr1:145507538	RBM8A	1.03	4.59	0.43	1.38e-5	Coronary heart disease (SNP X SNP interaction);
THYM	cis	rs2273669	0.504	rs78500387	chr6:109495761	T/C	cg17117243	chr6:109341365	SESN1	-0.82	-4.8	-0.44	5.98e-6	Prostate cancer;
THYM	cis	rs11112613	0.818	rs73184093	chr12:106010066	G/C	cg03607813	chr12:105948248	NA	0.97	5.28	0.48	8.22e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg18538332	chr22:24372958	LOC391322	0.99	9.68	0.7	7.96e-16	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs6009824	1.000	rs6009823	chr22:50086334	C/T	cg18178197	chr22:50098317	NA	0.85	6.73	0.57	1.3e-9	Natriuretic peptide levels;
THYM	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7172809	0.573	rs11853633	chr15:77466024	T/C	cg22256960	chr15:77711686	NA	-0.66	-4.86	-0.45	4.56e-6	Glucose homeostasis traits;
THYM	cis	rs11997175	0.624	rs7001604	chr8:33680979	T/C	ch.8.33884649F	chr8:33765107	NA	0.67	5.09	0.46	1.84e-6	Body mass index;
THYM	cis	rs4731207	0.698	rs10260710	chr7:124455986	C/A	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg17143192	chr8:8559678	CLDN23	0.91	6.74	0.57	1.2e-9	Obesity-related traits;
THYM	cis	rs7589342	0.831	rs6714861	chr2:106518893	C/T	cg14210321	chr2:106509881	NCK2	0.79	6.31	0.54	8.79e-9	Addiction;
THYM	cis	rs128738	0.500	rs907368	chr5:131573981	A/T	cg22598563	chr5:131563921	P4HA2	0.52	4.46	0.42	2.28e-5	Giant cell arteritis;
THYM	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg12564285	chr5:131593104	PDLIM4	0.5	5.34	0.48	6.22e-7	Acylcarnitine levels;
THYM	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg03079132	chr16:727212	RHBDL1	-0.38	-4.55	-0.42	1.56e-5	Height;
THYM	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg23711669	chr6:146136114	FBXO30	-0.85	-8.14	-0.64	1.52e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs55637147	0.703	rs3781899	chr11:57126897	G/A	cg15971518	chr11:57159174	PRG2	-0.67	-5.38	-0.48	5.25e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg11327659	chr7:150037044	RARRES2	0.42	4.97	0.45	2.94e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6547741	0.816	rs10201652	chr2:27874332	A/C	cg27432699	chr2:27873401	GPN1	-0.86	-7.63	-0.62	1.82e-11	Oral cavity cancer;
THYM	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg05283184	chr6:79620031	NA	-0.88	-8.43	-0.65	3.67e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.65	-8.72	-0.67	9.04e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg12165864	chr7:66369176	NA	-0.64	-4.97	-0.45	2.97e-6	Aortic root size;
THYM	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg06634786	chr22:41940651	POLR3H	0.73	5.36	0.48	5.89e-7	Vitiligo;
THYM	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg26597838	chr10:835615	NA	1.2	8.57	0.66	1.85e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg19016782	chr12:123741754	C12orf65	-0.7	-4.59	-0.43	1.35e-5	Neutrophil percentage of white cells;
THYM	cis	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs901683	1.000	rs12781186	chr10:46013438	A/G	cg18240400	chr10:46168597	ANUBL1	0.8	5.16	0.47	1.38e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg03806693	chr22:41940476	POLR3H	-1.16	-9.86	-0.71	3.34e-16	Vitiligo;
THYM	cis	rs7781977	0.554	rs6421315	chr7:50355207	C/G	cg01139861	chr7:50343298	IKZF1	0.55	5.15	0.47	1.41e-6	IgG glycosylation;
THYM	cis	rs12935418	0.616	rs11859567	chr16:80969848	A/G	cg16651780	chr16:81037892	C16orf61	0.88	5.55	0.49	2.58e-7	Mean corpuscular volume;
THYM	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg26384229	chr12:38710491	ALG10B	0.92	7.34	0.6	7.32e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg02187348	chr16:89574699	SPG7	0.78	6.59	0.56	2.46e-9	Multiple myeloma (IgH translocation);
THYM	cis	rs9611519	1.000	rs9611510	chr22:41569124	T/C	cg03806693	chr22:41940476	POLR3H	-0.84	-6.41	-0.55	5.51e-9	Neuroticism;
THYM	cis	rs9796	0.621	rs2928142	chr15:41470449	T/C	cg18705301	chr15:41695430	NDUFAF1	0.56	4.61	0.43	1.24e-5	Menopause (age at onset);
THYM	cis	rs7894051	1.000	rs7916900	chr10:135200291	T/G	cg20534287	chr10:135191450	PAOX	0.64	4.94	0.45	3.41e-6	Lifespan;
THYM	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg13395646	chr4:1353034	KIAA1530	0.6	5.41	0.49	4.77e-7	Obesity-related traits;
THYM	cis	rs6138458	0.816	rs2151463	chr20:24911819	A/C	cg06937882	chr20:24974362	C20orf3	-0.47	-4.54	-0.42	1.66e-5	Blood protein levels;
THYM	cis	rs17030434	0.906	rs5020754	chr4:154670444	T/C	cg14289246	chr4:154710475	SFRP2	-0.89	-5.73	-0.51	1.18e-7	Electrocardiographic conduction measures;
THYM	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg03115019	chr17:80708279	FN3K	0.69	5.4	0.48	4.81e-7	Glycated hemoglobin levels;
THYM	cis	rs10769945	0.538	rs217217	chr11:2006730	G/A	cg27617775	chr11:1989850	NA	-0.5	-4.91	-0.45	3.75e-6	DNA methylation (variation);
THYM	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11122895	1.000	rs11685349	chr2:112463125	C/T	cg23262488	chr2:112468472	NA	0.64	8.95	0.68	2.85e-14	Allergic sensitization;
THYM	cis	rs4919694	0.611	rs7091462	chr10:104948615	C/T	cg04362960	chr10:104952993	NT5C2	0.97	6.36	0.55	6.88e-9	Arsenic metabolism;
THYM	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg01268866	chr2:3683757	COLEC11	-0.73	-4.73	-0.44	7.82e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg10505658	chr17:80084571	CCDC57	0.72	7.99	0.63	3.21e-12	Life satisfaction;
THYM	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg19077165	chr18:44547161	KATNAL2	0.58	6.98	0.58	4.04e-10	Personality dimensions;
THYM	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	7.86	0.63	6.06e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11009175	0.615	rs6481819	chr10:33299459	T/C	cg00146027	chr10:33299147	NA	-0.68	-5.13	-0.47	1.55e-6	Depression (quantitative trait);
THYM	cis	rs7107174	0.901	rs2912	chr11:77926292	G/A	cg02023728	chr11:77925099	USP35	0.7	6.19	0.54	1.5e-8	Testicular germ cell tumor;
THYM	cis	rs3772130	0.962	rs9883467	chr3:121517833	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs2495707	0.624	rs10883518	chr10:102416555	C/A	cg03943218	chr10:102419600	NA	-0.6	-6.03	-0.53	3.11e-8	Body mass index;
THYM	cis	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg05335186	chr13:53173507	NA	-0.37	-4.79	-0.44	6.11e-6	Lewy body disease;
THYM	cis	rs40363	0.716	rs9926612	chr16:3540968	A/C	cg05754148	chr16:3507555	NAT15	-0.85	-5.92	-0.52	5.19e-8	Tuberculosis;
THYM	cis	rs4792901	1.000	rs8182301	chr17:41658043	T/C	cg21940313	chr17:41620911	ETV4	0.5	5.48	0.49	3.54e-7	Dupuytren's disease;
THYM	cis	rs6032067	0.641	rs34811768	chr20:43765800	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.47	-5.31	-0.48	7.26e-7	Blood protein levels;
THYM	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21659725	chr3:3221576	CRBN	0.89	9.76	0.71	5.32e-16	Intelligence (multi-trait analysis);
THYM	cis	rs478304	0.651	rs4014192	chr11:65498915	C/T	cg27068330	chr11:65405492	SIPA1	-0.95	-8.8	-0.67	6.03e-14	Acne (severe);
THYM	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7173743	0.730	rs6495340	chr15:79128396	A/G	cg15571903	chr15:79123663	NA	0.54	6.2	0.54	1.48e-8	Coronary artery disease;
THYM	trans	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg10856724	chr12:34555212	NA	-0.96	-8.75	-0.67	7.78e-14	Drug-induced liver injury (flucloxacillin);
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg18416251	chr7:148506233	EZH2	1.32	7.09	0.59	2.38e-10	Pulmonary function decline;
THYM	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg15445000	chr17:37608096	MED1	-0.38	-4.58	-0.42	1.43e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg10803722	chr21:46713166	LOC642852	-0.37	-4.88	-0.45	4.22e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg07936489	chr17:37558343	FBXL20	-0.66	-4.54	-0.42	1.62e-5	Asthma;
THYM	cis	rs9796	0.624	rs9920619	chr15:41318845	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.68	-5.95	-0.52	4.38e-8	Menopause (age at onset);
THYM	cis	rs8078723	1.000	rs6503530	chr17:38161823	T/C	cg17467752	chr17:38218738	THRA	0.86	7.09	0.59	2.4e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs8033133	0.958	rs6420956	chr15:25309559	T/C	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.75	-5.25	-0.47	9.4e-7	Blood osmolality (transformed sodium);
THYM	cis	rs2730245	0.527	rs842702	chr7:158696814	C/T	cg11984989	chr7:158649758	WDR60	1.01	8.5	0.66	2.65e-13	Height;
THYM	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg05283184	chr6:79620031	NA	-0.88	-8.44	-0.65	3.53e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7412746	0.611	rs4970985	chr1:150887442	C/T	cg15448220	chr1:150897856	SETDB1	-0.86	-6.94	-0.58	4.73e-10	Melanoma;
THYM	cis	rs2120019	0.567	rs72625793	chr15:75207083	A/G	cg17294928	chr15:75287854	SCAMP5	-0.73	-4.86	-0.45	4.59e-6	Blood trace element (Zn levels);
THYM	cis	rs7772486	0.641	rs2748489	chr6:146331287	T/G	cg23711669	chr6:146136114	FBXO30	0.85	7.94	0.63	4.02e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs600806	0.888	rs3853498	chr1:109860144	T/C	cg02175308	chr1:109941060	SORT1	-0.57	-4.96	-0.45	3.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1278769	0.735	rs12585036	chr13:113535741	C/T	cg01161842	chr13:113518337	ATP11A	0.68	4.64	0.43	1.11e-5	Interstitial lung disease;
THYM	cis	rs6768930	0.509	rs6445929	chr3:57815602	T/G	cg24033633	chr3:57945695	NA	-0.39	-5.63	-0.5	1.85e-7	Obesity-related traits;
THYM	cis	rs875971	1.000	rs1544549	chr7:66090663	T/A	cg18252515	chr7:66147081	NA	0.66	4.96	0.45	3.11e-6	Aortic root size;
THYM	cis	rs6546324	0.580	rs4362541	chr2:67842866	A/T	cg18237512	chr2:67827392	NA	-0.83	-4.88	-0.45	4.26e-6	Endometriosis;
THYM	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.61	5.22	0.47	1.03e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1278352	0.728	rs1278345	chr10:127771695	G/C	cg08295661	chr10:127769903	ADAM12	-0.55	-5.5	-0.49	3.16e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg10803722	chr21:46713166	LOC642852	-0.39	-4.48	-0.42	2.1e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6450176	1.000	rs12521454	chr5:53297304	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.81	-6.03	-0.53	3.17e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs61931739	0.517	rs2636074	chr12:34064056	C/T	cg10856724	chr12:34555212	NA	-0.79	-7.41	-0.61	5.14e-11	Morning vs. evening chronotype;
THYM	cis	rs11690935	1.000	rs34542126	chr2:172542705	C/T	cg13550731	chr2:172543902	DYNC1I2	0.87	6.55	0.56	2.97e-9	Schizophrenia;
THYM	cis	rs6121246	0.559	rs6058465	chr20:30397691	G/A	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs1933112	1.000	rs1024177	chr1:168526715	T/C	cg17186328	chr1:168545835	XCL1	-0.55	-4.59	-0.43	1.37e-5	Blood protein levels;
THYM	cis	rs9296092	0.500	rs9469503	chr6:33527234	G/T	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs7582180	0.577	rs6542942	chr2:100985378	G/T	cg21926883	chr2:100939477	LONRF2	-0.65	-5.89	-0.52	5.84e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2295499	0.623	rs17164051	chr4:2567296	T/G	cg17924901	chr4:3475233	DOK7	0.21	4.51	0.42	1.84e-5	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs56104184	0.775	rs73061692	chr19:49399676	T/C	cg21252483	chr19:49399788	TULP2	-0.96	-7.25	-0.6	1.09e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs4595586	0.525	rs12812749	chr12:39363254	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg25072359	chr17:41440525	NA	0.66	4.63	0.43	1.17e-5	Menopause (age at onset);
THYM	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg12419862	chr22:24373484	LOC391322	-0.72	-6.61	-0.56	2.26e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs8192282	0.691	rs6696177	chr1:154477263	G/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.6	-5.48	-0.49	3.55e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs9810089	0.903	rs7432375	chr3:136288405	G/A	cg12473912	chr3:136751656	NA	0.62	5.22	0.47	1.05e-6	Gestational age at birth (child effect);
THYM	cis	rs9534288	0.699	rs9534320	chr13:46665572	A/G	cg15192986	chr13:46630673	CPB2	-0.65	-4.55	-0.42	1.6e-5	Blood protein levels;
THYM	cis	rs7426056	0.530	rs17533594	chr2:204581195	A/G	cg13651908	chr2:204570033	CD28	-0.7	-5.33	-0.48	6.55e-7	Primary sclerosing cholangitis;
THYM	cis	rs6570726	0.791	rs6900040	chr6:145893134	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-4.99	-0.46	2.75e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9311676	0.618	rs12152337	chr3:58365271	T/C	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-4.48	-0.42	2.05e-5	Aortic root size;
THYM	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg15592062	chr6:167189543	RPS6KA2	0.59	6.16	0.53	1.73e-8	Crohn's disease;
THYM	cis	rs6964587	0.620	rs6967588	chr7:91643402	G/T	cg22709100	chr7:91322751	NA	0.61	4.57	0.42	1.44e-5	Breast cancer;
THYM	trans	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg20587970	chr11:113659929	NA	-1.27	-9.15	-0.68	1.08e-14	Hip circumference adjusted for BMI;
THYM	cis	rs885814	0.878	rs2071424	chr1:21886819	C/T	cg14781605	chr1:21864896	ALPL	-0.67	-5.15	-0.47	1.42e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg10661904	chr17:79619235	PDE6G	-0.65	-6.24	-0.54	1.19e-8	Eye color traits;
THYM	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg06238570	chr21:40685208	BRWD1	0.88	6.33	0.54	7.97e-9	Cognitive function;
THYM	cis	rs7833986	0.501	rs2719258	chr8:56941389	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	6.62	0.56	2.13e-9	Height;
THYM	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg14779329	chr11:130786720	SNX19	-0.48	-4.84	-0.44	5.05e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11563648	0.553	rs6467118	chr7:126958741	C/A	cg23081781	chr7:127225937	GCC1	-0.34	-4.59	-0.43	1.36e-5	Resting heart rate;
THYM	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg14186256	chr22:23484241	RTDR1	0.96	9.71	0.71	6.85e-16	Bone mineral density;
THYM	cis	rs17253792	0.822	rs75991559	chr14:56092419	A/T	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs35883536	0.626	rs7545966	chr1:101047633	G/A	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7568458	0.837	rs12714145	chr2:85787341	C/T	cg17127132	chr2:85788382	GGCX	0.59	4.46	0.42	2.28e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	7.45	0.61	4.17e-11	Platelet count;
THYM	cis	rs3015497	0.789	rs923908	chr14:51123595	C/T	cg04730355	chr14:51134070	SAV1	-0.53	-4.7	-0.43	8.68e-6	Mean platelet volume;
THYM	cis	rs11225247	0.772	rs35569122	chr11:102232348	C/T	cg06323957	chr11:102217781	BIRC2	1.02	4.74	0.44	7.52e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.48	-0.42	2.05e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg08213375	chr14:104286397	PPP1R13B	0.47	5.68	0.5	1.48e-7	Schizophrenia;
THYM	cis	rs870825	0.616	rs7692104	chr4:185650895	T/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs902774	0.597	rs7299694	chr12:53352572	A/C	cg14581129	chr12:53358946	NA	-0.84	-6.13	-0.53	1.99e-8	Prostate cancer;
THYM	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg12179176	chr11:130786555	SNX19	0.95	9.21	0.69	8.05e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg01483505	chr11:975446	AP2A2	0.58	4.75	0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs11032090	1	rs11032090	chr11:4417129	A/G	cg09983885	chr11:4415245	TRIM21	0.53	6.16	0.53	1.72e-8	Lung cancer;
THYM	cis	rs2901656	0.583	rs6702667	chr1:172400484	A/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.55	5.45	0.49	3.91e-7	Red cell distribution width;Platelet distribution width;
THYM	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.92	-6.03	-0.53	3.11e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg27541892	chr1:1571801	CDK11B	-0.76	-7.31	-0.6	8.45e-11	Body mass index;
THYM	cis	rs854765	0.618	rs9908017	chr17:17774422	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-6.73	-0.57	1.3e-9	Total body bone mineral density;
THYM	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg14517863	chr17:44321492	NA	0.48	5.17	0.47	1.28e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs4749080	0.573	rs11014960	chr10:26408276	G/A	cg00192819	chr18:76486611	NA	0.99	6.94	0.58	4.75e-10	Obesity-related traits;
THYM	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg13609457	chr4:120235615	NA	-0.5	-4.76	-0.44	6.95e-6	Corneal astigmatism;
THYM	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg05043794	chr9:111880884	C9orf5	-0.42	-5.99	-0.52	3.78e-8	Menarche (age at onset);
THYM	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	10.0	0.72	1.67e-16	Platelet count;
THYM	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg24503407	chr1:205819492	PM20D1	0.84	7.31	0.6	8.45e-11	Monocyte percentage of white cells;
THYM	cis	rs11771526	0.901	rs62457469	chr7:32303052	T/C	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg07061783	chr6:25882402	NA	0.58	4.58	0.43	1.39e-5	Schizophrenia;
THYM	cis	rs9565309	0.579	rs79325097	chr13:77587240	C/T	cg13866767	chr13:78470850	EDNRB	1.06	4.81	0.44	5.76e-6	Morning vs. evening chronotype;
THYM	cis	rs7250872	0.606	rs2289286	chr19:1822668	T/C	cg10370574	chr19:1840461	REXO1	-0.95	-8.04	-0.64	2.44e-12	Bipolar disorder;
THYM	cis	rs4606347	0.789	rs61780878	chr1:66166128	T/C	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg06600287	chr1:53387719	ECHDC2	-0.3	-4.9	-0.45	3.86e-6	Monocyte count;
THYM	cis	rs6430585	0.527	rs6753232	chr2:136436317	C/T	cg07169764	chr2:136633963	MCM6	-1.06	-8.73	-0.67	8.64e-14	Corneal structure;
THYM	cis	rs7584330	0.554	rs10183995	chr2:238433307	G/A	cg14458575	chr2:238380390	NA	0.82	4.89	0.45	4.16e-6	Prostate cancer;
THYM	cis	rs7226229	1.000	rs9902303	chr17:20927931	T/C	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	trans	rs3903072	0.652	rs501630	chr11:65637273	A/G	cg17712092	chr4:129076599	LARP1B	-0.92	-8.12	-0.64	1.66e-12	Breast cancer;
THYM	trans	rs28595532	0.841	rs115918392	chr4:119610356	T/A	cg13773247	chr2:42276988	PKDCC	0.89	6.93	0.58	4.92e-10	Cannabis dependence symptom count;
THYM	cis	rs9633835	0.925	rs10741616	chr11:13333851	G/A	cg13286116	chr11:13302098	ARNTL	0.64	6.96	0.58	4.26e-10	Body mass index;
THYM	cis	rs4930103	0.682	rs217714	chr11:2011512	C/T	cg06197492	chr11:2016605	H19	0.58	4.78	0.44	6.4e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs6768930	0.509	rs4530498	chr3:57724602	A/G	cg24033633	chr3:57945695	NA	-0.39	-5.41	-0.49	4.75e-7	Obesity-related traits;
THYM	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg23758822	chr17:41437982	NA	1.17	11.04	0.75	1.02e-18	Menopause (age at onset);
THYM	trans	rs1974653	0.672	rs9606248	chr22:20087539	A/G	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg04111992	chr7:158790115	NA	-0.57	-5.05	-0.46	2.13e-6	Facial morphology (factor 20);
THYM	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg06221963	chr1:154839813	KCNN3	-0.89	-11.0	-0.75	1.23e-18	Prostate cancer;
THYM	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	4.49	0.42	2.03e-5	Axial length;
THYM	cis	rs1443512	0.947	rs4759309	chr12:54342786	G/A	cg15261861	chr12:54132255	NA	-0.47	-4.54	-0.42	1.64e-5	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg07930192	chr7:1003750	NA	0.58	4.8	0.44	5.99e-6	Longevity;Endometriosis;
THYM	cis	rs6542838	0.597	rs35107109	chr2:99386210	C/G	cg08885076	chr2:99613938	TSGA10	-0.55	-4.61	-0.43	1.24e-5	Fear of minor pain;
THYM	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg10589385	chr1:150898437	SETDB1	0.7	6.04	0.53	2.92e-8	Tonsillectomy;
THYM	cis	rs7523273	0.565	rs2796239	chr1:207902206	G/A	cg22525895	chr1:207977042	MIR29B2	-0.53	-5.08	-0.46	1.91e-6	Schizophrenia;
THYM	cis	rs1401999	0.628	rs6798870	chr3:183740350	G/A	cg01324343	chr3:183735012	ABCC5	0.77	10.0	0.72	1.63e-16	Anterior chamber depth;
THYM	cis	rs25645	0.502	rs7223318	chr17:38108553	G/C	cg26162295	chr17:38119207	GSDMA	-0.42	-5.05	-0.46	2.09e-6	Myeloid white cell count;
THYM	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-5.84	-0.51	7.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg27535305	chr1:53392650	SCP2	-0.41	-4.71	-0.44	8.48e-6	Monocyte count;
THYM	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.67e-7	Corneal astigmatism;
THYM	cis	rs9807841	0.568	rs1560707	chr19:10750738	A/C	cg17848348	chr19:10766748	ILF3	-0.82	-6.8	-0.57	9.43e-10	Inflammatory skin disease;
THYM	cis	rs7833986	0.501	rs2953909	chr8:56968200	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.4	0.6	5.43e-11	Height;
THYM	cis	rs2495707	0.624	rs2489007	chr10:102422046	A/G	cg03943218	chr10:102419600	NA	0.63	6.81	0.57	8.72e-10	Body mass index;
THYM	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg10515332	chr4:99064459	C4orf37	0.73	4.47	0.42	2.17e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9814567	0.712	rs4245905	chr3:134328864	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7107174	1.000	rs10899451	chr11:77991222	A/C	cg02023728	chr11:77925099	USP35	0.67	5.86	0.52	6.61e-8	Testicular germ cell tumor;
THYM	cis	rs761746	0.960	rs5753734	chr22:32028721	A/C	cg10537193	chr22:32026975	PISD	-0.35	-5.0	-0.46	2.67e-6	Intelligence;
THYM	cis	rs2273669	0.915	rs6904998	chr6:109311560	G/T	cg17117243	chr6:109341365	SESN1	0.82	5.1	0.46	1.73e-6	Prostate cancer;
THYM	cis	rs4731207	0.698	rs10252039	chr7:124539537	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs3750965	0.919	rs12280942	chr11:68859683	A/G	cg06846819	chr11:68850022	TPCN2	0.69	5.41	0.49	4.76e-7	Hair color;
THYM	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg08470875	chr2:26401718	FAM59B	0.74	4.59	0.43	1.35e-5	Mean corpuscular hemoglobin;
THYM	cis	rs3820068	0.608	rs11544523	chr1:15904318	C/T	cg05660106	chr1:15850417	CASP9	1.15	9.45	0.7	2.49e-15	Systolic blood pressure;
THYM	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg06064525	chr11:970664	AP2A2	-0.35	-6.67	-0.56	1.69e-9	Alzheimer's disease (late onset);
THYM	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	7.35	0.6	6.78e-11	Platelet count;
THYM	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.71	-7.66	-0.62	1.54e-11	Crohn's disease;
THYM	cis	rs2236918	0.710	rs1635510	chr1:242027500	G/T	cg21919602	chr1:242011447	EXO1	-0.6	-4.46	-0.42	2.29e-5	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg21862992	chr11:68658383	NA	0.23	4.48	0.42	2.07e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs17608059	0.518	rs4792436	chr17:13972307	T/A	cg11395062	chr17:14139857	CDRT15	-0.62	-5.61	-0.5	1.97e-7	Temperament;
THYM	cis	rs854765	0.718	rs7224815	chr17:17845800	A/T	cg04398451	chr17:18023971	MYO15A	-0.78	-6.54	-0.56	3.09e-9	Total body bone mineral density;
THYM	cis	rs12579753	1.000	rs7306395	chr12:82175867	A/G	cg21231944	chr12:82153410	PPFIA2	-0.69	-5.26	-0.47	8.95e-7	Resting heart rate;
THYM	cis	rs524023	0.914	rs2360873	chr11:64391157	G/C	cg19131476	chr11:64387923	NRXN2	-0.39	-5.54	-0.49	2.7e-7	Urate levels in obese individuals;
THYM	cis	rs4731207	0.623	rs1481342	chr7:124651479	A/C	cg05285228	chr7:124571219	POT1	-0.72	-5.53	-0.49	2.81e-7	Cutaneous malignant melanoma;
THYM	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	10.62	0.74	7.85e-18	Chronic sinus infection;
THYM	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.84	4.66	0.43	1.04e-5	Initial pursuit acceleration;
THYM	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs10799590	0.927	rs298732	chr1:224842140	C/T	cg01808320	chr1:224927238	CNIH3	-0.52	-4.69	-0.43	9.28e-6	Opioid dependence;
THYM	cis	rs7027203	0.828	rs10761288	chr9:96609363	C/T	cg14598338	chr9:96623480	NA	-0.52	-5.77	-0.51	9.71e-8	DNA methylation (variation);
THYM	cis	rs1021993	0.597	rs10494924	chr1:209527706	A/C	cg24997231	chr1:209527535	NA	-0.58	-5.28	-0.48	8.07e-7	Gut microbiome composition (winter);
THYM	cis	rs35883536	1.000	rs2491822	chr1:101115839	T/C	cg06223162	chr1:101003688	GPR88	-0.67	-5.08	-0.46	1.86e-6	Monocyte count;
THYM	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs1065852	0.526	rs2097562	chr22:42389500	T/C	cg22189786	chr22:42395067	WBP2NL	0.54	5.55	0.49	2.6e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs7786808	0.530	rs6459875	chr7:158186141	C/T	cg01191920	chr7:158217561	PTPRN2	0.92	9.52	0.7	1.77e-15	Obesity-related traits;
THYM	cis	rs4523957	0.651	rs1002136	chr17:2098006	C/A	cg16513277	chr17:2031491	SMG6	-0.84	-8.22	-0.64	1.03e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs977987	0.872	rs4887825	chr16:75472422	C/A	cg03315344	chr16:75512273	CHST6	0.74	5.92	0.52	5.08e-8	Dupuytren's disease;
THYM	cis	rs7772486	0.790	rs2253764	chr6:146199881	T/A	cg13319975	chr6:146136371	FBXO30	-0.71	-5.72	-0.51	1.24e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg01579765	chr21:45077557	HSF2BP	-0.46	-7.29	-0.6	9.2e-11	Mean corpuscular volume;
THYM	cis	rs2456568	0.803	rs10765641	chr11:93640312	T/C	cg26875233	chr11:93583750	C11orf90	-0.54	-5.78	-0.51	9.51e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	trans	rs877282	0.853	rs7079299	chr10:756455	A/G	cg22713356	chr15:30763199	NA	1.27	9.37	0.69	3.62e-15	Uric acid levels;
THYM	cis	rs3796352	0.527	rs11715498	chr3:52943551	G/C	cg24530246	chr3:53118167	NA	-0.66	-4.57	-0.42	1.44e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg18305652	chr10:134549665	INPP5A	0.79	6.5	0.55	3.69e-9	Migraine;
THYM	cis	rs7107174	1.000	rs2511178	chr11:77923220	C/T	cg19901956	chr11:77921274	USP35	-0.75	-5.88	-0.52	6.01e-8	Testicular germ cell tumor;
THYM	cis	rs4845875	0.534	rs4846052	chr1:11857951	T/C	cg24844545	chr1:11908347	NPPA	0.49	4.75	0.44	7.11e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.89	9.06	0.68	1.73e-14	Chronic sinus infection;
THYM	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg19418458	chr7:158789849	NA	0.68	6.64	0.56	1.97e-9	Facial morphology (factor 20);
THYM	cis	rs4731207	0.698	rs10156168	chr7:124494410	G/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg22920501	chr2:26401640	FAM59B	1.01	8.6	0.66	1.63e-13	Gut microbiome composition (summer);
THYM	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg17264618	chr3:40429014	ENTPD3	-0.53	-5.15	-0.47	1.38e-6	Renal cell carcinoma;
THYM	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg13395646	chr4:1353034	KIAA1530	0.59	5.67	0.5	1.51e-7	Obesity-related traits;
THYM	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs929596	0.639	rs7571915	chr2:234586574	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.82	-6.44	-0.55	4.79e-9	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs485842	1.000	rs483905	chr11:96023427	G/A	cg23866687	chr11:96026956	MAML2	0.44	6.23	0.54	1.28e-8	Corneal astigmatism;
THYM	cis	rs2404602	0.647	rs7181506	chr15:76935677	G/T	cg23625390	chr15:77176239	SCAPER	0.91	6.78	0.57	1.02e-9	Blood metabolite levels;
THYM	cis	rs4737010	0.501	rs10099197	chr8:41654458	C/T	cg08923054	chr8:41654455	ANK1	0.81	4.91	0.45	3.81e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
THYM	cis	rs6500395	0.775	rs1968903	chr16:48664014	C/T	cg04672837	chr16:48644449	N4BP1	0.47	4.62	0.43	1.18e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg06718696	chr17:78121285	EIF4A3	1.03	7.4	0.6	5.29e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
THYM	cis	rs9660180	0.967	rs6664664	chr1:1751264	G/A	cg06981504	chr1:1234844	ACAP3	0.54	4.94	0.45	3.32e-6	Body mass index;
THYM	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg26446133	chr18:72167187	CNDP2	-1.02	-7.49	-0.61	3.5e-11	Refractive error;
THYM	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.72	0.51	1.23e-7	Lung cancer in ever smokers;
THYM	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg19875535	chr5:140030758	IK	-0.63	-5.61	-0.5	1.98e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg16342193	chr10:102329863	NA	-0.53	-5.45	-0.49	4.01e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-4.88	-0.45	4.26e-6	Hemoglobin concentration;
THYM	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg18402987	chr7:1209562	NA	0.73	5.27	0.48	8.58e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs858239	0.699	rs1881201	chr7:23194013	C/T	cg18081818	chr7:23246105	NA	0.6	5.5	0.49	3.17e-7	Cerebrospinal fluid biomarker levels;
THYM	cis	rs8067545	0.641	rs2108978	chr17:19861458	C/T	cg20830565	chr17:20408647	MGC102966	-0.54	-4.95	-0.45	3.2e-6	Schizophrenia;
THYM	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg13609457	chr4:120235615	NA	0.6	5.34	0.48	6.23e-7	Corneal astigmatism;
THYM	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg26384229	chr12:38710491	ALG10B	0.81	6.34	0.55	7.65e-9	Heart rate;
THYM	cis	rs420259	0.516	rs1135045	chr16:23489711	C/G	cg00143387	chr16:23521605	GGA2	-0.76	-5.33	-0.48	6.5e-7	Bipolar disorder;
THYM	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg13770153	chr20:60521292	NA	-0.64	-4.54	-0.42	1.66e-5	Body mass index;
THYM	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs936229	0.690	rs2472300	chr15:75033909	A/G	cg14664628	chr15:75095509	CSK	-0.74	-5.26	-0.48	8.82e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs988913	0.915	rs9475107	chr6:54853342	G/A	cg19716238	chr6:54711378	FAM83B	0.5	4.91	0.45	3.76e-6	Menarche (age at onset);
THYM	cis	rs483180	0.512	rs612430	chr1:120216025	A/G	cg19096424	chr1:120255104	PHGDH	0.67	5.25	0.47	9.26e-7	Macular telangiectasia type 2;
THYM	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg00576331	chr11:65640516	EFEMP2	-0.68	-4.58	-0.43	1.42e-5	Crohn's disease;
THYM	cis	rs12519773	0.526	rs4551051	chr5:92518724	T/C	cg18783429	chr5:92414398	NA	0.5	4.91	0.45	3.72e-6	Migraine;
THYM	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs600806	0.850	rs115935180	chr1:109976775	C/G	cg23032129	chr1:109941072	SORT1	-0.57	-4.82	-0.44	5.54e-6	Intelligence (multi-trait analysis);
THYM	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg01073479	chr16:3509474	NAT15	0.62	4.8	0.44	5.98e-6	Tuberculosis;
THYM	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg15691649	chr6:25882328	NA	-0.68	-5.25	-0.47	9.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg05973401	chr12:123451056	ABCB9	0.68	4.55	0.42	1.58e-5	Neutrophil percentage of white cells;
THYM	cis	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg26384229	chr12:38710491	ALG10B	-0.72	-5.62	-0.5	1.94e-7	Morning vs. evening chronotype;
THYM	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg06027949	chr8:82754900	SNX16	-0.64	-5.35	-0.48	6.18e-7	Diastolic blood pressure;
THYM	trans	rs7918405	0.724	rs11196062	chr10:114457943	C/T	cg24847366	chr12:125034283	NA	-0.83	-7.57	-0.61	2.41e-11	QRS duration;
THYM	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.27	0.54	1.07e-8	Platelet count;
THYM	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.62	-4.64	-0.43	1.11e-5	Age at first birth;
THYM	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg03476357	chr21:30257390	N6AMT1	-0.6	-4.55	-0.42	1.58e-5	Dental caries;
THYM	trans	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg15744005	chr10:104629667	AS3MT	0.81	7.63	0.62	1.84e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6998277	0.830	rs965661	chr8:103597586	C/T	cg10187029	chr8:103597600	NA	0.51	4.49	0.42	2.03e-5	Migraine;
THYM	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	-0.48	-4.58	-0.43	1.41e-5	Schizophrenia;
THYM	cis	rs314370	0.904	rs13244629	chr7:100509253	A/C	cg10426581	chr7:100472382	SRRT	1.13	8.97	0.68	2.57e-14	Resting heart rate;
THYM	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg09034736	chr1:150693464	HORMAD1	0.53	4.85	0.45	4.83e-6	Tonsillectomy;
THYM	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg11502198	chr6:26597334	ABT1	0.63	5.6	0.5	2.09e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.7	6.0	0.52	3.55e-8	Total body bone mineral density;
THYM	cis	rs9462846	0.725	rs9471969	chr6:42906384	G/T	cg09436375	chr6:42928200	GNMT	-0.43	-4.52	-0.42	1.76e-5	Blood protein levels;
THYM	cis	rs8070624	0.543	rs11870660	chr17:17877096	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	6.7	0.57	1.48e-9	Total body bone mineral density;
THYM	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.6	-0.56	2.37e-9	Chronic sinus infection;
THYM	cis	rs5758511	0.689	rs17002947	chr22:42688532	C/T	cg08431931	chr22:42394659	WBP2NL	-0.74	-4.85	-0.45	4.87e-6	Birth weight;
THYM	cis	rs7264396	0.887	rs750487	chr20:34066645	T/C	cg26038318	chr20:34205095	SPAG4	0.53	4.47	0.42	2.15e-5	Total cholesterol levels;
THYM	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg05872129	chr22:39784769	NA	0.91	7.55	0.61	2.58e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs56104184	0.830	rs73061614	chr19:49343289	T/C	cg15549821	chr19:49342101	PLEKHA4	-1.25	-8.53	-0.66	2.24e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2932538	0.922	rs34531155	chr1:113141550	C/T	cg22162597	chr1:113214053	CAPZA1	0.63	4.96	0.45	3.13e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs4930776	0.897	rs1860955	chr12:5765128	T/A	cg02086166	chr12:5775618	ANO2	-0.58	-5.71	-0.51	1.3e-7	Plasma clusterin levels;
THYM	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg17333051	chr19:2783644	SGTA	0.74	6.44	0.55	4.92e-9	Total cholesterol levels;
THYM	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	6.18	0.54	1.56e-8	Monocyte percentage of white cells;
THYM	cis	rs17401966	0.838	rs2182326	chr1:10385664	G/A	cg19773385	chr1:10388646	KIF1B	-0.59	-4.82	-0.44	5.39e-6	Hepatocellular carcinoma;
THYM	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.56	-4.73	-0.44	7.72e-6	Hip circumference adjusted for BMI;
THYM	cis	rs1915146	0.967	rs57592469	chr10:126850489	A/G	cg23000734	chr10:126850823	CTBP2	0.85	10.86	0.74	2.49e-18	Menarche (age at onset);
THYM	cis	rs16866061	1.000	rs7588380	chr2:225341304	A/T	cg22455342	chr2:225449267	CUL3	-0.68	-4.88	-0.45	4.23e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs2295359	1.000	rs963427	chr1:67609347	A/G	cg11235152	chr1:67600687	NA	0.62	5.07	0.46	1.98e-6	Psoriasis;
THYM	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg15247329	chr7:2764246	NA	0.72	6.01	0.52	3.49e-8	Height;
THYM	cis	rs28595532	0.920	rs17324968	chr4:119772316	A/G	cg11846333	chr4:119757529	SEC24D	1.36	4.83	0.44	5.31e-6	Cannabis dependence symptom count;
THYM	cis	rs754466	0.580	rs1344966	chr10:79534527	T/C	cg17075019	chr10:79541650	NA	-0.7	-5.84	-0.51	7.23e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	trans	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg19862616	chr7:65841803	NCRNA00174	1.05	11.42	0.76	1.59e-19	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg18240062	chr17:79603768	NPLOC4	0.56	4.75	0.44	7.07e-6	Eye color traits;
THYM	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg04234412	chr22:24373322	LOC391322	0.9	9.01	0.68	2.14e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg13683864	chr3:40499215	RPL14	-0.85	-7.94	-0.63	4.12e-12	Renal cell carcinoma;
THYM	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg14458575	chr2:238380390	NA	1.0	7.74	0.62	1.07e-11	Prostate cancer;
THYM	cis	rs12956009	0.583	rs12965907	chr18:44888455	C/G	cg19077165	chr18:44547161	KATNAL2	-0.49	-4.7	-0.43	8.81e-6	Educational attainment (years of education);
THYM	cis	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg21775007	chr8:11205619	TDH	0.63	5.1	0.46	1.75e-6	Retinal vascular caliber;
THYM	cis	rs4845875	0.626	rs6540999	chr1:11833366	A/G	cg25341925	chr1:11908058	NPPA	0.43	4.64	0.43	1.1e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	5.02	0.46	2.39e-6	Menarche (age at onset);
THYM	cis	rs877282	0.891	rs11253393	chr10:788824	G/T	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg22467129	chr15:76604101	ETFA	-0.55	-5.08	-0.46	1.92e-6	Blood metabolite levels;
THYM	cis	rs12579753	0.957	rs35001833	chr12:82188510	C/G	cg07988820	chr12:82153109	PPFIA2	-0.75	-4.67	-0.43	9.89e-6	Resting heart rate;
THYM	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs665401	0.692	rs1512658	chr6:117122495	G/A	cg20376953	chr6:117187980	NA	-0.61	-4.77	-0.44	6.56e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07167872	chr1:205819463	PM20D1	0.96	9.18	0.69	9.45e-15	Menarche (age at onset);
THYM	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg23803603	chr1:2058230	PRKCZ	0.59	4.56	0.42	1.52e-5	Height;
THYM	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg08999081	chr20:33150536	PIGU	-0.77	-6.89	-0.58	6.01e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg11245990	chr11:68621969	NA	0.58	7.59	0.61	2.21e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6500602	0.819	rs3747580	chr16:4455675	G/A	cg08645402	chr16:4508243	NA	0.68	5.52	0.49	2.91e-7	Schizophrenia;
THYM	cis	rs3799379	0.550	rs2072804	chr6:26391190	G/A	cg12826209	chr6:26865740	GUSBL1	0.7	5.17	0.47	1.32e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg26384229	chr12:38710491	ALG10B	0.99	7.63	0.62	1.81e-11	Bladder cancer;
THYM	cis	rs7809950	1.000	rs10258385	chr7:107243350	T/C	cg23024343	chr7:107201750	COG5	0.92	7.65	0.62	1.63e-11	Coronary artery disease;
THYM	cis	rs910187	0.624	rs6066219	chr20:45793967	A/T	cg27589058	chr20:45804311	EYA2	-0.57	-4.85	-0.45	4.79e-6	Migraine;
THYM	cis	rs2463822	1.000	rs951677	chr11:62107249	G/C	cg06239285	chr11:62104954	ASRGL1	1.41	7.05	0.59	2.86e-10	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg00640147	chr17:61958756	GH2	-0.44	-4.68	-0.43	9.69e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.95	9.99	0.72	1.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs96067	0.805	rs1033890	chr1:36608414	C/T	cg24686825	chr1:36642396	MAP7D1	-0.67	-4.51	-0.42	1.87e-5	Corneal structure;
THYM	cis	rs2235642	0.826	rs8048410	chr16:1614097	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.53	-4.49	-0.42	2.02e-5	Coronary artery disease;
THYM	cis	rs1696756	0.877	rs2587500	chr17:77827362	A/T	cg00646381	chr17:77835854	NA	0.39	4.6	0.43	1.3e-5	Glucocorticoid-induced osteonecrosis (age 10 years and older);
THYM	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg05362011	chr13:21860987	NA	0.57	4.71	0.44	8.41e-6	White matter hyperintensity burden;
THYM	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg26597838	chr10:835615	NA	0.86	4.92	0.45	3.62e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs11645898	0.688	rs437638	chr16:72095452	C/T	cg03805757	chr16:71968109	PKD1L3	-0.71	-4.91	-0.45	3.82e-6	Blood protein levels;
THYM	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs7616559	0.962	rs6769719	chr3:156719694	A/T	cg15697575	chr3:156784781	NA	-0.39	-5.08	-0.46	1.85e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs4343996	0.558	rs1554500	chr7:3415864	T/C	cg21248987	chr7:3385318	SDK1	0.4	4.91	0.45	3.72e-6	Motion sickness;
THYM	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg23711669	chr6:146136114	FBXO30	-0.93	-9.17	-0.69	9.81e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs662064	0.963	rs636291	chr1:10556097	G/A	cg20482658	chr1:10539492	PEX14	-0.45	-5.97	-0.52	4.05e-8	Asthma;
THYM	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg11764359	chr7:65958608	NA	0.83	7.0	0.58	3.54e-10	Aortic root size;
THYM	cis	rs4343996	0.558	rs11981092	chr7:3412100	C/T	cg21248987	chr7:3385318	SDK1	0.4	4.94	0.45	3.32e-6	Motion sickness;
THYM	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22968622	chr17:43663579	NA	1.07	9.46	0.7	2.33e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12579753	1.000	rs17692461	chr12:82171755	C/G	cg21231944	chr12:82153410	PPFIA2	-0.68	-5.16	-0.47	1.36e-6	Resting heart rate;
THYM	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg09436375	chr6:42928200	GNMT	-0.44	-5.59	-0.5	2.15e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs988913	1.000	rs9382404	chr6:54835218	C/G	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.75e-6	Menarche (age at onset);
THYM	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg05373962	chr22:49881684	NA	-0.63	-5.62	-0.5	1.87e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7586879	1.000	rs7608185	chr2:25115432	G/C	cg15423357	chr2:25149977	NA	0.56	5.49	0.49	3.41e-7	Body mass index;
THYM	cis	rs1472147	0.696	rs1532222	chr7:128516945	A/C	cg00260937	chr7:128520193	KCP	-0.66	-6.52	-0.56	3.34e-9	Calcium levels;
THYM	cis	rs1018836	0.923	rs2105965	chr8:91537690	T/C	cg16814680	chr8:91681699	NA	-0.86	-7.97	-0.63	3.49e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg22841779	chr14:105766346	BRF1	-0.47	-5.87	-0.52	6.35e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7246657	0.943	rs10420754	chr19:37959372	C/G	cg22634378	chr19:37742834	NA	0.62	5.18	0.47	1.22e-6	Coronary artery calcification;
THYM	cis	rs425535	0.941	rs450373	chr4:74858051	G/A	cg07868155	chr4:74864709	CXCL5	0.61	5.11	0.46	1.68e-6	Blood protein levels;
THYM	cis	rs35883536	0.626	rs10493933	chr1:101111282	A/G	cg06223162	chr1:101003688	GPR88	-0.7	-5.87	-0.52	6.48e-8	Monocyte count;
THYM	cis	rs763014	0.714	rs3743901	chr16:632699	C/G	cg00908189	chr16:619842	PIGQ	1.05	9.44	0.7	2.54e-15	Height;
THYM	cis	rs11648785	0.590	rs4324129	chr16:90099061	C/T	cg04240660	chr16:89714849	CHMP1A	-0.58	-4.53	-0.42	1.75e-5	Tanning;
THYM	cis	rs870825	0.616	rs6552806	chr4:185638231	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.5	-4.57	-0.42	1.47e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7772486	0.790	rs2249386	chr6:146186611	G/A	cg23711669	chr6:146136114	FBXO30	0.96	10.07	0.72	1.15e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg20283391	chr11:68216788	NA	-0.6	-4.78	-0.44	6.49e-6	Total body bone mineral density;
THYM	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg27494647	chr7:150038898	RARRES2	0.47	5.43	0.49	4.32e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4470825	0.837	rs628629	chr6:83894382	T/C	cg02405813	chr6:83072522	TPBG	-0.58	-4.45	-0.42	2.35e-5	Schizophrenia;
THYM	cis	rs7901056	0.967	rs3006819	chr10:26718561	A/G	cg23318538	chr10:26883079	C10orf50	-0.37	-4.96	-0.45	3.12e-6	Lymphocyte counts;
THYM	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs737337	0.623	rs12974173	chr19:11333359	A/T	cg00586551	chr19:11347513	LOC55908;DOCK6	0.66	4.7	0.43	8.89e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs4654899	0.931	rs935917	chr1:21167102	A/T	cg01072550	chr1:21505969	NA	-0.71	-6.56	-0.56	2.78e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs858239	0.537	rs6955115	chr7:23227144	A/G	cg09755872	chr7:23245557	NA	-0.52	-4.85	-0.45	4.76e-6	Cerebrospinal fluid biomarker levels;
THYM	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg01341218	chr17:43662625	NA	1.13	9.52	0.7	1.72e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg07936489	chr17:37558343	FBXL20	-0.8	-5.57	-0.5	2.37e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg11764359	chr7:65958608	NA	0.84	6.87	0.58	6.77e-10	Aortic root size;
THYM	cis	rs7119	0.717	rs12902896	chr15:77809150	G/T	cg27398640	chr15:77910606	LINGO1	0.55	5.61	0.5	1.95e-7	Type 2 diabetes;
THYM	cis	rs1395	0.778	rs62128747	chr2:27412605	T/C	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.4	-0.48	4.88e-7	Blood metabolite levels;
THYM	cis	rs10779751	1.000	rs4845987	chr1:11306279	G/C	cg08854313	chr1:11322531	MTOR	1.04	10.45	0.73	1.85e-17	Body mass index;
THYM	cis	rs514406	0.525	rs269291	chr1:53189297	C/T	cg24675658	chr1:53192096	ZYG11B	-0.83	-7.63	-0.62	1.76e-11	Monocyte count;
THYM	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2279817	0.863	rs12023877	chr1:18025633	A/C	cg21791023	chr1:18019539	ARHGEF10L	0.75	4.73	0.44	7.76e-6	Neuroticism;
THYM	cis	rs7580658	0.676	rs2174270	chr2:128006078	C/T	cg09152259	chr2:128156114	NA	-0.33	-4.48	-0.42	2.05e-5	Protein C levels;
THYM	cis	rs7553864	0.636	rs7543740	chr1:87609026	C/T	cg17420885	chr1:87600446	LOC339524	-0.85	-7.65	-0.62	1.63e-11	Smoking behavior;
THYM	cis	rs7586879	0.662	rs2384059	chr2:25100338	C/T	cg27107076	chr2:25050844	ADCY3	-0.3	-4.8	-0.44	5.92e-6	Body mass index;
THYM	cis	rs4557020	0.967	rs4429513	chr2:54709061	G/C	cg11007406	chr2:54682859	SPTBN1	-0.37	-4.64	-0.43	1.11e-5	Myopia (pathological);
THYM	cis	rs925255	0.591	rs7559046	chr2:28644670	G/C	cg01273330	chr2:28605224	NA	-0.47	-4.45	-0.42	2.35e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg24733560	chr20:60626293	TAF4	0.62	6.63	0.56	2.01e-9	Body mass index;
THYM	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg16414030	chr3:133502952	NA	-0.83	-8.08	-0.64	2.01e-12	Iron status biomarkers;
THYM	cis	rs10504073	0.626	rs9298106	chr8:50007508	T/G	cg00325661	chr8:49890786	NA	0.87	7.79	0.62	8.16e-12	Blood metabolite ratios;
THYM	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg26818010	chr10:134567672	INPP5A	-0.93	-7.48	-0.61	3.71e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs72772090	0.539	rs55996659	chr5:96114150	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9612	1.000	rs16976747	chr19:44238152	G/A	cg08581076	chr19:44259116	C19orf61	0.67	4.49	0.42	2.03e-5	Exhaled nitric oxide output;
THYM	cis	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg07460842	chr6:66804631	NA	1.1	8.21	0.64	1.08e-12	Exhaled nitric oxide output;
THYM	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg01097406	chr16:89675127	NA	-0.61	-5.06	-0.46	2.07e-6	Vitiligo;
THYM	cis	rs4731207	0.596	rs6961441	chr7:124590871	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs886126	0.650	rs4766566	chr12:111706877	C/T	cg10833066	chr12:111807467	FAM109A	0.53	6.72	0.57	1.36e-9	Coronary heart disease;
THYM	cis	rs9640161	0.789	rs10248490	chr7:150051418	C/G	cg17279839	chr7:150038598	RARRES2	0.52	4.63	0.43	1.15e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs9796	0.870	rs7162992	chr15:41290861	T/C	cg21153102	chr15:41252147	NA	0.7	6.38	0.55	6.34e-9	Menopause (age at onset);
THYM	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg09184832	chr6:79620586	NA	0.56	4.46	0.42	2.24e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11890956	chr21:40555474	PSMG1	-0.65	-6.03	-0.53	3.17e-8	Menarche (age at onset);
THYM	cis	rs7705042	0.761	rs10062349	chr5:141509597	G/A	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs7020830	0.867	rs1472169	chr9:37209396	C/T	cg14294708	chr9:37120828	ZCCHC7	1.27	16.47	0.86	1.37e-29	Schizophrenia;
THYM	cis	rs9814567	0.806	rs2888670	chr3:134326684	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.83	-0.63	6.69e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs8017423	0.967	rs61592400	chr14:90703252	T/C	cg04239629	chr14:90701769	NA	-0.61	-4.46	-0.42	2.28e-5	Mortality in heart failure;
THYM	cis	rs2857078	0.732	rs9893756	chr17:42321109	T/C	cg13607699	chr17:42295918	UBTF	-0.89	-7.78	-0.62	8.55e-12	Red cell distribution width;Reticulocyte count;
THYM	cis	rs984222	0.775	rs2645294	chr1:119574587	C/T	cg06528645	chr1:119534088	NA	0.49	4.5	0.42	1.93e-5	Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist-hip ratio;
THYM	cis	rs7512552	0.582	rs834233	chr1:150354276	G/A	cg15654264	chr1:150340011	RPRD2	0.49	5.68	0.5	1.47e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.92	-6.03	-0.53	3.11e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg00012203	chr2:219082015	ARPC2	-0.56	-4.89	-0.45	4.07e-6	Colorectal cancer;
THYM	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg12311346	chr5:56204834	C5orf35	0.61	4.61	0.43	1.23e-5	Initial pursuit acceleration;
THYM	cis	rs72627123	0.867	rs74395411	chr14:74478584	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.52	0.56	3.44e-9	Morning vs. evening chronotype;
THYM	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg25811766	chr13:21894605	NA	0.71	6.01	0.53	3.36e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg00757033	chr12:89920650	WDR51B	0.68	8.97	0.68	2.68e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs4930776	0.900	rs393557	chr12:5759247	T/C	cg02086166	chr12:5775618	ANO2	0.61	6.07	0.53	2.57e-8	Plasma clusterin levels;
THYM	cis	rs11186	0.584	rs111915005	chr2:189961171	A/C	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg24375607	chr4:120327624	NA	0.68	5.27	0.48	8.61e-7	Corneal astigmatism;
THYM	trans	rs8073060	0.586	rs225288	chr17:33929291	G/A	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg17333051	chr19:2783644	SGTA	0.74	6.39	0.55	6.06e-9	Total cholesterol levels;
THYM	cis	rs2688608	0.560	rs10128354	chr10:75470045	T/C	cg19442545	chr10:75533431	FUT11	-0.62	-6.56	-0.56	2.84e-9	Inflammatory bowel disease;
THYM	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg22117172	chr7:91764530	CYP51A1	0.36	4.47	0.42	2.14e-5	Breast cancer;
THYM	cis	rs4845459	0.967	rs477392	chr1:152555176	C/G	cg26135325	chr1:152595322	LCE3A	-0.45	-5.21	-0.47	1.09e-6	Psoriasis;
THYM	cis	rs4072705	1.000	rs6478680	chr9:127458468	G/A	cg13476313	chr9:127244764	NR5A1	0.34	5.23	0.47	1e-6	Menarche (age at onset);
THYM	cis	rs6032067	0.516	rs991049	chr20:43898139	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	0.6	5.85	0.51	6.81e-8	Blood protein levels;
THYM	cis	rs6430585	0.528	rs56064699	chr2:136595706	G/A	cg23851026	chr2:136556271	LCT	0.81	7.55	0.61	2.68e-11	Corneal structure;
THYM	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg04362960	chr10:104952993	NT5C2	0.57	4.65	0.43	1.07e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg25566285	chr7:158114605	PTPRN2	0.9	10.51	0.73	1.32e-17	Calcium levels;
THYM	cis	rs12802200	0.535	rs12282299	chr11:570009	T/C	cg16486109	chr11:613632	IRF7	0.48	5.3	0.48	7.49e-7	Systemic lupus erythematosus;
THYM	cis	rs2456568	0.802	rs11020586	chr11:93638547	G/A	cg26875233	chr11:93583750	C11orf90	-0.53	-5.53	-0.49	2.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22496380	chr5:211416	CCDC127	-1.3	-8.28	-0.65	7.84e-13	Breast cancer;
THYM	cis	rs4654899	0.865	rs6700459	chr1:21279396	T/C	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.29e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs10227331	0.617	rs55977076	chr7:157301739	A/G	cg04156418	chr7:157293606	NA	0.77	6.64	0.56	1.97e-9	Inattentive symptoms;
THYM	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg03709012	chr19:19516395	GATAD2A	-0.84	-7.3	-0.6	8.83e-11	Tonsillectomy;
THYM	cis	rs11696501	0.739	rs6073821	chr20:44251791	A/G	cg11783356	chr20:44313418	WFDC10B	-0.66	-4.52	-0.42	1.77e-5	Brain structure;
THYM	cis	rs9549260	0.592	rs9532588	chr13:41302913	G/A	cg21288729	chr13:41239152	FOXO1	0.62	4.73	0.44	7.88e-6	Red blood cell count;
THYM	cis	rs6047844	0.569	rs6113526	chr20:22094215	A/G	cg16502866	chr20:23015624	SSTR4	-0.58	-4.61	-0.43	1.25e-5	Male-pattern baldness;
THYM	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.68	6.04	0.53	2.94e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4242434	0.927	rs57594397	chr8:22475657	T/C	cg01710189	chr8:22454888	PDLIM2	-0.56	-5.31	-0.48	7.28e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs240764	0.817	rs12201852	chr6:101149576	T/C	cg21058520	chr6:100914733	NA	0.6	5.37	0.48	5.6e-7	Neuroticism;
THYM	cis	rs300703	0.542	rs300696	chr2:183330	G/A	cg21211680	chr2:198530	NA	-0.96	-6.35	-0.55	7.3e-9	Blood protein levels;
THYM	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg15921436	chr17:44337874	NA	0.95	6.92	0.58	5.33e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.83	0.67	5.15e-14	Colorectal cancer;
THYM	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg06238570	chr21:40685208	BRWD1	-0.96	-9.16	-0.68	1.02e-14	Cognitive function;
THYM	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg08859206	chr1:53392774	SCP2	-0.51	-5.37	-0.48	5.47e-7	Monocyte count;
THYM	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg18252515	chr7:66147081	NA	0.62	4.6	0.43	1.31e-5	Aortic root size;
THYM	cis	rs2688608	0.592	rs7076585	chr10:75503692	T/C	cg15838173	chr10:75533400	FUT11	-0.54	-5.36	-0.48	5.84e-7	Inflammatory bowel disease;
THYM	cis	rs6032067	0.929	rs17424474	chr20:43804797	C/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs34912216	0.542	rs55805280	chr7:4124101	A/G	cg03141780	chr7:4150753	SDK1	0.71	5.12	0.47	1.57e-6	Motion sickness;
THYM	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs1351164	1.000	rs10181989	chr2:218294915	T/C	cg15335768	chr2:218268053	DIRC3	-0.38	-5.1	-0.46	1.77e-6	Height;
THYM	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg00684032	chr4:1343700	KIAA1530	0.75	6.5	0.55	3.68e-9	Obesity-related traits;
THYM	cis	rs3126085	1.000	rs2338555	chr1:152309380	G/A	cg10321714	chr1:152280068	FLG	-0.72	-5.44	-0.49	4.14e-7	Atopic dermatitis;
THYM	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg22875332	chr1:76189707	ACADM	-0.87	-10.93	-0.75	1.76e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4654899	0.802	rs17410008	chr1:21220701	G/C	cg01072550	chr1:21505969	NA	-0.7	-6.17	-0.53	1.69e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs7512552	0.839	rs2647373	chr1:150320570	G/C	cg15654264	chr1:150340011	RPRD2	0.45	5.2	0.47	1.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs752010	0.841	rs11210498	chr1:42077958	T/G	cg13396354	chr1:41153348	NA	-0.48	-4.64	-0.43	1.11e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs12540874	0.698	rs3823674	chr7:50571996	C/T	cg18232548	chr7:50535776	DDC	-0.87	-7.89	-0.63	5.06e-12	Systemic sclerosis;
THYM	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg09307838	chr4:120376055	NA	0.66	4.47	0.42	2.14e-5	Corneal astigmatism;
THYM	cis	rs8077889	0.703	rs231534	chr17:41945564	C/T	cg26893861	chr17:41843967	DUSP3	-0.66	-4.94	-0.45	3.35e-6	Triglycerides;
THYM	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg20887711	chr4:1340912	KIAA1530	-0.7	-6.05	-0.53	2.8e-8	Obesity-related traits;
THYM	cis	rs7819412	0.537	rs2127127	chr8:11434792	C/G	cg11009520	chr8:12052164	FAM86B1	0.58	4.75	0.44	7.07e-6	Triglycerides;
THYM	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg08431931	chr22:42394659	WBP2NL	0.63	4.66	0.43	1.02e-5	Birth weight;
THYM	cis	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg10518543	chr12:38710700	ALG10B	-0.59	-4.7	-0.43	8.88e-6	Bladder cancer;
THYM	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg07636037	chr3:49044803	WDR6	0.94	9.95	0.71	2.13e-16	Parkinson's disease;
THYM	cis	rs10237377	0.539	rs7781964	chr7:139749346	G/A	cg14674361	chr7:138916732	UBN2	0.66	4.45	0.42	2.33e-5	Coronary artery disease;
THYM	cis	rs28595532	0.925	rs56200441	chr4:119497440	T/G	cg11846333	chr4:119757529	SEC24D	1.36	4.83	0.44	5.23e-6	Cannabis dependence symptom count;
THYM	cis	rs9611519	0.780	rs5751071	chr22:41656332	G/A	cg03806693	chr22:41940476	POLR3H	-0.81	-7.13	-0.59	2e-10	Neuroticism;
THYM	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.53	4.87	0.45	4.41e-6	Lymphocyte counts;
THYM	cis	rs10929159	0.928	rs1349732	chr2:236923716	G/A	cg20128773	chr2:236923534	AGAP1	0.35	4.66	0.43	1.01e-5	Parkinson's disease;
THYM	cis	rs6980334	0.680	rs10244249	chr7:137790650	A/C	cg11874123	chr7:137028198	PTN	0.67	5.17	0.47	1.29e-6	Blood metabolite ratios;
THYM	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg18230493	chr5:56204884	C5orf35	-0.82	-5.98	-0.52	3.83e-8	Initial pursuit acceleration;
THYM	cis	rs7084402	0.870	rs4948525	chr10:60361270	G/A	cg09696939	chr10:60272079	BICC1	-0.48	-5.74	-0.51	1.15e-7	Refractive error;
THYM	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg00191853	chr8:101177733	SPAG1	0.55	5.08	0.46	1.91e-6	Atrioventricular conduction;
THYM	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg13390004	chr1:15929781	NA	0.62	4.72	0.44	8.11e-6	Systolic blood pressure;
THYM	cis	rs425277	1.000	rs385039	chr1:2077409	C/T	cg13918804	chr1:2043761	PRKCZ	0.61	4.74	0.44	7.45e-6	Height;
THYM	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg24250549	chr1:154909240	PMVK	0.75	6.45	0.55	4.66e-9	Prostate cancer;
THYM	cis	rs2235649	0.833	rs7190337	chr16:1850469	A/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.75	5.64	0.5	1.73e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06850241	chr22:41845214	NA	0.59	5.41	0.49	4.76e-7	Vitiligo;
THYM	cis	rs2732480	0.538	rs1387260	chr12:48703091	A/C	cg21466736	chr12:48725269	NA	-0.58	-5.25	-0.47	9.41e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg16586182	chr3:47516702	SCAP	-0.63	-5.52	-0.49	2.96e-7	Colorectal cancer;
THYM	cis	rs28595532	0.920	rs28837152	chr4:119782868	G/A	cg11846333	chr4:119757529	SEC24D	1.39	5.31	0.48	7.04e-7	Cannabis dependence symptom count;
THYM	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg13609457	chr4:120235615	NA	0.6	5.34	0.48	6.23e-7	Corneal astigmatism;
THYM	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.52	0.73	1.31e-17	Prudent dietary pattern;
THYM	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg23682913	chr1:2080710	PRKCZ	-0.59	-5.24	-0.47	9.66e-7	Height;
THYM	cis	rs1346	0.552	rs7946115	chr11:65366192	G/C	cg27068330	chr11:65405492	SIPA1	0.7	4.54	0.42	1.67e-5	Vertical cup-disc ratio;Optic cup area;
THYM	cis	rs55871839	0.598	rs4737525	chr8:59799781	G/A	cg07426533	chr8:59803705	TOX	-0.61	-6.02	-0.53	3.2e-8	Pneumonia;
THYM	cis	rs1971762	1.000	rs3892761	chr12:54070445	A/T	cg16917193	chr12:54089295	NA	0.57	4.45	0.42	2.33e-5	Height;
THYM	cis	rs7043114	0.525	rs7863406	chr9:95053381	T/C	cg14631576	chr9:95140430	CENPP	-0.85	-9.03	-0.68	1.99e-14	Height;
THYM	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.79	6.94	0.58	4.8e-10	Tonsillectomy;
THYM	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg26031613	chr14:104095156	KLC1	-0.77	-4.79	-0.44	6.09e-6	Bone mineral density;
THYM	trans	rs6588480	0.667	rs496126	chr1:53981615	A/G	cg04105923	chr6:106451610	NA	-0.76	-7.18	-0.59	1.55e-10	Response to statin therapy;
THYM	cis	rs686320	0.666	rs11605125	chr11:65211019	C/G	cg19332572	chr11:65321591	LTBP3	0.77	4.68	0.43	9.51e-6	Hip circumference adjusted for BMI;
THYM	cis	rs17539620	0.624	rs4566892	chr6:154837346	C/T	cg20019720	chr6:154832845	CNKSR3	0.47	4.79	0.44	6.17e-6	Lipoprotein (a) levels;
THYM	cis	rs6430585	0.527	rs2304366	chr2:136467119	C/T	cg07169764	chr2:136633963	MCM6	1.02	8.98	0.68	2.47e-14	Corneal structure;
THYM	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg25072359	chr17:41440525	NA	-0.66	-5.02	-0.46	2.43e-6	Menopause (age at onset);
THYM	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg20283391	chr11:68216788	NA	-0.74	-5.43	-0.49	4.25e-7	Total body bone mineral density;
THYM	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg11494091	chr17:61959527	GH2	1.07	16.26	0.86	3.42e-29	Prudent dietary pattern;
THYM	cis	rs7772486	0.875	rs1331637	chr6:146337087	T/C	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6542838	0.588	rs4851175	chr2:99530118	A/G	cg08885076	chr2:99613938	TSGA10	-0.47	-4.63	-0.43	1.17e-5	Fear of minor pain;
THYM	cis	rs2209875	0.573	rs74703137	chr9:91951344	C/T	cg13881405	chr9:92220388	GADD45G	-0.48	-4.93	-0.45	3.44e-6	Pelvic organ prolapse (moderate/severe);
THYM	cis	rs3126085	0.935	rs1496046	chr1:152184534	C/G	cg26020982	chr1:152196106	HRNR	0.38	5.02	0.46	2.42e-6	Atopic dermatitis;
THYM	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg12031863	chr16:4587854	C16orf5	-0.46	-5.01	-0.46	2.5e-6	Schizophrenia;
THYM	cis	rs11252926	0.800	rs12763675	chr10:744591	C/T	cg16346588	chr10:242978	ZMYND11	-0.59	-4.74	-0.44	7.57e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs4805272	0.512	rs66830923	chr19:29321277	C/T	cg14983838	chr19:29218262	NA	0.83	5.48	0.49	3.46e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03517284	chr6:25882590	NA	-0.74	-5.89	-0.52	5.89e-8	Blood metabolite levels;
THYM	cis	rs11634944	0.644	rs2554419	chr15:25240165	C/T	cg10601234	chr15:25523666	NA	-0.5	-4.62	-0.43	1.2e-5	Interleukin-8 levels;
THYM	cis	rs4642101	0.793	rs3889513	chr3:12844070	G/A	cg05775895	chr3:12838266	CAND2	0.94	8.62	0.66	1.49e-13	QRS complex (12-leadsum);
THYM	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	5.2	0.47	1.15e-6	Hip circumference adjusted for BMI;
THYM	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg18512352	chr11:47633146	NA	-0.52	-6.14	-0.53	1.92e-8	Subjective well-being;
THYM	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.72	5.58	0.5	2.3e-7	Height;
THYM	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg06481639	chr22:41940642	POLR3H	-0.74	-4.85	-0.45	4.81e-6	Vitiligo;
THYM	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg10518543	chr12:38710700	ALG10B	-0.58	-4.78	-0.44	6.43e-6	Morning vs. evening chronotype;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg13433994	chr3:23958502	NKIRAS1;RPL15	-1.3	-6.86	-0.58	7.1e-10	Pulmonary function decline;
THYM	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg00684032	chr4:1343700	KIAA1530	0.54	4.67	0.43	9.81e-6	Obesity-related traits;
THYM	cis	rs1692580	0.682	rs12045693	chr1:2205581	A/C	cg21442419	chr1:2182373	SKI	0.42	4.8	0.44	5.89e-6	Coronary artery disease;
THYM	cis	rs4930103	0.935	rs2075745	chr11:2018336	A/T	cg21926276	chr11:2035255	NA	0.27	4.53	0.42	1.7e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs4383453	0.539	rs60870039	chr3:123101990	A/G	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg11789530	chr4:8429930	ACOX3	-0.74	-5.99	-0.52	3.74e-8	Response to antineoplastic agents;
THYM	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg23758822	chr17:41437982	NA	1.17	11.04	0.75	1.02e-18	Menopause (age at onset);
THYM	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg14018140	chr10:458528	DIP2C	-0.61	-7.18	-0.59	1.52e-10	Psychosis in Alzheimer's disease;
THYM	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg14798641	chr3:49314920	USP4;C3orf62	-0.67	-4.52	-0.42	1.78e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg03676636	chr4:99064102	C4orf37	-0.44	-6.64	-0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg24846343	chr22:24311635	DDTL	0.43	5.83	0.51	7.67e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg02734326	chr4:10020555	SLC2A9	0.75	6.28	0.54	9.97e-9	Bone mineral density;
THYM	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.59	4.5	0.42	1.91e-5	Tonsillectomy;
THYM	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg13939156	chr17:80058883	NA	0.41	5.37	0.48	5.6e-7	Life satisfaction;
THYM	cis	rs1957429	0.901	rs1957432	chr14:65352796	A/G	cg23373153	chr14:65346875	NA	1.04	6.18	0.54	1.57e-8	Pediatric areal bone mineral density (radius);
THYM	cis	rs11671005	0.735	rs35652377	chr19:58929200	A/C	cg18639983	chr19:58920768	ZNF584	0.61	5.02	0.46	2.37e-6	Mean platelet volume;
THYM	cis	rs2073300	1.000	rs6048810	chr20:23446429	G/A	cg12062639	chr20:23401060	NAPB	1.32	6.15	0.53	1.81e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.79	-0.44	6.18e-6	Mean corpuscular volume;
THYM	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg06634786	chr22:41940651	POLR3H	-0.55	-4.54	-0.42	1.68e-5	Vitiligo;
THYM	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-4.96	-0.45	3.03e-6	NT-proBNP levels in acute coronary syndrome;
THYM	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4746818	0.892	rs2394505	chr10:70871598	A/G	cg24417845	chr10:70816008	NA	-0.52	-4.57	-0.42	1.47e-5	Left atrial antero-posterior diameter;
THYM	cis	rs4148689	1.000	rs4148690	chr7:117150075	C/A	cg17204129	chr7:117119601	CFTR	-0.65	-5.08	-0.46	1.87e-6	Gout;
THYM	cis	rs2071403	0.527	rs2071402	chr2:1417199	A/G	cg06500727	chr2:1417164	TPO	0.56	4.58	0.43	1.39e-5	Thyroid peroxidase antibody positivity;
THYM	cis	rs514406	0.505	rs269293	chr1:53187767	A/C	cg16325326	chr1:53192061	ZYG11B	0.98	10.84	0.74	2.68e-18	Monocyte count;
THYM	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg01579765	chr21:45077557	HSF2BP	-0.46	-7.29	-0.6	9.2e-11	Mean corpuscular volume;
THYM	cis	rs6906287	0.669	rs2184402	chr6:118935341	T/C	cg21191810	chr6:118973309	C6orf204	0.58	5.8	0.51	8.72e-8	Electrocardiographic conduction measures;
THYM	cis	rs7172118	1	rs7172118	chr15:78862453	C/A	cg04882995	chr15:78912658	CHRNA3	0.54	4.54	0.42	1.62e-5	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg11764359	chr7:65958608	NA	0.69	4.78	0.44	6.35e-6	Aortic root size;
THYM	cis	rs57590327	0.555	rs3755713	chr3:81811224	A/G	cg07356753	chr3:81810745	GBE1	-0.88	-6.73	-0.57	1.31e-9	Extraversion;
THYM	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg15691649	chr6:25882328	NA	-0.73	-6.18	-0.54	1.58e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg06634786	chr22:41940651	POLR3H	-0.58	-4.88	-0.45	4.22e-6	Vitiligo;
THYM	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg12386194	chr3:101231763	SENP7	0.66	4.88	0.45	4.28e-6	Colorectal cancer;
THYM	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg11764359	chr7:65958608	NA	-0.81	-6.42	-0.55	5.45e-9	Aortic root size;
THYM	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs11209185	0.509	rs9436791	chr1:68452857	A/C	cg22082780	chr1:68452167	NA	0.7	9.22	0.69	7.84e-15	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs995000	0.931	rs1748197	chr1:63056112	G/A	cg06896770	chr1:63153194	DOCK7	0.92	7.57	0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs6032067	0.852	rs17333180	chr20:43803708	C/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.93	-0.58	5.03e-10	Blood protein levels;
THYM	cis	rs17102423	0.623	rs2898862	chr14:65612144	G/A	cg11161011	chr14:65562177	MAX	-0.58	-4.65	-0.43	1.08e-5	Obesity-related traits;
THYM	cis	rs3741151	0.773	rs58564192	chr11:73228904	G/A	cg12959048	chr11:73096162	RELT	-0.51	-4.51	-0.42	1.87e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs17174870	0.955	rs6737989	chr2:112779449	A/C	cg17354880	chr2:112658759	MERTK	-0.59	-4.47	-0.42	2.13e-5	Multiple sclerosis;
THYM	cis	rs9959145	1.000	rs9966118	chr18:12548858	C/T	cg14160804	chr18:12703040	PSMG2;CEP76	-0.92	-4.53	-0.42	1.74e-5	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg12011299	chr4:100065546	ADH4	0.75	7.3	0.6	8.58e-11	Alcohol dependence;
THYM	cis	rs6840360	0.571	rs7692700	chr4:152552797	C/T	cg22705602	chr4:152727874	NA	-0.8	-8.47	-0.66	3e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4803468	0.967	rs67047091	chr19:41938684	C/T	cg09537434	chr19:41945824	ATP5SL	1.02	8.94	0.68	3.1e-14	Height;
THYM	cis	rs35883536	1.000	rs12724990	chr1:101137030	G/A	cg06223162	chr1:101003688	GPR88	0.63	4.79	0.44	6.24e-6	Monocyte count;
THYM	cis	rs853679	1.000	rs1936365	chr6:28268452	C/G	cg17849569	chr6:28058911	ZSCAN12L1	-0.73	-4.61	-0.43	1.27e-5	Depression;
THYM	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9900497	0.504	rs2228100	chr17:19642952	C/G	cg22552966	chr17:19620595	SLC47A2	0.62	5.67	0.5	1.51e-7	Response to paliperidone in schizophrenia (CGI-S score);
THYM	cis	rs12410462	0.581	rs12402691	chr1:227543693	G/A	cg23173402	chr1:227635558	NA	0.65	5.07	0.46	1.95e-6	Major depressive disorder;
THYM	cis	rs9399401	0.925	rs1360194	chr6:142752595	A/G	cg03128060	chr6:142623767	GPR126	-0.36	-4.67	-0.43	9.85e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg03159660	chr11:2078197	NA	-0.63	-4.58	-0.43	1.43e-5	Longevity;
THYM	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg16325326	chr1:53192061	ZYG11B	0.82	7.77	0.62	9e-12	Monocyte count;
THYM	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg12386194	chr3:101231763	SENP7	0.71	5.39	0.48	5.17e-7	Colorectal cancer;
THYM	cis	rs2639990	1.000	rs2639990	chr18:72915551	T/C	cg02750262	chr18:72916776	ZADH2	1.34	6.41	0.55	5.54e-9	Vascular endothelial growth factor levels;
THYM	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg00631329	chr6:26305371	NA	0.59	5.61	0.5	2.01e-7	Mosquito bite size;
THYM	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg16586182	chr3:47516702	SCAP	0.67	5.61	0.5	1.99e-7	Colorectal cancer;
THYM	cis	rs10484885	0.878	rs72921937	chr6:90579863	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.87	-7.73	-0.62	1.13e-11	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg11764359	chr7:65958608	NA	0.66	4.69	0.43	8.98e-6	Aortic root size;
THYM	cis	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg01386294	chr6:25732093	NA	0.89	4.51	0.42	1.84e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg08885076	chr2:99613938	TSGA10	0.62	5.67	0.5	1.5e-7	Chronic sinus infection;
THYM	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg10862848	chr6:42927986	GNMT	-0.52	-6.87	-0.58	6.64e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1642645	0.831	rs6689536	chr1:42487523	T/C	cg06092502	chr1:42611687	NA	0.61	4.74	0.44	7.58e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs61931739	0.578	rs74627697	chr12:33628193	G/A	cg06521331	chr12:34319734	NA	0.62	4.47	0.42	2.13e-5	Morning vs. evening chronotype;
THYM	cis	rs662064	0.748	rs2506889	chr1:10596022	C/T	cg20482658	chr1:10539492	PEX14	0.5	6.32	0.54	8.53e-9	Asthma;
THYM	cis	rs2456568	0.548	rs6483280	chr11:93661592	T/C	cg17595323	chr11:93583763	C11orf90	-0.49	-5.28	-0.48	8.16e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg10150615	chr22:24372951	LOC391322	-0.84	-9.06	-0.68	1.7e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs35264875	1.000	rs72917389	chr11:68822831	C/T	cg23845249	chr11:68861649	NA	0.54	5.51	0.49	3.08e-7	Blond vs. brown hair color;
THYM	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs4523957	0.583	rs903159	chr17:2055109	C/T	cg16513277	chr17:2031491	SMG6	-1.01	-9.62	-0.7	1.06e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg06634786	chr22:41940651	POLR3H	-0.73	-5.44	-0.49	4.17e-7	Vitiligo;
THYM	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg04234412	chr22:24373322	LOC391322	-0.91	-9.19	-0.69	8.9e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs9992101	0.645	rs2870229	chr4:77281077	G/A	cg20311846	chr4:77356250	SHROOM3	-0.54	-5.96	-0.52	4.32e-8	Creatinine levels;
THYM	cis	rs9790314	0.846	rs6768818	chr3:160951648	A/G	cg03342759	chr3:160939853	NMD3	-0.95	-9.47	-0.7	2.2e-15	Morning vs. evening chronotype;
THYM	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs12282928	0.959	rs1109905	chr11:48284000	T/C	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs448720	0.875	rs338339	chr15:68201653	G/A	cg24579218	chr15:68104479	NA	-0.53	-4.73	-0.44	7.66e-6	Cognitive performance;
THYM	cis	rs7000551	0.715	rs7828610	chr8:22307326	C/T	cg12081754	chr8:22256438	SLC39A14	0.63	5.08	0.46	1.91e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs2336384	0.593	rs2295281	chr1:12059412	A/G	cg25283284	chr1:12291198	VPS13D	0.45	4.52	0.42	1.82e-5	Platelet count;
THYM	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg09354556	chr3:47051341	NA	0.44	4.57	0.42	1.46e-5	Colorectal cancer;
THYM	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg02503808	chr4:7069936	GRPEL1	-0.85	-5.8	-0.51	8.66e-8	Monocyte percentage of white cells;
THYM	cis	rs2302612	0.528	rs3821206	chr2:102817648	C/T	cg13315345	chr2:102803985	IL1RL2	0.68	4.58	0.43	1.4e-5	Serum protein levels (sST2);
THYM	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs6960043	0.738	rs6461153	chr7:15059796	G/C	cg19272540	chr7:15055459	NA	-0.57	-6.17	-0.54	1.64e-8	Type 2 diabetes;
THYM	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg24733560	chr20:60626293	TAF4	0.52	4.69	0.43	9.24e-6	Body mass index;
THYM	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg27541892	chr1:1571801	CDK11B	-0.77	-7.26	-0.6	1.07e-10	Body mass index;
THYM	cis	rs75920871	0.588	rs10892055	chr11:116868371	G/A	cg20608306	chr11:116969690	SIK3	-0.5	-5.39	-0.48	5.05e-7	Subjective well-being;
THYM	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg26441486	chr22:50317300	CRELD2	0.44	7.61	0.62	1.94e-11	Schizophrenia;
THYM	cis	rs7666738	0.688	rs4632667	chr4:98748299	A/G	cg03676636	chr4:99064102	C4orf37	0.45	4.87	0.45	4.42e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1079204	1.000	rs1017697	chr2:219170462	C/T	cg05728596	chr2:219128475	GPBAR1	1.25	5.0	0.46	2.63e-6	Smooth-surface caries;
THYM	cis	rs7975161	0.572	rs7957725	chr12:104574749	A/T	cg25273343	chr12:104657179	TXNRD1	-0.71	-4.85	-0.45	4.77e-6	Toenail selenium levels;
THYM	cis	rs7772486	0.597	rs6570732	chr6:146245151	G/A	cg23711669	chr6:146136114	FBXO30	-0.85	-8.02	-0.64	2.76e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg10760299	chr15:45669010	GATM	0.76	5.79	0.51	8.99e-8	Homoarginine levels;
THYM	cis	rs3087591	0.959	rs8076441	chr17:29405878	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.62	-5.13	-0.47	1.56e-6	Hip circumference;
THYM	cis	rs554111	0.656	rs4654893	chr1:21305596	G/C	cg00373020	chr1:21041521	KIF17	-0.53	-4.57	-0.42	1.47e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg16586182	chr3:47516702	SCAP	-0.6	-5.11	-0.46	1.63e-6	Colorectal cancer;
THYM	cis	rs4845875	0.626	rs10779764	chr1:11832311	G/C	cg25341925	chr1:11908058	NPPA	0.43	4.64	0.43	1.1e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg16068833	chr1:26644515	UBXN11;CD52	0.26	4.5	0.42	1.9e-5	Obesity-related traits;
THYM	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg09436375	chr6:42928200	GNMT	-0.44	-5.71	-0.51	1.29e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.81	-0.67	5.84e-14	Mean corpuscular volume;
THYM	trans	rs877282	0.629	rs78997110	chr10:764388	A/G	cg22713356	chr15:30763199	NA	1.4	10.24	0.72	5.16e-17	Uric acid levels;
THYM	cis	rs9902453	0.817	rs2729449	chr17:28089751	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-5.13	-0.47	1.5e-6	Coffee consumption (cups per day);
THYM	cis	rs75920871	0.588	rs10892054	chr11:116868221	C/T	cg20608306	chr11:116969690	SIK3	-0.5	-5.39	-0.48	5.05e-7	Subjective well-being;
THYM	cis	rs113835537	0.529	rs117112180	chr11:66293273	A/G	cg10315249	chr11:66235081	PELI3	0.45	4.79	0.44	6.13e-6	Airway imaging phenotypes;
THYM	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg23708337	chr7:1209742	NA	0.74	5.49	0.49	3.36e-7	Longevity;Endometriosis;
THYM	cis	rs9486719	0.843	rs2499793	chr6:96846402	A/C	cg18709589	chr6:96969512	KIAA0776	0.75	4.49	0.42	2.02e-5	Migraine;Coronary artery disease;
THYM	cis	rs41311933	1.000	rs12685289	chr9:123755383	T/A	cg13567360	chr9:123745713	C5	-1.0	-5.28	-0.48	8.32e-7	Coronary artery disease;
THYM	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg04043695	chr12:129287642	SLC15A4	0.63	5.22	0.47	1.04e-6	Systemic lupus erythematosus;
THYM	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg26314531	chr2:26401878	FAM59B	0.78	5.13	0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg16928487	chr17:17741425	SREBF1	-0.54	-5.21	-0.47	1.08e-6	Total body bone mineral density;
THYM	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg00271210	chr6:167070053	RPS6KA2	0.72	7.78	0.62	8.54e-12	Crohn's disease;
THYM	cis	rs7818345	0.967	rs7015440	chr8:19276991	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.65	0.43	1.07e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs1629083	0.738	rs590580	chr11:118066104	C/T	cg18857871	chr11:118064634	AMICA1	-0.43	-4.52	-0.42	1.78e-5	Lung cancer;
THYM	cis	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg01264106	chr22:38071602	LGALS1	0.37	4.77	0.44	6.59e-6	Fat distribution (HIV);
THYM	trans	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg25214090	chr10:38739885	LOC399744	0.95	8.14	0.64	1.53e-12	Corneal astigmatism;
THYM	cis	rs11997175	0.846	rs11776207	chr8:33765126	G/T	ch.8.33884649F	chr8:33765107	NA	-0.71	-5.6	-0.5	2.1e-7	Body mass index;
THYM	cis	rs11748327	0.576	rs17719935	chr5:4090300	A/G	cg02332293	chr5:4093632	NA	-0.67	-4.47	-0.42	2.18e-5	Myocardial infarction;
THYM	cis	rs2069036	0.951	rs2355246	chr10:16100899	A/C	cg26633223	chr10:15133461	NA	0.68	4.76	0.44	6.94e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs35160687	0.814	rs6547673	chr2:86528938	A/G	cg10973622	chr2:86423274	IMMT	0.53	5.04	0.46	2.25e-6	Night sleep phenotypes;
THYM	cis	rs713587	0.935	rs4430895	chr2:25161386	C/T	cg01884057	chr2:25150051	NA	0.6	6.11	0.53	2.23e-8	Body mass index in non-asthmatics;
THYM	cis	rs7084402	0.934	rs1649021	chr10:60286028	C/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs1728785	1.000	rs4783656	chr16:68580722	C/T	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	trans	rs2307394	0.896	rs1424949	chr2:148542963	T/G	cg25833989	chr15:74426957	ISLR2	-0.76	-7.15	-0.59	1.8e-10	Urate levels;
THYM	cis	rs3741151	0.686	rs7129990	chr11:73124441	A/G	cg12959048	chr11:73096162	RELT	-0.43	-4.5	-0.42	1.9e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.11	8.07	0.64	2.15e-12	Cognitive test performance;
THYM	cis	rs4780401	0.609	rs11639945	chr16:11824056	T/G	cg01061890	chr16:11836724	TXNDC11	-0.7	-5.69	-0.5	1.42e-7	Rheumatoid arthritis;
THYM	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg07169764	chr2:136633963	MCM6	0.67	6.25	0.54	1.18e-8	Mosquito bite size;
THYM	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg00071950	chr4:10020882	SLC2A9	-0.55	-4.78	-0.44	6.41e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1003719	0.742	rs8129231	chr21:38501034	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-4.75	-0.44	7.3e-6	Eye color traits;
THYM	cis	rs6450176	0.585	rs255761	chr5:53321956	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.91	-7.36	-0.6	6.67e-11	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg15247329	chr7:2764246	NA	-0.65	-5.39	-0.48	5.14e-7	Height;
THYM	cis	rs17253792	0.822	rs113350960	chr14:56087713	G/A	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs6570726	0.935	rs384453	chr6:145815145	G/C	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg03929089	chr4:120376271	NA	-1.02	-12.97	-0.8	9.51e-23	Height;
THYM	cis	rs2120243	0.539	rs7617727	chr3:157105558	A/C	cg24825693	chr3:157122686	VEPH1	0.48	4.67	0.43	9.96e-6	Hepatocellular carcinoma in hepatitis B infection;
THYM	cis	rs4285028	0.948	rs2877560	chr3:121699238	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.73	-5.04	-0.46	2.26e-6	Multiple sclerosis;
THYM	cis	rs17443541	0.507	rs6755597	chr2:200451440	A/G	cg01795955	chr2:200468626	NA	-0.73	-4.86	-0.45	4.61e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg22875332	chr1:76189707	ACADM	0.88	9.09	0.68	1.44e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2282032	0.527	rs8009799	chr14:90766365	A/G	cg14092571	chr14:90743983	NA	0.64	6.32	0.54	8.28e-9	Longevity;
THYM	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2777491	0.872	rs61037359	chr15:41585926	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.13	-12.36	-0.79	1.76e-21	Ulcerative colitis;
THYM	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg05973401	chr12:123451056	ABCB9	0.65	4.7	0.43	8.64e-6	Platelet count;
THYM	cis	rs17453880	0.929	rs6860209	chr5:152049547	A/G	cg12297329	chr5:152029980	NA	-0.59	-4.48	-0.42	2.06e-5	Subjective well-being;
THYM	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg10515332	chr4:99064459	C4orf37	0.72	5.7	0.5	1.35e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs12627970	0.565	rs5757613	chr22:39715262	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.61	4.68	0.43	9.61e-6	Inflammatory bowel disease;
THYM	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg22974920	chr21:40686053	BRWD1	-0.58	-4.58	-0.43	1.4e-5	Cognitive function;
THYM	cis	rs3764563	1.000	rs4239617	chr19:15741537	C/T	cg20725493	chr19:15740067	CYP4F8	-1.02	-4.62	-0.43	1.2e-5	Inflammatory biomarkers;
THYM	cis	rs6593803	0.553	rs11582163	chr1:147167854	G/T	cg06627043	chr1:147838662	NA	0.51	4.75	0.44	7.16e-6	Methotrexate-induced interstitial lung disease in rheumatoid arthritis;
THYM	cis	rs28647808	1.000	rs28478220	chr9:136273312	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs6964587	1.000	rs6942649	chr7:91594510	A/G	cg17063962	chr7:91808500	NA	0.76	5.21	0.47	1.1e-6	Breast cancer;
THYM	cis	rs4722585	0.764	rs4259314	chr7:26182214	A/G	cg07876897	chr7:26191696	NFE2L3	-0.64	-5.21	-0.47	1.1e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs12188164	0.965	rs55948934	chr5:423671	C/T	cg26850624	chr5:429559	AHRR	-0.7	-5.5	-0.49	3.15e-7	Cystic fibrosis severity;
THYM	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg20283391	chr11:68216788	NA	-0.62	-4.6	-0.43	1.3e-5	Total body bone mineral density;
THYM	cis	rs12216545	0.765	rs2140142	chr7:150249068	T/C	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg14186256	chr22:23484241	RTDR1	0.97	9.46	0.7	2.38e-15	Bone mineral density;
THYM	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg02725872	chr8:58115012	NA	-1.11	-6.84	-0.57	7.55e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg18898632	chr2:242989856	NA	-0.66	-4.46	-0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg07690219	chr3:49449608	TCTA;RHOA	-0.69	-4.62	-0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg14582100	chr15:45693742	SPATA5L1	0.63	5.17	0.47	1.32e-6	Homoarginine levels;
THYM	cis	rs62070183	0.766	rs62070229	chr17:31227593	A/G	cg02981443	chr17:31254875	TMEM98	-0.53	-4.72	-0.44	8.17e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs1003719	0.715	rs2835657	chr21:38565064	T/C	cg01329690	chr21:38580129	DSCR9	-0.4	-5.64	-0.5	1.74e-7	Eye color traits;
THYM	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg19016782	chr12:123741754	C12orf65	-0.69	-4.5	-0.42	1.94e-5	Neutrophil percentage of white cells;
THYM	cis	rs10489525	0.583	rs12034918	chr1:115626285	C/T	cg01522456	chr1:115632236	TSPAN2	0.69	4.63	0.43	1.18e-5	Autism;
THYM	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.66	-4.47	-0.42	2.16e-5	Body mass index;
THYM	cis	rs990171	1.000	rs6705001	chr2:103076210	A/G	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.13	-0.47	1.5e-6	Lymphocyte counts;
THYM	cis	rs7072216	0.727	rs942807	chr10:100168219	G/A	cg26618903	chr10:100175079	PYROXD2	-0.48	-4.6	-0.43	1.33e-5	Metabolite levels;
THYM	cis	rs425277	0.917	rs262656	chr1:2088754	A/C	cg13918804	chr1:2043761	PRKCZ	-0.61	-4.62	-0.43	1.19e-5	Height;
THYM	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg18252515	chr7:66147081	NA	-0.63	-4.69	-0.43	8.99e-6	Aortic root size;
THYM	cis	rs7631605	0.905	rs11708049	chr3:37261396	T/C	cg21328643	chr3:37258149	NA	-0.58	-5.57	-0.5	2.39e-7	Cerebrospinal P-tau181p levels;
THYM	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg23649088	chr2:200775458	C2orf69	0.76	5.75	0.51	1.1e-7	Schizophrenia;
THYM	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.57	-0.42	1.47e-5	Morning vs. evening chronotype;
THYM	cis	rs2073300	0.609	rs3746737	chr20:23424638	C/T	cg12062639	chr20:23401060	NAPB	1.08	5.67	0.5	1.55e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs28595532	0.920	rs116106661	chr4:119749794	A/G	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg06028808	chr11:68637592	NA	0.71	7.61	0.62	1.99e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg02953382	chr22:24373134	LOC391322	-0.87	-9.59	-0.7	1.24e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6087990	0.871	rs1007122	chr20:31346001	C/T	cg13636640	chr20:31349939	DNMT3B	0.91	9.05	0.68	1.75e-14	Ulcerative colitis;
THYM	cis	rs34638657	0.673	rs62045961	chr16:82199723	A/G	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.25	-0.47	9.14e-7	Lung adenocarcinoma;
THYM	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg24531977	chr5:56204891	C5orf35	-1.01	-8.29	-0.65	7.47e-13	Initial pursuit acceleration;
THYM	cis	rs9486719	0.948	rs2092095	chr6:96870864	T/G	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs1499972	0.941	rs62263115	chr3:117622116	G/A	cg07612923	chr3:117604196	NA	1.19	5.0	0.46	2.66e-6	Schizophrenia;
THYM	cis	rs2440012	0.633	rs7333955	chr13:19400622	C/A	cg05791018	chr13:19965014	NA	-0.64	-4.47	-0.42	2.2e-5	Longevity;
THYM	cis	rs7107174	0.688	rs881361	chr11:78128047	C/G	cg02023728	chr11:77925099	USP35	0.54	4.53	0.42	1.69e-5	Testicular germ cell tumor;
THYM	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7589728	0.563	rs78168096	chr2:88473575	G/A	cg04511125	chr2:88470314	THNSL2	0.66	4.62	0.43	1.21e-5	Plasma clusterin levels;
THYM	cis	rs2016266	0.859	rs10747668	chr12:53737461	C/T	cg26875137	chr12:53738046	NA	0.85	6.53	0.56	3.3e-9	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs11711311	1.000	rs9863050	chr3:113508888	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.62	-5.52	-0.49	2.89e-7	IgG glycosylation;
THYM	cis	rs4924935	1.000	rs6502674	chr17:18776897	A/G	cg26378065	chr17:18585709	ZNF286B	0.69	5.19	0.47	1.17e-6	Pancreatic cancer;
THYM	cis	rs12188164	1.000	rs72717410	chr5:428785	A/T	cg14137381	chr5:502291	SLC9A3	-0.62	-4.57	-0.42	1.45e-5	Cystic fibrosis severity;
THYM	cis	rs7200543	0.883	rs4985148	chr16:15147788	A/C	cg01933576	chr16:15083564	PDXDC1	-0.95	-7.97	-0.63	3.5e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs12134245	0.776	rs12124682	chr1:91995542	A/G	cg25838465	chr1:92012736	NA	-0.9	-8.55	-0.66	2.09e-13	Breast cancer;
THYM	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg09877947	chr5:131593287	PDLIM4	0.67	5.56	0.5	2.51e-7	Acylcarnitine levels;
THYM	cis	rs514406	0.698	rs11206055	chr1:53436632	A/T	cg16325326	chr1:53192061	ZYG11B	-0.69	-5.67	-0.5	1.56e-7	Monocyte count;
THYM	cis	rs2898681	1.000	rs4864690	chr4:53750771	T/A	cg00791764	chr4:53727839	RASL11B	0.48	5.78	0.51	9.28e-8	Optic nerve measurement (cup area);
THYM	cis	rs9527	0.590	rs10883834	chr10:104881402	T/C	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs2109514	1.000	rs2109514	chr7:116159961	G/A	cg12739419	chr7:116140593	CAV2	-0.47	-4.57	-0.42	1.44e-5	Prevalent atrial fibrillation;
THYM	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg12011299	chr4:100065546	ADH4	0.75	7.3	0.6	8.58e-11	Alcohol dependence;
THYM	cis	rs3892630	0.878	rs7246451	chr19:33209614	C/G	cg22980127	chr19:33182716	NUDT19	1.15	9.47	0.7	2.23e-15	Red blood cell traits;
THYM	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg14004847	chr7:1930337	MAD1L1	-0.7	-5.58	-0.5	2.27e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg08125733	chr17:73851984	WBP2	0.85	5.75	0.51	1.1e-7	Psoriasis;
THYM	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs4430311	0.723	rs7548254	chr1:243891570	C/T	cg25706552	chr1:244017396	NA	-0.58	-5.05	-0.46	2.17e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg26384229	chr12:38710491	ALG10B	-0.9	-7.35	-0.6	6.77e-11	Morning vs. evening chronotype;
THYM	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg23803603	chr1:2058230	PRKCZ	0.59	4.56	0.42	1.52e-5	Height;
THYM	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg24397884	chr7:158709396	WDR60	-0.42	-4.86	-0.45	4.64e-6	Height;
THYM	cis	rs4460079	0.531	rs11943440	chr4:114835504	C/T	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg26384229	chr12:38710491	ALG10B	-0.87	-7.26	-0.6	1.06e-10	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg14972814	chr11:95582409	MTMR2	-0.78	-6.61	-0.56	2.25e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg06009448	chr7:1102226	C7orf50	0.53	5.55	0.49	2.6e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10463554	0.927	rs158250	chr5:102406779	G/C	cg23492399	chr5:102201601	PAM	-0.68	-5.13	-0.47	1.56e-6	Parkinson's disease;
THYM	cis	rs4481887	0.741	rs6681758	chr1:248540413	T/A	cg00666640	chr1:248458726	OR2T12	0.55	4.73	0.44	7.65e-6	Common traits (Other);
THYM	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg00254258	chr1:3105189	PRDM16	-0.65	-5.57	-0.5	2.32e-7	Migraine;
THYM	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	9.38	0.69	3.49e-15	Chronic sinus infection;
THYM	cis	rs7943358	1.000	rs2068011	chr11:15685678	C/G	cg11966998	chr11:15692519	NA	0.48	4.86	0.45	4.7e-6	Gut microbiome composition (summer);
THYM	cis	rs1357245	0.631	rs12330906	chr3:27096656	T/C	cg03895047	chr3:27114861	NA	0.49	4.58	0.43	1.42e-5	Breast cancer;
THYM	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	cis	rs752010	0.695	rs10890156	chr1:42108090	T/C	cg06885757	chr1:42089581	HIVEP3	0.49	5.95	0.52	4.46e-8	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg03709012	chr19:19516395	GATAD2A	0.76	6.05	0.53	2.87e-8	Tonsillectomy;
THYM	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg15704280	chr7:45808275	SEPT13	-1.02	-13.18	-0.8	3.51e-23	Height;
THYM	cis	rs7551222	0.721	rs4252717	chr1:204512100	T/C	cg20240347	chr1:204465584	NA	-0.51	-4.54	-0.42	1.64e-5	Schizophrenia;
THYM	cis	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg24692254	chr21:30365293	RNF160	-0.79	-4.48	-0.42	2.07e-5	Cognitive test performance;
THYM	cis	rs854765	0.583	rs7214002	chr17:17852104	G/C	cg04398451	chr17:18023971	MYO15A	-0.8	-7.37	-0.6	6.13e-11	Total body bone mineral density;
THYM	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg02725872	chr8:58115012	NA	-1.15	-7.75	-0.62	1.01e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	10.54	0.73	1.14e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4499344	0.920	rs2868149	chr19:33086096	C/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.77	-5.45	-0.49	3.92e-7	Mean platelet volume;
THYM	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg03806693	chr22:41940476	POLR3H	1.19	10.28	0.73	4.12e-17	Vitiligo;
THYM	cis	rs514406	0.861	rs11206026	chr1:53281708	G/A	cg25767906	chr1:53392781	SCP2	-0.53	-5.29	-0.48	7.84e-7	Monocyte count;
THYM	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg22166914	chr1:53195759	ZYG11B	-0.8	-8.04	-0.64	2.5e-12	Monocyte count;
THYM	cis	rs4746818	1.000	rs6480383	chr10:70890482	C/T	cg04149295	chr10:70884716	VPS26A	0.84	5.92	0.52	5.05e-8	Left atrial antero-posterior diameter;
THYM	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg00599163	chr2:162100495	NA	0.83	7.68	0.62	1.41e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs17854409	0.803	rs1063246	chr20:61472116	G/A	cg05147244	chr20:61493195	TCFL5	0.9	4.96	0.45	3.07e-6	Obesity-related traits;
THYM	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg25358565	chr5:93447407	FAM172A	-1.31	-11.22	-0.76	4.12e-19	Diabetic retinopathy;
THYM	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg10047753	chr17:41438598	NA	1.0	8.45	0.65	3.4e-13	Menopause (age at onset);
THYM	cis	rs7191700	0.509	rs416603	chr16:11364079	A/T	cg00044050	chr16:11439710	C16orf75	-0.63	-4.89	-0.45	4.15e-6	Multiple sclerosis;
THYM	cis	rs6964587	0.692	rs4729018	chr7:91644613	C/T	cg17063962	chr7:91808500	NA	0.94	8.14	0.64	1.53e-12	Breast cancer;
THYM	cis	rs4940575	0.786	rs6567327	chr18:60840750	G/A	cg25271770	chr18:61057090	VPS4B	0.82	4.92	0.45	3.69e-6	Breast cancer;
THYM	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs4396968	0.891	rs10003525	chr4:47088349	T/C	cg12205729	chr4:46391694	GABRA2	-0.7	-4.49	-0.42	2.03e-5	Cervical cancer;
THYM	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-5.61	-0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg25767906	chr1:53392781	SCP2	0.58	5.84	0.51	7.3e-8	Monocyte count;
THYM	cis	rs877282	0.583	rs10904566	chr10:821662	C/G	cg10556349	chr10:835070	NA	-0.84	-5.48	-0.49	3.43e-7	Uric acid levels;
THYM	cis	rs8016982	0.674	rs6574631	chr14:81675772	C/T	cg01989461	chr14:81687754	GTF2A1	0.86	7.64	0.62	1.67e-11	Schizophrenia;
THYM	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg07570687	chr10:102243282	WNT8B	0.76	6.83	0.57	8.09e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg06618935	chr21:46677482	NA	-0.96	-9.3	-0.69	5.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6011002	1.000	rs75897888	chr20:62303558	C/G	cg08432509	chr20:62317768	RTEL1	0.69	4.47	0.42	2.14e-5	Dental caries;
THYM	cis	rs34638657	0.732	rs4889477	chr16:82201302	C/T	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.25	-0.47	9.14e-7	Lung adenocarcinoma;
THYM	cis	rs752010	0.523	rs943376	chr1:42122117	A/G	cg06885757	chr1:42089581	HIVEP3	0.65	8.75	0.67	7.64e-14	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03517284	chr6:25882590	NA	1.01	9.24	0.69	6.85e-15	Blood metabolite levels;
THYM	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg26384229	chr12:38710491	ALG10B	0.97	7.44	0.61	4.48e-11	Bladder cancer;
THYM	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg25554036	chr4:6271136	WFS1	0.59	5.47	0.49	3.68e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs595982	0.702	rs623520	chr19:49369943	A/G	cg19746536	chr19:49375674	PPP1R15A	1.31	17.78	0.88	5.55e-32	Red cell distribution width;
THYM	cis	rs6032067	0.777	rs13044826	chr20:43801865	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.52	-5.69	-0.5	1.42e-7	Blood protein levels;
THYM	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg06238570	chr21:40685208	BRWD1	-0.73	-6.27	-0.54	1.05e-8	Menarche (age at onset);
THYM	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg09549813	chr16:4587862	C16orf5	-0.59	-6.82	-0.57	8.32e-10	Schizophrenia;
THYM	cis	rs9644630	1.000	rs9644629	chr8:19369290	T/C	cg01280390	chr8:19363452	CSGALNACT1	0.78	8.32	0.65	6.36e-13	Oropharynx cancer;
THYM	cis	rs34912216	0.551	rs13230345	chr7:4118584	G/A	cg03141780	chr7:4150753	SDK1	0.62	4.61	0.43	1.25e-5	Motion sickness;
THYM	cis	rs17152411	0.817	rs4478950	chr10:126596425	T/C	cg07906193	chr10:126599966	NA	0.7	4.7	0.43	8.65e-6	Height;
THYM	cis	rs28595532	0.920	rs114213539	chr4:119758794	G/C	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg08133631	chr1:26527909	CATSPER4	-0.55	-4.47	-0.42	2.17e-5	Obesity-related traits;
THYM	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13326165	0.543	rs11707056	chr3:52321976	C/A	cg08438690	chr3:52279403	PPM1M	-0.89	-5.12	-0.46	1.62e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg27129171	chr3:47204927	SETD2	0.69	5.56	0.5	2.51e-7	Birth weight;
THYM	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg14456004	chr13:21872349	NA	-1.26	-10.58	-0.74	9.76e-18	White matter hyperintensity burden;
THYM	cis	rs1448094	0.511	rs2405623	chr12:86153466	G/A	cg02569458	chr12:86230093	RASSF9	-0.61	-5.12	-0.47	1.57e-6	Major depressive disorder;
THYM	cis	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg00495681	chr13:53174319	NA	0.74	6.36	0.55	6.93e-9	Lewy body disease;
THYM	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg27446573	chr6:127587934	RNF146	0.92	7.36	0.6	6.45e-11	Breast cancer;
THYM	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg12599982	chr1:44399894	ARTN	0.58	4.7	0.43	8.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg26384229	chr12:38710491	ALG10B	1.02	8.22	0.64	1.05e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg12863693	chr15:85201151	NMB	0.62	5.42	0.49	4.52e-7	Schizophrenia;
THYM	cis	rs4951018	0.526	rs6693913	chr1:205654061	G/C	cg07167872	chr1:205819463	PM20D1	-0.62	-4.66	-0.43	1.05e-5	Prostate-specific antigen levels;
THYM	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg17063962	chr7:91808500	NA	1.14	12.62	0.79	4.97e-22	Breast cancer;
THYM	cis	rs6665290	0.669	rs34267809	chr1:227176162	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.08	-12.43	-0.79	1.26e-21	Myeloid white cell count;
THYM	cis	rs9660180	0.967	rs12034740	chr1:1728969	C/A	cg20999797	chr1:1681921	NA	0.5	5.26	0.47	8.96e-7	Body mass index;
THYM	cis	rs16866061	1.000	rs72972378	chr2:225372562	A/G	cg22455342	chr2:225449267	CUL3	0.68	4.88	0.45	4.23e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs9880211	0.821	rs9832813	chr3:136065565	A/G	cg21827317	chr3:136751795	NA	-0.58	-4.64	-0.43	1.1e-5	Body mass index;Height;
THYM	cis	rs61990749	0.597	rs8003691	chr14:78211225	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.02	0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg16006841	chr5:176797999	RGS14	-0.52	-5.85	-0.51	6.93e-8	Urate levels in lean individuals;
THYM	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs11608355	0.576	rs1477117	chr12:109888779	A/G	cg11367159	chr12:110044531	NA	-0.6	-4.54	-0.42	1.66e-5	Neuroticism;
THYM	cis	rs7584330	0.740	rs10184904	chr2:238428186	G/C	cg16989719	chr2:238392110	NA	-0.5	-4.95	-0.45	3.16e-6	Prostate cancer;
THYM	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.73	-5.9	-0.52	5.54e-8	Tonsillectomy;
THYM	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9733	0.650	rs11204668	chr1:150543686	G/A	cg13175981	chr1:150552382	MCL1	0.76	5.33	0.48	6.47e-7	Tonsillectomy;
THYM	trans	rs9929218	0.529	rs11075694	chr16:68730366	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.06	13.03	0.8	7.1e-23	Colorectal cancer;
THYM	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg24531977	chr5:56204891	C5orf35	0.73	5.92	0.52	5.12e-8	Initial pursuit acceleration;
THYM	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg27211696	chr2:191398769	TMEM194B	0.84	8.28	0.65	7.62e-13	Pulse pressure;
THYM	cis	rs7071206	1.000	rs7071206	chr10:79401316	C/T	cg07817648	chr10:79422355	NA	0.65	4.99	0.46	2.69e-6	Bone mineral density;
THYM	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.07	-0.46	1.97e-6	Bipolar disorder;
THYM	cis	rs2507	0.578	rs3816197	chr15:74282880	C/T	cg17221444	chr15:74284820	STOML1	-0.58	-4.74	-0.44	7.48e-6	Coronary artery disease;
THYM	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg07636037	chr3:49044803	WDR6	0.97	9.94	0.71	2.24e-16	Parkinson's disease;
THYM	cis	rs2997447	0.846	rs61775419	chr1:26395539	C/T	cg03844060	chr1:26490628	NA	0.66	4.5	0.42	1.96e-5	QRS complex (12-leadsum);
THYM	cis	rs9914544	0.545	rs1037037	chr17:18765021	A/G	cg26378065	chr17:18585709	ZNF286B	0.6	4.71	0.43	8.56e-6	Educational attainment (years of education);
THYM	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg15604051	chr3:44754201	ZNF502	-0.6	-5.32	-0.48	6.91e-7	Depressive symptoms;
THYM	trans	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg19862616	chr7:65841803	NCRNA00174	1.09	12.64	0.79	4.47e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg26028573	chr6:26043587	HIST1H2BB	0.52	4.59	0.43	1.35e-5	Blood metabolite levels;
THYM	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg19318889	chr4:1322082	MAEA	0.55	4.95	0.45	3.27e-6	Longevity;
THYM	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg05368731	chr17:41323189	NBR1	1.22	10.98	0.75	1.35e-18	Menopause (age at onset);
THYM	cis	rs6456156	0.774	rs2021999	chr6:167529766	G/C	cg09487078	chr6:167525398	CCR6	-0.44	-4.92	-0.45	3.63e-6	Primary biliary cholangitis;
THYM	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg18402987	chr7:1209562	NA	1.03	6.06	0.53	2.77e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs198426	0.506	rs11230767	chr11:61426932	G/A	cg23976388	chr11:61510081	DAGLA	0.52	4.99	0.46	2.7e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
THYM	cis	rs596169	0.655	rs676386	chr1:219111758	C/G	cg19270308	chr1:218458869	RRP15	1.24	4.52	0.42	1.81e-5	Intraocular pressure;
THYM	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs78579285	0.544	rs11549835	chr16:88781073	G/A	cg04002220	chr16:89598305	SPG7	0.65	4.73	0.44	7.78e-6	Joint mobility (Beighton score);
THYM	cis	rs1445130	0.786	rs16985390	chr2:18837158	C/A	cg21927971	chr2:17837235	VSNL1	0.82	4.6	0.43	1.3e-5	Bulimia nervosa;
THYM	cis	rs2806561	0.894	rs628106	chr1:23537685	C/T	cg19743168	chr1:23544995	NA	0.68	7.55	0.61	2.67e-11	Height;
THYM	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs9658691	0.607	rs9658788	chr10:90776486	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.88	-5.86	-0.52	6.56e-8	Mosquito bite size;
THYM	cis	rs6840360	0.615	rs72728171	chr4:152469372	C/A	cg22705602	chr4:152727874	NA	-0.71	-7.43	-0.61	4.71e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg19761014	chr17:28927070	LRRC37B2	0.8	4.73	0.44	7.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg23422044	chr7:1970798	MAD1L1	-0.77	-5.3	-0.48	7.56e-7	Bipolar disorder;
THYM	cis	rs514406	0.893	rs1242330	chr1:53396842	T/G	cg06600287	chr1:53387719	ECHDC2	-0.31	-5.11	-0.46	1.68e-6	Monocyte count;
THYM	cis	rs9796	0.870	rs3900905	chr15:41260801	G/A	cg21153102	chr15:41252147	NA	-0.68	-6.31	-0.54	8.8e-9	Menopause (age at onset);
THYM	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	trans	rs8073060	0.544	rs9912939	chr17:34005264	T/G	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs2898681	0.561	rs6855240	chr4:53740787	G/A	cg21521518	chr4:53727714	RASL11B	0.61	5.4	0.48	4.9e-7	Optic nerve measurement (cup area);
THYM	cis	rs13315871	0.929	rs13080398	chr3:58300282	A/G	cg00563845	chr3:58318305	PXK	0.59	5.03	0.46	2.29e-6	Cholesterol, total;
THYM	cis	rs6835098	0.924	rs12639929	chr4:174156538	C/T	cg08422745	chr4:174089978	GALNT7	-1.0	-7.84	-0.63	6.46e-12	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg14582100	chr15:45693742	SPATA5L1	0.59	4.91	0.45	3.79e-6	Homoarginine levels;
THYM	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg20242066	chr2:136595261	LCT	-0.59	-7.25	-0.6	1.09e-10	Mosquito bite size;
THYM	cis	rs17641971	0.684	rs7835336	chr8:49957895	A/G	cg00325661	chr8:49890786	NA	0.62	4.66	0.43	1.04e-5	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs240764	0.817	rs240110	chr6:101059629	T/C	cg21058520	chr6:100914733	NA	-0.57	-5.02	-0.46	2.46e-6	Neuroticism;
THYM	cis	rs8048589	1.000	rs9925009	chr16:12186352	T/A	cg01990910	chr16:12207648	SNX29	-0.43	-4.58	-0.43	1.39e-5	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	trans	rs11186	0.556	rs72906358	chr2:189962199	A/G	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	cis	rs2456568	0.771	rs8181530	chr11:93638678	G/A	cg17595323	chr11:93583763	C11orf90	-0.58	-6.09	-0.53	2.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs9875589	0.509	rs12330714	chr3:14040342	A/T	cg03204825	chr3:13978759	TPRXL	-0.55	-4.78	-0.44	6.32e-6	Ovarian reserve;
THYM	cis	rs12142240	0.698	rs17361763	chr1:46810670	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs8018808	0.935	rs2091916	chr14:77914752	A/G	cg20045696	chr14:77926864	AHSA1	0.5	4.46	0.42	2.27e-5	Myeloid white cell count;
THYM	cis	rs11696845	0.666	rs13042905	chr20:43379454	T/C	cg09357268	chr20:43379437	KCNK15	0.48	4.74	0.44	7.44e-6	Obesity-related traits;
THYM	cis	rs4242434	0.927	rs35952885	chr8:22491622	T/G	cg21658235	chr8:22456391	C8orf58	0.6	5.45	0.49	3.92e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2404602	0.647	rs11072607	chr15:76908529	C/T	cg23625390	chr15:77176239	SCAPER	-0.94	-6.6	-0.56	2.35e-9	Blood metabolite levels;
THYM	cis	rs600806	0.850	rs10776807	chr1:109956156	A/G	cg02175308	chr1:109941060	SORT1	0.61	5.4	0.48	5e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10744422	1.000	rs7139055	chr12:123364198	A/G	cg25930673	chr12:123319894	HIP1R	0.79	4.49	0.42	1.98e-5	Schizophrenia;
THYM	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs7586879	1.000	rs11683212	chr2:25120196	T/C	cg01884057	chr2:25150051	NA	0.63	6.3	0.54	9.31e-9	Body mass index;
THYM	cis	rs758324	0.732	rs154733	chr5:131472366	C/T	cg16205897	chr5:131564050	P4HA2	0.52	4.6	0.43	1.29e-5	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs546131	0.600	rs502857	chr11:34854662	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.58	4.6	0.43	1.33e-5	Lung disease severity in cystic fibrosis;
THYM	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg24874828	chr4:187887005	NA	-0.72	-7.44	-0.61	4.48e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4731207	0.596	rs7786384	chr7:124577270	C/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs72627123	0.867	rs77321049	chr14:74455219	G/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	4.87	0.45	4.38e-6	Morning vs. evening chronotype;
THYM	cis	rs6964587	0.692	rs17672805	chr7:91573466	A/G	cg17063962	chr7:91808500	NA	-1.04	-9.32	-0.69	4.62e-15	Breast cancer;
THYM	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg02176678	chr2:219576539	TTLL4	0.72	7.17	0.59	1.63e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg08999081	chr20:33150536	PIGU	-0.57	-5.09	-0.46	1.8e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs911555	0.570	rs752624	chr14:104020454	T/C	cg12935359	chr14:103987150	CKB	-0.52	-6.33	-0.54	8.21e-9	Intelligence (multi-trait analysis);
THYM	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg22307297	chr20:60903441	LAMA5	-0.54	-4.76	-0.44	6.8e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs2985684	0.901	rs7146248	chr14:50112067	C/T	cg02151108	chr14:50098012	C14orf104	-0.68	-5.5	-0.49	3.24e-7	Carotid intima media thickness;
THYM	cis	rs17401966	1.000	rs12132635	chr1:10430479	G/A	cg19773385	chr1:10388646	KIF1B	-0.65	-4.72	-0.44	8.03e-6	Hepatocellular carcinoma;
THYM	cis	rs8018808	0.905	rs7142380	chr14:77931231	T/C	cg20045696	chr14:77926864	AHSA1	0.5	4.54	0.42	1.63e-5	Myeloid white cell count;
THYM	cis	rs2295499	0.643	rs2298965	chr4:2699655	C/G	cg14003022	chr4:3043019	NA	-0.51	-4.54	-0.42	1.65e-5	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs2845885	0.793	rs35927325	chr11:63882495	C/T	cg15432711	chr11:63952213	STIP1	0.62	4.91	0.45	3.72e-6	Body mass index;
THYM	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg20607798	chr8:58055168	NA	-0.82	-4.48	-0.42	2.09e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs7927771	0.524	rs10742814	chr11:47554337	G/A	cg18512352	chr11:47633146	NA	0.41	4.67	0.43	1.01e-5	Subjective well-being;
THYM	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg08999081	chr20:33150536	PIGU	-0.77	-6.95	-0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs2276314	0.512	rs1789506	chr18:33625370	G/A	cg19628046	chr18:33552617	C18orf21	-0.65	-4.98	-0.46	2.8e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.75	5.13	0.47	1.55e-6	Height;
THYM	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg23758822	chr17:41437982	NA	1.18	11.13	0.75	6.64e-19	Menopause (age at onset);
THYM	cis	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.62	0.43	1.23e-5	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4810479	0.513	rs3746506	chr20:44586036	G/A	cg04940435	chr20:44420291	WFDC3;DNTTIP1	0.47	5.11	0.46	1.64e-6	Metabolite levels;
THYM	cis	rs10214930	1.000	rs10241783	chr7:27857520	A/G	cg04422003	chr7:28448295	CREB5	-0.62	-4.62	-0.43	1.21e-5	Hypospadias;
THYM	cis	rs6499129	0.571	rs12051249	chr16:67241427	A/G	cg03615565	chr16:67572595	FAM65A	0.56	4.66	0.43	1.02e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg05738196	chr6:26577821	NA	0.83	8.34	0.65	5.8e-13	Intelligence (multi-trait analysis);
THYM	cis	rs1371867	0.875	rs1962901	chr8:101326428	A/G	cg06636551	chr8:101224915	SPAG1	-0.63	-6.33	-0.54	8.05e-9	Atrioventricular conduction;
THYM	cis	rs12530845	0.943	rs11984203	chr7:135325947	C/T	cg23117316	chr7:135346802	PL-5283	0.68	6.15	0.53	1.79e-8	Red blood cell traits;
THYM	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.66	-5.68	-0.5	1.48e-7	Renal function-related traits (BUN);
THYM	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg08999081	chr20:33150536	PIGU	0.59	5.22	0.47	1.03e-6	Height;
THYM	cis	rs2730245	0.527	rs62475645	chr7:158656825	G/A	cg11984989	chr7:158649758	WDR60	1.02	8.59	0.66	1.67e-13	Height;
THYM	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg02734326	chr4:10020555	SLC2A9	-0.61	-5.09	-0.46	1.8e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11190604	0.767	rs872290	chr10:102198879	G/A	cg16342193	chr10:102329863	NA	-0.51	-5.29	-0.48	7.96e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4523957	0.963	rs216178	chr17:2168840	T/C	cg16513277	chr17:2031491	SMG6	0.79	7.45	0.61	4.21e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.8e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg16006841	chr5:176797999	RGS14	0.49	5.78	0.51	9.61e-8	Hemoglobin concentration;Hematocrit;
THYM	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7829975	0.653	rs13259070	chr8:8690787	C/T	cg15556689	chr8:8085844	FLJ10661	0.67	5.4	0.48	4.82e-7	Mood instability;
THYM	cis	rs7833986	1.000	rs36103212	chr8:57101475	G/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	4.78	0.44	6.48e-6	Height;
THYM	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg05872129	chr22:39784769	NA	-1.09	-12.07	-0.78	6.85e-21	Intelligence (multi-trait analysis);
THYM	cis	rs9399401	0.626	rs7756434	chr6:142775295	A/G	cg04461802	chr6:142623433	GPR126	0.76	7.5	0.61	3.32e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs600806	0.888	rs444387	chr1:109851127	A/G	cg02175308	chr1:109941060	SORT1	-0.56	-4.87	-0.45	4.5e-6	Intelligence (multi-trait analysis);
THYM	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.79	6.94	0.58	4.8e-10	Tonsillectomy;
THYM	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg00383909	chr3:49044727	WDR6	1.05	5.99	0.52	3.79e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg04315214	chr1:2043799	PRKCZ	0.68	5.61	0.5	2.02e-7	Height;
THYM	cis	rs6867032	0.570	rs13166888	chr5:1982966	G/T	cg26168224	chr5:2018326	NA	-0.89	-6.57	-0.56	2.67e-9	Gut microbiome composition (winter);
THYM	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg15592062	chr6:167189543	RPS6KA2	-0.47	-4.76	-0.44	7.02e-6	Crohn's disease;
THYM	cis	rs9318086	0.712	rs9318100	chr13:24442482	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.54	-4.66	-0.43	1.02e-5	Myopia (pathological);
THYM	cis	rs11809207	0.574	rs2783630	chr1:26504741	G/A	cg00300879	chr1:26503847	CNKSR1	0.43	5.78	0.51	9.31e-8	Height;
THYM	trans	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs981844	1.000	rs55792703	chr4:154668278	C/A	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs6835098	0.961	rs28709762	chr4:174099149	T/C	cg08422745	chr4:174089978	GALNT7	-0.99	-8.26	-0.65	8.41e-13	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs6500395	0.963	rs4785528	chr16:48687908	A/C	cg04672837	chr16:48644449	N4BP1	-0.48	-4.72	-0.44	8.24e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2276314	0.857	rs7237599	chr18:33639396	T/C	cg19628046	chr18:33552617	C18orf21	0.74	5.43	0.49	4.29e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs2692947	0.696	rs2576437	chr2:96800417	T/C	cg23100626	chr2:96804247	ASTL	0.37	4.98	0.46	2.79e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg16989719	chr2:238392110	NA	-0.66	-6.0	-0.52	3.6e-8	Prostate cancer;
THYM	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg20295408	chr7:1910781	MAD1L1	-0.63	-4.74	-0.44	7.49e-6	Schizophrenia;
THYM	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2229238	0.911	rs3811448	chr1:154516578	G/A	cg21262032	chr1:154437693	IL6R	-0.62	-5.23	-0.47	1.01e-6	Coronary heart disease;
THYM	cis	rs985746	0.614	rs1370458	chr4:36800664	C/T	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs4243830	0.850	rs1114661	chr1:6596871	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.11	-7.56	-0.61	2.57e-11	Body mass index;
THYM	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.69	-6.2	-0.54	1.45e-8	Total body bone mineral density;
THYM	cis	rs870825	0.616	rs2130394	chr4:185642577	C/A	cg04058563	chr4:185651563	MLF1IP	1.06	9.58	0.7	1.33e-15	Blood protein levels;
THYM	cis	rs7771547	0.573	rs664370	chr6:36393816	A/G	cg07856975	chr6:36356162	ETV7	0.52	4.72	0.44	8.26e-6	Platelet distribution width;
THYM	cis	rs904251	0.828	rs1757174	chr6:37486695	G/A	cg01843034	chr6:37503916	NA	-0.71	-5.61	-0.5	1.98e-7	Cognitive performance;
THYM	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg21138405	chr5:131827807	IRF1	-0.83	-9.0	-0.68	2.3e-14	Asthma (sex interaction);
THYM	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.47	0.49	3.63e-7	Bipolar disorder;
THYM	cis	rs10158481	0.759	rs9438893	chr1:25488741	A/G	cg09264742	chr1:25757510	TMEM57	-0.64	-4.55	-0.42	1.57e-5	Urate levels in obese individuals;
THYM	cis	rs2637266	1.000	rs10824429	chr10:78346196	G/T	cg18941641	chr10:78392320	NA	0.72	6.33	0.54	8.03e-9	Pulmonary function;
THYM	cis	rs7107174	1.000	rs12270434	chr11:78103300	G/A	cg19901956	chr11:77921274	USP35	-0.65	-5.34	-0.48	6.41e-7	Testicular germ cell tumor;
THYM	cis	rs1642645	0.872	rs3856258	chr1:42473397	A/G	cg10197057	chr1:42612518	NA	0.44	4.81	0.44	5.59e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg24250549	chr1:154909240	PMVK	0.82	6.5	0.56	3.62e-9	Prostate cancer;
THYM	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-4.94	-0.45	3.37e-6	Lymphocyte counts;
THYM	cis	rs11621135	0.605	rs10129216	chr14:71664289	G/C	cg18506020	chr14:71758942	NA	-0.48	-4.51	-0.42	1.85e-5	Hair greying;
THYM	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	4.99	0.46	2.72e-6	Total body bone mineral density;
THYM	cis	rs854765	0.583	rs9912895	chr17:17826020	C/T	cg16928487	chr17:17741425	SREBF1	0.57	5.5	0.49	3.25e-7	Total body bone mineral density;
THYM	cis	rs61931739	0.500	rs11836207	chr12:34315177	G/A	cg10856724	chr12:34555212	NA	-0.76	-6.89	-0.58	6.13e-10	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg16342193	chr10:102329863	NA	-0.53	-5.21	-0.47	1.1e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1878931	0.597	rs2680221	chr16:3462595	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.7	-4.61	-0.43	1.26e-5	Body mass index (adult);
THYM	cis	rs36051895	0.623	rs6476957	chr9:5261324	A/G	cg02405213	chr9:5042618	JAK2	-0.96	-9.77	-0.71	5.02e-16	Pediatric autoimmune diseases;
THYM	cis	rs7084402	0.967	rs1658486	chr10:60288081	A/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs490234	0.841	rs626667	chr9:128428404	A/G	cg14078157	chr9:128172775	NA	0.62	4.9	0.45	4.01e-6	Mean arterial pressure;
THYM	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg22709100	chr7:91322751	NA	-0.71	-5.58	-0.5	2.22e-7	Breast cancer;
THYM	cis	rs16912285	0.688	rs10834313	chr11:24348447	G/C	ch.11.24196551F	chr11:24239977	NA	0.84	5.77	0.51	9.88e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg08999081	chr20:33150536	PIGU	-0.6	-5.51	-0.49	3.09e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg09034736	chr1:150693464	HORMAD1	0.51	4.49	0.42	1.98e-5	Melanoma;
THYM	cis	rs3008870	1.000	rs2755245	chr1:67487964	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.93	7.76	0.62	9.52e-12	Lymphocyte percentage of white cells;
THYM	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg25282410	chr6:160211355	TCP1;MRPL18	-1.12	-10.6	-0.74	8.67e-18	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg15693483	chr7:1102177	C7orf50	0.35	4.82	0.44	5.34e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg21433313	chr16:3507492	NAT15	0.58	4.91	0.45	3.74e-6	Body mass index (adult);
THYM	cis	rs7115242	0.702	rs672058	chr11:116764021	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.83	4.69	0.43	9.03e-6	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
THYM	cis	rs7772486	0.790	rs1062067	chr6:146207563	A/G	cg13319975	chr6:146136371	FBXO30	-0.74	-6.33	-0.54	7.91e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9296092	0.538	rs62405953	chr6:33524760	C/T	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg03278299	chr11:945202	AP2A2	-0.97	-7.61	-0.62	2e-11	Depressive symptoms;
THYM	cis	rs7100689	0.784	rs7078075	chr10:82162768	A/G	cg09936400	chr10:82049201	MAT1A	0.45	4.6	0.43	1.29e-5	Post bronchodilator FEV1;
THYM	cis	rs2692947	0.711	rs56791141	chr2:96587496	C/T	cg22654517	chr2:96458247	NA	0.59	4.45	0.42	2.32e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg13683864	chr3:40499215	RPL14	-0.88	-8.56	-0.66	1.96e-13	Renal cell carcinoma;
THYM	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.68	-5.06	-0.46	2.08e-6	Colorectal cancer;
THYM	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg02018176	chr4:1364513	KIAA1530	0.74	7.08	0.59	2.48e-10	Longevity;
THYM	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	6.16	0.53	1.74e-8	Obesity-related traits;
THYM	cis	rs4733781	0.770	rs7464885	chr8:131179235	C/T	cg16277922	chr8:131349729	ASAP1	0.66	5.2	0.47	1.16e-6	Tuberculosis;
THYM	cis	rs13082711	0.834	rs2172297	chr3:27428423	C/T	cg02860705	chr3:27208620	NA	0.66	4.66	0.43	1.02e-5	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19346786	chr7:2764209	NA	-0.71	-6.14	-0.53	1.89e-8	Height;
THYM	cis	rs7098100	0.688	rs2183271	chr10:21957229	T/C	cg10900703	chr10:21824407	MLLT10	-0.41	-4.46	-0.42	2.26e-5	Breast cancer;
THYM	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg13695892	chr22:41940480	POLR3H	-0.85	-6.94	-0.58	4.74e-10	Vitiligo;
THYM	cis	rs2915864	0.800	rs6580231	chr5:141530146	C/A	cg03486475	chr5:140796240	PCDHGA4;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	0.76	4.66	0.43	1.01e-5	Facial morphology (factor 20);
THYM	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg10589385	chr1:150898437	SETDB1	0.62	5.08	0.46	1.9e-6	Melanoma;
THYM	cis	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg09029085	chr17:47094198	IGF2BP1	0.47	6.53	0.56	3.17e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.62	5.67	0.5	1.54e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7705502	1.000	rs72812818	chr5:173356752	G/C	cg18693985	chr5:173351052	CPEB4	-0.75	-5.7	-0.5	1.35e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs6809651	0.524	rs7622914	chr3:185790895	T/C	cg00760338	chr3:185826511	ETV5	-0.91	-7.2	-0.59	1.38e-10	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
THYM	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23248424	chr5:179741104	GFPT2	-0.84	-6.59	-0.56	2.49e-9	Height;
THYM	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg06713675	chr4:122721982	EXOSC9	-0.88	-9.96	-0.71	1.96e-16	Type 2 diabetes;
THYM	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg23711669	chr6:146136114	FBXO30	0.91	9.57	0.7	1.4e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg15592062	chr6:167189543	RPS6KA2	-0.48	-4.71	-0.44	8.34e-6	Crohn's disease;
THYM	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06850241	chr22:41845214	NA	0.57	5.31	0.48	7.16e-7	Vitiligo;
THYM	cis	rs1933112	1.000	rs10753777	chr1:168527787	T/G	cg17186328	chr1:168545835	XCL1	-0.56	-4.61	-0.43	1.26e-5	Blood protein levels;
THYM	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg26384229	chr12:38710491	ALG10B	0.95	7.5	0.61	3.35e-11	Bladder cancer;
THYM	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg17264618	chr3:40429014	ENTPD3	0.53	4.99	0.46	2.69e-6	Renal cell carcinoma;
THYM	cis	rs9733	0.596	rs6587518	chr1:150661787	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs1348850	0.645	rs10181259	chr2:178428256	C/A	cg27490568	chr2:178487706	NA	0.61	5.21	0.47	1.11e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg26384229	chr12:38710491	ALG10B	-0.73	-6.01	-0.52	3.42e-8	Morning vs. evening chronotype;
THYM	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.59	-0.61	2.14e-11	Intelligence (multi-trait analysis);
THYM	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg25811766	chr13:21894605	NA	0.78	5.19	0.47	1.19e-6	White matter hyperintensity burden;
THYM	cis	rs9314614	0.763	rs2977796	chr8:6709725	G/A	cg27319216	chr8:6693540	XKR5	-0.54	-5.65	-0.5	1.69e-7	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06850241	chr22:41845214	NA	0.59	5.41	0.49	4.76e-7	Vitiligo;
THYM	cis	rs10819861	0.645	rs4078421	chr9:98863169	G/A	cg14508093	chr9:98862825	NA	-0.24	-4.57	-0.42	1.48e-5	Electrocardiographic traits;
THYM	cis	rs4930776	1.000	rs251779	chr12:5773975	G/A	cg02086166	chr12:5775618	ANO2	0.6	6.08	0.53	2.54e-8	Plasma clusterin levels;
THYM	cis	rs10089	1.000	rs3805606	chr5:127470813	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-1.02	-6.68	-0.57	1.62e-9	Ileal carcinoids;
THYM	cis	rs240764	0.853	rs11155498	chr6:101019551	G/C	cg21058520	chr6:100914733	NA	0.57	5.02	0.46	2.36e-6	Neuroticism;
THYM	cis	rs6430585	1.000	rs6732236	chr2:136501509	T/G	cg20242066	chr2:136595261	LCT	0.54	5.46	0.49	3.87e-7	Corneal structure;
THYM	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg26597838	chr10:835615	NA	1.19	7.83	0.63	6.88e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs7089973	0.668	rs61868024	chr10:116637939	A/G	cg23260525	chr10:116636907	FAM160B1	0.59	6.06	0.53	2.74e-8	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs35150201	0.818	rs7810260	chr7:135311120	G/A	cg23117316	chr7:135346802	PL-5283	-0.6	-6.88	-0.58	6.39e-10	Plateletcrit;Mean corpuscular hemoglobin;Mean platelet volume;
THYM	cis	rs6912958	0.500	rs4706287	chr6:87806496	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.28	-0.48	8.14e-7	Monocyte percentage of white cells;
THYM	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg10523679	chr1:76189770	ACADM	-0.55	-4.67	-0.43	9.97e-6	Daytime sleep phenotypes;
THYM	cis	rs6980334	1.000	rs13243992	chr7:137784790	C/T	cg06915773	chr7:137028165	PTN	0.58	4.79	0.44	6.22e-6	Blood metabolite ratios;
THYM	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg24642844	chr7:1081250	C7orf50	-1.29	-8.31	-0.65	6.62e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg27490568	chr2:178487706	NA	0.57	5.25	0.47	9.18e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg24450063	chr1:156163899	SLC25A44	1.15	9.49	0.7	2.06e-15	Testicular germ cell tumor;
THYM	cis	rs9527	0.590	rs2182348	chr10:104872684	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs11671005	0.735	rs3826682	chr19:58918748	C/T	cg18639983	chr19:58920768	ZNF584	0.59	5.0	0.46	2.63e-6	Mean platelet volume;
THYM	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg25208724	chr1:156163844	SLC25A44	1.06	8.44	0.65	3.54e-13	Testicular germ cell tumor;
THYM	cis	rs12935418	0.634	rs9934940	chr16:81049626	A/G	cg16651780	chr16:81037892	C16orf61	0.83	6.11	0.53	2.15e-8	Mean corpuscular volume;
THYM	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg02353165	chr6:42928485	GNMT	0.84	7.53	0.61	2.95e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs870825	0.932	rs28702958	chr4:185575562	C/T	cg04058563	chr4:185651563	MLF1IP	0.94	6.42	0.55	5.44e-9	Blood protein levels;
THYM	cis	rs4919694	1.000	rs58700372	chr10:104800205	T/C	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg04398451	chr17:18023971	MYO15A	-0.83	-7.67	-0.62	1.51e-11	Total body bone mineral density;
THYM	cis	rs259282	0.605	rs3760937	chr19:33106893	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.6	5.04	0.46	2.2e-6	Schizophrenia;
THYM	cis	rs8067545	1.000	rs8067545	chr17:19912710	T/C	cg08626831	chr17:20841558	NA	-0.49	-4.68	-0.43	9.4e-6	Schizophrenia;
THYM	cis	rs1467026	0.691	rs9985266	chr3:12803162	C/T	cg11882607	chr3:12858926	CAND2	0.44	4.9	0.45	4.01e-6	P wave duration;
THYM	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2562456	0.833	rs2562487	chr19:21651382	C/T	cg21751540	chr19:21541537	ZNF738	-0.78	-5.18	-0.47	1.22e-6	Pain;
THYM	cis	rs2898681	0.581	rs28618986	chr4:53677902	G/C	cg00791764	chr4:53727839	RASL11B	0.42	5.11	0.46	1.68e-6	Optic nerve measurement (cup area);
THYM	cis	rs977987	0.843	rs59465235	chr16:75483810	C/G	cg03315344	chr16:75512273	CHST6	0.73	5.95	0.52	4.4e-8	Dupuytren's disease;
THYM	cis	rs672413	0.739	rs500390	chr5:78283656	C/T	cg17845680	chr5:78281827	ARSB	-0.56	-5.15	-0.47	1.41e-6	Blood and toenail selenium levels;Blood protein levels;
THYM	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg21100191	chr22:23484243	RTDR1	0.69	6.02	0.53	3.21e-8	Bone mineral density;
THYM	cis	rs2806561	0.828	rs944509	chr1:23542242	C/T	cg19743168	chr1:23544995	NA	-0.66	-7.05	-0.59	2.92e-10	Height;
THYM	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg16325326	chr1:53192061	ZYG11B	0.84	8.36	0.65	5.23e-13	Monocyte count;
THYM	cis	rs17685	0.753	rs869806	chr7:75688623	C/T	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.56	-0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg11812906	chr14:75593930	NEK9	0.89	8.2	0.64	1.11e-12	Height;
THYM	cis	rs61990749	0.544	rs3759728	chr14:78230159	A/T	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.02	0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg23933602	chr10:16859644	RSU1	0.74	6.51	0.56	3.45e-9	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg00733288	chr13:111358885	CARS2	0.98	6.99	0.58	3.82e-10	Depressive symptoms;
THYM	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg15536230	chr21:44985092	HSF2BP	-0.42	-5.23	-0.47	1.02e-6	Mean corpuscular volume;
THYM	cis	rs7809950	1.000	rs28714607	chr7:107106253	T/C	cg23024343	chr7:107201750	COG5	-0.93	-8.24	-0.65	9.6e-13	Coronary artery disease;
THYM	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.78	5.24	0.47	9.6e-7	Gut microbiome composition (summer);
THYM	cis	rs10463554	0.963	rs12054848	chr5:102380440	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg22431228	chr1:16359049	CLCNKA	-0.53	-5.13	-0.47	1.51e-6	Dilated cardiomyopathy;
THYM	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg04362960	chr10:104952993	NT5C2	0.58	4.69	0.43	9.04e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs72627123	0.656	rs75646425	chr14:74529433	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.29	7.08	0.59	2.46e-10	Morning vs. evening chronotype;
THYM	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg07537917	chr2:241836409	C2orf54	-0.21	-4.72	-0.44	8.01e-6	Urinary metabolites;
THYM	cis	rs308447	0.522	rs309363	chr4:123658169	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.69	4.71	0.44	8.35e-6	Perceived unattractiveness to mosquitoes;
THYM	cis	rs9399401	0.634	rs984932	chr6:142803037	C/T	cg04461802	chr6:142623433	GPR126	0.5	4.89	0.45	4.07e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg03859395	chr2:55845619	SMEK2	0.6	5.46	0.49	3.72e-7	Metabolic syndrome;
THYM	cis	rs2072499	0.898	rs2758609	chr1:156202868	G/A	cg06970220	chr1:156163860	SLC25A44	0.73	6.03	0.53	3.15e-8	Testicular germ cell tumor;
THYM	trans	rs10118776	0.826	rs13301448	chr9:6201001	T/C	cg02532923	chr16:89110004	NA	1.01	7.85	0.63	6.11e-12	Small cell lung carcinoma;
THYM	cis	rs4919694	1.000	rs77318450	chr10:104733098	A/G	cg15744005	chr10:104629667	AS3MT	-0.85	-4.65	-0.43	1.08e-5	Arsenic metabolism;
THYM	cis	rs2625529	0.652	rs2957734	chr15:72261385	A/G	cg16672083	chr15:72433130	SENP8	0.49	4.48	0.42	2.09e-5	Red blood cell count;
THYM	trans	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg20587970	chr11:113659929	NA	-1.28	-9.2	-0.69	8.57e-15	Hip circumference adjusted for BMI;
THYM	cis	rs7553864	0.574	rs6576867	chr1:87615796	A/T	cg17420885	chr1:87600446	LOC339524	-0.83	-7.15	-0.59	1.75e-10	Smoking behavior;
THYM	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg11752832	chr7:134001865	SLC35B4	0.72	4.92	0.45	3.6e-6	Mean platelet volume;
THYM	cis	rs6840360	0.615	rs4696096	chr4:152475387	A/G	cg17479576	chr4:152424074	FAM160A1	-0.83	-6.46	-0.55	4.43e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7772486	0.840	rs2814867	chr6:146334030	C/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.67	-0.5	1.51e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17433780	0.504	rs6428494	chr1:89472196	C/T	cg10631373	chr1:89457642	RBMXL1;CCBL2	0.33	5.12	0.46	1.61e-6	Carotid intima media thickness;
THYM	cis	rs11025559	0.812	rs10766679	chr11:20509190	T/C	cg19653624	chr11:20408972	PRMT3	-0.76	-5.23	-0.47	1.01e-6	Pursuit maintenance gain;
THYM	cis	rs6840360	0.516	rs6535794	chr4:152302783	G/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-5.38	-0.48	5.38e-7	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs10799590	1.000	rs10915684	chr1:224828325	A/C	cg01808320	chr1:224927238	CNIH3	-0.55	-4.87	-0.45	4.46e-6	Opioid dependence;
THYM	cis	rs61931739	0.817	rs2203086	chr12:34232590	T/C	cg06521331	chr12:34319734	NA	-0.64	-5.37	-0.48	5.62e-7	Morning vs. evening chronotype;
THYM	cis	rs887829	0.570	rs11680450	chr2:234597483	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-6.51	-0.56	3.47e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg10523679	chr1:76189770	ACADM	0.91	9.71	0.71	7.02e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs3796352	1.000	rs34933390	chr3:53006265	T/G	cg04865290	chr3:52927548	TMEM110	-0.89	-4.65	-0.43	1.08e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs1018836	0.851	rs2023624	chr8:91618874	T/C	cg16814680	chr8:91681699	NA	-0.99	-9.24	-0.69	7.07e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs12580035	0.524	rs3741973	chr12:1914321	T/C	cg04012082	chr12:1905096	CACNA2D4	0.39	4.67	0.43	9.88e-6	Urate levels in lean individuals;
THYM	cis	rs73198271	0.960	rs12155530	chr8:8610964	C/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-4.48	-0.42	2.04e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08704250	chr15:31115839	NA	-0.54	-6.18	-0.54	1.59e-8	Huntington's disease progression;
THYM	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg24812749	chr6:127587940	RNF146	0.99	8.06	0.64	2.3e-12	Breast cancer;
THYM	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg03605463	chr16:89740564	NA	0.66	5.35	0.48	6.14e-7	Hemoglobin concentration;
THYM	cis	rs763014	0.898	rs35666389	chr16:629458	A/G	cg07343612	chr16:622815	PIGQ	-1.08	-11.08	-0.75	8.48e-19	Height;
THYM	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs58530613	1.000	rs58530613	chr4:124727524	T/C	cg11268546	chr4:124983615	NA	0.7	4.45	0.42	2.36e-5	Platelet count;
THYM	cis	rs57590327	0.503	rs13075250	chr3:81907952	T/C	cg07356753	chr3:81810745	GBE1	-0.74	-5.43	-0.49	4.33e-7	Extraversion;
THYM	cis	rs89107	0.576	rs6906287	chr6:118962740	T/C	cg01113488	chr6:119027122	NA	0.54	4.51	0.42	1.84e-5	Cardiac structure and function;
THYM	trans	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg19862616	chr7:65841803	NCRNA00174	1.05	11.42	0.76	1.59e-19	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs11651000	0.894	rs41519545	chr17:45811549	G/T	cg24803719	chr17:45855879	NA	-0.65	-5.39	-0.48	5.11e-7	IgG glycosylation;
THYM	cis	rs4849845	0.812	rs3931843	chr2:121039308	T/G	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs7772486	0.764	rs7762562	chr6:146158994	T/C	cg23711669	chr6:146136114	FBXO30	0.9	9.26	0.69	6.45e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1062746	0.558	rs889608	chr16:87337543	A/G	cg27365499	chr16:87376795	FBXO31	0.52	5.03	0.46	2.28e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs7818345	0.967	rs10107416	chr8:19286253	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.44	-4.8	-0.44	5.82e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs2797160	0.967	rs4897151	chr6:125993202	T/G	cg16306078	chr6:126000798	NA	-0.54	-5.61	-0.5	2.02e-7	Endometrial cancer;
THYM	cis	rs13177918	0.501	rs2545345	chr5:149843643	A/G	cg14059543	chr5:149831962	NA	-0.89	-7.38	-0.6	6.1e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg08885076	chr2:99613938	TSGA10	0.65	6.02	0.53	3.2e-8	Chronic sinus infection;
THYM	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg15448220	chr1:150897856	SETDB1	0.86	6.94	0.58	4.73e-10	Melanoma;
THYM	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg11764359	chr7:65958608	NA	0.8	6.58	0.56	2.51e-9	Aortic root size;
THYM	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg14675211	chr2:100938903	LONRF2	0.73	7.27	0.6	1.02e-10	Intelligence (multi-trait analysis);
THYM	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg04865290	chr3:52927548	TMEM110	-0.96	-5.03	-0.46	2.34e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg02221750	chr19:17393354	ANKLE1	-0.94	-8.56	-0.66	1.92e-13	Systemic lupus erythematosus;
THYM	cis	rs28595532	0.920	rs114051506	chr4:119772893	A/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs2336384	0.593	rs2295281	chr1:12059412	A/G	cg24492058	chr1:12203751	TNFRSF8	0.59	5.48	0.49	3.47e-7	Platelet count;
THYM	cis	rs3087591	0.879	rs12103564	chr17:29607243	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.69	-5.47	-0.49	3.68e-7	Hip circumference;
THYM	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs7578361	0.959	rs1196673	chr2:150335553	C/G	cg17961725	chr2:150454027	NA	0.62	4.92	0.45	3.56e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg07460842	chr6:66804631	NA	-0.9	-6.53	-0.56	3.15e-9	Exhaled nitric oxide output;
THYM	cis	rs6876348	0.516	rs258000	chr5:128318616	G/A	cg25555059	chr5:128301488	SLC27A6	-0.45	-4.62	-0.43	1.21e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6087990	0.965	rs2424904	chr20:31352316	T/C	cg13636640	chr20:31349939	DNMT3B	0.93	9.85	0.71	3.45e-16	Ulcerative colitis;
THYM	cis	rs34638657	1.000	rs34638657	chr16:82153538	A/C	cg09894383	chr16:82067445	HSD17B2	0.49	4.91	0.45	3.77e-6	Lung adenocarcinoma;
THYM	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.34	-0.48	6.24e-7	Monocyte percentage of white cells;
THYM	cis	rs757081	0.702	rs522619	chr11:17204448	A/G	cg07093617	chr11:18158918	MRGPRX3	-0.49	-4.61	-0.43	1.23e-5	Systolic blood pressure;
THYM	cis	rs6763768	0.602	rs71301827	chr3:53423343	T/C	cg16894138	chr3:53270350	TKT	0.76	5.77	0.51	9.72e-8	Bacterial meningitis;
THYM	cis	rs293526	0.959	rs2770676	chr6:83669888	T/G	cg23278060	chr6:83777448	DOPEY1	0.63	4.68	0.43	9.4e-6	Crohn's disease;
THYM	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg03676636	chr4:99064102	C4orf37	0.46	6.97	0.58	4.18e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6496667	0.865	rs7169196	chr15:90877484	C/T	cg22089800	chr15:90895588	ZNF774	0.73	4.5	0.42	1.93e-5	Rheumatoid arthritis;
THYM	cis	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg07460842	chr6:66804631	NA	-1.24	-15.46	-0.85	1.1e-27	Exhaled nitric oxide output;
THYM	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg06565975	chr8:143823917	SLURP1	-0.76	-8.91	-0.67	3.46e-14	Urinary tract infection frequency;
THYM	cis	rs3857067	0.806	rs6532471	chr4:95108584	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs3768617	0.510	rs2027083	chr1:183088330	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs57920188	0.584	rs12080562	chr1:4089697	C/A	cg20703997	chr1:4087676	NA	0.74	5.29	0.48	7.79e-7	Interleukin-17 levels;
THYM	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg18252515	chr7:66147081	NA	-0.64	-4.9	-0.45	3.89e-6	Aortic root size;
THYM	cis	rs1728785	0.792	rs1111502	chr16:68581209	A/G	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg02820040	chr2:241836501	C2orf54	-0.32	-6.66	-0.56	1.75e-9	Urinary metabolites;
THYM	cis	rs950880	0.710	rs4851011	chr2:103089678	A/G	cg03938978	chr2:103052716	IL18RAP	0.56	4.83	0.44	5.2e-6	Serum protein levels (sST2);
THYM	cis	rs4363385	0.773	rs310122	chr1:153064288	C/T	cg13444842	chr1:152974279	SPRR3	0.58	4.5	0.42	1.95e-5	Inflammatory skin disease;
THYM	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg07777115	chr5:623756	CEP72	-0.87	-5.41	-0.49	4.76e-7	Obesity-related traits;
THYM	cis	rs7917772	0.582	rs10883753	chr10:104372441	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.69	0.57	1.57e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs8013055	0.846	rs12893999	chr14:105970842	C/G	cg04429589	chr14:105992532	TMEM121	-0.46	-5.08	-0.46	1.87e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg27394845	chr17:28928406	LRRC37B2	0.98	4.83	0.44	5.31e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17125944	0.686	rs7158114	chr14:53353471	C/G	cg00686598	chr14:53173677	PSMC6	-1.01	-4.55	-0.42	1.56e-5	Alzheimer's disease (late onset);
THYM	cis	rs4631830	0.863	rs6481329	chr10:51529746	G/A	cg16070123	chr10:51489643	NA	-0.49	-4.48	-0.42	2.1e-5	Prostate-specific antigen levels;
THYM	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg16586182	chr3:47516702	SCAP	-0.71	-5.96	-0.52	4.23e-8	Colorectal cancer;
THYM	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg20891283	chr12:69753455	YEATS4	1.06	10.24	0.72	5.15e-17	Blood protein levels;
THYM	cis	rs6466832	0.506	rs73220284	chr7:122332062	C/T	cg22586324	chr7:123296098	LMOD2	-0.94	-5.1	-0.46	1.72e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs308403	0.568	rs309358	chr4:123653926	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.69	4.76	0.44	6.93e-6	Blood protein levels;
THYM	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg12408189	chr10:30722286	MAP3K8	-0.58	-4.72	-0.44	7.97e-6	Inflammatory bowel disease;
THYM	cis	rs6087771	0.662	rs6058298	chr20:30247916	C/T	cg13852791	chr20:30311386	BCL2L1	0.86	8.08	0.64	2.03e-12	Subcortical brain region volumes;Putamen volume;
THYM	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	trans	rs10118776	0.826	rs66887324	chr9:6200562	G/T	cg02532923	chr16:89110004	NA	1.01	7.85	0.63	6.11e-12	Small cell lung carcinoma;
THYM	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg23730037	chr7:158596552	ESYT2	-0.47	-4.67	-0.43	9.77e-6	Height;
THYM	cis	rs1784581	0.855	rs1893101	chr6:162384371	G/C	cg17173639	chr6:162384350	PARK2	-0.95	-9.4	-0.69	3.2e-15	Itch intensity from mosquito bite;
THYM	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.24	-0.65	9.17e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs9419702	0.568	rs9419635	chr10:133546164	C/T	cg20568497	chr10:133558893	NA	0.47	4.66	0.43	1.02e-5	Survival in rectal cancer;
THYM	cis	rs3862030	0.720	rs11593583	chr10:104228149	A/G	cg00122347	chr10:104236741	TMEM180	-0.46	-7.08	-0.59	2.44e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06634786	chr22:41940651	POLR3H	0.82	6.08	0.53	2.53e-8	Vitiligo;
THYM	cis	rs10487112	1.000	rs12704535	chr7:90050405	G/T	cg26521402	chr7:89842741	STEAP2	0.51	4.67	0.43	1.01e-5	Perceived unattractiveness to mosquitoes;
THYM	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg08017756	chr2:100939284	LONRF2	-0.74	-7.3	-0.6	8.73e-11	Intelligence (multi-trait analysis);
THYM	cis	rs977987	0.836	rs8055974	chr16:75470986	C/G	cg03315344	chr16:75512273	CHST6	0.74	6.1	0.53	2.24e-8	Dupuytren's disease;
THYM	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg05335186	chr13:53173507	NA	-0.4	-5.03	-0.46	2.36e-6	Lewy body disease;
THYM	cis	rs2985684	1.000	rs2985696	chr14:50094913	C/A	cg02151108	chr14:50098012	C14orf104	-0.67	-5.36	-0.48	5.94e-7	Carotid intima media thickness;
THYM	trans	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs3768617	0.510	rs2027075	chr1:183073266	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg03295274	chr13:50190584	NA	0.69	5.19	0.47	1.18e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg22681709	chr2:178499509	PDE11A	-0.62	-5.91	-0.52	5.41e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg21280719	chr6:42927975	GNMT	-0.53	-7.15	-0.59	1.75e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs478304	0.754	rs2004649	chr11:65380916	G/A	cg27068330	chr11:65405492	SIPA1	-0.9	-8.27	-0.65	7.96e-13	Acne (severe);
THYM	cis	rs6918586	0.658	rs198840	chr6:26112164	T/G	cg03264133	chr6:25882463	NA	0.64	4.94	0.45	3.41e-6	Schizophrenia;
THYM	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg02018176	chr4:1364513	KIAA1530	0.55	4.7	0.43	8.82e-6	Obesity-related traits;
THYM	cis	rs1580019	0.961	rs1610143	chr7:32498331	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.59	0.56	2.42e-9	Cognitive ability;
THYM	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg13695892	chr22:41940480	POLR3H	-1.06	-8.46	-0.66	3.24e-13	Vitiligo;
THYM	cis	rs539096	0.715	rs6665014	chr1:44226004	G/T	cg15962314	chr1:44399869	ARTN	-0.52	-5.02	-0.46	2.38e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12137294	0.866	rs1078362	chr1:205209530	A/G	cg17889831	chr1:205181581	DSTYK	-0.41	-5.05	-0.46	2.13e-6	Red cell distribution width;
THYM	cis	rs611744	0.647	rs10106246	chr8:109268710	T/C	cg21045802	chr8:109455806	TTC35	0.62	5.38	0.48	5.32e-7	Dupuytren's disease;
THYM	cis	rs728616	0.614	rs61860414	chr10:81730180	A/T	cg27452691	chr10:81370291	SFTPA1	0.59	4.5	0.42	1.9e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9378357	0.558	rs6909994	chr6:3293284	A/G	cg08754725	chr6:3293098	SLC22A23	-0.74	-5.0	-0.46	2.59e-6	Obesity-related traits;
THYM	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg06636001	chr8:8085503	FLJ10661	0.76	6.85	0.57	7.39e-10	Neuroticism;
THYM	cis	rs16866061	1.000	rs12470077	chr2:225334971	T/C	cg12698349	chr2:225449008	CUL3	1.1	9.52	0.7	1.78e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.73	7.01	0.58	3.48e-10	Lymphocyte counts;
THYM	cis	rs6430585	0.528	rs56064699	chr2:136595706	G/A	cg07169764	chr2:136633963	MCM6	1.24	13.19	0.8	3.49e-23	Corneal structure;
THYM	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg08000102	chr2:233561755	GIGYF2	-0.67	-5.88	-0.52	6.09e-8	Coronary artery disease;
THYM	cis	rs752010	1.000	rs4999015	chr1:42093547	G/A	cg22486000	chr1:42919398	ZMYND12	-0.42	-4.95	-0.45	3.22e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs673253	0.520	rs3791034	chr1:44145130	A/G	cg24466421	chr1:44070974	PTPRF	-0.57	-4.8	-0.44	5.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg12165864	chr7:66369176	NA	-0.65	-4.91	-0.45	3.75e-6	Aortic root size;
THYM	cis	rs11971779	0.838	rs11764161	chr7:139115198	T/C	cg07862535	chr7:139043722	LUC7L2	0.65	4.63	0.43	1.14e-5	Diisocyanate-induced asthma;
THYM	cis	rs1978968	0.956	rs2017932	chr22:18439190	C/A	cg01550578	chr22:18484421	MICAL3	0.68	5.16	0.47	1.33e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs7113850	0.541	rs75850541	chr11:24211467	C/G	ch.11.24196551F	chr11:24239977	NA	0.89	4.56	0.42	1.53e-5	Bone fracture in osteoporosis;
THYM	cis	rs6866344	0.526	rs34981407	chr5:178152195	A/C	cg10224037	chr5:178157518	ZNF354A	0.99	8.07	0.64	2.1e-12	Neutrophil percentage of white cells;
THYM	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg18876405	chr7:65276391	NA	0.62	5.54	0.49	2.66e-7	Aortic root size;
THYM	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg17294928	chr15:75287854	SCAMP5	-0.95	-8.08	-0.64	2.01e-12	Blood trace element (Zn levels);
THYM	cis	rs4631830	0.832	rs11005089	chr10:51510813	C/A	cg10326726	chr10:51549505	MSMB	0.5	5.01	0.46	2.47e-6	Prostate-specific antigen levels;
THYM	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg19774624	chr17:42201019	HDAC5	-0.85	-8.23	-0.65	9.73e-13	Total body bone mineral density;
THYM	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.92	-6.89	-0.58	5.96e-10	Electrocardiographic conduction measures;
THYM	cis	rs782590	0.967	rs782592	chr2:55843875	T/A	cg03859395	chr2:55845619	SMEK2	0.53	4.62	0.43	1.22e-5	Metabolic syndrome;
THYM	cis	rs6127978	0.702	rs6127975	chr20:55811300	G/A	cg15851418	chr20:55835831	BMP7	0.68	4.89	0.45	4.12e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg07599136	chr5:415885	AHRR	0.93	5.17	0.47	1.29e-6	Fat distribution (HIV);
THYM	cis	rs2898681	0.739	rs1047959	chr4:53739856	C/G	cg21521518	chr4:53727714	RASL11B	0.45	5.13	0.47	1.51e-6	Optic nerve measurement (cup area);
THYM	cis	rs4660261	0.526	rs2040950	chr1:44315113	G/C	cg13246856	chr1:44399776	ARTN	0.48	4.95	0.45	3.27e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.76	8.46	0.66	3.25e-13	Breast cancer;
THYM	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22590775	chr19:49891494	CCDC155	0.82	6.7	0.57	1.49e-9	Multiple sclerosis;
THYM	cis	rs2412459	0.572	rs536503	chr15:40253674	G/A	cg16127683	chr15:40268777	EIF2AK4	0.53	4.63	0.43	1.16e-5	Response to haloperidol in psychosis;
THYM	cis	rs10751667	1.000	rs10902246	chr11:953674	T/C	ch.11.42038R	chr11:967971	AP2A2	0.55	4.46	0.42	2.28e-5	Alzheimer's disease (late onset);
THYM	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg13902645	chr11:5959945	NA	-0.55	-4.82	-0.44	5.5e-6	DNA methylation (variation);
THYM	cis	rs73219805	0.759	rs3758098	chr8:26239383	C/A	cg22757399	chr8:26370552	PNMA2	-0.71	-4.82	-0.44	5.35e-6	Schizophrenia;
THYM	cis	rs4638749	0.627	rs6542753	chr2:108815852	T/A	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg03709012	chr19:19516395	GATAD2A	0.84	7.3	0.6	8.83e-11	Tonsillectomy;
THYM	cis	rs11696501	0.789	rs1487319	chr20:44295943	A/G	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	cis	rs1728785	1.000	rs1170426	chr16:68603798	C/T	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.39e-6	Ulcerative colitis;
THYM	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg06028605	chr16:24865363	SLC5A11	0.63	5.18	0.47	1.26e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12519773	0.662	rs6883741	chr5:92491481	T/A	cg18783429	chr5:92414398	NA	0.54	5.11	0.46	1.68e-6	Migraine;
THYM	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg10518543	chr12:38710700	ALG10B	-0.55	-4.57	-0.42	1.45e-5	Morning vs. evening chronotype;
THYM	cis	rs981844	0.740	rs1020702	chr4:154685712	A/C	cg09973105	chr4:154681532	RNF175	0.54	4.98	0.45	2.88e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs9420	0.884	rs673344	chr11:57657141	G/A	cg19752551	chr11:57585705	CTNND1	0.72	7.34	0.6	7.26e-11	Schizophrenia;
THYM	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg03877680	chr5:178157825	ZNF354A	0.74	4.96	0.45	3.1e-6	Neutrophil percentage of white cells;
THYM	cis	rs10882165	0.779	rs11596090	chr10:94909481	C/T	cg04755607	chr10:94000543	CPEB3	0.65	4.66	0.43	1.03e-5	Refractive error;
THYM	cis	rs40363	1.000	rs37769	chr16:3514580	C/G	cg05754148	chr16:3507555	NAT15	0.91	8.19	0.64	1.18e-12	Tuberculosis;
THYM	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg26441486	chr22:50317300	CRELD2	0.4	5.9	0.52	5.48e-8	Schizophrenia;
THYM	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg01966878	chr4:90757139	SNCA	-0.65	-5.17	-0.47	1.27e-6	Neuroticism;
THYM	cis	rs9371942	0.737	rs9384400	chr6:156281754	A/T	cg23560388	chr6:155542639	TIAM2	-0.81	-4.6	-0.43	1.28e-5	Lachrymal/Salivary gland lesion in type 1 autoimmune pancreatitis;
THYM	cis	rs12291225	0.679	rs11023172	chr11:14295367	C/G	cg19336497	chr11:14380999	RRAS2	-0.82	-9.53	-0.7	1.67e-15	Sense of smell;
THYM	cis	rs13418717	1.000	rs10084325	chr2:127670496	G/A	cg25501666	chr2:127640322	NA	1.58	6.21	0.54	1.4e-8	Heart failure;
THYM	cis	rs3771317	0.941	rs10931468	chr2:191538562	C/A	cg17118478	chr2:191543902	NAB1	-0.63	-4.45	-0.42	2.35e-5	Primary biliary cholangitis;
THYM	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg03983476	chr2:10830698	NOL10	-0.61	-5.87	-0.52	6.46e-8	Prostate cancer;
THYM	cis	rs6840360	0.571	rs4696099	chr4:152501951	C/G	cg17479576	chr4:152424074	FAM160A1	-0.78	-5.66	-0.5	1.59e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11645898	0.935	rs11641721	chr16:72155241	G/A	cg14768367	chr16:72042858	DHODH	-0.73	-5.18	-0.47	1.23e-6	Blood protein levels;
THYM	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg11494091	chr17:61959527	GH2	1.07	16.52	0.86	1.13e-29	Prudent dietary pattern;
THYM	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg14779329	chr11:130786720	SNX19	0.51	5.26	0.47	8.96e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1113500	0.836	rs2801220	chr1:108584649	A/G	cg06207961	chr1:108661230	NA	-0.71	-5.55	-0.49	2.63e-7	Growth-regulated protein alpha levels;
THYM	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.24	4.89	0.45	4.13e-6	Obesity-related traits;
THYM	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg12000587	chr17:30186630	C17orf79	0.39	4.48	0.42	2.1e-5	Hip circumference adjusted for BMI;
THYM	cis	rs9470366	0.848	rs66761782	chr6:36636080	T/C	cg11920449	chr6:36645608	CDKN1A	-0.75	-5.81	-0.51	8.32e-8	QRS duration;
THYM	cis	rs11690935	0.802	rs34636594	chr2:172911094	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.79	-5.75	-0.51	1.09e-7	Schizophrenia;
THYM	cis	rs240110	0.546	rs12525818	chr6:101263484	C/T	cg21058520	chr6:100914733	NA	-0.59	-4.61	-0.43	1.27e-5	Neuroticism;
THYM	cis	rs8067545	0.750	rs7208635	chr17:19990990	T/C	cg13482628	chr17:19912719	NA	0.58	4.85	0.45	4.75e-6	Schizophrenia;
THYM	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.55	-4.68	-0.43	9.35e-6	Platelet count;
THYM	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg07570687	chr10:102243282	WNT8B	0.76	6.78	0.57	9.91e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs6121246	0.559	rs6087771	chr20:30306724	A/G	cg13852791	chr20:30311386	BCL2L1	1.01	10.39	0.73	2.45e-17	Mean corpuscular hemoglobin;
THYM	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg12698349	chr2:225449008	CUL3	1.14	13.02	0.8	7.44e-23	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs1756650	0.528	rs2401693	chr14:87922878	C/A	cg10325478	chr14:88793021	KCNK10	-0.6	-4.57	-0.42	1.48e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
THYM	cis	rs9527	0.590	rs11191513	chr10:104772984	T/G	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs11677370	0.603	rs10174064	chr2:3849806	C/T	cg17052675	chr2:3827356	NA	-0.71	-6.57	-0.56	2.7e-9	Type 2 diabetes;
THYM	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg25251562	chr2:3704773	ALLC	0.82	6.5	0.55	3.65e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg24818145	chr4:99064322	C4orf37	0.74	5.81	0.51	8.15e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17789174	0.951	rs12596553	chr16:85104752	G/T	cg01715842	chr16:85045600	ZDHHC7	-0.44	-4.67	-0.43	9.8e-6	Dysphagia;
THYM	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg06026331	chr20:60912101	LAMA5	0.74	5.64	0.5	1.75e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2555603	1.000	rs2858134	chr13:33815503	G/A	cg07499182	chr13:33825496	STARD13	-0.52	-4.94	-0.45	3.35e-6	Body mass index in asthmatics;
THYM	cis	rs7107174	1.000	rs58565853	chr11:78036707	C/T	cg19901956	chr11:77921274	USP35	-0.67	-5.58	-0.5	2.27e-7	Testicular germ cell tumor;
THYM	cis	rs7584330	0.780	rs7582828	chr2:238378476	A/C	cg16989719	chr2:238392110	NA	0.6	5.59	0.5	2.21e-7	Prostate cancer;
THYM	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs950776	0.752	rs62010327	chr15:78892784	G/A	cg06917634	chr15:78832804	PSMA4	0.85	6.87	0.58	6.59e-10	Sudden cardiac arrest;
THYM	cis	rs10463554	0.889	rs34822	chr5:102437711	T/C	cg23492399	chr5:102201601	PAM	-0.7	-5.18	-0.47	1.24e-6	Parkinson's disease;
THYM	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg00071950	chr4:10020882	SLC2A9	-0.75	-7.53	-0.61	2.88e-11	Bone mineral density;
THYM	cis	rs2282300	0.739	rs1222208	chr11:30361377	A/C	cg09906309	chr11:30344399	C11orf46	-0.77	-5.77	-0.51	1.01e-7	Morning vs. evening chronotype;
THYM	cis	rs13064411	0.696	rs9860549	chr3:113148368	G/A	cg10517650	chr3:113235015	CCDC52	-0.54	-4.64	-0.43	1.13e-5	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg09904177	chr6:26538194	HMGN4	0.53	4.47	0.42	2.16e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2227564	0.620	rs11000787	chr10:75584383	T/C	cg00564723	chr10:75632066	CAMK2G	-0.56	-5.36	-0.48	5.9e-7	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs78761021	0.720	rs874175	chr17:9798595	T/G	cg26853458	chr17:9805074	RCVRN	0.53	4.46	0.42	2.24e-5	Type 2 diabetes;
THYM	cis	rs11122895	1.000	rs11122893	chr2:112468088	A/G	cg23262488	chr2:112468472	NA	-0.67	-9.57	-0.7	1.36e-15	Allergic sensitization;
THYM	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs733592	0.524	rs10875727	chr12:48426143	T/C	cg21466736	chr12:48725269	NA	0.45	4.89	0.45	4.07e-6	Plateletcrit;
THYM	cis	rs79387448	0.745	rs59126438	chr2:103165142	T/G	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg00071950	chr4:10020882	SLC2A9	0.75	7.49	0.61	3.45e-11	Bone mineral density;
THYM	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs4474465	1.000	rs2063729	chr11:78185969	C/T	cg02023728	chr11:77925099	USP35	0.53	4.65	0.43	1.08e-5	Alzheimer's disease (survival time);
THYM	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg11764359	chr7:65958608	NA	-0.75	-6.04	-0.53	2.97e-8	Aortic root size;
THYM	cis	rs2637266	0.935	rs2583054	chr10:78401442	A/G	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs9581857	0.579	rs7332104	chr13:27957831	C/G	cg22138327	chr13:27999177	GTF3A	-0.91	-5.11	-0.46	1.66e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg02478829	chr6:26598070	ABT1	-0.4	-5.09	-0.46	1.79e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2281845	0.929	rs2057579	chr1:201099275	T/C	cg17810781	chr1:201082982	CACNA1S	0.66	6.84	0.57	7.58e-10	Permanent tooth development;
THYM	cis	rs4474465	0.850	rs4597089	chr11:78262244	A/G	cg19901956	chr11:77921274	USP35	0.61	4.64	0.43	1.1e-5	Alzheimer's disease (survival time);
THYM	cis	rs11690935	1.000	rs312924	chr2:172564021	A/T	cg13550731	chr2:172543902	DYNC1I2	0.85	6.19	0.54	1.51e-8	Schizophrenia;
THYM	cis	rs673253	0.608	rs605709	chr1:44058467	C/T	cg24466421	chr1:44070974	PTPRF	-0.6	-5.34	-0.48	6.24e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg00990874	chr7:1149470	C7orf50	-0.56	-4.58	-0.43	1.39e-5	Longevity;Endometriosis;
THYM	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	trans	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg17830980	chr10:43048298	ZNF37B	0.82	6.99	0.58	3.81e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs4654899	0.931	rs4654727	chr1:21214735	C/T	cg01072550	chr1:21505969	NA	0.72	6.62	0.56	2.14e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs2811415	0.597	rs9827668	chr3:127775480	G/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg07936489	chr17:37558343	FBXL20	0.87	5.78	0.51	9.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs3774830	0.649	rs41268643	chr4:5469916	G/A	cg26943120	chr4:5472116	STK32B	0.55	4.66	0.43	1.04e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg14675211	chr2:100938903	LONRF2	0.75	7.78	0.62	8.53e-12	Intelligence (multi-trait analysis);
THYM	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-1.02	-9.95	-0.71	2.08e-16	Colorectal cancer;
THYM	cis	rs2290159	0.752	rs73130368	chr3:12667374	C/T	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.66	4.9	0.45	3.99e-6	Cognitive test performance;
THYM	cis	rs7267979	0.833	rs6138556	chr20:25243310	C/T	cg08601574	chr20:25228251	PYGB	0.58	4.58	0.43	1.4e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg13010199	chr12:38710504	ALG10B	-0.62	-4.5	-0.42	1.95e-5	Bladder cancer;
THYM	cis	rs13202913	0.837	rs9397052	chr6:151779228	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.89	-5.16	-0.47	1.37e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs28595532	0.920	rs115118317	chr4:119736613	C/T	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg14458575	chr2:238380390	NA	0.96	7.46	0.61	4.11e-11	Prostate cancer;
THYM	cis	rs7119	0.634	rs2667782	chr15:77862296	A/C	cg10437265	chr15:77819839	NA	-0.72	-7.52	-0.61	3.06e-11	Type 2 diabetes;
THYM	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg03609598	chr5:56110824	MAP3K1	-0.83	-5.57	-0.5	2.35e-7	Initial pursuit acceleration;
THYM	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg26850624	chr5:429559	AHRR	-0.65	-4.98	-0.46	2.79e-6	Cystic fibrosis severity;
THYM	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg14779329	chr11:130786720	SNX19	0.55	5.83	0.51	7.58e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg03806693	chr22:41940476	POLR3H	-0.83	-7.48	-0.61	3.7e-11	Neuroticism;
THYM	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg01819863	chr10:32635814	EPC1	1.02	6.49	0.55	3.83e-9	Sexual dysfunction (female);
THYM	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg24818145	chr4:99064322	C4orf37	0.7	5.43	0.49	4.24e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg23758822	chr17:41437982	NA	1.2	12.73	0.79	2.99e-22	Menopause (age at onset);
THYM	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg04315214	chr1:2043799	PRKCZ	-0.58	-4.54	-0.42	1.67e-5	Height;
THYM	cis	rs929354	1.000	rs1182384	chr7:157040642	A/G	cg05182265	chr7:156933206	UBE3C	0.64	8.1	0.64	1.81e-12	Body mass index;
THYM	cis	rs2070677	0.935	rs7907312	chr10:135417364	A/G	cg20169779	chr10:135381914	SYCE1	-0.75	-5.76	-0.51	1.03e-7	Gout;
THYM	cis	rs2066819	1.000	rs76151170	chr12:56659320	C/T	cg26714650	chr12:56694279	CS	-1.29	-6.45	-0.55	4.57e-9	Psoriasis vulgaris;
THYM	cis	rs12579753	0.917	rs10129029	chr12:82180324	G/A	cg21231944	chr12:82153410	PPFIA2	-0.68	-5.12	-0.46	1.6e-6	Resting heart rate;
THYM	cis	rs10782582	0.593	rs79552201	chr1:76215497	A/T	cg10523679	chr1:76189770	ACADM	-0.55	-4.49	-0.42	1.99e-5	Daytime sleep phenotypes;
THYM	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg26418147	chr1:205743515	RAB7L1	-0.59	-4.88	-0.45	4.32e-6	Menarche (age at onset);
THYM	cis	rs600231	0.683	rs588298	chr11:65253574	A/G	cg17120908	chr11:65337727	SSSCA1	-0.61	-4.72	-0.44	8.17e-6	Bone mineral density;
THYM	cis	rs7172809	0.599	rs11856084	chr15:77750410	T/G	cg10437265	chr15:77819839	NA	-0.5	-4.57	-0.42	1.47e-5	Glucose homeostasis traits;
THYM	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7429990	0.932	rs4293721	chr3:48045137	C/A	cg02219026	chr3:48282209	ZNF589	0.6	4.5	0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg14972814	chr11:95582409	MTMR2	-0.72	-6.08	-0.53	2.51e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06850241	chr22:41845214	NA	0.6	5.3	0.48	7.51e-7	Vitiligo;
THYM	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg12379764	chr21:47803548	PCNT	-0.83	-5.37	-0.48	5.52e-7	Testicular germ cell tumor;
THYM	cis	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.7	-5.35	-0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs790123	1.000	rs790117	chr3:122380888	C/T	cg17380795	chr3:122379686	NA	0.59	5.42	0.49	4.57e-7	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs8133932	0.724	rs11701249	chr21:47050714	G/A	cg20357416	chr21:47294739	PCBP3	0.77	4.8	0.44	5.79e-6	Schizophrenia;
THYM	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg13695892	chr22:41940480	POLR3H	-0.9	-6.65	-0.56	1.83e-9	Vitiligo;
THYM	cis	rs977987	0.806	rs35937717	chr16:75331567	C/A	cg03315344	chr16:75512273	CHST6	0.83	7.05	0.59	2.81e-10	Dupuytren's disease;
THYM	cis	rs11235843	0.706	rs11235933	chr11:73576748	C/T	cg20718724	chr11:72929382	P2RY2	0.88	4.47	0.42	2.19e-5	Hand grip strength;
THYM	cis	rs11809207	0.523	rs2783707	chr1:26504196	C/G	cg23602478	chr1:26503979	CNKSR1	0.36	4.97	0.45	2.96e-6	Height;
THYM	cis	rs1448094	0.512	rs6539924	chr12:86236935	T/C	cg02569458	chr12:86230093	RASSF9	0.58	5.04	0.46	2.22e-6	Major depressive disorder;
THYM	cis	rs6694672	0.867	rs2786114	chr1:197302717	T/C	cg13682187	chr1:196946512	CFHR5	0.87	5.08	0.46	1.9e-6	Asthma;
THYM	cis	rs3008870	0.959	rs2985810	chr1:67376162	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.95	7.79	0.62	8.27e-12	Lymphocyte percentage of white cells;
THYM	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13012494	chr21:47604986	C21orf56	-0.73	-5.03	-0.46	2.34e-6	Testicular germ cell tumor;
THYM	cis	rs714515	0.546	rs57668887	chr1:172327399	T/C	cg01573306	chr1:172330400	DNM3	-0.62	-5.42	-0.49	4.46e-7	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs860818	1.000	rs858276	chr7:23252553	A/G	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs240764	0.817	rs12214151	chr6:101159516	G/T	cg21058520	chr6:100914733	NA	0.58	5.22	0.47	1.06e-6	Neuroticism;
THYM	cis	rs7267979	0.903	rs2500400	chr20:25354705	A/G	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg24692254	chr21:30365293	RNF160	0.65	4.87	0.45	4.39e-6	Cognitive test performance;
THYM	cis	rs4664308	0.875	rs7593593	chr2:160933811	C/T	cg03641300	chr2:160917029	PLA2R1	-0.78	-6.97	-0.58	4.25e-10	Idiopathic membranous nephropathy;
THYM	cis	rs2688608	0.672	rs2633321	chr10:75693695	C/T	cg02947784	chr10:75434997	AGAP5	0.52	4.83	0.44	5.12e-6	Inflammatory bowel disease;
THYM	cis	rs259282	0.519	rs259276	chr19:33160953	C/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.93	6.28	0.54	9.98e-9	Schizophrenia;
THYM	cis	rs7267979	0.903	rs2474769	chr20:25248725	C/T	cg08601574	chr20:25228251	PYGB	0.59	4.79	0.44	6.25e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9467160	0.817	rs12194966	chr6:24437611	G/A	cg20631270	chr6:24437470	GPLD1	0.78	4.54	0.42	1.67e-5	Liver enzyme levels;
THYM	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg26384229	chr12:38710491	ALG10B	1.02	8.22	0.64	1.05e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg04944784	chr2:26401820	FAM59B	-1.03	-8.32	-0.65	6.39e-13	Gut microbiome composition (summer);
THYM	cis	rs863345	0.604	rs2873593	chr1:158504711	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs860554	0.640	rs2268153	chr1:201262184	A/G	cg01022117	chr1:201258280	PKP1	-0.67	-6.52	-0.56	3.36e-9	Panic disorder;
THYM	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.27e-5	Gut microbiome composition (summer);
THYM	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	4.46	0.42	2.23e-5	Rheumatoid arthritis;
THYM	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg21226059	chr5:178986404	RUFY1	-0.61	-7.09	-0.59	2.41e-10	Lung cancer;
THYM	cis	rs4654899	1.000	rs7554997	chr1:21400139	C/T	cg01072550	chr1:21505969	NA	-0.75	-6.82	-0.57	8.26e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg09455208	chr3:40491958	NA	0.5	5.14	0.47	1.45e-6	Renal cell carcinoma;
THYM	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7429990	0.803	rs11714518	chr3:48156635	T/C	cg02219026	chr3:48282209	ZNF589	0.59	4.46	0.42	2.23e-5	Educational attainment (years of education);
THYM	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.78	0.51	9.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01341218	chr17:43662625	NA	1.15	9.87	0.71	3.19e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9866391	0.584	rs1991431	chr3:141133450	G/A	cg13411656	chr3:141121016	ZBTB38	-0.32	-4.67	-0.43	9.8e-6	Myopia;
THYM	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg07362569	chr17:61921086	SMARCD2	-0.67	-5.89	-0.52	5.86e-8	Prudent dietary pattern;
THYM	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3126085	0.800	rs55650366	chr1:152279920	A/G	cg10321714	chr1:152280068	FLG	-0.68	-4.95	-0.45	3.18e-6	Atopic dermatitis;
THYM	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg10560079	chr2:191398806	TMEM194B	-0.89	-7.93	-0.63	4.3e-12	Pulse pressure;
THYM	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.58	-4.98	-0.46	2.78e-6	Platelet count;
THYM	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg21775007	chr8:11205619	TDH	0.64	5.06	0.46	2.06e-6	Retinal vascular caliber;
THYM	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg08847533	chr14:75593920	NEK9	1.02	11.25	0.76	3.61e-19	Height;
THYM	cis	rs611744	0.967	rs608115	chr8:109231948	T/A	cg21045802	chr8:109455806	TTC35	0.6	5.31	0.48	7.15e-7	Dupuytren's disease;
THYM	cis	rs8114671	0.967	rs4911476	chr20:33780768	A/C	cg08999081	chr20:33150536	PIGU	-0.53	-4.75	-0.44	7.13e-6	Height;
THYM	cis	rs611744	0.647	rs1379336	chr8:109276606	G/T	cg21045802	chr8:109455806	TTC35	0.66	5.64	0.5	1.74e-7	Dupuytren's disease;
THYM	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg05731713	chr7:157510257	PTPRN2	0.53	5.14	0.47	1.46e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs131777	0.575	rs131760	chr22:51011936	T/C	cg00083937	chr22:51039805	MAPK8IP2	0.59	5.24	0.47	9.48e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg12310025	chr6:25882481	NA	-0.84	-7.43	-0.61	4.75e-11	Intelligence (multi-trait analysis);
THYM	cis	rs2456568	0.900	rs2511399	chr11:93682156	C/T	cg26875233	chr11:93583750	C11orf90	0.5	4.88	0.45	4.28e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs1445130	0.892	rs10495689	chr2:18832132	C/T	cg26077359	chr2:19280274	NA	0.82	4.52	0.42	1.76e-5	Bulimia nervosa;
THYM	cis	rs3008870	0.959	rs2985816	chr1:67387750	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.92	7.43	0.61	4.77e-11	Lymphocyte percentage of white cells;
THYM	cis	rs7584330	0.554	rs113271883	chr2:238425594	A/G	cg14458575	chr2:238380390	NA	0.79	4.65	0.43	1.06e-5	Prostate cancer;
THYM	cis	rs2742234	0.541	rs10899779	chr10:43723976	C/T	cg06632098	chr10:43605906	RET	0.8	5.26	0.47	8.98e-7	Hirschsprung disease;
THYM	cis	rs67460515	0.892	rs4856757	chr3:160999418	A/T	cg03342759	chr3:160939853	NMD3	-0.93	-7.98	-0.63	3.34e-12	Parkinson's disease;
THYM	cis	rs4940575	0.786	rs6567326	chr18:60840608	G/T	cg25271770	chr18:61057090	VPS4B	0.82	4.92	0.45	3.69e-6	Breast cancer;
THYM	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-7.41	-0.61	5.06e-11	Schizophrenia;
THYM	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	7.98	0.63	3.34e-12	Platelet count;
THYM	cis	rs2658782	0.547	rs3020065	chr11:93059899	A/G	cg15737290	chr11:93063684	CCDC67	1.16	11.14	0.75	6.15e-19	Pulmonary function decline;
THYM	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg00686598	chr14:53173677	PSMC6	1.39	7.01	0.58	3.52e-10	Alzheimer's disease (late onset);
THYM	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg22974920	chr21:40686053	BRWD1	0.66	4.54	0.42	1.67e-5	Cognitive function;
THYM	cis	rs17152411	0.947	rs733400	chr10:126594340	G/A	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs4509693	1.000	rs4277047	chr10:102499416	T/A	cg15234845	chr10:102496500	NA	0.65	4.6	0.43	1.3e-5	Alzheimer's disease;
THYM	cis	rs4638749	0.677	rs7370742	chr2:108815385	T/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs11089937	0.609	rs9622980	chr22:22504281	G/T	cg21401457	chr22:22472743	NA	0.56	4.47	0.42	2.14e-5	Periodontitis (PAL4Q3);
THYM	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg06219351	chr7:158114137	PTPRN2	-0.74	-7.14	-0.59	1.86e-10	Calcium levels;
THYM	cis	rs892961	1.000	rs2164449	chr17:75401190	G/A	cg05865280	chr17:75406074	SEPT9	0.49	8.48	0.66	2.87e-13	Airflow obstruction;
THYM	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg08000102	chr2:233561755	GIGYF2	-0.81	-7.27	-0.6	9.94e-11	Coronary artery disease;
THYM	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg20290983	chr6:43655470	MRPS18A	0.89	6.88	0.58	6.31e-10	IgG glycosylation;
THYM	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg10802521	chr3:52805072	NEK4	-0.73	-6.4	-0.55	5.97e-9	Bipolar disorder;
THYM	cis	rs28476539	1.000	rs28476539	chr4:83552291	G/A	cg10249074	chr4:83542146	C4orf11	-0.64	-5.06	-0.46	2.05e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg26384229	chr12:38710491	ALG10B	-0.72	-6.0	-0.52	3.63e-8	Morning vs. evening chronotype;
THYM	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.28	-6.03	-0.53	3.11e-8	Obesity-related traits;
THYM	cis	rs1650123	0.932	rs703627	chr12:104037293	T/A	cg23227824	chr12:103980017	STAB2	0.46	4.81	0.44	5.58e-6	IgG glycosylation;
THYM	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg21194808	chr1:2205498	SKI	-0.33	-4.47	-0.42	2.19e-5	Height;
THYM	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12586317	0.545	rs58342373	chr14:35395269	T/C	cg05294307	chr14:35346193	BAZ1A	-0.71	-5.27	-0.48	8.64e-7	Psoriasis;
THYM	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11890956	chr21:40555474	PSMG1	1.17	12.99	0.8	8.73e-23	Cognitive function;
THYM	trans	rs11109072	1.000	rs11109079	chr12:97905989	C/A	cg17633015	chr7:2020501	MAD1L1	0.95	7.08	0.59	2.49e-10	Obesity (early onset extreme);
THYM	cis	rs7089973	0.872	rs12773943	chr10:116631184	G/A	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.05	-0.46	2.15e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs4589258	0.788	rs4753030	chr11:90477870	A/G	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.83	-0.44	5.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg24531977	chr5:56204891	C5orf35	-0.69	-5.33	-0.48	6.72e-7	Coronary artery disease;
THYM	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg11335335	chr11:637885	DRD4	-0.69	-6.23	-0.54	1.24e-8	Systemic lupus erythematosus;
THYM	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.64	-0.62	1.74e-11	Personality dimensions;
THYM	cis	rs1728785	1.000	rs8058314	chr16:68584151	G/A	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg18252515	chr7:66147081	NA	-0.66	-5.01	-0.46	2.55e-6	Aortic root size;
THYM	cis	rs7968440	0.715	rs7967954	chr12:50673484	G/A	cg20014596	chr12:50898483	DIP2B	-0.49	-4.59	-0.43	1.37e-5	Fibrinogen;
THYM	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg13319975	chr6:146136371	FBXO30	-0.66	-5.4	-0.48	4.98e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg26516362	chr5:178986906	RUFY1	0.37	4.69	0.43	9.01e-6	Lung cancer;
THYM	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs6840360	0.615	rs9884167	chr4:152470799	A/G	cg17479576	chr4:152424074	FAM160A1	-0.83	-6.46	-0.55	4.43e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg26131816	chr17:42072204	PYY	0.54	4.65	0.43	1.07e-5	Menopause (age at onset);
THYM	cis	rs2637266	0.756	rs846631	chr10:78536928	T/G	cg18941641	chr10:78392320	NA	0.69	5.52	0.49	2.99e-7	Pulmonary function;
THYM	cis	rs861020	1.000	rs12134698	chr1:209987801	C/A	cg05527609	chr1:210001259	C1orf107	-1.04	-7.82	-0.63	7.16e-12	Orofacial clefts;
THYM	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg20887711	chr4:1340912	KIAA1530	0.97	8.91	0.67	3.52e-14	Longevity;
THYM	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg07537917	chr2:241836409	C2orf54	-0.26	-6.35	-0.55	7.26e-9	Urinary metabolites;
THYM	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg20503657	chr10:835505	NA	0.81	4.97	0.45	2.98e-6	Eosinophil percentage of granulocytes;
THYM	trans	rs4262150	0.846	rs113568682	chr5:152299754	A/T	cg08281791	chr5:76607845	PDE8B	0.93	7.1	0.59	2.24e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.52	0.73	1.31e-17	Prudent dietary pattern;
THYM	cis	rs2067615	0.579	rs66716938	chr12:107196825	T/C	cg15890332	chr12:107067104	RFX4	0.48	5.63	0.5	1.81e-7	Heart rate;
THYM	cis	rs988913	0.706	rs1155749	chr6:54730383	T/C	cg18532076	chr6:54711417	FAM83B	0.53	4.94	0.45	3.4e-6	Menarche (age at onset);
THYM	cis	rs259282	0.583	rs3760938	chr19:33106907	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.72	5.96	0.52	4.22e-8	Schizophrenia;
THYM	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg07362569	chr17:61921086	SMARCD2	0.72	6.4	0.55	5.96e-9	Prudent dietary pattern;
THYM	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02475777	chr4:1388615	CRIPAK	0.72	5.2	0.47	1.13e-6	Longevity;
THYM	cis	rs7264396	0.676	rs6060729	chr20:34557004	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-4.8	-0.44	6.01e-6	Total cholesterol levels;
THYM	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs4746818	1.000	rs906217	chr10:70954661	T/C	cg11621586	chr10:70884670	VPS26A	1.17	7.32	0.6	8.04e-11	Left atrial antero-posterior diameter;
THYM	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg03060546	chr3:49711283	APEH	0.75	6.08	0.53	2.55e-8	Resting heart rate;
THYM	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs6138458	1.000	rs227632	chr20:24913729	G/A	cg26195577	chr20:24973756	C20orf3	1.11	10.52	0.73	1.29e-17	Blood protein levels;
THYM	cis	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg09307838	chr4:120376055	NA	0.7	5.27	0.48	8.48e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500395	1.000	rs9933314	chr16:48676608	T/C	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs6598955	0.543	rs57564009	chr1:26557618	A/T	cg04990556	chr1:26633338	UBXN11	0.94	5.95	0.52	4.44e-8	Obesity-related traits;
THYM	cis	rs6840360	0.571	rs7664663	chr4:152508014	G/C	cg17479576	chr4:152424074	FAM160A1	-0.81	-5.73	-0.51	1.2e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.61e-20	Menopause (age at onset);
THYM	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg02896835	chr1:92012615	NA	0.61	4.71	0.43	8.55e-6	Eosinophil percentage of white cells;
THYM	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg01483505	chr11:975446	AP2A2	0.58	4.73	0.44	7.82e-6	Alzheimer's disease (late onset);
THYM	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg10047753	chr17:41438598	NA	0.97	7.99	0.63	3.21e-12	Menopause (age at onset);
THYM	cis	rs6584283	0.846	rs7917446	chr10:101286207	T/C	cg07044859	chr10:101282883	NA	-0.41	-4.71	-0.44	8.36e-6	Ulcerative colitis;
THYM	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg26384229	chr12:38710491	ALG10B	0.99	7.67	0.62	1.46e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs17708984	0.606	rs3786577	chr19:16192958	A/G	cg13618979	chr19:16186840	TPM4	0.35	4.67	0.43	1e-5	Platelet count;Platelet distribution width;
THYM	cis	rs67460515	0.892	rs7610985	chr3:161062848	G/A	cg03342759	chr3:160939853	NMD3	-0.88	-7.52	-0.61	3e-11	Parkinson's disease;
THYM	cis	rs9486719	1.000	rs12190508	chr6:96898269	T/C	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg05802129	chr4:122689817	NA	-0.6	-4.94	-0.45	3.35e-6	Type 2 diabetes;
THYM	cis	rs3008870	1.000	rs2815352	chr1:67482104	A/G	cg02640540	chr1:67518911	SLC35D1	0.65	4.83	0.44	5.32e-6	Lymphocyte percentage of white cells;
THYM	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg12564285	chr5:131593104	PDLIM4	0.6	6.64	0.56	1.95e-9	Acylcarnitine levels;
THYM	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg00191853	chr8:101177733	SPAG1	-0.56	-5.59	-0.5	2.15e-7	Atrioventricular conduction;
THYM	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.61	0.43	1.27e-5	Breast cancer;
THYM	cis	rs10029851	0.627	rs72893189	chr4:109556733	C/T	cg21648245	chr4:109541405	LOC285456;RPL34	-0.62	-4.7	-0.43	8.77e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21659725	chr3:3221576	CRBN	0.88	9.81	0.71	4.18e-16	Intelligence (multi-trait analysis);
THYM	cis	rs654384	0.507	rs1077473	chr7:4175508	C/T	cg04612959	chr7:4183976	SDK1	0.51	4.47	0.42	2.13e-5	Positive affect;
THYM	cis	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs2072499	0.767	rs3001789	chr1:156197614	T/G	cg25208724	chr1:156163844	SLC25A44	0.97	9.94	0.71	2.21e-16	Testicular germ cell tumor;
THYM	cis	rs9311676	0.618	rs11130639	chr3:58406004	G/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs7729447	0.566	rs3828589	chr5:32713327	T/C	cg16267343	chr5:32710456	NPR3	0.8	6.97	0.58	4.09e-10	Blood pressure;
THYM	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg17366294	chr4:99064904	C4orf37	0.48	5.42	0.49	4.47e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs669446	0.591	rs586339	chr1:44137257	C/A	cg12599982	chr1:44399894	ARTN	0.52	4.45	0.42	2.35e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs12049351	0.612	rs10916487	chr1:229612742	A/T	cg11742688	chr1:229674241	ABCB10	-0.54	-4.57	-0.42	1.46e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs12912251	0.947	rs36094159	chr15:38998395	G/A	cg08274633	chr15:38988533	C15orf53	-0.24	-4.97	-0.45	2.94e-6	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
THYM	cis	rs10484885	0.824	rs72919981	chr6:90528977	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.86	-7.66	-0.62	1.54e-11	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg07414643	chr4:187882934	NA	0.64	5.75	0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg27168131	chr21:44088823	PDE9A	-0.48	-4.87	-0.45	4.37e-6	Mean corpuscular volume;
THYM	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg12288994	chr5:1860383	NA	0.86	7.23	0.6	1.19e-10	Cardiovascular disease risk factors;
THYM	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg04518342	chr5:131593106	PDLIM4	0.45	5.02	0.46	2.37e-6	Breast cancer;
THYM	cis	rs920590	0.721	rs67989257	chr8:19660278	G/A	cg01411142	chr8:19674711	INTS10	0.65	4.73	0.44	7.87e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1062746	1.000	rs1062746	chr16:87364650	A/G	cg02258303	chr16:87377426	FBXO31	-0.59	-5.0	-0.46	2.66e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs17253792	0.822	rs77599953	chr14:56058905	C/T	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg17757837	chr7:157058334	UBE3C	0.65	5.24	0.47	9.83e-7	Body mass index;
THYM	cis	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg06789500	chr7:2109450	MAD1L1	-0.66	-4.48	-0.42	2.05e-5	Neuroticism;
THYM	cis	rs10992471	0.729	rs13284038	chr9:95555488	A/G	cg14631576	chr9:95140430	CENPP	-0.87	-7.64	-0.62	1.73e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.56	0.81	6.23e-24	Height;
THYM	cis	rs678347	1.000	rs507201	chr8:102462292	T/C	cg27484483	chr8:103249853	RRM2B	-0.52	-4.56	-0.42	1.5e-5	Rheumatoid arthritis;
THYM	cis	rs79149102	0.579	rs9673012	chr15:75293737	C/T	cg17294928	chr15:75287854	SCAMP5	-1.06	-5.68	-0.5	1.49e-7	Lung cancer;
THYM	cis	rs9677476	0.689	rs6761645	chr2:232055153	T/A	cg07929768	chr2:232055508	NA	0.64	6.45	0.55	4.73e-9	Food antigen IgG levels;
THYM	cis	rs2455799	0.613	rs11128760	chr3:15873407	A/G	cg16303742	chr3:15540471	COLQ	-0.54	-5.57	-0.5	2.37e-7	Mean platelet volume;
THYM	cis	rs3017493	1.000	rs3017493	chr11:70665521	A/G	cg19942459	chr11:70508110	SHANK2	0.83	4.61	0.43	1.27e-5	Renal transplant outcome;
THYM	cis	rs7226229	0.847	rs4985949	chr17:20894748	C/T	cg21263980	chr17:20946333	USP22	0.72	5.05	0.46	2.16e-6	Blood trace element (Se levels);
THYM	cis	rs1374313	1.000	rs6542527	chr2:120148080	A/T	cg18093372	chr2:119607603	NA	0.43	4.61	0.43	1.27e-5	Obesity-related traits;
THYM	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg08901578	chr4:187885870	NA	-0.64	-6.03	-0.53	3.1e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg25554036	chr4:6271136	WFS1	0.56	5.29	0.48	7.94e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg18132916	chr6:79620363	NA	-0.59	-5.15	-0.47	1.4e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg03188948	chr7:1209495	NA	0.91	5.04	0.46	2.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg12179176	chr11:130786555	SNX19	0.87	8.18	0.64	1.27e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs28595532	1.000	rs11931194	chr4:119631160	C/T	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs868036	0.681	rs4776981	chr15:68109474	G/A	cg24579218	chr15:68104479	NA	-0.83	-8.84	-0.67	5e-14	Restless legs syndrome;
THYM	cis	rs860818	1.000	rs858296	chr7:23245548	C/T	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg03474202	chr17:45855739	NA	-0.76	-6.7	-0.57	1.45e-9	IgG glycosylation;
THYM	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg27034606	chr17:28928453	LRRC37B2	0.75	4.55	0.42	1.61e-5	Body mass index;
THYM	cis	rs7818345	0.935	rs6983973	chr8:19287867	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.65	0.43	1.09e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg02269571	chr22:50332266	NA	1.12	5.92	0.52	5.15e-8	Schizophrenia;
THYM	cis	rs28785552	0.554	rs11084184	chr19:53213939	G/A	cg10871876	chr19:53194124	ZNF83	0.72	5.6	0.5	2.05e-7	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs1057239	0.739	rs1014554	chr1:175133626	A/G	cg08873628	chr1:175162347	KIAA0040	0.51	4.59	0.43	1.34e-5	Diastolic blood pressure;
THYM	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg27490568	chr2:178487706	NA	0.56	4.86	0.45	4.56e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1971762	0.545	rs10783585	chr12:53977317	T/G	cg16917193	chr12:54089295	NA	0.72	6.7	0.57	1.45e-9	Height;
THYM	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg05762616	chr10:133787150	BNIP3	-0.69	-4.46	-0.42	2.26e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs9796	0.562	rs3959554	chr15:41443924	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.65	-5.11	-0.46	1.65e-6	Menopause (age at onset);
THYM	cis	rs9435341	0.929	rs1762509	chr1:107592959	A/G	cg09367891	chr1:107599246	PRMT6	-0.72	-5.01	-0.46	2.5e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs10927875	0.518	rs732286	chr1:16344360	A/G	cg21385522	chr1:16154831	NA	0.65	4.65	0.43	1.08e-5	Dilated cardiomyopathy;
THYM	cis	rs7192380	1.000	rs11075726	chr16:69584523	A/G	cg09409435	chr16:70099608	PDXDC2	0.62	4.75	0.44	7.2e-6	Sjögren's syndrome;
THYM	cis	rs10779751	0.690	rs28729193	chr1:11180151	T/C	cg08854313	chr1:11322531	MTOR	-0.72	-5.7	-0.5	1.37e-7	Body mass index;
THYM	cis	rs7020830	0.931	rs7034554	chr9:37081301	A/G	cg14294708	chr9:37120828	ZCCHC7	1.26	16.19	0.86	4.51e-29	Schizophrenia;
THYM	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg19077165	chr18:44547161	KATNAL2	0.5	5.84	0.51	7.15e-8	Personality dimensions;
THYM	cis	rs1535500	0.756	rs3807042	chr6:39290834	G/T	cg00012638	chr6:39280541	KCNK17	-0.58	-7.22	-0.6	1.27e-10	Type 2 diabetes;
THYM	cis	rs7828089	1.000	rs7837964	chr8:22264417	G/C	cg13512537	chr8:22265999	SLC39A14	-0.61	-5.13	-0.47	1.55e-6	Verbal declarative memory;
THYM	cis	rs8017423	0.967	rs28424204	chr14:90705669	G/C	cg04239629	chr14:90701769	NA	-0.62	-4.52	-0.42	1.81e-5	Mortality in heart failure;
THYM	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg18811423	chr2:55921094	PNPT1	0.68	5.81	0.51	8.25e-8	Metabolic syndrome;
THYM	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg09359103	chr1:154839909	KCNN3	-0.81	-10.3	-0.73	3.79e-17	Prostate cancer;
THYM	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg06636001	chr8:8085503	FLJ10661	-0.73	-6.27	-0.54	1.07e-8	Joint mobility (Beighton score);
THYM	cis	rs2235573	0.594	rs4821730	chr22:38441587	A/G	cg19171272	chr22:38449367	NA	-0.51	-5.38	-0.48	5.38e-7	Glioblastoma;Glioma;
THYM	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2274459	0.841	rs10947432	chr6:33676556	A/G	cg06253072	chr6:33679850	C6orf125	-0.5	-4.93	-0.45	3.43e-6	Obesity (extreme);
THYM	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg17063962	chr7:91808500	NA	-1.1	-12.09	-0.78	6.22e-21	Breast cancer;
THYM	cis	rs886126	1.000	rs7973104	chr12:111670774	C/G	cg10833066	chr12:111807467	FAM109A	0.43	5.27	0.48	8.53e-7	Coronary heart disease;
THYM	trans	rs6089829	0.888	rs4809268	chr20:61675249	C/G	cg23505145	chr19:12996616	KLF1	1.03	10.05	0.72	1.28e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs919433	0.713	rs1455653	chr2:198478320	G/A	cg00792783	chr2:198669748	PLCL1	0.82	5.73	0.51	1.17e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4718428	0.705	rs13227468	chr7:66433563	T/C	cg26963428	chr7:66367121	NA	-0.6	-4.73	-0.44	7.67e-6	Corneal structure;
THYM	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg13114125	chr14:105738426	BRF1	0.7	5.36	0.48	5.88e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7980799	0.682	rs7311794	chr12:33635630	C/T	cg06521331	chr12:34319734	NA	0.67	4.74	0.44	7.63e-6	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg26149184	chr10:133730230	NA	0.77	4.65	0.43	1.07e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs548181	0.545	rs1054997	chr11:125618813	G/A	cg03464685	chr11:125439445	EI24	-1.34	-8.02	-0.64	2.7e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg27286337	chr10:134555280	INPP5A	0.96	7.9	0.63	4.94e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg00310523	chr12:86230176	RASSF9	-0.52	-4.65	-0.43	1.07e-5	Major depressive disorder;
THYM	cis	rs4803468	1.000	rs10413735	chr19:41921071	C/T	cg09537434	chr19:41945824	ATP5SL	-1.06	-9.81	-0.71	4.27e-16	Height;
THYM	cis	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg10518543	chr12:38710700	ALG10B	-0.59	-4.71	-0.43	8.5e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs34638657	0.872	rs6420435	chr16:82184201	A/C	cg09894383	chr16:82067445	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21659725	chr3:3221576	CRBN	0.89	9.76	0.71	5.32e-16	Intelligence (multi-trait analysis);
THYM	cis	rs858239	0.539	rs4559148	chr7:23185967	G/A	cg09755872	chr7:23245557	NA	-0.5	-4.71	-0.43	8.55e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs728616	0.614	rs61860413	chr10:81730119	T/G	cg27452691	chr10:81370291	SFTPA1	0.59	4.6	0.43	1.33e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs1670533	1.000	rs641987	chr4:1077542	C/T	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.98	0.45	2.85e-6	Obesity-related traits;
THYM	cis	rs4072705	1.000	rs7874367	chr9:127377780	A/T	cg13476313	chr9:127244764	NR5A1	-0.35	-5.34	-0.48	6.36e-7	Menarche (age at onset);
THYM	trans	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg25214090	chr10:38739885	LOC399744	0.97	8.33	0.65	5.98e-13	Corneal astigmatism;
THYM	cis	rs79349575	0.777	rs28517720	chr17:46976756	C/G	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg06558623	chr16:89946397	TCF25	1.33	5.62	0.5	1.94e-7	Skin colour saturation;
THYM	cis	rs7119	0.635	rs2682910	chr15:77880114	C/A	cg10437265	chr15:77819839	NA	-0.61	-5.83	-0.51	7.54e-8	Type 2 diabetes;
THYM	cis	rs600806	0.850	rs4970729	chr1:109979202	G/A	cg23616212	chr1:109941201	SORT1	-0.48	-4.47	-0.42	2.17e-5	Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.917	rs78395918	chr1:2045876	G/A	cg13918804	chr1:2043761	PRKCZ	-0.65	-4.73	-0.44	7.73e-6	Height;
THYM	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg19774624	chr17:42201019	HDAC5	0.78	7.29	0.6	9.12e-11	Total body bone mineral density;
THYM	cis	rs36051895	0.659	rs62541556	chr9:5049092	G/T	cg02405213	chr9:5042618	JAK2	-1.04	-10.96	-0.75	1.52e-18	Pediatric autoimmune diseases;
THYM	cis	rs3925075	0.833	rs11641202	chr16:31330161	A/G	cg02846316	chr16:31340340	ITGAM	0.55	5.5	0.49	3.2e-7	IgA nephropathy;
THYM	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg22681709	chr2:178499509	PDE11A	-0.6	-5.28	-0.48	8.28e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Body mass index;
THYM	cis	rs4332037	0.539	rs11982455	chr7:1911458	A/C	cg23422044	chr7:1970798	MAD1L1	-0.87	-6.07	-0.53	2.6e-8	Bipolar disorder;
THYM	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	cis	rs2688608	0.592	rs3849967	chr10:75483366	C/T	cg15838173	chr10:75533400	FUT11	-0.5	-5.09	-0.46	1.82e-6	Inflammatory bowel disease;
THYM	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg02527881	chr3:46936655	PTH1R	0.6	5.51	0.49	3.06e-7	Colorectal cancer;
THYM	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.64	5.07	0.46	1.94e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9443189	0.774	rs2647405	chr6:76450023	C/T	cg01950844	chr6:76311363	SENP6	-0.77	-4.53	-0.42	1.73e-5	Prostate cancer;
THYM	cis	rs501916	0.833	rs11855134	chr15:48047676	A/G	cg16110827	chr15:48056943	SEMA6D	-0.61	-4.47	-0.42	2.12e-5	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg13114125	chr14:105738426	BRF1	-0.74	-5.88	-0.52	6.07e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg06108461	chr20:60628389	TAF4	-1.06	-9.09	-0.68	1.47e-14	Body mass index;
THYM	cis	rs2237457	0.525	rs6948032	chr7:50705117	A/G	cg08586669	chr7:50727761	GRB10	-0.3	-4.92	-0.45	3.61e-6	Schizophrenia (treatment resistant);
THYM	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.04	-7.12	-0.59	2.06e-10	Platelet count;
THYM	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.04	8.99	0.68	2.42e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg23730037	chr7:158596552	ESYT2	-0.55	-5.69	-0.5	1.38e-7	Height;
THYM	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg11301795	chr4:187892539	NA	-1.11	-18.07	-0.88	1.66e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs62229266	0.626	rs7280896	chr21:37460906	G/A	cg12218747	chr21:37451666	NA	-0.65	-6.14	-0.53	1.88e-8	Mitral valve prolapse;
THYM	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.85	8.2	0.64	1.16e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4601821	0.895	rs2282511	chr11:113244177	A/C	cg14159747	chr11:113255604	NA	0.25	4.47	0.42	2.13e-5	Alcoholic chronic pancreatitis;
THYM	cis	rs72720396	0.803	rs115552537	chr1:91190856	C/A	cg13456504	chr1:91191583	NA	1.03	6.98	0.58	3.91e-10	Morning vs. evening chronotype;Chronotype;
THYM	cis	rs7639513	0.767	rs9861472	chr3:12707776	A/T	cg23032965	chr3:12705835	RAF1	-0.99	-8.0	-0.63	3e-12	Itch intensity from mosquito bite;
THYM	cis	rs854765	0.624	rs7501812	chr17:17750907	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-5.71	-0.51	1.28e-7	Total body bone mineral density;
THYM	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.64	4.47	0.42	2.13e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg11846333	chr4:119757529	SEC24D	1.34	5.19	0.47	1.19e-6	Cannabis dependence symptom count;
THYM	cis	rs7819412	0.534	rs4489292	chr8:10907120	C/T	cg16664915	chr8:10907788	XKR6	0.56	4.63	0.43	1.16e-5	Triglycerides;
THYM	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.89	-8.67	-0.66	1.15e-13	Lung cancer;
THYM	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg01579765	chr21:45077557	HSF2BP	0.51	8.14	0.64	1.55e-12	Mean corpuscular volume;
THYM	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.85	-5.77	-0.51	1e-7	Yeast infection;
THYM	cis	rs35883536	0.626	rs7545966	chr1:101047633	G/A	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs17407555	0.738	rs10516198	chr4:10059448	T/C	cg00071950	chr4:10020882	SLC2A9	-0.73	-5.48	-0.49	3.46e-7	Schizophrenia (age at onset);
THYM	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4499344	0.693	rs8106502	chr19:33097796	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.48	0.61	3.64e-11	Mean platelet volume;
THYM	cis	rs6570726	0.935	rs419847	chr6:145827278	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg15561933	chr1:57319350	C8A	-0.9	-7.12	-0.59	2.08e-10	Depressive symptoms;
THYM	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg10589385	chr1:150898437	SETDB1	0.64	5.36	0.48	5.82e-7	Melanoma;
THYM	cis	rs9470366	0.848	rs9470361	chr6:36623379	G/A	cg11920449	chr6:36645608	CDKN1A	-0.7	-5.37	-0.48	5.5e-7	QRS duration;
THYM	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg13695892	chr22:41940480	POLR3H	-1.04	-8.36	-0.65	5.34e-13	Vitiligo;
THYM	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.0	10.07	0.72	1.18e-16	Cognitive ability;
THYM	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg06481639	chr22:41940642	POLR3H	0.75	5.04	0.46	2.19e-6	Vitiligo;
THYM	cis	rs367615	0.660	rs4632850	chr5:108832883	C/G	cg17395555	chr5:108820864	NA	0.74	8.76	0.67	7.24e-14	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11890956	chr21:40555474	PSMG1	1.08	7.04	0.59	2.95e-10	Cognitive function;
THYM	cis	rs7567389	0.535	rs4150416	chr2:128046548	C/A	cg06038358	chr2:128176007	PROC	-0.42	-4.47	-0.42	2.16e-5	Self-rated health;
THYM	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs36051895	0.672	rs12353218	chr9:5162828	T/C	cg02405213	chr9:5042618	JAK2	-1.03	-11.38	-0.76	1.97e-19	Pediatric autoimmune diseases;
THYM	cis	rs6598541	0.928	rs8038015	chr15:99263274	T/C	cg13297560	chr15:99320054	IGF1R	-0.49	-5.13	-0.47	1.53e-6	Urate levels;
THYM	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg16060761	chr17:80687452	NA	0.69	5.9	0.52	5.45e-8	Glycated hemoglobin levels;
THYM	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg19761014	chr17:28927070	LRRC37B2	0.92	5.32	0.48	6.87e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17253792	0.822	rs10483646	chr14:56103872	A/C	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg15605315	chr1:45957053	TESK2	0.78	6.78	0.57	9.97e-10	High light scatter reticulocyte count;
THYM	cis	rs11563648	0.573	rs10241915	chr7:126949074	C/T	cg23081781	chr7:127225937	GCC1	-0.37	-5.19	-0.47	1.17e-6	Resting heart rate;
THYM	cis	rs13126513	0.708	rs7665289	chr4:100448167	G/T	cg05468953	chr4:100565104	NA	0.64	5.88	0.52	6.06e-8	Metabolite levels (MHPG);
THYM	cis	rs4568518	0.503	rs12699956	chr7:18061766	T/C	cg00911873	chr7:18067463	PRPS1L1	-0.58	-4.67	-0.43	9.79e-6	Measles;
THYM	cis	rs4919687	0.550	rs10748828	chr10:104456794	C/T	cg05855489	chr10:104503620	C10orf26	-0.67	-5.23	-0.47	9.94e-7	Colorectal cancer;
THYM	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.7	6.53	0.56	3.28e-9	Total body bone mineral density;
THYM	cis	rs4731207	0.698	rs12538083	chr7:124554057	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg07936489	chr17:37558343	FBXL20	-0.67	-4.9	-0.45	3.86e-6	Asthma;
THYM	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg25036284	chr2:26402008	FAM59B	0.8	5.36	0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg18681998	chr4:17616180	MED28	-0.82	-6.72	-0.57	1.32e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs933688	0.532	rs2367292	chr5:90556785	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.68	-4.7	-0.43	8.89e-6	Smoking behavior;
THYM	cis	rs11779988	0.543	rs410445	chr8:17882304	C/T	cg01800426	chr8:17659068	MTUS1	-0.79	-5.68	-0.5	1.46e-7	Breast cancer;
THYM	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.32	0.54	8.42e-9	Platelet count;
THYM	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg00981070	chr1:2046702	PRKCZ	0.48	5.41	0.49	4.69e-7	Height;
THYM	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg03609598	chr5:56110824	MAP3K1	0.74	4.78	0.44	6.4e-6	Initial pursuit acceleration;
THYM	cis	rs4936894	0.519	rs3905280	chr11:124149820	A/C	cg23571170	chr11:124180298	OR8D1	-0.51	-4.52	-0.42	1.8e-5	Aging (time to death);
THYM	cis	rs2075230	0.705	rs2955613	chr17:7549342	T/C	cg27413385	chr17:7515425	FXR2	-0.36	-5.31	-0.48	7.3e-7	Hormone measurements;
THYM	cis	rs2276498	0.751	rs2107327	chr20:52663409	G/T	cg23682609	chr20:52687365	BCAS1	0.56	4.55	0.42	1.6e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs728616	0.867	rs61860034	chr10:81931848	C/T	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs2625529	0.775	rs62023342	chr15:72161305	A/C	cg16672083	chr15:72433130	SENP8	-0.51	-4.58	-0.43	1.39e-5	Red blood cell count;
THYM	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.76	6.18	0.54	1.58e-8	Monocyte percentage of white cells;
THYM	cis	rs2229238	0.911	rs59239860	chr1:154492107	G/T	cg21262032	chr1:154437693	IL6R	-0.57	-5.02	-0.46	2.37e-6	Coronary heart disease;
THYM	cis	rs912057	0.965	rs1294415	chr6:6740633	G/A	cg06612196	chr6:6737390	NA	0.69	9.84	0.71	3.66e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs614367	1.000	rs614367	chr11:69328764	A/G	cg08353955	chr11:69289746	NA	1.02	5.14	0.47	1.44e-6	Breast cancer;Breast cancer (early onset);
THYM	trans	rs11186	0.591	rs72906361	chr2:189962558	T/G	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg02753203	chr1:228287806	NA	1.03	8.85	0.67	4.76e-14	Diastolic blood pressure;
THYM	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg01751800	chr4:77820391	ANKRD56	0.55	4.49	0.42	2.03e-5	Emphysema distribution in smoking;
THYM	cis	rs4731207	0.596	rs13231916	chr7:124640225	A/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg02228675	chr17:40259724	DHX58	-0.66	-5.49	-0.49	3.28e-7	Fibrinogen levels;
THYM	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg08772003	chr10:104629869	AS3MT	-0.57	-4.93	-0.45	3.55e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2354432	0.607	rs894469	chr1:146672906	C/T	cg25205988	chr1:146714368	CHD1L	1.1	4.92	0.45	3.66e-6	Mitochondrial DNA levels;
THYM	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg01416388	chr22:39784598	NA	-0.74	-5.9	-0.52	5.63e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg04267008	chr7:1944627	MAD1L1	-0.6	-4.95	-0.45	3.19e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11648796	0.765	rs2003832	chr16:769538	G/A	cg16899442	chr16:776458	CCDC78;HAGHL	0.46	5.22	0.47	1.07e-6	Height;
THYM	trans	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg23505145	chr19:12996616	KLF1	1.01	10.01	0.72	1.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg06766960	chr11:133703094	NA	-0.61	-5.42	-0.49	4.41e-7	Childhood ear infection;
THYM	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg14416269	chr4:6271139	WFS1	0.54	5.62	0.5	1.93e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg06640241	chr16:89574553	SPG7	0.78	5.51	0.49	3.02e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs4589258	0.933	rs1792602	chr11:90439633	C/T	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg26384229	chr12:38710491	ALG10B	0.97	8.57	0.66	1.86e-13	Morning vs. evening chronotype;
THYM	cis	rs919433	0.756	rs7575389	chr2:198198489	A/G	cg00792783	chr2:198669748	PLCL1	-0.74	-5.56	-0.5	2.5e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs807669	0.903	rs1771540	chr22:19173933	T/A	cg02655711	chr22:19163373	SLC25A1	0.97	11.57	0.76	7.63e-20	Metabolite levels;
THYM	cis	rs12310956	0.510	rs10844690	chr12:33854752	C/A	cg06521331	chr12:34319734	NA	-0.57	-4.59	-0.43	1.35e-5	Morning vs. evening chronotype;
THYM	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg06873352	chr17:61820015	STRADA	0.51	4.92	0.45	3.67e-6	Height;
THYM	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg08000102	chr2:233561755	GIGYF2	-0.69	-6.17	-0.53	1.69e-8	Coronary artery disease;
THYM	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs761746	0.882	rs5998032	chr22:31928890	T/G	cg10537193	chr22:32026975	PISD	0.42	5.47	0.49	3.67e-7	Intelligence;
THYM	cis	rs67385638	1.000	rs72872548	chr11:5289139	C/A	cg12559170	chr11:5275217	HBG2	0.93	9.25	0.69	6.65e-15	Hemoglobin levels;
THYM	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg08859206	chr1:53392774	SCP2	-0.65	-7.39	-0.6	5.57e-11	Monocyte count;
THYM	cis	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg13443165	chr9:33130375	B4GALT1	-0.86	-7.96	-0.63	3.71e-12	IgG glycosylation;
THYM	cis	rs1160297	0.576	rs1451456	chr2:53092604	A/C	cg07782112	chr2:53107842	NA	0.77	6.24	0.54	1.19e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs3849570	0.961	rs3821548	chr3:81758728	C/G	cg07356753	chr3:81810745	GBE1	-0.93	-7.68	-0.62	1.43e-11	Waist circumference;Body mass index;
THYM	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg25817165	chr18:72167213	CNDP2	-0.97	-10.17	-0.72	7.3e-17	Refractive error;
THYM	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.68	-5.45	-0.49	3.96e-7	Lung cancer in ever smokers;
THYM	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs2270875	0.660	rs6982719	chr8:132930163	G/T	cg15420926	chr8:132929147	EFR3A	0.63	4.82	0.44	5.33e-6	Response to cholinesterase inhibitors in Alzheimer's disease;
THYM	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg09455208	chr3:40491958	NA	0.45	4.85	0.45	4.77e-6	Renal cell carcinoma;
THYM	cis	rs752010	0.746	rs11210499	chr1:42089703	C/T	cg06885757	chr1:42089581	HIVEP3	-0.6	-7.73	-0.62	1.12e-11	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs2859741	0.546	rs2134846	chr1:37500723	G/A	cg09363841	chr1:37513479	NA	-0.69	-5.35	-0.48	6.08e-7	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs11997175	0.545	rs66783231	chr8:33811467	A/T	ch.8.33884649F	chr8:33765107	NA	0.67	5.0	0.46	2.61e-6	Body mass index;
THYM	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.1	8.65	0.66	1.29e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11009175	0.725	rs10827170	chr10:33290343	C/G	cg00146027	chr10:33299147	NA	0.71	5.18	0.47	1.27e-6	Depression (quantitative trait);
THYM	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs6496667	0.542	rs58182460	chr15:90897309	A/T	cg22089800	chr15:90895588	ZNF774	0.74	5.0	0.46	2.65e-6	Rheumatoid arthritis;
THYM	cis	rs3771570	1.000	rs62190370	chr2:242384194	C/G	cg21155796	chr2:242212141	HDLBP	1.25	6.07	0.53	2.57e-8	Prostate cancer;
THYM	cis	rs11785693	0.862	rs6994323	chr8:4996786	T/A	cg26367366	chr8:4980734	NA	1.21	5.9	0.52	5.46e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg04398451	chr17:18023971	MYO15A	-0.76	-6.96	-0.58	4.39e-10	Total body bone mineral density;
THYM	cis	rs420259	0.516	rs120963	chr16:23608070	A/G	cg00143387	chr16:23521605	GGA2	0.76	5.6	0.5	2.1e-7	Bipolar disorder;
THYM	cis	rs9810259	0.586	rs17817276	chr3:12397392	A/G	cg05467012	chr3:12595696	NA	0.54	4.46	0.42	2.25e-5	Platelet count;
THYM	cis	rs863345	0.604	rs1342946	chr1:158453187	C/T	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs7695732	0.595	rs16996143	chr4:89897359	A/G	cg17769793	chr4:89976368	FAM13A	-0.5	-5.57	-0.5	2.36e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs11733284	0.515	rs10025104	chr4:47855999	T/C	cg12147198	chr4:47838169	CORIN	-0.45	-4.5	-0.42	1.92e-5	Renal underexcretion gout;Gout;
THYM	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg02187348	chr16:89574699	SPG7	0.78	6.59	0.56	2.46e-9	Multiple myeloma (IgH translocation);
THYM	cis	rs4072705	1.000	rs4836991	chr9:127512040	A/G	cg13476313	chr9:127244764	NR5A1	-0.34	-5.06	-0.46	2.08e-6	Menarche (age at onset);
THYM	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg20891283	chr12:69753455	YEATS4	0.62	4.51	0.42	1.85e-5	Response to diuretic therapy;
THYM	cis	rs2694917	0.680	rs2638314	chr12:56866334	T/A	cg03677924	chr12:56849618	MIP	-0.57	-4.49	-0.42	2.02e-5	Blood metabolite ratios;
THYM	cis	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6754311	0.544	rs11678022	chr2:136809033	A/T	cg07169764	chr2:136633963	MCM6	-0.68	-5.0	-0.46	2.66e-6	Mosquito bite size;
THYM	cis	rs34638657	0.702	rs35865749	chr16:82199677	T/C	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.11	-0.64	1.73e-12	Lung adenocarcinoma;
THYM	cis	rs2658782	0.547	rs3020052	chr11:93055184	C/G	cg02384510	chr11:93059814	NA	-0.46	-4.46	-0.42	2.24e-5	Pulmonary function decline;
THYM	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg07936489	chr17:37558343	FBXL20	-0.8	-5.57	-0.5	2.37e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs12549902	0.966	rs10504042	chr8:41515993	G/A	cg21772509	chr8:41503840	NKX6-3	0.72	6.79	0.57	9.78e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
THYM	cis	rs4919087	0.892	rs10882880	chr10:99008068	G/A	cg19453742	chr10:98862320	SLIT1	-0.63	-4.76	-0.44	6.83e-6	Monocyte count;
THYM	cis	rs7584330	0.518	rs74003103	chr2:238446699	G/A	cg08992911	chr2:238395768	MLPH	0.9	5.47	0.49	3.65e-7	Prostate cancer;
THYM	cis	rs13102973	0.640	rs10434069	chr4:135840778	G/A	cg14419869	chr4:135874104	NA	0.72	5.86	0.51	6.78e-8	Subjective well-being;
THYM	cis	rs1003719	0.743	rs2835615	chr21:38497303	G/A	cg01329690	chr21:38580129	DSCR9	-0.37	-5.01	-0.46	2.53e-6	Eye color traits;
THYM	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg14196790	chr5:131705035	SLC22A5	0.56	4.94	0.45	3.36e-6	Blood metabolite levels;
THYM	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg20744362	chr22:50050164	C22orf34	0.77	6.97	0.58	4.25e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg13393036	chr8:95962371	TP53INP1	-0.49	-4.97	-0.45	2.9e-6	Type 2 diabetes;
THYM	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg06112835	chr11:68658793	MRPL21	0.44	6.27	0.54	1.05e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs17407555	0.821	rs4533775	chr4:10141404	G/C	cg00071950	chr4:10020882	SLC2A9	-0.76	-5.68	-0.5	1.45e-7	Schizophrenia (age at onset);
THYM	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg08999081	chr20:33150536	PIGU	0.81	7.94	0.63	4.05e-12	Coronary artery disease;
THYM	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg14779329	chr11:130786720	SNX19	0.48	4.93	0.45	3.51e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	7.48	0.61	3.78e-11	Smoking behavior;
THYM	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs34779708	0.966	rs34630580	chr10:35449228	A/G	cg03585969	chr10:35415529	CREM	0.65	4.51	0.42	1.87e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4662750	0.743	rs1835431	chr2:128375943	A/G	cg01966334	chr2:128378434	MYO7B	0.69	6.2	0.54	1.43e-8	Renal cell carcinoma;
THYM	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.03	-4.79	-0.44	6.14e-6	Body mass index;
THYM	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg14004847	chr7:1930337	MAD1L1	-0.64	-5.02	-0.46	2.41e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg26384229	chr12:38710491	ALG10B	1.0	8.01	0.63	2.86e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs28595532	0.920	rs114544767	chr4:119728364	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs11157436	0.918	rs2178788	chr14:22618870	T/C	cg26433554	chr14:23315189	MMP14	0.44	4.61	0.43	1.24e-5	Neurocognitive impairment in HIV-1 infection (continuous);
THYM	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs2219968	0.525	rs7000023	chr8:78875077	C/T	cg00738934	chr8:78996279	NA	0.61	4.93	0.45	3.5e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg18681998	chr4:17616180	MED28	0.99	10.08	0.72	1.13e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg06623918	chr6:96969491	KIAA0776	1.09	9.94	0.71	2.21e-16	Headache;
THYM	cis	rs7927771	0.524	rs2242081	chr11:47500267	T/C	cg20307385	chr11:47447363	PSMC3	0.63	4.83	0.44	5.13e-6	Subjective well-being;
THYM	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs1957429	0.901	rs1957435	chr14:65349697	G/A	cg23373153	chr14:65346875	NA	1.07	6.45	0.55	4.75e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs472109	0.565	rs183110	chr11:9811616	C/G	cg06876053	chr11:9810051	SBF2	-0.64	-4.96	-0.45	3.14e-6	Coronary artery disease;
THYM	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs3087591	0.922	rs757383	chr17:29596045	C/G	cg24425628	chr17:29625626	OMG;NF1	0.68	5.95	0.52	4.46e-8	Hip circumference;
THYM	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg08132940	chr7:1081526	C7orf50	-1.03	-6.29	-0.54	9.48e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9549260	0.816	rs964901	chr13:41248698	C/T	cg21288729	chr13:41239152	FOXO1	0.7	5.32	0.48	6.91e-7	Red blood cell count;
THYM	cis	rs7474896	0.507	rs2474555	chr10:38465220	G/C	cg13531842	chr10:38383804	ZNF37A	-0.73	-4.47	-0.42	2.2e-5	Obesity (extreme);
THYM	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg23711669	chr6:146136114	FBXO30	0.95	9.55	0.7	1.52e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11696501	0.588	rs6073831	chr20:44279550	A/T	cg11783356	chr20:44313418	WFDC10B	-0.69	-4.73	-0.44	7.72e-6	Brain structure;
THYM	cis	rs6693295	0.536	rs6662962	chr1:246226180	T/A	cg11798871	chr1:246315928	SMYD3	-0.78	-4.71	-0.43	8.52e-6	Migraine - clinic-based;Migraine with aura;
THYM	cis	rs8028313	0.529	rs16951358	chr15:68153732	G/C	cg24579218	chr15:68104479	NA	-0.78	-6.97	-0.58	4.21e-10	Obesity;
THYM	cis	rs4750440	0.702	rs4750445	chr10:14030314	C/T	cg27542038	chr10:14027202	FRMD4A	-0.5	-4.45	-0.42	2.36e-5	Adiponectin levels;
THYM	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9826463	0.759	rs56161530	chr3:142332376	C/A	cg20824294	chr3:142316082	PLS1	0.69	4.62	0.43	1.19e-5	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs28595532	0.920	rs116559327	chr4:119754526	T/G	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg12031863	chr16:4587854	C16orf5	-0.42	-4.54	-0.42	1.63e-5	Schizophrenia;
THYM	cis	rs7178572	0.962	rs1022172	chr15:77793359	A/G	cg22256960	chr15:77711686	NA	-0.93	-7.77	-0.62	9.35e-12	Type 2 diabetes;
THYM	cis	rs28795989	0.931	rs28726254	chr4:7897682	C/G	cg00251875	chr4:7801337	AFAP1	0.56	4.51	0.42	1.88e-5	Intraocular pressure;
THYM	cis	rs7614311	0.731	rs73130544	chr3:63868596	G/A	cg22134162	chr3:63841271	THOC7	-0.56	-6.61	-0.56	2.18e-9	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg04398451	chr17:18023971	MYO15A	-0.92	-9.33	-0.69	4.39e-15	Total body bone mineral density;
THYM	cis	rs7772486	0.790	rs7753833	chr6:146161432	C/A	cg13319975	chr6:146136371	FBXO30	-0.69	-5.57	-0.5	2.32e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg24209194	chr3:40518798	ZNF619	-0.55	-4.54	-0.42	1.66e-5	Renal cell carcinoma;
THYM	cis	rs7020830	0.861	rs6476622	chr9:37308049	T/A	cg14294708	chr9:37120828	ZCCHC7	1.19	15.05	0.84	6.82e-27	Schizophrenia;
THYM	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg04156016	chr5:1868137	NA	0.54	5.16	0.47	1.36e-6	Cardiovascular disease risk factors;
THYM	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg24069376	chr3:38537580	EXOG	0.64	6.35	0.55	7.43e-9	Electrocardiographic conduction measures;
THYM	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs9653442	0.593	rs10865036	chr2:100860595	A/G	cg08017756	chr2:100939284	LONRF2	-0.68	-5.13	-0.47	1.53e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs13082711	0.555	rs73149363	chr3:27265394	C/A	cg02860705	chr3:27208620	NA	0.96	7.63	0.62	1.77e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg03929089	chr4:120376271	NA	-1.01	-13.68	-0.81	3.47e-24	Height;
THYM	cis	rs823143	0.607	rs823105	chr1:205657570	G/A	cg14159672	chr1:205819179	PM20D1	0.88	8.22	0.64	1.02e-12	Monocyte percentage of white cells;
THYM	cis	rs7584330	0.518	rs74003108	chr2:238448000	T/C	cg08992911	chr2:238395768	MLPH	0.9	5.44	0.49	4.18e-7	Prostate cancer;
THYM	cis	rs9443189	0.762	rs2647417	chr6:76435943	A/G	cg01950844	chr6:76311363	SENP6	-0.79	-4.56	-0.42	1.54e-5	Prostate cancer;
THYM	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg26597838	chr10:835615	NA	1.11	7.6	0.61	2.06e-11	Eosinophil percentage of granulocytes;
THYM	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg13609457	chr4:120235615	NA	0.65	5.13	0.47	1.53e-6	Corneal astigmatism;
THYM	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.78	0.51	9.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2658782	0.547	rs3020064	chr11:93060851	A/G	cg02384510	chr11:93059814	NA	-0.48	-4.6	-0.43	1.28e-5	Pulmonary function decline;
THYM	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg07936489	chr17:37558343	FBXL20	0.82	5.61	0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg26384229	chr12:38710491	ALG10B	1.05	10.44	0.73	1.86e-17	Heart rate;
THYM	cis	rs1448094	0.511	rs17279261	chr12:86162714	C/T	cg02569458	chr12:86230093	RASSF9	0.69	5.77	0.51	9.84e-8	Major depressive disorder;
THYM	cis	rs11148252	0.740	rs7983971	chr13:52790700	C/T	cg05335186	chr13:53173507	NA	-0.46	-5.63	-0.5	1.83e-7	Lewy body disease;
THYM	cis	rs34526934	0.608	rs66727747	chr2:177032386	T/C	cg14324370	chr2:177042789	NA	-0.7	-5.97	-0.52	4.16e-8	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs1150668	0.796	rs1124132	chr6:28380321	T/G	cg13525197	chr6:28411240	ZSCAN23	-0.62	-4.91	-0.45	3.77e-6	Pubertal anthropometrics;
THYM	cis	rs2456568	0.867	rs2462744	chr11:93682913	G/A	cg17595323	chr11:93583763	C11orf90	-0.54	-5.22	-0.47	1.04e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7631605	0.905	rs3172297	chr3:37032370	T/C	cg21328643	chr3:37258149	NA	-0.48	-4.58	-0.43	1.41e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs4654899	0.965	rs6692081	chr1:21296363	T/C	cg01072550	chr1:21505969	NA	-0.73	-6.55	-0.56	2.95e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs2070677	0.935	rs12245318	chr10:135419483	A/G	cg20169779	chr10:135381914	SYCE1	-0.75	-5.76	-0.51	1.03e-7	Gout;
THYM	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs7683537	0.725	rs28837443	chr4:185641497	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Systemic lupus erythematosus;
THYM	cis	rs7626444	0.625	rs2931210	chr3:196476676	G/C	cg12930392	chr3:196481615	PAK2	0.4	4.92	0.45	3.58e-6	Monocyte count;
THYM	cis	rs1885364	0.533	rs9613517	chr22:28104754	A/T	cg17187762	chr22:28070120	NA	0.46	5.24	0.47	9.55e-7	Facial morphology (factor 8, orbital inclination due to vertical and horizontal position of exocanthion);
THYM	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg07424592	chr7:64974309	NA	-1.04	-5.4	-0.48	4.87e-7	Diabetic kidney disease;
THYM	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg13607699	chr17:42295918	UBTF	0.89	8.57	0.66	1.84e-13	Red cell distribution width;Reticulocyte count;
THYM	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.56	-5.27	-0.48	8.6e-7	Lymphocyte counts;
THYM	cis	rs911555	0.673	rs7144271	chr14:103890674	A/G	cg12935359	chr14:103987150	CKB	-0.51	-6.07	-0.53	2.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs501916	0.761	rs79925748	chr15:48046412	G/C	cg16110827	chr15:48056943	SEMA6D	-0.65	-4.89	-0.45	4.12e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs7264396	0.635	rs6060692	chr20:34517925	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.66	5.13	0.47	1.53e-6	Total cholesterol levels;
THYM	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	8.85	0.67	4.81e-14	Chronic sinus infection;
THYM	cis	rs208520	0.690	rs864314	chr6:66814830	G/A	cg07460842	chr6:66804631	NA	-1.26	-16.01	-0.85	1.01e-28	Exhaled nitric oxide output;
THYM	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg16230307	chr14:35515116	FAM177A1	0.92	5.82	0.51	8.07e-8	Psoriasis;
THYM	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg01236616	chr12:121019343	POP5	-1.24	-10.39	-0.73	2.47e-17	Type 1 diabetes nephropathy;
THYM	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg22875332	chr1:76189707	ACADM	0.89	12.06	0.78	7.38e-21	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs78456975	0.941	rs13423300	chr2:1553809	C/A	cg14129053	chr2:1895732	MYT1L	1.13	4.49	0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs9311676	0.618	rs12152336	chr3:58365146	T/A	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs665401	0.932	rs1358793	chr6:117229593	G/C	cg20376953	chr6:117187980	NA	0.63	5.08	0.46	1.87e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs6032067	0.929	rs17425504	chr20:43880089	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.72	-6.57	-0.56	2.73e-9	Blood protein levels;
THYM	cis	rs7246657	0.943	rs4452075	chr19:37879589	A/G	cg22634378	chr19:37742834	NA	0.62	5.2	0.47	1.12e-6	Coronary artery calcification;
THYM	cis	rs12142240	0.698	rs56130131	chr1:46861306	A/C	cg00530320	chr1:46809349	NSUN4	0.74	5.13	0.47	1.5e-6	Menopause (age at onset);
THYM	cis	rs9364687	0.664	rs2294706	chr6:163942162	C/T	cg01639524	chr6:163818125	NA	-0.48	-4.78	-0.44	6.36e-6	Body mass index;
THYM	trans	rs877282	0.853	rs12763400	chr10:763617	C/T	cg22713356	chr15:30763199	NA	1.36	10.13	0.72	8.77e-17	Uric acid levels;
THYM	cis	rs4771122	0.740	rs1006353	chr13:28047269	A/G	cg22138327	chr13:27999177	GTF3A	-0.56	-4.98	-0.45	2.84e-6	Body mass index;
THYM	cis	rs2066819	0.786	rs116934693	chr12:56696545	T/G	cg26714650	chr12:56694279	CS	-1.33	-6.61	-0.56	2.26e-9	Psoriasis vulgaris;
THYM	cis	rs1018836	0.923	rs9643308	chr8:91625399	A/C	cg16814680	chr8:91681699	NA	-0.85	-7.17	-0.59	1.59e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7078219	0.714	rs10883359	chr10:101274033	C/T	cg17888390	chr10:101282816	NA	0.48	4.57	0.42	1.47e-5	Dental caries;
THYM	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.64	0.5	1.77e-7	Height;
THYM	cis	rs55871839	0.708	rs6651298	chr8:59808307	C/G	cg07426533	chr8:59803705	TOX	-0.64	-6.17	-0.53	1.67e-8	Pneumonia;
THYM	cis	rs7719624	0.870	rs1990199	chr5:135395543	G/C	cg12897067	chr5:135418308	NA	0.57	4.55	0.42	1.56e-5	Response to cytidine analogues (gemcitabine);
THYM	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg08999081	chr20:33150536	PIGU	-0.78	-7.16	-0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs11690935	0.959	rs10174525	chr2:172635697	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.83	-5.99	-0.52	3.66e-8	Schizophrenia;
THYM	cis	rs11621135	0.626	rs6574008	chr14:71652891	C/G	cg18506020	chr14:71758942	NA	-0.47	-4.5	-0.42	1.9e-5	Hair greying;
THYM	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.74	7.33	0.6	7.54e-11	Lymphocyte counts;
THYM	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs807669	0.935	rs712963	chr22:19156543	A/G	cg02655711	chr22:19163373	SLC25A1	0.74	8.64	0.66	1.34e-13	Metabolite levels;
THYM	cis	rs865483	0.895	rs2107104	chr17:35835031	G/A	cg06716730	chr17:35851459	DUSP14	0.43	7.3	0.6	8.71e-11	Monocyte count;
THYM	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg10661904	chr17:79619235	PDE6G	-0.58	-5.3	-0.48	7.36e-7	Eye color traits;
THYM	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg05896524	chr21:47604654	C21orf56	0.74	5.2	0.47	1.16e-6	Testicular germ cell tumor;
THYM	cis	rs3809566	1.000	rs4775610	chr15:63332057	C/T	cg00520135	chr15:63333846	TPM1	0.59	5.21	0.47	1.12e-6	Platelet count;
THYM	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs9393692	0.620	rs9393691	chr6:26272829	T/C	cg13736514	chr6:26305472	NA	-0.48	-5.01	-0.46	2.49e-6	Educational attainment;
THYM	cis	rs6882076	0.961	rs55776147	chr5:156400808	A/G	cg12943317	chr5:156479607	HAVCR1	-0.71	-5.83	-0.51	7.67e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs4535497	0.544	rs4975642	chr5:1107828	G/A	cg01551729	chr5:1099476	SLC12A7	0.74	6.26	0.54	1.13e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8050907	0.744	rs17887050	chr16:4524584	C/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.28	5.13	0.47	1.5e-6	Obesity-related traits;
THYM	cis	rs10992471	0.603	rs12336884	chr9:95234183	A/C	cg14631576	chr9:95140430	CENPP	-0.99	-9.94	-0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs11809207	0.523	rs7087	chr1:26496651	T/C	cg26412358	chr1:26503933	CNKSR1	0.36	5.01	0.46	2.48e-6	Height;
THYM	cis	rs11577318	0.853	rs4471263	chr1:26622700	C/T	cg00852783	chr1:26633632	UBXN11	0.7	5.88	0.52	6.16e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs11008222	0.690	rs12259731	chr10:31066248	A/G	cg00941203	chr10:31016591	NA	0.34	4.82	0.44	5.52e-6	Congenital left-sided heart lesions (maternal effect);
THYM	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg24812749	chr6:127587940	RNF146	0.98	7.94	0.63	4.04e-12	Breast cancer;
THYM	cis	rs3781663	0.553	rs875108	chr11:70004695	G/A	cg11240634	chr11:69519263	FGF19	0.66	4.53	0.42	1.73e-5	Survival in rectal cancer;
THYM	cis	rs7078219	1.000	rs7078219	chr10:101274365	A/G	cg23904955	chr10:101282759	NA	0.44	5.25	0.47	9.32e-7	Dental caries;
THYM	cis	rs736801	0.521	rs41525648	chr5:131827775	A/G	cg02551604	chr5:131831745	NA	0.62	4.89	0.45	4.12e-6	Breast cancer;Mosquito bite size;
THYM	cis	rs863345	0.604	rs2157687	chr1:158493000	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs12039431	0.788	rs61776188	chr1:38021326	C/T	cg17933807	chr1:38061675	GNL2	-0.87	-6.48	-0.55	4.07e-9	Epithelial ovarian cancer;
THYM	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg06634786	chr22:41940651	POLR3H	0.7	4.92	0.45	3.59e-6	Vitiligo;
THYM	cis	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg13443165	chr9:33130375	B4GALT1	-0.86	-7.83	-0.63	6.91e-12	IgG glycosylation;
THYM	cis	rs4509693	0.943	rs6584393	chr10:102497206	C/G	cg15234845	chr10:102496500	NA	0.65	4.6	0.43	1.3e-5	Alzheimer's disease;
THYM	cis	rs2463822	0.925	rs74692811	chr11:62156572	G/A	cg06239285	chr11:62104954	ASRGL1	-1.44	-7.7	-0.62	1.3e-11	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg06728252	chr6:26598149	ABT1	-0.43	-5.11	-0.46	1.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6674970	0.777	rs12087892	chr1:151118500	T/C	cg11822372	chr1:151115635	SEMA6C	-1.1	-8.3	-0.65	7.13e-13	Childhood ear infection;
THYM	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19346786	chr7:2764209	NA	-0.7	-5.95	-0.52	4.55e-8	Height;
THYM	cis	rs981844	0.712	rs6535956	chr4:154746001	G/A	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs3750965	1.000	rs3750965	chr11:68840160	A/G	cg01403660	chr11:68851641	TPCN2	0.73	5.81	0.51	8.29e-8	Hair color;
THYM	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg06481639	chr22:41940642	POLR3H	0.82	5.68	0.5	1.49e-7	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs9914988	0.943	rs4795465	chr17:27151498	A/G	cg20469991	chr17:27169893	C17orf63	0.77	4.72	0.44	8.03e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg15448220	chr1:150897856	SETDB1	0.87	7.38	0.6	6.09e-11	Melanoma;
THYM	cis	rs4654899	0.931	rs12723255	chr1:21233570	C/T	cg01072550	chr1:21505969	NA	0.67	6.29	0.54	9.58e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg06636001	chr8:8085503	FLJ10661	0.72	6.6	0.56	2.35e-9	Mood instability;
THYM	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg12011299	chr4:100065546	ADH4	0.85	8.22	0.64	1.02e-12	Alcohol dependence;
THYM	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg17211192	chr8:82754475	SNX16	-0.82	-7.16	-0.59	1.67e-10	Diastolic blood pressure;
THYM	cis	rs2932538	0.922	rs12750023	chr1:113118329	G/A	cg22162597	chr1:113214053	CAPZA1	0.65	5.32	0.48	6.9e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.67	8.61	0.66	1.51e-13	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs425277	1.000	rs427811	chr1:2075560	T/G	cg23803603	chr1:2058230	PRKCZ	0.59	4.56	0.42	1.52e-5	Height;
THYM	cis	rs6867032	0.958	rs4975797	chr5:2015573	G/A	cg26168224	chr5:2018326	NA	1.29	15.53	0.85	8.25e-28	Gut microbiome composition (winter);
THYM	cis	rs925255	0.817	rs12624279	chr2:28634790	G/A	cg01273330	chr2:28605224	NA	0.7	6.24	0.54	1.23e-8	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs887829	0.531	rs4338954	chr2:234593931	C/G	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.59	-0.43	1.36e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg01751800	chr4:77820391	ANKRD56	0.55	4.59	0.43	1.36e-5	Emphysema distribution in smoking;
THYM	cis	rs13064411	0.696	rs6438159	chr3:113217341	T/C	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg23161317	chr6:28129485	ZNF389	0.91	6.48	0.55	4.13e-9	Parkinson's disease;
THYM	cis	rs5771069	0.897	rs137858	chr22:50445601	T/C	cg27467552	chr22:50353597	PIM3	-0.47	-5.02	-0.46	2.42e-6	Ulcerative colitis;
THYM	cis	rs887829	0.569	rs3821242	chr2:234637803	T/C	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.58	-0.43	1.39e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.16	-0.47	1.36e-6	Chronic sinus infection;
THYM	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg03806693	chr22:41940476	POLR3H	-1.04	-8.13	-0.64	1.62e-12	Vitiligo;
THYM	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.24	4.96	0.45	3.04e-6	Obesity-related traits;
THYM	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.83	-5.25	-0.47	9.38e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs4478037	0.558	rs4456812	chr3:33080882	G/A	cg19404215	chr3:33155277	CRTAP	-0.97	-5.66	-0.5	1.6e-7	Major depressive disorder;
THYM	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg26818010	chr10:134567672	INPP5A	-0.93	-7.48	-0.61	3.71e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg06618935	chr21:46677482	NA	-0.95	-8.95	-0.68	2.86e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7084402	0.935	rs10763559	chr10:60347410	C/T	cg27040468	chr10:60456715	BICC1	-0.54	-4.49	-0.42	1.98e-5	Refractive error;
THYM	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg18876405	chr7:65276391	NA	-0.64	-5.55	-0.49	2.58e-7	Aortic root size;
THYM	cis	rs4523957	0.651	rs8082485	chr17:2060407	A/G	cg16513277	chr17:2031491	SMG6	-0.94	-8.42	-0.65	3.95e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg16778714	chr17:28903809	LRRC37B2	-0.76	-4.49	-0.42	2.03e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs921968	0.678	rs2230115	chr2:219509618	C/A	cg01872077	chr2:219646372	CYP27A1	0.58	4.49	0.42	2e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg16414030	chr3:133502952	NA	-0.84	-8.51	-0.66	2.52e-13	Iron status biomarkers;
THYM	cis	rs854765	0.551	rs8070748	chr17:17859421	A/G	cg16928487	chr17:17741425	SREBF1	-0.55	-5.47	-0.49	3.62e-7	Total body bone mineral density;
THYM	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs929596	0.556	rs4477910	chr2:234643737	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.84	-7.24	-0.6	1.17e-10	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs1448094	0.511	rs10506918	chr12:86227913	A/G	cg02569458	chr12:86230093	RASSF9	-0.57	-4.83	-0.44	5.31e-6	Major depressive disorder;
THYM	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.68	-4.87	-0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs7011507	0.594	rs72639027	chr8:49346630	C/T	cg08774009	chr8:49309094	NA	-0.6	-4.71	-0.44	8.47e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg24060327	chr5:131705240	SLC22A5	-0.76	-5.73	-0.51	1.16e-7	Blood metabolite levels;
THYM	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg24112000	chr20:60950667	NA	-0.68	-5.62	-0.5	1.92e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs514406	0.763	rs6685599	chr1:53213172	G/A	cg24675658	chr1:53192096	ZYG11B	0.58	4.66	0.43	1.04e-5	Monocyte count;
THYM	cis	rs12519773	0.517	rs17360811	chr5:92492349	G/A	cg18783429	chr5:92414398	NA	0.5	4.95	0.45	3.23e-6	Migraine;
THYM	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.61	-4.79	-0.44	6.17e-6	Platelet count;
THYM	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs2688608	0.592	rs7909802	chr10:75484186	G/C	cg15838173	chr10:75533400	FUT11	-0.5	-5.09	-0.46	1.82e-6	Inflammatory bowel disease;
THYM	cis	rs7582180	0.568	rs10186134	chr2:100939501	T/A	cg21926883	chr2:100939477	LONRF2	-0.64	-5.9	-0.52	5.54e-8	Intelligence (multi-trait analysis);
THYM	cis	rs34779708	0.966	rs12765038	chr10:35416513	G/C	cg03585969	chr10:35415529	CREM	0.67	4.76	0.44	6.91e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs17711722	0.583	rs10085415	chr7:65093568	T/A	cg18876405	chr7:65276391	NA	-0.74	-6.66	-0.56	1.8e-9	Calcium levels;
THYM	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs4409675	0.576	rs7536088	chr1:28234325	A/G	cg23691781	chr1:28212827	C1orf38	0.46	4.51	0.42	1.86e-5	Corneal astigmatism;
THYM	cis	rs921968	0.643	rs3845836	chr2:219504955	C/T	cg02176678	chr2:219576539	TTLL4	0.61	5.86	0.52	6.61e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg12573674	chr2:1569213	NA	-1.22	-4.82	-0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs9768139	0.658	rs73746486	chr7:158113191	A/G	cg06219351	chr7:158114137	PTPRN2	-0.79	-8.18	-0.64	1.27e-12	Calcium levels;
THYM	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg19318889	chr4:1322082	MAEA	0.55	4.95	0.45	3.27e-6	Longevity;
THYM	cis	rs55728055	0.661	rs55931230	chr22:32028028	T/A	cg10537193	chr22:32026975	PISD	-0.86	-5.48	-0.49	3.48e-7	Age-related hearing impairment;
THYM	cis	rs4919687	0.550	rs12761195	chr10:104465374	T/C	cg18761893	chr10:103892519	PPRC1	0.61	4.69	0.43	9.13e-6	Colorectal cancer;
THYM	cis	rs17767294	0.708	rs115714358	chr6:27964332	A/C	cg08851530	chr6:28072375	NA	1.39	5.71	0.51	1.31e-7	Parkinson's disease;
THYM	cis	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg13446199	chr8:143762866	PSCA	-0.41	-4.53	-0.42	1.7e-5	Urinary tract infection frequency;
THYM	cis	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg05800356	chr16:74706258	MLKL	0.68	4.97	0.45	2.98e-6	Energy expenditure (24h);
THYM	cis	rs7944735	0.607	rs34895872	chr11:48021778	A/G	cg25800328	chr11:47736132	AGBL2	0.41	4.54	0.42	1.66e-5	Intraocular pressure;
THYM	cis	rs4076764	0.846	rs4255362	chr1:163424630	G/A	cg06092702	chr1:163392909	NA	-0.58	-4.92	-0.45	3.58e-6	Motion sickness;
THYM	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg11789530	chr4:8429930	ACOX3	-0.53	-4.53	-0.42	1.7e-5	Response to antineoplastic agents;
THYM	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.71	-4.73	-0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg24209194	chr3:40518798	ZNF619	-0.56	-4.68	-0.43	9.42e-6	Renal cell carcinoma;
THYM	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.38	0.55	6.27e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2160908	0.694	rs229521	chr22:37578852	C/T	cg26999345	chr22:37584441	C1QTNF6	-0.39	-4.53	-0.42	1.75e-5	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs539096	0.500	rs2906457	chr1:44338575	A/C	cg13246856	chr1:44399776	ARTN	0.49	4.95	0.45	3.26e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg05738196	chr6:26577821	NA	-0.65	-5.1	-0.46	1.7e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs17122693	0.818	rs113230118	chr14:51160977	G/A	cg04730355	chr14:51134070	SAV1	0.93	5.59	0.5	2.2e-7	Cognitive performance;
THYM	cis	rs7072216	0.763	rs4475861	chr10:100164989	C/T	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.47	-0.42	2.19e-5	Metabolite levels;
THYM	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg13443165	chr9:33130375	B4GALT1	-0.85	-7.73	-0.62	1.14e-11	IgG glycosylation;
THYM	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg18538332	chr22:24372958	LOC391322	-1.05	-13.01	-0.8	8.12e-23	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg05373962	chr22:49881684	NA	-0.6	-5.47	-0.49	3.61e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg21773646	chr17:80085082	CCDC57	0.31	4.49	0.42	2.02e-5	Life satisfaction;
THYM	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs6570726	0.791	rs9497357	chr6:145912888	G/A	cg23711669	chr6:146136114	FBXO30	0.95	9.91	0.71	2.53e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4481887	0.927	rs10888344	chr1:248446655	T/C	cg00666640	chr1:248458726	OR2T12	0.54	4.57	0.42	1.48e-5	Common traits (Other);
THYM	cis	rs3760982	0.585	rs4803659	chr19:44290235	C/T	cg11993925	chr19:44307056	LYPD5	0.63	4.93	0.45	3.45e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs9326248	0.581	rs6589582	chr11:116829200	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.66	5.38	0.48	5.34e-7	Blood protein levels;
THYM	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.91	7.88	0.63	5.3e-12	Multiple sclerosis;
THYM	cis	rs1691799	0.777	rs11176145	chr12:66719795	A/G	cg16791601	chr12:66731901	HELB	0.66	5.39	0.48	5.2e-7	White blood cell count (basophil);
THYM	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg13390004	chr1:15929781	NA	0.6	4.58	0.43	1.39e-5	Systolic blood pressure;
THYM	cis	rs3820068	0.580	rs12760698	chr1:16009814	G/A	cg27534772	chr1:16042836	PLEKHM2	0.5	5.26	0.48	8.76e-7	Systolic blood pressure;
THYM	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg04043695	chr12:129287642	SLC15A4	0.6	4.87	0.45	4.4e-6	Systemic lupus erythematosus;
THYM	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg26513180	chr16:89883248	FANCA	0.5	4.82	0.44	5.39e-6	Vitiligo;
THYM	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs3741798	0.901	rs61922024	chr12:12485881	C/A	cg08615371	chr12:12503544	MANSC1	0.88	4.89	0.45	4.17e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs2072499	0.767	rs3001789	chr1:156197614	T/G	cg24450063	chr1:156163899	SLC25A44	1.0	11.18	0.75	5.17e-19	Testicular germ cell tumor;
THYM	cis	rs9296092	0.560	rs9469511	chr6:33530930	T/G	cg13560919	chr6:33536144	NA	-0.94	-9.17	-0.69	9.74e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg22467129	chr15:76604101	ETFA	-0.56	-5.37	-0.48	5.47e-7	Blood metabolite levels;
THYM	cis	rs1775715	0.707	rs2808087	chr10:32146444	C/G	cg04359828	chr10:32216031	ARHGAP12	0.41	5.12	0.46	1.62e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg17279839	chr7:150038598	RARRES2	0.56	5.41	0.49	4.78e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7463256	1.000	rs12542630	chr8:23103658	A/T	cg14349055	chr8:23104193	CHMP7	-1.04	-12.95	-0.8	1.07e-22	Attention deficit hyperactivity disorder;
THYM	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg19748678	chr4:122722346	EXOSC9	0.73	5.15	0.47	1.42e-6	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg05340658	chr4:99064831	C4orf37	0.54	4.51	0.42	1.83e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7267979	1.000	rs4815418	chr20:25382211	T/G	cg08601574	chr20:25228251	PYGB	-0.57	-4.62	-0.43	1.19e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7119	0.717	rs12909645	chr15:77816819	A/T	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.2e-16	Bone mineral density;
THYM	cis	rs2046867	0.908	rs28822756	chr3:72825011	C/T	cg25664220	chr3:72788482	NA	-0.77	-5.8	-0.51	8.6e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs259282	0.605	rs8101007	chr19:33109557	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.57	4.74	0.44	7.36e-6	Schizophrenia;
THYM	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg24675056	chr1:15929824	NA	0.73	5.79	0.51	9.09e-8	Systolic blood pressure;
THYM	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg08859206	chr1:53392774	SCP2	-0.66	-7.55	-0.61	2.7e-11	Monocyte count;
THYM	cis	rs4363385	0.818	rs1415966	chr1:153002864	A/G	cg13444842	chr1:152974279	SPRR3	-0.59	-4.81	-0.44	5.61e-6	Inflammatory skin disease;
THYM	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg10553204	chr2:20871195	GDF7	-0.76	-6.52	-0.56	3.37e-9	Abdominal aortic aneurysm;
THYM	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs4974559	0.594	rs59544360	chr4:1313575	G/T	cg16185996	chr4:1008614	FGFRL1	-0.42	-4.69	-0.43	8.99e-6	Systolic blood pressure;
THYM	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg26031613	chr14:104095156	KLC1	0.79	5.11	0.46	1.66e-6	Body mass index;
THYM	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-4.96	-0.45	3.03e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg15704280	chr7:45808275	SEPT13	-0.94	-7.21	-0.59	1.35e-10	Coronary artery disease;
THYM	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg05768032	chr16:30646687	NA	0.55	5.56	0.5	2.46e-7	Multiple myeloma;
THYM	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs6032067	0.929	rs17424696	chr20:43810734	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.73	-8.04	-0.64	2.47e-12	Blood protein levels;
THYM	cis	rs6430585	0.583	rs7581814	chr2:136641593	C/G	cg04750100	chr2:136595281	LCT	-0.56	-5.26	-0.47	8.94e-7	Corneal structure;
THYM	cis	rs9527	0.640	rs7089061	chr10:104723015	C/A	cg04362960	chr10:104952993	NT5C2	0.6	4.62	0.43	1.2e-5	Arsenic metabolism;
THYM	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6748734	0.625	rs10172404	chr2:241820906	T/C	cg02820040	chr2:241836501	C2orf54	-0.24	-4.5	-0.42	1.89e-5	Urinary metabolites;
THYM	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06481639	chr22:41940642	POLR3H	-0.8	-5.54	-0.49	2.72e-7	Vitiligo;
THYM	cis	rs11779988	0.545	rs415840	chr8:17782134	C/T	cg01800426	chr8:17659068	MTUS1	-0.72	-5.11	-0.46	1.63e-6	Breast cancer;
THYM	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg20476274	chr7:133979776	SLC35B4	0.71	4.82	0.44	5.42e-6	Mean platelet volume;
THYM	cis	rs929596	0.793	rs2741044	chr2:234579368	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.87	-5.82	-0.51	8.08e-8	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs6598541	0.963	rs2871974	chr15:99284074	C/T	cg13297560	chr15:99320054	IGF1R	0.46	4.6	0.43	1.32e-5	Urate levels;
THYM	cis	rs2172802	0.693	rs7660566	chr4:62481231	G/T	cg04118610	chr4:62707027	LPHN3	0.7	4.81	0.44	5.74e-6	Partial epilepsies;
THYM	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg05738196	chr6:26577821	NA	0.95	9.91	0.71	2.53e-16	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg05368731	chr17:41323189	NBR1	1.25	11.17	0.75	5.29e-19	Menopause (age at onset);
THYM	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg12311346	chr5:56204834	C5orf35	-0.61	-4.67	-0.43	9.99e-6	Initial pursuit acceleration;
THYM	trans	rs11030122	0.660	rs10160703	chr11:3893213	A/C	cg04516757	chr7:75599274	POR	0.7	6.98	0.58	3.97e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11690935	0.595	rs788171	chr2:172921832	A/G	cg13550731	chr2:172543902	DYNC1I2	0.7	5.87	0.52	6.45e-8	Schizophrenia;
THYM	cis	rs10911232	0.507	rs4642853	chr1:182996242	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs6754311	0.593	rs313522	chr2:136430866	T/A	cg23851026	chr2:136556271	LCT	0.59	5.62	0.5	1.91e-7	Mosquito bite size;
THYM	cis	rs6074022	0.513	rs9074	chr20:44688665	G/A	cg20003638	chr20:44687730	SLC12A5	0.75	5.26	0.47	8.85e-7	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
THYM	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14893161	chr1:205819251	PM20D1	1.04	12.11	0.78	5.68e-21	Menarche (age at onset);
THYM	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs2361718	0.568	rs1042397	chr17:78092063	G/A	cg06586046	chr17:78038103	CCDC40	-0.43	-4.58	-0.43	1.43e-5	Yeast infection;
THYM	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.28e-8	Intelligence (multi-trait analysis);
THYM	trans	rs11175492	1.000	rs11175486	chr12:65032744	C/G	cg12514734	chr12:3216258	TSPAN9	-1.59	-7.44	-0.61	4.38e-11	Platelet count;
THYM	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18402987	chr7:1209562	NA	0.74	5.32	0.48	6.94e-7	Longevity;Endometriosis;
THYM	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg22907277	chr7:1156413	C7orf50	0.82	4.98	0.46	2.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs901683	1.000	rs36100685	chr10:46086854	G/A	cg18240400	chr10:46168597	ANUBL1	0.73	4.73	0.44	7.89e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg19077165	chr18:44547161	KATNAL2	-0.62	-7.9	-0.63	4.78e-12	Personality dimensions;
THYM	cis	rs929596	0.697	rs17863787	chr2:234611094	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.82	-6.55	-0.56	2.99e-9	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-1.07	-7.63	-0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg23187316	chr7:1099788	C7orf50	0.59	4.52	0.42	1.76e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg07022442	chr13:21864356	NA	0.7	4.64	0.43	1.12e-5	White matter hyperintensity burden;
THYM	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6956675	1.000	rs10280052	chr7:62600311	C/T	cg27518014	chr7:62859535	LOC100287834	0.66	5.15	0.47	1.43e-6	Obesity-related traits;
THYM	cis	rs4363385	0.510	rs6686526	chr1:153044996	T/C	cg13444842	chr1:152974279	SPRR3	-0.6	-4.68	-0.43	9.48e-6	Inflammatory skin disease;
THYM	cis	rs2241584	1.000	rs2241584	chr5:175956177	C/T	cg27658698	chr5:175955578	RNF44	-0.46	-5.55	-0.49	2.6e-7	Menopause (age at onset);
THYM	trans	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg10856724	chr12:34555212	NA	-0.89	-7.85	-0.63	6.11e-12	Bladder cancer;
THYM	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.42	-0.49	4.57e-7	Bipolar disorder;
THYM	cis	rs72828912	0.808	rs9379633	chr6:24057572	A/G	cg26336265	chr6:25042955	NA	-0.93	-5.5	-0.49	3.17e-7	Squamous cell lung carcinoma;
THYM	cis	rs6988636	0.901	rs62521825	chr8:124185786	C/A	cg26140120	chr8:124219575	FAM83A	0.87	4.81	0.44	5.77e-6	Urinary uromodulin levels;
THYM	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg22841779	chr14:105766346	BRF1	-0.49	-6.27	-0.54	1.04e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg20007245	chr22:24372913	LOC391322	-0.71	-6.39	-0.55	6.22e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg22535103	chr8:58192502	C8orf71	-0.96	-5.75	-0.51	1.06e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg26963428	chr7:66367121	NA	-0.57	-4.81	-0.44	5.77e-6	Corneal structure;
THYM	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg21427119	chr20:30132790	HM13	0.71	4.79	0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs3772130	0.540	rs11717089	chr3:121563271	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.86	7.17	0.59	1.63e-10	Cognitive performance;
THYM	cis	rs4363385	0.693	rs576941	chr1:153040165	A/G	cg13444842	chr1:152974279	SPRR3	0.62	5.29	0.48	7.86e-7	Inflammatory skin disease;
THYM	cis	rs7772486	0.641	rs2777485	chr6:146334377	G/A	cg23711669	chr6:146136114	FBXO30	0.81	7.57	0.61	2.45e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7119	0.623	rs12905318	chr15:77845873	T/C	cg10437265	chr15:77819839	NA	0.68	6.14	0.53	1.94e-8	Type 2 diabetes;
THYM	cis	rs4731207	0.596	rs10081226	chr7:124575529	C/A	cg05285228	chr7:124571219	POT1	-0.69	-5.25	-0.47	9.35e-7	Cutaneous malignant melanoma;
THYM	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg10360139	chr7:1886902	MAD1L1	-0.82	-7.52	-0.61	3.01e-11	Bipolar disorder and schizophrenia;
THYM	cis	rs868036	0.718	rs7170185	chr15:68117300	T/A	cg24579218	chr15:68104479	NA	-0.8	-8.27	-0.65	8.25e-13	Restless legs syndrome;
THYM	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg23161317	chr6:28129485	ZNF389	0.89	6.12	0.53	2.06e-8	Parkinson's disease;
THYM	cis	rs2354432	0.556	rs72710311	chr1:146698256	A/G	cg25205988	chr1:146714368	CHD1L	-1.05	-5.61	-0.5	1.95e-7	Mitochondrial DNA levels;
THYM	cis	rs4776059	1.000	rs12902679	chr15:52881317	C/T	cg22715398	chr15:52968154	KIAA1370	0.56	4.46	0.42	2.2e-5	Schizophrenia;
THYM	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg19693284	chr19:2783607	SGTA	0.82	5.94	0.52	4.66e-8	Total cholesterol levels;
THYM	cis	rs7914558	0.902	rs3736922	chr10:104850632	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	4.54	0.42	1.62e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4072705	0.967	rs10739650	chr9:127323776	C/T	cg13476313	chr9:127244764	NR5A1	0.31	4.78	0.44	6.36e-6	Menarche (age at onset);
THYM	cis	rs7511006	0.893	rs760743	chr22:50647375	C/T	cg16294310	chr22:50629110	TRABD	0.65	5.11	0.46	1.69e-6	Obesity-related traits;
THYM	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.71	0.57	1.41e-9	Prudent dietary pattern;
THYM	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg17264618	chr3:40429014	ENTPD3	0.52	4.95	0.45	3.22e-6	Renal cell carcinoma;
THYM	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.86	-0.52	6.67e-8	Chronic sinus infection;
THYM	cis	rs28374715	0.617	rs16971735	chr15:41563970	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.9	-7.84	-0.63	6.58e-12	Ulcerative colitis;
THYM	cis	rs2354432	0.607	rs2353999	chr1:146830686	T/C	cg25205988	chr1:146714368	CHD1L	-1.03	-5.4	-0.48	5.01e-7	Mitochondrial DNA levels;
THYM	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.6	0.5	2.04e-7	Lung cancer in ever smokers;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg06830724	chr14:101359903	MEG8	-0.97	-7.03	-0.58	3.09e-10	Depressive symptoms;
THYM	cis	rs1018836	0.570	rs6471084	chr8:91463666	T/C	cg16814680	chr8:91681699	NA	-0.67	-5.08	-0.46	1.85e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs1062746	0.544	rs3762182	chr16:87326113	A/G	cg02258303	chr16:87377426	FBXO31	0.6	4.5	0.42	1.94e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs6700896	0.931	rs7546242	chr1:66093030	C/T	cg04111102	chr1:66153794	NA	0.55	5.18	0.47	1.25e-6	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9388451	0.874	rs9388454	chr6:126115383	A/C	cg05901451	chr6:126070800	HEY2	-0.92	-8.91	-0.67	3.6e-14	Brugada syndrome;
THYM	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg07570687	chr10:102243282	WNT8B	0.74	6.43	0.55	5.18e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2281636	0.540	rs1057490	chr10:101466606	G/T	cg05149213	chr10:101381631	SLC25A28	-0.44	-4.51	-0.42	1.84e-5	Obesity-related traits;
THYM	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg06634786	chr22:41940651	POLR3H	-0.74	-5.23	-0.47	9.94e-7	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg18252515	chr7:66147081	NA	-1.37	-8.05	-0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs13256369	0.802	rs11249883	chr8:8561537	G/A	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg12667521	chr19:29218732	NA	-0.65	-4.76	-0.44	7.04e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs7943358	0.955	rs747784	chr11:15713477	G/A	cg11966998	chr11:15692519	NA	-0.48	-4.6	-0.43	1.3e-5	Gut microbiome composition (summer);
THYM	cis	rs332507	0.830	rs3821532	chr3:124402618	G/T	cg14688451	chr3:124303035	KALRN	0.6	4.62	0.43	1.21e-5	Plateletcrit;
THYM	cis	rs3087591	0.920	rs2905881	chr17:29547862	T/C	cg24425628	chr17:29625626	OMG;NF1	0.65	5.69	0.5	1.38e-7	Hip circumference;
THYM	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg12564285	chr5:131593104	PDLIM4	0.52	5.69	0.5	1.38e-7	Breast cancer;
THYM	cis	rs7772486	0.754	rs2064185	chr6:146066814	G/A	cg23711669	chr6:146136114	FBXO30	-0.97	-10.49	-0.73	1.45e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.37	-0.55	6.73e-9	Personality dimensions;
THYM	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg08736216	chr1:53307985	ZYG11A	-0.65	-5.78	-0.51	9.47e-8	Monocyte count;
THYM	cis	rs728616	0.764	rs117833443	chr10:81738136	A/C	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7809950	0.530	rs111865019	chr7:106812246	A/G	cg23024343	chr7:107201750	COG5	-0.87	-7.19	-0.59	1.49e-10	Coronary artery disease;
THYM	cis	rs919433	0.679	rs10931788	chr2:198531084	A/G	cg00792783	chr2:198669748	PLCL1	0.82	5.44	0.49	4.16e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg06108461	chr20:60628389	TAF4	-0.81	-6.73	-0.57	1.28e-9	Body mass index;
THYM	cis	rs6733011	0.578	rs10181972	chr2:99497284	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.69	-0.43	9.32e-6	Bipolar disorder;
THYM	cis	rs3087591	1.000	rs9902427	chr17:29625430	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.69	-6.04	-0.53	2.94e-8	Hip circumference;
THYM	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg03806693	chr22:41940476	POLR3H	-0.83	-6.47	-0.55	4.19e-9	Vitiligo;
THYM	cis	rs11886999	0.951	rs11551400	chr2:96914636	T/C	cg18419276	chr2:96971862	SNRNP200	-0.49	-5.45	-0.49	4.04e-7	Cardiac Troponin-T levels;
THYM	cis	rs921665	0.748	rs1869420	chr2:3202073	C/T	cg16434511	chr2:3151078	NA	-0.84	-5.41	-0.49	4.61e-7	World class endurance athleticism;
THYM	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg08736216	chr1:53307985	ZYG11A	-0.73	-6.35	-0.55	7.48e-9	Monocyte count;
THYM	cis	rs7828089	0.522	rs4872484	chr8:22255859	C/T	cg12081754	chr8:22256438	SLC39A14	1.04	9.93	0.71	2.36e-16	Verbal declarative memory;
THYM	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg04234412	chr22:24373322	LOC391322	-0.9	-10.18	-0.72	6.78e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs728616	0.867	rs1923534	chr10:81710485	A/G	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs11048434	0.736	rs12821842	chr12:9108984	G/A	cg04155231	chr12:9217510	LOC144571	0.47	4.47	0.42	2.14e-5	Sjögren's syndrome;
THYM	cis	rs4642101	0.824	rs9820977	chr3:12842932	G/A	cg05775895	chr3:12838266	CAND2	0.94	8.62	0.66	1.49e-13	QRS complex (12-leadsum);
THYM	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs10489202	1.000	rs718885	chr1:167954659	A/G	cg24449463	chr1:168025552	DCAF6	-0.83	-6.51	-0.56	3.58e-9	Schizophrenia;
THYM	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08704250	chr15:31115839	NA	0.69	7.77	0.62	9.15e-12	Huntington's disease progression;
THYM	cis	rs11690935	0.851	rs7573003	chr2:172741415	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.69	-4.76	-0.44	6.92e-6	Schizophrenia;
THYM	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg17796960	chr10:135278976	LOC619207	-0.58	-4.82	-0.44	5.45e-6	Systemic lupus erythematosus;
THYM	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs9527	0.590	rs7088200	chr10:104793235	G/A	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs3847687	1.000	rs34853396	chr12:131519265	G/T	cg13586425	chr12:131519906	GPR133	-0.32	-5.09	-0.46	1.8e-6	Longevity;
THYM	cis	rs7511006	0.893	rs760743	chr22:50647375	C/T	cg01917657	chr22:50617092	PANX2	-0.4	-4.5	-0.42	1.92e-5	Obesity-related traits;
THYM	cis	rs10992471	0.528	rs7031567	chr9:95241363	A/G	cg14631576	chr9:95140430	CENPP	-0.84	-8.02	-0.64	2.69e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6584283	0.846	rs7917446	chr10:101286207	T/C	cg17888390	chr10:101282816	NA	-0.44	-4.58	-0.43	1.41e-5	Ulcerative colitis;
THYM	cis	rs35160687	0.862	rs13023154	chr2:86516984	A/G	cg10973622	chr2:86423274	IMMT	-0.53	-4.67	-0.43	9.75e-6	Night sleep phenotypes;
THYM	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg12893697	chr11:970389	AP2A2	-0.31	-5.21	-0.47	1.1e-6	Alzheimer's disease (late onset);
THYM	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg16680214	chr1:154839983	KCNN3	0.45	5.28	0.48	8.13e-7	Prostate cancer;
THYM	cis	rs7580658	0.864	rs4150441	chr2:128040915	T/C	cg10021288	chr2:128175891	PROC	-0.72	-6.36	-0.55	7.09e-9	Protein C levels;
THYM	cis	rs9595908	0.869	rs7337687	chr13:33169697	C/T	cg12383807	chr13:33924137	NA	0.48	4.46	0.42	2.24e-5	Body mass index;
THYM	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg16506815	chr2:162101123	NA	0.6	4.48	0.42	2.1e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7312774	0.618	rs9651926	chr12:107356820	G/A	cg16260113	chr12:107380972	MTERFD3	1.36	6.52	0.56	3.4e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs12765878	0.967	rs10883940	chr10:105650598	G/A	cg11005552	chr10:105648138	OBFC1	0.87	11.39	0.76	1.84e-19	Coronary artery disease;
THYM	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg10760299	chr15:45669010	GATM	-0.71	-5.12	-0.46	1.62e-6	Homoarginine levels;
THYM	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg08742575	chr21:47604166	C21orf56	-0.64	-4.8	-0.44	5.85e-6	Testicular germ cell tumor;
THYM	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg20503657	chr10:835505	NA	1.01	5.73	0.51	1.17e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg17775962	chr7:1200435	ZFAND2A	0.43	5.19	0.47	1.19e-6	Longevity;Endometriosis;
THYM	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg15704280	chr7:45808275	SEPT13	0.91	9.1	0.68	1.4e-14	Coronary artery disease;
THYM	cis	rs4363385	0.626	rs6667103	chr1:153064438	A/G	cg06563695	chr1:153756334	NA	-0.61	-5.01	-0.46	2.52e-6	Inflammatory skin disease;
THYM	trans	rs75518195	0.566	rs62302826	chr4:64740532	T/C	cg14706739	chr8:21916355	EPB49	0.72	6.91	0.58	5.57e-10	Triptolide cytotoxicity;
THYM	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.49	-4.53	-0.42	1.69e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs7927771	0.524	rs1056387	chr11:47681370	A/C	cg18512352	chr11:47633146	NA	0.51	4.5	0.42	1.94e-5	Subjective well-being;
THYM	cis	rs6430585	0.591	rs77096272	chr2:136663605	C/A	cg07169764	chr2:136633963	MCM6	1.18	10.98	0.75	1.39e-18	Corneal structure;
THYM	cis	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg21775007	chr8:11205619	TDH	0.7	6.37	0.55	6.82e-9	Retinal vascular caliber;
THYM	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg26924012	chr15:45694286	SPATA5L1	1.12	10.37	0.73	2.72e-17	Homoarginine levels;
THYM	cis	rs12765878	0.603	rs2475216	chr10:105660651	G/A	cg11005552	chr10:105648138	OBFC1	-0.52	-4.54	-0.42	1.67e-5	Coronary artery disease;
THYM	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg18252515	chr7:66147081	NA	0.64	4.85	0.45	4.8e-6	Aortic root size;
THYM	cis	rs6782025	0.609	rs9863608	chr3:121244356	G/A	cg21456320	chr3:121264201	POLQ	0.62	4.47	0.42	2.17e-5	Aging (facial);
THYM	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.73	-4.82	-0.44	5.35e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs8101881	0.576	rs7250662	chr19:33364092	T/G	cg05467458	chr19:33361032	SLC7A9	-0.56	-5.1	-0.46	1.73e-6	Blood metabolite levels;Urinary metabolites;Urinary metabolites (H-NMR features);
THYM	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg11941060	chr3:133502564	NA	-0.73	-6.23	-0.54	1.24e-8	Iron status biomarkers;
THYM	cis	rs7084402	0.967	rs1649060	chr10:60310480	C/G	cg07615347	chr10:60278583	BICC1	-0.58	-5.37	-0.48	5.64e-7	Refractive error;
THYM	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg10553204	chr2:20871195	GDF7	-0.79	-6.75	-0.57	1.18e-9	Abdominal aortic aneurysm;
THYM	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg08835221	chr22:38071607	LGALS1	0.38	5.04	0.46	2.21e-6	Fat distribution (HIV);
THYM	trans	rs4749080	0.541	rs3818957	chr10:26443625	A/C	cg00192819	chr18:76486611	NA	1.0	7.09	0.59	2.41e-10	Obesity-related traits;
THYM	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg27394845	chr17:28928406	LRRC37B2	0.98	4.82	0.44	5.45e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs828999	0.715	rs34406538	chr1:108719468	G/A	cg24323958	chr1:108741884	SLC25A24	0.57	5.61	0.5	1.97e-7	Monocyte percentage of white cells;
THYM	cis	rs9403317	0.960	rs8180607	chr6:141877035	G/A	cg15052665	chr6:141804349	NA	0.88	8.79	0.67	6.49e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9916302	0.706	rs6503521	chr17:37715551	A/C	cg07936489	chr17:37558343	FBXL20	0.76	4.68	0.43	9.61e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg06618935	chr21:46677482	NA	-0.92	-9.19	-0.69	9.04e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.78	-7.17	-0.59	1.61e-10	Personality dimensions;
THYM	cis	rs7336332	0.517	rs9581842	chr13:27978953	G/C	cg22138327	chr13:27999177	GTF3A	0.81	6.44	0.55	4.98e-9	Weight;
THYM	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.8	6.76	0.57	1.09e-9	Lymphocyte percentage of white cells;
THYM	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13006833	0.668	rs291466	chr2:191184475	A/G	cg11845111	chr2:191398756	TMEM194B	0.65	4.48	0.42	2.07e-5	Urinary metabolites;
THYM	cis	rs3816788	0.670	rs748350	chr8:21867834	A/G	cg17168535	chr8:21777572	XPO7	0.79	6.63	0.56	2e-9	Lung cancer in ever smokers;
THYM	cis	rs454510	0.542	rs10754417	chr1:120177454	G/T	cg16322792	chr1:120165303	ZNF697	0.56	5.01	0.46	2.47e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
THYM	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg06634786	chr22:41940651	POLR3H	-0.7	-5.01	-0.46	2.55e-6	Vitiligo;
THYM	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg10802521	chr3:52805072	NEK4	-0.77	-7.14	-0.59	1.84e-10	Electroencephalogram traits;
THYM	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg07532245	chr17:28927093	LRRC37B2	0.71	4.48	0.42	2.04e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7809950	1.000	rs2712191	chr7:107182724	C/G	cg23024343	chr7:107201750	COG5	-0.94	-8.59	-0.66	1.7e-13	Coronary artery disease;
THYM	cis	rs728616	0.614	rs10887243	chr10:81717095	G/T	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg27490568	chr2:178487706	NA	0.63	6.05	0.53	2.91e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6032067	1.000	rs13038434	chr20:43888106	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.42	-4.46	-0.42	2.27e-5	Blood protein levels;
THYM	cis	rs747334	0.807	rs7099420	chr10:92719538	G/A	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs7772486	0.682	rs1337840	chr6:146042558	T/C	cg23711669	chr6:146136114	FBXO30	-0.83	-7.91	-0.63	4.62e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3126085	0.935	rs11204951	chr1:152224404	A/G	cg26020982	chr1:152196106	HRNR	0.37	4.98	0.45	2.89e-6	Atopic dermatitis;
THYM	cis	rs600806	0.850	rs10858091	chr1:109935578	T/C	cg23616212	chr1:109941201	SORT1	-0.5	-4.65	-0.43	1.06e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg10047753	chr17:41438598	NA	1.18	11.26	0.76	3.4e-19	Menopause (age at onset);
THYM	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.64	-0.5	1.73e-7	Menopause (age at onset);
THYM	cis	rs9682041	0.668	rs6784631	chr3:170100476	T/C	cg11886554	chr3:170076028	SKIL	1.38	5.34	0.48	6.34e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs11574514	1.000	rs114884917	chr16:67951830	G/A	cg09738193	chr16:67926317	PSKH1	-0.93	-4.57	-0.42	1.46e-5	Crohn's disease;
THYM	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25427524	chr10:38739819	LOC399744	-0.72	-6.64	-0.56	1.92e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs916888	0.558	rs199521	chr17:44853456	G/C	cg15921436	chr17:44337874	NA	-0.76	-5.97	-0.52	4.06e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6032067	1.000	rs34685021	chr20:43888042	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-5.35	-0.48	6.01e-7	Blood protein levels;
THYM	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg12560992	chr17:57184187	TRIM37	0.7	5.55	0.49	2.59e-7	Testicular germ cell tumor;
THYM	cis	rs1371867	0.555	rs2861348	chr8:101285074	A/G	cg00191853	chr8:101177733	SPAG1	-0.5	-5.01	-0.46	2.54e-6	Atrioventricular conduction;
THYM	cis	rs9992101	0.636	rs72657813	chr4:77258307	G/T	cg20311846	chr4:77356250	SHROOM3	-0.54	-5.95	-0.52	4.39e-8	Creatinine levels;
THYM	cis	rs7772486	0.754	rs9497419	chr6:146142609	T/C	cg23711669	chr6:146136114	FBXO30	0.92	9.0	0.68	2.32e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9649213	0.537	rs35997266	chr7:97965566	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg00383909	chr3:49044727	WDR6	1.2	6.89	0.58	6.14e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs28595532	0.841	rs55744948	chr4:119769243	T/C	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg11247378	chr22:39784982	NA	-1.03	-11.17	-0.75	5.3e-19	Intelligence (multi-trait analysis);
THYM	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg06271696	chr7:157225062	NA	-0.61	-4.58	-0.43	1.42e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg20587970	chr11:113659929	NA	-1.37	-8.96	-0.68	2.79e-14	Hip circumference adjusted for BMI;
THYM	cis	rs7084402	0.935	rs4948524	chr10:60351224	C/A	cg27040468	chr10:60456715	BICC1	-0.54	-4.49	-0.42	1.98e-5	Refractive error;
THYM	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7267979	1.000	rs2258135	chr20:25272323	C/A	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4780401	0.609	rs55934118	chr16:11820003	G/C	cg01061890	chr16:11836724	TXNDC11	-0.66	-5.44	-0.49	4.22e-7	Rheumatoid arthritis;
THYM	cis	rs870825	0.698	rs72703549	chr4:185623963	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs4792901	0.759	rs2271957	chr17:41598940	A/G	cg21940313	chr17:41620911	ETV4	-0.55	-5.42	-0.49	4.55e-7	Dupuytren's disease;
THYM	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg01483505	chr11:975446	AP2A2	0.57	4.63	0.43	1.16e-5	Alzheimer's disease (late onset);
THYM	cis	rs3126085	1.000	rs3126098	chr1:152311923	T/C	cg10321714	chr1:152280068	FLG	-0.73	-5.41	-0.49	4.67e-7	Atopic dermatitis;
THYM	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg14675211	chr2:100938903	LONRF2	0.76	8.42	0.65	3.99e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.641	rs62206437	chr20:43759316	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.67	-5.94	-0.52	4.77e-8	Blood protein levels;
THYM	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg21433313	chr16:3507492	NAT15	0.59	5.05	0.46	2.1e-6	Body mass index (adult);
THYM	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg04865290	chr3:52927548	TMEM110	-0.96	-4.97	-0.45	2.97e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	4.69	0.43	9e-6	Menarche (age at onset);
THYM	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg13319975	chr6:146136371	FBXO30	-0.74	-6.33	-0.54	8.16e-9	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs8002861	0.935	rs7319725	chr13:44445421	T/C	cg17145862	chr1:211918768	LPGAT1	0.96	9.83	0.71	3.86e-16	Leprosy;
THYM	cis	rs12310956	0.510	rs4931759	chr12:33871969	T/C	cg06521331	chr12:34319734	NA	-0.57	-4.62	-0.43	1.21e-5	Morning vs. evening chronotype;
THYM	cis	rs6901250	0.851	rs9374624	chr6:117145837	A/C	cg12892004	chr6:117198278	RFX6	0.7	6.85	0.57	7.3e-10	C-reactive protein levels;
THYM	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg16586182	chr3:47516702	SCAP	-0.62	-5.32	-0.48	6.98e-7	Colorectal cancer;
THYM	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg14517863	chr17:44321492	NA	-0.44	-5.0	-0.46	2.59e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg05283184	chr6:79620031	NA	-0.88	-8.41	-0.65	4.12e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg07936489	chr17:37558343	FBXL20	-0.76	-5.25	-0.47	9.27e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.76	-0.51	1.03e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7607369	0.719	rs690882	chr2:219640620	T/C	cg02176678	chr2:219576539	TTLL4	-0.48	-4.71	-0.44	8.46e-6	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs61990749	0.597	rs2299930	chr14:78163722	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-1.18	-8.12	-0.64	1.65e-12	Fibroblast growth factor basic levels;
THYM	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg07212818	chr11:638076	DRD4	-0.79	-6.69	-0.57	1.57e-9	Systemic lupus erythematosus;
THYM	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs6450176	0.597	rs1541682	chr5:53304401	C/T	ch.5.1024479R	chr5:53302184	ARL15	-1.23	-10.23	-0.72	5.24e-17	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg11245990	chr11:68621969	NA	0.53	6.78	0.57	1.03e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7772486	0.774	rs2748503	chr6:146295042	T/C	cg13319975	chr6:146136371	FBXO30	-0.71	-6.13	-0.53	1.97e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs6032067	0.641	rs17423617	chr20:43768050	G/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.41	-0.49	4.61e-7	Blood protein levels;
THYM	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03452623	chr4:187889614	NA	-1.17	-20.04	-0.9	6.92e-36	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg09537434	chr19:41945824	ATP5SL	-1.03	-9.37	-0.69	3.66e-15	Height;
THYM	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.38	5.34	0.48	6.27e-7	Obesity-related traits;
THYM	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg18904891	chr8:8559673	CLDN23	-0.62	-5.08	-0.46	1.87e-6	Mood instability;
THYM	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12530845	0.623	rs73721662	chr7:135341314	G/A	cg19897172	chr7:135347071	PL-5283	-0.59	-5.31	-0.48	7.23e-7	Red blood cell traits;
THYM	cis	rs362272	0.524	rs7435601	chr4:3369645	A/G	cg14583973	chr4:3374767	RGS12	0.67	6.59	0.56	2.5e-9	Serum sulfate level;
THYM	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2658782	1.000	rs2658779	chr11:93163137	G/T	cg16424440	chr11:93231842	C11orf75	0.74	4.69	0.43	9.19e-6	Pulmonary function decline;
THYM	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.66	-5.37	-0.48	5.61e-7	Tonsillectomy;
THYM	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.68	6.23	0.54	1.29e-8	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs3862030	0.720	rs11191295	chr10:104231054	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.71	-5.96	-0.52	4.3e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg09033563	chr22:24373618	LOC391322	0.54	4.54	0.42	1.62e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6500395	0.788	rs12446280	chr16:48651171	G/T	cg04672837	chr16:48644449	N4BP1	0.49	4.6	0.43	1.31e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9733	0.596	rs7412396	chr1:150666797	C/T	cg15448220	chr1:150897856	SETDB1	0.85	7.11	0.59	2.17e-10	Tonsillectomy;
THYM	cis	rs3820068	0.608	rs7514858	chr1:16035246	G/A	cg05660106	chr1:15850417	CASP9	0.72	5.59	0.5	2.2e-7	Systolic blood pressure;
THYM	cis	rs12446552	0.661	rs72781050	chr16:11707795	G/A	cg09662852	chr16:11707685	NA	-0.67	-6.06	-0.53	2.68e-8	Colorectal or endometrial cancer;
THYM	cis	rs11585357	0.895	rs72633823	chr1:17630779	G/A	cg08277548	chr1:17600880	PADI3	-0.88	-5.22	-0.47	1.05e-6	Hair shape;
THYM	cis	rs9563576	0.518	rs9563528	chr13:58314069	T/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.63	4.89	0.45	4.04e-6	Body mass index;
THYM	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.66	-5.63	-0.5	1.8e-7	Total body bone mineral density;
THYM	cis	rs868036	0.609	rs2045960	chr15:68092079	G/A	cg26545918	chr15:68124484	LBXCOR1	0.54	4.77	0.44	6.76e-6	Restless legs syndrome;
THYM	cis	rs9733	0.596	rs11204687	chr1:150629880	C/A	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg07570687	chr10:102243282	WNT8B	0.76	6.93	0.58	5.03e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.62	4.79	0.44	6.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs6842047	1.000	rs6842047	chr4:187133576	A/C	cg09526685	chr4:187126073	CYP4V2	1.23	6.35	0.55	7.22e-9	Blood protein levels;
THYM	cis	rs3947	1.000	rs1692812	chr8:11703523	T/G	cg26752888	chr8:11627280	NEIL2	-0.7	-4.57	-0.42	1.49e-5	Blood protein levels;
THYM	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3810291	0.927	rs4804025	chr19:47609223	G/A	cg12068280	chr19:46804528	HIF3A	-0.4	-4.49	-0.42	2.03e-5	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);BMI in smokers;Hip circumference;Body mass index;Body mass index in physically active individuals;
THYM	cis	rs7224737	1.000	rs2014521	chr17:40283413	C/G	cg00647820	chr17:40259828	DHX58	-0.62	-4.65	-0.43	1.06e-5	Fibrinogen levels;
THYM	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg18876405	chr7:65276391	NA	-0.61	-5.2	-0.47	1.13e-6	Aortic root size;
THYM	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7677751	0.806	rs7678144	chr4:55102425	T/C	cg17187183	chr4:55093834	PDGFRA	0.75	5.65	0.5	1.66e-7	Corneal astigmatism;
THYM	cis	rs7578361	0.879	rs4667425	chr2:150393850	A/G	cg17961725	chr2:150454027	NA	-0.76	-5.5	-0.49	3.18e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg03806693	chr22:41940476	POLR3H	-1.16	-9.9	-0.71	2.75e-16	Vitiligo;
THYM	cis	rs11295209	1	rs11295209	chr4:120480233	TA/T	cg13609457	chr4:120235615	NA	-0.47	-4.92	-0.45	3.59e-6	Plateletcrit;
THYM	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg22875332	chr1:76189707	ACADM	0.88	11.22	0.75	4.31e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs62103177	0.608	rs551643	chr18:77838970	C/G	cg07235805	chr18:78004237	PARD6G	-0.48	-5.47	-0.49	3.62e-7	Opioid sensitivity;
THYM	cis	rs13247936	0.574	rs12702800	chr7:8965291	A/G	cg15444149	chr7:8029589	GLCCI1	-0.71	-4.85	-0.45	4.73e-6	Schizophrenia;
THYM	cis	rs11563648	0.553	rs2285338	chr7:127008430	A/C	cg23081781	chr7:127225937	GCC1	0.34	4.56	0.42	1.53e-5	Resting heart rate;
THYM	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg24209194	chr3:40518798	ZNF619	0.62	4.92	0.45	3.58e-6	Renal cell carcinoma;
THYM	cis	rs4072705	0.967	rs4838200	chr9:127451057	A/G	cg13476313	chr9:127244764	NR5A1	-0.32	-4.75	-0.44	7.27e-6	Menarche (age at onset);
THYM	cis	rs1214752	0.935	rs9369410	chr6:43382318	A/C	cg09674015	chr6:43045187	PTK7	-0.51	-4.79	-0.44	6.02e-6	Coronary artery disease;
THYM	cis	rs4654899	0.931	rs10753506	chr1:21141022	A/G	cg01072550	chr1:21505969	NA	0.7	6.41	0.55	5.56e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs6754311	0.773	rs188680	chr2:136630989	A/G	cg23851026	chr2:136556271	LCT	-0.5	-4.76	-0.44	6.97e-6	Mosquito bite size;
THYM	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg25554036	chr4:6271136	WFS1	-0.58	-4.55	-0.42	1.61e-5	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg16586182	chr3:47516702	SCAP	0.61	5.21	0.47	1.1e-6	Colorectal cancer;
THYM	cis	rs919433	0.783	rs2565155	chr2:198236425	A/G	cg00792783	chr2:198669748	PLCL1	0.78	5.6	0.5	2.12e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs1061377	1.000	rs2163273	chr4:39114455	T/G	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg26818010	chr10:134567672	INPP5A	-0.79	-6.31	-0.54	8.83e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7178572	1.000	rs11633054	chr15:77747276	A/G	cg22256960	chr15:77711686	NA	-0.94	-7.93	-0.63	4.23e-12	Type 2 diabetes;
THYM	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg03264133	chr6:25882463	NA	0.65	5.06	0.46	2e-6	Schizophrenia;
THYM	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.01	-9.8	-0.71	4.35e-16	Primary sclerosing cholangitis;
THYM	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.9	-0.45	4.01e-6	Monocyte count;
THYM	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg26384229	chr12:38710491	ALG10B	1.03	10.33	0.73	3.29e-17	Heart rate;
THYM	cis	rs12549902	0.871	rs4736819	chr8:41509915	C/T	cg21772509	chr8:41503840	NKX6-3	0.62	5.41	0.49	4.69e-7	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
THYM	cis	rs10463554	0.927	rs34810	chr5:102430749	A/T	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs7582403	0.510	rs12691774	chr2:148874073	G/T	cg23727674	chr2:148602993	ACVR2A	0.64	4.68	0.43	9.47e-6	Neuroticism;
THYM	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg23711669	chr6:146136114	FBXO30	0.8	7.12	0.59	2.02e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4343996	0.870	rs4722712	chr7:3389147	C/T	cg21248987	chr7:3385318	SDK1	-0.4	-4.88	-0.45	4.23e-6	Motion sickness;
THYM	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg15693483	chr7:1102177	C7orf50	0.47	5.52	0.49	2.91e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg21984481	chr17:79567631	NPLOC4	0.61	6.89	0.58	6.13e-10	Eye color traits;
THYM	cis	rs477692	0.544	rs7904404	chr10:131447612	G/A	cg06209143	chr10:131448811	MGMT	-0.56	-4.46	-0.42	2.26e-5	Response to temozolomide;
THYM	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg22968622	chr17:43663579	NA	-1.09	-10.27	-0.73	4.3e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg00271210	chr6:167070053	RPS6KA2	-0.48	-4.9	-0.45	3.92e-6	Primary biliary cholangitis;
THYM	cis	rs9522267	1.000	rs9522267	chr13:112196367	C/T	cg10483660	chr13:112241077	NA	-0.49	-4.96	-0.45	3.1e-6	Hepatitis;
THYM	cis	rs17300741	0.509	rs4930195	chr11:64310649	C/T	cg08822897	chr11:64258103	NA	-0.7	-5.78	-0.51	9.29e-8	Uric acid levels;
THYM	cis	rs672413	0.739	rs336526	chr5:78287579	T/G	cg11541897	chr5:78281793	ARSB	-0.55	-5.0	-0.46	2.6e-6	Blood and toenail selenium levels;Blood protein levels;
THYM	cis	rs354225	0.626	rs6740893	chr2:54834380	G/A	cg23486701	chr2:54789491	SPTBN1	0.38	4.65	0.43	1.06e-5	Schizophrenia;
THYM	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg11941060	chr3:133502564	NA	-0.74	-6.3	-0.54	9.29e-9	Iron status biomarkers;
THYM	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg03388043	chr17:80084554	CCDC57	0.7	6.09	0.53	2.36e-8	Life satisfaction;
THYM	cis	rs7107174	0.792	rs2888465	chr11:77945807	T/C	cg02023728	chr11:77925099	USP35	0.71	6.22	0.54	1.34e-8	Testicular germ cell tumor;
THYM	cis	rs910187	0.605	rs6124961	chr20:45804467	G/C	cg27589058	chr20:45804311	EYA2	-0.7	-6.45	-0.55	4.68e-9	Migraine;
THYM	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg06238570	chr21:40685208	BRWD1	-0.88	-6.05	-0.53	2.9e-8	Cognitive function;
THYM	cis	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg07460842	chr6:66804631	NA	-1.24	-15.46	-0.85	1.1e-27	Exhaled nitric oxide output;
THYM	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.72	5.7	0.51	1.32e-7	Tonsillectomy;
THYM	cis	rs2276498	0.816	rs2299705	chr20:52657462	G/C	cg23682609	chr20:52687365	BCAS1	0.54	4.49	0.42	2.04e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs11096990	0.593	rs35552004	chr4:39172534	C/T	cg24403649	chr4:39172243	NA	0.57	4.95	0.45	3.28e-6	Cognitive function;
THYM	cis	rs12282928	0.959	rs2170663	chr11:48319806	A/T	cg22827986	chr11:48284249	OR4X1	-0.49	-5.17	-0.47	1.32e-6	Migraine - clinic-based;
THYM	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg17063962	chr7:91808500	NA	1.13	12.56	0.79	6.81e-22	Breast cancer;
THYM	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.14	-0.47	1.47e-6	Total cholesterol levels;
THYM	cis	rs12478296	0.591	rs6746311	chr2:243001279	A/G	cg06360820	chr2:242988706	NA	-0.78	-5.17	-0.47	1.3e-6	Obesity-related traits;
THYM	cis	rs6960043	0.905	rs10231021	chr7:15060429	T/A	cg19272540	chr7:15055459	NA	-0.49	-5.57	-0.5	2.38e-7	Type 2 diabetes;
THYM	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg05043794	chr9:111880884	C9orf5	-0.43	-6.21	-0.54	1.39e-8	Menarche (age at onset);
THYM	cis	rs1466662	0.641	rs34503070	chr4:155299027	C/T	cg05574313	chr4:155338166	DCHS2	0.66	4.84	0.44	5.09e-6	Alzheimer's disease (age of onset);
THYM	cis	rs1568889	1.000	rs7933332	chr11:28036392	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	4.49	0.42	2.03e-5	Bipolar disorder;
THYM	cis	rs2806561	1.000	rs2746553	chr1:23493246	T/C	cg08872493	chr1:23521417	HTR1D	0.38	4.86	0.45	4.59e-6	Height;
THYM	cis	rs28476539	0.640	rs6837562	chr4:83556408	C/T	cg10249074	chr4:83542146	C4orf11	0.62	4.96	0.45	3.12e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs2933343	0.533	rs13086121	chr3:128704290	A/T	cg11901034	chr3:128598214	ACAD9	-0.69	-4.89	-0.45	4.03e-6	IgG glycosylation;
THYM	cis	rs3741151	0.773	rs79915238	chr11:73272947	C/T	cg12959048	chr11:73096162	RELT	-0.52	-4.62	-0.43	1.21e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7224737	1.000	rs35184688	chr17:40272406	G/C	cg20291162	chr17:40259547	DHX58	-0.7	-6.47	-0.55	4.18e-9	Fibrinogen levels;
THYM	cis	rs6754311	0.513	rs1438304	chr2:136503157	A/G	cg20242066	chr2:136595261	LCT	-0.57	-6.93	-0.58	4.9e-10	Mosquito bite size;
THYM	cis	rs131777	0.547	rs131753	chr22:51022862	A/G	cg00083937	chr22:51039805	MAPK8IP2	0.59	5.17	0.47	1.3e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs17122693	1.000	rs1494176	chr14:51083372	A/C	cg04730355	chr14:51134070	SAV1	0.97	5.42	0.49	4.46e-7	Cognitive performance;
THYM	cis	rs9653442	0.522	rs4851274	chr2:100870862	T/C	cg08017756	chr2:100939284	LONRF2	-0.72	-5.71	-0.51	1.31e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs193541	0.509	rs7720862	chr5:122168115	C/A	cg19808643	chr5:122110361	SNX2	-0.57	-4.96	-0.45	3.1e-6	Glucose homeostasis traits;
THYM	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg11890956	chr21:40555474	PSMG1	0.99	8.41	0.65	4.12e-13	Cognitive function;
THYM	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg07157834	chr1:205819609	PM20D1	-0.6	-4.66	-0.43	1.02e-5	Menarche (age at onset);
THYM	cis	rs4072705	0.935	rs2184219	chr9:127532904	A/G	cg01786973	chr9:127249749	NR5A1	0.36	4.84	0.44	5.02e-6	Menarche (age at onset);
THYM	cis	rs7107770	1.000	rs4936997	chr11:125090227	C/T	cg04164023	chr11:125106101	PKNOX2	-0.82	-4.59	-0.43	1.35e-5	Photic sneeze reflex;
THYM	cis	rs11148252	0.538	rs2408611	chr13:52709742	C/T	cg00495681	chr13:53174319	NA	0.6	5.68	0.5	1.44e-7	Lewy body disease;
THYM	cis	rs6490294	0.659	rs608848	chr12:112146964	C/T	cg10833066	chr12:111807467	FAM109A	0.51	5.55	0.49	2.55e-7	Mean platelet volume;
THYM	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg13683864	chr3:40499215	RPL14	-1.06	-11.61	-0.77	6.25e-20	Renal cell carcinoma;
THYM	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg10518543	chr12:38710700	ALG10B	0.51	4.49	0.42	2.04e-5	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7943358	0.911	rs11023684	chr11:15706908	A/G	cg11966998	chr11:15692519	NA	-0.48	-4.66	-0.43	1.03e-5	Gut microbiome composition (summer);
THYM	cis	rs1065852	0.526	rs7290655	chr22:42390225	C/G	cg01059385	chr22:42394853	WBP2NL	0.57	4.66	0.43	1.04e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg18402987	chr7:1209562	NA	1.03	6.06	0.53	2.77e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7772486	0.875	rs854145	chr6:146349650	C/T	cg23711669	chr6:146136114	FBXO30	0.93	9.79	0.71	4.72e-16	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.6	-11.28	-0.76	3.1400000000000002e-19	Hemostatic factors and hematological phenotypes;
THYM	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg00012203	chr2:219082015	ARPC2	0.85	7.65	0.62	1.64e-11	Colorectal cancer;
THYM	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg06108461	chr20:60628389	TAF4	-0.81	-6.74	-0.57	1.22e-9	Body mass index;
THYM	cis	rs8141529	0.687	rs6005867	chr22:29165120	T/C	cg02153584	chr22:29168773	CCDC117	0.69	5.4	0.48	4.96e-7	Lymphocyte counts;
THYM	cis	rs72949976	0.606	rs11898263	chr2:214030649	A/G	cg08319019	chr2:214017104	IKZF2	0.74	6.14	0.53	1.92e-8	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs4363385	0.679	rs6686285	chr1:152984561	T/G	cg13444842	chr1:152974279	SPRR3	-0.61	-4.98	-0.45	2.84e-6	Inflammatory skin disease;
THYM	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg18681998	chr4:17616180	MED28	0.85	7.68	0.62	1.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07157834	chr1:205819609	PM20D1	0.88	8.8	0.67	6.18e-14	Menarche (age at onset);
THYM	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.33	0.48	6.74e-7	Height;
THYM	cis	rs447921	0.724	rs346797	chr17:74378901	A/C	cg17201438	chr17:74438067	UBE2O	-0.81	-5.89	-0.52	5.72e-8	Mitochondrial DNA levels;
THYM	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg15704280	chr7:45808275	SEPT13	-0.78	-7.08	-0.59	2.51e-10	Coronary artery disease;
THYM	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg00990874	chr7:1149470	C7orf50	-0.67	-5.23	-0.47	1.01e-6	Bronchopulmonary dysplasia;
THYM	cis	rs28595532	0.920	rs115484560	chr4:119756781	T/G	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg04731861	chr2:219085781	ARPC2	-0.54	-5.22	-0.47	1.03e-6	Colorectal cancer;
THYM	cis	rs600806	0.893	rs370088	chr1:109858119	T/C	cg02175308	chr1:109941060	SORT1	-0.54	-4.71	-0.43	8.55e-6	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.66e-18	Prudent dietary pattern;
THYM	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.12e-15	Body mass index;
THYM	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25427524	chr10:38739819	LOC399744	-0.73	-6.77	-0.57	1.04e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs9733	0.596	rs72702557	chr1:150680130	A/G	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs10037758	0.643	rs2526242	chr5:128300005	A/G	cg02841155	chr5:128301328	SLC27A6	-0.59	-5.87	-0.52	6.46e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg09436375	chr6:42928200	GNMT	-0.44	-5.9	-0.52	5.58e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg00684032	chr4:1343700	KIAA1530	0.63	5.4	0.48	4.93e-7	Obesity-related traits;
THYM	cis	rs9644630	1.000	rs9644628	chr8:19369134	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.73	7.15	0.59	1.77e-10	Oropharynx cancer;
THYM	cis	rs4919087	0.962	rs3740522	chr10:99019144	C/T	cg19453742	chr10:98862320	SLIT1	-0.64	-4.82	-0.44	5.36e-6	Monocyte count;
THYM	cis	rs13082711	0.953	rs13096477	chr3:27490194	T/C	cg02860705	chr3:27208620	NA	0.85	5.85	0.51	7e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs192264	0.614	rs166210	chr16:65979838	C/T	cg02795155	chr16:66785218	DYNC1LI2	-0.59	-4.76	-0.44	6.9e-6	Subjective well-being;
THYM	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg04362960	chr10:104952993	NT5C2	0.59	4.96	0.45	3.02e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1322639	0.614	rs6900200	chr6:169566173	T/C	cg04662567	chr6:169592167	NA	-0.73	-5.71	-0.51	1.29e-7	Pulse pressure;
THYM	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg08720517	chr5:138729919	LOC389333	0.59	4.97	0.45	2.92e-6	Esophageal squamous cell carcinoma;
THYM	cis	rs9677476	1.000	rs12621567	chr2:232118813	T/C	cg07929768	chr2:232055508	NA	0.53	5.43	0.49	4.24e-7	Food antigen IgG levels;
THYM	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03576123	chr11:487126	PTDSS2	-1.3	-6.61	-0.56	2.21e-9	Body mass index;
THYM	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg05373962	chr22:49881684	NA	-0.67	-6.31	-0.54	8.78e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6456156	0.774	rs6916486	chr6:167530735	T/C	cg09487078	chr6:167525398	CCR6	-0.41	-4.62	-0.43	1.22e-5	Primary biliary cholangitis;
THYM	cis	rs7568458	0.905	rs10187424	chr2:85794297	T/C	cg17127132	chr2:85788382	GGCX	0.68	5.47	0.49	3.71e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs4604732	0.536	rs10925056	chr1:247650472	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.7	4.58	0.43	1.38e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs10503733	0.868	rs6998881	chr8:23483957	T/C	cg20272884	chr8:23712762	STC1	-0.47	-4.67	-0.43	9.9e-6	Prostate cancer;
THYM	cis	rs7777677	0.925	rs4726544	chr7:142367113	A/T	cg21785750	chr7:142428317	NA	0.65	4.78	0.44	6.5e-6	Alcoholic chronic pancreatitis;
THYM	cis	rs1030877	0.889	rs2576746	chr2:105909559	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.55	4.61	0.43	1.28e-5	Obesity-related traits;
THYM	cis	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg00495681	chr13:53174319	NA	0.75	6.95	0.58	4.47e-10	Lewy body disease;
THYM	cis	rs8067545	0.586	rs57837691	chr17:20203073	T/C	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs7635838	0.684	rs2594965	chr3:11323799	G/C	cg00170343	chr3:11313890	ATG7	0.58	4.59	0.43	1.33e-5	HDL cholesterol;
THYM	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13082711	0.596	rs479404	chr3:27363064	T/C	cg02860705	chr3:27208620	NA	0.68	5.13	0.47	1.55e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs554111	0.656	rs4654900	chr1:21422021	G/C	cg01072550	chr1:21505969	NA	0.59	5.17	0.47	1.3e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg25566285	chr7:158114605	PTPRN2	0.89	10.22	0.72	5.47e-17	Calcium levels;
THYM	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg02527881	chr3:46936655	PTH1R	0.65	6.41	0.55	5.71e-9	Colorectal cancer;
THYM	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg04156016	chr5:1868137	NA	0.5	4.63	0.43	1.17e-5	Cardiovascular disease risk factors;
THYM	cis	rs11031096	0.711	rs10767881	chr11:4205122	C/G	cg22027985	chr11:4115532	RRM1	-0.54	-5.04	-0.46	2.21e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg27034606	chr17:28928453	LRRC37B2	0.79	4.89	0.45	4.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg12292205	chr6:26970375	C6orf41	-0.97	-4.68	-0.43	9.51e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs921968	0.612	rs4674323	chr2:219517088	T/C	cg02176678	chr2:219576539	TTLL4	0.6	5.84	0.51	7.3e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg09877947	chr5:131593287	PDLIM4	0.7	6.33	0.54	7.92e-9	Acylcarnitine levels;
THYM	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg00012203	chr2:219082015	ARPC2	-0.88	-8.59	-0.66	1.66e-13	Colorectal cancer;
THYM	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg12963246	chr6:28129442	ZNF389	0.72	6.2	0.54	1.44e-8	Parkinson's disease;
THYM	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg10803722	chr21:46713166	LOC642852	-0.43	-5.66	-0.5	1.59e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-6.2	-0.54	1.47e-8	Total body bone mineral density;
THYM	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg14893161	chr1:205819251	PM20D1	-0.59	-4.57	-0.42	1.49e-5	Menarche (age at onset);
THYM	cis	rs6684428	0.610	rs10888940	chr1:56315779	C/T	cg11651538	chr1:56320950	NA	-0.7	-4.7	-0.43	8.73e-6	Airflow obstruction;
THYM	cis	rs240764	0.764	rs10457800	chr6:100936628	C/T	cg21058520	chr6:100914733	NA	0.55	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg17143192	chr8:8559678	CLDN23	0.94	7.03	0.59	3.1e-10	Obesity-related traits;
THYM	cis	rs9914578	1.000	rs8082647	chr17:2010597	C/T	cg16513277	chr17:2031491	SMG6	0.7	4.59	0.43	1.38e-5	Body mass index;
THYM	cis	rs7113850	0.551	rs4365050	chr11:24245730	G/A	ch.11.24196551F	chr11:24239977	NA	1.03	5.48	0.49	3.53e-7	Bone fracture in osteoporosis;
THYM	trans	rs1974653	0.672	rs7284918	chr22:20086737	T/C	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs12410462	0.579	rs116423559	chr1:227575014	A/G	cg04117972	chr1:227635322	NA	0.83	4.91	0.45	3.73e-6	Major depressive disorder;
THYM	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11890956	chr21:40555474	PSMG1	1.07	10.55	0.73	1.12e-17	Cognitive function;
THYM	cis	rs4072705	0.646	rs4838187	chr9:127242076	G/C	cg13476313	chr9:127244764	NR5A1	0.36	5.1	0.46	1.76e-6	Menarche (age at onset);
THYM	cis	rs9326248	0.559	rs12808524	chr11:116890993	T/C	cg20608306	chr11:116969690	SIK3	0.62	7.42	0.61	4.94e-11	Blood protein levels;
THYM	cis	rs4601821	0.823	rs4938015	chr11:113264644	C/T	cg14159747	chr11:113255604	NA	-0.24	-4.48	-0.42	2.12e-5	Alcoholic chronic pancreatitis;
THYM	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg15556689	chr8:8085844	FLJ10661	0.74	6.66	0.56	1.74e-9	Systolic blood pressure;
THYM	cis	rs7582403	0.844	rs1234410	chr2:148840507	G/T	cg23727674	chr2:148602993	ACVR2A	0.58	4.79	0.44	6.24e-6	Neuroticism;
THYM	cis	rs61931739	1.000	rs1852223	chr12:34013251	C/T	cg10856724	chr12:34555212	NA	0.58	4.99	0.46	2.75e-6	Morning vs. evening chronotype;
THYM	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg05754148	chr16:3507555	NAT15	0.88	7.96	0.63	3.57e-12	Tuberculosis;
THYM	cis	rs7104764	0.957	rs3817629	chr11:237312	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs259282	0.605	rs17692992	chr19:33099430	T/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.7	5.73	0.51	1.17e-7	Schizophrenia;
THYM	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg22683308	chr4:1340831	KIAA1530	-0.64	-4.66	-0.43	1.01e-5	Obesity-related traits;
THYM	cis	rs28595532	0.841	rs115907265	chr4:119730593	G/A	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs17253792	0.822	rs28478195	chr14:56047851	G/A	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs34638657	0.702	rs35865749	chr16:82199677	T/C	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.25	-0.47	9.14e-7	Lung adenocarcinoma;
THYM	cis	rs1003719	0.679	rs2835638	chr21:38534533	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs7582180	0.625	rs12612755	chr2:100906061	T/C	cg14675211	chr2:100938903	LONRF2	0.69	6.3	0.54	9.2e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg18357526	chr6:26021779	HIST1H4A	0.72	5.3	0.48	7.54e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.698	rs10954048	chr7:124533740	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	trans	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg19862616	chr7:65841803	NCRNA00174	1.13	13.2	0.8	3.22e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1829883	1.000	rs2460683	chr5:98778568	A/G	cg08333243	chr5:99726346	NA	-0.57	-5.59	-0.5	2.13e-7	Hemostatic factors and hematological phenotypes;
THYM	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg15921436	chr17:44337874	NA	0.95	6.92	0.58	5.33e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.22	-15.45	-0.85	1.18e-27	Primary sclerosing cholangitis;
THYM	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg16405210	chr4:1374714	KIAA1530	-1.05	-9.68	-0.7	8.17e-16	Longevity;
THYM	cis	rs7084921	0.526	rs2077191	chr10:101887978	A/G	cg11344164	chr10:101878520	NA	-0.55	-5.18	-0.47	1.25e-6	Bone mineral density;
THYM	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg01448562	chr3:133502909	NA	0.82	6.76	0.57	1.12e-9	Iron status biomarkers;
THYM	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg06221963	chr1:154839813	KCNN3	-0.77	-9.84	-0.71	3.56e-16	Prostate cancer;
THYM	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11644478	chr21:40555479	PSMG1	-0.56	-4.69	-0.43	9.07e-6	Menarche (age at onset);
THYM	cis	rs6674176	0.696	rs4448553	chr1:44411589	A/G	cg15962314	chr1:44399869	ARTN	0.55	5.18	0.47	1.24e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg26721908	chr21:47610096	LSS	0.87	6.77	0.57	1.08e-9	Testicular germ cell tumor;
THYM	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.6	-5.0	-0.46	2.66e-6	Coronary artery disease;
THYM	cis	rs3750965	0.959	rs11228490	chr11:68860872	C/G	cg01403660	chr11:68851641	TPCN2	-0.72	-5.75	-0.51	1.07e-7	Hair color;
THYM	cis	rs2795502	0.564	rs11239842	chr10:43444882	A/G	cg08461752	chr10:43522343	NA	-0.77	-4.66	-0.43	1.04e-5	Blood protein levels;
THYM	cis	rs7100689	0.784	rs6585986	chr10:82171559	T/C	cg01528321	chr10:82214614	TSPAN14	1.1	9.02	0.68	2.1e-14	Post bronchodilator FEV1;
THYM	cis	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg09307838	chr4:120376055	NA	0.69	5.18	0.47	1.24e-6	Corneal astigmatism;
THYM	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg03452623	chr4:187889614	NA	-1.19	-19.05	-0.89	3.26e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs72627123	0.867	rs113954406	chr14:74396434	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs4903604	0.581	rs11850485	chr14:78033863	A/G	cg18872420	chr14:78023429	SPTLC2	0.54	4.56	0.42	1.5e-5	Gut microbiome composition (winter);
THYM	cis	rs12791968	0.765	rs12226848	chr11:45009204	C/T	cg11846598	chr11:44996168	LOC221122	-0.78	-5.78	-0.51	9.31e-8	Inhibitory control;
THYM	cis	rs8018808	0.905	rs11159259	chr14:77892393	C/T	cg20045696	chr14:77926864	AHSA1	0.51	4.6	0.43	1.29e-5	Myeloid white cell count;
THYM	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg08109568	chr15:31115862	NA	-0.63	-5.93	-0.52	4.78e-8	Huntington's disease progression;
THYM	cis	rs4563143	0.647	rs117442062	chr19:29256823	A/T	cg12667521	chr19:29218732	NA	0.96	8.39	0.65	4.58e-13	Methadone dose in opioid dependence;
THYM	cis	rs10208649	0.908	rs11884857	chr2:54260322	G/A	cg04546899	chr2:54196757	PSME4	0.68	4.7	0.43	8.91e-6	Body mass index;
THYM	cis	rs240764	0.658	rs6925823	chr6:101179273	C/A	cg21058520	chr6:100914733	NA	0.56	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs2354432	0.607	rs6658763	chr1:146692373	C/T	cg25205988	chr1:146714368	CHD1L	-1.04	-5.46	-0.49	3.82e-7	Mitochondrial DNA levels;
THYM	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg03877680	chr5:178157825	ZNF354A	0.67	4.62	0.43	1.18e-5	Neutrophil percentage of white cells;
THYM	cis	rs8070128	0.688	rs59304093	chr17:17875407	A/G	cg16928487	chr17:17741425	SREBF1	-0.51	-4.63	-0.43	1.18e-5	Total body bone mineral density;
THYM	cis	rs3741151	0.764	rs73548680	chr11:73271335	T/C	cg12959048	chr11:73096162	RELT	-0.52	-4.62	-0.43	1.21e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	trans	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg25214090	chr10:38739885	LOC399744	0.97	8.53	0.66	2.25e-13	Corneal astigmatism;
THYM	cis	rs863345	0.604	rs6664542	chr1:158462431	G/T	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs2294693	0.947	rs736793	chr6:40997919	A/T	cg14769373	chr6:40998127	UNC5CL	-0.61	-4.9	-0.45	4e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg03806693	chr22:41940476	POLR3H	1.1	8.41	0.65	4.11e-13	Vitiligo;
THYM	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs8064299	0.565	rs12453550	chr17:72786086	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.88	8.67	0.66	1.17e-13	Monocyte count;
THYM	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg10047753	chr17:41438598	NA	1.14	10.41	0.73	2.21e-17	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg03676636	chr4:99064102	C4orf37	0.39	5.53	0.49	2.76e-7	Colonoscopy-negative controls vs population controls;
THYM	trans	rs28595532	0.920	rs17257039	chr4:119603703	G/A	cg13773247	chr2:42276988	PKDCC	0.89	6.93	0.58	4.92e-10	Cannabis dependence symptom count;
THYM	cis	rs7681440	0.606	rs2583973	chr4:90747499	C/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs4737010	0.570	rs2111804	chr8:41644266	A/T	cg08923054	chr8:41654455	ANK1	0.74	4.63	0.43	1.14e-5	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
THYM	cis	rs2932538	0.883	rs7549547	chr1:113086717	A/T	cg22162597	chr1:113214053	CAPZA1	0.66	5.21	0.47	1.09e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs6089829	0.888	rs4809471	chr20:61684287	G/A	cg02380750	chr20:61661411	NA	0.62	6.16	0.53	1.73e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg10802521	chr3:52805072	NEK4	-0.72	-6.16	-0.53	1.77e-8	Bipolar disorder;
THYM	cis	rs2932538	0.922	rs12750621	chr1:113206502	G/C	cg22162597	chr1:113214053	CAPZA1	0.63	4.96	0.45	3.13e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs59112743	0.510	rs2743553	chr6:15562750	G/A	cg10111214	chr6:14815676	NA	0.74	4.84	0.44	5.08e-6	Multiple keratinocyte cancers;
THYM	cis	rs1062746	0.711	rs8056833	chr16:87378388	G/C	cg02258303	chr16:87377426	FBXO31	-0.56	-5.17	-0.47	1.32e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs3850699	0.666	rs7905481	chr10:104476292	T/C	cg04362960	chr10:104952993	NT5C2	0.61	4.88	0.45	4.22e-6	Prostate cancer;
THYM	cis	rs9653442	0.648	rs11123805	chr2:100643464	A/G	cg07810366	chr2:100720526	AFF3	-0.39	-5.55	-0.49	2.61e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs8114671	0.562	rs2064454	chr20:33496169	C/T	cg08999081	chr20:33150536	PIGU	0.63	5.21	0.47	1.09e-6	Height;
THYM	cis	rs2997447	0.846	rs61775416	chr1:26393329	C/T	cg03844060	chr1:26490628	NA	0.66	4.5	0.42	1.96e-5	QRS complex (12-leadsum);
THYM	cis	rs8077889	0.672	rs1230397	chr17:41844689	A/G	cg26893861	chr17:41843967	DUSP3	1.18	21.87	0.91	7.52e-39	Triglycerides;
THYM	cis	rs78761021	0.867	rs17681684	chr17:9792768	A/G	cg26853458	chr17:9805074	RCVRN	-0.54	-4.72	-0.44	8.26e-6	Type 2 diabetes;
THYM	cis	rs8067545	0.641	rs203479	chr17:19829311	T/C	cg20830565	chr17:20408647	MGC102966	-0.53	-4.83	-0.44	5.29e-6	Schizophrenia;
THYM	cis	rs7681440	0.606	rs2619360	chr4:90756191	C/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs7113850	0.541	rs77699762	chr11:24236448	C/T	ch.11.24196551F	chr11:24239977	NA	0.98	5.14	0.47	1.49e-6	Bone fracture in osteoporosis;
THYM	cis	rs17407555	0.738	rs3806817	chr4:10118914	C/T	cg11266682	chr4:10021025	SLC2A9	-0.61	-5.58	-0.5	2.26e-7	Schizophrenia (age at onset);
THYM	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs10769945	0.679	rs217213	chr11:1979118	C/G	cg22172494	chr11:2017362	H19	0.53	4.59	0.43	1.38e-5	DNA methylation (variation);
THYM	cis	rs4851254	0.660	rs35869550	chr2:100684578	T/A	cg22139774	chr2:100720529	AFF3	-0.41	-4.69	-0.43	9.07e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.24	-5.22	-0.47	1.05e-6	Obesity-related traits;
THYM	cis	rs17122693	0.748	rs72681607	chr14:51115866	T/C	cg04730355	chr14:51134070	SAV1	0.96	6.13	0.53	2e-8	Cognitive performance;
THYM	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg11905131	chr22:24372483	LOC391322	-0.92	-9.61	-0.7	1.14e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4764487	0.735	rs2072372	chr12:6344600	C/A	cg08284733	chr12:6341482	CD9	0.44	4.79	0.44	6.17e-6	Mean platelet volume;
THYM	cis	rs447921	0.861	rs452868	chr17:74421483	C/A	cg17201438	chr17:74438067	UBE2O	-0.81	-5.85	-0.51	6.9e-8	Mitochondrial DNA levels;
THYM	cis	rs295140	0.605	rs10931893	chr2:201114652	A/G	cg23649088	chr2:200775458	C2orf69	-0.61	-5.1	-0.46	1.74e-6	QT interval;
THYM	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg20203395	chr5:56204925	C5orf35	-0.65	-4.47	-0.42	2.15e-5	Initial pursuit acceleration;
THYM	cis	rs10789491	1.000	rs601060	chr1:47139580	C/G	cg15501359	chr1:47185051	KIAA0494	-1.16	-8.72	-0.67	8.86e-14	Response to hepatitis C treatment;
THYM	cis	rs11825685	0.887	rs4359223	chr11:134563721	T/G	cg02395454	chr11:134605862	NA	-0.98	-4.88	-0.45	4.22e-6	IgG glycosylation;
THYM	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg06697600	chr4:7070879	GRPEL1	-0.55	-4.91	-0.45	3.84e-6	Monocyte percentage of white cells;
THYM	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.65	-0.62	1.63e-11	Schizophrenia;
THYM	cis	rs1298062	0.771	rs4801833	chr19:50995932	T/G	cg11430371	chr19:50961752	MYBPC2	0.45	4.45	0.42	2.34e-5	Age of smoking initiation;
THYM	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11644478	chr21:40555479	PSMG1	0.98	7.72	0.62	1.15e-11	Cognitive function;
THYM	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg22841779	chr14:105766346	BRF1	-0.49	-6.26	-0.54	1.11e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6495122	0.651	rs11636952	chr15:75114322	T/C	cg14664628	chr15:75095509	CSK	-0.89	-6.75	-0.57	1.18e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg17143192	chr8:8559678	CLDN23	0.64	4.66	0.43	1.04e-5	Mood instability;
THYM	cis	rs6700896	0.931	rs10443261	chr1:66129121	T/C	cg04111102	chr1:66153794	NA	0.56	5.27	0.48	8.45e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.43	-5.55	-0.49	2.58e-7	Monocyte percentage of white cells;
THYM	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg13683864	chr3:40499215	RPL14	1.07	12.42	0.79	1.31e-21	Renal cell carcinoma;
THYM	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg18230493	chr5:56204884	C5orf35	-0.95	-7.0	-0.58	3.62e-10	Initial pursuit acceleration;
THYM	cis	rs1395	0.744	rs11126935	chr2:27476740	G/T	cg23587288	chr2:27483067	SLC30A3	-0.69	-6.19	-0.54	1.53e-8	Blood metabolite levels;
THYM	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg08999081	chr20:33150536	PIGU	-0.57	-5.03	-0.46	2.3e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs754466	0.606	rs56402185	chr10:79585848	G/A	cg17075019	chr10:79541650	NA	-0.73	-6.05	-0.53	2.86e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs16912285	0.688	rs7126291	chr11:24312936	A/C	ch.11.24196551F	chr11:24239977	NA	1.0	7.22	0.6	1.29e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs67981189	0.529	rs61990380	chr14:71471946	G/A	cg15910301	chr14:71632612	NA	0.56	4.88	0.45	4.23e-6	Schizophrenia;
THYM	cis	rs5167	0.750	rs3786505	chr19:45490570	A/G	cg09555818	chr19:45449301	APOC2	0.46	4.85	0.45	4.89e-6	Blood protein levels;
THYM	cis	rs73072330	1.000	rs73072330	chr3:48165089	G/A	cg09665691	chr3:47563885	NA	1.32	4.91	0.45	3.81e-6	Stem cell growth factor beta levels;
THYM	cis	rs6430585	0.527	rs1438303	chr2:136429857	C/T	cg07169764	chr2:136633963	MCM6	0.97	8.76	0.67	7.3e-14	Corneal structure;
THYM	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg21252483	chr19:49399788	TULP2	-0.81	-5.67	-0.5	1.56e-7	Red cell distribution width;
THYM	cis	rs904251	0.861	rs1757183	chr6:37484790	C/T	cg25019722	chr6:37503610	NA	0.64	5.42	0.49	4.5e-7	Cognitive performance;
THYM	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14240646	chr10:27532245	ACBD5	0.85	5.0	0.46	2.65e-6	Breast cancer;
THYM	cis	rs6723226	0.739	rs2069213	chr2:32743084	C/T	cg02381751	chr2:32503542	YIPF4	0.69	5.79	0.51	9.19e-8	Intelligence (multi-trait analysis);
THYM	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg21784768	chr11:537496	LRRC56	-1.16	-5.78	-0.51	9.66e-8	Body mass index;
THYM	cis	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg21915799	chr8:10282809	MSRA	-0.48	-4.55	-0.42	1.61e-5	Neuroticism;
THYM	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg02398342	chr17:80708632	TBCD;FN3K	0.73	5.54	0.49	2.73e-7	Glycated hemoglobin levels;
THYM	cis	rs2361710	0.611	rs12051781	chr17:78074468	A/G	cg04028464	chr17:78073854	GAA;CCDC40	0.71	6.28	0.54	1.02e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
THYM	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg22907277	chr7:1156413	C7orf50	0.63	5.59	0.5	2.13e-7	Longevity;Endometriosis;
THYM	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg05347473	chr6:146136440	FBXO30	0.58	4.62	0.43	1.19e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg16615211	chr3:44902933	MIR564;TMEM42	0.58	6.12	0.53	2.12e-8	Depressive symptoms;
THYM	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg14004847	chr7:1930337	MAD1L1	-0.62	-4.84	-0.44	5.04e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg12826209	chr6:26865740	GUSBL1	0.84	6.07	0.53	2.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9443645	0.507	rs9352648	chr6:79479741	A/G	cg05283184	chr6:79620031	NA	-0.63	-4.95	-0.45	3.21e-6	Intelligence (multi-trait analysis);
THYM	cis	rs673253	0.686	rs17371903	chr1:44070691	A/G	cg24466421	chr1:44070974	PTPRF	-0.62	-5.39	-0.48	5.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.841	rs115924581	chr4:119786333	T/C	cg14228332	chr4:119757509	SEC24D	1.39	4.82	0.44	5.49e-6	Cannabis dependence symptom count;
THYM	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg17054759	chr22:49844102	NA	0.48	4.61	0.43	1.28e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7173743	0.756	rs8030937	chr15:79129587	G/T	cg15571903	chr15:79123663	NA	0.58	6.52	0.56	3.43e-9	Coronary artery disease;
THYM	cis	rs2806561	0.765	rs643492	chr1:23501354	C/T	cg08872493	chr1:23521417	HTR1D	-0.36	-4.63	-0.43	1.16e-5	Height;
THYM	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg00129232	chr17:37814104	STARD3	-0.77	-5.27	-0.48	8.58e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6733011	0.628	rs6713991	chr2:99464384	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.56	-0.42	1.54e-5	Bipolar disorder;
THYM	cis	rs2267137	0.843	rs570731	chr22:29758817	A/G	cg26480862	chr22:28839667	TTC28	-0.46	-4.49	-0.42	1.99e-5	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-4.93	-0.45	3.42e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg27532560	chr4:187881888	NA	-0.95	-11.68	-0.77	4.63e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg26408565	chr15:76604113	ETFA	-0.55	-4.77	-0.44	6.55e-6	Blood metabolite levels;
THYM	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg06112835	chr11:68658793	MRPL21	0.43	6.08	0.53	2.48e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1829883	0.898	rs2460686	chr5:98770831	T/C	cg08333243	chr5:99726346	NA	-0.54	-5.02	-0.46	2.45e-6	Hemostatic factors and hematological phenotypes;
THYM	cis	rs669446	0.533	rs28833034	chr1:44212942	A/G	cg15962314	chr1:44399869	ARTN	0.47	5.05	0.46	2.16e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7107174	1.000	rs948662	chr11:77979829	A/G	cg02023728	chr11:77925099	USP35	0.64	5.76	0.51	1.05e-7	Testicular germ cell tumor;
THYM	cis	rs3923380	0.607	rs17002080	chr4:77464524	A/G	cg07933720	chr4:77468187	SHROOM3	-0.35	-4.45	-0.42	2.33e-5	Craniofacial microsomia;
THYM	cis	rs425277	0.958	rs626479	chr1:2110260	A/G	cg00981070	chr1:2046702	PRKCZ	-0.45	-5.12	-0.46	1.61e-6	Height;
THYM	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg03188948	chr7:1209495	NA	0.66	4.52	0.42	1.76e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3806843	0.766	rs2530239	chr5:140062547	C/T	cg19875535	chr5:140030758	IK	-0.64	-5.57	-0.5	2.37e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg27129171	chr3:47204927	SETD2	0.73	7.17	0.59	1.64e-10	Colorectal cancer;
THYM	cis	rs17030434	0.906	rs78436201	chr4:154661755	C/A	cg14289246	chr4:154710475	SFRP2	-0.87	-5.61	-0.5	2.01e-7	Electrocardiographic conduction measures;
THYM	cis	rs2731664	0.792	rs335432	chr5:176866258	G/A	cg14098951	chr5:176875120	PRR7	0.56	5.0	0.46	2.57e-6	Intelligence (multi-trait analysis);
THYM	cis	rs78456975	0.699	rs17091772	chr2:1519679	A/C	cg12573674	chr2:1569213	NA	-1.35	-6.39	-0.55	6.13e-9	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.82	-7.92	-0.63	4.45e-12	Intelligence (multi-trait analysis);
THYM	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg14829155	chr15:31115871	NA	0.75	6.38	0.55	6.46e-9	Huntington's disease progression;
THYM	cis	rs6430585	0.528	rs309133	chr2:136751842	A/C	cg04750100	chr2:136595281	LCT	0.55	5.55	0.49	2.61e-7	Corneal structure;
THYM	cis	rs2637266	0.846	rs2583045	chr10:78412385	C/G	cg18941641	chr10:78392320	NA	-0.85	-7.02	-0.58	3.23e-10	Pulmonary function;
THYM	cis	rs36051895	0.589	rs1322222	chr9:5190444	A/G	cg02405213	chr9:5042618	JAK2	-0.93	-10.17	-0.72	7.24e-17	Pediatric autoimmune diseases;
THYM	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg11266682	chr4:10021025	SLC2A9	-0.61	-7.57	-0.61	2.4e-11	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9479482	0.935	rs563278	chr6:150364427	G/C	cg25797454	chr6:150327115	RAET1K	0.44	4.69	0.43	9.06e-6	Alopecia areata;
THYM	cis	rs7119038	0.607	rs12365699	chr11:118743286	C/T	cg19308663	chr11:118741387	NA	0.66	5.59	0.5	2.21e-7	Sjögren's syndrome;
THYM	cis	rs7302981	0.667	rs7308692	chr12:50627654	C/T	cg20014596	chr12:50898483	DIP2B	-0.53	-5.01	-0.46	2.54e-6	Systolic blood pressure;
THYM	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg13852791	chr20:30311386	BCL2L1	0.93	7.14	0.59	1.83e-10	Mean corpuscular hemoglobin;
THYM	cis	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.64	0.43	1.12e-5	Obesity-related traits;
THYM	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs4642101	0.824	rs9835677	chr3:12845158	G/A	cg05775895	chr3:12838266	CAND2	0.94	8.62	0.66	1.49e-13	QRS complex (12-leadsum);
THYM	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs28595532	0.925	rs116785973	chr4:119611350	G/A	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg11812906	chr14:75593930	NEK9	-0.77	-7.03	-0.58	3.14e-10	Height;
THYM	cis	rs4776059	1.000	rs12914047	chr15:52970993	G/A	cg22715398	chr15:52968154	KIAA1370	-0.61	-4.82	-0.44	5.48e-6	Schizophrenia;
THYM	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg05738196	chr6:26577821	NA	0.88	8.09	0.64	1.92e-12	Intelligence (multi-trait analysis);
THYM	cis	rs300703	0.515	rs300695	chr2:182644	C/A	cg21211680	chr2:198530	NA	-0.86	-5.61	-0.5	1.95e-7	Blood protein levels;
THYM	cis	rs2718058	0.639	rs2597270	chr7:37762014	A/G	cg15028436	chr7:37888078	TXNDC3	-0.59	-4.5	-0.42	1.95e-5	Alzheimer's disease (late onset);
THYM	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg07061783	chr6:25882402	NA	-1.1	-10.85	-0.74	2.5e-18	Urate levels;
THYM	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg08508325	chr11:3079039	CARS	0.57	6.29	0.54	9.87e-9	Longevity;
THYM	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg09877947	chr5:131593287	PDLIM4	0.57	4.61	0.43	1.24e-5	Blood metabolite levels;
THYM	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg27572855	chr1:25598939	RHD	0.65	5.11	0.46	1.64e-6	Erythrocyte sedimentation rate;
THYM	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg18105134	chr13:113819100	PROZ	-0.96	-8.77	-0.67	6.94e-14	Platelet distribution width;
THYM	cis	rs61008539	0.741	rs11767322	chr7:867405	A/G	cg00475322	chr7:917719	C7orf20	0.53	6.41	0.55	5.49e-9	Perceived unattractiveness to mosquitoes;
THYM	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.56	-5.15	-0.47	1.39e-6	Type 2 diabetes;
THYM	cis	rs11190604	1.000	rs28522614	chr10:102323141	T/A	cg07570687	chr10:102243282	WNT8B	0.73	6.37	0.55	6.64e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg21138405	chr5:131827807	IRF1	-0.84	-9.6	-0.7	1.21e-15	Asthma (sex interaction);
THYM	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.26	-5.21	-0.47	1.1e-6	Obesity-related traits;
THYM	cis	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg24692254	chr21:30365293	RNF160	-0.84	-5.22	-0.47	1.04e-6	Cognitive test performance;
THYM	cis	rs12936587	0.538	rs1869771	chr17:17561094	C/A	cg04398451	chr17:18023971	MYO15A	0.65	5.15	0.47	1.38e-6	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
THYM	cis	rs1971762	0.504	rs1843318	chr12:53958077	C/T	cg16917193	chr12:54089295	NA	0.71	6.19	0.54	1.54e-8	Height;
THYM	cis	rs11792861	0.566	rs11792635	chr9:111848819	A/G	cg05043794	chr9:111880884	C9orf5	-0.3	-4.47	-0.42	2.18e-5	Menarche (age at onset);
THYM	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-4.49	-0.42	1.99e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs314370	0.818	rs12705091	chr7:100472380	C/T	cg08558340	chr7:100472263	SRRT	0.5	4.61	0.43	1.26e-5	Resting heart rate;
THYM	cis	rs986417	0.818	rs10144990	chr14:60927816	T/C	cg27398547	chr14:60952738	C14orf39	1.21	6.17	0.53	1.69e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs34293785	1.000	rs34293785	chr1:66137192	T/C	cg04111102	chr1:66153794	NA	0.56	5.16	0.47	1.37e-6	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;
THYM	cis	rs990171	1.000	rs6543141	chr2:103076351	G/A	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.13	-0.47	1.5e-6	Lymphocyte counts;
THYM	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg03929089	chr4:120376271	NA	-1.01	-13.5	-0.81	8.17e-24	Height;
THYM	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.61	-4.45	-0.42	2.34e-5	Colorectal cancer;
THYM	cis	rs3925075	1.000	rs12923297	chr16:31360944	T/C	cg02846316	chr16:31340340	ITGAM	0.56	5.87	0.52	6.33e-8	IgA nephropathy;
THYM	cis	rs9359856	0.510	rs2748298	chr6:90436877	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.83	-8.12	-0.64	1.67e-12	Bipolar disorder;
THYM	cis	rs314370	0.951	rs17884589	chr7:100493711	G/A	cg10426581	chr7:100472382	SRRT	1.13	8.97	0.68	2.57e-14	Resting heart rate;
THYM	cis	rs62103177	0.608	rs613847	chr18:77845644	A/G	cg07235805	chr18:78004237	PARD6G	-0.48	-5.47	-0.49	3.62e-7	Opioid sensitivity;
THYM	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg15448220	chr1:150897856	SETDB1	0.89	7.59	0.61	2.17e-11	Melanoma;
THYM	cis	rs758324	0.627	rs269900	chr5:131482244	A/T	cg16205897	chr5:131564050	P4HA2	0.57	4.86	0.45	4.56e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs7551222	0.752	rs1380576	chr1:204488278	G/C	cg20240347	chr1:204465584	NA	-0.51	-4.54	-0.42	1.62e-5	Schizophrenia;
THYM	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg02725872	chr8:58115012	NA	-0.73	-5.38	-0.48	5.3e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs10493773	0.532	rs12064199	chr1:86187073	A/T	cg17807903	chr1:86174739	ZNHIT6	-0.61	-9.14	-0.68	1.12e-14	Urate levels in overweight individuals;
THYM	cis	rs10927875	0.691	rs2017583	chr1:16350028	A/G	cg22431228	chr1:16359049	CLCNKA	-0.51	-4.93	-0.45	3.47e-6	Dilated cardiomyopathy;
THYM	trans	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs12530845	0.673	rs4073627	chr7:135312572	A/G	cg23117316	chr7:135346802	PL-5283	0.68	5.69	0.5	1.38e-7	Red blood cell traits;
THYM	cis	rs1003719	0.680	rs2835670	chr21:38581114	T/C	cg01329690	chr21:38580129	DSCR9	-0.36	-4.98	-0.46	2.81e-6	Eye color traits;
THYM	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9326248	0.861	rs4938352	chr11:117027481	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.67	4.78	0.44	6.35e-6	Blood protein levels;
THYM	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg02153584	chr22:29168773	CCDC117	0.58	4.56	0.42	1.52e-5	Lymphocyte counts;
THYM	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg24642844	chr7:1081250	C7orf50	-1.17	-7.15	-0.59	1.75e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2034650	0.525	rs11790	chr15:40712737	T/C	cg12699599	chr15:40643142	PHGR1	-0.56	-5.26	-0.47	8.88e-7	Interstitial lung disease;
THYM	cis	rs7666738	0.687	rs6830176	chr4:99093955	G/C	cg24818145	chr4:99064322	C4orf37	0.67	5.2	0.47	1.13e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2282300	0.739	rs6484478	chr11:30306440	A/G	cg25418670	chr11:30344373	C11orf46	0.82	6.97	0.58	4.25e-10	Morning vs. evening chronotype;
THYM	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg13147721	chr7:65941812	NA	0.69	4.5	0.42	1.92e-5	Diabetic kidney disease;
THYM	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs651907	0.588	rs2860329	chr3:101632426	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.62	5.31	0.48	7.21e-7	Colorectal cancer;
THYM	cis	rs4595586	0.545	rs12812959	chr12:39371197	T/C	cg13010199	chr12:38710504	ALG10B	0.67	4.92	0.45	3.57e-6	Morning vs. evening chronotype;
THYM	cis	rs2046867	0.628	rs61159664	chr3:72916958	C/G	cg25664220	chr3:72788482	NA	-0.77	-6.41	-0.55	5.49e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg05738196	chr6:26577821	NA	-0.59	-4.57	-0.42	1.49e-5	Intelligence (multi-trait analysis);
THYM	cis	rs5758659	0.633	rs762995	chr22:42672124	A/G	cg00645731	chr22:42541494	CYP2D7P1	-0.39	-4.81	-0.44	5.58e-6	Cognitive function;
THYM	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg17911788	chr17:44343683	NA	0.71	6.76	0.57	1.09e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg01191920	chr7:158217561	PTPRN2	-1.02	-11.62	-0.77	5.94e-20	Obesity-related traits;
THYM	cis	rs981844	1.000	rs62325083	chr4:154661775	T/C	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs9534288	0.797	rs6561281	chr13:46596601	C/T	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg26850624	chr5:429559	AHRR	-0.71	-5.23	-0.47	1.02e-6	Cystic fibrosis severity;
THYM	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg23758822	chr17:41437982	NA	1.13	10.31	0.73	3.52e-17	Menopause (age at onset);
THYM	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg07936489	chr17:37558343	FBXL20	-0.82	-5.42	-0.49	4.49e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg06640241	chr16:89574553	SPG7	0.59	4.56	0.42	1.55e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg00908189	chr16:619842	PIGQ	1.02	9.27	0.69	6.03e-15	Height;
THYM	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg03959625	chr15:84868606	LOC388152	0.49	4.77	0.44	6.64e-6	Schizophrenia;
THYM	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11644478	chr21:40555479	PSMG1	-0.56	-4.69	-0.43	9.07e-6	Menarche (age at onset);
THYM	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg24250549	chr1:154909240	PMVK	0.7	5.14	0.47	1.47e-6	Prostate cancer;
THYM	trans	rs9747201	0.894	rs9944398	chr17:80177439	A/G	cg07393940	chr7:158741817	NA	1.1	8.4	0.65	4.38e-13	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs919433	0.679	rs10497806	chr2:198508951	G/A	cg05783139	chr2:198650985	BOLL	0.67	5.05	0.46	2.12e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7772486	0.754	rs864148	chr6:145976675	T/C	cg13319975	chr6:146136371	FBXO30	0.65	5.26	0.48	8.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6035126	1.000	rs13433287	chr20:1931519	A/G	cg07210840	chr20:1927816	NA	1.04	4.75	0.44	7.18e-6	Liver enzyme levels (alanine transaminase);
THYM	cis	rs17401966	1.000	rs11121533	chr1:10292888	G/C	cg20482658	chr1:10539492	PEX14	0.37	4.5	0.42	1.91e-5	Hepatocellular carcinoma;
THYM	cis	rs3960554	0.808	rs2286829	chr7:75677739	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-4.47	-0.42	2.18e-5	Eotaxin levels;
THYM	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg06565975	chr8:143823917	SLURP1	0.71	8.6	0.66	1.61e-13	Urinary tract infection frequency;
THYM	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg07061783	chr6:25882402	NA	-0.58	-4.59	-0.43	1.37e-5	Schizophrenia;
THYM	cis	rs6127978	0.702	rs4810061	chr20:55801652	G/C	cg15851418	chr20:55835831	BMP7	0.66	4.61	0.43	1.27e-5	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs13323323	0.691	rs9815769	chr3:44663014	A/T	cg16615211	chr3:44902933	MIR564;TMEM42	0.55	4.81	0.44	5.71e-6	IgG glycosylation;
THYM	cis	rs17604090	0.793	rs10241305	chr7:29689929	T/C	cg19413766	chr7:29689036	LOC646762	-0.89	-4.92	-0.45	3.62e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs7248779	0.512	rs3848635	chr19:2410332	T/C	cg22729335	chr19:2427816	TIMM13	1.2	13.07	0.8	6.08e-23	Cortisol levels (saliva);
THYM	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-8.09	-0.64	1.93e-12	Height;
THYM	cis	rs4731207	0.565	rs10227119	chr7:124593780	T/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs11809207	0.568	rs1892494	chr1:26497626	C/G	cg26412358	chr1:26503933	CNKSR1	0.36	5.01	0.46	2.48e-6	Height;
THYM	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg24209194	chr3:40518798	ZNF619	0.65	5.27	0.48	8.46e-7	Renal cell carcinoma;
THYM	cis	rs9880211	1.000	rs6775314	chr3:136275948	G/A	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs12519773	0.717	rs67779882	chr5:92488009	A/G	cg18783429	chr5:92414398	NA	0.54	5.11	0.46	1.68e-6	Migraine;
THYM	trans	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg13615516	chr5:77269221	NA	0.86	8.01	0.63	2.88e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg21433313	chr16:3507492	NAT15	0.78	6.7	0.57	1.43e-9	Tuberculosis;
THYM	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg19016782	chr12:123741754	C12orf65	-0.7	-4.61	-0.43	1.25e-5	Neutrophil percentage of white cells;
THYM	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg12573674	chr2:1569213	NA	-1.19	-4.49	-0.42	2.02e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs7818345	0.624	rs12682196	chr8:19332963	A/C	cg11303988	chr8:19266685	CSGALNACT1	-0.47	-4.75	-0.44	7.1e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-15.39	-0.84	1.51e-27	Height;
THYM	cis	rs2997447	0.761	rs60404932	chr1:26454881	C/T	cg03844060	chr1:26490628	NA	0.67	4.52	0.42	1.79e-5	QRS complex (12-leadsum);
THYM	cis	rs17597773	0.527	rs1537806	chr1:221084222	G/A	cg16008148	chr1:221062819	NA	0.36	5.13	0.47	1.51e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7582180	0.602	rs7585582	chr2:100998030	G/C	cg21926883	chr2:100939477	LONRF2	-0.65	-6.1	-0.53	2.25e-8	Intelligence (multi-trait analysis);
THYM	cis	rs897984	0.537	rs8045637	chr16:30818662	C/T	cg02466173	chr16:30829666	NA	-0.53	-4.56	-0.42	1.51e-5	Dementia with Lewy bodies;
THYM	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06873352	chr17:61820015	STRADA	0.56	5.66	0.5	1.63e-7	Height;
THYM	cis	rs6032067	0.929	rs6017511	chr20:43833132	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs7246657	0.943	rs8106839	chr19:37958475	C/G	cg22634378	chr19:37742834	NA	0.64	5.43	0.49	4.26e-7	Coronary artery calcification;
THYM	cis	rs6450176	0.909	rs6884760	chr5:53293077	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-6.61	-0.56	2.22e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg14829155	chr15:31115871	NA	-0.58	-5.15	-0.47	1.4e-6	Huntington's disease progression;
THYM	cis	rs4072705	0.615	rs7028021	chr9:127249022	A/G	cg01786973	chr9:127249749	NR5A1	0.4	5.42	0.49	4.43e-7	Menarche (age at onset);
THYM	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg20744362	chr22:50050164	C22orf34	0.82	8.02	0.64	2.68e-12	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4343996	0.902	rs4521670	chr7:3383603	C/T	cg21248987	chr7:3385318	SDK1	0.42	5.05	0.46	2.12e-6	Motion sickness;
THYM	cis	rs2963155	0.518	rs862489	chr5:142634355	T/C	cg17617527	chr5:142782415	NR3C1	1.2	6.6	0.56	2.37e-9	Breast cancer;
THYM	cis	rs6032067	0.641	rs17332243	chr20:43756071	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.67	-5.92	-0.52	5.17e-8	Blood protein levels;
THYM	cis	rs757081	0.606	rs679201	chr11:17200891	T/C	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.6	-0.43	1.29e-5	Systolic blood pressure;
THYM	cis	rs2562456	0.876	rs2681395	chr19:21738140	T/C	cg21751540	chr19:21541537	ZNF738	-0.69	-4.75	-0.44	7.1e-6	Pain;
THYM	cis	rs6500602	0.826	rs9932461	chr16:4454170	A/G	cg09549813	chr16:4587862	C16orf5	-0.59	-5.72	-0.51	1.23e-7	Schizophrenia;
THYM	cis	rs308447	0.576	rs7678199	chr4:123724239	A/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.86	6.67	0.56	1.68e-9	Perceived unattractiveness to mosquitoes;
THYM	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg04043695	chr12:129287642	SLC15A4	0.61	5.07	0.46	1.98e-6	Systemic lupus erythematosus;
THYM	cis	rs7011507	0.537	rs16937171	chr8:49356735	C/T	cg08774009	chr8:49309094	NA	0.67	6.07	0.53	2.62e-8	Inflammatory bowel disease;Ulcerative colitis;
THYM	trans	rs4262150	0.883	rs12153071	chr5:152247852	C/A	cg08281791	chr5:76607845	PDE8B	0.92	6.91	0.58	5.62e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs904251	0.861	rs2776875	chr6:37486796	G/C	cg25019722	chr6:37503610	NA	-0.66	-5.67	-0.5	1.53e-7	Cognitive performance;
THYM	cis	rs9682041	0.660	rs13089256	chr3:170113601	G/A	cg11886554	chr3:170076028	SKIL	1.0	4.56	0.42	1.54e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	trans	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2319125	0.650	rs11079630	chr17:64023800	C/T	cg04446870	chr17:64440273	PRKCA	0.51	4.61	0.43	1.27e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.24	0.6	1.18e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs977987	0.843	rs11644741	chr16:75466433	C/A	cg03315344	chr16:75512273	CHST6	0.73	5.88	0.52	6.15e-8	Dupuytren's disease;
THYM	cis	rs7107174	1.000	rs11237469	chr11:78072875	A/T	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg07424592	chr7:64974309	NA	-0.99	-5.15	-0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg17063962	chr7:91808500	NA	-1.05	-10.96	-0.75	1.53e-18	Breast cancer;
THYM	cis	rs5758659	0.652	rs133340	chr22:42417687	A/T	cg22189786	chr22:42395067	WBP2NL	0.38	4.45	0.42	2.35e-5	Cognitive function;
THYM	cis	rs10089	1.000	rs1962291	chr5:127445373	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-1.02	-7.11	-0.59	2.11e-10	Ileal carcinoids;
THYM	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.17	-8.75	-0.67	7.68e-14	Platelet count;
THYM	cis	rs11249608	0.548	rs62393074	chr5:178450476	G/C	cg01312482	chr5:178451176	ZNF879	-0.76	-6.36	-0.55	7e-9	Pubertal anthropometrics;
THYM	cis	rs4930103	1.000	rs4930103	chr11:2024544	G/A	cg18511798	chr11:2018149	H19;MIR675	-0.6	-6.12	-0.53	2.12e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs6570726	0.818	rs952405	chr6:145925952	T/C	cg13319975	chr6:146136371	FBXO30	-0.66	-5.22	-0.47	1.06e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4654899	0.680	rs4233274	chr1:21121678	C/T	cg01072550	chr1:21505969	NA	-0.66	-6.02	-0.53	3.2e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.9	-4.67	-0.43	9.98e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4731207	0.597	rs12536017	chr7:124562301	A/G	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7512552	0.839	rs834231	chr1:150389392	A/T	cg15654264	chr1:150340011	RPRD2	-0.46	-5.4	-0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs11634944	0.506	rs765438	chr15:25236128	A/G	cg21061553	chr15:25124213	SNRPN	-0.54	-4.47	-0.42	2.2e-5	Interleukin-8 levels;
THYM	cis	rs9790314	1.000	rs9846756	chr3:160983809	A/C	cg04691961	chr3:161091175	C3orf57	-0.59	-5.0	-0.46	2.59e-6	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg12000587	chr17:30186630	C17orf79	0.43	4.63	0.43	1.17e-5	Hip circumference adjusted for BMI;
THYM	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg23758822	chr17:41437982	NA	-1.16	-10.95	-0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs7084402	0.967	rs1649036	chr10:60331878	C/A	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs17125944	0.686	rs9646151	chr14:53354464	C/G	cg00686598	chr14:53173677	PSMC6	-1.01	-4.54	-0.42	1.65e-5	Alzheimer's disease (late onset);
THYM	cis	rs782590	0.967	rs62165173	chr2:55741666	T/C	cg18811423	chr2:55921094	PNPT1	0.74	7.05	0.59	2.83e-10	Metabolic syndrome;
THYM	cis	rs901683	0.702	rs76551593	chr10:46110981	A/G	cg18240400	chr10:46168597	ANUBL1	0.68	4.67	0.43	9.88e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	6.73	0.57	1.25e-9	Electrocardiographic conduction measures;
THYM	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg01616529	chr11:638424	DRD4	-0.78	-6.62	-0.56	2.16e-9	Systemic lupus erythematosus;
THYM	cis	rs357618	0.581	rs165359	chr5:150861036	G/A	cg24040989	chr5:149979572	SYNPO	0.43	4.59	0.43	1.35e-5	Basophil percentage of white cells;
THYM	cis	rs713587	0.626	rs62140636	chr2:25233811	T/C	cg01884057	chr2:25150051	NA	-0.57	-5.88	-0.52	6.18e-8	Body mass index in non-asthmatics;
THYM	cis	rs4845459	0.967	rs477392	chr1:152555176	C/G	cg27206522	chr1:152595629	LCE3A	-0.51	-4.54	-0.42	1.66e-5	Psoriasis;
THYM	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg07648498	chr16:89883185	FANCA	0.63	4.78	0.44	6.49e-6	Vitiligo;
THYM	cis	rs2456568	0.802	rs8181567	chr11:93637209	C/T	cg17595323	chr11:93583763	C11orf90	-0.58	-6.09	-0.53	2.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7247513	0.930	rs2861408	chr19:12702099	A/G	cg01871581	chr19:12707946	ZNF490	-0.87	-9.38	-0.69	3.46e-15	Bipolar disorder;
THYM	cis	rs6598955	0.670	rs7531518	chr1:26539749	T/C	cg00852783	chr1:26633632	UBXN11	0.82	7.73	0.62	1.12e-11	Obesity-related traits;
THYM	cis	rs11696501	0.688	rs6073851	chr20:44306978	C/T	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	trans	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg19875535	chr5:140030758	IK	-0.6	-4.78	-0.44	6.41e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg07636037	chr3:49044803	WDR6	0.78	5.69	0.5	1.39e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg02825527	chr7:2087843	MAD1L1	-0.77	-5.17	-0.47	1.29e-6	Bipolar disorder;
THYM	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg27170947	chr2:26402098	FAM59B	-0.8	-6.37	-0.55	6.74e-9	Gut microbiome composition (summer);
THYM	cis	rs4909189	0.957	rs11766348	chr7:158135857	G/A	cg15736062	chr7:158136485	PTPRN2	-0.61	-4.86	-0.45	4.64e-6	Response to amphetamines;
THYM	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg05896524	chr21:47604654	C21orf56	0.81	5.13	0.47	1.54e-6	Testicular germ cell tumor;
THYM	cis	rs288326	0.561	rs77541378	chr2:183886271	C/A	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg06238570	chr21:40685208	BRWD1	-0.68	-5.74	-0.51	1.15e-7	Menarche (age at onset);
THYM	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg24692254	chr21:30365293	RNF160	1.01	9.59	0.7	1.23e-15	Dental caries;
THYM	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.75	0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs3885907	0.869	rs61947373	chr13:31287268	G/A	cg19953038	chr13:31306303	NA	-0.67	-5.53	-0.49	2.79e-7	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU);
THYM	cis	rs4481887	0.927	rs4578248	chr1:248434069	G/A	cg00666640	chr1:248458726	OR2T12	0.58	4.87	0.45	4.42e-6	Common traits (Other);
THYM	cis	rs7131987	0.650	rs3782509	chr12:29453778	G/A	cg09582351	chr12:29534625	ERGIC2	-0.53	-4.68	-0.43	9.37e-6	QT interval;
THYM	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg00898013	chr13:113819073	PROZ	0.9	8.81	0.67	5.86e-14	Platelet distribution width;
THYM	cis	rs9314614	0.789	rs2951863	chr8:6710502	A/C	cg27319216	chr8:6693540	XKR5	-0.53	-5.4	-0.48	5.01e-7	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs425535	0.757	rs1594229	chr4:74841564	C/G	cg07868155	chr4:74864709	CXCL5	0.65	4.95	0.45	3.24e-6	Blood protein levels;
THYM	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg15704280	chr7:45808275	SEPT13	-1.04	-14.05	-0.82	6.23e-25	Height;
THYM	cis	rs3087591	0.919	rs2952983	chr17:29470288	G/C	cg24425628	chr17:29625626	OMG;NF1	0.67	5.34	0.48	6.37e-7	Hip circumference;
THYM	cis	rs6763768	0.606	rs7648309	chr3:53291982	C/T	cg22900224	chr3:52804907	NEK4	0.87	4.8	0.44	5.88e-6	Bacterial meningitis;
THYM	cis	rs4731207	0.535	rs28820311	chr7:124598989	C/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1113500	0.541	rs11185241	chr1:108583025	T/C	cg06207961	chr1:108661230	NA	0.7	4.87	0.45	4.51e-6	Growth-regulated protein alpha levels;
THYM	cis	rs1062746	0.711	rs2303763	chr16:87376605	C/T	cg27119004	chr16:87376851	FBXO31	-0.5	-5.14	-0.47	1.49e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs2213920	0.569	rs6478170	chr9:118246331	G/A	cg13918206	chr9:118159781	DEC1	0.84	4.63	0.43	1.17e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs7107174	1.000	rs10899457	chr11:78001163	T/A	cg19901956	chr11:77921274	USP35	-0.69	-5.3	-0.48	7.42e-7	Testicular germ cell tumor;
THYM	cis	rs6956675	1.000	rs1609527	chr7:62599257	C/T	cg27518014	chr7:62859535	LOC100287834	0.65	5.03	0.46	2.3e-6	Obesity-related traits;
THYM	cis	rs2505998	1.000	rs2505998	chr10:43570925	A/G	cg06632098	chr10:43605906	RET	-1.05	-9.64	-0.7	9.8e-16	Hirschsprung disease;
THYM	cis	rs10463554	0.963	rs6883113	chr5:102377889	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.03	-0.46	2.27e-6	Parkinson's disease;
THYM	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg23131131	chr22:24373011	LOC391322	-0.8	-8.24	-0.65	9.54e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs8002861	0.781	rs3816311	chr13:44453783	G/A	cg17145862	chr1:211918768	LPGAT1	0.98	10.45	0.73	1.82e-17	Leprosy;
THYM	cis	rs3126085	0.935	rs4845426	chr1:152195359	A/G	cg10321714	chr1:152280068	FLG	0.68	5.07	0.46	1.98e-6	Atopic dermatitis;
THYM	cis	rs4940575	0.679	rs11875184	chr18:60829553	A/G	cg25271770	chr18:61057090	VPS4B	0.78	4.56	0.42	1.53e-5	Breast cancer;
THYM	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg06634786	chr22:41940651	POLR3H	0.65	5.21	0.47	1.1e-6	Vitiligo;
THYM	cis	rs1642645	0.872	rs348139	chr1:42470901	C/T	cg10197057	chr1:42612518	NA	0.46	5.04	0.46	2.22e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs17534004	1.000	rs12876002	chr13:31467467	A/G	cg00367615	chr13:31480979	C13orf33	0.65	4.65	0.43	1.06e-5	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs56322409	0.561	rs11188397	chr10:97367511	C/A	cg00110277	chr10:97668174	C10orf131	-0.58	-4.91	-0.45	3.72e-6	Blood metabolite levels;
THYM	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg19077165	chr18:44547161	KATNAL2	-0.66	-8.44	-0.65	3.55e-13	Personality dimensions;
THYM	cis	rs7772486	0.875	rs2748502	chr6:146298239	A/G	cg23711669	chr6:146136114	FBXO30	0.9	8.92	0.68	3.32e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6754311	0.593	rs55825471	chr2:136526981	T/A	cg23851026	chr2:136556271	LCT	-0.59	-6.18	-0.54	1.58e-8	Mosquito bite size;
THYM	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.79	-4.99	-0.46	2.73e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg11764359	chr7:65958608	NA	0.69	4.78	0.44	6.35e-6	Aortic root size;
THYM	cis	rs236907	0.859	rs7522582	chr1:171770111	G/C	cg20598894	chr1:171756153	METTL13	-0.74	-5.48	-0.49	3.46e-7	Mean platelet volume;
THYM	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg25358565	chr5:93447407	FAM172A	-1.36	-10.83	-0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03647317	chr4:187891568	NA	-0.83	-9.53	-0.7	1.69e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7107174	1.000	rs10899474	chr11:78043636	T/C	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs7072216	0.726	rs4474372	chr10:100164571	C/T	cg03852570	chr10:100175106	PYROXD2	0.37	4.78	0.44	6.49e-6	Metabolite levels;
THYM	cis	rs1448094	0.512	rs7960130	chr12:86243191	T/C	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs11096990	0.819	rs2435528	chr4:39157536	A/G	cg24403649	chr4:39172243	NA	-0.6	-5.09	-0.46	1.77e-6	Cognitive function;
THYM	trans	rs3960554	0.808	rs867973	chr7:75686007	G/A	cg19862616	chr7:65841803	NCRNA00174	0.93	6.95	0.58	4.6e-10	Eotaxin levels;
THYM	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs17407555	0.909	rs58440238	chr4:10245311	C/A	cg11266682	chr4:10021025	SLC2A9	-0.53	-4.9	-0.45	4e-6	Schizophrenia (age at onset);
THYM	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg13010199	chr12:38710504	ALG10B	0.72	5.78	0.51	9.6e-8	Heart rate;
THYM	cis	rs868036	0.958	rs12593813	chr15:68036852	C/T	cg24579218	chr15:68104479	NA	-0.64	-6.08	-0.53	2.53e-8	Restless legs syndrome;
THYM	cis	rs9403317	0.960	rs55959773	chr6:141851155	T/C	cg15052665	chr6:141804349	NA	0.86	7.61	0.62	1.94e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg11764359	chr7:65958608	NA	-0.82	-6.37	-0.55	6.65e-9	Aortic root size;
THYM	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg00376283	chr12:123451042	ABCB9	0.72	4.94	0.45	3.36e-6	Neutrophil percentage of white cells;
THYM	cis	rs7172809	0.796	rs4886870	chr15:77827471	A/C	cg22256960	chr15:77711686	NA	-0.67	-4.64	-0.43	1.13e-5	Glucose homeostasis traits;
THYM	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4731207	0.569	rs1986124	chr7:124641717	A/C	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs7975161	0.630	rs7978101	chr12:104630510	A/G	cg25273343	chr12:104657179	TXNRD1	-0.78	-5.35	-0.48	6.15e-7	Toenail selenium levels;
THYM	cis	rs6430585	0.528	rs3112496	chr2:136711064	C/T	cg23851026	chr2:136556271	LCT	0.68	6.64	0.56	1.94e-9	Corneal structure;
THYM	cis	rs7107174	0.901	rs2510053	chr11:77959435	T/C	cg02023728	chr11:77925099	USP35	0.73	6.53	0.56	3.25e-9	Testicular germ cell tumor;
THYM	cis	rs55728055	0.661	rs75785548	chr22:31991363	C/T	cg01338084	chr22:32026380	PISD	1.36	5.56	0.5	2.44e-7	Age-related hearing impairment;
THYM	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg26769984	chr7:1090371	C7orf50	0.63	4.79	0.44	6.25e-6	Bronchopulmonary dysplasia;
THYM	cis	rs7106204	0.543	rs16912423	chr11:24322678	C/G	ch.11.24196551F	chr11:24239977	NA	-0.99	-6.03	-0.53	3.1e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs526231	0.543	rs246900	chr5:102534629	T/A	cg23492399	chr5:102201601	PAM	-0.71	-5.32	-0.48	6.82e-7	Primary biliary cholangitis;
THYM	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg05335186	chr13:53173507	NA	-0.5	-7.02	-0.58	3.22e-10	Lewy body disease;
THYM	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg09549813	chr16:4587862	C16orf5	-0.57	-6.46	-0.55	4.43e-9	Schizophrenia;
THYM	cis	rs1065852	0.526	rs9611700	chr22:42401514	C/T	cg08431931	chr22:42394659	WBP2NL	0.74	6.08	0.53	2.48e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg20476274	chr7:133979776	SLC35B4	0.66	4.58	0.43	1.42e-5	Mean platelet volume;
THYM	cis	rs747782	0.527	rs7113857	chr11:48141859	G/T	cg24672777	chr11:48374446	OR4C45	-1.01	-5.56	-0.5	2.46e-7	Intraocular pressure;
THYM	cis	rs425277	0.583	rs4648807	chr1:2040898	A/G	cg00981070	chr1:2046702	PRKCZ	-0.39	-4.92	-0.45	3.65e-6	Height;
THYM	cis	rs791888	0.858	rs2180968	chr10:89418730	A/C	cg10377144	chr10:89419177	PAPSS2	0.42	7.27	0.6	1.02e-10	Magnesium levels;
THYM	cis	rs17102423	0.826	rs12887607	chr14:65596887	G/A	cg11161011	chr14:65562177	MAX	-0.85	-7.15	-0.59	1.77e-10	Obesity-related traits;
THYM	cis	rs11711311	0.911	rs9831422	chr3:113398195	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.57	-4.78	-0.44	6.38e-6	IgG glycosylation;
THYM	cis	rs7781557	0.938	rs73192015	chr7:102511732	C/T	cg06322601	chr7:102330635	NA	0.63	4.86	0.45	4.72e-6	Colorectal adenoma (advanced);
THYM	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg13944838	chr5:179740914	GFPT2	-0.83	-6.47	-0.55	4.27e-9	Height;
THYM	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2820651	0.614	rs116335204	chr10:1480569	A/G	cg13720710	chr10:1452970	ADARB2	0.71	4.63	0.43	1.15e-5	Migraine with aura;
THYM	cis	rs4788570	0.667	rs8053186	chr16:71790166	G/A	cg06353428	chr16:71660113	MARVELD3	1.43	8.68	0.67	1.09e-13	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg23711669	chr6:146136114	FBXO30	0.89	8.38	0.65	4.8e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs216026	0.689	rs4765701	chr12:2770891	C/T	cg19945202	chr12:2788847	CACNA1C	0.75	5.07	0.46	1.98e-6	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs7089973	0.966	rs17721283	chr10:116644141	A/G	cg23260525	chr10:116636907	FAM160B1	0.59	5.36	0.48	5.76e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg14895029	chr7:2775587	GNA12	0.63	4.49	0.42	1.97e-5	Height;
THYM	cis	rs28595532	0.920	rs115214765	chr4:119728167	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs2625529	0.818	rs16956241	chr15:72111688	G/T	cg16672083	chr15:72433130	SENP8	-0.6	-5.24	-0.47	9.84e-7	Red blood cell count;
THYM	cis	rs9443645	0.509	rs9361459	chr6:79572922	A/G	cg18132916	chr6:79620363	NA	0.51	4.61	0.43	1.28e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4866334	1.000	rs76306109	chr5:18481141	A/C	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg15744005	chr10:104629667	AS3MT	-0.83	-7.76	-0.62	9.7e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs3771570	1.000	rs62193197	chr2:242294301	G/A	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg24642844	chr7:1081250	C7orf50	-1.29	-8.31	-0.65	6.62e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg15212455	chr7:39170539	POU6F2	0.66	6.02	0.53	3.26e-8	IgG glycosylation;
THYM	cis	rs67385638	1.000	rs2855121	chr11:5277291	C/T	cg12559170	chr11:5275217	HBG2	0.9	8.93	0.68	3.21e-14	Hemoglobin levels;
THYM	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg19052272	chr2:3704530	ALLC	-0.68	-5.08	-0.46	1.92e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs11089937	0.522	rs2005239	chr22:22532473	G/A	cg06866756	chr22:22471216	NA	-0.43	-4.66	-0.43	1.02e-5	Periodontitis (PAL4Q3);
THYM	cis	rs6138458	1.000	rs6114988	chr20:24977586	C/T	cg06937882	chr20:24974362	C20orf3	-0.46	-4.64	-0.43	1.11e-5	Blood protein levels;
THYM	cis	rs921968	0.541	rs10200507	chr2:219335944	C/A	cg02176678	chr2:219576539	TTLL4	-0.73	-7.24	-0.6	1.18e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2806561	0.929	rs6669568	chr1:23540469	G/A	cg08872493	chr1:23521417	HTR1D	-0.37	-4.61	-0.43	1.25e-5	Height;
THYM	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg08564027	chr20:61660810	NA	0.92	9.77	0.71	5.02e-16	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg25214090	chr10:38739885	LOC399744	0.85	7.16	0.59	1.7e-10	Corneal astigmatism;
THYM	cis	rs7119038	0.774	rs11217020	chr11:118639353	G/A	cg19308663	chr11:118741387	NA	0.61	5.57	0.5	2.41e-7	Sjögren's syndrome;
THYM	trans	rs629535	0.814	rs571682	chr8:70062793	A/G	cg21567404	chr3:27674614	NA	1.04	9.6	0.7	1.16e-15	Dupuytren's disease;
THYM	cis	rs6598955	0.671	rs12088858	chr1:26643708	C/A	cg20415053	chr1:26527928	CATSPER4	-0.58	-4.71	-0.43	8.58e-6	Obesity-related traits;
THYM	cis	rs7980799	0.682	rs1447873	chr12:33615236	A/G	cg10856724	chr12:34555212	NA	0.6	4.5	0.42	1.93e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg09990169	chr2:241835740	C2orf54	-0.34	-5.49	-0.49	3.34e-7	Urinary metabolites;
THYM	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg27168131	chr21:44088823	PDE9A	-0.47	-4.48	-0.42	2.06e-5	Mean corpuscular volume;
THYM	cis	rs72627123	1.000	rs72627117	chr14:74355233	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs1150668	0.830	rs2859365	chr6:28391465	C/T	cg09682330	chr6:28411287	ZSCAN23	0.52	4.6	0.43	1.29e-5	Pubertal anthropometrics;
THYM	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	5.11	0.46	1.69e-6	Menarche (age at onset);
THYM	cis	rs34779708	0.966	rs10827487	chr10:35406878	T/A	cg03585969	chr10:35415529	CREM	0.67	4.76	0.44	6.91e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4523957	0.583	rs9303251	chr17:2047214	C/T	cg16513277	chr17:2031491	SMG6	-1.01	-9.62	-0.7	1.06e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6840360	0.571	rs4696099	chr4:152501951	C/G	cg22705602	chr4:152727874	NA	-0.76	-8.31	-0.65	6.56e-13	Intelligence (multi-trait analysis);
THYM	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg20203395	chr5:56204925	C5orf35	0.67	4.57	0.42	1.45e-5	Initial pursuit acceleration;
THYM	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg24308560	chr3:49941425	MST1R	-0.76	-6.48	-0.55	4.1e-9	Intelligence (multi-trait analysis);
THYM	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg18538332	chr22:24372958	LOC391322	0.87	8.42	0.65	3.9e-13	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs2075230	0.705	rs1641525	chr17:7549211	A/G	cg10509001	chr17:7553872	ATP1B2	0.58	4.55	0.42	1.62e-5	Hormone measurements;
THYM	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg07870213	chr5:140052090	DND1	0.7	7.7	0.62	1.28e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1957429	0.614	rs73279812	chr14:65348012	G/A	cg23373153	chr14:65346875	NA	-1.29	-5.55	-0.49	2.56e-7	Pediatric areal bone mineral density (radius);
THYM	cis	rs4907240	0.806	rs4907237	chr2:97190497	C/T	cg18419276	chr2:96971862	SNRNP200	-0.44	-5.31	-0.48	7.32e-7	Event-related brain oscillations;
THYM	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg20007245	chr22:24372913	LOC391322	-0.81	-8.14	-0.64	1.54e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-4.59	-0.43	1.34e-5	Prudent dietary pattern;
THYM	cis	rs17641971	0.684	rs4873100	chr8:50025772	G/A	cg00325661	chr8:49890786	NA	0.58	4.48	0.42	2.04e-5	Blood metabolite levels;
THYM	cis	rs7584330	0.736	rs6431541	chr2:238376190	A/T	cg14458575	chr2:238380390	NA	0.92	7.79	0.62	8.4e-12	Prostate cancer;
THYM	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg14779329	chr11:130786720	SNX19	0.47	4.92	0.45	3.67e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs346785	0.640	rs11077809	chr17:74284854	A/C	cg09812376	chr17:74270190	QRICH2	-0.5	-5.09	-0.46	1.8e-6	White matter hyperintensities in ischemic stroke;
THYM	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg12011299	chr4:100065546	ADH4	0.74	7.23	0.6	1.24e-10	Alcohol dependence;
THYM	cis	rs2806561	0.929	rs2746556	chr1:23524541	G/A	cg19743168	chr1:23544995	NA	0.67	7.3	0.6	8.57e-11	Height;
THYM	cis	rs35934224	0.891	rs33997573	chr22:19868951	C/T	cg11182965	chr22:19864308	TXNRD2	-0.93	-7.29	-0.6	9.33e-11	Glaucoma (primary open-angle);
THYM	cis	rs17401966	0.894	rs61778406	chr1:10435816	G/A	cg19773385	chr1:10388646	KIF1B	-0.58	-4.52	-0.42	1.81e-5	Hepatocellular carcinoma;
THYM	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs4631830	0.900	rs10763546	chr10:51536399	C/G	cg16070123	chr10:51489643	NA	-0.52	-4.74	-0.44	7.41e-6	Prostate-specific antigen levels;
THYM	cis	rs7000551	0.642	rs2122880	chr8:22375042	C/A	cg12081754	chr8:22256438	SLC39A14	0.67	5.98	0.52	3.85e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs977987	0.527	rs62059844	chr16:75429737	T/C	cg03315344	chr16:75512273	CHST6	0.73	6.16	0.53	1.73e-8	Dupuytren's disease;
THYM	cis	rs9788682	0.706	rs924840	chr15:78731808	A/T	cg18825076	chr15:78729989	IREB2	0.66	5.04	0.46	2.22e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs6964587	0.547	rs12704628	chr7:91478070	G/A	cg17063962	chr7:91808500	NA	-0.99	-8.35	-0.65	5.51e-13	Breast cancer;
THYM	cis	rs28595532	0.920	rs115154776	chr4:119774803	A/G	cg21605333	chr4:119757512	SEC24D	1.67	6.17	0.53	1.69e-8	Cannabis dependence symptom count;
THYM	cis	rs2066819	1.000	rs41392645	chr12:56696742	A/G	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg22535103	chr8:58192502	C8orf71	-1.06	-6.61	-0.56	2.24e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7246657	0.943	rs10415358	chr19:37808863	C/A	cg22634378	chr19:37742834	NA	0.68	5.67	0.5	1.55e-7	Coronary artery calcification;
THYM	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg20283391	chr11:68216788	NA	-0.6	-4.69	-0.43	9.02e-6	Total body bone mineral density;
THYM	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg20283391	chr11:68216788	NA	0.58	4.47	0.42	2.16e-5	Total body bone mineral density;
THYM	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg20295408	chr7:1910781	MAD1L1	-0.68	-5.59	-0.5	2.17e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs9790314	0.905	rs7632797	chr3:161002694	C/T	cg03342759	chr3:160939853	NMD3	0.81	7.28	0.6	9.51e-11	Morning vs. evening chronotype;
THYM	cis	rs790123	1.000	rs790115	chr3:122381117	C/T	cg17380795	chr3:122379686	NA	0.63	5.75	0.51	1.06e-7	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs9326248	0.530	rs2471884	chr11:117010320	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.96	5.39	0.48	5.22e-7	Blood protein levels;
THYM	cis	rs6570726	0.905	rs1355146	chr6:145781741	A/C	cg23711669	chr6:146136114	FBXO30	-0.77	-7.2	-0.59	1.39e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4343996	0.807	rs6964838	chr7:3509969	A/G	cg21248987	chr7:3385318	SDK1	-0.39	-4.61	-0.43	1.25e-5	Motion sickness;
THYM	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg09197432	chr4:183729176	NA	0.82	5.23	0.47	1.03e-6	Pediatric autoimmune diseases;
THYM	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg26441486	chr22:50317300	CRELD2	0.44	7.45	0.61	4.35e-11	Schizophrenia;
THYM	cis	rs6473252	0.584	rs6989517	chr8:81806206	A/G	cg08595989	chr8:81827712	NA	-0.5	-5.45	-0.49	4.02e-7	Breast cancer;
THYM	cis	rs595982	0.527	rs35023389	chr19:49377873	G/A	cg17863274	chr19:49399704	TULP2	-0.94	-5.52	-0.49	2.88e-7	Red cell distribution width;
THYM	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.4	-4.77	-0.44	6.77e-6	Longevity;Endometriosis;
THYM	cis	rs1474256	0.708	rs74485555	chr15:79454077	C/T	cg17916960	chr15:79447300	NA	0.66	6.89	0.58	6.04e-10	Bronchopulmonary dysplasia;
THYM	cis	rs13256369	0.511	rs7012395	chr8:8538009	T/C	cg18904891	chr8:8559673	CLDN23	-0.63	-4.54	-0.42	1.67e-5	Obesity-related traits;
THYM	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg18681998	chr4:17616180	MED28	0.96	9.4	0.69	3.12e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs7119	0.651	rs12904823	chr15:77837662	G/A	cg10437265	chr15:77819839	NA	0.79	7.83	0.63	6.84e-12	Type 2 diabetes;
THYM	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg05182265	chr7:156933206	UBE3C	-0.69	-9.32	-0.69	4.58e-15	Body mass index;
THYM	cis	rs9560113	1.000	rs9560104	chr13:112174389	A/G	cg10483660	chr13:112241077	NA	0.53	4.78	0.44	6.46e-6	Menarche (age at onset);
THYM	cis	rs9972944	0.756	rs9907996	chr17:63754889	C/T	cg07283582	chr17:63770753	CCDC46	-0.62	-4.75	-0.44	7.08e-6	Total body bone mineral density;
THYM	cis	rs9992101	0.645	rs17252554	chr4:77303621	C/T	cg20311846	chr4:77356250	SHROOM3	-0.54	-5.96	-0.52	4.32e-8	Creatinine levels;
THYM	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg17211192	chr8:82754475	SNX16	0.91	7.3	0.6	8.57e-11	Diastolic blood pressure;
THYM	cis	rs11563648	0.553	rs9656363	chr7:127056042	C/T	cg23081781	chr7:127225937	GCC1	-0.33	-4.52	-0.42	1.78e-5	Resting heart rate;
THYM	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-4.84	-0.44	5.01e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.59	-4.48	-0.42	2.09e-5	Longevity;Endometriosis;
THYM	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg17178900	chr1:205818956	PM20D1	1.05	11.42	0.76	1.62e-19	Menarche (age at onset);
THYM	cis	rs4731207	0.698	rs4319000	chr7:124528055	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg05738196	chr6:26577821	NA	0.86	8.72	0.67	9.13e-14	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.12	7.7	0.62	1.28e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4792901	0.802	rs8079750	chr17:41578497	C/T	cg21940313	chr17:41620911	ETV4	-0.51	-5.2	-0.47	1.12e-6	Dupuytren's disease;
THYM	cis	rs11030122	0.673	rs4910869	chr11:4006438	C/T	cg18678763	chr11:4115507	RRM1	-0.45	-5.78	-0.51	9.37e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg13393036	chr8:95962371	TP53INP1	0.47	4.9	0.45	3.95e-6	Type 2 diabetes;
THYM	cis	rs941408	0.515	rs1736193	chr19:2785273	G/C	cg17333051	chr19:2783644	SGTA	0.73	6.3	0.54	9.26e-9	Total cholesterol levels;
THYM	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.35	0.48	6.04e-7	Tonsillectomy;
THYM	cis	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.55	-5.53	-0.49	2.86e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.22e-16	Bone mineral density;
THYM	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg23281280	chr6:28129359	ZNF389	0.61	4.74	0.44	7.58e-6	Parkinson's disease;
THYM	trans	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs7027203	0.828	rs4744291	chr9:96598297	A/G	cg14598338	chr9:96623480	NA	-0.49	-5.22	-0.47	1.07e-6	DNA methylation (variation);
THYM	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg19508488	chr2:152266495	RIF1	0.82	6.77	0.57	1.05e-9	Lung cancer;
THYM	cis	rs1881509	0.748	rs10766598	chr11:1419349	C/G	cg23946462	chr11:890331	CHID1	0.48	4.5	0.42	1.95e-5	Heroin dependence;
THYM	cis	rs9318086	0.712	rs3794339	chr13:24434065	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.5	4.47	0.42	2.13e-5	Myopia (pathological);
THYM	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs2487048	0.761	rs2980083	chr9:107691362	A/C	cg14019050	chr9:107690770	ABCA1	-0.73	-10.41	-0.73	2.16e-17	Intraocular pressure;
THYM	cis	rs7084402	0.967	rs12261597	chr10:60297662	T/C	cg09696939	chr10:60272079	BICC1	0.47	5.54	0.49	2.65e-7	Refractive error;
THYM	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg06028808	chr11:68637592	NA	0.69	7.34	0.6	7.12e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs3087591	0.887	rs7503395	chr17:29440554	C/T	cg24425628	chr17:29625626	OMG;NF1	0.65	5.53	0.49	2.83e-7	Hip circumference;
THYM	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg21926883	chr2:100939477	LONRF2	-0.65	-5.97	-0.52	4.11e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1981331	0.609	rs76691528	chr21:48027823	T/C	cg23283320	chr21:48055893	PRMT2	1.56	7.35	0.6	6.77e-11	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.96	-8.0	-0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg06558623	chr16:89946397	TCF25	1.45	7.27	0.6	9.84e-11	Skin colour saturation;
THYM	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg17328964	chr8:145687451	CYHR1	-0.69	-6.37	-0.55	6.86e-9	Age at first birth;
THYM	cis	rs1448094	0.556	rs11611968	chr12:86168022	G/A	cg00310523	chr12:86230176	RASSF9	0.56	4.94	0.45	3.29e-6	Major depressive disorder;
THYM	cis	rs13315871	0.929	rs7635697	chr3:58313706	G/A	cg12435725	chr3:58293450	RPP14	-0.53	-5.51	-0.49	3.09e-7	Cholesterol, total;
THYM	cis	rs9457247	0.534	rs1130033	chr6:167385623	C/T	cg23791538	chr6:167370224	RNASET2	-0.83	-7.47	-0.61	3.78e-11	Crohn's disease;
THYM	cis	rs6570726	0.577	rs406868	chr6:145809983	C/T	cg23711669	chr6:146136114	FBXO30	0.8	7.12	0.59	2.02e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg06481639	chr22:41940642	POLR3H	-0.62	-4.78	-0.44	6.36e-6	Neuroticism;
THYM	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg20744362	chr22:50050164	C22orf34	0.79	6.9	0.58	5.71e-10	Monocyte count;Monocyte percentage of white cells;
THYM	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.65	-11.83	-0.77	2.19e-20	Hemostatic factors and hematological phenotypes;
THYM	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs9515203	0.596	rs9521731	chr13:111032699	C/G	cg15455643	chr13:111040242	COL4A2	0.59	5.14	0.47	1.47e-6	Coronary artery disease;
THYM	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg02734326	chr4:10020555	SLC2A9	0.76	6.89	0.58	6.16e-10	Bone mineral density;
THYM	cis	rs9733	0.596	rs12063547	chr1:150674053	G/T	cg10589385	chr1:150898437	SETDB1	-0.64	-5.35	-0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs4604732	0.588	rs9943231	chr1:247629829	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.7	4.88	0.45	4.32e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg02527881	chr3:46936655	PTH1R	-0.63	-6.29	-0.54	9.52e-9	Colorectal cancer;
THYM	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg10253484	chr15:75165896	SCAMP2	-0.67	-4.47	-0.42	2.12e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg07648498	chr16:89883185	FANCA	0.61	4.49	0.42	1.99e-5	Vitiligo;
THYM	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg22709100	chr7:91322751	NA	0.7	5.16	0.47	1.35e-6	Breast cancer;
THYM	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg01324343	chr3:183735012	ABCC5	0.65	8.76	0.67	7.19e-14	Anterior chamber depth;
THYM	cis	rs2997447	0.655	rs12059101	chr1:26384013	A/G	cg03844060	chr1:26490628	NA	0.62	4.46	0.42	2.22e-5	QRS complex (12-leadsum);
THYM	cis	rs6430585	0.583	rs2322813	chr2:136582809	A/G	cg23851026	chr2:136556271	LCT	0.81	7.89	0.63	5.05e-12	Corneal structure;
THYM	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.78	-6.86	-0.58	7.08e-10	Intelligence (multi-trait analysis);
THYM	cis	rs1150668	0.699	rs12214383	chr6:28223731	T/C	cg13525197	chr6:28411240	ZSCAN23	0.68	5.43	0.49	4.38e-7	Pubertal anthropometrics;
THYM	cis	rs870825	0.549	rs7699919	chr4:185648610	A/C	cg04058563	chr4:185651563	MLF1IP	1.08	9.83	0.71	3.88e-16	Blood protein levels;
THYM	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg17143192	chr8:8559678	CLDN23	0.91	6.74	0.57	1.2e-9	Obesity-related traits;
THYM	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg05754148	chr16:3507555	NAT15	0.58	4.82	0.44	5.49e-6	Body mass index (adult);
THYM	cis	rs7772486	0.790	rs6923545	chr6:146244743	A/G	cg13319975	chr6:146136371	FBXO30	0.7	5.77	0.51	1.01e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs904251	0.861	rs1776456	chr6:37484698	C/G	cg01843034	chr6:37503916	NA	-0.65	-4.58	-0.42	1.43e-5	Cognitive performance;
THYM	cis	rs740474	0.569	rs4912762	chr5:140881691	A/G	cg24137543	chr5:140893634	NA	0.4	4.8	0.44	5.99e-6	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg13010199	chr12:38710504	ALG10B	0.74	5.64	0.5	1.75e-7	Heart rate;
THYM	cis	rs1011018	0.955	rs6978085	chr7:139454463	C/T	cg06079564	chr7:139468310	HIPK2	-0.77	-6.04	-0.53	3.05e-8	Systolic blood pressure;
THYM	cis	rs2882877	0.648	rs17271134	chr2:190389803	A/G	cg10752008	chr2:190445175	SLC40A1	-0.71	-6.01	-0.52	3.46e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4242434	0.787	rs1545837	chr8:22477807	T/C	cg01710189	chr8:22454888	PDLIM2	-0.6	-5.57	-0.5	2.36e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs4766646	0.640	rs10850891	chr12:110299223	G/A	cg10794374	chr12:110278745	NA	-0.22	-4.97	-0.45	3.01e-6	Metabolite levels (MHPG);
THYM	cis	rs9807989	0.839	rs4988956	chr2:102968007	G/A	cg03938978	chr2:103052716	IL18RAP	0.63	6.56	0.56	2.81e-9	Asthma;
THYM	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg15445000	chr17:37608096	MED1	0.41	4.73	0.44	7.67e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs8133932	0.654	rs413517	chr21:47347545	C/G	cg20357416	chr21:47294739	PCBP3	0.8	4.88	0.45	4.26e-6	Schizophrenia;
THYM	cis	rs3126085	0.935	rs4511111	chr1:152211624	C/G	cg10321714	chr1:152280068	FLG	-0.73	-5.4	-0.48	4.94e-7	Atopic dermatitis;
THYM	cis	rs4953076	0.573	rs6738023	chr2:44405931	T/C	cg04920474	chr2:44395004	PPM1B	0.65	5.43	0.49	4.32e-7	Height;
THYM	cis	rs4731207	0.741	rs1557969	chr7:124405738	A/G	cg05285228	chr7:124571219	POT1	0.69	5.3	0.48	7.36e-7	Cutaneous malignant melanoma;
THYM	cis	rs6840360	0.967	rs7695162	chr4:152510541	G/A	cg22705602	chr4:152727874	NA	-0.62	-6.85	-0.58	7.2e-10	Intelligence (multi-trait analysis);
THYM	cis	rs1018836	0.847	rs35409073	chr8:91648036	G/T	cg16814680	chr8:91681699	NA	-0.85	-7.17	-0.59	1.59e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs79149102	0.579	rs6495137	chr15:75295541	G/A	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	cis	rs7119	0.717	rs11636529	chr15:77816220	T/C	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs7119	0.717	rs12902925	chr15:77819141	T/C	cg10437265	chr15:77819839	NA	0.76	7.54	0.61	2.76e-11	Type 2 diabetes;
THYM	cis	rs892961	0.720	rs103458	chr17:75416031	A/G	cg11351908	chr17:75402473	SEPT9	0.58	5.66	0.5	1.62e-7	Airflow obstruction;
THYM	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg23205692	chr1:25664452	TMEM50A	0.87	6.72	0.57	1.32e-9	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg10802521	chr3:52805072	NEK4	-0.79	-7.45	-0.61	4.36e-11	Intelligence (multi-trait analysis);
THYM	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs61931739	0.612	rs2004961	chr12:33994599	A/G	cg10856724	chr12:34555212	NA	-0.65	-6.14	-0.53	1.9e-8	Morning vs. evening chronotype;
THYM	cis	rs7106204	0.668	rs7119198	chr11:24218267	A/G	ch.11.24196551F	chr11:24239977	NA	1.04	7.55	0.61	2.59e-11	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs12310956	0.532	rs7967627	chr12:33974669	G/T	cg10856724	chr12:34555212	NA	-0.75	-6.8	-0.57	9.1e-10	Morning vs. evening chronotype;
THYM	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg25566285	chr7:158114605	PTPRN2	-0.87	-10.63	-0.74	7.52e-18	Calcium levels;
THYM	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg19913688	chr11:428466	ANO9	-0.9	-4.64	-0.43	1.13e-5	Body mass index;
THYM	cis	rs7084402	0.935	rs7474570	chr10:60343085	C/G	cg07615347	chr10:60278583	BICC1	0.56	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs757081	0.667	rs476890	chr11:17209962	A/G	cg07093617	chr11:18158918	MRGPRX3	-0.49	-4.61	-0.43	1.23e-5	Systolic blood pressure;
THYM	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg03388043	chr17:80084554	CCDC57	-0.73	-6.11	-0.53	2.19e-8	Life satisfaction;
THYM	cis	rs2456568	0.564	rs6483270	chr11:93624380	C/T	cg09189538	chr11:93579666	C11orf90	-0.57	-5.38	-0.48	5.42e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7000551	0.715	rs12544074	chr8:22338378	A/G	cg12081754	chr8:22256438	SLC39A14	0.64	5.6	0.5	2.05e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg13609457	chr4:120235615	NA	0.53	5.0	0.46	2.59e-6	Corneal astigmatism;
THYM	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg24531977	chr5:56204891	C5orf35	-1.0	-8.34	-0.65	5.78e-13	Initial pursuit acceleration;
THYM	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	5.78	0.51	9.32e-8	Personality dimensions;
THYM	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg08885076	chr2:99613938	TSGA10	0.57	5.28	0.48	8.05e-7	Chronic sinus infection;
THYM	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg20486651	chr6:167070296	RPS6KA2	-0.46	-4.51	-0.42	1.82e-5	Crohn's disease;
THYM	cis	rs10992471	0.528	rs10514815	chr9:95256695	C/A	cg14631576	chr9:95140430	CENPP	-0.84	-8.02	-0.64	2.69e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6430585	0.941	rs10496737	chr2:136540083	A/G	cg20242066	chr2:136595261	LCT	0.55	5.64	0.5	1.73e-7	Corneal structure;
THYM	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.78	0.51	9.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6674176	0.660	rs3791112	chr1:44379248	T/G	cg12908607	chr1:44402522	ARTN	-0.59	-4.98	-0.46	2.78e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs61990749	0.500	rs8011337	chr14:78272626	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	1.18	7.96	0.63	3.64e-12	Fibroblast growth factor basic levels;
THYM	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.72	5.7	0.5	1.36e-7	Blood protein levels;
THYM	cis	rs7772486	0.875	rs2814875	chr6:146305810	G/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.66	-0.5	1.62e-7	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg03929089	chr4:120376271	NA	-1.03	-12.43	-0.79	1.26e-21	Height;
THYM	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg01448562	chr3:133502909	NA	-0.95	-8.12	-0.64	1.68e-12	Iron status biomarkers;
THYM	cis	rs6547741	1.000	rs76784350	chr2:27764278	A/G	cg27432699	chr2:27873401	GPN1	0.68	5.97	0.52	4.17e-8	Oral cavity cancer;
THYM	cis	rs2976388	1.000	rs2978982	chr8:143763490	T/C	cg13446199	chr8:143762866	PSCA	0.51	6.42	0.55	5.46e-9	Urinary tract infection frequency;
THYM	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg24803719	chr17:45855879	NA	-0.6	-6.28	-0.54	1.02e-8	IgG glycosylation;
THYM	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg27170947	chr2:26402098	FAM59B	-0.78	-6.09	-0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs700651	0.753	rs10207232	chr2:198893813	A/G	cg00792783	chr2:198669748	PLCL1	0.82	5.63	0.5	1.79e-7	Intracranial aneurysm;
THYM	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg18404041	chr3:52824283	ITIH1	-0.56	-5.77	-0.51	9.75e-8	Bipolar disorder;
THYM	cis	rs7119	0.717	rs8033067	chr15:77825495	G/T	cg27398640	chr15:77910606	LINGO1	-0.55	-5.53	-0.49	2.82e-7	Type 2 diabetes;
THYM	cis	rs11249608	0.548	rs12152869	chr5:178462520	A/G	cg01312482	chr5:178451176	ZNF879	-0.76	-6.3	-0.54	9.29e-9	Pubertal anthropometrics;
THYM	cis	rs2282300	0.739	rs7925340	chr11:30280408	A/C	cg06241208	chr11:30344200	C11orf46	0.78	5.65	0.5	1.67e-7	Morning vs. evening chronotype;
THYM	cis	rs59112743	0.510	rs2619546	chr6:15632813	G/A	cg10111214	chr6:14815676	NA	0.74	4.84	0.44	5.08e-6	Multiple keratinocyte cancers;
THYM	cis	rs2933343	0.649	rs2638845	chr3:128587369	A/G	cg11901034	chr3:128598214	ACAD9	-0.7	-5.68	-0.5	1.47e-7	IgG glycosylation;
THYM	cis	rs2404602	0.647	rs35940181	chr15:77180019	G/A	cg23625390	chr15:77176239	SCAPER	-0.77	-5.54	-0.49	2.64e-7	Blood metabolite levels;
THYM	cis	rs56104184	0.723	rs1058483	chr19:49407660	G/A	cg21252483	chr19:49399788	TULP2	-0.95	-7.2	-0.59	1.41e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs17001868	0.568	rs9611329	chr22:40792038	G/T	cg07138101	chr22:40742427	ADSL	0.91	5.57	0.5	2.39e-7	Mammographic density (dense area);
THYM	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg06808227	chr14:105710500	BRF1	1.02	8.79	0.67	6.26e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6163	0.727	rs284862	chr10:104572081	C/T	cg15744005	chr10:104629667	AS3MT	0.9	9.49	0.7	2.01e-15	Waist circumference;Hip circumference;
THYM	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg10505658	chr17:80084571	CCDC57	-0.74	-8.13	-0.64	1.59e-12	Life satisfaction;
THYM	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.76	6.74	0.57	1.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs4650994	0.525	rs2493864	chr1:178545003	A/C	cg05059571	chr16:84539110	KIAA1609	-0.89	-10.47	-0.73	1.64e-17	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs6032067	0.777	rs2868235	chr20:43794069	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs1158570	0.564	rs2791343	chr8:131316030	C/T	cg16277922	chr8:131349729	ASAP1	-0.58	-4.7	-0.43	8.77e-6	Platelet count;
THYM	cis	rs4595586	0.545	rs6580888	chr12:39369704	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg27398817	chr8:82754497	SNX16	-0.71	-6.05	-0.53	2.89e-8	Diastolic blood pressure;
THYM	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg04398451	chr17:18023971	MYO15A	0.89	7.89	0.63	5.03e-12	Total body bone mineral density;
THYM	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs733175	0.855	rs9291641	chr4:10007259	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	4.6	0.43	1.31e-5	Psychosis and Alzheimer's disease;
THYM	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg02753203	chr1:228287806	NA	-0.62	-5.43	-0.49	4.3e-7	Diastolic blood pressure;
THYM	cis	rs6754311	0.551	rs2304599	chr2:136528004	C/G	cg20242066	chr2:136595261	LCT	-0.51	-5.6	-0.5	2.06e-7	Mosquito bite size;
THYM	cis	rs11989744	0.956	rs35693687	chr8:23575746	A/G	cg04349084	chr8:23602677	NA	0.52	5.51	0.49	3.07e-7	Waist-hip ratio;
THYM	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs747334	0.811	rs10881866	chr10:92715784	A/T	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg06640241	chr16:89574553	SPG7	0.89	7.97	0.63	3.5e-12	Multiple myeloma (IgH translocation);
THYM	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs1062753	0.527	rs6519296	chr22:42348602	G/C	cg11601000	chr22:42348013	LOC339674	-0.45	-4.84	-0.44	5.09e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	trans	rs4650994	0.525	rs2493848	chr1:178547838	T/A	cg05059571	chr16:84539110	KIAA1609	0.88	9.96	0.71	2e-16	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg23758822	chr17:41437982	NA	1.22	11.97	0.78	1.12e-20	Menopause (age at onset);
THYM	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg27532560	chr4:187881888	NA	0.96	12.62	0.79	5.09e-22	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs4650994	0.525	rs2761463	chr1:178557137	T/C	cg05059571	chr16:84539110	KIAA1609	0.9	10.36	0.73	2.78e-17	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg26384229	chr12:38710491	ALG10B	-0.87	-8.5	-0.66	2.59e-13	Heart rate;
THYM	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	0.47	4.71	0.43	8.51e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg06481639	chr22:41940642	POLR3H	0.74	4.85	0.45	4.81e-6	Vitiligo;
THYM	cis	rs12478296	1.000	rs55777943	chr2:243040686	T/C	cg06360820	chr2:242988706	NA	-1.08	-6.65	-0.56	1.86e-9	Obesity-related traits;
THYM	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg07884673	chr3:53033167	SFMBT1	1.25	6.34	0.55	7.83e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg02725872	chr8:58115012	NA	-1.15	-6.14	-0.53	1.87e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg02725872	chr8:58115012	NA	-0.75	-5.58	-0.5	2.28e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs6032067	0.929	rs13039213	chr20:43805712	A/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs9355610	0.609	rs3756838	chr6:167371251	G/A	cg02289903	chr6:166876736	RPS6KA2	0.41	4.47	0.42	2.13e-5	Graves' disease;
THYM	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg17911788	chr17:44343683	NA	-0.75	-7.05	-0.59	2.81e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6503525	0.628	rs4065985	chr17:38101932	G/C	cg24910161	chr17:38119198	GSDMA	-0.52	-5.96	-0.52	4.31e-8	Asthma;
THYM	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.6	4.63	0.43	1.18e-5	Tonsillectomy;
THYM	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg09877947	chr5:131593287	PDLIM4	0.59	5.01	0.46	2.56e-6	Breast cancer;
THYM	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	5.55	0.49	2.6e-7	Cognitive function;
THYM	cis	rs6763768	0.710	rs13080668	chr3:53443354	C/T	cg05923681	chr3:52580707	PBRM1	-0.7	-4.51	-0.42	1.87e-5	Bacterial meningitis;
THYM	cis	rs40363	1.000	rs37768	chr16:3514777	T/C	cg21433313	chr16:3507492	NAT15	0.81	6.9	0.58	5.87e-10	Tuberculosis;
THYM	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs4974559	0.790	rs2293631	chr4:1315917	C/A	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.43	-4.92	-0.45	3.61e-6	Systolic blood pressure;
THYM	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg10465839	chr16:1584050	IFT140;TMEM204	-0.65	-5.75	-0.51	1.06e-7	Coronary artery disease;
THYM	cis	rs6840360	0.571	rs11736116	chr4:152531816	A/G	cg22705602	chr4:152727874	NA	-0.78	-8.73	-0.67	8.56e-14	Intelligence (multi-trait analysis);
THYM	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg12698349	chr2:225449008	CUL3	0.73	5.45	0.49	4.03e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs2717559	0.542	rs2717560	chr8:143881670	G/A	cg03405983	chr8:143858548	LYNX1	-0.54	-5.74	-0.51	1.12e-7	Urinary tract infection frequency;
THYM	cis	rs13315871	0.722	rs3952239	chr3:58312057	G/T	cg00563845	chr3:58318305	PXK	0.55	4.74	0.44	7.49e-6	Cholesterol, total;
THYM	cis	rs4654899	1.000	rs6426659	chr1:21361302	G/A	cg01072550	chr1:21505969	NA	-0.75	-6.82	-0.57	8.26e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06481639	chr22:41940642	POLR3H	-0.72	-5.15	-0.47	1.42e-6	Vitiligo;
THYM	cis	rs2070488	1.000	rs13079757	chr3:38491444	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	7.18	0.59	1.57e-10	Electrocardiographic conduction measures;
THYM	cis	rs3796352	0.568	rs11713376	chr3:52958927	A/G	cg04865290	chr3:52927548	TMEM110	-0.85	-5.54	-0.49	2.7e-7	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg06238570	chr21:40685208	BRWD1	0.9	6.44	0.55	4.94e-9	Cognitive function;
THYM	cis	rs7901056	0.901	rs11591540	chr10:26734517	G/A	cg23318538	chr10:26883079	C10orf50	0.39	5.05	0.46	2.13e-6	Lymphocyte counts;
THYM	cis	rs10782582	0.593	rs12129523	chr1:76129223	C/A	cg22875332	chr1:76189707	ACADM	-0.54	-5.07	-0.46	1.96e-6	Daytime sleep phenotypes;
THYM	cis	rs7688540	0.771	rs7674560	chr4:263319	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.64	4.87	0.45	4.5e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg16325326	chr1:53192061	ZYG11B	0.74	6.21	0.54	1.4e-8	Monocyte count;
THYM	cis	rs593982	0.920	rs645621	chr11:65490756	T/C	cg08755490	chr11:65554678	OVOL1	1.29	4.66	0.43	1.03e-5	Atopic dermatitis;
THYM	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg05340658	chr4:99064831	C4orf37	0.54	4.55	0.42	1.61e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs919433	0.680	rs6434934	chr2:198437386	C/G	cg00792783	chr2:198669748	PLCL1	0.8	5.6	0.5	2.11e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs1335645	0.570	rs56740658	chr1:111647508	C/G	cg00321911	chr1:111669324	DRAM2	-1.14	-6.19	-0.54	1.49e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2404602	0.647	rs12903586	chr15:77168240	G/A	cg23625390	chr15:77176239	SCAPER	-0.8	-5.61	-0.5	1.95e-7	Blood metabolite levels;
THYM	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs4474465	0.850	rs4590904	chr11:78263847	C/T	cg19901956	chr11:77921274	USP35	0.65	4.74	0.44	7.5e-6	Alzheimer's disease (survival time);
THYM	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg05340658	chr4:99064831	C4orf37	0.55	4.65	0.43	1.09e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	cis	rs11157436	0.918	rs1983520	chr14:22618343	A/C	cg26433554	chr14:23315189	MMP14	0.44	4.64	0.43	1.12e-5	Neurocognitive impairment in HIV-1 infection (continuous);
THYM	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg03762994	chr17:6899332	ALOX12	0.72	10.18	0.72	6.86e-17	Tonsillectomy;
THYM	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg18357526	chr6:26021779	HIST1H4A	0.83	7.13	0.59	1.91e-10	Intelligence (multi-trait analysis);
THYM	cis	rs960902	0.747	rs62135566	chr2:37718930	C/T	cg25341268	chr2:37734390	NA	0.56	4.72	0.44	8.06e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg26384229	chr12:38710491	ALG10B	-0.87	-8.5	-0.66	2.59e-13	Heart rate;
THYM	cis	rs360798	0.512	rs4461246	chr2:63027671	C/T	cg17519650	chr2:63277830	OTX1	-0.68	-4.88	-0.45	4.21e-6	Coronary artery disease;
THYM	cis	rs13177918	0.603	rs2748241	chr5:149827494	C/T	cg22640213	chr5:149340154	SLC26A2	0.63	4.68	0.43	9.42e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs17433780	0.964	rs12146148	chr1:89471892	C/T	cg09516651	chr1:89888402	LOC400759	0.85	6.43	0.55	5.09e-9	Carotid intima media thickness;
THYM	cis	rs7100689	0.577	rs9420359	chr10:82054873	C/T	cg01528321	chr10:82214614	TSPAN14	0.94	7.0	0.58	3.53e-10	Post bronchodilator FEV1;
THYM	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg10661904	chr17:79619235	PDE6G	-0.57	-5.3	-0.48	7.61e-7	Eye color traits;
THYM	cis	rs2742234	0.541	rs10899786	chr10:43744583	G/A	cg06632098	chr10:43605906	RET	0.75	5.01	0.46	2.5e-6	Hirschsprung disease;
THYM	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg02018176	chr4:1364513	KIAA1530	0.57	4.73	0.44	7.67e-6	Obesity-related traits;
THYM	cis	rs6570726	0.875	rs368744	chr6:145812622	A/G	cg23711669	chr6:146136114	FBXO30	0.77	7.34	0.6	7.09e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg03209412	chr4:183728196	NA	0.73	6.93	0.58	4.93e-10	Pediatric autoimmune diseases;
THYM	cis	rs6964587	0.626	rs6972945	chr7:91549576	C/G	cg22709100	chr7:91322751	NA	-0.62	-4.64	-0.43	1.1e-5	Breast cancer;
THYM	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg12311346	chr5:56204834	C5orf35	-0.61	-4.67	-0.43	9.99e-6	Initial pursuit acceleration;
THYM	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	4.46	0.42	2.21e-5	Diabetic retinopathy;
THYM	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.16	-0.47	1.36e-6	Chronic sinus infection;
THYM	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg09307838	chr4:120376055	NA	0.72	5.48	0.49	3.51e-7	Corneal astigmatism;
THYM	cis	rs11992162	0.636	rs4841644	chr8:11798433	A/C	cg21775007	chr8:11205619	TDH	0.61	4.82	0.44	5.41e-6	Monocyte count;
THYM	cis	rs7264396	0.887	rs3818441	chr20:34046501	G/A	cg26038318	chr20:34205095	SPAG4	0.53	4.47	0.42	2.15e-5	Total cholesterol levels;
THYM	cis	rs28647808	1.000	rs2285483	chr9:136271838	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs13082711	0.554	rs6804440	chr3:27398150	C/T	cg02860705	chr3:27208620	NA	0.87	6.18	0.54	1.58e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg15704280	chr7:45808275	SEPT13	-1.06	-12.6	-0.79	5.54e-22	Height;
THYM	trans	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg07211511	chr3:129823064	LOC729375	-0.9	-7.15	-0.59	1.8e-10	Blood pressure (smoking interaction);
THYM	cis	rs1994135	0.692	rs7958788	chr12:33692179	T/C	cg06521331	chr12:34319734	NA	-0.65	-4.68	-0.43	9.49e-6	Resting heart rate;
THYM	cis	rs611744	0.967	rs652485	chr8:109202696	G/A	cg21045802	chr8:109455806	TTC35	0.58	5.03	0.46	2.29e-6	Dupuytren's disease;
THYM	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg01528321	chr10:82214614	TSPAN14	1.02	7.84	0.63	6.52e-12	Post bronchodilator FEV1;
THYM	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs11225247	0.772	rs35569122	chr11:102232348	C/T	cg11690896	chr11:102217788	BIRC2	1.12	5.18	0.47	1.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.63	4.62	0.43	1.23e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg00071950	chr4:10020882	SLC2A9	-0.68	-7.07	-0.59	2.61e-10	Bone mineral density;
THYM	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg00071950	chr4:10020882	SLC2A9	0.88	9.22	0.69	7.56e-15	Bone mineral density;
THYM	cis	rs6867032	0.958	rs4975795	chr5:2015390	G/A	cg26168224	chr5:2018326	NA	1.29	15.53	0.85	8.25e-28	Gut microbiome composition (winter);
THYM	cis	rs7927771	0.864	rs3781627	chr11:47441472	T/A	cg18512352	chr11:47633146	NA	0.5	6.29	0.54	9.63e-9	Subjective well-being;
THYM	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg07884673	chr3:53033167	SFMBT1	-1.0	-5.07	-0.46	1.94e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs919433	0.679	rs10203581	chr2:198515900	G/A	cg05783139	chr2:198650985	BOLL	0.66	4.96	0.45	3.04e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4363385	0.747	rs3737867	chr1:152976474	A/C	cg13444842	chr1:152974279	SPRR3	-0.62	-5.04	-0.46	2.22e-6	Inflammatory skin disease;
THYM	cis	rs7267979	0.966	rs2261794	chr20:25263062	T/G	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9430161	0.611	rs35033941	chr1:11034382	C/T	cg27631724	chr1:11040367	C1orf127	0.64	5.61	0.5	1.98e-7	Ewing sarcoma;
THYM	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-4.75	-0.44	7.13e-6	Type 2 diabetes;
THYM	cis	rs539096	0.692	rs7549094	chr1:44213178	C/A	cg12599982	chr1:44399894	ARTN	0.52	4.74	0.44	7.55e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12643440	0.538	rs62296726	chr4:17143914	T/C	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	6.52	0.56	3.43e-9	Total body bone mineral density;
THYM	cis	rs240764	0.659	rs240776	chr6:101020453	T/C	cg21058520	chr6:100914733	NA	0.61	4.88	0.45	4.21e-6	Neuroticism;
THYM	cis	rs7567389	0.677	rs10496661	chr2:128090144	G/T	cg09760422	chr2:128146352	NA	0.4	4.52	0.42	1.8e-5	Self-rated health;
THYM	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg09354556	chr3:47051341	NA	0.43	4.53	0.42	1.74e-5	Colorectal cancer;
THYM	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg01579765	chr21:45077557	HSF2BP	-0.48	-7.87	-0.63	5.72e-12	Mean corpuscular volume;
THYM	cis	rs7772486	0.651	rs1292338	chr6:145967471	A/C	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11948739	0.610	rs2522031	chr5:130242429	C/T	cg08523029	chr5:130500466	HINT1	-0.82	-5.88	-0.52	6.16e-8	Pediatric bone mineral content (hip);
THYM	cis	rs9896933	0.708	rs9908751	chr17:80791830	C/T	cg22325292	chr17:80708367	FN3K	-0.82	-4.74	-0.44	7.4e-6	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
THYM	cis	rs11209002	0.614	rs10736406	chr1:67573238	A/T	cg21115004	chr1:67520352	SLC35D1	0.43	4.91	0.45	3.83e-6	Crohn's disease;
THYM	cis	rs4664308	0.935	rs6744567	chr2:160933781	C/G	cg03641300	chr2:160917029	PLA2R1	-0.78	-6.97	-0.58	4.25e-10	Idiopathic membranous nephropathy;
THYM	cis	rs9522267	0.966	rs9515443	chr13:112197387	T/C	cg10483660	chr13:112241077	NA	-0.49	-4.98	-0.45	2.86e-6	Hepatitis;
THYM	cis	rs11577318	0.853	rs4526602	chr1:26648034	C/T	cg00852783	chr1:26633632	UBXN11	0.7	5.86	0.52	6.64e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.86	-8.14	-0.64	1.51e-12	Lung cancer;
THYM	cis	rs3755605	0.828	rs6787266	chr3:169777572	A/G	cg18444028	chr3:169782040	GPR160	0.6	4.89	0.45	4.04e-6	Testicular germ cell tumor;
THYM	trans	rs9929218	0.861	rs3114409	chr16:68732049	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.9	-7.7	-0.62	1.29e-11	Colorectal cancer;
THYM	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg08736216	chr1:53307985	ZYG11A	0.58	5.29	0.48	7.85e-7	Monocyte count;
THYM	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg27034606	chr17:28928453	LRRC37B2	0.76	5.06	0.46	2.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg08847533	chr14:75593920	NEK9	-0.97	-10.4	-0.73	2.35e-17	Height;
THYM	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7580658	0.891	rs55998967	chr2:128048674	A/C	cg10021288	chr2:128175891	PROC	-0.78	-6.82	-0.57	8.26e-10	Protein C levels;
THYM	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1385374	0.858	rs12305142	chr12:129277490	C/T	cg04043695	chr12:129287642	SLC15A4	-0.81	-4.89	-0.45	4.04e-6	Systemic lupus erythematosus;
THYM	cis	rs3925075	0.903	rs36100148	chr16:31345023	C/T	cg02846316	chr16:31340340	ITGAM	0.58	6.06	0.53	2.7e-8	IgA nephropathy;
THYM	cis	rs11039798	0.660	rs28435129	chr11:48629795	A/T	cg24672777	chr11:48374446	OR4C45	-0.93	-6.01	-0.52	3.39e-8	Axial length;
THYM	cis	rs72829446	0.530	rs4796422	chr17:7380004	T/C	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs425277	0.917	rs78609670	chr1:2045886	G/T	cg23803603	chr1:2058230	PRKCZ	0.68	5.24	0.47	9.67e-7	Height;
THYM	cis	rs2361718	0.590	rs4527052	chr17:78140910	A/G	cg09238746	chr17:78121135	EIF4A3	-0.95	-8.21	-0.64	1.09e-12	Yeast infection;
THYM	cis	rs981844	0.740	rs12644642	chr4:154686550	G/C	cg09973105	chr4:154681532	RNF175	0.54	4.98	0.45	2.88e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs911263	1.000	rs911263	chr14:68753593	C/T	cg18825221	chr14:68749962	RAD51L1	0.59	6.55	0.56	2.96e-9	Primary biliary cholangitis;
THYM	cis	rs34638657	0.702	rs62044259	chr16:82199523	A/T	cg07307142	chr16:82071433	HSD17B2	-0.88	-8.06	-0.64	2.2e-12	Lung adenocarcinoma;
THYM	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg03806693	chr22:41940476	POLR3H	1.1	8.41	0.65	4.11e-13	Vitiligo;
THYM	cis	rs1830074	1	rs1830074	chr7:6718674	T/C	cg09896999	chr7:6746977	ZNF12	-0.44	-4.63	-0.43	1.16e-5	Body mass index;
THYM	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg07930552	chr6:133119739	C6orf192	0.91	5.3	0.48	7.39e-7	Type 2 diabetes nephropathy;
THYM	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg13114125	chr14:105738426	BRF1	-0.74	-5.73	-0.51	1.16e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg02527881	chr3:46936655	PTH1R	-0.65	-6.44	-0.55	4.94e-9	Colorectal cancer;
THYM	cis	rs4924935	0.887	rs2428380	chr17:18843089	C/A	cg26378065	chr17:18585709	ZNF286B	-0.78	-5.0	-0.46	2.61e-6	Pancreatic cancer;
THYM	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg02269571	chr22:50332266	NA	-0.76	-5.39	-0.48	5.1e-7	Schizophrenia;
THYM	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg20203395	chr5:56204925	C5orf35	-0.67	-4.58	-0.42	1.44e-5	Initial pursuit acceleration;
THYM	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg18032289	chr17:61959525	GH2	-0.49	-4.7	-0.43	8.9e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs2239785	0.959	rs713929	chr22:36657596	A/G	cg15716373	chr22:36655542	APOL1	-0.4	-5.01	-0.46	2.51e-6	Glomerulosclerosis;
THYM	cis	rs17443541	0.507	rs971325	chr2:200450294	A/G	cg01795955	chr2:200468626	NA	-0.73	-4.86	-0.45	4.61e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12465778	0.550	rs11897813	chr2:144167920	C/T	cg17056048	chr2:144271431	ARHGAP15	0.52	5.27	0.48	8.6e-7	Intelligence (multi-trait analysis);
THYM	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.63	-4.79	-0.44	6.22e-6	Tonsillectomy;
THYM	cis	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg10856724	chr12:34555212	NA	-0.83	-7.32	-0.6	7.93e-11	Morning vs. evening chronotype;
THYM	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg06112835	chr11:68658793	MRPL21	0.45	6.4	0.55	5.97e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs12643440	0.538	rs882315	chr4:17149123	A/T	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.9	-5.84	-0.51	7.37e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	trans	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg10856724	chr12:34555212	NA	-0.95	-8.21	-0.64	1.07e-12	Bladder cancer;
THYM	cis	rs2637266	1.000	rs7082587	chr10:78386328	C/T	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs12140637	0.627	rs17576636	chr1:92447668	C/T	cg00308185	chr1:92414910	BRDT	-0.54	-4.48	-0.42	2.11e-5	Lung function (FEV1/FVC);
THYM	cis	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg24672777	chr11:48374446	OR4C45	-0.99	-6.44	-0.55	4.78e-9	Axial length;
THYM	cis	rs478304	0.654	rs6591185	chr11:65455742	A/G	cg27068330	chr11:65405492	SIPA1	-1.03	-10.31	-0.73	3.55e-17	Acne (severe);
THYM	cis	rs7917772	0.582	rs3977756	chr10:104398582	G/A	cg00122347	chr10:104236741	TMEM180	0.41	5.46	0.49	3.82e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs314370	0.951	rs13226502	chr7:100506381	C/T	cg10426581	chr7:100472382	SRRT	1.13	8.97	0.68	2.57e-14	Resting heart rate;
THYM	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg14018140	chr10:458528	DIP2C	0.64	6.1	0.53	2.32e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs9560113	1.000	rs9555805	chr13:112179765	C/T	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg26384229	chr12:38710491	ALG10B	0.73	5.35	0.48	6.04e-7	Morning vs. evening chronotype;
THYM	cis	rs11252926	0.661	rs7077209	chr10:484159	A/G	cg14018140	chr10:458528	DIP2C	0.58	6.08	0.53	2.49e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs7772486	0.875	rs9403763	chr6:146357655	A/G	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg22920501	chr2:26401640	FAM59B	-0.74	-6.28	-0.54	9.97e-9	Gut microbiome composition (summer);
THYM	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg07570687	chr10:102243282	WNT8B	0.84	8.04	0.64	2.45e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4664308	0.935	rs4520994	chr2:160937750	G/A	cg03641300	chr2:160917029	PLA2R1	-0.78	-6.97	-0.58	4.25e-10	Idiopathic membranous nephropathy;
THYM	cis	rs986417	0.786	rs7156379	chr14:61110634	G/C	cg27398547	chr14:60952738	C14orf39	1.26	6.1	0.53	2.29e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg23260525	chr10:116636907	FAM160B1	0.49	4.89	0.45	4.09e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs2294693	0.947	rs9369254	chr6:40989408	T/C	cg14418226	chr6:40996092	UNC5CL	0.72	6.48	0.55	4.14e-9	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs427394	0.659	rs175594	chr5:6729885	T/G	cg10857441	chr5:6722123	POLS	-0.7	-7.53	-0.61	2.93e-11	Menopause (age at onset);
THYM	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg15440763	chr7:158190612	PTPRN2	0.48	4.46	0.42	2.29e-5	Obesity-related traits;
THYM	cis	rs7805747	0.523	rs13239239	chr7:151423196	C/T	cg17611936	chr7:151411526	PRKAG2	-0.65	-5.42	-0.49	4.51e-7	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
THYM	cis	rs4604732	0.527	rs7539082	chr1:247627260	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.69	4.61	0.43	1.28e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg24818145	chr4:99064322	C4orf37	0.76	6.04	0.53	3.05e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg09455208	chr3:40491958	NA	0.44	4.67	0.43	1e-5	Renal cell carcinoma;
THYM	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg04117972	chr1:227635322	NA	0.81	4.63	0.43	1.17e-5	Major depressive disorder;
THYM	cis	rs3204270	0.639	rs1126818	chr17:79617830	G/A	cg18367735	chr17:79674897	NA	0.75	4.51	0.42	1.87e-5	Dental caries;
THYM	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg04896959	chr15:78267971	NA	0.93	7.68	0.62	1.43e-11	Coronary artery disease or large artery stroke;
THYM	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	4.93	0.45	3.51e-6	Motion sickness;
THYM	cis	rs7264396	0.790	rs6058283	chr20:34216276	A/G	cg26038318	chr20:34205095	SPAG4	0.64	5.28	0.48	8.13e-7	Total cholesterol levels;
THYM	cis	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg04990556	chr1:26633338	UBXN11	-0.87	-8.25	-0.65	8.82e-13	Obesity-related traits;
THYM	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg18904891	chr8:8559673	CLDN23	0.65	4.9	0.45	3.88e-6	Obesity-related traits;
THYM	cis	rs7614311	0.636	rs73117045	chr3:63910613	A/G	cg22134162	chr3:63841271	THOC7	-0.58	-6.83	-0.57	8.07e-10	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs2219968	1.000	rs16939594	chr8:78969920	T/A	cg00738934	chr8:78996279	NA	0.91	9.74	0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7681440	0.606	rs2583985	chr4:90755939	A/G	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs1318862	0.578	rs3133370	chr11:92026446	A/G	ch.11.91116131R	chr11:91476483	NA	0.75	5.0	0.46	2.65e-6	Subcortical brain region volumes;
THYM	cis	rs5771069	0.931	rs5771222	chr22:50445704	C/T	cg27467552	chr22:50353597	PIM3	0.47	5.02	0.46	2.42e-6	Ulcerative colitis;
THYM	cis	rs425277	0.527	rs3107144	chr1:2045380	C/A	cg00981070	chr1:2046702	PRKCZ	-0.44	-5.4	-0.48	4.93e-7	Height;
THYM	cis	rs2991971	0.716	rs7532573	chr1:45915892	A/T	cg15605315	chr1:45957053	TESK2	-0.66	-5.33	-0.48	6.62e-7	High light scatter reticulocyte count;
THYM	cis	rs10425738	0.830	rs12459565	chr19:41427539	G/C	cg17435250	chr19:41386441	CYP2A7	-0.63	-4.52	-0.42	1.79e-5	nicotine metabolite ratio in current smokers;Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
THYM	cis	rs2066819	1.000	rs57137641	chr12:56741228	G/A	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg09263875	chr16:632152	PIGQ	0.73	6.29	0.54	9.69e-9	Height;
THYM	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg02869364	chr7:1081709	C7orf50	-0.59	-4.91	-0.45	3.81e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6570726	0.764	rs367065	chr6:145882309	T/G	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs637571	0.607	rs589253	chr11:65693080	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.7	5.31	0.48	7.04e-7	Eosinophil percentage of white cells;
THYM	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg14074117	chr16:1909714	C16orf73	-0.7	-4.45	-0.42	2.3e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs9733	0.519	rs72704603	chr1:150707992	C/T	cg04414720	chr1:150670196	GOLPH3L	0.59	4.46	0.42	2.24e-5	Tonsillectomy;
THYM	cis	rs2458413	0.563	rs2458422	chr8:105332817	C/T	cg23108931	chr8:105342351	NA	-0.32	-5.97	-0.52	4.11e-8	Paget's disease;
THYM	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg03676636	chr4:99064102	C4orf37	0.35	4.89	0.45	4.02e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03264133	chr6:25882463	NA	0.7	5.51	0.49	3.06e-7	Blood metabolite levels;
THYM	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.62	0.43	1.2e-5	Obesity-related traits;
THYM	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg06766960	chr11:133703094	NA	-0.53	-4.84	-0.44	5.06e-6	Childhood ear infection;
THYM	cis	rs10504073	0.584	rs60449482	chr8:49974865	G/A	cg00325661	chr8:49890786	NA	1.08	10.51	0.73	1.32e-17	Blood metabolite ratios;
THYM	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg17173187	chr15:85201210	NMB	0.58	5.95	0.52	4.43e-8	Schizophrenia;
THYM	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg14018140	chr10:458528	DIP2C	0.63	5.43	0.49	4.36e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs9649465	0.935	rs3807636	chr7:123368488	G/A	cg15443791	chr7:124364398	NA	0.6	4.97	0.45	3.01e-6	Migraine;
THYM	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs28595532	0.841	rs116452272	chr4:119770802	T/C	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg13397359	chr6:42928475	GNMT	0.57	4.9	0.45	3.9e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg26314531	chr2:26401878	FAM59B	0.78	5.13	0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg13397359	chr6:42928475	GNMT	0.69	6.37	0.55	6.82e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9326248	0.581	rs10892061	chr11:116886114	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.66	5.28	0.48	8.14e-7	Blood protein levels;
THYM	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg11375102	chr16:1583810	IFT140;TMEM204	-0.61	-5.12	-0.46	1.62e-6	Coronary artery disease;
THYM	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06634786	chr22:41940651	POLR3H	-0.64	-5.19	-0.47	1.19e-6	Vitiligo;
THYM	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg27129171	chr3:47204927	SETD2	0.78	7.57	0.61	2.45e-11	Colorectal cancer;
THYM	cis	rs941408	1.000	rs1736184	chr19:2810248	G/A	cg19693284	chr19:2783607	SGTA	0.67	5.3	0.48	7.41e-7	Total cholesterol levels;
THYM	cis	rs8038465	0.638	rs11637091	chr15:73943715	C/T	cg15420318	chr15:73925796	NPTN	0.63	5.35	0.48	5.99e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg23205692	chr1:25664452	TMEM50A	0.86	6.69	0.57	1.54e-9	Erythrocyte sedimentation rate;
THYM	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	5.51	0.49	3.1e-7	Schizophrenia;
THYM	cis	rs4722166	0.645	rs1404006	chr7:22795077	T/C	cg05472934	chr7:22766657	IL6	0.71	5.93	0.52	4.84e-8	Lung cancer;
THYM	cis	rs6930083	0.527	rs9368950	chr6:36627872	T/C	cg11920449	chr6:36645608	CDKN1A	0.72	5.48	0.49	3.5e-7	Coronary artery disease;
THYM	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg10911889	chr6:126070802	HEY2	0.59	4.74	0.44	7.54e-6	Brugada syndrome;
THYM	cis	rs425277	0.539	rs3107142	chr1:2044542	T/C	cg24578937	chr1:2090814	PRKCZ	-0.65	-6.85	-0.58	7.29e-10	Height;
THYM	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg00631329	chr6:26305371	NA	-0.6	-7.22	-0.6	1.27e-10	Educational attainment;
THYM	cis	rs11974702	1	rs11974702	chr7:99163951	A/G	cg12290671	chr7:99195819	NA	-0.99	-4.83	-0.44	5.27e-6	Blood metabolite levels;
THYM	cis	rs13064411	0.660	rs1872747	chr3:113175785	T/A	cg10517650	chr3:113235015	CCDC52	-0.57	-4.75	-0.44	7.26e-6	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg02788857	chr8:22132959	PIWIL2	-0.53	-4.89	-0.45	4.09e-6	Hypertriglyceridemia;
THYM	cis	rs3008870	1.000	rs2755250	chr1:67495283	A/G	cg02640540	chr1:67518911	SLC35D1	0.65	4.83	0.44	5.32e-6	Lymphocyte percentage of white cells;
THYM	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg14895029	chr7:2775587	GNA12	-0.68	-5.03	-0.46	2.27e-6	Height;
THYM	cis	rs900145	0.773	rs11022750	chr11:13307594	C/T	cg13286116	chr11:13302098	ARNTL	0.61	4.82	0.44	5.39e-6	Menarche (age at onset);
THYM	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg18402987	chr7:1209562	NA	0.75	5.42	0.49	4.58e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12142240	1.000	rs12146051	chr1:46742952	G/C	cg00530320	chr1:46809349	NSUN4	0.85	5.5	0.49	3.27e-7	Menopause (age at onset);
THYM	cis	rs1499972	1.000	rs1499972	chr3:117719538	A/C	cg07612923	chr3:117604196	NA	-1.5	-5.16	-0.47	1.38e-6	Schizophrenia;
THYM	cis	rs4523957	0.820	rs216193	chr17:2203453	A/G	cg16513277	chr17:2031491	SMG6	0.79	7.38	0.6	5.92e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs977987	0.771	rs4888387	chr16:75389755	T/G	cg03315344	chr16:75512273	CHST6	0.74	6.05	0.53	2.9e-8	Dupuytren's disease;
THYM	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg00078996	chr12:132293329	NA	-0.7	-6.23	-0.54	1.25e-8	Migraine;
THYM	cis	rs1451375	0.617	rs2876829	chr7:50566762	A/G	cg18232548	chr7:50535776	DDC	0.69	5.23	0.47	9.94e-7	Malaria;
THYM	cis	rs7172809	0.500	rs17385059	chr15:77637812	T/C	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs9486715	0.867	rs9373907	chr6:96981189	G/A	cg06623918	chr6:96969491	KIAA0776	1.06	8.87	0.67	4.37e-14	Headache;
THYM	cis	rs3772130	0.564	rs28760466	chr3:121601510	A/G	cg20356878	chr3:121714668	ILDR1	0.71	6.34	0.55	7.58e-9	Cognitive performance;
THYM	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg11526020	chr17:80870163	TBCD	-0.44	-4.56	-0.42	1.53e-5	Breast cancer;
THYM	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg27494647	chr7:150038898	RARRES2	0.46	5.78	0.51	9.34e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6074022	0.700	rs6131010	chr20:44724305	C/T	cg20003638	chr20:44687730	SLC12A5	0.77	5.51	0.49	3.1e-7	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
THYM	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg00383909	chr3:49044727	WDR6	1.06	6.05	0.53	2.82e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs9479482	0.935	rs9479513	chr6:150367320	G/T	cg25797454	chr6:150327115	RAET1K	0.47	5.02	0.46	2.41e-6	Alopecia areata;
THYM	cis	rs35883536	0.647	rs2783703	chr1:101040794	T/C	cg09408571	chr1:101003634	GPR88	0.51	5.56	0.5	2.44e-7	Monocyte count;
THYM	cis	rs9902453	0.904	rs4375718	chr17:28363642	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.54	-0.56	3.11e-9	Coffee consumption (cups per day);
THYM	cis	rs11025559	0.796	rs11603462	chr11:20412180	C/A	cg19653624	chr11:20408972	PRMT3	-0.73	-5.11	-0.46	1.68e-6	Pursuit maintenance gain;
THYM	cis	rs6467136	0.765	rs58894662	chr7:127193533	C/T	cg23081781	chr7:127225937	GCC1	-0.32	-4.55	-0.42	1.57e-5	Type 2 diabetes;
THYM	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg21427119	chr20:30132790	HM13	-1.0	-7.05	-0.59	2.92e-10	Mean corpuscular hemoglobin;
THYM	cis	rs9311676	0.609	rs11925862	chr3:58417927	A/C	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs7020830	0.861	rs13289001	chr9:37311592	A/G	cg14294708	chr9:37120828	ZCCHC7	1.29	17.01	0.87	1.4e-30	Schizophrenia;
THYM	cis	rs55728055	0.661	rs9619215	chr22:32042732	A/G	cg01338084	chr22:32026380	PISD	1.14	5.88	0.52	6.08e-8	Age-related hearing impairment;
THYM	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg12407791	chr17:73824354	UNC13D	-0.41	-4.52	-0.42	1.81e-5	White matter hyperintensity burden;
THYM	cis	rs7189233	0.911	rs8057808	chr16:53520613	G/A	cg02965178	chr16:53538660	AKTIP	-0.61	-5.01	-0.46	2.48e-6	Intelligence (multi-trait analysis);
THYM	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg23131131	chr22:24373011	LOC391322	0.86	8.33	0.65	5.9e-13	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg14416269	chr4:6271139	WFS1	0.54	5.62	0.5	1.93e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs11039798	0.588	rs666165	chr11:48457439	C/T	cg24672777	chr11:48374446	OR4C45	0.97	6.24	0.54	1.22e-8	Axial length;
THYM	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg20744362	chr22:50050164	C22orf34	0.78	7.04	0.59	3e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.09	-0.46	1.83e-6	Life satisfaction;
THYM	cis	rs7580658	0.637	rs9636236	chr2:127982941	G/A	cg10021288	chr2:128175891	PROC	-0.63	-5.6	-0.5	2.1e-7	Protein C levels;
THYM	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg18132916	chr6:79620363	NA	-0.58	-5.27	-0.48	8.5e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3087591	0.960	rs4559963	chr17:29438558	G/A	cg24425628	chr17:29625626	OMG;NF1	0.64	5.54	0.49	2.68e-7	Hip circumference;
THYM	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg19747945	chr6:42946146	PEX6	-0.33	-5.0	-0.46	2.65e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg05552183	chr6:42928497	GNMT	0.59	4.69	0.43	9.17e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	trans	rs10802346	0.545	rs4607841	chr1:246373295	T/C	cg13514129	chr1:39547527	MACF1	1.03	10.27	0.73	4.39e-17	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	4.46	0.42	2.23e-5	Rheumatoid arthritis;
THYM	cis	rs3091242	0.781	rs71652378	chr1:25721457	G/C	cg10117171	chr1:25599238	RHD	-0.66	-4.73	-0.44	7.79e-6	Erythrocyte sedimentation rate;
THYM	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg08000102	chr2:233561755	GIGYF2	-0.81	-7.27	-0.6	9.94e-11	Coronary artery disease;
THYM	cis	rs11148252	0.514	rs1886539	chr13:52726090	C/T	cg05335186	chr13:53173507	NA	-0.41	-4.74	-0.44	7.53e-6	Lewy body disease;
THYM	cis	rs12611088	0.600	rs12978269	chr19:44004419	T/C	cg18042043	chr19:44147545	NA	-0.43	-4.93	-0.45	3.49e-6	Plasma amyloid beta peptide concentrations (ABx-42);
THYM	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg18681998	chr4:17616180	MED28	0.98	9.67	0.7	8.41e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg00376283	chr12:123451042	ABCB9	0.73	4.87	0.45	4.45e-6	Neutrophil percentage of white cells;
THYM	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg04025307	chr7:1156635	C7orf50	0.78	6.72	0.57	1.32e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs250585	0.646	rs66569010	chr16:23486952	C/T	cg00143387	chr16:23521605	GGA2	-0.78	-5.56	-0.5	2.52e-7	Egg allergy;
THYM	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg24020549	chr11:64937741	SPDYC	-0.46	-4.45	-0.42	2.29e-5	Eosinophil percentage of white cells;
THYM	cis	rs9443189	0.813	rs2842556	chr6:76447204	T/C	cg01950844	chr6:76311363	SENP6	-0.77	-4.53	-0.42	1.73e-5	Prostate cancer;
THYM	cis	rs9790314	0.605	rs2593812	chr3:160703069	T/G	cg04691961	chr3:161091175	C3orf57	0.58	4.63	0.43	1.15e-5	Morning vs. evening chronotype;
THYM	cis	rs12928939	0.517	rs71384782	chr16:71978591	A/G	cg03805757	chr16:71968109	PKD1L3	-1.09	-11.04	-0.75	1.02e-18	Post bronchodilator FEV1;
THYM	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg13319975	chr6:146136371	FBXO30	0.63	5.11	0.46	1.67e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3916	0.911	rs7313271	chr12:121152667	C/T	cg10600917	chr12:121163489	ACADS	0.6	5.19	0.47	1.2e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs4631830	0.720	rs2125770	chr10:51514824	T/C	cg20129853	chr10:51489980	NA	-0.32	-4.63	-0.43	1.18e-5	Prostate-specific antigen levels;
THYM	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg17426766	chr1:2046864	PRKCZ	-0.38	-4.58	-0.43	1.4e-5	Height;
THYM	cis	rs17604090	0.938	rs850029	chr7:29678087	A/G	cg19413766	chr7:29689036	LOC646762	-0.93	-5.12	-0.47	1.56e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs7943358	0.910	rs1471759	chr11:15729415	A/G	cg11966998	chr11:15692519	NA	-0.47	-4.72	-0.44	7.97e-6	Gut microbiome composition (summer);
THYM	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg08305652	chr11:111469057	NA	0.53	4.51	0.42	1.84e-5	Primary sclerosing cholangitis;
THYM	cis	rs1557488	0.565	rs7127122	chr11:126719482	T/C	cg03950493	chr11:126582183	KIRREL3	-0.39	-4.56	-0.42	1.52e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg23958373	chr8:599963	NA	0.88	4.56	0.42	1.52e-5	IgG glycosylation;
THYM	cis	rs7772486	0.754	rs702323	chr6:146008274	A/G	cg13319975	chr6:146136371	FBXO30	0.68	5.47	0.49	3.61e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.59	-4.55	-0.42	1.61e-5	Blood metabolite levels;
THYM	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg17264618	chr3:40429014	ENTPD3	-0.53	-5.02	-0.46	2.41e-6	Renal cell carcinoma;
THYM	cis	rs7829975	0.511	rs2980512	chr8:8140901	T/C	cg08975724	chr8:8085496	FLJ10661	0.62	4.95	0.45	3.17e-6	Mood instability;
THYM	cis	rs7851660	0.874	rs7847010	chr9:100630439	T/C	cg13688889	chr9:100608707	NA	-0.77	-5.31	-0.48	7.25e-7	Strep throat;
THYM	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg04362960	chr10:104952993	NT5C2	-0.6	-5.12	-0.46	1.61e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs9906944	0.707	rs8068981	chr17:47122525	T/C	cg18128536	chr17:47092178	IGF2BP1	-0.43	-4.71	-0.44	8.43e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg12386194	chr3:101231763	SENP7	0.7	5.29	0.48	7.86e-7	Colorectal cancer;
THYM	cis	rs3847687	1.000	rs11061303	chr12:131526322	A/G	cg25772418	chr12:131519998	GPR133	-0.48	-7.08	-0.59	2.43e-10	Longevity;
THYM	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg16680214	chr1:154839983	KCNN3	-0.58	-7.53	-0.61	2.88e-11	Prostate cancer;
THYM	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg11247378	chr22:39784982	NA	-1.05	-13.69	-0.81	3.41e-24	Intelligence (multi-trait analysis);
THYM	cis	rs4713118	0.513	rs149944	chr6:28002818	C/T	cg23161317	chr6:28129485	ZNF389	0.66	5.26	0.47	8.9e-7	Parkinson's disease;
THYM	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg20999797	chr1:1681921	NA	0.5	5.51	0.49	3.07e-7	Body mass index;
THYM	cis	rs735539	1.000	rs735539	chr13:21280034	A/G	cg02792322	chr13:21280448	IL17D	0.66	4.85	0.45	4.9100000000000004e-06	Dental caries;
THYM	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg05335186	chr13:53173507	NA	-0.41	-4.85	-0.45	4.74e-6	Lewy body disease;
THYM	cis	rs4794106	0.792	rs11365	chr17:48211533	T/G	cg13127421	chr17:48202128	SAMD14	-0.6	-4.72	-0.44	8.13e-6	Temporomandibular joint disorder;
THYM	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02018176	chr4:1364513	KIAA1530	0.94	8.64	0.66	1.33e-13	Longevity;
THYM	cis	rs28476539	0.567	rs1526061	chr4:83581750	G/A	cg10249074	chr4:83542146	C4orf11	-0.64	-5.12	-0.46	1.62e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs17253792	0.822	rs13379343	chr14:56050205	G/A	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg15110403	chr19:17392923	ANKLE1	-0.58	-4.99	-0.46	2.76e-6	Systemic lupus erythematosus;
THYM	cis	rs2273669	0.667	rs78714994	chr6:109350351	G/C	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs9359856	0.623	rs7742602	chr6:90327385	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.36	-0.6	6.68e-11	Bipolar disorder;
THYM	cis	rs6009824	1.000	rs6009824	chr22:50086373	C/T	cg27029450	chr22:50098074	NA	0.84	5.48	0.49	3.55e-7	Natriuretic peptide levels;
THYM	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg09904177	chr6:26538194	HMGN4	0.62	4.96	0.45	3.06e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg14993813	chr1:46806288	NSUN4	0.69	4.66	0.43	1.02e-5	Menopause (age at onset);
THYM	cis	rs2290159	0.800	rs5746191	chr3:12658774	G/A	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg03433033	chr1:76189801	ACADM	0.67	5.75	0.51	1.09e-7	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1747683	0.932	rs10752298	chr10:13382754	T/C	cg25835351	chr10:13388524	SEPHS1	-0.35	-5.9	-0.52	5.49e-8	IgG glycosylation;
THYM	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg17063962	chr7:91808500	NA	1.08	11.35	0.76	2.25e-19	Breast cancer;
THYM	cis	rs13256369	0.802	rs11249885	chr8:8562008	C/T	cg00074818	chr8:8560427	CLDN23	0.61	5.7	0.51	1.32e-7	Obesity-related traits;
THYM	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg00852783	chr1:26633632	UBXN11	0.7	5.82	0.51	7.93e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs7917772	0.582	rs12779854	chr10:104358474	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-5.7	-0.5	1.33e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.54	-5.05	-0.46	2.12e-6	Lymphocyte counts;
THYM	cis	rs3796352	0.568	rs11713376	chr3:52958927	A/G	cg07884673	chr3:53033167	SFMBT1	0.98	5.92	0.52	5.01e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7084402	0.967	rs12569559	chr10:60312711	T/G	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg21984481	chr17:79567631	NPLOC4	-0.5	-5.39	-0.48	5.2e-7	Eye color traits;
THYM	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs7119	0.717	rs12916642	chr15:77818426	G/T	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs6429082	0.634	rs3856245	chr1:235571428	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.62	-4.62	-0.43	1.19e-5	Adiposity;
THYM	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg25566285	chr7:158114605	PTPRN2	0.9	10.51	0.73	1.32e-17	Calcium levels;
THYM	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg06917634	chr15:78832804	PSMA4	-0.83	-6.85	-0.58	7.29e-10	Sudden cardiac arrest;
THYM	cis	rs9828933	0.882	rs3733127	chr3:63988174	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	-0.88	-5.39	-0.48	5.21e-7	Type 2 diabetes;
THYM	cis	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg21775007	chr8:11205619	TDH	0.65	5.29	0.48	7.91e-7	Retinal vascular caliber;
THYM	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg08132940	chr7:1081526	C7orf50	-0.77	-5.19	-0.47	1.2e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7000551	0.700	rs7431	chr8:22398462	G/A	cg12081754	chr8:22256438	SLC39A14	0.69	6.19	0.54	1.53e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg18132916	chr6:79620363	NA	-0.55	-4.85	-0.45	4.82e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9318086	0.673	rs7981928	chr13:24435180	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.5	4.48	0.42	2.05e-5	Myopia (pathological);
THYM	cis	rs62229266	0.771	rs7280136	chr21:37432910	C/G	cg08632701	chr21:37451849	NA	0.55	4.46	0.42	2.22e-5	Mitral valve prolapse;
THYM	cis	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-4.6	-0.43	1.32e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11711311	0.911	rs34337798	chr3:113396704	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.57	-4.78	-0.44	6.38e-6	IgG glycosylation;
THYM	cis	rs7818345	0.967	rs11787230	chr8:19280982	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.63	0.43	1.16e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.67	5.17	0.47	1.32e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7224737	1.000	rs11869069	chr17:40287101	C/G	cg20291162	chr17:40259547	DHX58	-0.7	-6.47	-0.55	4.18e-9	Fibrinogen levels;
THYM	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs4253772	0.530	rs6008774	chr22:46755298	C/G	cg24881330	chr22:46731750	TRMU	0.87	5.02	0.46	2.39e-6	LDL cholesterol;Cholesterol, total;
THYM	cis	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg13443165	chr9:33130375	B4GALT1	-0.76	-5.46	-0.49	3.8e-7	IgG glycosylation;
THYM	cis	rs733592	0.931	rs765260	chr12:48431936	C/T	cg21466736	chr12:48725269	NA	0.49	5.36	0.48	5.84e-7	Plateletcrit;
THYM	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg07424592	chr7:64974309	NA	-1.04	-5.27	-0.48	8.52e-7	Diabetic kidney disease;
THYM	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.72	0.44	8.16e-6	Breast cancer;
THYM	cis	rs17401966	0.838	rs6541089	chr1:10402785	A/G	cg19773385	chr1:10388646	KIF1B	-0.59	-4.82	-0.44	5.39e-6	Hepatocellular carcinoma;
THYM	cis	rs2963155	0.518	rs2918419	chr5:142722353	T/C	cg17617527	chr5:142782415	NR3C1	1.12	6.01	0.52	3.43e-8	Breast cancer;
THYM	cis	rs28493229	0.881	rs59459325	chr19:41175390	C/T	cg21869046	chr19:41225005	ITPKC	0.59	5.58	0.5	2.29e-7	Kawasaki disease;
THYM	cis	rs977987	0.778	rs35415181	chr16:75403124	T/C	cg03315344	chr16:75512273	CHST6	0.68	5.58	0.5	2.3e-7	Dupuytren's disease;
THYM	cis	rs2639990	1.000	rs609303	chr18:72895242	C/T	cg21330207	chr18:72916311	ZADH2	1.21	6.2	0.54	1.45e-8	Vascular endothelial growth factor levels;
THYM	cis	rs259282	0.692	rs35972270	chr19:33128457	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	6.55	0.56	2.98e-9	Schizophrenia;
THYM	cis	rs7599312	0.534	rs6735626	chr2:213403972	G/A	cg20637307	chr2:213403960	ERBB4	1.04	11.16	0.75	5.66e-19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11096990	0.634	rs6531704	chr4:39283746	T/C	cg24403649	chr4:39172243	NA	-0.67	-5.84	-0.51	7.33e-8	Cognitive function;
THYM	cis	rs9915657	0.870	rs35271702	chr17:70140516	G/A	cg06234051	chr17:70120541	SOX9	-0.67	-6.02	-0.53	3.33e-8	Thyroid hormone levels;
THYM	cis	rs9807989	0.501	rs11903946	chr2:103005330	A/G	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.65	0.5	1.64e-7	Tonsillectomy;
THYM	cis	rs7631605	0.905	rs7634972	chr3:37205716	C/T	cg21328643	chr3:37258149	NA	-0.51	-4.96	-0.45	3.08e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs1371867	0.846	rs1660346	chr8:101312497	A/G	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg10645314	chr2:3704589	ALLC	-1.19	-9.23	-0.69	7.17e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg24910161	chr17:38119198	GSDMA	0.42	4.45	0.42	2.31e-5	Self-reported allergy;
THYM	cis	rs4242434	0.819	rs1871902	chr8:22470710	G/A	cg21658235	chr8:22456391	C8orf58	0.45	4.6	0.43	1.29e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg07959070	chr22:50026188	C22orf34	-0.25	-4.69	-0.43	9.18e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg04398451	chr17:18023971	MYO15A	0.93	10.27	0.73	4.43e-17	Total body bone mineral density;
THYM	cis	rs4460079	0.531	rs4585376	chr4:114847657	A/G	cg02060584	chr4:113970739	ANK2	0.59	4.93	0.45	3.48e-6	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg11335335	chr11:637885	DRD4	-0.67	-5.12	-0.46	1.62e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs981844	0.775	rs62324020	chr4:154763851	G/A	cg09973105	chr4:154681532	RNF175	-0.62	-5.1	-0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs34421088	0.585	rs1390950	chr8:11595829	C/T	cg12395012	chr8:11607386	GATA4	0.63	5.15	0.47	1.43e-6	Neuroticism;
THYM	cis	rs684232	0.666	rs423887	chr17:593600	A/G	cg15660573	chr17:549704	VPS53	-0.9	-8.28	-0.65	7.71e-13	Prostate cancer;
THYM	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg06808227	chr14:105710500	BRF1	-0.99	-8.42	-0.65	3.95e-13	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6570726	0.935	rs369458	chr6:145812809	A/G	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7078219	0.505	rs4409764	chr10:101284237	T/G	cg04972745	chr10:101287846	NA	-0.5	-4.65	-0.43	1.09e-5	Dental caries;
THYM	cis	rs1065656	0.581	rs1065666	chr16:1839134	T/C	cg14074117	chr16:1909714	C16orf73	0.6	4.59	0.43	1.37e-5	Insulin-like growth factors;
THYM	cis	rs7580658	0.864	rs34832797	chr2:128119441	T/C	cg10021288	chr2:128175891	PROC	-0.76	-6.54	-0.56	3.05e-9	Protein C levels;
THYM	cis	rs2116941	0.523	rs17000211	chr19:10369086	C/T	cg01850179	chr19:10340795	S1PR2	0.54	5.95	0.52	4.38e-8	Pulse pressure;
THYM	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06850241	chr22:41845214	NA	-0.6	-5.39	-0.48	5.12e-7	Vitiligo;
THYM	cis	rs12291225	0.679	rs4757245	chr11:14297872	A/C	cg05501817	chr11:14380813	RRAS2	-0.75	-5.72	-0.51	1.24e-7	Sense of smell;
THYM	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg24733560	chr20:60626293	TAF4	-0.59	-4.76	-0.44	6.8e-6	Body mass index;
THYM	cis	rs7809950	1.000	rs2520271	chr7:107194949	C/T	cg23024343	chr7:107201750	COG5	-0.94	-8.66	-0.66	1.21e-13	Coronary artery disease;
THYM	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.88	5.64	0.5	1.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs67311347	0.668	rs73071710	chr3:40288587	A/G	cg13683864	chr3:40499215	RPL14	-0.7	-6.22	-0.54	1.34e-8	Renal cell carcinoma;
THYM	cis	rs7567389	0.600	rs11679414	chr2:128151003	G/A	cg06038358	chr2:128176007	PROC	0.47	5.15	0.47	1.4e-6	Self-rated health;
THYM	cis	rs7020830	0.898	rs12555207	chr9:37315476	C/T	cg14294708	chr9:37120828	ZCCHC7	1.18	14.37	0.83	1.47e-25	Schizophrenia;
THYM	cis	rs4363385	0.818	rs9659389	chr1:152989844	T/C	cg13444842	chr1:152974279	SPRR3	-0.61	-5.08	-0.46	1.86e-6	Inflammatory skin disease;
THYM	cis	rs4664308	0.935	rs4637057	chr2:160950161	G/T	cg03641300	chr2:160917029	PLA2R1	-0.78	-6.97	-0.58	4.25e-10	Idiopathic membranous nephropathy;
THYM	cis	rs10489202	0.612	rs3820401	chr1:168074753	T/C	cg24449463	chr1:168025552	DCAF6	-0.79	-7.66	-0.62	1.56e-11	Schizophrenia;
THYM	cis	rs7586879	0.639	rs4077678	chr2:25122840	C/G	cg27107076	chr2:25050844	ADCY3	-0.28	-4.46	-0.42	2.28e-5	Body mass index;
THYM	cis	rs11771526	0.901	rs17161084	chr7:32293192	G/C	cg13207630	chr7:32358064	NA	0.78	5.0	0.46	2.64e-6	Body mass index;
THYM	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	5.16	0.47	1.36e-6	Schizophrenia;
THYM	cis	rs10752881	0.901	rs10911201	chr1:183001622	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Colorectal cancer;
THYM	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg12963246	chr6:28129442	ZNF389	0.72	6.12	0.53	2.05e-8	Parkinson's disease;
THYM	cis	rs113835537	0.529	rs11227512	chr11:66281291	T/C	cg24851651	chr11:66362959	CCS	0.7	4.85	0.45	4.88e-6	Airway imaging phenotypes;
THYM	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg22875332	chr1:76189707	ACADM	-0.93	-10.85	-0.74	2.61e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg09184832	chr6:79620586	NA	-0.56	-4.46	-0.42	2.24e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9549367	0.712	rs2316443	chr13:113864837	G/A	cg18105134	chr13:113819100	PROZ	-1.01	-8.73	-0.67	8.57e-14	Platelet distribution width;
THYM	cis	rs9880211	0.613	rs6767060	chr3:135867090	C/G	cg21827317	chr3:136751795	NA	-0.71	-5.16	-0.47	1.33e-6	Body mass index;Height;
THYM	cis	rs12216545	0.765	rs7785909	chr7:150222230	A/T	cg00323915	chr7:150264987	GIMAP4	-0.49	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	trans	rs6089829	0.888	rs6011559	chr20:61675620	C/T	cg23505145	chr19:12996616	KLF1	-1.07	-10.27	-0.73	4.4e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6674176	0.597	rs4031031	chr1:44393533	C/T	cg15962314	chr1:44399869	ARTN	0.52	4.93	0.45	3.42e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg18252515	chr7:66147081	NA	1.48	8.83	0.67	5.15e-14	Diabetic kidney disease;
THYM	cis	rs17401966	0.931	rs2185252	chr1:10415912	T/C	cg19773385	chr1:10388646	KIF1B	-0.6	-4.7	-0.43	8.88e-6	Hepatocellular carcinoma;
THYM	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg16405210	chr4:1374714	KIAA1530	-1.1	-10.6	-0.74	8.64e-18	Longevity;
THYM	cis	rs3126085	0.560	rs2065954	chr1:152321344	T/G	cg10321714	chr1:152280068	FLG	-0.73	-5.04	-0.46	2.26e-6	Atopic dermatitis;
THYM	cis	rs12458462	0.851	rs62097746	chr18:77487508	G/A	cg11879182	chr18:77439856	CTDP1	0.82	7.9	0.63	4.96e-12	Monocyte count;
THYM	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Alcohol dependence;
THYM	cis	rs3741151	1.000	rs76570090	chr11:73066321	A/T	cg17517138	chr11:73019481	ARHGEF17	0.99	5.88	0.52	5.97e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2361718	0.629	rs12945868	chr17:78084941	C/T	cg09238746	chr17:78121135	EIF4A3	-0.94	-6.8	-0.57	9.25e-10	Yeast infection;
THYM	cis	rs988913	0.874	rs9382398	chr6:54783266	C/T	cg19716238	chr6:54711378	FAM83B	0.5	5.0	0.46	2.64e-6	Menarche (age at onset);
THYM	cis	rs9905704	0.647	rs6503892	chr17:57067086	G/A	cg12560992	chr17:57184187	TRIM37	0.7	5.45	0.49	3.9e-7	Testicular germ cell tumor;
THYM	cis	rs892961	1.000	rs1110638	chr17:75400690	T/C	cg05865280	chr17:75406074	SEPT9	0.51	8.79	0.67	6.21e-14	Airflow obstruction;
THYM	cis	rs747782	0.585	rs1316604	chr11:48279796	G/A	cg24672777	chr11:48374446	OR4C45	-1.17	-7.15	-0.59	1.78e-10	Intraocular pressure;
THYM	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg07606381	chr6:8435919	SLC35B3	0.66	4.93	0.45	3.51e-6	Motion sickness;
THYM	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg02527881	chr3:46936655	PTH1R	0.56	5.47	0.49	3.58e-7	Colorectal cancer;
THYM	cis	rs2067615	0.579	rs7297592	chr12:107223969	G/T	cg15890332	chr12:107067104	RFX4	0.44	5.05	0.46	2.13e-6	Heart rate;
THYM	cis	rs9875589	0.509	rs7614591	chr3:14061118	A/T	cg03204825	chr3:13978759	TPRXL	-0.51	-4.46	-0.42	2.26e-5	Ovarian reserve;
THYM	cis	rs8020441	0.588	rs45558232	chr14:51188754	C/T	cg04730355	chr14:51134070	SAV1	0.8	4.67	0.43	9.92e-6	Cognitive performance;
THYM	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg03806693	chr22:41940476	POLR3H	-0.86	-8.51	-0.66	2.47e-13	Vitiligo;
THYM	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg05660106	chr1:15850417	CASP9	0.76	6.27	0.54	1.06e-8	Systolic blood pressure;
THYM	cis	rs595982	0.510	rs3826817	chr19:49401444	C/T	cg21252483	chr19:49399788	TULP2	-0.68	-6.8	-0.57	9.39e-10	Red cell distribution width;
THYM	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg22166914	chr1:53195759	ZYG11B	-0.76	-7.45	-0.61	4.36e-11	Monocyte count;
THYM	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg15557168	chr22:42548783	NA	-0.61	-4.74	-0.44	7.4e-6	Schizophrenia;
THYM	cis	rs11997175	1.000	rs7838577	chr8:33760802	A/G	ch.8.33884649F	chr8:33765107	NA	0.63	4.94	0.45	3.35e-6	Body mass index;
THYM	cis	rs7851660	0.874	rs1443436	chr9:100631298	T/A	cg13688889	chr9:100608707	NA	-0.79	-5.92	-0.52	5.07e-8	Strep throat;
THYM	cis	rs995000	0.931	rs656297	chr1:62907595	A/G	cg06896770	chr1:63153194	DOCK7	0.91	7.48	0.61	3.73e-11	Triglyceride levels;
THYM	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06850241	chr22:41845214	NA	-0.6	-5.28	-0.48	7.99e-7	Vitiligo;
THYM	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg13683864	chr3:40499215	RPL14	-0.93	-9.62	-0.7	1.09e-15	Renal cell carcinoma;
THYM	cis	rs3760776	0.522	rs8111600	chr19:5821968	C/T	cg25387410	chr19:5844109	FUT3	-1.01	-4.85	-0.45	4.89e-6	N-glycan levels;Tumor biomarkers;Vitamin B12 levels;
THYM	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg12863693	chr15:85201151	NMB	0.65	5.75	0.51	1.1e-7	Schizophrenia;
THYM	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.23	-8.82	-0.67	5.57e-14	Gut microbiome composition (summer);
THYM	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg02640540	chr1:67518911	SLC35D1	0.64	4.68	0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs75920871	0.528	rs10466590	chr11:116894413	C/G	cg20608306	chr11:116969690	SIK3	-0.53	-5.89	-0.52	5.93e-8	Subjective well-being;
THYM	cis	rs7973719	0.868	rs2053887	chr12:7346530	G/A	cg07052231	chr12:7363540	PEX5	0.57	4.65	0.43	1.07e-5	IgG glycosylation;
THYM	cis	rs1957429	0.901	rs1957427	chr14:65354085	A/G	cg23373153	chr14:65346875	NA	0.93	5.21	0.47	1.08e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg23682913	chr1:2080710	PRKCZ	-0.55	-5.03	-0.46	2.32e-6	Height;
THYM	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg20608306	chr11:116969690	SIK3	0.46	5.68	0.5	1.45e-7	Blood protein levels;
THYM	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg06636551	chr8:101224915	SPAG1	-0.67	-6.49	-0.55	3.93e-9	Atrioventricular conduction;
THYM	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.69	-7.42	-0.61	4.85e-11	Crohn's disease;
THYM	cis	rs2133450	0.508	rs6443100	chr3:7333382	G/T	cg19930620	chr3:7340148	GRM7	0.55	5.52	0.49	2.96e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg27490568	chr2:178487706	NA	0.62	5.82	0.51	7.82e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg24675658	chr1:53192096	ZYG11B	0.79	7.24	0.6	1.15e-10	Monocyte count;
THYM	cis	rs775227	0.574	rs34049435	chr3:113099499	C/T	cg18753928	chr3:113234510	CCDC52	-0.76	-5.35	-0.48	6.02e-7	Dental caries;
THYM	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-1.1	-12.37	-0.79	1.68e-21	Intelligence (multi-trait analysis);
THYM	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg06238570	chr21:40685208	BRWD1	-0.64	-4.52	-0.42	1.77e-5	Menarche (age at onset);
THYM	cis	rs79387448	0.745	rs78136548	chr2:103103740	T/G	cg09003973	chr2:102972529	NA	0.8	4.47	0.42	2.16e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs939658	1.000	rs8027411	chr15:79461029	G/T	cg17916960	chr15:79447300	NA	0.74	8.54	0.66	2.17e-13	Refractive error;
THYM	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.4	0.55	5.92e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7769051	0.711	rs7758703	chr6:133085417	T/C	cg07930552	chr6:133119739	C6orf192	0.97	5.34	0.48	6.46e-7	Type 2 diabetes nephropathy;
THYM	cis	rs9462846	0.725	rs9471969	chr6:42906384	G/T	cg10862848	chr6:42927986	GNMT	-0.45	-4.6	-0.43	1.29e-5	Blood protein levels;
THYM	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg04282206	chr17:62833786	PLEKHM1P	0.84	8.28	0.65	7.73e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg10661904	chr17:79619235	PDE6G	-0.53	-4.66	-0.43	1.03e-5	Eye color traits;
THYM	cis	rs2268241	0.938	rs28653198	chr21:34782395	A/C	cg14850771	chr21:34775459	IFNGR2	1.04	6.96	0.58	4.26e-10	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	6.71	0.57	1.42e-9	Smoking behavior;
THYM	cis	rs886774	0.526	rs12669950	chr7:107508000	C/T	cg23293999	chr7:106826042	HBP1	0.58	4.59	0.43	1.35e-5	Ulcerative colitis;
THYM	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg02953382	chr22:24373134	LOC391322	-0.81	-8.78	-0.67	6.55e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7640424	0.929	rs327139	chr3:107822481	G/C	cg09227934	chr3:107805635	CD47	0.56	4.91	0.45	3.85e-6	Body mass index;
THYM	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg08773314	chr2:239334832	ASB1	0.6	8.73	0.67	8.55e-14	Multiple system atrophy;
THYM	cis	rs3204270	0.639	rs79193599	chr17:79651490	C/A	cg13117272	chr17:79681052	SLC25A10	-0.76	-4.7	-0.43	8.93e-6	Dental caries;
THYM	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg18755752	chr8:142205143	DENND3	-0.75	-7.22	-0.6	1.27e-10	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs4535497	0.525	rs4975639	chr5:1108250	A/G	cg14116129	chr5:1140748	NA	0.27	4.52	0.42	1.77e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg06850241	chr22:41845214	NA	0.54	4.85	0.45	4.87e-6	Vitiligo;
THYM	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg19901468	chr14:105411992	AHNAK2	-0.77	-6.26	-0.54	1.1e-8	Rheumatoid arthritis;
THYM	cis	rs7107770	1.000	rs34573992	chr11:125107141	T/C	cg07747661	chr11:125106135	PKNOX2	-0.92	-5.19	-0.47	1.17e-6	Photic sneeze reflex;
THYM	cis	rs7590720	1.000	rs934156	chr2:216901482	C/T	cg12620499	chr2:216877984	MREG	-0.77	-5.21	-0.47	1.1e-6	Alcohol dependence;
THYM	cis	rs7267979	0.816	rs1044573	chr20:25206654	A/G	cg08601574	chr20:25228251	PYGB	0.61	4.82	0.44	5.49e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg00487526	chr15:90818384	NA	-0.64	-5.16	-0.47	1.33e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs13315871	0.929	rs9857333	chr3:58293551	G/C	cg00563845	chr3:58318305	PXK	0.56	4.83	0.44	5.15e-6	Cholesterol, total;
THYM	cis	rs10089	0.904	rs2195921	chr5:127489754	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.02	7.11	0.59	2.11e-10	Ileal carcinoids;
THYM	cis	rs7107770	1.000	rs35459519	chr11:125107290	C/T	cg07747661	chr11:125106135	PKNOX2	-0.92	-5.28	-0.48	8.31e-7	Photic sneeze reflex;
THYM	cis	rs3126085	0.877	rs4457589	chr1:152247860	T/C	cg10321714	chr1:152280068	FLG	0.64	4.81	0.44	5.57e-6	Atopic dermatitis;
THYM	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.52	0.49	2.99e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg17054759	chr22:49844102	NA	-0.53	-5.17	-0.47	1.32e-6	Monocyte count;Monocyte percentage of white cells;
THYM	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg15704280	chr7:45808275	SEPT13	-1.04	-14.47	-0.83	9.54e-26	Height;
THYM	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg18876405	chr7:65276391	NA	0.59	5.09	0.46	1.82e-6	Aortic root size;
THYM	cis	rs4363385	0.818	rs12085426	chr1:153003074	C/A	cg13444842	chr1:152974279	SPRR3	-0.59	-4.83	-0.44	5.24e-6	Inflammatory skin disease;
THYM	cis	rs4595586	0.545	rs12812262	chr12:39392567	T/A	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs9560113	0.573	rs9560134	chr13:112244011	C/T	cg10483660	chr13:112241077	NA	0.7	8.38	0.65	4.79e-13	Menarche (age at onset);
THYM	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Bladder cancer;
THYM	cis	rs7953508	0.506	rs3782415	chr12:93967755	T/C	cg18151635	chr12:93972918	NA	-0.87	-6.12	-0.53	2.07e-8	Pubertal anthropometrics;
THYM	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	4.46	0.42	2.21e-5	Diabetic retinopathy;
THYM	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.26	10.26	0.73	4.55e-17	Platelet count;
THYM	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg12923728	chr3:195709715	SDHAP1	-0.78	-6.38	-0.55	6.41e-9	Pancreatic cancer;
THYM	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs3768617	0.510	rs7529465	chr1:183096880	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	5.95	0.52	4.53e-8	Schizophrenia;
THYM	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.96	0.45	3.03e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg02751453	chr18:77725136	HSBP1L1	-0.6	-4.99	-0.46	2.73e-6	Opioid sensitivity;
THYM	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg09307838	chr4:120376055	NA	0.6	4.54	0.42	1.63e-5	Corneal astigmatism;
THYM	cis	rs9906944	0.707	rs8068981	chr17:47122525	T/C	cg09029085	chr17:47094198	IGF2BP1	0.47	6.53	0.56	3.17e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg11266682	chr4:10021025	SLC2A9	0.7	10.42	0.73	2.06e-17	Bone mineral density;
THYM	cis	rs4866334	1.000	rs74805322	chr5:18487623	C/A	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs786425	0.585	rs2333838	chr12:124220354	A/C	cg15249119	chr12:124971054	NCOR2	0.52	4.78	0.44	6.4e-6	Pubertal anthropometrics;
THYM	cis	rs4363385	0.818	rs436621	chr1:153005492	A/G	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs7567389	0.600	rs72845979	chr2:128095754	C/A	cg06038358	chr2:128176007	PROC	0.47	5.28	0.48	8.28e-7	Self-rated health;
THYM	cis	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.57	-6.29	-0.54	9.85e-9	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs8077889	0.871	rs17675370	chr17:41900030	T/C	cg26893861	chr17:41843967	DUSP3	1.11	10.19	0.72	6.43e-17	Triglycerides;
THYM	cis	rs16912285	0.688	rs12276587	chr11:24280656	C/G	ch.11.24196551F	chr11:24239977	NA	-0.99	-6.85	-0.58	7.19e-10	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg02782426	chr3:40428986	ENTPD3	0.53	4.66	0.43	1.04e-5	Renal cell carcinoma;
THYM	cis	rs4242434	0.672	rs3758042	chr8:22486951	T/C	cg01710189	chr8:22454888	PDLIM2	-0.48	-5.12	-0.47	1.56e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	4.98	0.45	2.88e-6	Schizophrenia;
THYM	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11890956	chr21:40555474	PSMG1	-0.92	-10.18	-0.72	6.82e-17	Cognitive function;
THYM	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg12560992	chr17:57184187	TRIM37	0.94	8.84	0.67	5.01e-14	Intelligence (multi-trait analysis);
THYM	cis	rs981844	0.735	rs17371573	chr4:154765216	G/A	cg09973105	chr4:154681532	RNF175	-0.62	-5.1	-0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg02931644	chr1:25747376	RHCE	0.6	4.58	0.43	1.41e-5	Erythrocyte sedimentation rate;
THYM	cis	rs11785693	0.862	rs11774099	chr8:4988218	C/T	cg26367366	chr8:4980734	NA	0.94	4.74	0.44	7.42e-6	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg15536230	chr21:44985092	HSF2BP	-0.46	-5.5	-0.49	3.14e-7	Mean corpuscular volume;
THYM	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-6.33	-0.54	8.23e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs3819817	0.545	rs7488038	chr12:96352568	A/T	cg26410635	chr12:96350720	AMDHD1	0.53	5.02	0.46	2.38e-6	Vitamin D levels;
THYM	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Gout;
THYM	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3204270	0.639	rs11871678	chr17:79654285	G/A	cg13117272	chr17:79681052	SLC25A10	-0.76	-4.7	-0.43	8.93e-6	Dental caries;
THYM	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg19729930	chr2:74357872	NA	1.25	12.57	0.79	6.31e-22	Gestational age at birth (maternal effect);
THYM	cis	rs7246657	0.653	rs10425441	chr19:37670648	T/C	cg23950597	chr19:37808831	NA	-0.81	-4.88	-0.45	4.35e-6	Coronary artery calcification;
THYM	cis	rs6732160	0.588	rs3891890	chr2:73378049	A/G	cg24220031	chr2:73402428	NA	-0.71	-5.79	-0.51	8.94e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg09354556	chr3:47051341	NA	0.45	4.58	0.43	1.41e-5	Colorectal cancer;
THYM	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg20387954	chr3:183756860	HTR3D	0.56	4.64	0.43	1.11e-5	Anterior chamber depth;
THYM	cis	rs600806	0.850	rs11102981	chr1:109967323	G/C	cg16988986	chr1:109941118	SORT1	-0.44	-4.67	-0.43	9.83e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10924970	0.781	rs10802589	chr1:235444049	A/G	cg26050004	chr1:235667680	B3GALNT2	0.6	4.58	0.43	1.4e-5	Asthma;
THYM	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.64	-5.53	-0.49	2.78e-7	Systemic lupus erythematosus;
THYM	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg04455712	chr21:45112962	RRP1B	0.59	5.77	0.51	9.86e-8	Mean corpuscular volume;
THYM	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7152530	0.571	rs10144091	chr14:98640452	A/G	cg05180522	chr14:98101740	NA	0.6	4.77	0.44	6.56e-6	Staphylococcus aureus infection;
THYM	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs8100891	0.734	rs4804990	chr19:32837429	C/G	cg16662424	chr19:32837316	ZNF507	-0.44	-4.75	-0.44	7.15e-6	Neuroticism;
THYM	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg09060608	chr5:178986726	RUFY1	-0.58	-6.23	-0.54	1.29e-8	Lung cancer;
THYM	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03517284	chr6:25882590	NA	-1.02	-9.92	-0.71	2.43e-16	Intelligence (multi-trait analysis);
THYM	cis	rs7084402	0.967	rs1649045	chr10:60327047	T/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs1011018	0.826	rs1860509	chr7:139478175	T/G	cg06079564	chr7:139468310	HIPK2	-0.69	-4.91	-0.45	3.74e-6	Systolic blood pressure;
THYM	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg00898013	chr13:113819073	PROZ	0.88	8.73	0.67	8.51e-14	Platelet distribution width;
THYM	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg13695892	chr22:41940480	POLR3H	0.89	6.74	0.57	1.2e-9	Vitiligo;
THYM	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg01236616	chr12:121019343	POP5	1.31	10.38	0.73	2.57e-17	Type 1 diabetes nephropathy;
THYM	cis	rs3845702	0.736	rs2678936	chr2:180872179	G/C	cg01881094	chr2:180872142	CWC22	0.92	5.53	0.49	2.76e-7	Schizophrenia;
THYM	cis	rs3820068	0.608	rs12091326	chr1:16048005	A/G	cg13390004	chr1:15929781	NA	0.65	4.88	0.45	4.3e-6	Systolic blood pressure;
THYM	trans	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg25517755	chr10:38738941	LOC399744	-0.76	-6.92	-0.58	5.26e-10	Corneal astigmatism;
THYM	cis	rs1348850	0.574	rs10195917	chr2:178443121	C/T	cg27490568	chr2:178487706	NA	0.51	4.5	0.42	1.96e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1448094	0.556	rs4897831	chr12:86168248	C/T	cg00310523	chr12:86230176	RASSF9	0.56	4.94	0.45	3.29e-6	Major depressive disorder;
THYM	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg17264618	chr3:40429014	ENTPD3	0.51	4.81	0.44	5.7e-6	Renal cell carcinoma;
THYM	cis	rs7247513	0.897	rs12979146	chr19:12717904	C/T	cg01871581	chr19:12707946	ZNF490	-0.93	-10.97	-0.75	1.45e-18	Bipolar disorder;
THYM	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.49	-0.49	3.3e-7	Gut microbiome composition (summer);
THYM	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg24642439	chr20:33292090	TP53INP2	0.68	5.14	0.47	1.45e-6	Coronary artery disease;
THYM	cis	rs4792901	0.802	rs9901586	chr17:41580891	T/G	cg21940313	chr17:41620911	ETV4	-0.54	-5.14	-0.47	1.45e-6	Dupuytren's disease;
THYM	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg11494091	chr17:61959527	GH2	-1.07	-16.26	-0.86	3.42e-29	Prudent dietary pattern;
THYM	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg26384229	chr12:38710491	ALG10B	0.96	7.77	0.62	8.98e-12	Bladder cancer;
THYM	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg14004847	chr7:1930337	MAD1L1	-0.64	-5.12	-0.46	1.62e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg14972814	chr11:95582409	MTMR2	-0.7	-6.18	-0.54	1.57e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg15744692	chr15:45671195	LOC145663;GATM	-0.45	-4.48	-0.42	2.08e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs921968	0.565	rs6723334	chr2:219629303	C/T	cg02176678	chr2:219576539	TTLL4	0.45	4.55	0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs877282	0.945	rs17293517	chr10:778770	C/T	cg10556349	chr10:835070	NA	-0.77	-5.22	-0.47	1.06e-6	Uric acid levels;
THYM	cis	rs2625529	0.775	rs12913042	chr15:72202309	C/T	cg16672083	chr15:72433130	SENP8	-0.52	-4.66	-0.43	1.01e-5	Red blood cell count;
THYM	cis	rs17511627	0.755	rs4770933	chr13:26741822	C/T	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs868036	0.718	rs28587941	chr15:68122509	T/C	cg24579218	chr15:68104479	NA	-0.79	-8.4	-0.65	4.38e-13	Restless legs syndrome;
THYM	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg03929089	chr4:120376271	NA	-0.94	-10.74	-0.74	4.27e-18	Coronary artery disease;
THYM	cis	rs11696501	0.688	rs6104293	chr20:44326298	T/C	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg05234568	chr11:5960015	NA	0.59	5.3	0.48	7.5e-7	DNA methylation (variation);
THYM	cis	rs4819052	0.851	rs2838867	chr21:46713092	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.03	9.36	0.69	3.81e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs714027	0.626	rs4336042	chr22:30552511	G/A	cg27665648	chr22:30112403	NA	-0.52	-4.73	-0.44	7.79e-6	Lymphocyte counts;
THYM	cis	rs9807989	0.839	rs3755276	chr2:102978459	C/T	cg03938978	chr2:103052716	IL18RAP	0.63	6.55	0.56	2.99e-9	Asthma;
THYM	cis	rs11563648	0.553	rs6978090	chr7:127029429	C/A	cg23081781	chr7:127225937	GCC1	-0.34	-4.64	-0.43	1.14e-5	Resting heart rate;
THYM	cis	rs3087591	1.000	rs984125	chr17:29547254	A/G	cg24425628	chr17:29625626	OMG;NF1	0.63	5.52	0.49	2.96e-7	Hip circumference;
THYM	cis	rs977987	0.835	rs3863445	chr16:75371744	C/G	cg03315344	chr16:75512273	CHST6	0.8	6.6	0.56	2.37e-9	Dupuytren's disease;
THYM	cis	rs7772486	0.875	rs865913	chr6:146308874	C/T	cg23711669	chr6:146136114	FBXO30	0.96	10.29	0.73	3.99e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg12564285	chr5:131593104	PDLIM4	0.44	4.57	0.42	1.46e-5	Blood metabolite levels;
THYM	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	4.68	0.43	9.46e-6	Schizophrenia;
THYM	cis	rs34172651	0.917	rs11640931	chr16:24797919	A/G	cg06028605	chr16:24865363	SLC5A11	0.58	5.69	0.5	1.42e-7	Intelligence (multi-trait analysis);
THYM	cis	rs34638657	0.797	rs11645045	chr16:82202137	G/A	cg07307142	chr16:82071433	HSD17B2	-0.89	-7.34	-0.6	7.18e-11	Lung adenocarcinoma;
THYM	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.77	-0.57	1.04e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11039798	0.588	rs6485891	chr11:48612024	T/A	cg24672777	chr11:48374446	OR4C45	-0.93	-6.01	-0.52	3.39e-8	Axial length;
THYM	cis	rs2237457	0.543	rs2715116	chr7:50700836	G/T	cg08586669	chr7:50727761	GRB10	0.29	4.84	0.44	5.02e-6	Schizophrenia (treatment resistant);
THYM	cis	rs34638657	0.872	rs7192444	chr16:82180338	C/G	cg07307142	chr16:82071433	HSD17B2	1.04	8.76	0.67	7.54e-14	Lung adenocarcinoma;
THYM	cis	rs12600053	0.687	rs11149686	chr16:84847247	A/G	cg09249803	chr16:84846936	NA	0.41	4.47	0.42	2.18e-5	Asthma (childhood onset);
THYM	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg12379764	chr21:47803548	PCNT	-0.83	-5.37	-0.48	5.52e-7	Testicular germ cell tumor;
THYM	cis	rs4474465	0.850	rs10793326	chr11:78255422	A/C	cg19901956	chr11:77921274	USP35	0.68	5.07	0.46	1.96e-6	Alzheimer's disease (survival time);
THYM	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67460515	0.892	rs11718905	chr3:161051793	G/A	cg03342759	chr3:160939853	NMD3	-0.94	-8.14	-0.64	1.55e-12	Parkinson's disease;
THYM	cis	rs9467711	0.651	rs16891334	chr6:26124303	T/C	cg01386294	chr6:25732093	NA	0.9	4.88	0.45	4.34e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4363385	0.773	rs310122	chr1:153064288	C/T	cg06563695	chr1:153756334	NA	0.6	4.6	0.43	1.28e-5	Inflammatory skin disease;
THYM	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.94	-0.75	1.65e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs36051895	0.632	rs62541944	chr9:5159318	G/T	cg02405213	chr9:5042618	JAK2	-1.05	-11.06	-0.75	9.03e-19	Pediatric autoimmune diseases;
THYM	cis	rs11645898	0.935	rs11647125	chr16:72243277	T/C	cg14768367	chr16:72042858	DHODH	-0.71	-5.08	-0.46	1.88e-6	Blood protein levels;
THYM	cis	rs41005	0.597	rs35400177	chr2:8101757	C/T	cg03155496	chr2:8117019	LOC339788	-0.76	-5.25	-0.47	9.32e-7	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	trans	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg07211511	chr3:129823064	LOC729375	-0.9	-7.15	-0.59	1.8e-10	Blood pressure (smoking interaction);
THYM	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg25918947	chr17:41365094	TMEM106A	-0.57	-4.79	-0.44	6.13e-6	Menopause (age at onset);
THYM	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg07570687	chr10:102243282	WNT8B	0.75	6.63	0.56	2.02e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg12826209	chr6:26865740	GUSBL1	1.03	6.64	0.56	1.94e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg23758822	chr17:41437982	NA	1.16	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs11966931	1.000	rs11962140	chr6:108121326	A/T	cg25323841	chr6:108444506	NA	0.64	4.46	0.42	2.23e-5	Neutrophil percentage of white cells;
THYM	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg25811766	chr13:21894605	NA	-0.78	-5.02	-0.46	2.38e-6	White matter hyperintensity burden;
THYM	cis	rs888194	0.544	rs7316486	chr12:109849540	A/G	cg11367159	chr12:110044531	NA	0.61	5.54	0.49	2.74e-7	Neuroticism;
THYM	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg26022315	chr17:47021804	SNF8	0.51	4.87	0.45	4.45e-6	Type 2 diabetes;
THYM	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg17143192	chr8:8559678	CLDN23	0.59	4.48	0.42	2.12e-5	Mood instability;
THYM	cis	rs7616559	0.512	rs6799034	chr3:156717880	C/T	cg15697575	chr3:156784781	NA	0.35	5.27	0.48	8.46e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs863345	0.604	rs10797013	chr1:158465506	G/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs6496667	0.557	rs2589951	chr15:90958392	T/C	cg22089800	chr15:90895588	ZNF774	0.61	4.46	0.42	2.29e-5	Rheumatoid arthritis;
THYM	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg11764359	chr7:65958608	NA	-0.82	-6.6	-0.56	2.29e-9	Aortic root size;
THYM	cis	rs1981331	0.609	rs8127722	chr21:48077293	A/C	cg17243659	chr21:48055224	PRMT2	1.25	5.29	0.48	7.9e-7	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs1448094	0.512	rs6539933	chr12:86247611	T/C	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg25838465	chr1:92012736	NA	-0.71	-5.02	-0.46	2.44e-6	Eosinophil percentage of white cells;
THYM	cis	rs11671005	0.570	rs73062110	chr19:58936642	G/T	cg18639983	chr19:58920768	ZNF584	0.61	5.02	0.46	2.37e-6	Mean platelet volume;
THYM	cis	rs2069036	1.000	rs11253761	chr10:16110387	T/A	cg26633223	chr10:15133461	NA	0.71	5.24	0.47	9.71e-7	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs6754311	0.593	rs11679508	chr2:136474098	A/T	cg23851026	chr2:136556271	LCT	-0.59	-5.53	-0.49	2.85e-7	Mosquito bite size;
THYM	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg21475434	chr5:93447410	FAM172A	0.86	5.59	0.5	2.14e-7	Diabetic retinopathy;
THYM	cis	rs1278352	0.737	rs898323	chr10:127776851	A/G	cg08295661	chr10:127769903	ADAM12	-0.54	-5.42	-0.49	4.58e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs6840360	0.554	rs58751443	chr4:152709905	A/G	cg22705602	chr4:152727874	NA	-0.82	-11.15	-0.75	6.01e-19	Intelligence (multi-trait analysis);
THYM	cis	rs586688	1.000	rs125872	chr1:201635798	C/T	cg07139329	chr1:201708558	NAV1	0.5	4.78	0.44	6.46e-6	Obesity-related traits;
THYM	cis	rs55728055	0.661	rs16989682	chr22:31900224	A/G	cg01338084	chr22:32026380	PISD	-1.41	-5.12	-0.46	1.62e-6	Age-related hearing impairment;
THYM	trans	rs11722228	0.522	rs1109472	chr4:10134448	C/G	cg26043149	chr18:55253948	FECH	1.09	10.12	0.72	8.97e-17	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg06074448	chr4:187884817	NA	-1.04	-13.69	-0.81	3.39e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs728616	0.867	rs61860039	chr10:81939906	G/A	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs10871290	0.881	rs11649338	chr16:74471420	C/T	cg01733217	chr16:74700730	RFWD3	-0.63	-5.45	-0.49	4.01e-7	Breast cancer;
THYM	cis	rs1395	0.778	rs4665959	chr2:27443256	C/T	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.52	-0.49	2.95e-7	Blood metabolite levels;
THYM	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg15556689	chr8:8085844	FLJ10661	0.83	7.75	0.62	1.03e-11	Neuroticism;
THYM	cis	rs990171	0.955	rs6708413	chr2:103063369	C/T	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.13	-0.47	1.5e-6	Lymphocyte counts;
THYM	cis	rs2806561	0.578	rs6702719	chr1:23302576	T/C	cg12483005	chr1:23474871	LUZP1	0.51	4.96	0.45	3.05e-6	Height;
THYM	cis	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg09307838	chr4:120376055	NA	-0.75	-5.91	-0.52	5.25e-8	Corneal astigmatism;
THYM	cis	rs7119	0.651	rs35657172	chr15:77847813	T/C	cg10437265	chr15:77819839	NA	0.68	6.22	0.54	1.33e-8	Type 2 diabetes;
THYM	cis	rs6032067	0.759	rs3761193	chr20:43885827	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.59	-6.37	-0.55	6.81e-9	Blood protein levels;
THYM	cis	rs6835098	0.924	rs2332669	chr4:174163398	G/A	cg08422745	chr4:174089978	GALNT7	-1.03	-9.15	-0.68	1.09e-14	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs6032067	1.000	rs6032059	chr20:43852443	A/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.71	-7.53	-0.61	2.95e-11	Blood protein levels;
THYM	cis	rs7646881	1.000	rs59313096	chr3:158452242	G/C	cg18349298	chr3:158450550	RARRES1	0.48	4.48	0.42	2.05e-5	Tetralogy of Fallot;
THYM	cis	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg11879182	chr18:77439856	CTDP1	0.8	7.8	0.62	7.91e-12	Monocyte count;
THYM	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.65	-4.7	-0.43	8.92e-6	Colorectal cancer;
THYM	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs6430585	0.528	rs115553816	chr2:136692893	G/A	cg04750100	chr2:136595281	LCT	0.56	4.94	0.45	3.41e-6	Corneal structure;
THYM	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg12386194	chr3:101231763	SENP7	0.66	5.0	0.46	2.59e-6	Colorectal cancer;
THYM	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs12476592	0.602	rs262530	chr2:63904274	A/T	cg17519650	chr2:63277830	OTX1	-0.72	-4.68	-0.43	9.38e-6	Childhood ear infection;
THYM	cis	rs2276498	0.751	rs1381984	chr20:52655304	G/A	cg23682609	chr20:52687365	BCAS1	0.54	4.51	0.42	1.87e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs117352156	0.506	rs6481552	chr10:29225286	C/T	cg22576165	chr10:29214191	NA	0.6	4.9	0.45	3.86e-6	Aggressiveness in attention deficit hyperactivity disorder;
THYM	cis	rs12134245	0.747	rs11164912	chr1:92005191	A/T	cg21854759	chr1:92012499	NA	-0.7	-5.67	-0.5	1.5e-7	Breast cancer;
THYM	cis	rs8050907	0.744	rs7195209	chr16:4565426	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.13	4.76	0.44	6.97e-6	Obesity-related traits;
THYM	cis	rs651907	0.640	rs771574	chr3:101620682	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	6.21	0.54	1.41e-8	Colorectal cancer;
THYM	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg20203395	chr5:56204925	C5orf35	-0.67	-4.6	-0.43	1.3e-5	Initial pursuit acceleration;
THYM	cis	rs4148087	0.719	rs9978956	chr21:43599950	T/C	cg09727148	chr21:43560719	UMODL1	0.63	5.05	0.46	2.16e-6	Eating disorder in bipolar disorder;
THYM	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg11764359	chr7:65958608	NA	0.69	4.67	0.43	9.75e-6	Aortic root size;
THYM	cis	rs11048434	0.761	rs1805721	chr12:9147569	A/G	cg04155231	chr12:9217510	LOC144571	-0.5	-4.86	-0.45	4.7e-6	Sjögren's syndrome;
THYM	cis	rs870825	0.616	rs7654208	chr4:185648877	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs9399401	0.614	rs262125	chr6:142838355	A/T	cg04461802	chr6:142623433	GPR126	0.57	5.14	0.47	1.47e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs4523957	0.928	rs7213232	chr17:2165340	A/G	cg16513277	chr17:2031491	SMG6	-0.79	-7.41	-0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg17747265	chr1:1875780	NA	0.77	8.83	0.67	5.35e-14	Body mass index;
THYM	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg04447362	chr2:237654635	NA	0.48	4.49	0.42	2.03e-5	Prostate cancer;
THYM	cis	rs13064411	0.542	rs9846539	chr3:113228688	A/G	cg18753928	chr3:113234510	CCDC52	-0.84	-7.9	-0.63	4.79e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.7	-5.63	-0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs7191439	0.858	rs4390574	chr16:88776297	T/C	cg04602696	chr16:88846723	FAM38A	-0.73	-5.81	-0.51	8.35e-8	Plateletcrit;
THYM	cis	rs4474465	1.000	rs11237510	chr11:78173584	G/A	cg19901956	chr11:77921274	USP35	-0.6	-4.55	-0.42	1.56e-5	Alzheimer's disease (survival time);
THYM	cis	rs7772486	0.846	rs2748496	chr6:146321829	T/A	cg13319975	chr6:146136371	FBXO30	-0.72	-6.1	-0.53	2.24e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9875589	0.509	rs6442423	chr3:14016062	G/A	cg03204825	chr3:13978759	TPRXL	-0.51	-4.46	-0.42	2.26e-5	Ovarian reserve;
THYM	cis	rs7828089	0.646	rs7000551	chr8:22276251	A/G	cg13512537	chr8:22265999	SLC39A14	-0.66	-4.99	-0.46	2.74e-6	Verbal declarative memory;
THYM	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg07837209	chr13:79184101	NA	-0.8	-5.06	-0.46	2.01e-6	Large artery stroke;
THYM	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg01069141	chr11:67398826	TBX10;NUDT8	0.55	5.74	0.51	1.11e-7	Mean corpuscular volume;
THYM	cis	rs7342694	0.525	rs7184247	chr16:81907752	C/T	cg08344351	chr16:81507328	CMIP	0.32	4.55	0.42	1.59e-5	Coronary artery disease;
THYM	cis	rs28595532	0.920	rs115738062	chr4:119725490	C/T	cg11846333	chr4:119757529	SEC24D	1.35	5.12	0.46	1.6e-6	Cannabis dependence symptom count;
THYM	cis	rs7582180	0.663	rs4850930	chr2:100990955	T/C	cg14675211	chr2:100938903	LONRF2	0.59	5.65	0.5	1.67e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg06060754	chr5:176797920	RGS14	0.34	4.97	0.45	2.94e-6	Urinary electrolytes (magnesium/calcium ratio);
THYM	cis	rs4499344	0.960	rs17833075	chr19:33075134	G/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.77	-5.45	-0.49	3.92e-7	Mean platelet volume;
THYM	cis	rs6598955	0.627	rs7550127	chr1:26592871	C/T	cg08133631	chr1:26527909	CATSPER4	-0.61	-5.01	-0.46	2.55e-6	Obesity-related traits;
THYM	cis	rs13418717	1.000	rs13411741	chr2:127666335	G/A	cg25501666	chr2:127640322	NA	1.52	7.06	0.59	2.67e-10	Heart failure;
THYM	cis	rs9430161	0.644	rs6685766	chr1:11037051	T/C	cg02454025	chr1:11042201	C1orf127	0.85	9.91	0.71	2.54e-16	Ewing sarcoma;
THYM	cis	rs7843479	1.000	rs2306641	chr8:21833965	A/G	cg17168535	chr8:21777572	XPO7	-0.7	-5.42	-0.49	4.45e-7	Mean corpuscular volume;
THYM	cis	rs12704876	0.509	rs10257162	chr7:96343642	T/C	cg03808172	chr7:96339361	SHFM1	0.74	5.28	0.48	8.02e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg03806693	chr22:41940476	POLR3H	0.91	7.39	0.6	5.62e-11	Vitiligo;
THYM	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03517284	chr6:25882590	NA	-0.76	-5.89	-0.52	5.78e-8	Blood metabolite levels;
THYM	cis	rs425535	0.757	rs6820253	chr4:74839071	T/C	cg07868155	chr4:74864709	CXCL5	0.61	4.57	0.42	1.45e-5	Blood protein levels;
THYM	cis	rs36051895	0.664	rs12344629	chr9:5109208	C/T	cg02405213	chr9:5042618	JAK2	-1.0	-11.0	-0.75	1.23e-18	Pediatric autoimmune diseases;
THYM	cis	rs9527	0.641	rs4919684	chr10:104587024	A/G	cg15744005	chr10:104629667	AS3MT	-0.67	-5.33	-0.48	6.6e-7	Arsenic metabolism;
THYM	cis	rs35883536	0.669	rs1932352	chr1:101161251	G/A	cg09408571	chr1:101003634	GPR88	-0.45	-4.87	-0.45	4.36e-6	Monocyte count;
THYM	cis	rs3820068	0.608	rs12091326	chr1:16048005	A/G	cg24675056	chr1:15929824	NA	0.77	6.17	0.53	1.67e-8	Systolic blood pressure;
THYM	cis	rs4732038	0.565	rs12673319	chr7:134278968	G/C	cg06906464	chr7:134288099	NA	-0.52	-5.31	-0.48	7.3e-7	Longevity;
THYM	cis	rs11190604	0.767	rs7392696	chr10:102182141	G/A	cg07570687	chr10:102243282	WNT8B	0.81	7.79	0.62	8.34e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17122693	0.748	rs72679598	chr14:51107157	C/G	cg04730355	chr14:51134070	SAV1	0.92	5.34	0.48	6.27e-7	Cognitive performance;
THYM	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg00801512	chr17:28996047	NA	-0.76	-5.02	-0.46	2.41e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs58688157	0.705	rs936468	chr11:607175	G/A	cg00645579	chr11:617140	IRF7;MUPCDH	-0.48	-5.63	-0.5	1.86e-7	Systemic lupus erythematosus;
THYM	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg20469991	chr17:27169893	C17orf63	-0.79	-4.79	-0.44	6.18e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs13202913	0.837	rs9383901	chr6:151788059	T/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.83	5.12	0.46	1.62e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22455342	chr2:225449267	CUL3	0.96	8.91	0.67	3.56e-14	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs2463822	0.583	rs72919467	chr11:62040102	G/A	cg06239285	chr11:62104954	ASRGL1	-1.04	-5.14	-0.47	1.45e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg20891283	chr12:69753455	YEATS4	1.06	10.24	0.72	5.15e-17	Blood protein levels;
THYM	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs34638657	0.702	rs11866709	chr16:82201017	A/G	cg09439754	chr16:82129088	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	cis	rs56309584	0.673	rs11650444	chr17:8106317	C/T	cg08322244	chr17:8066669	VAMP2	-0.53	-4.77	-0.44	6.75e-6	Initial pursuit acceleration;
THYM	cis	rs2717559	0.515	rs55720963	chr8:143895957	T/A	cg17252645	chr8:143867129	LY6D	-0.61	-6.42	-0.55	5.42e-9	Urinary tract infection frequency;
THYM	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg24675658	chr1:53192096	ZYG11B	-0.6	-4.93	-0.45	3.43e-6	Monocyte count;
THYM	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg26384229	chr12:38710491	ALG10B	0.92	7.67	0.62	1.45e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7107174	0.901	rs10899494	chr11:78122208	G/T	cg19901956	chr11:77921274	USP35	-0.68	-5.47	-0.49	3.6e-7	Testicular germ cell tumor;
THYM	cis	rs3017493	0.786	rs74344478	chr11:70681107	G/A	cg03578926	chr11:70508032	SHANK2	0.86	4.79	0.44	6.06e-6	Renal transplant outcome;
THYM	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg18850127	chr7:39170497	POU6F2	0.55	4.96	0.45	3.12e-6	IgG glycosylation;
THYM	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg02153584	chr22:29168773	CCDC117	0.58	4.56	0.42	1.52e-5	Lymphocyte counts;
THYM	cis	rs6429082	1.000	rs2055127	chr1:235598973	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.52	-4.56	-0.42	1.53e-5	Adiposity;
THYM	cis	rs7178572	0.743	rs62009090	chr15:77837055	T/G	cg22256960	chr15:77711686	NA	-0.81	-6.85	-0.58	7.14e-10	Type 2 diabetes;
THYM	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.32	0.54	8.42e-9	Platelet count;
THYM	cis	rs892961	0.899	rs35217221	chr17:75412385	G/A	cg11351908	chr17:75402473	SEPT9	0.56	5.52	0.49	2.95e-7	Airflow obstruction;
THYM	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg06108461	chr20:60628389	TAF4	-1.06	-9.1	-0.68	1.39e-14	Body mass index;
THYM	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06634786	chr22:41940651	POLR3H	0.63	4.92	0.45	3.62e-6	Cannabis dependence symptom count;
THYM	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg11266682	chr4:10021025	SLC2A9	0.73	11.88	0.77	1.74e-20	Bone mineral density;
THYM	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg18512352	chr11:47633146	NA	0.48	5.85	0.51	6.84e-8	Subjective well-being;
THYM	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg13683864	chr3:40499215	RPL14	0.94	9.74	0.71	6.07e-16	Renal cell carcinoma;
THYM	cis	rs6570726	0.935	rs376991	chr6:145828073	G/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1691799	0.867	rs1168332	chr12:66761548	C/T	cg16791601	chr12:66731901	HELB	-0.67	-5.83	-0.51	7.76e-8	White blood cell count (basophil);
THYM	cis	rs6032067	0.683	rs16989769	chr20:43780475	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	0.67	8.06	0.64	2.29e-12	Blood protein levels;
THYM	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs921665	0.748	rs1869419	chr2:3202080	C/T	cg16434511	chr2:3151078	NA	-0.84	-5.41	-0.49	4.61e-7	World class endurance athleticism;
THYM	cis	rs7107174	1.000	rs2450129	chr11:77940385	T/C	cg19901956	chr11:77921274	USP35	-0.71	-5.63	-0.5	1.81e-7	Testicular germ cell tumor;
THYM	cis	rs1878931	0.582	rs4785933	chr16:3419741	T/A	cg22508957	chr16:3507546	NAT15	-0.49	-5.2	-0.47	1.13e-6	Body mass index (adult);
THYM	cis	rs4595586	0.679	rs4768471	chr12:39325960	G/A	cg13010199	chr12:38710504	ALG10B	0.56	4.54	0.42	1.65e-5	Morning vs. evening chronotype;
THYM	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg24250549	chr1:154909240	PMVK	0.66	5.05	0.46	2.09e-6	Prostate cancer;
THYM	cis	rs9590974	0.605	rs9534444	chr13:47204385	C/G	cg00476653	chr13:47169346	LRCH1	0.4	4.88	0.45	4.22e-6	PR segment;
THYM	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg02640540	chr1:67518911	SLC35D1	0.59	4.64	0.43	1.09e-5	Lymphocyte percentage of white cells;
THYM	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs2554380	0.943	rs2562776	chr15:84368163	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.65	-5.09	-0.46	1.83e-6	Height;
THYM	cis	rs6684428	0.706	rs11206677	chr1:56335237	C/A	cg11651538	chr1:56320950	NA	-0.66	-5.22	-0.47	1.04e-6	Airflow obstruction;
THYM	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.0	10.07	0.72	1.16e-16	Cognitive ability;
THYM	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg05294307	chr14:35346193	BAZ1A	-0.82	-5.51	-0.49	3.06e-7	Psoriasis;
THYM	cis	rs12410462	0.681	rs4614224	chr1:227574966	C/T	cg04117972	chr1:227635322	NA	0.8	4.82	0.44	5.36e-6	Major depressive disorder;
THYM	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-15.39	-0.84	1.51e-27	Height;
THYM	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg04362960	chr10:104952993	NT5C2	0.58	4.8	0.44	5.8e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg04842962	chr6:43655489	MRPS18A	1.4	15.42	0.85	1.3e-27	IgG glycosylation;
THYM	cis	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg07460842	chr6:66804631	NA	1.08	8.22	0.64	1.03e-12	Exhaled nitric oxide output;
THYM	cis	rs6754311	0.551	rs10928545	chr2:136501840	A/G	cg04750100	chr2:136595281	LCT	-0.56	-6.22	-0.54	1.3e-8	Mosquito bite size;
THYM	cis	rs17534004	0.720	rs78587212	chr13:31485323	A/C	cg00367615	chr13:31480979	C13orf33	0.72	5.03	0.46	2.29e-6	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg04315214	chr1:2043799	PRKCZ	0.65	5.63	0.5	1.8e-7	Height;
THYM	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg00012203	chr2:219082015	ARPC2	0.83	7.56	0.61	2.54e-11	Colorectal cancer;
THYM	cis	rs34779708	0.966	rs34296409	chr10:35404613	C/G	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs12540874	0.698	rs3807566	chr7:50564204	G/T	cg00647317	chr7:50633725	DDC	0.3	4.48	0.42	2.09e-5	Systemic sclerosis;
THYM	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.55	-5.23	-0.47	1e-6	Lymphocyte counts;
THYM	cis	rs288326	0.561	rs75936972	chr2:183756989	C/T	cg09997497	chr2:183902928	NCKAP1	1.16	5.14	0.47	1.46e-6	Blood protein levels;
THYM	cis	rs28595532	0.920	rs116145969	chr4:119770908	T/C	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2637266	1.000	rs12251568	chr10:78345667	C/T	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg14584255	chr6:163149320	PACRG;PARK2	0.62	5.68	0.5	1.48e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs8067545	0.611	rs6587219	chr17:20034531	T/G	cg13482628	chr17:19912719	NA	0.55	4.7	0.43	8.82e-6	Schizophrenia;
THYM	cis	rs1829883	1.000	rs2461991	chr5:98793332	C/G	cg08333243	chr5:99726346	NA	-0.57	-5.5	-0.49	3.26e-7	Hemostatic factors and hematological phenotypes;
THYM	cis	rs2075371	0.796	rs35336643	chr7:134010640	G/A	cg11752832	chr7:134001865	SLC35B4	0.69	4.67	0.43	1.01e-5	Mean platelet volume;
THYM	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg14972814	chr11:95582409	MTMR2	-0.72	-6.7	-0.57	1.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4638749	0.677	rs7599646	chr2:108852343	C/T	cg25838818	chr2:108905173	SULT1C2	0.51	5.14	0.47	1.48e-6	Blood pressure;
THYM	trans	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs34526934	0.566	rs1374325	chr2:177043971	G/A	cg14324370	chr2:177042789	NA	-0.7	-6.13	-0.53	2e-8	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs35306767	0.623	rs12354710	chr10:1114020	C/T	cg20503657	chr10:835505	NA	0.86	5.36	0.48	5.74e-7	Eosinophil percentage of granulocytes;
THYM	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg20290983	chr6:43655470	MRPS18A	1.44	16.17	0.86	4.93e-29	IgG glycosylation;
THYM	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg05738196	chr6:26577821	NA	0.68	5.61	0.5	1.96e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg04663057	chr3:46933782	PTH1R	-0.58	-6.32	-0.54	8.57e-9	Birth weight;
THYM	cis	rs2276314	0.857	rs4799409	chr18:33592602	C/T	cg05985134	chr18:33552581	C18orf21	0.66	4.84	0.44	5.02e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7107174	1.000	rs10899460	chr11:78010080	A/G	cg02023728	chr11:77925099	USP35	0.65	5.83	0.51	7.52e-8	Testicular germ cell tumor;
THYM	cis	rs4919694	1.000	rs4917986	chr10:104630181	T/C	cg04362960	chr10:104952993	NT5C2	1.0	6.01	0.52	3.45e-8	Arsenic metabolism;
THYM	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg11764359	chr7:65958608	NA	-0.71	-5.4	-0.48	4.89e-7	Aortic root size;
THYM	cis	rs924712	0.677	rs1580893	chr6:54859452	C/T	cg04690482	chr6:54711388	FAM83B	0.44	5.26	0.47	9.06e-7	Breast cancer;
THYM	cis	rs6575793	1.000	rs8006176	chr14:101033288	A/G	cg13521842	chr14:101036202	BEGAIN	-0.53	-4.82	-0.44	5.33e-6	Menarche (age at onset);
THYM	cis	rs9788682	0.747	rs11072766	chr15:78771546	C/T	cg18825076	chr15:78729989	IREB2	0.7	5.57	0.5	2.39e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.77	-7.13	-0.59	1.95e-10	Personality dimensions;
THYM	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg18876405	chr7:65276391	NA	0.57	4.83	0.44	5.27e-6	Aortic root size;
THYM	cis	rs7529073	0.545	rs340884	chr1:214145389	T/C	cg24083324	chr1:214162604	PROX1	0.71	5.2	0.47	1.15e-6	Schizophrenia;
THYM	cis	rs7512552	0.839	rs1498308	chr1:150295131	G/T	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs72829446	0.530	rs3853820	chr17:7396781	A/T	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg24375607	chr4:120327624	NA	0.64	5.09	0.46	1.84e-6	Corneal astigmatism;
THYM	cis	rs1775715	0.769	rs2808102	chr10:32117749	A/T	cg04359828	chr10:32216031	ARHGAP12	0.38	4.82	0.44	5.48e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	trans	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg02593932	chr2:154728308	GALNT13	0.81	7.06	0.59	2.77e-10	Coronary artery disease;
THYM	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg10295955	chr4:187884368	NA	-1.22	-17.54	-0.87	1.51e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs459571	0.920	rs433402	chr9:136898627	A/G	cg13789015	chr9:136890014	NCRNA00094	0.82	7.14	0.59	1.84e-10	Platelet distribution width;
THYM	cis	rs17253792	0.545	rs34136598	chr14:56013238	C/T	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs16857609	1.000	rs13388294	chr2:218295406	A/G	cg15335768	chr2:218268053	DIRC3	0.34	4.8	0.44	5.87e-6	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg05855489	chr10:104503620	C10orf26	0.58	4.69	0.43	9.04e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg14972814	chr11:95582409	MTMR2	-0.72	-5.89	-0.52	5.93e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.6	4.61	0.43	1.23e-5	Renal function-related traits (BUN);
THYM	cis	rs10751667	0.961	rs6597953	chr11:991099	G/A	cg01483505	chr11:975446	AP2A2	0.64	4.94	0.45	3.35e-6	Alzheimer's disease (late onset);
THYM	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs1747683	0.966	rs584285	chr10:13366237	C/T	cg00142036	chr10:13388442	SEPHS1	0.3	5.3	0.48	7.38e-7	IgG glycosylation;
THYM	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.14e-7	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg26384229	chr12:38710491	ALG10B	-0.73	-6.06	-0.53	2.67e-8	Morning vs. evening chronotype;
THYM	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg24503407	chr1:205819492	PM20D1	0.89	8.11	0.64	1.75e-12	Menarche (age at onset);
THYM	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg26752003	chr8:145688521	CYHR1	0.68	5.92	0.52	5.14e-8	Age at first birth;
THYM	cis	rs7772486	0.875	rs9403770	chr6:146423334	C/T	cg23711669	chr6:146136114	FBXO30	0.97	10.56	0.73	1.05e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg16006841	chr5:176797999	RGS14	0.53	6.38	0.55	6.52e-9	Hemoglobin concentration;Hematocrit;
THYM	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg06627557	chr7:32535165	LSM5;AVL9	1.03	10.73	0.74	4.6e-18	Cognitive ability;
THYM	cis	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg00495681	chr13:53174319	NA	0.63	5.75	0.51	1.07e-7	Lewy body disease;
THYM	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.69	-4.59	-0.43	1.36e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1065656	0.553	rs344360	chr16:1839221	T/C	cg14074117	chr16:1909714	C16orf73	0.6	4.59	0.43	1.37e-5	Insulin-like growth factors;
THYM	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg05754148	chr16:3507555	NAT15	0.88	7.96	0.63	3.57e-12	Tuberculosis;
THYM	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg16586182	chr3:47516702	SCAP	-0.67	-5.62	-0.5	1.9e-7	Colorectal cancer;
THYM	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06873352	chr17:61820015	STRADA	0.54	5.45	0.49	3.9e-7	Height;
THYM	cis	rs4919687	0.550	rs10748828	chr10:104456794	C/T	cg15744005	chr10:104629667	AS3MT	0.57	4.48	0.42	2.05e-5	Colorectal cancer;
THYM	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg00450029	chr8:599525	NA	-0.94	-4.67	-0.43	9.83e-6	IgG glycosylation;
THYM	cis	rs2806561	0.695	rs67238799	chr1:23335012	G/A	cg12483005	chr1:23474871	LUZP1	0.53	5.42	0.49	4.43e-7	Height;
THYM	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg05373962	chr22:49881684	NA	-0.66	-6.02	-0.53	3.27e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs910187	0.605	rs62201430	chr20:45808227	A/T	cg27589058	chr20:45804311	EYA2	-0.68	-6.03	-0.53	3.15e-8	Migraine;
THYM	cis	rs995000	0.931	rs12029068	chr1:62904295	C/T	cg06896770	chr1:63153194	DOCK7	0.92	7.12	0.59	2.07e-10	Triglyceride levels;
THYM	cis	rs3947	0.951	rs1692817	chr8:11704719	C/A	cg26752888	chr8:11627280	NEIL2	-0.71	-4.69	-0.43	9.24e-6	Blood protein levels;
THYM	cis	rs9563576	0.778	rs12866015	chr13:58653365	C/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.6	4.5	0.42	1.9e-5	Body mass index;
THYM	cis	rs67072384	1.000	rs7120700	chr11:72444676	A/G	cg01380194	chr11:72452482	ARAP1	-0.81	-4.57	-0.42	1.48e-5	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs67385638	1.000	rs10837697	chr11:5281018	G/C	cg12559170	chr11:5275217	HBG2	0.91	9.46	0.7	2.35e-15	Hemoglobin levels;
THYM	cis	rs10463554	0.963	rs62364875	chr5:102392190	T/C	cg23492399	chr5:102201601	PAM	-0.68	-5.13	-0.47	1.56e-6	Parkinson's disease;
THYM	cis	rs9814567	1.000	rs4535272	chr3:134299916	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.8	7.81	0.63	7.42e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs4940575	0.679	rs12606418	chr18:60833672	G/T	cg25271770	chr18:61057090	VPS4B	0.78	4.68	0.43	9.43e-6	Breast cancer;
THYM	cis	rs4851266	0.898	rs2309812	chr2:100869702	C/T	cg08017756	chr2:100939284	LONRF2	-0.56	-4.45	-0.42	2.31e-5	Educational attainment;
THYM	cis	rs924712	0.677	rs239781	chr6:54754292	C/T	cg04690482	chr6:54711388	FAM83B	0.45	5.37	0.48	5.54e-7	Breast cancer;
THYM	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg27490568	chr2:178487706	NA	0.61	5.63	0.5	1.82e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4918072	0.637	rs61861138	chr10:105613417	G/A	cg11005552	chr10:105648138	OBFC1	0.66	5.03	0.46	2.3e-6	Coronary artery disease;
THYM	cis	rs514406	0.505	rs431459	chr1:53183230	T/G	cg08859206	chr1:53392774	SCP2	-0.5	-5.23	-0.47	1e-6	Monocyte count;
THYM	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg10760299	chr15:45669010	GATM	0.86	6.7	0.57	1.49e-9	Homoarginine levels;
THYM	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg24818145	chr4:99064322	C4orf37	0.9	7.36	0.6	6.5e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs698813	0.637	rs7579841	chr2:44498887	T/A	cg04920474	chr2:44395004	PPM1B	0.56	4.46	0.42	2.23e-5	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
THYM	cis	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs7107174	0.901	rs2450139	chr11:77924544	G/A	cg19901956	chr11:77921274	USP35	-0.67	-5.07	-0.46	1.95e-6	Testicular germ cell tumor;
THYM	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08219700	chr8:58056026	NA	0.68	4.87	0.45	4.41e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs250677	0.522	rs10042466	chr5:148393634	T/C	cg18129178	chr5:148520854	ABLIM3	-0.71	-5.31	-0.48	7.05e-7	Breast cancer;
THYM	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs425277	0.917	rs78395918	chr1:2045876	G/A	cg23803603	chr1:2058230	PRKCZ	0.68	5.24	0.47	9.67e-7	Height;
THYM	cis	rs7927771	0.801	rs12798028	chr11:47604639	C/T	cg18512352	chr11:47633146	NA	-0.46	-5.56	-0.5	2.48e-7	Subjective well-being;
THYM	cis	rs2991971	0.934	rs2991974	chr1:46020654	A/G	cg15605315	chr1:45957053	TESK2	0.65	5.12	0.46	1.6e-6	High light scatter reticulocyte count;
THYM	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg16586182	chr3:47516702	SCAP	0.65	5.61	0.5	1.99e-7	Colorectal cancer;
THYM	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	trans	rs877282	0.891	rs11599917	chr10:762288	G/A	cg22713356	chr15:30763199	NA	1.37	10.07	0.72	1.18e-16	Uric acid levels;
THYM	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg08859206	chr1:53392774	SCP2	-0.74	-8.59	-0.66	1.69e-13	Monocyte count;
THYM	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg15693483	chr7:1102177	C7orf50	0.54	6.26	0.54	1.1e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg17775962	chr7:1200435	ZFAND2A	0.42	4.91	0.45	3.81e-6	Longevity;Endometriosis;
THYM	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg27394845	chr17:28928406	LRRC37B2	0.91	4.58	0.42	1.44e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg07936489	chr17:37558343	FBXL20	-0.64	-4.71	-0.43	8.56e-6	Asthma;
THYM	cis	rs11718455	0.883	rs6795366	chr3:44005735	C/T	cg08738300	chr3:44038990	NA	0.65	4.54	0.42	1.64e-5	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg20283391	chr11:68216788	NA	-0.57	-4.49	-0.42	2.03e-5	Total body bone mineral density;
THYM	cis	rs11077998	0.935	rs9893826	chr17:80511128	C/T	cg11779900	chr17:80519722	FOXK2	-0.53	-4.55	-0.42	1.56e-5	Reticulocyte fraction of red cells;
THYM	cis	rs36051895	0.632	rs10118930	chr9:5148278	C/T	cg02405213	chr9:5042618	JAK2	-1.04	-11.65	-0.77	5.32e-20	Pediatric autoimmune diseases;
THYM	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg02187348	chr16:89574699	SPG7	0.72	6.11	0.53	2.19e-8	Multiple myeloma (IgH translocation);
THYM	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs1967309	0.625	rs730242	chr16:4070433	C/T	cg00061520	chr16:4070371	ADCY9	0.48	4.86	0.45	4.65e-6	Response to Dalcetrapib treatment in acute coronary syndrome;
THYM	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg20476274	chr7:133979776	SLC35B4	0.66	4.58	0.43	1.43e-5	Mean platelet volume;
THYM	cis	rs939658	0.776	rs869672	chr15:79430860	G/A	cg17916960	chr15:79447300	NA	-0.73	-8.4	-0.65	4.34e-13	Refractive error;
THYM	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg03433033	chr1:76189801	ACADM	-0.65	-6.0	-0.52	3.54e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs875971	0.638	rs35986979	chr7:66088990	G/A	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs2404618	0.624	rs7012381	chr8:1475357	C/T	cg13402656	chr8:1511478	DLGAP2	-0.72	-6.66	-0.56	1.73e-9	Lung cancer;
THYM	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg12564285	chr5:131593104	PDLIM4	0.43	4.67	0.43	9.75e-6	Blood metabolite levels;
THYM	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg22117172	chr7:91764530	CYP51A1	0.39	4.49	0.42	2.02e-5	Breast cancer;
THYM	cis	rs3126085	0.935	rs10749669	chr1:152177289	A/C	cg10321714	chr1:152280068	FLG	-0.68	-5.11	-0.46	1.69e-6	Atopic dermatitis;
THYM	cis	rs2279817	0.955	rs2270978	chr1:18023365	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.75	4.73	0.44	7.76e-6	Neuroticism;
THYM	cis	rs11677370	0.603	rs10178523	chr2:3854169	G/A	cg17052675	chr2:3827356	NA	-0.7	-6.61	-0.56	2.24e-9	Type 2 diabetes;
THYM	cis	rs1278352	1.000	rs1278352	chr10:127773376	C/T	cg08295661	chr10:127769903	ADAM12	0.47	5.16	0.47	1.35e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.15	-0.47	1.4e-6	Total cholesterol levels;
THYM	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg12908607	chr1:44402522	ARTN	-0.5	-4.64	-0.43	1.1e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg17747265	chr1:1875780	NA	0.75	8.47	0.66	3.06e-13	Body mass index;
THYM	cis	rs3087591	1.000	rs2905870	chr17:29521833	G/A	cg24425628	chr17:29625626	OMG;NF1	0.61	5.23	0.47	1.02e-6	Hip circumference;
THYM	cis	rs11711311	1.000	rs13073843	chr3:113449150	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.27	-0.48	8.41e-7	IgG glycosylation;
THYM	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg02725872	chr8:58115012	NA	1.09	7.08	0.59	2.49e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs4383453	0.539	rs3845913	chr3:123100606	T/A	cg04890266	chr3:123102914	ADCY5	0.82	8.01	0.63	2.85e-12	Gestational age at birth (maternal effect);
THYM	trans	rs8073060	0.544	rs225249	chr17:33942540	T/C	cg19694781	chr19:47549865	TMEM160	-1.05	-9.1	-0.68	1.42e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7196129	0.966	rs12598978	chr16:30482540	A/C	cg24033122	chr16:30485383	ITGAL	0.4	4.91	0.45	3.78e-6	Monocyte count;
THYM	cis	rs7772486	0.875	rs1331640	chr6:146427250	G/A	cg05347473	chr6:146136440	FBXO30	0.6	4.87	0.45	4.45e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6570726	0.935	rs416987	chr6:145847005	G/C	cg23711669	chr6:146136114	FBXO30	0.9	9.23	0.69	7.15e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3768617	0.510	rs20563	chr1:183085755	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.59	-4.92	-0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs2985684	1.000	rs2224949	chr14:50096560	A/G	cg02151108	chr14:50098012	C14orf104	0.67	5.33	0.48	6.48e-7	Carotid intima media thickness;
THYM	cis	rs7772486	0.659	rs9376957	chr6:146011064	C/T	cg13319975	chr6:146136371	FBXO30	0.67	5.47	0.49	3.57e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg11279151	chr3:101281821	RG9MTD1	0.67	4.93	0.45	3.42e-6	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4919687	0.550	rs12780827	chr10:104467954	T/C	cg15744005	chr10:104629667	AS3MT	-0.59	-4.65	-0.43	1.07e-5	Colorectal cancer;
THYM	cis	rs4731207	0.698	rs4728009	chr7:124470961	A/C	cg05285228	chr7:124571219	POT1	-0.65	-5.1	-0.46	1.73e-6	Cutaneous malignant melanoma;
THYM	cis	rs4363385	0.818	rs1334850	chr1:153004519	G/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	trans	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg10856724	chr12:34555212	NA	-0.9	-8.08	-0.64	2.05e-12	Bladder cancer;
THYM	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg05340658	chr4:99064831	C4orf37	0.55	4.73	0.44	7.86e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7186908	0.711	rs9923344	chr16:72190653	T/C	cg23815491	chr16:72088622	HP	0.84	6.74	0.57	1.2e-9	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs72828912	0.731	rs9348628	chr6:24066519	C/T	cg26336265	chr6:25042955	NA	-0.85	-5.33	-0.48	6.54e-7	Squamous cell lung carcinoma;
THYM	cis	rs2731664	0.792	rs335467	chr5:176890642	A/G	cg14098951	chr5:176875120	PRR7	0.57	5.17	0.47	1.31e-6	Intelligence (multi-trait analysis);
THYM	cis	rs713587	0.525	rs11687089	chr2:25082926	T/C	cg01884057	chr2:25150051	NA	0.64	5.98	0.52	3.82e-8	Body mass index in non-asthmatics;
THYM	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg08999081	chr20:33150536	PIGU	-0.77	-6.95	-0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs11779988	0.545	rs454692	chr8:17789298	T/C	cg01800426	chr8:17659068	MTUS1	-0.76	-5.32	-0.48	6.94e-7	Breast cancer;
THYM	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.43	0.7	2.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7584330	0.518	rs78358347	chr2:238413566	C/T	cg08992911	chr2:238395768	MLPH	1.16	6.68	0.57	1.6e-9	Prostate cancer;
THYM	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg17063962	chr7:91808500	NA	-1.13	-12.74	-0.79	2.8e-22	Breast cancer;
THYM	cis	rs34638657	0.702	rs11866709	chr16:82201017	A/G	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.11	-0.64	1.73e-12	Lung adenocarcinoma;
THYM	cis	rs7688540	0.723	rs17521834	chr4:225449	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	-0.72	-4.88	-0.45	4.35e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs7107174	0.892	rs10899482	chr11:78060081	A/C	cg19901956	chr11:77921274	USP35	-0.65	-5.4	-0.48	5.01e-7	Testicular germ cell tumor;
THYM	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.29	-9.45	-0.7	2.43e-15	Gut microbiome composition (summer);
THYM	cis	rs6980334	0.911	rs2166188	chr7:137773563	A/C	cg11874123	chr7:137028198	PTN	0.66	5.04	0.46	2.2e-6	Blood metabolite ratios;
THYM	cis	rs10089	1.000	rs72794401	chr5:127517626	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.94	5.66	0.5	1.6e-7	Ileal carcinoids;
THYM	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg08048268	chr3:133502702	NA	-0.66	-5.59	-0.5	2.13e-7	Iron status biomarkers;
THYM	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg24675658	chr1:53192096	ZYG11B	-0.77	-6.92	-0.58	5.37e-10	Monocyte count;
THYM	cis	rs4631830	0.863	rs10826125	chr10:51530505	G/A	cg16070123	chr10:51489643	NA	-0.49	-4.48	-0.42	2.1e-5	Prostate-specific antigen levels;
THYM	cis	rs2455799	0.613	rs13071303	chr3:15958203	C/T	cg16303742	chr3:15540471	COLQ	-0.54	-5.37	-0.48	5.67e-7	Mean platelet volume;
THYM	cis	rs6754311	0.773	rs309178	chr2:136611624	C/T	cg23851026	chr2:136556271	LCT	-0.53	-5.14	-0.47	1.48e-6	Mosquito bite size;
THYM	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg16049864	chr8:95962084	TP53INP1	-0.82	-7.42	-0.61	4.99e-11	Type 2 diabetes;
THYM	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg27534772	chr1:16042836	PLEKHM2	0.53	5.67	0.5	1.53e-7	Systolic blood pressure;
THYM	cis	rs2915864	0.861	rs2961719	chr5:141580020	G/A	cg00542992	chr5:141595654	NA	0.62	4.65	0.43	1.06e-5	Facial morphology (factor 20);
THYM	cis	rs35883536	0.545	rs115017855	chr1:101101830	T/A	cg09408571	chr1:101003634	GPR88	0.43	5.16	0.47	1.34e-6	Monocyte count;
THYM	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11644478	chr21:40555479	PSMG1	-0.58	-4.76	-0.44	6.94e-6	Menarche (age at onset);
THYM	cis	rs7681423	1.000	rs12644950	chr4:155537321	G/A	cg20735720	chr4:155535218	FGG	-0.74	-5.81	-0.51	8.33e-8	Fibrinogen;
THYM	cis	rs9560113	0.509	rs4773390	chr13:112208904	G/A	cg15979348	chr13:112237479	NA	0.54	4.8	0.44	5.8e-6	Menarche (age at onset);
THYM	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.81	6.04	0.53	3e-8	Cognitive test performance;
THYM	cis	rs7107174	0.579	rs1981405	chr11:77976208	C/T	cg19901956	chr11:77921274	USP35	-0.8	-5.38	-0.48	5.36e-7	Testicular germ cell tumor;
THYM	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.0	0.63	2.98e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4790333	0.529	rs3101409	chr17:2258147	C/T	cg02569219	chr17:2266849	SGSM2	0.71	5.94	0.52	4.73e-8	Proinsulin levels;
THYM	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.02	6.67	0.56	1.66e-9	Platelet count;
THYM	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg03806693	chr22:41940476	POLR3H	-0.84	-6.41	-0.55	5.51e-9	Neuroticism;
THYM	cis	rs7586879	0.796	rs10187348	chr2:25078415	G/C	cg01884057	chr2:25150051	NA	0.51	4.73	0.44	7.92e-6	Body mass index;
THYM	cis	rs4919694	1.000	rs12258551	chr10:104767892	C/G	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg21798802	chr22:38057573	PDXP	-0.48	-5.51	-0.49	3.07e-7	Fat distribution (HIV);
THYM	cis	rs7250872	0.647	rs12976128	chr19:1817113	A/C	cg10370574	chr19:1840461	REXO1	-0.97	-8.34	-0.65	5.79e-13	Bipolar disorder;
THYM	cis	rs4523957	0.614	rs2984941	chr17:2031543	A/G	cg16513277	chr17:2031491	SMG6	-0.96	-8.72	-0.67	9.17e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs921968	0.678	rs2230115	chr2:219509618	C/A	cg02176678	chr2:219576539	TTLL4	0.6	5.84	0.51	7.3e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs28595532	0.920	rs116550416	chr4:119753467	A/C	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs916888	0.647	rs199519	chr17:44853924	G/A	cg15921436	chr17:44337874	NA	-0.74	-5.96	-0.52	4.26e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4975709	0.531	rs6884044	chr5:1871599	C/T	cg19770292	chr5:1868693	NA	0.52	4.96	0.45	3.03e-6	Cardiovascular disease risk factors;
THYM	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg03676636	chr4:99064102	C4orf37	0.38	5.36	0.48	5.76e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2276498	0.751	rs6127063	chr20:52640570	T/G	cg23682609	chr20:52687365	BCAS1	0.56	4.57	0.42	1.45e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg16558253	chr16:72132732	DHX38	-0.59	-5.05	-0.46	2.17e-6	Fibrinogen levels;
THYM	cis	rs25645	0.792	rs8077456	chr17:38128765	C/G	cg02059268	chr17:38576278	NA	0.45	4.7	0.43	8.62e-6	Myeloid white cell count;
THYM	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg12826209	chr6:26865740	GUSBL1	1.04	5.69	0.5	1.37e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6087990	0.965	rs6058869	chr20:31348750	C/T	cg13636640	chr20:31349939	DNMT3B	0.96	10.76	0.74	4.02e-18	Ulcerative colitis;
THYM	cis	rs7695732	0.572	rs2704573	chr4:89896413	T/C	cg17769793	chr4:89976368	FAM13A	-0.48	-5.23	-0.47	1.02e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs10504073	0.647	rs9643395	chr8:50014500	A/C	cg00325661	chr8:49890786	NA	0.86	7.69	0.62	1.35e-11	Blood metabolite ratios;
THYM	cis	rs7578361	0.918	rs6751489	chr2:150378346	C/T	cg17961725	chr2:150454027	NA	-0.77	-5.72	-0.51	1.25e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg10802521	chr3:52805072	NEK4	-0.73	-6.35	-0.55	7.48e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9796	0.870	rs3214068	chr15:41313064	C/G	cg21153102	chr15:41252147	NA	0.71	6.51	0.56	3.61e-9	Menopause (age at onset);
THYM	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg02915803	chr1:1606292	LOC728661;CDK11B	0.63	5.32	0.48	7.01e-7	Body mass index;
THYM	cis	rs4595586	0.545	rs1562728	chr12:39405740	C/T	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg02734326	chr4:10020555	SLC2A9	0.75	6.26	0.54	1.1e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs6462411	0.818	rs2057919	chr7:3909875	T/C	cg14907788	chr19:2555976	GNG7	0.69	7.12	0.59	2.06e-10	Quantitative traits;
THYM	cis	rs8033133	0.957	rs3742952	chr15:25351026	A/G	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.72	-5.3	-0.48	7.6e-7	Blood osmolality (transformed sodium);
THYM	cis	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg21231944	chr12:82153410	PPFIA2	-0.61	-4.45	-0.42	2.33e-5	Resting heart rate;
THYM	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg26384229	chr12:38710491	ALG10B	0.96	7.46	0.61	3.98e-11	Bladder cancer;
THYM	cis	rs7100689	0.784	rs7895042	chr10:82095276	G/A	cg01528321	chr10:82214614	TSPAN14	1.02	7.84	0.63	6.52e-12	Post bronchodilator FEV1;
THYM	cis	rs56775891	1.000	rs4799088	chr18:77573548	A/G	cg25357022	chr18:77495084	CTDP1	-0.64	-4.5	-0.42	1.96e-5	Schizophrenia;
THYM	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg06627628	chr2:24431161	ITSN2	0.77	5.38	0.48	5.26e-7	Asthma;
THYM	cis	rs7578361	0.918	rs6714859	chr2:150378299	T/G	cg17961725	chr2:150454027	NA	-0.77	-5.67	-0.5	1.56e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg06784218	chr1:46089804	CCDC17	-0.29	-4.54	-0.42	1.65e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg07636037	chr3:49044803	WDR6	0.82	5.89	0.52	5.91e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs1670533	1.000	rs6822863	chr4:1055606	G/A	cg27284194	chr4:1044797	NA	0.62	4.73	0.44	7.81e-6	Recombination rate (females);
THYM	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg14820908	chr5:178986412	RUFY1	0.54	5.64	0.5	1.72e-7	Lung cancer;
THYM	cis	rs4523957	0.651	rs4790316	chr17:2074977	T/C	cg16513277	chr17:2031491	SMG6	-0.94	-8.81	-0.67	5.81e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg08431931	chr22:42394659	WBP2NL	0.71	5.07	0.46	1.98e-6	Birth weight;
THYM	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg15704280	chr7:45808275	SEPT13	1.04	12.01	0.78	9.15e-21	Height;
THYM	cis	rs34638657	0.797	rs11645045	chr16:82202137	G/A	cg09439754	chr16:82129088	HSD17B2	-0.64	-6.32	-0.54	8.35e-9	Lung adenocarcinoma;
THYM	cis	rs9914544	0.524	rs7209853	chr17:18798600	G/A	cg26378065	chr17:18585709	ZNF286B	0.58	4.65	0.43	1.05e-5	Educational attainment (years of education);
THYM	cis	rs11711311	0.824	rs35341324	chr3:113351719	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.05	-0.46	2.11e-6	IgG glycosylation;
THYM	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg11266682	chr4:10021025	SLC2A9	-0.52	-6.3	-0.54	9.06e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9527	0.544	rs3781280	chr10:104863843	T/G	cg04362960	chr10:104952993	NT5C2	0.63	4.72	0.44	7.96e-6	Arsenic metabolism;
THYM	cis	rs12368653	0.607	rs7966795	chr12:58031413	C/A	cg12615879	chr12:58013172	SLC26A10	0.61	6.31	0.54	8.87e-9	Multiple sclerosis;
THYM	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg11366901	chr6:160182831	ACAT2	1.08	9.54	0.7	1.56e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs3804749	0.966	rs4677875	chr3:122841062	G/A	cg26084141	chr3:122786895	PDIA5	0.45	4.51	0.42	1.84e-5	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg26038318	chr20:34205095	SPAG4	0.59	4.68	0.43	9.66e-6	Total cholesterol levels;
THYM	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7236492	0.688	rs9709477	chr18:77202786	C/A	cg15644404	chr18:77186268	NFATC1	-1.05	-4.96	-0.45	3.04e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg27532560	chr4:187881888	NA	-0.95	-11.61	-0.77	6.5e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2522056	1.000	rs11242113	chr5:131777234	G/A	cg24060327	chr5:131705240	SLC22A5	0.74	4.79	0.44	6.25e-6	Lymphocyte counts;Fibrinogen;
THYM	cis	rs4589258	0.933	rs1792604	chr11:90437329	G/T	cg26138821	chr11:89956704	CHORDC1	-0.72	-6.06	-0.53	2.78e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2018683	0.707	rs4719961	chr7:28969513	C/T	cg27487796	chr7:28973253	NA	-0.25	-4.47	-0.42	2.16e-5	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
THYM	cis	rs6835098	0.924	rs7672108	chr4:174165126	A/G	cg08422745	chr4:174089978	GALNT7	0.98	8.61	0.66	1.54e-13	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs6842789	0.510	rs1996580	chr4:124871513	A/G	cg01723706	chr4:124814442	LOC285419	-0.74	-4.69	-0.43	9.17e-6	Neuroticism;
THYM	cis	rs7943203	0.568	rs597788	chr11:108256859	C/T	cg04873221	chr11:107992290	ACAT1	-0.7	-4.65	-0.43	1.08e-5	Red blood cell count;Mean corpuscular volume;
THYM	cis	rs4638749	0.501	rs2378096	chr2:108765031	A/G	cg25838818	chr2:108905173	SULT1C2	-0.49	-4.88	-0.45	4.3e-6	Blood pressure;
THYM	cis	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg19847130	chr8:10466454	RP1L1	0.5	4.56	0.42	1.55e-5	Neuroticism;
THYM	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg07936489	chr17:37558343	FBXL20	0.81	5.85	0.51	6.81e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg07341220	chr16:1583899	IFT140;TMEM204	-0.72	-6.12	-0.53	2.09e-8	Coronary artery disease;
THYM	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg24250549	chr1:154909240	PMVK	0.66	5.03	0.46	2.27e-6	Prostate cancer;
THYM	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.89	9.22	0.69	7.51e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7830933	0.955	rs7002330	chr8:23590900	A/G	cg04349084	chr8:23602677	NA	0.58	6.09	0.53	2.42e-8	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg20387954	chr3:183756860	HTR3D	0.54	5.21	0.47	1.09e-6	Anterior chamber depth;
THYM	cis	rs7127900	0.851	rs10743176	chr11:2225626	T/C	cg25635251	chr11:2234043	NA	0.79	5.08	0.46	1.9e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs2070433	0.752	rs11701058	chr21:47776382	T/C	cg12379764	chr21:47803548	PCNT	0.84	5.03	0.46	2.35e-6	Lymphocyte counts;
THYM	cis	rs7927771	0.524	rs7129797	chr11:47667167	G/C	cg18512352	chr11:47633146	NA	0.41	4.54	0.42	1.63e-5	Subjective well-being;
THYM	cis	rs2229238	0.911	rs41313910	chr1:154514203	C/G	cg21262032	chr1:154437693	IL6R	-0.64	-5.79	-0.51	8.9e-8	Coronary heart disease;
THYM	cis	rs3741151	0.773	rs73544710	chr11:73162273	A/G	cg12959048	chr11:73096162	RELT	-0.53	-5.08	-0.46	1.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs818427	0.737	rs411356	chr5:112172219	G/A	cg04614008	chr5:112630677	MCC	-0.63	-4.46	-0.42	2.29e-5	Total body bone mineral density;
THYM	cis	rs826838	0.967	rs7965656	chr12:38807244	G/A	cg26384229	chr12:38710491	ALG10B	1.12	10.37	0.73	2.73e-17	Heart rate;
THYM	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg16423285	chr20:60520624	NA	1.24	10.04	0.72	1.39e-16	Obesity-related traits;
THYM	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg12373951	chr3:133503437	NA	0.56	6.17	0.53	1.69e-8	Iron status biomarkers;
THYM	cis	rs10752881	1.000	rs10797810	chr1:182980950	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs6809651	0.524	rs10937240	chr3:185802823	C/T	cg00760338	chr3:185826511	ETV5	-0.89	-7.0	-0.58	3.55e-10	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
THYM	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03517284	chr6:25882590	NA	0.87	7.1	0.59	2.24e-10	Intelligence (multi-trait analysis);
THYM	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg12963246	chr6:28129442	ZNF389	0.57	5.06	0.46	2.09e-6	Cardiac Troponin-T levels;
THYM	cis	rs2040771	0.770	rs2518840	chr22:19255856	A/C	cg02655711	chr22:19163373	SLC25A1	0.58	6.04	0.53	2.93e-8	Metabolite levels (small molecules and protein measures);
THYM	cis	rs2694917	0.631	rs2657879	chr12:56865338	C/T	cg03677924	chr12:56849618	MIP	0.57	4.47	0.42	2.17e-5	Blood metabolite ratios;
THYM	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg14829155	chr15:31115871	NA	-0.53	-5.08	-0.46	1.86e-6	Huntington's disease progression;
THYM	cis	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg24675056	chr1:15929824	NA	0.73	5.86	0.52	6.71e-8	Systolic blood pressure;
THYM	cis	rs2131877	0.871	rs2279633	chr3:194869225	G/A	cg21937377	chr3:194868750	C3orf21	0.39	4.53	0.42	1.69e-5	Non-small cell lung cancer;
THYM	trans	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg07211511	chr3:129823064	LOC729375	-1.27	-10.36	-0.73	2.8e-17	Blood pressure (smoking interaction);
THYM	cis	rs6510489	1.000	rs62111717	chr19:35978567	T/C	cg19537317	chr19:36337105	NPHS1	-0.55	-4.47	-0.42	2.13e-5	Bipolar disorder;
THYM	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs2747539	0.920	rs4911134	chr20:32452215	C/T	cg06304546	chr20:32448765	NA	-0.75	-4.62	-0.43	1.22e-5	Dysphagia;
THYM	cis	rs55728055	0.661	rs62237857	chr22:32039311	G/A	cg10537193	chr22:32026975	PISD	-0.69	-4.75	-0.44	7.11e-6	Age-related hearing impairment;
THYM	cis	rs11771526	0.901	rs1530823	chr7:32311420	G/T	cg27532318	chr7:32358331	NA	-0.75	-4.95	-0.45	3.21e-6	Body mass index;
THYM	cis	rs6539288	0.745	rs2041895	chr12:107350088	C/G	cg26297688	chr12:107349093	C12orf23	-0.51	-5.91	-0.52	5.42e-8	Total body bone mineral density;
THYM	cis	rs981844	0.775	rs1020704	chr4:154736494	C/T	cg09973105	chr4:154681532	RNF175	-0.65	-5.4	-0.48	4.88e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg03180552	chr7:157981849	PTPRN2	0.56	4.92	0.45	3.7e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7071206	0.898	rs28706743	chr10:79394329	T/G	cg07817648	chr10:79422355	NA	-0.93	-7.44	-0.61	4.5e-11	Bone mineral density;
THYM	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg14298792	chr15:30685198	CHRFAM7A	0.75	4.95	0.45	3.17e-6	Huntington's disease progression;
THYM	cis	rs2820651	0.614	rs56368317	chr10:1490983	G/A	cg27404824	chr10:1454848	ADARB2	0.87	4.72	0.44	8.03e-6	Migraine with aura;
THYM	cis	rs6032067	0.537	rs6032033	chr20:43795081	G/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-6.26	-0.54	1.12e-8	Blood protein levels;
THYM	cis	rs1007190	0.881	rs12937256	chr17:42981499	C/T	cg15406952	chr17:42872593	NA	0.79	5.46	0.49	3.83e-7	DNA methylation (variation);
THYM	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg16558253	chr16:72132732	DHX38	-0.57	-4.83	-0.44	5.29e-6	Fibrinogen levels;
THYM	cis	rs995000	0.965	rs10889334	chr1:62957199	C/G	cg06896770	chr1:63153194	DOCK7	0.96	7.88	0.63	5.37e-12	Triglyceride levels;
THYM	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg03929089	chr4:120376271	NA	-0.99	-12.81	-0.8	2.07e-22	Height;
THYM	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg03476357	chr21:30257390	N6AMT1	0.64	4.97	0.45	2.97e-6	Cognitive test performance;
THYM	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg27170947	chr2:26402098	FAM59B	-0.83	-6.86	-0.58	6.94e-10	Gut microbiome composition (summer);
THYM	cis	rs6964587	0.692	rs4729021	chr7:91758422	C/A	cg17063962	chr7:91808500	NA	1.05	9.23	0.69	7.33e-15	Breast cancer;
THYM	cis	rs7246657	0.882	rs10422667	chr19:37937876	T/C	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg03684893	chr10:554711	DIP2C	0.63	5.33	0.48	6.72e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs713587	0.521	rs35177510	chr2:25089594	C/A	cg15423357	chr2:25149977	NA	0.61	5.85	0.51	6.83e-8	Body mass index in non-asthmatics;
THYM	cis	rs7781977	0.782	rs9886239	chr7:50336551	A/C	cg01139861	chr7:50343298	IKZF1	0.68	6.4	0.55	5.76e-9	IgG glycosylation;
THYM	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg24675056	chr1:15929824	NA	0.73	5.89	0.52	5.95e-8	Systolic blood pressure;
THYM	cis	rs9926296	0.632	rs72807526	chr16:89775946	A/G	cg01097406	chr16:89675127	NA	0.72	6.34	0.55	7.82e-9	Vitiligo;
THYM	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg03161606	chr19:29218774	NA	0.87	7.71	0.62	1.23e-11	Methadone dose in opioid dependence;
THYM	cis	rs9902453	0.967	rs6505155	chr17:28372783	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs9902453	0.933	rs8074028	chr17:28461687	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.83	0.44	5.26e-6	Coffee consumption (cups per day);
THYM	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg08017756	chr2:100939284	LONRF2	-0.71	-7.37	-0.6	6.18e-11	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.641	rs34622539	chr20:43756548	A/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.67	-5.94	-0.52	4.77e-8	Blood protein levels;
THYM	cis	rs9394152	0.845	rs4713632	chr6:33472990	G/T	cg13560919	chr6:33536144	NA	0.73	6.26	0.54	1.09e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg13736514	chr6:26305472	NA	0.6	7.44	0.61	4.46e-11	Educational attainment;
THYM	cis	rs4595586	0.505	rs12827136	chr12:39412790	C/T	cg26384229	chr12:38710491	ALG10B	0.7	5.38	0.48	5.32e-7	Morning vs. evening chronotype;
THYM	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg14972814	chr11:95582409	MTMR2	-0.64	-5.4	-0.48	4.89e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4234284	0.556	rs7650549	chr3:126968288	C/T	cg27326032	chr3:127006922	NA	-0.82	-5.37	-0.48	5.46e-7	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel);
THYM	cis	rs17331151	0.505	rs71299613	chr3:52698805	G/A	cg17372223	chr3:52568218	NT5DC2	0.6	4.7	0.43	8.8e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs3925075	1.000	rs11859274	chr16:31361059	C/T	cg02846316	chr16:31340340	ITGAM	0.56	5.87	0.52	6.33e-8	IgA nephropathy;
THYM	cis	rs362272	0.524	rs2857982	chr4:3358665	G/A	cg22655196	chr4:3374909	RGS12	0.65	8.19	0.64	1.17e-12	Serum sulfate level;
THYM	cis	rs28595532	0.920	rs114966881	chr4:119761078	C/G	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12122100	0.651	rs12129691	chr1:146554147	C/T	cg03526459	chr1:146549940	NA	-0.66	-4.49	-0.42	1.97e-5	HIV-1 control;
THYM	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg18681998	chr4:17616180	MED28	0.96	9.17	0.69	9.69e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs13082711	0.871	rs7624790	chr3:27468601	C/A	cg02860705	chr3:27208620	NA	0.69	4.99	0.46	2.75e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs6930083	0.527	rs9470367	chr6:36626932	G/C	cg24425727	chr6:36645648	CDKN1A	0.71	5.83	0.51	7.61e-8	Coronary artery disease;
THYM	cis	rs3820068	0.705	rs4645983	chr1:15850603	G/A	cg05660106	chr1:15850417	CASP9	1.11	9.62	0.7	1.09e-15	Systolic blood pressure;
THYM	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg22764044	chr5:178986830	RUFY1	-0.55	-5.73	-0.51	1.2e-7	Lung cancer;
THYM	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg17279839	chr7:150038598	RARRES2	0.53	5.12	0.47	1.57e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2066819	1.000	rs17118439	chr12:56667604	C/T	cg26714650	chr12:56694279	CS	1.27	6.66	0.56	1.77e-9	Psoriasis vulgaris;
THYM	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg23281280	chr6:28129359	ZNF389	0.61	4.88	0.45	4.21e-6	Depression;
THYM	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg20891558	chr2:74357851	NA	1.17	12.06	0.78	7.44e-21	Gestational age at birth (maternal effect);
THYM	cis	rs4731207	0.596	rs10252579	chr7:124637106	A/T	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs6840360	1.000	rs1366909	chr4:152588421	A/C	cg22705602	chr4:152727874	NA	-0.62	-6.79	-0.57	9.45e-10	Intelligence (multi-trait analysis);
THYM	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18404041	chr3:52824283	ITIH1	0.57	5.76	0.51	1.02e-7	Bipolar disorder;
THYM	cis	rs533123	0.701	rs204054	chr1:29160462	T/C	cg08366446	chr1:29138936	OPRD1	1.11	5.63	0.5	1.84e-7	Schizophrenia;
THYM	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg07606381	chr6:8435919	SLC35B3	0.61	4.46	0.42	2.21e-5	Motion sickness;
THYM	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg15744005	chr10:104629667	AS3MT	0.91	9.71	0.71	6.97e-16	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs6722750	0.818	rs12104940	chr2:64385774	A/G	cg22352474	chr2:64371530	PELI1	0.74	6.53	0.56	3.2e-9	Neuroticism;
THYM	cis	rs6430585	0.583	rs76097170	chr2:136593498	C/T	cg07169764	chr2:136633963	MCM6	1.11	12.18	0.78	4.16e-21	Corneal structure;
THYM	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs4664308	0.935	rs877200	chr2:160903723	G/C	cg03641300	chr2:160917029	PLA2R1	-0.74	-6.81	-0.57	8.93e-10	Idiopathic membranous nephropathy;
THYM	cis	rs12282928	1.000	rs11039657	chr11:48320979	A/G	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg18850127	chr7:39170497	POU6F2	0.6	5.66	0.5	1.57e-7	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.56	-0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg13695892	chr22:41940480	POLR3H	-0.84	-6.22	-0.54	1.34e-8	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs2340727	0.524	rs4656342	chr1:161942491	C/G	ch.1.159725313R	chr1:161458689	NA	0.77	5.32	0.48	6.92e-7	White blood cell count;Hematology traits;
THYM	cis	rs2997447	0.668	rs59978831	chr1:26446351	T/A	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs9560113	1.000	rs4773379	chr13:112176088	G/C	cg14154082	chr13:112174009	NA	0.86	8.0	0.63	2.95e-12	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7940866	0.838	rs10750455	chr11:130800330	C/T	cg12179176	chr11:130786555	SNX19	0.73	5.95	0.52	4.41e-8	Schizophrenia;
THYM	cis	rs4285028	0.747	rs7647351	chr3:121422109	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.84	-7.2	-0.59	1.37e-10	Multiple sclerosis;
THYM	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg21385522	chr1:16154831	NA	0.67	5.62	0.5	1.89e-7	Systolic blood pressure;
THYM	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg10523679	chr1:76189770	ACADM	0.91	9.7	0.71	7.37e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg21028142	chr17:79581711	NPLOC4	-0.64	-6.74	-0.57	1.23e-9	Eye color traits;
THYM	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg17366294	chr4:99064904	C4orf37	0.57	6.82	0.57	8.42e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg23187316	chr7:1099788	C7orf50	0.61	4.7	0.43	8.68e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs28595532	0.920	rs10018977	chr4:119785229	C/T	cg14228332	chr4:119757509	SEC24D	1.3	4.73	0.44	7.91e-6	Cannabis dependence symptom count;
THYM	cis	rs2067615	0.579	rs1922438	chr12:107085171	C/G	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-4.61	-0.43	1.26e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg17105886	chr17:28927953	LRRC37B2	1.32	6.56	0.56	2.79e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg10505658	chr17:80084571	CCDC57	-0.74	-8.13	-0.64	1.59e-12	Life satisfaction;
THYM	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg06481639	chr22:41940642	POLR3H	-0.66	-4.76	-0.44	6.94e-6	Vitiligo;
THYM	cis	rs7246657	0.943	rs10409204	chr19:37917692	G/A	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	8.85	0.67	4.81e-14	Chronic sinus infection;
THYM	cis	rs9910055	0.550	rs850856	chr17:42157739	C/T	cg19774624	chr17:42201019	HDAC5	0.57	4.48	0.42	2.12e-5	Total body bone mineral density;
THYM	cis	rs8170	0.603	rs11086068	chr19:17420165	T/C	cg04749549	chr19:17459798	NA	-0.41	-5.08	-0.46	1.92e-6	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
THYM	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg20291162	chr17:40259547	DHX58	0.69	6.44	0.55	4.96e-9	Fibrinogen levels;
THYM	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg12310025	chr6:25882481	NA	0.69	5.58	0.5	2.3e-7	Blood metabolite levels;
THYM	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9905704	0.881	rs2611774	chr17:56732304	G/A	cg12560992	chr17:57184187	TRIM37	0.67	4.58	0.43	1.41e-5	Testicular germ cell tumor;
THYM	cis	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg24672777	chr11:48374446	OR4C45	-0.98	-6.39	-0.55	6.21e-9	Axial length;
THYM	cis	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs9796	0.689	rs561301	chr15:41444723	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.62	-4.92	-0.45	3.61e-6	Menopause (age at onset);
THYM	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.66	5.28	0.48	8.15e-7	Lung cancer in ever smokers;
THYM	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg15164180	chr2:241846931	NA	0.35	4.73	0.44	7.87e-6	Urinary metabolites;
THYM	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg10295955	chr4:187884368	NA	-1.12	-13.64	-0.81	4.24e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.32e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg05962950	chr11:130786565	SNX19	-0.95	-9.45	-0.7	2.44e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2080501	0.601	rs3803665	chr16:49672520	A/G	cg03087880	chr16:49666012	ZNF423	0.72	9.12	0.68	1.29e-14	IgG glycosylation;
THYM	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.97	8.88	0.67	4.01e-14	Colorectal cancer;
THYM	cis	rs11771526	0.892	rs62457504	chr7:32336097	G/A	cg27532318	chr7:32358331	NA	0.87	5.35	0.48	6.1e-7	Body mass index;
THYM	cis	rs12474201	0.588	rs3768719	chr2:46987935	T/G	cg03034696	chr2:47400023	CALM2	0.28	4.83	0.44	5.28e-6	Height;
THYM	cis	rs17598306	1.000	rs722470	chr7:96581466	C/G	cg23184042	chr7:96615519	DLX6AS	0.61	4.76	0.44	6.82e-6	Radiation response;
THYM	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.52e-7	Heart rate;
THYM	cis	rs60871478	0.685	rs34421533	chr7:816638	A/G	cg10248100	chr7:872053	UNC84A	-0.68	-4.78	-0.44	6.39e-6	Cerebrospinal P-tau181p levels;
THYM	trans	rs10838798	0.523	rs4752907	chr11:48170581	G/A	cg00717180	chr2:96193071	NA	-0.65	-7.15	-0.59	1.81e-10	Height;
THYM	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg00339695	chr16:24857497	SLC5A11	0.7	6.51	0.56	3.46e-9	Intelligence (multi-trait analysis);
THYM	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg18850127	chr7:39170497	POU6F2	0.62	5.85	0.51	7.08e-8	IgG glycosylation;
THYM	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.73	5.4	0.48	4.97e-7	Lung cancer in ever smokers;
THYM	cis	rs916888	0.647	rs199520	chr17:44853872	G/A	cg15921436	chr17:44337874	NA	-0.74	-5.96	-0.52	4.26e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg24578937	chr1:2090814	PRKCZ	0.75	7.56	0.61	2.54e-11	Height;
THYM	cis	rs7923452	0.507	rs215494	chr10:30776589	T/G	cg02070205	chr10:30722105	MAP3K8	-0.58	-4.79	-0.44	6.06e-6	Itch intensity from mosquito bite;
THYM	cis	rs2046867	0.908	rs9811830	chr3:72809591	A/G	cg25664220	chr3:72788482	NA	-0.8	-6.15	-0.53	1.81e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7089973	0.872	rs35628210	chr10:116630031	G/A	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.12	-0.46	1.62e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg09060608	chr5:178986726	RUFY1	-0.59	-6.47	-0.55	4.15e-9	Lung cancer;
THYM	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg14675211	chr2:100938903	LONRF2	0.73	7.21	0.59	1.35e-10	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs116149978	chr4:119761069	A/C	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg26384229	chr12:38710491	ALG10B	1.02	8.22	0.64	1.05e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg20607798	chr8:58055168	NA	1.02	8.29	0.65	7.24e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs4638749	1.000	rs12472278	chr2:108873433	A/T	cg06795125	chr2:108905320	SULT1C2	0.41	5.5	0.49	3.2e-7	Blood pressure;
THYM	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg04990556	chr1:26633338	UBXN11	-0.89	-8.52	-0.66	2.34e-13	Obesity-related traits;
THYM	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg24154853	chr7:158122151	PTPRN2	0.56	5.04	0.46	2.25e-6	Calcium levels;
THYM	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg22875332	chr1:76189707	ACADM	-0.9	-10.62	-0.74	7.94e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg16188243	chr19:2783719	SGTA	0.72	5.11	0.46	1.64e-6	Total cholesterol levels;
THYM	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg08999081	chr20:33150536	PIGU	0.62	5.02	0.46	2.41e-6	Coronary artery disease;
THYM	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg05962950	chr11:130786565	SNX19	0.93	8.84	0.67	5.06e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg07075026	chr17:47091521	IGF2BP1	-0.65	-6.77	-0.57	1.07e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs509477	0.887	rs657018	chr18:32558960	C/T	cg23791764	chr18:32556832	MAPRE2	0.74	5.25	0.47	9.19e-7	Cerebrospinal fluid AB1-42 levels;
THYM	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	15.57	0.85	6.94e-28	Chronic sinus infection;
THYM	cis	rs968451	0.789	rs1569498	chr22:39714704	C/T	cg24268161	chr22:39747459	SYNGR1	-0.72	-5.12	-0.47	1.58e-6	Primary biliary cholangitis;
THYM	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs4474465	0.850	rs4945287	chr11:78226521	C/T	cg19901956	chr11:77921274	USP35	0.62	4.76	0.44	7.04e-6	Alzheimer's disease (survival time);
THYM	cis	rs7149242	0.922	rs9671394	chr14:101159674	C/T	cg18089426	chr14:101175970	NA	-0.58	-5.78	-0.51	9.52e-8	Platelet count;
THYM	cis	rs17641971	0.708	rs4873303	chr8:49922675	G/A	cg00325661	chr8:49890786	NA	0.64	4.74	0.44	7.51e-6	Blood metabolite levels;
THYM	cis	rs796364	0.589	rs55700082	chr2:201135669	G/A	cg17644776	chr2:200775616	C2orf69	-0.74	-4.47	-0.42	2.18e-5	Schizophrenia;
THYM	cis	rs2073300	1.000	rs6048803	chr20:23438889	A/G	cg12062639	chr20:23401060	NAPB	1.33	6.19	0.54	1.5e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg02136620	chr5:178986620	RUFY1	0.6	5.68	0.5	1.49e-7	Lung cancer;
THYM	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.95	0.71	2.08e-16	Colorectal cancer;
THYM	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg10802521	chr3:52805072	NEK4	-0.64	-5.28	-0.48	8.14e-7	Electroencephalogram traits;
THYM	cis	rs7084402	0.967	rs1649026	chr10:60281400	A/G	cg09696939	chr10:60272079	BICC1	0.47	5.54	0.49	2.66e-7	Refractive error;
THYM	cis	rs2933343	0.700	rs1683779	chr3:128642048	A/G	cg11901034	chr3:128598214	ACAD9	-0.69	-5.57	-0.5	2.32e-7	IgG glycosylation;
THYM	cis	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg06521331	chr12:34319734	NA	-1.04	-10.35	-0.73	2.92e-17	Morning vs. evening chronotype;
THYM	cis	rs34638657	0.732	rs12102917	chr16:82196808	G/A	cg09894383	chr16:82067445	HSD17B2	-0.43	-5.17	-0.47	1.32e-6	Lung adenocarcinoma;
THYM	cis	rs11779988	0.545	rs208749	chr8:17777204	T/A	cg01800426	chr8:17659068	MTUS1	-0.71	-4.9	-0.45	4.01e-6	Breast cancer;
THYM	cis	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg06521331	chr12:34319734	NA	-0.73	-5.66	-0.5	1.59e-7	Morning vs. evening chronotype;
THYM	cis	rs6876348	0.516	rs258004	chr5:128319330	T/G	cg02841155	chr5:128301328	SLC27A6	-0.5	-4.89	-0.45	4.18e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg12310025	chr6:25882481	NA	0.69	5.64	0.5	1.74e-7	Schizophrenia;
THYM	cis	rs7762018	0.607	rs79897010	chr6:170042874	C/G	cg19338460	chr6:170058176	WDR27	-1.06	-6.21	-0.54	1.39e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg10523679	chr1:76189770	ACADM	-0.57	-4.68	-0.43	9.33e-6	Daytime sleep phenotypes;
THYM	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg00024416	chr22:24240387	NA	0.79	7.45	0.61	4.36e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs8070740	0.786	rs8067738	chr17:5328661	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.66	5.2	0.47	1.16e-6	Menopause (age at onset);
THYM	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg03929089	chr4:120376271	NA	-1.01	-13.5	-0.81	8.17e-24	Height;
THYM	cis	rs9880211	0.718	rs28631273	chr3:135934711	G/A	cg21827317	chr3:136751795	NA	-0.68	-4.76	-0.44	7e-6	Body mass index;Height;
THYM	cis	rs977987	0.806	rs12051136	chr16:75435731	G/T	cg03315344	chr16:75512273	CHST6	0.77	6.31	0.54	8.75e-9	Dupuytren's disease;
THYM	cis	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg07460842	chr6:66804631	NA	-0.91	-6.25	-0.54	1.14e-8	Exhaled nitric oxide output;
THYM	cis	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs10847980	0.590	rs79798267	chr12:123321819	A/T	cg25930673	chr12:123319894	HIP1R	1.08	5.36	0.48	5.72e-7	Adiponectin levels;
THYM	cis	rs17407555	0.697	rs73212821	chr4:10069451	T/A	cg13000635	chr4:9523653	NA	0.66	4.52	0.42	1.78e-5	Schizophrenia (age at onset);
THYM	cis	rs6430585	0.583	rs4594504	chr2:136625113	A/C	cg04750100	chr2:136595281	LCT	0.57	5.29	0.48	7.86e-7	Corneal structure;
THYM	cis	rs17001868	0.568	rs17001846	chr22:40744053	A/G	cg07138101	chr22:40742427	ADSL	0.94	5.71	0.51	1.3e-7	Mammographic density (dense area);
THYM	cis	rs73086581	0.787	rs73084505	chr20:3856874	C/T	cg02187196	chr20:3869020	PANK2	0.44	5.03	0.46	2.36e-6	Response to antidepressants in depression;
THYM	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg09359103	chr1:154839909	KCNN3	-0.76	-9.72	-0.71	6.56e-16	Prostate cancer;
THYM	trans	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg10856724	chr12:34555212	NA	-0.9	-8.08	-0.64	2.05e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11577318	0.538	rs10902745	chr1:26687070	G/C	cg16664472	chr1:26644822	UBXN11;CD52	0.34	4.95	0.45	3.19e-6	Granulocyte percentage of myeloid white cells;
THYM	cis	rs9914988	0.673	rs9890212	chr17:27169890	G/C	cg20469991	chr17:27169893	C17orf63	-0.83	-5.29	-0.48	7.98e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs986417	0.901	rs6573314	chr14:60972045	C/T	cg27398547	chr14:60952738	C14orf39	1.13	5.43	0.49	4.26e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs2133450	0.712	rs1546236	chr3:7366676	G/A	cg19930620	chr3:7340148	GRM7	-0.48	-4.49	-0.42	1.98e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg22508957	chr16:3507546	NAT15	0.67	9.74	0.71	5.91e-16	Tuberculosis;
THYM	cis	rs9486719	1.000	rs6923212	chr6:97061940	A/G	cg18709589	chr6:96969512	KIAA0776	-0.67	-4.79	-0.44	6.06e-6	Migraine;Coronary artery disease;
THYM	cis	rs7481584	0.624	rs440130	chr11:3051476	A/G	cg03159660	chr11:2078197	NA	0.62	4.6	0.43	1.3e-5	Calcium levels;
THYM	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	trans	rs208520	0.690	rs864314	chr6:66814830	G/T	cg08225398	chr13:45563328	KIAA1704;NUFIP1	1.41	7.9	0.63	4.79e-12	Exhaled nitric oxide output;
THYM	cis	rs35934224	0.783	rs12159647	chr22:19860575	C/T	cg11182965	chr22:19864308	TXNRD2	-0.71	-5.85	-0.51	7.1e-8	Glaucoma (primary open-angle);
THYM	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg21159260	chr5:475889	SLC9A3	0.42	4.89	0.45	4.16e-6	Cystic fibrosis severity;
THYM	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs7107174	0.901	rs2511159	chr11:77974193	G/T	cg02023728	chr11:77925099	USP35	-0.68	-6.37	-0.55	6.69e-9	Testicular germ cell tumor;
THYM	cis	rs8135828	0.770	rs2302141	chr22:29925284	T/C	cg16189954	chr22:29138267	HSCB;CHEK2	0.72	4.62	0.43	1.21e-5	Lipid traits;
THYM	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg02734326	chr4:10020555	SLC2A9	-0.64	-5.9	-0.52	5.59e-8	Bone mineral density;
THYM	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7586879	0.616	rs6726199	chr2:25126328	G/C	cg15423357	chr2:25149977	NA	0.7	7.74	0.62	1.03e-11	Body mass index;
THYM	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	8.67	0.66	1.16e-13	Lung cancer in ever smokers;
THYM	cis	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg19847130	chr8:10466454	RP1L1	0.56	5.28	0.48	8.27e-7	Neuroticism;
THYM	cis	rs9788682	0.747	rs2958719	chr15:78743029	G/A	cg18825076	chr15:78729989	IREB2	-0.69	-5.51	-0.49	3.05e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg13607699	chr17:42295918	UBTF	0.59	4.86	0.45	4.58e-6	Total body bone mineral density;
THYM	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03576123	chr11:487126	PTDSS2	-1.24	-5.21	-0.47	1.1e-6	Body mass index;
THYM	cis	rs3750965	0.839	rs921670	chr11:68871639	C/T	cg01403660	chr11:68851641	TPCN2	0.65	5.32	0.48	7e-7	Hair color;
THYM	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg09165964	chr15:75287851	SCAMP5	-1.08	-10.79	-0.74	3.35e-18	Blood trace element (Zn levels);
THYM	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg06238570	chr21:40685208	BRWD1	0.88	6.33	0.54	7.97e-9	Cognitive function;
THYM	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg27286337	chr10:134555280	INPP5A	0.89	6.88	0.58	6.33e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7246967	0.551	rs8102812	chr19:22879243	A/T	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.1	8.39	0.65	4.46e-13	Cognitive test performance;
THYM	cis	rs4474465	0.850	rs10793330	chr11:78269985	T/C	cg19901956	chr11:77921274	USP35	0.65	4.71	0.44	8.39e-6	Alzheimer's disease (survival time);
THYM	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2066819	1.000	rs79750959	chr12:56702012	C/A	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs7072216	0.763	rs2147900	chr10:100174721	T/C	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs6032067	0.929	rs13038355	chr20:43805555	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg03929089	chr4:120376271	NA	-1.03	-8.74	-0.67	8.32e-14	Coronary artery disease;
THYM	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06850241	chr22:41845214	NA	0.6	5.26	0.47	8.97e-7	Vitiligo;
THYM	cis	rs6429082	0.755	rs291370	chr1:235693041	A/G	cg26050004	chr1:235667680	B3GALNT2	0.78	7.09	0.59	2.34e-10	Adiposity;
THYM	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg22875332	chr1:76189707	ACADM	0.89	12.06	0.78	7.38e-21	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6598541	0.832	rs11857366	chr15:99263801	A/G	cg13297560	chr15:99320054	IGF1R	0.45	4.57	0.42	1.48e-5	Urate levels;
THYM	cis	rs1994135	0.692	rs7297538	chr12:33693438	T/C	cg10856724	chr12:34555212	NA	-0.74	-5.54	-0.49	2.74e-7	Resting heart rate;
THYM	cis	rs17818399	0.548	rs1989720	chr2:46854364	C/T	cg09399716	chr2:46890238	NA	-0.44	-4.49	-0.42	1.98e-5	Height;
THYM	cis	rs9527	0.590	rs12415199	chr10:104895536	T/C	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs4836891	0.667	rs7860446	chr9:125332930	A/G	cg13808240	chr9:125109458	NA	-0.89	-4.94	-0.45	3.34e-6	Colorectal cancer;
THYM	cis	rs9534288	0.797	rs9534282	chr13:46588944	T/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs59112743	0.510	rs2743552	chr6:15566674	T/C	cg10111214	chr6:14815676	NA	0.74	4.84	0.44	5.08e-6	Multiple keratinocyte cancers;
THYM	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg04990556	chr1:26633338	UBXN11	-0.89	-8.52	-0.66	2.34e-13	Obesity-related traits;
THYM	cis	rs6901250	0.568	rs4946198	chr6:117176599	C/T	cg12892004	chr6:117198278	RFX6	-0.61	-4.76	-0.44	7.04e-6	C-reactive protein levels;
THYM	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg23583168	chr7:148888333	NA	-1.02	-13.89	-0.82	1.32e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs2688608	0.587	rs2894040	chr10:75478159	A/C	cg15838173	chr10:75533400	FUT11	-0.5	-5.09	-0.46	1.82e-6	Inflammatory bowel disease;
THYM	cis	rs7189233	0.956	rs62048486	chr16:53448339	G/T	cg02965178	chr16:53538660	AKTIP	-0.57	-4.57	-0.42	1.45e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2732480	0.577	rs2450994	chr12:48721832	G/A	cg21466736	chr12:48725269	NA	-0.54	-4.91	-0.45	3.72e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg10295955	chr4:187884368	NA	-1.22	-17.51	-0.87	1.72e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1278352	0.691	rs985461	chr10:127769545	A/G	cg08295661	chr10:127769903	ADAM12	0.53	5.33	0.48	6.58e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg00254258	chr1:3105189	PRDM16	-0.65	-5.57	-0.5	2.32e-7	Migraine;
THYM	cis	rs7260598	0.642	rs73023276	chr19:24158847	T/A	cg15526094	chr19:24182596	NA	-0.66	-4.77	-0.44	6.7e-6	Response to taxane treatment (placlitaxel);
THYM	cis	rs11264213	0.901	rs614235	chr1:36450565	G/A	cg27506609	chr1:36549197	TEKT2	0.88	4.64	0.43	1.1e-5	Schizophrenia;
THYM	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02018176	chr4:1364513	KIAA1530	-1.0	-10.17	-0.72	7e-17	Longevity;
THYM	cis	rs9633835	0.524	rs6486110	chr11:13270920	C/G	cg13286116	chr11:13302098	ARNTL	0.73	8.04	0.64	2.47e-12	Body mass index;
THYM	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs539514	0.501	rs8000656	chr13:76400640	A/G	cg08579070	chr13:76210054	LMO7	-0.44	-4.55	-0.42	1.59e-5	Type 1 diabetes;
THYM	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs901683	0.867	rs17157885	chr10:46020094	G/A	cg18240400	chr10:46168597	ANUBL1	0.8	5.19	0.47	1.19e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs7426056	0.671	rs3115966	chr2:204590335	A/T	cg07930752	chr2:204569955	CD28	-0.67	-4.74	-0.44	7.48e-6	Primary sclerosing cholangitis;
THYM	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg00684032	chr4:1343700	KIAA1530	0.6	5.27	0.48	8.65e-7	Obesity-related traits;
THYM	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08704250	chr15:31115839	NA	-0.53	-6.04	-0.53	2.93e-8	Huntington's disease progression;
THYM	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg25427524	chr10:38739819	LOC399744	-0.58	-5.11	-0.46	1.69e-6	Extrinsic epigenetic age acceleration;
THYM	cis	rs17401966	0.931	rs12131441	chr1:10428952	G/A	cg19773385	chr1:10388646	KIF1B	-0.6	-4.7	-0.43	8.88e-6	Hepatocellular carcinoma;
THYM	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.95	5.13	0.47	1.51e-6	Initial pursuit acceleration;
THYM	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg07167872	chr1:205819463	PM20D1	-0.64	-4.67	-0.43	9.75e-6	Menarche (age at onset);
THYM	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg06238570	chr21:40685208	BRWD1	-0.69	-5.72	-0.51	1.24e-7	Menarche (age at onset);
THYM	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg11317459	chr13:21872234	NA	-1.21	-9.22	-0.69	7.83e-15	White matter hyperintensity burden;
THYM	cis	rs300703	0.542	rs376385	chr2:190245	G/A	cg21211680	chr2:198530	NA	0.95	6.34	0.55	7.76e-9	Blood protein levels;
THYM	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg01831904	chr17:28903510	LRRC37B2	-1.04	-5.05	-0.46	2.17e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg17173187	chr15:85201210	NMB	0.57	5.85	0.51	6.94e-8	Schizophrenia;
THYM	cis	rs7729447	0.566	rs1421811	chr5:32714270	C/G	cg14311471	chr5:32711095	NPR3	0.58	4.79	0.44	6.08e-6	Blood pressure;
THYM	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs476633	0.679	rs72737734	chr15:41432899	T/C	cg21153102	chr15:41252147	NA	0.59	4.58	0.42	1.44e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs4383453	0.539	rs4678014	chr3:123100170	A/G	cg04890266	chr3:123102914	ADCY5	-0.83	-8.64	-0.66	1.32e-13	Gestational age at birth (maternal effect);
THYM	cis	rs490234	0.702	rs10120000	chr9:128288428	C/T	cg14078157	chr9:128172775	NA	-0.75	-6.08	-0.53	2.45e-8	Mean arterial pressure;
THYM	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs9649213	0.593	rs6465666	chr7:97937258	C/T	cg07830472	chr7:97983916	BAIAP2L1	0.44	4.55	0.42	1.6e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.68	5.47	0.49	3.7e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1395	0.744	rs11126934	chr2:27476613	T/C	cg23587288	chr2:27483067	SLC30A3	-0.69	-6.19	-0.54	1.53e-8	Blood metabolite levels;
THYM	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg18681998	chr4:17616180	MED28	0.99	10.18	0.72	6.74e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs13006833	0.668	rs291449	chr2:191177467	A/G	cg11845111	chr2:191398756	TMEM194B	-0.65	-4.65	-0.43	1.09e-5	Urinary metabolites;
THYM	cis	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg26384229	chr12:38710491	ALG10B	0.98	8.08	0.64	2.01e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs11771526	0.792	rs62457499	chr7:32319197	T/C	cg13207630	chr7:32358064	NA	0.84	5.28	0.48	8.15e-7	Body mass index;
THYM	cis	rs909002	0.849	rs10914456	chr1:32088171	T/C	cg13919466	chr1:32135498	COL16A1	-0.49	-4.7	-0.43	8.86e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	0.931	rs2989330	chr21:40716209	A/G	cg06238570	chr21:40685208	BRWD1	0.92	6.2	0.54	1.42e-8	Cognitive function;
THYM	cis	rs7119	0.667	rs2867312	chr15:77902293	A/G	cg10437265	chr15:77819839	NA	0.56	5.61	0.5	1.95e-7	Type 2 diabetes;
THYM	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs7665590	1	rs7665590	chr4:99796784	T/C	cg12011299	chr4:100065546	ADH4	-0.6	-5.66	-0.5	1.61e-7	Primary biliary cholangitis;
THYM	cis	rs17539620	0.506	rs62432749	chr6:154839219	G/A	cg20019720	chr6:154832845	CNKSR3	0.47	4.78	0.44	6.35e-6	Lipoprotein (a) levels;
THYM	cis	rs6430585	0.583	rs4988163	chr2:136628121	G/T	cg04750100	chr2:136595281	LCT	0.52	4.95	0.45	3.26e-6	Corneal structure;
THYM	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg08835221	chr22:38071607	LGALS1	0.35	4.88	0.45	4.34e-6	Fat distribution (HIV);
THYM	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg15448220	chr1:150897856	SETDB1	-0.87	-7.15	-0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs9554348	0.541	rs61966905	chr13:96972661	T/C	cg25169784	chr13:96706045	UGGT2	0.85	4.55	0.42	1.58e-5	Schizophrenia;
THYM	cis	rs2066819	1.000	rs79824801	chr12:56728137	T/C	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.32	-0.48	6.97e-7	Monocyte percentage of white cells;
THYM	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg26384229	chr12:38710491	ALG10B	-0.72	-5.66	-0.5	1.58e-7	Morning vs. evening chronotype;
THYM	cis	rs1883415	0.534	rs2760149	chr6:24477848	C/T	cg20631270	chr6:24437470	GPLD1	0.53	4.46	0.42	2.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9527	0.590	rs11191578	chr10:104902337	A/T	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.72	0.57	1.37e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs11039798	0.841	rs7950737	chr11:48590678	T/G	cg24672777	chr11:48374446	OR4C45	-1.14	-6.95	-0.58	4.55e-10	Axial length;
THYM	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg08999081	chr20:33150536	PIGU	0.58	4.99	0.46	2.67e-6	Coronary artery disease;
THYM	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg03929089	chr4:120376271	NA	-0.98	-12.21	-0.78	3.51e-21	Coronary artery disease;
THYM	cis	rs2820651	0.614	rs56385558	chr10:1490864	G/T	cg13720710	chr10:1452970	ADARB2	0.79	5.05	0.46	2.17e-6	Migraine with aura;
THYM	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg14228332	chr4:119757509	SEC24D	1.36	5.21	0.47	1.12e-6	Cannabis dependence symptom count;
THYM	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg18904891	chr8:8559673	CLDN23	-0.56	-4.89	-0.45	4.14e-6	Mood instability;
THYM	cis	rs7731657	0.518	rs7706328	chr5:130218943	G/C	cg08523029	chr5:130500466	HINT1	-0.77	-5.24	-0.47	9.47e-7	Fasting plasma glucose;
THYM	cis	rs4417704	0.551	rs11886565	chr2:241898520	T/C	cg15164180	chr2:241846931	NA	-0.39	-4.81	-0.44	5.6e-6	Joint mobility (Beighton score);
THYM	cis	rs9905704	0.918	rs34430710	chr17:56876627	A/T	cg12560992	chr17:57184187	TRIM37	0.68	4.71	0.44	8.49e-6	Testicular germ cell tumor;
THYM	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19346786	chr7:2764209	NA	-0.77	-6.81	-0.57	8.83e-10	Height;
THYM	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg06108461	chr20:60628389	TAF4	-1.07	-9.19	-0.69	9.08e-15	Body mass index;
THYM	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg06636001	chr8:8085503	FLJ10661	0.58	4.62	0.43	1.19e-5	Mood instability;
THYM	cis	rs828999	0.618	rs11185284	chr1:108695000	T/A	cg24323958	chr1:108741884	SLC25A24	0.51	5.06	0.46	2.02e-6	Monocyte percentage of white cells;
THYM	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg18402987	chr7:1209562	NA	1.01	6.06	0.53	2.68e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs73086581	0.947	rs56123574	chr20:3878081	C/G	cg02187196	chr20:3869020	PANK2	0.41	4.77	0.44	6.7e-6	Response to antidepressants in depression;
THYM	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg08000102	chr2:233561755	GIGYF2	-0.69	-6.26	-0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg15736062	chr7:158136485	PTPRN2	-0.63	-5.03	-0.46	2.34e-6	Response to amphetamines;
THYM	cis	rs11186	0.556	rs72906379	chr2:189966466	T/C	cg11041835	chr2:189156425	GULP1	0.8	4.58	0.43	1.41e-5	Parkinson's disease;
THYM	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg26963428	chr7:66367121	NA	-0.57	-4.57	-0.42	1.48e-5	Corneal structure;
THYM	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg13114125	chr14:105738426	BRF1	-0.77	-6.12	-0.53	2.12e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11719291	0.651	rs1134043	chr3:49200137	G/T	cg00383909	chr3:49044727	WDR6	0.8	4.81	0.44	5.62e-6	Cognitive function;
THYM	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.72	-4.46	-0.42	2.25e-5	Cardiac Troponin-T levels;
THYM	cis	rs714027	1.000	rs2412975	chr22:30540590	T/C	cg11564601	chr22:30592435	NA	-0.3	-5.45	-0.49	3.98e-7	Lymphocyte counts;
THYM	cis	rs877282	0.898	rs2004478	chr10:770709	C/A	cg10556349	chr10:835070	NA	-0.7	-4.84	-0.44	4.99e-6	Uric acid levels;
THYM	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.75	-6.27	-0.54	1.07e-8	Blood metabolite levels;
THYM	cis	rs2898681	0.561	rs6855240	chr4:53740787	G/A	cg00791764	chr4:53727839	RASL11B	0.63	6.4	0.55	5.81e-9	Optic nerve measurement (cup area);
THYM	cis	rs8067354	0.645	rs9899611	chr17:57832190	A/G	cg20151207	chr17:57696971	CLTC	-0.7	-4.67	-0.43	9.76e-6	Hemoglobin concentration;
THYM	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs2798269	0.604	rs2798275	chr13:22159035	T/A	cg18095732	chr13:22033692	ZDHHC20	-0.61	-4.55	-0.42	1.6e-5	PR segment;
THYM	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg06558623	chr16:89946397	TCF25	1.34	4.76	0.44	6.97e-6	Skin colour saturation;
THYM	trans	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Bladder cancer;
THYM	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2039659	0.719	rs9547327	chr13:86277125	A/G	cg25308322	chr13:86268291	NA	0.67	6.04	0.53	2.93e-8	Blood osmolality (transformed sodium);
THYM	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.36	0.69	3.89e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2456568	0.564	rs7119708	chr11:93626641	T/C	cg26875233	chr11:93583750	C11orf90	0.51	5.54	0.49	2.7e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg01528321	chr10:82214614	TSPAN14	0.66	5.16	0.47	1.35e-6	Post bronchodilator FEV1;
THYM	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg21361702	chr7:150065534	REPIN1	0.68	4.98	0.46	2.8e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg01579765	chr21:45077557	HSF2BP	-0.46	-7.3	-0.6	8.71e-11	Mean corpuscular volume;
THYM	cis	rs554111	0.613	rs3816455	chr1:21191430	A/G	cg01072550	chr1:21505969	NA	0.56	4.86	0.45	4.65e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs367615	0.552	rs2963024	chr5:108730773	C/T	cg17395555	chr5:108820864	NA	-0.53	-6.5	-0.56	3.63e-9	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	5.59	0.5	2.16e-7	Monocyte percentage of white cells;
THYM	cis	rs7769051	0.522	rs6569852	chr6:133108333	C/A	cg07930552	chr6:133119739	C6orf192	1.14	4.51	0.42	1.82e-5	Type 2 diabetes nephropathy;
THYM	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.82	-5.45	-0.49	3.92e-7	Body mass index;
THYM	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg20387954	chr3:183756860	HTR3D	0.58	4.81	0.44	5.56e-6	Anterior chamber depth;
THYM	cis	rs7119	0.671	rs10152850	chr15:77904426	G/A	cg27398640	chr15:77910606	LINGO1	0.67	8.46	0.66	3.23e-13	Type 2 diabetes;
THYM	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg18131467	chr2:239335373	ASB1	1.08	10.47	0.73	1.65e-17	Multiple system atrophy;
THYM	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.66	5.7	0.51	1.32e-7	Personality dimensions;
THYM	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Body mass index;
THYM	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.87	6.7	0.57	1.44e-9	Electrocardiographic conduction measures;
THYM	trans	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg10856724	chr12:34555212	NA	0.9	8.08	0.64	2.05e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4919044	0.808	rs2486687	chr10:94778283	T/C	cg05127821	chr10:94822908	CYP26C1	-1.31	-6.9	-0.58	5.75e-10	Coronary artery disease;
THYM	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg18904891	chr8:8559673	CLDN23	-0.61	-4.85	-0.45	4.87e-6	Neuroticism;
THYM	cis	rs733175	0.855	rs10023068	chr4:10004832	C/T	cg11266682	chr4:10021025	SLC2A9	-0.52	-4.6	-0.43	1.31e-5	Psychosis and Alzheimer's disease;
THYM	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs3126085	0.935	rs2338430	chr1:152214420	C/T	cg26020982	chr1:152196106	HRNR	-0.35	-4.59	-0.43	1.34e-5	Atopic dermatitis;
THYM	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg20387954	chr3:183756860	HTR3D	0.59	4.9	0.45	4.01e-6	Anterior chamber depth;
THYM	cis	rs67311347	0.568	rs9864544	chr3:40336204	T/C	cg13683864	chr3:40499215	RPL14	-0.79	-7.44	-0.61	4.43e-11	Renal cell carcinoma;
THYM	cis	rs6430585	0.941	rs12469551	chr2:136510012	T/G	cg04750100	chr2:136595281	LCT	-0.53	-5.1	-0.46	1.71e-6	Corneal structure;
THYM	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg12756686	chr19:29218302	NA	0.85	6.0	0.52	3.52e-8	Methadone dose in opioid dependence;
THYM	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg16099169	chr2:106886729	NA	-0.7	-8.56	-0.66	1.96e-13	Facial morphology (factor 23);
THYM	trans	rs1920324	0.622	rs13077247	chr3:103903383	T/G	cg01901466	chr14:93388880	CHGA	0.65	6.91	0.58	5.4e-10	Colorectal cancer;
THYM	cis	rs7236492	0.683	rs59828426	chr18:77204397	T/C	cg15644404	chr18:77186268	NFATC1	-0.77	-4.73	-0.44	7.75e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs1696756	1.000	rs1696756	chr17:77827973	C/T	cg00646381	chr17:77835854	NA	0.45	5.71	0.51	1.26e-7	Glucocorticoid-induced osteonecrosis (age 10 years and older);
THYM	cis	rs35934224	0.504	rs10372	chr22:19837298	G/A	cg11182965	chr22:19864308	TXNRD2	-0.76	-5.74	-0.51	1.11e-7	Glaucoma (primary open-angle);
THYM	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.43	0.7	2.73e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6924995	0.501	rs2142670	chr6:16197492	A/G	cg11805552	chr6:16175128	NA	0.57	4.85	0.45	4.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs4076764	0.881	rs10917758	chr1:163430652	G/A	cg06092702	chr1:163392909	NA	-0.57	-4.85	-0.45	4.85e-6	Motion sickness;
THYM	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg01475377	chr6:109611718	NA	-0.57	-4.88	-0.45	4.28e-6	Reticulocyte fraction of red cells;
THYM	cis	rs6539288	0.677	rs2216221	chr12:107327231	A/T	cg26297688	chr12:107349093	C12orf23	-0.51	-6.04	-0.53	2.94e-8	Total body bone mineral density;
THYM	cis	rs62158800	0.568	rs62161319	chr2:108363138	C/A	cg10013287	chr2:108537568	NA	1.2	5.61	0.5	1.95e-7	Facial morphology (factor 22);
THYM	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg08000102	chr2:233561755	GIGYF2	0.68	6.04	0.53	3.05e-8	Coronary artery disease;
THYM	cis	rs3741151	1.000	rs7125978	chr11:73039229	G/A	cg12959048	chr11:73096162	RELT	-0.43	-4.54	-0.42	1.62e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7078219	0.543	rs7092009	chr10:101277239	A/G	cg23904955	chr10:101282759	NA	-0.42	-5.46	-0.49	3.74e-7	Dental caries;
THYM	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs9287719	0.781	rs6714795	chr2:10759134	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-4.77	-0.44	6.77e-6	Prostate cancer;
THYM	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	6.63	0.56	1.99e-9	Total body bone mineral density;
THYM	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg08975724	chr8:8085496	FLJ10661	-0.63	-4.82	-0.44	5.43e-6	Mood instability;
THYM	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg13607699	chr17:42295918	UBTF	0.59	4.86	0.45	4.58e-6	Total body bone mineral density;
THYM	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg06623918	chr6:96969491	KIAA0776	1.09	10.37	0.73	2.65e-17	Headache;
THYM	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg19016782	chr12:123741754	C12orf65	-0.71	-4.58	-0.42	1.43e-5	Neutrophil percentage of white cells;
THYM	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg11189052	chr15:85197271	WDR73	0.63	5.42	0.49	4.48e-7	P wave terminal force;
THYM	cis	rs2625529	0.652	rs2930069	chr15:72226977	G/A	cg16672083	chr15:72433130	SENP8	0.5	4.5	0.42	1.96e-5	Red blood cell count;
THYM	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg06074448	chr4:187884817	NA	-1.02	-13.05	-0.8	6.55e-23	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg08885076	chr2:99613938	TSGA10	0.55	5.04	0.46	2.18e-6	Chronic sinus infection;
THYM	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg00684032	chr4:1343700	KIAA1530	-0.61	-5.44	-0.49	4.08e-7	Obesity-related traits;
THYM	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg06074448	chr4:187884817	NA	-0.97	-11.64	-0.77	5.54e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28595532	0.920	rs114165587	chr4:119779525	C/T	cg21605333	chr4:119757512	SEC24D	1.67	6.17	0.53	1.69e-8	Cannabis dependence symptom count;
THYM	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg08847533	chr14:75593920	NEK9	1.01	11.32	0.76	2.63e-19	Height;
THYM	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.25	-10.14	-0.72	8.26e-17	Platelet count;
THYM	cis	rs4499344	0.633	rs166310	chr19:33155187	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.92	7.83	0.63	6.82e-12	Mean platelet volume;
THYM	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg10523679	chr1:76189770	ACADM	0.89	8.55	0.66	2.05e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg02734326	chr4:10020555	SLC2A9	0.76	7.25	0.6	1.13e-10	Bone mineral density;
THYM	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg21926883	chr2:100939477	LONRF2	-0.66	-6.17	-0.54	1.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg26769984	chr7:1090371	C7orf50	0.8	5.36	0.48	5.9e-7	Bronchopulmonary dysplasia;
THYM	cis	rs10457678	0.564	rs7746303	chr6:139108026	C/T	cg05131254	chr6:138188363	TNFAIP3	0.63	4.45	0.42	2.33e-5	Colorectal or endometrial cancer;
THYM	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg24578937	chr1:2090814	PRKCZ	0.81	8.54	0.66	2.22e-13	Height;
THYM	cis	rs17345786	0.520	rs13062677	chr3:101305078	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	6.18	0.54	1.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg11843238	chr5:131593191	PDLIM4	0.46	4.59	0.43	1.36e-5	Acylcarnitine levels;
THYM	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg06636001	chr8:8085503	FLJ10661	0.62	5.37	0.48	5.48e-7	Mood instability;
THYM	cis	rs500891	0.525	rs1145902	chr6:84038531	A/G	cg08257003	chr6:84140564	ME1	0.56	4.47	0.42	2.19e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg17264618	chr3:40429014	ENTPD3	0.55	5.21	0.47	1.08e-6	Renal cell carcinoma;
THYM	cis	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-6.16	-0.53	1.75e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs501916	0.634	rs1045688	chr15:48065487	A/G	cg20869673	chr15:48010124	SEMA6D	-0.63	-4.49	-0.42	1.99e-5	Inflammatory bowel disease;Ulcerative colitis;
THYM	trans	rs4940575	0.679	rs11875184	chr18:60829553	A/G	cg01781374	chr5:110777659	CAMK4	0.99	6.94	0.58	4.79e-10	Breast cancer;
THYM	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg10862848	chr6:42927986	GNMT	-0.54	-7.36	-0.6	6.51e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg13852791	chr20:30311386	BCL2L1	0.87	6.96	0.58	4.36e-10	Mean corpuscular hemoglobin;
THYM	cis	rs7119	0.717	rs11639293	chr15:77810845	T/C	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs7553864	0.966	rs11161935	chr1:87614191	G/A	cg17420885	chr1:87600446	LOC339524	-0.75	-6.27	-0.54	1.06e-8	Smoking behavior;
THYM	cis	rs8103278	1.000	rs7258283	chr19:46335511	C/T	cg14061069	chr19:46274453	DMPK	-0.55	-5.26	-0.47	9.02e-7	Coronary artery disease;
THYM	cis	rs12282928	0.959	rs7928042	chr11:48257996	C/T	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg06027949	chr8:82754900	SNX16	-0.62	-5.06	-0.46	2.01e-6	Diastolic blood pressure;
THYM	cis	rs7084402	1.000	rs12250013	chr10:60265957	C/A	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs7695732	0.595	rs12645240	chr4:89912706	A/G	cg17769793	chr4:89976368	FAM13A	-0.49	-5.2	-0.47	1.17e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs9479482	0.935	rs5017315	chr6:150333574	C/T	cg07578070	chr6:150326732	RAET1K	0.54	4.51	0.42	1.88e-5	Alopecia areata;
THYM	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.99	-4.96	-0.45	3.11e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs35110281	0.575	rs2876854	chr21:44979232	A/G	cg01579765	chr21:45077557	HSF2BP	-0.47	-7.44	-0.61	4.41e-11	Mean corpuscular volume;
THYM	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.62	0.66	1.45e-13	Cognitive test performance;
THYM	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1551570	0.755	rs11667630	chr19:10229297	A/C	cg07543883	chr19:10213271	ANGPTL6	0.48	5.04	0.46	2.26e-6	Narcolepsy;
THYM	cis	rs834811	0.829	rs834818	chr7:135895070	A/G	cg01726295	chr7:135938950	NA	0.66	5.57	0.5	2.36e-7	Post-traumatic stress disorder;
THYM	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	1.12	7.89	0.63	5.16e-12	Body mass index;
THYM	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg09184832	chr6:79620586	NA	-0.58	-4.83	-0.44	5.2e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg03806693	chr22:41940476	POLR3H	1.06	8.57	0.66	1.87e-13	Vitiligo;
THYM	cis	rs7757969	1.000	rs2148710	chr6:112122226	C/T	cg08601457	chr6:112115117	FYN	0.42	4.88	0.45	4.22e-6	Schizophrenia;
THYM	cis	rs870825	0.616	rs61653735	chr4:185630025	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6047844	0.545	rs6113539	chr20:22123129	A/G	cg16502866	chr20:23015624	SSTR4	0.58	4.8	0.44	6e-6	Male-pattern baldness;
THYM	cis	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg11905131	chr22:24372483	LOC391322	-0.97	-10.93	-0.75	1.77e-18	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6496667	0.510	rs16944405	chr15:90975517	A/G	cg00487526	chr15:90818384	NA	-0.62	-4.52	-0.42	1.76e-5	Rheumatoid arthritis;
THYM	cis	rs28829049	0.597	rs72651403	chr1:19519887	G/C	cg13387374	chr1:19411106	UBR4	0.65	4.79	0.44	6.17e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs1978968	1.000	rs5992921	chr22:18445263	C/T	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg15693483	chr7:1102177	C7orf50	0.41	5.93	0.52	4.81e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7586879	0.658	rs7563204	chr2:25125075	T/G	cg27107076	chr2:25050844	ADCY3	-0.29	-4.72	-0.44	8.01e-6	Body mass index;
THYM	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs2797685	1.000	rs707472	chr1:7906008	A/C	cg06712362	chr1:7811235	CAMTA1	-0.7	-4.99	-0.46	2.67e-6	Crohn's disease;
THYM	cis	rs2797160	0.935	rs1739379	chr6:126012593	T/C	cg16306078	chr6:126000798	NA	0.55	5.64	0.5	1.72e-7	Endometrial cancer;
THYM	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.89	5.72	0.51	1.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1335645	0.570	rs10494126	chr1:111671707	A/C	cg00321911	chr1:111669324	DRAM2	1.43	8.28	0.65	7.86e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg02475777	chr4:1388615	CRIPAK	0.65	4.66	0.43	1.02e-5	Longevity;
THYM	cis	rs62070183	0.808	rs79957065	chr17:31142749	C/T	cg23177095	chr17:30873196	MYO1D	0.61	4.82	0.44	5.36e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg05335186	chr13:53173507	NA	0.5	6.93	0.58	4.97e-10	Lewy body disease;
THYM	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg17105886	chr17:28927953	LRRC37B2	1.13	6.42	0.55	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg18252515	chr7:66147081	NA	-0.61	-4.5	-0.42	1.9e-5	Aortic root size;
THYM	cis	rs7953249	0.594	rs11065384	chr12:121423285	T/C	cg14101638	chr12:121416612	HNF1A	-0.51	-5.16	-0.47	1.36e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg25358565	chr5:93447407	FAM172A	-0.97	-7.06	-0.59	2.66e-10	Diabetic retinopathy;
THYM	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg15921436	chr17:44337874	NA	0.95	6.92	0.58	5.33e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12216545	0.737	rs2103034	chr7:150237917	T/C	cg08960815	chr7:150264767	GIMAP4	-0.89	-8.27	-0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs34638657	0.732	rs2911425	chr16:82203026	T/C	cg09894383	chr16:82067445	HSD17B2	-0.45	-4.95	-0.45	3.15e-6	Lung adenocarcinoma;
THYM	cis	rs288326	0.561	rs17265859	chr2:183724612	A/T	cg09997497	chr2:183902928	NCKAP1	1.09	5.06	0.46	2.03e-6	Blood protein levels;
THYM	cis	rs6558530	0.932	rs10102731	chr8:1709020	A/G	cg09410841	chr8:1729607	CLN8	0.75	5.51	0.49	3.01e-7	Systolic blood pressure;
THYM	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg09359103	chr1:154839909	KCNN3	-0.81	-10.3	-0.73	3.84e-17	Prostate cancer;
THYM	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg10802521	chr3:52805072	NEK4	-0.71	-5.96	-0.52	4.22e-8	Bipolar disorder;
THYM	cis	rs208520	0.690	rs207107	chr6:66794385	T/C	cg07460842	chr6:66804631	NA	-1.06	-7.89	-0.63	5.14e-12	Exhaled nitric oxide output;
THYM	cis	rs9527	0.615	rs7899622	chr10:104727333	C/T	cg15744005	chr10:104629667	AS3MT	-0.6	-4.46	-0.42	2.28e-5	Arsenic metabolism;
THYM	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11644478	chr21:40555479	PSMG1	0.64	4.68	0.43	9.58e-6	Cognitive function;
THYM	cis	rs425277	0.958	rs262652	chr1:2090816	T/C	cg24578937	chr1:2090814	PRKCZ	0.81	8.54	0.66	2.22e-13	Height;
THYM	cis	rs1557488	0.553	rs4935993	chr11:126666284	C/G	cg03950493	chr11:126582183	KIRREL3	-0.36	-4.75	-0.44	7.07e-6	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs4589258	1.000	rs4753029	chr11:90477728	C/G	cg26138821	chr11:89956704	CHORDC1	-0.68	-5.48	-0.49	3.52e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.78	-5.52	-0.49	2.89e-7	Body mass index;
THYM	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg09307838	chr4:120376055	NA	0.6	4.54	0.42	1.63e-5	Corneal astigmatism;
THYM	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg25703541	chr22:24373054	LOC391322	-0.89	-11.38	-0.76	1.92e-19	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg08132940	chr7:1081526	C7orf50	-1.16	-6.72	-0.57	1.36e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg06028808	chr11:68637592	NA	0.66	7.16	0.59	1.72e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs8112449	1.000	rs35916055	chr19:10526831	G/A	cg01466491	chr19:10523363	NA	-0.64	-5.91	-0.52	5.43e-8	Multiple sclerosis;Gastritis;
THYM	cis	rs9902453	0.904	rs55633288	chr17:28368196	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.22	-0.54	1.3e-8	Coffee consumption (cups per day);
THYM	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.33e-5	Retinal vascular caliber;
THYM	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg13010199	chr12:38710504	ALG10B	0.73	5.82	0.51	7.99e-8	Heart rate;
THYM	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg09033563	chr22:24373618	LOC391322	-0.62	-5.69	-0.5	1.42e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7010267	0.902	rs7006553	chr8:119970779	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.6	4.87	0.45	4.36e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs2885056	0.739	rs4363951	chr19:10649473	G/A	cg04833646	chr19:10679720	CDKN2D	1.07	9.15	0.68	1.08e-14	Red cell distribution width;
THYM	cis	rs4523957	0.928	rs216189	chr17:2187401	A/G	cg16513277	chr17:2031491	SMG6	-0.79	-7.26	-0.6	1.07e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg08779649	chr13:50194554	NA	0.58	5.05	0.46	2.16e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs2303759	0.709	rs3760667	chr19:49814832	C/T	cg22133161	chr19:49891603	CCDC155	0.71	4.53	0.42	1.68e-5	Multiple sclerosis;
THYM	cis	rs8067354	0.645	rs72840522	chr17:57829992	G/A	cg20151207	chr17:57696971	CLTC	-0.7	-4.67	-0.43	9.76e-6	Hemoglobin concentration;
THYM	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg12179176	chr11:130786555	SNX19	0.78	6.73	0.57	1.27e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg23131131	chr22:24373011	LOC391322	0.86	8.11	0.64	1.79e-12	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs2625529	0.824	rs7183749	chr15:72377278	G/A	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg14895029	chr7:2775587	GNA12	-0.66	-4.86	-0.45	4.68e-6	Height;
THYM	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg12379764	chr21:47803548	PCNT	-0.83	-5.37	-0.48	5.52e-7	Testicular germ cell tumor;
THYM	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg13289132	chr10:30722225	MAP3K8	-0.61	-5.09	-0.46	1.8e-6	Inflammatory bowel disease;
THYM	cis	rs4474465	0.915	rs12288436	chr11:78161430	T/C	cg19901956	chr11:77921274	USP35	-0.6	-4.55	-0.42	1.56e-5	Alzheimer's disease (survival time);
THYM	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg21475434	chr5:93447410	FAM172A	0.71	4.51	0.42	1.83e-5	Diabetic retinopathy;
THYM	cis	rs12478296	0.515	rs13412492	chr2:243000583	T/G	cg06360820	chr2:242988706	NA	-0.85	-5.35	-0.48	6.1e-7	Obesity-related traits;
THYM	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg23161317	chr6:28129485	ZNF389	0.85	6.33	0.54	8.19e-9	Depression;
THYM	cis	rs763014	0.833	rs3743902	chr16:632728	T/C	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg07167872	chr1:205819463	PM20D1	0.59	4.57	0.42	1.45e-5	Parkinson's disease;
THYM	cis	rs9876781	1.000	rs898225	chr3:48413179	G/T	cg06066452	chr3:48470258	PLXNB1	-0.26	-4.82	-0.44	5.53e-6	Longevity;
THYM	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs636291	0.510	rs1307487	chr1:10506667	G/A	cg20482658	chr1:10539492	PEX14	-0.35	-5.23	-0.47	9.97e-7	Prostate cancer;
THYM	cis	rs10158481	0.667	rs7417756	chr1:25478027	A/G	cg09264742	chr1:25757510	TMEM57	-0.68	-5.04	-0.46	2.19e-6	Urate levels in obese individuals;
THYM	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg23711669	chr6:146136114	FBXO30	0.85	8.17	0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17001868	0.568	rs470113	chr22:40729614	A/G	cg07138101	chr22:40742427	ADSL	0.8	4.75	0.44	7.07e-6	Mammographic density (dense area);
THYM	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg26384229	chr12:38710491	ALG10B	0.95	7.61	0.62	1.97e-11	Bladder cancer;
THYM	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.81	5.6	0.5	2.11e-7	Smoking behavior;
THYM	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg08704250	chr15:31115839	NA	-0.71	-7.56	-0.61	2.5e-11	Huntington's disease progression;
THYM	cis	rs76662990	0.610	rs6874600	chr5:73945738	A/T	cg13275603	chr5:73927487	ENC1	-0.76	-4.61	-0.43	1.26e-5	Residual cognition;
THYM	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg25072359	chr17:41440525	NA	0.76	4.61	0.43	1.23e-5	Menopause (age at onset);
THYM	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg07424592	chr7:64974309	NA	-1.08	-4.76	-0.44	6.9e-6	Diabetic kidney disease;
THYM	cis	rs9913156	0.793	rs56020376	chr17:4560909	A/G	cg19197139	chr17:4613644	ARRB2	0.83	5.0	0.46	2.63e-6	Lymphocyte counts;
THYM	cis	rs7264396	0.790	rs6060516	chr20:34214368	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-5.65	-0.5	1.67e-7	Total cholesterol levels;
THYM	cis	rs9733	0.596	rs2867300	chr1:150666990	C/G	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs2142672	0.892	rs9396647	chr6:16190511	T/C	cg11805552	chr6:16175128	NA	0.54	4.54	0.42	1.66e-5	LDL cholesterol;
THYM	cis	rs2658782	0.547	rs2085334	chr11:93181050	C/T	cg15737290	chr11:93063684	CCDC67	0.65	5.2	0.47	1.16e-6	Pulmonary function decline;
THYM	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg21773646	chr17:80085082	CCDC57	-0.34	-4.91	-0.45	3.76e-6	Life satisfaction;
THYM	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg24818145	chr4:99064322	C4orf37	-0.76	-6.1	-0.53	2.32e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2455799	0.574	rs2455801	chr3:15701857	C/T	cg16303742	chr3:15540471	COLQ	-0.56	-5.62	-0.5	1.92e-7	Mean platelet volume;
THYM	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg19346786	chr7:2764209	NA	-0.71	-5.98	-0.52	3.95e-8	Height;
THYM	cis	rs8001976	0.517	rs1924794	chr13:48275412	A/G	cg04001071	chr13:47613485	NA	0.7	4.61	0.43	1.28e-5	Aging (time to event);
THYM	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg08999081	chr20:33150536	PIGU	0.64	5.33	0.48	6.63e-7	Coronary artery disease;
THYM	cis	rs6840360	0.642	rs7678823	chr4:152357119	A/G	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs289828	0.839	rs289833	chr2:152132742	A/G	cg05960677	chr2:152117363	RBM43	0.61	6.11	0.53	2.2e-8	Blood protein levels;
THYM	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs9880211	0.613	rs34864445	chr3:135822924	C/T	cg21827317	chr3:136751795	NA	-0.71	-5.16	-0.47	1.33e-6	Body mass index;Height;
THYM	cis	rs4595586	0.545	rs11615700	chr12:39365104	A/G	cg13010199	chr12:38710504	ALG10B	0.61	4.65	0.43	1.05e-5	Morning vs. evening chronotype;
THYM	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg09703963	chr11:616879	IRF7;MUPCDH	-0.62	-4.67	-0.43	1.01e-5	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg06636001	chr8:8085503	FLJ10661	-0.78	-7.33	-0.6	7.58e-11	Mood instability;
THYM	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs6960043	0.846	rs7781710	chr7:15056045	T/A	cg19272540	chr7:15055459	NA	0.48	5.14	0.47	1.45e-6	Type 2 diabetes;
THYM	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg12963246	chr6:28129442	ZNF389	0.57	4.75	0.44	7.24e-6	Cardiac Troponin-T levels;
THYM	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs11096990	0.892	rs11730558	chr4:39229771	A/G	cg24403649	chr4:39172243	NA	0.66	5.65	0.5	1.68e-7	Cognitive function;
THYM	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.58	0.43	1.41e-5	Bipolar disorder;
THYM	cis	rs67981189	0.896	rs4132849	chr14:71459523	A/G	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs863345	0.604	rs1342953	chr1:158464499	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs6951245	0.515	rs73257955	chr7:1007014	G/A	cg08883853	chr7:1026168	CYP2W1	-0.83	-4.87	-0.45	4.36e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7769051	0.522	rs73554461	chr6:133139087	T/G	cg22852734	chr6:133119734	C6orf192	1.42	5.82	0.51	7.93e-8	Type 2 diabetes nephropathy;
THYM	cis	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg23758822	chr17:41437982	NA	1.21	12.96	0.8	1.02e-22	Menopause (age at onset);
THYM	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.58	0.43	1.41e-5	Bipolar disorder;
THYM	cis	rs7809950	0.954	rs2520245	chr7:107137428	G/C	cg23024343	chr7:107201750	COG5	-0.93	-8.3	-0.65	7.11e-13	Coronary artery disease;
THYM	cis	rs7319311	1.000	rs7319311	chr13:111030578	A/G	cg06243866	chr13:111019493	COL4A2	0.75	6.28	0.54	9.93e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.8	-5.41	-0.49	4.66e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	trans	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg06636001	chr8:8085503	FLJ10661	0.76	6.85	0.57	7.39e-10	Myopia (pathological);
THYM	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg05340658	chr4:99064831	C4orf37	0.55	4.6	0.43	1.29e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs870825	0.616	rs1401360	chr4:185643571	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.6	4.63	0.43	1.18e-5	Tonsillectomy;
THYM	cis	rs478304	0.627	rs11227254	chr11:65454000	A/G	cg27068330	chr11:65405492	SIPA1	-1.03	-10.31	-0.73	3.55e-17	Acne (severe);
THYM	cis	rs12216545	0.765	rs2373808	chr7:150249391	A/G	cg00323915	chr7:150264987	GIMAP4	-0.51	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs9303280	0.901	rs8067378	chr17:38051348	A/G	cg24910161	chr17:38119198	GSDMA	0.46	4.7	0.43	8.72e-6	Self-reported allergy;
THYM	cis	rs9646944	0.501	rs3732127	chr2:103013750	G/C	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg26384229	chr12:38710491	ALG10B	0.92	7.03	0.58	3.08e-10	Morning vs. evening chronotype;
THYM	cis	rs7937890	0.681	rs4756784	chr11:14270904	G/A	cg22961513	chr11:14280813	SPON1	0.39	4.54	0.42	1.65e-5	Mitochondrial DNA levels;
THYM	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.68	5.34	0.48	6.26e-7	Tonsillectomy;
THYM	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg05295671	chr13:79234353	RNF219	0.95	7.17	0.59	1.6e-10	Large artery stroke;
THYM	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg23750338	chr8:142222470	SLC45A4	0.49	4.59	0.43	1.36e-5	Immature fraction of reticulocytes;
THYM	cis	rs4722166	0.630	rs1581497	chr7:22779503	C/A	cg05472934	chr7:22766657	IL6	0.73	5.55	0.49	2.62e-7	Lung cancer;
THYM	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2742417	0.624	rs2673030	chr3:45757900	T/G	cg04837898	chr3:45731254	SACM1L	-0.74	-5.4	-0.48	4.94e-7	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg23803603	chr1:2058230	PRKCZ	0.62	5.67	0.5	1.54e-7	Height;
THYM	cis	rs9393692	0.620	rs6908402	chr6:26293014	A/T	cg13736514	chr6:26305472	NA	-0.48	-5.02	-0.46	2.44e-6	Educational attainment;
THYM	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg11494091	chr17:61959527	GH2	0.69	6.31	0.54	8.65e-9	Height;
THYM	cis	rs524023	0.957	rs12365089	chr11:64364735	A/T	cg19131476	chr11:64387923	NRXN2	-0.37	-5.38	-0.48	5.36e-7	Urate levels in obese individuals;
THYM	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg25554036	chr4:6271136	WFS1	0.5	4.47	0.42	2.19e-5	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs28785552	0.765	rs28850924	chr19:53234323	T/G	cg22067481	chr19:53234126	ZNF611	-1.04	-11.47	-0.76	1.24e-19	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg03609598	chr5:56110824	MAP3K1	-0.87	-5.86	-0.52	6.63e-8	Initial pursuit acceleration;
THYM	cis	rs4363385	0.693	rs4845331	chr1:152982623	A/G	cg13444842	chr1:152974279	SPRR3	-0.59	-4.68	-0.43	9.52e-6	Inflammatory skin disease;
THYM	cis	rs1003719	0.788	rs2835600	chr21:38468958	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg07621104	chr11:117668040	DSCAML1	0.8	6.5	0.56	3.63e-9	Myopia;
THYM	cis	rs75920871	0.588	rs7112111	chr11:116980858	T/G	cg20608306	chr11:116969690	SIK3	-0.51	-6.03	-0.53	3.15e-8	Subjective well-being;
THYM	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12711979	0.509	rs1031478	chr2:3827425	G/A	cg17052675	chr2:3827356	NA	-0.91	-15.53	-0.85	8.23e-28	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs4845875	0.530	rs6667720	chr1:11831615	A/G	cg06193043	chr1:11908199	NPPA	-0.58	-4.82	-0.44	5.41e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg13147721	chr7:65941812	NA	-1.0	-6.2	-0.54	1.47e-8	Diabetic kidney disease;
THYM	cis	rs4242434	0.927	rs35952885	chr8:22491622	T/G	cg03733263	chr8:22462867	KIAA1967	1.18	11.7	0.77	4.16e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9807841	0.617	rs2360944	chr19:10769974	T/C	cg16900796	chr19:10755136	SLC44A2	0.32	4.87	0.45	4.5e-6	Inflammatory skin disease;
THYM	cis	rs793571	0.502	rs387812	chr15:59074786	T/C	cg05156742	chr15:59063176	FAM63B	0.58	4.95	0.45	3.23e-6	Schizophrenia;
THYM	cis	rs17253792	0.822	rs2274075	chr14:56096731	A/G	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs7107174	0.681	rs4340079	chr11:78007920	C/T	cg02023728	chr11:77925099	USP35	0.67	6.21	0.54	1.38e-8	Testicular germ cell tumor;
THYM	cis	rs2806561	0.765	rs1738469	chr1:23511407	G/C	cg12483005	chr1:23474871	LUZP1	0.59	6.3	0.54	9.23e-9	Height;
THYM	cis	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	5.09	0.46	1.8e-6	Menarche (age at onset);
THYM	trans	rs9951602	0.512	rs12455591	chr18:76656028	A/G	cg02800362	chr5:177631904	HNRNPAB	1.12	8.72	0.67	8.79e-14	Obesity-related traits;
THYM	cis	rs16912285	0.688	rs1899540	chr11:24339992	A/G	ch.11.24196551F	chr11:24239977	NA	0.89	6.29	0.54	9.85e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2278255	1.000	rs2278255	chr5:170720733	C/G	cg19110895	chr5:170733072	NA	-0.97	-4.64	-0.43	1.12e-5	Visceral fat;
THYM	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg18128536	chr17:47092178	IGF2BP1	-0.44	-4.91	-0.45	3.84e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7226229	0.821	rs7207753	chr17:20919337	G/C	cg21263980	chr17:20946333	USP22	0.67	4.98	0.45	2.88e-6	Blood trace element (Se levels);
THYM	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.87	-4.64	-0.43	1.11e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1883415	0.727	rs2760115	chr6:24504304	C/G	cg00346970	chr6:24499591	ALDH5A1	0.42	5.64	0.5	1.73e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9581943	0.901	rs9579127	chr13:28477268	A/G	cg16302790	chr13:28498334	PDX1	0.52	4.73	0.44	7.69e-6	Pancreatic cancer;
THYM	cis	rs12579753	0.956	rs11115039	chr12:82217338	A/C	cg21231944	chr12:82153410	PPFIA2	-0.65	-4.96	-0.45	3.1e-6	Resting heart rate;
THYM	cis	rs9393692	0.620	rs9393697	chr6:26293841	C/T	cg00631329	chr6:26305371	NA	-0.47	-4.79	-0.44	6.14e-6	Educational attainment;
THYM	cis	rs11711311	0.955	rs9860642	chr3:113419211	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.57	-4.79	-0.44	6.06e-6	IgG glycosylation;
THYM	cis	rs1728785	1.000	rs1728780	chr16:68567642	G/C	cg02972257	chr16:68554789	NA	-0.74	-4.54	-0.42	1.63e-5	Ulcerative colitis;
THYM	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg06850241	chr22:41845214	NA	0.54	4.68	0.43	9.37e-6	Vitiligo;
THYM	cis	rs7084402	0.967	rs1649038	chr10:60330439	G/A	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs2050392	0.789	rs303438	chr10:30733493	C/T	cg18806716	chr10:30721971	MAP3K8	0.45	4.51	0.42	1.83e-5	Inflammatory bowel disease;
THYM	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg10515332	chr4:99064459	C4orf37	0.62	4.96	0.45	3.06e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg24675056	chr1:15929824	NA	0.74	6.14	0.53	1.93e-8	Systolic blood pressure;
THYM	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-4.98	-0.45	2.87e-6	Life satisfaction;
THYM	cis	rs9807841	0.670	rs3843750	chr19:10748073	C/G	cg17848348	chr19:10766748	ILF3	-0.85	-7.5	-0.61	3.33e-11	Inflammatory skin disease;
THYM	cis	rs7705502	1.000	rs113932433	chr5:173357206	G/A	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs17407555	0.683	rs2192095	chr4:10274173	T/C	cg00071950	chr4:10020882	SLC2A9	0.5	4.68	0.43	9.41e-6	Schizophrenia (age at onset);
THYM	cis	rs2280630	0.898	rs1828678	chr3:39195517	C/G	cg15678707	chr3:39149194	GORASP1;TTC21A	0.56	4.7	0.43	8.93e-6	Verbal declarative memory;
THYM	cis	rs17407555	0.683	rs6833035	chr4:10272269	C/T	cg00071950	chr4:10020882	SLC2A9	0.52	4.95	0.45	3.17e-6	Schizophrenia (age at onset);
THYM	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg01073479	chr16:3509474	NAT15	0.57	4.83	0.44	5.33e-6	Tuberculosis;
THYM	cis	rs2067615	0.579	rs10861667	chr12:107194776	T/G	cg15890332	chr12:107067104	RFX4	0.48	5.63	0.5	1.81e-7	Heart rate;
THYM	cis	rs3773445	0.740	rs1730223	chr3:25618814	G/A	cg02315353	chr3:25825455	NGLY1	0.56	4.77	0.44	6.63e-6	Airway responsiveness in chronic obstructive pulmonary disease;
THYM	cis	rs7772486	0.790	rs2814879	chr6:146201743	T/C	cg13319975	chr6:146136371	FBXO30	-0.71	-5.72	-0.51	1.24e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12594515	1.000	rs6493169	chr15:45986994	A/G	cg01629716	chr15:45996671	NA	-0.49	-4.97	-0.45	2.98e-6	Waist circumference;Weight;
THYM	cis	rs4474465	1.000	rs10899534	chr11:78210502	G/C	cg19901956	chr11:77921274	USP35	0.65	4.8	0.44	5.97e-6	Alzheimer's disease (survival time);
THYM	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg06027949	chr8:82754900	SNX16	0.64	5.35	0.48	6.18e-7	Diastolic blood pressure;
THYM	cis	rs4792901	0.765	rs2127224	chr17:41569025	C/T	cg21940313	chr17:41620911	ETV4	-0.53	-5.03	-0.46	2.28e-6	Dupuytren's disease;
THYM	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg11189052	chr15:85197271	WDR73	-0.62	-4.7	-0.43	8.86e-6	P wave terminal force;
THYM	cis	rs7772486	0.686	rs9497396	chr6:146014963	C/A	cg13319975	chr6:146136371	FBXO30	0.67	5.47	0.49	3.57e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg23281280	chr6:28129359	ZNF389	0.57	5.01	0.46	2.56e-6	Depression;
THYM	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg26967526	chr14:35346199	BAZ1A	-0.74	-4.84	-0.44	4.99e-6	Psoriasis;
THYM	cis	rs2692947	0.673	rs4907279	chr2:96399968	G/C	cg22654517	chr2:96458247	NA	0.71	5.14	0.47	1.47e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.7	4.71	0.43	8.57e-6	Menarche (age at onset);
THYM	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg03806693	chr22:41940476	POLR3H	1.11	8.99	0.68	2.33e-14	Vitiligo;
THYM	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg10150615	chr22:24372951	LOC391322	-1.01	-11.49	-0.76	1.12e-19	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7523273	0.564	rs1977265	chr1:207880683	G/T	cg22525895	chr1:207977042	MIR29B2	-0.53	-4.87	-0.45	4.49e-6	Schizophrenia;
THYM	cis	rs478304	0.651	rs12225620	chr11:65505448	T/C	cg27068330	chr11:65405492	SIPA1	-0.96	-9.31	-0.69	4.93e-15	Acne (severe);
THYM	cis	rs9633835	0.642	rs1982350	chr11:13350131	A/G	cg13286116	chr11:13302098	ARNTL	-0.65	-6.72	-0.57	1.35e-9	Body mass index;
THYM	cis	rs6809651	0.524	rs1356291	chr3:185824644	C/T	cg00760338	chr3:185826511	ETV5	0.89	6.99	0.58	3.77e-10	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
THYM	cis	rs4363385	0.693	rs2339487	chr1:152983528	C/T	cg13444842	chr1:152974279	SPRR3	-0.58	-4.72	-0.44	8.22e-6	Inflammatory skin disease;
THYM	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg11764359	chr7:65958608	NA	0.7	4.89	0.45	4.09e-6	Aortic root size;
THYM	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-11.18	-0.75	5.02e-19	Height;
THYM	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.85	7.62	0.62	1.88e-11	Cognitive ability;
THYM	cis	rs1349547	0.510	rs12708194	chr8:39496029	T/C	cg01911981	chr8:39380341	ADAM3A	-0.52	-4.55	-0.42	1.6e-5	HIV-1 susceptibility;
THYM	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg24308560	chr3:49941425	MST1R	-0.76	-6.48	-0.55	4.12e-9	Intelligence (multi-trait analysis);
THYM	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg05025164	chr4:1340916	KIAA1530	0.65	4.74	0.44	7.39e-6	Longevity;
THYM	cis	rs9649213	0.614	rs12539761	chr7:98013839	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.68	-5.75	-0.51	1.08e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12519773	0.526	rs4285204	chr5:92528272	C/T	cg18783429	chr5:92414398	NA	0.5	4.94	0.45	3.31e-6	Migraine;
THYM	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg23583168	chr7:148888333	NA	-1.02	-14.11	-0.82	4.74e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs4808199	0.847	rs34647936	chr19:19548239	T/G	cg03709012	chr19:19516395	GATAD2A	1.17	7.57	0.61	2.43e-11	Nonalcoholic fatty liver disease;
THYM	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg27532560	chr4:187881888	NA	-0.96	-11.3	-0.76	2.88e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1003719	0.762	rs8130846	chr21:38480242	G/A	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg05738196	chr6:26577821	NA	0.83	7.86	0.63	6e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7432375	1.000	rs6439649	chr3:136371691	G/T	cg21827317	chr3:136751795	NA	-0.57	-4.86	-0.45	4.62e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.77	-5.61	-0.5	1.98e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7000551	0.751	rs2469755	chr8:22360212	G/A	cg12081754	chr8:22256438	SLC39A14	0.68	6.12	0.53	2.07e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg04865290	chr3:52927548	TMEM110	-0.96	-4.97	-0.45	2.97e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs7106204	0.609	rs11827033	chr11:24305935	A/G	ch.11.24196551F	chr11:24239977	NA	1.02	6.49	0.55	3.95e-9	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg07936489	chr17:37558343	FBXL20	-0.79	-5.34	-0.48	6.34e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg15242686	chr22:24348715	GSTTP1	0.55	5.08	0.46	1.9e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs600550	0.528	rs10897007	chr11:59851999	A/C	cg02771260	chr11:59836817	MS4A3	0.8	6.21	0.54	1.42e-8	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs7616559	0.849	rs4680334	chr3:156761722	A/G	cg15697575	chr3:156784781	NA	0.42	5.37	0.48	5.54e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs7572733	0.555	rs2164071	chr2:198915467	T/C	cg00792783	chr2:198669748	PLCL1	0.73	4.79	0.44	6.22e-6	Dermatomyositis;
THYM	cis	rs7115242	0.699	rs12285074	chr11:116762028	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.89	-4.55	-0.42	1.58e-5	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
THYM	cis	rs61931739	0.782	rs451940	chr12:34196005	T/C	cg10856724	chr12:34555212	NA	-0.6	-5.47	-0.49	3.6e-7	Morning vs. evening chronotype;
THYM	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	8.85	0.67	4.81e-14	Chronic sinus infection;
THYM	cis	rs7943203	0.886	rs10890848	chr11:108361278	A/G	cg04873221	chr11:107992290	ACAT1	-0.62	-4.51	-0.42	1.88e-5	Red blood cell count;Mean corpuscular volume;
THYM	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg23131131	chr22:24373011	LOC391322	0.82	6.51	0.56	3.59e-9	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg16558253	chr16:72132732	DHX38	-0.57	-4.83	-0.44	5.22e-6	Fibrinogen levels;
THYM	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg03806693	chr22:41940476	POLR3H	1.04	7.62	0.62	1.86e-11	Vitiligo;
THYM	cis	rs6496667	0.509	rs57962570	chr15:90985596	C/G	cg22089800	chr15:90895588	ZNF774	0.66	4.88	0.45	4.26e-6	Rheumatoid arthritis;
THYM	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg05025164	chr4:1340916	KIAA1530	0.65	5.02	0.46	2.39e-6	Longevity;
THYM	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg12011299	chr4:100065546	ADH4	0.87	8.38	0.65	4.76e-13	Smoking initiation;
THYM	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg02038168	chr22:39784481	NA	-0.6	-4.69	-0.43	9.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2404602	0.647	rs12440965	chr15:76958591	G/A	cg23625390	chr15:77176239	SCAPER	-0.86	-5.94	-0.52	4.58e-8	Blood metabolite levels;
THYM	cis	rs6906287	0.609	rs13191610	chr6:118945317	G/A	cg21191810	chr6:118973309	C6orf204	0.57	5.73	0.51	1.17e-7	Electrocardiographic conduction measures;
THYM	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg24112000	chr20:60950667	NA	-0.82	-7.34	-0.6	7.37e-11	Colorectal cancer;
THYM	cis	rs7781557	1.000	rs12113073	chr7:102482527	T/C	cg06322601	chr7:102330635	NA	0.67	4.99	0.46	2.75e-6	Colorectal adenoma (advanced);
THYM	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg08859206	chr1:53392774	SCP2	-0.79	-9.57	-0.7	1.39e-15	Monocyte count;
THYM	cis	rs2997447	0.655	rs2275950	chr1:26385003	T/C	cg19633962	chr1:26362018	EXTL1	-0.69	-4.52	-0.42	1.81e-5	QRS complex (12-leadsum);
THYM	cis	rs10851411	1.000	rs10851411	chr15:42859235	T/G	cg04308337	chr15:42867303	STARD9	-0.64	-4.86	-0.45	4.54e-6	Glucose homeostasis traits;
THYM	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg21100191	chr22:23484243	RTDR1	0.72	6.3	0.54	9.05e-9	Bone mineral density;
THYM	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs79149102	0.579	rs59303424	chr15:75370014	G/A	cg09165964	chr15:75287851	SCAMP5	-0.92	-5.22	-0.47	1.04e-6	Lung cancer;
THYM	cis	rs1129187	0.837	rs4714634	chr6:42901120	G/A	cg21280719	chr6:42927975	GNMT	-0.51	-6.48	-0.55	4e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.44e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs6032067	0.777	rs34073275	chr20:43788917	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg10047753	chr17:41438598	NA	1.18	11.26	0.76	3.4e-19	Menopause (age at onset);
THYM	cis	rs12282928	1.000	rs12292297	chr11:48329794	C/A	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs6842047	1.000	rs72647308	chr4:187135129	G/A	cg09526685	chr4:187126073	CYP4V2	-1.23	-6.35	-0.55	7.22e-9	Blood protein levels;
THYM	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg27284194	chr4:1044797	NA	0.62	4.73	0.44	7.81e-6	Recombination rate (females);
THYM	cis	rs10992471	0.512	rs331379	chr9:95261104	A/G	cg14631576	chr9:95140430	CENPP	-0.57	-4.65	-0.43	1.06e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs3008870	0.755	rs10749766	chr1:67376921	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.76	6.44	0.55	4.77e-9	Lymphocyte percentage of white cells;
THYM	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.16	-8.93	-0.68	3.25e-14	Platelet count;
THYM	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg24578937	chr1:2090814	PRKCZ	0.55	5.39	0.48	5.14e-7	Height;
THYM	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg17178900	chr1:205818956	PM20D1	0.79	8.0	0.63	3e-12	Menarche (age at onset);
THYM	cis	rs7224296	0.709	rs199518	chr17:44854580	A/C	cg15921436	chr17:44337874	NA	-0.73	-5.8	-0.51	8.8e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9583531	0.600	rs6492305	chr13:111361400	C/T	cg24331049	chr13:111365604	ING1	0.72	6.04	0.53	2.96e-8	Coronary artery disease;
THYM	cis	rs11031096	0.711	rs10835694	chr11:4178757	G/C	cg22027985	chr11:4115532	RRM1	-0.5	-4.6	-0.43	1.3e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg20503657	chr10:835505	NA	1.17	8.37	0.65	5e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg06808227	chr14:105710500	BRF1	-1.02	-8.64	-0.66	1.33e-13	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg06634786	chr22:41940651	POLR3H	0.64	4.7	0.43	8.65e-6	Vitiligo;
THYM	cis	rs7772486	0.686	rs9373473	chr6:146082282	A/G	cg23711669	chr6:146136114	FBXO30	0.83	7.91	0.63	4.62e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7729447	0.813	rs4867121	chr5:32692548	T/C	cg16267343	chr5:32710456	NPR3	0.79	7.16	0.59	1.69e-10	Blood pressure;
THYM	cis	rs9906944	0.703	rs940088	chr17:47145848	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.5	-4.95	-0.45	3.25e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg09549813	chr16:4587862	C16orf5	0.57	6.23	0.54	1.24e-8	Schizophrenia;
THYM	cis	rs11731175	1.000	rs78853394	chr4:189860440	A/G	cg00431894	chr4:189871012	NA	-0.82	-6.24	-0.54	1.2e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg04681579	chr7:75027559	TRIM73;TRIM74	0.75	5.84	0.51	7.38e-8	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs28595532	0.920	rs114796605	chr4:119744472	C/A	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs921968	0.565	rs6436070	chr2:219597960	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8133932	0.654	rs375254	chr21:47337151	T/A	cg20357416	chr21:47294739	PCBP3	0.8	4.88	0.45	4.26e-6	Schizophrenia;
THYM	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg02269571	chr22:50332266	NA	-0.71	-4.91	-0.45	3.78e-6	Schizophrenia;
THYM	cis	rs12476592	0.543	rs262537	chr2:63907331	T/C	cg17519650	chr2:63277830	OTX1	0.72	4.73	0.44	7.77e-6	Childhood ear infection;
THYM	cis	rs4499344	0.556	rs259219	chr19:33138067	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.93	6.54	0.56	3.01e-9	Mean platelet volume;
THYM	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.8	-7.41	-0.61	5.14e-11	Personality dimensions;
THYM	cis	rs4654899	0.785	rs12070677	chr1:21337322	A/G	cg01072550	chr1:21505969	NA	-0.79	-7.73	-0.62	1.11e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg12560992	chr17:57184187	TRIM37	-0.92	-8.68	-0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs750460	1.000	rs750460	chr15:74241506	G/A	cg23484268	chr15:74220776	LOXL1	-0.4	-4.45	-0.42	2.34e-5	Height;
THYM	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg00677455	chr12:58241039	CTDSP2	0.72	4.87	0.45	4.51e-6	Multiple sclerosis;
THYM	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs1198430	0.759	rs1198438	chr1:23749557	C/G	cg19827787	chr1:23763612	ASAP3	0.58	4.6	0.43	1.32e-5	Total cholesterol levels;
THYM	cis	rs7586879	0.639	rs6713978	chr2:25120851	T/C	cg01884057	chr2:25150051	NA	0.71	7.7	0.62	1.31e-11	Body mass index;
THYM	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.9	9.4	0.69	3.1e-15	Chronic sinus infection;
THYM	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.66	4.63	0.43	1.18e-5	Aortic root size;
THYM	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg16306078	chr6:126000798	NA	-0.54	-5.49	-0.49	3.35e-7	Endometrial cancer;
THYM	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg17911788	chr17:44343683	NA	0.6	6.01	0.52	3.4e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs78761021	0.514	rs4791906	chr17:9795452	A/G	cg26853458	chr17:9805074	RCVRN	-0.47	-4.54	-0.42	1.66e-5	Type 2 diabetes;
THYM	cis	rs13064411	0.696	rs6773497	chr3:113186514	T/C	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg00129232	chr17:37814104	STARD3	0.77	5.27	0.48	8.58e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2219968	0.525	rs10103514	chr8:78872622	C/T	cg00738934	chr8:78996279	NA	0.61	4.95	0.45	3.21e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10504906	0.643	rs10099661	chr8:92414961	A/G	cg09373786	chr8:93156639	NA	1.3	4.56	0.42	1.5e-5	Fat distribution (HIV);
THYM	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs6500395	1.000	rs2355297	chr16:48685338	T/C	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg18512352	chr11:47633146	NA	-0.48	-5.88	-0.52	6.08e-8	Subjective well-being;
THYM	cis	rs35883536	0.528	rs10783138	chr1:101031061	C/T	cg06223162	chr1:101003688	GPR88	0.86	7.07	0.59	2.63e-10	Monocyte count;
THYM	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg18252515	chr7:66147081	NA	-1.44	-8.51	-0.66	2.48e-13	Diabetic kidney disease;
THYM	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg26597838	chr10:835615	NA	-0.88	-5.11	-0.46	1.67e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg24375607	chr4:120327624	NA	0.58	4.74	0.44	7.61e-6	Corneal astigmatism;
THYM	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg22815214	chr1:201083145	CACNA1S	0.74	6.78	0.57	1.01e-9	Permanent tooth development;
THYM	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg12311346	chr5:56204834	C5orf35	-0.78	-5.72	-0.51	1.26e-7	Initial pursuit acceleration;
THYM	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg21640587	chr11:117668038	DSCAML1	1.04	9.4	0.69	3.13e-15	Myopia;
THYM	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7267979	1.000	rs2424713	chr20:25418482	C/T	cg08601574	chr20:25228251	PYGB	0.58	4.69	0.43	8.97e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg18876405	chr7:65276391	NA	0.58	4.83	0.44	5.18e-6	Aortic root size;
THYM	cis	rs9435341	0.965	rs1335055	chr1:107624563	A/G	cg00944433	chr1:107599041	PRMT6	-0.4	-5.21	-0.47	1.08e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs2219968	0.962	rs13266874	chr8:78946400	T/C	cg00738934	chr8:78996279	NA	0.79	8.42	0.65	3.88e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg26879891	chr1:152191343	HRNR	-0.56	-4.86	-0.45	4.69e-6	Inflammatory skin disease;
THYM	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg13026072	chr11:65380126	MAP3K11	0.58	4.9	0.45	3.9e-6	Blood pressure (age interaction);
THYM	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg16325326	chr1:53192061	ZYG11B	-0.77	-5.72	-0.51	1.21e-7	Monocyte count;
THYM	cis	rs6930083	0.510	rs4713994	chr6:36621533	A/G	cg11920449	chr6:36645608	CDKN1A	0.75	5.67	0.5	1.52e-7	Coronary artery disease;
THYM	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs11651000	0.894	rs11650354	chr17:45822092	A/G	cg24803719	chr17:45855879	NA	0.62	5.28	0.48	8.19e-7	IgG glycosylation;
THYM	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg10802521	chr3:52805072	NEK4	-0.8	-7.53	-0.61	2.92e-11	Bipolar disorder;
THYM	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg17105886	chr17:28927953	LRRC37B2	1.32	6.56	0.56	2.79e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.16	-8.93	-0.68	3.28e-14	Schizophrenia;
THYM	cis	rs7103648	0.864	rs12801188	chr11:47388214	G/A	cg20307385	chr11:47447363	PSMC3	0.82	6.55	0.56	2.97e-9	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs1448094	0.512	rs6539928	chr12:86244920	G/A	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs3008870	1.000	rs3008848	chr1:67379284	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	7.79	0.62	8.27e-12	Lymphocyte percentage of white cells;
THYM	cis	rs9790314	0.601	rs1450519	chr3:161094930	A/G	cg03342759	chr3:160939853	NMD3	-0.64	-5.28	-0.48	8.11e-7	Morning vs. evening chronotype;
THYM	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg22907277	chr7:1156413	C7orf50	0.81	4.89	0.45	4.1e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2295359	0.892	rs72676067	chr1:67658803	G/A	cg11235152	chr1:67600687	NA	0.66	5.35	0.48	6.17e-7	Psoriasis;
THYM	cis	rs2862064	1.000	rs6896499	chr5:156431325	A/G	cg12943317	chr5:156479607	HAVCR1	-0.86	-5.28	-0.48	8.3e-7	Platelet count;
THYM	cis	rs12935418	0.523	rs1469126	chr16:81029889	G/A	cg16651780	chr16:81037892	C16orf61	-0.84	-6.39	-0.55	6.03e-9	Mean corpuscular volume;
THYM	cis	rs11166927	0.934	rs7015426	chr8:140802688	C/G	cg16909799	chr8:140841666	TRAPPC9	0.61	5.37	0.48	5.55e-7	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg10047753	chr17:41438598	NA	1.07	9.29	0.69	5.32e-15	Menopause (age at onset);
THYM	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg27398817	chr8:82754497	SNX16	0.71	6.05	0.53	2.89e-8	Diastolic blood pressure;
THYM	cis	rs6570726	0.791	rs378937	chr6:145834745	C/T	cg23711669	chr6:146136114	FBXO30	0.96	9.31	0.69	5.05e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs2738048	0.545	rs2738168	chr8:6824577	G/T	cg24860332	chr8:6827800	DEFA10P	-0.7	-5.49	-0.49	3.38e-7	IgA nephropathy;
THYM	cis	rs8133932	0.906	rs112980369	chr21:47063054	C/T	cg20357416	chr21:47294739	PCBP3	0.84	4.85	0.45	4.87e-6	Schizophrenia;
THYM	cis	rs938554	0.571	rs12509955	chr4:10024303	C/T	cg26689780	chr4:10079554	WDR1	0.41	4.54	0.42	1.68e-5	Blood metabolite levels;
THYM	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg10515332	chr4:99064459	C4orf37	0.57	4.54	0.42	1.68e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg14159672	chr1:205819179	PM20D1	0.72	5.67	0.5	1.53e-7	Menarche (age at onset);
THYM	cis	rs3820068	0.608	rs12091750	chr1:16042766	T/C	cg13390004	chr1:15929781	NA	0.65	4.81	0.44	5.56e-6	Systolic blood pressure;
THYM	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs992157	0.932	rs4672884	chr2:219182481	G/A	cg00012203	chr2:219082015	ARPC2	-0.61	-5.26	-0.48	8.81e-7	Colorectal cancer;
THYM	cis	rs944002	1.000	rs62006947	chr14:103565370	A/G	cg16996574	chr14:103691482	NA	0.52	4.79	0.44	6.21e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;
THYM	cis	rs977987	0.806	rs4638613	chr16:75425553	C/T	cg03315344	chr16:75512273	CHST6	0.73	6.16	0.53	1.73e-8	Dupuytren's disease;
THYM	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg03806693	chr22:41940476	POLR3H	1.25	10.88	0.74	2.22e-18	Vitiligo;
THYM	cis	rs595982	0.527	rs73061656	chr19:49372355	G/A	cg19746536	chr19:49375674	PPP1R15A	0.81	4.45	0.42	2.35e-5	Red cell distribution width;
THYM	cis	rs1448094	0.510	rs1993806	chr12:86147151	T/C	cg00310523	chr12:86230176	RASSF9	-0.57	-5.07	-0.46	1.98e-6	Major depressive disorder;
THYM	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg15536230	chr21:44985092	HSF2BP	-0.43	-5.4	-0.48	4.83e-7	Mean corpuscular volume;
THYM	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg18230493	chr5:56204884	C5orf35	-0.91	-6.9	-0.58	5.71e-10	Initial pursuit acceleration;
THYM	cis	rs6500602	0.778	rs7184899	chr16:4472087	T/A	cg09549813	chr16:4587862	C16orf5	-0.49	-5.27	-0.48	8.52e-7	Schizophrenia;
THYM	cis	rs42648	0.837	rs13239439	chr7:89924400	C/A	cg25739043	chr7:89950458	NA	-0.53	-4.53	-0.42	1.72e-5	Homocysteine levels;
THYM	cis	rs9788721	1.000	rs8031948	chr15:78816057	G/T	cg18825076	chr15:78729989	IREB2	-0.59	-5.36	-0.48	5.92e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs1629083	0.967	rs4938492	chr11:118126675	T/C	cg25155064	chr11:118100782	MPZL3	-0.57	-5.03	-0.46	2.34e-6	Lung cancer;
THYM	cis	rs9486719	0.857	rs4265039	chr6:96878929	T/C	cg18709589	chr6:96969512	KIAA0776	0.64	4.56	0.42	1.5e-5	Migraine;Coronary artery disease;
THYM	cis	rs4148087	0.932	rs2839476	chr21:43609680	A/T	cg09727148	chr21:43560719	UMODL1	0.67	5.24	0.47	9.71e-7	Eating disorder in bipolar disorder;
THYM	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg06074448	chr4:187884817	NA	-0.77	-7.94	-0.63	4.02e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	trans	rs17685	0.753	rs10476	chr7:75696420	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.1	-12.69	-0.79	3.63e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7258465	0.965	rs2385088	chr19:18545540	A/G	cg01380346	chr19:18557039	ELL	-0.49	-5.01	-0.46	2.53e-6	Breast cancer;
THYM	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs988913	0.957	rs932452	chr6:54801928	C/T	cg18532076	chr6:54711417	FAM83B	0.52	4.8	0.44	5.92e-6	Menarche (age at onset);
THYM	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg08213375	chr14:104286397	PPP1R13B	0.5	6.09	0.53	2.39e-8	Schizophrenia;
THYM	cis	rs4654899	0.758	rs7530739	chr1:21447480	C/A	cg01072550	chr1:21505969	NA	-0.76	-7.43	-0.61	4.71e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs79387448	0.655	rs79144324	chr2:102932814	G/A	cg09003973	chr2:102972529	NA	1.29	6.82	0.57	8.38e-10	Gut microbiota (bacterial taxa);
THYM	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg20891558	chr2:74357851	NA	1.12	11.34	0.76	2.33e-19	Gestational age at birth (maternal effect);
THYM	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg02527881	chr3:46936655	PTH1R	0.54	5.22	0.47	1.07e-6	Colorectal cancer;
THYM	cis	rs8135828	0.770	rs5763303	chr22:29929744	A/G	cg16189954	chr22:29138267	HSCB;CHEK2	0.77	4.7	0.43	8.66e-6	Lipid traits;
THYM	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.6	-0.5	2.11e-7	Menopause (age at onset);
THYM	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	trans	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg19862616	chr7:65841803	NCRNA00174	1.08	12.96	0.8	1.02e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg26031613	chr14:104095156	KLC1	0.98	7.74	0.62	1.07e-11	Body mass index;
THYM	cis	rs7582180	0.663	rs10199518	chr2:100946041	G/A	cg21926883	chr2:100939477	LONRF2	-0.64	-5.9	-0.52	5.54e-8	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs654950	0.875	rs586055	chr1:41999076	T/C	cg06885757	chr1:42089581	HIVEP3	0.46	5.44	0.49	4.1e-7	Airway imaging phenotypes;
THYM	cis	rs9902453	0.967	rs8082175	chr17:28430303	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.76	0.44	6.86e-6	Coffee consumption (cups per day);
THYM	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs2282300	0.739	rs7952339	chr11:30327344	C/T	cg06241208	chr11:30344200	C11orf46	0.79	5.98	0.52	3.94e-8	Morning vs. evening chronotype;
THYM	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs72627123	1.000	rs17093474	chr14:74342413	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.74	4.63	0.43	1.15e-5	Morning vs. evening chronotype;
THYM	cis	rs2637266	1.000	rs2579750	chr10:78340260	C/G	cg18941641	chr10:78392320	NA	-0.78	-6.74	-0.57	1.23e-9	Pulmonary function;
THYM	cis	rs1957429	0.634	rs7143541	chr14:65419777	G/T	cg23373153	chr14:65346875	NA	-0.92	-5.45	-0.49	3.88e-7	Pediatric areal bone mineral density (radius);
THYM	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg26513180	chr16:89883248	FANCA	0.72	7.28	0.6	9.52e-11	Vitiligo;
THYM	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg07884673	chr3:53033167	SFMBT1	1.11	5.86	0.52	6.73e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs13315871	0.929	rs35007301	chr3:58230352	G/A	cg12435725	chr3:58293450	RPP14	-0.52	-5.62	-0.5	1.91e-7	Cholesterol, total;
THYM	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00908189	chr16:619842	PIGQ	1.03	9.46	0.7	2.34e-15	Height;
THYM	cis	rs2273669	0.504	rs79498470	chr6:109499259	A/G	cg17117243	chr6:109341365	SESN1	-0.77	-4.56	-0.42	1.5e-5	Prostate cancer;
THYM	cis	rs1003719	0.715	rs2835642	chr21:38539066	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs1568889	0.838	rs1525717	chr11:28081205	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.82	6.81	0.57	8.87e-10	Bipolar disorder;
THYM	cis	rs1784581	0.599	rs1789992	chr6:162401854	A/G	cg17173639	chr6:162384350	PARK2	-0.87	-7.94	-0.63	4.12e-12	Itch intensity from mosquito bite;
THYM	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7568458	0.870	rs1010	chr2:85808982	C/T	cg17127132	chr2:85788382	GGCX	-0.59	-4.46	-0.42	2.23e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs41005	0.805	rs10469618	chr2:8117622	C/T	cg03155496	chr2:8117019	LOC339788	-0.91	-9.01	-0.68	2.16e-14	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs2294693	0.945	rs9462668	chr6:41004194	T/C	cg14418226	chr6:40996092	UNC5CL	0.68	5.62	0.5	1.9e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg19196401	chr6:110721138	DDO	0.61	7.02	0.58	3.24e-10	Platelet distribution width;
THYM	cis	rs7084402	0.902	rs3001715	chr10:60285509	A/G	cg07615347	chr10:60278583	BICC1	0.61	5.57	0.5	2.41e-7	Refractive error;
THYM	cis	rs524281	0.773	rs2155030	chr11:66030687	A/G	cg00563793	chr11:65837595	PACS1	0.81	4.87	0.45	4.42e-6	Electroencephalogram traits;
THYM	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg03452623	chr4:187889614	NA	-1.19	-19.02	-0.89	3.66e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2811415	0.597	rs9882664	chr3:127766058	A/C	cg05377949	chr3:127951287	EEFSEC	-0.39	-4.83	-0.44	5.14e-6	Lung function (FEV1/FVC);
THYM	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg24675658	chr1:53192096	ZYG11B	0.58	4.66	0.43	1.04e-5	Monocyte count;
THYM	cis	rs6430585	0.759	rs4954623	chr2:136535876	G/A	cg23851026	chr2:136556271	LCT	-0.8	-7.6	-0.61	2.12e-11	Corneal structure;
THYM	cis	rs72827839	0.739	rs16953235	chr17:46244948	A/G	cg23391107	chr17:45924227	SP6	0.83	5.6	0.5	2.08e-7	Ease of getting up in the morning;
THYM	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg13390004	chr1:15929781	NA	0.59	4.57	0.42	1.47e-5	Systolic blood pressure;
THYM	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg11764359	chr7:65958608	NA	0.74	5.45	0.49	4e-7	Aortic root size;
THYM	cis	rs4363385	0.588	rs6660878	chr1:153027068	A/G	cg13444842	chr1:152974279	SPRR3	-0.62	-4.98	-0.45	2.89e-6	Inflammatory skin disease;
THYM	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg23958373	chr8:599963	NA	0.94	4.75	0.44	7.32e-6	IgG glycosylation;
THYM	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1456522	0.500	rs12615032	chr2:199838620	G/A	ch.2.199792288R	chr2:200084043	NA	0.57	4.56	0.42	1.53e-5	Menarche (age at onset);
THYM	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg15744005	chr10:104629667	AS3MT	-0.83	-7.67	-0.62	1.47e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg06558623	chr16:89946397	TCF25	1.29	5.94	0.52	4.62e-8	Skin colour saturation;
THYM	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg19507638	chr5:93509721	C5orf36	-0.69	-4.54	-0.42	1.62e-5	Diabetic retinopathy;
THYM	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg02070205	chr10:30722105	MAP3K8	-0.67	-6.05	-0.53	2.88e-8	Inflammatory bowel disease;
THYM	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg08847533	chr14:75593920	NEK9	-1.02	-11.28	-0.76	3.21e-19	Height;
THYM	cis	rs10887741	0.966	rs7085195	chr10:89429897	T/C	cg13926569	chr10:89418898	PAPSS2	0.59	5.98	0.52	3.93e-8	Exercise (leisure time);
THYM	cis	rs12200782	0.530	rs9379892	chr6:26582414	G/A	cg12826209	chr6:26865740	GUSBL1	0.84	5.11	0.46	1.63e-6	Small cell lung carcinoma;
THYM	cis	rs10857712	0.521	rs10857714	chr10:135235370	C/A	cg19904058	chr10:135279010	LOC619207	-0.45	-4.68	-0.43	9.64e-6	Systemic lupus erythematosus;
THYM	cis	rs7107174	1.000	rs7112234	chr11:78102470	G/A	cg19901956	chr11:77921274	USP35	-0.66	-5.48	-0.49	3.55e-7	Testicular germ cell tumor;
THYM	cis	rs4631830	0.832	rs2843554	chr10:51523861	G/T	cg10326726	chr10:51549505	MSMB	-0.55	-5.5	-0.49	3.19e-7	Prostate-specific antigen levels;
THYM	cis	rs3744028	0.532	rs9903200	chr17:73839498	G/A	cg07010633	chr17:73824396	UNC13D	-0.55	-5.42	-0.49	4.49e-7	White matter hyperintensity burden;
THYM	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg23649088	chr2:200775458	C2orf69	0.83	7.09	0.59	2.39e-10	Osteoporosis;
THYM	cis	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg07460842	chr6:66804631	NA	-0.9	-6.58	-0.56	2.6e-9	Exhaled nitric oxide output;
THYM	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg12310025	chr6:25882481	NA	-0.69	-5.58	-0.5	2.3e-7	Blood metabolite levels;
THYM	cis	rs786425	0.585	rs2333834	chr12:124246004	G/A	cg15249119	chr12:124971054	NCOR2	0.54	4.86	0.45	4.62e-6	Pubertal anthropometrics;
THYM	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg17366294	chr4:99064904	C4orf37	0.57	6.82	0.57	8.42e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.71	5.63	0.5	1.8e-7	Tonsillectomy;
THYM	cis	rs17152411	1.000	rs7077936	chr10:126650065	C/T	cg07906193	chr10:126599966	NA	0.68	4.69	0.43	8.98e-6	Height;
THYM	cis	rs17125944	0.615	rs1998777	chr14:53295706	C/T	cg00686598	chr14:53173677	PSMC6	-0.88	-4.49	-0.42	2.02e-5	Alzheimer's disease (late onset);
THYM	cis	rs9302065	0.636	rs2389235	chr13:95955623	G/T	cg24476569	chr13:95954382	ABCC4	-0.76	-7.57	-0.61	2.38e-11	Blood metabolite levels;
THYM	cis	rs2811415	0.531	rs13063727	chr3:127767618	C/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4523957	0.890	rs12941836	chr17:2194874	C/G	cg16513277	chr17:2031491	SMG6	0.77	7.24	0.6	1.15e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg10755058	chr3:40428713	ENTPD3	-0.54	-4.57	-0.42	1.47e-5	Renal cell carcinoma;
THYM	cis	rs8092503	0.536	rs12962587	chr18:52459472	C/T	cg07519816	chr18:53447596	NA	0.83	4.84	0.44	5.05e-6	Childhood body mass index;
THYM	cis	rs7512552	0.839	rs1694369	chr1:150351101	A/G	cg15654264	chr1:150340011	RPRD2	0.45	5.2	0.47	1.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg02196655	chr2:10830764	NOL10	-0.42	-4.46	-0.42	2.28e-5	Prostate cancer;
THYM	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg19729930	chr2:74357872	NA	1.29	13.66	0.81	3.83e-24	Gestational age at birth (maternal effect);
THYM	cis	rs12142240	0.698	rs12385697	chr1:46818898	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs12257961	0.640	rs3891994	chr10:15388903	A/G	cg10616319	chr10:15468812	NA	0.54	4.51	0.42	1.86e-5	Selective IgA deficiency;
THYM	cis	rs1267303	0.642	rs7542296	chr1:46998009	A/G	cg25110126	chr1:46999211	NA	0.71	5.92	0.52	5.04e-8	Monobrow;
THYM	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg15744005	chr10:104629667	AS3MT	-0.82	-7.79	-0.62	8.37e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg23791538	chr6:167370224	RNASET2	0.74	5.92	0.52	5.06e-8	Crohn's disease;
THYM	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg13319975	chr6:146136371	FBXO30	-0.68	-5.91	-0.52	5.44e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11039798	0.925	rs7482967	chr11:48613527	T/A	cg24672777	chr11:48374446	OR4C45	-1.14	-6.95	-0.58	4.55e-10	Axial length;
THYM	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg21798802	chr22:38057573	PDXP	0.47	5.37	0.48	5.51e-7	Fat distribution (HIV);
THYM	cis	rs6980334	1.000	rs6977075	chr7:137775867	C/T	cg22979093	chr7:137028410	PTN	-0.61	-4.91	-0.45	3.77e-6	Blood metabolite ratios;
THYM	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg13695892	chr22:41940480	POLR3H	-0.86	-7.38	-0.6	5.88e-11	Vitiligo;
THYM	cis	rs981844	0.712	rs921882	chr4:154752878	A/C	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs79149102	0.579	rs8034149	chr15:75311842	G/C	cg09165964	chr15:75287851	SCAMP5	-1.11	-6.45	-0.55	4.67e-9	Lung cancer;
THYM	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg06074448	chr4:187884817	NA	-1.01	-13.54	-0.81	6.7e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg18876405	chr7:65276391	NA	0.58	4.83	0.44	5.18e-6	Aortic root size;
THYM	cis	rs10911251	0.509	rs4652780	chr1:183105923	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.75	0.44	7.18e-6	Colorectal cancer;
THYM	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg00129232	chr17:37814104	STARD3	-0.76	-5.13	-0.47	1.52e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs8050907	0.744	rs17137053	chr16:4524155	C/G	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.3	5.2	0.47	1.16e-6	Obesity-related traits;
THYM	cis	rs56161922	0.818	rs55638397	chr1:207856040	G/A	cg09557387	chr1:207818395	CR1L	1.15	5.31	0.48	7.12e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	trans	rs629535	0.814	rs78813708	chr8:70073977	A/G	cg21567404	chr3:27674614	NA	1.08	10.14	0.72	8.19e-17	Dupuytren's disease;
THYM	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg00271210	chr6:167070053	RPS6KA2	0.72	7.96	0.63	3.73e-12	Crohn's disease;
THYM	cis	rs10463554	0.927	rs34769	chr5:102447227	T/C	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Parkinson's disease;
THYM	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg18402987	chr7:1209562	NA	1.04	6.25	0.54	1.16e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs17689437	0.813	rs11644787	chr16:68668852	A/G	cg26468152	chr16:69355012	VPS4A	-0.66	-4.75	-0.44	7.34e-6	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
THYM	cis	rs1467026	0.691	rs9985266	chr3:12803162	C/T	cg05775895	chr3:12838266	CAND2	-0.84	-7.2	-0.59	1.41e-10	P wave duration;
THYM	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg17063962	chr7:91808500	NA	1.1	12.12	0.78	5.59e-21	Breast cancer;
THYM	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg05425664	chr17:57184151	TRIM37	0.59	4.75	0.44	7.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2273669	0.504	rs11966104	chr6:109459287	A/G	cg17117243	chr6:109341365	SESN1	-0.85	-4.99	-0.46	2.77e-6	Prostate cancer;
THYM	cis	rs55665837	1.000	rs2305305	chr11:14540942	C/T	cg19336497	chr11:14380999	RRAS2	-0.63	-6.91	-0.58	5.58e-10	Vitamin D levels;
THYM	cis	rs3820068	0.705	rs72645804	chr1:15868387	A/C	cg05660106	chr1:15850417	CASP9	1.14	9.89	0.71	2.91e-16	Systolic blood pressure;
THYM	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg10792982	chr14:105748885	BRF1	0.75	7.8	0.62	7.96e-12	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs2502731	0.539	rs3003609	chr9:130984755	A/G	cg13642260	chr9:130955380	CIZ1	-0.67	-5.27	-0.48	8.4e-7	Attention deficit hyperactivity disorder;
THYM	cis	rs9560113	0.573	rs9560134	chr13:112244011	C/T	cg15979348	chr13:112237479	NA	0.57	5.3	0.48	7.54e-7	Menarche (age at onset);
THYM	cis	rs6547741	0.874	rs58737572	chr2:27852118	A/C	cg27432699	chr2:27873401	GPN1	0.73	6.58	0.56	2.54e-9	Oral cavity cancer;
THYM	cis	rs977987	0.843	rs4888415	chr16:75448921	C/T	cg03315344	chr16:75512273	CHST6	0.76	6.16	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs12711979	0.509	rs10178286	chr2:3823821	A/G	cg17052675	chr2:3827356	NA	0.88	13.79	0.82	2.09e-24	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs10463554	0.759	rs34781	chr5:102454439	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.49e-6	Parkinson's disease;
THYM	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg16586182	chr3:47516702	SCAP	-0.59	-5.08	-0.46	1.88e-6	Colorectal cancer;
THYM	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.71	5.31	0.48	7.11e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4285028	0.747	rs7153	chr3:121383297	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.84	-7.2	-0.59	1.37e-10	Multiple sclerosis;
THYM	cis	rs6964587	0.626	rs10280301	chr7:91524258	A/T	cg17063962	chr7:91808500	NA	-1.01	-9.06	-0.68	1.73e-14	Breast cancer;
THYM	cis	rs2281845	0.895	rs7513829	chr1:201079590	C/A	cg22815214	chr1:201083145	CACNA1S	0.73	7.28	0.6	9.64e-11	Permanent tooth development;
THYM	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg11266682	chr4:10021025	SLC2A9	-0.52	-6.34	-0.55	7.56e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4901869	0.902	rs10149194	chr14:59308198	A/G	cg02291164	chr14:59296302	NA	-0.98	-10.6	-0.74	8.64e-18	Panic disorder;
THYM	cis	rs6565180	0.791	rs4247355	chr16:30392099	A/G	cg17640201	chr16:30407289	ZNF48	0.85	7.19	0.59	1.45e-10	Tonsillectomy;
THYM	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg15704280	chr7:45808275	SEPT13	1.02	11.76	0.77	3.15e-20	Coronary artery disease;
THYM	cis	rs9611565	0.506	rs1883825	chr22:41703408	A/G	cg06481639	chr22:41940642	POLR3H	-0.61	-4.7	-0.43	8.89e-6	Vitiligo;
THYM	cis	rs9814567	1.000	rs6793487	chr3:134299426	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.81	8.15	0.64	1.43e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs57920188	0.640	rs4311852	chr1:4085353	C/A	cg20703997	chr1:4087676	NA	1.13	7.47	0.61	3.89e-11	Interleukin-17 levels;
THYM	cis	rs985746	0.614	rs2118354	chr4:36802953	A/G	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg13397359	chr6:42928475	GNMT	0.61	5.49	0.49	3.39e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	trans	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg25214090	chr10:38739885	LOC399744	0.94	7.93	0.63	4.26e-12	Corneal astigmatism;
THYM	cis	rs35110281	0.575	rs2876854	chr21:44979232	A/G	cg27168131	chr21:44088823	PDE9A	-0.45	-4.47	-0.42	2.12e-5	Mean corpuscular volume;
THYM	cis	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg00495681	chr13:53174319	NA	0.6	5.68	0.5	1.44e-7	Lewy body disease;
THYM	cis	rs7695732	0.572	rs1903006	chr4:89891874	A/G	cg17769793	chr4:89976368	FAM13A	-0.5	-5.57	-0.5	2.36e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6032067	0.641	rs17423617	chr20:43768050	G/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.67	-5.94	-0.52	4.77e-8	Blood protein levels;
THYM	cis	rs36051895	0.658	rs10975029	chr9:5251068	T/C	cg02405213	chr9:5042618	JAK2	-0.94	-9.71	-0.71	6.99e-16	Pediatric autoimmune diseases;
THYM	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.85	8.97	0.68	2.63e-14	Menarche (age at onset);
THYM	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.03	9.65	0.7	9.36e-16	Colorectal cancer;
THYM	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	5.99	0.52	3.75e-8	Obesity-related traits;
THYM	cis	rs12410462	0.581	rs7547204	chr1:227560909	C/T	cg23173402	chr1:227635558	NA	0.75	5.92	0.52	5.2e-8	Major depressive disorder;
THYM	cis	rs4280164	0.551	rs3212242	chr14:24810401	C/T	cg22990158	chr14:24802150	ADCY4	0.55	4.86	0.45	4.64e-6	Parent of origin effect on language impairment (paternal);
THYM	cis	rs7828089	0.935	rs2293144	chr8:22262418	A/G	cg13512537	chr8:22265999	SLC39A14	-0.59	-4.79	-0.44	6.21e-6	Verbal declarative memory;
THYM	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs877282	0.945	rs12776447	chr10:790625	A/G	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs4713118	0.539	rs200951	chr6:27835930	A/G	cg08968635	chr6:28129556	ZNF389	0.42	4.61	0.43	1.26e-5	Parkinson's disease;
THYM	cis	rs12410462	0.681	rs74582965	chr1:227610126	C/T	cg23173402	chr1:227635558	NA	0.67	4.75	0.44	7.32e-6	Major depressive disorder;
THYM	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg17644776	chr2:200775616	C2orf69	-0.71	-5.03	-0.46	2.3e-6	Schizophrenia;
THYM	cis	rs73787773	0.668	rs73787784	chr5:111497125	G/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.93	-5.0	-0.46	2.61e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	trans	rs10752961	0.604	rs2024901	chr1:185996262	G/A	cg05824762	chr9:131533797	ZER1	-0.87	-6.98	-0.58	3.99e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.66	-4.8	-0.44	5.88e-6	Colorectal cancer;
THYM	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs4788570	0.566	rs16972808	chr16:71478717	A/G	cg06353428	chr16:71660113	MARVELD3	-0.94	-4.76	-0.44	6.89e-6	Intelligence (multi-trait analysis);
THYM	cis	rs673253	0.638	rs3791140	chr1:44051778	G/A	cg24466421	chr1:44070974	PTPRF	-0.62	-5.48	-0.49	3.5e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11039798	0.623	rs594615	chr11:48402804	T/C	cg24672777	chr11:48374446	OR4C45	0.96	6.27	0.54	1.05e-8	Axial length;
THYM	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg08999081	chr20:33150536	PIGU	-0.59	-5.28	-0.48	8.16e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs11739663	0.553	rs60444023	chr5:586340	A/C	cg16624210	chr5:671434	TPPP	0.69	6.83	0.57	8.19e-10	Ulcerative colitis;
THYM	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg00990874	chr7:1149470	C7orf50	0.63	4.66	0.43	1.01e-5	Bronchopulmonary dysplasia;
THYM	cis	rs1878931	0.582	rs9921152	chr16:3421199	A/G	cg22508957	chr16:3507546	NAT15	-0.49	-5.2	-0.47	1.13e-6	Body mass index (adult);
THYM	cis	rs12682352	0.652	rs3827806	chr8:8724276	C/T	cg17143192	chr8:8559678	CLDN23	0.62	4.73	0.44	7.76e-6	Neuroticism;
THYM	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.48	-5.22	-0.47	1.05e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10463554	0.926	rs3776858	chr5:102357494	A/G	cg23492399	chr5:102201601	PAM	-0.67	-5.18	-0.47	1.26e-6	Parkinson's disease;
THYM	cis	rs28595532	0.920	rs17324884	chr4:119771477	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs931127	1.000	rs931127	chr11:65405300	G/A	cg17480646	chr11:65405466	SIPA1	-0.64	-4.93	-0.45	3.43e-6	Systemic lupus erythematosus;
THYM	cis	rs1395	0.925	rs1659701	chr2:27414877	T/C	cg23587288	chr2:27483067	SLC30A3	0.57	5.09	0.46	1.78e-6	Blood metabolite levels;
THYM	cis	rs75920871	0.528	rs11216241	chr11:116899249	A/C	cg20608306	chr11:116969690	SIK3	-0.52	-5.85	-0.51	6.81e-8	Subjective well-being;
THYM	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg26513180	chr16:89883248	FANCA	0.53	4.76	0.44	6.99e-6	Vitiligo;
THYM	cis	rs868036	1.000	rs1026735	chr15:68101700	A/G	cg24579218	chr15:68104479	NA	-0.65	-6.51	-0.56	3.59e-9	Restless legs syndrome;
THYM	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg13395646	chr4:1353034	KIAA1530	-0.68	-6.12	-0.53	2.05e-8	Obesity-related traits;
THYM	cis	rs3903072	0.652	rs501630	chr11:65637273	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.63	-4.76	-0.44	6.83e-6	Breast cancer;
THYM	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg08847533	chr14:75593920	NEK9	-1.01	-11.32	-0.76	2.63e-19	Height;
THYM	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg10334053	chr1:2078117	PRKCZ	0.48	4.73	0.44	7.65e-6	Height;
THYM	cis	rs2637266	0.783	rs846640	chr10:78524293	T/C	cg18941641	chr10:78392320	NA	0.65	5.36	0.48	5.76e-7	Pulmonary function;
THYM	cis	rs9522267	1.000	rs9522265	chr13:112195182	A/G	cg10483660	chr13:112241077	NA	-0.48	-4.89	-0.45	4.09e-6	Hepatitis;
THYM	cis	rs4713118	0.955	rs9393848	chr6:27688369	C/T	cg08968635	chr6:28129556	ZNF389	0.75	5.95	0.52	4.53e-8	Parkinson's disease;
THYM	cis	rs362296	0.550	rs3135064	chr4:3285389	T/C	cg22655196	chr4:3374909	RGS12	0.41	4.63	0.43	1.16e-5	Parental longevity (mother's age at death);
THYM	cis	rs7828089	0.646	rs3943520	chr8:22282732	A/G	cg12081754	chr8:22256438	SLC39A14	0.83	7.45	0.61	4.26e-11	Verbal declarative memory;
THYM	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.53	-4.46	-0.42	2.24e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg27286337	chr10:134555280	INPP5A	-1.02	-9.53	-0.7	1.66e-15	Migraine;
THYM	cis	rs6496667	1.000	rs7182544	chr15:90897480	G/C	cg22089800	chr15:90895588	ZNF774	0.74	5.0	0.46	2.65e-6	Rheumatoid arthritis;
THYM	cis	rs3771570	1.000	rs62193202	chr2:242303717	G/A	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg20295408	chr7:1910781	MAD1L1	-0.62	-4.98	-0.46	2.8e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg15440763	chr7:158190612	PTPRN2	0.48	4.57	0.42	1.47e-5	Obesity-related traits;
THYM	cis	rs7107770	0.739	rs4936995	chr11:125081694	G/T	cg04164023	chr11:125106101	PKNOX2	-0.71	-4.55	-0.42	1.56e-5	Photic sneeze reflex;
THYM	cis	rs8102476	0.703	rs4803899	chr19:38727640	A/T	cg05778847	chr19:38746538	PPP1R14A	0.49	5.26	0.47	8.89e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg10117171	chr1:25599238	RHD	-0.68	-4.87	-0.45	4.52e-6	Erythrocyte sedimentation rate;
THYM	cis	rs2273669	0.667	rs9688496	chr6:109364825	G/T	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs6840360	0.582	rs2709823	chr4:152340446	T/C	cg17479576	chr4:152424074	FAM160A1	-0.74	-5.64	-0.5	1.73e-7	Intelligence (multi-trait analysis);
THYM	cis	rs13014235	0.532	rs13029007	chr2:202264877	G/T	cg12544106	chr2:202507780	ALS2CR4	-0.63	-4.67	-0.43	1e-5	Basal cell carcinoma;
THYM	cis	rs447921	0.861	rs56154175	chr17:74419086	C/T	cg17201438	chr17:74438067	UBE2O	0.81	5.89	0.52	5.72e-8	Mitochondrial DNA levels;
THYM	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg26384229	chr12:38710491	ALG10B	0.97	7.38	0.6	5.91e-11	Bladder cancer;
THYM	cis	rs9486719	1.000	rs926276	chr6:96868735	C/T	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg27532560	chr4:187881888	NA	-0.96	-11.4	-0.76	1.72e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs9906944	0.545	rs2088140	chr17:47094599	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.59	-7.28	-0.6	9.64e-11	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg20966754	chr17:47091339	IGF2BP1	-0.54	-7.31	-0.6	8.28e-11	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg22875332	chr1:76189707	ACADM	0.87	10.83	0.74	2.76e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs3126085	0.935	rs4634913	chr1:152249932	T/C	cg10321714	chr1:152280068	FLG	0.67	5.14	0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.82	6.59	0.56	2.48e-9	Urate levels;
THYM	cis	rs11792861	0.619	rs2289480	chr9:111705501	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.83	7.2	0.59	1.43e-10	Menarche (age at onset);
THYM	cis	rs7523273	0.526	rs677715	chr1:208047284	A/G	cg22525895	chr1:207977042	MIR29B2	0.52	4.57	0.42	1.47e-5	Schizophrenia;
THYM	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg04025307	chr7:1156635	C7orf50	0.78	6.67	0.56	1.66e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs4595586	0.525	rs35046524	chr12:39414535	A/G	cg13010199	chr12:38710504	ALG10B	0.66	4.55	0.42	1.57e-5	Morning vs. evening chronotype;
THYM	cis	rs7193541	0.646	rs7188880	chr16:74664810	A/T	cg01733217	chr16:74700730	RFWD3	0.97	11.3	0.76	2.79e-19	Multiple myeloma;
THYM	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg03806693	chr22:41940476	POLR3H	-0.84	-6.41	-0.55	5.51e-9	Neuroticism;
THYM	cis	rs7084402	0.967	rs1427222	chr10:60290970	A/G	cg09696939	chr10:60272079	BICC1	-0.5	-5.96	-0.52	4.19e-8	Refractive error;
THYM	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg23281280	chr6:28129359	ZNF389	0.59	4.51	0.42	1.86e-5	Parkinson's disease;
THYM	cis	rs4866334	1.000	rs79107423	chr5:18501522	A/G	cg24599790	chr5:18972260	NA	-1.15	-4.67	-0.43	9.77e-6	IgG glycosylation;
THYM	cis	rs78773383	0.505	rs10033019	chr4:39391940	A/G	cg16714752	chr4:39368184	RFC1	0.55	5.41	0.49	4.73e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg18200150	chr17:30822561	MYO1D	0.86	8.47	0.66	3.11e-13	Schizophrenia;
THYM	cis	rs7078219	0.524	rs6584277	chr10:101278055	A/G	cg07044859	chr10:101282883	NA	-0.44	-5.14	-0.47	1.48e-6	Dental caries;
THYM	cis	rs11771526	0.901	rs7357136	chr7:32302338	G/T	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg00310523	chr12:86230176	RASSF9	0.61	5.33	0.48	6.57e-7	Major depressive disorder;
THYM	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg10150615	chr22:24372951	LOC391322	-0.97	-12.09	-0.78	6.34e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg08305652	chr11:111469057	NA	0.53	4.51	0.42	1.88e-5	Primary sclerosing cholangitis;
THYM	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.98	-6.68	-0.57	1.62e-9	Platelet count;
THYM	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.8	-5.5	-0.49	3.14e-7	Huntington's disease progression;
THYM	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	Reticulocyte fraction of red cells;
THYM	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg18252515	chr7:66147081	NA	0.63	4.83	0.44	5.14e-6	Aortic root size;
THYM	cis	rs2188554	0.785	rs2518881	chr7:117172731	A/G	cg25509184	chr7:117119382	CFTR	0.53	4.73	0.44	7.77e-6	Esophageal adenocarcinoma;
THYM	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg03388025	chr16:89894329	SPIRE2	0.55	4.76	0.44	7e-6	Vitiligo;
THYM	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg17054759	chr22:49844102	NA	-0.48	-4.49	-0.42	2e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6032067	0.850	rs34274189	chr20:43864298	G/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.69	-6.04	-0.53	2.94e-8	Blood protein levels;
THYM	cis	rs1457451	1.000	rs6725950	chr2:65864263	G/A	cg16240816	chr2:65861662	NA	0.67	6.91	0.58	5.61e-10	Iron status biomarkers;
THYM	cis	rs4409675	0.576	rs10794507	chr1:28216072	T/C	cg23691781	chr1:28212827	C1orf38	0.44	4.48	0.42	2.08e-5	Corneal astigmatism;
THYM	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs73086581	1.000	rs34640283	chr20:3989576	T/A	cg02187196	chr20:3869020	PANK2	0.5	5.57	0.5	2.37e-7	Response to antidepressants in depression;
THYM	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg08999081	chr20:33150536	PIGU	-0.57	-4.95	-0.45	3.25e-6	Height;
THYM	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg11247378	chr22:39784982	NA	-1.04	-13.87	-0.82	1.47e-24	Intelligence (multi-trait analysis);
THYM	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg07884673	chr3:53033167	SFMBT1	1.19	6.0	0.52	3.59e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg00129232	chr17:37814104	STARD3	-0.98	-8.93	-0.68	3.2e-14	Asthma;
THYM	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-5.15	-0.47	1.43e-6	Longevity;
THYM	cis	rs3136739	0.764	rs7018383	chr8:42064535	C/T	cg16230352	chr8:42123158	NA	0.8	4.76	0.44	6.84e-6	Plasma plasminogen activator levels;
THYM	cis	rs2507	0.578	rs11072460	chr15:74280867	T/G	cg17221444	chr15:74284820	STOML1	-0.58	-4.81	-0.44	5.69e-6	Coronary artery disease;
THYM	cis	rs2142672	0.892	rs57977865	chr6:16189618	C/T	cg11805552	chr6:16175128	NA	0.54	4.54	0.42	1.66e-5	LDL cholesterol;
THYM	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg13447684	chr7:1895903	MAD1L1	0.55	4.66	0.43	1.01e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg18758796	chr5:131593413	PDLIM4	-0.5	-4.78	-0.44	6.37e-6	Breast cancer;
THYM	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg24846680	chr1:228362309	C1orf69	0.59	4.83	0.44	5.21e-6	Diastolic blood pressure;
THYM	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg24060327	chr5:131705240	SLC22A5	-0.76	-5.73	-0.51	1.16e-7	Blood metabolite levels;
THYM	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg11764359	chr7:65958608	NA	0.82	6.56	0.56	2.81e-9	Aortic root size;
THYM	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.9e-10	Alzheimer's disease (late onset);
THYM	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg05368731	chr17:41323189	NBR1	1.26	11.55	0.76	8.34e-20	Menopause (age at onset);
THYM	cis	rs6450176	0.909	rs66872223	chr5:53292730	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-6.61	-0.56	2.22e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg24531977	chr5:56204891	C5orf35	-1.02	-8.59	-0.66	1.73e-13	Initial pursuit acceleration;
THYM	cis	rs8067545	1.000	rs7211535	chr17:19922364	A/G	cg13482628	chr17:19912719	NA	0.59	4.93	0.45	3.42e-6	Schizophrenia;
THYM	cis	rs4642101	0.640	rs9877049	chr3:12821231	A/G	cg11882607	chr3:12858926	CAND2	-0.42	-4.61	-0.43	1.25e-5	QRS complex (12-leadsum);
THYM	cis	rs9796	0.870	rs3986311	chr15:41264339	C/G	cg21153102	chr15:41252147	NA	0.72	6.75	0.57	1.18e-9	Menopause (age at onset);
THYM	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg22875332	chr1:76189707	ACADM	0.9	10.62	0.74	7.94e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs35123175	1	rs35123175	chr21:45006610	CA/C	cg01579765	chr21:45077557	HSF2BP	0.72	4.71	0.44	8.4e-6	Diastolic blood pressure;
THYM	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs34638657	0.872	rs6420437	chr16:82187181	T/C	cg19807685	chr16:82068980	HSD17B2	-0.66	-5.08	-0.46	1.85e-6	Lung adenocarcinoma;
THYM	cis	rs12681287	0.547	rs13260345	chr8:87483721	T/C	cg27223183	chr8:87520930	FAM82B	-0.67	-5.05	-0.46	2.17e-6	Caudate activity during reward;
THYM	cis	rs17598306	1.000	rs722470	chr7:96581466	C/G	cg26766885	chr7:96220185	NA	0.62	5.13	0.47	1.56e-6	Radiation response;
THYM	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2742417	0.603	rs7631818	chr3:45775931	A/T	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.92	-7.95	-0.63	3.81e-12	Menarche (age at onset);
THYM	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg08859206	chr1:53392774	SCP2	0.52	5.4	0.48	4.89e-7	Monocyte count;
THYM	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs2455799	0.573	rs2174172	chr3:15768579	C/A	cg16303742	chr3:15540471	COLQ	-0.57	-6.09	-0.53	2.39e-8	Mean platelet volume;
THYM	cis	rs4690686	0.538	rs7436387	chr4:177257723	T/G	cg17059388	chr4:177262070	NA	0.45	6.1	0.53	2.25e-8	Essential tremor;
THYM	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg00640147	chr17:61958756	GH2	-0.42	-4.53	-0.42	1.71e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs4919687	0.550	rs11191372	chr10:104462187	T/C	cg18761893	chr10:103892519	PPRC1	0.61	4.69	0.43	9.13e-6	Colorectal cancer;
THYM	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg00024416	chr22:24240387	NA	-0.68	-7.19	-0.59	1.49e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11112613	0.775	rs10778413	chr12:105962118	G/A	cg03607813	chr12:105948248	NA	1.01	8.2	0.64	1.13e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs870825	0.616	rs2141258	chr4:185609576	A/C	cg04058563	chr4:185651563	MLF1IP	-1.13	-8.9	-0.67	3.63e-14	Blood protein levels;
THYM	cis	rs11166927	0.524	rs10092101	chr8:140830697	C/T	cg16909799	chr8:140841666	TRAPPC9	-0.83	-7.71	-0.62	1.21e-11	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg04865290	chr3:52927548	TMEM110	-0.89	-4.65	-0.43	1.08e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg00383909	chr3:49044727	WDR6	1.22	7.16	0.59	1.73e-10	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs17473412	1.000	rs114337292	chr5:122738201	A/C	cg18093572	chr5:122598329	NA	0.53	4.45	0.42	2.33e-5	Total body bone mineral density;
THYM	cis	rs9649213	0.593	rs62478200	chr7:97980045	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs41311933	1.000	rs16910254	chr9:123751661	A/G	cg13567360	chr9:123745713	C5	-0.96	-5.55	-0.49	2.57e-7	Coronary artery disease;
THYM	cis	rs7586879	0.616	rs6722587	chr2:25132192	C/A	cg27107076	chr2:25050844	ADCY3	-0.29	-4.73	-0.44	7.91e-6	Body mass index;
THYM	cis	rs12208915	0.848	rs2174740	chr6:79536565	A/G	cg05283184	chr6:79620031	NA	-0.71	-4.66	-0.43	1.03e-5	Left atrial antero-posterior diameter;
THYM	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg18876405	chr7:65276391	NA	0.73	6.81	0.57	8.77e-10	Aortic root size;
THYM	cis	rs728616	0.614	rs61858839	chr10:81713918	T/A	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg17426766	chr1:2046864	PRKCZ	0.45	5.47	0.49	3.69e-7	Height;
THYM	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.24	-4.55	-0.42	1.58e-5	Obesity-related traits;
THYM	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs7224737	1.000	rs7224737	chr17:40289364	A/G	cg02228675	chr17:40259724	DHX58	0.62	5.13	0.47	1.55e-6	Fibrinogen levels;
THYM	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	5.02	0.46	2.39e-6	Menarche (age at onset);
THYM	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg01097406	chr16:89675127	NA	0.81	7.34	0.6	7.22e-11	Vitiligo;
THYM	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg23187316	chr7:1099788	C7orf50	0.47	5.28	0.48	8.07e-7	Longevity;Endometriosis;
THYM	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-5.33	-0.48	6.7e-7	Hemoglobin concentration;
THYM	cis	rs4730276	0.674	rs4727692	chr7:107526014	A/T	cg23293999	chr7:106826042	HBP1	-0.56	-4.47	-0.42	2.16e-5	Ulcerative colitis;
THYM	cis	rs9311676	0.656	rs11917567	chr3:58382254	C/T	cg26110898	chr3:58419937	PDHB	0.45	4.79	0.44	6.17e-6	Systemic lupus erythematosus;
THYM	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg24578937	chr1:2090814	PRKCZ	-0.53	-5.38	-0.48	5.38e-7	Height;
THYM	cis	rs9733	0.519	rs11807450	chr1:150677719	C/T	cg04414720	chr1:150670196	GOLPH3L	0.62	4.58	0.43	1.41e-5	Tonsillectomy;
THYM	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg08213375	chr14:104286397	PPP1R13B	0.45	4.71	0.44	8.42e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs7267979	1.000	rs6050562	chr20:25336186	C/G	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7119038	0.818	rs10892279	chr11:118611781	G/A	cg19308663	chr11:118741387	NA	0.46	4.71	0.44	8.41e-6	Sjögren's syndrome;
THYM	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg19875535	chr5:140030758	IK	-0.65	-5.69	-0.5	1.39e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs1823778	0.609	rs8085960	chr18:67647035	C/A	cg13164537	chr18:67624071	CD226	1.15	4.8	0.44	5.83e-6	Mean platelet volume;
THYM	cis	rs8064454	0.967	rs10908278	chr17:36099952	T/A	cg00994583	chr17:36613498	ARHGAP23	-0.6	-4.5	-0.42	1.94e-5	Prostate cancer;
THYM	cis	rs295140	0.605	rs295149	chr2:201175244	A/G	cg17644776	chr2:200775616	C2orf69	-0.6	-4.71	-0.44	8.41e-6	QT interval;
THYM	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg04248312	chr19:17393744	ANKLE1	-0.96	-12.68	-0.79	3.82e-22	Systemic lupus erythematosus;
THYM	cis	rs7429990	0.932	rs6442101	chr3:48130893	C/T	cg02219026	chr3:48282209	ZNF589	0.64	4.71	0.44	8.47e-6	Educational attainment (years of education);
THYM	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg01236616	chr12:121019343	POP5	-1.24	-10.39	-0.73	2.47e-17	Type 1 diabetes nephropathy;
THYM	cis	rs1505368	0.532	rs2888093	chr2:213328348	G/A	cg20637307	chr2:213403960	ERBB4	0.58	4.56	0.42	1.53e-5	Symmetrical dimethylarginine levels;
THYM	cis	rs9682041	0.736	rs34237232	chr3:170063753	C/T	cg11886554	chr3:170076028	SKIL	-1.22	-4.82	-0.44	5.37e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs13315871	0.929	rs73835170	chr3:58318448	A/G	cg12435725	chr3:58293450	RPP14	-0.52	-5.47	-0.49	3.67e-7	Cholesterol, total;
THYM	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg06634786	chr22:41940651	POLR3H	0.73	5.33	0.48	6.69e-7	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.62	-4.5	-0.42	1.93e-5	Colorectal cancer;
THYM	cis	rs7586879	0.616	rs6545814	chr2:25131316	A/G	cg01884057	chr2:25150051	NA	0.73	7.92	0.63	4.47e-12	Body mass index;
THYM	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg06636001	chr8:8085503	FLJ10661	0.77	7.05	0.59	2.87e-10	Mood instability;
THYM	cis	rs73198271	0.737	rs535094	chr8:8633928	A/G	cg06636001	chr8:8085503	FLJ10661	-0.67	-4.96	-0.45	3.12e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg23750338	chr8:142222470	SLC45A4	0.52	4.87	0.45	4.48e-6	Immature fraction of reticulocytes;
THYM	cis	rs6754311	0.509	rs13412397	chr2:136470714	G/A	cg23851026	chr2:136556271	LCT	-0.59	-5.53	-0.49	2.85e-7	Mosquito bite size;
THYM	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg12981288	chr8:11183844	MTMR9	-0.48	-4.66	-0.43	1.02e-5	Retinal vascular caliber;
THYM	cis	rs981844	0.725	rs872453	chr4:154727131	T/C	cg22178613	chr4:154710499	SFRP2	-0.59	-4.93	-0.45	3.48e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03517284	chr6:25882590	NA	-0.95	-8.59	-0.66	1.67e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg07414643	chr4:187882934	NA	0.64	5.75	0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg17480646	chr11:65405466	SIPA1	-0.94	-8.85	-0.67	4.72e-14	Acne (severe);
THYM	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg07606381	chr6:8435919	SLC35B3	0.65	4.91	0.45	3.71e-6	Motion sickness;
THYM	cis	rs600806	0.888	rs4603158	chr1:109879549	C/T	cg23032129	chr1:109941072	SORT1	-0.57	-4.84	-0.44	5.11e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4660306	0.614	rs11211116	chr1:45930038	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.66	4.74	0.44	7.56e-6	Homocysteine levels;
THYM	cis	rs7302981	0.667	rs7136648	chr12:50624822	A/G	cg20014596	chr12:50898483	DIP2B	0.53	5.01	0.46	2.54e-6	Systolic blood pressure;
THYM	cis	rs748404	0.660	rs690446	chr15:43761264	G/C	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs9810089	0.967	rs7372313	chr3:135872958	G/C	cg12473912	chr3:136751656	NA	0.62	5.37	0.48	5.67e-7	Gestational age at birth (child effect);
THYM	cis	rs4595586	0.545	rs9669705	chr12:39374459	C/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs7617773	0.780	rs71323396	chr3:48374734	T/G	cg02219026	chr3:48282209	ZNF589	-0.69	-4.81	-0.44	5.6e-6	Coronary artery disease;
THYM	cis	rs483180	0.511	rs496195	chr1:120207182	A/G	cg19096424	chr1:120255104	PHGDH	-0.63	-4.88	-0.45	4.26e-6	Macular telangiectasia type 2;
THYM	cis	rs6009824	1.000	rs6009824	chr22:50086373	C/T	cg22070880	chr22:50098194	NA	0.67	4.78	0.44	6.41e-6	Natriuretic peptide levels;
THYM	trans	rs112998813	0.571	rs11147317	chr13:114939396	A/G	cg07263694	chr12:111748299	CUX2	1.1	6.99	0.58	3.7e-10	Nodular sclerosis Hodgkin lymphoma;
THYM	cis	rs6835098	1.000	rs1054496	chr4:174089080	A/G	cg08422745	chr4:174089978	GALNT7	-1.02	-8.43	-0.65	3.75e-13	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.73	7.27	0.6	1.02e-10	Lymphocyte counts;
THYM	cis	rs4363385	0.818	rs368912	chr1:153016204	C/G	cg13444842	chr1:152974279	SPRR3	-0.59	-4.81	-0.44	5.61e-6	Inflammatory skin disease;
THYM	cis	rs931812	0.757	rs4734492	chr8:101901901	C/T	cg07239293	chr8:101170671	SPAG1	-0.65	-4.55	-0.42	1.56e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs4455778	0.580	rs3924858	chr7:49121340	G/A	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg07424592	chr7:64974309	NA	1.02	5.29	0.48	7.76e-7	Diabetic kidney disease;
THYM	cis	rs6009824	0.891	rs11090995	chr22:50085210	G/A	cg27029450	chr22:50098074	NA	0.88	5.68	0.5	1.46e-7	Natriuretic peptide levels;
THYM	cis	rs4974559	0.594	rs11946384	chr4:1313566	T/C	cg16185996	chr4:1008614	FGFRL1	-0.4	-4.57	-0.42	1.45e-5	Systolic blood pressure;
THYM	cis	rs13126513	0.582	rs2584449	chr4:100393276	G/T	cg05468953	chr4:100565104	NA	-0.65	-5.49	-0.49	3.3e-7	Metabolite levels (MHPG);
THYM	cis	rs1497406	0.744	rs12562207	chr1:16508059	G/A	cg20430773	chr1:16534157	ARHGEF19	0.49	5.51	0.49	3.02e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg27168131	chr21:44088823	PDE9A	0.46	4.5	0.42	1.94e-5	Mean corpuscular volume;
THYM	cis	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg06521331	chr12:34319734	NA	-1.01	-10.11	-0.72	9.81e-17	Morning vs. evening chronotype;
THYM	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg12501888	chr15:85177176	SCAND2	-0.6	-4.5	-0.42	1.92e-5	P wave terminal force;
THYM	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg22117172	chr7:91764530	CYP51A1	0.35	4.46	0.42	2.27e-5	Breast cancer;
THYM	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Gout;
THYM	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs10779751	0.770	rs11121691	chr1:11181327	C/T	cg08854313	chr1:11322531	MTOR	-0.72	-5.71	-0.51	1.3e-7	Body mass index;
THYM	cis	rs7236492	0.748	rs11663202	chr18:77209180	T/C	cg15644404	chr18:77186268	NFATC1	-1.06	-4.97	-0.45	2.96e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6665290	0.901	rs68087483	chr1:227202668	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.15	-16.89	-0.87	2.27e-30	Myeloid white cell count;
THYM	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg12419862	chr22:24373484	LOC391322	-0.73	-6.88	-0.58	6.22e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03517284	chr6:25882590	NA	-0.77	-6.07	-0.53	2.56e-8	Blood metabolite levels;
THYM	cis	rs4642101	0.765	rs1985428	chr3:12829315	A/G	cg05775895	chr3:12838266	CAND2	-0.72	-5.92	-0.52	5.06e-8	QRS complex (12-leadsum);
THYM	cis	rs35883536	0.647	rs1995142	chr1:101041174	G/A	cg09408571	chr1:101003634	GPR88	0.51	5.56	0.5	2.44e-7	Monocyte count;
THYM	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg12863693	chr15:85201151	NMB	0.53	4.82	0.44	5.45e-6	Schizophrenia;
THYM	cis	rs10819861	0.611	rs10760747	chr9:98851504	A/G	cg14508093	chr9:98862825	NA	0.24	4.48	0.42	2.05e-5	Electrocardiographic traits;
THYM	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg01570182	chr17:44337453	NA	0.87	9.49	0.7	2e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg14768367	chr16:72042858	DHODH	0.62	4.8	0.44	5.92e-6	Fibrinogen levels;
THYM	cis	rs3892630	0.817	rs12609866	chr19:33184412	C/T	cg22980127	chr19:33182716	NUDT19	1.13	9.17	0.69	9.73e-15	Red blood cell traits;
THYM	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.71	6.39	0.55	6.24e-9	Blood protein levels;
THYM	cis	rs7851660	0.967	rs6478437	chr9:100607497	A/G	cg13688889	chr9:100608707	NA	-0.84	-7.25	-0.6	1.09e-10	Strep throat;
THYM	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.53	-0.61	2.88e-11	Personality dimensions;
THYM	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs988913	0.958	rs1503140	chr6:54810766	A/G	cg19716238	chr6:54711378	FAM83B	0.49	5.07	0.46	1.99e-6	Menarche (age at onset);
THYM	cis	rs1784581	0.588	rs1784583	chr6:162410132	C/T	cg17173639	chr6:162384350	PARK2	-0.8	-7.47	-0.61	3.85e-11	Itch intensity from mosquito bite;
THYM	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17407555	0.821	rs73215081	chr4:10137326	C/G	cg00071950	chr4:10020882	SLC2A9	-0.76	-5.68	-0.5	1.45e-7	Schizophrenia (age at onset);
THYM	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg24163568	chr5:669837	TPPP	-0.59	-5.5	-0.49	3.27e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	trans	rs2274089	0.649	rs79580305	chr6:25538447	C/G	cg12244275	chr2:70355397	NA	1.28	6.93	0.58	4.98e-10	Iron status biomarkers;
THYM	cis	rs7119	0.931	rs12901998	chr15:77833524	G/T	cg10437265	chr15:77819839	NA	0.77	7.39	0.6	5.75e-11	Type 2 diabetes;
THYM	cis	rs56775891	1.000	rs56775891	chr18:77575613	C/T	cg13263691	chr18:77568018	NA	0.69	5.0	0.46	2.65e-6	Schizophrenia;
THYM	cis	rs12142240	0.770	rs112869704	chr1:46780285	C/T	cg00530320	chr1:46809349	NSUN4	0.86	5.59	0.5	2.19e-7	Menopause (age at onset);
THYM	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03264133	chr6:25882463	NA	-0.76	-5.81	-0.51	8.44e-8	Blood metabolite levels;
THYM	cis	rs684232	0.602	rs35206514	chr17:519859	T/C	cg15660573	chr17:549704	VPS53	-1.01	-11.19	-0.75	4.87e-19	Prostate cancer;
THYM	cis	rs73193808	1.000	rs2832232	chr21:30540559	A/G	cg06824297	chr21:30391795	RWDD2B	-0.69	-4.46	-0.42	2.24e-5	Coronary artery disease;
THYM	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg15704280	chr7:45808275	SEPT13	-0.84	-8.4	-0.65	4.31e-13	Height;
THYM	cis	rs9646944	0.501	rs3213733	chr2:102997884	C/A	cg01241218	chr2:102972058	NA	0.81	5.28	0.48	8.09e-7	Blood protein levels;
THYM	cis	rs7264396	0.563	rs2225950	chr20:34333015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Total cholesterol levels;
THYM	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.46	0.49	3.85e-7	Platelet count;
THYM	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13012494	chr21:47604986	C21orf56	0.85	5.62	0.5	1.87e-7	Testicular germ cell tumor;
THYM	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg20744362	chr22:50050164	C22orf34	0.67	6.06	0.53	2.74e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs8041943	0.550	rs12593537	chr15:79897654	A/C	cg20511832	chr15:78934280	CHRNB4	0.43	4.49	0.42	2.01e-5	Bone mineral density (spine) and age at menarche;
THYM	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	5.19	0.47	1.2e-6	Schizophrenia;
THYM	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg26384229	chr12:38710491	ALG10B	-0.72	-5.64	-0.5	1.76e-7	Morning vs. evening chronotype;
THYM	cis	rs1461503	0.966	rs10790545	chr11:122838350	G/C	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs6754311	0.731	rs13404551	chr2:136721995	T/C	cg04750100	chr2:136595281	LCT	0.55	6.07	0.53	2.6e-8	Mosquito bite size;
THYM	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	7.86	0.63	6.06e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg07061783	chr6:25882402	NA	-1.03	-9.79	-0.71	4.7e-16	Intelligence (multi-trait analysis);
THYM	cis	rs55883249	1.000	rs62119423	chr2:9726601	C/T	cg23886495	chr2:9695866	ADAM17	0.82	5.32	0.48	6.79e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg21475434	chr5:93447410	FAM172A	0.85	5.55	0.49	2.56e-7	Diabetic retinopathy;
THYM	cis	rs3008870	0.755	rs1925409	chr1:67365089	C/T	cg02640540	chr1:67518911	SLC35D1	-0.58	-4.47	-0.42	2.16e-5	Lymphocyte percentage of white cells;
THYM	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg10661904	chr17:79619235	PDE6G	0.53	4.74	0.44	7.56e-6	Eye color traits;
THYM	cis	rs1403694	0.515	rs1622922	chr3:186449884	C/T	cg12454167	chr3:186435060	KNG1	0.44	5.89	0.52	5.76e-8	Blood protein levels;
THYM	cis	rs67981189	0.821	rs34257131	chr14:71520440	A/G	cg15910301	chr14:71632612	NA	0.51	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs4555082	1.000	rs66777564	chr14:105760245	A/G	cg10792982	chr14:105748885	BRF1	0.67	6.67	0.56	1.7e-9	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13732083	chr21:47605072	C21orf56	0.76	4.97	0.45	2.94e-6	Testicular germ cell tumor;
THYM	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9399401	0.925	rs2294764	chr6:142737504	G/A	cg04461802	chr6:142623433	GPR126	0.49	4.92	0.45	3.68e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs3847687	1.000	rs11061291	chr12:131518875	C/T	cg25772418	chr12:131519998	GPR133	-0.47	-6.61	-0.56	2.21e-9	Longevity;
THYM	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg26354017	chr1:205819088	PM20D1	0.78	7.22	0.6	1.29e-10	Monocyte percentage of white cells;
THYM	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg19761014	chr17:28927070	LRRC37B2	0.73	4.46	0.42	2.21e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg18252515	chr7:66147081	NA	-1.45	-8.59	-0.66	1.68e-13	Diabetic kidney disease;
THYM	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs7078219	0.714	rs10883359	chr10:101274033	C/T	cg23904955	chr10:101282759	NA	0.4	4.75	0.44	7.1e-6	Dental caries;
THYM	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs11671005	0.735	rs11667591	chr19:58937637	G/A	cg18639983	chr19:58920768	ZNF584	0.6	5.01	0.46	2.48e-6	Mean platelet volume;
THYM	cis	rs73198271	0.813	rs56007835	chr8:8610026	G/A	cg15556689	chr8:8085844	FLJ10661	-0.75	-4.79	-0.44	6.17e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg04476341	chr5:669733	TPPP	0.47	4.78	0.44	6.31e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg10505658	chr17:80084571	CCDC57	-0.74	-8.21	-0.64	1.06e-12	Life satisfaction;
THYM	cis	rs654950	0.934	rs654220	chr1:42002556	A/T	cg06885757	chr1:42089581	HIVEP3	-0.56	-7.36	-0.6	6.66e-11	Airway imaging phenotypes;
THYM	cis	rs9906944	0.933	rs12945020	chr17:47082775	G/A	cg22947322	chr17:47091978	IGF2BP1	-0.55	-4.46	-0.42	2.22e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg22117172	chr7:91764530	CYP51A1	0.37	4.6	0.43	1.32e-5	Breast cancer;
THYM	cis	rs11711311	0.955	rs12636536	chr3:113474226	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.62	-5.52	-0.49	2.89e-7	IgG glycosylation;
THYM	cis	rs12310956	0.510	rs7301767	chr12:33886529	A/T	cg06521331	chr12:34319734	NA	-0.57	-4.6	-0.43	1.33e-5	Morning vs. evening chronotype;
THYM	cis	rs10499694	0.901	rs6975453	chr7:50585211	A/T	cg00647317	chr7:50633725	DDC	0.3	4.56	0.42	1.53e-5	Body mass index;
THYM	cis	rs1371867	0.875	rs1125706	chr8:101326739	T/A	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg11764359	chr7:65958608	NA	0.67	4.77	0.44	6.52e-6	Aortic root size;
THYM	cis	rs1670533	0.872	rs11727135	chr4:1051803	G/C	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs2898681	0.614	rs58260946	chr4:53675420	A/G	cg00791764	chr4:53727839	RASL11B	0.42	5.07	0.46	1.95e-6	Optic nerve measurement (cup area);
THYM	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg02527881	chr3:46936655	PTH1R	-0.65	-6.44	-0.55	4.94e-9	Colorectal cancer;
THYM	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs400736	0.930	rs408320	chr1:8085328	T/C	cg22678073	chr1:8087421	ERRFI1	0.46	4.83	0.44	5.25e-6	Response to antidepressants and depression;
THYM	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs73086581	1.000	rs11906274	chr20:3945536	G/A	cg02187196	chr20:3869020	PANK2	0.5	5.62	0.5	1.92e-7	Response to antidepressants in depression;
THYM	cis	rs13256369	1.000	rs13282915	chr8:8570891	T/G	cg18904891	chr8:8559673	CLDN23	0.73	5.58	0.5	2.29e-7	Obesity-related traits;
THYM	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22857025	chr5:266934	NA	-1.53	-9.51	-0.7	1.88e-15	Breast cancer;
THYM	cis	rs12711979	0.740	rs6711963	chr2:3820915	A/T	cg17052675	chr2:3827356	NA	-0.48	-5.19	-0.47	1.19e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg24209194	chr3:40518798	ZNF619	-0.73	-6.31	-0.54	8.87e-9	Renal cell carcinoma;
THYM	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg17063962	chr7:91808500	NA	-1.08	-11.41	-0.76	1.71e-19	Breast cancer;
THYM	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg00640147	chr17:61958756	GH2	-0.43	-4.54	-0.42	1.64e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg24060327	chr5:131705240	SLC22A5	-0.76	-5.73	-0.51	1.16e-7	Blood metabolite levels;
THYM	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.33	9.84	0.71	3.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg18252515	chr7:66147081	NA	0.65	4.73	0.44	7.72e-6	Aortic root size;
THYM	cis	rs7246657	0.941	rs7256130	chr19:37933981	T/C	cg22634378	chr19:37742834	NA	0.63	5.17	0.47	1.28e-6	Coronary artery calcification;
THYM	cis	rs6570726	0.791	rs7755253	chr6:145858893	C/G	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg01416388	chr22:39784598	NA	0.75	5.98	0.52	3.87e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg10018233	chr7:150070692	REPIN1	0.5	7.76	0.62	9.42e-12	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs1558375	0.679	rs31671	chr7:87059403	C/G	cg04996195	chr7:87105398	ABCB4	0.59	4.53	0.42	1.73e-5	Gallbladder cancer;
THYM	cis	rs7942486	0.895	rs11825452	chr11:13269722	A/C	cg13286116	chr11:13302098	ARNTL	-0.72	-8.03	-0.64	2.61e-12	Neuroticism;
THYM	cis	rs10208649	0.908	rs11887593	chr2:54267775	C/G	cg04546899	chr2:54196757	PSME4	0.68	4.72	0.44	8.15e-6	Body mass index;
THYM	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg16586182	chr3:47516702	SCAP	-0.59	-5.08	-0.46	1.88e-6	Colorectal cancer;
THYM	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg26597838	chr10:835615	NA	1.21	8.65	0.66	1.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg26441486	chr22:50317300	CRELD2	0.45	7.5	0.61	3.39e-11	Schizophrenia;
THYM	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg09359103	chr1:154839909	KCNN3	-0.81	-10.3	-0.73	3.84e-17	Prostate cancer;
THYM	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg00898013	chr13:113819073	PROZ	-0.89	-9.29	-0.69	5.34e-15	Platelet distribution width;
THYM	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.32	0.6	7.76e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg26384229	chr12:38710491	ALG10B	-0.72	-5.57	-0.5	2.33e-7	Morning vs. evening chronotype;
THYM	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg19748678	chr4:122722346	EXOSC9	0.71	4.98	0.45	2.9e-6	Type 2 diabetes;
THYM	cis	rs68170813	0.559	rs80017637	chr7:107050660	T/C	cg00661777	chr7:106511741	PIK3CG	-0.67	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs9788721	0.802	rs56219465	chr15:78742579	A/G	cg18825076	chr15:78729989	IREB2	-0.66	-6.19	-0.54	1.54e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs7009516	0.692	rs9650409	chr8:24240704	A/G	cg01759110	chr8:24241694	ADAMDEC1	0.52	4.91	0.45	3.83e-6	Hair greying;
THYM	cis	rs6570726	0.935	rs365658	chr6:145844588	C/T	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg02353165	chr6:42928485	GNMT	0.87	8.22	0.64	1.02e-12	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs13202913	0.779	rs9383896	chr6:151768495	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.81	-4.54	-0.42	1.65e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7572733	0.534	rs10931794	chr2:198776140	C/T	cg05783139	chr2:198650985	BOLL	-0.62	-4.89	-0.45	4.15e-6	Dermatomyositis;
THYM	cis	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg07460842	chr6:66804631	NA	-0.9	-6.58	-0.56	2.6e-9	Exhaled nitric oxide output;
THYM	cis	rs2731664	0.792	rs466256	chr5:176875956	C/A	cg14098951	chr5:176875120	PRR7	0.56	4.97	0.45	2.93e-6	Intelligence (multi-trait analysis);
THYM	cis	rs17174870	0.868	rs56272510	chr2:112727604	T/G	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg22841779	chr14:105766346	BRF1	0.47	5.76	0.51	1.04e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7917772	0.582	rs4919665	chr10:104366042	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.77	-6.73	-0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1079204	1.000	rs59549705	chr2:219166649	C/G	cg05728596	chr2:219128475	GPBAR1	1.25	5.0	0.46	2.63e-6	Smooth-surface caries;
THYM	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg04267008	chr7:1944627	MAD1L1	-0.68	-6.29	-0.54	9.85e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg23161317	chr6:28129485	ZNF389	0.7	5.47	0.49	3.66e-7	Cardiac Troponin-T levels;
THYM	cis	rs9649213	0.613	rs7777415	chr7:97959214	A/T	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.6e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	6.94	0.58	4.86e-10	Prudent dietary pattern;
THYM	cis	rs1371867	0.875	rs1788169	chr8:101326314	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs79149102	0.579	rs79916508	chr15:75373721	A/C	cg17294928	chr15:75287854	SCAMP5	-0.82	-4.47	-0.42	2.17e-5	Lung cancer;
THYM	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg13683864	chr3:40499215	RPL14	-0.75	-6.99	-0.58	3.84e-10	Renal cell carcinoma;
THYM	cis	rs7264396	0.563	rs2425116	chr20:34323553	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Total cholesterol levels;
THYM	cis	rs7772486	0.875	rs6938972	chr6:146410608	G/A	cg13319975	chr6:146136371	FBXO30	-0.61	-4.96	-0.45	3.05e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs4731207	0.698	rs11978656	chr7:124449965	C/T	cg05285228	chr7:124571219	POT1	0.66	5.24	0.47	9.66e-7	Cutaneous malignant melanoma;
THYM	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	0.92	7.34	0.6	7.16e-11	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2969070	0.867	rs2906166	chr7:2508072	A/G	cg25507518	chr7:2405875	EIF3B	-0.46	-4.49	-0.42	1.97e-5	Diastolic blood pressure;
THYM	cis	rs9527	0.615	rs4917991	chr10:104783833	T/C	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs13065560	0.594	rs7633981	chr3:38889901	A/C	cg15678707	chr3:39149194	GORASP1;TTC21A	0.57	4.54	0.42	1.64e-5	Interleukin-18 levels;
THYM	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.66	-5.38	-0.48	5.44e-7	Blood metabolite levels;
THYM	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg26314531	chr2:26401878	FAM59B	0.78	5.13	0.47	1.55e-6	Mean corpuscular hemoglobin;
THYM	cis	rs2797160	1.000	rs1612249	chr6:126014916	C/A	cg16306078	chr6:126000798	NA	0.54	5.53	0.49	2.75e-7	Endometrial cancer;
THYM	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg13607699	chr17:42295918	UBTF	0.66	5.44	0.49	4.13e-7	Total body bone mineral density;
THYM	cis	rs250585	0.736	rs250559	chr16:23452824	G/A	cg00143387	chr16:23521605	GGA2	0.74	5.27	0.48	8.6e-7	Egg allergy;
THYM	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.79	4.92	0.45	3.61e-6	Diabetic retinopathy;
THYM	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg11764359	chr7:65958608	NA	0.8	6.5	0.55	3.78e-9	Aortic root size;
THYM	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4383453	0.539	rs12629585	chr3:123097706	T/A	cg04890266	chr3:123102914	ADCY5	-0.84	-8.5	-0.66	2.61e-13	Gestational age at birth (maternal effect);
THYM	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg04750100	chr2:136595281	LCT	0.58	6.27	0.54	1.08e-8	Mosquito bite size;
THYM	cis	rs28595532	0.920	rs114789346	chr4:119748652	G/A	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs10929159	0.928	rs9636243	chr2:236925259	C/T	cg14895183	chr2:236924282	AGAP1	0.53	4.56	0.42	1.5e-5	Parkinson's disease;
THYM	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg26769984	chr7:1090371	C7orf50	0.8	5.66	0.5	1.62e-7	Bronchopulmonary dysplasia;
THYM	cis	rs4074961	0.586	rs10908360	chr1:38058693	T/C	cg17933807	chr1:38061675	GNL2	1.04	11.67	0.77	4.64e-20	Axial length;
THYM	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg08859206	chr1:53392774	SCP2	-0.53	-5.71	-0.51	1.27e-7	Monocyte count;
THYM	cis	rs4727027	0.704	rs1123992	chr7:148907201	C/G	cg23583168	chr7:148888333	NA	-1.04	-15.08	-0.84	6.11e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs7592578	0.882	rs7569128	chr2:191446691	C/A	cg10560079	chr2:191398806	TMEM194B	0.93	7.28	0.6	9.81e-11	Diastolic blood pressure;
THYM	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg12560992	chr17:57184187	TRIM37	0.94	8.84	0.67	5.01e-14	Intelligence (multi-trait analysis);
THYM	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg11526020	chr17:80870163	TBCD	-0.44	-4.68	-0.43	9.44e-6	Breast cancer;
THYM	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.12	7.97	0.63	3.53e-12	Cognitive test performance;
THYM	cis	rs4808199	0.739	rs2240117	chr19:19418916	C/T	cg03709012	chr19:19516395	GATAD2A	1.21	6.31	0.54	8.9e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs791590	0.941	rs12722489	chr10:6102012	C/T	cg17191567	chr10:6178319	NA	0.8	5.67	0.5	1.55e-7	Soluble interleukin-2 receptor subunit alpha;
THYM	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg04842962	chr6:43655489	MRPS18A	1.01	8.6	0.66	1.59e-13	IgG glycosylation;
THYM	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg14433983	chr11:636460	DRD4	-0.63	-4.57	-0.42	1.48e-5	Systemic lupus erythematosus;
THYM	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg24733560	chr20:60626293	TAF4	0.5	4.51	0.42	1.86e-5	Body mass index;
THYM	cis	rs2303759	0.918	rs9749416	chr19:49885005	G/A	cg22590775	chr19:49891494	CCDC155	0.81	6.72	0.57	1.36e-9	Multiple sclerosis;
THYM	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg08847533	chr14:75593920	NEK9	-0.96	-10.92	-0.75	1.85e-18	Height;
THYM	cis	rs7520050	0.553	rs2993263	chr1:46021630	A/G	cg15605315	chr1:45957053	TESK2	-0.59	-4.54	-0.42	1.66e-5	Red blood cell count;Reticulocyte count;
THYM	cis	rs6754311	0.638	rs2322659	chr2:136555659	A/G	cg07169764	chr2:136633963	MCM6	-0.63	-5.54	-0.49	2.72e-7	Mosquito bite size;
THYM	cis	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg17143192	chr8:8559678	CLDN23	0.66	4.63	0.43	1.17e-5	Obesity-related traits;
THYM	cis	rs11096990	0.634	rs2086752	chr4:39282106	A/G	cg24403649	chr4:39172243	NA	-0.67	-5.84	-0.51	7.33e-8	Cognitive function;
THYM	cis	rs6998277	0.830	rs12543008	chr8:103603747	C/T	cg10187029	chr8:103597600	NA	0.53	4.78	0.44	6.37e-6	Migraine;
THYM	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg06221963	chr1:154839813	KCNN3	-0.78	-9.74	-0.71	5.93e-16	Prostate cancer;
THYM	cis	rs1003719	0.591	rs2040125	chr21:38549236	C/T	cg01329690	chr21:38580129	DSCR9	0.34	4.6	0.43	1.29e-5	Eye color traits;
THYM	cis	rs888194	0.966	rs7313797	chr12:109896165	A/G	cg10504392	chr12:110044639	NA	0.6	5.61	0.5	1.99e-7	Neuroticism;
THYM	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg05182265	chr7:156933206	UBE3C	0.69	9.42	0.69	2.89e-15	Body mass index;
THYM	cis	rs3091242	0.933	rs28530483	chr1:25740847	A/C	cg09222892	chr1:25734099	RHCE	0.62	4.81	0.44	5.58e-6	Erythrocyte sedimentation rate;
THYM	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg00631329	chr6:26305371	NA	-0.63	-7.61	-0.62	2.01e-11	Educational attainment;
THYM	cis	rs2820651	0.614	rs12264424	chr10:1482307	C/T	cg13720710	chr10:1452970	ADARB2	0.7	4.58	0.43	1.43e-5	Migraine with aura;
THYM	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg13609457	chr4:120235615	NA	0.52	4.76	0.44	7.02e-6	Corneal astigmatism;
THYM	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg27490568	chr2:178487706	NA	0.55	4.64	0.43	1.11e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2404602	0.684	rs157759	chr15:76846990	T/A	cg23625390	chr15:77176239	SCAPER	0.84	6.0	0.52	3.59e-8	Blood metabolite levels;
THYM	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg06565975	chr8:143823917	SLURP1	-0.76	-8.91	-0.67	3.46e-14	Urinary tract infection frequency;
THYM	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg22875332	chr1:76189707	ACADM	-0.74	-6.34	-0.55	7.84e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs3741151	1.000	rs7129663	chr11:73045129	C/T	cg17517138	chr11:73019481	ARHGEF17	0.99	5.88	0.52	5.97e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	trans	rs916888	0.558	rs199521	chr17:44853456	G/C	cg01341218	chr17:43662625	NA	-0.85	-7.21	-0.59	1.34e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs939658	0.805	rs35602654	chr15:79417527	T/A	cg17916960	chr15:79447300	NA	-0.68	-7.85	-0.63	6.28e-12	Refractive error;
THYM	cis	rs5985	0.659	rs3024323	chr6:6317960	A/G	cg22185065	chr6:6318785	F13A1	0.78	5.74	0.51	1.15e-7	End-stage coagulation;
THYM	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.27	5.94	0.52	4.63e-8	Obesity-related traits;
THYM	cis	rs13256369	0.950	rs12548792	chr8:8568031	T/C	cg17143192	chr8:8559678	CLDN23	0.91	6.74	0.57	1.2e-9	Obesity-related traits;
THYM	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg16586182	chr3:47516702	SCAP	-0.6	-5.11	-0.46	1.63e-6	Colorectal cancer;
THYM	cis	rs2276498	1.000	rs6127054	chr20:52619331	C/T	cg23682609	chr20:52687365	BCAS1	0.63	4.87	0.45	4.4e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.39	6.99	0.58	3.87e-10	Obesity-related traits;
THYM	cis	rs11645898	0.935	rs4788605	chr16:72154682	G/T	cg03805757	chr16:71968109	PKD1L3	-0.73	-5.41	-0.49	4.66e-7	Blood protein levels;
THYM	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg11266682	chr4:10021025	SLC2A9	-0.69	-9.91	-0.71	2.64e-16	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs55637147	0.671	rs2276041	chr11:57137126	C/T	cg15971518	chr11:57159174	PRG2	-0.6	-4.82	-0.44	5.37e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs67460515	0.563	rs11713441	chr3:160906855	T/C	cg03342759	chr3:160939853	NMD3	-0.69	-5.23	-0.47	1.01e-6	Parkinson's disease;
THYM	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg22166914	chr1:53195759	ZYG11B	0.8	8.26	0.65	8.33e-13	Monocyte count;
THYM	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg22535103	chr8:58192502	C8orf71	-0.89	-5.1	-0.46	1.73e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg14004847	chr7:1930337	MAD1L1	-0.61	-4.63	-0.43	1.15e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg12560992	chr17:57184187	TRIM37	0.94	8.83	0.67	5.11e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg07917127	chr4:99064746	C4orf37	0.59	4.47	0.42	2.17e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Body mass index;
THYM	cis	rs416603	0.967	rs11644184	chr16:11365104	G/A	cg00044050	chr16:11439710	C16orf75	-0.77	-5.86	-0.52	6.69e-8	Type 1 diabetes;
THYM	cis	rs554111	0.679	rs906254	chr1:21324760	G/A	cg01072550	chr1:21505969	NA	0.59	5.17	0.47	1.3e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg15997130	chr1:24165203	NA	0.77	7.05	0.59	2.84e-10	Immature fraction of reticulocytes;
THYM	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg06238570	chr21:40685208	BRWD1	0.92	6.85	0.57	7.35e-10	Cognitive function;
THYM	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.8	6.76	0.57	1.09e-9	Lymphocyte percentage of white cells;
THYM	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg02403541	chr12:121454288	C12orf43	0.81	7.13	0.59	1.96e-10	N-glycan levels;
THYM	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2916260	0.733	rs9394689	chr6:40388567	A/G	cg17190781	chr6:40387783	LRFN2	-1.01	-4.65	-0.43	1.09e-5	Incident coronary heart disease;
THYM	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg08999081	chr20:33150536	PIGU	0.58	4.95	0.45	3.22e-6	Height;
THYM	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg22920501	chr2:26401640	FAM59B	1.07	9.54	0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs9443189	0.570	rs6903448	chr6:76173832	C/T	cg01950844	chr6:76311363	SENP6	1.0	5.57	0.5	2.39e-7	Prostate cancer;
THYM	cis	rs6473252	0.546	rs7816651	chr8:81822709	A/T	cg08595989	chr8:81827712	NA	-0.55	-5.87	-0.52	6.37e-8	Breast cancer;
THYM	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg16558253	chr16:72132732	DHX38	-0.57	-4.83	-0.44	5.29e-6	Fibrinogen levels;
THYM	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.79e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg22709100	chr7:91322751	NA	-0.6	-4.8	-0.44	5.84e-6	Breast cancer;
THYM	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg11812906	chr14:75593930	NEK9	-0.83	-7.53	-0.61	2.92e-11	Height;
THYM	cis	rs9788682	0.747	rs28511883	chr15:78783683	C/T	cg18825076	chr15:78729989	IREB2	0.7	5.57	0.5	2.39e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg03388043	chr17:80084554	CCDC57	-0.73	-6.06	-0.53	2.74e-8	Life satisfaction;
THYM	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg14456004	chr13:21872349	NA	-1.25	-10.18	-0.72	6.85e-17	White matter hyperintensity burden;
THYM	cis	rs1003719	0.762	rs1155786	chr21:38448025	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.67	4.61	0.43	1.25e-5	Eye color traits;
THYM	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg02734326	chr4:10020555	SLC2A9	-0.56	-4.63	-0.43	1.17e-5	Bone mineral density;
THYM	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg22709100	chr7:91322751	NA	-0.62	-4.9	-0.45	3.98e-6	Breast cancer;
THYM	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	trans	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg19862616	chr7:65841803	NCRNA00174	-1.1	-13.18	-0.8	3.53e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2439831	1.000	rs689826	chr15:43749916	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg04731861	chr2:219085781	ARPC2	-0.49	-4.69	-0.43	9.3e-6	Colorectal cancer;
THYM	cis	rs6960043	1.000	rs6980437	chr7:15054916	T/G	cg19272540	chr7:15055459	NA	-0.52	-6.24	-0.54	1.2e-8	Type 2 diabetes;
THYM	cis	rs892961	0.899	rs72896162	chr17:75412521	A/G	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.27	-5.73	-0.51	1.2e-7	Obesity-related traits;
THYM	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.63	-4.48	-0.42	2.05e-5	Gut microbiome composition (summer);
THYM	cis	rs6500602	0.563	rs917305	chr16:4440593	C/T	cg08645402	chr16:4508243	NA	0.76	5.93	0.52	4.89e-8	Schizophrenia;
THYM	cis	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg02475374	chr8:10988117	XKR6	0.6	4.56	0.42	1.54e-5	Triglycerides;
THYM	cis	rs7000551	0.751	rs2469770	chr8:22379856	G/A	cg12081754	chr8:22256438	SLC39A14	0.64	5.83	0.51	7.7e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs1198430	0.852	rs909537	chr1:23810063	C/G	cg19827787	chr1:23763612	ASAP3	0.82	5.24	0.47	9.49e-7	Total cholesterol levels;
THYM	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	cg00122347	chr10:104236741	TMEM180	-0.41	-5.55	-0.49	2.57e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg11764359	chr7:65958608	NA	-0.85	-7.43	-0.61	4.73e-11	Aortic root size;
THYM	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9902453	0.845	rs3102559	chr17:28029723	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	4.69	0.43	8.97e-6	Coffee consumption (cups per day);
THYM	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.72	0.51	1.23e-7	Lung cancer in ever smokers;
THYM	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg25358565	chr5:93447407	FAM172A	1.37	10.94	0.75	1.67e-18	Diabetic retinopathy;
THYM	cis	rs11085466	0.615	rs76695906	chr19:21766710	G/A	cg23004160	chr19:21646329	NA	-0.66	-4.78	-0.44	6.36e-6	Colorectal or endometrial cancer;
THYM	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg12826209	chr6:26865740	GUSBL1	1.04	6.68	0.57	1.63e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg03806693	chr22:41940476	POLR3H	1.07	9.87	0.71	3.08e-16	Vitiligo;
THYM	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg03476357	chr21:30257390	N6AMT1	-0.61	-4.58	-0.43	1.41e-5	Dental caries;
THYM	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg12016809	chr21:47604291	C21orf56	0.78	5.53	0.49	2.82e-7	Testicular germ cell tumor;
THYM	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg08470875	chr2:26401718	FAM59B	-0.76	-4.75	-0.44	7.32e-6	Gut microbiome composition (summer);
THYM	cis	rs9549260	0.709	rs4581585	chr13:41203905	C/T	cg21288729	chr13:41239152	FOXO1	0.72	5.55	0.49	2.61e-7	Red blood cell count;
THYM	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg20291162	chr17:40259547	DHX58	-0.7	-6.47	-0.55	4.18e-9	Fibrinogen levels;
THYM	cis	rs6988636	1.000	rs4377946	chr8:124185887	T/C	cg26140120	chr8:124219575	FAM83A	0.87	4.81	0.44	5.77e-6	Urinary uromodulin levels;
THYM	cis	rs4638749	1.000	rs1466211	chr2:108856412	G/A	cg06795125	chr2:108905320	SULT1C2	-0.41	-5.38	-0.48	5.42e-7	Blood pressure;
THYM	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg16486109	chr11:613632	IRF7	0.47	5.59	0.5	2.19e-7	Systemic lupus erythematosus;
THYM	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg22920501	chr2:26401640	FAM59B	1.02	6.9	0.58	5.76e-10	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12310956	0.532	rs1589902	chr12:33989289	G/A	cg06521331	chr12:34319734	NA	-0.92	-8.57	-0.66	1.89e-13	Morning vs. evening chronotype;
THYM	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg27125505	chr17:43679177	LOC644172	0.77	6.97	0.58	4.25e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg18357526	chr6:26021779	HIST1H4A	0.74	6.49	0.55	3.91e-9	Intelligence (multi-trait analysis);
THYM	cis	rs13315871	0.790	rs28502788	chr3:58296208	A/T	cg00563845	chr3:58318305	PXK	0.56	4.83	0.44	5.15e-6	Cholesterol, total;
THYM	cis	rs2067615	0.579	rs10778509	chr12:107162918	G/A	cg15890332	chr12:107067104	RFX4	0.49	5.75	0.51	1.1e-7	Heart rate;
THYM	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.01	-9.8	-0.71	4.35e-16	Primary sclerosing cholangitis;
THYM	cis	rs1971762	0.965	rs1800633	chr12:54063501	G/A	cg22997177	chr12:54070527	ATP5G2	-0.49	-5.19	-0.47	1.19e-6	Height;
THYM	cis	rs9611519	0.964	rs2179744	chr22:41621714	G/A	cg06481639	chr22:41940642	POLR3H	-0.68	-4.95	-0.45	3.17e-6	Neuroticism;
THYM	cis	rs2075230	0.850	rs60920983	chr17:7478962	A/G	cg10509001	chr17:7553872	ATP1B2	0.59	4.69	0.43	9e-6	Hormone measurements;
THYM	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.64	-4.68	-0.43	9.69e-6	Colorectal cancer;
THYM	cis	rs67981189	0.501	rs3829954	chr14:71455540	A/G	cg15910301	chr14:71632612	NA	0.56	4.88	0.45	4.23e-6	Schizophrenia;
THYM	cis	rs7236492	0.748	rs76617579	chr18:77200655	C/T	cg15644404	chr18:77186268	NFATC1	-1.04	-4.91	-0.45	3.79e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.15	6.86	0.58	7.08e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg12963246	chr6:28129442	ZNF389	0.72	6.2	0.54	1.44e-8	Depression;
THYM	cis	rs7107174	0.901	rs2511162	chr11:77927101	A/G	cg19901956	chr11:77921274	USP35	-0.69	-5.4	-0.48	4.97e-7	Testicular germ cell tumor;
THYM	cis	rs4455778	0.580	rs4270911	chr7:49112131	T/A	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs6815814	0.799	rs11466640	chr4:38778903	A/G	cg02016764	chr4:38805732	TLR1	0.54	4.57	0.42	1.45e-5	Breast cancer;
THYM	cis	rs9595908	0.965	rs4941612	chr13:33123928	C/T	cg12383807	chr13:33924137	NA	-0.53	-4.59	-0.43	1.36e-5	Body mass index;
THYM	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.87	0.45	4.52e-6	Prudent dietary pattern;
THYM	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg24257776	chr3:47051546	LOC100129354	0.41	4.73	0.44	7.73e-6	Colorectal cancer;
THYM	cis	rs17125944	0.686	rs7160582	chr14:53341445	G/T	cg00686598	chr14:53173677	PSMC6	1.12	5.02	0.46	2.38e-6	Alzheimer's disease (late onset);
THYM	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Body mass index;
THYM	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg18132916	chr6:79620363	NA	-0.57	-5.05	-0.46	2.16e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.519	rs1336900	chr1:150679033	C/T	cg09034736	chr1:150693464	HORMAD1	0.53	4.7	0.43	8.84e-6	Tonsillectomy;
THYM	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg11663144	chr21:46675770	NA	-0.71	-9.92	-0.71	2.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7264396	0.676	rs1341603	chr20:34556216	A/G	cg26038318	chr20:34205095	SPAG4	0.59	4.81	0.44	5.6e-6	Total cholesterol levels;
THYM	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9733	0.519	rs11204717	chr1:150709129	T/A	cg09034736	chr1:150693464	HORMAD1	0.52	4.68	0.43	9.35e-6	Tonsillectomy;
THYM	cis	rs791888	0.698	rs7893652	chr10:89431060	A/G	cg13926569	chr10:89418898	PAPSS2	-0.68	-7.81	-0.63	7.51e-12	Magnesium levels;
THYM	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10463554	0.927	rs158399	chr5:102413268	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs7178572	0.568	rs12901297	chr15:77386675	G/A	cg22256960	chr15:77711686	NA	-0.98	-7.31	-0.6	8.43e-11	Type 2 diabetes;
THYM	cis	rs7189233	1.000	rs62048520	chr16:53491095	C/A	cg02965178	chr16:53538660	AKTIP	-0.6	-4.83	-0.44	5.26e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4389656	0.740	rs412643	chr5:6720715	A/G	cg10857441	chr5:6722123	POLS	-0.44	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs9361491	0.608	rs9448542	chr6:79444365	G/T	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs754466	0.606	rs55854323	chr10:79589904	C/T	cg17075019	chr10:79541650	NA	-0.7	-5.73	-0.51	1.2e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11190604	0.767	rs4919459	chr10:102200371	C/T	cg16342193	chr10:102329863	NA	-0.51	-5.29	-0.48	7.96e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	5.61	0.5	1.97e-7	Monocyte percentage of white cells;
THYM	cis	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg01364799	chr7:75623366	TMEM120A	-0.62	-4.46	-0.42	2.22e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs11645898	0.935	rs3812985	chr16:72187957	A/T	cg14768367	chr16:72042858	DHODH	-0.69	-5.22	-0.47	1.05e-6	Blood protein levels;
THYM	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg09359103	chr1:154839909	KCNN3	-0.73	-9.25	-0.69	6.79e-15	Prostate cancer;
THYM	cis	rs12935418	0.672	rs12446810	chr16:81042974	T/C	cg16651780	chr16:81037892	C16orf61	0.87	6.38	0.55	6.35e-9	Mean corpuscular volume;
THYM	cis	rs2251260	0.685	rs2246850	chr14:62009606	C/T	cg13564459	chr14:62004353	PRKCH	0.42	5.39	0.48	5.02e-7	Yeast infection;
THYM	cis	rs7000551	0.532	rs55726237	chr8:22252985	C/T	cg12081754	chr8:22256438	SLC39A14	1.14	11.39	0.76	1.87e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs4242434	0.819	rs2306518	chr8:22470308	A/G	cg03733263	chr8:22462867	KIAA1967	0.97	10.82	0.74	2.99e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7264396	0.508	rs6060739	chr20:34567592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-4.67	-0.43	1e-5	Total cholesterol levels;
THYM	cis	rs4786125	0.636	rs9932626	chr16:6917014	C/G	cg03623568	chr16:6915990	A2BP1	-0.97	-9.77	-0.71	5.03e-16	Heart rate variability traits (SDNN);
THYM	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs9902453	1.000	rs4575590	chr17:28361969	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg06481639	chr22:41940642	POLR3H	0.71	5.15	0.47	1.43e-6	Vitiligo;
THYM	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg24579218	chr15:68104479	NA	-0.83	-7.87	-0.63	5.69e-12	Restless legs syndrome;
THYM	cis	rs994014	0.847	rs1473160	chr4:82279399	C/T	cg17825130	chr4:82283507	NA	0.47	4.48	0.42	2.12e-5	Height;
THYM	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg23791538	chr6:167370224	RNASET2	0.74	5.83	0.51	7.46e-8	Crohn's disease;
THYM	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7127900	0.948	rs71455920	chr11:2226789	A/C	cg25635251	chr11:2234043	NA	0.8	5.11	0.46	1.67e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg27490568	chr2:178487706	NA	0.59	5.04	0.46	2.2e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg26384229	chr12:38710491	ALG10B	0.73	5.35	0.48	6.04e-7	Morning vs. evening chronotype;
THYM	cis	rs8133932	0.521	rs1625244	chr21:47364499	C/T	cg20357416	chr21:47294739	PCBP3	0.74	4.57	0.42	1.45e-5	Schizophrenia;
THYM	cis	rs3112255	0.905	rs4850945	chr2:101287063	A/T	cg01042948	chr2:101319752	NA	-0.56	-4.63	-0.43	1.15e-5	Intelligence (multi-trait analysis);
THYM	cis	rs860818	1.000	rs858247	chr7:23221283	C/A	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	trans	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg25214090	chr10:38739885	LOC399744	0.83	7.11	0.59	2.14e-10	Corneal astigmatism;
THYM	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg15445000	chr17:37608096	MED1	0.44	5.18	0.47	1.23e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9563576	0.778	rs12873071	chr13:58624785	T/C	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg24812749	chr6:127587940	RNF146	0.79	5.99	0.52	3.76e-8	Breast cancer;
THYM	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg00852783	chr1:26633632	UBXN11	0.86	8.81	0.67	5.74e-14	Obesity-related traits;
THYM	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg13695892	chr22:41940480	POLR3H	-0.93	-7.08	-0.59	2.5e-10	Vitiligo;
THYM	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.78	-7.17	-0.59	1.61e-10	Personality dimensions;
THYM	cis	rs1061377	1.000	rs9990755	chr4:39121439	G/T	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs7542375	0.683	rs11587049	chr1:221099886	A/G	cg16008148	chr1:221062819	NA	-0.45	-4.6	-0.43	1.28e-5	Obesity-related traits;
THYM	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg02070205	chr10:30722105	MAP3K8	-0.6	-4.96	-0.45	3.08e-6	Inflammatory bowel disease;
THYM	cis	rs62158800	0.568	rs62162980	chr2:108374371	C/T	cg10013287	chr2:108537568	NA	1.12	5.41	0.49	4.61e-7	Facial morphology (factor 22);
THYM	cis	rs12824058	0.798	rs7968728	chr12:130804696	T/A	cg24838063	chr12:130822603	PIWIL1	0.91	6.9	0.58	5.85e-10	Menopause (age at onset);
THYM	cis	rs3087591	0.919	rs2072131	chr17:29559588	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.67	-5.82	-0.51	7.89e-8	Hip circumference;
THYM	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.43	0.7	2.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs249733	0.526	rs249734	chr5:141888107	T/C	cg08816023	chr5:142065539	FGF1	0.27	4.99	0.46	2.68e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg24308560	chr3:49941425	MST1R	-0.59	-4.46	-0.42	2.29e-5	Body mass index;
THYM	cis	rs2456568	0.709	rs1546400	chr11:93639203	G/A	cg26875233	chr11:93583750	C11orf90	0.49	5.37	0.48	5.63e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg19761014	chr17:28927070	LRRC37B2	0.72	4.53	0.42	1.72e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg17775962	chr7:1200435	ZFAND2A	0.43	5.19	0.47	1.19e-6	Longevity;Endometriosis;
THYM	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg23187316	chr7:1099788	C7orf50	0.49	5.26	0.47	8.87e-7	Longevity;Endometriosis;
THYM	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg10661904	chr17:79619235	PDE6G	-0.58	-5.3	-0.48	7.36e-7	Eye color traits;
THYM	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs8099917	0.682	rs8105790	chr19:39732501	T/C	cg16476317	chr19:39737804	NA	0.44	4.73	0.44	7.71e-6	Response to hepatitis C treatment;Chronic hepatitis C infection;
THYM	cis	rs2257129	1.000	rs6585696	chr10:122921563	C/T	cg22762615	chr10:123358210	FGFR2	-1.33	-4.73	-0.44	7.77e-6	Coronary artery disease;Body mass index;
THYM	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg20999797	chr1:1681921	NA	0.5	5.51	0.49	3.07e-7	Body mass index;
THYM	cis	rs12291225	0.639	rs61883858	chr11:14294708	C/T	cg05501817	chr11:14380813	RRAS2	-0.75	-5.72	-0.51	1.24e-7	Sense of smell;
THYM	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg11279151	chr3:101281821	RG9MTD1	-0.67	-4.9	-0.45	3.87e-6	Colorectal cancer;
THYM	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.72	6.61	0.56	2.26e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	9.82	0.71	4.08e-16	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg21231944	chr12:82153410	PPFIA2	-0.69	-5.14	-0.47	1.48e-6	Resting heart rate;
THYM	cis	rs9311676	0.656	rs7620012	chr3:58373716	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	4.46	0.42	2.21e-5	Diabetic retinopathy;
THYM	cis	rs807669	0.869	rs1061325	chr22:19184095	T/C	cg02655711	chr22:19163373	SLC25A1	0.62	6.9	0.58	5.74e-10	Metabolite levels;
THYM	cis	rs4866334	1.000	rs116499870	chr5:18479009	G/A	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.58	-10.88	-0.74	2.23e-18	Hemostatic factors and hematological phenotypes;
THYM	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.24	-4.55	-0.42	1.58e-5	Obesity-related traits;
THYM	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg24675056	chr1:15929824	NA	0.69	5.69	0.5	1.4e-7	Systolic blood pressure;
THYM	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7224737	0.956	rs8081327	chr17:40274200	G/A	cg20291162	chr17:40259547	DHX58	-0.7	-6.47	-0.55	4.18e-9	Fibrinogen levels;
THYM	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02475777	chr4:1388615	CRIPAK	0.72	5.21	0.47	1.09e-6	Longevity;
THYM	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg12165864	chr7:66369176	NA	-0.65	-5.08	-0.46	1.89e-6	Aortic root size;
THYM	cis	rs10782582	0.593	rs12131344	chr1:76136437	C/T	cg22875332	chr1:76189707	ACADM	-0.53	-4.92	-0.45	3.68e-6	Daytime sleep phenotypes;
THYM	cis	rs10861661	0.569	rs10778514	chr12:107303577	G/A	cg13944111	chr12:107296891	NA	0.68	5.49	0.49	3.34e-7	Triglyceride levels;
THYM	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg18681998	chr4:17616180	MED28	0.81	6.87	0.58	6.5e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4589258	0.830	rs7942616	chr11:90424251	A/T	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.519	rs1336899	chr1:150678910	T/C	cg15448220	chr1:150897856	SETDB1	0.88	7.27	0.6	1.02e-10	Tonsillectomy;
THYM	cis	rs3820068	0.506	rs17448966	chr1:15990983	T/G	cg27534772	chr1:16042836	PLEKHM2	0.52	5.51	0.49	3.07e-7	Systolic blood pressure;
THYM	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg06634786	chr22:41940651	POLR3H	0.63	4.75	0.44	7.33e-6	Vitiligo;
THYM	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	6.84	0.57	7.71e-10	Prudent dietary pattern;
THYM	cis	rs4343996	0.692	rs34148253	chr7:3454978	A/G	cg21248987	chr7:3385318	SDK1	0.4	4.89	0.45	4.14e-6	Motion sickness;
THYM	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg00419117	chr1:228361641	C1orf69	0.47	4.54	0.42	1.67e-5	Diastolic blood pressure;
THYM	cis	rs7258465	0.965	rs2385088	chr19:18545540	A/G	cg04166595	chr19:18636596	NA	0.62	4.7	0.43	8.77e-6	Breast cancer;
THYM	cis	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.57	-6.07	-0.53	2.64e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg08901578	chr4:187885870	NA	-0.68	-6.68	-0.57	1.62e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6733011	0.519	rs6739097	chr2:99458601	G/A	cg08885076	chr2:99613938	TSGA10	-0.5	-4.78	-0.44	6.36e-6	Bipolar disorder;
THYM	cis	rs877282	0.853	rs11253332	chr10:755262	G/C	cg10556349	chr10:835070	NA	-0.69	-4.49	-0.42	2.03e-5	Uric acid levels;
THYM	cis	rs6732160	0.613	rs62151837	chr2:73390396	G/T	cg24220031	chr2:73402428	NA	-0.72	-5.95	-0.52	4.41e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg14675211	chr2:100938903	LONRF2	0.77	8.5	0.66	2.68e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg15445000	chr17:37608096	MED1	-0.44	-5.22	-0.47	1.05e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs2376015	1	rs2376015	chr1:66123774	A/G	cg04111102	chr1:66153794	NA	0.56	5.25	0.47	9.2e-7	Fibrinogen levels;
THYM	cis	rs7809950	0.954	rs12673675	chr7:107113220	T/C	cg23024343	chr7:107201750	COG5	-0.92	-8.15	-0.64	1.45e-12	Coronary artery disease;
THYM	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg24450063	chr1:156163899	SLC25A44	1.18	9.94	0.71	2.2e-16	Testicular germ cell tumor;
THYM	cis	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg01364799	chr7:75623366	TMEM120A	-0.64	-4.75	-0.44	7.32e-6	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2041895	0.509	rs1838445	chr12:107314585	T/A	cg13944111	chr12:107296891	NA	0.65	5.23	0.47	1.01e-6	Glaucoma (low intraocular pressure);
THYM	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs61931739	0.817	rs7297799	chr12:34260142	T/C	cg10856724	chr12:34555212	NA	-0.66	-5.76	-0.51	1.03e-7	Morning vs. evening chronotype;
THYM	cis	rs10751667	0.857	rs6597952	chr11:991109	C/G	ch.11.42038R	chr11:967971	AP2A2	0.61	4.81	0.44	5.58e-6	Alzheimer's disease (late onset);
THYM	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.59	4.45	0.42	2.35e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs6009824	0.891	rs6009822	chr22:50085731	C/T	cg27029450	chr22:50098074	NA	0.85	5.48	0.49	3.56e-7	Natriuretic peptide levels;
THYM	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg15592062	chr6:167189543	RPS6KA2	-0.47	-4.76	-0.44	7.02e-6	Crohn's disease;
THYM	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg22467129	chr15:76604101	ETFA	-0.56	-5.27	-0.48	8.62e-7	Blood metabolite levels;
THYM	trans	rs9951602	0.512	rs1599635	chr18:76643819	G/A	cg02800362	chr5:177631904	HNRNPAB	1.11	8.66	0.66	1.21e-13	Obesity-related traits;
THYM	cis	rs7567851	0.623	rs1898010	chr2:178952219	A/T	cg17320194	chr2:178042734	NA	-0.8	-4.45	-0.42	2.36e-5	Height;
THYM	cis	rs4690686	0.500	rs72623907	chr4:177261965	C/G	cg17059388	chr4:177262070	NA	0.48	6.73	0.57	1.29e-9	Essential tremor;
THYM	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs790123	0.666	rs28666491	chr3:122389184	G/A	cg15604389	chr3:122379662	NA	0.58	4.8	0.44	5.91e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs11018874	0.597	rs10765243	chr11:89855118	C/G	cg14505434	chr11:89522851	NA	0.66	4.67	0.43	9.76e-6	White blood cell types;
THYM	cis	rs12579753	0.872	rs7956132	chr12:82178709	A/G	cg07988820	chr12:82153109	PPFIA2	-0.76	-4.83	-0.44	5.26e-6	Resting heart rate;
THYM	cis	rs854765	0.663	rs3744115	chr17:17749822	G/A	cg04398451	chr17:18023971	MYO15A	0.82	7.57	0.61	2.42e-11	Total body bone mineral density;
THYM	cis	rs7172677	1.000	rs2415159	chr15:75430715	T/A	cg09165964	chr15:75287851	SCAMP5	-0.63	-4.75	-0.44	7.24e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg17333051	chr19:2783644	SGTA	0.71	6.12	0.53	2.11e-8	Total cholesterol levels;
THYM	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg04414720	chr1:150670196	GOLPH3L	0.62	4.58	0.43	1.41e-5	Melanoma;
THYM	cis	rs28595532	0.920	rs115797971	chr4:119779620	A/G	cg11846333	chr4:119757529	SEC24D	1.45	5.08	0.46	1.92e-6	Cannabis dependence symptom count;
THYM	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg07075026	chr17:47091521	IGF2BP1	0.53	5.59	0.5	2.13e-7	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs7843479	0.601	rs12056476	chr8:21854188	T/A	cg17168535	chr8:21777572	XPO7	0.91	7.94	0.63	3.94e-12	Mean corpuscular volume;
THYM	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.87e-6	Resting heart rate;
THYM	cis	rs1691799	0.867	rs1168338	chr12:66759369	T/C	cg16791601	chr12:66731901	HELB	-0.72	-6.82	-0.57	8.35e-10	White blood cell count (basophil);
THYM	cis	rs2354432	0.607	rs11579626	chr1:146741960	A/C	cg25205988	chr1:146714368	CHD1L	-1.08	-5.63	-0.5	1.86e-7	Mitochondrial DNA levels;
THYM	cis	rs7582403	0.844	rs12615059	chr2:148850489	C/T	cg23727674	chr2:148602993	ACVR2A	-0.58	-4.79	-0.44	6.24e-6	Neuroticism;
THYM	cis	rs6733011	0.628	rs6542838	chr2:99452458	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.51	-4.46	-0.42	2.26e-5	Bipolar disorder;
THYM	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.57	4.56	0.42	1.54e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6424115	0.737	rs10917430	chr1:24170458	C/T	cg15997130	chr1:24165203	NA	-0.71	-5.34	-0.48	6.26e-7	Immature fraction of reticulocytes;
THYM	cis	rs2294693	0.679	rs4317403	chr6:40971173	C/T	cg14418226	chr6:40996092	UNC5CL	0.7	5.17	0.47	1.28e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg24910161	chr17:38119198	GSDMA	0.46	4.62	0.43	1.19e-5	Self-reported allergy;
THYM	cis	rs192264	0.551	rs8044539	chr16:65986490	C/G	cg02795155	chr16:66785218	DYNC1LI2	0.58	4.8	0.44	5.85e-6	Subjective well-being;
THYM	cis	rs11668609	0.505	rs60888272	chr19:24151293	A/G	cg15526094	chr19:24182596	NA	-0.63	-4.47	-0.42	2.13e-5	Response to taxane treatment (docetaxel);
THYM	cis	rs12148488	0.763	rs12898551	chr15:75297907	C/G	cg17294928	chr15:75287854	SCAMP5	0.64	4.53	0.42	1.72e-5	Caffeine consumption;
THYM	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg23708337	chr7:1209742	NA	0.84	4.45	0.42	2.35e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg11548083	chr8:10208156	MSRA	-0.46	-5.03	-0.46	2.28e-6	Neuroticism;
THYM	cis	rs35883536	0.647	rs55728953	chr1:101046863	T/C	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs4595586	0.545	rs12812762	chr12:39371141	T/C	cg26384229	chr12:38710491	ALG10B	0.72	5.42	0.49	4.52e-7	Morning vs. evening chronotype;
THYM	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.29	0.6	9.09e-11	Bladder cancer;
THYM	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg14004847	chr7:1930337	MAD1L1	-0.63	-4.83	-0.44	5.3e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.17	0.53	1.69e-8	Coronary artery disease;
THYM	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg26384229	chr12:38710491	ALG10B	0.99	7.82	0.63	7.12e-12	Bladder cancer;
THYM	cis	rs7193541	0.550	rs28607667	chr16:74476015	C/T	cg01733217	chr16:74700730	RFWD3	-0.83	-8.45	-0.66	3.34e-13	Multiple myeloma;
THYM	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.41	-6.4	-0.55	5.78e-9	Obesity-related traits;
THYM	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.15	-11.35	-0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs2039659	0.641	rs2255983	chr13:86254426	C/T	cg25308322	chr13:86268291	NA	0.66	5.51	0.49	3.11e-7	Blood osmolality (transformed sodium);
THYM	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg24060327	chr5:131705240	SLC22A5	-0.78	-6.23	-0.54	1.27e-8	Breast cancer;
THYM	cis	rs9790314	0.602	rs4679926	chr3:160677240	A/T	cg04691961	chr3:161091175	C3orf57	0.58	4.63	0.43	1.15e-5	Morning vs. evening chronotype;
THYM	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg03388043	chr17:80084554	CCDC57	-0.66	-5.66	-0.5	1.61e-7	Life satisfaction;
THYM	cis	rs10504073	0.584	rs55838473	chr8:49948281	C/A	cg00325661	chr8:49890786	NA	1.08	10.81	0.74	3.14e-18	Blood metabolite ratios;
THYM	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg26597838	chr10:835615	NA	1.42	9.79	0.71	4.66e-16	Eosinophil percentage of granulocytes;
THYM	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg14416269	chr4:6271139	WFS1	0.55	5.69	0.5	1.41e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.06	-0.64	2.22e-12	Personality dimensions;
THYM	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg24399712	chr22:39784796	NA	-0.93	-10.65	-0.74	6.66e-18	Intelligence (multi-trait analysis);
THYM	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg03929089	chr4:120376271	NA	-0.95	-10.24	-0.72	5.05e-17	Coronary artery disease;
THYM	cis	rs7084402	0.967	rs1593678	chr10:60291548	A/G	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs12983058	1.000	rs12983058	chr19:51642784	A/C	cg17923401	chr19:51644168	SIGLEC7	-0.52	-4.6	-0.43	1.32e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2777491	0.574	rs11858812	chr15:41731550	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.23	-14.42	-0.83	1.16e-25	Ulcerative colitis;
THYM	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg06221963	chr1:154839813	KCNN3	-0.73	-8.62	-0.66	1.5e-13	Prostate cancer;
THYM	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06873352	chr17:61820015	STRADA	0.79	9.87	0.71	3.15e-16	Prudent dietary pattern;
THYM	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.38	5.34	0.48	6.28e-7	Obesity-related traits;
THYM	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg18230493	chr5:56204884	C5orf35	-0.86	-6.44	-0.55	4.87e-9	Initial pursuit acceleration;
THYM	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg20307385	chr11:47447363	PSMC3	0.72	6.1	0.53	2.31e-8	Neuroticism;Neuroticism (multi-trait analysis);
THYM	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg13395646	chr4:1353034	KIAA1530	-0.75	-7.14	-0.59	1.83e-10	Obesity-related traits;
THYM	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg23173402	chr1:227635558	NA	0.75	6.06	0.53	2.72e-8	Major depressive disorder;
THYM	cis	rs6430585	0.702	rs3213890	chr2:136552188	G/A	cg07169764	chr2:136633963	MCM6	1.19	13.81	0.82	1.9e-24	Corneal structure;
THYM	cis	rs7584330	0.518	rs80282956	chr2:238447929	G/A	cg14458575	chr2:238380390	NA	0.82	4.53	0.42	1.74e-5	Prostate cancer;
THYM	cis	rs17854409	1.000	rs66634465	chr20:61482306	C/T	cg06598544	chr20:61472147	COL9A3	-1.12	-7.44	-0.61	4.5e-11	Obesity-related traits;
THYM	cis	rs7584330	0.518	rs74003109	chr2:238448150	C/T	cg14458575	chr2:238380390	NA	0.82	4.53	0.42	1.73e-5	Prostate cancer;
THYM	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	5.02	0.46	2.41e-6	Motion sickness;
THYM	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg17074396	chr22:49843754	NA	-0.39	-4.59	-0.43	1.33e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg11871910	chr12:69753446	YEATS4	0.85	7.03	0.59	3.09e-10	Blood protein levels;
THYM	cis	rs995000	0.899	rs35529421	chr1:62965621	T/A	cg06896770	chr1:63153194	DOCK7	0.99	8.1	0.64	1.87e-12	Triglyceride levels;
THYM	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg27572855	chr1:25598939	RHD	0.69	5.3	0.48	7.64e-7	Erythrocyte sedimentation rate;
THYM	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg24069376	chr3:38537580	EXOG	0.66	6.6	0.56	2.29e-9	Electrocardiographic conduction measures;
THYM	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg20891283	chr12:69753455	YEATS4	1.05	10.03	0.72	1.44e-16	Blood protein levels;
THYM	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg17426766	chr1:2046864	PRKCZ	-0.39	-4.76	-0.44	6.9e-6	Height;
THYM	cis	rs986417	0.818	rs1950311	chr14:60989604	A/C	cg27398547	chr14:60952738	C14orf39	1.25	6.45	0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs6448317	0.863	rs2695228	chr4:24901985	C/T	cg22968281	chr4:24586266	DHX15	-0.7	-5.2	-0.47	1.15e-6	Heschl's gyrus morphology;
THYM	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs58235267	0.553	rs1025132	chr2:63360639	G/A	cg17519650	chr2:63277830	OTX1	0.61	5.1	0.46	1.7e-6	Prostate-specific antigen levels (conditioned on lead SNPs);
THYM	cis	rs854765	0.663	rs3744115	chr17:17749822	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.66	-5.76	-0.51	1.04e-7	Total body bone mineral density;
THYM	cis	rs13102973	0.899	rs4541577	chr4:135901087	G/T	cg14419869	chr4:135874104	NA	0.8	6.72	0.57	1.35e-9	Subjective well-being;
THYM	cis	rs6490294	0.583	rs2339973	chr12:112520883	C/T	cg10833066	chr12:111807467	FAM109A	0.47	5.23	0.47	1.02e-6	Mean platelet volume;
THYM	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs75518195	0.520	rs11733488	chr4:64662645	G/A	cg14706739	chr8:21916355	EPB49	0.75	7.37	0.6	6.22e-11	Triptolide cytotoxicity;
THYM	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg12573674	chr2:1569213	NA	-1.16	-8.21	-0.64	1.1e-12	IgG glycosylation;
THYM	cis	rs10832963	0.686	rs11024743	chr11:18653712	A/G	cg09201001	chr11:18656081	SPTY2D1	1.05	9.24	0.69	6.91e-15	Breast cancer;
THYM	cis	rs8130944	0.730	rs2250870	chr21:44157187	C/T	cg03543861	chr21:44258195	NA	0.48	4.51	0.42	1.87e-5	Perceived unattractiveness to mosquitoes;
THYM	cis	rs7071206	0.947	rs4979902	chr10:79399946	C/T	cg07817648	chr10:79422355	NA	0.97	7.5	0.61	3.32e-11	Bone mineral density;
THYM	cis	rs2717559	0.541	rs11774054	chr8:143881976	T/C	cg17252645	chr8:143867129	LY6D	-0.6	-5.68	-0.5	1.49e-7	Urinary tract infection frequency;
THYM	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg02782426	chr3:40428986	ENTPD3	0.51	4.61	0.43	1.24e-5	Renal cell carcinoma;
THYM	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.68	-5.28	-0.48	8.12e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs4866334	1.000	rs77523779	chr5:18486747	C/A	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs3806843	0.868	rs2531352	chr5:140119534	A/G	cg19875535	chr5:140030758	IK	-0.6	-4.75	-0.44	7.26e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs67460515	0.596	rs35589595	chr3:160930984	G/A	cg03342759	chr3:160939853	NMD3	-0.69	-5.23	-0.47	1.01e-6	Parkinson's disease;
THYM	cis	rs6032067	0.714	rs6094110	chr20:43864889	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-6.24	-0.54	1.22e-8	Blood protein levels;
THYM	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg01256987	chr12:42539512	GXYLT1	-0.68	-4.94	-0.45	3.35e-6	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
THYM	cis	rs7113850	0.541	rs74708033	chr11:24223512	C/T	ch.11.24196551F	chr11:24239977	NA	0.92	4.89	0.45	4.04e-6	Bone fracture in osteoporosis;
THYM	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg03877680	chr5:178157825	ZNF354A	0.78	5.25	0.47	9.37e-7	Neutrophil percentage of white cells;
THYM	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg02493740	chr2:85810744	VAMP5	0.64	5.06	0.46	2.06e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs6942756	1.000	rs1473236	chr7:128880831	G/T	cg02491457	chr7:128862824	NA	-0.44	-4.5	-0.42	1.91e-5	White matter hyperintensity burden;
THYM	cis	rs61931739	0.529	rs1525900	chr12:33976652	T/G	cg06521331	chr12:34319734	NA	-0.59	-4.94	-0.45	3.29e-6	Morning vs. evening chronotype;
THYM	cis	rs1056053	0.539	rs3099270	chr6:166571525	T/C	cg11088901	chr6:166572345	T	-0.58	-5.22	-0.47	1.05e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6424115	0.743	rs2229580	chr1:24201109	C/T	cg15997130	chr1:24165203	NA	0.76	6.39	0.55	6.14e-9	Immature fraction of reticulocytes;
THYM	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg19077165	chr18:44547161	KATNAL2	0.61	7.59	0.61	2.23e-11	Personality dimensions;
THYM	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg09858108	chr8:58055024	NA	0.81	5.43	0.49	4.32e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs11008222	0.967	rs2105282	chr10:31049601	T/A	cg00941203	chr10:31016591	NA	-0.35	-4.84	-0.44	5.05e-6	Congenital left-sided heart lesions (maternal effect);
THYM	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06850241	chr22:41845214	NA	-0.58	-5.19	-0.47	1.18e-6	Vitiligo;
THYM	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg02753203	chr1:228287806	NA	0.98	8.36	0.65	5.22e-13	Diastolic blood pressure;
THYM	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg01751800	chr4:77820391	ANKRD56	0.56	4.63	0.43	1.15e-5	Emphysema distribution in smoking;
THYM	cis	rs4148087	1.000	rs28485452	chr21:43615131	G/A	cg09727148	chr21:43560719	UMODL1	0.6	4.7	0.43	8.81e-6	Eating disorder in bipolar disorder;
THYM	cis	rs899997	0.954	rs4887091	chr15:79043580	T/C	cg04896959	chr15:78267971	NA	0.93	7.59	0.61	2.22e-11	Coronary artery disease or large artery stroke;
THYM	cis	rs9970807	1.000	rs56186267	chr1:56970418	C/A	cg11959316	chr1:57001742	PPAP2B	0.74	5.33	0.48	6.64e-7	Myocardial infarction;Coronary artery disease;
THYM	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg13695892	chr22:41940480	POLR3H	0.86	5.96	0.52	4.19e-8	Cannabis dependence symptom count;
THYM	cis	rs6901250	1.000	rs993394	chr6:117117143	G/A	cg12892004	chr6:117198278	RFX6	0.72	6.64	0.56	1.94e-9	C-reactive protein levels;
THYM	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg01324343	chr3:183735012	ABCC5	0.9	13.62	0.81	4.71e-24	Anterior chamber depth;
THYM	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.64	-0.62	1.74e-11	Personality dimensions;
THYM	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg08736216	chr1:53307985	ZYG11A	0.61	5.57	0.5	2.41e-7	Monocyte count;
THYM	cis	rs2898681	0.511	rs881743	chr4:53727450	A/G	cg00791764	chr4:53727839	RASL11B	0.43	6.1	0.53	2.25e-8	Optic nerve measurement (cup area);
THYM	cis	rs909002	0.800	rs3753613	chr1:32082000	C/T	cg13919466	chr1:32135498	COL16A1	0.5	5.06	0.46	2.01e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6754311	0.597	rs2278544	chr2:136546110	A/G	cg07169764	chr2:136633963	MCM6	-0.67	-5.82	-0.51	7.78e-8	Mosquito bite size;
THYM	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs9527	0.614	rs11191589	chr10:104930382	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.49	-0.42	1.98e-5	Arsenic metabolism;
THYM	cis	rs2285947	1.000	rs2285949	chr7:21584243	G/A	cg04471919	chr7:21584483	DNAH11	0.45	4.46	0.42	2.29e-5	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
THYM	cis	rs7575217	0.643	rs2309996	chr2:101735838	T/G	cg23907051	chr2:101730305	TBC1D8	-0.42	-5.63	-0.5	1.79e-7	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg09307838	chr4:120376055	NA	0.72	5.1	0.46	1.75e-6	Corneal astigmatism;
THYM	cis	rs1829883	0.804	rs1608435	chr5:98817492	A/G	cg08333243	chr5:99726346	NA	-0.56	-5.29	-0.48	7.81e-7	Hemostatic factors and hematological phenotypes;
THYM	cis	rs17401966	0.838	rs34636442	chr1:10427459	T/G	cg19773385	chr1:10388646	KIF1B	-0.57	-4.58	-0.43	1.4e-5	Hepatocellular carcinoma;
THYM	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg10360139	chr7:1886902	MAD1L1	0.6	5.21	0.47	1.1e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg23649088	chr2:200775458	C2orf69	0.79	6.78	0.57	9.92e-10	Schizophrenia;
THYM	cis	rs2273669	0.504	rs77608624	chr6:109442854	A/G	cg17117243	chr6:109341365	SESN1	-0.92	-5.47	-0.49	3.63e-7	Prostate cancer;
THYM	cis	rs919433	0.680	rs7582536	chr2:198436103	C/T	cg05783139	chr2:198650985	BOLL	-0.58	-4.65	-0.43	1.08e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs17407555	0.520	rs4292327	chr4:9943700	G/A	cg00071950	chr4:10020882	SLC2A9	-0.7	-5.3	-0.48	7.56e-7	Schizophrenia (age at onset);
THYM	cis	rs2522056	1.000	rs62385693	chr5:131773674	T/C	cg24060327	chr5:131705240	SLC22A5	0.7	4.53	0.42	1.74e-5	Lymphocyte counts;Fibrinogen;
THYM	cis	rs4523957	0.788	rs2169357	chr17:2096441	C/T	cg16513277	chr17:2031491	SMG6	-0.83	-8.22	-0.64	1.01e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg19774624	chr17:42201019	HDAC5	0.65	5.35	0.48	6.04e-7	Total body bone mineral density;
THYM	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg14004847	chr7:1930337	MAD1L1	-0.71	-5.51	-0.49	3.02e-7	Schizophrenia;
THYM	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg24375607	chr4:120327624	NA	-0.68	-5.44	-0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs2302612	0.528	rs3755286	chr2:102843841	G/C	cg13315345	chr2:102803985	IL1RL2	0.72	4.88	0.45	4.28e-6	Serum protein levels (sST2);
THYM	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg13390004	chr1:15929781	NA	0.63	4.74	0.44	7.61e-6	Systolic blood pressure;
THYM	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg04234412	chr22:24373322	LOC391322	-0.98	-12.22	-0.78	3.35e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg06611532	chr13:114900021	NA	0.64	7.17	0.59	1.61e-10	Schizophrenia;
THYM	cis	rs12681288	0.550	rs60530879	chr8:958381	G/C	cg08648136	chr8:956695	NA	0.57	4.93	0.45	3.44e-6	Schizophrenia;
THYM	cis	rs11648796	0.959	rs9928077	chr16:784765	C/T	cg09263875	chr16:632152	PIGQ	0.68	4.95	0.45	3.23e-6	Height;
THYM	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg08999081	chr20:33150536	PIGU	0.57	4.78	0.44	6.41e-6	Coronary artery disease;
THYM	cis	rs6988636	1.000	rs10096350	chr8:124184470	T/C	cg26140120	chr8:124219575	FAM83A	0.87	4.81	0.44	5.77e-6	Urinary uromodulin levels;
THYM	cis	rs12509991	0.582	rs4833335	chr4:127049131	A/G	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7830933	0.955	rs7835797	chr8:23597020	A/G	cg04349084	chr8:23602677	NA	0.7	7.42	0.61	5.01e-11	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs9329221	0.741	rs58689676	chr8:9806492	T/C	cg19847130	chr8:10466454	RP1L1	0.62	5.91	0.52	5.26e-8	Neuroticism;
THYM	cis	rs10203711	0.933	rs907110	chr2:239566391	C/T	cg14580085	chr2:239553406	NA	0.68	6.17	0.53	1.65e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11690935	0.655	rs17614941	chr2:172541378	A/G	cg13550731	chr2:172543902	DYNC1I2	0.64	5.07	0.46	1.96e-6	Schizophrenia;
THYM	cis	rs4363385	0.693	rs608509	chr1:153034650	G/C	cg13444842	chr1:152974279	SPRR3	-0.62	-5.07	-0.46	1.96e-6	Inflammatory skin disease;
THYM	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg00495681	chr13:53174319	NA	0.92	9.72	0.71	6.39e-16	Lewy body disease;
THYM	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg14458575	chr2:238380390	NA	0.9	7.53	0.61	2.94e-11	Prostate cancer;
THYM	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg07936489	chr17:37558343	FBXL20	0.87	5.78	0.51	9.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs3126085	0.935	rs3120660	chr1:152258701	G/T	cg10321714	chr1:152280068	FLG	-0.67	-5.14	-0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg19875535	chr5:140030758	IK	-0.58	-4.92	-0.45	3.6e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg23978390	chr7:1156363	C7orf50	0.61	4.66	0.43	1.02e-5	Longevity;Endometriosis;
THYM	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg06238570	chr21:40685208	BRWD1	-0.71	-6.26	-0.54	1.13e-8	Menarche (age at onset);
THYM	cis	rs3087591	0.959	rs2940182	chr17:29410944	A/G	cg24425628	chr17:29625626	OMG;NF1	0.66	5.67	0.5	1.54e-7	Hip circumference;
THYM	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg27572855	chr1:25598939	RHD	0.65	4.92	0.45	3.57e-6	Erythrocyte sedimentation rate;
THYM	cis	rs4072705	1.000	rs4836985	chr9:127407894	C/T	cg13476313	chr9:127244764	NR5A1	0.32	5.0	0.46	2.6e-6	Menarche (age at onset);
THYM	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	5.35	0.48	6.01e-7	Menarche (age at onset);
THYM	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22496380	chr5:211416	CCDC127	-1.39	-8.78	-0.67	6.55e-14	Breast cancer;
THYM	cis	rs622217	0.656	rs414868	chr6:160719037	C/T	cg11363108	chr6:160501266	IGF2R	-0.57	-4.45	-0.42	2.36e-5	Type 2 diabetes;
THYM	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg22709100	chr7:91322751	NA	0.6	4.69	0.43	9.3e-6	Breast cancer;
THYM	cis	rs57994353	0.760	rs4413892	chr9:139330158	G/A	cg14115884	chr9:139300582	SDCCAG3	0.67	4.59	0.43	1.33e-5	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs72627123	0.867	rs78496651	chr14:74480070	C/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.14	6.41	0.55	5.69e-9	Morning vs. evening chronotype;
THYM	cis	rs17681684	0.505	rs17682156	chr17:9802931	T/C	cg26853458	chr17:9805074	RCVRN	0.57	4.45	0.42	2.34e-5	GIP levels in response to oral glucose tolerance test (fasting);
THYM	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg13010199	chr12:38710504	ALG10B	-0.63	-4.47	-0.42	2.14e-5	Bladder cancer;
THYM	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg08017756	chr2:100939284	LONRF2	-0.74	-7.57	-0.61	2.44e-11	Intelligence (multi-trait analysis);
THYM	cis	rs665401	0.965	rs339350	chr6:117221186	C/T	cg20376953	chr6:117187980	NA	0.6	4.82	0.44	5.5e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg13695892	chr22:41940480	POLR3H	-0.93	-7.08	-0.59	2.5e-10	Vitiligo;
THYM	cis	rs11645898	0.872	rs72787070	chr16:72151101	T/C	cg03805757	chr16:71968109	PKD1L3	-0.73	-5.41	-0.49	4.66e-7	Blood protein levels;
THYM	cis	rs4072705	0.615	rs7869829	chr9:127247177	G/A	cg14219918	chr9:127249562	NR5A1	-0.3	-4.45	-0.42	2.34e-5	Menarche (age at onset);
THYM	cis	rs11008222	0.967	rs7919817	chr10:31048097	G/A	cg00941203	chr10:31016591	NA	-0.35	-4.82	-0.44	5.46e-6	Congenital left-sided heart lesions (maternal effect);
THYM	cis	rs9309711	0.961	rs11678655	chr2:3476234	T/G	cg10845886	chr2:3471009	TTC15	-0.57	-4.61	-0.43	1.24e-5	Neurofibrillary tangles;
THYM	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg03188948	chr7:1209495	NA	0.67	4.67	0.43	9.76e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs858239	0.699	rs1881201	chr7:23194013	C/T	cg05407003	chr7:23246146	NA	0.71	6.1	0.53	2.3e-8	Cerebrospinal fluid biomarker levels;
THYM	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs892961	0.777	rs747483	chr17:75412091	C/T	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs2075230	0.705	rs11078702	chr17:7543508	T/G	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	-0.31	-4.51	-0.42	1.82e-5	Hormone measurements;
THYM	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.91	5.88	0.52	6.07e-8	Smoking behavior;
THYM	cis	rs11039798	0.588	rs589834	chr11:48419382	C/G	cg24672777	chr11:48374446	OR4C45	0.96	6.22	0.54	1.3e-8	Axial length;
THYM	cis	rs7757969	0.500	rs58691769	chr6:112159068	C/T	cg08601457	chr6:112115117	FYN	0.4	4.88	0.45	4.29e-6	Schizophrenia;
THYM	cis	rs7762018	0.607	rs77972667	chr6:170130456	G/C	cg19338460	chr6:170058176	WDR27	-1.01	-5.94	-0.52	4.68e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.64	-7.4	-0.6	5.31e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs4363385	0.510	rs6664380	chr1:153030365	G/T	cg13444842	chr1:152974279	SPRR3	-0.62	-4.94	-0.45	3.34e-6	Inflammatory skin disease;
THYM	cis	rs11760633	0.607	rs11760284	chr7:1827569	C/T	cg23422044	chr7:1970798	MAD1L1	-0.62	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.19	-9.87	-0.71	3.15e-16	Platelet count;
THYM	cis	rs1728785	1.000	rs1728765	chr16:68589433	G/A	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	7.86	0.63	5.9e-12	Chronic sinus infection;
THYM	cis	rs899997	0.906	rs1809415	chr15:79028201	C/T	cg10852096	chr15:79043040	NA	0.74	4.81	0.44	5.61e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs9326248	0.861	rs11216172	chr11:116749878	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.66	4.92	0.45	3.6e-6	Blood protein levels;
THYM	cis	rs6840360	0.571	rs2165789	chr4:152510130	A/T	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12367572	0.965	rs10785539	chr12:45233023	G/C	cg03114573	chr12:45410052	DBX2	-0.56	-5.21	-0.47	1.1e-6	Gut microbiome composition (summer);
THYM	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg09549813	chr16:4587862	C16orf5	-0.49	-5.0	-0.46	2.67e-6	Schizophrenia;
THYM	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg17178900	chr1:205818956	PM20D1	0.54	4.53	0.42	1.72e-5	Parkinson's disease;
THYM	cis	rs2066819	1.000	rs77447765	chr12:56690662	G/A	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg05283184	chr6:79620031	NA	-0.88	-8.41	-0.65	4.14e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.89	-8.71	-0.67	9.57e-14	Lung cancer;
THYM	cis	rs9733	0.596	rs72702585	chr1:150696427	G/A	cg04414720	chr1:150670196	GOLPH3L	0.62	4.71	0.44	8.35e-6	Tonsillectomy;
THYM	cis	rs12410462	1.000	rs12410462	chr1:227667790	A/G	cg23173402	chr1:227635558	NA	-0.66	-5.99	-0.52	3.71e-8	Major depressive disorder;
THYM	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg07424592	chr7:64974309	NA	1.09	5.01	0.46	2.55e-6	Diabetic kidney disease;
THYM	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg16928487	chr17:17741425	SREBF1	-0.49	-4.55	-0.42	1.58e-5	Total body bone mineral density;
THYM	cis	rs5769707	0.592	rs6009783	chr22:50011001	C/G	cg23428387	chr22:49814324	NA	-0.57	-5.4	-0.48	4.99e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7119	0.635	rs2667767	chr15:77876031	T/C	cg27398640	chr15:77910606	LINGO1	0.72	8.56	0.66	1.98e-13	Type 2 diabetes;
THYM	cis	rs2282300	0.739	rs2225909	chr11:30329744	T/C	cg06241208	chr11:30344200	C11orf46	0.78	5.65	0.5	1.64e-7	Morning vs. evening chronotype;
THYM	trans	rs637571	0.676	rs634534	chr11:65665256	A/G	cg17712092	chr4:129076599	LARP1B	-1.07	-10.8	-0.74	3.26e-18	Eosinophil percentage of white cells;
THYM	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg09323728	chr8:95962352	TP53INP1	-0.45	-4.67	-0.43	9.99e-6	Type 2 diabetes;
THYM	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg13695892	chr22:41940480	POLR3H	0.89	6.39	0.55	6.2e-9	Vitiligo;
THYM	trans	rs10962692	0.608	rs10962647	chr9:16868380	T/G	cg03221025	chr16:88955224	CBFA2T3	0.75	7.2	0.59	1.37e-10	Ovarian cancer in BRCA2 mutation carriers;Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;
THYM	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg01069141	chr11:67398826	TBX10;NUDT8	0.49	5.34	0.48	6.25e-7	Mean corpuscular volume;
THYM	cis	rs3826795	0.530	rs7256047	chr19:46796033	T/C	cg15229275	chr19:46800054	HIF3A	0.92	5.54	0.49	2.69e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs6964587	0.839	rs6949700	chr7:91467435	A/G	cg17063962	chr7:91808500	NA	1.11	11.82	0.77	2.27e-20	Breast cancer;
THYM	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	5.11	0.46	1.64e-6	Motion sickness;
THYM	cis	rs753955	0.798	rs9580740	chr13:24286322	A/T	cg26748598	chr13:24091341	NA	0.52	4.45	0.42	2.34e-5	Lung cancer;
THYM	cis	rs7267979	1.000	rs2482919	chr20:25299756	T/C	cg08601574	chr20:25228251	PYGB	-0.57	-4.49	-0.42	2.02e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg02734326	chr4:10020555	SLC2A9	0.76	6.89	0.58	6.16e-10	Bone mineral density;
THYM	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg09184832	chr6:79620586	NA	-0.58	-4.53	-0.42	1.68e-5	Intelligence (multi-trait analysis);
THYM	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs9583531	0.600	rs3809344	chr13:111358705	G/A	cg24331049	chr13:111365604	ING1	0.72	6.04	0.53	2.96e-8	Coronary artery disease;
THYM	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	6.7	0.57	1.44e-9	Platelet count;
THYM	cis	rs12950390	0.548	rs7215477	chr17:45858117	A/C	cg06532163	chr17:45867833	NA	0.56	6.03	0.53	3.08e-8	IgG glycosylation;
THYM	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg18131467	chr2:239335373	ASB1	1.1	11.05	0.75	9.8e-19	Multiple system atrophy;
THYM	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.52	-5.37	-0.48	5.48e-7	Crohn's disease;
THYM	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg03806693	chr22:41940476	POLR3H	1.1	8.83	0.67	5.2e-14	Vitiligo;
THYM	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg26384229	chr12:38710491	ALG10B	-0.7	-5.69	-0.5	1.41e-7	Morning vs. evening chronotype;
THYM	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg10523679	chr1:76189770	ACADM	0.94	8.52	0.66	2.42e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs12282928	1.000	rs10769343	chr11:48321098	G/A	cg22827986	chr11:48284249	OR4X1	0.53	5.5	0.49	3.18e-7	Migraine - clinic-based;
THYM	cis	rs72627123	1.000	rs72627130	chr14:74374897	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs7589342	0.791	rs4438504	chr2:106461035	A/C	cg14210321	chr2:106509881	NCK2	-0.74	-5.3	-0.48	7.5e-7	Addiction;
THYM	cis	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg07460842	chr6:66804631	NA	1.11	8.25	0.65	8.78e-13	Exhaled nitric oxide output;
THYM	cis	rs9814567	0.896	rs58491661	chr3:134355189	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.78	7.64	0.62	1.72e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7944735	0.507	rs17198607	chr11:48028343	A/C	cg24672777	chr11:48374446	OR4C45	0.99	5.48	0.49	3.42e-7	Intraocular pressure;
THYM	cis	rs9287719	0.674	rs10929690	chr2:10805974	T/C	cg03983476	chr2:10830698	NOL10	0.63	5.39	0.48	5.19e-7	Prostate cancer;
THYM	cis	rs10905065	0.965	rs10795520	chr10:5764160	G/A	cg11519256	chr10:5708881	ASB13	0.49	4.7	0.43	8.67e-6	Menopause (age at onset);
THYM	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg20242066	chr2:136595261	LCT	-0.54	-6.83	-0.57	7.89e-10	Mosquito bite size;
THYM	cis	rs9515201	1.000	rs9515201	chr13:111040798	A/C	cg06243866	chr13:111019493	COL4A2	0.69	5.36	0.48	5.78e-7	White matter hyperintensity burden;
THYM	cis	rs10140922	0.931	rs4982262	chr14:35822193	C/T	cg07166546	chr14:35805898	NA	-0.27	-6.45	-0.55	4.69e-9	Hip circumference adjusted for BMI;
THYM	cis	rs754466	0.605	rs10824578	chr10:79578244	G/C	cg17075019	chr10:79541650	NA	-0.67	-5.5	-0.49	3.16e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	6.9	0.58	5.76e-10	Smoking behavior;
THYM	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.51	0.81	7.55e-24	Height;
THYM	cis	rs7943358	0.911	rs1471758	chr11:15729314	G/A	cg11966998	chr11:15692519	NA	-0.46	-4.6	-0.43	1.32e-5	Gut microbiome composition (summer);
THYM	cis	rs4262150	0.883	rs111770575	chr5:152242327	C/T	cg06854687	chr5:151642065	NA	0.66	4.59	0.43	1.36e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg18876405	chr7:65276391	NA	0.63	5.53	0.49	2.83e-7	Aortic root size;
THYM	cis	rs73735248	0.852	rs11758178	chr6:21823978	C/G	cg17770034	chr6:22249139	NA	-0.74	-4.5	-0.42	1.92e-5	Plateletcrit;
THYM	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06481639	chr22:41940642	POLR3H	-0.79	-5.46	-0.49	3.87e-7	Vitiligo;
THYM	cis	rs2712184	0.756	rs2024489	chr2:217661530	A/G	cg05032264	chr2:217675019	NA	-0.54	-4.46	-0.42	2.22e-5	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs9902453	0.904	rs55866125	chr17:28312993	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.22	0.54	1.3e-8	Coffee consumption (cups per day);
THYM	cis	rs17443541	0.507	rs10196195	chr2:200456620	C/T	cg01795955	chr2:200468626	NA	-0.72	-5.0	-0.46	2.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10857712	0.950	rs7906765	chr10:135225460	G/T	cg17796960	chr10:135278976	LOC619207	-0.57	-4.79	-0.44	6.25e-6	Systemic lupus erythematosus;
THYM	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.42	4.47	0.42	2.17e-5	Hemoglobin concentration;
THYM	cis	rs295140	0.526	rs295113	chr2:201197816	C/G	cg23649088	chr2:200775458	C2orf69	0.61	5.01	0.46	2.53e-6	QT interval;
THYM	cis	rs11190604	1.000	rs4919470	chr10:102298920	C/T	cg07570687	chr10:102243282	WNT8B	0.75	6.3	0.54	9.28e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs34638657	0.732	rs12595971	chr16:82200309	T/C	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.11	-0.64	1.73e-12	Lung adenocarcinoma;
THYM	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg26384229	chr12:38710491	ALG10B	0.73	5.4	0.48	5.01e-7	Morning vs. evening chronotype;
THYM	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg05234568	chr11:5960015	NA	-0.63	-5.58	-0.5	2.3e-7	DNA methylation (variation);
THYM	cis	rs35264875	1.000	rs72928644	chr11:68849845	A/G	cg23845249	chr11:68861649	NA	0.55	6.53	0.56	3.22e-9	Blond vs. brown hair color;
THYM	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg05738196	chr6:26577821	NA	0.83	8.34	0.65	5.8e-13	Intelligence (multi-trait analysis);
THYM	cis	rs365132	1.000	rs1700490	chr5:176402401	G/A	cg17809377	chr5:176326619	HK3	-0.31	-4.89	-0.45	4.03e-6	Menarche and menopause (age at onset);Menopause (age at onset);
THYM	cis	rs9948	1.000	rs58147284	chr2:97508082	G/C	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.83	-0.44	5.18e-6	Erectile dysfunction and prostate cancer treatment;
THYM	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg13677785	chr22:42548868	NA	-0.55	-4.46	-0.42	2.23e-5	Schizophrenia;
THYM	cis	rs4889855	0.530	rs8079792	chr17:78609394	A/G	cg16591659	chr17:78472290	NA	-0.4	-5.09	-0.46	1.83e-6	Fractional excretion of uric acid;
THYM	cis	rs7017697	1.000	rs10092772	chr8:19686385	A/T	cg03894339	chr8:19674705	INTS10	-0.54	-4.82	-0.44	5.51e-6	Breast cancer;
THYM	cis	rs9790314	1.000	rs1382428	chr3:161032386	A/C	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs2072732	0.861	rs12048975	chr1:2962225	T/C	cg08733933	chr1:2954429	NA	-0.64	-4.55	-0.42	1.61e-5	Plateletcrit;
THYM	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	5.55	0.49	2.58e-7	Platelet count;
THYM	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14240646	chr10:27532245	ACBD5	-0.82	-4.7	-0.43	8.74e-6	Breast cancer;
THYM	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg26384229	chr12:38710491	ALG10B	-0.61	-4.61	-0.43	1.26e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg18252515	chr7:66147081	NA	1.35	8.09	0.64	1.98e-12	Diabetic kidney disease;
THYM	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6121246	0.559	rs6121038	chr20:30254773	T/G	cg13852791	chr20:30311386	BCL2L1	1.02	9.92	0.71	2.5e-16	Mean corpuscular hemoglobin;
THYM	cis	rs10158481	0.759	rs4649069	chr1:25481747	C/T	cg09264742	chr1:25757510	TMEM57	-0.68	-4.9	-0.45	3.99e-6	Urate levels in obese individuals;
THYM	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg26924012	chr15:45694286	SPATA5L1	0.66	4.86	0.45	4.69e-6	Response to fenofibrate (adiponectin levels);
THYM	cis	rs595982	0.527	rs12151238	chr19:49368613	T/C	cg15549821	chr19:49342101	PLEKHA4	-0.97	-5.47	-0.49	3.64e-7	Red cell distribution width;
THYM	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.25	-5.11	-0.46	1.64e-6	Obesity-related traits;
THYM	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg16325326	chr1:53192061	ZYG11B	-0.82	-8.46	-0.66	3.1400000000000003e-13	Monocyte count;
THYM	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg10792982	chr14:105748885	BRF1	0.7	7.07	0.59	2.55e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2354432	0.607	rs7537279	chr1:146673642	A/G	cg25205988	chr1:146714368	CHD1L	1.1	4.92	0.45	3.66e-6	Mitochondrial DNA levels;
THYM	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.09	-0.46	1.81e-6	Total cholesterol levels;
THYM	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.84	0.44	5.01e-6	Breast cancer;
THYM	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg16329197	chr12:53359506	NA	-0.58	-4.58	-0.43	1.43e-5	Cancer (pleiotropy);
THYM	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.93	6.05	0.53	2.87e-8	Platelet count;
THYM	cis	rs4266144	0.544	rs6805781	chr3:156830569	C/G	cg16248515	chr3:156840234	NA	0.58	5.38	0.48	5.46e-7	Coronary artery disease;
THYM	cis	rs2046867	0.908	rs67967166	chr3:72794198	A/G	cg25664220	chr3:72788482	NA	-0.77	-5.95	-0.52	4.54e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs2273669	0.588	rs78276890	chr6:109305299	G/A	cg17117243	chr6:109341365	SESN1	-0.84	-4.94	-0.45	3.41e-6	Prostate cancer;
THYM	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.72	0.57	1.37e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg08999081	chr20:33150536	PIGU	0.79	7.48	0.61	3.72e-11	Coronary artery disease;
THYM	cis	rs1003719	0.715	rs2835649	chr21:38552230	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.66	4.68	0.43	9.45e-6	Eye color traits;
THYM	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.63	0.56	2.07e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg06618935	chr21:46677482	NA	-0.95	-8.99	-0.68	2.43e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11644478	chr21:40555479	PSMG1	-0.98	-7.42	-0.61	4.91e-11	Cognitive function;
THYM	cis	rs28476539	0.567	rs6824723	chr4:83562313	A/G	cg10249074	chr4:83542146	C4orf11	-0.66	-5.27	-0.48	8.48e-7	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs13064411	0.597	rs2291905	chr3:113010466	C/T	cg18753928	chr3:113234510	CCDC52	-0.88	-8.01	-0.63	2.87e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs3820068	0.608	rs12760450	chr1:16037282	G/A	cg24675056	chr1:15929824	NA	0.78	6.21	0.54	1.4e-8	Systolic blood pressure;
THYM	cis	rs6860806	0.603	rs112300250	chr5:131583292	G/A	cg09877947	chr5:131593287	PDLIM4	0.58	4.77	0.44	6.61e-6	Breast cancer;
THYM	cis	rs700651	0.821	rs700690	chr2:198727626	A/G	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Intracranial aneurysm;
THYM	cis	rs3087591	0.960	rs6505232	chr17:29611411	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.63	-5.35	-0.48	6.1e-7	Hip circumference;
THYM	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg12935359	chr14:103987150	CKB	-0.64	-6.43	-0.55	5.14e-9	Body mass index;
THYM	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg24163568	chr5:669837	TPPP	-0.59	-5.5	-0.49	3.26e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs11997175	1.000	rs10453046	chr8:33773179	T/C	ch.8.33884649F	chr8:33765107	NA	0.65	5.07	0.46	1.94e-6	Body mass index;
THYM	cis	rs7246657	0.943	rs10405325	chr19:37883477	G/C	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg04043695	chr12:129287642	SLC15A4	0.62	4.98	0.46	2.81e-6	Systemic lupus erythematosus;
THYM	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17122693	1.000	rs2934682	chr14:51061207	A/T	cg04730355	chr14:51134070	SAV1	0.95	5.27	0.48	8.65e-7	Cognitive performance;
THYM	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.43	-0.49	4.24e-7	Mean corpuscular volume;
THYM	cis	rs10208649	0.908	rs3930909	chr2:54204922	C/T	cg04546899	chr2:54196757	PSME4	0.6	4.62	0.43	1.22e-5	Body mass index;
THYM	cis	rs13185784	0.703	rs55756747	chr5:179675052	C/A	cg23248424	chr5:179741104	GFPT2	0.72	4.76	0.44	6.87e-6	TRAIL levels;
THYM	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg24250549	chr1:154909240	PMVK	0.79	6.73	0.57	1.27e-9	Prostate cancer;
THYM	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg02725872	chr8:58115012	NA	-0.98	-7.38	-0.6	5.95e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs13256369	1.000	rs13256369	chr8:8577379	T/C	cg17143192	chr8:8559678	CLDN23	0.93	7.02	0.58	3.22e-10	Obesity-related traits;
THYM	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg08975724	chr8:8085496	FLJ10661	0.66	5.45	0.49	3.96e-7	Mood instability;
THYM	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.73	0.57	1.29e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	trans	rs8073060	0.586	rs225305	chr17:33921160	C/T	cg19694781	chr19:47549865	TMEM160	-0.98	-8.54	-0.66	2.12e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs11771526	0.901	rs10282699	chr7:32297967	C/T	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.73	5.22	0.47	1.05e-6	Height;
THYM	cis	rs7772486	0.875	rs1125461	chr6:146417653	C/T	cg23711669	chr6:146136114	FBXO30	0.97	10.56	0.73	1.05e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs554111	0.656	rs6685914	chr1:21362378	G/A	cg01072550	chr1:21505969	NA	0.59	5.14	0.47	1.45e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs73198271	0.740	rs10100066	chr8:8650393	T/G	cg06636001	chr8:8085503	FLJ10661	-0.7	-4.77	-0.44	6.56e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg22920501	chr2:26401640	FAM59B	-0.77	-6.7	-0.57	1.45e-9	Gut microbiome composition (summer);
THYM	cis	rs10751667	0.857	rs7481221	chr11:966813	G/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg24803719	chr17:45855879	NA	-0.59	-6.1	-0.53	2.23e-8	IgG glycosylation;
THYM	cis	rs57590327	0.503	rs13073613	chr3:81888512	C/A	cg07356753	chr3:81810745	GBE1	-0.78	-5.68	-0.5	1.45e-7	Extraversion;
THYM	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg23649088	chr2:200775458	C2orf69	-0.75	-5.73	-0.51	1.19e-7	Schizophrenia;
THYM	cis	rs10743315	0.557	rs77299796	chr12:19365100	T/C	cg02471346	chr12:19282374	PLEKHA5	1.09	4.55	0.42	1.58e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs4950928	0.823	rs2486065	chr1:203167871	A/G	cg14085262	chr1:203155938	CHI3L1	-0.74	-4.92	-0.45	3.66e-6	YKL-40 levels;
THYM	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	4.96	0.45	3.07e-6	Hip circumference adjusted for BMI;
THYM	cis	rs58873874	1.000	rs58873874	chr5:156945148	T/C	cg08916508	chr5:156566250	MED7	-1.35	-5.33	-0.48	6.66e-7	Bipolar disorder (body mass index interaction);
THYM	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg02725872	chr8:58115012	NA	-0.98	-7.38	-0.6	5.95e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.69	-4.54	-0.42	1.63e-5	Menarche (age at onset);
THYM	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg05962950	chr11:130786565	SNX19	0.91	7.76	0.62	9.5e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7084402	1.000	rs34774248	chr10:60269691	A/G	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg26597838	chr10:835615	NA	1.42	9.79	0.71	4.66e-16	Eosinophil percentage of granulocytes;
THYM	cis	rs728616	0.867	rs56008106	chr10:81953776	T/C	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4481887	0.708	rs28729425	chr1:248563027	T/C	cg00666640	chr1:248458726	OR2T12	0.54	4.62	0.43	1.22e-5	Common traits (Other);
THYM	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg17063962	chr7:91808500	NA	1.16	12.78	0.8	2.34e-22	Breast cancer;
THYM	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.68	-4.63	-0.43	1.18e-5	Body mass index;
THYM	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs74997117	1.000	rs2581849	chr7:154841572	C/T	cg07365299	chr7:154685823	DPP6	-0.92	-4.55	-0.42	1.61e-5	Sulfasalazine-induced agranulocytosis;
THYM	cis	rs11771526	0.901	rs62457473	chr7:32306990	G/A	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs3087591	0.960	rs9898664	chr17:29567152	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.63	-5.33	-0.48	6.51e-7	Hip circumference;
THYM	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg04750100	chr2:136595281	LCT	-0.58	-6.94	-0.58	4.82e-10	Mosquito bite size;
THYM	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.3	-0.48	7.34e-7	Monocyte percentage of white cells;
THYM	cis	rs3017493	0.786	rs112552548	chr11:70675096	G/A	cg21202716	chr11:70508022	SHANK2	1.02	5.29	0.48	7.89e-7	Renal transplant outcome;
THYM	cis	rs7426056	0.530	rs34813348	chr2:204573302	A/G	cg07930752	chr2:204569955	CD28	-0.7	-4.99	-0.46	2.72e-6	Primary sclerosing cholangitis;
THYM	cis	rs8180040	0.903	rs2276854	chr3:47276968	C/T	cg02527881	chr3:46936655	PTH1R	-0.63	-6.19	-0.54	1.52e-8	Colorectal cancer;
THYM	cis	rs2075230	0.705	rs1641536	chr17:7545984	T/C	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.74	-0.44	7.55e-6	Hormone measurements;
THYM	trans	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs1160297	0.544	rs10173886	chr2:53094788	T/C	cg07782112	chr2:53107842	NA	0.77	6.13	0.53	1.98e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs4589258	0.933	rs1783788	chr11:90434191	A/G	cg26138821	chr11:89956704	CHORDC1	-0.7	-5.86	-0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs10501293	0.746	rs7952412	chr11:43017772	C/T	cg03447554	chr11:43094025	NA	0.6	4.46	0.42	2.21e-5	Cognitive performance;
THYM	cis	rs3126085	0.935	rs114825811	chr1:152231877	G/A	cg10321714	chr1:152280068	FLG	-0.76	-5.68	-0.5	1.47e-7	Atopic dermatitis;
THYM	cis	rs6840360	0.642	rs1899550	chr4:152407236	T/C	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9309473	0.519	rs4852951	chr2:73869796	C/G	cg19565262	chr2:73869966	NAT8	0.53	4.51	0.42	1.88e-5	Metabolite levels;
THYM	cis	rs8180040	0.767	rs11920853	chr3:47308183	G/A	cg02527881	chr3:46936655	PTH1R	0.59	5.48	0.49	3.44e-7	Colorectal cancer;
THYM	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg20283391	chr11:68216788	NA	-0.63	-5.08	-0.46	1.85e-6	Total body bone mineral density;
THYM	cis	rs10463554	0.889	rs246911	chr5:102563203	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.16	-0.47	1.33e-6	Parkinson's disease;
THYM	cis	rs977987	0.815	rs11149821	chr16:75422817	C/T	cg03315344	chr16:75512273	CHST6	0.73	6.17	0.53	1.66e-8	Dupuytren's disease;
THYM	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1061377	1.000	rs17508864	chr4:39130645	A/G	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg21775007	chr8:11205619	TDH	0.67	5.06	0.46	2.08e-6	Retinal vascular caliber;
THYM	cis	rs539096	0.540	rs37452	chr1:44297573	A/C	cg12599982	chr1:44399894	ARTN	0.58	5.04	0.46	2.18e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg17105886	chr17:28927953	LRRC37B2	1.13	6.42	0.55	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg13852791	chr20:30311386	BCL2L1	-0.67	-4.8	-0.44	5.83e-6	Mean corpuscular hemoglobin;
THYM	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg03806693	chr22:41940476	POLR3H	-1.11	-8.99	-0.68	2.33e-14	Vitiligo;
THYM	cis	rs72828912	0.519	rs9358744	chr6:24053169	A/G	cg26336265	chr6:25042955	NA	-0.75	-5.17	-0.47	1.27e-6	Squamous cell lung carcinoma;
THYM	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg13939156	chr17:80058883	NA	0.4	5.3	0.48	7.64e-7	Life satisfaction;
THYM	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs55871839	0.533	rs1375193	chr8:59846943	T/C	cg07426533	chr8:59803705	TOX	0.65	5.25	0.47	9.41e-7	Pneumonia;
THYM	cis	rs270601	0.690	rs162907	chr5:131580152	A/G	cg12564285	chr5:131593104	PDLIM4	-0.54	-5.76	-0.51	1.03e-7	Acylcarnitine levels;
THYM	cis	rs7412746	0.552	rs4970980	chr1:150864992	A/C	cg10589385	chr1:150898437	SETDB1	0.57	4.55	0.42	1.56e-5	Melanoma;
THYM	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg25767906	chr1:53392781	SCP2	0.51	5.04	0.46	2.22e-6	Monocyte count;
THYM	cis	rs4455778	0.580	rs4276634	chr7:49118612	A/G	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg06532163	chr17:45867833	NA	0.65	6.55	0.56	2.91e-9	IgG glycosylation;
THYM	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg03732007	chr1:2071316	PRKCZ	0.5	4.6	0.43	1.29e-5	Height;
THYM	cis	rs892961	0.932	rs11655686	chr17:75419535	G/A	cg11351908	chr17:75402473	SEPT9	0.59	5.73	0.51	1.19e-7	Airflow obstruction;
THYM	cis	rs1843834	0.858	rs4674933	chr2:225514923	C/T	cg22455342	chr2:225449267	CUL3	0.68	4.93	0.45	3.45e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs28595532	0.920	rs116607127	chr4:119731072	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.92	-8.15	-0.64	1.45e-12	Cognitive ability;
THYM	cis	rs6032067	0.714	rs6032057	chr20:43839761	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.61	-5.89	-0.52	5.91e-8	Blood protein levels;
THYM	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.42	-5.09	-0.46	1.78e-6	Longevity;Endometriosis;
THYM	cis	rs2067615	0.560	rs2044304	chr12:107184363	T/G	cg15890332	chr12:107067104	RFX4	0.48	5.63	0.5	1.81e-7	Heart rate;
THYM	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Blood protein levels;
THYM	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg18512352	chr11:47633146	NA	-0.49	-5.88	-0.52	6.07e-8	Subjective well-being;
THYM	cis	rs2562456	0.792	rs2562398	chr19:21722949	A/G	cg21751540	chr19:21541537	ZNF738	0.68	4.69	0.43	8.99e-6	Pain;
THYM	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg12310025	chr6:25882481	NA	0.95	8.61	0.66	1.5e-13	Blood metabolite levels;
THYM	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs61990749	0.597	rs4632066	chr14:78247282	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-1.16	-7.96	-0.63	3.68e-12	Fibroblast growth factor basic levels;
THYM	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs8016982	0.633	rs72695758	chr14:81720146	T/C	cg21807262	chr14:81713016	NA	-0.58	-5.69	-0.5	1.42e-7	Schizophrenia;
THYM	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg25358565	chr5:93447407	FAM172A	1.37	10.94	0.75	1.67e-18	Diabetic retinopathy;
THYM	cis	rs2997447	0.761	rs72886625	chr1:26455319	A/G	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg26963428	chr7:66367121	NA	-0.59	-4.65	-0.43	1.05e-5	Corneal structure;
THYM	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg13695892	chr22:41940480	POLR3H	0.81	7.01	0.58	3.51e-10	Vitiligo;
THYM	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg05283184	chr6:79620031	NA	-0.88	-8.44	-0.65	3.53e-13	Intelligence (multi-trait analysis);
THYM	cis	rs986417	0.551	rs1956553	chr14:60952298	T/A	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs6480314	0.831	rs11813170	chr10:69975123	G/C	cg27159792	chr10:69524182	NA	0.74	4.75	0.44	7.33e-6	Optic nerve measurement (disc area);
THYM	cis	rs4919044	0.808	rs835271	chr10:94791678	C/T	cg05127821	chr10:94822908	CYP26C1	-1.23	-6.66	-0.56	1.76e-9	Coronary artery disease;
THYM	cis	rs3126085	0.560	rs12027445	chr1:152344787	A/T	cg10321714	chr1:152280068	FLG	-0.7	-5.19	-0.47	1.19e-6	Atopic dermatitis;
THYM	cis	rs10463554	1.000	rs12659870	chr5:102336571	T/C	cg23492399	chr5:102201601	PAM	-0.64	-4.98	-0.46	2.83e-6	Parkinson's disease;
THYM	cis	rs6964587	0.626	rs10234074	chr7:91520119	C/T	cg17063962	chr7:91808500	NA	-1.01	-9.06	-0.68	1.73e-14	Breast cancer;
THYM	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.57	-4.88	-0.45	4.34e-6	Prudent dietary pattern;
THYM	cis	rs7927771	0.507	rs3740699	chr11:47504075	G/T	cg18512352	chr11:47633146	NA	0.43	4.69	0.43	9.13e-6	Subjective well-being;
THYM	cis	rs362272	0.524	rs2749781	chr4:3346617	T/C	cg14583973	chr4:3374767	RGS12	0.66	6.45	0.55	4.56e-9	Serum sulfate level;
THYM	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg02725872	chr8:58115012	NA	-0.91	-5.43	-0.49	4.32e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg15445000	chr17:37608096	MED1	0.44	5.07	0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg08859206	chr1:53392774	SCP2	-0.66	-7.55	-0.61	2.7e-11	Monocyte count;
THYM	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.15	-0.59	1.77e-10	Triglycerides;
THYM	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg11327659	chr7:150037044	RARRES2	0.43	5.27	0.48	8.39e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs500891	0.525	rs1144181	chr6:84023171	G/A	cg08257003	chr6:84140564	ME1	0.57	4.6	0.43	1.3e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg10803722	chr21:46713166	LOC642852	0.38	4.87	0.45	4.45e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs863345	0.604	rs12041348	chr1:158482042	A/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs10870270	0.957	rs10870307	chr10:133780610	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.93	-6.02	-0.53	3.22e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7404928	1.000	rs2023669	chr16:23905013	A/G	cg26685404	chr16:23957272	PRKCB	0.48	4.83	0.44	5.27e-6	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.43	-6.6	-0.56	2.34e-9	Obesity-related traits;
THYM	cis	rs7107770	1.000	rs4936998	chr11:125096254	C/T	cg04164023	chr11:125106101	PKNOX2	-0.79	-4.72	-0.44	8.1e-6	Photic sneeze reflex;
THYM	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs17006441	1.000	rs11716109	chr3:69832234	A/C	cg18496212	chr3:69797108	MITF	0.69	6.86	0.58	6.97e-10	Hemoglobin concentration;
THYM	cis	rs10457678	0.549	rs7772915	chr6:139105637	A/G	cg05131254	chr6:138188363	TNFAIP3	0.63	4.45	0.42	2.33e-5	Colorectal or endometrial cancer;
THYM	cis	rs7772486	0.754	rs9497401	chr6:146051271	T/C	cg23711669	chr6:146136114	FBXO30	-0.98	-10.65	-0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6815814	0.898	rs2174284	chr4:38859339	C/T	cg02016764	chr4:38805732	TLR1	-0.54	-4.81	-0.44	5.64e-6	Breast cancer;
THYM	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg22875332	chr1:76189707	ACADM	0.74	5.86	0.52	6.56e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.45	-0.49	4.05e-7	Mean corpuscular volume;
THYM	cis	rs7200543	1.000	rs4985154	chr16:15131642	G/C	cg01933576	chr16:15083564	PDXDC1	-0.99	-8.04	-0.64	2.48e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs35362007	0.530	rs11621250	chr14:96011442	C/T	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.93	4.54	0.42	1.63e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11644478	chr21:40555479	PSMG1	-0.77	-6.66	-0.56	1.73e-9	Cognitive function;
THYM	cis	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg13078421	chr19:2624622	GNG7	0.56	4.55	0.42	1.57e-5	Total cholesterol levels;
THYM	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg15691649	chr6:25882328	NA	-0.68	-5.21	-0.47	1.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4845875	0.600	rs4846041	chr1:11837051	C/T	cg06193043	chr1:11908199	NPPA	0.58	4.95	0.45	3.18e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs6957923	0.655	rs10232644	chr7:23591920	A/G	cg20265043	chr7:23510089	IGF2BP3	0.5	5.32	0.48	6.81e-7	Height;
THYM	cis	rs4148689	0.951	rs4148706	chr7:117190996	T/G	cg17204129	chr7:117119601	CFTR	-0.59	-4.6	-0.43	1.32e-5	Gout;
THYM	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg11752832	chr7:134001865	SLC35B4	0.74	5.65	0.5	1.69e-7	Mean platelet volume;
THYM	cis	rs28595532	1.000	rs17323012	chr4:119605671	A/G	cg21605333	chr4:119757512	SEC24D	1.44	4.87	0.45	4.49e-6	Cannabis dependence symptom count;
THYM	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg19507638	chr5:93509721	C5orf36	-0.66	-4.6	-0.43	1.3e-5	Diabetic retinopathy;
THYM	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg00376283	chr12:123451042	ABCB9	0.68	5.2	0.47	1.12e-6	Height;Educational attainment;Head circumference (infant);
THYM	cis	rs10489202	0.632	rs202268	chr1:167927339	T/C	cg24449463	chr1:168025552	DCAF6	-0.88	-9.13	-0.68	1.19e-14	Schizophrenia;
THYM	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs9796	0.866	rs692155	chr15:41407061	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.58	-4.74	-0.44	7.37e-6	Menopause (age at onset);
THYM	cis	rs6694672	1.000	rs1759008	chr1:197026895	G/T	cg13682187	chr1:196946512	CFHR5	-0.76	-4.66	-0.43	1.05e-5	Asthma;
THYM	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg04455712	chr21:45112962	RRP1B	0.49	4.48	0.42	2.07e-5	Mean corpuscular volume;
THYM	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg22920501	chr2:26401640	FAM59B	1.03	7.88	0.63	5.43e-12	Gut microbiome composition (summer);
THYM	cis	rs11690935	1.000	rs12053003	chr2:172537350	A/C	cg13550731	chr2:172543902	DYNC1I2	0.86	6.3	0.54	9.09e-9	Schizophrenia;
THYM	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.54	-6.0	-0.52	3.58e-8	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6558530	0.730	rs10100341	chr8:1723749	A/G	cg09410841	chr8:1729607	CLN8	0.79	6.15	0.53	1.84e-8	Systolic blood pressure;
THYM	cis	rs6570726	0.537	rs1280279	chr6:145884048	G/T	cg23711669	chr6:146136114	FBXO30	0.84	7.04	0.59	2.98e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg06784218	chr1:46089804	CCDC17	-0.31	-4.57	-0.42	1.46e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.72	-0.67	9.16e-14	Mean corpuscular volume;
THYM	cis	rs7584330	0.554	rs76605518	chr2:238425992	G/A	cg08992911	chr2:238395768	MLPH	0.85	5.39	0.48	5.19e-7	Prostate cancer;
THYM	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg07507251	chr3:52567010	NT5DC2	0.4	4.61	0.43	1.27e-5	Electroencephalogram traits;
THYM	cis	rs2404602	0.684	rs1011083	chr15:77007527	C/T	cg23625390	chr15:77176239	SCAPER	-0.82	-5.85	-0.51	6.95e-8	Blood metabolite levels;
THYM	cis	rs714027	0.626	rs7287570	chr22:30507358	G/C	cg27665648	chr22:30112403	NA	-0.52	-4.73	-0.44	7.79e-6	Lymphocyte counts;
THYM	cis	rs981844	0.712	rs4616729	chr4:154746900	T/G	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs4919044	0.799	rs56024810	chr10:94753313	G/A	cg05127821	chr10:94822908	CYP26C1	-1.12	-6.54	-0.56	3.11e-9	Coronary artery disease;
THYM	cis	rs3087591	0.922	rs11867284	chr17:29597464	G/A	cg24425628	chr17:29625626	OMG;NF1	0.63	5.4	0.48	4.98e-7	Hip circumference;
THYM	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg07424592	chr7:64974309	NA	1.0	5.12	0.47	1.58e-6	Diabetic kidney disease;
THYM	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg26384229	chr12:38710491	ALG10B	-0.92	-7.03	-0.58	3.08e-10	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg02869364	chr7:1081709	C7orf50	-0.61	-4.91	-0.45	3.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9372253	0.678	rs9372251	chr6:110700656	A/G	cg01119278	chr6:110721349	DDO	-0.55	-6.31	-0.54	8.81e-9	Platelet distribution width;
THYM	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg18538332	chr22:24372958	LOC391322	-0.97	-11.32	-0.76	2.61e-19	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs34638657	0.833	rs4889479	chr16:82201474	T/C	cg07307142	chr16:82071433	HSD17B2	-0.93	-8.28	-0.65	7.8e-13	Lung adenocarcinoma;
THYM	cis	rs8077889	0.672	rs3785810	chr17:41850689	C/G	cg26893861	chr17:41843967	DUSP3	1.14	14.7	0.83	3.37e-26	Triglycerides;
THYM	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg15744005	chr10:104629667	AS3MT	-0.8	-7.58	-0.61	2.34e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg22841779	chr14:105766346	BRF1	-0.47	-5.88	-0.52	5.97e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.69	6.58	0.56	2.51e-9	Lymphocyte counts;
THYM	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.42	4.6	0.43	1.3e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs13256369	1.000	rs7004438	chr8:8574379	C/T	cg00074818	chr8:8560427	CLDN23	0.53	4.76	0.44	6.82e-6	Obesity-related traits;
THYM	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg16624210	chr5:671434	TPPP	-0.64	-6.72	-0.57	1.32e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs13256369	1.000	rs4841017	chr8:8577093	A/G	cg17143192	chr8:8559678	CLDN23	0.87	6.53	0.56	3.24e-9	Obesity-related traits;
THYM	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg24818145	chr4:99064322	C4orf37	0.7	5.43	0.49	4.24e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg10518543	chr12:38710700	ALG10B	-0.54	-4.54	-0.42	1.65e-5	Morning vs. evening chronotype;
THYM	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg12560992	chr17:57184187	TRIM37	0.92	8.46	0.66	3.23e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg04546413	chr19:29218101	NA	1.06	8.75	0.67	7.75e-14	Methadone dose in opioid dependence;
THYM	cis	rs6087990	0.584	rs6058897	chr20:31398105	G/T	cg13636640	chr20:31349939	DNMT3B	-0.7	-8.17	-0.64	1.32e-12	Ulcerative colitis;
THYM	cis	rs886144	0.730	rs9646229	chr15:91728343	T/G	cg10978402	chr15:90931990	IQGAP1	-0.59	-4.57	-0.42	1.46e-5	Metabolite levels;
THYM	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg05973401	chr12:123451056	ABCB9	0.67	4.49	0.42	2.02e-5	Neutrophil percentage of white cells;
THYM	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg20587970	chr11:113659929	NA	-1.37	-8.96	-0.68	2.79e-14	Hip circumference adjusted for BMI;
THYM	cis	rs2688608	1.000	rs2688608	chr10:75658349	G/T	cg19442545	chr10:75533431	FUT11	-0.42	-4.63	-0.43	1.16e-5	Inflammatory bowel disease;
THYM	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg22868518	chr11:507468	RNH1	-1.1	-4.55	-0.42	1.62e-5	Body mass index;
THYM	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg23281280	chr6:28129359	ZNF389	0.61	4.94	0.45	3.3e-6	Parkinson's disease;
THYM	cis	rs10779751	0.734	rs2261217	chr1:11127764	C/A	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs2742540	0.505	rs2742493	chr11:8967592	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.56	5.19	0.47	1.21e-6	Hematocrit;
THYM	cis	rs870825	0.616	rs67641203	chr4:185623845	A/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs10216189	0.967	rs4724700	chr7:5526789	A/G	cg08928675	chr7:5528044	FBXL18	0.5	5.0	0.46	2.59e-6	Relative hand skill in reading disability;
THYM	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg24812749	chr6:127587940	RNF146	0.81	6.18	0.54	1.56e-8	Breast cancer;
THYM	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4523957	0.890	rs216191	chr17:2188639	C/T	cg16513277	chr17:2031491	SMG6	0.79	7.43	0.61	4.62e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4688759	0.609	rs113176147	chr3:49534439	G/T	cg00383909	chr3:49044727	WDR6	1.12	5.67	0.5	1.56e-7	Blood protein levels;
THYM	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg13683864	chr3:40499215	RPL14	-1.05	-11.57	-0.76	7.71e-20	Renal cell carcinoma;
THYM	cis	rs2227564	0.574	rs3849969	chr10:75525999	C/T	cg23231163	chr10:75533350	FUT11	0.37	4.66	0.43	1.03e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs9660180	0.967	rs11260623	chr1:1781456	G/T	cg02915803	chr1:1606292	LOC728661;CDK11B	0.62	5.25	0.47	9.11e-7	Body mass index;
THYM	cis	rs2439831	1.000	rs2584726	chr15:43715382	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs6429082	0.683	rs2131920	chr1:235579912	T/A	cg26050004	chr1:235667680	B3GALNT2	-0.63	-5.31	-0.48	7.25e-7	Adiposity;
THYM	cis	rs7512552	0.809	rs698923	chr1:150379159	G/A	cg15654264	chr1:150340011	RPRD2	0.45	5.2	0.47	1.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03647317	chr4:187891568	NA	-0.84	-9.05	-0.68	1.74e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	5.92	0.52	5.15e-8	Total body bone mineral density;
THYM	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg04731861	chr2:219085781	ARPC2	-0.52	-4.74	-0.44	7.37e-6	Colorectal cancer;
THYM	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg27034606	chr17:28928453	LRRC37B2	0.79	4.89	0.45	4.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7843479	0.965	rs1484162	chr8:21831385	A/G	cg17168535	chr8:21777572	XPO7	0.7	5.28	0.48	8.17e-7	Mean corpuscular volume;
THYM	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg26750617	chr12:132293702	NA	-0.56	-4.69	-0.43	9.25e-6	Migraine;
THYM	trans	rs4866334	0.850	rs75263301	chr5:18463357	T/G	cg08675002	chr5:90437527	GPR98	-1.55	-7.13	-0.59	1.91e-10	IgG glycosylation;
THYM	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg00990874	chr7:1149470	C7orf50	-0.61	-4.74	-0.44	7.41e-6	Bronchopulmonary dysplasia;
THYM	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg18252515	chr7:66147081	NA	0.63	4.65	0.43	1.09e-5	Aortic root size;
THYM	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg24257776	chr3:47051546	LOC100129354	0.41	4.73	0.44	7.73e-6	Colorectal cancer;
THYM	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	13.76	0.82	2.43e-24	Chronic sinus infection;
THYM	cis	rs6032067	0.683	rs13042431	chr20:43781253	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.67	-7.93	-0.63	4.13e-12	Blood protein levels;
THYM	cis	rs7106204	0.534	rs76997388	chr11:24272878	C/G	ch.11.24196551F	chr11:24239977	NA	0.92	4.75	0.44	7.06e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg12408189	chr10:30722286	MAP3K8	-0.52	-4.49	-0.42	2.01e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs4568518	0.535	rs7800421	chr7:18062755	T/G	cg00911873	chr7:18067463	PRPS1L1	-0.57	-4.62	-0.43	1.23e-5	Measles;
THYM	cis	rs501916	0.796	rs628501	chr15:48027328	C/G	cg20869673	chr15:48010124	SEMA6D	0.72	5.54	0.49	2.66e-7	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs7651039	0.846	rs2174267	chr3:15645835	T/C	cg16303742	chr3:15540471	COLQ	0.58	5.46	0.49	3.77e-7	Coronary heart disease;
THYM	cis	rs754466	0.580	rs1866437	chr10:79526766	A/G	cg17075019	chr10:79541650	NA	-0.67	-5.56	-0.5	2.42e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg03859395	chr2:55845619	SMEK2	0.61	5.46	0.49	3.86e-7	Metabolic syndrome;
THYM	cis	rs41005	1.000	rs41004	chr2:8111580	C/T	cg03155496	chr2:8117019	LOC339788	0.95	9.15	0.68	1.08e-14	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg20295408	chr7:1910781	MAD1L1	-0.68	-5.59	-0.5	2.17e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg00071950	chr4:10020882	SLC2A9	0.86	10.33	0.73	3.3e-17	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg14196790	chr5:131705035	SLC22A5	0.54	5.11	0.46	1.66e-6	Blood metabolite levels;
THYM	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg07414643	chr4:187882934	NA	0.58	5.13	0.47	1.54e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11247915	0.622	rs36024412	chr1:26670444	G/T	cg00852783	chr1:26633632	UBXN11	0.76	6.08	0.53	2.47e-8	Obesity-related traits;
THYM	cis	rs36051895	0.623	rs2381215	chr9:5262607	C/T	cg02405213	chr9:5042618	JAK2	-0.94	-9.01	-0.68	2.18e-14	Pediatric autoimmune diseases;
THYM	cis	rs7078219	0.505	rs7916751	chr10:101285650	T/A	cg04972745	chr10:101287846	NA	-0.5	-4.66	-0.43	1.03e-5	Dental caries;
THYM	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg12893697	chr11:970389	AP2A2	-0.31	-5.16	-0.47	1.34e-6	Alzheimer's disease (late onset);
THYM	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	9.42	0.69	2.88e-15	Chronic sinus infection;
THYM	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs4780401	0.609	rs9923954	chr16:11816855	G/T	cg01061890	chr16:11836724	TXNDC11	-0.66	-5.44	-0.49	4.22e-7	Rheumatoid arthritis;
THYM	cis	rs67478160	0.595	rs12433109	chr14:104196607	G/A	cg08213375	chr14:104286397	PPP1R13B	0.43	5.17	0.47	1.31e-6	Schizophrenia;
THYM	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg13289132	chr10:30722225	MAP3K8	-0.54	-4.55	-0.42	1.6e-5	Inflammatory bowel disease;
THYM	cis	rs9457247	0.508	rs9457268	chr6:167503639	A/T	cg00271210	chr6:167070053	RPS6KA2	-0.48	-4.61	-0.43	1.24e-5	Crohn's disease;
THYM	cis	rs2816062	0.786	rs2745317	chr1:18896552	G/A	cg18795169	chr1:18902165	NA	-0.99	-12.14	-0.78	5.02e-21	Urate levels in lean individuals;
THYM	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07343612	chr16:622815	PIGQ	-1.04	-9.97	-0.71	1.96e-16	Height;
THYM	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg17105886	chr17:28927953	LRRC37B2	1.21	6.66	0.56	1.73e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg19774624	chr17:42201019	HDAC5	0.77	7.16	0.59	1.73e-10	Total body bone mineral density;
THYM	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg08704250	chr15:31115839	NA	0.47	5.54	0.49	2.68e-7	Huntington's disease progression;
THYM	cis	rs11886999	0.812	rs4371393	chr2:96903360	A/G	cg18419276	chr2:96971862	SNRNP200	-0.51	-4.88	-0.45	4.21e-6	Cardiac Troponin-T levels;
THYM	cis	rs113835537	0.529	rs11824771	chr11:66262550	T/C	cg24851651	chr11:66362959	CCS	0.7	4.92	0.45	3.61e-6	Airway imaging phenotypes;
THYM	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg13683864	chr3:40499215	RPL14	-0.83	-7.81	-0.63	7.51e-12	Renal cell carcinoma;
THYM	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	trans	rs9951602	0.512	rs4799244	chr18:76649763	T/C	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs61931739	0.635	rs3937819	chr12:33942715	A/G	cg06521331	chr12:34319734	NA	-0.57	-4.76	-0.44	7e-6	Morning vs. evening chronotype;
THYM	cis	rs2066819	1.000	rs75265219	chr12:56640341	G/A	cg26714650	chr12:56694279	CS	-1.27	-6.32	-0.54	8.6e-9	Psoriasis vulgaris;
THYM	cis	rs11671005	0.504	rs7257669	chr19:59064939	T/C	cg04170623	chr19:59071414	UBE2M;LOC100131691	-0.57	-4.83	-0.44	5.24e-6	Mean platelet volume;
THYM	cis	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg21602179	chr17:71189219	COG1	-1.02	-4.8	-0.44	5.84e-6	Pulmonary function decline;
THYM	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg18252515	chr7:66147081	NA	0.7	5.46	0.49	3.77e-7	Aortic root size;
THYM	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg17178900	chr1:205818956	PM20D1	0.89	8.54	0.66	2.18e-13	Menarche (age at onset);
THYM	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs9902453	0.845	rs7209622	chr17:28256807	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.87	6.64	0.56	1.98e-9	Coffee consumption (cups per day);
THYM	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg05717871	chr11:638507	DRD4	-0.66	-4.83	-0.44	5.17e-6	Systemic lupus erythematosus;
THYM	cis	rs7107174	1.000	rs1006441	chr11:77932126	G/C	cg02023728	chr11:77925099	USP35	0.68	6.18	0.54	1.61e-8	Testicular germ cell tumor;
THYM	cis	rs8005962	0.717	rs911687	chr14:96048480	A/G	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.63	4.65	0.43	1.09e-5	Tuberculosis;
THYM	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.58	-5.63	-0.5	1.84e-7	Caffeine consumption;
THYM	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg04043695	chr12:129287642	SLC15A4	0.6	4.66	0.43	1.03e-5	Systemic lupus erythematosus;
THYM	cis	rs7631605	0.967	rs9859086	chr3:37146191	A/C	cg21328643	chr3:37258149	NA	-0.47	-4.47	-0.42	2.17e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs889398	0.741	rs7190013	chr16:69908248	G/A	cg09409435	chr16:70099608	PDXDC2	0.67	5.39	0.48	5.13e-7	Body mass index;
THYM	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg26031613	chr14:104095156	KLC1	0.78	5.2	0.47	1.14e-6	Body mass index;
THYM	cis	rs7255436	0.965	rs12981318	chr19:8451430	G/A	cg10174797	chr19:8464628	RAB11B	0.43	5.19	0.47	1.21e-6	HDL cholesterol;
THYM	cis	rs2562456	0.833	rs2681388	chr19:21732253	G/C	cg21751540	chr19:21541537	ZNF738	-0.69	-4.75	-0.44	7.1e-6	Pain;
THYM	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg05234568	chr11:5960015	NA	-0.6	-4.84	-0.44	4.97e-6	DNA methylation (variation);
THYM	cis	rs1062746	0.771	rs10514621	chr16:87369578	G/T	cg27365499	chr16:87376795	FBXO31	0.56	6.17	0.54	1.63e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs2811415	0.597	rs9813824	chr3:127761959	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs635808	0.565	rs6912712	chr6:167174124	C/A	cg17732216	chr6:167178280	RPS6KA2	0.59	4.76	0.44	7e-6	Dental caries;
THYM	cis	rs10851411	0.730	rs2595938	chr15:42760159	A/G	cg04857231	chr15:42782520	NA	0.51	4.68	0.43	9.53e-6	Glucose homeostasis traits;
THYM	cis	rs9972944	0.756	rs7223214	chr17:63761473	C/T	cg07283582	chr17:63770753	CCDC46	-0.64	-4.91	-0.45	3.77e-6	Total body bone mineral density;
THYM	cis	rs7584330	0.518	rs74478860	chr2:238437364	C/G	cg14458575	chr2:238380390	NA	1.03	5.54	0.49	2.71e-7	Prostate cancer;
THYM	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2219968	0.651	rs11778947	chr8:78899906	T/C	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs78456975	0.607	rs73909625	chr2:1541934	A/G	cg12573674	chr2:1569213	NA	-1.25	-4.59	-0.43	1.37e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs1642645	0.831	rs2042064	chr1:42491429	C/T	cg06092502	chr1:42611687	NA	0.61	4.74	0.44	7.58e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg24692254	chr21:30365293	RNF160	-0.85	-7.06	-0.59	2.74e-10	Dental caries;
THYM	cis	rs6570726	1.000	rs951143	chr6:145932576	C/T	cg23711669	chr6:146136114	FBXO30	0.77	7.11	0.59	2.18e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8030379	0.967	rs12900412	chr15:84553066	G/A	cg15564896	chr15:84287328	SH3GL3	0.57	4.77	0.44	6.57e-6	Waist circumference adjusted for body mass index;Waist circumference;
THYM	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg06028808	chr11:68637592	NA	0.65	6.7	0.57	1.44e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs72781680	1.000	rs72781632	chr2:24198342	A/C	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.790	rs4435956	chr6:146232403	G/C	cg13319975	chr6:146136371	FBXO30	0.73	6.11	0.53	2.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11190604	0.697	rs10748795	chr10:102194818	A/T	cg16342193	chr10:102329863	NA	0.48	4.88	0.45	4.33e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.22e-16	Bone mineral density;
THYM	cis	rs4499344	0.633	rs259262	chr19:33153951	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.92	7.75	0.62	1.02e-11	Mean platelet volume;
THYM	cis	rs2282300	0.739	rs1222216	chr11:30346052	C/T	cg25418670	chr11:30344373	C11orf46	-0.82	-6.98	-0.58	3.93e-10	Morning vs. evening chronotype;
THYM	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg02038168	chr22:39784481	NA	-0.63	-5.18	-0.47	1.25e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg07936489	chr17:37558343	FBXL20	-0.82	-5.61	-0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.15	9.01	0.68	2.18e-14	Cognitive test performance;
THYM	cis	rs854765	0.693	rs35451946	chr17:17764061	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-6.77	-0.57	1.08e-9	Total body bone mineral density;
THYM	cis	rs6840360	0.571	rs4696275	chr4:152530981	C/T	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9858542	0.597	rs56116382	chr3:49606188	A/C	cg03060546	chr3:49711283	APEH	-0.65	-4.67	-0.43	9.92e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg04317338	chr11:64019027	PLCB3	0.86	5.89	0.52	5.78e-8	Mean platelet volume;
THYM	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg07424592	chr7:64974309	NA	-1.03	-5.36	-0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs55794721	0.509	rs2375313	chr1:25748235	G/A	cg09222892	chr1:25734099	RHCE	0.63	4.92	0.45	3.61e-6	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs3796352	1.000	rs11720191	chr3:53013839	T/C	cg24530246	chr3:53118167	NA	-0.81	-4.62	-0.43	1.23e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg22535103	chr8:58192502	C8orf71	-0.96	-5.47	-0.49	3.7e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs1270639	0.778	rs1796272	chr7:157437832	C/T	cg13357408	chr7:157437802	PTPRN2	-0.48	-5.2	-0.47	1.15e-6	Colorectal cancer;
THYM	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg11366901	chr6:160182831	ACAT2	1.0	8.33	0.65	6.14e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg12310025	chr6:25882481	NA	0.72	5.86	0.52	6.59e-8	Blood metabolite levels;
THYM	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg09877947	chr5:131593287	PDLIM4	0.63	5.59	0.5	2.18e-7	Blood metabolite levels;
THYM	cis	rs1729951	0.546	rs12054219	chr3:136677472	G/A	cg21827317	chr3:136751795	NA	0.74	6.6	0.56	2.29e-9	Neuroticism;
THYM	cis	rs6988636	1.000	rs28537152	chr8:124189071	T/C	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs2803122	0.846	rs7851656	chr9:19213960	C/T	cg19584733	chr9:19298547	DENND4C	-0.55	-4.61	-0.43	1.24e-5	Pulse pressure;
THYM	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg20503657	chr10:835505	NA	1.17	8.2	0.64	1.16e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg24675658	chr1:53192096	ZYG11B	-0.8	-6.16	-0.53	1.74e-8	Monocyte count;
THYM	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg03929089	chr4:120376271	NA	-1.03	-8.74	-0.67	8.32e-14	Coronary artery disease;
THYM	trans	rs8002861	0.905	rs12428350	chr13:44446161	G/A	cg17145862	chr1:211918768	LPGAT1	-0.97	-9.31	-0.69	4.82e-15	Leprosy;
THYM	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.22e-7	Corneal astigmatism;
THYM	cis	rs17407555	0.601	rs73229828	chr4:10026833	A/G	cg13000635	chr4:9523653	NA	0.65	4.45	0.42	2.33e-5	Schizophrenia (age at onset);
THYM	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg00677455	chr12:58241039	CTDSP2	0.73	4.95	0.45	3.22e-6	Multiple sclerosis;
THYM	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg26031613	chr14:104095156	KLC1	0.75	5.11	0.46	1.63e-6	Body mass index;
THYM	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg15448220	chr1:150897856	SETDB1	0.85	7.1	0.59	2.25e-10	Tonsillectomy;
THYM	cis	rs2290159	0.800	rs7636754	chr3:12678725	C/G	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs7772486	0.806	rs4075696	chr6:146250947	T/C	cg23711669	chr6:146136114	FBXO30	-0.87	-8.4	-0.65	4.29e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6450176	1.000	rs3776715	chr5:53299095	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.14	-0.53	1.94e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs9333029	0.908	rs115074133	chr1:47409419	C/T	cg13353942	chr1:47010223	NA	0.62	4.53	0.42	1.69e-5	Blood metabolite levels;
THYM	cis	rs6450176	1.000	rs12654393	chr5:53302620	A/C	ch.5.1024479R	chr5:53302184	ARL15	0.82	6.14	0.53	1.94e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs4565302	0.670	rs72851447	chr6:38336075	C/T	cg06347083	chr6:39282316	KCNK17	-0.44	-4.85	-0.45	4.86e-6	Mammographic density;
THYM	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs4919694	1.000	rs4919694	chr10:104698978	T/C	cg04362960	chr10:104952993	NT5C2	0.95	6.18	0.54	1.62e-8	Arsenic metabolism;
THYM	cis	rs3768617	0.528	rs4651144	chr1:183097421	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.91	0.45	3.8e-6	Fuchs's corneal dystrophy;
THYM	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg22467129	chr15:76604101	ETFA	-0.56	-5.14	-0.47	1.44e-6	Blood metabolite levels;
THYM	cis	rs7084402	0.967	rs2842083	chr10:60329230	A/C	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs12410462	0.502	rs114121935	chr1:227959336	A/G	cg23173402	chr1:227635558	NA	0.66	4.8	0.44	5.99e-6	Major depressive disorder;
THYM	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg02734326	chr4:10020555	SLC2A9	0.78	6.67	0.56	1.68e-9	Bone mineral density;
THYM	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg21926883	chr2:100939477	LONRF2	-0.55	-4.99	-0.46	2.74e-6	Intelligence (multi-trait analysis);
THYM	cis	rs262147	1.000	rs262147	chr7:158745142	A/G	cg11984989	chr7:158649758	WDR60	1.23	5.88	0.52	5.97e-8	Hippocampal volume;
THYM	cis	rs600806	0.850	rs12073497	chr1:109974450	A/C	cg23616212	chr1:109941201	SORT1	-0.48	-4.53	-0.42	1.71e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9302635	0.513	rs8061459	chr16:72156063	C/T	cg23815491	chr16:72088622	HP	0.7	5.32	0.48	6.83e-7	Blood protein levels;
THYM	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg07636037	chr3:49044803	WDR6	-0.9	-8.04	-0.64	2.45e-12	Parkinson's disease;
THYM	cis	rs6032067	0.714	rs3761192	chr20:43885764	C/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.39	-4.59	-0.43	1.33e-5	Blood protein levels;
THYM	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg20891283	chr12:69753455	YEATS4	1.09	12.1	0.78	6.02e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg05738196	chr6:26577821	NA	0.84	8.48	0.66	2.87e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg26038318	chr20:34205095	SPAG4	0.65	5.25	0.47	9.22e-7	Total cholesterol levels;
THYM	cis	rs7727544	0.582	rs7703009	chr5:131552385	C/G	cg16205897	chr5:131564050	P4HA2	-0.45	-4.55	-0.42	1.56e-5	Blood metabolite levels;
THYM	cis	rs4780401	0.609	rs8055247	chr16:11827543	G/A	cg01061890	chr16:11836724	TXNDC11	-0.71	-5.75	-0.51	1.07e-7	Rheumatoid arthritis;
THYM	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg09197432	chr4:183729176	NA	0.83	5.18	0.47	1.22e-6	Pediatric autoimmune diseases;
THYM	cis	rs2982552	0.775	rs2982563	chr6:152052311	T/C	cg18132851	chr6:152085641	ESR1	0.39	4.57	0.42	1.47e-5	Bone properties (heel);
THYM	cis	rs977987	0.843	rs12443834	chr16:75438469	C/T	cg03315344	chr16:75512273	CHST6	0.77	6.31	0.54	8.75e-9	Dupuytren's disease;
THYM	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg21280719	chr6:42927975	GNMT	-0.54	-7.06	-0.59	2.76e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.27	5.46	0.49	3.88e-7	Obesity-related traits;
THYM	cis	rs57545798	0.963	rs34357020	chr15:100644127	G/C	cg20941820	chr15:100882334	ADAMTS17	0.57	4.72	0.44	8.18e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg24642844	chr7:1081250	C7orf50	-0.73	-5.13	-0.47	1.51e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs75518195	0.590	rs17637374	chr4:64734418	C/T	cg14706739	chr8:21916355	EPB49	-0.76	-7.35	-0.6	6.93e-11	Triptolide cytotoxicity;
THYM	cis	rs9419702	0.568	rs11156445	chr10:133542301	T/C	cg23460707	chr10:133558971	NA	0.43	4.54	0.42	1.67e-5	Survival in rectal cancer;
THYM	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg15693483	chr7:1102177	C7orf50	0.54	6.29	0.54	9.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg03806693	chr22:41940476	POLR3H	-0.95	-7.84	-0.63	6.61e-12	Vitiligo;
THYM	cis	rs7688540	0.609	rs78896226	chr4:232533	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.72	4.88	0.45	4.35e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs2235649	0.828	rs9936486	chr16:1849888	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.64	-5.57	-0.5	2.39e-7	Blood metabolite levels;
THYM	cis	rs2404602	0.530	rs12915184	chr15:76965922	G/A	cg23625390	chr15:77176239	SCAPER	-0.79	-4.87	-0.45	4.41e-6	Blood metabolite levels;
THYM	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg16405210	chr4:1374714	KIAA1530	0.86	7.57	0.61	2.42e-11	Obesity-related traits;
THYM	cis	rs1345301	0.587	rs12464251	chr2:102867208	C/G	cg03938978	chr2:103052716	IL18RAP	-0.51	-4.97	-0.45	2.93e-6	Waist circumference;
THYM	cis	rs9457247	0.534	rs4710149	chr6:167386346	T/C	cg00271210	chr6:167070053	RPS6KA2	0.48	4.72	0.44	8e-6	Crohn's disease;
THYM	cis	rs4962416	0.509	rs1970811	chr10:126696496	T/C	cg04494136	chr10:126703576	CTBP2	-0.39	-5.58	-0.5	2.3e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg16586182	chr3:47516702	SCAP	-0.65	-5.49	-0.49	3.29e-7	Colorectal cancer;
THYM	cis	rs6541297	1.000	rs6686680	chr1:230280522	T/C	cg20703242	chr1:230279135	GALNT2	0.92	5.97	0.52	4e-8	Coronary artery disease;
THYM	cis	rs6546537	1.000	rs12478540	chr2:69844524	C/T	cg10773587	chr2:69614142	GFPT1	-0.55	-4.48	-0.42	2.08e-5	Serum thyroid-stimulating hormone levels;
THYM	cis	rs514406	0.858	rs574853	chr1:53310959	A/T	cg24675658	chr1:53192096	ZYG11B	-0.62	-4.97	-0.45	2.93e-6	Monocyte count;
THYM	cis	rs2133450	0.712	rs28368666	chr3:7367258	C/G	cg19930620	chr3:7340148	GRM7	-0.48	-4.49	-0.42	1.98e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10479542	0.784	rs7703730	chr5:178986632	C/A	cg09060608	chr5:178986726	RUFY1	-0.6	-6.85	-0.57	7.45e-10	Lung cancer;
THYM	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg12963246	chr6:28129442	ZNF389	0.57	5.03	0.46	2.32e-6	Cardiac Troponin-T levels;
THYM	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs35264875	1.000	rs35264875	chr11:68846399	A/T	cg01993067	chr11:68851601	TPCN2	1.0	4.68	0.43	9.62e-6	Blond vs. brown hair color;
THYM	cis	rs2319125	0.683	rs12602306	chr17:64045018	C/T	cg04446870	chr17:64440273	PRKCA	-0.5	-4.49	-0.42	2.03e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs73198271	0.740	rs10094270	chr8:8646633	G/A	cg15556689	chr8:8085844	FLJ10661	-0.73	-4.58	-0.43	1.39e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg12573674	chr2:1569213	NA	-1.35	-8.81	-0.67	5.84e-14	IgG glycosylation;
THYM	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg13609457	chr4:120235615	NA	0.6	5.34	0.48	6.23e-7	Corneal astigmatism;
THYM	cis	rs9733	0.596	rs6587516	chr1:150623221	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs981844	1.000	rs2118862	chr4:154657782	A/T	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg21394778	chr1:3037102	PRDM16	0.48	4.68	0.43	9.64e-6	Height;
THYM	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg06636001	chr8:8085503	FLJ10661	0.81	7.71	0.62	1.24e-11	Mood instability;
THYM	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg18681998	chr4:17616180	MED28	0.79	6.69	0.57	1.51e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg08999081	chr20:33150536	PIGU	-0.78	-7.16	-0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs57920188	0.703	rs72852539	chr1:4087765	G/C	cg20703997	chr1:4087676	NA	1.05	7.44	0.61	4.47e-11	Interleukin-17 levels;
THYM	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg18681998	chr4:17616180	MED28	0.9	8.59	0.66	1.67e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7586879	0.796	rs916484	chr2:25082588	A/C	cg01884057	chr2:25150051	NA	0.51	4.66	0.43	1.04e-5	Body mass index;
THYM	cis	rs34779708	0.966	rs4934539	chr10:35472199	A/G	cg03585969	chr10:35415529	CREM	0.63	4.54	0.42	1.62e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs11048434	0.736	rs2377673	chr12:9112551	A/G	cg13575925	chr12:9217583	LOC144571	0.52	4.97	0.45	2.96e-6	Sjögren's syndrome;
THYM	cis	rs7000551	0.725	rs2461489	chr8:22370253	G/A	cg12081754	chr8:22256438	SLC39A14	0.63	5.71	0.51	1.27e-7	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs8112211	1.000	rs73043010	chr19:38823202	T/G	cg25820703	chr19:38877220	GGN	-0.48	-4.53	-0.42	1.71e-5	Blood protein levels;
THYM	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg10760299	chr15:45669010	GATM	-0.87	-6.83	-0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg12311346	chr5:56204834	C5orf35	-0.7	-5.3	-0.48	7.6e-7	Coronary artery disease;
THYM	cis	rs9876781	1.000	rs9838618	chr3:48487353	A/C	cg06066452	chr3:48470258	PLXNB1	0.27	4.88	0.45	4.32e-6	Longevity;
THYM	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg18252515	chr7:66147081	NA	0.64	4.89	0.45	4.09e-6	Aortic root size;
THYM	cis	rs1609391	0.543	rs6761993	chr3:136625902	C/T	cg15507776	chr3:136538369	TMEM22	0.64	4.9	0.45	4.02e-6	Neuroticism;
THYM	cis	rs7586879	0.964	rs4077680	chr2:25122942	A/G	cg15423357	chr2:25149977	NA	0.57	5.6	0.5	2.09e-7	Body mass index;
THYM	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7578361	0.959	rs4547502	chr2:150446083	A/G	cg17961725	chr2:150454027	NA	0.74	6.39	0.55	6.02e-9	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg03433033	chr1:76189801	ACADM	-0.52	-5.42	-0.49	4.44e-7	Daytime sleep phenotypes;
THYM	cis	rs36051895	0.632	rs10116823	chr9:5171944	T/A	cg02405213	chr9:5042618	JAK2	-0.99	-10.88	-0.74	2.2e-18	Pediatric autoimmune diseases;
THYM	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.7	5.69	0.5	1.38e-7	Blood metabolite levels;
THYM	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg09359103	chr1:154839909	KCNN3	-0.69	-8.43	-0.65	3.66e-13	Prostate cancer;
THYM	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg17264618	chr3:40429014	ENTPD3	-0.55	-5.44	-0.49	4.18e-7	Renal cell carcinoma;
THYM	cis	rs713587	0.967	rs6752378	chr2:25150116	C/A	cg01884057	chr2:25150051	NA	0.75	8.47	0.66	3.12e-13	Body mass index in non-asthmatics;
THYM	cis	rs3136739	0.764	rs56068620	chr8:42071173	G/A	cg12091331	chr8:42065314	PLAT	-0.64	-4.85	-0.45	4.89e-6	Plasma plasminogen activator levels;
THYM	cis	rs8050907	0.744	rs13330134	chr16:4526923	T/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.58	0.43	1.38e-5	Obesity-related traits;
THYM	cis	rs1448094	0.511	rs11117042	chr12:86207547	G/T	cg02569458	chr12:86230093	RASSF9	0.57	4.87	0.45	4.36e-6	Major depressive disorder;
THYM	cis	rs7617773	0.780	rs34630841	chr3:48343261	G/A	cg02219026	chr3:48282209	ZNF589	-0.64	-4.58	-0.43	1.39e-5	Coronary artery disease;
THYM	cis	rs11574514	0.661	rs35356834	chr16:67696365	G/A	cg09738193	chr16:67926317	PSKH1	-0.91	-4.66	-0.43	1.01e-5	Crohn's disease;
THYM	cis	rs7582180	0.715	rs764828	chr2:100908634	A/C	cg21926883	chr2:100939477	LONRF2	-0.57	-4.86	-0.45	4.68e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9644630	1.000	rs9644630	chr8:19370598	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.78	8.47	0.66	3.01e-13	Oropharynx cancer;
THYM	cis	rs4953076	0.573	rs9973609	chr2:44450435	T/C	cg04920474	chr2:44395004	PPM1B	0.65	5.46	0.49	3.75e-7	Height;
THYM	cis	rs7719624	1.000	rs2282791	chr5:135377730	T/G	cg15329133	chr5:135467951	SMAD5;SMAD5OS	0.53	4.56	0.42	1.51e-5	Response to cytidine analogues (gemcitabine);
THYM	cis	rs6960043	0.818	rs12699673	chr7:15049604	T/C	cg19272540	chr7:15055459	NA	0.52	5.46	0.49	3.87e-7	Type 2 diabetes;
THYM	cis	rs514406	0.763	rs9988539	chr1:53213884	T/C	cg08859206	chr1:53392774	SCP2	0.6	6.72	0.57	1.34e-9	Monocyte count;
THYM	cis	rs2282300	0.739	rs34855782	chr11:30225470	G/A	cg25418670	chr11:30344373	C11orf46	-0.79	-6.85	-0.58	7.18e-10	Morning vs. evening chronotype;
THYM	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14159672	chr1:205819179	PM20D1	-0.74	-6.95	-0.58	4.64e-10	Monocyte percentage of white cells;
THYM	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg24812749	chr6:127587940	RNF146	0.96	7.77	0.62	9.12e-12	Breast cancer;
THYM	cis	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg07988820	chr12:82153109	PPFIA2	-0.81	-5.15	-0.47	1.38e-6	Resting heart rate;
THYM	cis	rs7567389	0.510	rs6755028	chr2:128195442	G/A	cg06038358	chr2:128176007	PROC	-0.42	-4.84	-0.44	5e-6	Self-rated health;
THYM	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg14972814	chr11:95582409	MTMR2	-0.55	-4.76	-0.44	6.87e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs1267303	0.642	rs11588450	chr1:47000996	C/T	cg25110126	chr1:46999211	NA	-0.69	-5.28	-0.48	8.23e-7	Monobrow;
THYM	cis	rs13177918	0.677	rs3797622	chr5:149827098	G/A	cg14059543	chr5:149831962	NA	-0.99	-7.62	-0.62	1.89e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg22907277	chr7:1156413	C7orf50	0.63	5.61	0.5	2e-7	Longevity;Endometriosis;
THYM	cis	rs425277	1.000	rs12401379	chr1:2058580	G/C	cg09260853	chr1:2094483	PRKCZ	0.51	4.81	0.44	5.76e-6	Height;
THYM	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg24399712	chr22:39784796	NA	-0.82	-8.35	-0.65	5.41e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg13010199	chr12:38710504	ALG10B	0.64	4.77	0.44	6.7e-6	Morning vs. evening chronotype;
THYM	cis	rs7646881	1.000	rs73015652	chr3:158451383	A/G	cg18349298	chr3:158450550	RARRES1	0.52	5.0	0.46	2.57e-6	Tetralogy of Fallot;
THYM	cis	rs10887741	0.646	rs11202499	chr10:89433211	C/G	cg13926569	chr10:89418898	PAPSS2	0.63	7.28	0.6	9.67e-11	Exercise (leisure time);
THYM	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg00533182	chr8:145726136	PPP1R16A	-0.59	-4.73	-0.44	7.72e-6	Age at first birth;
THYM	cis	rs1524976	1.000	rs62255277	chr3:65470507	A/G	cg16238336	chr3:65465873	MAGI1	-1.01	-6.33	-0.54	8.04e-9	PR interval;
THYM	cis	rs9549367	0.711	rs9994	chr13:113884301	T/C	cg18105134	chr13:113819100	PROZ	-1.03	-8.86	-0.67	4.45e-14	Platelet distribution width;
THYM	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg13010199	chr12:38710504	ALG10B	0.64	4.61	0.43	1.25e-5	Morning vs. evening chronotype;
THYM	cis	rs4749080	0.646	rs11014930	chr10:26344948	T/G	cg15678844	chr10:26500780	MYO3A	-0.63	-4.46	-0.42	2.29e-5	Obesity-related traits;
THYM	cis	rs7560272	0.723	rs7609249	chr2:73813820	G/A	cg19565262	chr2:73869966	NAT8	-0.61	-5.0	-0.46	2.65e-6	Schizophrenia;
THYM	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs9992101	0.838	rs17319721	chr4:77368847	A/G	cg20311846	chr4:77356250	SHROOM3	0.59	5.38	0.48	5.32e-7	Creatinine levels;
THYM	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg13683864	chr3:40499215	RPL14	-1.05	-11.46	-0.76	1.29e-19	Renal cell carcinoma;
THYM	cis	rs10739663	0.520	rs1566362	chr9:128163132	C/T	cg14078157	chr9:128172775	NA	0.93	8.06	0.64	2.23e-12	Resting heart rate;
THYM	cis	rs59698941	0.943	rs12520928	chr5:132305891	C/A	cg02081065	chr5:132209139	LEAP2	-0.82	-5.78	-0.51	9.43e-8	Apolipoprotein A-IV levels;
THYM	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7107174	1.000	rs2510036	chr11:77966788	G/T	cg19901956	chr11:77921274	USP35	-0.76	-5.83	-0.51	7.53e-8	Testicular germ cell tumor;
THYM	cis	rs921968	0.565	rs7580147	chr2:219643036	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs79149102	0.579	rs58068887	chr15:75286140	G/A	cg17294928	chr15:75287854	SCAMP5	-1.06	-5.68	-0.5	1.49e-7	Lung cancer;
THYM	cis	rs924712	0.526	rs12664732	chr6:54711714	C/G	cg19716238	chr6:54711378	FAM83B	-0.47	-4.49	-0.42	1.99e-5	Breast cancer;
THYM	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg06636001	chr8:8085503	FLJ10661	0.66	5.77	0.51	1e-7	Mood instability;
THYM	cis	rs1065852	0.526	rs9611700	chr22:42401514	C/T	cg09667013	chr22:42394590	WBP2NL	0.54	4.8	0.44	5.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs4523957	0.786	rs9897624	chr17:2121745	A/G	cg16513277	chr17:2031491	SMG6	-0.8	-7.85	-0.63	6.16e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs12282928	1.000	rs10160559	chr11:48280684	T/C	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg03396347	chr1:1875803	NA	-0.66	-6.68	-0.57	1.64e-9	Body mass index;
THYM	cis	rs17006441	0.866	rs6782552	chr3:69879756	C/A	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs1003719	0.788	rs2835576	chr21:38457393	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.71	5.03	0.46	2.32e-6	Eye color traits;
THYM	cis	rs7833986	0.501	rs2667981	chr8:56894303	T/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	6.4	0.55	5.76e-9	Height;
THYM	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg08859206	chr1:53392774	SCP2	-0.65	-7.45	-0.61	4.17e-11	Monocyte count;
THYM	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs1349547	0.510	rs1376720	chr8:39494502	A/T	cg01911981	chr8:39380341	ADAM3A	0.53	4.8	0.44	5.85e-6	HIV-1 susceptibility;
THYM	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg07690219	chr3:49449608	TCTA;RHOA	0.7	4.71	0.43	8.57e-6	Menarche (age at onset);
THYM	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg22508957	chr16:3507546	NAT15	0.45	4.98	0.46	2.81e-6	Body mass index (adult);
THYM	cis	rs7226229	1.000	rs4613123	chr17:20929295	A/G	cg21263980	chr17:20946333	USP22	0.66	4.86	0.45	4.58e-6	Blood trace element (Se levels);
THYM	cis	rs28476539	0.610	rs7679857	chr4:83569737	A/T	cg10249074	chr4:83542146	C4orf11	0.75	5.63	0.5	1.86e-7	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs6964587	0.626	rs12704631	chr7:91523525	T/C	cg22709100	chr7:91322751	NA	-0.62	-4.67	-0.43	9.72e-6	Breast cancer;
THYM	cis	rs877282	1.000	rs34257857	chr10:772993	C/A	cg10556349	chr10:835070	NA	-0.69	-4.81	-0.44	5.75e-6	Uric acid levels;
THYM	cis	rs58950470	0.521	rs7950197	chr11:65446126	T/C	cg17480646	chr11:65405466	SIPA1	-0.72	-5.89	-0.52	5.95e-8	Schizophrenia;
THYM	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg11189052	chr15:85197271	WDR73	-0.6	-4.49	-0.42	1.98e-5	P wave terminal force;
THYM	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg05985134	chr18:33552581	C18orf21	0.68	4.77	0.44	6.59e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg02953382	chr22:24373134	LOC391322	-0.7	-6.35	-0.55	7.34e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg24399712	chr22:39784796	NA	0.9	9.41	0.69	3.04e-15	Intelligence (multi-trait analysis);
THYM	cis	rs8016982	0.633	rs7160342	chr14:81713427	G/C	cg21807262	chr14:81713016	NA	-0.59	-5.67	-0.5	1.52e-7	Schizophrenia;
THYM	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg14675211	chr2:100938903	LONRF2	0.75	8.18	0.64	1.28e-12	Intelligence (multi-trait analysis);
THYM	trans	rs4866334	1.000	rs76836105	chr5:18467089	T/G	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs10752881	1.000	rs12126434	chr1:182988414	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.59	-4.69	-0.43	9.26e-6	Colorectal cancer;
THYM	cis	rs7553864	0.966	rs4529687	chr1:87614083	T/C	cg17420885	chr1:87600446	LOC339524	-0.77	-6.37	-0.55	6.71e-9	Smoking behavior;
THYM	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg06713675	chr4:122721982	EXOSC9	-0.85	-9.54	-0.7	1.57e-15	Type 2 diabetes;
THYM	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg11764359	chr7:65958608	NA	0.8	6.58	0.56	2.51e-9	Aortic root size;
THYM	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg01874867	chr7:94954059	PON1	-0.82	-6.83	-0.57	7.85e-10	Paraoxonase activity;
THYM	cis	rs6076065	0.630	rs2424559	chr20:23430519	A/G	cg11657817	chr20:23433608	CST11	0.38	5.9	0.52	5.52e-8	Facial morphology (factor 15, philtrum width);
THYM	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg10760299	chr15:45669010	GATM	0.86	6.71	0.57	1.38e-9	Homoarginine levels;
THYM	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03647317	chr4:187891568	NA	-0.84	-9.05	-0.68	1.74e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg00071950	chr4:10020882	SLC2A9	0.87	10.34	0.73	3.16e-17	Bone mineral density;
THYM	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg06656553	chr16:89960601	TCF25	0.81	4.7	0.43	8.84e-6	Skin colour saturation;
THYM	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg00129232	chr17:37814104	STARD3	-0.84	-5.96	-0.52	4.35e-8	Asthma;
THYM	cis	rs5769707	0.616	rs6009786	chr22:50015145	A/G	cg05373962	chr22:49881684	NA	-0.7	-6.43	-0.55	5.05e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg10760299	chr15:45669010	GATM	0.93	7.63	0.62	1.79e-11	Homoarginine levels;
THYM	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg27170947	chr2:26402098	FAM59B	-0.8	-6.37	-0.55	6.74e-9	Gut microbiome composition (summer);
THYM	cis	rs4664308	0.967	rs17241973	chr2:160918601	A/G	cg03641300	chr2:160917029	PLA2R1	-0.78	-6.97	-0.58	4.25e-10	Idiopathic membranous nephropathy;
THYM	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8067545	0.717	rs34401389	chr17:19989436	A/T	cg08626831	chr17:20841558	NA	-0.48	-4.53	-0.42	1.7e-5	Schizophrenia;
THYM	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg18681998	chr4:17616180	MED28	0.79	6.77	0.57	1.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6754459	0.502	rs34759180	chr2:3707394	C/T	cg19825600	chr2:3704501	ALLC	-0.78	-6.45	-0.55	4.66e-9	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs11223731	0.672	rs12226809	chr11:134130189	C/T	cg18040241	chr11:134201582	GLB1L2	-0.72	-4.63	-0.43	1.18e-5	Verbal declarative memory;
THYM	cis	rs2898681	0.874	rs59649036	chr4:53741175	T/C	cg00338735	chr4:53728038	RASL11B	0.57	5.14	0.47	1.45e-6	Optic nerve measurement (cup area);
THYM	trans	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs4888262	0.526	rs7193423	chr16:74626340	A/C	cg01733217	chr16:74700730	RFWD3	0.86	8.95	0.68	2.84e-14	Testicular germ cell tumor;
THYM	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg11812906	chr14:75593930	NEK9	0.78	7.06	0.59	2.69e-10	Height;
THYM	cis	rs1957429	0.808	rs4902327	chr14:65344803	C/T	cg23373153	chr14:65346875	NA	1.0	5.38	0.48	5.34e-7	Pediatric areal bone mineral density (radius);
THYM	cis	rs7106204	0.534	rs113048476	chr11:24257588	T/C	ch.11.24196551F	chr11:24239977	NA	0.9	4.55	0.42	1.61e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs4481887	1.000	rs6697735	chr1:248465315	G/C	cg13385794	chr1:248469461	NA	0.67	4.6	0.43	1.29e-5	Common traits (Other);
THYM	cis	rs6558530	0.698	rs7015858	chr8:1724307	C/T	cg09410841	chr8:1729607	CLN8	0.79	5.82	0.51	7.82e-8	Systolic blood pressure;
THYM	cis	rs1018836	0.923	rs62526886	chr8:91627676	G/A	cg16814680	chr8:91681699	NA	-0.85	-7.17	-0.59	1.59e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs55702914	0.809	rs6738721	chr2:198182334	A/G	cg00792783	chr2:198669748	PLCL1	-0.66	-5.08	-0.46	1.9e-6	Major depression and alcohol dependence;
THYM	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg08901578	chr4:187885870	NA	-0.63	-5.72	-0.51	1.21e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7580658	0.724	rs6712446	chr2:127998399	G/T	cg09152259	chr2:128156114	NA	-0.41	-5.29	-0.48	7.7e-7	Protein C levels;
THYM	cis	rs2361701	0.500	rs12602593	chr17:78076879	G/T	cg04028464	chr17:78073854	GAA;CCDC40	0.98	5.96	0.52	4.18e-8	IgG glycosylation;
THYM	trans	rs7819412	0.618	rs13276836	chr8:10981003	A/C	cg06636001	chr8:8085503	FLJ10661	-0.79	-7.09	-0.59	2.41e-10	Triglycerides;
THYM	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	7.04	0.59	2.93e-10	Smoking behavior;
THYM	cis	rs951188	0.688	rs1196666	chr2:150329726	G/C	cg17961725	chr2:150454027	NA	0.9	4.46	0.42	2.25e-5	Daytime sleep phenotypes;
THYM	cis	rs7481584	0.581	rs366422	chr11:3053873	C/T	cg03159660	chr11:2078197	NA	0.63	4.74	0.44	7.52e-6	Calcium levels;
THYM	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg17366294	chr4:99064904	C4orf37	0.56	6.57	0.56	2.62e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg08999081	chr20:33150536	PIGU	0.76	6.73	0.57	1.27e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs8030379	0.967	rs2401171	chr15:84557676	T/G	cg15564896	chr15:84287328	SH3GL3	0.58	4.91	0.45	3.84e-6	Waist circumference adjusted for body mass index;Waist circumference;
THYM	cis	rs6669072	0.528	rs3856226	chr1:91245109	C/T	cg08895590	chr1:91227319	NA	0.46	5.26	0.48	8.71e-7	Cognitive function;
THYM	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg16850897	chr7:100343110	ZAN	-0.71	-5.37	-0.48	5.67e-7	Other erythrocyte phenotypes;
THYM	cis	rs6570726	0.791	rs11155432	chr6:145898761	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-5.02	-0.46	2.43e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9790314	1.000	rs1382428	chr3:161032386	A/C	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs4731207	0.596	rs7779244	chr7:124652930	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.53	-0.49	2.81e-7	Cutaneous malignant melanoma;
THYM	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg23815491	chr16:72088622	HP	0.84	6.94	0.58	4.78e-10	Fibrinogen levels;
THYM	cis	rs3781426	0.824	rs3824797	chr10:126708194	T/C	cg04494136	chr10:126703576	CTBP2	-0.42	-6.01	-0.53	3.35e-8	Height;
THYM	cis	rs7511006	0.859	rs7292228	chr22:50649560	C/G	cg01917657	chr22:50617092	PANX2	-0.41	-4.55	-0.42	1.57e-5	Obesity-related traits;
THYM	cis	rs4866334	1.000	rs77743777	chr5:18488452	G/A	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg06481639	chr22:41940642	POLR3H	0.84	6.06	0.53	2.69e-8	Vitiligo;
THYM	cis	rs2637266	0.935	rs2252652	chr10:78405022	C/T	cg18941641	chr10:78392320	NA	0.77	6.59	0.56	2.41e-9	Pulmonary function;
THYM	cis	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg05084668	chr3:125655381	ALG1L	-0.79	-4.47	-0.42	2.18e-5	Blood pressure (smoking interaction);
THYM	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg24578937	chr1:2090814	PRKCZ	-0.65	-6.85	-0.58	7.29e-10	Height;
THYM	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs877282	0.853	rs7083589	chr10:754494	G/A	cg22713356	chr15:30763199	NA	1.27	9.37	0.69	3.62e-15	Uric acid levels;
THYM	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg12292205	chr6:26970375	C6orf41	0.57	4.78	0.44	6.44e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.22	-0.47	1.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg07424592	chr7:64974309	NA	1.1	5.08	0.46	1.87e-6	Diabetic kidney disease;
THYM	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg24675056	chr1:15929824	NA	0.72	5.71	0.51	1.26e-7	Systolic blood pressure;
THYM	cis	rs4788570	0.584	rs6499530	chr16:71723089	C/G	cg06353428	chr16:71660113	MARVELD3	1.23	8.95	0.68	2.96e-14	Intelligence (multi-trait analysis);
THYM	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg25382214	chr1:3105252	PRDM16	-0.55	-4.71	-0.44	8.37e-6	Migraine;
THYM	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg14074117	chr16:1909714	C16orf73	-0.7	-4.45	-0.42	2.3e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs3847687	1.000	rs3847688	chr12:131525310	C/T	cg25772418	chr12:131519998	GPR133	-0.5	-7.73	-0.62	1.14e-11	Longevity;
THYM	cis	rs877282	0.945	rs10904555	chr10:787740	C/A	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs7626444	0.625	rs1403101	chr3:196485074	G/A	cg12930392	chr3:196481615	PAK2	0.4	4.97	0.45	2.97e-6	Monocyte count;
THYM	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs728616	0.764	rs56122289	chr10:81746027	G/A	cg27452691	chr10:81370291	SFTPA1	0.84	4.59	0.43	1.35e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9467160	0.651	rs9393558	chr6:24454196	G/T	cg20631270	chr6:24437470	GPLD1	0.57	4.79	0.44	6.18e-6	Liver enzyme levels;
THYM	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg16524936	chr4:1340807	KIAA1530	-0.68	-5.44	-0.49	4.06e-7	Longevity;
THYM	cis	rs2219968	0.962	rs13263076	chr8:78970258	T/C	cg00738934	chr8:78996279	NA	0.91	9.74	0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs622217	0.656	rs650154	chr6:160718539	C/T	cg11363108	chr6:160501266	IGF2R	-0.57	-4.45	-0.42	2.36e-5	Type 2 diabetes;
THYM	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg15556689	chr8:8085844	FLJ10661	0.71	6.11	0.53	2.22e-8	Mood instability;
THYM	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg18404041	chr3:52824283	ITIH1	-0.57	-5.74	-0.51	1.13e-7	Bipolar disorder;
THYM	cis	rs2455799	0.573	rs2470520	chr3:15762920	C/T	cg16303742	chr3:15540471	COLQ	-0.56	-5.98	-0.52	3.83e-8	Mean platelet volume;
THYM	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg11247378	chr22:39784982	NA	-1.06	-13.37	-0.81	1.49e-23	Intelligence (multi-trait analysis);
THYM	cis	rs6906287	0.647	rs7772921	chr6:118964623	C/G	cg21191810	chr6:118973309	C6orf204	0.62	6.2	0.54	1.42e-8	Electrocardiographic conduction measures;
THYM	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg10802521	chr3:52805072	NEK4	-0.73	-6.4	-0.55	5.97e-9	Bipolar disorder;
THYM	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-14.05	-0.82	6.23e-25	Height;
THYM	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg21862992	chr11:68658383	NA	0.24	4.56	0.42	1.53e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs10197940	0.662	rs1047957	chr2:152333773	C/T	cg19508488	chr2:152266495	RIF1	0.76	5.95	0.52	4.46e-8	Lung cancer;
THYM	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg07061783	chr6:25882402	NA	-0.86	-7.49	-0.61	3.5e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg16778714	chr17:28903809	LRRC37B2	-0.76	-4.49	-0.42	2.03e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs59227481	1	rs59227481	chr12:110007993	A/G	cg13986417	chr12:110012484	MVK;MMAB	-0.61	-5.5	-0.49	3.18e-7	Age-related nuclear cataracts;
THYM	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg18758796	chr5:131593413	PDLIM4	-0.6	-5.62	-0.5	1.94e-7	Acylcarnitine levels;
THYM	cis	rs931127	0.547	rs3886859	chr11:65458310	C/T	cg27068330	chr11:65405492	SIPA1	-0.83	-7.52	-0.61	3.07e-11	Systemic lupus erythematosus;
THYM	cis	rs9583531	0.689	rs2165418	chr13:111379365	G/T	cg24331049	chr13:111365604	ING1	-0.62	-5.5	-0.49	3.21e-7	Coronary artery disease;
THYM	cis	rs2730245	0.527	rs712199	chr7:158662250	A/G	cg24397884	chr7:158709396	WDR60	0.57	5.38	0.48	5.37e-7	Height;
THYM	cis	rs4268898	0.636	rs72787371	chr2:24570073	T/A	cg06627628	chr2:24431161	ITSN2	-0.73	-5.17	-0.47	1.31e-6	Asthma;
THYM	cis	rs250585	0.790	rs7204714	chr16:23483353	A/C	cg00143387	chr16:23521605	GGA2	0.74	4.7	0.43	8.63e-6	Egg allergy;
THYM	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg15212455	chr7:39170539	POU6F2	0.58	5.32	0.48	6.95e-7	IgG glycosylation;
THYM	cis	rs73193808	1.000	rs73193820	chr21:30544669	T/C	cg06824297	chr21:30391795	RWDD2B	-0.69	-4.47	-0.42	2.14e-5	Coronary artery disease;
THYM	cis	rs7219021	0.705	rs11869991	chr17:47027763	C/T	cg09029085	chr17:47094198	IGF2BP1	0.33	4.48	0.42	2.04e-5	Schizophrenia or bipolar disorder;
THYM	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg17063962	chr7:91808500	NA	1.11	9.47	0.7	2.29e-15	Breast cancer;
THYM	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg09263875	chr16:632152	PIGQ	0.73	6.29	0.54	9.69e-9	Height;
THYM	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs250585	0.736	rs727238	chr16:23521066	C/T	cg00143387	chr16:23521605	GGA2	-0.7	-4.53	-0.42	1.73e-5	Egg allergy;
THYM	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11644478	chr21:40555479	PSMG1	-0.56	-4.69	-0.43	9.07e-6	Menarche (age at onset);
THYM	cis	rs4891159	0.548	rs690414	chr18:74117840	T/C	cg24786174	chr18:74118243	ZNF516	0.97	14.75	0.83	2.65e-26	Longevity;
THYM	cis	rs6074578	0.709	rs1594917	chr20:143723	G/A	cg16931068	chr20:139680	DEFB127	0.4	4.47	0.42	2.19e-5	Hirschsprung disease;
THYM	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg16230307	chr14:35515116	FAM177A1	0.83	5.32	0.48	6.89e-7	Psoriasis;
THYM	cis	rs7772486	0.686	rs9403741	chr6:146030548	G/A	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg03676636	chr4:99064102	C4orf37	0.42	6.24	0.54	1.23e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6835098	0.646	rs10012395	chr4:174078772	A/G	cg08422745	chr4:174089978	GALNT7	-0.93	-7.38	-0.6	5.97e-11	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.33	9.84	0.71	3.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	6.66	0.56	1.74e-9	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2731664	0.792	rs1130857	chr5:176863519	G/C	cg14098951	chr5:176875120	PRR7	0.54	4.77	0.44	6.71e-6	Intelligence (multi-trait analysis);
THYM	cis	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.55	-5.53	-0.49	2.86e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7582180	0.663	rs2053263	chr2:100971407	A/G	cg21926883	chr2:100939477	LONRF2	-0.66	-6.12	-0.53	2.1e-8	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs10001115	chr4:119781867	A/C	cg11846333	chr4:119757529	SEC24D	1.39	5.31	0.48	7.04e-7	Cannabis dependence symptom count;
THYM	cis	rs7830933	0.955	rs1550279	chr8:23600854	C/G	cg04349084	chr8:23602677	NA	0.65	7.16	0.59	1.67e-10	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg22117172	chr7:91764530	CYP51A1	0.39	4.79	0.44	6.17e-6	Breast cancer;
THYM	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs36051895	0.575	rs7035251	chr9:5133665	T/A	cg02405213	chr9:5042618	JAK2	-1.03	-11.6	-0.77	6.52e-20	Pediatric autoimmune diseases;
THYM	cis	rs73086581	1.000	rs17286768	chr20:3924569	A/G	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs7078219	0.686	rs12412214	chr10:101276256	G/A	cg07044859	chr10:101282883	NA	-0.46	-4.94	-0.45	3.34e-6	Dental caries;
THYM	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Body mass index;
THYM	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg20887711	chr4:1340912	KIAA1530	0.68	5.98	0.52	3.89e-8	Longevity;
THYM	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg21385522	chr1:16154831	NA	-0.94	-6.85	-0.57	7.39e-10	Dilated cardiomyopathy;
THYM	cis	rs1347297	0.526	rs919177	chr2:179258923	C/T	cg03991736	chr2:179345203	MIR548N;PLEKHA3	-0.6	-4.65	-0.43	1.07e-5	Alzheimer disease and age of onset;
THYM	cis	rs2073300	1.000	rs6137975	chr20:23461778	A/G	cg12062639	chr20:23401060	NAPB	-0.96	-4.84	-0.45	4.95e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs3087591	1.000	rs2905791	chr17:29472888	T/C	cg24425628	chr17:29625626	OMG;NF1	0.64	5.54	0.49	2.68e-7	Hip circumference;
THYM	cis	rs611744	0.934	rs673356	chr8:109185159	A/T	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg13877915	chr19:58951672	ZNF132	0.9	8.81	0.67	5.8e-14	Uric acid clearance;
THYM	cis	rs4732038	0.510	rs28817066	chr7:134277491	G/A	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg01097406	chr16:89675127	NA	0.51	4.58	0.43	1.4e-5	Vitiligo;
THYM	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg19346786	chr7:2764209	NA	-0.73	-6.14	-0.53	1.9e-8	Height;
THYM	cis	rs1448094	0.549	rs10863085	chr12:86236328	G/A	cg00310523	chr12:86230176	RASSF9	0.59	5.41	0.49	4.71e-7	Major depressive disorder;
THYM	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-6.12	-0.53	2.09e-8	Chronic sinus infection;
THYM	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg05662444	chr5:154026397	NA	0.55	4.83	0.44	5.29e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs4242434	0.927	rs11136092	chr8:22466488	T/G	cg21658235	chr8:22456391	C8orf58	0.6	5.64	0.5	1.77e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs789852	0.867	rs1773175	chr3:194317732	G/A	cg18000598	chr3:194342907	TMEM44	-1.14	-6.96	-0.58	4.36e-10	QT interval;
THYM	cis	rs6032067	0.777	rs2868235	chr20:43794069	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg13397359	chr6:42928475	GNMT	0.69	6.42	0.55	5.32e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs9810089	0.814	rs696518	chr3:136120300	A/C	cg21827317	chr3:136751795	NA	0.59	5.23	0.47	1.01e-6	Gestational age at birth (child effect);
THYM	cis	rs10037758	0.643	rs2526242	chr5:128300005	A/G	cg25555059	chr5:128301488	SLC27A6	-0.5	-5.27	-0.48	8.56e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17818399	0.547	rs12997164	chr2:46758746	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.64	-4.45	-0.42	2.3e-5	Height;
THYM	cis	rs9326248	0.813	rs474488	chr11:117068977	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.68	4.86	0.45	4.72e-6	Blood protein levels;
THYM	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg27534772	chr1:16042836	PLEKHM2	0.55	5.87	0.52	6.33e-8	Systolic blood pressure;
THYM	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg01475377	chr6:109611718	NA	-0.57	-4.88	-0.45	4.28e-6	Reticulocyte fraction of red cells;
THYM	trans	rs1974653	0.672	rs75967927	chr22:20068496	C/T	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg24812749	chr6:127587940	RNF146	0.97	7.72	0.62	1.14e-11	Breast cancer;
THYM	cis	rs74417235	0.639	rs2396994	chr5:154052750	A/T	cg05662444	chr5:154026397	NA	-0.57	-5.12	-0.46	1.63e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs6860806	0.661	rs4705927	chr5:131578608	C/G	cg24060327	chr5:131705240	SLC22A5	-0.68	-5.28	-0.48	8.17e-7	Breast cancer;
THYM	cis	rs1692120	0.669	rs61898510	chr11:61425464	T/C	cg23976388	chr11:61510081	DAGLA	0.55	5.29	0.48	7.88e-7	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
THYM	cis	rs4919694	1.000	rs4917379	chr10:104752831	A/T	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	cis	rs1395	1.000	rs1275530	chr2:27432547	A/G	cg23587288	chr2:27483067	SLC30A3	0.57	5.1	0.46	1.73e-6	Blood metabolite levels;
THYM	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23221052	chr5:179740743	GFPT2	-0.9	-6.79	-0.57	9.56e-10	Height;
THYM	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg05335186	chr13:53173507	NA	-0.46	-5.86	-0.52	6.6e-8	Lewy body disease;
THYM	cis	rs4786125	0.665	rs1565633	chr16:6919428	G/C	cg03623568	chr16:6915990	A2BP1	-1.02	-10.42	-0.73	2.1e-17	Heart rate variability traits (SDNN);
THYM	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg25427524	chr10:38739819	LOC399744	0.71	6.42	0.55	5.39e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs60871478	0.735	rs62432241	chr7:795360	G/A	cg10248100	chr7:872053	UNC84A	-0.71	-4.52	-0.42	1.75e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg18681998	chr4:17616180	MED28	0.97	9.75	0.71	5.71e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7727544	0.740	rs419291	chr5:131633355	T/C	cg14196790	chr5:131705035	SLC22A5	0.54	4.74	0.44	7.4e-6	Blood metabolite levels;
THYM	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg12310025	chr6:25882481	NA	-0.68	-5.3	-0.48	7.65e-7	Height;
THYM	cis	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg24375607	chr4:120327624	NA	0.58	4.74	0.44	7.61e-6	Corneal astigmatism;
THYM	cis	rs778371	0.723	rs35491427	chr2:233688542	C/T	cg08000102	chr2:233561755	GIGYF2	-0.79	-6.96	-0.58	4.28e-10	Schizophrenia;
THYM	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg03806693	chr22:41940476	POLR3H	-1.17	-9.66	-0.7	8.8e-16	Vitiligo;
THYM	cis	rs6960043	0.905	rs2215381	chr7:15054935	G/T	cg19272540	chr7:15055459	NA	0.53	5.95	0.52	4.43e-8	Type 2 diabetes;
THYM	cis	rs12579753	1.000	rs2401004	chr12:82214822	T/C	cg21231944	chr12:82153410	PPFIA2	-0.65	-4.96	-0.45	3.1e-6	Resting heart rate;
THYM	cis	rs250585	0.736	rs30014	chr16:23415898	C/T	cg00143387	chr16:23521605	GGA2	0.74	5.25	0.47	9.16e-7	Egg allergy;
THYM	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs12478296	1.000	rs59036157	chr2:243040228	C/A	cg06360820	chr2:242988706	NA	-1.05	-6.52	-0.56	3.31e-9	Obesity-related traits;
THYM	cis	rs12410462	0.681	rs4131980	chr1:227572123	A/G	cg04117972	chr1:227635322	NA	0.8	4.82	0.44	5.36e-6	Major depressive disorder;
THYM	cis	rs956237	0.966	rs10025623	chr4:109049374	G/A	cg15700776	chr4:108852048	CYP2U1	0.57	4.62	0.43	1.22e-5	Systemic lupus erythematosus;
THYM	cis	rs2637266	0.967	rs6480826	chr10:78356154	A/G	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg10523679	chr1:76189770	ACADM	0.95	12.11	0.78	5.63e-21	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg12908607	chr1:44402522	ARTN	-0.52	-4.67	-0.43	9.88e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7740797	0.791	rs9384245	chr6:155160128	T/C	cg02865717	chr6:155053990	RBM16	0.48	4.81	0.44	5.65e-6	Colorectal or endometrial cancer;
THYM	cis	rs36051895	0.623	rs11506292	chr9:5257048	C/A	cg02405213	chr9:5042618	JAK2	-0.93	-9.34	-0.69	4.28e-15	Pediatric autoimmune diseases;
THYM	cis	rs1190596	0.525	rs6575897	chr14:102647125	G/A	cg08231664	chr14:102516632	DYNC1H1	0.41	4.92	0.45	3.58e-6	Behavioural disinhibition (generation interaction);
THYM	cis	rs13232179	1.000	rs4404834	chr7:151116702	A/T	cg05714773	chr7:150493706	TMEM176B	0.67	4.68	0.43	9.33e-6	Coronary heart disease;
THYM	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg06618935	chr21:46677482	NA	-0.98	-9.58	-0.7	1.28e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1003719	0.788	rs8133549	chr21:38447489	C/T	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs2730245	0.527	rs842695	chr7:158662182	G/A	cg11984989	chr7:158649758	WDR60	1.03	8.36	0.65	5.29e-13	Height;
THYM	cis	rs6570726	0.935	rs12663205	chr6:145818378	G/A	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11850957	0.502	rs17109457	chr14:25463393	C/G	cg26846476	chr14:24838993	NFATC4	0.88	4.55	0.42	1.61e-5	Subcutaneous adipose tissue;
THYM	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg06238570	chr21:40685208	BRWD1	-0.72	-6.28	-0.54	9.9e-9	Menarche (age at onset);
THYM	cis	rs523395	0.630	rs616111	chr1:120269991	C/G	cg19096424	chr1:120255104	PHGDH	-0.75	-6.17	-0.53	1.7e-8	Red blood cell count;
THYM	cis	rs1642645	0.957	rs7550497	chr1:42505510	C/T	cg10197057	chr1:42612518	NA	-0.45	-4.84	-0.44	5.05e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs9486719	1.000	rs2179126	chr6:96871350	A/G	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg24399712	chr22:39784796	NA	-0.9	-10.0	-0.72	1.65e-16	Intelligence (multi-trait analysis);
THYM	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg07424592	chr7:64974309	NA	1.16	5.55	0.5	2.55e-7	Diabetic kidney disease;
THYM	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs12898370	0.641	rs11632999	chr15:77436995	T/G	cg10437265	chr15:77819839	NA	0.66	5.2	0.47	1.17e-6	Risky sexual behaviors (alcohol dependence interaction);
THYM	cis	rs828999	0.688	rs11185286	chr1:108698434	T/A	cg24323958	chr1:108741884	SLC25A24	0.54	5.32	0.48	6.79e-7	Monocyte percentage of white cells;
THYM	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg12016809	chr21:47604291	C21orf56	0.79	5.35	0.48	6.05e-7	Testicular germ cell tumor;
THYM	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg25811766	chr13:21894605	NA	0.75	6.12	0.53	2.06e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg16615211	chr3:44902933	MIR564;TMEM42	0.47	4.52	0.42	1.78e-5	Depressive symptoms;
THYM	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs10931896	0.531	rs295118	chr2:201144004	C/T	cg23649088	chr2:200775458	C2orf69	0.66	5.66	0.5	1.61e-7	Systolic blood pressure;
THYM	cis	rs6496667	0.955	rs8039263	chr15:90900597	G/A	cg22089800	chr15:90895588	ZNF774	0.69	4.52	0.42	1.79e-5	Rheumatoid arthritis;
THYM	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg24733560	chr20:60626293	TAF4	0.62	6.5	0.55	3.69e-9	Body mass index;
THYM	cis	rs7264396	0.563	rs2425111	chr20:34319765	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.82	-0.44	5.51e-6	Total cholesterol levels;
THYM	cis	rs67072384	1.000	rs7125722	chr11:72449716	G/A	cg01380194	chr11:72452482	ARAP1	-0.93	-5.07	-0.46	1.98e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs2276314	0.857	rs28791905	chr18:33602213	G/A	cg19628046	chr18:33552617	C18orf21	0.75	5.62	0.5	1.91e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs988913	0.874	rs12662124	chr6:54802336	A/G	cg04690482	chr6:54711388	FAM83B	0.5	5.32	0.48	6.99e-7	Menarche (age at onset);
THYM	cis	rs1775715	0.707	rs2808094	chr10:32133756	T/C	cg04359828	chr10:32216031	ARHGAP12	0.38	4.82	0.44	5.48e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs6754311	0.593	rs1438305	chr2:136502792	C/G	cg07169764	chr2:136633963	MCM6	-0.67	-5.92	-0.52	5.11e-8	Mosquito bite size;
THYM	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg06728252	chr6:26598149	ABT1	-0.44	-5.24	-0.47	9.76e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2219968	1.000	rs35551201	chr8:78963968	G/A	cg00738934	chr8:78996279	NA	0.91	9.75	0.71	5.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6032067	0.929	rs6017504	chr20:43818920	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.01	-9.8	-0.71	4.35e-16	Primary sclerosing cholangitis;
THYM	cis	rs907683	0.559	rs11685408	chr2:220291474	T/C	cg15015639	chr2:220282977	DES	0.39	5.13	0.47	1.53e-6	Resting heart rate;
THYM	cis	rs2354432	1.000	rs6680778	chr1:146747153	T/C	cg25205988	chr1:146714368	CHD1L	1.35	10.55	0.73	1.08e-17	Mitochondrial DNA levels;
THYM	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg27532560	chr4:187881888	NA	-0.96	-12.62	-0.79	5.09e-22	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg17279839	chr7:150038598	RARRES2	0.55	5.44	0.49	4.08e-7	Blood protein levels;Circulating chemerin levels;
THYM	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg04842962	chr6:43655489	MRPS18A	0.98	8.35	0.65	5.51e-13	IgG glycosylation;
THYM	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.4	0.6	5.38e-11	Obesity-related traits;
THYM	cis	rs7731657	0.510	rs10045858	chr5:130251039	C/T	cg08523029	chr5:130500466	HINT1	0.89	5.95	0.52	4.48e-8	Fasting plasma glucose;
THYM	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg04362960	chr10:104952993	NT5C2	0.64	5.59	0.5	2.15e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs2933343	0.601	rs1680758	chr3:128594897	T/C	cg11901034	chr3:128598214	ACAD9	-0.7	-5.68	-0.5	1.47e-7	IgG glycosylation;
THYM	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg26031613	chr14:104095156	KLC1	0.78	5.2	0.47	1.14e-6	Body mass index;
THYM	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg23711669	chr6:146136114	FBXO30	-0.97	-10.49	-0.73	1.45e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg00640147	chr17:61958756	GH2	-0.42	-4.48	-0.42	2.09e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs61990749	0.597	rs2267761	chr14:78147849	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	-1.17	-8.04	-0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs1728785	0.892	rs4783648	chr16:68558334	C/T	cg02972257	chr16:68554789	NA	0.8	5.14	0.47	1.49e-6	Ulcerative colitis;
THYM	cis	rs7942486	0.895	rs4372426	chr11:13275240	A/G	cg13286116	chr11:13302098	ARNTL	0.76	8.59	0.66	1.73e-13	Neuroticism;
THYM	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg05872129	chr22:39784769	NA	-0.97	-9.48	-0.7	2.15e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7107174	1.000	rs2511170	chr11:77980582	A/G	cg19901956	chr11:77921274	USP35	-0.68	-5.26	-0.48	8.74e-7	Testicular germ cell tumor;
THYM	cis	rs77106637	0.722	rs11605691	chr11:72419514	C/T	cg03713592	chr11:72463424	ARAP1	1.12	4.55	0.42	1.58e-5	Type 2 diabetes;
THYM	cis	rs9810089	0.900	rs480162	chr3:136068695	A/T	cg12473912	chr3:136751656	NA	0.58	4.69	0.43	9.32e-6	Gestational age at birth (child effect);
THYM	cis	rs514406	0.505	rs146750	chr1:53183447	C/G	cg16325326	chr1:53192061	ZYG11B	0.97	11.07	0.75	8.85e-19	Monocyte count;
THYM	cis	rs4595586	0.563	rs2388178	chr12:39364366	T/G	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs7523273	0.565	rs2796234	chr1:207900695	T/A	cg22525895	chr1:207977042	MIR29B2	-0.53	-5.08	-0.46	1.91e-6	Schizophrenia;
THYM	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg24112000	chr20:60950667	NA	0.66	5.45	0.49	4.02e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg11266682	chr4:10021025	SLC2A9	0.73	12.79	0.8	2.29e-22	Bone mineral density;
THYM	cis	rs2717559	0.522	rs2949872	chr8:143872904	T/C	cg17252645	chr8:143867129	LY6D	0.8	9.79	0.71	4.68e-16	Urinary tract infection frequency;
THYM	cis	rs10799590	1.000	rs298733	chr1:224842251	A/C	cg01808320	chr1:224927238	CNIH3	0.52	4.7	0.43	8.78e-6	Opioid dependence;
THYM	cis	rs425277	0.628	rs3128340	chr1:2047496	C/G	cg17426766	chr1:2046864	PRKCZ	-0.4	-4.62	-0.43	1.21e-5	Height;
THYM	cis	rs6087771	0.682	rs2038397	chr20:30217759	A/G	cg13852791	chr20:30311386	BCL2L1	0.8	7.42	0.61	5.02e-11	Subcortical brain region volumes;Putamen volume;
THYM	cis	rs2658782	0.951	rs72972364	chr11:93122128	C/T	cg15737290	chr11:93063684	CCDC67	-0.94	-6.63	-0.56	2.06e-9	Pulmonary function decline;
THYM	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.95	0.71	2.08e-16	Colorectal cancer;
THYM	cis	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg07988820	chr12:82153109	PPFIA2	-0.82	-5.23	-0.47	9.93e-7	Resting heart rate;
THYM	cis	rs2116941	1.000	rs2033493	chr19:10340854	A/C	cg01850179	chr19:10340795	S1PR2	-0.65	-8.72	-0.67	8.76e-14	Pulse pressure;
THYM	cis	rs6906287	0.631	rs9320665	chr6:118986309	G/A	cg01113488	chr6:119027122	NA	0.55	4.55	0.42	1.6e-5	Electrocardiographic conduction measures;
THYM	cis	rs2412459	0.635	rs514152	chr15:40255156	A/G	cg16127683	chr15:40268777	EIF2AK4	0.53	4.63	0.43	1.16e-5	Response to haloperidol in psychosis;
THYM	cis	rs7177699	0.557	rs12898452	chr15:79112628	C/A	cg15571903	chr15:79123663	NA	0.58	6.5	0.55	3.66e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs3806843	0.766	rs2251860	chr5:140048209	T/C	cg19875535	chr5:140030758	IK	-0.64	-5.5	-0.49	3.19e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs4523957	0.651	rs9894613	chr17:2071058	C/T	cg16513277	chr17:2031491	SMG6	-0.96	-8.75	-0.67	7.8500000000000006e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg24112000	chr20:60950667	NA	0.8	6.61	0.56	2.19e-9	Colorectal cancer;
THYM	cis	rs10197940	0.532	rs13425170	chr2:152387112	A/C	cg06191203	chr2:152266755	RIF1	-0.79	-4.94	-0.45	3.32e-6	Lung cancer;
THYM	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs859767	0.741	rs13432068	chr2:135382914	G/A	cg12500956	chr2:135428796	TMEM163	-0.49	-4.98	-0.46	2.8e-6	Neuroticism;
THYM	cis	rs877282	0.898	rs12359731	chr10:759497	A/G	cg10556349	chr10:835070	NA	-0.82	-5.62	-0.5	1.89e-7	Uric acid levels;
THYM	cis	rs6503525	0.628	rs62068171	chr17:38103242	G/A	cg24910161	chr17:38119198	GSDMA	-0.58	-6.82	-0.57	8.35e-10	Asthma;
THYM	cis	rs11190604	0.767	rs10883479	chr10:102162860	A/G	cg07570687	chr10:102243282	WNT8B	0.81	7.68	0.62	1.44e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs35660623	1.000	rs6993463	chr8:10669815	G/A	cg12395012	chr8:11607386	GATA4	0.96	5.3	0.48	7.48e-7	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs7084402	0.967	rs1658429	chr10:60330422	T/C	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs854765	0.583	rs7222480	chr17:17818817	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.34	0.55	7.83e-9	Total body bone mineral density;
THYM	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg09307838	chr4:120376055	NA	-0.74	-5.45	-0.49	3.94e-7	Corneal astigmatism;
THYM	cis	rs728616	0.867	rs7080405	chr10:81901943	G/C	cg05935833	chr10:81318306	SFTPA2	-0.73	-4.5	-0.42	1.93e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg18305652	chr10:134549665	INPP5A	0.89	8.52	0.66	2.39e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs6542838	0.673	rs1949424	chr2:99468341	C/T	cg08885076	chr2:99613938	TSGA10	0.47	4.56	0.42	1.55e-5	Fear of minor pain;
THYM	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg22875332	chr1:76189707	ACADM	0.81	7.2	0.59	1.43e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg03929089	chr4:120376271	NA	1.03	8.55	0.66	2.06e-13	Coronary artery disease;
THYM	cis	rs4595586	0.545	rs7486598	chr12:39371159	C/T	cg13010199	chr12:38710504	ALG10B	0.68	5.03	0.46	2.3e-6	Morning vs. evening chronotype;
THYM	cis	rs7000551	0.725	rs2461486	chr8:22392008	T/C	cg12081754	chr8:22256438	SLC39A14	0.68	6.35	0.55	7.29e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs11190604	0.767	rs10748794	chr10:102175918	G/T	cg16342193	chr10:102329863	NA	0.45	4.47	0.42	2.16e-5	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9868809	0.656	rs13324119	chr3:48710606	G/C	cg00383909	chr3:49044727	WDR6	1.04	5.4	0.48	4.88e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg13607699	chr17:42295918	UBTF	-0.6	-5.03	-0.46	2.33e-6	Total body bone mineral density;
THYM	cis	rs6882716	1.000	rs6882716	chr5:10797886	G/A	cg14521931	chr5:10832172	NA	-0.71	-5.62	-0.5	1.89e-7	Alcohol consumption (maxi-drinks);
THYM	cis	rs11096990	0.855	rs2566169	chr4:39152040	G/T	cg24403649	chr4:39172243	NA	-0.62	-5.3	-0.48	7.5e-7	Cognitive function;
THYM	cis	rs6503525	0.591	rs8080734	chr17:38103285	G/A	cg24910161	chr17:38119198	GSDMA	-0.52	-6.01	-0.52	3.41e-8	Asthma;
THYM	cis	rs6840360	0.571	rs17275536	chr4:152498625	C/T	cg17479576	chr4:152424074	FAM160A1	-0.79	-5.89	-0.52	5.81e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg10589385	chr1:150898437	SETDB1	0.63	5.2	0.47	1.14e-6	Melanoma;
THYM	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg06636001	chr8:8085503	FLJ10661	-0.71	-5.85	-0.51	6.8e-8	Joint mobility (Beighton score);
THYM	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg19507638	chr5:93509721	C5orf36	-0.68	-4.6	-0.43	1.28e-5	Diabetic retinopathy;
THYM	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg16482183	chr6:26056742	HIST1H1C	0.96	5.97	0.52	4.07e-8	Iron status biomarkers;
THYM	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg07212818	chr11:638076	DRD4	-0.75	-5.99	-0.52	3.66e-8	Systemic lupus erythematosus;
THYM	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg13695892	chr22:41940480	POLR3H	-0.94	-7.28	-0.6	9.75e-11	Vitiligo;
THYM	cis	rs2290159	0.800	rs56363132	chr3:12680403	T/C	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs7224737	1.000	rs7214921	chr17:40294025	T/C	cg02228675	chr17:40259724	DHX58	-0.62	-5.13	-0.47	1.55e-6	Fibrinogen levels;
THYM	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg06697600	chr4:7070879	GRPEL1	-0.54	-4.78	-0.44	6.39e-6	Monocyte percentage of white cells;
THYM	cis	rs748404	0.631	rs7166812	chr15:43644760	T/C	cg12861797	chr15:43585817	TGM7	0.44	4.67	0.43	9.79e-6	Lung cancer;
THYM	cis	rs919433	0.617	rs12619333	chr2:198567638	C/G	cg00792783	chr2:198669748	PLCL1	-0.77	-5.4	-0.48	4.91e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2066819	1.000	rs35526714	chr12:56634639	G/C	cg26714650	chr12:56694279	CS	-1.3	-5.96	-0.52	4.24e-8	Psoriasis vulgaris;
THYM	cis	rs6430585	0.527	rs2254780	chr2:136435526	C/T	cg04750100	chr2:136595281	LCT	0.53	5.18	0.47	1.25e-6	Corneal structure;
THYM	cis	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg09307838	chr4:120376055	NA	-0.74	-5.8	-0.51	8.52e-8	Corneal astigmatism;
THYM	cis	rs477692	0.604	rs1008982	chr10:131445731	T/C	cg05714579	chr10:131428358	MGMT	-0.94	-8.87	-0.67	4.23e-14	Response to temozolomide;
THYM	cis	rs41005	1.000	rs193932	chr2:8107383	C/T	cg03155496	chr2:8117019	LOC339788	-0.97	-9.05	-0.68	1.78e-14	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs16866061	1.000	rs11694987	chr2:225397409	C/G	cg22455342	chr2:225449267	CUL3	0.66	4.76	0.44	6.99e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg01579765	chr21:45077557	HSF2BP	-0.48	-7.42	-0.61	4.93e-11	Mean corpuscular volume;
THYM	cis	rs1775715	0.677	rs2808074	chr10:32179184	A/C	cg04359828	chr10:32216031	ARHGAP12	0.41	5.12	0.46	1.62e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs4474465	0.920	rs4945285	chr11:78221698	C/T	cg19901956	chr11:77921274	USP35	0.67	4.92	0.45	3.69e-6	Alzheimer's disease (survival time);
THYM	cis	rs9394438	0.628	rs2153947	chr6:37544930	A/G	cg00985040	chr6:37553208	NA	-0.44	-4.68	-0.43	9.53e-6	IgG glycosylation;
THYM	cis	rs4363385	0.818	rs11205166	chr1:152988627	C/G	cg13444842	chr1:152974279	SPRR3	-0.57	-4.76	-0.44	6.94e-6	Inflammatory skin disease;
THYM	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg25072359	chr17:41440525	NA	0.72	5.26	0.47	8.95e-7	Menopause (age at onset);
THYM	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.69	4.62	0.43	1.22e-5	Cognitive test performance;
THYM	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.97	8.79	0.67	6.29e-14	Chronic sinus infection;
THYM	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	6.33	0.54	8.19e-9	Platelet count;
THYM	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg09338302	chr7:1325757	NA	0.48	4.55	0.42	1.6e-5	Bipolar disorder;
THYM	cis	rs2862064	1.000	rs1910052	chr5:156429154	T/C	cg12943317	chr5:156479607	HAVCR1	-0.88	-5.3	-0.48	7.43e-7	Platelet count;
THYM	cis	rs7586879	0.964	rs6545795	chr2:25116783	C/T	cg01884057	chr2:25150051	NA	0.63	6.3	0.54	9.31e-9	Body mass index;
THYM	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs365132	1.000	rs2292256	chr5:176333126	C/T	cg17809377	chr5:176326619	HK3	-0.3	-4.55	-0.42	1.59e-5	Menarche and menopause (age at onset);Menopause (age at onset);
THYM	cis	rs4803468	1.000	rs10417311	chr19:41902038	G/A	cg09537434	chr19:41945824	ATP5SL	-1.12	-10.57	-0.74	1.03e-17	Height;
THYM	cis	rs548181	0.736	rs1941558	chr11:125425606	C/T	cg03464685	chr11:125439445	EI24	1.54	9.15	0.68	1.1e-14	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs919433	0.679	rs6719832	chr2:198533369	C/T	cg05783139	chr2:198650985	BOLL	-0.66	-4.98	-0.46	2.78e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg11764359	chr7:65958608	NA	0.63	4.92	0.45	3.66e-6	Aortic root size;
THYM	cis	rs12291225	0.546	rs12795545	chr11:14355564	G/A	cg05501817	chr11:14380813	RRAS2	-0.8	-6.63	-0.56	2.05e-9	Sense of smell;
THYM	cis	rs9419702	0.568	rs9419635	chr10:133546164	C/T	cg23460707	chr10:133558971	NA	0.44	4.51	0.42	1.82e-5	Survival in rectal cancer;
THYM	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.75	7.26	0.6	1.05e-10	Lymphocyte counts;
THYM	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs9649465	1.000	rs3807635	chr7:123382152	A/C	cg15443791	chr7:124364398	NA	0.58	4.78	0.44	6.46e-6	Migraine;
THYM	cis	rs9814567	1.000	rs13322305	chr3:134310791	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.5	-0.66	2.69e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs4509693	0.782	rs7897782	chr10:102495856	C/A	cg24127310	chr10:102502104	NA	1.29	10.03	0.72	1.4e-16	Alzheimer's disease;
THYM	cis	rs4242434	0.854	rs4872007	chr8:22538879	G/A	cg03733263	chr8:22462867	KIAA1967	-1.13	-10.54	-0.73	1.15e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs79387448	0.655	rs76930359	chr2:102924684	G/A	cg09003973	chr2:102972529	NA	1.25	6.26	0.54	1.12e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg11335335	chr11:637885	DRD4	-0.56	-4.46	-0.42	2.27e-5	Systemic lupus erythematosus;
THYM	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg04455712	chr21:45112962	RRP1B	0.52	4.88	0.45	4.28e-6	Mean corpuscular volume;
THYM	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg26924012	chr15:45694286	SPATA5L1	0.97	8.09	0.64	1.97e-12	Homoarginine levels;
THYM	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg20637307	chr2:213403960	ERBB4	-0.57	-4.5	-0.42	1.96e-5	Symmetrical dimethylarginine levels;
THYM	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg26384229	chr12:38710491	ALG10B	-1.01	-10.19	-0.72	6.41e-17	Heart rate;
THYM	cis	rs9880211	0.948	rs17298525	chr3:136193025	G/C	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs4718428	0.705	rs13227468	chr7:66433563	T/C	cg18252515	chr7:66147081	NA	-0.89	-6.67	-0.56	1.65e-9	Corneal structure;
THYM	cis	rs11214589	0.719	rs10891535	chr11:113201280	C/G	cg14159747	chr11:113255604	NA	0.3	5.74	0.51	1.12e-7	Neuroticism;
THYM	cis	rs476633	0.708	rs8030657	chr15:41444979	T/C	cg21153102	chr15:41252147	NA	0.59	4.6	0.43	1.28e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs904251	0.861	rs2776877	chr6:37487135	G/A	cg25019722	chr6:37503610	NA	-0.65	-5.57	-0.5	2.37e-7	Cognitive performance;
THYM	cis	rs1994135	0.669	rs11052747	chr12:33697913	C/G	cg06521331	chr12:34319734	NA	-0.74	-5.52	-0.49	2.92e-7	Resting heart rate;
THYM	cis	rs2276314	0.857	rs28435069	chr18:33628475	A/G	cg19628046	chr18:33552617	C18orf21	0.74	5.43	0.49	4.29e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg11327659	chr7:150037044	RARRES2	0.47	5.32	0.48	6.94e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg16928487	chr17:17741425	SREBF1	0.51	5.14	0.47	1.48e-6	Total body bone mineral density;
THYM	cis	rs9938149	0.706	rs12711488	chr16:88319421	C/G	cg09385650	chr16:88018033	BANP	-0.28	-4.95	-0.45	3.15e-6	Corneal structure;Central corneal thickness;
THYM	trans	rs877282	1.000	rs2004479	chr10:770854	G/A	cg22713356	chr15:30763199	NA	1.37	11.1	0.75	7.69e-19	Uric acid levels;
THYM	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg12408189	chr10:30722286	MAP3K8	-0.66	-5.82	-0.51	7.83e-8	Inflammatory bowel disease;
THYM	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg13695892	chr22:41940480	POLR3H	-1.06	-8.46	-0.66	3.24e-13	Vitiligo;
THYM	cis	rs17006441	1.000	rs17006441	chr3:69841880	C/A	cg18496212	chr3:69797108	MITF	0.68	6.78	0.57	1.01e-9	Hemoglobin concentration;
THYM	trans	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8067545	0.750	rs9897246	chr17:19965702	T/G	cg13482628	chr17:19912719	NA	0.56	4.7	0.43	8.78e-6	Schizophrenia;
THYM	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs7833986	0.501	rs17812659	chr8:56889862	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.57	6.33	0.54	7.98e-9	Height;
THYM	cis	rs4409675	0.576	rs6691656	chr1:28221130	C/G	cg23691781	chr1:28212827	C1orf38	0.44	4.5	0.42	1.92e-5	Corneal astigmatism;
THYM	cis	rs2299587	0.585	rs2299590	chr8:17802192	A/C	cg01800426	chr8:17659068	MTUS1	-0.68	-5.17	-0.47	1.27e-6	Economic and political preferences;
THYM	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg08999081	chr20:33150536	PIGU	0.81	7.94	0.63	4.05e-12	Coronary artery disease;
THYM	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg11247378	chr22:39784982	NA	-0.99	-9.81	-0.71	4.19e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs761746	0.960	rs9621279	chr22:31949800	T/A	cg10537193	chr22:32026975	PISD	-0.35	-4.66	-0.43	1.01e-5	Intelligence;
THYM	cis	rs936229	0.813	rs1350193	chr15:75084281	G/C	cg10253484	chr15:75165896	SCAMP2	-0.66	-4.59	-0.43	1.38e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs4808199	0.948	rs11085261	chr19:19462606	G/A	cg03709012	chr19:19516395	GATAD2A	1.05	5.98	0.52	3.95e-8	Nonalcoholic fatty liver disease;
THYM	cis	rs9747347	1	rs9747347	chr17:79606820	T/C	cg21984481	chr17:79567631	NPLOC4	-0.54	-5.14	-0.47	1.46e-6	Myopia;
THYM	cis	rs6964587	0.626	rs4729011	chr7:91515419	G/A	cg17063962	chr7:91808500	NA	-1.0	-8.67	-0.66	1.16e-13	Breast cancer;
THYM	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.63	5.54	0.49	2.66e-7	Total body bone mineral density;
THYM	cis	rs9302635	0.513	rs12928732	chr16:72188683	C/T	cg16558253	chr16:72132732	DHX38	-0.55	-4.53	-0.42	1.7e-5	Blood protein levels;
THYM	cis	rs4731207	0.698	rs6968187	chr7:124563340	T/G	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	trans	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg25214090	chr10:38739885	LOC399744	-0.8	-6.86	-0.58	6.84e-10	Corneal astigmatism;
THYM	cis	rs61931739	0.517	rs1843735	chr12:34047389	C/G	cg10856724	chr12:34555212	NA	-0.75	-6.73	-0.57	1.25e-9	Morning vs. evening chronotype;
THYM	cis	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg00495681	chr13:53174319	NA	0.73	7.36	0.6	6.45e-11	Lewy body disease;
THYM	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	4.79	0.44	6.04e-6	Menarche (age at onset);
THYM	cis	rs713587	0.806	rs6737082	chr2:25138040	A/C	cg01884057	chr2:25150051	NA	0.7	7.77	0.62	9.14e-12	Body mass index in non-asthmatics;
THYM	cis	rs728616	0.867	rs118134654	chr10:81744381	G/A	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs295137	0.836	rs1217456	chr2:201092279	C/T	cg03447810	chr2:200324230	SATB2	0.62	4.73	0.44	7.92e-6	Asthma (bronchodilator response);
THYM	cis	rs2180341	0.842	rs9372860	chr6:127546605	G/A	cg24812749	chr6:127587940	RNF146	0.92	6.3	0.54	9.22e-9	Breast cancer;
THYM	cis	rs240764	0.584	rs11155653	chr6:101217123	G/A	cg21058520	chr6:100914733	NA	0.6	5.25	0.47	9.27e-7	Neuroticism;
THYM	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg08885076	chr2:99613938	TSGA10	0.62	5.67	0.5	1.5e-7	Chronic sinus infection;
THYM	cis	rs1395	0.744	rs11126929	chr2:27472027	C/T	cg23587288	chr2:27483067	SLC30A3	0.69	6.19	0.54	1.53e-8	Blood metabolite levels;
THYM	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg06981504	chr1:1234844	ACAP3	-0.51	-4.63	-0.43	1.14e-5	Body mass index;
THYM	cis	rs1629083	0.790	rs647573	chr11:118067132	C/T	cg18857871	chr11:118064634	AMICA1	0.44	4.68	0.43	9.48e-6	Lung cancer;
THYM	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11644478	chr21:40555479	PSMG1	0.9	6.61	0.56	2.2e-9	Cognitive function;
THYM	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg03213289	chr20:61660250	NA	0.9	9.37	0.69	3.59e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs13082711	0.911	rs11719386	chr3:27505636	G/C	cg02860705	chr3:27208620	NA	0.72	5.14	0.47	1.46e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg13695892	chr22:41940480	POLR3H	0.89	6.74	0.57	1.2e-9	Vitiligo;
THYM	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg10803722	chr21:46713166	LOC642852	-0.5	-6.16	-0.53	1.77e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg09359103	chr1:154839909	KCNN3	-0.72	-9.45	-0.7	2.44e-15	Prostate cancer;
THYM	cis	rs981844	0.775	rs17299211	chr4:154738284	G/A	cg09973105	chr4:154681532	RNF175	-0.62	-5.1	-0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs11997175	0.624	rs6996590	chr8:33680486	A/G	ch.8.33884649F	chr8:33765107	NA	0.66	5.0	0.46	2.57e-6	Body mass index;
THYM	cis	rs6480314	0.831	rs2166221	chr10:69982298	A/G	cg27159792	chr10:69524182	NA	-0.74	-4.75	-0.44	7.33e-6	Optic nerve measurement (disc area);
THYM	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg00666640	chr1:248458726	OR2T12	0.58	4.72	0.44	8.11e-6	Common traits (Other);
THYM	cis	rs2340727	0.604	rs3767637	chr1:161817024	C/A	cg06514368	chr1:161719587	DUSP12	-0.81	-4.62	-0.43	1.2e-5	White blood cell count;Hematology traits;
THYM	cis	rs10979	1.000	rs1416206	chr6:143889385	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs1417569	1.000	rs1417569	chr10:31101743	C/T	cg00941203	chr10:31016591	NA	0.35	4.45	0.42	2.3e-5	Tuberculosis;
THYM	cis	rs3126085	0.515	rs10888484	chr1:152352514	C/T	cg10321714	chr1:152280068	FLG	-0.64	-4.61	-0.43	1.25e-5	Atopic dermatitis;
THYM	cis	rs2708977	0.867	rs12717782	chr2:97254116	G/A	cg01950434	chr2:97203154	ARID5A	0.59	4.73	0.44	7.83e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs6867032	1.000	rs4975802	chr5:2019750	T/C	cg26168224	chr5:2018326	NA	1.3	15.43	0.85	1.28e-27	Gut microbiome composition (winter);
THYM	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg06197492	chr11:2016605	H19	0.54	4.7	0.43	8.7e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg21644426	chr2:191273491	MFSD6	0.78	6.38	0.55	6.52e-9	Pulse pressure;
THYM	cis	rs4474465	1.000	rs10899523	chr11:78190808	C/T	cg19901956	chr11:77921274	USP35	-0.61	-4.6	-0.43	1.3e-5	Alzheimer's disease (survival time);
THYM	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg12031863	chr16:4587854	C16orf5	0.46	4.96	0.45	3.09e-6	Schizophrenia;
THYM	cis	rs3892630	0.878	rs7246451	chr19:33209614	C/G	cg22928329	chr19:33183273	NUDT19	-0.77	-5.88	-0.52	6e-8	Red blood cell traits;
THYM	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.7	-4.79	-0.44	6.25e-6	Body mass index (adult);
THYM	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.27	-5.73	-0.51	1.2e-7	Obesity-related traits;
THYM	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg19346786	chr7:2764209	NA	-0.55	-4.79	-0.44	6.2e-6	Height;
THYM	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.25	5.24	0.47	9.82e-7	Obesity-related traits;
THYM	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg22508957	chr16:3507546	NAT15	0.7	7.9	0.63	4.94e-12	Tuberculosis;
THYM	cis	rs17030434	0.749	rs1125228	chr4:154769052	C/T	cg14289246	chr4:154710475	SFRP2	-0.67	-4.77	-0.44	6.78e-6	Electrocardiographic conduction measures;
THYM	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs870825	0.518	rs12512933	chr4:185665055	C/T	cg04058563	chr4:185651563	MLF1IP	1.06	7.44	0.61	4.54e-11	Blood protein levels;
THYM	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg07424592	chr7:64974309	NA	1.08	5.7	0.51	1.32e-7	Diabetic kidney disease;
THYM	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg18876405	chr7:65276391	NA	0.63	5.56	0.5	2.48e-7	Aortic root size;
THYM	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg22508957	chr16:3507546	NAT15	0.47	4.91	0.45	3.83e-6	Body mass index (adult);
THYM	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg18305652	chr10:134549665	INPP5A	0.79	6.5	0.55	3.69e-9	Migraine;
THYM	cis	rs8070624	0.502	rs12951376	chr17:17752809	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.61	5.16	0.47	1.33e-6	Total body bone mineral density;
THYM	cis	rs9902453	0.757	rs12453308	chr17:28441604	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	4.76	0.44	6.96e-6	Coffee consumption (cups per day);
THYM	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg05368731	chr17:41323189	NBR1	-1.2	-10.93	-0.75	1.72e-18	Menopause (age at onset);
THYM	cis	rs11792861	0.589	rs2176692	chr9:111927723	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	4.67	0.43	9.86e-6	Menarche (age at onset);
THYM	cis	rs11031096	0.711	rs12270809	chr11:4206537	G/A	cg08557956	chr11:4115526	RRM1	-0.55	-5.01	-0.46	2.53e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg08133631	chr1:26527909	CATSPER4	-0.55	-4.59	-0.43	1.34e-5	Obesity-related traits;
THYM	cis	rs6669072	0.647	rs698274	chr1:91244177	A/G	cg08895590	chr1:91227319	NA	-0.55	-6.75	-0.57	1.18e-9	Cognitive function;
THYM	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg24675658	chr1:53192096	ZYG11B	0.83	7.52	0.61	3.01e-11	Monocyte count;
THYM	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28595532	0.920	rs115744897	chr4:119749064	A/G	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs6921919	0.583	rs35560946	chr6:28395437	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.59	-4.53	-0.42	1.74e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg18811423	chr2:55921094	PNPT1	0.73	6.88	0.58	6.46e-10	Metabolic syndrome;
THYM	cis	rs9880211	0.948	rs13316214	chr3:136158221	A/G	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg05393297	chr12:53359155	NA	-0.61	-6.96	-0.58	4.45e-10	Cancer (pleiotropy);
THYM	cis	rs9992101	0.547	rs7654754	chr4:77409795	C/T	cg27417997	chr4:77356416	SHROOM3	-0.4	-4.79	-0.44	6.05e-6	Creatinine levels;
THYM	cis	rs11585357	0.895	rs72633814	chr1:17626456	T/C	cg08277548	chr1:17600880	PADI3	-0.88	-5.22	-0.47	1.05e-6	Hair shape;
THYM	trans	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs67460515	0.531	rs13060601	chr3:160823159	G/A	cg12349858	chr3:160822545	B3GALNT1	0.58	4.67	0.43	9.98e-6	Parkinson's disease;
THYM	cis	rs16866061	0.962	rs16866045	chr2:225413020	G/A	cg12698349	chr2:225449008	CUL3	1.14	10.45	0.73	1.77e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg26924012	chr15:45694286	SPATA5L1	1.02	9.12	0.68	1.27e-14	Homoarginine levels;
THYM	cis	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg12193833	chr17:30244370	NA	-0.7	-4.99	-0.46	2.78e-6	Hip circumference adjusted for BMI;
THYM	cis	rs244731	0.959	rs3105419	chr5:176551396	G/C	cg16006841	chr5:176797999	RGS14	0.53	6.04	0.53	2.96e-8	Urate levels in lean individuals;
THYM	cis	rs80319144	1.000	rs113144913	chr2:159290486	G/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs6495367	1.000	rs6495367	chr15:79375347	C/T	cg17916960	chr15:79447300	NA	0.54	5.96	0.52	4.35e-8	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg25358565	chr5:93447407	FAM172A	1.34	10.59	0.74	9.3e-18	Diabetic retinopathy;
THYM	cis	rs7973719	1.000	rs7973719	chr12:7334813	C/T	cg07052231	chr12:7363540	PEX5	0.62	5.52	0.49	2.97e-7	IgG glycosylation;
THYM	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg13918804	chr1:2043761	PRKCZ	-0.61	-4.62	-0.43	1.19e-5	Height;
THYM	cis	rs9595908	0.869	rs9595946	chr13:33203135	G/A	cg12383807	chr13:33924137	NA	-0.54	-4.73	-0.44	7.67e-6	Body mass index;
THYM	cis	rs10256972	0.552	rs6953538	chr7:1196974	A/G	cg23708337	chr7:1209742	NA	0.67	4.86	0.45	4.65e-6	Longevity;Endometriosis;
THYM	cis	rs7267979	0.873	rs6132822	chr20:25228695	C/T	cg08601574	chr20:25228251	PYGB	0.7	5.75	0.51	1.1e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg16928487	chr17:17741425	SREBF1	-0.55	-5.04	-0.46	2.21e-6	Total body bone mineral density;
THYM	cis	rs4660306	0.744	rs11583290	chr1:45926363	C/T	cg03123370	chr1:45965343	CCDC163P;MMACHC	0.61	4.53	0.42	1.73e-5	Homocysteine levels;
THYM	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg13010199	chr12:38710504	ALG10B	0.71	5.49	0.49	3.34e-7	Heart rate;
THYM	cis	rs9814567	1.000	rs1814337	chr3:134200682	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-8.14	-0.64	1.56e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs929596	0.755	rs4148324	chr2:234672722	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.89	-7.26	-0.6	1.08e-10	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.01	-10.05	-0.72	1.29e-16	Primary sclerosing cholangitis;
THYM	cis	rs6754311	0.550	rs12994270	chr2:136518103	T/A	cg20242066	chr2:136595261	LCT	-0.57	-6.93	-0.58	4.9e-10	Mosquito bite size;
THYM	cis	rs944002	1.000	rs72706640	chr14:103569748	T/C	cg16996574	chr14:103691482	NA	0.51	4.69	0.43	9.23e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;
THYM	cis	rs8106657	1.000	rs2335525	chr19:7785713	A/G	cg10162210	chr19:7852238	CLEC4GP1	-0.49	-5.02	-0.46	2.36e-6	Blood protein levels;
THYM	cis	rs4262150	0.883	rs72804786	chr5:152317799	G/A	cg06854687	chr5:151642065	NA	0.68	4.86	0.45	4.58e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4731207	0.533	rs1481340	chr7:124582051	C/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs1747683	0.966	rs10796059	chr10:13368987	T/C	cg00142036	chr10:13388442	SEPHS1	-0.29	-5.17	-0.47	1.27e-6	IgG glycosylation;
THYM	cis	rs4660306	1.000	rs2077808	chr1:45988115	G/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.43	-0.49	4.37e-7	Homocysteine levels;
THYM	cis	rs6840360	0.642	rs10454251	chr4:152383962	A/G	cg17479576	chr4:152424074	FAM160A1	-0.67	-5.07	-0.46	1.98e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg25566285	chr7:158114605	PTPRN2	0.95	12.11	0.78	5.62e-21	Calcium levels;
THYM	cis	rs10904908	0.931	rs7903137	chr10:17259567	C/T	cg01003015	chr10:17271136	VIM	-0.6	-5.22	-0.47	1.06e-6	Total cholesterol levels;Cholesterol, total;
THYM	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg05147244	chr20:61493195	TCFL5	-1.0	-6.03	-0.53	3.18e-8	Obesity-related traits;
THYM	cis	rs6450176	0.564	rs6874524	chr5:53343529	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.87	7.53	0.61	2.85e-11	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2085601	0.542	rs1398947	chr4:89963824	C/T	cg17769793	chr4:89976368	FAM13A	-0.59	-6.86	-0.58	6.96e-10	Hair greying;
THYM	cis	rs899997	1.000	rs11633170	chr15:79004642	A/G	cg04896959	chr15:78267971	NA	-0.99	-7.17	-0.59	1.64e-10	Coronary artery disease or large artery stroke;
THYM	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg12893697	chr11:970389	AP2A2	-0.31	-5.15	-0.47	1.42e-6	Alzheimer's disease (late onset);
THYM	cis	rs2637266	0.538	rs2130800	chr10:78274818	C/T	cg18941641	chr10:78392320	NA	-0.61	-5.01	-0.46	2.5e-6	Pulmonary function;
THYM	cis	rs9796	0.870	rs2925346	chr15:41315695	G/A	cg21153102	chr15:41252147	NA	-0.68	-6.12	-0.53	2.08e-8	Menopause (age at onset);
THYM	cis	rs965469	1.000	rs6051838	chr20:3389012	A/C	cg25506879	chr20:3388711	C20orf194	-0.78	-4.45	-0.42	2.35e-5	IFN-related cytopenia;
THYM	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.67	-4.68	-0.43	9.41e-6	Aortic root size;
THYM	cis	rs1843834	0.755	rs10192196	chr2:225577135	C/T	cg22455342	chr2:225449267	CUL3	0.57	4.5	0.42	1.91e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs288326	0.561	rs77460513	chr2:183819625	C/T	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs7688540	0.511	rs11731927	chr4:174105	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.93	5.62	0.5	1.93e-7	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9595908	0.827	rs9595885	chr13:33168050	G/A	cg12383807	chr13:33924137	NA	-0.54	-4.68	-0.43	9.67e-6	Body mass index;
THYM	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg12292205	chr6:26970375	C6orf41	0.58	4.84	0.44	5.12e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg01097406	chr16:89675127	NA	0.84	7.48	0.61	3.68e-11	Vitiligo;
THYM	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6032067	0.636	rs6032092	chr20:43911886	A/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.63	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs4731207	0.562	rs6466991	chr7:124691966	T/G	cg05285228	chr7:124571219	POT1	-0.63	-4.76	-0.44	6.82e-6	Cutaneous malignant melanoma;
THYM	cis	rs8106542	0.906	rs8108741	chr19:10739073	G/A	cg17848348	chr19:10766748	ILF3	-0.81	-6.67	-0.56	1.7e-9	Platelet distribution width;
THYM	cis	rs9527	0.590	rs2148198	chr10:104915310	A/G	cg04362960	chr10:104952993	NT5C2	-0.68	-5.21	-0.47	1.08e-6	Arsenic metabolism;
THYM	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg06808227	chr14:105710500	BRF1	-1.02	-8.85	-0.67	4.76e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs17407555	0.821	rs55919137	chr4:10133803	C/A	cg00071950	chr4:10020882	SLC2A9	-0.74	-5.44	-0.49	4.18e-7	Schizophrenia (age at onset);
THYM	cis	rs1483890	0.605	rs1483889	chr3:69413324	A/G	cg22125112	chr3:69402811	FRMD4B	0.39	5.03	0.46	2.3e-6	Resting heart rate;
THYM	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	9.56	0.7	1.47e-15	Platelet count;
THYM	cis	rs236907	0.859	rs12730717	chr1:171756515	C/T	cg20598894	chr1:171756153	METTL13	-0.74	-5.59	-0.5	2.16e-7	Mean platelet volume;
THYM	cis	rs8067545	0.611	rs733794	chr17:20157957	T/C	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs6558530	0.965	rs730377	chr8:1707951	G/A	cg09410841	chr8:1729607	CLN8	0.75	5.76	0.51	1.05e-7	Systolic blood pressure;
THYM	cis	rs2404602	0.622	rs9635380	chr15:77103479	A/G	cg23625390	chr15:77176239	SCAPER	-0.87	-6.12	-0.53	2.05e-8	Blood metabolite levels;
THYM	cis	rs4731207	0.591	rs11772336	chr7:124589796	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs4713118	0.955	rs9468206	chr6:27690453	G/T	cg08968635	chr6:28129556	ZNF389	0.69	5.18	0.47	1.22e-6	Parkinson's disease;
THYM	cis	rs7772486	0.534	rs34541797	chr6:146205304	A/G	cg05347473	chr6:146136440	FBXO30	0.81	7.21	0.59	1.34e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs422249	0.512	rs174566	chr11:61592362	A/G	cg19610905	chr11:61596333	FADS2	-0.61	-5.17	-0.47	1.3e-6	Trans fatty acid levels;
THYM	cis	rs56161922	0.749	rs3738469	chr1:207818422	G/A	cg09557387	chr1:207818395	CR1L	1.15	5.27	0.48	8.55e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs7772486	0.902	rs2777480	chr6:146309983	T/A	cg23711669	chr6:146136114	FBXO30	0.87	8.52	0.66	2.36e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg00383909	chr3:49044727	WDR6	1.09	5.67	0.5	1.52e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs12681287	0.752	rs1080170	chr8:87310108	C/T	cg27223183	chr8:87520930	FAM82B	-0.68	-5.19	-0.47	1.2e-6	Caudate activity during reward;
THYM	cis	rs4285028	0.948	rs34543553	chr3:121675637	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg22117172	chr7:91764530	CYP51A1	0.39	5.07	0.46	1.99e-6	Breast cancer;
THYM	cis	rs8038465	0.622	rs2509	chr15:73859488	A/T	cg15420318	chr15:73925796	NPTN	-0.61	-5.26	-0.48	8.8e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg02269571	chr22:50332266	NA	-1.16	-6.15	-0.53	1.81e-8	Schizophrenia;
THYM	cis	rs752010	0.841	rs6661784	chr1:42080312	A/T	cg06885757	chr1:42089581	HIVEP3	0.47	5.27	0.48	8.47e-7	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs67460515	0.531	rs1585483	chr3:160843111	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-4.68	-0.43	9.48e-6	Parkinson's disease;
THYM	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg18252515	chr7:66147081	NA	-1.56	-8.47	-0.66	3e-13	Diabetic kidney disease;
THYM	cis	rs7631605	0.647	rs59594366	chr3:37173774	A/C	cg21328643	chr3:37258149	NA	-0.48	-4.61	-0.43	1.25e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs10779751	0.610	rs2486921	chr1:11124943	G/A	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs10009206	chr4:99056900	A/C	cg24818145	chr4:99064322	C4orf37	-0.77	-6.07	-0.53	2.6e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6032067	0.641	rs17423617	chr20:43768050	G/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.73	-7.71	-0.62	1.23e-11	Blood protein levels;
THYM	cis	rs4731207	0.698	rs7793441	chr7:124536238	A/G	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs2108622	0.958	rs56340170	chr19:15981877	G/C	cg13772218	chr19:15982569	NA	0.6	5.2	0.47	1.14e-6	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs2011503	0.941	rs55822665	chr19:19383298	C/T	cg02887458	chr19:19495540	GATAD2A	-0.44	-5.16	-0.47	1.33e-6	Bipolar disorder;
THYM	cis	rs1018836	0.923	rs4735230	chr8:91574184	G/C	cg16814680	chr8:91681699	NA	-0.78	-6.45	-0.55	4.73e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4363385	0.747	rs6704105	chr1:152964397	C/G	cg04546999	chr1:152956429	SPRR1A	-0.46	-4.54	-0.42	1.63e-5	Inflammatory skin disease;
THYM	trans	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg25517755	chr10:38738941	LOC399744	-0.77	-7.48	-0.61	3.65e-11	Corneal astigmatism;
THYM	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg03060546	chr3:49711283	APEH	-0.67	-5.08	-0.46	1.85e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg03929089	chr4:120376271	NA	-0.76	-6.96	-0.58	4.35e-10	Coronary artery disease;
THYM	cis	rs2456568	0.741	rs10831137	chr11:93636912	C/T	cg17595323	chr11:93583763	C11orf90	-0.58	-6.09	-0.53	2.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs13256369	1.000	rs10098234	chr8:8576692	G/A	cg00074818	chr8:8560427	CLDN23	0.57	5.35	0.48	6e-7	Obesity-related traits;
THYM	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs295140	1.000	rs7599609	chr2:201177653	G/A	cg04283868	chr2:201171347	SPATS2L	0.74	5.53	0.49	2.81e-7	QT interval;
THYM	cis	rs7100689	0.622	rs2342816	chr10:82086546	G/A	cg01528321	chr10:82214614	TSPAN14	0.84	6.43	0.55	5.15e-9	Post bronchodilator FEV1;
THYM	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg07636037	chr3:49044803	WDR6	0.98	10.15	0.72	8.06e-17	Parkinson's disease;
THYM	cis	rs6842789	0.510	rs2390616	chr4:124891343	C/T	cg01723706	chr4:124814442	LOC285419	0.75	4.7	0.43	8.94e-6	Neuroticism;
THYM	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg05043794	chr9:111880884	C9orf5	-0.43	-6.35	-0.55	7.29e-9	Menarche (age at onset);
THYM	cis	rs740474	0.831	rs1479585	chr5:140976528	G/C	cg24137543	chr5:140893634	NA	0.51	6.08	0.53	2.5e-8	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg18681998	chr4:17616180	MED28	-0.84	-7.05	-0.59	2.85e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg17143192	chr8:8559678	CLDN23	0.64	4.74	0.44	7.51e-6	Mood instability;
THYM	cis	rs7781977	0.669	rs7791218	chr7:50353627	G/A	cg01139861	chr7:50343298	IKZF1	0.62	5.9	0.52	5.47e-8	IgG glycosylation;
THYM	cis	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg21110456	chr7:2059412	MAD1L1	-0.44	-4.67	-0.43	9.74e-6	Bipolar disorder;
THYM	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg06481639	chr22:41940642	POLR3H	-0.83	-6.13	-0.53	2e-8	Vitiligo;
THYM	trans	rs9929218	0.581	rs12185157	chr16:68784587	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.01	10.95	0.75	1.55e-18	Colorectal cancer;
THYM	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg13581527	chr7:1708566	NA	-0.75	-5.22	-0.47	1.03e-6	Multiple sclerosis;
THYM	cis	rs250585	0.736	rs250583	chr16:23403510	A/G	cg00143387	chr16:23521605	GGA2	-0.69	-4.84	-0.44	5.05e-6	Egg allergy;
THYM	cis	rs7119	0.931	rs7176875	chr15:77832675	A/G	cg27398640	chr15:77910606	LINGO1	0.52	5.14	0.47	1.46e-6	Type 2 diabetes;
THYM	cis	rs13082711	0.522	rs515402	chr3:27331022	G/T	cg02860705	chr3:27208620	NA	0.65	5.09	0.46	1.79e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg06634786	chr22:41940651	POLR3H	-0.73	-5.33	-0.48	6.69e-7	Vitiligo;
THYM	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	-0.46	-5.84	-0.51	7.33e-8	Monocyte percentage of white cells;
THYM	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg09904177	chr6:26538194	HMGN4	0.64	5.41	0.49	4.64e-7	Intelligence (multi-trait analysis);
THYM	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08109568	chr15:31115862	NA	-0.78	-6.5	-0.55	3.66e-9	Huntington's disease progression;
THYM	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg26924012	chr15:45694286	SPATA5L1	0.66	4.86	0.45	4.65e-6	Response to fenofibrate (adiponectin levels);
THYM	cis	rs757081	0.667	rs569780	chr11:17206745	C/T	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.6	-0.43	1.29e-5	Systolic blood pressure;
THYM	cis	rs17253792	0.822	rs79921041	chr14:56090779	T/C	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1957429	0.808	rs9783609	chr14:65352282	A/G	cg23373153	chr14:65346875	NA	1.07	6.45	0.55	4.75e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs11785693	0.862	rs6995565	chr8:4990461	C/T	cg26367366	chr8:4980734	NA	-1.05	-5.1	-0.46	1.72e-6	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs7106204	0.534	rs1443050	chr11:24275162	C/T	ch.11.24196551F	chr11:24239977	NA	0.92	4.75	0.44	7.06e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs870825	0.860	rs72689297	chr4:185600957	A/T	cg04058563	chr4:185651563	MLF1IP	1.05	7.96	0.63	3.6e-12	Blood protein levels;
THYM	cis	rs61931739	0.929	rs10844748	chr12:34092930	G/T	cg10856724	chr12:34555212	NA	0.62	5.39	0.48	5.06e-7	Morning vs. evening chronotype;
THYM	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg07061783	chr6:25882402	NA	-1.05	-9.22	-0.69	7.65e-15	Intelligence (multi-trait analysis);
THYM	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.79	-6.79	-0.57	9.74e-10	Lung cancer;
THYM	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg06481639	chr22:41940642	POLR3H	0.86	5.47	0.49	3.6e-7	Vitiligo;
THYM	cis	rs7107174	0.579	rs10793299	chr11:78018954	T/A	cg19901956	chr11:77921274	USP35	-0.74	-5.57	-0.5	2.39e-7	Testicular germ cell tumor;
THYM	cis	rs11771526	0.901	rs62457468	chr7:32301341	C/T	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7089973	0.604	rs11196939	chr10:116593175	A/G	cg23260525	chr10:116636907	FAM160B1	-0.52	-5.12	-0.47	1.58e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg20503657	chr10:835505	NA	1.14	7.96	0.63	3.64e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs2625529	0.761	rs3743224	chr15:72466799	C/T	cg16672083	chr15:72433130	SENP8	-0.56	-4.99	-0.46	2.73e-6	Red blood cell count;
THYM	cis	rs12765878	0.934	rs58543155	chr10:105643244	G/A	cg11005552	chr10:105648138	OBFC1	0.85	11.02	0.75	1.12e-18	Coronary artery disease;
THYM	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.36	0.69	3.89e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs4654899	0.758	rs7556221	chr1:21455559	C/G	cg01072550	chr1:21505969	NA	-0.79	-7.73	-0.62	1.11e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs3781684	1.000	rs875874	chr11:76834616	G/A	cg08036798	chr11:76839191	MYO7A	0.76	4.5	0.42	1.9e-5	Cognitive performance;
THYM	cis	rs6542838	0.583	rs7565819	chr2:99519265	C/T	cg08885076	chr2:99613938	TSGA10	-0.5	-4.66	-0.43	1.03e-5	Fear of minor pain;
THYM	cis	rs10782582	0.593	rs12142247	chr1:76235746	C/T	cg22875332	chr1:76189707	ACADM	-0.53	-4.69	-0.43	9.07e-6	Daytime sleep phenotypes;
THYM	cis	rs12310956	0.527	rs10772117	chr12:33900096	C/T	cg10856724	chr12:34555212	NA	-0.64	-5.71	-0.51	1.28e-7	Morning vs. evening chronotype;
THYM	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg23982607	chr1:1823379	GNB1	-0.9	-9.11	-0.68	1.32e-14	Body mass index;
THYM	cis	rs2859741	0.565	rs12031540	chr1:37513757	C/T	cg09363841	chr1:37513479	NA	-0.74	-6.36	-0.55	7.1e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg06481639	chr22:41940642	POLR3H	0.72	4.68	0.43	9.65e-6	Vitiligo;
THYM	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg21394778	chr1:3037102	PRDM16	0.46	4.47	0.42	2.12e-5	Height;
THYM	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg26513180	chr16:89883248	FANCA	-0.46	-4.45	-0.42	2.33e-5	Vitiligo;
THYM	cis	rs10463554	0.927	rs185387	chr5:102420019	T/C	cg23492399	chr5:102201601	PAM	-0.69	-5.17	-0.47	1.27e-6	Parkinson's disease;
THYM	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.26	-9.1	-0.68	1.4e-14	Gut microbiome composition (summer);
THYM	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg26769984	chr7:1090371	C7orf50	0.64	4.94	0.45	3.31e-6	Bronchopulmonary dysplasia;
THYM	cis	rs860818	1.000	rs858238	chr7:23239133	C/T	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs7364180	0.515	rs6002503	chr22:42208672	A/G	cg03806693	chr22:41940476	POLR3H	-0.61	-4.69	-0.43	9.07e-6	Alzheimer's disease biomarkers;
THYM	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	6.71	0.57	1.37e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg08017756	chr2:100939284	LONRF2	-0.71	-7.59	-0.61	2.17e-11	Intelligence (multi-trait analysis);
THYM	cis	rs13102973	0.899	rs4643872	chr4:135901432	A/G	cg14419869	chr4:135874104	NA	0.82	6.86	0.58	7.03e-10	Subjective well-being;
THYM	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg08999081	chr20:33150536	PIGU	0.8	7.37	0.6	6.23e-11	Coronary artery disease;
THYM	cis	rs4731207	0.596	rs10228686	chr7:124663086	G/A	cg05285228	chr7:124571219	POT1	-0.6	-4.52	-0.42	1.76e-5	Cutaneous malignant melanoma;
THYM	cis	rs7172809	0.587	rs75238644	chr15:77848578	C/T	cg22256960	chr15:77711686	NA	-0.79	-5.72	-0.51	1.25e-7	Glucose homeostasis traits;
THYM	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.6	-0.5	2.08e-7	Type 2 diabetes;
THYM	cis	rs1335645	0.570	rs10494127	chr1:111671783	A/C	cg00321911	chr1:111669324	DRAM2	-1.26	-7.24	-0.6	1.15e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4789939	0.851	rs2009187	chr17:76870675	A/G	cg26927190	chr17:76875678	TIMP2	-0.86	-5.45	-0.49	4.02e-7	Dupuytren's disease;
THYM	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs4788570	0.667	rs4788557	chr16:71804802	C/T	cg06353428	chr16:71660113	MARVELD3	1.41	8.69	0.67	1.03e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg11663144	chr21:46675770	NA	-0.72	-10.17	-0.72	7.22e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9902453	0.817	rs17226179	chr17:28168573	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.79	0.44	6.07e-6	Coffee consumption (cups per day);
THYM	cis	rs6430585	0.528	rs75753154	chr2:136665711	T/C	cg20242066	chr2:136595261	LCT	0.51	4.9	0.45	3.9e-6	Corneal structure;
THYM	cis	rs7592578	1.000	rs7592578	chr2:191439591	T/G	cg11845111	chr2:191398756	TMEM194B	1.0	7.65	0.62	1.66e-11	Diastolic blood pressure;
THYM	cis	rs3126085	0.867	rs36033453	chr1:152221226	T/G	cg10321714	chr1:152280068	FLG	-0.69	-4.92	-0.45	3.67e-6	Atopic dermatitis;
THYM	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg06728252	chr6:26598149	ABT1	-0.43	-5.11	-0.46	1.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.18	8.91	0.67	3.51e-14	Cognitive test performance;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg25953958	chr17:8485965	MYH10	-0.96	-7.13	-0.59	1.96e-10	Depressive symptoms;
THYM	cis	rs7200543	0.666	rs34955778	chr16:15139594	T/C	cg01933576	chr16:15083564	PDXDC1	-0.81	-6.14	-0.53	1.92e-8	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs775227	0.574	rs34286076	chr3:113269695	G/C	cg18753928	chr3:113234510	CCDC52	-0.76	-5.25	-0.47	9.11e-7	Dental caries;
THYM	cis	rs9972944	0.756	rs6416945	chr17:63763942	G/A	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg16586182	chr3:47516702	SCAP	0.65	5.53	0.49	2.84e-7	Colorectal cancer;
THYM	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.55	-5.23	-0.47	1e-6	Lymphocyte counts;
THYM	cis	rs208520	0.802	rs208499	chr6:66932146	C/T	cg07460842	chr6:66804631	NA	-0.78	-5.05	-0.46	2.16e-6	Exhaled nitric oxide output;
THYM	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.02	-9.52	-0.7	1.73e-15	Primary sclerosing cholangitis;
THYM	cis	rs5769707	0.740	rs79946167	chr22:50017556	G/A	cg23428387	chr22:49814324	NA	-0.58	-5.86	-0.52	6.76e-8	Monocyte count;Monocyte percentage of white cells;
THYM	trans	rs877282	0.898	rs10904546	chr10:757222	A/G	cg22713356	chr15:30763199	NA	1.35	9.87	0.71	3.11e-16	Uric acid levels;
THYM	cis	rs911555	0.570	rs752624	chr14:104020454	T/C	cg24130564	chr14:104152367	KLC1	-0.63	-5.3	-0.48	7.52e-7	Intelligence (multi-trait analysis);
THYM	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg12863693	chr15:85201151	NMB	0.65	5.9	0.52	5.46e-8	Schizophrenia;
THYM	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg16486109	chr11:613632	IRF7	0.47	5.59	0.5	2.19e-7	Systemic lupus erythematosus;
THYM	cis	rs35883536	0.506	rs2809814	chr1:101031829	C/T	cg09408571	chr1:101003634	GPR88	0.52	5.68	0.5	1.44e-7	Monocyte count;
THYM	cis	rs11031096	0.782	rs4910889	chr11:4153231	T/C	cg18678763	chr11:4115507	RRM1	-0.38	-5.17	-0.47	1.27e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs6598955	0.543	rs60676610	chr1:26543421	G/C	cg04990556	chr1:26633338	UBXN11	0.96	6.06	0.53	2.7e-8	Obesity-related traits;
THYM	cis	rs6430585	0.591	rs12477421	chr2:136433740	A/G	cg23851026	chr2:136556271	LCT	0.65	5.55	0.49	2.59e-7	Corneal structure;
THYM	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg27494647	chr7:150038898	RARRES2	0.47	5.68	0.5	1.47e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.77	0.82	2.32e-24	Height;
THYM	cis	rs6840360	1.000	rs2007445	chr4:152600370	C/T	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2070488	0.965	rs3762791	chr3:38568828	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-6.55	-0.56	2.97e-9	Electrocardiographic conduction measures;
THYM	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg00101154	chr16:420108	MRPL28	0.34	4.73	0.44	7.76e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs7578361	0.918	rs16827089	chr2:150344259	A/G	cg17961725	chr2:150454027	NA	-0.77	-5.69	-0.5	1.43e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9467711	0.651	rs17526722	chr6:25918855	G/A	cg16898833	chr6:26189333	HIST1H4D	1.33	4.61	0.43	1.28e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg22681709	chr2:178499509	PDE11A	-0.51	-4.51	-0.42	1.87e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg20283391	chr11:68216788	NA	-0.74	-5.43	-0.49	4.25e-7	Total body bone mineral density;
THYM	cis	rs6032067	0.929	rs35475980	chr20:43821080	A/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs2299587	0.531	rs28839855	chr8:17855983	T/C	cg01800426	chr8:17659068	MTUS1	-0.7	-5.09	-0.46	1.78e-6	Economic and political preferences;
THYM	cis	rs7408868	1.000	rs4809029	chr19:15273248	A/C	cg14696996	chr19:15285081	NOTCH3	0.99	5.63	0.5	1.81e-7	Pulse pressure;
THYM	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg26168224	chr5:2018326	NA	-0.88	-6.41	-0.55	5.53e-9	Gut microbiome composition (winter);
THYM	cis	rs2046867	0.818	rs60228315	chr3:72805034	C/A	cg25664220	chr3:72788482	NA	-0.89	-6.78	-0.57	9.92e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg24102700	chr17:3721585	C17orf85	-1.0	-7.7	-0.62	1.27e-11	Depressive symptoms;
THYM	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg20302533	chr7:39170763	POU6F2	0.63	4.66	0.43	1.05e-5	IgG glycosylation;
THYM	cis	rs4606347	0.789	rs61780872	chr1:66164536	A/C	cg04111102	chr1:66153794	NA	0.67	5.35	0.48	6.08e-7	Cerebrospinal fluid biomarker levels;
THYM	cis	rs10744422	0.925	rs2061098	chr12:123349410	T/C	cg25930673	chr12:123319894	HIP1R	-0.83	-4.87	-0.45	4.45e-6	Schizophrenia;
THYM	cis	rs7631605	0.905	rs9869432	chr3:37196601	A/G	cg21328643	chr3:37258149	NA	-0.52	-4.95	-0.45	3.21e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg20295408	chr7:1910781	MAD1L1	-0.62	-4.98	-0.46	2.8e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs1267303	0.637	rs1745371	chr1:46985192	C/T	cg16387850	chr1:46982889	NA	-0.44	-5.6	-0.5	2.04e-7	Monobrow;
THYM	cis	rs889398	0.741	rs7193038	chr16:69926134	T/G	cg09409435	chr16:70099608	PDXDC2	0.63	4.89	0.45	4.04e-6	Body mass index;
THYM	cis	rs10889850	0.675	rs1796964	chr1:70215029	C/T	cg01711146	chr1:70671364	SFRS11;LRRC40	0.76	4.48	0.42	2.1e-5	Body mass index;
THYM	cis	rs12142240	0.698	rs66972124	chr1:46807445	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs9677476	0.863	rs2006780	chr2:232066704	T/G	cg23338755	chr2:231921595	PSMD1	0.72	5.43	0.49	4.31e-7	Food antigen IgG levels;
THYM	cis	rs72829446	0.530	rs2228132	chr17:7411770	C/T	cg02795151	chr17:7402630	POLR2A	0.49	4.68	0.43	9.62e-6	Androgen levels;
THYM	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg24375607	chr4:120327624	NA	0.7	5.63	0.5	1.82e-7	Corneal astigmatism;
THYM	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg11812906	chr14:75593930	NEK9	-0.79	-6.99	-0.58	3.86e-10	Height;
THYM	cis	rs6987853	0.749	rs13250124	chr8:42404737	G/A	cg09913449	chr8:42400586	C8orf40	1.1	12.33	0.78	1.96e-21	Mean corpuscular hemoglobin concentration;
THYM	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg02725872	chr8:58115012	NA	-0.71	-5.22	-0.47	1.05e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7843479	0.601	rs878873	chr8:21834581	T/C	cg17168535	chr8:21777572	XPO7	0.93	8.61	0.66	1.51e-13	Mean corpuscular volume;
THYM	cis	rs7656342	0.607	rs7669444	chr4:9893577	A/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-4.48	-0.42	2.11e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs4654899	0.743	rs61781069	chr1:21130735	T/C	cg01072550	chr1:21505969	NA	-0.69	-6.04	-0.53	3.01e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs1150668	0.796	rs2247002	chr6:28397951	G/C	cg13525197	chr6:28411240	ZSCAN23	-0.67	-5.35	-0.48	5.95e-7	Pubertal anthropometrics;
THYM	cis	rs793108	0.804	rs1538981	chr10:31411355	C/T	cg07137701	chr10:31611868	ZEB1	-0.51	-4.82	-0.44	5.47e-6	Multiple sclerosis;Rheumatoid arthritis;
THYM	cis	rs858239	0.730	rs858279	chr7:23251005	T/C	cg05407003	chr7:23246146	NA	-0.69	-5.54	-0.49	2.74e-7	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7772486	0.875	rs9390377	chr6:146386932	G/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.63	5.38	0.48	5.35e-7	Lung disease severity in cystic fibrosis;
THYM	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06481639	chr22:41940642	POLR3H	0.8	5.63	0.5	1.81e-7	Vitiligo;
THYM	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2109514	1.000	rs2270188	chr7:116140524	G/T	cg12739419	chr7:116140593	CAV2	-0.48	-4.65	-0.43	1.09e-5	Prevalent atrial fibrillation;
THYM	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg13393036	chr8:95962371	TP53INP1	-0.48	-4.72	-0.44	8.22e-6	Type 2 diabetes;
THYM	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg15242686	chr22:24348715	GSTTP1	-0.56	-5.1	-0.46	1.72e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7771547	0.573	rs629721	chr6:36398229	T/C	cg07856975	chr6:36356162	ETV7	0.52	4.72	0.44	8.26e-6	Platelet distribution width;
THYM	cis	rs28476539	0.640	rs7672496	chr4:83554988	G/A	cg10249074	chr4:83542146	C4orf11	-0.64	-5.06	-0.46	2.03e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs6430585	0.878	rs9677760	chr2:136538939	T/A	cg20242066	chr2:136595261	LCT	-0.52	-5.13	-0.47	1.51e-6	Corneal structure;
THYM	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03517284	chr6:25882590	NA	-0.83	-6.4	-0.55	5.75e-9	Blood metabolite levels;
THYM	cis	rs1697139	0.935	rs1625369	chr5:66513022	C/T	cg11553311	chr5:66541588	NA	0.48	5.12	0.46	1.61e-6	Breast cancer;
THYM	cis	rs9992101	0.532	rs1986734	chr4:77420784	C/T	cg20311846	chr4:77356250	SHROOM3	-0.58	-6.55	-0.56	2.89e-9	Creatinine levels;
THYM	cis	rs4430311	0.688	rs12142652	chr1:243953583	A/G	cg25706552	chr1:244017396	NA	-0.6	-5.17	-0.47	1.32e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs12931792	0.712	rs2887799	chr16:30163833	G/A	cg17640201	chr16:30407289	ZNF48	0.62	5.03	0.46	2.31e-6	Tonsillectomy;
THYM	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	7.11	0.59	2.1e-10	Platelet count;
THYM	cis	rs2702888	0.503	rs2702931	chr8:6758979	A/C	cg03082247	chr8:6756796	NA	-0.6	-5.07	-0.46	1.96e-6	Blood pressure;
THYM	cis	rs714031	0.902	rs4820388	chr22:40070642	C/G	cg21377881	chr22:40064566	CACNA1I	-0.62	-5.3	-0.48	7.65e-7	Schizophrenia;
THYM	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.31	8.7	0.67	9.92e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6430585	0.583	rs2322813	chr2:136582809	A/G	cg07169764	chr2:136633963	MCM6	1.2	12.81	0.8	2.08e-22	Corneal structure;
THYM	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg03476357	chr21:30257390	N6AMT1	-0.6	-4.55	-0.42	1.58e-5	Dental caries;
THYM	cis	rs2964802	0.505	rs13179252	chr5:10805662	A/G	cg14521931	chr5:10832172	NA	-0.62	-5.2	-0.47	1.13e-6	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg18876405	chr7:65276391	NA	0.54	4.62	0.43	1.2e-5	Aortic root size;
THYM	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg20607798	chr8:58055168	NA	0.82	6.28	0.54	1.02e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg17426766	chr1:2046864	PRKCZ	-0.44	-5.07	-0.46	1.97e-6	Height;
THYM	cis	rs2235649	0.798	rs9932875	chr16:1848012	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-4.78	-0.44	6.27e-6	Blood metabolite levels;
THYM	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg17143192	chr8:8559678	CLDN23	-0.57	-4.53	-0.42	1.68e-5	Mood instability;
THYM	cis	rs9326248	0.530	rs2075292	chr11:116732512	G/T	cg01368799	chr11:117014884	PAFAH1B2	0.92	5.28	0.48	8.11e-7	Blood protein levels;
THYM	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg10802521	chr3:52805072	NEK4	-0.55	-4.65	-0.43	1.06e-5	Electroencephalogram traits;
THYM	cis	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg16524733	chr11:117070046	TAGLN	0.42	4.49	0.42	2.02e-5	Blood protein levels;
THYM	cis	rs7089973	0.872	rs7909566	chr10:116629136	A/G	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.14	-0.47	1.5e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9470366	1.000	rs9470366	chr6:36625562	C/T	cg11920449	chr6:36645608	CDKN1A	-0.68	-5.16	-0.47	1.37e-6	QRS duration;
THYM	cis	rs733592	0.929	rs4760678	chr12:48461581	T/C	cg21466736	chr12:48725269	NA	0.48	5.29	0.48	7.82e-7	Plateletcrit;
THYM	trans	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg10856724	chr12:34555212	NA	-1.01	-9.32	-0.69	4.76e-15	Bladder cancer;
THYM	cis	rs7011507	0.700	rs72639012	chr8:49332429	G/A	cg08774009	chr8:49309094	NA	-0.62	-4.83	-0.44	5.19e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg11245990	chr11:68621969	NA	0.55	6.85	0.57	7.33e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6733011	0.628	rs10188156	chr2:99465875	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.56	-0.42	1.54e-5	Bipolar disorder;
THYM	cis	rs12802200	0.535	rs12282299	chr11:570009	T/C	cg03909863	chr11:638404	DRD4	-0.63	-4.46	-0.42	2.22e-5	Systemic lupus erythematosus;
THYM	cis	rs600806	0.751	rs7551176	chr1:109961965	C/T	cg23616212	chr1:109941201	SORT1	-0.5	-4.78	-0.44	6.34e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8040855	1.000	rs6496768	chr15:85702932	A/G	cg04831495	chr15:85060580	GOLGA6L5	0.6	4.81	0.44	5.75e-6	Bulimia nervosa;
THYM	cis	rs1971256	0.500	rs6925359	chr6:151798783	A/G	cg25855249	chr6:151646817	AKAP12	0.8	4.52	0.42	1.8e-5	Endometriosis;
THYM	cis	rs7103648	0.695	rs10838726	chr11:47568344	C/G	cg20307385	chr11:47447363	PSMC3	0.88	6.93	0.58	5.09e-10	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs728616	0.557	rs17107449	chr10:81715696	C/T	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg24675658	chr1:53192096	ZYG11B	0.78	7.02	0.58	3.33e-10	Monocyte count;
THYM	cis	rs4866334	0.867	rs76734676	chr5:18487735	G/T	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs6732160	0.588	rs1430344	chr2:73373344	G/A	cg24220031	chr2:73402428	NA	-0.71	-5.79	-0.51	8.94e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2307394	1.000	rs2113793	chr2:148623453	T/G	cg02093647	chr2:148602395	ACVR2A	-0.6	-4.47	-0.42	2.2e-5	Urate levels;
THYM	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg25358565	chr5:93447407	FAM172A	-0.95	-6.68	-0.57	1.64e-9	Diabetic retinopathy;
THYM	cis	rs2913737	0.530	rs2913901	chr5:175926746	G/C	cg27658698	chr5:175955578	RNF44	0.59	4.66	0.43	1.03e-5	Obesity-related traits;
THYM	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	7.35	0.6	6.79e-11	Platelet count;
THYM	cis	rs34734847	1.000	rs2948149	chr12:121162854	T/G	cg21892295	chr12:121157589	UNC119B	-0.59	-6.39	-0.55	6.01e-9	Mean corpuscular volume;
THYM	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg13695892	chr22:41940480	POLR3H	-0.95	-8.3	-0.65	7.08e-13	Vitiligo;
THYM	cis	rs6430585	0.583	rs3769012	chr2:136556480	C/T	cg07169764	chr2:136633963	MCM6	1.19	13.9	0.82	1.26e-24	Corneal structure;
THYM	cis	rs921968	0.509	rs832813	chr2:219354569	T/C	cg02176678	chr2:219576539	TTLL4	0.76	7.55	0.61	2.66e-11	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4718428	1.000	rs1830070	chr7:66349671	T/C	cg26963428	chr7:66367121	NA	-0.58	-4.87	-0.45	4.36e-6	Corneal structure;
THYM	cis	rs4664308	0.905	rs7567781	chr2:160999537	A/G	cg03641300	chr2:160917029	PLA2R1	-0.75	-6.87	-0.58	6.63e-10	Idiopathic membranous nephropathy;
THYM	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg26513180	chr16:89883248	FANCA	-0.54	-4.91	-0.45	3.72e-6	Vitiligo;
THYM	cis	rs9388451	0.505	rs9372828	chr6:126175185	A/T	cg10911889	chr6:126070802	HEY2	0.64	4.58	0.42	1.44e-5	Brugada syndrome;
THYM	cis	rs9807841	0.670	rs8107719	chr19:10804389	T/C	cg16900796	chr19:10755136	SLC44A2	0.32	4.87	0.45	4.5e-6	Inflammatory skin disease;
THYM	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg20387954	chr3:183756860	HTR3D	0.57	4.64	0.43	1.09e-5	Anterior chamber depth;
THYM	cis	rs8058578	0.943	rs7197770	chr16:30715908	T/C	cg05768032	chr16:30646687	NA	0.56	5.61	0.5	1.98e-7	Multiple myeloma;
THYM	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg19378624	chr17:45501242	LOC100272146;C17orf57	-0.42	-4.5	-0.42	1.92e-5	Very long-chain saturated fatty acid levels (fatty acid 20:0);
THYM	cis	rs4790333	0.539	rs67887169	chr17:2256828	G/A	cg02569219	chr17:2266849	SGSM2	0.71	6.2	0.54	1.48e-8	Proinsulin levels;
THYM	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg06634786	chr22:41940651	POLR3H	-0.73	-5.36	-0.48	5.89e-7	Vitiligo;
THYM	cis	rs6430585	0.697	rs6724569	chr2:136516970	G/A	cg04750100	chr2:136595281	LCT	0.53	4.86	0.45	4.59e-6	Corneal structure;
THYM	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg03676636	chr4:99064102	C4orf37	-0.45	-6.72	-0.57	1.33e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9560113	1.000	rs60374273	chr13:112179206	A/T	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs4746818	1.000	rs10823301	chr10:70885875	G/A	cg11621586	chr10:70884670	VPS26A	1.3	11.57	0.76	7.68e-20	Left atrial antero-posterior diameter;
THYM	cis	rs4731207	0.698	rs10250911	chr7:124473034	G/A	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7524258	0.868	rs6577428	chr1:7314655	C/T	cg07173049	chr1:7289937	CAMTA1	-0.82	-6.3	-0.54	9.37e-9	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg09877947	chr5:131593287	PDLIM4	0.58	4.82	0.44	5.38e-6	Blood metabolite levels;
THYM	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg05660106	chr1:15850417	CASP9	0.76	6.27	0.54	1.06e-8	Systolic blood pressure;
THYM	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg24692254	chr21:30365293	RNF160	0.65	4.87	0.45	4.39e-6	Cognitive test performance;
THYM	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg24308560	chr3:49941425	MST1R	-0.78	-6.88	-0.58	6.42e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg18128536	chr17:47092178	IGF2BP1	-0.61	-9.55	-0.7	1.49e-15	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs6542838	0.611	rs7588441	chr2:99518858	G/A	cg08885076	chr2:99613938	TSGA10	-0.5	-4.66	-0.43	1.03e-5	Fear of minor pain;
THYM	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg06850241	chr22:41845214	NA	0.54	4.68	0.43	9.37e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs13223928	0.538	rs10951042	chr7:3139417	T/C	cg19214707	chr7:3157722	NA	-0.89	-7.69	-0.62	1.34e-11	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs7586879	0.765	rs6545758	chr2:25074874	C/T	cg01884057	chr2:25150051	NA	-0.52	-4.79	-0.44	6.08e-6	Body mass index;
THYM	cis	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg09307838	chr4:120376055	NA	0.7	5.27	0.48	8.48e-7	Corneal astigmatism;
THYM	cis	rs9355610	0.927	rs2757041	chr6:167370532	C/G	cg00271210	chr6:167070053	RPS6KA2	0.48	4.67	0.43	9.9e-6	Graves' disease;
THYM	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs3741151	0.686	rs11544310	chr11:73107592	A/G	cg17517138	chr11:73019481	ARHGEF17	0.79	4.86	0.45	4.54e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs89107	0.576	rs117344633	chr6:118837268	T/C	cg21191810	chr6:118973309	C6orf204	0.51	5.13	0.47	1.52e-6	Cardiac structure and function;
THYM	cis	rs4731207	0.698	rs7781148	chr7:124458044	G/A	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs35934224	0.740	rs35142928	chr22:19847751	T/C	cg11182965	chr22:19864308	TXNRD2	-0.72	-5.82	-0.51	7.88e-8	Glaucoma (primary open-angle);
THYM	cis	rs7000551	0.581	rs2293145	chr8:22262654	A/T	cg12081754	chr8:22256438	SLC39A14	1.14	11.63	0.77	5.79e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.43	4.64	0.43	1.12e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg02503808	chr4:7069936	GRPEL1	-0.97	-8.34	-0.65	5.64e-13	Monocyte percentage of white cells;
THYM	cis	rs9902453	0.904	rs7212292	chr17:28409264	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.81	-6.09	-0.53	2.43e-8	Coffee consumption (cups per day);
THYM	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg10802521	chr3:52805072	NEK4	-0.72	-6.12	-0.53	2.09e-8	Bipolar disorder;
THYM	cis	rs62151617	0.527	rs4852683	chr2:70814202	A/T	cg23637349	chr2:70262301	NA	0.44	4.46	0.42	2.29e-5	Hair shape;
THYM	cis	rs2302729	0.929	rs7136355	chr12:2783476	T/C	cg19945202	chr12:2788847	CACNA1C	-0.9	-5.9	-0.52	5.5e-8	Sleep quality;
THYM	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs3847687	1.000	rs3847688	chr12:131525310	C/T	cg13586425	chr12:131519906	GPR133	-0.33	-5.46	-0.49	3.79e-7	Longevity;
THYM	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg18681998	chr4:17616180	MED28	-0.86	-7.22	-0.6	1.26e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg06640241	chr16:89574553	SPG7	-0.87	-8.16	-0.64	1.4e-12	Multiple myeloma (IgH translocation);
THYM	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg23281280	chr6:28129359	ZNF389	0.61	4.48	0.42	2.04e-5	Parkinson's disease;
THYM	trans	rs2014511	1.000	rs2014511	chr4:154457519	G/A	cg26834479	chr1:41327090	CITED4	-1.93	-6.89	-0.58	6.17e-10	Platelet distribution width;Mean platelet volume;
THYM	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg08807101	chr21:30365312	RNF160	-0.81	-6.26	-0.54	1.1e-8	Dental caries;
THYM	cis	rs367615	0.704	rs72802966	chr5:108846754	T/G	cg17395555	chr5:108820864	NA	0.74	8.82	0.67	5.59e-14	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs1371867	0.875	rs1788176	chr8:101332112	A/G	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs960902	0.713	rs6757678	chr2:37723610	A/G	cg25341268	chr2:37734390	NA	0.57	4.89	0.45	4.18e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs4713118	0.662	rs149946	chr6:27970031	A/C	cg23281280	chr6:28129359	ZNF389	-0.59	-4.51	-0.42	1.86e-5	Parkinson's disease;
THYM	cis	rs28374715	0.557	rs11855854	chr15:41434729	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.01	-8.11	-0.64	1.79e-12	Ulcerative colitis;
THYM	cis	rs6430585	0.941	rs6708957	chr2:136520043	C/T	cg07169764	chr2:136633963	MCM6	0.94	8.32	0.65	6.19e-13	Corneal structure;
THYM	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg17143192	chr8:8559678	CLDN23	0.64	4.74	0.44	7.51e-6	Mood instability;
THYM	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg02527881	chr3:46936655	PTH1R	0.57	5.05	0.46	2.15e-6	Colorectal cancer;
THYM	cis	rs2495707	0.624	rs1419177	chr10:102423699	G/C	cg07099331	chr10:102419617	NA	-0.44	-5.16	-0.47	1.37e-6	Body mass index;
THYM	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg14582100	chr15:45693742	SPATA5L1	0.56	4.5	0.42	1.89e-5	Homoarginine levels;
THYM	cis	rs6980334	1.000	rs13243992	chr7:137784790	C/T	cg26979473	chr7:137028389	PTN	0.61	4.5	0.42	1.92e-5	Blood metabolite ratios;
THYM	cis	rs3091242	0.804	rs631133	chr1:25724146	T/C	cg00786635	chr1:25594202	NA	0.89	7.04	0.59	2.98e-10	Erythrocyte sedimentation rate;
THYM	cis	rs7975161	0.630	rs4964732	chr12:104652705	A/T	cg25273343	chr12:104657179	TXNRD1	-0.82	-4.75	-0.44	7.08e-6	Toenail selenium levels;
THYM	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg05738196	chr6:26577821	NA	0.83	8.21	0.64	1.09e-12	Intelligence (multi-trait analysis);
THYM	cis	rs13256369	0.802	rs12681326	chr8:8566389	G/A	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg22709100	chr7:91322751	NA	-0.62	-4.87	-0.45	4.41e-6	Breast cancer;
THYM	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg21784768	chr11:537496	LRRC56	-1.02	-5.17	-0.47	1.3e-6	Body mass index;
THYM	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg10760299	chr15:45669010	GATM	0.87	6.78	0.57	1.03e-9	Homoarginine levels;
THYM	cis	rs9880211	1.000	rs9869630	chr3:136248019	A/C	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs12282928	0.959	rs1393788	chr11:48279416	A/G	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11890956	chr21:40555474	PSMG1	0.95	10.43	0.73	2.02e-17	Cognitive function;
THYM	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	7.34	0.6	7.22e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1163251	0.902	rs627707	chr1:120217133	C/G	cg19096424	chr1:120255104	PHGDH	0.67	5.25	0.47	9.26e-7	Blood metabolite levels;
THYM	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg02018176	chr4:1364513	KIAA1530	0.53	4.46	0.42	2.27e-5	Obesity-related traits;
THYM	cis	rs4733781	0.965	rs17285138	chr8:131297696	T/A	cg16277922	chr8:131349729	ASAP1	0.64	4.5	0.42	1.93e-5	Tuberculosis;
THYM	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg16031515	chr1:205743344	RAB7L1	0.69	7.2	0.59	1.4e-10	Menarche (age at onset);
THYM	cis	rs3820068	0.580	rs12082523	chr1:16005792	A/G	cg05660106	chr1:15850417	CASP9	-0.72	-5.8	-0.51	8.78e-8	Systolic blood pressure;
THYM	cis	rs2073300	1.000	rs12626013	chr20:23442215	G/A	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs17321999	1.000	rs1001204	chr2:30478779	A/G	cg05247661	chr2:30472410	LBH	0.64	4.6	0.43	1.29e-5	Systemic lupus erythematosus;
THYM	cis	rs6964587	0.692	rs2299233	chr7:91626953	C/T	cg17063962	chr7:91808500	NA	-0.94	-8.14	-0.64	1.53e-12	Breast cancer;
THYM	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg18681998	chr4:17616180	MED28	0.96	9.17	0.69	9.69e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg21784768	chr11:537496	LRRC56	-1.14	-5.72	-0.51	1.21e-7	Body mass index;
THYM	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg15704280	chr7:45808275	SEPT13	-1.07	-15.3	-0.84	2.26e-27	Height;
THYM	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg22841779	chr14:105766346	BRF1	-0.45	-5.55	-0.49	2.6e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs3849570	0.961	rs10154945	chr3:81833766	A/C	cg07356753	chr3:81810745	GBE1	-0.91	-7.45	-0.61	4.23e-11	Waist circumference;Body mass index;
THYM	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg01557791	chr16:72042693	DHODH	0.65	5.48	0.49	3.54e-7	Prostate cancer;
THYM	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03517284	chr6:25882590	NA	-0.99	-8.59	-0.66	1.67e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4589258	1.000	rs10830564	chr11:90460614	G/C	cg26138821	chr11:89956704	CHORDC1	-0.7	-5.64	-0.5	1.74e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.51	-4.74	-0.44	7.59e-6	Crohn's disease;
THYM	cis	rs7584330	0.740	rs2292885	chr2:238443407	G/C	cg16989719	chr2:238392110	NA	-0.48	-4.78	-0.44	6.27e-6	Prostate cancer;
THYM	cis	rs637571	0.676	rs634534	chr11:65665256	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.53	-5.14	-0.47	1.5e-6	Eosinophil percentage of white cells;
THYM	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg00071950	chr4:10020882	SLC2A9	-0.53	-4.67	-0.43	9.99e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	7.78	0.62	8.83e-12	Platelet count;
THYM	cis	rs7635838	0.684	rs2606750	chr3:11372151	T/C	cg00170343	chr3:11313890	ATG7	0.58	4.58	0.43	1.39e-5	HDL cholesterol;
THYM	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg19774624	chr17:42201019	HDAC5	0.72	6.34	0.55	7.6e-9	Total body bone mineral density;
THYM	cis	rs9311676	0.632	rs6445978	chr3:58379586	T/A	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs7772486	0.641	rs2253757	chr6:146199686	C/T	cg05347473	chr6:146136440	FBXO30	0.8	7.14	0.59	1.83e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4606347	0.872	rs61779664	chr1:66124477	G/T	cg04111102	chr1:66153794	NA	0.59	4.46	0.42	2.29e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs669446	0.533	rs4660261	chr1:44229597	G/A	cg12599982	chr1:44399894	ARTN	0.52	4.75	0.44	7.2e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs75920871	0.588	rs1815789	chr11:116834953	T/C	cg20608306	chr11:116969690	SIK3	-0.47	-4.94	-0.45	3.37e-6	Subjective well-being;
THYM	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg12564285	chr5:131593104	PDLIM4	0.5	5.34	0.48	6.22e-7	Acylcarnitine levels;
THYM	cis	rs7646881	0.812	rs73015644	chr3:158447744	C/T	cg19483011	chr3:158453295	NA	-0.75	-4.69	-0.43	9.31e-6	Tetralogy of Fallot;
THYM	cis	rs2637266	0.756	rs2583064	chr10:78557708	A/G	cg18941641	chr10:78392320	NA	0.72	5.7	0.51	1.32e-7	Pulmonary function;
THYM	cis	rs2282300	0.739	rs35229181	chr11:30241698	A/G	cg09906309	chr11:30344399	C11orf46	-0.72	-5.34	-0.48	6.24e-7	Morning vs. evening chronotype;
THYM	cis	rs2637266	0.783	rs846642	chr10:78522318	A/G	cg18941641	chr10:78392320	NA	-0.63	-4.83	-0.44	5.31e-6	Pulmonary function;
THYM	cis	rs55637147	0.671	rs2276039	chr11:57137371	A/G	cg15971518	chr11:57159174	PRG2	0.61	4.86	0.45	4.61e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs13315871	0.929	rs28659863	chr3:58328072	C/T	cg00563845	chr3:58318305	PXK	0.58	4.81	0.44	5.65e-6	Cholesterol, total;
THYM	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg21475434	chr5:93447410	FAM172A	0.96	6.1	0.53	2.29e-8	Diabetic retinopathy;
THYM	cis	rs988913	0.957	rs1910350	chr6:54852462	C/A	cg19716238	chr6:54711378	FAM83B	0.51	5.1	0.46	1.71e-6	Menarche (age at onset);
THYM	cis	rs747334	0.846	rs4423105	chr10:92724446	C/G	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs2820651	0.614	rs75834807	chr10:1485054	T/C	cg02445968	chr10:1449028	ADARB2	-1.07	-5.44	-0.49	4.17e-7	Migraine with aura;
THYM	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.74	0.71	6.03e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4509693	1.000	rs4917908	chr10:102502674	G/C	cg24127310	chr10:102502104	NA	1.32	10.1	0.72	1.03e-16	Alzheimer's disease;
THYM	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg10465839	chr16:1584050	IFT140;TMEM204	-0.66	-5.82	-0.51	7.88e-8	Coronary artery disease;
THYM	cis	rs7172677	1.000	rs7178784	chr15:75425444	A/G	cg09165964	chr15:75287851	SCAMP5	-0.6	-4.7	-0.43	8.82e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg11335335	chr11:637885	DRD4	-0.69	-6.23	-0.54	1.24e-8	Systemic lupus erythematosus;
THYM	cis	rs4792901	0.959	rs7208294	chr17:41658263	C/G	cg21940313	chr17:41620911	ETV4	-0.48	-5.24	-0.47	9.61e-7	Dupuytren's disease;
THYM	cis	rs11249608	0.548	rs6860309	chr5:178451428	T/C	cg01312482	chr5:178451176	ZNF879	-0.75	-6.25	-0.54	1.19e-8	Pubertal anthropometrics;
THYM	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg24375607	chr4:120327624	NA	0.64	5.06	0.46	2.05e-6	Corneal astigmatism;
THYM	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14159672	chr1:205819179	PM20D1	1.0	10.54	0.73	1.14e-17	Menarche (age at onset);
THYM	cis	rs11997175	0.583	rs17780153	chr8:33789161	A/G	ch.8.33884649F	chr8:33765107	NA	0.75	5.4	0.48	4.92e-7	Body mass index;
THYM	cis	rs7103648	0.864	rs10742802	chr11:47432725	T/G	cg20307385	chr11:47447363	PSMC3	0.93	8.66	0.66	1.23e-13	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	5.41	0.49	4.67e-7	Platelet count;
THYM	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg13147721	chr7:65941812	NA	-0.73	-4.56	-0.42	1.52e-5	Diabetic kidney disease;
THYM	cis	rs6754311	0.544	rs11693502	chr2:136808949	C/T	cg07169764	chr2:136633963	MCM6	-0.68	-5.0	-0.46	2.66e-6	Mosquito bite size;
THYM	cis	rs2276314	0.793	rs77590522	chr18:33629410	C/G	cg19628046	chr18:33552617	C18orf21	0.77	5.45	0.49	4.01e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg23205692	chr1:25664452	TMEM50A	0.79	6.53	0.56	3.17e-9	Erythrocyte sedimentation rate;
THYM	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg08045932	chr20:61659980	NA	0.93	10.4	0.73	2.3e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs1385374	0.858	rs10847692	chr12:129289679	A/T	cg04043695	chr12:129287642	SLC15A4	-0.8	-4.83	-0.44	5.3e-6	Systemic lupus erythematosus;
THYM	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg03159660	chr11:2078197	NA	-0.63	-4.58	-0.43	1.42e-5	Longevity;
THYM	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg02734326	chr4:10020555	SLC2A9	0.76	6.88	0.58	6.2e-10	Bone mineral density;
THYM	cis	rs2688608	0.672	rs2688622	chr10:75688981	C/A	cg02947784	chr10:75434997	AGAP5	0.54	5.22	0.47	1.07e-6	Inflammatory bowel disease;
THYM	cis	rs11089937	0.667	rs5757081	chr22:22500665	G/A	cg21401457	chr22:22472743	NA	0.55	4.46	0.42	2.21e-5	Periodontitis (PAL4Q3);
THYM	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg23758822	chr17:41437982	NA	1.16	11.04	0.75	1.02e-18	Menopause (age at onset);
THYM	cis	rs870825	0.616	rs2003994	chr4:185636568	G/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs10782582	0.593	rs77208152	chr1:76124255	T/C	cg22875332	chr1:76189707	ACADM	-0.54	-5.07	-0.46	1.96e-6	Daytime sleep phenotypes;
THYM	cis	rs17824247	0.505	rs12465778	chr2:144255201	T/C	cg17056048	chr2:144271431	ARHGAP15	-0.58	-6.05	-0.53	2.84e-8	Educational attainment (years of education);
THYM	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.11	12.19	0.78	3.87e-21	Intelligence (multi-trait analysis);
THYM	cis	rs6570726	0.935	rs1883406	chr6:145823205	A/G	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg06784218	chr1:46089804	CCDC17	0.3	4.85	0.45	4.84e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg10505658	chr17:80084571	CCDC57	-0.74	-8.13	-0.64	1.59e-12	Life satisfaction;
THYM	cis	rs8013055	0.846	rs10152050	chr14:105984145	C/G	cg04429589	chr14:105992532	TMEM121	-0.51	-5.4	-0.48	4.95e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs7688540	0.511	rs6845131	chr4:200147	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.91	5.56	0.5	2.45e-7	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.91	-6.52	-0.56	3.31e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2069036	1.000	rs7899730	chr10:16100127	C/T	cg26633223	chr10:15133461	NA	-0.7	-4.98	-0.46	2.8e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs7258465	1.000	rs34746918	chr19:18539744	C/T	cg04166595	chr19:18636596	NA	0.67	5.03	0.46	2.34e-6	Breast cancer;
THYM	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg11764359	chr7:65958608	NA	-0.85	-7.43	-0.61	4.73e-11	Aortic root size;
THYM	cis	rs7432375	0.901	rs7616204	chr3:136444589	C/T	cg12473912	chr3:136751656	NA	-0.62	-5.27	-0.48	8.44e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs6840360	0.593	rs7654294	chr4:152690975	T/C	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg26597838	chr10:835615	NA	0.84	4.73	0.44	7.71e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg14784868	chr12:69753453	YEATS4	0.82	6.36	0.55	7.18e-9	Response to diuretic therapy;
THYM	cis	rs2820651	1.000	rs79446083	chr10:1476044	T/A	cg02445968	chr10:1449028	ADARB2	-1.25	-6.3	-0.54	9.36e-9	Migraine with aura;
THYM	cis	rs4474465	0.850	rs10793322	chr11:78242615	T/C	cg19901956	chr11:77921274	USP35	0.67	4.95	0.45	3.16e-6	Alzheimer's disease (survival time);
THYM	cis	rs7582180	0.590	rs11123828	chr2:100960918	T/G	cg21926883	chr2:100939477	LONRF2	-0.67	-6.14	-0.53	1.92e-8	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.26	-5.22	-0.47	1.07e-6	Obesity-related traits;
THYM	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	9.42	0.69	2.88e-15	Chronic sinus infection;
THYM	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg00012203	chr2:219082015	ARPC2	-0.67	-5.5	-0.49	3.17e-7	Pyoderma gangrenosum in inflammatory bowel disease;
THYM	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.22	9.36	0.69	3.93e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs13256369	0.789	rs13282500	chr8:8568489	A/T	cg17143192	chr8:8559678	CLDN23	0.77	5.87	0.52	6.38e-8	Obesity-related traits;
THYM	cis	rs7090512	0.592	rs4749997	chr10:6161781	C/T	cg17191567	chr10:6178319	NA	-0.52	-5.2	-0.47	1.13e-6	Multiple sclerosis;
THYM	cis	rs988913	0.957	rs4437472	chr6:54838438	C/T	cg04690482	chr6:54711388	FAM83B	0.49	5.28	0.48	8.01e-7	Menarche (age at onset);
THYM	cis	rs6121246	0.609	rs2377317	chr20:30402502	A/G	cg13852791	chr20:30311386	BCL2L1	-0.87	-8.17	-0.64	1.31e-12	Mean corpuscular hemoglobin;
THYM	cis	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg17063962	chr7:91808500	NA	1.14	12.62	0.79	4.97e-22	Breast cancer;
THYM	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg27087555	chr16:88793112	FAM38A	-1.23	-7.52	-0.61	3.09e-11	Plateletcrit;
THYM	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.78	-6.87	-0.58	6.69e-10	Intelligence (multi-trait analysis);
THYM	cis	rs4889911	0.544	rs2587498	chr17:77830737	G/A	cg00646381	chr17:77835854	NA	0.47	5.37	0.48	5.53e-7	Electroencephalogram traits;
THYM	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg08188268	chr10:116634841	FAM160B1	-0.27	-4.67	-0.43	9.98e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs11225247	1.000	rs115349957	chr11:102271809	C/G	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs6496667	0.865	rs1971899	chr15:90890664	C/A	cg22089800	chr15:90895588	ZNF774	0.72	4.83	0.44	5.23e-6	Rheumatoid arthritis;
THYM	cis	rs7851660	0.967	rs12348691	chr9:100608682	G/A	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs1079204	1.000	rs11888211	chr2:219146988	G/A	cg05728596	chr2:219128475	GPBAR1	1.21	5.25	0.47	9.39e-7	Smooth-surface caries;
THYM	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg03877680	chr5:178157825	ZNF354A	0.71	4.77	0.44	6.78e-6	Neutrophil percentage of white cells;
THYM	cis	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-5.89	-0.52	5.81e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs477692	0.569	rs871028	chr10:131293478	C/T	cg05714579	chr10:131428358	MGMT	-0.6	-4.89	-0.45	4.02e-6	Response to temozolomide;
THYM	cis	rs7119	0.717	rs12902852	chr15:77809016	C/G	cg27398640	chr15:77910606	LINGO1	-0.57	-5.69	-0.5	1.4e-7	Type 2 diabetes;
THYM	cis	rs7592578	0.664	rs10931461	chr2:191405280	T/A	cg10560079	chr2:191398806	TMEM194B	0.94	7.32	0.6	7.82e-11	Diastolic blood pressure;
THYM	cis	rs4731207	0.698	rs4728010	chr7:124481420	T/A	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg10911889	chr6:126070802	HEY2	0.56	4.66	0.43	1.03e-5	Brugada syndrome;
THYM	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg00254258	chr1:3105189	PRDM16	0.58	4.9	0.45	3.91e-6	Migraine;
THYM	cis	rs12368653	0.701	rs238517	chr12:58117737	T/G	cg12615879	chr12:58013172	SLC26A10	0.53	5.34	0.48	6.42e-7	Multiple sclerosis;
THYM	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg06558623	chr16:89946397	TCF25	1.42	6.85	0.58	7.17e-10	Skin colour saturation;
THYM	cis	rs6430585	0.528	rs16832205	chr2:136684632	G/A	cg20242066	chr2:136595261	LCT	0.56	5.17	0.47	1.28e-6	Corneal structure;
THYM	cis	rs34638657	0.872	rs2911423	chr16:82188801	C/T	cg09894383	chr16:82067445	HSD17B2	-0.52	-5.23	-0.47	1.01e-6	Lung adenocarcinoma;
THYM	cis	rs8180040	0.676	rs1108301	chr3:47029426	G/A	cg16586182	chr3:47516702	SCAP	0.58	4.91	0.45	3.84e-6	Colorectal cancer;
THYM	cis	rs56104184	0.887	rs4801778	chr19:49370609	G/T	cg19746536	chr19:49375674	PPP1R15A	0.85	5.02	0.46	2.42e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg21775007	chr8:11205619	TDH	-0.68	-5.53	-0.49	2.77e-7	Retinal vascular caliber;
THYM	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg14582100	chr15:45693742	SPATA5L1	0.59	4.91	0.45	3.86e-6	Homoarginine levels;
THYM	cis	rs55728055	0.661	rs62237798	chr22:31976839	G/T	cg01338084	chr22:32026380	PISD	1.36	5.56	0.5	2.44e-7	Age-related hearing impairment;
THYM	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg19016782	chr12:123741754	C12orf65	-0.69	-4.5	-0.42	1.94e-5	Allergic disease (asthma, hay fever or eczema);
THYM	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	trans	rs2201841	0.640	rs1343152	chr1:67704332	A/C	cg21743712	chr3:79817125	ROBO1	-0.53	-6.85	-0.57	7.39e-10	Ulcerative colitis;Psoriasis;Crohn's disease;
THYM	cis	rs11089937	0.616	rs6001224	chr22:22540432	C/T	cg06866756	chr22:22471216	NA	-0.46	-5.09	-0.46	1.79e-6	Periodontitis (PAL4Q3);
THYM	cis	rs6669072	0.647	rs814543	chr1:91241709	C/T	cg08895590	chr1:91227319	NA	0.68	8.44	0.65	3.46e-13	Cognitive function;
THYM	cis	rs2046867	0.908	rs2322610	chr3:72793651	C/A	cg25664220	chr3:72788482	NA	-0.77	-5.95	-0.52	4.54e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs3771570	1.000	rs16843590	chr2:242298228	G/A	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs10823500	0.777	rs10509321	chr10:71985733	A/G	cg25502086	chr10:71892093	AIFM2	0.56	5.08	0.46	1.87e-6	Blood protein levels;
THYM	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg12560992	chr17:57184187	TRIM37	-0.88	-7.82	-0.63	7.09e-12	Intelligence (multi-trait analysis);
THYM	cis	rs6500602	0.535	rs758044	chr16:4431202	A/G	cg08645402	chr16:4508243	NA	0.74	5.63	0.5	1.8e-7	Schizophrenia;
THYM	cis	rs6076065	0.683	rs2424557	chr20:23422159	C/G	cg11657817	chr20:23433608	CST11	-0.32	-4.56	-0.42	1.54e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg17063962	chr7:91808500	NA	1.14	12.62	0.79	4.97e-22	Breast cancer;
THYM	cis	rs7677751	0.806	rs7689569	chr4:55096398	G/A	cg17187183	chr4:55093834	PDGFRA	0.74	5.53	0.49	2.78e-7	Corneal astigmatism;
THYM	cis	rs4425211	0.811	rs6772646	chr3:36959792	G/A	cg21328643	chr3:37258149	NA	-0.48	-4.62	-0.43	1.2e-5	Iris color (L* coordinate);
THYM	cis	rs2898681	0.580	rs41279517	chr4:53729771	T/C	cg21521518	chr4:53727714	RASL11B	0.63	5.48	0.49	3.5e-7	Optic nerve measurement (cup area);
THYM	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg04518342	chr5:131593106	PDLIM4	0.42	4.52	0.42	1.81e-5	Blood metabolite levels;
THYM	cis	rs72712511	0.571	rs10024138	chr4:140764347	C/T	cg15010390	chr4:140216957	NDUFC1	0.62	4.51	0.42	1.87e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2299587	0.642	rs2073570	chr8:17782627	C/G	cg01800426	chr8:17659068	MTUS1	-0.59	-4.75	-0.44	7.18e-6	Economic and political preferences;
THYM	cis	rs4732038	0.510	rs56816317	chr7:134278493	C/T	cg06906464	chr7:134288099	NA	-0.52	-4.96	-0.45	3.04e-6	Longevity;
THYM	cis	rs9399401	0.710	rs10484733	chr6:142710988	C/G	cg04461802	chr6:142623433	GPR126	0.76	7.27	0.6	1.01e-10	Chronic obstructive pulmonary disease;
THYM	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03264133	chr6:25882463	NA	0.79	6.26	0.54	1.12e-8	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	trans	rs4866334	1.000	rs76790673	chr5:18502463	G/C	cg08675002	chr5:90437527	GPR98	-1.55	-7.42	-0.61	4.86e-11	IgG glycosylation;
THYM	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg23758822	chr17:41437982	NA	1.24	13.12	0.8	4.76e-23	Menopause (age at onset);
THYM	cis	rs9563576	0.778	rs9569810	chr13:58641746	T/C	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.63	4.51	0.42	1.85e-5	Body mass index;
THYM	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg03806693	chr22:41940476	POLR3H	-0.86	-7.21	-0.59	1.34e-10	Neuroticism;
THYM	cis	rs7404928	0.651	rs9940744	chr16:23943445	A/G	cg26685404	chr16:23957272	PRKCB	0.68	8.04	0.64	2.51e-12	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs3017493	0.786	rs79792601	chr11:70675171	G/A	cg19942459	chr11:70508110	SHANK2	1.23	7.65	0.62	1.64e-11	Renal transplant outcome;
THYM	cis	rs7267979	1.000	rs2257808	chr20:25266450	G/C	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	5.75	0.51	1.08e-7	Blood metabolite levels;
THYM	cis	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg10856724	chr12:34555212	NA	-1.07	-10.09	-0.72	1.09e-16	Morning vs. evening chronotype;
THYM	cis	rs2976388	1.000	rs2920296	chr8:143763109	A/G	cg13446199	chr8:143762866	PSCA	0.51	6.42	0.55	5.46e-9	Urinary tract infection frequency;
THYM	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg11752832	chr7:134001865	SLC35B4	0.73	5.24	0.47	9.53e-7	Mean platelet volume;
THYM	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.74	7.42	0.61	4.94e-11	Lymphocyte counts;
THYM	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs4731207	0.596	rs2127971	chr7:124595309	G/C	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg23711669	chr6:146136114	FBXO30	0.9	9.26	0.69	6.45e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs34638657	0.827	rs11641736	chr16:82206279	G/A	cg09439754	chr16:82129088	HSD17B2	-0.65	-5.62	-0.5	1.94e-7	Lung adenocarcinoma;
THYM	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg08017634	chr8:144659831	NAPRT1	-1.13	-6.32	-0.54	8.4e-9	Attention deficit hyperactivity disorder;
THYM	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg04518342	chr5:131593106	PDLIM4	0.54	6.27	0.54	1.06e-8	Acylcarnitine levels;
THYM	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.91	9.42	0.69	2.88e-15	Chronic sinus infection;
THYM	cis	rs7567389	0.677	rs7607907	chr2:128144286	C/T	cg09760422	chr2:128146352	NA	-0.39	-4.51	-0.42	1.86e-5	Self-rated health;
THYM	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg07606381	chr6:8435919	SLC35B3	0.62	4.74	0.44	7.56e-6	Motion sickness;
THYM	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18402987	chr7:1209562	NA	0.76	5.47	0.49	3.69e-7	Longevity;Endometriosis;
THYM	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.16	-5.63	-0.5	1.85e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8135828	0.770	rs469253	chr22:29953805	A/G	cg16189954	chr22:29138267	HSCB;CHEK2	0.72	4.68	0.43	9.34e-6	Lipid traits;
THYM	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg02782426	chr3:40428986	ENTPD3	-0.51	-4.54	-0.42	1.67e-5	Renal cell carcinoma;
THYM	cis	rs11098499	0.821	rs56155624	chr4:120291026	C/G	cg13609457	chr4:120235615	NA	0.52	4.77	0.44	6.72e-6	Corneal astigmatism;
THYM	cis	rs7177699	0.581	rs7165081	chr15:79123396	C/G	cg00540400	chr15:79124168	NA	0.65	7.03	0.58	3.16e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs4389656	0.857	rs274715	chr5:6723429	C/T	cg10857441	chr5:6722123	POLS	0.44	4.59	0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.96e-6	Resting heart rate;
THYM	cis	rs4849845	0.889	rs17050090	chr2:121054868	G/C	cg03575764	chr2:121493832	NA	-0.66	-4.95	-0.45	3.22e-6	Mean platelet volume;
THYM	cis	rs89107	0.549	rs4945623	chr6:118980556	G/C	cg21191810	chr6:118973309	C6orf204	0.57	5.95	0.52	4.46e-8	Cardiac structure and function;
THYM	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg26597838	chr10:835615	NA	0.81	4.94	0.45	3.34e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs2303759	0.670	rs45549132	chr19:49794028	G/T	cg22307029	chr19:49891270	CCDC155	0.58	4.62	0.43	1.23e-5	Multiple sclerosis;
THYM	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	7.35	0.6	6.91e-11	Platelet count;
THYM	cis	rs1461503	0.934	rs7113330	chr11:122843358	C/T	cg27398637	chr11:122830231	C11orf63	-0.62	-5.64	-0.5	1.77e-7	Menarche (age at onset);
THYM	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	cis	rs11077998	0.901	rs4789798	chr17:80531643	C/G	cg10255544	chr17:80519551	FOXK2	0.51	4.51	0.42	1.84e-5	Reticulocyte fraction of red cells;
THYM	cis	rs1650123	0.617	rs1427797	chr12:104022681	T/A	cg23227824	chr12:103980017	STAB2	0.48	5.08	0.46	1.92e-6	IgG glycosylation;
THYM	cis	rs9858542	0.537	rs115753735	chr3:49355005	T/C	cg00383909	chr3:49044727	WDR6	0.69	4.67	0.43	1.01e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs4242434	0.747	rs6986550	chr8:22467870	T/A	cg21658235	chr8:22456391	C8orf58	0.44	4.56	0.42	1.54e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9646944	0.501	rs12991737	chr2:103018128	T/A	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	cis	rs921968	0.541	rs4674310	chr2:219318078	T/C	cg02176678	chr2:219576539	TTLL4	-0.74	-7.3	-0.6	8.93e-11	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.33e-5	Alzheimer's disease;
THYM	cis	rs4654899	0.802	rs2167811	chr1:21194510	A/G	cg01072550	chr1:21505969	NA	0.71	6.47	0.55	4.16e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs425277	0.917	rs78609670	chr1:2045886	G/T	cg09260853	chr1:2094483	PRKCZ	0.53	4.88	0.45	4.22e-6	Height;
THYM	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs17854409	0.803	rs1063246	chr20:61472116	G/A	cg06598544	chr20:61472147	COL9A3	-1.12	-6.98	-0.58	3.91e-10	Obesity-related traits;
THYM	cis	rs6570726	0.791	rs11155426	chr6:145817130	T/C	cg23711669	chr6:146136114	FBXO30	0.95	9.55	0.7	1.52e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8067545	0.578	rs62066870	chr17:20063758	A/C	cg13482628	chr17:19912719	NA	0.55	4.68	0.43	9.41e-6	Schizophrenia;
THYM	cis	rs1003719	0.751	rs10154032	chr21:38453459	T/C	cg01329690	chr21:38580129	DSCR9	0.39	5.25	0.47	9.23e-7	Eye color traits;
THYM	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg26031613	chr14:104095156	KLC1	0.73	4.99	0.46	2.74e-6	Body mass index;
THYM	cis	rs9583531	0.600	rs6492303	chr13:111356800	G/A	cg24331049	chr13:111365604	ING1	0.72	6.04	0.53	2.96e-8	Coronary artery disease;
THYM	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg15448220	chr1:150897856	SETDB1	0.85	6.7	0.57	1.47e-9	Melanoma;
THYM	cis	rs7584330	0.744	rs10929235	chr2:238380272	A/G	cg14458575	chr2:238380390	NA	1.09	8.79	0.67	6.36e-14	Prostate cancer;
THYM	cis	rs425277	0.606	rs424079	chr1:2071340	C/A	cg10334053	chr1:2078117	PRKCZ	-0.47	-4.56	-0.42	1.55e-5	Height;
THYM	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg13354988	chr2:263656	ACP1;SH3YL1	0.35	4.68	0.43	9.33e-6	Spherical equivalent (joint analysis main effects and education interaction);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg22225685	chr22:38203998	GCAT	-0.99	-6.99	-0.58	3.86e-10	Depressive symptoms;
THYM	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08704250	chr15:31115839	NA	-0.7	-7.88	-0.63	5.33e-12	Huntington's disease progression;
THYM	cis	rs35883536	0.566	rs4908086	chr1:101088124	C/T	cg06223162	chr1:101003688	GPR88	0.62	5.51	0.49	3.05e-7	Monocyte count;
THYM	cis	rs6032067	0.759	rs1007138	chr20:43816835	A/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-6.1	-0.53	2.33e-8	Blood protein levels;
THYM	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg12893697	chr11:970389	AP2A2	-0.33	-5.52	-0.49	2.92e-7	Alzheimer's disease (late onset);
THYM	cis	rs7772486	0.790	rs9485024	chr6:146142487	A/G	cg23711669	chr6:146136114	FBXO30	-0.89	-8.24	-0.65	9.53e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg07061783	chr6:25882402	NA	-0.91	-8.2	-0.64	1.13e-12	Intelligence (multi-trait analysis);
THYM	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg11764359	chr7:65958608	NA	-0.85	-7.43	-0.61	4.73e-11	Aortic root size;
THYM	cis	rs2333194	0.772	rs8009466	chr14:73832313	C/T	cg09844916	chr14:74004424	HEATR4;ACOT1	0.62	4.92	0.45	3.7e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg18876405	chr7:65276391	NA	0.63	5.53	0.49	2.83e-7	Aortic root size;
THYM	cis	rs2963155	0.518	rs55817235	chr5:142765733	C/T	cg17617527	chr5:142782415	NR3C1	1.15	4.94	0.45	3.32e-6	Breast cancer;
THYM	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10979	1.000	rs9390112	chr6:143896147	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6430585	0.941	rs10496737	chr2:136540083	A/G	cg07169764	chr2:136633963	MCM6	0.94	8.32	0.65	6.19e-13	Corneal structure;
THYM	cis	rs11008222	0.870	rs11812207	chr10:31041280	C/T	cg00941203	chr10:31016591	NA	-0.35	-4.91	-0.45	3.76e-6	Congenital left-sided heart lesions (maternal effect);
THYM	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg01819863	chr10:32635814	EPC1	1.04	6.64	0.56	1.9e-9	Sexual dysfunction (female);
THYM	cis	rs9788682	0.655	rs578776	chr15:78888400	G/A	cg18825076	chr15:78729989	IREB2	0.54	4.54	0.42	1.68e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	trans	rs2136093	0.568	rs114447975	chr1:90891603	G/A	cg19688584	chr6:167529678	CCR6	0.51	7.04	0.59	3.01e-10	Response to antidepressants;
THYM	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg12011299	chr4:100065546	ADH4	0.7	6.49	0.55	3.85e-9	Alcohol dependence;
THYM	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg05855489	chr10:104503620	C10orf26	0.71	5.9	0.52	5.55e-8	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7919823	0.661	rs7095000	chr10:21732912	C/A	cg26899113	chr10:22625733	NA	-1.04	-4.57	-0.42	1.47e-5	Subcutaneous adipose tissue;
THYM	trans	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg25214090	chr10:38739885	LOC399744	0.97	8.4	0.65	4.27e-13	Corneal astigmatism;
THYM	cis	rs2070488	1.000	rs7373805	chr3:38455439	C/T	cg24069376	chr3:38537580	EXOG	0.66	6.49	0.55	3.91e-9	Electrocardiographic conduction measures;
THYM	cis	rs13232179	1.000	rs7798194	chr7:151117695	C/T	cg05714773	chr7:150493706	TMEM176B	0.64	4.59	0.43	1.33e-5	Coronary heart disease;
THYM	cis	rs514406	0.858	rs564640	chr1:53285187	T/C	cg27535305	chr1:53392650	SCP2	0.42	4.82	0.44	5.54e-6	Monocyte count;
THYM	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg18105134	chr13:113819100	PROZ	-0.98	-9.0	-0.68	2.28e-14	Platelet distribution width;
THYM	cis	rs11096990	0.634	rs1451818	chr4:39258771	G/A	cg24403649	chr4:39172243	NA	0.67	5.88	0.52	6e-8	Cognitive function;
THYM	cis	rs12935418	0.672	rs3826048	chr16:81056835	G/A	cg16651780	chr16:81037892	C16orf61	0.78	5.68	0.5	1.46e-7	Mean corpuscular volume;
THYM	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg13531842	chr10:38383804	ZNF37A	0.56	4.63	0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg13147721	chr7:65941812	NA	1.06	6.36	0.55	6.9e-9	Diabetic kidney disease;
THYM	cis	rs67981189	0.529	rs2526850	chr14:71417249	A/T	cg15910301	chr14:71632612	NA	-0.56	-4.88	-0.45	4.23e-6	Schizophrenia;
THYM	cis	rs13102973	0.965	rs4469136	chr4:135850051	C/T	cg14419869	chr4:135874104	NA	0.9	8.46	0.66	3.24e-13	Subjective well-being;
THYM	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg23205692	chr1:25664452	TMEM50A	0.8	6.33	0.54	8.21e-9	Erythrocyte sedimentation rate;
THYM	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg07424592	chr7:64974309	NA	-0.99	-5.15	-0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs67981189	0.865	rs2526876	chr14:71378188	T/C	cg15910301	chr14:71632612	NA	-0.52	-4.79	-0.44	6.15e-6	Schizophrenia;
THYM	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg00376283	chr12:123451042	ABCB9	0.71	4.75	0.44	7.32e-6	Neutrophil percentage of white cells;
THYM	cis	rs12509991	0.582	rs2062210	chr4:127045066	T/G	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs10109541	0.532	rs1703904	chr8:557079	A/T	cg11416102	chr8:651193	ERICH1	-0.62	-4.48	-0.42	2.11e-5	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
THYM	cis	rs76662990	0.610	rs10474422	chr5:73943353	A/G	cg13275603	chr5:73927487	ENC1	-0.77	-4.63	-0.43	1.17e-5	Residual cognition;
THYM	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg23131131	chr22:24373011	LOC391322	-0.8	-8.24	-0.65	9.54e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9902453	0.765	rs2447935	chr17:28057524	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs7172677	1.000	rs8032261	chr15:75424012	A/T	cg09165964	chr15:75287851	SCAMP5	-0.61	-4.72	-0.44	8.25e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg14784868	chr12:69753453	YEATS4	1.13	12.35	0.79	1.8e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg03806693	chr22:41940476	POLR3H	-1.15	-9.82	-0.71	4.04e-16	Vitiligo;
THYM	cis	rs7246657	1.000	rs1823061	chr19:37800626	G/A	cg22634378	chr19:37742834	NA	0.63	5.28	0.48	8.18e-7	Coronary artery calcification;
THYM	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg13852791	chr20:30311386	BCL2L1	0.87	6.96	0.58	4.36e-10	Mean corpuscular hemoglobin;
THYM	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.06	9.33	0.69	4.37e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7082209	0.540	rs800310	chr10:44815048	A/T	cg08683644	chr10:44853092	NA	0.6	4.45	0.42	2.31e-5	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
THYM	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg25588787	chr5:154027256	NA	0.9	4.6	0.43	1.32e-5	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg18252515	chr7:66147081	NA	-0.71	-5.46	-0.49	3.86e-7	Aortic root size;
THYM	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11644478	chr21:40555479	PSMG1	-0.76	-6.49	-0.55	3.85e-9	Cognitive function;
THYM	cis	rs7209460	0.518	rs9894634	chr17:1967501	C/T	cg15816464	chr17:2026533	SMG6	0.38	4.98	0.45	2.89e-6	Coronary artery disease;Total body bone mineral density;
THYM	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg24399712	chr22:39784796	NA	-0.95	-10.92	-0.75	1.82e-18	Intelligence (multi-trait analysis);
THYM	cis	rs7104764	0.778	rs7930823	chr11:206767	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	-0.87	-7.37	-0.6	6.38e-11	Menarche (age at onset);
THYM	cis	rs28595532	0.920	rs56227053	chr4:119772460	C/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs909002	0.849	rs2280386	chr1:32086912	A/C	cg13919466	chr1:32135498	COL16A1	-0.49	-4.56	-0.42	1.54e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg22709100	chr7:91322751	NA	0.6	4.69	0.43	9.3e-6	Breast cancer;
THYM	cis	rs4731207	0.596	rs12111658	chr7:124584768	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs10504073	0.647	rs4873317	chr8:50021111	C/T	cg00325661	chr8:49890786	NA	0.92	8.49	0.66	2.72e-13	Blood metabolite ratios;
THYM	cis	rs1061377	0.585	rs3733271	chr4:39049568	A/G	cg24403649	chr4:39172243	NA	0.57	4.57	0.42	1.48e-5	Uric acid levels;
THYM	cis	rs9660180	0.967	rs9660106	chr1:1797947	A/G	cg06981504	chr1:1234844	ACAP3	0.53	4.85	0.45	4.73e-6	Body mass index;
THYM	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.5	0.42	1.96e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg23505145	chr19:12996616	KLF1	1.01	10.01	0.72	1.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11997175	0.550	rs7459565	chr8:33836717	C/T	ch.8.33884649F	chr8:33765107	NA	0.67	5.17	0.47	1.29e-6	Body mass index;
THYM	cis	rs7267979	1.000	rs6083813	chr20:25337671	A/G	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs554111	0.656	rs4654893	chr1:21305596	G/C	cg01072550	chr1:21505969	NA	0.6	5.34	0.48	6.45e-7	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg02527881	chr3:46936655	PTH1R	0.6	5.69	0.5	1.42e-7	Colorectal cancer;
THYM	cis	rs752010	0.806	rs6696511	chr1:42110888	T/C	cg06885757	chr1:42089581	HIVEP3	0.62	8.02	0.64	2.74e-12	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs1568889	0.838	rs7127069	chr11:28325412	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.37	0.6	6.17e-11	Bipolar disorder;
THYM	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg01264106	chr22:38071602	LGALS1	0.41	4.97	0.45	2.94e-6	Fat distribution (HIV);
THYM	cis	rs10911251	0.508	rs10797854	chr1:183106739	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.67	0.43	9.88e-6	Colorectal cancer;
THYM	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.17	0.64	1.34e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs11767557	1.000	rs11763230	chr7:143108841	C/T	cg05908241	chr7:143109367	NA	-0.63	-6.2	-0.54	1.45e-8	Alzheimer's disease (late onset);
THYM	trans	rs4650994	0.905	rs12753251	chr1:178529898	G/A	cg05059571	chr16:84539110	KIAA1609	-0.77	-8.56	-0.66	1.94e-13	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg16586182	chr3:47516702	SCAP	-0.59	-4.93	-0.45	3.52e-6	Colorectal cancer;
THYM	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg08213375	chr14:104286397	PPP1R13B	0.45	4.74	0.44	7.48e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg06634786	chr22:41940651	POLR3H	0.73	5.33	0.48	6.69e-7	Vitiligo;
THYM	cis	rs12478296	0.792	rs57482298	chr2:243011148	C/A	cg06360820	chr2:242988706	NA	-1.09	-6.77	-0.57	1.07e-9	Obesity-related traits;
THYM	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg17105886	chr17:28927953	LRRC37B2	1.22	7.15	0.59	1.81e-10	Body mass index;
THYM	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg17264618	chr3:40429014	ENTPD3	-0.5	-4.91	-0.45	3.74e-6	Renal cell carcinoma;
THYM	cis	rs714027	0.546	rs5763614	chr22:30331290	A/G	cg27665648	chr22:30112403	NA	0.53	4.74	0.44	7.42e-6	Lymphocyte counts;
THYM	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg02398342	chr17:80708632	TBCD;FN3K	0.69	5.22	0.47	1.05e-6	Glycated hemoglobin levels;
THYM	cis	rs72717009	0.825	rs7552317	chr1:161479438	C/T	cg23840854	chr1:161414152	NA	-1.01	-5.36	-0.48	5.81e-7	Rheumatoid arthritis;
THYM	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg06728252	chr6:26598149	ABT1	-0.44	-5.15	-0.47	1.43e-6	Intelligence (multi-trait analysis);
THYM	cis	rs858239	1.000	rs199348	chr7:23293098	C/A	cg05407003	chr7:23246146	NA	-0.62	-4.65	-0.43	1.06e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs28647808	0.786	rs28458971	chr9:136255736	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs3923380	0.585	rs7659268	chr4:77466254	T/C	cg07933720	chr4:77468187	SHROOM3	0.38	4.76	0.44	6.9e-6	Craniofacial microsomia;
THYM	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.76	-0.44	6.97e-6	Mean corpuscular volume;
THYM	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg13175981	chr1:150552382	MCL1	0.7	4.99	0.46	2.72e-6	Tonsillectomy;
THYM	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg00495681	chr13:53174319	NA	0.77	6.97	0.58	4.24e-10	Lewy body disease;
THYM	cis	rs1003719	1.000	rs2835607	chr21:38491973	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.72	5.19	0.47	1.18e-6	Eye color traits;
THYM	cis	rs4523957	0.928	rs11872068	chr17:2176528	G/A	cg16513277	chr17:2031491	SMG6	-0.8	-7.64	-0.62	1.69e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.72	-0.44	7.98e-6	Fear of minor pain;
THYM	cis	rs611744	0.647	rs11785776	chr8:109264933	C/T	cg21045802	chr8:109455806	TTC35	0.62	5.38	0.48	5.32e-7	Dupuytren's disease;
THYM	cis	rs6840360	0.550	rs12651635	chr4:152557786	C/T	cg22705602	chr4:152727874	NA	-0.8	-8.47	-0.66	3e-13	Intelligence (multi-trait analysis);
THYM	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg05043794	chr9:111880884	C9orf5	-0.4	-5.64	-0.5	1.71e-7	Menarche (age at onset);
THYM	cis	rs7107174	1.000	rs11601161	chr11:78073280	A/G	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg04362960	chr10:104952993	NT5C2	0.6	5.11	0.46	1.66e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2635047	0.512	rs9962436	chr18:44599109	A/G	cg19077165	chr18:44547161	KATNAL2	-0.43	-4.62	-0.43	1.2e-5	Educational attainment;
THYM	cis	rs9814567	0.722	rs13083717	chr3:134348796	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.75	6.35	0.55	7.31e-9	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2282300	0.956	rs594937	chr11:30390132	A/G	cg06241208	chr11:30344200	C11orf46	0.8	5.64	0.5	1.73e-7	Morning vs. evening chronotype;
THYM	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.86	-5.62	-0.5	1.94e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs9443189	0.865	rs2133190	chr6:76443493	A/G	cg01950844	chr6:76311363	SENP6	-0.78	-4.57	-0.42	1.47e-5	Prostate cancer;
THYM	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg18252515	chr7:66147081	NA	-1.42	-8.45	-0.66	3.31e-13	Diabetic kidney disease;
THYM	cis	rs870825	0.929	rs10027213	chr4:185579871	C/G	cg04058563	chr4:185651563	MLF1IP	0.96	6.74	0.57	1.21e-9	Blood protein levels;
THYM	cis	rs4803468	1.000	rs284650	chr19:41927129	A/G	cg09537434	chr19:41945824	ATP5SL	-1.05	-9.33	-0.69	4.53e-15	Height;
THYM	cis	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.33e-5	Retinal vascular caliber;
THYM	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg14517863	chr17:44321492	NA	-0.44	-5.0	-0.46	2.59e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg05335186	chr13:53173507	NA	-0.47	-5.92	-0.52	5.1e-8	Lewy body disease;
THYM	cis	rs4732038	0.510	rs4345502	chr7:134271015	G/C	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs7119	0.689	rs12907630	chr15:77812906	G/T	cg27398640	chr15:77910606	LINGO1	-0.57	-5.76	-0.51	1.03e-7	Type 2 diabetes;
THYM	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.76	0.44	7.04e-6	Bipolar disorder;
THYM	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg02038168	chr22:39784481	NA	-0.67	-5.24	-0.47	9.53e-7	Intelligence (multi-trait analysis);
THYM	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg18352616	chr4:3374830	RGS12	-0.74	-8.26	-0.65	8.57e-13	Serum sulfate level;
THYM	cis	rs13064411	0.542	rs11537650	chr3:113222036	G/A	cg18753928	chr3:113234510	CCDC52	-0.84	-7.97	-0.63	3.49e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg11526020	chr17:80870163	TBCD	0.48	4.72	0.44	8e-6	Glycated hemoglobin levels;
THYM	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg12560992	chr17:57184187	TRIM37	-0.94	-9.16	-0.68	1.04e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7426056	0.530	rs62183985	chr2:204577204	G/A	cg07930752	chr2:204569955	CD28	-0.73	-5.28	-0.48	8.21e-7	Primary sclerosing cholangitis;
THYM	cis	rs6429082	0.818	rs834198	chr1:235671987	A/G	cg26050004	chr1:235667680	B3GALNT2	0.74	5.91	0.52	5.24e-8	Adiposity;
THYM	cis	rs4889855	0.556	rs4278795	chr17:78533189	A/T	cg16591659	chr17:78472290	NA	0.42	4.81	0.44	5.59e-6	Fractional excretion of uric acid;
THYM	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg06108461	chr20:60628389	TAF4	-1.03	-8.58	-0.66	1.8e-13	Body mass index;
THYM	cis	rs28595532	0.920	rs115084148	chr4:119739290	A/G	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs17767294	0.708	rs72851160	chr6:28067841	T/G	cg08851530	chr6:28072375	NA	1.15	4.46	0.42	2.28e-5	Parkinson's disease;
THYM	cis	rs4731207	0.592	rs6967988	chr7:124570472	T/A	cg05285228	chr7:124571219	POT1	-0.69	-5.26	-0.47	8.94e-7	Cutaneous malignant melanoma;
THYM	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg16797656	chr11:68205561	LRP5	0.48	5.11	0.46	1.67e-6	Total body bone mineral density;
THYM	cis	rs9486719	1.000	rs9486719	chr6:97060124	G/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-5.38	-0.48	5.41e-7	Migraine;Coronary artery disease;
THYM	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	6.89	0.58	5.96e-10	Electrocardiographic conduction measures;
THYM	cis	rs2455799	0.613	rs6789076	chr3:15807725	A/T	cg16303742	chr3:15540471	COLQ	0.54	5.78	0.51	9.67e-8	Mean platelet volume;
THYM	cis	rs34779708	0.966	rs2045915	chr10:35418616	G/C	cg03585969	chr10:35415529	CREM	0.67	5.01	0.46	2.51e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs10927875	0.800	rs1627145	chr1:16328116	C/T	cg22431228	chr1:16359049	CLCNKA	-0.53	-5.17	-0.47	1.28e-6	Dilated cardiomyopathy;
THYM	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg15164180	chr2:241846931	NA	-0.34	-4.7	-0.43	8.9e-6	Urinary metabolites;
THYM	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg16680214	chr1:154839983	KCNN3	-0.5	-6.08	-0.53	2.55e-8	Prostate cancer;
THYM	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg02487422	chr3:49467188	NICN1	0.63	4.9	0.45	3.96e-6	Resting heart rate;
THYM	cis	rs9435341	1.000	rs1762484	chr1:107613923	A/C	cg09367891	chr1:107599246	PRMT6	-0.69	-4.88	-0.45	4.2e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs13064411	0.696	rs35860985	chr3:113209828	C/T	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg00645579	chr11:617140	IRF7;MUPCDH	-0.41	-4.72	-0.44	8.08e-6	Systemic lupus erythematosus;
THYM	cis	rs10992471	0.580	rs12341093	chr9:95234182	G/T	cg14631576	chr9:95140430	CENPP	-0.99	-9.94	-0.71	2.19e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg07404485	chr7:94953653	PON1	-0.66	-4.55	-0.42	1.6e-5	Yu-Zhi constitution type in type 2 diabetes;
THYM	cis	rs4604732	0.536	rs76191272	chr1:247628055	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.69	4.8	0.44	5.99e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg13395646	chr4:1353034	KIAA1530	-0.61	-5.23	-0.47	1.02e-6	Obesity-related traits;
THYM	cis	rs2408955	0.542	rs7975632	chr12:48443048	C/T	cg21466736	chr12:48725269	NA	-0.51	-5.21	-0.47	1.09e-6	Glycated hemoglobin levels;
THYM	cis	rs61931739	0.929	rs10844740	chr12:34067930	C/T	cg06521331	chr12:34319734	NA	0.58	4.74	0.44	7.59e-6	Morning vs. evening chronotype;
THYM	cis	rs10992471	0.639	rs10125587	chr9:95499882	G/A	cg14631576	chr9:95140430	CENPP	-0.95	-8.6	-0.66	1.58e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg17747265	chr1:1875780	NA	-0.79	-9.12	-0.68	1.23e-14	Body mass index;
THYM	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7818345	0.935	rs4333618	chr8:19283442	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.53	0.42	1.73e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs56104184	0.887	rs16982311	chr19:49342188	C/T	cg16594139	chr19:49340574	PLEKHA4;HSD17B14	1.04	6.49	0.55	3.96e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg07570687	chr10:102243282	WNT8B	0.84	8.13	0.64	1.59e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9361491	0.608	rs4706723	chr6:79462736	C/G	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg08213375	chr14:104286397	PPP1R13B	0.45	4.75	0.44	7.26e-6	Reticulocyte count;
THYM	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg04607235	chr12:12878440	APOLD1	0.69	5.68	0.5	1.45e-7	Birth weight;
THYM	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg27398817	chr8:82754497	SNX16	-0.84	-6.75	-0.57	1.15e-9	Diastolic blood pressure;
THYM	cis	rs3804749	0.966	rs9823527	chr3:122842611	G/A	cg10259872	chr3:122802215	PDIA5	0.49	5.46	0.49	3.85e-7	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs3772130	0.962	rs6768621	chr3:121530274	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs7575217	0.697	rs2582930	chr2:101721369	T/A	cg23907051	chr2:101730305	TBC1D8	-0.41	-5.62	-0.5	1.91e-7	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs7607369	0.617	rs12987009	chr2:219658170	A/T	cg02176678	chr2:219576539	TTLL4	-0.56	-4.91	-0.45	3.78e-6	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs9527	0.615	rs7073295	chr10:104672233	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-5.01	-0.46	2.51e-6	Arsenic metabolism;
THYM	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg01751800	chr4:77820391	ANKRD56	0.55	4.59	0.43	1.36e-5	Emphysema distribution in smoking;
THYM	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg09436375	chr6:42928200	GNMT	0.45	5.79	0.51	8.96e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs13064411	0.518	rs1471883	chr3:113211828	C/T	cg18753928	chr3:113234510	CCDC52	-0.78	-7.16	-0.59	1.68e-10	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs8073060	0.963	rs35614987	chr17:33869466	A/C	cg24895173	chr17:33825374	SLFN12L	0.62	5.09	0.46	1.78e-6	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs981844	0.796	rs17030437	chr4:154704225	A/C	cg22178613	chr4:154710499	SFRP2	0.59	4.78	0.44	6.39e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs7523273	0.606	rs2724380	chr1:207949682	C/T	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	cis	rs2303759	0.874	rs10411630	chr19:49891314	C/A	cg22307029	chr19:49891270	CCDC155	0.87	8.02	0.64	2.74e-12	Multiple sclerosis;
THYM	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.32	0.54	8.42e-9	Platelet count;
THYM	cis	rs2072499	0.966	rs2853643	chr1:156184831	G/A	cg25208724	chr1:156163844	SLC25A44	1.11	12.12	0.78	5.46e-21	Testicular germ cell tumor;
THYM	cis	rs7567389	0.719	rs4150404	chr2:128050000	A/G	cg06038358	chr2:128176007	PROC	-0.43	-4.53	-0.42	1.7e-5	Self-rated health;
THYM	cis	rs12594515	0.874	rs8032878	chr15:45998015	A/G	cg01629716	chr15:45996671	NA	0.53	5.27	0.48	8.47e-7	Waist circumference;Weight;
THYM	cis	rs4523957	0.928	rs4790325	chr17:2192085	C/T	cg16513277	chr17:2031491	SMG6	-0.79	-7.37	-0.6	6.32e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg18876405	chr7:65276391	NA	-0.61	-5.26	-0.47	8.91e-7	Aortic root size;
THYM	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg09035930	chr12:129282057	SLC15A4	0.86	12.0	0.78	9.76e-21	Systemic lupus erythematosus;
THYM	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg08859206	chr1:53392774	SCP2	0.43	4.48	0.42	2.05e-5	Monocyte count;
THYM	trans	rs1997103	0.911	rs10238738	chr7:55412359	T/C	cg20935933	chr6:143382018	AIG1	0.86	6.91	0.58	5.41e-10	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg00012203	chr2:219082015	ARPC2	-0.66	-5.32	-0.48	7.03e-7	Colorectal cancer;
THYM	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg02891314	chr5:179741120	GFPT2	-0.88	-7.14	-0.59	1.88e-10	Height;
THYM	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg14634687	chr17:47094252	IGF2BP1	0.31	4.64	0.43	1.09e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs8018808	0.935	rs12436593	chr14:77928476	C/T	cg20045696	chr14:77926864	AHSA1	0.52	4.7	0.43	8.72e-6	Myeloid white cell count;
THYM	cis	rs7020830	0.898	rs308492	chr9:37298020	C/T	cg14294708	chr9:37120828	ZCCHC7	1.24	15.36	0.84	1.74e-27	Schizophrenia;
THYM	cis	rs988913	1.000	rs988913	chr6:54756308	C/T	cg19716238	chr6:54711378	FAM83B	0.49	5.07	0.46	1.93e-6	Menarche (age at onset);
THYM	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg02753203	chr1:228287806	NA	0.74	6.42	0.55	5.31e-9	Diastolic blood pressure;
THYM	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg06481639	chr22:41940642	POLR3H	0.79	5.65	0.5	1.69e-7	Vitiligo;
THYM	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg14004847	chr7:1930337	MAD1L1	-0.63	-4.79	-0.44	6.15e-6	Bipolar disorder and schizophrenia;
THYM	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg15704280	chr7:45808275	SEPT13	1.02	8.31	0.65	6.7e-13	Coronary artery disease;
THYM	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg01324343	chr3:183735012	ABCC5	-0.76	-8.71	-0.67	9.41e-14	Anterior chamber depth;
THYM	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg24209194	chr3:40518798	ZNF619	0.57	4.59	0.43	1.35e-5	Renal cell carcinoma;
THYM	cis	rs13064411	0.735	rs6438157	chr3:113207316	G/T	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7737355	0.741	rs6875363	chr5:130581195	A/G	cg26967385	chr5:130501764	HINT1	-0.53	-4.71	-0.43	8.49e-6	Life satisfaction;
THYM	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg18512352	chr11:47633146	NA	-0.53	-6.99	-0.58	3.7e-10	Subjective well-being;
THYM	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg23356831	chr14:105996513	TMEM121	0.58	6.23	0.54	1.25e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg18252515	chr7:66147081	NA	0.63	4.7	0.43	8.9e-6	Aortic root size;
THYM	cis	rs17443541	0.507	rs971326	chr2:200450244	A/G	cg03741458	chr2:200468445	NA	0.78	5.67	0.5	1.54e-7	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg03517284	chr6:25882590	NA	-0.66	-4.9	-0.45	3.99e-6	Height;
THYM	cis	rs12049351	0.613	rs7552561	chr1:229580986	C/T	cg11742688	chr1:229674241	ABCB10	-0.55	-4.62	-0.43	1.2e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg09184832	chr6:79620586	NA	-0.59	-4.72	-0.44	8.17e-6	Intelligence (multi-trait analysis);
THYM	trans	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg10856724	chr12:34555212	NA	-1.01	-9.33	-0.69	4.53e-15	Bladder cancer;
THYM	cis	rs4474465	0.915	rs10899504	chr11:78157983	C/A	cg19901956	chr11:77921274	USP35	-0.62	-4.63	-0.43	1.15e-5	Alzheimer's disease (survival time);
THYM	cis	rs4654899	0.802	rs12137203	chr1:21109088	T/A	cg01072550	chr1:21505969	NA	-0.61	-5.27	-0.48	8.41e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs4654899	0.714	rs12401630	chr1:21495049	G/A	cg01072550	chr1:21505969	NA	-0.73	-6.58	-0.56	2.6e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs7584330	0.554	rs3751110	chr2:238427142	T/C	cg14458575	chr2:238380390	NA	0.79	4.65	0.43	1.06e-5	Prostate cancer;
THYM	cis	rs367615	0.512	rs246105	chr5:108672946	C/T	cg17395555	chr5:108820864	NA	0.56	6.99	0.58	3.83e-10	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs5760092	0.717	rs5760101	chr22:24248712	T/C	cg00024416	chr22:24240387	NA	-0.72	-6.59	-0.56	2.43e-9	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs4911259	0.552	rs13041458	chr20:31467376	G/T	cg13636640	chr20:31349939	DNMT3B	-0.61	-5.88	-0.52	6.05e-8	Inflammatory bowel disease;
THYM	cis	rs10799590	1.000	rs298730	chr1:224841244	C/T	cg01808320	chr1:224927238	CNIH3	0.52	4.74	0.44	7.54e-6	Opioid dependence;
THYM	cis	rs58785573	0.624	rs2126526	chr4:38618689	A/G	cg24279243	chr4:38676559	KLF3	0.46	4.53	0.42	1.68e-5	Lymphocyte percentage of white cells;
THYM	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg25754956	chr12:51612065	POU6F1	1.04	7.47	0.61	3.94e-11	Cisplatin-induced ototoxicity;
THYM	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg19693284	chr19:2783607	SGTA	0.85	6.26	0.54	1.11e-8	Total cholesterol levels;
THYM	cis	rs9914544	0.564	rs9907723	chr17:18758853	T/C	cg26378065	chr17:18585709	ZNF286B	0.59	4.58	0.43	1.4e-5	Educational attainment (years of education);
THYM	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg08484992	chr16:88977278	CBFA2T3	-0.44	-5.37	-0.48	5.48e-7	Social autistic-like traits;
THYM	cis	rs7633770	0.841	rs11709936	chr3:46680483	C/G	cg11219411	chr3:46661640	NA	0.45	4.7	0.43	8.96e-6	Coronary artery disease;
THYM	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg09904177	chr6:26538194	HMGN4	0.64	5.41	0.49	4.78e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6430585	0.583	rs7561565	chr2:136640787	A/C	cg23851026	chr2:136556271	LCT	0.75	7.16	0.59	1.7e-10	Corneal structure;
THYM	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg27034606	chr17:28928453	LRRC37B2	0.79	4.89	0.45	4.06e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs6840360	0.967	rs4383600	chr4:152694383	T/C	cg22705602	chr4:152727874	NA	-0.6	-6.54	-0.56	3.08e-9	Intelligence (multi-trait analysis);
THYM	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg09517075	chr8:22133004	PIWIL2	0.65	5.75	0.51	1.08e-7	Hypertriglyceridemia;
THYM	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-15.41	-0.85	1.38e-27	Height;
THYM	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg18681998	chr4:17616180	MED28	0.94	8.82	0.67	5.62e-14	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg26441486	chr22:50317300	CRELD2	0.44	6.39	0.55	6.13e-9	Schizophrenia;
THYM	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-15.39	-0.84	1.51e-27	Height;
THYM	cis	rs6032067	0.866	rs2233901	chr20:43851094	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	0.71	6.41	0.55	5.57e-9	Blood protein levels;
THYM	cis	rs10927875	0.526	rs35340817	chr1:16178917	T/C	cg21385522	chr1:16154831	NA	-1.09	-7.8	-0.62	7.98e-12	Dilated cardiomyopathy;
THYM	cis	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg06640241	chr16:89574553	SPG7	0.9	8.1	0.64	1.84e-12	Multiple myeloma (IgH translocation);
THYM	cis	rs2742417	0.603	rs2064064	chr3:45759995	C/T	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs1461503	0.966	rs10892936	chr11:122841720	G/A	cg27398637	chr11:122830231	C11orf63	-0.71	-6.64	-0.56	1.95e-9	Menarche (age at onset);
THYM	cis	rs4474465	1.000	rs11237508	chr11:78173297	C/T	cg19901956	chr11:77921274	USP35	-0.6	-4.55	-0.42	1.56e-5	Alzheimer's disease (survival time);
THYM	cis	rs2625529	0.938	rs2625530	chr15:72126034	G/A	cg16672083	chr15:72433130	SENP8	-0.57	-4.79	-0.44	6.07e-6	Red blood cell count;
THYM	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg17279839	chr7:150038598	RARRES2	0.56	5.0	0.46	2.62e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg21394778	chr1:3037102	PRDM16	0.46	4.47	0.42	2.12e-5	Height;
THYM	cis	rs6964587	0.692	rs4729018	chr7:91644613	C/T	cg22709100	chr7:91322751	NA	0.61	4.57	0.42	1.44e-5	Breast cancer;
THYM	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg24642439	chr20:33292090	TP53INP2	0.63	4.95	0.45	3.19e-6	Coronary artery disease;
THYM	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg05962950	chr11:130786565	SNX19	-0.91	-8.9	-0.67	3.75e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs3741151	0.656	rs11544311	chr11:73106237	A/C	cg12959048	chr11:73096162	RELT	-0.52	-5.04	-0.46	2.21e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7264396	0.887	rs736031	chr20:34048625	T/C	cg26038318	chr20:34205095	SPAG4	0.53	4.47	0.42	2.15e-5	Total cholesterol levels;
THYM	cis	rs9361491	0.608	rs7766791	chr6:79458753	G/A	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7264396	0.887	rs2236160	chr20:34101821	A/G	cg26038318	chr20:34205095	SPAG4	0.53	4.47	0.42	2.15e-5	Total cholesterol levels;
THYM	cis	rs6906287	0.647	rs35962656	chr6:118919593	G/T	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg03806693	chr22:41940476	POLR3H	0.99	8.12	0.64	1.7e-12	Vitiligo;
THYM	cis	rs1524976	1.000	rs2177685	chr3:65491171	T/C	cg16238336	chr3:65465873	MAGI1	-1.04	-5.76	-0.51	1.03e-7	PR interval;
THYM	cis	rs10186029	0.582	rs1992395	chr2:214003871	G/T	cg08319019	chr2:214017104	IKZF2	-0.76	-5.98	-0.52	3.96e-8	Systemic sclerosis;
THYM	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.73	5.41	0.49	4.77e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg13918804	chr1:2043761	PRKCZ	0.9	9.76	0.71	5.4e-16	Height;
THYM	cis	rs7809950	1.000	rs12668402	chr7:107173020	G/A	cg23024343	chr7:107201750	COG5	-0.92	-8.37	-0.65	4.88e-13	Coronary artery disease;
THYM	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg13852791	chr20:30311386	BCL2L1	0.74	5.35	0.48	6.15e-7	Mean corpuscular hemoglobin;
THYM	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg07362569	chr17:61921086	SMARCD2	0.66	5.61	0.5	2.03e-7	Prudent dietary pattern;
THYM	cis	rs6700896	0.864	rs6588153	chr1:66092017	T/A	cg04111102	chr1:66153794	NA	0.56	5.24	0.47	9.48e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7572733	0.514	rs770659	chr2:198669754	G/C	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs6728302	1.000	rs12620618	chr2:232877509	A/G	cg15348839	chr2:232224846	NA	-1.12	-4.49	-0.42	1.98e-5	Height;
THYM	cis	rs9733	0.596	rs72700897	chr1:150626038	C/G	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs8114671	0.967	rs9574	chr20:33764632	C/G	cg08999081	chr20:33150536	PIGU	0.53	4.77	0.44	6.63e-6	Height;
THYM	cis	rs2522056	0.808	rs7704457	chr5:131744790	C/T	cg24060327	chr5:131705240	SLC22A5	-0.71	-4.5	-0.42	1.93e-5	Lymphocyte counts;Fibrinogen;
THYM	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11890956	chr21:40555474	PSMG1	-0.99	-8.4	-0.65	4.29e-13	Cognitive function;
THYM	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg00129232	chr17:37814104	STARD3	0.69	4.51	0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg20887711	chr4:1340912	KIAA1530	0.97	8.88	0.67	4.02e-14	Longevity;
THYM	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg11764359	chr7:65958608	NA	0.85	7.06	0.59	2.78e-10	Aortic root size;
THYM	cis	rs10979	1.000	rs9399447	chr6:143896163	T/A	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs1933112	1.000	rs1933110	chr1:168523455	A/G	cg00154920	chr1:168513310	XCL2	-0.5	-5.03	-0.46	2.31e-6	Blood protein levels;
THYM	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg22920501	chr2:26401640	FAM59B	1.07	9.54	0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs6430585	0.583	rs78364332	chr2:136640101	T/C	cg20242066	chr2:136595261	LCT	0.51	4.89	0.45	4.06e-6	Corneal structure;
THYM	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg27432699	chr2:27873401	GPN1	0.75	6.73	0.57	1.26e-9	Oral cavity cancer;
THYM	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg08132940	chr7:1081526	C7orf50	-0.77	-5.21	-0.47	1.1e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2637266	0.905	rs4357630	chr10:78382883	T/G	cg18941641	chr10:78392320	NA	0.56	4.55	0.42	1.59e-5	Pulmonary function;
THYM	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg14349672	chr11:133703707	NA	-0.54	-4.86	-0.45	4.63e-6	Childhood ear infection;
THYM	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg13736514	chr6:26305472	NA	-0.54	-6.42	-0.55	5.41e-9	Educational attainment;
THYM	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg16586182	chr3:47516702	SCAP	-0.66	-5.58	-0.5	2.25e-7	Colorectal cancer;
THYM	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs9527	0.615	rs7917295	chr10:104701187	A/G	cg15744005	chr10:104629667	AS3MT	-0.6	-4.48	-0.42	2.1e-5	Arsenic metabolism;
THYM	trans	rs561341	0.714	rs474455	chr17:30312465	A/T	cg20587970	chr11:113659929	NA	-1.25	-9.01	-0.68	2.13e-14	Hip circumference adjusted for BMI;
THYM	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.57	-5.57	-0.5	2.41e-7	Lymphocyte counts;
THYM	cis	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg24672777	chr11:48374446	OR4C45	-0.99	-6.44	-0.55	4.78e-9	Axial length;
THYM	cis	rs7580658	0.724	rs12623948	chr2:128001342	G/A	cg09152259	chr2:128156114	NA	-0.36	-4.78	-0.44	6.46e-6	Protein C levels;
THYM	cis	rs600806	0.888	rs12046539	chr1:109875415	C/T	cg02175308	chr1:109941060	SORT1	-0.54	-4.71	-0.43	8.55e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7312774	0.881	rs60941459	chr12:107318583	T/C	cg16260113	chr12:107380972	MTERFD3	0.96	5.17	0.47	1.32e-6	Severe influenza A (H1N1) infection;
THYM	cis	rs34172651	0.917	rs200538	chr16:24735736	C/T	cg06028605	chr16:24865363	SLC5A11	-0.57	-5.59	-0.5	2.13e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg12564285	chr5:131593104	PDLIM4	-0.43	-4.66	-0.43	1.03e-5	Breast cancer;
THYM	cis	rs6570726	0.643	rs9403735	chr6:145936591	C/T	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2282300	0.702	rs4379811	chr11:30294760	C/T	cg09906309	chr11:30344399	C11orf46	0.73	5.38	0.48	5.3e-7	Morning vs. evening chronotype;
THYM	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.84e-8	Systolic blood pressure;
THYM	cis	rs490234	0.702	rs4838275	chr9:128352785	C/T	cg14078157	chr9:128172775	NA	-0.77	-6.1	-0.53	2.27e-8	Mean arterial pressure;
THYM	cis	rs34638657	1.000	rs11639926	chr16:82152710	A/C	cg07307142	chr16:82071433	HSD17B2	-0.77	-5.7	-0.51	1.33e-7	Lung adenocarcinoma;
THYM	cis	rs4654899	1.000	rs6663452	chr1:21423154	T/C	cg01072550	chr1:21505969	NA	-0.75	-6.73	-0.57	1.26e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs6087771	0.642	rs6060411	chr20:30222139	T/C	cg13852791	chr20:30311386	BCL2L1	0.79	7.38	0.6	5.91e-11	Subcortical brain region volumes;Putamen volume;
THYM	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg08564027	chr20:61660810	NA	0.92	9.77	0.71	5.02e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg19875535	chr5:140030758	IK	-0.59	-5.17	-0.47	1.27e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs6598541	0.890	rs28733344	chr15:99281289	A/G	cg13297560	chr15:99320054	IGF1R	-0.49	-4.49	-0.42	2.02e-5	Urate levels;
THYM	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	trans	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs34375054	0.525	rs7133006	chr12:125606123	G/A	cg25124228	chr12:125621409	AACS	-0.8	-6.86	-0.58	6.94e-10	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg06064525	chr11:970664	AP2A2	-0.36	-7.1	-0.59	2.29e-10	Alzheimer's disease (late onset);
THYM	cis	rs7584330	0.617	rs10202195	chr2:238352128	A/G	cg14458575	chr2:238380390	NA	0.89	6.93	0.58	4.97e-10	Prostate cancer;
THYM	cis	rs6674970	1.000	rs6676190	chr1:151079317	C/T	cg11822372	chr1:151115635	SEMA6C	0.74	5.07	0.46	1.95e-6	Childhood ear infection;
THYM	cis	rs61931739	0.929	rs3912551	chr12:34076696	C/T	cg10856724	chr12:34555212	NA	0.6	5.36	0.48	5.8e-7	Morning vs. evening chronotype;
THYM	cis	rs1580019	0.961	rs766660	chr7:32499077	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.62	0.56	2.16e-9	Cognitive ability;
THYM	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.34	0.55	7.55e-9	Total body bone mineral density;
THYM	cis	rs3810291	1.000	rs8101091	chr19:47600601	A/G	cg12068280	chr19:46804528	HIF3A	-0.44	-4.93	-0.45	3.52e-6	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);BMI in smokers;Hip circumference;Body mass index;Body mass index in physically active individuals;
THYM	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg20295408	chr7:1910781	MAD1L1	-0.63	-4.54	-0.42	1.67e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs4242434	0.857	rs11777808	chr8:22462755	A/C	cg01710189	chr8:22454888	PDLIM2	-0.55	-5.77	-0.51	9.8e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg27572855	chr1:25598939	RHD	0.63	4.96	0.45	3.14e-6	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg00898013	chr13:113819073	PROZ	-0.88	-9.0	-0.68	2.24e-14	Platelet distribution width;
THYM	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs854765	0.693	rs8079418	chr17:17924060	C/T	cg04398451	chr17:18023971	MYO15A	-0.82	-7.14	-0.59	1.9e-10	Total body bone mineral density;
THYM	cis	rs611744	0.517	rs62537573	chr8:109269281	C/T	cg21045802	chr8:109455806	TTC35	0.71	6.6	0.56	2.32e-9	Dupuytren's disease;
THYM	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg26850624	chr5:429559	AHRR	-0.72	-5.74	-0.51	1.11e-7	Cystic fibrosis severity;
THYM	cis	rs7173743	0.756	rs12903668	chr15:79129320	A/G	cg15571903	chr15:79123663	NA	0.55	6.25	0.54	1.14e-8	Coronary artery disease;
THYM	cis	rs7582180	0.614	rs3748930	chr2:101010082	G/C	cg21926883	chr2:100939477	LONRF2	-0.66	-6.02	-0.53	3.23e-8	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg02478829	chr6:26598070	ABT1	-0.33	-4.49	-0.42	1.97e-5	Intelligence (multi-trait analysis);
THYM	cis	rs478304	0.651	rs4930312	chr11:65499719	G/A	cg27068330	chr11:65405492	SIPA1	-0.95	-8.8	-0.67	6.03e-14	Acne (severe);
THYM	cis	rs8112211	1.000	rs12609247	chr19:38821697	C/T	cg25820703	chr19:38877220	GGN	-0.48	-4.53	-0.42	1.71e-5	Blood protein levels;
THYM	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg00757033	chr12:89920650	WDR51B	0.77	11.72	0.77	3.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs921968	0.565	rs608047	chr2:219615910	A/C	cg02176678	chr2:219576539	TTLL4	0.47	4.67	0.43	9.92e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7178572	0.633	rs11854328	chr15:77840129	A/G	cg22256960	chr15:77711686	NA	-0.77	-5.95	-0.52	4.39e-8	Type 2 diabetes;
THYM	cis	rs3768617	0.510	rs7525917	chr1:183065406	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.83	0.44	5.26e-6	Fuchs's corneal dystrophy;
THYM	cis	rs6939532	0.648	rs9379862	chr6:26370707	T/C	cg14345882	chr6:26364793	BTN3A2	0.45	5.47	0.49	3.69e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs473651	0.904	rs551859	chr2:239371836	T/C	cg18131467	chr2:239335373	ASB1	1.09	10.0	0.72	1.68e-16	Multiple system atrophy;
THYM	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg00852783	chr1:26633632	UBXN11	0.86	8.77	0.67	7e-14	Obesity-related traits;
THYM	cis	rs2898681	0.642	rs62336790	chr4:53728000	T/C	cg21521518	chr4:53727714	RASL11B	0.45	5.27	0.48	8.54e-7	Optic nerve measurement (cup area);
THYM	cis	rs4294134	0.832	rs12707241	chr7:135259183	T/C	cg08396481	chr7:135194601	CNOT4	-0.81	-4.58	-0.43	1.42e-5	Paget's disease;
THYM	cis	rs4742045	1.000	rs4742045	chr9:4746363	G/T	cg14441153	chr9:4763200	NA	0.58	4.85	0.45	4.9e-6	Mean corpuscular hemoglobin;
THYM	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg09165964	chr15:75287851	SCAMP5	-1.1	-6.31	-0.54	8.71e-9	Lung cancer;
THYM	cis	rs10819861	0.645	rs4743527	chr9:98851075	C/G	cg14508093	chr9:98862825	NA	-0.24	-4.65	-0.43	1.08e-5	Electrocardiographic traits;
THYM	cis	rs669446	0.561	rs571862	chr1:44083110	C/T	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs901683	1.000	rs71496623	chr10:46085866	A/G	cg18240400	chr10:46168597	ANUBL1	0.73	4.73	0.44	7.89e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs2290405	0.527	rs4690329	chr4:931385	T/A	cg04824913	chr4:887549	GAK	0.74	5.5	0.49	3.2e-7	Systemic sclerosis;
THYM	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg27490568	chr2:178487706	NA	0.61	5.63	0.5	1.8e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	trans	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg20587970	chr11:113659929	NA	-1.26	-9.01	-0.68	2.16e-14	Hip circumference adjusted for BMI;
THYM	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg04025307	chr7:1156635	C7orf50	0.65	5.73	0.51	1.2e-7	Longevity;Endometriosis;
THYM	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg01819863	chr10:32635814	EPC1	1.04	6.64	0.56	1.9e-9	Sexual dysfunction (female);
THYM	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg14458575	chr2:238380390	NA	0.9	7.53	0.61	2.94e-11	Prostate cancer;
THYM	cis	rs1448094	0.511	rs11117023	chr12:86145329	G/A	cg00310523	chr12:86230176	RASSF9	-0.57	-5.07	-0.46	1.98e-6	Major depressive disorder;
THYM	cis	rs2282300	0.910	rs528292	chr11:30389710	A/G	cg06241208	chr11:30344200	C11orf46	0.8	5.64	0.5	1.73e-7	Morning vs. evening chronotype;
THYM	cis	rs3820068	0.608	rs12092485	chr1:16048038	A/G	cg13390004	chr1:15929781	NA	0.65	4.88	0.45	4.3e-6	Systolic blood pressure;
THYM	cis	rs1003719	0.762	rs6517402	chr21:38447423	A/C	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs2806561	0.765	rs2806556	chr1:23502850	G/A	cg19743168	chr1:23544995	NA	0.54	5.62	0.5	1.91e-7	Height;
THYM	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg18301423	chr5:131593218	PDLIM4	0.51	4.5	0.42	1.89e-5	Acylcarnitine levels;
THYM	cis	rs9527	0.590	rs1046411	chr10:104837816	G/A	cg04362960	chr10:104952993	NT5C2	0.64	5.02	0.46	2.4e-6	Arsenic metabolism;
THYM	cis	rs4731207	0.698	rs7796015	chr7:124521146	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg23428387	chr22:49814324	NA	-0.57	-5.41	-0.49	4.77e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg13010199	chr12:38710504	ALG10B	-0.58	-4.53	-0.42	1.72e-5	Morning vs. evening chronotype;
THYM	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg18538332	chr22:24372958	LOC391322	-1.03	-14.91	-0.84	1.27e-26	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2085601	0.566	rs1795721	chr4:89943473	C/G	cg17769793	chr4:89976368	FAM13A	-0.53	-5.83	-0.51	7.75e-8	Hair greying;
THYM	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06850241	chr22:41845214	NA	0.59	5.36	0.48	5.81e-7	Vitiligo;
THYM	cis	rs422249	0.504	rs174538	chr11:61560081	G/A	cg19610905	chr11:61596333	FADS2	-0.63	-5.29	-0.48	7.74e-7	Trans fatty acid levels;
THYM	trans	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs2046867	0.818	rs17690720	chr3:72866030	T/C	cg25664220	chr3:72788482	NA	-0.95	-7.97	-0.63	3.52e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs503425	0.546	rs540716	chr11:118685015	C/T	cg07003643	chr11:119217537	C1QTNF5;MFRP	-0.68	-4.49	-0.42	2.03e-5	Systemic lupus erythematosus;
THYM	cis	rs3796352	1.000	rs11717619	chr3:53003179	A/C	cg07884673	chr3:53033167	SFMBT1	1.13	5.83	0.51	7.45e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2970992	0.764	rs2175791	chr2:101330661	G/A	cg01042948	chr2:101319752	NA	0.59	5.84	0.51	7.15e-8	Educational attainment;
THYM	cis	rs3781426	0.920	rs3781395	chr10:126726827	C/T	cg04494136	chr10:126703576	CTBP2	-0.4	-5.37	-0.48	5.61e-7	Height;
THYM	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg02228675	chr17:40259724	DHX58	-0.66	-5.49	-0.49	3.28e-7	Fibrinogen levels;
THYM	cis	rs6988636	1.000	rs7002021	chr8:124185250	G/A	cg23067535	chr8:124195133	FAM83A	-1.1	-5.77	-0.51	9.8e-8	Urinary uromodulin levels;
THYM	cis	rs877282	1.000	rs12779159	chr10:772143	T/C	cg10556349	chr10:835070	NA	-0.73	-4.86	-0.45	4.71e-6	Uric acid levels;
THYM	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Gout;
THYM	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg05425664	chr17:57184151	TRIM37	-0.56	-4.48	-0.42	2.06e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs7607369	0.791	rs72965151	chr2:219344165	G/T	cg02176678	chr2:219576539	TTLL4	-0.73	-6.92	-0.58	5.15e-10	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs6570726	0.620	rs367693	chr6:145815949	G/A	cg13319975	chr6:146136371	FBXO30	-0.66	-5.23	-0.47	9.87e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12042938	0.507	rs1655301	chr1:231731730	T/C	cg04892437	chr1:231737901	TSNAX-DISC1	-0.48	-4.59	-0.43	1.36e-5	Neuranatomic and neurocognitive phenotypes;
THYM	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg20848291	chr7:100343083	ZAN	-0.61	-4.48	-0.42	2.04e-5	Other erythrocyte phenotypes;
THYM	cis	rs13102973	0.965	rs10434072	chr4:135867883	C/T	cg14419869	chr4:135874104	NA	-0.82	-7.94	-0.63	4.06e-12	Subjective well-being;
THYM	cis	rs28595532	0.920	rs116548907	chr4:119735285	G/A	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs3540	0.514	rs2601192	chr15:90936704	G/A	cg22089800	chr15:90895588	ZNF774	0.68	5.12	0.46	1.61e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs854765	0.583	rs11871899	chr17:17826748	C/G	cg04398451	chr17:18023971	MYO15A	-0.8	-7.33	-0.6	7.5e-11	Total body bone mineral density;
THYM	cis	rs16870629	1.000	rs16870629	chr5:1015063	C/T	cg00278107	chr5:1061253	SLC12A7	-0.68	-5.9	-0.52	5.67e-8	QT interval;
THYM	cis	rs747334	0.846	rs12780522	chr10:92720160	A/G	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg12419862	chr22:24373484	LOC391322	-0.88	-10.24	-0.72	5.07e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg27129171	chr3:47204927	SETD2	-0.75	-7.46	-0.61	4.1e-11	Colorectal cancer;
THYM	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6570726	0.902	rs396681	chr6:145853603	T/C	cg13319975	chr6:146136371	FBXO30	-0.71	-5.91	-0.52	5.28e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.5	-4.66	-0.43	1.04e-5	Lymphocyte counts;
THYM	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg23161317	chr6:28129485	ZNF389	0.7	5.17	0.47	1.3e-6	Cardiac Troponin-T levels;
THYM	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg11245990	chr11:68621969	NA	0.57	7.46	0.61	4.06e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg13390004	chr1:15929781	NA	0.58	4.51	0.42	1.86e-5	Systolic blood pressure;
THYM	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg06028605	chr16:24865363	SLC5A11	-0.63	-5.02	-0.46	2.43e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg20203395	chr5:56204925	C5orf35	-0.65	-4.53	-0.42	1.68e-5	Initial pursuit acceleration;
THYM	cis	rs34779708	0.966	rs7913615	chr10:35422957	T/G	cg03585969	chr10:35415529	CREM	0.65	4.51	0.42	1.87e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6732160	0.588	rs13394018	chr2:73372605	C/T	cg24220031	chr2:73402428	NA	-0.69	-5.79	-0.51	9.13e-8	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg03929089	chr4:120376271	NA	-1.01	-13.71	-0.82	3.1e-24	Height;
THYM	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg07424592	chr7:64974309	NA	1.09	5.14	0.47	1.5e-6	Diabetic kidney disease;
THYM	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs892961	0.932	rs7208336	chr17:75412932	T/C	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg14416269	chr4:6271139	WFS1	0.48	4.65	0.43	1.09e-5	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	trans	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg25214090	chr10:38739885	LOC399744	0.83	7.11	0.59	2.14e-10	Corneal astigmatism;
THYM	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg03929089	chr4:120376271	NA	-0.8	-8.05	-0.64	2.39e-12	Height;
THYM	trans	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg18335740	chr13:41363409	SLC25A15	0.7	8.14	0.64	1.54e-12	Lewy body disease;
THYM	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg09035930	chr12:129282057	SLC15A4	0.84	10.7	0.74	5.31e-18	Systemic lupus erythematosus;
THYM	cis	rs7580658	0.724	rs7568261	chr2:128117324	C/T	cg10021288	chr2:128175891	PROC	-0.65	-6.12	-0.53	2.12e-8	Protein C levels;
THYM	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg09367891	chr1:107599246	PRMT6	0.71	5.25	0.47	9.38e-7	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs7719624	0.870	rs10042825	chr5:135396084	A/T	cg15329133	chr5:135467951	SMAD5;SMAD5OS	0.52	4.46	0.42	2.28e-5	Response to cytidine analogues (gemcitabine);
THYM	cis	rs11225247	1.000	rs11547915	chr11:102272839	C/A	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs2346160	0.899	rs172283	chr6:167691225	T/C	cg21686812	chr6:168078911	NA	-0.53	-4.72	-0.44	8.23e-6	Parental extreme longevity (95 years and older);
THYM	cis	rs7583236	0.500	rs7565597	chr2:70336070	T/G	cg19638749	chr2:70312615	NA	0.78	4.83	0.44	5.13e-6	Obesity-related traits;
THYM	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.63	-0.66	1.37e-13	Mean corpuscular volume;
THYM	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg07747251	chr5:1868357	NA	0.67	5.85	0.51	7e-8	Cardiovascular disease risk factors;
THYM	cis	rs7575217	0.622	rs12466496	chr2:101768115	T/C	cg23907051	chr2:101730305	TBC1D8	-0.33	-4.49	-0.42	2.02e-5	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs72829446	0.505	rs72842824	chr17:7352910	G/A	cg02795151	chr17:7402630	POLR2A	0.56	5.6	0.5	2.05e-7	Androgen levels;
THYM	cis	rs7772486	0.790	rs4314514	chr6:146260010	A/G	cg13319975	chr6:146136371	FBXO30	0.73	6.11	0.53	2.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs2456568	0.867	rs72962810	chr11:93663619	A/G	cg17595323	chr11:93583763	C11orf90	-0.56	-5.46	-0.49	3.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg11245990	chr11:68621969	NA	0.55	7.26	0.6	1.03e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs10911232	0.507	rs10797815	chr1:182996827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs6906287	0.531	rs72962938	chr6:119016221	T/C	cg21191810	chr6:118973309	C6orf204	0.56	5.26	0.47	8.93e-7	Electrocardiographic conduction measures;
THYM	cis	rs2303759	0.881	rs10412811	chr19:49884495	G/A	cg22133161	chr19:49891603	CCDC155	0.85	5.73	0.51	1.19e-7	Multiple sclerosis;
THYM	cis	rs56161922	1.000	rs11118363	chr1:207859251	G/A	cg09557387	chr1:207818395	CR1L	-1.27	-5.76	-0.51	1.02e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7942486	0.895	rs11603808	chr11:13274991	A/G	cg13286116	chr11:13302098	ARNTL	0.77	8.34	0.65	5.66e-13	Neuroticism;
THYM	cis	rs10779751	0.770	rs2258621	chr1:11141187	C/G	cg08854313	chr1:11322531	MTOR	0.81	5.94	0.52	4.76e-8	Body mass index;
THYM	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7107174	1.000	rs2510046	chr11:77988817	T/C	cg02023728	chr11:77925099	USP35	0.65	5.83	0.51	7.52e-8	Testicular germ cell tumor;
THYM	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg11812906	chr14:75593930	NEK9	-0.83	-7.48	-0.61	3.63e-11	Height;
THYM	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg03264133	chr6:25882463	NA	0.65	5.06	0.46	2e-6	Schizophrenia;
THYM	cis	rs485842	1.000	rs476940	chr11:96026842	C/T	cg23866687	chr11:96026956	MAML2	0.45	6.36	0.55	6.98e-9	Corneal astigmatism;
THYM	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg03188948	chr7:1209495	NA	0.89	6.89	0.58	6.01e-10	Longevity;Endometriosis;
THYM	cis	rs13326165	0.585	rs11708811	chr3:52328607	C/T	cg08438690	chr3:52279403	PPM1M	-0.78	-4.51	-0.42	1.88e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs3916	0.955	rs35771722	chr12:121154000	A/G	cg21892295	chr12:121157589	UNC119B	-0.51	-5.03	-0.46	2.27e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg23428387	chr22:49814324	NA	-0.55	-5.65	-0.5	1.65e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs79149102	0.579	rs12591994	chr15:75320306	A/G	cg17294928	chr15:75287854	SCAMP5	-1.01	-4.92	-0.45	3.66e-6	Lung cancer;
THYM	cis	rs778371	0.723	rs10933406	chr2:233559312	T/C	cg08000102	chr2:233561755	GIGYF2	0.84	7.55	0.61	2.64e-11	Schizophrenia;
THYM	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg22709100	chr7:91322751	NA	-0.63	-4.86	-0.45	4.55e-6	Breast cancer;
THYM	cis	rs7584330	0.740	rs13425580	chr2:238447168	T/C	cg14458575	chr2:238380390	NA	0.62	4.88	0.45	4.23e-6	Prostate cancer;
THYM	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg00814883	chr7:100076585	TSC22D4	-0.96	-6.46	-0.55	4.51e-9	Platelet count;
THYM	cis	rs754466	0.580	rs10430530	chr10:79582812	T/C	cg17075019	chr10:79541650	NA	-0.72	-6.01	-0.52	3.4e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7191700	0.674	rs12597893	chr16:11426331	A/G	cg00044050	chr16:11439710	C16orf75	0.8	6.36	0.55	7.04e-9	Multiple sclerosis;
THYM	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.67	-4.49	-0.42	1.97e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2507	0.603	rs9630436	chr15:74276551	T/C	cg17221444	chr15:74284820	STOML1	-0.61	-4.97	-0.45	2.92e-6	Coronary artery disease;
THYM	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg07870213	chr5:140052090	DND1	0.73	8.28	0.65	7.61e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg11752832	chr7:134001865	SLC35B4	0.71	4.83	0.44	5.26e-6	Mean platelet volume;
THYM	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg08736216	chr1:53307985	ZYG11A	-0.61	-5.57	-0.5	2.41e-7	Monocyte count;
THYM	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.01	11.04	0.75	9.94e-19	Intelligence (multi-trait analysis);
THYM	cis	rs9309473	0.607	rs12478346	chr2:73584360	C/T	cg20560298	chr2:73613845	ALMS1	-0.67	-4.71	-0.43	8.52e-6	Metabolite levels;
THYM	cis	rs752010	1.000	rs2077172	chr1:42093340	A/G	cg06885757	chr1:42089581	HIVEP3	0.41	4.67	0.43	9.9e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs11771526	1.000	rs11764617	chr7:32339102	T/C	cg27511599	chr7:32358540	NA	0.71	4.9	0.45	4e-6	Body mass index;
THYM	cis	rs67072384	1.000	rs7122017	chr11:72448558	C/G	cg01380194	chr11:72452482	ARAP1	-0.93	-5.07	-0.46	1.98e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs9790314	1.000	rs336579	chr3:161086610	G/A	cg03342759	chr3:160939853	NMD3	-0.73	-6.57	-0.56	2.67e-9	Morning vs. evening chronotype;
THYM	cis	rs2879627	0.560	rs2154281	chr10:53677635	A/G	cg26332926	chr10:52835078	PRKG1	0.71	4.72	0.44	7.98e-6	Coronary artery disease;
THYM	cis	rs13253111	0.687	rs7840565	chr8:28060783	C/T	cg26534493	chr8:28060551	NA	-0.55	-5.64	-0.5	1.76e-7	Childhood body mass index;
THYM	cis	rs2290159	0.848	rs6771385	chr3:12639419	A/G	cg05467012	chr3:12595696	NA	0.65	4.53	0.42	1.7e-5	Cholesterol, total;
THYM	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg02640540	chr1:67518911	SLC35D1	0.64	4.68	0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs7584330	0.780	rs12474519	chr2:238377012	G/A	cg16989719	chr2:238392110	NA	-0.61	-5.75	-0.51	1.08e-7	Prostate cancer;
THYM	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg17775962	chr7:1200435	ZFAND2A	0.42	5.16	0.47	1.32e-6	Longevity;Endometriosis;
THYM	cis	rs4273100	0.688	rs4924967	chr17:19172196	T/G	cg25447019	chr17:19030144	GRAPL	-0.79	-6.19	-0.54	1.49e-8	Schizophrenia;
THYM	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg12310025	chr6:25882481	NA	-0.69	-5.58	-0.5	2.3e-7	Blood metabolite levels;
THYM	cis	rs67460515	0.500	rs1868105	chr3:160645335	A/G	cg12349858	chr3:160822545	B3GALNT1	0.55	4.45	0.42	2.29e-5	Parkinson's disease;
THYM	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-15.39	-0.84	1.51e-27	Height;
THYM	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg11673840	chr17:47092156	IGF2BP1	-0.5	-5.02	-0.46	2.38e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs10927875	0.619	rs2013019	chr1:16129320	T/C	cg21385522	chr1:16154831	NA	-0.75	-6.19	-0.54	1.52e-8	Dilated cardiomyopathy;
THYM	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg21100191	chr22:23484243	RTDR1	0.82	7.06	0.59	2.77e-10	Bone mineral density;
THYM	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22857025	chr5:266934	NA	-1.5	-9.71	-0.71	6.9e-16	Breast cancer;
THYM	cis	rs11585357	0.843	rs113593167	chr1:17613355	G/A	cg08277548	chr1:17600880	PADI3	-0.9	-5.43	-0.49	4.38e-7	Hair shape;
THYM	cis	rs7772486	0.875	rs9403768	chr6:146406458	A/C	cg23711669	chr6:146136114	FBXO30	0.96	10.28	0.73	4.19e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg02353165	chr6:42928485	GNMT	0.87	8.22	0.64	1.02e-12	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg27534772	chr1:16042836	PLEKHM2	0.53	6.07	0.53	2.6e-8	Systolic blood pressure;
THYM	cis	rs2236918	0.687	rs1776176	chr1:242012554	C/T	cg21919602	chr1:242011447	EXO1	-0.6	-4.5	-0.42	1.95e-5	Menopause (age at onset);
THYM	cis	rs6840360	0.571	rs2165789	chr4:152510130	A/T	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7107174	1.000	rs11237460	chr11:78056274	G/A	cg02023728	chr11:77925099	USP35	0.64	6.31	0.54	8.65e-9	Testicular germ cell tumor;
THYM	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg11905131	chr22:24372483	LOC391322	0.92	9.9	0.71	2.74e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg24675056	chr1:15929824	NA	0.73	5.79	0.51	9.09e-8	Systolic blood pressure;
THYM	cis	rs7809615	0.901	rs11981478	chr7:99163950	C/T	cg12290671	chr7:99195819	NA	-0.99	-4.83	-0.44	5.27e-6	Blood metabolite ratios;
THYM	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg09085632	chr11:111637200	PPP2R1B	0.87	7.38	0.6	5.97e-11	Primary sclerosing cholangitis;
THYM	cis	rs9880211	1.000	rs12695649	chr3:136271916	T/C	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs7264396	0.790	rs2425160	chr20:34425968	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-5.77	-0.51	9.89e-8	Total cholesterol levels;
THYM	cis	rs870825	0.790	rs12513128	chr4:185576729	G/C	cg04058563	chr4:185651563	MLF1IP	0.9	6.24	0.54	1.19e-8	Blood protein levels;
THYM	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg16586182	chr3:47516702	SCAP	0.68	5.64	0.5	1.71e-7	Colorectal cancer;
THYM	cis	rs854765	0.624	rs7501812	chr17:17750907	G/A	cg04398451	chr17:18023971	MYO15A	0.8	7.42	0.61	4.97e-11	Total body bone mineral density;
THYM	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg20891283	chr12:69753455	YEATS4	1.09	12.03	0.78	8.44e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg11663144	chr21:46675770	NA	-0.7	-9.97	-0.71	1.96e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg21609526	chr1:3105151	PRDM16	-0.66	-5.56	-0.5	2.52e-7	Migraine;
THYM	cis	rs4478037	0.915	rs78193453	chr3:33141680	G/T	cg19404215	chr3:33155277	CRTAP	1.22	8.04	0.64	2.42e-12	Major depressive disorder;
THYM	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg12310025	chr6:25882481	NA	-0.67	-5.44	-0.49	4.07e-7	Blood metabolite levels;
THYM	cis	rs13315871	0.790	rs13071148	chr3:58310838	A/C	cg00563845	chr3:58318305	PXK	0.59	5.02	0.46	2.37e-6	Cholesterol, total;
THYM	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg07570687	chr10:102243282	WNT8B	0.75	6.61	0.56	2.26e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2273669	0.667	rs7761290	chr6:109326621	T/G	cg17117243	chr6:109341365	SESN1	-0.9	-5.38	-0.48	5.45e-7	Prostate cancer;
THYM	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg07870213	chr5:140052090	DND1	0.73	8.28	0.65	7.61e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9565309	0.579	rs12431286	chr13:77585432	T/C	cg13866767	chr13:78470850	EDNRB	1.06	4.81	0.44	5.76e-6	Morning vs. evening chronotype;
THYM	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg24112000	chr20:60950667	NA	0.61	5.05	0.46	2.11e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs4836694	0.517	rs1017112	chr9:132936804	A/G	cg05251000	chr9:132935664	FREQ	0.8	5.51	0.49	3.04e-7	Alzheimer's disease (cognitive decline);
THYM	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs4819052	0.851	rs2838867	chr21:46713092	C/T	cg06618935	chr21:46677482	NA	-0.92	-8.63	-0.66	1.36e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg01097406	chr16:89675127	NA	-0.64	-5.33	-0.48	6.66e-7	Vitiligo;
THYM	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.72	-0.44	7.98e-6	Bipolar disorder;
THYM	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg08885076	chr2:99613938	TSGA10	0.57	5.28	0.48	8.05e-7	Chronic sinus infection;
THYM	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg26038318	chr20:34205095	SPAG4	0.64	5.22	0.47	1.04e-6	Total cholesterol levels;
THYM	cis	rs3126085	0.877	rs2338431	chr1:152169305	A/G	cg10321714	chr1:152280068	FLG	0.69	5.08	0.46	1.88e-6	Atopic dermatitis;
THYM	trans	rs629535	0.814	rs558511	chr8:70069908	C/A	cg21567404	chr3:27674614	NA	1.08	10.14	0.72	8.19e-17	Dupuytren's disease;
THYM	cis	rs9790314	0.645	rs6778254	chr3:160892792	T/C	cg03342759	chr3:160939853	NMD3	-0.62	-4.76	-0.44	7.01e-6	Morning vs. evening chronotype;
THYM	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg04282206	chr17:62833786	PLEKHM1P	0.85	8.2	0.64	1.16e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs470093	1.000	rs470093	chr22:44276171	T/G	cg09142166	chr22:44276013	PNPLA5	-0.61	-5.83	-0.51	7.72e-8	Staphylococcus aureus infection;
THYM	cis	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs2463822	1.000	rs2463825	chr11:62094493	G/A	cg06239285	chr11:62104954	ASRGL1	1.44	7.77	0.62	9.14e-12	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg13647721	chr17:30228624	UTP6	0.72	4.47	0.42	2.2e-5	Hip circumference adjusted for BMI;
THYM	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg21385522	chr1:16154831	NA	-0.95	-6.98	-0.58	4.02e-10	Dilated cardiomyopathy;
THYM	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03576123	chr11:487126	PTDSS2	-1.3	-6.61	-0.56	2.21e-9	Body mass index;
THYM	cis	rs1003719	0.715	rs2252893	chr21:38507572	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-4.75	-0.44	7.3e-6	Eye color traits;
THYM	cis	rs2219968	1.000	rs11777219	chr8:78959566	A/T	cg00738934	chr8:78996279	NA	0.91	9.75	0.71	5.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs738322	0.718	rs3761445	chr22:38595411	G/A	cg25457927	chr22:38595422	NA	0.51	5.31	0.48	7.17e-7	Cutaneous nevi;
THYM	cis	rs7809950	0.954	rs2712229	chr7:107295326	T/A	cg23024343	chr7:107201750	COG5	0.74	6.36	0.55	7.04e-9	Coronary artery disease;
THYM	cis	rs9443645	0.527	rs12194642	chr6:79538791	G/A	cg05283184	chr6:79620031	NA	-0.6	-4.7	-0.43	8.7e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg14675211	chr2:100938903	LONRF2	0.77	8.5	0.66	2.68e-13	Intelligence (multi-trait analysis);
THYM	cis	rs240764	0.528	rs6570969	chr6:101233016	T/A	cg21058520	chr6:100914733	NA	-0.57	-4.51	-0.42	1.86e-5	Neuroticism;
THYM	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03647317	chr4:187891568	NA	-0.82	-8.81	-0.67	5.87e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.62	4.6	0.43	1.28e-5	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs7264396	0.635	rs6058365	chr20:34508092	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.67	-5.16	-0.47	1.36e-6	Total cholesterol levels;
THYM	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg07424592	chr7:64974309	NA	1.16	5.55	0.5	2.55e-7	Diabetic kidney disease;
THYM	cis	rs40363	1.000	rs28401	chr16:3515354	C/G	cg22508957	chr16:3507546	NAT15	0.72	7.97	0.63	3.4e-12	Tuberculosis;
THYM	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.76	6.76	0.57	1.1e-9	Chronic sinus infection;
THYM	cis	rs4481887	0.741	rs6587467	chr1:248550976	T/G	cg00666640	chr1:248458726	OR2T12	0.54	4.62	0.43	1.22e-5	Common traits (Other);
THYM	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg04282206	chr17:62833786	PLEKHM1P	-0.83	-8.06	-0.64	2.23e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg18252515	chr7:66147081	NA	0.64	4.6	0.43	1.29e-5	Aortic root size;
THYM	cis	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.53	4.98	0.45	2.88e-6	Lymphocyte counts;
THYM	cis	rs10911232	0.507	rs10797822	chr1:183017769	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs17407555	0.821	rs56267284	chr4:10134370	T/C	cg11266682	chr4:10021025	SLC2A9	-0.6	-5.64	-0.5	1.76e-7	Schizophrenia (age at onset);
THYM	cis	rs2219968	0.828	rs12545997	chr8:78910679	C/A	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1728785	1.000	rs7205960	chr16:68565604	G/C	cg02972257	chr16:68554789	NA	-0.75	-4.57	-0.42	1.47e-5	Ulcerative colitis;
THYM	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg06387496	chr7:2775674	GNA12	-0.43	-4.48	-0.42	2.1e-5	Height;
THYM	cis	rs143283559	1	rs143283559	chr18:77567761	T/G	cg25357022	chr18:77495084	CTDP1	-0.67	-4.8	-0.44	5.79e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg19729930	chr2:74357872	NA	1.25	12.52	0.79	8.21e-22	Gestational age at birth (maternal effect);
THYM	cis	rs6032067	0.561	rs2233093	chr20:43933196	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.57	-5.19	-0.47	1.17e-6	Blood protein levels;
THYM	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.68	-5.06	-0.46	2.08e-6	Colorectal cancer;
THYM	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg26384229	chr12:38710491	ALG10B	0.94	7.82	0.63	7.06e-12	Bladder cancer;
THYM	cis	rs526231	0.511	rs56235607	chr5:102372606	G/A	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Primary biliary cholangitis;
THYM	cis	rs2859741	0.967	rs535876	chr1:37484052	C/G	cg09363841	chr1:37513479	NA	-0.71	-6.62	-0.56	2.16e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg09703963	chr11:616879	IRF7;MUPCDH	-0.64	-5.53	-0.49	2.78e-7	Systemic lupus erythematosus;
THYM	cis	rs939658	0.776	rs68147688	chr15:79443848	G/A	cg17916960	chr15:79447300	NA	-0.75	-8.88	-0.67	4.18e-14	Refractive error;
THYM	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1580019	0.961	rs1580022	chr7:32497712	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.59	0.56	2.42e-9	Cognitive ability;
THYM	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg04772025	chr11:68637568	NA	0.63	6.58	0.56	2.59e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1499972	0.713	rs9861346	chr3:117508846	C/T	cg07612923	chr3:117604196	NA	-1.07	-4.45	-0.42	2.35e-5	Schizophrenia;
THYM	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06873352	chr17:61820015	STRADA	0.78	9.89	0.71	2.85e-16	Prudent dietary pattern;
THYM	cis	rs870825	0.616	rs4416519	chr4:185639502	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.27	6.26	0.54	1.09e-8	Obesity-related traits;
THYM	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg24006582	chr15:45444508	DUOX1	0.77	6.04	0.53	3.05e-8	Uric acid levels;
THYM	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.55	0.49	2.56e-7	Tonsillectomy;
THYM	cis	rs2219968	0.683	rs35336251	chr8:78908359	A/G	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.63	-6.77	-0.57	1.04e-9	Longevity;Endometriosis;
THYM	cis	rs5769765	0.720	rs9628127	chr22:50166092	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-5.16	-0.47	1.33e-6	Schizophrenia;
THYM	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg05182265	chr7:156933206	UBE3C	0.7	9.62	0.7	1.06e-15	Body mass index;
THYM	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs7113850	0.541	rs7927067	chr11:24232604	G/A	ch.11.24196551F	chr11:24239977	NA	0.92	4.92	0.45	3.58e-6	Bone fracture in osteoporosis;
THYM	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg13395646	chr4:1353034	KIAA1530	-0.55	-4.58	-0.43	1.42e-5	Longevity;
THYM	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07157834	chr1:205819609	PM20D1	0.89	9.0	0.68	2.28e-14	Menarche (age at onset);
THYM	cis	rs6546537	1.000	rs2048256	chr2:69847357	G/C	cg10773587	chr2:69614142	GFPT1	-0.58	-5.1	-0.46	1.76e-6	Serum thyroid-stimulating hormone levels;
THYM	cis	rs7084402	0.967	rs1621811	chr10:60320664	T/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.47	-0.49	3.63e-7	Refractive error;
THYM	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg03609598	chr5:56110824	MAP3K1	-0.81	-5.23	-0.47	1.02e-6	Initial pursuit acceleration;
THYM	cis	rs4662750	0.828	rs2248519	chr2:128377833	C/G	cg01966334	chr2:128378434	MYO7B	0.69	6.2	0.54	1.43e-8	Renal cell carcinoma;
THYM	cis	rs4619890	0.649	rs28542374	chr4:7783163	G/A	cg00251875	chr4:7801337	AFAP1	-0.76	-6.06	-0.53	2.79e-8	Glaucoma (primary open-angle);
THYM	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs75920871	0.528	rs12274465	chr11:116957189	C/T	cg20608306	chr11:116969690	SIK3	-0.52	-5.67	-0.5	1.51e-7	Subjective well-being;
THYM	cis	rs17401966	1.000	rs3748578	chr1:10420918	A/G	cg20482658	chr1:10539492	PEX14	-0.4	-5.01	-0.46	2.56e-6	Hepatocellular carcinoma;
THYM	cis	rs35934224	0.710	rs73877376	chr22:19857207	C/T	cg11182965	chr22:19864308	TXNRD2	-0.76	-4.7	-0.43	8.81e-6	Glaucoma (primary open-angle);
THYM	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.6	-4.77	-0.44	6.61e-6	Chronic sinus infection;
THYM	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02475777	chr4:1388615	CRIPAK	-0.76	-5.63	-0.5	1.81e-7	Longevity;
THYM	cis	rs35883536	0.647	rs945329	chr1:101084273	C/T	cg06223162	chr1:101003688	GPR88	-0.78	-6.57	-0.56	2.67e-9	Monocyte count;
THYM	cis	rs57927100	1.000	rs57927100	chr17:75317300	C/G	cg18271897	chr17:75316784	SEPT9	0.76	7.73	0.62	1.1e-11	Systolic blood pressure;
THYM	cis	rs1003719	0.715	rs6579	chr21:38568308	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.64	-4.53	-0.42	1.72e-5	Eye color traits;
THYM	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg12863693	chr15:85201151	NMB	0.62	5.49	0.49	3.38e-7	Schizophrenia;
THYM	cis	rs3781426	1.000	rs3781409	chr10:126715629	C/T	cg04494136	chr10:126703576	CTBP2	-0.39	-5.31	-0.48	7.21e-7	Height;
THYM	cis	rs1167827	0.680	rs1167800	chr7:75176196	G/A	cg16384552	chr7:74938386	SPDYE8P	-0.75	-6.12	-0.53	2.08e-8	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	7.74	0.62	1.08e-11	Smoking behavior;
THYM	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs9411298	0.630	rs9411299	chr9:139938793	C/G	cg14024893	chr9:139943146	ENTPD2	-0.81	-6.22	-0.54	1.32e-8	Monocyte percentage of white cells;
THYM	cis	rs7836436	1.000	rs6986597	chr8:121010615	G/A	cg05020510	chr8:120428057	NOV	1.23	5.79	0.51	8.92e-8	HIV-1 viral setpoint;
THYM	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg18681998	chr4:17616180	MED28	0.88	8.21	0.64	1.08e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs259282	0.851	rs174083	chr19:33141180	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.98	8.52	0.66	2.4e-13	Schizophrenia;
THYM	cis	rs6860806	0.661	rs2171247	chr5:131580234	G/T	cg24060327	chr5:131705240	SLC22A5	-0.7	-5.35	-0.48	6.11e-7	Breast cancer;
THYM	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10256972	0.504	rs2949178	chr7:1209925	T/C	cg03188948	chr7:1209495	NA	0.91	7.19	0.59	1.48e-10	Longevity;Endometriosis;
THYM	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28647808	1.000	rs4962141	chr9:136274478	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg10656845	chr7:44159780	POLD2	-0.77	-4.58	-0.43	1.42e-5	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
THYM	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg24818145	chr4:99064322	C4orf37	0.82	6.46	0.55	4.38e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg00071950	chr4:10020882	SLC2A9	0.86	8.92	0.68	3.37e-14	Bone mineral density;
THYM	cis	rs760805	0.965	rs11249203	chr1:25258585	G/C	cg22509179	chr1:25234806	RUNX3	-0.73	-6.72	-0.57	1.34e-9	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs8114671	0.967	rs2378337	chr20:33771435	G/A	cg08999081	chr20:33150536	PIGU	0.52	4.67	0.43	9.71e-6	Height;
THYM	cis	rs1448094	0.511	rs7967183	chr12:86216845	T/G	cg00310523	chr12:86230176	RASSF9	0.51	4.6	0.43	1.31e-5	Major depressive disorder;
THYM	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.81	-6.29	-0.54	9.55e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1971762	0.527	rs6580950	chr12:53926656	T/A	cg16917193	chr12:54089295	NA	0.7	6.18	0.54	1.6e-8	Height;
THYM	cis	rs2135507	0.515	rs12647788	chr4:83532376	C/G	cg10249074	chr4:83542146	C4orf11	0.58	4.63	0.43	1.17e-5	Juvenile osteochondritis dissecans;
THYM	cis	rs2274459	1.000	rs12189725	chr6:33703394	G/T	cg06253072	chr6:33679850	C6orf125	0.52	5.32	0.48	6.92e-7	Obesity (extreme);
THYM	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg08807101	chr21:30365312	RNF160	0.94	7.64	0.62	1.69e-11	Dental caries;
THYM	cis	rs7586879	0.593	rs10198275	chr2:25130542	A/C	cg27107076	chr2:25050844	ADCY3	-0.29	-4.73	-0.44	7.91e-6	Body mass index;
THYM	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg11890956	chr21:40555474	PSMG1	0.99	8.41	0.65	4.12e-13	Cognitive function;
THYM	cis	rs9914544	1.000	rs28436199	chr17:18751730	C/T	cg26378065	chr17:18585709	ZNF286B	0.61	4.97	0.45	3.01e-6	Educational attainment (years of education);
THYM	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg00495681	chr13:53174319	NA	-0.77	-6.97	-0.58	4.24e-10	Lewy body disease;
THYM	cis	rs7586879	0.681	rs6723803	chr2:25120713	G/C	cg27107076	chr2:25050844	ADCY3	-0.29	-4.66	-0.43	1.04e-5	Body mass index;
THYM	cis	rs4523957	0.651	rs8068642	chr17:2060353	T/C	cg16513277	chr17:2031491	SMG6	-0.94	-8.42	-0.65	3.95e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7173743	0.756	rs8030937	chr15:79129587	G/T	cg00540400	chr15:79124168	NA	0.66	6.98	0.58	3.93e-10	Coronary artery disease;
THYM	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg00277334	chr10:82204260	NA	-0.52	-5.32	-0.48	6.88e-7	Post bronchodilator FEV1;
THYM	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg12893697	chr11:970389	AP2A2	-0.31	-5.21	-0.47	1.08e-6	Alzheimer's disease (late onset);
THYM	cis	rs7267979	1.000	rs2474777	chr20:25272633	A/G	cg08601574	chr20:25228251	PYGB	0.59	4.81	0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	4.78	0.44	6.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11696501	0.739	rs4812933	chr20:44230792	C/A	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.57	-0.42	1.46e-5	Brain structure;
THYM	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg20891558	chr2:74357851	NA	1.18	12.27	0.78	2.67e-21	Gestational age at birth (maternal effect);
THYM	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg13695892	chr22:41940480	POLR3H	-1.05	-8.51	-0.66	2.45e-13	Vitiligo;
THYM	cis	rs7523273	0.606	rs2724391	chr1:207953244	T/C	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	cis	rs6032067	0.538	rs62206429	chr20:43730333	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.61	-6.26	-0.54	1.11e-8	Blood protein levels;
THYM	cis	rs6076065	0.644	rs1056394	chr20:23337422	G/A	cg11657817	chr20:23433608	CST11	0.31	4.47	0.42	2.15e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs67981189	0.896	rs17108804	chr14:71441524	A/G	cg15910301	chr14:71632612	NA	-0.5	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.02	10.76	0.74	3.96e-18	Intelligence (multi-trait analysis);
THYM	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg26441486	chr22:50317300	CRELD2	-0.42	-6.38	-0.55	6.55e-9	Schizophrenia;
THYM	cis	rs3820068	0.532	rs1547034	chr1:15919049	T/A	cg05660106	chr1:15850417	CASP9	0.76	6.14	0.53	1.9e-8	Systolic blood pressure;
THYM	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg15744005	chr10:104629667	AS3MT	-0.83	-7.65	-0.62	1.61e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6463094	0.713	rs4724101	chr7:42270322	C/G	cg00560277	chr7:42267269	GLI3	0.58	4.59	0.43	1.38e-5	Gut microbiome composition (summer);
THYM	cis	rs17125944	0.615	rs6572867	chr14:53319283	C/T	cg00686598	chr14:53173677	PSMC6	-1.03	-4.67	-0.43	9.78e-6	Alzheimer's disease (late onset);
THYM	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs7968679	1	rs7968679	chr12:9313304	A/G	cg12214032	chr12:8375674	FAM90A1	0.67	5.38	0.48	5.4e-7	Myopia;
THYM	cis	rs17253792	0.749	rs74979160	chr14:56097568	G/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs28595532	0.920	rs55633605	chr4:119761589	G/A	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg18876405	chr7:65276391	NA	-0.57	-4.86	-0.45	4.62e-6	Aortic root size;
THYM	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07157834	chr1:205819609	PM20D1	1.0	10.2	0.72	6.05e-17	Menarche (age at onset);
THYM	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg11764359	chr7:65958608	NA	-0.87	-7.46	-0.61	4.01e-11	Aortic root size;
THYM	cis	rs17152411	1.000	rs7083336	chr10:126590771	T/C	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg13789015	chr9:136890014	NCRNA00094	0.76	6.38	0.55	6.47e-9	Platelet distribution width;
THYM	cis	rs9790314	0.779	rs12493960	chr3:160899772	T/C	cg04691961	chr3:161091175	C3orf57	-0.59	-4.83	-0.44	5.31e-6	Morning vs. evening chronotype;
THYM	cis	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg13609457	chr4:120235615	NA	0.56	5.24	0.47	9.58e-7	Corneal astigmatism;
THYM	cis	rs2018683	0.707	rs10279870	chr7:28968935	A/G	cg27487796	chr7:28973253	NA	-0.25	-4.47	-0.42	2.19e-5	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
THYM	cis	rs1050631	0.623	rs7242481	chr18:33709217	G/A	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.62	4.83	0.44	5.2e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs12496230	1.000	rs62258957	chr3:66864153	G/T	cg17646820	chr3:66848679	NA	0.8	5.03	0.46	2.32e-6	Type 2 diabetes;
THYM	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg26039829	chr8:22132926	PIWIL2	0.69	6.07	0.53	2.66e-8	Hypertriglyceridemia;
THYM	cis	rs7267979	1.000	rs6037121	chr20:25428311	G/A	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg10802521	chr3:52805072	NEK4	-0.71	-6.18	-0.54	1.57e-8	Bipolar disorder;
THYM	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg03647317	chr4:187891568	NA	-0.81	-8.55	-0.66	2.03e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4595586	0.545	rs4438082	chr12:39363870	C/T	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs2073300	1.000	rs6137959	chr20:23442640	T/C	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs4631830	0.720	rs113082846	chr10:51502802	G/C	cg10326726	chr10:51549505	MSMB	-0.61	-6.17	-0.53	1.67e-8	Prostate-specific antigen levels;
THYM	cis	rs9992101	0.532	rs4447885	chr4:77422171	A/G	cg20311846	chr4:77356250	SHROOM3	-0.59	-6.62	-0.56	2.16e-9	Creatinine levels;
THYM	cis	rs416603	0.967	rs7191538	chr16:11363389	C/G	cg00044050	chr16:11439710	C16orf75	-0.74	-5.56	-0.5	2.49e-7	Type 1 diabetes;
THYM	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg22920501	chr2:26401640	FAM59B	0.77	5.88	0.52	6.04e-8	Gut microbiome composition (summer);
THYM	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs1971762	0.545	rs7485472	chr12:54044438	T/C	cg16917193	chr12:54089295	NA	0.77	7.34	0.6	7.04e-11	Height;
THYM	cis	rs10158481	0.592	rs2143163	chr1:25473290	A/G	cg09264742	chr1:25757510	TMEM57	-0.67	-4.7	-0.43	8.72e-6	Urate levels in obese individuals;
THYM	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-5.34	-0.48	6.25e-7	Gut microbiome composition (summer);
THYM	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg24209194	chr3:40518798	ZNF619	-0.73	-6.31	-0.54	8.87e-9	Renal cell carcinoma;
THYM	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1467026	0.719	rs17037220	chr3:12818103	A/G	cg05775895	chr3:12838266	CAND2	1.1	10.45	0.73	1.81e-17	P wave duration;
THYM	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg22709100	chr7:91322751	NA	0.63	4.86	0.45	4.55e-6	Breast cancer;
THYM	trans	rs17001239	0.850	rs73158419	chr21:26964194	T/C	cg20081244	chr17:79859945	NPB	0.7	6.94	0.58	4.7e-10	Cognitive performance;
THYM	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg09307838	chr4:120376055	NA	0.66	4.93	0.45	3.45e-6	Corneal astigmatism;
THYM	cis	rs11574514	1.000	rs117447021	chr16:67669455	G/A	cg09738193	chr16:67926317	PSKH1	-0.92	-4.53	-0.42	1.73e-5	Crohn's disease;
THYM	cis	rs6570726	0.755	rs451699	chr6:145830594	C/G	cg23711669	chr6:146136114	FBXO30	0.95	9.55	0.7	1.52e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	trans	rs3213961	0.683	rs62149034	chr2:33806967	A/T	cg19997179	chr2:620310	NA	0.56	7.08	0.59	2.47e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
THYM	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg06481639	chr22:41940642	POLR3H	0.71	5.15	0.47	1.43e-6	Cannabis dependence symptom count;
THYM	cis	rs40363	1.000	rs37771	chr16:3512866	G/T	cg05754148	chr16:3507555	NAT15	0.92	8.18	0.64	1.27e-12	Tuberculosis;
THYM	cis	rs4619890	0.649	rs7654949	chr4:7784194	A/G	cg00251875	chr4:7801337	AFAP1	0.76	6.15	0.53	1.86e-8	Glaucoma (primary open-angle);
THYM	cis	rs7772486	0.754	rs6906258	chr6:146089356	A/G	cg23711669	chr6:146136114	FBXO30	-0.98	-10.47	-0.73	1.68e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9326248	0.530	rs900012	chr11:116966435	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.91	5.11	0.46	1.67e-6	Blood protein levels;
THYM	cis	rs13082711	0.911	rs34422761	chr3:27513366	C/A	cg02860705	chr3:27208620	NA	0.72	5.15	0.47	1.39e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs4285028	0.948	rs2332033	chr3:121699548	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.73	-5.04	-0.46	2.26e-6	Multiple sclerosis;
THYM	cis	rs2290159	0.706	rs6442319	chr3:12647029	G/A	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg10802521	chr3:52805072	NEK4	-0.8	-7.53	-0.61	2.92e-11	Bipolar disorder;
THYM	cis	rs2834081	0.536	rs11702285	chr21:34474294	G/A	cg04836472	chr21:34405997	NA	0.58	6.43	0.55	5.15e-9	Sum eosinophil basophil counts;
THYM	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg03351412	chr1:154909251	PMVK	0.71	5.6	0.5	2.12e-7	Prostate cancer;
THYM	cis	rs747334	0.791	rs10881868	chr10:92716072	A/T	cg07620928	chr10:92689909	NA	0.65	5.96	0.52	4.28e-8	Fibroblast growth factor basic levels;
THYM	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg18252515	chr7:66147081	NA	0.63	4.69	0.43	8.99e-6	Aortic root size;
THYM	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.62	0.74	7.83e-18	Prudent dietary pattern;
THYM	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.72	5.73	0.51	1.19e-7	Blood metabolite levels;
THYM	cis	rs11018874	0.597	rs4393275	chr11:89886397	C/T	cg05041596	chr11:89867385	NAALAD2	0.74	4.85	0.45	4.85e-6	White blood cell types;
THYM	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg17509989	chr5:176798049	RGS14	-0.67	-5.95	-0.52	4.45e-8	Urate levels in lean individuals;
THYM	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs3820068	0.580	rs12746773	chr1:16001588	C/T	cg27534772	chr1:16042836	PLEKHM2	0.5	5.47	0.49	3.64e-7	Systolic blood pressure;
THYM	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg05234568	chr11:5960015	NA	0.6	5.37	0.48	5.68e-7	DNA methylation (variation);
THYM	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	trans	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg25214090	chr10:38739885	LOC399744	0.81	6.93	0.58	4.99e-10	Corneal astigmatism;
THYM	cis	rs9646944	0.501	rs741284	chr2:103083324	G/C	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	cis	rs4455778	0.600	rs4478520	chr7:49079788	A/G	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs6980507	0.523	rs2974293	chr8:42369455	C/T	cg09913449	chr8:42400586	C8orf40	-0.76	-6.53	-0.56	3.24e-9	Glycated hemoglobin levels;
THYM	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.67	4.76	0.44	6.93e-6	Aortic root size;
THYM	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9611519	1.000	rs5758268	chr22:41622419	A/T	cg03806693	chr22:41940476	POLR3H	-0.78	-5.92	-0.52	5.11e-8	Neuroticism;
THYM	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg03806693	chr22:41940476	POLR3H	-0.75	-5.72	-0.51	1.26e-7	Vitiligo;
THYM	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg02527881	chr3:46936655	PTH1R	-0.67	-6.75	-0.57	1.18e-9	Colorectal cancer;
THYM	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg24596788	chr1:163392923	NA	-0.77	-7.43	-0.61	4.68e-11	Motion sickness;
THYM	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg18681998	chr4:17616180	MED28	0.99	10.18	0.72	6.74e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg09307838	chr4:120376055	NA	-0.77	-5.63	-0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs2456568	0.778	rs7940973	chr11:93682045	C/G	cg17595323	chr11:93583763	C11orf90	0.56	5.18	0.47	1.22e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg25427524	chr10:38739819	LOC399744	-0.71	-4.59	-0.43	1.34e-5	Obesity (extreme);
THYM	trans	rs28595532	0.920	rs17258050	chr4:119672019	G/A	cg13773247	chr2:42276988	PKDCC	0.89	6.93	0.58	4.92e-10	Cannabis dependence symptom count;
THYM	cis	rs7843479	0.506	rs7818430	chr8:21798429	C/T	cg17168535	chr8:21777572	XPO7	0.91	8.25	0.65	9.03e-13	Mean corpuscular volume;
THYM	cis	rs2811415	0.597	rs9869012	chr3:127728663	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg10193763	chr2:225306901	NA	-0.51	-5.42	-0.49	4.49e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.24e-7	Corneal astigmatism;
THYM	cis	rs8044995	0.563	rs8058517	chr16:68379860	A/G	cg06647218	chr16:68279240	PLA2G15	-0.72	-4.55	-0.42	1.56e-5	Schizophrenia;
THYM	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg20469991	chr17:27169893	C17orf63	0.77	4.87	0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg05147244	chr20:61493195	TCFL5	0.9	4.96	0.45	3.07e-6	Obesity-related traits;
THYM	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg02887458	chr19:19495540	GATAD2A	0.43	5.05	0.46	2.15e-6	Bipolar disorder;
THYM	cis	rs900145	0.859	rs1481892	chr11:13301921	C/G	cg13286116	chr11:13302098	ARNTL	0.61	4.58	0.43	1.38e-5	Menarche (age at onset);
THYM	cis	rs758324	0.633	rs2667737	chr5:131525883	C/T	cg16205897	chr5:131564050	P4HA2	0.61	5.11	0.46	1.64e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs16866061	1.000	rs72974219	chr2:225423784	G/C	cg12698349	chr2:225449008	CUL3	1.14	10.45	0.73	1.77e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs3126085	0.935	rs1353436	chr1:152172658	G/A	cg10321714	chr1:152280068	FLG	0.68	5.07	0.46	1.98e-6	Atopic dermatitis;
THYM	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg06850241	chr22:41845214	NA	0.54	4.6	0.43	1.33e-5	Vitiligo;
THYM	cis	rs2242663	0.581	rs2511224	chr11:66262606	T/C	cg22973812	chr11:65786500	CATSPER1	0.55	4.51	0.42	1.86e-5	Bipolar disorder;
THYM	cis	rs34779708	0.897	rs34481177	chr10:35380913	C/T	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	trans	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg10856724	chr12:34555212	NA	-0.87	-7.41	-0.61	5.14e-11	Bladder cancer;
THYM	trans	rs1974653	0.672	rs2008701	chr22:20104235	C/T	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs31251	0.500	rs2107607	chr5:130380598	C/T	cg08523029	chr5:130500466	HINT1	0.75	4.95	0.45	3.26e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg11247378	chr22:39784982	NA	-1.08	-13.56	-0.81	6.12e-24	Intelligence (multi-trait analysis);
THYM	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg19077165	chr18:44547161	KATNAL2	0.61	7.58	0.61	2.28e-11	Personality dimensions;
THYM	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg15604051	chr3:44754201	ZNF502	-0.61	-5.59	-0.5	2.19e-7	Depressive symptoms;
THYM	cis	rs4595586	0.545	rs1303886	chr12:39366876	G/A	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg06618935	chr21:46677482	NA	-0.98	-9.5	-0.7	1.95e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12549902	0.966	rs716199	chr8:41515531	A/G	cg21772509	chr8:41503840	NKX6-3	0.72	6.79	0.57	9.78e-10	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
THYM	cis	rs983545	0.548	rs1348109	chr3:16949514	A/G	cg24159436	chr3:16974681	PLCL2	0.31	4.73	0.44	7.72e-6	Blood protein levels;
THYM	cis	rs36051895	0.632	rs62541916	chr9:5151904	C/A	cg02405213	chr9:5042618	JAK2	-1.03	-10.78	-0.74	3.54e-18	Pediatric autoimmune diseases;
THYM	cis	rs314370	0.951	rs17881696	chr7:100493359	G/A	cg08558340	chr7:100472263	SRRT	0.61	4.99	0.46	2.75e-6	Resting heart rate;
THYM	cis	rs10887741	0.646	rs4934355	chr10:89425411	G/A	cg13926569	chr10:89418898	PAPSS2	0.66	7.72	0.62	1.16e-11	Exercise (leisure time);
THYM	cis	rs478304	0.593	rs75162774	chr11:65492483	G/A	cg27068330	chr11:65405492	SIPA1	-1.04	-10.69	-0.74	5.67e-18	Acne (severe);
THYM	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg03264133	chr6:25882463	NA	0.64	4.92	0.45	3.61e-6	Schizophrenia;
THYM	cis	rs12500824	0.528	rs7677266	chr4:77278251	G/A	cg27417997	chr4:77356416	SHROOM3	0.43	4.48	0.42	2.11e-5	Coronary artery disease;
THYM	cis	rs4919694	1.000	rs11191490	chr10:104745174	T/A	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg00677455	chr12:58241039	CTDSP2	0.72	4.87	0.45	4.51e-6	Multiple sclerosis;
THYM	cis	rs11711311	1.000	rs9848993	chr3:113497914	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.17	-0.47	1.3e-6	IgG glycosylation;
THYM	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg19507638	chr5:93509721	C5orf36	-0.68	-4.6	-0.43	1.28e-5	Diabetic retinopathy;
THYM	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg06028808	chr11:68637592	NA	-0.71	-7.65	-0.62	1.62e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs28595532	0.920	rs114093638	chr4:119729819	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs1775715	0.707	rs2808073	chr10:32179275	A/G	cg04359828	chr10:32216031	ARHGAP12	0.41	5.12	0.46	1.62e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs9420	0.784	rs12790660	chr11:57667222	T/C	cg19752551	chr11:57585705	CTNND1	-0.72	-7.2	-0.59	1.42e-10	Schizophrenia;
THYM	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.76	-7.11	-0.59	2.11e-10	Personality dimensions;
THYM	cis	rs1747683	0.585	rs72781386	chr10:13355602	C/G	cg25835351	chr10:13388524	SEPHS1	-0.27	-4.66	-0.43	1.01e-5	IgG glycosylation;
THYM	cis	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs807669	0.525	rs2282684	chr22:19184244	C/T	cg02655711	chr22:19163373	SLC25A1	0.6	6.47	0.55	4.17e-9	Metabolite levels;
THYM	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg03605463	chr16:89740564	NA	0.91	6.91	0.58	5.61e-10	Vitiligo;
THYM	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg03159660	chr11:2078197	NA	-0.67	-5.23	-0.47	1.01e-6	Longevity;
THYM	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg19774624	chr17:42201019	HDAC5	0.73	6.41	0.55	5.54e-9	Total body bone mineral density;
THYM	cis	rs593982	1.000	rs665191	chr11:65493658	G/A	cg08755490	chr11:65554678	OVOL1	1.4	7.82	0.63	7.34e-12	Atopic dermatitis;
THYM	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg07169764	chr2:136633963	MCM6	0.7	5.89	0.52	5.94e-8	Mosquito bite size;
THYM	cis	rs367615	0.513	rs11741087	chr5:108807760	G/A	cg17395555	chr5:108820864	NA	0.73	9.23	0.69	7.27e-15	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-6.75	-0.57	1.18e-9	Platelet count;
THYM	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg27494647	chr7:150038898	RARRES2	0.41	4.59	0.43	1.34e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg15133208	chr4:90757351	SNCA	-0.57	-4.7	-0.43	8.94e-6	Neuroticism;
THYM	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg04193835	chr16:28379378	NA	-0.5	-4.66	-0.43	1.03e-5	Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs2455799	0.519	rs2062821	chr3:15697644	A/T	cg16303742	chr3:15540471	COLQ	-0.52	-5.29	-0.48	7.81e-7	Mean platelet volume;
THYM	cis	rs7106204	0.748	rs11820336	chr11:24219701	G/A	ch.11.24196551F	chr11:24239977	NA	1.04	7.55	0.61	2.59e-11	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg04362960	chr10:104952993	NT5C2	0.57	4.68	0.43	9.7e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4951018	0.526	rs4245718	chr1:205652472	G/A	cg07167872	chr1:205819463	PM20D1	-0.63	-4.8	-0.44	5.99e-6	Prostate-specific antigen levels;
THYM	cis	rs7224737	1.000	rs739637	chr17:40280944	G/C	cg00647820	chr17:40259828	DHX58	-0.62	-4.65	-0.43	1.06e-5	Fibrinogen levels;
THYM	cis	rs12043259	1.000	rs7537504	chr1:204833630	A/G	cg08830492	chr1:204899141	NFASC	-1.02	-4.49	-0.42	1.97e-5	Addiction;
THYM	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	4.82	0.44	5.52e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg11245990	chr11:68621969	NA	0.55	7.26	0.6	1.03e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg22709100	chr7:91322751	NA	0.62	4.85	0.45	4.77e-6	Breast cancer;
THYM	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Body mass index;
THYM	cis	rs4589258	0.689	rs9645609	chr11:90466858	T/A	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.81	-0.44	5.58e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg00129232	chr17:37814104	STARD3	0.77	5.27	0.48	8.58e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg25703541	chr22:24373054	LOC391322	-0.91	-11.01	-0.75	1.17e-18	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12935418	0.523	rs2549840	chr16:81023422	G/T	cg16651780	chr16:81037892	C16orf61	-0.82	-6.37	-0.55	6.81e-9	Mean corpuscular volume;
THYM	cis	rs10788264	0.504	rs7069328	chr10:124030741	G/C	cg09507567	chr10:124027408	NA	0.51	5.24	0.47	9.85e-7	Total body bone mineral density;
THYM	cis	rs863345	0.604	rs11265024	chr1:158513255	A/G	cg12129480	chr1:158549410	OR10X1	-0.51	-5.06	-0.46	2.05e-6	Pneumococcal bacteremia;
THYM	cis	rs514406	0.929	rs554301	chr1:53321948	A/T	cg08859206	chr1:53392774	SCP2	0.66	7.55	0.61	2.7e-11	Monocyte count;
THYM	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg22166914	chr1:53195759	ZYG11B	0.89	10.32	0.73	3.4e-17	Monocyte count;
THYM	cis	rs859767	0.741	rs2176341	chr2:135371421	A/G	cg12500956	chr2:135428796	TMEM163	-0.49	-4.98	-0.46	2.8e-6	Neuroticism;
THYM	cis	rs10193935	0.901	rs10171643	chr2:42532912	C/T	cg27598129	chr2:42591480	NA	-0.75	-4.61	-0.43	1.25e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs892961	1.000	rs11077909	chr17:75403480	T/C	cg11351908	chr17:75402473	SEPT9	0.6	6.03	0.53	3.1e-8	Airflow obstruction;
THYM	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg22841779	chr14:105766346	BRF1	-0.46	-5.72	-0.51	1.25e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.28	4.5	0.42	1.9e-5	Obesity-related traits;
THYM	cis	rs4930103	0.619	rs739905	chr11:1980360	G/C	cg06197492	chr11:2016605	H19	0.55	4.68	0.43	9.44e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs870825	0.616	rs6817521	chr4:185649827	A/G	cg04058563	chr4:185651563	MLF1IP	-1.08	-9.13	-0.68	1.21e-14	Blood protein levels;
THYM	cis	rs7084402	0.967	rs1365740	chr10:60277549	A/C	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs4595586	0.545	rs969468	chr12:39367278	A/C	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg25072359	chr17:41440525	NA	0.72	5.3	0.48	7.63e-7	Menopause (age at onset);
THYM	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg00990874	chr7:1149470	C7orf50	-0.63	-5.0	-0.46	2.6e-6	Bronchopulmonary dysplasia;
THYM	cis	rs7084402	0.967	rs2917949	chr10:60329166	G/A	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg11752832	chr7:134001865	SLC35B4	0.69	5.17	0.47	1.28e-6	Mean platelet volume;
THYM	cis	rs2554380	0.891	rs2562782	chr15:84300081	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.64	-4.99	-0.46	2.72e-6	Height;
THYM	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg23352942	chr3:46931381	PTH1R	-0.81	-8.25	-0.65	9.01e-13	Birth weight;
THYM	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	7.64	0.62	1.73e-11	Smoking behavior;
THYM	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.67	6.03	0.53	3.08e-8	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs2555603	0.857	rs2764619	chr13:33823988	G/A	cg07499182	chr13:33825496	STARD13	-0.5	-4.77	-0.44	6.71e-6	Body mass index in asthmatics;
THYM	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg27490568	chr2:178487706	NA	0.63	6.08	0.53	2.49e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs11671005	0.735	rs11670871	chr19:58940514	C/T	cg18639983	chr19:58920768	ZNF584	-0.6	-5.01	-0.46	2.48e-6	Mean platelet volume;
THYM	cis	rs6500395	1.000	rs12933948	chr16:48705825	C/G	cg04672837	chr16:48644449	N4BP1	-0.52	-5.05	-0.46	2.16e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6138458	1.000	rs6114981	chr20:24974401	C/T	cg26195577	chr20:24973756	C20orf3	-1.09	-10.72	-0.74	4.84e-18	Blood protein levels;
THYM	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.49	-4.72	-0.44	8.04e-6	Crohn's disease;
THYM	cis	rs514406	0.895	rs1925673	chr1:53326984	T/G	cg22166914	chr1:53195759	ZYG11B	0.8	8.04	0.64	2.5e-12	Monocyte count;
THYM	cis	rs6542838	0.704	rs56125264	chr2:99516699	A/G	cg08885076	chr2:99613938	TSGA10	-0.51	-5.19	-0.47	1.19e-6	Fear of minor pain;
THYM	cis	rs7113850	0.541	rs7116120	chr11:24235050	A/G	ch.11.24196551F	chr11:24239977	NA	0.87	4.66	0.43	1.04e-5	Bone fracture in osteoporosis;
THYM	cis	rs2456568	0.803	rs10765642	chr11:93640355	C/T	cg17595323	chr11:93583763	C11orf90	0.6	6.33	0.54	8.23e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg08431931	chr22:42394659	WBP2NL	0.85	5.33	0.48	6.65e-7	Birth weight;
THYM	cis	rs4638749	0.734	rs6722745	chr2:108875244	C/T	cg25838818	chr2:108905173	SULT1C2	0.54	5.84	0.51	7.43e-8	Blood pressure;
THYM	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.69	-5.16	-0.47	1.36e-6	Tonsillectomy;
THYM	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg25918947	chr17:41365094	TMEM106A	0.61	5.08	0.46	1.92e-6	Menopause (age at onset);
THYM	cis	rs7226229	0.519	rs71371043	chr17:20946558	G/C	cg21263980	chr17:20946333	USP22	0.67	4.92	0.45	3.6e-6	Blood trace element (Se levels);
THYM	cis	rs13082711	0.595	rs17681498	chr3:27331258	T/C	cg02860705	chr3:27208620	NA	0.94	7.1	0.59	2.29e-10	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.57	4.54	0.42	1.65e-5	Platelet count;
THYM	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg24397884	chr7:158709396	WDR60	0.43	4.66	0.43	1.02e-5	Height;
THYM	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg13395646	chr4:1353034	KIAA1530	-0.51	-4.55	-0.42	1.57e-5	Obesity-related traits;
THYM	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg06028808	chr11:68637592	NA	0.68	7.49	0.61	3.59e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs977987	0.836	rs35209155	chr16:75470496	G/A	cg03315344	chr16:75512273	CHST6	0.73	5.88	0.52	6.15e-8	Dupuytren's disease;
THYM	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg00495681	chr13:53174319	NA	0.69	6.88	0.58	6.34e-10	Lewy body disease;
THYM	cis	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg09307838	chr4:120376055	NA	0.78	5.89	0.52	5.7e-8	Corneal astigmatism;
THYM	cis	rs34638657	0.732	rs61111557	chr16:82201102	A/C	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.11	-0.64	1.73e-12	Lung adenocarcinoma;
THYM	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg02527881	chr3:46936655	PTH1R	-0.68	-7.13	-0.59	1.97e-10	Colorectal cancer;
THYM	cis	rs28795989	0.896	rs34685551	chr4:7887463	C/A	cg12728606	chr4:7903970	AFAP1	0.44	4.64	0.43	1.09e-5	Intraocular pressure;
THYM	cis	rs7584330	0.554	rs3751109	chr2:238427194	T/C	cg14458575	chr2:238380390	NA	0.79	4.65	0.43	1.06e-5	Prostate cancer;
THYM	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg23758822	chr17:41437982	NA	-1.22	-13.08	-0.8	5.68e-23	Menopause (age at onset);
THYM	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg11526020	chr17:80870163	TBCD	-0.43	-4.67	-0.43	9.74e-6	Breast cancer;
THYM	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg02734326	chr4:10020555	SLC2A9	-0.59	-4.53	-0.42	1.74e-5	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs4650994	0.524	rs1998544	chr1:178605276	T/C	cg05059571	chr16:84539110	KIAA1609	0.92	10.28	0.73	4.14e-17	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.33e-5	Neuroticism;
THYM	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg11965913	chr1:205819406	PM20D1	0.97	10.78	0.74	3.61e-18	Menarche (age at onset);
THYM	cis	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-5.43	-0.49	4.23e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs61931739	0.570	rs7315655	chr12:33912869	G/A	cg10856724	chr12:34555212	NA	-0.63	-5.9	-0.52	5.54e-8	Morning vs. evening chronotype;
THYM	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg24642844	chr7:1081250	C7orf50	-1.29	-8.31	-0.65	6.75e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg06238570	chr21:40685208	BRWD1	-0.96	-9.12	-0.68	1.28e-14	Cognitive function;
THYM	cis	rs7011507	0.594	rs72639025	chr8:49344134	C/G	cg08774009	chr8:49309094	NA	-0.6	-4.71	-0.44	8.47e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs11252926	0.563	rs10904173	chr10:462885	G/A	cg03684893	chr10:554711	DIP2C	0.78	7.18	0.59	1.58e-10	Psychosis in Alzheimer's disease;
THYM	cis	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg21775007	chr8:11205619	TDH	0.65	5.28	0.48	8.03e-7	Retinal vascular caliber;
THYM	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg18825531	chr11:62321136	NA	-0.45	-5.11	-0.46	1.63e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg00814883	chr7:100076585	TSC22D4	-0.95	-6.36	-0.55	6.93e-9	Platelet count;
THYM	cis	rs60695258	0.550	rs340641	chr4:87951393	C/T	cg10685359	chr4:87814065	C4orf36	0.45	5.81	0.51	8.24e-8	Hematocrit;
THYM	cis	rs8114671	0.869	rs6060199	chr20:33654773	A/G	cg08999081	chr20:33150536	PIGU	-0.56	-4.83	-0.44	5.18e-6	Height;
THYM	cis	rs6920965	0.509	rs575811	chr6:126162282	T/C	cg05901451	chr6:126070800	HEY2	0.58	4.93	0.45	3.45e-6	High light scatter reticulocyte count;
THYM	cis	rs9527	0.590	rs3861984	chr10:104916980	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs11048434	0.518	rs2377679	chr12:9176470	A/G	cg26114124	chr12:9217669	LOC144571	0.52	4.57	0.42	1.49e-5	Sjögren's syndrome;
THYM	cis	rs889398	0.741	rs3790075	chr16:69907811	A/G	cg09409435	chr16:70099608	PDXDC2	0.67	5.39	0.48	5.13e-7	Body mass index;
THYM	cis	rs7894051	0.764	rs11101726	chr10:135194741	T/A	cg01120434	chr10:134937798	GPR123	-0.92	-5.42	-0.49	4.55e-7	Lifespan;
THYM	cis	rs1003719	0.707	rs9976360	chr21:38587860	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.5	-0.42	1.95e-5	Eye color traits;
THYM	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg21280719	chr6:42927975	GNMT	-0.53	-7.25	-0.6	1.12e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1371867	0.875	rs1371868	chr8:101330267	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs6754459	1.000	rs6754459	chr2:3707423	C/T	cg25251562	chr2:3704773	ALLC	-0.81	-6.18	-0.54	1.59e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs7731657	0.537	rs13165574	chr5:130354079	G/C	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17331151	0.505	rs35225119	chr3:52623465	A/T	cg17372223	chr3:52568218	NT5DC2	0.59	4.68	0.43	9.37e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs1129187	0.755	rs2296804	chr6:42931261	C/G	cg10862848	chr6:42927986	GNMT	-0.53	-7.24	-0.6	1.18e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7224314	1.000	rs62084079	chr17:65386917	C/T	cg01507342	chr17:65387096	PITPNC1	-0.91	-10.03	-0.72	1.41e-16	Diisocyanate-induced asthma;
THYM	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg13010199	chr12:38710504	ALG10B	-0.63	-4.57	-0.42	1.48e-5	Morning vs. evening chronotype;
THYM	cis	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg04990556	chr1:26633338	UBXN11	0.98	7.88	0.63	5.5e-12	Obesity-related traits;
THYM	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg11245990	chr11:68621969	NA	0.57	7.27	0.6	9.85e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg03806693	chr22:41940476	POLR3H	-1.23	-10.89	-0.75	2.09e-18	Vitiligo;
THYM	cis	rs17443541	0.516	rs1450569	chr2:200443111	A/T	cg03741458	chr2:200468445	NA	-0.77	-5.51	-0.49	3.03e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.564	rs10234592	chr7:124611656	A/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.2e-7	Cutaneous malignant melanoma;
THYM	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg08885076	chr2:99613938	TSGA10	-0.65	-5.63	-0.5	1.82e-7	Chronic sinus infection;
THYM	cis	rs11711311	0.955	rs3796254	chr3:113380332	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.57	-4.79	-0.44	6.03e-6	IgG glycosylation;
THYM	cis	rs6539288	0.803	rs7307895	chr12:107332126	A/C	cg26297688	chr12:107349093	C12orf23	-0.52	-6.11	-0.53	2.16e-8	Total body bone mineral density;
THYM	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	7.68	0.62	1.38e-11	Platelet count;
THYM	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg06600287	chr1:53387719	ECHDC2	-0.29	-4.69	-0.43	9.17e-6	Monocyte count;
THYM	cis	rs9649213	0.593	rs736754	chr7:97931559	C/T	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.6e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg03060546	chr3:49711283	APEH	0.67	5.55	0.5	2.54e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs72901758	0.774	rs72909022	chr17:76248666	C/T	cg25512537	chr17:76250053	NA	0.43	6.26	0.54	1.13e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
THYM	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg02018176	chr4:1364513	KIAA1530	0.82	7.46	0.61	4.1e-11	Longevity;
THYM	cis	rs6876348	0.516	rs2577415	chr5:128327425	A/C	cg02841155	chr5:128301328	SLC27A6	-0.55	-5.6	-0.5	2.11e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg15744005	chr10:104629667	AS3MT	-0.83	-7.75	-0.62	9.94e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs6430585	0.528	rs309154	chr2:136726567	C/T	cg23851026	chr2:136556271	LCT	0.77	7.17	0.59	1.65e-10	Corneal structure;
THYM	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg24308560	chr3:49941425	MST1R	0.79	6.8	0.57	9.31e-10	Intelligence (multi-trait analysis);
THYM	cis	rs1345301	1.000	rs12474199	chr2:102868980	G/A	cg03938978	chr2:103052716	IL18RAP	-0.6	-6.0	-0.52	3.55e-8	Waist circumference;
THYM	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg08355456	chr11:67383691	NA	-0.67	-4.64	-0.43	1.1e-5	Mean corpuscular volume;
THYM	cis	rs1113500	0.862	rs11185264	chr1:108640506	T/C	cg06207961	chr1:108661230	NA	0.64	5.09	0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs9560113	0.959	rs9555803	chr13:112179560	G/T	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs12594515	1.000	rs8032835	chr15:45997897	C/G	cg01629716	chr15:45996671	NA	0.53	5.27	0.48	8.47e-7	Waist circumference;Weight;
THYM	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.46	0.49	3.85e-7	Platelet count;
THYM	cis	rs9677476	0.863	rs60953838	chr2:232065864	G/C	cg07929768	chr2:232055508	NA	0.61	6.17	0.53	1.65e-8	Food antigen IgG levels;
THYM	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg02398342	chr17:80708632	TBCD;FN3K	0.67	5.01	0.46	2.55e-6	Glycated hemoglobin levels;
THYM	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg19913688	chr11:428466	ANO9	-0.89	-4.6	-0.43	1.28e-5	Body mass index;
THYM	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg26384229	chr12:38710491	ALG10B	-0.9	-7.35	-0.6	6.77e-11	Morning vs. evening chronotype;
THYM	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg03433033	chr1:76189801	ACADM	0.65	6.31	0.54	8.8e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	trans	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg25214090	chr10:38739885	LOC399744	1.01	8.67	0.66	1.15e-13	Corneal astigmatism;
THYM	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.13	-0.64	1.6e-12	Mean corpuscular volume;
THYM	cis	rs7107174	0.901	rs2512525	chr11:77923019	T/C	cg19901956	chr11:77921274	USP35	-0.8	-6.2	-0.54	1.48e-8	Testicular germ cell tumor;
THYM	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg06850241	chr22:41845214	NA	-0.57	-5.01	-0.46	2.56e-6	Vitiligo;
THYM	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg06917634	chr15:78832804	PSMA4	-0.7	-4.66	-0.43	1.03e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs73198271	0.740	rs964771	chr8:8650939	A/G	cg06636001	chr8:8085503	FLJ10661	0.7	4.77	0.44	6.56e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs35264875	1.000	rs72919430	chr11:68829817	G/T	cg23845249	chr11:68861649	NA	0.54	5.48	0.49	3.53e-7	Blond vs. brown hair color;
THYM	cis	rs7226229	0.904	rs7224746	chr17:20927600	A/G	cg21263980	chr17:20946333	USP22	0.66	4.78	0.44	6.45e-6	Blood trace element (Se levels);
THYM	cis	rs10818894	0.772	rs10120705	chr9:126692600	T/G	cg16191174	chr9:126692580	DENND1A	0.88	5.6	0.5	2.05e-7	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
THYM	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg10505658	chr17:80084571	CCDC57	0.7	8.07	0.64	2.18e-12	Life satisfaction;
THYM	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg05234568	chr11:5960015	NA	0.56	4.89	0.45	4.17e-6	DNA methylation (variation);
THYM	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg22166914	chr1:53195759	ZYG11B	-0.9	-10.28	-0.73	4.19e-17	Monocyte count;
THYM	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.77	7.38	0.6	6.04e-11	Lymphocyte counts;
THYM	cis	rs887829	0.569	rs4663967	chr2:234653184	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.67	-5.17	-0.47	1.31e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg12311346	chr5:56204834	C5orf35	-0.82	-5.47	-0.49	3.62e-7	Initial pursuit acceleration;
THYM	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs2806561	1.000	rs2806563	chr1:23506625	C/T	cg12483005	chr1:23474871	LUZP1	-0.61	-6.28	-0.54	1.02e-8	Height;
THYM	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.63	5.55	0.5	2.53e-7	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs2235649	0.789	rs9929803	chr16:1852748	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs34375054	0.526	rs883315	chr12:125676889	T/C	cg25124228	chr12:125621409	AACS	-0.76	-5.75	-0.51	1.1e-7	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg00278517	chr6:167070616	RPS6KA2	-0.33	-4.52	-0.42	1.79e-5	Crohn's disease;
THYM	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg03733263	chr8:22462867	KIAA1967	1.1	9.97	0.71	1.95e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs172166	0.538	rs149956	chr6:28036251	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.72	-5.44	-0.49	4.19e-7	Cardiac Troponin-T levels;
THYM	cis	rs7582180	0.638	rs9973536	chr2:100942243	C/T	cg21926883	chr2:100939477	LONRF2	-0.65	-6.15	-0.53	1.82e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9486719	1.000	rs12212614	chr6:97036466	T/G	cg18709589	chr6:96969512	KIAA0776	-0.67	-4.64	-0.43	1.1e-5	Migraine;Coronary artery disease;
THYM	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07157834	chr1:205819609	PM20D1	0.87	8.66	0.66	1.19e-13	Menarche (age at onset);
THYM	cis	rs7631605	0.935	rs9854641	chr3:37218461	T/C	cg21328643	chr3:37258149	NA	-0.53	-5.12	-0.47	1.57e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.79	6.34	0.55	7.85e-9	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	6.9	0.58	5.76e-10	Smoking behavior;
THYM	cis	rs2067615	0.579	rs9651957	chr12:107170128	A/G	cg15890332	chr12:107067104	RFX4	0.41	4.6	0.43	1.31e-5	Heart rate;
THYM	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs8038465	0.638	rs7495543	chr15:73955133	G/C	cg15420318	chr15:73925796	NPTN	0.62	5.46	0.49	3.74e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6665290	0.870	rs17600725	chr1:227204231	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.13	-15.41	-0.85	1.4e-27	Myeloid white cell count;
THYM	cis	rs892961	0.932	rs3987886	chr17:75414980	A/G	cg11351908	chr17:75402473	SEPT9	0.56	5.5	0.49	3.23e-7	Airflow obstruction;
THYM	cis	rs990171	0.770	rs6543116	chr2:102927726	A/G	cg13897122	chr2:103039542	IL18RAP	-0.42	-4.87	-0.45	4.41e-6	Lymphocyte counts;
THYM	cis	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg07460842	chr6:66804631	NA	-0.98	-6.02	-0.53	3.32e-8	Exhaled nitric oxide levels;
THYM	trans	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17712092	chr4:129076599	LARP1B	0.91	7.63	0.62	1.83e-11	Eosinophil percentage of white cells;
THYM	cis	rs1003719	0.715	rs8129942	chr21:38552070	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs870825	0.616	rs28636679	chr4:185627481	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.69	0.71	7.45e-16	Blood protein levels;
THYM	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg00677455	chr12:58241039	CTDSP2	0.7	4.68	0.43	9.62e-6	Multiple sclerosis;
THYM	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg02038168	chr22:39784481	NA	-0.78	-5.73	-0.51	1.17e-7	Post bronchodilator FEV1;
THYM	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg11663144	chr21:46675770	NA	-0.76	-10.98	-0.75	1.34e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2109514	0.765	rs9649392	chr7:116107386	G/A	cg12739419	chr7:116140593	CAV2	-0.47	-4.83	-0.44	5.18e-6	Prevalent atrial fibrillation;
THYM	cis	rs7512552	0.839	rs2867894	chr1:150452912	T/A	cg15654264	chr1:150340011	RPRD2	0.45	5.32	0.48	7.01e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs988913	1.000	rs9367601	chr6:54839162	G/T	cg18532076	chr6:54711417	FAM83B	0.5	4.91	0.45	3.78e-6	Menarche (age at onset);
THYM	cis	rs6686842	0.931	rs4360513	chr1:41480799	G/A	cg03387723	chr1:41708464	SCMH1	-0.44	-5.15	-0.47	1.42e-6	Height;
THYM	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg09359103	chr1:154839909	KCNN3	-0.69	-8.46	-0.66	3.21e-13	Prostate cancer;
THYM	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg09021430	chr5:549028	NA	0.61	5.8	0.51	8.66e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg22981736	chr15:31284413	MTMR10	-0.55	-4.66	-0.43	1.03e-5	Huntington's disease progression;
THYM	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg13393036	chr8:95962371	TP53INP1	-0.49	-4.98	-0.46	2.81e-6	Type 2 diabetes;
THYM	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs2050392	0.928	rs6481677	chr10:30701816	A/G	cg02070205	chr10:30722105	MAP3K8	-0.54	-4.87	-0.45	4.44e-6	Inflammatory bowel disease;
THYM	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg10360139	chr7:1886902	MAD1L1	-0.86	-7.83	-0.63	6.99e-12	Bipolar disorder and schizophrenia;
THYM	cis	rs7772486	0.686	rs9399564	chr6:146078907	C/T	cg23711669	chr6:146136114	FBXO30	-0.91	-8.87	-0.67	4.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs853679	0.550	rs1233701	chr6:28168726	C/G	cg23281280	chr6:28129359	ZNF389	-0.67	-5.26	-0.47	8.87e-7	Depression;
THYM	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg27279351	chr12:120934652	DYNLL1	0.96	8.75	0.67	7.6e-14	High light scatter reticulocyte count;
THYM	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg03709012	chr19:19516395	GATAD2A	-0.81	-6.42	-0.55	5.22e-9	Tonsillectomy;
THYM	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg25036284	chr2:26402008	FAM59B	-0.74	-4.87	-0.45	4.39e-6	Gut microbiome composition (summer);
THYM	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg13010199	chr12:38710504	ALG10B	0.63	4.65	0.43	1.07e-5	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg05340658	chr4:99064831	C4orf37	0.54	4.51	0.42	1.83e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs78456975	0.550	rs11904276	chr2:1524006	T/C	cg12573674	chr2:1569213	NA	-1.25	-7.81	-0.63	7.44e-12	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg11247378	chr22:39784982	NA	-1.06	-13.37	-0.81	1.49e-23	Intelligence (multi-trait analysis);
THYM	cis	rs1122401	0.515	rs2564981	chr5:53870905	A/G	cg04014864	chr5:54603544	SKIV2L2;DHX29	0.72	4.82	0.44	5.55e-6	Smoking initiation;
THYM	cis	rs6768930	0.509	rs28495214	chr3:57746474	G/C	cg24033633	chr3:57945695	NA	-0.38	-5.27	-0.48	8.55e-7	Obesity-related traits;
THYM	cis	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg24375607	chr4:120327624	NA	0.58	4.74	0.44	7.61e-6	Corneal astigmatism;
THYM	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg12292205	chr6:26970375	C6orf41	0.53	4.55	0.42	1.6e-5	Schizophrenia;
THYM	cis	rs6473252	0.584	rs735839	chr8:81808254	C/G	cg08595989	chr8:81827712	NA	-0.5	-5.45	-0.49	4.02e-7	Breast cancer;
THYM	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg23649088	chr2:200775458	C2orf69	-0.74	-5.59	-0.5	2.17e-7	Schizophrenia;
THYM	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg03676636	chr4:99064102	C4orf37	0.33	4.57	0.42	1.45e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg11494091	chr17:61959527	GH2	0.68	6.25	0.54	1.14e-8	Height;
THYM	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg14582100	chr15:45693742	SPATA5L1	0.57	4.69	0.43	9.01e-6	Homoarginine levels;
THYM	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg05313129	chr8:58192883	C8orf71	-0.81	-4.73	-0.44	7.78e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6768930	0.509	rs9811191	chr3:57765644	A/G	cg24033633	chr3:57945695	NA	-0.39	-5.67	-0.5	1.55e-7	Obesity-related traits;
THYM	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-14.22	-0.82	2.89e-25	Height;
THYM	cis	rs600806	0.815	rs10858094	chr1:109950858	T/C	cg02175308	chr1:109941060	SORT1	-0.6	-5.3	-0.48	7.58e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.85	5.77	0.51	1.01e-7	Platelet count;
THYM	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg01236616	chr12:121019343	POP5	1.31	10.38	0.73	2.57e-17	Type 1 diabetes nephropathy;
THYM	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs870825	0.616	rs4256263	chr4:185622959	C/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs7127900	0.898	rs11043135	chr11:2232696	A/C	cg25635251	chr11:2234043	NA	0.74	4.71	0.44	8.43e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs34112283	0.568	rs35981015	chr2:144231259	T/G	cg17056048	chr2:144271431	ARHGAP15	0.63	5.89	0.52	5.93e-8	Neuroticism;
THYM	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg00012203	chr2:219082015	ARPC2	0.6	5.24	0.47	9.84e-7	Colorectal cancer;
THYM	cis	rs2795502	0.506	rs11819501	chr10:43465544	C/T	cg08461752	chr10:43522343	NA	-0.84	-4.98	-0.45	2.89e-6	Blood protein levels;
THYM	cis	rs6754311	0.550	rs12994270	chr2:136518103	T/A	cg07169764	chr2:136633963	MCM6	-0.67	-5.92	-0.52	5.11e-8	Mosquito bite size;
THYM	cis	rs28595532	0.841	rs114970257	chr4:119756937	G/A	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg18681998	chr4:17616180	MED28	1.01	10.39	0.73	2.42e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2963155	0.518	rs6196	chr5:142661490	A/G	cg17617527	chr5:142782415	NR3C1	1.14	6.55	0.56	2.88e-9	Breast cancer;
THYM	cis	rs13082711	0.640	rs66941564	chr3:27259702	C/A	cg02860705	chr3:27208620	NA	0.94	7.6	0.61	2.08e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg10515332	chr4:99064459	C4orf37	0.67	5.33	0.48	6.48e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs713587	0.934	rs6738433	chr2:25159501	G/C	cg15423357	chr2:25149977	NA	0.66	7.21	0.59	1.3100000000000001e-10	Body mass index in non-asthmatics;
THYM	cis	rs3772130	1.000	rs62268732	chr3:121370455	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.74	4.5	0.42	1.93e-5	Cognitive performance;
THYM	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg09085632	chr11:111637200	PPP2R1B	0.94	8.25	0.65	8.98e-13	Primary sclerosing cholangitis;
THYM	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg23131131	chr22:24373011	LOC391322	-0.68	-6.0	-0.52	3.64e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9733	0.596	rs12089731	chr1:150647798	T/C	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg11812906	chr14:75593930	NEK9	0.89	8.2	0.64	1.11e-12	Height;
THYM	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg04234412	chr22:24373322	LOC391322	-0.98	-12.23	-0.78	3.24e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg13683864	chr3:40499215	RPL14	-0.83	-7.81	-0.63	7.51e-12	Renal cell carcinoma;
THYM	cis	rs172166	0.561	rs149976	chr6:27987776	C/T	cg09682330	chr6:28411287	ZSCAN23	0.61	5.43	0.49	4.38e-7	Cardiac Troponin-T levels;
THYM	cis	rs17443541	0.507	rs1823488	chr2:200463830	G/A	cg01795955	chr2:200468626	NA	-0.72	-5.0	-0.46	2.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6906287	0.625	rs7764272	chr6:118692498	A/C	cg21191810	chr6:118973309	C6orf204	0.63	6.0	0.52	3.56e-8	Electrocardiographic conduction measures;
THYM	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg00290607	chr11:67383545	NA	1.0	8.94	0.68	3e-14	Mean corpuscular volume;
THYM	cis	rs4849845	0.925	rs10180681	chr2:121012029	A/G	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg02038168	chr22:39784481	NA	-0.69	-5.59	-0.5	2.15e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2562456	0.761	rs35008138	chr19:21731624	A/T	cg21751540	chr19:21541537	ZNF738	-0.69	-4.75	-0.44	7.1e-6	Pain;
THYM	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg18230493	chr5:56204884	C5orf35	0.64	4.8	0.44	5.87e-6	Initial pursuit acceleration;
THYM	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs11599315	0.507	rs12220555	chr10:1341858	C/T	cg09624528	chr10:1369823	ADARB2	0.77	6.14	0.53	1.87e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs6430585	0.528	rs115553816	chr2:136692893	G/A	cg07169764	chr2:136633963	MCM6	1.19	11.38	0.76	1.91e-19	Corneal structure;
THYM	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs4654899	0.772	rs951805	chr1:21060356	A/G	cg01072550	chr1:21505969	NA	0.64	5.56	0.5	2.43e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	10.09	0.72	1.05e-16	Platelet count;
THYM	cis	rs2070488	0.965	rs2154778	chr3:38553639	C/T	cg24069376	chr3:38537580	EXOG	-0.66	-6.36	-0.55	7.17e-9	Electrocardiographic conduction measures;
THYM	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg10802521	chr3:52805072	NEK4	-0.74	-6.66	-0.56	1.79e-9	Bipolar disorder;
THYM	cis	rs11077998	0.967	rs12185229	chr17:80499065	G/C	cg11779900	chr17:80519722	FOXK2	-0.53	-4.51	-0.42	1.83e-5	Reticulocyte fraction of red cells;
THYM	cis	rs4930776	0.618	rs251773	chr12:5775556	G/A	cg02086166	chr12:5775618	ANO2	0.56	4.76	0.44	6.89e-6	Plasma clusterin levels;
THYM	cis	rs7267979	1.000	rs2500405	chr20:25360826	A/G	cg08601574	chr20:25228251	PYGB	-0.58	-4.71	-0.43	8.54e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg22907277	chr7:1156413	C7orf50	0.87	8.76	0.67	7.42e-14	Longevity;Endometriosis;
THYM	cis	rs34375054	0.624	rs7132026	chr12:125678096	A/G	cg25124228	chr12:125621409	AACS	0.65	4.68	0.43	9.46e-6	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs12530845	1.000	rs4291211	chr7:135335373	C/T	cg23117316	chr7:135346802	PL-5283	-0.67	-6.24	-0.54	1.2e-8	Red blood cell traits;
THYM	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg12179176	chr11:130786555	SNX19	0.88	8.07	0.64	2.13e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg04398451	chr17:18023971	MYO15A	0.83	7.71	0.62	1.22e-11	Total body bone mineral density;
THYM	cis	rs2747539	1.000	rs6087532	chr20:32422597	T/C	cg06304546	chr20:32448765	NA	-0.81	-5.08	-0.46	1.9e-6	Dysphagia;
THYM	cis	rs854765	0.583	rs10048206	chr17:17866897	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.58	0.56	2.61e-9	Total body bone mineral density;
THYM	cis	rs72627123	0.867	rs73301475	chr14:74462868	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs6906287	0.647	rs35730412	chr6:118707343	T/C	cg21191810	chr6:118973309	C6orf204	0.56	5.45	0.49	3.93e-7	Electrocardiographic conduction measures;
THYM	cis	rs7119	0.651	rs12915057	chr15:77847745	C/A	cg10437265	chr15:77819839	NA	0.68	6.22	0.54	1.33e-8	Type 2 diabetes;
THYM	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9660180	0.967	rs6603802	chr1:1812521	C/T	cg24362661	chr1:871546	SAMD11	-0.31	-4.52	-0.42	1.76e-5	Body mass index;
THYM	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg05043794	chr9:111880884	C9orf5	0.43	6.21	0.54	1.39e-8	Menarche (age at onset);
THYM	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.53	-4.86	-0.45	4.56e-6	Lymphocyte counts;
THYM	cis	rs9992101	0.669	rs10006043	chr4:77357747	C/T	cg20311846	chr4:77356250	SHROOM3	-0.55	-6.39	-0.55	6.26e-9	Creatinine levels;
THYM	cis	rs9361491	0.608	rs9352619	chr6:79442714	G/A	cg04547799	chr6:79944526	HMGN3	-0.66	-4.69	-0.43	9.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg04320152	chr17:18167836	SMCR7	0.59	4.72	0.44	7.96e-6	Total body bone mineral density;
THYM	cis	rs988913	0.957	rs9296771	chr6:54782274	T/A	cg19716238	chr6:54711378	FAM83B	0.51	5.02	0.46	2.4e-6	Menarche (age at onset);
THYM	cis	rs12496230	1.000	rs17782285	chr3:66833592	A/G	cg17646820	chr3:66848679	NA	0.82	4.85	0.45	4.79e-6	Type 2 diabetes;
THYM	cis	rs8050907	0.590	rs2270364	chr16:4526750	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.22	4.58	0.43	1.43e-5	Obesity-related traits;
THYM	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg04518342	chr5:131593106	PDLIM4	0.45	5.17	0.47	1.32e-6	Blood metabolite levels;
THYM	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg07343612	chr16:622815	PIGQ	-1.08	-11.34	-0.76	2.36e-19	Height;
THYM	cis	rs899997	0.953	rs11633519	chr15:78999552	A/G	cg22753661	chr15:79092743	ADAMTS7	0.7	4.54	0.42	1.65e-5	Coronary artery disease or large artery stroke;
THYM	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg16342193	chr10:102329863	NA	-0.5	-5.13	-0.47	1.54e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11174202	0.786	rs57407071	chr12:62230559	T/C	cg11441379	chr12:63026424	NA	0.58	4.46	0.42	2.24e-5	Anorexia nervosa;
THYM	cis	rs72772090	0.539	rs116360011	chr5:96117797	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.66	5.44	0.49	4.2e-7	Blood metabolite levels;
THYM	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg22841779	chr14:105766346	BRF1	-0.47	-5.88	-0.52	5.97e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg18132916	chr6:79620363	NA	-0.55	-4.85	-0.45	4.82e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6545977	0.531	rs2539982	chr2:63111004	G/A	cg17519650	chr2:63277830	OTX1	0.72	5.71	0.51	1.28e-7	Prostate cancer;
THYM	cis	rs3540	0.512	rs3862433	chr15:91076028	G/A	cg22089800	chr15:90895588	ZNF774	-0.7	-5.44	-0.49	4.14e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11096990	0.613	rs6840578	chr4:39208616	A/G	cg24403649	chr4:39172243	NA	0.6	5.16	0.47	1.35e-6	Cognitive function;
THYM	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg18758796	chr5:131593413	PDLIM4	-0.5	-4.72	-0.44	8.15e-6	Breast cancer;
THYM	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	5.5	0.49	3.14e-7	Mood instability;
THYM	cis	rs7772486	0.875	rs7739418	chr6:146359188	G/A	cg13319975	chr6:146136371	FBXO30	-0.72	-6.02	-0.53	3.33e-8	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg17830980	chr10:43048298	ZNF37B	-1.02	-10.31	-0.73	3.57e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg11266682	chr4:10021025	SLC2A9	-0.49	-4.87	-0.45	4.41e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg25767906	chr1:53392781	SCP2	-0.66	-6.2	-0.54	1.43e-8	Monocyte count;
THYM	cis	rs7098414	0.530	rs10749572	chr10:82136664	G/T	cg00277334	chr10:82204260	NA	-0.49	-4.96	-0.45	3.14e-6	Post bronchodilator FEV1;
THYM	cis	rs7584330	0.554	rs55919896	chr2:238428823	A/T	cg08992911	chr2:238395768	MLPH	0.69	4.79	0.44	6.17e-6	Prostate cancer;
THYM	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.17	-0.53	1.69e-8	Developmental language disorder (linguistic errors);
THYM	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2970992	0.817	rs10197891	chr2:101334579	C/T	cg01042948	chr2:101319752	NA	0.59	5.84	0.51	7.15e-8	Educational attainment;
THYM	cis	rs13256369	0.950	rs1522839	chr8:8580453	C/T	cg00074818	chr8:8560427	CLDN23	0.58	5.28	0.48	8.28e-7	Obesity-related traits;
THYM	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg07570687	chr10:102243282	WNT8B	0.76	6.93	0.58	5.03e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs297325	0.812	rs11826990	chr11:16760724	T/G	cg20214553	chr11:17278779	NA	0.4	4.48	0.42	2.09e-5	Obesity and osteoporosis;
THYM	cis	rs7833986	0.501	rs2719259	chr8:56941630	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.55	6.55	0.56	2.92e-9	Height;
THYM	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg17178900	chr1:205818956	PM20D1	1.06	12.16	0.78	4.43e-21	Menarche (age at onset);
THYM	cis	rs1061377	1.000	rs12646251	chr4:39134371	G/A	cg24403649	chr4:39172243	NA	0.55	4.46	0.42	2.28e-5	Uric acid levels;
THYM	cis	rs400736	0.860	rs2294890	chr1:8086527	T/G	cg22678073	chr1:8087421	ERRFI1	0.47	5.0	0.46	2.58e-6	Response to antidepressants and depression;
THYM	cis	rs6427356	0.513	rs2004705	chr1:157143512	G/A	cg27547283	chr1:156698502	C1orf66;ISG20L2	-0.58	-4.49	-0.42	2.02e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs2279817	1.000	rs4920620	chr1:18023154	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.79	5.0	0.46	2.67e-6	Neuroticism;
THYM	cis	rs728616	0.867	rs118134654	chr10:81744381	G/A	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg00684032	chr4:1343700	KIAA1530	0.53	4.55	0.42	1.61e-5	Longevity;
THYM	cis	rs6582630	0.516	rs8186746	chr12:38347638	G/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.47	-0.42	2.17e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07167872	chr1:205819463	PM20D1	1.18	13.1	0.8	5.21e-23	Menarche (age at onset);
THYM	trans	rs8002861	0.664	rs2325089	chr13:44450222	C/G	cg17145862	chr1:211918768	LPGAT1	-0.88	-8.09	-0.64	1.97e-12	Leprosy;
THYM	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	5.02	0.46	2.38e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg04429589	chr14:105992532	TMEM121	-0.48	-5.28	-0.48	8.21e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg04772025	chr11:68637568	NA	0.63	6.58	0.56	2.59e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs829883	0.664	rs1096148	chr12:98851005	A/G	cg25150519	chr12:98850993	NA	0.55	5.49	0.49	3.29e-7	Colorectal adenoma (advanced);
THYM	cis	rs12042938	0.600	rs4658880	chr1:231764621	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.7	4.98	0.46	2.8e-6	Neuranatomic and neurocognitive phenotypes;
THYM	cis	rs12579753	0.879	rs12579544	chr12:82164043	A/C	cg07988820	chr12:82153109	PPFIA2	-0.85	-5.59	-0.5	2.16e-7	Resting heart rate;
THYM	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg02018176	chr4:1364513	KIAA1530	0.71	6.69	0.57	1.55e-9	Longevity;
THYM	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs6087771	0.926	rs6058431	chr20:30297133	C/T	cg13852791	chr20:30311386	BCL2L1	0.88	8.4	0.65	4.37e-13	Subcortical brain region volumes;Putamen volume;
THYM	cis	rs17122693	0.551	rs2934681	chr14:51061491	C/T	cg04730355	chr14:51134070	SAV1	1.02	7.1	0.59	2.29e-10	Cognitive performance;
THYM	cis	rs12738007	0.544	rs4654390	chr1:29439016	T/A	cg01925633	chr1:29338769	EPB41	0.57	4.95	0.45	3.26e-6	Schizophrenia;
THYM	cis	rs892961	0.899	rs312911	chr17:75414585	A/C	cg11351908	chr17:75402473	SEPT9	0.61	6.19	0.54	1.52e-8	Airflow obstruction;
THYM	cis	rs40363	0.645	rs37774	chr16:3512695	T/C	cg01073479	chr16:3509474	NAT15	0.58	5.59	0.5	2.16e-7	Tuberculosis;
THYM	cis	rs7193541	0.684	rs4888262	chr16:74670458	C/T	cg01733217	chr16:74700730	RFWD3	0.99	11.93	0.77	1.36e-20	Multiple myeloma;
THYM	cis	rs9399401	0.667	rs6912639	chr6:142770548	T/C	cg04461802	chr6:142623433	GPR126	0.76	7.5	0.61	3.32e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.66	5.33	0.48	6.61e-7	Intelligence (multi-trait analysis);
THYM	cis	rs34286592	0.929	rs11863748	chr16:29835588	G/C	cg04633683	chr16:29837056	MVP	0.57	4.57	0.42	1.44e-5	Multiple sclerosis;
THYM	cis	rs4889855	0.530	rs4889865	chr17:78568447	A/T	cg16591659	chr17:78472290	NA	0.45	5.14	0.47	1.46e-6	Fractional excretion of uric acid;
THYM	cis	rs858239	0.539	rs10247268	chr7:23187179	G/A	cg09755872	chr7:23245557	NA	-0.5	-4.71	-0.43	8.55e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	4.93	0.45	3.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs7584330	0.554	rs3751107	chr2:238427251	G/A	cg14458575	chr2:238380390	NA	0.79	4.65	0.43	1.06e-5	Prostate cancer;
THYM	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg09904177	chr6:26538194	HMGN4	0.6	4.95	0.45	3.24e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6430585	0.527	rs2304366	chr2:136467119	C/T	cg23851026	chr2:136556271	LCT	0.68	6.08	0.53	2.49e-8	Corneal structure;
THYM	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg03647317	chr4:187891568	NA	-0.84	-9.02	-0.68	2.08e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10896135	0.526	rs484262	chr11:66399681	C/T	cg24851651	chr11:66362959	CCS	-0.8	-6.7	-0.57	1.47e-9	Bipolar disorder;
THYM	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg18758796	chr5:131593413	PDLIM4	0.5	4.92	0.45	3.64e-6	Blood metabolite levels;
THYM	cis	rs7432375	1.000	rs940174	chr3:136309710	T/C	cg21827317	chr3:136751795	NA	0.57	4.86	0.45	4.62e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	trans	rs11165623	0.715	rs1980769	chr1:96888201	A/T	cg10631902	chr5:14652156	NA	-0.64	-6.85	-0.57	7.46e-10	Hip circumference;Waist circumference;
THYM	cis	rs599083	0.530	rs689179	chr11:68179166	A/G	cg16797656	chr11:68205561	LRP5	-0.47	-5.03	-0.46	2.35e-6	Bone mineral density (spine);
THYM	cis	rs4787491	0.729	rs11642399	chr16:30059593	T/G	cg06015834	chr16:30021696	DOC2A	-0.52	-4.67	-0.43	9.88e-6	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6980334	0.911	rs2166188	chr7:137773563	A/C	cg18769353	chr7:137028617	PTN	0.61	4.82	0.44	5.34e-6	Blood metabolite ratios;
THYM	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg25036284	chr2:26402008	FAM59B	-0.74	-4.87	-0.45	4.39e-6	Gut microbiome composition (summer);
THYM	cis	rs6500395	0.963	rs2111242	chr16:48708300	T/C	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg15744005	chr10:104629667	AS3MT	-0.86	-8.65	-0.66	1.29e-13	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg12419862	chr22:24373484	LOC391322	-0.74	-7.13	-0.59	1.99e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs236907	0.812	rs17596025	chr1:171746247	T/C	cg20598894	chr1:171756153	METTL13	-0.71	-5.41	-0.48	4.79e-7	Mean platelet volume;
THYM	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Body mass index;
THYM	cis	rs67385638	0.802	rs11036635	chr11:5308896	C/T	cg12559170	chr11:5275217	HBG2	0.73	6.41	0.55	5.57e-9	Hemoglobin levels;
THYM	cis	rs28595532	0.920	rs115464801	chr4:119730673	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs7131987	0.622	rs7294598	chr12:29531989	A/C	cg09582351	chr12:29534625	ERGIC2	0.56	4.87	0.45	4.37e-6	QT interval;
THYM	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg04287289	chr16:89883240	FANCA	0.65	5.87	0.52	6.49e-8	Vitiligo;
THYM	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7084402	0.935	rs1649068	chr10:60304864	A/C	cg07615347	chr10:60278583	BICC1	0.55	5.12	0.47	1.58e-6	Refractive error;
THYM	trans	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg25517755	chr10:38738941	LOC399744	-0.79	-7.77	-0.62	9.18e-12	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.74	-5.6	-0.5	2.05e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.44	0.61	4.48e-11	Bladder cancer;
THYM	cis	rs11628318	0.515	rs11627756	chr14:103096606	C/T	cg27124170	chr14:102829869	TECPR2;CINP	-0.67	-4.62	-0.43	1.19e-5	Platelet count;
THYM	cis	rs35883536	0.967	rs2297713	chr1:101092766	T/G	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg06634786	chr22:41940651	POLR3H	0.66	4.8	0.44	5.78e-6	Vitiligo;
THYM	cis	rs944002	1.000	rs36027406	chr14:103565080	T/C	cg16996574	chr14:103691482	NA	0.52	4.69	0.43	9e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;
THYM	cis	rs4749080	0.646	rs12774203	chr10:26351867	G/A	cg15678844	chr10:26500780	MYO3A	-0.64	-4.46	-0.42	2.26e-5	Obesity-related traits;
THYM	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg08885076	chr2:99613938	TSGA10	0.63	5.66	0.5	1.57e-7	Chronic sinus infection;
THYM	cis	rs6598955	0.671	rs75517917	chr1:26612926	G/T	cg19677267	chr1:26645161	CD52;UBXN11	0.49	4.52	0.42	1.75e-5	Obesity-related traits;
THYM	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.64	4.91	0.45	3.81e-6	Multiple sclerosis;
THYM	cis	rs4731207	0.724	rs10229152	chr7:124538285	G/A	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs9549367	0.588	rs9549360	chr13:113893032	C/G	cg18105134	chr13:113819100	PROZ	-0.94	-6.29	-0.54	9.85e-9	Platelet distribution width;
THYM	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.58	-4.63	-0.43	1.17e-5	Response to bleomycin (chromatid breaks);
THYM	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg08847533	chr14:75593920	NEK9	1.02	11.25	0.76	3.61e-19	Height;
THYM	cis	rs13102973	0.965	rs7693757	chr4:135856609	C/T	cg14419869	chr4:135874104	NA	0.9	8.82	0.67	5.39e-14	Subjective well-being;
THYM	cis	rs6732160	0.613	rs10179063	chr2:73385111	T/A	cg24220031	chr2:73402428	NA	-0.71	-5.79	-0.51	8.94e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg08000102	chr2:233561755	GIGYF2	-0.56	-5.02	-0.46	2.37e-6	Coronary artery disease;
THYM	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.55	0.42	1.57e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg08999081	chr20:33150536	PIGU	-0.59	-5.41	-0.48	4.79e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.22	-0.47	1.07e-6	Mean corpuscular volume;
THYM	cis	rs513349	0.964	rs210141	chr6:33546825	T/C	cg07679836	chr6:33548423	BAK1	0.35	4.91	0.45	3.83e-6	Platelet count;
THYM	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs6980334	0.817	rs10263205	chr7:137792922	C/T	cg18769353	chr7:137028617	PTN	0.64	5.06	0.46	2.01e-6	Blood metabolite ratios;
THYM	cis	rs4262150	0.883	rs72802891	chr5:152255602	C/G	cg06854687	chr5:151642065	NA	0.64	4.46	0.42	2.27e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs7119	0.717	rs35268067	chr15:77753688	C/G	cg10437265	chr15:77819839	NA	0.56	4.99	0.46	2.78e-6	Type 2 diabetes;
THYM	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg06238570	chr21:40685208	BRWD1	0.92	6.85	0.57	7.35e-10	Cognitive function;
THYM	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg25427524	chr10:38739819	LOC399744	0.67	6.25	0.54	1.16e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs7582180	0.614	rs4340543	chr2:101005511	G/A	cg21926883	chr2:100939477	LONRF2	-0.66	-6.11	-0.53	2.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4595586	0.525	rs12809307	chr12:39365927	A/G	cg13010199	chr12:38710504	ALG10B	0.61	4.65	0.43	1.05e-5	Morning vs. evening chronotype;
THYM	cis	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg06521331	chr12:34319734	NA	-0.73	-5.66	-0.5	1.59e-7	Morning vs. evening chronotype;
THYM	cis	rs8014204	0.869	rs2070599	chr14:75361177	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.57	-5.49	-0.49	3.29e-7	Caffeine consumption;
THYM	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg06112835	chr11:68658793	MRPL21	0.45	6.44	0.55	4.77e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs8180040	0.726	rs2305638	chr3:47046842	G/C	cg02527881	chr3:46936655	PTH1R	-0.64	-5.79	-0.51	8.86e-8	Colorectal cancer;
THYM	cis	rs611744	0.967	rs636904	chr8:109197565	T/C	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs3126085	0.877	rs1552992	chr1:152171625	C/G	cg10321714	chr1:152280068	FLG	0.68	5.07	0.46	1.98e-6	Atopic dermatitis;
THYM	cis	rs67981189	0.896	rs3814869	chr14:71495699	C/T	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg17554472	chr22:41940697	POLR3H	-0.73	-4.61	-0.43	1.27e-5	Vitiligo;
THYM	cis	rs9581857	0.615	rs9581849	chr13:28005782	G/T	cg22138327	chr13:27999177	GTF3A	0.98	5.5	0.49	3.19e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs1061377	1.000	rs1897136	chr4:39132862	C/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7705502	0.855	rs72810972	chr5:173307328	G/T	cg18693985	chr5:173351052	CPEB4	-0.8	-5.74	-0.51	1.13e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs2276314	0.857	rs28379448	chr18:33604364	C/A	cg05985134	chr18:33552581	C18orf21	0.69	4.88	0.45	4.22e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg22875332	chr1:76189707	ACADM	0.89	12.06	0.78	7.38e-21	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4072705	0.586	rs7855247	chr9:127246644	T/C	cg13476313	chr9:127244764	NR5A1	-0.39	-5.96	-0.52	4.23e-8	Menarche (age at onset);
THYM	cis	rs7044106	0.791	rs4836831	chr9:123496570	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	6.56	0.56	2.81e-9	Hip circumference adjusted for BMI;
THYM	cis	rs2835345	0.596	rs62229441	chr21:37819857	C/A	cg20643029	chr21:37915044	CLDN14	0.61	4.84	0.44	5.12e-6	Pulmonary function;
THYM	cis	rs7264396	0.563	rs2425079	chr20:34298191	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.76	-0.44	6.84e-6	Total cholesterol levels;
THYM	cis	rs11969893	0.850	rs9404055	chr6:101302260	C/T	cg12253828	chr6:101329408	ASCC3	1.03	6.07	0.53	2.56e-8	Economic and political preferences (immigration/crime);
THYM	cis	rs2276498	0.751	rs2299701	chr20:52659477	T/C	cg23682609	chr20:52687365	BCAS1	0.56	4.55	0.42	1.6e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs1957429	0.614	rs117316280	chr14:65388641	T/C	cg23373153	chr14:65346875	NA	-1.25	-5.03	-0.46	2.29e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs6906287	0.531	rs72962938	chr6:119016221	T/C	cg01113488	chr6:119027122	NA	0.63	5.14	0.47	1.45e-6	Electrocardiographic conduction measures;
THYM	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg25703541	chr22:24373054	LOC391322	-0.93	-12.25	-0.78	2.89e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2364543	0.624	rs61774752	chr1:41847024	T/C	cg08462924	chr1:41848221	NA	0.81	9.26	0.69	6.22e-15	Intelligence (multi-trait analysis);
THYM	trans	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg05926928	chr17:57297772	GDPD1	1.25	9.97	0.72	1.88e-16	Opioid sensitivity;
THYM	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg00129232	chr17:37814104	STARD3	-0.87	-7.23	-0.6	1.23e-10	Asthma;
THYM	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg04398451	chr17:18023971	MYO15A	0.9	9.71	0.71	6.98e-16	Total body bone mineral density;
THYM	cis	rs7731657	0.537	rs7736085	chr5:130324525	A/C	cg08523029	chr5:130500466	HINT1	-0.85	-6.0	-0.52	3.55e-8	Fasting plasma glucose;
THYM	cis	rs28647808	1.000	rs28489061	chr9:136270319	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22496380	chr5:211416	CCDC127	-1.28	-7.72	-0.62	1.17e-11	Breast cancer;
THYM	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg06618935	chr21:46677482	NA	-0.96	-6.92	-0.58	5.18e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg20607798	chr8:58055168	NA	0.83	4.68	0.43	9.53e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs8133932	0.701	rs2330327	chr21:47305177	A/G	cg20357416	chr21:47294739	PCBP3	-0.88	-5.72	-0.51	1.23e-7	Schizophrenia;
THYM	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg23018236	chr17:30244563	NA	-0.6	-4.45	-0.42	2.3e-5	Hip circumference adjusted for BMI;
THYM	cis	rs2836633	0.895	rs2836598	chr21:40024758	C/G	cg12884169	chr21:40033163	ERG	0.67	8.47	0.66	3e-13	Coronary artery disease;
THYM	cis	rs2046867	0.908	rs62251634	chr3:72788705	A/C	cg25664220	chr3:72788482	NA	-0.83	-6.25	-0.54	1.18e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs12142240	0.621	rs66828173	chr1:46818166	G/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs36051895	0.658	rs10815145	chr9:5013309	G/A	cg02405213	chr9:5042618	JAK2	-1.05	-11.55	-0.76	8.48e-20	Pediatric autoimmune diseases;
THYM	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg07343612	chr16:622815	PIGQ	-1.08	-11.34	-0.76	2.36e-19	Height;
THYM	cis	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg12165864	chr7:66369176	NA	0.62	4.74	0.44	7.55e-6	Aortic root size;
THYM	cis	rs17253792	0.822	rs79262019	chr14:56092704	A/G	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.67	4.76	0.44	6.84e-6	Height;
THYM	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.7	5.33	0.48	6.5e-7	Tonsillectomy;
THYM	cis	rs7319311	0.899	rs9521729	chr13:111029970	G/A	cg05272587	chr13:111038400	COL4A2	0.61	4.9	0.45	3.94e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg16325326	chr1:53192061	ZYG11B	-0.77	-5.72	-0.51	1.21e-7	Monocyte count;
THYM	cis	rs7078219	0.714	rs10883359	chr10:101274033	C/T	cg07044859	chr10:101282883	NA	0.44	4.65	0.43	1.08e-5	Dental caries;
THYM	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg24642844	chr7:1081250	C7orf50	-1.29	-8.31	-0.65	6.62e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg26408565	chr15:76604113	ETFA	-0.53	-4.64	-0.43	1.13e-5	Blood metabolite levels;
THYM	cis	rs6840360	0.571	rs55808836	chr4:152554991	C/T	cg22705602	chr4:152727874	NA	-0.8	-8.47	-0.66	3e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.62	-7.29	-0.6	9e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs2295359	0.892	rs2064689	chr1:67653010	G/A	cg11235152	chr1:67600687	NA	0.69	5.69	0.5	1.37e-7	Psoriasis;
THYM	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.49	-4.83	-0.44	5.32e-6	Schizophrenia;
THYM	cis	rs7584330	0.910	rs6713555	chr2:238398182	A/G	cg14458575	chr2:238380390	NA	-1.01	-7.51	-0.61	3.28e-11	Prostate cancer;
THYM	cis	rs662064	0.963	rs10864460	chr1:10563671	C/G	cg20482658	chr1:10539492	PEX14	-0.47	-6.08	-0.53	2.49e-8	Asthma;
THYM	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg10295955	chr4:187884368	NA	-1.19	-16.46	-0.86	1.45e-29	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2109514	0.870	rs6976316	chr7:116122943	G/A	cg12739419	chr7:116140593	CAV2	-0.48	-4.79	-0.44	6.1e-6	Prevalent atrial fibrillation;
THYM	cis	rs2133450	0.712	rs1508708	chr3:7364572	G/A	cg19930620	chr3:7340148	GRM7	-0.51	-4.59	-0.43	1.36e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs4563143	0.514	rs73029081	chr19:29295583	C/G	cg12667521	chr19:29218732	NA	0.76	5.59	0.5	2.14e-7	Methadone dose in opioid dependence;
THYM	cis	rs12096438	0.903	rs3924486	chr1:25892880	G/T	cg08876437	chr1:25228690	RUNX3	0.54	4.67	0.43	9.83e-6	Platelet count;Mean platelet volume;
THYM	cis	rs35849525	0.814	rs7635601	chr3:50044006	A/T	cg14019146	chr3:50243930	SLC38A3	-0.59	-4.56	-0.42	1.55e-5	Intelligence (multi-trait analysis);
THYM	cis	rs798766	1.000	rs1665362	chr4:1726367	T/A	cg00006948	chr4:1768889	NA	-0.91	-4.83	-0.44	5.32e-6	Bladder cancer;Urinary bladder cancer;
THYM	cis	rs28830936	0.528	rs11630242	chr15:42124643	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.29	-4.88	-0.45	4.26e-6	Diastolic blood pressure;
THYM	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg05335186	chr13:53173507	NA	-0.46	-5.84	-0.51	7.26e-8	Lewy body disease;
THYM	cis	rs12935418	0.673	rs2602428	chr16:81062171	C/T	cg16651780	chr16:81037892	C16orf61	-0.77	-5.59	-0.5	2.2e-7	Mean corpuscular volume;
THYM	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs7584330	0.737	rs11886117	chr2:238361650	A/T	cg16989719	chr2:238392110	NA	-0.6	-5.82	-0.51	8.08e-8	Prostate cancer;
THYM	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	6.71	0.57	1.37e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs4792901	0.729	rs12603059	chr17:41538446	G/A	cg21940313	chr17:41620911	ETV4	-0.51	-5.05	-0.46	2.15e-6	Dupuytren's disease;
THYM	cis	rs11585357	0.895	rs112208664	chr1:17632010	G/A	cg08277548	chr1:17600880	PADI3	-0.82	-4.95	-0.45	3.23e-6	Hair shape;
THYM	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg00383909	chr3:49044727	WDR6	1.05	5.98	0.52	3.82e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs600550	0.528	rs11824940	chr11:59826857	A/G	cg02771260	chr11:59836817	MS4A3	0.69	5.13	0.47	1.55e-6	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs875971	0.964	rs160635	chr7:65528918	T/C	cg11764359	chr7:65958608	NA	0.8	6.5	0.55	3.78e-9	Aortic root size;
THYM	cis	rs4285028	0.747	rs11928871	chr3:121483388	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.87	-6.37	-0.55	6.7e-9	Multiple sclerosis;
THYM	cis	rs4638749	0.677	rs6713634	chr2:108827907	T/G	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg11335335	chr11:637885	DRD4	-0.69	-6.23	-0.54	1.24e-8	Systemic lupus erythematosus;
THYM	cis	rs4481887	1.000	rs6666690	chr1:248465323	T/C	cg00666640	chr1:248458726	OR2T12	0.58	4.72	0.44	8.11e-6	Common traits (Other);
THYM	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg23803603	chr1:2058230	PRKCZ	0.63	5.37	0.48	5.58e-7	Height;
THYM	cis	rs9297145	0.715	rs62473008	chr7:98751541	A/G	cg05967295	chr7:98741636	SMURF1	0.88	6.53	0.56	3.19e-9	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg00071950	chr4:10020882	SLC2A9	0.72	6.53	0.56	3.17e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg23803603	chr1:2058230	PRKCZ	0.64	4.98	0.46	2.8e-6	Height;
THYM	cis	rs288326	0.561	rs77024950	chr2:183797227	T/C	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg11327659	chr7:150037044	RARRES2	0.47	5.32	0.48	6.94e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7572733	0.534	rs1436131	chr2:198731230	A/C	cg00792783	chr2:198669748	PLCL1	0.8	5.48	0.49	3.53e-7	Dermatomyositis;
THYM	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg20891558	chr2:74357851	NA	1.13	11.85	0.77	1.96e-20	Gestational age at birth (maternal effect);
THYM	cis	rs4950928	0.774	rs4950931	chr1:203164075	G/A	cg14085262	chr1:203155938	CHI3L1	-0.79	-5.42	-0.49	4.56e-7	YKL-40 levels;
THYM	cis	rs9296092	0.538	rs115770720	chr6:33517032	A/T	cg13560919	chr6:33536144	NA	-0.94	-9.16	-0.68	1.03e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	9.39	0.69	3.37e-15	Chronic sinus infection;
THYM	cis	rs8044868	0.586	rs2070937	chr16:72089740	A/G	cg06353428	chr16:71660113	MARVELD3	0.59	4.5	0.42	1.89e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs6763768	0.600	rs11705809	chr3:53363940	T/C	cg16894138	chr3:53270350	TKT	0.72	5.47	0.49	3.68e-7	Bacterial meningitis;
THYM	cis	rs61332075	0.504	rs7596847	chr2:239321118	T/A	cg18131467	chr2:239335373	ASB1	-0.8	-4.92	-0.45	3.67e-6	Lung function (FEV1/FVC);
THYM	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg23649088	chr2:200775458	C2orf69	0.81	6.14	0.53	1.88e-8	Schizophrenia;
THYM	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg05373962	chr22:49881684	NA	0.59	5.83	0.51	7.7e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs988913	0.768	rs2179786	chr6:54753340	G/T	cg19716238	chr6:54711378	FAM83B	0.51	5.64	0.5	1.76e-7	Menarche (age at onset);
THYM	cis	rs7113850	0.541	rs76166238	chr11:24235418	G/A	ch.11.24196551F	chr11:24239977	NA	0.87	4.66	0.43	1.04e-5	Bone fracture in osteoporosis;
THYM	cis	rs6032067	0.777	rs13037087	chr20:43834313	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs11771526	0.901	rs62456036	chr7:32266182	C/T	cg27532318	chr7:32358331	NA	0.73	5.03	0.46	2.34e-6	Body mass index;
THYM	cis	rs7267979	1.000	rs4815405	chr20:25317492	T/C	cg08601574	chr20:25228251	PYGB	-0.57	-4.59	-0.43	1.35e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg04414720	chr1:150670196	GOLPH3L	0.62	4.58	0.43	1.41e-5	Tonsillectomy;
THYM	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg00080972	chr5:178986291	RUFY1	-0.62	-8.78	-0.67	6.66e-14	Lung cancer;
THYM	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs6450176	1.000	rs67473746	chr5:53296730	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.81	-6.03	-0.53	3.17e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs988913	0.914	rs9396006	chr6:54787888	G/A	cg19716238	chr6:54711378	FAM83B	0.52	5.18	0.47	1.26e-6	Menarche (age at onset);
THYM	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg22166914	chr1:53195759	ZYG11B	0.9	10.56	0.73	1.04e-17	Monocyte count;
THYM	cis	rs986417	0.786	rs2038277	chr14:61083662	G/A	cg27398547	chr14:60952738	C14orf39	1.26	6.1	0.53	2.29e-8	Gut microbiota (bacterial taxa);
THYM	trans	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg10856724	chr12:34555212	NA	-0.79	-6.98	-0.58	3.9e-10	Heart rate;
THYM	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg09033563	chr22:24373618	LOC391322	-0.6	-5.77	-0.51	9.94e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10992471	0.580	rs13284106	chr9:95433845	G/A	cg14631576	chr9:95140430	CENPP	-0.93	-7.4	-0.6	5.33e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs448720	0.811	rs694267	chr15:68183377	C/T	cg23793686	chr15:68133972	NA	-0.56	-5.04	-0.46	2.22e-6	Cognitive performance;
THYM	cis	rs17152411	0.895	rs11245418	chr10:126586319	T/C	cg07906193	chr10:126599966	NA	0.68	4.65	0.43	1.08e-5	Height;
THYM	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg11871910	chr12:69753446	YEATS4	0.75	6.09	0.53	2.39e-8	Blood protein levels;
THYM	cis	rs2712184	0.729	rs4674115	chr2:217659628	C/G	cg05032264	chr2:217675019	NA	-0.54	-4.46	-0.42	2.22e-5	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs7546094	0.935	rs7554345	chr1:113122956	T/G	cg22162597	chr1:113214053	CAPZA1	0.45	4.63	0.43	1.15e-5	Platelet distribution width;
THYM	cis	rs6450176	0.909	rs2448	chr5:53302354	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-6.2	-0.54	1.45e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs28595532	0.920	rs115294251	chr4:119772833	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10929159	0.928	rs7569558	chr2:236924309	G/A	cg14895183	chr2:236924282	AGAP1	0.52	4.49	0.42	2.03e-5	Parkinson's disease;
THYM	cis	rs2456568	0.867	rs4753111	chr11:93658410	A/G	cg26875233	chr11:93583750	C11orf90	-0.52	-5.13	-0.47	1.53e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg08968635	chr6:28129556	ZNF389	-0.62	-5.18	-0.47	1.24e-6	Depression;
THYM	cis	rs7258465	1.000	rs2007981	chr19:18567555	C/A	cg01380346	chr19:18557039	ELL	-0.47	-4.69	-0.43	8.97e-6	Breast cancer;
THYM	cis	rs2404602	0.709	rs11072597	chr15:76763514	C/A	cg23625390	chr15:77176239	SCAPER	-0.71	-4.87	-0.45	4.37e-6	Blood metabolite levels;
THYM	cis	rs12310956	0.531	rs10772110	chr12:33841755	A/G	cg10856724	chr12:34555212	NA	-0.6	-5.16	-0.47	1.37e-6	Morning vs. evening chronotype;
THYM	cis	rs9527	0.615	rs7089065	chr10:104723022	C/T	cg04362960	chr10:104952993	NT5C2	0.6	4.62	0.43	1.2e-5	Arsenic metabolism;
THYM	cis	rs8070740	0.731	rs980406	chr17:5338783	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.72	5.7	0.5	1.34e-7	Menopause (age at onset);
THYM	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs2658782	0.901	rs10466368	chr11:93229756	T/C	cg15737290	chr11:93063684	CCDC67	1.06	7.29	0.6	9.08e-11	Pulmonary function decline;
THYM	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg12292205	chr6:26970375	C6orf41	-0.64	-5.19	-0.47	1.19e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs57590327	0.528	rs11707026	chr3:81694044	C/A	cg07356753	chr3:81810745	GBE1	-0.84	-6.17	-0.53	1.67e-8	Extraversion;
THYM	cis	rs870825	0.698	rs28412823	chr4:185638829	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs986417	1.000	rs10144805	chr14:60927652	T/C	cg27398547	chr14:60952738	C14orf39	1.15	5.91	0.52	5.37e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	5.93	0.52	4.96e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg07936489	chr17:37558343	FBXL20	0.83	5.77	0.51	1e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs236907	0.812	rs17657363	chr1:171801416	C/T	cg20598894	chr1:171756153	METTL13	0.68	4.57	0.42	1.45e-5	Mean platelet volume;
THYM	cis	rs9534288	0.797	rs6561280	chr13:46583691	T/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs7432375	0.901	rs9836231	chr3:136414321	C/T	cg12473912	chr3:136751656	NA	-0.62	-5.27	-0.48	8.44e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg24818145	chr4:99064322	C4orf37	0.73	5.74	0.51	1.13e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs735539	0.521	rs2585898	chr13:21400301	T/C	cg02792322	chr13:21280448	IL17D	-0.65	-4.63	-0.43	1.16e-5	Dental caries;
THYM	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg09307838	chr4:120376055	NA	0.77	5.56	0.5	2.5e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg22535103	chr8:58192502	C8orf71	-0.88	-4.93	-0.45	3.51e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06481639	chr22:41940642	POLR3H	0.87	5.95	0.52	4.49e-8	Vitiligo;
THYM	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs154659	1.000	rs154659	chr16:89667337	C/T	cg01710450	chr16:89662404	CPNE7	0.65	5.62	0.5	1.93e-7	Tanning;
THYM	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs986417	1.000	rs1254296	chr14:60870389	T/C	cg27398547	chr14:60952738	C14orf39	-1.32	-6.48	-0.55	4.09e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs11711311	0.955	rs78029398	chr3:113421321	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.59	-5.04	-0.46	2.24e-6	IgG glycosylation;
THYM	cis	rs9649465	0.935	rs1506641	chr7:123390143	G/A	cg15443791	chr7:124364398	NA	0.57	4.7	0.43	8.85e-6	Migraine;
THYM	cis	rs9733	0.596	rs72702580	chr1:150691285	A/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg01699819	chr7:1052092	C7orf50	-0.59	-5.04	-0.46	2.23e-6	Bronchopulmonary dysplasia;
THYM	cis	rs7131987	0.650	rs67146951	chr12:29450553	C/A	cg09582351	chr12:29534625	ERGIC2	-0.53	-4.68	-0.43	9.37e-6	QT interval;
THYM	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg15445000	chr17:37608096	MED1	-0.44	-5.22	-0.47	1.07e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7084402	0.870	rs4948525	chr10:60361270	G/A	cg07615347	chr10:60278583	BICC1	0.54	4.97	0.45	2.96e-6	Refractive error;
THYM	cis	rs7512552	0.809	rs696618	chr1:150376139	T/G	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs28595532	0.920	rs114928651	chr4:119734194	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs7586879	0.558	rs6718510	chr2:25122323	A/C	cg27107076	chr2:25050844	ADCY3	-0.29	-4.62	-0.43	1.18e-5	Body mass index;
THYM	cis	rs910187	0.678	rs6122564	chr20:45814745	A/C	cg27589058	chr20:45804311	EYA2	-0.59	-5.04	-0.46	2.22e-6	Migraine;
THYM	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08704250	chr15:31115839	NA	-0.51	-6.06	-0.53	2.68e-8	Huntington's disease progression;
THYM	cis	rs7705502	0.890	rs72810976	chr5:173309057	G/A	cg18693985	chr5:173351052	CPEB4	-0.8	-5.74	-0.51	1.13e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7084921	0.578	rs11190393	chr10:101869988	C/T	cg11344164	chr10:101878520	NA	-0.6	-5.27	-0.48	8.55e-7	Bone mineral density;
THYM	cis	rs7901056	0.837	rs4749126	chr10:26727682	C/A	cg23318538	chr10:26883079	C10orf50	-0.39	-4.96	-0.45	3.05e-6	Lymphocyte counts;
THYM	cis	rs34330	0.562	rs10845615	chr12:12863470	C/T	cg09462578	chr12:12878428	APOLD1	-0.91	-5.48	-0.49	3.43e-7	Systemic lupus erythematosus;
THYM	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs17577085	0.704	rs77475235	chr5:141867250	T/G	cg07247133	chr5:142066658	FGF1	0.76	4.83	0.44	5.24e-6	Coronary heart disease;
THYM	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs12928939	0.911	rs11645725	chr16:71826883	C/T	cg03805757	chr16:71968109	PKD1L3	-0.7	-5.31	-0.48	7.25e-7	Post bronchodilator FEV1;
THYM	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg18240062	chr17:79603768	NPLOC4	-0.73	-6.57	-0.56	2.74e-9	Eye color traits;
THYM	cis	rs7211079	0.879	rs61357240	chr17:78131775	A/G	cg09238746	chr17:78121135	EIF4A3	-0.74	-4.51	-0.42	1.83e-5	Myocardial infarction;
THYM	cis	rs4845459	0.933	rs6662654	chr1:152593081	G/T	cg26135325	chr1:152595322	LCE3A	-0.45	-5.13	-0.47	1.54e-6	Psoriasis;
THYM	cis	rs7107174	1.000	rs11237468	chr11:78072833	A/G	cg19901956	chr11:77921274	USP35	-0.65	-5.37	-0.48	5.66e-7	Testicular germ cell tumor;
THYM	cis	rs2637266	0.846	rs2583051	chr10:78403542	T/C	cg18941641	chr10:78392320	NA	0.6	4.79	0.44	6.07e-6	Pulmonary function;
THYM	cis	rs988913	0.957	rs9382405	chr6:54836613	T/C	cg04690482	chr6:54711388	FAM83B	0.47	5.03	0.46	2.3e-6	Menarche (age at onset);
THYM	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg18876405	chr7:65276391	NA	-0.61	-5.24	-0.47	9.48e-7	Aortic root size;
THYM	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg24675056	chr1:15929824	NA	0.72	5.71	0.51	1.26e-7	Systolic blood pressure;
THYM	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg05973401	chr12:123451056	ABCB9	-0.69	-4.59	-0.43	1.36e-5	Neutrophil percentage of white cells;
THYM	cis	rs6546324	0.625	rs6717863	chr2:67844799	C/A	cg18237512	chr2:67827392	NA	-0.8	-4.77	-0.44	6.69e-6	Endometriosis;
THYM	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg23803603	chr1:2058230	PRKCZ	-0.59	-5.04	-0.46	2.25e-6	Height;
THYM	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg01528321	chr10:82214614	TSPAN14	0.66	5.16	0.47	1.35e-6	Post bronchodilator FEV1;
THYM	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	9.78	0.71	4.77e-16	Platelet count;
THYM	cis	rs2109514	0.902	rs28495552	chr7:116113744	C/G	cg12739419	chr7:116140593	CAV2	-0.48	-4.92	-0.45	3.58e-6	Prevalent atrial fibrillation;
THYM	cis	rs4919694	1.000	rs4919694	chr10:104698978	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.8	-4.48	-0.42	2.06e-5	Arsenic metabolism;
THYM	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg03433033	chr1:76189801	ACADM	-0.76	-9.02	-0.68	2.01e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9790314	0.967	rs7623206	chr3:160971518	G/A	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs1692120	0.545	rs962371	chr11:61408285	T/G	cg19838087	chr11:61442541	NA	0.52	5.97	0.52	4.17e-8	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);
THYM	cis	rs11039798	0.920	rs116109043	chr11:48976940	C/T	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs4363385	0.818	rs1415965	chr1:153002750	G/A	cg13444842	chr1:152974279	SPRR3	-0.59	-4.81	-0.44	5.61e-6	Inflammatory skin disease;
THYM	cis	rs289828	0.929	rs10490523	chr2:152085984	A/G	cg05960677	chr2:152117363	RBM43	-0.63	-6.02	-0.53	3.21e-8	Blood protein levels;
THYM	cis	rs7586879	0.593	rs11689543	chr2:25130440	A/T	cg15423357	chr2:25149977	NA	0.71	7.63	0.62	1.77e-11	Body mass index;
THYM	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg15448220	chr1:150897856	SETDB1	0.93	7.88	0.63	5.38e-12	Melanoma;
THYM	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg00256281	chr22:41985642	PMM1	0.64	4.96	0.45	3.14e-6	Vitiligo;
THYM	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg20891283	chr12:69753455	YEATS4	1.06	10.24	0.72	5.15e-17	Blood protein levels;
THYM	cis	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.29	-0.54	9.48e-9	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg01017244	chr2:74357527	NA	1.11	8.91	0.67	3.54e-14	Gestational age at birth (maternal effect);
THYM	cis	rs7107174	1.000	rs2256051	chr11:77920457	G/A	cg02023728	chr11:77925099	USP35	0.69	6.61	0.56	2.26e-9	Testicular germ cell tumor;
THYM	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg03929089	chr4:120376271	NA	-1.02	-10.68	-0.74	5.96e-18	Height;
THYM	cis	rs11771526	0.901	rs62457494	chr7:32312299	T/G	cg27532318	chr7:32358331	NA	0.77	5.06	0.46	2.03e-6	Body mass index;
THYM	cis	rs752010	0.841	rs6661784	chr1:42080312	A/T	cg22486000	chr1:42919398	ZMYND12	-0.45	-5.05	-0.46	2.09e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-4.73	-0.44	7.71e-6	Mood instability;
THYM	cis	rs9733	0.566	rs72702554	chr1:150678234	A/G	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs1018836	1.000	rs1018836	chr8:91570362	A/G	cg16814680	chr8:91681699	NA	-0.78	-6.42	-0.55	5.41e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg11871910	chr12:69753446	YEATS4	0.81	6.9	0.58	5.67e-10	Cerebrospinal fluid biomarker levels;
THYM	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg12179176	chr11:130786555	SNX19	0.88	8.2	0.64	1.16e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9470366	0.816	rs1321310	chr6:36623124	C/T	cg11920449	chr6:36645608	CDKN1A	0.65	5.1	0.46	1.72e-6	QRS duration;
THYM	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg12419862	chr22:24373484	LOC391322	-0.77	-8.22	-0.64	1.05e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg08999081	chr20:33150536	PIGU	0.78	7.21	0.59	1.3100000000000001e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg14664628	chr15:75095509	CSK	-0.67	-5.09	-0.46	1.8e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs6763768	0.606	rs2029213	chr3:53378245	C/T	cg22900224	chr3:52804907	NEK4	0.72	4.67	0.43	9.85e-6	Bacterial meningitis;
THYM	cis	rs2361718	0.568	rs1042397	chr17:78092063	G/A	cg09238746	chr17:78121135	EIF4A3	-0.74	-5.29	-0.48	7.98e-7	Yeast infection;
THYM	cis	rs4285028	0.747	rs77570895	chr3:121384565	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.78	-5.48	-0.49	3.46e-7	Multiple sclerosis;
THYM	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg16486109	chr11:613632	IRF7	0.47	5.59	0.5	2.19e-7	Systemic lupus erythematosus;
THYM	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs7267979	1.000	rs1046073	chr20:25281333	G/A	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg02725872	chr8:58115012	NA	-1.11	-8.56	-0.66	1.98e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs986417	0.901	rs1007152	chr14:60999493	C/T	cg27398547	chr14:60952738	C14orf39	1.12	6.0	0.52	3.61e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6127978	0.702	rs162321	chr20:55818634	T/C	cg15851418	chr20:55835831	BMP7	0.71	5.07	0.46	1.93e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs6750795	0.569	rs1667308	chr2:232406344	T/C	cg19187155	chr2:232395269	NMUR1	0.9	9.04	0.68	1.87e-14	Height;
THYM	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg20891558	chr2:74357851	NA	1.22	11.58	0.76	7.47e-20	Gestational age at birth (maternal effect);
THYM	cis	rs9500256	1.000	rs9500256	chr6:58308955	C/T	cg16251399	chr6:58287822	GUSBL2	0.68	5.72	0.51	1.22e-7	Eosinophilic esophagitis (pediatric);
THYM	cis	rs6499129	0.571	rs868213	chr16:67220457	A/G	cg26912222	chr16:68000829	SLC12A4	0.71	4.81	0.44	5.55e-6	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9914544	0.545	rs9915343	chr17:18766494	A/G	cg26378065	chr17:18585709	ZNF286B	0.6	4.71	0.43	8.56e-6	Educational attainment (years of education);
THYM	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg10150615	chr22:24372951	LOC391322	-1.02	-12.23	-0.78	3.19e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs988913	0.957	rs932452	chr6:54801928	C/T	cg19716238	chr6:54711378	FAM83B	0.51	5.09	0.46	1.81e-6	Menarche (age at onset);
THYM	cis	rs3820068	0.705	rs11583306	chr1:15860803	A/G	cg05660106	chr1:15850417	CASP9	-1.1	-9.92	-0.71	2.48e-16	Systolic blood pressure;
THYM	cis	rs2731664	0.792	rs465670	chr5:176877624	C/T	cg14098951	chr5:176875120	PRR7	0.57	5.16	0.47	1.33e-6	Intelligence (multi-trait analysis);
THYM	cis	rs981844	0.921	rs2606336	chr4:154656792	C/T	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs9677476	0.909	rs10181602	chr2:232121642	G/C	cg23338755	chr2:231921595	PSMD1	0.67	4.83	0.44	5.2e-6	Food antigen IgG levels;
THYM	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg03806693	chr22:41940476	POLR3H	-0.89	-8.28	-0.65	7.78e-13	Vitiligo;
THYM	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg08213375	chr14:104286397	PPP1R13B	0.45	4.63	0.43	1.16e-5	Reticulocyte count;
THYM	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg21475434	chr5:93447410	FAM172A	-0.97	-6.16	-0.53	1.71e-8	Diabetic retinopathy;
THYM	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg23260525	chr10:116636907	FAM160B1	0.51	5.12	0.46	1.62e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs526231	0.543	rs60633061	chr5:102330049	C/T	cg23492399	chr5:102201601	PAM	-0.65	-5.1	-0.46	1.73e-6	Primary biliary cholangitis;
THYM	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg06221963	chr1:154839813	KCNN3	-0.86	-11.16	-0.75	5.62e-19	Prostate cancer;
THYM	cis	rs1957429	1.000	rs1957431	chr14:65353187	A/G	cg23373153	chr14:65346875	NA	1.11	6.67	0.56	1.7e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.63	5.02	0.46	2.37e-6	Intelligence (multi-trait analysis);
THYM	cis	rs654384	0.898	rs13242365	chr7:4175025	G/T	cg13153353	chr7:4175865	SDK1	0.47	4.52	0.42	1.77e-5	Positive affect;
THYM	cis	rs2456568	0.802	rs1506656	chr11:93639813	G/A	cg17347335	chr11:93583973	C11orf90	-0.48	-4.58	-0.43	1.4e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs3809566	1.000	rs3809566	chr15:63333724	A/G	cg00520135	chr15:63333846	TPM1	-0.59	-5.07	-0.46	1.93e-6	Platelet count;
THYM	cis	rs860818	1.000	rs1637220	chr7:23232851	C/G	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs7224737	1.000	rs2240009	chr17:40283142	C/G	cg00647820	chr17:40259828	DHX58	-0.62	-4.65	-0.43	1.06e-5	Fibrinogen levels;
THYM	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg06718696	chr17:78121285	EIF4A3	1.02	7.38	0.6	5.95e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
THYM	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg22857025	chr5:266934	NA	1.42	9.65	0.7	9.32e-16	Breast cancer;
THYM	cis	rs4889855	0.556	rs11547301	chr17:78518780	C/T	cg16591659	chr17:78472290	NA	0.42	4.79	0.44	6.21e-6	Fractional excretion of uric acid;
THYM	cis	rs4731207	0.662	rs2219954	chr7:124555855	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs79349575	0.756	rs2643361	chr17:46977462	T/G	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs3925075	0.934	rs9673522	chr16:31347648	T/C	cg02846316	chr16:31340340	ITGAM	0.58	6.08	0.53	2.44e-8	IgA nephropathy;
THYM	cis	rs34779708	0.966	rs998658	chr10:35408654	A/G	cg03585969	chr10:35415529	CREM	0.67	5.01	0.46	2.51e-6	Inflammatory bowel disease;Crohn's disease;
THYM	trans	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg07211511	chr3:129823064	LOC729375	-1.34	-11.58	-0.77	7.46e-20	Blood pressure (smoking interaction);
THYM	cis	rs6812193	0.518	rs62300825	chr4:77205319	G/A	cg20311846	chr4:77356250	SHROOM3	0.52	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg01097406	chr16:89675127	NA	0.62	5.57	0.5	2.32e-7	Vitiligo;
THYM	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg22764591	chr12:58329936	NA	0.85	5.95	0.52	4.5e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs17407555	0.738	rs10516198	chr4:10059448	T/C	cg11266682	chr4:10021025	SLC2A9	-0.57	-5.55	-0.49	2.59e-7	Schizophrenia (age at onset);
THYM	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg19077165	chr18:44547161	KATNAL2	-0.5	-5.82	-0.51	8.05e-8	Personality dimensions;
THYM	cis	rs11223731	0.708	rs61703311	chr11:134108059	G/T	cg18040241	chr11:134201582	GLB1L2	-0.75	-4.82	-0.44	5.34e-6	Verbal declarative memory;
THYM	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg05090351	chr10:126851162	NA	-0.64	-6.8	-0.57	9.32e-10	Menarche (age at onset);
THYM	cis	rs35881094	0.966	rs6724384	chr2:58879493	C/T	cg09452692	chr2:58468460	FANCL	0.57	4.46	0.42	2.27e-5	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.57	4.55	0.42	1.61e-5	Platelet count;
THYM	cis	rs28595532	0.920	rs116607127	chr4:119731072	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg17366294	chr4:99064904	C4orf37	0.57	6.82	0.57	8.42e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg21775007	chr8:11205619	TDH	-0.73	-5.68	-0.5	1.49e-7	Retinal vascular caliber;
THYM	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg24642844	chr7:1081250	C7orf50	-1.11	-6.35	-0.55	7.45e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs666930	0.519	rs662602	chr1:120266903	C/G	cg19096424	chr1:120255104	PHGDH	0.91	7.57	0.61	2.37e-11	Breast cancer;
THYM	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg08213375	chr14:104286397	PPP1R13B	0.5	6.09	0.53	2.39e-8	Schizophrenia;
THYM	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg23791538	chr6:167370224	RNASET2	-0.58	-4.53	-0.42	1.72e-5	Crohn's disease;
THYM	cis	rs4363385	0.530	rs10888529	chr1:153050654	G/T	cg13444842	chr1:152974279	SPRR3	-0.6	-4.84	-0.44	5.06e-6	Inflammatory skin disease;
THYM	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg08859206	chr1:53392774	SCP2	-0.77	-9.43	-0.7	2.75e-15	Monocyte count;
THYM	cis	rs7610301	1.000	rs4683247	chr3:46643052	G/C	cg22951056	chr3:46887651	NA	-0.77	-5.06	-0.46	2.06e-6	Blood protein levels;
THYM	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	7.66	0.62	1.54e-11	Platelet count;
THYM	trans	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg10856724	chr12:34555212	NA	-0.91	-8.12	-0.64	1.64e-12	Heart rate;
THYM	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg00256281	chr22:41985642	PMM1	0.62	4.76	0.44	6.91e-6	Vitiligo;
THYM	trans	rs10838798	0.523	rs2019093	chr11:48196553	G/A	cg00717180	chr2:96193071	NA	-0.64	-6.92	-0.58	5.16e-10	Height;
THYM	cis	rs2811415	0.597	rs13097739	chr3:127739076	T/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg04455712	chr21:45112962	RRP1B	0.49	4.48	0.42	2.07e-5	Mean corpuscular volume;
THYM	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg18252515	chr7:66147081	NA	0.72	5.6	0.5	2.03e-7	Aortic root size;
THYM	trans	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg25214090	chr10:38739885	LOC399744	0.89	7.04	0.59	2.94e-10	Corneal astigmatism;
THYM	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg08431931	chr22:42394659	WBP2NL	0.63	4.66	0.43	1.02e-5	Birth weight;
THYM	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2404602	0.735	rs4886805	chr15:76739384	A/G	cg23625390	chr15:77176239	SCAPER	0.7	4.9	0.45	3.96e-6	Blood metabolite levels;
THYM	cis	rs76878669	0.561	rs7110944	chr11:66118217	C/T	cg18002602	chr11:66138449	SLC29A2	-0.49	-4.77	-0.44	6.59e-6	Educational attainment (years of education);
THYM	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg20887711	chr4:1340912	KIAA1530	0.58	5.02	0.46	2.43e-6	Obesity-related traits;
THYM	cis	rs9876781	1.000	rs6442120	chr3:48464503	C/T	cg06066452	chr3:48470258	PLXNB1	0.27	4.77	0.44	6.64e-6	Longevity;
THYM	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg14779329	chr11:130786720	SNX19	0.56	6.17	0.54	1.63e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs853679	0.550	rs1233707	chr6:28172953	G/A	cg12963246	chr6:28129442	ZNF389	0.67	6.23	0.54	1.25e-8	Depression;
THYM	cis	rs2276314	0.857	rs16967327	chr18:33587036	C/T	cg05985134	chr18:33552581	C18orf21	0.66	4.79	0.44	6.02e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs184539343	1	rs184539343	chr2:159293749	C/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Cerebrospinal fluid AB1-42 levels;
THYM	cis	rs11771526	0.901	rs28631129	chr7:32305044	G/C	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg08999081	chr20:33150536	PIGU	-0.78	-7.16	-0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg10523679	chr1:76189770	ACADM	-0.85	-6.88	-0.58	6.47e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg24733560	chr20:60626293	TAF4	0.51	4.58	0.43	1.41e-5	Body mass index;
THYM	cis	rs9677476	0.689	rs55748426	chr2:232054897	G/C	cg20307347	chr2:231734563	ITM2C	-0.53	-4.47	-0.42	2.16e-5	Food antigen IgG levels;
THYM	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg02782426	chr3:40428986	ENTPD3	-0.57	-5.25	-0.47	9.31e-7	Renal cell carcinoma;
THYM	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg14458575	chr2:238380390	NA	0.99	7.13	0.59	1.93e-10	Prostate cancer;
THYM	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg20503657	chr10:835505	NA	1.17	8.2	0.64	1.16e-12	Eosinophil percentage of granulocytes;
THYM	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.87	-0.82	1.48e-24	Height;
THYM	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg04455712	chr21:45112962	RRP1B	-0.53	-4.54	-0.42	1.66e-5	Mean corpuscular volume;
THYM	cis	rs929596	0.556	rs10168416	chr2:234597087	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.81	-6.41	-0.55	5.5e-9	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs28476539	0.567	rs17006028	chr4:83574748	C/A	cg10249074	chr4:83542146	C4orf11	-0.65	-5.13	-0.47	1.51e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs524281	0.773	rs10896105	chr11:66002260	A/G	cg00563793	chr11:65837595	PACS1	0.79	4.71	0.43	8.53e-6	Electroencephalogram traits;
THYM	cis	rs4363385	0.818	rs370162	chr1:153005488	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs13631	0.965	rs9411307	chr9:139994947	C/T	cg03717367	chr9:139980219	LOC100289341;MAN1B1	0.61	5.42	0.49	4.41e-7	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg10523679	chr1:76189770	ACADM	-0.87	-8.86	-0.67	4.47e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg02403541	chr12:121454288	C12orf43	0.81	7.16	0.59	1.67e-10	N-glycan levels;
THYM	cis	rs6665290	0.904	rs6690803	chr1:227189106	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.07	-14.96	-0.84	1.04e-26	Myeloid white cell count;
THYM	cis	rs4474465	1.000	rs10899509	chr11:78170811	C/T	cg19901956	chr11:77921274	USP35	-0.62	-4.6	-0.43	1.29e-5	Alzheimer's disease (survival time);
THYM	cis	rs7828089	0.582	rs13259873	chr8:22266292	C/T	cg12081754	chr8:22256438	SLC39A14	0.89	9.11	0.68	1.34e-14	Verbal declarative memory;
THYM	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg00376283	chr12:123451042	ABCB9	0.74	5.11	0.46	1.67e-6	Neutrophil percentage of white cells;
THYM	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg04756594	chr16:24857601	SLC5A11	0.8	5.79	0.51	9.08e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4409675	0.576	rs7356	chr1:28218100	T/C	cg23691781	chr1:28212827	C1orf38	0.44	4.5	0.42	1.92e-5	Corneal astigmatism;
THYM	cis	rs3820068	0.705	rs11589076	chr1:15827027	C/T	cg05660106	chr1:15850417	CASP9	1.13	10.23	0.72	5.39e-17	Systolic blood pressure;
THYM	cis	rs72781680	0.898	rs72796154	chr2:23933839	G/A	cg08917208	chr2:24149416	ATAD2B	1.1	4.81	0.44	5.71e-6	Lymphocyte counts;
THYM	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg13010199	chr12:38710504	ALG10B	0.76	6.19	0.54	1.52e-8	Heart rate;
THYM	cis	rs6570726	0.837	rs636894	chr6:145864122	T/C	cg23711669	chr6:146136114	FBXO30	0.84	8.52	0.66	2.44e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg27532560	chr4:187881888	NA	0.95	11.68	0.77	4.63e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs10751667	0.600	rs11246377	chr11:999796	G/T	cg20946044	chr11:1010712	AP2A2	-0.57	-4.83	-0.44	5.27e-6	Alzheimer's disease (late onset);
THYM	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg07061783	chr6:25882402	NA	0.82	7.15	0.59	1.81e-10	Blood metabolite levels;
THYM	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.12	0.59	2.03e-10	Lung cancer in ever smokers;
THYM	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.19	-9.36	-0.69	3.85e-15	Platelet count;
THYM	cis	rs6860806	0.507	rs270615	chr5:131641573	G/C	cg14196790	chr5:131705035	SLC22A5	0.49	4.52	0.42	1.75e-5	Breast cancer;
THYM	cis	rs9287719	0.674	rs1387566	chr2:10828650	C/T	cg03983476	chr2:10830698	NOL10	0.61	5.27	0.48	8.48e-7	Prostate cancer;
THYM	cis	rs6988636	1.000	rs28513831	chr8:124189208	T/C	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg06453172	chr10:134556979	INPP5A	-0.66	-4.77	-0.44	6.78e-6	Migraine;
THYM	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs2282300	0.739	rs1222219	chr11:30344345	G/C	cg06241208	chr11:30344200	C11orf46	-0.78	-5.65	-0.5	1.64e-7	Morning vs. evening chronotype;
THYM	cis	rs72772090	0.539	rs11750934	chr5:96118487	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1061377	1.000	rs13144374	chr4:39130479	A/G	cg24403649	chr4:39172243	NA	0.59	4.78	0.44	6.29e-6	Uric acid levels;
THYM	cis	rs7078219	0.543	rs7095491	chr10:101274058	A/G	cg07044859	chr10:101282883	NA	-0.43	-4.87	-0.45	4.44e-6	Dental caries;
THYM	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06850241	chr22:41845214	NA	-0.54	-4.74	-0.44	7.44e-6	Vitiligo;
THYM	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg09904177	chr6:26538194	HMGN4	0.53	4.47	0.42	2.16e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg27034606	chr17:28928453	LRRC37B2	-0.84	-5.59	-0.5	2.21e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg19746536	chr19:49375674	PPP1R15A	0.81	4.59	0.43	1.34e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg10802521	chr3:52805072	NEK4	-0.79	-7.47	-0.61	3.96e-11	Bipolar disorder;
THYM	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4474465	0.679	rs10899537	chr11:78222424	C/G	cg19901956	chr11:77921274	USP35	0.66	4.84	0.44	4.99e-6	Alzheimer's disease (survival time);
THYM	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg07936489	chr17:37558343	FBXL20	0.85	5.64	0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.58	0.5	2.29e-7	Rheumatoid arthritis;
THYM	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6570726	0.791	rs398408	chr6:145801020	G/A	cg23711669	chr6:146136114	FBXO30	0.96	9.68	0.7	7.83e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6500395	1.000	rs3848321	chr16:48620780	A/T	cg04672837	chr16:48644449	N4BP1	0.51	4.98	0.45	2.85e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs11168351	0.864	rs10875743	chr12:48498413	C/T	cg21466736	chr12:48725269	NA	0.49	4.85	0.45	4.81e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg23682913	chr1:2080710	PRKCZ	-0.55	-5.16	-0.47	1.34e-6	Height;
THYM	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs901683	0.850	rs112114291	chr10:46102010	C/T	cg18240400	chr10:46168597	ANUBL1	0.67	5.22	0.47	1.04e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs2219968	0.961	rs4460363	chr8:78962903	G/A	cg00738934	chr8:78996279	NA	0.88	9.31	0.69	4.91e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg06481639	chr22:41940642	POLR3H	0.71	4.58	0.43	1.42e-5	Vitiligo;
THYM	cis	rs9733	0.596	rs7529998	chr1:150662531	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	5.72	0.51	1.23e-7	Platelet count;
THYM	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.42	4.64	0.43	1.13e-5	Hemoglobin concentration;
THYM	cis	rs7909074	1.000	rs10751360	chr10:45396971	G/A	cg05187965	chr10:45406764	TMEM72	-0.54	-5.12	-0.46	1.62e-6	Mean corpuscular volume;
THYM	cis	rs314370	1.000	rs314370	chr7:100453208	T/C	cg08558340	chr7:100472263	SRRT	0.61	4.98	0.46	2.82e-6	Resting heart rate;
THYM	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg24253500	chr15:84953950	NA	0.54	4.5	0.42	1.89e-5	Schizophrenia;
THYM	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4455778	0.538	rs4288325	chr7:49130239	G/A	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs17209837	0.607	rs17149644	chr7:87086218	T/C	cg04996195	chr7:87105398	ABCB4	0.63	4.79	0.44	6.03e-6	Gallbladder cancer;
THYM	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg06009448	chr7:1102226	C7orf50	0.52	5.44	0.49	4.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7592578	0.766	rs62182885	chr2:191437024	A/G	cg10560079	chr2:191398806	TMEM194B	-0.93	-6.8	-0.57	9.12e-10	Diastolic blood pressure;
THYM	cis	rs9790314	0.586	rs11710086	chr3:161125858	A/T	cg03342759	chr3:160939853	NMD3	-0.84	-7.31	-0.6	8.38e-11	Morning vs. evening chronotype;
THYM	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg22920501	chr2:26401640	FAM59B	-1.05	-9.27	-0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs11771526	0.901	rs10223907	chr7:32297813	G/C	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs539096	0.781	rs2970609	chr1:44097514	C/G	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg00071950	chr4:10020882	SLC2A9	0.72	6.53	0.56	3.17e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs362272	0.545	rs3135146	chr4:3307638	C/G	cg14583973	chr4:3374767	RGS12	-0.65	-6.3	-0.54	9.06e-9	Serum sulfate level;
THYM	cis	rs12956009	0.518	rs1434518	chr18:44833498	G/A	cg19077165	chr18:44547161	KATNAL2	-0.49	-4.56	-0.42	1.5e-5	Educational attainment (years of education);
THYM	cis	rs6952808	0.929	rs2280546	chr7:1976863	G/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.3	-0.48	7.57e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs11603020	0.904	rs4926	chr11:57381989	G/A	cg19752551	chr11:57585705	CTNND1	-0.6	-5.02	-0.46	2.42e-6	Blood protein levels;
THYM	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6430585	0.941	rs6708957	chr2:136520043	C/T	cg23851026	chr2:136556271	LCT	0.64	5.85	0.51	6.99e-8	Corneal structure;
THYM	cis	rs11214589	0.651	rs11214596	chr11:113264511	C/G	cg14159747	chr11:113255604	NA	0.37	7.8	0.62	8.01e-12	Neuroticism;
THYM	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg03877680	chr5:178157825	ZNF354A	-0.71	-4.95	-0.45	3.15e-6	Neutrophil percentage of white cells;
THYM	cis	rs12711979	0.509	rs13021385	chr2:3826387	T/C	cg17052675	chr2:3827356	NA	-0.88	-13.79	-0.82	2.09e-24	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs17253792	0.822	rs80328469	chr14:56067701	G/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs988913	0.957	rs7746965	chr6:54844432	G/T	cg18532076	chr6:54711417	FAM83B	0.52	4.95	0.45	3.25e-6	Menarche (age at onset);
THYM	cis	rs10924970	0.967	rs2152955	chr1:235417773	G/A	cg26050004	chr1:235667680	B3GALNT2	0.6	4.57	0.42	1.46e-5	Asthma;
THYM	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.48	-0.42	2.05e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs8014204	1.000	rs8014204	chr14:75322794	A/G	cg06637938	chr14:75390232	RPS6KL1	0.58	5.59	0.5	2.13e-7	Caffeine consumption;
THYM	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.12	-0.72	9.21e-17	Primary sclerosing cholangitis;
THYM	cis	rs11792861	0.566	rs11792635	chr9:111848819	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	5.08	0.46	1.85e-6	Menarche (age at onset);
THYM	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg15556689	chr8:8085844	FLJ10661	0.68	5.55	0.49	2.62e-7	Mood instability;
THYM	cis	rs59698941	0.882	rs56353702	chr5:132248575	A/G	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs2130392	0.962	rs35613786	chr4:185625657	A/G	cg04058563	chr4:185651563	MLF1IP	-0.58	-5.54	-0.49	2.66e-7	Kawasaki disease;
THYM	cis	rs6531656	0.604	rs729063	chr4:38689837	G/C	cg24279243	chr4:38676559	KLF3	0.85	7.79	0.62	8.37e-12	Lymphocyte counts;
THYM	cis	rs7264396	0.563	rs2425136	chr20:34344782	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-4.59	-0.43	1.34e-5	Total cholesterol levels;
THYM	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg06026331	chr20:60912101	LAMA5	0.75	5.87	0.52	6.28e-8	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs9831754	0.526	rs11927217	chr3:78341723	A/G	cg06138941	chr3:78371609	NA	-0.57	-4.95	-0.45	3.18e-6	Calcium levels;
THYM	cis	rs939658	0.805	rs8036435	chr15:79420031	T/C	cg17916960	chr15:79447300	NA	-0.7	-8.14	-0.64	1.53e-12	Refractive error;
THYM	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg05335186	chr13:53173507	NA	-0.53	-6.8	-0.57	9.37e-10	Lewy body disease;
THYM	cis	rs2440129	0.611	rs1126667	chr17:6902760	C/T	cg12262378	chr17:6899522	ALOX12	-0.68	-9.35	-0.69	4e-15	Tonsillectomy;
THYM	cis	rs1395	0.925	rs1275541	chr2:27389195	A/G	cg23587288	chr2:27483067	SLC30A3	0.52	4.69	0.43	9.07e-6	Blood metabolite levels;
THYM	cis	rs7226229	1.000	rs5005801	chr17:20944154	A/G	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs17401966	1.000	rs2229687	chr1:10473196	C/T	cg19773385	chr1:10388646	KIF1B	-0.61	-4.75	-0.44	7.06e-6	Hepatocellular carcinoma;
THYM	cis	rs7100689	0.784	rs7082705	chr10:82170856	C/T	cg01528321	chr10:82214614	TSPAN14	-1.1	-9.02	-0.68	2.1e-14	Post bronchodilator FEV1;
THYM	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg05313129	chr8:58192883	C8orf71	-0.73	-4.47	-0.42	2.18e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg00744431	chr10:134226547	PWWP2B	-0.62	-4.9	-0.45	3.93e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg11247378	chr22:39784982	NA	-1.08	-13.6	-0.81	5.05e-24	Intelligence (multi-trait analysis);
THYM	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg11789530	chr4:8429930	ACOX3	-0.7	-5.64	-0.5	1.73e-7	Response to antineoplastic agents;
THYM	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg24675056	chr1:15929824	NA	0.73	5.79	0.51	9.09e-8	Systolic blood pressure;
THYM	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	trans	rs1974653	0.672	rs8139591	chr22:20093317	A/G	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs12579753	1.000	rs11115015	chr12:82174543	T/C	cg07988820	chr12:82153109	PPFIA2	-0.78	-4.97	-0.45	2.92e-6	Resting heart rate;
THYM	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03576123	chr11:487126	PTDSS2	-1.23	-6.11	-0.53	2.16e-8	Body mass index;
THYM	cis	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg21231944	chr12:82153410	PPFIA2	-0.61	-4.45	-0.42	2.33e-5	Resting heart rate;
THYM	cis	rs6918586	0.616	rs1056314	chr6:26114653	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.83	7.59	0.61	2.14e-11	Schizophrenia;
THYM	cis	rs7432375	0.641	rs835649	chr3:136671890	G/A	cg12473912	chr3:136751656	NA	0.58	4.79	0.44	6.12e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs2219968	0.798	rs4739185	chr8:78879189	A/G	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3772130	0.923	rs4298081	chr3:121526037	T/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg07362569	chr17:61921086	SMARCD2	0.64	5.71	0.51	1.28e-7	Prudent dietary pattern;
THYM	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg03396347	chr1:1875803	NA	-0.67	-6.86	-0.58	6.87e-10	Body mass index;
THYM	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg12923728	chr3:195709715	SDHAP1	-0.72	-6.15	-0.53	1.79e-8	Pancreatic cancer;
THYM	cis	rs17331151	0.573	rs3755801	chr3:52865798	G/A	cg07884673	chr3:53033167	SFMBT1	0.71	4.61	0.43	1.25e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs17253792	0.545	rs12879705	chr14:56017684	C/G	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg26384229	chr12:38710491	ALG10B	0.94	7.38	0.6	5.97e-11	Bladder cancer;
THYM	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.84	-5.3	-0.48	7.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17443541	0.507	rs35916771	chr2:200464855	T/C	cg01795955	chr2:200468626	NA	-0.66	-4.59	-0.43	1.38e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1499972	0.941	rs62263121	chr3:117630348	T/C	cg07612923	chr3:117604196	NA	1.19	5.0	0.46	2.66e-6	Schizophrenia;
THYM	cis	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.85	-6.34	-0.55	7.79e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg06238570	chr21:40685208	BRWD1	-0.72	-6.28	-0.54	9.9e-9	Menarche (age at onset);
THYM	cis	rs17443541	0.507	rs10196380	chr2:200456655	G/C	cg01795955	chr2:200468626	NA	-0.72	-5.0	-0.46	2.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs654128	0.640	rs6914581	chr6:117228916	C/T	cg12892004	chr6:117198278	RFX6	0.72	5.66	0.5	1.61e-7	Telomere length;
THYM	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg01475377	chr6:109611718	NA	0.56	4.76	0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg22676075	chr6:135203613	NA	0.73	7.01	0.58	3.46e-10	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs1728785	0.818	rs1728769	chr16:68564186	C/T	cg02972257	chr16:68554789	NA	-0.74	-4.54	-0.42	1.63e-5	Ulcerative colitis;
THYM	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg23791538	chr6:167370224	RNASET2	-0.78	-6.28	-0.54	1.02e-8	Crohn's disease;
THYM	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.85	-5.32	-0.48	6.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs6815814	0.950	rs56408159	chr4:38812116	T/A	cg06935464	chr4:38784597	TLR10	0.72	4.71	0.44	8.42e-6	Breast cancer;
THYM	cis	rs4731207	0.565	rs10954053	chr7:124586815	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg11526020	chr17:80870163	TBCD	-0.43	-4.67	-0.43	9.74e-6	Breast cancer;
THYM	cis	rs2859741	0.967	rs534131	chr1:37484237	T/C	cg09363841	chr1:37513479	NA	-0.7	-6.59	-0.56	2.4e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs9549260	0.755	rs4943798	chr13:41202948	T/C	cg21288729	chr13:41239152	FOXO1	0.72	5.55	0.49	2.61e-7	Red blood cell count;
THYM	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg23992470	chr4:843637	GAK	0.88	4.52	0.42	1.76e-5	Intelligence (multi-trait analysis);
THYM	cis	rs675209	0.552	rs13208234	chr6:7119134	G/A	cg24899545	chr6:7112846	RREB1	-0.47	-4.87	-0.45	4.38e-6	Urate levels;
THYM	cis	rs8018808	0.935	rs12433766	chr14:77930293	C/T	cg20045696	chr14:77926864	AHSA1	0.5	4.54	0.42	1.63e-5	Myeloid white cell count;
THYM	cis	rs6456042	0.893	rs3127440	chr6:166558950	C/T	cg11088901	chr6:166572345	T	-0.51	-4.87	-0.45	4.52e-6	Asthma;
THYM	cis	rs35264875	1.000	rs7110274	chr11:68842704	A/G	cg23845249	chr11:68861649	NA	0.54	5.48	0.49	3.53e-7	Blond vs. brown hair color;
THYM	cis	rs7584330	0.554	rs10173100	chr2:238433040	A/G	cg14458575	chr2:238380390	NA	0.82	4.89	0.45	4.16e-6	Prostate cancer;
THYM	cis	rs1949733	0.848	rs2255501	chr4:8475014	G/A	cg25982657	chr4:8193353	NA	-0.37	-4.64	-0.43	1.11e-5	Response to antineoplastic agents;
THYM	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.25	-10.33	-0.73	3.19e-17	Platelet count;
THYM	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11890956	chr21:40555474	PSMG1	1.1	10.98	0.75	1.36e-18	Cognitive function;
THYM	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12643440	0.538	rs12650732	chr4:17141641	A/T	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs11096990	0.855	rs2566178	chr4:39156814	G/C	cg24403649	chr4:39172243	NA	-0.6	-5.09	-0.46	1.77e-6	Cognitive function;
THYM	cis	rs7731657	0.537	rs2097797	chr5:130355151	C/T	cg08523029	chr5:130500466	HINT1	-0.81	-5.6	-0.5	2.04e-7	Fasting plasma glucose;
THYM	cis	rs6473252	1.000	rs6473252	chr8:81800193	C/T	cg08595989	chr8:81827712	NA	-0.41	-4.48	-0.42	2.05e-5	Breast cancer;
THYM	cis	rs1322639	0.614	rs9364361	chr6:169580499	C/T	cg04662567	chr6:169592167	NA	-0.74	-6.43	-0.55	5.21e-9	Pulse pressure;
THYM	cis	rs7631605	0.905	rs1399178	chr3:37258669	G/A	cg21328643	chr3:37258149	NA	-0.58	-5.57	-0.5	2.39e-7	Cerebrospinal P-tau181p levels;
THYM	cis	rs10231759	0.583	rs4015632	chr7:150516826	A/G	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.64	5.2	0.47	1.14e-6	Height;
THYM	cis	rs2985684	0.948	rs12897941	chr14:50016701	G/C	cg02151108	chr14:50098012	C14orf104	-0.74	-6.05	-0.53	2.84e-8	Carotid intima media thickness;
THYM	cis	rs35934224	0.783	rs34545894	chr22:19857942	C/G	cg11182965	chr22:19864308	TXNRD2	-0.68	-5.58	-0.5	2.3e-7	Glaucoma (primary open-angle);
THYM	cis	rs7104764	1.000	rs10902114	chr11:246234	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs665401	0.692	rs9400959	chr6:117133634	G/A	cg20376953	chr6:117187980	NA	-0.61	-4.77	-0.44	6.56e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs17030434	0.822	rs4696492	chr4:154679981	T/A	cg14289246	chr4:154710475	SFRP2	0.76	5.42	0.49	4.52e-7	Electrocardiographic conduction measures;
THYM	cis	rs12540874	0.794	rs1470750	chr7:50576648	C/G	cg18232548	chr7:50535776	DDC	-0.72	-5.4	-0.48	4.88e-7	Systemic sclerosis;
THYM	cis	rs7552404	0.556	rs12124417	chr1:76353294	T/C	cg10523679	chr1:76189770	ACADM	0.72	6.02	0.53	3.32e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs12282928	0.918	rs117447853	chr11:48315758	T/G	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs526231	0.543	rs152137	chr5:102560063	C/T	cg23492399	chr5:102201601	PAM	-0.7	-5.11	-0.46	1.64e-6	Primary biliary cholangitis;
THYM	cis	rs7078219	0.743	rs11190128	chr10:101275149	A/C	cg17888390	chr10:101282816	NA	-0.5	-4.84	-0.44	4.98e-6	Dental caries;
THYM	cis	rs7115242	0.567	rs10047462	chr11:116722041	G/T	cg01368799	chr11:117014884	PAFAH1B2	0.91	4.81	0.44	5.61e-6	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
THYM	cis	rs10463554	0.784	rs187424	chr5:102587583	T/C	cg23492399	chr5:102201601	PAM	-0.6	-4.62	-0.43	1.21e-5	Parkinson's disease;
THYM	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg26513180	chr16:89883248	FANCA	0.72	7.13	0.59	1.98e-10	Vitiligo;
THYM	cis	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg12826209	chr6:26865740	GUSBL1	1.04	5.69	0.5	1.37e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1957429	0.803	rs10873177	chr14:65318228	G/C	cg10794733	chr14:65257245	SPTB	-0.46	-4.46	-0.42	2.21e-5	Pediatric areal bone mineral density (radius);
THYM	cis	rs7107174	1.000	rs10793309	chr11:78093799	G/A	cg02023728	chr11:77925099	USP35	0.63	6.11	0.53	2.23e-8	Testicular germ cell tumor;
THYM	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.92	-7.95	-0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg08564027	chr20:61660810	NA	-0.94	-9.79	-0.71	4.65e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11910985	0.546	rs113970410	chr21:48080896	C/G	cg23283320	chr21:48055893	PRMT2	1.57	7.92	0.63	4.41e-12	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	trans	rs877282	0.797	rs35927768	chr10:753095	T/C	cg22713356	chr15:30763199	NA	1.29	9.34	0.69	4.23e-15	Uric acid levels;
THYM	cis	rs6430585	0.528	rs75667274	chr2:136682486	C/T	cg04750100	chr2:136595281	LCT	0.55	4.6	0.43	1.28e-5	Corneal structure;
THYM	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg08807101	chr21:30365312	RNF160	0.82	6.16	0.53	1.75e-8	Dental caries;
THYM	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs3126085	0.935	rs4845423	chr1:152184950	T/G	cg26020982	chr1:152196106	HRNR	0.38	5.14	0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg07343612	chr16:622815	PIGQ	-1.05	-10.74	-0.74	4.28e-18	Height;
THYM	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg26418147	chr1:205743515	RAB7L1	-0.52	-4.51	-0.42	1.88e-5	Menarche (age at onset);
THYM	cis	rs28595532	0.920	rs114696063	chr4:119760624	T/A	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs6728642	0.572	rs2872686	chr2:97601024	A/G	cg26665480	chr2:98280029	ACTR1B	-0.77	-5.33	-0.48	6.6e-7	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg12826209	chr6:26865740	GUSBL1	0.87	4.6	0.43	1.28e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1883415	0.648	rs72834956	chr6:24506316	A/C	cg00346970	chr6:24499591	ALDH5A1	0.48	6.11	0.53	2.17e-8	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2235649	0.663	rs6600167	chr16:1848912	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.93	-0.45	3.45e-6	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7217780	0.778	rs2024157	chr17:15196537	C/T	cg21969477	chr17:15166505	PMP22	-0.53	-4.98	-0.45	2.86e-6	Preterm birth (maternal effect);
THYM	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.72	-7.78	-0.62	8.78e-12	Prudent dietary pattern;
THYM	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg14675211	chr2:100938903	LONRF2	0.77	8.23	0.65	9.81e-13	Intelligence (multi-trait analysis);
THYM	cis	rs586688	1.000	rs647130	chr1:201637982	A/G	cg14168733	chr1:201708718	NAV1	-0.48	-4.55	-0.42	1.61e-5	Obesity-related traits;
THYM	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs1784581	0.569	rs9365357	chr6:162414913	A/G	cg17173639	chr6:162384350	PARK2	0.81	7.47	0.61	3.78e-11	Itch intensity from mosquito bite;
THYM	cis	rs4363385	0.818	rs10888526	chr1:153000311	G/T	cg13444842	chr1:152974279	SPRR3	-0.59	-4.81	-0.44	5.61e-6	Inflammatory skin disease;
THYM	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg03474202	chr17:45855739	NA	-0.76	-6.7	-0.57	1.45e-9	IgG glycosylation;
THYM	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg01341218	chr17:43662625	NA	-1.06	-9.4	-0.69	3.14e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9361491	0.578	rs2145688	chr6:79460217	T/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2016266	0.859	rs10783575	chr12:53742885	C/T	cg26875137	chr12:53738046	NA	-0.82	-6.29	-0.54	9.83e-9	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs7246657	0.943	rs1373991	chr19:37838911	T/C	cg22634378	chr19:37742834	NA	0.65	5.34	0.48	6.2e-7	Coronary artery calcification;
THYM	cis	rs8033133	0.602	rs3803326	chr15:25328715	A/G	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.69	-5.47	-0.49	3.6e-7	Blood osmolality (transformed sodium);
THYM	cis	rs55728055	0.661	rs62239169	chr22:32042514	G/A	cg01338084	chr22:32026380	PISD	1.5	6.36	0.55	6.89e-9	Age-related hearing impairment;
THYM	cis	rs3204270	0.714	rs7503307	chr17:79674929	C/G	cg13117272	chr17:79681052	SLC25A10	-0.76	-4.76	-0.44	6.85e-6	Dental caries;
THYM	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22857025	chr5:266934	NA	-1.46	-10.2	-0.72	6.16e-17	Breast cancer;
THYM	cis	rs983545	0.927	rs2014490	chr3:16972211	A/G	cg19448816	chr3:16974217	PLCL2	-0.6	-4.94	-0.45	3.38e-6	Blood protein levels;
THYM	cis	rs2273669	0.748	rs11759732	chr6:109370006	A/G	cg17117243	chr6:109341365	SESN1	-0.85	-5.17	-0.47	1.27e-6	Prostate cancer;
THYM	cis	rs920590	0.627	rs28585593	chr8:19646084	A/C	cg03894339	chr8:19674705	INTS10	0.61	4.81	0.44	5.67e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs600806	0.888	rs592107	chr1:109848726	A/T	cg02175308	chr1:109941060	SORT1	-0.54	-4.64	-0.43	1.14e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.636	rs6032095	chr20:43913255	A/T	cg27176129	chr20:43937155	MATN4;RBPJL	0.44	4.82	0.44	5.34e-6	Blood protein levels;
THYM	cis	rs8013055	0.846	rs8013827	chr14:105970176	C/T	cg04429589	chr14:105992532	TMEM121	0.49	5.24	0.47	9.79e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	8.04	0.64	2.52e-12	Monocyte percentage of white cells;
THYM	cis	rs6665290	0.904	rs1045286	chr1:227179037	A/C	cg10327440	chr1:227177885	CDC42BPA	1.14	16.31	0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs939658	0.805	rs11630571	chr15:79432992	C/A	cg17916960	chr15:79447300	NA	-0.75	-8.62	-0.66	1.48e-13	Refractive error;
THYM	cis	rs4631830	0.863	rs57263518	chr10:51519154	A/G	cg10326726	chr10:51549505	MSMB	-0.5	-5.1	-0.46	1.71e-6	Prostate-specific antigen levels;
THYM	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.48	-0.55	4.1e-9	Personality dimensions;
THYM	cis	rs12216545	0.737	rs10226860	chr7:150234749	A/G	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4499344	0.730	rs377044	chr19:33105951	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.85	6.96	0.58	4.28e-10	Mean platelet volume;
THYM	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg08498830	chr11:832797	CD151	-0.62	-4.57	-0.42	1.45e-5	Mean platelet volume;
THYM	cis	rs4792901	0.729	rs12603059	chr17:41538446	G/A	cg26543989	chr17:42187485	HDAC5	0.62	4.46	0.42	2.21e-5	Dupuytren's disease;
THYM	cis	rs9677476	0.909	rs60240472	chr2:232131217	A/G	cg07929768	chr2:232055508	NA	0.62	6.15	0.53	1.8e-8	Food antigen IgG levels;
THYM	cis	rs3106136	0.546	rs2664880	chr4:95144177	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.1	-0.46	1.7e-6	Capecitabine sensitivity;
THYM	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg12310025	chr6:25882481	NA	0.68	5.56	0.5	2.5e-7	Schizophrenia;
THYM	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg15556689	chr8:8085844	FLJ10661	0.65	4.85	0.45	4.81e-6	Neuroticism;
THYM	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg18132916	chr6:79620363	NA	-0.59	-5.3	-0.48	7.54e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7429990	0.932	rs12486714	chr3:48148700	C/G	cg02219026	chr3:48282209	ZNF589	0.59	4.46	0.42	2.23e-5	Educational attainment (years of education);
THYM	cis	rs6502050	0.835	rs35038106	chr17:80180346	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.01	-0.52	3.39e-8	Life satisfaction;
THYM	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg06713675	chr4:122721982	EXOSC9	-0.51	-4.75	-0.44	7.13e-6	Type 2 diabetes;
THYM	cis	rs11563648	0.553	rs1419419	chr7:127016871	G/A	cg23081781	chr7:127225937	GCC1	-0.35	-4.78	-0.44	6.41e-6	Resting heart rate;
THYM	cis	rs7429990	0.901	rs9825114	chr3:48138082	A/G	cg02219026	chr3:48282209	ZNF589	0.62	4.64	0.43	1.12e-5	Educational attainment (years of education);
THYM	cis	rs72901758	0.696	rs72909029	chr17:76249451	A/G	cg25512537	chr17:76250053	NA	0.42	6.27	0.54	1.06e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
THYM	trans	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg10856724	chr12:34555212	NA	-0.9	-8.08	-0.64	2.05e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10751647	0.804	rs3809112	chr11:307036	C/T	cg06046490	chr11:320940	IFITM3	0.42	4.8	0.44	5.8e-6	Monocyte count;
THYM	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg22947322	chr17:47091978	IGF2BP1	-0.65	-6.63	-0.56	2.04e-9	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs782590	0.818	rs2627765	chr2:55883317	G/T	cg03859395	chr2:55845619	SMEK2	0.56	4.85	0.45	4.82e-6	Metabolic syndrome;
THYM	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.74	-6.13	-0.53	1.98e-8	Lung cancer in ever smokers;
THYM	cis	rs2637266	1.000	rs2130795	chr10:78333892	C/G	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg01324343	chr3:183735012	ABCC5	0.89	13.33	0.81	1.82e-23	Anterior chamber depth;
THYM	cis	rs7715811	0.913	rs73749951	chr5:13762514	G/A	cg07548982	chr5:13769939	DNAH5	-0.5	-4.47	-0.42	2.2e-5	Subclinical atherosclerosis traits (other);
THYM	cis	rs11711311	0.784	rs13081931	chr3:113349928	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.55	-4.64	-0.43	1.1e-5	IgG glycosylation;
THYM	cis	rs4907240	0.961	rs66727130	chr2:97324991	G/C	cg01950434	chr2:97203154	ARID5A	-0.59	-4.95	-0.45	3.2e-6	Event-related brain oscillations;
THYM	cis	rs4746818	1.000	rs7899844	chr10:70949694	A/G	cg11621586	chr10:70884670	VPS26A	1.28	11.12	0.75	6.73e-19	Left atrial antero-posterior diameter;
THYM	cis	rs4845570	0.764	rs12122917	chr1:151716712	C/A	cg07092448	chr1:151763213	TDRKH	-0.98	-5.27	-0.48	8.55e-7	Coronary artery disease;
THYM	trans	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs259282	0.646	rs34182086	chr19:33125823	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.76	6.55	0.56	2.98e-9	Schizophrenia;
THYM	cis	rs9992101	0.547	rs11722924	chr4:77396854	G/C	cg20311846	chr4:77356250	SHROOM3	-0.46	-4.73	-0.44	7.76e-6	Creatinine levels;
THYM	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg18681998	chr4:17616180	MED28	0.79	7.01	0.58	3.44e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7581030	0.583	rs2058896	chr2:71518171	T/C	cg01579289	chr2:71503740	NA	0.73	4.61	0.43	1.26e-5	Testicular germ cell tumor;
THYM	cis	rs7107174	1.000	rs10899476	chr11:78051794	A/G	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs2976388	1.000	rs2294010	chr8:143762430	A/G	cg13446199	chr8:143762866	PSCA	0.51	6.42	0.55	5.46e-9	Urinary tract infection frequency;
THYM	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg07424592	chr7:64974309	NA	-0.99	-5.15	-0.47	1.42e-6	Diabetic kidney disease;
THYM	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21659725	chr3:3221576	CRBN	0.87	9.66	0.7	8.65e-16	Intelligence (multi-trait analysis);
THYM	cis	rs6430585	0.941	rs10496737	chr2:136540083	A/G	cg04750100	chr2:136595281	LCT	0.53	5.13	0.47	1.55e-6	Corneal structure;
THYM	cis	rs4148689	0.951	rs2027944	chr7:117187659	T/C	cg17204129	chr7:117119601	CFTR	-0.59	-4.6	-0.43	1.32e-5	Gout;
THYM	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg11764359	chr7:65958608	NA	0.69	4.67	0.43	9.75e-6	Aortic root size;
THYM	cis	rs2235649	0.663	rs12596160	chr16:1848784	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.46	-4.93	-0.45	3.41e-6	Blood metabolite levels;
THYM	cis	rs6499255	0.951	rs61310815	chr16:69701239	A/T	cg00738113	chr16:70207722	CLEC18C	-0.43	-4.57	-0.42	1.46e-5	IgE levels;
THYM	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg00339695	chr16:24857497	SLC5A11	0.47	4.7	0.43	8.71e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9287719	0.674	rs1387566	chr2:10828650	C/T	cg02196655	chr2:10830764	NOL10	0.49	4.99	0.46	2.77e-6	Prostate cancer;
THYM	cis	rs3020333	0.653	rs851984	chr6:152023191	G/A	cg22157087	chr6:152012887	ESR1	0.47	5.04	0.46	2.19e-6	Total body bone mineral density;
THYM	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg10053473	chr17:62856997	LRRC37A3	0.92	7.34	0.6	7.17e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg26384229	chr12:38710491	ALG10B	0.97	7.38	0.6	5.91e-11	Morning vs. evening chronotype;
THYM	cis	rs7669967	0.576	rs7654604	chr4:156058956	G/C	cg17641028	chr4:156585641	NA	-0.57	-5.13	-0.47	1.53e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg07570687	chr10:102243282	WNT8B	0.77	6.86	0.58	6.9e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.73	7.2	0.59	1.4e-10	Lymphocyte counts;
THYM	cis	rs748404	0.631	rs560191	chr15:43767774	G/C	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs728616	0.867	rs17884637	chr10:81687922	G/C	cg18148530	chr10:81370782	SFTPA1	0.77	4.88	0.45	4.23e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7626444	0.625	rs2686590	chr3:196492439	A/T	cg12930392	chr3:196481615	PAK2	0.39	4.61	0.43	1.27e-5	Monocyte count;
THYM	cis	rs2219968	0.683	rs6999586	chr8:78904933	C/G	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8180040	0.800	rs11130126	chr3:47306894	A/G	cg16586182	chr3:47516702	SCAP	0.69	6.0	0.52	3.63e-8	Colorectal cancer;
THYM	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg24069376	chr3:38537580	EXOG	0.67	6.87	0.58	6.55e-10	Electrocardiographic conduction measures;
THYM	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg20887711	chr4:1340912	KIAA1530	-0.58	-4.64	-0.43	1.13e-5	Obesity-related traits;
THYM	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg02196655	chr2:10830764	NOL10	-0.42	-4.47	-0.42	2.13e-5	Prostate cancer;
THYM	cis	rs6500602	0.592	rs28789232	chr16:4447552	C/A	cg08645402	chr16:4508243	NA	0.74	6.1	0.53	2.27e-8	Schizophrenia;
THYM	cis	rs7572733	0.515	rs1836234	chr2:198882873	T/G	cg00792783	chr2:198669748	PLCL1	0.83	5.9	0.52	5.65e-8	Dermatomyositis;
THYM	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg18512352	chr11:47633146	NA	-0.48	-5.47	-0.49	3.64e-7	Subjective well-being;
THYM	cis	rs9814567	0.712	rs4955545	chr3:134332926	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2777491	0.957	rs8026197	chr15:41711447	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.12	-12.75	-0.79	2.77e-22	Ulcerative colitis;
THYM	cis	rs3741151	0.764	rs7101561	chr11:73264219	G/C	cg12959048	chr11:73096162	RELT	-0.52	-4.62	-0.43	1.21e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.46	-4.51	-0.42	1.82e-5	Crohn's disease;
THYM	cis	rs17598306	1.000	rs73402670	chr7:96580336	A/G	cg13449377	chr7:96631089	DLX6AS	0.76	4.78	0.44	6.38e-6	Radiation response;
THYM	cis	rs6987853	0.933	rs2923424	chr8:42382222	A/G	cg09913449	chr8:42400586	C8orf40	-0.95	-9.27	-0.69	6.09e-15	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.07	-0.82	5.85e-25	Height;
THYM	cis	rs2073300	1.000	rs6114142	chr20:23461082	A/G	cg12062639	chr20:23401060	NAPB	0.96	4.84	0.45	4.95e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.01	-0.46	2.53e-6	Life satisfaction;
THYM	cis	rs995000	0.931	rs1629122	chr1:63046578	C/A	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg12419862	chr22:24373484	LOC391322	-0.85	-9.81	-0.71	4.24e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg26513180	chr16:89883248	FANCA	0.74	7.34	0.6	7.27e-11	Vitiligo;
THYM	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg17366294	chr4:99064904	C4orf37	0.54	6.33	0.54	8.05e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11696501	0.688	rs1013562	chr20:44310744	A/G	cg11783356	chr20:44313418	WFDC10B	-0.7	-4.61	-0.43	1.28e-5	Brain structure;
THYM	cis	rs35883536	0.900	rs7520474	chr1:101091376	T/C	cg06223162	chr1:101003688	GPR88	-0.68	-5.22	-0.47	1.06e-6	Monocyte count;
THYM	trans	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg10856724	chr12:34555212	NA	-1.02	-9.32	-0.69	4.7e-15	Morning vs. evening chronotype;
THYM	cis	rs2816062	0.813	rs2745325	chr1:18880442	C/A	cg18795169	chr1:18902165	NA	-0.94	-10.8	-0.74	3.3e-18	Urate levels in lean individuals;
THYM	cis	rs5769707	0.521	rs739244	chr22:50060158	A/G	cg17054759	chr22:49844102	NA	-0.48	-4.57	-0.42	1.45e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs11696845	0.649	rs6031782	chr20:43383832	A/G	cg09357268	chr20:43379437	KCNK15	-0.5	-4.81	-0.44	5.58e-6	Obesity-related traits;
THYM	cis	rs8064299	0.655	rs12797	chr17:72766993	G/A	cg21922841	chr17:72744131	SLC9A3R1	0.35	4.77	0.44	6.75e-6	Monocyte count;
THYM	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg00684032	chr4:1343700	KIAA1530	0.51	4.48	0.42	2.11e-5	Longevity;
THYM	cis	rs1950626	0.750	rs35820579	chr14:101435515	T/C	cg11887864	chr14:101510502	MIR1185-2	0.54	4.52	0.42	1.75e-5	Pelvic organ prolapse (moderate/severe);
THYM	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs1692580	0.870	rs590367	chr1:2162944	C/T	cg21442419	chr1:2182373	SKI	-0.43	-4.79	-0.44	6.05e-6	Coronary artery disease;
THYM	cis	rs9902453	0.845	rs2321493	chr17:28230359	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.65	0.43	1.07e-5	Coffee consumption (cups per day);
THYM	cis	rs10979	1.000	rs9386038	chr6:143896358	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03647317	chr4:187891568	NA	0.82	8.3	0.65	7.13e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7809950	0.678	rs2237661	chr7:106863123	T/C	cg23024343	chr7:107201750	COG5	-1.0	-8.43	-0.65	3.79e-13	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg03676636	chr4:99064102	C4orf37	0.45	6.66	0.56	1.75e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	4.84	0.44	4.97e-6	Menarche (age at onset);
THYM	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs7072216	0.763	rs3814142	chr10:100171104	C/G	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs55728055	0.661	rs62237845	chr22:32027892	G/A	cg01338084	chr22:32026380	PISD	1.5	6.36	0.55	6.89e-9	Age-related hearing impairment;
THYM	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg12698349	chr2:225449008	CUL3	0.73	5.45	0.49	4.03e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs7590720	1.000	rs7590720	chr2:216898658	A/G	cg12620499	chr2:216877984	MREG	-0.83	-5.71	-0.51	1.29e-7	Alcohol dependence;
THYM	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-4.49	-0.42	1.98e-5	Monocyte percentage of white cells;
THYM	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg17644776	chr2:200775616	C2orf69	-0.92	-7.74	-0.62	1.05e-11	Osteoporosis;
THYM	cis	rs6669072	0.565	rs66467457	chr1:91271406	C/T	cg08895590	chr1:91227319	NA	-0.39	-4.45	-0.42	2.32e-5	Cognitive function;
THYM	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg17775962	chr7:1200435	ZFAND2A	0.5	5.65	0.5	1.66e-7	Longevity;Endometriosis;
THYM	cis	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs7607369	0.648	rs55983650	chr2:219654932	T/C	cg02176678	chr2:219576539	TTLL4	-0.62	-5.74	-0.51	1.12e-7	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs9902453	0.845	rs12602426	chr17:28158815	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.73	0.44	7.7e-6	Coffee consumption (cups per day);
THYM	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg04756594	chr16:24857601	SLC5A11	0.79	5.61	0.5	2e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg06092702	chr1:163392909	NA	-0.62	-5.65	-0.5	1.69e-7	Motion sickness;
THYM	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	7.92	0.63	4.42e-12	Smoking behavior;
THYM	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7677751	0.806	rs890203	chr4:55097405	A/C	cg17187183	chr4:55093834	PDGFRA	0.73	5.43	0.49	4.25e-7	Corneal astigmatism;
THYM	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg26446133	chr18:72167187	CNDP2	-1.0	-9.97	-0.72	1.88e-16	Refractive error;
THYM	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg04990556	chr1:26633338	UBXN11	-0.88	-8.39	-0.65	4.55e-13	Obesity-related traits;
THYM	cis	rs12348691	0.503	rs1867279	chr9:100616041	T/C	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Alopecia areata;
THYM	cis	rs854765	0.583	rs8080823	chr17:17864048	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	6.4	0.55	5.73e-9	Total body bone mineral density;
THYM	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs7786808	0.776	rs11983316	chr7:158209742	A/G	cg01191920	chr7:158217561	PTPRN2	-0.99	-11.06	-0.75	9.02e-19	Obesity-related traits;
THYM	cis	rs6430585	0.591	rs61187091	chr2:136468238	G/A	cg07169764	chr2:136633963	MCM6	1.15	11.03	0.75	1.08e-18	Corneal structure;
THYM	cis	rs289828	0.538	rs67725431	chr2:152151259	T/A	cg05960677	chr2:152117363	RBM43	0.75	7.25	0.6	1.1e-10	Blood protein levels;
THYM	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg06221963	chr1:154839813	KCNN3	-0.81	-10.27	-0.73	4.36e-17	Prostate cancer;
THYM	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg03060546	chr3:49711283	APEH	0.74	6.04	0.53	2.97e-8	Resting heart rate;
THYM	cis	rs35110281	0.508	rs2838351	chr21:45110784	A/G	cg15536230	chr21:44985092	HSF2BP	-0.39	-4.49	-0.42	2.03e-5	Mean corpuscular volume;
THYM	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	4.91	0.45	3.74e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg22467129	chr15:76604101	ETFA	-0.56	-5.37	-0.48	5.47e-7	Blood metabolite levels;
THYM	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg17173187	chr15:85201210	NMB	0.54	5.31	0.48	7.17e-7	Schizophrenia;
THYM	cis	rs6032067	0.929	rs17334064	chr20:43839197	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.76	-0.51	1.01e-7	Blood protein levels;
THYM	cis	rs8044868	0.586	rs7190994	chr16:72099241	T/A	cg06353428	chr16:71660113	MARVELD3	0.61	4.55	0.42	1.57e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs8067545	0.611	rs16960697	chr17:20027718	A/G	cg13482628	chr17:19912719	NA	0.55	4.7	0.43	8.91e-6	Schizophrenia;
THYM	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg13010199	chr12:38710504	ALG10B	-0.73	-5.82	-0.51	7.99e-8	Heart rate;
THYM	trans	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17712092	chr4:129076599	LARP1B	0.92	7.66	0.62	1.56e-11	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs58873874	0.737	rs10476052	chr5:156900534	C/A	cg08916508	chr5:156566250	MED7	-1.17	-4.52	-0.42	1.8e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs9938149	0.736	rs6540223	chr16:88321436	A/G	cg09385650	chr16:88018033	BANP	0.28	5.18	0.47	1.24e-6	Corneal structure;Central corneal thickness;
THYM	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.76	-5.06	-0.46	2.05e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Body mass index;
THYM	cis	rs7940866	0.774	rs12420126	chr11:130834811	C/T	cg23692386	chr11:131799662	NTM	0.47	5.0	0.46	2.58e-6	Schizophrenia;
THYM	cis	rs6430585	0.583	rs111837148	chr2:136612036	G/A	cg20242066	chr2:136595261	LCT	0.51	4.87	0.45	4.44e-6	Corneal structure;
THYM	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7677751	0.806	rs7681399	chr4:55090886	T/G	cg17187183	chr4:55093834	PDGFRA	0.71	5.49	0.49	3.35e-7	Corneal astigmatism;
THYM	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	4.91	0.45	3.71e-6	Schizophrenia;
THYM	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4950928	0.887	rs7556099	chr1:203166198	C/G	cg14085262	chr1:203155938	CHI3L1	-0.75	-5.14	-0.47	1.47e-6	YKL-40 levels;
THYM	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg02725872	chr8:58115012	NA	-1.08	-8.26	-0.65	8.3e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg15242686	chr22:24348715	GSTTP1	0.67	7.26	0.6	1.06e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg23260525	chr10:116636907	FAM160B1	0.53	5.33	0.48	6.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7119	0.636	rs34020536	chr15:77819586	G/A	cg27398640	chr15:77910606	LINGO1	-0.52	-4.88	-0.45	4.2e-6	Type 2 diabetes;
THYM	cis	rs554111	0.593	rs7540023	chr1:21310092	T/C	cg00373020	chr1:21041521	KIF17	-0.55	-4.75	-0.44	7.23e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs600806	0.850	rs1343465	chr1:109937426	T/C	cg23032129	chr1:109941072	SORT1	-0.59	-5.03	-0.46	2.31e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1728785	1.000	rs821167	chr16:68577222	T/G	cg02972257	chr16:68554789	NA	-0.77	-4.9	-0.45	3.98e-6	Ulcerative colitis;
THYM	cis	rs6835098	0.692	rs6553679	chr4:174072292	C/T	cg08422745	chr4:174089978	GALNT7	-0.93	-7.38	-0.6	5.97e-11	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.84	0.44	5.01e-6	Breast cancer;
THYM	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs67981189	0.789	rs12101246	chr14:71551335	A/G	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1034435	0.755	rs6007871	chr22:48894392	C/G	cg05992904	chr22:48892994	FAM19A5	-0.76	-7.96	-0.63	3.72e-12	Late-onset Alzheimer's disease;
THYM	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.86	-5.38	-0.48	5.43e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg06238570	chr21:40685208	BRWD1	0.91	6.77	0.57	1.08e-9	Cognitive function;
THYM	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg26408565	chr15:76604113	ETFA	-0.55	-4.77	-0.44	6.53e-6	Blood metabolite levels;
THYM	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg12963246	chr6:28129442	ZNF389	0.51	4.53	0.42	1.72e-5	Parkinson's disease;
THYM	cis	rs988913	0.706	rs7761336	chr6:54734602	A/T	cg18532076	chr6:54711417	FAM83B	0.52	5.04	0.46	2.2e-6	Menarche (age at onset);
THYM	cis	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg27107076	chr2:25050844	ADCY3	0.3	4.79	0.44	6.24e-6	Body mass index;
THYM	cis	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg03213289	chr20:61660250	NA	0.95	9.86	0.71	3.29e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs595982	0.702	rs609985	chr19:49370648	A/G	cg21252483	chr19:49399788	TULP2	-0.55	-4.87	-0.45	4.52e-6	Red cell distribution width;
THYM	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg06191203	chr2:152266755	RIF1	-0.71	-4.75	-0.44	7.08e-6	Lung cancer;
THYM	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.65	4.98	0.46	2.8e-6	Eosinophil percentage of white cells;
THYM	cis	rs2084637	0.965	rs118028534	chr11:122420646	G/A	cg16865908	chr11:121970496	LOC399959;MIR125B1	0.32	4.49	0.42	2.02e-5	Stroke;
THYM	cis	rs7578361	0.959	rs4667422	chr2:150420788	G/T	cg17961725	chr2:150454027	NA	-0.76	-6.22	-0.54	1.32e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs79149102	0.579	rs7182286	chr15:75293839	A/G	cg17294928	chr15:75287854	SCAMP5	-1.06	-5.68	-0.5	1.49e-7	Lung cancer;
THYM	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11644478	chr21:40555479	PSMG1	-0.59	-4.9	-0.45	3.91e-6	Menarche (age at onset);
THYM	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg05973401	chr12:123451056	ABCB9	0.68	4.55	0.42	1.58e-5	Neutrophil percentage of white cells;
THYM	cis	rs1371867	0.839	rs1788186	chr8:101335686	T/C	cg06636551	chr8:101224915	SPAG1	-0.63	-6.33	-0.54	8.05e-9	Atrioventricular conduction;
THYM	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs960902	1.000	rs10204024	chr2:37732029	A/G	cg25341268	chr2:37734390	NA	-0.56	-4.62	-0.43	1.19e-5	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg02825527	chr7:2087843	MAD1L1	-0.79	-4.93	-0.45	3.45e-6	Neuroticism;
THYM	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg20387954	chr3:183756860	HTR3D	0.59	4.85	0.45	4.87e-6	Anterior chamber depth;
THYM	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs2456568	0.570	rs1518579	chr11:93656821	A/G	cg26875233	chr11:93583750	C11orf90	-0.52	-5.88	-0.52	6.02e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs13102973	0.965	rs4437307	chr4:135861598	C/T	cg14419869	chr4:135874104	NA	-0.82	-7.94	-0.63	4.06e-12	Subjective well-being;
THYM	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg01045337	chr16:374988	AXIN1	0.63	5.0	0.46	2.62e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs3806843	0.900	rs2262576	chr5:140135536	T/C	cg19875535	chr5:140030758	IK	-0.58	-4.52	-0.42	1.76e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs12347191	0.500	rs1465965	chr9:100620326	C/T	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Orofacial clefts;
THYM	cis	rs2806561	0.929	rs2867315	chr1:23541286	C/T	cg19743168	chr1:23544995	NA	-0.66	-7.05	-0.59	2.92e-10	Height;
THYM	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg04990556	chr1:26633338	UBXN11	-0.89	-8.52	-0.66	2.34e-13	Obesity-related traits;
THYM	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg00278517	chr6:167070616	RPS6KA2	-0.33	-4.52	-0.42	1.79e-5	Crohn's disease;
THYM	cis	rs2964802	0.505	rs4314375	chr5:10803435	C/T	cg14521931	chr5:10832172	NA	0.61	5.22	0.47	1.06e-6	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg21926883	chr2:100939477	LONRF2	-0.62	-5.43	-0.49	4.32e-7	Intelligence (multi-trait analysis);
THYM	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.12	-0.64	1.72e-12	Mean corpuscular volume;
THYM	trans	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg10856724	chr12:34555212	NA	-1.0	-8.95	-0.68	2.84e-14	Bladder cancer;
THYM	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg23161317	chr6:28129485	ZNF389	0.85	6.33	0.54	8.19e-9	Depression;
THYM	trans	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	3.97e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Body mass index;
THYM	cis	rs4974559	1.000	rs1882099	chr4:1352685	A/G	cg02980000	chr4:1222292	CTBP1	0.68	4.58	0.42	1.43e-5	Systolic blood pressure;
THYM	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg00801512	chr17:28996047	NA	-0.74	-4.64	-0.43	1.11e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs977987	0.835	rs11641532	chr16:75329480	T/C	cg03315344	chr16:75512273	CHST6	0.84	7.12	0.59	2.04e-10	Dupuytren's disease;
THYM	cis	rs262150	0.536	rs73167296	chr7:158783129	C/T	cg12257156	chr7:158823799	VIPR2	0.62	5.31	0.48	7.04e-7	Facial morphology (factor 20);
THYM	cis	rs6025261	0.506	rs6069938	chr20:55537812	A/G	cg04763273	chr20:55502381	NA	-0.59	-4.98	-0.46	2.83e-6	Verbal memory performance (delayed recall level);
THYM	cis	rs11563648	0.535	rs6962137	chr7:127026342	G/A	cg23081781	chr7:127225937	GCC1	-0.36	-4.96	-0.45	3.02e-6	Resting heart rate;
THYM	cis	rs6754311	0.593	rs7355359	chr2:136462441	C/T	cg07169764	chr2:136633963	MCM6	-0.7	-5.68	-0.5	1.48e-7	Mosquito bite size;
THYM	cis	rs6700896	0.931	rs7531867	chr1:66107546	A/G	cg04111102	chr1:66153794	NA	-0.55	-5.23	-0.47	9.89e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6084875	0.840	rs2104143	chr20:4723157	G/A	cg19614321	chr20:4804581	RASSF2	0.44	4.47	0.42	2.19e-5	Systemic lupus erythematosus;
THYM	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg24531977	chr5:56204891	C5orf35	-1.01	-8.29	-0.65	7.47e-13	Initial pursuit acceleration;
THYM	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg05717871	chr11:638507	DRD4	-0.69	-6.03	-0.53	3.1e-8	Systemic lupus erythematosus;
THYM	cis	rs4499344	0.696	rs2868154	chr19:33099305	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.88	7.54	0.61	2.77e-11	Mean platelet volume;
THYM	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg24209194	chr3:40518798	ZNF619	0.67	5.48	0.49	3.47e-7	Renal cell carcinoma;
THYM	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg14581129	chr12:53358946	NA	-1.03	-7.38	-0.6	6.05e-11	Cancer (pleiotropy);
THYM	cis	rs17331151	0.573	rs3755801	chr3:52865798	G/A	cg04865290	chr3:52927548	TMEM110	-0.64	-4.49	-0.42	2.04e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg03060546	chr3:49711283	APEH	-0.66	-5.1	-0.46	1.71e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs10463554	0.963	rs27970	chr5:102486723	G/C	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.54e-6	Parkinson's disease;
THYM	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.09e-8	Systolic blood pressure;
THYM	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg04455712	chr21:45112962	RRP1B	0.54	5.04	0.46	2.22e-6	Mean corpuscular volume;
THYM	cis	rs9314614	0.763	rs2980947	chr8:6713941	C/T	cg27319216	chr8:6693540	XKR5	-0.54	-5.29	-0.48	7.69e-7	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg16188243	chr19:2783719	SGTA	0.65	4.53	0.42	1.74e-5	Total cholesterol levels;
THYM	cis	rs4951011	0.786	rs7540455	chr1:203761716	C/A	cg24343524	chr1:203763352	ZC3H11A	0.71	6.32	0.54	8.49e-9	Breast cancer;
THYM	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9309473	0.519	rs7598901	chr2:73675844	C/T	cg19565262	chr2:73869966	NAT8	0.55	4.71	0.43	8.5e-6	Metabolite levels;
THYM	cis	rs7589342	0.839	rs35812588	chr2:106432201	C/T	cg14210321	chr2:106509881	NCK2	-0.69	-4.9	-0.45	3.95e-6	Addiction;
THYM	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg18876405	chr7:65276391	NA	-0.55	-4.73	-0.44	7.84e-6	Aortic root size;
THYM	cis	rs757110	1.000	rs757110	chr11:17418477	C/A	cg15432903	chr11:17409602	KCNJ11	0.66	7.55	0.61	2.64e-11	Type 2 diabetes;
THYM	cis	rs853679	0.550	rs1237875	chr6:28173010	A/G	cg08968635	chr6:28129556	ZNF389	-0.71	-5.82	-0.51	8.03e-8	Depression;
THYM	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.27	-7.32	-0.6	7.79e-11	Gut microbiome composition (summer);
THYM	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg13695892	chr22:41940480	POLR3H	-0.83	-5.98	-0.52	3.93e-8	Vitiligo;
THYM	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg14019146	chr3:50243930	SLC38A3	0.54	4.48	0.42	2.11e-5	Body mass index;
THYM	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.39	-0.48	5.14e-7	Menopause (age at onset);
THYM	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg06028605	chr16:24865363	SLC5A11	0.63	5.18	0.47	1.26e-6	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.78	-6.97	-0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs2404602	0.684	rs3910756	chr15:76945369	C/T	cg23625390	chr15:77176239	SCAPER	-0.87	-5.61	-0.5	1.97e-7	Blood metabolite levels;
THYM	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg06636001	chr8:8085503	FLJ10661	0.62	5.37	0.48	5.48e-7	Mood instability;
THYM	cis	rs57590327	0.508	rs10511101	chr3:81950302	A/C	cg07356753	chr3:81810745	GBE1	-0.71	-4.8	-0.44	5.99e-6	Extraversion;
THYM	cis	rs2976388	0.967	rs2976387	chr8:143759364	G/A	cg13446199	chr8:143762866	PSCA	0.53	5.86	0.52	6.72e-8	Urinary tract infection frequency;
THYM	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg10760299	chr15:45669010	GATM	0.86	6.7	0.57	1.49e-9	Homoarginine levels;
THYM	cis	rs67460515	0.892	rs11929238	chr3:161045937	A/T	cg03342759	chr3:160939853	NMD3	-0.94	-8.14	-0.64	1.55e-12	Parkinson's disease;
THYM	cis	rs12579753	0.869	rs12366920	chr12:82223015	G/A	cg21231944	chr12:82153410	PPFIA2	-0.65	-4.93	-0.45	3.52e-6	Resting heart rate;
THYM	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg11663144	chr21:46675770	NA	-0.71	-9.99	-0.72	1.76e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs56309584	0.523	rs3027172	chr17:8055723	A/G	cg08322244	chr17:8066669	VAMP2	-0.57	-5.43	-0.49	4.32e-7	Initial pursuit acceleration;
THYM	cis	rs11039798	0.610	rs11530356	chr11:48836290	C/A	cg24672777	chr11:48374446	OR4C45	-1.13	-6.84	-0.57	7.58e-10	Axial length;
THYM	cis	rs6754311	0.593	rs313524	chr2:136444123	C/T	cg04750100	chr2:136595281	LCT	0.56	5.89	0.52	5.87e-8	Mosquito bite size;
THYM	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs1986734	0.619	rs13106413	chr4:77418698	G/T	cg20311846	chr4:77356250	SHROOM3	-0.43	-4.66	-0.43	1.01e-5	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
THYM	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg12000587	chr17:30186630	C17orf79	0.47	5.31	0.48	7.22e-7	Hip circumference adjusted for BMI;
THYM	cis	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	12.82	0.8	1.97e-22	Chronic sinus infection;
THYM	trans	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs7106204	0.609	rs55751762	chr11:24296146	C/T	ch.11.24196551F	chr11:24239977	NA	0.99	6.11	0.53	2.16e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs4731207	0.596	rs1013754	chr7:124642047	T/C	cg05285228	chr7:124571219	POT1	-0.71	-5.45	-0.49	3.91e-7	Cutaneous malignant melanoma;
THYM	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg10523679	chr1:76189770	ACADM	-0.89	-9.4	-0.69	3.18e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg24399712	chr22:39784796	NA	-0.9	-9.86	-0.71	3.31e-16	Intelligence (multi-trait analysis);
THYM	cis	rs12291225	0.535	rs16930126	chr11:14404983	C/T	cg05501817	chr11:14380813	RRAS2	0.76	6.27	0.54	1.06e-8	Sense of smell;
THYM	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg25072359	chr17:41440525	NA	-0.75	-5.49	-0.49	3.33e-7	Menopause (age at onset);
THYM	cis	rs4631830	0.720	rs2611512	chr10:51515534	A/G	cg10326726	chr10:51549505	MSMB	-0.48	-4.77	-0.44	6.52e-6	Prostate-specific antigen levels;
THYM	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg26408565	chr15:76604113	ETFA	-0.54	-4.64	-0.43	1.13e-5	Blood metabolite levels;
THYM	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg05335186	chr13:53173507	NA	-0.39	-4.79	-0.44	6.12e-6	Lewy body disease;
THYM	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg11764359	chr7:65958608	NA	-0.78	-6.19	-0.54	1.54e-8	Aortic root size;
THYM	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg13114125	chr14:105738426	BRF1	-0.75	-5.96	-0.52	4.21e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4919687	0.550	rs7904396	chr10:104456838	C/T	cg05855489	chr10:104503620	C10orf26	0.65	5.12	0.47	1.57e-6	Colorectal cancer;
THYM	cis	rs7178572	0.524	rs12914128	chr15:77493875	T/C	cg22256960	chr15:77711686	NA	-1.04	-8.57	-0.66	1.83e-13	Type 2 diabetes;
THYM	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg12165864	chr7:66369176	NA	0.61	4.62	0.43	1.2e-5	Aortic root size;
THYM	cis	rs7267979	1.000	rs6050632	chr20:25432601	A/G	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.6	-5.21	-0.47	1.1e-6	Electroencephalogram traits;
THYM	cis	rs9660180	0.967	rs2272908	chr1:1721479	A/G	cg20999797	chr1:1681921	NA	-0.49	-5.44	-0.49	4.22e-7	Body mass index;
THYM	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg07362569	chr17:61921086	SMARCD2	0.66	5.61	0.5	2.03e-7	Prudent dietary pattern;
THYM	cis	rs921968	0.541	rs7574429	chr2:219498759	T/G	cg02176678	chr2:219576539	TTLL4	0.73	7.3	0.6	8.89e-11	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg10792982	chr14:105748885	BRF1	0.72	7.38	0.6	5.93e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7412746	0.611	rs4509581	chr1:150774465	A/G	cg15448220	chr1:150897856	SETDB1	0.87	7.37	0.6	6.4e-11	Melanoma;
THYM	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg11247378	chr22:39784982	NA	-0.99	-9.81	-0.71	4.19e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs4851266	0.898	rs2309812	chr2:100869702	C/T	cg14675211	chr2:100938903	LONRF2	0.67	5.59	0.5	2.15e-7	Educational attainment;
THYM	cis	rs922692	0.744	rs11639044	chr15:79083814	C/T	cg15571903	chr15:79123663	NA	-0.54	-5.11	-0.46	1.63e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7100689	0.577	rs1417219	chr10:82041409	C/T	cg01528321	chr10:82214614	TSPAN14	0.96	7.48	0.61	3.7e-11	Post bronchodilator FEV1;
THYM	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg15448220	chr1:150897856	SETDB1	0.86	6.94	0.58	4.73e-10	Melanoma;
THYM	cis	rs7213347	0.780	rs9892016	chr17:2146422	A/G	cg19216660	chr17:2268602	SGSM2	0.5	4.45	0.42	2.32e-5	Total body bone mineral density;
THYM	cis	rs1559088	1.000	rs7245404	chr19:33550589	C/T	cg03563238	chr19:33554763	RHPN2	-0.5	-4.48	-0.42	2.04e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs17665859	0.925	rs13258819	chr8:479636	G/A	cg17960703	chr8:356704	FBXO25	0.92	4.45	0.42	2.32e-5	Bilirubin levels;
THYM	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg19774624	chr17:42201019	HDAC5	0.76	6.75	0.57	1.17e-9	Total body bone mineral density;
THYM	cis	rs87938	1.000	rs376362	chr3:41111939	A/T	cg02247160	chr3:41243829	CTNNB1	-0.34	-4.71	-0.43	8.59e-6	Bone mineral density (hip);
THYM	cis	rs7809950	1.000	rs986994	chr7:107104115	G/T	cg23024343	chr7:107201750	COG5	-0.93	-8.22	-0.64	1.02e-12	Coronary artery disease;
THYM	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg26513180	chr16:89883248	FANCA	0.74	7.34	0.6	7.27e-11	Vitiligo;
THYM	cis	rs748404	0.660	rs542898	chr15:43719392	C/T	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs2274459	0.778	rs9296097	chr6:33660143	G/A	cg06253072	chr6:33679850	C6orf125	0.49	4.97	0.45	2.98e-6	Obesity (extreme);
THYM	cis	rs804292	0.763	rs8191514	chr8:11627113	C/G	cg26752888	chr8:11627280	NEIL2	1.16	8.12	0.64	1.69e-12	Alcohol dependence;Nicotine use;
THYM	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.81	-7.05	-0.59	2.81e-10	Monocyte percentage of white cells;
THYM	cis	rs4499344	0.664	rs259284	chr19:33163262	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.33	0.6	7.39e-11	Mean platelet volume;
THYM	cis	rs11039798	0.614	rs11039954	chr11:48741818	A/G	cg24672777	chr11:48374446	OR4C45	-1.12	-6.73	-0.57	1.28e-9	Axial length;
THYM	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg02782426	chr3:40428986	ENTPD3	0.51	4.5	0.42	1.95e-5	Renal cell carcinoma;
THYM	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg18252515	chr7:66147081	NA	-0.88	-6.71	-0.57	1.4e-9	Corneal structure;
THYM	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg07343612	chr16:622815	PIGQ	-1.05	-10.74	-0.74	4.28e-18	Height;
THYM	cis	rs6840360	0.533	rs4696295	chr4:152717430	T/C	cg22705602	chr4:152727874	NA	0.77	9.96	0.71	2.01e-16	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs490234	0.783	rs13283793	chr9:128441641	C/T	cg14452096	chr9:127703551	GOLGA1	-0.58	-4.54	-0.42	1.67e-5	Mean arterial pressure;
THYM	trans	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg10856724	chr12:34555212	NA	-0.8	-6.99	-0.58	3.71e-10	Bladder cancer;
THYM	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.26	-9.1	-0.68	1.4e-14	Gut microbiome composition (summer);
THYM	cis	rs13256369	1.000	rs4840351	chr8:8573148	A/G	cg04654363	chr8:8581213	NA	-0.48	-4.62	-0.43	1.22e-5	Obesity-related traits;
THYM	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.53	-4.92	-0.45	3.67e-6	Lymphocyte counts;
THYM	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg03605463	chr16:89740564	NA	-0.62	-5.01	-0.46	2.47e-6	Hemoglobin concentration;
THYM	cis	rs2072732	0.861	rs72629498	chr1:2954203	C/T	cg08733933	chr1:2954429	NA	-0.64	-4.62	-0.43	1.22e-5	Plateletcrit;
THYM	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg24675658	chr1:53192096	ZYG11B	-0.81	-7.29	-0.6	8.99e-11	Monocyte count;
THYM	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg23131131	chr22:24373011	LOC391322	-0.71	-5.36	-0.48	5.79e-7	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7843479	0.544	rs4872110	chr8:21784989	A/G	cg17168535	chr8:21777572	XPO7	0.84	7.29	0.6	9.11e-11	Mean corpuscular volume;
THYM	cis	rs977987	0.671	rs9922008	chr16:75335406	T/C	cg03315344	chr16:75512273	CHST6	0.72	5.75	0.51	1.06e-7	Dupuytren's disease;
THYM	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	7.5	0.61	3.28e-11	Platelet count;
THYM	trans	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg25214090	chr10:38739885	LOC399744	0.83	7.11	0.59	2.14e-10	Corneal astigmatism;
THYM	cis	rs7704138	0.639	rs11745525	chr5:55015518	C/T	cg18456523	chr5:54516805	NA	-0.58	-4.59	-0.43	1.34e-5	Height;
THYM	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg13609457	chr4:120235615	NA	0.56	4.7	0.43	8.86e-6	Corneal astigmatism;
THYM	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.72	0.57	1.37e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg07414643	chr4:187882934	NA	0.6	5.18	0.47	1.22e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg24874828	chr4:187887005	NA	-0.73	-7.49	-0.61	3.59e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.23	-9.3	-0.69	5.17e-15	Platelet count;
THYM	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	5.23	0.47	1e-6	Obesity-related traits;
THYM	cis	rs9399401	0.601	rs262120	chr6:142842360	C/A	cg04461802	chr6:142623433	GPR126	0.58	5.21	0.47	1.07e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs2237898	0.585	rs12802488	chr11:2876533	T/C	cg12614029	chr11:2160564	INS-IGF2;IGF2AS;IGF2	-1.21	-4.48	-0.42	2.05e-5	Mosquito bite size;
THYM	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg07621104	chr11:117668040	DSCAML1	0.85	6.77	0.57	1.06e-9	Myopia;
THYM	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg09436375	chr6:42928200	GNMT	-0.42	-5.48	-0.49	3.51e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs669446	0.527	rs585711	chr1:44099863	G/T	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs6828523	0.698	rs4695984	chr4:175858796	C/T	cg14561282	chr4:175839468	ADAM29	0.62	4.53	0.42	1.7e-5	Breast cancer;
THYM	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg21237687	chr17:6899380	ALOX12	0.76	9.74	0.71	6.04e-16	Tonsillectomy;
THYM	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2976388	0.967	rs2976397	chr8:143764613	G/T	cg13446199	chr8:143762866	PSCA	0.54	6.26	0.54	1.12e-8	Urinary tract infection frequency;
THYM	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg26384229	chr12:38710491	ALG10B	-0.91	-7.51	-0.61	3.16e-11	Bladder cancer;
THYM	cis	rs4746818	1.000	rs10823313	chr10:70952115	G/A	cg04149295	chr10:70884716	VPS26A	0.78	5.31	0.48	7.18e-7	Left atrial antero-posterior diameter;
THYM	cis	rs72829446	0.530	rs66616380	chr17:7380188	C/A	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs1034435	0.755	rs5768681	chr22:48894501	C/T	cg05992904	chr22:48892994	FAM19A5	-0.81	-8.83	-0.67	5.15e-14	Late-onset Alzheimer's disease;
THYM	cis	rs10463554	0.963	rs257319	chr5:102445827	T/A	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Parkinson's disease;
THYM	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs1461503	0.966	rs11218908	chr11:122841687	A/G	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs11585357	0.947	rs11585118	chr1:17605774	C/A	cg08277548	chr1:17600880	PADI3	-0.93	-6.22	-0.54	1.3e-8	Hair shape;
THYM	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg16423285	chr20:60520624	NA	-0.63	-4.47	-0.42	2.19e-5	Body mass index;
THYM	cis	rs2731664	0.819	rs449351	chr5:176872591	T/C	cg14098951	chr5:176875120	PRR7	0.56	4.99	0.46	2.69e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.9	-8.59	-0.66	1.69e-13	Lung cancer;
THYM	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg17294928	chr15:75287854	SCAMP5	-0.94	-7.94	-0.63	4.01e-12	Blood trace element (Zn levels);
THYM	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg13447684	chr7:1895903	MAD1L1	0.58	4.92	0.45	3.63e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg08999081	chr20:33150536	PIGU	0.76	6.73	0.57	1.27e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	9.67	0.7	8.34e-16	Platelet count;
THYM	cis	rs12496230	0.953	rs1036972	chr3:66846010	C/T	cg04995300	chr3:66848608	NA	1.11	6.63	0.56	2.02e-9	Type 2 diabetes;
THYM	cis	rs10927875	0.526	rs2179615	chr1:16282426	G/A	cg21385522	chr1:16154831	NA	-1.04	-7.41	-0.61	5.23e-11	Dilated cardiomyopathy;
THYM	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.56	-4.5	-0.42	1.93e-5	Platelet count;
THYM	cis	rs2980439	0.807	rs2980438	chr8:8094825	T/C	cg06636001	chr8:8085503	FLJ10661	0.79	7.4	0.6	5.29e-11	Neuroticism;
THYM	cis	rs11651000	0.654	rs12451801	chr17:45820975	T/C	cg24803719	chr17:45855879	NA	-0.57	-5.96	-0.52	4.29e-8	IgG glycosylation;
THYM	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg06636001	chr8:8085503	FLJ10661	-0.83	-7.06	-0.59	2.73e-10	Joint mobility (Beighton score);
THYM	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg26149184	chr10:133730230	NA	0.77	4.65	0.43	1.07e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg02353165	chr6:42928485	GNMT	1.02	11.21	0.75	4.51e-19	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs60871478	0.735	rs4721501	chr7:862166	G/T	cg10248100	chr7:872053	UNC84A	0.72	4.65	0.43	1.09e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs56104184	0.775	rs56146968	chr19:49398847	A/G	cg19746536	chr19:49375674	PPP1R15A	0.81	4.64	0.43	1.12e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg00640147	chr17:61958756	GH2	-0.43	-4.61	-0.43	1.24e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg26441486	chr22:50317300	CRELD2	0.45	7.74	0.62	1.05e-11	Schizophrenia;
THYM	cis	rs9649213	0.593	rs1859482	chr7:97983774	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9914544	0.545	rs9912713	chr17:18771145	G/A	cg26378065	chr17:18585709	ZNF286B	0.59	4.49	0.42	1.97e-5	Educational attainment (years of education);
THYM	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg22875332	chr1:76189707	ACADM	0.88	9.09	0.68	1.44e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1050631	0.592	rs948417	chr18:33711274	A/G	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.58	4.56	0.42	1.54e-5	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg07936489	chr17:37558343	FBXL20	0.82	5.61	0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	trans	rs4650994	1.000	rs4511075	chr1:178518636	G/A	cg05059571	chr16:84539110	KIAA1609	-0.75	-8.02	-0.64	2.68e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs8180040	0.800	rs7632501	chr3:47268306	T/C	cg27129171	chr3:47204927	SETD2	-0.75	-7.03	-0.58	3.18e-10	Colorectal cancer;
THYM	cis	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg02825527	chr7:2087843	MAD1L1	-0.75	-5.01	-0.46	2.5e-6	Bipolar disorder;
THYM	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs526231	0.543	rs34766	chr5:102510923	T/C	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Primary biliary cholangitis;
THYM	cis	rs6988636	1.000	rs13261066	chr8:124190276	G/A	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg03732007	chr1:2071316	PRKCZ	-0.48	-4.46	-0.42	2.28e-5	Height;
THYM	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11890956	chr21:40555474	PSMG1	-0.66	-6.38	-0.55	6.51e-9	Menarche (age at onset);
THYM	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg01416388	chr22:39784598	NA	-0.79	-6.23	-0.54	1.25e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg19318889	chr4:1322082	MAEA	0.65	5.61	0.5	1.95e-7	Longevity;
THYM	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg23711669	chr6:146136114	FBXO30	-0.83	-7.77	-0.62	9.16e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4866334	1.000	rs114114986	chr5:18428605	C/A	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02018176	chr4:1364513	KIAA1530	0.99	10.1	0.72	1.02e-16	Longevity;
THYM	cis	rs28595532	0.920	rs114789346	chr4:119748652	G/A	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg27170947	chr2:26402098	FAM59B	-0.85	-6.64	-0.56	1.96e-9	Gut microbiome composition (summer);
THYM	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.6	-5.85	-0.51	6.92e-8	Longevity;Endometriosis;
THYM	cis	rs17321999	0.951	rs73925103	chr2:30474515	A/C	cg05247661	chr2:30472410	LBH	0.65	4.71	0.44	8.43e-6	Systemic lupus erythematosus;
THYM	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg16506815	chr2:162101123	NA	0.6	4.48	0.42	2.1e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs13102973	0.720	rs4473702	chr4:135851159	C/G	cg14419869	chr4:135874104	NA	0.88	7.79	0.62	8.22e-12	Subjective well-being;
THYM	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg27286337	chr10:134555280	INPP5A	0.87	6.75	0.57	1.17e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg09549813	chr16:4587862	C16orf5	-0.58	-6.59	-0.56	2.47e-9	Schizophrenia;
THYM	cis	rs6573333	1.000	rs1571388	chr14:61402545	A/C	cg15534086	chr14:61120234	NA	1.57	4.66	0.43	1.04e-5	Immune reponse to smallpox (secreted IFN-alpha);
THYM	cis	rs28647808	0.881	rs7042326	chr9:136266636	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs2408955	0.522	rs7139330	chr12:48483484	A/C	cg21466736	chr12:48725269	NA	0.51	5.11	0.46	1.69e-6	Glycated hemoglobin levels;
THYM	cis	rs7168353	1.000	rs7168353	chr15:93638401	C/G	cg12595281	chr15:93633172	RGMA	0.7	4.96	0.45	3.13e-6	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
THYM	cis	rs6570726	1.000	rs1935615	chr6:145921117	G/T	cg23711669	chr6:146136114	FBXO30	0.77	7.17	0.59	1.63e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs36051895	0.623	rs17426903	chr9:5203292	A/C	cg02405213	chr9:5042618	JAK2	-0.89	-8.2	-0.64	1.14e-12	Pediatric autoimmune diseases;
THYM	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs7123876	0.830	rs59311588	chr11:72435996	A/G	cg04827223	chr11:72435913	ARAP1	-0.56	-4.51	-0.42	1.88e-5	Body mass index;
THYM	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg07930552	chr6:133119739	C6orf192	1.03	6.0	0.52	3.63e-8	Type 2 diabetes nephropathy;
THYM	cis	rs7192750	0.563	rs11649672	chr16:71952614	G/C	cg06353428	chr16:71660113	MARVELD3	0.72	5.11	0.46	1.64e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs4595586	0.545	rs12833238	chr12:39373898	T/C	cg13010199	chr12:38710504	ALG10B	0.61	4.65	0.43	1.05e-5	Morning vs. evening chronotype;
THYM	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg14581129	chr12:53358946	NA	-1.04	-7.43	-0.61	4.58e-11	Cancer (pleiotropy);
THYM	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg18105134	chr13:113819100	PROZ	-0.99	-9.17	-0.69	9.65e-15	Platelet distribution width;
THYM	cis	rs9359856	0.564	rs72915944	chr6:90447226	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.9	-7.81	-0.63	7.61e-12	Bipolar disorder;
THYM	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.57	-5.65	-0.5	1.67e-7	Eosinophil percentage of white cells;
THYM	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.75	-5.09	-0.46	1.82e-6	Body mass index;
THYM	cis	rs9359856	1.000	rs2094487	chr6:90314072	T/A	cg13799429	chr6:90582589	CASP8AP2	0.47	4.56	0.42	1.51e-5	Bipolar disorder;
THYM	cis	rs12216545	0.765	rs2204129	chr7:150251439	A/G	cg00323915	chr7:150264987	GIMAP4	-0.49	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg09085632	chr11:111637200	PPP2R1B	1.22	15.45	0.85	1.18e-27	Primary sclerosing cholangitis;
THYM	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg06009448	chr7:1102226	C7orf50	0.53	5.59	0.5	2.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11249608	0.548	rs34881171	chr5:178451932	C/T	cg01312482	chr5:178451176	ZNF879	-0.75	-6.25	-0.54	1.18e-8	Pubertal anthropometrics;
THYM	cis	rs67460515	0.500	rs9832109	chr3:160723364	T/C	cg12349858	chr3:160822545	B3GALNT1	0.59	4.79	0.44	6.12e-6	Parkinson's disease;
THYM	cis	rs911555	0.519	rs8014069	chr14:104004311	A/C	cg12935359	chr14:103987150	CKB	-0.57	-5.34	-0.48	6.45e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg08742575	chr21:47604166	C21orf56	0.68	5.41	0.49	4.7e-7	Testicular germ cell tumor;
THYM	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg22189786	chr22:42395067	WBP2NL	0.57	5.14	0.47	1.47e-6	Birth weight;
THYM	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg13147721	chr7:65941812	NA	-0.73	-4.56	-0.42	1.52e-5	Diabetic kidney disease;
THYM	cis	rs3862260	0.509	rs12076924	chr1:120165826	C/T	cg11530693	chr1:120165357	ZNF697	1.08	12.42	0.79	1.33e-21	Systemic lupus erythematosus;
THYM	cis	rs6840360	1.000	rs9998462	chr4:152646548	T/A	cg22705602	chr4:152727874	NA	-0.59	-6.36	-0.55	7.09e-9	Intelligence (multi-trait analysis);
THYM	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg06656553	chr16:89960601	TCF25	-0.8	-4.74	-0.44	7.37e-6	Skin colour saturation;
THYM	cis	rs7582180	0.764	rs12999779	chr2:100924321	T/G	cg21926883	chr2:100939477	LONRF2	-0.61	-5.52	-0.49	2.91e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7107174	1.000	rs10899468	chr11:78016650	C/T	cg19901956	chr11:77921274	USP35	-0.74	-5.57	-0.5	2.39e-7	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg27168131	chr21:44088823	PDE9A	-0.48	-4.88	-0.45	4.23e-6	Mean corpuscular volume;
THYM	cis	rs6876348	0.516	rs2526254	chr5:128311451	A/C	cg02841155	chr5:128301328	SLC27A6	0.51	5.07	0.46	1.98e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg05457628	chr5:178986728	RUFY1	0.57	5.72	0.51	1.26e-7	Lung cancer;
THYM	cis	rs4790333	0.562	rs2447104	chr17:2257532	C/T	cg02569219	chr17:2266849	SGSM2	0.7	5.87	0.52	6.33e-8	Proinsulin levels;
THYM	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.59	4.49	0.42	1.98e-5	Breast cancer;
THYM	cis	rs4589258	0.872	rs34255967	chr11:90413988	C/A	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs6956675	1.000	rs1967430	chr7:62599308	C/T	cg08930214	chr7:62859557	LOC100287834	0.65	4.79	0.44	6.1e-6	Obesity-related traits;
THYM	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg12826209	chr6:26865740	GUSBL1	0.86	4.94	0.45	3.4e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9616064	0.506	rs3747255	chr22:47074281	G/A	cg05621596	chr22:47072043	GRAMD4	-0.56	-4.68	-0.43	9.4e-6	Urate levels in obese individuals;
THYM	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg11965913	chr1:205819406	PM20D1	0.92	9.68	0.7	7.89e-16	Menarche (age at onset);
THYM	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg14019146	chr3:50243930	SLC38A3	-0.61	-5.25	-0.47	9.45e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4430311	0.655	rs12138753	chr1:243795607	G/A	cg25706552	chr1:244017396	NA	-0.54	-4.48	-0.42	2.06e-5	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs4243830	0.850	rs3761927	chr1:6601773	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.11	-7.56	-0.61	2.57e-11	Body mass index;
THYM	cis	rs12208915	0.708	rs9361481	chr6:79726750	T/A	cg05283184	chr6:79620031	NA	0.64	4.62	0.43	1.2e-5	Left atrial antero-posterior diameter;
THYM	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg20503657	chr10:835505	NA	1.37	9.33	0.69	4.52e-15	Eosinophil percentage of granulocytes;
THYM	cis	rs10992471	0.528	rs10115290	chr9:95195858	G/A	cg14631576	chr9:95140430	CENPP	-0.84	-8.02	-0.64	2.69e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4474465	1.000	rs873311	chr11:78145886	G/C	cg19901956	chr11:77921274	USP35	-0.62	-4.63	-0.43	1.15e-5	Alzheimer's disease (survival time);
THYM	cis	rs9457247	0.534	rs9356551	chr6:167400345	T/C	cg15592062	chr6:167189543	RPS6KA2	0.52	5.32	0.48	6.84e-7	Crohn's disease;
THYM	cis	rs9311676	0.656	rs12497250	chr3:58399399	T/C	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg14019146	chr3:50243930	SLC38A3	-0.82	-7.29	-0.6	9.1e-11	Intelligence (multi-trait analysis);
THYM	cis	rs13256369	1.000	rs12550458	chr8:8567832	G/A	cg18904891	chr8:8559673	CLDN23	0.67	4.97	0.45	3e-6	Obesity-related traits;
THYM	cis	rs9914988	0.887	rs11080072	chr17:27081160	G/T	cg20469991	chr17:27169893	C17orf63	-0.89	-5.53	-0.49	2.83e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg02524346	chr8:600233	NA	-0.93	-4.8	-0.44	5.95e-6	IgG glycosylation;
THYM	cis	rs13082711	0.911	rs74279676	chr3:27512944	G/A	cg02860705	chr3:27208620	NA	0.72	5.06	0.46	2.01e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs1061377	1.000	rs13182	chr4:39122913	T/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg03733263	chr8:22462867	KIAA1967	1.17	11.79	0.77	2.66e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	trans	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7616559	0.719	rs9860977	chr3:156773837	G/A	cg15697575	chr3:156784781	NA	0.44	5.73	0.51	1.18e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg10360139	chr7:1886902	MAD1L1	-0.59	-5.09	-0.46	1.81e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg04602696	chr16:88846723	FAM38A	-0.67	-5.19	-0.47	1.18e-6	Plateletcrit;
THYM	cis	rs2836633	1.000	rs2836634	chr21:40068230	T/A	cg12884169	chr21:40033163	ERG	0.61	7.53	0.61	2.89e-11	Coronary artery disease;
THYM	cis	rs7614311	0.636	rs73117059	chr3:63916028	A/G	cg22134162	chr3:63841271	THOC7	-0.56	-6.45	-0.55	4.61e-9	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs778371	0.723	rs283470	chr2:233656918	G/A	cg08000102	chr2:233561755	GIGYF2	0.81	7.33	0.6	7.53e-11	Schizophrenia;
THYM	cis	rs7666738	0.785	rs11097614	chr4:99092175	G/C	cg17366294	chr4:99064904	C4orf37	0.53	5.49	0.49	3.32e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs72827839	0.793	rs72823513	chr17:46048920	A/G	cg23391107	chr17:45924227	SP6	0.76	4.89	0.45	4.1e-6	Ease of getting up in the morning;
THYM	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13732083	chr21:47605072	C21orf56	-0.76	-4.97	-0.45	2.94e-6	Testicular germ cell tumor;
THYM	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg19507638	chr5:93509721	C5orf36	-0.67	-4.48	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs8014204	0.836	rs7150254	chr14:75299101	G/A	cg06637938	chr14:75390232	RPS6KL1	0.55	5.34	0.48	6.42e-7	Caffeine consumption;
THYM	cis	rs7119038	0.818	rs11217032	chr11:118669605	T/A	cg19308663	chr11:118741387	NA	0.57	5.87	0.52	6.34e-8	Sjögren's syndrome;
THYM	cis	rs6542838	0.646	rs17756034	chr2:99382810	A/C	cg08885076	chr2:99613938	TSGA10	-0.55	-4.62	-0.43	1.22e-5	Fear of minor pain;
THYM	cis	rs10504229	0.593	rs116916898	chr8:57984958	G/A	cg02725872	chr8:58115012	NA	-0.93	-4.59	-0.43	1.34e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg08439880	chr3:133502540	NA	-0.63	-4.69	-0.43	9.28e-6	Iron status biomarkers;
THYM	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg22920501	chr2:26401640	FAM59B	-1.05	-9.27	-0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs28595532	0.920	rs115853212	chr4:119765354	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs7590720	0.851	rs13006614	chr2:216876204	C/T	cg25588852	chr2:216877276	MREG	-0.64	-6.05	-0.53	2.79e-8	Alcohol dependence;
THYM	cis	rs6840360	0.571	rs17275536	chr4:152498625	C/T	cg22705602	chr4:152727874	NA	-0.78	-8.89	-0.67	3.8e-14	Intelligence (multi-trait analysis);
THYM	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg19318889	chr4:1322082	MAEA	0.63	5.45	0.49	3.93e-7	Longevity;
THYM	cis	rs7107174	0.892	rs11601866	chr11:78011153	G/A	cg02023728	chr11:77925099	USP35	0.65	5.83	0.51	7.52e-8	Testicular germ cell tumor;
THYM	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.68	-5.28	-0.48	8.12e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1729951	0.575	rs1682357	chr3:136692009	G/A	cg12473912	chr3:136751656	NA	0.63	5.13	0.47	1.55e-6	Neuroticism;
THYM	cis	rs7100689	0.646	rs7899791	chr10:82091950	A/T	cg01528321	chr10:82214614	TSPAN14	0.84	6.43	0.55	5.15e-9	Post bronchodilator FEV1;
THYM	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg23161317	chr6:28129485	ZNF389	0.72	4.79	0.44	6.09e-6	Parkinson's disease;
THYM	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg03806693	chr22:41940476	POLR3H	-1.25	-11.51	-0.76	1.01e-19	Vitiligo;
THYM	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.96	0.45	3.1e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9314614	0.789	rs2980951	chr8:6712684	A/G	cg27319216	chr8:6693540	XKR5	-0.62	-6.63	-0.56	2.07e-9	IgA nephropathy;White blood cell count (basophil);
THYM	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg13695892	chr22:41940480	POLR3H	-0.72	-6.71	-0.57	1.39e-9	Vitiligo;
THYM	cis	rs7572263	0.959	rs12995271	chr2:209048136	T/C	cg23998903	chr2:209048830	C2orf80	-0.43	-5.66	-0.5	1.6e-7	Glioma;Non-glioblastoma glioma;
THYM	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg26031613	chr14:104095156	KLC1	0.78	5.2	0.47	1.14e-6	Body mass index;
THYM	cis	rs1018836	0.923	rs6998150	chr8:91645969	A/C	cg16814680	chr8:91681699	NA	-0.84	-7.27	-0.6	1.01e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.21	-0.47	1.11e-6	Hemoglobin concentration;
THYM	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg03806693	chr22:41940476	POLR3H	1.07	8.31	0.65	6.6e-13	Vitiligo;
THYM	cis	rs2862064	0.872	rs6555776	chr5:156403505	C/A	cg12943317	chr5:156479607	HAVCR1	-0.86	-5.04	-0.46	2.21e-6	Platelet count;
THYM	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg05738196	chr6:26577821	NA	0.84	8.48	0.66	2.87e-13	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	cis	rs9326248	0.581	rs7120963	chr11:116830261	C/T	cg20608306	chr11:116969690	SIK3	-0.63	-7.82	-0.63	7.08e-12	Blood protein levels;
THYM	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg11764359	chr7:65958608	NA	0.66	4.59	0.43	1.38e-5	Aortic root size;
THYM	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg05043794	chr9:111880884	C9orf5	-0.36	-4.97	-0.45	3.02e-6	Menarche (age at onset);
THYM	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg13319975	chr6:146136371	FBXO30	-0.6	-4.87	-0.45	4.44e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg07884673	chr3:53033167	SFMBT1	1.19	6.0	0.52	3.59e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7186908	0.711	rs9923344	chr16:72190653	T/C	cg16558253	chr16:72132732	DHX38	-0.53	-4.45	-0.42	2.3e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs28647808	0.867	rs28534766	chr9:136273381	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs28459962	0.545	rs1708681	chr4:89965459	T/A	cg17769793	chr4:89976368	FAM13A	-0.48	-5.02	-0.46	2.42e-6	Post bronchodilator FEV1;
THYM	cis	rs559389	0.740	rs11235451	chr11:71853099	T/A	cg23619769	chr11:71952356	PHOX2A	-0.67	-4.71	-0.43	8.56e-6	Pulmonary function in asthmatics;
THYM	cis	rs7614738	1	rs7614738	chr3:49311131	C/G	cg07636037	chr3:49044803	WDR6	0.76	5.54	0.49	2.65e-7	Red cell distribution width;
THYM	cis	rs337100	0.540	rs434775	chr5:122548994	A/T	cg04547002	chr5:122551801	NA	-0.65	-5.0	-0.46	2.62e-6	Pulse pressure;
THYM	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg03806693	chr22:41940476	POLR3H	-1.21	-10.47	-0.73	1.63e-17	Vitiligo;
THYM	trans	rs11186	0.556	rs72906337	chr2:189959204	G/A	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs4731207	0.724	rs35535003	chr7:124442464	A/T	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg22875332	chr1:76189707	ACADM	0.88	11.01	0.75	1.2e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs7524258	0.835	rs7543228	chr1:7306538	G/C	cg07173049	chr1:7289937	CAMTA1	0.72	5.92	0.52	5.05e-8	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs2552220	0.818	rs13279623	chr8:6012583	C/G	cg06481462	chr8:7005678	NA	0.48	5.3	0.48	7.62e-7	Interleukin-8 levels;
THYM	cis	rs77320796	1.000	rs4381172	chr1:40400397	C/T	cg05657805	chr1:40942785	ZNF642	0.78	4.55	0.42	1.58e-5	Platelet count;
THYM	cis	rs72717009	0.825	rs10494360	chr1:161475750	G/A	cg15358701	chr1:161410459	NA	-0.95	-5.06	-0.46	2.08e-6	Rheumatoid arthritis;
THYM	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7107174	0.748	rs11237458	chr11:78050849	A/T	cg02023728	chr11:77925099	USP35	0.64	6.31	0.54	8.65e-9	Testicular germ cell tumor;
THYM	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08109568	chr15:31115862	NA	-0.72	-6.5	-0.55	3.74e-9	Huntington's disease progression;
THYM	trans	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7584330	0.554	rs79213383	chr2:238426890	A/G	cg08992911	chr2:238395768	MLPH	0.85	5.39	0.48	5.19e-7	Prostate cancer;
THYM	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg16342193	chr10:102329863	NA	-0.53	-5.45	-0.49	4.01e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs314370	0.855	rs76181418	chr7:100494960	G/T	cg08558340	chr7:100472263	SRRT	0.61	4.99	0.46	2.75e-6	Resting heart rate;
THYM	cis	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs34638657	0.702	rs62044259	chr16:82199523	A/T	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.23	-0.47	9.91e-7	Lung adenocarcinoma;
THYM	cis	rs2139634	0.864	rs885485	chr3:46511168	C/A	cg02332537	chr3:46540019	RTP3	0.44	4.49	0.42	2.02e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs1691799	0.528	rs1472314	chr12:66788838	C/G	cg16791601	chr12:66731901	HELB	-0.61	-5.29	-0.48	7.95e-7	White blood cell count (basophil);
THYM	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg15247329	chr7:2764246	NA	-0.67	-5.55	-0.5	2.53e-7	Height;
THYM	cis	rs1371867	0.817	rs1788208	chr8:101312515	T/C	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs4845875	0.626	rs6540999	chr1:11833366	A/G	cg24844545	chr1:11908347	NPPA	0.45	4.6	0.43	1.28e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs2832077	0.506	rs2832085	chr21:30155258	G/T	cg24692254	chr21:30365293	RNF160	-0.88	-6.37	-0.55	6.78e-9	Cognitive test performance;
THYM	cis	rs2916260	0.733	rs6925172	chr6:40391564	C/T	cg17190781	chr6:40387783	LRFN2	1.24	4.76	0.44	6.94e-6	Incident coronary heart disease;
THYM	cis	rs7772486	0.790	rs4896852	chr6:146284621	T/C	cg13319975	chr6:146136371	FBXO30	0.7	5.77	0.51	9.94e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18252515	chr7:66147081	NA	-0.7	-5.29	-0.48	7.95e-7	Aortic root size;
THYM	cis	rs7589342	0.839	rs6747023	chr2:106431856	A/G	cg14210321	chr2:106509881	NCK2	-0.69	-4.9	-0.45	3.95e-6	Addiction;
THYM	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg14893161	chr1:205819251	PM20D1	0.62	5.78	0.51	9.61e-8	Menarche (age at onset);
THYM	cis	rs2219968	0.923	rs7004112	chr8:78941331	G/T	cg00738934	chr8:78996279	NA	0.77	8.01	0.63	2.9e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg13609457	chr4:120235615	NA	-0.58	-5.21	-0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs4589258	1.000	rs2156830	chr11:90462927	T/A	cg26138821	chr11:89956704	CHORDC1	-0.71	-5.7	-0.5	1.37e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg10295955	chr4:187884368	NA	-1.22	-17.54	-0.87	1.51e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg27532560	chr4:187881888	NA	-0.91	-10.77	-0.74	3.86e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7168353	1.000	rs7168353	chr15:93638401	C/G	cg02918577	chr15:93633145	RGMA	0.6	4.55	0.42	1.56e-5	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
THYM	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.61	-0.43	1.27e-5	Type 2 diabetes;
THYM	cis	rs1797081	0.542	rs2603796	chr10:16871456	C/T	cg23933602	chr10:16859644	RSU1	0.59	4.81	0.44	5.56e-6	Platelet distribution width;
THYM	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg01966878	chr4:90757139	SNCA	-0.54	-4.48	-0.42	2.07e-5	Neuroticism;
THYM	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	5.14	0.47	1.48e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7872515	0.536	rs28883017	chr9:94774870	T/C	cg13922115	chr9:95397568	IPPK	0.88	4.46	0.42	2.25e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs9733	0.565	rs7524620	chr1:150616699	C/T	cg09034736	chr1:150693464	HORMAD1	-0.52	-4.66	-0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg12379764	chr21:47803548	PCNT	-0.78	-4.89	-0.45	4.03e-6	Testicular germ cell tumor;
THYM	cis	rs7772486	0.790	rs2253880	chr6:146200774	T/C	cg23711669	chr6:146136114	FBXO30	0.93	9.04	0.68	1.9e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13006833	0.739	rs291470	chr2:191189558	T/A	cg21644426	chr2:191273491	MFSD6	0.62	4.49	0.42	1.99e-5	Urinary metabolites;
THYM	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg26963428	chr7:66367121	NA	-0.59	-4.72	-0.44	8.08e-6	Corneal structure;
THYM	cis	rs35883536	0.647	rs2783696	chr1:101044089	G/A	cg06223162	chr1:101003688	GPR88	0.81	6.95	0.58	4.53e-10	Monocyte count;
THYM	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg07570687	chr10:102243282	WNT8B	0.77	6.9	0.58	5.65e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg03806693	chr22:41940476	POLR3H	-0.77	-5.95	-0.52	4.56e-8	Neuroticism;
THYM	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Bladder cancer;
THYM	cis	rs7119	0.604	rs2271396	chr15:77907535	C/G	cg27398640	chr15:77910606	LINGO1	0.63	8.15	0.64	1.45e-12	Type 2 diabetes;
THYM	cis	rs2806561	0.828	rs604030	chr1:23518227	T/C	cg12483005	chr1:23474871	LUZP1	0.59	6.29	0.54	9.59e-9	Height;
THYM	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg19508488	chr2:152266495	RIF1	0.68	5.59	0.5	2.13e-7	Lung cancer;
THYM	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg00376283	chr12:123451042	ABCB9	0.69	4.65	0.43	1.09e-5	Neutrophil percentage of white cells;
THYM	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg22907277	chr7:1156413	C7orf50	0.86	7.19	0.59	1.47e-10	Longevity;Endometriosis;
THYM	cis	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg10856724	chr12:34555212	NA	-1.07	-9.99	-0.72	1.72e-16	Morning vs. evening chronotype;
THYM	cis	rs7927592	0.913	rs4316515	chr11:68308840	A/T	cg20283391	chr11:68216788	NA	0.69	5.14	0.47	1.49e-6	Total body bone mineral density;
THYM	cis	rs7772486	0.686	rs1045820	chr6:145947080	C/T	cg13319975	chr6:146136371	FBXO30	-0.67	-5.46	-0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.98	0.45	2.85e-6	Obesity-related traits;
THYM	cis	rs17818399	0.962	rs2122715	chr2:46845849	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.71	5.24	0.47	9.76e-7	Height;
THYM	cis	rs10911251	0.546	rs3768625	chr1:183078712	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.61	5.11	0.46	1.64e-6	Colorectal cancer;
THYM	cis	rs4951011	0.938	rs4951233	chr1:203763289	G/T	cg24343524	chr1:203763352	ZC3H11A	0.71	6.38	0.55	6.4e-9	Breast cancer;
THYM	cis	rs6980334	0.817	rs10228366	chr7:137794905	T/A	cg11874123	chr7:137028198	PTN	0.67	5.17	0.47	1.29e-6	Blood metabolite ratios;
THYM	cis	rs7681440	0.560	rs986610	chr4:90751655	T/C	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs1430128	0.584	rs11681655	chr2:218458646	G/A	cg27640316	chr2:217799104	NA	0.68	4.77	0.44	6.59e-6	Congenital heart disease (inherited effect);
THYM	cis	rs75920871	0.528	rs12279066	chr11:116913909	C/G	cg20608306	chr11:116969690	SIK3	-0.54	-6.01	-0.52	3.45e-8	Subjective well-being;
THYM	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg03859395	chr2:55845619	SMEK2	0.64	5.71	0.51	1.29e-7	Metabolic syndrome;
THYM	cis	rs4523957	0.928	rs441750	chr17:2190767	T/C	cg16513277	chr17:2031491	SMG6	0.79	7.41	0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7246967	0.544	rs403717	chr19:23008803	A/G	cg05241461	chr19:22816980	ZNF492	0.55	4.67	0.43	1e-5	Bronchopulmonary dysplasia;
THYM	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.73	7.2	0.59	1.4e-10	Lymphocyte counts;
THYM	cis	rs13315871	1.000	rs71311873	chr3:58447106	C/A	cg00563845	chr3:58318305	PXK	0.53	4.67	0.43	9.78e-6	Cholesterol, total;
THYM	cis	rs9549260	0.755	rs2721069	chr13:41143720	C/T	cg21288729	chr13:41239152	FOXO1	0.73	5.6	0.5	2.11e-7	Red blood cell count;
THYM	cis	rs9814567	0.752	rs4634170	chr3:134335471	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.9	-0.63	4.93e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2742234	0.590	rs2435376	chr10:43684963	A/G	cg06632098	chr10:43605906	RET	-0.79	-5.1	-0.46	1.73e-6	Hirschsprung disease;
THYM	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg13246856	chr1:44399776	ARTN	0.48	4.95	0.45	3.27e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg02869364	chr7:1081709	C7orf50	-0.44	-4.97	-0.45	2.99e-6	Longevity;Endometriosis;
THYM	cis	rs6840360	0.571	rs6833814	chr4:152539679	A/G	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4589258	0.762	rs10830567	chr11:90476845	A/G	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.83	-0.44	5.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6728642	0.572	rs13387563	chr2:97600916	C/A	cg01990225	chr2:97406019	LMAN2L	-0.77	-4.61	-0.43	1.23e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg17063962	chr7:91808500	NA	-1.12	-12.68	-0.79	3.85e-22	Breast cancer;
THYM	cis	rs12788925	0.504	rs7124873	chr11:102803476	A/G	cg19620758	chr11:102826565	MMP13	-0.53	-4.6	-0.43	1.29e-5	Coronary artery disease;
THYM	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg03433033	chr1:76189801	ACADM	-0.62	-6.16	-0.53	1.76e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs1499972	0.941	rs6794831	chr3:117642484	C/A	cg07612923	chr3:117604196	NA	1.3	5.07	0.46	1.94e-6	Schizophrenia;
THYM	cis	rs71403859	0.502	rs71403847	chr16:71468226	T/C	cg08717414	chr16:71523259	ZNF19	-1.44	-7.36	-0.6	6.5e-11	Post bronchodilator FEV1;
THYM	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg26038318	chr20:34205095	SPAG4	0.63	5.16	0.47	1.36e-6	Total cholesterol levels;
THYM	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs877282	1.000	rs71494928	chr10:769134	A/G	cg10556349	chr10:835070	NA	-0.83	-5.7	-0.51	1.32e-7	Uric acid levels;
THYM	cis	rs3960554	0.569	rs11973658	chr7:75882026	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.51	-4.68	-0.43	9.47e-6	Eotaxin levels;
THYM	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg19077165	chr18:44547161	KATNAL2	-0.66	-8.47	-0.66	3.08e-13	Personality dimensions;
THYM	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg11327659	chr7:150037044	RARRES2	0.4	4.63	0.43	1.15e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2089222	1.000	rs2089222	chr12:117002658	A/G	cg08693490	chr12:116757896	NA	1.25	4.73	0.44	7.86e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs10992471	0.565	rs12552866	chr9:95110549	G/A	cg14631576	chr9:95140430	CENPP	-0.71	-6.41	-0.55	5.55e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg04362960	chr10:104952993	NT5C2	0.59	4.96	0.45	3.02e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg08213375	chr14:104286397	PPP1R13B	0.52	6.23	0.54	1.26e-8	Schizophrenia;
THYM	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg08847533	chr14:75593920	NEK9	0.97	10.48	0.73	1.56e-17	Height;
THYM	cis	rs9522267	0.535	rs6492373	chr13:112238627	T/C	cg10483660	chr13:112241077	NA	0.59	6.84	0.57	7.61e-10	Hepatitis;
THYM	cis	rs10782582	0.593	rs12126155	chr1:76131555	C/G	cg22875332	chr1:76189707	ACADM	-0.54	-5.15	-0.47	1.39e-6	Daytime sleep phenotypes;
THYM	cis	rs89107	0.576	rs17227124	chr6:118741382	T/C	cg01113488	chr6:119027122	NA	0.53	4.53	0.42	1.74e-5	Cardiac structure and function;
THYM	cis	rs2108622	0.701	rs3093209	chr19:15988420	G/C	cg13772218	chr19:15982569	NA	0.5	4.48	0.42	2.06e-5	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs3540	0.533	rs937793	chr15:91053583	A/G	cg22089800	chr15:90895588	ZNF774	-0.72	-5.45	-0.49	3.95e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs7553864	0.667	rs4656143	chr1:87605208	G/A	cg17420885	chr1:87600446	LOC339524	-0.85	-7.62	-0.62	1.86e-11	Smoking behavior;
THYM	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg08975724	chr8:8085496	FLJ10661	0.75	6.25	0.54	1.15e-8	Mood instability;
THYM	cis	rs7584330	0.554	rs76980036	chr2:238426750	G/A	cg08992911	chr2:238395768	MLPH	0.85	5.39	0.48	5.19e-7	Prostate cancer;
THYM	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg16006841	chr5:176797999	RGS14	0.5	6.34	0.55	7.69e-9	Urinary electrolytes (magnesium/calcium ratio);
THYM	cis	rs2273669	0.504	rs112211350	chr6:109457989	T/C	cg17117243	chr6:109341365	SESN1	-0.85	-4.99	-0.46	2.77e-6	Prostate cancer;
THYM	cis	rs1065852	0.503	rs9620006	chr22:42399547	T/A	cg09667013	chr22:42394590	WBP2NL	0.54	4.8	0.44	5.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs4363385	0.747	rs9919276	chr1:152968654	A/T	cg13444842	chr1:152974279	SPRR3	-0.6	-4.79	-0.44	6.2e-6	Inflammatory skin disease;
THYM	cis	rs7107174	0.892	rs2510033	chr11:77941771	T/G	cg19901956	chr11:77921274	USP35	-0.82	-6.2	-0.54	1.44e-8	Testicular germ cell tumor;
THYM	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg12908607	chr1:44402522	ARTN	-0.52	-4.67	-0.43	9.88e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10752881	1.000	rs12403189	chr1:182983832	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg17063962	chr7:91808500	NA	1.1	11.9	0.77	1.56e-20	Breast cancer;
THYM	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg04944784	chr2:26401820	FAM59B	-0.67	-5.05	-0.46	2.14e-6	Gut microbiome composition (summer);
THYM	cis	rs13315871	0.790	rs13071148	chr3:58310838	A/C	cg12435725	chr3:58293450	RPP14	-0.53	-5.51	-0.49	3.09e-7	Cholesterol, total;
THYM	cis	rs362272	0.524	rs6819202	chr4:3368264	G/A	cg14583973	chr4:3374767	RGS12	0.64	6.17	0.53	1.65e-8	Serum sulfate level;
THYM	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg27129171	chr3:47204927	SETD2	0.69	6.63	0.56	2.04e-9	Colorectal cancer;
THYM	cis	rs10463554	0.927	rs34813	chr5:102433409	G/A	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.75e-6	Parkinson's disease;
THYM	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg08847533	chr14:75593920	NEK9	1.01	11.32	0.76	2.63e-19	Height;
THYM	trans	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg25214090	chr10:38739885	LOC399744	0.93	7.84	0.63	6.64e-12	Corneal astigmatism;
THYM	cis	rs1448094	0.511	rs4469976	chr12:86146723	T/C	cg02569458	chr12:86230093	RASSF9	-0.66	-5.63	-0.5	1.84e-7	Major depressive disorder;
THYM	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg02398342	chr17:80708632	TBCD;FN3K	-0.73	-6.48	-0.55	4.14e-9	Glycated hemoglobin levels;
THYM	cis	rs854765	0.583	rs4553680	chr17:17857722	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	6.4	0.55	5.73e-9	Total body bone mineral density;
THYM	cis	rs988913	1.000	rs1503136	chr6:54851965	A/C	cg04690482	chr6:54711388	FAM83B	0.46	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	cis	rs6496667	0.533	rs886491	chr15:90993215	G/A	cg00425431	chr15:90792223	TTLL13	0.4	4.64	0.43	1.11e-5	Rheumatoid arthritis;
THYM	cis	rs72772090	0.539	rs11738810	chr5:96119055	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2997447	0.655	rs1317709	chr1:26384690	A/C	cg19633962	chr1:26362018	EXTL1	-0.69	-4.62	-0.43	1.21e-5	QRS complex (12-leadsum);
THYM	cis	rs896854	0.517	rs2013597	chr8:95951807	G/A	cg16049864	chr8:95962084	TP53INP1	-0.79	-5.75	-0.51	1.08e-7	Type 2 diabetes;
THYM	cis	rs7771547	0.519	rs67313027	chr6:36363487	G/C	cg04289385	chr6:36355825	ETV7	0.54	4.49	0.42	1.98e-5	Platelet distribution width;
THYM	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg08885076	chr2:99613938	TSGA10	-0.58	-5.74	-0.51	1.11e-7	Chronic sinus infection;
THYM	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg12935359	chr14:103987150	CKB	-0.51	-6.07	-0.53	2.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs3892630	0.878	rs1061686	chr19:33204544	C/T	cg02283691	chr19:33182526	NUDT19	0.4	4.71	0.44	8.35e-6	Red blood cell traits;
THYM	cis	rs12580035	0.568	rs7300241	chr12:1912526	C/T	cg25356715	chr12:1904796	CACNA2D4	-0.44	-4.51	-0.42	1.89e-5	Urate levels in lean individuals;
THYM	cis	rs9527	0.615	rs4919685	chr10:104587362	G/T	cg08772003	chr10:104629869	AS3MT	-0.59	-4.72	-0.44	8.24e-6	Arsenic metabolism;
THYM	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg16325326	chr1:53192061	ZYG11B	-0.73	-7.1	-0.59	2.23e-10	Monocyte count;
THYM	trans	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg26384229	chr12:38710491	ALG10B	0.89	6.9	0.58	5.73e-10	Morning vs. evening chronotype;
THYM	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	6.42	0.55	5.25e-9	Platelet count;
THYM	cis	rs1203833	0.573	rs2685131	chr16:209764	G/C	cg25425005	chr16:202905	HBZ	-0.8	-5.84	-0.51	7.14e-8	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
THYM	cis	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg07460842	chr6:66804631	NA	-1.24	-15.46	-0.85	1.1e-27	Exhaled nitric oxide output;
THYM	cis	rs7104764	0.957	rs10794301	chr11:220401	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	1.1	9.77	0.71	5.16e-16	Menarche (age at onset);
THYM	cis	rs9899728	0.706	rs7211930	chr17:73018326	C/T	cg15864779	chr17:73043180	ATP5H;KCTD2	-1.41	-4.69	-0.43	9.08e-6	Alzheimer's disease or small vessel stroke;
THYM	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs72828912	0.731	rs9379636	chr6:24069649	G/T	cg26336265	chr6:25042955	NA	-0.86	-5.43	-0.49	4.31e-7	Squamous cell lung carcinoma;
THYM	cis	rs7107174	1.000	rs10899478	chr11:78052238	C/T	cg02023728	chr11:77925099	USP35	0.61	5.85	0.51	7e-8	Testicular germ cell tumor;
THYM	cis	rs7219585	1.000	rs7219585	chr17:72268208	A/G	cg10520594	chr17:73127197	NT5C	0.86	4.8	0.44	5.93e-6	Information processing speed;
THYM	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs7216064	1.000	rs3206817	chr17:65892834	A/G	cg12091567	chr17:66097778	LOC651250	-0.69	-4.51	-0.42	1.86e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg23750338	chr8:142222470	SLC45A4	0.52	4.87	0.45	4.48e-6	Immature fraction of reticulocytes;
THYM	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.9	-10.0	-0.72	1.61e-16	Prudent dietary pattern;
THYM	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.73	5.22	0.47	1.05e-6	Height;
THYM	cis	rs3771570	1.000	rs12619369	chr2:242282957	A/T	cg21155796	chr2:242212141	HDLBP	1.16	6.55	0.56	2.88e-9	Prostate cancer;
THYM	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg23205692	chr1:25664452	TMEM50A	0.86	6.55	0.56	2.91e-9	Erythrocyte sedimentation rate;
THYM	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg24375607	chr4:120327624	NA	0.65	5.42	0.49	4.43e-7	Corneal astigmatism;
THYM	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.8	7.58	0.61	2.3e-11	Calcium levels;
THYM	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg19610905	chr11:61596333	FADS2	-0.58	-4.66	-0.43	1.03e-5	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
THYM	cis	rs752010	0.574	rs12130138	chr1:42117792	A/C	cg06885757	chr1:42089581	HIVEP3	0.5	5.27	0.48	8.68e-7	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs36051895	0.632	rs7032616	chr9:5180996	T/C	cg02405213	chr9:5042618	JAK2	-1.0	-10.96	-0.75	1.53e-18	Pediatric autoimmune diseases;
THYM	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.94	-7.34	-0.6	7.09e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg24579218	chr15:68104479	NA	-0.83	-7.87	-0.63	5.69e-12	Restless legs syndrome;
THYM	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg08859206	chr1:53392774	SCP2	-0.79	-9.59	-0.7	1.22e-15	Monocyte count;
THYM	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg19875535	chr5:140030758	IK	-0.63	-5.69	-0.5	1.43e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.52e-7	Heart rate;
THYM	cis	rs7757969	1.000	rs9481192	chr6:112130478	C/T	cg08601457	chr6:112115117	FYN	0.42	4.79	0.44	6.23e-6	Schizophrenia;
THYM	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg01699819	chr7:1052092	C7orf50	-0.6	-5.09	-0.46	1.83e-6	Bronchopulmonary dysplasia;
THYM	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg07169764	chr2:136633963	MCM6	0.69	5.81	0.51	8.17e-8	Mosquito bite size;
THYM	cis	rs6032067	0.714	rs6513969	chr20:43878475	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-6.24	-0.54	1.22e-8	Blood protein levels;
THYM	cis	rs7677751	0.806	rs73252942	chr4:55104604	T/C	cg17187183	chr4:55093834	PDGFRA	0.71	5.45	0.49	3.99e-7	Corneal astigmatism;
THYM	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg15691649	chr6:25882328	NA	-0.78	-6.35	-0.55	7.45e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2777491	0.915	rs16971767	chr15:41623308	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.14	-12.89	-0.8	1.38e-22	Ulcerative colitis;
THYM	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg14664628	chr15:75095509	CSK	1.08	9.57	0.7	1.35e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs55962025	0.804	rs2071703	chr4:3241413	A/C	cg25216704	chr4:3485393	DOK7	0.48	4.46	0.42	2.22e-5	Parental longevity (mother's age at death);
THYM	cis	rs1298062	0.861	rs2431821	chr19:50995098	G/A	cg11430371	chr19:50961752	MYBPC2	0.46	4.53	0.42	1.73e-5	Age of smoking initiation;
THYM	cis	rs7084402	0.967	rs1649076	chr10:60294061	A/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.65e-7	Refractive error;
THYM	cis	rs877282	1.000	rs877282	chr10:771532	G/A	cg10556349	chr10:835070	NA	-0.78	-5.38	-0.48	5.34e-7	Uric acid levels;
THYM	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg06600287	chr1:53387719	ECHDC2	-0.29	-4.54	-0.42	1.67e-5	Monocyte count;
THYM	cis	rs12681288	0.550	rs12675410	chr8:957845	T/C	cg08648136	chr8:956695	NA	0.6	5.16	0.47	1.36e-6	Schizophrenia;
THYM	cis	rs4474465	1.000	rs7128417	chr11:78205974	C/G	cg19901956	chr11:77921274	USP35	0.65	4.8	0.44	5.97e-6	Alzheimer's disease (survival time);
THYM	cis	rs1788820	0.917	rs4800489	chr18:21125942	A/G	cg14672496	chr18:21087552	C18orf8	0.81	6.51	0.56	3.49e-9	Body mass index;
THYM	cis	rs6920965	0.503	rs2475851	chr6:126174215	T/C	cg05901451	chr6:126070800	HEY2	-0.62	-5.22	-0.47	1.03e-6	High light scatter reticulocyte count;
THYM	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg20203395	chr5:56204925	C5orf35	-0.65	-4.53	-0.42	1.68e-5	Initial pursuit acceleration;
THYM	cis	rs4363385	0.818	rs2070963	chr1:153004004	G/A	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs2067615	0.579	rs11113119	chr12:107200056	C/A	cg15890332	chr12:107067104	RFX4	0.48	5.63	0.5	1.81e-7	Heart rate;
THYM	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg26513180	chr16:89883248	FANCA	0.72	7.38	0.6	5.86e-11	Vitiligo;
THYM	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg17264618	chr3:40429014	ENTPD3	0.52	4.97	0.45	2.94e-6	Renal cell carcinoma;
THYM	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg08975724	chr8:8085496	FLJ10661	0.76	6.33	0.54	8.16e-9	Mood instability;
THYM	cis	rs11025559	0.812	rs10766678	chr11:20507180	A/G	cg19653624	chr11:20408972	PRMT3	-0.76	-5.23	-0.47	1.01e-6	Pursuit maintenance gain;
THYM	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg03452623	chr4:187889614	NA	-1.17	-18.46	-0.88	3.54e-33	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9880211	0.563	rs9848926	chr3:135816302	A/G	cg21827317	chr3:136751795	NA	-0.74	-5.19	-0.47	1.19e-6	Body mass index;Height;
THYM	cis	rs9420	0.961	rs17455520	chr11:57540458	C/A	cg19752551	chr11:57585705	CTNND1	-0.73	-7.98	-0.63	3.28e-12	Schizophrenia;
THYM	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1018836	0.923	rs7837230	chr8:91574281	C/T	cg16814680	chr8:91681699	NA	-0.75	-6.25	-0.54	1.16e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs17744026	0.586	rs75261499	chr11:123726515	G/A	cg00079598	chr11:123676903	OR6M1	-0.49	-4.47	-0.42	2.14e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs11166927	1.000	rs10435690	chr8:140802093	C/T	cg16909799	chr8:140841666	TRAPPC9	0.62	5.62	0.5	1.89e-7	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs11711311	0.955	rs12630833	chr3:113390883	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.55	-4.58	-0.43	1.4e-5	IgG glycosylation;
THYM	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg15556689	chr8:8085844	FLJ10661	-0.84	-7.67	-0.62	1.46e-11	Neuroticism;
THYM	cis	rs6964587	0.626	rs404	chr7:91544316	G/T	cg17063962	chr7:91808500	NA	-1.01	-9.06	-0.68	1.73e-14	Breast cancer;
THYM	cis	rs4808199	1.000	rs7258508	chr19:19475469	T/C	cg03709012	chr19:19516395	GATAD2A	1.11	6.53	0.56	3.22e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs1150668	0.830	rs2531831	chr6:28388765	C/G	cg09682330	chr6:28411287	ZSCAN23	-0.5	-4.48	-0.42	2.06e-5	Pubertal anthropometrics;
THYM	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.94	6.09	0.53	2.4e-8	Smoking behavior;
THYM	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg17372223	chr3:52568218	NT5DC2	0.33	5.09	0.46	1.84e-6	Bipolar disorder;
THYM	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg03676636	chr4:99064102	C4orf37	0.38	5.14	0.47	1.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7224314	1.000	rs7224314	chr17:65386214	A/C	cg01507342	chr17:65387096	PITPNC1	-0.92	-9.9	-0.71	2.68e-16	Diisocyanate-induced asthma;
THYM	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg10760299	chr15:45669010	GATM	0.87	6.8	0.57	9.43e-10	Homoarginine levels;
THYM	cis	rs501916	0.833	rs11629796	chr15:48045248	A/G	cg20869673	chr15:48010124	SEMA6D	0.7	5.28	0.48	8.21e-7	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs4430311	0.723	rs1870272	chr1:243924743	T/A	cg25706552	chr1:244017396	NA	-0.59	-5.14	-0.47	1.49e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs55871839	0.643	rs10105665	chr8:59799367	A/G	cg07426533	chr8:59803705	TOX	-0.61	-6.02	-0.53	3.2e-8	Pneumonia;
THYM	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg02725872	chr8:58115012	NA	-0.73	-5.38	-0.48	5.3e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg16586182	chr3:47516702	SCAP	-0.6	-5.16	-0.47	1.34e-6	Colorectal cancer;
THYM	cis	rs7432375	1.000	rs940174	chr3:136309710	T/C	cg12473912	chr3:136751656	NA	0.62	5.19	0.47	1.18e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg01236616	chr12:121019343	POP5	-1.25	-10.43	-0.73	1.96e-17	Type 1 diabetes nephropathy;
THYM	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.87	-7.15	-0.59	1.82e-10	Primary sclerosing cholangitis;
THYM	trans	rs629535	0.783	rs538832	chr8:70033817	A/G	cg21567404	chr3:27674614	NA	1.12	10.86	0.74	2.44e-18	Dupuytren's disease;
THYM	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg03806693	chr22:41940476	POLR3H	-1.11	-8.99	-0.68	2.33e-14	Vitiligo;
THYM	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs17401966	1.000	rs12734068	chr1:10376803	G/A	cg20482658	chr1:10539492	PEX14	0.37	4.55	0.42	1.59e-5	Hepatocellular carcinoma;
THYM	cis	rs1003719	0.645	rs8131944	chr21:38547215	G/A	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs10089	0.953	rs4835940	chr5:127406596	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.96	6.36	0.55	7.05e-9	Ileal carcinoids;
THYM	cis	rs901683	1.000	rs71496608	chr10:46017132	G/A	cg18240400	chr10:46168597	ANUBL1	0.8	5.19	0.47	1.19e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg03859395	chr2:55845619	SMEK2	0.65	6.04	0.53	3.03e-8	Metabolic syndrome;
THYM	cis	rs6500395	1.000	rs7185899	chr16:48714101	A/G	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-5.16	-0.47	1.35e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7107174	1.000	rs2510039	chr11:77944480	G/A	cg02023728	chr11:77925099	USP35	0.73	6.33	0.54	7.9e-9	Testicular germ cell tumor;
THYM	cis	rs1371867	0.817	rs7846076	chr8:101327629	A/G	cg00191853	chr8:101177733	SPAG1	-0.5	-5.12	-0.47	1.59e-6	Atrioventricular conduction;
THYM	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg18811423	chr2:55921094	PNPT1	0.72	6.56	0.56	2.79e-9	Metabolic syndrome;
THYM	trans	rs1920324	0.622	rs9848289	chr3:103904369	C/A	cg01901466	chr14:93388880	CHGA	0.65	6.91	0.58	5.4e-10	Colorectal cancer;
THYM	cis	rs10870270	0.917	rs11146417	chr10:133791034	C/G	cg00744431	chr10:134226547	PWWP2B	-0.56	-4.79	-0.44	6.16e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs761746	0.960	rs4820980	chr22:31917415	A/G	cg10537193	chr22:32026975	PISD	0.38	5.08	0.46	1.89e-6	Intelligence;
THYM	cis	rs9677476	0.863	rs4637098	chr2:232075528	C/T	cg20307347	chr2:231734563	ITM2C	-0.55	-4.85	-0.45	4.76e-6	Food antigen IgG levels;
THYM	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3791556	0.504	rs1001285	chr2:240107814	A/G	cg27074582	chr2:240114406	HDAC4	0.52	5.38	0.48	5.36e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2552220	1.000	rs13252545	chr8:6006311	G/C	cg06481462	chr8:7005678	NA	0.46	4.61	0.43	1.28e-5	Interleukin-8 levels;
THYM	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg25811766	chr13:21894605	NA	-0.77	-4.99	-0.46	2.77e-6	White matter hyperintensity burden;
THYM	trans	rs4650994	1.000	rs10913568	chr1:178513411	C/T	cg05059571	chr16:84539110	KIAA1609	-0.75	-7.94	-0.63	4.01e-12	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	6.11	0.53	2.14e-8	Rheumatoid arthritis;
THYM	cis	rs919433	0.679	rs10931788	chr2:198531084	A/G	cg05783139	chr2:198650985	BOLL	0.66	4.98	0.46	2.78e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs10193935	0.901	rs13393459	chr2:42463124	C/T	cg27598129	chr2:42591480	NA	-0.75	-4.6	-0.43	1.29e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg23978390	chr7:1156363	C7orf50	0.74	5.76	0.51	1.03e-7	Longevity;Endometriosis;
THYM	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22857025	chr5:266934	NA	-1.37	-8.88	-0.67	4.08e-14	Breast cancer;
THYM	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg14004847	chr7:1930337	MAD1L1	-0.65	-5.29	-0.48	7.86e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs13102973	0.965	rs28874134	chr4:135867088	C/A	cg14419869	chr4:135874104	NA	-0.82	-7.94	-0.63	4.06e-12	Subjective well-being;
THYM	cis	rs4144027	0.904	rs10438244	chr14:104346185	A/G	cg08213375	chr14:104286397	PPP1R13B	-0.44	-4.6	-0.43	1.31e-5	Blood metabolite levels;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg09048823	chr6:21228164	CDKAL1	-0.96	-7.04	-0.59	3.05e-10	Depressive symptoms;
THYM	cis	rs9875589	0.509	rs2733555	chr3:14099649	C/T	cg03204825	chr3:13978759	TPRXL	-0.55	-4.78	-0.44	6.3e-6	Ovarian reserve;
THYM	trans	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg19862616	chr7:65841803	NCRNA00174	1.09	12.64	0.79	4.47e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs10431058	0.965	rs1939895	chr11:107483469	C/T	cg18204760	chr11:107461044	ELMOD1;LOC643923	0.77	6.0	0.52	3.59e-8	Common traits (Other);
THYM	cis	rs7560272	0.723	rs7562047	chr2:73725168	G/T	cg19565262	chr2:73869966	NAT8	-0.56	-4.75	-0.44	7.18e-6	Schizophrenia;
THYM	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.62	-5.34	-0.48	6.21e-7	Intelligence (multi-trait analysis);
THYM	cis	rs526231	0.543	rs246909	chr5:102563677	A/G	cg23492399	chr5:102201601	PAM	-0.69	-5.24	-0.47	9.75e-7	Primary biliary cholangitis;
THYM	cis	rs4474465	0.915	rs4944204	chr11:78222013	G/T	cg19901956	chr11:77921274	USP35	0.66	4.84	0.44	4.99e-6	Alzheimer's disease (survival time);
THYM	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg18252515	chr7:66147081	NA	-1.37	-8.05	-0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs863345	0.526	rs2051067	chr1:158507398	G/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	trans	rs637571	0.607	rs574586	chr11:65697083	G/A	cg17712092	chr4:129076599	LARP1B	1.03	9.83	0.71	3.74e-16	Eosinophil percentage of white cells;
THYM	cis	rs9361491	0.657	rs13198615	chr6:79430552	A/G	cg04547799	chr6:79944526	HMGN3	-0.68	-4.92	-0.45	3.66e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2444217	0.872	rs2531977	chr16:4043701	C/G	cg09300795	chr16:4042428	ADCY9	0.61	4.62	0.43	1.22e-5	Body mass index;
THYM	cis	rs2273669	0.667	rs12214567	chr6:109317330	C/T	cg17117243	chr6:109341365	SESN1	-0.9	-5.38	-0.48	5.45e-7	Prostate cancer;
THYM	cis	rs1883415	0.727	rs2760118	chr6:24503590	C/T	cg00346970	chr6:24499591	ALDH5A1	0.39	5.13	0.47	1.5e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs910187	0.631	rs2228	chr20:45809941	G/A	cg27589058	chr20:45804311	EYA2	-0.59	-5.04	-0.46	2.2e-6	Migraine;
THYM	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00908189	chr16:619842	PIGQ	1.03	9.46	0.7	2.34e-15	Height;
THYM	cis	rs7246657	0.943	rs2291004	chr19:37997952	C/A	cg23950597	chr19:37808831	NA	-0.73	-4.65	-0.43	1.09e-5	Coronary artery calcification;
THYM	cis	rs11031096	0.711	rs1348309	chr11:4202000	A/T	cg18678763	chr11:4115507	RRM1	-0.41	-4.82	-0.44	5.4e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs12956009	0.518	rs1347343	chr18:44818996	T/A	cg19077165	chr18:44547161	KATNAL2	-0.48	-4.48	-0.42	2.06e-5	Educational attainment (years of education);
THYM	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg06917634	chr15:78832804	PSMA4	0.92	8.46	0.66	3.27e-13	Sudden cardiac arrest;
THYM	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg26752003	chr8:145688521	CYHR1	-0.76	-6.35	-0.55	7.48e-9	Age at first birth;
THYM	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg10150615	chr22:24372951	LOC391322	-0.83	-8.92	-0.68	3.38e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2180341	0.814	rs6919082	chr6:127737888	T/G	cg27446573	chr6:127587934	RNF146	0.73	6.41	0.55	5.53e-9	Breast cancer;
THYM	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg13607699	chr17:42295918	UBTF	0.75	5.72	0.51	1.24e-7	Total body bone mineral density;
THYM	cis	rs754466	0.651	rs11815015	chr10:79625482	C/T	cg17075019	chr10:79541650	NA	-0.69	-5.85	-0.51	6.94e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9992101	0.547	rs13146163	chr4:77412091	G/T	cg27417997	chr4:77356416	SHROOM3	-0.37	-4.46	-0.42	2.22e-5	Creatinine levels;
THYM	cis	rs9649213	0.593	rs36017146	chr7:97974617	C/T	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs2933343	0.729	rs813732	chr3:128619357	C/T	cg11901034	chr3:128598214	ACAD9	-0.7	-5.48	-0.49	3.44e-7	IgG glycosylation;
THYM	cis	rs9902453	0.904	rs9900974	chr17:28364456	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.24	-0.54	1.24e-8	Coffee consumption (cups per day);
THYM	cis	rs763014	0.898	rs62030902	chr16:638264	C/G	cg07343612	chr16:622815	PIGQ	-1.15	-12.09	-0.78	6.29e-21	Height;
THYM	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg05973401	chr12:123451056	ABCB9	0.69	4.61	0.43	1.25e-5	Neutrophil percentage of white cells;
THYM	cis	rs3733631	1.000	rs6533106	chr4:104596455	A/G	cg24090629	chr4:104641072	TACR3	-0.87	-5.51	-0.49	3.08e-7	Menarche (age at onset);
THYM	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg10224037	chr5:178157518	ZNF354A	1.0	8.0	0.63	2.99e-12	Neutrophil percentage of white cells;
THYM	cis	rs7620457	1.000	rs7620457	chr3:183747266	A/G	cg01324343	chr3:183735012	ABCC5	-0.57	-4.55	-0.42	1.57e-5	Body mass index;
THYM	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg00825309	chr19:58991885	ZNF446	-0.6	-4.69	-0.43	9.02e-6	Uric acid clearance;
THYM	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg15557168	chr22:42548783	NA	-0.59	-4.61	-0.43	1.25e-5	Schizophrenia;
THYM	cis	rs1499972	0.941	rs62266065	chr3:117547059	C/T	cg07612923	chr3:117604196	NA	1.16	4.77	0.44	6.52e-6	Schizophrenia;
THYM	cis	rs537626	0.767	rs680618	chr11:69316881	T/C	cg16475811	chr11:69308726	NA	-0.61	-4.97	-0.45	2.9e-6	Breast cancer (early onset);
THYM	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg22875332	chr1:76189707	ACADM	-0.87	-10.77	-0.74	3.75e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg02493740	chr2:85810744	VAMP5	-0.61	-4.71	-0.43	8.53e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg01341218	chr17:43662625	NA	0.86	7.43	0.61	4.66e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs986417	1.000	rs1254286	chr14:60858300	T/C	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs11587400	0.532	rs2268700	chr1:115228879	T/G	cg12756093	chr1:115239321	AMPD1	-0.76	-6.15	-0.53	1.84e-8	Autism;
THYM	trans	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs9810089	0.708	rs619605	chr3:136087012	G/C	cg12473912	chr3:136751656	NA	0.58	4.74	0.44	7.45e-6	Gestational age at birth (child effect);
THYM	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs4262150	0.883	rs72802877	chr5:152241855	A/G	cg06854687	chr5:151642065	NA	0.64	4.46	0.42	2.27e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs6980334	0.798	rs10280394	chr7:137767201	C/A	cg11874123	chr7:137028198	PTN	0.68	5.18	0.47	1.26e-6	Blood metabolite ratios;
THYM	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg17063962	chr7:91808500	NA	1.16	13.12	0.8	4.77e-23	Breast cancer;
THYM	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Body mass index;
THYM	cis	rs854765	0.693	rs8079321	chr17:17760789	C/T	cg16928487	chr17:17741425	SREBF1	-0.53	-5.28	-0.48	8.19e-7	Total body bone mineral density;
THYM	cis	rs892961	0.932	rs7222170	chr17:75413096	G/A	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg10950924	chr17:47092072	IGF2BP1	0.68	8.08	0.64	1.99e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs11031096	0.678	rs61899754	chr11:4201312	A/T	cg22027985	chr11:4115532	RRM1	-0.55	-5.06	-0.46	2.06e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs28595532	0.920	rs114051506	chr4:119772893	A/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg02527881	chr3:46936655	PTH1R	-0.69	-7.11	-0.59	2.11e-10	Colorectal cancer;
THYM	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg03351412	chr1:154909251	PMVK	0.73	5.58	0.5	2.3e-7	Prostate cancer;
THYM	cis	rs7107174	1.000	rs10899456	chr11:78000155	C/G	cg02023728	chr11:77925099	USP35	0.64	5.85	0.51	7.04e-8	Testicular germ cell tumor;
THYM	cis	rs6430585	0.583	rs59213715	chr2:136646582	A/C	cg04750100	chr2:136595281	LCT	0.56	4.96	0.45	3.13e-6	Corneal structure;
THYM	cis	rs9443645	0.527	rs9361479	chr6:79723755	T/A	cg05283184	chr6:79620031	NA	-0.58	-4.51	-0.42	1.84e-5	Intelligence (multi-trait analysis);
THYM	cis	rs11039798	0.588	rs7108164	chr11:48626363	A/C	cg24672777	chr11:48374446	OR4C45	-0.93	-6.01	-0.52	3.39e-8	Axial length;
THYM	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	14.47	0.83	9.53e-26	Chronic sinus infection;
THYM	cis	rs6980334	0.551	rs2035647	chr7:137799569	A/G	cg11874123	chr7:137028198	PTN	0.65	4.72	0.44	8.26e-6	Blood metabolite ratios;
THYM	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg06766960	chr11:133703094	NA	-0.61	-5.42	-0.49	4.41e-7	Childhood ear infection;
THYM	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg03388043	chr17:80084554	CCDC57	-0.73	-6.06	-0.53	2.74e-8	Life satisfaction;
THYM	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg11812906	chr14:75593930	NEK9	-0.87	-8.2	-0.64	1.16e-12	Height;
THYM	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg24060327	chr5:131705240	SLC22A5	-0.68	-5.07	-0.46	1.97e-6	Breast cancer;
THYM	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg11266682	chr4:10021025	SLC2A9	-0.62	-7.81	-0.63	7.54e-12	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11089937	0.647	rs743516	chr22:22521498	G/A	cg21401457	chr22:22472743	NA	0.55	4.64	0.43	1.12e-5	Periodontitis (PAL4Q3);
THYM	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg27588902	chr6:42928151	GNMT	-0.56	-5.77	-0.51	1.01e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg15704280	chr7:45808275	SEPT13	1.01	8.14	0.64	1.49e-12	Height;
THYM	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg23815491	chr16:72088622	HP	-0.79	-6.44	-0.55	4.87e-9	Fibrinogen levels;
THYM	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4631830	0.720	rs2611471	chr10:51503559	G/C	cg10326726	chr10:51549505	MSMB	-0.61	-6.17	-0.53	1.67e-8	Prostate-specific antigen levels;
THYM	cis	rs2348418	0.643	rs7316831	chr12:28455998	C/A	cg13890972	chr12:28721907	NA	-0.48	-4.5	-0.42	1.93e-5	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs4930103	0.935	rs4930110	chr11:2026701	G/C	cg21926276	chr11:2035255	NA	0.27	4.53	0.42	1.74e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs7412746	0.611	rs10788794	chr1:150728676	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.32	0.48	7.02e-7	Melanoma;
THYM	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg08645402	chr16:4508243	NA	0.76	6.87	0.58	6.72e-10	Schizophrenia;
THYM	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs4606347	0.872	rs17415296	chr1:66099013	C/A	cg04111102	chr1:66153794	NA	0.59	4.54	0.42	1.67e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg17644776	chr2:200775616	C2orf69	0.74	5.24	0.47	9.63e-7	Schizophrenia;
THYM	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg27490568	chr2:178487706	NA	0.63	6.02	0.53	3.29e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7463256	1.000	rs12543373	chr8:23104622	A/G	cg14349055	chr8:23104193	CHMP7	-1.03	-12.1	-0.78	5.94e-21	Attention deficit hyperactivity disorder;
THYM	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.38	0.6	5.91e-11	Morning vs. evening chronotype;
THYM	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg27490568	chr2:178487706	NA	0.6	5.22	0.47	1.05e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs367615	0.704	rs11747622	chr5:108844720	G/A	cg17395555	chr5:108820864	NA	0.76	9.29	0.69	5.53e-15	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg15536230	chr21:44985092	HSF2BP	-0.38	-4.53	-0.42	1.69e-5	Mean corpuscular volume;
THYM	cis	rs2282300	0.739	rs7952339	chr11:30327344	C/T	cg22891988	chr11:30607959	MPPED2	0.69	4.58	0.43	1.41e-5	Morning vs. evening chronotype;
THYM	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg24531977	chr5:56204891	C5orf35	-0.93	-7.44	-0.61	4.48e-11	Initial pursuit acceleration;
THYM	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg09021430	chr5:549028	NA	0.62	5.9	0.52	5.53e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs4589258	0.933	rs4753294	chr11:90409152	T/C	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6121246	0.559	rs1484994	chr20:30305975	A/G	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg02887458	chr19:19495540	GATAD2A	-0.45	-4.89	-0.45	4.05e-6	Bipolar disorder;
THYM	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg17426766	chr1:2046864	PRKCZ	-0.4	-4.9	-0.45	3.86e-6	Height;
THYM	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg14895029	chr7:2775587	GNA12	-0.67	-4.83	-0.44	5.21e-6	Height;
THYM	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03517284	chr6:25882590	NA	-0.71	-5.34	-0.48	6.32e-7	Height;
THYM	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg06600287	chr1:53387719	ECHDC2	-0.31	-5.09	-0.46	1.78e-6	Monocyte count;
THYM	cis	rs236907	0.812	rs2232807	chr1:171750095	T/C	cg20598894	chr1:171756153	METTL13	-0.73	-5.54	-0.49	2.74e-7	Mean platelet volume;
THYM	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg23428387	chr22:49814324	NA	-0.58	-5.96	-0.52	4.34e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4482178	1.000	rs2343057	chr13:86263440	G/A	cg25308322	chr13:86268291	NA	0.68	4.75	0.44	7.32e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg24675056	chr1:15929824	NA	0.73	5.86	0.52	6.71e-8	Systolic blood pressure;
THYM	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.25	-10.33	-0.73	3.19e-17	Platelet count;
THYM	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg20744362	chr22:50050164	C22orf34	0.82	8.14	0.64	1.52e-12	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs2712184	0.875	rs1015784	chr2:217681833	G/C	cg05032264	chr2:217675019	NA	-0.57	-5.05	-0.46	2.1e-6	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs11645898	1.000	rs11645898	chr16:72229532	A/G	cg14768367	chr16:72042858	DHODH	-0.63	-4.6	-0.43	1.33e-5	Blood protein levels;
THYM	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg12564285	chr5:131593104	PDLIM4	0.42	4.5	0.42	1.89e-5	Breast cancer;
THYM	cis	rs2050392	0.965	rs2480279	chr10:30700032	C/T	cg02070205	chr10:30722105	MAP3K8	-0.5	-4.49	-0.42	2.01e-5	Inflammatory bowel disease;
THYM	cis	rs713587	0.713	rs12466350	chr2:25239969	A/G	cg15423357	chr2:25149977	NA	0.59	6.37	0.55	6.69e-9	Body mass index in non-asthmatics;
THYM	cis	rs6121246	0.657	rs74392247	chr20:30241737	C/T	cg13852791	chr20:30311386	BCL2L1	0.9	5.85	0.51	7.06e-8	Mean corpuscular hemoglobin;
THYM	cis	rs763014	0.931	rs3752567	chr16:628130	A/G	cg07343612	chr16:622815	PIGQ	-1.06	-10.68	-0.74	5.88e-18	Height;
THYM	cis	rs920590	0.684	rs57837509	chr8:19670088	A/G	cg03894339	chr8:19674705	INTS10	0.62	4.79	0.44	6.22e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg12863693	chr15:85201151	NMB	0.52	4.45	0.42	2.3e-5	Schizophrenia;
THYM	cis	rs76878669	0.561	rs4930178	chr11:66129442	C/G	cg18002602	chr11:66138449	SLC29A2	0.49	4.98	0.45	2.86e-6	Educational attainment (years of education);
THYM	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.87	-0.45	4.45e-6	Eye color traits;
THYM	cis	rs6993813	0.678	rs2062376	chr8:120010009	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.57	4.54	0.42	1.65e-5	Bone mineral density (hip);
THYM	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg08999081	chr20:33150536	PIGU	0.77	6.95	0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs1499972	0.941	rs817507	chr3:117681065	A/C	cg07612923	chr3:117604196	NA	-1.42	-5.49	-0.49	3.4e-7	Schizophrenia;
THYM	cis	rs7177699	0.557	rs6495335	chr15:79117133	G/T	cg15571903	chr15:79123663	NA	0.57	6.57	0.56	2.71e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7666738	0.712	rs11731393	chr4:98859070	G/C	cg03676636	chr4:99064102	C4orf37	0.46	5.02	0.46	2.41e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg02753203	chr1:228287806	NA	-0.82	-7.7	-0.62	1.28e-11	Parkinson's disease;
THYM	cis	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg10856724	chr12:34555212	NA	0.85	7.53	0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg07636037	chr3:49044803	WDR6	0.8	5.68	0.5	1.44e-7	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg06009448	chr7:1102226	C7orf50	0.53	5.59	0.5	2.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12478296	0.685	rs6705935	chr2:242995110	C/T	cg06360820	chr2:242988706	NA	-1.05	-7.36	-0.6	6.61e-11	Obesity-related traits;
THYM	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg11166453	chr1:247681781	NA	-0.62	-4.91	-0.45	3.83e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg06636001	chr8:8085503	FLJ10661	0.58	4.66	0.43	1.04e-5	Mood instability;
THYM	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg02187348	chr16:89574699	SPG7	0.74	4.78	0.44	6.43e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs10779751	0.887	rs2300095	chr1:11265717	A/G	cg08854313	chr1:11322531	MTOR	0.9	7.64	0.62	1.75e-11	Body mass index;
THYM	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg09904177	chr6:26538194	HMGN4	0.53	4.47	0.42	2.16e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10911232	0.507	rs4422969	chr1:183020762	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs4285028	0.948	rs12493952	chr3:121708497	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-5.08	-0.46	1.87e-6	Multiple sclerosis;
THYM	cis	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg01364799	chr7:75623366	TMEM120A	0.61	4.55	0.42	1.61e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9828933	0.752	rs13434089	chr3:63948566	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.96	5.66	0.5	1.58e-7	Type 2 diabetes;
THYM	cis	rs7000551	0.556	rs35359294	chr8:22249755	G/A	cg12081754	chr8:22256438	SLC39A14	1.13	11.24	0.76	3.77e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs4924935	0.509	rs28540773	chr17:18761754	T/C	cg26378065	chr17:18585709	ZNF286B	0.6	4.71	0.43	8.56e-6	Pancreatic cancer;
THYM	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.8	7.93	0.63	4.29e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2346160	0.899	rs206977	chr6:167690746	G/C	cg21686812	chr6:168078911	NA	-0.53	-4.72	-0.44	8.23e-6	Parental extreme longevity (95 years and older);
THYM	cis	rs11186	0.556	rs72906358	chr2:189962199	A/G	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	cis	rs8050907	0.744	rs7195782	chr16:4539861	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.45	5.39	0.48	5.08e-7	Obesity-related traits;
THYM	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4919044	0.808	rs9420608	chr10:94800903	C/G	cg05127821	chr10:94822908	CYP26C1	1.23	6.66	0.56	1.76e-9	Coronary artery disease;
THYM	cis	rs7828089	0.935	rs4872485	chr8:22255990	G/T	cg12081754	chr8:22256438	SLC39A14	0.65	5.59	0.5	2.19e-7	Verbal declarative memory;
THYM	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg10523679	chr1:76189770	ACADM	-0.55	-4.49	-0.42	1.97e-5	Daytime sleep phenotypes;
THYM	cis	rs11690935	0.531	rs62183800	chr2:172867273	C/T	cg13550731	chr2:172543902	DYNC1I2	0.56	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs75920871	0.528	rs11600552	chr11:116900947	T/C	cg20608306	chr11:116969690	SIK3	-0.54	-6.01	-0.52	3.45e-8	Subjective well-being;
THYM	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg27535305	chr1:53392650	SCP2	-0.54	-6.32	-0.54	8.36e-9	Monocyte count;
THYM	cis	rs6988636	1.000	rs16898084	chr8:124190377	A/T	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg17330251	chr7:94953956	PON1	-0.82	-7.52	-0.61	3.02e-11	Paraoxonase activity;
THYM	cis	rs740474	0.533	rs3844598	chr5:140992235	A/G	cg24137543	chr5:140893634	NA	0.5	6.84	0.57	7.49e-10	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg10518543	chr12:38710700	ALG10B	0.58	4.51	0.42	1.85e-5	Morning vs. evening chronotype;
THYM	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg23131131	chr22:24373011	LOC391322	-0.77	-7.1	-0.59	2.3e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2637266	1.000	rs3923670	chr10:78375001	C/G	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.4	-0.48	4.95e-7	Longevity;
THYM	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06481639	chr22:41940642	POLR3H	-0.8	-5.55	-0.49	2.63e-7	Vitiligo;
THYM	cis	rs7481584	0.581	rs406598	chr11:3076285	G/A	cg03159660	chr11:2078197	NA	0.61	4.6	0.43	1.28e-5	Calcium levels;
THYM	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg20283391	chr11:68216788	NA	-0.71	-5.27	-0.48	8.44e-7	Total body bone mineral density;
THYM	cis	rs7119	0.717	rs62009070	chr15:77817884	G/C	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs9563576	0.778	rs60597190	chr13:58637289	G/C	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.63	4.68	0.43	9.64e-6	Body mass index;
THYM	cis	rs2811415	0.597	rs11719889	chr3:127805780	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs1568889	1.000	rs12790932	chr11:28046189	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	4.49	0.42	2.03e-5	Bipolar disorder;
THYM	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.46e-7	Corneal astigmatism;
THYM	cis	rs189798	1.000	rs189798	chr8:8990577	A/G	cg18904891	chr8:8559673	CLDN23	-0.62	-5.1	-0.46	1.73e-6	Myopia (pathological);
THYM	cis	rs533581	0.844	rs548591	chr16:88974516	A/G	cg07027457	chr16:89025522	CBFA2T3	-0.52	-4.64	-0.43	1.09e-5	Social autistic-like traits;
THYM	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg18240062	chr17:79603768	NPLOC4	0.73	6.55	0.56	2.9e-9	Eye color traits;
THYM	cis	rs7727544	0.547	rs56083751	chr5:131664638	T/A	cg14196790	chr5:131705035	SLC22A5	0.59	5.62	0.5	1.94e-7	Blood metabolite levels;
THYM	cis	rs1981331	0.609	rs7282611	chr21:48043297	C/A	cg17243659	chr21:48055224	PRMT2	1.03	4.51	0.42	1.86e-5	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs4631830	0.900	rs7920517	chr10:51532621	G/A	cg10326726	chr10:51549505	MSMB	-0.6	-6.06	-0.53	2.76e-8	Prostate-specific antigen levels;
THYM	cis	rs4790333	0.757	rs2429906	chr17:2265113	C/A	cg02569219	chr17:2266849	SGSM2	0.69	5.76	0.51	1.05e-7	Proinsulin levels;
THYM	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.66	5.78	0.51	9.39e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg24690094	chr11:67383802	NA	0.91	7.49	0.61	3.52e-11	Mean corpuscular volume;
THYM	cis	rs761746	0.960	rs738656	chr22:31935347	G/A	cg10537193	chr22:32026975	PISD	0.43	5.69	0.5	1.39e-7	Intelligence;
THYM	trans	rs4650994	1.000	rs10798619	chr1:178532517	A/G	cg05059571	chr16:84539110	KIAA1609	-0.76	-8.28	-0.65	7.7e-13	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs1298062	0.717	rs74176110	chr19:50995568	G/C	cg11430371	chr19:50961752	MYBPC2	0.45	4.45	0.42	2.34e-5	Age of smoking initiation;
THYM	cis	rs7772486	0.902	rs1125462	chr6:146417832	A/G	cg13319975	chr6:146136371	FBXO30	-0.63	-5.21	-0.47	1.12e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg00339695	chr16:24857497	SLC5A11	-0.68	-6.43	-0.55	5.15e-9	Intelligence (multi-trait analysis);
THYM	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	6.86	0.58	7.07e-10	Total body bone mineral density;
THYM	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs950880	0.710	rs3771150	chr2:103060851	G/A	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.66	-0.43	1.04e-5	Serum protein levels (sST2);
THYM	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.83	0.44	5.33e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2273669	0.667	rs28504359	chr6:109330417	C/T	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg07606381	chr6:8435919	SLC35B3	0.62	4.49	0.42	1.97e-5	Motion sickness;
THYM	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg20503657	chr10:835505	NA	1.17	8.2	0.64	1.16e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg03709012	chr19:19516395	GATAD2A	0.85	7.08	0.59	2.49e-10	Tonsillectomy;
THYM	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs1957429	0.708	rs8019346	chr14:65353011	G/A	cg23373153	chr14:65346875	NA	-1.35	-5.73	-0.51	1.19e-7	Pediatric areal bone mineral density (radius);
THYM	cis	rs295140	0.507	rs1369842	chr2:201108987	C/A	cg03447810	chr2:200324230	SATB2	-0.59	-4.48	-0.42	2.06e-5	QT interval;
THYM	cis	rs12310956	0.532	rs10844720	chr12:33987859	G/T	cg10856724	chr12:34555212	NA	-0.75	-6.8	-0.57	9.1e-10	Morning vs. evening chronotype;
THYM	cis	rs2795502	0.564	rs72777192	chr10:43436778	G/A	cg08461752	chr10:43522343	NA	-0.76	-4.62	-0.43	1.2e-5	Blood protein levels;
THYM	cis	rs10463554	0.963	rs158254	chr5:102394883	G/A	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs9361491	0.608	rs1588086	chr6:79475887	T/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.88e-5	Intelligence (multi-trait analysis);
THYM	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg16405210	chr4:1374714	KIAA1530	-0.64	-5.31	-0.48	7.21e-7	Longevity;
THYM	cis	rs6032067	0.929	rs17424474	chr20:43804797	C/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs6844506	0.565	rs10008153	chr4:185227184	C/T	cg12654155	chr4:185238627	NA	-0.6	-4.83	-0.44	5.17e-6	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
THYM	cis	rs11089937	0.568	rs5756988	chr22:22486790	A/G	cg21401457	chr22:22472743	NA	-0.56	-4.52	-0.42	1.78e-5	Periodontitis (PAL4Q3);
THYM	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg13695892	chr22:41940480	POLR3H	0.86	6.43	0.55	5.06e-9	Vitiligo;
THYM	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg10505658	chr17:80084571	CCDC57	-0.72	-7.84	-0.63	6.62e-12	Life satisfaction;
THYM	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg03188948	chr7:1209495	NA	-0.64	-4.9	-0.45	3.89e-6	Longevity;Endometriosis;
THYM	cis	rs806215	1.000	rs806219	chr7:127240094	A/C	cg08586737	chr7:127225949	GCC1	0.39	5.04	0.46	2.19e-6	Type 2 diabetes;
THYM	cis	rs9660180	0.967	rs6603803	chr1:1812688	A/G	cg13866156	chr1:1669148	SLC35E2	-0.66	-6.69	-0.57	1.53e-9	Body mass index;
THYM	cis	rs9807841	0.592	rs10401513	chr19:10778763	A/T	cg16900796	chr19:10755136	SLC44A2	0.35	5.72	0.51	1.23e-7	Inflammatory skin disease;
THYM	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07167872	chr1:205819463	PM20D1	0.74	6.87	0.58	6.7e-10	Menarche (age at onset);
THYM	cis	rs1050631	0.564	rs681757	chr18:33744766	A/C	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.61	4.68	0.43	9.46e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg03060546	chr3:49711283	APEH	0.78	6.44	0.55	4.91e-9	Resting heart rate;
THYM	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg01528321	chr10:82214614	TSPAN14	0.66	5.16	0.47	1.35e-6	Post bronchodilator FEV1;
THYM	cis	rs4523957	0.928	rs12949991	chr17:2197185	G/A	cg16513277	chr17:2031491	SMG6	0.77	7.16	0.59	1.73e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6598955	0.671	rs41285347	chr1:26644399	C/T	cg08133631	chr1:26527909	CATSPER4	-0.63	-5.22	-0.47	1.05e-6	Obesity-related traits;
THYM	cis	rs11645898	0.504	rs118034653	chr16:71922944	T/C	cg03805757	chr16:71968109	PKD1L3	-0.85	-6.49	-0.55	3.83e-9	Blood protein levels;
THYM	cis	rs422249	0.512	rs99780	chr11:61596633	C/T	cg19610905	chr11:61596333	FADS2	-0.61	-5.17	-0.47	1.28e-6	Trans fatty acid levels;
THYM	cis	rs8060598	0.745	rs748855	chr16:50751398	C/T	cg05261686	chr16:50743296	NOD2	-0.41	-5.01	-0.46	2.55e-6	Leprosy;
THYM	cis	rs1062746	0.544	rs8059287	chr16:87332956	G/A	cg02258303	chr16:87377426	FBXO31	-0.61	-4.61	-0.43	1.25e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs7772486	0.846	rs2748499	chr6:146315002	T/C	cg23711669	chr6:146136114	FBXO30	0.97	10.75	0.74	4.13e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg20476274	chr7:133979776	SLC35B4	0.67	4.61	0.43	1.25e-5	Mean platelet volume;
THYM	cis	rs854765	0.552	rs6502624	chr17:17847936	G/A	cg04398451	chr17:18023971	MYO15A	-0.77	-7.04	-0.59	3.02e-10	Total body bone mineral density;
THYM	trans	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.24	-14.98	-0.84	9.39e-27	Exhaled nitric oxide output;
THYM	cis	rs7605378	1.000	rs769954	chr2:200692159	C/G	cg17644776	chr2:200775616	C2orf69	-0.64	-4.97	-0.45	2.96e-6	Osteoporosis;
THYM	cis	rs7107174	1.000	rs2256187	chr11:77919768	G/A	cg19901956	chr11:77921274	USP35	-0.8	-6.16	-0.53	1.77e-8	Testicular germ cell tumor;
THYM	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg03264133	chr6:25882463	NA	0.72	5.71	0.51	1.29e-7	Blood metabolite levels;
THYM	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg02503808	chr4:7069936	GRPEL1	0.93	7.72	0.62	1.19e-11	Monocyte percentage of white cells;
THYM	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	7.2	0.59	1.38e-10	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg18538332	chr22:24372958	LOC391322	-1.05	-13.8	-0.82	2e-24	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs7635838	0.653	rs2606749	chr3:11373635	A/G	cg00170343	chr3:11313890	ATG7	0.57	4.54	0.42	1.66e-5	HDL cholesterol;
THYM	cis	rs792448	0.743	rs351373	chr1:212426631	G/T	cg14523881	chr1:213164074	VASH2	0.59	4.5	0.42	1.89e-5	White blood cell count (basophil);
THYM	trans	rs9951602	0.512	rs77157626	chr18:76644771	C/T	cg02800362	chr5:177631904	HNRNPAB	1.12	8.77	0.67	6.87e-14	Obesity-related traits;
THYM	cis	rs7772486	0.764	rs2265471	chr6:146220250	G/A	cg13319975	chr6:146136371	FBXO30	-0.73	-6.08	-0.53	2.44e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7103648	0.897	rs2278890	chr11:47399602	G/A	cg20307385	chr11:47447363	PSMC3	0.86	6.86	0.58	6.91e-10	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs911119	1.000	rs35488434	chr20:23620401	T/C	cg16589663	chr20:23618590	CST3	0.76	4.69	0.43	9.26e-6	Chronic kidney disease;
THYM	cis	rs595982	0.527	rs35087747	chr19:49377918	G/T	cg15549821	chr19:49342101	PLEKHA4	-0.92	-4.97	-0.45	3e-6	Red cell distribution width;
THYM	cis	rs6987853	0.787	rs2974346	chr8:42401205	T/C	cg09913449	chr8:42400586	C8orf40	1.09	12.3	0.78	2.28e-21	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg16586182	chr3:47516702	SCAP	-0.62	-5.42	-0.49	4.52e-7	Colorectal cancer;
THYM	cis	rs28595532	0.920	rs115838006	chr4:119754356	T/C	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs7772486	0.754	rs857881	chr6:145970793	C/A	cg13319975	chr6:146136371	FBXO30	0.63	5.17	0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9470366	0.545	rs4713999	chr6:36633069	A/G	cg11920449	chr6:36645608	CDKN1A	0.7	5.84	0.51	7.37e-8	QRS duration;
THYM	cis	rs9563576	0.778	rs9316967	chr13:58586097	G/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg03929089	chr4:120376271	NA	-0.94	-10.4	-0.73	2.34e-17	Coronary artery disease;
THYM	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg15744005	chr10:104629667	AS3MT	-0.83	-7.65	-0.62	1.61e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs12142240	0.698	rs1057535	chr1:46815898	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs2439831	0.850	rs3097773	chr15:43893072	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.77	-6.2	-0.54	1.46e-8	Lung cancer in ever smokers;
THYM	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg27494647	chr7:150038898	RARRES2	0.39	4.58	0.43	1.43e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.6	-0.5	2.08e-7	Type 2 diabetes;
THYM	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg27490568	chr2:178487706	NA	0.57	5.34	0.48	6.43e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg01616529	chr11:638424	DRD4	-0.74	-5.68	-0.5	1.48e-7	Systemic lupus erythematosus;
THYM	cis	rs7192750	0.586	rs1981874	chr16:71897244	C/T	cg06353428	chr16:71660113	MARVELD3	-0.71	-5.0	-0.46	2.62e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg08125733	chr17:73851984	WBP2	0.85	5.96	0.52	4.23e-8	Psoriasis;
THYM	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg19901468	chr14:105411992	AHNAK2	-0.82	-6.74	-0.57	1.24e-9	Rheumatoid arthritis;
THYM	cis	rs9649213	0.574	rs12873	chr7:97922773	T/C	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs792448	0.603	rs4951588	chr1:212500433	C/T	cg14523881	chr1:213164074	VASH2	0.58	4.62	0.43	1.19e-5	White blood cell count (basophil);
THYM	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg27398817	chr8:82754497	SNX16	-0.71	-6.05	-0.53	2.89e-8	Diastolic blood pressure;
THYM	cis	rs9467711	0.651	rs35506517	chr6:26044864	T/C	cg16898833	chr6:26189333	HIST1H4D	1.33	4.61	0.43	1.24e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg18127003	chr8:11614472	GATA4	-0.47	-4.56	-0.42	1.55e-5	Retinal vascular caliber;
THYM	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs752010	0.841	rs7519983	chr1:42083369	C/T	cg13396354	chr1:41153348	NA	-0.49	-4.73	-0.44	7.92e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg22907277	chr7:1156413	C7orf50	0.83	7.12	0.59	2.04e-10	Longevity;Endometriosis;
THYM	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.87	-6.05	-0.53	2.82e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06634786	chr22:41940651	POLR3H	-0.79	-5.87	-0.52	6.38e-8	Vitiligo;
THYM	cis	rs17470137	1.000	rs17470137	chr5:122531347	G/A	cg04547002	chr5:122551801	NA	0.65	4.62	0.43	1.22e-5	Aortic root size;
THYM	cis	rs990171	0.607	rs2192752	chr2:102769373	A/C	cg13315345	chr2:102803985	IL1RL2	-0.53	-4.46	-0.42	2.25e-5	Lymphocyte counts;
THYM	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3804749	0.966	rs3792369	chr3:122840731	C/T	cg10259872	chr3:122802215	PDIA5	-0.49	-5.46	-0.49	3.85e-7	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg14019146	chr3:50243930	SLC38A3	-0.6	-4.99	-0.46	2.74e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8014204	0.836	rs11159099	chr14:75235397	A/G	cg06637938	chr14:75390232	RPS6KL1	0.55	5.34	0.48	6.42e-7	Caffeine consumption;
THYM	cis	rs28595532	0.920	rs114162429	chr4:119741078	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg10224037	chr5:178157518	ZNF354A	0.97	8.11	0.64	1.8e-12	Neutrophil percentage of white cells;
THYM	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	4.49	0.42	2.03e-5	Axial length;
THYM	cis	rs8050907	0.744	rs11076843	chr16:4649955	T/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	-1.17	-4.87	-0.45	4.37e-6	Obesity-related traits;
THYM	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06850241	chr22:41845214	NA	-0.6	-5.36	-0.48	5.82e-7	Vitiligo;
THYM	cis	rs684232	0.666	rs366151	chr17:598311	A/C	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.39	-4.72	-0.44	8.25e-6	Prostate cancer;
THYM	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.77	7.13	0.59	1.95e-10	Personality dimensions;
THYM	cis	rs11608355	0.573	rs7970666	chr12:109793495	T/G	cg10504392	chr12:110044639	NA	0.54	5.04	0.46	2.21e-6	Neuroticism;
THYM	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg11214544	chr1:2391121	NA	-0.64	-6.06	-0.53	2.74e-8	Non-obstructive azoospermia;
THYM	cis	rs10752881	0.743	rs10737244	chr1:183098417	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Colorectal cancer;
THYM	cis	rs13256369	0.851	rs13266562	chr8:8564065	T/C	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06481639	chr22:41940642	POLR3H	0.86	5.86	0.52	6.56e-8	Vitiligo;
THYM	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs10782582	0.545	rs12138018	chr1:76186794	T/C	cg22875332	chr1:76189707	ACADM	-0.53	-4.83	-0.44	5.2e-6	Daytime sleep phenotypes;
THYM	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg04234412	chr22:24373322	LOC391322	-0.91	-9.25	-0.69	6.71e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg10802521	chr3:52805072	NEK4	-0.73	-6.21	-0.54	1.42e-8	Bipolar disorder;
THYM	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.68	-5.9	-0.52	5.63e-8	Renal function-related traits (BUN);
THYM	cis	rs2637266	0.783	rs1797500	chr10:78510400	G/A	cg18941641	chr10:78392320	NA	0.71	5.69	0.5	1.38e-7	Pulmonary function;
THYM	cis	rs7578361	0.918	rs1818997	chr2:150349931	G/A	cg17961725	chr2:150454027	NA	0.76	5.55	0.49	2.62e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs6835098	0.692	rs7657374	chr4:174065756	A/T	cg08422745	chr4:174089978	GALNT7	-0.92	-7.54	-0.61	2.73e-11	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03517284	chr6:25882590	NA	0.82	6.55	0.56	2.89e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg03433033	chr1:76189801	ACADM	0.8	10.81	0.74	3.15e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs28595532	0.841	rs56388366	chr4:119769242	A/G	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs6992820	0.967	rs13265995	chr8:56684796	C/A	cg06880721	chr8:56792545	LYN	-0.57	-4.45	-0.42	2.34e-5	Mean platelet volume;
THYM	cis	rs11229030	0.893	rs2581925	chr11:57207414	G/A	cg00522883	chr11:57194120	SLC43A3	-0.62	-4.91	-0.45	3.71e-6	Crohn's disease;
THYM	cis	rs61990749	0.597	rs9323650	chr14:78150336	A/G	cg23188588	chr14:78226832	SNW1;C14orf178	0.76	4.62	0.43	1.19e-5	Fibroblast growth factor basic levels;
THYM	cis	rs6076065	0.723	rs7988	chr20:23352685	C/A	cg11657817	chr20:23433608	CST11	0.31	4.57	0.42	1.48e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg01073479	chr16:3509474	NAT15	0.48	4.79	0.44	6.21e-6	Tuberculosis;
THYM	cis	rs11214589	0.870	rs10789942	chr11:113236199	C/T	cg14159747	chr11:113255604	NA	-0.37	-7.8	-0.63	7.76e-12	Neuroticism;
THYM	cis	rs2075371	0.835	rs1646724	chr7:134001875	T/G	cg11752832	chr7:134001865	SLC35B4	0.78	5.72	0.51	1.25e-7	Mean platelet volume;
THYM	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg06634786	chr22:41940651	POLR3H	-0.66	-4.85	-0.45	4.82e-6	Vitiligo;
THYM	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg00080972	chr5:178986291	RUFY1	-0.56	-7.01	-0.58	3.37e-10	Lung cancer;
THYM	cis	rs62103177	0.564	rs1715230	chr18:77848002	C/T	cg07235805	chr18:78004237	PARD6G	0.49	5.62	0.5	1.89e-7	Opioid sensitivity;
THYM	cis	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs2976388	0.587	rs2717606	chr8:143799496	G/A	cg06565975	chr8:143823917	SLURP1	0.5	5.62	0.5	1.9e-7	Urinary tract infection frequency;
THYM	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg02953382	chr22:24373134	LOC391322	-0.73	-6.6	-0.56	2.36e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg11764359	chr7:65958608	NA	-0.85	-7.43	-0.61	4.73e-11	Aortic root size;
THYM	cis	rs2050392	0.767	rs1536833	chr10:30699265	C/T	cg12408189	chr10:30722286	MAP3K8	0.58	5.19	0.47	1.2e-6	Inflammatory bowel disease;
THYM	cis	rs750134	0.901	rs3741781	chr12:109178003	C/A	cg07887608	chr12:109221600	SSH1	0.87	4.77	0.44	6.77e-6	Low high density lipoprotein cholesterol levels;
THYM	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg03388043	chr17:80084554	CCDC57	0.69	5.98	0.52	3.85e-8	Life satisfaction;
THYM	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg12408189	chr10:30722286	MAP3K8	0.58	5.19	0.47	1.2e-6	Inflammatory bowel disease;
THYM	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg24531977	chr5:56204891	C5orf35	-1.0	-8.34	-0.65	5.78e-13	Initial pursuit acceleration;
THYM	cis	rs9810089	0.814	rs834305	chr3:136119354	C/T	cg21827317	chr3:136751795	NA	0.59	5.18	0.47	1.26e-6	Gestational age at birth (child effect);
THYM	cis	rs9876781	1.000	rs4858817	chr3:48416756	A/G	cg06066452	chr3:48470258	PLXNB1	-0.25	-4.64	-0.43	1.12e-5	Longevity;
THYM	cis	rs7267979	0.668	rs4815398	chr20:25237338	C/T	cg08601574	chr20:25228251	PYGB	-0.62	-4.92	-0.45	3.61e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.51	0.81	7.55e-24	Height;
THYM	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg10334053	chr1:2078117	PRKCZ	-0.5	-5.01	-0.46	2.48e-6	Height;
THYM	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	7.86	0.63	6.06e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg00852783	chr1:26633632	UBXN11	0.69	5.79	0.51	9.09e-8	Monocyte percentage of white cells;
THYM	cis	rs6032067	0.516	rs57047308	chr20:43899974	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.39	-4.67	-0.43	9.85e-6	Blood protein levels;
THYM	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	4.56	0.42	1.5e-5	Bipolar disorder;
THYM	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg03351412	chr1:154909251	PMVK	0.73	5.58	0.5	2.27e-7	Prostate cancer;
THYM	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg26116260	chr4:7069785	GRPEL1	1.09	10.34	0.73	3.05e-17	Monocyte percentage of white cells;
THYM	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs9814567	0.752	rs6764764	chr3:134331167	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	6.83	0.57	7.97e-10	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2742234	0.541	rs1317214	chr10:43733531	C/G	cg06632098	chr10:43605906	RET	0.74	4.97	0.45	2.95e-6	Hirschsprung disease;
THYM	cis	rs4808199	0.895	rs2285628	chr19:19467996	T/A	cg03709012	chr19:19516395	GATAD2A	1.13	6.33	0.54	8.16e-9	Nonalcoholic fatty liver disease;
THYM	cis	rs713587	0.713	rs12466350	chr2:25239969	A/G	cg01884057	chr2:25150051	NA	0.57	5.86	0.52	6.56e-8	Body mass index in non-asthmatics;
THYM	cis	rs62158800	0.568	rs78879709	chr2:108373597	G/T	cg09155462	chr2:109189131	NA	1.11	4.51	0.42	1.86e-5	Facial morphology (factor 22);
THYM	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg06453172	chr10:134556979	INPP5A	-0.66	-4.77	-0.44	6.78e-6	Migraine;
THYM	cis	rs6942756	0.955	rs9641849	chr7:128899238	C/T	cg02491457	chr7:128862824	NA	-0.44	-4.53	-0.42	1.69e-5	White matter hyperintensity burden;
THYM	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg04025307	chr7:1156635	C7orf50	0.78	6.67	0.56	1.66e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs761746	0.960	rs5753667	chr22:31905703	G/A	cg10537193	chr22:32026975	PISD	0.4	5.17	0.47	1.3e-6	Intelligence;
THYM	trans	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs79387448	0.638	rs11465698	chr2:103054577	T/C	cg09003973	chr2:102972529	NA	1.02	5.74	0.51	1.13e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg18252515	chr7:66147081	NA	-1.65	-9.03	-0.68	1.94e-14	Diabetic kidney disease;
THYM	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg00717180	chr2:96193071	NA	-0.68	-6.98	-0.58	3.96e-10	HDL cholesterol;
THYM	cis	rs3857067	0.806	rs6825522	chr4:95108140	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg16325326	chr1:53192061	ZYG11B	0.93	10.11	0.72	9.54e-17	Monocyte count;
THYM	cis	rs2404602	0.647	rs36114653	chr15:77025393	G/A	cg23625390	chr15:77176239	SCAPER	-0.83	-5.57	-0.5	2.36e-7	Blood metabolite levels;
THYM	cis	rs10751667	0.961	rs7395303	chr11:986221	T/A	cg01483505	chr11:975446	AP2A2	0.63	4.98	0.45	2.88e-6	Alzheimer's disease (late onset);
THYM	cis	rs59698941	0.943	rs17691584	chr5:132284251	A/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.63	4.74	0.44	7.44e-6	Apolipoprotein A-IV levels;
THYM	cis	rs7084402	0.967	rs10826199	chr10:60274213	T/C	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg12311346	chr5:56204834	C5orf35	-0.81	-5.9	-0.52	5.54e-8	Initial pursuit acceleration;
THYM	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg16486109	chr11:613632	IRF7	0.48	5.38	0.48	5.31e-7	Systemic lupus erythematosus;
THYM	cis	rs10744422	0.920	rs897393	chr12:123312051	A/G	cg25930673	chr12:123319894	HIP1R	0.88	5.15	0.47	1.43e-6	Schizophrenia;
THYM	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg22433210	chr17:43662623	NA	-1.05	-8.08	-0.64	2e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs9788721	0.835	rs17487223	chr15:78923987	A/G	cg22563815	chr15:78856949	CHRNA5	0.6	4.56	0.42	1.55e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03576123	chr11:487126	PTDSS2	-1.23	-6.11	-0.53	2.16e-8	Body mass index;
THYM	cis	rs2997447	0.761	rs17184884	chr1:26446565	G/A	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg11845111	chr2:191398756	TMEM194B	0.95	8.42	0.65	3.95e-13	Pulse pressure;
THYM	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4866334	0.867	rs78519816	chr5:18463568	G/A	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs4077515	0.504	rs7628	chr9:139318071	A/G	cg14115884	chr9:139300582	SDCCAG3	0.7	6.09	0.53	2.35e-8	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs2898681	0.581	rs28618986	chr4:53677902	G/C	cg21521518	chr4:53727714	RASL11B	0.45	5.03	0.46	2.27e-6	Optic nerve measurement (cup area);
THYM	cis	rs861020	1.000	rs861020	chr1:209977111	A/G	cg05527609	chr1:210001259	C1orf107	1.02	7.78	0.62	8.75e-12	Orofacial clefts;
THYM	cis	rs8048589	0.615	rs12599107	chr16:12238602	G/A	cg02910054	chr16:12241554	SNX29	0.83	7.02	0.58	3.27e-10	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs2273669	0.504	rs75307211	chr6:109464284	G/A	cg17117243	chr6:109341365	SESN1	-0.85	-4.99	-0.46	2.77e-6	Prostate cancer;
THYM	cis	rs6430585	0.583	rs4988145	chr2:136632300	A/C	cg23851026	chr2:136556271	LCT	0.79	7.55	0.61	2.66e-11	Corneal structure;
THYM	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg25072359	chr17:41440525	NA	0.7	4.87	0.45	4.43e-6	Menopause (age at onset);
THYM	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg23583168	chr7:148888333	NA	-1.0	-13.2	-0.8	3.29e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs12142240	0.698	rs72677593	chr1:46824363	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg24060327	chr5:131705240	SLC22A5	0.74	5.38	0.48	5.28e-7	Blood metabolite levels;
THYM	cis	rs2219968	1.000	rs13248343	chr8:78975745	A/G	cg00738934	chr8:78996279	NA	0.91	9.74	0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg02527881	chr3:46936655	PTH1R	0.56	5.05	0.46	2.12e-6	Colorectal cancer;
THYM	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg06713675	chr4:122721982	EXOSC9	-0.51	-4.75	-0.44	7.13e-6	Type 2 diabetes;
THYM	cis	rs7769051	0.522	rs6930703	chr6:133111266	C/T	cg22852734	chr6:133119734	C6orf192	1.45	6.1	0.53	2.32e-8	Type 2 diabetes nephropathy;
THYM	cis	rs2069036	0.678	rs7894488	chr10:16120934	A/T	cg26633223	chr10:15133461	NA	0.72	5.25	0.47	9.44e-7	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs4285028	0.948	rs76593525	chr3:121690477	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.35	-0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs2075230	0.642	rs1642797	chr17:7543017	C/T	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.72	-0.44	8.04e-6	Hormone measurements;
THYM	cis	rs7107770	1.000	rs4935913	chr11:125103146	C/G	cg07747661	chr11:125106135	PKNOX2	-0.79	-4.85	-0.45	4.81e-6	Photic sneeze reflex;
THYM	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06850241	chr22:41845214	NA	-0.51	-4.83	-0.44	5.28e-6	Vitiligo;
THYM	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg10253484	chr15:75165896	SCAMP2	-0.63	-4.61	-0.43	1.23e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs17125944	0.686	rs7145242	chr14:53349842	G/A	cg00686598	chr14:53173677	PSMC6	-1.01	-4.55	-0.42	1.56e-5	Alzheimer's disease (late onset);
THYM	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg09307838	chr4:120376055	NA	-0.64	-4.7	-0.43	8.72e-6	Corneal astigmatism;
THYM	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg23161317	chr6:28129485	ZNF389	0.98	7.27	0.6	1.03e-10	Parkinson's disease;
THYM	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg13695892	chr22:41940480	POLR3H	-0.99	-7.48	-0.61	3.62e-11	Vitiligo;
THYM	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg17178900	chr1:205818956	PM20D1	0.99	10.59	0.74	9.28e-18	Menarche (age at onset);
THYM	cis	rs6838801	0.823	rs7677054	chr4:77594463	A/C	cg01477861	chr4:77609841	SHROOM3	0.47	4.71	0.43	8.6e-6	Cleft lip with or without cleft palate;
THYM	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs539096	0.831	rs650729	chr1:44042539	C/G	cg00143623	chr1:44495758	SLC6A9	0.68	5.38	0.48	5.23e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1962636	1	rs1962636	chr16:22064395	A/C	cg09370801	chr16:22207107	NA	0.59	5.12	0.47	1.58e-6	Schizophrenia;
THYM	cis	rs490234	0.588	rs35278449	chr9:128172963	C/G	cg13590414	chr9:128173245	NA	-0.58	-4.63	-0.43	1.15e-5	Mean arterial pressure;
THYM	cis	rs4474465	1.000	rs7950865	chr11:78157401	A/G	cg19901956	chr11:77921274	USP35	-0.61	-4.57	-0.42	1.46e-5	Alzheimer's disease (survival time);
THYM	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17443541	0.507	rs11677019	chr2:200468754	G/C	cg01795955	chr2:200468626	NA	-0.66	-4.59	-0.43	1.38e-5	Intelligence (multi-trait analysis);
THYM	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00908189	chr16:619842	PIGQ	1.03	9.46	0.7	2.34e-15	Height;
THYM	cis	rs7705042	0.865	rs7709361	chr5:141513854	T/C	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg06634786	chr22:41940651	POLR3H	0.69	4.94	0.45	3.31e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg18758796	chr5:131593413	PDLIM4	0.5	4.8	0.44	5.79e-6	Acylcarnitine levels;
THYM	cis	rs611744	0.647	rs631775	chr8:109252746	T/C	cg21045802	chr8:109455806	TTC35	0.66	5.99	0.52	3.78e-8	Dupuytren's disease;
THYM	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs34779708	0.931	rs34815241	chr10:35296676	T/C	cg03585969	chr10:35415529	CREM	0.64	4.5	0.42	1.93e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7688540	0.723	rs1986386	chr4:228809	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.74	4.51	0.42	1.88e-5	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs7586879	0.639	rs6545776	chr2:25099357	A/C	cg15423357	chr2:25149977	NA	0.65	6.93	0.58	4.99e-10	Body mass index;
THYM	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg08859206	chr1:53392774	SCP2	0.47	4.84	0.44	5.09e-6	Monocyte count;
THYM	cis	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg06636001	chr8:8085503	FLJ10661	0.69	5.71	0.51	1.28e-7	Neuroticism;
THYM	cis	rs11077998	0.903	rs8064554	chr17:80501093	A/G	cg11779900	chr17:80519722	FOXK2	-0.53	-4.52	-0.42	1.79e-5	Reticulocyte fraction of red cells;
THYM	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg17063962	chr7:91808500	NA	-1.12	-12.68	-0.79	3.85e-22	Breast cancer;
THYM	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	5.32	0.48	6.99e-7	Menarche (age at onset);
THYM	cis	rs7917772	0.582	rs4285804	chr10:104386309	T/A	cg00122347	chr10:104236741	TMEM180	0.38	5.5	0.49	3.26e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg17279839	chr7:150038598	RARRES2	0.56	5.45	0.49	3.92e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.57	-5.18	-0.47	1.23e-6	Type 2 diabetes;
THYM	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg10792982	chr14:105748885	BRF1	0.73	7.54	0.61	2.72e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2219968	1.000	rs7465474	chr8:78959166	C/T	cg00738934	chr8:78996279	NA	0.91	9.75	0.71	5.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs859767	0.704	rs7570717	chr2:135361035	C/T	cg12500956	chr2:135428796	TMEM163	-0.49	-4.95	-0.45	3.22e-6	Neuroticism;
THYM	cis	rs57545798	0.963	rs35116176	chr15:100639967	G/C	cg20941820	chr15:100882334	ADAMTS17	0.55	4.62	0.43	1.19e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs9790314	1.000	rs6775627	chr3:160953609	A/G	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs9359856	0.636	rs6454767	chr6:90317335	G/A	cg13799429	chr6:90582589	CASP8AP2	0.77	7.08	0.59	2.53e-10	Bipolar disorder;
THYM	cis	rs17598306	0.935	rs17598579	chr7:96590472	G/T	cg13449377	chr7:96631089	DLX6AS	0.76	4.78	0.44	6.38e-6	Radiation response;
THYM	cis	rs4523957	0.928	rs12943566	chr17:2157774	A/G	cg16513277	chr17:2031491	SMG6	0.79	7.41	0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.79	0.51	9.18e-8	Rheumatoid arthritis;
THYM	cis	rs35264875	1.000	rs1542334	chr11:68850773	G/C	cg01993067	chr11:68851601	TPCN2	1.0	5.3	0.48	7.4e-7	Blond vs. brown hair color;
THYM	cis	rs259282	0.538	rs8105481	chr19:33118095	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.61	4.6	0.43	1.29e-5	Schizophrenia;
THYM	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs977987	0.806	rs4993970	chr16:75411619	G/A	cg03315344	chr16:75512273	CHST6	0.71	6.13	0.53	1.96e-8	Dupuytren's disease;
THYM	cis	rs4499344	0.556	rs865659	chr19:33139967	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.93	6.54	0.56	3.01e-9	Mean platelet volume;
THYM	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg23428387	chr22:49814324	NA	-0.57	-5.97	-0.52	4.07e-8	Monocyte count;Monocyte percentage of white cells;
THYM	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg01341218	chr17:43662625	NA	-1.07	-9.27	-0.69	5.9e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.94	7.82	0.63	7.23e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7953249	0.656	rs2178463	chr12:121389721	A/G	cg14101638	chr12:121416612	HNF1A	-0.48	-5.23	-0.47	1.01e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs4455778	0.600	rs4404870	chr7:49078959	G/A	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs11123610	0.698	rs72769388	chr2:3725964	C/T	cg00999904	chr2:3704751	ALLC	-0.62	-4.76	-0.44	7.04e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs9649465	1.000	rs13224762	chr7:123370710	A/G	cg15443791	chr7:124364398	NA	0.6	4.97	0.45	3.01e-6	Migraine;
THYM	cis	rs4595586	0.545	rs925828	chr12:39364222	A/G	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs11585357	0.843	rs72633805	chr1:17617471	A/T	cg08277548	chr1:17600880	PADI3	-0.9	-5.43	-0.49	4.38e-7	Hair shape;
THYM	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-4.8	-0.44	5.91e-6	Schizophrenia;
THYM	cis	rs1215050	0.740	rs1084777	chr4:99017542	C/T	cg17366294	chr4:99064904	C4orf37	-0.41	-4.55	-0.42	1.56e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2882877	0.648	rs11680808	chr2:190376493	A/G	cg10752008	chr2:190445175	SLC40A1	0.74	6.23	0.54	1.25e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs539096	0.918	rs519669	chr1:44075505	G/C	cg00143623	chr1:44495758	SLC6A9	0.68	5.32	0.48	7e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3741151	0.656	rs12290785	chr11:73259012	G/T	cg12959048	chr11:73096162	RELT	-0.52	-4.58	-0.43	1.43e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6032067	0.777	rs34855539	chr20:43799036	T/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs2637266	0.783	rs2583070	chr10:78518555	C/T	cg18941641	chr10:78392320	NA	0.68	5.52	0.49	2.9e-7	Pulmonary function;
THYM	cis	rs6876348	0.543	rs257899	chr5:128314616	G/A	cg02841155	chr5:128301328	SLC27A6	-0.5	-4.86	-0.45	4.54e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg11764359	chr7:65958608	NA	0.62	4.73	0.44	7.94e-6	Aortic root size;
THYM	cis	rs7769051	0.522	rs60133731	chr6:133095818	T/C	cg22852734	chr6:133119734	C6orf192	1.59	7.01	0.58	3.47e-10	Type 2 diabetes nephropathy;
THYM	cis	rs11112613	0.713	rs11112586	chr12:105939816	C/T	cg03607813	chr12:105948248	NA	1.0	8.61	0.66	1.53e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs1691799	0.899	rs1168294	chr12:66733988	T/C	cg16791601	chr12:66731901	HELB	-0.76	-7.14	-0.59	1.9e-10	White blood cell count (basophil);
THYM	cis	rs765787	0.530	rs28524974	chr15:45543528	C/T	cg24006582	chr15:45444508	DUOX1	-0.84	-7.23	-0.6	1.23e-10	Uric acid levels;
THYM	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg06009448	chr7:1102226	C7orf50	0.52	5.44	0.49	4.1e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1003719	0.788	rs2835575	chr21:38455936	A/G	cg01329690	chr21:38580129	DSCR9	0.39	5.25	0.47	9.23e-7	Eye color traits;
THYM	cis	rs17407555	0.741	rs12509713	chr4:10107069	C/T	cg00071950	chr4:10020882	SLC2A9	-0.57	-5.23	-0.47	1.01e-6	Schizophrenia (age at onset);
THYM	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg19507638	chr5:93509721	C5orf36	-0.67	-4.48	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs870825	0.616	rs7692367	chr4:185651056	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg17554472	chr22:41940697	POLR3H	-0.71	-4.8	-0.44	5.87e-6	Vitiligo;
THYM	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg03388025	chr16:89894329	SPIRE2	0.54	4.54	0.42	1.67e-5	Vitiligo;
THYM	cis	rs950776	0.790	rs2067808	chr15:78911780	G/A	cg06917634	chr15:78832804	PSMA4	0.86	6.97	0.58	4.2e-10	Sudden cardiac arrest;
THYM	cis	rs9287719	0.747	rs1534400	chr2:10696833	T/C	cg03983476	chr2:10830698	NOL10	-0.54	-4.71	-0.44	8.47e-6	Prostate cancer;
THYM	cis	rs7809950	0.648	rs114452520	chr7:107176780	C/T	cg23024343	chr7:107201750	COG5	-0.94	-8.59	-0.66	1.7e-13	Coronary artery disease;
THYM	cis	rs7731657	0.518	rs115937761	chr5:130379766	C/A	cg08523029	chr5:130500466	HINT1	-0.82	-5.21	-0.47	1.1e-6	Fasting plasma glucose;
THYM	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg04546413	chr19:29218101	NA	0.97	6.81	0.57	8.69e-10	Methadone dose in opioid dependence;
THYM	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9595908	1.000	rs3742320	chr13:33164418	G/A	cg12383807	chr13:33924137	NA	-0.53	-4.71	-0.43	8.6e-6	Body mass index;
THYM	cis	rs1348850	0.526	rs4144278	chr2:178412378	C/T	cg27490568	chr2:178487706	NA	0.62	5.0	0.46	2.6e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg24846343	chr22:24311635	DDTL	0.41	5.47	0.49	3.63e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11169225	0.906	rs399023	chr12:50338952	A/C	cg04450003	chr12:50355995	AQP5	0.95	7.64	0.62	1.7e-11	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg24253500	chr15:84953950	NA	0.6	5.01	0.46	2.5e-6	Schizophrenia;
THYM	cis	rs4911259	0.552	rs62208880	chr20:31463284	T/C	cg13636640	chr20:31349939	DNMT3B	-0.63	-6.18	-0.54	1.61e-8	Inflammatory bowel disease;
THYM	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg14008862	chr17:28927542	LRRC37B2	0.85	4.47	0.42	2.18e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs34779708	0.966	rs17499811	chr10:35456215	G/A	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-7.08	-0.59	2.42e-10	Chronic sinus infection;
THYM	trans	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg10856724	chr12:34555212	NA	-1.0	-8.86	-0.67	4.42e-14	Bladder cancer;
THYM	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6840360	0.967	rs6535815	chr4:152609700	A/C	cg22705602	chr4:152727874	NA	-0.56	-6.1	-0.53	2.31e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg05368731	chr17:41323189	NBR1	1.2	10.93	0.75	1.72e-18	Menopause (age at onset);
THYM	cis	rs9914988	0.832	rs35033748	chr17:27179590	T/C	cg20469991	chr17:27169893	C17orf63	-0.81	-5.28	-0.48	8.08e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs910187	0.678	rs6122563	chr20:45813885	C/T	cg27589058	chr20:45804311	EYA2	-0.59	-5.07	-0.46	1.95e-6	Migraine;
THYM	cis	rs1670533	1.000	rs11725984	chr4:1087338	C/T	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.44	0.7	2.59e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3820068	0.580	rs36100011	chr1:16046920	C/T	cg05660106	chr1:15850417	CASP9	0.72	5.67	0.5	1.54e-7	Systolic blood pressure;
THYM	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg10523679	chr1:76189770	ACADM	0.83	6.95	0.58	4.61e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6047844	0.722	rs6113518	chr20:22086439	G/A	cg16502866	chr20:23015624	SSTR4	-0.57	-4.47	-0.42	2.12e-5	Male-pattern baldness;
THYM	cis	rs7666738	0.924	rs11097592	chr4:98927532	C/T	cg07917127	chr4:99064746	C4orf37	0.59	4.5	0.42	1.93e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs1784581	0.631	rs3016544	chr6:162393065	T/C	cg17173639	chr6:162384350	PARK2	-0.85	-7.71	-0.62	1.25e-11	Itch intensity from mosquito bite;
THYM	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg01557791	chr16:72042693	DHODH	0.64	5.33	0.48	6.58e-7	Prostate cancer;
THYM	cis	rs870825	0.616	rs6825561	chr4:185615532	A/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs969413	0.624	rs7213540	chr17:79255912	C/T	cg15215033	chr17:79258732	SLC38A10	0.37	4.6	0.43	1.31e-5	Frontotemporal dementia;
THYM	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.17	-18.68	-0.89	1.42e-33	Chronic sinus infection;
THYM	cis	rs35883536	0.647	rs945329	chr1:101084273	C/T	cg09408571	chr1:101003634	GPR88	-0.42	-4.5	-0.42	1.91e-5	Monocyte count;
THYM	cis	rs4975616	0.773	rs10078017	chr5:1314009	C/T	cg07493874	chr5:1342172	CLPTM1L	0.74	6.36	0.55	7.11e-9	Lung cancer;
THYM	cis	rs1448094	0.512	rs7299285	chr12:86244959	A/T	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs62435770	1.000	rs62433597	chr6:169519543	A/G	cg07652237	chr6:170125491	PHF10	0.55	4.91	0.45	3.84e-6	Loneliness;
THYM	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs1448094	0.511	rs17280643	chr12:86210154	C/T	cg00310523	chr12:86230176	RASSF9	-0.52	-4.69	-0.43	9.28e-6	Major depressive disorder;
THYM	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg15557168	chr22:42548783	NA	-0.59	-4.76	-0.44	6.99e-6	Schizophrenia;
THYM	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg24812749	chr6:127587940	RNF146	-0.91	-7.09	-0.59	2.36e-10	Breast cancer;
THYM	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg11327659	chr7:150037044	RARRES2	0.42	5.17	0.47	1.29e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs3026101	0.624	rs1806255	chr17:5314263	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.57	5.19	0.47	1.18e-6	Body mass index;
THYM	cis	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg09085632	chr11:111637200	PPP2R1B	1.19	12.92	0.8	1.2e-22	Primary sclerosing cholangitis;
THYM	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg11494091	chr17:61959527	GH2	1.07	17.57	0.87	1.34e-31	Prudent dietary pattern;
THYM	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg18252515	chr7:66147081	NA	-1.44	-8.7	-0.67	9.82e-14	Diabetic kidney disease;
THYM	cis	rs11030122	0.702	rs995498	chr11:3967791	A/G	cg22027985	chr11:4115532	RRM1	-0.48	-4.59	-0.43	1.36e-5	Mean platelet volume;Platelet distribution width;
THYM	cis	rs35883536	1.000	rs2297716	chr1:101092526	G/C	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg03188948	chr7:1209495	NA	0.67	5.25	0.47	9.18e-7	Longevity;Endometriosis;
THYM	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg12826209	chr6:26865740	GUSBL1	0.99	5.61	0.5	1.95e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg08645402	chr16:4508243	NA	-0.63	-5.52	-0.49	2.89e-7	Schizophrenia;
THYM	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg13695892	chr22:41940480	POLR3H	-0.87	-6.35	-0.55	7.28e-9	Vitiligo;
THYM	cis	rs798766	1.000	rs798754	chr4:1720757	A/G	cg00006948	chr4:1768889	NA	-0.92	-5.24	-0.47	9.51e-7	Bladder cancer;Urinary bladder cancer;
THYM	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.3	-0.48	7.34e-7	Monocyte percentage of white cells;
THYM	cis	rs7084402	1.000	rs717452	chr10:60268270	A/G	cg07615347	chr10:60278583	BICC1	0.55	4.99	0.46	2.69e-6	Refractive error;
THYM	cis	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-5.83	-0.51	7.47e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2658782	0.724	rs2605626	chr11:93253903	A/G	cg15737290	chr11:93063684	CCDC67	1.02	7.8	0.62	8e-12	Pulmonary function decline;
THYM	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg05043794	chr9:111880884	C9orf5	-0.41	-6.15	-0.53	1.8e-8	Menarche (age at onset);
THYM	cis	rs7635879	0.533	rs12486721	chr3:193744854	A/G	cg01524723	chr3:193718032	NA	-0.58	-4.62	-0.43	1.2e-5	Breastfeeding duration;
THYM	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11890956	chr21:40555474	PSMG1	1.07	10.39	0.73	2.41e-17	Cognitive function;
THYM	cis	rs2046867	0.819	rs34132129	chr3:72829100	A/G	cg25664220	chr3:72788482	NA	-0.85	-6.63	-0.56	2.01e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05901451	chr6:126070800	HEY2	0.87	8.73	0.67	8.42e-14	Brugada syndrome;
THYM	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg05043794	chr9:111880884	C9orf5	-0.43	-6.31	-0.54	8.79e-9	Menarche (age at onset);
THYM	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg17366294	chr4:99064904	C4orf37	0.54	6.33	0.54	8.05e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6882076	1.000	rs6874202	chr5:156391628	T/C	cg12943317	chr5:156479607	HAVCR1	-0.72	-5.96	-0.52	4.36e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs6840360	0.571	rs62327277	chr4:152555905	C/T	cg17479576	chr4:152424074	FAM160A1	-0.79	-5.55	-0.49	2.59e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.777	rs34233258	chr20:43788265	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs3820068	0.581	rs6429762	chr1:15945595	A/C	cg05660106	chr1:15850417	CASP9	0.77	6.49	0.55	3.79e-9	Systolic blood pressure;
THYM	cis	rs3768617	0.510	rs2296291	chr1:183079509	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg01252526	chr16:711033	WDR90	0.69	6.47	0.55	4.16e-9	Height;
THYM	cis	rs2013441	0.866	rs7207817	chr17:20221328	A/G	cg20830565	chr17:20408647	MGC102966	0.5	4.46	0.42	2.22e-5	Obesity-related traits;
THYM	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg11871910	chr12:69753446	YEATS4	1.06	9.77	0.71	5.01e-16	Blood protein levels;
THYM	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg14129053	chr2:1895732	MYT1L	1.13	4.49	0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.61	-0.43	1.27e-5	Type 2 diabetes;
THYM	cis	rs11726022	1.000	rs11726022	chr4:188170467	A/G	cg09690449	chr4:187998952	NA	0.43	4.46	0.42	2.27e-5	Systolic blood pressure (cigarette smoking interaction);
THYM	cis	rs9790314	1.000	rs9790314	chr3:161019558	T/C	cg04691961	chr3:161091175	C3orf57	-0.53	-4.55	-0.42	1.56e-5	Morning vs. evening chronotype;
THYM	cis	rs8040855	1.000	rs8040855	chr15:85699207	G/C	cg04831495	chr15:85060580	GOLGA6L5	0.56	4.49	0.42	1.99e-5	Bulimia nervosa;
THYM	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs9929218	0.529	rs8059194	chr16:68749663	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.08	13.26	0.81	2.45e-23	Colorectal cancer;
THYM	cis	rs4731207	0.596	rs6466982	chr7:124656788	G/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.0	-5.33	-0.48	6.57e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg12016809	chr21:47604291	C21orf56	0.66	4.83	0.44	5.24e-6	Testicular germ cell tumor;
THYM	cis	rs6665290	0.836	rs56029302	chr1:227203390	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.12	-14.77	-0.83	2.42e-26	Myeloid white cell count;
THYM	cis	rs289828	0.579	rs10210155	chr2:152158424	A/G	cg05960677	chr2:152117363	RBM43	0.69	6.56	0.56	2.86e-9	Blood protein levels;
THYM	cis	rs2073300	0.609	rs6137936	chr20:23385232	C/T	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs17511627	0.755	rs7985782	chr13:26746409	C/G	cg13319468	chr13:27597730	NA	-0.68	-5.38	-0.48	5.34e-7	Alzheimer's disease;
THYM	cis	rs240764	0.817	rs240147	chr6:101078300	G/A	cg21058520	chr6:100914733	NA	-0.57	-5.06	-0.46	2.04e-6	Neuroticism;
THYM	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg21926883	chr2:100939477	LONRF2	-0.65	-5.97	-0.52	4.11e-8	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.67	-0.81	3.71e-24	Height;
THYM	cis	rs4731207	0.698	rs10085888	chr7:124486391	T/C	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg25358565	chr5:93447407	FAM172A	1.34	10.5	0.73	1.44e-17	Diabetic retinopathy;
THYM	cis	rs2124969	0.527	rs72982044	chr2:161049395	G/A	cg03641300	chr2:160917029	PLA2R1	-0.67	-4.69	-0.43	8.99e-6	Waist circumference adjusted for body mass index;
THYM	cis	rs763014	0.932	rs4984898	chr16:641164	G/T	cg07343612	chr16:622815	PIGQ	-1.15	-12.08	-0.78	6.5e-21	Height;
THYM	cis	rs939658	1.000	rs11072826	chr15:79461516	C/T	cg17916960	chr15:79447300	NA	0.75	8.75	0.67	7.74e-14	Refractive error;
THYM	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg11366901	chr6:160182831	ACAT2	1.08	9.54	0.7	1.56e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg17178900	chr1:205818956	PM20D1	0.93	9.43	0.7	2.75e-15	Menarche (age at onset);
THYM	cis	rs9902453	0.904	rs4461132	chr17:28423430	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.85	6.74	0.57	1.24e-9	Coffee consumption (cups per day);
THYM	cis	rs6748734	0.625	rs4675871	chr2:241823849	G/A	cg02820040	chr2:241836501	C2orf54	-0.24	-4.55	-0.42	1.61e-5	Urinary metabolites;
THYM	cis	rs6570726	0.967	rs418662	chr6:145848832	A/C	cg23711669	chr6:146136114	FBXO30	0.75	6.81	0.57	8.76e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg12560992	chr17:57184187	TRIM37	0.93	8.87	0.67	4.31e-14	Intelligence (multi-trait analysis);
THYM	cis	rs11645898	0.935	rs11647125	chr16:72243277	T/C	cg03805757	chr16:71968109	PKD1L3	-0.74	-5.62	-0.5	1.92e-7	Blood protein levels;
THYM	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg01483505	chr11:975446	AP2A2	0.57	4.53	0.42	1.73e-5	Alzheimer's disease (late onset);
THYM	cis	rs7246967	0.673	rs34425596	chr19:22899779	T/C	cg05241461	chr19:22816980	ZNF492	0.6	4.66	0.43	1.05e-5	Bronchopulmonary dysplasia;
THYM	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg13695892	chr22:41940480	POLR3H	0.95	7.68	0.62	1.4e-11	Vitiligo;
THYM	cis	rs7512552	0.966	rs2147324	chr1:150255587	T/C	cg15654264	chr1:150340011	RPRD2	-0.5	-5.92	-0.52	5.2100000000000003e-08	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs40363	0.720	rs4453493	chr16:3533881	T/C	cg05754148	chr16:3507555	NAT15	-0.58	-5.15	-0.47	1.41e-6	Tuberculosis;
THYM	cis	rs79349575	0.651	rs4378658	chr17:46993370	G/A	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs13082711	0.522	rs653886	chr3:27343549	C/T	cg02860705	chr3:27208620	NA	0.65	5.07	0.46	1.94e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9660180	0.967	rs10907191	chr1:1774820	A/T	cg23982607	chr1:1823379	GNB1	-0.94	-10.26	-0.73	4.58e-17	Body mass index;
THYM	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg17264618	chr3:40429014	ENTPD3	-0.53	-5.08	-0.46	1.86e-6	Renal cell carcinoma;
THYM	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg17863274	chr19:49399704	TULP2	-1.0	-6.15	-0.53	1.85e-8	Red cell distribution width;
THYM	trans	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.78	7.85	0.63	6.23e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg22913843	chr11:65353092	EHBP1L1	-0.59	-4.57	-0.42	1.45e-5	Eosinophil percentage of white cells;
THYM	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg19678392	chr7:94953810	PON1	-0.73	-5.92	-0.52	5.07e-8	Paraoxonase activity;
THYM	cis	rs6964587	0.839	rs2049314	chr7:91464134	C/T	cg22709100	chr7:91322751	NA	0.66	4.93	0.45	3.52e-6	Breast cancer;
THYM	cis	rs6539288	0.933	rs759605	chr12:107307179	T/C	cg26297688	chr12:107349093	C12orf23	-0.47	-4.89	-0.45	4.15e-6	Total body bone mineral density;
THYM	cis	rs7084402	0.905	rs7914888	chr10:60308558	T/C	cg09696939	chr10:60272079	BICC1	0.47	5.54	0.49	2.65e-7	Refractive error;
THYM	cis	rs988913	0.957	rs10485136	chr6:54756495	A/G	cg18532076	chr6:54711417	FAM83B	-0.47	-4.56	-0.42	1.55e-5	Menarche (age at onset);
THYM	cis	rs2075230	0.850	rs78553499	chr17:7478498	G/A	cg10509001	chr17:7553872	ATP1B2	0.59	4.69	0.43	9e-6	Hormone measurements;
THYM	cis	rs951188	0.688	rs13412063	chr2:150436841	C/T	cg17961725	chr2:150454027	NA	-0.95	-5.09	-0.46	1.81e-6	Daytime sleep phenotypes;
THYM	cis	rs10851411	0.789	rs12898937	chr15:42770853	G/A	cg04308337	chr15:42867303	STARD9	-0.62	-4.68	-0.43	9.42e-6	Glucose homeostasis traits;
THYM	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg11266682	chr4:10021025	SLC2A9	0.73	12.79	0.8	2.29e-22	Bone mineral density;
THYM	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg23711669	chr6:146136114	FBXO30	0.86	8.06	0.64	2.28e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs289828	0.868	rs3771887	chr2:152138749	A/T	cg05960677	chr2:152117363	RBM43	0.61	6.05	0.53	2.89e-8	Blood protein levels;
THYM	cis	rs7578361	0.918	rs1918250	chr2:150364015	G/A	cg17961725	chr2:150454027	NA	0.74	5.41	0.48	4.79e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs12586317	0.620	rs58320987	chr14:35587726	T/C	cg16230307	chr14:35515116	FAM177A1	0.92	5.88	0.52	5.99e-8	Psoriasis;
THYM	cis	rs2637266	0.935	rs1978927	chr10:78399786	A/T	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	11.96	0.78	1.18e-20	Chronic sinus infection;
THYM	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	4.79	0.44	6.04e-6	Menarche (age at onset);
THYM	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg24675056	chr1:15929824	NA	0.71	5.65	0.5	1.68e-7	Systolic blood pressure;
THYM	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg26028573	chr6:26043587	HIST1H2BB	0.52	4.56	0.42	1.51e-5	Blood metabolite levels;
THYM	cis	rs2075230	1.000	rs2075230	chr17:7487108	A/G	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	0.29	4.46	0.42	2.27e-5	Hormone measurements;
THYM	cis	rs7191439	0.584	rs8048897	chr16:88744470	T/G	cg27087555	chr16:88793112	FAM38A	-1.34	-6.1	-0.53	2.26e-8	Plateletcrit;
THYM	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg12386194	chr3:101231763	SENP7	0.66	5.0	0.46	2.59e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg27284194	chr4:1044797	NA	0.63	4.73	0.44	7.94e-6	Recombination rate (females);
THYM	cis	rs470093	1.000	rs138127	chr22:44272236	C/G	cg09142166	chr22:44276013	PNPLA5	0.58	5.83	0.51	7.65e-8	Staphylococcus aureus infection;
THYM	trans	rs9929218	0.817	rs3114400	chr16:68719430	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.0	-8.22	-0.64	1.06e-12	Colorectal cancer;
THYM	cis	rs12410462	0.581	rs7541809	chr1:227547299	G/A	cg04117972	chr1:227635322	NA	0.77	4.7	0.43	8.68e-6	Major depressive disorder;
THYM	cis	rs7179456	0.557	rs446126	chr15:59113102	A/G	cg05156742	chr15:59063176	FAM63B	0.58	4.95	0.45	3.22e-6	Asperger disorder;
THYM	cis	rs7727544	0.582	rs3749756	chr5:131534499	C/T	cg16205897	chr5:131564050	P4HA2	-0.45	-4.51	-0.42	1.83e-5	Blood metabolite levels;
THYM	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg11764359	chr7:65958608	NA	-0.83	-6.96	-0.58	4.35e-10	Aortic root size;
THYM	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.86	-4.7	-0.43	8.9e-6	Body mass index;
THYM	cis	rs8067545	0.586	rs2526478	chr17:20130452	A/G	cg20830565	chr17:20408647	MGC102966	-0.49	-4.57	-0.42	1.49e-5	Schizophrenia;
THYM	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.26	10.1	0.72	1.01e-16	Platelet count;
THYM	cis	rs910187	0.605	rs6063079	chr20:45804275	C/G	cg27589058	chr20:45804311	EYA2	-0.74	-6.95	-0.58	4.64e-10	Migraine;
THYM	cis	rs28595532	0.920	rs114243409	chr4:119756585	C/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg12311346	chr5:56204834	C5orf35	-0.94	-5.44	-0.49	4.07e-7	Type 2 diabetes;
THYM	cis	rs6084875	0.932	rs6084856	chr20:4728491	G/A	cg19614321	chr20:4804581	RASSF2	-0.46	-4.63	-0.43	1.16e-5	Systemic lupus erythematosus;
THYM	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg11764359	chr7:65958608	NA	-0.74	-6.15	-0.53	1.85e-8	Aortic root size;
THYM	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg13918804	chr1:2043761	PRKCZ	0.83	7.31	0.6	8.31e-11	Height;
THYM	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg00376283	chr12:123451042	ABCB9	0.71	4.64	0.43	1.11e-5	Neutrophil percentage of white cells;
THYM	cis	rs1692580	0.846	rs377599	chr1:2164699	C/T	cg24578937	chr1:2090814	PRKCZ	0.53	5.38	0.48	5.24e-7	Coronary artery disease;
THYM	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	4.56	0.42	1.5e-5	Bipolar disorder;
THYM	cis	rs10504073	0.647	rs56057508	chr8:49982793	G/T	cg00325661	chr8:49890786	NA	1.0	9.8	0.71	4.49e-16	Blood metabolite ratios;
THYM	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg09263875	chr16:632152	PIGQ	0.7	5.71	0.51	1.27e-7	Height;
THYM	cis	rs7072216	0.763	rs2274243	chr10:100175267	T/C	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs11997175	0.550	rs10954943	chr8:33815972	A/G	ch.8.33884649F	chr8:33765107	NA	0.7	5.4	0.48	5e-7	Body mass index;
THYM	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg02725872	chr8:58115012	NA	-1.09	-8.15	-0.64	1.43e-12	Developmental language disorder (linguistic errors);
THYM	cis	rs3017493	0.786	rs78344725	chr11:70687830	G/A	cg19942459	chr11:70508110	SHANK2	1.26	7.38	0.6	5.94e-11	Renal transplant outcome;
THYM	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg05335186	chr13:53173507	NA	-0.46	-5.6	-0.5	2.11e-7	Lewy body disease;
THYM	cis	rs4780401	0.755	rs8191297	chr16:11766986	T/C	cg01061890	chr16:11836724	TXNDC11	-0.63	-4.86	-0.45	4.62e-6	Rheumatoid arthritis;
THYM	cis	rs240764	0.658	rs4840147	chr6:101182323	T/C	cg21058520	chr6:100914733	NA	0.56	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg04455712	chr21:45112962	RRP1B	0.54	5.04	0.46	2.22e-6	Mean corpuscular volume;
THYM	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg08736216	chr1:53307985	ZYG11A	-0.62	-5.5	-0.49	3.22e-7	Monocyte count;
THYM	cis	rs7582180	0.627	rs2241811	chr2:101011724	C/T	cg21926883	chr2:100939477	LONRF2	-0.67	-6.27	-0.54	1.04e-8	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg02725872	chr8:58115012	NA	-0.89	-5.27	-0.48	8.45e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg16586182	chr3:47516702	SCAP	-0.61	-5.25	-0.47	9.2e-7	Colorectal cancer;
THYM	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg12564285	chr5:131593104	PDLIM4	-0.44	-4.83	-0.44	5.29e-6	Breast cancer;
THYM	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs981844	0.857	rs62325141	chr4:154716407	A/G	cg09973105	chr4:154681532	RNF175	-0.65	-5.58	-0.5	2.27e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs490234	0.812	rs12351825	chr9:128265736	T/C	cg14078157	chr9:128172775	NA	-0.66	-5.6	-0.5	2.1e-7	Mean arterial pressure;
THYM	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg02038168	chr22:39784481	NA	-0.68	-4.84	-0.45	4.92e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.53	0.49	2.84e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg07157834	chr1:205819609	PM20D1	0.53	4.72	0.44	7.98e-6	Menarche (age at onset);
THYM	cis	rs17270561	0.541	rs2009610	chr6:25967068	C/T	cg17691542	chr6:26056736	HIST1H1C	0.91	5.33	0.48	6.66e-7	Iron status biomarkers;
THYM	cis	rs11711311	1.000	rs11711311	chr3:113430599	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.27	-0.48	8.41e-7	IgG glycosylation;
THYM	cis	rs4866334	1.000	rs74720949	chr5:18503571	T/C	cg04591469	chr5:17810299	NA	-1.14	-4.6	-0.43	1.28e-5	IgG glycosylation;
THYM	cis	rs10089	0.953	rs4836359	chr5:127385518	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.97	6.65	0.56	1.82e-9	Ileal carcinoids;
THYM	cis	rs1801251	0.711	rs778368	chr2:233745333	G/C	cg25237894	chr2:233734115	C2orf82	-0.37	-5.2	-0.47	1.12e-6	Coronary artery disease;
THYM	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.0	-0.46	2.64e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg24675056	chr1:15929824	NA	0.72	5.71	0.51	1.26e-7	Systolic blood pressure;
THYM	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg22166914	chr1:53195759	ZYG11B	-0.76	-8.12	-0.64	1.72e-12	Monocyte count;
THYM	cis	rs6032067	0.929	rs35880287	chr20:43821001	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.58	-0.56	2.55e-9	Blood protein levels;
THYM	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg16342193	chr10:102329863	NA	-0.5	-5.13	-0.47	1.54e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4660456	0.572	rs1008204	chr1:41165861	A/C	cg11417323	chr1:41160271	NFYC	0.42	4.69	0.43	9.05e-6	Platelet count;
THYM	cis	rs12681287	0.752	rs4534114	chr8:87271956	A/G	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.6	5.48	0.49	3.44e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs8133932	0.701	rs6518258	chr21:47281829	C/T	cg08707771	chr21:46690014	POFUT2	-0.76	-4.62	-0.43	1.22e-5	Schizophrenia;
THYM	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg17264618	chr3:40429014	ENTPD3	0.52	4.94	0.45	3.33e-6	Renal cell carcinoma;
THYM	cis	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg21775007	chr8:11205619	TDH	-0.73	-5.68	-0.5	1.49e-7	Retinal vascular caliber;
THYM	cis	rs6443245	0.611	rs2648385	chr3:9618767	T/C	cg20517764	chr3:9027454	SRGAP3	-0.6	-4.56	-0.42	1.51e-5	Daytime sleep phenotypes;
THYM	cis	rs8048589	1.000	rs8048589	chr16:12185810	A/G	cg02910054	chr16:12241554	SNX29	0.69	5.64	0.5	1.77e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs295137	0.836	rs1217429	chr2:201094151	G/T	cg03447810	chr2:200324230	SATB2	0.61	4.66	0.43	1.04e-5	Asthma (bronchodilator response);
THYM	cis	rs6918586	0.616	rs198836	chr6:26113616	T/A	cg12310025	chr6:25882481	NA	0.68	5.49	0.49	3.3e-7	Schizophrenia;
THYM	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg06481639	chr22:41940642	POLR3H	-0.83	-6.19	-0.54	1.55e-8	Vitiligo;
THYM	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg26384229	chr12:38710491	ALG10B	1.03	9.92	0.71	2.51e-16	Heart rate;
THYM	cis	rs1050631	0.592	rs1785921	chr18:33737196	A/C	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.58	4.56	0.42	1.54e-5	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg02640540	chr1:67518911	SLC35D1	-0.64	-4.68	-0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg19442545	chr10:75533431	FUT11	-0.53	-5.63	-0.5	1.82e-7	Inflammatory bowel disease;
THYM	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06634786	chr22:41940651	POLR3H	0.84	6.24	0.54	1.21e-8	Vitiligo;
THYM	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg02734326	chr4:10020555	SLC2A9	-0.72	-6.37	-0.55	6.8e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs6728642	0.708	rs115507803	chr2:97752054	T/C	cg26665480	chr2:98280029	ACTR1B	-0.96	-4.64	-0.43	1.1e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg26384229	chr12:38710491	ALG10B	0.94	7.62	0.62	1.86e-11	Bladder cancer;
THYM	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.43	0.7	2.73e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg21775007	chr8:11205619	TDH	-0.73	-5.68	-0.5	1.49e-7	Retinal vascular caliber;
THYM	cis	rs6496667	0.779	rs8033512	chr15:90945307	A/T	cg22089800	chr15:90895588	ZNF774	0.76	4.9	0.45	4.01e-6	Rheumatoid arthritis;
THYM	cis	rs7809950	0.773	rs62483722	chr7:107186349	C/T	cg23024343	chr7:107201750	COG5	-0.93	-8.53	-0.66	2.33e-13	Coronary artery disease;
THYM	cis	rs7560272	0.723	rs6722867	chr2:73816285	A/G	cg19565262	chr2:73869966	NAT8	-0.59	-4.87	-0.45	4.53e-6	Schizophrenia;
THYM	cis	rs10911251	0.546	rs3359	chr1:183112041	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	4.74	0.44	7.63e-6	Colorectal cancer;
THYM	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg03188948	chr7:1209495	NA	0.91	5.04	0.46	2.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3008870	1.000	rs3008855	chr1:67386204	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.86	-7.07	-0.59	2.59e-10	Lymphocyte percentage of white cells;
THYM	cis	rs7428297	0.943	rs36047743	chr3:127074189	C/T	cg21487550	chr3:127056955	NA	0.73	4.58	0.42	1.43e-5	Clozapine-induced agranulocytosis;
THYM	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg26384229	chr12:38710491	ALG10B	0.91	7.02	0.58	3.28e-10	Morning vs. evening chronotype;
THYM	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11890956	chr21:40555474	PSMG1	-0.66	-6.38	-0.55	6.51e-9	Menarche (age at onset);
THYM	cis	rs714031	0.934	rs4820387	chr22:40070446	A/G	cg21377881	chr22:40064566	CACNA1I	-0.55	-4.97	-0.45	2.95e-6	Schizophrenia;
THYM	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs2213920	0.522	rs7847118	chr9:118199763	T/C	cg13918206	chr9:118159781	DEC1	0.86	4.9	0.45	3.86e-6	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs763014	0.931	rs62030903	chr16:638323	T/A	cg00908189	chr16:619842	PIGQ	1.16	11.18	0.75	5.05e-19	Height;
THYM	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs28374715	0.532	rs7164211	chr15:41705041	A/T	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.93	-0.84	1.16e-26	Ulcerative colitis;
THYM	cis	rs10496702	0.818	rs17800749	chr2:134003754	C/T	cg05012457	chr2:133672682	NCKAP5	-0.92	-5.11	-0.46	1.68e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg17143192	chr8:8559678	CLDN23	0.98	7.44	0.61	4.46e-11	Obesity-related traits;
THYM	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg12573674	chr2:1569213	NA	-1.38	-9.08	-0.68	1.52e-14	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs2932538	0.922	rs3790612	chr1:113084146	G/A	cg22162597	chr1:113214053	CAPZA1	0.61	4.95	0.45	3.25e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg15557168	chr22:42548783	NA	0.6	4.66	0.43	1.02e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-5.74	-0.51	1.12e-7	Systemic lupus erythematosus;
THYM	cis	rs892961	1.000	rs11653743	chr17:75401923	C/A	cg05865280	chr17:75406074	SEPT9	0.5	8.56	0.66	1.99e-13	Airflow obstruction;
THYM	cis	rs9796	0.558	rs11855102	chr15:41513257	T/C	cg21153102	chr15:41252147	NA	0.53	4.5	0.42	1.92e-5	Menopause (age at onset);
THYM	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg09165964	chr15:75287851	SCAMP5	-1.09	-10.42	-0.73	2.09e-17	Blood trace element (Zn levels);
THYM	cis	rs9787249	0.957	rs10888958	chr1:40211737	T/C	cg02773041	chr1:40204384	PPIE	0.77	5.99	0.52	3.8e-8	Blood protein levels;
THYM	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg14895029	chr7:2775587	GNA12	-0.67	-4.87	-0.45	4.42e-6	Height;
THYM	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg04607235	chr12:12878440	APOLD1	-1.05	-10.0	-0.72	1.66e-16	Lymphocyte counts;
THYM	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg24596788	chr1:163392923	NA	-0.78	-7.5	-0.61	3.38e-11	Motion sickness;
THYM	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg14456004	chr13:21872349	NA	-1.24	-10.0	-0.72	1.63e-16	White matter hyperintensity burden;
THYM	cis	rs13082711	0.522	rs608374	chr3:27345397	G/A	cg02860705	chr3:27208620	NA	0.65	5.07	0.46	1.94e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs4595586	0.545	rs11611625	chr12:39387207	T/C	cg13010199	chr12:38710504	ALG10B	0.61	4.65	0.43	1.05e-5	Morning vs. evening chronotype;
THYM	trans	rs8002861	0.781	rs7322781	chr13:44442238	T/C	cg17145862	chr1:211918768	LPGAT1	0.94	9.74	0.71	6.04e-16	Leprosy;
THYM	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs12291225	0.546	rs12291662	chr11:14342949	T/C	cg05501817	chr11:14380813	RRAS2	-0.8	-6.63	-0.56	2.05e-9	Sense of smell;
THYM	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg27534772	chr1:16042836	PLEKHM2	0.54	5.92	0.52	5.1e-8	Systolic blood pressure;
THYM	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg27034606	chr17:28928453	LRRC37B2	0.76	5.06	0.46	2.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg02527881	chr3:46936655	PTH1R	-0.61	-5.7	-0.51	1.33e-7	Colorectal cancer;
THYM	cis	rs5015933	0.734	rs10126025	chr9:128146064	C/G	cg14078157	chr9:128172775	NA	-0.56	-4.99	-0.46	2.77e-6	Body mass index;
THYM	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-5.96	-0.52	4.23e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg04287289	chr16:89883240	FANCA	-0.5	-4.59	-0.43	1.38e-5	Vitiligo;
THYM	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg19770292	chr5:1868693	NA	0.56	5.16	0.47	1.34e-6	Cardiovascular disease risk factors;
THYM	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg24154853	chr7:158122151	PTPRN2	0.56	5.04	0.46	2.23e-6	Calcium levels;
THYM	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg00922110	chr4:57842668	C4orf14	-0.45	-5.24	-0.47	9.8e-7	Response to bleomycin (chromatid breaks);
THYM	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg18538332	chr22:24372958	LOC391322	0.93	8.03	0.64	2.62e-12	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg22764591	chr12:58329936	NA	1.27	10.42	0.73	2.15e-17	Intelligence (multi-trait analysis);
THYM	cis	rs3809566	1.000	rs10851721	chr15:63332383	T/C	cg00520135	chr15:63333846	TPM1	-0.56	-4.87	-0.45	4.5e-6	Platelet count;
THYM	cis	rs9649213	0.593	rs1468340	chr7:97987676	T/G	cg09267113	chr7:98030324	BAIAP2L1	0.5	4.56	0.42	1.51e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs425535	0.817	rs394408	chr4:74849352	A/G	cg07868155	chr4:74864709	CXCL5	0.65	5.47	0.49	3.66e-7	Blood protein levels;
THYM	cis	rs723080	0.702	rs1160306	chr20:39387958	C/T	cg14276730	chr20:40040268	CHD6	-0.47	-4.55	-0.42	1.61e-5	Paneth cell defects in Crohn's disease;
THYM	cis	rs7586879	1.000	rs10207698	chr2:25117672	C/T	cg01884057	chr2:25150051	NA	0.63	6.3	0.54	9.31e-9	Body mass index;
THYM	cis	rs7131987	0.650	rs11050187	chr12:29472876	T/C	cg09582351	chr12:29534625	ERGIC2	-0.59	-5.13	-0.47	1.53e-6	QT interval;
THYM	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg23187316	chr7:1099788	C7orf50	0.48	5.45	0.49	3.98e-7	Longevity;Endometriosis;
THYM	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg06558623	chr16:89946397	TCF25	1.27	5.06	0.46	2.05e-6	Skin colour saturation;
THYM	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg18252515	chr7:66147081	NA	1.37	8.05	0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg26384229	chr12:38710491	ALG10B	0.97	7.89	0.63	5.19e-12	Bladder cancer;
THYM	cis	rs41005	1.000	rs798449	chr2:8106533	G/A	cg03155496	chr2:8117019	LOC339788	0.99	9.16	0.68	1.05e-14	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg11871910	chr12:69753446	YEATS4	-0.87	-7.45	-0.61	4.24e-11	Blood protein levels;
THYM	cis	rs10992471	0.603	rs747628	chr9:95289532	A/T	cg14631576	chr9:95140430	CENPP	-0.96	-9.19	-0.69	9.02e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs3126085	0.877	rs1552996	chr1:152171104	C/A	cg10321714	chr1:152280068	FLG	0.68	5.07	0.46	1.98e-6	Atopic dermatitis;
THYM	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg05347473	chr6:146136440	FBXO30	0.6	4.8	0.44	5.96e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10191773	0.584	rs72831633	chr2:112945932	T/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.78	-4.65	-0.43	1.07e-5	Yeast infection;
THYM	trans	rs9929218	0.906	rs9933844	chr16:68747001	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-7.29	-0.6	9.13e-11	Colorectal cancer;
THYM	cis	rs7772486	0.654	rs6906402	chr6:146089307	C/G	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.43e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg06521331	chr12:34319734	NA	-0.71	-5.47	-0.49	3.57e-7	Morning vs. evening chronotype;
THYM	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg12826209	chr6:26865740	GUSBL1	0.75	5.23	0.47	9.98e-7	Intelligence (multi-trait analysis);
THYM	cis	rs8070624	0.543	rs7219320	chr17:17880877	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	6.7	0.57	1.48e-9	Total body bone mineral density;
THYM	cis	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs13004237	1	rs13004237	chr2:172833139	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.63	-4.79	-0.44	6.04e-6	Schizophrenia;
THYM	cis	rs7772486	0.754	rs12199362	chr6:146118225	A/G	cg13319975	chr6:146136371	FBXO30	-0.65	-5.27	-0.48	8.43e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg23332699	chr15:44069569	ELL3	0.76	4.61	0.43	1.26e-5	Lung cancer in ever smokers;
THYM	cis	rs921968	0.643	rs559722	chr2:219398159	A/G	cg02176678	chr2:219576539	TTLL4	0.68	6.71	0.57	1.42e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg17775962	chr7:1200435	ZFAND2A	0.41	4.72	0.44	8.04e-6	Longevity;Endometriosis;
THYM	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg00012203	chr2:219082015	ARPC2	-0.6	-5.01	-0.46	2.48e-6	Colorectal cancer;
THYM	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg09877947	chr5:131593287	PDLIM4	0.58	4.82	0.44	5.38e-6	Blood metabolite levels;
THYM	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg04944784	chr2:26401820	FAM59B	1.09	8.74	0.67	8.1e-14	Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs758324	0.732	rs154724	chr5:131445660	A/T	cg16205897	chr5:131564050	P4HA2	0.58	4.96	0.45	3.03e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg06221963	chr1:154839813	KCNN3	0.75	9.92	0.71	2.42e-16	Prostate cancer;
THYM	cis	rs6450176	0.859	rs3776719	chr5:53298684	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-6.2	-0.54	1.45e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg21252483	chr19:49399788	TULP2	-0.87	-6.06	-0.53	2.77e-8	Red cell distribution width;
THYM	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg03676636	chr4:99064102	C4orf37	0.5	7.65	0.62	1.6e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg23758822	chr17:41437982	NA	1.23	12.03	0.78	8.21e-21	Menopause (age at onset);
THYM	cis	rs2033711	0.503	rs7254299	chr19:58884965	A/G	cg08504662	chr19:58868256	ZNF497	-0.52	-4.91	-0.45	3.79e-6	Uric acid clearance;
THYM	cis	rs863345	0.564	rs34701257	chr1:158480955	A/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs4731207	0.698	rs11980925	chr7:124483707	T/A	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg06634786	chr22:41940651	POLR3H	0.74	6.13	0.53	1.97e-8	Vitiligo;
THYM	cis	rs4731207	0.596	rs11761669	chr7:124586301	C/T	cg05285228	chr7:124571219	POT1	0.69	5.25	0.47	9.35e-7	Cutaneous malignant melanoma;
THYM	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg10802521	chr3:52805072	NEK4	-0.77	-6.83	-0.57	7.95e-10	Bipolar disorder;
THYM	cis	rs9649213	0.593	rs13246942	chr7:97915021	C/T	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs13185784	0.667	rs6882940	chr5:179648989	A/G	cg13944838	chr5:179740914	GFPT2	-0.72	-4.66	-0.43	1.02e-5	TRAIL levels;
THYM	cis	rs2229238	0.911	rs57783436	chr1:154511709	A/G	cg21262032	chr1:154437693	IL6R	-0.64	-5.79	-0.51	8.9e-8	Coronary heart disease;
THYM	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7507204	0.767	rs62125962	chr19:3410852	A/G	cg08380311	chr19:3435252	NFIC	0.92	7.36	0.6	6.63e-11	Height;
THYM	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs28453840	1	rs28453840	chr2:136522941	G/A	cg20242066	chr2:136595261	LCT	-0.56	-6.93	-0.58	5.1e-10	Cholesterol, total;
THYM	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg02527881	chr3:46936655	PTH1R	-0.53	-5.02	-0.46	2.46e-6	Colorectal cancer;
THYM	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg12863693	chr15:85201151	NMB	0.63	5.55	0.49	2.59e-7	Schizophrenia;
THYM	cis	rs28476539	0.567	rs7679380	chr4:83563298	T/C	cg10249074	chr4:83542146	C4orf11	-0.66	-5.27	-0.48	8.48e-7	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs7119	0.679	rs12914932	chr15:77839051	G/A	cg10437265	chr15:77819839	NA	0.8	8.02	0.64	2.77e-12	Type 2 diabetes;
THYM	cis	rs4595586	0.505	rs12826314	chr12:39379435	A/C	cg26384229	chr12:38710491	ALG10B	0.71	5.42	0.49	4.58e-7	Morning vs. evening chronotype;
THYM	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg09417038	chr21:47716443	C21orf57	-0.54	-4.45	-0.42	2.29e-5	Testicular germ cell tumor;
THYM	cis	rs921968	0.643	rs598701	chr2:219387005	C/G	cg02176678	chr2:219576539	TTLL4	-0.64	-6.08	-0.53	2.49e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4355801	0.536	rs3103995	chr8:119872951	A/C	cg17171407	chr8:119960777	TNFRSF11B	-0.61	-4.99	-0.46	2.7e-6	Bone mineral density;
THYM	cis	rs1747683	0.966	rs10906348	chr10:13368088	A/G	cg25835351	chr10:13388524	SEPHS1	-0.34	-5.59	-0.5	2.14e-7	IgG glycosylation;
THYM	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg27286337	chr10:134555280	INPP5A	-0.82	-5.71	-0.51	1.29e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg12560992	chr17:57184187	TRIM37	0.87	8.15	0.64	1.43e-12	Intelligence (multi-trait analysis);
THYM	cis	rs6754311	0.512	rs12998387	chr2:136507039	A/G	cg07169764	chr2:136633963	MCM6	-0.67	-5.92	-0.52	5.11e-8	Mosquito bite size;
THYM	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg05802129	chr4:122689817	NA	-0.65	-5.34	-0.48	6.45e-7	Type 2 diabetes;
THYM	cis	rs34779708	0.931	rs35136660	chr10:35385973	C/A	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs9435341	0.965	rs6669831	chr1:107608607	G/A	cg09367891	chr1:107599246	PRMT6	-0.7	-5.11	-0.46	1.67e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg13393036	chr8:95962371	TP53INP1	-0.47	-4.9	-0.45	3.95e-6	Type 2 diabetes;
THYM	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs240764	0.817	rs11155610	chr6:101170233	T/C	cg21058520	chr6:100914733	NA	0.58	5.22	0.47	1.06e-6	Neuroticism;
THYM	cis	rs7772486	0.790	rs2247429	chr6:146217769	T/C	cg23711669	chr6:146136114	FBXO30	0.95	9.84	0.71	3.6e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7582180	0.663	rs930374	chr2:100962700	A/G	cg14675211	chr2:100938903	LONRF2	0.67	6.48	0.55	4.06e-9	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg05313129	chr8:58192883	C8orf71	-0.78	-4.61	-0.43	1.23e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs8044995	0.563	rs1110572	chr16:68396119	A/G	cg09835421	chr16:68378352	PRMT7	-0.68	-4.54	-0.42	1.68e-5	Schizophrenia;
THYM	cis	rs11250464	0.833	rs4554799	chr10:1407728	C/T	cg08668359	chr10:1443807	ADARB2	0.64	5.66	0.5	1.6e-7	Radiation response;
THYM	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg07570687	chr10:102243282	WNT8B	0.76	6.93	0.58	5.03e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs6456042	0.965	rs3127411	chr6:166534776	A/G	cg11088901	chr6:166572345	T	-0.51	-4.82	-0.44	5.5e-6	Asthma;
THYM	cis	rs7944584	0.545	rs7118178	chr11:47659135	G/A	cg20307385	chr11:47447363	PSMC3	0.82	5.74	0.51	1.14e-7	Fasting blood glucose;Fasting blood glucose (BMI interaction);
THYM	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9814567	1.000	rs2056603	chr3:134312749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.49	-0.66	2.74e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs1335645	0.502	rs646734	chr1:111628733	A/G	cg00321911	chr1:111669324	DRAM2	1.0	5.71	0.51	1.31e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7729447	0.813	rs7715779	chr5:32690199	T/G	cg16267343	chr5:32710456	NPR3	0.78	7.17	0.59	1.64e-10	Blood pressure;
THYM	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.3	6.14	0.53	1.91e-8	Obesity-related traits;
THYM	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg26028573	chr6:26043587	HIST1H2BB	-0.52	-4.59	-0.43	1.35e-5	Blood metabolite levels;
THYM	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg17264618	chr3:40429014	ENTPD3	0.53	4.94	0.45	3.41e-6	Renal cell carcinoma;
THYM	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9733	0.628	rs11807409	chr1:150683423	C/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg19847130	chr8:10466454	RP1L1	0.57	5.32	0.48	7.01e-7	Neuroticism;
THYM	cis	rs3791406	0.963	rs3791408	chr2:240030591	C/T	cg05758467	chr2:240035894	HDAC4	-0.44	-4.51	-0.42	1.84e-5	Skin aging (microtopography measurement);
THYM	cis	rs2245008	0.774	rs253136	chr16:83979601	A/C	cg07978099	chr16:83986941	OSGIN1	-0.62	-4.8	-0.44	5.96e-6	Pursuit maintenance gain;
THYM	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.8e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2730245	0.608	rs2657391	chr7:158741776	T/C	cg11984989	chr7:158649758	WDR60	-0.97	-8.69	-0.67	1.02e-13	Height;
THYM	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg14972814	chr11:95582409	MTMR2	-0.76	-6.22	-0.54	1.33e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg18477163	chr1:228402036	OBSCN	0.57	6.33	0.54	8.11e-9	Diastolic blood pressure;
THYM	cis	rs921968	0.565	rs6733892	chr2:219616002	C/A	cg02176678	chr2:219576539	TTLL4	-0.53	-5.36	-0.48	5.71e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg27129171	chr3:47204927	SETD2	0.7	6.7	0.57	1.44e-9	Colorectal cancer;
THYM	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg02463440	chr8:22132932	PIWIL2	0.55	4.59	0.43	1.34e-5	Hypertriglyceridemia;
THYM	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg10523679	chr1:76189770	ACADM	0.91	9.7	0.71	7.37e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg14895029	chr7:2775587	GNA12	-0.7	-5.09	-0.46	1.84e-6	Height;
THYM	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg12419862	chr22:24373484	LOC391322	-0.73	-6.63	-0.56	2.03e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg19077165	chr18:44547161	KATNAL2	0.61	7.64	0.62	1.7e-11	Personality dimensions;
THYM	cis	rs28595532	0.920	rs17325129	chr4:119778284	T/C	cg11846333	chr4:119757529	SEC24D	1.45	5.08	0.46	1.92e-6	Cannabis dependence symptom count;
THYM	cis	rs13202913	0.837	rs9397054	chr6:151789912	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.88	-5.03	-0.46	2.35e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	8.7	0.67	9.67e-14	Chronic sinus infection;
THYM	cis	rs9303401	0.703	rs9911583	chr17:57210721	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.67	-4.99	-0.46	2.76e-6	Cognitive test performance;
THYM	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg18132916	chr6:79620363	NA	-0.54	-4.8	-0.44	5.95e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9527	0.590	rs726010	chr10:104841977	C/T	cg15744005	chr10:104629667	AS3MT	-0.61	-4.57	-0.42	1.45e-5	Arsenic metabolism;
THYM	cis	rs56104184	0.779	rs2131093	chr19:49350693	A/T	cg21252483	chr19:49399788	TULP2	-0.79	-5.4	-0.48	4.87e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg08645402	chr16:4508243	NA	0.76	6.87	0.58	6.72e-10	Schizophrenia;
THYM	cis	rs7262634	1.000	rs73302060	chr20:45829086	G/A	cg18599129	chr20:45867857	ZMYND8	0.83	4.87	0.45	4.48e-6	Response to protease inhibitor treatment in hepatitis c (bilirubin toxicity);
THYM	cis	rs8114671	0.935	rs945960	chr20:33762854	A/G	cg08999081	chr20:33150536	PIGU	0.53	4.77	0.44	6.63e-6	Height;
THYM	cis	rs422249	0.512	rs174574	chr11:61600342	A/C	cg19610905	chr11:61596333	FADS2	0.61	5.14	0.47	1.45e-6	Trans fatty acid levels;
THYM	cis	rs12282928	0.921	rs7479951	chr11:48295508	C/G	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs7917772	0.582	rs4919661	chr10:104358403	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.68	-5.91	-0.52	5.35e-8	Lymphocyte counts;
THYM	cis	rs6920965	0.527	rs7763515	chr6:126174714	C/G	cg05901451	chr6:126070800	HEY2	-0.62	-5.23	-0.47	1e-6	High light scatter reticulocyte count;
THYM	cis	rs7408868	0.908	rs10418660	chr19:15278635	A/G	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs2806561	0.734	rs2806564	chr1:23506685	T/C	cg12483005	chr1:23474871	LUZP1	0.59	6.32	0.54	8.59e-9	Height;
THYM	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	5.09	0.46	1.84e-6	Prudent dietary pattern;
THYM	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg17294928	chr15:75287854	SCAMP5	-0.94	-7.94	-0.63	4.01e-12	Blood trace element (Zn levels);
THYM	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg11266682	chr4:10021025	SLC2A9	-0.68	-9.74	-0.71	5.95e-16	Bone mineral density;
THYM	cis	rs8013055	0.699	rs66798104	chr14:105987782	C/G	cg11597832	chr14:105993747	TMEM121	-0.53	-4.72	-0.44	7.99e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg01699819	chr7:1052092	C7orf50	-0.73	-5.96	-0.52	4.19e-8	Bronchopulmonary dysplasia;
THYM	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg14784868	chr12:69753453	YEATS4	0.86	7.45	0.61	4.2e-11	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9788682	0.747	rs8042059	chr15:78907859	A/C	cg18825076	chr15:78729989	IREB2	0.62	5.13	0.47	1.51e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	trans	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs7772486	0.875	rs9322046	chr6:146393625	A/G	cg23711669	chr6:146136114	FBXO30	0.91	8.98	0.68	2.53e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs637571	0.544	rs500161	chr11:65695438	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.7	5.31	0.48	7.04e-7	Eosinophil percentage of white cells;
THYM	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03264133	chr6:25882463	NA	0.93	8.24	0.65	9.46e-13	Blood metabolite levels;
THYM	cis	rs420259	0.516	rs428438	chr16:23461754	A/C	cg00143387	chr16:23521605	GGA2	0.77	5.56	0.5	2.45e-7	Bipolar disorder;
THYM	cis	rs12476592	0.602	rs1348806	chr2:63895884	A/T	cg17519650	chr2:63277830	OTX1	-0.72	-4.68	-0.43	9.38e-6	Childhood ear infection;
THYM	cis	rs6893300	0.745	rs6639	chr5:179156782	G/T	cg01213455	chr5:179280345	C5orf45	-0.57	-4.48	-0.42	2.08e-5	Resting heart rate;
THYM	cis	rs13256369	1.000	rs10088439	chr8:8576699	T/G	cg17143192	chr8:8559678	CLDN23	0.87	6.53	0.56	3.24e-9	Obesity-related traits;
THYM	cis	rs79149102	0.579	rs73436579	chr15:75294514	C/T	cg17294928	chr15:75287854	SCAMP5	-1.06	-5.68	-0.5	1.49e-7	Lung cancer;
THYM	cis	rs11214589	0.651	rs17600713	chr11:113259947	C/T	cg14159747	chr11:113255604	NA	0.37	7.8	0.62	8.01e-12	Neuroticism;
THYM	cis	rs1642645	0.831	rs768613	chr1:42485263	T/C	cg22816091	chr1:42611670	NA	0.62	5.52	0.49	2.99e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs1050631	0.592	rs9958282	chr18:33710440	T/A	cg25426722	chr18:33708991	SLC39A6;ELP2	-0.66	-5.19	-0.47	1.21e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs13082711	0.554	rs73055724	chr3:27380397	T/G	cg02860705	chr3:27208620	NA	0.88	6.28	0.54	1.01e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs7487075	0.797	rs10785630	chr12:46880380	G/A	cg15584813	chr12:47219626	SLC38A4	0.49	4.62	0.43	1.22e-5	Itch intensity from mosquito bite;
THYM	cis	rs6906287	0.647	rs11753128	chr6:118853514	C/T	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg10792982	chr14:105748885	BRF1	0.7	7.07	0.59	2.55e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg14004847	chr7:1930337	MAD1L1	-0.66	-4.87	-0.45	4.5e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs600806	0.815	rs4970758	chr1:109979617	A/G	cg02175308	chr1:109941060	SORT1	-0.56	-4.88	-0.45	4.33e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg10505658	chr17:80084571	CCDC57	0.57	4.55	0.42	1.59e-5	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs9486719	0.843	rs2205754	chr6:96843134	T/C	cg18709589	chr6:96969512	KIAA0776	0.75	4.49	0.42	2.02e-5	Migraine;Coronary artery disease;
THYM	cis	rs6930083	0.527	rs9470367	chr6:36626932	G/C	cg11920449	chr6:36645608	CDKN1A	0.72	5.48	0.49	3.5e-7	Coronary artery disease;
THYM	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg08975724	chr8:8085496	FLJ10661	-0.76	-6.23	-0.54	1.27e-8	Mood instability;
THYM	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg00898013	chr13:113819073	PROZ	-0.89	-9.29	-0.69	5.34e-15	Platelet distribution width;
THYM	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg07424592	chr7:64974309	NA	-0.99	-5.15	-0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7584099	0.590	rs12105745	chr2:148673662	G/A	cg23727674	chr2:148602993	ACVR2A	0.55	4.56	0.42	1.53e-5	Response to statin therapy;
THYM	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22433210	chr17:43662623	NA	-0.87	-7.03	-0.58	3.2e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs600550	0.588	rs11230239	chr11:60072149	C/T	cg05040360	chr11:60102449	MS4A6E	-0.48	-4.52	-0.42	1.76e-5	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs7771547	0.519	rs12202691	chr6:36377820	G/A	cg07856975	chr6:36356162	ETV7	0.64	5.42	0.49	4.54e-7	Platelet distribution width;
THYM	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg14019146	chr3:50243930	SLC38A3	-0.6	-5.08	-0.46	1.88e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2456568	0.548	rs4753113	chr11:93660974	G/A	cg14065697	chr11:93583672	C11orf90	-0.48	-4.52	-0.42	1.77e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7119	0.667	rs907392	chr15:77903393	T/C	cg10437265	chr15:77819839	NA	-0.57	-5.64	-0.5	1.73e-7	Type 2 diabetes;
THYM	cis	rs7772486	0.686	rs2142983	chr6:146069701	G/C	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9563576	0.735	rs7317079	chr13:58598193	A/G	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.62	4.49	0.42	2.01e-5	Body mass index;
THYM	cis	rs12049351	0.774	rs3738187	chr1:229683264	G/A	cg11742688	chr1:229674241	ABCB10	-0.56	-4.63	-0.43	1.16e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs881375	0.669	rs73541868	chr9:123639264	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.49	4.45	0.42	2.34e-5	Rheumatoid arthritis;
THYM	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg10862848	chr6:42927986	GNMT	-0.51	-6.83	-0.57	8.14e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9326248	0.530	rs72645460	chr11:116771375	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.95	-5.27	-0.48	8.43e-7	Blood protein levels;
THYM	cis	rs911119	1.000	rs1010117	chr20:23608421	G/C	cg16589663	chr20:23618590	CST3	0.77	4.71	0.44	8.31e-6	Chronic kidney disease;
THYM	trans	rs9951602	1.000	rs1903723	chr18:76646571	A/G	cg02800362	chr5:177631904	HNRNPAB	1.21	7.03	0.58	3.1e-10	Obesity-related traits;
THYM	cis	rs3011225	0.691	rs3791102	chr1:44366617	C/T	cg12908607	chr1:44402522	ARTN	-0.56	-4.87	-0.45	4.53e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg24257776	chr3:47051546	LOC100129354	-0.4	-4.65	-0.43	1.08e-5	Colorectal cancer;
THYM	cis	rs7107174	0.688	rs3740677	chr11:77928036	A/C	cg02023728	chr11:77925099	USP35	0.53	5.11	0.46	1.65e-6	Testicular germ cell tumor;
THYM	cis	rs9807989	0.507	rs6745614	chr2:102991213	A/G	cg03938978	chr2:103052716	IL18RAP	0.75	9.6	0.7	1.17e-15	Asthma;
THYM	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg12386194	chr3:101231763	SENP7	-0.93	-7.05	-0.59	2.82e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs933688	0.818	rs10052492	chr5:90759930	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.86	5.85	0.51	6.83e-8	Smoking behavior;
THYM	cis	rs427394	0.659	rs274675	chr5:6755319	C/T	cg10857441	chr5:6722123	POLS	-0.72	-7.75	-0.62	9.95e-12	Menopause (age at onset);
THYM	cis	rs1113500	0.548	rs11185271	chr1:108659933	A/G	cg06207961	chr1:108661230	NA	0.66	4.74	0.44	7.63e-6	Growth-regulated protein alpha levels;
THYM	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg05294307	chr14:35346193	BAZ1A	-0.85	-6.07	-0.53	2.57e-8	Psoriasis;
THYM	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.77	-0.51	1.01e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg07022442	chr13:21864356	NA	-0.69	-4.67	-0.43	9.9e-6	White matter hyperintensity burden;
THYM	cis	rs834811	0.505	rs7789711	chr7:135938979	C/T	cg01726295	chr7:135938950	NA	-0.8	-7.75	-0.62	1.03e-11	Post-traumatic stress disorder;
THYM	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg11812906	chr14:75593930	NEK9	-0.86	-8.02	-0.64	2.74e-12	Height;
THYM	cis	rs28374715	0.662	rs28587487	chr15:41495460	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.02	-8.4	-0.65	4.27e-13	Ulcerative colitis;
THYM	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs6570726	0.935	rs12663204	chr6:145818373	G/A	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg11663144	chr21:46675770	NA	-0.71	-9.92	-0.71	2.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg22974920	chr21:40686053	BRWD1	0.74	5.03	0.46	2.36e-6	Cognitive function;
THYM	cis	rs2730245	0.527	rs1188971	chr7:158664463	G/T	cg24397884	chr7:158709396	WDR60	0.55	5.36	0.48	5.79e-7	Height;
THYM	cis	rs921968	0.643	rs500317	chr2:219432953	G/C	cg02176678	chr2:219576539	TTLL4	0.68	6.71	0.57	1.42e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9915657	0.870	rs759499	chr17:70133177	C/T	cg09344028	chr17:70110421	NA	0.51	5.21	0.47	1.11e-6	Thyroid hormone levels;
THYM	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg26441486	chr22:50317300	CRELD2	0.45	7.6	0.62	2.04e-11	Schizophrenia;
THYM	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.49	-4.85	-0.45	4.73e-6	Eosinophil percentage of white cells;
THYM	cis	rs7584330	0.737	rs11886117	chr2:238361650	A/T	cg14458575	chr2:238380390	NA	0.9	7.53	0.61	2.94e-11	Prostate cancer;
THYM	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg20283391	chr11:68216788	NA	-0.59	-4.47	-0.42	2.16e-5	Total body bone mineral density;
THYM	cis	rs9810089	0.967	rs7372313	chr3:135872958	G/C	cg21827317	chr3:136751795	NA	0.56	4.91	0.45	3.82e-6	Gestational age at birth (child effect);
THYM	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg15557168	chr22:42548783	NA	-0.61	-4.75	-0.44	7.12e-6	Schizophrenia;
THYM	cis	rs6032067	0.777	rs34163611	chr20:43778990	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.52	-5.89	-0.52	5.76e-8	Blood protein levels;
THYM	cis	rs17750015	0.733	rs12454365	chr18:54396215	G/A	cg18434998	chr18:54306185	TXNL1	-0.6	-4.92	-0.45	3.7e-6	Depression and alcohol dependence;
THYM	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg10760299	chr15:45669010	GATM	0.75	5.63	0.5	1.79e-7	Homoarginine levels;
THYM	cis	rs7246967	0.673	rs3853649	chr19:22880460	C/G	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs3768617	0.510	rs10752900	chr1:183086238	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs665401	0.653	rs339365	chr6:117172218	A/G	cg20376953	chr6:117187980	NA	0.61	4.89	0.45	4.05e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg21226059	chr5:178986404	RUFY1	0.62	7.43	0.61	4.71e-11	Lung cancer;
THYM	cis	rs2074585	0.679	rs2601195	chr15:90938232	G/A	cg00487526	chr15:90818384	NA	-0.59	-4.62	-0.43	1.22e-5	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
THYM	cis	rs12282928	1.000	rs10769346	chr11:48336287	T/C	cg22827986	chr11:48284249	OR4X1	0.53	5.59	0.5	2.21e-7	Migraine - clinic-based;
THYM	cis	rs611744	0.967	rs702805	chr8:109235929	G/A	cg21045802	chr8:109455806	TTC35	0.59	5.25	0.47	9.08e-7	Dupuytren's disease;
THYM	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	5.09	0.46	1.81e-6	Hip circumference adjusted for BMI;
THYM	cis	rs77372450	0.551	rs6892478	chr5:157106968	C/T	cg00312553	chr5:157098553	C5orf52	-0.63	-4.52	-0.42	1.81e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg04944784	chr2:26401820	FAM59B	1.09	8.74	0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg16586182	chr3:47516702	SCAP	0.63	5.58	0.5	2.26e-7	Colorectal cancer;
THYM	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg16342193	chr10:102329863	NA	-0.59	-6.35	-0.55	7.46e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7264396	0.623	rs2590984	chr20:34597031	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.65	-4.87	-0.45	4.43e-6	Total cholesterol levels;
THYM	cis	rs2730245	0.527	rs62476464	chr7:158698063	C/T	cg01219135	chr7:158766336	NA	0.56	4.49	0.42	2.01e-5	Height;
THYM	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg22709100	chr7:91322751	NA	0.62	4.78	0.44	6.41e-6	Breast cancer;
THYM	cis	rs6768930	0.509	rs9811191	chr3:57765644	A/G	cg07735586	chr3:57945651	NA	-0.32	-5.04	-0.46	2.2e-6	Obesity-related traits;
THYM	cis	rs6840360	0.692	rs1838043	chr4:152411462	T/C	cg22705602	chr4:152727874	NA	-0.54	-5.5	-0.49	3.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs61990749	0.597	rs1006039	chr14:78263196	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-1.17	-8.01	-0.63	2.93e-12	Fibroblast growth factor basic levels;
THYM	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg01616529	chr11:638424	DRD4	-0.78	-6.61	-0.56	2.23e-9	Systemic lupus erythematosus;
THYM	cis	rs7216064	1.000	rs4318247	chr17:65882172	A/G	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg19346786	chr7:2764209	NA	0.71	5.99	0.52	3.7e-8	Height;
THYM	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg03188948	chr7:1209495	NA	0.9	5.02	0.46	2.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg23262073	chr20:60523788	NA	-0.89	-6.11	-0.53	2.21e-8	Obesity-related traits;
THYM	cis	rs11645898	0.748	rs72791120	chr16:72224583	G/T	cg14768367	chr16:72042858	DHODH	-0.68	-4.97	-0.45	2.9e-6	Blood protein levels;
THYM	cis	rs2070488	0.965	rs1870915	chr3:38494228	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.91	7.18	0.59	1.54e-10	Electrocardiographic conduction measures;
THYM	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg22907277	chr7:1156413	C7orf50	0.82	5.0	0.46	2.58e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg12615879	chr12:58013172	SLC26A10	0.54	5.45	0.49	3.95e-7	Multiple sclerosis;
THYM	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg17830980	chr10:43048298	ZNF37B	-1.0	-9.77	-0.71	5.04e-16	Extrinsic epigenetic age acceleration;
THYM	cis	rs6665290	0.904	rs1045290	chr1:227178700	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs11190604	0.790	rs11190535	chr10:102197441	A/T	cg16342193	chr10:102329863	NA	-0.51	-5.29	-0.48	7.96e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg27129171	chr3:47204927	SETD2	0.79	7.46	0.61	4.01e-11	Colorectal cancer;
THYM	cis	rs490234	0.783	rs10986848	chr9:128461889	T/C	cg14078157	chr9:128172775	NA	-0.66	-5.01	-0.46	2.48e-6	Mean arterial pressure;
THYM	cis	rs4481887	0.741	rs6674078	chr1:248543026	G/A	cg00666640	chr1:248458726	OR2T12	0.55	4.73	0.44	7.65e-6	Common traits (Other);
THYM	cis	rs3796352	1.000	rs750474	chr3:53085280	A/C	cg07884673	chr3:53033167	SFMBT1	0.95	5.75	0.51	1.09e-7	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg04750100	chr2:136595281	LCT	-0.55	-6.2	-0.54	1.44e-8	Mosquito bite size;
THYM	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg00631329	chr6:26305371	NA	-0.6	-7.22	-0.6	1.27e-10	Educational attainment;
THYM	cis	rs11577318	0.579	rs11247934	chr1:26695758	A/T	cg19677267	chr1:26645161	CD52;UBXN11	0.51	5.7	0.51	1.33e-7	Granulocyte percentage of myeloid white cells;
THYM	cis	rs941408	0.515	rs759066	chr19:2775337	G/T	cg19693284	chr19:2783607	SGTA	0.73	4.93	0.45	3.48e-6	Total cholesterol levels;
THYM	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07167872	chr1:205819463	PM20D1	0.99	9.9	0.71	2.71e-16	Menarche (age at onset);
THYM	cis	rs7582180	0.903	rs2309821	chr2:100900304	A/G	cg14675211	chr2:100938903	LONRF2	0.6	4.54	0.42	1.68e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg03433033	chr1:76189801	ACADM	0.77	10.09	0.72	1.07e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9565309	0.579	rs9573978	chr13:77589256	A/G	cg13866767	chr13:78470850	EDNRB	1.06	4.81	0.44	5.76e-6	Morning vs. evening chronotype;
THYM	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg04842962	chr6:43655489	MRPS18A	1.25	12.39	0.79	1.5e-21	IgG glycosylation;
THYM	cis	rs6754311	0.597	rs2082729	chr2:136550109	C/T	cg07169764	chr2:136633963	MCM6	-0.67	-5.88	-0.52	5.96e-8	Mosquito bite size;
THYM	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs1003719	0.788	rs9977314	chr21:38471963	G/T	cg01329690	chr21:38580129	DSCR9	0.42	5.74	0.51	1.13e-7	Eye color traits;
THYM	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1461503	0.934	rs930982	chr11:122834378	C/T	cg27398637	chr11:122830231	C11orf63	-0.63	-5.49	-0.49	3.34e-7	Menarche (age at onset);
THYM	cis	rs7189233	1.000	rs62048543	chr16:53534624	T/C	cg02965178	chr16:53538660	AKTIP	-0.66	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs17407555	0.657	rs6856199	chr4:10271592	G/A	cg00071950	chr4:10020882	SLC2A9	0.53	5.02	0.46	2.43e-6	Schizophrenia (age at onset);
THYM	cis	rs9486719	0.894	rs34826652	chr6:96899085	A/G	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21582582	chr3:182698605	DCUN1D1	0.8	7.0	0.58	3.67e-10	Intelligence (multi-trait analysis);
THYM	cis	rs17152411	0.895	rs7094381	chr10:126585848	G/A	cg07906193	chr10:126599966	NA	0.68	4.65	0.43	1.08e-5	Height;
THYM	cis	rs7781977	0.554	rs7797255	chr7:50351604	C/T	cg01139861	chr7:50343298	IKZF1	-0.53	-5.05	-0.46	2.13e-6	IgG glycosylation;
THYM	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg13695892	chr22:41940480	POLR3H	-0.9	-7.83	-0.63	7e-12	Vitiligo;
THYM	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg11764359	chr7:65958608	NA	0.85	7.0	0.58	3.62e-10	Aortic root size;
THYM	cis	rs6541297	0.793	rs6692319	chr1:230284375	C/T	cg05784532	chr1:230284198	GALNT2	0.7	4.56	0.42	1.51e-5	Coronary artery disease;
THYM	cis	rs8103278	1.000	rs8102876	chr19:46332842	C/T	cg14061069	chr19:46274453	DMPK	-0.55	-5.26	-0.47	9.02e-7	Coronary artery disease;
THYM	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg26039829	chr8:22132926	PIWIL2	0.71	6.36	0.55	7.01e-9	Hypertriglyceridemia;
THYM	cis	rs4148883	0.645	rs1154404	chr4:100009004	A/T	cg12011299	chr4:100065546	ADH4	0.69	6.24	0.54	1.23e-8	Alcohol dependence;
THYM	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg03517284	chr6:25882590	NA	0.68	5.24	0.47	9.49e-7	Height;
THYM	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg21984481	chr17:79567631	NPLOC4	0.46	4.87	0.45	4.45e-6	Eye color traits;
THYM	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	13.53	0.81	7.07e-24	Height;
THYM	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.75	8.21	0.64	1.06e-12	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs9915657	0.870	rs720244	chr17:70131643	G/T	cg09344028	chr17:70110421	NA	0.53	5.32	0.48	6.76e-7	Thyroid hormone levels;
THYM	cis	rs2495707	0.624	rs2489006	chr10:102419893	G/A	cg07099331	chr10:102419617	NA	-0.46	-5.37	-0.48	5.62e-7	Body mass index;
THYM	cis	rs939658	1.000	rs12439908	chr15:79456381	T/C	cg17916960	chr15:79447300	NA	0.75	8.81	0.67	5.71e-14	Refractive error;
THYM	cis	rs3862030	0.839	rs7078679	chr10:104284017	C/G	cg00122347	chr10:104236741	TMEM180	0.48	7.33	0.6	7.69e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs4474465	0.850	rs10899545	chr11:78250371	C/T	cg19901956	chr11:77921274	USP35	0.61	4.56	0.42	1.55e-5	Alzheimer's disease (survival time);
THYM	cis	rs2219968	1.000	rs6982487	chr8:78972260	C/A	cg00738934	chr8:78996279	NA	0.91	9.74	0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg18477163	chr1:228402036	OBSCN	-0.43	-4.69	-0.43	8.96e-6	Diastolic blood pressure;
THYM	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg01577475	chr2:114033581	PAX8;LOC440839	-0.49	-4.59	-0.43	1.37e-5	Lymphocyte counts;
THYM	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg13390004	chr1:15929781	NA	0.64	4.85	0.45	4.88e-6	Systolic blood pressure;
THYM	cis	rs7107770	1.000	rs61911056	chr11:125088380	A/T	cg04164023	chr11:125106101	PKNOX2	-0.83	-5.05	-0.46	2.11e-6	Photic sneeze reflex;
THYM	cis	rs7078219	0.543	rs4919342	chr10:101282553	G/C	cg17888390	chr10:101282816	NA	-0.45	-4.47	-0.42	2.12e-5	Dental caries;
THYM	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs4363385	0.818	rs10788856	chr1:153011517	G/C	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs28595532	0.920	rs56322132	chr4:119742496	T/A	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg14349672	chr11:133703707	NA	-0.54	-4.72	-0.44	8.07e-6	Childhood ear infection;
THYM	cis	rs3126085	0.877	rs6662450	chr1:152191709	C/G	cg26020982	chr1:152196106	HRNR	0.38	5.14	0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-4.66	-0.43	1.03e-5	Mood instability;
THYM	cis	rs7772486	0.641	rs9390374	chr6:146368175	A/T	cg23711669	chr6:146136114	FBXO30	0.82	7.6	0.61	2.11e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg11266682	chr4:10021025	SLC2A9	-0.52	-6.42	-0.55	5.41e-9	Bone mineral density;
THYM	cis	rs17598306	1.000	rs17598306	chr7:96581811	A/G	cg23184042	chr7:96615519	DLX6AS	-0.61	-4.76	-0.44	6.82e-6	Radiation response;
THYM	cis	rs17401966	0.838	rs11579365	chr1:10470846	G/T	cg19773385	chr1:10388646	KIF1B	-0.6	-4.89	-0.45	4.13e-6	Hepatocellular carcinoma;
THYM	cis	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg13443165	chr9:33130375	B4GALT1	-0.83	-7.72	-0.62	1.15e-11	IgG glycosylation;
THYM	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg03859395	chr2:55845619	SMEK2	-0.6	-5.52	-0.49	2.95e-7	Metabolic syndrome;
THYM	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.0	-5.48	-0.49	3.49e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10089	0.953	rs17164427	chr5:127361736	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.96	-6.36	-0.55	7.05e-9	Ileal carcinoids;
THYM	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg00744431	chr10:134226547	PWWP2B	-0.58	-4.77	-0.44	6.63e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg02725872	chr8:58115012	NA	-0.86	-6.04	-0.53	2.97e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs11148252	0.840	rs56304200	chr13:52781763	T/A	cg05335186	chr13:53173507	NA	-0.52	-6.54	-0.56	3.07e-9	Lewy body disease;
THYM	cis	rs1122608	0.504	rs76499861	chr19:11072192	C/T	cg17326582	chr19:11976514	ZNF439	0.63	4.87	0.45	4.52e-6	Coronary artery disease or ischemic stroke;Coronary artery disease;Coronary artery disease or large artery stroke;Coronary heart disease;Myocardial infarction (early onset);
THYM	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg13695892	chr22:41940480	POLR3H	-0.87	-6.35	-0.55	7.28e-9	Vitiligo;
THYM	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg04602696	chr16:88846723	FAM38A	-0.64	-4.85	-0.45	4.83e-6	Plateletcrit;
THYM	cis	rs677665	0.722	rs10746487	chr1:9338689	T/C	cg03265564	chr1:9748971	PIK3CD	-0.26	-4.89	-0.45	4.05e-6	Eosinophil percentage of white cells;
THYM	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	8.42	0.65	3.98e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg01304814	chr3:48885189	PRKAR2A	0.9	4.49	0.42	2.01e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs7084402	1.000	rs12259315	chr10:60266152	T/C	cg07615347	chr10:60278583	BICC1	-0.55	-4.99	-0.46	2.69e-6	Refractive error;
THYM	cis	rs55637147	0.553	rs55741081	chr11:57129309	G/T	cg15971518	chr11:57159174	PRG2	-0.62	-5.12	-0.47	1.59e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg24818145	chr4:99064322	C4orf37	0.67	5.2	0.47	1.13e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1048238	0.545	rs848199	chr1:16292742	C/T	cg21385522	chr1:16154831	NA	-0.67	-5.59	-0.5	2.15e-7	Systolic blood pressure;
THYM	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg24733560	chr20:60626293	TAF4	0.56	4.51	0.42	1.88e-5	Body mass index;
THYM	cis	rs6918586	0.658	rs13161	chr6:26114702	C/T	cg03517284	chr6:25882590	NA	0.71	5.57	0.5	2.33e-7	Schizophrenia;
THYM	cis	rs61931739	0.817	rs1705772	chr12:34174756	G/A	cg10856724	chr12:34555212	NA	-0.65	-5.88	-0.52	6.08e-8	Morning vs. evening chronotype;
THYM	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg21226059	chr5:178986404	RUFY1	0.62	7.25	0.6	1.1e-10	Lung cancer;
THYM	cis	rs11030122	0.702	rs17081	chr11:3987830	A/G	cg18678763	chr11:4115507	RRM1	0.42	5.32	0.48	6.76e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs28795989	1.000	rs28795989	chr4:7891545	A/G	cg12728606	chr4:7903970	AFAP1	0.44	4.71	0.44	8.46e-6	Intraocular pressure;
THYM	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.91	5.65	0.5	1.69e-7	Smoking behavior;
THYM	cis	rs7757969	0.877	rs4427030	chr6:112114249	A/G	cg08601457	chr6:112115117	FYN	0.42	4.79	0.44	6.23e-6	Schizophrenia;
THYM	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs4849845	1.000	rs4849845	chr2:121013169	G/A	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs6754311	0.509	rs10188066	chr2:136539513	G/A	cg20242066	chr2:136595261	LCT	-0.51	-5.6	-0.5	2.06e-7	Mosquito bite size;
THYM	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs6456156	0.565	rs6921588	chr6:167494397	G/T	cg00271210	chr6:167070053	RPS6KA2	-0.5	-4.87	-0.45	4.37e-6	Primary biliary cholangitis;
THYM	cis	rs36051895	0.632	rs12352022	chr9:5161836	T/G	cg02405213	chr9:5042618	JAK2	-1.07	-11.45	-0.76	1.35e-19	Pediatric autoimmune diseases;
THYM	cis	rs7078219	0.543	rs10786556	chr10:101278324	C/T	cg23904955	chr10:101282759	NA	-0.41	-5.23	-0.47	9.88e-7	Dental caries;
THYM	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.27	0.69	5.96e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6490294	0.583	rs7314282	chr12:112502438	A/G	cg10833066	chr12:111807467	FAM109A	0.47	5.23	0.47	1.02e-6	Mean platelet volume;
THYM	cis	rs6063312	1.000	rs6063312	chr20:47343059	G/T	cg18078177	chr20:47281410	PREX1	0.75	4.56	0.42	1.5e-5	Tonometry;
THYM	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	4.86	0.45	4.63e-6	Hip circumference adjusted for BMI;
THYM	cis	rs10203711	1.000	rs907113	chr2:239567724	T/C	cg14580085	chr2:239553406	NA	0.68	6.18	0.54	1.6e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2041895	0.509	rs2072559	chr12:107307287	T/G	cg26297688	chr12:107349093	C12orf23	-0.48	-4.64	-0.43	1.12e-5	Glaucoma (low intraocular pressure);
THYM	cis	rs1178127	0.573	rs6461384	chr7:18825453	G/T	cg13420273	chr7:18810212	HDAC9	0.68	5.32	0.48	7.04e-7	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg24308560	chr3:49941425	MST1R	-0.76	-6.28	-0.54	1.01e-8	Intelligence (multi-trait analysis);
THYM	cis	rs782590	0.582	rs2627767	chr2:55926815	A/T	cg18811423	chr2:55921094	PNPT1	0.69	5.89	0.52	5.87e-8	Metabolic syndrome;
THYM	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg11871910	chr12:69753446	YEATS4	0.69	5.7	0.5	1.34e-7	Blood protein levels;
THYM	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg25918947	chr17:41365094	TMEM106A	-0.69	-5.84	-0.51	7.34e-8	Menopause (age at onset);
THYM	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg12379764	chr21:47803548	PCNT	-0.83	-5.37	-0.48	5.52e-7	Testicular germ cell tumor;
THYM	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06850241	chr22:41845214	NA	-0.57	-5.07	-0.46	1.97e-6	Vitiligo;
THYM	cis	rs7104764	1.000	rs1128320	chr11:244167	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-5.36	-0.48	5.92e-7	Chronic sinus infection;
THYM	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg03909863	chr11:638404	DRD4	-0.77	-5.68	-0.5	1.44e-7	Systemic lupus erythematosus;
THYM	cis	rs2073016	0.569	rs35608434	chr6:40944066	C/T	cg21128951	chr6:40996213	UNC5CL	0.64	4.59	0.43	1.37e-5	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);
THYM	cis	rs9677476	0.909	rs13428369	chr2:232125632	T/C	cg07929768	chr2:232055508	NA	0.52	5.36	0.48	5.87e-7	Food antigen IgG levels;
THYM	cis	rs17321999	1.000	rs3817143	chr2:30482285	G/A	cg05247661	chr2:30472410	LBH	0.67	4.46	0.42	2.25e-5	Systemic lupus erythematosus;
THYM	cis	rs7267979	0.966	rs2482923	chr20:25308981	T/C	cg08601574	chr20:25228251	PYGB	-0.57	-4.49	-0.42	2.02e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs11048434	0.761	rs1805721	chr12:9147569	A/G	cg26114124	chr12:9217669	LOC144571	-0.47	-4.66	-0.43	1.01e-5	Sjögren's syndrome;
THYM	cis	rs986417	0.818	rs10139251	chr14:60959958	A/C	cg27398547	chr14:60952738	C14orf39	1.16	6.51	0.56	3.6e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs28476539	0.640	rs7656006	chr4:83554867	T/C	cg10249074	chr4:83542146	C4orf11	-0.64	-5.06	-0.46	2.03e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs7731657	0.537	rs4705924	chr5:130210792	G/A	cg08523029	chr5:130500466	HINT1	-0.78	-5.32	-0.48	7e-7	Fasting plasma glucose;
THYM	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg14004847	chr7:1930337	MAD1L1	-0.63	-4.98	-0.45	2.86e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6700896	0.931	rs1938490	chr1:66132800	T/A	cg04111102	chr1:66153794	NA	0.56	5.27	0.48	8.45e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg07870213	chr5:140052090	DND1	-0.69	-8.1	-0.64	1.86e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12122100	0.526	rs12122534	chr1:146504399	A/G	cg02487331	chr1:146550467	NA	0.6	4.82	0.44	5.41e-6	HIV-1 control;
THYM	cis	rs485842	1.000	rs502822	chr11:96022489	C/T	cg23866687	chr11:96026956	MAML2	0.44	6.23	0.54	1.28e-8	Corneal astigmatism;
THYM	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg05182265	chr7:156933206	UBE3C	-0.69	-9.32	-0.69	4.58e-15	Body mass index;
THYM	cis	rs11731175	1.000	rs10001577	chr4:189850773	C/T	cg00431894	chr4:189871012	NA	-0.81	-6.19	-0.54	1.52e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4849845	0.812	rs3931844	chr2:121039263	G/A	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg20891283	chr12:69753455	YEATS4	1.09	12.05	0.78	7.75e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs4731207	0.698	rs7782340	chr7:124506025	A/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.74	-0.44	7.64e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7131987	0.630	rs1006409	chr12:29435675	A/G	cg09582351	chr12:29534625	ERGIC2	-0.47	-4.83	-0.44	5.12e-6	QT interval;
THYM	cis	rs3135063	0.884	rs3129317	chr4:3287655	A/G	cg18352616	chr4:3374830	RGS12	0.46	4.47	0.42	2.18e-5	Blood protein levels;
THYM	cis	rs7104764	1.000	rs6598061	chr11:243853	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs2811415	0.597	rs9861755	chr3:127739721	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3862030	0.668	rs12781718	chr10:104227433	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.66	-5.41	-0.49	4.72e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs7177026	0.500	rs17193483	chr15:79930878	A/G	cg20511832	chr15:78934280	CHRNB4	-0.45	-5.02	-0.46	2.46e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg19318889	chr4:1322082	MAEA	0.65	5.61	0.5	1.95e-7	Longevity;
THYM	cis	rs9646944	0.501	rs3771158	chr2:103009894	A/G	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg22655196	chr4:3374909	RGS12	0.62	7.61	0.62	1.99e-11	Serum sulfate level;
THYM	cis	rs2862064	0.929	rs2088917	chr5:156432215	A/G	cg12943317	chr5:156479607	HAVCR1	-0.86	-5.28	-0.48	8.3e-7	Platelet count;
THYM	cis	rs611744	0.967	rs641820	chr8:109190717	T/C	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg10053473	chr17:62856997	LRRC37A3	0.8	6.84	0.57	7.63e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs28459962	0.545	rs2704571	chr4:89960285	A/G	cg17769793	chr4:89976368	FAM13A	-0.46	-4.78	-0.44	6.39e-6	Post bronchodilator FEV1;
THYM	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg25767906	chr1:53392781	SCP2	-0.67	-6.38	-0.55	6.52e-9	Monocyte count;
THYM	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs87938	0.799	rs4973920	chr3:41155345	G/T	cg02247160	chr3:41243829	CTNNB1	-0.35	-4.81	-0.44	5.56e-6	Bone mineral density (hip);
THYM	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg12011299	chr4:100065546	ADH4	-0.78	-7.84	-0.63	6.64e-12	Alcohol dependence;
THYM	cis	rs28595532	0.920	rs114168088	chr4:119772666	G/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg20966754	chr17:47091339	IGF2BP1	-0.55	-7.38	-0.6	6.02e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs11771526	0.551	rs1123868	chr7:32251972	C/T	cg13207630	chr7:32358064	NA	0.68	4.67	0.43	9.72e-6	Body mass index;
THYM	cis	rs2120243	0.539	rs7618737	chr3:157095621	G/A	cg24825693	chr3:157122686	VEPH1	-0.48	-4.48	-0.42	2.09e-5	Hepatocellular carcinoma in hepatitis B infection;
THYM	cis	rs4589258	1.000	rs10765387	chr11:90486851	G/A	cg26138821	chr11:89956704	CHORDC1	-0.69	-5.52	-0.49	3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4606347	0.932	rs1938493	chr1:66117819	G/T	cg04111102	chr1:66153794	NA	0.6	4.53	0.42	1.7e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs1499972	0.941	rs62264783	chr3:117658033	G/A	cg07612923	chr3:117604196	NA	1.3	5.07	0.46	1.94e-6	Schizophrenia;
THYM	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg00376283	chr12:123451042	ABCB9	0.76	6.25	0.54	1.17e-8	Platelet count;
THYM	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.79	5.69	0.5	1.39e-7	Height;
THYM	cis	rs259282	0.605	rs2302970	chr19:33098632	G/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.7	5.73	0.51	1.17e-7	Schizophrenia;
THYM	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	4.94	0.45	3.4e-6	Height;
THYM	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg07700843	chr1:2391317	NA	-0.59	-4.59	-0.43	1.36e-5	Non-obstructive azoospermia;
THYM	cis	rs924712	0.844	rs931766	chr6:54726869	C/T	cg19716238	chr6:54711378	FAM83B	-0.45	-4.54	-0.42	1.64e-5	Breast cancer;
THYM	cis	rs6568490	0.556	rs1850654	chr6:108095250	T/C	cg03500965	chr6:108145777	SCML4	0.41	4.67	0.43	9.84e-6	Lymphocyte counts;
THYM	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg12031863	chr16:4587854	C16orf5	-0.46	-4.96	-0.45	3.09e-6	Schizophrenia;
THYM	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg00825309	chr19:58991885	ZNF446	-0.59	-4.7	-0.43	8.69e-6	Uric acid clearance;
THYM	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9563576	0.778	rs9569780	chr13:58510376	G/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.63	4.68	0.43	9.55e-6	Body mass index;
THYM	cis	rs977987	0.800	rs4888378	chr16:75332041	A/G	cg03315344	chr16:75512273	CHST6	0.83	6.93	0.58	5e-10	Dupuytren's disease;
THYM	cis	rs9790314	0.967	rs10804790	chr3:161039300	T/A	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs9527	0.615	rs10883781	chr10:104581130	A/G	cg15744005	chr10:104629667	AS3MT	-0.77	-6.45	-0.55	4.6e-9	Arsenic metabolism;
THYM	cis	rs7640424	0.784	rs68044584	chr3:107845395	A/G	cg09227934	chr3:107805635	CD47	-0.53	-4.53	-0.42	1.71e-5	Body mass index;
THYM	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-4.73	-0.44	7.71e-6	Mood instability;
THYM	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg04317338	chr11:64019027	PLCB3	0.85	5.81	0.51	8.33e-8	Mean platelet volume;
THYM	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg02527881	chr3:46936655	PTH1R	-0.69	-7.11	-0.59	2.11e-10	Colorectal cancer;
THYM	cis	rs72827839	0.740	rs72823594	chr17:46124276	C/T	cg23391107	chr17:45924227	SP6	0.79	5.07	0.46	1.96e-6	Ease of getting up in the morning;
THYM	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.25	5.31	0.48	7.24e-7	Obesity-related traits;
THYM	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4523957	0.615	rs59207721	chr17:2070479	C/A	cg16513277	chr17:2031491	SMG6	-0.92	-8.15	-0.64	1.48e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6121246	0.542	rs76513665	chr20:30450232	T/C	cg09796376	chr20:30640595	HCK	0.85	4.51	0.42	1.83e-5	Mean corpuscular hemoglobin;
THYM	cis	rs9658691	0.736	rs9658727	chr10:90761865	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.82	-4.79	-0.44	6.09e-6	Mosquito bite size;
THYM	cis	rs2066819	1.000	rs11171803	chr12:56718422	T/C	cg26714650	chr12:56694279	CS	-1.38	-7.1	-0.59	2.22e-10	Psoriasis vulgaris;
THYM	cis	rs9796	0.835	rs28455998	chr15:41430969	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.57	-4.58	-0.43	1.42e-5	Menopause (age at onset);
THYM	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9563576	0.778	rs1409524	chr13:58661135	G/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.6	4.5	0.42	1.9e-5	Body mass index;
THYM	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.42	4.61	0.43	1.27e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28374715	0.578	rs72739630	chr15:41631064	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.21	-13.52	-0.81	7.22e-24	Ulcerative colitis;
THYM	cis	rs7917772	0.582	rs12782153	chr10:104368294	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-5.7	-0.5	1.33e-7	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg03806693	chr22:41940476	POLR3H	1.11	8.83	0.67	5.26e-14	Vitiligo;
THYM	cis	rs2658782	0.688	rs2658768	chr11:93250827	T/C	cg15737290	chr11:93063684	CCDC67	1.02	7.68	0.62	1.39e-11	Pulmonary function decline;
THYM	cis	rs34638657	0.500	rs12446210	chr16:82185762	G/A	cg07307142	chr16:82071433	HSD17B2	-0.89	-7.88	-0.63	5.3e-12	Lung adenocarcinoma;
THYM	cis	rs7901056	0.967	rs9299821	chr10:26722759	G/A	cg23318538	chr10:26883079	C10orf50	-0.37	-4.96	-0.45	3.12e-6	Lymphocyte counts;
THYM	cis	rs7731657	0.537	rs4705907	chr5:130191437	T/A	cg08523029	chr5:130500466	HINT1	-0.74	-5.19	-0.47	1.2e-6	Fasting plasma glucose;
THYM	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.82	-7.3	-0.6	8.93e-11	Intelligence (multi-trait analysis);
THYM	cis	rs1557614	0.544	rs7098406	chr10:125246705	G/T	cg03974204	chr10:124252811	HTRA1	-0.51	-4.47	-0.42	2.14e-5	Colorectal cancer;
THYM	cis	rs9500256	0.966	rs1322446	chr6:58311950	C/T	cg16251399	chr6:58287822	GUSBL2	0.68	5.72	0.51	1.22e-7	Eosinophilic esophagitis (pediatric);
THYM	cis	rs6539288	0.630	rs1055332	chr12:107348625	T/A	cg26297688	chr12:107349093	C12orf23	-0.5	-6.02	-0.53	3.22e-8	Total body bone mineral density;
THYM	cis	rs1403694	0.695	rs1523435	chr3:186436306	G/A	cg12454167	chr3:186435060	KNG1	0.53	7.54	0.61	2.83e-11	Blood protein levels;
THYM	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg18335740	chr13:41363409	SLC25A15	0.76	9.19	0.69	8.81e-15	Lewy body disease;
THYM	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg27588902	chr6:42928151	GNMT	-0.59	-5.89	-0.52	5.73e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11644478	chr21:40555479	PSMG1	0.95	7.1	0.59	2.31e-10	Cognitive function;
THYM	cis	rs6032067	0.929	rs35869085	chr20:43805134	G/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs921968	0.565	rs35594672	chr2:219589280	T/A	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1003719	0.613	rs9978998	chr21:38535848	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg04455712	chr21:45112962	RRP1B	0.54	5.06	0.46	2.07e-6	Mean corpuscular volume;
THYM	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg19346786	chr7:2764209	NA	-0.55	-4.74	-0.44	7.61e-6	Height;
THYM	cis	rs12653946	0.846	rs4975758	chr5:1891174	C/G	cg22472608	chr5:1891194	NA	-0.73	-5.85	-0.51	6.97e-8	Prostate cancer;
THYM	cis	rs7211079	0.917	rs8067991	chr17:78119302	G/C	cg09238746	chr17:78121135	EIF4A3	-0.74	-4.64	-0.43	1.1e-5	Myocardial infarction;
THYM	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.69	-0.62	1.33e-11	Personality dimensions;
THYM	cis	rs11039798	0.764	rs76882342	chr11:48939091	A/T	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs4455778	0.580	rs4270913	chr7:49112389	T/C	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg24692254	chr21:30365293	RNF160	-0.99	-9.12	-0.68	1.25e-14	Dental caries;
THYM	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-5.33	-0.48	6.7e-7	Hemoglobin concentration;
THYM	cis	rs6531656	0.663	rs337622	chr4:38624629	C/T	cg24279243	chr4:38676559	KLF3	-0.81	-6.99	-0.58	3.82e-10	Lymphocyte counts;
THYM	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs981844	1.000	rs2606337	chr4:154656845	C/T	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs4499344	0.696	rs10402929	chr19:33100245	C/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.61	0.62	2.02e-11	Mean platelet volume;
THYM	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26314531	chr2:26401878	FAM59B	-0.81	-5.4	-0.48	5.01e-7	Gut microbiome composition (summer);
THYM	cis	rs41271473	0.526	rs942853	chr1:228730949	G/T	cg10167378	chr1:228756711	NA	0.77	4.58	0.43	1.38e-5	Chronic lymphocytic leukemia;
THYM	cis	rs4919694	1.000	rs77318450	chr10:104733098	A/G	cg04362960	chr10:104952993	NT5C2	1.13	6.86	0.58	6.9e-10	Arsenic metabolism;
THYM	cis	rs1448094	0.512	rs7953318	chr12:86245929	G/A	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs6815814	0.861	rs6843043	chr4:38843136	A/G	cg02016764	chr4:38805732	TLR1	-0.5	-5.28	-0.48	8.24e-7	Breast cancer;
THYM	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26314531	chr2:26401878	FAM59B	-0.76	-4.99	-0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs2133450	0.712	rs28571091	chr3:7367231	A/G	cg19930620	chr3:7340148	GRM7	-0.48	-4.49	-0.42	1.98e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg08439880	chr3:133502540	NA	-0.82	-6.96	-0.58	4.26e-10	Iron status biomarkers;
THYM	cis	rs8008758	0.517	rs1620117	chr14:101696931	C/A	cg26224664	chr14:101693935	NA	-0.78	-8.56	-0.66	1.98e-13	Body mass index (alcohol intake interaction);
THYM	cis	rs11997175	0.624	rs7388511	chr8:33735582	C/G	ch.8.33884649F	chr8:33765107	NA	0.74	5.12	0.46	1.6e-6	Body mass index;
THYM	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg14820908	chr5:178986412	RUFY1	0.63	6.34	0.55	7.73e-9	Lung cancer;
THYM	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg21773646	chr17:80085082	CCDC57	0.36	5.06	0.46	2.03e-6	Life satisfaction;
THYM	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg06481639	chr22:41940642	POLR3H	0.84	6.06	0.53	2.69e-8	Vitiligo;
THYM	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg21100191	chr22:23484243	RTDR1	0.71	6.59	0.56	2.39e-9	Bone mineral density;
THYM	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg08779649	chr13:50194554	NA	0.58	5.03	0.46	2.31e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs4891159	0.548	rs654754	chr18:74143695	T/C	cg24786174	chr18:74118243	ZNF516	0.97	14.36	0.83	1.54e-25	Longevity;
THYM	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.69	-5.76	-0.51	1.06e-7	Height;
THYM	cis	rs9788721	0.900	rs72740964	chr15:78868636	G/A	cg18825076	chr15:78729989	IREB2	-0.54	-4.81	-0.44	5.71e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg27535305	chr1:53392650	SCP2	0.4	4.67	0.43	9.89e-6	Monocyte count;
THYM	cis	rs8018808	0.935	rs8018711	chr14:77921749	G/A	cg20045696	chr14:77926864	AHSA1	0.51	4.6	0.43	1.29e-5	Myeloid white cell count;
THYM	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.11	-10.66	-0.74	6.57e-18	Primary sclerosing cholangitis;
THYM	trans	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg23505145	chr19:12996616	KLF1	1.02	9.83	0.71	3.86e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg08847533	chr14:75593920	NEK9	-0.96	-10.45	-0.73	1.82e-17	Height;
THYM	cis	rs67460515	0.596	rs35127376	chr3:160927289	T/C	cg03342759	chr3:160939853	NMD3	-0.69	-5.14	-0.47	1.44e-6	Parkinson's disease;
THYM	cis	rs2235649	0.798	rs9932983	chr16:1848184	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.44	-4.78	-0.44	6.27e-6	Blood metabolite levels;
THYM	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.64	5.48	0.49	3.55e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4919044	0.542	rs12360261	chr10:94783360	A/G	cg05127821	chr10:94822908	CYP26C1	-1.58	-5.83	-0.51	7.61e-8	Coronary artery disease;
THYM	trans	rs8002861	0.905	rs12874590	chr13:44433363	C/T	cg17145862	chr1:211918768	LPGAT1	-0.85	-7.81	-0.63	7.59e-12	Leprosy;
THYM	cis	rs3772130	0.962	rs35679661	chr3:121484763	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.75	4.65	0.43	1.06e-5	Cognitive performance;
THYM	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg00898013	chr13:113819073	PROZ	-1.06	-9.63	-0.7	1.04e-15	Platelet distribution width;
THYM	cis	rs4455778	0.580	rs7796664	chr7:49117787	C/G	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs17597773	0.638	rs7544735	chr1:220998913	A/G	cg16008148	chr1:221062819	NA	-0.43	-4.47	-0.42	2.17e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg19346786	chr7:2764209	NA	-0.54	-4.58	-0.43	1.42e-5	Height;
THYM	cis	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg02176678	chr2:219576539	TTLL4	0.72	7.04	0.59	3.04e-10	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg15536230	chr21:44985092	HSF2BP	-0.38	-4.54	-0.42	1.64e-5	Mean corpuscular volume;
THYM	cis	rs7582403	0.510	rs7592576	chr2:148839547	A/G	cg23727674	chr2:148602993	ACVR2A	-0.63	-4.61	-0.43	1.24e-5	Neuroticism;
THYM	cis	rs11008222	0.935	rs11008231	chr10:31048837	A/G	cg00941203	chr10:31016591	NA	-0.37	-5.04	-0.46	2.22e-6	Congenital left-sided heart lesions (maternal effect);
THYM	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	6.49	0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg12893697	chr11:970389	AP2A2	-0.31	-5.15	-0.47	1.42e-6	Alzheimer's disease (late onset);
THYM	cis	rs995000	0.965	rs10789119	chr1:63098235	G/A	cg06896770	chr1:63153194	DOCK7	0.99	8.07	0.64	2.19e-12	Triglyceride levels;
THYM	cis	rs354225	0.544	rs3796019	chr2:54807279	G/A	cg23486701	chr2:54789491	SPTBN1	0.36	4.77	0.44	6.58e-6	Schizophrenia;
THYM	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs9733	0.596	rs72702504	chr1:150635374	G/C	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.48	-0.42	2.05e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg00599273	chr12:58146742	CDK4	0.4	4.58	0.43	1.41e-5	Multiple sclerosis;
THYM	cis	rs36051895	0.589	rs4560849	chr9:5203866	C/G	cg02405213	chr9:5042618	JAK2	-0.9	-9.02	-0.68	2.02e-14	Pediatric autoimmune diseases;
THYM	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg10047753	chr17:41438598	NA	1.19	11.63	0.77	5.87e-20	Menopause (age at onset);
THYM	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	7.91	0.63	4.74e-12	Lung cancer in ever smokers;
THYM	cis	rs7107174	0.901	rs2450138	chr11:77924870	C/T	cg02023728	chr11:77925099	USP35	0.71	6.44	0.55	4.97e-9	Testicular germ cell tumor;
THYM	cis	rs7646881	1.000	rs73015654	chr3:158451654	G/A	cg19483011	chr3:158453295	NA	-0.77	-5.54	-0.49	2.65e-7	Tetralogy of Fallot;
THYM	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg06009448	chr7:1102226	C7orf50	0.5	5.27	0.48	8.44e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg19875535	chr5:140030758	IK	-0.58	-4.54	-0.42	1.63e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg10295955	chr4:187884368	NA	-1.22	-17.5	-0.87	1.76e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg24910161	chr17:38119198	GSDMA	0.42	4.45	0.42	2.31e-5	Self-reported allergy;
THYM	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg12826209	chr6:26865740	GUSBL1	0.84	6.07	0.53	2.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9309473	0.519	rs2421545	chr2:73639476	T/C	cg19565262	chr2:73869966	NAT8	0.64	5.07	0.46	1.96e-6	Metabolite levels;
THYM	cis	rs7084402	0.967	rs1658460	chr10:60299151	T/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.64	-0.5	1.72e-7	Refractive error;
THYM	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg16586182	chr3:47516702	SCAP	-0.64	-5.61	-0.5	2.03e-7	Colorectal cancer;
THYM	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg24060327	chr5:131705240	SLC22A5	-0.76	-5.68	-0.5	1.46e-7	High light scatter reticulocyte percentage of red cells;
THYM	cis	rs728616	0.867	rs56198874	chr10:81686488	C/T	cg27452691	chr10:81370291	SFTPA1	0.83	4.49	0.42	2.03e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg27129171	chr3:47204927	SETD2	0.7	6.3	0.54	9.04e-9	Colorectal cancer;
THYM	cis	rs7769051	0.522	rs6928933	chr6:133116073	G/A	cg07930552	chr6:133119739	C6orf192	1.14	4.51	0.42	1.82e-5	Type 2 diabetes nephropathy;
THYM	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg15445000	chr17:37608096	MED1	-0.44	-5.19	-0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2309757	1	rs2309757	chr2:100807725	T/C	cg07810366	chr2:100720526	AFF3	-0.34	-4.46	-0.42	2.26e-5	Educational attainment (college completion);
THYM	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03452623	chr4:187889614	NA	1.14	17.71	0.88	7.56e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4917300	0.605	rs10108708	chr8:143102886	A/G	cg25363559	chr8:143086065	NA	-0.56	-5.13	-0.47	1.55e-6	Amyotrophic lateral sclerosis;
THYM	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg02018176	chr4:1364513	KIAA1530	0.56	4.57	0.42	1.49e-5	Obesity-related traits;
THYM	cis	rs8114671	0.967	rs2065979	chr20:33767690	T/C	cg08999081	chr20:33150536	PIGU	0.52	4.67	0.43	9.71e-6	Height;
THYM	cis	rs11112613	0.818	rs73184099	chr12:106018143	A/G	cg03607813	chr12:105948248	NA	0.91	5.13	0.47	1.51e-6	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs3771570	1.000	rs55645375	chr2:242269024	A/G	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg18252515	chr7:66147081	NA	-0.6	-4.51	-0.42	1.82e-5	Aortic root size;
THYM	cis	rs6956675	1.000	rs10231112	chr7:62601257	A/G	cg27518014	chr7:62859535	LOC100287834	0.58	4.63	0.43	1.18e-5	Obesity-related traits;
THYM	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg13395646	chr4:1353034	KIAA1530	-0.6	-5.83	-0.51	7.64e-8	Obesity-related traits;
THYM	cis	rs116095464	1.000	rs7723693	chr5:306032	G/A	cg22857025	chr5:266934	NA	-1.45	-5.27	-0.48	8.45e-7	Breast cancer;
THYM	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg14004847	chr7:1930337	MAD1L1	-0.65	-4.69	-0.43	9.29e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg11663144	chr21:46675770	NA	-0.72	-10.48	-0.73	1.54e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6754311	0.593	rs7355359	chr2:136462441	C/T	cg23851026	chr2:136556271	LCT	-0.59	-5.65	-0.5	1.65e-7	Mosquito bite size;
THYM	cis	rs10905065	0.965	rs2890365	chr10:5773876	C/A	cg11519256	chr10:5708881	ASB13	-0.49	-4.85	-0.45	4.79e-6	Menopause (age at onset);
THYM	cis	rs11771526	0.901	rs7791914	chr7:32296754	A/G	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Body mass index;
THYM	cis	rs28595532	0.920	rs56104443	chr4:119752052	G/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg18538332	chr22:24372958	LOC391322	0.94	11.35	0.76	2.21e-19	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7429990	0.965	rs7431572	chr3:48027851	G/T	cg02219026	chr3:48282209	ZNF589	0.6	4.5	0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs986417	1.000	rs10130267	chr14:60944527	A/G	cg27398547	chr14:60952738	C14orf39	1.14	5.33	0.48	6.64e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs1065852	0.526	rs9623490	chr22:42398266	G/C	cg08431931	chr22:42394659	WBP2NL	0.74	6.08	0.53	2.48e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs4430311	0.723	rs6429435	chr1:243945131	T/C	cg25706552	chr1:244017396	NA	-0.56	-4.97	-0.45	2.93e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs17604090	1.000	rs17603986	chr7:29690489	C/T	cg19413766	chr7:29689036	LOC646762	-0.93	-4.9	-0.45	3.97e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg13944838	chr5:179740914	GFPT2	-0.85	-6.63	-0.56	1.99e-9	Height;
THYM	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg12573674	chr2:1569213	NA	-1.22	-4.82	-0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs9572053	0.550	rs9529468	chr13:69552643	C/T	cg16757992	chr13:69559194	NA	-0.57	-4.6	-0.43	1.33e-5	Subjective well-being;
THYM	cis	rs9486719	0.843	rs2499796	chr6:96848364	A/G	cg18709589	chr6:96969512	KIAA0776	0.75	4.49	0.42	2.02e-5	Migraine;Coronary artery disease;
THYM	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg18252515	chr7:66147081	NA	-1.33	-7.89	-0.63	5.22e-12	Diabetic kidney disease;
THYM	cis	rs7084402	0.967	rs1658454	chr10:60306770	G/A	cg07615347	chr10:60278583	BICC1	0.56	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs4690686	0.500	rs7657249	chr4:177275198	A/G	cg17059388	chr4:177262070	NA	0.49	6.85	0.58	7.24e-10	Essential tremor;
THYM	cis	rs11597390	0.867	rs11596837	chr10:101850079	C/A	cg11344164	chr10:101878520	NA	-0.56	-4.81	-0.44	5.61e-6	Liver enzyme levels;
THYM	cis	rs6127978	0.702	rs465840	chr20:55809883	T/C	cg15851418	chr20:55835831	BMP7	0.68	4.89	0.45	4.12e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs854765	0.603	rs854789	chr17:18026566	C/T	cg04398451	chr17:18023971	MYO15A	-0.97	-10.7	-0.74	5.21e-18	Total body bone mineral density;
THYM	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg02527881	chr3:46936655	PTH1R	-0.63	-6.29	-0.54	9.52e-9	Colorectal cancer;
THYM	cis	rs3796619	1.000	rs11939380	chr4:1086871	C/T	cg27284194	chr4:1044797	NA	-0.53	-4.95	-0.45	3.22e-6	Recombination rate (males);
THYM	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg24308560	chr3:49941425	MST1R	0.76	6.5	0.55	3.73e-9	Intelligence (multi-trait analysis);
THYM	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg02896835	chr1:92012615	NA	-0.65	-5.74	-0.51	1.15e-7	Breast cancer;
THYM	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg03690763	chr11:133734501	NA	-0.61	-4.73	-0.44	7.77e-6	Childhood ear infection;
THYM	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg04317338	chr11:64019027	PLCB3	0.85	5.81	0.51	8.33e-8	Mean platelet volume;
THYM	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg20744362	chr22:50050164	C22orf34	0.69	6.33	0.54	7.96e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg04267008	chr7:1944627	MAD1L1	-0.67	-6.12	-0.53	2.07e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg27170947	chr2:26402098	FAM59B	-0.78	-6.09	-0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs8070740	0.841	rs4790771	chr17:5324966	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.72	5.98	0.52	3.87e-8	Menopause (age at onset);
THYM	cis	rs4589258	0.933	rs4491180	chr11:90406024	G/A	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.68	-5.59	-0.5	2.19e-7	Blood metabolite levels;
THYM	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg18477163	chr1:228402036	OBSCN	-0.43	-4.69	-0.43	8.96e-6	Diastolic blood pressure;
THYM	cis	rs6430585	0.528	rs3098102	chr2:136654833	C/T	cg04750100	chr2:136595281	LCT	0.54	5.46	0.49	3.78e-7	Corneal structure;
THYM	cis	rs7772486	0.754	rs4896832	chr6:145964151	G/A	cg13319975	chr6:146136371	FBXO30	-0.66	-5.42	-0.49	4.51e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7705042	0.865	rs6580229	chr5:141510754	A/G	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs1371867	0.846	rs1788167	chr8:101319996	C/T	cg06636551	chr8:101224915	SPAG1	-0.63	-6.33	-0.54	8.05e-9	Atrioventricular conduction;
THYM	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.23	-0.47	9.91e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs2228479	0.681	rs8044906	chr16:89969603	T/C	cg06558623	chr16:89946397	TCF25	0.95	5.15	0.47	1.42e-6	Skin colour saturation;
THYM	cis	rs2274459	1.000	rs66670017	chr6:33763563	C/T	cg06253072	chr6:33679850	C6orf125	0.52	4.67	0.43	1e-5	Obesity (extreme);
THYM	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg27129171	chr3:47204927	SETD2	-0.7	-6.59	-0.56	2.47e-9	Colorectal cancer;
THYM	cis	rs533581	0.866	rs502258	chr16:88968547	G/A	cg06763375	chr16:89025547	CBFA2T3	-0.53	-4.51	-0.42	1.87e-5	Social autistic-like traits;
THYM	cis	rs3820068	0.608	rs12091750	chr1:16042766	T/C	cg24675056	chr1:15929824	NA	0.78	6.16	0.53	1.73e-8	Systolic blood pressure;
THYM	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg11645453	chr3:52864694	ITIH4	0.3	4.69	0.43	8.99e-6	Schizophrenia;
THYM	cis	rs912057	0.526	rs737449	chr6:6733729	A/G	cg06612196	chr6:6737390	NA	-0.77	-11.68	-0.77	4.46e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs12802200	0.561	rs7940600	chr11:572105	A/G	cg14433983	chr11:636460	DRD4	-0.62	-4.47	-0.42	2.13e-5	Systemic lupus erythematosus;
THYM	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6565180	0.926	rs12446288	chr16:30388709	A/G	cg17640201	chr16:30407289	ZNF48	0.92	8.46	0.66	3.1400000000000003e-13	Tonsillectomy;
THYM	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg14517863	chr17:44321492	NA	0.47	5.15	0.47	1.39e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7943203	0.568	rs228593	chr11:108141134	G/A	cg04873221	chr11:107992290	ACAT1	-0.73	-4.95	-0.45	3.15e-6	Red blood cell count;Mean corpuscular volume;
THYM	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg11494091	chr17:61959527	GH2	1.08	17.14	0.87	7.96e-31	Prudent dietary pattern;
THYM	cis	rs887829	0.609	rs7597496	chr2:234630443	A/G	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.6	-0.43	1.3e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg23750338	chr8:142222470	SLC45A4	0.52	4.87	0.45	4.48e-6	Immature fraction of reticulocytes;
THYM	cis	rs5758511	0.508	rs2854827	chr22:42461918	G/A	cg22189786	chr22:42395067	WBP2NL	0.62	5.17	0.47	1.32e-6	Birth weight;
THYM	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg04944784	chr2:26401820	FAM59B	-0.74	-5.89	-0.52	5.91e-8	Gut microbiome composition (summer);
THYM	cis	rs9467160	0.511	rs2817220	chr6:24505221	G/A	cg00346970	chr6:24499591	ALDH5A1	0.48	5.71	0.51	1.28e-7	Liver enzyme levels;
THYM	cis	rs4606347	0.789	rs61780881	chr1:66167805	C/T	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs55728055	0.661	rs62237833	chr22:32012141	G/A	cg10537193	chr22:32026975	PISD	-0.81	-5.27	-0.48	8.55e-7	Age-related hearing impairment;
THYM	cis	rs11264213	0.818	rs2765012	chr1:36356457	A/G	cg27506609	chr1:36549197	TEKT2	0.92	4.83	0.44	5.3e-6	Schizophrenia;
THYM	cis	rs79149102	0.579	rs8034149	chr15:75311842	G/C	cg17294928	chr15:75287854	SCAMP5	-0.99	-5.4	-0.48	4.9e-7	Lung cancer;
THYM	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg09165964	chr15:75287851	SCAMP5	-1.06	-10.7	-0.74	5.29e-18	Blood trace element (Zn levels);
THYM	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg15604051	chr3:44754201	ZNF502	-0.52	-4.75	-0.44	7.07e-6	Depressive symptoms;
THYM	cis	rs4242434	0.819	rs55776566	chr8:22469492	T/C	cg11461670	chr8:22454935	PDLIM2	-0.32	-6.15	-0.53	1.79e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6032067	0.929	rs2868238	chr20:43826993	C/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg12573674	chr2:1569213	NA	1.22	4.82	0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg03264133	chr6:25882463	NA	-0.68	-5.68	-0.5	1.49e-7	Intelligence (multi-trait analysis);
THYM	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg03929089	chr4:120376271	NA	-1.03	-12.19	-0.78	3.85e-21	Height;
THYM	cis	rs67981189	0.896	rs3814871	chr14:71444788	G/A	cg15910301	chr14:71632612	NA	0.5	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg10802521	chr3:52805072	NEK4	-0.63	-5.33	-0.48	6.63e-7	Electroencephalogram traits;
THYM	trans	rs9929218	1.000	rs28549017	chr16:68758828	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-7.22	-0.6	1.3e-10	Colorectal cancer;
THYM	cis	rs6430585	0.527	rs2254780	chr2:136435526	C/T	cg23851026	chr2:136556271	LCT	0.63	5.81	0.51	8.26e-8	Corneal structure;
THYM	cis	rs6424115	0.830	rs1130321	chr1:24200524	C/T	cg15997130	chr1:24165203	NA	0.76	6.39	0.55	6.14e-9	Immature fraction of reticulocytes;
THYM	cis	rs4563143	0.592	rs12151001	chr19:29283386	C/G	cg12667521	chr19:29218732	NA	0.86	7.18	0.59	1.56e-10	Methadone dose in opioid dependence;
THYM	cis	rs877282	0.945	rs12782447	chr10:771870	C/T	cg10556349	chr10:835070	NA	-0.79	-5.36	-0.48	5.87e-7	Uric acid levels;
THYM	cis	rs459571	0.635	rs379471	chr9:136890649	G/A	cg13789015	chr9:136890014	NCRNA00094	0.83	7.19	0.59	1.45e-10	Platelet distribution width;
THYM	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg10515332	chr4:99064459	C4orf37	0.71	5.67	0.5	1.51e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs478304	0.619	rs10791822	chr11:65428706	T/C	cg27068330	chr11:65405492	SIPA1	-1.07	-11.58	-0.76	7.51e-20	Acne (severe);
THYM	cis	rs1620921	0.967	rs11902	chr6:161174871	C/G	cg17993073	chr6:160527228	IGF2R	0.56	4.45	0.42	2.32e-5	Lipoprotein (a) - cholesterol levels;
THYM	cis	rs9527	0.590	rs2281877	chr10:104866062	C/T	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg17178900	chr1:205818956	PM20D1	-0.67	-5.2	-0.47	1.14e-6	Menarche (age at onset);
THYM	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-15.24	-0.84	2.93e-27	Height;
THYM	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.22	8.06	0.64	2.25e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg00129232	chr17:37814104	STARD3	-0.87	-7.23	-0.6	1.23e-10	Asthma;
THYM	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg17747265	chr1:1875780	NA	-0.8	-9.16	-0.68	1.01e-14	Body mass index;
THYM	cis	rs1499972	0.941	rs62264819	chr3:117671941	T/C	cg07612923	chr3:117604196	NA	1.42	5.49	0.49	3.4e-7	Schizophrenia;
THYM	cis	rs5995756	0.600	rs5757748	chr22:40010636	T/A	cg21377881	chr22:40064566	CACNA1I	-0.55	-4.72	-0.44	8.03e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Bladder cancer;
THYM	cis	rs4662945	0.762	rs2406822	chr2:130218178	C/T	cg05903289	chr2:130345205	NA	-0.57	-5.46	-0.49	3.75e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs6496667	0.533	rs7172909	chr15:90991416	C/T	cg00425431	chr15:90792223	TTLL13	0.4	4.64	0.43	1.11e-5	Rheumatoid arthritis;
THYM	cis	rs490234	0.902	rs7853181	chr9:128223024	C/T	cg14078157	chr9:128172775	NA	0.63	4.8	0.44	5.95e-6	Mean arterial pressure;
THYM	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg04518342	chr5:131593106	PDLIM4	0.48	5.43	0.49	4.4e-7	Blood metabolite levels;
THYM	cis	rs3857067	0.740	rs6532470	chr4:95108211	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs10463554	0.892	rs158408	chr5:102407374	G/A	cg23492399	chr5:102201601	PAM	-0.69	-5.09	-0.46	1.83e-6	Parkinson's disease;
THYM	cis	rs6438424	0.521	rs10934426	chr3:117717570	T/G	cg07910724	chr3:117604411	NA	0.51	4.75	0.44	7.11e-6	Menarche (age at onset);
THYM	cis	rs986417	1.000	rs2351175	chr14:61066730	C/T	cg27398547	chr14:60952738	C14orf39	1.29	6.24	0.54	1.22e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs17641971	0.708	rs2137013	chr8:49981091	C/T	cg00325661	chr8:49890786	NA	0.66	5.01	0.46	2.49e-6	Blood metabolite levels;
THYM	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.97	-5.16	-0.47	1.35e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs17001239	0.850	rs4143370	chr21:26936973	G/C	cg20081244	chr17:79859945	NPB	0.7	6.94	0.58	4.7e-10	Cognitive performance;
THYM	trans	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg05926928	chr17:57297772	GDPD1	1.25	9.86	0.71	3.35e-16	Opioid sensitivity;
THYM	cis	rs1775715	0.870	rs1755080	chr10:32255195	G/A	cg04359828	chr10:32216031	ARHGAP12	0.41	5.21	0.47	1.11e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.75	-5.5	-0.49	3.17e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs747334	0.811	rs11594833	chr10:92715869	T/C	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg06784218	chr1:46089804	CCDC17	-0.32	-4.82	-0.44	5.41e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg13607699	chr17:42295918	UBTF	-0.64	-5.2	-0.47	1.13e-6	Total body bone mineral density;
THYM	cis	rs9733	0.596	rs1336898	chr1:150665050	G/A	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.98	-7.75	-0.62	1.03e-11	Homoarginine levels;
THYM	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg17749961	chr2:30669863	LCLAT1	1.64	7.08	0.59	2.49e-10	Midgestational circulating levels of PBDEs (fetal genetic effect);
THYM	cis	rs4719841	0.662	rs6980357	chr7:25994009	A/G	cg10085138	chr7:25991722	NA	0.57	4.99	0.46	2.74e-6	Triglyceride levels;
THYM	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg02018176	chr4:1364513	KIAA1530	0.56	4.49	0.42	1.99e-5	Obesity-related traits;
THYM	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg24818145	chr4:99064322	C4orf37	0.9	7.52	0.61	3.12e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg06636001	chr8:8085503	FLJ10661	-0.62	-5.37	-0.48	5.66e-7	Mood instability;
THYM	cis	rs2455799	0.613	rs11128762	chr3:15883439	C/T	cg16303742	chr3:15540471	COLQ	-0.56	-5.87	-0.52	6.41e-8	Mean platelet volume;
THYM	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg06238570	chr21:40685208	BRWD1	0.88	6.38	0.55	6.47e-9	Cognitive function;
THYM	cis	rs6570726	0.935	rs384806	chr6:145814889	C/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg14690197	chr8:22456421	C8orf58	-0.52	-4.95	-0.45	3.27e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6960043	0.818	rs6947830	chr7:15064984	A/G	cg19272540	chr7:15055459	NA	0.45	5.03	0.46	2.35e-6	Type 2 diabetes;
THYM	cis	rs6565180	0.888	rs13333093	chr16:30407269	C/A	cg17640201	chr16:30407289	ZNF48	0.92	8.59	0.66	1.71e-13	Tonsillectomy;
THYM	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg05283184	chr6:79620031	NA	-0.89	-8.95	-0.68	2.92e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7010267	0.935	rs6469789	chr8:119960661	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.6	4.87	0.45	4.36e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs28785552	0.931	rs8112235	chr19:53239010	C/G	cg22067481	chr19:53234126	ZNF611	-0.99	-10.22	-0.72	5.6e-17	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs11651000	0.947	rs11657376	chr17:45835984	A/T	cg03474202	chr17:45855739	NA	-0.72	-4.87	-0.45	4.42e-6	IgG glycosylation;
THYM	cis	rs7572733	0.534	rs700678	chr2:198705820	T/C	cg00792783	chr2:198669748	PLCL1	0.83	5.77	0.51	9.68e-8	Dermatomyositis;
THYM	cis	rs4595586	0.545	rs11609541	chr12:39378331	T/C	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs6032067	0.636	rs7272597	chr20:43908869	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.66	-7.12	-0.59	2.02e-10	Blood protein levels;
THYM	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.27	10.84	0.74	2.66e-18	Platelet count;
THYM	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg12311346	chr5:56204834	C5orf35	-0.84	-6.2	-0.54	1.47e-8	Initial pursuit acceleration;
THYM	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg03517284	chr6:25882590	NA	-0.69	-4.66	-0.43	1.02e-5	Height;
THYM	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11563648	0.535	rs4731354	chr7:127019101	C/A	cg23081781	chr7:127225937	GCC1	-0.34	-4.64	-0.43	1.14e-5	Resting heart rate;
THYM	cis	rs7809950	1.000	rs7793613	chr7:107250484	C/T	cg23024343	chr7:107201750	COG5	-0.9	-8.13	-0.64	1.57e-12	Coronary artery disease;
THYM	cis	rs2574704	1.000	rs7433453	chr3:11647416	C/T	cg07643000	chr3:11666825	VGLL4	-0.4	-4.67	-0.43	9.88e-6	Body mass index;
THYM	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg06481639	chr22:41940642	POLR3H	-0.6	-4.78	-0.44	6.26e-6	Neuroticism;
THYM	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs7178572	0.568	rs12914345	chr15:77670401	A/C	cg22256960	chr15:77711686	NA	-0.97	-7.57	-0.61	2.34e-11	Type 2 diabetes;
THYM	cis	rs7681440	0.606	rs986609	chr4:90751415	C/G	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11190604	0.731	rs10883480	chr10:102163821	G/T	cg07570687	chr10:102243282	WNT8B	-0.82	-7.64	-0.62	1.69e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4819052	0.851	rs2838867	chr21:46713092	C/T	cg10803722	chr21:46713166	LOC642852	-0.41	-5.42	-0.49	4.42e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg00024416	chr22:24240387	NA	-0.68	-7.96	-0.63	3.68e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4909189	1.000	rs11764065	chr7:158135974	T/C	cg06219351	chr7:158114137	PTPRN2	-0.8	-7.12	-0.59	2.04e-10	Response to amphetamines;
THYM	cis	rs7177699	0.557	rs8027833	chr15:79112837	T/C	cg15571903	chr15:79123663	NA	0.57	6.57	0.56	2.71e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs12134245	0.776	rs12122066	chr1:92005140	C/T	cg21854759	chr1:92012499	NA	-0.7	-5.67	-0.5	1.5e-7	Breast cancer;
THYM	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22496380	chr5:211416	CCDC127	-1.33	-7.99	-0.63	3.21e-12	Breast cancer;
THYM	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg04317338	chr11:64019027	PLCB3	0.86	5.9	0.52	5.67e-8	Mean platelet volume;
THYM	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg08807101	chr21:30365312	RNF160	-0.67	-4.87	-0.45	4.5e-6	Dental caries;
THYM	cis	rs2811415	0.597	rs9814694	chr3:127792615	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg10018233	chr7:150070692	REPIN1	0.4	5.73	0.51	1.18e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs240110	0.525	rs6917195	chr6:101277926	C/T	cg21058520	chr6:100914733	NA	-0.59	-4.58	-0.43	1.39e-5	Neuroticism;
THYM	cis	rs4523957	0.614	rs1563966	chr17:2095954	A/G	cg16513277	chr17:2031491	SMG6	0.64	5.48	0.49	3.45e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs12765878	1.000	rs4918067	chr10:105644636	A/C	cg11005552	chr10:105648138	OBFC1	0.85	11.02	0.75	1.12e-18	Coronary artery disease;
THYM	cis	rs7940866	0.834	rs7939417	chr11:130853832	T/A	cg23692386	chr11:131799662	NTM	0.51	5.35	0.48	6.1e-7	Schizophrenia;
THYM	cis	rs4919687	0.550	rs11191371	chr10:104459897	G/C	cg18761893	chr10:103892519	PPRC1	0.61	4.69	0.43	9.13e-6	Colorectal cancer;
THYM	cis	rs67981189	0.727	rs221903	chr14:71600208	A/G	cg15910301	chr14:71632612	NA	-0.53	-4.78	-0.44	6.28e-6	Schizophrenia;
THYM	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg24308560	chr3:49941425	MST1R	-0.59	-4.46	-0.42	2.29e-5	Body mass index;
THYM	cis	rs240764	0.507	rs2101814	chr6:101202822	T/A	cg21058520	chr6:100914733	NA	-0.58	-4.54	-0.42	1.66e-5	Neuroticism;
THYM	cis	rs17253792	0.822	rs79483507	chr14:56164718	G/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs728616	0.614	rs11200859	chr10:81713561	A/G	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs77372450	0.551	rs62387669	chr5:157071930	A/G	cg00312553	chr5:157098553	C5orf52	-0.65	-4.63	-0.43	1.16e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg15741354	chr8:8146129	NA	0.3	5.11	0.46	1.63e-6	Joint mobility (Beighton score);
THYM	cis	rs7408868	1.000	rs10415431	chr19:15277027	G/A	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg03388025	chr16:89894329	SPIRE2	0.54	4.54	0.42	1.67e-5	Vitiligo;
THYM	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg08645402	chr16:4508243	NA	0.67	5.4	0.48	4.84e-7	Schizophrenia;
THYM	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg11494091	chr17:61959527	GH2	1.07	16.52	0.86	1.13e-29	Prudent dietary pattern;
THYM	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg20744362	chr22:50050164	C22orf34	0.75	6.87	0.58	6.65e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-5.13	-0.47	1.55e-6	Lymphocyte counts;
THYM	cis	rs11190604	1.000	rs17746014	chr10:102315354	T/C	cg07570687	chr10:102243282	WNT8B	0.75	6.62	0.56	2.11e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs220324	0.688	rs2017391	chr21:43588394	C/T	cg09727148	chr21:43560719	UMODL1	0.66	6.12	0.53	2.08e-8	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg12893697	chr11:970389	AP2A2	-0.31	-5.21	-0.47	1.1e-6	Alzheimer's disease (late onset);
THYM	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg09436375	chr6:42928200	GNMT	-0.45	-5.68	-0.5	1.49e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg27284194	chr4:1044797	NA	0.61	4.6	0.43	1.29e-5	Recombination rate (females);
THYM	cis	rs2282300	0.739	rs1222211	chr11:30362239	A/C	cg06241208	chr11:30344200	C11orf46	-0.86	-6.21	-0.54	1.4e-8	Morning vs. evening chronotype;
THYM	cis	rs7695732	0.550	rs13148188	chr4:89917987	G/A	cg17769793	chr4:89976368	FAM13A	-0.51	-5.44	-0.49	4.15e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs2811415	0.627	rs4602340	chr3:127732942	A/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs3862030	0.839	rs2274351	chr10:104264107	C/T	cg00122347	chr10:104236741	TMEM180	0.48	7.33	0.6	7.69e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs9326248	0.530	rs2127905	chr11:117026374	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.86	4.73	0.44	7.82e-6	Blood protein levels;
THYM	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-15.39	-0.84	1.51e-27	Height;
THYM	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.67	5.9	0.52	5.62e-8	Lung disease severity in cystic fibrosis;
THYM	cis	rs3743104	0.534	rs11854391	chr15:33022582	A/T	cg07179000	chr15:33023586	GREM1	-0.61	-5.7	-0.5	1.35e-7	Hypospadias;
THYM	cis	rs11651000	0.625	rs58067360	chr17:45819587	G/C	cg03474202	chr17:45855739	NA	-0.75	-6.85	-0.57	7.36e-10	IgG glycosylation;
THYM	cis	rs6570726	0.967	rs9497316	chr6:145792387	G/T	cg23711669	chr6:146136114	FBXO30	-0.75	-7.06	-0.59	2.77e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9560113	1.000	rs2104790	chr13:112177412	C/T	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs7943358	0.955	rs1484425	chr11:15693576	A/G	cg11966998	chr11:15692519	NA	-0.5	-5.11	-0.46	1.65e-6	Gut microbiome composition (summer);
THYM	cis	rs1994135	0.669	rs11052746	chr12:33697473	A/C	cg10856724	chr12:34555212	NA	0.66	5.37	0.48	5.49e-7	Resting heart rate;
THYM	cis	rs2777491	0.540	rs7164684	chr15:41705008	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.21	-13.52	-0.81	7.22e-24	Ulcerative colitis;
THYM	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs7512552	0.839	rs1260405	chr1:150304781	A/G	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg09549813	chr16:4587862	C16orf5	-0.56	-6.62	-0.56	2.12e-9	Schizophrenia;
THYM	cis	rs13256369	0.901	rs12681298	chr8:8566235	A/G	cg18904891	chr8:8559673	CLDN23	-0.73	-5.59	-0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs4930776	0.966	rs251783	chr12:5771008	T/G	cg02086166	chr12:5775618	ANO2	0.57	5.51	0.49	3.1e-7	Plasma clusterin levels;
THYM	cis	rs9399401	0.601	rs643975	chr6:142844251	C/G	cg03128060	chr6:142623767	GPR126	-0.55	-6.75	-0.57	1.16e-9	Chronic obstructive pulmonary disease;
THYM	cis	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg13609457	chr4:120235615	NA	0.59	5.39	0.48	5.05e-7	Corneal astigmatism;
THYM	cis	rs4731207	0.596	rs1021080	chr7:124633805	C/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs11696501	0.688	rs2072974	chr20:44313401	G/A	cg11783356	chr20:44313418	WFDC10B	-0.71	-4.79	-0.44	6.07e-6	Brain structure;
THYM	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.65	-11.83	-0.77	2.19e-20	Hemostatic factors and hematological phenotypes;
THYM	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs9470366	0.883	rs12199346	chr6:36641546	C/A	cg24425727	chr6:36645648	CDKN1A	-0.63	-4.95	-0.45	3.17e-6	QRS duration;
THYM	cis	rs6809651	0.524	rs56940353	chr3:185798296	T/C	cg00760338	chr3:185826511	ETV5	-0.89	-7.0	-0.58	3.55e-10	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
THYM	cis	rs3924048	0.574	rs12410270	chr1:12612843	G/A	cg00291366	chr1:12616550	NA	0.41	6.37	0.55	6.58e-9	Optic cup area;
THYM	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg23708337	chr7:1209742	NA	0.78	5.92	0.52	4.99e-8	Longevity;Endometriosis;
THYM	cis	rs1445130	0.786	rs16985390	chr2:18837158	C/A	cg26077359	chr2:19280274	NA	0.87	4.47	0.42	2.17e-5	Bulimia nervosa;
THYM	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21582582	chr3:182698605	DCUN1D1	0.78	6.87	0.58	6.69e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.86	6.62	0.56	2.11e-9	Cognitive test performance;
THYM	cis	rs9814567	0.806	rs4074521	chr3:134325536	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.8	7.87	0.63	5.68e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	trans	rs10802346	0.514	rs5024440	chr1:246372608	G/C	cg22732515	chr19:44031385	ETHE1	1.06	9.24	0.69	7.1e-15	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs3960554	0.733	rs59170362	chr7:75629267	G/C	cg17325771	chr7:75508891	RHBDD2	-0.41	-4.72	-0.44	8.25e-6	Eotaxin levels;
THYM	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg04398451	chr17:18023971	MYO15A	-0.9	-8.29	-0.65	7.43e-13	Total body bone mineral density;
THYM	cis	rs6429082	0.597	rs6683978	chr1:235541425	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.63	-4.69	-0.43	9.16e-6	Adiposity;
THYM	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg12560992	chr17:57184187	TRIM37	-0.92	-8.68	-0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg06074448	chr4:187884817	NA	-1.01	-13.54	-0.81	6.7e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg26441486	chr22:50317300	CRELD2	0.43	6.18	0.54	1.57e-8	Schizophrenia;
THYM	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg22535103	chr8:58192502	C8orf71	-0.93	-4.56	-0.42	1.52e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs17102423	0.963	rs11626496	chr14:65600981	C/G	cg11161011	chr14:65562177	MAX	-0.75	-6.75	-0.57	1.16e-9	Obesity-related traits;
THYM	cis	rs11997175	0.624	rs66475930	chr8:33752570	G/A	ch.8.33884649F	chr8:33765107	NA	0.79	5.51	0.49	3.1e-7	Body mass index;
THYM	cis	rs9326248	0.581	rs7120706	chr11:116830087	C/T	cg20608306	chr11:116969690	SIK3	-0.63	-7.93	-0.63	4.29e-12	Blood protein levels;
THYM	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg04398451	chr17:18023971	MYO15A	0.8	7.75	0.62	1.02e-11	Total body bone mineral density;
THYM	cis	rs7078219	0.714	rs12360459	chr10:101286154	A/G	cg23904955	chr10:101282759	NA	-0.42	-4.97	-0.45	2.99e-6	Dental caries;
THYM	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.58	-0.5	2.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.43	-7.31	-0.6	8.16e-11	Obesity-related traits;
THYM	cis	rs17152411	1.000	rs17152374	chr10:126592644	T/C	cg07906193	chr10:126599966	NA	0.68	4.68	0.43	9.65e-6	Height;
THYM	cis	rs12802200	0.535	rs35391985	chr11:570280	T/C	cg14433983	chr11:636460	DRD4	-0.62	-4.47	-0.42	2.13e-5	Systemic lupus erythematosus;
THYM	cis	rs790123	0.692	rs790118	chr3:122380614	C/A	cg15604389	chr3:122379662	NA	0.59	4.74	0.44	7.47e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs6138458	1.000	rs6138458	chr20:24973769	C/T	cg26195577	chr20:24973756	C20orf3	1.09	11.01	0.75	1.16e-18	Blood protein levels;
THYM	cis	rs16854884	0.632	rs35362423	chr3:143687441	C/A	cg05063096	chr3:143689810	C3orf58	0.72	4.8	0.44	5.9e-6	Economic and political preferences (feminism/equality);
THYM	cis	rs7584330	0.666	rs72620817	chr2:238353661	C/T	cg16989719	chr2:238392110	NA	-0.64	-4.94	-0.45	3.3e-6	Prostate cancer;
THYM	cis	rs6840360	1.000	rs6535818	chr4:152650882	T/G	cg22705602	chr4:152727874	NA	-0.59	-6.36	-0.55	7.09e-9	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg13609457	chr4:120235615	NA	0.5	4.76	0.44	6.95e-6	Corneal astigmatism;
THYM	cis	rs9399401	0.614	rs262125	chr6:142838355	A/T	cg03128060	chr6:142623767	GPR126	0.54	6.43	0.55	5.13e-9	Chronic obstructive pulmonary disease;
THYM	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg06271696	chr7:157225062	NA	-0.7	-6.28	-0.54	1.03e-8	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg06481639	chr22:41940642	POLR3H	-0.75	-5.22	-0.47	1.06e-6	Vitiligo;
THYM	cis	rs9467160	0.581	rs2817244	chr6:24464511	G/T	cg00346970	chr6:24499591	ALDH5A1	0.34	4.63	0.43	1.17e-5	Liver enzyme levels;
THYM	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	5.87	0.52	6.41e-8	Rheumatoid arthritis;
THYM	cis	rs2463822	1.000	rs2513074	chr11:62100880	A/C	cg06239285	chr11:62104954	ASRGL1	1.44	7.77	0.62	9.14e-12	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs1499972	0.938	rs1604060	chr3:117772036	A/G	cg07612923	chr3:117604196	NA	-1.33	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	cis	rs10744422	0.925	rs2292132	chr12:123332834	T/C	cg25930673	chr12:123319894	HIP1R	-0.86	-4.84	-0.44	5.09e-6	Schizophrenia;
THYM	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg24209194	chr3:40518798	ZNF619	0.66	5.36	0.48	5.76e-7	Renal cell carcinoma;
THYM	trans	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg06636001	chr8:8085503	FLJ10661	0.76	6.84	0.57	7.63e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg26384229	chr12:38710491	ALG10B	0.97	8.41	0.65	4.01e-13	Morning vs. evening chronotype;
THYM	cis	rs59698941	0.943	rs67860107	chr5:132276825	G/C	cg02081065	chr5:132209139	LEAP2	-0.73	-4.79	-0.44	6.17e-6	Apolipoprotein A-IV levels;
THYM	cis	rs4319547	0.695	rs6489002	chr12:122929822	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.76	-4.99	-0.46	2.73e-6	Body mass index;
THYM	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg02275930	chr1:2372054	NA	-1.02	-9.0	-0.68	2.27e-14	Non-obstructive azoospermia;
THYM	cis	rs791888	1.000	rs791888	chr10:89412575	G/T	cg13926569	chr10:89418898	PAPSS2	-0.66	-7.22	-0.59	1.3100000000000001e-10	Magnesium levels;
THYM	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.68	6.23	0.54	1.29e-8	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg12000587	chr17:30186630	C17orf79	-0.46	-6.94	-0.58	4.78e-10	Hip circumference adjusted for BMI;
THYM	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg03476357	chr21:30257390	N6AMT1	-0.61	-4.59	-0.43	1.38e-5	Dental caries;
THYM	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg00484396	chr16:3507460	NAT15	-0.77	-10.57	-0.74	1.02e-17	Tuberculosis;
THYM	cis	rs28595532	0.920	rs55640619	chr4:119761999	C/T	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg15704280	chr7:45808275	SEPT13	-0.91	-7.23	-0.6	1.2e-10	Coronary artery disease;
THYM	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-4.48	-0.42	2.06e-5	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg06766960	chr11:133703094	NA	-0.64	-5.86	-0.52	6.62e-8	Childhood ear infection;
THYM	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg08999081	chr20:33150536	PIGU	0.75	6.9	0.58	5.73e-10	Coronary artery disease;
THYM	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	6.13	0.53	1.95e-8	Total body bone mineral density;
THYM	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg07690219	chr3:49449608	TCTA;RHOA	0.69	4.62	0.43	1.19e-5	Menarche (age at onset);
THYM	cis	rs11864146	0.557	rs113190222	chr16:84045361	C/T	cg06701800	chr16:84600468	COTL1	1.01	4.52	0.42	1.77e-5	Non-alcoholic fatty liver disease histology (other);
THYM	cis	rs2404602	0.660	rs11852777	chr15:76929792	A/G	cg23625390	chr15:77176239	SCAPER	-0.93	-6.46	-0.55	4.39e-9	Blood metabolite levels;
THYM	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	13.4	0.81	1.29e-23	Chronic sinus infection;
THYM	cis	rs1975974	1.000	rs4889703	chr17:21721663	T/C	cg18423549	chr17:21743878	NA	-0.55	-4.47	-0.42	2.14e-5	Psoriasis;
THYM	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg00640147	chr17:61958756	GH2	-0.44	-4.68	-0.43	9.62e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg27572855	chr1:25598939	RHD	0.69	5.34	0.48	6.29e-7	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	8.38	0.65	4.65e-13	Lung cancer in ever smokers;
THYM	cis	rs2637266	0.875	rs2395409	chr10:78381004	A/G	cg18941641	chr10:78392320	NA	0.6	4.79	0.44	6.09e-6	Pulmonary function;
THYM	cis	rs9790314	0.875	rs336580	chr3:161082982	A/T	cg04691961	chr3:161091175	C3orf57	-0.65	-5.72	-0.51	1.24e-7	Morning vs. evening chronotype;
THYM	cis	rs35883536	0.588	rs955338	chr1:101108794	G/C	cg06223162	chr1:101003688	GPR88	0.58	5.16	0.47	1.34e-6	Monocyte count;
THYM	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg22875332	chr1:76189707	ACADM	-0.54	-5.15	-0.47	1.39e-6	Daytime sleep phenotypes;
THYM	trans	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg10856724	chr12:34555212	NA	-0.87	-7.41	-0.61	5.14e-11	Bladder cancer;
THYM	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.37	-0.48	5.64e-7	Total cholesterol levels;
THYM	cis	rs3126085	0.935	rs1390485	chr1:152182168	C/T	cg10321714	chr1:152280068	FLG	-0.69	-5.03	-0.46	2.27e-6	Atopic dermatitis;
THYM	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs36051895	0.695	rs11794778	chr9:5023794	G/T	cg02405213	chr9:5042618	JAK2	-1.02	-10.56	-0.73	1.04e-17	Pediatric autoimmune diseases;
THYM	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg07167872	chr1:205819463	PM20D1	0.69	4.54	0.42	1.62e-5	Parkinson's disease;
THYM	cis	rs2072510	0.618	rs12302993	chr12:96393261	A/G	cg18817487	chr12:96390143	HAL	0.48	6.19	0.54	1.55e-8	Metabolite levels (small molecules and protein measures);
THYM	cis	rs4901869	0.966	rs1820557	chr14:59334863	C/G	cg02291164	chr14:59296302	NA	0.8	7.85	0.63	6.35e-12	Panic disorder;
THYM	cis	rs8112449	0.894	rs12982179	chr19:10512400	G/A	cg01466491	chr19:10523363	NA	-0.67	-6.42	-0.55	5.34e-9	Multiple sclerosis;Gastritis;
THYM	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	8.87	0.67	4.33e-14	Chronic sinus infection;
THYM	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg24163568	chr5:669837	TPPP	0.59	5.48	0.49	3.53e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs6495367	1.000	rs745030	chr15:79381705	G/A	cg17916960	chr15:79447300	NA	0.59	6.49	0.55	3.8e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg13679303	chr9:96623674	NA	-0.57	-5.87	-0.52	6.5e-8	DNA methylation (variation);
THYM	cis	rs4646404	0.509	rs897450	chr17:17475350	T/G	cg11245205	chr17:17398264	RASD1	-0.41	-4.65	-0.43	1.06e-5	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
THYM	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg15704280	chr7:45808275	SEPT13	1.02	8.22	0.64	1.04e-12	Coronary artery disease;
THYM	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg15110403	chr19:17392923	ANKLE1	-0.58	-5.01	-0.46	2.46e-6	Systemic lupus erythematosus;
THYM	cis	rs17534004	1.000	rs35955426	chr13:31471381	A/G	cg13251181	chr13:31481184	C13orf33	0.55	4.52	0.42	1.77e-5	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs5758511	0.680	rs5751243	chr22:42617177	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.47	4.6	0.43	1.31e-5	Birth weight;
THYM	cis	rs910187	0.678	rs3818014	chr20:45816649	C/T	cg27589058	chr20:45804311	EYA2	-0.59	-5.04	-0.46	2.21e-6	Migraine;
THYM	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg14784868	chr12:69753453	YEATS4	1.13	12.26	0.78	2.8e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs988913	1.000	rs960834	chr6:54823431	C/T	cg18532076	chr6:54711417	FAM83B	0.55	5.31	0.48	7.21e-7	Menarche (age at onset);
THYM	cis	rs7828089	1.000	rs34542820	chr8:22264079	C/T	cg12081754	chr8:22256438	SLC39A14	0.63	5.51	0.49	3.02e-7	Verbal declarative memory;
THYM	cis	rs9419702	0.614	rs9419567	chr10:133535149	C/G	cg23460707	chr10:133558971	NA	0.44	4.55	0.42	1.58e-5	Survival in rectal cancer;
THYM	cis	rs12190007	0.508	rs9406321	chr6:169726841	A/T	cg16388071	chr6:169726476	NA	0.77	6.69	0.57	1.54e-9	Obesity-related traits;
THYM	cis	rs12200560	0.505	rs4839848	chr6:97076577	G/A	cg06623918	chr6:96969491	KIAA0776	0.78	6.01	0.52	3.39e-8	Coronary heart disease;
THYM	cis	rs300703	0.935	rs10167992	chr2:263270	C/T	cg21211680	chr2:198530	NA	-1.22	-5.23	-0.47	9.98e-7	Blood protein levels;
THYM	cis	rs1011018	0.628	rs73158616	chr7:139438551	T/C	cg06079564	chr7:139468310	HIPK2	-0.73	-4.8	-0.44	6e-6	Systolic blood pressure;
THYM	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24549020	chr5:56110836	MAP3K1	0.69	4.52	0.42	1.8e-5	Initial pursuit acceleration;
THYM	cis	rs1371867	0.875	rs1788176	chr8:101332112	A/G	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs1978968	1.000	rs5992919	chr22:18443855	A/G	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs7592578	0.771	rs4439990	chr2:191398353	A/C	cg21644426	chr2:191273491	MFSD6	-0.65	-4.48	-0.42	2.11e-5	Diastolic blood pressure;
THYM	cis	rs6674176	0.597	rs2352990	chr1:44393276	T/A	cg13246856	chr1:44399776	ARTN	0.49	4.69	0.43	9.01e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg07936489	chr17:37558343	FBXL20	0.87	5.78	0.51	9.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg08564027	chr20:61660810	NA	0.9	9.5	0.7	1.96e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.81	-6.18	-0.54	1.57e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12681287	0.547	rs13261956	chr8:87478765	G/A	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs3771570	0.901	rs28433352	chr2:242339656	A/G	cg21155796	chr2:242212141	HDLBP	1.09	6.4	0.55	5.95e-9	Prostate cancer;
THYM	cis	rs7178572	0.633	rs4886876	chr15:77838491	C/T	cg22256960	chr15:77711686	NA	-0.77	-5.95	-0.52	4.54e-8	Type 2 diabetes;
THYM	cis	rs896854	0.517	rs1011796	chr8:95951273	A/G	cg16049864	chr8:95962084	TP53INP1	0.78	5.72	0.51	1.22e-7	Type 2 diabetes;
THYM	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg03806693	chr22:41940476	POLR3H	-1.05	-8.68	-0.66	1.11e-13	Vitiligo;
THYM	cis	rs4243830	1.000	rs41278014	chr1:6579653	G/C	cg22792644	chr1:6614718	TAS1R1;NOL9	1.11	6.31	0.54	8.67e-9	Body mass index;
THYM	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg21280719	chr6:42927975	GNMT	-0.53	-7.35	-0.6	6.87e-11	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg16624210	chr5:671434	TPPP	-0.64	-6.68	-0.57	1.61e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.83	-6.89	-0.58	6.14e-10	Menarche (age at onset);
THYM	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg02725872	chr8:58115012	NA	-0.9	-5.24	-0.47	9.85e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg09307838	chr4:120376055	NA	0.78	5.89	0.52	5.7e-8	Corneal astigmatism;
THYM	cis	rs859767	0.741	rs7602801	chr2:135363870	A/G	cg12500956	chr2:135428796	TMEM163	-0.49	-4.98	-0.46	2.8e-6	Neuroticism;
THYM	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg00012203	chr2:219082015	ARPC2	0.89	8.63	0.66	1.37e-13	Colorectal cancer;
THYM	cis	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg14019146	chr3:50243930	SLC38A3	0.53	4.56	0.42	1.51e-5	Menarche (age at onset);
THYM	cis	rs6430585	0.528	rs309162	chr2:136690783	T/A	cg20242066	chr2:136595261	LCT	0.47	4.64	0.43	1.11e-5	Corneal structure;
THYM	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.63	5.57	0.5	2.33e-7	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs4285214	0.715	rs12515071	chr5:124031011	C/T	cg15082166	chr5:124005151	ZNF608	0.57	4.59	0.43	1.34e-5	Survival in pancreatic cancer;
THYM	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg00376283	chr12:123451042	ABCB9	0.8	6.39	0.55	6.04e-9	Platelet count;
THYM	cis	rs6565180	0.962	rs6565182	chr16:30374381	C/T	cg17640201	chr16:30407289	ZNF48	-0.87	-7.42	-0.61	4.83e-11	Tonsillectomy;
THYM	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg07599136	chr5:415885	AHRR	0.93	5.17	0.47	1.29e-6	Fat distribution (HIV);
THYM	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg17689763	chr4:710664	PCGF3	-1.12	-10.08	-0.72	1.11e-16	White blood cell count;
THYM	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg16586182	chr3:47516702	SCAP	0.65	5.74	0.51	1.15e-7	Colorectal cancer;
THYM	cis	rs28595532	0.920	rs116668854	chr4:119707642	A/G	cg14228332	chr4:119757509	SEC24D	1.35	4.52	0.42	1.81e-5	Cannabis dependence symptom count;
THYM	cis	rs9515201	0.774	rs9521739	chr13:111038803	A/G	cg26053697	chr13:111039873	COL4A2	0.54	4.57	0.42	1.47e-5	White matter hyperintensity burden;
THYM	cis	rs11645898	0.511	rs72787023	chr16:72031105	T/C	cg03805757	chr16:71968109	PKD1L3	-0.61	-4.62	-0.43	1.21e-5	Blood protein levels;
THYM	cis	rs3126085	0.935	rs991231	chr1:152211898	T/G	cg10321714	chr1:152280068	FLG	-0.65	-4.67	-0.43	9.95e-6	Atopic dermatitis;
THYM	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg26384229	chr12:38710491	ALG10B	0.94	7.82	0.63	7.06e-12	Bladder cancer;
THYM	cis	rs427394	0.659	rs274678	chr5:6752385	A/G	cg10857441	chr5:6722123	POLS	0.69	7.51	0.61	3.18e-11	Menopause (age at onset);
THYM	cis	rs35883536	0.588	rs72977389	chr1:101107053	A/C	cg09408571	chr1:101003634	GPR88	0.4	4.9	0.45	3.88e-6	Monocyte count;
THYM	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg04944784	chr2:26401820	FAM59B	1.09	8.74	0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs1729951	0.575	rs1682333	chr3:136688618	G/A	cg12473912	chr3:136751656	NA	0.63	5.12	0.47	1.57e-6	Neuroticism;
THYM	cis	rs765787	0.530	rs1706834	chr15:45517854	G/A	cg24006582	chr15:45444508	DUOX1	-0.84	-7.2	-0.59	1.39e-10	Uric acid levels;
THYM	cis	rs4731207	0.698	rs12533560	chr7:124561882	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.76	-0.44	6.98e-6	Crohn's disease;
THYM	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg25554036	chr4:6271136	WFS1	0.59	5.47	0.49	3.68e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	trans	rs877282	0.945	rs11253398	chr10:790012	T/C	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg18132916	chr6:79620363	NA	-0.59	-5.3	-0.48	7.63e-7	Intelligence (multi-trait analysis);
THYM	cis	rs665401	1.000	rs63749614	chr6:117257006	A/C	cg20376953	chr6:117187980	NA	0.55	4.49	0.42	1.99e-5	Neutrophil percentage of granulocytes;
THYM	trans	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.94	-8.76	-0.67	7.24e-14	Brugada syndrome;
THYM	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg13114125	chr14:105738426	BRF1	-0.73	-5.64	-0.5	1.73e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4845459	0.935	rs4845449	chr1:152591024	A/T	cg26135325	chr1:152595322	LCE3A	-0.4	-4.64	-0.43	1.12e-5	Psoriasis;
THYM	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg10802521	chr3:52805072	NEK4	-0.71	-5.96	-0.52	4.22e-8	Bipolar disorder;
THYM	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg05896524	chr21:47604654	C21orf56	-0.83	-5.44	-0.49	4.15e-7	Testicular germ cell tumor;
THYM	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg05738196	chr6:26577821	NA	-0.57	-4.55	-0.42	1.58e-5	Schizophrenia;
THYM	cis	rs11756438	0.683	rs72962906	chr6:119008305	C/T	cg01113488	chr6:119027122	NA	0.56	4.5	0.42	1.92e-5	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9510787	0.947	rs9510785	chr13:24189149	T/C	cg24659858	chr13:24270321	NA	0.48	4.55	0.42	1.59e-5	Nasopharyngeal carcinoma;
THYM	cis	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg16898833	chr6:26189333	HIST1H4D	1.33	4.95	0.45	3.27e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg16989719	chr2:238392110	NA	-0.65	-5.95	-0.52	4.44e-8	Prostate cancer;
THYM	cis	rs9682041	0.561	rs6790483	chr3:170154406	G/A	cg11886554	chr3:170076028	SKIL	1.4	5.58	0.5	2.24e-7	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs4363385	0.747	rs4478766	chr1:152984906	G/A	cg13444842	chr1:152974279	SPRR3	-0.58	-4.71	-0.44	8.32e-6	Inflammatory skin disease;
THYM	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg18230493	chr5:56204884	C5orf35	-0.89	-6.53	-0.56	3.25e-9	Initial pursuit acceleration;
THYM	cis	rs2066819	0.786	rs111580405	chr12:56739557	A/G	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs595982	0.527	rs17206707	chr19:49361441	A/C	cg21252483	chr19:49399788	TULP2	-0.83	-5.69	-0.5	1.38e-7	Red cell distribution width;
THYM	cis	rs4642101	0.561	rs7638333	chr3:12806142	T/C	cg05775895	chr3:12838266	CAND2	0.74	5.93	0.52	4.79e-8	QRS complex (12-leadsum);
THYM	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg00530320	chr1:46809349	NSUN4	0.75	5.26	0.47	8.89e-7	Menopause (age at onset);
THYM	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg24874828	chr4:187887005	NA	-0.76	-8.24	-0.65	9.29e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7312774	0.618	rs3759317	chr12:107370252	T/C	cg16260113	chr12:107380972	MTERFD3	1.34	7.29	0.6	9.07e-11	Severe influenza A (H1N1) infection;
THYM	cis	rs977987	0.806	rs34996006	chr16:75479434	A/G	cg03315344	chr16:75512273	CHST6	0.74	5.92	0.52	5.07e-8	Dupuytren's disease;
THYM	cis	rs4731207	0.596	rs2170351	chr7:124642197	A/G	cg05285228	chr7:124571219	POT1	-0.68	-5.08	-0.46	1.88e-6	Cutaneous malignant melanoma;
THYM	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg02038168	chr22:39784481	NA	-0.62	-5.08	-0.46	1.92e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs17407555	0.779	rs6851524	chr4:10155041	C/A	cg00071950	chr4:10020882	SLC2A9	-0.76	-5.68	-0.5	1.45e-7	Schizophrenia (age at onset);
THYM	cis	rs1894633	0.574	rs56340136	chr1:172326143	A/T	cg13446689	chr1:172328377	DNM3	0.53	4.84	0.44	5.02e-6	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg12292205	chr6:26970375	C6orf41	-0.79	-4.95	-0.45	3.16e-6	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg06521331	chr12:34319734	NA	-1.03	-10.3	-0.73	3.74e-17	Morning vs. evening chronotype;
THYM	cis	rs9790314	1.000	rs459697	chr3:161093420	G/A	cg04691961	chr3:161091175	C3orf57	-0.6	-5.24	-0.47	9.62e-7	Morning vs. evening chronotype;
THYM	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg01324343	chr3:183735012	ABCC5	0.72	8.35	0.65	5.61e-13	Anterior chamber depth;
THYM	cis	rs11225247	1.000	rs17350205	chr11:102296024	A/G	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs2273669	0.504	rs112774011	chr6:109495028	G/A	cg17117243	chr6:109341365	SESN1	-0.82	-4.8	-0.44	5.98e-6	Prostate cancer;
THYM	cis	rs28595532	0.764	rs116158926	chr4:119730572	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs12643440	0.538	rs60281935	chr4:17143251	G/A	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2806561	0.765	rs9426692	chr1:23508426	C/T	cg19743168	chr1:23544995	NA	0.55	5.6	0.5	2.09e-7	Height;
THYM	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs4919687	0.550	rs11191372	chr10:104462187	T/C	cg05855489	chr10:104503620	C10orf26	0.68	5.35	0.48	5.95e-7	Colorectal cancer;
THYM	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2901656	0.652	rs3213563	chr1:172412995	T/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.61	6.75	0.57	1.16e-9	Red cell distribution width;Platelet distribution width;
THYM	cis	rs7769051	0.522	rs6934190	chr6:133116664	G/A	cg07930552	chr6:133119739	C6orf192	1.14	4.51	0.42	1.82e-5	Type 2 diabetes nephropathy;
THYM	cis	rs4713118	0.662	rs149969	chr6:27977737	A/G	cg23161317	chr6:28129485	ZNF389	0.9	6.59	0.56	2.41e-9	Parkinson's disease;
THYM	cis	rs1609391	0.543	rs9828009	chr3:136631275	C/T	cg15507776	chr3:136538369	TMEM22	0.64	4.9	0.45	4.02e-6	Neuroticism;
THYM	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg08048268	chr3:133502702	NA	-0.69	-5.64	-0.5	1.78e-7	Iron status biomarkers;
THYM	cis	rs10911232	0.507	rs4652763	chr1:182994084	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg22841779	chr14:105766346	BRF1	0.49	6.25	0.54	1.15e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1691799	0.899	rs1168307	chr12:66739539	A/G	cg16791601	chr12:66731901	HELB	-0.76	-7.18	-0.59	1.54e-10	White blood cell count (basophil);
THYM	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	trans	rs208520	0.661	rs207090	chr6:66783963	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.66	-0.62	1.53e-11	Exhaled nitric oxide output;
THYM	cis	rs9399401	0.677	rs11155241	chr6:142664439	T/A	cg03128060	chr6:142623767	GPR126	0.69	8.6	0.66	1.65e-13	Chronic obstructive pulmonary disease;
THYM	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg24375607	chr4:120327624	NA	0.65	4.53	0.42	1.69e-5	Corneal astigmatism;
THYM	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11890956	chr21:40555474	PSMG1	-0.63	-5.73	-0.51	1.2e-7	Menarche (age at onset);
THYM	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08704250	chr15:31115839	NA	-0.51	-6.06	-0.53	2.67e-8	Huntington's disease progression;
THYM	cis	rs4363385	0.747	rs946098	chr1:152975038	A/C	cg13444842	chr1:152974279	SPRR3	-0.6	-4.78	-0.44	6.32e-6	Inflammatory skin disease;
THYM	cis	rs425535	0.817	rs168449	chr4:74850623	T/C	cg07868155	chr4:74864709	CXCL5	0.66	5.57	0.5	2.41e-7	Blood protein levels;
THYM	cis	rs12681288	0.823	rs4735974	chr8:1000218	T/G	cg04918696	chr8:1004106	NA	-0.46	-4.96	-0.45	3.03e-6	Schizophrenia;
THYM	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg06481639	chr22:41940642	POLR3H	-0.62	-4.54	-0.42	1.62e-5	Neuroticism;
THYM	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg08885076	chr2:99613938	TSGA10	0.69	6.47	0.55	4.31e-9	Chronic sinus infection;
THYM	cis	rs28595532	0.841	rs114155681	chr4:119736427	A/G	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs8067545	1.000	rs28807825	chr17:19942850	G/A	cg20830565	chr17:20408647	MGC102966	-0.48	-4.46	-0.42	2.23e-5	Schizophrenia;
THYM	cis	rs4660531	1.000	rs61774746	chr1:41838561	T/G	cg19619003	chr1:41846758	NA	-0.24	-4.58	-0.43	1.4e-5	Bipolar disorder;
THYM	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg19913688	chr11:428466	ANO9	-0.93	-4.71	-0.43	8.59e-6	Body mass index;
THYM	cis	rs7084402	0.967	rs7098606	chr10:60277089	C/T	cg09696939	chr10:60272079	BICC1	0.47	5.47	0.49	3.63e-7	Refractive error;
THYM	cis	rs17854409	0.881	rs68066790	chr20:61487150	T/A	cg06598544	chr20:61472147	COL9A3	-1.13	-7.52	-0.61	2.98e-11	Obesity-related traits;
THYM	cis	rs9419702	0.568	rs11156445	chr10:133542301	T/C	cg04492858	chr10:133558786	NA	0.43	4.45	0.42	2.29e-5	Survival in rectal cancer;
THYM	cis	rs10231759	0.617	rs4725947	chr7:150514529	A/G	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.61	4.77	0.44	6.57e-6	Height;
THYM	cis	rs28595532	0.920	rs113034745	chr4:119750044	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs8064024	0.513	rs1049208	chr16:4934549	G/A	cg08329684	chr16:4932620	PPL	-0.34	-4.56	-0.42	1.55e-5	Cancer;
THYM	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg10856724	chr12:34555212	NA	-0.92	-9.27	-0.69	6.02e-15	Morning vs. evening chronotype;
THYM	cis	rs7567389	0.564	rs10209483	chr2:128158637	C/T	cg06038358	chr2:128176007	PROC	-0.46	-5.1	-0.46	1.72e-6	Self-rated health;
THYM	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg20503657	chr10:835505	NA	1.14	8.1	0.64	1.82e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs7586879	0.789	rs17046737	chr2:25127835	C/T	cg01884057	chr2:25150051	NA	0.53	4.64	0.43	1.13e-5	Body mass index;
THYM	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg05182265	chr7:156933206	UBE3C	-0.69	-9.32	-0.69	4.58e-15	Body mass index;
THYM	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg08132940	chr7:1081526	C7orf50	-1.17	-6.67	-0.56	1.7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9902453	0.704	rs1972305	chr17:28533880	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.79	0.44	6.11e-6	Coffee consumption (cups per day);
THYM	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg21926883	chr2:100939477	LONRF2	-0.67	-6.31	-0.54	8.96e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg08772003	chr10:104629869	AS3MT	-0.63	-5.62	-0.5	1.87e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg21427119	chr20:30132790	HM13	-0.86	-5.96	-0.52	4.2e-8	Mean corpuscular hemoglobin;
THYM	cis	rs2898681	0.874	rs4864688	chr4:53742636	A/G	cg00791764	chr4:53727839	RASL11B	0.46	5.72	0.51	1.24e-7	Optic nerve measurement (cup area);
THYM	cis	rs6953213	0.793	rs117303191	chr7:7300574	G/A	cg19603390	chr7:7222222	C1GALT1	1.03	4.53	0.42	1.73e-5	Smooth-surface caries;
THYM	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg22907277	chr7:1156413	C7orf50	0.63	5.61	0.5	2.02e-7	Longevity;Endometriosis;
THYM	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg22166914	chr1:53195759	ZYG11B	0.82	7.82	0.63	7.16e-12	Monocyte count;
THYM	cis	rs55728055	0.661	rs8142821	chr22:31941240	A/C	cg10537193	chr22:32026975	PISD	-0.92	-5.68	-0.5	1.45e-7	Age-related hearing impairment;
THYM	cis	rs4642101	0.824	rs3889514	chr3:12844072	T/C	cg05775895	chr3:12838266	CAND2	0.94	8.62	0.66	1.49e-13	QRS complex (12-leadsum);
THYM	cis	rs1642645	0.831	rs7541929	chr1:42479393	G/A	cg06092502	chr1:42611687	NA	0.61	4.74	0.44	7.58e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs2522056	1.000	rs6874639	chr5:131778716	C/T	cg24060327	chr5:131705240	SLC22A5	-0.77	-5.1	-0.46	1.71e-6	Lymphocyte counts;Fibrinogen;
THYM	cis	rs7432375	0.899	rs6439655	chr3:136466599	A/G	cg21827317	chr3:136751795	NA	-0.65	-5.52	-0.49	2.99e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg03684893	chr10:554711	DIP2C	0.61	5.2	0.47	1.14e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.56	0.5	2.47e-7	Height;
THYM	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03517284	chr6:25882590	NA	-0.78	-6.24	-0.54	1.22e-8	Blood metabolite levels;
THYM	cis	rs3020333	0.875	rs2941742	chr6:152012988	A/G	cg22157087	chr6:152012887	ESR1	0.44	4.94	0.45	3.36e-6	Total body bone mineral density;
THYM	cis	rs68170813	0.559	rs12538090	chr7:106974647	T/C	cg00661777	chr7:106511741	PIK3CG	-0.66	-4.61	-0.43	1.25e-5	Coronary artery disease;
THYM	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg06634786	chr22:41940651	POLR3H	0.68	5.44	0.49	4.14e-7	Vitiligo;
THYM	cis	rs55728055	0.661	rs55931230	chr22:32028028	T/A	cg01338084	chr22:32026380	PISD	1.5	6.36	0.55	6.89e-9	Age-related hearing impairment;
THYM	cis	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs72828912	0.831	rs2176934	chr6:24094194	A/T	cg19882886	chr6:25043046	NA	0.78	5.35	0.48	6.08e-7	Squamous cell lung carcinoma;
THYM	cis	rs1957429	0.808	rs763346	chr14:65330386	A/G	cg23373153	chr14:65346875	NA	-0.95	-5.17	-0.47	1.28e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg08296037	chr16:1584118	IFT140;TMEM204	-0.63	-5.5	-0.49	3.21e-7	Coronary artery disease;
THYM	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg08999081	chr20:33150536	PIGU	0.79	7.48	0.61	3.72e-11	Coronary artery disease;
THYM	cis	rs2637266	0.543	rs1907327	chr10:78254112	A/G	cg18941641	chr10:78392320	NA	0.6	4.55	0.42	1.57e-5	Pulmonary function;
THYM	cis	rs9790314	0.586	rs16832279	chr3:161120483	C/T	cg03342759	chr3:160939853	NMD3	-0.84	-7.31	-0.6	8.38e-11	Morning vs. evening chronotype;
THYM	cis	rs3750965	0.959	rs2253658	chr11:68856804	C/G	cg06818126	chr11:68850279	TPCN2	-0.66	-4.47	-0.42	2.14e-5	Hair color;
THYM	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg15212455	chr7:39170539	POU6F2	0.64	6.01	0.52	3.44e-8	IgG glycosylation;
THYM	cis	rs1021993	0.868	rs6674103	chr1:209530638	A/G	cg24997231	chr1:209527535	NA	-0.59	-4.59	-0.43	1.36e-5	Gut microbiome composition (winter);
THYM	cis	rs6430585	0.528	rs115469964	chr2:136696608	A/C	cg20242066	chr2:136595261	LCT	0.5	4.86	0.45	4.68e-6	Corneal structure;
THYM	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7617773	0.743	rs11715876	chr3:48377922	G/A	cg02219026	chr3:48282209	ZNF589	-0.69	-4.77	-0.44	6.55e-6	Coronary artery disease;
THYM	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-13.94	-0.82	1.07e-24	Height;
THYM	cis	rs12135062	0.755	rs1553287	chr1:3101277	G/A	cg25382214	chr1:3105252	PRDM16	-0.54	-4.5	-0.42	1.94e-5	Migraine;
THYM	cis	rs1061377	1.000	rs9998867	chr4:39119162	G/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs12935418	0.672	rs9925780	chr16:81045176	C/T	cg16651780	chr16:81037892	C16orf61	0.89	6.43	0.55	5.07e-9	Mean corpuscular volume;
THYM	cis	rs9914988	0.943	rs28847895	chr17:27172520	T/C	cg20469991	chr17:27169893	C17orf63	-0.83	-5.36	-0.48	5.75e-7	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs36051895	0.559	rs10815172	chr9:5212254	T/A	cg02405213	chr9:5042618	JAK2	-0.88	-8.68	-0.66	1.11e-13	Pediatric autoimmune diseases;
THYM	cis	rs13088645	0.683	rs9790169	chr3:134151959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-5.5	-0.49	3.16e-7	Coronary artery disease;
THYM	cis	rs4638749	0.953	rs4676033	chr2:108869368	G/A	cg06795125	chr2:108905320	SULT1C2	-0.42	-5.48	-0.49	3.42e-7	Blood pressure;
THYM	cis	rs4242434	0.889	rs4592028	chr8:22449484	T/C	cg01710189	chr8:22454888	PDLIM2	-0.54	-5.08	-0.46	1.9e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.63	-4.6	-0.43	1.31e-5	Aortic root size;
THYM	cis	rs240764	0.717	rs1039031	chr6:101161812	A/G	cg21058520	chr6:100914733	NA	-0.59	-5.13	-0.47	1.52e-6	Neuroticism;
THYM	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg18357526	chr6:26021779	HIST1H4A	0.71	6.12	0.53	2.04e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9905704	0.918	rs4132924	chr17:56937653	C/T	cg12560992	chr17:57184187	TRIM37	0.67	4.68	0.43	9.59e-6	Testicular germ cell tumor;
THYM	cis	rs6960043	0.818	rs4719433	chr7:15065003	A/G	cg19272540	chr7:15055459	NA	-0.45	-5.03	-0.46	2.35e-6	Type 2 diabetes;
THYM	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs2898681	0.642	rs62336790	chr4:53728000	T/C	cg00338735	chr4:53728038	RASL11B	0.57	5.4	0.48	4.86e-7	Optic nerve measurement (cup area);
THYM	cis	rs2018683	0.677	rs12540529	chr7:28969384	A/G	cg27487796	chr7:28973253	NA	-0.26	-4.62	-0.43	1.19e-5	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
THYM	cis	rs9393777	0.588	rs4518487	chr6:26467531	A/G	cg12826209	chr6:26865740	GUSBL1	1.0	6.87	0.58	6.74e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6980334	1.000	rs6977075	chr7:137775867	C/T	cg26979473	chr7:137028389	PTN	-0.61	-4.5	-0.42	1.92e-5	Blood metabolite ratios;
THYM	cis	rs40363	0.857	rs55989968	chr16:3530658	C/G	cg21433313	chr16:3507492	NAT15	0.78	6.7	0.57	1.43e-9	Tuberculosis;
THYM	cis	rs778371	1.000	rs709937	chr2:233744021	A/G	cg08000102	chr2:233561755	GIGYF2	0.83	6.81	0.57	8.6e-10	Schizophrenia;
THYM	cis	rs10489202	0.909	rs61809580	chr1:168091602	A/C	cg24449463	chr1:168025552	DCAF6	-0.67	-4.97	-0.45	2.94e-6	Schizophrenia;
THYM	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg13918804	chr1:2043761	PRKCZ	-0.61	-4.62	-0.43	1.19e-5	Height;
THYM	cis	rs4866334	1.000	rs74851546	chr5:18487135	C/T	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs61931739	0.890	rs1705748	chr12:34133171	A/G	cg10856724	chr12:34555212	NA	-0.6	-5.27	-0.48	8.62e-7	Morning vs. evening chronotype;
THYM	cis	rs7072216	0.763	rs7914401	chr10:100163928	A/G	cg03852570	chr10:100175106	PYROXD2	0.35	4.52	0.42	1.81e-5	Metabolite levels;
THYM	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg04362960	chr10:104952993	NT5C2	0.57	4.68	0.43	9.7e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7772486	0.720	rs6931553	chr6:146112348	T/C	cg23711669	chr6:146136114	FBXO30	-0.98	-10.47	-0.73	1.68e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg25208724	chr1:156163844	SLC25A44	1.01	10.48	0.73	1.58e-17	Testicular germ cell tumor;
THYM	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg24803719	chr17:45855879	NA	-0.6	-6.24	-0.54	1.22e-8	IgG glycosylation;
THYM	cis	rs7640424	0.620	rs71321252	chr3:107813107	A/C	cg09227934	chr3:107805635	CD47	-0.7	-5.2	-0.47	1.16e-6	Body mass index;
THYM	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.66	5.65	0.5	1.71e-7	Chronic sinus infection;
THYM	cis	rs4648845	0.777	rs2477686	chr1:2392648	C/G	cg02275930	chr1:2372054	NA	-0.77	-6.2	-0.54	1.47e-8	Schizophrenia;
THYM	cis	rs4285028	0.603	rs79312528	chr3:121608997	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.82	-5.82	-0.51	7.91e-8	Multiple sclerosis;
THYM	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg13010199	chr12:38710504	ALG10B	0.72	5.61	0.5	1.98e-7	Heart rate;
THYM	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg04520793	chr17:42248056	ASB16	0.34	4.77	0.44	6.73e-6	Total body bone mineral density;
THYM	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg00080972	chr5:178986291	RUFY1	0.49	5.58	0.5	2.29e-7	Lung cancer;
THYM	cis	rs11456569	1	rs11456569	chr1:19749551	C/CT	cg24593138	chr1:19687988	CAPZB	0.54	4.95	0.45	3.2e-6	Plateletcrit;
THYM	cis	rs10788264	0.504	rs10749452	chr10:124028141	A/G	cg09507567	chr10:124027408	NA	0.52	5.39	0.48	5.03e-7	Total body bone mineral density;
THYM	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	5.19	0.47	1.2e-6	Schizophrenia;
THYM	cis	rs7122539	0.646	rs627330	chr11:66602099	C/T	cg24851651	chr11:66362959	CCS	0.65	5.7	0.5	1.37e-7	HIV-1 susceptibility;
THYM	cis	rs12681287	0.546	rs11539113	chr8:87497176	G/A	cg27223183	chr8:87520930	FAM82B	-0.71	-5.09	-0.46	1.82e-6	Caudate activity during reward;
THYM	cis	rs713587	0.719	rs58048722	chr2:25187825	C/T	cg15423357	chr2:25149977	NA	-0.58	-5.95	-0.52	4.43e-8	Body mass index in non-asthmatics;
THYM	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg14584255	chr6:163149320	PACRG;PARK2	-0.54	-4.81	-0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1003719	0.788	rs2835582	chr21:38458773	C/G	cg01329690	chr21:38580129	DSCR9	0.37	5.07	0.46	1.94e-6	Eye color traits;
THYM	cis	rs8114671	0.967	rs1577924	chr20:33784288	C/G	cg08999081	chr20:33150536	PIGU	-0.53	-4.77	-0.44	6.63e-6	Height;
THYM	cis	rs12367572	0.663	rs4561266	chr12:45415763	C/T	cg03114573	chr12:45410052	DBX2	-0.58	-5.36	-0.48	5.75e-7	Gut microbiome composition (summer);
THYM	cis	rs13070279	0.655	rs13079978	chr3:71786919	A/C	cg19388776	chr3:71835112	PROK2	0.88	5.11	0.46	1.67e-6	Monocyte count;
THYM	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	7.59	0.61	2.15e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg11502198	chr6:26597334	ABT1	0.64	5.68	0.5	1.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.893	rs6661115	chr1:53426148	G/A	cg25767906	chr1:53392781	SCP2	0.59	5.75	0.51	1.09e-7	Monocyte count;
THYM	cis	rs16917546	1.000	rs7090073	chr10:64423505	G/T	cg03961010	chr10:64397487	ZNF365	-0.79	-6.78	-0.57	9.94e-10	Basal cell carcinoma;
THYM	cis	rs4604732	0.642	rs4266925	chr1:247639165	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	4.8	0.44	5.87e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg04362960	chr10:104952993	NT5C2	0.64	5.58	0.5	2.24e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs3091242	1.000	rs9689	chr1:25688276	A/G	cg23205692	chr1:25664452	TMEM50A	0.79	6.21	0.54	1.37e-8	Erythrocyte sedimentation rate;
THYM	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22857025	chr5:266934	NA	-1.43	-9.54	-0.7	1.58e-15	Breast cancer;
THYM	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg08132940	chr7:1081526	C7orf50	-1.16	-6.72	-0.57	1.36e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4792901	0.918	rs67063813	chr17:41626728	T/C	cg21940313	chr17:41620911	ETV4	-0.49	-5.31	-0.48	7.22e-7	Dupuytren's disease;
THYM	cis	rs28595532	0.920	rs55758547	chr4:119769475	T/C	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs2504916	0.784	rs2504957	chr6:160752092	C/A	cg19643109	chr6:160697625	NA	-0.66	-4.86	-0.45	4.54e-6	Response to hepatitis C treatment;
THYM	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg14584255	chr6:163149320	PACRG;PARK2	0.71	6.25	0.54	1.16e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7106204	0.609	rs12788438	chr11:24284068	G/T	ch.11.24196551F	chr11:24239977	NA	0.95	5.82	0.51	7.9e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs3809566	1.000	rs4775612	chr15:63332157	T/C	cg00520135	chr15:63333846	TPM1	-0.6	-5.18	-0.47	1.24e-6	Platelet count;
THYM	cis	rs7551222	0.752	rs10900597	chr1:204522489	C/T	cg20240347	chr1:204465584	NA	-0.55	-4.98	-0.46	2.79e-6	Schizophrenia;
THYM	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	9.67	0.7	8.34e-16	Platelet count;
THYM	cis	rs11126435	0.516	rs6707302	chr2:74761422	T/C	cg04255230	chr2:74727010	LBX2	0.54	4.74	0.44	7.62e-6	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg01324343	chr3:183735012	ABCC5	0.9	13.47	0.81	9.06e-24	Anterior chamber depth;
THYM	cis	rs2294693	0.730	rs9369248	chr6:40959664	G/T	cg21128951	chr6:40996213	UNC5CL	-0.6	-4.48	-0.42	2.12e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg22709100	chr7:91322751	NA	0.61	4.86	0.45	4.66e-6	Breast cancer;
THYM	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg02136620	chr5:178986620	RUFY1	0.5	4.86	0.45	4.64e-6	Lung cancer;
THYM	cis	rs9486719	1.000	rs4839837	chr6:96908706	G/A	cg18709589	chr6:96969512	KIAA0776	0.75	5.02	0.46	2.39e-6	Migraine;Coronary artery disease;
THYM	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg08999081	chr20:33150536	PIGU	0.78	7.16	0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs6032067	0.759	rs6032043	chr20:43817897	A/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.67	-7.66	-0.62	1.54e-11	Blood protein levels;
THYM	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg00278517	chr6:167070616	RPS6KA2	0.35	4.58	0.42	1.44e-5	Lung cancer;
THYM	cis	rs1003719	0.788	rs11911508	chr21:38470504	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs240764	0.817	rs239232	chr6:101103038	G/A	cg21058520	chr6:100914733	NA	-0.57	-5.07	-0.46	1.96e-6	Neuroticism;
THYM	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.51	6.03	0.53	3.12e-8	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs72949976	0.934	rs1922794	chr2:214026181	G/A	cg08319019	chr2:214017104	IKZF2	-0.7	-5.2	-0.47	1.14e-6	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg26597838	chr10:835615	NA	1.07	7.19	0.59	1.49e-10	Eosinophil percentage of granulocytes;
THYM	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg12560992	chr17:57184187	TRIM37	0.91	8.46	0.66	3.24e-13	Intelligence (multi-trait analysis);
THYM	cis	rs293526	0.959	rs293514	chr6:83639969	A/G	cg23278060	chr6:83777448	DOPEY1	0.61	4.48	0.42	2.1e-5	Crohn's disease;
THYM	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg13695892	chr22:41940480	POLR3H	-0.75	-5.98	-0.52	3.82e-8	Vitiligo;
THYM	cis	rs2235573	0.638	rs742396	chr22:38452254	C/G	cg19171272	chr22:38449367	NA	-0.51	-5.31	-0.48	7.3e-7	Glioblastoma;Glioma;
THYM	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7523273	0.565	rs2796280	chr1:207889345	C/T	cg22525895	chr1:207977042	MIR29B2	-0.53	-5.04	-0.46	2.19e-6	Schizophrenia;
THYM	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg22166914	chr1:53195759	ZYG11B	0.77	7.55	0.61	2.66e-11	Monocyte count;
THYM	cis	rs7010267	0.902	rs10505348	chr8:119972696	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.6	4.87	0.45	4.36e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs8067545	0.611	rs77449863	chr17:20191860	C/G	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg00495681	chr13:53174319	NA	0.73	6.69	0.57	1.57e-9	Lewy body disease;
THYM	cis	rs6456042	0.756	rs3099265	chr6:166581751	C/G	cg11088901	chr6:166572345	T	-0.56	-5.37	-0.48	5.64e-7	Asthma;
THYM	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg21773646	chr17:80085082	CCDC57	-0.37	-5.16	-0.47	1.32e-6	Life satisfaction;
THYM	cis	rs457717	0.798	rs6881371	chr5:75922669	A/G	cg08241785	chr5:75919281	F2RL2;IQGAP2	-0.33	-4.7	-0.43	8.7e-6	Hearing impairment;
THYM	cis	rs988913	1.000	rs7764641	chr6:54835469	A/T	cg18532076	chr6:54711417	FAM83B	0.5	4.91	0.45	3.78e-6	Menarche (age at onset);
THYM	cis	rs72720396	0.789	rs12022460	chr1:91202257	A/G	cg13456504	chr1:91191583	NA	-0.79	-5.51	-0.49	3e-7	Morning vs. evening chronotype;Chronotype;
THYM	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg23161317	chr6:28129485	ZNF389	0.85	6.33	0.54	8.19e-9	Parkinson's disease;
THYM	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg06532163	chr17:45867833	NA	0.66	6.75	0.57	1.17e-9	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8102476	0.905	rs7250689	chr19:38753625	C/T	cg08196968	chr19:38746749	PPP1R14A	0.47	5.68	0.5	1.46e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs877282	0.583	rs112372193	chr10:826602	A/G	cg10556349	chr10:835070	NA	-0.8	-5.46	-0.49	3.82e-7	Uric acid levels;
THYM	cis	rs2455799	0.613	rs9848007	chr3:15852593	T/A	cg16303742	chr3:15540471	COLQ	-0.54	-5.78	-0.51	9.67e-8	Mean platelet volume;
THYM	cis	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg16306078	chr6:126000798	NA	0.55	5.49	0.49	3.31e-7	Endometrial cancer;
THYM	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Body mass index;
THYM	cis	rs34638657	0.732	rs61111557	chr16:82201102	A/C	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.25	-0.47	9.14e-7	Lung adenocarcinoma;
THYM	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg22709100	chr7:91322751	NA	0.63	4.97	0.45	2.94e-6	Breast cancer;
THYM	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg22189786	chr22:42395067	WBP2NL	0.57	5.12	0.47	1.59e-6	Birth weight;
THYM	cis	rs533123	0.818	rs204051	chr1:29166578	A/G	cg08366446	chr1:29138936	OPRD1	1.11	5.66	0.5	1.61e-7	Schizophrenia;
THYM	cis	rs763014	0.865	rs8675	chr16:633843	A/G	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs12126655	0.529	rs10494080	chr1:108402075	A/C	cg20016673	chr1:108023366	NTNG1	-0.42	-4.72	-0.44	8.19e-6	Plasma thyroid-stimulating hormone levels;
THYM	cis	rs13040088	0.872	rs13039291	chr20:61572760	C/T	cg23096297	chr20:61557774	DIDO1	1.09	7.51	0.61	3.19e-11	Menopause (age at onset);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg26512406	chr16:28223152	XPO6	-1.0	-7.38	-0.6	6.08e-11	Depressive symptoms;
THYM	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg06521331	chr12:34319734	NA	-0.68	-5.0	-0.46	2.62e-6	Resting heart rate;
THYM	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg09990169	chr2:241835740	C2orf54	-0.37	-5.89	-0.52	5.87e-8	Urinary metabolites;
THYM	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg22166914	chr1:53195759	ZYG11B	0.64	5.57	0.5	2.37e-7	Monocyte count;
THYM	cis	rs12410462	0.581	rs73102371	chr1:227554880	G/A	cg23173402	chr1:227635558	NA	0.65	5.08	0.46	1.91e-6	Major depressive disorder;
THYM	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg18681998	chr4:17616180	MED28	0.83	7.55	0.61	2.6e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg03929089	chr4:120376271	NA	1.02	8.48	0.66	2.88e-13	Height;
THYM	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg11871910	chr12:69753446	YEATS4	1.06	9.8	0.71	4.32e-16	Blood protein levels;
THYM	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs892961	0.899	rs7222532	chr17:75413302	G/C	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-5.13	-0.47	1.55e-6	Lymphocyte counts;
THYM	cis	rs2288884	0.806	rs11084141	chr19:52587907	G/A	cg05974498	chr19:52599256	ZNF841	0.37	4.86	0.45	4.63e-6	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs858239	0.932	rs199355	chr7:23296533	C/T	cg05407003	chr7:23246146	NA	-0.61	-4.52	-0.42	1.81e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11644478	chr21:40555479	PSMG1	-0.81	-7.24	-0.6	1.14e-10	Cognitive function;
THYM	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg13385794	chr1:248469461	NA	0.67	4.58	0.43	1.4e-5	Common traits (Other);
THYM	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg22875332	chr1:76189707	ACADM	0.83	8.04	0.64	2.48e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7851660	0.809	rs7037324	chr9:100658318	A/G	cg13688889	chr9:100608707	NA	-0.76	-5.48	-0.49	3.51e-7	Strep throat;
THYM	cis	rs3784262	0.679	rs4238326	chr15:58336000	C/T	cg12031962	chr15:58353849	ALDH1A2	0.59	4.46	0.42	2.23e-5	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
THYM	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12073837	0.784	rs6673877	chr1:220990984	T/C	cg16008148	chr1:221062819	NA	0.41	4.54	0.42	1.62e-5	F-cell distribution;
THYM	cis	rs2228479	0.614	rs1137042	chr16:89975638	A/G	cg26513180	chr16:89883248	FANCA	0.65	4.68	0.43	9.33e-6	Skin colour saturation;
THYM	cis	rs3820068	0.656	rs72645829	chr1:15889748	A/G	cg05660106	chr1:15850417	CASP9	1.16	10.06	0.72	1.25e-16	Systolic blood pressure;
THYM	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.0	9.43	0.7	2.72e-15	Colorectal cancer;
THYM	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg07936489	chr17:37558343	FBXL20	-0.78	-5.41	-0.48	4.79e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7617773	0.780	rs13066044	chr3:48377276	C/T	cg02219026	chr3:48282209	ZNF589	-0.71	-4.97	-0.45	3.01e-6	Coronary artery disease;
THYM	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg24531977	chr5:56204891	C5orf35	-0.66	-5.07	-0.46	2e-6	Coronary artery disease;
THYM	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg10862848	chr6:42927986	GNMT	-0.51	-6.73	-0.57	1.26e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-5.19	-0.47	1.21e-6	Chronic sinus infection;
THYM	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg12311346	chr5:56204834	C5orf35	-0.82	-6.04	-0.53	3.01e-8	Initial pursuit acceleration;
THYM	cis	rs9913156	0.793	rs55682338	chr17:4582183	G/A	cg19197139	chr17:4613644	ARRB2	0.82	4.96	0.45	3.05e-6	Lymphocyte counts;
THYM	cis	rs2295499	0.754	rs16843291	chr4:2728092	C/G	cg14003022	chr4:3043019	NA	0.52	4.45	0.42	2.3e-5	Cognitive ability;Cognitive ability (multi-trait analysis);Intelligence (multi-trait analysis);
THYM	cis	rs9972944	0.756	rs6504352	chr17:63765287	C/T	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg16006841	chr5:176797999	RGS14	0.53	6.38	0.55	6.52e-9	Hemoglobin concentration;Hematocrit;
THYM	cis	rs4589258	0.737	rs34249130	chr11:90414427	C/A	cg26138821	chr11:89956704	CHORDC1	0.56	4.67	0.43	9.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs314370	0.951	rs17881696	chr7:100493359	G/A	cg10426581	chr7:100472382	SRRT	1.13	8.97	0.68	2.57e-14	Resting heart rate;
THYM	cis	rs9818758	0.556	rs73077200	chr3:49826987	C/T	cg00383909	chr3:49044727	WDR6	1.12	5.62	0.5	1.94e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs6032067	0.929	rs13039213	chr20:43805712	A/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs4243830	0.737	rs4908923	chr1:6614535	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.06	-7.01	-0.58	3.46e-10	Body mass index;
THYM	cis	rs939658	0.967	rs7171067	chr15:79452727	G/T	cg17916960	chr15:79447300	NA	0.76	9.06	0.68	1.71e-14	Refractive error;
THYM	cis	rs7635838	0.617	rs346074	chr3:11294310	T/C	cg00170343	chr3:11313890	ATG7	0.68	5.31	0.48	7.06e-7	HDL cholesterol;
THYM	cis	rs7404928	0.651	rs8051531	chr16:23944619	C/T	cg26685404	chr16:23957272	PRKCB	0.61	7.0	0.58	3.53e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs901683	0.850	rs75402959	chr10:46092807	C/G	cg18240400	chr10:46168597	ANUBL1	0.68	5.03	0.46	2.31e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs11671005	0.693	rs11084542	chr19:58932099	T/A	cg18639983	chr19:58920768	ZNF584	0.61	5.05	0.46	2.1e-6	Mean platelet volume;
THYM	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.84	0.44	5.01e-6	Breast cancer;
THYM	cis	rs782590	0.902	rs4672052	chr2:55732018	A/C	cg18811423	chr2:55921094	PNPT1	0.68	6.16	0.53	1.76e-8	Metabolic syndrome;
THYM	cis	rs919433	0.679	rs10166328	chr2:198511917	A/G	cg00792783	chr2:198669748	PLCL1	0.79	5.13	0.47	1.53e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg17264618	chr3:40429014	ENTPD3	0.52	4.87	0.45	4.42e-6	Renal cell carcinoma;
THYM	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg03188948	chr7:1209495	NA	0.74	5.81	0.51	8.13e-8	Longevity;Endometriosis;
THYM	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg27034606	chr17:28928453	LRRC37B2	0.81	5.38	0.48	5.39e-7	Body mass index;
THYM	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs12950390	0.512	rs59396604	chr17:45837777	G/A	cg24803719	chr17:45855879	NA	-0.63	-5.23	-0.47	1.01e-6	IgG glycosylation;
THYM	cis	rs9467773	0.526	rs10946817	chr6:26364056	C/T	cg14345882	chr6:26364793	BTN3A2	0.35	4.66	0.43	1.01e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg10295955	chr4:187884368	NA	-1.22	-17.54	-0.87	1.51e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2870238	0.540	rs28687959	chr4:77421345	C/T	cg20311846	chr4:77356250	SHROOM3	-0.56	-6.4	-0.55	5.9e-9	Hemoglobin concentration;Hematocrit;
THYM	cis	rs11779988	0.545	rs448882	chr8:17794039	C/T	cg01800426	chr8:17659068	MTUS1	-0.75	-5.17	-0.47	1.32e-6	Breast cancer;
THYM	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg05973401	chr12:123451056	ABCB9	0.7	4.6	0.43	1.28e-5	Neutrophil percentage of white cells;
THYM	cis	rs554111	0.634	rs12026318	chr1:21316623	T/C	cg01072550	chr1:21505969	NA	0.59	5.17	0.47	1.3e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-5.98	-0.52	3.86e-8	Prostate cancer;
THYM	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg24692254	chr21:30365293	RNF160	1.06	9.93	0.71	2.29e-16	Dental caries;
THYM	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg08772003	chr10:104629869	AS3MT	-0.55	-4.88	-0.45	4.35e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7618915	0.962	rs13094687	chr3:52450043	A/G	cg07507251	chr3:52567010	NT5DC2	0.49	4.84	0.44	5.07e-6	Bipolar disorder;
THYM	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg17279839	chr7:150038598	RARRES2	0.55	5.34	0.48	6.26e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs9420	0.961	rs11229131	chr11:57562525	G/A	cg19752551	chr11:57585705	CTNND1	-0.73	-7.98	-0.63	3.28e-12	Schizophrenia;
THYM	cis	rs7106204	0.764	rs79362440	chr11:24212972	G/A	ch.11.24196551F	chr11:24239977	NA	0.88	4.52	0.42	1.78e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg22875332	chr1:76189707	ACADM	0.88	11.22	0.75	4.31e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg26384229	chr12:38710491	ALG10B	0.97	7.38	0.6	5.91e-11	Morning vs. evening chronotype;
THYM	cis	rs4660261	0.526	rs810680	chr1:44347856	C/T	cg13246856	chr1:44399776	ARTN	0.49	4.82	0.44	5.43e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg06728252	chr6:26598149	ABT1	-0.43	-5.08	-0.46	1.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2976388	0.934	rs2920279	chr8:143762135	A/C	cg06565975	chr8:143823917	SLURP1	-0.45	-5.23	-0.47	9.95e-7	Urinary tract infection frequency;
THYM	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg11166453	chr1:247681781	NA	0.66	5.18	0.47	1.26e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1691799	0.836	rs1168334	chr12:66760972	A/G	cg16791601	chr12:66731901	HELB	-0.68	-5.92	-0.52	5.07e-8	White blood cell count (basophil);
THYM	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg01831904	chr17:28903510	LRRC37B2	-1.0	-5.11	-0.46	1.65e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg14004847	chr7:1930337	MAD1L1	-0.59	-4.58	-0.43	1.38e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs600806	0.854	rs367586	chr1:109850122	C/A	cg23032129	chr1:109941072	SORT1	-0.55	-4.59	-0.43	1.36e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg24060327	chr5:131705240	SLC22A5	-0.8	-5.86	-0.52	6.69e-8	Blood metabolite levels;
THYM	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg06784218	chr1:46089804	CCDC17	-0.32	-4.82	-0.44	5.41e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs800586	0.595	rs2737245	chr8:116658583	G/T	cg04656070	chr8:116661063	TRPS1	-0.56	-5.61	-0.5	1.97e-7	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg06634786	chr22:41940651	POLR3H	-0.68	-5.0	-0.46	2.65e-6	Vitiligo;
THYM	cis	rs79149102	0.579	rs7342601	chr15:75306795	G/T	cg09165964	chr15:75287851	SCAMP5	1.1	6.31	0.54	8.71e-9	Lung cancer;
THYM	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg08132940	chr7:1081526	C7orf50	-1.16	-6.72	-0.57	1.36e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2898681	0.519	rs3811781	chr4:53729166	T/G	cg21521518	chr4:53727714	RASL11B	0.51	4.78	0.44	6.31e-6	Optic nerve measurement (cup area);
THYM	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.96	0.45	3.04e-6	Prudent dietary pattern;
THYM	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg00071950	chr4:10020882	SLC2A9	-0.79	-8.15	-0.64	1.42e-12	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	5.75	0.51	1.1e-7	Height;
THYM	cis	rs1395	0.744	rs7600932	chr2:27474869	G/A	cg23587288	chr2:27483067	SLC30A3	-0.69	-6.19	-0.54	1.53e-8	Blood metabolite levels;
THYM	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg23574427	chr4:122746245	BBS7;CCNA2	-0.57	-5.18	-0.47	1.23e-6	Type 2 diabetes;
THYM	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg22875332	chr1:76189707	ACADM	0.88	11.22	0.75	4.31e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7582180	0.790	rs4851288	chr2:100920451	T/C	cg21926883	chr2:100939477	LONRF2	-0.66	-6.01	-0.52	3.43e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg27284194	chr4:1044797	NA	0.62	4.73	0.44	7.81e-6	Recombination rate (females);
THYM	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs9296092	0.538	rs62407565	chr6:33535739	A/G	cg13560919	chr6:33536144	NA	-0.92	-8.88	-0.67	4.09e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg16680214	chr1:154839983	KCNN3	-0.46	-5.11	-0.46	1.66e-6	Prostate cancer;
THYM	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg26038318	chr20:34205095	SPAG4	0.65	5.25	0.47	9.22e-7	Total cholesterol levels;
THYM	cis	rs2736337	0.530	rs11782375	chr8:11294934	C/T	cg11009520	chr8:12052164	FAM86B1	-0.65	-5.13	-0.47	1.55e-6	Rheumatoid arthritis;
THYM	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg18681998	chr4:17616180	MED28	-0.85	-7.15	-0.59	1.75e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs7772486	0.806	rs2265477	chr6:146212338	T/C	cg13319975	chr6:146136371	FBXO30	-0.74	-6.33	-0.54	8.16e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7639513	0.737	rs13070228	chr3:12706914	G/A	cg23032965	chr3:12705835	RAF1	0.99	7.86	0.63	5.93e-12	Itch intensity from mosquito bite;
THYM	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg17173187	chr15:85201210	NMB	0.54	5.31	0.48	7.17e-7	Schizophrenia;
THYM	cis	rs2439831	0.618	rs999026	chr15:43690215	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.68	4.7	0.43	8.71e-6	Lung cancer in ever smokers;
THYM	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg17366294	chr4:99064904	C4orf37	0.54	6.33	0.54	8.05e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg13073409	chr1:197099113	ASPM	-0.77	-5.21	-0.47	1.1e-6	Depressive symptoms;
THYM	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.17	0.64	1.34e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs259964	0.874	rs259958	chr20:57828583	C/A	cg16205854	chr20:57875318	EDN3	-0.4	-4.52	-0.42	1.81e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg02782426	chr3:40428986	ENTPD3	0.55	4.96	0.45	3.05e-6	Renal cell carcinoma;
THYM	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg18512352	chr11:47633146	NA	-0.55	-7.18	-0.59	1.53e-10	Subjective well-being;
THYM	trans	rs8002861	0.754	rs4053664	chr13:44429172	A/C	cg17145862	chr1:211918768	LPGAT1	0.87	9.02	0.68	2.02e-14	Leprosy;
THYM	cis	rs9790314	1.000	rs336577	chr3:161066294	C/T	cg04691961	chr3:161091175	C3orf57	-0.6	-5.24	-0.47	9.71e-7	Morning vs. evening chronotype;
THYM	cis	rs7666738	1.000	rs13116475	chr4:99054843	C/T	cg07917127	chr4:99064746	C4orf37	-0.59	-4.48	-0.42	2.05e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs921968	0.565	rs7605055	chr2:219627050	G/C	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17511627	1.000	rs17511627	chr13:26724328	A/C	cg13319468	chr13:27597730	NA	0.74	5.53	0.49	2.87e-7	Alzheimer's disease;
THYM	cis	rs4787491	0.729	rs3814878	chr16:30041966	A/G	cg06015834	chr16:30021696	DOC2A	-0.51	-4.63	-0.43	1.15e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.63	4.9	0.45	4.01e-6	Height;
THYM	cis	rs7264396	0.563	rs2425121	chr20:34326186	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.82	-0.44	5.51e-6	Total cholesterol levels;
THYM	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs7107174	1.000	rs7107174	chr11:77997936	C/T	cg02023728	chr11:77925099	USP35	0.67	5.86	0.52	6.61e-8	Testicular germ cell tumor;
THYM	cis	rs11603020	0.950	rs28362948	chr11:57369013	A/C	cg19752551	chr11:57585705	CTNND1	-0.57	-4.8	-0.44	5.82e-6	Blood protein levels;
THYM	cis	rs6430585	0.583	rs58116536	chr2:136585323	C/T	cg23851026	chr2:136556271	LCT	0.77	7.55	0.61	2.64e-11	Corneal structure;
THYM	cis	rs7681423	0.951	rs11099961	chr4:155503212	C/T	cg20735720	chr4:155535218	FGG	-0.63	-4.73	-0.44	7.78e-6	Fibrinogen;
THYM	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg07636037	chr3:49044803	WDR6	0.81	5.82	0.51	7.99e-8	Menarche (age at onset);
THYM	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11890956	chr21:40555474	PSMG1	-0.63	-5.73	-0.51	1.2e-7	Menarche (age at onset);
THYM	cis	rs7772486	0.686	rs9390347	chr6:146044747	G/T	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg27129171	chr3:47204927	SETD2	-0.7	-6.22	-0.54	1.35e-8	Colorectal cancer;
THYM	cis	rs7772486	0.714	rs1883365	chr6:146076749	C/T	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1829883	0.898	rs1464639	chr5:98786821	A/G	cg08333243	chr5:99726346	NA	-0.55	-5.01	-0.46	2.5e-6	Hemostatic factors and hematological phenotypes;
THYM	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg21280719	chr6:42927975	GNMT	-0.5	-6.77	-0.57	1.04e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs3138083	0.645	rs2039767	chr9:35638955	C/T	cg07116010	chr9:35646325	NA	0.89	8.91	0.67	3.51e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);
THYM	cis	rs9733	0.596	rs56058687	chr1:150635066	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg07414643	chr4:187882934	NA	0.57	4.95	0.45	3.16e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs600550	0.588	rs7943848	chr11:60092590	T/C	cg05040360	chr11:60102449	MS4A6E	-0.5	-4.64	-0.43	1.1e-5	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs3741151	1.000	rs112840535	chr11:73066771	G/A	cg17517138	chr11:73019481	ARHGEF17	0.99	5.88	0.52	5.97e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg02782426	chr3:40428986	ENTPD3	-0.51	-4.55	-0.42	1.6e-5	Renal cell carcinoma;
THYM	cis	rs7246967	0.736	rs436595	chr19:22993045	G/T	cg05241461	chr19:22816980	ZNF492	0.61	4.74	0.44	7.5e-6	Bronchopulmonary dysplasia;
THYM	cis	rs11690935	0.959	rs10204622	chr2:172588982	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.88	-6.5	-0.55	3.76e-9	Schizophrenia;
THYM	cis	rs12530845	1.000	rs12537555	chr7:135334061	G/A	cg23117316	chr7:135346802	PL-5283	-0.66	-5.88	-0.52	6.21e-8	Red blood cell traits;
THYM	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg00012203	chr2:219082015	ARPC2	-0.81	-7.59	-0.61	2.2e-11	Colorectal cancer;
THYM	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.79	-6.34	-0.55	7.85e-9	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg15212455	chr7:39170539	POU6F2	0.64	6.01	0.52	3.44e-8	IgG glycosylation;
THYM	cis	rs13315871	0.929	rs9818581	chr3:58293101	A/G	cg00563845	chr3:58318305	PXK	0.59	5.03	0.46	2.29e-6	Cholesterol, total;
THYM	cis	rs79149102	0.579	rs12591994	chr15:75320306	A/G	cg09165964	chr15:75287851	SCAMP5	-1.0	-4.96	-0.45	3.08e-6	Lung cancer;
THYM	cis	rs2075165	0.836	rs7512751	chr1:156234439	T/G	cg20302342	chr1:156215951	PAQR6	0.46	4.61	0.43	1.23e-5	Tonsillectomy;
THYM	cis	rs752010	0.806	rs11210500	chr1:42089737	A/G	cg06885757	chr1:42089581	HIVEP3	0.59	7.55	0.61	2.66e-11	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs6669072	1.000	rs6676886	chr1:91244343	C/G	cg08895590	chr1:91227319	NA	0.54	6.43	0.55	5.19e-9	Cognitive function;
THYM	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs769267	0.631	rs7252981	chr19:19692579	T/C	cg03709012	chr19:19516395	GATAD2A	-0.66	-4.9	-0.45	3.86e-6	Tonsillectomy;
THYM	cis	rs2033562	0.965	rs2033561	chr8:103546435	G/T	cg20611272	chr8:103548145	NA	-0.4	-4.99	-0.46	2.77e-6	IgA nephropathy;
THYM	cis	rs7312774	0.618	rs7304621	chr12:107325888	C/T	cg16260113	chr12:107380972	MTERFD3	1.34	6.39	0.55	6.14e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.51	5.06	0.46	2.07e-6	Schizophrenia;
THYM	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg10911889	chr6:126070802	HEY2	0.56	4.61	0.43	1.25e-5	Brugada syndrome;
THYM	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg25703541	chr22:24373054	LOC391322	0.89	9.82	0.71	3.96e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs35883536	0.647	rs10875315	chr1:101044062	G/A	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs9633835	0.524	rs55689167	chr11:13279979	G/A	cg13286116	chr11:13302098	ARNTL	-0.71	-7.84	-0.63	6.41e-12	Body mass index;
THYM	cis	rs728616	0.850	rs3889823	chr10:81918362	T/C	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2708977	0.933	rs6576972	chr2:97152446	C/T	cg01950434	chr2:97203154	ARID5A	-0.51	-4.49	-0.42	1.99e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs742614	0.533	rs13041078	chr20:32435497	G/T	cg06304546	chr20:32448765	NA	-0.95	-10.1	-0.72	1.03e-16	Stearic acid (18:0) levels;
THYM	cis	rs2797160	0.967	rs1777224	chr6:126019527	T/C	cg16306078	chr6:126000798	NA	0.52	5.18	0.47	1.25e-6	Endometrial cancer;
THYM	cis	rs28595532	0.841	rs115233595	chr4:119744214	T/C	cg14228332	chr4:119757509	SEC24D	1.48	5.63	0.5	1.84e-7	Cannabis dependence symptom count;
THYM	cis	rs2928148	0.522	rs11858278	chr15:41416276	T/C	cg21153102	chr15:41252147	NA	0.61	4.61	0.43	1.23e-5	Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs9486719	0.857	rs4839833	chr6:96882069	T/C	cg06623918	chr6:96969491	KIAA0776	0.77	4.67	0.43	9.75e-6	Migraine;Coronary artery disease;
THYM	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg10802521	chr3:52805072	NEK4	-0.79	-6.34	-0.55	7.71e-9	Bipolar disorder;
THYM	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg01264106	chr22:38071602	LGALS1	0.41	4.97	0.45	2.94e-6	Fat distribution (HIV);
THYM	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg20607798	chr8:58055168	NA	0.9	4.85	0.45	4.86e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1061377	1.000	rs10030904	chr4:39115223	G/T	cg24403649	chr4:39172243	NA	0.59	4.81	0.44	5.71e-6	Uric acid levels;
THYM	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3741151	0.773	rs17310374	chr11:73274874	T/C	cg17517138	chr11:73019481	ARHGEF17	0.9	4.68	0.43	9.36e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg06713675	chr4:122721982	EXOSC9	-0.85	-9.54	-0.7	1.57e-15	Type 2 diabetes;
THYM	cis	rs4792901	0.959	rs9899005	chr17:41642868	C/T	cg21940313	chr17:41620911	ETV4	-0.47	-4.83	-0.44	5.15e-6	Dupuytren's disease;
THYM	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg10661904	chr17:79619235	PDE6G	-0.59	-5.65	-0.5	1.69e-7	Eye color traits;
THYM	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg07341220	chr16:1583899	IFT140;TMEM204	-0.66	-5.57	-0.5	2.39e-7	Coronary artery disease;
THYM	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg18681998	chr4:17616180	MED28	0.84	7.76	0.62	9.42e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg23711669	chr6:146136114	FBXO30	-0.94	-9.85	-0.71	3.42e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg13010199	chr12:38710504	ALG10B	0.76	6.07	0.53	2.59e-8	Heart rate;
THYM	cis	rs9646944	0.501	rs12712144	chr2:102995600	C/G	cg01241218	chr2:102972058	NA	0.81	5.28	0.48	8.09e-7	Blood protein levels;
THYM	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg00256281	chr22:41985642	PMM1	0.57	4.88	0.45	4.3e-6	Vitiligo;
THYM	cis	rs55637147	0.671	rs59455760	chr11:57134437	T/C	cg15971518	chr11:57159174	PRG2	-0.67	-5.37	-0.48	5.46e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs10927875	0.632	rs904911	chr1:16126932	C/T	cg21385522	chr1:16154831	NA	-1.32	-13.48	-0.81	9e-24	Dilated cardiomyopathy;
THYM	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg03407747	chr17:6899364	ALOX12	0.79	9.99	0.72	1.73e-16	Tonsillectomy;
THYM	cis	rs752010	0.619	rs7539238	chr1:42113572	A/C	cg06885757	chr1:42089581	HIVEP3	0.71	10.0	0.72	1.68e-16	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg07917127	chr4:99064746	C4orf37	0.59	4.5	0.42	1.93e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.76	-6.19	-0.54	1.53e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2903698	0.565	rs10009558	chr4:76447270	T/C	cg03209871	chr4:76438412	RCHY1;THAP6	0.38	4.48	0.42	2.05e-5	Prion diseases;
THYM	cis	rs6924995	0.501	rs6459452	chr6:16187522	C/G	cg11805552	chr6:16175128	NA	0.58	4.8	0.44	5.89e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs2742417	0.603	rs1468542	chr3:45779136	A/T	cg04837898	chr3:45731254	SACM1L	0.72	5.21	0.47	1.08e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs35883536	1.000	rs1832123	chr1:101168196	A/G	cg06223162	chr1:101003688	GPR88	0.63	4.83	0.44	5.25e-6	Monocyte count;
THYM	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg07537917	chr2:241836409	C2orf54	-0.28	-6.47	-0.55	4.22e-9	Urinary metabolites;
THYM	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-8.52	-0.66	2.33e-13	Schizophrenia;
THYM	cis	rs7412746	0.611	rs10888391	chr1:150729983	G/A	cg15448220	chr1:150897856	SETDB1	0.89	7.36	0.6	6.64e-11	Melanoma;
THYM	cis	rs6920965	0.507	rs9401853	chr6:126215197	A/T	cg10911889	chr6:126070802	HEY2	0.7	4.96	0.45	3.12e-6	High light scatter reticulocyte count;
THYM	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg06026331	chr20:60912101	LAMA5	-0.62	-4.9	-0.45	3.89e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs868036	1.000	rs868037	chr15:68054996	A/G	cg24579218	chr15:68104479	NA	0.67	6.42	0.55	5.4e-9	Restless legs syndrome;
THYM	trans	rs9951602	0.512	rs7237214	chr18:76657394	C/G	cg02800362	chr5:177631904	HNRNPAB	1.14	9.13	0.68	1.21e-14	Obesity-related traits;
THYM	trans	rs4749080	0.573	rs2275727	chr10:26409836	C/A	cg00192819	chr18:76486611	NA	1.0	7.09	0.59	2.41e-10	Obesity-related traits;
THYM	cis	rs2806561	1.000	rs2776819	chr1:23470116	A/T	cg12483005	chr1:23474871	LUZP1	0.6	6.05	0.53	2.9e-8	Height;
THYM	cis	rs2456568	0.900	rs2000960	chr11:93682348	C/T	cg17595323	chr11:93583763	C11orf90	-0.54	-5.22	-0.47	1.04e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs919433	0.679	rs10166328	chr2:198511917	A/G	cg05783139	chr2:198650985	BOLL	0.67	5.05	0.46	2.12e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs220324	0.688	rs915840	chr21:43560871	T/C	cg09727148	chr21:43560719	UMODL1	0.84	9.89	0.71	2.8e-16	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs9810089	0.967	rs10935177	chr3:135851077	G/T	cg12473912	chr3:136751656	NA	-0.62	-5.37	-0.48	5.46e-7	Gestational age at birth (child effect);
THYM	cis	rs1971762	0.545	rs3864905	chr12:54058324	C/T	cg16917193	chr12:54089295	NA	0.84	8.02	0.64	2.76e-12	Height;
THYM	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	ch.11.102211250F	chr11:102706040	NA	0.95	6.88	0.58	6.26e-10	Depressive symptoms;
THYM	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.04	-0.46	2.24e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4242434	0.857	rs11777808	chr8:22462755	A/C	cg14690197	chr8:22456421	C8orf58	0.48	4.74	0.44	7.46e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.59	4.8	0.44	5.88e-6	Hip circumference adjusted for BMI;
THYM	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg02627403	chr17:73823769	UNC13D	-0.46	-4.85	-0.45	4.8e-6	White matter hyperintensity burden;
THYM	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg18402987	chr7:1209562	NA	1.04	6.23	0.54	1.27e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2599510	0.934	rs2710634	chr2:32808804	T/C	cg02381751	chr2:32503542	YIPF4	0.56	4.48	0.42	2.12e-5	Interleukin-18 levels;
THYM	cis	rs4478037	0.731	rs9835090	chr3:33107671	G/T	cg19404215	chr3:33155277	CRTAP	0.94	6.05	0.53	2.88e-8	Major depressive disorder;
THYM	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg24531977	chr5:56204891	C5orf35	-0.69	-5.41	-0.49	4.63e-7	Coronary artery disease;
THYM	cis	rs4575098	0.652	rs11576058	chr1:161111446	C/A	cg24329783	chr1:161160887	ADAMTS4	-0.63	-5.67	-0.5	1.55e-7	Monocyte percentage of white cells;
THYM	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg06074448	chr4:187884817	NA	-1.01	-13.0	-0.8	8.38e-23	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3818717	0.538	rs12945601	chr17:17653411	C/T	cg04398451	chr17:18023971	MYO15A	-0.63	-5.25	-0.47	9.39e-7	Lymphocyte counts;
THYM	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg02269571	chr22:50332266	NA	-0.71	-4.91	-0.45	3.78e-6	Schizophrenia;
THYM	cis	rs2080501	0.601	rs3803665	chr16:49672520	A/G	cg05126388	chr16:49670144	ZNF423	0.88	12.09	0.78	6.29e-21	IgG glycosylation;
THYM	cis	rs12579753	0.917	rs7138533	chr12:82187885	C/G	cg21231944	chr12:82153410	PPFIA2	-0.68	-5.12	-0.46	1.6e-6	Resting heart rate;
THYM	cis	rs6598955	0.671	rs11247904	chr1:26621804	G/A	cg08133631	chr1:26527909	CATSPER4	-0.57	-4.69	-0.43	9.29e-6	Obesity-related traits;
THYM	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg21138405	chr5:131827807	IRF1	0.84	9.6	0.7	1.17e-15	Asthma (sex interaction);
THYM	cis	rs2458413	0.543	rs2514658	chr8:105337871	G/A	cg23108931	chr8:105342351	NA	-0.33	-6.12	-0.53	2.05e-8	Paget's disease;
THYM	cis	rs17253792	0.818	rs78393484	chr14:56065802	T/C	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.31	8.7	0.67	9.92e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4962416	0.785	rs4962418	chr10:126697086	A/G	cg04494136	chr10:126703576	CTBP2	0.35	4.79	0.44	6.03e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2797160	1.000	rs1935772	chr6:125994708	T/C	cg16306078	chr6:126000798	NA	-0.52	-5.34	-0.48	6.31e-7	Endometrial cancer;
THYM	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg23758822	chr17:41437982	NA	1.18	11.13	0.75	6.64e-19	Menopause (age at onset);
THYM	cis	rs3087591	0.960	rs7212264	chr17:29454766	C/T	cg24425628	chr17:29625626	OMG;NF1	0.65	5.41	0.49	4.76e-7	Hip circumference;
THYM	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6496667	0.533	rs2589949	chr15:90955015	C/T	cg00425431	chr15:90792223	TTLL13	0.4	4.65	0.43	1.07e-5	Rheumatoid arthritis;
THYM	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg23711669	chr6:146136114	FBXO30	-0.96	-10.03	-0.72	1.41e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs900145	0.814	rs4353253	chr11:13310263	G/C	cg13286116	chr11:13302098	ARNTL	-0.59	-4.73	-0.44	7.89e-6	Menarche (age at onset);
THYM	cis	rs11645898	0.935	rs11641721	chr16:72155241	G/A	cg03805757	chr16:71968109	PKD1L3	-0.73	-5.41	-0.49	4.66e-7	Blood protein levels;
THYM	cis	rs854765	0.964	rs72827413	chr17:17988299	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-4.88	-0.45	4.33e-6	Total body bone mineral density;
THYM	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg11764359	chr7:65958608	NA	0.84	7.06	0.59	2.78e-10	Aortic root size;
THYM	cis	rs6980334	0.817	rs1038626	chr7:137797477	A/T	cg11874123	chr7:137028198	PTN	0.64	4.82	0.44	5.4e-6	Blood metabolite ratios;
THYM	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg06784218	chr1:46089804	CCDC17	-0.29	-4.57	-0.42	1.45e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs4845875	0.626	rs1889292	chr1:11840943	T/C	cg25341925	chr1:11908058	NPPA	0.42	4.49	0.42	1.99e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs2505998	1.000	rs2435357	chr10:43582056	T/C	cg06632098	chr10:43605906	RET	-1.04	-9.21	-0.69	8.15e-15	Hirschsprung disease;
THYM	cis	rs367615	1.000	rs58931051	chr5:108907732	A/G	cg17395555	chr5:108820864	NA	0.53	4.79	0.44	6.05e-6	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs10929159	0.894	rs765880	chr2:236940317	C/A	cg20128773	chr2:236923534	AGAP1	0.35	4.46	0.42	2.21e-5	Parkinson's disease;
THYM	cis	rs6032067	0.714	rs6032057	chr20:43839761	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.37	-0.48	5.59e-7	Blood protein levels;
THYM	cis	rs1065852	0.526	rs11090066	chr22:42398195	A/G	cg08431931	chr22:42394659	WBP2NL	0.77	6.39	0.55	6.08e-9	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg15445000	chr17:37608096	MED1	0.44	5.1	0.46	1.73e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9906944	0.707	rs3816272	chr17:47120467	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.49	-4.47	-0.42	2.15e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg06640241	chr16:89574553	SPG7	0.91	8.25	0.65	9.05e-13	Multiple myeloma (IgH translocation);
THYM	cis	rs2888674	0.527	rs12673413	chr7:150512379	C/G	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.57	4.55	0.42	1.56e-5	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
THYM	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg26418147	chr1:205743515	RAB7L1	0.53	4.59	0.43	1.34e-5	Menarche (age at onset);
THYM	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	8.95	0.68	2.83e-14	Chronic sinus infection;
THYM	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg08807101	chr21:30365312	RNF160	-0.67	-4.87	-0.45	4.5e-6	Dental caries;
THYM	cis	rs7224737	1.000	rs7219220	chr17:40294280	T/C	cg00647820	chr17:40259828	DHX58	-0.6	-4.53	-0.42	1.72e-5	Fibrinogen levels;
THYM	cis	rs155076	0.666	rs4770128	chr13:21881922	A/G	cg25811766	chr13:21894605	NA	0.71	4.78	0.44	6.32e-6	White matter hyperintensity burden;
THYM	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg27170947	chr2:26402098	FAM59B	-0.8	-6.37	-0.55	6.74e-9	Gut microbiome composition (summer);
THYM	cis	rs9660180	0.780	rs12038111	chr1:1703849	T/C	cg02915803	chr1:1606292	LOC728661;CDK11B	0.6	4.96	0.45	3.03e-6	Body mass index;
THYM	cis	rs9649213	0.593	rs6949214	chr7:97960233	G/A	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.6e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7246657	0.943	rs6508733	chr19:38000548	A/T	cg22634378	chr19:37742834	NA	0.56	4.61	0.43	1.26e-5	Coronary artery calcification;
THYM	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs2070488	1.000	rs3792528	chr3:38493303	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.93	6.99	0.58	3.82e-10	Electrocardiographic conduction measures;
THYM	cis	rs3768617	0.510	rs4651140	chr1:183096952	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.49	-4.9	-0.45	3.93e-6	Primary biliary cholangitis;
THYM	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg14820908	chr5:178986412	RUFY1	0.64	7.17	0.59	1.58e-10	Lung cancer;
THYM	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs11966931	0.947	rs72935321	chr6:108122137	G/A	cg25323841	chr6:108444506	NA	0.64	4.46	0.42	2.23e-5	Neutrophil percentage of white cells;
THYM	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg04455712	chr21:45112962	RRP1B	0.54	5.16	0.47	1.32e-6	Coronary artery disease;
THYM	cis	rs4888262	0.545	rs7195499	chr16:74693973	C/G	cg01733217	chr16:74700730	RFWD3	0.87	9.06	0.68	1.69e-14	Testicular germ cell tumor;
THYM	cis	rs73198271	0.740	rs10092720	chr8:8649117	A/C	cg06636001	chr8:8085503	FLJ10661	-0.8	-5.64	-0.5	1.77e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7267979	0.868	rs6138550	chr20:25223430	C/T	cg08601574	chr20:25228251	PYGB	0.59	4.79	0.44	6.25e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs3781426	0.920	rs11245481	chr10:126732558	A/G	cg04494136	chr10:126703576	CTBP2	0.37	4.99	0.46	2.75e-6	Height;
THYM	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg18512352	chr11:47633146	NA	0.51	6.11	0.53	2.21e-8	Subjective well-being;
THYM	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg13902645	chr11:5959945	NA	-0.55	-4.89	-0.45	4.02e-6	DNA methylation (variation);
THYM	cis	rs2637266	1.000	rs12414151	chr10:78359041	T/G	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs7523273	0.597	rs6657476	chr1:207960104	G/T	cg22525895	chr1:207977042	MIR29B2	-0.76	-5.16	-0.47	1.35e-6	Schizophrenia;
THYM	cis	rs6025261	0.520	rs1276448	chr20:55540140	C/T	cg04763273	chr20:55502381	NA	0.59	4.98	0.45	2.86e-6	Verbal memory performance (delayed recall level);
THYM	cis	rs28595532	0.920	rs115530096	chr4:119760512	T/G	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs3136739	0.867	rs9298619	chr8:42085572	C/A	cg16230352	chr8:42123158	NA	0.71	4.52	0.42	1.79e-5	Plasma plasminogen activator levels;
THYM	cis	rs4930776	0.838	rs368436	chr12:5754618	T/C	cg02086166	chr12:5775618	ANO2	0.63	5.9	0.52	5.51e-8	Plasma clusterin levels;
THYM	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06634786	chr22:41940651	POLR3H	-0.79	-5.91	-0.52	5.34e-8	Vitiligo;
THYM	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg09904177	chr6:26538194	HMGN4	-0.64	-5.11	-0.46	1.65e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg07061783	chr6:25882402	NA	0.76	6.23	0.54	1.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11039798	0.557	rs4436575	chr11:48398894	T/C	cg24672777	chr11:48374446	OR4C45	0.96	6.27	0.54	1.05e-8	Axial length;
THYM	cis	rs10519937	1.000	rs6595769	chr5:126734365	C/T	cg19552640	chr5:126627061	MEGF10	-0.61	-4.49	-0.42	2.01e-5	IgG glycosylation;
THYM	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg06634786	chr22:41940651	POLR3H	0.68	4.97	0.45	3.01e-6	Vitiligo;
THYM	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg07414643	chr4:187882934	NA	0.64	5.75	0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs875971	1.000	rs697970	chr7:65560052	G/C	cg18252515	chr7:66147081	NA	0.61	4.47	0.42	2.18e-5	Aortic root size;
THYM	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg03388043	chr17:80084554	CCDC57	-0.66	-5.66	-0.5	1.61e-7	Life satisfaction;
THYM	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg10803722	chr21:46713166	LOC642852	-0.41	-5.26	-0.47	9e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg20744362	chr22:50050164	C22orf34	0.83	8.49	0.66	2.73e-13	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1883415	0.553	rs699463	chr6:24544903	G/A	cg00346970	chr6:24499591	ALDH5A1	0.36	4.48	0.42	2.06e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg02269571	chr22:50332266	NA	0.68	5.31	0.48	7.18e-7	Schizophrenia;
THYM	cis	rs611744	0.839	rs672552	chr8:109164223	A/G	cg21045802	chr8:109455806	TTC35	0.7	6.78	0.57	1.02e-9	Dupuytren's disease;
THYM	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg21427119	chr20:30132790	HM13	-0.82	-5.61	-0.5	2.01e-7	Mean corpuscular hemoglobin;
THYM	cis	rs600806	0.850	rs11102981	chr1:109967323	G/C	cg23616212	chr1:109941201	SORT1	-0.51	-4.75	-0.44	7.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06238570	chr21:40685208	BRWD1	-0.8	-5.3	-0.48	7.59e-7	Cognitive function;
THYM	cis	rs7909074	0.798	rs914699	chr10:45377066	A/C	cg04218760	chr10:45406644	TMEM72	-0.56	-5.1	-0.46	1.73e-6	Mean corpuscular volume;
THYM	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg10523679	chr1:76189770	ACADM	0.91	7.59	0.61	2.14e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4595586	0.545	rs7967931	chr12:39375162	A/C	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.673	rs9889755	chr17:29234505	A/G	cg17105886	chr17:28927953	LRRC37B2	-1.0	-5.66	-0.5	1.62e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs728616	0.717	rs12415523	chr10:81691976	T/C	cg27452691	chr10:81370291	SFTPA1	0.83	4.49	0.42	2.03e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs664172	1	rs664172	chr15:78862762	G/A	cg18825076	chr15:78729989	IREB2	0.61	4.93	0.45	3.52e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg10117171	chr1:25599238	RHD	-0.72	-5.79	-0.51	9.05e-8	Erythrocyte sedimentation rate;
THYM	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg15921436	chr17:44337874	NA	-0.76	-6.28	-0.54	1.03e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg07424592	chr7:64974309	NA	1.06	5.48	0.49	3.47e-7	Diabetic kidney disease;
THYM	cis	rs2219968	0.828	rs12543027	chr8:78887060	T/A	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.49e-10	Prudent dietary pattern;
THYM	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg10047753	chr17:41438598	NA	1.2	11.68	0.77	4.5e-20	Menopause (age at onset);
THYM	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg06713675	chr4:122721982	EXOSC9	-0.55	-5.09	-0.46	1.81e-6	Type 2 diabetes;
THYM	cis	rs3806843	1.000	rs10223116	chr5:140192643	C/T	cg19875535	chr5:140030758	IK	0.6	4.76	0.44	6.87e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg00339695	chr16:24857497	SLC5A11	0.68	6.27	0.54	1.07e-8	Intelligence (multi-trait analysis);
THYM	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg18538332	chr22:24372958	LOC391322	-0.91	-7.8	-0.62	7.79e-12	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7666738	0.819	rs13139560	chr4:99081188	C/T	cg03676636	chr4:99064102	C4orf37	0.49	6.45	0.55	4.67e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.82	-7.5	-0.61	3.29e-11	Schizophrenia;
THYM	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.38	0.55	6.27e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9457247	0.905	rs444210	chr6:167390242	A/G	cg23791538	chr6:167370224	RNASET2	-0.71	-5.93	-0.52	4.97e-8	Crohn's disease;
THYM	cis	rs13326165	0.531	rs73088791	chr3:52318281	C/A	cg08438690	chr3:52279403	PPM1M	-0.88	-5.21	-0.47	1.1e-6	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs7084402	0.967	rs2393448	chr10:60333260	T/G	cg07615347	chr10:60278583	BICC1	0.55	5.21	0.47	1.09e-6	Refractive error;
THYM	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs9527	0.590	rs7067663	chr10:104883650	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	trans	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	3.97e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg11882607	chr3:12858926	CAND2	-0.42	-4.65	-0.43	1.09e-5	QRS complex (12-leadsum);
THYM	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg22431228	chr1:16359049	CLCNKA	-0.51	-5.15	-0.47	1.42e-6	Dilated cardiomyopathy;
THYM	cis	rs7107174	1.000	rs2511156	chr11:77971167	G/C	cg19901956	chr11:77921274	USP35	-0.76	-5.83	-0.51	7.53e-8	Testicular germ cell tumor;
THYM	cis	rs9309473	0.500	rs4852308	chr2:73834035	T/G	cg19565262	chr2:73869966	NAT8	0.55	4.67	0.43	9.96e-6	Metabolite levels;
THYM	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg06481639	chr22:41940642	POLR3H	-0.82	-5.68	-0.5	1.49e-7	Vitiligo;
THYM	cis	rs7192750	0.586	rs13329779	chr16:71943940	T/C	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs6542838	0.641	rs4553869	chr2:99505940	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-4.48	-0.42	2.1e-5	Fear of minor pain;
THYM	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg05368731	chr17:41323189	NBR1	1.17	9.81	0.71	4.15e-16	Menopause (age at onset);
THYM	cis	rs10463554	0.892	rs158252	chr5:102406250	A/G	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs478304	0.627	rs1073602	chr11:65455386	G/C	cg17480646	chr11:65405466	SIPA1	-0.97	-8.99	-0.68	2.44e-14	Acne (severe);
THYM	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9880211	1.000	rs6771002	chr3:136241028	T/A	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs11563648	0.553	rs6973862	chr7:127015257	T/C	cg23081781	chr7:127225937	GCC1	-0.35	-4.78	-0.44	6.41e-6	Resting heart rate;
THYM	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg17747265	chr1:1875780	NA	-0.78	-8.65	-0.66	1.26e-13	Body mass index;
THYM	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg04944784	chr2:26401820	FAM59B	1.02	7.8	0.62	8.05e-12	Gut microbiome composition (summer);
THYM	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg14768367	chr16:72042858	DHODH	0.62	4.75	0.44	7.33e-6	Fibrinogen levels;
THYM	cis	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg10856724	chr12:34555212	NA	0.79	7.41	0.61	5.14e-11	Morning vs. evening chronotype;
THYM	cis	rs13315871	0.860	rs9842759	chr3:58244748	C/T	cg12435725	chr3:58293450	RPP14	-0.53	-5.7	-0.5	1.34e-7	Cholesterol, total;
THYM	cis	rs3845702	0.736	rs1904850	chr2:180852767	A/G	cg01881094	chr2:180872142	CWC22	-0.89	-5.34	-0.48	6.22e-7	Schizophrenia;
THYM	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg03433033	chr1:76189801	ACADM	-0.52	-5.42	-0.49	4.44e-7	Daytime sleep phenotypes;
THYM	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg00981070	chr1:2046702	PRKCZ	0.47	5.63	0.5	1.85e-7	Height;
THYM	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg16928487	chr17:17741425	SREBF1	-0.56	-5.53	-0.49	2.81e-7	Total body bone mineral density;
THYM	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg00744431	chr10:134226547	PWWP2B	-0.6	-4.7	-0.43	8.67e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg16240275	chr20:61666158	NCRNA00029	0.33	4.46	0.42	2.29e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10479542	0.752	rs7704349	chr5:178986978	C/G	cg05457628	chr5:178986728	RUFY1	-0.69	-7.36	-0.6	6.64e-11	Lung cancer;
THYM	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg17509989	chr5:176798049	RGS14	-0.67	-5.81	-0.51	8.35e-8	Urate levels in lean individuals;
THYM	cis	rs11785693	0.730	rs62489552	chr8:4956801	T/C	cg26367366	chr8:4980734	NA	1.08	4.89	0.45	4.08e-6	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs28595532	0.920	rs55633605	chr4:119761589	G/A	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.77	-6.6	-0.56	2.36e-9	Tonsillectomy;
THYM	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs1018836	0.923	rs2157607	chr8:91600268	A/G	cg16814680	chr8:91681699	NA	-0.86	-7.18	-0.59	1.56e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg18305652	chr10:134549665	INPP5A	0.79	6.98	0.58	4.02e-10	Migraine;
THYM	cis	rs9326248	0.569	rs4938315	chr11:116731205	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.85	4.79	0.44	6.08e-6	Blood protein levels;
THYM	cis	rs7772486	0.790	rs80050589	chr6:146230454	T/C	cg23711669	chr6:146136114	FBXO30	-0.96	-10.01	-0.72	1.54e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8077889	1.000	rs17674998	chr17:41879544	A/G	cg26893861	chr17:41843967	DUSP3	0.98	8.64	0.66	1.31e-13	Triglycerides;
THYM	cis	rs80319144	1.000	rs77150481	chr2:159213758	G/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.58	4.66	0.43	1.05e-5	Restless legs syndrome;
THYM	cis	rs40363	0.716	rs9926612	chr16:3540968	A/C	cg00484396	chr16:3507460	NAT15	-0.65	-5.1	-0.46	1.77e-6	Tuberculosis;
THYM	cis	rs7586879	0.638	rs13035244	chr2:25134009	T/C	cg01884057	chr2:25150051	NA	0.73	7.92	0.63	4.47e-12	Body mass index;
THYM	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg05182265	chr7:156933206	UBE3C	-0.69	-9.34	-0.69	4.32e-15	Body mass index;
THYM	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg02953382	chr22:24373134	LOC391322	-0.7	-6.28	-0.54	9.97e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2072499	0.966	rs887953	chr1:156191149	T/C	cg06970220	chr1:156163860	SLC25A44	0.71	5.68	0.5	1.47e-7	Testicular germ cell tumor;
THYM	cis	rs56104184	0.615	rs73061693	chr19:49399941	C/A	cg17863274	chr19:49399704	TULP2	-1.01	-6.47	-0.55	4.29e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7769051	1.000	rs9399041	chr6:133096233	T/G	cg07930552	chr6:133119739	C6orf192	1.02	5.81	0.51	8.43e-8	Type 2 diabetes nephropathy;
THYM	cis	rs6840360	0.615	rs4696097	chr4:152479765	C/T	cg22705602	chr4:152727874	NA	0.71	7.94	0.63	4.03e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7799006	0.723	rs2270052	chr7:2291399	C/T	cg08027265	chr7:2291960	NA	-0.46	-5.57	-0.5	2.41e-7	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2742417	0.624	rs2742394	chr3:45757591	C/T	cg04837898	chr3:45731254	SACM1L	-0.74	-5.4	-0.48	4.94e-7	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs2404602	0.735	rs4886493	chr15:76679026	A/G	cg23482746	chr15:76478102	C15orf27	0.45	4.57	0.42	1.44e-5	Blood metabolite levels;
THYM	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg07424592	chr7:64974309	NA	-1.06	-5.38	-0.48	5.23e-7	Diabetic kidney disease;
THYM	cis	rs6570726	0.846	rs1935616	chr6:145943512	C/T	cg13319975	chr6:146136371	FBXO30	-0.67	-5.46	-0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg23187316	chr7:1099788	C7orf50	0.58	4.45	0.42	2.32e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6430585	0.528	rs12474975	chr2:136702118	A/T	cg07169764	chr2:136633963	MCM6	1.19	11.38	0.76	1.91e-19	Corneal structure;
THYM	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	trans	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg02187348	chr16:89574699	SPG7	0.8	6.54	0.56	3.11e-9	Multiple myeloma (IgH translocation);
THYM	cis	rs728616	0.867	rs56198874	chr10:81686488	C/T	cg05935833	chr10:81318306	SFTPA2	-0.77	-4.66	-0.43	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs960902	0.747	rs9941697	chr2:37728687	T/C	cg25341268	chr2:37734390	NA	0.59	4.97	0.45	2.98e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg21475434	chr5:93447410	FAM172A	-0.71	-4.51	-0.42	1.83e-5	Diabetic retinopathy;
THYM	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-5.73	-0.51	1.15e-7	Systemic lupus erythematosus;
THYM	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg12179176	chr11:130786555	SNX19	0.88	8.3	0.65	7.08e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg21028142	chr17:79581711	NPLOC4	0.61	6.22	0.54	1.32e-8	Eye color traits;
THYM	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.22	9.36	0.69	3.93e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg02675527	chr2:114030824	PAX8;LOC440839	-0.7	-6.1	-0.53	2.31e-8	Lymphocyte counts;
THYM	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg01416388	chr22:39784598	NA	0.86	8.61	0.66	1.54e-13	IgG glycosylation;
THYM	cis	rs1904096	0.513	rs2632405	chr4:95152215	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.1	-0.46	1.7e-6	Type 2 diabetes;
THYM	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg18876405	chr7:65276391	NA	0.58	4.84	0.44	5.11e-6	Aortic root size;
THYM	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11890956	chr21:40555474	PSMG1	-0.93	-10.03	-0.72	1.43e-16	Cognitive function;
THYM	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg25208724	chr1:156163844	SLC25A44	1.11	8.66	0.66	1.22e-13	Testicular germ cell tumor;
THYM	cis	rs3806843	0.897	rs2531338	chr5:140136957	A/T	cg19875535	chr5:140030758	IK	-0.58	-4.53	-0.42	1.69e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs472402	0.580	rs3736316	chr5:6656210	G/A	cg12648172	chr5:5886274	NA	0.52	4.72	0.44	7.99e-6	Response to amphetamines;
THYM	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.65	-0.5	1.64e-7	Prostate cancer;
THYM	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg21605333	chr4:119757512	SEC24D	1.54	6.13	0.53	1.97e-8	Cannabis dependence symptom count;
THYM	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg18681998	chr4:17616180	MED28	0.88	8.21	0.64	1.09e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg04025307	chr7:1156635	C7orf50	0.67	5.64	0.5	1.76e-7	Longevity;Endometriosis;
THYM	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.89	5.72	0.51	1.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11148252	0.870	rs11148246	chr13:52797537	C/T	cg05335186	chr13:53173507	NA	-0.52	-6.57	-0.56	2.69e-9	Lewy body disease;
THYM	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg11366901	chr6:160182831	ACAT2	1.05	9.61	0.7	1.11e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6531656	0.605	rs4240247	chr4:38689190	C/T	cg24279243	chr4:38676559	KLF3	0.86	7.91	0.63	4.72e-12	Lymphocyte counts;
THYM	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs4372836	0.704	rs3190	chr2:29025479	A/G	cg09522027	chr2:28974177	PPP1CB	-0.63	-5.0	-0.46	2.58e-6	Body mass index;
THYM	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg24692254	chr21:30365293	RNF160	-1.05	-9.9	-0.71	2.65e-16	Dental caries;
THYM	cis	rs12142240	0.660	rs112560929	chr1:46822297	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs10924970	0.967	rs2152954	chr1:235417780	A/G	cg26050004	chr1:235667680	B3GALNT2	0.6	4.48	0.42	2.07e-5	Asthma;
THYM	cis	rs4595586	0.545	rs12809435	chr12:39404341	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-5.1	-0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs854765	0.604	rs12948749	chr17:17949802	G/A	cg04398451	chr17:18023971	MYO15A	0.86	8.7	0.67	1.01e-13	Total body bone mineral density;
THYM	cis	rs2319125	0.649	rs34489012	chr17:64045784	G/A	cg04446870	chr17:64440273	PRKCA	0.5	4.48	0.42	2.12e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs1747683	0.809	rs1547772	chr10:13383449	T/C	cg11679871	chr10:13388567	SEPHS1	-0.31	-4.6	-0.43	1.3e-5	IgG glycosylation;
THYM	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg11752832	chr7:134001865	SLC35B4	0.76	5.72	0.51	1.24e-7	Mean platelet volume;
THYM	cis	rs4660531	1.000	rs34883982	chr1:41849873	C/T	cg08462924	chr1:41848221	NA	0.63	6.0	0.52	3.5e-8	Bipolar disorder;
THYM	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg11764359	chr7:65958608	NA	0.81	6.42	0.55	5.31e-9	Aortic root size;
THYM	cis	rs1190596	0.526	rs1190572	chr14:102634589	A/G	cg08231664	chr14:102516632	DYNC1H1	-0.4	-4.77	-0.44	6.6e-6	Behavioural disinhibition (generation interaction);
THYM	cis	rs7771547	0.573	rs619011	chr6:36476592	A/G	cg07856975	chr6:36356162	ETV7	0.53	5.09	0.46	1.84e-6	Platelet distribution width;
THYM	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg01017244	chr2:74357527	NA	1.08	8.79	0.67	6.44e-14	Gestational age at birth (maternal effect);
THYM	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg18825531	chr11:62321136	NA	0.45	5.07	0.46	2e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.8	5.24	0.47	9.84e-7	Platelet count;
THYM	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.68	5.24	0.47	9.75e-7	Tonsillectomy;
THYM	cis	rs28595532	0.841	rs115987912	chr4:119737085	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs5985	0.687	rs55742486	chr6:6317589	T/C	cg16530177	chr6:6320324	F13A1	0.7	5.83	0.51	7.44e-8	End-stage coagulation;
THYM	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6032067	0.929	rs17424356	chr20:43804190	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.16	-0.64	1.36e-12	Blood protein levels;
THYM	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg00898013	chr13:113819073	PROZ	0.89	9.29	0.69	5.34e-15	Platelet distribution width;
THYM	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg11905131	chr22:24372483	LOC391322	0.72	5.53	0.49	2.81e-7	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs11785693	0.862	rs7007542	chr8:4996718	G/A	cg26367366	chr8:4980734	NA	1.21	5.9	0.52	5.46e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-5.64	-0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg13402656	chr8:1511478	DLGAP2	0.78	7.88	0.63	5.39e-12	Lung cancer;
THYM	cis	rs4072705	0.646	rs10120967	chr9:127244134	C/T	cg01786973	chr9:127249749	NR5A1	0.4	5.21	0.47	1.09e-6	Menarche (age at onset);
THYM	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg27398817	chr8:82754497	SNX16	0.71	6.05	0.53	2.89e-8	Diastolic blood pressure;
THYM	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6459804	0.935	rs72505543	chr7:157508867	G/A	cg11757124	chr7:157526947	PTPRN2	-0.65	-5.19	-0.47	1.21e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22496380	chr5:211416	CCDC127	-1.39	-8.13	-0.64	1.62e-12	Breast cancer;
THYM	cis	rs2195525	0.572	rs1320679	chr11:119219124	G/T	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.43	4.83	0.44	5.19e-6	Urate levels;
THYM	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06634786	chr22:41940651	POLR3H	0.84	6.24	0.54	1.21e-8	Vitiligo;
THYM	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg03476357	chr21:30257390	N6AMT1	0.6	4.57	0.42	1.49e-5	Dental caries;
THYM	cis	rs4919694	0.901	rs74376228	chr10:104677662	G/C	cg04362960	chr10:104952993	NT5C2	1.15	7.03	0.59	3.1e-10	Arsenic metabolism;
THYM	cis	rs10895275	0.625	rs10895269	chr11:102039296	A/G	cg24447756	chr11:102105824	NA	0.48	4.52	0.42	1.8e-5	Migraine;
THYM	cis	rs12149862	1.000	rs9930728	chr16:69466275	A/G	cg02524010	chr16:69117679	TMCO7	-0.63	-4.54	-0.42	1.63e-5	Blood pressure (smoking interaction);
THYM	cis	rs714031	0.934	rs5757768	chr22:40071322	G/A	cg21377881	chr22:40064566	CACNA1I	-0.62	-5.56	-0.5	2.51e-7	Schizophrenia;
THYM	cis	rs11997175	1.000	rs6468200	chr8:33745191	A/T	ch.8.33884649F	chr8:33765107	NA	0.63	4.94	0.45	3.36e-6	Body mass index;
THYM	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.35	-0.73	2.93e-17	Extrinsic epigenetic age acceleration;
THYM	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg15704280	chr7:45808275	SEPT13	-1.06	-15.39	-0.84	1.51e-27	Height;
THYM	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.68	5.15	0.47	1.4e-6	Total cholesterol levels;
THYM	trans	rs208520	0.661	rs150263	chr6:66777620	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-7.96	-0.63	3.63e-12	Exhaled nitric oxide output;
THYM	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg12310025	chr6:25882481	NA	-0.65	-5.07	-0.46	1.98e-6	Height;
THYM	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.24	4.92	0.45	3.64e-6	Obesity-related traits;
THYM	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21582582	chr3:182698605	DCUN1D1	0.78	6.87	0.58	6.69e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs2303759	0.918	rs2288480	chr19:49867016	C/G	cg22307029	chr19:49891270	CCDC155	0.81	7.2	0.59	1.42e-10	Multiple sclerosis;
THYM	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs61931739	0.890	rs11053018	chr12:34105962	T/G	cg10856724	chr12:34555212	NA	0.61	5.29	0.48	7.89e-7	Morning vs. evening chronotype;
THYM	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.83	5.25	0.47	9.31e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg06636001	chr8:8085503	FLJ10661	0.68	5.32	0.48	6.93e-7	Mood instability;
THYM	cis	rs2241584	0.967	rs56030800	chr5:175946238	A/G	cg27658698	chr5:175955578	RNF44	-0.48	-5.67	-0.5	1.53e-7	Menopause (age at onset);
THYM	cis	rs17407555	0.738	rs73212895	chr4:10121025	C/T	cg14348967	chr4:10160060	NA	0.56	4.48	0.42	2.09e-5	Schizophrenia (age at onset);
THYM	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg05932139	chr16:680872	WFIKKN1	-0.59	-4.84	-0.44	5.07e-6	Height;
THYM	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg04455712	chr21:45112962	RRP1B	0.51	4.72	0.44	8.23e-6	Mean corpuscular volume;
THYM	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg21475434	chr5:93447410	FAM172A	0.93	5.81	0.51	8.12e-8	Diabetic retinopathy;
THYM	cis	rs9880211	0.898	rs28877020	chr3:136395716	T/G	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs950394	0.767	rs10176377	chr2:104970824	A/G	cg20302975	chr2:105468274	NA	0.6	4.5	0.42	1.91e-5	Schizophrenia;
THYM	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg24375607	chr4:120327624	NA	0.64	5.06	0.46	2.06e-6	Corneal astigmatism;
THYM	cis	rs877282	0.898	rs11253356	chr10:768604	G/A	cg10556349	chr10:835070	NA	-0.82	-5.8	-0.51	8.78e-8	Uric acid levels;
THYM	cis	rs10489202	0.632	rs149912	chr1:167957803	A/T	cg24449463	chr1:168025552	DCAF6	-0.9	-9.11	-0.68	1.3e-14	Schizophrenia;
THYM	cis	rs9611519	0.780	rs9611527	chr22:41644428	G/A	cg06634786	chr22:41940651	POLR3H	-0.58	-4.65	-0.43	1.09e-5	Neuroticism;
THYM	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg09184832	chr6:79620586	NA	-0.58	-4.53	-0.42	1.73e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4646404	0.526	rs11867345	chr17:17478390	C/T	cg11245205	chr17:17398264	RASD1	-0.42	-4.66	-0.43	1.03e-5	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;
THYM	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg07537917	chr2:241836409	C2orf54	-0.25	-5.47	-0.49	3.7e-7	Urinary metabolites;
THYM	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	9.51	0.7	1.85e-15	Platelet count;
THYM	cis	rs12282928	0.959	rs1354293	chr11:48264370	A/G	cg22827986	chr11:48284249	OR4X1	-0.53	-5.5	-0.49	3.18e-7	Migraine - clinic-based;
THYM	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg08807101	chr21:30365312	RNF160	0.96	8.26	0.65	8.48e-13	Dental caries;
THYM	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg03690763	chr11:133734501	NA	-0.61	-4.77	-0.44	6.59e-6	Childhood ear infection;
THYM	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg00071950	chr4:10020882	SLC2A9	-0.68	-7.07	-0.59	2.61e-10	Bone mineral density;
THYM	cis	rs4589258	0.737	rs7127743	chr11:90394540	T/C	cg26138821	chr11:89956704	CHORDC1	0.56	4.68	0.43	9.36e-6	Intelligence (multi-trait analysis);
THYM	cis	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg07460842	chr6:66804631	NA	0.92	5.5	0.49	3.15e-7	Exhaled nitric oxide levels;
THYM	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4631830	1.000	rs4631830	chr10:51543344	C/T	cg10326726	chr10:51549505	MSMB	-0.5	-4.94	-0.45	3.38e-6	Prostate-specific antigen levels;
THYM	cis	rs941873	0.900	rs7092536	chr10:81131332	A/C	cg09469691	chr10:81107165	PPIF	0.72	6.01	0.53	3.36e-8	Height;
THYM	cis	rs2282300	0.739	rs1717775	chr11:30350254	T/G	cg25418670	chr11:30344373	C11orf46	-0.82	-6.98	-0.58	3.93e-10	Morning vs. evening chronotype;
THYM	cis	rs6722750	0.783	rs11125991	chr2:64387765	A/G	cg22352474	chr2:64371530	PELI1	0.74	6.55	0.56	2.93e-9	Neuroticism;
THYM	cis	rs765787	0.530	rs2899379	chr15:45534799	C/T	cg25801113	chr15:45476975	SHF	-0.39	-4.57	-0.42	1.48e-5	Uric acid levels;
THYM	cis	rs28595532	0.920	rs115860303	chr4:119734526	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs9359856	0.510	rs4235839	chr6:90472410	A/G	cg13799429	chr6:90582589	CASP8AP2	0.84	8.26	0.65	8.31e-13	Bipolar disorder;
THYM	cis	rs907683	0.546	rs1058261	chr2:220285309	C/T	cg15015639	chr2:220282977	DES	-0.42	-5.71	-0.51	1.3e-7	Resting heart rate;
THYM	cis	rs2658782	0.526	rs7131487	chr11:93185952	T/C	cg15737290	chr11:93063684	CCDC67	0.65	5.29	0.48	7.79e-7	Pulmonary function decline;
THYM	cis	rs7107174	1.000	rs4945274	chr11:78109260	G/A	cg19901956	chr11:77921274	USP35	-0.65	-5.34	-0.48	6.41e-7	Testicular germ cell tumor;
THYM	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg03168497	chr17:48586147	MYCBPAP	-0.5	-4.63	-0.43	1.17e-5	Visceral fat;
THYM	cis	rs10911251	0.528	rs2182020	chr1:183074964	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Colorectal cancer;
THYM	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg15445000	chr17:37608096	MED1	-0.45	-5.34	-0.48	6.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs61931739	0.853	rs11053002	chr12:34083499	T/C	cg10856724	chr12:34555212	NA	0.6	5.23	0.47	1e-6	Morning vs. evening chronotype;
THYM	cis	rs600806	0.813	rs4970760	chr1:109985439	A/G	cg23616212	chr1:109941201	SORT1	-0.48	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7575217	0.697	rs796067	chr2:101707009	C/T	cg23907051	chr2:101730305	TBC1D8	-0.41	-5.62	-0.5	1.91e-7	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs6570726	0.967	rs374728	chr6:145854598	T/A	cg23711669	chr6:146136114	FBXO30	0.91	9.55	0.7	1.49e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6438424	1.000	rs13100226	chr3:117590202	C/T	cg07190778	chr3:117604296	NA	-0.4	-5.53	-0.49	2.81e-7	Menarche (age at onset);
THYM	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg27034606	chr17:28928453	LRRC37B2	0.83	5.47	0.49	3.6e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6768930	0.527	rs6804765	chr3:57831211	A/G	cg24033633	chr3:57945695	NA	-0.35	-4.79	-0.44	6.2e-6	Obesity-related traits;
THYM	cis	rs72792324	0.655	rs6896353	chr5:140757036	A/G	cg21929183	chr5:140807225	PCDHGA4;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB8P;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	-0.84	-4.5	-0.42	1.96e-5	Mean platelet volume;
THYM	cis	rs7189233	1.000	rs7189233	chr16:53455383	C/T	cg02965178	chr16:53538660	AKTIP	-0.61	-4.9	-0.45	3.93e-6	Intelligence (multi-trait analysis);
THYM	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg16049864	chr8:95962084	TP53INP1	-0.69	-6.21	-0.54	1.41e-8	Type 2 diabetes;
THYM	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg05932139	chr16:680872	WFIKKN1	-0.64	-5.31	-0.48	7.21e-7	Height;
THYM	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg11317459	chr13:21872234	NA	-1.22	-9.26	-0.69	6.43e-15	White matter hyperintensity burden;
THYM	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.77	-5.2	-0.47	1.16e-6	Body mass index;
THYM	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs4732038	0.565	rs706200	chr7:134265938	T/G	cg06906464	chr7:134288099	NA	-0.47	-4.72	-0.44	8.06e-6	Longevity;
THYM	cis	rs7582180	0.627	rs6749018	chr2:101001859	G/T	cg08017756	chr2:100939284	LONRF2	-0.75	-7.83	-0.63	6.9e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg12826209	chr6:26865740	GUSBL1	-0.85	-4.67	-0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg10589385	chr1:150898437	SETDB1	0.66	5.48	0.49	3.44e-7	Melanoma;
THYM	cis	rs2811415	0.597	rs9833838	chr3:127741134	C/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg26384229	chr12:38710491	ALG10B	-0.72	-5.64	-0.5	1.76e-7	Morning vs. evening chronotype;
THYM	cis	rs2624839	0.704	rs12632110	chr3:50224225	A/G	cg14019146	chr3:50243930	SLC38A3	0.69	5.76	0.51	1.02e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9914988	0.778	rs9907192	chr17:27122426	C/G	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg23982607	chr1:1823379	GNB1	-0.94	-10.22	-0.72	5.49e-17	Body mass index;
THYM	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg13010199	chr12:38710504	ALG10B	-0.59	-5.14	-0.47	1.46e-6	Heart rate;
THYM	cis	rs1642645	0.793	rs7546128	chr1:42473659	C/A	cg22816091	chr1:42611670	NA	0.64	5.76	0.51	1.04e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg24006582	chr15:45444508	DUOX1	-0.79	-6.6	-0.56	2.31e-9	Uric acid levels;
THYM	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06634786	chr22:41940651	POLR3H	-0.91	-7.01	-0.58	3.4e-10	Vitiligo;
THYM	cis	rs6840360	1.000	rs2278304	chr4:152593409	C/T	cg22705602	chr4:152727874	NA	0.63	6.81	0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg17074396	chr22:49843754	NA	-0.4	-4.7	-0.43	8.73e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg06718696	chr17:78121285	EIF4A3	0.9	6.14	0.53	1.93e-8	Plateletcrit;Mean corpuscular hemoglobin concentration;
THYM	cis	rs11563648	0.553	rs1419421	chr7:127017694	A/T	cg23081781	chr7:127225937	GCC1	-0.34	-4.64	-0.43	1.14e-5	Resting heart rate;
THYM	cis	rs7578361	0.842	rs10932584	chr2:150450787	G/A	cg17961725	chr2:150454027	NA	0.75	6.45	0.55	4.58e-9	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9326248	0.689	rs4516002	chr11:116999059	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.85	5.21	0.47	1.12e-6	Blood protein levels;
THYM	cis	rs9399401	0.890	rs2294771	chr6:142760962	T/G	cg04461802	chr6:142623433	GPR126	0.49	4.92	0.45	3.68e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs9612	1.000	rs2074634	chr19:44238347	C/T	cg08581076	chr19:44259116	C19orf61	-0.68	-4.61	-0.43	1.26e-5	Exhaled nitric oxide output;
THYM	cis	rs335206	0.641	rs335210	chr5:122501864	A/G	cg16368670	chr5:122501738	PRDM6	-0.58	-4.58	-0.43	1.39e-5	QRS duration;
THYM	cis	rs3741151	0.773	rs73544767	chr11:73204619	C/T	cg12959048	chr11:73096162	RELT	-0.49	-4.58	-0.43	1.41e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs4144027	0.935	rs881056	chr14:104354225	G/A	cg08213375	chr14:104286397	PPP1R13B	-0.45	-4.69	-0.43	9.2e-6	Blood metabolite levels;
THYM	cis	rs1003719	0.788	rs2835595	chr21:38466203	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg00271210	chr6:167070053	RPS6KA2	-0.54	-5.37	-0.48	5.53e-7	Crohn's disease;
THYM	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg03188948	chr7:1209495	NA	0.76	5.92	0.52	5.07e-8	Longevity;Endometriosis;
THYM	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.88	5.64	0.5	1.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4631830	0.863	rs4935162	chr10:51525699	C/G	cg10326726	chr10:51549505	MSMB	-0.59	-5.86	-0.52	6.68e-8	Prostate-specific antigen levels;
THYM	cis	rs888194	0.898	rs10850379	chr12:110002777	A/G	cg10504392	chr12:110044639	NA	-0.67	-6.56	-0.56	2.86e-9	Neuroticism;
THYM	cis	rs3820068	0.705	rs57238793	chr1:15890029	A/G	cg05660106	chr1:15850417	CASP9	1.14	9.3	0.69	5.19e-15	Systolic blood pressure;
THYM	cis	rs3087591	0.960	rs8067021	chr17:29555078	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.6	-5.16	-0.47	1.35e-6	Hip circumference;
THYM	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg25554036	chr4:6271136	WFS1	0.5	4.54	0.42	1.62e-5	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg11764359	chr7:65958608	NA	0.86	7.24	0.6	1.14e-10	Aortic root size;
THYM	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg10792982	chr14:105748885	BRF1	0.72	7.3	0.6	8.67e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9646954	0.791	rs4851300	chr2:100958804	C/A	cg14675211	chr2:100938903	LONRF2	0.7	6.74	0.57	1.2e-9	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.966	rs11914795	chr3:47557722	G/A	cg02527881	chr3:46936655	PTH1R	-0.61	-5.74	-0.51	1.15e-7	Colorectal cancer;
THYM	cis	rs4986172	0.840	rs8067974	chr17:43232566	A/G	cg06100756	chr17:43221575	NA	0.56	6.24	0.54	1.2e-8	Height;
THYM	trans	rs637571	0.544	rs617791	chr11:65702523	C/G	cg17712092	chr4:129076599	LARP1B	0.93	8.48	0.66	2.84e-13	Eosinophil percentage of white cells;
THYM	cis	rs3819817	0.575	rs7965042	chr12:96357132	G/A	cg26410635	chr12:96350720	AMDHD1	0.53	5.02	0.46	2.38e-6	Vitamin D levels;
THYM	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg18876405	chr7:65276391	NA	0.61	5.2	0.47	1.13e-6	Aortic root size;
THYM	cis	rs2663905	0.605	rs2683235	chr15:81398791	A/G	cg09888468	chr15:81410853	NA	-0.78	-5.94	-0.52	4.62e-8	QT interval (drug interaction);
THYM	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg16524936	chr4:1340807	KIAA1530	-0.67	-5.19	-0.47	1.17e-6	Longevity;
THYM	cis	rs2953805	1	rs2953805	chr8:8914757	T/C	cg18904891	chr8:8559673	CLDN23	0.62	4.82	0.44	5.37e-6	Neuroticism;Morning vs. evening chronotype;
THYM	cis	rs7584330	0.554	rs75559690	chr2:238428454	T/C	cg14458575	chr2:238380390	NA	0.96	5.14	0.47	1.48e-6	Prostate cancer;
THYM	cis	rs7769051	0.803	rs34334052	chr6:133231829	C/T	cg22852734	chr6:133119734	C6orf192	1.07	5.73	0.51	1.16e-7	Type 2 diabetes nephropathy;
THYM	cis	rs6084875	0.840	rs6084858	chr20:4731109	A/G	cg19614321	chr20:4804581	RASSF2	-0.45	-4.66	-0.43	1.02e-5	Systemic lupus erythematosus;
THYM	cis	rs4918072	0.834	rs12413741	chr10:105711283	C/G	cg11005552	chr10:105648138	OBFC1	0.57	4.61	0.43	1.26e-5	Coronary artery disease;
THYM	cis	rs4731207	0.698	rs2079368	chr7:124485311	C/T	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs790123	1.000	rs790123	chr3:122388993	T/C	cg17380795	chr3:122379686	NA	0.57	5.16	0.47	1.38e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg13683864	chr3:40499215	RPL14	-0.88	-8.8	-0.67	5.95e-14	Renal cell carcinoma;
THYM	cis	rs2108225	0.934	rs2301989	chr7:107443871	G/A	cg18560240	chr7:107437656	SLC26A3	-0.72	-5.0	-0.46	2.66e-6	Ulcerative colitis;
THYM	cis	rs7113850	0.541	rs74702708	chr11:24226866	T/C	ch.11.24196551F	chr11:24239977	NA	1.03	5.41	0.49	4.67e-7	Bone fracture in osteoporosis;
THYM	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg22709100	chr7:91322751	NA	0.68	5.42	0.49	4.59e-7	Breast cancer;
THYM	cis	rs4731207	0.561	rs12706631	chr7:124586580	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg04520793	chr17:42248056	ASB16	-0.33	-4.56	-0.42	1.54e-5	Total body bone mineral density;
THYM	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg01579765	chr21:45077557	HSF2BP	-0.47	-7.37	-0.6	6.12e-11	Mean corpuscular volume;
THYM	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg11752832	chr7:134001865	SLC35B4	0.67	4.71	0.43	8.58e-6	Mean platelet volume;
THYM	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg18252515	chr7:66147081	NA	-1.37	-8.05	-0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg22862634	chr11:62369728	EML3;MTA2	-0.61	-7.9	-0.63	4.95e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg23131131	chr22:24373011	LOC391322	0.76	5.84	0.51	7.25e-8	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs10269006	0.537	rs12155354	chr7:94371291	A/C	cg00347863	chr7:94220697	SGCE	0.56	4.83	0.44	5.19e-6	Breast cancer;
THYM	cis	rs17443541	0.507	rs971326	chr2:200450244	A/G	cg01795955	chr2:200468626	NA	0.72	4.83	0.44	5.26e-6	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg19507638	chr5:93509721	C5orf36	-0.7	-4.71	-0.44	8.43e-6	Diabetic retinopathy;
THYM	cis	rs28498503	1.000	rs7238497	chr18:76660481	G/C	cg24134504	chr18:76639479	NA	0.71	4.79	0.44	6.21e-6	Attention function in attention deficit hyperactive disorder;
THYM	cis	rs2018683	0.683	rs12538606	chr7:28969408	T/C	cg27487796	chr7:28973253	NA	-0.27	-4.69	-0.43	9.24e-6	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
THYM	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg16778714	chr17:28903809	LRRC37B2	-0.76	-4.49	-0.42	2.03e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.63	-6.21	-0.54	1.38e-8	Caffeine consumption;
THYM	cis	rs7107174	0.901	rs1055250	chr11:77925708	C/G	cg19901956	chr11:77921274	USP35	-0.73	-5.65	-0.5	1.64e-7	Testicular germ cell tumor;
THYM	cis	rs7917772	0.565	rs1043450	chr10:104434209	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.93	6.76	0.57	1.13e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6032067	0.527	rs6104011	chr20:43733503	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.39	-4.7	-0.43	8.94e-6	Blood protein levels;
THYM	trans	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg10856724	chr12:34555212	NA	-0.89	-8.35	-0.65	5.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg11266682	chr4:10021025	SLC2A9	0.74	12.07	0.78	6.86e-21	Bone mineral density;
THYM	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg19077165	chr18:44547161	KATNAL2	-0.62	-7.94	-0.63	4.03e-12	Personality dimensions;
THYM	cis	rs3741151	0.686	rs12288753	chr11:73136261	A/T	cg17517138	chr11:73019481	ARHGEF17	0.79	4.86	0.45	4.54e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs6840360	1.000	rs6840360	chr4:152604031	C/T	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg14196790	chr5:131705035	SLC22A5	0.56	5.1	0.46	1.74e-6	Blood metabolite levels;
THYM	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg16558253	chr16:72132732	DHX38	-0.58	-5.02	-0.46	2.46e-6	Fibrinogen levels;
THYM	cis	rs4803468	1.000	rs4803468	chr19:41922352	A/G	cg09537434	chr19:41945824	ATP5SL	-1.06	-9.81	-0.71	4.27e-16	Height;
THYM	cis	rs3204270	0.684	rs62080212	chr17:79642500	G/A	cg13117272	chr17:79681052	SLC25A10	-0.72	-4.48	-0.42	2.05e-5	Dental caries;
THYM	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06481639	chr22:41940642	POLR3H	0.84	5.85	0.51	6.94e-8	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg00129232	chr17:37814104	STARD3	0.69	4.51	0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg24060327	chr5:131705240	SLC22A5	0.77	5.62	0.5	1.86e-7	Blood metabolite levels;
THYM	cis	rs800586	0.500	rs2737253	chr8:116663922	A/G	cg04656070	chr8:116661063	TRPS1	0.59	6.81	0.57	8.62e-10	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs346785	0.518	rs11077811	chr17:74285242	G/A	cg09812376	chr17:74270190	QRICH2	-0.6	-6.22	-0.54	1.34e-8	White matter hyperintensities in ischemic stroke;
THYM	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg06558623	chr16:89946397	TCF25	1.46	7.34	0.6	7.19e-11	Skin colour saturation;
THYM	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.9	10.5	0.73	1.44e-17	Prudent dietary pattern;
THYM	cis	rs308447	0.576	rs10005301	chr4:123715055	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	-0.86	-6.94	-0.58	4.75e-10	Perceived unattractiveness to mosquitoes;
THYM	cis	rs7769051	0.615	rs12209144	chr6:133191064	A/T	cg22852734	chr6:133119734	C6orf192	1.11	5.57	0.5	2.36e-7	Type 2 diabetes nephropathy;
THYM	cis	rs7772486	0.840	rs854144	chr6:146360880	G/T	cg23711669	chr6:146136114	FBXO30	-0.73	-6.9	-0.58	5.81e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3540	0.576	rs1974519	chr15:91036460	A/G	cg00487526	chr15:90818384	NA	-0.58	-4.47	-0.42	2.19e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg22535103	chr8:58192502	C8orf71	-0.96	-5.47	-0.49	3.7e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs4731207	0.596	rs1994024	chr7:124660845	A/G	cg05285228	chr7:124571219	POT1	-0.67	-5.18	-0.47	1.24e-6	Cutaneous malignant melanoma;
THYM	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg06634786	chr22:41940651	POLR3H	-0.7	-4.92	-0.45	3.59e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg00495681	chr13:53174319	NA	0.73	6.74	0.57	1.25e-9	Lewy body disease;
THYM	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9790314	1.000	rs189270	chr3:161063504	T/C	cg03342759	chr3:160939853	NMD3	-0.73	-6.48	-0.55	4.06e-9	Morning vs. evening chronotype;
THYM	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg03060546	chr3:49711283	APEH	0.75	6.08	0.53	2.55e-8	Resting heart rate;
THYM	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg15744005	chr10:104629667	AS3MT	-0.78	-7.33	-0.6	7.48e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7917772	0.582	rs729024	chr10:104341975	T/C	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs763014	0.802	rs4262946	chr16:632138	C/T	cg00908189	chr16:619842	PIGQ	1.16	11.18	0.75	5.05e-19	Height;
THYM	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs11008222	0.967	rs7097132	chr10:31042804	A/G	cg00941203	chr10:31016591	NA	-0.35	-4.9	-0.45	4e-6	Congenital left-sided heart lesions (maternal effect);
THYM	cis	rs986417	0.901	rs1884094	chr14:61016933	C/G	cg27398547	chr14:60952738	C14orf39	1.11	5.4	0.48	4.89e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs8114671	0.836	rs6142294	chr20:33671497	A/G	cg08999081	chr20:33150536	PIGU	-0.56	-4.83	-0.44	5.18e-6	Height;
THYM	cis	rs2668423	0.922	rs2668418	chr19:1366422	C/G	cg02639931	chr19:1387894	NDUFS7	-0.53	-6.19	-0.54	1.51e-8	Nonalcoholic fatty liver disease;
THYM	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg09354556	chr3:47051341	NA	0.46	4.74	0.44	7.63e-6	Colorectal cancer;
THYM	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.72	0.57	1.37e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg08392591	chr16:89556376	ANKRD11	0.56	4.6	0.43	1.33e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs3780378	0.875	rs7028112	chr9:5048814	G/A	cg02405213	chr9:5042618	JAK2	-0.78	-7.34	-0.6	7.17e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs12752838	0.713	rs6577536	chr1:8910110	A/G	cg06972019	chr1:8937448	ENO1	-0.82	-9.15	-0.68	1.09e-14	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs17401966	1.000	rs2275424	chr1:10356562	C/A	cg20482658	chr1:10539492	PEX14	0.41	5.0	0.46	2.57e-6	Hepatocellular carcinoma;
THYM	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg26031613	chr14:104095156	KLC1	1.21	12.73	0.79	3.03e-22	Body mass index;
THYM	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11662586	0.517	rs7230837	chr18:77695384	A/T	cg20368463	chr18:77673604	PQLC1	0.68	5.09	0.46	1.8e-6	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
THYM	cis	rs425277	1.000	rs262665	chr1:2083173	A/G	cg21394778	chr1:3037102	PRDM16	0.46	4.47	0.42	2.12e-5	Height;
THYM	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg15744005	chr10:104629667	AS3MT	-0.8	-7.6	-0.61	2.08e-11	Reticulocyte count;
THYM	trans	rs4650994	0.544	rs2476561	chr1:178619900	C/T	cg05059571	chr16:84539110	KIAA1609	-0.84	-8.56	-0.66	1.99e-13	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg21394778	chr1:3037102	PRDM16	0.47	4.6	0.43	1.31e-5	Height;
THYM	cis	rs829880	0.858	rs733180	chr12:98842588	C/T	cg25150519	chr12:98850993	NA	0.51	4.45	0.42	2.34e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3820068	0.705	rs58424111	chr1:15868470	A/C	cg05660106	chr1:15850417	CASP9	1.14	9.89	0.71	2.91e-16	Systolic blood pressure;
THYM	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg13695892	chr22:41940480	POLR3H	-0.98	-7.49	-0.61	3.58e-11	Vitiligo;
THYM	cis	rs7586879	0.681	rs6752483	chr2:25120086	C/T	cg15423357	chr2:25149977	NA	0.68	7.5	0.61	3.37e-11	Body mass index;
THYM	cis	rs981844	0.775	rs62323975	chr4:154737617	A/G	cg09973105	chr4:154681532	RNF175	-0.62	-5.1	-0.46	1.72e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg03188948	chr7:1209495	NA	0.87	4.88	0.45	4.26e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg12386194	chr3:101231763	SENP7	0.95	7.47	0.61	3.85e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4481887	1.000	rs4244183	chr1:248471222	G/A	cg13385794	chr1:248469461	NA	0.65	4.66	0.43	1.04e-5	Common traits (Other);
THYM	cis	rs7584330	0.554	rs7587496	chr2:238387632	A/G	cg08992911	chr2:238395768	MLPH	1.18	7.03	0.59	3.12e-10	Prostate cancer;
THYM	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg07424592	chr7:64974309	NA	1.05	5.47	0.49	3.61e-7	Diabetic kidney disease;
THYM	cis	rs1461503	0.966	rs11218907	chr11:122841562	A/G	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs6430585	0.583	rs58509842	chr2:136586027	G/A	cg04750100	chr2:136595281	LCT	0.52	4.96	0.45	3.05e-6	Corneal structure;
THYM	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg20219074	chr11:18656078	SPTY2D1	0.79	6.46	0.55	4.47e-9	Breast cancer;
THYM	cis	rs2294693	0.891	rs9381024	chr6:40984262	A/C	cg14418226	chr6:40996092	UNC5CL	-0.6	-4.53	-0.42	1.73e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	6.7	0.57	1.5e-9	Total body bone mineral density;
THYM	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07167872	chr1:205819463	PM20D1	0.97	9.38	0.69	3.58e-15	Menarche (age at onset);
THYM	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.63	0.5	1.81e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs931127	0.747	rs11820062	chr11:65429936	T/C	cg17480646	chr11:65405466	SIPA1	-0.75	-6.27	-0.54	1.05e-8	Systemic lupus erythematosus;
THYM	cis	rs7512552	0.839	rs834232	chr1:150354682	T/C	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg09904177	chr6:26538194	HMGN4	0.53	4.47	0.42	2.16e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6430585	0.697	rs7607174	chr2:136513670	T/A	cg20242066	chr2:136595261	LCT	0.5	4.7	0.43	8.63e-6	Corneal structure;
THYM	trans	rs6089829	0.962	rs2314131	chr20:61665225	A/G	cg13615516	chr5:77269221	NA	0.86	7.21	0.59	1.33e-10	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4343996	0.727	rs7798418	chr7:3387048	C/G	cg21248987	chr7:3385318	SDK1	-0.38	-4.58	-0.43	1.43e-5	Motion sickness;
THYM	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg00484396	chr16:3507460	NAT15	0.48	4.62	0.43	1.2e-5	Body mass index (adult);
THYM	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg25566285	chr7:158114605	PTPRN2	0.89	10.94	0.75	1.63e-18	Calcium levels;
THYM	cis	rs7264396	0.747	rs2425158	chr20:34419664	T/C	cg26038318	chr20:34205095	SPAG4	0.6	4.7	0.43	8.69e-6	Total cholesterol levels;
THYM	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg08310116	chr14:75594752	NEK9	0.37	4.47	0.42	2.14e-5	Height;
THYM	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.83	-6.4	-0.55	5.87e-9	IgG glycosylation;
THYM	cis	rs2286885	0.965	rs4836548	chr9:129255456	G/A	cg14294646	chr9:129243551	FAM125B	-0.58	-5.35	-0.48	6.02e-7	Intraocular pressure;
THYM	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg24505687	chr6:33548425	BAK1	0.52	4.8	0.44	5.81e-6	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
THYM	cis	rs2456568	0.802	rs8181578	chr11:93637442	G/A	cg26875233	chr11:93583750	C11orf90	-0.53	-5.53	-0.49	2.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs6831256	0.583	rs10937929	chr4:3483037	C/T	cg16415104	chr4:3496300	NA	-0.51	-4.81	-0.44	5.72e-6	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
THYM	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg24675056	chr1:15929824	NA	0.73	5.86	0.52	6.71e-8	Systolic blood pressure;
THYM	cis	rs9303401	0.646	rs9892425	chr17:57241938	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.65	4.87	0.45	4.39e-6	Cognitive test performance;
THYM	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg12863693	chr15:85201151	NMB	0.56	4.85	0.45	4.73e-6	Schizophrenia;
THYM	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.66	5.22	0.47	1.07e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg18305652	chr10:134549665	INPP5A	0.81	7.16	0.59	1.68e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg16586182	chr3:47516702	SCAP	-0.67	-5.62	-0.5	1.9e-7	Colorectal cancer;
THYM	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg06713675	chr4:122721982	EXOSC9	-0.68	-6.77	-0.57	1.06e-9	Type 2 diabetes;
THYM	cis	rs9309473	0.607	rs10196402	chr2:73572081	A/C	cg20560298	chr2:73613845	ALMS1	-0.65	-4.62	-0.43	1.19e-5	Metabolite levels;
THYM	cis	rs4654899	1.000	rs7554770	chr1:21481361	A/T	cg01072550	chr1:21505969	NA	-0.74	-6.63	-0.56	2.02e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs7216064	0.954	rs4790974	chr17:65951107	A/T	cg12091567	chr17:66097778	LOC651250	0.72	5.05	0.46	2.15e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs888194	0.677	rs2164743	chr12:109875163	C/T	cg11367159	chr12:110044531	NA	0.53	4.82	0.44	5.39e-6	Neuroticism;
THYM	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs7567389	0.740	rs1604817	chr2:127999921	C/T	cg09760422	chr2:128146352	NA	-0.51	-6.42	-0.55	5.27e-9	Self-rated health;
THYM	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg03576123	chr11:487126	PTDSS2	-1.11	-4.78	-0.44	6.51e-6	Body mass index;
THYM	cis	rs7179456	0.544	rs7168776	chr15:58875398	A/G	cg05156742	chr15:59063176	FAM63B	0.61	5.1	0.46	1.74e-6	Asperger disorder;
THYM	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg08645402	chr16:4508243	NA	0.67	5.81	0.51	8.13e-8	Schizophrenia;
THYM	cis	rs2721195	0.845	rs3757966	chr8:145744618	G/A	cg26752003	chr8:145688521	CYHR1	-0.8	-6.76	-0.57	1.12e-9	Age at first birth;
THYM	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg05043794	chr9:111880884	C9orf5	-0.43	-6.35	-0.55	7.29e-9	Menarche (age at onset);
THYM	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg11461670	chr8:22454935	PDLIM2	-0.34	-5.99	-0.52	3.7e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.59	-7.26	-0.6	1.07e-10	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg27168131	chr21:44088823	PDE9A	-0.49	-4.86	-0.45	4.66e-6	Mean corpuscular volume;
THYM	cis	rs420259	0.516	rs722069	chr16:23506940	A/G	cg00143387	chr16:23521605	GGA2	0.74	5.26	0.47	8.91e-7	Bipolar disorder;
THYM	cis	rs4481887	0.927	rs4586010	chr1:248437568	G/A	cg00666640	chr1:248458726	OR2T12	0.56	4.76	0.44	6.8e-6	Common traits (Other);
THYM	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg27490568	chr2:178487706	NA	0.61	5.63	0.5	1.82e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9583531	0.689	rs4773244	chr13:111383937	A/T	cg24331049	chr13:111365604	ING1	-0.64	-5.26	-0.47	8.93e-7	Coronary artery disease;
THYM	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg03433033	chr1:76189801	ACADM	-0.66	-6.37	-0.55	6.72e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2456568	0.802	rs1506656	chr11:93639813	G/A	cg17595323	chr11:93583763	C11orf90	-0.59	-6.09	-0.53	2.34e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs288326	0.561	rs77496277	chr2:183761706	C/T	cg09997497	chr2:183902928	NCKAP1	1.16	5.02	0.46	2.41e-6	Blood protein levels;
THYM	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg23356831	chr14:105996513	TMEM121	0.58	6.23	0.54	1.25e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs3741151	1.000	rs60924672	chr11:73098724	A/C	cg17517138	chr11:73019481	ARHGEF17	0.99	5.77	0.51	9.92e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7084402	0.967	rs1621227	chr10:60327734	C/G	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs10779751	0.881	rs2744820	chr1:11365015	G/A	cg08854313	chr1:11322531	MTOR	-0.94	-8.43	-0.65	3.74e-13	Body mass index;
THYM	cis	rs360798	0.512	rs2430388	chr2:63106784	T/C	cg17519650	chr2:63277830	OTX1	0.68	4.87	0.45	4.44e-6	Coronary artery disease;
THYM	cis	rs10463554	0.963	rs17154953	chr5:102355261	A/G	cg23492399	chr5:102201601	PAM	-0.69	-5.14	-0.47	1.5e-6	Parkinson's disease;
THYM	trans	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg26677194	chr12:130822605	PIWIL1	-0.82	-6.47	-0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.53	0.49	2.84e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6163	0.588	rs10786706	chr10:104500659	C/T	cg04362960	chr10:104952993	NT5C2	0.56	4.78	0.44	6.5e-6	Waist circumference;Hip circumference;
THYM	trans	rs877282	0.842	rs7092986	chr10:756373	G/A	cg22713356	chr15:30763199	NA	1.27	9.37	0.69	3.62e-15	Uric acid levels;
THYM	cis	rs1371867	0.846	rs1660345	chr8:101322762	C/A	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs6138458	0.962	rs6036976	chr20:24901567	T/G	cg06937882	chr20:24974362	C20orf3	0.47	4.48	0.42	2.08e-5	Blood protein levels;
THYM	cis	rs875971	1.000	rs1183245	chr7:65541185	C/T	cg11764359	chr7:65958608	NA	-0.84	-6.74	-0.57	1.24e-9	Aortic root size;
THYM	cis	rs854765	0.663	rs3744113	chr17:17748645	T/C	cg04398451	chr17:18023971	MYO15A	0.81	7.33	0.6	7.62e-11	Total body bone mineral density;
THYM	cis	rs9905704	0.918	rs302862	chr17:56697444	G/T	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.7e-6	Testicular germ cell tumor;
THYM	cis	rs4788570	0.615	rs7195059	chr16:71718366	C/T	cg06353428	chr16:71660113	MARVELD3	1.29	8.69	0.67	1.06e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7192750	0.586	rs9937936	chr16:71934419	A/T	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg13010199	chr12:38710504	ALG10B	0.64	5.43	0.49	4.24e-7	Heart rate;
THYM	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg10360139	chr7:1886902	MAD1L1	-0.66	-5.62	-0.5	1.88e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7638995	1.000	rs7638995	chr3:69173375	A/C	cg26574240	chr3:69171822	LMOD3	0.59	4.85	0.45	4.77e-6	Alzheimer's disease (late onset);
THYM	cis	rs1467026	0.523	rs9865548	chr3:12801785	C/T	cg05775895	chr3:12838266	CAND2	0.79	6.39	0.55	6.14e-9	P wave duration;
THYM	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg09667013	chr22:42394590	WBP2NL	0.72	5.04	0.46	2.18e-6	Birth weight;
THYM	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg24450063	chr1:156163899	SLC25A44	1.16	14.22	0.82	2.98e-25	Testicular germ cell tumor;
THYM	cis	rs490234	0.812	rs10121109	chr9:128455206	C/A	cg14078157	chr9:128172775	NA	-0.67	-5.01	-0.46	2.46e-6	Mean arterial pressure;
THYM	cis	rs11227306	0.902	rs625652	chr11:65641931	T/A	cg00576331	chr11:65640516	EFEMP2	0.71	5.48	0.49	3.49e-7	DNA methylation (variation);
THYM	cis	rs1050631	0.564	rs948416	chr18:33715673	A/G	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.58	4.56	0.42	1.54e-5	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs7772486	0.875	rs2814863	chr6:146347299	C/T	cg13319975	chr6:146136371	FBXO30	0.69	5.71	0.51	1.27e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1943345	0.686	rs10898088	chr11:82874970	G/A	cg07047830	chr11:82868014	PCF11	0.7	5.77	0.51	9.69e-8	Obesity-related traits;
THYM	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg18105134	chr13:113819100	PROZ	1.15	10.31	0.73	3.57e-17	Platelet distribution width;
THYM	cis	rs7429990	0.901	rs6442091	chr3:48043058	T/C	cg02219026	chr3:48282209	ZNF589	0.64	4.71	0.44	8.47e-6	Educational attainment (years of education);
THYM	cis	rs11645898	0.748	rs11641424	chr16:72066879	C/T	cg03805757	chr16:71968109	PKD1L3	-0.72	-5.25	-0.47	9.38e-7	Blood protein levels;
THYM	cis	rs9443189	0.570	rs276684	chr6:76427065	A/G	cg01950844	chr6:76311363	SENP6	-1.03	-6.61	-0.56	2.18e-9	Prostate cancer;
THYM	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg16624210	chr5:671434	TPPP	0.82	6.13	0.53	1.99e-8	Obesity-related traits;
THYM	cis	rs6435161	0.959	rs1971740	chr2:203484736	G/A	cg18429434	chr2:203499731	FAM117B	-0.68	-4.47	-0.42	2.14e-5	Total cholesterol levels;
THYM	cis	rs4363385	0.818	rs3181787	chr1:153004809	T/C	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs9905704	0.846	rs7212271	chr17:56863918	C/T	cg12560992	chr17:57184187	TRIM37	0.64	4.5	0.42	1.93e-5	Testicular germ cell tumor;
THYM	cis	rs985746	0.614	rs10024111	chr4:36809212	T/C	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs3126085	0.673	rs3126089	chr1:152306187	T/A	cg10321714	chr1:152280068	FLG	-0.72	-5.44	-0.49	4.14e-7	Atopic dermatitis;
THYM	trans	rs877282	0.947	rs957642	chr10:773966	C/T	cg22713356	chr15:30763199	NA	1.26	10.12	0.72	9.24e-17	Uric acid levels;
THYM	cis	rs62435770	1.000	rs9455869	chr6:169541720	T/A	cg07652237	chr6:170125491	PHF10	0.53	4.74	0.44	7.5e-6	Loneliness;
THYM	cis	rs6882076	1.000	rs13167071	chr5:156373637	G/C	cg12943317	chr5:156479607	HAVCR1	-0.78	-6.55	-0.56	2.9e-9	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs6570726	0.935	rs447818	chr6:145868996	C/T	cg13319975	chr6:146136371	FBXO30	-0.67	-5.89	-0.52	5.9e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17006441	0.932	rs7634543	chr3:69869339	G/A	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg06238570	chr21:40685208	BRWD1	-0.73	-6.27	-0.54	1.05e-8	Menarche (age at onset);
THYM	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg24596788	chr1:163392923	NA	-0.77	-7.43	-0.61	4.68e-11	Motion sickness;
THYM	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg09033563	chr22:24373618	LOC391322	-0.6	-5.78	-0.51	9.63e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3750965	0.806	rs7107680	chr11:68859894	C/T	cg06818126	chr11:68850279	TPCN2	-0.66	-4.47	-0.42	2.14e-5	Hair color;
THYM	cis	rs7119	0.667	rs907390	chr15:77902419	T/C	cg10437265	chr15:77819839	NA	-0.54	-5.29	-0.48	7.88e-7	Type 2 diabetes;
THYM	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.79	-6.54	-0.56	3.08e-9	Intelligence (multi-trait analysis);
THYM	trans	rs561341	1.000	rs535151	chr17:30317405	C/T	cg20587970	chr11:113659929	NA	-1.0	-6.93	-0.58	4.94e-10	Hip circumference adjusted for BMI;
THYM	cis	rs55728055	1.000	rs16989427	chr22:32108475	C/T	cg01338084	chr22:32026380	PISD	1.55	6.04	0.53	3.03e-8	Age-related hearing impairment;
THYM	cis	rs7719624	1.000	rs2107331	chr5:135377349	A/C	cg15329133	chr5:135467951	SMAD5;SMAD5OS	-0.56	-4.78	-0.44	6.49e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg27168131	chr21:44088823	PDE9A	-0.48	-4.54	-0.42	1.64e-5	Mean corpuscular volume;
THYM	cis	rs892961	0.966	rs4386185	chr17:75400891	G/A	cg11351908	chr17:75402473	SEPT9	0.58	5.53	0.49	2.84e-7	Airflow obstruction;
THYM	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.5	-4.66	-0.43	1.04e-5	Lymphocyte counts;
THYM	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg00677455	chr12:58241039	CTDSP2	0.84	6.74	0.57	1.22e-9	Multiple sclerosis;
THYM	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	trans	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	3.97e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg26116260	chr4:7069785	GRPEL1	1.12	11.02	0.75	1.14e-18	Monocyte percentage of white cells;
THYM	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg16524733	chr11:117070046	TAGLN	-0.43	-4.75	-0.44	7.12e-6	Blood protein levels;
THYM	cis	rs3540	0.533	rs4932342	chr15:90982923	C/T	cg00487526	chr15:90818384	NA	-0.61	-4.59	-0.43	1.38e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs10095849	0.529	rs7830101	chr8:39408428	G/T	cg01911981	chr8:39380341	ADAM3A	0.56	4.77	0.44	6.54e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg05340658	chr4:99064831	C4orf37	0.55	4.65	0.43	1.09e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg26149184	chr10:133730230	NA	0.79	4.77	0.44	6.64e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg26031613	chr14:104095156	KLC1	0.79	5.22	0.47	1.06e-6	Body mass index;
THYM	cis	rs863345	0.604	rs1894040	chr1:158456336	C/T	cg12129480	chr1:158549410	OR10X1	0.49	4.68	0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs2404602	0.684	rs10851888	chr15:76902506	C/T	cg23625390	chr15:77176239	SCAPER	-0.93	-6.31	-0.54	8.9e-9	Blood metabolite levels;
THYM	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.43	4.64	0.43	1.12e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg12419862	chr22:24373484	LOC391322	-0.92	-11.07	-0.75	8.66e-19	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg03605463	chr16:89740564	NA	0.87	6.63	0.56	2.05e-9	Vitiligo;
THYM	cis	rs289828	0.538	rs4665169	chr2:152152449	A/G	cg05960677	chr2:152117363	RBM43	0.72	6.75	0.57	1.17e-9	Blood protein levels;
THYM	cis	rs13082711	0.911	rs13078798	chr3:27445971	A/G	cg02860705	chr3:27208620	NA	-0.69	-4.99	-0.46	2.75e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg07936489	chr17:37558343	FBXL20	0.83	5.84	0.51	7.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs4919669	0.546	rs4919656	chr10:104282861	G/A	cg00122347	chr10:104236741	TMEM180	-0.59	-4.8	-0.44	5.93e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
THYM	cis	rs12216545	0.765	rs4725347	chr7:150252573	T/C	cg08960815	chr7:150264767	GIMAP4	-0.87	-7.96	-0.63	3.61e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg19847130	chr8:10466454	RP1L1	0.56	5.35	0.48	6.05e-7	Neuroticism;
THYM	cis	rs4866334	1.000	rs78178098	chr5:18487497	T/C	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs4148087	1.000	rs9984673	chr21:43615709	T/C	cg09727148	chr21:43560719	UMODL1	0.6	4.7	0.43	8.81e-6	Eating disorder in bipolar disorder;
THYM	trans	rs2307394	0.714	rs4972270	chr2:148543331	A/T	cg25833989	chr15:74426957	ISLR2	-0.76	-7.15	-0.59	1.8e-10	Urate levels;
THYM	cis	rs10227331	0.846	rs10807647	chr7:157298007	A/G	cg04156418	chr7:157293606	NA	-0.73	-6.57	-0.56	2.68e-9	Inattentive symptoms;
THYM	cis	rs2046867	0.774	rs62249873	chr3:72907115	G/A	cg25664220	chr3:72788482	NA	-0.95	-7.8	-0.62	7.83e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg03609598	chr5:56110824	MAP3K1	-0.85	-5.85	-0.51	6.86e-8	Initial pursuit acceleration;
THYM	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg02136620	chr5:178986620	RUFY1	-0.58	-5.79	-0.51	9.05e-8	Lung cancer;
THYM	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg26384229	chr12:38710491	ALG10B	0.97	7.38	0.6	5.91e-11	Morning vs. evening chronotype;
THYM	cis	rs13315871	0.929	rs35557787	chr3:58234536	T/C	cg12435725	chr3:58293450	RPP14	-0.52	-5.64	-0.5	1.77e-7	Cholesterol, total;
THYM	cis	rs983545	0.800	rs4685400	chr3:16947451	C/T	cg19448816	chr3:16974217	PLCL2	0.54	4.71	0.44	8.3e-6	Blood protein levels;
THYM	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg21926883	chr2:100939477	LONRF2	-0.67	-6.3	-0.54	9.28e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7554511	0.858	rs11584383	chr1:200935866	C/T	cg16409409	chr1:200861597	C1orf106	0.45	4.54	0.42	1.65e-5	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7084402	0.967	rs1658483	chr10:60288933	C/T	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs2637266	0.905	rs3923669	chr10:78375047	T/C	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg11189052	chr15:85197271	WDR73	-0.65	-5.09	-0.46	1.8e-6	P wave terminal force;
THYM	cis	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg21775007	chr8:11205619	TDH	-0.73	-5.68	-0.5	1.49e-7	Retinal vascular caliber;
THYM	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg26384229	chr12:38710491	ALG10B	-0.72	-5.6	-0.5	2.09e-7	Morning vs. evening chronotype;
THYM	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-14.05	-0.82	6.23e-25	Height;
THYM	cis	rs2273669	0.667	rs10457185	chr6:109322477	G/C	cg17117243	chr6:109341365	SESN1	-0.9	-5.38	-0.48	5.45e-7	Prostate cancer;
THYM	cis	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs7119	0.931	rs11630540	chr15:77833625	G/A	cg10437265	chr15:77819839	NA	0.77	7.39	0.6	5.75e-11	Type 2 diabetes;
THYM	cis	rs55871839	0.708	rs10098750	chr8:59813205	T/G	cg07426533	chr8:59803705	TOX	-0.67	-6.88	-0.58	6.33e-10	Pneumonia;
THYM	cis	rs55728055	0.661	rs7285091	chr22:31996363	A/G	cg01338084	chr22:32026380	PISD	1.36	5.56	0.5	2.44e-7	Age-related hearing impairment;
THYM	cis	rs10744422	0.925	rs2880678	chr12:123317099	C/T	cg25930673	chr12:123319894	HIP1R	-0.88	-5.15	-0.47	1.43e-6	Schizophrenia;
THYM	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg20295408	chr7:1910781	MAD1L1	-0.72	-5.86	-0.52	6.74e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs7267979	0.932	rs2387891	chr20:25470328	C/G	cg03522245	chr20:25566470	NINL	0.57	4.48	0.42	2.1e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg09904177	chr6:26538194	HMGN4	0.54	4.57	0.42	1.47e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg02887458	chr19:19495540	GATAD2A	-0.44	-5.19	-0.47	1.17e-6	Bipolar disorder;
THYM	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg10802521	chr3:52805072	NEK4	-0.69	-5.91	-0.52	5.33e-8	Bipolar disorder;
THYM	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg13683864	chr3:40499215	RPL14	-1.05	-11.46	-0.76	1.29e-19	Renal cell carcinoma;
THYM	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.4	-0.55	5.94e-9	Personality dimensions;
THYM	cis	rs12586317	0.620	rs76293361	chr14:35570889	G/A	cg16230307	chr14:35515116	FAM177A1	0.9	5.84	0.51	7.37e-8	Psoriasis;
THYM	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg11941060	chr3:133502564	NA	-0.73	-6.42	-0.55	5.36e-9	Iron status biomarkers;
THYM	cis	rs208520	0.874	rs208514	chr6:66945520	G/A	cg07460842	chr6:66804631	NA	-0.78	-5.05	-0.46	2.16e-6	Exhaled nitric oxide output;
THYM	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs76662990	0.610	rs6864196	chr5:73944444	A/G	cg13275603	chr5:73927487	ENC1	-0.77	-4.63	-0.43	1.17e-5	Residual cognition;
THYM	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg26384229	chr12:38710491	ALG10B	-0.74	-5.8	-0.51	8.85e-8	Bladder cancer;
THYM	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg06636001	chr8:8085503	FLJ10661	0.88	9.05	0.68	1.79e-14	Neuroticism;
THYM	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg12893428	chr3:195717962	SDHAP1	0.54	4.83	0.44	5.31e-6	Pancreatic cancer;
THYM	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg04731861	chr2:219085781	ARPC2	0.54	5.25	0.47	9.2e-7	Colorectal cancer;
THYM	cis	rs4731207	0.596	rs13234368	chr7:124676054	A/C	cg05285228	chr7:124571219	POT1	-0.63	-4.74	-0.44	7.37e-6	Cutaneous malignant melanoma;
THYM	cis	rs524281	0.773	rs2155198	chr11:66014300	C/T	cg00563793	chr11:65837595	PACS1	0.79	4.71	0.43	8.53e-6	Electroencephalogram traits;
THYM	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.69	6.3	0.54	9.03e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7614311	0.731	rs3733121	chr3:63850660	C/G	cg22134162	chr3:63841271	THOC7	-0.68	-8.51	-0.66	2.56e-13	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs7084402	0.935	rs12263522	chr10:60343527	C/A	cg07615347	chr10:60278583	BICC1	0.57	5.33	0.48	6.57e-7	Refractive error;
THYM	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg19904058	chr10:135279010	LOC619207	-0.57	-5.32	-0.48	7.02e-7	Systemic lupus erythematosus;
THYM	cis	rs9633740	0.773	rs1870148	chr10:82271341	G/A	cg01528321	chr10:82214614	TSPAN14	0.96	4.46	0.42	2.28e-5	Post bronchodilator FEV1;
THYM	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg07537917	chr2:241836409	C2orf54	-0.26	-6.35	-0.55	7.26e-9	Urinary metabolites;
THYM	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg15536230	chr21:44985092	HSF2BP	-0.41	-4.99	-0.46	2.78e-6	Mean corpuscular volume;
THYM	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg06636001	chr8:8085503	FLJ10661	-0.62	-5.2	-0.47	1.16e-6	Mood instability;
THYM	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg18230493	chr5:56204884	C5orf35	-0.9	-6.78	-0.57	9.95e-10	Initial pursuit acceleration;
THYM	cis	rs7119	0.651	rs8041520	chr15:77839169	C/T	cg10437265	chr15:77819839	NA	0.8	8.02	0.64	2.77e-12	Type 2 diabetes;
THYM	cis	rs7584330	0.697	rs1979762	chr2:238436502	T/C	cg16989719	chr2:238392110	NA	-0.48	-4.78	-0.44	6.3e-6	Prostate cancer;
THYM	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg19052272	chr2:3704530	ALLC	-0.68	-5.08	-0.46	1.92e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22496380	chr5:211416	CCDC127	-1.34	-7.78	-0.62	8.85e-12	Breast cancer;
THYM	cis	rs3892630	0.878	rs7246451	chr19:33209614	C/G	cg02283691	chr19:33182526	NUDT19	-0.4	-4.82	-0.44	5.36e-6	Red blood cell traits;
THYM	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.15e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7681440	0.606	rs2737001	chr4:90753477	G/A	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs2046867	0.818	rs17010184	chr3:72870242	A/T	cg25664220	chr3:72788482	NA	1.0	8.36	0.65	5.1e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg06728252	chr6:26598149	ABT1	-0.43	-5.11	-0.46	1.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.01	7.9	0.63	4.97e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9403317	0.960	rs9376628	chr6:141860331	G/T	cg15052665	chr6:141804349	NA	0.86	8.81	0.67	5.68e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg18811423	chr2:55921094	PNPT1	0.69	6.41	0.55	5.6e-9	Metabolic syndrome;
THYM	cis	rs13315871	0.929	rs35376204	chr3:58325563	T/C	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs7267979	0.903	rs1118963	chr20:25247449	G/A	cg08601574	chr20:25228251	PYGB	0.59	4.68	0.43	9.42e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg18252515	chr7:66147081	NA	-1.5	-9.32	-0.69	4.61e-15	Diabetic kidney disease;
THYM	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	15.57	0.85	6.94e-28	Chronic sinus infection;
THYM	cis	rs9644630	0.672	rs4486225	chr8:19313404	A/G	cg01280390	chr8:19363452	CSGALNACT1	0.65	6.96	0.58	4.31e-10	Oropharynx cancer;
THYM	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg06481639	chr22:41940642	POLR3H	0.84	5.85	0.51	6.94e-8	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1978968	0.717	rs1072405	chr22:18406068	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.55	-4.76	-0.44	6.79e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs2859741	0.967	rs575939	chr1:37513854	T/C	cg09363841	chr1:37513479	NA	-0.86	-9.2	-0.69	8.67e-15	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs7426056	0.530	rs17533594	chr2:204581195	A/G	cg07930752	chr2:204569955	CD28	-0.73	-5.28	-0.48	8.21e-7	Primary sclerosing cholangitis;
THYM	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.69	0.74	5.59e-18	Chronic sinus infection;
THYM	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg08000102	chr2:233561755	GIGYF2	-0.68	-6.11	-0.53	2.16e-8	Coronary artery disease;
THYM	cis	rs2832077	0.506	rs2832093	chr21:30164855	C/T	cg24692254	chr21:30365293	RNF160	-0.88	-6.37	-0.55	6.78e-9	Cognitive test performance;
THYM	cis	rs1163251	0.837	rs595283	chr1:120247887	C/G	cg19096424	chr1:120255104	PHGDH	-0.71	-5.24	-0.47	9.57e-7	Blood metabolite levels;
THYM	cis	rs654950	0.875	rs633297	chr1:41985453	A/C	cg06885757	chr1:42089581	HIVEP3	0.44	5.27	0.48	8.5e-7	Airway imaging phenotypes;
THYM	cis	rs4460079	0.531	rs4502752	chr4:114839700	C/G	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs941408	0.964	rs1736186	chr19:2815372	A/G	cg17333051	chr19:2783644	SGTA	0.54	4.8	0.44	5.99e-6	Total cholesterol levels;
THYM	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg06108461	chr20:60628389	TAF4	-0.78	-6.11	-0.53	2.18e-8	Body mass index;
THYM	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg18240062	chr17:79603768	NPLOC4	-0.73	-6.55	-0.56	2.9e-9	Eye color traits;
THYM	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs6570726	0.526	rs7755237	chr6:145731852	T/C	cg23711669	chr6:146136114	FBXO30	-0.63	-4.99	-0.46	2.73e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg04362960	chr10:104952993	NT5C2	0.58	4.82	0.44	5.34e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2997447	0.761	rs55960411	chr1:26437741	G/C	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs3768617	0.510	rs10797843	chr1:183081995	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs7772486	0.790	rs2250387	chr6:146205233	C/T	cg13319975	chr6:146136371	FBXO30	-0.73	-6.09	-0.53	2.41e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg06028605	chr16:24865363	SLC5A11	0.56	5.49	0.49	3.34e-7	Intelligence (multi-trait analysis);
THYM	cis	rs490234	0.841	rs497531	chr9:128314664	C/T	cg14078157	chr9:128172775	NA	0.67	5.28	0.48	8.02e-7	Mean arterial pressure;
THYM	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	4.46	0.42	2.21e-5	Diabetic retinopathy;
THYM	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg23583168	chr7:148888333	NA	-1.06	-13.95	-0.82	1.01e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg11764359	chr7:65958608	NA	0.8	6.54	0.56	3.08e-9	Aortic root size;
THYM	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg20302533	chr7:39170763	POU6F2	0.65	4.51	0.42	1.82e-5	IgG glycosylation;
THYM	cis	rs8112211	0.834	rs4312417	chr19:38797189	A/G	cg25820703	chr19:38877220	GGN	-0.49	-4.72	-0.44	8.26e-6	Blood protein levels;
THYM	cis	rs425277	1.000	rs262651	chr1:2091397	A/G	cg24578937	chr1:2090814	PRKCZ	0.81	8.54	0.66	2.22e-13	Height;
THYM	cis	rs420259	0.516	rs6497664	chr16:23485353	G/C	cg00143387	chr16:23521605	GGA2	-0.7	-4.9	-0.45	3.95e-6	Bipolar disorder;
THYM	cis	rs7851660	0.901	rs2401639	chr9:100607837	T/C	cg13688889	chr9:100608707	NA	-0.84	-7.29	-0.6	8.94e-11	Strep throat;
THYM	cis	rs2299587	0.610	rs6987474	chr8:17773298	T/C	cg01800426	chr8:17659068	MTUS1	-0.68	-5.18	-0.47	1.26e-6	Economic and political preferences;
THYM	cis	rs11563648	0.553	rs4731352	chr7:127006220	C/A	cg23081781	chr7:127225937	GCC1	-0.34	-4.57	-0.42	1.45e-5	Resting heart rate;
THYM	cis	rs55665837	0.583	rs78843135	chr11:14411254	T/G	cg19336497	chr11:14380999	RRAS2	-0.83	-11.13	-0.75	6.64e-19	Vitamin D levels;
THYM	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.66	-4.76	-0.44	6.89e-6	Colorectal cancer;
THYM	cis	rs4654899	0.664	rs10799665	chr1:21152640	C/T	cg01072550	chr1:21505969	NA	-0.59	-4.8	-0.44	5.84e-6	Superior frontal gyrus grey matter volume;
THYM	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg27286337	chr10:134555280	INPP5A	0.93	6.98	0.58	3.98e-10	Migraine;
THYM	cis	rs754466	0.580	rs10824577	chr10:79577408	G/C	cg17075019	chr10:79541650	NA	-0.69	-5.72	-0.51	1.26e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2085601	0.542	rs1795728	chr4:89962341	C/T	cg17769793	chr4:89976368	FAM13A	-0.59	-6.62	-0.56	2.17e-9	Hair greying;
THYM	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.22e-7	Corneal astigmatism;
THYM	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg11663144	chr21:46675770	NA	-0.68	-9.08	-0.68	1.51e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4746818	1.000	rs10998614	chr10:70923347	G/T	cg04149295	chr10:70884716	VPS26A	0.78	5.31	0.48	7.18e-7	Left atrial antero-posterior diameter;
THYM	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg00271210	chr6:167070053	RPS6KA2	0.72	7.96	0.63	3.73e-12	Crohn's disease;
THYM	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg26031613	chr14:104095156	KLC1	0.77	4.79	0.44	6.18e-6	Body mass index;
THYM	cis	rs6500395	1.000	rs8052640	chr16:48604096	G/T	cg04672837	chr16:48644449	N4BP1	0.49	5.05	0.46	2.14e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs637571	0.544	rs500161	chr11:65695438	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.62	6.34	0.55	7.83e-9	Eosinophil percentage of white cells;
THYM	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg17757837	chr7:157058334	UBE3C	0.65	5.22	0.47	1.05e-6	Body mass index;
THYM	cis	rs7582180	0.614	rs1030901	chr2:101007314	G/A	cg21926883	chr2:100939477	LONRF2	-0.66	-6.02	-0.53	3.23e-8	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg08859206	chr1:53392774	SCP2	-0.51	-5.37	-0.48	5.47e-7	Monocyte count;
THYM	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg08847533	chr14:75593920	NEK9	-0.96	-10.3	-0.73	3.86e-17	Height;
THYM	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03517284	chr6:25882590	NA	-0.76	-5.98	-0.52	3.87e-8	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg27490568	chr2:178487706	NA	0.72	6.15	0.53	1.78e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7631605	0.905	rs9755599	chr3:37208192	T/C	cg21328643	chr3:37258149	NA	-0.51	-4.96	-0.45	3.08e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs13256369	0.802	rs11249888	chr8:8564934	T/C	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	trans	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.21	-14.37	-0.83	1.5e-25	Exhaled nitric oxide output;
THYM	cis	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg07460842	chr6:66804631	NA	1.15	13.75	0.82	2.58e-24	Exhaled nitric oxide output;
THYM	cis	rs4780401	0.609	rs8063099	chr16:11806714	T/G	cg01061890	chr16:11836724	TXNDC11	-0.66	-5.44	-0.49	4.13e-7	Rheumatoid arthritis;
THYM	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg02398342	chr17:80708632	TBCD;FN3K	-0.69	-5.22	-0.47	1.05e-6	Glycated hemoglobin levels;
THYM	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg27170947	chr2:26402098	FAM59B	-0.61	-5.04	-0.46	2.25e-6	Gut microbiome composition (summer);
THYM	cis	rs9733	0.566	rs878471	chr1:150547747	G/A	cg13175981	chr1:150552382	MCL1	0.72	5.06	0.46	2.01e-6	Tonsillectomy;
THYM	cis	rs28493229	0.708	rs73546845	chr19:41158717	C/T	cg21869046	chr19:41225005	ITPKC	0.49	4.46	0.42	2.28e-5	Kawasaki disease;
THYM	cis	rs8067545	0.750	rs4924804	chr17:19991839	C/T	cg13482628	chr17:19912719	NA	0.57	4.61	0.43	1.24e-5	Schizophrenia;
THYM	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg04520793	chr17:42248056	ASB16	-0.33	-4.56	-0.42	1.54e-5	Total body bone mineral density;
THYM	cis	rs7009516	0.846	rs13257546	chr8:24218697	C/T	cg01759110	chr8:24241694	ADAMDEC1	0.51	4.59	0.43	1.36e-5	Hair greying;
THYM	cis	rs7107174	1.000	rs10793308	chr11:78086005	C/T	cg19901956	chr11:77921274	USP35	-0.65	-5.34	-0.48	6.41e-7	Testicular germ cell tumor;
THYM	cis	rs2073300	0.609	rs74273791	chr20:23418067	A/T	cg12062639	chr20:23401060	NAPB	1.1	5.73	0.51	1.16e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs11039798	0.588	rs12294395	chr11:48476860	C/T	cg24672777	chr11:48374446	OR4C45	-0.97	-6.24	-0.54	1.22e-8	Axial length;
THYM	cis	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg05084668	chr3:125655381	ALG1L	-0.76	-4.77	-0.44	6.59e-6	Blood pressure (smoking interaction);
THYM	cis	rs16976116	0.951	rs8043029	chr15:55486011	C/G	cg11288833	chr15:55489084	RSL24D1	0.71	4.45	0.42	2.34e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg10792982	chr14:105748885	BRF1	0.75	7.88	0.63	5.47e-12	Mean platelet volume;Platelet distribution width;
THYM	trans	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg07393940	chr7:158741817	NA	1.1	8.37	0.65	4.87e-13	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6032067	1.000	rs13038434	chr20:43888106	G/A	cg17412248	chr20:44803411	CDH22	0.57	4.46	0.42	2.26e-5	Blood protein levels;
THYM	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.53	-4.99	-0.46	2.67e-6	Lymphocyte counts;
THYM	cis	rs7829975	0.748	rs693109	chr8:8640172	C/A	cg06636001	chr8:8085503	FLJ10661	-0.68	-6.56	-0.56	2.84e-9	Mood instability;
THYM	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs977987	0.771	rs8048527	chr16:75422054	C/A	cg03315344	chr16:75512273	CHST6	0.7	6.0	0.52	3.52e-8	Dupuytren's disease;
THYM	cis	rs13102973	0.710	rs4428340	chr4:135886451	C/T	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg03709012	chr19:19516395	GATAD2A	-0.71	-5.13	-0.47	1.51e-6	Tonsillectomy;
THYM	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg12386194	chr3:101231763	SENP7	-0.66	-5.0	-0.46	2.59e-6	Colorectal cancer;
THYM	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	4.54	0.42	1.67e-5	Alzheimer's disease;
THYM	cis	rs4589258	1.000	rs7937113	chr11:90466385	C/G	cg26138821	chr11:89956704	CHORDC1	-0.67	-5.33	-0.48	6.73e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6480314	0.831	rs6480317	chr10:69976594	C/A	cg27159792	chr10:69524182	NA	-0.71	-4.47	-0.42	2.17e-5	Optic nerve measurement (disc area);
THYM	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg06212747	chr3:49208901	KLHDC8B	0.63	4.54	0.42	1.67e-5	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs4242434	0.672	rs4615566	chr8:22520682	T/C	cg01710189	chr8:22454888	PDLIM2	0.47	4.87	0.45	4.44e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs12200560	0.505	rs984520	chr6:97076454	A/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-6.01	-0.52	3.39e-8	Coronary heart disease;
THYM	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg00757033	chr12:89920650	WDR51B	0.65	8.94	0.68	3.07e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2625529	0.878	rs4777478	chr15:72279085	T/C	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg26038318	chr20:34205095	SPAG4	0.59	4.65	0.43	1.08e-5	Total cholesterol levels;
THYM	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg05872129	chr22:39784769	NA	-0.92	-7.7	-0.62	1.31e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg00999904	chr2:3704751	ALLC	-0.71	-4.85	-0.45	4.75e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg07648498	chr16:89883185	FANCA	0.62	4.67	0.43	9.7e-6	Vitiligo;
THYM	cis	rs7968440	1.000	rs2684900	chr12:51019556	A/T	cg20014596	chr12:50898483	DIP2B	0.56	4.55	0.42	1.57e-5	Fibrinogen;
THYM	cis	rs600550	0.588	rs2304936	chr11:60102156	T/C	cg05040360	chr11:60102449	MS4A6E	-0.5	-4.7	-0.43	8.83e-6	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg10802521	chr3:52805072	NEK4	-0.73	-6.4	-0.55	5.97e-9	Bipolar disorder;
THYM	cis	rs1448094	0.511	rs1993807	chr12:86146833	A/G	cg00310523	chr12:86230176	RASSF9	-0.57	-5.07	-0.46	1.98e-6	Major depressive disorder;
THYM	cis	rs7107174	1.000	rs10899483	chr11:78061057	G/C	cg19901956	chr11:77921274	USP35	-0.65	-5.4	-0.48	5.01e-7	Testicular germ cell tumor;
THYM	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg00898013	chr13:113819073	PROZ	-0.87	-8.78	-0.67	6.82e-14	Platelet distribution width;
THYM	cis	rs28795989	0.896	rs9330348	chr4:7883887	C/G	cg12728606	chr4:7903970	AFAP1	0.44	4.64	0.43	1.09e-5	Intraocular pressure;
THYM	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg25427524	chr10:38739819	LOC399744	-0.65	-5.96	-0.52	4.23e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs939658	0.805	rs35318825	chr15:79447098	C/A	cg17916960	chr15:79447300	NA	-0.74	-8.74	-0.67	7.93e-14	Refractive error;
THYM	cis	rs36051895	0.658	rs10974914	chr9:5014332	C/T	cg02405213	chr9:5042618	JAK2	-1.06	-11.62	-0.77	5.95e-20	Pediatric autoimmune diseases;
THYM	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg27286337	chr10:134555280	INPP5A	0.82	5.74	0.51	1.12e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs66887589	0.776	rs10518337	chr4:120574874	A/C	cg13609457	chr4:120235615	NA	-0.52	-5.22	-0.47	1.05e-6	Diastolic blood pressure;
THYM	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg11984989	chr7:158649758	WDR60	1.15	13.77	0.82	2.29e-24	Height;
THYM	cis	rs6519955	0.866	rs9626920	chr22:46428993	A/G	cg05468064	chr22:46423449	NA	-0.49	-7.12	-0.59	2e-10	Dupuytren's disease;
THYM	cis	rs7178572	0.633	rs12901130	chr15:77848806	C/T	cg22256960	chr15:77711686	NA	-0.74	-5.64	-0.5	1.72e-7	Type 2 diabetes;
THYM	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-5.39	-0.48	5.22e-7	Hemoglobin concentration;
THYM	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg26384229	chr12:38710491	ALG10B	0.99	7.63	0.62	1.81e-11	Bladder cancer;
THYM	cis	rs6700896	0.898	rs1938495	chr1:66106469	A/G	cg04111102	chr1:66153794	NA	0.55	5.23	0.47	9.89e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg03433033	chr1:76189801	ACADM	0.66	6.52	0.56	3.44e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.96	0.45	3.04e-6	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	4.96	0.45	3.07e-6	Hip circumference adjusted for BMI;
THYM	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg24209194	chr3:40518798	ZNF619	0.62	4.86	0.45	4.54e-6	Renal cell carcinoma;
THYM	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg04842962	chr6:43655489	MRPS18A	1.2	7.53	0.61	2.86e-11	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504073	0.506	rs7007271	chr8:49941897	T/C	cg00325661	chr8:49890786	NA	1.1	11.62	0.77	6.03e-20	Blood metabolite ratios;
THYM	cis	rs4690686	0.500	rs11725547	chr4:177268444	T/C	cg17059388	chr4:177262070	NA	0.48	6.73	0.57	1.29e-9	Essential tremor;
THYM	cis	rs12310956	0.510	rs11612987	chr12:33879130	T/C	cg06521331	chr12:34319734	NA	-0.57	-4.58	-0.43	1.42e-5	Morning vs. evening chronotype;
THYM	cis	rs6546324	0.625	rs6546317	chr2:67828793	C/G	cg18237512	chr2:67827392	NA	-0.78	-4.63	-0.43	1.16e-5	Endometriosis;
THYM	cis	rs7809950	0.678	rs2395869	chr7:106940098	C/A	cg23024343	chr7:107201750	COG5	-1.0	-8.0	-0.63	2.96e-12	Coronary artery disease;
THYM	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg26967526	chr14:35346199	BAZ1A	-0.74	-4.83	-0.44	5.2e-6	Psoriasis;
THYM	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs208520	0.661	rs704519	chr6:66801136	T/C	cg07460842	chr6:66804631	NA	-1.05	-7.62	-0.62	1.84e-11	Exhaled nitric oxide output;
THYM	cis	rs11039798	1.000	rs10838942	chr11:48557163	C/G	cg24672777	chr11:48374446	OR4C45	-1.14	-6.95	-0.58	4.55e-10	Axial length;
THYM	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg06238570	chr21:40685208	BRWD1	0.9	6.51	0.56	3.6e-9	Cognitive function;
THYM	cis	rs868036	0.681	rs13329567	chr15:68104367	C/T	cg24579218	chr15:68104479	NA	-0.82	-8.85	-0.67	4.77e-14	Restless legs syndrome;
THYM	cis	rs6570726	0.764	rs4896821	chr6:145896181	G/A	cg23711669	chr6:146136114	FBXO30	0.87	8.07	0.64	2.16e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg13114125	chr14:105738426	BRF1	-0.71	-5.42	-0.49	4.58e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4343996	0.720	rs10250421	chr7:3458288	A/T	cg21248987	chr7:3385318	SDK1	0.4	4.89	0.45	4.14e-6	Motion sickness;
THYM	cis	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg19847130	chr8:10466454	RP1L1	0.5	4.8	0.44	5.96e-6	Neuroticism;
THYM	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg03709012	chr19:19516395	GATAD2A	0.73	5.59	0.5	2.16e-7	Tonsillectomy;
THYM	cis	rs870825	0.929	rs1405941	chr4:185591518	A/C	cg04058563	chr4:185651563	MLF1IP	-0.98	-6.73	-0.57	1.3e-9	Blood protein levels;
THYM	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg15744005	chr10:104629667	AS3MT	-0.83	-7.65	-0.62	1.61e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7107174	0.681	rs11237443	chr11:78005089	C/A	cg19901956	chr11:77921274	USP35	-0.69	-5.29	-0.48	7.94e-7	Testicular germ cell tumor;
THYM	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg03929089	chr4:120376271	NA	-0.93	-9.33	-0.69	4.54e-15	Coronary artery disease;
THYM	cis	rs7582180	0.903	rs2309818	chr2:100898634	G/T	cg14675211	chr2:100938903	LONRF2	0.65	5.52	0.49	2.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs873946	0.586	rs11146503	chr10:134565388	T/C	cg06453172	chr10:134556979	INPP5A	-0.73	-5.22	-0.47	1.05e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs80319144	1.000	rs113658628	chr2:159215951	G/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.58	4.66	0.43	1.05e-5	Restless legs syndrome;
THYM	cis	rs459571	0.959	rs378740	chr9:136890876	C/A	cg13789015	chr9:136890014	NCRNA00094	0.83	7.13	0.59	1.94e-10	Platelet distribution width;
THYM	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg17173187	chr15:85201210	NMB	0.58	5.69	0.5	1.43e-7	Schizophrenia;
THYM	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.99	9.55	0.7	1.48e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg07936489	chr17:37558343	FBXL20	0.82	5.61	0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs17006441	0.932	rs7636802	chr3:69845216	G/T	cg18496212	chr3:69797108	MITF	0.7	7.17	0.59	1.64e-10	Hemoglobin concentration;
THYM	cis	rs7777677	0.925	rs4726542	chr7:142367013	G/T	cg21785750	chr7:142428317	NA	0.65	5.65	0.5	1.67e-7	Alcoholic chronic pancreatitis;
THYM	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg02527881	chr3:46936655	PTH1R	0.6	5.51	0.49	3.06e-7	Colorectal cancer;
THYM	cis	rs6087990	0.806	rs4911258	chr20:31369479	G/A	cg13636640	chr20:31349939	DNMT3B	0.94	10.02	0.72	1.51e-16	Ulcerative colitis;
THYM	trans	rs8073060	0.518	rs225285	chr17:33931084	G/C	cg19694781	chr19:47549865	TMEM160	-0.78	-6.95	-0.58	4.61e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs55871839	0.559	rs1448549	chr8:59836138	C/T	cg07426533	chr8:59803705	TOX	0.62	5.11	0.46	1.63e-6	Pneumonia;
THYM	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg01097406	chr16:89675127	NA	-0.6	-5.01	-0.46	2.55e-6	Vitiligo;
THYM	cis	rs9430161	0.579	rs11576658	chr1:11037736	C/T	cg02454025	chr1:11042201	C1orf127	0.95	11.03	0.75	1.06e-18	Ewing sarcoma;
THYM	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9393692	0.620	rs4412193	chr6:26338056	A/G	cg00631329	chr6:26305371	NA	-0.45	-4.53	-0.42	1.72e-5	Educational attainment;
THYM	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs9297145	0.565	rs6952161	chr7:98733337	A/G	cg05967295	chr7:98741636	SMURF1	0.71	5.67	0.5	1.55e-7	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs34526934	0.566	rs34028621	chr2:177042779	C/T	cg26754761	chr2:177040938	NA	-0.74	-6.5	-0.55	3.7e-9	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs7546094	0.905	rs12046208	chr1:113171589	C/T	cg22162597	chr1:113214053	CAPZA1	-0.48	-4.52	-0.42	1.76e-5	Platelet distribution width;
THYM	cis	rs35160687	0.901	rs7571424	chr2:86539160	A/G	cg10973622	chr2:86423274	IMMT	0.48	4.54	0.42	1.65e-5	Night sleep phenotypes;
THYM	cis	rs7000551	0.621	rs4872497	chr8:22289582	G/C	cg12081754	chr8:22256438	SLC39A14	0.98	8.32	0.65	6.41e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg08213375	chr14:104286397	PPP1R13B	0.47	5.53	0.49	2.76e-7	Schizophrenia;
THYM	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg18357526	chr6:26021779	HIST1H4A	0.66	4.73	0.44	7.76e-6	Intelligence (multi-trait analysis);
THYM	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg15704280	chr7:45808275	SEPT13	1.03	11.84	0.77	2.09e-20	Coronary artery disease;
THYM	cis	rs13082711	0.554	rs73055750	chr3:27401505	C/G	cg02860705	chr3:27208620	NA	0.85	5.96	0.52	4.35e-8	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs28595532	1.000	rs17258106	chr4:119675406	C/T	cg21605333	chr4:119757512	SEC24D	-1.49	-4.87	-0.45	4.42e-6	Cannabis dependence symptom count;
THYM	cis	rs28374715	0.532	rs316604	chr15:41775221	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.19	-14.06	-0.82	6.11e-25	Ulcerative colitis;
THYM	cis	rs13126513	0.529	rs1388293	chr4:100601319	C/T	cg05468953	chr4:100565104	NA	0.66	6.1	0.53	2.25e-8	Metabolite levels (MHPG);
THYM	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.58	0.5	2.29e-7	Rheumatoid arthritis;
THYM	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg23758822	chr17:41437982	NA	1.16	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs8192282	0.739	rs10752642	chr1:154481624	C/T	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs1298062	0.689	rs12985344	chr19:50954750	T/C	cg11430371	chr19:50961752	MYBPC2	0.48	4.57	0.42	1.49e-5	Age of smoking initiation;
THYM	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg10589385	chr1:150898437	SETDB1	0.67	5.55	0.49	2.58e-7	Melanoma;
THYM	cis	rs9326248	0.530	rs7122944	chr11:117034619	G/T	cg01368799	chr11:117014884	PAFAH1B2	0.95	5.34	0.48	6.34e-7	Blood protein levels;
THYM	cis	rs4907240	0.925	rs4907242	chr2:97273113	C/A	cg18419276	chr2:96971862	SNRNP200	-0.4	-4.76	-0.44	6.95e-6	Event-related brain oscillations;
THYM	cis	rs4889855	0.585	rs72855201	chr17:78530597	A/G	cg16591659	chr17:78472290	NA	0.43	4.9	0.45	3.92e-6	Fractional excretion of uric acid;
THYM	cis	rs12039431	0.666	rs61778058	chr1:37968992	C/T	cg17933807	chr1:38061675	GNL2	-0.75	-5.36	-0.48	5.93e-7	Epithelial ovarian cancer;
THYM	cis	rs4144027	0.967	rs56126771	chr14:104361143	C/G	cg08213375	chr14:104286397	PPP1R13B	0.43	4.57	0.42	1.45e-5	Blood metabolite levels;
THYM	cis	rs3796352	1.000	rs35507120	chr3:53053924	C/T	cg04865290	chr3:52927548	TMEM110	-0.96	-4.97	-0.45	2.97e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg01416388	chr22:39784598	NA	-0.94	-9.27	-0.69	5.98e-15	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03452623	chr4:187889614	NA	-1.17	-20.04	-0.9	6.92e-36	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg17264618	chr3:40429014	ENTPD3	-0.51	-4.72	-0.44	8.26e-6	Renal cell carcinoma;
THYM	cis	rs7542375	0.534	rs56369151	chr1:221039053	T/A	cg16008148	chr1:221062819	NA	0.46	4.71	0.44	8.42e-6	Obesity-related traits;
THYM	cis	rs8014204	0.804	rs34956813	chr14:75254167	G/A	cg06637938	chr14:75390232	RPS6KL1	0.56	5.49	0.49	3.27e-7	Caffeine consumption;
THYM	cis	rs7570971	1.000	rs6730157	chr2:135907088	C/T	cg04750100	chr2:136595281	LCT	-0.48	-4.45	-0.42	2.33e-5	Blood metabolite levels;Body mass index;Cholesterol, total;
THYM	cis	rs9420	0.961	rs10896647	chr11:57571883	C/T	cg19752551	chr11:57585705	CTNND1	-0.72	-7.73	-0.62	1.09e-11	Schizophrenia;
THYM	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	4.51	0.42	1.84e-5	Calcium levels;
THYM	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg08017756	chr2:100939284	LONRF2	-0.72	-7.31	-0.6	8.31e-11	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg22920501	chr2:26401640	FAM59B	0.72	6.52	0.56	3.31e-9	Gut microbiome composition (summer);
THYM	cis	rs9560113	0.959	rs4773385	chr13:112178452	C/T	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg03060546	chr3:49711283	APEH	-0.74	-6.21	-0.54	1.42e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs6815814	0.898	rs73236616	chr4:38789675	G/A	cg02016764	chr4:38805732	TLR1	-0.55	-5.29	-0.48	7.91e-7	Breast cancer;
THYM	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg03806693	chr22:41940476	POLR3H	-1.21	-10.85	-0.74	2.54e-18	Vitiligo;
THYM	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg04398451	chr17:18023971	MYO15A	0.83	7.73	0.62	1.1e-11	Total body bone mineral density;
THYM	cis	rs7586879	0.789	rs13382979	chr2:25131736	G/A	cg01884057	chr2:25150051	NA	0.52	4.54	0.42	1.63e-5	Body mass index;
THYM	cis	rs7731657	0.537	rs6595989	chr5:130359215	C/T	cg08523029	chr5:130500466	HINT1	-0.85	-6.19	-0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs1113500	0.933	rs4517375	chr1:108638330	A/C	cg06207961	chr1:108661230	NA	-0.64	-5.09	-0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs62070183	0.882	rs17183628	chr17:31184631	C/T	cg23177095	chr17:30873196	MYO1D	-0.61	-4.74	-0.44	7.55e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg05660106	chr1:15850417	CASP9	0.77	6.33	0.54	7.9e-9	Systolic blood pressure;
THYM	cis	rs922692	0.744	rs12899147	chr15:79079512	A/G	cg22753661	chr15:79092743	ADAMTS7	0.65	4.95	0.45	3.16e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs3091242	0.809	rs660129	chr1:25727438	C/T	cg09222892	chr1:25734099	RHCE	0.62	4.83	0.44	5.21e-6	Erythrocyte sedimentation rate;
THYM	cis	rs490234	0.702	rs7864945	chr9:128373469	C/T	cg14078157	chr9:128172775	NA	-0.77	-5.97	-0.52	4.01e-8	Mean arterial pressure;
THYM	cis	rs6980334	0.911	rs10280628	chr7:137767310	C/T	cg18769353	chr7:137028617	PTN	0.65	5.05	0.46	2.13e-6	Blood metabolite ratios;
THYM	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7940866	0.740	rs7131121	chr11:130806424	A/G	cg05962950	chr11:130786565	SNX19	0.78	6.31	0.54	8.98e-9	Schizophrenia;
THYM	cis	rs2970992	0.817	rs2137670	chr2:101330834	G/T	cg01042948	chr2:101319752	NA	0.6	5.89	0.52	5.76e-8	Educational attainment;
THYM	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg02734326	chr4:10020555	SLC2A9	-0.55	-4.64	-0.43	1.13e-5	Bone mineral density;
THYM	cis	rs6598955	0.543	rs79778574	chr1:26538482	A/G	cg04990556	chr1:26633338	UBXN11	0.96	6.06	0.53	2.7e-8	Obesity-related traits;
THYM	cis	rs10089	0.953	rs2190797	chr5:127352875	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.96	6.47	0.55	4.19e-9	Ileal carcinoids;
THYM	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg22508957	chr16:3507546	NAT15	0.67	9.74	0.71	5.91e-16	Tuberculosis;
THYM	cis	rs921968	0.565	rs7603709	chr2:219642601	C/T	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.65	-5.08	-0.46	1.9e-6	Chronic sinus infection;
THYM	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg13695892	chr22:41940480	POLR3H	-0.86	-5.96	-0.52	4.19e-8	Vitiligo;
THYM	cis	rs1466662	0.814	rs9307922	chr4:155313844	C/T	cg05574313	chr4:155338166	DCHS2	-0.68	-4.83	-0.44	5.24e-6	Alzheimer's disease (age of onset);
THYM	cis	rs17867775	0.623	rs12670241	chr7:126692465	G/A	cg02090654	chr7:126698344	MIR592;GRM8	0.83	4.67	0.43	9.93e-6	Anti-saccade response;
THYM	trans	rs629535	0.814	rs62513373	chr8:70080753	C/T	cg21567404	chr3:27674614	NA	-1.09	-10.28	-0.73	4.24e-17	Dupuytren's disease;
THYM	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg14784868	chr12:69753453	YEATS4	0.81	6.43	0.55	5.14e-9	Blood protein levels;
THYM	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg07022442	chr13:21864356	NA	0.72	4.76	0.44	6.91e-6	White matter hyperintensity burden;
THYM	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.01	4.95	0.45	3.26e-6	Initial pursuit acceleration;
THYM	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs4242434	0.889	rs11783129	chr8:22453426	G/A	cg03733263	chr8:22462867	KIAA1967	1.11	11.28	0.76	3.1e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6456156	1.000	rs9457274	chr6:167520865	G/T	cg09487078	chr6:167525398	CCR6	0.44	4.52	0.42	1.76e-5	Primary biliary cholangitis;
THYM	cis	rs10193935	0.792	rs10204778	chr2:42498121	G/T	cg27598129	chr2:42591480	NA	-0.74	-4.45	-0.42	2.37e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3767633	0.612	rs2490427	chr1:161943070	T/C	cg27495845	chr1:161693088	FCRLB	-0.67	-4.56	-0.42	1.55e-5	IgG glycosylation;
THYM	cis	rs7089973	0.872	rs11818115	chr10:116634891	G/A	cg23260525	chr10:116636907	FAM160B1	0.52	4.66	0.43	1.02e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs13102973	0.931	rs12499856	chr4:135868573	C/T	cg14419869	chr4:135874104	NA	0.85	8.16	0.64	1.35e-12	Subjective well-being;
THYM	cis	rs6918586	0.658	rs198838	chr6:26113340	C/T	cg03264133	chr6:25882463	NA	-0.6	-4.58	-0.42	1.43e-5	Schizophrenia;
THYM	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg19875535	chr5:140030758	IK	-0.59	-5.11	-0.46	1.63e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7584330	0.554	rs13392410	chr2:238430273	G/A	cg14458575	chr2:238380390	NA	0.8	4.67	0.43	9.97e-6	Prostate cancer;
THYM	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg22907277	chr7:1156413	C7orf50	0.63	5.61	0.5	2.02e-7	Longevity;Endometriosis;
THYM	cis	rs926938	0.520	rs969273	chr1:115256669	G/A	cg12756093	chr1:115239321	AMPD1	-0.56	-4.55	-0.42	1.59e-5	Autism;
THYM	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg07414643	chr4:187882934	NA	0.67	5.92	0.52	5.16e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg04398451	chr17:18023971	MYO15A	-0.76	-6.96	-0.58	4.39e-10	Total body bone mineral density;
THYM	cis	rs6565180	0.888	rs12447833	chr16:30390314	T/C	cg17640201	chr16:30407289	ZNF48	0.85	7.2	0.59	1.43e-10	Tonsillectomy;
THYM	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg00256281	chr22:41985642	PMM1	0.64	5.02	0.46	2.42e-6	Vitiligo;
THYM	cis	rs4733781	1.000	rs2033059	chr8:131271216	A/G	cg16277922	chr8:131349729	ASAP1	-0.64	-4.54	-0.42	1.64e-5	Tuberculosis;
THYM	cis	rs981844	0.961	rs6827685	chr4:154662227	C/T	cg09973105	chr4:154681532	RNF175	-0.7	-6.29	-0.54	9.61e-9	Response to statins (LDL cholesterol change);
THYM	cis	rs4631830	0.832	rs10825652	chr10:51510761	G/A	cg10326726	chr10:51549505	MSMB	0.5	5.01	0.46	2.47e-6	Prostate-specific antigen levels;
THYM	cis	rs912057	1.000	rs1294410	chr6:6738752	C/T	cg13809441	chr6:6737631	NA	-0.43	-4.85	-0.45	4.72e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs6500596	0.570	rs8055628	chr16:4447477	G/A	cg09549813	chr16:4587862	C16orf5	-0.48	-4.84	-0.44	5.09e-6	Schizophrenia;
THYM	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg26924012	chr15:45694286	SPATA5L1	-1.11	-10.95	-0.75	1.56e-18	Homoarginine levels;
THYM	cis	rs4638749	0.677	rs2378098	chr2:108849381	T/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg24578937	chr1:2090814	PRKCZ	-0.64	-6.48	-0.55	4.14e-9	Height;
THYM	cis	rs12681287	0.640	rs6992287	chr8:87418960	G/A	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg10505658	chr17:80084571	CCDC57	-0.67	-7.58	-0.61	2.32e-11	Life satisfaction;
THYM	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs765787	0.530	rs12442533	chr15:45529631	G/C	cg24006582	chr15:45444508	DUOX1	0.81	6.55	0.56	2.99e-9	Uric acid levels;
THYM	cis	rs7312774	0.618	rs57361179	chr12:107337483	T/C	cg16260113	chr12:107380972	MTERFD3	1.3	6.13	0.53	2.01e-8	Severe influenza A (H1N1) infection;
THYM	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg12935359	chr14:103987150	CKB	-0.53	-6.3	-0.54	9.24e-9	Intelligence (multi-trait analysis);
THYM	cis	rs11563648	0.553	rs10279882	chr7:127004132	C/T	cg23081781	chr7:127225937	GCC1	-0.34	-4.57	-0.42	1.45e-5	Resting heart rate;
THYM	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg08645402	chr16:4508243	NA	0.63	5.22	0.47	1.05e-6	Schizophrenia;
THYM	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg15592062	chr6:167189543	RPS6KA2	0.47	4.76	0.44	7.02e-6	Crohn's disease;
THYM	cis	rs9467160	0.822	rs9461013	chr6:24443683	A/G	cg20631270	chr6:24437470	GPLD1	0.65	4.95	0.45	3.19e-6	Liver enzyme levels;
THYM	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	12.98	0.8	9.27e-23	Chronic sinus infection;
THYM	cis	rs921968	0.540	rs10190250	chr2:219457731	C/T	cg02176678	chr2:219576539	TTLL4	-0.72	-7.15	-0.59	1.75e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs12142240	0.698	rs68191463	chr1:46808695	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs1371867	0.817	rs1660314	chr8:101332953	C/T	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs7584330	0.518	rs7585969	chr2:238439073	G/A	cg08992911	chr2:238395768	MLPH	1.05	6.53	0.56	3.16e-9	Prostate cancer;
THYM	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11644478	chr21:40555479	PSMG1	1.09	9.28	0.69	5.81e-15	Cognitive function;
THYM	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg10802521	chr3:52805072	NEK4	-0.59	-5.12	-0.46	1.63e-6	Electroencephalogram traits;
THYM	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06850241	chr22:41845214	NA	0.58	5.36	0.48	5.76e-7	Vitiligo;
THYM	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9790314	1.000	rs1993891	chr3:161047467	A/G	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg27490568	chr2:178487706	NA	0.69	6.47	0.55	4.28e-9	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg04287289	chr16:89883240	FANCA	0.64	5.97	0.52	4.11e-8	Vitiligo;
THYM	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg04234412	chr22:24373322	LOC391322	-1.0	-11.94	-0.77	1.27e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11644478	chr21:40555479	PSMG1	-0.8	-6.93	-0.58	4.93e-10	Cognitive function;
THYM	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.96	0.45	3.1e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg07978099	chr16:83986941	OSGIN1	-0.55	-4.55	-0.42	1.56e-5	Pursuit maintenance gain;
THYM	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg10560079	chr2:191398806	TMEM194B	0.9	8.45	0.65	3.42e-13	Pulse pressure;
THYM	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg03433033	chr1:76189801	ACADM	-0.51	-5.4	-0.48	4.84e-7	Daytime sleep phenotypes;
THYM	cis	rs7586879	0.964	rs11688665	chr2:25121168	G/T	cg01884057	chr2:25150051	NA	0.66	6.46	0.55	4.51e-9	Body mass index;
THYM	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg14895029	chr7:2775587	GNA12	-0.67	-4.92	-0.45	3.7e-6	Height;
THYM	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg18850127	chr7:39170497	POU6F2	0.6	5.66	0.5	1.57e-7	IgG glycosylation;
THYM	cis	rs4481887	0.741	rs7540715	chr1:248544206	C/T	cg17299007	chr1:248814626	OR2T27	0.43	4.58	0.43	1.41e-5	Common traits (Other);
THYM	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg05294307	chr14:35346193	BAZ1A	-0.93	-6.68	-0.57	1.64e-9	Psoriasis;
THYM	cis	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs3110496	0.685	rs550818	chr17:27901975	A/G	cg05877788	chr17:27899874	TP53I13	-0.45	-5.42	-0.49	4.5e-7	Height;
THYM	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg08885076	chr2:99613938	TSGA10	0.69	6.47	0.55	4.31e-9	Chronic sinus infection;
THYM	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg03806693	chr22:41940476	POLR3H	-1.12	-9.01	-0.68	2.21e-14	Vitiligo;
THYM	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg08470875	chr2:26401718	FAM59B	-0.72	-4.46	-0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs2456568	0.835	rs1518578	chr11:93656854	G/T	cg17347335	chr11:93583973	C11orf90	-0.48	-4.47	-0.42	2.16e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.57	4.49	0.42	2.01e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7695732	0.508	rs2609276	chr4:89895621	T/A	cg17769793	chr4:89976368	FAM13A	-0.5	-5.57	-0.5	2.36e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs9790314	1.000	rs7653361	chr3:160992291	C/T	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg06453172	chr10:134556979	INPP5A	-0.67	-4.84	-0.44	5.1e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs12188164	0.812	rs9313065	chr5:423426	T/C	cg00049323	chr5:472564	LOC25845	-0.41	-4.73	-0.44	7.83e-6	Cystic fibrosis severity;
THYM	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	6.07	0.53	2.67e-8	Schizophrenia;
THYM	cis	rs7246657	0.943	rs3803895	chr19:37898669	A/G	cg22634378	chr19:37742834	NA	0.62	5.18	0.47	1.22e-6	Coronary artery calcification;
THYM	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.11	10.49	0.73	1.5e-17	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg02782426	chr3:40428986	ENTPD3	-0.51	-4.48	-0.42	2.1e-5	Renal cell carcinoma;
THYM	cis	rs7681423	1.000	rs2066865	chr4:155525276	G/A	cg20735720	chr4:155535218	FGG	-0.71	-5.57	-0.5	2.39e-7	Fibrinogen;
THYM	cis	rs2933343	0.700	rs1680788	chr3:128625318	C/T	cg11901034	chr3:128598214	ACAD9	-0.68	-5.57	-0.5	2.4e-7	IgG glycosylation;
THYM	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg27490568	chr2:178487706	NA	0.68	6.2	0.54	1.44e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7216064	1.000	rs9915108	chr17:65874463	T/C	cg12091567	chr17:66097778	LOC651250	-0.69	-4.65	-0.43	1.05e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs11608355	1.000	rs7970482	chr12:109862335	G/A	cg11367159	chr12:110044531	NA	0.63	5.92	0.52	5.1e-8	Neuroticism;
THYM	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg08213375	chr14:104286397	PPP1R13B	0.43	4.49	0.42	1.97e-5	Reticulocyte count;
THYM	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.72	-5.56	-0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg03609598	chr5:56110824	MAP3K1	-0.85	-5.83	-0.51	7.62e-8	Initial pursuit acceleration;
THYM	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg22166914	chr1:53195759	ZYG11B	-0.77	-8.25	-0.65	8.81e-13	Monocyte count;
THYM	cis	rs7119	0.604	rs2271396	chr15:77907535	C/G	cg10437265	chr15:77819839	NA	-0.49	-4.97	-0.45	2.97e-6	Type 2 diabetes;
THYM	cis	rs7264396	0.563	rs6060580	chr20:34310512	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.77	-0.44	6.57e-6	Total cholesterol levels;
THYM	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg08645402	chr16:4508243	NA	0.68	5.02	0.46	2.4e-6	Schizophrenia;
THYM	cis	rs4930103	0.935	rs11042170	chr11:2021625	C/T	cg18511798	chr11:2018149	H19;MIR675	-0.57	-5.57	-0.5	2.39e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg08000102	chr2:233561755	GIGYF2	0.69	6.09	0.53	2.35e-8	Coronary artery disease;
THYM	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.44e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	5.76	0.51	1.02e-7	Schizophrenia;
THYM	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Body mass index;
THYM	cis	rs7267979	0.903	rs6115118	chr20:25246734	G/A	cg08601574	chr20:25228251	PYGB	0.59	4.68	0.43	9.42e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg03806693	chr22:41940476	POLR3H	1.1	8.83	0.67	5.2e-14	Vitiligo;
THYM	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.48	-4.9	-0.45	3.92e-6	Primary biliary cholangitis;
THYM	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06873352	chr17:61820015	STRADA	0.56	5.59	0.5	2.18e-7	Height;
THYM	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg17333051	chr19:2783644	SGTA	-0.74	-6.47	-0.55	4.15e-9	Total cholesterol levels;
THYM	cis	rs700651	0.789	rs1813106	chr2:198880589	A/G	cg00792783	chr2:198669748	PLCL1	0.83	5.9	0.52	5.65e-8	Intracranial aneurysm;
THYM	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg23815491	chr16:72088622	HP	0.81	6.98	0.58	4.03e-10	Prostate cancer;
THYM	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg05738196	chr6:26577821	NA	-0.63	-5.12	-0.46	1.63e-6	Intelligence (multi-trait analysis);
THYM	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg23161317	chr6:28129485	ZNF389	0.69	5.6	0.5	2.06e-7	Cardiac Troponin-T levels;
THYM	cis	rs1034435	0.692	rs6008739	chr22:48892542	T/C	cg05992904	chr22:48892994	FAM19A5	-0.83	-9.23	-0.69	7.31e-15	Late-onset Alzheimer's disease;
THYM	cis	rs2811415	0.597	rs9813438	chr3:127797796	C/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs11186	0.556	rs55778292	chr2:189970620	G/T	cg11041835	chr2:189156425	GULP1	0.8	4.52	0.42	1.79e-5	Parkinson's disease;
THYM	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg24692254	chr21:30365293	RNF160	1.03	9.95	0.71	2.13e-16	Dental caries;
THYM	cis	rs6430585	0.759	rs12467770	chr2:136536095	G/A	cg07169764	chr2:136633963	MCM6	1.22	13.28	0.81	2.23e-23	Corneal structure;
THYM	cis	rs9309711	0.961	rs11692184	chr2:3480710	C/T	cg10845886	chr2:3471009	TTC15	-0.6	-5.12	-0.47	1.58e-6	Neurofibrillary tangles;
THYM	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg02725872	chr8:58115012	NA	-0.85	-5.95	-0.52	4.55e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2309752	1	rs2309752	chr2:100762169	T/A	cg07810366	chr2:100720526	AFF3	-0.41	-6.24	-0.54	1.19e-8	Intelligence (multi-trait analysis);
THYM	cis	rs10887741	0.624	rs9633742	chr10:89432286	A/G	cg13926569	chr10:89418898	PAPSS2	0.62	6.97	0.58	4.19e-10	Exercise (leisure time);
THYM	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.79	-6.78	-0.57	1.01e-9	Lung cancer;
THYM	cis	rs514406	0.505	rs387436	chr1:53179376	C/T	cg08859206	chr1:53392774	SCP2	0.49	5.18	0.47	1.26e-6	Monocyte count;
THYM	trans	rs4866334	1.000	rs75533364	chr5:18453341	G/A	cg08675002	chr5:90437527	GPR98	-1.55	-7.42	-0.61	4.85e-11	IgG glycosylation;
THYM	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs6430585	0.583	rs4988163	chr2:136628121	G/T	cg07169764	chr2:136633963	MCM6	1.21	14.02	0.82	7.37e-25	Corneal structure;
THYM	cis	rs2290159	0.800	rs5746195	chr3:12653800	A/G	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs1048238	0.506	rs1262788	chr1:16215608	G/C	cg22431228	chr1:16359049	CLCNKA	0.43	4.66	0.43	1.03e-5	Systolic blood pressure;
THYM	cis	rs11102986	0.607	rs10776909	chr9:137288746	T/C	cg00753924	chr9:137298813	RXRA	-0.6	-5.49	-0.49	3.32e-7	Intelligence;
THYM	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg24399712	chr22:39784796	NA	-0.84	-8.53	-0.66	2.28e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg17063962	chr7:91808500	NA	-1.13	-12.81	-0.8	2.07e-22	Breast cancer;
THYM	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg01416388	chr22:39784598	NA	-0.98	-10.06	-0.72	1.25e-16	Intelligence (multi-trait analysis);
THYM	cis	rs7100689	0.622	rs10887798	chr10:82131613	G/A	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	2.96e-8	Post bronchodilator FEV1;
THYM	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg08901578	chr4:187885870	NA	-0.64	-6.06	-0.53	2.71e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11644478	chr21:40555479	PSMG1	-0.58	-4.76	-0.44	6.94e-6	Menarche (age at onset);
THYM	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.93	6.95	0.58	4.61e-10	Smoking behavior;
THYM	cis	rs9653442	0.675	rs1115910	chr2:100647872	A/G	cg07810366	chr2:100720526	AFF3	-0.42	-5.89	-0.52	5.76e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs2046867	0.862	rs58538718	chr3:72800563	C/A	cg25664220	chr3:72788482	NA	-0.87	-6.53	-0.56	3.22e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg23205692	chr1:25664452	TMEM50A	0.86	6.69	0.57	1.54e-9	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs17122693	0.748	rs72679596	chr14:51103595	C/T	cg04730355	chr14:51134070	SAV1	0.96	6.13	0.53	2e-8	Cognitive performance;
THYM	cis	rs988913	1.000	rs6941291	chr6:54837376	A/G	cg18532076	chr6:54711417	FAM83B	0.49	4.71	0.44	8.33e-6	Menarche (age at onset);
THYM	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg09260853	chr1:2094483	PRKCZ	0.48	4.95	0.45	3.26e-6	Height;
THYM	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg16989719	chr2:238392110	NA	-0.65	-5.9	-0.52	5.63e-8	Prostate cancer;
THYM	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs55665837	1.000	rs12288873	chr11:14450465	C/T	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs7626444	0.605	rs7642801	chr3:196490306	G/C	cg12930392	chr3:196481615	PAK2	0.41	5.04	0.46	2.18e-6	Monocyte count;
THYM	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg20007245	chr22:24372913	LOC391322	-0.61	-4.61	-0.43	1.27e-5	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg07460842	chr6:66804631	NA	-0.91	-6.25	-0.54	1.14e-8	Exhaled nitric oxide output;
THYM	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11890956	chr21:40555474	PSMG1	0.96	10.57	0.74	9.9e-18	Cognitive function;
THYM	cis	rs1568889	0.838	rs10835283	chr11:28214985	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22968622	chr17:43663579	NA	0.82	6.99	0.58	3.76e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg11789530	chr4:8429930	ACOX3	-0.75	-6.02	-0.53	3.23e-8	Response to antineoplastic agents;
THYM	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg08999081	chr20:33150536	PIGU	0.55	4.86	0.45	4.61e-6	Height;
THYM	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4808199	1.000	rs12972397	chr19:19562349	G/A	cg03709012	chr19:19516395	GATAD2A	1.19	7.25	0.6	1.12e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg00074818	chr8:8560427	CLDN23	0.6	5.47	0.49	3.64e-7	Obesity-related traits;
THYM	cis	rs7091068	0.532	rs559590	chr10:95398886	C/T	cg20715218	chr10:95462985	C10orf4	-0.67	-4.92	-0.45	3.62e-6	Urinary tract infection frequency;
THYM	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg14018140	chr10:458528	DIP2C	-0.6	-7.09	-0.59	2.38e-10	Psychosis in Alzheimer's disease;
THYM	cis	rs1847202	0.859	rs4274693	chr3:72949375	A/G	cg27402429	chr3:72788294	NA	-0.69	-4.48	-0.42	2.07e-5	Motion sickness;
THYM	cis	rs1267303	0.636	rs1267310	chr1:46987307	A/T	cg25110126	chr1:46999211	NA	-0.68	-5.3	-0.48	7.63e-7	Monobrow;
THYM	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg06618935	chr21:46677482	NA	-0.96	-9.3	-0.69	5.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs877282	0.891	rs12767043	chr10:797943	C/T	cg10556349	chr10:835070	NA	-0.79	-5.42	-0.49	4.56e-7	Uric acid levels;
THYM	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg11301795	chr4:187892539	NA	-1.13	-17.11	-0.87	9.08e-31	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg03929089	chr4:120376271	NA	-0.99	-12.32	-0.78	2.08e-21	Height;
THYM	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.73	-0.44	7.7e-6	Crohn's disease;
THYM	cis	rs2070488	0.965	rs2366123	chr3:38493153	G/A	cg24069376	chr3:38537580	EXOG	0.68	6.73	0.57	1.26e-9	Electrocardiographic conduction measures;
THYM	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-4.71	-0.43	8.5e-6	Monocyte percentage of white cells;
THYM	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg20887711	chr4:1340912	KIAA1530	0.97	8.89	0.67	3.9e-14	Longevity;
THYM	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg04025307	chr7:1156635	C7orf50	0.72	4.46	0.42	2.27e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9486719	1.000	rs6921291	chr6:97066242	C/T	cg18709589	chr6:96969512	KIAA0776	-0.69	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg13010199	chr12:38710504	ALG10B	0.65	4.65	0.43	1.06e-5	Morning vs. evening chronotype;
THYM	cis	rs8041943	0.643	rs4779128	chr15:79919955	G/T	cg03800648	chr15:79044299	NA	-0.59	-4.49	-0.42	1.99e-5	Bone mineral density (spine) and age at menarche;
THYM	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg04063615	chr12:132293388	NA	-0.64	-5.42	-0.49	4.58e-7	Migraine;
THYM	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg00300879	chr1:26503847	CNKSR1	-0.43	-5.74	-0.51	1.15e-7	Height;
THYM	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg24818145	chr4:99064322	C4orf37	0.9	7.36	0.6	6.5e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg20387954	chr3:183756860	HTR3D	0.56	4.63	0.43	1.15e-5	Anterior chamber depth;
THYM	cis	rs595982	0.527	rs56021835	chr19:49369989	G/A	cg17863274	chr19:49399704	TULP2	-1.0	-6.15	-0.53	1.85e-8	Red cell distribution width;
THYM	cis	rs4950928	0.712	rs7518666	chr1:203163590	C/T	cg17014757	chr1:203156097	CHI3L1	-1.11	-6.68	-0.57	1.6e-9	YKL-40 levels;
THYM	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg12310025	chr6:25882481	NA	-0.9	-7.96	-0.63	3.65e-12	Intelligence (multi-trait analysis);
THYM	cis	rs1113500	0.933	rs61797345	chr1:108623728	G/A	cg06207961	chr1:108661230	NA	0.66	5.18	0.47	1.24e-6	Growth-regulated protein alpha levels;
THYM	trans	rs3960554	0.673	rs112680895	chr7:75623520	G/A	cg19862616	chr7:65841803	NCRNA00174	0.98	7.44	0.61	4.52e-11	Eotaxin levels;
THYM	cis	rs72627123	0.656	rs117129791	chr14:74520871	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.29	7.08	0.59	2.46e-10	Morning vs. evening chronotype;
THYM	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg06636551	chr8:101224915	SPAG1	-0.67	-6.52	-0.56	3.36e-9	Atrioventricular conduction;
THYM	cis	rs7772486	0.521	rs9485017	chr6:146023326	C/T	cg23711669	chr6:146136114	FBXO30	0.76	6.94	0.58	4.78e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7246657	0.943	rs7255972	chr19:37933841	T/C	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg27279351	chr12:120934652	DYNLL1	0.95	8.63	0.66	1.42e-13	High light scatter reticulocyte count;
THYM	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.95	0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs73787773	0.866	rs73227493	chr5:111477659	A/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.9	-4.56	-0.42	1.54e-5	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs7169223	0.653	rs1564499	chr15:79084808	C/T	cg21242079	chr15:79101063	ADAMTS7	-0.52	-4.85	-0.45	4.74e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17443541	0.507	rs6726848	chr2:200451027	G/A	cg03741458	chr2:200468445	NA	-0.8	-5.86	-0.52	6.75e-8	Intelligence (multi-trait analysis);
THYM	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg08704250	chr15:31115839	NA	-0.57	-6.3	-0.54	9.17e-9	Huntington's disease progression;
THYM	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	7.92	0.63	4.49e-12	Smoking behavior;
THYM	cis	rs7246657	0.943	rs3760825	chr19:37945601	C/T	cg22634378	chr19:37742834	NA	0.62	5.18	0.47	1.22e-6	Coronary artery calcification;
THYM	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg23758822	chr17:41437982	NA	1.16	11.1	0.75	7.47e-19	Menopause (age at onset);
THYM	cis	rs7731657	0.537	rs4235804	chr5:130358417	C/G	cg08523029	chr5:130500466	HINT1	0.85	6.0	0.52	3.63e-8	Fasting plasma glucose;
THYM	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg18681998	chr4:17616180	MED28	0.99	10.27	0.73	4.28e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2458413	0.669	rs1812214	chr8:105344070	A/G	cg13045555	chr8:105342365	NA	-0.27	-4.79	-0.44	6.07e-6	Paget's disease;
THYM	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg07404485	chr7:94953653	PON1	-0.83	-7.32	-0.6	7.94e-11	Paraoxonase activity;
THYM	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg26545918	chr15:68124484	LBXCOR1	0.54	4.55	0.42	1.57e-5	Restless legs syndrome;
THYM	cis	rs11039798	0.777	rs2202454	chr11:49011009	T/C	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs6570726	0.791	rs621382	chr6:145799144	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.46	-0.49	3.77e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611519	1.000	rs4820433	chr22:41607065	C/G	cg03806693	chr22:41940476	POLR3H	-0.75	-5.82	-0.51	8.05e-8	Neuroticism;
THYM	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg26446133	chr18:72167187	CNDP2	-1.02	-10.28	-0.73	4.26e-17	Refractive error;
THYM	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg23791538	chr6:167370224	RNASET2	0.72	5.66	0.5	1.58e-7	Crohn's disease;
THYM	cis	rs73086581	1.000	rs56141565	chr20:3998603	G/A	cg02187196	chr20:3869020	PANK2	0.49	5.35	0.48	6.18e-7	Response to antidepressants in depression;
THYM	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg15247329	chr7:2764246	NA	-0.71	-5.89	-0.52	5.77e-8	Height;
THYM	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg11266682	chr4:10021025	SLC2A9	0.74	12.07	0.78	6.92e-21	Bone mineral density;
THYM	cis	rs2213920	0.679	rs7860135	chr9:118242257	G/A	cg13918206	chr9:118159781	DEC1	0.84	4.63	0.43	1.17e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs6430585	1.000	rs6430585	chr2:136506927	A/C	cg07169764	chr2:136633963	MCM6	-0.94	-8.56	-0.66	1.95e-13	Corneal structure;
THYM	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4478037	0.558	rs57502645	chr3:33082174	G/A	cg19404215	chr3:33155277	CRTAP	0.94	4.97	0.45	2.9e-6	Major depressive disorder;
THYM	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg17173187	chr15:85201210	NMB	0.57	5.68	0.5	1.5e-7	Schizophrenia;
THYM	cis	rs7072216	0.763	rs45523432	chr10:100167436	T/C	cg03852570	chr10:100175106	PYROXD2	0.38	4.89	0.45	4.04e-6	Metabolite levels;
THYM	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg20283391	chr11:68216788	NA	0.61	4.58	0.43	1.41e-5	Total body bone mineral density;
THYM	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07167872	chr1:205819463	PM20D1	1.18	13.14	0.8	4.36e-23	Menarche (age at onset);
THYM	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg10047753	chr17:41438598	NA	1.14	10.51	0.73	1.38e-17	Menopause (age at onset);
THYM	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs6897795	0.680	rs9329135	chr5:177611055	G/C	cg25087499	chr5:177592761	NA	0.55	4.82	0.44	5.37e-6	Plateletcrit;
THYM	cis	rs7818345	0.637	rs3923920	chr8:19359184	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.47	-4.86	-0.45	4.54e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg23791538	chr6:167370224	RNASET2	0.84	7.49	0.61	3.58e-11	Crohn's disease;
THYM	cis	rs250677	0.522	rs10477400	chr5:148359598	T/C	cg18129178	chr5:148520854	ABLIM3	0.72	5.4	0.48	4.94e-7	Breast cancer;
THYM	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg08772003	chr10:104629869	AS3MT	-0.57	-4.92	-0.45	3.69e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg24154853	chr7:158122151	PTPRN2	-0.52	-4.71	-0.43	8.52e-6	Calcium levels;
THYM	cis	rs3780378	0.875	rs4587378	chr9:5002011	C/T	cg02405213	chr9:5042618	JAK2	-0.62	-4.87	-0.45	4.43e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs11096990	0.634	rs2276888	chr4:39279907	C/T	cg24403649	chr4:39172243	NA	-0.64	-5.53	-0.49	2.81e-7	Cognitive function;
THYM	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.76	-0.44	6.98e-6	Crohn's disease;
THYM	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg14893161	chr1:205819251	PM20D1	-0.74	-7.0	-0.58	3.56e-10	Menarche (age at onset);
THYM	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.71	9.54	0.7	1.62e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9921192	0.843	rs251731	chr16:4310709	T/C	cg00021532	chr16:4324280	TFAP4	0.8	6.82	0.57	8.46e-10	Prostate-specific antigen levels;
THYM	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg09703963	chr11:616879	IRF7;MUPCDH	-0.74	-5.52	-0.49	2.88e-7	Systemic lupus erythematosus;
THYM	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.87e-6	Resting heart rate;
THYM	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg06558623	chr16:89946397	TCF25	1.1	5.93	0.52	4.8e-8	Skin colour saturation;
THYM	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17750015	1.000	rs17750015	chr18:54397622	T/C	cg18434998	chr18:54306185	TXNL1	-0.64	-4.67	-0.43	9.8e-6	Depression and alcohol dependence;
THYM	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg14517863	chr17:44321492	NA	0.43	4.81	0.44	5.57e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.68	-5.66	-0.5	1.63e-7	Lymphocyte counts;
THYM	cis	rs7586879	0.609	rs7608976	chr2:25075281	G/A	cg01884057	chr2:25150051	NA	0.65	6.53	0.56	3.21e-9	Body mass index;
THYM	cis	rs10489202	0.608	rs7553238	chr1:168076768	G/A	cg24449463	chr1:168025552	DCAF6	-0.7	-6.06	-0.53	2.77e-8	Schizophrenia;
THYM	cis	rs13082711	0.689	rs34946790	chr3:27345170	G/A	cg02860705	chr3:27208620	NA	1.09	8.1	0.64	1.83e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg19626725	chr5:178986131	RUFY1	-0.3	-4.55	-0.42	1.56e-5	Lung cancer;
THYM	cis	rs977987	0.815	rs11861810	chr16:75461829	A/G	cg03315344	chr16:75512273	CHST6	0.76	6.17	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs7084402	0.935	rs10763564	chr10:60360423	C/A	cg27040468	chr10:60456715	BICC1	-0.54	-4.64	-0.43	1.11e-5	Refractive error;
THYM	cis	rs7078219	0.714	rs12360459	chr10:101286154	A/G	cg07044859	chr10:101282883	NA	-0.48	-5.23	-0.47	1.01e-6	Dental caries;
THYM	cis	rs12477602	0.938	rs17199249	chr2:203426668	A/C	cg10634136	chr2:202901470	FZD7	0.68	4.63	0.43	1.16e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7084402	0.967	rs1649042	chr10:60328663	T/C	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg05804949	chr7:23719620	C7orf46	0.45	5.16	0.47	1.34e-6	Schizophrenia;
THYM	cis	rs2108622	0.727	rs62107763	chr19:15982598	T/C	cg13772218	chr19:15982569	NA	0.5	4.48	0.42	2.06e-5	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs8112449	1.000	rs7253917	chr19:10522176	A/T	cg01466491	chr19:10523363	NA	-0.68	-6.58	-0.56	2.59e-9	Multiple sclerosis;Gastritis;
THYM	cis	rs9660180	1.000	rs9660180	chr1:1723031	G/A	cg06981504	chr1:1234844	ACAP3	0.53	4.91	0.45	3.71e-6	Body mass index;
THYM	cis	rs989128	0.600	rs9913430	chr17:48628470	A/T	cg20467136	chr17:48638190	CACNA1G	0.59	4.55	0.42	1.6e-5	Type 2 diabetes;
THYM	cis	rs735396	0.770	rs2264782	chr12:121432603	C/T	cg02403541	chr12:121454288	C12orf43	0.59	4.73	0.44	7.67e-6	N-glycan levels;
THYM	cis	rs28647808	1.000	rs28591209	chr9:136259668	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg23583168	chr7:148888333	NA	-1.03	-13.26	-0.81	2.41e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg17333051	chr19:2783644	SGTA	0.73	6.3	0.54	9.26e-9	Total cholesterol levels;
THYM	cis	rs7100689	0.646	rs4357632	chr10:82131783	C/T	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs6076065	0.723	rs2144381	chr20:23369940	C/T	cg11657817	chr20:23433608	CST11	0.31	4.57	0.42	1.48e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs977987	0.806	rs12444589	chr16:75454404	A/T	cg03315344	chr16:75512273	CHST6	-0.75	-6.18	-0.54	1.61e-8	Dupuytren's disease;
THYM	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg26418147	chr1:205743515	RAB7L1	-0.52	-4.46	-0.42	2.23e-5	Menarche (age at onset);
THYM	trans	rs17716202	0.826	rs13175762	chr5:55900249	T/G	cg01557754	chr17:7342661	FGF11	0.98	7.0	0.58	3.61e-10	Psychosis in Alzheimer's disease;
THYM	cis	rs1018836	0.564	rs7821994	chr8:91700916	C/T	cg16814680	chr8:91681699	NA	-0.89	-8.7	-0.67	9.71e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs425277	0.628	rs3107145	chr1:2047547	G/A	cg09260853	chr1:2094483	PRKCZ	-0.46	-4.66	-0.43	1.03e-5	Height;
THYM	cis	rs7809615	0.901	rs6947941	chr7:99156446	G/T	cg12290671	chr7:99195819	NA	-0.99	-4.83	-0.44	5.27e-6	Blood metabolite ratios;
THYM	cis	rs7264396	0.887	rs2236159	chr20:34102189	A/G	cg26038318	chr20:34205095	SPAG4	0.53	4.45	0.42	2.33e-5	Total cholesterol levels;
THYM	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg10802521	chr3:52805072	NEK4	-0.68	-5.75	-0.51	1.08e-7	Bipolar disorder;
THYM	cis	rs4936891	0.577	rs4935862	chr11:123921479	C/T	cg22125253	chr11:123886957	OR10G4	0.54	4.56	0.42	1.53e-5	Male fertility;
THYM	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.73	-5.81	-0.51	8.18e-8	Systemic lupus erythematosus;
THYM	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg26116260	chr4:7069785	GRPEL1	1.12	11.02	0.75	1.14e-18	Monocyte percentage of white cells;
THYM	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg20744362	chr22:50050164	C22orf34	0.83	8.41	0.65	4.11e-13	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2456568	0.933	rs1518577	chr11:93674907	C/T	cg17595323	chr11:93583763	C11orf90	-0.54	-5.23	-0.47	1.02e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg04518342	chr5:131593106	PDLIM4	0.46	5.17	0.47	1.3e-6	Blood metabolite levels;
THYM	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg04756594	chr16:24857601	SLC5A11	0.75	5.23	0.47	1.01e-6	Intelligence (multi-trait analysis);
THYM	cis	rs672413	0.739	rs336526	chr5:78287579	T/G	cg17845680	chr5:78281827	ARSB	-0.62	-5.76	-0.51	1.02e-7	Blood and toenail selenium levels;Blood protein levels;
THYM	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.87	-7.46	-0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs4452313	0.532	rs58765457	chr3:16990003	T/A	cg19448816	chr3:16974217	PLCL2	0.59	4.5	0.42	1.91e-5	Rheumatoid arthritis;
THYM	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg08901578	chr4:187885870	NA	0.62	5.62	0.5	1.9e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13064411	0.696	rs6769516	chr3:113219905	T/C	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs2455799	0.573	rs2455836	chr3:15754538	A/G	cg16303742	chr3:15540471	COLQ	-0.54	-5.64	-0.5	1.77e-7	Mean platelet volume;
THYM	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10826182	0.643	rs4397793	chr10:60145597	C/G	cg23243718	chr10:60144880	TFAM	0.63	4.61	0.43	1.25e-5	Midgestational circulating levels of PCBs;
THYM	cis	rs4372836	0.729	rs6547874	chr2:28982030	A/G	cg09522027	chr2:28974177	PPP1CB	-0.65	-5.12	-0.46	1.62e-6	Body mass index;
THYM	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.11e-10	Schizophrenia;
THYM	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7432375	0.901	rs1017882	chr3:136357705	T/C	cg12473912	chr3:136751656	NA	0.62	5.24	0.47	9.59e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs7172809	0.523	rs76675107	chr15:77552944	T/C	cg22256960	chr15:77711686	NA	-0.65	-4.86	-0.45	4.71e-6	Glucose homeostasis traits;
THYM	cis	rs12410462	0.681	rs12401677	chr1:227608577	T/C	cg23173402	chr1:227635558	NA	0.75	6.06	0.53	2.72e-8	Major depressive disorder;
THYM	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.76	-6.05	-0.53	2.89e-8	Chronic sinus infection;
THYM	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs6980334	1.000	rs13243992	chr7:137784790	C/T	cg22979093	chr7:137028410	PTN	0.61	4.91	0.45	3.77e-6	Blood metabolite ratios;
THYM	cis	rs6570726	0.905	rs442435	chr6:145815559	C/T	cg23711669	chr6:146136114	FBXO30	0.77	7.34	0.6	7.09e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9486719	0.656	rs4839826	chr6:96853616	A/G	cg18709589	chr6:96969512	KIAA0776	-0.67	-4.7	-0.43	8.84e-6	Migraine;Coronary artery disease;
THYM	cis	rs929596	0.561	rs7564935	chr2:234645186	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.94	-8.01	-0.63	2.87e-12	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs7084402	0.967	rs12261597	chr10:60297662	T/C	cg07615347	chr10:60278583	BICC1	-0.56	-5.21	-0.47	1.09e-6	Refractive error;
THYM	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg18904891	chr8:8559673	CLDN23	0.6	5.1	0.46	1.77e-6	Joint mobility (Beighton score);
THYM	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg21862992	chr11:68658383	NA	0.24	4.46	0.42	2.23e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg20503657	chr10:835505	NA	1.13	8.02	0.64	2.78e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg00256281	chr22:41985642	PMM1	0.63	4.86	0.45	4.67e-6	Vitiligo;
THYM	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg03388043	chr17:80084554	CCDC57	0.66	5.54	0.49	2.66e-7	Life satisfaction;
THYM	cis	rs10457678	0.564	rs2327900	chr6:139109784	T/C	cg05131254	chr6:138188363	TNFAIP3	0.63	4.45	0.42	2.33e-5	Colorectal or endometrial cancer;
THYM	cis	rs3204270	0.683	rs13372	chr17:79617705	G/A	cg18367735	chr17:79674897	NA	0.75	4.51	0.42	1.87e-5	Dental caries;
THYM	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg22920501	chr2:26401640	FAM59B	-1.04	-9.12	-0.68	1.26e-14	Gut microbiome composition (summer);
THYM	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg04362960	chr10:104952993	NT5C2	0.58	4.75	0.44	7.17e-6	Arsenic metabolism;
THYM	cis	rs17253792	0.822	rs13379340	chr14:56050346	C/G	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs9467711	0.790	rs17598658	chr6:26175866	A/C	cg16898833	chr6:26189333	HIST1H4D	1.28	4.86	0.45	4.61e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg08859206	chr1:53392774	SCP2	0.43	4.48	0.42	2.05e-5	Monocyte count;
THYM	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg00277334	chr10:82204260	NA	-0.83	-10.18	-0.72	6.99e-17	Post bronchodilator FEV1;
THYM	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg27398817	chr8:82754497	SNX16	-0.71	-6.05	-0.53	2.89e-8	Diastolic blood pressure;
THYM	cis	rs9905704	0.836	rs12952429	chr17:56843070	C/T	cg12560992	chr17:57184187	TRIM37	0.64	4.5	0.42	1.93e-5	Testicular germ cell tumor;
THYM	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg11526020	chr17:80870163	TBCD	0.43	4.67	0.43	9.74e-6	Breast cancer;
THYM	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg22590775	chr19:49891494	CCDC155	0.83	6.89	0.58	5.97e-10	Multiple sclerosis;
THYM	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg01416388	chr22:39784598	NA	0.9	7.88	0.63	5.33e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7104764	1.000	rs7481993	chr11:237875	C/T	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg24209194	chr3:40518798	ZNF619	0.61	4.79	0.44	6.14e-6	Renal cell carcinoma;
THYM	cis	rs9527	0.615	rs7917295	chr10:104701187	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-4.62	-0.43	1.2e-5	Arsenic metabolism;
THYM	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg04865290	chr3:52927548	TMEM110	-0.96	-5.03	-0.46	2.34e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg04546413	chr19:29218101	NA	1.09	9.4	0.69	3.15e-15	Methadone dose in opioid dependence;
THYM	cis	rs4919087	1.000	rs7067835	chr10:99074649	T/C	cg19453742	chr10:98862320	SLIT1	-0.62	-4.86	-0.45	4.69e-6	Monocyte count;
THYM	cis	rs4430311	0.723	rs7551241	chr1:243943907	A/G	cg25706552	chr1:244017396	NA	-0.56	-4.97	-0.45	2.93e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg14018140	chr10:458528	DIP2C	-0.61	-7.15	-0.59	1.76e-10	Psychosis in Alzheimer's disease;
THYM	trans	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Bladder cancer;
THYM	cis	rs782590	0.517	rs13013133	chr2:55889466	G/A	cg03859395	chr2:55845619	SMEK2	-0.52	-4.56	-0.42	1.55e-5	Metabolic syndrome;
THYM	cis	rs854765	0.624	rs11657423	chr17:17728574	T/C	cg04398451	chr17:18023971	MYO15A	0.83	7.58	0.61	2.24e-11	Total body bone mineral density;
THYM	cis	rs17534004	1.000	rs35955426	chr13:31471381	A/G	cg00367615	chr13:31480979	C13orf33	0.66	4.76	0.44	7.05e-6	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs2806561	0.729	rs35919647	chr1:23326072	C/T	cg12483005	chr1:23474871	LUZP1	-0.51	-4.58	-0.43	1.4e-5	Height;
THYM	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg26149184	chr10:133730230	NA	0.77	4.65	0.43	1.07e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg13852791	chr20:30311386	BCL2L1	0.93	7.14	0.59	1.83e-10	Mean corpuscular hemoglobin;
THYM	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg16524936	chr4:1340807	KIAA1530	-0.64	-4.68	-0.43	9.5e-6	Longevity;
THYM	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg03060546	chr3:49711283	APEH	-0.72	-5.77	-0.51	9.81e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	5.77	0.51	1e-7	Obesity-related traits;
THYM	cis	rs2371030	1.000	rs10184528	chr2:211575134	A/T	cg18417063	chr2:211583084	NA	-0.53	-4.57	-0.42	1.48e-5	Non-small cell lung cancer;
THYM	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg17054759	chr22:49844102	NA	-0.52	-4.71	-0.44	8.39e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9364687	0.664	rs9346960	chr6:163885290	C/T	cg01639524	chr6:163818125	NA	0.46	4.48	0.42	2.06e-5	Body mass index;
THYM	cis	rs2455799	0.613	rs2654654	chr3:15789242	C/T	cg16303742	chr3:15540471	COLQ	-0.56	-5.73	-0.51	1.18e-7	Mean platelet volume;
THYM	cis	rs6032067	1.000	rs2233896	chr20:43850400	C/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.5	-0.49	3.14e-7	Blood protein levels;
THYM	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg20891283	chr12:69753455	YEATS4	0.73	5.98	0.52	3.92e-8	Blood protein levels;
THYM	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg24675056	chr1:15929824	NA	0.73	5.9	0.52	5.62e-8	Systolic blood pressure;
THYM	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.09	0.64	1.96e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg18512352	chr11:47633146	NA	0.5	6.42	0.55	5.46e-9	Subjective well-being;
THYM	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg08213375	chr14:104286397	PPP1R13B	0.52	6.23	0.54	1.25e-8	Schizophrenia;
THYM	cis	rs6960043	0.683	rs10278686	chr7:15031450	C/T	cg19272540	chr7:15055459	NA	0.54	6.22	0.54	1.31e-8	Type 2 diabetes;
THYM	cis	rs9660180	0.967	rs6687065	chr1:1778469	A/G	cg20999797	chr1:1681921	NA	0.5	5.51	0.49	3.1e-7	Body mass index;
THYM	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg18252515	chr7:66147081	NA	-0.61	-4.5	-0.42	1.9e-5	Aortic root size;
THYM	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg08045932	chr20:61659980	NA	0.85	7.67	0.62	1.48e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6570726	0.905	rs452770	chr6:145847162	T/C	cg23711669	chr6:146136114	FBXO30	0.9	9.23	0.69	7.15e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg08305652	chr11:111469057	NA	-0.53	-4.51	-0.42	1.87e-5	Primary sclerosing cholangitis;
THYM	cis	rs9372253	0.645	rs7753212	chr6:110700229	T/C	cg00083206	chr6:110721305	DDO	-0.49	-5.62	-0.5	1.94e-7	Platelet distribution width;
THYM	cis	rs4731207	0.564	rs6967420	chr7:124609360	C/T	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs5769765	1.000	rs5770755	chr22:50280136	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-4.98	-0.46	2.81e-6	Schizophrenia;
THYM	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg19506201	chr17:79936561	ASPSCR1	-0.51	-4.53	-0.42	1.69e-5	Glycated hemoglobin levels;
THYM	cis	rs7511006	0.859	rs7292228	chr22:50649560	C/G	cg16294310	chr22:50629110	TRABD	0.65	5.04	0.46	2.23e-6	Obesity-related traits;
THYM	cis	rs2235649	0.833	rs9929185	chr16:1852070	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.62	-5.39	-0.48	5.21e-7	Blood metabolite levels;
THYM	cis	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg09307838	chr4:120376055	NA	0.62	4.46	0.42	2.24e-5	Corneal astigmatism;
THYM	cis	rs9790314	0.967	rs1382427	chr3:161032576	T/C	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg06028808	chr11:68637592	NA	0.68	7.24	0.6	1.18e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2016266	0.787	rs61928080	chr12:53752204	G/A	cg26875137	chr12:53738046	NA	-0.69	-4.88	-0.45	4.34e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs6815814	0.950	rs56289835	chr4:38811845	G/C	cg02016764	chr4:38805732	TLR1	-0.57	-5.49	-0.49	3.41e-7	Breast cancer;
THYM	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg10523679	chr1:76189770	ACADM	0.9	9.47	0.7	2.2e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg21775007	chr8:11205619	TDH	-0.73	-5.68	-0.5	1.49e-7	Retinal vascular caliber;
THYM	cis	rs425277	1.000	rs55826501	chr1:2059143	G/A	cg00981070	chr1:2046702	PRKCZ	0.47	5.28	0.48	8.31e-7	Height;
THYM	cis	rs9875589	0.509	rs1586514	chr3:14050157	G/A	cg03204825	chr3:13978759	TPRXL	-0.55	-4.78	-0.44	6.32e-6	Ovarian reserve;
THYM	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg17264618	chr3:40429014	ENTPD3	-0.52	-5.11	-0.46	1.66e-6	Renal cell carcinoma;
THYM	trans	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg10856724	chr12:34555212	NA	-1.01	-9.23	-0.69	7.34e-15	Bladder cancer;
THYM	cis	rs995000	0.931	rs1168018	chr1:63001120	A/C	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs7731657	0.537	rs10478956	chr5:130318514	C/G	cg08523029	chr5:130500466	HINT1	0.84	6.14	0.53	1.87e-8	Fasting plasma glucose;
THYM	cis	rs4343996	0.747	rs1403158	chr7:3464896	A/G	cg21248987	chr7:3385318	SDK1	0.39	4.69	0.43	9e-6	Motion sickness;
THYM	cis	rs7666738	0.962	rs17550217	chr4:98999699	T/A	cg03467027	chr4:99064603	C4orf37	0.59	4.5	0.42	1.92e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs877282	0.947	rs7923867	chr10:768094	G/A	cg22713356	chr15:30763199	NA	1.38	11.2	0.75	4.69e-19	Uric acid levels;
THYM	cis	rs2219968	0.962	rs4380933	chr8:78944192	A/G	cg00738934	chr8:78996279	NA	0.79	8.42	0.65	3.88e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs16866061	1.000	rs72972378	chr2:225372562	A/G	cg12698349	chr2:225449008	CUL3	1.1	9.52	0.7	1.78e-15	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs2067615	0.560	rs1882542	chr12:107070049	A/C	cg15890332	chr12:107067104	RFX4	0.5	5.77	0.51	9.73e-8	Heart rate;
THYM	cis	rs9902453	1.000	rs12600855	chr17:28279591	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.81	0.44	5.74e-6	Coffee consumption (cups per day);
THYM	cis	rs2625529	0.824	rs16953769	chr15:72463325	G/A	cg16672083	chr15:72433130	SENP8	-0.56	-5.04	-0.46	2.2e-6	Red blood cell count;
THYM	cis	rs747334	0.811	rs7099671	chr10:92719727	G/A	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs863345	0.604	rs7518808	chr1:158491820	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg06636551	chr8:101224915	SPAG1	-0.67	-6.52	-0.56	3.36e-9	Atrioventricular conduction;
THYM	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg03060546	chr3:49711283	APEH	-0.74	-6.21	-0.54	1.42e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg19847130	chr8:10466454	RP1L1	0.5	4.75	0.44	7.15e-6	Neuroticism;
THYM	cis	rs7705502	1.000	rs72812832	chr5:173372625	G/A	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg14349672	chr11:133703707	NA	-0.52	-4.85	-0.45	4.92e-6	Childhood ear infection;
THYM	cis	rs7626444	0.584	rs844542	chr3:196479303	C/T	cg12930392	chr3:196481615	PAK2	0.4	4.92	0.45	3.58e-6	Monocyte count;
THYM	cis	rs1994135	0.647	rs66542958	chr12:33695385	T/G	cg10856724	chr12:34555212	NA	-0.74	-5.54	-0.49	2.74e-7	Resting heart rate;
THYM	cis	rs9660180	0.868	rs72634846	chr1:1704915	C/G	cg17747265	chr1:1875780	NA	-0.8	-9.17	-0.69	9.98e-15	Body mass index;
THYM	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg07570687	chr10:102243282	WNT8B	0.76	6.93	0.58	5.03e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg03709012	chr19:19516395	GATAD2A	0.74	5.71	0.51	1.31e-7	Tonsillectomy;
THYM	cis	rs6732160	0.932	rs6546803	chr2:73381315	C/G	cg24220031	chr2:73402428	NA	-0.65	-6.38	-0.55	6.44e-9	Intelligence (multi-trait analysis);
THYM	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg02953382	chr22:24373134	LOC391322	-0.7	-6.21	-0.54	1.42e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4148689	0.951	rs957461	chr7:117172257	G/A	cg17204129	chr7:117119601	CFTR	-0.62	-4.79	-0.44	6.23e-6	Gout;
THYM	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg02038168	chr22:39784481	NA	-0.66	-5.56	-0.5	2.49e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3820068	0.608	rs2057304	chr1:16017710	A/G	cg05660106	chr1:15850417	CASP9	0.72	5.61	0.5	1.95e-7	Systolic blood pressure;
THYM	cis	rs11785693	0.909	rs62489557	chr8:4968371	A/G	cg26367366	chr8:4980734	NA	1.16	5.47	0.49	3.64e-7	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs1451375	1.000	rs1451375	chr7:50622712	A/C	cg18232548	chr7:50535776	DDC	-0.73	-5.57	-0.5	2.35e-7	Malaria;
THYM	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg24163568	chr5:669837	TPPP	0.6	5.57	0.5	2.32e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs2133450	0.526	rs17047062	chr3:7343383	A/G	cg19930620	chr3:7340148	GRM7	-0.5	-5.46	-0.49	3.72e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs4242434	0.672	rs4615566	chr8:22520682	T/C	cg11461670	chr8:22454935	PDLIM2	0.33	6.04	0.53	2.96e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg22968622	chr17:43663579	NA	-0.82	-7.04	-0.59	2.97e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg23711669	chr6:146136114	FBXO30	0.97	10.49	0.73	1.45e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg23649088	chr2:200775458	C2orf69	-0.78	-6.58	-0.56	2.54e-9	Schizophrenia;
THYM	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg05872129	chr22:39784769	NA	0.99	11.48	0.76	1.2e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg08847533	chr14:75593920	NEK9	-0.94	-9.85	-0.71	3.49e-16	Height;
THYM	cis	rs4631830	0.863	rs6481329	chr10:51529746	G/A	cg10326726	chr10:51549505	MSMB	-0.55	-5.57	-0.5	2.32e-7	Prostate-specific antigen levels;
THYM	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs6669072	0.679	rs1766162	chr1:91313066	C/T	cg08895590	chr1:91227319	NA	0.51	5.81	0.51	8.11e-8	Cognitive function;
THYM	cis	rs977987	0.966	rs8055490	chr16:75497135	C/T	cg03315344	chr16:75512273	CHST6	0.7	5.71	0.51	1.3e-7	Dupuytren's disease;
THYM	cis	rs2075230	0.705	rs1642808	chr17:7545464	G/C	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.74	-0.44	7.55e-6	Hormone measurements;
THYM	cis	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg09307838	chr4:120376055	NA	0.73	5.51	0.49	3.11e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.92	0.45	3.58e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11225247	0.649	rs11605087	chr11:102225219	C/T	cg11690896	chr11:102217788	BIRC2	1.18	4.71	0.44	8.31e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26314531	chr2:26401878	FAM59B	0.78	5.13	0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.69	6.15	0.53	1.82e-8	Personality dimensions;
THYM	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.49	0.42	1.97e-5	Diabetic retinopathy;
THYM	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg16586182	chr3:47516702	SCAP	-0.61	-5.25	-0.47	9.2e-7	Colorectal cancer;
THYM	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.34	-0.65	5.7e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg24060327	chr5:131705240	SLC22A5	0.76	5.58	0.5	2.26e-7	Blood metabolite levels;
THYM	cis	rs4499344	0.531	rs863905	chr19:33146403	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.75	5.58	0.5	2.26e-7	Mean platelet volume;
THYM	cis	rs977102	0.556	rs4856846	chr3:67356977	G/A	cg06096184	chr3:66549732	LRIG1	0.66	4.6	0.43	1.32e-5	Response to amphetamines;
THYM	cis	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg12981288	chr8:11183844	MTMR9	0.45	4.48	0.42	2.09e-5	Retinal vascular caliber;
THYM	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.6	4.51	0.42	1.84e-5	Renal function-related traits (BUN);
THYM	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg12893697	chr11:970389	AP2A2	-0.31	-5.21	-0.47	1.1e-6	Alzheimer's disease (late onset);
THYM	cis	rs4243830	0.850	rs1010584	chr1:6579843	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.08	-7.53	-0.61	2.9100000000000002e-11	Body mass index;
THYM	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg00631329	chr6:26305371	NA	-0.49	-5.05	-0.46	2.12e-6	Educational attainment;
THYM	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg08859206	chr1:53392774	SCP2	-0.73	-8.24	-0.65	9.39e-13	Monocyte count;
THYM	cis	rs12765878	0.812	rs2475214	chr10:105660986	T/C	cg11005552	chr10:105648138	OBFC1	-0.62	-5.93	-0.52	4.78e-8	Coronary artery disease;
THYM	cis	rs4631830	0.720	rs2012677	chr10:51504797	T/A	cg16070123	chr10:51489643	NA	-0.52	-4.8	-0.44	5.87e-6	Prostate-specific antigen levels;
THYM	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg11266682	chr4:10021025	SLC2A9	0.76	12.85	0.8	1.71e-22	Bone mineral density;
THYM	cis	rs12530845	1.000	rs78186690	chr7:135334991	G/C	cg23117316	chr7:135346802	PL-5283	-0.66	-5.88	-0.52	6.21e-8	Red blood cell traits;
THYM	cis	rs9649213	0.593	rs6944262	chr7:97985415	T/G	cg09267113	chr7:98030324	BAIAP2L1	0.52	4.62	0.43	1.19e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6586111	0.647	rs76120037	chr10:82371930	C/G	cg03086067	chr10:82368399	SH2D4B	-0.64	-8.74	-0.67	8e-14	Capecitabine sensitivity;
THYM	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg10589385	chr1:150898437	SETDB1	0.65	5.45	0.49	4.01e-7	Melanoma;
THYM	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg06360820	chr2:242988706	NA	-0.97	-6.78	-0.57	1.01e-9	Obesity-related traits;
THYM	cis	rs12681287	0.752	rs10100235	chr8:87249294	A/G	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs1011018	0.955	rs12703062	chr7:139419104	T/C	cg06079564	chr7:139468310	HIPK2	-0.73	-5.52	-0.49	2.93e-7	Systolic blood pressure;
THYM	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg03609598	chr5:56110824	MAP3K1	-0.89	-6.13	-0.53	2e-8	Initial pursuit acceleration;
THYM	cis	rs939658	0.967	rs11629665	chr15:79457133	C/T	cg17916960	chr15:79447300	NA	0.72	8.61	0.66	1.51e-13	Refractive error;
THYM	cis	rs6450176	0.909	rs3776721	chr5:53292522	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-6.61	-0.56	2.22e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs863345	0.604	rs12044288	chr1:158463863	C/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs5769707	0.642	rs4824070	chr22:50031521	T/C	cg20744362	chr22:50050164	C22orf34	0.76	6.85	0.58	7.15e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs757081	0.667	rs34724588	chr11:17137581	T/C	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.6	-0.43	1.29e-5	Systolic blood pressure;
THYM	cis	rs13418717	0.793	rs3795874	chr2:127656383	A/G	cg25501666	chr2:127640322	NA	1.37	6.76	0.57	1.12e-9	Heart failure;
THYM	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg05340658	chr4:99064831	C4orf37	0.54	4.46	0.42	2.22e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7100689	0.725	rs10749574	chr10:82136856	T/C	cg01528321	chr10:82214614	TSPAN14	0.97	7.37	0.6	6.38e-11	Post bronchodilator FEV1;
THYM	cis	rs9807989	0.801	rs10176664	chr2:102976172	G/A	cg03938978	chr2:103052716	IL18RAP	0.63	6.55	0.56	2.99e-9	Asthma;
THYM	cis	rs1198430	0.759	rs1198427	chr1:23752898	G/C	cg19827787	chr1:23763612	ASAP3	0.58	4.6	0.43	1.32e-5	Total cholesterol levels;
THYM	cis	rs6127978	0.702	rs4811828	chr20:55809047	T/C	cg15851418	chr20:55835831	BMP7	0.68	4.89	0.45	4.12e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs4638749	0.680	rs12612935	chr2:108818409	A/G	cg06795125	chr2:108905320	SULT1C2	-0.57	-6.42	-0.55	5.37e-9	Blood pressure;
THYM	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg17063962	chr7:91808500	NA	1.08	11.35	0.76	2.25e-19	Breast cancer;
THYM	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.03	9.77	0.71	5.25e-16	Colorectal cancer;
THYM	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg03405983	chr8:143858548	LYNX1	-0.55	-6.02	-0.53	3.33e-8	Urinary tract infection frequency;
THYM	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg06766960	chr11:133703094	NA	-0.6	-5.5	-0.49	3.19e-7	Childhood ear infection;
THYM	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs4654899	0.897	rs7548649	chr1:21090081	A/G	cg01072550	chr1:21505969	NA	-0.61	-5.27	-0.48	8.41e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg00083206	chr6:110721305	DDO	-0.54	-5.83	-0.51	7.67e-8	Platelet distribution width;
THYM	cis	rs72627123	0.867	rs73301493	chr14:74472197	C/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs916888	0.647	rs199517	chr17:44854587	A/G	cg01570182	chr17:44337453	NA	-0.66	-7.17	-0.59	1.62e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2455799	0.593	rs2047852	chr3:15732539	T/G	cg16303742	chr3:15540471	COLQ	-0.53	-5.54	-0.49	2.74e-7	Mean platelet volume;
THYM	cis	rs7107174	1.000	rs1893447	chr11:77973182	A/G	cg02023728	chr11:77925099	USP35	0.67	6.08	0.53	2.45e-8	Testicular germ cell tumor;
THYM	cis	rs12594515	1.000	rs12595137	chr15:45986105	G/T	cg01629716	chr15:45996671	NA	0.54	5.52	0.49	2.91e-7	Waist circumference;Weight;
THYM	cis	rs4901869	0.966	rs9972208	chr14:59336116	C/T	cg02291164	chr14:59296302	NA	0.8	7.85	0.63	6.35e-12	Panic disorder;
THYM	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg08645402	chr16:4508243	NA	-0.78	-7.73	-0.62	1.09e-11	Schizophrenia;
THYM	cis	rs2108622	0.727	rs3093207	chr19:15988658	T/C	cg13772218	chr19:15982569	NA	0.5	4.48	0.42	2.06e-5	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg10856724	chr12:34555212	NA	-0.79	-7.37	-0.6	6.29e-11	Morning vs. evening chronotype;
THYM	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg20295408	chr7:1910781	MAD1L1	-0.68	-5.09	-0.46	1.78e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9420	0.961	rs7121169	chr11:57452543	G/A	cg19752551	chr11:57585705	CTNND1	-0.73	-8.02	-0.64	2.79e-12	Schizophrenia;
THYM	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg18105134	chr13:113819100	PROZ	-1.12	-10.05	-0.72	1.28e-16	Platelet distribution width;
THYM	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	7.1	0.59	2.3e-10	Platelet count;
THYM	cis	rs2282930	0.512	rs2282929	chr7:50720335	A/G	cg08586669	chr7:50727761	GRB10	0.3	4.55	0.42	1.56e-5	Bone mineral density;
THYM	cis	rs17174870	0.955	rs75508922	chr2:112688397	G/T	cg17354880	chr2:112658759	MERTK	-0.61	-4.56	-0.42	1.5e-5	Multiple sclerosis;
THYM	cis	rs990171	0.955	rs4241210	chr2:103078740	G/A	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.13	-0.47	1.56e-6	Lymphocyte counts;
THYM	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg19346786	chr7:2764209	NA	-0.71	-6.02	-0.53	3.21e-8	Height;
THYM	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg15704280	chr7:45808275	SEPT13	-1.08	-13.87	-0.82	1.48e-24	Height;
THYM	cis	rs6988636	1.000	rs16898088	chr8:124190501	G/A	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg06623918	chr6:96969491	KIAA0776	1.09	9.94	0.71	2.21e-16	Headache;
THYM	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.07	-7.5	-0.61	3.41e-11	Platelet count;
THYM	cis	rs4363385	0.510	rs61811886	chr1:153035743	G/A	cg13444842	chr1:152974279	SPRR3	-0.61	-4.72	-0.44	7.97e-6	Inflammatory skin disease;
THYM	cis	rs490234	0.683	rs9409281	chr9:128159171	C/G	cg14078157	chr9:128172775	NA	-0.84	-6.98	-0.58	4e-10	Mean arterial pressure;
THYM	cis	rs72827839	0.748	rs72833470	chr17:45950721	A/G	cg23391107	chr17:45924227	SP6	0.72	5.38	0.48	5.3e-7	Ease of getting up in the morning;
THYM	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg16586182	chr3:47516702	SCAP	-0.6	-5.16	-0.47	1.34e-6	Colorectal cancer;
THYM	cis	rs7193541	0.694	rs3896277	chr16:74480694	A/T	cg01733217	chr16:74700730	RFWD3	0.84	8.1	0.64	1.84e-12	Multiple myeloma;
THYM	cis	rs853679	1.000	rs853685	chr6:28288785	C/T	cg17849569	chr6:28058911	ZSCAN12L1	0.73	4.57	0.42	1.46e-5	Depression;
THYM	cis	rs986417	1.000	rs4901985	chr14:60948318	A/C	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs34638657	0.732	rs2911425	chr16:82203026	T/C	cg07307142	chr16:82071433	HSD17B2	-0.88	-7.6	-0.61	2.11e-11	Lung adenocarcinoma;
THYM	cis	rs12579753	1.000	rs11115017	chr12:82176914	C/A	cg21231944	chr12:82153410	PPFIA2	-0.68	-5.17	-0.47	1.3e-6	Resting heart rate;
THYM	cis	rs34638657	0.797	rs7203990	chr16:82185320	A/G	cg07307142	chr16:82071433	HSD17B2	-1.05	-8.46	-0.66	3.23e-13	Lung adenocarcinoma;
THYM	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg01073479	chr16:3509474	NAT15	-0.56	-5.36	-0.48	5.91e-7	Tuberculosis;
THYM	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs910187	0.605	rs6063080	chr20:45805091	G/A	cg27589058	chr20:45804311	EYA2	-0.68	-6.04	-0.53	3.03e-8	Migraine;
THYM	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7786808	0.552	rs12539355	chr7:158187565	C/T	cg15440763	chr7:158190612	PTPRN2	0.49	4.61	0.43	1.24e-5	Obesity-related traits;
THYM	cis	rs2073300	0.609	rs2281434	chr20:23378101	C/A	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs747334	0.791	rs7916859	chr10:92730932	C/T	cg07620928	chr10:92689909	NA	0.62	5.4	0.48	4.82e-7	Fibroblast growth factor basic levels;
THYM	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg10792982	chr14:105748885	BRF1	0.7	7.04	0.59	2.92e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg26384229	chr12:38710491	ALG10B	0.97	7.47	0.61	3.8e-11	Drug-induced liver injury (flucloxacillin);
THYM	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg04842962	chr6:43655489	MRPS18A	1.4	15.48	0.85	1.01e-27	IgG glycosylation;
THYM	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03264133	chr6:25882463	NA	-0.81	-6.69	-0.57	1.5e-9	Intelligence (multi-trait analysis);
THYM	cis	rs2072499	0.932	rs2540183	chr1:156164885	C/G	cg25208724	chr1:156163844	SLC25A44	1.16	12.72	0.79	3.19e-22	Testicular germ cell tumor;
THYM	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg06238570	chr21:40685208	BRWD1	-0.95	-8.85	-0.67	4.7e-14	Cognitive function;
THYM	cis	rs2479106	0.727	rs2159793	chr9:126701763	T/C	cg16191174	chr9:126692580	DENND1A	0.71	4.5	0.42	1.92e-5	Polycystic ovary syndrome;
THYM	trans	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg25214090	chr10:38739885	LOC399744	0.83	7.11	0.59	2.14e-10	Corneal astigmatism;
THYM	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg21427119	chr20:30132790	HM13	-0.82	-5.5	-0.49	3.19e-7	Mean corpuscular hemoglobin;
THYM	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg17264618	chr3:40429014	ENTPD3	-0.53	-5.15	-0.47	1.38e-6	Renal cell carcinoma;
THYM	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg07837209	chr13:79184101	NA	-0.8	-5.06	-0.46	2.01e-6	Large artery stroke;
THYM	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs747782	0.528	rs4370963	chr11:48433943	C/G	cg24672777	chr11:48374446	OR4C45	-1.16	-7.24	-0.6	1.16e-10	Intraocular pressure;
THYM	cis	rs992157	0.798	rs2382819	chr2:219155909	G/T	cg00012203	chr2:219082015	ARPC2	-0.69	-5.69	-0.5	1.43e-7	Colorectal cancer;
THYM	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs4363385	0.818	rs3820141	chr1:153004778	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	12.1	0.78	6.07e-21	Height;
THYM	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg06238570	chr21:40685208	BRWD1	0.88	6.33	0.54	7.97e-9	Cognitive function;
THYM	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg10852096	chr15:79043040	NA	-0.64	-4.47	-0.42	2.16e-5	Coronary artery disease or large artery stroke;
THYM	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.71	-7.66	-0.62	1.54e-11	Crohn's disease;
THYM	trans	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg05926928	chr17:57297772	GDPD1	1.26	10.02	0.72	1.5e-16	Opioid sensitivity;
THYM	cis	rs2797160	1.000	rs926853	chr6:126021435	A/T	cg16306078	chr6:126000798	NA	0.52	5.31	0.48	7.3e-7	Endometrial cancer;
THYM	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg06074448	chr4:187884817	NA	-1.0	-13.81	-0.82	1.9e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9296092	0.538	rs7761464	chr6:33519417	C/A	cg13560919	chr6:33536144	NA	-0.95	-9.43	-0.7	2.72e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg13390004	chr1:15929781	NA	0.63	4.77	0.44	6.76e-6	Systolic blood pressure;
THYM	cis	rs2046867	0.908	rs9841994	chr3:72820503	A/C	cg25664220	chr3:72788482	NA	-0.81	-6.15	-0.53	1.81e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg00024416	chr22:24240387	NA	0.68	7.08	0.59	2.47e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg04990556	chr1:26633338	UBXN11	-0.87	-7.92	-0.63	4.4e-12	Obesity-related traits;
THYM	cis	rs13064411	0.735	rs9875025	chr3:113147552	T/C	cg10517650	chr3:113235015	CCDC52	-0.57	-4.96	-0.45	3.13e-6	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg08975724	chr8:8085496	FLJ10661	-0.67	-4.97	-0.45	2.96e-6	Neuroticism;
THYM	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs10979	1.000	rs9399448	chr6:143896315	G/T	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg12334488	chr2:20871173	GDF7	-0.71	-6.52	-0.56	3.38e-9	Abdominal aortic aneurysm;
THYM	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg22841779	chr14:105766346	BRF1	-0.47	-5.88	-0.52	6.12e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9733	0.596	rs72702523	chr1:150650425	G/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs5758511	0.680	rs5751243	chr22:42617177	T/C	cg22189786	chr22:42395067	WBP2NL	0.48	4.46	0.42	2.28e-5	Birth weight;
THYM	cis	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg12963246	chr6:28129442	ZNF389	0.72	5.1	0.46	1.73e-6	Depression;
THYM	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg06784218	chr1:46089804	CCDC17	-0.32	-4.77	-0.44	6.73e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs12142240	0.698	rs17357711	chr1:46829013	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7177699	0.557	rs9920968	chr15:79118747	G/A	cg15571903	chr15:79123663	NA	0.58	6.75	0.57	1.15e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg18252515	chr7:66147081	NA	0.62	4.55	0.42	1.59e-5	Aortic root size;
THYM	cis	rs7809950	0.773	rs9791733	chr7:107041730	T/C	cg23024343	chr7:107201750	COG5	-0.97	-7.67	-0.62	1.5e-11	Coronary artery disease;
THYM	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg11871910	chr12:69753446	YEATS4	1.06	9.77	0.71	5.12e-16	Blood protein levels;
THYM	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg06766960	chr11:133703094	NA	-0.52	-4.83	-0.44	5.25e-6	Childhood ear infection;
THYM	cis	rs9948	1.000	rs59244622	chr2:97501632	C/T	cg01990225	chr2:97406019	LMAN2L	-0.91	-4.69	-0.43	9.26e-6	Erectile dysfunction and prostate cancer treatment;
THYM	cis	rs4642101	0.793	rs12714880	chr3:12832101	G/A	cg11882607	chr3:12858926	CAND2	-0.4	-4.52	-0.42	1.76e-5	QRS complex (12-leadsum);
THYM	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg00383909	chr3:49044727	WDR6	1.03	5.9	0.52	5.64e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg18477163	chr1:228402036	OBSCN	-0.46	-5.0	-0.46	2.64e-6	Diastolic blood pressure;
THYM	cis	rs7584330	0.657	rs10202599	chr2:238352465	A/C	cg16989719	chr2:238392110	NA	-0.57	-5.08	-0.46	1.91e-6	Prostate cancer;
THYM	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg17063962	chr7:91808500	NA	-1.11	-11.73	-0.77	3.52e-20	Breast cancer;
THYM	trans	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs2639990	0.744	rs640261	chr18:72905808	C/T	cg18449964	chr18:72917101	ZADH2	1.29	6.0	0.52	3.55e-8	Vascular endothelial growth factor levels;
THYM	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8106657	1.000	rs2335525	chr19:7785713	A/G	cg12105671	chr19:7852207	CLEC4GP1	-0.4	-4.96	-0.45	3.03e-6	Blood protein levels;
THYM	cis	rs9876781	1.000	rs7636782	chr3:48421387	G/T	cg06066452	chr3:48470258	PLXNB1	0.25	4.62	0.43	1.22e-5	Longevity;
THYM	cis	rs6089829	0.962	rs2314131	chr20:61665225	A/G	cg08045932	chr20:61659980	NA	0.83	7.63	0.62	1.78e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.93	-4.79	-0.44	6.14e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4455778	0.580	rs4551289	chr7:49112437	G/T	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6882076	1.000	rs12657266	chr5:156396003	C/T	cg12943317	chr5:156479607	HAVCR1	-0.72	-5.96	-0.52	4.36e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg06766960	chr11:133703094	NA	0.58	4.91	0.45	3.84e-6	Childhood ear infection;
THYM	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg05025164	chr4:1340916	KIAA1530	0.9	6.86	0.58	6.98e-10	Longevity;
THYM	cis	rs1499972	0.938	rs861001	chr3:117720355	C/T	cg07612923	chr3:117604196	NA	1.5	5.16	0.47	1.38e-6	Schizophrenia;
THYM	cis	rs9470366	0.637	rs730506	chr6:36645968	G/C	cg24425727	chr6:36645648	CDKN1A	-0.64	-4.69	-0.43	9.01e-6	QRS duration;
THYM	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.77	-6.42	-0.55	5.46e-9	Systemic lupus erythematosus;
THYM	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg18755752	chr8:142205143	DENND3	-0.78	-7.59	-0.61	2.17e-11	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs554111	0.634	rs12026318	chr1:21316623	T/C	cg00373020	chr1:21041521	KIF17	-0.53	-4.47	-0.42	2.14e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	5.03	0.46	2.33e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08109568	chr15:31115862	NA	0.72	6.68	0.57	1.58e-9	Huntington's disease progression;
THYM	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg24692254	chr21:30365293	RNF160	0.99	9.28	0.69	5.71e-15	Dental caries;
THYM	cis	rs250585	0.736	rs250584	chr16:23403031	A/T	cg00143387	chr16:23521605	GGA2	0.67	4.59	0.43	1.34e-5	Egg allergy;
THYM	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg00475322	chr7:917719	C7orf20	0.59	7.88	0.63	5.46e-12	Perceived unattractiveness to mosquitoes;
THYM	cis	rs2483374	0.527	rs9507423	chr13:25436257	T/C	cg14860438	chr13:24731302	NA	-0.54	-4.66	-0.43	1.03e-5	Obesity-related traits;
THYM	cis	rs11822910	0.815	rs12422015	chr11:57193653	A/G	cg00522883	chr11:57194120	SLC43A3	0.65	4.9	0.45	3.92e-6	Platelet distribution width;
THYM	cis	rs3768617	0.510	rs1886501	chr1:183095234	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs59698941	0.943	rs67860107	chr5:132276825	G/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.63	4.74	0.44	7.44e-6	Apolipoprotein A-IV levels;
THYM	cis	rs11096990	0.855	rs3796524	chr4:39195987	A/G	cg24403649	chr4:39172243	NA	-0.65	-5.47	-0.49	3.69e-7	Cognitive function;
THYM	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg26384229	chr12:38710491	ALG10B	-0.72	-5.79	-0.51	8.96e-8	Morning vs. evening chronotype;
THYM	cis	rs9814567	0.806	rs2293294	chr3:134322814	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.8	7.87	0.63	5.68e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7107174	0.901	rs866901	chr11:77926309	C/T	cg19901956	chr11:77921274	USP35	-0.8	-6.2	-0.54	1.48e-8	Testicular germ cell tumor;
THYM	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.61	-0.43	1.27e-5	Type 2 diabetes;
THYM	cis	rs4077515	0.934	rs10781507	chr9:139272058	A/G	cg14115884	chr9:139300582	SDCCAG3	0.73	6.92	0.58	5.29e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6754311	0.689	rs192822	chr2:136682274	A/T	cg04750100	chr2:136595281	LCT	0.56	6.2	0.54	1.45e-8	Mosquito bite size;
THYM	cis	rs34526934	0.566	rs35563571	chr2:177044459	T/G	cg14324370	chr2:177042789	NA	-0.72	-6.27	-0.54	1.04e-8	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs3942852	0.868	rs7122335	chr11:48106486	C/T	cg25800328	chr11:47736132	AGBL2	-0.5	-4.77	-0.44	6.72e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg12031863	chr16:4587854	C16orf5	-0.46	-4.96	-0.45	3.09e-6	Schizophrenia;
THYM	cis	rs4589258	1.000	rs10765384	chr11:90484027	A/C	cg26138821	chr11:89956704	CHORDC1	-0.69	-5.52	-0.49	3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg26384229	chr12:38710491	ALG10B	0.97	7.89	0.63	5.19e-12	Bladder cancer;
THYM	cis	rs3916	1.000	rs2014355	chr12:121175524	A/G	cg10600917	chr12:121163489	ACADS	0.57	4.77	0.44	6.57e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs1018836	0.923	rs11784529	chr8:91640956	C/A	cg16814680	chr8:91681699	NA	-0.85	-7.26	-0.6	1.08e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs988913	1.000	rs6902422	chr6:54811210	C/T	cg04690482	chr6:54711388	FAM83B	-0.51	-5.68	-0.5	1.46e-7	Menarche (age at onset);
THYM	cis	rs2430307	0.556	rs3905501	chr7:76542080	C/T	cg15770687	chr7:76625569	PMS2L11	-0.86	-5.9	-0.52	5.63e-8	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	trans	rs10802346	0.545	rs10802347	chr1:246374268	G/A	cg22732515	chr19:44031385	ETHE1	1.05	8.72	0.67	8.78e-14	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs1728785	1.000	rs1645927	chr16:68589300	T/G	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg06028808	chr11:68637592	NA	0.65	6.79	0.57	9.52e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs13256369	0.901	rs12681327	chr8:8566414	G/T	cg00074818	chr8:8560427	CLDN23	0.6	5.47	0.49	3.64e-7	Obesity-related traits;
THYM	cis	rs2933343	0.553	rs71331686	chr3:128711428	T/A	cg11901034	chr3:128598214	ACAD9	-0.64	-4.45	-0.42	2.35e-5	IgG glycosylation;
THYM	cis	rs9486719	0.948	rs2499813	chr6:96875338	T/C	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs56161922	1.000	rs74692669	chr1:207818120	G/C	cg09557387	chr1:207818395	CR1L	1.14	5.09	0.46	1.79e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg07424592	chr7:64974309	NA	1.08	5.16	0.47	1.33e-6	Diabetic kidney disease;
THYM	cis	rs9972944	0.902	rs10512504	chr17:63772091	C/T	cg07283582	chr17:63770753	CCDC46	0.67	5.41	0.49	4.74e-7	Total body bone mineral density;
THYM	cis	rs2361710	0.611	rs12451471	chr17:78102517	C/T	cg04028464	chr17:78073854	GAA;CCDC40	0.73	6.61	0.56	2.21e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
THYM	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg06611532	chr13:114900021	NA	0.63	6.9	0.58	5.85e-10	Schizophrenia;
THYM	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg14584255	chr6:163149320	PACRG;PARK2	0.73	6.38	0.55	6.27e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg05738196	chr6:26577821	NA	0.6	4.91	0.45	3.71e-6	Schizophrenia;
THYM	cis	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg13609457	chr4:120235615	NA	-0.56	-5.24	-0.47	9.65e-7	Corneal astigmatism;
THYM	cis	rs1865721	0.804	rs72977816	chr18:73146779	A/T	cg26385618	chr18:73139727	C18orf62	-0.63	-4.56	-0.42	1.5e-5	Intelligence;
THYM	cis	rs2282300	0.739	rs1222215	chr11:30347596	C/T	cg25418670	chr11:30344373	C11orf46	-0.82	-6.98	-0.58	3.93e-10	Morning vs. evening chronotype;
THYM	cis	rs11096990	0.855	rs2711988	chr4:39152748	C/T	cg24403649	chr4:39172243	NA	-0.6	-5.12	-0.46	1.6e-6	Cognitive function;
THYM	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg20486651	chr6:167070296	RPS6KA2	0.52	4.98	0.45	2.84e-6	Crohn's disease;
THYM	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg11871910	chr12:69753446	YEATS4	1.01	9.87	0.71	3.09e-16	Cerebrospinal fluid biomarker levels;
THYM	cis	rs75920871	0.528	rs1531706	chr11:116943952	C/A	cg20608306	chr11:116969690	SIK3	-0.54	-6.01	-0.52	3.45e-8	Subjective well-being;
THYM	cis	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-5.43	-0.49	4.23e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg13609457	chr4:120235615	NA	0.54	5.0	0.46	2.63e-6	Corneal astigmatism;
THYM	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	trans	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg10856724	chr12:34555212	NA	-0.88	-7.53	-0.61	2.92e-11	Bladder cancer;
THYM	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg03676636	chr4:99064102	C4orf37	0.43	6.09	0.53	2.34e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs34638657	0.500	rs7405197	chr16:82169833	C/A	cg09439754	chr16:82129088	HSD17B2	-0.56	-5.32	-0.48	7.03e-7	Lung adenocarcinoma;
THYM	cis	rs2745959	0.548	rs2745949	chr1:208058183	T/C	cg11195082	chr1:207670065	CR1	-0.55	-4.61	-0.43	1.24e-5	Resting heart rate;
THYM	cis	rs2239547	0.603	rs6805298	chr3:53096552	A/G	cg11645453	chr3:52864694	ITIH4	-0.3	-4.76	-0.44	6.98e-6	Schizophrenia;
THYM	cis	rs28595532	1.000	rs55634130	chr4:119655093	C/T	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2692947	0.696	rs2969490	chr2:96803904	A/G	cg23100626	chr2:96804247	ASTL	0.36	4.97	0.45	3.01e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs7084402	1.000	rs1427202	chr10:60267917	A/T	cg09696939	chr10:60272079	BICC1	0.48	5.58	0.5	2.31e-7	Refractive error;
THYM	cis	rs6674176	0.542	rs3011225	chr1:44319373	G/A	cg15962314	chr1:44399869	ARTN	0.49	4.68	0.43	9.61e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs9900497	0.569	rs2072327	chr17:19651482	G/T	cg22552966	chr17:19620595	SLC47A2	-0.68	-6.0	-0.52	3.62e-8	Response to paliperidone in schizophrenia (CGI-S score);
THYM	cis	rs7246967	0.608	rs453175	chr19:23014087	A/G	cg05241461	chr19:22816980	ZNF492	0.54	4.53	0.42	1.74e-5	Bronchopulmonary dysplasia;
THYM	cis	rs7072216	0.763	rs942805	chr10:100168372	G/A	cg03852570	chr10:100175106	PYROXD2	0.38	4.89	0.45	4.04e-6	Metabolite levels;
THYM	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg07606381	chr6:8435919	SLC35B3	0.62	4.62	0.43	1.21e-5	Motion sickness;
THYM	cis	rs1065852	0.526	rs7290907	chr22:42390209	G/A	cg08431931	chr22:42394659	WBP2NL	0.74	6.08	0.53	2.48e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg16325326	chr1:53192061	ZYG11B	0.85	8.17	0.64	1.35e-12	Monocyte count;
THYM	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg13319975	chr6:146136371	FBXO30	0.66	5.46	0.49	3.78e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg22920501	chr2:26401640	FAM59B	-1.03	-9.17	-0.69	9.78e-15	Gut microbiome composition (summer);
THYM	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs6435161	0.919	rs72930744	chr2:203597269	C/T	cg18429434	chr2:203499731	FAM117B	-0.79	-5.3	-0.48	7.37e-7	Total cholesterol levels;
THYM	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs367615	0.512	rs814153	chr5:108667829	A/C	cg17395555	chr5:108820864	NA	0.56	6.98	0.58	3.99e-10	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06481639	chr22:41940642	POLR3H	0.87	5.95	0.52	4.49e-8	Vitiligo;
THYM	cis	rs870825	0.581	rs7675106	chr4:185652388	C/G	cg04058563	chr4:185651563	MLF1IP	-1.06	-9.32	-0.69	4.75e-15	Blood protein levels;
THYM	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg09704166	chr2:114031854	PAX8;LOC440839	-0.66	-5.58	-0.5	2.3e-7	Lymphocyte counts;
THYM	cis	rs300703	0.719	rs389621	chr2:206636	C/T	cg21211680	chr2:198530	NA	-1.29	-7.52	-0.61	3e-11	Blood protein levels;
THYM	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg07061783	chr6:25882402	NA	-0.61	-4.59	-0.43	1.35e-5	Blood metabolite levels;
THYM	cis	rs4788570	0.615	rs7206470	chr16:71668800	G/A	cg06353428	chr16:71660113	MARVELD3	1.37	9.44	0.7	2.65e-15	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg00684032	chr4:1343700	KIAA1530	0.55	4.76	0.44	7.03e-6	Obesity-related traits;
THYM	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Intelligence (multi-trait analysis);
THYM	cis	rs12048904	0.541	rs6699536	chr1:101276544	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.86	6.83	0.57	7.91e-10	Multiple sclerosis;
THYM	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg00071950	chr4:10020882	SLC2A9	0.69	6.14	0.53	1.95e-8	Bone mineral density;
THYM	cis	rs9914988	0.943	rs9913801	chr17:27132105	G/A	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs13102973	0.646	rs4428339	chr4:135886187	C/T	cg14419869	chr4:135874104	NA	0.89	8.23	0.65	9.64e-13	Subjective well-being;
THYM	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	7.86	0.63	6.01e-12	Platelet count;
THYM	cis	rs2985684	1.000	rs7142457	chr14:50097862	C/T	cg02151108	chr14:50098012	C14orf104	-0.67	-5.33	-0.48	6.48e-7	Carotid intima media thickness;
THYM	trans	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg25214090	chr10:38739885	LOC399744	0.85	7.16	0.59	1.7e-10	Corneal astigmatism;
THYM	cis	rs873946	0.564	rs2803992	chr10:134550882	T/C	cg18305652	chr10:134549665	INPP5A	0.91	8.93	0.68	3.22e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg11871910	chr12:69753446	YEATS4	1.01	9.85	0.71	3.53e-16	Cerebrospinal fluid biomarker levels;
THYM	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg09455208	chr3:40491958	NA	0.46	4.67	0.43	9.9e-6	Renal cell carcinoma;
THYM	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs11671007	1	rs11671007	chr19:2893405	A/G	cg08634464	chr19:2901147	ZNF57	-1.23	-4.59	-0.43	1.33e-5	Daytime sleep phenotypes;
THYM	cis	rs2295359	0.892	rs72676069	chr1:67658954	T/C	cg11235152	chr1:67600687	NA	0.66	5.35	0.48	6.17e-7	Psoriasis;
THYM	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg20295408	chr7:1910781	MAD1L1	0.65	5.21	0.47	1.11e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg23758822	chr17:41437982	NA	-1.16	-12.95	-0.8	1.03e-22	Menopause (age at onset);
THYM	cis	rs11809207	0.501	rs2232654	chr1:26496870	A/G	cg00147160	chr1:26503991	CNKSR1	0.5	6.33	0.54	8.16e-9	Height;
THYM	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg11189052	chr15:85197271	WDR73	-0.68	-5.12	-0.47	1.58e-6	P wave terminal force;
THYM	cis	rs4072705	0.869	rs2416951	chr9:127550603	C/G	cg13476313	chr9:127244764	NR5A1	0.31	4.48	0.42	2.04e-5	Menarche (age at onset);
THYM	cis	rs7631605	0.905	rs11714716	chr3:37269678	A/G	cg21328643	chr3:37258149	NA	-0.6	-5.66	-0.5	1.6e-7	Cerebrospinal P-tau181p levels;
THYM	trans	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg10856724	chr12:34555212	NA	-1.02	-9.41	-0.69	2.96e-15	Morning vs. evening chronotype;
THYM	cis	rs13315871	1.000	rs9862969	chr3:58341917	A/G	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg15744005	chr10:104629667	AS3MT	-0.78	-7.33	-0.6	7.61e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs55637147	0.671	rs2013314	chr11:57128317	C/T	cg15971518	chr11:57159174	PRG2	0.64	5.26	0.48	8.77e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg06611532	chr13:114900021	NA	0.64	7.17	0.59	1.61e-10	Schizophrenia;
THYM	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg05347473	chr6:146136440	FBXO30	0.57	4.65	0.43	1.06e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs61931739	0.890	rs1849160	chr12:34140191	A/G	cg10856724	chr12:34555212	NA	-0.62	-5.42	-0.49	4.53e-7	Morning vs. evening chronotype;
THYM	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg20295408	chr7:1910781	MAD1L1	-0.6	-4.83	-0.44	5.29e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg11764359	chr7:65958608	NA	0.66	4.69	0.43	8.98e-6	Aortic root size;
THYM	cis	rs7683537	0.692	rs12509936	chr4:185662203	G/A	cg27112742	chr4:185696749	ACSL1	-0.92	-4.78	-0.44	6.35e-6	Systemic lupus erythematosus;
THYM	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs854765	0.663	rs1052299	chr17:17750419	A/G	cg04398451	chr17:18023971	MYO15A	0.82	7.64	0.62	1.72e-11	Total body bone mineral density;
THYM	cis	rs1387259	0.931	rs1107654	chr12:48681097	T/G	cg21466736	chr12:48725269	NA	-0.53	-4.91	-0.45	3.78e-6	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs6840360	0.571	rs17275577	chr4:152519899	G/A	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs2273669	0.504	rs11962354	chr6:109496192	C/T	cg17117243	chr6:109341365	SESN1	-0.82	-4.8	-0.44	5.98e-6	Prostate cancer;
THYM	cis	rs6754311	0.589	rs749873	chr2:136817088	C/T	cg07169764	chr2:136633963	MCM6	-0.63	-4.48	-0.42	2.1e-5	Mosquito bite size;
THYM	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg17173187	chr15:85201210	NMB	0.56	5.66	0.5	1.6e-7	Schizophrenia;
THYM	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg06582575	chr6:163149167	PACRG;PARK2	1.08	7.64	0.62	1.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg10224037	chr5:178157518	ZNF354A	1.0	7.92	0.63	4.43e-12	Neutrophil percentage of white cells;
THYM	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.43	0.7	2.73e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1801251	0.964	rs12997185	chr2:233560587	A/T	cg08000102	chr2:233561755	GIGYF2	0.72	6.65	0.56	1.83e-9	Coronary artery disease;
THYM	cis	rs2637266	0.783	rs846647	chr10:78515508	C/G	cg18941641	chr10:78392320	NA	0.71	5.69	0.5	1.38e-7	Pulmonary function;
THYM	cis	rs992157	0.798	rs2382819	chr2:219155909	G/T	cg04731861	chr2:219085781	ARPC2	0.55	5.1	0.46	1.71e-6	Colorectal cancer;
THYM	cis	rs11771526	0.892	rs1376282	chr7:32370492	A/G	cg27532318	chr7:32358331	NA	0.95	5.63	0.5	1.85e-7	Body mass index;
THYM	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg04772025	chr11:68637568	NA	-0.59	-6.21	-0.54	1.39e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2916260	0.733	rs6927927	chr6:40388800	A/G	cg17190781	chr6:40387783	LRFN2	1.07	4.74	0.44	7.63e-6	Incident coronary heart disease;
THYM	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg05717871	chr11:638507	DRD4	-0.66	-4.83	-0.44	5.17e-6	Systemic lupus erythematosus;
THYM	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg24530246	chr3:53118167	NA	-0.85	-4.82	-0.44	5.52e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg24675056	chr1:15929824	NA	0.74	6.14	0.53	1.93e-8	Systolic blood pressure;
THYM	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg18876405	chr7:65276391	NA	-0.57	-4.76	-0.44	7e-6	Aortic root size;
THYM	cis	rs7592578	0.679	rs62181020	chr2:191325601	A/C	cg10560079	chr2:191398806	TMEM194B	-0.85	-6.33	-0.54	8.22e-9	Diastolic blood pressure;
THYM	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs11625487	0.957	rs10145540	chr14:77957354	C/T	cg20045696	chr14:77926864	AHSA1	-0.7	-4.92	-0.45	3.69e-6	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
THYM	cis	rs6906287	0.647	rs6936178	chr6:118718242	C/T	cg21191810	chr6:118973309	C6orf204	0.57	5.5	0.49	3.26e-7	Electrocardiographic conduction measures;
THYM	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg22875332	chr1:76189707	ACADM	0.89	12.06	0.78	7.38e-21	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.54	-4.79	-0.44	6.04e-6	Platelet count;
THYM	cis	rs5769707	0.616	rs6009786	chr22:50015145	A/G	cg20744362	chr22:50050164	C22orf34	0.8	6.92	0.58	5.17e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2361710	0.611	rs12051781	chr17:78074468	A/G	cg06718696	chr17:78121285	EIF4A3	0.59	4.53	0.42	1.71e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
THYM	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg13607699	chr17:42295918	UBTF	0.9	9.27	0.69	5.91e-15	Total body bone mineral density;
THYM	cis	rs3857067	0.806	rs17302467	chr4:95112056	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs2562152	0.786	rs216594	chr16:103009	A/T	cg08336687	chr16:907744	LMF1	-0.8	-4.71	-0.44	8.45e-6	Glioblastoma;
THYM	cis	rs4988958	0.525	rs3771159	chr2:103004958	T/C	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma (childhood onset);
THYM	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.76	-6.39	-0.55	6.15e-9	Tonsillectomy;
THYM	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg04248312	chr19:17393744	ANKLE1	-0.98	-13.19	-0.8	3.47e-23	Systemic lupus erythematosus;
THYM	cis	rs2456568	0.802	rs8181567	chr11:93637209	C/T	cg17347335	chr11:93583973	C11orf90	-0.48	-4.58	-0.43	1.39e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs4930103	0.904	rs59121562	chr11:2025034	A/T	cg18511798	chr11:2018149	H19;MIR675	-0.57	-5.84	-0.51	7.32e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg08999081	chr20:33150536	PIGU	-0.73	-6.56	-0.56	2.86e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	5.54	0.49	2.69e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg03859395	chr2:55845619	SMEK2	0.58	5.06	0.46	2.02e-6	Metabolic syndrome;
THYM	cis	rs9788721	0.836	rs17484235	chr15:78761414	C/G	cg18825076	chr15:78729989	IREB2	-0.67	-6.17	-0.54	1.63e-8	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs4866334	1.000	rs80033831	chr5:18481972	A/G	cg04591469	chr5:17810299	NA	-1.21	-4.77	-0.44	6.75e-6	IgG glycosylation;
THYM	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg07570687	chr10:102243282	WNT8B	0.75	6.59	0.56	2.4e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.65	-4.72	-0.44	8.09e-6	Colorectal cancer;
THYM	cis	rs28595532	1.000	rs28600971	chr4:119712728	G/T	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg17366294	chr4:99064904	C4orf37	0.58	7.0	0.58	3.67e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs870825	0.616	rs6419939	chr4:185642869	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs478304	0.654	rs6591187	chr11:65460086	C/G	cg17480646	chr11:65405466	SIPA1	-0.97	-8.99	-0.68	2.44e-14	Acne (severe);
THYM	cis	rs7106204	0.609	rs16912391	chr11:24310637	G/A	ch.11.24196551F	chr11:24239977	NA	0.99	6.11	0.53	2.16e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs4523957	0.651	rs7212342	chr17:2084305	A/G	cg16513277	chr17:2031491	SMG6	-0.95	-8.69	-0.67	1.05e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9826463	0.582	rs73238130	chr3:142004004	G/A	cg20824294	chr3:142316082	PLS1	0.76	5.28	0.48	8.31e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs800586	0.500	rs2721959	chr8:116656207	T/G	cg04656070	chr8:116661063	TRPS1	-0.55	-6.57	-0.56	2.67e-9	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg06221963	chr1:154839813	KCNN3	-0.8	-8.92	-0.67	3.43e-14	Prostate cancer;
THYM	cis	rs4499344	0.535	rs7260509	chr19:33121595	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.75	6.52	0.56	3.35e-9	Mean platelet volume;
THYM	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg10802521	chr3:52805072	NEK4	-0.7	-6.29	-0.54	9.55e-9	Bipolar disorder;
THYM	cis	rs11096990	0.656	rs4580661	chr4:39296350	T/C	cg24403649	chr4:39172243	NA	-0.64	-5.49	-0.49	3.36e-7	Cognitive function;
THYM	cis	rs7940866	0.804	rs10894289	chr11:130808685	C/T	cg12179176	chr11:130786555	SNX19	0.64	4.89	0.45	4.04e-6	Schizophrenia;
THYM	cis	rs4243830	1.000	rs12047931	chr1:6587614	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.13	5.85	0.51	6.88e-8	Body mass index;
THYM	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg11764359	chr7:65958608	NA	0.66	5.14	0.47	1.45e-6	Aortic root size;
THYM	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg02725872	chr8:58115012	NA	-1.1	-8.24	-0.65	9.17e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs17338034	0.752	rs9932253	chr16:51382864	A/G	cg06173956	chr16:50666302	NKD1	0.57	4.45	0.42	2.31e-5	Left superior temporal gyrus thickness (schizophrenia interaction);
THYM	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg27170947	chr2:26402098	FAM59B	-0.8	-6.37	-0.55	6.74e-9	Gut microbiome composition (summer);
THYM	cis	rs7772486	0.754	rs9399561	chr6:145955687	C/G	cg13319975	chr6:146136371	FBXO30	-0.59	-4.76	-0.44	6.82e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11644478	chr21:40555479	PSMG1	-0.54	-4.53	-0.42	1.72e-5	Menarche (age at onset);
THYM	cis	rs11264213	0.591	rs603945	chr1:36490186	C/T	cg27506609	chr1:36549197	TEKT2	-0.95	-5.02	-0.46	2.4e-6	Schizophrenia;
THYM	cis	rs447921	0.736	rs28715905	chr17:74448063	A/C	cg17201438	chr17:74438067	UBE2O	-0.77	-5.46	-0.49	3.74e-7	Mitochondrial DNA levels;
THYM	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg27129171	chr3:47204927	SETD2	-0.68	-6.47	-0.55	4.18e-9	Colorectal cancer;
THYM	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg25427524	chr10:38739819	LOC399744	0.66	6.01	0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg24257776	chr3:47051546	LOC100129354	0.41	4.78	0.44	6.38e-6	Colorectal cancer;
THYM	cis	rs7572733	0.534	rs1401092	chr2:198792320	C/A	cg05783139	chr2:198650985	BOLL	-0.62	-4.91	-0.45	3.8e-6	Dermatomyositis;
THYM	cis	rs673253	0.686	rs501299	chr1:44051834	A/C	cg24466421	chr1:44070974	PTPRF	-0.6	-5.34	-0.48	6.24e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1981331	0.609	rs59121565	chr21:48043023	A/G	cg23283320	chr21:48055893	PRMT2	1.4	6.76	0.57	1.12e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg17264618	chr3:40429014	ENTPD3	0.5	4.7	0.43	8.93e-6	Renal cell carcinoma;
THYM	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg04282206	chr17:62833786	PLEKHM1P	0.84	7.74	0.62	1.06e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg04362960	chr10:104952993	NT5C2	-0.6	-5.12	-0.46	1.61e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs9972944	0.756	rs9894298	chr17:63769225	G/A	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs11264213	0.901	rs2765013	chr1:36374101	C/T	cg27506609	chr1:36549197	TEKT2	0.97	5.15	0.47	1.4e-6	Schizophrenia;
THYM	cis	rs524281	0.773	rs4393319	chr11:66001878	A/T	cg00563793	chr11:65837595	PACS1	0.79	4.71	0.43	8.53e-6	Electroencephalogram traits;
THYM	cis	rs317689	0.690	rs317630	chr12:69637847	T/C	cg20891283	chr12:69753455	YEATS4	0.62	4.55	0.42	1.59e-5	Response to diuretic therapy;
THYM	cis	rs420259	0.516	rs11642434	chr16:23540237	C/T	cg00143387	chr16:23521605	GGA2	0.76	5.6	0.5	2.1e-7	Bipolar disorder;
THYM	cis	rs713587	0.646	rs34697209	chr2:25127394	A/G	cg01884057	chr2:25150051	NA	0.66	6.46	0.55	4.52e-9	Body mass index in non-asthmatics;
THYM	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg17509989	chr5:176798049	RGS14	-0.66	-5.8	-0.51	8.71e-8	Urate levels in lean individuals;
THYM	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.0	6.7	0.57	1.44e-9	Platelet count;
THYM	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg05373962	chr22:49881684	NA	-0.63	-5.88	-0.52	6.17e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg01416388	chr22:39784598	NA	-0.89	-8.34	-0.65	5.81e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg02915803	chr1:1606292	LOC728661;CDK11B	-0.56	-4.56	-0.42	1.54e-5	Body mass index;
THYM	cis	rs7010267	0.935	rs6469788	chr8:119952750	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.59	4.79	0.44	6.12e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg14019146	chr3:50243930	SLC38A3	-0.55	-4.48	-0.42	2.07e-5	Body mass index;
THYM	cis	rs2658782	0.724	rs2605629	chr11:93264037	C/G	cg15737290	chr11:93063684	CCDC67	-0.99	-7.23	-0.6	1.19e-10	Pulmonary function decline;
THYM	cis	rs7119	0.651	rs35657172	chr15:77847813	T/C	cg27398640	chr15:77910606	LINGO1	-0.59	-5.84	-0.51	7.15e-8	Type 2 diabetes;
THYM	cis	rs2350702	0.614	rs17489085	chr2:49952622	G/T	cg22592722	chr2:49566210	NA	0.58	4.69	0.43	9.18e-6	Morning vs. evening chronotype;
THYM	cis	rs1398942	0.522	rs10027874	chr4:89962286	T/C	cg17769793	chr4:89976368	FAM13A	-0.43	-4.54	-0.42	1.62e-5	Post bronchodilator FEV1;
THYM	cis	rs7236492	0.532	rs3786184	chr18:77195885	A/C	cg15644404	chr18:77186268	NFATC1	-0.73	-4.49	-0.42	2.02e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg07959070	chr22:50026188	C22orf34	-0.28	-4.91	-0.45	3.82e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg15164180	chr2:241846931	NA	-0.34	-4.63	-0.43	1.15e-5	Urinary metabolites;
THYM	cis	rs3772130	0.583	rs58088236	chr3:121561765	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.86	7.17	0.59	1.63e-10	Cognitive performance;
THYM	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs2913737	0.563	rs2963658	chr5:175881696	C/T	cg27658698	chr5:175955578	RNF44	-0.54	-4.65	-0.43	1.06e-5	Obesity-related traits;
THYM	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg03806693	chr22:41940476	POLR3H	-0.89	-8.14	-0.64	1.55e-12	Vitiligo;
THYM	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg07424592	chr7:64974309	NA	-0.99	-5.15	-0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs6815814	0.861	rs1135430	chr4:38789361	T/C	cg02016764	chr4:38805732	TLR1	-0.44	-4.48	-0.42	2.05e-5	Breast cancer;
THYM	cis	rs7264396	0.887	rs4911503	chr20:34063095	C/T	cg26038318	chr20:34205095	SPAG4	0.56	4.73	0.44	7.84e-6	Total cholesterol levels;
THYM	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg15704280	chr7:45808275	SEPT13	1.01	11.27	0.76	3.31e-19	Coronary artery disease;
THYM	cis	rs13064411	0.696	rs869342	chr3:113226330	C/T	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs17443541	0.507	rs4675712	chr2:200460112	A/C	cg01795955	chr2:200468626	NA	-0.66	-4.59	-0.43	1.38e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1747683	0.867	rs3824655	chr10:13370779	G/C	cg00142036	chr10:13388442	SEPHS1	-0.29	-5.22	-0.47	1.03e-6	IgG glycosylation;
THYM	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22509189	chr2:225307070	NA	-0.87	-7.39	-0.6	5.67e-11	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg14779329	chr11:130786720	SNX19	-0.52	-5.67	-0.5	1.52e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg21237687	chr17:6899380	ALOX12	0.73	9.21	0.69	8.04e-15	Tonsillectomy;
THYM	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg21385522	chr1:16154831	NA	0.65	4.65	0.43	1.08e-5	Dilated cardiomyopathy;
THYM	trans	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg18335740	chr13:41363409	SLC25A15	0.68	7.45	0.61	4.37e-11	Lewy body disease;
THYM	cis	rs7584330	0.554	rs13411613	chr2:238437560	T/C	cg14458575	chr2:238380390	NA	0.81	4.86	0.45	4.63e-6	Prostate cancer;
THYM	cis	rs16912285	0.535	rs7109619	chr11:24251339	G/A	ch.11.24196551F	chr11:24239977	NA	0.95	6.57	0.56	2.67e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.68	8.94	0.68	2.99e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg25767906	chr1:53392781	SCP2	-0.64	-6.42	-0.55	5.39e-9	Monocyte count;
THYM	cis	rs4072705	0.967	rs4076333	chr9:127385609	A/G	cg01786973	chr9:127249749	NR5A1	0.35	4.69	0.43	9.25e-6	Menarche (age at onset);
THYM	cis	rs1953600	0.645	rs2819945	chr10:81952956	G/A	cg11900509	chr10:81946545	ANXA11	0.45	4.69	0.43	9.07e-6	Sarcoidosis;
THYM	cis	rs137603	1.000	rs137607	chr22:39695505	G/A	cg24268161	chr22:39747459	SYNGR1	0.57	5.08	0.46	1.87e-6	Primary biliary cholangitis;
THYM	cis	rs28830936	0.510	rs11070349	chr15:42085017	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.33	-5.55	-0.49	2.55e-7	Diastolic blood pressure;
THYM	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg09021430	chr5:549028	NA	-0.7	-5.28	-0.48	8.14e-7	Obesity-related traits;
THYM	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg19077165	chr18:44547161	KATNAL2	0.49	5.69	0.5	1.42e-7	Personality dimensions;
THYM	cis	rs9910055	0.573	rs113184718	chr17:42206543	A/T	cg13607699	chr17:42295918	UBTF	-0.65	-5.28	-0.48	8.1e-7	Total body bone mineral density;
THYM	cis	rs684232	0.623	rs12601935	chr17:519325	G/A	cg15660573	chr17:549704	VPS53	-1.01	-11.19	-0.75	4.87e-19	Prostate cancer;
THYM	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg01579765	chr21:45077557	HSF2BP	0.47	6.71	0.57	1.42e-9	Mean corpuscular volume;
THYM	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg15242686	chr22:24348715	GSTTP1	0.54	4.97	0.45	2.92e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs757081	0.637	rs586785	chr11:17208714	T/C	cg07093617	chr11:18158918	MRGPRX3	-0.49	-4.51	-0.42	1.87e-5	Systolic blood pressure;
THYM	cis	rs9287719	0.753	rs1990613	chr2:10781975	C/T	cg03983476	chr2:10830698	NOL10	0.59	5.19	0.47	1.19e-6	Prostate cancer;
THYM	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs8018808	0.935	rs11625365	chr14:77908588	A/G	cg20045696	chr14:77926864	AHSA1	0.5	4.46	0.42	2.27e-5	Myeloid white cell count;
THYM	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg03388043	chr17:80084554	CCDC57	-0.71	-5.87	-0.52	6.23e-8	Life satisfaction;
THYM	cis	rs12137294	0.866	rs1172140	chr1:205213024	G/A	cg17889831	chr1:205181581	DSTYK	-0.41	-5.09	-0.46	1.82e-6	Red cell distribution width;
THYM	cis	rs34779708	0.931	rs2001893	chr10:35300623	G/A	cg03585969	chr10:35415529	CREM	0.63	4.66	0.43	1.01e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs62435770	0.858	rs62433638	chr6:169531223	C/T	cg07652237	chr6:170125491	PHF10	0.55	4.91	0.45	3.84e-6	Loneliness;
THYM	cis	rs3796352	0.892	rs2581807	chr3:53088844	G/A	cg07884673	chr3:53033167	SFMBT1	-1.04	-6.05	-0.53	2.79e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs4474465	0.833	rs7934912	chr11:78218556	A/T	cg19901956	chr11:77921274	USP35	0.65	4.9	0.45	3.99e-6	Alzheimer's disease (survival time);
THYM	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg25208724	chr1:156163844	SLC25A44	1.16	13.18	0.8	3.54e-23	Testicular germ cell tumor;
THYM	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	6.15	0.53	1.79e-8	Uric acid levels;
THYM	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg03647317	chr4:187891568	NA	-0.84	-9.05	-0.68	1.74e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7178572	0.849	rs1005752	chr15:77818128	C/A	cg22256960	chr15:77711686	NA	-0.94	-7.69	-0.62	1.33e-11	Type 2 diabetes;
THYM	cis	rs7646881	1.000	rs7646881	chr3:158453279	C/A	cg18349298	chr3:158450550	RARRES1	0.48	4.48	0.42	2.05e-5	Tetralogy of Fallot;
THYM	cis	rs8070740	0.841	rs2189337	chr17:5326178	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.72	6.03	0.53	3.15e-8	Menopause (age at onset);
THYM	cis	rs28719689	1.000	rs28719689	chr8:1270670	C/T	cg11592242	chr8:1263433	NA	0.73	4.55	0.42	1.61e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg08213375	chr14:104286397	PPP1R13B	0.52	6.25	0.54	1.18e-8	Schizophrenia;
THYM	cis	rs7582180	0.627	rs6542947	chr2:100999647	C/G	cg14675211	chr2:100938903	LONRF2	-0.62	-6.14	-0.53	1.92e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg26038318	chr20:34205095	SPAG4	0.63	5.13	0.47	1.54e-6	Total cholesterol levels;
THYM	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11644478	chr21:40555479	PSMG1	-0.76	-6.49	-0.55	3.85e-9	Cognitive function;
THYM	cis	rs921968	0.540	rs646295	chr2:219408558	A/C	cg02176678	chr2:219576539	TTLL4	0.66	6.56	0.56	2.83e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs1270639	0.778	rs2707942	chr7:157445750	G/C	cg13357408	chr7:157437802	PTPRN2	0.47	4.77	0.44	6.64e-6	Colorectal cancer;
THYM	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs2836633	1.000	rs11088437	chr21:40053372	A/G	cg12884169	chr21:40033163	ERG	0.68	8.73	0.67	8.44e-14	Coronary artery disease;
THYM	cis	rs988913	0.957	rs72645372	chr6:54788822	C/T	cg19716238	chr6:54711378	FAM83B	0.51	5.02	0.46	2.4e-6	Menarche (age at onset);
THYM	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22496380	chr5:211416	CCDC127	-1.33	-7.99	-0.63	3.21e-12	Breast cancer;
THYM	cis	rs4936891	0.577	rs11219422	chr11:123920178	C/T	cg22125253	chr11:123886957	OR10G4	-0.54	-4.56	-0.42	1.53e-5	Male fertility;
THYM	cis	rs9420	0.703	rs10896661	chr11:57679029	C/A	cg19752551	chr11:57585705	CTNND1	-0.69	-6.64	-0.56	1.95e-9	Schizophrenia;
THYM	cis	rs3008870	1.000	rs2065000	chr1:67468124	G/C	cg02640540	chr1:67518911	SLC35D1	-0.64	-4.62	-0.43	1.19e-5	Lymphocyte percentage of white cells;
THYM	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg10018233	chr7:150070692	REPIN1	0.37	5.34	0.48	6.26e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs59698941	0.882	rs66537260	chr5:132309237	C/T	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.84	-5.3	-0.48	7.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12476592	0.602	rs171902	chr2:63903236	C/T	cg17519650	chr2:63277830	OTX1	-0.72	-4.68	-0.43	9.38e-6	Childhood ear infection;
THYM	cis	rs9906944	0.707	rs9899931	chr17:47108282	G/A	cg09029085	chr17:47094198	IGF2BP1	0.47	6.53	0.56	3.17e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg24397884	chr7:158709396	WDR60	-0.42	-4.85	-0.45	4.8e-6	Height;
THYM	cis	rs4606347	0.872	rs76637555	chr1:66133064	G/A	cg04111102	chr1:66153794	NA	0.69	5.21	0.47	1.07e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs346785	0.965	rs164009	chr17:74283669	C/T	cg09812376	chr17:74270190	QRICH2	0.61	7.02	0.58	3.31e-10	White matter hyperintensities in ischemic stroke;
THYM	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.97	0.58	4.07e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.722	rs7552139	chr1:53387379	G/C	cg22166914	chr1:53195759	ZYG11B	0.78	7.68	0.62	1.38e-11	Monocyte count;
THYM	cis	rs1003719	0.591	rs2835618	chr21:38503126	A/G	cg01329690	chr21:38580129	DSCR9	-0.36	-4.81	-0.44	5.75e-6	Eye color traits;
THYM	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9583531	0.689	rs9588247	chr13:111375571	G/T	cg24331049	chr13:111365604	ING1	-0.61	-5.17	-0.47	1.3e-6	Coronary artery disease;
THYM	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.52e-10	Prudent dietary pattern;
THYM	trans	rs6462411	0.646	rs6975723	chr7:3908727	T/A	cg14907788	chr19:2555976	GNG7	0.67	6.9	0.58	5.79e-10	Quantitative traits;
THYM	cis	rs7107174	1.000	rs2511166	chr11:77964331	T/C	cg19901956	chr11:77921274	USP35	-0.71	-5.46	-0.49	3.75e-7	Testicular germ cell tumor;
THYM	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg07341220	chr16:1583899	IFT140;TMEM204	-0.66	-5.41	-0.49	4.64e-7	Coronary artery disease;
THYM	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg24675056	chr1:15929824	NA	0.73	5.79	0.51	9.09e-8	Systolic blood pressure;
THYM	cis	rs7616559	0.924	rs6774012	chr3:156747593	A/G	cg15697575	chr3:156784781	NA	0.4	5.03	0.46	2.35e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg21028142	chr17:79581711	NPLOC4	0.61	6.22	0.54	1.32e-8	Eye color traits;
THYM	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg00129232	chr17:37814104	STARD3	0.69	4.51	0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs3106136	0.527	rs2883	chr4:95158610	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.12	-0.46	1.63e-6	Capecitabine sensitivity;
THYM	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg27034606	chr17:28928453	LRRC37B2	0.76	5.06	0.46	2.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg07511668	chr11:68622177	NA	0.43	4.64	0.43	1.11e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs728616	0.717	rs12415523	chr10:81691976	T/C	cg18148530	chr10:81370782	SFTPA1	0.77	4.88	0.45	4.23e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs939658	0.805	rs35832166	chr15:79417994	G/T	cg17916960	chr15:79447300	NA	-0.68	-7.85	-0.63	6.28e-12	Refractive error;
THYM	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg03676636	chr4:99064102	C4orf37	0.43	6.47	0.55	4.29e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg24020549	chr11:64937741	SPDYC	-0.47	-4.5	-0.42	1.93e-5	Eosinophil percentage of white cells;
THYM	cis	rs10504073	0.584	rs4873304	chr8:49922733	G/A	cg00325661	chr8:49890786	NA	1.04	10.53	0.73	1.2e-17	Blood metabolite ratios;
THYM	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg11247378	chr22:39784982	NA	-0.89	-5.94	-0.52	4.68e-8	IgG glycosylation;
THYM	cis	rs6570726	0.935	rs454370	chr6:145846729	T/G	cg13319975	chr6:146136371	FBXO30	-0.68	-5.75	-0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs986417	1.000	rs1254322	chr14:60906976	G/A	cg27398547	chr14:60952738	C14orf39	-1.21	-6.17	-0.53	1.69e-8	Gut microbiota (bacterial taxa);
THYM	trans	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg10856724	chr12:34555212	NA	-0.96	-8.66	-0.66	1.22e-13	Bladder cancer;
THYM	cis	rs61931739	0.793	rs609886	chr12:34138160	T/G	cg06521331	chr12:34319734	NA	-0.67	-5.41	-0.49	4.78e-7	Morning vs. evening chronotype;
THYM	cis	rs6840360	1.000	rs10007167	chr4:152603655	C/T	cg22705602	chr4:152727874	NA	-0.57	-5.12	-0.47	1.58e-6	Intelligence (multi-trait analysis);
THYM	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg19717773	chr7:2847554	GNA12	0.54	4.72	0.44	8.04e-6	Loneliness (linear analysis);
THYM	cis	rs7843479	1.000	rs17615788	chr8:21814739	C/T	cg17168535	chr8:21777572	XPO7	0.73	5.25	0.47	9.34e-7	Mean corpuscular volume;
THYM	cis	rs988913	0.793	rs995851	chr6:54735594	G/A	cg04690482	chr6:54711388	FAM83B	0.47	4.81	0.44	5.66e-6	Menarche (age at onset);
THYM	cis	rs2663905	0.706	rs7162859	chr15:81360038	C/T	cg27419860	chr15:81426477	C15orf26	0.75	5.02	0.46	2.37e-6	QT interval (drug interaction);
THYM	cis	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg18304052	chr3:189614536	TP63	-0.69	-4.52	-0.42	1.81e-5	Lung adenocarcinoma;
THYM	cis	rs55702914	0.935	rs17405525	chr2:198214183	C/G	cg00792783	chr2:198669748	PLCL1	-0.6	-4.48	-0.42	2.04e-5	Major depression and alcohol dependence;
THYM	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs7192750	0.527	rs30433	chr16:72145404	T/C	cg06353428	chr16:71660113	MARVELD3	1.2	4.86	0.45	4.56e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs7917772	0.582	rs4919663	chr10:104363293	T/C	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs981844	0.753	rs1105491	chr4:154726634	A/C	cg22178613	chr4:154710499	SFRP2	-0.53	-4.6	-0.43	1.33e-5	Response to statins (LDL cholesterol change);
THYM	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.5	-4.64	-0.43	1.13e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs4919694	1.000	rs79254677	chr10:104691567	A/G	cg08772003	chr10:104629869	AS3MT	-0.81	-4.72	-0.44	8.24e-6	Arsenic metabolism;
THYM	cis	rs4849845	0.925	rs7587975	chr2:121022740	G/T	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg04267008	chr7:1944627	MAD1L1	-0.62	-5.48	-0.49	3.43e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg17105886	chr17:28927953	LRRC37B2	1.13	6.42	0.55	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg03188948	chr7:1209495	NA	1.11	5.46	0.49	3.83e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.7	5.26	0.47	8.85e-7	Eosinophil percentage of white cells;
THYM	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6754311	0.551	rs313519	chr2:136439517	A/C	cg07169764	chr2:136633963	MCM6	0.7	5.68	0.5	1.48e-7	Mosquito bite size;
THYM	cis	rs6032067	0.641	rs34313230	chr20:43755858	C/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.39	-0.48	5.13e-7	Blood protein levels;
THYM	cis	rs5753037	0.629	rs140138	chr22:30164628	T/G	cg27665648	chr22:30112403	NA	0.53	4.7	0.43	8.88e-6	Type 1 diabetes;
THYM	cis	rs36051895	0.659	rs57299248	chr9:5062932	C/G	cg02405213	chr9:5042618	JAK2	-1.02	-11.46	-0.76	1.32e-19	Pediatric autoimmune diseases;
THYM	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg24920358	chr1:40204285	PPIE	0.6	5.57	0.5	2.39e-7	Blood protein levels;
THYM	cis	rs3126085	1.000	rs72696969	chr1:152196339	G/A	cg10321714	chr1:152280068	FLG	-0.74	-5.53	-0.49	2.82e-7	Atopic dermatitis;
THYM	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg01699819	chr7:1052092	C7orf50	-0.65	-5.46	-0.49	3.85e-7	Bronchopulmonary dysplasia;
THYM	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg26384229	chr12:38710491	ALG10B	1.07	10.43	0.73	2.04e-17	Heart rate;
THYM	cis	rs9796	0.870	rs3900905	chr15:41260801	G/A	cg18705301	chr15:41695430	NDUFAF1	0.57	4.75	0.44	7.06e-6	Menopause (age at onset);
THYM	cis	rs11718455	0.960	rs11929518	chr3:44016874	A/G	cg08738300	chr3:44038990	NA	0.75	4.5	0.42	1.94e-5	Coronary artery disease;
THYM	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg12564285	chr5:131593104	PDLIM4	0.43	4.66	0.43	1.04e-5	Acylcarnitine levels;
THYM	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg18252515	chr7:66147081	NA	-0.66	-4.91	-0.45	3.8e-6	Aortic root size;
THYM	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.59	-4.77	-0.44	6.69e-6	Response to bleomycin (chromatid breaks);
THYM	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg18252515	chr7:66147081	NA	-0.66	-5.01	-0.46	2.55e-6	Aortic root size;
THYM	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.61	-5.13	-0.47	1.53e-6	Renal function-related traits (BUN);
THYM	cis	rs2249625	0.508	rs114505309	chr6:72892383	G/A	cg27608224	chr6:72922399	RIMS1	-0.58	-4.9	-0.45	3.94e-6	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
THYM	cis	rs2835345	0.563	rs2835361	chr21:37824997	T/C	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs11690935	0.959	rs11897196	chr2:172585595	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.88	-6.5	-0.55	3.76e-9	Schizophrenia;
THYM	cis	rs11264213	0.901	rs67641270	chr1:36413329	T/C	cg27506609	chr1:36549197	TEKT2	0.92	4.83	0.44	5.3e-6	Schizophrenia;
THYM	cis	rs586688	0.582	rs662852	chr1:201672614	T/G	cg14168733	chr1:201708718	NAV1	-0.59	-5.33	-0.48	6.58e-7	Obesity-related traits;
THYM	cis	rs478304	0.934	rs1193496	chr11:65537556	C/T	cg17480646	chr11:65405466	SIPA1	-0.7	-6.13	-0.53	2e-8	Acne (severe);
THYM	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13256369	0.901	rs12679831	chr8:8566411	T/G	cg17143192	chr8:8559678	CLDN23	0.97	7.28	0.6	9.72e-11	Obesity-related traits;
THYM	cis	rs600806	0.888	rs3853501	chr1:109864374	G/A	cg02175308	chr1:109941060	SORT1	-0.57	-4.96	-0.45	3.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs36051895	0.659	rs10974944	chr9:5070831	C/G	cg02405213	chr9:5042618	JAK2	-0.99	-11.12	-0.75	6.76e-19	Pediatric autoimmune diseases;
THYM	cis	rs13082711	0.554	rs1494423	chr3:27375345	A/G	cg02860705	chr3:27208620	NA	-0.83	-6.4	-0.55	5.94e-9	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs28595532	0.920	rs116145969	chr4:119770908	T/C	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs7975161	0.630	rs7138317	chr12:104650271	G/A	cg25273343	chr12:104657179	TXNRD1	-0.77	-4.59	-0.43	1.35e-5	Toenail selenium levels;
THYM	cis	rs17818399	0.926	rs1378764	chr2:46839681	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.63	4.59	0.43	1.37e-5	Height;
THYM	cis	rs950880	0.710	rs11123929	chr2:103067143	G/A	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.74	-0.44	7.54e-6	Serum protein levels (sST2);
THYM	cis	rs761746	0.739	rs5753691	chr22:31952045	A/G	cg10537193	chr22:32026975	PISD	-0.41	-5.12	-0.46	1.61e-6	Intelligence;
THYM	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg23260525	chr10:116636907	FAM160B1	0.52	5.19	0.47	1.19e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs3126085	0.778	rs9887901	chr1:152248552	A/C	cg10321714	chr1:152280068	FLG	0.64	4.81	0.44	5.57e-6	Atopic dermatitis;
THYM	cis	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg21775007	chr8:11205619	TDH	-0.68	-5.27	-0.48	8.47e-7	Retinal vascular caliber;
THYM	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg14004847	chr7:1930337	MAD1L1	-0.62	-4.81	-0.44	5.67e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	10.77	0.74	3.77e-18	Chronic sinus infection;
THYM	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg20744362	chr22:50050164	C22orf34	0.83	8.22	0.64	1.05e-12	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg05043794	chr9:111880884	C9orf5	-0.4	-5.64	-0.5	1.71e-7	Menarche (age at onset);
THYM	cis	rs11608355	0.618	rs60819157	chr12:109795766	G/A	cg10504392	chr12:110044639	NA	0.55	4.94	0.45	3.41e-6	Neuroticism;
THYM	cis	rs9326248	0.530	rs2513095	chr11:116806269	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.86	4.7	0.43	8.89e-6	Blood protein levels;
THYM	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg11502198	chr6:26597334	ABT1	0.64	5.68	0.5	1.48e-7	Intelligence (multi-trait analysis);
THYM	trans	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.66	-0.62	1.53e-11	Exhaled nitric oxide output;
THYM	cis	rs7487075	0.780	rs1873793	chr12:46761324	A/G	cg21428710	chr12:47219797	SLC38A4	-0.49	-4.77	-0.44	6.67e-6	Itch intensity from mosquito bite;
THYM	cis	rs854765	0.693	rs9907246	chr17:17770965	T/C	cg04398451	chr17:18023971	MYO15A	0.83	8.06	0.64	2.26e-12	Total body bone mineral density;
THYM	cis	rs9902453	0.845	rs2259855	chr17:28097860	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-4.85	-0.45	4.89e-6	Coffee consumption (cups per day);
THYM	cis	rs7100689	0.725	rs2487074	chr10:82064104	A/G	cg01528321	chr10:82214614	TSPAN14	1.02	7.55	0.61	2.63e-11	Post bronchodilator FEV1;
THYM	cis	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg05084668	chr3:125655381	ALG1L	-0.82	-5.0	-0.46	2.57e-6	Blood pressure (smoking interaction);
THYM	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05901451	chr6:126070800	HEY2	-0.97	-9.76	-0.71	5.32e-16	Brugada syndrome;
THYM	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg26963428	chr7:66367121	NA	-0.59	-4.69	-0.43	9.05e-6	Corneal structure;
THYM	cis	rs6835098	0.509	rs2332655	chr4:174093002	A/G	cg08422745	chr4:174089978	GALNT7	0.76	6.57	0.56	2.71e-9	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs4589258	0.933	rs1621068	chr11:90440698	A/G	cg26138821	chr11:89956704	CHORDC1	0.7	5.9	0.52	5.64e-8	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg17202724	chr17:61916730	SMARCD2	-0.44	-4.49	-0.42	1.98e-5	Prudent dietary pattern;
THYM	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg16049864	chr8:95962084	TP53INP1	-0.69	-6.21	-0.54	1.41e-8	Type 2 diabetes;
THYM	cis	rs9905704	0.918	rs186221	chr17:56695967	C/T	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.74e-6	Testicular germ cell tumor;
THYM	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg06623918	chr6:96969491	KIAA0776	1.09	9.82	0.71	3.91e-16	Headache;
THYM	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9831754	0.906	rs7611939	chr3:78392751	A/C	cg06138941	chr3:78371609	NA	-0.64	-4.55	-0.42	1.6e-5	Calcium levels;
THYM	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg11266682	chr4:10021025	SLC2A9	-0.68	-9.72	-0.71	6.47e-16	Bone mineral density;
THYM	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg03160526	chr17:80928410	B3GNTL1	-0.49	-4.83	-0.44	5.26e-6	Glycated hemoglobin levels;
THYM	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg07936489	chr17:37558343	FBXL20	0.83	5.84	0.51	7.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs28595532	0.920	rs116697254	chr4:119733603	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg14798641	chr3:49314920	USP4;C3orf62	-0.66	-4.63	-0.43	1.17e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs11809207	0.523	rs2783626	chr1:26501044	C/T	cg00147160	chr1:26503991	CNKSR1	-0.53	-7.17	-0.59	1.65e-10	Height;
THYM	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg02725872	chr8:58115012	NA	-1.08	-8.26	-0.65	8.3e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs2370759	0.945	rs3740237	chr10:32557592	G/C	cg01819863	chr10:32635814	EPC1	0.98	4.87	0.45	4.36e-6	Sexual dysfunction (female);
THYM	cis	rs72627123	0.619	rs79575309	chr14:74590230	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.29	7.08	0.59	2.46e-10	Morning vs. evening chronotype;
THYM	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg23682913	chr1:2080710	PRKCZ	-0.56	-4.91	-0.45	3.75e-6	Height;
THYM	cis	rs12681287	0.517	rs7462883	chr8:87526790	G/A	cg27223183	chr8:87520930	FAM82B	-0.71	-5.56	-0.5	2.44e-7	Caudate activity during reward;
THYM	cis	rs2803122	0.838	rs10757033	chr9:19223304	T/G	cg19584733	chr9:19298547	DENND4C	-0.54	-4.69	-0.43	9.01e-6	Pulse pressure;
THYM	cis	rs2742417	0.603	rs2064062	chr3:45761115	G/C	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs2273669	1.000	rs2273669	chr6:109285189	A/G	cg17117243	chr6:109341365	SESN1	-0.82	-5.02	-0.46	2.45e-6	Prostate cancer;
THYM	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg17554472	chr22:41940697	POLR3H	0.68	4.51	0.42	1.82e-5	Vitiligo;
THYM	cis	rs912057	0.601	rs1294405	chr6:6737591	A/G	cg06612196	chr6:6737390	NA	0.77	14.14	0.82	4.16e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs17739794	0.557	rs7823906	chr8:814710	A/G	cg07178994	chr8:816998	NA	-0.49	-4.85	-0.45	4.76e-6	Clozapine-induced cytotoxicity;
THYM	cis	rs7772486	0.875	rs9390371	chr6:146363180	A/G	cg13319975	chr6:146136371	FBXO30	-0.72	-6.02	-0.53	3.33e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7918232	0.943	rs6482593	chr10:27371437	A/G	cg14442939	chr10:27389572	ANKRD26	0.85	4.79	0.44	6.24e-6	Breast cancer;
THYM	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg15556689	chr8:8085844	FLJ10661	-0.63	-5.11	-0.46	1.69e-6	Mood instability;
THYM	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg21475434	chr5:93447410	FAM172A	0.97	6.1	0.53	2.3e-8	Diabetic retinopathy;
THYM	cis	rs8078723	0.966	rs57968500	chr17:38145828	A/G	cg17467752	chr17:38218738	THRA	0.87	7.22	0.59	1.3e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs7020830	0.823	rs7019699	chr9:37125081	C/A	cg14294708	chr9:37120828	ZCCHC7	1.33	17.97	0.88	2.58e-32	Schizophrenia;
THYM	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg12386194	chr3:101231763	SENP7	0.7	5.29	0.48	7.86e-7	Colorectal cancer;
THYM	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg13609457	chr4:120235615	NA	0.51	4.76	0.44	6.87e-6	Educational attainment;
THYM	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg15704280	chr7:45808275	SEPT13	1.0	11.4	0.76	1.77e-19	Coronary artery disease;
THYM	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11890956	chr21:40555474	PSMG1	0.73	6.1	0.53	2.25e-8	Cognitive function;
THYM	cis	rs5758511	0.680	rs17002902	chr22:42625509	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.5	4.61	0.43	1.27e-5	Birth weight;
THYM	cis	rs6723226	0.572	rs176411	chr2:32643528	A/G	cg02381751	chr2:32503542	YIPF4	0.55	4.93	0.45	3.52e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs6435161	0.879	rs72928949	chr2:203570761	G/C	cg18429434	chr2:203499731	FAM117B	-0.79	-5.3	-0.48	7.37e-7	Total cholesterol levels;
THYM	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg16325326	chr1:53192061	ZYG11B	0.74	6.39	0.55	6.2e-9	Monocyte count;
THYM	cis	rs2067615	0.542	rs11113120	chr12:107203460	T/C	cg15890332	chr12:107067104	RFX4	0.48	5.63	0.5	1.81e-7	Heart rate;
THYM	cis	rs6956675	0.915	rs7790432	chr7:62631824	T/C	cg08930214	chr7:62859557	LOC100287834	0.6	4.64	0.43	1.11e-5	Obesity-related traits;
THYM	cis	rs9733	0.596	rs2275236	chr1:150669952	A/G	cg09034736	chr1:150693464	HORMAD1	-0.52	-4.66	-0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7712401	0.517	rs11958469	chr5:122385290	T/G	cg19808643	chr5:122110361	SNX2	-0.55	-4.63	-0.43	1.18e-5	Mean platelet volume;
THYM	cis	rs9902453	0.845	rs7222842	chr17:28246943	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.64	0.43	1.11e-5	Coffee consumption (cups per day);
THYM	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg26446133	chr18:72167187	CNDP2	-1.0	-7.99	-0.63	3.12e-12	Refractive error;
THYM	cis	rs6032067	1.000	rs35284867	chr20:43845836	A/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.71	-7.45	-0.61	4.34e-11	Blood protein levels;
THYM	cis	rs11096990	0.964	rs16988409	chr4:39269350	A/G	cg24403649	chr4:39172243	NA	0.65	5.39	0.48	5.04e-7	Cognitive function;
THYM	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs420259	0.516	rs7199108	chr16:23548801	G/A	cg00143387	chr16:23521605	GGA2	-0.75	-5.37	-0.48	5.57e-7	Bipolar disorder;
THYM	cis	rs4731207	0.565	rs6466978	chr7:124643786	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg11764359	chr7:65958608	NA	-0.62	-4.73	-0.44	7.94e-6	Aortic root size;
THYM	cis	rs7084402	0.967	rs2438182	chr10:60314815	A/T	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	trans	rs9951602	0.512	rs8085719	chr18:76649111	A/G	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs10484885	0.793	rs9359862	chr6:90474508	A/G	cg13799429	chr6:90582589	CASP8AP2	0.84	8.26	0.65	8.31e-13	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs960902	0.764	rs11124586	chr2:37728467	G/A	cg25341268	chr2:37734390	NA	-0.54	-4.49	-0.42	2.02e-5	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs2797160	1.000	rs6934435	chr6:126017481	T/G	cg16306078	chr6:126000798	NA	0.54	5.45	0.49	3.96e-7	Endometrial cancer;
THYM	cis	rs8018808	0.935	rs17824034	chr14:77878683	A/G	cg20045696	chr14:77926864	AHSA1	0.58	5.36	0.48	5.81e-7	Myeloid white cell count;
THYM	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg06634786	chr22:41940651	POLR3H	0.73	5.33	0.48	6.69e-7	Vitiligo;
THYM	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg03806693	chr22:41940476	POLR3H	-0.95	-8.7	-0.67	1.01e-13	Vitiligo;
THYM	cis	rs40363	0.523	rs757270	chr16:3534451	C/T	cg21433313	chr16:3507492	NAT15	-0.73	-7.6	-0.61	2.12e-11	Tuberculosis;
THYM	cis	rs7551222	0.716	rs10494852	chr1:204457786	A/G	cg20240347	chr1:204465584	NA	0.5	4.52	0.42	1.8e-5	Schizophrenia;
THYM	cis	rs4849845	0.886	rs13412677	chr2:121029517	C/G	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.73	7.99	0.63	3.09e-12	Eosinophil percentage of white cells;
THYM	cis	rs741677	0.586	rs58180134	chr17:499297	C/A	cg15660573	chr17:549704	VPS53	-0.75	-5.42	-0.49	4.45e-7	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);
THYM	trans	rs629535	0.783	rs510632	chr8:70034570	A/G	cg21567404	chr3:27674614	NA	1.12	10.86	0.74	2.44e-18	Dupuytren's disease;
THYM	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs870825	0.616	rs4594761	chr4:185643002	A/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs5771242	1.000	rs5771242	chr22:50661869	T/C	cg16473166	chr22:50639996	SELO	0.72	4.63	0.43	1.16e-5	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
THYM	cis	rs9787249	0.957	rs56064244	chr1:40213890	C/T	cg19912559	chr1:40204330	PPIE	0.64	4.92	0.45	3.61e-6	Blood protein levels;
THYM	cis	rs4631830	0.900	rs10763576	chr10:51538813	A/T	cg16070123	chr10:51489643	NA	-0.5	-4.48	-0.42	2.11e-5	Prostate-specific antigen levels;
THYM	cis	rs11608355	0.705	rs6663	chr12:109886603	G/A	cg11367159	chr12:110044531	NA	0.62	5.42	0.49	4.44e-7	Neuroticism;
THYM	cis	rs72627509	0.904	rs17081935	chr4:57823476	C/T	cg26694713	chr4:57773883	REST	0.76	4.56	0.42	1.53e-5	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg18876405	chr7:65276391	NA	0.63	5.56	0.5	2.48e-7	Aortic root size;
THYM	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg15592062	chr6:167189543	RPS6KA2	-0.49	-4.74	-0.44	7.58e-6	Crohn's disease;
THYM	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg25072359	chr17:41440525	NA	0.69	4.8	0.44	5.91e-6	Menopause (age at onset);
THYM	trans	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg10856724	chr12:34555212	NA	-0.78	-7.08	-0.59	2.48e-10	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2108225	0.967	rs7785790	chr7:107449896	C/T	cg18560240	chr7:107437656	SLC26A3	0.8	5.95	0.52	4.41e-8	Ulcerative colitis;
THYM	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.94	0.45	3.37e-6	Prudent dietary pattern;
THYM	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg18451016	chr1:38461880	NA	-0.38	-4.56	-0.42	1.54e-5	Coronary artery disease;
THYM	cis	rs9420	0.528	rs10896632	chr11:57390302	G/A	cg19752551	chr11:57585705	CTNND1	-0.58	-5.17	-0.47	1.3e-6	Schizophrenia;
THYM	cis	rs17598306	0.873	rs17657291	chr7:96603943	T/A	cg26766885	chr7:96220185	NA	0.62	5.13	0.47	1.56e-6	Radiation response;
THYM	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs3110496	0.650	rs614334	chr17:27904985	A/G	cg05877788	chr17:27899874	TP53I13	-0.45	-5.42	-0.49	4.53e-7	Height;
THYM	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg05872129	chr22:39784769	NA	-0.99	-8.17	-0.64	1.35e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs2282300	0.739	rs34855782	chr11:30225470	G/A	cg09906309	chr11:30344399	C11orf46	-0.67	-4.95	-0.45	3.23e-6	Morning vs. evening chronotype;
THYM	cis	rs56036086	0.824	rs73187254	chr22:50642359	C/T	cg16473166	chr22:50639996	SELO	0.76	4.78	0.44	6.47e-6	Platelet count;Plateletcrit;
THYM	cis	rs240764	0.594	rs9403997	chr6:101163433	A/C	cg21058520	chr6:100914733	NA	-0.6	-4.97	-0.45	2.93e-6	Neuroticism;
THYM	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg22709100	chr7:91322751	NA	-0.7	-5.45	-0.49	4e-7	Breast cancer;
THYM	cis	rs6490294	0.718	rs11065976	chr12:112047571	T/C	cg10833066	chr12:111807467	FAM109A	0.52	5.97	0.52	4.05e-8	Mean platelet volume;
THYM	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg06112835	chr11:68658793	MRPL21	0.45	6.42	0.55	5.25e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs12681287	0.640	rs13267782	chr8:87481887	G/T	cg27223183	chr8:87520930	FAM82B	-0.67	-5.05	-0.46	2.17e-6	Caudate activity during reward;
THYM	cis	rs9653442	0.704	rs10211595	chr2:100726476	G/C	cg07810366	chr2:100720526	AFF3	-0.37	-5.37	-0.48	5.55e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs28785552	0.931	rs8113078	chr19:53239084	T/G	cg10871876	chr19:53194124	ZNF83	0.82	6.87	0.58	6.68e-10	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02463440	chr8:22132932	PIWIL2	0.59	5.07	0.46	1.94e-6	Hypertriglyceridemia;
THYM	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2282300	0.739	rs1765139	chr11:30353725	T/C	cg25418670	chr11:30344373	C11orf46	-0.81	-7.07	-0.59	2.6200000000000003e-10	Morning vs. evening chronotype;
THYM	cis	rs9581857	0.579	rs9581843	chr13:27980507	T/G	cg22138327	chr13:27999177	GTF3A	1.04	6.13	0.53	1.97e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs1775715	0.870	rs1775731	chr10:32253512	A/G	cg04359828	chr10:32216031	ARHGAP12	0.42	5.17	0.47	1.3e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs6500395	1.000	rs9933237	chr16:48676562	T/C	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs12188164	1.000	rs72717411	chr5:429124	C/G	cg14137381	chr5:502291	SLC9A3	-0.62	-4.57	-0.42	1.45e-5	Cystic fibrosis severity;
THYM	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs7267979	0.933	rs2387887	chr20:25427081	G/T	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs11785693	0.862	rs17435612	chr8:4987896	C/T	cg26367366	chr8:4980734	NA	-0.95	-5.25	-0.47	9.31e-7	Neuroticism (multi-trait analysis);Neuroticism;
THYM	trans	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7772486	0.754	rs2328707	chr6:146053498	G/A	cg23711669	chr6:146136114	FBXO30	-0.98	-10.55	-0.73	1.11e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6987853	0.712	rs56220385	chr8:42428862	A/T	cg09913449	chr8:42400586	C8orf40	1.07	12.64	0.79	4.53e-22	Mean corpuscular hemoglobin concentration;
THYM	cis	rs13315871	0.929	rs11706920	chr3:58279672	C/T	cg00563845	chr3:58318305	PXK	0.58	4.92	0.45	3.61e-6	Cholesterol, total;
THYM	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg18305652	chr10:134549665	INPP5A	0.91	8.78	0.67	6.7e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs4499344	0.693	rs8106944	chr19:33097783	A/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.48	0.61	3.64e-11	Mean platelet volume;
THYM	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg00383909	chr3:49044727	WDR6	0.86	4.64	0.43	1.11e-5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg08213375	chr14:104286397	PPP1R13B	0.45	4.63	0.43	1.16e-5	Reticulocyte count;
THYM	cis	rs289828	0.579	rs12693004	chr2:152148718	G/A	cg05960677	chr2:152117363	RBM43	0.75	7.12	0.59	2.02e-10	Blood protein levels;
THYM	cis	rs11209185	0.602	rs12029657	chr1:68432702	G/C	cg22082780	chr1:68452167	NA	-0.49	-5.74	-0.51	1.14e-7	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs3126085	0.935	rs72696975	chr1:152206090	A/G	cg10321714	chr1:152280068	FLG	-0.73	-5.4	-0.48	4.94e-7	Atopic dermatitis;
THYM	cis	rs11608355	0.846	rs4766472	chr12:109853602	C/G	cg11367159	chr12:110044531	NA	0.59	5.06	0.46	2.04e-6	Neuroticism;
THYM	cis	rs4242434	0.927	rs746011	chr8:22457804	C/T	cg01710189	chr8:22454888	PDLIM2	-0.56	-5.22	-0.47	1.07e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg09455208	chr3:40491958	NA	0.44	4.6	0.43	1.29e-5	Renal cell carcinoma;
THYM	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg00908189	chr16:619842	PIGQ	1.05	9.25	0.69	6.62e-15	Height;
THYM	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11890956	chr21:40555474	PSMG1	-0.66	-6.38	-0.55	6.51e-9	Menarche (age at onset);
THYM	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg00484396	chr16:3507460	NAT15	-0.74	-9.01	-0.68	2.2e-14	Tuberculosis;
THYM	cis	rs4378999	0.528	rs2355350	chr3:50814508	G/A	cg27233566	chr3:49894142	TRAIP	0.77	4.47	0.42	2.16e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg07061783	chr6:25882402	NA	-0.86	-7.5	-0.61	3.39e-11	Intelligence (multi-trait analysis);
THYM	cis	rs6987853	0.563	rs2923414	chr8:42455509	G/A	cg09913449	chr8:42400586	C8orf40	0.57	4.87	0.45	4.45e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg16586182	chr3:47516702	SCAP	-0.63	-5.52	-0.49	2.96e-7	Colorectal cancer;
THYM	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg03806693	chr22:41940476	POLR3H	1.16	10.2	0.72	6.06e-17	Vitiligo;
THYM	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg13397359	chr6:42928475	GNMT	-0.64	-5.55	-0.49	2.57e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4589258	0.762	rs4306265	chr11:90472732	G/C	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.83	-0.44	5.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.693	rs8079418	chr17:17924060	C/T	cg16928487	chr17:17741425	SREBF1	-0.55	-5.07	-0.46	1.93e-6	Total body bone mineral density;
THYM	cis	rs10779751	1.000	rs11121702	chr1:11293147	C/T	cg08854313	chr1:11322531	MTOR	0.9	7.42	0.61	4.94e-11	Body mass index;
THYM	cis	rs10823500	0.748	rs2394668	chr10:71943951	G/A	cg04118878	chr10:71993077	PPA1	0.61	4.46	0.42	2.23e-5	Blood protein levels;
THYM	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	10.0	0.72	1.67e-16	Platelet count;
THYM	cis	rs13102973	0.965	rs4597893	chr4:135863043	C/T	cg14419869	chr4:135874104	NA	-0.82	-7.94	-0.63	4.06e-12	Subjective well-being;
THYM	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg03647317	chr4:187891568	NA	-0.84	-9.02	-0.68	2.08e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg08439880	chr3:133502540	NA	-0.73	-6.46	-0.55	4.44e-9	Iron status biomarkers;
THYM	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.01	6.91	0.58	5.64e-10	Platelet count;
THYM	cis	rs3741151	0.764	rs7101561	chr11:73264219	G/C	cg17517138	chr11:73019481	ARHGEF17	0.9	4.68	0.43	9.36e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg11941060	chr3:133502564	NA	-0.71	-6.04	-0.53	3e-8	Iron status biomarkers;
THYM	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg15536230	chr21:44985092	HSF2BP	-0.43	-5.25	-0.47	9.18e-7	Mean corpuscular volume;
THYM	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg07424592	chr7:64974309	NA	1.08	5.7	0.51	1.32e-7	Diabetic kidney disease;
THYM	cis	rs72781680	0.848	rs55725028	chr2:23966447	A/G	cg08917208	chr2:24149416	ATAD2B	1.1	4.81	0.44	5.71e-6	Lymphocyte counts;
THYM	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg14186256	chr22:23484241	RTDR1	0.95	9.24	0.69	7.12e-15	Bone mineral density;
THYM	cis	rs13315871	0.858	rs4075404	chr3:58411419	C/T	cg12435725	chr3:58293450	RPP14	-0.46	-4.93	-0.45	3.54e-6	Cholesterol, total;
THYM	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg26750617	chr12:132293702	NA	-0.64	-5.51	-0.49	3.06e-7	Migraine;
THYM	cis	rs6980334	0.871	rs4732285	chr7:137754127	A/T	cg18769353	chr7:137028617	PTN	0.58	4.58	0.43	1.39e-5	Blood metabolite ratios;
THYM	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg24578937	chr1:2090814	PRKCZ	0.57	6.05	0.53	2.86e-8	Height;
THYM	cis	rs10208649	0.908	rs9678301	chr2:54241510	G/T	cg04546899	chr2:54196757	PSME4	0.68	4.73	0.44	7.94e-6	Body mass index;
THYM	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg00271210	chr6:167070053	RPS6KA2	-0.71	-7.66	-0.62	1.54e-11	Crohn's disease;
THYM	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9560113	0.622	rs4773388	chr13:112195250	A/C	cg15979348	chr13:112237479	NA	0.51	4.51	0.42	1.89e-5	Menarche (age at onset);
THYM	cis	rs10832963	0.924	rs10832950	chr11:18635815	A/G	cg20219074	chr11:18656078	SPTY2D1	0.81	6.58	0.56	2.52e-9	Breast cancer;
THYM	cis	rs2273669	0.667	rs76430494	chr6:109350128	C/A	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs28595532	0.841	rs115725150	chr4:119768647	T/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs7772486	0.686	rs7744014	chr6:146123818	G/A	cg23711669	chr6:146136114	FBXO30	0.83	7.92	0.63	4.52e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg06521331	chr12:34319734	NA	-0.96	-9.28	-0.69	5.69e-15	Morning vs. evening chronotype;
THYM	cis	rs1775715	0.737	rs1023207	chr10:32094890	C/A	cg04359828	chr10:32216031	ARHGAP12	0.37	4.83	0.44	5.3e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg26384229	chr12:38710491	ALG10B	-0.75	-6.25	-0.54	1.14e-8	Morning vs. evening chronotype;
THYM	cis	rs10992471	0.533	rs331377	chr9:95243549	C/T	cg14631576	chr9:95140430	CENPP	-0.6	-4.77	-0.44	6.61e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg08847533	chr14:75593920	NEK9	-0.98	-10.79	-0.74	3.45e-18	Height;
THYM	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg22920501	chr2:26401640	FAM59B	-0.8	-6.57	-0.56	2.64e-9	Gut microbiome composition (summer);
THYM	cis	rs1461503	0.932	rs56778812	chr11:122840491	C/T	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg26963428	chr7:66367121	NA	-0.58	-4.62	-0.43	1.22e-5	Corneal structure;
THYM	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg12826209	chr6:26865740	GUSBL1	0.84	6.07	0.53	2.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1499972	0.941	rs2860308	chr3:117690309	T/G	cg07612923	chr3:117604196	NA	-1.42	-5.49	-0.49	3.4e-7	Schizophrenia;
THYM	cis	rs1878931	0.597	rs37816	chr16:3456371	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.68	-4.5	-0.42	1.91e-5	Body mass index (adult);
THYM	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03264133	chr6:25882463	NA	-0.67	-5.03	-0.46	2.36e-6	Height;
THYM	cis	rs611744	0.870	rs57723916	chr8:109191433	A/T	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs899997	0.731	rs58717592	chr15:79030417	T/C	cg00639195	chr15:79103007	ADAMTS7	0.78	4.86	0.45	4.61e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs9810089	0.777	rs2688601	chr3:136252601	G/A	cg21827317	chr3:136751795	NA	0.59	5.05	0.46	2.11e-6	Gestational age at birth (child effect);
THYM	cis	rs9326248	0.530	rs473188	chr11:116812029	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.85	4.58	0.43	1.43e-5	Blood protein levels;
THYM	cis	rs4638749	0.953	rs4676033	chr2:108869368	G/A	cg23163573	chr2:108905468	SULT1C2	-0.29	-4.47	-0.42	2.15e-5	Blood pressure;
THYM	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg24803719	chr17:45855879	NA	-0.6	-6.33	-0.54	7.96e-9	IgG glycosylation;
THYM	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06634786	chr22:41940651	POLR3H	0.84	6.24	0.54	1.21e-8	Vitiligo;
THYM	cis	rs11186	0.504	rs7424585	chr2:189941784	C/A	cg11041835	chr2:189156425	GULP1	0.78	4.69	0.43	9.21e-6	Parkinson's disease;
THYM	cis	rs13102973	0.640	rs13113331	chr4:135838729	C/T	cg14419869	chr4:135874104	NA	0.72	5.86	0.51	6.78e-8	Subjective well-being;
THYM	cis	rs3112255	0.967	rs2015067	chr2:101305478	T/C	cg01042948	chr2:101319752	NA	0.72	6.28	0.54	1.02e-8	Intelligence (multi-trait analysis);
THYM	cis	rs10463554	0.927	rs464702	chr5:102406884	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.13	-0.47	1.56e-6	Parkinson's disease;
THYM	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg06784218	chr1:46089804	CCDC17	0.29	4.57	0.42	1.48e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg18252515	chr7:66147081	NA	-1.5	-9.13	-0.68	1.2e-14	Diabetic kidney disease;
THYM	cis	rs6138458	1.000	rs227651	chr20:24929834	A/G	cg26195577	chr20:24973756	C20orf3	1.11	10.36	0.73	2.84e-17	Blood protein levels;
THYM	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg21028142	chr17:79581711	NPLOC4	0.52	5.13	0.47	1.52e-6	Eye color traits;
THYM	cis	rs9653442	0.712	rs6714788	chr2:100686173	A/G	cg07810366	chr2:100720526	AFF3	0.41	6.06	0.53	2.79e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs7592578	0.508	rs62180987	chr2:191267173	A/G	cg10560079	chr2:191398806	TMEM194B	-0.75	-5.67	-0.5	1.52e-7	Diastolic blood pressure;
THYM	cis	rs73416724	1.000	rs73416724	chr6:43337802	A/G	cg26312998	chr6:43337775	ZNF318	1.25	5.85	0.51	6.88e-8	Autism spectrum disorder or schizophrenia;
THYM	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg09703963	chr11:616879	IRF7;MUPCDH	-0.74	-5.52	-0.49	2.88e-7	Systemic lupus erythematosus;
THYM	cis	rs7412746	0.563	rs3768013	chr1:150815411	G/A	cg10589385	chr1:150898437	SETDB1	0.61	5.13	0.47	1.51e-6	Melanoma;
THYM	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg00981070	chr1:2046702	PRKCZ	-0.44	-5.4	-0.48	4.93e-7	Height;
THYM	cis	rs4786125	0.665	rs6500857	chr16:6903364	C/T	cg03623568	chr16:6915990	A2BP1	-1.01	-9.88	-0.71	2.98e-16	Heart rate variability traits (SDNN);
THYM	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg27535305	chr1:53392650	SCP2	-0.47	-5.35	-0.48	6.07e-7	Monocyte count;
THYM	trans	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg23352942	chr3:46931381	PTH1R	0.62	5.79	0.51	9.03e-8	Birth weight;
THYM	cis	rs4363385	0.755	rs516198	chr1:153026196	T/C	cg13444842	chr1:152974279	SPRR3	-0.63	-5.12	-0.47	1.58e-6	Inflammatory skin disease;
THYM	cis	rs11190604	1.000	rs10883513	chr10:102316964	A/G	cg07570687	chr10:102243282	WNT8B	0.73	6.21	0.54	1.42e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg26031613	chr14:104095156	KLC1	0.78	5.2	0.47	1.14e-6	Body mass index;
THYM	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.73	7.01	0.58	3.48e-10	Lymphocyte counts;
THYM	cis	rs6732160	0.631	rs7557285	chr2:73442812	G/A	cg24220031	chr2:73402428	NA	-0.8	-9.34	-0.69	4.32e-15	Intelligence (multi-trait analysis);
THYM	cis	rs728616	0.867	rs61860039	chr10:81939906	G/A	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs9858542	0.537	rs34915642	chr3:49358646	G/A	cg00383909	chr3:49044727	WDR6	0.69	4.67	0.43	1.01e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs11089937	0.616	rs928895	chr22:22540305	T/C	cg06866756	chr22:22471216	NA	-0.46	-5.09	-0.46	1.79e-6	Periodontitis (PAL4Q3);
THYM	cis	rs2806561	0.828	rs944509	chr1:23542242	C/T	cg12483005	chr1:23474871	LUZP1	-0.55	-5.65	-0.5	1.66e-7	Height;
THYM	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg11189052	chr15:85197271	WDR73	-0.59	-4.51	-0.42	1.89e-5	P wave terminal force;
THYM	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	trans	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs1691799	0.899	rs1168328	chr12:66729250	T/C	cg16791601	chr12:66731901	HELB	-0.75	-7.25	-0.6	1.08e-10	White blood cell count (basophil);
THYM	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03264133	chr6:25882463	NA	-0.67	-5.03	-0.46	2.36e-6	Height;
THYM	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.82	-4.55	-0.42	1.56e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs4936891	0.563	rs78294880	chr11:123890006	C/T	cg22125253	chr11:123886957	OR10G4	0.51	4.64	0.43	1.12e-5	Male fertility;
THYM	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg19774624	chr17:42201019	HDAC5	0.67	5.92	0.52	5.01e-8	Total body bone mineral density;
THYM	cis	rs35660623	0.718	rs13273767	chr8:10632548	C/T	cg12395012	chr8:11607386	GATA4	0.96	4.66	0.43	1.05e-5	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs7267979	1.000	rs2258563	chr20:25273435	C/T	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1557488	0.599	rs1540245	chr11:126694407	T/C	cg03950493	chr11:126582183	KIRREL3	-0.38	-4.48	-0.42	2.11e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs56104184	0.775	rs55756106	chr19:49403055	A/G	cg17863274	chr19:49399704	TULP2	-1.01	-6.47	-0.55	4.29e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7917772	0.582	rs4919661	chr10:104358403	T/C	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7107174	1.000	rs2510047	chr11:77988668	C/T	cg02023728	chr11:77925099	USP35	-0.62	-5.86	-0.52	6.73e-8	Testicular germ cell tumor;
THYM	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.63	-5.23	-0.47	1.02e-6	Age at first birth;
THYM	cis	rs12549902	0.897	rs12549294	chr8:41506380	A/G	cg21772509	chr8:41503840	NKX6-3	0.71	6.58	0.56	2.6e-9	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
THYM	cis	rs898549	0.569	rs10899963	chr10:44501123	A/C	cg08683644	chr10:44853092	NA	0.47	4.57	0.42	1.48e-5	Obesity-related traits;
THYM	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg11764359	chr7:65958608	NA	-0.82	-6.6	-0.56	2.29e-9	Aortic root size;
THYM	cis	rs2135507	0.565	rs906150	chr4:83537686	A/C	cg10249074	chr4:83542146	C4orf11	-0.58	-4.56	-0.42	1.55e-5	Juvenile osteochondritis dissecans;
THYM	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg19077165	chr18:44547161	KATNAL2	0.57	5.99	0.52	3.77e-8	Educational attainment;
THYM	cis	rs7578361	0.918	rs2377262	chr2:150354811	G/A	cg17961725	chr2:150454027	NA	0.74	5.41	0.48	4.79e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs2806561	0.808	rs2294518	chr1:23372771	T/C	cg19743168	chr1:23544995	NA	-0.57	-5.28	-0.48	8.27e-7	Height;
THYM	cis	rs7616559	0.789	rs9818500	chr3:156760139	C/T	cg15697575	chr3:156784781	NA	0.41	5.3	0.48	7.61e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs4930776	0.932	rs454704	chr12:5758662	C/T	cg02086166	chr12:5775618	ANO2	-0.62	-6.17	-0.53	1.69e-8	Plasma clusterin levels;
THYM	cis	rs13177918	0.559	rs10447224	chr5:149834365	G/A	cg14059543	chr5:149831962	NA	-0.92	-7.65	-0.62	1.64e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4930103	0.619	rs10769945	chr11:1985127	C/T	cg18511798	chr11:2018149	H19;MIR675	-0.54	-5.34	-0.48	6.25e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg10661904	chr17:79619235	PDE6G	-0.65	-6.24	-0.54	1.19e-8	Eye color traits;
THYM	cis	rs2742234	0.541	rs10793422	chr10:43703874	G/A	cg06632098	chr10:43605906	RET	0.8	5.18	0.47	1.22e-6	Hirschsprung disease;
THYM	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11890956	chr21:40555474	PSMG1	-0.66	-6.38	-0.55	6.51e-9	Menarche (age at onset);
THYM	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg07570687	chr10:102243282	WNT8B	0.74	6.47	0.55	4.35e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg18252515	chr7:66147081	NA	-0.62	-4.55	-0.42	1.59e-5	Aortic root size;
THYM	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg26038318	chr20:34205095	SPAG4	0.63	5.16	0.47	1.36e-6	Total cholesterol levels;
THYM	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg15741354	chr8:8146129	NA	-0.31	-5.24	-0.47	9.49e-7	Joint mobility (Beighton score);
THYM	cis	rs2820651	0.614	rs56003778	chr10:1490006	C/T	cg13720710	chr10:1452970	ADARB2	0.79	4.99	0.46	2.72e-6	Migraine with aura;
THYM	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg00463982	chr16:1583984	IFT140;TMEM204	-0.62	-5.22	-0.47	1.05e-6	Coronary artery disease;
THYM	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg25358565	chr5:93447407	FAM172A	0.96	7.02	0.58	3.36e-10	Diabetic retinopathy;
THYM	cis	rs36051895	0.589	rs16922779	chr9:5200127	G/A	cg02405213	chr9:5042618	JAK2	-0.87	-8.75	-0.67	7.64e-14	Pediatric autoimmune diseases;
THYM	cis	rs4731207	0.565	rs1994022	chr7:124580877	C/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs861020	0.630	rs585627	chr1:210004199	C/G	cg05527609	chr1:210001259	C1orf107	0.83	6.55	0.56	2.9e-9	Orofacial clefts;
THYM	cis	rs2282300	0.653	rs12800124	chr11:30239865	A/G	cg06241208	chr11:30344200	C11orf46	-0.77	-5.59	-0.5	2.15e-7	Morning vs. evening chronotype;
THYM	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs9814567	0.806	rs4074523	chr3:134325657	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.79	-7.82	-0.63	7.09e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs16904191	0.684	rs747499	chr8:131030628	T/C	cg00659129	chr8:131414614	ASAP1	0.3	4.6	0.43	1.31e-5	Migraine;
THYM	cis	rs2285947	1.000	rs6970985	chr7:21583597	G/T	cg04471919	chr7:21584483	DNAH11	0.45	4.46	0.42	2.29e-5	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
THYM	cis	rs10484885	0.680	rs72921943	chr6:90581542	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.91	-9.55	-0.7	1.5e-15	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs11711311	1.000	rs10212375	chr3:113471336	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.61	-5.45	-0.49	4.02e-7	IgG glycosylation;
THYM	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg12463550	chr7:65579703	CRCP	-0.57	-4.62	-0.43	1.23e-5	Aortic root size;
THYM	cis	rs4866334	0.850	rs75263301	chr5:18463357	T/G	cg04591469	chr5:17810299	NA	-1.13	-4.46	-0.42	2.24e-5	IgG glycosylation;
THYM	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg05234568	chr11:5960015	NA	-0.62	-5.51	-0.49	3.05e-7	DNA methylation (variation);
THYM	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.47	-0.55	4.29e-9	Developmental language disorder (linguistic errors);
THYM	trans	rs877282	0.898	rs11253338	chr10:759559	C/T	cg22713356	chr15:30763199	NA	1.33	9.41	0.69	2.94e-15	Uric acid levels;
THYM	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg03060546	chr3:49711283	APEH	0.77	6.37	0.55	6.65e-9	Resting heart rate;
THYM	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg03433033	chr1:76189801	ACADM	-0.76	-10.0	-0.72	1.68e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs907683	0.584	rs2854903	chr2:220288979	C/T	cg15015639	chr2:220282977	DES	-0.42	-5.71	-0.51	1.3e-7	Resting heart rate;
THYM	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.8e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7100689	0.646	rs1890889	chr10:82090827	G/T	cg01528321	chr10:82214614	TSPAN14	0.84	6.43	0.55	5.15e-9	Post bronchodilator FEV1;
THYM	cis	rs2730245	0.615	rs2527207	chr7:158743078	A/G	cg11984989	chr7:158649758	WDR60	-0.95	-7.04	-0.59	2.99e-10	Height;
THYM	cis	rs2282300	0.702	rs2211018	chr11:30330079	C/T	cg06241208	chr11:30344200	C11orf46	0.78	5.65	0.5	1.64e-7	Morning vs. evening chronotype;
THYM	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18402987	chr7:1209562	NA	0.73	5.4	0.48	4.85e-7	Longevity;Endometriosis;
THYM	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7626444	0.625	rs2669637	chr3:196477369	G/A	cg12930392	chr3:196481615	PAK2	0.4	4.92	0.45	3.58e-6	Monocyte count;
THYM	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7106204	0.514	rs7107321	chr11:24259879	T/C	ch.11.24196551F	chr11:24239977	NA	0.99	7.06	0.59	2.66e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg18132916	chr6:79620363	NA	-0.59	-5.32	-0.48	6.96e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg03806693	chr22:41940476	POLR3H	-0.84	-7.2	-0.59	1.37e-10	Neuroticism;
THYM	cis	rs57920188	0.703	rs10915642	chr1:4089244	T/C	cg08764037	chr1:3634867	TP73	-0.45	-4.63	-0.43	1.15e-5	Interleukin-17 levels;
THYM	cis	rs7584330	0.518	rs74003103	chr2:238446699	G/A	cg14458575	chr2:238380390	NA	0.82	4.53	0.42	1.74e-5	Prostate cancer;
THYM	cis	rs116095464	0.558	rs114607464	chr5:300468	C/T	cg22496380	chr5:211416	CCDC127	-1.28	-7.75	-0.62	1.03e-11	Breast cancer;
THYM	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.02	-7.03	-0.59	3.07e-10	Platelet count;
THYM	cis	rs514406	0.800	rs7548519	chr1:53294473	A/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-5.16	-0.47	1.36e-6	Monocyte count;
THYM	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg13918804	chr1:2043761	PRKCZ	0.89	8.38	0.65	4.69e-13	Height;
THYM	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg05738196	chr6:26577821	NA	0.86	8.72	0.67	9.13e-14	Intelligence (multi-trait analysis);
THYM	cis	rs6960043	0.818	rs1974619	chr7:15065300	C/T	cg19272540	chr7:15055459	NA	-0.44	-4.88	-0.45	4.23e-6	Type 2 diabetes;
THYM	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg03733263	chr8:22462867	KIAA1967	1.13	12.95	0.8	1.04e-22	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg14416269	chr4:6271139	WFS1	0.49	4.74	0.44	7.44e-6	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg21798802	chr22:38057573	PDXP	0.47	5.34	0.48	6.29e-7	Fat distribution (HIV);
THYM	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg04455712	chr21:45112962	RRP1B	-0.51	-4.71	-0.44	8.41e-6	Mean corpuscular volume;
THYM	cis	rs9915657	0.870	rs34129640	chr17:70125665	A/C	cg06234051	chr17:70120541	SOX9	-0.71	-6.63	-0.56	2.02e-9	Thyroid hormone levels;
THYM	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg06766960	chr11:133703094	NA	-0.61	-5.8	-0.51	8.64e-8	Childhood ear infection;
THYM	cis	rs6956675	0.534	rs1806453	chr7:62641533	A/G	cg27518014	chr7:62859535	LOC100287834	-0.52	-4.5	-0.42	1.96e-5	Obesity-related traits;
THYM	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg23422044	chr7:1970798	MAD1L1	-0.77	-5.39	-0.48	5.19e-7	Bipolar disorder;
THYM	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.14	-0.64	1.51e-12	Personality dimensions;
THYM	cis	rs4595586	0.563	rs2388178	chr12:39364366	T/G	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs10095849	0.576	rs4733917	chr8:39476978	T/C	cg01911981	chr8:39380341	ADAM3A	-0.59	-5.05	-0.46	2.13e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs1160297	0.585	rs2356681	chr2:53097750	C/T	cg07782112	chr2:53107842	NA	0.79	6.37	0.55	6.61e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg03609598	chr5:56110824	MAP3K1	-0.7	-5.32	-0.48	6.82e-7	Type 2 diabetes;
THYM	cis	rs3780378	0.967	rs7037207	chr9:5043156	C/T	cg02405213	chr9:5042618	JAK2	-0.78	-7.34	-0.6	7.17e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs17597773	1.000	rs17597773	chr1:221054761	C/G	cg16008148	chr1:221062819	NA	0.45	5.11	0.46	1.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9875589	0.509	rs28865280	chr3:14064958	C/T	cg03204825	chr3:13978759	TPRXL	-0.54	-4.69	-0.43	9.31e-6	Ovarian reserve;
THYM	cis	rs7572733	0.534	rs1401091	chr2:198790423	T/G	cg05783139	chr2:198650985	BOLL	-0.62	-4.91	-0.45	3.8e-6	Dermatomyositis;
THYM	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg19016782	chr12:123741754	C12orf65	-0.68	-4.48	-0.42	2.05e-5	Neutrophil percentage of white cells;
THYM	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg02478829	chr6:26598070	ABT1	-0.33	-4.49	-0.42	1.97e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg18512352	chr11:47633146	NA	-0.51	-5.96	-0.52	4.17e-8	Subjective well-being;
THYM	cis	rs12216545	0.737	rs1916007	chr7:150240289	A/G	cg08960815	chr7:150264767	GIMAP4	-0.89	-8.27	-0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4372836	0.729	rs10166861	chr2:29061111	A/G	cg09522027	chr2:28974177	PPP1CB	-0.66	-5.08	-0.46	1.89e-6	Body mass index;
THYM	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg13770153	chr20:60521292	NA	-0.65	-4.62	-0.43	1.19e-5	Body mass index;
THYM	cis	rs34599045	0.708	rs12027303	chr1:152897923	C/T	cg24332770	chr1:152658287	LCE2B	-0.48	-4.68	-0.43	9.6e-6	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs3741151	1.000	rs79794992	chr11:73049352	A/G	cg12959048	chr11:73096162	RELT	-0.5	-4.78	-0.44	6.38e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg12564285	chr5:131593104	PDLIM4	0.5	5.34	0.48	6.22e-7	Acylcarnitine levels;
THYM	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg02086790	chr16:375327	AXIN1	-0.47	-4.96	-0.45	3.04e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs12257961	0.640	rs7897087	chr10:15376516	C/T	cg10616319	chr10:15468812	NA	-0.61	-5.07	-0.46	1.93e-6	Selective IgA deficiency;
THYM	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg23815491	chr16:72088622	HP	0.78	6.16	0.53	1.75e-8	Fibrinogen levels;
THYM	cis	rs3015497	0.789	rs3015500	chr14:51108877	C/T	cg04730355	chr14:51134070	SAV1	-0.53	-4.7	-0.43	8.68e-6	Mean platelet volume;
THYM	cis	rs1728785	0.818	rs1645984	chr16:68628850	T/C	cg02972257	chr16:68554789	NA	-0.78	-4.97	-0.45	3e-6	Ulcerative colitis;
THYM	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg17757837	chr7:157058334	UBE3C	-0.74	-6.08	-0.53	2.45e-8	Body mass index;
THYM	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs7106204	0.748	rs11027754	chr11:24203657	G/C	ch.11.24196551F	chr11:24239977	NA	0.97	6.93	0.58	5.07e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs4803468	0.967	rs3745290	chr19:41890003	C/T	cg09537434	chr19:41945824	ATP5SL	-1.13	-10.6	-0.74	8.86e-18	Height;
THYM	cis	rs6952808	0.929	rs2280548	chr7:1976667	G/T	cg20295408	chr7:1910781	MAD1L1	-0.65	-4.93	-0.45	3.42e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg04025307	chr7:1156635	C7orf50	0.86	9.17	0.69	9.89e-15	Longevity;Endometriosis;
THYM	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg18538332	chr22:24372958	LOC391322	-1.04	-15.99	-0.85	1.1e-28	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs916888	0.647	rs199520	chr17:44853872	G/A	cg01341218	chr17:43662625	NA	-0.81	-6.97	-0.58	4.15e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1823778	0.520	rs2365742	chr18:67700998	A/C	cg12929678	chr18:67624393	CD226	1.3	4.63	0.43	1.14e-5	Mean platelet volume;
THYM	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg04111992	chr7:158790115	NA	-0.55	-4.94	-0.45	3.41e-6	Facial morphology (factor 20);
THYM	cis	rs13256369	0.901	rs4841015	chr8:8567140	C/G	cg18904891	chr8:8559673	CLDN23	0.67	4.97	0.45	3e-6	Obesity-related traits;
THYM	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg13695892	chr22:41940480	POLR3H	-0.82	-5.95	-0.52	4.43e-8	Vitiligo;
THYM	cis	rs35160687	0.814	rs7563887	chr2:86516121	C/T	cg10973622	chr2:86423274	IMMT	0.53	5.19	0.47	1.2e-6	Night sleep phenotypes;
THYM	cis	rs6456156	0.774	rs6931530	chr6:167527200	A/C	cg09487078	chr6:167525398	CCR6	-0.45	-5.07	-0.46	1.93e-6	Primary biliary cholangitis;
THYM	cis	rs2371030	0.965	rs2216403	chr2:211573391	G/T	cg18417063	chr2:211583084	NA	-0.53	-4.56	-0.42	1.52e-5	Non-small cell lung cancer;
THYM	cis	rs6543140	0.964	rs1523206	chr2:103070175	A/T	cg03938978	chr2:103052716	IL18RAP	0.61	6.13	0.53	2.03e-8	Blood protein levels;
THYM	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	5.1	0.46	1.74e-6	Schizophrenia;
THYM	cis	rs17006441	0.932	rs35022873	chr3:69891388	C/T	cg18496212	chr3:69797108	MITF	0.65	6.36	0.55	7.15e-9	Hemoglobin concentration;
THYM	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg08901578	chr4:187885870	NA	-0.68	-6.86	-0.58	6.97e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2832077	0.943	rs11701445	chr21:30160807	C/T	cg24692254	chr21:30365293	RNF160	-0.84	-5.22	-0.47	1.04e-6	Cognitive test performance;
THYM	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-5.77	-0.51	9.69e-8	Gut microbiome composition (summer);
THYM	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg08645402	chr16:4508243	NA	0.68	5.12	0.46	1.62e-6	Schizophrenia;
THYM	cis	rs2281845	0.929	rs2057579	chr1:201099275	T/C	cg22815214	chr1:201083145	CACNA1S	0.74	6.78	0.57	1.01e-9	Permanent tooth development;
THYM	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg27490568	chr2:178487706	NA	0.57	5.19	0.47	1.18e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs11997175	1.000	rs7464996	chr8:33770925	G/T	ch.8.33884649F	chr8:33765107	NA	0.65	5.07	0.46	1.94e-6	Body mass index;
THYM	cis	rs9807989	0.507	rs3732124	chr2:103018052	A/G	cg03938978	chr2:103052716	IL18RAP	-0.75	-9.83	-0.71	3.79e-16	Asthma;
THYM	cis	rs28830936	0.510	rs7175346	chr15:42100674	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.36	-6.42	-0.55	5.28e-9	Diastolic blood pressure;
THYM	cis	rs13279522	0.536	rs884839	chr8:67019988	A/C	cg20171999	chr8:67343066	NA	-0.46	-4.6	-0.43	1.3e-5	Coronary heart disease event reduction (statin therapy interaction);
THYM	cis	rs425277	0.583	rs12059660	chr1:2041461	C/T	cg00981070	chr1:2046702	PRKCZ	-0.41	-5.09	-0.46	1.83e-6	Height;
THYM	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg03467027	chr4:99064603	C4orf37	0.59	4.5	0.42	1.92e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-4.93	-0.45	3.51e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg04234412	chr22:24373322	LOC391322	-1.04	-13.45	-0.81	1.01e-23	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9972944	0.902	rs59009755	chr17:63772263	C/T	cg07283582	chr17:63770753	CCDC46	0.66	5.42	0.49	4.59e-7	Total body bone mineral density;
THYM	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg06634786	chr22:41940651	POLR3H	0.69	5.12	0.46	1.61e-6	Vitiligo;
THYM	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.78	0.51	9.58e-8	Rheumatoid arthritis;
THYM	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1808579	0.904	rs2960578	chr18:21143739	A/C	cg14672496	chr18:21087552	C18orf8	0.52	4.8	0.44	5.87e-6	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
THYM	cis	rs1018836	0.892	rs10105142	chr8:91547420	C/T	cg16814680	chr8:91681699	NA	-0.82	-7.41	-0.6	5.27e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs2276314	0.857	rs28396546	chr18:33639024	T/C	cg19628046	chr18:33552617	C18orf21	0.75	5.33	0.48	6.55e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg03609598	chr5:56110824	MAP3K1	-0.89	-6.07	-0.53	2.63e-8	Initial pursuit acceleration;
THYM	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg04267008	chr7:1944627	MAD1L1	-0.58	-4.71	-0.44	8.29e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs800586	0.956	rs800554	chr8:116816165	T/C	cg04656070	chr8:116661063	TRPS1	0.49	4.7	0.43	8.9e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs4523957	0.928	rs216219	chr17:2147291	T/C	cg16513277	chr17:2031491	SMG6	0.8	7.55	0.61	2.58e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11225247	1.000	rs116917439	chr11:102314742	A/G	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg17143192	chr8:8559678	CLDN23	0.74	5.43	0.49	4.27e-7	Obesity-related traits;
THYM	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs425277	0.959	rs77665022	chr1:2065958	C/T	cg23803603	chr1:2058230	PRKCZ	0.6	4.64	0.43	1.1e-5	Height;
THYM	cis	rs9297145	0.678	rs62473051	chr7:98781955	C/T	cg05967295	chr7:98741636	SMURF1	0.8	5.91	0.52	5.37e-8	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg13319975	chr6:146136371	FBXO30	-0.65	-5.26	-0.47	8.97e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs714031	1.000	rs714031	chr22:40070234	C/T	cg21377881	chr22:40064566	CACNA1I	0.55	4.97	0.45	2.95e-6	Schizophrenia;
THYM	cis	rs514406	0.929	rs1672908	chr1:53340885	A/G	cg22166914	chr1:53195759	ZYG11B	0.8	8.1	0.64	1.82e-12	Monocyte count;
THYM	cis	rs3892630	0.878	rs8112955	chr19:33191192	C/T	cg22928329	chr19:33183273	NUDT19	-0.77	-5.83	-0.51	7.74e-8	Red blood cell traits;
THYM	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg20608306	chr11:116969690	SIK3	0.49	4.57	0.42	1.49e-5	Blood protein levels;
THYM	cis	rs7769051	0.522	rs7761207	chr6:133110430	G/A	cg07930552	chr6:133119739	C6orf192	1.21	5.29	0.48	7.84e-7	Type 2 diabetes nephropathy;
THYM	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.52	-4.74	-0.44	7.38e-6	Prudent dietary pattern;
THYM	cis	rs2294693	0.945	rs9369255	chr6:40989503	T/C	cg14769373	chr6:40998127	UNC5CL	-0.6	-4.47	-0.42	2.19e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs11039798	0.544	rs113253936	chr11:48160609	C/T	cg24672777	chr11:48374446	OR4C45	-1.1	-5.3	-0.48	7.55e-7	Axial length;
THYM	cis	rs79387448	0.745	rs72993760	chr2:103151704	G/A	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg15704280	chr7:45808275	SEPT13	-1.0	-8.07	-0.64	2.18e-12	Coronary artery disease;
THYM	cis	rs6840360	1.000	rs6849050	chr4:152599902	C/T	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg15445000	chr17:37608096	MED1	-0.44	-5.07	-0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg16586182	chr3:47516702	SCAP	-0.67	-5.65	-0.5	1.68e-7	Colorectal cancer;
THYM	cis	rs7833986	1.000	rs56699713	chr8:57096670	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.51	4.85	0.45	4.74e-6	Height;
THYM	cis	rs338389	0.586	rs10851782	chr15:68265049	G/A	cg07562100	chr15:68569975	FEM1B	0.74	5.26	0.47	8.87e-7	Survival in rectal cancer;
THYM	cis	rs10411262	0.506	rs6509290	chr19:47183840	T/C	cg18040997	chr19:47551898	TMEM160	0.72	4.55	0.42	1.56e-5	Tonsillectomy;
THYM	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2e-5	Diabetic retinopathy;
THYM	cis	rs9595908	0.931	rs9591001	chr13:33042870	A/G	cg12383807	chr13:33924137	NA	0.52	4.48	0.42	2.09e-5	Body mass index;
THYM	cis	rs6988636	1.000	rs58741168	chr8:124191852	G/A	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg16031515	chr1:205743344	RAB7L1	-0.66	-6.73	-0.57	1.28e-9	Menarche (age at onset);
THYM	cis	rs17006441	0.932	rs9864949	chr3:69878549	C/T	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs61774743	0.754	rs11578963	chr1:41834183	A/G	cg01193554	chr1:41846683	NA	0.33	4.74	0.44	7.41e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4792901	0.959	rs12603053	chr17:41628292	A/G	cg21940313	chr17:41620911	ETV4	-0.53	-5.63	-0.5	1.8e-7	Dupuytren's disease;
THYM	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg06718696	chr17:78121285	EIF4A3	-0.97	-7.28	-0.6	9.7e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
THYM	cis	rs9515201	0.859	rs9515199	chr13:111033704	C/T	cg06243866	chr13:111019493	COL4A2	0.94	8.91	0.67	3.46e-14	White matter hyperintensity burden;
THYM	cis	rs1270639	0.778	rs2530403	chr7:157445639	C/T	cg13357408	chr7:157437802	PTPRN2	0.46	4.92	0.45	3.65e-6	Colorectal cancer;
THYM	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg23758822	chr17:41437982	NA	1.07	7.5	0.61	3.28e-11	Menopause (age at onset);
THYM	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg00129232	chr17:37814104	STARD3	0.69	4.51	0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs4731207	0.689	rs1481341	chr7:124567123	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.13	-0.47	1.56e-6	Cutaneous malignant melanoma;
THYM	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg14507445	chr22:49886340	NA	-0.51	-4.58	-0.43	1.4e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4730276	0.674	rs13226236	chr7:107544742	T/C	cg23293999	chr7:106826042	HBP1	-0.6	-4.89	-0.45	4.08e-6	Ulcerative colitis;
THYM	cis	rs728616	0.867	rs12412257	chr10:81729603	C/T	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6032067	0.777	rs62208382	chr20:43785549	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs4746818	1.000	rs6480383	chr10:70890482	C/T	cg11621586	chr10:70884670	VPS26A	1.31	11.97	0.78	1.11e-20	Left atrial antero-posterior diameter;
THYM	cis	rs654128	0.640	rs339342	chr6:117216125	G/A	cg12892004	chr6:117198278	RFX6	-0.72	-5.66	-0.5	1.61e-7	Telomere length;
THYM	cis	rs654950	0.875	rs2810550	chr1:41995339	T/C	cg06885757	chr1:42089581	HIVEP3	-0.44	-5.26	-0.47	9e-7	Airway imaging phenotypes;
THYM	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg12463550	chr7:65579703	CRCP	-0.57	-4.62	-0.43	1.23e-5	Aortic root size;
THYM	cis	rs7027203	1.000	rs34624092	chr9:96523092	G/A	cg14598338	chr9:96623480	NA	0.45	4.81	0.44	5.72e-6	DNA methylation (variation);
THYM	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.67	8.43	0.65	3.73e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7267979	0.966	rs6083817	chr20:25343998	G/C	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9302065	0.565	rs2992910	chr13:95962216	T/A	cg26751094	chr13:95954534	ABCC4	-0.49	-5.49	-0.49	3.39e-7	Blood metabolite levels;
THYM	cis	rs2702888	0.502	rs2702935	chr8:6751827	A/G	cg03082247	chr8:6756796	NA	-0.55	-4.48	-0.42	2.1e-5	Blood pressure;
THYM	cis	rs995000	0.931	rs1168132	chr1:63133468	T/A	cg06896770	chr1:63153194	DOCK7	-0.94	-7.36	-0.6	6.66e-11	Triglyceride levels;
THYM	cis	rs1113500	0.548	rs6583062	chr1:108656463	G/A	cg06207961	chr1:108661230	NA	0.66	4.74	0.44	7.63e-6	Growth-regulated protein alpha levels;
THYM	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs1395	1.000	rs3769143	chr2:27450724	A/G	cg23587288	chr2:27483067	SLC30A3	0.56	5.03	0.46	2.3e-6	Blood metabolite levels;
THYM	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	trans	rs877282	0.898	rs11253343	chr10:765117	C/T	cg22713356	chr15:30763199	NA	1.36	10.13	0.72	8.77e-17	Uric acid levels;
THYM	cis	rs7226229	1.000	rs7207724	chr17:20924236	A/G	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs40363	0.767	rs1003330	chr16:3541039	A/G	cg00484396	chr16:3507460	NAT15	-0.65	-5.1	-0.46	1.77e-6	Tuberculosis;
THYM	cis	rs7551222	0.752	rs4951075	chr1:204464446	C/A	cg20240347	chr1:204465584	NA	-0.57	-5.22	-0.47	1.05e-6	Schizophrenia;
THYM	cis	rs2075230	0.705	rs1642795	chr17:7542591	C/T	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.72	-0.44	8.04e-6	Hormone measurements;
THYM	cis	rs3764563	1.000	rs1022413	chr19:15741984	G/A	cg20725493	chr19:15740067	CYP4F8	-1.02	-4.62	-0.43	1.2e-5	Inflammatory biomarkers;
THYM	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs72627123	0.656	rs17096949	chr14:74602360	A/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.28	7.05	0.59	2.86e-10	Morning vs. evening chronotype;
THYM	cis	rs11628318	0.515	rs1190334	chr14:103112591	T/C	cg27124170	chr14:102829869	TECPR2;CINP	0.65	4.63	0.43	1.14e-5	Platelet count;
THYM	cis	rs6835098	0.500	rs13112928	chr4:174158132	A/G	cg08422745	chr4:174089978	GALNT7	0.69	5.47	0.49	3.69e-7	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg01191920	chr7:158217561	PTPRN2	-1.03	-12.2	-0.78	3.65e-21	Obesity-related traits;
THYM	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg02869364	chr7:1081709	C7orf50	-0.61	-4.91	-0.45	3.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.67	-5.18	-0.47	1.22e-6	Tonsillectomy;
THYM	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg13699009	chr12:122356056	WDR66	0.53	5.66	0.5	1.63e-7	Mean corpuscular volume;
THYM	cis	rs17718580	0.536	rs17122701	chr14:51094401	C/T	cg04730355	chr14:51134070	SAV1	0.97	5.07	0.46	1.94e-6	Cognitive performance;
THYM	cis	rs7312774	0.748	rs12320535	chr12:107295813	T/C	cg16260113	chr12:107380972	MTERFD3	1.05	5.57	0.5	2.4e-7	Severe influenza A (H1N1) infection;
THYM	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs57784326	1	rs57784326	chr15:49796630	A/AG	cg12131419	chr15:49353073	NA	0.72	6.37	0.55	6.61e-9	Bacterial meningitis;
THYM	cis	rs1728785	1.000	rs1170429	chr16:68604126	A/G	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.39e-6	Ulcerative colitis;
THYM	cis	rs904251	0.828	rs1757178	chr6:37486310	C/T	cg25019722	chr6:37503610	NA	0.64	5.5	0.49	3.19e-7	Cognitive performance;
THYM	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg14983838	chr19:29218262	NA	1.09	9.83	0.71	3.85e-16	Methadone dose in opioid dependence;
THYM	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.78	6.24	0.54	1.21e-8	Urate levels;
THYM	cis	rs7216064	0.953	rs12450907	chr17:65870644	T/G	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs7119	0.717	rs12899390	chr15:77815238	A/C	cg10437265	chr15:77819839	NA	0.77	7.63	0.62	1.78e-11	Type 2 diabetes;
THYM	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg02734326	chr4:10020555	SLC2A9	0.76	6.44	0.55	4.94e-9	Bone mineral density;
THYM	cis	rs6430585	0.591	rs309118	chr2:136746224	G/C	cg07169764	chr2:136633963	MCM6	1.02	10.81	0.74	3.14e-18	Corneal structure;
THYM	cis	rs12928939	0.774	rs7205340	chr16:71645670	A/T	cg00287165	chr16:71523304	ZNF19	0.74	4.87	0.45	4.51e-6	Post bronchodilator FEV1;
THYM	cis	rs80319144	0.904	rs77571593	chr2:159300402	T/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs782590	0.935	rs2627779	chr2:55892356	A/G	cg18811423	chr2:55921094	PNPT1	0.75	7.13	0.59	1.94e-10	Metabolic syndrome;
THYM	cis	rs995000	0.931	rs28641195	chr1:63128081	C/T	cg06896770	chr1:63153194	DOCK7	-0.9	-7.2	-0.59	1.43e-10	Triglyceride levels;
THYM	cis	rs78647349	1.000	rs57877426	chr4:5240505	T/C	cg21164242	chr4:4250161	TMEM128	-1.16	-4.51	-0.42	1.86e-5	Alzheimer's disease (cognitive decline);
THYM	cis	rs854765	0.624	rs1889018	chr17:17734740	G/A	cg04398451	chr17:18023971	MYO15A	0.87	7.92	0.63	4.37e-12	Total body bone mineral density;
THYM	cis	rs28595532	0.841	rs115918392	chr4:119610356	T/A	cg21605333	chr4:119757512	SEC24D	1.42	4.79	0.44	6.16e-6	Cannabis dependence symptom count;
THYM	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg23422044	chr7:1970798	MAD1L1	-0.76	-5.24	-0.47	9.64e-7	Bipolar disorder;
THYM	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.16e-6	Corneal astigmatism;
THYM	cis	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg10856724	chr12:34555212	NA	-0.91	-8.9	-0.67	3.68e-14	Morning vs. evening chronotype;
THYM	cis	rs7172809	0.573	rs78481361	chr15:77654784	C/T	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs6701037	0.681	rs6664840	chr1:175128726	A/G	cg00958927	chr1:175162553	KIAA0040	-0.33	-4.48	-0.42	2.06e-5	Alcohol dependence;
THYM	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg07636037	chr3:49044803	WDR6	0.98	10.05	0.72	1.28e-16	Parkinson's disease;
THYM	cis	rs4638749	0.677	rs13423385	chr2:108826435	C/G	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs36051895	0.659	rs62541540	chr9:5040080	A/G	cg02405213	chr9:5042618	JAK2	-1.02	-10.5	-0.73	1.44e-17	Pediatric autoimmune diseases;
THYM	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg24642844	chr7:1081250	C7orf50	-1.18	-8.44	-0.65	3.54e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6860806	0.631	rs4705931	chr5:131588345	T/C	cg18758796	chr5:131593413	PDLIM4	0.64	6.19	0.54	1.5e-8	Breast cancer;
THYM	cis	rs4642101	0.561	rs9812144	chr3:12805910	G/A	cg05775895	chr3:12838266	CAND2	0.75	6.02	0.53	3.26e-8	QRS complex (12-leadsum);
THYM	cis	rs2720044	1.000	rs2720044	chr8:37980587	G/T	cg14618996	chr8:38964944	ADAM32	0.84	4.93	0.45	3.42e-6	Menopause (age at onset);
THYM	cis	rs6987853	0.865	rs2923445	chr8:42400743	C/A	cg09913449	chr8:42400586	C8orf40	0.94	8.91	0.67	3.56e-14	Mean corpuscular hemoglobin concentration;
THYM	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg03929089	chr4:120376271	NA	-1.01	-13.45	-0.81	1.04e-23	Height;
THYM	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.65	-4.72	-0.44	8.09e-6	Colorectal cancer;
THYM	cis	rs7772486	0.875	rs2073287	chr6:146350264	T/C	cg13319975	chr6:146136371	FBXO30	-0.72	-6.09	-0.53	2.36e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7106204	0.609	rs12801799	chr11:24300630	A/T	ch.11.24196551F	chr11:24239977	NA	1.03	6.5	0.55	3.68e-9	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs1981331	0.609	rs73907584	chr21:48079678	A/G	cg17243659	chr21:48055224	PRMT2	1.06	5.19	0.47	1.19e-6	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg22166914	chr1:53195759	ZYG11B	0.77	7.6	0.62	2.04e-11	Monocyte count;
THYM	cis	rs11771526	0.901	rs11773754	chr7:32304801	A/G	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg00255919	chr5:131827918	IRF1	-0.45	-5.04	-0.46	2.26e-6	Asthma (sex interaction);
THYM	cis	rs2066819	1.000	rs78495928	chr12:56635080	G/C	cg26714650	chr12:56694279	CS	-1.27	-6.32	-0.54	8.6e-9	Psoriasis vulgaris;
THYM	cis	rs7412746	0.611	rs6660084	chr1:150748803	T/C	cg15448220	chr1:150897856	SETDB1	0.88	7.31	0.6	8.35e-11	Melanoma;
THYM	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.84	-5.79	-0.51	9.16e-8	Body mass index;
THYM	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg03929089	chr4:120376271	NA	0.95	7.21	0.59	1.34e-10	Coronary artery disease;
THYM	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg11812906	chr14:75593930	NEK9	-0.76	-6.86	-0.58	7.09e-10	Height;
THYM	cis	rs1270639	0.778	rs2530404	chr7:157445995	C/T	cg13357408	chr7:157437802	PTPRN2	-0.46	-4.92	-0.45	3.65e-6	Colorectal cancer;
THYM	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg13683864	chr3:40499215	RPL14	-0.76	-6.9	-0.58	5.8e-10	Renal cell carcinoma;
THYM	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg14582100	chr15:45693742	SPATA5L1	0.63	5.33	0.48	6.54e-7	Homoarginine levels;
THYM	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs8017423	0.967	rs11621364	chr14:90709115	A/G	cg04239629	chr14:90701769	NA	-0.61	-4.46	-0.42	2.28e-5	Mortality in heart failure;
THYM	cis	rs3106136	0.527	rs10016806	chr4:95158495	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.12	-0.46	1.63e-6	Capecitabine sensitivity;
THYM	cis	rs868036	0.718	rs8030456	chr15:68076856	C/T	cg24579218	chr15:68104479	NA	-0.82	-9.12	-0.68	1.26e-14	Restless legs syndrome;
THYM	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs36051895	0.589	rs6476946	chr9:5195275	C/G	cg02405213	chr9:5042618	JAK2	0.91	9.11	0.68	1.31e-14	Pediatric autoimmune diseases;
THYM	cis	rs10231759	0.617	rs12112782	chr7:150501635	C/T	cg05103803	chr7:150883361	ASB10	0.67	4.51	0.42	1.86e-5	Height;
THYM	cis	rs7818345	0.637	rs4599829	chr8:19358434	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.64	5.49	0.49	3.28e-7	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs4731207	0.672	rs11983251	chr7:124459925	G/A	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs72949976	0.584	rs4673729	chr2:214023810	A/G	cg08319019	chr2:214017104	IKZF2	0.82	7.3	0.6	8.83e-11	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs447921	0.861	rs66686654	chr17:74430310	A/T	cg17201438	chr17:74438067	UBE2O	0.81	5.85	0.51	6.9e-8	Mitochondrial DNA levels;
THYM	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg18132916	chr6:79620363	NA	-0.55	-4.84	-0.44	4.98e-6	Intelligence (multi-trait analysis);
THYM	cis	rs5758511	0.731	rs5751186	chr22:42349710	G/A	cg08431931	chr22:42394659	WBP2NL	-0.71	-4.46	-0.42	2.25e-5	Birth weight;
THYM	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg17757837	chr7:157058334	UBE3C	-0.9	-8.43	-0.65	3.73e-13	Body mass index;
THYM	cis	rs6842047	1.000	rs4862665	chr4:187136142	C/T	cg09526685	chr4:187126073	CYP4V2	-1.1	-5.43	-0.49	4.41e-7	Blood protein levels;
THYM	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg25703541	chr22:24373054	LOC391322	-0.86	-9.9	-0.71	2.71e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1448094	0.511	rs2405621	chr12:86149336	A/T	cg00310523	chr12:86230176	RASSF9	-0.55	-4.87	-0.45	4.51e-6	Major depressive disorder;
THYM	cis	rs12134245	0.776	rs12137878	chr1:91973210	G/T	cg02896835	chr1:92012615	NA	-0.63	-5.42	-0.49	4.51e-7	Breast cancer;
THYM	cis	rs2069036	0.951	rs4748245	chr10:16118555	C/T	cg26633223	chr10:15133461	NA	-0.68	-4.84	-0.44	5e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs854765	0.583	rs7503334	chr17:17779458	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-6.13	-0.53	2.04e-8	Total body bone mineral density;
THYM	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.8	-5.1	-0.46	1.75e-6	Schizophrenia;
THYM	cis	rs662064	0.852	rs617728	chr1:10566522	C/T	cg20482658	chr1:10539492	PEX14	0.5	6.1	0.53	2.24e-8	Asthma;
THYM	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03452623	chr4:187889614	NA	1.16	21.11	0.91	1.23e-37	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11809443	0.569	rs11800309	chr1:228391808	G/T	cg07021033	chr1:228135961	WNT9A	0.81	4.62	0.43	1.22e-5	Coronary artery disease;
THYM	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg02753203	chr1:228287806	NA	0.86	7.79	0.62	8.26e-12	Diastolic blood pressure;
THYM	cis	rs4930776	0.868	rs368789	chr12:5756561	C/T	cg02086166	chr12:5775618	ANO2	0.62	6.27	0.54	1.04e-8	Plasma clusterin levels;
THYM	cis	rs11031096	0.679	rs12292515	chr11:4206385	T/G	cg22027985	chr11:4115532	RRM1	-0.53	-4.91	-0.45	3.77e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4731207	0.596	rs7806807	chr7:124611300	G/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs6032067	0.714	rs6104065	chr20:43848079	C/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.37	-0.48	5.59e-7	Blood protein levels;
THYM	cis	rs13006833	1.000	rs13006833	chr2:191205499	G/C	cg11845111	chr2:191398756	TMEM194B	0.65	4.48	0.42	2.09e-5	Urinary metabolites;
THYM	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg02153584	chr22:29168773	CCDC117	0.58	4.56	0.42	1.52e-5	Lymphocyte counts;
THYM	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg20486651	chr6:167070296	RPS6KA2	-0.48	-4.79	-0.44	6.1e-6	Crohn's disease;
THYM	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg15445000	chr17:37608096	MED1	-0.44	-5.07	-0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2554380	0.943	rs2585052	chr15:84355990	T/A	cg14598478	chr15:84363061	ADAMTSL3	-0.65	-5.09	-0.46	1.83e-6	Height;
THYM	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg08125733	chr17:73851984	WBP2	1.24	8.44	0.65	3.45e-13	Psoriasis;
THYM	cis	rs13082711	0.911	rs34981505	chr3:27437322	A/T	cg02860705	chr3:27208620	NA	0.69	4.99	0.46	2.75e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs478304	0.654	rs1074156	chr11:65458169	G/T	cg27068330	chr11:65405492	SIPA1	-1.0	-9.36	-0.69	3.89e-15	Acne (severe);
THYM	cis	rs12291225	0.679	rs11605531	chr11:14291594	A/G	cg19336497	chr11:14380999	RRAS2	-0.82	-9.53	-0.7	1.67e-15	Sense of smell;
THYM	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg23205692	chr1:25664452	TMEM50A	0.81	6.54	0.56	3.11e-9	Erythrocyte sedimentation rate;
THYM	cis	rs1467026	0.523	rs9865548	chr3:12801785	C/T	cg11882607	chr3:12858926	CAND2	-0.49	-5.61	-0.5	2e-7	P wave duration;
THYM	cis	rs9876781	1.000	rs2279077	chr3:48474249	A/G	cg06066452	chr3:48470258	PLXNB1	0.27	4.77	0.44	6.64e-6	Longevity;
THYM	cis	rs10540	0.509	rs36002993	chr11:540005	C/T	cg03576123	chr11:487126	PTDSS2	-1.2	-5.19	-0.47	1.17e-6	Body mass index;
THYM	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg17178900	chr1:205818956	PM20D1	0.98	10.62	0.74	7.77e-18	Menarche (age at onset);
THYM	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg08109568	chr15:31115862	NA	0.54	5.23	0.47	1.02e-6	Huntington's disease progression;
THYM	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg26769984	chr7:1090371	C7orf50	-0.78	-5.2	-0.47	1.16e-6	Bronchopulmonary dysplasia;
THYM	cis	rs28795989	0.931	rs34317049	chr4:7898044	C/T	cg00251875	chr4:7801337	AFAP1	0.56	4.51	0.42	1.88e-5	Intraocular pressure;
THYM	cis	rs651907	0.588	rs797866	chr3:101658031	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	5.42	0.49	4.47e-7	Colorectal cancer;
THYM	cis	rs3015497	0.789	rs7147956	chr14:51142605	G/A	cg04730355	chr14:51134070	SAV1	-0.53	-4.65	-0.43	1.05e-5	Mean platelet volume;
THYM	cis	rs7771547	0.573	rs621796	chr6:36472259	A/T	cg07856975	chr6:36356162	ETV7	0.52	5.01	0.46	2.48e-6	Platelet distribution width;
THYM	cis	rs4076764	0.801	rs6698738	chr1:163359918	G/A	cg24596788	chr1:163392923	NA	-0.73	-6.01	-0.53	3.35e-8	Motion sickness;
THYM	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg00757033	chr12:89920650	WDR51B	0.75	12.04	0.78	7.96e-21	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7169223	0.615	rs11630027	chr15:79096983	C/A	cg21242079	chr15:79101063	ADAMTS7	0.52	4.77	0.44	6.59e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs2637266	0.783	rs10824437	chr10:78469493	C/T	cg18941641	chr10:78392320	NA	0.77	6.17	0.54	1.64e-8	Pulmonary function;
THYM	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg08975724	chr8:8085496	FLJ10661	-0.65	-5.23	-0.47	9.94e-7	Schizophrenia;
THYM	cis	rs4509693	0.882	rs7900763	chr10:102492559	A/C	cg27380429	chr10:102498823	NA	0.82	4.97	0.45	3e-6	Alzheimer's disease;
THYM	cis	rs16865717	1.000	rs16865716	chr2:7032398	A/G	cg20486407	chr2:7037101	RSAD2	-1.17	-9.7	-0.71	7.3e-16	Venous thromboembolism (SNP x SNP interaction);
THYM	cis	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.53	-4.93	-0.45	3.48e-6	Lymphocyte counts;
THYM	cis	rs10887741	0.865	rs2145818	chr10:89418988	T/A	cg13926569	chr10:89418898	PAPSS2	-0.66	-7.0	-0.58	3.57e-10	Exercise (leisure time);
THYM	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.73	-4.75	-0.44	7.21e-6	Mean platelet volume;
THYM	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg07884673	chr3:53033167	SFMBT1	1.25	6.36	0.55	6.97e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs10992471	0.605	rs7872375	chr9:95064843	C/G	cg14631576	chr9:95140430	CENPP	-0.85	-9.03	-0.68	1.99e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2274459	1.000	rs68168863	chr6:33758238	C/T	cg06253072	chr6:33679850	C6orf125	0.52	4.65	0.43	1.07e-5	Obesity (extreme);
THYM	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg12310025	chr6:25882481	NA	-0.68	-5.38	-0.48	5.32e-7	Blood metabolite levels;
THYM	cis	rs9650657	0.615	rs6601536	chr8:10696311	C/G	cg12981288	chr8:11183844	MTMR9	-0.48	-4.51	-0.42	1.84e-5	Neuroticism;
THYM	cis	rs6586111	0.904	rs6586105	chr10:82372248	A/G	cg03086067	chr10:82368399	SH2D4B	-0.51	-6.5	-0.56	3.64e-9	Capecitabine sensitivity;
THYM	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg08859206	chr1:53392774	SCP2	0.65	7.33	0.6	7.72e-11	Monocyte count;
THYM	cis	rs10927875	0.722	rs9442216	chr1:16353400	T/C	cg21385522	chr1:16154831	NA	0.66	4.89	0.45	4.17e-6	Dilated cardiomyopathy;
THYM	cis	rs7927771	0.524	rs7943213	chr11:47715524	T/C	cg20307385	chr11:47447363	PSMC3	0.6	4.51	0.42	1.87e-5	Subjective well-being;
THYM	cis	rs9814567	0.929	rs1863912	chr3:134205227	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.86	-8.85	-0.67	4.76e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6430585	0.528	rs309119	chr2:136710372	T/C	cg04750100	chr2:136595281	LCT	0.56	5.51	0.49	3.01e-7	Corneal structure;
THYM	cis	rs939658	1.000	rs34286854	chr15:79454374	C/T	cg17916960	chr15:79447300	NA	-0.77	-9.12	-0.68	1.24e-14	Refractive error;
THYM	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.65	4.69	0.43	8.99e-6	Height;
THYM	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg12311346	chr5:56204834	C5orf35	0.81	5.9	0.52	5.54e-8	Initial pursuit acceleration;
THYM	cis	rs1878931	0.582	rs10048083	chr16:3417465	A/C	cg21433313	chr16:3507492	NAT15	-0.54	-4.69	-0.43	9.2e-6	Body mass index (adult);
THYM	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg24818145	chr4:99064322	C4orf37	0.74	5.97	0.52	4.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs72627123	0.867	rs74492048	chr14:74439895	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	4.87	0.45	4.38e-6	Morning vs. evening chronotype;
THYM	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	6.31	0.54	8.76e-9	Platelet count;
THYM	cis	rs28595532	0.920	rs56342843	chr4:119765070	G/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs1122401	0.515	rs2548638	chr5:53869576	A/C	cg04014864	chr5:54603544	SKIV2L2;DHX29	0.75	4.76	0.44	6.96e-6	Smoking initiation;
THYM	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.76	0.51	1.02e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2811415	0.597	rs2878507	chr3:127793923	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg16558253	chr16:72132732	DHX38	-0.56	-4.9	-0.45	3.89e-6	Fibrinogen levels;
THYM	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11644478	chr21:40555479	PSMG1	1.03	8.53	0.66	2.25e-13	Cognitive function;
THYM	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10089	1.000	rs17164310	chr5:127493679	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.96	5.89	0.52	5.87e-8	Ileal carcinoids;
THYM	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg09307838	chr4:120376055	NA	0.71	5.07	0.46	1.98e-6	Corneal astigmatism;
THYM	cis	rs34638657	0.872	rs2967350	chr16:82196130	T/C	cg19807685	chr16:82068980	HSD17B2	-0.63	-4.96	-0.45	3.07e-6	Lung adenocarcinoma;
THYM	cis	rs2903698	0.585	rs11944808	chr4:76362416	G/A	cg03209871	chr4:76438412	RCHY1;THAP6	0.44	5.09	0.46	1.83e-6	Prion diseases;
THYM	cis	rs7020830	0.830	rs17487601	chr9:37213641	G/A	cg14294708	chr9:37120828	ZCCHC7	1.21	14.1	0.82	5.06e-25	Schizophrenia;
THYM	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg26597838	chr10:835615	NA	1.25	9.08	0.68	1.54e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs1975974	1.000	rs111981054	chr17:21725592	C/G	cg18423549	chr17:21743878	NA	-0.57	-4.47	-0.42	2.19e-5	Psoriasis;
THYM	cis	rs13006833	0.739	rs172366	chr2:191191233	G/T	cg11845111	chr2:191398756	TMEM194B	0.66	4.71	0.43	8.54e-6	Urinary metabolites;
THYM	cis	rs4866334	1.000	rs75485994	chr5:18488330	A/G	cg24599790	chr5:18972260	NA	-1.07	-4.47	-0.42	2.12e-5	IgG glycosylation;
THYM	cis	rs13256369	0.802	rs13256404	chr8:8562974	T/C	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.65	-11.83	-0.77	2.19e-20	Hemostatic factors and hematological phenotypes;
THYM	cis	rs3820068	0.705	rs2145396	chr1:15875184	A/G	cg05660106	chr1:15850417	CASP9	1.15	9.97	0.72	1.88e-16	Systolic blood pressure;
THYM	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg14129053	chr2:1895732	MYT1L	1.13	4.49	0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	trans	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Bladder cancer;
THYM	cis	rs6840360	0.642	rs2709820	chr4:152384039	A/G	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg11812906	chr14:75593930	NEK9	-0.89	-8.22	-0.64	1.03e-12	Height;
THYM	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg22981736	chr15:31284413	MTMR10	-0.57	-4.77	-0.44	6.64e-6	Huntington's disease progression;
THYM	cis	rs1499614	1.000	rs34250985	chr7:66161062	A/T	cg13147721	chr7:65941812	NA	-1.13	-7.34	-0.6	7.35e-11	Gout;
THYM	cis	rs6840360	0.571	rs62327271	chr4:152535916	A/G	cg22705602	chr4:152727874	NA	-0.78	-8.16	-0.64	1.38e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9302065	0.565	rs2993584	chr13:95961678	C/A	cg26751094	chr13:95954534	ABCC4	-0.49	-5.49	-0.49	3.39e-7	Blood metabolite levels;
THYM	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg06697600	chr4:7070879	GRPEL1	-0.57	-4.77	-0.44	6.6e-6	Monocyte percentage of white cells;
THYM	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg24531977	chr5:56204891	C5orf35	-1.0	-8.34	-0.65	5.78e-13	Initial pursuit acceleration;
THYM	cis	rs595982	0.527	rs73061659	chr19:49373556	G/A	cg19746536	chr19:49375674	PPP1R15A	0.81	4.45	0.42	2.35e-5	Red cell distribution width;
THYM	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg04673462	chr1:38461896	NA	0.57	7.79	0.62	8.37e-12	Coronary artery disease;
THYM	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg04676771	chr1:91176081	NA	0.62	4.56	0.42	1.53e-5	Eosinophil percentage of white cells;
THYM	cis	rs10203711	0.966	rs4998693	chr2:239564753	G/T	cg14580085	chr2:239553406	NA	0.68	6.07	0.53	2.58e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg11266682	chr4:10021025	SLC2A9	0.73	12.79	0.8	2.29e-22	Bone mineral density;
THYM	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg12165864	chr7:66369176	NA	-0.81	-6.03	-0.53	3.07e-8	Corneal structure;
THYM	cis	rs9361491	0.608	rs7383685	chr6:79455982	T/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg01119278	chr6:110721349	DDO	-0.64	-7.12	-0.59	2e-10	Platelet distribution width;
THYM	cis	rs2302777	0.507	rs9889716	chr17:38108298	A/G	cg26162295	chr17:38119207	GSDMA	-0.42	-5.05	-0.46	2.09e-6	Multiple myeloma (hyperdiploidy);
THYM	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg19346786	chr7:2764209	NA	-0.81	-7.28	-0.6	9.58e-11	Height;
THYM	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7828089	0.582	rs13282084	chr8:22266280	T/C	cg12081754	chr8:22256438	SLC39A14	0.89	9.11	0.68	1.34e-14	Verbal declarative memory;
THYM	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg11764359	chr7:65958608	NA	-0.81	-6.42	-0.55	5.45e-9	Aortic root size;
THYM	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg24375607	chr4:120327624	NA	-0.64	-4.99	-0.46	2.69e-6	Corneal astigmatism;
THYM	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	7.64	0.62	1.72e-11	Platelet count;
THYM	cis	rs7833986	0.501	rs2719226	chr8:57044066	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	0.57	6.61	0.56	2.27e-9	Height;
THYM	cis	rs34779708	0.931	rs4934723	chr10:35381763	A/G	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	trans	rs877282	0.891	rs34652870	chr10:772218	T/C	cg22713356	chr15:30763199	NA	1.38	11.57	0.76	7.71e-20	Uric acid levels;
THYM	cis	rs11225247	0.881	rs11604271	chr11:102250601	A/C	cg06323957	chr11:102217781	BIRC2	1.08	4.83	0.44	5.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs3791406	1.000	rs3791405	chr2:240030284	G/A	cg27074582	chr2:240114406	HDAC4	-0.44	-4.48	-0.42	2.05e-5	Skin aging (microtopography measurement);
THYM	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg20608306	chr11:116969690	SIK3	0.59	7.92	0.63	4.51e-12	Blood protein levels;
THYM	cis	rs57545798	0.889	rs35418412	chr15:100639274	C/T	cg20941820	chr15:100882334	ADAMTS17	0.55	4.62	0.43	1.19e-5	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg14159672	chr1:205819179	PM20D1	-0.76	-6.16	-0.53	1.74e-8	Menarche (age at onset);
THYM	cis	rs4900538	0.855	rs12586378	chr14:102853150	T/C	cg18135206	chr14:102964638	TECPR2	-0.81	-6.24	-0.54	1.2e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs250677	0.522	rs4705302	chr5:148354962	G/C	cg18129178	chr5:148520854	ABLIM3	0.72	5.42	0.49	4.44e-7	Breast cancer;
THYM	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg26031613	chr14:104095156	KLC1	1.08	9.69	0.71	7.44e-16	Body mass index;
THYM	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg10862848	chr6:42927986	GNMT	-0.55	-7.16	-0.59	1.68e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9420	0.961	rs11607056	chr11:57496820	C/T	cg19752551	chr11:57585705	CTNND1	-0.73	-8.02	-0.64	2.79e-12	Schizophrenia;
THYM	cis	rs56079296	0.929	rs10069116	chr5:121374825	G/T	cg05256605	chr5:121412184	LOX	0.59	4.47	0.42	2.18e-5	Coronary artery disease;
THYM	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.83	-0.44	5.29e-6	Mean corpuscular volume;
THYM	cis	rs4919044	0.808	rs835280	chr10:94811786	A/G	cg05127821	chr10:94822908	CYP26C1	-1.26	-7.09	-0.59	2.33e-10	Coronary artery disease;
THYM	cis	rs9644630	0.932	rs4921653	chr8:19359853	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.74	7.77	0.62	9.33e-12	Oropharynx cancer;
THYM	cis	rs7828089	0.646	rs2122877	chr8:22282416	T/C	cg12081754	chr8:22256438	SLC39A14	0.81	7.17	0.59	1.62e-10	Verbal declarative memory;
THYM	cis	rs7084402	0.967	rs1658435	chr10:60327527	A/G	cg07615347	chr10:60278583	BICC1	0.55	5.19	0.47	1.21e-6	Refractive error;
THYM	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2286885	1.000	rs1537989	chr9:129241824	C/T	cg14319473	chr9:129242481	FAM125B	0.66	5.01	0.46	2.52e-6	Intraocular pressure;
THYM	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.84	0.44	4.97e-6	Bipolar disorder;
THYM	cis	rs77372450	1.000	rs77372450	chr5:156970144	A/C	cg08916508	chr5:156566250	MED7	-1.23	-4.61	-0.43	1.23e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg13695892	chr22:41940480	POLR3H	0.85	6.11	0.53	2.23e-8	Vitiligo;
THYM	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg15693483	chr7:1102177	C7orf50	0.54	6.26	0.54	1.1e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg06009448	chr7:1102226	C7orf50	0.43	4.86	0.45	4.54e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg00376283	chr12:123451042	ABCB9	0.67	5.17	0.47	1.31e-6	Height;Educational attainment;Head circumference (infant);
THYM	cis	rs2806561	0.765	rs682766	chr1:23516397	C/G	cg12483005	chr1:23474871	LUZP1	0.59	6.29	0.54	9.59e-9	Height;
THYM	cis	rs11249608	0.590	rs36051170	chr5:178447971	T/C	cg21905437	chr5:178450457	ZNF879	0.6	4.48	0.42	2.06e-5	Pubertal anthropometrics;
THYM	cis	rs4389656	0.857	rs274709	chr5:6726464	T/C	cg10857441	chr5:6722123	POLS	-0.44	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs425535	0.817	rs2457996	chr4:74856535	C/T	cg07868155	chr4:74864709	CXCL5	0.61	5.07	0.46	1.92e-6	Blood protein levels;
THYM	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg06028605	chr16:24865363	SLC5A11	0.55	5.13	0.47	1.55e-6	Intelligence (multi-trait analysis);
THYM	cis	rs554111	0.593	rs7540023	chr1:21310092	T/C	cg01072550	chr1:21505969	NA	0.59	5.22	0.47	1.03e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg24642844	chr7:1081250	C7orf50	-0.74	-5.14	-0.47	1.49e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1448094	0.512	rs61930861	chr12:86245023	G/T	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg08645402	chr16:4508243	NA	0.72	6.45	0.55	4.6e-9	Schizophrenia;
THYM	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-5.75	-0.51	1.09e-7	Systemic lupus erythematosus;
THYM	cis	rs654950	0.934	rs653369	chr1:42002376	A/T	cg06885757	chr1:42089581	HIVEP3	-0.6	-7.98	-0.63	3.38e-12	Airway imaging phenotypes;
THYM	cis	rs35883536	0.647	rs2783702	chr1:101040836	G/A	cg06223162	chr1:101003688	GPR88	0.83	7.06	0.59	2.67e-10	Monocyte count;
THYM	cis	rs172166	0.637	rs1233708	chr6:28173219	C/T	cg03597347	chr6:28058909	ZSCAN12L1	0.7	4.79	0.44	6.04e-6	Cardiac Troponin-T levels;
THYM	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg01751800	chr4:77820391	ANKRD56	0.55	4.59	0.43	1.36e-5	Emphysema distribution in smoking;
THYM	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg18132916	chr6:79620363	NA	-0.55	-4.84	-0.44	4.98e-6	Intelligence (multi-trait analysis);
THYM	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Body mass index;
THYM	cis	rs1512268	0.526	rs7006278	chr8:23518058	C/T	cg20272884	chr8:23712762	STC1	-0.45	-4.47	-0.42	2.17e-5	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4803468	1.000	rs11670757	chr19:41913431	G/T	cg09537434	chr19:41945824	ATP5SL	-1.15	-11.44	-0.76	1.44e-19	Height;
THYM	cis	rs4606347	0.789	rs17407426	chr1:66167582	A/G	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg14779329	chr11:130786720	SNX19	-0.56	-6.17	-0.54	1.63e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs57590327	0.555	rs13084107	chr3:81833577	T/C	cg07356753	chr3:81810745	GBE1	-0.86	-6.59	-0.56	2.41e-9	Extraversion;
THYM	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg15448220	chr1:150897856	SETDB1	0.9	7.66	0.62	1.56e-11	Melanoma;
THYM	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg17054759	chr22:49844102	NA	-0.51	-4.63	-0.43	1.14e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg22117172	chr7:91764530	CYP51A1	0.36	4.59	0.43	1.37e-5	Breast cancer;
THYM	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg12935359	chr14:103987150	CKB	-0.65	-6.4	-0.55	5.78e-9	Body mass index;
THYM	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.84	4.66	0.43	1.04e-5	Initial pursuit acceleration;
THYM	cis	rs7216064	0.953	rs62086043	chr17:65968003	A/G	cg12091567	chr17:66097778	LOC651250	-0.7	-4.68	-0.43	9.46e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs3820068	0.705	rs4646092	chr1:15821673	C/T	cg05660106	chr1:15850417	CASP9	1.13	10.23	0.72	5.39e-17	Systolic blood pressure;
THYM	cis	rs669446	0.533	rs2158956	chr1:44211697	T/C	cg15962314	chr1:44399869	ARTN	0.47	5.05	0.46	2.16e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg18681998	chr4:17616180	MED28	1.0	10.49	0.73	1.52e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg15605315	chr1:45957053	TESK2	0.79	6.68	0.57	1.61e-9	High light scatter reticulocyte count;
THYM	cis	rs490234	0.769	rs519812	chr9:128348790	T/G	cg14078157	chr9:128172775	NA	0.63	4.79	0.44	6.06e-6	Mean arterial pressure;
THYM	cis	rs778371	0.723	rs12619195	chr2:233678326	G/A	cg08000102	chr2:233561755	GIGYF2	-0.84	-7.45	-0.61	4.31e-11	Schizophrenia;
THYM	cis	rs354225	0.544	rs10187447	chr2:54806711	A/T	cg23486701	chr2:54789491	SPTBN1	0.36	4.77	0.44	6.58e-6	Schizophrenia;
THYM	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg12310025	chr6:25882481	NA	0.95	8.61	0.66	1.5e-13	Blood metabolite levels;
THYM	cis	rs1472147	0.955	rs3736611	chr7:128509243	C/G	cg00260937	chr7:128520193	KCP	0.53	4.89	0.45	4.04e-6	Calcium levels;
THYM	cis	rs8050907	0.744	rs13330957	chr16:4525330	G/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.3	5.2	0.47	1.16e-6	Obesity-related traits;
THYM	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg02640540	chr1:67518911	SLC35D1	0.62	4.53	0.42	1.72e-5	Lymphocyte percentage of white cells;
THYM	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg16535667	chr11:65410126	SIPA1	-0.76	-4.47	-0.42	2.19e-5	Blood pressure (age interaction);
THYM	cis	rs72781680	0.898	rs72782106	chr2:24022009	A/G	cg08917208	chr2:24149416	ATAD2B	1.11	4.97	0.45	2.9e-6	Lymphocyte counts;
THYM	cis	rs9814567	0.752	rs4318591	chr3:134328333	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg27535305	chr1:53392650	SCP2	-0.41	-4.69	-0.43	9.1e-6	Monocyte count;
THYM	cis	rs4919087	1.000	rs3740512	chr10:99078745	C/T	cg19453742	chr10:98862320	SLIT1	-0.62	-5.11	-0.46	1.67e-6	Monocyte count;
THYM	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg23711669	chr6:146136114	FBXO30	-0.97	-10.49	-0.73	1.45e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7762018	0.607	rs77004024	chr6:170063437	G/A	cg19338460	chr6:170058176	WDR27	-1.04	-6.19	-0.54	1.5e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg01475377	chr6:109611718	NA	0.56	4.76	0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs3733631	1.000	rs10007754	chr4:104627442	T/G	cg24090629	chr4:104641072	TACR3	-0.86	-5.41	-0.49	4.62e-7	Menarche (age at onset);
THYM	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.14	-0.64	1.54e-12	Mean corpuscular volume;
THYM	cis	rs9381107	0.585	rs9471256	chr6:9451361	G/A	cg27283345	chr6:10416531	TFAP2A	-0.44	-4.51	-0.42	1.85e-5	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg12698349	chr2:225449008	CUL3	0.73	5.43	0.49	4.29e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg12826209	chr6:26865740	GUSBL1	0.84	6.07	0.53	2.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6987853	0.933	rs55881007	chr8:42367290	A/G	cg09913449	chr8:42400586	C8orf40	-0.88	-8.12	-0.64	1.7e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6939532	0.522	rs2073528	chr6:26375143	G/C	cg14345882	chr6:26364793	BTN3A2	0.4	5.13	0.47	1.51e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.53	-5.15	-0.47	1.43e-6	Crohn's disease;
THYM	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg26384229	chr12:38710491	ALG10B	0.72	5.6	0.5	2.09e-7	Morning vs. evening chronotype;
THYM	cis	rs4664308	0.935	rs58354887	chr2:160927112	C/T	cg03641300	chr2:160917029	PLA2R1	-0.78	-6.97	-0.58	4.25e-10	Idiopathic membranous nephropathy;
THYM	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg07959070	chr22:50026188	C22orf34	-0.28	-4.88	-0.45	4.19e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg22535103	chr8:58192502	C8orf71	-1.02	-6.22	-0.54	1.33e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg02487422	chr3:49467188	NICN1	0.63	4.84	0.44	4.96e-6	Resting heart rate;
THYM	cis	rs470093	0.866	rs80627	chr22:44245081	T/C	cg09142166	chr22:44276013	PNPLA5	-0.57	-5.43	-0.49	4.38e-7	Staphylococcus aureus infection;
THYM	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg26384229	chr12:38710491	ALG10B	-0.95	-7.55	-0.61	2.7e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Body mass index;
THYM	cis	rs986417	1.000	rs986417	chr14:60858761	C/T	cg27398547	chr14:60952738	C14orf39	-1.12	-5.78	-0.51	9.3e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs1983170	0.935	rs578155	chr1:91976541	G/A	cg25838465	chr1:92012736	NA	-0.66	-4.48	-0.42	2.09e-5	Eosinophil percentage of white cells;
THYM	cis	rs2276498	0.751	rs6127058	chr20:52628804	A/G	cg23682609	chr20:52687365	BCAS1	0.63	4.99	0.46	2.68e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg12826209	chr6:26865740	GUSBL1	0.92	4.98	0.45	2.89e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2294693	0.679	rs1534995	chr6:40960731	G/A	cg14418226	chr6:40996092	UNC5CL	0.71	5.47	0.49	3.59e-7	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg14456004	chr13:21872349	NA	-1.25	-10.18	-0.72	6.85e-17	White matter hyperintensity burden;
THYM	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	cg20946044	chr11:1010712	AP2A2	-0.55	-4.6	-0.43	1.29e-5	Alzheimer's disease (late onset);
THYM	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs1747683	0.528	rs1983830	chr10:13363636	A/G	cg00142036	chr10:13388442	SEPHS1	-0.25	-4.77	-0.44	6.62e-6	IgG glycosylation;
THYM	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg15693483	chr7:1102177	C7orf50	0.5	5.79	0.51	8.93e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.98	0.45	2.85e-6	Obesity-related traits;
THYM	cis	rs12410462	0.582	rs12408978	chr1:227596235	A/T	cg04117972	chr1:227635322	NA	-0.82	-5.01	-0.46	2.55e-6	Major depressive disorder;
THYM	cis	rs7112925	0.738	rs11227673	chr11:66832528	C/T	cg24851651	chr11:66362959	CCS	-0.62	-5.06	-0.46	2.08e-6	Height;
THYM	cis	rs9361491	0.608	rs9448553	chr6:79463645	T/G	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.841	rs116582665	chr4:119487248	G/C	cg11846333	chr4:119757529	SEC24D	1.37	4.91	0.45	3.85e-6	Cannabis dependence symptom count;
THYM	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03452623	chr4:187889614	NA	-1.16	-18.39	-0.88	4.68e-33	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7772486	0.655	rs2142981	chr6:146071695	G/C	cg05347473	chr6:146136440	FBXO30	-0.56	-4.45	-0.42	2.34e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs140330585	1	rs140330585	chr15:78866445	G/A	cg18825076	chr15:78729989	IREB2	-0.54	-4.77	-0.44	6.53e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs36051895	0.659	rs12336577	chr9:5063690	T/A	cg02405213	chr9:5042618	JAK2	-1.03	-10.99	-0.75	1.31e-18	Pediatric autoimmune diseases;
THYM	cis	rs2282300	1.000	rs12799529	chr11:30408552	T/C	cg25418670	chr11:30344373	C11orf46	-0.67	-5.29	-0.48	7.91e-7	Morning vs. evening chronotype;
THYM	cis	rs11209185	0.509	rs9436356	chr1:68447202	A/G	cg22082780	chr1:68452167	NA	0.53	6.09	0.53	2.34e-8	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg02734326	chr4:10020555	SLC2A9	0.76	6.88	0.58	6.3e-10	Bone mineral density;
THYM	cis	rs2495707	0.624	rs10883518	chr10:102416555	C/A	cg18033436	chr10:102982347	NA	0.64	4.59	0.43	1.36e-5	Body mass index;
THYM	cis	rs76878669	0.606	rs1785639	chr11:66100430	G/A	cg18002602	chr11:66138449	SLC29A2	0.48	4.91	0.45	3.74e-6	Educational attainment (years of education);
THYM	cis	rs3806843	0.900	rs2531340	chr5:140131046	C/T	cg19875535	chr5:140030758	IK	-0.58	-4.52	-0.42	1.76e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg23161317	chr6:28129485	ZNF389	0.67	5.33	0.48	6.55e-7	Parkinson's disease;
THYM	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg00339695	chr16:24857497	SLC5A11	-0.7	-6.02	-0.53	3.27e-8	Intelligence (multi-trait analysis);
THYM	cis	rs717423	0.961	rs10973775	chr9:3847878	C/T	cg14199540	chr9:3305273	RFX3	-0.61	-4.51	-0.42	1.87e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs868036	0.718	rs28463100	chr15:68078769	T/C	cg24579218	chr15:68104479	NA	-0.82	-9.12	-0.68	1.26e-14	Restless legs syndrome;
THYM	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg06582575	chr6:163149167	PACRG;PARK2	1.15	6.71	0.57	1.43e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg18850127	chr7:39170497	POU6F2	0.6	5.66	0.5	1.57e-7	IgG glycosylation;
THYM	cis	rs17741873	0.614	rs16931042	chr10:75692923	A/C	cg02947784	chr10:75434997	AGAP5	-0.67	-4.64	-0.43	1.13e-5	Paclitaxel disposition in epithelial ovarian cancer;
THYM	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg17105886	chr17:28927953	LRRC37B2	1.29	6.73	0.57	1.26e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg10047753	chr17:41438598	NA	1.19	11.15	0.75	5.97e-19	Menopause (age at onset);
THYM	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11890956	chr21:40555474	PSMG1	-0.66	-6.23	-0.54	1.27e-8	Menarche (age at onset);
THYM	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg14779329	chr11:130786720	SNX19	0.53	5.25	0.47	9.17e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg23682913	chr1:2080710	PRKCZ	0.59	4.7	0.43	8.7e-6	Height;
THYM	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs11048434	0.761	rs1805723	chr12:9142297	T/C	cg04155231	chr12:9217510	LOC144571	0.5	4.95	0.45	3.27e-6	Sjögren's syndrome;
THYM	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg27394845	chr17:28928406	LRRC37B2	0.91	4.58	0.42	1.44e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs524023	1.000	rs537246	chr11:64360630	G/A	cg19131476	chr11:64387923	NRXN2	0.32	4.53	0.42	1.7e-5	Urate levels in obese individuals;
THYM	cis	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg01364799	chr7:75623366	TMEM120A	-0.64	-4.56	-0.42	1.52e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg24399712	chr22:39784796	NA	-0.77	-6.87	-0.58	6.69e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs986417	0.901	rs10134736	chr14:60998540	A/T	cg27398547	chr14:60952738	C14orf39	1.0	5.05	0.46	2.14e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs11148252	0.634	rs1571189	chr13:52731004	A/T	cg05335186	chr13:53173507	NA	-0.38	-4.59	-0.43	1.37e-5	Lewy body disease;
THYM	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21582582	chr3:182698605	DCUN1D1	0.81	7.07	0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7428297	0.943	rs13078084	chr3:127074386	A/G	cg21487550	chr3:127056955	NA	-0.81	-5.31	-0.48	7.34e-7	Clozapine-induced agranulocytosis;
THYM	cis	rs654128	0.640	rs173089	chr6:117216666	C/T	cg12892004	chr6:117198278	RFX6	-0.72	-5.66	-0.5	1.61e-7	Telomere length;
THYM	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg15556689	chr8:8085844	FLJ10661	-0.64	-4.86	-0.45	4.7e-6	Neuroticism;
THYM	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg06618935	chr21:46677482	NA	0.78	7.07	0.59	2.65e-10	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg09549813	chr16:4587862	C16orf5	0.57	6.23	0.54	1.24e-8	Schizophrenia;
THYM	cis	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs28595532	0.920	rs55726697	chr4:119742863	G/A	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs80319144	1.000	rs74970153	chr2:159251210	C/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg11245990	chr11:68621969	NA	0.57	7.11	0.59	2.15e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs55728055	0.661	rs62237765	chr22:31956981	A/G	cg01338084	chr22:32026380	PISD	1.48	7.33	0.6	7.69e-11	Age-related hearing impairment;
THYM	cis	rs1158570	0.773	rs6984963	chr8:131332096	A/G	cg16277922	chr8:131349729	ASAP1	0.65	5.66	0.5	1.57e-7	Platelet count;
THYM	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg27490568	chr2:178487706	NA	0.54	4.64	0.43	1.11e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg10852096	chr15:79043040	NA	0.64	4.9	0.45	3.97e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs13256369	0.774	rs13248423	chr8:8577602	C/G	cg00074818	chr8:8560427	CLDN23	0.52	4.71	0.44	8.3e-6	Obesity-related traits;
THYM	cis	rs6032067	0.641	rs13038485	chr20:43767759	T/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.41	-0.49	4.61e-7	Blood protein levels;
THYM	cis	rs2681472	0.524	rs7314459	chr12:89956341	T/A	cg00757033	chr12:89920650	WDR51B	0.49	5.08	0.46	1.89e-6	Diastolic blood pressure;Coronary artery disease;Systolic blood pressure;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Hypertension;
THYM	cis	rs6138458	1.000	rs227615	chr20:24908721	T/C	cg06937882	chr20:24974362	C20orf3	-0.47	-4.48	-0.42	2.08e-5	Blood protein levels;
THYM	cis	rs7582180	0.627	rs4407265	chr2:101005846	C/G	cg08017756	chr2:100939284	LONRF2	-0.72	-7.55	-0.61	2.61e-11	Intelligence (multi-trait analysis);
THYM	cis	rs10489202	1.000	rs1846416	chr1:167905411	G/A	cg24449463	chr1:168025552	DCAF6	-0.85	-6.66	-0.56	1.81e-9	Schizophrenia;
THYM	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg19774624	chr17:42201019	HDAC5	-0.85	-8.23	-0.65	9.73e-13	Total body bone mineral density;
THYM	cis	rs865483	0.860	rs2522968	chr17:35830300	G/A	cg06716730	chr17:35851459	DUSP14	0.43	7.3	0.6	8.71e-11	Monocyte count;
THYM	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	4.8	0.44	5.96e-6	Total body bone mineral density;
THYM	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg20744362	chr22:50050164	C22orf34	0.77	6.97	0.58	4.25e-10	Monocyte count;Monocyte percentage of white cells;
THYM	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.99	-0.75	1.26e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs6696239	0.840	rs10799445	chr1:227911883	A/C	cg02736395	chr1:227748424	NA	-0.64	-5.23	-0.47	1e-6	Height;
THYM	cis	rs7107174	0.681	rs11237443	chr11:78005089	C/A	cg02023728	chr11:77925099	USP35	0.65	5.91	0.52	5.31e-8	Testicular germ cell tumor;
THYM	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.3	-4.73	-0.44	7.88e-6	Obesity-related traits;
THYM	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.06	0.46	2.05e-6	Tonsillectomy;
THYM	cis	rs6840360	0.571	rs4696100	chr4:152514242	C/T	cg17479576	chr4:152424074	FAM160A1	-0.8	-5.65	-0.5	1.68e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg06627628	chr2:24431161	ITSN2	-0.79	-5.5	-0.49	3.18e-7	Asthma;
THYM	cis	rs7572733	0.534	rs1435570	chr2:198731371	T/C	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	7.73	0.62	1.1e-11	Smoking behavior;
THYM	cis	rs2279817	0.743	rs12023874	chr1:18025612	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.75	4.73	0.44	7.76e-6	Neuroticism;
THYM	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.84	4.66	0.43	1.04e-5	Initial pursuit acceleration;
THYM	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg01528321	chr10:82214614	TSPAN14	0.66	5.16	0.47	1.35e-6	Post bronchodilator FEV1;
THYM	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.48	-0.42	2.05e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs8048589	0.604	rs62038898	chr16:12223637	A/G	cg02910054	chr16:12241554	SNX29	0.83	6.83	0.57	8.12e-10	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03517284	chr6:25882590	NA	0.99	8.81	0.67	5.73e-14	Intelligence (multi-trait analysis);
THYM	cis	rs6430585	0.591	rs309118	chr2:136746224	G/C	cg20242066	chr2:136595261	LCT	0.51	5.54	0.49	2.71e-7	Corneal structure;
THYM	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.65	-11.76	-0.77	3.01e-20	Hemostatic factors and hematological phenotypes;
THYM	cis	rs10463554	1.000	rs56372231	chr5:102321905	C/T	cg23492399	chr5:102201601	PAM	-0.64	-4.92	-0.45	3.6e-6	Parkinson's disease;
THYM	cis	rs7692299	0.688	rs6821590	chr4:124713216	C/T	cg11268546	chr4:124983615	NA	0.75	4.5	0.42	1.89e-5	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs782590	0.807	rs782642	chr2:55928444	G/T	cg03859395	chr2:55845619	SMEK2	0.62	5.41	0.49	4.68e-7	Metabolic syndrome;
THYM	cis	rs4481887	0.888	rs4525076	chr1:248456876	T/G	cg13385794	chr1:248469461	NA	0.67	4.58	0.43	1.4e-5	Common traits (Other);
THYM	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg17143192	chr8:8559678	CLDN23	-0.63	-4.69	-0.43	9.06e-6	Mood instability;
THYM	cis	rs713587	0.607	rs6725517	chr2:25129473	A/G	cg01884057	chr2:25150051	NA	0.66	6.46	0.55	4.52e-9	Body mass index in non-asthmatics;
THYM	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg13683864	chr3:40499215	RPL14	-0.85	-7.88	-0.63	5.41e-12	Renal cell carcinoma;
THYM	cis	rs2806561	0.929	rs9426694	chr1:23539742	T/C	cg19743168	chr1:23544995	NA	0.7	7.68	0.62	1.38e-11	Height;
THYM	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg03806693	chr22:41940476	POLR3H	1.1	8.83	0.67	5.2e-14	Vitiligo;
THYM	cis	rs9311676	0.632	rs6785572	chr3:58361517	A/G	cg26110898	chr3:58419937	PDHB	-0.44	-4.6	-0.43	1.29e-5	Systemic lupus erythematosus;
THYM	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg13395646	chr4:1353034	KIAA1530	-0.55	-4.6	-0.43	1.29e-5	Longevity;
THYM	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs2985684	0.846	rs11157693	chr14:50048426	T/C	cg02151108	chr14:50098012	C14orf104	-0.73	-6.05	-0.53	2.84e-8	Carotid intima media thickness;
THYM	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg10295955	chr4:187884368	NA	-1.19	-17.25	-0.87	5.06e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg00852783	chr1:26633632	UBXN11	0.67	5.62	0.5	1.87e-7	Granulocyte percentage of myeloid white cells;
THYM	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg05182265	chr7:156933206	UBE3C	-0.65	-8.02	-0.64	2.68e-12	Body mass index;
THYM	trans	rs59551326	0.517	rs2829650	chr21:26601770	A/C	cg17452615	chr12:122019080	KDM2B	-0.8	-6.84	-0.57	7.67e-10	Alcohol dependence;
THYM	cis	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs3741151	0.773	rs73544711	chr11:73164870	T/A	cg17517138	chr11:73019481	ARHGEF17	0.94	5.48	0.49	3.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9796	0.558	rs4445868	chr15:41531991	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.58	-4.74	-0.44	7.59e-6	Menopause (age at onset);
THYM	cis	rs10501293	0.703	rs7937137	chr11:43031342	C/T	cg03447554	chr11:43094025	NA	0.61	4.51	0.42	1.83e-5	Cognitive performance;
THYM	cis	rs4474465	0.850	rs7938257	chr11:78224908	A/G	cg19901956	chr11:77921274	USP35	0.71	5.24	0.47	9.65e-7	Alzheimer's disease (survival time);
THYM	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.57	5.76	0.51	1.02e-7	Schizophrenia;
THYM	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7084402	0.967	rs1658468	chr10:60292664	A/G	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs4262150	0.846	rs113568682	chr5:152299754	A/T	cg06854687	chr5:151642065	NA	0.66	4.7	0.43	8.85e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs677665	0.537	rs6688233	chr1:9335745	A/G	cg03265564	chr1:9748971	PIK3CD	-0.26	-4.73	-0.44	7.77e-6	Eosinophil percentage of white cells;
THYM	cis	rs2463822	1.000	rs2513749	chr11:62105391	C/T	cg06239285	chr11:62104954	ASRGL1	1.44	7.7	0.62	1.3e-11	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4595586	0.525	rs7968458	chr12:39377139	C/A	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg06634786	chr22:41940651	POLR3H	0.71	5.04	0.46	2.19e-6	Vitiligo;
THYM	cis	rs1395	0.813	rs11685326	chr2:27453679	A/G	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.52	-0.49	2.95e-7	Blood metabolite levels;
THYM	cis	rs17401966	0.838	rs12738317	chr1:10419663	C/T	cg19773385	chr1:10388646	KIF1B	-0.57	-4.58	-0.43	1.4e-5	Hepatocellular carcinoma;
THYM	cis	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg11009520	chr8:12052164	FAM86B1	0.59	4.73	0.44	7.8e-6	Morning vs. evening chronotype;
THYM	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.64	-0.74	7.23e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs863345	0.604	rs6669271	chr1:158471999	A/G	cg12129480	chr1:158549410	OR10X1	-0.49	-4.84	-0.44	5.03e-6	Pneumococcal bacteremia;
THYM	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg01699819	chr7:1052092	C7orf50	-0.73	-6.07	-0.53	2.59e-8	Bronchopulmonary dysplasia;
THYM	cis	rs7572733	0.534	rs1436131	chr2:198731230	A/C	cg05783139	chr2:198650985	BOLL	0.64	5.0	0.46	2.6e-6	Dermatomyositis;
THYM	cis	rs7122937	1.000	rs12280952	chr11:2488873	G/A	cg27115973	chr11:2481206	KCNQ1	0.61	6.01	0.52	3.44e-8	QT interval;
THYM	cis	rs17641971	0.708	rs1511363	chr8:49901023	C/T	cg00325661	chr8:49890786	NA	0.67	5.14	0.47	1.49e-6	Blood metabolite levels;
THYM	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg24530246	chr3:53118167	NA	-0.85	-4.82	-0.44	5.52e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs898549	0.520	rs10899970	chr10:44515716	G/A	cg27599783	chr10:45480162	RASSF4	0.49	4.5	0.42	1.96e-5	Obesity-related traits;
THYM	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg15604051	chr3:44754201	ZNF502	-0.58	-5.24	-0.47	9.64e-7	Depressive symptoms;
THYM	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs2806561	0.929	rs856508	chr1:23532995	A/C	cg19743168	chr1:23544995	NA	0.67	6.94	0.58	4.71e-10	Height;
THYM	cis	rs10992471	0.603	rs7045572	chr9:95137964	T/C	cg14631576	chr9:95140430	CENPP	-1.04	-11.32	-0.76	2.57e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg07870213	chr5:140052090	DND1	0.7	7.7	0.62	1.28e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2075230	0.642	rs1641535	chr17:7546133	T/C	cg27413385	chr17:7515425	FXR2	-0.35	-5.06	-0.46	2.06e-6	Hormone measurements;
THYM	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	10.36	0.73	2.81e-17	Chronic sinus infection;
THYM	cis	rs72627123	0.656	rs17096314	chr14:74567952	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.29	7.08	0.59	2.46e-10	Morning vs. evening chronotype;
THYM	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg13395646	chr4:1353034	KIAA1530	-0.53	-4.96	-0.45	3.06e-6	Obesity-related traits;
THYM	cis	rs7769051	0.522	rs10457596	chr6:133169974	T/G	cg22852734	chr6:133119734	C6orf192	0.99	4.69	0.43	9.1e-6	Type 2 diabetes nephropathy;
THYM	cis	rs56036086	0.702	rs6010152	chr22:50618278	C/T	cg16473166	chr22:50639996	SELO	-0.88	-4.72	-0.44	8.13e-6	Platelet count;Plateletcrit;
THYM	cis	rs909002	0.887	rs10914463	chr1:32132063	C/T	cg13919466	chr1:32135498	COL16A1	-0.47	-4.73	-0.44	7.95e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg00310523	chr12:86230176	RASSF9	0.52	4.65	0.43	1.07e-5	Major depressive disorder;
THYM	cis	rs17030434	0.953	rs6535953	chr4:154728186	G/A	cg14289246	chr4:154710475	SFRP2	-0.78	-5.26	-0.48	8.83e-7	Electrocardiographic conduction measures;
THYM	cis	rs921968	0.643	rs2303561	chr2:219527005	C/T	cg01872077	chr2:219646372	CYP27A1	-0.58	-4.49	-0.42	2e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs673253	0.556	rs10789442	chr1:44140075	G/T	cg24466421	chr1:44070974	PTPRF	0.56	4.76	0.44	6.96e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12200560	0.505	rs2387378	chr6:97077504	C/A	cg06623918	chr6:96969491	KIAA0776	0.78	6.01	0.52	3.39e-8	Coronary heart disease;
THYM	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.63	-4.61	-0.43	1.27e-5	Colorectal cancer;
THYM	cis	rs7084402	0.967	rs1658447	chr10:60313174	G/A	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs877282	1.000	rs12763443	chr10:771941	G/A	cg10556349	chr10:835070	NA	-0.77	-5.28	-0.48	8.04e-7	Uric acid levels;
THYM	cis	rs748404	0.660	rs690012	chr15:43719755	C/T	cg12861797	chr15:43585817	TGM7	0.45	4.63	0.43	1.18e-5	Lung cancer;
THYM	cis	rs526231	0.511	rs10515341	chr5:102317117	G/A	cg23492399	chr5:102201601	PAM	-0.66	-5.15	-0.47	1.4e-6	Primary biliary cholangitis;
THYM	cis	rs7586879	0.964	rs13412941	chr2:25102709	C/T	cg01884057	chr2:25150051	NA	0.53	4.7	0.43	8.85e-6	Body mass index;
THYM	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.52	0.73	1.31e-17	Prudent dietary pattern;
THYM	cis	rs12188164	0.575	rs112126699	chr5:419462	A/T	cg26850624	chr5:429559	AHRR	-0.63	-4.84	-0.45	4.94e-6	Cystic fibrosis severity;
THYM	cis	rs6964587	0.677	rs62467839	chr7:91967371	A/G	cg17063962	chr7:91808500	NA	0.96	7.65	0.62	1.61e-11	Breast cancer;
THYM	cis	rs40363	0.723	rs4785936	chr16:3535116	A/G	cg00484396	chr16:3507460	NAT15	-0.57	-4.96	-0.45	3.15e-6	Tuberculosis;
THYM	cis	rs9527	0.641	rs34130454	chr10:104903638	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg09074113	chr2:20870087	GDF7	-0.76	-6.69	-0.57	1.5e-9	Abdominal aortic aneurysm;
THYM	cis	rs854765	0.583	rs8075965	chr17:17853180	A/T	cg04398451	chr17:18023971	MYO15A	-0.79	-7.19	-0.59	1.45e-10	Total body bone mineral density;
THYM	trans	rs8002861	0.664	rs4942247	chr13:44405107	A/G	cg17145862	chr1:211918768	LPGAT1	0.85	7.65	0.62	1.63e-11	Leprosy;
THYM	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg12863693	chr15:85201151	NMB	0.62	5.46	0.49	3.81e-7	Schizophrenia;
THYM	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg10523679	chr1:76189770	ACADM	0.55	4.67	0.43	9.97e-6	Daytime sleep phenotypes;
THYM	cis	rs9653442	0.547	rs1062143	chr2:100659796	A/G	cg07810366	chr2:100720526	AFF3	-0.42	-5.89	-0.52	5.9e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg24955955	chr5:415729	AHRR	1.13	6.55	0.56	2.9e-9	Fat distribution (HIV);
THYM	cis	rs6430585	0.528	rs115469964	chr2:136696608	A/C	cg07169764	chr2:136633963	MCM6	1.23	14.81	0.84	1.97e-26	Corneal structure;
THYM	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg09323728	chr8:95962352	TP53INP1	0.43	4.56	0.42	1.54e-5	Type 2 diabetes;
THYM	cis	rs9430161	0.644	rs34365965	chr1:11034442	G/A	cg02454025	chr1:11042201	C1orf127	0.92	11.02	0.75	1.13e-18	Ewing sarcoma;
THYM	cis	rs7818345	0.967	rs13255946	chr8:19275354	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.54	0.42	1.67e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg05182265	chr7:156933206	UBE3C	0.7	9.62	0.7	1.05e-15	Body mass index;
THYM	cis	rs13102973	0.932	rs13112852	chr4:135838470	C/T	cg14419869	chr4:135874104	NA	0.9	8.46	0.66	3.24e-13	Subjective well-being;
THYM	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg03806693	chr22:41940476	POLR3H	-1.21	-10.2	-0.72	6.07e-17	Vitiligo;
THYM	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg12016809	chr21:47604291	C21orf56	0.66	4.83	0.44	5.24e-6	Testicular germ cell tumor;
THYM	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.73	0.44	7.73e-6	Alzheimer's disease (late onset);
THYM	cis	rs2073300	1.000	rs6114126	chr20:23452127	A/T	cg12062639	chr20:23401060	NAPB	1.2	5.64	0.5	1.73e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg16342193	chr10:102329863	NA	-0.53	-5.45	-0.49	4.01e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6531656	0.796	rs337639	chr4:38607248	A/G	cg24279243	chr4:38676559	KLF3	0.81	6.03	0.53	3.11e-8	Lymphocyte counts;
THYM	cis	rs12216545	0.737	rs6464075	chr7:150234541	G/A	cg08960815	chr7:150264767	GIMAP4	-0.89	-8.27	-0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs362272	0.545	rs2748447	chr4:3337831	G/A	cg14583973	chr4:3374767	RGS12	0.69	6.75	0.57	1.14e-9	Serum sulfate level;
THYM	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg09549813	chr16:4587862	C16orf5	-0.56	-6.31	-0.54	8.98e-9	Schizophrenia;
THYM	cis	rs113835537	0.529	rs11227502	chr11:66274148	T/G	cg24851651	chr11:66362959	CCS	0.7	4.82	0.44	5.46e-6	Airway imaging phenotypes;
THYM	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg02640540	chr1:67518911	SLC35D1	0.59	4.58	0.43	1.41e-5	Lymphocyte percentage of white cells;
THYM	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg00129232	chr17:37814104	STARD3	-0.96	-8.55	-0.66	2.06e-13	Asthma;
THYM	cis	rs500891	0.525	rs1145895	chr6:84042326	C/A	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs9790314	0.875	rs55688744	chr3:160944222	G/A	cg03342759	chr3:160939853	NMD3	-0.95	-9.48	-0.7	2.12e-15	Morning vs. evening chronotype;
THYM	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg10802521	chr3:52805072	NEK4	-0.72	-6.07	-0.53	2.55e-8	Bipolar disorder;
THYM	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg22841779	chr14:105766346	BRF1	-0.47	-5.81	-0.51	8.18e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03647317	chr4:187891568	NA	-0.83	-9.1	-0.68	1.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg24530246	chr3:53118167	NA	-0.83	-4.78	-0.44	6.39e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs909002	0.800	rs2176807	chr1:32092735	T/G	cg13919466	chr1:32135498	COL16A1	-0.5	-5.13	-0.47	1.51e-6	Intelligence (multi-trait analysis);
THYM	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21582582	chr3:182698605	DCUN1D1	0.81	7.09	0.59	2.35e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.41	-5.2	-0.47	1.15e-6	Monocyte percentage of white cells;
THYM	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17209837	0.573	rs45537841	chr7:87110640	C/T	cg04996195	chr7:87105398	ABCB4	0.65	4.73	0.44	7.65e-6	Gallbladder cancer;
THYM	cis	rs6988636	1.000	rs60362869	chr8:124189971	A/G	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs9399401	0.593	rs262117	chr6:142807093	G/A	cg03128060	chr6:142623767	GPR126	0.66	9.02	0.68	2.02e-14	Chronic obstructive pulmonary disease;
THYM	cis	rs9581943	0.967	rs7995917	chr13:28472724	T/C	cg16302790	chr13:28498334	PDX1	0.52	4.6	0.43	1.33e-5	Pancreatic cancer;
THYM	cis	rs11574514	1.000	rs1133090	chr16:68021468	G/C	cg04582263	chr16:67973788	LCAT	1.0	4.73	0.44	7.9e-6	Crohn's disease;
THYM	cis	rs11190604	0.767	rs7076606	chr10:102192267	T/C	cg16342193	chr10:102329863	NA	-0.5	-5.17	-0.47	1.29e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg07837209	chr13:79184101	NA	0.7	4.62	0.43	1.19e-5	Large artery stroke;
THYM	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg07424592	chr7:64974309	NA	0.99	5.15	0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg21475434	chr5:93447410	FAM172A	0.97	6.1	0.53	2.3e-8	Diabetic retinopathy;
THYM	cis	rs4688759	0.686	rs73079033	chr3:49979174	T/C	cg00383909	chr3:49044727	WDR6	1.1	5.42	0.49	4.43e-7	Blood protein levels;
THYM	cis	rs758324	0.645	rs154734	chr5:131472553	C/T	cg16205897	chr5:131564050	P4HA2	0.53	4.63	0.43	1.18e-5	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs40363	0.716	rs9926612	chr16:3540968	A/C	cg22508957	chr16:3507546	NAT15	-0.73	-6.54	-0.56	3.05e-9	Tuberculosis;
THYM	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg25358565	chr5:93447407	FAM172A	-0.93	-6.7	-0.57	1.44e-9	Diabetic retinopathy;
THYM	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg05738196	chr6:26577821	NA	0.84	8.48	0.66	2.87e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg14004847	chr7:1930337	MAD1L1	0.69	5.53	0.49	2.83e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg19761014	chr17:28927070	LRRC37B2	0.78	4.99	0.46	2.76e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg18032289	chr17:61959525	GH2	-0.49	-4.67	-0.43	9.78e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	trans	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg25767906	chr1:53392781	SCP2	-0.53	-5.2	-0.47	1.13e-6	Monocyte count;
THYM	cis	rs7084402	1.000	rs1346301	chr10:60267310	G/A	cg09696939	chr10:60272079	BICC1	0.47	5.42	0.49	4.46e-7	Refractive error;
THYM	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg13397359	chr6:42928475	GNMT	0.61	5.44	0.49	4.07e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs919433	0.783	rs788007	chr2:198233676	T/G	cg05783139	chr2:198650985	BOLL	0.56	4.5	0.42	1.96e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7216064	1.000	rs4791212	chr17:65975385	C/T	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.79e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs710216	0.879	rs710218	chr1:43427218	A/T	cg16738646	chr1:43409193	SLC2A1	-0.55	-4.88	-0.45	4.26e-6	Red cell distribution width;
THYM	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs9790314	0.846	rs9809522	chr3:160983768	G/C	cg03342759	chr3:160939853	NMD3	-0.95	-9.47	-0.7	2.2e-15	Morning vs. evening chronotype;
THYM	cis	rs988913	0.957	rs1393774	chr6:54838449	G/C	cg04690482	chr6:54711388	FAM83B	0.49	5.28	0.48	8.01e-7	Menarche (age at onset);
THYM	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg06634786	chr22:41940651	POLR3H	-0.55	-4.54	-0.42	1.68e-5	Vitiligo;
THYM	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg01097406	chr16:89675127	NA	-0.59	-4.93	-0.45	3.43e-6	Vitiligo;
THYM	cis	rs4731207	0.596	rs723443	chr7:124659301	A/T	cg05285228	chr7:124571219	POT1	-0.69	-5.25	-0.47	9.35e-7	Cutaneous malignant melanoma;
THYM	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg26354017	chr1:205819088	PM20D1	0.8	8.33	0.65	5.96e-13	Menarche (age at onset);
THYM	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.44	6.67	0.56	1.67e-9	Obesity-related traits;
THYM	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg07870213	chr5:140052090	DND1	0.71	8.17	0.64	1.32e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs3087591	1.000	rs2905884	chr17:29512476	A/G	cg24425628	chr17:29625626	OMG;NF1	0.61	5.23	0.47	1.02e-6	Hip circumference;
THYM	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg14458575	chr2:238380390	NA	1.13	8.48	0.66	2.87e-13	Prostate cancer;
THYM	cis	rs2637266	1.000	rs7914880	chr10:78363693	A/G	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs8038465	0.662	rs12594595	chr15:73986347	A/G	cg15420318	chr15:73925796	NPTN	0.7	5.82	0.51	8e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg16586182	chr3:47516702	SCAP	0.67	5.62	0.5	1.9e-7	Colorectal cancer;
THYM	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg08859206	chr1:53392774	SCP2	-0.49	-5.11	-0.46	1.66e-6	Monocyte count;
THYM	cis	rs7772486	0.754	rs4896841	chr6:146041522	T/C	cg13319975	chr6:146136371	FBXO30	0.63	5.17	0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17001868	0.568	rs3788578	chr22:40742921	C/T	cg07138101	chr22:40742427	ADSL	0.94	5.71	0.51	1.3e-7	Mammographic density (dense area);
THYM	cis	rs11771526	1.000	rs11771526	chr7:32342618	A/G	cg27532318	chr7:32358331	NA	0.91	5.46	0.49	3.88e-7	Body mass index;
THYM	cis	rs1808579	0.904	rs1631685	chr18:21134239	C/T	cg14672496	chr18:21087552	C18orf8	0.53	4.86	0.45	4.63e-6	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
THYM	cis	rs4466137	0.903	rs3734092	chr5:83016743	C/T	cg16102102	chr5:83017553	HAPLN1	-1.11	-11.0	-0.75	1.21e-18	Prostate cancer;
THYM	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg16524733	chr11:117070046	TAGLN	0.42	4.69	0.43	9.27e-6	Blood protein levels;
THYM	cis	rs12682352	0.652	rs3827806	chr8:8724276	C/T	cg06636001	chr8:8085503	FLJ10661	0.61	5.22	0.47	1.06e-6	Neuroticism;
THYM	cis	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg06521331	chr12:34319734	NA	-1.0	-8.74	-0.67	8.12e-14	Morning vs. evening chronotype;
THYM	trans	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17712092	chr4:129076599	LARP1B	0.9	7.58	0.61	2.33e-11	Eosinophil percentage of white cells;
THYM	cis	rs775227	0.574	rs3732809	chr3:113045561	A/G	cg18753928	chr3:113234510	CCDC52	-0.75	-5.16	-0.47	1.35e-6	Dental caries;
THYM	cis	rs941873	0.900	rs4979861	chr10:81131595	A/G	cg09469691	chr10:81107165	PPIF	0.72	5.81	0.51	8.19e-8	Height;
THYM	cis	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-5.84	-0.51	7.42e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg01252526	chr16:711033	WDR90	-0.7	-6.53	-0.56	3.23e-9	Height;
THYM	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg06784218	chr1:46089804	CCDC17	-0.29	-4.5	-0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs4845875	0.626	rs11121827	chr1:11832100	T/A	cg24844545	chr1:11908347	NPPA	0.45	4.6	0.43	1.28e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.51	5.32	0.48	6.93e-7	Schizophrenia;
THYM	cis	rs11648796	0.765	rs2003832	chr16:769538	G/A	cg05638439	chr16:711235	WDR90	-0.59	-5.38	-0.48	5.28e-7	Height;
THYM	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg26384229	chr12:38710491	ALG10B	0.96	7.77	0.62	8.98e-12	Bladder cancer;
THYM	cis	rs9595908	0.900	rs731413	chr13:33175656	G/A	cg12383807	chr13:33924137	NA	-0.54	-4.85	-0.45	4.85e-6	Body mass index;
THYM	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg02734326	chr4:10020555	SLC2A9	0.77	7.16	0.59	1.73e-10	Bone mineral density;
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg11809123	chr19:1584870	MBD3	-0.95	-7.53	-0.61	2.88e-11	Energy expenditure (24h);
THYM	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg26441486	chr22:50317300	CRELD2	0.4	6.46	0.55	4.54e-9	Schizophrenia;
THYM	cis	rs6674970	0.518	rs15740	chr1:151040435	G/A	cg03258749	chr1:151040405	MLLT11	-0.69	-5.88	-0.52	6e-8	Childhood ear infection;
THYM	cis	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs1448094	0.511	rs2405616	chr12:86148042	A/G	cg02569458	chr12:86230093	RASSF9	-0.66	-5.63	-0.5	1.84e-7	Major depressive disorder;
THYM	cis	rs7523273	0.597	rs2761437	chr1:207923081	A/G	cg22525895	chr1:207977042	MIR29B2	0.76	5.18	0.47	1.27e-6	Schizophrenia;
THYM	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.2	8.02	0.64	2.74e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7980799	0.682	rs1384599	chr12:33624579	G/A	cg06521331	chr12:34319734	NA	0.69	4.85	0.45	4.81e-6	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs9362426	1.000	rs6930076	chr6:88088654	G/A	cg10393598	chr6:87862264	NA	-0.6	-4.75	-0.44	7.14e-6	Depressive episodes in bipolar disorder;
THYM	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg12373951	chr3:133503437	NA	0.65	7.08	0.59	2.44e-10	Iron status biomarkers;
THYM	cis	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs1371867	1.000	rs1371867	chr8:101330209	A/C	cg06636551	chr8:101224915	SPAG1	-0.55	-5.19	-0.47	1.21e-6	Atrioventricular conduction;
THYM	cis	rs270601	0.817	rs460089	chr5:131629772	C/G	cg12564285	chr5:131593104	PDLIM4	0.5	5.22	0.47	1.05e-6	Acylcarnitine levels;
THYM	cis	rs2279817	1.000	rs10788681	chr1:18019524	C/A	cg21791023	chr1:18019539	ARHGEF10L	0.77	4.85	0.45	4.86e-6	Neuroticism;
THYM	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg17775962	chr7:1200435	ZFAND2A	0.42	5.1	0.46	1.75e-6	Longevity;Endometriosis;
THYM	cis	rs62064224	0.818	rs11080180	chr17:30682998	G/A	cg18200150	chr17:30822561	MYO1D	0.86	7.63	0.62	1.79e-11	Schizophrenia;
THYM	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs12216545	0.737	rs4725911	chr7:150237328	A/G	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.42	0.49	4.44e-7	Height;
THYM	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg00717180	chr2:96193071	NA	-0.71	-7.41	-0.61	5.21e-11	HDL cholesterol;
THYM	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg11266682	chr4:10021025	SLC2A9	0.67	9.84	0.71	3.56e-16	Bone mineral density;
THYM	cis	rs56161922	1.000	rs12567945	chr1:207841934	T/C	cg09557387	chr1:207818395	CR1L	1.14	5.13	0.47	1.52e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs981844	0.813	rs72731678	chr4:154671476	T/C	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg27129171	chr3:47204927	SETD2	0.77	7.65	0.62	1.67e-11	Colorectal cancer;
THYM	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-5.9	-0.52	5.58e-8	Total cholesterol levels;
THYM	cis	rs7677751	0.806	rs4864860	chr4:55090021	T/C	cg17187183	chr4:55093834	PDGFRA	0.72	5.56	0.5	2.49e-7	Corneal astigmatism;
THYM	cis	rs6748734	0.625	rs6437372	chr2:241822406	A/G	cg07537917	chr2:241836409	C2orf54	0.22	5.01	0.46	2.54e-6	Urinary metabolites;
THYM	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg13683864	chr3:40499215	RPL14	-1.05	-11.77	-0.77	2.9e-20	Renal cell carcinoma;
THYM	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs262150	0.502	rs73167295	chr7:158782949	T/A	cg23058037	chr7:158824108	VIPR2	0.5	4.5	0.42	1.93e-5	Facial morphology (factor 20);
THYM	cis	rs7104764	1.000	rs10902110	chr11:237648	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs240764	0.853	rs108422	chr6:101039279	G/C	cg21058520	chr6:100914733	NA	-0.56	-4.8	-0.44	5.9e-6	Neuroticism;
THYM	cis	rs17539620	0.519	rs12665532	chr6:154835182	C/G	cg20019720	chr6:154832845	CNKSR3	0.6	6.6	0.56	2.31e-9	Lipoprotein (a) levels;
THYM	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg03676636	chr4:99064102	C4orf37	0.42	6.37	0.55	6.64e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg03433033	chr1:76189801	ACADM	0.76	9.93	0.71	2.38e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs995000	0.895	rs631106	chr1:62901807	C/A	cg06896770	chr1:63153194	DOCK7	0.92	7.03	0.58	3.17e-10	Triglyceride levels;
THYM	cis	rs4713118	0.662	rs149970	chr6:27980220	C/T	cg23281280	chr6:28129359	ZNF389	0.62	5.0	0.46	2.58e-6	Parkinson's disease;
THYM	cis	rs11096990	0.892	rs1901404	chr4:39212610	A/C	cg24403649	chr4:39172243	NA	-0.62	-5.17	-0.47	1.31e-6	Cognitive function;
THYM	trans	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg25214090	chr10:38739885	LOC399744	0.86	7.44	0.61	4.54e-11	Corneal astigmatism;
THYM	cis	rs17597773	0.674	rs10863569	chr1:221018940	T/C	cg16008148	chr1:221062819	NA	0.44	4.5	0.42	1.96e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-6.77	-0.57	1.08e-9	Total body bone mineral density;
THYM	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs61931739	0.635	rs1852224	chr12:33963080	A/C	cg10856724	chr12:34555212	NA	-0.64	-6.04	-0.53	3.04e-8	Morning vs. evening chronotype;
THYM	cis	rs931127	0.505	rs2306362	chr11:65405510	G/T	cg17480646	chr11:65405466	SIPA1	-0.93	-8.3	-0.65	6.86e-13	Systemic lupus erythematosus;
THYM	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg24812749	chr6:127587940	RNF146	0.92	7.35	0.6	6.98e-11	Breast cancer;
THYM	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/C	cg00825309	chr19:58991885	ZNF446	-1.08	-10.17	-0.72	7.06e-17	Mean platelet volume;
THYM	cis	rs11771526	1.000	rs6462350	chr7:32342000	G/A	cg13207630	chr7:32358064	NA	1.02	5.88	0.52	6.13e-8	Body mass index;
THYM	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg18825531	chr11:62321136	NA	-0.46	-5.14	-0.47	1.44e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.81	-7.48	-0.61	3.66e-11	Personality dimensions;
THYM	cis	rs6748734	0.625	rs4312490	chr2:241821481	A/G	cg09990169	chr2:241835740	C2orf54	-0.31	-5.13	-0.47	1.51e-6	Urinary metabolites;
THYM	cis	rs13185784	0.703	rs1127580	chr5:179661528	C/T	cg23221052	chr5:179740743	GFPT2	0.66	4.63	0.43	1.14e-5	TRAIL levels;
THYM	cis	rs6127978	0.702	rs162313	chr20:55804177	C/T	cg15851418	chr20:55835831	BMP7	0.68	4.89	0.45	4.12e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs11711311	1.000	rs9865965	chr3:113450495	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.27	-0.48	8.41e-7	IgG glycosylation;
THYM	cis	rs11971779	1.000	rs11971779	chr7:139040258	A/G	cg07862535	chr7:139043722	LUC7L2	-0.69	-4.57	-0.42	1.45e-5	Diisocyanate-induced asthma;
THYM	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg24920358	chr1:40204285	PPIE	0.56	4.88	0.45	4.25e-6	Blood protein levels;
THYM	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg14196790	chr5:131705035	SLC22A5	0.55	4.93	0.45	3.55e-6	Blood metabolite levels;
THYM	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg18477163	chr1:228402036	OBSCN	0.59	6.59	0.56	2.4e-9	Diastolic blood pressure;
THYM	cis	rs7917772	0.582	rs7906115	chr10:104327164	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs600806	0.888	rs3879449	chr1:109904971	A/T	cg23616212	chr1:109941201	SORT1	-0.5	-4.72	-0.44	8.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg18876405	chr7:65276391	NA	-0.62	-5.58	-0.5	2.29e-7	Aortic root size;
THYM	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg20503657	chr10:835505	NA	1.18	8.24	0.65	9.47e-13	Eosinophil percentage of granulocytes;
THYM	trans	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg07211511	chr3:129823064	LOC729375	-1.24	-10.17	-0.72	7.21e-17	Blood pressure (smoking interaction);
THYM	cis	rs13401104	0.587	rs7569760	chr2:237145713	A/C	cg19324714	chr2:237145437	ASB18	0.63	4.68	0.43	9.6e-6	Educational attainment;
THYM	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg18806716	chr10:30721971	MAP3K8	-0.48	-4.58	-0.43	1.41e-5	Inflammatory bowel disease;
THYM	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg13695892	chr22:41940480	POLR3H	0.99	7.48	0.61	3.75e-11	Vitiligo;
THYM	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg14159672	chr1:205819179	PM20D1	0.69	6.39	0.55	6.26e-9	Menarche (age at onset);
THYM	cis	rs1267303	0.675	rs1745370	chr1:46982863	C/G	cg16387850	chr1:46982889	NA	0.46	5.49	0.49	3.41e-7	Monobrow;
THYM	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	6.26	0.54	1.13e-8	Smoking behavior;
THYM	cis	rs2688608	0.588	rs10128205	chr10:75469648	C/G	cg23231163	chr10:75533350	FUT11	-0.45	-6.13	-0.53	1.96e-8	Inflammatory bowel disease;
THYM	cis	rs7681440	0.560	rs2619371	chr4:90736678	A/G	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg24818145	chr4:99064322	C4orf37	0.72	5.66	0.5	1.62e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-10.91	-0.75	1.95e-18	Primary sclerosing cholangitis;
THYM	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.87	6.27	0.54	1.04e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg00376283	chr12:123451042	ABCB9	0.71	4.76	0.44	6.85e-6	Neutrophil percentage of white cells;
THYM	cis	rs1160297	0.575	rs6715857	chr2:53097395	T/G	cg07782112	chr2:53107842	NA	0.79	6.38	0.55	6.33e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs2069036	0.903	rs11253750	chr10:16085782	T/C	cg26633223	chr10:15133461	NA	0.7	5.04	0.46	2.2e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs6009824	0.891	rs6009820	chr22:50085456	C/T	cg18178197	chr22:50098317	NA	0.84	6.66	0.56	1.75e-9	Natriuretic peptide levels;
THYM	cis	rs7119	0.651	rs12904208	chr15:77845911	C/T	cg27398640	chr15:77910606	LINGO1	-0.61	-6.05	-0.53	2.92e-8	Type 2 diabetes;
THYM	cis	rs807669	0.548	rs885978	chr22:19198226	A/G	cg02655711	chr22:19163373	SLC25A1	0.72	8.14	0.64	1.5e-12	Metabolite levels;
THYM	cis	rs9733	0.596	rs72702573	chr1:150689050	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs747334	0.846	rs3885868	chr10:92723406	T/C	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs2688608	0.592	rs10762559	chr10:75486453	G/C	cg23231163	chr10:75533350	FUT11	-0.44	-6.22	-0.54	1.34e-8	Inflammatory bowel disease;
THYM	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg00024416	chr22:24240387	NA	0.66	6.97	0.58	4.23e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg22117172	chr7:91764530	CYP51A1	0.37	4.84	0.44	5.01e-6	Breast cancer;
THYM	cis	rs17125944	0.615	rs12590862	chr14:53297008	A/G	cg00686598	chr14:53173677	PSMC6	-1.01	-4.78	-0.44	6.39e-6	Alzheimer's disease (late onset);
THYM	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg03806693	chr22:41940476	POLR3H	-0.99	-7.63	-0.62	1.82e-11	Vitiligo;
THYM	cis	rs7078219	0.714	rs11190137	chr10:101287944	G/T	cg17888390	chr10:101282816	NA	0.54	5.26	0.47	8.91e-7	Dental caries;
THYM	cis	rs2458413	0.563	rs2458419	chr8:105337141	G/C	cg04554929	chr8:105342491	NA	-0.5	-8.01	-0.63	2.85e-12	Paget's disease;
THYM	cis	rs9733	0.596	rs7538493	chr1:150655421	T/C	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	7.73	0.62	1.1e-11	Smoking behavior;
THYM	cis	rs6430585	0.583	rs6728946	chr2:136635343	C/G	cg07169764	chr2:136633963	MCM6	1.25	14.39	0.83	1.36e-25	Corneal structure;
THYM	cis	rs36051895	0.593	rs62541903	chr9:5146952	G/C	cg02405213	chr9:5042618	JAK2	-1.04	-10.87	-0.74	2.36e-18	Pediatric autoimmune diseases;
THYM	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.7	5.84	0.51	7.4e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-4.93	-0.45	3.45e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg07936489	chr17:37558343	FBXL20	0.82	5.61	0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg02725872	chr8:58115012	NA	-1.11	-8.56	-0.66	1.98e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg10518543	chr12:38710700	ALG10B	-0.56	-4.46	-0.42	2.29e-5	Bladder cancer;
THYM	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg25703541	chr22:24373054	LOC391322	-0.84	-8.79	-0.67	6.37e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12134245	0.747	rs35654098	chr1:92001452	T/A	cg21854759	chr1:92012499	NA	-0.7	-5.67	-0.5	1.5e-7	Breast cancer;
THYM	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7843479	0.601	rs11785043	chr8:21810377	C/T	cg17168535	chr8:21777572	XPO7	0.94	8.69	0.67	1.06e-13	Mean corpuscular volume;
THYM	cis	rs10463554	0.750	rs26257	chr5:102550531	C/T	cg23492399	chr5:102201601	PAM	-0.71	-5.32	-0.48	6.82e-7	Parkinson's disease;
THYM	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.99	0.46	2.67e-6	Prudent dietary pattern;
THYM	cis	rs10779751	0.922	rs2746638	chr1:11278125	T/C	cg08854313	chr1:11322531	MTOR	0.9	7.65	0.62	1.61e-11	Body mass index;
THYM	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg26924012	chr15:45694286	SPATA5L1	1.15	11.26	0.76	3.52e-19	Homoarginine levels;
THYM	cis	rs2219968	0.692	rs9657044	chr8:78942084	A/G	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg18811423	chr2:55921094	PNPT1	0.68	5.81	0.51	8.25e-8	Metabolic syndrome;
THYM	cis	rs4953076	0.573	rs6726680	chr2:44406686	C/G	cg04920474	chr2:44395004	PPM1B	0.65	5.43	0.49	4.32e-7	Height;
THYM	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg12560992	chr17:57184187	TRIM37	-0.76	-6.24	-0.54	1.2e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6499255	0.951	rs56316408	chr16:69658776	A/G	cg00738113	chr16:70207722	CLEC18C	-0.45	-4.45	-0.42	2.32e-5	IgE levels;
THYM	trans	rs8073060	0.586	rs2011897	chr17:34054408	A/T	cg19694781	chr19:47549865	TMEM160	1.01	8.58	0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs72717751	0.504	rs78360804	chr14:55957886	T/C	cg01858014	chr14:56050164	KTN1	-1.3	-4.81	-0.44	5.69e-6	Platelet distribution width;
THYM	cis	rs4474465	0.850	rs6592789	chr11:78246767	G/C	cg19901956	chr11:77921274	USP35	0.67	5.02	0.46	2.42e-6	Alzheimer's disease (survival time);
THYM	cis	rs4638749	1.000	rs12616140	chr2:108867728	A/G	cg06795125	chr2:108905320	SULT1C2	-0.41	-5.38	-0.48	5.27e-7	Blood pressure;
THYM	cis	rs2050392	0.792	rs684395	chr10:30719112	C/G	cg02070205	chr10:30722105	MAP3K8	-0.53	-4.54	-0.42	1.62e-5	Inflammatory bowel disease;
THYM	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg02493740	chr2:85810744	VAMP5	-0.64	-4.99	-0.46	2.75e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs931127	0.692	rs7934517	chr11:65445673	C/T	cg17480646	chr11:65405466	SIPA1	-0.77	-6.7	-0.57	1.44e-9	Systemic lupus erythematosus;
THYM	cis	rs7107174	0.892	rs4945273	chr11:78096977	T/C	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg13147721	chr7:65941812	NA	-0.89	-5.31	-0.48	7.23e-7	Diabetic kidney disease;
THYM	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06850241	chr22:41845214	NA	-0.63	-5.55	-0.49	2.58e-7	Vitiligo;
THYM	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.81	7.32	0.6	7.82e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.41	6.35	0.55	7.28e-9	Obesity-related traits;
THYM	cis	rs600806	0.821	rs3879451	chr1:109909269	C/T	cg23032129	chr1:109941072	SORT1	-0.54	-4.55	-0.42	1.58e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6584283	1.000	rs6584283	chr10:101290301	A/G	cg23904955	chr10:101282759	NA	-0.37	-4.48	-0.42	2.1e-5	Ulcerative colitis;
THYM	cis	rs2976388	0.609	rs2717602	chr8:143805683	G/A	cg13446199	chr8:143762866	PSCA	-0.44	-4.91	-0.45	3.82e-6	Urinary tract infection frequency;
THYM	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg19761014	chr17:28927070	LRRC37B2	0.8	4.73	0.44	7.8e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg09904177	chr6:26538194	HMGN4	-0.54	-4.54	-0.42	1.63e-5	Intelligence (multi-trait analysis);
THYM	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg06130144	chr11:64578348	MEN1	0.82	5.09	0.46	1.79e-6	Mean platelet volume;
THYM	cis	rs7107174	0.786	rs4945266	chr11:78027488	A/G	cg19901956	chr11:77921274	USP35	-0.69	-5.3	-0.48	7.42e-7	Testicular germ cell tumor;
THYM	cis	rs28374715	0.681	rs8037574	chr15:41630770	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.17	-14.19	-0.82	3.41e-25	Ulcerative colitis;
THYM	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg22189786	chr22:42395067	WBP2NL	0.56	5.09	0.46	1.79e-6	Birth weight;
THYM	cis	rs6815814	0.950	rs66922907	chr4:38812537	A/G	cg06935464	chr4:38784597	TLR10	0.72	4.71	0.44	8.42e-6	Breast cancer;
THYM	cis	rs514406	0.698	rs522259	chr1:53365481	A/G	cg25767906	chr1:53392781	SCP2	-0.64	-6.42	-0.55	5.39e-9	Monocyte count;
THYM	cis	rs6701037	0.566	rs10753091	chr1:175134571	T/C	cg00958927	chr1:175162553	KIAA0040	0.35	4.88	0.45	4.32e-6	Alcohol dependence;
THYM	cis	rs17102423	0.723	rs8181937	chr14:65555707	A/C	cg11161011	chr14:65562177	MAX	-0.88	-7.49	-0.61	3.58e-11	Obesity-related traits;
THYM	cis	rs9420	0.961	rs576859	chr11:57480623	A/C	cg19752551	chr11:57585705	CTNND1	0.66	7.66	0.62	1.55e-11	Schizophrenia;
THYM	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg02887458	chr19:19495540	GATAD2A	-0.45	-4.89	-0.45	4.05e-6	Bipolar disorder;
THYM	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg09469691	chr10:81107165	PPIF	0.73	5.92	0.52	5.04e-8	Height;
THYM	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.57	-4.49	-0.42	2e-5	Aortic root size;
THYM	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg06064525	chr11:970664	AP2A2	-0.35	-6.59	-0.56	2.4e-9	Alzheimer's disease (late onset);
THYM	cis	rs2279817	0.863	rs28481933	chr1:18026277	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.74	4.64	0.43	1.13e-5	Neuroticism;
THYM	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg23281280	chr6:28129359	ZNF389	0.61	4.88	0.45	4.21e-6	Depression;
THYM	cis	rs13315871	0.929	rs13097873	chr3:58267924	C/T	cg00563845	chr3:58318305	PXK	0.55	4.88	0.45	4.32e-6	Cholesterol, total;
THYM	cis	rs1971762	0.527	rs11170590	chr12:53938913	G/A	cg16917193	chr12:54089295	NA	0.7	6.18	0.54	1.6e-8	Height;
THYM	cis	rs6980334	1.000	rs6977075	chr7:137775867	C/T	cg06915773	chr7:137028165	PTN	-0.58	-4.79	-0.44	6.22e-6	Blood metabolite ratios;
THYM	cis	rs11574514	1.000	rs79631436	chr16:67728369	T/A	cg09738193	chr16:67926317	PSKH1	-0.91	-4.63	-0.43	1.16e-5	Crohn's disease;
THYM	cis	rs80319144	1.000	rs2356091	chr2:159239443	A/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs72960926	0.744	rs11753898	chr6:74861057	C/T	cg03266952	chr6:74778945	NA	-0.9	-5.14	-0.47	1.49e-6	Metabolite levels (MHPG);
THYM	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg16405210	chr4:1374714	KIAA1530	1.02	9.29	0.69	5.53e-15	Longevity;
THYM	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg13683864	chr3:40499215	RPL14	-0.75	-6.78	-0.57	1.03e-9	Renal cell carcinoma;
THYM	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg08772003	chr10:104629869	AS3MT	-0.55	-4.9	-0.45	3.97e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs12579753	0.872	rs34415838	chr12:82122078	T/C	cg07988820	chr12:82153109	PPFIA2	-0.8	-5.29	-0.48	7.83e-7	Resting heart rate;
THYM	cis	rs9644630	1.000	rs9644631	chr8:19370830	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.76	8.22	0.64	1.04e-12	Oropharynx cancer;
THYM	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	7.72	0.62	1.15e-11	Monocyte percentage of white cells;
THYM	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	6.05	0.53	2.83e-8	Platelet count;
THYM	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22496380	chr5:211416	CCDC127	-1.3	-8.28	-0.65	7.84e-13	Breast cancer;
THYM	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg06027949	chr8:82754900	SNX16	-0.64	-5.35	-0.48	6.18e-7	Diastolic blood pressure;
THYM	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg11812906	chr14:75593930	NEK9	0.81	7.29	0.6	9.26e-11	Height;
THYM	cis	rs6840360	0.642	rs2724551	chr4:152355383	T/C	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11890956	chr21:40555474	PSMG1	0.68	5.44	0.49	4.16e-7	Cognitive function;
THYM	cis	rs7843479	0.965	rs878872	chr8:21834567	A/G	cg17168535	chr8:21777572	XPO7	0.7	5.29	0.48	7.87e-7	Mean corpuscular volume;
THYM	cis	rs854765	0.594	rs8066560	chr17:17728043	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.6	-5.11	-0.46	1.65e-6	Total body bone mineral density;
THYM	cis	rs765787	0.530	rs12913123	chr15:45516425	C/T	cg25801113	chr15:45476975	SHF	-0.38	-4.53	-0.42	1.68e-5	Uric acid levels;
THYM	cis	rs10162002	1.000	rs17078796	chr13:24043830	A/G	cg00158254	chr13:24040743	NA	-0.7	-4.68	-0.43	9.46e-6	Hypothyroidism;
THYM	cis	rs3850699	0.609	rs12763720	chr10:104241983	T/C	cg04362960	chr10:104952993	NT5C2	0.68	4.68	0.43	9.34e-6	Prostate cancer;
THYM	cis	rs977987	0.835	rs4888379	chr16:75340231	A/T	cg03315344	chr16:75512273	CHST6	0.84	6.86	0.58	6.98e-10	Dupuytren's disease;
THYM	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg18402987	chr7:1209562	NA	0.75	5.42	0.49	4.58e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-15.47	-0.85	1.07e-27	Height;
THYM	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg13531842	chr10:38383804	ZNF37A	-0.55	-4.61	-0.43	1.28e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg23758822	chr17:41437982	NA	1.27	14.18	0.82	3.54e-25	Menopause (age at onset);
THYM	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg22681709	chr2:178499509	PDE11A	-0.53	-5.05	-0.46	2.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7107174	1.000	rs2511186	chr11:77984306	C/G	cg19901956	chr11:77921274	USP35	-0.68	-5.25	-0.47	9.31e-7	Testicular germ cell tumor;
THYM	cis	rs61774743	0.521	rs60144015	chr1:41845246	C/A	cg01193554	chr1:41846683	NA	-0.37	-5.19	-0.47	1.19e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg07167872	chr1:205819463	PM20D1	-0.6	-4.69	-0.43	9.12e-6	Prostate-specific antigen levels;
THYM	cis	rs986417	0.818	rs7156317	chr14:61087740	G/A	cg27398547	chr14:60952738	C14orf39	0.94	5.21	0.47	1.07e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs2692947	0.770	rs12471925	chr2:96555522	C/A	cg23100626	chr2:96804247	ASTL	0.41	5.1	0.46	1.71e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs2731664	0.792	rs2630767	chr5:176870700	T/C	cg14098951	chr5:176875120	PRR7	0.57	5.01	0.46	2.49e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2505998	0.957	rs2435359	chr10:43580015	A/G	cg06632098	chr10:43605906	RET	-1.03	-9.18	-0.69	9.4e-15	Hirschsprung disease;
THYM	cis	rs67460515	0.852	rs2404341	chr3:161092405	T/C	cg03342759	chr3:160939853	NMD3	-0.9	-7.93	-0.63	4.25e-12	Parkinson's disease;
THYM	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.72	5.72	0.51	1.24e-7	Blood protein levels;
THYM	cis	rs2075230	0.642	rs1642797	chr17:7543017	C/T	cg27413385	chr17:7515425	FXR2	-0.36	-5.07	-0.46	1.95e-6	Hormone measurements;
THYM	cis	rs6009824	0.891	rs6009822	chr22:50085731	C/T	cg22070880	chr22:50098194	NA	0.67	4.74	0.44	7.39e-6	Natriuretic peptide levels;
THYM	cis	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg06521331	chr12:34319734	NA	0.76	5.88	0.52	6.13e-8	Morning vs. evening chronotype;
THYM	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg06634786	chr22:41940651	POLR3H	-0.65	-4.79	-0.44	6.06e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4642101	0.824	rs11717013	chr3:12843862	A/C	cg05775895	chr3:12838266	CAND2	0.94	8.62	0.66	1.49e-13	QRS complex (12-leadsum);
THYM	cis	rs28595532	0.925	rs116785973	chr4:119611350	G/A	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg26850624	chr5:429559	AHRR	-0.7	-5.6	-0.5	2.07e-7	Cystic fibrosis severity;
THYM	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.01	-9.8	-0.71	4.35e-16	Primary sclerosing cholangitis;
THYM	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg27446573	chr6:127587934	RNF146	0.76	6.64	0.56	1.9e-9	Breast cancer;
THYM	cis	rs2070488	1.000	rs3792528	chr3:38493303	T/C	cg24069376	chr3:38537580	EXOG	0.67	6.48	0.55	3.98e-9	Electrocardiographic conduction measures;
THYM	cis	rs13082711	0.871	rs35701251	chr3:27529753	T/A	cg02860705	chr3:27208620	NA	0.72	5.06	0.46	2.01e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg08999081	chr20:33150536	PIGU	0.75	6.53	0.56	3.16e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg06481639	chr22:41940642	POLR3H	0.71	5.27	0.48	8.43e-7	Vitiligo;
THYM	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg10803722	chr21:46713166	LOC642852	-0.43	-5.74	-0.51	1.13e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg05660106	chr1:15850417	CASP9	0.76	6.27	0.54	1.06e-8	Systolic blood pressure;
THYM	cis	rs526231	0.543	rs4386712	chr5:102369234	T/C	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Primary biliary cholangitis;
THYM	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg27494647	chr7:150038898	RARRES2	0.39	4.51	0.42	1.84e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg05872129	chr22:39784769	NA	-0.88	-5.54	-0.49	2.75e-7	IgG glycosylation;
THYM	cis	rs2229238	0.866	rs59741504	chr1:154504601	T/C	cg21262032	chr1:154437693	IL6R	-0.63	-5.65	-0.5	1.68e-7	Coronary heart disease;
THYM	cis	rs6840360	0.571	rs718800	chr4:152549307	A/T	cg17479576	chr4:152424074	FAM160A1	0.82	5.79	0.51	8.9e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.519	rs7511673	chr1:150707636	A/T	cg15448220	chr1:150897856	SETDB1	0.86	7.21	0.59	1.33e-10	Tonsillectomy;
THYM	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg03351412	chr1:154909251	PMVK	0.73	5.58	0.5	2.27e-7	Prostate cancer;
THYM	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg25566285	chr7:158114605	PTPRN2	-0.84	-10.37	-0.73	2.73e-17	Calcium levels;
THYM	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg06558623	chr16:89946397	TCF25	1.45	7.27	0.6	9.84e-11	Skin colour saturation;
THYM	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14159672	chr1:205819179	PM20D1	1.12	12.33	0.78	1.96e-21	Menarche (age at onset);
THYM	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg24006582	chr15:45444508	DUOX1	0.81	6.32	0.54	8.51e-9	Uric acid levels;
THYM	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg11461670	chr8:22454935	PDLIM2	-0.34	-5.75	-0.51	1.09e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	trans	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg12573674	chr2:1569213	NA	-1.35	-8.81	-0.67	5.84e-14	IgG glycosylation;
THYM	cis	rs823143	0.549	rs1094647	chr1:205655378	G/A	cg11965913	chr1:205819406	PM20D1	0.85	8.36	0.65	5.21e-13	Monocyte percentage of white cells;
THYM	cis	rs2066819	1.000	rs77120931	chr12:56646213	A/C	cg26714650	chr12:56694279	CS	-1.27	-6.32	-0.54	8.6e-9	Psoriasis vulgaris;
THYM	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg00383909	chr3:49044727	WDR6	1.08	6.19	0.54	1.54e-8	Cognitive function;
THYM	cis	rs988913	0.793	rs9370332	chr6:54727075	A/G	cg04690482	chr6:54711388	FAM83B	0.46	4.64	0.43	1.12e-5	Menarche (age at onset);
THYM	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg10760299	chr15:45669010	GATM	0.72	5.03	0.46	2.27e-6	Homoarginine levels;
THYM	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg11812906	chr14:75593930	NEK9	0.8	7.18	0.59	1.51e-10	Height;
THYM	cis	rs13315871	1.000	rs74834816	chr3:58321828	G/A	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs9790314	0.560	rs1450521	chr3:161091237	C/A	cg04691961	chr3:161091175	C3orf57	-0.59	-4.87	-0.45	4.45e-6	Morning vs. evening chronotype;
THYM	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg00757033	chr12:89920650	WDR51B	0.77	11.72	0.77	3.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg12863693	chr15:85201151	NMB	0.62	5.39	0.48	5.18e-7	Schizophrenia;
THYM	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.78	-5.1	-0.46	1.71e-6	Huntington's disease progression;
THYM	cis	rs2235573	0.594	rs12157609	chr22:38432277	C/T	cg19171272	chr22:38449367	NA	-0.51	-5.38	-0.48	5.38e-7	Glioblastoma;Glioma;
THYM	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs7830933	0.955	rs12716531	chr8:23595427	C/T	cg04349084	chr8:23602677	NA	0.6	6.43	0.55	5.02e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg22920501	chr2:26401640	FAM59B	-0.71	-6.33	-0.54	7.92e-9	Gut microbiome composition (summer);
THYM	cis	rs6840360	1.000	rs6834095	chr4:152603278	C/T	cg22705602	chr4:152727874	NA	-0.6	-6.48	-0.55	4.07e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6539288	0.563	rs11113122	chr12:107211325	T/C	cg15890332	chr12:107067104	RFX4	0.43	4.9	0.45	3.94e-6	Total body bone mineral density;
THYM	cis	rs42648	0.748	rs10227385	chr7:89890368	C/A	cg03688058	chr7:89840708	STEAP2	-0.54	-4.45	-0.42	2.36e-5	Homocysteine levels;
THYM	cis	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg06521331	chr12:34319734	NA	-0.72	-4.99	-0.46	2.68e-6	Resting heart rate;
THYM	cis	rs7843479	0.965	rs1564305	chr8:21803816	A/C	cg17168535	chr8:21777572	XPO7	0.72	5.25	0.47	9.39e-7	Mean corpuscular volume;
THYM	cis	rs4767364	0.848	rs10774649	chr12:112539516	A/G	cg10833066	chr12:111807467	FAM109A	0.47	5.2	0.47	1.14e-6	Oral cavity and pharyngeal cancer;
THYM	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg12935359	chr14:103987150	CKB	-0.58	-5.66	-0.5	1.61e-7	Body mass index;
THYM	cis	rs11190604	0.767	rs7916904	chr10:102186778	C/G	cg07570687	chr10:102243282	WNT8B	0.85	8.46	0.66	3.16e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs539096	0.692	rs6686238	chr1:44210253	C/G	cg15962314	chr1:44399869	ARTN	0.47	5.05	0.46	2.16e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7100689	0.542	rs7096715	chr10:82195949	T/C	cg01528321	chr10:82214614	TSPAN14	0.59	4.79	0.44	6.18e-6	Post bronchodilator FEV1;
THYM	cis	rs17604090	1.000	rs17661896	chr7:29692708	G/A	cg19413766	chr7:29689036	LOC646762	-1.05	-5.89	-0.52	5.72e-8	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs6860806	0.661	rs334902	chr5:131586559	C/G	cg12564285	chr5:131593104	PDLIM4	0.53	5.87	0.52	6.43e-8	Breast cancer;
THYM	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs11585357	0.793	rs112597506	chr1:17628832	A/G	cg08277548	chr1:17600880	PADI3	-0.88	-5.22	-0.47	1.05e-6	Hair shape;
THYM	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg08885076	chr2:99613938	TSGA10	0.57	5.31	0.48	7.23e-7	Chronic sinus infection;
THYM	cis	rs4866334	1.000	rs74368495	chr5:18483062	T/C	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg24209194	chr3:40518798	ZNF619	0.63	5.12	0.47	1.56e-6	Renal cell carcinoma;
THYM	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg18128536	chr17:47092178	IGF2BP1	0.58	8.31	0.65	6.64e-13	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs7607369	0.759	rs10179708	chr2:219390967	T/A	cg02176678	chr2:219576539	TTLL4	-0.73	-7.24	-0.6	1.18e-10	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2985684	0.894	rs4900927	chr14:50018741	G/T	cg02151108	chr14:50098012	C14orf104	-0.74	-6.04	-0.53	3.03e-8	Carotid intima media thickness;
THYM	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg05368731	chr17:41323189	NBR1	1.25	11.17	0.75	5.29e-19	Menopause (age at onset);
THYM	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg17063962	chr7:91808500	NA	1.16	13.12	0.8	4.77e-23	Breast cancer;
THYM	cis	rs2637266	0.714	rs6480835	chr10:78446863	T/C	cg18941641	chr10:78392320	NA	0.73	5.85	0.51	7.02e-8	Pulmonary function;
THYM	cis	rs9788721	0.934	rs1051730	chr15:78894339	G/A	cg18825076	chr15:78729989	IREB2	-0.54	-4.77	-0.44	6.54e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs57590327	0.528	rs3821552	chr3:81702139	A/G	cg07356753	chr3:81810745	GBE1	-0.84	-6.0	-0.52	3.55e-8	Extraversion;
THYM	cis	rs12049351	0.665	rs66521073	chr1:229570518	C/G	cg11742688	chr1:229674241	ABCB10	-0.54	-4.53	-0.42	1.74e-5	Circulating myeloperoxidase levels (plasma);
THYM	cis	rs17102423	0.755	rs942627	chr14:65550025	A/G	cg11161011	chr14:65562177	MAX	-0.83	-6.62	-0.56	2.13e-9	Obesity-related traits;
THYM	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.94	-7.84	-0.63	6.55e-12	Lymphocyte percentage of white cells;
THYM	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg08645402	chr16:4508243	NA	0.61	5.47	0.49	3.64e-7	Schizophrenia;
THYM	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg00484396	chr16:3507460	NAT15	0.48	4.59	0.43	1.35e-5	Body mass index (adult);
THYM	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs1451375	1.000	rs921451	chr7:50623285	A/G	cg18232548	chr7:50535776	DDC	0.73	5.57	0.5	2.35e-7	Malaria;
THYM	cis	rs6768930	0.509	rs6445927	chr3:57741346	A/G	cg24033633	chr3:57945695	NA	-0.39	-5.41	-0.49	4.73e-7	Obesity-related traits;
THYM	cis	rs1349547	0.510	rs3824144	chr8:39495325	G/A	cg01911981	chr8:39380341	ADAM3A	-0.52	-4.55	-0.42	1.6e-5	HIV-1 susceptibility;
THYM	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.94	0.45	3.37e-6	Prudent dietary pattern;
THYM	cis	rs7172809	0.573	rs12324366	chr15:77547102	G/C	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs7267979	1.000	rs4815426	chr20:25405186	A/C	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg23851026	chr2:136556271	LCT	0.5	4.76	0.44	6.97e-6	Mosquito bite size;
THYM	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg04455712	chr21:45112962	RRP1B	0.49	4.48	0.42	2.07e-5	Mean corpuscular volume;
THYM	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.68	9.11	0.68	1.34e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg08773314	chr2:239334832	ASB1	0.64	9.71	0.71	7.05e-16	Multiple system atrophy;
THYM	cis	rs1061377	0.608	rs35168672	chr4:39080522	A/G	cg24403649	chr4:39172243	NA	0.56	4.47	0.42	2.2e-5	Uric acid levels;
THYM	cis	rs854765	0.583	rs7214536	chr17:17852446	G/A	cg04398451	chr17:18023971	MYO15A	-0.79	-7.44	-0.61	4.44e-11	Total body bone mineral density;
THYM	cis	rs11756438	0.572	rs2638551	chr6:118998756	T/C	cg21191810	chr6:118973309	C6orf204	0.56	5.65	0.5	1.7e-7	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg24399712	chr22:39784796	NA	-0.76	-6.8	-0.57	9.11e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg25237894	chr2:233734115	C2orf82	0.34	4.45	0.42	2.32e-5	Coronary artery disease;
THYM	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg01710189	chr8:22454888	PDLIM2	-0.51	-4.84	-0.44	4.98e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs10489202	0.632	rs12401555	chr1:168069473	G/C	cg24449463	chr1:168025552	DCAF6	-0.73	-6.43	-0.55	5.07e-9	Schizophrenia;
THYM	trans	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg10856724	chr12:34555212	NA	-0.89	-8.35	-0.65	5.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs265548	0.646	rs36689	chr19:17910639	A/G	cg21960279	chr19:17905606	B3GNT3	0.6	5.73	0.51	1.2e-7	Tumor biomarkers;
THYM	cis	rs11948739	0.576	rs11242051	chr5:130261276	G/A	cg08523029	chr5:130500466	HINT1	0.85	5.36	0.48	5.78e-7	Pediatric bone mineral content (hip);
THYM	cis	rs7572733	0.515	rs893808	chr2:198860837	C/G	cg00792783	chr2:198669748	PLCL1	0.82	5.63	0.5	1.79e-7	Dermatomyositis;
THYM	cis	rs983545	0.548	rs34149515	chr3:16953337	A/G	cg19448816	chr3:16974217	PLCL2	0.52	4.8	0.44	5.92e-6	Blood protein levels;
THYM	cis	rs2455799	0.573	rs62243672	chr3:15937200	C/T	cg16303742	chr3:15540471	COLQ	-0.55	-5.44	-0.49	4.21e-7	Mean platelet volume;
THYM	cis	rs4660531	0.890	rs61229336	chr1:41834935	C/T	cg19619003	chr1:41846758	NA	-0.24	-4.52	-0.42	1.8e-5	Bipolar disorder;
THYM	cis	rs7824557	0.614	rs2060459	chr8:11212599	C/T	cg21775007	chr8:11205619	TDH	0.72	6.22	0.54	1.35e-8	Retinal vascular caliber;
THYM	cis	rs11711311	1.000	rs9828099	chr3:113518402	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.17	-0.47	1.3e-6	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg02820040	chr2:241836501	C2orf54	-0.31	-6.26	-0.54	1.13e-8	Urinary metabolites;
THYM	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg06873352	chr17:61820015	STRADA	0.78	9.23	0.69	7.48e-15	Prudent dietary pattern;
THYM	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg04731861	chr2:219085781	ARPC2	-0.56	-5.39	-0.48	5.21e-7	Colorectal cancer;
THYM	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg27394845	chr17:28928406	LRRC37B2	0.89	4.59	0.43	1.36e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11811982	0.793	rs77071507	chr1:227407469	T/C	cg09853570	chr1:228403422	OBSCN	1.21	4.67	0.43	9.81e-6	Optic disc area;
THYM	cis	rs10489202	0.954	rs12403023	chr1:168086999	A/G	cg24449463	chr1:168025552	DCAF6	-0.63	-4.63	-0.43	1.15e-5	Schizophrenia;
THYM	cis	rs7772486	0.875	rs2748485	chr6:146332421	T/C	cg23711669	chr6:146136114	FBXO30	0.94	9.59	0.7	1.23e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12410462	0.581	rs113827839	chr1:227547180	C/T	cg23173402	chr1:227635558	NA	0.67	5.39	0.48	5.02e-7	Major depressive disorder;
THYM	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg27535305	chr1:53392650	SCP2	-0.54	-6.32	-0.54	8.36e-9	Monocyte count;
THYM	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg03676636	chr4:99064102	C4orf37	0.5	7.65	0.62	1.6e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg18876405	chr7:65276391	NA	0.63	5.56	0.5	2.48e-7	Aortic root size;
THYM	cis	rs2562456	0.793	rs2562420	chr19:21631305	T/A	cg21751540	chr19:21541537	ZNF738	0.8	5.29	0.48	7.69e-7	Pain;
THYM	cis	rs9790314	1.000	rs336593	chr3:161076431	T/C	cg04691961	chr3:161091175	C3orf57	-0.6	-5.27	-0.48	8.6e-7	Morning vs. evening chronotype;
THYM	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg26384229	chr12:38710491	ALG10B	0.94	6.53	0.56	3.16e-9	Bladder cancer;
THYM	cis	rs11048434	0.761	rs2110192	chr12:9136351	A/T	cg14913610	chr12:9142341	KLRG1	-0.29	-4.45	-0.42	2.33e-5	Sjögren's syndrome;
THYM	cis	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg08133631	chr1:26527909	CATSPER4	-0.61	-5.08	-0.46	1.92e-6	Obesity-related traits;
THYM	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg18230493	chr5:56204884	C5orf35	0.65	4.92	0.45	3.59e-6	Initial pursuit acceleration;
THYM	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.69	-5.16	-0.47	1.36e-6	Tonsillectomy;
THYM	cis	rs7943358	0.711	rs2351061	chr11:15700618	T/A	cg11966998	chr11:15692519	NA	-0.49	-5.13	-0.47	1.54e-6	Gut microbiome composition (summer);
THYM	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg18132916	chr6:79620363	NA	-0.58	-5.27	-0.48	8.5e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg09034736	chr1:150693464	HORMAD1	0.51	4.49	0.42	1.98e-5	Tonsillectomy;
THYM	cis	rs4237845	0.513	rs7134797	chr12:58263852	C/T	cg00677455	chr12:58241039	CTDSP2	0.68	5.12	0.46	1.61e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4690686	0.538	rs10520346	chr4:177259088	C/G	cg17059388	chr4:177262070	NA	0.45	6.01	0.52	3.49e-8	Essential tremor;
THYM	cis	rs8014204	0.806	rs11159105	chr14:75298052	C/T	cg06637938	chr14:75390232	RPS6KL1	0.55	5.34	0.48	6.42e-7	Caffeine consumption;
THYM	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg02788857	chr8:22132959	PIWIL2	0.58	5.53	0.49	2.76e-7	Hypertriglyceridemia;
THYM	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11890956	chr21:40555474	PSMG1	-0.66	-6.44	-0.55	4.92e-9	Menarche (age at onset);
THYM	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.38	-0.48	5.36e-7	Menopause (age at onset);
THYM	cis	rs11122272	0.735	rs2474631	chr1:231541341	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.72	-5.96	-0.52	4.26e-8	Hemoglobin concentration;
THYM	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2487048	0.725	rs2422493	chr9:107690995	G/A	cg14019050	chr9:107690770	ABCA1	-0.71	-10.79	-0.74	3.4e-18	Intraocular pressure;
THYM	cis	rs854765	0.624	rs11657130	chr17:17733826	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-5.45	-0.49	3.94e-7	Total body bone mineral density;
THYM	cis	rs7940866	0.874	rs10894306	chr11:130873882	A/C	cg05962950	chr11:130786565	SNX19	0.63	4.79	0.44	6.03e-6	Schizophrenia;
THYM	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	5.44	0.49	4.09e-7	Obesity-related traits;
THYM	cis	rs6450176	1.000	rs3776702	chr5:53305419	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.13	-0.53	2.01e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg10253484	chr15:75165896	SCAMP2	-0.63	-4.57	-0.42	1.45e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg05376756	chr1:101493828	NA	0.88	6.99	0.58	3.78e-10	Energy expenditure (24h);
THYM	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg03188948	chr7:1209495	NA	0.78	4.45	0.42	2.3e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg14186256	chr22:23484241	RTDR1	0.96	9.57	0.7	1.38e-15	Bone mineral density;
THYM	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7107174	0.581	rs11237485	chr11:78126011	G/A	cg19901956	chr11:77921274	USP35	-0.71	-5.4	-0.48	4.99e-7	Testicular germ cell tumor;
THYM	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg04362960	chr10:104952993	NT5C2	0.57	4.67	0.43	9.99e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg04663057	chr3:46933782	PTH1R	0.52	4.89	0.45	4.12e-6	Birth weight;
THYM	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg00383909	chr3:49044727	WDR6	1.12	6.66	0.56	1.75e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.73	7.09	0.59	2.35e-10	Lymphocyte counts;
THYM	cis	rs7851660	0.809	rs10984230	chr9:100660284	C/T	cg13688889	chr9:100608707	NA	-0.71	-4.84	-0.44	4.97e-6	Strep throat;
THYM	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2273669	0.915	rs6941125	chr6:109287209	T/A	cg17117243	chr6:109341365	SESN1	-0.75	-4.54	-0.42	1.63e-5	Prostate cancer;
THYM	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg02153584	chr22:29168773	CCDC117	0.6	4.68	0.43	9.56e-6	Lymphocyte counts;
THYM	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7737355	0.947	rs6596009	chr5:130608093	C/A	cg26967385	chr5:130501764	HINT1	0.53	4.5	0.42	1.96e-5	Life satisfaction;
THYM	cis	rs10158481	0.759	rs6600261	chr1:25480587	T/C	cg09264742	chr1:25757510	TMEM57	-0.69	-5.06	-0.46	2.07e-6	Urate levels in obese individuals;
THYM	cis	rs4732038	0.510	rs67549894	chr7:134271985	C/G	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	trans	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg07393940	chr7:158741817	NA	1.1	8.37	0.65	4.87e-13	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-7.02	-0.58	3.26e-10	Monocyte percentage of white cells;
THYM	cis	rs4242434	0.672	rs900266	chr8:22485295	A/T	cg11461670	chr8:22454935	PDLIM2	-0.33	-6.26	-0.54	1.09e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg04772025	chr11:68637568	NA	0.66	6.9	0.58	5.88e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4662750	0.859	rs2245297	chr2:128382859	C/T	cg01966334	chr2:128378434	MYO7B	0.68	6.25	0.54	1.13e-8	Renal cell carcinoma;
THYM	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg15133208	chr4:90757351	SNCA	-0.57	-4.7	-0.43	8.94e-6	Neuroticism;
THYM	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg22841779	chr14:105766346	BRF1	-0.49	-6.09	-0.53	2.42e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7914606	0.570	rs59745636	chr10:85214249	C/T	cg01558777	chr10:85933798	C10orf99	-1.09	-4.69	-0.43	9.07e-6	Trans fatty acid levels;
THYM	cis	rs425277	0.606	rs262663	chr1:2084598	T/C	cg23682913	chr1:2080710	PRKCZ	0.63	5.67	0.5	1.51e-7	Height;
THYM	cis	rs6570726	0.791	rs9373466	chr6:145912016	T/C	cg05347473	chr6:146136440	FBXO30	0.58	4.51	0.42	1.85e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg10164272	chr16:89456328	ANKRD11	-0.57	-4.49	-0.42	2.04e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg12826209	chr6:26865740	GUSBL1	0.87	4.6	0.43	1.28e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs77372450	0.551	rs6872995	chr5:157045629	G/C	cg00312553	chr5:157098553	C5orf52	-0.65	-4.63	-0.43	1.16e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg12463550	chr7:65579703	CRCP	-0.57	-4.76	-0.44	7.01e-6	Aortic root size;
THYM	cis	rs10203711	1.000	rs6716457	chr2:239577621	C/T	cg14580085	chr2:239553406	NA	0.68	6.18	0.54	1.58e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9790314	0.846	rs4470535	chr3:160974468	G/A	cg03342759	chr3:160939853	NMD3	-0.93	-8.74	-0.67	8.11e-14	Morning vs. evening chronotype;
THYM	cis	rs612683	0.735	rs3754131	chr1:100931073	A/C	cg09408571	chr1:101003634	GPR88	0.4	4.49	0.42	2.02e-5	Breast cancer;
THYM	cis	rs10769945	0.606	rs217236	chr11:1981259	T/C	cg22172494	chr11:2017362	H19	0.54	4.54	0.42	1.64e-5	DNA methylation (variation);
THYM	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg03060546	chr3:49711283	APEH	0.78	6.42	0.55	5.42e-9	Resting heart rate;
THYM	cis	rs8038465	0.615	rs62004618	chr15:73962164	A/G	cg15420318	chr15:73925796	NPTN	0.6	5.21	0.47	1.1e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6570726	0.902	rs373321	chr6:145854150	T/A	cg23711669	chr6:146136114	FBXO30	0.91	9.55	0.7	1.49e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4950928	0.823	rs2494277	chr1:203168092	A/G	cg14085262	chr1:203155938	CHI3L1	-0.69	-4.88	-0.45	4.18e-6	YKL-40 levels;
THYM	cis	rs9900497	0.752	rs758427	chr17:19620477	A/G	cg22552966	chr17:19620595	SLC47A2	0.65	6.1	0.53	2.24e-8	Response to paliperidone in schizophrenia (CGI-S score);
THYM	cis	rs2235649	0.746	rs35104579	chr16:1848657	A/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs8112211	0.911	rs60071299	chr19:38850246	G/A	cg09474229	chr19:39360330	RINL	-0.49	-4.46	-0.42	2.23e-5	Blood protein levels;
THYM	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.77	-0.51	1.01e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs28595532	0.920	rs115994240	chr4:119744622	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg07424592	chr7:64974309	NA	-1.02	-5.16	-0.47	1.33e-6	Diabetic kidney disease;
THYM	cis	rs72627123	0.867	rs73301485	chr14:74468643	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs8006682	0.541	rs2273486	chr14:69093707	G/C	cg21123519	chr14:69095679	NA	-0.63	-4.73	-0.44	7.73e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.58	-5.83	-0.51	7.47e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	trans	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg20587970	chr11:113659929	NA	-1.08	-7.11	-0.59	2.17e-10	Hip circumference adjusted for BMI;
THYM	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-15.24	-0.84	2.93e-27	Height;
THYM	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg22681709	chr2:178499509	PDE11A	-0.59	-5.62	-0.5	1.91e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg24578937	chr1:2090814	PRKCZ	-0.57	-5.46	-0.49	3.79e-7	Height;
THYM	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg04865290	chr3:52927548	TMEM110	-0.96	-4.97	-0.45	2.97e-6	Immune reponse to smallpox (secreted IL-2);
THYM	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.78	-6.87	-0.58	6.69e-10	Intelligence (multi-trait analysis);
THYM	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg24846680	chr1:228362309	C1orf69	0.51	4.53	0.42	1.74e-5	Diastolic blood pressure;
THYM	cis	rs4072705	1.000	rs6478671	chr9:127373995	T/A	cg13476313	chr9:127244764	NR5A1	0.32	4.94	0.45	3.32e-6	Menarche (age at onset);
THYM	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg00012203	chr2:219082015	ARPC2	-0.65	-5.3	-0.48	7.35e-7	Colorectal cancer;
THYM	cis	rs9326248	0.581	rs10790167	chr11:116800943	T/C	cg20608306	chr11:116969690	SIK3	0.66	8.25	0.65	9.08e-13	Blood protein levels;
THYM	cis	rs13256369	0.802	rs11249887	chr8:8562184	T/C	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs4595586	0.525	rs4511319	chr12:39340457	T/C	cg26384229	chr12:38710491	ALG10B	0.68	5.24	0.47	9.49e-7	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg27034606	chr17:28928453	LRRC37B2	0.76	5.06	0.46	2.04e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg00495681	chr13:53174319	NA	0.73	6.66	0.56	1.79e-9	Lewy body disease;
THYM	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg16624210	chr5:671434	TPPP	0.76	5.54	0.49	2.71e-7	Obesity-related traits;
THYM	cis	rs1568889	0.838	rs10835273	chr11:28156598	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs6754311	0.593	rs6755383	chr2:136416941	C/T	cg20242066	chr2:136595261	LCT	0.55	6.04	0.53	3.05e-8	Mosquito bite size;
THYM	cis	rs9814567	1.000	rs1814336	chr3:134200823	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-8.49	-0.66	2.78e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6032067	0.516	rs6017530	chr20:43899731	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.61	-6.91	-0.58	5.45e-10	Blood protein levels;
THYM	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.87	-0.82	1.48e-24	Height;
THYM	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg15432903	chr11:17409602	KCNJ11	0.63	7.52	0.61	3.04e-11	Type 2 diabetes;
THYM	cis	rs9796	0.689	rs6492983	chr15:41436049	T/G	cg21153102	chr15:41252147	NA	0.6	4.93	0.45	3.43e-6	Menopause (age at onset);
THYM	cis	rs6964587	0.692	rs7807490	chr7:91773359	A/G	cg22709100	chr7:91322751	NA	0.67	5.07	0.46	1.97e-6	Breast cancer;
THYM	cis	rs6032067	0.641	rs761500	chr20:43772272	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	0.55	5.38	0.48	5.32e-7	Blood protein levels;
THYM	cis	rs79387448	0.701	rs76943877	chr2:102970677	T/C	cg09003973	chr2:102972529	NA	1.38	7.38	0.6	5.96e-11	Gut microbiota (bacterial taxa);
THYM	cis	rs1971762	1.000	rs10783594	chr12:54067135	A/C	cg16917193	chr12:54089295	NA	0.58	4.47	0.42	2.12e-5	Height;
THYM	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg11764359	chr7:65958608	NA	0.69	4.78	0.44	6.27e-6	Aortic root size;
THYM	cis	rs1122401	0.576	rs766529	chr5:53873455	C/G	cg04014864	chr5:54603544	SKIV2L2;DHX29	0.63	4.49	0.42	2.02e-5	Smoking initiation;
THYM	cis	rs2133450	0.526	rs62234954	chr3:7342912	A/G	cg19930620	chr3:7340148	GRM7	-0.5	-5.46	-0.49	3.72e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs12188164	1.000	rs72717414	chr5:429818	C/G	cg14137381	chr5:502291	SLC9A3	-0.62	-4.57	-0.42	1.45e-5	Cystic fibrosis severity;
THYM	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.62	5.61	0.5	2.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3087591	0.919	rs2285892	chr17:29553485	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.59	-5.07	-0.46	1.95e-6	Hip circumference;
THYM	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg27170947	chr2:26402098	FAM59B	0.79	6.27	0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs859767	0.709	rs7575742	chr2:135429002	A/G	cg12500956	chr2:135428796	TMEM163	-0.51	-5.31	-0.48	7.1e-7	Neuroticism;
THYM	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg05738196	chr6:26577821	NA	0.83	8.34	0.65	5.8e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.596	rs6945951	chr7:124667200	T/C	cg05285228	chr7:124571219	POT1	-0.6	-4.52	-0.42	1.81e-5	Cutaneous malignant melanoma;
THYM	cis	rs7011507	0.700	rs72639004	chr8:49319079	T/C	cg08774009	chr8:49309094	NA	-0.65	-5.1	-0.46	1.75e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs4938534	0.559	rs1944919	chr11:111259876	A/C	cg20140034	chr11:111250355	POU2AF1	0.55	5.01	0.46	2.53e-6	Primary biliary cholangitis;
THYM	cis	rs28595532	0.920	rs114940990	chr4:119758568	A/G	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs901683	1.000	rs77649955	chr10:46050689	G/A	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg22431228	chr1:16359049	CLCNKA	-0.43	-4.66	-0.43	1.03e-5	Systolic blood pressure;
THYM	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg24874828	chr4:187887005	NA	-0.73	-7.36	-0.6	6.52e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg04756594	chr16:24857601	SLC5A11	0.72	4.85	0.45	4.73e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs2046867	0.862	rs6766747	chr3:72856551	T/C	cg25664220	chr3:72788482	NA	-0.93	-7.47	-0.61	3.83e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg25287198	chr4:183728479	NA	0.75	4.56	0.42	1.5e-5	Pediatric autoimmune diseases;
THYM	cis	rs7829975	0.511	rs2980512	chr8:8140901	T/C	cg15556689	chr8:8085844	FLJ10661	0.71	6.18	0.54	1.59e-8	Mood instability;
THYM	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg11871910	chr12:69753446	YEATS4	0.85	7.03	0.59	3.09e-10	Blood protein levels;
THYM	cis	rs9462846	0.853	rs7757363	chr6:42876386	C/T	cg09436375	chr6:42928200	GNMT	-0.39	-4.69	-0.43	9.03e-6	Blood protein levels;
THYM	cis	rs863345	0.604	rs12120526	chr1:158498404	T/C	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg12011299	chr4:100065546	ADH4	0.69	6.2	0.54	1.46e-8	Alcohol dependence;
THYM	cis	rs7122937	0.906	rs7939542	chr11:2485486	G/A	cg27115973	chr11:2481206	KCNQ1	0.62	6.22	0.54	1.3e-8	QT interval;
THYM	cis	rs6032067	0.571	rs6017536	chr20:43907369	G/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.66	-7.03	-0.59	3.1e-10	Blood protein levels;
THYM	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs1371867	0.817	rs1788179	chr8:101333345	A/G	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs4919694	1.000	rs11191525	chr10:104793435	G/C	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs10203711	1.000	rs10207724	chr2:239566705	G/C	cg14580085	chr2:239553406	NA	0.68	6.18	0.54	1.6e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg10334053	chr1:2078117	PRKCZ	0.48	4.73	0.44	7.65e-6	Height;
THYM	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2354432	0.607	rs72692962	chr1:146802674	C/A	cg25205988	chr1:146714368	CHD1L	-1.03	-5.4	-0.48	4.84e-7	Mitochondrial DNA levels;
THYM	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs1865760	0.688	rs9379814	chr6:25979869	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.75	5.79	0.51	8.97e-8	Height;
THYM	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg06108461	chr20:60628389	TAF4	-0.79	-6.2	-0.54	1.46e-8	Body mass index;
THYM	cis	rs8020441	0.541	rs67447434	chr14:51156101	G/A	cg04730355	chr14:51134070	SAV1	1.03	6.05	0.53	2.87e-8	Cognitive performance;
THYM	cis	rs7166081	0.704	rs2414952	chr15:67724392	A/T	cg24579218	chr15:68104479	NA	-0.72	-6.5	-0.55	3.72e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs10411161	0.702	rs10423838	chr19:52387283	C/T	cg25361850	chr19:52391789	ZNF577	0.75	5.28	0.48	8.02e-7	Breast cancer;
THYM	cis	rs901683	1.000	rs71496624	chr10:46085949	C/T	cg18240400	chr10:46168597	ANUBL1	0.73	4.73	0.44	7.89e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs9733	0.519	rs7521898	chr1:150707596	G/A	cg15448220	chr1:150897856	SETDB1	0.86	7.21	0.59	1.33e-10	Tonsillectomy;
THYM	cis	rs4664308	1.000	rs17831191	chr2:160911332	T/C	cg03641300	chr2:160917029	PLA2R1	-0.76	-6.83	-0.57	7.92e-10	Idiopathic membranous nephropathy;
THYM	cis	rs6723226	0.732	rs390480	chr2:32510072	A/C	cg02381751	chr2:32503542	YIPF4	-0.7	-5.87	-0.52	6.44e-8	Intelligence (multi-trait analysis);
THYM	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg05717871	chr11:638507	DRD4	-0.64	-5.11	-0.46	1.69e-6	Systemic lupus erythematosus;
THYM	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg17294928	chr15:75287854	SCAMP5	-0.99	-9.14	-0.68	1.15e-14	Blood trace element (Zn levels);
THYM	cis	rs7394190	0.748	rs11000771	chr10:75524458	T/G	cg07699608	chr10:75541558	CHCHD1	0.89	5.09	0.46	1.79e-6	Incident atrial fibrillation;
THYM	trans	rs34156428	0.858	rs67891751	chr11:16507622	C/T	cg02688867	chr12:133019854	NA	0.54	6.89	0.58	6.12e-10	Coronary artery disease;
THYM	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg22166914	chr1:53195759	ZYG11B	0.84	8.13	0.64	1.58e-12	Monocyte count;
THYM	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.76	-5.96	-0.52	4.18e-8	Age at first birth;
THYM	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.69	5.65	0.5	1.67e-7	Lung cancer in ever smokers;
THYM	cis	rs7546094	0.905	rs12046208	chr1:113171589	C/T	cg25616829	chr1:112535356	NA	-0.55	-4.51	-0.42	1.88e-5	Platelet distribution width;
THYM	cis	rs9486719	0.948	rs11152953	chr6:96894305	C/T	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs1604897	0.573	rs74364642	chr8:122177482	T/C	cg19275050	chr8:122653619	HAS2;HAS2AS	-1.01	-4.64	-0.43	1.11e-5	IgG glycosylation;
THYM	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.63	5.08	0.46	1.9e-6	Blood protein levels;
THYM	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg16586182	chr3:47516702	SCAP	-0.6	-5.11	-0.46	1.63e-6	Colorectal cancer;
THYM	cis	rs7772486	0.594	rs6901864	chr6:146023050	C/A	cg13319975	chr6:146136371	FBXO30	0.65	5.2	0.47	1.15e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	4.65	0.43	1.09e-5	Schizophrenia;
THYM	cis	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg18512352	chr11:47633146	NA	-0.38	-4.49	-0.42	2.02e-5	HDL cholesterol;
THYM	cis	rs7944735	0.517	rs74763661	chr11:48233772	T/C	cg24672777	chr11:48374446	OR4C45	-1.14	-6.78	-0.57	1e-9	Intraocular pressure;
THYM	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg24163568	chr5:669837	TPPP	0.58	5.39	0.48	5.06e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg06636001	chr8:8085503	FLJ10661	0.77	7.11	0.59	2.17e-10	Triglycerides;
THYM	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg16797656	chr11:68205561	LRP5	-0.45	-4.75	-0.44	7.08e-6	Total body bone mineral density;
THYM	cis	rs10751667	1.000	rs11246359	chr11:967943	T/C	cg01483505	chr11:975446	AP2A2	0.69	5.59	0.5	2.14e-7	Alzheimer's disease (late onset);
THYM	cis	rs6430585	0.646	rs1057031	chr2:136633962	G/A	cg23851026	chr2:136556271	LCT	0.76	7.42	0.61	4.91e-11	Corneal structure;
THYM	cis	rs28595532	0.920	rs56389935	chr4:119683571	G/A	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs75920871	0.588	rs1940626	chr11:116828121	T/C	cg20608306	chr11:116969690	SIK3	-0.47	-4.87	-0.45	4.53e-6	Subjective well-being;
THYM	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	4.99	0.46	2.73e-6	Menarche (age at onset);
THYM	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	7.74	0.62	1.08e-11	Smoking behavior;
THYM	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg17063962	chr7:91808500	NA	-1.09	-11.65	-0.77	5.37e-20	Breast cancer;
THYM	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg06238570	chr21:40685208	BRWD1	-0.96	-8.95	-0.68	2.83e-14	Cognitive function;
THYM	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg22875332	chr1:76189707	ACADM	-0.75	-6.46	-0.55	4.51e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg05283184	chr6:79620031	NA	-0.88	-8.43	-0.65	3.67e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6980334	0.817	rs1038626	chr7:137797477	A/T	cg18769353	chr7:137028617	PTN	0.59	4.5	0.42	1.9e-5	Blood metabolite ratios;
THYM	cis	rs6754311	0.517	rs1865452	chr2:136539330	C/T	cg20242066	chr2:136595261	LCT	0.55	5.64	0.5	1.73e-7	Mosquito bite size;
THYM	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.88	0.63	5.43e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	trans	rs9747201	1.000	rs4347682	chr17:80175591	A/G	cg07393940	chr7:158741817	NA	1.1	8.4	0.65	4.38e-13	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-6.65	-0.56	1.84e-9	Chronic sinus infection;
THYM	cis	rs4474465	1.000	rs7943815	chr11:78173160	A/G	cg19901956	chr11:77921274	USP35	-0.59	-4.48	-0.42	2.08e-5	Alzheimer's disease (survival time);
THYM	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg24675658	chr1:53192096	ZYG11B	-0.59	-4.8	-0.44	5.97e-6	Monocyte count;
THYM	cis	rs7542375	0.683	rs7546886	chr1:221099995	G/A	cg16008148	chr1:221062819	NA	0.46	4.82	0.44	5.46e-6	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg26384229	chr12:38710491	ALG10B	-0.74	-5.69	-0.5	1.42e-7	Bladder cancer;
THYM	cis	rs3768617	0.510	rs10911243	chr1:183075415	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs2797160	0.905	rs1418641	chr6:125999854	C/T	cg16306078	chr6:126000798	NA	-0.53	-5.51	-0.49	3.09e-7	Endometrial cancer;
THYM	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03264133	chr6:25882463	NA	-0.7	-5.51	-0.49	3.06e-7	Blood metabolite levels;
THYM	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg04025307	chr7:1156635	C7orf50	0.61	5.51	0.49	3.02e-7	Longevity;Endometriosis;
THYM	cis	rs919433	0.783	rs788011	chr2:198230771	A/G	cg00792783	chr2:198669748	PLCL1	0.82	5.84	0.51	7.37e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg08132940	chr7:1081526	C7orf50	-1.16	-6.65	-0.56	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6500395	1.000	rs1558816	chr16:48704868	T/A	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7020830	0.928	rs11544336	chr9:37089150	A/G	cg14294708	chr9:37120828	ZCCHC7	1.22	15.71	0.85	3.64e-28	Schizophrenia;
THYM	trans	rs877282	0.838	rs34912955	chr10:772222	T/C	cg22713356	chr15:30763199	NA	1.38	11.57	0.76	7.71e-20	Uric acid levels;
THYM	cis	rs4851254	0.584	rs56935201	chr2:100637788	G/A	cg22139774	chr2:100720529	AFF3	-0.4	-4.49	-0.42	2.01e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs887829	0.570	rs6736508	chr2:234595747	C/T	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.59	-0.43	1.36e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6754311	0.593	rs656326	chr2:136428460	A/C	cg07169764	chr2:136633963	MCM6	0.7	5.67	0.5	1.53e-7	Mosquito bite size;
THYM	cis	rs2180341	0.814	rs6919277	chr6:127738050	T/C	cg27446573	chr6:127587934	RNF146	0.72	6.22	0.54	1.3e-8	Breast cancer;
THYM	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg00129232	chr17:37814104	STARD3	0.7	4.79	0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2070677	0.935	rs4351775	chr10:135402200	C/T	cg20169779	chr10:135381914	SYCE1	-0.73	-5.75	-0.51	1.07e-7	Gout;
THYM	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.89	0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg08645402	chr16:4508243	NA	-0.76	-6.6	-0.56	2.28e-9	Schizophrenia;
THYM	cis	rs13064411	0.696	rs6783965	chr3:113198722	C/T	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg08885076	chr2:99613938	TSGA10	0.7	6.51	0.56	3.59e-9	Chronic sinus infection;
THYM	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg05768032	chr16:30646687	NA	0.55	5.56	0.5	2.46e-7	Multiple myeloma;
THYM	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg10515332	chr4:99064459	C4orf37	0.57	4.56	0.42	1.54e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4481887	1.000	rs4244180	chr1:248471033	A/G	cg13385794	chr1:248469461	NA	0.65	4.66	0.43	1.04e-5	Common traits (Other);
THYM	cis	rs2033562	1.000	rs4734637	chr8:103549379	G/A	cg20611272	chr8:103548145	NA	0.42	5.11	0.46	1.65e-6	IgA nephropathy;
THYM	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs2816062	0.813	rs2816040	chr1:18889536	C/T	cg18795169	chr1:18902165	NA	0.97	11.55	0.76	8.48e-20	Urate levels in lean individuals;
THYM	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.48	-4.67	-0.43	9.83e-6	Crohn's disease;
THYM	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg23958373	chr8:599963	NA	1.01	4.92	0.45	3.7e-6	IgG glycosylation;
THYM	trans	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9660180	0.875	rs4648727	chr1:1776269	C/A	cg03396347	chr1:1875803	NA	0.65	6.54	0.56	3.15e-9	Body mass index;
THYM	cis	rs2067615	0.579	rs3782709	chr12:107205753	A/G	cg15890332	chr12:107067104	RFX4	0.47	5.54	0.49	2.7e-7	Heart rate;
THYM	cis	rs34172651	0.837	rs12596793	chr16:24823667	C/G	cg06028605	chr16:24865363	SLC5A11	0.53	5.08	0.46	1.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs829883	0.659	rs10860342	chr12:98941223	C/T	cg25150519	chr12:98850993	NA	0.73	4.9	0.45	3.9e-6	Colorectal adenoma (advanced);
THYM	cis	rs2235649	0.798	rs9922462	chr16:1848011	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.57	-4.91	-0.45	3.81e-6	Blood metabolite levels;
THYM	cis	rs13082711	0.555	rs7627508	chr3:27252495	A/C	cg02860705	chr3:27208620	NA	0.94	7.6	0.61	2.08e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs67311347	0.544	rs6762121	chr3:40355313	G/A	cg13683864	chr3:40499215	RPL14	-0.71	-6.29	-0.54	9.68e-9	Renal cell carcinoma;
THYM	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg00376283	chr12:123451042	ABCB9	0.93	7.77	0.62	9.29e-12	Platelet count;
THYM	trans	rs9929218	0.817	rs3118228	chr16:68710737	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.97	-7.77	-0.62	9.31e-12	Colorectal cancer;
THYM	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg27490568	chr2:178487706	NA	0.62	5.82	0.51	7.82e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg19346786	chr7:2764209	NA	-0.56	-4.62	-0.43	1.23e-5	Height;
THYM	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs6720763	0.891	rs67386767	chr2:168024025	A/T	cg10633051	chr2:168042982	XIRP2	-0.69	-4.73	-0.44	7.73e-6	Atopic dermatitis;
THYM	cis	rs7695732	0.595	rs10030965	chr4:89901415	C/A	cg17769793	chr4:89976368	FAM13A	-0.49	-5.2	-0.47	1.17e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg24692254	chr21:30365293	RNF160	-0.98	-8.78	-0.67	6.83e-14	Dental caries;
THYM	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg14349672	chr11:133703707	NA	-0.54	-4.74	-0.44	7.5e-6	Childhood ear infection;
THYM	cis	rs854765	0.647	rs8066764	chr17:17974668	C/T	cg04398451	chr17:18023971	MYO15A	-0.92	-9.55	-0.7	1.54e-15	Total body bone mineral density;
THYM	cis	rs6430585	0.759	rs12467770	chr2:136536095	G/A	cg20242066	chr2:136595261	LCT	0.5	4.7	0.43	8.63e-6	Corneal structure;
THYM	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	5.0	0.46	2.62e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs59698941	0.943	rs67460003	chr5:132289501	C/G	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs12257961	0.576	rs11259621	chr10:15400417	C/T	cg10616319	chr10:15468812	NA	0.53	4.64	0.43	1.12e-5	Selective IgA deficiency;
THYM	cis	rs11039798	1.000	rs9667626	chr11:48485877	T/C	cg24672777	chr11:48374446	OR4C45	-1.14	-6.89	-0.58	6.15e-10	Axial length;
THYM	cis	rs2219968	1.000	rs13260890	chr8:78970064	G/A	cg00738934	chr8:78996279	NA	0.91	9.74	0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2742417	0.587	rs2742375	chr3:45784602	G/A	cg04837898	chr3:45731254	SACM1L	-0.72	-5.01	-0.46	2.54e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs6570726	0.577	rs403345	chr6:145845171	T/C	cg13319975	chr6:146136371	FBXO30	-0.66	-5.23	-0.47	9.87e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7712401	0.599	rs7731806	chr5:122353194	A/G	cg19808643	chr5:122110361	SNX2	-0.64	-5.56	-0.5	2.52e-7	Mean platelet volume;
THYM	cis	rs4792901	0.722	rs34558675	chr17:41550591	C/A	cg21940313	chr17:41620911	ETV4	-0.51	-5.2	-0.47	1.12e-6	Dupuytren's disease;
THYM	cis	rs4589258	0.931	rs4550185	chr11:90508050	A/C	cg26138821	chr11:89956704	CHORDC1	-0.58	-4.74	-0.44	7.58e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg10515332	chr4:99064459	C4orf37	0.67	5.33	0.48	6.48e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2658782	1.000	rs2658781	chr11:93166368	C/T	cg18152523	chr11:93063302	CCDC67	0.51	4.5	0.42	1.89e-5	Pulmonary function decline;
THYM	cis	rs7264396	0.511	rs2425102	chr20:34312303	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-4.69	-0.43	9.21e-6	Total cholesterol levels;
THYM	cis	rs7580658	0.637	rs4662710	chr2:127976817	C/G	cg09152259	chr2:128156114	NA	-0.36	-4.7	-0.43	8.71e-6	Protein C levels;
THYM	trans	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs34311866	0.808	rs748483	chr4:952409	A/G	cg11017086	chr4:979022	SLC26A1	0.71	4.45	0.42	2.34e-5	Parkinson's disease;
THYM	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg20503657	chr10:835505	NA	1.01	5.76	0.51	1.04e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs7616559	0.739	rs6441109	chr3:156782536	T/C	cg15697575	chr3:156784781	NA	0.46	5.68	0.5	1.45e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs2075230	0.705	rs1641538	chr17:7545588	C/T	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.74	-0.44	7.55e-6	Hormone measurements;
THYM	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg12262378	chr17:6899522	ALOX12	0.69	9.32	0.69	4.67e-15	Tonsillectomy;
THYM	cis	rs1062746	0.771	rs12447487	chr16:87377036	C/T	cg02258303	chr16:87377426	FBXO31	0.61	5.57	0.5	2.36e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg12863693	chr15:85201151	NMB	0.63	5.46	0.49	3.78e-7	Schizophrenia;
THYM	cis	rs2276314	0.857	rs28651028	chr18:33638910	G/A	cg19628046	chr18:33552617	C18orf21	0.74	5.43	0.49	4.29e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs791888	0.965	rs791877	chr10:89406863	A/G	cg13926569	chr10:89418898	PAPSS2	0.66	7.15	0.59	1.77e-10	Magnesium levels;
THYM	cis	rs11096990	0.892	rs2381349	chr4:39212010	C/T	cg24403649	chr4:39172243	NA	-0.63	-5.5	-0.49	3.15e-7	Cognitive function;
THYM	cis	rs4731207	0.698	rs4311608	chr7:124519707	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs425277	0.606	rs451061	chr1:2075068	C/G	cg09260853	chr1:2094483	PRKCZ	0.47	4.84	0.44	4.99e-6	Height;
THYM	cis	rs8048589	1.000	rs11642386	chr16:12184064	C/A	cg02910054	chr16:12241554	SNX29	0.69	5.74	0.51	1.13e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs883565	0.655	rs7633233	chr3:39146724	G/T	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	4.98	0.46	2.82e-6	Handedness;
THYM	cis	rs9914988	0.943	rs9891925	chr17:27104540	A/T	cg20469991	chr17:27169893	C17orf63	-0.77	-4.59	-0.43	1.33e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	trans	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.1	-13.67	-0.81	3.71e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.34	0.48	6.29e-7	Height;
THYM	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg17054759	chr22:49844102	NA	-0.53	-5.17	-0.47	1.32e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs11214589	0.747	rs11214577	chr11:113204266	A/G	cg14159747	chr11:113255604	NA	-0.3	-5.74	-0.51	1.15e-7	Neuroticism;
THYM	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	7.32	0.6	7.96e-11	Platelet count;
THYM	cis	rs4481887	0.751	rs28706835	chr1:248520460	A/G	cg00666640	chr1:248458726	OR2T12	0.52	4.52	0.42	1.77e-5	Common traits (Other);
THYM	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg08847533	chr14:75593920	NEK9	-0.61	-5.38	-0.48	5.4e-7	Neuroticism;
THYM	trans	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg10856724	chr12:34555212	NA	-0.96	-6.93	-0.58	5.04e-10	Bladder cancer;
THYM	cis	rs28647808	0.881	rs28617580	chr9:136252952	G/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.11	-4.8	-0.44	5.91e-6	Blood protein levels;
THYM	cis	rs240764	0.711	rs240112	chr6:101059253	C/A	cg21058520	chr6:100914733	NA	-0.57	-5.02	-0.46	2.46e-6	Neuroticism;
THYM	cis	rs34779708	0.966	rs4934732	chr10:35431684	T/C	cg03585969	chr10:35415529	CREM	0.66	4.76	0.44	6.85e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs2139634	0.929	rs12490169	chr3:46547400	C/T	cg02332537	chr3:46540019	RTP3	0.48	4.9	0.45	3.89e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs514406	0.893	rs6588445	chr1:53424928	T/C	cg06600287	chr1:53387719	ECHDC2	0.31	5.11	0.46	1.68e-6	Monocyte count;
THYM	cis	rs9913156	0.748	rs56364707	chr17:4562579	A/T	cg19197139	chr17:4613644	ARRB2	0.78	4.92	0.45	3.63e-6	Lymphocyte counts;
THYM	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	5.38	0.48	5.27e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs10823500	0.777	rs7919014	chr10:71944577	T/C	cg25502086	chr10:71892093	AIFM2	-0.51	-4.66	-0.43	1.05e-5	Blood protein levels;
THYM	cis	rs7113850	0.541	rs78363992	chr11:24232126	C/T	ch.11.24196551F	chr11:24239977	NA	0.94	5.04	0.46	2.21e-6	Bone fracture in osteoporosis;
THYM	cis	rs4866334	1.000	rs75023127	chr5:18487706	A/G	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs4595586	0.505	rs12827136	chr12:39412790	C/T	cg13010199	chr12:38710504	ALG10B	0.61	4.58	0.42	1.43e-5	Morning vs. evening chronotype;
THYM	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg23482746	chr15:76478102	C15orf27	-0.38	-4.46	-0.42	2.22e-5	Blood metabolite levels;
THYM	cis	rs12930096	1.000	rs67188060	chr16:11679517	A/G	cg03200631	chr16:11375333	PRM1	0.48	4.46	0.42	2.24e-5	QT interval;
THYM	cis	rs10489525	0.583	rs6660550	chr1:115650850	C/G	cg01522456	chr1:115632236	TSPAN2	0.79	5.14	0.47	1.45e-6	Autism;
THYM	cis	rs4363385	0.510	rs11803710	chr1:153053096	C/G	cg13444842	chr1:152974279	SPRR3	-0.6	-4.84	-0.44	5.06e-6	Inflammatory skin disease;
THYM	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg24692254	chr21:30365293	RNF160	-0.89	-7.8	-0.62	7.91e-12	Dental caries;
THYM	cis	rs28595532	0.764	rs55704595	chr4:119780607	G/A	cg21605333	chr4:119757512	SEC24D	1.61	6.06	0.53	2.69e-8	Cannabis dependence symptom count;
THYM	cis	rs12496230	1.000	rs12496230	chr3:66829908	A/G	cg23477460	chr3:66848765	NA	1.18	7.78	0.62	8.83e-12	Type 2 diabetes;
THYM	cis	rs17401966	1.000	rs4846208	chr1:10313839	T/C	cg20482658	chr1:10539492	PEX14	0.39	4.66	0.43	1.04e-5	Hepatocellular carcinoma;
THYM	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg25487775	chr2:162093969	NA	0.68	5.82	0.51	8e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg06634786	chr22:41940651	POLR3H	0.72	5.22	0.47	1.04e-6	Vitiligo;
THYM	cis	rs7582403	0.844	rs1234413	chr2:148844369	C/T	cg23727674	chr2:148602993	ACVR2A	-0.58	-4.79	-0.44	6.24e-6	Neuroticism;
THYM	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg12564285	chr5:131593104	PDLIM4	0.43	4.83	0.44	5.3e-6	Acylcarnitine levels;
THYM	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg25918947	chr17:41365094	TMEM106A	-0.56	-4.62	-0.43	1.22e-5	Menopause (age at onset);
THYM	cis	rs3820068	0.562	rs10927841	chr1:16045261	T/C	cg05660106	chr1:15850417	CASP9	0.72	5.47	0.49	3.66e-7	Systolic blood pressure;
THYM	cis	rs79149102	0.579	rs74025863	chr15:75284161	T/C	cg09165964	chr15:75287851	SCAMP5	-1.12	-6.24	-0.54	1.22e-8	Lung cancer;
THYM	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.84	-6.12	-0.53	2.12e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg25036284	chr2:26402008	FAM59B	-0.74	-4.87	-0.45	4.39e-6	Gut microbiome composition (summer);
THYM	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg10334053	chr1:2078117	PRKCZ	0.48	4.73	0.44	7.65e-6	Height;
THYM	cis	rs7084402	0.565	rs6481407	chr10:60335090	C/T	cg09696939	chr10:60272079	BICC1	0.5	5.71	0.51	1.27e-7	Refractive error;
THYM	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg17757837	chr7:157058334	UBE3C	0.65	5.24	0.47	9.83e-7	Body mass index;
THYM	cis	rs733592	0.524	rs10875726	chr12:48425992	A/G	cg21466736	chr12:48725269	NA	0.45	4.89	0.45	4.07e-6	Plateletcrit;
THYM	cis	rs4836694	0.517	rs1017112	chr9:132936804	A/G	cg13414629	chr9:132935646	FREQ	0.78	5.56	0.5	2.47e-7	Alzheimer's disease (cognitive decline);
THYM	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg18230493	chr5:56204884	C5orf35	-0.89	-6.53	-0.56	3.25e-9	Initial pursuit acceleration;
THYM	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg08736216	chr1:53307985	ZYG11A	-0.58	-5.29	-0.48	7.85e-7	Monocyte count;
THYM	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg00256281	chr22:41985642	PMM1	-0.59	-4.71	-0.44	8.44e-6	Vitiligo;
THYM	cis	rs295140	0.526	rs295113	chr2:201197816	C/G	cg17644776	chr2:200775616	C2orf69	0.58	4.5	0.42	1.91e-5	QT interval;
THYM	cis	rs7312774	0.618	rs11612483	chr12:107346884	A/G	cg16260113	chr12:107380972	MTERFD3	1.3	6.63	0.56	2.04e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg19346786	chr7:2764209	NA	-0.73	-6.2	-0.54	1.47e-8	Height;
THYM	cis	rs920590	0.684	rs57462676	chr8:19670848	G/C	cg03894339	chr8:19674705	INTS10	0.62	4.79	0.44	6.22e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9790314	0.905	rs4856739	chr3:160986710	A/C	cg03342759	chr3:160939853	NMD3	-0.81	-7.28	-0.6	9.51e-11	Morning vs. evening chronotype;
THYM	cis	rs1747683	0.966	rs3781085	chr10:13370958	G/T	cg00142036	chr10:13388442	SEPHS1	-0.29	-5.09	-0.46	1.83e-6	IgG glycosylation;
THYM	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg10862848	chr6:42927986	GNMT	-0.51	-6.7	-0.57	1.44e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg06784218	chr1:46089804	CCDC17	0.31	4.57	0.42	1.46e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs2219968	0.962	rs4565449	chr8:78939877	C/T	cg00738934	chr8:78996279	NA	-0.79	-8.42	-0.65	3.88e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs1045902	0.532	rs10185579	chr2:73456342	C/T	cg24220031	chr2:73402428	NA	-0.59	-4.92	-0.45	3.57e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg25811766	chr13:21894605	NA	0.72	6.17	0.53	1.67e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.47	-0.49	3.59e-7	Mean corpuscular volume;
THYM	cis	rs8048589	1.000	rs8059989	chr16:12185746	C/T	cg01990910	chr16:12207648	SNX29	-0.44	-5.02	-0.46	2.45e-6	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs2663905	0.706	rs2683260	chr15:81385552	A/C	cg26546864	chr15:81426434	C15orf26	-0.75	-4.92	-0.45	3.61e-6	QT interval (drug interaction);
THYM	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg11266682	chr4:10021025	SLC2A9	-0.66	-8.14	-0.64	1.53e-12	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg07061783	chr6:25882402	NA	-0.61	-4.61	-0.43	1.26e-5	Blood metabolite levels;
THYM	cis	rs9992101	0.547	rs2137152	chr4:77411710	T/C	cg20311846	chr4:77356250	SHROOM3	-0.45	-4.72	-0.44	8.12e-6	Creatinine levels;
THYM	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg02569458	chr12:86230093	RASSF9	-0.66	-5.63	-0.5	1.84e-7	Major depressive disorder;
THYM	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg11266682	chr4:10021025	SLC2A9	0.66	9.35	0.69	4.01e-15	Bone mineral density;
THYM	cis	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg21775007	chr8:11205619	TDH	0.65	5.29	0.48	7.91e-7	Retinal vascular caliber;
THYM	cis	rs995000	0.783	rs993013	chr1:63111069	G/T	cg06896770	chr1:63153194	DOCK7	-0.92	-7.54	-0.61	2.71e-11	Triglyceride levels;
THYM	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg07212818	chr11:638076	DRD4	-0.79	-6.69	-0.57	1.57e-9	Systemic lupus erythematosus;
THYM	cis	rs3007168	0.557	rs12586836	chr14:51735194	C/T	cg22800400	chr14:51955524	FRMD6	0.38	4.98	0.46	2.81e-6	Cancer;
THYM	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg12031863	chr16:4587854	C16orf5	-0.46	-4.96	-0.45	3.09e-6	Schizophrenia;
THYM	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg05472934	chr7:22766657	IL6	0.84	6.81	0.57	8.75e-10	Lung cancer;
THYM	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14240646	chr10:27532245	ACBD5	-0.78	-4.74	-0.44	7.52e-6	Breast cancer;
THYM	cis	rs425277	0.606	rs2503705	chr1:2076741	A/G	cg10334053	chr1:2078117	PRKCZ	0.45	4.58	0.43	1.39e-5	Height;
THYM	cis	rs10463554	0.892	rs13340345	chr5:102339222	T/A	cg23492399	chr5:102201601	PAM	-0.69	-5.24	-0.47	9.68e-7	Parkinson's disease;
THYM	cis	rs2976388	0.507	rs13279795	chr8:143838669	G/A	cg17252645	chr8:143867129	LY6D	0.55	5.55	0.49	2.58e-7	Urinary tract infection frequency;
THYM	cis	rs8050907	0.590	rs2270364	chr16:4526750	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.28	5.13	0.47	1.5e-6	Obesity-related traits;
THYM	cis	rs6032067	0.929	rs62205504	chr20:43867894	C/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.72	-6.57	-0.56	2.73e-9	Blood protein levels;
THYM	cis	rs34526934	0.608	rs13017511	chr2:177035395	A/G	cg14324370	chr2:177042789	NA	-0.7	-5.88	-0.52	5.98e-8	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs58873874	1.000	rs75720504	chr5:156935973	A/C	cg08916508	chr5:156566250	MED7	-1.34	-5.3	-0.48	7.59e-7	Bipolar disorder (body mass index interaction);
THYM	cis	rs9393777	0.513	rs6904071	chr6:27047256	G/A	cg12292205	chr6:26970375	C6orf41	-0.97	-4.68	-0.43	9.51e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12611088	0.602	rs6509092	chr19:44022305	A/T	cg18042043	chr19:44147545	NA	-0.42	-4.94	-0.45	3.3e-6	Plasma amyloid beta peptide concentrations (ABx-42);
THYM	cis	rs13177918	0.581	rs2245384	chr5:149817268	G/C	cg14059543	chr5:149831962	NA	-1.0	-9.14	-0.68	1.14e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg01616529	chr11:638424	DRD4	-0.76	-5.38	-0.48	5.42e-7	Systemic lupus erythematosus;
THYM	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg13852791	chr20:30311386	BCL2L1	0.87	6.96	0.58	4.36e-10	Mean corpuscular hemoglobin;
THYM	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg07537917	chr2:241836409	C2orf54	-0.27	-6.46	-0.55	4.47e-9	Urinary metabolites;
THYM	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg04772025	chr11:68637568	NA	0.63	6.58	0.56	2.59e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs823143	0.549	rs1094647	chr1:205655378	G/A	cg26354017	chr1:205819088	PM20D1	0.84	7.82	0.63	7.08e-12	Monocyte percentage of white cells;
THYM	cis	rs9972944	0.729	rs10512505	chr17:63776696	A/G	cg07283582	chr17:63770753	CCDC46	0.65	5.35	0.48	6.17e-7	Total body bone mineral density;
THYM	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg06028605	chr16:24865363	SLC5A11	0.55	5.15	0.47	1.41e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9959145	1.000	rs9989546	chr18:12562537	A/C	cg14160804	chr18:12703040	PSMG2;CEP76	-0.91	-4.52	-0.42	1.79e-5	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-5.34	-0.48	6.41e-7	Lymphocyte counts;
THYM	cis	rs6121246	0.633	rs6060986	chr20:30426297	G/A	cg13852791	chr20:30311386	BCL2L1	0.95	8.88	0.67	4.13e-14	Mean corpuscular hemoglobin;
THYM	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg25767906	chr1:53392781	SCP2	-0.53	-5.2	-0.47	1.13e-6	Monocyte count;
THYM	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg08999081	chr20:33150536	PIGU	0.75	6.69	0.57	1.55e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs11690935	0.885	rs7602037	chr2:172817794	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.69	-4.83	-0.44	5.29e-6	Schizophrenia;
THYM	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg06558623	chr16:89946397	TCF25	1.34	5.7	0.51	1.32e-7	Skin colour saturation;
THYM	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg16586182	chr3:47516702	SCAP	-0.61	-5.18	-0.47	1.26e-6	Colorectal cancer;
THYM	cis	rs7727544	0.548	rs35696821	chr5:131508017	C/T	cg16205897	chr5:131564050	P4HA2	-0.45	-4.54	-0.42	1.67e-5	Blood metabolite levels;
THYM	cis	rs2976388	0.609	rs2585153	chr8:143785345	G/A	cg06565975	chr8:143823917	SLURP1	0.47	5.22	0.47	1.06e-6	Urinary tract infection frequency;
THYM	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg04362960	chr10:104952993	NT5C2	0.58	4.93	0.45	3.52e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03517284	chr6:25882590	NA	0.91	7.49	0.61	3.59e-11	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg25918947	chr17:41365094	TMEM106A	-0.6	-4.67	-0.43	1e-5	Menopause (age at onset);
THYM	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.32	0.54	8.42e-9	Platelet count;
THYM	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.67	-0.81	3.63e-24	Height;
THYM	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg04362960	chr10:104952993	NT5C2	0.59	4.96	0.45	3.02e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9467711	0.651	rs13206443	chr6:26119245	C/T	cg01386294	chr6:25732093	NA	0.88	4.7	0.43	8.83e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9303280	0.836	rs12453507	chr17:38053207	C/G	cg24910161	chr17:38119198	GSDMA	0.45	4.54	0.42	1.66e-5	Self-reported allergy;
THYM	cis	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg17294928	chr15:75287854	SCAMP5	-0.95	-8.08	-0.64	2.01e-12	Blood trace element (Zn levels);
THYM	cis	rs337100	0.521	rs1644317	chr5:122532869	G/A	cg04547002	chr5:122551801	NA	0.6	4.52	0.42	1.8e-5	Pulse pressure;
THYM	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	5.25	0.47	9.38e-7	Obesity-related traits;
THYM	cis	rs3772130	0.962	rs1920320	chr3:121547527	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.73	4.62	0.43	1.22e-5	Cognitive performance;
THYM	cis	rs7044106	1.000	rs7044106	chr9:123494062	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	4.95	0.45	3.27e-6	Hip circumference adjusted for BMI;
THYM	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg22920501	chr2:26401640	FAM59B	-1.05	-8.66	-0.66	1.18e-13	Gut microbiome composition (summer);
THYM	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg17063962	chr7:91808500	NA	-1.1	-11.62	-0.77	5.94e-20	Breast cancer;
THYM	cis	rs4242434	0.927	rs11136093	chr8:22479988	C/G	cg01710189	chr8:22454888	PDLIM2	-0.57	-5.4	-0.48	4.97e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg03709012	chr19:19516395	GATAD2A	-0.74	-5.8	-0.51	8.48e-8	Tonsillectomy;
THYM	cis	rs1003719	0.715	rs8130643	chr21:38551715	T/A	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg10515332	chr4:99064459	C4orf37	0.6	4.75	0.44	7.27e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg02527881	chr3:46936655	PTH1R	0.6	5.69	0.5	1.42e-7	Colorectal cancer;
THYM	cis	rs61931739	0.517	rs11052980	chr12:34036036	T/C	cg10856724	chr12:34555212	NA	-0.75	-6.73	-0.57	1.25e-9	Morning vs. evening chronotype;
THYM	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9296092	0.538	rs3916674	chr6:33522975	C/T	cg13560919	chr6:33536144	NA	-0.94	-9.31	-0.69	4.9e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs1499972	0.941	rs56148567	chr3:117540528	A/G	cg07612923	chr3:117604196	NA	1.3	5.34	0.48	6.23e-7	Schizophrenia;
THYM	cis	rs6754311	0.593	rs313528	chr2:136445869	G/A	cg04750100	chr2:136595281	LCT	0.56	5.89	0.52	5.87e-8	Mosquito bite size;
THYM	cis	rs10911251	0.546	rs2027081	chr1:183074576	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.56	4.56	0.42	1.53e-5	Colorectal cancer;
THYM	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg25319279	chr11:5960081	NA	-0.64	-5.61	-0.5	2.02e-7	DNA methylation (variation);
THYM	cis	rs1843834	0.755	rs11898692	chr2:225575173	T/C	cg10193763	chr2:225306901	NA	-0.42	-4.54	-0.42	1.64e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs4343996	0.521	rs10278205	chr7:3424878	C/T	cg21248987	chr7:3385318	SDK1	0.39	4.99	0.46	2.68e-6	Motion sickness;
THYM	cis	rs9534288	0.700	rs9316178	chr13:46570449	A/G	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg18132916	chr6:79620363	NA	-0.59	-5.5	-0.49	3.19e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11599315	1.000	rs11599315	chr10:1343017	C/T	cg09624528	chr10:1369823	ADARB2	0.7	5.91	0.52	5.22e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.87e-6	Resting heart rate;
THYM	cis	rs1062746	0.683	rs891094	chr16:87378001	C/G	cg27365499	chr16:87376795	FBXO31	-0.59	-6.86	-0.58	6.88e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs2903698	0.651	rs6838603	chr4:76421050	C/T	cg03209871	chr4:76438412	RCHY1;THAP6	0.41	4.45	0.42	2.33e-5	Prion diseases;
THYM	cis	rs4737010	0.511	rs7006871	chr8:41670952	A/G	cg08923054	chr8:41654455	ANK1	0.77	4.74	0.44	7.63e-6	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
THYM	trans	rs1972460	0.506	rs62012050	chr15:82532274	T/G	cg04831495	chr15:85060580	GOLGA6L5	-0.81	-6.92	-0.58	5.29e-10	Intelligence (multi-trait analysis);
THYM	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg14500267	chr11:67383377	NA	0.8	6.62	0.56	2.11e-9	Mean corpuscular volume;
THYM	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg25072359	chr17:41440525	NA	0.7	4.92	0.45	3.6e-6	Menopause (age at onset);
THYM	cis	rs11031096	0.711	rs10835719	chr11:4203906	A/G	cg22027985	chr11:4115532	RRM1	0.5	4.7	0.43	8.77e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7584330	0.910	rs6713555	chr2:238398182	A/G	cg16989719	chr2:238392110	NA	0.6	4.99	0.46	2.69e-6	Prostate cancer;
THYM	cis	rs9486719	0.857	rs4486027	chr6:96911886	T/C	cg06623918	chr6:96969491	KIAA0776	-0.79	-4.66	-0.43	1.01e-5	Migraine;Coronary artery disease;
THYM	cis	rs7772486	0.875	rs863820	chr6:146347402	C/T	cg13319975	chr6:146136371	FBXO30	0.68	5.63	0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11711311	1.000	rs13070720	chr3:113473754	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.61	-5.45	-0.49	4.02e-7	IgG glycosylation;
THYM	cis	rs6032067	0.925	rs6032061	chr20:43853276	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.41	-0.55	5.57e-9	Blood protein levels;
THYM	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg13683864	chr3:40499215	RPL14	-1.06	-11.6	-0.77	6.54e-20	Renal cell carcinoma;
THYM	cis	rs10089	1.000	rs4836361	chr5:127459991	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs9938149	0.705	rs7405095	chr16:88307825	C/T	cg09385650	chr16:88018033	BANP	0.28	4.84	0.44	4.98e-6	Corneal structure;Central corneal thickness;
THYM	cis	rs1003719	0.680	rs2835620	chr21:38505581	C/T	cg01329690	chr21:38580129	DSCR9	-0.38	-5.21	-0.47	1.09e-6	Eye color traits;
THYM	cis	rs6722750	0.846	rs34923691	chr2:64395183	C/T	cg22352474	chr2:64371530	PELI1	0.72	6.39	0.55	6.17e-9	Neuroticism;
THYM	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	5.87	0.52	6.23e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg13880726	chr7:1868755	MAD1L1	0.77	5.23	0.47	9.88e-7	Bipolar disorder;
THYM	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg18105134	chr13:113819100	PROZ	1.07	9.73	0.71	6.27e-16	Platelet distribution width;
THYM	cis	rs9543976	0.925	rs2876706	chr13:76186305	T/G	cg01531495	chr13:76123901	UCHL3	0.75	5.05	0.46	2.1e-6	Diabetic retinopathy;
THYM	cis	rs12802200	0.561	rs7940600	chr11:572105	A/G	cg16486109	chr11:613632	IRF7	0.49	5.42	0.49	4.56e-7	Systemic lupus erythematosus;
THYM	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg16486109	chr11:613632	IRF7	0.5	5.59	0.5	2.16e-7	Systemic lupus erythematosus;
THYM	cis	rs6032067	0.673	rs991048	chr20:43898227	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	0.42	4.48	0.42	2.05e-5	Blood protein levels;
THYM	cis	rs17407555	0.821	rs56267284	chr4:10134370	T/C	cg00071950	chr4:10020882	SLC2A9	-0.77	-5.67	-0.5	1.55e-7	Schizophrenia (age at onset);
THYM	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg04248312	chr19:17393744	ANKLE1	-0.97	-12.99	-0.8	8.88e-23	Systemic lupus erythematosus;
THYM	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg01528321	chr10:82214614	TSPAN14	0.63	5.29	0.48	7.7300000000000005e-07	Post bronchodilator FEV1;
THYM	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.16	9.31	0.69	4.92e-15	Cognitive test performance;
THYM	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg04362960	chr10:104952993	NT5C2	0.57	4.67	0.43	9.99e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg10523679	chr1:76189770	ACADM	0.9	9.47	0.7	2.2e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs3017493	0.786	rs78344725	chr11:70687830	G/A	cg21202716	chr11:70508022	SHANK2	0.99	4.73	0.44	7.66e-6	Renal transplant outcome;
THYM	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.27	0.54	1.07e-8	Platelet count;
THYM	cis	rs9826463	0.582	rs73238136	chr3:142038959	T/C	cg20824294	chr3:142316082	PLS1	0.81	5.53	0.49	2.76e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs763014	0.833	rs916415	chr16:632115	G/A	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs9902453	0.904	rs8078638	chr17:28290358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.57	0.56	2.63e-9	Coffee consumption (cups per day);
THYM	cis	rs4149423	1.000	rs4149423	chr2:108916044	A/G	cg25838818	chr2:108905173	SULT1C2	-0.8	-6.06	-0.53	2.75e-8	Lobe size;
THYM	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg04043695	chr12:129287642	SLC15A4	0.59	4.6	0.43	1.33e-5	Systemic lupus erythematosus;
THYM	cis	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg26384229	chr12:38710491	ALG10B	0.97	7.24	0.6	1.14e-10	Morning vs. evening chronotype;
THYM	cis	rs2806561	0.704	rs2868573	chr1:23508253	C/G	cg12483005	chr1:23474871	LUZP1	0.59	6.31	0.54	9.03e-9	Height;
THYM	cis	rs3204270	0.639	rs62077183	chr17:79658940	C/A	cg18367735	chr17:79674897	NA	0.75	4.51	0.42	1.85e-5	Dental caries;
THYM	cis	rs4595586	0.545	rs12833238	chr12:39373898	T/C	cg26384229	chr12:38710491	ALG10B	0.69	5.35	0.48	6.11e-7	Morning vs. evening chronotype;
THYM	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs728616	0.867	rs56000427	chr10:81986946	A/G	cg18148530	chr10:81370782	SFTPA1	0.75	4.87	0.45	4.4e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs8180040	0.726	rs11130112	chr3:47024495	G/T	cg27129171	chr3:47204927	SETD2	0.68	6.58	0.56	2.5e-9	Colorectal cancer;
THYM	cis	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg09359103	chr1:154839909	KCNN3	0.54	5.71	0.51	1.27e-7	Prostate cancer;
THYM	cis	rs3892630	0.817	rs35408716	chr19:33187961	A/C	cg22980127	chr19:33182716	NUDT19	1.14	9.17	0.69	9.93e-15	Red blood cell traits;
THYM	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg19318889	chr4:1322082	MAEA	0.65	5.64	0.5	1.76e-7	Longevity;
THYM	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg13852791	chr20:30311386	BCL2L1	0.74	5.35	0.48	6.15e-7	Mean corpuscular hemoglobin;
THYM	cis	rs1775715	0.870	rs3847414	chr10:32219176	A/G	cg04359828	chr10:32216031	ARHGAP12	0.4	5.16	0.47	1.37e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs4950928	0.823	rs7541061	chr1:203163367	G/T	cg17014757	chr1:203156097	CHI3L1	1.04	6.37	0.55	6.6e-9	YKL-40 levels;
THYM	cis	rs921943	0.554	rs163132	chr5:78285921	A/G	cg02582925	chr5:78281734	ARSB	0.52	4.67	0.43	1.01e-5	Blood and toenail selenium levels;Blood trace element (Se levels);
THYM	cis	rs9393777	0.513	rs6924727	chr6:26491234	A/G	cg12826209	chr6:26865740	GUSBL1	1.02	6.88	0.58	6.48e-10	Intelligence (multi-trait analysis);
THYM	cis	rs4273100	0.688	rs4143829	chr17:19241505	G/A	cg25447019	chr17:19030144	GRAPL	0.79	6.24	0.54	1.2e-8	Schizophrenia;
THYM	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg12935359	chr14:103987150	CKB	-0.64	-6.43	-0.55	5.14e-9	Bone mineral density;
THYM	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs17253792	0.822	rs17253716	chr14:56153661	G/C	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs892961	0.836	rs8071497	chr17:75414358	T/C	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs2625529	0.938	rs9120	chr15:72115763	G/A	cg16672083	chr15:72433130	SENP8	-0.56	-4.74	-0.44	7.62e-6	Red blood cell count;
THYM	cis	rs3118914	0.694	rs3118906	chr13:51106788	G/A	cg17056618	chr13:50216117	NA	-0.7	-4.63	-0.43	1.15e-5	Height;
THYM	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg21226059	chr5:178986404	RUFY1	-0.62	-7.25	-0.6	1.1e-10	Lung cancer;
THYM	cis	rs2227564	0.649	rs2242258	chr10:75607168	T/C	cg00564723	chr10:75632066	CAMK2G	0.49	4.85	0.45	4.9100000000000004e-06	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs28647808	0.881	rs28461467	chr9:136261288	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs9309473	0.500	rs11688718	chr2:73760939	C/T	cg19565262	chr2:73869966	NAT8	-0.59	-4.88	-0.45	4.33e-6	Metabolite levels;
THYM	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	15.57	0.85	6.94e-28	Chronic sinus infection;
THYM	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	7.84	0.63	6.39e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg12963246	chr6:28129442	ZNF389	0.52	4.59	0.43	1.33e-5	Cardiac Troponin-T levels;
THYM	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg12165864	chr7:66369176	NA	-0.81	-6.08	-0.53	2.47e-8	Corneal structure;
THYM	cis	rs17608059	0.710	rs8080167	chr17:13949828	G/A	cg11395062	chr17:14139857	CDRT15	0.64	5.85	0.51	7.1e-8	Temperament;
THYM	cis	rs11731175	1.000	rs62342327	chr4:189849153	T/A	cg00431894	chr4:189871012	NA	-0.88	-6.75	-0.57	1.15e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4792901	0.759	rs12601484	chr17:41578874	A/G	cg21940313	chr17:41620911	ETV4	-0.51	-5.2	-0.47	1.12e-6	Dupuytren's disease;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg00616447	chr15:41694635	NDUFAF1	1.0	6.86	0.58	7.08e-10	Depressive symptoms;
THYM	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg17178900	chr1:205818956	PM20D1	0.96	9.99	0.72	1.71e-16	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg03676636	chr4:99064102	C4orf37	-0.42	-6.18	-0.54	1.6e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg14784868	chr12:69753453	YEATS4	0.79	6.45	0.55	4.63e-9	Blood protein levels;
THYM	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg20290983	chr6:43655470	MRPS18A	1.44	16.02	0.85	9.41e-29	IgG glycosylation;
THYM	cis	rs7250872	0.647	rs12976128	chr19:1817113	A/C	cg18850929	chr19:1828978	REXO1	0.56	4.79	0.44	6.1e-6	Bipolar disorder;
THYM	cis	rs3733631	1.000	rs28878597	chr4:104591916	A/G	cg24090629	chr4:104641072	TACR3	-0.87	-5.51	-0.49	3.08e-7	Menarche (age at onset);
THYM	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg00814883	chr7:100076585	TSC22D4	-0.95	-6.39	-0.55	6.08e-9	Platelet count;
THYM	cis	rs4733781	0.901	rs7012705	chr8:131189480	C/A	cg16277922	chr8:131349729	ASAP1	0.7	5.21	0.47	1.1e-6	Tuberculosis;
THYM	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg22907277	chr7:1156413	C7orf50	0.8	4.85	0.45	4.84e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2658782	0.789	rs2605580	chr11:93147054	C/T	cg15737290	chr11:93063684	CCDC67	0.87	6.68	0.57	1.59e-9	Pulmonary function decline;
THYM	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs4953076	0.574	rs4953074	chr2:44464629	C/T	cg04920474	chr2:44395004	PPM1B	0.68	5.29	0.48	7.7300000000000005e-07	Height;
THYM	cis	rs7177699	0.557	rs8027833	chr15:79112837	T/C	cg00540400	chr15:79124168	NA	0.64	6.93	0.58	4.98e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.36	0.48	5.75e-7	Height;
THYM	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.26	0.48	8.81e-7	Melanoma;
THYM	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg08439880	chr3:133502540	NA	-0.69	-5.85	-0.51	6.98e-8	Iron status biomarkers;
THYM	cis	rs4950928	0.823	rs4950882	chr1:203164848	A/G	cg14085262	chr1:203155938	CHI3L1	-0.79	-5.42	-0.49	4.56e-7	YKL-40 levels;
THYM	cis	rs6575793	0.967	rs11845605	chr14:101037726	C/T	cg13521842	chr14:101036202	BEGAIN	0.51	4.68	0.43	9.41e-6	Menarche (age at onset);
THYM	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.74	5.52	0.49	2.99e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs921968	0.643	rs2556384	chr2:219532903	C/T	cg01872077	chr2:219646372	CYP27A1	-0.58	-4.49	-0.42	2e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4243830	1.000	rs12027598	chr1:6600804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.1	5.8	0.51	8.69e-8	Body mass index;
THYM	cis	rs6732160	0.613	rs6546804	chr2:73385919	G/A	cg24220031	chr2:73402428	NA	-0.71	-5.79	-0.51	8.94e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg19442545	chr10:75533431	FUT11	-0.66	-7.04	-0.59	2.99e-10	Inflammatory bowel disease;
THYM	cis	rs72627123	0.749	rs10149956	chr14:74649106	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	-1.27	-7.16	-0.59	1.71e-10	Morning vs. evening chronotype;
THYM	cis	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg21775007	chr8:11205619	TDH	0.6	4.6	0.43	1.32e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg18876405	chr7:65276391	NA	-0.64	-5.58	-0.5	2.27e-7	Aortic root size;
THYM	cis	rs858239	0.730	rs858289	chr7:23248158	C/T	cg05407003	chr7:23246146	NA	-0.73	-6.39	-0.55	6e-9	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11890956	chr21:40555474	PSMG1	-0.65	-6.23	-0.54	1.28e-8	Menarche (age at onset);
THYM	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg15556689	chr8:8085844	FLJ10661	-0.64	-5.35	-0.48	6.11e-7	Mood instability;
THYM	cis	rs6570726	0.791	rs9373464	chr6:145907167	T/C	cg23711669	chr6:146136114	FBXO30	0.93	9.25	0.69	6.65e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9902453	0.817	rs55974138	chr17:28215546	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.65	0.43	1.07e-5	Coffee consumption (cups per day);
THYM	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg00640147	chr17:61958756	GH2	-0.43	-4.57	-0.42	1.48e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7757969	0.500	rs9487731	chr6:112154848	T/C	cg08601457	chr6:112115117	FYN	0.39	4.59	0.43	1.35e-5	Schizophrenia;
THYM	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg02869364	chr7:1081709	C7orf50	-0.49	-4.96	-0.45	3.04e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7432375	0.901	rs35874192	chr3:136470004	G/C	cg12473912	chr3:136751656	NA	-0.62	-5.24	-0.47	9.64e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg09877947	chr5:131593287	PDLIM4	0.72	6.56	0.56	2.8e-9	Acylcarnitine levels;
THYM	cis	rs2302612	0.615	rs2287041	chr2:102852866	A/C	cg13315345	chr2:102803985	IL1RL2	-0.69	-5.33	-0.48	6.49e-7	Serum protein levels (sST2);
THYM	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg01699819	chr7:1052092	C7orf50	-0.57	-4.82	-0.44	5.34e-6	Bronchopulmonary dysplasia;
THYM	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs3741151	0.773	rs11820577	chr11:73261424	C/G	cg12959048	chr11:73096162	RELT	-0.52	-4.62	-0.43	1.21e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7586879	0.598	rs6724772	chr2:25128730	T/C	cg01884057	chr2:25150051	NA	0.73	7.92	0.63	4.47e-12	Body mass index;
THYM	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg03806693	chr22:41940476	POLR3H	-1.09	-8.62	-0.66	1.45e-13	Vitiligo;
THYM	trans	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg10856724	chr12:34555212	NA	-0.91	-8.12	-0.64	1.64e-12	Heart rate;
THYM	cis	rs2273669	0.667	rs6899723	chr6:109362749	T/G	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs854765	0.693	rs4924822	chr17:17748013	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.66	-5.85	-0.51	7.08e-8	Total body bone mineral density;
THYM	cis	rs6500395	0.926	rs8057777	chr16:48565643	T/C	cg04672837	chr16:48644449	N4BP1	0.47	4.46	0.42	2.23e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg05043794	chr9:111880884	C9orf5	-0.36	-5.04	-0.46	2.2e-6	Menarche (age at onset);
THYM	cis	rs1023500	1.000	rs1047997	chr22:42334953	C/G	cg19448990	chr22:41842841	TOB2	-0.76	-4.81	-0.44	5.66e-6	Schizophrenia;
THYM	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg24675056	chr1:15929824	NA	-0.7	-5.73	-0.51	1.17e-7	Systolic blood pressure;
THYM	cis	rs7954638	1	rs7954638	chr12:96314795	C/A	cg19863595	chr12:96350605	AMDHD1	0.49	4.89	0.45	4.03e-6	Metabolite levels (small molecules and protein measures);
THYM	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg17279839	chr7:150038598	RARRES2	0.56	5.36	0.48	5.85e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs1385374	0.800	rs12321679	chr12:129284791	G/A	cg04043695	chr12:129287642	SLC15A4	-0.8	-4.82	-0.44	5.4e-6	Systemic lupus erythematosus;
THYM	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg10803722	chr21:46713166	LOC642852	-0.49	-6.39	-0.55	6e-9	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7429990	1.000	rs7429990	chr3:47901803	C/A	cg17215036	chr3:48129188	MAP4	0.63	4.51	0.42	1.85e-5	Educational attainment (years of education);
THYM	cis	rs13006833	0.668	rs291447	chr2:191177005	A/C	cg11845111	chr2:191398756	TMEM194B	0.65	4.65	0.43	1.09e-5	Urinary metabolites;
THYM	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg15440763	chr7:158190612	PTPRN2	0.48	4.57	0.42	1.47e-5	Obesity-related traits;
THYM	cis	rs6570726	0.902	rs973855	chr6:145781850	C/T	cg23711669	chr6:146136114	FBXO30	-0.83	-7.84	-0.63	6.69e-12	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.64	-0.74	7.23e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs9677476	0.779	rs72983683	chr2:232100970	G/T	cg23338755	chr2:231921595	PSMD1	0.73	4.67	0.43	9.92e-6	Food antigen IgG levels;
THYM	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg22907277	chr7:1156413	C7orf50	0.67	5.86	0.51	6.79e-8	Longevity;Endometriosis;
THYM	cis	rs6570726	0.791	rs6923074	chr6:145893332	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-4.99	-0.46	2.75e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6499129	0.702	rs8058861	chr16:67234134	A/G	cg26912222	chr16:68000829	SLC12A4	0.73	4.81	0.44	5.71e-6	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg03909863	chr11:638404	DRD4	-0.76	-6.1	-0.53	2.33e-8	Systemic lupus erythematosus;
THYM	cis	rs4888262	0.526	rs4887776	chr16:74635632	A/G	cg01733217	chr16:74700730	RFWD3	0.82	8.54	0.66	2.2e-13	Testicular germ cell tumor;
THYM	cis	rs4285028	0.747	rs12496318	chr3:121561500	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.91	6.83	0.57	8.05e-10	Multiple sclerosis;
THYM	cis	rs55728055	0.661	rs62237814	chr22:31992574	G/C	cg10537193	chr22:32026975	PISD	-0.66	-4.61	-0.43	1.26e-5	Age-related hearing impairment;
THYM	cis	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg09085632	chr11:111637200	PPP2R1B	1.19	12.69	0.79	3.69e-22	Primary sclerosing cholangitis;
THYM	cis	rs6754311	0.731	rs309134	chr2:136755684	A/G	cg20242066	chr2:136595261	LCT	-0.54	-6.4	-0.55	5.97e-9	Mosquito bite size;
THYM	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg07362569	chr17:61921086	SMARCD2	0.73	6.45	0.55	4.66e-9	Prudent dietary pattern;
THYM	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs924712	0.677	rs239837	chr6:54768159	A/G	cg19716238	chr6:54711378	FAM83B	-0.42	-4.49	-0.42	2.01e-5	Breast cancer;
THYM	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg18252515	chr7:66147081	NA	-1.56	-8.47	-0.66	3e-13	Diabetic kidney disease;
THYM	cis	rs9364687	0.664	rs4709718	chr6:163895788	A/G	cg01639524	chr6:163818125	NA	0.46	4.48	0.42	2.06e-5	Body mass index;
THYM	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg24818145	chr4:99064322	C4orf37	0.67	5.2	0.47	1.15e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs78456975	0.506	rs10206900	chr2:1552841	T/C	cg12573674	chr2:1569213	NA	-1.35	-8.97	-0.68	2.67e-14	Placebo response in major depressive disorder (% change in symptom score);
THYM	trans	rs877282	0.853	rs10904545	chr10:757100	G/A	cg22713356	chr15:30763199	NA	1.37	10.37	0.73	2.69e-17	Uric acid levels;
THYM	cis	rs3857067	0.806	rs6532472	chr4:95110113	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs10463554	0.857	rs158397	chr5:102412201	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg19912559	chr1:40204330	PPIE	0.63	4.82	0.44	5.34e-6	Blood protein levels;
THYM	cis	rs3892630	0.824	rs7247264	chr19:33239846	T/G	cg22928329	chr19:33183273	NUDT19	-0.77	-5.75	-0.51	1.08e-7	Red blood cell traits;
THYM	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg20283391	chr11:68216788	NA	-0.61	-4.58	-0.43	1.41e-5	Total body bone mineral density;
THYM	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11905131	chr22:24372483	LOC391322	0.93	11.03	0.75	1.06e-18	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs34912216	0.619	rs12701401	chr7:4133399	C/T	cg03141780	chr7:4150753	SDK1	0.68	5.17	0.47	1.29e-6	Motion sickness;
THYM	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg12501888	chr15:85177176	SCAND2	-0.6	-4.49	-0.42	1.96e-5	P wave terminal force;
THYM	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.62	0.56	2.09e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg10117171	chr1:25599238	RHD	-0.75	-5.57	-0.5	2.39e-7	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg00271210	chr6:167070053	RPS6KA2	-0.54	-5.24	-0.47	9.81e-7	Crohn's disease;
THYM	cis	rs10207060	0.778	rs6543581	chr2:240702308	C/T	cg20333904	chr2:240724165	NA	0.64	5.64	0.5	1.76e-7	Obesity-related traits;
THYM	cis	rs919433	0.684	rs55775495	chr2:198245965	C/T	cg05783139	chr2:198650985	BOLL	0.59	4.58	0.43	1.41e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg10518543	chr12:38710700	ALG10B	-0.57	-4.47	-0.42	2.16e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg27446573	chr6:127587934	RNF146	0.74	6.53	0.56	3.27e-9	Breast cancer;
THYM	cis	rs9788721	0.933	rs72738786	chr15:78828086	G/T	cg18825076	chr15:78729989	IREB2	-0.57	-4.95	-0.45	3.25e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg00684032	chr4:1343700	KIAA1530	0.54	4.68	0.43	9.51e-6	Obesity-related traits;
THYM	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg17264618	chr3:40429014	ENTPD3	0.52	4.86	0.45	4.57e-6	Renal cell carcinoma;
THYM	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	trans	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg25517755	chr10:38738941	LOC399744	0.75	7.33	0.6	7.48e-11	Corneal astigmatism;
THYM	cis	rs4731207	0.697	rs4360235	chr7:124526542	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7100689	0.577	rs2236569	chr10:82043576	G/A	cg09936400	chr10:82049201	MAT1A	0.48	5.0	0.46	2.62e-6	Post bronchodilator FEV1;
THYM	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg07936489	chr17:37558343	FBXL20	0.82	5.61	0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6763768	0.606	rs11707463	chr3:53362565	A/G	cg22900224	chr3:52804907	NEK4	0.72	4.71	0.43	8.6e-6	Bacterial meningitis;
THYM	cis	rs4731207	0.672	rs2286174	chr7:124465876	C/G	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg21475434	chr5:93447410	FAM172A	0.95	5.87	0.52	6.25e-8	Diabetic retinopathy;
THYM	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg19693284	chr19:2783607	SGTA	-0.85	-6.38	-0.55	6.45e-9	Total cholesterol levels;
THYM	cis	rs9297145	0.509	rs13222381	chr7:98785024	T/G	cg05967295	chr7:98741636	SMURF1	-0.67	-4.96	-0.45	3.09e-6	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	trans	rs9951602	0.512	rs1599636	chr18:76643916	G/A	cg02800362	chr5:177631904	HNRNPAB	1.11	8.66	0.66	1.21e-13	Obesity-related traits;
THYM	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg00129232	chr17:37814104	STARD3	0.7	4.79	0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs686320	1.000	rs679643	chr11:65250590	C/A	cg21144158	chr11:65211084	MIR612	0.65	4.7	0.43	8.95e-6	Hip circumference adjusted for BMI;
THYM	cis	rs3741151	0.773	rs11235770	chr11:73184002	C/T	cg12959048	chr11:73096162	RELT	-0.45	-4.84	-0.44	5.1e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs8192282	0.739	rs12124333	chr1:154478292	T/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.6	-5.48	-0.49	3.55e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs7809950	0.834	rs3801946	chr7:107242995	T/A	cg23024343	chr7:107201750	COG5	0.92	7.65	0.62	1.63e-11	Coronary artery disease;
THYM	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs28595532	0.920	rs116428408	chr4:119758514	G/C	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs10227331	0.846	rs12673606	chr7:157297518	C/G	cg04156418	chr7:157293606	NA	0.82	7.33	0.6	7.58e-11	Inattentive symptoms;
THYM	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg09877947	chr5:131593287	PDLIM4	0.61	5.08	0.46	1.86e-6	Acylcarnitine levels;
THYM	cis	rs9660180	0.846	rs10907195	chr1:1713348	C/T	cg06981504	chr1:1234844	ACAP3	-0.53	-4.8	-0.44	5.93e-6	Body mass index;
THYM	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg24642439	chr20:33292090	TP53INP2	0.59	4.51	0.42	1.88e-5	Coronary artery disease;
THYM	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.78	-5.52	-0.49	2.89e-7	Body mass index;
THYM	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg23649088	chr2:200775458	C2orf69	-0.76	-5.56	-0.5	2.46e-7	Schizophrenia;
THYM	cis	rs7584330	0.638	rs13429533	chr2:238448712	A/G	cg14458575	chr2:238380390	NA	0.6	4.7	0.43	8.63e-6	Prostate cancer;
THYM	cis	rs425535	0.536	rs6819566	chr4:74787142	A/G	cg07868155	chr4:74864709	CXCL5	0.55	4.69	0.43	9.11e-6	Blood protein levels;
THYM	cis	rs6499255	0.951	rs12595878	chr16:69628217	C/T	cg00738113	chr16:70207722	CLEC18C	-0.45	-4.45	-0.42	2.32e-5	IgE levels;
THYM	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg24209194	chr3:40518798	ZNF619	0.56	4.56	0.42	1.55e-5	Renal cell carcinoma;
THYM	trans	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs17511627	0.808	rs4770934	chr13:26742032	A/G	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg18105134	chr13:113819100	PROZ	-0.99	-9.17	-0.69	9.97e-15	Platelet distribution width;
THYM	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg04520793	chr17:42248056	ASB16	-0.34	-4.78	-0.44	6.45e-6	Total body bone mineral density;
THYM	cis	rs6754311	0.731	rs309168	chr2:136670298	C/T	cg20242066	chr2:136595261	LCT	0.61	7.05	0.59	2.89e-10	Mosquito bite size;
THYM	cis	rs9653442	0.866	rs12712065	chr2:100761105	C/G	cg07810366	chr2:100720526	AFF3	-0.41	-6.34	-0.55	7.56e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.59	4.58	0.43	1.41e-5	Height;
THYM	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.95	0.71	2.16e-16	Gut microbiome composition (summer);
THYM	cis	rs11089937	0.825	rs4820339	chr22:22521158	G/T	cg21401457	chr22:22472743	NA	0.54	4.53	0.42	1.69e-5	Periodontitis (PAL4Q3);
THYM	cis	rs7580658	0.724	rs71414745	chr2:127992588	A/G	cg10021288	chr2:128175891	PROC	-0.64	-5.69	-0.5	1.43e-7	Protein C levels;
THYM	cis	rs11264213	0.901	rs630364	chr1:36449304	C/T	cg27506609	chr1:36549197	TEKT2	0.92	4.83	0.44	5.3e-6	Schizophrenia;
THYM	cis	rs1497406	0.744	rs12057175	chr1:16508375	A/G	cg03887218	chr1:16534349	ARHGEF19	0.48	4.49	0.42	1.99e-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg16586182	chr3:47516702	SCAP	-0.65	-5.62	-0.5	1.94e-7	Colorectal cancer;
THYM	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg25072359	chr17:41440525	NA	0.72	5.31	0.48	7.04e-7	Menopause (age at onset);
THYM	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg06418219	chr1:154948305	SHC1;CKS1B	-0.75	-6.02	-0.53	3.27e-8	Prostate cancer;
THYM	cis	rs7772486	0.654	rs702321	chr6:146006695	A/G	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6546324	0.625	rs2861687	chr2:67838184	C/G	cg18237512	chr2:67827392	NA	-0.78	-4.63	-0.43	1.16e-5	Endometriosis;
THYM	cis	rs7107174	1.000	rs2512547	chr11:77960888	T/C	cg02023728	chr11:77925099	USP35	0.71	6.17	0.54	1.64e-8	Testicular germ cell tumor;
THYM	cis	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg05084668	chr3:125655381	ALG1L	-0.71	-4.61	-0.43	1.23e-5	Blood pressure (smoking interaction);
THYM	cis	rs11096990	0.656	rs7693837	chr4:39303101	T/C	cg24403649	chr4:39172243	NA	0.63	5.5	0.49	3.14e-7	Cognitive function;
THYM	cis	rs877282	0.685	rs56234340	chr10:781339	A/G	cg10556349	chr10:835070	NA	-0.78	-5.74	-0.51	1.12e-7	Uric acid levels;
THYM	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.41	6.49	0.55	3.84e-9	Obesity-related traits;
THYM	cis	rs13256369	0.951	rs13270852	chr8:8566853	A/G	cg18904891	chr8:8559673	CLDN23	0.67	4.97	0.45	3e-6	Obesity-related traits;
THYM	cis	rs853679	0.527	rs853693	chr6:28282648	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.64	-4.57	-0.42	1.49e-5	Depression;
THYM	cis	rs2075230	0.705	rs1641517	chr17:7551730	T/G	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.28	-4.62	-0.43	1.21e-5	Hormone measurements;
THYM	cis	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg07460842	chr6:66804631	NA	-0.91	-6.58	-0.56	2.6e-9	Exhaled nitric oxide output;
THYM	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	5.93	0.52	4.96e-8	Lung cancer in ever smokers;
THYM	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg00786635	chr1:25594202	NA	0.99	8.19	0.64	1.19e-12	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs59698941	0.943	rs12516596	chr5:132273608	C/G	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.5	0.42	1.89e-5	Apolipoprotein A-IV levels;
THYM	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs1801251	0.752	rs4144796	chr2:233562210	T/C	cg08000102	chr2:233561755	GIGYF2	0.67	5.91	0.52	5.3e-8	Coronary artery disease;
THYM	cis	rs9906944	0.707	rs729003	chr17:47117775	C/T	cg18128536	chr17:47092178	IGF2BP1	-0.43	-4.71	-0.44	8.43e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg14784868	chr12:69753453	YEATS4	0.7	5.75	0.51	1.06e-7	Blood protein levels;
THYM	cis	rs892961	0.932	rs7208671	chr17:75413129	T/C	cg11351908	chr17:75402473	SEPT9	0.56	5.45	0.49	3.91e-7	Airflow obstruction;
THYM	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg24112000	chr20:60950667	NA	0.8	6.51	0.56	3.49e-9	Colorectal cancer;
THYM	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.63	-5.25	-0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	7.73	0.62	1.1e-11	Monocyte percentage of white cells;
THYM	cis	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs6964587	0.626	rs10225241	chr7:91524940	A/G	cg22709100	chr7:91322751	NA	-0.63	-4.68	-0.43	9.65e-6	Breast cancer;
THYM	cis	rs5758511	0.680	rs5758662	chr22:42628088	T/C	cg08431931	chr22:42394659	WBP2NL	0.69	4.78	0.44	6.32e-6	Birth weight;
THYM	trans	rs8073060	0.586	rs2523114	chr17:34023762	G/A	cg19694781	chr19:47549865	TMEM160	-1.01	-8.47	-0.66	3.07e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg10661904	chr17:79619235	PDE6G	-0.54	-4.79	-0.44	6.25e-6	Eye color traits;
THYM	cis	rs112998813	0.571	rs7332124	chr13:114930057	A/C	cg26703057	chr13:114071457	NA	0.73	4.69	0.43	9.15e-6	Nodular sclerosis Hodgkin lymphoma;
THYM	cis	rs4889911	0.544	rs1285271	chr17:77834197	C/T	cg00646381	chr17:77835854	NA	-0.45	-4.87	-0.45	4.45e-6	Electroencephalogram traits;
THYM	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.7	-6.96	-0.58	4.31e-10	Lymphocyte counts;
THYM	cis	rs4866334	1.000	rs116117462	chr5:18452827	C/A	cg02002538	chr5:17811409	NA	-1.09	-4.54	-0.42	1.67e-5	IgG glycosylation;
THYM	cis	rs3741151	0.773	rs7925226	chr11:73137362	A/G	cg12959048	chr11:73096162	RELT	-0.53	-5.08	-0.46	1.92e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9790314	1.000	rs336548	chr3:161058412	T/C	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs6032067	1.000	rs34885285	chr20:43804789	C/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg04663057	chr3:46933782	PTH1R	0.62	6.22	0.54	1.35e-8	Birth weight;
THYM	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg15744005	chr10:104629667	AS3MT	-0.86	-8.33	-0.65	6.01e-13	Arsenic metabolism;
THYM	cis	rs6499255	0.951	rs8046314	chr16:69697922	T/A	cg00738113	chr16:70207722	CLEC18C	-0.44	-4.57	-0.42	1.45e-5	IgE levels;
THYM	cis	rs7258465	0.931	rs34053595	chr19:18556749	T/C	cg01380346	chr19:18557039	ELL	-0.46	-4.55	-0.42	1.6e-5	Breast cancer;
THYM	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg16586182	chr3:47516702	SCAP	0.67	5.5	0.49	3.18e-7	Colorectal cancer;
THYM	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.0	-5.11	-0.46	1.65e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6918586	1.000	rs198811	chr6:26128446	A/G	cg12310025	chr6:25882481	NA	-0.67	-5.31	-0.48	7.08e-7	Schizophrenia;
THYM	cis	rs10851411	0.908	rs2617236	chr15:42815733	A/T	cg04308337	chr15:42867303	STARD9	0.63	4.67	0.43	9.99e-6	Glucose homeostasis traits;
THYM	cis	rs7771547	0.573	rs629297	chr6:36398146	C/T	cg07856975	chr6:36356162	ETV7	0.52	4.72	0.44	8.26e-6	Platelet distribution width;
THYM	cis	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg07061783	chr6:25882402	NA	-1.09	-10.11	-0.72	9.46e-17	Intelligence (multi-trait analysis);
THYM	cis	rs4072705	1.000	rs4838203	chr9:127498374	T/C	cg13476313	chr9:127244764	NR5A1	0.35	5.3	0.48	7.44e-7	Menarche (age at onset);
THYM	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg12560992	chr17:57184187	TRIM37	0.9	8.25	0.65	9.12e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6995541	0.505	rs7001887	chr8:10695263	A/G	cg13457217	chr8:10683266	MIR1322;PINX1	-0.67	-5.0	-0.46	2.64e-6	Triglyceride levels;
THYM	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg18758796	chr5:131593413	PDLIM4	0.51	4.83	0.44	5.32e-6	Breast cancer;
THYM	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg15110403	chr19:17392923	ANKLE1	-0.57	-4.94	-0.45	3.36e-6	Systemic lupus erythematosus;
THYM	cis	rs863345	0.584	rs11265018	chr1:158506409	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs67311347	0.549	rs60249586	chr3:40246659	G/A	cg02782426	chr3:40428986	ENTPD3	0.5	4.63	0.43	1.16e-5	Renal cell carcinoma;
THYM	cis	rs3820068	0.581	rs68052904	chr1:15916714	T/C	cg13390004	chr1:15929781	NA	0.62	4.75	0.44	7.15e-6	Systolic blood pressure;
THYM	cis	rs11645898	0.748	rs72787042	chr16:72067522	A/G	cg14768367	chr16:72042858	DHODH	-0.81	-5.89	-0.52	5.95e-8	Blood protein levels;
THYM	cis	rs4660261	0.526	rs803680	chr1:44364370	G/C	cg15962314	chr1:44399869	ARTN	0.55	5.35	0.48	6.12e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg20295408	chr7:1910781	MAD1L1	-0.65	-4.8	-0.44	5.98e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs11588062	0.745	rs5019033	chr1:46735072	C/T	cg22112435	chr1:46664449	POMGNT1	-0.47	-5.03	-0.46	2.32e-6	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg25287198	chr4:183728479	NA	0.76	4.65	0.43	1.08e-5	Pediatric autoimmune diseases;
THYM	cis	rs6882076	0.961	rs4704827	chr5:156392089	T/C	cg12943317	chr5:156479607	HAVCR1	-0.72	-5.96	-0.52	4.36e-8	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	6.89	0.58	5.96e-10	Electrocardiographic conduction measures;
THYM	cis	rs12044355	0.516	rs2356383	chr1:231742973	G/C	cg04892437	chr1:231737901	TSNAX-DISC1	-0.57	-5.13	-0.47	1.51e-6	Alzheimer's disease;
THYM	cis	rs1451375	1.000	rs2329341	chr7:50620275	A/C	cg18232548	chr7:50535776	DDC	0.73	5.66	0.5	1.57e-7	Malaria;
THYM	cis	rs946836	0.562	rs10789521	chr1:48401587	T/C	cg18376692	chr1:48452465	NA	-0.5	-4.97	-0.45	2.94e-6	White matter integrity;
THYM	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.55	5.8	0.51	8.79e-8	Mean corpuscular volume;
THYM	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg21784768	chr11:537496	LRRC56	-1.37	-6.17	-0.53	1.7e-8	Body mass index;
THYM	cis	rs4455778	0.538	rs9642332	chr7:49113177	T/G	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg04282206	chr17:62833786	PLEKHM1P	0.82	7.53	0.61	2.9100000000000002e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs877282	0.853	rs12779017	chr10:763619	T/C	cg10556349	chr10:835070	NA	-0.78	-5.06	-0.46	2.06e-6	Uric acid levels;
THYM	cis	rs7818345	0.595	rs12155539	chr8:19316086	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.6	4.73	0.44	7.65e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs8133932	0.654	rs2839050	chr21:47326666	G/A	cg20357416	chr21:47294739	PCBP3	-0.81	-4.92	-0.45	3.56e-6	Schizophrenia;
THYM	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg26384229	chr12:38710491	ALG10B	-0.71	-5.66	-0.5	1.58e-7	Morning vs. evening chronotype;
THYM	cis	rs548181	1.000	rs548181	chr11:125461709	A/G	cg03464685	chr11:125439445	EI24	1.31	7.7	0.62	1.28e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs13256369	1.000	rs9329166	chr8:8576655	C/T	cg18904891	chr8:8559673	CLDN23	0.65	5.14	0.47	1.48e-6	Obesity-related traits;
THYM	trans	rs10802346	0.545	rs12134404	chr1:246372144	A/G	cg13514129	chr1:39547527	MACF1	1.03	10.85	0.74	2.56e-18	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg13609457	chr4:120235615	NA	0.64	5.08	0.46	1.86e-6	Corneal astigmatism;
THYM	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg12179176	chr11:130786555	SNX19	0.95	9.69	0.71	7.59e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs3768617	0.510	rs10752899	chr1:183081241	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg21100191	chr22:23484243	RTDR1	0.75	6.63	0.56	2.01e-9	Bone mineral density;
THYM	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6866344	0.697	rs58549512	chr5:178133204	C/T	cg03877680	chr5:178157825	ZNF354A	0.74	5.13	0.47	1.53e-6	Neutrophil percentage of white cells;
THYM	cis	rs939658	0.967	rs7172074	chr15:79452726	T/C	cg17916960	chr15:79447300	NA	0.75	8.81	0.67	5.71e-14	Refractive error;
THYM	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs877282	0.853	rs11593836	chr10:756715	G/A	cg22713356	chr15:30763199	NA	1.27	9.37	0.69	3.62e-15	Uric acid levels;
THYM	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.81	-8.26	-0.65	8.61e-13	Prudent dietary pattern;
THYM	cis	rs9393692	0.620	rs9358918	chr6:26286744	C/T	cg13736514	chr6:26305472	NA	-0.48	-5.01	-0.46	2.49e-6	Educational attainment;
THYM	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg03264133	chr6:25882463	NA	0.72	5.67	0.5	1.51e-7	Blood metabolite levels;
THYM	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.11	10.32	0.73	3.51e-17	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs8050907	0.744	rs77430528	chr16:4523389	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.22	4.58	0.43	1.43e-5	Obesity-related traits;
THYM	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs55871839	0.708	rs4738735	chr8:59816985	T/C	cg07426533	chr8:59803705	TOX	-0.72	-7.5	-0.61	3.37e-11	Pneumonia;
THYM	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	4.61	0.43	1.24e-5	Prudent dietary pattern;
THYM	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg09085632	chr11:111637200	PPP2R1B	0.95	8.44	0.65	3.45e-13	Primary sclerosing cholangitis;
THYM	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg00129232	chr17:37814104	STARD3	0.74	4.99	0.46	2.76e-6	Glomerular filtration rate (creatinine);
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg25001140	chr2:61990915	NA	-0.89	-6.84	-0.57	7.69e-10	Energy expenditure (24h);
THYM	cis	rs57920188	0.537	rs4347180	chr1:4074985	C/T	cg20703997	chr1:4087676	NA	1.07	7.67	0.62	1.46e-11	Interleukin-17 levels;
THYM	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg00256281	chr22:41985642	PMM1	0.52	4.68	0.43	9.62e-6	Vitiligo;
THYM	cis	rs754466	0.606	rs12356375	chr10:79594514	C/A	cg17075019	chr10:79541650	NA	-0.72	-6.01	-0.52	3.4e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11247915	0.644	rs11588739	chr1:26653319	G/A	cg00852783	chr1:26633632	UBXN11	0.73	5.89	0.52	5.74e-8	Obesity-related traits;
THYM	cis	rs3733631	0.557	rs74851354	chr4:104689591	C/A	cg24090629	chr4:104641072	TACR3	-0.86	-4.55	-0.42	1.57e-5	Menarche (age at onset);
THYM	cis	rs17604090	0.756	rs10249388	chr7:29729135	G/T	cg19413766	chr7:29689036	LOC646762	-0.95	-5.37	-0.48	5.65e-7	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg09263875	chr16:632152	PIGQ	0.7	5.56	0.5	2.46e-7	Height;
THYM	cis	rs11676855	0.927	rs4663180	chr2:235921195	A/G	cg14917874	chr2:235941519	SH3BP4	0.61	5.18	0.47	1.25e-6	Dialysis-related mortality;
THYM	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs6980334	0.817	rs10263205	chr7:137792922	C/T	cg06915773	chr7:137028165	PTN	0.58	4.74	0.44	7.59e-6	Blood metabolite ratios;
THYM	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg00898013	chr13:113819073	PROZ	-0.88	-9.0	-0.68	2.24e-14	Platelet distribution width;
THYM	cis	rs28595532	0.920	rs55668908	chr4:119769799	C/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg13393036	chr8:95962371	TP53INP1	-0.47	-4.9	-0.45	3.95e-6	Type 2 diabetes;
THYM	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-5.6	-0.5	2.1e-7	Schizophrenia;
THYM	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg09455208	chr3:40491958	NA	0.5	5.24	0.47	9.76e-7	Renal cell carcinoma;
THYM	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg18876405	chr7:65276391	NA	-0.57	-4.83	-0.44	5.19e-6	Aortic root size;
THYM	cis	rs2915864	1.000	rs2906067	chr5:141580122	T/G	cg00542992	chr5:141595654	NA	0.62	4.65	0.43	1.06e-5	Facial morphology (factor 20);
THYM	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.85	-6.19	-0.54	1.51e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	4.63	0.43	1.15e-5	Hip circumference adjusted for BMI;
THYM	cis	rs9733	0.596	rs12086472	chr1:150697710	G/A	cg04414720	chr1:150670196	GOLPH3L	0.62	4.71	0.44	8.35e-6	Tonsillectomy;
THYM	cis	rs7020830	0.898	rs308523	chr9:37338785	C/T	cg14294708	chr9:37120828	ZCCHC7	1.24	14.04	0.82	6.64e-25	Schizophrenia;
THYM	trans	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg25214090	chr10:38739885	LOC399744	0.92	7.76	0.62	9.72e-12	Corneal astigmatism;
THYM	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg15445000	chr17:37608096	MED1	0.44	5.22	0.47	1.07e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs4733781	0.563	rs7387699	chr8:131339029	T/C	cg16277922	chr8:131349729	ASAP1	-0.65	-5.64	-0.5	1.71e-7	Tuberculosis;
THYM	cis	rs4474465	0.915	rs11237505	chr11:78171261	A/G	cg02023728	chr11:77925099	USP35	0.52	4.54	0.42	1.67e-5	Alzheimer's disease (survival time);
THYM	cis	rs4919044	0.600	rs78586043	chr10:94612458	T/G	cg05127821	chr10:94822908	CYP26C1	-1.14	-6.87	-0.58	6.78e-10	Coronary artery disease;
THYM	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs6918586	0.658	rs198814	chr6:26127759	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.65	-0.62	1.6e-11	Schizophrenia;
THYM	cis	rs425277	0.539	rs3128337	chr1:2045882	A/G	cg09260853	chr1:2094483	PRKCZ	-0.49	-4.88	-0.45	4.27e-6	Height;
THYM	cis	rs4363385	0.747	rs6671414	chr1:152974119	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.53	-0.42	1.74e-5	Inflammatory skin disease;
THYM	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg13319975	chr6:146136371	FBXO30	-0.66	-5.33	-0.48	6.53e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.98	-9.49	-0.7	2.06e-15	Intelligence (multi-trait analysis);
THYM	cis	rs2109514	0.765	rs11769417	chr7:116103778	A/G	cg12739419	chr7:116140593	CAV2	-0.47	-4.83	-0.44	5.18e-6	Prevalent atrial fibrillation;
THYM	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg10295955	chr4:187884368	NA	-1.17	-17.37	-0.87	3.11e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1371867	0.775	rs6511	chr8:101252680	T/C	cg06636551	chr8:101224915	SPAG1	0.65	5.89	0.52	5.91e-8	Atrioventricular conduction;
THYM	cis	rs7607369	0.714	rs4674332	chr2:219604326	C/T	cg02176678	chr2:219576539	TTLL4	0.6	5.71	0.51	1.29e-7	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs711830	1.000	rs711830	chr2:177037311	C/T	cg26754761	chr2:177040938	NA	0.56	4.96	0.45	3.11e-6	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs7589728	0.563	rs78685993	chr2:88447026	T/C	cg04511125	chr2:88470314	THNSL2	0.66	4.62	0.43	1.21e-5	Plasma clusterin levels;
THYM	cis	rs6840360	0.593	rs10013612	chr4:152693622	A/G	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs8133932	0.861	rs71324439	chr21:47085925	A/C	cg20357416	chr21:47294739	PCBP3	0.84	4.81	0.44	5.62e-6	Schizophrenia;
THYM	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg19875535	chr5:140030758	IK	-0.58	-4.57	-0.42	1.44e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs17152411	1.000	rs7092008	chr10:126638226	G/A	cg07906193	chr10:126599966	NA	0.68	4.69	0.43	8.98e-6	Height;
THYM	cis	rs79349575	0.783	rs15563	chr17:47005193	A/G	cg26022315	chr17:47021804	SNF8	0.48	4.5	0.42	1.95e-5	Type 2 diabetes;
THYM	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.09	0.46	1.78e-6	Obesity-related traits;
THYM	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg06221963	chr1:154839813	KCNN3	0.85	11.28	0.76	3.08e-19	Prostate cancer;
THYM	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.23	-0.47	9.91e-7	Monocyte percentage of white cells;
THYM	cis	rs55665837	1.000	rs7945167	chr11:14451820	T/G	cg19336497	chr11:14380999	RRAS2	-0.64	-7.04	-0.59	3e-10	Vitamin D levels;
THYM	cis	rs7119	0.689	rs12901765	chr15:77819103	C/A	cg27398640	chr15:77910606	LINGO1	-0.56	-5.61	-0.5	2.03e-7	Type 2 diabetes;
THYM	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06873352	chr17:61820015	STRADA	0.56	5.63	0.5	1.84e-7	Height;
THYM	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03517284	chr6:25882590	NA	0.72	5.76	0.51	1.04e-7	Blood metabolite levels;
THYM	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg02527881	chr3:46936655	PTH1R	-0.69	-7.14	-0.59	1.9e-10	Colorectal cancer;
THYM	cis	rs11771526	0.901	rs62457469	chr7:32303052	T/C	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	trans	rs4866334	1.000	rs116117462	chr5:18452827	C/A	cg08675002	chr5:90437527	GPR98	-1.55	-7.42	-0.61	4.85e-11	IgG glycosylation;
THYM	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg27534772	chr1:16042836	PLEKHM2	0.54	5.92	0.52	5.1e-8	Systolic blood pressure;
THYM	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg03762994	chr17:6899332	ALOX12	0.73	10.11	0.72	9.74e-17	Tonsillectomy;
THYM	cis	rs7107174	1.000	rs2292572	chr11:78052864	G/T	cg19901956	chr11:77921274	USP35	-0.65	-5.34	-0.48	6.25e-7	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs240764	0.621	rs11155623	chr6:101184373	A/G	cg21058520	chr6:100914733	NA	0.6	5.32	0.48	6.98e-7	Neuroticism;
THYM	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.29e-7	Corneal astigmatism;
THYM	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg03563238	chr19:33554763	RHPN2	-0.5	-4.48	-0.42	2.04e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08704250	chr15:31115839	NA	-0.54	-6.1	-0.53	2.23e-8	Huntington's disease progression;
THYM	cis	rs3892630	0.818	rs80137870	chr19:33182750	C/T	cg02283691	chr19:33182526	NUDT19	-0.4	-4.74	-0.44	7.36e-6	Red blood cell traits;
THYM	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg10523679	chr1:76189770	ACADM	0.92	10.35	0.73	2.94e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs61931739	0.513	rs10743833	chr12:33897481	C/T	cg10856724	chr12:34555212	NA	-0.62	-5.57	-0.5	2.36e-7	Morning vs. evening chronotype;
THYM	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4435363	0.834	rs75432130	chr19:47075541	G/A	cg10017888	chr19:47105860	CALM3	0.82	5.39	0.48	5.06e-7	Immature fraction of reticulocytes;P wave terminal force;
THYM	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg04972856	chr6:88032051	C6orf162;GJB7	0.44	5.4	0.48	4.98e-7	Monocyte percentage of white cells;
THYM	cis	rs9296092	0.521	rs9461886	chr6:33526770	T/C	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg22105103	chr4:187893119	NA	0.88	9.57	0.7	1.35e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14240646	chr10:27532245	ACBD5	-0.82	-5.08	-0.46	1.88e-6	Breast cancer;
THYM	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg26384229	chr12:38710491	ALG10B	-0.9	-7.35	-0.6	6.77e-11	Bladder cancer;
THYM	cis	rs189798	0.845	rs330904	chr8:8991825	T/G	cg06636001	chr8:8085503	FLJ10661	-0.68	-5.52	-0.49	2.99e-7	Myopia (pathological);
THYM	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg03517284	chr6:25882590	NA	0.83	6.56	0.56	2.76e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg10047753	chr17:41438598	NA	1.18	11.26	0.76	3.4e-19	Menopause (age at onset);
THYM	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg05368731	chr17:41323189	NBR1	1.19	10.46	0.73	1.71e-17	Menopause (age at onset);
THYM	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg26354017	chr1:205819088	PM20D1	1.02	10.98	0.75	1.32e-18	Menarche (age at onset);
THYM	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg03732007	chr1:2071316	PRKCZ	0.5	4.51	0.42	1.89e-5	Height;
THYM	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg09184832	chr6:79620586	NA	-0.57	-4.45	-0.42	2.35e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg09165964	chr15:75287851	SCAMP5	-1.0	-9.02	-0.68	2.08e-14	Blood trace element (Zn levels);
THYM	cis	rs9790314	0.818	rs6797066	chr3:161008725	T/A	cg03342759	chr3:160939853	NMD3	-0.95	-9.47	-0.7	2.2e-15	Morning vs. evening chronotype;
THYM	cis	rs2067615	0.579	rs4964492	chr12:107222774	C/T	cg15890332	chr12:107067104	RFX4	0.41	4.6	0.43	1.29e-5	Heart rate;
THYM	cis	rs79149102	0.579	rs8033125	chr15:75374970	G/C	cg09165964	chr15:75287851	SCAMP5	-0.92	-5.22	-0.47	1.04e-6	Lung cancer;
THYM	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg06238570	chr21:40685208	BRWD1	-0.97	-9.38	-0.69	3.44e-15	Cognitive function;
THYM	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg25427524	chr10:38739819	LOC399744	-0.7	-6.38	-0.55	6.44e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg25918947	chr17:41365094	TMEM106A	-0.69	-5.63	-0.5	1.86e-7	Menopause (age at onset);
THYM	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg03806693	chr22:41940476	POLR3H	-1.16	-10.39	-0.73	2.4e-17	Vitiligo;
THYM	cis	rs2354432	0.607	rs1890039	chr1:146681951	T/C	cg25205988	chr1:146714368	CHD1L	1.1	4.92	0.45	3.66e-6	Mitochondrial DNA levels;
THYM	cis	rs514406	0.767	rs551591	chr1:53301876	A/G	cg06600287	chr1:53387719	ECHDC2	-0.31	-4.76	-0.44	7.03e-6	Monocyte count;
THYM	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg27490568	chr2:178487706	NA	0.57	5.16	0.47	1.36e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6720763	0.945	rs6740526	chr2:168006149	C/A	cg10633051	chr2:168042982	XIRP2	-0.68	-4.69	-0.43	9.2e-6	Atopic dermatitis;
THYM	cis	rs2273669	0.667	rs12374597	chr6:109346184	A/G	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg27532560	chr4:187881888	NA	-0.96	-11.41	-0.76	1.68e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7246967	0.673	rs12971914	chr19:22888898	A/T	cg05241461	chr19:22816980	ZNF492	0.6	4.64	0.43	1.11e-5	Bronchopulmonary dysplasia;
THYM	cis	rs1298062	0.689	rs12985344	chr19:50954750	T/C	cg10687087	chr19:50962411	MYBPC2	0.58	4.88	0.45	4.3e-6	Age of smoking initiation;
THYM	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg02527881	chr3:46936655	PTH1R	-0.61	-5.71	-0.51	1.28e-7	Colorectal cancer;
THYM	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg07537917	chr2:241836409	C2orf54	-0.26	-6.19	-0.54	1.54e-8	Urinary metabolites;
THYM	cis	rs6980334	0.871	rs10246884	chr7:137759521	T/C	cg18769353	chr7:137028617	PTN	0.57	4.5	0.42	1.9e-5	Blood metabolite ratios;
THYM	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg09640425	chr7:158790006	NA	0.54	4.55	0.42	1.6e-5	Facial morphology (factor 20);
THYM	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg18512352	chr11:47633146	NA	-0.54	-7.07	-0.59	2.54e-10	Subjective well-being;
THYM	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg07131210	chr7:1025825	CYP2W1	-0.83	-4.89	-0.45	4.13e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs977987	0.806	rs4887824	chr16:75441613	T/C	cg03315344	chr16:75512273	CHST6	0.77	6.31	0.54	8.75e-9	Dupuytren's disease;
THYM	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg11764359	chr7:65958608	NA	-0.89	-7.72	-0.62	1.19e-11	Aortic root size;
THYM	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.41	6.36	0.55	6.9e-9	Obesity-related traits;
THYM	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs4866334	1.000	rs75534671	chr5:18487744	G/A	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs11648796	0.765	rs2003832	chr16:769538	G/A	cg20104307	chr16:778658	HAGHL	0.4	5.92	0.52	5.13e-8	Height;
THYM	cis	rs3136516	0.537	rs2291443	chr11:47179861	C/A	cg00724111	chr11:47209415	PACSIN3	-0.38	-4.71	-0.43	8.51e-6	Venous thromboembolism;
THYM	cis	rs7432375	0.901	rs900818	chr3:136471815	C/T	cg21827317	chr3:136751795	NA	-0.59	-5.0	-0.46	2.58e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs7258465	0.965	rs10409003	chr19:18543054	C/T	cg01380346	chr19:18557039	ELL	-0.49	-5.01	-0.46	2.53e-6	Breast cancer;
THYM	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg17264618	chr3:40429014	ENTPD3	0.49	4.62	0.43	1.18e-5	Renal cell carcinoma;
THYM	cis	rs3857067	0.806	rs9996975	chr4:95101338	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.47	-0.42	2.13e-5	QT interval;
THYM	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs11756438	0.683	rs4027595	chr6:119017504	C/T	cg01113488	chr6:119027122	NA	-0.61	-4.85	-0.45	4.73e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs4731207	0.564	rs13234634	chr7:124676033	G/A	cg05285228	chr7:124571219	POT1	-0.61	-4.58	-0.43	1.39e-5	Cutaneous malignant melanoma;
THYM	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.49	-6.14	-0.53	1.9e-8	Schizophrenia;
THYM	cis	rs1371867	0.846	rs1660316	chr8:101333049	T/C	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	trans	rs1973993	0.691	rs11165623	chr1:96893000	G/A	cg10631902	chr5:14652156	NA	0.76	9.07	0.68	1.59e-14	Weight;
THYM	cis	rs9814567	1.000	rs9834755	chr3:134206845	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.86	-8.85	-0.67	4.76e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs11771526	0.901	rs28631129	chr7:32305044	G/C	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg23758822	chr17:41437982	NA	1.12	7.79	0.62	8.28e-12	Menopause (age at onset);
THYM	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg00383909	chr3:49044727	WDR6	1.21	7.52	0.61	3.1e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs2816062	0.813	rs2745321	chr1:18889198	G/C	cg18795169	chr1:18902165	NA	-0.99	-11.58	-0.77	7.31e-20	Urate levels in lean individuals;
THYM	cis	rs7267979	0.966	rs2257461	chr20:25265554	A/G	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs514406	0.679	rs545719	chr1:53304922	T/C	cg27535305	chr1:53392650	SCP2	-0.61	-6.96	-0.58	4.43e-10	Monocyte count;
THYM	cis	rs1018836	0.631	rs61276517	chr8:91474406	A/G	cg16814680	chr8:91681699	NA	-0.72	-5.85	-0.51	6.83e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs79387448	0.701	rs11465586	chr2:102982709	C/G	cg09003973	chr2:102972529	NA	1.3	7.64	0.62	1.69e-11	Gut microbiota (bacterial taxa);
THYM	cis	rs2985684	1.000	rs17121651	chr14:50097172	T/C	cg02151108	chr14:50098012	C14orf104	-0.67	-5.33	-0.48	6.48e-7	Carotid intima media thickness;
THYM	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg24308560	chr3:49941425	MST1R	0.64	4.9	0.45	4.01e-6	Body mass index;
THYM	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg21644426	chr2:191273491	MFSD6	-0.78	-6.28	-0.54	9.92e-9	Pulse pressure;
THYM	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.55	-5.64	-0.5	1.72e-7	Crohn's disease;
THYM	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg01299579	chr2:10830716	NOL10	-0.49	-4.57	-0.42	1.46e-5	Prostate cancer;
THYM	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg09455208	chr3:40491958	NA	0.45	4.8	0.44	5.95e-6	Renal cell carcinoma;
THYM	cis	rs6032067	0.929	rs34412950	chr20:43805132	C/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs9814567	0.752	rs1880378	chr3:134330709	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.68	-0.62	1.39e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs28595532	0.920	rs115240535	chr4:119745395	G/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs9796	0.870	rs28501589	chr15:41282534	G/A	cg21153102	chr15:41252147	NA	0.7	6.29	0.54	9.85e-9	Menopause (age at onset);
THYM	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg06238570	chr21:40685208	BRWD1	-0.76	-6.7	-0.57	1.45e-9	Menarche (age at onset);
THYM	cis	rs7219021	0.705	rs28635466	chr17:46983820	G/A	cg09029085	chr17:47094198	IGF2BP1	0.33	4.5	0.42	1.91e-5	Schizophrenia or bipolar disorder;
THYM	cis	rs6785206	1.000	rs6785206	chr3:128412024	A/G	cg16766828	chr3:128327626	NA	-0.77	-7.49	-0.61	3.53e-11	Lymphocyte percentage of white cells;
THYM	cis	rs1448094	0.511	rs11610371	chr12:86163487	A/G	cg00310523	chr12:86230176	RASSF9	0.61	5.31	0.48	7.29e-7	Major depressive disorder;
THYM	cis	rs2286885	0.965	rs4837092	chr9:129250251	T/C	cg14294646	chr9:129243551	FAM125B	-0.57	-5.17	-0.47	1.32e-6	Intraocular pressure;
THYM	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg11764359	chr7:65958608	NA	-0.82	-6.44	-0.55	4.87e-9	Aortic root size;
THYM	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg04234412	chr22:24373322	LOC391322	-0.86	-8.06	-0.64	2.27e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3008870	1.000	rs2985811	chr1:67377722	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	7.79	0.62	8.27e-12	Lymphocyte percentage of white cells;
THYM	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.45	-4.89	-0.45	4.03e-6	Schizophrenia;
THYM	cis	rs4866334	0.557	rs116250256	chr5:18457657	A/T	cg02002538	chr5:17811409	NA	-1.09	-4.54	-0.42	1.67e-5	IgG glycosylation;
THYM	cis	rs722599	0.501	rs10139347	chr14:75390135	T/C	cg08847533	chr14:75593920	NEK9	0.59	5.16	0.47	1.36e-6	IgG glycosylation;
THYM	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg17063962	chr7:91808500	NA	1.14	12.52	0.79	8.22e-22	Breast cancer;
THYM	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg05662444	chr5:154026397	NA	-0.55	-4.83	-0.44	5.29e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.36	-0.48	5.78e-7	Monocyte percentage of white cells;
THYM	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg23161317	chr6:28129485	ZNF389	-0.96	-7.95	-0.63	3.89e-12	Depression;
THYM	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg27286337	chr10:134555280	INPP5A	0.8	5.52	0.49	2.9e-7	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg04025307	chr7:1156635	C7orf50	0.79	6.89	0.58	5.97e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6138458	1.000	rs227624	chr20:24911562	T/C	cg06937882	chr20:24974362	C20orf3	-0.47	-4.54	-0.42	1.66e-5	Blood protein levels;
THYM	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg17105886	chr17:28927953	LRRC37B2	-1.26	-7.59	-0.61	2.23e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg03060546	chr3:49711283	APEH	0.77	6.37	0.55	6.65e-9	Resting heart rate;
THYM	cis	rs12476592	0.516	rs1348804	chr2:63895672	C/T	cg17519650	chr2:63277830	OTX1	-0.69	-4.69	-0.43	9.3e-6	Childhood ear infection;
THYM	cis	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-5.43	-0.49	4.23e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs79387448	0.592	rs76362690	chr2:102951477	A/G	cg09003973	chr2:102972529	NA	1.25	6.21	0.54	1.41e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs7769051	0.522	rs77652453	chr6:133142421	A/G	cg22852734	chr6:133119734	C6orf192	1.35	4.73	0.44	7.88e-6	Type 2 diabetes nephropathy;
THYM	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg00757033	chr12:89920650	WDR51B	0.75	11.88	0.77	1.76e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs11645898	0.810	rs11646364	chr16:72108687	A/T	cg03805757	chr16:71968109	PKD1L3	-0.72	-5.23	-0.47	9.9e-7	Blood protein levels;
THYM	cis	rs6558530	1.000	rs6558530	chr8:1706207	A/G	cg09410841	chr8:1729607	CLN8	0.67	4.91	0.45	3.85e-6	Systolic blood pressure;
THYM	cis	rs35934224	0.504	rs7288631	chr22:19836148	C/T	cg11182965	chr22:19864308	TXNRD2	-0.76	-5.72	-0.51	1.23e-7	Glaucoma (primary open-angle);
THYM	cis	rs4631830	0.863	rs2926494	chr10:51517356	T/C	cg10326726	chr10:51549505	MSMB	-0.52	-5.22	-0.47	1.03e-6	Prostate-specific antigen levels;
THYM	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.93	-5.49	-0.49	3.35e-7	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs568617	1.000	rs10791830	chr11:65661291	C/T	cg06443583	chr11:65626142	CFL1	-0.71	-4.46	-0.42	2.26e-5	Crohn's disease;
THYM	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.33	10.0	0.72	1.62e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg25282410	chr6:160211355	TCP1;MRPL18	0.97	7.84	0.63	6.44e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg05738196	chr6:26577821	NA	-0.95	-9.91	-0.71	2.53e-16	Intelligence (multi-trait analysis);
THYM	cis	rs8028313	0.630	rs28565266	chr15:67938011	C/G	cg24579218	chr15:68104479	NA	-0.7	-6.43	-0.55	5.04e-9	Obesity;
THYM	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg02825527	chr7:2087843	MAD1L1	-0.69	-4.62	-0.43	1.19e-5	Bipolar disorder;
THYM	cis	rs354225	0.554	rs4374410	chr2:54819088	G/T	cg23486701	chr2:54789491	SPTBN1	0.35	4.68	0.43	9.65e-6	Schizophrenia;
THYM	cis	rs73206853	0.620	rs73194035	chr12:111165793	A/G	cg24010859	chr12:110868153	NA	0.64	4.48	0.42	2.05e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
THYM	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.78	-6.94	-0.58	4.76e-10	Prudent dietary pattern;
THYM	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35883536	0.609	rs12747197	chr1:101036831	A/C	cg06223162	chr1:101003688	GPR88	-0.83	-7.09	-0.59	2.39e-10	Monocyte count;
THYM	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg18538332	chr22:24372958	LOC391322	-1.05	-13.88	-0.82	1.4e-24	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs28595532	0.841	rs114735834	chr4:119772722	G/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs6840360	0.571	rs28608620	chr4:152504791	C/T	cg22705602	chr4:152727874	NA	-0.78	-8.74	-0.67	8.17e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg17105886	chr17:28927953	LRRC37B2	1.1	5.73	0.51	1.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg06917634	chr15:78832804	PSMA4	0.96	8.76	0.67	7.4e-14	Sudden cardiac arrest;
THYM	cis	rs7086627	0.506	rs10749575	chr10:82136921	C/T	cg01528321	chr10:82214614	TSPAN14	0.61	5.06	0.46	2.06e-6	Post bronchodilator FEV1;
THYM	cis	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg08133631	chr1:26527909	CATSPER4	-0.59	-4.94	-0.45	3.38e-6	Obesity-related traits;
THYM	cis	rs10463554	0.667	rs34782	chr5:102454470	G/T	cg23492399	chr5:102201601	PAM	-0.69	-5.1	-0.46	1.76e-6	Parkinson's disease;
THYM	cis	rs208520	0.690	rs207102	chr6:66795671	G/A	cg07460842	chr6:66804631	NA	-1.06	-7.89	-0.63	5.14e-12	Exhaled nitric oxide output;
THYM	cis	rs7107174	1.000	rs10899467	chr11:78014057	G/T	cg19901956	chr11:77921274	USP35	-0.7	-5.42	-0.49	4.56e-7	Testicular germ cell tumor;
THYM	cis	rs12530845	0.623	rs77454235	chr7:135341862	T/C	cg19897172	chr7:135347071	PL-5283	-0.59	-5.22	-0.47	1.06e-6	Red blood cell traits;
THYM	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg17366294	chr4:99064904	C4orf37	0.54	5.97	0.52	4.05e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg17173187	chr15:85201210	NMB	0.54	5.31	0.48	7.17e-7	Schizophrenia;
THYM	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg00990874	chr7:1149470	C7orf50	-0.69	-5.2	-0.47	1.14e-6	Bronchopulmonary dysplasia;
THYM	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg18128536	chr17:47092178	IGF2BP1	-0.54	-8.58	-0.66	1.75e-13	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg23791538	chr6:167370224	RNASET2	-0.72	-5.66	-0.5	1.58e-7	Crohn's disease;
THYM	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	5.99	0.52	3.75e-8	Schizophrenia;
THYM	cis	rs9807841	0.592	rs3810155	chr19:10764867	C/G	cg17848348	chr19:10766748	ILF3	-0.75	-6.08	-0.53	2.53e-8	Inflammatory skin disease;
THYM	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.89	5.66	0.5	1.63e-7	Yeast infection;
THYM	cis	rs9906944	0.713	rs9899580	chr17:47106878	T/G	cg10950924	chr17:47092072	IGF2BP1	-0.49	-4.47	-0.42	2.15e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs6568490	0.556	rs7770059	chr6:108091350	A/G	cg03500965	chr6:108145777	SCML4	0.4	4.75	0.44	7.2e-6	Lymphocyte counts;
THYM	cis	rs854765	0.583	rs11650649	chr17:17790319	C/A	cg16928487	chr17:17741425	SREBF1	0.56	5.37	0.48	5.68e-7	Total body bone mineral density;
THYM	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg04287289	chr16:89883240	FANCA	0.63	5.71	0.51	1.26e-7	Vitiligo;
THYM	cis	rs6430585	0.528	rs10496738	chr2:136751488	C/T	cg04750100	chr2:136595281	LCT	0.56	4.94	0.45	3.41e-6	Corneal structure;
THYM	cis	rs9788682	0.747	rs2568490	chr15:78738370	T/C	cg18825076	chr15:78729989	IREB2	-0.7	-5.36	-0.48	5.71e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.67	5.87	0.52	6.43e-8	Lung disease severity in cystic fibrosis;
THYM	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.02	6.81	0.57	8.7e-10	Cognitive test performance;
THYM	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg06728252	chr6:26598149	ABT1	-0.42	-4.76	-0.44	6.98e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.42	0.49	4.5e-7	Height;
THYM	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.96e-6	Resting heart rate;
THYM	cis	rs9810089	0.802	rs833861	chr3:136231067	T/A	cg12473912	chr3:136751656	NA	0.57	4.82	0.44	5.48e-6	Gestational age at birth (child effect);
THYM	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg06028605	chr16:24865363	SLC5A11	0.58	5.69	0.5	1.42e-7	Intelligence (multi-trait analysis);
THYM	cis	rs300703	0.935	rs300704	chr2:240255	A/C	cg21211680	chr2:198530	NA	1.33	5.61	0.5	1.97e-7	Blood protein levels;
THYM	cis	rs2282930	0.512	rs7797159	chr7:50707563	T/C	cg08586669	chr7:50727761	GRB10	0.31	4.77	0.44	6.66e-6	Bone mineral density;
THYM	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg04990556	chr1:26633338	UBXN11	-0.87	-8.37	-0.65	4.99e-13	Obesity-related traits;
THYM	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs9486719	0.948	rs2499817	chr6:96878321	C/T	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs13315871	1.000	rs1131052	chr3:58411530	A/T	cg00563845	chr3:58318305	PXK	0.53	4.67	0.43	9.78e-6	Cholesterol, total;
THYM	cis	rs89107	0.576	rs763254	chr6:118886615	T/C	cg21191810	chr6:118973309	C6orf204	0.52	5.13	0.47	1.56e-6	Cardiac structure and function;
THYM	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg03806693	chr22:41940476	POLR3H	1.05	9.54	0.7	1.59e-15	Vitiligo;
THYM	cis	rs988913	0.957	rs9382396	chr6:54760686	G/T	cg04690482	chr6:54711388	FAM83B	0.46	4.96	0.45	3.05e-6	Menarche (age at onset);
THYM	cis	rs2742234	0.911	rs3004214	chr10:43631698	C/T	cg06632098	chr10:43605906	RET	-0.75	-4.98	-0.45	2.88e-6	Hirschsprung disease;
THYM	cis	rs4227	0.565	rs8066665	chr17:7485852	A/G	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	-0.26	-4.72	-0.44	8.06e-6	IgA nephropathy;
THYM	cis	rs7809950	1.000	rs3801948	chr7:107238447	A/T	cg23024343	chr7:107201750	COG5	-0.9	-7.78	-0.62	8.57e-12	Coronary artery disease;
THYM	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg06481639	chr22:41940642	POLR3H	0.68	4.49	0.42	2e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg13852791	chr20:30311386	BCL2L1	0.8	6.17	0.54	1.63e-8	Mean corpuscular volume;
THYM	cis	rs2898681	0.739	rs8287	chr4:53732586	T/C	cg00338735	chr4:53728038	RASL11B	0.52	4.78	0.44	6.4e-6	Optic nerve measurement (cup area);
THYM	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg06618935	chr21:46677482	NA	-0.97	-8.09	-0.64	1.92e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg07169764	chr2:136633963	MCM6	-0.7	-6.22	-0.54	1.34e-8	Mosquito bite size;
THYM	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg13114125	chr14:105738426	BRF1	-0.74	-5.88	-0.52	6.07e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6586163	0.546	rs12359362	chr10:90753145	G/C	cg03111039	chr10:90751583	FAS;ACTA2	0.55	5.27	0.48	8.52e-7	Chronic lymphocytic leukemia;
THYM	cis	rs35883536	0.647	rs10875316	chr1:101044150	G/A	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg15556689	chr8:8085844	FLJ10661	0.64	4.94	0.45	3.38e-6	Mood instability;
THYM	cis	rs56235845	0.685	rs35630910	chr5:176757841	A/C	cg16006841	chr5:176797999	RGS14	0.56	6.64	0.56	1.95e-9	Hemoglobin concentration;Hematocrit;
THYM	cis	rs1609391	0.567	rs835633	chr3:136676496	T/C	cg21827317	chr3:136751795	NA	0.74	6.6	0.56	2.29e-9	Neuroticism;
THYM	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg24642844	chr7:1081250	C7orf50	-1.26	-8.11	-0.64	1.74e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7727544	0.582	rs2278398	chr5:131530441	C/T	cg16205897	chr5:131564050	P4HA2	0.46	4.74	0.44	7.53e-6	Blood metabolite levels;
THYM	cis	rs931812	0.691	rs884488	chr8:101898523	C/G	cg07239293	chr8:101170671	SPAG1	0.63	4.53	0.42	1.73e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg18811423	chr2:55921094	PNPT1	0.74	6.62	0.56	2.1e-9	Metabolic syndrome;
THYM	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs11025559	0.812	rs10833336	chr11:20514288	C/G	cg19653624	chr11:20408972	PRMT3	-0.71	-4.94	-0.45	3.31e-6	Pursuit maintenance gain;
THYM	cis	rs892961	1.000	rs11077907	chr17:75400706	G/A	cg05865280	chr17:75406074	SEPT9	0.5	8.39	0.65	4.57e-13	Airflow obstruction;
THYM	cis	rs12291225	0.535	rs10832248	chr11:14413087	G/A	cg19336497	chr11:14380999	RRAS2	-0.83	-11.23	-0.76	4.06e-19	Sense of smell;
THYM	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg14675211	chr2:100938903	LONRF2	0.77	8.32	0.65	6.49e-13	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg25918947	chr17:41365094	TMEM106A	-0.56	-4.62	-0.43	1.22e-5	Menopause (age at onset);
THYM	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.37	-0.55	6.73e-9	Personality dimensions;
THYM	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs8018808	0.935	rs4899654	chr14:77867314	A/C	cg20045696	chr14:77926864	AHSA1	0.53	4.73	0.44	7.91e-6	Myeloid white cell count;
THYM	cis	rs2282930	0.512	rs2237448	chr7:50707858	C/T	cg08586669	chr7:50727761	GRB10	-0.31	-4.68	-0.43	9.37e-6	Bone mineral density;
THYM	cis	rs11190604	1.000	rs74210981	chr10:102287520	C/T	cg16342193	chr10:102329863	NA	-0.47	-4.62	-0.43	1.2e-5	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11760633	0.526	rs11764562	chr7:1827577	T/C	cg27050990	chr7:2629313	IQCE	0.63	4.71	0.44	8.29e-6	Coronary artery disease;
THYM	cis	rs9434723	0.920	rs9434725	chr1:9293861	C/T	cg04199779	chr1:9294473	H6PD	0.79	4.48	0.42	2.12e-5	Height;
THYM	trans	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs11190604	0.943	rs3750632	chr10:102279295	G/C	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs539096	0.607	rs11210871	chr1:44029353	C/G	cg00143623	chr1:44495758	SLC6A9	-0.57	-4.95	-0.45	3.26e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg17294928	chr15:75287854	SCAMP5	-1.01	-9.27	-0.69	6.1e-15	Blood trace element (Zn levels);
THYM	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs986417	1.000	rs4901994	chr14:61090202	C/T	cg27398547	chr14:60952738	C14orf39	1.26	6.1	0.53	2.29e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg06609049	chr19:2785107	THOP1	-1.13	-11.16	-0.75	5.56e-19	Total cholesterol levels;
THYM	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg17757837	chr7:157058334	UBE3C	0.66	5.29	0.48	7.81e-7	Body mass index;
THYM	cis	rs4731207	0.698	rs4731217	chr7:124471889	T/C	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs10799590	1.000	rs1603917	chr1:224827532	C/G	cg01808320	chr1:224927238	CNIH3	0.56	5.11	0.46	1.67e-6	Opioid dependence;
THYM	cis	rs1922291	0.546	rs12472872	chr2:102840844	T/G	cg13315345	chr2:102803985	IL1RL2	0.61	7.0	0.58	3.67e-10	Blood protein levels;
THYM	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg13395646	chr4:1353034	KIAA1530	-0.56	-5.35	-0.48	6.09e-7	Obesity-related traits;
THYM	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.46e-7	Heart rate;
THYM	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg04362960	chr10:104952993	NT5C2	0.58	4.77	0.44	6.61e-6	Arsenic metabolism;
THYM	cis	rs259282	0.538	rs62124303	chr19:33113042	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.63	4.93	0.45	3.5e-6	Schizophrenia;
THYM	cis	rs2135507	0.530	rs34777349	chr4:83521544	A/G	cg10249074	chr4:83542146	C4orf11	-0.59	-4.52	-0.42	1.75e-5	Juvenile osteochondritis dissecans;
THYM	cis	rs2688608	0.698	rs2227578	chr10:75678715	C/T	cg02947784	chr10:75434997	AGAP5	0.49	4.61	0.43	1.26e-5	Inflammatory bowel disease;
THYM	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg25767906	chr1:53392781	SCP2	-0.64	-6.3	-0.54	9.33e-9	Monocyte count;
THYM	cis	rs4662750	0.536	rs4662744	chr2:128350965	C/T	cg01966334	chr2:128378434	MYO7B	0.62	5.52	0.49	2.98e-7	Renal cell carcinoma;
THYM	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg07599136	chr5:415885	AHRR	0.94	5.32	0.48	6.83e-7	Fat distribution (HIV);
THYM	cis	rs7617773	0.743	rs4632568	chr3:48367819	C/T	cg02219026	chr3:48282209	ZNF589	-0.67	-4.69	-0.43	9.05e-6	Coronary artery disease;
THYM	cis	rs4866334	1.000	rs76258230	chr5:18433807	G/C	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg06636001	chr8:8085503	FLJ10661	0.88	9.12	0.68	1.26e-14	Neuroticism;
THYM	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg03209412	chr4:183728196	NA	0.66	5.94	0.52	4.59e-8	Pediatric autoimmune diseases;
THYM	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4523957	0.671	rs9910849	chr17:2175768	A/G	cg16513277	chr17:2031491	SMG6	0.58	4.47	0.42	2.18e-5	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs3862030	0.839	rs7078679	chr10:104284017	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.68	-5.74	-0.51	1.15e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs4638749	0.677	rs115510885	chr2:108824365	C/T	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs6835098	0.924	rs13125240	chr4:174151619	T/C	cg08422745	chr4:174089978	GALNT7	1.0	7.53	0.61	2.88e-11	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	trans	rs17716202	0.826	rs13187546	chr5:55899269	G/A	cg01557754	chr17:7342661	FGF11	0.98	7.0	0.58	3.61e-10	Psychosis in Alzheimer's disease;
THYM	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg05340658	chr4:99064831	C4orf37	0.55	4.65	0.43	1.09e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg27494647	chr7:150038898	RARRES2	0.48	6.0	0.52	3.53e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs56104184	0.887	rs55869333	chr19:49342145	T/G	cg19024700	chr19:49340765	PLEKHA4;HSD17B14	0.64	4.76	0.44	6.88e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg22467129	chr15:76604101	ETFA	-0.51	-4.99	-0.46	2.71e-6	Blood metabolite levels;
THYM	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03264133	chr6:25882463	NA	-0.69	-5.32	-0.48	7.03e-7	Blood metabolite levels;
THYM	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg12893697	chr11:970389	AP2A2	0.31	5.15	0.47	1.4e-6	Alzheimer's disease (late onset);
THYM	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg11764359	chr7:65958608	NA	0.66	5.18	0.47	1.25e-6	Aortic root size;
THYM	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg01579765	chr21:45077557	HSF2BP	0.45	6.87	0.58	6.55e-10	Mean corpuscular volume;
THYM	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg17644776	chr2:200775616	C2orf69	0.8	4.75	0.44	7.1e-6	Schizophrenia;
THYM	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg19626725	chr5:178986131	RUFY1	-0.32	-4.94	-0.45	3.36e-6	Lung cancer;
THYM	cis	rs11948739	0.573	rs736046	chr5:130278613	A/G	cg08523029	chr5:130500466	HINT1	0.76	5.21	0.47	1.11e-6	Pediatric bone mineral content (hip);
THYM	cis	rs55871839	0.708	rs13261666	chr8:59814666	G/T	cg07426533	chr8:59803705	TOX	-0.69	-7.22	-0.6	1.27e-10	Pneumonia;
THYM	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs78707713	0.560	rs61848397	chr10:71225584	C/A	cg08851181	chr10:71228077	TSPAN15	-0.79	-5.86	-0.52	6.58e-8	Venous thromboembolism;
THYM	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg11266682	chr4:10021025	SLC2A9	-0.62	-8.41	-0.65	4.12e-13	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.22	-15.26	-0.84	2.65e-27	Primary sclerosing cholangitis;
THYM	cis	rs55883249	1.000	rs10495571	chr2:9736066	A/G	cg23886495	chr2:9695866	ADAM17	0.79	5.28	0.48	8.14e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs4389656	0.857	rs5001282	chr5:6757668	T/C	cg10857441	chr5:6722123	POLS	-0.43	-4.52	-0.42	1.81e-5	Coronary artery disease;
THYM	cis	rs7178572	0.598	rs907373	chr15:77844554	T/C	cg22256960	chr15:77711686	NA	-0.8	-7.04	-0.59	2.94e-10	Type 2 diabetes;
THYM	cis	rs9467160	0.871	rs9467168	chr6:24449036	A/G	cg20631270	chr6:24437470	GPLD1	0.75	5.95	0.52	4.43e-8	Liver enzyme levels;
THYM	cis	rs6032067	0.714	rs6032076	chr20:43887682	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.38	-4.48	-0.42	2.07e-5	Blood protein levels;
THYM	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg02478829	chr6:26598070	ABT1	-0.33	-4.46	-0.42	2.27e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3820068	0.580	rs12760698	chr1:16009814	G/A	cg13390004	chr1:15929781	NA	0.65	4.89	0.45	4.15e-6	Systolic blood pressure;
THYM	cis	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg07460842	chr6:66804631	NA	-1.25	-15.98	-0.85	1.15e-28	Exhaled nitric oxide output;
THYM	cis	rs240764	0.697	rs370757	chr6:101134156	T/C	cg21058520	chr6:100914733	NA	-0.59	-5.23	-0.47	9.96e-7	Neuroticism;
THYM	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg13877915	chr19:58951672	ZNF132	0.97	9.56	0.7	1.43e-15	Uric acid clearance;
THYM	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg24675056	chr1:15929824	NA	0.72	5.71	0.51	1.26e-7	Systolic blood pressure;
THYM	cis	rs425277	0.958	rs7546523	chr1:2043792	G/A	cg24578937	chr1:2090814	PRKCZ	0.77	7.74	0.62	1.04e-11	Height;
THYM	cis	rs2227564	0.620	rs11000765	chr10:75512452	G/C	cg23231163	chr10:75533350	FUT11	-0.37	-4.72	-0.44	8.23e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg06238570	chr21:40685208	BRWD1	-0.68	-5.74	-0.51	1.15e-7	Menarche (age at onset);
THYM	cis	rs4363385	0.747	rs9659623	chr1:152965158	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.47	-0.42	2.13e-5	Inflammatory skin disease;
THYM	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg17143192	chr8:8559678	CLDN23	0.57	4.66	0.43	1.03e-5	Mood instability;
THYM	cis	rs1011018	0.628	rs73158614	chr7:139436800	G/A	cg06079564	chr7:139468310	HIPK2	-0.72	-4.77	-0.44	6.71e-6	Systolic blood pressure;
THYM	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.67	-5.7	-0.5	1.37e-7	Coronary artery disease;
THYM	cis	rs4595586	0.545	rs9668716	chr12:39378833	G/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs4746818	1.000	rs10762263	chr10:70970178	A/G	cg04149295	chr10:70884716	VPS26A	0.8	5.15	0.47	1.43e-6	Left atrial antero-posterior diameter;
THYM	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg24531977	chr5:56204891	C5orf35	-1.02	-8.69	-0.67	1.06e-13	Initial pursuit acceleration;
THYM	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg02569458	chr12:86230093	RASSF9	-0.65	-5.54	-0.49	2.66e-7	Major depressive disorder;
THYM	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg26354017	chr1:205819088	PM20D1	-0.59	-4.61	-0.43	1.24e-5	Parkinson's disease;
THYM	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg15556689	chr8:8085844	FLJ10661	0.71	5.79	0.51	9.14e-8	Mood instability;
THYM	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg07936489	chr17:37558343	FBXL20	-0.82	-5.65	-0.5	1.7e-7	Lung function (FEV1);
THYM	cis	rs1198430	0.636	rs1009590	chr1:23823798	C/G	cg19827787	chr1:23763612	ASAP3	-0.72	-4.85	-0.45	4.92e-6	Total cholesterol levels;
THYM	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-5.1	-0.46	1.75e-6	Gut microbiome composition (summer);
THYM	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg23758822	chr17:41437982	NA	1.22	11.97	0.78	1.12e-20	Menopause (age at onset);
THYM	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg07157834	chr1:205819609	PM20D1	0.88	8.76	0.67	7.25e-14	Menarche (age at onset);
THYM	cis	rs500891	0.525	rs7758989	chr6:84061319	T/C	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg26384229	chr12:38710491	ALG10B	0.96	7.4	0.6	5.43e-11	Bladder cancer;
THYM	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg04025307	chr7:1156635	C7orf50	0.72	4.46	0.42	2.27e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7582180	0.614	rs10193204	chr2:101004540	A/G	cg08017756	chr2:100939284	LONRF2	0.74	7.6	0.62	2.03e-11	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg07936489	chr17:37558343	FBXL20	-0.89	-5.66	-0.5	1.58e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2806561	0.929	rs2903545	chr1:23541108	C/T	cg19743168	chr1:23544995	NA	-0.66	-7.05	-0.59	2.92e-10	Height;
THYM	cis	rs6674176	0.660	rs2108202	chr1:44395786	A/G	cg13246856	chr1:44399776	ARTN	-0.5	-4.8	-0.44	5.97e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs3026101	0.576	rs56188406	chr17:5316769	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.57	5.19	0.47	1.18e-6	Body mass index;
THYM	cis	rs1267303	0.675	rs2476164	chr1:46985274	T/C	cg16387850	chr1:46982889	NA	0.44	5.6	0.5	2.04e-7	Monobrow;
THYM	cis	rs9876781	1.000	rs2290822	chr3:48473204	A/G	cg06066452	chr3:48470258	PLXNB1	0.27	4.85	0.45	4.78e-6	Longevity;
THYM	cis	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg24375607	chr4:120327624	NA	0.62	5.11	0.46	1.7e-6	Corneal astigmatism;
THYM	cis	rs9902453	0.817	rs9909128	chr17:28161482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.83	6.53	0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg11905131	chr22:24372483	LOC391322	-0.92	-9.99	-0.72	1.73e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3741151	0.656	rs73550316	chr11:73299799	G/A	cg12959048	chr11:73096162	RELT	-0.52	-4.58	-0.43	1.43e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7177699	0.557	rs12898712	chr15:79112622	G/T	cg15571903	chr15:79123663	NA	0.58	6.5	0.55	3.66e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs17030434	0.911	rs75822357	chr4:154738258	T/C	cg14289246	chr4:154710475	SFRP2	-0.89	-6.0	-0.52	3.56e-8	Electrocardiographic conduction measures;
THYM	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg02187348	chr16:89574699	SPG7	0.68	5.34	0.48	6.21e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs7572733	0.534	rs6434943	chr2:198762192	T/G	cg00792783	chr2:198669748	PLCL1	0.84	5.97	0.52	4.15e-8	Dermatomyositis;
THYM	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.5	-4.93	-0.45	3.5e-6	Crohn's disease;
THYM	cis	rs7178572	0.568	rs8037561	chr15:77680462	A/G	cg22256960	chr15:77711686	NA	-1.05	-8.4	-0.65	4.29e-13	Type 2 diabetes;
THYM	cis	rs900145	0.859	rs3993105	chr11:13303071	C/T	cg13286116	chr11:13302098	ARNTL	-0.59	-4.47	-0.42	2.13e-5	Menarche (age at onset);
THYM	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg04362960	chr10:104952993	NT5C2	0.6	5.11	0.46	1.66e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9807841	0.592	rs10419865	chr19:10772685	C/G	cg16900796	chr19:10755136	SLC44A2	0.4	6.3	0.54	9.4e-9	Inflammatory skin disease;
THYM	cis	rs7953508	0.506	rs930316	chr12:93967035	A/G	cg18151635	chr12:93972918	NA	-0.87	-6.12	-0.53	2.07e-8	Pubertal anthropometrics;
THYM	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4930776	0.966	rs1860954	chr12:5765271	A/C	cg02086166	chr12:5775618	ANO2	-0.58	-5.71	-0.51	1.3e-7	Plasma clusterin levels;
THYM	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg08470875	chr2:26401718	FAM59B	-0.74	-4.59	-0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg01097406	chr16:89675127	NA	-0.62	-5.04	-0.46	2.23e-6	Vitiligo;
THYM	cis	rs11711311	0.955	rs10934247	chr3:113534941	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.62	-5.38	-0.48	5.33e-7	IgG glycosylation;
THYM	cis	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg10856724	chr12:34555212	NA	-0.8	-7.01	-0.58	3.46e-10	Morning vs. evening chronotype;
THYM	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg22709100	chr7:91322751	NA	-0.61	-4.78	-0.44	6.46e-6	Breast cancer;
THYM	cis	rs12369179	1.000	rs12369179	chr12:122963550	C/T	cg18578876	chr12:123200353	GPR109B	-1.3	-6.04	-0.53	2.93e-8	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
THYM	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg06784218	chr1:46089804	CCDC17	-0.29	-4.54	-0.42	1.65e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg23649088	chr2:200775458	C2orf69	0.81	6.14	0.53	1.88e-8	Schizophrenia;
THYM	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg15744692	chr15:45671195	LOC145663;GATM	0.44	4.46	0.42	2.22e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs4731207	0.698	rs34618371	chr7:124496170	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs12935418	0.583	rs2549861	chr16:81028304	G/T	cg16651780	chr16:81037892	C16orf61	-0.79	-6.12	-0.53	2.08e-8	Mean corpuscular volume;
THYM	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg18252515	chr7:66147081	NA	0.64	4.69	0.43	9.21e-6	Aortic root size;
THYM	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg05738196	chr6:26577821	NA	0.57	4.7	0.43	8.72e-6	Schizophrenia;
THYM	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg02527881	chr3:46936655	PTH1R	-0.65	-6.55	-0.56	2.97e-9	Colorectal cancer;
THYM	cis	rs7681440	0.583	rs2737022	chr4:90739662	A/C	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg09537434	chr19:41945824	ATP5SL	1.06	9.81	0.71	4.27e-16	Height;
THYM	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg06636001	chr8:8085503	FLJ10661	0.79	7.22	0.6	1.28e-10	Mood instability;
THYM	cis	rs1981331	0.609	rs77725404	chr21:48080376	C/T	cg17243659	chr21:48055224	PRMT2	1.36	6.3	0.54	9.09e-9	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs7107174	1.000	rs4945274	chr11:78109260	G/A	cg02023728	chr11:77925099	USP35	0.63	6.11	0.53	2.23e-8	Testicular germ cell tumor;
THYM	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg00376283	chr12:123451042	ABCB9	0.73	4.97	0.45	2.96e-6	Neutrophil percentage of white cells;
THYM	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg15164180	chr2:241846931	NA	-0.33	-4.55	-0.42	1.6e-5	Urinary metabolites;
THYM	cis	rs2219968	0.669	rs10099742	chr8:78871804	C/G	cg00738934	chr8:78996279	NA	-0.83	-8.56	-0.66	1.94e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7762018	0.556	rs78864023	chr6:170059755	T/A	cg19338460	chr6:170058176	WDR27	-1.04	-6.21	-0.54	1.42e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs2652822	0.571	rs62012880	chr15:63527162	A/G	cg09251291	chr15:63483946	RAB8B	0.59	5.18	0.47	1.22e-6	Metabolic traits;
THYM	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg05552183	chr6:42928497	GNMT	0.72	5.99	0.52	3.66e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.25	-4.99	-0.46	2.73e-6	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs1372520	0.684	rs356188	chr4:90691537	T/C	cg01966878	chr4:90757139	SNCA	0.59	4.52	0.42	1.75e-5	Neuroticism;
THYM	cis	rs2658782	0.526	rs3020062	chr11:93061159	T/C	cg02384510	chr11:93059814	NA	-0.48	-4.6	-0.43	1.28e-5	Pulmonary function decline;
THYM	cis	rs7772486	0.641	rs960385	chr6:146371074	G/A	cg23711669	chr6:146136114	FBXO30	0.85	7.94	0.63	4.02e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1448094	0.511	rs4492889	chr12:86146735	C/A	cg00310523	chr12:86230176	RASSF9	-0.57	-5.07	-0.46	1.98e-6	Major depressive disorder;
THYM	cis	rs7043114	0.525	rs2516567	chr9:95187418	C/T	cg14631576	chr9:95140430	CENPP	-0.82	-8.34	-0.65	5.87e-13	Height;
THYM	cis	rs9902453	0.967	rs61014003	chr17:28485233	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	4.6	0.43	1.33e-5	Coffee consumption (cups per day);
THYM	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg10053473	chr17:62856997	LRRC37A3	0.95	7.29	0.6	9.32e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs362272	0.524	rs13150241	chr4:3367281	A/G	cg14583973	chr4:3374767	RGS12	0.68	6.61	0.56	2.24e-9	Serum sulfate level;
THYM	cis	rs514406	0.928	rs1672917	chr1:53291550	A/G	cg22166914	chr1:53195759	ZYG11B	0.8	8.11	0.64	1.78e-12	Monocyte count;
THYM	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg22907277	chr7:1156413	C7orf50	0.83	5.1	0.46	1.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg22718636	chr4:961658	DGKQ	0.58	4.53	0.42	1.7e-5	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
THYM	cis	rs13177918	0.651	rs13184111	chr5:149814212	C/T	cg14059543	chr5:149831962	NA	-0.99	-7.41	-0.6	5.27e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7246657	0.943	rs10417844	chr19:37837587	C/T	cg22634378	chr19:37742834	NA	0.65	5.34	0.48	6.2e-7	Coronary artery calcification;
THYM	cis	rs2282300	0.739	rs34855782	chr11:30225470	G/A	cg06241208	chr11:30344200	C11orf46	-0.74	-5.38	-0.48	5.44e-7	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs34112283	0.592	rs35645933	chr2:144169416	C/G	cg17056048	chr2:144271431	ARHGAP15	0.63	6.09	0.53	2.41e-8	Neuroticism;
THYM	cis	rs4474465	0.920	rs10899527	chr11:78207394	A/G	cg19901956	chr11:77921274	USP35	0.65	4.8	0.44	5.97e-6	Alzheimer's disease (survival time);
THYM	cis	rs7104764	1.000	rs6598074	chr11:219398	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.11	9.57	0.7	1.4e-15	Menarche (age at onset);
THYM	cis	rs72627123	0.749	rs117292950	chr14:74306527	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	5.52	0.49	2.9e-7	Morning vs. evening chronotype;
THYM	cis	rs259282	0.518	rs259257	chr19:33152296	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.95	6.43	0.55	5.12e-9	Schizophrenia;
THYM	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.49	4.56	0.42	1.53e-5	Birth weight;
THYM	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg23682913	chr1:2080710	PRKCZ	-0.57	-5.0	-0.46	2.57e-6	Height;
THYM	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg26384229	chr12:38710491	ALG10B	-0.89	-9.06	-0.68	1.67e-14	Heart rate;
THYM	cis	rs870825	1.000	rs72689245	chr4:185579788	G/A	cg04058563	chr4:185651563	MLF1IP	1.0	6.98	0.58	3.96e-10	Blood protein levels;
THYM	cis	rs3741151	0.686	rs7125598	chr11:73160589	C/T	cg17517138	chr11:73019481	ARHGEF17	-0.73	-4.66	-0.43	1.03e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg16145915	chr7:1198662	ZFAND2A	0.42	5.1	0.46	1.7e-6	Longevity;Endometriosis;
THYM	cis	rs4786125	0.587	rs6500861	chr16:6923966	A/G	cg03623568	chr16:6915990	A2BP1	-1.0	-9.83	-0.71	3.85e-16	Heart rate variability traits (SDNN);
THYM	cis	rs885814	1.000	rs2840331	chr1:21861656	A/G	cg14781605	chr1:21864896	ALPL	0.67	5.34	0.48	6.37e-7	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg07936489	chr17:37558343	FBXL20	-0.7	-4.91	-0.45	3.82e-6	Asthma;
THYM	cis	rs752010	0.806	rs1109255	chr1:42091708	C/T	cg06885757	chr1:42089581	HIVEP3	0.55	6.52	0.56	3.4e-9	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg27286337	chr10:134555280	INPP5A	0.95	7.78	0.62	8.82e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg27572855	chr1:25598939	RHD	-0.67	-5.06	-0.46	2.03e-6	Erythrocyte sedimentation rate;
THYM	cis	rs4523957	0.614	rs2316512	chr17:2064710	A/T	cg16513277	chr17:2031491	SMG6	-0.94	-8.37	-0.65	5.05e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6032067	0.929	rs2664581	chr20:43804522	A/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.7	-7.67	-0.62	1.48e-11	Blood protein levels;
THYM	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs25645	0.502	rs7209742	chr17:38108708	A/G	cg24910161	chr17:38119198	GSDMA	-0.58	-6.31	-0.54	8.93e-9	Myeloid white cell count;
THYM	cis	rs6700896	0.931	rs12042779	chr1:66133950	T/C	cg04111102	chr1:66153794	NA	0.56	5.27	0.48	8.45e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs786425	0.530	rs7397745	chr12:124218026	A/G	cg15249119	chr12:124971054	NCOR2	0.53	4.98	0.46	2.8e-6	Pubertal anthropometrics;
THYM	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs72960926	0.744	rs56405366	chr6:75035257	T/C	cg03266952	chr6:74778945	NA	-0.86	-4.52	-0.42	1.78e-5	Metabolite levels (MHPG);
THYM	cis	rs6087990	0.842	rs4911105	chr20:31330413	G/A	cg13636640	chr20:31349939	DNMT3B	0.92	9.68	0.7	8.12e-16	Ulcerative colitis;
THYM	cis	rs2898681	0.614	rs28758563	chr4:53677777	C/T	cg21521518	chr4:53727714	RASL11B	0.5	5.34	0.48	6.44e-7	Optic nerve measurement (cup area);
THYM	cis	rs425277	1.000	rs262641	chr1:2104981	C/T	cg24578937	chr1:2090814	PRKCZ	-0.79	-8.04	-0.64	2.48e-12	Height;
THYM	cis	rs911119	1.000	rs734801	chr20:23612791	A/G	cg16589663	chr20:23618590	CST3	0.78	4.77	0.44	6.71e-6	Chronic kidney disease;
THYM	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-4.95	-0.45	3.19e-6	Schizophrenia;
THYM	cis	rs892961	0.899	rs3650	chr17:75415835	T/C	cg11351908	chr17:75402473	SEPT9	0.56	5.52	0.49	2.95e-7	Airflow obstruction;
THYM	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg01483505	chr11:975446	AP2A2	0.58	4.85	0.45	4.9100000000000004e-06	Alzheimer's disease (late onset);
THYM	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg03676636	chr4:99064102	C4orf37	0.38	5.2	0.47	1.13e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7580658	0.637	rs4580338	chr2:127974937	T/C	cg18942985	chr2:128523110	WDR33	-0.47	-4.5	-0.42	1.92e-5	Protein C levels;
THYM	cis	rs514406	0.825	rs1242328	chr1:53396869	A/G	cg08736216	chr1:53307985	ZYG11A	-0.6	-5.56	-0.5	2.5e-7	Monocyte count;
THYM	cis	rs12310956	0.532	rs11052922	chr12:33957476	A/G	cg10856724	chr12:34555212	NA	-0.72	-6.65	-0.56	1.82e-9	Morning vs. evening chronotype;
THYM	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.41	7.1	0.59	2.3e-10	Obesity-related traits;
THYM	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg27211696	chr2:191398769	TMEM194B	0.85	8.79	0.67	6.5e-14	Pulse pressure;
THYM	cis	rs6906287	0.647	rs6569013	chr6:118681328	G/T	cg21191810	chr6:118973309	C6orf204	-0.58	-5.09	-0.46	1.84e-6	Electrocardiographic conduction measures;
THYM	cis	rs10779751	1.000	rs12124983	chr1:11286178	C/T	cg08854313	chr1:11322531	MTOR	-1.03	-9.64	-0.7	9.79e-16	Body mass index;
THYM	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg00256281	chr22:41985642	PMM1	0.63	5.06	0.46	2.04e-6	Vitiligo;
THYM	cis	rs28595532	0.920	rs56389935	chr4:119683571	G/A	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs6547741	1.000	rs6718128	chr2:27833752	A/G	cg27432699	chr2:27873401	GPN1	-0.68	-5.97	-0.52	4.14e-8	Oral cavity cancer;
THYM	cis	rs11166927	1.000	rs11166926	chr8:140795752	A/G	cg16909799	chr8:140841666	TRAPPC9	0.6	5.17	0.47	1.3e-6	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg17845761	chr1:175162550	KIAA0040	-0.36	-4.57	-0.42	1.45e-5	Alcohol dependence;
THYM	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg17849569	chr6:28058911	ZSCAN12L1	0.79	4.79	0.44	6.17e-6	Depression;
THYM	cis	rs8114671	0.967	rs1415773	chr20:33765585	G/A	cg08999081	chr20:33150536	PIGU	0.53	4.77	0.44	6.63e-6	Height;
THYM	cis	rs7119	0.667	rs907392	chr15:77903393	T/C	cg27398640	chr15:77910606	LINGO1	0.68	8.73	0.67	8.58e-14	Type 2 diabetes;
THYM	cis	rs470093	0.866	rs80628	chr22:44245179	G/T	cg09142166	chr22:44276013	PNPLA5	-0.6	-5.77	-0.51	9.87e-8	Staphylococcus aureus infection;
THYM	cis	rs6674176	0.542	rs803675	chr1:44353237	G/A	cg13246856	chr1:44399776	ARTN	0.48	4.62	0.43	1.19e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg07343612	chr16:622815	PIGQ	-1.08	-10.52	-0.73	1.28e-17	Height;
THYM	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg24846343	chr22:24311635	DDTL	0.44	5.47	0.49	3.59e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9733	0.526	rs11204696	chr1:150658721	T/C	cg04414720	chr1:150670196	GOLPH3L	0.62	4.58	0.43	1.41e-5	Tonsillectomy;
THYM	cis	rs2625529	0.652	rs12148078	chr15:72300471	G/C	cg16672083	chr15:72433130	SENP8	0.51	4.67	0.43	9.89e-6	Red blood cell count;
THYM	cis	rs710865	0.527	rs2275403	chr1:19557713	C/G	cg13387374	chr1:19411106	UBR4	-0.59	-4.63	-0.43	1.15e-5	Brain structure;
THYM	cis	rs714027	1.000	rs714027	chr22:30577771	A/G	cg11564601	chr22:30592435	NA	0.31	5.57	0.5	2.32e-7	Lymphocyte counts;
THYM	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg26441486	chr22:50317300	CRELD2	0.42	7.41	0.61	5.09e-11	Schizophrenia;
THYM	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg27129171	chr3:47204927	SETD2	-0.7	-6.73	-0.57	1.3e-9	Colorectal cancer;
THYM	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.62	5.61	0.5	2.01e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg23989207	chr17:80870107	TBCD	0.63	5.35	0.48	6.17e-7	Glycated hemoglobin levels;
THYM	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg12560992	chr17:57184187	TRIM37	0.66	4.49	0.42	2.01e-5	Cognitive test performance;
THYM	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	14.47	0.83	9.53e-26	Chronic sinus infection;
THYM	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg06108461	chr20:60628389	TAF4	-1.06	-9.1	-0.68	1.39e-14	Body mass index;
THYM	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg18876405	chr7:65276391	NA	0.61	5.2	0.47	1.13e-6	Aortic root size;
THYM	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg22974920	chr21:40686053	BRWD1	-0.58	-4.58	-0.43	1.4e-5	Cognitive function;
THYM	cis	rs2461751	0.527	rs80242318	chr2:176487179	G/A	cg05500840	chr2:176972068	HOXD11	0.85	4.66	0.43	1.03e-5	Electrocardiographic conduction measures;
THYM	cis	rs7267979	0.934	rs2261115	chr20:25259807	G/A	cg08601574	chr20:25228251	PYGB	0.57	4.56	0.42	1.55e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2404602	0.735	rs12906143	chr15:76709523	T/A	cg23482746	chr15:76478102	C15orf27	0.47	4.61	0.43	1.25e-5	Blood metabolite levels;
THYM	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg06481639	chr22:41940642	POLR3H	-0.73	-4.81	-0.44	5.71e-6	Vitiligo;
THYM	cis	rs2710642	0.861	rs2710644	chr2:63248968	A/C	cg17519650	chr2:63277830	OTX1	0.71	4.87	0.45	4.37e-6	LDL cholesterol levels;LDL cholesterol;
THYM	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg27286337	chr10:134555280	INPP5A	0.98	7.48	0.61	3.62e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg19016782	chr12:123741754	C12orf65	0.69	4.47	0.42	2.18e-5	Neutrophil percentage of white cells;
THYM	cis	rs7772486	0.875	rs969694	chr6:146394655	A/G	cg05347473	chr6:146136440	FBXO30	0.6	4.81	0.44	5.7e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9733	0.519	rs6700022	chr1:150670484	G/T	cg10589385	chr1:150898437	SETDB1	-0.66	-5.58	-0.5	2.27e-7	Tonsillectomy;
THYM	cis	rs6032067	1.000	rs62205501	chr20:43864089	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg17054759	chr22:49844102	NA	-0.52	-4.72	-0.44	8.24e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.44	-7.54	-0.61	2.77e-11	Obesity-related traits;
THYM	cis	rs7512552	0.839	rs1260421	chr1:150357780	G/A	cg15654264	chr1:150340011	RPRD2	0.45	5.2	0.47	1.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	4.66	0.43	1.04e-5	Diabetic retinopathy;
THYM	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg10518543	chr12:38710700	ALG10B	-0.55	-4.5	-0.42	1.93e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg11812906	chr14:75593930	NEK9	0.84	7.66	0.62	1.58e-11	Height;
THYM	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg12863693	chr15:85201151	NMB	0.63	5.49	0.49	3.38e-7	Schizophrenia;
THYM	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg10802521	chr3:52805072	NEK4	-0.74	-6.49	-0.55	3.86e-9	Bipolar disorder;
THYM	cis	rs478304	0.593	rs75162774	chr11:65492483	G/A	cg17480646	chr11:65405466	SIPA1	-0.94	-8.68	-0.67	1.08e-13	Acne (severe);
THYM	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg00129232	chr17:37814104	STARD3	-0.9	-7.1	-0.59	2.26e-10	Asthma;
THYM	cis	rs17407555	0.821	rs73215081	chr4:10137326	C/G	cg11266682	chr4:10021025	SLC2A9	-0.6	-5.79	-0.51	8.88e-8	Schizophrenia (age at onset);
THYM	cis	rs3820068	0.608	rs12092485	chr1:16048038	A/G	cg27534772	chr1:16042836	PLEKHM2	0.48	4.99	0.46	2.71e-6	Systolic blood pressure;
THYM	cis	rs10791111	1	rs10791111	chr11:130856099	T/G	cg23692386	chr11:131799662	NTM	0.49	5.07	0.46	1.93e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg20608306	chr11:116969690	SIK3	-0.52	-5.64	-0.5	1.78e-7	Blood protein levels;
THYM	cis	rs9515201	0.859	rs9515199	chr13:111033704	C/T	cg26053697	chr13:111039873	COL4A2	-0.56	-4.56	-0.42	1.53e-5	White matter hyperintensity burden;
THYM	cis	rs113835537	0.529	rs2305532	chr11:66298594	C/T	cg24851651	chr11:66362959	CCS	0.71	4.84	0.44	4.96e-6	Airway imaging phenotypes;
THYM	cis	rs9896052	0.649	rs6501798	chr17:73444647	C/T	cg27112972	chr17:74378252	NA	0.55	4.49	0.42	2e-5	Sight-threatening diabetic retinopathy in type 2 diabetes;
THYM	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg15704280	chr7:45808275	SEPT13	-1.0	-8.07	-0.64	2.18e-12	Height;
THYM	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg01304814	chr3:48885189	PRKAR2A	0.89	4.66	0.43	1.03e-5	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg06009448	chr7:1102226	C7orf50	0.52	5.51	0.49	3.01e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg17143192	chr8:8559678	CLDN23	-0.65	-5.13	-0.47	1.56e-6	Neuroticism;
THYM	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg04865290	chr3:52927548	TMEM110	-0.89	-4.65	-0.43	1.08e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05901451	chr6:126070800	HEY2	-0.68	-5.92	-0.52	5.07e-8	Brugada syndrome;
THYM	trans	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg23505145	chr19:12996616	KLF1	1.01	9.96	0.71	1.99e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8028313	0.630	rs12900208	chr15:67963058	C/G	cg24579218	chr15:68104479	NA	-0.66	-6.08	-0.53	2.52e-8	Obesity;
THYM	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg18135555	chr8:22132992	PIWIL2	0.55	4.64	0.43	1.12e-5	Hypertriglyceridemia;
THYM	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg26963428	chr7:66367121	NA	-0.59	-4.72	-0.44	8.08e-6	Corneal structure;
THYM	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs8073060	0.671	rs9894813	chr17:33873848	C/T	cg19694781	chr19:47549865	TMEM160	0.77	7.0	0.58	3.65e-10	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7586879	0.929	rs6545808	chr2:25124388	C/A	cg01884057	chr2:25150051	NA	0.65	6.42	0.55	5.27e-9	Body mass index;
THYM	cis	rs1050631	0.564	rs1785905	chr18:33713287	T/A	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.6	4.69	0.43	9.09e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs9527	0.590	rs10883836	chr10:104891198	T/C	cg15744005	chr10:104629667	AS3MT	-0.59	-4.48	-0.42	2.12e-5	Arsenic metabolism;
THYM	cis	rs9393692	0.620	rs9393696	chr6:26291591	T/C	cg13736514	chr6:26305472	NA	-0.47	-4.87	-0.45	4.39e-6	Educational attainment;
THYM	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11890956	chr21:40555474	PSMG1	1.17	13.11	0.8	4.95e-23	Cognitive function;
THYM	cis	rs1267303	0.798	rs1267302	chr1:46990545	G/C	cg25110126	chr1:46999211	NA	-0.74	-5.28	-0.48	8.22e-7	Monobrow;
THYM	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg12863693	chr15:85201151	NMB	0.62	5.39	0.48	5.18e-7	Schizophrenia;
THYM	cis	rs7408868	1.000	rs7247906	chr19:15271135	T/G	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.75	5.13	0.47	1.55e-6	Height;
THYM	cis	rs12310956	0.532	rs11052935	chr12:33970946	C/T	cg06521331	chr12:34319734	NA	-0.92	-8.57	-0.66	1.89e-13	Morning vs. evening chronotype;
THYM	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg08859206	chr1:53392774	SCP2	-0.81	-9.43	-0.7	2.78e-15	Monocyte count;
THYM	cis	rs7084402	0.967	rs1649055	chr10:60320045	T/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.47	-0.49	3.63e-7	Refractive error;
THYM	cis	rs149313	0.577	rs26506	chr5:96079402	C/T	cg24982541	chr5:96078678	CAST	-0.42	-4.96	-0.45	3.13e-6	Blood protein levels;
THYM	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg08000102	chr2:233561755	GIGYF2	-0.54	-4.77	-0.44	6.59e-6	Coronary artery disease;
THYM	trans	rs8073060	0.544	rs17550716	chr17:33893208	A/G	cg19694781	chr19:47549865	TMEM160	0.96	8.32	0.65	6.47e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	13.34	0.81	1.71e-23	Height;
THYM	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg20891558	chr2:74357851	NA	1.19	12.34	0.78	1.92e-21	Gestational age at birth (maternal effect);
THYM	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.58	4.95	0.45	3.25e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.64	0.43	1.1e-5	Bipolar disorder;
THYM	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg03597347	chr6:28058909	ZSCAN12L1	0.62	4.55	0.42	1.62e-5	Cardiac Troponin-T levels;
THYM	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg26384229	chr12:38710491	ALG10B	-0.75	-6.0	-0.52	3.55e-8	Morning vs. evening chronotype;
THYM	cis	rs924712	0.677	rs181155	chr6:54752693	C/T	cg04690482	chr6:54711388	FAM83B	0.45	5.37	0.48	5.53e-7	Breast cancer;
THYM	cis	rs11096990	0.892	rs3733288	chr4:39218569	G/T	cg24403649	chr4:39172243	NA	-0.68	-5.74	-0.51	1.13e-7	Cognitive function;
THYM	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg01097406	chr16:89675127	NA	0.63	5.52	0.49	2.96e-7	Vitiligo;
THYM	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg24874828	chr4:187887005	NA	-0.75	-7.9	-0.63	4.98e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12667521	chr19:29218732	NA	0.88	7.82	0.63	7.26e-12	Methadone dose in opioid dependence;
THYM	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9394152	0.845	rs9296092	chr6:33478496	C/T	cg13560919	chr6:33536144	NA	-0.73	-6.54	-0.56	3.13e-9	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg00228476	chr11:92617656	FAT3	-0.75	-4.71	-0.44	8.45e-6	Subcortical brain region volumes;
THYM	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg12698349	chr2:225449008	CUL3	0.73	5.47	0.49	3.64e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg01448562	chr3:133502909	NA	-0.97	-8.3	-0.65	6.86e-13	Iron status biomarkers;
THYM	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg25588787	chr5:154027256	NA	0.9	4.6	0.43	1.32e-5	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs4819143	0.517	rs439145	chr21:47373995	G/A	cg20357416	chr21:47294739	PCBP3	0.72	4.72	0.44	8.24e-6	Insulin resistance/response;
THYM	cis	rs57920188	0.640	rs10915600	chr1:4082105	T/G	cg20703997	chr1:4087676	NA	0.91	6.1	0.53	2.24e-8	Interleukin-17 levels;
THYM	cis	rs4242434	0.597	rs876714	chr8:22482799	A/G	cg01710189	chr8:22454888	PDLIM2	-0.51	-5.2	-0.47	1.15e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg08133631	chr1:26527909	CATSPER4	-0.59	-4.94	-0.45	3.38e-6	Obesity-related traits;
THYM	cis	rs34779708	0.771	rs12098283	chr10:35478115	G/T	cg03585969	chr10:35415529	CREM	0.68	4.74	0.44	7.51e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg22681709	chr2:178499509	PDE11A	-0.59	-5.11	-0.46	1.65e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs12190007	0.508	rs6605539	chr6:169731997	A/T	cg16388071	chr6:169726476	NA	0.7	5.99	0.52	3.72e-8	Obesity-related traits;
THYM	cis	rs11089937	0.651	rs928894	chr22:22540272	T/C	cg06866756	chr22:22471216	NA	-0.46	-5.28	-0.48	8.24e-7	Periodontitis (PAL4Q3);
THYM	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg14820908	chr5:178986412	RUFY1	0.55	5.41	0.49	4.76e-7	Lung cancer;
THYM	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg03806693	chr22:41940476	POLR3H	1.1	8.83	0.67	5.2e-14	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9810089	0.903	rs711975	chr3:136235908	T/C	cg21827317	chr3:136751795	NA	0.57	4.87	0.45	4.42e-6	Gestational age at birth (child effect);
THYM	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg12935359	chr14:103987150	CKB	-0.64	-6.25	-0.54	1.15e-8	Body mass index;
THYM	cis	rs887829	0.569	rs4294999	chr2:234635467	A/G	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.61	-0.43	1.24e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs7572733	0.534	rs13026569	chr2:198783330	C/G	cg05783139	chr2:198650985	BOLL	-0.62	-4.91	-0.45	3.8e-6	Dermatomyositis;
THYM	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.92	-6.03	-0.53	3.11e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.88	0.63	5.43e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg22709100	chr7:91322751	NA	0.63	4.86	0.45	4.55e-6	Breast cancer;
THYM	trans	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg03865648	chr3:173113856	NA	0.95	6.86	0.58	7.03e-10	Lung adenocarcinoma;
THYM	cis	rs8192282	0.739	rs6656395	chr1:154500016	T/C	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg02527881	chr3:46936655	PTH1R	0.57	5.22	0.47	1.04e-6	Colorectal cancer;
THYM	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg10047753	chr17:41438598	NA	0.98	8.23	0.65	9.67e-13	Menopause (age at onset);
THYM	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22496380	chr5:211416	CCDC127	-1.31	-8.26	-0.65	8.38e-13	Breast cancer;
THYM	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg11494091	chr17:61959527	GH2	0.71	6.01	0.52	3.47e-8	Height;
THYM	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.15	14.79	0.83	2.2e-26	Chronic sinus infection;
THYM	cis	rs1050631	0.592	rs1785933	chr18:33719191	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.32	0.48	6.94e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs995000	0.965	rs1690761	chr1:62955862	C/T	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg24250549	chr1:154909240	PMVK	-0.79	-7.03	-0.59	3.09e-10	Prostate cancer;
THYM	cis	rs6430585	0.528	rs309113	chr2:136737460	C/A	cg23851026	chr2:136556271	LCT	0.68	6.64	0.56	1.94e-9	Corneal structure;
THYM	cis	rs6686842	1.000	rs213754	chr1:41598848	G/T	cg03387723	chr1:41708464	SCMH1	0.44	5.27	0.48	8.4e-7	Height;
THYM	cis	rs7107174	1.000	rs2511171	chr11:77930935	G/A	cg02023728	chr11:77925099	USP35	0.75	6.63	0.56	2.04e-9	Testicular germ cell tumor;
THYM	cis	rs36051895	0.632	rs10974984	chr9:5150427	T/C	cg02405213	chr9:5042618	JAK2	-1.05	-11.21	-0.75	4.42e-19	Pediatric autoimmune diseases;
THYM	cis	rs3087591	1.000	rs2953015	chr17:29495341	A/G	cg24425628	chr17:29625626	OMG;NF1	0.65	5.69	0.5	1.38e-7	Hip circumference;
THYM	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg05890377	chr2:74357713	NA	1.08	10.15	0.72	7.89e-17	Gestational age at birth (maternal effect);
THYM	cis	rs1497406	0.744	rs1007887	chr1:16509029	C/T	cg20430773	chr1:16534157	ARHGEF19	0.49	5.51	0.49	3.02e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10489202	0.608	rs16828093	chr1:168078384	C/T	cg24449463	chr1:168025552	DCAF6	-0.78	-7.4	-0.6	5.43e-11	Schizophrenia;
THYM	cis	rs2229238	0.911	rs112394421	chr1:154512008	T/C	cg21262032	chr1:154437693	IL6R	-0.64	-5.79	-0.51	8.9e-8	Coronary heart disease;
THYM	cis	rs365132	1.000	rs353464	chr5:176403023	A/G	cg17809377	chr5:176326619	HK3	-0.3	-4.55	-0.42	1.59e-5	Menarche and menopause (age at onset);Menopause (age at onset);
THYM	cis	rs2130392	0.961	rs2696035	chr4:185612953	A/G	cg04058563	chr4:185651563	MLF1IP	0.57	5.27	0.48	8.66e-7	Kawasaki disease;
THYM	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg03476357	chr21:30257390	N6AMT1	0.58	4.53	0.42	1.7e-5	Dental caries;
THYM	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg23791538	chr6:167370224	RNASET2	0.72	5.66	0.5	1.58e-7	Crohn's disease;
THYM	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg03388025	chr16:89894329	SPIRE2	0.52	4.57	0.42	1.45e-5	Vitiligo;
THYM	cis	rs55882075	0.750	rs13184690	chr5:179146993	T/C	cg14593053	chr5:179126677	CANX	0.62	4.75	0.44	7.1e-6	Monocyte percentage of white cells;
THYM	cis	rs10256972	0.678	rs6962989	chr7:1017512	G/A	cg08883853	chr7:1026168	CYP2W1	-0.71	-4.91	-0.45	3.76e-6	Longevity;Endometriosis;
THYM	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg12963246	chr6:28129442	ZNF389	0.72	6.12	0.53	2.05e-8	Depression;
THYM	cis	rs7172809	0.897	rs78412727	chr15:77827185	A/G	cg22256960	chr15:77711686	NA	-0.67	-4.61	-0.43	1.27e-5	Glucose homeostasis traits;
THYM	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg12893697	chr11:970389	AP2A2	-0.31	-5.15	-0.47	1.42e-6	Alzheimer's disease (late onset);
THYM	cis	rs11792861	0.546	rs7873569	chr9:111796753	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	5.09	0.46	1.84e-6	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3126085	0.935	rs4361987	chr1:152229701	A/G	cg10321714	chr1:152280068	FLG	0.67	5.14	0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs1538970	0.816	rs12029322	chr1:45970446	C/T	cg05343316	chr1:45956843	TESK2	0.85	5.45	0.49	3.93e-7	Platelet count;
THYM	cis	rs986417	0.901	rs1950310	chr14:60988526	T/A	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs600806	0.850	rs10745354	chr1:109931908	C/T	cg23032129	chr1:109941072	SORT1	-0.59	-5.03	-0.46	2.31e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg06238570	chr21:40685208	BRWD1	-0.96	-9.14	-0.68	1.13e-14	Cognitive function;
THYM	cis	rs11118993	1.000	rs11118993	chr1:206715851	A/G	cg19452316	chr1:206680966	RASSF5	0.63	5.15	0.47	1.43e-6	Neurofibrillary tangles;
THYM	cis	rs921665	0.749	rs2368682	chr2:3197387	C/T	cg16434511	chr2:3151078	NA	-0.87	-5.44	-0.49	4.16e-7	World class endurance athleticism;
THYM	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	4.98	0.45	2.88e-6	Schizophrenia;
THYM	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08704250	chr15:31115839	NA	-0.65	-7.42	-0.61	4.86e-11	Huntington's disease progression;
THYM	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg05182265	chr7:156933206	UBE3C	-0.69	-9.34	-0.69	4.32e-15	Body mass index;
THYM	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg00147160	chr1:26503991	CNKSR1	0.53	7.08	0.59	2.42e-10	Height;
THYM	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg22920501	chr2:26401640	FAM59B	-0.8	-7.26	-0.6	1.08e-10	Gut microbiome composition (summer);
THYM	cis	rs7267979	1.000	rs447722	chr20:25443510	C/T	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg13789015	chr9:136890014	NCRNA00094	0.84	7.22	0.6	1.29e-10	Platelet distribution width;
THYM	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg20503657	chr10:835505	NA	1.15	8.11	0.64	1.78e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg26384229	chr12:38710491	ALG10B	-0.93	-7.72	-0.62	1.16e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg08132940	chr7:1081526	C7orf50	-1.15	-6.58	-0.56	2.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1448094	0.512	rs12314318	chr12:86249238	T/C	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs2976388	1.000	rs2920297	chr8:143763083	A/G	cg13446199	chr8:143762866	PSCA	0.51	6.42	0.55	5.46e-9	Urinary tract infection frequency;
THYM	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg15164180	chr2:241846931	NA	-0.34	-4.63	-0.43	1.15e-5	Urinary metabolites;
THYM	cis	rs1451375	0.669	rs59086818	chr7:50653830	G/A	cg18232548	chr7:50535776	DDC	0.69	5.35	0.48	6.03e-7	Malaria;
THYM	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg11764359	chr7:65958608	NA	0.66	4.59	0.43	1.38e-5	Aortic root size;
THYM	cis	rs1165472	0.755	rs6669971	chr1:56155543	A/G	cg11523071	chr1:56160889	NA	-0.44	-4.66	-0.43	1.03e-5	Paclitaxel-induced neuropathy;
THYM	cis	rs4900538	0.963	rs4906205	chr14:102932447	A/G	cg18135206	chr14:102964638	TECPR2	0.98	8.23	0.65	9.92e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg12615879	chr12:58013172	SLC26A10	0.57	5.41	0.49	4.71e-7	Multiple sclerosis;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg12128740	chr1:62207888	INADL	1.03	7.18	0.59	1.51e-10	Depressive symptoms;
THYM	cis	rs7172809	0.599	rs74026910	chr15:77728444	G/C	cg22256960	chr15:77711686	NA	-0.62	-4.57	-0.42	1.45e-5	Glucose homeostasis traits;
THYM	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg08885076	chr2:99613938	TSGA10	0.66	5.97	0.52	4.17e-8	Chronic sinus infection;
THYM	trans	rs916888	0.779	rs199526	chr17:44847707	C/G	cg07870213	chr5:140052090	DND1	-0.63	-7.71	-0.62	1.23e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg04320152	chr17:18167836	SMCR7	0.62	4.81	0.44	5.7e-6	Total body bone mineral density;
THYM	cis	rs754466	0.580	rs10824571	chr10:79531931	G/A	cg17075019	chr10:79541650	NA	-0.69	-5.73	-0.51	1.17e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3126085	0.935	rs11204967	chr1:152249720	A/G	cg26020982	chr1:152196106	HRNR	-0.33	-4.64	-0.43	1.09e-5	Atopic dermatitis;
THYM	cis	rs752010	0.662	rs10890154	chr1:42106740	C/T	cg06885757	chr1:42089581	HIVEP3	0.44	4.99	0.46	2.78e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs55788414	0.872	rs12102958	chr16:81186207	T/A	cg06400318	chr16:81190750	PKD1L2	-0.85	-4.61	-0.43	1.28e-5	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs4713118	0.869	rs6914924	chr6:27711530	C/T	cg12963246	chr6:28129442	ZNF389	0.64	4.86	0.45	4.62e-6	Parkinson's disease;
THYM	cis	rs10819861	0.621	rs7046587	chr9:98847387	C/T	cg14508093	chr9:98862825	NA	-0.24	-4.64	-0.43	1.11e-5	Electrocardiographic traits;
THYM	cis	rs8048589	0.615	rs34147612	chr16:12233188	G/A	cg02910054	chr16:12241554	SNX29	0.84	7.03	0.58	3.19e-10	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg26384229	chr12:38710491	ALG10B	0.9	7.73	0.62	1.12e-11	Bladder cancer;
THYM	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg14416269	chr4:6271139	WFS1	0.52	5.33	0.48	6.52e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg05182265	chr7:156933206	UBE3C	0.63	7.88	0.63	5.39e-12	Body mass index;
THYM	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg08975724	chr8:8085496	FLJ10661	-0.65	-5.02	-0.46	2.38e-6	Mood instability;
THYM	cis	rs36051895	0.659	rs7046077	chr9:5045328	C/G	cg02405213	chr9:5042618	JAK2	-1.05	-10.84	-0.74	2.65e-18	Pediatric autoimmune diseases;
THYM	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-6.65	-0.56	1.84e-9	Chronic sinus infection;
THYM	cis	rs4242434	0.889	rs11785755	chr8:22453223	C/A	cg03733263	chr8:22462867	KIAA1967	1.17	11.3	0.76	2.8e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.31	4.72	0.44	8.25e-6	Obesity-related traits;
THYM	cis	rs10504073	0.647	rs12156111	chr8:50017328	G/C	cg00325661	chr8:49890786	NA	0.86	7.69	0.62	1.35e-11	Blood metabolite ratios;
THYM	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg07988820	chr12:82153109	PPFIA2	-0.81	-5.15	-0.47	1.38e-6	Resting heart rate;
THYM	cis	rs1267303	0.642	rs7542296	chr1:46998009	A/G	cg16387850	chr1:46982889	NA	-0.48	-6.4	-0.55	5.76e-9	Monobrow;
THYM	cis	rs6598955	1.000	rs10902728	chr1:26598281	T/C	cg00852783	chr1:26633632	UBXN11	-0.73	-5.5	-0.49	3.16e-7	Obesity-related traits;
THYM	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg01341218	chr17:43662625	NA	-1.08	-8.68	-0.67	1.12e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2066819	1.000	rs57870697	chr12:56752874	A/G	cg26714650	chr12:56694279	CS	-1.38	-6.84	-0.57	7.68e-10	Psoriasis vulgaris;
THYM	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg09085632	chr11:111637200	PPP2R1B	0.98	8.91	0.67	3.61e-14	Primary sclerosing cholangitis;
THYM	cis	rs11225247	0.772	rs34104132	chr11:102232160	T/G	cg11690896	chr11:102217788	BIRC2	1.12	5.18	0.47	1.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg25358565	chr5:93447407	FAM172A	1.38	11.24	0.76	3.82e-19	Diabetic retinopathy;
THYM	cis	rs478304	0.654	rs10896029	chr11:65452952	C/T	cg27068330	chr11:65405492	SIPA1	-1.03	-10.31	-0.73	3.55e-17	Acne (severe);
THYM	cis	rs1336149	0.901	rs865239	chr1:156896164	A/G	cg04298847	chr1:156447084	MEF2D	-0.35	-4.66	-0.43	1.04e-5	Chin dimples;
THYM	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg01236616	chr12:121019343	POP5	-1.24	-9.25	-0.69	6.66e-15	Type 1 diabetes nephropathy;
THYM	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg25838465	chr1:92012736	NA	0.9	8.55	0.66	2.09e-13	Breast cancer;
THYM	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg21361702	chr7:150065534	REPIN1	0.74	5.14	0.47	1.48e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs28595532	0.920	rs56302600	chr4:119770162	T/C	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs1642645	0.831	rs784103	chr1:42487059	A/G	cg10197057	chr1:42612518	NA	0.47	5.24	0.47	9.65e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs997295	0.618	rs3784698	chr15:68007582	G/C	cg24579218	chr15:68104479	NA	0.66	6.36	0.55	7.12e-9	Motion sickness;
THYM	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg00024416	chr22:24240387	NA	-0.66	-6.97	-0.58	4.23e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6570726	0.967	rs403584	chr6:145807010	G/A	cg23711669	chr6:146136114	FBXO30	0.82	7.75	0.62	1.03e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg16325326	chr1:53192061	ZYG11B	0.99	11.27	0.76	3.38e-19	Monocyte count;
THYM	cis	rs7586879	0.639	rs7567997	chr2:25096952	A/G	cg01884057	chr2:25150051	NA	0.7	7.3	0.6	8.8e-11	Body mass index;
THYM	cis	rs2281845	0.859	rs58364051	chr1:201077667	A/G	cg22815214	chr1:201083145	CACNA1S	0.75	7.38	0.6	5.9e-11	Permanent tooth development;
THYM	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg00757033	chr12:89920650	WDR51B	-0.67	-9.36	-0.69	3.91e-15	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg13683864	chr3:40499215	RPL14	1.05	11.64	0.77	5.54e-20	Renal cell carcinoma;
THYM	cis	rs7193541	0.510	rs79473128	chr16:74589192	G/A	cg01733217	chr16:74700730	RFWD3	0.64	4.69	0.43	9.02e-6	Multiple myeloma;
THYM	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2836633	0.929	rs4514962	chr21:40041753	C/T	cg05519781	chr21:40033154	ERG	0.79	7.87	0.63	5.66e-12	Coronary artery disease;
THYM	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3087591	0.960	rs12942479	chr17:29461912	T/A	cg24425628	chr17:29625626	OMG;NF1	0.64	5.45	0.49	3.96e-7	Hip circumference;
THYM	cis	rs2627019	0.526	rs2084578	chr2:148912642	A/G	cg23727674	chr2:148602993	ACVR2A	0.63	4.61	0.43	1.24e-5	Neuroticism;
THYM	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg01751800	chr4:77820391	ANKRD56	0.56	4.62	0.43	1.22e-5	Emphysema distribution in smoking;
THYM	cis	rs2898681	0.521	rs115874483	chr4:53728272	G/A	cg21521518	chr4:53727714	RASL11B	0.52	4.83	0.44	5.21e-6	Optic nerve measurement (cup area);
THYM	cis	rs11563648	0.553	rs4731356	chr7:127022714	C/A	cg23081781	chr7:127225937	GCC1	-0.34	-4.64	-0.43	1.14e-5	Resting heart rate;
THYM	cis	rs7100689	0.784	rs4934083	chr10:82116501	G/C	cg01528321	chr10:82214614	TSPAN14	0.99	7.67	0.62	1.51e-11	Post bronchodilator FEV1;
THYM	cis	rs2976388	0.524	rs7012804	chr8:143844650	A/G	cg17252645	chr8:143867129	LY6D	0.64	7.28	0.6	9.37e-11	Urinary tract infection frequency;
THYM	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg23708337	chr7:1209742	NA	0.68	4.81	0.44	5.59e-6	Longevity;Endometriosis;
THYM	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg18252515	chr7:66147081	NA	-1.45	-8.88	-0.67	4.01e-14	Diabetic kidney disease;
THYM	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg02221750	chr19:17393354	ANKLE1	-0.94	-8.56	-0.66	1.92e-13	Systemic lupus erythematosus;
THYM	cis	rs3796352	1.000	rs34244302	chr3:53102236	C/G	cg24530246	chr3:53118167	NA	-0.82	-4.67	-0.43	9.89e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg10505658	chr17:80084571	CCDC57	0.68	7.62	0.62	1.85e-11	Life satisfaction;
THYM	cis	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg12000587	chr17:30186630	C17orf79	0.5	7.14	0.59	1.84e-10	Hip circumference adjusted for BMI;
THYM	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg07167872	chr1:205819463	PM20D1	-0.61	-4.76	-0.44	6.86e-6	Parkinson's disease;
THYM	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.55	-4.69	-0.43	9.11e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg20302533	chr7:39170763	POU6F2	0.62	4.61	0.43	1.25e-5	IgG glycosylation;
THYM	cis	rs9814567	1.000	rs7645295	chr3:134307734	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.5	-0.66	2.7e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs8070740	0.838	rs8072363	chr17:5335752	C/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.7	5.16	0.47	1.34e-6	Menopause (age at onset);
THYM	cis	rs6768930	0.509	rs6445928	chr3:57758655	T/C	cg24033633	chr3:57945695	NA	-0.38	-5.27	-0.48	8.55e-7	Obesity-related traits;
THYM	cis	rs4455778	0.580	rs7783068	chr7:49120791	A/G	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.2e-16	Bone mineral density;
THYM	cis	rs7578361	0.801	rs12464848	chr2:150357426	G/T	cg17961725	chr2:150454027	NA	0.72	5.25	0.47	9.22e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs4642101	0.618	rs11128614	chr3:12819212	A/G	cg05775895	chr3:12838266	CAND2	1.07	10.78	0.74	3.56e-18	QRS complex (12-leadsum);
THYM	cis	rs17604090	0.938	rs73088374	chr7:29654819	C/A	cg19413766	chr7:29689036	LOC646762	-0.96	-5.14	-0.47	1.45e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs1568889	0.938	rs11601602	chr11:28233768	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	4.58	0.43	1.4e-5	Bipolar disorder;
THYM	cis	rs2742234	0.504	rs7093409	chr10:43740067	A/G	cg06632098	chr10:43605906	RET	0.69	4.74	0.44	7.37e-6	Hirschsprung disease;
THYM	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg10295955	chr4:187884368	NA	-1.19	-17.25	-0.87	5.06e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg00640147	chr17:61958756	GH2	-0.43	-4.61	-0.43	1.25e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs2035647	0.537	rs3857868	chr7:137797764	T/A	cg22979093	chr7:137028410	PTN	0.67	5.48	0.49	3.52e-7	Blood metabolite levels;
THYM	cis	rs4638749	0.677	rs7568919	chr2:108832376	C/A	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.53	4.76	0.44	6.8e-6	Birth weight;
THYM	cis	rs7226229	0.950	rs7218443	chr17:20926438	C/G	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg05973401	chr12:123451056	ABCB9	0.71	4.82	0.44	5.46e-6	Neutrophil percentage of white cells;
THYM	cis	rs977987	0.872	rs4243111	chr16:75320827	C/T	cg03315344	chr16:75512273	CHST6	0.83	7.05	0.59	2.81e-10	Dupuytren's disease;
THYM	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg02527881	chr3:46936655	PTH1R	0.6	5.55	0.5	2.53e-7	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7236492	0.935	rs11659416	chr18:77226973	C/T	cg15644404	chr18:77186268	NFATC1	-1.06	-4.94	-0.45	3.41e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg07636037	chr3:49044803	WDR6	0.83	5.28	0.48	8.19e-7	Menarche (age at onset);
THYM	cis	rs10028773	0.632	rs34481394	chr4:120248374	C/T	cg13609457	chr4:120235615	NA	0.55	5.13	0.47	1.5e-6	Educational attainment;
THYM	cis	rs4805272	0.539	rs1075733	chr19:29324460	C/T	cg03161606	chr19:29218774	NA	0.65	4.58	0.43	1.39e-5	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.29	9.73	0.71	6.33e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7719624	0.756	rs13168506	chr5:135396452	A/G	cg15329133	chr5:135467951	SMAD5;SMAD5OS	0.54	4.82	0.44	5.49e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs17539620	0.624	rs111484697	chr6:154838903	A/G	cg17771515	chr6:154831774	CNKSR3	0.84	4.5	0.42	1.94e-5	Lipoprotein (a) levels;
THYM	trans	rs4650994	0.524	rs2209170	chr1:178607388	C/A	cg05059571	chr16:84539110	KIAA1609	0.92	10.28	0.73	4.14e-17	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg10505658	chr17:80084571	CCDC57	0.71	7.51	0.61	3.2e-11	Life satisfaction;
THYM	cis	rs17407555	0.633	rs6836916	chr4:10277792	C/G	cg00071950	chr4:10020882	SLC2A9	0.5	4.72	0.44	8.25e-6	Schizophrenia (age at onset);
THYM	cis	rs9790314	0.690	rs6783085	chr3:160830929	A/G	cg03342759	chr3:160939853	NMD3	-0.6	-4.47	-0.42	2.18e-5	Morning vs. evening chronotype;
THYM	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg17063962	chr7:91808500	NA	-1.1	-11.62	-0.77	5.94e-20	Breast cancer;
THYM	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg24209194	chr3:40518798	ZNF619	0.62	5.25	0.47	9.28e-7	Renal cell carcinoma;
THYM	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg14895029	chr7:2775587	GNA12	-0.69	-5.08	-0.46	1.86e-6	Height;
THYM	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg06636001	chr8:8085503	FLJ10661	0.61	4.68	0.43	9.5e-6	Parkinson's disease;
THYM	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg27394845	chr17:28928406	LRRC37B2	0.98	4.71	0.43	8.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg23583168	chr7:148888333	NA	-1.06	-13.95	-0.82	1.01e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs12142240	0.698	rs9661240	chr1:46827050	G/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg11245990	chr11:68621969	NA	0.58	7.52	0.61	3.09e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg27534772	chr1:16042836	PLEKHM2	0.49	5.28	0.48	8.22e-7	Systolic blood pressure;
THYM	cis	rs2732480	0.577	rs2634693	chr12:48706498	C/T	cg21466736	chr12:48725269	NA	-0.62	-5.52	-0.49	2.92e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg13289132	chr10:30722225	MAP3K8	0.62	5.02	0.46	2.38e-6	Inflammatory bowel disease;
THYM	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs79387448	0.638	rs13405222	chr2:102981891	T/C	cg09003973	chr2:102972529	NA	1.38	7.38	0.6	6.05e-11	Gut microbiota (bacterial taxa);
THYM	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg19770292	chr5:1868693	NA	0.5	4.62	0.43	1.19e-5	Cardiovascular disease risk factors;
THYM	cis	rs4474465	0.850	rs11237546	chr11:78266924	T/C	cg19901956	chr11:77921274	USP35	0.61	4.47	0.42	2.14e-5	Alzheimer's disease (survival time);
THYM	cis	rs4930776	0.900	rs453285	chr12:5759785	A/G	cg02086166	chr12:5775618	ANO2	0.61	6.07	0.53	2.57e-8	Plasma clusterin levels;
THYM	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg18252515	chr7:66147081	NA	-1.57	-8.55	-0.66	2.07e-13	Diabetic kidney disease;
THYM	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg13880726	chr7:1868755	MAD1L1	0.61	4.5	0.42	1.92e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg13683864	chr3:40499215	RPL14	-1.05	-11.46	-0.76	1.29e-19	Renal cell carcinoma;
THYM	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg15744005	chr10:104629667	AS3MT	-0.84	-8.33	-0.65	6.07e-13	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7731657	0.537	rs1074840	chr5:130251717	A/G	cg08523029	chr5:130500466	HINT1	-0.95	-5.73	-0.51	1.18e-7	Fasting plasma glucose;
THYM	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg18512352	chr11:47633146	NA	0.49	5.95	0.52	4.52e-8	Subjective well-being;
THYM	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg10760299	chr15:45669010	GATM	0.75	5.63	0.5	1.79e-7	Homoarginine levels;
THYM	cis	rs79387448	0.745	rs72993722	chr2:103124916	A/G	cg09003973	chr2:102972529	NA	0.78	4.75	0.44	7.17e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg05738196	chr6:26577821	NA	0.95	9.91	0.71	2.53e-16	Intelligence (multi-trait analysis);
THYM	cis	rs7191700	0.644	rs918738	chr16:11439679	C/G	cg00044050	chr16:11439710	C16orf75	-0.92	-8.39	-0.65	4.6e-13	Multiple sclerosis;
THYM	cis	rs5985	0.659	rs3024322	chr6:6318073	G/C	cg22185065	chr6:6318785	F13A1	0.78	5.74	0.51	1.15e-7	End-stage coagulation;
THYM	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg24450063	chr1:156163899	SLC25A44	1.16	14.83	0.84	1.8e-26	Testicular germ cell tumor;
THYM	cis	rs13418717	1.000	rs12329197	chr2:127645411	A/G	cg25501666	chr2:127640322	NA	-1.68	-7.27	-0.6	9.85e-11	Heart failure;
THYM	trans	rs10802346	0.545	rs10924545	chr1:246364592	C/T	cg13514129	chr1:39547527	MACF1	-0.95	-9.82	-0.71	3.97e-16	Fractional exhaled nitric oxide (childhood);
THYM	trans	rs3960554	0.808	rs79864016	chr7:75655838	A/G	cg19862616	chr7:65841803	NCRNA00174	0.94	7.19	0.59	1.48e-10	Eotaxin levels;
THYM	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.48	-4.8	-0.44	5.86e-6	Crohn's disease;
THYM	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg24846343	chr22:24311635	DDTL	-0.43	-5.83	-0.51	7.67e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs899997	0.906	rs6495318	chr15:78992137	G/C	cg00639195	chr15:79103007	ADAMTS7	0.72	5.53	0.49	2.76e-7	Coronary artery disease or large artery stroke;
THYM	cis	rs7119	0.717	rs11636529	chr15:77816220	T/C	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs2219968	0.525	rs6994730	chr8:78874193	C/T	cg00738934	chr8:78996279	NA	0.61	4.93	0.45	3.5e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs483180	0.511	rs496198	chr1:120207177	A/G	cg19096424	chr1:120255104	PHGDH	-0.63	-4.88	-0.45	4.26e-6	Macular telangiectasia type 2;
THYM	cis	rs754466	0.606	rs11002315	chr10:79617385	T/G	cg17075019	chr10:79541650	NA	-0.69	-5.92	-0.52	5.14e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg06636551	chr8:101224915	SPAG1	-0.67	-6.52	-0.56	3.36e-9	Atrioventricular conduction;
THYM	cis	rs34638657	0.732	rs11866711	chr16:82201038	A/C	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.11	-0.64	1.73e-12	Lung adenocarcinoma;
THYM	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-10.37	-0.73	2.72e-17	Primary sclerosing cholangitis;
THYM	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg03433033	chr1:76189801	ACADM	-0.64	-5.88	-0.52	6.11e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2075230	0.850	rs9896688	chr17:7483915	A/T	cg16696476	chr17:8191344	RANGRF;SLC25A35	0.29	4.64	0.43	1.09e-5	Hormone measurements;
THYM	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg12923728	chr3:195709715	SDHAP1	-0.69	-5.54	-0.49	2.64e-7	Pancreatic cancer;
THYM	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11089937	0.616	rs6001227	chr22:22541489	C/A	cg06866756	chr22:22471216	NA	-0.46	-5.09	-0.46	1.79e-6	Periodontitis (PAL4Q3);
THYM	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Body mass index;
THYM	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg24209194	chr3:40518798	ZNF619	0.63	5.06	0.46	2.04e-6	Renal cell carcinoma;
THYM	cis	rs7119	0.717	rs12899390	chr15:77815238	A/C	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.59e-7	Type 2 diabetes;
THYM	cis	rs9788721	0.934	rs55676755	chr15:78898932	C/G	cg04882995	chr15:78912658	CHRNA3	0.54	4.55	0.42	1.61e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg06618935	chr21:46677482	NA	-0.98	-9.5	-0.7	1.95e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14442939	chr10:27389572	ANKRD26	0.95	4.66	0.43	1.04e-5	Breast cancer;
THYM	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg23187316	chr7:1099788	C7orf50	0.47	5.23	0.47	9.9e-7	Longevity;Endometriosis;
THYM	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs61008539	0.537	rs7793929	chr7:855076	A/T	cg00475322	chr7:917719	C7orf20	0.5	6.2	0.54	1.44e-8	Perceived unattractiveness to mosquitoes;
THYM	cis	rs1878931	0.597	rs2680221	chr16:3462595	A/G	cg22508957	chr16:3507546	NAT15	0.52	5.39	0.48	5.22e-7	Body mass index (adult);
THYM	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg11673840	chr17:47092156	IGF2BP1	-0.49	-4.95	-0.45	3.22e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs6840360	0.571	rs6811676	chr4:152562726	T/C	cg17479576	chr4:152424074	FAM160A1	-0.79	-5.55	-0.49	2.59e-7	Intelligence (multi-trait analysis);
THYM	cis	rs8064299	0.597	rs9893035	chr17:72783798	A/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.91	9.2	0.69	8.64e-15	Monocyte count;
THYM	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg13390004	chr1:15929781	NA	0.61	4.63	0.43	1.15e-5	Systolic blood pressure;
THYM	cis	rs7719624	0.870	rs58759191	chr5:135395827	C/G	cg12897067	chr5:135418308	NA	0.55	4.61	0.43	1.27e-5	Response to cytidine analogues (gemcitabine);
THYM	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.77	6.66	0.56	1.78e-9	Menarche (age at onset);
THYM	cis	rs1971762	0.602	rs4759283	chr12:54079243	C/T	cg16917193	chr12:54089295	NA	0.9	9.22	0.69	7.82e-15	Height;
THYM	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14159672	chr1:205819179	PM20D1	0.82	8.27	0.65	7.96e-13	Menarche (age at onset);
THYM	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg04842962	chr6:43655489	MRPS18A	1.41	15.7	0.85	3.85e-28	IgG glycosylation;
THYM	cis	rs10109552	1.000	rs10109552	chr8:18308810	G/T	cg23370213	chr8:17355133	SLC7A2	0.65	4.96	0.45	3.06e-6	Essential tremor;
THYM	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg25427524	chr10:38739819	LOC399744	-0.65	-5.96	-0.52	4.23e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg14456004	chr13:21872349	NA	1.21	9.94	0.71	2.25e-16	White matter hyperintensity burden;
THYM	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg21433313	chr16:3507492	NAT15	0.85	10.09	0.72	1.08e-16	Tuberculosis;
THYM	cis	rs9534288	0.783	rs7987385	chr13:46634131	A/G	cg15192986	chr13:46630673	CPB2	-0.66	-4.66	-0.43	1.03e-5	Blood protein levels;
THYM	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg24257776	chr3:47051546	LOC100129354	0.38	4.51	0.42	1.85e-5	Colorectal cancer;
THYM	cis	rs1395	0.925	rs1659689	chr2:27393030	A/G	cg23587288	chr2:27483067	SLC30A3	0.54	4.5	0.42	1.9e-5	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg24818145	chr4:99064322	C4orf37	-0.75	-6.03	-0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	4.79	0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs2456568	0.709	rs7942444	chr11:93637160	G/A	cg17595323	chr11:93583763	C11orf90	0.57	6.39	0.55	6.12e-9	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg26769984	chr7:1090371	C7orf50	0.83	5.52	0.49	2.95e-7	Bronchopulmonary dysplasia;
THYM	cis	rs66887589	0.967	rs1155577	chr4:120449810	C/T	cg13609457	chr4:120235615	NA	-0.47	-4.92	-0.45	3.59e-6	Diastolic blood pressure;
THYM	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs921968	0.643	rs2243911	chr2:219529348	C/T	cg02176678	chr2:219576539	TTLL4	-0.6	-5.84	-0.51	7.3e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs807669	0.504	rs8141941	chr22:19166263	G/A	cg02655711	chr22:19163373	SLC25A1	0.63	7.11	0.59	2.16e-10	Metabolite levels;
THYM	cis	rs87938	0.799	rs7632244	chr3:41168955	G/C	cg02247160	chr3:41243829	CTNNB1	-0.34	-4.62	-0.43	1.18e-5	Bone mineral density (hip);
THYM	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg06640241	chr16:89574553	SPG7	0.89	8.36	0.65	5.25e-13	Multiple myeloma (IgH translocation);
THYM	cis	rs1483890	0.642	rs9825849	chr3:69404575	C/T	cg22125112	chr3:69402811	FRMD4B	0.56	7.09	0.59	2.36e-10	Resting heart rate;
THYM	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg13609457	chr4:120235615	NA	0.6	5.26	0.47	9.03e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg27446573	chr6:127587934	RNF146	1.03	9.77	0.71	5.21e-16	Breast cancer;
THYM	cis	rs9796	0.621	rs28737302	chr15:41469943	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.58	-4.79	-0.44	6.07e-6	Menopause (age at onset);
THYM	cis	rs2219968	0.798	rs57034374	chr8:78911919	T/C	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.49	-4.76	-0.44	6.83e-6	Primary biliary cholangitis;
THYM	cis	rs273218	0.573	rs16882051	chr5:53342979	T/C	ch.5.1024479R	chr5:53302184	ARL15	-1.08	-9.13	-0.68	1.22e-14	Migraine;
THYM	cis	rs4731207	0.698	rs6959712	chr7:124499003	T/A	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.91	-6.52	-0.56	3.31e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg24818145	chr4:99064322	C4orf37	0.73	5.87	0.52	6.3e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3087591	0.922	rs12939969	chr17:29463577	A/G	cg24425628	chr17:29625626	OMG;NF1	0.62	5.34	0.48	6.25e-7	Hip circumference;
THYM	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg10150615	chr22:24372951	LOC391322	-0.86	-8.94	-0.68	3.08e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.96	-6.76	-0.57	1.12e-9	Schizophrenia;
THYM	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg08132940	chr7:1081526	C7orf50	-1.25	-7.04	-0.59	3e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6831352	0.879	rs35146617	chr4:100066686	C/T	cg12011299	chr4:100065546	ADH4	-0.82	-7.62	-0.62	1.91e-11	Alcohol dependence;
THYM	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg16778714	chr17:28903809	LRRC37B2	-0.76	-4.49	-0.42	2.03e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4713118	0.869	rs9393851	chr6:27699581	A/T	cg12963246	chr6:28129442	ZNF389	0.64	4.86	0.45	4.62e-6	Parkinson's disease;
THYM	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg17757837	chr7:157058334	UBE3C	-0.66	-5.33	-0.48	6.62e-7	Body mass index;
THYM	cis	rs75059851	0.756	rs11223652	chr11:133841207	A/G	cg14047540	chr11:133829660	NA	-1.1	-7.34	-0.6	7.1e-11	Schizophrenia;
THYM	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg00684032	chr4:1343700	KIAA1530	0.8	7.13	0.59	1.91e-10	Obesity-related traits;
THYM	cis	rs9649213	0.555	rs12667634	chr7:97965442	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.22	-0.47	1.06e-6	Chronic sinus infection;
THYM	cis	rs2070677	0.932	rs3020499	chr10:135381215	A/G	cg20169779	chr10:135381914	SYCE1	0.77	5.93	0.52	4.93e-8	Gout;
THYM	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7953508	0.506	rs10777530	chr12:93961110	C/T	cg18151635	chr12:93972918	NA	-0.87	-6.12	-0.53	2.07e-8	Pubertal anthropometrics;
THYM	cis	rs6754311	0.638	rs1011361	chr2:136553639	G/A	cg04750100	chr2:136595281	LCT	-0.55	-6.35	-0.55	7.49e-9	Mosquito bite size;
THYM	cis	rs5753037	0.809	rs5763512	chr22:30212366	C/T	cg27665648	chr22:30112403	NA	0.5	4.52	0.42	1.76e-5	Type 1 diabetes;
THYM	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg17173187	chr15:85201210	NMB	0.56	5.66	0.5	1.6e-7	Schizophrenia;
THYM	cis	rs79149102	0.579	rs6495140	chr15:75306041	T/C	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	cis	rs17152411	0.895	rs61872118	chr10:126583450	C/T	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	9.83e-6	Height;
THYM	cis	rs12681288	0.523	rs112307130	chr8:962483	G/A	cg08648136	chr8:956695	NA	0.55	4.62	0.43	1.19e-5	Schizophrenia;
THYM	cis	rs10924970	0.870	rs2382569	chr1:235469032	A/G	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs7078219	0.505	rs4409764	chr10:101284237	T/G	cg23904955	chr10:101282759	NA	-0.36	-4.61	-0.43	1.28e-5	Dental caries;
THYM	cis	rs9457247	0.534	rs4710149	chr6:167386346	T/C	cg23791538	chr6:167370224	RNASET2	0.83	7.32	0.6	7.9e-11	Crohn's disease;
THYM	cis	rs6866344	0.569	rs56070635	chr5:178150169	A/C	cg03877680	chr5:178157825	ZNF354A	0.81	5.74	0.51	1.12e-7	Neutrophil percentage of white cells;
THYM	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg03859395	chr2:55845619	SMEK2	0.64	6.0	0.52	3.54e-8	Metabolic syndrome;
THYM	cis	rs600550	0.759	rs562028	chr11:59877850	A/C	cg02771260	chr11:59836817	MS4A3	-0.63	-4.59	-0.43	1.34e-5	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs28595532	0.920	rs116717907	chr4:119762568	A/G	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06634786	chr22:41940651	POLR3H	0.82	6.08	0.53	2.53e-8	Vitiligo;
THYM	cis	rs709400	0.588	rs61996718	chr14:104048834	G/A	cg12935359	chr14:103987150	CKB	-0.55	-4.46	-0.42	2.21e-5	Body mass index;
THYM	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg24955955	chr5:415729	AHRR	1.02	5.72	0.51	1.21e-7	Fat distribution (HIV);
THYM	cis	rs1775715	0.707	rs2808079	chr10:32167385	C/T	cg04359828	chr10:32216031	ARHGAP12	0.38	4.8	0.44	5.89e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs36051895	0.593	rs12682970	chr9:5168137	C/T	cg02405213	chr9:5042618	JAK2	-1.01	-10.07	-0.72	1.16e-16	Pediatric autoimmune diseases;
THYM	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg18512352	chr11:47633146	NA	0.48	5.86	0.52	6.55e-8	Neuroticism;Neuroticism (multi-trait analysis);
THYM	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg10150615	chr22:24372951	LOC391322	-0.9	-9.78	-0.71	4.82e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg00071950	chr4:10020882	SLC2A9	-0.59	-5.37	-0.48	5.6e-7	Bone mineral density;
THYM	cis	rs2075230	0.642	rs1641528	chr17:7548320	A/G	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.55	-0.42	1.56e-5	Hormone measurements;
THYM	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg13147721	chr7:65941812	NA	-1.16	-7.64	-0.62	1.7e-11	Diabetic kidney disease;
THYM	cis	rs61931739	0.570	rs7315655	chr12:33912869	G/A	cg06521331	chr12:34319734	NA	-0.57	-4.76	-0.44	7e-6	Morning vs. evening chronotype;
THYM	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg17143192	chr8:8559678	CLDN23	-0.62	-4.89	-0.45	4.11e-6	Mood instability;
THYM	cis	rs2075230	0.705	rs1642809	chr17:7545496	T/C	cg10509001	chr17:7553872	ATP1B2	-0.56	-4.52	-0.42	1.79e-5	Hormone measurements;
THYM	cis	rs7089973	0.872	rs36036948	chr10:116631649	A/G	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.05	-0.46	2.15e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs3960554	0.610	rs11971800	chr7:75731608	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.57	-4.7	-0.43	8.73e-6	Eotaxin levels;
THYM	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg15744005	chr10:104629667	AS3MT	-0.83	-7.76	-0.62	9.84e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	trans	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.95	-8.78	-0.67	6.6e-14	Brugada syndrome;
THYM	cis	rs61990749	0.597	rs12887282	chr14:78200585	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.02	0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	6.13	0.53	2.04e-8	Total body bone mineral density;
THYM	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg12407791	chr17:73824354	UNC13D	0.41	4.61	0.43	1.26e-5	White matter hyperintensity burden;
THYM	cis	rs807669	0.835	rs1780639	chr22:19174603	T/C	cg02655711	chr22:19163373	SLC25A1	0.97	11.57	0.76	7.63e-20	Metabolite levels;
THYM	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg06618935	chr21:46677482	NA	-0.96	-9.38	-0.69	3.52e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4919694	1.000	rs10509760	chr10:104634107	A/G	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg25358565	chr5:93447407	FAM172A	1.36	10.94	0.75	1.62e-18	Diabetic retinopathy;
THYM	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg19077165	chr18:44547161	KATNAL2	0.51	5.99	0.52	3.73e-8	Personality dimensions;
THYM	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg11301795	chr4:187892539	NA	-1.11	-17.65	-0.88	9.45e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg12935359	chr14:103987150	CKB	-0.53	-6.3	-0.54	9.24e-9	Intelligence (multi-trait analysis);
THYM	cis	rs11209185	0.509	rs9436789	chr1:68441456	G/A	cg22082780	chr1:68452167	NA	0.52	5.84	0.51	7.42e-8	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg08975724	chr8:8085496	FLJ10661	0.74	6.05	0.53	2.88e-8	Mood instability;
THYM	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Body mass index;
THYM	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.68	9.03	0.68	1.97e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs295140	0.605	rs159321	chr2:201184713	C/T	cg17644776	chr2:200775616	C2orf69	-0.59	-4.56	-0.42	1.52e-5	QT interval;
THYM	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg27141850	chr2:20869434	GDF7	-0.54	-4.75	-0.44	7.34e-6	Abdominal aortic aneurysm;
THYM	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg02675527	chr2:114030824	PAX8;LOC440839	0.68	5.17	0.47	1.29e-6	Renal function-related traits (BUN);
THYM	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg06481639	chr22:41940642	POLR3H	0.69	5.1	0.46	1.75e-6	Vitiligo;
THYM	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs7772486	0.790	rs6570724	chr6:146151283	T/C	cg13319975	chr6:146136371	FBXO30	-0.69	-5.65	-0.5	1.7e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2219968	0.683	rs6986684	chr8:78907660	G/T	cg00738934	chr8:78996279	NA	-0.65	-5.32	-0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10037758	0.504	rs257900	chr5:128315174	G/C	cg25555059	chr5:128301488	SLC27A6	-0.45	-4.73	-0.44	7.81e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6539288	0.933	rs6539289	chr12:107309316	A/C	cg26297688	chr12:107349093	C12orf23	0.5	5.31	0.48	7.04e-7	Total body bone mineral density;
THYM	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg00256281	chr22:41985642	PMM1	0.58	4.63	0.43	1.18e-5	Vitiligo;
THYM	cis	rs72781680	0.752	rs55801864	chr2:23922325	C/T	cg08917208	chr2:24149416	ATAD2B	1.11	4.97	0.45	2.9e-6	Lymphocyte counts;
THYM	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg12311346	chr5:56204834	C5orf35	-0.77	-5.59	-0.5	2.18e-7	Initial pursuit acceleration;
THYM	cis	rs11948739	0.610	rs4705853	chr5:130232339	T/C	cg08523029	chr5:130500466	HINT1	-0.82	-5.78	-0.51	9.5e-8	Pediatric bone mineral content (hip);
THYM	cis	rs6840360	0.550	rs12651635	chr4:152557786	C/T	cg17479576	chr4:152424074	FAM160A1	-0.83	-5.86	-0.52	6.62e-8	Intelligence (multi-trait analysis);
THYM	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg01448562	chr3:133502909	NA	-0.97	-8.39	-0.65	4.41e-13	Iron status biomarkers;
THYM	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg04731861	chr2:219085781	ARPC2	-0.49	-4.69	-0.43	9.3e-6	Colorectal cancer;
THYM	cis	rs7681440	0.606	rs1372516	chr4:90755730	G/A	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs7584330	0.518	rs11903073	chr2:238432766	C/T	cg14458575	chr2:238380390	NA	0.8	4.67	0.43	9.97e-6	Prostate cancer;
THYM	cis	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg07460842	chr6:66804631	NA	1.11	8.25	0.65	8.78e-13	Exhaled nitric oxide output;
THYM	cis	rs73072330	1.000	rs17729010	chr3:47912703	A/G	cg09665691	chr3:47563885	NA	-1.28	-4.81	-0.44	5.74e-6	Stem cell growth factor beta levels;
THYM	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg23711669	chr6:146136114	FBXO30	0.86	8.1	0.64	1.86e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs202126107	1	rs202126107	chr17:38006767	GCATATTATA/G	cg24910161	chr17:38119198	GSDMA	0.47	4.91	0.45	3.79e-6	Eosinophil percentage of white cells;
THYM	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg10360139	chr7:1886902	MAD1L1	0.52	4.65	0.43	1.08e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs4866334	0.867	rs78373067	chr5:18463912	A/G	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs6430585	0.583	rs61253125	chr2:136618178	T/C	cg20242066	chr2:136595261	LCT	0.51	4.87	0.45	4.44e-6	Corneal structure;
THYM	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs10463554	0.759	rs461609	chr5:102447305	G/A	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.49e-6	Parkinson's disease;
THYM	cis	rs6670533	0.571	rs7540973	chr1:24864576	G/T	cg25806492	chr1:24970113	SRRM1	-1.47	-4.48	-0.42	2.06e-5	Fasting blood insulin (BMI interaction);
THYM	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg06850241	chr22:41845214	NA	0.52	4.51	0.42	1.88e-5	Cannabis dependence symptom count;
THYM	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg13695892	chr22:41940480	POLR3H	0.83	6.07	0.53	2.67e-8	Vitiligo;
THYM	cis	rs11087123	0.500	rs1657957	chr20:15121088	C/A	cg09937190	chr20:15177509	MACROD2	-0.47	-5.15	-0.47	1.42e-6	Eating disorders;
THYM	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg06108461	chr20:60628389	TAF4	-1.03	-8.14	-0.64	1.49e-12	Body mass index;
THYM	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg13397359	chr6:42928475	GNMT	0.7	6.4	0.55	5.96e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg19875535	chr5:140030758	IK	-0.69	-6.02	-0.53	3.29e-8	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7267979	0.903	rs2474766	chr20:25246153	A/G	cg08601574	chr20:25228251	PYGB	0.59	4.79	0.44	6.25e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2085601	0.542	rs1708675	chr4:89973400	G/A	cg17769793	chr4:89976368	FAM13A	-0.59	-6.86	-0.58	6.96e-10	Hair greying;
THYM	cis	rs2820651	0.708	rs17156341	chr10:1478227	A/G	cg02445968	chr10:1449028	ADARB2	0.95	5.71	0.51	1.29e-7	Migraine with aura;
THYM	cis	rs17125944	0.615	rs2025633	chr14:53317340	C/T	cg00686598	chr14:53173677	PSMC6	-1.03	-4.69	-0.43	9.19e-6	Alzheimer's disease (late onset);
THYM	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg03859395	chr2:55845619	SMEK2	0.65	6.04	0.53	3.03e-8	Metabolic syndrome;
THYM	cis	rs747334	0.683	rs6583743	chr10:92747951	A/G	cg07620928	chr10:92689909	NA	0.58	5.07	0.46	1.98e-6	Fibroblast growth factor basic levels;
THYM	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg11247378	chr22:39784982	NA	-1.06	-13.62	-0.81	4.63e-24	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs4144027	0.967	rs12879686	chr14:104360741	C/T	cg08213375	chr14:104286397	PPP1R13B	0.43	4.51	0.42	1.86e-5	Blood metabolite levels;
THYM	cis	rs3780378	1.000	rs10815158	chr9:5112844	G/A	cg02405213	chr9:5042618	JAK2	-0.63	-5.63	-0.5	1.81e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs1512268	0.526	rs1512270	chr8:23520043	A/T	cg20272884	chr8:23712762	STC1	0.45	4.47	0.42	2.17e-5	Prostate cancer;Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9527	0.615	rs4919685	chr10:104587362	G/T	cg04362960	chr10:104952993	NT5C2	0.66	5.07	0.46	1.96e-6	Arsenic metabolism;
THYM	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg24060327	chr5:131705240	SLC22A5	-0.73	-5.47	-0.49	3.61e-7	Blood metabolite levels;
THYM	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg25918947	chr17:41365094	TMEM106A	-0.69	-5.84	-0.51	7.34e-8	Menopause (age at onset);
THYM	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg15782153	chr7:917662	C7orf20	0.46	4.86	0.45	4.54e-6	Perceived unattractiveness to mosquitoes;
THYM	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg23583168	chr7:148888333	NA	1.02	14.09	0.82	5.29e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg14582100	chr15:45693742	SPATA5L1	0.58	4.67	0.43	9.87e-6	Homoarginine levels;
THYM	cis	rs7927771	0.507	rs7119517	chr11:47675316	T/C	cg18512352	chr11:47633146	NA	0.41	4.6	0.43	1.33e-5	Subjective well-being;
THYM	cis	rs754466	0.606	rs3740250	chr10:79580101	C/T	cg17075019	chr10:79541650	NA	-0.7	-5.78	-0.51	9.61e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg21427119	chr20:30132790	HM13	-0.74	-5.03	-0.46	2.28e-6	Mean corpuscular hemoglobin;
THYM	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	13.59	0.81	5.3e-24	Chronic sinus infection;
THYM	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs28595532	0.920	rs114390336	chr4:119771452	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg03733263	chr8:22462867	KIAA1967	1.11	13.42	0.81	1.19e-23	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs669446	0.591	rs483679	chr1:44108119	T/A	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs2354432	0.607	rs1530335	chr1:146685288	T/C	cg25205988	chr1:146714368	CHD1L	1.1	4.92	0.45	3.66e-6	Mitochondrial DNA levels;
THYM	cis	rs9906944	0.707	rs9899931	chr17:47108282	G/A	cg18128536	chr17:47092178	IGF2BP1	-0.43	-4.71	-0.44	8.43e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg08017756	chr2:100939284	LONRF2	-0.73	-7.6	-0.62	2.06e-11	Intelligence (multi-trait analysis);
THYM	cis	rs10751667	0.961	rs6421967	chr11:983966	T/C	cg01483505	chr11:975446	AP2A2	0.62	4.88	0.45	4.33e-6	Alzheimer's disease (late onset);
THYM	cis	rs3106136	0.546	rs2664881	chr4:95143484	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.1	-0.46	1.7e-6	Capecitabine sensitivity;
THYM	cis	rs10426930	0.621	rs10409229	chr19:5009545	C/T	cg25246084	chr19:4971487	KDM4B	-0.54	-4.72	-0.44	8.21e-6	Monocyte percentage of white cells;
THYM	cis	rs3819817	0.575	rs4762257	chr12:96357635	T/C	cg26410635	chr12:96350720	AMDHD1	0.53	5.03	0.46	2.36e-6	Vitamin D levels;
THYM	cis	rs875971	1.000	rs1144895	chr7:65541307	C/G	cg18876405	chr7:65276391	NA	-0.65	-5.53	-0.49	2.85e-7	Aortic root size;
THYM	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.55	-0.56	2.92e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1797885	0.689	rs796169	chr3:12565796	T/C	cg05467012	chr3:12595696	NA	0.54	4.59	0.43	1.35e-5	Immature fraction of reticulocytes;
THYM	cis	rs6089829	0.888	rs4809467	chr20:61671688	A/G	cg02380750	chr20:61661411	NA	0.63	6.16	0.53	1.72e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.04	0.46	2.18e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9733	0.596	rs2065900	chr1:150652202	A/G	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.78	7.18	0.59	1.54e-10	Personality dimensions;
THYM	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg23281280	chr6:28129359	ZNF389	0.61	4.94	0.45	3.3e-6	Parkinson's disease;
THYM	cis	rs7078219	0.505	rs7077040	chr10:101281014	C/G	cg04972745	chr10:101287846	NA	-0.52	-4.74	-0.44	7.55e-6	Dental caries;
THYM	cis	rs36051895	0.632	rs7849717	chr9:5170080	G/A	cg02405213	chr9:5042618	JAK2	-0.98	-9.59	-0.7	1.25e-15	Pediatric autoimmune diseases;
THYM	cis	rs11651000	0.857	rs57171311	chr17:45826168	A/G	cg24803719	chr17:45855879	NA	-0.61	-6.2	-0.54	1.47e-8	IgG glycosylation;
THYM	cis	rs7089973	0.872	rs7072364	chr10:116620840	G/A	cg23260525	chr10:116636907	FAM160B1	0.52	4.72	0.44	8.04e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9560113	0.959	rs9555803	chr13:112179560	G/T	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg02527881	chr3:46936655	PTH1R	0.62	6.09	0.53	2.34e-8	Colorectal cancer;
THYM	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg18252515	chr7:66147081	NA	-1.48	-8.83	-0.67	5.23e-14	Diabetic kidney disease;
THYM	cis	rs72949976	0.584	rs12467619	chr2:214022933	T/C	cg08319019	chr2:214017104	IKZF2	0.81	7.05	0.59	2.91e-10	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg08305652	chr11:111469057	NA	-0.53	-4.51	-0.42	1.87e-5	Primary sclerosing cholangitis;
THYM	cis	rs711830	1.000	rs1051929	chr2:177036754	T/C	cg13092806	chr2:177043255	NA	0.59	4.75	0.44	7.22e-6	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg09549813	chr16:4587862	C16orf5	-0.57	-6.63	-0.56	2.06e-9	Schizophrenia;
THYM	cis	rs11030122	0.702	rs10835406	chr11:3992954	G/T	cg18678763	chr11:4115507	RRM1	0.44	5.59	0.5	2.17e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg08109568	chr15:31115862	NA	0.76	6.82	0.57	8.54e-10	Huntington's disease progression;
THYM	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg27532560	chr4:187881888	NA	0.94	11.0	0.75	1.2e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6901250	0.851	rs607372	chr6:117155929	A/G	cg12892004	chr6:117198278	RFX6	-0.71	-6.97	-0.58	4.22e-10	C-reactive protein levels;
THYM	cis	rs6032067	0.641	rs34602589	chr20:43768734	T/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.41	-0.49	4.61e-7	Blood protein levels;
THYM	cis	rs208520	0.690	rs207091	chr6:66799847	G/T	cg07460842	chr6:66804631	NA	-1.06	-7.89	-0.63	5.14e-12	Exhaled nitric oxide output;
THYM	cis	rs2404602	0.647	rs116505114	chr15:77074794	T/C	cg23625390	chr15:77176239	SCAPER	-0.86	-6.21	-0.54	1.4e-8	Blood metabolite levels;
THYM	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg17644776	chr2:200775616	C2orf69	-0.79	-4.49	-0.42	2.01e-5	Schizophrenia;
THYM	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg03909863	chr11:638404	DRD4	-0.78	-5.75	-0.51	1.07e-7	Systemic lupus erythematosus;
THYM	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg09323728	chr8:95962352	TP53INP1	-0.44	-4.5	-0.42	1.96e-5	Type 2 diabetes;
THYM	cis	rs9646944	0.540	rs12712148	chr2:103025547	G/A	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	cis	rs1005224	0.853	rs12898082	chr14:76306359	A/C	cg04684003	chr14:76127793	TTLL5;C14orf1	0.65	5.13	0.47	1.54e-6	Large artery stroke;
THYM	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	12.89	0.8	1.41e-22	Height;
THYM	cis	rs6840360	0.530	rs6839802	chr4:152485834	G/A	cg17479576	chr4:152424074	FAM160A1	-0.8	-5.92	-0.52	5.02e-8	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg24209194	chr3:40518798	ZNF619	0.61	4.98	0.45	2.85e-6	Renal cell carcinoma;
THYM	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg02551604	chr5:131831745	NA	-0.73	-5.73	-0.51	1.2e-7	Asthma (sex interaction);
THYM	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	trans	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg23505145	chr19:12996616	KLF1	1.01	10.17	0.72	7.34e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8044868	0.586	rs7199261	chr16:72082788	A/G	cg06353428	chr16:71660113	MARVELD3	0.6	4.56	0.42	1.54e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs2463822	1.000	rs2463821	chr11:62111662	T/C	cg06239285	chr11:62104954	ASRGL1	1.41	7.07	0.59	2.63e-10	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7824557	0.585	rs2572385	chr8:11208903	G/A	cg21775007	chr8:11205619	TDH	0.67	5.26	0.47	9.04e-7	Retinal vascular caliber;
THYM	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg16586182	chr3:47516702	SCAP	0.65	5.63	0.5	1.85e-7	Colorectal cancer;
THYM	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg08470875	chr2:26401718	FAM59B	-0.72	-4.46	-0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs89107	0.543	rs72952795	chr6:118894271	G/T	cg21191810	chr6:118973309	C6orf204	0.51	5.1	0.46	1.71e-6	Cardiac structure and function;
THYM	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg23984312	chr1:154112300	NUP210L	-0.89	-7.13	-0.59	1.99e-10	Depressive symptoms;
THYM	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.95	8.24	0.65	9.16e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9527	0.590	rs7092029	chr10:104823909	A/T	cg04362960	chr10:104952993	NT5C2	0.6	4.55	0.42	1.56e-5	Arsenic metabolism;
THYM	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg03517284	chr6:25882590	NA	0.72	5.62	0.5	1.88e-7	Schizophrenia;
THYM	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg24642844	chr7:1081250	C7orf50	-1.15	-8.25	-0.65	8.86e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs9951602	0.512	rs8089108	chr18:76651361	C/T	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs7582180	0.903	rs7609376	chr2:100905828	A/G	cg14675211	chr2:100938903	LONRF2	0.64	5.24	0.47	9.56e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1401999	0.510	rs12634398	chr3:183708405	A/G	cg01324343	chr3:183735012	ABCC5	0.59	6.18	0.54	1.63e-8	Anterior chamber depth;
THYM	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg00024416	chr22:24240387	NA	-0.68	-7.33	-0.6	7.49e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7968440	0.933	rs2700480	chr12:51022431	A/T	cg20014596	chr12:50898483	DIP2B	0.56	4.55	0.42	1.57e-5	Fibrinogen;
THYM	cis	rs4454254	0.518	rs11778183	chr8:141054327	T/G	cg05910124	chr8:141057427	TRAPPC9	-0.6	-4.67	-0.43	1.01e-5	Pulse pressure;
THYM	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.61	-0.56	2.19e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg08133631	chr1:26527909	CATSPER4	-0.57	-4.69	-0.43	9.29e-6	Obesity-related traits;
THYM	cis	rs60871478	0.685	rs113591626	chr7:846680	C/T	cg10248100	chr7:872053	UNC84A	0.74	4.85	0.45	4.86e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs2456568	0.525	rs6483269	chr11:93620428	C/T	cg26875233	chr11:93583750	C11orf90	0.48	5.0	0.46	2.59e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg10792982	chr14:105748885	BRF1	0.75	7.8	0.62	7.96e-12	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9311676	0.656	rs59643048	chr3:58390248	A/G	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs4072705	1.000	rs4240487	chr9:127370307	C/T	cg13476313	chr9:127244764	NR5A1	0.32	5.0	0.46	2.6e-6	Menarche (age at onset);
THYM	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg19774624	chr17:42201019	HDAC5	-0.78	-7.43	-0.61	4.76e-11	Total body bone mineral density;
THYM	cis	rs7772486	0.875	rs6570738	chr6:146412695	G/A	cg05347473	chr6:146136440	FBXO30	0.6	4.8	0.44	5.96e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7942486	0.825	rs1351522	chr11:13268386	T/C	cg13286116	chr11:13302098	ARNTL	-0.72	-7.98	-0.63	3.36e-12	Neuroticism;
THYM	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg18252515	chr7:66147081	NA	0.65	4.73	0.44	7.72e-6	Aortic root size;
THYM	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg18252515	chr7:66147081	NA	-0.69	-5.5	-0.49	3.21e-7	Aortic root size;
THYM	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg20283391	chr11:68216788	NA	-0.69	-5.14	-0.47	1.49e-6	Total body bone mineral density;
THYM	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg24308560	chr3:49941425	MST1R	0.79	6.77	0.57	1.06e-9	Intelligence (multi-trait analysis);
THYM	cis	rs2440129	0.611	rs11571335	chr17:6904263	C/T	cg09737314	chr17:6899359	ALOX12	0.8	10.5	0.73	1.44e-17	Tonsillectomy;
THYM	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.16	-8.93	-0.68	3.25e-14	Platelet count;
THYM	cis	rs17030434	0.822	rs7686027	chr4:154680269	T/G	cg14289246	chr4:154710475	SFRP2	0.76	5.42	0.49	4.52e-7	Electrocardiographic conduction measures;
THYM	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-11.43	-0.76	1.54e-19	Height;
THYM	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg10792982	chr14:105748885	BRF1	0.75	7.8	0.62	7.96e-12	Mean platelet volume;Platelet distribution width;
THYM	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg14972814	chr11:95582409	MTMR2	-0.7	-6.4	-0.55	5.91e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg13683864	chr3:40499215	RPL14	0.86	8.02	0.64	2.67e-12	Renal cell carcinoma;
THYM	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg15744692	chr15:45671195	LOC145663;GATM	0.45	4.48	0.42	2.08e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs9902453	0.967	rs4294864	chr17:28440138	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.76	0.44	6.86e-6	Coffee consumption (cups per day);
THYM	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	4.66	0.43	1.02e-5	Schizophrenia;
THYM	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	6.08	0.53	2.46e-8	Schizophrenia;
THYM	cis	rs3773445	0.901	rs1730226	chr3:25620233	A/T	cg02315353	chr3:25825455	NGLY1	0.59	5.34	0.48	6.46e-7	Airway responsiveness in chronic obstructive pulmonary disease;
THYM	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg14458575	chr2:238380390	NA	0.9	7.53	0.61	2.94e-11	Prostate cancer;
THYM	cis	rs6500395	0.962	rs11647046	chr16:48623217	T/C	cg04672837	chr16:48644449	N4BP1	0.48	4.64	0.43	1.13e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg15704280	chr7:45808275	SEPT13	-0.99	-11.55	-0.76	8.36e-20	Height;
THYM	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg15536230	chr21:44985092	HSF2BP	-0.42	-5.18	-0.47	1.24e-6	Mean corpuscular volume;
THYM	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg23161317	chr6:28129485	ZNF389	0.66	5.26	0.47	8.9e-7	Parkinson's disease;
THYM	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg27588902	chr6:42928151	GNMT	-0.48	-4.62	-0.43	1.19e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg04546413	chr19:29218101	NA	1.11	9.63	0.7	1.02e-15	Methadone dose in opioid dependence;
THYM	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06850241	chr22:41845214	NA	0.59	5.36	0.48	5.81e-7	Vitiligo;
THYM	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg27490568	chr2:178487706	NA	0.58	5.27	0.48	8.47e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg13147721	chr7:65941812	NA	-0.93	-5.71	-0.51	1.26e-7	Diabetic kidney disease;
THYM	cis	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg16898833	chr6:26189333	HIST1H4D	1.33	4.95	0.45	3.27e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs61931739	0.857	rs1828514	chr12:34139600	A/G	cg10856724	chr12:34555212	NA	-0.6	-5.28	-0.48	8.14e-7	Morning vs. evening chronotype;
THYM	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg02734326	chr4:10020555	SLC2A9	0.76	6.94	0.58	4.75e-10	Bone mineral density;
THYM	cis	rs1729951	0.575	rs361248	chr3:136709066	G/A	cg12473912	chr3:136751656	NA	0.6	4.96	0.45	3.07e-6	Neuroticism;
THYM	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg16049864	chr8:95962084	TP53INP1	-0.82	-7.41	-0.6	5.27e-11	Type 2 diabetes;
THYM	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg10117171	chr1:25599238	RHD	-0.71	-5.16	-0.47	1.36e-6	Erythrocyte sedimentation rate;
THYM	cis	rs17604090	0.529	rs10239226	chr7:29716312	C/G	cg19413766	chr7:29689036	LOC646762	-0.82	-5.65	-0.5	1.68e-7	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs9914988	0.943	rs2242345	chr17:27185827	C/T	cg20469991	chr17:27169893	C17orf63	0.8	4.68	0.43	9.55e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg03806693	chr22:41940476	POLR3H	1.19	10.49	0.73	1.46e-17	Vitiligo;
THYM	cis	rs9359856	0.636	rs3748085	chr6:90315789	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.77	-7.08	-0.59	2.53e-10	Bipolar disorder;
THYM	cis	rs12643440	0.538	rs10489117	chr4:17145568	G/T	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs76878669	0.561	rs6591217	chr11:66174653	G/A	cg18002602	chr11:66138449	SLC29A2	-0.46	-4.64	-0.43	1.1e-5	Educational attainment (years of education);
THYM	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg07936489	chr17:37558343	FBXL20	-0.8	-5.28	-0.48	8.12e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs310642	0.831	rs404613	chr20:62173925	T/G	cg08767838	chr20:62209642	NA	-1.07	-4.52	-0.42	1.79e-5	Hair shape;
THYM	cis	rs4713118	0.662	rs9357060	chr6:28024486	C/G	cg08968635	chr6:28129556	ZNF389	0.59	4.57	0.42	1.46e-5	Parkinson's disease;
THYM	cis	rs10857712	0.904	rs7083614	chr10:135226236	G/A	cg19623624	chr10:135278901	LOC619207	-0.61	-4.83	-0.44	5.14e-6	Systemic lupus erythematosus;
THYM	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg11752832	chr7:134001865	SLC35B4	0.73	5.5	0.49	3.21e-7	Mean platelet volume;
THYM	cis	rs1161098	0.767	rs1161084	chr12:67828886	A/G	cg20473420	chr12:67782441	NA	0.93	4.77	0.44	6.59e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs6496667	0.865	rs75714371	chr15:90880602	G/A	cg22089800	chr15:90895588	ZNF774	0.76	4.69	0.43	9.31e-6	Rheumatoid arthritis;
THYM	cis	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg08133631	chr1:26527909	CATSPER4	-0.57	-4.63	-0.43	1.15e-5	Obesity-related traits;
THYM	cis	rs6032067	0.683	rs16989769	chr20:43780475	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	0.46	5.66	0.5	1.58e-7	Blood protein levels;
THYM	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs11696739	0.761	rs2254458	chr20:1551485	C/T	cg06479032	chr20:1246769	SNPH	0.58	4.45	0.42	2.33e-5	Mean platelet volume;
THYM	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs988913	1.000	rs9349741	chr6:54841709	G/C	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.75e-6	Menarche (age at onset);
THYM	cis	rs868036	0.681	rs4776978	chr15:68108305	A/G	cg24579218	chr15:68104479	NA	-0.83	-8.84	-0.67	5e-14	Restless legs syndrome;
THYM	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07157834	chr1:205819609	PM20D1	0.9	8.98	0.68	2.55e-14	Menarche (age at onset);
THYM	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg07959070	chr22:50026188	C22orf34	-0.27	-4.92	-0.45	3.56e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7408868	0.908	rs757474	chr19:15273624	T/C	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs539096	0.872	rs10890261	chr1:44052377	G/T	cg00143623	chr1:44495758	SLC6A9	-0.65	-5.03	-0.46	2.29e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg00012203	chr2:219082015	ARPC2	-0.69	-5.87	-0.52	6.36e-8	Colorectal cancer;
THYM	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg11764359	chr7:65958608	NA	0.69	4.78	0.44	6.27e-6	Aortic root size;
THYM	cis	rs1957429	0.614	rs61012404	chr14:65347649	C/T	cg23373153	chr14:65346875	NA	-1.29	-5.55	-0.49	2.56e-7	Pediatric areal bone mineral density (radius);
THYM	cis	rs9653442	0.648	rs6733895	chr2:100666082	C/G	cg07810366	chr2:100720526	AFF3	-0.4	-5.9	-0.52	5.64e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs986417	1.000	rs1955686	chr14:61093560	C/T	cg27398547	chr14:60952738	C14orf39	1.26	6.1	0.53	2.29e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs4242434	0.672	rs900266	chr8:22485295	A/T	cg01710189	chr8:22454888	PDLIM2	-0.48	-5.12	-0.47	1.56e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg17366294	chr4:99064904	C4orf37	0.57	6.96	0.58	4.44e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9913156	0.793	rs72835633	chr17:4562643	C/T	cg19197139	chr17:4613644	ARRB2	0.83	5.0	0.46	2.63e-6	Lymphocyte counts;
THYM	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg22907277	chr7:1156413	C7orf50	0.6	5.42	0.49	4.5e-7	Longevity;Endometriosis;
THYM	cis	rs995000	0.931	rs11207984	chr1:63013396	C/T	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs7100689	0.784	rs7081903	chr10:82162509	T/C	cg03086067	chr10:82368399	SH2D4B	-0.48	-4.55	-0.42	1.58e-5	Post bronchodilator FEV1;
THYM	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg24006582	chr15:45444508	DUOX1	-0.82	-6.89	-0.58	5.91e-10	Uric acid levels;
THYM	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg03433033	chr1:76189801	ACADM	0.76	9.93	0.71	2.38e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg16615211	chr3:44902933	MIR564;TMEM42	0.57	6.12	0.53	2.04e-8	Depressive symptoms;
THYM	cis	rs4713118	0.662	rs9468274	chr6:28026077	G/T	cg08968635	chr6:28129556	ZNF389	0.59	4.57	0.42	1.46e-5	Parkinson's disease;
THYM	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg03517284	chr6:25882590	NA	-0.7	-4.7	-0.43	8.76e-6	Height;
THYM	cis	rs7524258	0.900	rs7551574	chr1:7314363	G/T	cg07173049	chr1:7289937	CAMTA1	0.7	5.66	0.5	1.59e-7	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs2034088	0.833	rs7219151	chr17:440497	G/A	cg13332499	chr17:408570	NA	0.57	4.59	0.43	1.38e-5	Hip circumference adjusted for BMI;
THYM	cis	rs3540	0.513	rs2601154	chr15:90894284	T/C	cg22089800	chr15:90895588	ZNF774	0.83	6.85	0.57	7.4e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs12478296	0.792	rs3924263	chr2:243005167	A/C	cg06360820	chr2:242988706	NA	-0.97	-6.62	-0.56	2.16e-9	Obesity-related traits;
THYM	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.99	9.36	0.69	3.81e-15	Body mass index (adult);
THYM	cis	rs26232	0.517	rs154356	chr5:102499144	A/G	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.54e-6	Rheumatoid arthritis;
THYM	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs36051895	0.603	rs10123980	chr9:5130363	T/C	cg02405213	chr9:5042618	JAK2	-1.01	-10.97	-0.75	1.39e-18	Pediatric autoimmune diseases;
THYM	cis	rs4953911	0.601	rs7557129	chr2:135073476	C/G	cg18482303	chr2:135041380	MGAT5	0.27	4.47	0.42	2.18e-5	Multiple sclerosis (severity);
THYM	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg00278517	chr6:167070616	RPS6KA2	-0.34	-4.64	-0.43	1.13e-5	Crohn's disease;
THYM	cis	rs193541	0.509	rs6869268	chr5:122315510	T/C	cg19808643	chr5:122110361	SNX2	-0.65	-5.43	-0.49	4.32e-7	Glucose homeostasis traits;
THYM	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg01073479	chr16:3509474	NAT15	0.57	4.83	0.44	5.33e-6	Tuberculosis;
THYM	cis	rs425277	0.565	rs3128293	chr1:2065339	A/G	cg23803603	chr1:2058230	PRKCZ	-0.67	-5.67	-0.5	1.52e-7	Height;
THYM	cis	rs7100689	0.646	rs1340376	chr10:82128963	A/G	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs2456568	0.570	rs1827932	chr11:93663319	A/T	cg17595323	chr11:93583763	C11orf90	-0.51	-5.46	-0.49	3.83e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg03036452	chr22:46663545	TTC38	0.83	4.49	0.42	2e-5	LDL cholesterol;Cholesterol, total;
THYM	cis	rs8013055	0.846	rs7160747	chr14:105983740	A/G	cg04429589	chr14:105992532	TMEM121	-0.51	-5.4	-0.48	4.95e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs34638657	0.732	rs62045962	chr16:82200604	T/C	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.11	-0.64	1.73e-12	Lung adenocarcinoma;
THYM	cis	rs9611519	1.000	rs5751069	chr22:41627775	C/G	cg06481639	chr22:41940642	POLR3H	-0.6	-4.5	-0.42	1.93e-5	Neuroticism;
THYM	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	8.87	0.67	4.33e-14	Chronic sinus infection;
THYM	cis	rs7246657	0.882	rs6508716	chr19:37819010	T/C	cg22634378	chr19:37742834	NA	0.65	5.34	0.48	6.2e-7	Coronary artery calcification;
THYM	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08109568	chr15:31115862	NA	-0.63	-5.99	-0.52	3.68e-8	Huntington's disease progression;
THYM	cis	rs1158570	0.521	rs10089819	chr8:131172968	C/T	cg16277922	chr8:131349729	ASAP1	0.63	5.41	0.49	4.61e-7	Platelet count;
THYM	cis	rs7584330	0.554	rs77194105	chr2:238436463	T/C	cg08992911	chr2:238395768	MLPH	1.11	6.57	0.56	2.65e-9	Prostate cancer;
THYM	cis	rs2072510	0.593	rs2540499	chr12:96399869	A/C	cg18817487	chr12:96390143	HAL	-0.49	-6.1	-0.53	2.32e-8	Metabolite levels (small molecules and protein measures);
THYM	cis	rs478304	0.627	rs1073602	chr11:65455386	G/C	cg27068330	chr11:65405492	SIPA1	-1.03	-10.31	-0.73	3.55e-17	Acne (severe);
THYM	cis	rs6918586	0.615	rs198824	chr6:26122783	T/C	cg03517284	chr6:25882590	NA	0.71	5.54	0.49	2.68e-7	Schizophrenia;
THYM	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.44	-0.49	4.17e-7	Monocyte percentage of white cells;
THYM	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg18230493	chr5:56204884	C5orf35	-0.92	-6.99	-0.58	3.72e-10	Initial pursuit acceleration;
THYM	cis	rs854765	0.506	rs7210400	chr17:17949957	C/T	cg04398451	chr17:18023971	MYO15A	0.9	9.82	0.71	3.99e-16	Total body bone mineral density;
THYM	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg04990556	chr1:26633338	UBXN11	-0.89	-8.52	-0.66	2.34e-13	Obesity-related traits;
THYM	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg03354898	chr7:1950403	MAD1L1	-0.5	-4.73	-0.44	7.75e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2456568	0.771	rs8181530	chr11:93638678	G/A	cg26875233	chr11:93583750	C11orf90	-0.53	-5.53	-0.49	2.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs11186	0.556	rs58243388	chr2:189953551	G/A	cg11041835	chr2:189156425	GULP1	0.78	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12681287	0.752	rs13255058	chr8:87287445	G/A	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs9527	0.830	rs11191442	chr10:104643596	T/A	cg04362960	chr10:104952993	NT5C2	0.64	4.72	0.44	8.19e-6	Arsenic metabolism;
THYM	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	1.0	9.65	0.7	9.25e-16	Body mass index (adult);
THYM	cis	rs7078219	0.505	rs7916751	chr10:101285650	T/A	cg23904955	chr10:101282759	NA	-0.38	-4.79	-0.44	6.06e-6	Dental caries;
THYM	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg05962950	chr11:130786565	SNX19	0.89	8.5	0.66	2.63e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg12826209	chr6:26865740	GUSBL1	0.92	4.98	0.45	2.89e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg25554036	chr4:6271136	WFS1	0.61	5.66	0.5	1.59e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs35883536	0.647	rs17402630	chr1:101046587	C/T	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs7818345	0.967	rs13255677	chr8:19288985	C/T	cg11303988	chr8:19266685	CSGALNACT1	0.44	4.92	0.45	3.57e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs6754311	0.517	rs60453613	chr2:136527120	G/C	cg04750100	chr2:136595281	LCT	0.53	5.13	0.47	1.55e-6	Mosquito bite size;
THYM	cis	rs995000	0.899	rs1781212	chr1:62977419	G/A	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs2279817	1.000	rs2279816	chr1:18021867	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.75	4.65	0.43	1.07e-5	Neuroticism;
THYM	cis	rs6430585	0.697	rs7607174	chr2:136513670	T/A	cg23851026	chr2:136556271	LCT	0.79	7.53	0.61	2.86e-11	Corneal structure;
THYM	cis	rs4662945	0.603	rs2406981	chr2:130305487	A/G	cg05903289	chr2:130345205	NA	-0.57	-5.42	-0.49	4.45e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs1007190	0.881	rs9909048	chr17:42973517	G/C	cg15406952	chr17:42872593	NA	0.8	5.57	0.5	2.34e-7	DNA methylation (variation);
THYM	cis	rs17255340	0.539	rs1144185	chr6:84012619	A/G	cg08257003	chr6:84140564	ME1	0.53	4.64	0.43	1.13e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs6877440	1.000	rs73217335	chr5:109046373	T/C	cg17395555	chr5:108820864	NA	0.55	4.65	0.43	1.09e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs4746818	1.000	rs7918066	chr10:70913116	C/T	cg04149295	chr10:70884716	VPS26A	0.78	5.31	0.48	7.18e-7	Left atrial antero-posterior diameter;
THYM	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3812049	0.784	rs2568928	chr5:127487603	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.74	-5.42	-0.49	4.45e-7	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs7953508	0.750	rs7977788	chr12:93982332	G/A	cg13201927	chr12:93977447	NA	0.7	5.19	0.47	1.17e-6	Pubertal anthropometrics;
THYM	cis	rs2290159	0.800	rs5746195	chr3:12653800	A/G	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs9682041	0.932	rs6782252	chr3:170133639	C/T	cg11886554	chr3:170076028	SKIL	1.51	5.95	0.52	4.42e-8	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs939658	0.805	rs12902831	chr15:79433171	G/A	cg17916960	chr15:79447300	NA	-0.69	-8.1	-0.64	1.82e-12	Refractive error;
THYM	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.68	-4.57	-0.42	1.44e-5	Menarche (age at onset);
THYM	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg02527881	chr3:46936655	PTH1R	-0.61	-5.7	-0.51	1.33e-7	Colorectal cancer;
THYM	cis	rs1971762	0.523	rs7135101	chr12:54080605	G/A	cg16917193	chr12:54089295	NA	0.91	9.3	0.69	5.24e-15	Height;
THYM	cis	rs7546094	0.871	rs7512948	chr1:113081176	G/A	cg25616829	chr1:112535356	NA	0.56	4.68	0.43	9.65e-6	Platelet distribution width;
THYM	cis	rs2066819	0.892	rs17118431	chr12:56667100	A/G	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs1642645	0.757	rs3845574	chr1:42476574	C/A	cg22816091	chr1:42611670	NA	0.62	5.52	0.49	2.99e-7	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs10504073	0.647	rs10808745	chr8:49989037	G/A	cg00325661	chr8:49890786	NA	0.93	8.79	0.67	6.32e-14	Blood metabolite ratios;
THYM	cis	rs4563143	0.675	rs55976444	chr19:29265214	G/C	cg03161606	chr19:29218774	NA	0.87	7.73	0.62	1.09e-11	Methadone dose in opioid dependence;
THYM	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg04455712	chr21:45112962	RRP1B	0.54	5.16	0.47	1.32e-6	Mean corpuscular volume;
THYM	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg06026331	chr20:60912101	LAMA5	0.61	4.8	0.44	5.96e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	trans	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg18187862	chr3:45730750	SACM1L	-0.89	-7.39	-0.6	5.67e-11	Primary sclerosing cholangitis;
THYM	cis	rs3768617	0.510	rs3768615	chr1:183103604	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.92	0.45	3.58e-6	Fuchs's corneal dystrophy;
THYM	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg07936489	chr17:37558343	FBXL20	0.82	5.61	0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs5758511	0.508	rs2854827	chr22:42461918	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.57	4.94	0.45	3.28e-6	Birth weight;
THYM	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.85	0.51	6.98e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs17645023	0.501	rs7219496	chr17:64939936	C/T	cg24983862	chr17:65242497	HELZ	0.49	4.61	0.43	1.26e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.98	4.89	0.45	4.07e-6	Initial pursuit acceleration;
THYM	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg22166914	chr1:53195759	ZYG11B	0.95	12.14	0.78	4.96e-21	Monocyte count;
THYM	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg18681998	chr4:17616180	MED28	1.01	10.47	0.73	1.66e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg11279151	chr3:101281821	RG9MTD1	-1.06	-8.73	-0.67	8.69e-14	Colonoscopy-negative controls vs population controls;
THYM	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg11812906	chr14:75593930	NEK9	-0.82	-7.15	-0.59	1.8e-10	Height;
THYM	cis	rs4936891	0.645	rs896891	chr11:123910740	C/T	cg22125253	chr11:123886957	OR10G4	0.53	4.57	0.42	1.49e-5	Male fertility;
THYM	trans	rs28595532	0.920	rs114314373	chr4:119639128	G/A	cg13773247	chr2:42276988	PKDCC	0.89	6.93	0.58	4.92e-10	Cannabis dependence symptom count;
THYM	cis	rs986417	1.000	rs1950319	chr14:61048844	T/C	cg27398547	chr14:60952738	C14orf39	1.21	6.09	0.53	2.37e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg26513180	chr16:89883248	FANCA	0.73	7.48	0.61	3.74e-11	Vitiligo;
THYM	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg23161317	chr6:28129485	ZNF389	0.67	5.37	0.48	5.68e-7	Cardiac Troponin-T levels;
THYM	cis	rs28595532	0.920	rs115430947	chr4:119737149	C/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs11605275	1.000	rs77993017	chr11:20031388	C/G	cg14835545	chr11:20032148	NAV2	-1.38	-7.35	-0.6	7e-11	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg05340658	chr4:99064831	C4orf37	0.54	4.52	0.42	1.78e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10927875	0.541	rs1763596	chr1:16343835	C/T	cg21385522	chr1:16154831	NA	0.65	4.65	0.43	1.08e-5	Dilated cardiomyopathy;
THYM	cis	rs4481887	1.000	rs10888352	chr1:248451965	G/A	cg13385794	chr1:248469461	NA	0.69	4.71	0.43	8.6e-6	Common traits (Other);
THYM	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg14008862	chr17:28927542	LRRC37B2	0.96	4.51	0.42	1.85e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg26967526	chr14:35346199	BAZ1A	-0.8	-5.27	-0.48	8.47e-7	Psoriasis;
THYM	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs8016982	0.634	rs1035948	chr14:81682392	C/T	cg01989461	chr14:81687754	GTF2A1	0.82	7.05	0.59	2.9e-10	Schizophrenia;
THYM	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg18758796	chr5:131593413	PDLIM4	0.6	5.5	0.49	3.18e-7	Acylcarnitine levels;
THYM	trans	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg25214090	chr10:38739885	LOC399744	0.86	7.53	0.61	2.86e-11	Corneal astigmatism;
THYM	cis	rs892961	0.899	rs8071024	chr17:75414067	T/C	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs988913	0.813	rs2143798	chr6:54753054	A/T	cg18532076	chr6:54711417	FAM83B	0.5	5.07	0.46	1.95e-6	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs72772090	0.539	rs11746534	chr5:96124807	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg07424592	chr7:64974309	NA	-0.99	-5.15	-0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs11690935	0.731	rs10930491	chr2:172569824	A/G	cg13550731	chr2:172543902	DYNC1I2	0.57	4.45	0.42	2.33e-5	Schizophrenia;
THYM	cis	rs17739794	0.517	rs10106028	chr8:783286	C/A	cg07178994	chr8:816998	NA	-0.78	-7.14	-0.59	1.83e-10	Clozapine-induced cytotoxicity;
THYM	cis	rs1692580	0.840	rs696094	chr1:2169215	G/A	cg21442419	chr1:2182373	SKI	-0.41	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg09904177	chr6:26538194	HMGN4	0.54	4.57	0.42	1.47e-5	Intelligence (multi-trait analysis);
THYM	cis	rs208520	0.690	rs207081	chr6:66773742	A/G	cg07460842	chr6:66804631	NA	-1.09	-7.92	-0.63	4.41e-12	Exhaled nitric oxide output;
THYM	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg09033563	chr22:24373618	LOC391322	-0.6	-5.77	-0.51	9.78e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6570726	0.526	rs9403699	chr6:145730685	G/T	cg23711669	chr6:146136114	FBXO30	0.58	4.58	0.43	1.39e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg05872129	chr22:39784769	NA	-1.05	-8.93	-0.68	3.14e-14	Post bronchodilator FEV1;
THYM	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs709400	1.000	rs861538	chr14:104166733	C/T	cg26031613	chr14:104095156	KLC1	1.22	12.29	0.78	2.4e-21	Body mass index;
THYM	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-5.99	-0.52	3.73e-8	Personality dimensions;
THYM	cis	rs2440012	0.681	rs56963720	chr13:19405371	G/C	cg05791018	chr13:19965014	NA	-0.65	-4.54	-0.42	1.62e-5	Longevity;
THYM	cis	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg07988820	chr12:82153109	PPFIA2	-0.82	-5.23	-0.47	9.93e-7	Resting heart rate;
THYM	cis	rs61990749	0.597	rs176980	chr14:78198449	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	-1.17	-8.02	-0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg17294928	chr15:75287854	SCAMP5	-1.01	-9.1	-0.68	1.4e-14	Blood trace element (Zn levels);
THYM	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg06219351	chr7:158114137	PTPRN2	-0.74	-7.21	-0.59	1.32e-10	Calcium levels;
THYM	cis	rs55702914	0.628	rs788016	chr2:198352293	A/G	cg00792783	chr2:198669748	PLCL1	-0.63	-4.64	-0.43	1.11e-5	Major depression and alcohol dependence;
THYM	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg12935359	chr14:103987150	CKB	-0.64	-6.43	-0.55	5.14e-9	Body mass index;
THYM	cis	rs526231	0.543	rs72785717	chr5:102333105	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.18	-0.47	1.22e-6	Primary biliary cholangitis;
THYM	cis	rs1499972	0.878	rs56174517	chr3:117616218	G/T	cg07612923	chr3:117604196	NA	1.2	5.04	0.46	2.19e-6	Schizophrenia;
THYM	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg04842962	chr6:43655489	MRPS18A	1.4	15.48	0.85	1.01e-27	IgG glycosylation;
THYM	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg27168131	chr21:44088823	PDE9A	-0.45	-4.5	-0.42	1.92e-5	Mean corpuscular volume;
THYM	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg08000102	chr2:233561755	GIGYF2	-0.69	-6.11	-0.53	2.22e-8	Coronary artery disease;
THYM	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg16586182	chr3:47516702	SCAP	-0.64	-5.61	-0.5	2.03e-7	Colorectal cancer;
THYM	cis	rs4242434	0.699	rs878053	chr8:22483849	T/C	cg11461670	chr8:22454935	PDLIM2	-0.34	-6.28	-0.54	1.01e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg19913688	chr11:428466	ANO9	-0.86	-4.53	-0.42	1.69e-5	Body mass index;
THYM	cis	rs6076065	0.723	rs2275787	chr20:23338486	A/G	cg11657817	chr20:23433608	CST11	0.31	4.55	0.42	1.59e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs11776767	0.538	rs12546026	chr8:10710715	G/T	cg20449619	chr8:10581784	SOX7	0.51	4.55	0.42	1.59e-5	Triglycerides;
THYM	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg12564285	chr5:131593104	PDLIM4	-0.44	-4.76	-0.44	6.83e-6	Breast cancer;
THYM	cis	rs7309	0.870	rs2358016	chr2:162007430	C/G	cg16506815	chr2:162101123	NA	-0.55	-4.56	-0.42	1.55e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs9906944	0.657	rs4643373	chr17:47123423	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.52	-4.52	-0.42	1.75e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7078219	0.505	rs10883362	chr10:101286984	C/T	cg04972745	chr10:101287846	NA	-0.5	-4.65	-0.43	1.08e-5	Dental caries;
THYM	cis	rs1065852	0.526	rs9607869	chr22:42418110	T/A	cg08431931	chr22:42394659	WBP2NL	0.75	6.1	0.53	2.28e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs7226229	0.632	rs2364527	chr17:20899542	T/G	cg21263980	chr17:20946333	USP22	0.73	4.98	0.45	2.84e-6	Blood trace element (Se levels);
THYM	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3849570	0.925	rs6765917	chr3:81891116	C/T	cg07356753	chr3:81810745	GBE1	-0.84	-6.34	-0.55	7.84e-9	Waist circumference;Body mass index;
THYM	cis	rs9876781	1.000	rs9864371	chr3:48426766	A/C	cg06066452	chr3:48470258	PLXNB1	0.26	4.88	0.45	4.26e-6	Longevity;
THYM	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06873352	chr17:61820015	STRADA	0.78	9.87	0.71	3.13e-16	Prudent dietary pattern;
THYM	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg16342193	chr10:102329863	NA	-0.6	-6.21	-0.54	1.41e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg21385522	chr1:16154831	NA	0.76	5.61	0.5	2e-7	Dilated cardiomyopathy;
THYM	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg02527881	chr3:46936655	PTH1R	-0.65	-6.55	-0.56	2.97e-9	Colorectal cancer;
THYM	cis	rs12935418	0.561	rs2287991	chr16:81040555	G/T	cg16651780	chr16:81037892	C16orf61	0.89	6.16	0.53	1.78e-8	Mean corpuscular volume;
THYM	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg11812906	chr14:75593930	NEK9	0.82	7.45	0.61	4.18e-11	Height;
THYM	cis	rs3087591	0.960	rs2905797	chr17:29537458	G/C	cg24425628	chr17:29625626	OMG;NF1	0.67	5.36	0.48	5.77e-7	Hip circumference;
THYM	cis	rs6032067	0.777	rs2868234	chr20:43794026	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs7849270	0.959	rs2094704	chr9:131918294	A/G	cg14069949	chr9:131965419	NA	0.5	4.52	0.42	1.8e-5	Blood metabolite ratios;
THYM	cis	rs42648	0.869	rs10266179	chr7:89909982	C/T	cg25739043	chr7:89950458	NA	-0.53	-4.53	-0.42	1.72e-5	Homocysteine levels;
THYM	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs9309473	0.539	rs6745560	chr2:73827117	C/T	cg19565262	chr2:73869966	NAT8	-0.56	-4.75	-0.44	7.11e-6	Metabolite levels;
THYM	cis	rs10782582	0.593	rs11576534	chr1:76112751	C/T	cg10523679	chr1:76189770	ACADM	-0.55	-4.65	-0.43	1.06e-5	Daytime sleep phenotypes;
THYM	cis	rs6076065	0.630	rs6083127	chr20:23424886	T/C	cg11657817	chr20:23433608	CST11	0.41	6.14	0.53	1.87e-8	Facial morphology (factor 15, philtrum width);
THYM	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg18252515	chr7:66147081	NA	0.63	4.7	0.43	8.9e-6	Aortic root size;
THYM	cis	rs1065852	0.526	rs1062753	chr22:42392811	G/A	cg01059385	chr22:42394853	WBP2NL	0.57	4.66	0.43	1.04e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg02753203	chr1:228287806	NA	-0.61	-5.28	-0.48	8.19e-7	Diastolic blood pressure;
THYM	cis	rs72627123	0.867	rs11848920	chr14:74476866	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.52	0.56	3.44e-9	Morning vs. evening chronotype;
THYM	cis	rs1971762	0.563	rs7958775	chr12:54077556	T/C	cg16917193	chr12:54089295	NA	0.9	9.19	0.69	8.89e-15	Height;
THYM	cis	rs293526	0.959	rs293512	chr6:83640593	G/A	cg23278060	chr6:83777448	DOPEY1	0.61	4.48	0.42	2.1e-5	Crohn's disease;
THYM	cis	rs11225247	0.772	rs34296997	chr11:102238607	A/G	cg11690896	chr11:102217788	BIRC2	1.12	5.18	0.47	1.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.07	-5.3	-0.48	7.38e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6496667	0.683	rs1869180	chr15:90895467	T/C	cg22089800	chr15:90895588	ZNF774	0.81	6.32	0.54	8.55e-9	Rheumatoid arthritis;
THYM	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg04772025	chr11:68637568	NA	0.63	6.58	0.56	2.59e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg03474202	chr17:45855739	NA	-0.74	-6.48	-0.55	4.1e-9	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg10515332	chr4:99064459	C4orf37	0.58	4.64	0.43	1.13e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg11301795	chr4:187892539	NA	1.05	13.97	0.82	9.35e-25	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10147992	0.539	rs10141197	chr14:25504988	A/G	cg01495907	chr14:24842974	NFATC4	0.64	4.61	0.43	1.27e-5	White blood cell types;
THYM	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg13695892	chr22:41940480	POLR3H	0.86	6.75	0.57	1.18e-9	Vitiligo;
THYM	cis	rs9296092	0.538	rs9296094	chr6:33520064	A/G	cg13560919	chr6:33536144	NA	-0.94	-9.31	-0.69	4.9e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs648090	1.000	rs648090	chr11:125071163	A/G	cg03528824	chr11:125110227	PKNOX2	0.55	4.51	0.42	1.82e-5	Testicular germ cell tumor;
THYM	cis	rs6876348	0.516	rs257901	chr5:128315224	T/C	cg25555059	chr5:128301488	SLC27A6	-0.45	-4.73	-0.44	7.81e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg04518342	chr5:131593106	PDLIM4	-0.55	-6.18	-0.54	1.61e-8	Acylcarnitine levels;
THYM	cis	rs748404	0.578	rs2584701	chr15:43684939	T/C	cg12861797	chr15:43585817	TGM7	0.47	4.98	0.46	2.8e-6	Lung cancer;
THYM	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg12011299	chr4:100065546	ADH4	1.02	11.89	0.77	1.68e-20	Alcohol dependence;
THYM	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg26384229	chr12:38710491	ALG10B	-0.89	-9.05	-0.68	1.77e-14	Heart rate;
THYM	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg06627628	chr2:24431161	ITSN2	-0.75	-5.29	-0.48	7.82e-7	Asthma;
THYM	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg14895029	chr7:2775587	GNA12	-0.67	-4.83	-0.44	5.21e-6	Height;
THYM	cis	rs4731207	0.724	rs57458159	chr7:124500810	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg20486651	chr6:167070296	RPS6KA2	0.5	4.79	0.44	6.18e-6	Crohn's disease;
THYM	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg07371521	chr5:154026371	NA	0.57	5.45	0.49	3.96e-7	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs2637266	0.600	rs2579754	chr10:78269798	T/G	cg18941641	chr10:78392320	NA	0.6	4.65	0.43	1.07e-5	Pulmonary function;
THYM	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg20295408	chr7:1910781	MAD1L1	-0.58	-4.63	-0.43	1.14e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.64	-0.62	1.74e-11	Personality dimensions;
THYM	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg02887458	chr19:19495540	GATAD2A	-0.47	-5.17	-0.47	1.31e-6	Bipolar disorder;
THYM	cis	rs7078219	0.505	rs10883371	chr10:101292455	G/T	cg23904955	chr10:101282759	NA	-0.36	-4.56	-0.42	1.55e-5	Dental caries;
THYM	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	Reticulocyte fraction of red cells;
THYM	cis	rs3820068	0.677	rs72643691	chr1:15856251	T/C	cg05660106	chr1:15850417	CASP9	1.11	9.62	0.7	1.09e-15	Systolic blood pressure;
THYM	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg13609457	chr4:120235615	NA	0.59	5.27	0.48	8.38e-7	Corneal astigmatism;
THYM	cis	rs7772486	0.754	rs9390356	chr6:146118983	A/T	cg23711669	chr6:146136114	FBXO30	-0.98	-10.47	-0.73	1.68e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg20283391	chr11:68216788	NA	0.63	5.08	0.46	1.85e-6	Total body bone mineral density;
THYM	cis	rs1559088	1.000	rs12979164	chr19:33553228	G/C	cg03563238	chr19:33554763	RHPN2	-0.5	-4.48	-0.42	2.04e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg09682330	chr6:28411287	ZSCAN23	-0.51	-4.49	-0.42	1.97e-5	Pubertal anthropometrics;
THYM	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	7.17	0.59	1.64e-10	Lung cancer in ever smokers;
THYM	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg03351412	chr1:154909251	PMVK	0.73	5.14	0.47	1.49e-6	Prostate cancer;
THYM	cis	rs79387448	0.745	rs17027430	chr2:103163237	T/C	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs2229238	0.866	rs61403567	chr1:154504927	T/C	cg21262032	chr1:154437693	IL6R	-0.63	-5.65	-0.5	1.68e-7	Coronary heart disease;
THYM	cis	rs79387448	0.745	rs1880000	chr2:103099953	T/C	cg09003973	chr2:102972529	NA	0.78	4.85	0.45	4.84e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs2404602	0.647	rs4886840	chr15:77179002	A/G	cg23625390	chr15:77176239	SCAPER	-0.81	-5.75	-0.51	1.09e-7	Blood metabolite levels;
THYM	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	6.94	0.58	4.86e-10	Prudent dietary pattern;
THYM	cis	rs4474465	1.000	rs10899518	chr11:78180508	A/C	cg19901956	chr11:77921274	USP35	-0.6	-4.55	-0.42	1.59e-5	Alzheimer's disease (survival time);
THYM	cis	rs2857078	0.654	rs9896789	chr17:42314567	C/T	cg13607699	chr17:42295918	UBTF	0.91	8.67	0.66	1.13e-13	Red cell distribution width;Reticulocyte count;
THYM	cis	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs17539620	0.808	rs6904264	chr6:154878380	C/G	cg20019720	chr6:154832845	CNKSR3	-0.4	-4.55	-0.42	1.62e-5	Lipoprotein (a) levels;
THYM	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs986417	1.000	rs996285	chr14:60869837	T/G	cg27398547	chr14:60952738	C14orf39	-1.32	-6.48	-0.55	4.09e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs6430585	0.528	rs7573555	chr2:136694905	C/T	cg20242066	chr2:136595261	LCT	-0.5	-4.86	-0.45	4.68e-6	Corneal structure;
THYM	cis	rs4843185	0.637	rs4143866	chr16:85716366	A/G	cg26571870	chr16:85723150	GINS2	-0.4	-4.68	-0.43	9.61e-6	Platelet distribution width;
THYM	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg19761014	chr17:28927070	LRRC37B2	0.85	4.9	0.45	3.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11671005	0.735	rs34511020	chr19:58921296	A/G	cg18639983	chr19:58920768	ZNF584	0.59	5.0	0.46	2.63e-6	Mean platelet volume;
THYM	cis	rs9902453	0.740	rs2628189	chr17:28088813	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg02018176	chr4:1364513	KIAA1530	0.55	4.94	0.45	3.33e-6	Obesity-related traits;
THYM	cis	rs6570726	0.764	rs451108	chr6:145844309	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.42	-0.49	4.53e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg24642844	chr7:1081250	C7orf50	-1.2	-5.2	-0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9326248	0.559	rs4938334	chr11:116931042	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.66	5.27	0.48	8.49e-7	Blood protein levels;
THYM	cis	rs61774743	0.754	rs11581271	chr1:41835061	C/G	cg08462924	chr1:41848221	NA	0.77	9.13	0.68	1.17e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2340727	0.668	rs12045320	chr1:161828690	T/G	cg06514368	chr1:161719587	DUSP12	-0.81	-4.62	-0.43	1.2e-5	White blood cell count;Hematology traits;
THYM	cis	rs191220855	1	rs191220855	chr2:200778130	A/G	cg23649088	chr2:200775458	C2orf69	-0.88	-4.57	-0.42	1.47e-5	Chickenpox;
THYM	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg05855489	chr10:104503620	C10orf26	-0.59	-4.62	-0.43	1.23e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg09359103	chr1:154839909	KCNN3	-0.81	-10.62	-0.74	7.86e-18	Prostate cancer;
THYM	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs13082711	0.911	rs11708710	chr3:27457348	A/C	cg02860705	chr3:27208620	NA	0.72	5.14	0.47	1.46e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs4523957	0.583	rs923863	chr17:2031387	A/G	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	cis	rs3917265	0.602	rs3917290	chr2:102782079	C/T	cg13315345	chr2:102803985	IL1RL2	0.54	5.32	0.48	6.81e-7	Atopic dermatitis;
THYM	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.02	-9.79	-0.71	4.55e-16	Homoarginine levels;
THYM	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg26924012	chr15:45694286	SPATA5L1	1.13	11.02	0.75	1.11e-18	Homoarginine levels;
THYM	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs854765	0.587	rs12936927	chr17:17726965	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.63	-5.43	-0.49	4.37e-7	Total body bone mineral density;
THYM	cis	rs7119	0.717	rs11630916	chr15:77821331	G/A	cg10437265	chr15:77819839	NA	0.77	7.68	0.62	1.44e-11	Type 2 diabetes;
THYM	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs8060598	0.745	rs1861757	chr16:50752815	T/C	cg05261686	chr16:50743296	NOD2	0.4	4.84	0.44	5.09e-6	Leprosy;
THYM	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	-0.99	-8.16	-0.64	1.36e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs1883415	0.727	rs2760117	chr6:24504189	C/T	cg00346970	chr6:24499591	ALDH5A1	0.42	5.62	0.5	1.86e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7829975	0.774	rs11249893	chr8:8700851	C/T	cg08975724	chr8:8085496	FLJ10661	0.66	5.43	0.49	4.33e-7	Mood instability;
THYM	cis	rs752010	0.841	rs6661784	chr1:42080312	A/T	cg13396354	chr1:41153348	NA	-0.48	-4.71	-0.43	8.51e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg20387954	chr3:183756860	HTR3D	0.51	5.0	0.46	2.59e-6	Anterior chamber depth;
THYM	cis	rs73219805	0.838	rs17055172	chr8:26225612	G/A	cg22461835	chr8:26723365	ADRA1A	-0.54	-4.56	-0.42	1.54e-5	Schizophrenia;
THYM	cis	rs2702888	0.512	rs2738153	chr8:6751900	T/G	cg26795848	chr8:6756730	NA	-0.53	-4.66	-0.43	1.02e-5	Blood pressure;
THYM	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4478037	0.822	rs9868526	chr3:33124269	A/G	cg19404215	chr3:33155277	CRTAP	-0.88	-5.87	-0.52	6.25e-8	Major depressive disorder;
THYM	cis	rs3820068	0.580	rs34426856	chr1:16006315	C/T	cg05660106	chr1:15850417	CASP9	0.66	5.37	0.48	5.64e-7	Systolic blood pressure;
THYM	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg05896524	chr21:47604654	C21orf56	0.83	5.44	0.49	4.08e-7	Testicular germ cell tumor;
THYM	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs11586313	0.507	rs6658967	chr1:152870372	C/G	cg07796016	chr1:152779584	LCE1C	-0.75	-5.05	-0.46	2.16e-6	Vitamin D levels;
THYM	cis	rs11030122	0.702	rs10835403	chr11:3990941	A/C	cg18678763	chr11:4115507	RRM1	0.44	5.12	0.47	1.57e-6	Mean platelet volume;Platelet distribution width;
THYM	cis	rs12282928	0.670	rs12576395	chr11:48355132	A/G	cg22827986	chr11:48284249	OR4X1	-0.55	-5.67	-0.5	1.5e-7	Migraine - clinic-based;
THYM	cis	rs6763768	0.578	rs13090627	chr3:53406425	C/T	cg22900224	chr3:52804907	NEK4	0.72	4.67	0.43	9.9e-6	Bacterial meningitis;
THYM	cis	rs9311676	0.656	rs55711525	chr3:58397775	C/A	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs1729951	0.575	rs1654925	chr3:136690391	C/T	cg21827317	chr3:136751795	NA	-0.75	-6.64	-0.56	1.92e-9	Neuroticism;
THYM	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.22e-7	Corneal astigmatism;
THYM	cis	rs61931739	0.711	rs7968821	chr12:34318351	G/A	cg10856724	chr12:34555212	NA	-0.66	-5.89	-0.52	5.93e-8	Morning vs. evening chronotype;
THYM	cis	rs4523957	0.583	rs8077597	chr17:2043818	C/T	cg16513277	chr17:2031491	SMG6	-1.04	-9.87	-0.71	3.06e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg23711669	chr6:146136114	FBXO30	0.87	8.07	0.64	2.16e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg01324343	chr3:183735012	ABCC5	0.9	13.47	0.81	9.06e-24	Anterior chamber depth;
THYM	cis	rs1018836	0.923	rs4735268	chr8:91629715	C/T	cg16814680	chr8:91681699	NA	-0.84	-6.98	-0.58	4.03e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6430585	0.528	rs7573555	chr2:136694905	C/T	cg07169764	chr2:136633963	MCM6	-1.23	-14.81	-0.84	1.97e-26	Corneal structure;
THYM	cis	rs2276314	0.857	rs62101393	chr18:33592168	T/C	cg19628046	chr18:33552617	C18orf21	0.74	5.43	0.49	4.29e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg14018140	chr10:458528	DIP2C	0.57	6.45	0.55	4.6e-9	Psychosis in Alzheimer's disease;
THYM	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	cis	rs1534166	1.000	rs1534166	chr3:133537067	C/T	cg08439880	chr3:133502540	NA	-0.7	-5.4	-0.48	4.92e-7	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg11764359	chr7:65958608	NA	-0.82	-6.56	-0.56	2.81e-9	Aortic root size;
THYM	cis	rs1348850	0.526	rs935426	chr2:178369433	T/C	cg27490568	chr2:178487706	NA	0.68	5.53	0.49	2.77e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs79387448	0.745	rs2310294	chr2:103165706	A/G	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg17775962	chr7:1200435	ZFAND2A	0.4	4.9	0.45	3.87e-6	Longevity;Endometriosis;
THYM	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg18538332	chr22:24372958	LOC391322	-0.86	-8.76	-0.67	7.42e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7119	0.689	rs12901765	chr15:77819103	C/A	cg10437265	chr15:77819839	NA	0.76	7.54	0.61	2.76e-11	Type 2 diabetes;
THYM	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg03597347	chr6:28058909	ZSCAN12L1	0.62	4.55	0.42	1.62e-5	Cardiac Troponin-T levels;
THYM	cis	rs3862260	0.509	rs10754416	chr1:120163531	A/G	cg11530693	chr1:120165357	ZNF697	1.06	12.05	0.78	7.51e-21	Systemic lupus erythematosus;
THYM	cis	rs7246657	0.882	rs8112610	chr19:37928730	C/A	cg22634378	chr19:37742834	NA	0.62	5.18	0.47	1.22e-6	Coronary artery calcification;
THYM	cis	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg21775007	chr8:11205619	TDH	-0.71	-5.5	-0.49	3.18e-7	Retinal vascular caliber;
THYM	cis	rs2108225	0.837	rs6958729	chr7:107451211	A/G	cg18560240	chr7:107437656	SLC26A3	0.91	6.82	0.57	8.2e-10	Ulcerative colitis;
THYM	cis	rs12579753	1.000	rs7966755	chr12:82221604	A/G	cg07988820	chr12:82153109	PPFIA2	-0.73	-4.61	-0.43	1.23e-5	Resting heart rate;
THYM	cis	rs35264875	0.851	rs7933746	chr11:68867722	A/G	cg01993067	chr11:68851601	TPCN2	0.78	4.85	0.45	4.79e-6	Blond vs. brown hair color;
THYM	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.65	4.76	0.44	6.99e-6	Aortic root size;
THYM	cis	rs8048589	0.615	rs12924889	chr16:12241768	A/G	cg02910054	chr16:12241554	SNX29	0.83	7.02	0.58	3.27e-10	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs7631605	0.905	rs1392749	chr3:37205191	A/G	cg21328643	chr3:37258149	NA	0.52	5.12	0.47	1.58e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg07362569	chr17:61921086	SMARCD2	0.57	5.1	0.46	1.76e-6	Prudent dietary pattern;
THYM	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs6032067	1.000	rs35284867	chr20:43845836	A/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.69	-6.28	-0.54	1.02e-8	Blood protein levels;
THYM	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg04043695	chr12:129287642	SLC15A4	-0.64	-5.26	-0.47	9.04e-7	Systemic lupus erythematosus;
THYM	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg11494091	chr17:61959527	GH2	0.69	6.42	0.55	5.32e-9	Height;
THYM	cis	rs6032067	1.000	rs13038434	chr20:43888106	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-5.55	-0.49	2.63e-7	Blood protein levels;
THYM	cis	rs2286885	0.965	rs4837091	chr9:129244928	A/G	cg14294646	chr9:129243551	FAM125B	-0.67	-6.38	-0.55	6.32e-9	Intraocular pressure;
THYM	cis	rs2219968	0.961	rs2128016	chr8:78964507	C/T	cg00738934	chr8:78996279	NA	0.91	9.74	0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs236907	0.859	rs17596081	chr1:171746276	G/T	cg20598894	chr1:171756153	METTL13	-0.71	-5.41	-0.48	4.79e-7	Mean platelet volume;
THYM	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	5.52	0.49	2.88e-7	Hip circumference adjusted for BMI;
THYM	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-11.27	-0.76	3.31e-19	Coronary artery disease;
THYM	cis	rs2688608	0.901	rs2459446	chr10:75601596	C/T	cg23231163	chr10:75533350	FUT11	0.31	4.48	0.42	2.08e-5	Inflammatory bowel disease;
THYM	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7586879	0.828	rs10184813	chr2:25090236	T/C	cg01884057	chr2:25150051	NA	0.51	4.49	0.42	2.01e-5	Body mass index;
THYM	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg24375607	chr4:120327624	NA	0.65	5.42	0.49	4.43e-7	Corneal astigmatism;
THYM	cis	rs2836974	0.604	rs914156	chr21:40717478	C/A	cg06238570	chr21:40685208	BRWD1	0.65	4.5	0.42	1.92e-5	Cognitive function;
THYM	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg19077165	chr18:44547161	KATNAL2	0.46	4.83	0.44	5.25e-6	Educational attainment;
THYM	cis	rs7584330	0.737	rs13397017	chr2:238361241	G/A	cg16989719	chr2:238392110	NA	-0.6	-5.82	-0.51	8.08e-8	Prostate cancer;
THYM	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg02696790	chr15:75250997	RPP25	0.5	4.56	0.42	1.53e-5	Breast cancer;
THYM	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.61	4.63	0.43	1.16e-5	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs9733	0.596	rs7549795	chr1:150656873	G/A	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg27446573	chr6:127587934	RNF146	1.03	9.76	0.71	5.36e-16	Breast cancer;
THYM	cis	rs2637266	1.000	rs7098929	chr10:78361194	T/G	cg18941641	chr10:78392320	NA	0.72	6.33	0.54	8.03e-9	Pulmonary function;
THYM	cis	rs7586879	0.616	rs6545809	chr2:25126715	C/T	cg27107076	chr2:25050844	ADCY3	-0.29	-4.72	-0.44	8.01e-6	Body mass index;
THYM	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg17063962	chr7:91808500	NA	1.13	12.83	0.8	1.9e-22	Breast cancer;
THYM	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	1.0	9.47	0.7	2.25e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg24531977	chr5:56204891	C5orf35	-1.01	-8.29	-0.65	7.47e-13	Type 2 diabetes;
THYM	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg21475434	chr5:93447410	FAM172A	0.96	6.1	0.53	2.29e-8	Diabetic retinopathy;
THYM	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg13319975	chr6:146136371	FBXO30	-0.63	-5.18	-0.47	1.24e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs747334	0.846	rs4639846	chr10:92716578	G/A	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs7681423	0.951	rs13109457	chr4:155514879	G/A	cg20735720	chr4:155535218	FGG	-0.65	-4.79	-0.44	6.13e-6	Fibrinogen;
THYM	cis	rs1050631	0.592	rs1785932	chr18:33719434	C/T	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.58	4.56	0.42	1.54e-5	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs10492096	0.783	rs11064220	chr12:6592574	C/T	cg13857086	chr12:6580257	VAMP1	0.87	5.26	0.47	8.87e-7	Hip geometry;
THYM	cis	rs7107174	1.000	rs2512547	chr11:77960888	T/C	cg19901956	chr11:77921274	USP35	-0.8	-6.03	-0.53	3.09e-8	Testicular germ cell tumor;
THYM	cis	rs758324	0.687	rs159905	chr5:131502503	C/T	cg16205897	chr5:131564050	P4HA2	0.52	4.56	0.42	1.55e-5	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg10802521	chr3:52805072	NEK4	-0.71	-6.18	-0.54	1.57e-8	Bipolar disorder;
THYM	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg03929089	chr4:120376271	NA	-0.94	-10.56	-0.73	1.03e-17	Height;
THYM	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	5.47	0.49	3.58e-7	Personality dimensions;
THYM	cis	rs73787773	0.867	rs73787782	chr5:111494104	A/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.88	-4.76	-0.44	6.87e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	7.48	0.61	3.78e-11	Smoking behavior;
THYM	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11890956	chr21:40555474	PSMG1	0.92	7.5	0.61	3.31e-11	Cognitive function;
THYM	cis	rs8028313	0.630	rs4776373	chr15:67960523	G/A	cg26545918	chr15:68124484	LBXCOR1	0.56	4.92	0.45	3.56e-6	Obesity;
THYM	cis	rs236907	0.859	rs34320898	chr1:171759139	G/C	cg20598894	chr1:171756153	METTL13	-0.73	-5.28	-0.48	8.25e-7	Mean platelet volume;
THYM	cis	rs2456568	0.802	rs1108910	chr11:93629677	C/T	cg26875233	chr11:93583750	C11orf90	0.53	5.53	0.49	2.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs6598541	0.963	rs4966021	chr15:99285056	C/T	cg13297560	chr15:99320054	IGF1R	0.45	4.57	0.42	1.46e-5	Urate levels;
THYM	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg25811766	chr13:21894605	NA	0.8	5.42	0.49	4.53e-7	White matter hyperintensity burden;
THYM	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-5.08	-0.46	1.91e-6	Gut microbiome composition (summer);
THYM	cis	rs7681440	0.606	rs2583982	chr4:90753244	T/C	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg24675056	chr1:15929824	NA	0.75	6.08	0.53	2.5e-8	Systolic blood pressure;
THYM	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs7246657	0.882	rs59224125	chr19:37963205	T/C	cg22634378	chr19:37742834	NA	0.58	4.91	0.45	3.86e-6	Coronary artery calcification;
THYM	cis	rs7731657	0.537	rs2905534	chr5:130242005	C/T	cg08523029	chr5:130500466	HINT1	-0.77	-5.3	-0.48	7.38e-7	Fasting plasma glucose;
THYM	cis	rs67385638	0.962	rs72872549	chr11:5290053	C/T	cg12559170	chr11:5275217	HBG2	0.89	8.41	0.65	4.18e-13	Hemoglobin levels;
THYM	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg06221963	chr1:154839813	KCNN3	-0.88	-10.89	-0.75	2.08e-18	Prostate cancer;
THYM	cis	rs2504916	0.784	rs2504919	chr6:160773378	G/A	cg19643109	chr6:160697625	NA	-0.67	-4.67	-0.43	9.81e-6	Response to hepatitis C treatment;
THYM	cis	rs6430585	0.583	rs3769012	chr2:136556480	C/T	cg23851026	chr2:136556271	LCT	0.77	7.79	0.62	8.21e-12	Corneal structure;
THYM	cis	rs6047844	0.750	rs6137534	chr20:22073008	C/A	cg16502866	chr20:23015624	SSTR4	-0.58	-4.48	-0.42	2.07e-5	Male-pattern baldness;
THYM	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg01059385	chr22:42394853	WBP2NL	0.57	4.65	0.43	1.06e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg04842962	chr6:43655489	MRPS18A	1.4	15.42	0.85	1.3e-27	IgG glycosylation;
THYM	cis	rs6032067	0.929	rs17424356	chr20:43804190	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.72	-0.57	1.34e-9	Blood protein levels;
THYM	cis	rs6840360	0.615	rs6858483	chr4:152465509	C/T	cg22705602	chr4:152727874	NA	-0.71	-7.43	-0.61	4.71e-11	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs7772486	0.875	rs2814873	chr6:146308932	T/C	cg23711669	chr6:146136114	FBXO30	0.96	10.29	0.73	3.99e-17	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs6570726	0.791	rs7765687	chr6:145915100	A/C	cg13319975	chr6:146136371	FBXO30	-0.64	-5.11	-0.46	1.67e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4642101	0.561	rs6766744	chr3:12801843	C/T	cg11882607	chr3:12858926	CAND2	-0.46	-5.15	-0.47	1.43e-6	QRS complex (12-leadsum);
THYM	cis	rs2811415	0.597	rs1042907	chr3:127789172	G/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs1385374	0.858	rs12321643	chr12:129302867	A/T	cg04043695	chr12:129287642	SLC15A4	-0.8	-4.83	-0.44	5.3e-6	Systemic lupus erythematosus;
THYM	cis	rs1497406	0.744	rs4537547	chr1:16510798	C/T	cg03887218	chr1:16534349	ARHGEF19	-0.48	-4.49	-0.42	1.99e-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4690686	0.510	rs10520348	chr4:177261738	T/A	cg17059388	chr4:177262070	NA	0.48	6.73	0.57	1.29e-9	Essential tremor;
THYM	cis	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.98	0.45	2.85e-6	Obesity-related traits;
THYM	cis	rs3540	0.597	rs1978150	chr15:91037041	A/G	cg00487526	chr15:90818384	NA	0.58	4.47	0.42	2.16e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Body mass index;
THYM	cis	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg22857025	chr5:266934	NA	-1.54	-9.63	-0.7	1.03e-15	Breast cancer;
THYM	cis	rs7192750	0.586	rs12935795	chr16:71987452	G/C	cg06353428	chr16:71660113	MARVELD3	0.72	5.33	0.48	6.66e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs1003719	0.680	rs2187577	chr21:38533341	A/G	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg02187348	chr16:89574699	SPG7	0.75	5.88	0.52	5.99e-8	Multiple myeloma (IgH translocation);
THYM	cis	rs7575217	0.767	rs62152486	chr2:101745835	A/C	cg23907051	chr2:101730305	TBC1D8	-0.41	-5.42	-0.49	4.44e-7	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs13256369	1.000	rs13271966	chr8:8575472	T/C	cg00074818	chr8:8560427	CLDN23	0.53	4.76	0.44	6.82e-6	Obesity-related traits;
THYM	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg02018176	chr4:1364513	KIAA1530	0.94	8.73	0.67	8.68e-14	Longevity;
THYM	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg13695892	chr22:41940480	POLR3H	0.86	5.96	0.52	4.19e-8	Vitiligo;
THYM	cis	rs3806843	0.868	rs2531349	chr5:140120953	G/A	cg19875535	chr5:140030758	IK	-0.61	-4.91	-0.45	3.73e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs1800871	1.000	rs1800872	chr1:206946407	T/G	cg12587213	chr1:206589868	SRGAP2	0.46	4.47	0.42	2.15e-5	Gut microbiota (functional units);Behcet's disease;
THYM	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg23803603	chr1:2058230	PRKCZ	-0.55	-4.68	-0.43	9.58e-6	Height;
THYM	cis	rs13177918	0.677	rs13164105	chr5:149826066	T/A	cg14059543	chr5:149831962	NA	-1.01	-7.71	-0.62	1.21e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg24596788	chr1:163392923	NA	-0.77	-7.43	-0.61	4.68e-11	Motion sickness;
THYM	cis	rs8133932	0.906	rs78288391	chr21:47114310	A/G	cg20357416	chr21:47294739	PCBP3	0.86	4.94	0.45	3.33e-6	Schizophrenia;
THYM	cis	rs1829883	1.000	rs1403661	chr5:98777056	T/A	cg08333243	chr5:99726346	NA	-0.57	-5.59	-0.5	2.13e-7	Hemostatic factors and hematological phenotypes;
THYM	cis	rs1843834	0.858	rs2047136	chr2:225511361	A/T	cg10193763	chr2:225306901	NA	-0.49	-4.84	-0.44	5.02e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg18477163	chr1:228402036	OBSCN	0.59	6.59	0.56	2.4e-9	Diastolic blood pressure;
THYM	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg10053473	chr17:62856997	LRRC37A3	0.92	7.34	0.6	7.17e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6906287	0.625	rs9320648	chr6:118690014	A/C	cg21191810	chr6:118973309	C6orf204	0.63	6.14	0.53	1.95e-8	Electrocardiographic conduction measures;
THYM	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg05802129	chr4:122689817	NA	-0.59	-4.65	-0.43	1.08e-5	Type 2 diabetes;
THYM	cis	rs7586879	0.558	rs6718510	chr2:25122323	A/C	cg01884057	chr2:25150051	NA	0.7	7.45	0.61	4.29e-11	Body mass index;
THYM	cis	rs1371867	0.875	rs1788169	chr8:101326314	C/T	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs12802200	0.535	rs35391985	chr11:570280	T/C	cg16486109	chr11:613632	IRF7	0.49	5.42	0.49	4.56e-7	Systemic lupus erythematosus;
THYM	trans	rs11165623	0.792	rs13375510	chr1:96920723	A/G	cg10631902	chr5:14652156	NA	-0.63	-6.98	-0.58	3.98e-10	Hip circumference;Waist circumference;
THYM	cis	rs2229238	0.911	rs7526293	chr1:154444209	T/C	cg21262032	chr1:154437693	IL6R	0.59	5.16	0.47	1.37e-6	Coronary heart disease;
THYM	trans	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs12208915	0.848	rs955765	chr6:79532610	C/T	cg05283184	chr6:79620031	NA	0.74	4.84	0.44	5.06e-6	Left atrial antero-posterior diameter;
THYM	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg18681998	chr4:17616180	MED28	1.01	10.39	0.73	2.42e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs599083	0.530	rs686921	chr11:68170833	G/T	cg16797656	chr11:68205561	LRP5	-0.45	-4.85	-0.45	4.76e-6	Bone mineral density (spine);
THYM	cis	rs4845875	0.600	rs11805138	chr1:11833159	T/C	cg06193043	chr1:11908199	NPPA	0.58	4.83	0.44	5.24e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs2806561	0.704	rs667330	chr1:23515257	A/G	cg19743168	chr1:23544995	NA	0.55	5.61	0.5	1.99e-7	Height;
THYM	trans	rs58106596	0.800	rs11686900	chr2:232568692	A/G	cg01370599	chr3:116745421	NA	0.95	7.12	0.59	2.02e-10	White blood cell count;Lymphocyte counts;
THYM	cis	rs12681287	0.640	rs4587306	chr8:87385511	T/C	cg27223183	chr8:87520930	FAM82B	0.68	5.16	0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs9649213	0.593	rs6465664	chr7:97921834	A/G	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.2e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs13006833	0.694	rs291444	chr2:191176223	T/C	cg27211696	chr2:191398769	TMEM194B	0.56	4.47	0.42	2.19e-5	Urinary metabolites;
THYM	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg10465839	chr16:1584050	IFT140;TMEM204	-0.65	-5.7	-0.5	1.36e-7	Coronary artery disease;
THYM	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg22947322	chr17:47091978	IGF2BP1	-0.59	-6.52	-0.56	3.33e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs6840360	0.615	rs12641433	chr4:152607548	A/C	cg22705602	chr4:152727874	NA	-0.81	-10.89	-0.75	2.08e-18	Intelligence (multi-trait analysis);
THYM	cis	rs911119	0.909	rs111360484	chr20:23618984	G/C	cg16589663	chr20:23618590	CST3	0.76	4.69	0.43	9.26e-6	Chronic kidney disease;
THYM	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Gout;
THYM	cis	rs1113500	0.933	rs10881497	chr1:108634515	A/G	cg06207961	chr1:108661230	NA	-0.63	-4.92	-0.45	3.63e-6	Growth-regulated protein alpha levels;
THYM	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg04234412	chr22:24373322	LOC391322	-1.01	-11.59	-0.77	6.97e-20	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1395	0.744	rs62130709	chr2:27505782	C/T	cg23587288	chr2:27483067	SLC30A3	-0.62	-5.3	-0.48	7.55e-7	Blood metabolite levels;
THYM	cis	rs1448094	0.511	rs10863071	chr12:86145813	A/G	cg00310523	chr12:86230176	RASSF9	-0.57	-5.06	-0.46	2.04e-6	Major depressive disorder;
THYM	cis	rs16949788	1.000	rs41306345	chr15:66782048	C/T	cg08120210	chr15:66682733	MAP2K1	-0.77	-4.56	-0.42	1.54e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03264133	chr6:25882463	NA	0.81	6.04	0.53	3.02e-8	Blood metabolite levels;
THYM	cis	rs6500395	1.000	rs871902	chr16:48593779	A/G	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg23422044	chr7:1970798	MAD1L1	-0.95	-6.58	-0.56	2.51e-9	Bipolar disorder;
THYM	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6754311	0.593	rs313518	chr2:136439090	C/T	cg23851026	chr2:136556271	LCT	0.59	5.62	0.5	1.91e-7	Mosquito bite size;
THYM	cis	rs2806561	1.000	rs2473851	chr1:23489869	A/G	cg08872493	chr1:23521417	HTR1D	0.38	4.86	0.45	4.59e-6	Height;
THYM	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg00012203	chr2:219082015	ARPC2	-0.59	-4.89	-0.45	4.14e-6	Colorectal cancer;
THYM	cis	rs4918072	0.834	rs7079220	chr10:105710147	A/G	cg11005552	chr10:105648138	OBFC1	0.57	4.61	0.43	1.26e-5	Coronary artery disease;
THYM	trans	rs4596713	0.538	rs4421408	chr9:71760884	G/T	cg16512924	chr15:28394682	HERC2	0.83	6.91	0.58	5.43e-10	Headache;
THYM	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg06634786	chr22:41940651	POLR3H	-0.7	-5.38	-0.48	5.4e-7	Vitiligo;
THYM	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg17063962	chr7:91808500	NA	-1.1	-11.62	-0.77	5.94e-20	Breast cancer;
THYM	cis	rs240764	0.817	rs239190	chr6:101129067	C/T	cg21058520	chr6:100914733	NA	-0.57	-4.99	-0.46	2.77e-6	Neuroticism;
THYM	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7592578	0.766	rs62182865	chr2:191434180	T/C	cg10560079	chr2:191398806	TMEM194B	-0.92	-6.6	-0.56	2.32e-9	Diastolic blood pressure;
THYM	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.57	4.65	0.43	1.06e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs36051895	0.623	rs2208685	chr9:5251758	T/C	cg02405213	chr9:5042618	JAK2	-0.95	-9.72	-0.71	6.45e-16	Pediatric autoimmune diseases;
THYM	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg06640241	chr16:89574553	SPG7	0.9	8.02	0.64	2.68e-12	Multiple myeloma (IgH translocation);
THYM	cis	rs1371867	0.846	rs1692007	chr8:101268343	T/C	cg06636551	chr8:101224915	SPAG1	0.63	6.33	0.54	8.05e-9	Atrioventricular conduction;
THYM	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg23711669	chr6:146136114	FBXO30	0.97	10.56	0.73	1.05e-17	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg20587970	chr11:113659929	NA	-1.09	-7.49	-0.61	3.56e-11	Hip circumference adjusted for BMI;
THYM	cis	rs17209837	0.607	rs4148820	chr7:87080482	T/C	cg04996195	chr7:87105398	ABCB4	0.63	4.79	0.44	6.03e-6	Gallbladder cancer;
THYM	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg07061783	chr6:25882402	NA	0.9	7.95	0.63	3.82e-12	Intelligence (multi-trait analysis);
THYM	cis	rs16854884	0.657	rs13078840	chr3:143700753	A/G	cg05063096	chr3:143689810	C3orf58	0.69	4.53	0.42	1.69e-5	Economic and political preferences (feminism/equality);
THYM	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg14972814	chr11:95582409	MTMR2	-0.72	-6.7	-0.57	1.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2916260	0.733	rs79440993	chr6:40387974	C/T	cg08415973	chr6:40346114	TDRG1	0.75	4.71	0.43	8.6e-6	Incident coronary heart disease;
THYM	cis	rs7646881	1.000	rs73015654	chr3:158451654	G/A	cg18349298	chr3:158450550	RARRES1	0.48	4.48	0.42	2.05e-5	Tetralogy of Fallot;
THYM	cis	rs6768930	0.509	rs6445927	chr3:57741346	A/G	cg07735586	chr3:57945651	NA	-0.33	-4.96	-0.45	3.04e-6	Obesity-related traits;
THYM	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.96	8.0	0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	trans	rs3960554	0.867	rs10239209	chr7:75804085	G/A	cg19862616	chr7:65841803	NCRNA00174	0.94	6.97	0.58	4.23e-10	Eotaxin levels;
THYM	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg13683864	chr3:40499215	RPL14	-0.88	-8.67	-0.66	1.14e-13	Renal cell carcinoma;
THYM	cis	rs6495122	0.699	rs2168518	chr15:75081078	G/A	cg14664628	chr15:75095509	CSK	-0.81	-6.38	-0.55	6.5e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg20290983	chr6:43655470	MRPS18A	-0.89	-6.88	-0.58	6.31e-10	IgG glycosylation;
THYM	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	8.39	0.65	4.61e-13	Lung cancer in ever smokers;
THYM	cis	rs59698941	0.943	rs67074969	chr5:132251063	T/A	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs9296092	0.517	rs78978280	chr6:33520747	T/A	cg13560919	chr6:33536144	NA	-0.94	-9.31	-0.69	4.9e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs12410462	0.579	rs116701416	chr1:227641947	G/A	cg04117972	chr1:227635322	NA	1.13	5.29	0.48	7.94e-7	Major depressive disorder;
THYM	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg21475434	chr5:93447410	FAM172A	0.71	4.51	0.42	1.83e-5	Diabetic retinopathy;
THYM	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11644478	chr21:40555479	PSMG1	-0.59	-4.91	-0.45	3.74e-6	Menarche (age at onset);
THYM	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg18876405	chr7:65276391	NA	0.57	4.73	0.44	7.67e-6	Aortic root size;
THYM	cis	rs600806	0.850	rs10858086	chr1:109915075	C/A	cg23616212	chr1:109941201	SORT1	-0.49	-4.66	-0.43	1.01e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7681440	0.606	rs2583977	chr4:90750225	C/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.28	-0.48	8.31e-7	Dementia with Lewy bodies;
THYM	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9534288	0.730	rs7985754	chr13:46581287	G/A	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs2730245	0.527	rs2657362	chr7:158685095	A/G	cg11984989	chr7:158649758	WDR60	1.01	8.5	0.66	2.65e-13	Height;
THYM	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg05373962	chr22:49881684	NA	-0.65	-6.14	-0.53	1.94e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7122539	0.734	rs2513658	chr11:66628249	G/A	cg24851651	chr11:66362959	CCS	-0.63	-5.27	-0.48	8.59e-7	HIV-1 susceptibility;
THYM	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg14349672	chr11:133703707	NA	-0.5	-4.62	-0.43	1.2e-5	Childhood ear infection;
THYM	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg18032289	chr17:61959525	GH2	-0.48	-4.67	-0.43	9.97e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.96	6.24	0.54	1.22e-8	Smoking behavior;
THYM	cis	rs57481061	1	rs57481061	chr12:90019178	C/G	cg00757033	chr12:89920650	WDR51B	0.54	4.67	0.43	9.74e-6	Coronary artery disease;
THYM	cis	rs1129187	0.748	rs6458312	chr6:42904274	G/T	cg10862848	chr6:42927986	GNMT	-0.51	-6.7	-0.57	1.5e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6700896	0.897	rs7541434	chr1:66168499	A/C	cg04111102	chr1:66153794	NA	-0.6	-5.68	-0.5	1.45e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4731207	0.698	rs6973812	chr7:124506750	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg16486109	chr11:613632	IRF7	0.51	5.7	0.5	1.34e-7	Systemic lupus erythematosus;
THYM	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg26531700	chr6:26746687	NA	0.56	4.76	0.44	6.91e-6	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	1.000	rs61931739	chr12:34089973	C/T	cg06521331	chr12:34319734	NA	0.63	4.77	0.44	6.74e-6	Morning vs. evening chronotype;
THYM	cis	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg18512352	chr11:47633146	NA	-0.38	-4.52	-0.42	1.76e-5	HDL cholesterol;
THYM	cis	rs7567389	0.677	rs4662720	chr2:128076607	T/C	cg09760422	chr2:128146352	NA	-0.4	-4.52	-0.42	1.8e-5	Self-rated health;
THYM	cis	rs10484885	0.648	rs2777848	chr6:90535993	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.91	-9.55	-0.7	1.5e-15	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg12311346	chr5:56204834	C5orf35	-0.61	-4.67	-0.43	9.99e-6	Initial pursuit acceleration;
THYM	cis	rs400736	0.894	rs225092	chr1:8036075	G/C	cg22678073	chr1:8087421	ERRFI1	0.46	4.89	0.45	4.15e-6	Response to antidepressants and depression;
THYM	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg24020549	chr11:64937741	SPDYC	-0.46	-4.46	-0.42	2.26e-5	Eosinophil percentage of white cells;
THYM	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg18402987	chr7:1209562	NA	1.16	7.29	0.6	9.12e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4662945	0.603	rs1453147	chr2:130271510	A/C	cg05903289	chr2:130345205	NA	-0.56	-5.34	-0.48	6.3e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs12476592	0.602	rs262528	chr2:63903367	C/T	cg17519650	chr2:63277830	OTX1	-0.72	-4.68	-0.43	9.38e-6	Childhood ear infection;
THYM	cis	rs2797160	0.905	rs1418640	chr6:125999866	G/A	cg16306078	chr6:126000798	NA	-0.53	-5.51	-0.49	3.09e-7	Endometrial cancer;
THYM	cis	rs28785552	0.800	rs10853854	chr19:53232128	A/G	cg10871876	chr19:53194124	ZNF83	-0.71	-6.11	-0.53	2.23e-8	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg12031863	chr16:4587854	C16orf5	-0.43	-4.69	-0.43	9.1e-6	Schizophrenia;
THYM	cis	rs9595908	0.965	rs9595903	chr13:33182140	G/A	cg12383807	chr13:33924137	NA	-0.53	-4.59	-0.43	1.36e-5	Body mass index;
THYM	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg26384229	chr12:38710491	ALG10B	-0.87	-7.26	-0.6	1.06e-10	Bladder cancer;
THYM	cis	rs992157	1.000	rs11554825	chr2:219125809	C/T	cg00012203	chr2:219082015	ARPC2	0.85	7.65	0.62	1.64e-11	Colorectal cancer;
THYM	trans	rs4749080	0.573	rs4749092	chr10:26411093	A/G	cg00192819	chr18:76486611	NA	0.99	6.94	0.58	4.75e-10	Obesity-related traits;
THYM	cis	rs55665837	1.000	rs55665837	chr11:14495049	C/T	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs11223731	0.672	rs10894788	chr11:134111547	A/G	cg18040241	chr11:134201582	GLB1L2	-0.73	-4.7	-0.43	8.96e-6	Verbal declarative memory;
THYM	cis	rs2974760	0.606	rs2858918	chr16:201183	T/C	cg08400316	chr16:204221	HBZ	0.77	6.13	0.53	1.97e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs3126085	0.935	rs4845734	chr1:152167473	T/C	cg26020982	chr1:152196106	HRNR	0.36	4.7	0.43	8.63e-6	Atopic dermatitis;
THYM	cis	rs7246657	0.943	rs10420722	chr19:37973774	C/G	cg22634378	chr19:37742834	NA	0.65	5.35	0.48	6.07e-7	Coronary artery calcification;
THYM	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs877282	0.853	rs7079450	chr10:755932	T/A	cg10556349	chr10:835070	NA	-0.69	-4.49	-0.42	2.03e-5	Uric acid levels;
THYM	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg16342193	chr10:102329863	NA	-0.5	-5.13	-0.47	1.54e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs10992471	0.603	rs10114912	chr9:95307863	C/A	cg14631576	chr9:95140430	CENPP	-0.96	-8.92	-0.68	3.33e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs3741151	0.881	rs79623427	chr11:73094896	C/T	cg17517138	chr11:73019481	ARHGEF17	0.99	5.8	0.51	8.53e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	trans	rs3960554	0.808	rs78478514	chr7:75655896	C/T	cg19862616	chr7:65841803	NCRNA00174	0.94	7.19	0.59	1.48e-10	Eotaxin levels;
THYM	cis	rs2279817	1.000	rs1339801	chr1:18020298	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.77	4.89	0.45	4.1e-6	Neuroticism;
THYM	cis	rs7894051	1.000	rs77189950	chr10:135126722	A/T	cg07511014	chr10:135191624	PAOX	0.82	5.41	0.48	4.8e-7	Lifespan;
THYM	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg06640241	chr16:89574553	SPG7	-0.6	-4.76	-0.44	6.86e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg18252515	chr7:66147081	NA	-1.37	-8.05	-0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs2777491	0.915	rs7165675	chr15:41614704	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.14	-12.89	-0.8	1.38e-22	Ulcerative colitis;
THYM	cis	rs887829	0.570	rs6759892	chr2:234601669	G/T	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	0.54	4.57	0.42	1.45e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg01831904	chr17:28903510	LRRC37B2	1.01	4.79	0.44	6.02e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs62070183	0.882	rs62070187	chr17:31190724	A/G	cg23177095	chr17:30873196	MYO1D	0.6	4.58	0.43	1.39e-5	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs10865397	0.506	rs13414160	chr2:73383261	C/A	cg24220031	chr2:73402428	NA	-0.75	-6.87	-0.58	6.79e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.929	rs2143944	chr20:43819370	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs7927771	0.524	rs6485763	chr11:47627302	C/T	cg20307385	chr11:47447363	PSMC3	0.62	4.77	0.44	6.53e-6	Subjective well-being;
THYM	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg10518543	chr12:38710700	ALG10B	-0.57	-4.47	-0.42	2.16e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7769051	0.522	rs57176306	chr6:133142168	C/T	cg22852734	chr6:133119734	C6orf192	1.42	5.82	0.51	7.93e-8	Type 2 diabetes nephropathy;
THYM	cis	rs2901656	0.967	rs4916186	chr1:172396020	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.52	5.61	0.5	1.96e-7	Red cell distribution width;Platelet distribution width;
THYM	cis	rs6087990	0.735	rs6058891	chr20:31386347	T/C	cg13636640	chr20:31349939	DNMT3B	0.9	9.45	0.7	2.46e-15	Ulcerative colitis;
THYM	cis	rs6570726	0.738	rs4495284	chr6:145916617	T/A	cg23711669	chr6:146136114	FBXO30	0.95	10.09	0.72	1.07e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs61931739	0.749	rs7315233	chr12:34271975	G/T	cg06521331	chr12:34319734	NA	-0.64	-5.37	-0.48	5.62e-7	Morning vs. evening chronotype;
THYM	cis	rs6570726	1.000	rs374464	chr6:145846679	A/C	cg23711669	chr6:146136114	FBXO30	0.81	7.61	0.62	2.01e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg12165864	chr7:66369176	NA	-0.65	-5.08	-0.46	1.89e-6	Aortic root size;
THYM	cis	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg07988820	chr12:82153109	PPFIA2	-0.85	-5.59	-0.5	2.16e-7	Resting heart rate;
THYM	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg06074448	chr4:187884817	NA	-1.01	-13.54	-0.81	6.7e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11671005	0.735	rs12986387	chr19:58927215	C/T	cg18639983	chr19:58920768	ZNF584	0.59	5.0	0.46	2.63e-6	Mean platelet volume;
THYM	cis	rs9532580	0.620	rs2701859	chr13:41141232	T/C	cg21288729	chr13:41239152	FOXO1	0.67	4.7	0.43	8.74e-6	Mean corpuscular hemoglobin;
THYM	cis	rs7851660	0.809	rs7048255	chr9:100665698	A/G	cg13688889	chr9:100608707	NA	-0.79	-5.75	-0.51	1.06e-7	Strep throat;
THYM	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg05283184	chr6:79620031	NA	-0.89	-8.99	-0.68	2.38e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg13447684	chr7:1895903	MAD1L1	0.55	4.66	0.43	1.01e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs524023	1.000	rs3825018	chr11:64358809	G/A	cg19131476	chr11:64387923	NRXN2	-0.37	-5.09	-0.46	1.81e-6	Urate levels in obese individuals;
THYM	cis	rs7772486	0.790	rs2253307	chr6:146196181	T/G	cg23711669	chr6:146136114	FBXO30	0.92	9.33	0.69	4.37e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3796352	1.000	rs13078971	chr3:53103645	G/C	cg07884673	chr3:53033167	SFMBT1	1.15	5.63	0.5	1.85e-7	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs1007190	0.764	rs8082522	chr17:42876340	G/C	cg15406952	chr17:42872593	NA	-0.84	-5.95	-0.52	4.45e-8	DNA methylation (variation);
THYM	cis	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs854765	0.583	rs8078583	chr17:17811465	C/T	cg16928487	chr17:17741425	SREBF1	-0.56	-5.44	-0.49	4.09e-7	Total body bone mineral density;
THYM	cis	rs28647808	0.881	rs3739894	chr9:136270871	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg21194808	chr1:2205498	SKI	-0.33	-4.6	-0.43	1.3e-5	Height;
THYM	cis	rs800586	1.000	rs800586	chr8:116813905	G/A	cg04656070	chr8:116661063	TRPS1	0.48	4.98	0.45	2.88e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg18477163	chr1:228402036	OBSCN	0.59	6.61	0.56	2.25e-9	Diastolic blood pressure;
THYM	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg00757033	chr12:89920650	WDR51B	0.77	11.72	0.77	3.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg03806693	chr22:41940476	POLR3H	1.1	8.94	0.68	3.12e-14	Vitiligo;
THYM	cis	rs6047844	0.669	rs6113495	chr20:22061487	A/G	cg16502866	chr20:23015624	SSTR4	-0.58	-4.48	-0.42	2.07e-5	Male-pattern baldness;
THYM	cis	rs7119	0.717	rs12911963	chr15:77807175	G/C	cg10437265	chr15:77819839	NA	0.76	7.61	0.62	1.98e-11	Type 2 diabetes;
THYM	cis	rs6980334	0.817	rs3805360	chr7:137794589	G/A	cg11874123	chr7:137028198	PTN	0.67	5.17	0.47	1.29e-6	Blood metabolite ratios;
THYM	cis	rs4900538	0.855	rs72698602	chr14:102880454	T/C	cg18135206	chr14:102964638	TECPR2	-0.81	-6.24	-0.54	1.2e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2625529	0.701	rs12911154	chr15:72212653	G/A	cg16672083	chr15:72433130	SENP8	-0.56	-5.03	-0.46	2.35e-6	Red blood cell count;
THYM	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg05340658	chr4:99064831	C4orf37	0.54	4.55	0.42	1.61e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg26384229	chr12:38710491	ALG10B	0.7	5.46	0.49	3.75e-7	Morning vs. evening chronotype;
THYM	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg06238570	chr21:40685208	BRWD1	-0.72	-6.28	-0.54	9.9e-9	Menarche (age at onset);
THYM	trans	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg25214090	chr10:38739885	LOC399744	-0.95	-7.8	-0.62	7.74e-12	Corneal astigmatism;
THYM	cis	rs1639906	0.895	rs3800926	chr7:2205956	G/A	cg19897017	chr7:2163380	MAD1L1	-0.51	-4.75	-0.44	7.26e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2354432	0.660	rs10751415	chr1:146830785	T/A	cg25205988	chr1:146714368	CHD1L	1.01	5.52	0.49	2.91e-7	Mitochondrial DNA levels;
THYM	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg08885076	chr2:99613938	TSGA10	0.66	5.97	0.52	4.17e-8	Chronic sinus infection;
THYM	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg04267008	chr7:1944627	MAD1L1	-0.68	-6.25	-0.54	1.14e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs931812	0.535	rs3105452	chr8:101943618	A/G	cg04962480	chr8:101962118	YWHAZ	-0.39	-5.91	-0.52	5.35e-8	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg18357526	chr6:26021779	HIST1H4A	0.79	6.62	0.56	2.14e-9	Intelligence (multi-trait analysis);
THYM	cis	rs28795989	0.795	rs17770447	chr4:7903572	T/C	cg00251875	chr4:7801337	AFAP1	0.61	4.93	0.45	3.53e-6	Intraocular pressure;
THYM	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg24250549	chr1:154909240	PMVK	0.71	5.53	0.49	2.83e-7	Prostate cancer;
THYM	cis	rs2278491	0.528	rs4514005	chr8:117782385	C/T	cg23513447	chr8:117778558	UTP23	-0.67	-4.84	-0.44	5.05e-6	Body mass index;
THYM	cis	rs13256369	1.000	rs885000	chr8:8568875	G/T	cg00074818	chr8:8560427	CLDN23	0.58	5.4	0.48	4.91e-7	Obesity-related traits;
THYM	cis	rs240764	0.604	rs1336242	chr6:101199634	C/T	cg21058520	chr6:100914733	NA	-0.57	-5.0	-0.46	2.58e-6	Neuroticism;
THYM	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	5.07	0.46	1.92e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9814567	1.000	rs6790466	chr3:134197740	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.65	-0.62	1.62e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg27490568	chr2:178487706	NA	0.57	5.36	0.48	5.7e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs969413	0.535	rs8077394	chr17:79258787	A/G	cg06324037	chr17:79279053	C17orf55	0.45	4.45	0.42	2.35e-5	Frontotemporal dementia;
THYM	cis	rs4666002	0.789	rs4616435	chr2:27933642	C/T	cg27432699	chr2:27873401	GPN1	0.62	4.71	0.43	8.52e-6	Phospholipid levels (plasma);
THYM	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.48	-0.42	2.05e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs1062746	0.771	rs9308348	chr16:87371941	G/A	cg02258303	chr16:87377426	FBXO31	-0.54	-4.88	-0.45	4.27e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg10047753	chr17:41438598	NA	1.19	11.63	0.77	5.87e-20	Menopause (age at onset);
THYM	cis	rs2624839	0.704	rs11919418	chr3:50233215	T/G	cg14019146	chr3:50243930	SLC38A3	-0.85	-7.34	-0.6	7.09e-11	Intelligence (multi-trait analysis);
THYM	cis	rs6438424	1.000	rs10804533	chr3:117555219	T/C	cg07190778	chr3:117604296	NA	-0.38	-5.12	-0.47	1.59e-6	Menarche (age at onset);
THYM	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6570726	0.791	rs11759979	chr6:145918881	C/T	cg13319975	chr6:146136371	FBXO30	-0.65	-5.27	-0.48	8.54e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs420259	0.516	rs10459765	chr16:23467181	T/C	cg00143387	chr16:23521605	GGA2	0.77	5.56	0.5	2.45e-7	Bipolar disorder;
THYM	cis	rs6032067	0.777	rs13042694	chr20:43799368	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.18	-0.64	1.26e-12	Blood protein levels;
THYM	cis	rs17433780	0.857	rs12144445	chr1:89465238	C/T	cg09516651	chr1:89888402	LOC400759	0.85	6.43	0.55	5.2e-9	Carotid intima media thickness;
THYM	cis	rs56775891	1.000	rs34945223	chr18:77575871	A/G	cg25357022	chr18:77495084	CTDP1	-0.65	-4.48	-0.42	2.09e-5	Schizophrenia;
THYM	cis	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs80319144	1.000	rs76251234	chr2:159284526	G/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs12149862	1.000	rs7199957	chr16:69468435	C/A	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs4731207	0.565	rs12538641	chr7:124600671	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs6840360	0.667	rs2709832	chr4:152379394	C/G	cg17479576	chr4:152424074	FAM160A1	-0.68	-5.17	-0.47	1.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6138458	1.000	rs7268095	chr20:24972333	C/T	cg26195577	chr20:24973756	C20orf3	1.09	10.72	0.74	4.84e-18	Blood protein levels;
THYM	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg16031515	chr1:205743344	RAB7L1	0.52	4.51	0.42	1.88e-5	Menarche (age at onset);
THYM	cis	rs490234	0.719	rs13287525	chr9:128219180	T/C	cg14078157	chr9:128172775	NA	-0.73	-5.64	-0.5	1.74e-7	Mean arterial pressure;
THYM	cis	rs4242434	0.819	rs6558167	chr8:22473850	T/C	cg03733263	chr8:22462867	KIAA1967	0.98	11.26	0.76	3.52e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs950881	1.000	rs950881	chr2:102932512	G/T	cg20060108	chr2:102954350	IL1RL1	0.87	4.77	0.44	6.56e-6	Allergy;
THYM	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg10334053	chr1:2078117	PRKCZ	0.45	4.59	0.43	1.37e-5	Height;
THYM	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg07930552	chr6:133119739	C6orf192	0.99	5.89	0.52	5.77e-8	Type 2 diabetes nephropathy;
THYM	cis	rs955333	0.565	rs57776280	chr6:154896788	G/T	cg17771515	chr6:154831774	CNKSR3	0.67	4.62	0.43	1.18e-5	Diabetic kidney disease;
THYM	trans	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.12	8.09	0.64	1.9e-12	Exhaled nitric oxide output;
THYM	cis	rs9914544	1.000	rs8066385	chr17:18761133	C/T	cg26378065	chr17:18585709	ZNF286B	0.61	5.02	0.46	2.38e-6	Educational attainment (years of education);
THYM	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs28595532	0.920	rs114382134	chr4:119733215	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs11608355	0.846	rs60945232	chr12:109854401	A/G	cg10504392	chr12:110044639	NA	0.61	5.2	0.47	1.16e-6	Neuroticism;
THYM	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs1011018	0.955	rs1541480	chr7:139465278	G/A	cg06079564	chr7:139468310	HIPK2	-0.77	-5.98	-0.52	3.9e-8	Systolic blood pressure;
THYM	cis	rs2836974	0.566	rs2249666	chr21:40719241	C/T	cg11644478	chr21:40555479	PSMG1	0.67	4.87	0.45	4.36e-6	Cognitive function;
THYM	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg20891558	chr2:74357851	NA	1.22	11.67	0.77	4.73e-20	Gestational age at birth (maternal effect);
THYM	cis	rs2235573	0.625	rs10427673	chr22:38427551	G/C	cg19171272	chr22:38449367	NA	-0.5	-5.25	-0.47	9.25e-7	Glioblastoma;Glioma;
THYM	cis	rs988913	0.768	rs9370337	chr6:54750488	C/T	cg18532076	chr6:54711417	FAM83B	0.46	4.62	0.43	1.23e-5	Menarche (age at onset);
THYM	cis	rs17407555	0.909	rs56240429	chr4:10327589	G/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-4.68	-0.43	9.67e-6	Schizophrenia (age at onset);
THYM	cis	rs7107174	1.000	rs4945268	chr11:78037936	T/C	cg02023728	chr11:77925099	USP35	0.61	5.81	0.51	8.17e-8	Testicular germ cell tumor;
THYM	cis	rs17153755	0.931	rs12677897	chr8:11612963	G/A	cg12395012	chr8:11607386	GATA4	-0.62	-5.07	-0.46	1.99e-6	Testicular germ cell tumor;
THYM	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg02820040	chr2:241836501	C2orf54	-0.33	-6.84	-0.57	7.7e-10	Urinary metabolites;
THYM	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-5.16	-0.47	1.36e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1784581	0.588	rs9885762	chr6:162411954	G/A	cg17173639	chr6:162384350	PARK2	0.81	7.47	0.61	3.78e-11	Itch intensity from mosquito bite;
THYM	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg08188268	chr10:116634841	FAM160B1	-0.27	-4.67	-0.43	9.98e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg13770153	chr20:60521292	NA	-1.23	-10.88	-0.74	2.21e-18	Obesity-related traits;
THYM	cis	rs778371	0.723	rs1078323	chr2:233681512	T/G	cg08000102	chr2:233561755	GIGYF2	-0.75	-6.57	-0.56	2.69e-9	Schizophrenia;
THYM	cis	rs986417	1.000	rs1474999	chr14:60905920	T/C	cg27398547	chr14:60952738	C14orf39	-1.08	-5.91	-0.52	5.32e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.67	-5.18	-0.47	1.22e-6	Tonsillectomy;
THYM	cis	rs3008870	1.000	rs2985797	chr1:67431499	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-7.72	-0.62	1.16e-11	Lymphocyte percentage of white cells;
THYM	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg14074117	chr16:1909714	C16orf73	-0.71	-4.5	-0.42	1.89e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs80319144	1.000	rs7601440	chr2:159223180	T/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.58	4.66	0.43	1.05e-5	Restless legs syndrome;
THYM	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg20744362	chr22:50050164	C22orf34	0.82	7.95	0.63	3.79e-12	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg05717871	chr11:638507	DRD4	-0.64	-5.11	-0.46	1.69e-6	Systemic lupus erythematosus;
THYM	cis	rs7246967	0.611	rs2617780	chr19:22992190	T/A	cg05241461	chr19:22816980	ZNF492	0.65	4.65	0.43	1.06e-5	Bronchopulmonary dysplasia;
THYM	cis	rs1971762	0.966	rs11170631	chr12:54041192	T/C	cg22997177	chr12:54070527	ATP5G2	-0.42	-4.55	-0.42	1.59e-5	Height;
THYM	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg20891283	chr12:69753455	YEATS4	0.62	4.51	0.42	1.85e-5	Response to diuretic therapy;
THYM	cis	rs7107770	1.000	rs61912977	chr11:125100184	C/A	cg04164023	chr11:125106101	PKNOX2	-0.81	-4.68	-0.43	9.65e-6	Photic sneeze reflex;
THYM	cis	rs6840360	0.598	rs11944921	chr4:152731109	A/G	cg22705602	chr4:152727874	NA	0.62	6.94	0.58	4.79e-10	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg20607798	chr8:58055168	NA	0.88	4.59	0.43	1.33e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs11811982	0.793	rs7530155	chr1:227410186	C/A	cg09853570	chr1:228403422	OBSCN	1.3	4.91	0.45	3.82e-6	Optic disc area;
THYM	cis	rs11190604	1.000	rs4604805	chr10:102261409	C/G	cg16342193	chr10:102329863	NA	-0.51	-5.25	-0.47	9.1e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7172809	0.615	rs78021430	chr15:77846082	G/T	cg22256960	chr15:77711686	NA	-0.71	-5.27	-0.48	8.66e-7	Glucose homeostasis traits;
THYM	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	cis	rs4903604	0.581	rs11159278	chr14:78034001	C/G	cg18872420	chr14:78023429	SPTLC2	0.54	4.56	0.42	1.5e-5	Gut microbiome composition (winter);
THYM	cis	rs6089829	0.888	rs4809465	chr20:61671156	G/C	cg08564027	chr20:61660810	NA	0.96	10.36	0.73	2.87e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12478296	0.892	rs60545379	chr2:243034390	A/T	cg06360820	chr2:242988706	NA	-0.89	-5.44	-0.49	4.21e-7	Obesity-related traits;
THYM	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg05717871	chr11:638507	DRD4	-0.69	-5.26	-0.47	8.91e-7	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.76	4.9	0.45	3.98e-6	Smoking behavior;
THYM	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg18252515	chr7:66147081	NA	1.48	8.83	0.67	5.15e-14	Diabetic kidney disease;
THYM	cis	rs2839186	0.504	rs4347941	chr21:47938239	T/C	cg12379764	chr21:47803548	PCNT	0.91	7.3	0.6	8.7e-11	Testicular germ cell tumor;
THYM	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg12564285	chr5:131593104	PDLIM4	-0.57	-6.42	-0.55	5.44e-9	Acylcarnitine levels;
THYM	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg24578937	chr1:2090814	PRKCZ	0.81	8.54	0.66	2.22e-13	Height;
THYM	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg23161317	chr6:28129485	ZNF389	0.92	6.81	0.57	8.8e-10	Parkinson's disease;
THYM	cis	rs1728785	0.681	rs4783649	chr16:68558467	G/A	cg02972257	chr16:68554789	NA	0.8	5.14	0.47	1.49e-6	Ulcerative colitis;
THYM	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg16524936	chr4:1340807	KIAA1530	-0.66	-5.14	-0.47	1.49e-6	Longevity;
THYM	cis	rs7216064	1.000	rs7223930	chr17:65842186	G/A	cg12091567	chr17:66097778	LOC651250	-0.71	-4.76	-0.44	6.86e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs1003719	0.762	rs3787780	chr21:38462614	A/G	cg01329690	chr21:38580129	DSCR9	0.42	5.74	0.51	1.13e-7	Eye color traits;
THYM	cis	rs1021993	0.597	rs10494924	chr1:209527706	A/C	cg06155620	chr1:209527581	NA	-0.54	-4.77	-0.44	6.54e-6	Gut microbiome composition (winter);
THYM	cis	rs6665290	0.904	rs2297415	chr1:227172903	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.13	-16.21	-0.86	4.22e-29	Myeloid white cell count;
THYM	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22857025	chr5:266934	NA	1.5	9.71	0.71	6.9e-16	Breast cancer;
THYM	cis	rs10857712	0.551	rs12252576	chr10:135227244	T/C	cg19899694	chr10:135237140	SPRN	0.55	4.54	0.42	1.65e-5	Systemic lupus erythematosus;
THYM	cis	rs986417	0.748	rs4381505	chr14:61035968	C/T	cg27398547	chr14:60952738	C14orf39	1.1	6.18	0.54	1.59e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg00106254	chr7:1943704	MAD1L1	-0.5	-4.55	-0.42	1.58e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg24642844	chr7:1081250	C7orf50	-1.29	-8.3	-0.65	7.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs17086954	0.654	rs4425603	chr6:156301976	A/T	cg05282260	chr6:156983263	NA	1.31	5.22	0.47	1.07e-6	Early childhood aggressive behavior;
THYM	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg14345882	chr6:26364793	BTN3A2	0.57	5.21	0.47	1.09e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg08994789	chr17:28903642	LRRC37B2	-1.06	-6.18	-0.54	1.56e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7226229	1.000	rs4985962	chr17:20916035	A/G	cg21263980	chr17:20946333	USP22	0.67	5.02	0.46	2.38e-6	Blood trace element (Se levels);
THYM	cis	rs7586879	0.658	rs7563204	chr2:25125075	T/G	cg15423357	chr2:25149977	NA	0.7	7.74	0.62	1.03e-11	Body mass index;
THYM	cis	rs7107174	1.000	rs2373115	chr11:78091150	G/T	cg19901956	chr11:77921274	USP35	-0.6	-4.98	-0.45	2.84e-6	Testicular germ cell tumor;
THYM	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs7216064	0.636	rs4638	chr17:66039350	A/G	cg12091567	chr17:66097778	LOC651250	0.98	8.02	0.64	2.7e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg12463550	chr7:65579703	CRCP	-0.57	-4.76	-0.44	7.01e-6	Aortic root size;
THYM	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg10047753	chr17:41438598	NA	1.07	9.29	0.69	5.32e-15	Menopause (age at onset);
THYM	cis	rs7731657	0.537	rs6595982	chr5:130335557	G/A	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs4919087	0.810	rs1572437	chr10:99029278	A/G	cg19453742	chr10:98862320	SLIT1	-0.66	-5.19	-0.47	1.17e-6	Monocyte count;
THYM	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg06028808	chr11:68637592	NA	0.68	7.13	0.59	1.92e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs12410462	0.681	rs12401677	chr1:227608577	T/C	cg04117972	chr1:227635322	NA	0.8	4.79	0.44	6.09e-6	Major depressive disorder;
THYM	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg05043794	chr9:111880884	C9orf5	-0.35	-4.93	-0.45	3.42e-6	Menarche (age at onset);
THYM	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs13126513	0.708	rs883028	chr4:100451375	A/G	cg05468953	chr4:100565104	NA	0.64	5.88	0.52	6.06e-8	Metabolite levels (MHPG);
THYM	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg12031863	chr16:4587854	C16orf5	-0.44	-4.52	-0.42	1.78e-5	Schizophrenia;
THYM	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs2487048	0.804	rs2472496	chr9:107695353	C/T	cg14019050	chr9:107690770	ABCA1	-0.63	-7.04	-0.59	3.03e-10	Intraocular pressure;
THYM	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg18681998	chr4:17616180	MED28	0.97	9.52	0.7	1.74e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg00271210	chr6:167070053	RPS6KA2	-0.71	-7.66	-0.62	1.54e-11	Crohn's disease;
THYM	cis	rs6860806	0.631	rs6863548	chr5:131575920	G/A	cg04518342	chr5:131593106	PDLIM4	0.47	5.09	0.46	1.79e-6	Breast cancer;
THYM	cis	rs611744	0.538	rs13257548	chr8:109273185	G/A	cg21045802	chr8:109455806	TTC35	0.71	6.6	0.56	2.32e-9	Dupuytren's disease;
THYM	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg18512352	chr11:47633146	NA	-0.49	-5.93	-0.52	4.9e-8	Subjective well-being;
THYM	cis	rs2554380	0.843	rs2554386	chr15:84403522	T/C	cg14598478	chr15:84363061	ADAMTSL3	-0.65	-5.23	-0.47	1.02e-6	Height;
THYM	cis	rs11792861	0.641	rs10979586	chr9:111647764	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.68	5.34	0.48	6.26e-7	Menarche (age at onset);
THYM	cis	rs6759952	0.649	rs1382435	chr2:218296003	A/G	cg06280965	chr2:217410850	NA	0.58	4.67	0.43	9.91e-6	Thyroid cancer;
THYM	cis	rs6500395	0.735	rs7204345	chr16:48666726	T/C	cg04672837	chr16:48644449	N4BP1	0.47	4.62	0.43	1.18e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg08270630	chr22:50330655	NA	-0.83	-4.52	-0.42	1.8e-5	Schizophrenia;
THYM	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs55728055	0.661	rs8139560	chr22:32003798	C/T	cg10537193	chr22:32026975	PISD	-0.87	-5.53	-0.49	2.78e-7	Age-related hearing impairment;
THYM	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg06850241	chr22:41845214	NA	0.53	4.56	0.42	1.54e-5	Vitiligo;
THYM	cis	rs13418717	1.000	rs13401458	chr2:127657770	G/T	cg25501666	chr2:127640322	NA	1.61	6.45	0.55	4.76e-9	Heart failure;
THYM	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11644478	chr21:40555479	PSMG1	-0.82	-7.29	-0.6	9.29e-11	Cognitive function;
THYM	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg22535103	chr8:58192502	C8orf71	-0.93	-6.13	-0.53	1.98e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg14972814	chr11:95582409	MTMR2	-0.58	-5.31	-0.48	7.17e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2282300	0.739	rs1765139	chr11:30353725	T/C	cg09906309	chr11:30344399	C11orf46	-0.76	-5.87	-0.52	6.34e-8	Morning vs. evening chronotype;
THYM	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg11984989	chr7:158649758	WDR60	-1.02	-13.27	-0.81	2.39e-23	Height;
THYM	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg13695892	chr22:41940480	POLR3H	-0.75	-6.6	-0.56	2.29e-9	Vitiligo;
THYM	cis	rs6964587	0.692	rs6953256	chr7:91575417	C/T	cg17063962	chr7:91808500	NA	-1.04	-9.32	-0.69	4.62e-15	Breast cancer;
THYM	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg08000102	chr2:233561755	GIGYF2	0.69	6.09	0.53	2.35e-8	Coronary artery disease;
THYM	cis	rs1214752	0.935	rs9472049	chr6:43397259	C/T	cg09674015	chr6:43045187	PTK7	-0.5	-4.66	-0.43	1.02e-5	Coronary artery disease;
THYM	cis	rs6121246	0.559	rs6060716	chr20:30274847	C/G	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg08132940	chr7:1081526	C7orf50	-0.8	-5.42	-0.49	4.51e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.77	-5.56	-0.5	2.43e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1790761	0.802	rs2276118	chr11:67288594	A/G	cg01069141	chr11:67398826	TBX10;NUDT8	-0.45	-4.76	-0.44	6.79e-6	Mean corpuscular volume;
THYM	cis	rs4631830	0.869	rs11006207	chr10:51538176	T/C	cg10326726	chr10:51549505	MSMB	-0.62	-6.27	-0.54	1.07e-8	Prostate-specific antigen levels;
THYM	cis	rs854765	0.647	rs854817	chr17:18021882	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.58	4.77	0.44	6.55e-6	Total body bone mineral density;
THYM	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg16586182	chr3:47516702	SCAP	0.62	5.49	0.49	3.29e-7	Colorectal cancer;
THYM	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg24450063	chr1:156163899	SLC25A44	1.15	14.75	0.83	2.59e-26	Testicular germ cell tumor;
THYM	cis	rs3772130	0.923	rs7649092	chr3:121561950	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.75	4.64	0.43	1.1e-5	Cognitive performance;
THYM	cis	rs9902453	0.765	rs2628180	chr17:28101723	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs2836974	0.545	rs2776311	chr21:40716885	A/G	cg11644478	chr21:40555479	PSMG1	0.65	4.76	0.44	7.05e-6	Cognitive function;
THYM	cis	rs7980799	0.682	rs1580396	chr12:33615841	C/A	cg10856724	chr12:34555212	NA	0.6	4.5	0.42	1.93e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg26384229	chr12:38710491	ALG10B	0.97	7.35	0.6	7e-11	Bladder cancer;
THYM	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg24642844	chr7:1081250	C7orf50	-1.38	-5.93	-0.52	4.91e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9352866	0.935	rs2153241	chr6:81522123	T/A	cg08356243	chr6:80645827	ELOVL4	-0.45	-4.46	-0.42	2.23e-5	Antibody level in response to infection;
THYM	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg23758822	chr17:41437982	NA	1.16	10.86	0.74	2.48e-18	Menopause (age at onset);
THYM	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg03676636	chr4:99064102	C4orf37	0.43	6.43	0.55	5.1e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1580019	0.961	rs4357201	chr7:32496333	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.59	0.56	2.42e-9	Cognitive ability;
THYM	cis	rs12620999	1.000	rs10803655	chr2:238075551	C/T	cg23555395	chr2:238036564	NA	-0.61	-4.85	-0.45	4.87e-6	Systemic lupus erythematosus;
THYM	cis	rs554111	0.656	rs10916891	chr1:21199974	A/C	cg01072550	chr1:21505969	NA	0.57	4.99	0.46	2.74e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs6598541	0.962	rs59350108	chr15:99289607	G/C	cg13297560	chr15:99320054	IGF1R	-0.49	-5.06	-0.46	2.01e-6	Urate levels;
THYM	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg27446573	chr6:127587934	RNF146	0.87	6.74	0.57	1.22e-9	Breast cancer;
THYM	cis	rs2085601	0.631	rs28600923	chr4:89972465	T/C	cg17769793	chr4:89976368	FAM13A	-0.48	-5.02	-0.46	2.42e-6	Hair greying;
THYM	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4713118	0.539	rs200988	chr6:27819353	A/C	cg23161317	chr6:28129485	ZNF389	0.64	5.05	0.46	2.1e-6	Parkinson's disease;
THYM	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs4786125	0.519	rs1388805	chr16:6929947	C/T	cg03623568	chr16:6915990	A2BP1	-1.03	-8.74	-0.67	8.05e-14	Heart rate variability traits (SDNN);
THYM	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg00786635	chr1:25594202	NA	-0.9	-7.27	-0.6	1.02e-10	Erythrocyte sedimentation rate;
THYM	cis	rs11225247	1.000	rs78704392	chr11:102308053	G/A	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs7267979	1.000	rs761025	chr20:25426968	G/A	cg08601574	chr20:25228251	PYGB	0.59	4.81	0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg00071950	chr4:10020882	SLC2A9	-0.81	-8.01	-0.63	2.88e-12	Bone mineral density;
THYM	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg12463550	chr7:65579703	CRCP	-0.56	-4.67	-0.43	9.84e-6	Aortic root size;
THYM	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs728616	0.867	rs61859766	chr10:81683040	G/A	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg15592062	chr6:167189543	RPS6KA2	-0.58	-5.88	-0.52	6.01e-8	Crohn's disease;
THYM	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg13880726	chr7:1868755	MAD1L1	-0.7	-4.71	-0.43	8.6e-6	Bipolar disorder;
THYM	cis	rs62435770	1.000	rs62435798	chr6:169496724	G/A	cg07652237	chr6:170125491	PHF10	0.57	5.0	0.46	2.59e-6	Loneliness;
THYM	cis	rs853679	1.000	rs1778508	chr6:28229881	C/T	cg12963246	chr6:28129442	ZNF389	-0.67	-4.96	-0.45	3.13e-6	Depression;
THYM	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg06623918	chr6:96969491	KIAA0776	-1.09	-10.31	-0.73	3.58e-17	Headache;
THYM	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg14784868	chr12:69753453	YEATS4	0.79	6.48	0.55	4.06e-9	Blood protein levels;
THYM	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg26038318	chr20:34205095	SPAG4	-0.59	-4.8	-0.44	5.8e-6	Total cholesterol levels;
THYM	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg10518543	chr12:38710700	ALG10B	-0.59	-4.7	-0.43	8.88e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07157834	chr1:205819609	PM20D1	0.88	9.01	0.68	2.15e-14	Menarche (age at onset);
THYM	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg12419862	chr22:24373484	LOC391322	-0.75	-7.11	-0.59	2.19e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg18105134	chr13:113819100	PROZ	1.07	9.86	0.71	3.32e-16	Platelet distribution width;
THYM	cis	rs2717559	0.522	rs2949872	chr8:143872904	T/C	cg17888033	chr8:143858414	LYNX1	0.46	5.33	0.48	6.56e-7	Urinary tract infection frequency;
THYM	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg12863693	chr15:85201151	NMB	0.62	5.57	0.5	2.41e-7	Schizophrenia;
THYM	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg07424592	chr7:64974309	NA	-1.04	-5.27	-0.48	8.52e-7	Diabetic kidney disease;
THYM	cis	rs7000551	0.715	rs7839577	chr8:22307325	T/A	cg12081754	chr8:22256438	SLC39A14	0.63	5.08	0.46	1.91e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs951366	0.553	rs10900522	chr1:205684067	T/C	cg17178900	chr1:205818956	PM20D1	-0.63	-4.7	-0.43	8.82e-6	Menarche (age at onset);
THYM	cis	rs1422189	0.619	rs12655172	chr5:88010829	C/T	cg08455778	chr5:87975798	LOC645323	-0.59	-4.51	-0.42	1.87e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs2806561	0.765	rs652706	chr1:23514246	G/A	cg19743168	chr1:23544995	NA	0.55	5.64	0.5	1.74e-7	Height;
THYM	cis	rs28595532	0.920	rs114382134	chr4:119733215	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs7797990	0.585	rs9647668	chr7:156015535	G/A	cg03831405	chr7:155588795	NA	0.45	4.5	0.42	1.9e-5	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs13380717	0.657	rs4335778	chr16:86914742	A/G	cg05661093	chr16:86825505	NA	0.51	4.51	0.42	1.86e-5	Sepsis in extremely premature infants;
THYM	cis	rs2016266	0.784	rs12424778	chr12:53737840	A/T	cg26875137	chr12:53738046	NA	0.87	6.91	0.58	5.41e-10	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs16912285	0.539	rs11027824	chr11:24368141	A/G	ch.11.24196551F	chr11:24239977	NA	0.92	5.26	0.48	8.81e-7	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.89	-8.78	-0.67	6.71e-14	Lung cancer;
THYM	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.59	0.5	2.21e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7098414	0.530	rs4146515	chr10:82116602	G/A	cg00277334	chr10:82204260	NA	-0.44	-4.52	-0.42	1.76e-5	Post bronchodilator FEV1;
THYM	cis	rs6084875	0.840	rs2065704	chr20:4719344	A/T	cg19614321	chr20:4804581	RASSF2	0.45	4.53	0.42	1.7e-5	Systemic lupus erythematosus;
THYM	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.85	7.61	0.62	1.95e-11	Cognitive ability;
THYM	cis	rs919433	0.713	rs2045245	chr2:198485341	A/C	cg05783139	chr2:198650985	BOLL	0.58	4.48	0.42	2.11e-5	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22496380	chr5:211416	CCDC127	-1.42	-9.14	-0.68	1.15e-14	Breast cancer;
THYM	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs36051895	0.589	rs6476945	chr9:5191793	C/T	cg02405213	chr9:5042618	JAK2	-0.92	-10.13	-0.72	8.79e-17	Pediatric autoimmune diseases;
THYM	cis	rs9790314	0.521	rs1450523	chr3:161077270	G/A	cg03342759	chr3:160939853	NMD3	-0.71	-5.99	-0.52	3.81e-8	Morning vs. evening chronotype;
THYM	cis	rs7582180	0.627	rs6542947	chr2:100999647	C/G	cg08017756	chr2:100939284	LONRF2	0.74	7.82	0.63	7.31e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7192750	0.562	rs4788566	chr16:71893470	T/C	cg06353428	chr16:71660113	MARVELD3	0.78	5.77	0.51	1e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	trans	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs13102973	0.965	rs11099306	chr4:135895674	A/G	cg14419869	chr4:135874104	NA	0.89	8.63	0.66	1.39e-13	Subjective well-being;
THYM	cis	rs9581857	0.516	rs12323236	chr13:27971023	G/A	cg22138327	chr13:27999177	GTF3A	0.72	4.69	0.43	9.03e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg10589385	chr1:150898437	SETDB1	0.65	5.45	0.49	4.01e-7	Melanoma;
THYM	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg13114125	chr14:105738426	BRF1	-0.74	-5.72	-0.51	1.22e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg15744005	chr10:104629667	AS3MT	-0.78	-7.33	-0.6	7.48e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg06627628	chr2:24431161	ITSN2	-0.77	-5.38	-0.48	5.26e-7	Asthma;
THYM	cis	rs2046867	0.862	rs11922794	chr3:72813582	G/C	cg25664220	chr3:72788482	NA	-0.8	-6.0	-0.52	3.5e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs10463554	0.927	rs257308	chr5:102418261	A/C	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs7586879	1.000	rs1865687	chr2:25112885	G/A	cg15423357	chr2:25149977	NA	0.56	5.49	0.49	3.41e-7	Body mass index;
THYM	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg27490568	chr2:178487706	NA	0.58	5.64	0.5	1.73e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg23187316	chr7:1099788	C7orf50	0.59	4.52	0.42	1.76e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2625529	0.730	rs4777485	chr15:72389384	G/C	cg16672083	chr15:72433130	SENP8	-0.51	-4.56	-0.42	1.54e-5	Red blood cell count;
THYM	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg05368731	chr17:41323189	NBR1	1.26	11.18	0.75	5.03e-19	Menopause (age at onset);
THYM	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs887829	0.531	rs4338954	chr2:234593931	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-6.64	-0.56	1.98e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs6815814	0.898	rs5743592	chr4:38803063	A/G	cg06935464	chr4:38784597	TLR10	0.71	4.5	0.42	1.91e-5	Breast cancer;
THYM	cis	rs6087990	0.701	rs1997797	chr20:31387954	C/G	cg13636640	chr20:31349939	DNMT3B	0.93	9.73	0.71	6.1e-16	Ulcerative colitis;
THYM	cis	rs2282300	0.739	rs10835648	chr11:30320506	A/G	cg25418670	chr11:30344373	C11orf46	0.79	6.99	0.58	3.74e-10	Morning vs. evening chronotype;
THYM	cis	rs12142240	0.698	rs58162700	chr1:46816659	T/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	trans	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg10856724	chr12:34555212	NA	-0.78	-7.08	-0.59	2.48e-10	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11225247	0.772	rs35623064	chr11:102237391	T/C	cg11690896	chr11:102217788	BIRC2	1.12	5.18	0.47	1.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg05707623	chr12:122985044	ZCCHC8	0.73	5.06	0.46	2.06e-6	Body mass index;
THYM	cis	rs899997	0.953	rs11633519	chr15:78999552	A/G	cg00639195	chr15:79103007	ADAMTS7	-0.81	-5.86	-0.52	6.66e-8	Coronary artery disease or large artery stroke;
THYM	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	4.55	0.42	1.58e-5	Rheumatoid arthritis;
THYM	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg19729930	chr2:74357872	NA	1.26	10.75	0.74	4.16e-18	Gestational age at birth (maternal effect);
THYM	cis	rs9435341	0.965	rs2335104	chr1:107583641	A/T	cg09367891	chr1:107599246	PRMT6	0.71	4.94	0.45	3.35e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	trans	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg25214090	chr10:38739885	LOC399744	0.86	7.53	0.61	2.86e-11	Corneal astigmatism;
THYM	cis	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg00495681	chr13:53174319	NA	0.74	6.83	0.57	8.16e-10	Lewy body disease;
THYM	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg03676636	chr4:99064102	C4orf37	0.44	6.62	0.56	2.09e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11989744	1.000	rs17782264	chr8:23570489	C/T	cg04349084	chr8:23602677	NA	0.48	5.17	0.47	1.32e-6	Waist-hip ratio;
THYM	cis	rs1178127	0.611	rs2078869	chr7:18824971	C/T	cg13420273	chr7:18810212	HDAC9	-0.56	-5.07	-0.46	1.95e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg07061783	chr6:25882402	NA	0.84	7.17	0.59	1.58e-10	Blood metabolite levels;
THYM	cis	rs4845875	0.564	rs2151655	chr1:11845518	G/C	cg14194983	chr1:11908298	NPPA	0.56	5.18	0.47	1.23e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs262150	0.502	rs73167295	chr7:158782949	T/A	cg19418458	chr7:158789849	NA	0.66	4.73	0.44	7.69e-6	Facial morphology (factor 20);
THYM	cis	rs274567	0.711	rs404771	chr5:131635092	A/T	cg18758796	chr5:131593413	PDLIM4	0.52	4.91	0.45	3.8e-6	Blood metabolite levels;
THYM	cis	rs28476539	0.501	rs28512217	chr4:83540096	A/G	cg10249074	chr4:83542146	C4orf11	-0.7	-5.68	-0.5	1.44e-7	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs778371	0.752	rs283487	chr2:233644011	A/G	cg08000102	chr2:233561755	GIGYF2	0.79	6.97	0.58	4.21e-10	Schizophrenia;
THYM	cis	rs13358904	1.000	rs13358904	chr5:111602713	A/G	cg14511739	chr5:112073373	APC	0.67	4.45	0.42	2.33e-5	Suicide ideation score in major depressive disorder;
THYM	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg10193763	chr2:225306901	NA	-0.52	-5.48	-0.49	3.41e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs17401966	1.000	rs12130220	chr1:10359944	T/G	cg19773385	chr1:10388646	KIF1B	-0.62	-4.54	-0.42	1.67e-5	Hepatocellular carcinoma;
THYM	cis	rs13424612	0.839	rs6722915	chr2:240902569	C/A	cg01812947	chr2:240904978	NDUFA10	0.55	4.46	0.42	2.28e-5	Odorant perception (isobutyraldehyde);
THYM	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg07061783	chr6:25882402	NA	-0.9	-8.64	-0.66	1.33e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2625529	0.938	rs4238447	chr15:72131880	C/T	cg16672083	chr15:72433130	SENP8	-0.55	-4.77	-0.44	6.71e-6	Red blood cell count;
THYM	cis	rs13315871	0.929	rs77178267	chr3:58320657	T/G	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs11711311	0.712	rs11718013	chr3:113341661	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.53	-4.49	-0.42	1.96e-5	IgG glycosylation;
THYM	cis	rs17253792	0.511	rs76781598	chr14:55998379	G/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.87	-0.45	4.41e-6	Putamen volume;
THYM	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg27129171	chr3:47204927	SETD2	0.81	8.04	0.64	2.53e-12	Colorectal cancer;
THYM	cis	rs9549260	0.785	rs10507484	chr13:41218134	T/C	cg21288729	chr13:41239152	FOXO1	0.73	5.82	0.51	7.84e-8	Red blood cell count;
THYM	cis	rs4455778	0.757	rs9791574	chr7:49010732	A/C	cg26309511	chr7:48887640	NA	-0.53	-4.86	-0.45	4.63e-6	Lung cancer in never smokers;
THYM	cis	rs17407555	0.738	rs56143194	chr4:10067535	C/T	cg00071950	chr4:10020882	SLC2A9	-0.76	-6.14	-0.53	1.87e-8	Schizophrenia (age at onset);
THYM	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg00944433	chr1:107599041	PRMT6	0.41	5.18	0.47	1.24e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg05717871	chr11:638507	DRD4	-0.69	-6.08	-0.53	2.52e-8	Systemic lupus erythematosus;
THYM	cis	rs7799006	0.606	rs7792045	chr7:2316852	C/T	cg08027265	chr7:2291960	NA	-0.39	-5.0	-0.46	2.66e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7084402	0.967	rs1649038	chr10:60330439	G/A	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2069036	0.859	rs4748239	chr10:16095730	A/G	cg26633223	chr10:15133461	NA	0.66	4.65	0.43	1.08e-5	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg10760299	chr15:45669010	GATM	0.82	6.31	0.54	8.81e-9	Homoarginine levels;
THYM	cis	rs17401966	0.928	rs11121531	chr1:10277357	G/A	cg20482658	chr1:10539492	PEX14	0.4	4.79	0.44	6.2e-6	Hepatocellular carcinoma;
THYM	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg22117172	chr7:91764530	CYP51A1	-0.36	-4.7	-0.43	8.74e-6	Breast cancer;
THYM	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg02221750	chr19:17393354	ANKLE1	-0.99	-8.71	-0.67	9.58e-14	Systemic lupus erythematosus;
THYM	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs6866344	0.598	rs34703961	chr5:178147874	A/G	cg10224037	chr5:178157518	ZNF354A	1.03	8.58	0.66	1.76e-13	Neutrophil percentage of white cells;
THYM	cis	rs4523957	0.928	rs6502155	chr17:2176964	A/G	cg16513277	chr17:2031491	SMG6	-0.79	-7.41	-0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-10.71	-0.74	5.17e-18	Primary sclerosing cholangitis;
THYM	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg00383909	chr3:49044727	WDR6	1.08	6.19	0.54	1.54e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs11840576	0.588	rs331976	chr13:110317769	G/T	cg24915592	chr13:110319578	NA	-0.6	-5.0	-0.46	2.67e-6	Paclitaxel disposition in epithelial ovarian cancer;
THYM	cis	rs4731207	0.698	rs17147496	chr7:124449868	G/A	cg05285228	chr7:124571219	POT1	0.66	5.24	0.47	9.66e-7	Cutaneous malignant melanoma;
THYM	cis	rs13256369	0.760	rs7839473	chr8:8575836	C/T	cg00074818	chr8:8560427	CLDN23	0.53	4.76	0.44	6.82e-6	Obesity-related traits;
THYM	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	7.01	0.58	3.49e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.16	-5.63	-0.5	1.85e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7616559	0.924	rs4680328	chr3:156724717	A/G	cg15697575	chr3:156784781	NA	0.4	5.03	0.46	2.35e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.97	-9.35	-0.69	4.11e-15	Cognitive ability;
THYM	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg18252515	chr7:66147081	NA	-0.66	-4.87	-0.45	4.38e-6	Aortic root size;
THYM	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.65	5.62	0.5	1.88e-7	Personality dimensions;
THYM	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg15838173	chr10:75533400	FUT11	-0.62	-6.3	-0.54	9.28e-9	Inflammatory bowel disease;
THYM	cis	rs7394190	0.748	rs11000780	chr10:75559077	G/A	cg07699608	chr10:75541558	CHCHD1	0.96	5.1	0.46	1.77e-6	Incident atrial fibrillation;
THYM	cis	rs950394	1.000	rs7585377	chr2:104976101	A/C	cg20302975	chr2:105468274	NA	-0.71	-4.54	-0.42	1.64e-5	Schizophrenia;
THYM	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg12564285	chr5:131593104	PDLIM4	-0.42	-4.54	-0.42	1.67e-5	Breast cancer;
THYM	cis	rs11771526	0.748	rs4723142	chr7:32337569	C/A	cg13207630	chr7:32358064	NA	0.72	4.84	0.44	4.97e-6	Body mass index;
THYM	cis	rs4642101	0.512	rs12629892	chr3:12818920	A/G	cg05775895	chr3:12838266	CAND2	1.05	9.96	0.71	2.06e-16	QRS complex (12-leadsum);
THYM	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6087990	0.899	rs1003521	chr20:31366598	T/C	cg13636640	chr20:31349939	DNMT3B	0.93	9.97	0.72	1.89e-16	Ulcerative colitis;
THYM	cis	rs3771570	0.892	rs62186433	chr2:242257835	A/G	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs367615	0.959	rs17161951	chr5:108930590	A/G	cg17395555	chr5:108820864	NA	-0.55	-4.82	-0.44	5.41e-6	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg11905131	chr22:24372483	LOC391322	-0.9	-10.61	-0.74	8.19e-18	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg06481639	chr22:41940642	POLR3H	0.84	5.85	0.51	6.94e-8	Vitiligo;
THYM	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs986417	0.748	rs10147346	chr14:61083334	G/C	cg27398547	chr14:60952738	C14orf39	1.04	5.74	0.51	1.14e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs9443645	0.505	rs11752126	chr6:79707923	C/T	cg05283184	chr6:79620031	NA	-0.6	-4.67	-0.43	9.86e-6	Intelligence (multi-trait analysis);
THYM	cis	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg23161317	chr6:28129485	ZNF389	0.85	5.31	0.48	7.04e-7	Depression;
THYM	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg05347473	chr6:146136440	FBXO30	-0.6	-4.56	-0.42	1.55e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4919087	1.000	rs10786330	chr10:99074959	C/A	cg19453742	chr10:98862320	SLIT1	-0.6	-4.78	-0.44	6.43e-6	Monocyte count;
THYM	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg26354017	chr1:205819088	PM20D1	0.97	10.31	0.73	3.67e-17	Menarche (age at onset);
THYM	cis	rs9788721	1.000	rs10519203	chr15:78814046	C/T	cg18825076	chr15:78729989	IREB2	0.57	5.4	0.48	4.89e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg00383909	chr3:49044727	WDR6	1.25	6.49	0.55	3.81e-9	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg06521331	chr12:34319734	NA	-0.76	-5.95	-0.52	4.46e-8	Morning vs. evening chronotype;
THYM	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg21475434	chr5:93447410	FAM172A	-0.72	-4.8	-0.44	5.83e-6	Diabetic retinopathy;
THYM	cis	rs2195525	0.572	rs10790290	chr11:119218542	T/C	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.43	4.69	0.43	9.19e-6	Urate levels;
THYM	cis	rs7084402	0.967	rs1658443	chr10:60316926	G/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg08355456	chr11:67383691	NA	0.66	4.59	0.43	1.36e-5	Mean corpuscular volume;
THYM	cis	rs6728642	0.908	rs17842456	chr2:98014319	C/T	cg26665480	chr2:98280029	ACTR1B	0.82	4.82	0.44	5.48e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs4517514	0.509	rs11018870	chr11:89871409	T/G	cg23743573	chr11:89867420	NAALAD2	0.79	4.73	0.44	7.92e-6	Trans fatty acid levels;
THYM	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs992157	0.932	rs10194082	chr2:219188577	C/T	cg00012203	chr2:219082015	ARPC2	0.64	5.58	0.5	2.28e-7	Colorectal cancer;
THYM	cis	rs2273669	0.504	rs75555274	chr6:109478385	G/A	cg17117243	chr6:109341365	SESN1	-0.92	-5.47	-0.49	3.63e-7	Prostate cancer;
THYM	cis	rs4664308	0.935	rs6739867	chr2:160942818	G/A	cg03641300	chr2:160917029	PLA2R1	-0.78	-6.97	-0.58	4.25e-10	Idiopathic membranous nephropathy;
THYM	cis	rs4589258	0.898	rs12575063	chr11:90418766	T/C	cg26834418	chr11:89957033	CHORDC1	0.52	4.7	0.43	8.9e-6	Intelligence (multi-trait analysis);
THYM	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg22664400	chr11:66445111	RBM4B	0.66	4.47	0.42	2.14e-5	Crohn's disease;
THYM	cis	rs9329289	0.510	rs11251283	chr10:2555784	C/G	cg07014206	chr10:2547000	NA	-0.6	-5.33	-0.48	6.66e-7	Age-related hearing impairment;
THYM	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg14004847	chr7:1930337	MAD1L1	-0.58	-4.55	-0.42	1.56e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs470093	0.825	rs138125	chr22:44269322	T/C	cg09142166	chr22:44276013	PNPLA5	-0.57	-5.48	-0.49	3.43e-7	Staphylococcus aureus infection;
THYM	cis	rs10819861	0.547	rs10760781	chr9:98872831	G/A	cg14508093	chr9:98862825	NA	-0.25	-4.75	-0.44	7.31e-6	Electrocardiographic traits;
THYM	cis	rs9880211	0.613	rs6799056	chr3:135802350	C/T	cg21827317	chr3:136751795	NA	-0.72	-5.21	-0.47	1.11e-6	Body mass index;Height;
THYM	cis	rs735539	1.000	rs9506537	chr13:21280410	T/C	cg02792322	chr13:21280448	IL17D	0.67	4.95	0.45	3.17e-6	Dental caries;
THYM	cis	rs2274459	1.000	rs10456420	chr6:33754301	T/C	cg06253072	chr6:33679850	C6orf125	0.51	4.49	0.42	1.99e-5	Obesity (extreme);
THYM	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg20887711	chr4:1340912	KIAA1530	-0.58	-4.64	-0.43	1.13e-5	Obesity-related traits;
THYM	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg06028808	chr11:68637592	NA	0.65	6.7	0.57	1.44e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4732038	0.510	rs6948744	chr7:134278163	A/G	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg17911788	chr17:44343683	NA	-0.79	-7.48	-0.61	3.65e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.94	0.75	1.62e-18	Diabetic retinopathy;
THYM	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg08000102	chr2:233561755	GIGYF2	0.54	4.81	0.44	5.65e-6	Coronary artery disease;
THYM	cis	rs4849845	0.925	rs1370379	chr2:121014589	C/T	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs7590720	0.851	rs13006614	chr2:216876204	C/T	cg12620499	chr2:216877984	MREG	0.91	6.96	0.58	4.33e-10	Alcohol dependence;
THYM	trans	rs8073060	0.586	rs6505485	chr17:33996102	C/T	cg19694781	chr19:47549865	TMEM160	-1.06	-8.85	-0.67	4.75e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs3126085	0.935	rs3120659	chr1:152293202	A/G	cg26020982	chr1:152196106	HRNR	-0.35	-4.95	-0.45	3.26e-6	Atopic dermatitis;
THYM	cis	rs6570726	0.738	rs7746330	chr6:145899257	A/C	cg23711669	chr6:146136114	FBXO30	1.0	11.18	0.75	5.12e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17127169	0.667	rs10889512	chr1:65426306	C/A	cg12075498	chr1:65428216	JAK1	0.39	5.62	0.5	1.92e-7	Sitting height ratio;
THYM	cis	rs7072216	0.727	rs942809	chr10:100168001	G/A	cg03852570	chr10:100175106	PYROXD2	0.37	4.91	0.45	3.85e-6	Metabolite levels;
THYM	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg11812906	chr14:75593930	NEK9	0.8	7.18	0.59	1.51e-10	Height;
THYM	cis	rs900145	0.859	rs1351525	chr11:13301548	A/T	cg13286116	chr11:13302098	ARNTL	-0.61	-4.58	-0.43	1.38e-5	Menarche (age at onset);
THYM	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg01579765	chr21:45077557	HSF2BP	-0.48	-7.87	-0.63	5.72e-12	Mean corpuscular volume;
THYM	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg09222892	chr1:25734099	RHCE	0.63	4.95	0.45	3.17e-6	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs11190604	1.000	rs2495732	chr10:102357780	T/C	cg16342193	chr10:102329863	NA	-0.54	-5.25	-0.47	9.17e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11771526	0.901	rs17161086	chr7:32294254	A/G	cg13207630	chr7:32358064	NA	-0.78	-5.0	-0.46	2.64e-6	Body mass index;
THYM	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg02655623	chr17:3728468	C17orf85	-0.92	-6.86	-0.58	6.87e-10	Depressive symptoms;
THYM	cis	rs3741151	1.000	rs76570090	chr11:73066321	A/T	cg12959048	chr11:73096162	RELT	-0.5	-4.78	-0.44	6.38e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2688608	0.592	rs11000760	chr10:75493734	G/A	cg15838173	chr10:75533400	FUT11	-0.5	-5.09	-0.46	1.82e-6	Inflammatory bowel disease;
THYM	cis	rs4769475	0.957	rs301075	chr13:26703960	A/G	cg13319468	chr13:27597730	NA	0.65	5.22	0.47	1.05e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg01299579	chr2:10830716	NOL10	-0.5	-4.79	-0.44	6.23e-6	Prostate cancer;
THYM	cis	rs6570726	0.764	rs376257	chr6:145862949	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg10295955	chr4:187884368	NA	-1.18	-17.67	-0.88	8.7e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg19774624	chr17:42201019	HDAC5	0.66	5.75	0.51	1.1e-7	Total body bone mineral density;
THYM	cis	rs4499344	0.556	rs259236	chr19:33116122	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.98	6.95	0.58	4.58e-10	Mean platelet volume;
THYM	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg06808227	chr14:105710500	BRF1	-1.01	-8.62	-0.66	1.43e-13	Mean platelet volume;Platelet distribution width;
THYM	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Body mass index;
THYM	cis	rs7786877	0.723	rs6969584	chr7:100209747	A/C	cg04499151	chr7:100231278	TFR2	0.63	4.48	0.42	2.07e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4285028	0.948	rs34158925	chr3:121678465	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg27534772	chr1:16042836	PLEKHM2	0.56	6.24	0.54	1.23e-8	Systolic blood pressure;
THYM	cis	rs8017423	0.967	rs59980414	chr14:90687738	G/C	cg04239629	chr14:90701769	NA	-0.61	-4.53	-0.42	1.73e-5	Mortality in heart failure;
THYM	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg27034606	chr17:28928453	LRRC37B2	0.83	5.47	0.49	3.6e-7	Body mass index;
THYM	cis	rs11264213	0.591	rs274745	chr1:36538282	G/A	cg27506609	chr1:36549197	TEKT2	-1.35	-5.18	-0.47	1.25e-6	Schizophrenia;
THYM	cis	rs7635838	0.586	rs347617	chr3:11278211	C/T	cg00170343	chr3:11313890	ATG7	0.61	4.58	0.43	1.43e-5	HDL cholesterol;
THYM	cis	rs60695258	0.550	rs4693800	chr4:87915620	C/G	cg10685359	chr4:87814065	C4orf36	0.45	5.78	0.51	9.52e-8	Hematocrit;
THYM	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.19	-9.36	-0.69	3.85e-15	Platelet count;
THYM	cis	rs17604090	0.646	rs10258473	chr7:29690439	A/C	cg19413766	chr7:29689036	LOC646762	-0.91	-4.99	-0.46	2.69e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	4.83	0.44	5.25e-6	Hip circumference adjusted for BMI;
THYM	cis	rs1065852	0.526	rs11090066	chr22:42398195	A/G	cg04717802	chr22:42394638	WBP2NL	0.59	4.64	0.43	1.13e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs7769051	0.522	rs60631157	chr6:133094817	G/A	cg22852734	chr6:133119734	C6orf192	1.59	7.01	0.58	3.47e-10	Type 2 diabetes nephropathy;
THYM	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg08000102	chr2:233561755	GIGYF2	-0.54	-4.87	-0.45	4.52e-6	Coronary artery disease;
THYM	cis	rs4919044	0.756	rs2486686	chr10:94778511	G/T	cg05127821	chr10:94822908	CYP26C1	-1.31	-6.9	-0.58	5.75e-10	Coronary artery disease;
THYM	cis	rs9653442	0.704	rs10211595	chr2:100726476	G/C	cg22139774	chr2:100720529	AFF3	-0.32	-4.78	-0.44	6.26e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg26441486	chr22:50317300	CRELD2	0.36	5.15	0.47	1.41e-6	Schizophrenia;
THYM	cis	rs1994135	0.669	rs2121831	chr12:33697674	G/A	cg10856724	chr12:34555212	NA	-0.74	-5.57	-0.5	2.41e-7	Resting heart rate;
THYM	cis	rs1371867	0.875	rs1788187	chr8:101336099	A/G	cg00191853	chr8:101177733	SPAG1	-0.51	-5.03	-0.46	2.29e-6	Atrioventricular conduction;
THYM	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	5.51	0.49	3.1e-7	Schizophrenia;
THYM	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg22875332	chr1:76189707	ACADM	-0.75	-6.93	-0.58	4.97e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg02018176	chr4:1364513	KIAA1530	0.5	4.58	0.43	1.43e-5	Obesity-related traits;
THYM	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg23758822	chr17:41437982	NA	1.17	11.13	0.75	6.48e-19	Menopause (age at onset);
THYM	cis	rs12681287	0.511	rs9297923	chr8:87548989	T/C	cg27223183	chr8:87520930	FAM82B	0.71	5.56	0.5	2.44e-7	Caudate activity during reward;
THYM	cis	rs995000	0.899	rs1168027	chr1:62970184	T/C	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs919433	0.680	rs3792159	chr2:198403697	A/G	cg05783139	chr2:198650985	BOLL	-0.62	-4.82	-0.44	5.36e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6921919	0.583	rs9461459	chr6:28361916	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.5	-0.42	1.89e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.63	4.46	0.42	2.25e-5	Aortic root size;
THYM	cis	rs2898681	0.614	rs11947787	chr4:53705225	C/A	cg00338735	chr4:53728038	RASL11B	0.6	5.58	0.5	2.3e-7	Optic nerve measurement (cup area);
THYM	cis	rs1790761	0.667	rs1254123	chr11:67334812	T/C	cg01069141	chr11:67398826	TBX10;NUDT8	0.45	4.74	0.44	7.43e-6	Mean corpuscular volume;
THYM	cis	rs72627123	1.000	rs12050434	chr14:74341438	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg06191203	chr2:152266755	RIF1	-0.74	-4.99	-0.46	2.74e-6	Lung cancer;
THYM	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs13315871	1.000	rs71311868	chr3:58392874	A/G	cg12435725	chr3:58293450	RPP14	-0.47	-4.66	-0.43	1.05e-5	Cholesterol, total;
THYM	cis	rs3540	0.513	rs2589974	chr15:90891566	C/T	cg22089800	chr15:90895588	ZNF774	-0.84	-7.14	-0.59	1.82e-10	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs6840360	0.571	rs12650655	chr4:152556075	G/A	cg22705602	chr4:152727874	NA	-0.78	-8.53	-0.66	2.29e-13	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg19507638	chr5:93509721	C5orf36	-0.67	-4.48	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg06582575	chr6:163149167	PACRG;PARK2	1.14	6.64	0.56	1.9e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs56775891	0.959	rs7238071	chr18:77579812	C/T	cg26740109	chr18:77585428	NA	0.82	5.87	0.52	6.45e-8	Schizophrenia;
THYM	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg08772003	chr10:104629869	AS3MT	-0.55	-4.88	-0.45	4.23e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs753778	0.570	rs6578154	chr8:142210057	G/A	cg18755752	chr8:142205143	DENND3	-0.74	-7.51	-0.61	3.14e-11	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	trans	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg25214090	chr10:38739885	LOC399744	0.93	7.92	0.63	4.43e-12	Corneal astigmatism;
THYM	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg08132940	chr7:1081526	C7orf50	-0.77	-5.18	-0.47	1.25e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9443645	0.505	rs9359364	chr6:79795992	G/A	cg05283184	chr6:79620031	NA	-0.6	-4.68	-0.43	9.44e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg10911889	chr6:126070802	HEY2	0.58	4.62	0.43	1.19e-5	Brugada syndrome;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg13253642	chr6:132939906	TAAR2	-0.88	-6.91	-0.58	5.59e-10	Depressive symptoms;
THYM	cis	rs2688608	0.901	rs2675671	chr10:75632760	C/T	cg19442545	chr10:75533431	FUT11	-0.43	-4.56	-0.42	1.54e-5	Inflammatory bowel disease;
THYM	cis	rs1483890	0.517	rs6549198	chr3:69362959	A/G	cg22125112	chr3:69402811	FRMD4B	0.42	5.26	0.47	8.91e-7	Resting heart rate;
THYM	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg04520793	chr17:42248056	ASB16	-0.35	-4.82	-0.44	5.39e-6	Total body bone mineral density;
THYM	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg15247329	chr7:2764246	NA	-0.71	-5.88	-0.52	6.01e-8	Height;
THYM	cis	rs1048238	0.506	rs598371	chr1:16212739	G/A	cg21385522	chr1:16154831	NA	-0.7	-5.79	-0.51	8.9e-8	Systolic blood pressure;
THYM	cis	rs7487075	0.780	rs1873793	chr12:46761324	A/G	cg17501823	chr12:47219793	SLC38A4	-0.49	-4.75	-0.44	7.09e-6	Itch intensity from mosquito bite;
THYM	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg07169764	chr2:136633963	MCM6	0.71	6.05	0.53	2.81e-8	Mosquito bite size;
THYM	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg07570687	chr10:102243282	WNT8B	0.75	6.53	0.56	3.17e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs4731207	0.596	rs12055904	chr7:124662864	C/T	cg05285228	chr7:124571219	POT1	-0.6	-4.51	-0.42	1.82e-5	Cutaneous malignant melanoma;
THYM	cis	rs854765	0.663	rs3183702	chr17:17747289	A/G	cg04398451	chr17:18023971	MYO15A	0.8	7.38	0.6	5.95e-11	Total body bone mineral density;
THYM	trans	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Bladder cancer;
THYM	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.92	5.02	0.46	2.41e-6	Initial pursuit acceleration;
THYM	cis	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg13443165	chr9:33130375	B4GALT1	-0.86	-7.96	-0.63	3.71e-12	IgG glycosylation;
THYM	cis	rs6570726	0.599	rs9376951	chr6:145898911	C/T	cg05347473	chr6:146136440	FBXO30	0.81	7.26	0.6	1.06e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.58	-4.99	-0.46	2.72e-6	Hip circumference adjusted for BMI;
THYM	cis	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs2404602	0.647	rs12913024	chr15:77145216	C/T	cg23625390	chr15:77176239	SCAPER	-0.83	-5.85	-0.51	6.84e-8	Blood metabolite levels;
THYM	cis	rs61931739	0.612	rs1906136	chr12:33905293	C/T	cg10856724	chr12:34555212	NA	-0.62	-5.55	-0.49	2.56e-7	Morning vs. evening chronotype;
THYM	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.76	-0.44	6.96e-6	Type 2 diabetes;
THYM	cis	rs7011507	0.617	rs7816648	chr8:49319203	A/T	cg08774009	chr8:49309094	NA	-0.5	-4.51	-0.42	1.86e-5	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.46	-6.99	-0.58	3.86e-10	Obesity-related traits;
THYM	cis	rs7107174	1.000	rs10899479	chr11:78052539	A/G	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg23851026	chr2:136556271	LCT	0.55	5.58	0.5	2.28e-7	Mosquito bite size;
THYM	cis	rs899997	0.954	rs4887091	chr15:79043580	T/C	cg22753661	chr15:79092743	ADAMTS7	0.73	4.71	0.44	8.29e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs6964587	0.692	rs2374550	chr7:91820987	A/G	cg17063962	chr7:91808500	NA	0.98	8.49	0.66	2.78e-13	Breast cancer;
THYM	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg03060546	chr3:49711283	APEH	-0.62	-4.76	-0.44	6.89e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg15445000	chr17:37608096	MED1	-0.44	-5.07	-0.46	1.99e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9394438	0.628	rs4714078	chr6:37543852	G/A	cg00985040	chr6:37553208	NA	-0.43	-4.64	-0.43	1.11e-5	IgG glycosylation;
THYM	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs939658	0.683	rs1474256	chr15:79463847	C/T	cg17916960	chr15:79447300	NA	0.71	8.21	0.64	1.1e-12	Refractive error;
THYM	cis	rs9972944	0.756	rs9899781	chr17:63769384	C/T	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs4664308	0.694	rs4665140	chr2:160890710	T/A	cg03641300	chr2:160917029	PLA2R1	-0.67	-5.84	-0.51	7.12e-8	Idiopathic membranous nephropathy;
THYM	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg06850241	chr22:41845214	NA	-0.49	-4.75	-0.44	7.28e-6	Vitiligo;
THYM	cis	rs62070183	0.882	rs17781136	chr17:31185042	C/T	cg02981443	chr17:31254875	TMEM98	-0.52	-4.61	-0.43	1.25e-5	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs919433	0.680	rs6710530	chr2:198277551	G/A	cg00792783	chr2:198669748	PLCL1	0.82	5.67	0.5	1.54e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs40363	1.000	rs1690444	chr16:3518350	G/A	cg00484396	chr16:3507460	NAT15	0.66	6.44	0.55	4.97e-9	Tuberculosis;
THYM	cis	rs236907	0.859	rs2232824	chr1:171761458	T/C	cg20598894	chr1:171756153	METTL13	-0.74	-5.59	-0.5	2.16e-7	Mean platelet volume;
THYM	cis	rs2303759	0.709	rs10414921	chr19:49823047	C/T	cg22133161	chr19:49891603	CCDC155	0.75	4.97	0.45	2.94e-6	Multiple sclerosis;
THYM	cis	rs7100689	0.646	rs10736346	chr10:82134281	A/C	cg01528321	chr10:82214614	TSPAN14	0.79	6.01	0.52	3.47e-8	Post bronchodilator FEV1;
THYM	cis	rs7426056	0.530	rs2140148	chr2:204572140	A/C	cg07930752	chr2:204569955	CD28	-0.78	-5.62	-0.5	1.88e-7	Primary sclerosing cholangitis;
THYM	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg26384229	chr12:38710491	ALG10B	0.99	7.66	0.62	1.58e-11	Bladder cancer;
THYM	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg00990874	chr7:1149470	C7orf50	-0.56	-4.58	-0.43	1.39e-5	Longevity;Endometriosis;
THYM	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3112255	0.512	rs11123842	chr2:101337982	A/G	cg01042948	chr2:101319752	NA	-0.5	-4.96	-0.45	3.13e-6	Intelligence (multi-trait analysis);
THYM	cis	rs500891	0.525	rs36116892	chr6:84087567	T/A	cg21688264	chr6:84418724	SNAP91	0.78	5.0	0.46	2.6e-6	Platelet-derived growth factor BB levels;
THYM	cis	rs11997175	0.624	rs7464055	chr8:33679382	G/A	ch.8.33884649F	chr8:33765107	NA	0.66	5.0	0.46	2.57e-6	Body mass index;
THYM	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg13010199	chr12:38710504	ALG10B	0.73	5.82	0.51	7.99e-8	Heart rate;
THYM	cis	rs1883415	0.526	rs807536	chr6:24554274	A/C	cg00346970	chr6:24499591	ALDH5A1	-0.38	-4.67	-0.43	9.96e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9733	0.596	rs6692960	chr1:150695965	G/A	cg04414720	chr1:150670196	GOLPH3L	0.62	4.71	0.44	8.35e-6	Tonsillectomy;
THYM	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg02527881	chr3:46936655	PTH1R	-0.72	-7.5	-0.61	3.37e-11	Colorectal cancer;
THYM	cis	rs7731657	0.537	rs6595979	chr5:130335192	C/G	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs804280	0.525	rs1004712	chr8:11622293	C/T	cg12395012	chr8:11607386	GATA4	-0.61	-5.61	-0.5	1.99e-7	Myopia (pathological);
THYM	cis	rs1395	0.778	rs1439768	chr2:27389660	C/A	cg23587288	chr2:27483067	SLC30A3	-0.6	-5.25	-0.47	9.17e-7	Blood metabolite levels;
THYM	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg05283184	chr6:79620031	NA	-0.89	-8.99	-0.68	2.38e-14	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg07157834	chr1:205819609	PM20D1	-0.6	-4.66	-0.43	1.02e-5	Menarche (age at onset);
THYM	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg27068330	chr11:65405492	SIPA1	-0.81	-5.52	-0.49	2.95e-7	Breast cancer;
THYM	cis	rs3126085	0.935	rs12063165	chr1:152176357	C/T	cg26020982	chr1:152196106	HRNR	0.34	4.52	0.42	1.76e-5	Atopic dermatitis;
THYM	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03517284	chr6:25882590	NA	-0.9	-7.21	-0.59	1.36e-10	Intelligence (multi-trait analysis);
THYM	cis	rs8017423	0.967	rs59006192	chr14:90706456	C/T	cg04239629	chr14:90701769	NA	-0.62	-4.52	-0.42	1.81e-5	Mortality in heart failure;
THYM	cis	rs9572053	0.550	rs4884819	chr13:69554391	C/T	cg16757992	chr13:69559194	NA	-0.61	-4.91	-0.45	3.8e-6	Subjective well-being;
THYM	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg24733560	chr20:60626293	TAF4	0.64	6.68	0.57	1.65e-9	Body mass index;
THYM	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg15997130	chr1:24165203	NA	-0.71	-5.34	-0.48	6.26e-7	Immature fraction of reticulocytes;
THYM	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg08645402	chr16:4508243	NA	0.67	5.35	0.48	6.16e-7	Schizophrenia;
THYM	trans	rs6089829	0.962	rs2314131	chr20:61665225	A/G	cg23505145	chr19:12996616	KLF1	0.96	8.05	0.64	2.31e-12	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs1997103	0.954	rs6953004	chr7:55411919	G/A	cg20935933	chr6:143382018	AIG1	0.86	6.91	0.58	5.41e-10	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs6495367	0.844	rs4778879	chr15:79372875	A/G	cg17916960	chr15:79447300	NA	0.57	6.24	0.54	1.21e-8	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs1371867	0.846	rs1660324	chr8:101281271	C/T	cg00191853	chr8:101177733	SPAG1	-0.56	-5.59	-0.5	2.15e-7	Atrioventricular conduction;
THYM	cis	rs3126085	0.935	rs4361987	chr1:152229701	A/G	cg26020982	chr1:152196106	HRNR	0.35	4.95	0.45	3.26e-6	Atopic dermatitis;
THYM	cis	rs4930776	1.000	rs7486388	chr12:5766338	C/T	cg02086166	chr12:5775618	ANO2	-0.58	-5.71	-0.51	1.3e-7	Plasma clusterin levels;
THYM	cis	rs13082711	0.522	rs578501	chr3:27344963	A/G	cg02860705	chr3:27208620	NA	0.65	5.07	0.46	1.94e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs73206853	0.841	rs73191829	chr12:110948906	A/G	cg24010859	chr12:110868153	NA	0.62	4.46	0.42	2.25e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
THYM	cis	rs605843	0.724	rs674246	chr11:113141684	C/T	cg12243453	chr11:113775400	HTR3B	-0.53	-4.54	-0.42	1.63e-5	Sense of smell;
THYM	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg24642844	chr7:1081250	C7orf50	-1.29	-8.27	-0.65	8.2e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.7	6.62	0.56	2.17e-9	Lymphocyte counts;
THYM	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg16586182	chr3:47516702	SCAP	-0.67	-5.62	-0.5	1.9e-7	Colorectal cancer;
THYM	cis	rs2933343	0.761	rs789225	chr3:128600229	G/A	cg11901034	chr3:128598214	ACAD9	-0.7	-5.68	-0.5	1.47e-7	IgG glycosylation;
THYM	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg05855489	chr10:104503620	C10orf26	-0.75	-6.57	-0.56	2.69e-9	Immature fraction of reticulocytes;Schizophrenia;
THYM	trans	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs11771526	0.892	rs62457539	chr7:32364604	G/A	cg13207630	chr7:32358064	NA	1.06	6.2	0.54	1.44e-8	Body mass index;
THYM	cis	rs1878931	0.624	rs27241	chr16:3447282	C/G	cg22508957	chr16:3507546	NAT15	0.47	4.81	0.44	5.67e-6	Body mass index (adult);
THYM	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg16797656	chr11:68205561	LRP5	0.43	4.55	0.42	1.58e-5	Total body bone mineral density;
THYM	cis	rs7582180	0.903	rs2309819	chr2:100899665	C/T	cg14675211	chr2:100938903	LONRF2	0.65	5.52	0.49	2.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg14004847	chr7:1930337	MAD1L1	-0.66	-5.08	-0.46	1.86e-6	Schizophrenia;
THYM	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg00852783	chr1:26633632	UBXN11	0.86	8.81	0.67	5.74e-14	Obesity-related traits;
THYM	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg16031515	chr1:205743344	RAB7L1	-0.69	-7.18	-0.59	1.51e-10	Menarche (age at onset);
THYM	cis	rs10484885	0.878	rs72921959	chr6:90591326	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.87	-7.73	-0.62	1.13e-11	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs7592578	0.639	rs61709084	chr2:191287685	A/C	cg21644426	chr2:191273491	MFSD6	-0.72	-4.91	-0.45	3.74e-6	Diastolic blood pressure;
THYM	cis	rs34638657	0.673	rs67661146	chr16:82199669	G/A	cg09894383	chr16:82067445	HSD17B2	-0.45	-5.25	-0.47	9.14e-7	Lung adenocarcinoma;
THYM	cis	rs9361491	0.608	rs1319575	chr6:79459051	T/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.83	0.57	8.15e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs877282	0.755	rs2790388	chr10:786084	T/C	cg22713356	chr15:30763199	NA	1.18	9.79	0.71	4.66e-16	Uric acid levels;
THYM	trans	rs3960554	0.808	rs111764601	chr7:75706141	T/C	cg19862616	chr7:65841803	NCRNA00174	0.93	6.95	0.58	4.6e-10	Eotaxin levels;
THYM	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs861020	0.630	rs616544	chr1:210007368	T/C	cg05527609	chr1:210001259	C1orf107	0.85	6.82	0.57	8.53e-10	Orofacial clefts;
THYM	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.95	-7.56	-0.61	2.51e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg24675658	chr1:53192096	ZYG11B	-0.77	-6.92	-0.58	5.37e-10	Monocyte count;
THYM	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg03909863	chr11:638404	DRD4	-0.83	-5.8	-0.51	8.53e-8	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg25358565	chr5:93447407	FAM172A	1.26	9.94	0.71	2.19e-16	Diabetic retinopathy;
THYM	cis	rs6960043	0.714	rs4719430	chr7:15047280	C/G	cg19272540	chr7:15055459	NA	-0.53	-5.7	-0.5	1.36e-7	Type 2 diabetes;
THYM	cis	rs2050392	0.517	rs602097	chr10:30747546	C/T	cg12408189	chr10:30722286	MAP3K8	-0.59	-4.72	-0.44	8.13e-6	Inflammatory bowel disease;
THYM	cis	rs754466	0.651	rs10824583	chr10:79619402	C/T	cg17075019	chr10:79541650	NA	0.68	5.87	0.52	6.44e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7100689	0.646	rs10749581	chr10:82141651	A/G	cg01528321	chr10:82214614	TSPAN14	-0.79	-5.91	-0.52	5.27e-8	Post bronchodilator FEV1;
THYM	cis	rs9393777	0.668	rs72839449	chr6:27261661	A/C	cg22548220	chr6:27277996	POM121L2	0.83	5.2	0.47	1.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6496667	1.000	rs8023776	chr15:90897952	A/G	cg22089800	chr15:90895588	ZNF774	-0.71	-4.71	-0.43	8.55e-6	Rheumatoid arthritis;
THYM	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg08508325	chr11:3079039	CARS	-0.52	-6.62	-0.56	2.08e-9	Longevity;
THYM	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs11608355	1.000	rs9669684	chr12:109860644	C/T	cg11367159	chr12:110044531	NA	0.66	6.29	0.54	9.83e-9	Neuroticism;
THYM	cis	rs7616559	0.962	rs1600976	chr3:156751494	A/G	cg15697575	chr3:156784781	NA	0.41	5.09	0.46	1.82e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07157834	chr1:205819609	PM20D1	-0.65	-5.97	-0.52	4e-8	Monocyte percentage of white cells;
THYM	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg08017756	chr2:100939284	LONRF2	-0.74	-7.69	-0.62	1.32e-11	Intelligence (multi-trait analysis);
THYM	cis	rs4766566	0.568	rs11065857	chr12:111739500	A/G	cg10833066	chr12:111807467	FAM109A	0.65	8.96	0.68	2.74e-14	Atrial fibrillation;Renal underexcretion gout;Gout;Renal overload gout;
THYM	cis	rs9913156	0.748	rs72835630	chr17:4562449	C/T	cg19197139	chr17:4613644	ARRB2	0.78	4.92	0.45	3.63e-6	Lymphocyte counts;
THYM	cis	rs763014	0.932	rs4984898	chr16:641164	G/T	cg09263875	chr16:632152	PIGQ	0.73	5.95	0.52	4.49e-8	Height;
THYM	cis	rs8016982	0.657	rs11625861	chr14:81735001	C/T	cg01989461	chr14:81687754	GTF2A1	-0.72	-6.24	-0.54	1.21e-8	Schizophrenia;
THYM	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg17264618	chr3:40429014	ENTPD3	0.52	4.97	0.45	3e-6	Renal cell carcinoma;
THYM	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.79	-0.62	8.45e-12	Crohn's disease;
THYM	cis	rs28595532	0.844	rs115411027	chr4:119490685	T/C	cg11846333	chr4:119757529	SEC24D	1.36	4.83	0.44	5.23e-6	Cannabis dependence symptom count;
THYM	cis	rs6815814	0.898	rs73236646	chr4:38871385	T/C	cg14665413	chr4:38859728	TLR6	-0.4	-4.83	-0.44	5.23e-6	Breast cancer;
THYM	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg10057126	chr4:77819792	ANKRD56	0.71	6.06	0.53	2.78e-8	Emphysema distribution in smoking;
THYM	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg23260525	chr10:116636907	FAM160B1	0.52	5.19	0.47	1.19e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7107174	1.000	rs7939352	chr11:78003151	G/A	cg19901956	chr11:77921274	USP35	-0.66	-5.05	-0.46	2.13e-6	Testicular germ cell tumor;
THYM	cis	rs6763768	0.606	rs4687576	chr3:53385418	T/C	cg22900224	chr3:52804907	NEK4	0.72	4.71	0.43	8.6e-6	Bacterial meningitis;
THYM	cis	rs919433	0.679	rs6719832	chr2:198533369	C/T	cg00792783	chr2:198669748	PLCL1	-0.82	-5.44	-0.49	4.16e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs10540	0.841	rs35601764	chr11:532923	A/C	cg21784768	chr11:537496	LRRC56	-1.21	-5.55	-0.5	2.53e-7	Body mass index;
THYM	cis	rs3106136	0.527	rs2632410	chr4:95149507	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.1	-0.46	1.7e-6	Capecitabine sensitivity;
THYM	cis	rs2811415	0.597	rs2033445	chr3:127730507	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	5.43	0.49	4.31e-7	Height;
THYM	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.06	9.33	0.69	4.45e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10214930	0.958	rs10268051	chr7:27763590	A/C	cg04422003	chr7:28448295	CREB5	-0.62	-4.6	-0.43	1.28e-5	Hypospadias;
THYM	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg11764359	chr7:65958608	NA	-0.81	-6.42	-0.55	5.45e-9	Aortic root size;
THYM	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg08994789	chr17:28903642	LRRC37B2	-1.05	-5.39	-0.48	5.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg26513180	chr16:89883248	FANCA	0.67	6.65	0.56	1.87e-9	Vitiligo;
THYM	cis	rs2455799	0.613	rs7617039	chr3:15800740	A/G	cg16303742	chr3:15540471	COLQ	0.49	5.01	0.46	2.51e-6	Mean platelet volume;
THYM	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg00814883	chr7:100076585	TSC22D4	-0.96	-6.43	-0.55	5.12e-9	Platelet count;
THYM	cis	rs892961	0.932	rs8065422	chr17:75420165	T/C	cg05865280	chr17:75406074	SEPT9	0.5	8.5	0.66	2.58e-13	Airflow obstruction;
THYM	cis	rs9560113	0.960	rs953260	chr13:112173685	C/T	cg14154082	chr13:112174009	NA	0.85	7.71	0.62	1.23e-11	Menarche (age at onset);
THYM	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg18681998	chr4:17616180	MED28	0.97	9.52	0.7	1.74e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs883565	0.655	rs7619193	chr3:39044116	T/C	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	5.0	0.46	2.59e-6	Handedness;
THYM	cis	rs4780401	0.703	rs7193637	chr16:11764920	C/T	cg01061890	chr16:11836724	TXNDC11	-0.61	-4.66	-0.43	1.02e-5	Rheumatoid arthritis;
THYM	cis	rs67460515	0.563	rs13256	chr3:160796505	G/A	cg12349858	chr3:160822545	B3GALNT1	0.64	5.01	0.46	2.55e-6	Parkinson's disease;
THYM	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg07636037	chr3:49044803	WDR6	0.82	5.95	0.52	4.41e-8	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs765787	0.530	rs12323957	chr15:45490773	C/T	cg24006582	chr15:45444508	DUOX1	0.81	6.54	0.56	3.09e-9	Uric acid levels;
THYM	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg12311346	chr5:56204834	C5orf35	-0.77	-5.59	-0.5	2.18e-7	Initial pursuit acceleration;
THYM	trans	rs877282	0.755	rs2486578	chr10:785227	C/T	cg22713356	chr15:30763199	NA	-1.16	-9.65	-0.7	9.28e-16	Uric acid levels;
THYM	cis	rs420259	0.516	rs4968019	chr16:23557790	T/C	cg00143387	chr16:23521605	GGA2	-0.75	-5.37	-0.48	5.57e-7	Bipolar disorder;
THYM	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg22166914	chr1:53195759	ZYG11B	-0.69	-6.96	-0.58	4.39e-10	Monocyte count;
THYM	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.61	5.52	0.49	2.92e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg08000102	chr2:233561755	GIGYF2	-0.65	-5.67	-0.5	1.54e-7	Coronary artery disease;
THYM	cis	rs4530754	0.579	rs6595456	chr5:122864567	C/T	cg20708411	chr5:122847581	CSNK1G3	-0.37	-4.62	-0.43	1.21e-5	LDL cholesterol;Total cholesterol levels;Cholesterol, total;LDL cholesterol levels;
THYM	cis	rs12257961	0.710	rs10906883	chr10:15335808	A/T	cg10616319	chr10:15468812	NA	-0.61	-4.74	-0.44	7.47e-6	Selective IgA deficiency;
THYM	cis	rs4805272	0.626	rs12608533	chr19:29331405	C/G	cg03161606	chr19:29218774	NA	0.59	4.75	0.44	7.25e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs4121859	1.000	rs12575842	chr11:95176538	A/G	cg01219426	chr11:95856658	MAML2	-0.66	-4.48	-0.42	2.11e-5	Cancer;
THYM	trans	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg10856724	chr12:34555212	NA	-0.95	-8.21	-0.64	1.07e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6674176	0.593	rs6675620	chr1:44417630	C/T	cg13246856	chr1:44399776	ARTN	0.48	4.87	0.45	4.49e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs4589258	0.788	rs10741367	chr11:90491400	A/G	cg26138821	chr11:89956704	CHORDC1	-0.56	-4.52	-0.42	1.8e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg00898013	chr13:113819073	PROZ	-0.87	-8.78	-0.67	6.82e-14	Platelet distribution width;
THYM	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg10057126	chr4:77819792	ANKRD56	0.7	5.93	0.52	4.87e-8	Emphysema distribution in smoking;
THYM	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg23187316	chr7:1099788	C7orf50	0.59	4.52	0.42	1.76e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg03188948	chr7:1209495	NA	1.12	6.36	0.55	7.09e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg11245990	chr11:68621969	NA	0.57	7.2	0.59	1.41e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9326248	0.861	rs7120309	chr11:117042816	T/A	cg01368799	chr11:117014884	PAFAH1B2	0.67	4.78	0.44	6.35e-6	Blood protein levels;
THYM	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35264875	1.000	rs72919409	chr11:68826553	G/C	cg01993067	chr11:68851601	TPCN2	1.0	4.71	0.43	8.6e-6	Blond vs. brown hair color;
THYM	cis	rs6570726	0.791	rs11155435	chr6:145938545	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs597539	0.545	rs3794027	chr11:68697336	T/C	cg06028808	chr11:68637592	NA	0.65	6.59	0.56	2.45e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6570726	0.846	rs397311	chr6:145806701	C/T	cg13319975	chr6:146136371	FBXO30	0.72	5.95	0.52	4.42e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg11764359	chr7:65958608	NA	0.78	6.31	0.54	8.68e-9	Aortic root size;
THYM	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg04944784	chr2:26401820	FAM59B	1.08	6.83	0.57	7.98e-10	Gut microbiome composition (summer);
THYM	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs4631830	0.832	rs67289834	chr10:51501304	C/T	cg10326726	chr10:51549505	MSMB	0.57	5.68	0.5	1.49e-7	Prostate-specific antigen levels;
THYM	cis	rs78456975	0.622	rs11896517	chr2:1518112	A/G	cg12573674	chr2:1569213	NA	-1.22	-5.83	-0.51	7.71e-8	Placebo response in major depressive disorder (% change in symptom score);
THYM	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg04842962	chr6:43655489	MRPS18A	1.41	15.7	0.85	3.85e-28	IgG glycosylation;
THYM	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg07884673	chr3:53033167	SFMBT1	1.25	6.36	0.55	6.97e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.91	6.47	0.55	4.22e-9	Schizophrenia;
THYM	cis	rs2282300	0.739	rs1631451	chr11:30349133	G/C	cg25418670	chr11:30344373	C11orf46	-0.82	-6.98	-0.58	3.93e-10	Morning vs. evening chronotype;
THYM	cis	rs4866334	1.000	rs79036917	chr5:18441030	A/C	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs7828089	0.646	rs12679702	chr8:22282190	G/C	cg13512537	chr8:22265999	SLC39A14	-0.7	-5.46	-0.49	3.72e-7	Verbal declarative memory;
THYM	cis	rs4638749	0.627	rs1522020	chr2:108833346	C/G	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs7611238	0.538	rs13320698	chr3:195072319	C/T	cg26838900	chr3:194090132	LRRC15	0.55	4.46	0.42	2.28e-5	Body mass index;
THYM	cis	rs13315871	0.929	rs7635697	chr3:58313706	G/A	cg00563845	chr3:58318305	PXK	0.59	5.02	0.46	2.37e-6	Cholesterol, total;
THYM	cis	rs6942756	1.000	rs7780886	chr7:128879347	G/A	cg02491457	chr7:128862824	NA	-0.44	-4.53	-0.42	1.69e-5	White matter hyperintensity burden;
THYM	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13012494	chr21:47604986	C21orf56	0.65	4.58	0.43	1.42e-5	Testicular germ cell tumor;
THYM	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg02187348	chr16:89574699	SPG7	0.66	5.14	0.47	1.45e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg19077165	chr18:44547161	KATNAL2	-0.67	-8.6	-0.66	1.58e-13	Personality dimensions;
THYM	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.71	6.87	0.58	6.73e-10	Lymphocyte counts;
THYM	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg03433033	chr1:76189801	ACADM	-0.64	-6.0	-0.52	3.62e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs994014	0.691	rs11725731	chr4:82271434	C/T	cg17825130	chr4:82283507	NA	0.5	4.59	0.43	1.34e-5	Height;
THYM	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg11764359	chr7:65958608	NA	-0.8	-6.38	-0.55	6.55e-9	Aortic root size;
THYM	cis	rs6754311	0.517	rs1469996	chr2:136542560	A/G	cg04750100	chr2:136595281	LCT	0.56	5.22	0.47	1.03e-6	Mosquito bite size;
THYM	cis	rs7917772	0.560	rs10786697	chr10:104378563	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	8.1	0.64	1.86e-12	Monocyte percentage of white cells;
THYM	cis	rs7614311	1.000	rs2087704	chr3:63820493	A/C	cg22134162	chr3:63841271	THOC7	0.47	5.67	0.5	1.5e-7	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs9649465	1.000	rs2299985	chr7:123369044	T/C	cg15443791	chr7:124364398	NA	0.58	4.81	0.44	5.62e-6	Migraine;
THYM	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg13609457	chr4:120235615	NA	0.54	5.06	0.46	2.01e-6	Corneal astigmatism;
THYM	cis	rs8067545	0.611	rs2703788	chr17:20159686	T/C	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg18876405	chr7:65276391	NA	0.57	4.83	0.44	5.27e-6	Aortic root size;
THYM	cis	rs9633835	0.568	rs900144	chr11:13294268	A/G	cg13286116	chr11:13302098	ARNTL	0.75	8.79	0.67	6.29e-14	Body mass index;
THYM	trans	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs2294693	0.786	rs10456497	chr6:40989057	T/C	cg21128951	chr6:40996213	UNC5CL	0.6	4.53	0.42	1.69e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs977987	0.800	rs12935787	chr16:75332335	C/T	cg03315344	chr16:75512273	CHST6	0.83	6.93	0.58	5e-10	Dupuytren's disease;
THYM	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs11249608	0.636	rs13359549	chr5:178449178	T/A	cg01312482	chr5:178451176	ZNF879	-0.68	-5.27	-0.48	8.43e-7	Pubertal anthropometrics;
THYM	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg13683864	chr3:40499215	RPL14	-1.05	-11.64	-0.77	5.54e-20	Renal cell carcinoma;
THYM	cis	rs7666738	0.530	rs2865992	chr4:99067181	A/T	cg17366294	chr4:99064904	C4orf37	0.43	4.76	0.44	6.89e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7580658	0.895	rs7589451	chr2:128128775	T/C	cg10021288	chr2:128175891	PROC	-0.76	-6.54	-0.56	3.05e-9	Protein C levels;
THYM	cis	rs2898681	1.000	rs2046364	chr4:53743218	G/T	cg21521518	chr4:53727714	RASL11B	0.49	5.31	0.48	7.15e-7	Optic nerve measurement (cup area);
THYM	cis	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg24672777	chr11:48374446	OR4C45	-0.65	-4.54	-0.42	1.67e-5	Coronary artery disease;
THYM	cis	rs4455778	0.543	rs4357242	chr7:49067599	T/C	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.71e-7	Diabetic kidney disease;
THYM	cis	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg06636001	chr8:8085503	FLJ10661	-0.67	-5.49	-0.49	3.39e-7	Mood instability;
THYM	cis	rs6665290	0.870	rs1045289	chr1:227178713	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs951188	0.744	rs871	chr2:150329973	A/C	cg17961725	chr2:150454027	NA	0.92	4.68	0.43	9.39e-6	Daytime sleep phenotypes;
THYM	cis	rs6754311	0.512	rs12998387	chr2:136507039	A/G	cg23851026	chr2:136556271	LCT	-0.57	-5.96	-0.52	4.29e-8	Mosquito bite size;
THYM	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg08017756	chr2:100939284	LONRF2	-0.73	-7.54	-0.61	2.77e-11	Intelligence (multi-trait analysis);
THYM	cis	rs295140	1.000	rs3739121	chr2:201171014	G/C	cg04283868	chr2:201171347	SPATS2L	0.74	5.53	0.49	2.81e-7	QT interval;
THYM	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs7772486	0.712	rs6570726	chr6:146159460	T/C	cg23711669	chr6:146136114	FBXO30	0.76	7.08	0.59	2.49e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg14416269	chr4:6271139	WFS1	0.61	5.88	0.52	6.12e-8	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs68170813	0.641	rs77397573	chr7:107006892	G/A	cg00661777	chr7:106511741	PIK3CG	-0.66	-4.61	-0.43	1.25e-5	Coronary artery disease;
THYM	cis	rs2637266	1.000	rs10824425	chr10:78340310	C/G	cg18941641	chr10:78392320	NA	0.83	7.2	0.59	1.41e-10	Pulmonary function;
THYM	cis	rs2637266	0.935	rs1907299	chr10:78325316	T/C	cg18941641	chr10:78392320	NA	0.69	5.5	0.49	3.16e-7	Pulmonary function;
THYM	cis	rs11997175	0.583	rs56045827	chr8:33787015	G/A	ch.8.33884649F	chr8:33765107	NA	0.75	5.4	0.48	4.92e-7	Body mass index;
THYM	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg23791538	chr6:167370224	RNASET2	-0.61	-4.62	-0.43	1.21e-5	Crohn's disease;
THYM	cis	rs17152411	0.895	rs7906592	chr10:126627861	C/G	cg07906193	chr10:126599966	NA	0.69	4.71	0.44	8.45e-6	Height;
THYM	cis	rs61931739	0.635	rs1852225	chr12:33963004	C/T	cg06521331	chr12:34319734	NA	-0.56	-4.69	-0.43	8.97e-6	Morning vs. evening chronotype;
THYM	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs9318086	0.712	rs66683041	chr13:24442090	T/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.87	7.42	0.61	4.96e-11	Myopia (pathological);
THYM	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11890956	chr21:40555474	PSMG1	1.17	12.99	0.8	8.73e-23	Cognitive function;
THYM	cis	rs7426056	0.530	rs34813348	chr2:204573302	A/G	cg13651908	chr2:204570033	CD28	-0.7	-5.29	-0.48	7.76e-7	Primary sclerosing cholangitis;
THYM	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.72	-0.44	8.19e-6	Crohn's disease;
THYM	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg16325326	chr1:53192061	ZYG11B	-0.73	-7.1	-0.59	2.23e-10	Monocyte count;
THYM	cis	rs7833986	1.000	rs66553445	chr8:57096781	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	4.78	0.44	6.48e-6	Height;
THYM	cis	rs2625529	0.652	rs1481862	chr15:72245648	G/A	cg16672083	chr15:72433130	SENP8	0.49	4.47	0.42	2.17e-5	Red blood cell count;
THYM	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg04731861	chr2:219085781	ARPC2	-0.52	-4.94	-0.45	3.36e-6	Colorectal cancer;
THYM	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg00898013	chr13:113819073	PROZ	0.95	8.78	0.67	6.62e-14	Platelet distribution width;
THYM	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-6.65	-0.56	1.84e-9	Chronic sinus infection;
THYM	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg20295408	chr7:1910781	MAD1L1	-0.72	-5.86	-0.52	6.74e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs4237845	0.780	rs3751331	chr12:58290278	G/A	cg22764591	chr12:58329936	NA	0.84	5.9	0.52	5.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	7.74	0.62	1.08e-11	Smoking behavior;
THYM	cis	rs1011018	0.628	rs10254826	chr7:139433480	T/C	cg06079564	chr7:139468310	HIPK2	-0.72	-4.77	-0.44	6.71e-6	Systolic blood pressure;
THYM	cis	rs7267979	1.000	rs2482927	chr20:25327151	T/C	cg08601574	chr20:25228251	PYGB	-0.58	-4.71	-0.43	8.54e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs448720	0.811	rs694267	chr15:68183377	C/T	cg24579218	chr15:68104479	NA	-0.52	-4.47	-0.42	2.14e-5	Cognitive performance;
THYM	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs3741151	0.773	rs7931767	chr11:73239207	A/G	cg12959048	chr11:73096162	RELT	-0.51	-4.51	-0.42	1.87e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg04267008	chr7:1944627	MAD1L1	-0.7	-6.36	-0.55	6.96e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg03859395	chr2:55845619	SMEK2	0.59	5.04	0.46	2.21e-6	Metabolic syndrome;
THYM	cis	rs863345	0.584	rs1342949	chr1:158463295	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs981844	0.712	rs62325150	chr4:154728117	T/G	cg09973105	chr4:154681532	RNF175	-0.67	-6.2	-0.54	1.44e-8	Response to statins (LDL cholesterol change);
THYM	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg03806693	chr22:41940476	POLR3H	1.04	8.41	0.65	3.99e-13	Vitiligo;
THYM	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg23260525	chr10:116636907	FAM160B1	0.51	5.26	0.48	8.82e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs988913	0.678	rs9349753	chr6:54981922	A/T	cg18532076	chr6:54711417	FAM83B	0.48	4.48	0.42	2.1e-5	Menarche (age at onset);
THYM	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg17554472	chr22:41940697	POLR3H	0.66	4.69	0.43	9.23e-6	Vitiligo;
THYM	cis	rs12188164	0.575	rs112126699	chr5:419462	A/T	cg16322479	chr5:444228	EXOC3;C5orf55	0.57	4.65	0.43	1.07e-5	Cystic fibrosis severity;
THYM	cis	rs4363385	0.553	rs1415972	chr1:152953552	A/G	cg04546999	chr1:152956429	SPRR1A	0.5	4.65	0.43	1.08e-5	Inflammatory skin disease;
THYM	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg11502198	chr6:26597334	ABT1	0.64	5.68	0.5	1.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.72	0.51	1.23e-7	Lung cancer in ever smokers;
THYM	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs9972944	0.651	rs7222415	chr17:63765137	T/C	cg07283582	chr17:63770753	CCDC46	-0.65	-5.06	-0.46	2.01e-6	Total body bone mineral density;
THYM	cis	rs1994135	0.549	rs2218650	chr12:33734783	A/G	cg06521331	chr12:34319734	NA	-0.7	-5.01	-0.46	2.55e-6	Resting heart rate;
THYM	cis	rs2898681	0.519	rs76606067	chr4:53728221	G/T	cg00791764	chr4:53727839	RASL11B	0.61	6.76	0.57	1.09e-9	Optic nerve measurement (cup area);
THYM	cis	rs11574514	1.000	rs118008021	chr16:67722328	T/A	cg09738193	chr16:67926317	PSKH1	-0.91	-4.66	-0.43	1.01e-5	Crohn's disease;
THYM	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg02018176	chr4:1364513	KIAA1530	-0.8	-7.57	-0.61	2.41e-11	Obesity-related traits;
THYM	cis	rs2933343	0.553	rs35076317	chr3:128715535	T/C	cg11901034	chr3:128598214	ACAD9	-0.67	-4.86	-0.45	4.61e-6	IgG glycosylation;
THYM	cis	rs11731175	0.960	rs7435063	chr4:189858084	G/C	cg00431894	chr4:189871012	NA	-0.81	-6.19	-0.54	1.52e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs17006441	0.932	rs6793179	chr3:69903331	C/A	cg18496212	chr3:69797108	MITF	0.68	6.83	0.57	8.05e-10	Hemoglobin concentration;
THYM	cis	rs79815064	0.850	rs75994669	chr3:46300863	T/G	cg20674725	chr3:47020919	NBEAL2	0.71	4.7	0.43	8.76e-6	Macrophage inflammatory protein 1b levels;
THYM	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg06028808	chr11:68637592	NA	0.69	7.21	0.59	1.32e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6558530	0.730	rs4875958	chr8:1721090	A/G	cg09410841	chr8:1729607	CLN8	-0.79	-6.15	-0.53	1.84e-8	Systolic blood pressure;
THYM	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11890956	chr21:40555474	PSMG1	0.68	5.69	0.5	1.43e-7	Cognitive function;
THYM	cis	rs62051538	0.602	rs4553646	chr16:31536419	A/G	cg10091996	chr16:31548640	NA	0.5	4.5	0.42	1.96e-5	Mean corpuscular hemoglobin;
THYM	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg15744005	chr10:104629667	AS3MT	-0.85	-7.88	-0.63	5.39e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs244293	0.760	rs4794547	chr17:53011172	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.52	-4.49	-0.42	1.98e-5	Menarche (age at onset);
THYM	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.54	5.27	0.48	8.47e-7	Schizophrenia;
THYM	cis	rs4664308	0.692	rs10497213	chr2:160963603	G/A	cg03641300	chr2:160917029	PLA2R1	-0.59	-5.24	-0.47	9.56e-7	Idiopathic membranous nephropathy;
THYM	cis	rs6430585	0.528	rs114760827	chr2:136661110	G/A	cg23851026	chr2:136556271	LCT	0.77	6.81	0.57	8.95e-10	Corneal structure;
THYM	cis	rs6570726	0.846	rs409553	chr6:145886963	C/T	cg13319975	chr6:146136371	FBXO30	-0.67	-5.44	-0.49	4.21e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7659604	0.643	rs6838881	chr4:122663616	A/T	cg06713675	chr4:122721982	EXOSC9	-0.56	-5.04	-0.46	2.22e-6	Type 2 diabetes;
THYM	cis	rs9807989	0.507	rs6749014	chr2:103006448	C/T	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg17264618	chr3:40429014	ENTPD3	0.52	4.97	0.45	2.94e-6	Renal cell carcinoma;
THYM	cis	rs6032067	0.929	rs17424578	chr20:43806321	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs7584330	0.737	rs61212490	chr2:238365230	T/C	cg16989719	chr2:238392110	NA	-0.6	-5.82	-0.51	7.82e-8	Prostate cancer;
THYM	cis	rs4631830	0.869	rs7896437	chr10:51529593	A/C	cg16070123	chr10:51489643	NA	-0.5	-4.48	-0.42	2.09e-5	Prostate-specific antigen levels;
THYM	cis	rs7226229	0.950	rs7208779	chr17:20940347	G/A	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs6500395	1.000	rs6500402	chr16:48687354	C/T	cg04672837	chr16:48644449	N4BP1	0.52	5.09	0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs10851411	0.559	rs17767270	chr15:42898612	A/G	cg21293051	chr15:42870591	STARD9	-0.76	-4.48	-0.42	2.07e-5	Glucose homeostasis traits;
THYM	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg15247329	chr7:2764246	NA	-0.7	-5.91	-0.52	5.43e-8	Height;
THYM	cis	rs34638657	0.687	rs2303261	chr16:82203768	G/T	cg09894383	chr16:82067445	HSD17B2	-0.44	-4.91	-0.45	3.8e-6	Lung adenocarcinoma;
THYM	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg00129232	chr17:37814104	STARD3	-0.71	-4.8	-0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs1642645	0.831	rs2886564	chr1:42496924	G/A	cg06092502	chr1:42611687	NA	0.61	4.74	0.44	7.58e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.12	8.74	0.67	8.17e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9399401	0.667	rs7757571	chr6:142702589	A/C	cg03128060	chr6:142623767	GPR126	0.7	9.47	0.7	2.29e-15	Chronic obstructive pulmonary disease;
THYM	trans	rs10118776	0.510	rs13293142	chr9:6170924	A/C	cg02532923	chr16:89110004	NA	1.01	7.85	0.63	6.11e-12	Small cell lung carcinoma;
THYM	cis	rs596169	0.655	rs12061363	chr1:219174033	G/A	cg19270308	chr1:218458869	RRP15	-1.24	-4.52	-0.42	1.81e-5	Intraocular pressure;
THYM	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg06558623	chr16:89946397	TCF25	1.34	6.12	0.53	2.13e-8	Skin colour saturation;
THYM	cis	rs36051895	0.623	rs10118434	chr9:5238460	A/G	cg02405213	chr9:5042618	JAK2	-0.93	-9.39	-0.69	3.38e-15	Pediatric autoimmune diseases;
THYM	cis	rs7607369	0.714	rs4674334	chr2:219622811	T/C	cg02176678	chr2:219576539	TTLL4	-0.65	-6.28	-0.54	9.93e-9	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg22947322	chr17:47091978	IGF2BP1	0.6	6.18	0.54	1.57e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs7633857	0.512	rs745707	chr3:160652672	G/T	cg03342759	chr3:160939853	NMD3	-0.62	-4.72	-0.44	8.03e-6	Educational attainment (years of education);
THYM	cis	rs887829	0.569	rs4663967	chr2:234653184	A/C	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.56	-4.47	-0.42	2.13e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs7909074	0.798	rs10900126	chr10:45386322	G/T	cg04218760	chr10:45406644	TMEM72	-0.72	-6.56	-0.56	2.83e-9	Mean corpuscular volume;
THYM	cis	rs7809950	1.000	rs2894475	chr7:107262558	A/T	cg23024343	chr7:107201750	COG5	-0.87	-7.3	-0.6	8.61e-11	Coronary artery disease;
THYM	cis	rs1448094	0.547	rs7954472	chr12:86166258	T/C	cg00310523	chr12:86230176	RASSF9	0.61	5.34	0.48	6.44e-7	Major depressive disorder;
THYM	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg07936489	chr17:37558343	FBXL20	-0.81	-5.5	-0.49	3.17e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg12893697	chr11:970389	AP2A2	-0.32	-5.35	-0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg05973401	chr12:123451056	ABCB9	0.69	4.59	0.43	1.36e-5	Neutrophil percentage of white cells;
THYM	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg04267008	chr7:1944627	MAD1L1	-0.7	-6.55	-0.56	2.95e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs7909074	0.966	rs4245614	chr10:45397007	C/T	cg04218760	chr10:45406644	TMEM72	-0.64	-5.64	-0.5	1.76e-7	Mean corpuscular volume;
THYM	trans	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7107174	1.000	rs7117238	chr11:78040259	G/A	cg02023728	chr11:77925099	USP35	0.63	6.1	0.53	2.29e-8	Testicular germ cell tumor;
THYM	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg13647721	chr17:30228624	UTP6	0.69	4.64	0.43	1.11e-5	Hip circumference adjusted for BMI;
THYM	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg22433210	chr17:43662623	NA	-1.05	-8.08	-0.64	2e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4280164	0.551	rs3181251	chr14:24805824	C/T	cg18846074	chr14:24801073	ADCY4	-0.61	-4.79	-0.44	6.18e-6	Parent of origin effect on language impairment (paternal);
THYM	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs9814567	0.762	rs13070654	chr3:134219348	T/C	cg15484384	chr3:134203672	ANAPC13;CEP63	0.4	4.49	0.42	1.99e-5	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg18240062	chr17:79603768	NPLOC4	-0.73	-6.57	-0.56	2.74e-9	Eye color traits;
THYM	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg05340658	chr4:99064831	C4orf37	0.54	4.55	0.42	1.58e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs919433	0.680	rs2565160	chr2:198286474	A/G	cg00792783	chr2:198669748	PLCL1	0.82	5.67	0.5	1.54e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs804292	0.695	rs804279	chr8:11623889	A/T	cg26752888	chr8:11627280	NEIL2	0.84	7.13	0.59	1.99e-10	Alcohol dependence;Nicotine use;
THYM	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg05368731	chr17:41323189	NBR1	-1.13	-10.0	-0.72	1.64e-16	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg17366294	chr4:99064904	C4orf37	0.55	6.73	0.57	1.26e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs887829	0.570	rs6753320	chr2:234595615	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.78	6.64	0.56	1.98e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs2997447	0.761	rs17356867	chr1:26448849	C/T	cg03844060	chr1:26490628	NA	-0.69	-4.84	-0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs9828933	0.577	rs832193	chr3:63854445	C/T	cg16258503	chr3:63850278	ATXN7;THOC7	0.89	5.55	0.49	2.58e-7	Type 2 diabetes;
THYM	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.87	5.36	0.48	5.82e-7	Platelet count;
THYM	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11890956	chr21:40555474	PSMG1	0.99	8.41	0.65	4.12e-13	Cognitive function;
THYM	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	5.21	0.47	1.1e-6	Electroencephalogram traits;
THYM	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs6570726	0.791	rs427128	chr6:145865917	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg06634786	chr22:41940651	POLR3H	0.69	5.08	0.46	1.89e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7404928	0.557	rs10775269	chr16:23912136	A/C	cg26685404	chr16:23957272	PRKCB	0.55	6.11	0.53	2.16e-8	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs3087591	1.000	rs2012988	chr17:29547296	T/C	cg24425628	chr17:29625626	OMG;NF1	0.65	5.62	0.5	1.92e-7	Hip circumference;
THYM	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs2072499	0.833	rs2842870	chr1:156200671	T/C	cg24450063	chr1:156163899	SLC25A44	1.04	12.54	0.79	7.46e-22	Testicular germ cell tumor;
THYM	cis	rs2456568	0.778	rs2456563	chr11:93678675	C/T	cg17595323	chr11:93583763	C11orf90	-0.57	-5.06	-0.46	2.02e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg10803722	chr21:46713166	LOC642852	-0.43	-5.74	-0.51	1.13e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs904251	0.864	rs2797801	chr6:37487161	A/G	cg25019722	chr6:37503610	NA	-0.61	-4.99	-0.46	2.73e-6	Cognitive performance;
THYM	cis	rs7809950	0.817	rs4727678	chr7:107083635	C/G	cg23024343	chr7:107201750	COG5	-1.02	-8.69	-0.67	1.02e-13	Coronary artery disease;
THYM	cis	rs9303401	0.646	rs8067682	chr17:57219391	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.68	4.95	0.45	3.22e-6	Cognitive test performance;
THYM	cis	rs6815814	0.950	rs5743794	chr4:38832727	C/T	cg14665413	chr4:38859728	TLR6	-0.41	-4.87	-0.45	4.51e-6	Breast cancer;
THYM	cis	rs12347191	0.500	rs925486	chr9:100619733	C/T	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Orofacial clefts;
THYM	cis	rs7178572	0.889	rs7171448	chr15:77832316	C/G	cg22256960	chr15:77711686	NA	-0.96	-7.95	-0.63	3.8e-12	Type 2 diabetes;
THYM	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg19077165	chr18:44547161	KATNAL2	-0.48	-4.7	-0.43	8.8e-6	Educational attainment;
THYM	cis	rs11711311	1.000	rs9826808	chr3:113455644	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.27	-0.48	8.41e-7	IgG glycosylation;
THYM	cis	rs7851660	0.874	rs7037175	chr9:100631662	G/C	cg13688889	chr9:100608707	NA	-0.79	-5.92	-0.52	5.07e-8	Strep throat;
THYM	trans	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.72	-0.62	1.18e-11	Exhaled nitric oxide output;
THYM	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg26963428	chr7:66367121	NA	-0.59	-4.72	-0.44	8.08e-6	Corneal structure;
THYM	cis	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs2396545	0.638	rs1062099	chr11:567627	G/C	cg01616529	chr11:638424	DRD4	-0.78	-5.68	-0.5	1.44e-7	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg02825527	chr7:2087843	MAD1L1	-0.69	-4.45	-0.42	2.3e-5	Bipolar disorder;
THYM	cis	rs4243830	0.737	rs6692747	chr1:6610049	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.11	6.18	0.54	1.6e-8	Body mass index;
THYM	cis	rs34112283	0.592	rs13024145	chr2:144251789	T/A	cg17056048	chr2:144271431	ARHGAP15	0.65	6.26	0.54	1.09e-8	Neuroticism;
THYM	cis	rs1728785	1.000	rs698716	chr16:68560296	C/T	cg02972257	chr16:68554789	NA	-0.76	-4.82	-0.44	5.35e-6	Ulcerative colitis;
THYM	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9543976	0.544	rs73223950	chr13:76099037	T/G	cg01531495	chr13:76123901	UCHL3	-0.87	-4.75	-0.44	7.21e-6	Diabetic retinopathy;
THYM	cis	rs10887741	0.646	rs12413510	chr10:89436979	T/C	cg13926569	chr10:89418898	PAPSS2	0.63	7.28	0.6	9.67e-11	Exercise (leisure time);
THYM	trans	rs4596713	0.538	rs1416738	chr9:71787927	C/T	cg16512924	chr15:28394682	HERC2	0.83	6.92	0.58	5.28e-10	Headache;
THYM	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg13607699	chr17:42295918	UBTF	0.7	5.5	0.49	3.2e-7	Total body bone mineral density;
THYM	cis	rs3126085	0.877	rs7537633	chr1:152223333	T/G	cg10321714	chr1:152280068	FLG	0.65	4.64	0.43	1.1e-5	Atopic dermatitis;
THYM	cis	rs2932538	0.922	rs36029940	chr1:113106444	T/G	cg22162597	chr1:113214053	CAPZA1	0.63	4.96	0.45	3.13e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg19748678	chr4:122722346	EXOSC9	0.72	5.11	0.46	1.68e-6	Type 2 diabetes;
THYM	trans	rs8073060	0.586	rs9303690	chr17:34005513	C/T	cg19694781	chr19:47549865	TMEM160	-1.06	-9.08	-0.68	1.54e-14	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg09085632	chr11:111637200	PPP2R1B	1.06	9.94	0.71	2.22e-16	Primary sclerosing cholangitis;
THYM	cis	rs6539288	0.691	rs10746071	chr12:107353595	C/T	cg26297688	chr12:107349093	C12orf23	0.47	5.24	0.47	9.56e-7	Total body bone mineral density;
THYM	cis	rs4242434	0.689	rs4872006	chr8:22536502	T/C	cg11461670	chr8:22454935	PDLIM2	0.35	6.07	0.53	2.58e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg04455712	chr21:45112962	RRP1B	-0.49	-4.46	-0.42	2.21e-5	Mean corpuscular volume;
THYM	cis	rs1568889	1.000	rs78140392	chr11:28203231	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.66e-6	Bipolar disorder;
THYM	cis	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg06521331	chr12:34319734	NA	-1.02	-11.27	-0.76	3.37e-19	Morning vs. evening chronotype;
THYM	cis	rs4654899	0.802	rs7517642	chr1:21252696	T/C	cg01072550	chr1:21505969	NA	-0.69	-6.28	-0.54	1.02e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs981844	0.712	rs2405208	chr4:154755774	T/C	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs507506	0.771	rs929229	chr17:7105399	C/T	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.62	-5.18	-0.47	1.26e-6	Adiponectin levels;
THYM	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs6500395	0.928	rs2080509	chr16:48690915	T/C	cg04672837	chr16:48644449	N4BP1	-0.48	-4.72	-0.44	8.24e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg12935359	chr14:103987150	CKB	-0.65	-6.4	-0.55	5.78e-9	Body mass index;
THYM	trans	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg10856724	chr12:34555212	NA	-0.86	-7.61	-0.62	2.01e-11	Bladder cancer;
THYM	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.39	6.98	0.58	3.9e-10	Obesity-related traits;
THYM	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	5.42	0.49	4.47e-7	Schizophrenia;
THYM	cis	rs7757969	1.000	rs2148709	chr6:112121228	G/A	cg08601457	chr6:112115117	FYN	0.42	4.79	0.44	6.23e-6	Schizophrenia;
THYM	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg19774624	chr17:42201019	HDAC5	-0.76	-7.08	-0.59	2.43e-10	Total body bone mineral density;
THYM	cis	rs55728055	0.661	rs16989274	chr22:31955908	G/A	cg01338084	chr22:32026380	PISD	1.47	5.89	0.52	5.9e-8	Age-related hearing impairment;
THYM	cis	rs6840360	0.533	rs4696297	chr4:152725838	T/G	cg22705602	chr4:152727874	NA	0.76	9.95	0.71	2.12e-16	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs10886503	0.920	rs3009907	chr10:121262454	G/T	cg13260278	chr10:121265587	RGS10	0.64	5.89	0.52	5.85e-8	Obstetric antiphospholipid syndrome;
THYM	cis	rs7084921	0.521	rs12416247	chr10:101886505	A/G	cg11344164	chr10:101878520	NA	-0.55	-5.18	-0.47	1.25e-6	Bone mineral density;
THYM	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg23730037	chr7:158596552	ESYT2	-0.49	-5.0	-0.46	2.66e-6	Height;
THYM	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg10523679	chr1:76189770	ACADM	-0.9	-9.55	-0.7	1.52e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9324022	0.929	rs72698721	chr14:101181189	G/A	cg18089426	chr14:101175970	NA	0.75	5.15	0.47	1.38e-6	Plateletcrit;
THYM	cis	rs2408955	0.522	rs2051851	chr12:48485940	G/C	cg21466736	chr12:48725269	NA	0.51	5.11	0.46	1.69e-6	Glycated hemoglobin levels;
THYM	cis	rs2299587	0.643	rs6586680	chr8:17891178	C/T	cg18067069	chr8:17937731	ASAH1	-0.61	-4.51	-0.42	1.83e-5	Economic and political preferences;
THYM	cis	rs4654899	0.582	rs4654729	chr1:21224253	T/C	cg01072550	chr1:21505969	NA	0.72	6.77	0.57	1.06e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs9486719	0.947	rs12208556	chr6:96903486	C/T	cg18709589	chr6:96969512	KIAA0776	-0.71	-4.78	-0.44	6.46e-6	Migraine;Coronary artery disease;
THYM	cis	rs10540	0.778	rs34046876	chr11:539058	C/T	cg19913688	chr11:428466	ANO9	-0.95	-4.6	-0.43	1.29e-5	Body mass index;
THYM	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg01699819	chr7:1052092	C7orf50	-0.84	-7.05	-0.59	2.91e-10	Bronchopulmonary dysplasia;
THYM	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.72	4.62	0.43	1.22e-5	Smoking behavior;
THYM	cis	rs599083	0.530	rs667126	chr11:68177728	C/T	cg16797656	chr11:68205561	LRP5	-0.46	-4.99	-0.46	2.77e-6	Bone mineral density (spine);
THYM	cis	rs12530845	0.573	rs56411048	chr7:135364748	A/T	cg19897172	chr7:135347071	PL-5283	-0.62	-5.06	-0.46	2.08e-6	Red blood cell traits;
THYM	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg27286337	chr10:134555280	INPP5A	0.93	6.98	0.58	3.98e-10	Migraine;
THYM	cis	rs28595532	0.841	rs115851302	chr4:119776504	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.08	0.46	1.92e-6	Cannabis dependence symptom count;
THYM	cis	rs2273669	0.667	rs75263286	chr6:109350489	G/C	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	trans	rs9929218	0.954	rs112225541	chr16:68755165	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-7.29	-0.6	9.13e-11	Colorectal cancer;
THYM	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19346786	chr7:2764209	NA	-0.78	-7.06	-0.59	2.68e-10	Height;
THYM	trans	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.09	-13.51	-0.81	7.87e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg17509989	chr5:176798049	RGS14	0.57	4.86	0.45	4.58e-6	Urate levels in lean individuals;
THYM	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg06618935	chr21:46677482	NA	-0.81	-7.43	-0.61	4.59e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9527	0.568	rs12772775	chr10:104702999	C/A	cg15744005	chr10:104629667	AS3MT	-0.6	-4.58	-0.42	1.43e-5	Arsenic metabolism;
THYM	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13126513	0.519	rs959247	chr4:100556984	A/G	cg05468953	chr4:100565104	NA	0.69	6.61	0.56	2.22e-9	Metabolite levels (MHPG);
THYM	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg06600287	chr1:53387719	ECHDC2	-0.31	-5.04	-0.46	2.26e-6	Monocyte count;
THYM	cis	rs9326248	0.727	rs4938347	chr11:117021759	T/A	cg01368799	chr11:117014884	PAFAH1B2	0.67	4.78	0.44	6.35e-6	Blood protein levels;
THYM	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	trans	rs4596713	0.507	rs2275427	chr9:71792581	G/A	cg16512924	chr15:28394682	HERC2	0.83	6.93	0.58	5.02e-10	Headache;
THYM	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2333194	0.846	rs7159794	chr14:73804443	G/A	cg09844916	chr14:74004424	HEATR4;ACOT1	0.57	4.56	0.42	1.55e-5	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs10463554	0.963	rs34771	chr5:102450417	G/A	cg23492399	chr5:102201601	PAM	-0.7	-5.15	-0.47	1.38e-6	Parkinson's disease;
THYM	cis	rs13315871	1.000	rs75828026	chr3:58346736	C/T	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs61931739	0.635	rs1601627	chr12:33962420	G/A	cg06521331	chr12:34319734	NA	-0.56	-4.69	-0.43	8.97e-6	Morning vs. evening chronotype;
THYM	cis	rs62435770	1.000	rs62434680	chr6:169504729	G/A	cg07652237	chr6:170125491	PHF10	0.59	5.25	0.47	9.43e-7	Loneliness;
THYM	cis	rs3741151	0.773	rs28400367	chr11:73112421	C/A	cg17517138	chr11:73019481	ARHGEF17	0.97	5.57	0.5	2.41e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg01097406	chr16:89675127	NA	-0.56	-4.57	-0.42	1.49e-5	Vitiligo;
THYM	cis	rs11677370	0.561	rs4849990	chr2:3819558	A/G	cg17052675	chr2:3827356	NA	-0.63	-5.93	-0.52	4.86e-8	Type 2 diabetes;
THYM	cis	rs526231	0.511	rs3756582	chr5:102339552	G/C	cg23492399	chr5:102201601	PAM	-0.7	-5.19	-0.47	1.17e-6	Primary biliary cholangitis;
THYM	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2290159	0.800	rs5746187	chr3:12659419	A/G	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.45	0.42	2.3e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs4383453	0.539	rs2332509	chr3:123100177	T/C	cg04890266	chr3:123102914	ADCY5	-0.83	-8.64	-0.66	1.32e-13	Gestational age at birth (maternal effect);
THYM	cis	rs7772486	0.720	rs702320	chr6:146006654	G/A	cg23711669	chr6:146136114	FBXO30	-0.97	-10.49	-0.73	1.45e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.85	-5.32	-0.48	6.89e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.77	-4.96	-0.45	3.03e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs288326	0.561	rs76829215	chr2:183894452	A/G	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs17784882	0.524	rs7433300	chr3:47120640	G/A	cg16586182	chr3:47516702	SCAP	-0.67	-5.66	-0.5	1.59e-7	QT interval;
THYM	cis	rs2370759	1.000	rs2769241	chr10:32556229	T/C	cg01819863	chr10:32635814	EPC1	-1.04	-6.59	-0.56	2.43e-9	Sexual dysfunction (female);
THYM	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg08807101	chr21:30365312	RNF160	-0.95	-7.63	-0.62	1.84e-11	Dental caries;
THYM	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg26513180	chr16:89883248	FANCA	0.72	7.13	0.59	1.98e-10	Vitiligo;
THYM	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg02782426	chr3:40428986	ENTPD3	0.56	5.02	0.46	2.41e-6	Renal cell carcinoma;
THYM	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg17211192	chr8:82754475	SNX16	-0.91	-7.3	-0.6	8.57e-11	Diastolic blood pressure;
THYM	cis	rs747334	0.846	rs11186389	chr10:92717115	C/T	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg16558253	chr16:72132732	DHX38	0.64	5.66	0.5	1.63e-7	Fibrinogen levels;
THYM	cis	rs669446	0.558	rs609171	chr1:44110216	A/C	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	trans	rs4866334	1.000	rs74368495	chr5:18483062	T/C	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg02734326	chr4:10020555	SLC2A9	0.76	6.89	0.58	6.09e-10	Bone mineral density;
THYM	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4642101	0.512	rs9813960	chr3:12818205	A/G	cg05775895	chr3:12838266	CAND2	1.04	10.36	0.73	2.75e-17	QRS complex (12-leadsum);
THYM	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25427524	chr10:38739819	LOC399744	-0.73	-6.77	-0.57	1.04e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs11577318	0.538	rs10902745	chr1:26687070	G/C	cg19677267	chr1:26645161	CD52;UBXN11	0.53	5.95	0.52	4.51e-8	Granulocyte percentage of myeloid white cells;
THYM	trans	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg10856724	chr12:34555212	NA	-0.94	-8.22	-0.64	1.01e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg06481639	chr22:41940642	POLR3H	0.7	5.21	0.47	1.1e-6	Vitiligo;
THYM	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg17105886	chr17:28927953	LRRC37B2	1.13	6.42	0.55	5.25e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4455778	0.538	rs6965822	chr7:49123931	A/G	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.95	6.56	0.56	2.87e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7264396	0.887	rs4911502	chr20:34063034	C/T	cg26038318	chr20:34205095	SPAG4	0.56	4.71	0.43	8.58e-6	Total cholesterol levels;
THYM	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg27129171	chr3:47204927	SETD2	0.81	8.04	0.64	2.43e-12	Colorectal cancer;
THYM	cis	rs9733	0.596	rs6678013	chr1:150623285	T/G	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	trans	rs9929218	0.551	rs2296405	chr16:68721470	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.15	-16.76	-0.86	3.99e-30	Colorectal cancer;
THYM	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg23422044	chr7:1970798	MAD1L1	-0.77	-4.68	-0.43	9.51e-6	Neuroticism;
THYM	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg18402987	chr7:1209562	NA	0.97	5.74	0.51	1.12e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg14074117	chr16:1909714	C16orf73	0.75	5.09	0.46	1.8e-6	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs7127900	1.000	rs11043134	chr11:2232682	T/C	cg25635251	chr11:2234043	NA	0.74	4.71	0.44	8.43e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg16624210	chr5:671434	TPPP	0.67	4.79	0.44	6.25e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs860554	0.705	rs700469	chr1:201259981	C/T	cg01022117	chr1:201258280	PKP1	0.66	4.9	0.45	3.93e-6	Panic disorder;
THYM	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg06618935	chr21:46677482	NA	-0.96	-9.3	-0.69	5.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3204270	0.714	rs7189	chr17:79668897	C/T	cg09996840	chr17:79680718	SLC25A10	-0.59	-4.46	-0.42	2.24e-5	Dental caries;
THYM	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.73	0.57	1.29e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4242434	0.927	rs57594397	chr8:22475657	T/C	cg14690197	chr8:22456421	C8orf58	0.55	5.08	0.46	1.91e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg02782426	chr3:40428986	ENTPD3	0.51	4.55	0.42	1.57e-5	Renal cell carcinoma;
THYM	cis	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg09307838	chr4:120376055	NA	0.7	5.27	0.48	8.48e-7	Corneal astigmatism;
THYM	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg07636037	chr3:49044803	WDR6	0.81	5.86	0.52	6.7e-8	Menarche (age at onset);
THYM	cis	rs3087591	0.960	rs2905872	chr17:29525027	C/A	cg24425628	chr17:29625626	OMG;NF1	0.61	5.32	0.48	6.91e-7	Hip circumference;
THYM	cis	rs11645898	0.748	rs11647889	chr16:72052034	C/G	cg03805757	chr16:71968109	PKD1L3	-0.72	-5.3	-0.48	7.54e-7	Blood protein levels;
THYM	cis	rs4974559	0.790	rs6850727	chr4:1323273	G/C	cg02980000	chr4:1222292	CTBP1	0.77	4.82	0.44	5.41e-6	Systolic blood pressure;
THYM	cis	rs293526	0.917	rs293513	chr6:83640497	G/A	cg23278060	chr6:83777448	DOPEY1	0.61	4.48	0.42	2.1e-5	Crohn's disease;
THYM	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg06112835	chr11:68658793	MRPL21	-0.43	-6.08	-0.53	2.48e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.89	0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12142240	0.698	rs41294458	chr1:46810304	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs58749629	1.000	rs3827066	chr20:44586023	C/T	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.57	-5.26	-0.47	8.93e-7	Abdominal aortic aneurysm;
THYM	cis	rs2862064	0.799	rs4704835	chr5:156443251	G/A	cg12943317	chr5:156479607	HAVCR1	-0.77	-4.81	-0.44	5.61e-6	Platelet count;
THYM	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg04756594	chr16:24857601	SLC5A11	0.76	5.51	0.49	3e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6138458	1.000	rs227631	chr20:24913653	A/G	cg06937882	chr20:24974362	C20orf3	-0.47	-4.54	-0.42	1.66e-5	Blood protein levels;
THYM	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.1	-7.57	-0.61	2.45e-11	Schizophrenia;
THYM	cis	rs2625529	0.526	rs7183810	chr15:72560458	A/T	cg16672083	chr15:72433130	SENP8	0.5	4.48	0.42	2.07e-5	Red blood cell count;
THYM	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.94	8.7	0.67	9.67e-14	Chronic sinus infection;
THYM	cis	rs3812049	0.784	rs7734927	chr5:127453735	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	5.37	0.48	5.59e-7	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs11122272	0.705	rs2486731	chr1:231532511	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.58	4.64	0.43	1.1e-5	Hemoglobin concentration;
THYM	cis	rs7322722	0.891	rs11842917	chr13:77750114	A/T	cg04565255	chr13:77565759	CLN5	-0.44	-4.49	-0.42	2.03e-5	Preeclampsia;
THYM	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg04546413	chr19:29218101	NA	1.11	9.63	0.7	1.02e-15	Methadone dose in opioid dependence;
THYM	cis	rs611744	0.647	rs1448151	chr8:109276283	C/A	cg21045802	chr8:109455806	TTC35	0.65	5.55	0.49	2.56e-7	Dupuytren's disease;
THYM	cis	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg09085632	chr11:111637200	PPP2R1B	1.16	11.93	0.77	1.35e-20	Primary sclerosing cholangitis;
THYM	cis	rs7084402	0.967	rs1427200	chr10:60274928	C/T	cg26159090	chr10:60474252	BICC1;LOC728640	-0.43	-4.45	-0.42	2.3e-5	Refractive error;
THYM	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.06	-7.46	-0.61	4.05e-11	Platelet count;
THYM	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg11846333	chr4:119757529	SEC24D	1.35	5.12	0.46	1.6e-6	Cannabis dependence symptom count;
THYM	cis	rs10504073	0.584	rs11786103	chr8:49904077	A/G	cg00325661	chr8:49890786	NA	1.04	10.98	0.75	1.34e-18	Blood metabolite ratios;
THYM	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg22841779	chr14:105766346	BRF1	-0.46	-5.74	-0.51	1.13e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs599083	0.530	rs2472415	chr11:68185616	T/C	cg16797656	chr11:68205561	LRP5	-0.47	-5.14	-0.47	1.49e-6	Bone mineral density (spine);
THYM	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	5.51	0.49	3.1e-7	Schizophrenia;
THYM	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg17264618	chr3:40429014	ENTPD3	-0.46	-4.48	-0.42	2.09e-5	Renal cell carcinoma;
THYM	cis	rs28595532	0.841	rs115852209	chr4:119753465	A/G	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs67460515	0.563	rs9883566	chr3:160770323	C/T	cg12349858	chr3:160822545	B3GALNT1	-0.65	-5.49	-0.49	3.35e-7	Parkinson's disease;
THYM	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg08017756	chr2:100939284	LONRF2	-0.74	-7.72	-0.62	1.16e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7084402	0.619	rs12258523	chr10:60365975	T/C	cg09696939	chr10:60272079	BICC1	0.49	4.99	0.46	2.72e-6	Refractive error;
THYM	cis	rs6700896	0.864	rs56274111	chr1:66128511	A/C	cg04111102	chr1:66153794	NA	0.56	5.27	0.48	8.45e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	trans	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.07	-0.59	2.55e-10	Bladder cancer;
THYM	cis	rs6754311	0.689	rs191079	chr2:136633771	T/C	cg20242066	chr2:136595261	LCT	0.6	7.1	0.59	2.23e-10	Mosquito bite size;
THYM	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.85	-7.05	-0.59	2.87e-10	Systemic lupus erythematosus;
THYM	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg12000587	chr17:30186630	C17orf79	-0.49	-6.93	-0.58	4.91e-10	Hip circumference adjusted for BMI;
THYM	cis	rs4654899	0.680	rs6704421	chr1:21220674	A/C	cg01072550	chr1:21505969	NA	0.72	6.91	0.58	5.4e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg22166914	chr1:53195759	ZYG11B	-0.69	-6.96	-0.58	4.39e-10	Monocyte count;
THYM	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg03929089	chr4:120376271	NA	-0.95	-10.62	-0.74	7.7e-18	Height;
THYM	cis	rs8070740	0.617	rs1058117	chr17:5323206	T/G	cg25236894	chr17:5323110	RPAIN;NUP88	0.74	6.9	0.58	5.86e-10	Menopause (age at onset);
THYM	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg20891283	chr12:69753455	YEATS4	1.09	12.1	0.78	5.96e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	5.47	0.49	3.64e-7	Schizophrenia;
THYM	cis	rs478304	0.651	rs948493	chr11:65552154	C/T	cg27068330	chr11:65405492	SIPA1	-0.96	-9.31	-0.69	4.93e-15	Acne (severe);
THYM	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.59	-4.45	-0.42	2.35e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs6901250	0.851	rs7760125	chr6:117123391	A/C	cg12892004	chr6:117198278	RFX6	0.71	6.97	0.58	4.22e-10	C-reactive protein levels;
THYM	cis	rs4930776	0.900	rs411575	chr12:5758782	G/T	cg02086166	chr12:5775618	ANO2	0.62	6.17	0.53	1.69e-8	Plasma clusterin levels;
THYM	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg09549813	chr16:4587862	C16orf5	-0.59	-6.49	-0.55	3.89e-9	Schizophrenia;
THYM	cis	rs7189233	0.955	rs8044205	chr16:53515093	T/C	cg02965178	chr16:53538660	AKTIP	-0.58	-4.61	-0.43	1.26e-5	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs56104184	0.775	rs55981795	chr19:49401952	A/C	cg21252483	chr19:49399788	TULP2	-0.96	-7.25	-0.6	1.09e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs4919694	0.572	rs12240508	chr10:104939232	G/A	cg04362960	chr10:104952993	NT5C2	0.98	6.42	0.55	5.4e-9	Arsenic metabolism;
THYM	cis	rs420259	0.516	rs369856	chr16:23474664	T/C	cg00143387	chr16:23521605	GGA2	0.8	5.77	0.51	9.71e-8	Bipolar disorder;
THYM	cis	rs28785552	0.769	rs28796114	chr19:53234319	T/C	cg22067481	chr19:53234126	ZNF611	-1.06	-12.09	-0.78	6.34e-21	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs9393777	0.546	rs35589403	chr6:27219491	C/G	cg12292205	chr6:26970375	C6orf41	-0.77	-4.53	-0.42	1.74e-5	Intelligence (multi-trait analysis);
THYM	cis	rs12134245	1.000	rs12134245	chr1:92021464	C/T	cg25838465	chr1:92012736	NA	-0.73	-6.5	-0.56	3.62e-9	Breast cancer;
THYM	cis	rs2273669	0.667	rs11754955	chr6:109287459	A/G	cg17117243	chr6:109341365	SESN1	-0.85	-4.84	-0.44	5.02e-6	Prostate cancer;
THYM	trans	rs877282	0.945	rs10904554	chr10:786768	T/C	cg22713356	chr15:30763199	NA	1.4	11.86	0.77	1.9e-20	Uric acid levels;
THYM	cis	rs7107174	1.000	rs2510035	chr11:77953175	A/C	cg19901956	chr11:77921274	USP35	-0.83	-6.25	-0.54	1.17e-8	Testicular germ cell tumor;
THYM	cis	rs1113500	0.933	rs10494089	chr1:108626695	T/G	cg06207961	chr1:108661230	NA	0.66	5.17	0.47	1.28e-6	Growth-regulated protein alpha levels;
THYM	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg24579218	chr15:68104479	NA	-0.86	-8.33	-0.65	6.04e-13	Restless legs syndrome;
THYM	cis	rs611744	0.967	rs650968	chr8:109211055	C/G	cg21045802	chr8:109455806	TTC35	0.6	5.37	0.48	5.65e-7	Dupuytren's disease;
THYM	cis	rs4523957	0.928	rs4790072	chr17:2173497	A/G	cg16513277	chr17:2031491	SMG6	-0.79	-7.14	-0.59	1.86e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9914988	0.943	rs3181215	chr17:27077331	C/T	cg20469991	chr17:27169893	C17orf63	0.84	5.2	0.47	1.14e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs6942756	0.956	rs13235668	chr7:128879710	A/G	cg02491457	chr7:128862824	NA	-0.44	-4.53	-0.42	1.69e-5	White matter hyperintensity burden;
THYM	cis	rs7953249	0.656	rs1732391	chr12:121392341	C/T	cg14101638	chr12:121416612	HNF1A	-0.48	-5.02	-0.46	2.45e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs6500602	0.563	rs917304	chr16:4440426	C/G	cg08645402	chr16:4508243	NA	0.76	5.93	0.52	4.89e-8	Schizophrenia;
THYM	cis	rs12142240	0.698	rs932816	chr1:46859749	G/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg22496380	chr5:211416	CCDC127	-1.33	-7.61	-0.62	1.97e-11	Breast cancer;
THYM	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.76	4.9	0.45	3.98e-6	Smoking behavior;
THYM	cis	rs240764	0.578	rs12215909	chr6:101227598	T/C	cg21058520	chr6:100914733	NA	0.57	4.92	0.45	3.61e-6	Neuroticism;
THYM	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4563143	0.514	rs55727361	chr19:29300415	A/T	cg03161606	chr19:29218774	NA	0.81	6.24	0.54	1.23e-8	Methadone dose in opioid dependence;
THYM	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs7553864	1.000	rs7553864	chr1:87613358	T/C	cg17420885	chr1:87600446	LOC339524	-0.76	-6.52	-0.56	3.31e-9	Smoking behavior;
THYM	cis	rs2066819	1.000	rs2291361	chr12:56717805	G/A	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs765787	0.530	rs12904265	chr15:45526713	C/T	cg24006582	chr15:45444508	DUOX1	0.81	6.55	0.56	2.99e-9	Uric acid levels;
THYM	cis	rs1278352	0.655	rs1278354	chr10:127773975	A/G	cg08295661	chr10:127769903	ADAM12	-0.55	-5.64	-0.5	1.71e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg24689976	chr6:88187068	SLC35A1	-0.96	-7.4	-0.6	5.29e-11	Depressive symptoms;
THYM	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg10803722	chr21:46713166	LOC642852	-0.41	-5.16	-0.47	1.35e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg03474202	chr17:45855739	NA	-0.76	-6.7	-0.57	1.45e-9	IgG glycosylation;
THYM	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg27532560	chr4:187881888	NA	0.95	10.55	0.73	1.09e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9972944	0.729	rs10083877	chr17:63773623	T/C	cg07283582	chr17:63770753	CCDC46	0.68	5.54	0.49	2.69e-7	Total body bone mineral density;
THYM	cis	rs526231	0.512	rs34797	chr5:102425727	T/C	cg23492399	chr5:102201601	PAM	-0.67	-4.96	-0.45	3.05e-6	Primary biliary cholangitis;
THYM	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs901683	1.000	rs9422653	chr10:46048918	A/G	cg18240400	chr10:46168597	ANUBL1	-0.71	-4.89	-0.45	4.08e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs514406	0.547	rs377808	chr1:53190359	T/G	cg24675658	chr1:53192096	ZYG11B	-0.83	-7.56	-0.61	2.52e-11	Monocyte count;
THYM	cis	rs1451375	0.583	rs3807556	chr7:50610536	G/A	cg18232548	chr7:50535776	DDC	0.67	5.0	0.46	2.63e-6	Malaria;
THYM	cis	rs7246657	0.943	rs9917081	chr19:37876616	T/C	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg02887458	chr19:19495540	GATAD2A	-0.45	-4.89	-0.45	4.05e-6	Bipolar disorder;
THYM	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg06618935	chr21:46677482	NA	-0.98	-9.5	-0.7	1.95e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.819	rs13139560	chr4:99081188	C/T	cg18180107	chr4:99064573	C4orf37	0.6	4.53	0.42	1.72e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6598955	0.724	rs12068388	chr1:26621596	G/A	cg04990556	chr1:26633338	UBXN11	-0.89	-8.52	-0.66	2.34e-13	Obesity-related traits;
THYM	cis	rs1461503	0.934	rs7119533	chr11:122832683	A/T	cg27398637	chr11:122830231	C11orf63	-0.64	-5.52	-0.49	2.9e-7	Menarche (age at onset);
THYM	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg26384229	chr12:38710491	ALG10B	1.0	8.01	0.63	2.86e-12	Bladder cancer;
THYM	cis	rs4946717	0.716	rs4478446	chr6:106472120	T/A	cg02270332	chr6:106475062	NA	0.74	10.28	0.73	4.27e-17	Inflammatory bowel disease;
THYM	cis	rs7078219	0.505	rs10883373	chr10:101292484	G/A	cg04972745	chr10:101287846	NA	-0.52	-4.98	-0.45	2.85e-6	Dental caries;
THYM	cis	rs7772486	0.754	rs702324	chr6:146008793	A/G	cg13319975	chr6:146136371	FBXO30	0.69	5.32	0.48	7.03e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9790314	0.871	rs466626	chr3:161103629	A/C	cg03342759	chr3:160939853	NMD3	-0.8	-7.4	-0.6	5.36e-11	Morning vs. evening chronotype;
THYM	cis	rs7192750	0.519	rs2008675	chr16:71995980	A/C	cg06353428	chr16:71660113	MARVELD3	0.7	5.16	0.47	1.34e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs10781543	0.839	rs7863766	chr9:139381314	T/G	cg14115884	chr9:139300582	SDCCAG3	0.71	6.67	0.56	1.73e-9	Monocyte percentage of white cells;
THYM	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg16524733	chr11:117070046	TAGLN	0.4	4.45	0.42	2.34e-5	Blood protein levels;
THYM	cis	rs11166927	0.524	rs2035087	chr8:140831320	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.87	-8.12	-0.64	1.66e-12	Pediatric non-alcoholic fatty liver disease activity score;
THYM	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7586879	0.521	rs7597332	chr2:25075675	A/G	cg01884057	chr2:25150051	NA	0.65	6.53	0.56	3.2e-9	Body mass index;
THYM	cis	rs2976388	1.000	rs2920295	chr8:143764937	A/G	cg13446199	chr8:143762866	PSCA	0.51	6.41	0.55	5.48e-9	Urinary tract infection frequency;
THYM	cis	rs9560113	0.573	rs61955236	chr13:112242861	G/A	cg10483660	chr13:112241077	NA	0.7	8.63	0.66	1.41e-13	Menarche (age at onset);
THYM	cis	rs7107174	1.000	rs10899467	chr11:78014057	G/T	cg02023728	chr11:77925099	USP35	0.64	5.75	0.51	1.08e-7	Testicular germ cell tumor;
THYM	cis	rs3213545	0.700	rs2260445	chr12:121468863	C/A	cg02403541	chr12:121454288	C12orf43	0.62	5.1	0.46	1.72e-6	Subjective well-being;Cardiovascular disease risk factors;
THYM	cis	rs9948	1.000	rs9973492	chr2:97498481	T/A	cg01990225	chr2:97406019	LMAN2L	-0.88	-4.83	-0.44	5.18e-6	Erectile dysfunction and prostate cancer treatment;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg23920120	chr11:122239845	NA	-0.93	-6.96	-0.58	4.36e-10	Depressive symptoms;
THYM	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6748734	0.625	rs7598309	chr2:241824876	A/T	cg07537917	chr2:241836409	C2orf54	-0.21	-4.88	-0.45	4.25e-6	Urinary metabolites;
THYM	cis	rs708547	0.578	rs781665	chr4:57831461	G/A	cg25525207	chr4:57843836	C4orf14;POLR2B	-0.54	-4.53	-0.42	1.72e-5	Response to bleomycin (chromatid breaks);
THYM	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg07936489	chr17:37558343	FBXL20	0.85	5.64	0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg10150615	chr22:24372951	LOC391322	-0.97	-9.69	-0.71	7.49e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7943203	0.539	rs7946557	chr11:108284447	C/T	cg04873221	chr11:107992290	ACAT1	-0.72	-4.71	-0.43	8.56e-6	Red blood cell count;Mean corpuscular volume;
THYM	cis	rs4378999	0.660	rs9875961	chr3:50878122	G/A	cg27233566	chr3:49894142	TRAIP	0.77	4.47	0.42	2.16e-5	Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs17401966	0.931	rs3737155	chr1:10459779	G/A	cg19773385	chr1:10388646	KIF1B	-0.61	-4.75	-0.44	7.06e-6	Hepatocellular carcinoma;
THYM	cis	rs12802200	0.561	rs12792868	chr11:566647	T/A	cg01616529	chr11:638424	DRD4	-0.62	-4.5	-0.42	1.93e-5	Systemic lupus erythematosus;
THYM	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg11317459	chr13:21872234	NA	1.18	9.79	0.71	4.6e-16	White matter hyperintensity burden;
THYM	cis	rs2289328	1.000	rs2289328	chr15:40705417	G/A	cg13931752	chr15:40660718	DISP2	0.63	4.86	0.45	4.59e-6	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
THYM	cis	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg01364799	chr7:75623366	TMEM120A	0.63	4.56	0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7119	0.667	rs2867312	chr15:77902293	A/G	cg27398640	chr15:77910606	LINGO1	-0.67	-8.64	-0.66	1.33e-13	Type 2 diabetes;
THYM	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg08859206	chr1:53392774	SCP2	0.8	9.2	0.69	8.64e-15	Monocyte count;
THYM	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg10803722	chr21:46713166	LOC642852	-0.5	-6.23	-0.54	1.26e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs16889362	1.000	rs16889362	chr6:36965705	A/G	cg05466385	chr6:36956891	NA	0.77	5.6	0.5	2.04e-7	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
THYM	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg07936489	chr17:37558343	FBXL20	0.85	5.93	0.52	4.77e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs6438424	1.000	rs6804394	chr3:117592348	A/C	cg07190778	chr3:117604296	NA	0.38	5.33	0.48	6.53e-7	Menarche (age at onset);
THYM	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg18105134	chr13:113819100	PROZ	0.92	8.71	0.67	9.36e-14	Platelet distribution width;
THYM	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg08772003	chr10:104629869	AS3MT	-0.61	-5.47	-0.49	3.63e-7	Arsenic metabolism;
THYM	trans	rs9951602	0.512	rs1599634	chr18:76643645	T/C	cg02800362	chr5:177631904	HNRNPAB	1.11	8.66	0.66	1.21e-13	Obesity-related traits;
THYM	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03452623	chr4:187889614	NA	-1.16	-21.11	-0.91	1.23e-37	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg10515332	chr4:99064459	C4orf37	0.67	5.33	0.48	6.48e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6840360	0.615	rs72728179	chr4:152477877	A/G	cg17479576	chr4:152424074	FAM160A1	-0.85	-6.4	-0.55	5.9e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6723226	0.699	rs805830	chr2:32501475	T/C	cg02381751	chr2:32503542	YIPF4	0.64	5.38	0.48	5.37e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11096990	0.593	rs35937374	chr4:39186355	C/T	cg24403649	chr4:39172243	NA	0.6	5.16	0.47	1.35e-6	Cognitive function;
THYM	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg06640241	chr16:89574553	SPG7	0.66	4.75	0.44	7.31e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06850241	chr22:41845214	NA	-0.57	-5.05	-0.46	2.1e-6	Vitiligo;
THYM	cis	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg06521331	chr12:34319734	NA	-0.73	-5.66	-0.5	1.59e-7	Morning vs. evening chronotype;
THYM	cis	rs425277	0.585	rs364677	chr1:2071765	A/G	cg09260853	chr1:2094483	PRKCZ	-0.5	-5.1	-0.46	1.75e-6	Height;
THYM	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg17757837	chr7:157058334	UBE3C	0.65	5.24	0.47	9.83e-7	Body mass index;
THYM	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg14972814	chr11:95582409	MTMR2	-0.72	-6.7	-0.57	1.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs12282928	0.802	rs1105164	chr11:48285025	G/A	cg22827986	chr11:48284249	OR4X1	0.51	5.43	0.49	4.28e-7	Migraine - clinic-based;
THYM	cis	rs3126085	0.935	rs877776	chr1:152178018	C/G	cg26020982	chr1:152196106	HRNR	0.38	5.03	0.46	2.32e-6	Atopic dermatitis;
THYM	cis	rs4792901	0.877	rs9912927	chr17:41620035	C/G	cg21940313	chr17:41620911	ETV4	-0.52	-5.51	-0.49	3.08e-7	Dupuytren's disease;
THYM	cis	rs2282300	0.739	rs34234618	chr11:30241701	T/C	cg06241208	chr11:30344200	C11orf46	-0.77	-5.59	-0.5	2.15e-7	Morning vs. evening chronotype;
THYM	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.15	-0.59	1.77e-10	Triglycerides;
THYM	cis	rs7084402	0.967	rs7099881	chr10:60316211	A/G	cg07615347	chr10:60278583	BICC1	-0.56	-5.11	-0.46	1.69e-6	Refractive error;
THYM	cis	rs273218	1.000	rs156384	chr5:53371333	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.86	7.32	0.6	7.88e-11	Migraine;
THYM	cis	rs986417	1.000	rs761555	chr14:61109543	T/C	cg27398547	chr14:60952738	C14orf39	1.26	6.1	0.53	2.29e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs11677370	0.603	rs10198219	chr2:3854600	T/C	cg17052675	chr2:3827356	NA	-0.67	-6.17	-0.53	1.69e-8	Type 2 diabetes;
THYM	trans	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg25517755	chr10:38738941	LOC399744	0.76	6.92	0.58	5.26e-10	Corneal astigmatism;
THYM	cis	rs6867032	0.527	rs4371796	chr5:1977785	C/T	cg26168224	chr5:2018326	NA	-0.85	-6.02	-0.53	3.3e-8	Gut microbiome composition (winter);
THYM	cis	rs17443541	0.507	rs7576031	chr2:200470616	G/A	cg01795955	chr2:200468626	NA	-0.72	-5.0	-0.46	2.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.583	rs66531105	chr17:17809001	C/T	cg16928487	chr17:17741425	SREBF1	-0.56	-5.57	-0.5	2.37e-7	Total body bone mineral density;
THYM	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg12826209	chr6:26865740	GUSBL1	0.86	4.94	0.45	3.4e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6815814	0.851	rs17582893	chr4:38886420	G/A	cg02016764	chr4:38805732	TLR1	-0.47	-4.59	-0.43	1.34e-5	Breast cancer;
THYM	cis	rs240764	0.697	rs239195	chr6:101132368	T/C	cg21058520	chr6:100914733	NA	-0.59	-5.06	-0.46	2.05e-6	Neuroticism;
THYM	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg25703541	chr22:24373054	LOC391322	-1.0	-13.71	-0.82	3e-24	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg12826209	chr6:26865740	GUSBL1	0.94	5.02	0.46	2.37e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg18132916	chr6:79620363	NA	-0.55	-4.85	-0.45	4.82e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10484885	0.591	rs72912551	chr6:90178347	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.8	-6.58	-0.56	2.57e-9	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs4129767	0.869	rs4969142	chr17:76398304	G/A	cg05887092	chr17:76393375	PGS1	0.41	4.67	0.43	9.98e-6	HDL cholesterol;
THYM	cis	rs909002	0.789	rs56074668	chr1:32123801	T/C	cg13919466	chr1:32135498	COL16A1	-0.52	-5.02	-0.46	2.37e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9420	0.528	rs11607122	chr11:57389737	G/A	cg19752551	chr11:57585705	CTNND1	-0.55	-4.92	-0.45	3.62e-6	Schizophrenia;
THYM	cis	rs3796352	1.000	rs3097417	chr3:53088601	C/G	cg24530246	chr3:53118167	NA	0.69	4.47	0.42	2.2e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs34638657	0.752	rs2967374	chr16:82209861	A/G	cg07307142	chr16:82071433	HSD17B2	-0.94	-6.79	-0.57	9.66e-10	Lung adenocarcinoma;
THYM	cis	rs56046484	0.778	rs1606119	chr15:85671379	G/T	cg09425164	chr15:85552114	PDE8A	-0.45	-4.56	-0.42	1.55e-5	Testicular germ cell tumor;
THYM	cis	rs9399401	0.667	rs6922607	chr6:142703483	A/G	cg04461802	chr6:142623433	GPR126	0.77	7.68	0.62	1.42e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs1050631	0.564	rs684890	chr18:33744677	T/C	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.63	4.86	0.45	4.56e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg00495681	chr13:53174319	NA	0.97	9.92	0.71	2.43e-16	Lewy body disease;
THYM	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg26597838	chr10:835615	NA	1.22	8.65	0.66	1.29e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs6531656	0.796	rs168084	chr4:38619114	C/T	cg24279243	chr4:38676559	KLF3	0.85	6.35	0.55	7.45e-9	Lymphocyte counts;
THYM	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg24692254	chr21:30365293	RNF160	-1.01	-9.6	-0.7	1.19e-15	Dental caries;
THYM	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg16558253	chr16:72132732	DHX38	-0.56	-4.87	-0.45	4.39e-6	Fibrinogen levels;
THYM	cis	rs6674176	0.518	rs917294	chr1:44249485	A/G	cg12908607	chr1:44402522	ARTN	-0.51	-4.67	-0.43	9.77e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg01416388	chr22:39784598	NA	0.97	10.02	0.72	1.47e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs1061377	0.932	rs6855118	chr4:39115942	A/G	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.72	-0.67	9.16e-14	Mean corpuscular volume;
THYM	cis	rs11096990	1.000	rs11096990	chr4:39286949	A/G	cg24403649	chr4:39172243	NA	0.69	5.12	0.46	1.62e-6	Cognitive function;
THYM	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg23187316	chr7:1099788	C7orf50	0.59	4.49	0.42	2.01e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs911263	0.961	rs1950897	chr14:68760141	C/T	cg18825221	chr14:68749962	RAD51L1	0.58	6.38	0.55	6.44e-9	Primary biliary cholangitis;
THYM	cis	rs9359856	0.529	rs56352205	chr6:90439272	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.08	-0.64	2.03e-12	Bipolar disorder;
THYM	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg08859206	chr1:53392774	SCP2	0.81	8.47	0.66	3e-13	Monocyte count;
THYM	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg10589385	chr1:150898437	SETDB1	0.62	5.26	0.47	8.86e-7	Tonsillectomy;
THYM	cis	rs2219968	0.525	rs7823046	chr8:78885976	C/T	cg00738934	chr8:78996279	NA	-0.61	-4.95	-0.45	3.21e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10929159	0.928	rs3738994	chr2:236918539	T/C	cg14895183	chr2:236924282	AGAP1	0.54	4.67	0.43	9.73e-6	Parkinson's disease;
THYM	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs654950	0.806	rs1535505	chr1:42026152	A/G	cg06885757	chr1:42089581	HIVEP3	0.55	7.36	0.6	6.47e-11	Airway imaging phenotypes;
THYM	cis	rs1055129	0.655	rs7216615	chr17:73833910	T/C	cg02627403	chr17:73823769	UNC13D	-0.45	-4.63	-0.43	1.18e-5	White matter hyperintensity burden;
THYM	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg11764359	chr7:65958608	NA	-0.82	-6.44	-0.55	4.87e-9	Aortic root size;
THYM	cis	rs9560113	0.597	rs947170	chr13:112241062	G/A	cg10483660	chr13:112241077	NA	-0.67	-7.96	-0.63	3.67e-12	Menarche (age at onset);
THYM	cis	rs7631605	0.934	rs7610068	chr3:37257843	G/T	cg21328643	chr3:37258149	NA	-0.51	-4.76	-0.44	6.85e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs7103648	0.966	rs874896	chr11:47418953	C/G	cg20307385	chr11:47447363	PSMC3	0.94	8.55	0.66	2.1e-13	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs9649465	1.000	rs13230338	chr7:123373622	T/C	cg15443791	chr7:124364398	NA	0.6	4.97	0.45	3.01e-6	Migraine;
THYM	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg07424592	chr7:64974309	NA	-0.99	-5.03	-0.46	2.27e-6	Diabetic kidney disease;
THYM	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7578361	0.959	rs12999502	chr2:150430037	T/C	cg17961725	chr2:150454027	NA	0.71	5.98	0.52	3.97e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs227425	0.525	rs1547088	chr14:70413046	A/G	cg12046056	chr14:71067695	MED6	0.54	4.8	0.44	5.97e-6	Bone mineral density;
THYM	cis	rs3820068	0.705	rs57971278	chr1:15838604	G/A	cg05660106	chr1:15850417	CASP9	1.1	9.92	0.71	2.48e-16	Systolic blood pressure;
THYM	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.72	0.57	1.37e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg11752832	chr7:134001865	SLC35B4	0.64	4.54	0.42	1.63e-5	Mean platelet volume;
THYM	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg21773646	chr17:80085082	CCDC57	-0.33	-4.76	-0.44	6.83e-6	Life satisfaction;
THYM	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06850241	chr22:41845214	NA	0.6	5.3	0.48	7.51e-7	Vitiligo;
THYM	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg10360139	chr7:1886902	MAD1L1	0.59	4.99	0.46	2.69e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.58	-4.98	-0.46	2.78e-6	Platelet count;
THYM	cis	rs1048238	0.818	rs2017577	chr1:16350123	C/G	cg21385522	chr1:16154831	NA	0.68	4.65	0.43	1.08e-5	Systolic blood pressure;
THYM	cis	rs4474742	1	rs4474742	chr17:28065578	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.8	-0.57	9.08e-10	Monocyte count;
THYM	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg15428835	chr7:75027521	TRIM73;TRIM74	-0.84	-7.87	-0.63	5.69e-12	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg12863693	chr15:85201151	NMB	0.62	5.27	0.48	8.4e-7	Schizophrenia;
THYM	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs965469	0.895	rs6051841	chr20:3392871	A/G	cg25506879	chr20:3388711	C20orf194	-0.88	-5.23	-0.47	9.88e-7	IFN-related cytopenia;
THYM	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg15704280	chr7:45808275	SEPT13	-1.06	-15.41	-0.85	1.38e-27	Height;
THYM	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg13683864	chr3:40499215	RPL14	-0.87	-8.19	-0.64	1.2e-12	Renal cell carcinoma;
THYM	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg18127003	chr8:11614472	GATA4	-0.47	-4.56	-0.42	1.55e-5	Retinal vascular caliber;
THYM	cis	rs500891	0.525	rs12213724	chr6:84078990	A/C	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs17407555	0.909	rs73224409	chr4:10290646	G/T	cg11266682	chr4:10021025	SLC2A9	-0.51	-4.76	-0.44	6.81e-6	Schizophrenia (age at onset);
THYM	cis	rs10927875	0.501	rs9660676	chr1:16279041	C/T	cg21385522	chr1:16154831	NA	-1.04	-7.41	-0.61	5.23e-11	Dilated cardiomyopathy;
THYM	cis	rs929596	0.606	rs7604115	chr2:234658116	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.92	-7.83	-0.63	7.02e-12	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg14779329	chr11:130786720	SNX19	0.49	5.07	0.46	1.98e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs7043114	0.507	rs7856204	chr9:95173814	G/C	cg14631576	chr9:95140430	CENPP	-0.83	-8.41	-0.65	4.05e-13	Height;
THYM	cis	rs9733	0.569	rs11204691	chr1:150644339	A/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs7107770	0.941	rs12797405	chr11:125092491	G/A	cg07747661	chr11:125106135	PKNOX2	-0.85	-5.12	-0.47	1.59e-6	Photic sneeze reflex;
THYM	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.66	-5.14	-0.47	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-1.11	-8.14	-0.64	1.56e-12	Cognitive test performance;
THYM	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg26038318	chr20:34205095	SPAG4	0.58	4.6	0.43	1.3e-5	Total cholesterol levels;
THYM	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-6.65	-0.56	1.84e-9	Chronic sinus infection;
THYM	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg18230493	chr5:56204884	C5orf35	-0.82	-5.98	-0.52	3.83e-8	Initial pursuit acceleration;
THYM	cis	rs7078219	0.714	rs11190139	chr10:101288099	C/G	cg07044859	chr10:101282883	NA	-0.5	-5.48	-0.49	3.55e-7	Dental caries;
THYM	cis	rs77688320	0.500	rs10931948	chr2:202323922	G/A	cg06686451	chr2:201350984	NA	-0.59	-4.46	-0.42	2.28e-5	Breast cancer;
THYM	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg18252515	chr7:66147081	NA	0.64	4.83	0.44	5.14e-6	Aortic root size;
THYM	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg03354898	chr7:1950403	MAD1L1	-0.52	-5.1	-0.46	1.74e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6754311	0.689	rs191079	chr2:136633771	T/C	cg07169764	chr2:136633963	MCM6	0.71	6.05	0.53	2.81e-8	Mosquito bite size;
THYM	cis	rs380904	0.517	rs11775744	chr8:144649192	A/G	cg13446199	chr8:143762866	PSCA	0.43	4.56	0.42	1.51e-5	Venous thromboembolism (SNP x SNP interaction);
THYM	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg10645314	chr2:3704589	ALLC	-1.19	-9.23	-0.69	7.17e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6754311	0.593	rs4954280	chr2:136420690	C/T	cg07169764	chr2:136633963	MCM6	-0.7	-5.89	-0.52	5.88e-8	Mosquito bite size;
THYM	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg13695892	chr22:41940480	POLR3H	-0.91	-7.57	-0.61	2.45e-11	Vitiligo;
THYM	cis	rs750460	0.966	rs4243042	chr15:74241624	A/T	cg01349856	chr15:74220517	LOXL1	0.62	4.56	0.42	1.51e-5	Height;
THYM	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg12179176	chr11:130786555	SNX19	0.95	9.69	0.71	7.59e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs12594515	0.967	rs8039088	chr15:45990178	T/C	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg13447684	chr7:1895903	MAD1L1	0.58	4.87	0.45	4.38e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg17211192	chr8:82754475	SNX16	-0.8	-7.08	-0.59	2.52e-10	Diastolic blood pressure;
THYM	cis	rs7901056	0.901	rs2992334	chr10:26727737	T/C	cg23318538	chr10:26883079	C10orf50	-0.39	-4.96	-0.45	3.05e-6	Lymphocyte counts;
THYM	cis	rs9972944	0.702	rs987929	chr17:63765856	A/G	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg04362960	chr10:104952993	NT5C2	0.64	5.52	0.49	2.94e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs8050907	0.744	rs115616187	chr16:4562286	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.15	4.63	0.43	1.16e-5	Obesity-related traits;
THYM	cis	rs4589258	0.788	rs10734137	chr11:90497374	G/C	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.94	-0.45	3.36e-6	Intelligence (multi-trait analysis);
THYM	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.84	0.51	7.19e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2832077	0.505	rs9305386	chr21:30386751	A/G	cg03476357	chr21:30257390	N6AMT1	0.83	4.68	0.43	9.68e-6	Cognitive test performance;
THYM	cis	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg06565975	chr8:143823917	SLURP1	0.45	4.96	0.45	3.13e-6	Urinary tract infection frequency;
THYM	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg03388043	chr17:80084554	CCDC57	0.69	5.98	0.52	3.86e-8	Life satisfaction;
THYM	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg04398451	chr17:18023971	MYO15A	-0.91	-9.11	-0.68	1.35e-14	Total body bone mineral density;
THYM	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg07636037	chr3:49044803	WDR6	0.87	7.94	0.63	4.12e-12	Parkinson's disease;
THYM	cis	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg09307838	chr4:120376055	NA	0.7	5.27	0.48	8.48e-7	Corneal astigmatism;
THYM	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg21427119	chr20:30132790	HM13	-0.82	-5.61	-0.5	2.01e-7	Mean corpuscular hemoglobin;
THYM	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg24399712	chr22:39784796	NA	-0.79	-7.33	-0.6	7.72e-11	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs12476592	0.602	rs1374308	chr2:63895436	G/C	cg17519650	chr2:63277830	OTX1	-0.72	-4.68	-0.43	9.38e-6	Childhood ear infection;
THYM	cis	rs7216064	1.000	rs4569324	chr17:65872750	C/T	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs1395	1.000	rs1141313	chr2:27460968	A/G	cg23587288	chr2:27483067	SLC30A3	-0.56	-5.03	-0.46	2.35e-6	Blood metabolite levels;
THYM	cis	rs28595532	0.920	rs115683389	chr4:119735557	T/G	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs2273669	0.504	rs58411385	chr6:109498294	G/T	cg17117243	chr6:109341365	SESN1	-0.77	-4.56	-0.42	1.5e-5	Prostate cancer;
THYM	cis	rs514406	0.798	rs575138	chr1:53328394	C/G	cg16325326	chr1:53192061	ZYG11B	0.79	6.81	0.57	9e-10	Monocyte count;
THYM	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.61	-0.43	1.27e-5	Type 2 diabetes;
THYM	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06634786	chr22:41940651	POLR3H	-0.7	-5.21	-0.47	1.11e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs9362426	1.000	rs9362426	chr6:88089874	A/G	cg10393598	chr6:87862264	NA	-0.61	-4.86	-0.45	4.68e-6	Depressive episodes in bipolar disorder;
THYM	cis	rs12496230	1.000	rs4856828	chr3:66868008	A/T	cg17646820	chr3:66848679	NA	0.8	5.03	0.46	2.32e-6	Type 2 diabetes;
THYM	cis	rs6009824	1.000	rs6009823	chr22:50086334	C/T	cg22070880	chr22:50098194	NA	0.67	4.78	0.44	6.41e-6	Natriuretic peptide levels;
THYM	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.72	5.44	0.49	4.19e-7	Glycated hemoglobin levels;
THYM	cis	rs2991971	0.810	rs781058	chr1:45935056	C/G	cg15605315	chr1:45957053	TESK2	-0.66	-5.32	-0.48	6.98e-7	High light scatter reticulocyte count;
THYM	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg04043695	chr12:129287642	SLC15A4	0.61	5.07	0.46	1.98e-6	Systemic lupus erythematosus;
THYM	cis	rs10463554	0.927	rs34799	chr5:102426202	A/G	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22509189	chr2:225307070	NA	-0.88	-7.52	-0.61	3.1e-11	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.24	5.5	0.49	3.18e-7	Obesity-related traits;
THYM	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21582582	chr3:182698605	DCUN1D1	0.81	7.07	0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs711830	1.000	rs2249131	chr2:177032095	C/T	cg13092806	chr2:177043255	NA	0.59	4.49	0.42	1.99e-5	Serous invasive ovarian cancer;Epithelial ovarian cancer;Invasive epithelial ovarian cancer;Mucinous ovarian carcinoma;Low-grade serous and serous borderline ovarian cancer;Serous borderline ovarian cancer;High-grade serous ovarian cancer;
THYM	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg21773646	chr17:80085082	CCDC57	-0.37	-5.16	-0.47	1.36e-6	Life satisfaction;
THYM	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.7	-5.63	-0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg11764359	chr7:65958608	NA	0.78	6.31	0.54	8.68e-9	Aortic root size;
THYM	cis	rs1629083	1.000	rs1629083	chr11:118126576	C/T	cg25155064	chr11:118100782	MPZL3	-0.56	-5.01	-0.46	2.55e-6	Lung cancer;
THYM	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs17433780	0.504	rs1409150	chr1:89473175	A/G	cg09516651	chr1:89888402	LOC400759	0.7	5.51	0.49	3.08e-7	Carotid intima media thickness;
THYM	cis	rs9361491	0.608	rs6939263	chr6:79477648	C/T	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.88e-5	Intelligence (multi-trait analysis);
THYM	cis	rs13064411	0.696	rs6766615	chr3:113219342	T/C	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg19024700	chr19:49340765	PLEKHA4;HSD17B14	0.72	4.54	0.42	1.65e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs4237845	0.844	rs4628718	chr12:58301600	A/C	cg22764591	chr12:58329936	NA	0.77	5.54	0.49	2.66e-7	Intelligence (multi-trait analysis);
THYM	cis	rs59112743	0.510	rs7770921	chr6:15605114	C/T	cg10111214	chr6:14815676	NA	0.74	4.84	0.44	5.08e-6	Multiple keratinocyte cancers;
THYM	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg18252515	chr7:66147081	NA	0.6	4.54	0.42	1.63e-5	Aortic root size;
THYM	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg00383909	chr3:49044727	WDR6	1.21	7.52	0.61	3.1e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs941408	1.000	rs1736179	chr19:2795516	T/A	cg06609049	chr19:2785107	THOP1	0.68	5.6	0.5	2.03e-7	Total cholesterol levels;
THYM	cis	rs921968	0.508	rs72965103	chr2:219312469	T/C	cg02176678	chr2:219576539	TTLL4	-0.73	-7.3	-0.6	8.61e-11	Mean corpuscular hemoglobin concentration;
THYM	cis	rs3862260	0.509	rs2281493	chr1:120162787	T/C	cg11530693	chr1:120165357	ZNF697	1.08	12.42	0.79	1.33e-21	Systemic lupus erythematosus;
THYM	cis	rs8054556	0.539	rs12596543	chr16:30029135	A/G	cg06015834	chr16:30021696	DOC2A	-0.5	-4.46	-0.42	2.27e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg10515332	chr4:99064459	C4orf37	0.57	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6840360	0.557	rs4696261	chr4:152322659	C/G	cg17479576	chr4:152424074	FAM160A1	-0.74	-5.57	-0.5	2.36e-7	Intelligence (multi-trait analysis);
THYM	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18252515	chr7:66147081	NA	-0.66	-4.96	-0.45	3.11e-6	Aortic root size;
THYM	cis	rs12410462	0.901	rs16847844	chr1:227638110	A/G	cg23173402	chr1:227635558	NA	0.59	5.46	0.49	3.83e-7	Major depressive disorder;
THYM	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg02527881	chr3:46936655	PTH1R	-0.65	-6.55	-0.56	2.97e-9	Colorectal cancer;
THYM	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg06453172	chr10:134556979	INPP5A	-0.64	-4.53	-0.42	1.69e-5	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7106204	0.534	rs75297923	chr11:24253530	A/G	ch.11.24196551F	chr11:24239977	NA	0.89	4.62	0.43	1.22e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg10193763	chr2:225306901	NA	-0.51	-5.36	-0.48	5.86e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs10193935	0.892	rs12622152	chr2:42482929	C/A	cg27598129	chr2:42591480	NA	-0.75	-4.51	-0.42	1.87e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1994135	0.617	rs10844644	chr12:33735871	A/G	cg10856724	chr12:34555212	NA	-0.73	-5.71	-0.51	1.29e-7	Resting heart rate;
THYM	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg06219351	chr7:158114137	PTPRN2	0.67	6.66	0.56	1.73e-9	Calcium levels;
THYM	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs72949976	0.646	rs11681232	chr2:214033002	G/A	cg08319019	chr2:214017104	IKZF2	0.74	6.22	0.54	1.32e-8	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg13147721	chr7:65941812	NA	0.96	5.84	0.51	7.26e-8	Diabetic kidney disease;
THYM	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs5760092	0.842	rs5760103	chr22:24248781	A/G	cg02953382	chr22:24373134	LOC391322	-0.73	-5.29	-0.48	7.96e-7	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg15691649	chr6:25882328	NA	-0.72	-5.75	-0.51	1.1e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4654899	0.758	rs6693055	chr1:21421813	C/T	cg01072550	chr1:21505969	NA	-0.79	-7.73	-0.62	1.11e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs7809950	0.953	rs1468336	chr7:107208250	T/C	cg23024343	chr7:107201750	COG5	0.93	8.32	0.65	6.49e-13	Coronary artery disease;
THYM	cis	rs995000	0.931	rs10889336	chr1:62980410	T/C	cg06896770	chr1:63153194	DOCK7	1.0	7.96	0.63	3.66e-12	Triglyceride levels;
THYM	cis	rs73086581	1.000	rs73088416	chr20:3995276	A/G	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.23e-7	Response to antidepressants in depression;
THYM	cis	rs57244997	0.725	rs73785320	chr6:162439590	A/C	cg17173639	chr6:162384350	PARK2	-0.74	-4.96	-0.45	3.08e-6	Mosquito bite size;
THYM	cis	rs7010267	0.712	rs4567065	chr8:120008274	C/A	cg17171407	chr8:119960777	TNFRSF11B	0.59	4.82	0.44	5.33e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg22166914	chr1:53195759	ZYG11B	0.69	6.85	0.57	7.37e-10	Monocyte count;
THYM	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg16624210	chr5:671434	TPPP	0.66	4.81	0.44	5.7e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg13607699	chr17:42295918	UBTF	0.66	5.44	0.49	4.13e-7	Total body bone mineral density;
THYM	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg18305652	chr10:134549665	INPP5A	0.87	8.04	0.64	2.48e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg01483505	chr11:975446	AP2A2	0.58	4.75	0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg04362960	chr10:104952993	NT5C2	-0.6	-5.13	-0.47	1.51e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs34734847	0.842	rs696337	chr12:121159380	T/C	cg21892295	chr12:121157589	UNC119B	-0.48	-4.84	-0.44	4.97e-6	Mean corpuscular volume;
THYM	cis	rs9915657	0.803	rs12449851	chr17:70099002	C/T	cg06234051	chr17:70120541	SOX9	0.56	5.11	0.46	1.7e-6	Thyroid hormone levels;
THYM	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs4589258	0.898	rs10501733	chr11:90413222	C/T	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9549328	0.577	rs4907478	chr13:113618487	A/G	cg10588471	chr13:113632644	MCF2L	-0.66	-4.62	-0.43	1.22e-5	Systolic blood pressure;
THYM	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg10862848	chr6:42927986	GNMT	-0.48	-6.48	-0.55	4.04e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7575217	0.767	rs4851407	chr2:101759182	G/A	cg23907051	chr2:101730305	TBC1D8	-0.41	-5.5	-0.49	3.25e-7	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg18681998	chr4:17616180	MED28	-0.89	-7.5	-0.61	3.31e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg05335186	chr13:53173507	NA	-0.47	-5.51	-0.49	3.05e-7	Lewy body disease;
THYM	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg27168131	chr21:44088823	PDE9A	-0.48	-4.75	-0.44	7.14e-6	Mean corpuscular volume;
THYM	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs3204270	0.810	rs8077959	chr17:79670122	G/A	cg09996840	chr17:79680718	SLC25A10	-0.59	-4.46	-0.42	2.24e-5	Dental caries;
THYM	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg20503657	chr10:835505	NA	1.17	8.3	0.65	7.12e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs986417	0.748	rs4901986	chr14:60969333	T/C	cg27398547	chr14:60952738	C14orf39	1.13	6.18	0.54	1.57e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs6539288	0.901	rs4964505	chr12:107341840	T/G	cg26297688	chr12:107349093	C12orf23	-0.47	-4.94	-0.45	3.36e-6	Total body bone mineral density;
THYM	cis	rs2898681	0.561	rs58577680	chr4:53734294	C/T	cg00791764	chr4:53727839	RASL11B	0.56	6.09	0.53	2.43e-8	Optic nerve measurement (cup area);
THYM	cis	rs478304	0.651	rs11227279	chr11:65495211	G/A	cg27068330	chr11:65405492	SIPA1	-0.96	-9.31	-0.69	4.93e-15	Acne (severe);
THYM	cis	rs1550582	1.000	rs754234	chr8:135512875	A/G	cg17885191	chr8:135476712	NA	0.75	4.74	0.44	7.46e-6	Educational attainment;
THYM	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg22852734	chr6:133119734	C6orf192	1.23	7.73	0.62	1.1e-11	Type 2 diabetes nephropathy;
THYM	cis	rs7027203	0.828	rs3996239	chr9:96611290	T/A	cg13679303	chr9:96623674	NA	-0.51	-5.35	-0.48	6.06e-7	DNA methylation (variation);
THYM	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg09990169	chr2:241835740	C2orf54	-0.37	-5.89	-0.52	5.87e-8	Urinary metabolites;
THYM	cis	rs4705952	0.557	rs2079103	chr5:131864506	A/C	cg13566430	chr5:131992455	IL13	0.57	4.69	0.43	9.3e-6	C-reactive protein levels;
THYM	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs2273669	0.915	rs67708237	chr6:109292058	G/A	cg17117243	chr6:109341365	SESN1	-0.77	-4.68	-0.43	9.63e-6	Prostate cancer;
THYM	cis	rs57590327	0.503	rs13062741	chr3:81887124	C/T	cg07356753	chr3:81810745	GBE1	-0.78	-5.68	-0.5	1.45e-7	Extraversion;
THYM	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg09085632	chr11:111637200	PPP2R1B	1.11	11.2	0.75	4.55e-19	Primary sclerosing cholangitis;
THYM	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg16524733	chr11:117070046	TAGLN	0.43	4.76	0.44	6.82e-6	Blood protein levels;
THYM	cis	rs4780401	0.609	rs4781143	chr16:11809721	T/G	cg01061890	chr16:11836724	TXNDC11	-0.66	-5.44	-0.49	4.13e-7	Rheumatoid arthritis;
THYM	cis	rs6918586	0.658	rs198822	chr6:26123539	G/C	cg03264133	chr6:25882463	NA	0.65	5.06	0.46	2e-6	Schizophrenia;
THYM	cis	rs7677751	0.708	rs6554160	chr4:55077549	T/A	cg17187183	chr4:55093834	PDGFRA	0.66	5.06	0.46	2.02e-6	Corneal astigmatism;
THYM	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg06565975	chr8:143823917	SLURP1	-0.7	-8.27	-0.65	8.24e-13	Urinary tract infection frequency;
THYM	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg17105886	chr17:28927953	LRRC37B2	1.26	7.32	0.6	8.11e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2219968	0.740	rs7829841	chr8:78918716	G/T	cg00738934	chr8:78996279	NA	0.67	6.13	0.53	1.95e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg04750100	chr2:136595281	LCT	-0.55	-6.19	-0.54	1.51e-8	Mosquito bite size;
THYM	cis	rs112591243	0.570	rs117906758	chr21:48037968	T/C	cg26697654	chr21:47851941	PCNT	0.82	4.53	0.42	1.71e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg17366294	chr4:99064904	C4orf37	0.57	6.86	0.58	7.08e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	7.69	0.62	1.33e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg27534772	chr1:16042836	PLEKHM2	0.53	5.9	0.52	5.65e-8	Systolic blood pressure;
THYM	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg24812749	chr6:127587940	RNF146	0.97	7.72	0.62	1.14e-11	Breast cancer;
THYM	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12756686	chr19:29218302	NA	0.96	8.21	0.64	1.08e-12	Methadone dose in opioid dependence;
THYM	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-10.46	-0.73	1.72e-17	Primary sclerosing cholangitis;
THYM	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg07022442	chr13:21864356	NA	0.72	4.88	0.45	4.23e-6	White matter hyperintensity burden;
THYM	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg10515332	chr4:99064459	C4orf37	0.61	4.91	0.45	3.73e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2227564	0.597	rs2271271	chr10:75558867	G/A	cg00564723	chr10:75632066	CAMK2G	-0.5	-4.48	-0.42	2.1e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-5.43	-0.49	4.23e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7582180	0.764	rs12712075	chr2:100924129	T/C	cg21926883	chr2:100939477	LONRF2	-0.61	-5.52	-0.49	2.91e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg26384229	chr12:38710491	ALG10B	0.99	7.97	0.63	3.45e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs8044868	0.586	rs7190994	chr16:72099241	T/A	cg16558253	chr16:72132732	DHX38	-0.55	-4.56	-0.42	1.55e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.52	-5.14	-0.47	1.45e-6	Eosinophil percentage of white cells;
THYM	cis	rs28595532	0.841	rs114385163	chr4:119737058	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs3804749	0.966	rs3792369	chr3:122840731	C/T	cg26084141	chr3:122786895	PDIA5	-0.45	-4.53	-0.42	1.73e-5	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	trans	rs1880887	1.000	rs1880889	chr12:41721235	A/C	cg05258736	chr5:180591704	NA	0.95	7.72	0.62	1.17e-11	Protein quantitative trait loci;
THYM	cis	rs9527	0.662	rs10883783	chr10:104591152	T/A	cg15744005	chr10:104629667	AS3MT	-0.67	-5.33	-0.48	6.6e-7	Arsenic metabolism;
THYM	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg05025164	chr4:1340916	KIAA1530	-0.7	-5.38	-0.48	5.36e-7	Obesity-related traits;
THYM	cis	rs6956675	0.915	rs6977279	chr7:62630625	C/G	cg27518014	chr7:62859535	LOC100287834	0.59	4.75	0.44	7.32e-6	Obesity-related traits;
THYM	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg18402987	chr7:1209562	NA	0.84	5.27	0.48	8.61e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg05962950	chr11:130786565	SNX19	0.8	6.65	0.56	1.89e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg00814883	chr7:100076585	TSC22D4	-0.99	-6.77	-0.57	1.04e-9	Platelet count;
THYM	cis	rs514406	0.893	rs1242315	chr1:53417181	A/G	cg08859206	chr1:53392774	SCP2	-0.65	-7.33	-0.6	7.72e-11	Monocyte count;
THYM	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg14458575	chr2:238380390	NA	0.9	7.53	0.61	2.94e-11	Prostate cancer;
THYM	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg14159672	chr1:205819179	PM20D1	-0.69	-5.78	-0.51	9.58e-8	Prostate-specific antigen levels;
THYM	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg23187316	chr7:1099788	C7orf50	0.53	4.56	0.42	1.51e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7818345	0.649	rs13250181	chr8:19328766	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.6	5.25	0.47	9.13e-7	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs11671005	0.735	rs3764532	chr19:58929222	G/A	cg18639983	chr19:58920768	ZNF584	0.61	5.02	0.46	2.37e-6	Mean platelet volume;
THYM	cis	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg21394778	chr1:3037102	PRDM16	0.47	4.6	0.43	1.31e-5	Height;
THYM	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg15744005	chr10:104629667	AS3MT	-0.83	-7.67	-0.62	1.46e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7264396	0.561	rs6058387	chr20:34568092	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.64	-4.58	-0.43	1.41e-5	Total cholesterol levels;
THYM	cis	rs10857712	0.784	rs2265639	chr10:135221576	C/G	cg17796960	chr10:135278976	LOC619207	0.55	4.65	0.43	1.08e-5	Systemic lupus erythematosus;
THYM	cis	rs7149242	0.662	rs12881545	chr14:101176212	G/C	cg18089426	chr14:101175970	NA	-0.59	-5.93	-0.52	4.8e-8	Platelet count;
THYM	cis	rs55728055	0.661	rs55997441	chr22:31627989	A/G	cg01338084	chr22:32026380	PISD	1.3	4.51	0.42	1.82e-5	Age-related hearing impairment;
THYM	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg24375607	chr4:120327624	NA	0.68	5.43	0.49	4.29e-7	Corneal astigmatism;
THYM	cis	rs6032067	0.929	rs2233895	chr20:43850143	T/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.71	-7.53	-0.61	2.95e-11	Blood protein levels;
THYM	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg17644776	chr2:200775616	C2orf69	0.77	5.4	0.48	5.01e-7	Schizophrenia;
THYM	trans	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg25214090	chr10:38739885	LOC399744	0.87	7.52	0.61	2.99e-11	Corneal astigmatism;
THYM	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs1065852	0.526	rs2097561	chr22:42389431	T/C	cg22189786	chr22:42395067	WBP2NL	0.54	5.55	0.49	2.6e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg19747945	chr6:42946146	PEX6	-0.32	-4.65	-0.43	1.06e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg08132940	chr7:1081526	C7orf50	-1.12	-6.6	-0.56	2.32e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs16857609	0.529	rs74723351	chr2:218288217	G/A	cg15335768	chr2:218268053	DIRC3	-0.52	-7.56	-0.61	2.5e-11	Breast cancer;Breast cancer (estrogen-receptor negative);
THYM	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg09703963	chr11:616879	IRF7;MUPCDH	-0.61	-4.76	-0.44	6.98e-6	Systemic lupus erythematosus;
THYM	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.38	0.48	5.41e-7	Platelet count;
THYM	cis	rs4243830	0.850	rs7552196	chr1:6590502	G/A	cg04093404	chr1:6614507	TAS1R1;NOL9	-0.83	-4.64	-0.43	1.12e-5	Body mass index;
THYM	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg10018233	chr7:150070692	REPIN1	0.47	6.85	0.58	7.26e-10	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7688540	0.771	rs61795001	chr4:242057	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.72	4.88	0.45	4.35e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg04865290	chr3:52927548	TMEM110	-0.88	-4.75	-0.44	7.08e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7177699	0.557	rs8026598	chr15:79112938	A/G	cg00540400	chr15:79124168	NA	0.64	6.93	0.58	4.98e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg20503657	chr10:835505	NA	1.42	9.74	0.71	5.94e-16	Eosinophil percentage of granulocytes;
THYM	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg15691649	chr6:25882328	NA	-0.7	-5.47	-0.49	3.69e-7	Intelligence (multi-trait analysis);
THYM	cis	rs56079296	0.929	rs9327236	chr5:121279021	A/C	cg05256605	chr5:121412184	LOX	-0.61	-4.65	-0.43	1.06e-5	Coronary artery disease;
THYM	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.52e-10	Prudent dietary pattern;
THYM	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.53	0.56	3.27e-9	Total body bone mineral density;
THYM	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg12288994	chr5:1860383	NA	0.83	6.93	0.58	5e-10	Cardiovascular disease risk factors;
THYM	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg03806693	chr22:41940476	POLR3H	1.25	10.88	0.74	2.22e-18	Vitiligo;
THYM	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg22535103	chr8:58192502	C8orf71	-0.98	-5.82	-0.51	8e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7727544	0.544	rs55722650	chr5:131607300	C/T	cg18758796	chr5:131593413	PDLIM4	0.49	4.5	0.42	1.92e-5	Blood metabolite levels;
THYM	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg14829155	chr15:31115871	NA	0.75	6.38	0.55	6.46e-9	Huntington's disease progression;
THYM	cis	rs73086581	1.000	rs73084575	chr20:3906768	G/T	cg02187196	chr20:3869020	PANK2	0.46	5.22	0.47	1.03e-6	Response to antidepressants in depression;
THYM	cis	rs1349547	0.510	rs3864654	chr8:39497122	A/C	cg01911981	chr8:39380341	ADAM3A	-0.52	-4.55	-0.42	1.6e-5	HIV-1 susceptibility;
THYM	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg07777115	chr5:623756	CEP72	-0.78	-4.58	-0.43	1.38e-5	Obesity-related traits;
THYM	cis	rs595982	0.527	rs17272673	chr19:49362992	C/A	cg21252483	chr19:49399788	TULP2	-0.81	-5.67	-0.5	1.56e-7	Red cell distribution width;
THYM	cis	rs2074585	0.708	rs2601190	chr15:90932966	A/C	cg22089800	chr15:90895588	ZNF774	0.68	5.12	0.46	1.61e-6	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
THYM	cis	rs4845459	0.967	rs6700160	chr1:152593024	A/C	cg26135325	chr1:152595322	LCE3A	-0.45	-5.13	-0.47	1.54e-6	Psoriasis;
THYM	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg06634786	chr22:41940651	POLR3H	0.7	4.92	0.45	3.59e-6	Vitiligo;
THYM	cis	rs611744	0.658	rs2443775	chr8:109062481	A/G	cg21045802	chr8:109455806	TTC35	-0.61	-5.26	-0.47	9.02e-7	Dupuytren's disease;
THYM	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs28595532	0.920	rs116634064	chr4:119736514	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs7523273	0.606	rs1830764	chr1:207917052	G/A	cg22525895	chr1:207977042	MIR29B2	0.9	9.88	0.71	3.03e-16	Schizophrenia;
THYM	cis	rs7084402	0.967	rs1619284	chr10:60302515	C/T	cg07615347	chr10:60278583	BICC1	0.57	5.36	0.48	5.86e-7	Refractive error;
THYM	cis	rs13006833	0.739	rs291428	chr2:191197226	G/T	cg27211696	chr2:191398769	TMEM194B	0.56	4.47	0.42	2.17e-5	Urinary metabolites;
THYM	cis	rs9677476	0.909	rs13408391	chr2:232124127	G/T	cg23338755	chr2:231921595	PSMD1	0.67	4.83	0.44	5.2e-6	Food antigen IgG levels;
THYM	cis	rs11792861	0.641	rs10979586	chr9:111647764	C/T	cg05043794	chr9:111880884	C9orf5	-0.34	-4.62	-0.43	1.2e-5	Menarche (age at onset);
THYM	cis	rs4474465	1.000	rs11237500	chr11:78163636	G/A	cg19901956	chr11:77921274	USP35	-0.66	-4.91	-0.45	3.71e-6	Alzheimer's disease (survival time);
THYM	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14159672	chr1:205819179	PM20D1	0.97	10.17	0.72	7.06e-17	Menarche (age at onset);
THYM	cis	rs1784581	0.894	rs1626020	chr6:162383379	G/A	cg17173639	chr6:162384350	PARK2	-0.93	-9.0	-0.68	2.27e-14	Itch intensity from mosquito bite;
THYM	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg02734326	chr4:10020555	SLC2A9	0.73	6.5	0.55	3.74e-9	Bone mineral density;
THYM	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg06028808	chr11:68637592	NA	0.69	7.26	0.6	1.08e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg21394778	chr1:3037102	PRDM16	0.46	4.47	0.42	2.12e-5	Height;
THYM	cis	rs13177918	0.677	rs13183077	chr5:149826572	G/A	cg14059543	chr5:149831962	NA	-0.99	-7.58	-0.61	2.25e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs41005	1.000	rs41003	chr2:8111772	A/C	cg03155496	chr2:8117019	LOC339788	0.95	9.15	0.68	1.08e-14	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs4242434	0.699	rs878051	chr8:22483836	T/C	cg11461670	chr8:22454935	PDLIM2	-0.33	-6.03	-0.53	3.15e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.97	-7.62	-0.62	1.88e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	trans	rs629535	0.814	rs651985	chr8:70054966	G/A	cg21567404	chr3:27674614	NA	1.11	10.64	0.74	7.17e-18	Dupuytren's disease;
THYM	cis	rs761746	0.672	rs5753684	chr22:31939973	A/G	cg01338084	chr22:32026380	PISD	0.64	5.44	0.49	4.17e-7	Intelligence;
THYM	cis	rs28647808	0.881	rs28453162	chr9:136264382	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.22	-5.17	-0.47	1.27e-6	Blood protein levels;
THYM	cis	rs6754311	0.512	rs12998387	chr2:136507039	A/G	cg20242066	chr2:136595261	LCT	-0.57	-6.93	-0.58	4.9e-10	Mosquito bite size;
THYM	cis	rs2625529	0.642	rs2200056	chr15:72302667	T/C	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs950880	0.677	rs4851585	chr2:103062754	T/A	cg03938978	chr2:103052716	IL18RAP	-0.56	-4.84	-0.44	5.06e-6	Serum protein levels (sST2);
THYM	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg15744005	chr10:104629667	AS3MT	-0.86	-8.2	-0.64	1.16e-12	Arsenic metabolism;
THYM	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg09021430	chr5:549028	NA	-0.64	-4.84	-0.44	4.98e-6	Obesity-related traits;
THYM	cis	rs1457451	0.920	rs10179706	chr2:65863049	A/T	cg16240816	chr2:65861662	NA	0.65	6.92	0.58	5.27e-10	Iron status biomarkers;
THYM	cis	rs858239	0.601	rs28673077	chr7:23250854	C/T	cg09755872	chr7:23245557	NA	-0.52	-4.85	-0.45	4.76e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs79149102	0.579	rs7167415	chr15:75302570	C/T	cg17294928	chr15:75287854	SCAMP5	-1.06	-5.68	-0.5	1.49e-7	Lung cancer;
THYM	cis	rs9733	0.596	rs11204697	chr1:150658971	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs9814567	1.000	rs4334685	chr3:134304335	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.5	-0.66	2.69e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs11039798	0.588	rs11039855	chr11:48610091	A/G	cg24672777	chr11:48374446	OR4C45	-0.93	-6.01	-0.52	3.39e-8	Axial length;
THYM	cis	rs12579753	0.956	rs34146892	chr12:82188581	T/G	cg21231944	chr12:82153410	PPFIA2	-0.67	-5.02	-0.46	2.39e-6	Resting heart rate;
THYM	cis	rs6032067	0.852	rs17424751	chr20:43814622	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs9515201	0.781	rs2391825	chr13:111035483	G/A	cg06243866	chr13:111019493	COL4A2	-0.88	-7.61	-0.62	2.01e-11	White matter hyperintensity burden;
THYM	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg24812749	chr6:127587940	RNF146	-0.76	-5.71	-0.51	1.27e-7	Breast cancer;
THYM	cis	rs514406	0.893	rs2897561	chr1:53388747	C/A	cg22166914	chr1:53195759	ZYG11B	0.77	7.6	0.62	2.04e-11	Monocyte count;
THYM	cis	rs7149242	0.500	rs10144381	chr14:101173297	C/T	cg18089426	chr14:101175970	NA	0.58	5.74	0.51	1.12e-7	Platelet count;
THYM	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg17554472	chr22:41940697	POLR3H	0.71	4.68	0.43	9.61e-6	Vitiligo;
THYM	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg16797656	chr11:68205561	LRP5	0.53	6.16	0.53	1.77e-8	Total body bone mineral density;
THYM	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg05335186	chr13:53173507	NA	-0.46	-5.86	-0.52	6.6e-8	Lewy body disease;
THYM	cis	rs55665837	1.000	rs10832269	chr11:14465069	C/A	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg06481639	chr22:41940642	POLR3H	-0.82	-5.68	-0.5	1.49e-7	Vitiligo;
THYM	cis	rs12282928	0.918	rs7948903	chr11:48247305	T/C	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs17253792	0.545	rs12879564	chr14:56017694	A/G	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs898549	0.520	rs12570314	chr10:44529320	A/G	cg27599783	chr10:45480162	RASSF4	0.5	4.57	0.42	1.47e-5	Obesity-related traits;
THYM	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.61	7.94	0.63	4.1e-12	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs346785	0.692	rs8074821	chr17:74293099	A/G	cg09812376	chr17:74270190	QRICH2	-0.5	-5.07	-0.46	1.98e-6	White matter hyperintensities in ischemic stroke;
THYM	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg12011299	chr4:100065546	ADH4	0.57	5.14	0.47	1.48e-6	Alcohol dependence;
THYM	cis	rs17453880	0.929	rs62398709	chr5:152055235	A/T	cg12297329	chr5:152029980	NA	-0.61	-4.6	-0.43	1.32e-5	Subjective well-being;
THYM	cis	rs3796352	0.892	rs35076015	chr3:53026366	C/T	cg04865290	chr3:52927548	TMEM110	-0.96	-5.01	-0.46	2.52e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs807669	0.868	rs2800973	chr22:19168616	A/G	cg02655711	chr22:19163373	SLC25A1	0.9	10.77	0.74	3.86e-18	Metabolite levels;
THYM	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.78	-5.09	-0.46	1.8e-6	Mean platelet volume;
THYM	trans	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg25214090	chr10:38739885	LOC399744	0.85	7.16	0.59	1.7e-10	Corneal astigmatism;
THYM	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg22535103	chr8:58192502	C8orf71	-0.96	-5.47	-0.49	3.7e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs2692947	0.711	rs34639392	chr2:96508976	T/C	cg23100626	chr2:96804247	ASTL	0.36	4.74	0.44	7.52e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg22875332	chr1:76189707	ACADM	-0.88	-9.09	-0.68	1.44e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg11502198	chr6:26597334	ABT1	0.64	5.68	0.5	1.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg16342193	chr10:102329863	NA	-0.53	-5.45	-0.49	4.01e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg07636037	chr3:49044803	WDR6	0.96	10.42	0.73	2.05e-17	Parkinson's disease;
THYM	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.74	5.66	0.5	1.58e-7	Eosinophil percentage of white cells;
THYM	cis	rs11641365	1.000	rs11641365	chr16:88773893	A/G	cg00034003	chr16:88779146	CTU2	0.63	5.34	0.48	6.22e-7	Autism spectrum disorder-related traits;
THYM	cis	rs17453880	0.890	rs6860811	chr5:152049653	G/T	cg12297329	chr5:152029980	NA	-0.59	-4.48	-0.42	2.06e-5	Subjective well-being;
THYM	cis	rs858239	0.636	rs7808488	chr7:23221870	T/C	cg05407003	chr7:23246146	NA	-0.73	-6.39	-0.55	6e-9	Cerebrospinal fluid biomarker levels;
THYM	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06634786	chr22:41940651	POLR3H	0.79	5.9	0.52	5.57e-8	Vitiligo;
THYM	cis	rs12681287	0.547	rs60982560	chr8:87515046	C/T	cg27223183	chr8:87520930	FAM82B	-0.71	-5.44	-0.49	4.19e-7	Caudate activity during reward;
THYM	cis	rs6495122	0.699	rs34862454	chr15:75101530	C/T	cg14664628	chr15:75095509	CSK	-0.83	-6.53	-0.56	3.29e-9	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg18538332	chr22:24372958	LOC391322	-0.92	-11.38	-0.76	1.9e-19	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs989128	0.600	rs9913677	chr17:48628581	T/A	cg20467136	chr17:48638190	CACNA1G	0.6	4.61	0.43	1.23e-5	Type 2 diabetes;
THYM	cis	rs36051895	0.560	rs1575281	chr9:5219131	T/C	cg02405213	chr9:5042618	JAK2	-0.83	-7.85	-0.63	6.2e-12	Pediatric autoimmune diseases;
THYM	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg11965913	chr1:205819406	PM20D1	0.95	10.38	0.73	2.57e-17	Menarche (age at onset);
THYM	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg13695892	chr22:41940480	POLR3H	-0.89	-7.38	-0.6	5.83e-11	Vitiligo;
THYM	cis	rs10752881	0.809	rs3768613	chr1:183106296	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.61	0.43	1.24e-5	Colorectal cancer;
THYM	cis	rs8041943	0.550	rs11852833	chr15:79894316	G/A	cg20511832	chr15:78934280	CHRNB4	0.44	4.52	0.42	1.8e-5	Bone mineral density (spine) and age at menarche;
THYM	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg08859206	chr1:53392774	SCP2	0.51	5.48	0.49	3.5e-7	Monocyte count;
THYM	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.68	-5.15	-0.47	1.4e-6	Total cholesterol levels;
THYM	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg22907277	chr7:1156413	C7orf50	0.75	6.27	0.54	1.06e-8	Longevity;Endometriosis;
THYM	cis	rs790123	0.553	rs7612991	chr3:122351791	T/C	cg17380795	chr3:122379686	NA	0.54	4.84	0.45	4.92e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs981844	0.826	rs4585278	chr4:154684145	A/G	cg22178613	chr4:154710499	SFRP2	-0.58	-4.67	-0.43	9.88e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.6	-0.5	2.08e-7	Type 2 diabetes;
THYM	cis	rs6840360	0.615	rs4696096	chr4:152475387	A/G	cg22705602	chr4:152727874	NA	-0.71	-7.94	-0.63	4.03e-12	Intelligence (multi-trait analysis);
THYM	cis	rs3818285	0.632	rs536343	chr10:111632879	T/C	cg00817464	chr10:111662876	XPNPEP1	0.49	5.12	0.47	1.58e-6	Superior crus of antihelix expression;
THYM	cis	rs1011018	0.628	rs7787807	chr7:139433190	T/C	cg06079564	chr7:139468310	HIPK2	-0.72	-4.77	-0.44	6.71e-6	Systolic blood pressure;
THYM	cis	rs7828089	0.602	rs7005505	chr8:22276393	T/C	cg12081754	chr8:22256438	SLC39A14	0.92	8.73	0.67	8.64e-14	Verbal declarative memory;
THYM	cis	rs4631830	0.832	rs1585378	chr10:51523213	A/T	cg16070123	chr10:51489643	NA	-0.51	-4.7	-0.43	8.92e-6	Prostate-specific antigen levels;
THYM	cis	rs10911232	0.507	rs10797832	chr1:183044034	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg20887711	chr4:1340912	KIAA1530	0.67	5.77	0.51	9.77e-8	Longevity;
THYM	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg13736514	chr6:26305472	NA	0.6	7.08	0.59	2.45e-10	Educational attainment;
THYM	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg10505658	chr17:80084571	CCDC57	-0.75	-8.28	-0.65	7.76e-13	Life satisfaction;
THYM	cis	rs2219968	0.525	rs7819899	chr8:78872750	C/T	cg00738934	chr8:78996279	NA	0.6	4.94	0.45	3.35e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg10257693	chr21:44515416	U2AF1	0.53	4.5	0.42	1.94e-5	Mean corpuscular volume;
THYM	cis	rs448720	0.811	rs1996120	chr15:68181534	G/A	cg24579218	chr15:68104479	NA	-0.52	-4.61	-0.43	1.23e-5	Cognitive performance;
THYM	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg06917634	chr15:78832804	PSMA4	0.83	7.39	0.6	5.74e-11	Sudden cardiac arrest;
THYM	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg00981070	chr1:2046702	PRKCZ	0.47	5.63	0.5	1.85e-7	Height;
THYM	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.7	5.33	0.48	6.5e-7	Tonsillectomy;
THYM	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs763014	0.865	rs2071979	chr16:624114	A/G	cg07343612	chr16:622815	PIGQ	-1.05	-10.74	-0.74	4.28e-18	Height;
THYM	cis	rs9868809	0.772	rs2302295	chr3:48690110	T/C	cg00383909	chr3:49044727	WDR6	1.04	5.41	0.49	4.77e-7	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg22709100	chr7:91322751	NA	0.6	4.74	0.44	7.58e-6	Breast cancer;
THYM	cis	rs673253	0.556	rs35393217	chr1:44101648	G/A	cg09903430	chr1:44172605	ST3GAL3	-0.5	-4.54	-0.42	1.65e-5	Intelligence (multi-trait analysis);
THYM	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg06718696	chr17:78121285	EIF4A3	1.04	7.47	0.61	3.81e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
THYM	cis	rs1775715	0.737	rs2778672	chr10:32122419	T/C	cg04359828	chr10:32216031	ARHGAP12	0.36	4.76	0.44	6.9e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs7592578	0.771	rs4258824	chr2:191395027	C/T	cg27211696	chr2:191398769	TMEM194B	-0.65	-5.18	-0.47	1.26e-6	Diastolic blood pressure;
THYM	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg06532163	chr17:45867833	NA	0.64	6.45	0.55	4.65e-9	IgG glycosylation;
THYM	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs8016982	0.609	rs8009519	chr14:81702503	C/G	cg01989461	chr14:81687754	GTF2A1	0.88	7.91	0.63	4.61e-12	Schizophrenia;
THYM	cis	rs2227564	0.597	rs2271271	chr10:75558867	G/A	cg23231163	chr10:75533350	FUT11	-0.35	-4.58	-0.43	1.4e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg06618935	chr21:46677482	NA	-0.96	-8.89	-0.67	3.91e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7584330	0.518	rs79618460	chr2:238419959	T/C	cg08992911	chr2:238395768	MLPH	1.14	6.79	0.57	9.6e-10	Prostate cancer;
THYM	cis	rs11771526	0.901	rs10252303	chr7:32304438	C/T	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs7078219	0.505	rs10883372	chr10:101292483	T/A	cg23904955	chr10:101282759	NA	-0.36	-4.56	-0.42	1.55e-5	Dental caries;
THYM	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg00487526	chr15:90818384	NA	-0.58	-4.46	-0.42	2.29e-5	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg20203395	chr5:56204925	C5orf35	-0.65	-4.47	-0.42	2.17e-5	Initial pursuit acceleration;
THYM	cis	rs7107174	1.000	rs10899492	chr11:78109810	G/A	cg19901956	chr11:77921274	USP35	-0.65	-5.38	-0.48	5.26e-7	Testicular germ cell tumor;
THYM	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg00256281	chr22:41985642	PMM1	0.64	4.98	0.46	2.78e-6	Vitiligo;
THYM	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.13	-8.4	-0.65	4.36e-13	Platelet count;
THYM	cis	rs4072705	0.967	rs12339980	chr9:127318703	C/T	cg13476313	chr9:127244764	NR5A1	0.31	4.78	0.44	6.36e-6	Menarche (age at onset);
THYM	cis	rs854765	0.663	rs16960744	chr17:17755259	A/G	cg16928487	chr17:17741425	SREBF1	0.54	5.39	0.48	5.03e-7	Total body bone mineral density;
THYM	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg13010199	chr12:38710504	ALG10B	0.71	4.87	0.45	4.46e-6	Morning vs. evening chronotype;
THYM	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg20966754	chr17:47091339	IGF2BP1	-0.58	-7.45	-0.61	4.24e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg04944784	chr2:26401820	FAM59B	-0.79	-6.18	-0.54	1.61e-8	Gut microbiome composition (summer);
THYM	cis	rs13315871	0.929	rs13082278	chr3:58318224	A/G	cg00563845	chr3:58318305	PXK	0.58	4.99	0.46	2.73e-6	Cholesterol, total;
THYM	cis	rs34638657	0.702	rs62044258	chr16:82199461	C/T	cg07307142	chr16:82071433	HSD17B2	-0.88	-8.05	-0.64	2.34e-12	Lung adenocarcinoma;
THYM	cis	rs3768617	0.510	rs6691755	chr1:183099821	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs2354432	0.607	rs58941651	chr1:146784919	T/C	cg25205988	chr1:146714368	CHD1L	-1.0	-5.33	-0.48	6.54e-7	Mitochondrial DNA levels;
THYM	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg04944784	chr2:26401820	FAM59B	-1.05	-7.66	-0.62	1.54e-11	Gut microbiome composition (summer);
THYM	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	4.55	0.42	1.6e-5	Renal function-related traits (BUN);
THYM	cis	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg00074818	chr8:8560427	CLDN23	0.48	4.46	0.42	2.27e-5	Obesity-related traits;
THYM	cis	rs6980334	0.911	rs2166188	chr7:137773563	A/C	cg22979093	chr7:137028410	PTN	0.57	4.52	0.42	1.75e-5	Blood metabolite ratios;
THYM	cis	rs1018836	0.828	rs12547016	chr8:91563847	T/C	cg16814680	chr8:91681699	NA	-0.9	-7.85	-0.63	6.31e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7940866	0.834	rs10791105	chr11:130839161	A/G	cg23692386	chr11:131799662	NTM	0.5	5.3	0.48	7.66e-7	Schizophrenia;
THYM	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg04520793	chr17:42248056	ASB16	-0.35	-4.78	-0.44	6.48e-6	Total body bone mineral density;
THYM	cis	rs9810089	0.934	rs1279949	chr3:135996870	T/A	cg21827317	chr3:136751795	NA	0.54	4.47	0.42	2.18e-5	Gestational age at birth (child effect);
THYM	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18876405	chr7:65276391	NA	0.56	4.63	0.43	1.16e-5	Aortic root size;
THYM	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	6.05	0.53	2.89e-8	Obesity-related traits;
THYM	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg17775962	chr7:1200435	ZFAND2A	0.38	5.0	0.46	2.64e-6	Longevity;Endometriosis;
THYM	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg25427524	chr10:38739819	LOC399744	0.66	6.01	0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg14456004	chr13:21872349	NA	1.27	10.82	0.74	3.02e-18	White matter hyperintensity burden;
THYM	cis	rs1448094	0.512	rs11117060	chr12:86250788	G/T	cg02569458	chr12:86230093	RASSF9	-0.59	-5.07	-0.46	1.96e-6	Major depressive disorder;
THYM	cis	rs1524976	1.000	rs1554664	chr3:65501649	A/G	cg16238336	chr3:65465873	MAGI1	1.05	6.05	0.53	2.81e-8	PR interval;
THYM	cis	rs7941600	0.581	rs7103596	chr11:9338052	T/C	cg19415743	chr11:9336845	TMEM41B	1.1	5.74	0.51	1.14e-7	Coronary artery disease;
THYM	cis	rs3741798	1.000	rs78807762	chr12:12484136	G/A	cg08615371	chr12:12503544	MANSC1	0.88	4.9	0.45	3.92e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg27532560	chr4:187881888	NA	-0.97	-11.93	-0.77	1.37e-20	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg04842962	chr6:43655489	MRPS18A	-1.18	-7.6	-0.61	2.08e-11	IgG glycosylation;
THYM	trans	rs9929218	0.551	rs3785135	chr16:68728976	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.08	-13.58	-0.81	5.52e-24	Colorectal cancer;
THYM	cis	rs752010	0.871	rs10789405	chr1:42101962	C/T	cg22486000	chr1:42919398	ZMYND12	-0.41	-4.64	-0.43	1.12e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs4866334	1.000	rs75904205	chr5:18402670	C/T	cg24599790	chr5:18972260	NA	-1.18	-4.51	-0.42	1.84e-5	IgG glycosylation;
THYM	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg14983838	chr19:29218262	NA	1.09	9.77	0.71	5e-16	Methadone dose in opioid dependence;
THYM	cis	rs939658	0.935	rs34859518	chr15:79450422	A/G	cg17916960	chr15:79447300	NA	-0.77	-9.12	-0.68	1.24e-14	Refractive error;
THYM	trans	rs58106596	0.800	rs28883318	chr2:232562935	G/A	cg01370599	chr3:116745421	NA	0.94	7.06	0.59	2.75e-10	White blood cell count;Lymphocyte counts;
THYM	cis	rs10979	1.000	rs3748072	chr6:143889757	C/T	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs12291225	0.679	rs11023178	chr11:14310282	G/A	cg05501817	chr11:14380813	RRAS2	-0.75	-5.76	-0.51	1.02e-7	Sense of smell;
THYM	cis	rs2495707	0.624	rs2489006	chr10:102419893	G/A	cg07919443	chr10:102419409	NA	-0.65	-5.66	-0.5	1.63e-7	Body mass index;
THYM	cis	rs2456568	0.564	rs6483270	chr11:93624380	C/T	cg08514419	chr11:93583937	C11orf90	-0.49	-4.8	-0.44	5.96e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2692947	0.770	rs11689832	chr2:96554851	A/C	cg23100626	chr2:96804247	ASTL	0.41	5.15	0.47	1.43e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.66e-7	Corneal astigmatism;
THYM	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg06713675	chr4:122721982	EXOSC9	-0.68	-6.82	-0.57	8.28e-10	Type 2 diabetes;
THYM	cis	rs55637147	0.553	rs2276040	chr11:57137296	C/T	cg15971518	chr11:57159174	PRG2	0.58	4.81	0.44	5.73e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs2820651	1.000	rs79446083	chr10:1476044	T/A	cg27404824	chr10:1454848	ADARB2	0.99	5.23	0.47	1.02e-6	Migraine with aura;
THYM	cis	rs6032067	1.000	rs6032042	chr20:43815949	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	trans	rs10028773	0.632	rs34481394	chr4:120248374	C/T	cg25517755	chr10:38738941	LOC399744	-0.76	-6.9	-0.58	5.85e-10	Educational attainment;
THYM	cis	rs4523957	0.928	rs8066372	chr17:2180968	A/G	cg16513277	chr17:2031491	SMG6	-0.79	-7.41	-0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg14416269	chr4:6271139	WFS1	0.51	5.18	0.47	1.27e-6	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs35883536	0.647	rs11166485	chr1:101048805	G/C	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.52e-6	Monocyte count;
THYM	trans	rs1445130	0.892	rs10495689	chr2:18832132	C/T	cg07603449	chr1:11986842	KIAA2013	0.62	6.96	0.58	4.45e-10	Bulimia nervosa;
THYM	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs3820068	0.577	rs9728986	chr1:16040603	G/A	cg27534772	chr1:16042836	PLEKHM2	0.51	5.25	0.47	9.14e-7	Systolic blood pressure;
THYM	cis	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.59	6.1	0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4845459	0.967	rs4845447	chr1:152590886	T/C	cg26135325	chr1:152595322	LCE3A	-0.45	-5.21	-0.47	1.09e-6	Psoriasis;
THYM	cis	rs6701037	0.681	rs1057239	chr1:175130204	G/A	cg17845761	chr1:175162550	KIAA0040	-0.36	-4.56	-0.42	1.5e-5	Alcohol dependence;
THYM	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg15704280	chr7:45808275	SEPT13	-1.02	-8.31	-0.65	6.7e-13	Coronary artery disease;
THYM	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg10224037	chr5:178157518	ZNF354A	0.98	7.61	0.62	1.99e-11	Neutrophil percentage of white cells;
THYM	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg27535305	chr1:53392650	SCP2	-0.39	-4.46	-0.42	2.26e-5	Monocyte count;
THYM	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg05368731	chr17:41323189	NBR1	1.26	11.55	0.76	8.34e-20	Menopause (age at onset);
THYM	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.81	7.04	0.59	3e-10	Intelligence (multi-trait analysis);
THYM	cis	rs78579285	0.544	rs4782320	chr16:88779865	G/A	cg04002220	chr16:89598305	SPG7	0.65	4.73	0.44	7.78e-6	Joint mobility (Beighton score);
THYM	cis	rs6964587	0.626	rs68009402	chr7:91516226	G/A	cg22709100	chr7:91322751	NA	-0.64	-4.72	-0.44	8e-6	Breast cancer;
THYM	cis	rs9926296	0.557	rs11076618	chr16:89807705	T/C	cg26513180	chr16:89883248	FANCA	0.53	4.82	0.44	5.49e-6	Vitiligo;
THYM	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.64	-5.69	-0.5	1.43e-7	Renal function-related traits (BUN);
THYM	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg12311346	chr5:56204834	C5orf35	0.61	4.67	0.43	9.99e-6	Initial pursuit acceleration;
THYM	cis	rs71403859	0.803	rs7203606	chr16:71590511	A/C	cg08717414	chr16:71523259	ZNF19	-1.11	-5.87	-0.52	6.29e-8	Post bronchodilator FEV1;
THYM	cis	rs2898681	1.000	rs2003198	chr4:53748583	C/T	cg00791764	chr4:53727839	RASL11B	0.48	5.78	0.51	9.28e-8	Optic nerve measurement (cup area);
THYM	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg05025164	chr4:1340916	KIAA1530	0.89	6.81	0.57	8.8e-10	Longevity;
THYM	cis	rs7560272	0.723	rs62153184	chr2:73773869	G/C	cg19565262	chr2:73869966	NAT8	-0.53	-4.57	-0.42	1.44e-5	Schizophrenia;
THYM	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg10802521	chr3:52805072	NEK4	-0.63	-5.33	-0.48	6.63e-7	Electroencephalogram traits;
THYM	cis	rs7408868	0.908	rs4809028	chr19:15273231	A/G	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs4642101	0.639	rs9870433	chr3:12853566	T/C	cg05775895	chr3:12838266	CAND2	0.82	6.65	0.56	1.88e-9	QRS complex (12-leadsum);
THYM	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs28595532	0.920	rs116145969	chr4:119770908	T/C	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs2518683	0.808	rs131190	chr22:29692497	G/T	cg10230314	chr22:30552801	HORMAD2	0.61	4.51	0.42	1.88e-5	Platelet count;
THYM	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg06808227	chr14:105710500	BRF1	-1.02	-8.64	-0.66	1.33e-13	Mean platelet volume;Platelet distribution width;
THYM	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs34638657	0.732	rs2967359	chr16:82202968	G/C	cg07307142	chr16:82071433	HSD17B2	-0.88	-7.6	-0.61	2.11e-11	Lung adenocarcinoma;
THYM	cis	rs11089937	0.597	rs4145535	chr22:22498374	T/C	cg21401457	chr22:22472743	NA	0.57	4.67	0.43	9.84e-6	Periodontitis (PAL4Q3);
THYM	cis	rs11096990	0.819	rs2711992	chr4:39150271	A/G	cg24403649	chr4:39172243	NA	-0.63	-5.26	-0.47	8.95e-7	Cognitive function;
THYM	cis	rs995000	0.931	rs11207979	chr1:62982994	G/A	cg06896770	chr1:63153194	DOCK7	0.89	7.56	0.61	2.54e-11	Triglyceride levels;
THYM	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.73	-4.82	-0.44	5.35e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7113850	0.541	rs11826483	chr11:24237730	C/T	ch.11.24196551F	chr11:24239977	NA	0.87	4.66	0.43	1.04e-5	Bone fracture in osteoporosis;
THYM	cis	rs977987	0.806	rs17696696	chr16:75393352	G/T	cg03315344	chr16:75512273	CHST6	-0.73	-6.08	-0.53	2.5e-8	Dupuytren's disease;
THYM	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg09074113	chr2:20870087	GDF7	-0.81	-7.53	-0.61	2.84e-11	Abdominal aortic aneurysm;
THYM	trans	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg25517755	chr10:38738941	LOC399744	-0.77	-7.1	-0.59	2.23e-10	Corneal astigmatism;
THYM	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7635838	0.586	rs379241	chr3:11291565	G/A	cg00170343	chr3:11313890	ATG7	0.67	5.16	0.47	1.38e-6	HDL cholesterol;
THYM	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg16049864	chr8:95962084	TP53INP1	-0.69	-6.21	-0.54	1.41e-8	Type 2 diabetes;
THYM	cis	rs13315871	0.858	rs13090428	chr3:58314412	A/G	cg00563845	chr3:58318305	PXK	0.58	4.99	0.46	2.73e-6	Cholesterol, total;
THYM	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg23428387	chr22:49814324	NA	-0.59	-6.13	-0.53	2.01e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg24308560	chr3:49941425	MST1R	-0.76	-6.48	-0.55	4.12e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7264396	0.635	rs3827030	chr20:34474947	C/T	cg26038318	chr20:34205095	SPAG4	-0.58	-4.6	-0.43	1.3e-5	Total cholesterol levels;
THYM	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg00981070	chr1:2046702	PRKCZ	-0.47	-5.63	-0.5	1.85e-7	Height;
THYM	cis	rs763014	0.833	rs3743903	chr16:632736	T/C	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs7000551	0.751	rs1116085	chr8:22394920	A/G	cg12081754	chr8:22256438	SLC39A14	0.68	6.36	0.55	7.14e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg21775007	chr8:11205619	TDH	0.62	4.73	0.44	7.9e-6	Retinal vascular caliber;
THYM	cis	rs6876348	0.516	rs257898	chr5:128314586	A/G	cg25555059	chr5:128301488	SLC27A6	-0.45	-4.73	-0.44	7.81e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4631830	0.965	rs4306255	chr10:51542444	A/G	cg10326726	chr10:51549505	MSMB	-0.59	-5.85	-0.51	6.94e-8	Prostate-specific antigen levels;
THYM	cis	rs977987	0.806	rs4887818	chr16:75361995	T/C	cg03315344	chr16:75512273	CHST6	0.83	6.84	0.57	7.77e-10	Dupuytren's disease;
THYM	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg03806693	chr22:41940476	POLR3H	-0.77	-6.07	-0.53	2.59e-8	Neuroticism;
THYM	cis	rs9549260	0.564	rs9315784	chr13:41289166	G/A	cg21288729	chr13:41239152	FOXO1	0.63	4.63	0.43	1.15e-5	Red blood cell count;
THYM	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs859767	0.741	rs4954155	chr2:135383504	T/C	cg12500956	chr2:135428796	TMEM163	-0.49	-4.98	-0.46	2.8e-6	Neuroticism;
THYM	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg23428387	chr22:49814324	NA	-0.57	-5.41	-0.49	4.77e-7	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg24250549	chr1:154909240	PMVK	0.77	6.51	0.56	3.49e-9	Prostate cancer;
THYM	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg24397884	chr7:158709396	WDR60	-0.42	-4.87	-0.45	4.51e-6	Height;
THYM	cis	rs17407555	0.606	rs73229818	chr4:10019884	C/T	cg11266682	chr4:10021025	SLC2A9	-0.56	-5.73	-0.51	1.2e-7	Schizophrenia (age at onset);
THYM	cis	rs72829446	0.530	rs4796430	chr17:7401903	A/G	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg05333889	chr7:157238977	NA	-0.47	-4.64	-0.43	1.12e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs6541297	1.000	rs1997947	chr1:230283764	A/G	cg20703242	chr1:230279135	GALNT2	-0.94	-6.24	-0.54	1.2e-8	Coronary artery disease;
THYM	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg13695892	chr22:41940480	POLR3H	-1.01	-8.07	-0.64	2.11e-12	Vitiligo;
THYM	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg04317338	chr11:64019027	PLCB3	0.86	5.95	0.52	4.48e-8	Mean platelet volume;
THYM	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg07936489	chr17:37558343	FBXL20	0.81	5.85	0.51	6.81e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs870825	0.655	rs28604350	chr4:185638723	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs7772486	0.754	rs6932863	chr6:146021255	A/T	cg23711669	chr6:146136114	FBXO30	-0.97	-10.54	-0.73	1.14e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8028313	0.528	rs338361	chr15:68171116	T/C	cg24579218	chr15:68104479	NA	0.77	6.74	0.57	1.21e-9	Obesity;
THYM	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.76	0.44	7.04e-6	Bipolar disorder;
THYM	cis	rs859767	0.679	rs4954158	chr2:135426618	T/C	cg12500956	chr2:135428796	TMEM163	-0.51	-5.31	-0.48	7.1e-7	Neuroticism;
THYM	cis	rs854765	0.647	rs62073573	chr17:17976354	G/A	cg04398451	chr17:18023971	MYO15A	-0.97	-10.07	-0.72	1.19e-16	Total body bone mineral density;
THYM	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg12698349	chr2:225449008	CUL3	1.13	12.54	0.79	7.33e-22	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-4.55	-0.42	1.56e-5	Hemoglobin concentration;
THYM	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg19016782	chr12:123741754	C12orf65	-0.7	-4.59	-0.43	1.35e-5	Neutrophil percentage of white cells;
THYM	cis	rs9677476	1.000	rs12621280	chr2:232132984	C/G	cg23338755	chr2:231921595	PSMD1	0.66	4.73	0.44	7.83e-6	Food antigen IgG levels;
THYM	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.23	9.82	0.71	4.08e-16	Platelet count;
THYM	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg17775962	chr7:1200435	ZFAND2A	0.51	5.74	0.51	1.11e-7	Longevity;Endometriosis;
THYM	cis	rs12291225	0.645	rs3763950	chr11:14278049	T/A	cg19336497	chr11:14380999	RRAS2	-0.82	-9.58	-0.7	1.34e-15	Sense of smell;
THYM	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg20295408	chr7:1910781	MAD1L1	-0.72	-5.8	-0.51	8.65e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg06064525	chr11:970664	AP2A2	-0.35	-6.68	-0.57	1.63e-9	Alzheimer's disease (late onset);
THYM	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg05234568	chr11:5960015	NA	-0.59	-4.75	-0.44	7.28e-6	DNA methylation (variation);
THYM	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg08885076	chr2:99613938	TSGA10	0.7	6.51	0.56	3.59e-9	Chronic sinus infection;
THYM	cis	rs6919534	0.850	rs9380500	chr6:35266231	G/C	cg05593667	chr6:35490744	NA	0.5	4.71	0.43	8.53e-6	Height;
THYM	cis	rs78761021	0.867	rs17676067	chr17:9791375	C/T	cg26853458	chr17:9805074	RCVRN	-0.52	-4.65	-0.43	1.08e-5	Type 2 diabetes;
THYM	trans	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg24112000	chr20:60950667	NA	-0.83	-6.81	-0.57	8.76e-10	Colorectal cancer;
THYM	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs922692	1.000	rs4887077	chr15:78978364	A/G	cg15571903	chr15:79123663	NA	0.56	5.05	0.46	2.09e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs9296092	0.538	rs56205713	chr6:33517510	A/G	cg13560919	chr6:33536144	NA	-0.94	-9.16	-0.68	1.03e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg12963246	chr6:28129442	ZNF389	0.72	6.2	0.54	1.44e-8	Parkinson's disease;
THYM	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.65	-5.42	-0.49	4.47e-7	Blood metabolite levels;
THYM	cis	rs10929159	0.928	rs6431419	chr2:236919669	C/A	cg14895183	chr2:236924282	AGAP1	0.52	4.51	0.42	1.88e-5	Parkinson's disease;
THYM	cis	rs9880211	1.000	rs9818056	chr3:136210074	C/T	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg14345882	chr6:26364793	BTN3A2	0.56	4.45	0.42	2.36e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg14768367	chr16:72042858	DHODH	0.67	5.27	0.48	8.41e-7	Fibrinogen levels;
THYM	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs890749	1.000	rs890749	chr5:121436596	C/T	cg05256605	chr5:121412184	LOX	-0.57	-4.52	-0.42	1.8e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg26384229	chr12:38710491	ALG10B	-0.7	-5.46	-0.49	3.75e-7	Morning vs. evening chronotype;
THYM	cis	rs7560272	0.723	rs1083919	chr2:73713863	C/G	cg19565262	chr2:73869966	NAT8	0.56	4.76	0.44	7.01e-6	Schizophrenia;
THYM	cis	rs13256369	0.950	rs13255655	chr8:8577736	C/T	cg18904891	chr8:8559673	CLDN23	0.64	4.62	0.43	1.2e-5	Obesity-related traits;
THYM	cis	rs514406	0.698	rs11206043	chr1:53402552	C/T	cg16325326	chr1:53192061	ZYG11B	0.69	5.72	0.51	1.21e-7	Monocyte count;
THYM	cis	rs6430585	0.702	rs1042712	chr2:136545844	C/G	cg04750100	chr2:136595281	LCT	-0.53	-4.89	-0.45	4.17e-6	Corneal structure;
THYM	cis	rs250585	0.736	rs540719	chr16:23456578	T/C	cg00143387	chr16:23521605	GGA2	0.76	5.43	0.49	4.26e-7	Egg allergy;
THYM	cis	rs28795989	0.862	rs28464089	chr4:7889957	C/A	cg12728606	chr4:7903970	AFAP1	0.44	4.62	0.43	1.22e-5	Intraocular pressure;
THYM	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg08000102	chr2:233561755	GIGYF2	0.69	6.17	0.53	1.69e-8	Coronary artery disease;
THYM	cis	rs10744422	0.858	rs2292136	chr12:123339344	A/G	cg25930673	chr12:123319894	HIP1R	-0.86	-4.84	-0.44	5.09e-6	Schizophrenia;
THYM	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg07579946	chr22:19949893	COMT	0.43	4.98	0.46	2.83e-6	Blood metabolite levels;
THYM	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg26384229	chr12:38710491	ALG10B	-1.03	-9.96	-0.71	2.03e-16	Heart rate;
THYM	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg00852783	chr1:26633632	UBXN11	0.86	8.81	0.67	5.74e-14	Obesity-related traits;
THYM	cis	rs1461503	0.966	rs7113725	chr11:122843511	G/T	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.08	-7.53	-0.61	2.9100000000000002e-11	Body mass index;
THYM	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg06784218	chr1:46089804	CCDC17	-0.32	-4.82	-0.44	5.41e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg14008862	chr17:28927542	LRRC37B2	0.93	5.14	0.47	1.48e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7830933	0.780	rs6983481	chr8:23609009	G/T	cg04349084	chr8:23602677	NA	0.6	6.54	0.56	3.02e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs7084402	0.967	rs1658496	chr10:60279909	G/A	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs6430585	0.583	rs1435577	chr2:136624947	C/G	cg04750100	chr2:136595281	LCT	0.57	5.29	0.48	7.86e-7	Corneal structure;
THYM	trans	rs2562456	1.000	rs2359155	chr19:21671869	C/A	cg22241504	chr17:3539680	CTNS;SHPK	0.87	6.99	0.58	3.86e-10	Pain;
THYM	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs596169	0.655	rs596820	chr1:219143806	A/G	cg19270308	chr1:218458869	RRP15	1.24	4.52	0.42	1.81e-5	Intraocular pressure;
THYM	cis	rs6558530	0.730	rs13256424	chr8:1725004	G/A	cg09410841	chr8:1729607	CLN8	0.8	5.92	0.52	5.15e-8	Systolic blood pressure;
THYM	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.5	-5.96	-0.52	4.33e-8	Longevity;Endometriosis;
THYM	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg05738196	chr6:26577821	NA	-0.95	-9.51	-0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.92	5.12	0.46	1.6e-6	Initial pursuit acceleration;
THYM	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	4.64	0.43	1.1e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10751667	0.961	rs10794358	chr11:985547	C/T	cg01483505	chr11:975446	AP2A2	0.63	4.9	0.45	4.01e-6	Alzheimer's disease (late onset);
THYM	cis	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs1395	0.778	rs12465084	chr2:27414203	G/C	cg23587288	chr2:27483067	SLC30A3	-0.61	-5.35	-0.48	6.12e-7	Blood metabolite levels;
THYM	cis	rs7107174	1.000	rs2511169	chr11:77965321	T/C	cg19901956	chr11:77921274	USP35	-0.7	-5.37	-0.48	5.53e-7	Testicular germ cell tumor;
THYM	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg01579765	chr21:45077557	HSF2BP	-0.49	-7.89	-0.63	5.01e-12	Mean corpuscular volume;
THYM	cis	rs7119	0.651	rs34829483	chr15:77835986	C/T	cg10437265	chr15:77819839	NA	0.79	7.92	0.63	4.38e-12	Type 2 diabetes;
THYM	cis	rs7107174	1.000	rs2511168	chr11:77965081	T/G	cg19901956	chr11:77921274	USP35	-0.74	-5.74	-0.51	1.14e-7	Testicular germ cell tumor;
THYM	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg03295274	chr13:50190584	NA	0.69	5.19	0.47	1.18e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17443541	0.507	rs6435020	chr2:200448356	C/T	cg01795955	chr2:200468626	NA	-0.72	-4.77	-0.44	6.76e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6674970	0.518	rs6587552	chr1:151018861	C/T	cg03258749	chr1:151040405	MLLT11	0.62	5.87	0.52	6.36e-8	Childhood ear infection;
THYM	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg11764359	chr7:65958608	NA	-0.74	-6.02	-0.53	3.33e-8	Aortic root size;
THYM	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg02153584	chr22:29168773	CCDC117	0.59	4.57	0.42	1.46e-5	Lymphocyte counts;
THYM	cis	rs4988958	0.565	rs1420100	chr2:103037002	C/A	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma (childhood onset);
THYM	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg19897017	chr7:2163380	MAD1L1	0.43	4.46	0.42	2.22e-5	Schizophrenia;
THYM	cis	rs7195287	0.826	rs9925824	chr16:2827973	C/T	cg05687563	chr16:2837658	PRSS33	-0.55	-4.61	-0.43	1.25e-5	Eosinophil counts;
THYM	cis	rs9649465	1.000	rs608447	chr7:123395983	A/G	cg15443791	chr7:124364398	NA	-0.59	-4.98	-0.45	2.86e-6	Migraine;
THYM	cis	rs804292	0.803	rs8191598	chr8:11635616	A/G	cg26752888	chr8:11627280	NEIL2	1.23	8.57	0.66	1.85e-13	Alcohol dependence;Nicotine use;
THYM	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg11764359	chr7:65958608	NA	-0.69	-4.67	-0.43	9.75e-6	Aortic root size;
THYM	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg15744005	chr10:104629667	AS3MT	-0.76	-7.03	-0.58	3.13e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg07061783	chr6:25882402	NA	-0.71	-5.2	-0.47	1.15e-6	Intelligence (multi-trait analysis);
THYM	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg16624210	chr5:671434	TPPP	0.64	6.66	0.56	1.76e-9	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.59	-11.2	-0.75	4.73e-19	Hemostatic factors and hematological phenotypes;
THYM	cis	rs17253792	0.822	rs79807559	chr14:56108117	G/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg09455208	chr3:40491958	NA	0.46	4.92	0.45	3.65e-6	Renal cell carcinoma;
THYM	cis	rs9361491	0.578	rs1180826	chr6:79434602	C/G	cg04547799	chr6:79944526	HMGN3	-0.66	-4.88	-0.45	4.34e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg12560992	chr17:57184187	TRIM37	0.93	8.88	0.67	4.06e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2237457	0.543	rs2329487	chr7:50702520	T/C	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.48e-6	Schizophrenia (treatment resistant);
THYM	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-5.97	-0.52	4.14e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	6.29	0.54	9.84e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg07157834	chr1:205819609	PM20D1	-0.6	-4.66	-0.43	1.02e-5	Menarche (age at onset);
THYM	cis	rs10140922	0.966	rs28589517	chr14:35820643	G/A	cg07166546	chr14:35805898	NA	-0.26	-6.37	-0.55	6.73e-9	Hip circumference adjusted for BMI;
THYM	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg02038168	chr22:39784481	NA	-0.63	-4.81	-0.44	5.57e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs10493773	0.609	rs12097932	chr1:86182216	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.59	-9.23	-0.69	7.42e-15	Urate levels in overweight individuals;
THYM	cis	rs2976388	0.590	rs3758082	chr8:143824483	A/G	cg06565975	chr8:143823917	SLURP1	-0.61	-7.51	-0.61	3.22e-11	Urinary tract infection frequency;
THYM	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs1056053	0.514	rs3127334	chr6:166574246	G/A	cg11088901	chr6:166572345	T	-0.58	-5.01	-0.46	2.5e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.69	0.74	5.59e-18	Chronic sinus infection;
THYM	cis	rs2302729	0.545	rs10161275	chr12:2771018	A/G	cg19945202	chr12:2788847	CACNA1C	-0.69	-5.18	-0.47	1.26e-6	Sleep quality;
THYM	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.65	4.67	0.43	1.01e-5	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6754311	0.552	rs1030765	chr2:136553188	A/T	cg07169764	chr2:136633963	MCM6	-0.65	-5.81	-0.51	8.22e-8	Mosquito bite size;
THYM	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg13397359	chr6:42928475	GNMT	0.61	5.42	0.49	4.58e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6060717	0.702	rs6060756	chr20:34608479	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.68	4.98	0.45	2.87e-6	Hip circumference adjusted for BMI;
THYM	cis	rs9611519	1.000	rs9611510	chr22:41569124	T/C	cg06481639	chr22:41940642	POLR3H	-0.72	-5.25	-0.47	9.4e-7	Neuroticism;
THYM	cis	rs2625529	0.652	rs2957745	chr15:72288077	T/C	cg16672083	chr15:72433130	SENP8	0.5	4.5	0.42	1.92e-5	Red blood cell count;
THYM	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.15	8.29	0.65	7.25e-13	Cognitive test performance;
THYM	cis	rs924712	0.547	rs239794	chr6:54802375	C/T	cg19716238	chr6:54711378	FAM83B	-0.43	-4.64	-0.43	1.12e-5	Breast cancer;
THYM	cis	rs7843479	0.544	rs7839925	chr8:21792983	G/C	cg17168535	chr8:21777572	XPO7	0.86	7.59	0.61	2.13e-11	Mean corpuscular volume;
THYM	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg04362960	chr10:104952993	NT5C2	0.58	4.7	0.43	8.72e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs3820068	0.608	rs12734937	chr1:16047726	T/C	cg24675056	chr1:15929824	NA	0.78	6.16	0.53	1.73e-8	Systolic blood pressure;
THYM	cis	rs6733011	0.531	rs13004923	chr2:99497561	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.52	-4.69	-0.43	9.32e-6	Bipolar disorder;
THYM	cis	rs4589258	0.933	rs7102324	chr11:90396116	T/C	cg26138821	chr11:89956704	CHORDC1	0.71	6.0	0.52	3.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6430585	0.528	rs115553816	chr2:136692893	G/A	cg20242066	chr2:136595261	LCT	0.56	5.2	0.47	1.14e-6	Corneal structure;
THYM	trans	rs4866334	1.000	rs116499870	chr5:18479009	G/A	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg17366294	chr4:99064904	C4orf37	0.54	6.05	0.53	2.81e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs6499129	1.000	rs8047159	chr16:67453634	T/A	cg03615565	chr16:67572595	FAM65A	0.47	4.6	0.43	1.32e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg23989207	chr17:80870107	TBCD	0.6	4.97	0.45	3.02e-6	Glycated hemoglobin levels;
THYM	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg22920501	chr2:26401640	FAM59B	-0.83	-7.3	-0.6	8.69e-11	Gut microbiome composition (summer);
THYM	cis	rs17016200	0.513	rs73107737	chr3:78368350	A/G	cg24512093	chr3:78698151	ROBO1	0.95	5.24	0.47	9.53e-7	Facial emotion recognition;
THYM	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg24531977	chr5:56204891	C5orf35	-1.01	-8.29	-0.65	7.47e-13	Initial pursuit acceleration;
THYM	cis	rs6964587	0.692	rs2299233	chr7:91626953	C/T	cg22709100	chr7:91322751	NA	-0.61	-4.57	-0.42	1.44e-5	Breast cancer;
THYM	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg03684893	chr10:554711	DIP2C	-0.63	-5.54	-0.49	2.66e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg02734326	chr4:10020555	SLC2A9	0.77	7.16	0.59	1.73e-10	Bone mineral density;
THYM	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg20887711	chr4:1340912	KIAA1530	0.68	5.88	0.52	5.96e-8	Longevity;
THYM	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg24324837	chr19:49891574	CCDC155	0.66	6.33	0.54	8.23e-9	Multiple sclerosis;
THYM	cis	rs10744422	0.858	rs12426809	chr12:123327143	C/T	cg25930673	chr12:123319894	HIP1R	-0.88	-5.15	-0.47	1.43e-6	Schizophrenia;
THYM	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg05802129	chr4:122689817	NA	-0.59	-4.65	-0.43	1.08e-5	Type 2 diabetes;
THYM	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg22947322	chr17:47091978	IGF2BP1	-0.63	-6.49	-0.55	3.94e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7000551	0.751	rs2449341	chr8:22390937	C/A	cg12081754	chr8:22256438	SLC39A14	0.69	6.18	0.54	1.56e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs6570726	0.791	rs12208812	chr6:145900924	T/G	cg13319975	chr6:146136371	FBXO30	-0.64	-5.22	-0.47	1.03e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg12573674	chr2:1569213	NA	-1.22	-4.82	-0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg06917634	chr15:78832804	PSMA4	-0.82	-7.22	-0.6	1.3e-10	Sudden cardiac arrest;
THYM	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg05283184	chr6:79620031	NA	-0.92	-9.11	-0.68	1.3e-14	Intelligence (multi-trait analysis);
THYM	cis	rs612683	0.517	rs3767832	chr1:100943100	A/G	cg09408571	chr1:101003634	GPR88	-0.39	-4.52	-0.42	1.77e-5	Breast cancer;
THYM	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg20295408	chr7:1910781	MAD1L1	-0.73	-5.98	-0.52	3.93e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg08305652	chr11:111469057	NA	0.53	4.54	0.42	1.62e-5	Primary sclerosing cholangitis;
THYM	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs752010	0.967	rs4083593	chr1:42099583	A/G	cg22486000	chr1:42919398	ZMYND12	-0.41	-4.62	-0.43	1.23e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs4849845	0.889	rs4241156	chr2:121031695	C/T	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg07022442	chr13:21864356	NA	0.7	4.64	0.43	1.12e-5	White matter hyperintensity burden;
THYM	cis	rs1218582	0.741	rs705094	chr1:154917314	G/A	cg03351412	chr1:154909251	PMVK	0.62	4.62	0.43	1.21e-5	Prostate cancer;
THYM	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg07690219	chr3:49449608	TCTA;RHOA	0.67	4.49	0.42	1.98e-5	Menarche (age at onset);
THYM	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	15.61	0.85	5.73e-28	Chronic sinus infection;
THYM	cis	rs5758511	0.680	rs5758662	chr22:42628088	T/C	cg22189786	chr22:42395067	WBP2NL	0.58	5.11	0.46	1.66e-6	Birth weight;
THYM	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg13615516	chr5:77269221	NA	0.85	7.82	0.63	7.07e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg21475434	chr5:93447410	FAM172A	0.95	5.98	0.52	3.97e-8	Diabetic retinopathy;
THYM	cis	rs17006441	0.932	rs6778747	chr3:69869653	A/G	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg06112835	chr11:68658793	MRPL21	0.44	6.24	0.54	1.23e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs990171	1.000	rs1468791	chr2:103092021	A/G	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.07	-0.46	1.96e-6	Lymphocyte counts;
THYM	cis	rs72827839	0.744	rs16956892	chr17:46523919	C/G	cg23391107	chr17:45924227	SP6	0.86	5.55	0.5	2.54e-7	Ease of getting up in the morning;
THYM	cis	rs28595532	0.920	rs55869953	chr4:119751893	T/C	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg09517075	chr8:22133004	PIWIL2	0.64	5.7	0.51	1.32e-7	Hypertriglyceridemia;
THYM	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg16325326	chr1:53192061	ZYG11B	-0.9	-9.02	-0.68	2.08e-14	Monocyte count;
THYM	cis	rs1981331	0.609	rs7283588	chr21:48059038	T/C	cg23283320	chr21:48055893	PRMT2	1.55	7.43	0.61	4.71e-11	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs72949976	0.606	rs2178756	chr2:214031423	A/G	cg08319019	chr2:214017104	IKZF2	0.77	6.51	0.56	3.54e-9	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg16506815	chr2:162101123	NA	0.72	5.84	0.51	7.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg05283184	chr6:79620031	NA	-1.01	-9.47	-0.7	2.22e-15	Intelligence (multi-trait analysis);
THYM	cis	rs6768930	0.509	rs7649133	chr3:57771722	A/G	cg24033633	chr3:57945695	NA	-0.38	-5.41	-0.49	4.7e-7	Obesity-related traits;
THYM	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg00814883	chr7:100076585	TSC22D4	-0.96	-6.44	-0.55	4.85e-9	Platelet count;
THYM	cis	rs6121246	0.559	rs10439607	chr20:30258541	G/A	cg13852791	chr20:30311386	BCL2L1	0.87	8.51	0.66	2.54e-13	Mean corpuscular hemoglobin;
THYM	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	7.86	0.63	6.06e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs728616	0.850	rs3889823	chr10:81918362	T/C	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg00383909	chr3:49044727	WDR6	1.27	7.71	0.62	1.22e-11	Cognitive function;
THYM	cis	rs863345	0.564	rs7515245	chr1:158494110	A/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg27572855	chr1:25598939	RHD	0.68	5.25	0.47	9.45e-7	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs524281	0.731	rs2276036	chr11:66033430	C/T	cg00563793	chr11:65837595	PACS1	0.81	4.87	0.45	4.42e-6	Electroencephalogram traits;
THYM	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg04520793	chr17:42248056	ASB16	-0.34	-4.69	-0.43	8.96e-6	Total body bone mineral density;
THYM	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg12560992	chr17:57184187	TRIM37	0.94	8.84	0.67	5.01e-14	Intelligence (multi-trait analysis);
THYM	cis	rs6700896	0.897	rs7518710	chr1:66168238	G/A	cg04111102	chr1:66153794	NA	-0.59	-5.49	-0.49	3.35e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg21231944	chr12:82153410	PPFIA2	-0.61	-4.45	-0.42	2.33e-5	Resting heart rate;
THYM	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs2898681	1.000	rs2003198	chr4:53748583	C/T	cg21521518	chr4:53727714	RASL11B	0.51	5.6	0.5	2.06e-7	Optic nerve measurement (cup area);
THYM	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg06609049	chr19:2785107	THOP1	1.14	11.81	0.77	2.42e-20	Total cholesterol levels;
THYM	cis	rs4845459	0.933	rs11205044	chr1:152593437	T/C	cg26135325	chr1:152595322	LCE3A	-0.45	-5.13	-0.47	1.54e-6	Psoriasis;
THYM	cis	rs13315871	0.722	rs3952239	chr3:58312057	G/T	cg12435725	chr3:58293450	RPP14	-0.49	-5.18	-0.47	1.22e-6	Cholesterol, total;
THYM	cis	rs10927875	0.541	rs761759	chr1:16342350	A/T	cg22431228	chr1:16359049	CLCNKA	-0.53	-5.13	-0.47	1.51e-6	Dilated cardiomyopathy;
THYM	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg20203395	chr5:56204925	C5orf35	-0.65	-4.53	-0.42	1.68e-5	Initial pursuit acceleration;
THYM	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.73	-5.79	-0.51	8.93e-8	Intelligence (multi-trait analysis);
THYM	cis	rs35123781	0.580	rs355163	chr5:138958078	T/C	cg08720517	chr5:138729919	LOC389333	0.56	4.64	0.43	1.13e-5	Schizophrenia;
THYM	cis	rs26232	0.521	rs11958562	chr5:102363061	C/T	cg23492399	chr5:102201601	PAM	-0.67	-5.18	-0.47	1.26e-6	Rheumatoid arthritis;
THYM	cis	rs288326	0.561	rs77318535	chr2:183857319	C/T	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg03060546	chr3:49711283	APEH	0.75	6.08	0.53	2.55e-8	Resting heart rate;
THYM	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs10089	1.000	rs4836360	chr5:127458161	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.02	7.11	0.59	2.11e-10	Ileal carcinoids;
THYM	cis	rs17534004	1.000	rs17534137	chr13:31471920	G/A	cg00367615	chr13:31480979	C13orf33	0.66	4.76	0.44	7.05e-6	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs2637266	0.967	rs10400134	chr10:78365158	G/C	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	trans	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg10856724	chr12:34555212	NA	-0.94	-8.22	-0.64	1.01e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6754311	0.731	rs687670	chr2:136740900	T/C	cg23851026	chr2:136556271	LCT	0.49	4.55	0.42	1.58e-5	Mosquito bite size;
THYM	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg08470875	chr2:26401718	FAM59B	-0.79	-4.73	-0.44	7.85e-6	Gut microbiome composition (summer);
THYM	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg21475434	chr5:93447410	FAM172A	0.99	6.17	0.53	1.66e-8	Diabetic retinopathy;
THYM	cis	rs2075230	0.705	rs2543555	chr17:7548785	A/C	cg10509001	chr17:7553872	ATP1B2	-0.56	-4.52	-0.42	1.79e-5	Hormone measurements;
THYM	cis	rs4901869	0.966	rs12893803	chr14:59329655	T/C	cg02291164	chr14:59296302	NA	0.82	7.72	0.62	1.15e-11	Panic disorder;
THYM	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg24375607	chr4:120327624	NA	0.6	4.53	0.42	1.69e-5	Corneal astigmatism;
THYM	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg07169764	chr2:136633963	MCM6	0.68	5.97	0.52	4.02e-8	Mosquito bite size;
THYM	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg14779329	chr11:130786720	SNX19	0.47	4.94	0.45	3.41e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs7192750	0.586	rs4788576	chr16:71934105	C/T	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs1978968	0.912	rs12157484	chr22:18455122	C/T	cg01550578	chr22:18484421	MICAL3	0.6	4.55	0.42	1.59e-5	Presence of antiphospholipid antibodies;
THYM	cis	rs62103177	0.565	rs473119	chr18:77849459	T/G	cg07235805	chr18:78004237	PARD6G	-0.51	-5.85	-0.51	7.1e-8	Opioid sensitivity;
THYM	cis	rs59698941	0.943	rs4705978	chr5:132245433	C/T	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg18105134	chr13:113819100	PROZ	-1.15	-10.31	-0.73	3.57e-17	Platelet distribution width;
THYM	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg10518543	chr12:38710700	ALG10B	-0.57	-4.58	-0.43	1.4e-5	Morning vs. evening chronotype;
THYM	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg07424592	chr7:64974309	NA	1.16	5.55	0.5	2.55e-7	Diabetic kidney disease;
THYM	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11890956	chr21:40555474	PSMG1	1.15	12.16	0.78	4.51e-21	Cognitive function;
THYM	cis	rs877282	1.000	rs12219807	chr10:772870	A/C	cg10556349	chr10:835070	NA	-0.69	-4.81	-0.44	5.75e-6	Uric acid levels;
THYM	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg08000102	chr2:233561755	GIGYF2	0.68	6.11	0.53	2.16e-8	Coronary artery disease;
THYM	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg19318889	chr4:1322082	MAEA	0.64	5.52	0.49	2.93e-7	Longevity;
THYM	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg13607699	chr17:42295918	UBTF	0.59	4.86	0.45	4.58e-6	Total body bone mineral density;
THYM	cis	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05901451	chr6:126070800	HEY2	-0.55	-4.46	-0.42	2.29e-5	Endometrial cancer;
THYM	cis	rs1497406	0.744	rs7538216	chr1:16509671	T/C	cg20430773	chr1:16534157	ARHGEF19	0.49	5.51	0.49	3.02e-7	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg19507638	chr5:93509721	C5orf36	-0.64	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg08132940	chr7:1081526	C7orf50	-1.16	-6.65	-0.56	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.657	rs10434028	chr4:120294464	T/G	cg24375607	chr4:120327624	NA	0.65	5.42	0.49	4.43e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg11494091	chr17:61959527	GH2	-1.09	-17.19	-0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg21475434	chr5:93447410	FAM172A	0.92	5.45	0.49	4e-7	Diabetic retinopathy;
THYM	cis	rs854765	0.856	rs2955382	chr17:17947710	C/T	cg04398451	chr17:18023971	MYO15A	0.82	7.42	0.61	4.98e-11	Total body bone mineral density;
THYM	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg24399712	chr22:39784796	NA	-0.93	-10.65	-0.74	6.66e-18	Intelligence (multi-trait analysis);
THYM	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.96	-4.58	-0.43	1.41e-5	Alzheimer's disease;
THYM	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg16342193	chr10:102329863	NA	0.57	5.72	0.51	1.21e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg24675056	chr1:15929824	NA	0.73	5.86	0.52	6.71e-8	Systolic blood pressure;
THYM	cis	rs6539288	0.677	rs7315989	chr12:107339788	A/G	cg26297688	chr12:107349093	C12orf23	-0.5	-6.02	-0.53	3.22e-8	Total body bone mineral density;
THYM	cis	rs6541297	0.938	rs7551742	chr1:230290118	A/G	cg20703242	chr1:230279135	GALNT2	1.06	7.03	0.59	3.1e-10	Coronary artery disease;
THYM	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg24308560	chr3:49941425	MST1R	-0.76	-6.48	-0.55	4.12e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.68	-6.19	-0.54	1.5e-8	Total body bone mineral density;
THYM	cis	rs77372450	0.551	rs10866685	chr5:157104711	G/A	cg00312553	chr5:157098553	C5orf52	-0.65	-4.66	-0.43	1.03e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg13695892	chr22:41940480	POLR3H	0.87	6.87	0.58	6.76e-10	Vitiligo;
THYM	cis	rs7616559	0.962	rs9840284	chr3:156734219	G/A	cg15697575	chr3:156784781	NA	0.4	5.03	0.46	2.35e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.57	-4.61	-0.43	1.23e-5	Chronic sinus infection;
THYM	cis	rs1451375	0.617	rs9942686	chr7:50596381	G/A	cg18232548	chr7:50535776	DDC	0.67	5.03	0.46	2.31e-6	Malaria;
THYM	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg26597838	chr10:835615	NA	1.19	8.57	0.66	1.83e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg15445000	chr17:37608096	MED1	-0.44	-5.22	-0.47	1.07e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	5.72	0.51	1.23e-7	Platelet count;
THYM	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19346786	chr7:2764209	NA	-0.75	-6.49	-0.55	3.94e-9	Height;
THYM	cis	rs9611519	1.000	rs6002271	chr22:41566595	C/T	cg03806693	chr22:41940476	POLR3H	-0.84	-6.35	-0.55	7.49e-9	Neuroticism;
THYM	cis	rs10929159	0.928	rs3738993	chr2:236918671	C/T	cg14895183	chr2:236924282	AGAP1	0.54	4.67	0.43	9.73e-6	Parkinson's disease;
THYM	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg26149184	chr10:133730230	NA	0.77	4.65	0.43	1.07e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg14820908	chr5:178986412	RUFY1	0.64	6.95	0.58	4.6e-10	Lung cancer;
THYM	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.97	10.22	0.72	5.61e-17	Chronic sinus infection;
THYM	cis	rs9527	0.668	rs7092815	chr10:104736345	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-4.68	-0.43	9.59e-6	Arsenic metabolism;
THYM	cis	rs2717559	0.522	rs2585159	chr8:143875817	G/A	cg17888033	chr8:143858414	LYNX1	0.47	5.34	0.48	6.24e-7	Urinary tract infection frequency;
THYM	cis	rs2811415	0.597	rs9822021	chr3:127735238	T/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs7072216	0.763	rs6584201	chr10:100170209	T/C	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11890956	chr21:40555474	PSMG1	0.68	5.44	0.49	4.16e-7	Cognitive function;
THYM	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg05283184	chr6:79620031	NA	-0.91	-8.88	-0.67	4.11e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7914558	0.902	rs7092200	chr10:104844872	T/C	cg08772003	chr10:104629869	AS3MT	-0.59	-5.29	-0.48	7.84e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7818345	0.712	rs13261442	chr8:19352333	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.46	4.6	0.43	1.3e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs62435770	1.000	rs9505911	chr6:169543677	C/T	cg07652237	chr6:170125491	PHF10	-0.48	-4.51	-0.42	1.84e-5	Loneliness;
THYM	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg00645579	chr11:617140	IRF7;MUPCDH	-0.47	-6.04	-0.53	3.05e-8	Systemic lupus erythematosus;
THYM	cis	rs3820068	0.705	rs4646075	chr1:15827461	T/C	cg05660106	chr1:15850417	CASP9	1.13	10.23	0.72	5.39e-17	Systolic blood pressure;
THYM	cis	rs9926296	0.687	rs258323	chr16:89754694	G/C	cg01097406	chr16:89675127	NA	0.89	8.32	0.65	6.39e-13	Vitiligo;
THYM	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg06112835	chr11:68658793	MRPL21	0.44	6.35	0.55	7.47e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg06532163	chr17:45867833	NA	0.65	6.58	0.56	2.6e-9	IgG glycosylation;
THYM	cis	rs7631605	0.905	rs9852386	chr3:37222329	G/A	cg21328643	chr3:37258149	NA	-0.53	-5.15	-0.47	1.42e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs514406	0.698	rs11206055	chr1:53436632	A/T	cg25767906	chr1:53392781	SCP2	0.64	6.4	0.55	5.85e-9	Monocyte count;
THYM	cis	rs10411161	0.702	rs11878583	chr19:52388546	C/T	cg25361850	chr19:52391789	ZNF577	-0.74	-5.18	-0.47	1.22e-6	Breast cancer;
THYM	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg13390004	chr1:15929781	NA	0.61	4.63	0.43	1.15e-5	Systolic blood pressure;
THYM	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg05335186	chr13:53173507	NA	-0.41	-4.83	-0.44	5.21e-6	Lewy body disease;
THYM	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg12031863	chr16:4587854	C16orf5	0.42	4.57	0.42	1.47e-5	Schizophrenia;
THYM	cis	rs78707713	0.531	rs12411720	chr10:71192471	T/G	cg08851181	chr10:71228077	TSPAN15	-0.7	-4.6	-0.43	1.31e-5	Venous thromboembolism;
THYM	cis	rs3126085	0.935	rs1496050	chr1:152163549	T/C	cg10321714	chr1:152280068	FLG	0.65	4.72	0.44	8.02e-6	Atopic dermatitis;
THYM	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg24692254	chr21:30365293	RNF160	1.01	9.05	0.68	1.78e-14	Dental caries;
THYM	cis	rs3850699	0.666	rs7905481	chr10:104476292	T/C	cg05855489	chr10:104503620	C10orf26	0.69	5.49	0.49	3.32e-7	Prostate cancer;
THYM	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg13677785	chr22:42548868	NA	-0.56	-4.54	-0.42	1.66e-5	Schizophrenia;
THYM	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg10802521	chr3:52805072	NEK4	-0.81	-7.37	-0.6	6.13e-11	Bipolar disorder;
THYM	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.64	5.07	0.46	1.94e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg01475377	chr6:109611718	NA	0.58	4.86	0.45	4.65e-6	Reticulocyte fraction of red cells;
THYM	cis	rs2235642	0.533	rs9922661	chr16:1605163	C/A	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.53	-5.1	-0.46	1.75e-6	Coronary artery disease;
THYM	cis	rs1823778	0.609	rs7237171	chr18:67635948	C/T	cg12929678	chr18:67624393	CD226	1.3	4.63	0.43	1.14e-5	Mean platelet volume;
THYM	cis	rs782590	0.967	rs11125581	chr2:55796527	C/G	cg18811423	chr2:55921094	PNPT1	0.75	7.07	0.59	2.6e-10	Metabolic syndrome;
THYM	cis	rs9902453	0.934	rs7211246	chr17:28485762	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.83	0.44	5.26e-6	Coffee consumption (cups per day);
THYM	cis	rs9326248	0.530	rs510988	chr11:116813804	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.85	4.58	0.43	1.43e-5	Blood protein levels;
THYM	cis	rs1978968	0.912	rs34156568	chr22:18444261	C/T	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg09640425	chr7:158790006	NA	-0.54	-4.85	-0.45	4.86e-6	Facial morphology (factor 20);
THYM	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22133161	chr19:49891603	CCDC155	0.82	5.5	0.49	3.2e-7	Multiple sclerosis;
THYM	cis	rs7169223	0.653	rs1994017	chr15:79080306	T/C	cg21242079	chr15:79101063	ADAMTS7	0.52	4.76	0.44	7.05e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	6.76	0.57	1.12e-9	Schizophrenia;
THYM	cis	rs920590	0.758	rs17091534	chr8:19670651	C/T	cg01411142	chr8:19674711	INTS10	0.64	5.02	0.46	2.4e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg02136620	chr5:178986620	RUFY1	0.61	5.76	0.51	1.02e-7	Lung cancer;
THYM	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg16049864	chr8:95962084	TP53INP1	-0.65	-5.6	-0.5	2.08e-7	Type 2 diabetes;
THYM	cis	rs9880211	0.898	rs73231903	chr3:136561625	T/A	cg21827317	chr3:136751795	NA	-0.71	-4.84	-0.44	5.12e-6	Body mass index;Height;
THYM	cis	rs9355610	0.609	rs62436424	chr6:167374258	A/G	cg23791538	chr6:167370224	RNASET2	0.75	5.03	0.46	2.36e-6	Graves' disease;
THYM	cis	rs4731207	0.698	rs886704	chr7:124422266	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs12282928	0.959	rs1566737	chr11:48238302	A/C	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs1953600	0.645	rs2819950	chr10:81935279	G/A	cg11900509	chr10:81946545	ANXA11	0.45	4.77	0.44	6.62e-6	Sarcoidosis;
THYM	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.65	0.5	1.64e-7	Tonsillectomy;
THYM	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Gout;
THYM	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg05738196	chr6:26577821	NA	0.95	9.91	0.71	2.53e-16	Intelligence (multi-trait analysis);
THYM	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg02753203	chr1:228287806	NA	0.98	8.36	0.65	5.22e-13	Diastolic blood pressure;
THYM	cis	rs6674176	0.597	rs12127737	chr1:44402565	G/A	cg13246856	chr1:44399776	ARTN	0.52	4.85	0.45	4.79e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs7772486	0.875	rs9376975	chr6:146355581	T/G	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7943203	0.539	rs12226046	chr11:108335940	G/C	cg04873221	chr11:107992290	ACAT1	-0.72	-4.74	-0.44	7.37e-6	Red blood cell count;Mean corpuscular volume;
THYM	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8067545	0.750	rs7208025	chr17:19997870	T/C	cg13482628	chr17:19912719	NA	0.56	4.7	0.43	8.78e-6	Schizophrenia;
THYM	cis	rs9796	0.674	rs6492978	chr15:41317702	T/C	cg21153102	chr15:41252147	NA	0.68	6.08	0.53	2.44e-8	Menopause (age at onset);
THYM	cis	rs7940866	0.834	rs7939417	chr11:130853832	T/A	cg12179176	chr11:130786555	SNX19	0.68	5.15	0.47	1.41e-6	Schizophrenia;
THYM	cis	rs7127900	0.500	rs67798996	chr11:2233603	A/G	cg25635251	chr11:2234043	NA	0.71	5.42	0.49	4.51e-7	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg08807101	chr21:30365312	RNF160	0.96	8.31	0.65	6.73e-13	Dental caries;
THYM	cis	rs1062753	0.961	rs9620007	chr22:42405657	C/G	cg08431931	chr22:42394659	WBP2NL	0.74	6.08	0.53	2.48e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg12863693	chr15:85201151	NMB	0.62	5.39	0.48	5.18e-7	Schizophrenia;
THYM	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs4654899	0.833	rs10916919	chr1:21317524	A/G	cg01072550	chr1:21505969	NA	0.75	6.73	0.57	1.29e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs7131987	0.903	rs7974221	chr12:29399448	A/G	cg09582351	chr12:29534625	ERGIC2	-0.48	-4.66	-0.43	1.03e-5	QT interval;
THYM	trans	rs877282	0.842	rs35117541	chr10:764683	C/T	cg22713356	chr15:30763199	NA	1.36	10.13	0.72	8.77e-17	Uric acid levels;
THYM	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs3862260	0.509	rs10802124	chr1:120164252	G/A	cg11530693	chr1:120165357	ZNF697	1.08	12.42	0.79	1.33e-21	Systemic lupus erythematosus;
THYM	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11644478	chr21:40555479	PSMG1	0.56	4.69	0.43	9.07e-6	Menarche (age at onset);
THYM	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg18402987	chr7:1209562	NA	1.04	6.25	0.54	1.16e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg17264618	chr3:40429014	ENTPD3	0.53	4.93	0.45	3.52e-6	Renal cell carcinoma;
THYM	cis	rs73086581	1.000	rs17286349	chr20:3914302	G/A	cg02187196	chr20:3869020	PANK2	0.5	5.55	0.49	2.63e-7	Response to antidepressants in depression;
THYM	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg23791538	chr6:167370224	RNASET2	-0.7	-5.54	-0.49	2.71e-7	Crohn's disease;
THYM	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg03909863	chr11:638404	DRD4	-0.86	-5.99	-0.52	3.66e-8	Systemic lupus erythematosus;
THYM	cis	rs448720	1.000	rs392452	chr15:68207015	C/T	cg23793686	chr15:68133972	NA	-0.5	-4.63	-0.43	1.17e-5	Cognitive performance;
THYM	cis	rs9677476	0.863	rs10187005	chr2:232077948	C/T	cg07929768	chr2:232055508	NA	0.63	6.39	0.55	6.12e-9	Food antigen IgG levels;
THYM	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg12179176	chr11:130786555	SNX19	0.8	6.85	0.57	7.45e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14159672	chr1:205819179	PM20D1	1.1	11.96	0.78	1.18e-20	Menarche (age at onset);
THYM	cis	rs654950	0.934	rs665223	chr1:42000654	A/T	cg06885757	chr1:42089581	HIVEP3	-0.56	-7.44	-0.61	4.39e-11	Airway imaging phenotypes;
THYM	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg11245990	chr11:68621969	NA	0.56	7.23	0.6	1.2e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs526231	0.543	rs34809	chr5:102430117	C/A	cg23492399	chr5:102201601	PAM	-0.7	-5.18	-0.47	1.23e-6	Primary biliary cholangitis;
THYM	cis	rs245880	0.702	rs245884	chr7:29188475	T/G	cg17163760	chr7:29186267	CPVL	-0.61	-4.92	-0.45	3.59e-6	Warfarin maintenance dose;
THYM	cis	rs7267979	0.966	rs2424715	chr20:25420077	A/G	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg09469691	chr10:81107165	PPIF	0.73	5.92	0.52	5.04e-8	Height;
THYM	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06873352	chr17:61820015	STRADA	0.57	5.68	0.5	1.46e-7	Height;
THYM	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg18305652	chr10:134549665	INPP5A	0.79	6.49	0.55	3.84e-9	Migraine;
THYM	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg23205692	chr1:25664452	TMEM50A	-0.85	-6.62	-0.56	2.13e-9	Erythrocyte sedimentation rate;
THYM	cis	rs2717559	0.622	rs13255523	chr8:143887054	A/G	cg17252645	chr8:143867129	LY6D	-0.67	-7.66	-0.62	1.58e-11	Urinary tract infection frequency;
THYM	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg11812906	chr14:75593930	NEK9	-0.83	-7.48	-0.61	3.63e-11	Height;
THYM	cis	rs7178572	0.568	rs11853460	chr15:77515319	C/T	cg22256960	chr15:77711686	NA	-1.04	-8.57	-0.66	1.83e-13	Type 2 diabetes;
THYM	trans	rs8073060	0.544	rs8072676	chr17:33999517	C/T	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs854765	0.624	rs1889018	chr17:17734740	G/A	cg16928487	chr17:17741425	SREBF1	0.55	5.12	0.47	1.56e-6	Total body bone mineral density;
THYM	cis	rs6754311	0.593	rs12619365	chr2:136398174	C/T	cg23851026	chr2:136556271	LCT	0.59	5.62	0.5	1.91e-7	Mosquito bite size;
THYM	cis	rs8038465	0.622	rs710086	chr15:73877001	C/T	cg15420318	chr15:73925796	NPTN	0.63	5.35	0.48	5.98e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.64	-0.5	1.73e-7	Menopause (age at onset);
THYM	cis	rs308403	0.568	rs309344	chr4:123644812	G/A	cg10495464	chr4:123653540	BBS12;LOC729338	0.68	4.68	0.43	9.39e-6	Blood protein levels;
THYM	cis	rs4285028	0.747	rs7623901	chr3:121529011	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.92	6.85	0.57	7.3e-10	Multiple sclerosis;
THYM	cis	rs61931739	0.658	rs10772149	chr12:34285498	A/G	cg10856724	chr12:34555212	NA	-0.6	-5.26	-0.47	9.06e-7	Morning vs. evening chronotype;
THYM	cis	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg05335186	chr13:53173507	NA	-0.46	-5.86	-0.52	6.6e-8	Lewy body disease;
THYM	cis	rs10911232	0.507	rs4266836	chr1:183029070	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs7428	0.545	rs7572750	chr2:85552186	C/A	cg24342717	chr2:85555507	TGOLN2	-0.79	-6.39	-0.55	6.06e-9	Ear protrusion;
THYM	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg21280719	chr6:42927975	GNMT	-0.52	-7.0	-0.58	3.64e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs2038823	0.579	rs61966904	chr13:96962514	G/T	cg25169784	chr13:96706045	UGGT2	0.85	4.55	0.42	1.58e-5	Diabetic retinopathy;
THYM	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg22709100	chr7:91322751	NA	0.65	4.47	0.42	2.19e-5	Breast cancer;
THYM	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg18681998	chr4:17616180	MED28	1.01	10.48	0.73	1.53e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg26354017	chr1:205819088	PM20D1	0.92	9.08	0.68	1.56e-14	Menarche (age at onset);
THYM	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg27588902	chr6:42928151	GNMT	-0.59	-5.89	-0.52	5.79e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4756059	0.850	rs1907003	chr11:46088495	A/G	cg07713318	chr11:45703478	NA	0.88	4.62	0.43	1.23e-5	Menarche (age at onset);
THYM	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.99	0.58	3.73e-10	Prudent dietary pattern;
THYM	cis	rs6450176	1.000	rs3776718	chr5:53298714	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.14	-0.53	1.94e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg25072359	chr17:41440525	NA	0.64	4.48	0.42	2.05e-5	Menopause (age at onset);
THYM	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg06112835	chr11:68658793	MRPL21	0.45	6.29	0.54	9.72e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg09455208	chr3:40491958	NA	0.5	5.29	0.48	7.67e-7	Renal cell carcinoma;
THYM	cis	rs7589342	0.792	rs13426321	chr2:106500280	G/A	cg14210321	chr2:106509881	NCK2	-0.8	-6.09	-0.53	2.42e-8	Addiction;
THYM	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7582403	0.844	rs2890922	chr2:148886962	G/T	cg23727674	chr2:148602993	ACVR2A	-0.62	-5.11	-0.46	1.69e-6	Neuroticism;
THYM	cis	rs6450176	1.000	rs4588541	chr5:53300640	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.83	-6.19	-0.54	1.54e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs7843479	0.898	rs13282562	chr8:21869727	G/A	cg17168535	chr8:21777572	XPO7	0.65	4.98	0.45	2.85e-6	Mean corpuscular volume;
THYM	cis	rs6430585	0.527	rs57530667	chr2:136444338	A/G	cg07169764	chr2:136633963	MCM6	1.03	9.12	0.68	1.26e-14	Corneal structure;
THYM	cis	rs17443541	0.507	rs4675697	chr2:200450808	C/T	cg03741458	chr2:200468445	NA	-0.8	-5.86	-0.52	6.75e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7607369	0.648	rs7559490	chr2:219656867	A/T	cg02176678	chr2:219576539	TTLL4	-0.6	-5.51	-0.49	3.11e-7	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs7681440	0.606	rs2583983	chr4:90753960	C/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs9326248	0.581	rs10502222	chr11:116833730	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.66	5.39	0.48	5.22e-7	Blood protein levels;
THYM	cis	rs4711350	0.723	rs684119	chr6:33662667	C/T	cg16492833	chr6:33679775	C6orf125	-0.56	-4.63	-0.43	1.15e-5	Schizophrenia;
THYM	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg26850624	chr5:429559	AHRR	0.53	4.5	0.42	1.93e-5	Cystic fibrosis severity;
THYM	cis	rs6087771	0.747	rs6058261	chr20:30235470	C/A	cg13852791	chr20:30311386	BCL2L1	0.86	8.08	0.64	2.03e-12	Subcortical brain region volumes;Putamen volume;
THYM	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.97	8.9	0.67	3.72e-14	Chronic sinus infection;
THYM	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg06766960	chr11:133703094	NA	-0.59	-5.56	-0.5	2.51e-7	Childhood ear infection;
THYM	cis	rs2562456	0.876	rs11668606	chr19:21737420	T/G	cg21751540	chr19:21541537	ZNF738	-0.69	-4.75	-0.44	7.1e-6	Pain;
THYM	cis	rs2625529	0.824	rs11072346	chr15:72400434	G/A	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs2456568	0.803	rs10831142	chr11:93640781	A/G	cg26875233	chr11:93583750	C11orf90	0.54	5.78	0.51	9.51e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	7.66	0.62	1.54e-11	Platelet count;
THYM	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg08017756	chr2:100939284	LONRF2	-0.72	-7.35	-0.6	6.77e-11	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg10047753	chr17:41438598	NA	-0.97	-7.99	-0.63	3.21e-12	Menopause (age at onset);
THYM	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg11494091	chr17:61959527	GH2	-1.04	-20.29	-0.9	2.6e-36	Prudent dietary pattern;
THYM	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg15744005	chr10:104629667	AS3MT	-0.83	-7.78	-0.62	8.71e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2637266	0.714	rs7082421	chr10:78446313	G/A	cg18941641	chr10:78392320	NA	0.77	6.5	0.55	3.77e-9	Pulmonary function;
THYM	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg05342682	chr7:94953680	PON1	-0.57	-6.55	-0.56	2.9e-9	Paraoxonase activity;
THYM	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg11965913	chr1:205819406	PM20D1	0.93	10.13	0.72	8.64e-17	Menarche (age at onset);
THYM	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg03806693	chr22:41940476	POLR3H	-1.0	-8.87	-0.67	4.28e-14	Vitiligo;
THYM	cis	rs7688540	0.713	rs12511388	chr4:297547	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.64	4.87	0.45	4.5e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg26384229	chr12:38710491	ALG10B	1.03	10.33	0.73	3.26e-17	Heart rate;
THYM	cis	rs7408868	0.764	rs45504393	chr19:15277010	A/G	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	6.3	0.54	9.4e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4792901	0.959	rs72833148	chr17:41629163	G/A	cg21940313	chr17:41620911	ETV4	-0.52	-5.51	-0.49	3.08e-7	Dupuytren's disease;
THYM	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg26384229	chr12:38710491	ALG10B	0.99	7.46	0.61	4.12e-11	Bladder cancer;
THYM	cis	rs9563576	0.735	rs9569814	chr13:58666322	C/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.6	4.5	0.42	1.9e-5	Body mass index;
THYM	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg11812906	chr14:75593930	NEK9	-0.83	-7.41	-0.61	5.16e-11	Height;
THYM	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg11335335	chr11:637885	DRD4	-0.63	-5.11	-0.46	1.67e-6	Systemic lupus erythematosus;
THYM	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg02953382	chr22:24373134	LOC391322	-0.72	-6.57	-0.56	2.73e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg13683864	chr3:40499215	RPL14	-1.01	-10.28	-0.73	4.18e-17	Renal cell carcinoma;
THYM	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs7084402	0.967	rs3001717	chr10:60329125	A/G	cg07615347	chr10:60278583	BICC1	0.53	4.98	0.45	2.85e-6	Refractive error;
THYM	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg16049864	chr8:95962084	TP53INP1	-0.75	-6.69	-0.57	1.53e-9	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.69	-5.21	-0.47	1.09e-6	Multiple sclerosis;
THYM	cis	rs17030434	1.000	rs12651051	chr4:154722114	A/G	cg14289246	chr4:154710475	SFRP2	-0.76	-5.24	-0.47	9.79e-7	Electrocardiographic conduction measures;
THYM	cis	rs554111	0.613	rs6699704	chr1:21241432	G/C	cg00373020	chr1:21041521	KIF17	-0.53	-4.47	-0.42	2.14e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.82	5.65	0.5	1.71e-7	Gut microbiome composition (summer);
THYM	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg12826209	chr6:26865740	GUSBL1	0.85	4.68	0.43	9.63e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs904251	0.523	rs12202055	chr6:37486080	A/T	cg25019722	chr6:37503610	NA	-0.57	-4.82	-0.44	5.36e-6	Cognitive performance;
THYM	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22496380	chr5:211416	CCDC127	-1.3	-8.21	-0.64	1.1e-12	Breast cancer;
THYM	cis	rs10979	1.000	rs1416208	chr6:143889241	T/A	cg25407410	chr6:143891975	LOC285740	-0.61	-5.12	-0.46	1.6e-6	Hypospadias;
THYM	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg07424592	chr7:64974309	NA	1.05	5.47	0.49	3.61e-7	Diabetic kidney disease;
THYM	cis	rs2832191	0.967	rs2251377	chr21:30530599	T/C	cg24692254	chr21:30365293	RNF160	0.9	7.83	0.63	6.85e-12	Dental caries;
THYM	cis	rs425277	0.628	rs262662	chr1:2085033	A/G	cg09260853	chr1:2094483	PRKCZ	0.47	4.67	0.43	9.79e-6	Height;
THYM	cis	rs2294693	0.531	rs10947940	chr6:40948496	C/T	cg21128951	chr6:40996213	UNC5CL	0.64	4.59	0.43	1.37e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs652260	0.646	rs693941	chr19:7903851	C/T	cg15974673	chr19:7926970	EVI5L	-0.57	-5.38	-0.48	5.42e-7	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg21110456	chr7:2059412	MAD1L1	-0.44	-4.56	-0.42	1.5e-5	Neuroticism;
THYM	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg15704280	chr7:45808275	SEPT13	1.05	9.7	0.71	7.25e-16	Coronary artery disease;
THYM	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs17030434	1.000	rs12646124	chr4:154718084	G/T	cg14289246	chr4:154710475	SFRP2	-0.83	-5.58	-0.5	2.24e-7	Electrocardiographic conduction measures;
THYM	cis	rs7216064	0.531	rs62084683	chr17:66031725	A/G	cg12091567	chr17:66097778	LOC651250	0.98	8.02	0.64	2.7e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs2188554	0.740	rs6957018	chr7:117210368	C/T	cg21212505	chr7:117228958	CFTR	-0.63	-4.71	-0.44	8.47e-6	Esophageal adenocarcinoma;
THYM	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg15247329	chr7:2764246	NA	-0.71	-5.89	-0.52	5.77e-8	Height;
THYM	cis	rs12928939	0.862	rs7197104	chr16:71794061	C/T	cg03805757	chr16:71968109	PKD1L3	-0.72	-5.51	-0.49	3.1e-7	Post bronchodilator FEV1;
THYM	cis	rs289828	0.895	rs12465426	chr2:152086648	G/A	cg05960677	chr2:152117363	RBM43	-0.63	-6.02	-0.53	3.21e-8	Blood protein levels;
THYM	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-6.27	-0.54	1.08e-8	Mood instability;
THYM	cis	rs6840360	0.615	rs12647586	chr4:152607568	G/C	cg22705602	chr4:152727874	NA	-0.81	-10.62	-0.74	7.82e-18	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg24375607	chr4:120327624	NA	0.62	4.72	0.44	8.23e-6	Corneal astigmatism;
THYM	cis	rs62051538	0.602	rs7202020	chr16:31537655	G/A	cg10091996	chr16:31548640	NA	-0.5	-4.5	-0.42	1.96e-5	Mean corpuscular hemoglobin;
THYM	cis	rs9534288	0.699	rs2146886	chr13:46646711	C/T	cg15192986	chr13:46630673	CPB2	-0.65	-4.59	-0.43	1.36e-5	Blood protein levels;
THYM	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.22	-0.47	1.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3096299	0.866	rs4238829	chr16:89462262	G/A	cg10452248	chr16:89456354	ANKRD11	0.65	5.26	0.48	8.79e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs735539	1.000	rs3000676	chr13:21286442	A/T	cg02792322	chr13:21280448	IL17D	-0.7	-5.28	-0.48	8.04e-7	Dental caries;
THYM	cis	rs12529514	1.000	rs6932936	chr6:14115090	A/AT	cg11874760	chr6:14118415	CD83	0.76	5.1	0.46	1.74e-6	Rheumatoid arthritis;
THYM	cis	rs1018836	0.892	rs10103198	chr8:91579436	A/T	cg16814680	chr8:91681699	NA	-0.75	-6.24	-0.54	1.2e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-5.41	-0.49	4.61e-7	Vitiligo;
THYM	cis	rs7592578	0.771	rs62181034	chr2:191354963	C/A	cg21644426	chr2:191273491	MFSD6	-0.69	-4.78	-0.44	6.39e-6	Diastolic blood pressure;
THYM	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg02887458	chr19:19495540	GATAD2A	0.46	5.1	0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs7772486	0.688	rs1884364	chr6:146337817	C/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.78	-0.51	9.37e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.65	0.62	1.67e-11	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs10779751	0.726	rs1205593	chr1:11252716	T/C	cg08854313	chr1:11322531	MTOR	0.7	5.36	0.48	5.72e-7	Body mass index;
THYM	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.89	0.45	4.16e-6	Prudent dietary pattern;
THYM	cis	rs62045844	0.536	rs9940965	chr16:89180664	C/G	cg06035645	chr16:89190857	ACSF3	-0.89	-5.52	-0.49	2.88e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg18105134	chr13:113819100	PROZ	-0.98	-9.0	-0.68	2.28e-14	Platelet distribution width;
THYM	cis	rs74417235	0.673	rs6873342	chr5:154051835	A/G	cg25588787	chr5:154027256	NA	-0.95	-4.95	-0.45	3.24e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	trans	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.68	-6.85	-0.57	7.29e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9522267	1.000	rs1411628	chr13:112199321	G/A	cg10483660	chr13:112241077	NA	-0.5	-4.98	-0.46	2.83e-6	Hepatitis;
THYM	cis	rs7772486	0.902	rs2748500	chr6:146314852	C/A	cg23711669	chr6:146136114	FBXO30	0.88	8.89	0.67	3.82e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg08999081	chr20:33150536	PIGU	-0.6	-5.46	-0.49	3.78e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	trans	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg23505145	chr19:12996616	KLF1	1.01	10.01	0.72	1.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg06115741	chr20:33292138	TP53INP2	-0.74	-4.91	-0.45	3.83e-6	Coronary artery disease;
THYM	cis	rs7937	0.870	rs7252227	chr19:41301115	G/T	cg21869046	chr19:41225005	ITPKC	-0.34	-4.82	-0.44	5.45e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Chronic obstructive pulmonary disease;Emphysema imaging phenotypes;
THYM	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg22166914	chr1:53195759	ZYG11B	-0.96	-11.92	-0.77	1.4e-20	Monocyte count;
THYM	cis	rs4631830	0.720	rs113082846	chr10:51502802	G/C	cg16070123	chr10:51489643	NA	-0.53	-4.91	-0.45	3.71e-6	Prostate-specific antigen levels;
THYM	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg08999081	chr20:33150536	PIGU	-0.77	-6.95	-0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs6032067	1.000	rs6032065	chr20:43855649	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.45	-0.55	4.56e-9	Blood protein levels;
THYM	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs4731207	0.596	rs1525612	chr7:124684047	G/C	cg05285228	chr7:124571219	POT1	-0.63	-4.74	-0.44	7.37e-6	Cutaneous malignant melanoma;
THYM	cis	rs7589342	0.899	rs10185551	chr2:106492201	A/C	cg14210321	chr2:106509881	NCK2	-0.76	-5.84	-0.51	7.27e-8	Addiction;
THYM	cis	rs6693295	0.536	rs55912974	chr1:246225155	C/T	cg11798871	chr1:246315928	SMYD3	-0.78	-4.71	-0.43	8.52e-6	Migraine - clinic-based;Migraine with aura;
THYM	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg12000587	chr17:30186630	C17orf79	0.45	6.86	0.58	7.08e-10	Hip circumference adjusted for BMI;
THYM	cis	rs2455799	0.613	rs2470542	chr3:15724133	A/C	cg16303742	chr3:15540471	COLQ	-0.54	-5.48	-0.49	3.44e-7	Mean platelet volume;
THYM	cis	rs4273100	0.512	rs973650	chr17:19291785	A/G	cg25447019	chr17:19030144	GRAPL	0.75	5.86	0.52	6.62e-8	Schizophrenia;
THYM	cis	rs6032067	0.714	rs6094110	chr20:43864889	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.66	-7.59	-0.61	2.22e-11	Blood protein levels;
THYM	cis	rs868036	0.718	rs28675295	chr15:68116400	C/A	cg24579218	chr15:68104479	NA	-0.8	-8.27	-0.65	8.25e-13	Restless legs syndrome;
THYM	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg24675056	chr1:15929824	NA	0.74	6.15	0.53	1.85e-8	Systolic blood pressure;
THYM	cis	rs3126085	0.935	rs2184950	chr1:152272776	T/C	cg10321714	chr1:152280068	FLG	-0.67	-5.12	-0.46	1.62e-6	Atopic dermatitis;
THYM	cis	rs4499344	0.589	rs259218	chr19:33138125	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.81	5.52	0.49	2.94e-7	Mean platelet volume;
THYM	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2066819	1.000	rs79436528	chr12:56686997	C/T	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs1799949	0.832	rs2070835	chr17:41174025	A/C	cg10047753	chr17:41438598	NA	1.15	10.14	0.72	8.28e-17	Menopause (age at onset);
THYM	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg03235661	chr20:60525775	NA	-0.53	-4.52	-0.42	1.75e-5	Obesity-related traits;
THYM	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg10523679	chr1:76189770	ACADM	-0.83	-6.52	-0.56	3.44e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4731207	0.541	rs6960027	chr7:124543011	G/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs11225247	0.772	rs11225222	chr11:102230129	T/A	cg11690896	chr11:102217788	BIRC2	1.12	5.18	0.47	1.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs4563143	0.502	rs73029061	chr19:29283980	T/A	cg14983838	chr19:29218262	NA	1.09	8.97	0.68	2.58e-14	Methadone dose in opioid dependence;
THYM	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs754466	0.651	rs11002322	chr10:79649653	G/T	cg17075019	chr10:79541650	NA	-0.65	-5.3	-0.48	7.61e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg24818145	chr4:99064322	C4orf37	0.69	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg09455208	chr3:40491958	NA	0.45	4.7	0.43	8.76e-6	Renal cell carcinoma;
THYM	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg22875332	chr1:76189707	ACADM	0.78	7.32	0.6	8.09e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.75	6.41	0.55	5.65e-9	Lymphocyte percentage of white cells;
THYM	cis	rs7584330	0.784	rs6724766	chr2:238413600	A/G	cg16989719	chr2:238392110	NA	-0.66	-6.08	-0.53	2.53e-8	Prostate cancer;
THYM	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-6.11	-0.53	2.19e-8	Total body bone mineral density;
THYM	cis	rs596169	0.655	rs6696616	chr1:219169426	G/T	cg19270308	chr1:218458869	RRP15	-1.24	-4.52	-0.42	1.81e-5	Intraocular pressure;
THYM	cis	rs2262909	0.548	rs7249672	chr19:22301523	C/T	cg08394602	chr19:22123885	NA	-0.48	-4.51	-0.42	1.83e-5	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
THYM	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-8.1	-0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs9361491	0.608	rs4706072	chr6:79475491	G/A	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.88e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1371867	0.875	rs1371868	chr8:101330267	C/T	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs4666002	0.917	rs4666000	chr2:27839369	T/C	cg27432699	chr2:27873401	GPN1	0.58	4.56	0.42	1.53e-5	Phospholipid levels (plasma);
THYM	cis	rs3091242	0.935	rs3093632	chr1:25684012	C/T	cg00786635	chr1:25594202	NA	0.92	7.29	0.6	9.36e-11	Erythrocyte sedimentation rate;
THYM	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg22709100	chr7:91322751	NA	-0.59	-4.65	-0.43	1.08e-5	Breast cancer;
THYM	cis	rs289828	0.519	rs13020769	chr2:152153552	G/A	cg05960677	chr2:152117363	RBM43	0.69	6.54	0.56	3.11e-9	Blood protein levels;
THYM	cis	rs6598541	0.963	rs2137683	chr15:99289638	C/G	cg13297560	chr15:99320054	IGF1R	0.46	4.77	0.44	6.66e-6	Urate levels;
THYM	cis	rs738321	0.701	rs2413506	chr22:38593128	T/C	cg25457927	chr22:38595422	NA	-0.62	-5.78	-0.51	9.45e-8	Breast cancer;
THYM	cis	rs858239	0.730	rs858289	chr7:23248158	C/T	cg18081818	chr7:23246105	NA	-0.6	-5.43	-0.49	4.39e-7	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03517284	chr6:25882590	NA	1.06	10.0	0.72	1.63e-16	Blood metabolite levels;
THYM	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg13114125	chr14:105738426	BRF1	-0.77	-6.17	-0.53	1.67e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1983170	1.000	rs1983170	chr1:91986482	G/A	cg02896835	chr1:92012615	NA	0.63	4.61	0.43	1.24e-5	Eosinophil percentage of white cells;
THYM	cis	rs654128	0.640	rs339335	chr6:117213995	A/G	cg12892004	chr6:117198278	RFX6	0.72	5.66	0.5	1.61e-7	Telomere length;
THYM	cis	rs2073300	0.609	rs6137914	chr20:23358364	C/T	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.6	-4.62	-0.43	1.22e-5	Eosinophil percentage of white cells;
THYM	cis	rs616402	0.527	rs589151	chr1:10567711	C/T	cg20482658	chr1:10539492	PEX14	-0.34	-4.94	-0.45	3.29e-6	Breast size;
THYM	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.65	4.79	0.44	6.09e-6	Glycated hemoglobin levels;
THYM	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg17554472	chr22:41940697	POLR3H	-0.75	-5.12	-0.46	1.61e-6	Vitiligo;
THYM	cis	rs10979	1.000	rs9484767	chr6:143887912	C/A	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs5769707	0.706	rs763128	chr22:50018045	G/A	cg20744362	chr22:50050164	C22orf34	0.81	7.22	0.6	1.25e-10	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7799006	0.606	rs12535174	chr7:2310974	C/T	cg08027265	chr7:2291960	NA	-0.42	-5.04	-0.46	2.25e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg06558623	chr16:89946397	TCF25	1.33	5.65	0.5	1.64e-7	Skin colour saturation;
THYM	cis	rs28829049	0.597	rs34215816	chr1:19433953	G/A	cg13387374	chr1:19411106	UBR4	0.67	4.96	0.45	3.08e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs6987853	0.814	rs2923411	chr8:42455206	T/C	cg09913449	chr8:42400586	C8orf40	0.95	9.53	0.7	1.64e-15	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg27446573	chr6:127587934	RNF146	1.04	9.87	0.71	3.12e-16	Breast cancer;
THYM	cis	rs11096990	0.892	rs4974924	chr4:39197711	T/A	cg24403649	chr4:39172243	NA	-0.65	-5.47	-0.49	3.69e-7	Cognitive function;
THYM	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg02136620	chr5:178986620	RUFY1	0.56	5.72	0.51	1.24e-7	Lung cancer;
THYM	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7731657	0.559	rs2079209	chr5:130354909	A/G	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs752010	0.715	rs11807117	chr1:42101206	C/T	cg06885757	chr1:42089581	HIVEP3	0.75	10.32	0.73	3.46e-17	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs806215	1.000	rs2106186	chr7:127241352	G/C	cg08586737	chr7:127225949	GCC1	0.37	4.59	0.43	1.34e-5	Type 2 diabetes;
THYM	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg06917634	chr15:78832804	PSMA4	0.96	8.76	0.67	7.4e-14	Sudden cardiac arrest;
THYM	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg25036284	chr2:26402008	FAM59B	-0.76	-5.09	-0.46	1.82e-6	Gut microbiome composition (summer);
THYM	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg03709012	chr19:19516395	GATAD2A	0.84	7.23	0.6	1.23e-10	Tonsillectomy;
THYM	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11890956	chr21:40555474	PSMG1	-0.68	-6.42	-0.55	5.42e-9	Menarche (age at onset);
THYM	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	ch.11.42038R	chr11:967971	AP2A2	0.59	4.69	0.43	9.28e-6	Alzheimer's disease (late onset);
THYM	cis	rs2456568	0.531	rs7105060	chr11:93661268	C/A	cg17595323	chr11:93583763	C11orf90	-0.52	-5.52	-0.49	2.98e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs662064	0.962	rs596537	chr1:10554709	G/T	cg20482658	chr1:10539492	PEX14	-0.47	-5.99	-0.52	3.75e-8	Asthma;
THYM	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg22709100	chr7:91322751	NA	-0.61	-4.78	-0.44	6.46e-6	Breast cancer;
THYM	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg20242066	chr2:136595261	LCT	-0.6	-7.1	-0.59	2.23e-10	Mosquito bite size;
THYM	cis	rs9992101	0.547	rs10029777	chr4:77411030	C/T	cg27417997	chr4:77356416	SHROOM3	-0.37	-4.46	-0.42	2.22e-5	Creatinine levels;
THYM	trans	rs75518195	0.504	rs6858254	chr4:64842362	A/G	cg14706739	chr8:21916355	EPB49	0.69	6.85	0.57	7.17e-10	Triptolide cytotoxicity;
THYM	cis	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg15423357	chr2:25149977	NA	-0.64	-6.77	-0.57	1.05e-9	Body mass index;
THYM	cis	rs921968	0.608	rs11678428	chr2:219352598	C/T	cg02176678	chr2:219576539	TTLL4	0.65	5.98	0.52	3.82e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9790314	0.934	rs455386	chr3:161102495	A/T	cg03342759	chr3:160939853	NMD3	-0.77	-6.9	-0.58	5.9e-10	Morning vs. evening chronotype;
THYM	cis	rs8067545	1.000	rs7218708	chr17:19926836	A/G	cg20830565	chr17:20408647	MGC102966	-0.51	-4.49	-0.42	2.02e-5	Schizophrenia;
THYM	cis	rs887829	0.570	rs7608175	chr2:234599089	C/G	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	0.54	4.57	0.42	1.45e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs9287719	0.674	rs11691060	chr2:10827061	T/C	cg03983476	chr2:10830698	NOL10	0.61	5.27	0.48	8.48e-7	Prostate cancer;
THYM	cis	rs9972944	0.631	rs6504345	chr17:63757052	T/G	cg07283582	chr17:63770753	CCDC46	-0.65	-5.01	-0.46	2.5e-6	Total body bone mineral density;
THYM	cis	rs910316	0.646	rs11546525	chr14:75537381	C/T	cg11812906	chr14:75593930	NEK9	0.75	6.15	0.53	1.8e-8	Height;
THYM	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs11711311	0.911	rs13321446	chr3:113522544	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.63	-5.37	-0.48	5.53e-7	IgG glycosylation;
THYM	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg18252515	chr7:66147081	NA	-0.62	-4.55	-0.42	1.59e-5	Aortic root size;
THYM	cis	rs1003719	0.788	rs2835600	chr21:38468958	A/G	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.74	-5.69	-0.5	1.43e-7	Eosinophil percentage of white cells;
THYM	cis	rs4731207	0.596	rs1011723	chr7:124605261	G/C	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs2658782	0.756	rs3019223	chr11:93084182	G/A	cg15737290	chr11:93063684	CCDC67	0.99	8.2	0.64	1.16e-12	Pulmonary function decline;
THYM	cis	rs7084402	0.967	rs1658469	chr10:60292402	C/T	cg09696939	chr10:60272079	BICC1	0.45	5.27	0.48	8.44e-7	Refractive error;
THYM	cis	rs6450176	0.633	rs391448	chr5:53332323	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.92	-8.22	-0.64	1.04e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs7043114	0.507	rs10992340	chr9:95209693	T/C	cg14631576	chr9:95140430	CENPP	-0.82	-8.18	-0.64	1.27e-12	Height;
THYM	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg02527881	chr3:46936655	PTH1R	0.61	5.71	0.51	1.28e-7	Colorectal cancer;
THYM	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg21475434	chr5:93447410	FAM172A	0.86	5.57	0.5	2.35e-7	Diabetic retinopathy;
THYM	cis	rs12681287	0.752	rs10104242	chr8:87247714	G/C	cg27223183	chr8:87520930	FAM82B	-0.6	-4.64	-0.43	1.1e-5	Caudate activity during reward;
THYM	cis	rs12478296	0.818	rs57194240	chr2:243011545	A/G	cg18898632	chr2:242989856	NA	-0.66	-4.45	-0.42	2.35e-5	Obesity-related traits;
THYM	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs79387448	0.745	rs1523196	chr2:103163700	T/G	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs12216545	0.737	rs1568628	chr7:150239286	A/T	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg12310025	chr6:25882481	NA	-0.82	-6.19	-0.54	1.54e-8	Intelligence (multi-trait analysis);
THYM	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg21433313	chr16:3507492	NAT15	-0.85	-9.04	-0.68	1.82e-14	Tuberculosis;
THYM	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.27	-0.65	8.28e-13	Personality dimensions;
THYM	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg09549813	chr16:4587862	C16orf5	-0.51	-5.74	-0.51	1.14e-7	Schizophrenia;
THYM	cis	rs2055375	0.560	rs7446842	chr5:60533515	A/G	cg20565082	chr5:60525509	NA	-0.59	-5.62	-0.5	1.88e-7	Intelligence (multi-trait analysis);
THYM	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg23978390	chr7:1156363	C7orf50	0.6	4.55	0.42	1.58e-5	Longevity;Endometriosis;
THYM	cis	rs7631605	0.967	rs7638252	chr3:37141732	G/C	cg21328643	chr3:37258149	NA	-0.47	-4.6	-0.43	1.3e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg19875535	chr5:140030758	IK	-0.58	-4.54	-0.42	1.63e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs870825	0.858	rs2014964	chr4:185588836	G/A	cg04058563	chr4:185651563	MLF1IP	1.08	7.54	0.61	2.74e-11	Blood protein levels;
THYM	cis	rs7106204	0.764	rs58215218	chr11:24234720	G/T	ch.11.24196551F	chr11:24239977	NA	0.87	4.66	0.43	1.04e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs4478037	0.822	rs59834381	chr3:33116313	G/A	cg19404215	chr3:33155277	CRTAP	1.07	6.96	0.58	4.27e-10	Major depressive disorder;
THYM	cis	rs2073300	0.609	rs12625164	chr20:23354269	T/C	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs919433	0.929	rs7592511	chr2:198177974	A/G	cg00792783	chr2:198669748	PLCL1	-0.71	-5.23	-0.47	1e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.01	0.58	3.39e-10	Prudent dietary pattern;
THYM	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.91	7.88	0.63	5.43e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg01483505	chr11:975446	AP2A2	0.56	4.59	0.43	1.35e-5	Alzheimer's disease (late onset);
THYM	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg05182265	chr7:156933206	UBE3C	-0.69	-9.32	-0.69	4.58e-15	Body mass index;
THYM	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg18681998	chr4:17616180	MED28	0.81	6.87	0.58	6.5e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg12863693	chr15:85201151	NMB	0.55	4.81	0.44	5.72e-6	Schizophrenia;
THYM	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	6.07	0.53	2.59e-8	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg18132916	chr6:79620363	NA	-0.59	-5.16	-0.47	1.34e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.596	rs1904973	chr7:124669547	G/A	cg05285228	chr7:124571219	POT1	-0.65	-5.0	-0.46	2.64e-6	Cutaneous malignant melanoma;
THYM	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg08999081	chr20:33150536	PIGU	0.57	4.79	0.44	6.02e-6	Coronary artery disease;
THYM	cis	rs7582180	0.715	rs7571306	chr2:100906084	G/C	cg21926883	chr2:100939477	LONRF2	-0.59	-4.89	-0.45	4.08e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9515201	0.859	rs9521735	chr13:111037328	G/C	cg26053697	chr13:111039873	COL4A2	0.58	4.57	0.42	1.46e-5	White matter hyperintensity burden;
THYM	cis	rs3126085	0.736	rs12747962	chr1:152240456	G/A	cg10321714	chr1:152280068	FLG	0.7	5.48	0.49	3.49e-7	Atopic dermatitis;
THYM	cis	rs1113500	0.933	rs11185261	chr1:108638703	G/A	cg06207961	chr1:108661230	NA	0.64	5.09	0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs500891	0.525	rs1539439	chr6:84078564	C/T	cg21688264	chr6:84418724	SNAP91	-0.74	-4.59	-0.43	1.36e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs1499972	0.941	rs55779525	chr3:117651483	A/C	cg07612923	chr3:117604196	NA	1.3	5.07	0.46	1.94e-6	Schizophrenia;
THYM	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg08847533	chr14:75593920	NEK9	-0.97	-10.4	-0.73	2.29e-17	Height;
THYM	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg18230493	chr5:56204884	C5orf35	-0.91	-6.9	-0.58	5.71e-10	Initial pursuit acceleration;
THYM	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs11599315	0.757	rs11250392	chr10:1342543	T/C	cg09624528	chr10:1369823	ADARB2	0.84	7.64	0.62	1.74e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs12450688	1	rs12450688	chr17:38144229	G/A	cg17467752	chr17:38218738	THRA	-0.78	-6.4	-0.55	5.77e-9	Sum eosinophil basophil counts;
THYM	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg04944784	chr2:26401820	FAM59B	-0.74	-5.89	-0.52	5.91e-8	Gut microbiome composition (summer);
THYM	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg22709100	chr7:91322751	NA	0.62	4.85	0.45	4.77e-6	Breast cancer;
THYM	cis	rs416603	0.967	rs11640138	chr16:11362729	A/G	cg00044050	chr16:11439710	C16orf75	0.75	5.63	0.5	1.83e-7	Type 1 diabetes;
THYM	cis	rs11599315	0.507	rs12218307	chr10:1341914	G/A	cg01270228	chr10:1369114	ADARB2	0.72	5.82	0.51	7.86e-8	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs28595532	0.841	rs115852209	chr4:119753465	A/G	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg03060546	chr3:49711283	APEH	-0.66	-4.99	-0.46	2.7e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs4808199	0.895	rs2163805	chr19:19575945	G/A	cg03709012	chr19:19516395	GATAD2A	1.19	7.25	0.6	1.12e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg26354017	chr1:205819088	PM20D1	-0.58	-4.74	-0.44	7.46e-6	Parkinson's disease;
THYM	cis	rs4731207	0.596	rs10272889	chr7:124576641	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs2072499	0.966	rs2853646	chr1:156189626	C/T	cg06970220	chr1:156163860	SLC25A44	0.75	5.7	0.51	1.32e-7	Testicular germ cell tumor;
THYM	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg13939156	chr17:80058883	NA	0.4	5.29	0.48	7.68e-7	Life satisfaction;
THYM	cis	rs4732038	0.510	rs10085559	chr7:134271725	G/A	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs476633	0.708	rs28547298	chr15:41446951	C/T	cg21153102	chr15:41252147	NA	0.6	4.55	0.42	1.59e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg06656553	chr16:89960601	TCF25	-0.78	-4.45	-0.42	2.34e-5	Interleukin-17 levels;
THYM	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg10803722	chr21:46713166	LOC642852	-0.41	-5.33	-0.48	6.47e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6084875	0.840	rs2077519	chr20:4720750	A/G	cg19614321	chr20:4804581	RASSF2	0.45	4.53	0.42	1.7e-5	Systemic lupus erythematosus;
THYM	cis	rs4930103	0.935	rs2071095	chr11:2020627	C/A	cg06197492	chr11:2016605	H19	0.63	5.48	0.49	3.56e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg05472934	chr7:22766657	IL6	0.87	8.43	0.65	3.62e-13	Lung cancer;
THYM	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg25036284	chr2:26402008	FAM59B	-0.81	-5.18	-0.47	1.24e-6	Gut microbiome composition (summer);
THYM	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg24253500	chr15:84953950	NA	0.57	4.67	0.43	9.76e-6	Schizophrenia;
THYM	cis	rs57994353	0.897	rs11999609	chr9:139363539	C/T	cg14115884	chr9:139300582	SDCCAG3	0.73	5.4	0.48	4.9e-7	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg14779329	chr11:130786720	SNX19	0.54	5.72	0.51	1.22e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7267979	1.000	rs2297496	chr20:25295787	T/C	cg08601574	chr20:25228251	PYGB	-0.57	-4.61	-0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6992848	0.791	rs11166956	chr8:141177402	C/T	cg22504031	chr8:141147661	TRAPPC9	0.61	4.69	0.43	9.21e-6	Response to amphetamines;
THYM	cis	rs11225247	1.000	rs75000494	chr11:102288962	T/C	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs7666738	0.719	rs4699323	chr4:98967484	G/A	cg03676636	chr4:99064102	C4orf37	0.47	5.22	0.47	1.07e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg24060327	chr5:131705240	SLC22A5	0.81	6.71	0.57	1.4e-9	Acylcarnitine levels;
THYM	cis	rs4654899	0.758	rs6694455	chr1:21352185	C/T	cg01072550	chr1:21505969	NA	-0.76	-7.43	-0.61	4.71e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs995000	0.931	rs1168047	chr1:62983751	C/T	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs28595532	0.841	rs115209862	chr4:119742225	G/A	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3087591	1.000	rs2854322	chr17:29699416	C/T	cg24425628	chr17:29625626	OMG;NF1	0.61	5.38	0.48	5.38e-7	Hip circumference;
THYM	cis	rs11785693	0.865	rs7815144	chr8:4970788	G/T	cg26367366	chr8:4980734	NA	-1.05	-5.1	-0.46	1.72e-6	Neuroticism (multi-trait analysis);Neuroticism;
THYM	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg07870213	chr5:140052090	DND1	0.72	8.19	0.64	1.21e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg26818010	chr10:134567672	INPP5A	-0.83	-6.34	-0.55	7.76e-9	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs4523957	0.891	rs216200	chr17:2199846	C/T	cg16513277	chr17:2031491	SMG6	0.71	6.22	0.54	1.33e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs4076764	0.846	rs4255362	chr1:163424630	G/A	cg24596788	chr1:163392923	NA	-0.74	-6.47	-0.55	4.33e-9	Motion sickness;
THYM	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11890956	chr21:40555474	PSMG1	1.17	12.72	0.79	3.2e-22	Cognitive function;
THYM	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg18305652	chr10:134549665	INPP5A	0.75	5.92	0.52	5.16e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg25427524	chr10:38739819	LOC399744	-0.65	-6.16	-0.53	1.75e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs8063160	0.610	rs12931267	chr16:89818732	C/G	cg27050730	chr16:88968896	CBFA2T3	1.11	4.93	0.45	3.43e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg23649088	chr2:200775458	C2orf69	-0.74	-4.49	-0.42	2.02e-5	Schizophrenia;
THYM	trans	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg25517755	chr10:38738941	LOC399744	0.75	7.0	0.58	3.6e-10	Corneal astigmatism;
THYM	cis	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs986417	1.000	rs3931460	chr14:60939101	A/C	cg27398547	chr14:60952738	C14orf39	1.21	6.17	0.53	1.69e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.75	-5.5	-0.49	3.17e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg24910161	chr17:38119198	GSDMA	0.42	4.45	0.42	2.31e-5	Self-reported allergy;
THYM	cis	rs7106204	0.590	rs7115417	chr11:24247696	A/G	ch.11.24196551F	chr11:24239977	NA	0.93	6.46	0.55	4.54e-9	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg20891283	chr12:69753455	YEATS4	0.85	7.17	0.59	1.61e-10	Blood protein levels;
THYM	cis	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg21775007	chr8:11205619	TDH	-0.71	-5.5	-0.49	3.18e-7	Retinal vascular caliber;
THYM	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg23649088	chr2:200775458	C2orf69	-0.74	-4.49	-0.42	2.02e-5	Schizophrenia;
THYM	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg10523679	chr1:76189770	ACADM	0.88	7.58	0.61	2.28e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7255045	0.742	rs7251196	chr19:12950863	C/T	cg26870725	chr19:12978805	MAST1	-0.64	-4.82	-0.44	5.37e-6	Mean corpuscular volume;
THYM	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg23730037	chr7:158596552	ESYT2	-0.44	-4.68	-0.43	9.58e-6	Height;
THYM	cis	rs11096990	0.634	rs7654501	chr4:39283984	G/C	cg24403649	chr4:39172243	NA	-0.67	-5.84	-0.51	7.33e-8	Cognitive function;
THYM	cis	rs9677476	0.863	rs58383275	chr2:232063946	T/C	cg07929768	chr2:232055508	NA	0.63	6.28	0.54	1.01e-8	Food antigen IgG levels;
THYM	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2730245	0.527	rs62476462	chr7:158686619	A/G	cg01219135	chr7:158766336	NA	0.56	4.49	0.42	2.01e-5	Height;
THYM	cis	rs4242434	0.819	rs7843128	chr8:22473465	T/C	cg03733263	chr8:22462867	KIAA1967	0.98	11.26	0.76	3.52e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs11690935	0.959	rs7604918	chr2:172588094	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.88	-6.5	-0.55	3.76e-9	Schizophrenia;
THYM	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg04106633	chr4:1044584	NA	-0.51	-4.96	-0.45	3.05e-6	Recombination rate (males);
THYM	cis	rs6748734	0.895	rs4417704	chr2:241846573	A/G	cg15164180	chr2:241846931	NA	-0.41	-4.71	-0.43	8.5e-6	Urinary metabolites;
THYM	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2976388	1.000	rs2920293	chr8:143765414	C/G	cg06565975	chr8:143823917	SLURP1	-0.45	-5.19	-0.47	1.19e-6	Urinary tract infection frequency;
THYM	cis	rs6430585	0.702	rs73958637	chr2:136546927	C/T	cg04750100	chr2:136595281	LCT	0.5	4.73	0.44	7.82e-6	Corneal structure;
THYM	cis	rs921968	0.541	rs3821031	chr2:219295249	C/T	cg02176678	chr2:219576539	TTLL4	-0.76	-7.74	-0.62	1.07e-11	Mean corpuscular hemoglobin concentration;
THYM	cis	rs622217	0.629	rs3120152	chr6:160715858	C/A	cg11363108	chr6:160501266	IGF2R	-0.57	-4.45	-0.42	2.36e-5	Type 2 diabetes;
THYM	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg21784768	chr11:537496	LRRC56	-1.09	-5.41	-0.49	4.65e-7	Body mass index;
THYM	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs986417	1.000	rs7159212	chr14:61068725	T/C	cg27398547	chr14:60952738	C14orf39	1.3	6.11	0.53	2.15e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg26597838	chr10:835615	NA	1.09	6.27	0.54	1.06e-8	Eosinophil percentage of granulocytes;
THYM	cis	rs425277	0.606	rs3128295	chr1:2068480	C/T	cg24578937	chr1:2090814	PRKCZ	-0.6	-5.71	-0.51	1.31e-7	Height;
THYM	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg13390004	chr1:15929781	NA	0.64	4.85	0.45	4.88e-6	Systolic blood pressure;
THYM	cis	rs6840360	0.642	rs2724571	chr4:152376795	T/C	cg17479576	chr4:152424074	FAM160A1	-0.68	-5.17	-0.47	1.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8017423	0.967	rs6575117	chr14:90715412	G/A	cg04239629	chr14:90701769	NA	-0.62	-4.52	-0.42	1.81e-5	Mortality in heart failure;
THYM	cis	rs55728055	0.661	rs62237849	chr22:32029807	T/C	cg01338084	chr22:32026380	PISD	1.39	5.95	0.52	4.42e-8	Age-related hearing impairment;
THYM	cis	rs12543725	0.799	rs13252660	chr8:142239381	C/T	cg16341495	chr8:142228727	SLC45A4	0.63	4.54	0.42	1.67e-5	Birth weight;
THYM	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg07606381	chr6:8435919	SLC35B3	0.68	5.11	0.46	1.7e-6	Motion sickness;
THYM	cis	rs35995292	0.963	rs2392609	chr7:38952595	C/T	cg19166347	chr7:37955598	SFRP4	0.61	4.85	0.45	4.8e-6	Subjective well-being (multi-trait analysis);
THYM	cis	rs916888	0.558	rs199521	chr17:44853456	G/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.56	-4.58	-0.43	1.39e-5	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs922692	1.000	rs12901913	chr15:78981348	C/T	cg15571903	chr15:79123663	NA	-0.56	-5.05	-0.46	2.09e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg24209194	chr3:40518798	ZNF619	-0.73	-6.31	-0.54	8.87e-9	Renal cell carcinoma;
THYM	cis	rs514406	0.661	rs562641	chr1:53374666	C/T	cg22166914	chr1:53195759	ZYG11B	0.63	5.43	0.49	4.4e-7	Monocyte count;
THYM	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-5.88	-0.52	5.96e-8	Bipolar disorder and schizophrenia;
THYM	cis	rs6473252	0.966	rs4739760	chr8:81811312	T/C	cg08595989	chr8:81827712	NA	-0.41	-4.54	-0.42	1.65e-5	Breast cancer;
THYM	cis	rs6063312	0.667	rs9679994	chr20:47281853	T/C	cg18078177	chr20:47281410	PREX1	0.8	5.99	0.52	3.8e-8	Tonometry;
THYM	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03264133	chr6:25882463	NA	-0.69	-5.32	-0.48	7.03e-7	Blood metabolite levels;
THYM	cis	rs60871478	0.685	rs78903723	chr7:846983	G/C	cg10248100	chr7:872053	UNC84A	0.74	4.85	0.45	4.86e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs2294693	0.898	rs6458195	chr6:40972498	A/T	cg14418226	chr6:40996092	UNC5CL	-0.61	-5.22	-0.47	1.07e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4417704	0.551	rs4606922	chr2:241891207	G/A	cg15164180	chr2:241846931	NA	-0.36	-4.65	-0.43	1.08e-5	Joint mobility (Beighton score);
THYM	cis	rs11771526	1.000	rs17351142	chr7:32339843	T/G	cg27532318	chr7:32358331	NA	0.89	5.46	0.49	3.85e-7	Body mass index;
THYM	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg11871910	chr12:69753446	YEATS4	0.73	5.8	0.51	8.62e-8	Cerebrospinal fluid biomarker levels;
THYM	cis	rs941408	1.000	rs1736182	chr19:2798686	T/G	cg19693284	chr19:2783607	SGTA	0.7	5.53	0.49	2.75e-7	Total cholesterol levels;
THYM	cis	rs2273669	0.667	rs12374658	chr6:109345930	T/C	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg21361702	chr7:150065534	REPIN1	0.69	5.85	0.51	6.95e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs55728055	0.661	rs9621295	chr22:32007153	G/A	cg10537193	chr22:32026975	PISD	-0.68	-4.6	-0.43	1.32e-5	Age-related hearing impairment;
THYM	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03517284	chr6:25882590	NA	-0.77	-6.14	-0.53	1.87e-8	Blood metabolite levels;
THYM	cis	rs2073016	0.569	rs35608434	chr6:40944066	C/T	cg14418226	chr6:40996092	UNC5CL	0.72	5.42	0.49	4.49e-7	Progression free survival in metastatic colorectal cancer (CAPOX-B vs CAPOX-B plus cetuximab);
THYM	cis	rs7584330	0.554	rs6740722	chr2:238393288	T/C	cg14458575	chr2:238380390	NA	0.93	4.76	0.44	6.94e-6	Prostate cancer;
THYM	cis	rs9443645	0.527	rs10943595	chr6:79575291	C/G	cg05283184	chr6:79620031	NA	-0.6	-4.64	-0.43	1.1e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4713118	0.662	rs9380046	chr6:28030499	T/C	cg08968635	chr6:28129556	ZNF389	0.59	4.57	0.42	1.46e-5	Parkinson's disease;
THYM	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs8038465	0.615	rs11637315	chr15:73944068	G/C	cg15420318	chr15:73925796	NPTN	0.64	5.7	0.51	1.32e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	trans	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg15736062	chr7:158136485	PTPRN2	-0.61	-4.9	-0.45	3.94e-6	Response to amphetamines;
THYM	cis	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.96	0.45	3.04e-6	Obesity-related traits;
THYM	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg03433033	chr1:76189801	ACADM	0.76	10.1	0.72	1.02e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.39	6.97	0.58	4.08e-10	Obesity-related traits;
THYM	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.68	-0.67	1.07e-13	Mean corpuscular volume;
THYM	cis	rs7705502	0.962	rs55946741	chr5:173345023	A/G	cg18693985	chr5:173351052	CPEB4	-0.74	-5.45	-0.49	4.01e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs9902453	0.740	rs2244247	chr17:28110174	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg15605315	chr1:45957053	TESK2	0.78	6.5	0.55	3.7e-9	High light scatter reticulocyte count;
THYM	cis	rs3771570	1.000	rs56052835	chr2:242243251	T/G	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs2039659	0.719	rs1753741	chr13:86250565	A/G	cg25308322	chr13:86268291	NA	0.66	5.51	0.49	3.11e-7	Blood osmolality (transformed sodium);
THYM	cis	rs483180	0.512	rs594400	chr1:120214275	G/T	cg19096424	chr1:120255104	PHGDH	-0.67	-5.25	-0.47	9.26e-7	Macular telangiectasia type 2;
THYM	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg12826209	chr6:26865740	GUSBL1	0.84	6.07	0.53	2.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1568889	1.000	rs61889026	chr11:28274803	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.72	4.58	0.43	1.4e-5	Bipolar disorder;
THYM	cis	rs4919044	0.641	rs11187232	chr10:94737477	A/G	cg05127821	chr10:94822908	CYP26C1	-1.1	-6.18	-0.54	1.62e-8	Coronary artery disease;
THYM	cis	rs11190604	0.767	rs7916904	chr10:102186778	C/G	cg16342193	chr10:102329863	NA	-0.49	-5.03	-0.46	2.33e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs472402	0.580	rs6884552	chr5:6661966	C/T	cg12648172	chr5:5886274	NA	0.52	4.59	0.43	1.34e-5	Response to amphetamines;
THYM	cis	rs939574	1.000	rs2071385	chr2:220118782	T/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	1.32	5.96	0.52	4.29e-8	Platelet distribution width;
THYM	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg23649088	chr2:200775458	C2orf69	-0.74	-4.49	-0.42	2.02e-5	Schizophrenia;
THYM	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg06789500	chr7:2109450	MAD1L1	-0.65	-4.46	-0.42	2.24e-5	Bipolar disorder;
THYM	cis	rs2797160	1.000	rs1418951	chr6:125996185	A/G	cg16306078	chr6:126000798	NA	-0.54	-5.51	-0.49	3.05e-7	Endometrial cancer;
THYM	cis	rs988913	1.000	rs9370345	chr6:54825167	C/T	cg04690482	chr6:54711388	FAM83B	0.44	4.64	0.43	1.13e-5	Menarche (age at onset);
THYM	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg20503657	chr10:835505	NA	0.81	4.97	0.45	2.98e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg11327659	chr7:150037044	RARRES2	0.44	5.14	0.47	1.45e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs55637147	0.671	rs3781900	chr11:57126838	A/G	cg15971518	chr11:57159174	PRG2	-0.67	-5.38	-0.48	5.25e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg06558623	chr16:89946397	TCF25	1.42	6.85	0.58	7.17e-10	Skin colour saturation;
THYM	cis	rs9876781	1.000	rs9881491	chr3:48487911	G/A	cg06066452	chr3:48470258	PLXNB1	0.27	4.71	0.44	8.4e-6	Longevity;
THYM	cis	rs2219968	0.683	rs66508303	chr8:78909306	C/T	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs828999	0.688	rs10881508	chr1:108698098	A/G	cg24323958	chr1:108741884	SLC25A24	-0.54	-5.32	-0.48	6.79e-7	Monocyte percentage of white cells;
THYM	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10045504	1.000	rs10045504	chr5:38762288	A/C	cg18182111	chr5:37835111	GDNF	0.45	4.63	0.43	1.14e-5	Night sleep phenotypes;
THYM	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg02725872	chr8:58115012	NA	1.1	8.57	0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs1883415	0.553	rs807541	chr6:24559281	A/G	cg00346970	chr6:24499591	ALDH5A1	0.37	4.7	0.43	8.93e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg10803722	chr21:46713166	LOC642852	-0.41	-5.28	-0.48	8.15e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg03806693	chr22:41940476	POLR3H	1.19	10.49	0.73	1.46e-17	Vitiligo;
THYM	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg03806693	chr22:41940476	POLR3H	-1.24	-10.83	-0.74	2.84e-18	Vitiligo;
THYM	cis	rs9393692	0.578	rs806795	chr6:26205293	G/A	cg13736514	chr6:26305472	NA	-0.56	-6.41	-0.55	5.66e-9	Educational attainment;
THYM	cis	rs854765	0.547	rs8075189	chr17:17901946	C/G	cg04398451	chr17:18023971	MYO15A	-0.95	-9.84	-0.71	3.63e-16	Total body bone mineral density;
THYM	cis	rs514406	0.505	rs6703127	chr1:53180565	C/T	cg22166914	chr1:53195759	ZYG11B	0.91	10.7	0.74	5.4e-18	Monocyte count;
THYM	cis	rs7107174	1.000	rs7111986	chr11:78102266	G/T	cg02023728	chr11:77925099	USP35	0.63	6.11	0.53	2.19e-8	Testicular germ cell tumor;
THYM	cis	rs11039798	0.588	rs11039782	chr11:48524785	A/G	cg24672777	chr11:48374446	OR4C45	-0.98	-6.39	-0.55	6.21e-9	Axial length;
THYM	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7043114	0.563	rs7848391	chr9:95337520	C/T	cg14631576	chr9:95140430	CENPP	-0.77	-7.3	-0.6	8.56e-11	Height;
THYM	cis	rs6840360	0.642	rs7658169	chr4:152353414	G/A	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.32	-0.48	6.89e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-4.5	-0.42	1.89e-5	Gut microbiome composition (summer);
THYM	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg26441486	chr22:50317300	CRELD2	0.38	5.52	0.49	3e-7	Schizophrenia;
THYM	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg27394845	chr17:28928406	LRRC37B2	0.98	4.71	0.43	8.59e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg07507251	chr3:52567010	NT5DC2	0.4	4.61	0.43	1.27e-5	Electroencephalogram traits;
THYM	cis	rs7084402	1.000	rs28426375	chr10:60285478	T/A	cg07615347	chr10:60278583	BICC1	0.61	5.57	0.5	2.41e-7	Refractive error;
THYM	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg05347473	chr6:146136440	FBXO30	-0.82	-7.36	-0.6	6.62e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs72627123	0.749	rs58199545	chr14:74452495	G/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.14	6.41	0.55	5.69e-9	Morning vs. evening chronotype;
THYM	cis	rs514406	0.597	rs1241980	chr1:53286013	A/G	cg16325326	chr1:53192061	ZYG11B	-0.78	-5.59	-0.5	2.15e-7	Monocyte count;
THYM	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13012494	chr21:47604986	C21orf56	-0.69	-4.8	-0.44	5.95e-6	Testicular germ cell tumor;
THYM	cis	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg26384229	chr12:38710491	ALG10B	-0.72	-5.66	-0.5	1.6e-7	Morning vs. evening chronotype;
THYM	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg01483505	chr11:975446	AP2A2	0.58	4.73	0.44	7.73e-6	Alzheimer's disease (late onset);
THYM	cis	rs9825379	0.643	rs6762826	chr3:141145315	A/G	cg13411656	chr3:141121016	ZBTB38	-0.5	-4.7	-0.43	8.91e-6	Height;
THYM	cis	rs1629083	0.967	rs61900655	chr11:118120802	G/C	cg25155064	chr11:118100782	MPZL3	-0.57	-5.03	-0.46	2.34e-6	Lung cancer;
THYM	cis	rs13082711	0.522	rs3103745	chr3:27342927	T/C	cg02860705	chr3:27208620	NA	0.65	5.07	0.46	1.94e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs921968	0.565	rs6436071	chr2:219598041	A/T	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs61931739	0.929	rs2389274	chr12:34075149	T/C	cg06521331	chr12:34319734	NA	0.57	4.68	0.43	9.63e-6	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg03806693	chr22:41940476	POLR3H	1.16	10.2	0.72	6.06e-17	Vitiligo;
THYM	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg06481639	chr22:41940642	POLR3H	0.7	4.53	0.42	1.73e-5	Vitiligo;
THYM	cis	rs858239	0.508	rs10242104	chr7:23220450	C/T	cg09755872	chr7:23245557	NA	-0.51	-4.75	-0.44	7.31e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg02403541	chr12:121454288	C12orf43	0.81	7.13	0.59	1.96e-10	N-glycan levels;
THYM	cis	rs4242434	0.854	rs13258100	chr8:22451116	A/T	cg14690197	chr8:22456421	C8orf58	0.53	4.81	0.44	5.58e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs4363385	0.747	rs4845509	chr1:152981900	T/G	cg13444842	chr1:152974279	SPRR3	-0.59	-4.68	-0.43	9.52e-6	Inflammatory skin disease;
THYM	cis	rs6968419	0.788	rs10953810	chr7:115812378	A/G	cg02561103	chr7:115862891	TES	-0.71	-4.57	-0.42	1.47e-5	Intraocular pressure;
THYM	cis	rs4121859	1.000	rs61893564	chr11:95177032	T/C	cg01219426	chr11:95856658	MAML2	-0.66	-4.48	-0.42	2.11e-5	Cancer;
THYM	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg20007245	chr22:24372913	LOC391322	-0.77	-7.87	-0.63	5.59e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg11301795	chr4:187892539	NA	-1.12	-16.92	-0.87	2.01e-30	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs367615	0.840	rs113540823	chr5:108879084	C/T	cg17395555	chr5:108820864	NA	0.53	4.8	0.44	5.95e-6	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs514406	0.893	rs476108	chr1:53317351	C/T	cg16325326	chr1:53192061	ZYG11B	0.82	7.77	0.62	9e-12	Monocyte count;
THYM	cis	rs3126085	0.560	rs45541239	chr1:152346391	T/G	cg10321714	chr1:152280068	FLG	-0.69	-4.84	-0.44	5.1e-6	Atopic dermatitis;
THYM	cis	rs12216545	0.737	rs1879866	chr7:150258329	T/C	cg08960815	chr7:150264767	GIMAP4	-0.85	-7.68	-0.62	1.38e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg27279351	chr12:120934652	DYNLL1	0.96	8.75	0.67	7.6e-14	High light scatter reticulocyte count;
THYM	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg13395646	chr4:1353034	KIAA1530	-0.58	-5.56	-0.5	2.47e-7	Obesity-related traits;
THYM	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg04772025	chr11:68637568	NA	0.64	6.6	0.56	2.35e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13279522	0.536	rs10957366	chr8:67029940	C/G	cg20171999	chr8:67343066	NA	-0.47	-4.69	-0.43	9.22e-6	Coronary heart disease event reduction (statin therapy interaction);
THYM	cis	rs859767	0.704	rs1818614	chr2:135356351	A/G	cg12500956	chr2:135428796	TMEM163	-0.45	-4.58	-0.42	1.43e-5	Neuroticism;
THYM	cis	rs6547741	1.000	rs6547734	chr2:27830990	G/T	cg27432699	chr2:27873401	GPN1	0.68	5.97	0.52	4.14e-8	Oral cavity cancer;
THYM	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg27446573	chr6:127587934	RNF146	0.77	6.35	0.55	7.46e-9	Breast cancer;
THYM	cis	rs8050907	0.744	rs10438587	chr16:4522160	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.3	5.2	0.47	1.16e-6	Obesity-related traits;
THYM	cis	rs6032067	0.641	rs34313230	chr20:43755858	C/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.67	-5.92	-0.52	5.17e-8	Blood protein levels;
THYM	cis	rs11112613	0.713	rs871220	chr12:105938558	G/A	cg03607813	chr12:105948248	NA	1.06	8.98	0.68	2.52e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.4	5.85	0.51	6.99e-8	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs1011018	0.826	rs2109338	chr7:139459176	A/G	cg06079564	chr7:139468310	HIPK2	-0.73	-5.73	-0.51	1.2e-7	Systolic blood pressure;
THYM	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.66	4.9	0.45	3.99e-6	Cognitive test performance;
THYM	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg14784868	chr12:69753453	YEATS4	-0.63	-5.13	-0.47	1.5e-6	Blood protein levels;
THYM	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg20387954	chr3:183756860	HTR3D	0.59	4.85	0.45	4.87e-6	Anterior chamber depth;
THYM	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.68	9.11	0.68	1.34e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7551222	0.752	rs12125533	chr1:204529302	A/C	cg20240347	chr1:204465584	NA	-0.54	-4.94	-0.45	3.36e-6	Schizophrenia;
THYM	cis	rs7043114	0.525	rs9299404	chr9:95170338	A/G	cg14631576	chr9:95140430	CENPP	0.83	8.4	0.65	4.21e-13	Height;
THYM	cis	rs7084402	0.935	rs10763558	chr10:60341934	A/C	cg09696939	chr10:60272079	BICC1	0.47	5.63	0.5	1.83e-7	Refractive error;
THYM	cis	rs747334	0.811	rs7099297	chr10:92719573	C/T	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs1784581	0.894	rs1790001	chr6:162387504	G/T	cg17173639	chr6:162384350	PARK2	-0.96	-9.84	-0.71	3.66e-16	Itch intensity from mosquito bite;
THYM	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg13319975	chr6:146136371	FBXO30	-0.62	-5.05	-0.46	2.11e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17102423	0.755	rs884683	chr14:65574482	C/T	cg11161011	chr14:65562177	MAX	-0.85	-6.77	-0.57	1.04e-9	Obesity-related traits;
THYM	cis	rs7727544	0.526	rs17516457	chr5:131590387	T/C	cg09877947	chr5:131593287	PDLIM4	0.57	4.72	0.44	7.97e-6	Blood metabolite levels;
THYM	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg10523679	chr1:76189770	ACADM	0.9	9.47	0.7	2.2e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs554111	0.656	rs12567861	chr1:21395133	C/T	cg00373020	chr1:21041521	KIF17	-0.53	-4.48	-0.42	2.12e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs986417	0.748	rs1956552	chr14:60942685	A/G	cg27398547	chr14:60952738	C14orf39	1.25	6.45	0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs72627123	0.867	rs78496651	chr14:74480070	C/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	4.87	0.45	4.38e-6	Morning vs. evening chronotype;
THYM	cis	rs10929159	0.928	rs2123511	chr2:236923187	C/T	cg14895183	chr2:236924282	AGAP1	0.54	4.6	0.43	1.32e-5	Parkinson's disease;
THYM	cis	rs6430585	0.941	rs12469551	chr2:136510012	T/G	cg20242066	chr2:136595261	LCT	-0.52	-5.13	-0.47	1.51e-6	Corneal structure;
THYM	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs36051895	0.632	rs10974987	chr9:5169302	G/T	cg02405213	chr9:5042618	JAK2	-0.97	-9.56	-0.7	1.41e-15	Pediatric autoimmune diseases;
THYM	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg15704280	chr7:45808275	SEPT13	-0.77	-7.22	-0.6	1.28e-10	Coronary artery disease;
THYM	cis	rs870825	0.616	rs6552807	chr4:185640531	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.69	0.71	7.45e-16	Blood protein levels;
THYM	cis	rs7849270	1.000	rs932835	chr9:131887071	A/G	cg14069949	chr9:131965419	NA	0.5	4.52	0.42	1.8e-5	Blood metabolite ratios;
THYM	cis	rs7567389	0.677	rs61422716	chr2:128087651	C/T	cg09760422	chr2:128146352	NA	0.4	4.52	0.42	1.8e-5	Self-rated health;
THYM	cis	rs4842666	0.915	rs73437358	chr12:90072076	G/A	cg00757033	chr12:89920650	WDR51B	0.46	4.55	0.42	1.56e-5	Blood pressure;
THYM	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.84	-5.66	-0.5	1.57e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs55702914	0.746	rs7588530	chr2:198146698	A/C	cg00792783	chr2:198669748	PLCL1	-0.62	-4.63	-0.43	1.14e-5	Major depression and alcohol dependence;
THYM	cis	rs17006441	0.837	rs1430611	chr3:69853801	C/T	cg18496212	chr3:69797108	MITF	-0.71	-7.36	-0.6	6.62e-11	Hemoglobin concentration;
THYM	cis	rs2997447	0.761	rs112552200	chr1:26456947	G/A	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs4788570	0.537	rs12149254	chr16:71458851	G/A	cg06353428	chr16:71660113	MARVELD3	-1.18	-5.94	-0.52	4.62e-8	Intelligence (multi-trait analysis);
THYM	trans	rs59551326	0.517	rs2829643	chr21:26582390	G/T	cg17452615	chr12:122019080	KDM2B	0.8	6.84	0.57	7.67e-10	Alcohol dependence;
THYM	cis	rs2033711	0.870	rs4801583	chr19:58918405	A/G	cg00825309	chr19:58991885	ZNF446	-0.59	-4.72	-0.44	8.11e-6	Uric acid clearance;
THYM	cis	rs8048589	0.615	rs12924889	chr16:12241768	A/G	cg01990910	chr16:12207648	SNX29	-0.5	-5.68	-0.5	1.46e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs7973719	0.833	rs7970916	chr12:7357746	T/C	cg07052231	chr12:7363540	PEX5	0.61	5.26	0.48	8.71e-7	IgG glycosylation;
THYM	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg08999081	chr20:33150536	PIGU	0.77	6.95	0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs7404928	1.000	rs3826258	chr16:23903552	C/T	cg26685404	chr16:23957272	PRKCB	0.48	4.83	0.44	5.27e-6	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs7246657	0.653	rs10401525	chr19:37658979	C/G	cg23950597	chr19:37808831	NA	-0.81	-4.88	-0.45	4.35e-6	Coronary artery calcification;
THYM	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg13877915	chr19:58951672	ZNF132	0.9	8.63	0.66	1.38e-13	Uric acid clearance;
THYM	cis	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg21775007	chr8:11205619	TDH	0.66	5.35	0.48	6.19e-7	Retinal vascular caliber;
THYM	cis	rs870825	0.929	rs10015218	chr4:185589789	T/C	cg04058563	chr4:185651563	MLF1IP	0.96	6.66	0.56	1.78e-9	Blood protein levels;
THYM	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg13010199	chr12:38710504	ALG10B	0.69	5.43	0.49	4.35e-7	Heart rate;
THYM	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg03929089	chr4:120376271	NA	0.98	10.82	0.74	2.92e-18	Coronary artery disease;
THYM	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg15592062	chr6:167189543	RPS6KA2	-0.58	-5.79	-0.51	9.22e-8	Crohn's disease;
THYM	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.49	-4.74	-0.44	7.58e-6	Crohn's disease;
THYM	cis	rs13401104	0.587	rs55801537	chr2:237145481	C/T	cg19324714	chr2:237145437	ASB18	0.63	4.68	0.43	9.6e-6	Educational attainment;
THYM	cis	rs13137105	0.864	rs34402235	chr4:76448256	G/A	cg03209871	chr4:76438412	RCHY1;THAP6	0.39	4.59	0.43	1.33e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs6754311	0.773	rs680428	chr2:136630757	A/G	cg04750100	chr2:136595281	LCT	-0.56	-6.13	-0.53	1.97e-8	Mosquito bite size;
THYM	cis	rs34375054	0.660	rs57491100	chr12:125593010	C/T	cg25124228	chr12:125621409	AACS	-0.76	-5.92	-0.52	5.08e-8	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg02524346	chr8:600233	NA	1.07	4.81	0.44	5.75e-6	IgG glycosylation;
THYM	cis	rs7772486	0.790	rs2254257	chr6:146203724	C/T	cg23711669	chr6:146136114	FBXO30	0.95	9.84	0.71	3.6e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg20503657	chr10:835505	NA	1.17	8.29	0.65	7.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs9905704	0.647	rs10221208	chr17:57047885	T/C	cg12560992	chr17:57184187	TRIM37	0.71	5.49	0.49	3.35e-7	Testicular germ cell tumor;
THYM	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs7731657	0.509	rs6595984	chr5:130335884	A/G	cg08523029	chr5:130500466	HINT1	0.77	5.24	0.47	9.71e-7	Fasting plasma glucose;
THYM	cis	rs6815814	0.898	rs5743592	chr4:38803063	A/G	cg02016764	chr4:38805732	TLR1	-0.52	-4.8	-0.44	5.97e-6	Breast cancer;
THYM	cis	rs4363657	0.887	rs4149056	chr12:21331549	A/G	cg14622193	chr12:21587445	NA	0.74	4.69	0.43	9.11e-6	Bilirubin levels;Blood metabolite levels;
THYM	cis	rs4849845	0.889	rs11689112	chr2:121049166	A/C	cg03575764	chr2:121493832	NA	0.63	4.77	0.44	6.73e-6	Mean platelet volume;
THYM	cis	rs944002	1.000	rs2297067	chr14:103566785	A/G	cg16996574	chr14:103691482	NA	-0.52	-4.79	-0.44	6.21e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;
THYM	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg03159660	chr11:2078197	NA	-0.65	-5.01	-0.46	2.47e-6	Longevity;
THYM	cis	rs7404928	0.651	rs13338431	chr16:23937562	A/C	cg26685404	chr16:23957272	PRKCB	0.61	7.0	0.58	3.53e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs7572733	0.534	rs4550664	chr2:198691405	C/T	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs7772486	0.686	rs702305	chr6:145973840	A/G	cg13319975	chr6:146136371	FBXO30	0.65	5.22	0.47	1.05e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6500602	0.592	rs8051780	chr16:4434374	G/A	cg09549813	chr16:4587862	C16orf5	-0.48	-4.72	-0.44	8.08e-6	Schizophrenia;
THYM	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg01324343	chr3:183735012	ABCC5	0.68	9.31	0.69	4.93e-15	Anterior chamber depth;
THYM	trans	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg06636001	chr8:8085503	FLJ10661	-0.77	-7.29	-0.6	9.09e-11	Neuroticism;
THYM	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg15556689	chr8:8085844	FLJ10661	-0.71	-6.0	-0.52	3.54e-8	Mood instability;
THYM	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg25208724	chr1:156163844	SLC25A44	-1.12	-12.92	-0.8	1.2e-22	Testicular germ cell tumor;
THYM	cis	rs7512552	0.839	rs2794684	chr1:150320571	C/T	cg15654264	chr1:150340011	RPRD2	0.45	5.2	0.47	1.13e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg08109568	chr15:31115862	NA	-0.56	-5.14	-0.47	1.45e-6	Huntington's disease progression;
THYM	cis	rs2456568	0.805	rs55649862	chr11:93682888	G/T	cg17595323	chr11:93583763	C11orf90	-0.54	-5.22	-0.47	1.04e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs300703	0.816	rs434818	chr2:200477	G/A	cg21211680	chr2:198530	NA	1.26	6.34	0.55	7.68e-9	Blood protein levels;
THYM	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg06112835	chr11:68658793	MRPL21	0.46	6.5	0.56	3.63e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs3892630	0.588	rs7248798	chr19:33303684	G/T	cg22980127	chr19:33182716	NUDT19	1.14	10.64	0.74	7.27e-18	Red blood cell traits;
THYM	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg12963246	chr6:28129442	ZNF389	-0.86	-7.96	-0.63	3.74e-12	Depression;
THYM	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg02524346	chr8:600233	NA	0.96	4.88	0.45	4.33e-6	IgG glycosylation;
THYM	cis	rs61931739	0.635	rs10743836	chr12:33961680	C/T	cg10856724	chr12:34555212	NA	-0.64	-6.04	-0.53	3.04e-8	Morning vs. evening chronotype;
THYM	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg26384229	chr12:38710491	ALG10B	0.87	8.64	0.66	1.36e-13	Heart rate;
THYM	cis	rs72848980	0.706	rs11191732	chr10:105331761	G/A	cg23603852	chr10:105233423	CALHM3	0.62	4.72	0.44	8.13e-6	White matter hyperintensity burden;
THYM	cis	rs13256369	0.774	rs13248423	chr8:8577602	C/G	cg17143192	chr8:8559678	CLDN23	0.89	6.69	0.57	1.55e-9	Obesity-related traits;
THYM	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg24675658	chr1:53192096	ZYG11B	0.7	6.08	0.53	2.47e-8	Monocyte count;
THYM	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs2235642	0.750	rs2974845	chr16:1648162	T/C	cg07341220	chr16:1583899	IFT140;TMEM204	-0.59	-5.16	-0.47	1.33e-6	Coronary artery disease;
THYM	cis	rs539096	0.831	rs10789436	chr1:44040966	T/G	cg08936794	chr1:43833873	ELOVL1	0.67	4.63	0.43	1.17e-5	Intelligence (multi-trait analysis);
THYM	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg24803719	chr17:45855879	NA	-0.6	-6.33	-0.54	7.96e-9	IgG glycosylation;
THYM	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg10803722	chr21:46713166	LOC642852	-0.42	-5.58	-0.5	2.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7089973	0.872	rs7909566	chr10:116629136	A/G	cg23260525	chr10:116636907	FAM160B1	0.52	4.72	0.44	8.04e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs11779988	0.545	rs208764	chr8:17806270	G/A	cg01800426	chr8:17659068	MTUS1	-0.74	-5.29	-0.48	7.7e-7	Breast cancer;
THYM	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-7.18	-0.59	1.58e-10	Chronic sinus infection;
THYM	cis	rs988913	1.000	rs9382408	chr6:54836984	A/G	cg04690482	chr6:54711388	FAM83B	0.48	5.32	0.48	7.02e-7	Menarche (age at onset);
THYM	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg25072359	chr17:41440525	NA	0.75	5.75	0.51	1.07e-7	Menopause (age at onset);
THYM	cis	rs12367572	0.965	rs1506676	chr12:45237401	T/C	cg03114573	chr12:45410052	DBX2	-0.59	-5.45	-0.49	3.89e-7	Gut microbiome composition (summer);
THYM	cis	rs7250872	0.568	rs749109	chr19:1819736	G/A	cg18850929	chr19:1828978	REXO1	0.59	5.04	0.46	2.26e-6	Bipolar disorder;
THYM	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg26924012	chr15:45694286	SPATA5L1	1.08	10.33	0.73	3.27e-17	Homoarginine levels;
THYM	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg22907277	chr7:1156413	C7orf50	0.63	5.63	0.5	1.84e-7	Longevity;Endometriosis;
THYM	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg19378624	chr17:45501242	LOC100272146;C17orf57	0.46	4.92	0.45	3.63e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
THYM	cis	rs28595532	0.920	rs116108618	chr4:119763585	C/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs2227564	0.620	rs7098573	chr10:75580014	G/A	cg00564723	chr10:75632066	CAMK2G	-0.53	-5.04	-0.46	2.2e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg21100191	chr22:23484243	RTDR1	0.72	6.11	0.53	2.21e-8	Bone mineral density;
THYM	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7106204	0.534	rs16925305	chr11:24308924	A/G	ch.11.24196551F	chr11:24239977	NA	0.92	4.76	0.44	7.05e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs2919009	0.607	rs72826623	chr10:122712356	G/A	cg26518861	chr10:122708898	NA	-0.62	-4.52	-0.42	1.77e-5	Obesity-related traits;
THYM	cis	rs7617773	0.780	rs7653336	chr3:48369464	T/A	cg02219026	chr3:48282209	ZNF589	-0.69	-4.83	-0.44	5.12e-6	Coronary artery disease;
THYM	cis	rs3125734	0.633	rs12217669	chr10:63988456	A/G	cg09941381	chr10:64027924	RTKN2	0.55	4.56	0.42	1.51e-5	Rheumatoid arthritis;
THYM	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	7.14	0.59	1.88e-10	Platelet count;
THYM	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs9435341	0.826	rs1730858	chr1:107619244	T/C	cg00944433	chr1:107599041	PRMT6	0.42	5.42	0.49	4.52e-7	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs12971120	0.838	rs3794950	chr18:72182965	G/A	cg26446133	chr18:72167187	CNDP2	-1.02	-7.37	-0.6	6.31e-11	Refractive error;
THYM	cis	rs8038465	0.615	rs6495074	chr15:73959013	A/G	cg15420318	chr15:73925796	NPTN	0.6	5.17	0.47	1.29e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs28595532	0.764	rs116302502	chr4:119748848	T/A	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg04520793	chr17:42248056	ASB16	0.33	4.57	0.42	1.49e-5	Total body bone mineral density;
THYM	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg24060327	chr5:131705240	SLC22A5	0.8	6.52	0.56	3.35e-9	Breast cancer;
THYM	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg16615211	chr3:44902933	MIR564;TMEM42	0.47	5.17	0.47	1.27e-6	Depressive symptoms;
THYM	cis	rs4631830	0.812	rs11593361	chr10:51539156	A/G	cg16070123	chr10:51489643	NA	-0.5	-4.63	-0.43	1.16e-5	Prostate-specific antigen levels;
THYM	cis	rs7072216	0.763	rs12259939	chr10:100169021	T/C	cg26618903	chr10:100175079	PYROXD2	-0.47	-4.54	-0.42	1.62e-5	Metabolite levels;
THYM	cis	rs7589342	0.899	rs11885225	chr2:106486548	T/C	cg14210321	chr2:106509881	NCK2	-0.76	-5.84	-0.51	7.27e-8	Addiction;
THYM	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg00074818	chr8:8560427	CLDN23	0.59	5.46	0.49	3.78e-7	Obesity-related traits;
THYM	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg22920501	chr2:26401640	FAM59B	-0.79	-7.07	-0.59	2.63e-10	Gut microbiome composition (summer);
THYM	cis	rs7578361	0.959	rs10932467	chr2:150432469	G/T	cg17961725	chr2:150454027	NA	0.75	6.19	0.54	1.54e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs10911251	0.546	rs2027084	chr1:183110801	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.66	0.43	1.02e-5	Colorectal cancer;
THYM	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg13334819	chr7:99746414	C7orf59	-0.7	-4.84	-0.44	5e-6	Coronary artery disease;
THYM	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.02	-5.33	-0.48	6.6e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6570726	0.935	rs369214	chr6:145856709	G/A	cg23711669	chr6:146136114	FBXO30	0.91	9.55	0.7	1.49e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg05234568	chr11:5960015	NA	-0.63	-5.61	-0.5	2.02e-7	DNA methylation (variation);
THYM	cis	rs308403	0.506	rs309365	chr4:123659343	C/T	cg10495464	chr4:123653540	BBS12;LOC729338	0.7	4.87	0.45	4.49e-6	Blood protein levels;
THYM	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs12142240	0.698	rs1053627	chr1:46827728	A/C	cg00530320	chr1:46809349	NSUN4	0.78	5.47	0.49	3.71e-7	Menopause (age at onset);
THYM	cis	rs7336332	0.547	rs9581859	chr13:28035147	A/T	cg22138327	chr13:27999177	GTF3A	0.79	4.49	0.42	1.99e-5	Weight;
THYM	cis	rs3845702	0.736	rs6433821	chr2:180837806	T/A	cg01881094	chr2:180872142	CWC22	-0.89	-5.34	-0.48	6.22e-7	Schizophrenia;
THYM	cis	rs611744	0.647	rs689275	chr8:109241822	T/C	cg21045802	chr8:109455806	TTC35	0.64	5.74	0.51	1.13e-7	Dupuytren's disease;
THYM	cis	rs6424115	1.000	rs7521961	chr1:24157634	C/T	cg15997130	chr1:24165203	NA	-0.78	-6.79	-0.57	9.49e-10	Immature fraction of reticulocytes;
THYM	cis	rs854765	0.547	rs9913277	chr17:17919749	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.28	0.54	1.02e-8	Total body bone mineral density;
THYM	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg16342193	chr10:102329863	NA	-0.57	-5.81	-0.51	8.47e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1182436	1	rs1182436	chr7:157027753	T/C	cg05182265	chr7:156933206	UBE3C	0.74	7.16	0.59	1.67e-10	Type 2 diabetes;
THYM	cis	rs2066819	1.000	rs2066818	chr12:56753822	C/A	cg26714650	chr12:56694279	CS	-1.39	-6.91	-0.58	5.45e-10	Psoriasis vulgaris;
THYM	trans	rs4596713	0.507	rs9314865	chr9:71801495	A/G	cg16512924	chr15:28394682	HERC2	0.87	7.25	0.6	1.12e-10	Headache;
THYM	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg18132916	chr6:79620363	NA	-0.59	-5.3	-0.48	7.54e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9650657	0.615	rs2271355	chr8:10692158	C/T	cg12981288	chr8:11183844	MTMR9	-0.5	-4.72	-0.44	7.96e-6	Neuroticism;
THYM	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.36	0.48	5.75e-7	Height;
THYM	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.97	8.07	0.64	2.11e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs7843479	0.965	rs13278159	chr8:21799737	C/A	cg17168535	chr8:21777572	XPO7	0.72	5.12	0.47	1.57e-6	Mean corpuscular volume;
THYM	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg11673840	chr17:47092156	IGF2BP1	-0.54	-5.46	-0.49	3.79e-7	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg06481639	chr22:41940642	POLR3H	0.73	5.29	0.48	7.78e-7	Vitiligo;
THYM	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg27490568	chr2:178487706	NA	0.62	4.92	0.45	3.6e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.78	6.27	0.54	1.08e-8	Blood protein levels;
THYM	cis	rs2046867	0.862	rs9827405	chr3:72827115	C/T	cg25664220	chr3:72788482	NA	-0.8	-6.14	-0.53	1.94e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg05731713	chr7:157510257	PTPRN2	0.52	5.0	0.46	2.64e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg18477163	chr1:228402036	OBSCN	0.66	6.61	0.56	2.24e-9	Diastolic blood pressure;
THYM	cis	rs9790314	1.000	rs9872514	chr3:161042833	T/C	cg04691961	chr3:161091175	C3orf57	-0.53	-4.55	-0.42	1.56e-5	Morning vs. evening chronotype;
THYM	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.65	-5.39	-0.48	5.1e-7	Renal function-related traits (BUN);
THYM	cis	rs1448094	0.511	rs61930590	chr12:86159959	T/A	cg02569458	chr12:86230093	RASSF9	0.68	5.77	0.51	9.71e-8	Major depressive disorder;
THYM	cis	rs4262150	0.767	rs4958596	chr5:152327668	A/G	cg26064142	chr5:152867989	NA	-0.62	-4.56	-0.42	1.51e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs34112283	0.592	rs13004149	chr2:144252485	C/T	cg17056048	chr2:144271431	ARHGAP15	0.65	6.26	0.54	1.09e-8	Neuroticism;
THYM	cis	rs11190604	0.767	rs10883478	chr10:102162852	C/T	cg07570687	chr10:102243282	WNT8B	0.82	7.71	0.62	1.25e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg09307838	chr4:120376055	NA	-0.69	-5.27	-0.48	8.68e-7	Corneal astigmatism;
THYM	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs10203711	1.000	rs1810140	chr2:239568163	T/C	cg14580085	chr2:239553406	NA	0.68	6.18	0.54	1.6e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3733585	0.566	rs35955619	chr4:9918986	T/A	cg02734326	chr4:10020555	SLC2A9	-0.56	-4.6	-0.43	1.31e-5	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2073300	1.000	rs12625804	chr20:23441981	G/A	cg12062639	chr20:23401060	NAPB	1.33	6.11	0.53	2.18e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.65e-6	Aortic root size;
THYM	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg06238570	chr21:40685208	BRWD1	-0.96	-9.16	-0.68	1.02e-14	Cognitive function;
THYM	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs17331151	0.505	rs13066644	chr3:52565247	G/A	cg17372223	chr3:52568218	NT5DC2	0.61	4.96	0.45	3.02e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs12496230	1.000	rs13100186	chr3:66831642	T/C	cg17646820	chr3:66848679	NA	0.87	4.97	0.45	3e-6	Type 2 diabetes;
THYM	cis	rs2396545	0.591	rs12802200	chr11:566936	C/A	cg05717871	chr11:638507	DRD4	-0.7	-5.23	-0.47	9.95e-7	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs7940866	0.903	rs11222421	chr11:130872351	A/T	cg12179176	chr11:130786555	SNX19	0.66	5.18	0.47	1.26e-6	Schizophrenia;
THYM	cis	rs6835098	0.692	rs1316411	chr4:174075143	A/G	cg08422745	chr4:174089978	GALNT7	-0.93	-7.38	-0.6	5.97e-11	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg06064525	chr11:970664	AP2A2	-0.36	-6.98	-0.58	3.94e-10	Alzheimer's disease (late onset);
THYM	cis	rs11252926	0.523	rs816596	chr10:548004	C/T	cg14018140	chr10:458528	DIP2C	-0.55	-6.1	-0.53	2.25e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs1215050	0.740	rs10025482	chr4:99053277	T/C	cg17366294	chr4:99064904	C4orf37	0.43	4.91	0.45	3.73e-6	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg07936489	chr17:37558343	FBXL20	0.84	5.76	0.51	1.03e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs9527	0.590	rs10883836	chr10:104891198	T/C	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6897795	0.680	rs9329133	chr5:177609540	C/T	cg25087499	chr5:177592761	NA	0.55	4.83	0.44	5.21e-6	Plateletcrit;
THYM	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-5.16	-0.47	1.35e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.72	-5.56	-0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61931739	0.500	rs11836207	chr12:34315177	G/A	cg06521331	chr12:34319734	NA	-0.98	-9.64	-0.7	9.74e-16	Morning vs. evening chronotype;
THYM	cis	rs67478160	0.619	rs12897150	chr14:104319530	A/T	cg08213375	chr14:104286397	PPP1R13B	0.56	6.89	0.58	6.05e-10	Schizophrenia;
THYM	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg18132916	chr6:79620363	NA	-0.59	-5.29	-0.48	7.95e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg04972856	chr6:88032051	C6orf162;GJB7	-0.41	-4.8	-0.44	5.86e-6	Monocyte percentage of white cells;
THYM	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs10208940	0.614	rs71413137	chr2:68751578	G/T	cg09157127	chr2:69201416	GKN1	0.89	4.71	0.43	8.61e-6	Urate levels in lean individuals;
THYM	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg06600287	chr1:53387719	ECHDC2	-0.29	-4.69	-0.43	9.17e-6	Monocyte count;
THYM	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	15.13	0.84	4.91e-27	Chronic sinus infection;
THYM	cis	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs728616	0.867	rs61860400	chr10:81723427	T/C	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg20476274	chr7:133979776	SLC35B4	0.73	4.88	0.45	4.34e-6	Mean platelet volume;
THYM	cis	rs240764	0.658	rs6570922	chr6:101177262	C/T	cg21058520	chr6:100914733	NA	0.59	5.27	0.48	8.62e-7	Neuroticism;
THYM	cis	rs3845702	0.800	rs6744281	chr2:180844382	G/A	cg01881094	chr2:180872142	CWC22	-0.89	-5.34	-0.48	6.22e-7	Schizophrenia;
THYM	cis	rs4363385	0.620	rs4388644	chr1:152983674	A/G	cg13444842	chr1:152974279	SPRR3	-0.58	-4.71	-0.44	8.32e-6	Inflammatory skin disease;
THYM	cis	rs4604732	0.536	rs12058821	chr1:247649651	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.72	4.8	0.44	5.95e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs7267979	0.932	rs417130	chr20:25458320	T/C	cg03522245	chr20:25566470	NINL	0.57	4.48	0.42	2.1e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6988636	0.710	rs62521797	chr8:124134321	A/T	cg23067535	chr8:124195133	FAM83A	-1.03	-4.52	-0.42	1.76e-5	Urinary uromodulin levels;
THYM	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1729951	0.575	rs16844325	chr3:136678161	C/G	cg21827317	chr3:136751795	NA	0.75	6.64	0.56	1.92e-9	Neuroticism;
THYM	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg04315214	chr1:2043799	PRKCZ	0.54	4.64	0.43	1.09e-5	Height;
THYM	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg06728252	chr6:26598149	ABT1	-0.43	-5.08	-0.46	1.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8070740	0.891	rs2285747	chr17:5337137	G/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.71	5.22	0.47	1.04e-6	Menopause (age at onset);
THYM	cis	rs4730276	0.674	rs3801934	chr7:107540074	A/G	cg23293999	chr7:106826042	HBP1	-0.6	-4.86	-0.45	4.65e-6	Ulcerative colitis;
THYM	cis	rs2282300	0.739	rs34044331	chr11:30264486	T/C	cg25418670	chr11:30344373	C11orf46	-0.81	-6.87	-0.58	6.66e-10	Morning vs. evening chronotype;
THYM	cis	rs1011018	0.910	rs12673068	chr7:139434215	T/G	cg06079564	chr7:139468310	HIPK2	-0.73	-5.54	-0.49	2.65e-7	Systolic blood pressure;
THYM	cis	rs2625529	0.652	rs2929517	chr15:72332917	T/G	cg16672083	chr15:72433130	SENP8	0.5	4.59	0.43	1.37e-5	Red blood cell count;
THYM	cis	rs288326	0.561	rs77227040	chr2:183894166	T/C	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs35883536	1.000	rs1577508	chr1:101089289	T/C	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs2404602	0.647	rs7165053	chr15:76978918	A/G	cg23625390	chr15:77176239	SCAPER	-0.81	-5.75	-0.51	1.09e-7	Blood metabolite levels;
THYM	cis	rs4237845	0.537	rs9645819	chr12:58270063	T/C	cg00677455	chr12:58241039	CTDSP2	0.78	6.35	0.55	7.51e-9	Intelligence (multi-trait analysis);
THYM	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg21784768	chr11:537496	LRRC56	-1.16	-5.78	-0.51	9.66e-8	Body mass index;
THYM	cis	rs12208915	0.806	rs9361444	chr6:79500073	T/C	cg05283184	chr6:79620031	NA	0.8	5.21	0.47	1.08e-6	Left atrial antero-posterior diameter;
THYM	cis	rs174601	0.833	rs174541	chr11:61565908	T/C	cg19610905	chr11:61596333	FADS2	-0.59	-5.1	-0.46	1.73e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
THYM	cis	rs761746	0.881	rs12484606	chr22:31937476	C/T	cg01338084	chr22:32026380	PISD	-0.57	-4.88	-0.45	4.28e-6	Intelligence;
THYM	cis	rs7247513	0.964	rs1864083	chr19:12707302	T/C	cg01871581	chr19:12707946	ZNF490	-0.95	-11.42	-0.76	1.61e-19	Bipolar disorder;
THYM	cis	rs79815064	0.920	rs80054040	chr3:46340285	C/A	cg20674725	chr3:47020919	NBEAL2	0.71	4.57	0.42	1.47e-5	Macrophage inflammatory protein 1b levels;
THYM	cis	rs7580658	0.864	rs1566823	chr2:128018192	A/G	cg10021288	chr2:128175891	PROC	-0.72	-6.36	-0.55	7.09e-9	Protein C levels;
THYM	cis	rs9788721	0.934	rs1317286	chr15:78896129	A/G	cg18825076	chr15:78729989	IREB2	-0.56	-5.02	-0.46	2.36e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg08564027	chr20:61660810	NA	0.96	10.55	0.73	1.11e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9649213	0.593	rs7776638	chr7:97993506	C/T	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs113123495	0.510	rs1572491	chr19:5704691	A/C	cg26242866	chr19:5711310	LONP1	1.14	4.75	0.44	7.31e-6	Obsessive-compulsive symptoms;
THYM	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg11502198	chr6:26597334	ABT1	0.64	5.68	0.5	1.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg03060546	chr3:49711283	APEH	-0.64	-4.99	-0.46	2.72e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.64	-0.74	7.23e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs2439831	0.571	rs689883	chr15:43812596	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	6.86	0.58	6.84e-10	Lung cancer in ever smokers;
THYM	cis	rs4499344	0.696	rs2868153	chr19:33099277	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.88	7.54	0.61	2.76e-11	Mean platelet volume;
THYM	cis	rs1538970	0.851	rs2055145	chr1:45926495	C/G	cg05343316	chr1:45956843	TESK2	0.78	4.77	0.44	6.56e-6	Platelet count;
THYM	cis	rs13315871	0.858	rs9848825	chr3:58239001	A/G	cg12435725	chr3:58293450	RPP14	-0.53	-5.68	-0.5	1.47e-7	Cholesterol, total;
THYM	cis	rs2456568	0.548	rs7113080	chr11:93657520	G/A	cg26875233	chr11:93583750	C11orf90	-0.52	-5.88	-0.52	6.02e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7159131	0.747	rs11628556	chr14:37042459	G/A	cg01611862	chr14:36982649	SFTA3	0.52	4.72	0.44	7.97e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs6995541	0.529	rs6993121	chr8:10690124	C/T	cg13457217	chr8:10683266	MIR1322;PINX1	-0.67	-5.02	-0.46	2.39e-6	Triglyceride levels;
THYM	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg20887711	chr4:1340912	KIAA1530	-0.71	-6.11	-0.53	2.14e-8	Obesity-related traits;
THYM	cis	rs7264396	0.943	rs11167267	chr20:34109273	G/T	cg26038318	chr20:34205095	SPAG4	0.52	4.46	0.42	2.24e-5	Total cholesterol levels;
THYM	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.44	6.67	0.56	1.66e-9	Obesity-related traits;
THYM	trans	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg19862616	chr7:65841803	NCRNA00174	-1.12	-13.73	-0.82	2.82e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7246657	0.943	rs7252099	chr19:37933780	G/A	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs28595532	0.920	rs116047800	chr4:119773569	G/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg09904177	chr6:26538194	HMGN4	0.64	5.41	0.49	4.78e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	5.38	0.48	5.27e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6541297	0.938	rs1555289	chr1:230292499	C/T	cg05784532	chr1:230284198	GALNT2	-0.9	-5.51	-0.49	3.13e-7	Coronary artery disease;
THYM	cis	rs4919694	0.611	rs2271750	chr10:105174869	A/G	cg04362960	chr10:104952993	NT5C2	-0.78	-4.59	-0.43	1.35e-5	Arsenic metabolism;
THYM	cis	rs4638749	0.677	rs7594896	chr2:108835502	C/T	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.83	-0.44	5.26e-6	Blood pressure;
THYM	cis	rs56104184	0.723	rs73063515	chr19:49407715	C/T	cg17863274	chr19:49399704	TULP2	-1.02	-6.56	-0.56	2.8e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2997447	0.761	rs2802314	chr1:26431337	T/C	cg03844060	chr1:26490628	NA	0.66	4.48	0.42	2.09e-5	QRS complex (12-leadsum);
THYM	cis	rs7267979	1.000	rs6076339	chr20:25348712	T/C	cg08601574	chr20:25228251	PYGB	-0.57	-4.56	-0.42	1.53e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25427524	chr10:38739819	LOC399744	-0.73	-6.77	-0.57	1.04e-9	Extrinsic epigenetic age acceleration;
THYM	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	cis	rs654128	0.640	rs339339	chr6:117214866	A/C	cg12892004	chr6:117198278	RFX6	-0.72	-5.66	-0.5	1.61e-7	Telomere length;
THYM	cis	rs6032067	0.929	rs13039108	chr20:43829584	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13315871	1.000	rs11715445	chr3:58343888	T/C	cg00563845	chr3:58318305	PXK	0.58	5.13	0.47	1.53e-6	Cholesterol, total;
THYM	cis	rs34779708	0.966	rs2045917	chr10:35418526	G/A	cg03585969	chr10:35415529	CREM	0.67	4.76	0.44	6.91e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs1048238	0.506	rs10927867	chr1:16177285	A/G	cg21385522	chr1:16154831	NA	0.68	5.6	0.5	2.12e-7	Systolic blood pressure;
THYM	cis	rs28595532	0.920	rs114940990	chr4:119758568	A/G	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs11792861	0.566	rs966466	chr9:111851333	T/A	cg05043794	chr9:111880884	C9orf5	-0.3	-4.47	-0.42	2.18e-5	Menarche (age at onset);
THYM	cis	rs4363385	0.510	rs7531076	chr1:153039167	G/T	cg13444842	chr1:152974279	SPRR3	-0.61	-4.8	-0.44	5.87e-6	Inflammatory skin disease;
THYM	cis	rs112591243	0.685	rs2839341	chr21:47990008	A/G	cg26904215	chr21:47823096	PCNT	0.99	4.51	0.42	1.86e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg04455712	chr21:45112962	RRP1B	0.57	5.54	0.49	2.69e-7	Mean corpuscular volume;
THYM	cis	rs427394	0.664	rs274701	chr5:6728707	C/A	cg10857441	chr5:6722123	POLS	-0.69	-8.08	-0.64	2.05e-12	Menopause (age at onset);
THYM	cis	rs9790314	0.580	rs10936227	chr3:161043869	A/C	cg04691961	chr3:161091175	C3orf57	-0.56	-4.75	-0.44	7.07e-6	Morning vs. evening chronotype;
THYM	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	9.78	0.71	4.77e-16	Platelet count;
THYM	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg02187348	chr16:89574699	SPG7	0.76	6.18	0.54	1.6e-8	Multiple myeloma (IgH translocation);
THYM	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.78	-7.17	-0.59	1.61e-10	Personality dimensions;
THYM	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg17211192	chr8:82754475	SNX16	0.82	7.41	0.61	5.09e-11	Diastolic blood pressure;
THYM	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs17006441	0.866	rs6805924	chr3:69879670	G/T	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs2495707	0.647	rs1541266	chr10:102421292	C/T	cg00272971	chr10:102419564	NA	-0.55	-6.14	-0.53	1.93e-8	Body mass index;
THYM	cis	rs72712511	0.641	rs4863517	chr4:140773858	C/T	cg15010390	chr4:140216957	NDUFC1	0.62	4.45	0.42	2.33e-5	Intelligence (multi-trait analysis);
THYM	cis	rs240764	0.782	rs369125	chr6:101118400	G/A	cg21058520	chr6:100914733	NA	-0.57	-5.03	-0.46	2.29e-6	Neuroticism;
THYM	cis	rs870825	0.549	rs28542773	chr4:185617935	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs4363385	0.747	rs1415960	chr1:152973571	G/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.53	-0.42	1.71e-5	Inflammatory skin disease;
THYM	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg10057126	chr4:77819792	ANKRD56	0.71	6.06	0.53	2.78e-8	Emphysema distribution in smoking;
THYM	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg04398451	chr17:18023971	MYO15A	-0.83	-7.74	-0.62	1.04e-11	Total body bone mineral density;
THYM	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg05738196	chr6:26577821	NA	0.95	9.89	0.71	2.78e-16	Intelligence (multi-trait analysis);
THYM	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg27490568	chr2:178487706	NA	0.68	5.9	0.52	5.47e-8	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs757110	0.868	rs5219	chr11:17409572	T/C	cg15432903	chr11:17409602	KCNJ11	0.64	7.59	0.61	2.14e-11	Type 2 diabetes;
THYM	cis	rs3892630	0.824	rs2287884	chr19:33321447	A/G	cg22928329	chr19:33183273	NUDT19	-0.78	-5.85	-0.51	6.89e-8	Red blood cell traits;
THYM	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs12519773	0.501	rs4449514	chr5:92521022	T/C	cg18783429	chr5:92414398	NA	0.5	4.91	0.45	3.72e-6	Migraine;
THYM	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg26384229	chr12:38710491	ALG10B	0.94	7.38	0.6	5.97e-11	Bladder cancer;
THYM	cis	rs7107174	1.000	rs2511156	chr11:77971167	G/C	cg02023728	chr11:77925099	USP35	0.69	6.19	0.54	1.55e-8	Testicular germ cell tumor;
THYM	cis	rs611744	0.659	rs669584	chr8:109138107	G/A	cg21045802	chr8:109455806	TTC35	0.59	5.1	0.46	1.73e-6	Dupuytren's disease;
THYM	cis	rs8103278	0.894	rs74821481	chr19:46320041	G/T	cg14061069	chr19:46274453	DMPK	-0.59	-5.74	-0.51	1.13e-7	Coronary artery disease;
THYM	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg00256281	chr22:41985642	PMM1	0.52	4.68	0.43	9.62e-6	Vitiligo;
THYM	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg11861562	chr11:117069780	TAGLN	0.33	4.76	0.44	6.86e-6	Blood protein levels;
THYM	cis	rs897984	0.553	rs2335013	chr16:30877346	T/G	cg05768032	chr16:30646687	NA	-0.45	-4.46	-0.42	2.26e-5	Dementia with Lewy bodies;
THYM	cis	rs137603	0.644	rs94852	chr22:39712334	T/C	cg24268161	chr22:39747459	SYNGR1	0.66	5.38	0.48	5.24e-7	Primary biliary cholangitis;
THYM	cis	rs3135063	0.884	rs3129317	chr4:3287655	A/G	cg00060484	chr4:3287598	NA	-0.44	-4.51	-0.42	1.87e-5	Blood protein levels;
THYM	trans	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg10856724	chr12:34555212	NA	-0.9	-8.08	-0.64	2.05e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	6.26	0.54	1.1e-8	Coronary artery disease;
THYM	cis	rs1729407	0.649	rs2849176	chr11:116696921	C/T	cg08985259	chr11:116699649	APOC3	0.61	5.44	0.49	4.15e-7	Apolipoprotein A-IV levels;
THYM	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg09354556	chr3:47051341	NA	0.45	4.53	0.42	1.72e-5	Colorectal cancer;
THYM	cis	rs9311676	0.632	rs57700771	chr3:58360327	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.6	0.43	1.29e-5	Systemic lupus erythematosus;
THYM	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg08431931	chr22:42394659	WBP2NL	0.71	5.07	0.46	1.98e-6	Birth weight;
THYM	cis	rs61990749	0.544	rs1477259	chr14:78256138	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.0	0.63	3.03e-12	Fibroblast growth factor basic levels;
THYM	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg10862848	chr6:42927986	GNMT	-0.51	-6.79	-0.57	9.87e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7772486	0.875	rs1412080	chr6:146417304	T/C	cg13319975	chr6:146136371	FBXO30	-0.65	-5.32	-0.48	7.02e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9902453	0.740	rs1382391	chr17:28111986	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.46	-0.55	4.52e-9	Coffee consumption (cups per day);
THYM	cis	rs1008375	0.544	rs7685265	chr4:17568510	C/T	cg18681998	chr4:17616180	MED28	0.75	6.29	0.54	9.47e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg16325326	chr1:53192061	ZYG11B	-0.82	-8.47	-0.66	3.11e-13	Monocyte count;
THYM	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-7.53	-0.61	2.9e-11	Lymphocyte percentage of white cells;
THYM	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg03806693	chr22:41940476	POLR3H	1.1	8.41	0.65	4.11e-13	Vitiligo;
THYM	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg14345882	chr6:26364793	BTN3A2	0.63	5.76	0.51	1.01e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6500395	0.962	rs9921741	chr16:48589896	G/A	cg04672837	chr16:48644449	N4BP1	0.47	4.46	0.42	2.23e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg00074818	chr8:8560427	CLDN23	-0.58	-5.52	-0.49	2.9e-7	Obesity-related traits;
THYM	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg05283184	chr6:79620031	NA	-0.94	-9.25	-0.69	6.67e-15	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg24257776	chr3:47051546	LOC100129354	0.45	5.24	0.47	9.68e-7	Colorectal cancer;
THYM	cis	rs6542838	0.671	rs6752025	chr2:99505699	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.54	-4.71	-0.43	8.52e-6	Fear of minor pain;
THYM	cis	rs6570726	0.935	rs434298	chr6:145846873	G/A	cg13319975	chr6:146136371	FBXO30	-0.7	-6.02	-0.53	3.34e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg13395646	chr4:1353034	KIAA1530	-0.56	-5.15	-0.47	1.43e-6	Longevity;
THYM	cis	rs250585	0.736	rs30010	chr16:23422658	G/C	cg00143387	chr16:23521605	GGA2	0.72	5.01	0.46	2.47e-6	Egg allergy;
THYM	cis	rs4654899	0.680	rs4654879	chr1:21186378	G/A	cg01072550	chr1:21505969	NA	0.72	6.91	0.58	5.4e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg02136620	chr5:178986620	RUFY1	0.58	5.74	0.51	1.15e-7	Lung cancer;
THYM	cis	rs7827545	0.620	rs6578009	chr8:135522989	T/C	cg17885191	chr8:135476712	NA	-0.76	-5.77	-0.51	9.81e-8	Hypertension (SNP x SNP interaction);
THYM	cis	rs7528419	1.000	rs12740374	chr1:109817590	G/T	cg00908766	chr1:109817496	CELSR2	-0.91	-7.33	-0.6	7.73e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
THYM	cis	rs72720396	0.803	rs114328297	chr1:91190854	T/G	cg13456504	chr1:91191583	NA	1.03	6.98	0.58	3.91e-10	Morning vs. evening chronotype;Chronotype;
THYM	cis	rs11048434	0.761	rs10842660	chr12:9138897	G/A	cg26114124	chr12:9217669	LOC144571	0.47	4.66	0.43	1.01e-5	Sjögren's syndrome;
THYM	cis	rs7631605	0.870	rs6775008	chr3:37179031	A/G	cg21328643	chr3:37258149	NA	-0.51	-4.88	-0.45	4.33e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg08355456	chr11:67383691	NA	-0.77	-6.54	-0.56	3.05e-9	Mean corpuscular volume;
THYM	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.87	0.45	4.53e-6	Bipolar disorder;
THYM	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg06238570	chr21:40685208	BRWD1	0.72	6.28	0.54	9.9e-9	Menarche (age at onset);
THYM	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg10117171	chr1:25599238	RHD	-0.71	-5.52	-0.49	2.93e-7	Erythrocyte sedimentation rate;
THYM	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg00639195	chr15:79103007	ADAMTS7	0.77	5.97	0.52	4e-8	Coronary artery disease or large artery stroke;
THYM	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs12935418	0.552	rs2911148	chr16:81021894	A/G	cg16651780	chr16:81037892	C16orf61	-0.85	-6.53	-0.56	3.16e-9	Mean corpuscular volume;
THYM	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg22709100	chr7:91322751	NA	-0.62	-4.87	-0.45	4.41e-6	Breast cancer;
THYM	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg11062466	chr8:58055876	NA	0.9	4.5	0.42	1.95e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs6951245	0.542	rs28460147	chr7:1217192	G/A	cg24642844	chr7:1081250	C7orf50	-1.17	-6.05	-0.53	2.85e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs941408	1.000	rs2741990	chr19:2796644	C/T	cg19693284	chr19:2783607	SGTA	0.68	5.25	0.47	9.18e-7	Total cholesterol levels;
THYM	cis	rs611744	0.810	rs619227	chr8:109215100	C/A	cg21045802	chr8:109455806	TTC35	0.71	6.72	0.57	1.33e-9	Dupuytren's disease;
THYM	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg27532560	chr4:187881888	NA	-0.74	-7.62	-0.62	1.86e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg12165864	chr7:66369176	NA	-0.63	-4.95	-0.45	3.27e-6	Aortic root size;
THYM	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.92	-6.03	-0.53	3.11e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg05872129	chr22:39784769	NA	-0.99	-9.59	-0.7	1.25e-15	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs7107174	1.000	rs11237462	chr11:78058812	C/A	cg19901956	chr11:77921274	USP35	-0.67	-5.57	-0.5	2.37e-7	Testicular germ cell tumor;
THYM	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg25554036	chr4:6271136	WFS1	0.63	5.48	0.49	3.53e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg24069376	chr3:38537580	EXOG	0.66	6.58	0.56	2.52e-9	Electrocardiographic conduction measures;
THYM	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg08807101	chr21:30365312	RNF160	-0.81	-6.04	-0.53	2.96e-8	Dental caries;
THYM	cis	rs2806561	0.704	rs2746560	chr1:23526279	G/A	cg12483005	chr1:23474871	LUZP1	0.57	5.78	0.51	9.52e-8	Height;
THYM	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg11764359	chr7:65958608	NA	-0.64	-4.8	-0.44	5.88e-6	Aortic root size;
THYM	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-5.36	-0.48	5.83e-7	Hemoglobin concentration;
THYM	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg06238570	chr21:40685208	BRWD1	0.96	8.89	0.67	3.96e-14	Cognitive function;
THYM	cis	rs6842047	0.706	rs4862666	chr4:187136307	A/G	cg23442198	chr4:187126114	CYP4V2	0.96	4.48	0.42	2.1e-5	Blood protein levels;
THYM	cis	rs61931739	0.635	rs1852225	chr12:33963004	C/T	cg10856724	chr12:34555212	NA	-0.64	-6.04	-0.53	3.04e-8	Morning vs. evening chronotype;
THYM	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg15704280	chr7:45808275	SEPT13	-0.99	-11.39	-0.76	1.85e-19	Coronary artery disease;
THYM	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg04362960	chr10:104952993	NT5C2	0.57	4.68	0.43	9.61e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs250585	0.850	rs9707	chr16:23534098	G/A	cg00143387	chr16:23521605	GGA2	-0.72	-4.58	-0.42	1.43e-5	Egg allergy;
THYM	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg24692254	chr21:30365293	RNF160	-0.97	-9.06	-0.68	1.71e-14	Dental caries;
THYM	cis	rs7944584	0.511	rs10838725	chr11:47557871	T/C	cg20307385	chr11:47447363	PSMC3	0.88	6.93	0.58	5.09e-10	Fasting blood glucose;Fasting blood glucose (BMI interaction);
THYM	cis	rs941408	0.963	rs1640268	chr19:2791469	T/C	cg17333051	chr19:2783644	SGTA	0.58	5.08	0.46	1.89e-6	Total cholesterol levels;
THYM	cis	rs2625529	0.824	rs4411469	chr15:72421689	A/G	cg16672083	chr15:72433130	SENP8	-0.54	-4.78	-0.44	6.33e-6	Red blood cell count;
THYM	cis	rs12257961	0.521	rs10796280	chr10:15375511	A/T	cg10616319	chr10:15468812	NA	-0.66	-5.33	-0.48	6.53e-7	Selective IgA deficiency;
THYM	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg26384229	chr12:38710491	ALG10B	-0.9	-7.35	-0.6	6.77e-11	Bladder cancer;
THYM	cis	rs9921222	0.597	rs7193109	chr16:413523	T/G	cg07492924	chr16:433825	LOC100134368	0.44	5.2	0.47	1.15e-6	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg16405210	chr4:1374714	KIAA1530	-0.77	-6.65	-0.56	1.88e-9	Longevity;
THYM	cis	rs9906944	0.707	rs729003	chr17:47117775	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.49	-4.47	-0.42	2.15e-5	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs36051895	0.632	rs10121316	chr9:5147539	C/T	cg02405213	chr9:5042618	JAK2	1.03	11.3	0.76	2.81e-19	Pediatric autoimmune diseases;
THYM	cis	rs4662945	0.525	rs4662951	chr2:130256272	C/T	cg05903289	chr2:130345205	NA	-0.55	-5.12	-0.46	1.62e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs665401	0.965	rs1321366	chr6:117240593	G/A	cg20376953	chr6:117187980	NA	0.6	4.67	0.43	9.78e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg23978390	chr7:1156363	C7orf50	0.68	5.17	0.47	1.3e-6	Longevity;Endometriosis;
THYM	cis	rs28595532	0.920	rs116047800	chr4:119773569	G/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.12	8.84	0.67	5.07e-14	Cognitive test performance;
THYM	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs34638657	1.000	rs11639926	chr16:82152710	A/C	cg09894383	chr16:82067445	HSD17B2	-0.48	-4.91	-0.45	3.73e-6	Lung adenocarcinoma;
THYM	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg18876405	chr7:65276391	NA	0.58	4.83	0.44	5.18e-6	Aortic root size;
THYM	cis	rs6901250	1.000	rs6924002	chr6:117114223	A/T	cg12892004	chr6:117198278	RFX6	0.72	6.78	0.57	1.02e-9	C-reactive protein levels;
THYM	cis	rs1950500	0.509	rs12882558	chr14:24819233	G/A	cg22990158	chr14:24802150	ADCY4	-0.44	-4.84	-0.44	5.03e-6	Height;
THYM	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg01416388	chr22:39784598	NA	-0.71	-6.02	-0.53	3.3e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg09307838	chr4:120376055	NA	0.68	5.08	0.46	1.89e-6	Corneal astigmatism;
THYM	cis	rs7107174	1.000	rs1893448	chr11:77969180	G/A	cg02023728	chr11:77925099	USP35	0.7	6.44	0.55	4.94e-9	Testicular germ cell tumor;
THYM	cis	rs28595532	0.920	rs116791817	chr4:119763303	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.05	7.35	0.6	6.78e-11	Platelet count;
THYM	cis	rs7923452	0.507	rs215494	chr10:30776589	T/G	cg25182066	chr10:30743637	MAP3K8	-0.51	-4.46	-0.42	2.22e-5	Itch intensity from mosquito bite;
THYM	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg02136620	chr5:178986620	RUFY1	0.58	5.74	0.51	1.15e-7	Lung cancer;
THYM	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.1	-0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg10792982	chr14:105748885	BRF1	0.75	7.8	0.62	7.96e-12	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4660306	1.000	rs2356559	chr1:45981512	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.62	-4.94	-0.45	3.34e-6	Homocysteine levels;
THYM	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg08847533	chr14:75593920	NEK9	-1.02	-11.28	-0.76	3.21e-19	Height;
THYM	cis	rs1021993	0.868	rs6685289	chr1:209530669	G/C	cg06155620	chr1:209527581	NA	-0.65	-5.13	-0.47	1.52e-6	Gut microbiome composition (winter);
THYM	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs9527	0.590	rs943039	chr10:104825132	C/T	cg04362960	chr10:104952993	NT5C2	0.6	4.55	0.42	1.56e-5	Arsenic metabolism;
THYM	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs986417	1.000	rs1313243	chr14:60876398	C/T	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs7429990	0.965	rs9854454	chr3:48012797	A/G	cg02219026	chr3:48282209	ZNF589	0.6	4.5	0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs40363	0.680	rs72778116	chr16:3530752	A/G	cg00484396	chr16:3507460	NAT15	0.63	5.48	0.49	3.44e-7	Tuberculosis;
THYM	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6684428	1.000	rs7540772	chr1:56375368	C/G	cg11651538	chr1:56320950	NA	-0.58	-4.46	-0.42	2.24e-5	Airflow obstruction;
THYM	cis	rs9296092	0.517	rs55963187	chr6:33523778	G/C	cg13560919	chr6:33536144	NA	-0.96	-9.45	-0.7	2.53e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.5	-4.96	-0.45	3.07e-6	Crohn's disease;
THYM	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg25072359	chr17:41440525	NA	0.72	5.26	0.47	8.95e-7	Menopause (age at onset);
THYM	cis	rs7917772	0.582	rs10786696	chr10:104378134	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg27284194	chr4:1044797	NA	0.89	9.52	0.7	1.74e-15	Recombination rate (males);
THYM	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06481639	chr22:41940642	POLR3H	0.72	5.15	0.47	1.42e-6	Vitiligo;
THYM	cis	rs9644630	0.841	rs6984449	chr8:19327959	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.71	7.43	0.61	4.6e-11	Oropharynx cancer;
THYM	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21659725	chr3:3221576	CRBN	0.9	9.83	0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.526	rs835608	chr1:53169758	T/A	cg24675658	chr1:53192096	ZYG11B	0.83	7.23	0.6	1.22e-10	Monocyte count;
THYM	cis	rs12410462	0.581	rs75219436	chr1:227546617	C/T	cg04117972	chr1:227635322	NA	0.77	4.68	0.43	9.4e-6	Major depressive disorder;
THYM	cis	rs7119	0.635	rs938090	chr15:77879975	A/G	cg10437265	chr15:77819839	NA	-0.61	-5.83	-0.51	7.54e-8	Type 2 diabetes;
THYM	cis	rs9443645	0.507	rs9352633	chr6:79462623	C/G	cg04547799	chr6:79944526	HMGN3	-0.68	-5.07	-0.46	1.93e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4595586	0.545	rs2388177	chr12:39364403	T/C	cg13010199	chr12:38710504	ALG10B	0.61	4.65	0.43	1.05e-5	Morning vs. evening chronotype;
THYM	cis	rs1270639	0.778	rs2952650	chr7:157450939	C/T	cg13357408	chr7:157437802	PTPRN2	0.48	4.85	0.45	4.74e-6	Colorectal cancer;
THYM	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.83	8.44	0.65	3.47e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg17173187	chr15:85201210	NMB	0.54	5.31	0.48	7.17e-7	Schizophrenia;
THYM	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg00640147	chr17:61958756	GH2	-0.44	-4.82	-0.44	5.49e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs10516089	0.504	rs28439361	chr5:171139857	G/A	cg17535961	chr5:171094783	NA	0.41	4.47	0.42	2.18e-5	Venous thromboembolism (SNP x SNP interaction);
THYM	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg04282206	chr17:62833786	PLEKHM1P	0.82	7.53	0.61	2.9100000000000002e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg08859206	chr1:53392774	SCP2	-0.65	-7.37	-0.6	6.31e-11	Monocyte count;
THYM	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg01579765	chr21:45077557	HSF2BP	-0.51	-8.12	-0.64	1.72e-12	Mean corpuscular volume;
THYM	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg02725872	chr8:58115012	NA	-0.9	-5.24	-0.47	9.85e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs778371	0.723	rs1973675	chr2:233636450	C/T	cg08000102	chr2:233561755	GIGYF2	-0.86	-7.88	-0.63	5.28e-12	Schizophrenia;
THYM	cis	rs6598955	0.543	rs60433268	chr1:26548055	A/C	cg04990556	chr1:26633338	UBXN11	0.96	6.06	0.53	2.7e-8	Obesity-related traits;
THYM	cis	rs1267303	0.600	rs57100184	chr1:47004710	A/C	cg25110126	chr1:46999211	NA	0.77	6.12	0.53	2.06e-8	Monobrow;
THYM	cis	rs9733	0.596	rs72702552	chr1:150677462	G/A	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs11756438	0.683	rs4027595	chr6:119017504	C/T	cg21191810	chr6:118973309	C6orf204	-0.54	-5.08	-0.46	1.89e-6	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.23	4.86	0.45	4.72e-6	Obesity-related traits;
THYM	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg04455712	chr21:45112962	RRP1B	-0.56	-5.48	-0.49	3.47e-7	Mean corpuscular volume;
THYM	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg13147721	chr7:65941812	NA	-1.18	-7.66	-0.62	1.54e-11	Diabetic kidney disease;
THYM	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg01324343	chr3:183735012	ABCC5	0.9	13.47	0.81	9.06e-24	Anterior chamber depth;
THYM	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg26384229	chr12:38710491	ALG10B	-0.82	-8.17	-0.64	1.32e-12	Heart rate;
THYM	cis	rs317689	0.690	rs10878947	chr12:69642683	A/T	cg20891283	chr12:69753455	YEATS4	0.62	4.57	0.42	1.48e-5	Response to diuretic therapy;
THYM	cis	rs6570726	0.791	rs6570695	chr6:145911286	C/A	cg05347473	chr6:146136440	FBXO30	0.58	4.51	0.42	1.85e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs877282	0.947	rs7475589	chr10:767479	C/G	cg10556349	chr10:835070	NA	-0.82	-5.62	-0.5	1.87e-7	Uric acid levels;
THYM	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg07424592	chr7:64974309	NA	0.99	5.15	0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs3812049	0.784	rs6889311	chr5:127431285	A/G	cg05443326	chr5:126853169	PRRC1	-0.65	-4.49	-0.42	2.02e-5	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg06636001	chr8:8085503	FLJ10661	0.57	5.04	0.46	2.19e-6	Joint mobility (Beighton score);
THYM	cis	rs7508	0.535	rs11779988	chr8:17784414	T/C	cg18067069	chr8:17937731	ASAH1	-0.65	-4.97	-0.45	2.97e-6	Atrial fibrillation;
THYM	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg23758822	chr17:41437982	NA	1.19	11.23	0.76	3.96e-19	Menopause (age at onset);
THYM	cis	rs13185784	0.703	rs55756747	chr5:179675052	C/A	cg13944838	chr5:179740914	GFPT2	0.75	5.05	0.46	2.15e-6	TRAIL levels;
THYM	cis	rs3096299	0.838	rs3102376	chr16:89402473	A/C	cg10452248	chr16:89456354	ANKRD11	0.57	4.49	0.42	2e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg20387954	chr3:183756860	HTR3D	0.59	4.85	0.45	4.87e-6	Anterior chamber depth;
THYM	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg07690219	chr3:49449608	TCTA;RHOA	0.7	4.71	0.43	8.57e-6	Menarche (age at onset);
THYM	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg14893161	chr1:205819251	PM20D1	-0.59	-4.57	-0.42	1.49e-5	Menarche (age at onset);
THYM	cis	rs4285028	0.747	rs9824235	chr3:121432177	G/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.85	-7.37	-0.6	6.22e-11	Multiple sclerosis;
THYM	cis	rs112998813	0.571	rs7332124	chr13:114930057	A/C	cg09715768	chr13:114202537	TMCO3	0.71	4.63	0.43	1.15e-5	Nodular sclerosis Hodgkin lymphoma;
THYM	cis	rs921968	0.678	rs660432	chr2:219432127	C/T	cg02176678	chr2:219576539	TTLL4	0.64	6.08	0.53	2.49e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7524258	0.900	rs1476047	chr1:7312172	C/T	cg07173049	chr1:7289937	CAMTA1	0.71	5.66	0.5	1.59e-7	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs7213347	0.707	rs216196	chr17:2202943	T/C	cg27406664	chr17:2294951	MNT	0.56	4.45	0.42	2.36e-5	Total body bone mineral density;
THYM	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg00278517	chr6:167070616	RPS6KA2	-0.34	-4.64	-0.43	1.13e-5	Crohn's disease;
THYM	cis	rs240764	0.644	rs4329121	chr6:101087507	G/C	cg21058520	chr6:100914733	NA	-0.61	-5.13	-0.47	1.53e-6	Neuroticism;
THYM	cis	rs7071206	0.947	rs10509391	chr10:79422369	G/A	cg07817648	chr10:79422355	NA	-0.94	-7.17	-0.59	1.59e-10	Bone mineral density;
THYM	cis	rs8051149	0.688	rs12444670	chr16:87870312	C/T	cg01412419	chr16:87856264	NA	0.69	5.41	0.49	4.69e-7	Blood metabolite levels;
THYM	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg08835221	chr22:38071607	LGALS1	0.38	5.34	0.48	6.29e-7	Fat distribution (HIV);
THYM	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg20503657	chr10:835505	NA	1.01	5.76	0.51	1.04e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs5758511	0.514	rs5758586	chr22:42517471	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.66	6.84	0.57	7.82e-10	Birth weight;
THYM	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg18681998	chr4:17616180	MED28	0.85	7.68	0.62	1.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7937682	0.602	rs4936804	chr11:111743851	A/C	cg09085632	chr11:111637200	PPP2R1B	1.19	12.58	0.79	6.05e-22	Primary sclerosing cholangitis;
THYM	cis	rs2637266	0.935	rs2583055	chr10:78400029	C/T	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs7172809	0.599	rs2307141	chr15:77756418	A/G	cg10437265	chr15:77819839	NA	-0.5	-4.57	-0.42	1.47e-5	Glucose homeostasis traits;
THYM	cis	rs2041895	0.509	rs2072559	chr12:107307287	T/G	cg13944111	chr12:107296891	NA	0.68	5.36	0.48	5.94e-7	Glaucoma (low intraocular pressure);
THYM	cis	rs7786808	0.579	rs55701656	chr7:158188812	G/A	cg01191920	chr7:158217561	PTPRN2	-0.93	-9.5	-0.7	1.93e-15	Obesity-related traits;
THYM	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg12560992	chr17:57184187	TRIM37	-0.92	-8.68	-0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg16624210	chr5:671434	TPPP	0.74	6.34	0.54	7.87e-9	Obesity-related traits;
THYM	cis	rs868036	1.000	rs1026732	chr15:68095085	C/T	cg24579218	chr15:68104479	NA	-0.65	-6.51	-0.56	3.59e-9	Restless legs syndrome;
THYM	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-7.24	-0.6	1.15e-10	Schizophrenia;
THYM	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg15445000	chr17:37608096	MED1	-0.44	-5.1	-0.46	1.73e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7412746	0.611	rs10888394	chr1:150749913	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.25	0.47	9.11e-7	Melanoma;
THYM	cis	rs36051895	0.659	rs3780367	chr9:5068755	T/G	cg02405213	chr9:5042618	JAK2	-1.02	-11.39	-0.76	1.87e-19	Pediatric autoimmune diseases;
THYM	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.76	-0.44	7.03e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg04455712	chr21:45112962	RRP1B	0.54	5.05	0.46	2.15e-6	Mean corpuscular volume;
THYM	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg04317338	chr11:64019027	PLCB3	0.87	6.04	0.53	3.05e-8	Mean platelet volume;
THYM	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg03433033	chr1:76189801	ACADM	-0.64	-5.99	-0.52	3.72e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.73	-5.59	-0.5	2.17e-7	Eosinophil percentage of white cells;
THYM	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg26384229	chr12:38710491	ALG10B	0.73	5.4	0.48	5.01e-7	Morning vs. evening chronotype;
THYM	cis	rs7941600	0.786	rs7925418	chr11:9197500	T/C	cg21110646	chr11:9336536	TMEM41B	0.87	4.48	0.42	2.05e-5	Coronary artery disease;
THYM	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg18681998	chr4:17616180	MED28	0.82	6.88	0.58	6.2e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs12935418	0.583	rs2098726	chr16:81025275	C/T	cg16651780	chr16:81037892	C16orf61	-0.84	-6.56	-0.56	2.82e-9	Mean corpuscular volume;
THYM	cis	rs7586879	0.593	rs6733224	chr2:25130907	C/T	cg15423357	chr2:25149977	NA	-0.7	-7.76	-0.62	9.56e-12	Body mass index;
THYM	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg12560992	chr17:57184187	TRIM37	-0.77	-6.6	-0.56	2.3e-9	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg11663144	chr21:46675770	NA	-0.71	-8.52	-0.66	2.34e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg02820040	chr2:241836501	C2orf54	-0.32	-6.25	-0.54	1.19e-8	Urinary metabolites;
THYM	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9633740	1.000	rs7896832	chr10:82257570	T/C	cg01528321	chr10:82214614	TSPAN14	0.94	4.48	0.42	2.08e-5	Post bronchodilator FEV1;
THYM	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg23422044	chr7:1970798	MAD1L1	-0.74	-5.13	-0.47	1.56e-6	Bipolar disorder;
THYM	cis	rs1018836	0.923	rs7826178	chr8:91649592	C/A	cg16814680	chr8:91681699	NA	-0.99	-9.51	-0.7	1.85e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs990171	0.955	rs6761825	chr2:103075561	T/C	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.13	-0.47	1.5e-6	Lymphocyte counts;
THYM	cis	rs72627123	0.867	rs113257091	chr14:74461121	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs747334	0.811	rs11186384	chr10:92714887	C/G	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs6960043	0.818	rs10244051	chr7:15063833	T/G	cg19272540	chr7:15055459	NA	-0.46	-5.05	-0.46	2.14e-6	Type 2 diabetes;
THYM	cis	rs1160297	0.609	rs12622966	chr2:53078420	G/C	cg07782112	chr2:53107842	NA	0.77	6.38	0.55	6.52e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.01	8.08	0.64	2.07e-12	Age-related macular degeneration (geographic atrophy);
THYM	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.38	-8.77	-0.67	7.08e-14	Hemostatic factors and hematological phenotypes;
THYM	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.99	-12.49	-0.79	9.26e-22	Chronic sinus infection;
THYM	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg14004847	chr7:1930337	MAD1L1	-0.7	-5.48	-0.49	3.44e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg07606381	chr6:8435919	SLC35B3	0.62	4.52	0.42	1.76e-5	Motion sickness;
THYM	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	5.28	0.48	8.3e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4619890	0.677	rs11724720	chr4:7786031	C/T	cg00251875	chr4:7801337	AFAP1	-0.76	-6.06	-0.53	2.79e-8	Glaucoma (primary open-angle);
THYM	cis	rs8073060	0.963	rs35614987	chr17:33869466	A/C	cg07895132	chr17:33825172	SLFN12L	0.61	5.6	0.5	2.08e-7	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg04234412	chr22:24373322	LOC391322	-0.9	-8.82	-0.67	5.39e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.24	5.44	0.49	4.09e-7	Obesity-related traits;
THYM	cis	rs12282928	0.959	rs11039631	chr11:48297062	A/G	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg24006582	chr15:45444508	DUOX1	-0.83	-7.16	-0.59	1.7e-10	Uric acid levels;
THYM	cis	rs17209837	0.646	rs55747905	chr7:87127099	T/C	cg04996195	chr7:87105398	ABCB4	0.64	4.68	0.43	9.48e-6	Gallbladder cancer;
THYM	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11890956	chr21:40555474	PSMG1	0.68	5.44	0.49	4.16e-7	Cognitive function;
THYM	cis	rs7599312	0.534	rs7355673	chr2:213404389	T/C	cg16329650	chr2:213403929	ERBB4	1.04	12.32	0.78	2.07e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11077998	0.933	rs6502121	chr17:80531314	A/G	cg10255544	chr17:80519551	FOXK2	0.51	4.49	0.42	2.02e-5	Reticulocyte fraction of red cells;
THYM	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg02725872	chr8:58115012	NA	-1.09	-8.15	-0.64	1.43e-12	Developmental language disorder (linguistic errors);
THYM	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg24910161	chr17:38119198	GSDMA	0.47	4.93	0.45	3.55e-6	Self-reported allergy;
THYM	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg24874828	chr4:187887005	NA	-0.72	-7.44	-0.61	4.48e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs728616	0.867	rs12415870	chr10:81949470	A/G	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs10782582	0.593	rs11589276	chr1:76105545	G/A	cg22875332	chr1:76189707	ACADM	-0.54	-5.1	-0.46	1.75e-6	Daytime sleep phenotypes;
THYM	cis	rs4851254	0.579	rs78633727	chr2:100669457	T/C	cg22139774	chr2:100720529	AFF3	-0.39	-4.49	-0.42	1.99e-5	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg11764359	chr7:65958608	NA	-0.82	-6.45	-0.55	4.58e-9	Aortic root size;
THYM	cis	rs9790314	1.000	rs459697	chr3:161093420	G/A	cg03342759	chr3:160939853	NMD3	-0.75	-6.75	-0.57	1.18e-9	Morning vs. evening chronotype;
THYM	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg08736216	chr1:53307985	ZYG11A	-0.65	-5.73	-0.51	1.19e-7	Monocyte count;
THYM	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg20887711	chr4:1340912	KIAA1530	0.96	8.77	0.67	7.02e-14	Longevity;
THYM	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg06808227	chr14:105710500	BRF1	-1.03	-8.98	-0.68	2.5e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg06108461	chr20:60628389	TAF4	-0.83	-6.97	-0.58	4.2e-10	Body mass index;
THYM	cis	rs7843479	0.965	rs13269198	chr8:21823025	G/A	cg17168535	chr8:21777572	XPO7	0.71	5.15	0.47	1.39e-6	Mean corpuscular volume;
THYM	cis	rs34638657	0.872	rs2911423	chr16:82188801	C/T	cg09439754	chr16:82129088	HSD17B2	-0.6	-5.24	-0.47	9.81e-7	Lung adenocarcinoma;
THYM	cis	rs2070488	1.000	rs13089394	chr3:38446309	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	6.66	0.56	1.76e-9	Electrocardiographic conduction measures;
THYM	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg20887711	chr4:1340912	KIAA1530	0.62	4.73	0.44	7.79e-6	Obesity-related traits;
THYM	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg12379764	chr21:47803548	PCNT	-0.7	-4.94	-0.45	3.31e-6	Testicular germ cell tumor;
THYM	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg11764359	chr7:65958608	NA	0.72	5.0	0.46	2.66e-6	Aortic root size;
THYM	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg26513180	chr16:89883248	FANCA	0.67	6.59	0.56	2.39e-9	Vitiligo;
THYM	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg03806693	chr22:41940476	POLR3H	-1.23	-10.66	-0.74	6.4e-18	Vitiligo;
THYM	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.96	-4.8	-0.44	5.99e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs476633	0.708	rs8031159	chr15:41445199	T/C	cg21153102	chr15:41252147	NA	0.59	4.6	0.43	1.28e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs3892630	0.588	rs28787932	chr19:33226229	T/C	cg22980127	chr19:33182716	NUDT19	1.14	10.49	0.73	1.46e-17	Red blood cell traits;
THYM	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg17063962	chr7:91808500	NA	-1.1	-12.47	-0.79	1.01e-21	Breast cancer;
THYM	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg22433210	chr17:43662623	NA	-1.05	-8.08	-0.64	2e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7172809	0.599	rs17472200	chr15:77783812	C/G	cg22256960	chr15:77711686	NA	-0.61	-4.47	-0.42	2.18e-5	Glucose homeostasis traits;
THYM	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg15052019	chr19:19431593	KIAA0892;SF4	-0.66	-5.26	-0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg22166914	chr1:53195759	ZYG11B	-0.96	-11.92	-0.77	1.4e-20	Monocyte count;
THYM	cis	rs3814113	0.546	rs7868157	chr9:16851977	C/A	cg13173848	chr9:16870893	BNC2	0.73	5.15	0.47	1.44e-6	Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;Ovarian cancer;
THYM	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg11266682	chr4:10021025	SLC2A9	-0.68	-9.22	-0.69	7.53e-15	Bone mineral density;
THYM	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg00310523	chr12:86230176	RASSF9	0.53	4.79	0.44	6.05e-6	Major depressive disorder;
THYM	cis	rs868036	1.000	rs9972436	chr15:68098027	G/C	cg24579218	chr15:68104479	NA	-0.65	-6.51	-0.56	3.59e-9	Restless legs syndrome;
THYM	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.65e-6	Aortic root size;
THYM	cis	rs1524976	1.000	rs1524976	chr3:65486388	A/G	cg16238336	chr3:65465873	MAGI1	1.05	6.05	0.53	2.81e-8	PR interval;
THYM	cis	rs7507204	0.906	rs11671513	chr19:3429937	C/T	cg08380311	chr19:3435252	NFIC	0.82	6.77	0.57	1.07e-9	Height;
THYM	cis	rs4631830	0.720	rs2125771	chr10:51506957	C/T	cg16070123	chr10:51489643	NA	-0.53	-4.91	-0.45	3.71e-6	Prostate-specific antigen levels;
THYM	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg17294928	chr15:75287854	SCAMP5	1.02	9.28	0.69	5.6e-15	Blood trace element (Zn levels);
THYM	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2505998	0.833	rs752977	chr10:43588381	T/C	cg06632098	chr10:43605906	RET	-1.1	-10.7	-0.74	5.44e-18	Hirschsprung disease;
THYM	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg15741354	chr8:8146129	NA	-0.29	-4.82	-0.44	5.39e-6	Joint mobility (Beighton score);
THYM	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg19743168	chr1:23544995	NA	-0.63	-6.53	-0.56	3.22e-9	Height;
THYM	cis	rs8050907	0.661	rs74925434	chr16:4580079	G/A	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.13	4.76	0.44	6.97e-6	Obesity-related traits;
THYM	cis	rs7246657	0.550	rs10411176	chr19:37686953	G/T	cg23950597	chr19:37808831	NA	-0.81	-4.88	-0.45	4.35e-6	Coronary artery calcification;
THYM	cis	rs2688608	0.592	rs10762559	chr10:75486453	G/C	cg19442545	chr10:75533431	FUT11	-0.58	-5.96	-0.52	4.22e-8	Inflammatory bowel disease;
THYM	cis	rs752010	0.967	rs6703597	chr1:42097904	C/T	cg04490934	chr1:41978749	HIVEP3	-0.56	-4.49	-0.42	2.02e-5	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg18825531	chr11:62321136	NA	-0.44	-5.11	-0.46	1.66e-6	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6032067	1.000	rs13041304	chr20:43811697	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg18876405	chr7:65276391	NA	0.57	4.83	0.44	5.27e-6	Aortic root size;
THYM	cis	rs72781680	0.950	rs72798404	chr2:24180125	C/T	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs308403	0.509	rs7690409	chr4:123666757	A/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.97	7.96	0.63	3.73e-12	Blood protein levels;
THYM	cis	rs7082209	0.838	rs800332	chr10:44806670	C/A	cg08683644	chr10:44853092	NA	0.6	4.87	0.45	4.44e-6	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
THYM	cis	rs2273669	0.504	rs117426315	chr6:109450464	G/A	cg17117243	chr6:109341365	SESN1	-0.92	-5.47	-0.49	3.63e-7	Prostate cancer;
THYM	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg04944784	chr2:26401820	FAM59B	-1.05	-7.66	-0.62	1.54e-11	Gut microbiome composition (summer);
THYM	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg04111992	chr7:158790115	NA	0.59	4.84	0.44	5.04e-6	Facial morphology (factor 20);
THYM	cis	rs8070128	0.600	rs8071238	chr17:17900990	T/C	cg16928487	chr17:17741425	SREBF1	-0.47	-4.45	-0.42	2.3e-5	Total body bone mineral density;
THYM	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg26384229	chr12:38710491	ALG10B	0.99	7.63	0.62	1.81e-11	Bladder cancer;
THYM	cis	rs9359856	0.673	rs2039053	chr6:90303760	G/A	cg13799429	chr6:90582589	CASP8AP2	0.77	7.04	0.59	3.06e-10	Bipolar disorder;
THYM	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg26769984	chr7:1090371	C7orf50	0.83	5.41	0.49	4.73e-7	Bronchopulmonary dysplasia;
THYM	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg26879891	chr1:152191343	HRNR	-0.56	-4.86	-0.45	4.69e-6	Inflammatory skin disease;
THYM	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	5.99	0.52	3.67e-8	Rheumatoid arthritis;
THYM	cis	rs58785573	0.504	rs9522	chr4:38666972	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.56	4.49	0.42	1.99e-5	Lymphocyte percentage of white cells;
THYM	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg16405210	chr4:1374714	KIAA1530	-0.74	-6.07	-0.53	2.6e-8	Longevity;
THYM	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg00684032	chr4:1343700	KIAA1530	-0.61	-5.4	-0.48	4.94e-7	Obesity-related traits;
THYM	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg06766960	chr11:133703094	NA	0.52	4.83	0.44	5.25e-6	Childhood ear infection;
THYM	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg12908607	chr1:44402522	ARTN	-0.59	-4.96	-0.45	3.12e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs61990749	0.597	rs9323650	chr14:78150336	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	1.15	7.96	0.63	3.68e-12	Fibroblast growth factor basic levels;
THYM	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-7.24	-0.6	1.15e-10	Schizophrenia;
THYM	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7043114	0.563	rs987554	chr9:95298738	A/G	cg14631576	chr9:95140430	CENPP	-0.76	-7.12	-0.59	2.08e-10	Height;
THYM	cis	rs1185460	0.904	rs1003081	chr11:118913993	A/G	cg19721609	chr11:118800731	NA	-0.57	-4.64	-0.43	1.13e-5	Coronary artery disease;
THYM	cis	rs6496932	0.755	rs6497021	chr15:85896267	G/A	cg19183879	chr15:85880815	NA	-0.5	-4.49	-0.42	1.98e-5	Central corneal thickness;Corneal structure;
THYM	cis	rs61931739	0.817	rs10743841	chr12:34252870	T/C	cg06521331	chr12:34319734	NA	-0.61	-5.08	-0.46	1.92e-6	Morning vs. evening chronotype;
THYM	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg05802129	chr4:122689817	NA	-0.59	-4.63	-0.43	1.15e-5	Type 2 diabetes;
THYM	cis	rs4845570	1.000	rs6673002	chr1:151743275	G/T	cg07092448	chr1:151763213	TDRKH	1.03	6.71	0.57	1.42e-9	Coronary artery disease;
THYM	cis	rs1348850	0.645	rs7571386	chr2:178442687	A/C	cg27490568	chr2:178487706	NA	0.5	4.51	0.42	1.88e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs1335645	0.570	rs1591456	chr1:111632335	G/A	cg00321911	chr1:111669324	DRAM2	-1.23	-6.78	-0.57	1.02e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9486719	1.000	rs34209750	chr6:96882215	G/T	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs425277	0.958	rs262687	chr1:2117155	G/A	cg13918804	chr1:2043761	PRKCZ	-0.62	-4.6	-0.43	1.28e-5	Height;
THYM	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Body mass index;
THYM	cis	rs7781977	0.920	rs7805434	chr7:50340750	G/C	cg01139861	chr7:50343298	IKZF1	0.71	6.98	0.58	3.88e-10	IgG glycosylation;
THYM	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg22907277	chr7:1156413	C7orf50	0.73	4.45	0.42	2.32e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg24531977	chr5:56204891	C5orf35	-0.72	-5.83	-0.51	7.64e-8	Initial pursuit acceleration;
THYM	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg05283184	chr6:79620031	NA	-0.91	-8.67	-0.66	1.16e-13	Intelligence (multi-trait analysis);
THYM	cis	rs3126085	0.935	rs72696997	chr1:152257099	A/C	cg10321714	chr1:152280068	FLG	-0.76	-5.68	-0.5	1.47e-7	Atopic dermatitis;
THYM	cis	rs2732480	0.500	rs12829841	chr12:48628739	A/G	cg21466736	chr12:48725269	NA	-0.55	-5.02	-0.46	2.43e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg02487422	chr3:49467188	NICN1	0.62	4.8	0.44	5.96e-6	Resting heart rate;
THYM	cis	rs1065656	0.553	rs344357	chr16:1836255	C/G	cg14074117	chr16:1909714	C16orf73	-0.58	-4.68	-0.43	9.62e-6	Insulin-like growth factors;
THYM	cis	rs2885056	0.783	rs73007347	chr19:10650649	C/T	cg04833646	chr19:10679720	CDKN2D	1.09	9.3	0.69	5.22e-15	Red cell distribution width;
THYM	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9399401	0.667	rs34018047	chr6:142790873	G/C	cg03128060	chr6:142623767	GPR126	0.69	8.91	0.67	3.5e-14	Chronic obstructive pulmonary disease;
THYM	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg00277334	chr10:82204260	NA	-0.52	-5.37	-0.48	5.53e-7	Post bronchodilator FEV1;
THYM	cis	rs6500395	0.775	rs7198145	chr16:48666500	A/C	cg04672837	chr16:48644449	N4BP1	0.47	4.62	0.43	1.18e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2637266	0.783	rs7900420	chr10:78476543	T/C	cg18941641	chr10:78392320	NA	0.71	5.95	0.52	4.42e-8	Pulmonary function;
THYM	cis	rs1904096	0.506	rs4558832	chr4:95148042	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.1	-0.46	1.7e-6	Type 2 diabetes;
THYM	cis	rs6435161	1.000	rs72926976	chr2:203512138	C/A	cg18429434	chr2:203499731	FAM117B	-0.76	-5.01	-0.46	2.49e-6	Total cholesterol levels;
THYM	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg04267008	chr7:1944627	MAD1L1	-0.69	-6.47	-0.55	4.25e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs13102973	0.932	rs6858552	chr4:135864734	C/T	cg14419869	chr4:135874104	NA	-0.82	-7.94	-0.63	4.06e-12	Subjective well-being;
THYM	cis	rs17209837	0.564	rs117373803	chr7:87096783	A/G	cg04996195	chr7:87105398	ABCB4	0.63	4.79	0.44	6.03e-6	Gallbladder cancer;
THYM	cis	rs6669072	0.565	rs12029115	chr1:91276938	C/T	cg08895590	chr1:91227319	NA	-0.39	-4.45	-0.42	2.32e-5	Cognitive function;
THYM	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.53	-4.99	-0.46	2.68e-6	Lymphocyte counts;
THYM	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs478304	0.654	rs6591187	chr11:65460086	C/G	cg27068330	chr11:65405492	SIPA1	-1.03	-10.31	-0.73	3.55e-17	Acne (severe);
THYM	cis	rs73086581	1.000	rs73086544	chr20:3950928	C/A	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg03806693	chr22:41940476	POLR3H	-0.9	-8.21	-0.64	1.08e-12	Vitiligo;
THYM	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs41005	0.967	rs41002	chr2:8113921	C/T	cg03155496	chr2:8117019	LOC339788	0.98	9.59	0.7	1.26e-15	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs11186	0.556	rs10931395	chr2:189969392	A/G	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	cis	rs514406	0.763	rs7535088	chr1:53215042	A/G	cg24675658	chr1:53192096	ZYG11B	0.58	4.66	0.43	1.04e-5	Monocyte count;
THYM	cis	rs6032067	0.777	rs2868237	chr20:43794189	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs3204270	0.639	rs11867543	chr17:79655046	C/T	cg18367735	chr17:79674897	NA	0.8	4.77	0.44	6.61e-6	Dental caries;
THYM	cis	rs57244997	0.582	rs73030424	chr6:162434298	T/A	cg17173639	chr6:162384350	PARK2	-0.75	-4.75	-0.44	7.12e-6	Mosquito bite size;
THYM	cis	rs7000551	0.751	rs2461482	chr8:22382898	C/T	cg12081754	chr8:22256438	SLC39A14	0.65	5.95	0.52	4.48e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg10802521	chr3:52805072	NEK4	-0.74	-6.34	-0.55	7.65e-9	Bipolar disorder;
THYM	cis	rs4660261	0.526	rs2485996	chr1:44354661	C/T	cg13246856	chr1:44399776	ARTN	0.5	4.93	0.45	3.45e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4919044	0.808	rs7895700	chr10:94791099	A/G	cg05127821	chr10:94822908	CYP26C1	-1.23	-6.66	-0.56	1.76e-9	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs863345	0.604	rs6689657	chr1:158462509	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs514406	0.668	rs520281	chr1:53365235	G/C	cg06600287	chr1:53387719	ECHDC2	-0.37	-6.01	-0.52	3.45e-8	Monocyte count;
THYM	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	13.59	0.81	5.3e-24	Chronic sinus infection;
THYM	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg19346786	chr7:2764209	NA	-0.72	-6.09	-0.53	2.37e-8	Height;
THYM	cis	rs1008375	1.000	rs13149474	chr4:17688582	G/A	cg18681998	chr4:17616180	MED28	-0.85	-6.97	-0.58	4.15e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4792901	0.759	rs3179927	chr17:41601911	A/G	cg21940313	chr17:41620911	ETV4	-0.51	-5.2	-0.47	1.12e-6	Dupuytren's disease;
THYM	cis	rs4595586	0.545	rs61939643	chr12:39378460	G/A	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.98e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	13.56	0.81	6.23e-24	Height;
THYM	cis	rs4808199	0.947	rs2163804	chr19:19575965	G/A	cg03709012	chr19:19516395	GATAD2A	1.19	7.25	0.6	1.12e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs425277	0.606	rs377283	chr1:2075570	T/C	cg00981070	chr1:2046702	PRKCZ	0.47	5.63	0.5	1.85e-7	Height;
THYM	cis	rs6725517	0.737	rs7576788	chr2:25083310	A/G	cg15423357	chr2:25149977	NA	0.51	4.87	0.45	4.38e-6	Breast cancer;
THYM	trans	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.48	-4.95	-0.45	3.21e-6	Primary biliary cholangitis;
THYM	cis	rs12956009	0.583	rs1821446	chr18:44894422	C/T	cg19077165	chr18:44547161	KATNAL2	-0.51	-4.89	-0.45	4.04e-6	Educational attainment (years of education);
THYM	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg10803722	chr21:46713166	LOC642852	-0.42	-5.57	-0.5	2.4e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg12408189	chr10:30722286	MAP3K8	-0.66	-5.82	-0.51	7.83e-8	Inflammatory bowel disease;
THYM	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03517284	chr6:25882590	NA	-0.76	-5.98	-0.52	3.87e-8	Blood metabolite levels;
THYM	cis	rs9677476	1.000	rs6711312	chr2:232122348	T/C	cg07929768	chr2:232055508	NA	0.53	5.41	0.49	4.62e-7	Food antigen IgG levels;
THYM	cis	rs2273669	0.665	rs58453314	chr6:109388415	C/T	cg17117243	chr6:109341365	SESN1	-0.86	-5.26	-0.47	9.04e-7	Prostate cancer;
THYM	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs1448094	0.556	rs61930626	chr12:86167445	A/G	cg00310523	chr12:86230176	RASSF9	0.56	4.94	0.45	3.29e-6	Major depressive disorder;
THYM	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg17264618	chr3:40429014	ENTPD3	0.53	5.18	0.47	1.25e-6	Renal cell carcinoma;
THYM	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.66	-5.5	-0.49	3.22e-7	Renal function-related traits (BUN);
THYM	cis	rs55692411	0.537	rs13071931	chr3:50062878	G/A	cg14019146	chr3:50243930	SLC38A3	-0.59	-4.56	-0.42	1.55e-5	Intelligence (multi-trait analysis);
THYM	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg17830980	chr10:43048298	ZNF37B	-1.06	-10.64	-0.74	7.23e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs7394190	0.748	rs2306325	chr10:75506674	T/C	cg07699608	chr10:75541558	CHCHD1	0.84	4.62	0.43	1.23e-5	Incident atrial fibrillation;
THYM	cis	rs17318866	1.000	rs6934982	chr6:3834374	A/G	cg12534777	chr6:3064469	NA	0.63	4.53	0.42	1.71e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
THYM	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg06191203	chr2:152266755	RIF1	0.71	4.85	0.45	4.87e-6	Lung cancer;
THYM	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg02196655	chr2:10830764	NOL10	-0.42	-4.46	-0.42	2.28e-5	Prostate cancer;
THYM	cis	rs7106204	0.609	rs12788920	chr11:24284514	C/T	ch.11.24196551F	chr11:24239977	NA	0.95	5.82	0.51	7.9e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg06618935	chr21:46677482	NA	-0.94	-8.78	-0.67	6.77e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg02269571	chr22:50332266	NA	-0.71	-4.91	-0.45	3.78e-6	Schizophrenia;
THYM	cis	rs611744	0.624	rs2514844	chr8:109064809	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.11	0.46	1.68e-6	Dupuytren's disease;
THYM	cis	rs6570726	0.791	rs12205752	chr6:145896118	A/G	cg23711669	chr6:146136114	FBXO30	0.96	9.87	0.71	3.12e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11771526	0.551	rs6462344	chr7:32254889	T/C	cg13207630	chr7:32358064	NA	-0.74	-5.08	-0.46	1.92e-6	Body mass index;
THYM	cis	rs4654899	0.865	rs12131353	chr1:21321163	C/G	cg01072550	chr1:21505969	NA	-0.75	-6.74	-0.57	1.24e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg12863693	chr15:85201151	NMB	0.54	4.8	0.44	5.94e-6	Schizophrenia;
THYM	cis	rs7677751	0.806	rs7673853	chr4:55096606	T/C	cg17187183	chr4:55093834	PDGFRA	0.74	5.5	0.49	3.14e-7	Corneal astigmatism;
THYM	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg21926883	chr2:100939477	LONRF2	-0.65	-5.96	-0.52	4.24e-8	Intelligence (multi-trait analysis);
THYM	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg06453172	chr10:134556979	INPP5A	-0.69	-4.96	-0.45	3.04e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.96	8.0	0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.12	8.84	0.67	5.07e-14	Cognitive test performance;
THYM	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	7.51	0.61	3.16e-11	Smoking behavior;
THYM	cis	rs6430585	0.583	rs79176913	chr2:136638113	C/A	cg20242066	chr2:136595261	LCT	0.51	4.89	0.45	4.06e-6	Corneal structure;
THYM	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg04476341	chr5:669733	TPPP	0.63	5.44	0.49	4.07e-7	Obesity-related traits;
THYM	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg00256281	chr22:41985642	PMM1	0.48	4.61	0.43	1.27e-5	Vitiligo;
THYM	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg19077165	chr18:44547161	KATNAL2	-0.45	-4.57	-0.42	1.48e-5	Educational attainment;
THYM	cis	rs7772486	0.790	rs2254283	chr6:146204289	T/C	cg13319975	chr6:146136371	FBXO30	-0.74	-6.33	-0.54	7.91e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg10518543	chr12:38710700	ALG10B	0.49	4.48	0.42	2.08e-5	Heart rate;
THYM	cis	rs4557020	0.526	rs4362595	chr2:54698310	T/C	cg23486701	chr2:54789491	SPTBN1	0.35	4.79	0.44	6.02e-6	Myopia (pathological);
THYM	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg18105134	chr13:113819100	PROZ	-0.98	-9.0	-0.68	2.28e-14	Platelet distribution width;
THYM	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg00012203	chr2:219082015	ARPC2	-0.64	-5.21	-0.47	1.09e-6	Colorectal cancer;
THYM	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.82	7.24	0.6	1.16e-10	Monocyte percentage of white cells;
THYM	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg06108461	chr20:60628389	TAF4	-0.82	-6.79	-0.57	9.7e-10	Body mass index;
THYM	cis	rs2658782	0.547	rs3133454	chr11:93059019	A/C	cg15737290	chr11:93063684	CCDC67	1.16	11.14	0.75	6.15e-19	Pulmonary function decline;
THYM	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg17105886	chr17:28927953	LRRC37B2	1.25	6.76	0.57	1.12e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg03929089	chr4:120376271	NA	-0.97	-8.77	-0.67	6.88e-14	Coronary artery disease;
THYM	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-5.19	-0.47	1.21e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7394190	0.748	rs78790589	chr10:75539598	G/A	cg07699608	chr10:75541558	CHCHD1	0.96	5.1	0.46	1.77e-6	Incident atrial fibrillation;
THYM	cis	rs7586879	0.828	rs13428789	chr2:25087643	C/T	cg01884057	chr2:25150051	NA	0.54	4.92	0.45	3.67e-6	Body mass index;
THYM	cis	rs4563143	0.675	rs73029050	chr19:29276554	G/T	cg12756686	chr19:29218302	NA	0.98	8.72	0.67	9.12e-14	Methadone dose in opioid dependence;
THYM	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg16405210	chr4:1374714	KIAA1530	-0.9	-7.6	-0.62	2.05e-11	Longevity;
THYM	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg27490568	chr2:178487706	NA	0.57	5.0	0.46	2.61e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs921665	0.588	rs11676632	chr2:3203745	C/T	cg16434511	chr2:3151078	NA	1.05	5.23	0.47	1.01e-6	World class endurance athleticism;
THYM	cis	rs289828	0.507	rs4665137	chr2:152129295	A/G	cg05960677	chr2:152117363	RBM43	0.76	8.1	0.64	1.82e-12	Blood protein levels;
THYM	cis	rs997295	0.592	rs8026627	chr15:67770306	G/T	cg24579218	chr15:68104479	NA	-0.54	-4.72	-0.44	8.21e-6	Motion sickness;
THYM	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg16405210	chr4:1374714	KIAA1530	-1.09	-10.29	-0.73	4.03e-17	Longevity;
THYM	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg23428387	chr22:49814324	NA	-0.59	-6.13	-0.53	2.01e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs11690935	0.921	rs7594711	chr2:172895637	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.8	-5.88	-0.52	6.2e-8	Schizophrenia;
THYM	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg12863693	chr15:85201151	NMB	-0.57	-4.93	-0.45	3.54e-6	Schizophrenia;
THYM	cis	rs7172809	0.897	rs74026931	chr15:77825474	A/C	cg22256960	chr15:77711686	NA	-0.67	-4.61	-0.43	1.27e-5	Glucose homeostasis traits;
THYM	cis	rs4889855	0.556	rs3923514	chr17:78515210	A/G	cg16591659	chr17:78472290	NA	0.42	4.89	0.45	4.11e-6	Fractional excretion of uric acid;
THYM	cis	rs7968440	1.000	rs2731440	chr12:51057627	T/A	cg20014596	chr12:50898483	DIP2B	0.56	4.55	0.42	1.57e-5	Fibrinogen;
THYM	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	7.8	0.62	7.81e-12	Platelet count;
THYM	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg08873628	chr1:175162347	KIAA0040	0.51	4.65	0.43	1.09e-5	Alcohol dependence;
THYM	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	0.63	5.09	0.46	1.78e-6	Tonsillectomy;
THYM	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4589258	0.830	rs7930635	chr11:90424707	G/A	cg26138821	chr11:89956704	CHORDC1	0.59	4.96	0.45	3.06e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg00631329	chr6:26305371	NA	-0.61	-7.35	-0.6	6.96e-11	Educational attainment;
THYM	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg06009448	chr7:1102226	C7orf50	0.53	5.55	0.49	2.6e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9905704	0.918	rs304272	chr17:56803028	C/A	cg12560992	chr17:57184187	TRIM37	0.67	4.68	0.43	9.59e-6	Testicular germ cell tumor;
THYM	cis	rs7428	1.000	rs72840063	chr2:85550396	T/A	cg24342717	chr2:85555507	TGOLN2	-0.57	-4.8	-0.44	5.92e-6	Ear protrusion;
THYM	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg00801512	chr17:28996047	NA	-0.73	-4.67	-0.43	9.94e-6	Body mass index;
THYM	cis	rs1784581	0.722	rs1789993	chr6:162398976	T/C	cg17173639	chr6:162384350	PARK2	-0.85	-7.43	-0.61	4.72e-11	Itch intensity from mosquito bite;
THYM	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg00129232	chr17:37814104	STARD3	-0.71	-4.8	-0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg03806693	chr22:41940476	POLR3H	-0.85	-6.46	-0.55	4.44e-9	Neuroticism;
THYM	cis	rs3819817	0.642	rs4762255	chr12:96348191	G/A	cg26410635	chr12:96350720	AMDHD1	0.57	5.4	0.48	4.83e-7	Vitamin D levels;
THYM	cis	rs73198271	0.740	rs964771	chr8:8650939	A/G	cg15556689	chr8:8085844	FLJ10661	0.74	4.91	0.45	3.75e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg04918696	chr8:1004106	NA	-0.42	-4.67	-0.43	9.86e-6	Schizophrenia;
THYM	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21582582	chr3:182698605	DCUN1D1	0.78	6.87	0.58	6.69e-10	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg22920501	chr2:26401640	FAM59B	-1.05	-9.27	-0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg06453172	chr10:134556979	INPP5A	-0.66	-4.77	-0.44	6.78e-6	Migraine;
THYM	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg22875332	chr1:76189707	ACADM	0.83	8.91	0.67	3.56e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9359856	0.510	rs17293240	chr6:90396370	C/T	cg13799429	chr6:90582589	CASP8AP2	0.84	8.26	0.65	8.31e-13	Bipolar disorder;
THYM	cis	rs17407555	0.520	rs4292327	chr4:9943700	G/A	cg11266682	chr4:10021025	SLC2A9	-0.6	-5.94	-0.52	4.57e-8	Schizophrenia (age at onset);
THYM	cis	rs241257	0.583	rs241264	chr1:4619038	C/T	cg00505606	chr1:3620638	TP73	0.47	4.51	0.42	1.88e-5	Anxiety disorder;
THYM	trans	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg10856724	chr12:34555212	NA	-1.04	-9.61	-0.7	1.1e-15	Morning vs. evening chronotype;
THYM	cis	rs7586879	0.681	rs6752483	chr2:25120086	C/T	cg27107076	chr2:25050844	ADCY3	-0.29	-4.66	-0.43	1.02e-5	Body mass index;
THYM	cis	rs35883536	0.967	rs1577509	chr1:101089253	C/T	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs7465272	1.000	rs36050651	chr8:143681796	A/G	cg01509843	chr8:143695822	ARC	0.72	4.79	0.44	6.03e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs611744	0.647	rs12675265	chr8:109268805	C/T	cg21045802	chr8:109455806	TTC35	0.62	5.38	0.48	5.32e-7	Dupuytren's disease;
THYM	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg14129053	chr2:1895732	MYT1L	1.13	4.49	0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs36051895	0.697	rs11788790	chr9:5092263	G/T	cg02405213	chr9:5042618	JAK2	-1.0	-10.94	-0.75	1.67e-18	Pediatric autoimmune diseases;
THYM	cis	rs55871839	1.000	rs55871839	chr8:59816868	T/C	cg07426533	chr8:59803705	TOX	0.65	6.02	0.53	3.27e-8	Pneumonia;
THYM	cis	rs1448094	0.512	rs6539931	chr12:86247473	C/T	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	trans	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg13615516	chr5:77269221	NA	0.86	8.01	0.63	2.88e-12	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg15592062	chr6:167189543	RPS6KA2	-0.58	-5.88	-0.52	6.01e-8	Crohn's disease;
THYM	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.82	-0.82	1.83e-24	Height;
THYM	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	4.49	0.42	1.99e-5	Aortic root size;
THYM	cis	rs9992101	0.645	rs62303267	chr4:77306930	C/T	cg20311846	chr4:77356250	SHROOM3	-0.54	-5.96	-0.52	4.32e-8	Creatinine levels;
THYM	cis	rs7177699	0.557	rs7165902	chr15:79115872	T/G	cg00540400	chr15:79124168	NA	0.64	6.93	0.58	4.98e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6565180	0.888	rs11150586	chr16:30420851	T/C	cg17640201	chr16:30407289	ZNF48	0.98	9.62	0.7	1.06e-15	Tonsillectomy;
THYM	cis	rs6763768	0.565	rs11714096	chr3:53396145	G/C	cg22900224	chr3:52804907	NEK4	0.72	4.67	0.43	9.9e-6	Bacterial meningitis;
THYM	cis	rs6430585	0.528	rs660002	chr2:136723504	C/T	cg20242066	chr2:136595261	LCT	0.49	5.34	0.48	6.35e-7	Corneal structure;
THYM	cis	rs12142240	0.698	rs3991877	chr1:46853749	C/A	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs9880211	1.000	rs35899944	chr3:136229057	G/A	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg13647721	chr17:30228624	UTP6	0.77	4.91	0.45	3.85e-6	Hip circumference adjusted for BMI;
THYM	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg01304814	chr3:48885189	PRKAR2A	0.89	4.66	0.43	1.03e-5	Cognitive function;
THYM	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg23205692	chr1:25664452	TMEM50A	0.8	6.31	0.54	8.93e-9	Erythrocyte sedimentation rate;
THYM	cis	rs6500395	1.000	rs8044519	chr16:48669081	G/T	cg04672837	chr16:48644449	N4BP1	0.53	5.21	0.47	1.09e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs6584283	1.000	rs6584283	chr10:101290301	A/G	cg04972745	chr10:101287846	NA	-0.55	-5.16	-0.47	1.37e-6	Ulcerative colitis;
THYM	cis	rs11048434	0.761	rs10842662	chr12:9139344	G/A	cg04155231	chr12:9217510	LOC144571	0.5	4.95	0.45	3.27e-6	Sjögren's syndrome;
THYM	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg11247378	chr22:39784982	NA	-1.06	-13.37	-0.81	1.49e-23	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06481639	chr22:41940642	POLR3H	-0.8	-5.55	-0.49	2.63e-7	Vitiligo;
THYM	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg21970626	chr13:21893289	NA	-0.62	-5.39	-0.48	5.2e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs6565180	0.783	rs9888967	chr16:30407979	G/C	cg17640201	chr16:30407289	ZNF48	0.93	8.59	0.66	1.72e-13	Tonsillectomy;
THYM	cis	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1978968	0.956	rs7291155	chr22:18444599	C/T	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg12560992	chr17:57184187	TRIM37	0.94	8.84	0.67	5.01e-14	Intelligence (multi-trait analysis);
THYM	cis	rs12216545	0.737	rs1522598	chr7:150239836	G/A	cg08960815	chr7:150264767	GIMAP4	-0.89	-8.27	-0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06481639	chr22:41940642	POLR3H	-0.81	-5.69	-0.5	1.38e-7	Vitiligo;
THYM	cis	rs7246657	0.882	rs4803539	chr19:37897522	A/C	cg22634378	chr19:37742834	NA	0.63	5.17	0.47	1.28e-6	Coronary artery calcification;
THYM	cis	rs8001976	0.517	rs1924794	chr13:48275412	A/G	ch.13.628550F	chr13:47320782	LRCH1	-0.8	-4.45	-0.42	2.33e-5	Aging (time to event);
THYM	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg08736216	chr1:53307985	ZYG11A	-0.58	-5.29	-0.48	7.85e-7	Monocyte count;
THYM	cis	rs9902453	0.838	rs8064689	chr17:28217053	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.6	0.43	1.32e-5	Coffee consumption (cups per day);
THYM	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1550582	0.662	rs4909628	chr8:135502380	A/T	cg09855544	chr8:135498122	ZFAT	-0.67	-4.66	-0.43	1.04e-5	Educational attainment;
THYM	cis	rs13315871	0.929	rs13094898	chr3:58290143	G/A	cg12435725	chr3:58293450	RPP14	-0.53	-5.57	-0.5	2.32e-7	Cholesterol, total;
THYM	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg00684032	chr4:1343700	KIAA1530	0.57	5.02	0.46	2.42e-6	Obesity-related traits;
THYM	cis	rs11608355	1.000	rs10774690	chr12:109859682	G/A	cg10504392	chr12:110044639	NA	0.67	6.21	0.54	1.41e-8	Neuroticism;
THYM	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs920590	0.721	rs920587	chr8:19663339	C/A	cg01411142	chr8:19674711	INTS10	0.61	4.66	0.43	1.03e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg14768367	chr16:72042858	DHODH	0.68	5.29	0.48	7.98e-7	Fibrinogen levels;
THYM	cis	rs883565	0.771	rs3736573	chr3:39129742	A/C	cg15678707	chr3:39149194	GORASP1;TTC21A	0.77	5.52	0.49	2.95e-7	Handedness;
THYM	cis	rs920590	0.796	rs10888170	chr8:19635328	C/T	cg01411142	chr8:19674711	INTS10	0.7	5.47	0.49	3.59e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs9457247	0.534	rs7750593	chr6:167387359	C/G	cg00271210	chr6:167070053	RPS6KA2	0.48	4.72	0.44	8e-6	Crohn's disease;
THYM	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg04750100	chr2:136595281	LCT	0.56	6.13	0.53	1.97e-8	Mosquito bite size;
THYM	cis	rs61931739	0.583	rs1873011	chr12:33752808	T/C	cg06521331	chr12:34319734	NA	-0.6	-4.54	-0.42	1.64e-5	Morning vs. evening chronotype;
THYM	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.03	10.73	0.74	4.6e-18	Cognitive ability;
THYM	cis	rs7909074	1.000	rs12777258	chr10:45394961	A/G	cg06994016	chr10:45406847	TMEM72	0.46	4.54	0.42	1.66e-5	Mean corpuscular volume;
THYM	cis	rs3784262	0.528	rs4144005	chr15:58330094	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.65	-5.04	-0.46	2.24e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
THYM	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs2237898	0.585	rs12576054	chr11:2878619	C/A	cg12614029	chr11:2160564	INS-IGF2;IGF2AS;IGF2	-1.21	-4.5	-0.42	1.89e-5	Mosquito bite size;
THYM	cis	rs2067615	0.524	rs1922433	chr12:107077172	A/G	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg01570182	chr17:44337453	NA	-0.64	-6.88	-0.58	6.26e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs854765	0.964	rs72827413	chr17:17988299	C/T	cg04398451	chr17:18023971	MYO15A	0.9	8.48	0.66	2.92e-13	Total body bone mineral density;
THYM	cis	rs12935418	0.673	rs2602426	chr16:81061237	C/T	cg16651780	chr16:81037892	C16orf61	-0.77	-5.66	-0.5	1.57e-7	Mean corpuscular volume;
THYM	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg19077165	chr18:44547161	KATNAL2	0.56	6.98	0.58	3.96e-10	Personality dimensions;
THYM	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg13918804	chr1:2043761	PRKCZ	-0.61	-4.59	-0.43	1.38e-5	Height;
THYM	cis	rs2985684	1.000	rs8014170	chr14:50071694	C/G	cg02151108	chr14:50098012	C14orf104	-0.7	-5.81	-0.51	8.15e-8	Carotid intima media thickness;
THYM	cis	rs9787249	0.957	rs11206754	chr1:40216234	A/G	cg02773041	chr1:40204384	PPIE	0.77	5.94	0.52	4.71e-8	Blood protein levels;
THYM	trans	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg25517755	chr10:38738941	LOC399744	-0.79	-7.77	-0.62	9.18e-12	Corneal astigmatism;
THYM	cis	rs870825	0.616	rs7659201	chr4:185632013	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs11989744	1.000	rs17782111	chr8:23565784	A/G	cg04349084	chr8:23602677	NA	0.45	4.75	0.44	7.2e-6	Waist-hip ratio;
THYM	cis	rs1401999	0.714	rs1000002	chr3:183635768	A/G	cg20387954	chr3:183756860	HTR3D	-0.53	-5.11	-0.46	1.67e-6	Anterior chamber depth;
THYM	cis	rs863345	0.526	rs10908669	chr1:158501938	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.6e-6	Pneumococcal bacteremia;
THYM	cis	rs2806561	0.894	rs628106	chr1:23537685	C/T	cg12483005	chr1:23474871	LUZP1	0.52	5.23	0.47	1.01e-6	Height;
THYM	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg21658235	chr8:22456391	C8orf58	0.53	5.14	0.47	1.49e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg08999081	chr20:33150536	PIGU	0.77	6.95	0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs9302065	0.565	rs2993584	chr13:95961678	C/A	cg24476569	chr13:95954382	ABCC4	-0.79	-8.08	-0.64	2.05e-12	Blood metabolite levels;
THYM	cis	rs7894051	1.000	rs7074435	chr10:135190570	G/T	cg01120434	chr10:134937798	GPR123	0.82	4.57	0.42	1.45e-5	Lifespan;
THYM	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg11335335	chr11:637885	DRD4	-0.69	-6.23	-0.54	1.24e-8	Systemic lupus erythematosus;
THYM	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg24642844	chr7:1081250	C7orf50	-1.32	-8.72	-0.67	8.82e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4072705	0.967	rs10760369	chr9:127397400	A/G	cg01786973	chr9:127249749	NR5A1	0.35	4.69	0.43	9.25e-6	Menarche (age at onset);
THYM	cis	rs9972944	0.756	rs2318868	chr17:63767592	G/T	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs1559088	0.600	rs7256470	chr19:33558085	C/A	cg03563238	chr19:33554763	RHPN2	-0.55	-4.69	-0.43	8.98e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs11225247	0.881	rs12279056	chr11:102257584	T/A	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-5.08	-0.46	1.85e-6	Daytime sleep phenotypes;
THYM	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg01579765	chr21:45077557	HSF2BP	-0.48	-7.59	-0.61	2.23e-11	Mean corpuscular volume;
THYM	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg18402987	chr7:1209562	NA	1.16	7.29	0.6	9.12e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg00129232	chr17:37814104	STARD3	0.71	4.8	0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg22907277	chr7:1156413	C7orf50	0.6	5.07	0.46	1.94e-6	Longevity;Endometriosis;
THYM	cis	rs10089	1.000	rs10478803	chr5:127488855	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg15445000	chr17:37608096	MED1	0.41	4.72	0.44	8.17e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7631605	0.544	rs61493618	chr3:37173775	A/T	cg21328643	chr3:37258149	NA	-0.48	-4.61	-0.43	1.25e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs72827839	0.654	rs56104550	chr17:45941794	A/T	cg23391107	chr17:45924227	SP6	0.86	6.18	0.54	1.58e-8	Ease of getting up in the morning;
THYM	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg24579218	chr15:68104479	NA	-0.82	-7.88	-0.63	5.41e-12	Restless legs syndrome;
THYM	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg12386194	chr3:101231763	SENP7	-0.93	-7.21	-0.59	1.32e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs892961	1.000	rs11077909	chr17:75403480	T/C	cg05865280	chr17:75406074	SEPT9	0.5	8.7	0.67	9.98e-14	Airflow obstruction;
THYM	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.62	-4.5	-0.42	1.93e-5	Colorectal cancer;
THYM	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg13683864	chr3:40499215	RPL14	-0.87	-8.52	-0.66	2.33e-13	Renal cell carcinoma;
THYM	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13012494	chr21:47604986	C21orf56	0.75	5.19	0.47	1.18e-6	Testicular germ cell tumor;
THYM	cis	rs11264213	0.591	rs4653158	chr1:36556187	G/A	cg27506609	chr1:36549197	TEKT2	-1.18	-6.35	-0.55	7.44e-9	Schizophrenia;
THYM	cis	rs16944158	0.636	rs12919426	chr16:49646854	T/C	cg05126388	chr16:49670144	ZNF423	0.75	4.95	0.45	3.16e-6	IgG glycosylation;
THYM	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg00271210	chr6:167070053	RPS6KA2	-0.5	-4.73	-0.44	7.76e-6	Crohn's disease;
THYM	cis	rs9910055	0.552	rs4793084	chr17:42317371	G/T	cg13607699	chr17:42295918	UBTF	-0.9	-8.03	-0.64	2.58e-12	Total body bone mineral density;
THYM	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg07570687	chr10:102243282	WNT8B	0.75	6.53	0.56	3.17e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg26028573	chr6:26043587	HIST1H2BB	-0.58	-4.76	-0.44	6.82e-6	Blood metabolite levels;
THYM	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9522267	0.535	rs11069898	chr13:112231512	C/T	cg10483660	chr13:112241077	NA	-0.58	-6.7	-0.57	1.49e-9	Hepatitis;
THYM	cis	rs714027	1.000	rs4823074	chr22:30512478	G/A	cg11564601	chr22:30592435	NA	-0.3	-5.45	-0.49	3.98e-7	Lymphocyte counts;
THYM	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.24	9.94	0.71	2.26e-16	Platelet count;
THYM	cis	rs6674970	0.966	rs10788800	chr1:151104950	G/A	cg11822372	chr1:151115635	SEMA6C	0.71	4.92	0.45	3.6e-6	Childhood ear infection;
THYM	cis	rs40363	1.000	rs1690441	chr16:3517635	C/G	cg01073479	chr16:3509474	NAT15	0.57	4.83	0.44	5.33e-6	Tuberculosis;
THYM	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg09033563	chr22:24373618	LOC391322	0.64	5.72	0.51	1.21e-7	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs8014204	0.836	rs12588415	chr14:75278211	G/A	cg06637938	chr14:75390232	RPS6KL1	0.53	5.19	0.47	1.21e-6	Caffeine consumption;
THYM	cis	rs2811415	0.597	rs11710595	chr3:127767158	T/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg06238570	chr21:40685208	BRWD1	-0.98	-9.35	-0.69	4.01e-15	Cognitive function;
THYM	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg06238570	chr21:40685208	BRWD1	-0.98	-9.35	-0.69	4.01e-15	Cognitive function;
THYM	cis	rs981844	0.890	rs62325113	chr4:154692555	A/G	cg09973105	chr4:154681532	RNF175	-0.67	-5.54	-0.49	2.68e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg05457628	chr5:178986728	RUFY1	0.64	6.73	0.57	1.27e-9	Lung cancer;
THYM	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	trans	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs7432375	0.933	rs6791142	chr3:136377377	C/T	cg12473912	chr3:136751656	NA	0.62	5.27	0.48	8.44e-7	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg24531977	chr5:56204891	C5orf35	0.72	5.77	0.51	9.7e-8	Initial pursuit acceleration;
THYM	cis	rs6964587	0.839	rs9656002	chr7:91475007	A/G	cg22709100	chr7:91322751	NA	-0.63	-4.87	-0.45	4.53e-6	Breast cancer;
THYM	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg10661904	chr17:79619235	PDE6G	-0.57	-5.17	-0.47	1.32e-6	Eye color traits;
THYM	cis	rs7567389	0.740	rs4536600	chr2:128002572	A/G	cg09760422	chr2:128146352	NA	0.47	6.09	0.53	2.4e-8	Self-rated health;
THYM	cis	rs2242116	0.592	rs6442039	chr3:46960797	C/G	cg02527881	chr3:46936655	PTH1R	-0.69	-5.29	-0.48	7.72e-7	Birth weight;
THYM	cis	rs11608355	0.705	rs4766601	chr12:109890080	C/G	cg11367159	chr12:110044531	NA	0.58	4.97	0.45	2.98e-6	Neuroticism;
THYM	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	10.78	0.74	3.65e-18	Chronic sinus infection;
THYM	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.93	5.98	0.52	3.95e-8	Smoking behavior;
THYM	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.42	-0.49	4.57e-7	Bipolar disorder;
THYM	cis	rs4808199	0.895	rs10419672	chr19:19471241	T/C	cg03709012	chr19:19516395	GATAD2A	1.07	6.07	0.53	2.64e-8	Nonalcoholic fatty liver disease;
THYM	cis	rs13315871	0.929	rs9837903	chr3:58301906	A/T	cg12435725	chr3:58293450	RPP14	-0.53	-5.57	-0.5	2.32e-7	Cholesterol, total;
THYM	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs7107174	1.000	rs2511171	chr11:77930935	G/A	cg19901956	chr11:77921274	USP35	-0.81	-6.14	-0.53	1.93e-8	Testicular germ cell tumor;
THYM	cis	rs12257961	0.609	rs4750622	chr10:15382590	A/G	cg10616319	chr10:15468812	NA	0.63	5.42	0.49	4.58e-7	Selective IgA deficiency;
THYM	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg10518543	chr12:38710700	ALG10B	-0.57	-4.49	-0.42	2.04e-5	Bladder cancer;
THYM	cis	rs7219021	0.705	rs962273	chr17:46978353	T/C	cg09029085	chr17:47094198	IGF2BP1	-0.33	-4.48	-0.42	2.06e-5	Schizophrenia or bipolar disorder;
THYM	cis	rs4444359	0.941	rs8047470	chr16:11567032	G/A	cg01389428	chr16:11594557	NA	-0.66	-4.65	-0.43	1.08e-5	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg24818145	chr4:99064322	C4orf37	0.73	5.84	0.51	7.38e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg22920501	chr2:26401640	FAM59B	-0.68	-5.72	-0.51	1.24e-7	Gut microbiome composition (summer);
THYM	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg07061783	chr6:25882402	NA	-0.82	-7.2	-0.59	1.39e-10	Intelligence (multi-trait analysis);
THYM	cis	rs8018808	0.935	rs7146784	chr14:77932111	A/G	cg20045696	chr14:77926864	AHSA1	0.5	4.54	0.42	1.63e-5	Myeloid white cell count;
THYM	cis	rs11214589	0.747	rs2155462	chr11:113206799	A/C	cg14159747	chr11:113255604	NA	0.3	5.74	0.51	1.12e-7	Neuroticism;
THYM	cis	rs2742417	0.565	rs2673031	chr3:45756986	A/G	cg04837898	chr3:45731254	SACM1L	-0.73	-5.29	-0.48	7.85e-7	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs761746	0.960	rs9956	chr22:32015450	T/G	cg10537193	chr22:32026975	PISD	-0.35	-4.91	-0.45	3.85e-6	Intelligence;
THYM	cis	rs4595586	0.545	rs7970850	chr12:39397878	T/C	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs2668423	0.959	rs2526134	chr19:1365620	A/T	cg02639931	chr19:1387894	NDUFS7	-0.48	-5.6	-0.5	2.11e-7	Nonalcoholic fatty liver disease;
THYM	cis	rs4474465	0.679	rs4945288	chr11:78244823	C/A	cg19901956	chr11:77921274	USP35	0.66	4.91	0.45	3.85e-6	Alzheimer's disease (survival time);
THYM	cis	rs941408	0.928	rs2741991	chr19:2802092	T/C	cg17333051	chr19:2783644	SGTA	0.56	5.11	0.46	1.65e-6	Total cholesterol levels;
THYM	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg06558623	chr16:89946397	TCF25	-1.14	-6.15	-0.53	1.82e-8	Skin colour saturation;
THYM	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg11941060	chr3:133502564	NA	-0.74	-6.43	-0.55	5.19e-9	Iron status biomarkers;
THYM	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg04944784	chr2:26401820	FAM59B	-0.76	-6.06	-0.53	2.78e-8	Gut microbiome composition (summer);
THYM	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg05660106	chr1:15850417	CASP9	0.7	5.69	0.5	1.41e-7	Systolic blood pressure;
THYM	trans	rs629535	0.814	rs56301437	chr8:70108518	C/T	cg21567404	chr3:27674614	NA	-1.06	-9.7	-0.71	7.22e-16	Dupuytren's disease;
THYM	cis	rs7107174	1.000	rs10793311	chr11:78104399	G/C	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs59698941	0.765	rs12163971	chr5:132226669	C/A	cg02081065	chr5:132209139	LEAP2	-0.85	-5.74	-0.51	1.14e-7	Apolipoprotein A-IV levels;
THYM	cis	rs12282928	0.918	rs1503173	chr11:48246297	A/T	cg22827986	chr11:48284249	OR4X1	-0.51	-5.43	-0.49	4.28e-7	Migraine - clinic-based;
THYM	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg05738196	chr6:26577821	NA	-0.66	-5.16	-0.47	1.33e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg10802521	chr3:52805072	NEK4	-0.71	-5.96	-0.52	4.22e-8	Bipolar disorder;
THYM	cis	rs9302065	1.000	rs7490267	chr13:95970258	T/C	cg24476569	chr13:95954382	ABCC4	-0.57	-5.13	-0.47	1.51e-6	Blood metabolite levels;
THYM	cis	rs7246657	0.943	rs10404920	chr19:37881556	T/C	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs12478296	0.892	rs11893879	chr2:243010411	G/A	cg06360820	chr2:242988706	NA	-0.91	-5.94	-0.52	4.61e-8	Obesity-related traits;
THYM	cis	rs7487075	0.780	rs12320197	chr12:46738883	A/G	cg17501823	chr12:47219793	SLC38A4	0.49	4.73	0.44	7.94e-6	Itch intensity from mosquito bite;
THYM	cis	rs1784581	0.674	rs3016555	chr6:162391421	T/C	cg17173639	chr6:162384350	PARK2	-0.85	-7.71	-0.62	1.25e-11	Itch intensity from mosquito bite;
THYM	cis	rs6424115	0.800	rs2229583	chr1:24200983	C/T	cg15997130	chr1:24165203	NA	0.76	6.39	0.55	6.14e-9	Immature fraction of reticulocytes;
THYM	cis	rs6121246	0.609	rs6060948	chr20:30376393	C/G	cg13852791	chr20:30311386	BCL2L1	0.87	8.17	0.64	1.31e-12	Mean corpuscular hemoglobin;
THYM	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg13695892	chr22:41940480	POLR3H	0.85	6.16	0.53	1.72e-8	Vitiligo;
THYM	cis	rs10208940	0.614	rs7558616	chr2:68828038	G/T	cg09157127	chr2:69201416	GKN1	0.93	4.78	0.44	6.3e-6	Urate levels in lean individuals;
THYM	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.37	-0.48	5.64e-7	Total cholesterol levels;
THYM	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg13695892	chr22:41940480	POLR3H	-0.58	-4.65	-0.43	1.09e-5	Neuroticism;
THYM	cis	rs2964802	0.505	rs11957751	chr5:10819973	A/G	cg14521931	chr5:10832172	NA	0.62	5.12	0.46	1.63e-6	Major depressive disorder;Recurrent major depressive disorder;
THYM	cis	rs899997	1.000	rs8030335	chr15:79034124	G/A	cg22753661	chr15:79092743	ADAMTS7	0.72	4.61	0.43	1.23e-5	Coronary artery disease or large artery stroke;
THYM	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs55728055	0.661	rs62237775	chr22:31965401	A/G	cg01338084	chr22:32026380	PISD	1.48	7.31	0.6	8.42e-11	Age-related hearing impairment;
THYM	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg14391382	chr7:866102	UNC84A	0.6	4.68	0.43	9.4e-6	Subjective well-being;
THYM	cis	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg05335186	chr13:53173507	NA	-0.4	-5.03	-0.46	2.36e-6	Lewy body disease;
THYM	cis	rs2692947	0.683	rs1813381	chr2:96422939	C/T	cg23100626	chr2:96804247	ASTL	-0.39	-4.52	-0.42	1.75e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg03684893	chr10:554711	DIP2C	-0.59	-5.01	-0.46	2.47e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs6500395	0.926	rs11643272	chr16:48639723	T/C	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg05294307	chr14:35346193	BAZ1A	-0.88	-6.14	-0.53	1.87e-8	Psoriasis;
THYM	cis	rs2997447	0.761	rs17257107	chr1:26448447	A/G	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg26441486	chr22:50317300	CRELD2	0.44	7.57	0.61	2.37e-11	Schizophrenia;
THYM	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg03806693	chr22:41940476	POLR3H	-1.21	-10.75	-0.74	4.11e-18	Vitiligo;
THYM	cis	rs6163	0.588	rs12763284	chr10:104508202	C/T	cg04362960	chr10:104952993	NT5C2	-0.55	-4.79	-0.44	6.07e-6	Waist circumference;Hip circumference;
THYM	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg02782426	chr3:40428986	ENTPD3	0.51	4.5	0.42	1.95e-5	Renal cell carcinoma;
THYM	cis	rs6032067	0.516	rs6032087	chr20:43902305	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.61	-6.99	-0.58	3.81e-10	Blood protein levels;
THYM	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg02353165	chr6:42928485	GNMT	-1.01	-10.32	-0.73	3.41e-17	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs10992471	0.513	rs710163	chr9:95059804	C/T	cg14631576	chr9:95140430	CENPP	0.68	5.83	0.51	7.45e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs9880211	0.613	rs6786582	chr3:135898984	C/T	cg21827317	chr3:136751795	NA	0.74	5.19	0.47	1.19e-6	Body mass index;Height;
THYM	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg24733560	chr20:60626293	TAF4	-0.59	-6.04	-0.53	2.98e-8	Body mass index;
THYM	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg22875332	chr1:76189707	ACADM	0.78	6.3	0.54	9.44e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4654899	0.609	rs12131134	chr1:21534237	G/T	cg01072550	chr1:21505969	NA	-0.78	-7.51	-0.61	3.25e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05901451	chr6:126070800	HEY2	0.6	4.87	0.45	4.37e-6	Endometrial cancer;
THYM	cis	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg10856724	chr12:34555212	NA	-0.78	-6.99	-0.58	3.83e-10	Morning vs. evening chronotype;
THYM	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg22177976	chr4:84258471	NA	-1.02	-7.47	-0.61	3.79e-11	Depressive symptoms;
THYM	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg24874828	chr4:187887005	NA	-0.72	-7.44	-0.61	4.48e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05901451	chr6:126070800	HEY2	0.87	8.74	0.67	8.08e-14	Brugada syndrome;
THYM	cis	rs4285028	0.747	rs9820511	chr3:121361345	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.84	-7.15	-0.59	1.8e-10	Multiple sclerosis;
THYM	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg01831904	chr17:28903510	LRRC37B2	-1.13	-5.5	-0.49	3.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg01616529	chr11:638424	DRD4	-0.74	-5.68	-0.5	1.45e-7	Systemic lupus erythematosus;
THYM	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg21385522	chr1:16154831	NA	1.33	13.78	0.82	2.23e-24	Dilated cardiomyopathy;
THYM	cis	rs886774	0.507	rs6956680	chr7:107521173	A/C	cg23293999	chr7:106826042	HBP1	-0.6	-4.7	-0.43	8.78e-6	Ulcerative colitis;
THYM	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.04	7.56	0.61	2.56e-11	Smoking behavior;
THYM	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11890956	chr21:40555474	PSMG1	0.99	8.4	0.65	4.29e-13	Cognitive function;
THYM	cis	rs714027	0.585	rs41173	chr22:30424863	C/G	cg27665648	chr22:30112403	NA	-0.53	-4.69	-0.43	9e-6	Lymphocyte counts;
THYM	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg23281280	chr6:28129359	ZNF389	0.61	4.88	0.45	4.21e-6	Depression;
THYM	cis	rs9875589	0.509	rs6768383	chr3:14076952	G/A	cg03204825	chr3:13978759	TPRXL	-0.51	-4.46	-0.42	2.26e-5	Ovarian reserve;
THYM	cis	rs7119038	0.818	rs56758835	chr11:118615340	G/A	cg19308663	chr11:118741387	NA	0.57	5.34	0.48	6.23e-7	Sjögren's syndrome;
THYM	cis	rs1461503	0.934	rs7115679	chr11:122831963	A/G	cg27398637	chr11:122830231	C11orf63	-0.66	-5.62	-0.5	1.87e-7	Menarche (age at onset);
THYM	cis	rs6995541	0.647	rs7000939	chr8:10688874	C/G	cg13457217	chr8:10683266	MIR1322;PINX1	-0.62	-4.55	-0.42	1.6e-5	Triglyceride levels;
THYM	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg15604051	chr3:44754201	ZNF502	-0.56	-5.04	-0.46	2.18e-6	Depressive symptoms;
THYM	cis	rs1728785	1.000	rs1728789	chr16:68595776	C/T	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.46e-6	Ulcerative colitis;
THYM	cis	rs2057149	0.776	rs1980531	chr6:110724518	C/T	cg19196401	chr6:110721138	DDO	0.5	4.51	0.42	1.85e-5	Platelet distribution width;Mean platelet volume;
THYM	cis	rs11811982	0.793	rs115516662	chr1:227418455	T/C	cg09853570	chr1:228403422	OBSCN	1.21	4.67	0.43	9.81e-6	Optic disc area;
THYM	cis	rs4383453	0.539	rs4677888	chr3:123101253	G/T	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg18301423	chr5:131593218	PDLIM4	-0.51	-4.58	-0.43	1.43e-5	Acylcarnitine levels;
THYM	cis	rs61931739	0.517	rs1843737	chr12:34015305	A/G	cg10856724	chr12:34555212	NA	-0.72	-6.76	-0.57	1.13e-9	Morning vs. evening chronotype;
THYM	cis	rs6047844	0.569	rs6113535	chr20:22118733	A/G	cg16502866	chr20:23015624	SSTR4	-0.56	-4.65	-0.43	1.09e-5	Male-pattern baldness;
THYM	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg08975724	chr8:8085496	FLJ10661	-0.63	-4.73	-0.44	7.66e-6	Mood instability;
THYM	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg02734326	chr4:10020555	SLC2A9	0.6	4.85	0.45	4.9100000000000004e-06	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg03929089	chr4:120376271	NA	1.06	9.83	0.71	3.88e-16	Height;
THYM	cis	rs12208915	0.848	rs12213359	chr6:79534027	C/A	cg05283184	chr6:79620031	NA	0.74	4.84	0.44	5.06e-6	Left atrial antero-posterior diameter;
THYM	cis	rs6763768	0.541	rs35495179	chr3:53285424	G/C	cg16894138	chr3:53270350	TKT	0.83	6.7	0.57	1.48e-9	Bacterial meningitis;
THYM	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg26384229	chr12:38710491	ALG10B	0.97	7.29	0.6	9.09e-11	Bladder cancer;
THYM	cis	rs7589342	0.831	rs34554853	chr2:106448931	G/A	cg14210321	chr2:106509881	NCK2	-0.75	-5.36	-0.48	5.72e-7	Addiction;
THYM	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg02753203	chr1:228287806	NA	-0.6	-5.13	-0.47	1.55e-6	Diastolic blood pressure;
THYM	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg10018233	chr7:150070692	REPIN1	0.5	7.76	0.62	9.42e-12	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg04398451	chr17:18023971	MYO15A	-0.92	-10.21	-0.72	5.81e-17	Total body bone mineral density;
THYM	cis	rs10516089	0.504	rs7356653	chr5:171135328	C/T	cg17535961	chr5:171094783	NA	0.41	4.52	0.42	1.78e-5	Venous thromboembolism (SNP x SNP interaction);
THYM	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg22920501	chr2:26401640	FAM59B	-1.04	-8.41	-0.65	4.07e-13	Gut microbiome composition (summer);
THYM	cis	rs7106204	0.686	rs12791623	chr11:24277924	A/T	ch.11.24196551F	chr11:24239977	NA	0.89	5.08	0.46	1.92e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs10992471	0.597	rs11789163	chr9:95234973	T/C	cg14631576	chr9:95140430	CENPP	-0.82	-8.14	-0.64	1.56e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6456042	0.893	rs3099283	chr6:166554170	A/C	cg11088901	chr6:166572345	T	-0.53	-5.11	-0.46	1.67e-6	Asthma;
THYM	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.08	7.64	0.62	1.69e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	ch.11.42038R	chr11:967971	AP2A2	0.59	4.73	0.44	7.79e-6	Alzheimer's disease (late onset);
THYM	cis	rs7572733	0.515	rs700675	chr2:198700216	G/A	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.75	-5.09	-0.46	1.82e-6	Body mass index;
THYM	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg25072359	chr17:41440525	NA	0.64	4.48	0.42	2.05e-5	Menopause (age at onset);
THYM	cis	rs2898681	0.642	rs11538878	chr4:53728524	T/C	cg21521518	chr4:53727714	RASL11B	0.45	5.27	0.48	8.54e-7	Optic nerve measurement (cup area);
THYM	cis	rs7107174	1.000	rs2450129	chr11:77940385	T/C	cg02023728	chr11:77925099	USP35	0.66	6.12	0.53	2.12e-8	Testicular germ cell tumor;
THYM	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg15445000	chr17:37608096	MED1	0.44	5.22	0.47	1.05e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs863345	0.604	rs12133791	chr1:158506682	C/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg26039829	chr8:22132926	PIWIL2	0.7	6.29	0.54	9.49e-9	Hypertriglyceridemia;
THYM	cis	rs7688540	0.771	rs79366248	chr4:266659	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.68	4.82	0.44	5.43e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs73198271	0.740	rs10103163	chr8:8650675	T/C	cg06636001	chr8:8085503	FLJ10661	-0.7	-4.77	-0.44	6.56e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs72827839	0.846	rs72823601	chr17:46135208	C/T	cg23391107	chr17:45924227	SP6	0.83	5.6	0.5	2.08e-7	Ease of getting up in the morning;
THYM	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg03806693	chr22:41940476	POLR3H	-1.02	-8.36	-0.65	5.25e-13	Vitiligo;
THYM	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg25358565	chr5:93447407	FAM172A	1.31	11.12	0.75	6.98e-19	Diabetic retinopathy;
THYM	cis	rs12318506	0.826	rs34128238	chr12:75731819	T/C	cg04728562	chr12:75699417	CAPS2	-1.6	-5.54	-0.49	2.65e-7	Coronary artery calcification;
THYM	cis	rs8077889	0.917	rs72836547	chr17:41902799	G/T	cg26893861	chr17:41843967	DUSP3	1.11	10.19	0.72	6.43e-17	Triglycerides;
THYM	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg05368731	chr17:41323189	NBR1	1.25	11.15	0.75	6.02e-19	Menopause (age at onset);
THYM	cis	rs56104184	0.830	rs17272645	chr19:49342366	C/G	cg16594139	chr19:49340574	PLEKHA4;HSD17B14	-1.11	-6.92	-0.58	5.19e-10	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs4074961	0.669	rs6687545	chr1:38071195	C/T	cg17933807	chr1:38061675	GNL2	1.08	13.26	0.81	2.44e-23	Axial length;
THYM	cis	rs11190604	1.000	rs4919472	chr10:102315864	T/A	cg07570687	chr10:102243282	WNT8B	0.75	6.62	0.56	2.11e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg12564285	chr5:131593104	PDLIM4	-0.43	-4.66	-0.43	1.03e-5	Blood metabolite levels;
THYM	cis	rs12928939	0.815	rs1345868	chr16:71669624	G/T	cg02602352	chr16:70688171	IL34	0.44	4.98	0.46	2.78e-6	Post bronchodilator FEV1;
THYM	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg22920501	chr2:26401640	FAM59B	-1.04	-9.12	-0.68	1.26e-14	Gut microbiome composition (summer);
THYM	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg12501888	chr15:85177176	SCAND2	0.59	4.49	0.42	2.04e-5	P wave terminal force;
THYM	cis	rs10911232	0.507	rs10911231	chr1:183051745	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs6570726	0.905	rs388728	chr6:145816419	T/C	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10411161	0.702	rs10403189	chr19:52400673	A/G	cg25361850	chr19:52391789	ZNF577	-0.73	-4.79	-0.44	6.21e-6	Breast cancer;
THYM	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06481639	chr22:41940642	POLR3H	-0.79	-5.41	-0.49	4.65e-7	Vitiligo;
THYM	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg26597838	chr10:835615	NA	0.88	5.11	0.46	1.67e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.83	8.52	0.66	2.36e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg24020549	chr11:64937741	SPDYC	-0.5	-4.56	-0.42	1.5e-5	Breast cancer;
THYM	cis	rs9677476	0.955	rs9973370	chr2:232095587	A/G	cg07929768	chr2:232055508	NA	0.49	5.13	0.47	1.54e-6	Food antigen IgG levels;
THYM	cis	rs1448094	0.511	rs61930585	chr12:86158461	C/A	cg00310523	chr12:86230176	RASSF9	0.58	5.14	0.47	1.49e-6	Major depressive disorder;
THYM	cis	rs13256369	0.802	rs12541520	chr8:8564146	G/T	cg18904891	chr8:8559673	CLDN23	0.74	5.56	0.5	2.44e-7	Obesity-related traits;
THYM	cis	rs1003719	0.737	rs2835587	chr21:38461795	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs3804749	0.966	rs3792376	chr3:122844951	T/G	cg10259872	chr3:122802215	PDIA5	0.49	5.47	0.49	3.58e-7	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.65	-0.5	1.65e-7	Bone mineral density;
THYM	cis	rs11997175	0.550	rs10105616	chr8:33786830	G/A	ch.8.33884649F	chr8:33765107	NA	0.72	5.48	0.49	3.45e-7	Body mass index;
THYM	trans	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg10856724	chr12:34555212	NA	-0.9	-8.08	-0.64	2.05e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg11245990	chr11:68621969	NA	-0.55	-6.88	-0.58	6.36e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6596100	0.500	rs58840150	chr5:132248041	A/G	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Breast cancer;
THYM	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg26384229	chr12:38710491	ALG10B	-0.72	-5.64	-0.5	1.75e-7	Morning vs. evening chronotype;
THYM	cis	rs9914544	0.545	rs2386403	chr17:18769600	A/G	cg26378065	chr17:18585709	ZNF286B	0.59	4.5	0.42	1.9e-5	Educational attainment (years of education);
THYM	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg18252515	chr7:66147081	NA	-0.7	-5.35	-0.48	5.99e-7	Aortic root size;
THYM	cis	rs6032067	0.777	rs62208385	chr20:43789823	A/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg17644776	chr2:200775616	C2orf69	0.78	4.58	0.43	1.43e-5	Schizophrenia;
THYM	cis	rs2637266	0.967	rs2579748	chr10:78328313	T/C	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs9660180	0.783	rs1107910	chr1:1692321	C/T	cg13866156	chr1:1669148	SLC35E2	-0.61	-5.77	-0.51	1e-7	Body mass index;
THYM	cis	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg19442545	chr10:75533431	FUT11	-0.63	-6.41	-0.55	5.66e-9	Inflammatory bowel disease;
THYM	cis	rs6032067	0.632	rs62208389	chr20:43794783	A/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs920590	0.876	rs3907478	chr8:19657753	G/T	cg01411142	chr8:19674711	INTS10	0.58	4.5	0.42	1.91e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs728616	0.614	rs10887233	chr10:81715352	C/G	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7119	0.700	rs4886883	chr15:77888924	C/T	cg27398640	chr15:77910606	LINGO1	-0.67	-8.19	-0.64	1.21e-12	Type 2 diabetes;
THYM	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg18681998	chr4:17616180	MED28	0.97	9.8	0.71	4.41e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	trans	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg19862616	chr7:65841803	NCRNA00174	1.12	13.38	0.81	1.44e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs6860806	0.507	rs270615	chr5:131641573	G/C	cg09877947	chr5:131593287	PDLIM4	0.54	4.45	0.42	2.29e-5	Breast cancer;
THYM	trans	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg24209194	chr3:40518798	ZNF619	0.55	4.48	0.42	2.1e-5	Renal cell carcinoma;
THYM	cis	rs1881797	1.000	rs10925062	chr1:247658978	G/C	cg11166453	chr1:247681781	NA	0.69	5.06	0.46	2.01e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs28595532	0.920	rs114162429	chr4:119741078	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs3781426	0.960	rs11245478	chr10:126724796	G/C	cg04494136	chr10:126703576	CTBP2	-0.39	-5.18	-0.47	1.26e-6	Height;
THYM	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg02503808	chr4:7069936	GRPEL1	-0.82	-5.84	-0.51	7.38e-8	Monocyte percentage of white cells;
THYM	cis	rs56775891	1.000	rs34945223	chr18:77575871	A/G	cg13263691	chr18:77568018	NA	0.62	4.55	0.42	1.61e-5	Schizophrenia;
THYM	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg22868518	chr11:507468	RNH1	-1.1	-4.55	-0.42	1.62e-5	Body mass index;
THYM	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg11327659	chr7:150037044	RARRES2	0.42	5.0	0.46	2.59e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs1642645	0.757	rs3845574	chr1:42476574	C/A	cg06092502	chr1:42611687	NA	0.61	4.74	0.44	7.58e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs7772486	0.654	rs9376958	chr6:146023040	C/T	cg13319975	chr6:146136371	FBXO30	0.67	5.39	0.48	5.23e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg13695892	chr22:41940480	POLR3H	-0.86	-5.96	-0.52	4.19e-8	Vitiligo;
THYM	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.63	5.64	0.5	1.77e-7	Height;
THYM	cis	rs1003719	0.680	rs3992	chr21:38505969	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-4.75	-0.44	7.3e-6	Eye color traits;
THYM	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg18876405	chr7:65276391	NA	0.61	5.16	0.47	1.33e-6	Aortic root size;
THYM	cis	rs6701037	0.512	rs2285216	chr1:175133012	C/T	cg17845761	chr1:175162550	KIAA0040	0.38	4.81	0.44	5.73e-6	Alcohol dependence;
THYM	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg00277334	chr10:82204260	NA	-0.52	-5.37	-0.48	5.53e-7	Post bronchodilator FEV1;
THYM	cis	rs7177026	0.500	rs8028562	chr15:79929226	T/C	cg20511832	chr15:78934280	CHRNB4	0.44	5.04	0.46	2.21e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs13202913	0.709	rs11965449	chr6:151830598	C/T	cg03596678	chr6:151814994	C6orf97	0.68	4.46	0.42	2.23e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs10411161	0.702	rs10414472	chr19:52398597	C/T	cg25361850	chr19:52391789	ZNF577	0.74	5.07	0.46	1.94e-6	Breast cancer;
THYM	cis	rs11574514	0.744	rs75204333	chr16:67574408	T/C	cg09738193	chr16:67926317	PSKH1	-0.92	-4.49	-0.42	2e-5	Crohn's disease;
THYM	cis	rs7084402	1.000	rs1346301	chr10:60267310	G/A	cg07615347	chr10:60278583	BICC1	-0.55	-5.0	-0.46	2.63e-6	Refractive error;
THYM	cis	rs2219968	1.000	rs4333586	chr8:78971965	C/T	cg00738934	chr8:78996279	NA	0.91	9.74	0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06850241	chr22:41845214	NA	-0.61	-5.46	-0.49	3.87e-7	Vitiligo;
THYM	cis	rs4383453	0.539	rs12636451	chr3:123102924	A/C	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg09263875	chr16:632152	PIGQ	0.73	6.29	0.54	9.69e-9	Height;
THYM	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.77	4.62	0.43	1.21e-5	Gut microbiome composition (summer);
THYM	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg13319975	chr6:146136371	FBXO30	-0.63	-4.99	-0.46	2.75e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4148689	1.000	rs7793127	chr7:117138947	A/G	cg17204129	chr7:117119601	CFTR	-0.58	-4.57	-0.42	1.48e-5	Gout;
THYM	cis	rs6960043	0.818	rs1558318	chr7:15065612	A/T	cg19272540	chr7:15055459	NA	-0.42	-4.67	-0.43	9.72e-6	Type 2 diabetes;
THYM	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg12310025	chr6:25882481	NA	-0.93	-8.98	-0.68	2.48e-14	Intelligence (multi-trait analysis);
THYM	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg14416269	chr4:6271139	WFS1	0.54	5.62	0.5	1.93e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg24672777	chr11:48374446	OR4C45	-0.98	-6.39	-0.55	6.21e-9	Axial length;
THYM	cis	rs7107174	0.892	rs1017907	chr11:77959124	A/T	cg02023728	chr11:77925099	USP35	0.72	6.25	0.54	1.15e-8	Testicular germ cell tumor;
THYM	cis	rs9527	0.590	rs7067663	chr10:104883650	A/G	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs9649213	0.502	rs6465680	chr7:98005778	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1129187	0.935	rs9462859	chr6:42946943	G/A	cg02353165	chr6:42928485	GNMT	0.99	9.66	0.7	9.01e-16	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs62103177	0.608	rs4442895	chr18:77826399	C/G	cg07235805	chr18:78004237	PARD6G	-0.49	-5.64	-0.5	1.71e-7	Opioid sensitivity;
THYM	cis	rs4930103	0.619	rs739905	chr11:1980360	G/C	cg18511798	chr11:2018149	H19;MIR675	-0.56	-5.62	-0.5	1.87e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg09060608	chr5:178986726	RUFY1	0.52	5.14	0.47	1.46e-6	Lung cancer;
THYM	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg10281704	chr16:966864	LMF1	-0.26	-4.46	-0.42	2.24e-5	Height;
THYM	cis	rs4478037	1.000	rs57477065	chr3:33162532	A/C	cg19404215	chr3:33155277	CRTAP	1.12	7.55	0.61	2.6e-11	Major depressive disorder;
THYM	cis	rs3126085	0.935	rs12726613	chr1:152185500	C/G	cg26020982	chr1:152196106	HRNR	-0.34	-4.47	-0.42	2.14e-5	Atopic dermatitis;
THYM	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg18128536	chr17:47092178	IGF2BP1	-0.58	-8.33	-0.65	6.13e-13	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs9790314	1.000	rs9846756	chr3:160983809	A/C	cg03342759	chr3:160939853	NMD3	-0.76	-6.64	-0.56	1.92e-9	Morning vs. evening chronotype;
THYM	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs11608355	0.846	rs4766471	chr12:109853462	G/A	cg11367159	chr12:110044531	NA	0.59	5.06	0.46	2.04e-6	Neuroticism;
THYM	cis	rs3845702	0.736	rs259811	chr2:180787801	C/T	cg01881094	chr2:180872142	CWC22	-0.9	-5.24	-0.47	9.73e-7	Schizophrenia;
THYM	trans	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.07	-0.59	2.55e-10	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg24818145	chr4:99064322	C4orf37	0.74	6.0	0.52	3.62e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28595532	1.000	rs114912871	chr4:119697004	G/C	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg13683864	chr3:40499215	RPL14	-1.01	-10.37	-0.73	2.73e-17	Renal cell carcinoma;
THYM	cis	rs896322	0.777	rs10900458	chr1:205147584	C/G	cg21643547	chr1:205240462	TMCC2	-0.82	-4.47	-0.42	2.19e-5	Mean platelet volume;
THYM	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg12963246	chr6:28129442	ZNF389	0.77	6.3	0.54	9.31e-9	Depression;
THYM	cis	rs7592578	0.679	rs4287794	chr2:191327147	T/C	cg10560079	chr2:191398806	TMEM194B	-0.85	-6.33	-0.54	8.22e-9	Diastolic blood pressure;
THYM	cis	rs75920871	0.528	rs7124872	chr11:116927951	C/T	cg20608306	chr11:116969690	SIK3	0.57	6.49	0.55	3.82e-9	Subjective well-being;
THYM	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg08975724	chr8:8085496	FLJ10661	-0.67	-5.5	-0.49	3.14e-7	Mood instability;
THYM	cis	rs11039798	1.000	rs34044596	chr11:48527936	T/C	cg24672777	chr11:48374446	OR4C45	-1.14	-6.89	-0.58	6.15e-10	Axial length;
THYM	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg00129232	chr17:37814104	STARD3	-0.9	-7.07	-0.59	2.61e-10	Asthma;
THYM	cis	rs12149862	1.000	rs28674915	chr16:69471857	C/T	cg02524010	chr16:69117679	TMCO7	0.64	4.48	0.42	2.1e-5	Blood pressure (smoking interaction);
THYM	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg11764359	chr7:65958608	NA	-0.81	-6.43	-0.55	5.03e-9	Aortic root size;
THYM	cis	rs7772486	0.846	rs9373482	chr6:146363123	A/C	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg17830980	chr10:43048298	ZNF37B	1.01	9.51	0.7	1.89e-15	Extrinsic epigenetic age acceleration;
THYM	cis	rs1670533	1.000	rs1010342	chr4:1068819	C/T	cg27284194	chr4:1044797	NA	0.61	4.6	0.43	1.29e-5	Recombination rate (females);
THYM	cis	rs2282300	0.739	rs1631451	chr11:30349133	G/C	cg06241208	chr11:30344200	C11orf46	-0.78	-5.65	-0.5	1.64e-7	Morning vs. evening chronotype;
THYM	cis	rs985746	0.527	rs1437626	chr4:36798342	T/C	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs4919694	1.000	rs17787717	chr10:104695699	T/G	cg04362960	chr10:104952993	NT5C2	1.15	7.03	0.59	3.1e-10	Arsenic metabolism;
THYM	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg13609457	chr4:120235615	NA	0.5	4.77	0.44	6.72e-6	Corneal astigmatism;
THYM	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg23332699	chr15:44069569	ELL3	0.8	4.88	0.45	4.31e-6	Lung cancer in ever smokers;
THYM	cis	rs4930776	1.000	rs10774352	chr12:5767155	A/G	cg02086166	chr12:5775618	ANO2	-0.58	-5.71	-0.51	1.3e-7	Plasma clusterin levels;
THYM	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg24375607	chr4:120327624	NA	0.62	5.0	0.46	2.63e-6	Corneal astigmatism;
THYM	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg02018176	chr4:1364513	KIAA1530	0.49	4.5	0.42	1.95e-5	Obesity-related traits;
THYM	cis	rs9649465	0.967	rs2299986	chr7:123369539	T/C	cg15443791	chr7:124364398	NA	0.58	4.81	0.44	5.62e-6	Migraine;
THYM	cis	rs453301	0.653	rs2953806	chr8:8914124	C/T	cg15741354	chr8:8146129	NA	-0.32	-5.14	-0.47	1.44e-6	Joint mobility (Beighton score);
THYM	cis	rs12478296	0.901	rs73007142	chr2:243010852	T/C	cg06360820	chr2:242988706	NA	-1.2	-7.29	-0.6	9.05e-11	Obesity-related traits;
THYM	cis	rs59112743	0.510	rs9464803	chr6:15597737	G/A	cg10111214	chr6:14815676	NA	0.74	4.84	0.44	5.08e-6	Multiple keratinocyte cancers;
THYM	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg06221963	chr1:154839813	KCNN3	-0.73	-8.77	-0.67	7.12e-14	Prostate cancer;
THYM	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg06112835	chr11:68658793	MRPL21	0.44	6.39	0.55	6.23e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg12935359	chr14:103987150	CKB	0.6	6.21	0.54	1.41e-8	Body mass index;
THYM	cis	rs2219968	1.000	rs36124379	chr8:78963505	T/C	cg00738934	chr8:78996279	NA	0.91	9.75	0.71	5.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11771526	0.792	rs10249413	chr7:32304259	G/C	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg15962314	chr1:44399869	ARTN	0.52	4.99	0.46	2.72e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs2652822	0.530	rs1017545	chr15:63553994	A/G	cg09251291	chr15:63483946	RAB8B	0.56	5.15	0.47	1.4e-6	Metabolic traits;
THYM	cis	rs516243	0.703	rs169538	chr1:10737045	T/C	cg02903756	chr1:10750680	CASZ1	-0.6	-5.03	-0.46	2.27e-6	Migraine - clinic-based;
THYM	cis	rs7084402	0.967	rs1658460	chr10:60299151	T/G	cg07615347	chr10:60278583	BICC1	0.57	5.36	0.48	5.86e-7	Refractive error;
THYM	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg22920501	chr2:26401640	FAM59B	1.02	6.93	0.58	5.05e-10	Gut microbiome composition (summer);
THYM	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs1915146	0.901	rs6597884	chr10:126851174	T/C	cg23000734	chr10:126850823	CTBP2	0.85	10.93	0.75	1.74e-18	Menarche (age at onset);
THYM	cis	rs4654899	0.629	rs7515279	chr1:21172774	C/T	cg01072550	chr1:21505969	NA	0.71	6.94	0.58	4.74e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg13609457	chr4:120235615	NA	0.5	4.76	0.44	6.95e-6	Corneal astigmatism;
THYM	cis	rs7705502	0.926	rs72810983	chr5:173318254	A/G	cg18693985	chr5:173351052	CPEB4	-0.78	-5.64	-0.5	1.71e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs61931739	0.658	rs4476006	chr12:34237154	A/C	cg10856724	chr12:34555212	NA	-0.6	-5.51	-0.49	3e-7	Morning vs. evening chronotype;
THYM	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg22709100	chr7:91322751	NA	0.6	4.68	0.43	9.41e-6	Breast cancer;
THYM	cis	rs5758511	0.637	rs5751244	chr22:42617411	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.47	4.6	0.43	1.31e-5	Birth weight;
THYM	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg18252515	chr7:66147081	NA	-1.55	-8.6	-0.66	1.63e-13	Diabetic kidney disease;
THYM	cis	rs2806561	1.000	rs681753	chr1:23515216	T/C	cg19743168	chr1:23544995	NA	0.62	6.64	0.56	1.92e-9	Height;
THYM	cis	rs6763768	0.606	rs4687573	chr3:53292090	C/T	cg16894138	chr3:53270350	TKT	0.71	5.44	0.49	4.06e-7	Bacterial meningitis;
THYM	cis	rs10411161	0.721	rs1433082	chr19:52390726	A/C	cg25361850	chr19:52391789	ZNF577	-0.65	-4.96	-0.45	3.05e-6	Breast cancer;
THYM	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg11764359	chr7:65958608	NA	0.78	6.31	0.54	8.68e-9	Aortic root size;
THYM	cis	rs7172809	0.643	rs61097729	chr15:77834358	C/G	cg22256960	chr15:77711686	NA	-0.77	-5.68	-0.5	1.49e-7	Glucose homeostasis traits;
THYM	cis	rs4499344	0.730	rs12460663	chr19:33098238	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.9	7.48	0.61	3.73e-11	Mean platelet volume;
THYM	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.72	-4.98	-0.45	2.84e-6	Body mass index;
THYM	cis	rs7584330	0.554	rs6760913	chr2:238400702	C/T	cg08992911	chr2:238395768	MLPH	1.12	6.79	0.57	9.73e-10	Prostate cancer;
THYM	cis	rs758324	0.732	rs247293	chr5:131457162	A/G	cg16205897	chr5:131564050	P4HA2	0.56	4.82	0.44	5.53e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs4660261	0.526	rs2906466	chr1:44322220	A/G	cg12908607	chr1:44402522	ARTN	-0.52	-4.67	-0.43	9.88e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs977987	0.778	rs4888412	chr16:75443196	A/G	cg03315344	chr16:75512273	CHST6	0.77	6.29	0.54	9.48e-9	Dupuytren's disease;
THYM	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg06634786	chr22:41940651	POLR3H	-0.57	-4.55	-0.42	1.59e-5	Vitiligo;
THYM	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.66	4.59	0.43	1.37e-5	Aortic root size;
THYM	cis	rs4936891	0.599	rs2076941	chr11:123893286	A/G	cg22125253	chr11:123886957	OR10G4	0.55	4.79	0.44	6.15e-6	Male fertility;
THYM	cis	rs3020340	0.906	rs1101081	chr6:152032917	C/T	cg22157087	chr6:152012887	ESR1	0.49	4.76	0.44	7.03e-6	Bone mineral density (Ward's triangle area);
THYM	cis	rs7107174	0.892	rs2510042	chr11:77923665	C/T	cg02023728	chr11:77925099	USP35	0.67	6.04	0.53	3.04e-8	Testicular germ cell tumor;
THYM	cis	rs2066819	1.000	rs76745316	chr12:56627652	A/C	cg26714650	chr12:56694279	CS	-1.29	-6.29	-0.54	9.85e-9	Psoriasis vulgaris;
THYM	cis	rs11089937	0.616	rs4991801	chr22:22533348	C/A	cg06866756	chr22:22471216	NA	-0.42	-4.57	-0.42	1.44e-5	Periodontitis (PAL4Q3);
THYM	cis	rs6748734	0.625	rs7355583	chr2:241821707	T/C	cg07537917	chr2:241836409	C2orf54	-0.21	-4.95	-0.45	3.18e-6	Urinary metabolites;
THYM	trans	rs4866334	1.000	rs77699507	chr5:18481057	A/G	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs3892630	0.824	rs12327732	chr19:33221767	C/T	cg22980127	chr19:33182716	NUDT19	1.14	9.23	0.69	7.47e-15	Red blood cell traits;
THYM	cis	rs11225247	0.881	rs11603677	chr11:102259992	A/T	cg06323957	chr11:102217781	BIRC2	1.13	5.09	0.46	1.8e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs6500395	0.963	rs12444902	chr16:48667126	G/T	cg04672837	chr16:48644449	N4BP1	0.47	4.62	0.43	1.18e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg08885076	chr2:99613938	TSGA10	0.62	5.69	0.5	1.41e-7	Chronic sinus infection;
THYM	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg08017756	chr2:100939284	LONRF2	-0.73	-7.55	-0.61	2.6e-11	Intelligence (multi-trait analysis);
THYM	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs877282	0.898	rs11253343	chr10:765117	C/T	cg10556349	chr10:835070	NA	-0.78	-5.06	-0.46	2.06e-6	Uric acid levels;
THYM	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg06238570	chr21:40685208	BRWD1	0.92	6.87	0.58	6.76e-10	Cognitive function;
THYM	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg02527881	chr3:46936655	PTH1R	0.6	5.55	0.5	2.53e-7	Colorectal cancer;
THYM	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg20887711	chr4:1340912	KIAA1530	0.96	8.76	0.67	7.49e-14	Longevity;
THYM	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg21644426	chr2:191273491	MFSD6	-0.76	-6.32	-0.54	8.56e-9	Pulse pressure;
THYM	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.84e-8	Systolic blood pressure;
THYM	cis	rs2448490	0.629	rs7395672	chr11:65488982	G/A	cg17480646	chr11:65405466	SIPA1	0.71	5.66	0.5	1.57e-7	Platelet count;
THYM	cis	rs75920871	0.512	rs6589583	chr11:116863766	C/T	cg20608306	chr11:116969690	SIK3	-0.54	-6.03	-0.53	3.11e-8	Subjective well-being;
THYM	cis	rs7020830	0.825	rs66684257	chr9:37199087	G/T	cg14294708	chr9:37120828	ZCCHC7	1.21	13.58	0.81	5.59e-24	Schizophrenia;
THYM	cis	rs7769051	1.000	rs9493438	chr6:133098349	T/C	cg22852734	chr6:133119734	C6orf192	1.29	8.22	0.64	1.04e-12	Type 2 diabetes nephropathy;
THYM	cis	rs9515201	0.627	rs4773173	chr13:111025118	A/G	cg05272587	chr13:111038400	COL4A2	-0.55	-4.75	-0.44	7.28e-6	White matter hyperintensity burden;
THYM	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg20007245	chr22:24372913	LOC391322	0.74	6.63	0.56	2.03e-9	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs7107174	1.000	rs10899491	chr11:78106305	T/C	cg19901956	chr11:77921274	USP35	-0.69	-5.7	-0.5	1.35e-7	Testicular germ cell tumor;
THYM	cis	rs4845875	0.540	rs10864543	chr1:11844330	C/T	cg24844545	chr1:11908347	NPPA	0.47	4.55	0.42	1.59e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg01483505	chr11:975446	AP2A2	0.58	4.73	0.44	7.82e-6	Alzheimer's disease (late onset);
THYM	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg02640540	chr1:67518911	SLC35D1	0.62	4.53	0.42	1.72e-5	Lymphocyte percentage of white cells;
THYM	cis	rs9326248	0.559	rs609177	chr11:116770517	A/G	cg20608306	chr11:116969690	SIK3	0.62	7.39	0.6	5.73e-11	Blood protein levels;
THYM	cis	rs4788570	0.655	rs7359478	chr16:71825445	A/G	cg06353428	chr16:71660113	MARVELD3	1.41	8.74	0.67	8.32e-14	Intelligence (multi-trait analysis);
THYM	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg27129171	chr3:47204927	SETD2	0.7	6.7	0.57	1.44e-9	Colorectal cancer;
THYM	cis	rs7567389	0.719	rs4150476	chr2:128032822	A/T	cg09760422	chr2:128146352	NA	-0.4	-4.52	-0.42	1.8e-5	Self-rated health;
THYM	cis	rs6089829	0.851	rs10854168	chr20:61669550	A/G	cg03213289	chr20:61660250	NA	0.97	10.24	0.72	4.96e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2997447	0.739	rs72884784	chr1:26432246	G/A	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9311676	0.632	rs62259772	chr3:58417416	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs4389656	0.857	rs274676	chr5:6754762	T/C	cg10857441	chr5:6722123	POLS	-0.43	-4.52	-0.42	1.81e-5	Coronary artery disease;
THYM	cis	rs6980334	1.000	rs6980334	chr7:137788492	A/G	cg11874123	chr7:137028198	PTN	-0.67	-5.24	-0.47	9.68e-7	Blood metabolite ratios;
THYM	cis	rs10819861	0.621	rs4742839	chr9:98847910	C/T	cg14508093	chr9:98862825	NA	-0.24	-4.69	-0.43	9.01e-6	Electrocardiographic traits;
THYM	cis	rs2273669	0.667	rs11153150	chr6:109316652	C/G	cg17117243	chr6:109341365	SESN1	-0.9	-5.38	-0.48	5.45e-7	Prostate cancer;
THYM	cis	rs4474465	0.915	rs12794810	chr11:78212743	T/C	cg19901956	chr11:77921274	USP35	0.67	4.94	0.45	3.29e-6	Alzheimer's disease (survival time);
THYM	cis	rs3820068	0.705	rs4646031	chr1:15834648	A/G	cg05660106	chr1:15850417	CASP9	1.1	9.92	0.71	2.48e-16	Systolic blood pressure;
THYM	cis	rs10911232	0.507	rs10911234	chr1:183053001	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs1883415	0.759	rs2817222	chr6:24506770	C/T	cg00346970	chr6:24499591	ALDH5A1	0.48	5.7	0.5	1.36e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs34638657	0.732	rs10514532	chr16:82200337	C/T	cg09439754	chr16:82129088	HSD17B2	0.54	5.42	0.49	4.47e-7	Lung adenocarcinoma;
THYM	cis	rs72627123	0.867	rs73301500	chr14:74473413	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.93	5.3	0.48	7.37e-7	Morning vs. evening chronotype;
THYM	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg02725872	chr8:58115012	NA	-0.9	-5.24	-0.47	9.85e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg16486109	chr11:613632	IRF7	0.49	5.44	0.49	4.08e-7	Systemic lupus erythematosus;
THYM	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs10782582	0.593	rs11802717	chr1:76124648	C/T	cg22875332	chr1:76189707	ACADM	-0.54	-5.07	-0.46	1.96e-6	Daytime sleep phenotypes;
THYM	cis	rs7084402	0.967	rs1896243	chr10:60276291	C/T	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg22433210	chr17:43662623	NA	-1.07	-7.86	-0.63	6.04e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg11752832	chr7:134001865	SLC35B4	0.73	5.5	0.49	3.23e-7	Mean platelet volume;
THYM	cis	rs80319144	0.951	rs79560306	chr2:159244427	T/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs56104184	0.830	rs28556985	chr19:49351149	C/T	cg26267310	chr19:49340593	PLEKHA4;HSD17B14	0.92	5.29	0.48	7.89e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs654950	0.875	rs55865698	chr1:41986758	C/T	cg06885757	chr1:42089581	HIVEP3	-0.46	-5.41	-0.49	4.77e-7	Airway imaging phenotypes;
THYM	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12756686	chr19:29218302	NA	0.98	8.72	0.67	9.12e-14	Methadone dose in opioid dependence;
THYM	cis	rs4845875	0.602	rs2001584	chr1:11841351	G/A	cg25341925	chr1:11908058	NPPA	0.42	4.49	0.42	1.99e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs17125944	0.686	rs11621275	chr14:53363316	C/G	cg00686598	chr14:53173677	PSMC6	-1.08	-4.83	-0.44	5.23e-6	Alzheimer's disease (late onset);
THYM	cis	rs6500395	1.000	rs6500398	chr16:48650332	C/T	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7772486	0.713	rs1986729	chr6:146194831	G/A	cg23711669	chr6:146136114	FBXO30	0.96	10.07	0.72	1.15e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs863345	0.625	rs10752626	chr1:158528118	G/A	cg12129480	chr1:158549410	OR10X1	-0.52	-5.24	-0.47	9.55e-7	Pneumococcal bacteremia;
THYM	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg26441486	chr22:50317300	CRELD2	0.42	6.2	0.54	1.47e-8	Schizophrenia;
THYM	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg07424592	chr7:64974309	NA	1.16	5.55	0.5	2.55e-7	Diabetic kidney disease;
THYM	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg21100191	chr22:23484243	RTDR1	0.73	6.4	0.55	5.82e-9	Bone mineral density;
THYM	cis	rs56104184	0.830	rs55966626	chr19:49342396	G/T	cg16594139	chr19:49340574	PLEKHA4;HSD17B14	1.01	5.03	0.46	2.33e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg15556689	chr8:8085844	FLJ10661	-0.77	-6.68	-0.57	1.61e-9	Mood instability;
THYM	trans	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs28595532	0.920	rs115320476	chr4:119759680	G/A	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg13852791	chr20:30311386	BCL2L1	0.67	4.76	0.44	7.04e-6	Mean corpuscular hemoglobin;
THYM	cis	rs11711311	0.869	rs1026364	chr3:113370010	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.59	-4.96	-0.45	3.07e-6	IgG glycosylation;
THYM	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg06618935	chr21:46677482	NA	0.99	9.3	0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7772486	0.846	rs9376976	chr6:146355605	T/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg06481639	chr22:41940642	POLR3H	0.72	4.68	0.43	9.69e-6	Vitiligo;
THYM	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	6.7	0.57	1.44e-9	Total body bone mineral density;
THYM	cis	rs7941600	0.748	rs56077948	chr11:9176366	A/G	cg21110646	chr11:9336536	TMEM41B	0.9	4.94	0.45	3.35e-6	Coronary artery disease;
THYM	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12579753	0.871	rs10862364	chr12:82201280	C/T	cg21231944	chr12:82153410	PPFIA2	-0.66	-5.01	-0.46	2.51e-6	Resting heart rate;
THYM	cis	rs8033133	0.836	rs11634716	chr15:25306646	C/T	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	0.73	5.39	0.48	5.05e-7	Blood osmolality (transformed sodium);
THYM	cis	rs59698941	0.943	rs739863	chr5:132232315	C/T	cg02081065	chr5:132209139	LEAP2	-0.86	-5.85	-0.51	7.09e-8	Apolipoprotein A-IV levels;
THYM	cis	rs72717009	0.825	rs10494360	chr1:161475750	G/A	cg23840854	chr1:161414152	NA	-1.03	-5.5	-0.49	3.16e-7	Rheumatoid arthritis;
THYM	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg15691649	chr6:25882328	NA	-0.77	-5.92	-0.52	5e-8	Urate levels;
THYM	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg26384229	chr12:38710491	ALG10B	1.05	8.61	0.66	1.51e-13	Heart rate;
THYM	cis	rs72949976	0.966	rs6752061	chr2:214027818	C/T	cg08319019	chr2:214017104	IKZF2	-0.66	-4.83	-0.44	5.28e-6	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9486719	1.000	rs12213426	chr6:96896035	T/C	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg12165864	chr7:66369176	NA	-0.64	-4.97	-0.45	2.97e-6	Aortic root size;
THYM	cis	rs2147959	0.766	rs12035708	chr1:228743499	C/A	cg16512390	chr1:228756714	NA	0.73	4.72	0.44	8.01e-6	Adult asthma;
THYM	cis	rs10819861	0.655	rs55821317	chr9:98868372	G/A	cg14508093	chr9:98862825	NA	-0.25	-4.94	-0.45	3.29e-6	Electrocardiographic traits;
THYM	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg08470875	chr2:26401718	FAM59B	0.74	4.59	0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs7572733	0.534	rs11899188	chr2:198740121	C/T	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs1499972	0.938	rs1499971	chr3:117719537	A/C	cg07612923	chr3:117604196	NA	-1.5	-5.16	-0.47	1.38e-6	Schizophrenia;
THYM	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg00071950	chr4:10020882	SLC2A9	0.86	10.33	0.73	3.3e-17	Bone mineral density;
THYM	cis	rs2404602	0.735	rs11857015	chr15:76649390	T/C	cg23482746	chr15:76478102	C15orf27	0.5	4.95	0.45	3.16e-6	Blood metabolite levels;
THYM	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg15556689	chr8:8085844	FLJ10661	-0.86	-8.31	-0.65	6.78e-13	Schizophrenia;
THYM	cis	rs7260598	0.642	rs10424894	chr19:24160855	T/A	cg15526094	chr19:24182596	NA	-0.66	-4.72	-0.44	8.28e-6	Response to taxane treatment (placlitaxel);
THYM	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg06808227	chr14:105710500	BRF1	-1.05	-9.15	-0.68	1.07e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs13223928	0.565	rs10951053	chr7:3155579	C/T	cg19214707	chr7:3157722	NA	-0.9	-8.07	-0.64	2.12e-12	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs79149102	0.579	rs12593476	chr15:75282092	A/C	cg09165964	chr15:75287851	SCAMP5	-1.08	-5.99	-0.52	3.77e-8	Lung cancer;
THYM	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg09367891	chr1:107599246	PRMT6	0.7	5.02	0.46	2.42e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg12311346	chr5:56204834	C5orf35	0.62	4.74	0.44	7.4e-6	Initial pursuit acceleration;
THYM	cis	rs11771526	0.901	rs78065961	chr7:32300967	C/T	cg13207630	chr7:32358064	NA	0.81	5.16	0.47	1.38e-6	Body mass index;
THYM	cis	rs7926906	1.000	rs4298862	chr11:90523629	C/G	cg26138821	chr11:89956704	CHORDC1	-0.52	-4.69	-0.43	9.11e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12282928	1.000	rs10838860	chr11:48307374	T/C	cg22827986	chr11:48284249	OR4X1	0.52	5.4	0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs4787491	0.729	rs7191849	chr16:30023157	T/C	cg06015834	chr16:30021696	DOC2A	-0.5	-4.46	-0.42	2.27e-5	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg08994789	chr17:28903642	LRRC37B2	-1.07	-6.19	-0.54	1.52e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg08975724	chr8:8085496	FLJ10661	0.69	5.21	0.47	1.1e-6	Neuroticism;
THYM	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg12179176	chr11:130786555	SNX19	0.78	6.73	0.57	1.27e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9649213	0.593	rs6949718	chr7:97924483	G/A	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.61e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg12863693	chr15:85201151	NMB	0.62	5.43	0.49	4.26e-7	Schizophrenia;
THYM	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg03929089	chr4:120376271	NA	-1.03	-8.74	-0.67	8.32e-14	Coronary artery disease;
THYM	cis	rs303386	0.501	rs6698436	chr1:99588903	A/G	cg03593336	chr1:99471295	LPPR5	-0.4	-4.49	-0.42	2.01e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
THYM	cis	rs2319125	0.683	rs1373076	chr17:64050768	G/A	cg04446870	chr17:64440273	PRKCA	0.5	4.48	0.42	2.12e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs4731207	0.596	rs1871771	chr7:124679051	G/A	cg05285228	chr7:124571219	POT1	-0.63	-4.74	-0.44	7.37e-6	Cutaneous malignant melanoma;
THYM	cis	rs420259	0.516	rs2106456	chr16:23550931	C/T	cg00143387	chr16:23521605	GGA2	-0.75	-5.37	-0.48	5.57e-7	Bipolar disorder;
THYM	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg16586182	chr3:47516702	SCAP	-0.66	-5.58	-0.5	2.25e-7	Colorectal cancer;
THYM	cis	rs2562456	0.874	rs2562417	chr19:21711202	T/C	cg21751540	chr19:21541537	ZNF738	0.66	4.6	0.43	1.3e-5	Pain;
THYM	cis	rs12367572	0.641	rs7964973	chr12:45402893	T/C	cg03114573	chr12:45410052	DBX2	-0.51	-4.73	-0.44	7.74e-6	Gut microbiome composition (summer);
THYM	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg22117172	chr7:91764530	CYP51A1	-0.4	-4.7	-0.43	8.92e-6	Breast cancer;
THYM	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.59	-4.49	-0.42	1.98e-5	Breast cancer;
THYM	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg20469991	chr17:27169893	C17orf63	-0.76	-4.78	-0.44	6.27e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.51	-4.83	-0.44	5.26e-6	Crohn's disease;
THYM	cis	rs2219968	1.000	rs11776951	chr8:78971578	G/C	cg00738934	chr8:78996279	NA	0.91	9.74	0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg05043794	chr9:111880884	C9orf5	-0.43	-6.35	-0.55	7.29e-9	Menarche (age at onset);
THYM	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg24578937	chr1:2090814	PRKCZ	0.78	7.92	0.63	4.42e-12	Height;
THYM	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg23260525	chr10:116636907	FAM160B1	0.52	5.19	0.47	1.19e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs10892173	0.588	rs12363806	chr11:117658211	G/A	cg07621104	chr11:117668040	DSCAML1	0.88	6.96	0.58	4.33e-10	Myopia;
THYM	cis	rs2236918	0.687	rs2797600	chr1:242029331	C/T	cg21919602	chr1:242011447	EXO1	-0.6	-4.45	-0.42	2.35e-5	Menopause (age at onset);
THYM	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg08305652	chr11:111469057	NA	0.53	4.54	0.42	1.62e-5	Primary sclerosing cholangitis;
THYM	cis	rs909685	1.000	rs909685	chr22:39747671	T/A	cg24268161	chr22:39747459	SYNGR1	-0.88	-10.33	-0.73	3.25e-17	Rheumatoid arthritis;
THYM	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg06238570	chr21:40685208	BRWD1	0.89	6.43	0.55	5.21e-9	Cognitive function;
THYM	cis	rs3096299	0.933	rs2930219	chr16:89492049	G/A	cg06640241	chr16:89574553	SPG7	0.69	5.38	0.48	5.27e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg18512352	chr11:47633146	NA	-0.38	-4.52	-0.42	1.76e-5	HDL cholesterol;
THYM	cis	rs7582180	0.903	rs6755791	chr2:100895872	G/A	cg14675211	chr2:100938903	LONRF2	0.59	4.98	0.46	2.8e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg02915803	chr1:1606292	LOC728661;CDK11B	0.63	5.32	0.48	7.01e-7	Body mass index;
THYM	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg03676636	chr4:99064102	C4orf37	0.39	5.64	0.5	1.72e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg10515332	chr4:99064459	C4orf37	0.62	4.94	0.45	3.35e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11608355	0.846	rs35393419	chr12:109881809	C/T	cg11367159	chr12:110044531	NA	0.56	4.75	0.44	7.31e-6	Neuroticism;
THYM	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-4.73	-0.44	7.65e-6	Alzheimer's disease;
THYM	cis	rs829883	0.738	rs249846	chr12:98868739	T/C	cg25150519	chr12:98850993	NA	0.51	5.08	0.46	1.91e-6	Colorectal adenoma (advanced);
THYM	cis	rs13256369	0.802	rs35382339	chr8:8559255	G/A	cg18904891	chr8:8559673	CLDN23	0.72	5.47	0.49	3.66e-7	Obesity-related traits;
THYM	cis	rs11148252	0.514	rs3783242	chr13:52717950	C/T	cg05335186	chr13:53173507	NA	-0.39	-4.52	-0.42	1.79e-5	Lewy body disease;
THYM	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg08859206	chr1:53392774	SCP2	0.47	4.84	0.44	5.09e-6	Monocyte count;
THYM	cis	rs28595532	0.920	rs114390336	chr4:119771452	C/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs8067545	0.750	rs4267380	chr17:19971564	A/G	cg13482628	chr17:19912719	NA	0.56	4.7	0.43	8.78e-6	Schizophrenia;
THYM	cis	rs4589258	1.000	rs7112243	chr11:90457003	A/G	cg26138821	chr11:89956704	CHORDC1	-0.69	-5.52	-0.49	3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg06060754	chr5:176797920	RGS14	-0.34	-4.94	-0.45	3.38e-6	Urinary electrolytes (magnesium/calcium ratio);
THYM	cis	rs9309711	0.813	rs11690865	chr2:3471950	C/T	cg10845886	chr2:3471009	TTC15	-0.58	-4.46	-0.42	2.27e-5	Neurofibrillary tangles;
THYM	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg15448220	chr1:150897856	SETDB1	0.9	7.66	0.62	1.56e-11	Melanoma;
THYM	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg17143192	chr8:8559678	CLDN23	0.91	6.72	0.57	1.33e-9	Obesity-related traits;
THYM	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg23188684	chr11:67383651	NA	-0.6	-4.5	-0.42	1.96e-5	Mean corpuscular volume;
THYM	cis	rs6980334	1.000	rs6980334	chr7:137788492	A/G	cg22979093	chr7:137028410	PTN	-0.61	-4.91	-0.45	3.77e-6	Blood metabolite ratios;
THYM	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11644478	chr21:40555479	PSMG1	-0.76	-6.51	-0.56	3.49e-9	Cognitive function;
THYM	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg16680214	chr1:154839983	KCNN3	-0.45	-5.03	-0.46	2.32e-6	Prostate cancer;
THYM	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg10117171	chr1:25599238	RHD	-0.65	-4.76	-0.44	6.89e-6	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs7614311	0.552	rs73117078	chr3:63942084	G/A	cg22134162	chr3:63841271	THOC7	-0.57	-6.86	-0.58	7.07e-10	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg08807101	chr21:30365312	RNF160	0.94	8.18	0.64	1.24e-12	Dental caries;
THYM	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg08017756	chr2:100939284	LONRF2	-0.71	-7.37	-0.6	6.18e-11	Intelligence (multi-trait analysis);
THYM	trans	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg10856724	chr12:34555212	NA	-0.82	-7.07	-0.59	2.55e-10	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06481639	chr22:41940642	POLR3H	0.82	5.77	0.51	9.74e-8	Vitiligo;
THYM	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg11266682	chr4:10021025	SLC2A9	0.74	12.07	0.78	6.92e-21	Bone mineral density;
THYM	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg08645402	chr16:4508243	NA	0.77	6.78	0.57	9.89e-10	Schizophrenia;
THYM	cis	rs7106204	0.609	rs10500976	chr11:24335921	A/G	ch.11.24196551F	chr11:24239977	NA	-0.81	-4.93	-0.45	3.48e-6	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	6.89	0.58	5.96e-10	Electrocardiographic conduction measures;
THYM	cis	rs2075230	0.850	rs9908405	chr17:7467461	A/C	cg27413385	chr17:7515425	FXR2	0.32	4.47	0.42	2.17e-5	Hormone measurements;
THYM	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	5.16	0.47	1.34e-6	Neuroticism;
THYM	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg17366294	chr4:99064904	C4orf37	0.53	5.9	0.52	5.67e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7909791	0.632	rs3818278	chr10:105665323	G/T	cg24587175	chr10:105670608	OBFC1	0.76	7.41	0.61	5.2e-11	White matter hyperintensity burden;
THYM	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg03605463	chr16:89740564	NA	0.62	5.01	0.46	2.47e-6	Hemoglobin concentration;
THYM	cis	rs7267979	1.000	rs2258066	chr20:25271326	C/T	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4732038	0.510	rs10251749	chr7:134268548	G/T	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.91	-5.94	-0.52	4.65e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs11030122	0.702	rs12281293	chr11:3963814	C/T	cg22027985	chr11:4115532	RRM1	-0.48	-4.59	-0.43	1.36e-5	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg07570687	chr10:102243282	WNT8B	0.77	6.88	0.58	6.28e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2046867	0.862	rs7648954	chr3:72838756	C/A	cg25664220	chr3:72788482	NA	-0.82	-6.28	-0.54	1.02e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs478304	0.934	rs537786	chr11:65494987	C/T	cg17480646	chr11:65405466	SIPA1	0.7	6.03	0.53	3.11e-8	Acne (severe);
THYM	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs9355610	0.609	rs9366076	chr6:167373708	C/T	cg23791538	chr6:167370224	RNASET2	0.75	5.03	0.46	2.36e-6	Graves' disease;
THYM	cis	rs2836974	0.800	rs12482857	chr21:40514861	T/C	cg11890956	chr21:40555474	PSMG1	1.16	12.26	0.78	2.79e-21	Cognitive function;
THYM	cis	rs16912285	0.584	rs7131124	chr11:24249455	A/G	ch.11.24196551F	chr11:24239977	NA	0.96	6.74	0.57	1.24e-9	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6964587	0.626	rs404	chr7:91544316	G/T	cg22709100	chr7:91322751	NA	-0.62	-4.67	-0.43	9.72e-6	Breast cancer;
THYM	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.59	-9.22	-0.69	7.59e-15	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg27446573	chr6:127587934	RNF146	1.03	9.94	0.71	2.25e-16	Breast cancer;
THYM	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg02753203	chr1:228287806	NA	-0.61	-5.15	-0.47	1.4e-6	Diastolic blood pressure;
THYM	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg05043794	chr9:111880884	C9orf5	-0.44	-6.39	-0.55	6.03e-9	Menarche (age at onset);
THYM	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg26149184	chr10:133730230	NA	0.77	4.65	0.43	1.07e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs10887741	0.532	rs2755430	chr10:89415605	C/T	cg13926569	chr10:89418898	PAPSS2	-0.62	-5.89	-0.52	5.75e-8	Exercise (leisure time);
THYM	cis	rs9296092	0.538	rs9461880	chr6:33518714	C/T	cg13560919	chr6:33536144	NA	-0.94	-9.31	-0.69	4.9e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg24692254	chr21:30365293	RNF160	-0.99	-8.66	-0.66	1.23e-13	Dental caries;
THYM	cis	rs4746818	1.000	rs10823313	chr10:70952115	G/A	cg11621586	chr10:70884670	VPS26A	1.28	11.12	0.75	6.73e-19	Left atrial antero-posterior diameter;
THYM	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg24530246	chr3:53118167	NA	-0.85	-4.82	-0.44	5.52e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg03188948	chr7:1209495	NA	0.74	5.99	0.52	3.79e-8	Longevity;Endometriosis;
THYM	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg27446573	chr6:127587934	RNF146	0.7	6.13	0.53	1.99e-8	Breast cancer;
THYM	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg15556689	chr8:8085844	FLJ10661	0.65	5.13	0.47	1.55e-6	Mood instability;
THYM	cis	rs7119	1.000	rs7119	chr15:77777632	C/T	cg10437265	chr15:77819839	NA	0.68	7.05	0.59	2.84e-10	Type 2 diabetes;
THYM	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.72	4.58	0.43	1.39e-5	Lung cancer in ever smokers;
THYM	cis	rs4430311	0.723	rs971285	chr1:243919773	C/T	cg25706552	chr1:244017396	NA	-0.56	-4.71	-0.43	8.58e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg13104385	chr7:22767384	IL6	-0.56	-4.89	-0.45	4.12e-6	Lung cancer;
THYM	cis	rs6840360	0.571	rs1822346	chr4:152525303	G/C	cg17479576	chr4:152424074	FAM160A1	-0.78	-5.74	-0.51	1.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4606347	0.789	rs61780869	chr1:66163021	T/C	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7656342	0.543	rs6448981	chr4:9740325	G/C	cg21099470	chr4:10459141	ZNF518B	0.63	4.49	0.42	1.99e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs34779708	0.897	rs7900480	chr10:35338699	A/G	cg03585969	chr10:35415529	CREM	-0.67	-5.01	-0.46	2.51e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg14196790	chr5:131705035	SLC22A5	0.46	4.53	0.42	1.72e-5	Blood metabolite levels;
THYM	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg18681998	chr4:17616180	MED28	-0.93	-7.87	-0.63	5.57e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7131987	0.903	rs11050152	chr12:29404424	G/T	cg09582351	chr12:29534625	ERGIC2	-0.48	-4.59	-0.43	1.35e-5	QT interval;
THYM	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg12560992	chr17:57184187	TRIM37	-0.86	-7.66	-0.62	1.56e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7264396	0.563	rs17093093	chr20:34380925	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.74	-4.57	-0.42	1.45e-5	Total cholesterol levels;
THYM	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg22968622	chr17:43663579	NA	-1.1	-9.99	-0.72	1.7e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs909002	0.849	rs4949449	chr1:32088534	T/G	cg13919466	chr1:32135498	COL16A1	-0.49	-4.73	-0.44	7.75e-6	Intelligence (multi-trait analysis);
THYM	cis	rs12142240	0.738	rs41293277	chr1:46806550	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg11905131	chr22:24372483	LOC391322	0.83	8.02	0.64	2.74e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.64	0.43	1.12e-5	Obesity-related traits;
THYM	cis	rs11225247	0.772	rs34104132	chr11:102232160	T/G	cg06323957	chr11:102217781	BIRC2	1.02	4.74	0.44	7.52e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs11771526	0.901	rs11764193	chr7:32272200	C/T	cg13207630	chr7:32358064	NA	0.74	4.98	0.46	2.8e-6	Body mass index;
THYM	cis	rs10887741	0.646	rs7097212	chr10:89430067	G/A	cg13926569	chr10:89418898	PAPSS2	0.63	7.28	0.6	9.67e-11	Exercise (leisure time);
THYM	cis	rs10411161	0.702	rs17835311	chr19:52386781	A/C	cg25361850	chr19:52391789	ZNF577	0.73	5.09	0.46	1.84e-6	Breast cancer;
THYM	cis	rs8067545	0.586	rs2703819	chr17:20121401	A/G	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs10463554	1.000	rs3776864	chr5:102327868	A/C	cg23492399	chr5:102201601	PAM	-0.66	-5.15	-0.47	1.4e-6	Parkinson's disease;
THYM	cis	rs4713118	0.662	rs9468277	chr6:28028390	C/A	cg08968635	chr6:28129556	ZNF389	0.59	4.57	0.42	1.46e-5	Parkinson's disease;
THYM	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.49	-4.62	-0.43	1.21e-5	Crohn's disease;
THYM	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg26963428	chr7:66367121	NA	-0.61	-4.77	-0.44	6.78e-6	Corneal structure;
THYM	cis	rs7224737	0.956	rs7208907	chr17:40284783	C/T	cg02228675	chr17:40259724	DHX58	-0.66	-5.49	-0.49	3.28e-7	Fibrinogen levels;
THYM	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg08736216	chr1:53307985	ZYG11A	-0.69	-6.0	-0.52	3.5e-8	Monocyte count;
THYM	cis	rs89107	0.576	rs6906287	chr6:118962740	T/C	cg21191810	chr6:118973309	C6orf204	0.55	5.57	0.5	2.39e-7	Cardiac structure and function;
THYM	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg06623918	chr6:96969491	KIAA0776	-1.05	-10.47	-0.73	1.63e-17	Headache;
THYM	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg04944784	chr2:26401820	FAM59B	1.09	8.74	0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg20469991	chr17:27169893	C17orf63	-0.79	-4.79	-0.44	6.18e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03264133	chr6:25882463	NA	0.89	7.55	0.61	2.67e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7940866	0.903	rs11222421	chr11:130872351	A/T	cg05962950	chr11:130786565	SNX19	0.72	5.71	0.51	1.26e-7	Schizophrenia;
THYM	cis	rs7173743	0.756	rs8032771	chr15:79126059	A/G	cg15571903	chr15:79123663	NA	0.56	6.26	0.54	1.12e-8	Coronary artery disease;
THYM	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg00852783	chr1:26633632	UBXN11	0.86	8.81	0.67	5.74e-14	Obesity-related traits;
THYM	cis	rs2997447	0.761	rs17163588	chr1:26450009	C/T	cg03844060	chr1:26490628	NA	0.67	4.52	0.42	1.79e-5	QRS complex (12-leadsum);
THYM	cis	rs17125944	0.656	rs74825460	chr14:53390015	C/T	cg00686598	chr14:53173677	PSMC6	1.08	4.85	0.45	4.75e-6	Alzheimer's disease (late onset);
THYM	cis	rs13102973	0.965	rs11735381	chr4:135850474	T/C	cg14419869	chr4:135874104	NA	0.9	8.46	0.66	3.24e-13	Subjective well-being;
THYM	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg12573674	chr2:1569213	NA	-1.22	-4.82	-0.44	5.5e-6	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs11645898	0.688	rs398580	chr16:72095453	A/G	cg03805757	chr16:71968109	PKD1L3	-0.71	-4.91	-0.45	3.82e-6	Blood protein levels;
THYM	trans	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg25214090	chr10:38739885	LOC399744	0.86	7.35	0.6	6.87e-11	Corneal astigmatism;
THYM	cis	rs7267979	0.932	rs928121	chr20:25534818	A/G	cg03522245	chr20:25566470	NINL	0.59	4.59	0.43	1.33e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs12946454	0.668	rs4792867	chr17:43249444	C/T	cg10701640	chr17:43249399	NA	0.58	4.49	0.42	2.02e-5	Systolic blood pressure;
THYM	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	5.75	0.51	1.08e-7	Blood metabolite levels;
THYM	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg19774624	chr17:42201019	HDAC5	0.7	5.83	0.51	7.43e-8	Total body bone mineral density;
THYM	cis	rs2294693	0.945	rs2073015	chr6:41008747	A/G	cg21128951	chr6:40996213	UNC5CL	0.61	4.58	0.43	1.38e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14159672	chr1:205819179	PM20D1	0.96	9.84	0.71	3.58e-16	Menarche (age at onset);
THYM	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg10661904	chr17:79619235	PDE6G	0.57	5.3	0.48	7.61e-7	Eye color traits;
THYM	cis	rs2795502	0.564	rs72777187	chr10:43432224	C/T	cg08461752	chr10:43522343	NA	-0.74	-4.53	-0.42	1.73e-5	Blood protein levels;
THYM	cis	rs7705502	1.000	rs55646464	chr5:173324971	G/T	cg18693985	chr5:173351052	CPEB4	-0.78	-5.64	-0.5	1.71e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs2282300	0.696	rs1222214	chr11:30347695	C/G	cg06241208	chr11:30344200	C11orf46	-0.78	-5.65	-0.5	1.64e-7	Morning vs. evening chronotype;
THYM	cis	rs448720	0.935	rs9796591	chr15:68197835	C/G	cg23793686	chr15:68133972	NA	-0.5	-4.63	-0.43	1.17e-5	Cognitive performance;
THYM	cis	rs11089937	0.616	rs6001223	chr22:22539749	T/G	cg06866756	chr22:22471216	NA	-0.46	-5.09	-0.46	1.79e-6	Periodontitis (PAL4Q3);
THYM	cis	rs4343996	0.747	rs7791617	chr7:3504800	C/T	cg21248987	chr7:3385318	SDK1	-0.38	-4.67	-0.43	9.91e-6	Motion sickness;
THYM	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg02825527	chr7:2087843	MAD1L1	-0.82	-5.18	-0.47	1.24e-6	Neuroticism;
THYM	cis	rs79815064	0.850	rs78729754	chr3:46339185	C/A	cg20674725	chr3:47020919	NBEAL2	0.71	4.57	0.42	1.47e-5	Macrophage inflammatory protein 1b levels;
THYM	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.77	-7.01	-0.58	3.49e-10	Personality dimensions;
THYM	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg10523679	chr1:76189770	ACADM	-0.81	-6.31	-0.54	8.64e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs11096990	0.634	rs745642	chr4:39281262	G/T	cg24403649	chr4:39172243	NA	-0.67	-5.84	-0.51	7.33e-8	Cognitive function;
THYM	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.7	5.33	0.48	6.5e-7	Tonsillectomy;
THYM	cis	rs2976388	1.000	rs2920294	chr8:143765326	C/G	cg13446199	chr8:143762866	PSCA	0.51	6.41	0.55	5.48e-9	Urinary tract infection frequency;
THYM	cis	rs1003719	0.715	rs1981433	chr21:38542223	T/G	cg01329690	chr21:38580129	DSCR9	-0.36	-5.06	-0.46	2.03e-6	Eye color traits;
THYM	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg24642439	chr20:33292090	TP53INP2	0.68	5.14	0.47	1.45e-6	Coronary artery disease;
THYM	cis	rs2658782	0.789	rs2605574	chr11:93136444	T/G	cg15737290	chr11:93063684	CCDC67	0.87	6.71	0.57	1.38e-9	Pulmonary function decline;
THYM	cis	rs11779988	0.545	rs4124900	chr8:17785266	A/G	cg01800426	chr8:17659068	MTUS1	-0.76	-5.32	-0.48	6.94e-7	Breast cancer;
THYM	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg27170947	chr2:26402098	FAM59B	0.79	6.27	0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg07936489	chr17:37558343	FBXL20	-0.81	-5.5	-0.49	3.17e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10479542	0.752	rs12658664	chr5:178986987	C/T	cg02136620	chr5:178986620	RUFY1	0.58	5.83	0.51	7.46e-8	Lung cancer;
THYM	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.99	-5.43	-0.49	4.27e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.12	-0.64	1.66e-12	Mean corpuscular volume;
THYM	cis	rs4713118	0.869	rs9461401	chr6:27703291	G/A	cg12963246	chr6:28129442	ZNF389	0.64	4.86	0.45	4.62e-6	Parkinson's disease;
THYM	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs4343996	0.692	rs1546742	chr7:3456210	C/A	cg21248987	chr7:3385318	SDK1	0.4	4.89	0.45	4.14e-6	Motion sickness;
THYM	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg11905131	chr22:24372483	LOC391322	0.71	6.16	0.53	1.75e-8	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs868036	0.634	rs8028313	chr15:68043057	C/G	cg24579218	chr15:68104479	NA	-0.82	-8.06	-0.64	2.29e-12	Restless legs syndrome;
THYM	trans	rs4650994	0.525	rs2811295	chr1:178551267	C/T	cg05059571	chr16:84539110	KIAA1609	0.88	9.96	0.71	2e-16	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg02221750	chr19:17393354	ANKLE1	-0.94	-8.56	-0.66	1.92e-13	Systemic lupus erythematosus;
THYM	cis	rs2333194	0.739	rs61987083	chr14:73915861	T/C	cg09844916	chr14:74004424	HEATR4;ACOT1	0.64	4.99	0.46	2.69e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs9733	0.596	rs2867301	chr1:150653795	C/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs2302612	0.571	rs3755284	chr2:102852426	T/A	cg13315345	chr2:102803985	IL1RL2	0.68	5.23	0.47	1e-6	Serum protein levels (sST2);
THYM	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg18876405	chr7:65276391	NA	-0.53	-4.54	-0.42	1.68e-5	Aortic root size;
THYM	cis	rs6500395	1.000	rs4785247	chr16:48687732	A/C	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9311676	0.656	rs10866016	chr3:58390844	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs9653442	0.609	rs10209110	chr2:100672692	C/T	cg22139774	chr2:100720529	AFF3	-0.37	-5.64	-0.5	1.72e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg09307838	chr4:120376055	NA	0.75	5.39	0.48	5.21e-7	Corneal astigmatism;
THYM	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg18252515	chr7:66147081	NA	-0.66	-5.01	-0.46	2.55e-6	Aortic root size;
THYM	cis	rs17708984	0.606	rs10426172	chr19:16191579	A/G	cg13618979	chr19:16186840	TPM4	0.35	4.59	0.43	1.36e-5	Platelet count;Platelet distribution width;
THYM	cis	rs11850957	0.502	rs75772222	chr14:25447080	C/T	cg26846476	chr14:24838993	NFATC4	0.93	4.77	0.44	6.66e-6	Subcutaneous adipose tissue;
THYM	cis	rs4523957	0.614	rs2641439	chr17:2017561	C/G	cg16513277	chr17:2031491	SMG6	-0.96	-8.72	-0.67	9.17e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs34779708	0.966	rs2045918	chr10:35418517	T/G	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs7567389	0.719	rs6430936	chr2:128007686	A/C	cg06038358	chr2:128176007	PROC	-0.47	-4.45	-0.42	2.33e-5	Self-rated health;
THYM	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg21475434	chr5:93447410	FAM172A	0.97	6.1	0.53	2.3e-8	Diabetic retinopathy;
THYM	cis	rs910187	0.631	rs62201431	chr20:45810994	G/A	cg27589058	chr20:45804311	EYA2	-0.61	-5.38	-0.48	5.41e-7	Migraine;
THYM	cis	rs2072732	0.821	rs12037307	chr1:2947756	C/A	cg08733933	chr1:2954429	NA	-0.63	-4.53	-0.42	1.68e-5	Plateletcrit;
THYM	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg24818145	chr4:99064322	C4orf37	0.77	6.05	0.53	2.83e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg20295408	chr7:1910781	MAD1L1	-0.68	-5.38	-0.48	5.39e-7	Schizophrenia;
THYM	cis	rs11225247	0.772	rs34296997	chr11:102238607	A/G	cg06323957	chr11:102217781	BIRC2	1.02	4.74	0.44	7.52e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs12681287	0.517	rs13249753	chr8:87513216	A/G	cg27223183	chr8:87520930	FAM82B	-0.71	-5.46	-0.49	3.8e-7	Caudate activity during reward;
THYM	cis	rs11096990	0.855	rs2566183	chr4:39163908	T/G	cg24403649	chr4:39172243	NA	-0.64	-5.4	-0.48	4.82e-7	Cognitive function;
THYM	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg06481639	chr22:41940642	POLR3H	0.84	5.85	0.51	6.94e-8	Vitiligo;
THYM	cis	rs13223928	0.592	rs4722439	chr7:3155858	C/T	cg19214707	chr7:3157722	NA	0.85	7.31	0.6	8.38e-11	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil counts;
THYM	cis	rs2916260	0.733	rs75052889	chr6:40387918	G/A	cg08415973	chr6:40346114	TDRG1	0.75	4.71	0.43	8.56e-6	Incident coronary heart disease;
THYM	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg11247378	chr22:39784982	NA	-1.04	-9.72	-0.71	6.65e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs2034088	1.000	rs2034088	chr17:423051	T/C	cg06217071	chr17:408420	NA	0.76	7.66	0.62	1.58e-11	Hip circumference adjusted for BMI;
THYM	cis	rs9443189	0.526	rs10943255	chr6:76225928	T/A	cg01950844	chr6:76311363	SENP6	1.12	5.7	0.5	1.37e-7	Prostate cancer;
THYM	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg17105886	chr17:28927953	LRRC37B2	1.32	6.56	0.56	2.79e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12474201	0.963	rs11676737	chr2:46929873	T/C	cg09399716	chr2:46890238	NA	-0.52	-4.57	-0.42	1.47e-5	Height;
THYM	trans	rs208520	0.690	rs851467	chr6:66802721	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.72	-0.62	1.18e-11	Exhaled nitric oxide output;
THYM	cis	rs2251260	0.685	rs1088673	chr14:62005648	A/G	cg13564459	chr14:62004353	PRKCH	-0.45	-5.58	-0.5	2.28e-7	Yeast infection;
THYM	cis	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg09307838	chr4:120376055	NA	0.78	5.89	0.52	5.7e-8	Corneal astigmatism;
THYM	cis	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	0.59	6.1	0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6163	0.588	rs67506723	chr10:104509064	G/T	cg04362960	chr10:104952993	NT5C2	0.55	4.71	0.44	8.38e-6	Waist circumference;Hip circumference;
THYM	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg06002616	chr8:101225028	SPAG1	-0.46	-4.82	-0.44	5.46e-6	Atrioventricular conduction;
THYM	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg12386194	chr3:101231763	SENP7	0.97	7.83	0.63	6.87e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg12292205	chr6:26970375	C6orf41	-1.06	-5.11	-0.46	1.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2835345	0.595	rs78237434	chr21:37824124	A/G	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06481639	chr22:41940642	POLR3H	0.83	5.86	0.52	6.65e-8	Vitiligo;
THYM	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-5.6	-0.5	2.08e-7	Chronic sinus infection;
THYM	cis	rs654950	0.807	rs941970	chr1:41990867	G/A	cg13396354	chr1:41153348	NA	0.46	4.7	0.43	8.62e-6	Airway imaging phenotypes;
THYM	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06481639	chr22:41940642	POLR3H	0.8	5.63	0.5	1.81e-7	Vitiligo;
THYM	cis	rs61931739	0.782	rs3903201	chr12:34248275	G/A	cg10856724	chr12:34555212	NA	-0.62	-5.55	-0.49	2.62e-7	Morning vs. evening chronotype;
THYM	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg02734326	chr4:10020555	SLC2A9	0.77	7.16	0.59	1.73e-10	Bone mineral density;
THYM	cis	rs2976388	1.000	rs2294010	chr8:143762430	A/G	cg06565975	chr8:143823917	SLURP1	-0.45	-5.23	-0.47	9.95e-7	Urinary tract infection frequency;
THYM	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg06728252	chr6:26598149	ABT1	0.46	5.3	0.48	7.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg26384229	chr12:38710491	ALG10B	0.95	7.08	0.59	2.48e-10	Morning vs. evening chronotype;
THYM	cis	rs9470366	0.527	rs10807170	chr6:36629444	C/T	cg24425727	chr6:36645648	CDKN1A	0.7	6.63	0.56	2.07e-9	QRS duration;
THYM	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg18876405	chr7:65276391	NA	-0.73	-6.86	-0.58	6.85e-10	Aortic root size;
THYM	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg08213375	chr14:104286397	PPP1R13B	0.46	4.85	0.45	4.9e-6	Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs7771547	0.519	rs28371845	chr6:36377709	C/T	cg07856975	chr6:36356162	ETV7	0.64	5.42	0.49	4.54e-7	Platelet distribution width;
THYM	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs57590327	0.508	rs13093082	chr3:81949958	C/T	cg07356753	chr3:81810745	GBE1	-0.71	-4.8	-0.44	5.99e-6	Extraversion;
THYM	cis	rs3892630	1.000	rs3892630	chr19:33181484	A/G	cg22928329	chr19:33183273	NUDT19	0.8	6.33	0.54	8.18e-9	Red blood cell traits;
THYM	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg02734326	chr4:10020555	SLC2A9	0.63	5.27	0.48	8.55e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg16049864	chr8:95962084	TP53INP1	-0.75	-6.69	-0.57	1.53e-9	Type 2 diabetes;
THYM	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg11279151	chr3:101281821	RG9MTD1	0.62	4.5	0.42	1.93e-5	Colorectal cancer;
THYM	cis	rs2398893	0.960	rs7849645	chr9:96744232	A/T	cg14459158	chr9:96720562	NA	0.51	4.95	0.45	3.22e-6	Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;
THYM	trans	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg25214090	chr10:38739885	LOC399744	0.92	7.7	0.62	1.26e-11	Corneal astigmatism;
THYM	cis	rs7192750	0.538	rs8054403	chr16:71990573	G/A	cg06353428	chr16:71660113	MARVELD3	0.71	5.31	0.48	7.32e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs470093	0.932	rs138086	chr22:44244302	C/A	cg09142166	chr22:44276013	PNPLA5	-0.57	-5.43	-0.49	4.38e-7	Staphylococcus aureus infection;
THYM	cis	rs17739167	0.532	rs11638953	chr15:42245652	G/A	cg20935245	chr15:42234343	EHD4	0.38	4.65	0.43	1.09e-5	Monocyte count;
THYM	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg13683864	chr3:40499215	RPL14	-0.82	-7.52	-0.61	3.11e-11	Renal cell carcinoma;
THYM	cis	rs7264396	0.563	rs2425103	chr20:34312329	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-4.76	-0.44	6.84e-6	Total cholesterol levels;
THYM	cis	rs10203711	0.932	rs4353597	chr2:239597772	C/G	cg14580085	chr2:239553406	NA	0.66	5.88	0.52	5.96e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs480407	0.857	rs270964	chr2:161688340	A/T	cg06548410	chr19:1997657	BTBD2	0.7	6.87	0.58	6.79e-10	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs59698941	0.891	rs59707248	chr5:132267535	C/T	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs7599312	0.534	rs7596285	chr2:213406961	G/A	cg16329650	chr2:213403929	ERBB4	0.99	11.32	0.76	2.57e-19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs990171	1.000	rs6753717	chr2:102993161	A/C	cg13897122	chr2:103039542	IL18RAP	-0.4	-4.71	-0.44	8.29e-6	Lymphocyte counts;
THYM	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs500891	0.547	rs1144178	chr6:84029716	A/G	cg08257003	chr6:84140564	ME1	0.56	4.47	0.42	2.19e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg11494091	chr17:61959527	GH2	1.07	17.31	0.87	3.89e-31	Prudent dietary pattern;
THYM	cis	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg06565975	chr8:143823917	SLURP1	-0.75	-8.73	-0.67	8.64e-14	Urinary tract infection frequency;
THYM	cis	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg13789015	chr9:136890014	NCRNA00094	0.82	6.87	0.58	6.55e-10	Platelet distribution width;
THYM	cis	rs912057	0.526	rs1294400	chr6:6733421	A/G	cg06612196	chr6:6737390	NA	-0.78	-12.62	-0.79	5.08e-22	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs6121246	0.559	rs12479491	chr20:30265450	T/C	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs11186	0.591	rs55765720	chr2:189964970	T/A	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg26513180	chr16:89883248	FANCA	0.72	7.13	0.59	1.98e-10	Vitiligo;
THYM	cis	rs28595532	0.920	rs116046128	chr4:119741990	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.34	-0.48	6.24e-7	Monocyte percentage of white cells;
THYM	cis	rs7584330	0.868	rs7571898	chr2:238383028	T/C	cg16989719	chr2:238392110	NA	-0.63	-5.88	-0.52	5.96e-8	Prostate cancer;
THYM	cis	rs954108	0.809	rs1592059	chr13:29368961	G/A	cg11788234	chr13:29393811	NA	-0.58	-4.55	-0.42	1.59e-5	Obesity-related traits;
THYM	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg15704280	chr7:45808275	SEPT13	1.0	11.16	0.75	5.73e-19	Coronary artery disease;
THYM	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.28	6.38	0.55	6.44e-9	Obesity-related traits;
THYM	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg22117172	chr7:91764530	CYP51A1	-0.38	-4.85	-0.45	4.86e-6	Breast cancer;
THYM	cis	rs62435770	1.000	rs62435806	chr6:169502800	A/C	cg07652237	chr6:170125491	PHF10	0.55	4.91	0.45	3.84e-6	Loneliness;
THYM	cis	rs6032067	0.561	rs2743317	chr20:43936931	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.61	-6.41	-0.55	5.69e-9	Blood protein levels;
THYM	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg20637307	chr2:213403960	ERBB4	1.0	10.5	0.73	1.43e-17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7200543	1.000	rs16966953	chr16:15135854	A/G	cg01933576	chr16:15083564	PDXDC1	-0.99	-8.04	-0.64	2.48e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg17074396	chr22:49843754	NA	-0.39	-4.59	-0.43	1.33e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs2075230	0.705	rs2955612	chr17:7549356	G/A	cg27413385	chr17:7515425	FXR2	-0.36	-5.31	-0.48	7.3e-7	Hormone measurements;
THYM	cis	rs4980785	1.000	rs4980784	chr11:69231923	A/G	cg23978357	chr11:69490378	ORAOV1	-0.49	-4.62	-0.43	1.19e-5	Renal cell carcinoma;
THYM	cis	rs2080501	0.628	rs1861656	chr16:49663019	G/T	cg03087880	chr16:49666012	ZNF423	-0.67	-8.03	-0.64	2.57e-12	IgG glycosylation;
THYM	cis	rs3820068	0.580	rs12082523	chr1:16005792	A/G	cg24675056	chr1:15929824	NA	-0.74	-5.88	-0.52	5.96e-8	Systolic blood pressure;
THYM	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.65	5.0	0.46	2.57e-6	Multiple sclerosis;
THYM	cis	rs12611088	0.515	rs2599454	chr19:44025201	T/C	cg18042043	chr19:44147545	NA	-0.42	-4.94	-0.45	3.3e-6	Plasma amyloid beta peptide concentrations (ABx-42);
THYM	cis	rs4595586	0.545	rs12823487	chr12:39391286	A/G	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs7631605	0.905	rs6786906	chr3:37226016	T/C	cg21328643	chr3:37258149	NA	-0.51	-4.87	-0.45	4.36e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg17426766	chr1:2046864	PRKCZ	0.44	5.23	0.47	1.02e-6	Height;
THYM	cis	rs4713118	0.629	rs203890	chr6:28022248	T/C	cg23161317	chr6:28129485	ZNF389	0.94	7.03	0.58	3.18e-10	Parkinson's disease;
THYM	cis	rs2070677	0.935	rs2864985	chr10:135348757	C/G	cg20169779	chr10:135381914	SYCE1	0.81	5.79	0.51	8.91e-8	Gout;
THYM	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg18876405	chr7:65276391	NA	0.56	4.73	0.44	7.72e-6	Aortic root size;
THYM	cis	rs4731207	0.596	rs7779594	chr7:124636995	T/C	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg14895029	chr7:2775587	GNA12	-0.68	-4.93	-0.45	3.55e-6	Height;
THYM	cis	rs3126085	0.935	rs11204951	chr1:152224404	A/G	cg10321714	chr1:152280068	FLG	0.68	4.99	0.46	2.72e-6	Atopic dermatitis;
THYM	cis	rs89107	0.576	rs35029749	chr6:118892120	A/C	cg21191810	chr6:118973309	C6orf204	0.51	5.1	0.46	1.71e-6	Cardiac structure and function;
THYM	cis	rs1524976	0.843	rs11711704	chr3:65444814	T/C	cg16238336	chr3:65465873	MAGI1	-1.07	-6.73	-0.57	1.27e-9	PR interval;
THYM	cis	rs870825	0.655	rs67380800	chr4:185623788	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.69	0.71	7.45e-16	Blood protein levels;
THYM	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg14004847	chr7:1930337	MAD1L1	0.61	4.78	0.44	6.3e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12142240	0.698	rs6684274	chr1:46810842	A/G	cg00530320	chr1:46809349	NSUN4	-0.73	-5.06	-0.46	2.02e-6	Menopause (age at onset);
THYM	cis	rs7119	0.667	rs907393	chr15:77903447	T/C	cg10437265	chr15:77819839	NA	-0.57	-5.64	-0.5	1.73e-7	Type 2 diabetes;
THYM	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg25811766	chr13:21894605	NA	-0.77	-4.99	-0.46	2.77e-6	White matter hyperintensity burden;
THYM	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg09184832	chr6:79620586	NA	-0.58	-4.53	-0.42	1.68e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg18132916	chr6:79620363	NA	-0.6	-5.33	-0.48	6.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs526231	0.511	rs28062	chr5:102540201	A/G	cg23492399	chr5:102201601	PAM	-0.69	-5.2	-0.47	1.16e-6	Primary biliary cholangitis;
THYM	cis	rs13070279	0.708	rs7632932	chr3:71826986	C/A	cg19388776	chr3:71835112	PROK2	-0.77	-4.9	-0.45	3.95e-6	Monocyte count;
THYM	cis	rs11690935	0.632	rs35854151	chr2:172657439	G/A	cg13550731	chr2:172543902	DYNC1I2	0.64	5.23	0.47	9.97e-7	Schizophrenia;
THYM	cis	rs2237234	0.542	rs7755997	chr6:26483048	G/A	cg05738196	chr6:26577821	NA	0.65	4.83	0.44	5.31e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg15445000	chr17:37608096	MED1	-0.44	-5.22	-0.47	1.07e-6	Glomerular filtration rate (creatinine);
THYM	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg04842962	chr6:43655489	MRPS18A	1.41	15.7	0.85	3.85e-28	IgG glycosylation;
THYM	trans	rs112998813	0.571	rs12584203	chr13:114926296	G/A	cg07263694	chr12:111748299	CUX2	1.18	6.91	0.58	5.4e-10	Nodular sclerosis Hodgkin lymphoma;
THYM	cis	rs514406	0.698	rs511599	chr1:53362818	T/C	cg27535305	chr1:53392650	SCP2	-0.54	-6.29	-0.54	9.77e-9	Monocyte count;
THYM	cis	rs4919694	0.667	rs75890466	chr10:105076383	C/T	cg04362960	chr10:104952993	NT5C2	0.8	4.74	0.44	7.54e-6	Arsenic metabolism;
THYM	cis	rs2835345	0.630	rs73204235	chr21:37819218	C/A	cg20643029	chr21:37915044	CLDN14	0.59	4.64	0.43	1.12e-5	Pulmonary function;
THYM	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg07061783	chr6:25882402	NA	-1.03	-9.84	-0.71	3.58e-16	Urate levels;
THYM	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg06640241	chr16:89574553	SPG7	0.61	4.57	0.42	1.46e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs514406	0.929	rs483073	chr1:53314084	T/C	cg08736216	chr1:53307985	ZYG11A	-0.6	-5.44	-0.49	4.07e-7	Monocyte count;
THYM	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.52	5.98	0.52	3.86e-8	Schizophrenia;
THYM	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg15744005	chr10:104629667	AS3MT	-0.83	-7.65	-0.62	1.61e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1448094	0.512	rs7308229	chr12:86239849	A/T	cg00310523	chr12:86230176	RASSF9	-0.49	-4.5	-0.42	1.93e-5	Major depressive disorder;
THYM	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2730245	0.527	rs2527205	chr7:158706393	G/T	cg01219135	chr7:158766336	NA	-0.56	-4.49	-0.42	2.01e-5	Height;
THYM	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg01570182	chr17:44337453	NA	0.88	9.33	0.69	4.51e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs870825	0.616	rs877276	chr4:185621249	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs985746	0.614	rs7661741	chr4:36822029	A/G	cg04301614	chr4:37585993	C4orf19	0.56	4.55	0.42	1.58e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs2495707	0.624	rs2489007	chr10:102422046	A/G	cg07919443	chr10:102419409	NA	0.64	5.55	0.5	2.53e-7	Body mass index;
THYM	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg21773646	chr17:80085082	CCDC57	0.35	5.0	0.46	2.66e-6	Life satisfaction;
THYM	cis	rs17665859	1.000	rs17665859	chr8:445601	T/C	cg17960703	chr8:356704	FBXO25	0.97	4.75	0.44	7.3e-6	Bilirubin levels;
THYM	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg11062466	chr8:58055876	NA	0.95	4.91	0.45	3.78e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6570726	0.791	rs2096201	chr6:145934273	C/T	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9329221	0.741	rs56243511	chr8:9805695	T/C	cg19847130	chr8:10466454	RP1L1	0.62	5.88	0.52	5.96e-8	Neuroticism;
THYM	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg15744005	chr10:104629667	AS3MT	-0.84	-7.78	-0.62	8.67e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs985746	0.614	rs1380425	chr4:36814622	C/T	cg04301614	chr4:37585993	C4orf19	-0.55	-4.47	-0.42	2.19e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg13609457	chr4:120235615	NA	0.6	5.37	0.48	5.67e-7	Corneal astigmatism;
THYM	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg22981736	chr15:31284413	MTMR10	-0.58	-4.79	-0.44	6.1e-6	Huntington's disease progression;
THYM	cis	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg26384229	chr12:38710491	ALG10B	0.8	5.96	0.52	4.27e-8	Bladder cancer;
THYM	cis	rs7084402	0.934	rs1658471	chr10:60291911	A/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs2688608	0.592	rs3933085	chr10:75483331	C/T	cg23231163	chr10:75533350	FUT11	-0.44	-6.22	-0.54	1.34e-8	Inflammatory bowel disease;
THYM	cis	rs10819861	0.645	rs4743537	chr9:98862861	C/A	cg14508093	chr9:98862825	NA	-0.24	-4.57	-0.42	1.48e-5	Electrocardiographic traits;
THYM	trans	rs3960554	0.808	rs11983987	chr7:75657850	A/G	cg19862616	chr7:65841803	NCRNA00174	1.01	7.62	0.62	1.87e-11	Eotaxin levels;
THYM	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg04315214	chr1:2043799	PRKCZ	-0.58	-4.54	-0.42	1.67e-5	Height;
THYM	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg23958373	chr8:599963	NA	1.03	4.73	0.44	7.92e-6	IgG glycosylation;
THYM	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg04944784	chr2:26401820	FAM59B	0.71	5.67	0.5	1.55e-7	Gut microbiome composition (summer);
THYM	cis	rs11190604	1.000	rs2489047	chr10:102347028	A/G	cg16342193	chr10:102329863	NA	-0.55	-5.49	-0.49	3.37e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs988913	0.874	rs4712084	chr6:54861284	G/A	cg19716238	chr6:54711378	FAM83B	0.49	4.87	0.45	4.48e-6	Menarche (age at onset);
THYM	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.73	7.27	0.6	1.01e-10	Lymphocyte counts;
THYM	cis	rs2637266	0.935	rs7393727	chr10:78365977	T/A	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs7582180	0.903	rs13031493	chr2:100896376	G/C	cg14675211	chr2:100938903	LONRF2	0.64	5.43	0.49	4.28e-7	Intelligence (multi-trait analysis);
THYM	cis	rs17253792	0.822	rs13379353	chr14:56050478	G/C	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg18876405	chr7:65276391	NA	-0.65	-5.53	-0.49	2.85e-7	Aortic root size;
THYM	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg04320152	chr17:18167836	SMCR7	-0.62	-4.46	-0.42	2.27e-5	Total body bone mineral density;
THYM	cis	rs7818345	0.967	rs7006702	chr8:19272533	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.53	0.42	1.7e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs10865050	1	rs10865050	chr2:102941311	G/A	cg20060108	chr2:102954350	IL1RL1	0.87	4.77	0.44	6.56e-6	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg21784768	chr11:537496	LRRC56	1.07	5.36	0.48	5.7e-7	Body mass index;
THYM	cis	rs1018836	0.923	rs4735260	chr8:91617157	C/G	cg16814680	chr8:91681699	NA	0.85	7.17	0.59	1.59e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs2109514	0.650	rs12531767	chr7:116129005	T/A	cg12739419	chr7:116140593	CAV2	-0.48	-4.7	-0.43	8.75e-6	Prevalent atrial fibrillation;
THYM	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg03467027	chr4:99064603	C4orf37	0.59	4.5	0.42	1.92e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg12011299	chr4:100065546	ADH4	0.86	8.24	0.65	9.41e-13	Smoking initiation;
THYM	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg09060608	chr5:178986726	RUFY1	0.58	5.76	0.51	1.04e-7	Lung cancer;
THYM	cis	rs4776059	0.916	rs2414161	chr15:52883285	T/C	cg22715398	chr15:52968154	KIAA1370	-0.57	-4.48	-0.42	2.08e-5	Schizophrenia;
THYM	cis	rs988913	0.706	rs9382445	chr6:54937974	T/C	cg18532076	chr6:54711417	FAM83B	0.49	4.62	0.43	1.18e-5	Menarche (age at onset);
THYM	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg27170947	chr2:26402098	FAM59B	-0.61	-5.04	-0.46	2.25e-6	Gut microbiome composition (summer);
THYM	cis	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.59	5.22	0.47	1.05e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11711311	0.824	rs35952547	chr3:113352501	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.05	-0.46	2.11e-6	IgG glycosylation;
THYM	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg11166453	chr1:247681781	NA	0.69	5.38	0.48	5.45e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs8013055	0.846	rs10139744	chr14:105974696	G/A	cg11597832	chr14:105993747	TMEM121	-0.55	-4.74	-0.44	7.54e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs6032067	0.704	rs2223901	chr20:43789924	C/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs870825	0.655	rs2310104	chr4:185619967	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs6763768	0.606	rs11707463	chr3:53362565	A/G	cg16894138	chr3:53270350	TKT	0.72	5.47	0.49	3.68e-7	Bacterial meningitis;
THYM	cis	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg10856724	chr12:34555212	NA	-0.91	-9.08	-0.68	1.57e-14	Morning vs. evening chronotype;
THYM	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11644478	chr21:40555479	PSMG1	1.03	8.47	0.66	3.02e-13	Cognitive function;
THYM	cis	rs4845875	0.600	rs4846039	chr1:11836868	A/G	cg06193043	chr1:11908199	NPPA	0.58	4.95	0.45	3.18e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs868036	1.000	rs4776975	chr15:68102220	G/C	cg24579218	chr15:68104479	NA	-0.65	-6.51	-0.56	3.59e-9	Restless legs syndrome;
THYM	cis	rs919433	0.680	rs788022	chr2:198280586	T/C	cg05783139	chr2:198650985	BOLL	0.63	4.93	0.45	3.48e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs13082711	0.911	rs2172298	chr3:27425611	T/C	cg02860705	chr3:27208620	NA	0.66	4.64	0.43	1.13e-5	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9902453	0.935	rs9909093	chr17:28271207	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.11	0.53	2.19e-8	Coffee consumption (cups per day);
THYM	cis	rs13006833	0.739	rs172366	chr2:191191233	G/T	cg27211696	chr2:191398769	TMEM194B	0.56	4.47	0.42	2.17e-5	Urinary metabolites;
THYM	cis	rs986417	1.000	rs1254254	chr14:60831146	G/A	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs7264396	0.676	rs6058383	chr20:34556005	T/C	cg26038318	chr20:34205095	SPAG4	0.59	4.81	0.44	5.6e-6	Total cholesterol levels;
THYM	cis	rs10463554	0.963	rs26817	chr5:102540366	C/T	cg23492399	chr5:102201601	PAM	0.68	5.13	0.47	1.51e-6	Parkinson's disease;
THYM	cis	rs2932538	0.922	rs6690169	chr1:113114974	A/G	cg22162597	chr1:113214053	CAPZA1	0.65	5.32	0.48	6.9e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs828999	0.688	rs7555964	chr1:108697845	C/G	cg24323958	chr1:108741884	SLC25A24	0.54	5.33	0.48	6.7e-7	Monocyte percentage of white cells;
THYM	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg16524936	chr4:1340807	KIAA1530	-0.68	-5.34	-0.48	6.21e-7	Longevity;
THYM	cis	rs400736	0.894	rs226242	chr1:8033468	G/A	cg22678073	chr1:8087421	ERRFI1	0.46	4.94	0.45	3.33e-6	Response to antidepressants and depression;
THYM	cis	rs7432375	0.804	rs6764567	chr3:136425514	A/C	cg21827317	chr3:136751795	NA	-0.59	-5.05	-0.46	2.11e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.44	7.27	0.6	9.95e-11	Obesity-related traits;
THYM	cis	rs427394	0.593	rs880993	chr5:6732120	C/G	cg10857441	chr5:6722123	POLS	-0.7	-7.53	-0.61	2.93e-11	Menopause (age at onset);
THYM	cis	rs1843834	0.721	rs1434057	chr2:225606389	T/G	cg10193763	chr2:225306901	NA	-0.45	-4.87	-0.45	4.41e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg23428387	chr22:49814324	NA	-0.51	-4.86	-0.45	4.68e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg17554472	chr22:41940697	POLR3H	-0.71	-4.49	-0.42	2.01e-5	Vitiligo;
THYM	cis	rs11711311	0.955	rs7650764	chr3:113414439	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.6	-5.1	-0.46	1.72e-6	IgG glycosylation;
THYM	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg26038318	chr20:34205095	SPAG4	0.64	5.22	0.47	1.04e-6	Total cholesterol levels;
THYM	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg26963428	chr7:66367121	NA	-0.61	-4.77	-0.44	6.78e-6	Corneal structure;
THYM	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg10334053	chr1:2078117	PRKCZ	-0.47	-4.71	-0.44	8.45e-6	Height;
THYM	cis	rs7216064	0.684	rs62084675	chr17:66027025	A/G	cg12091567	chr17:66097778	LOC651250	0.98	8.02	0.64	2.7e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg18811423	chr2:55921094	PNPT1	0.79	7.61	0.62	1.97e-11	Metabolic syndrome;
THYM	cis	rs7274811	0.901	rs17404047	chr20:32305781	A/T	cg08240466	chr20:32847653	ASIP	-0.55	-4.65	-0.43	1.06e-5	Height;
THYM	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2976388	1.000	rs2294008	chr8:143761931	C/T	cg13446199	chr8:143762866	PSCA	0.52	6.44	0.55	4.92e-9	Urinary tract infection frequency;
THYM	cis	rs9543976	1.000	rs2328964	chr13:76138830	G/T	cg01531495	chr13:76123901	UCHL3	0.75	4.97	0.45	3.01e-6	Diabetic retinopathy;
THYM	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg06207460	chr9:4741011	AK3	-0.99	-6.99	-0.58	3.74e-10	Depressive symptoms;
THYM	cis	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg16068833	chr1:26644515	UBXN11;CD52	0.26	4.5	0.42	1.9e-5	Obesity-related traits;
THYM	cis	rs12318506	0.826	rs35933860	chr12:75731821	A/G	cg04728562	chr12:75699417	CAPS2	-1.6	-5.54	-0.49	2.65e-7	Coronary artery calcification;
THYM	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.9	7.81	0.63	7.43e-12	Multiple sclerosis;
THYM	cis	rs17102423	0.731	rs998247	chr14:65546299	C/T	cg11161011	chr14:65562177	MAX	-0.63	-5.46	-0.49	3.78e-7	Obesity-related traits;
THYM	cis	rs7267979	1.000	rs6050559	chr20:25329915	A/G	cg08601574	chr20:25228251	PYGB	0.59	4.81	0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg06718696	chr17:78121285	EIF4A3	1.03	7.4	0.6	5.29e-11	Plateletcrit;Mean corpuscular hemoglobin concentration;
THYM	cis	rs11767557	1.000	rs11762262	chr7:143107876	C/T	cg05908241	chr7:143109367	NA	-0.63	-6.17	-0.53	1.68e-8	Alzheimer's disease (late onset);
THYM	cis	rs36096196	0.891	rs74046969	chr1:2251348	G/A	cg17974515	chr1:2252516	NA	0.36	4.76	0.44	6.86e-6	Coronary artery disease;
THYM	cis	rs854765	0.583	rs4925130	chr17:17807858	G/A	cg16928487	chr17:17741425	SREBF1	-0.54	-5.15	-0.47	1.38e-6	Total body bone mineral density;
THYM	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg20486651	chr6:167070296	RPS6KA2	-0.46	-4.51	-0.42	1.82e-5	Crohn's disease;
THYM	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11644478	chr21:40555479	PSMG1	-0.76	-6.37	-0.55	6.67e-9	Cognitive function;
THYM	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg05552183	chr6:42928497	GNMT	0.68	5.36	0.48	5.78e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4919087	1.000	rs10786327	chr10:99071408	C/T	cg19453742	chr10:98862320	SLIT1	-0.63	-5.17	-0.47	1.31e-6	Monocyte count;
THYM	cis	rs7917772	0.560	rs35095897	chr10:104377759	T/C	cg00122347	chr10:104236741	TMEM180	0.42	6.17	0.53	1.66e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs34734847	0.787	rs658521	chr12:121162414	G/T	cg21892295	chr12:121157589	UNC119B	-0.48	-4.84	-0.44	4.97e-6	Mean corpuscular volume;
THYM	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg04842962	chr6:43655489	MRPS18A	1.28	9.29	0.69	5.41e-15	IgG glycosylation;
THYM	cis	rs6032067	1.000	rs6032066	chr20:43857700	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs6732160	0.588	rs2043100	chr2:73374096	T/C	cg24220031	chr2:73402428	NA	-0.71	-5.79	-0.51	8.94e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs67460515	0.563	rs1599388	chr3:160846866	A/G	cg12349858	chr3:160822545	B3GALNT1	0.57	4.53	0.42	1.71e-5	Parkinson's disease;
THYM	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg16102102	chr5:83017553	HAPLN1	-1.06	-9.76	-0.71	5.38e-16	Prostate cancer;
THYM	trans	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11122895	0.720	rs7559924	chr2:112467118	A/G	cg23262488	chr2:112468472	NA	0.47	5.33	0.48	6.64e-7	Allergic sensitization;
THYM	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg06532163	chr17:45867833	NA	-0.64	-6.45	-0.55	4.65e-9	IgG glycosylation;
THYM	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg15247329	chr7:2764246	NA	-0.69	-5.76	-0.51	1.02e-7	Height;
THYM	cis	rs2463822	1.000	rs2513744	chr11:62077785	C/A	cg06239285	chr11:62104954	ASRGL1	1.37	7.54	0.61	2.75e-11	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs11771526	0.901	rs10264511	chr7:32304170	T/C	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.81	-6.72	-0.57	1.34e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg00645579	chr11:617140	IRF7;MUPCDH	-0.47	-6.04	-0.53	3.05e-8	Systemic lupus erythematosus;
THYM	cis	rs250585	0.736	rs250578	chr16:23427110	C/T	cg00143387	chr16:23521605	GGA2	0.73	5.24	0.47	9.67e-7	Egg allergy;
THYM	cis	rs4363385	0.818	rs546666	chr1:153015385	A/G	cg13444842	chr1:152974279	SPRR3	-0.59	-4.81	-0.44	5.61e-6	Inflammatory skin disease;
THYM	cis	rs1448094	0.511	rs61930074	chr12:86218759	G/C	cg00310523	chr12:86230176	RASSF9	0.51	4.58	0.43	1.41e-5	Major depressive disorder;
THYM	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg00814883	chr7:100076585	TSC22D4	-1.0	-6.73	-0.57	1.26e-9	Platelet count;
THYM	cis	rs228769	0.792	rs454192	chr17:42171206	T/C	cg19774624	chr17:42201019	HDAC5	0.68	5.39	0.48	5.06e-7	Bone mineral density (hip);Bone mineral density (spine);
THYM	cis	rs13315871	0.929	rs13077539	chr3:58267846	T/C	cg12435725	chr3:58293450	RPP14	-0.48	-5.21	-0.47	1.11e-6	Cholesterol, total;
THYM	cis	rs7084402	0.967	rs7094882	chr10:60276829	C/T	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs6032067	0.852	rs2233882	chr20:43835683	T/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.76	-0.51	1.01e-7	Blood protein levels;
THYM	trans	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg10856724	chr12:34555212	NA	-0.86	-7.26	-0.6	1.04e-10	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg03806693	chr22:41940476	POLR3H	1.1	8.41	0.65	4.11e-13	Cannabis dependence symptom count;
THYM	cis	rs4909189	0.957	rs71547528	chr7:158135431	T/C	cg15736062	chr7:158136485	PTPRN2	-0.61	-4.86	-0.45	4.64e-6	Response to amphetamines;
THYM	cis	rs526231	0.575	rs55652053	chr5:102337170	T/A	cg23492399	chr5:102201601	PAM	-0.65	-5.07	-0.46	1.99e-6	Primary biliary cholangitis;
THYM	cis	rs7917772	0.582	rs10748826	chr10:104354804	T/C	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6924995	0.501	rs9383119	chr6:16186956	G/C	cg11805552	chr6:16175128	NA	0.58	4.8	0.44	5.89e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs11186	0.556	rs72906378	chr2:189966056	T/A	cg11041835	chr2:189156425	GULP1	0.8	4.58	0.43	1.41e-5	Parkinson's disease;
THYM	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg15693483	chr7:1102177	C7orf50	0.5	5.79	0.51	8.93e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7177699	0.525	rs56076311	chr15:79115120	A/G	cg00540400	chr15:79124168	NA	-0.62	-6.42	-0.55	5.35e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs16912285	0.585	rs7950920	chr11:24356464	G/A	ch.11.24196551F	chr11:24239977	NA	0.84	5.77	0.51	9.88e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg14004847	chr7:1930337	MAD1L1	-0.64	-5.12	-0.46	1.62e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs9517302	0.847	rs9517300	chr13:99095057	T/C	cg22223119	chr13:99095684	FARP1	-1.03	-7.71	-0.62	1.21e-11	Obesity-related traits;
THYM	cis	rs4851266	0.898	rs12994592	chr2:100857984	T/C	cg08017756	chr2:100939284	LONRF2	-0.56	-4.45	-0.42	2.31e-5	Educational attainment;
THYM	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg06060754	chr5:176797920	RGS14	-0.43	-6.16	-0.53	1.72e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs9581857	0.615	rs79793528	chr13:28007823	G/A	cg22138327	chr13:27999177	GTF3A	0.91	5.17	0.47	1.29e-6	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg07636037	chr3:49044803	WDR6	0.87	7.65	0.62	1.6e-11	Menarche (age at onset);
THYM	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg25072359	chr17:41440525	NA	0.68	4.62	0.43	1.21e-5	Menopause (age at onset);
THYM	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg23758822	chr17:41437982	NA	-1.17	-11.09	-0.75	7.92e-19	Menopause (age at onset);
THYM	cis	rs28795989	0.795	rs938604	chr4:7904363	G/A	cg00251875	chr4:7801337	AFAP1	0.6	4.77	0.44	6.57e-6	Intraocular pressure;
THYM	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg13695892	chr22:41940480	POLR3H	0.89	6.37	0.55	6.58e-9	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs988913	0.781	rs1963697	chr6:54772814	G/T	cg04690482	chr6:54711388	FAM83B	0.5	5.6	0.5	2.08e-7	Menarche (age at onset);
THYM	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg24812749	chr6:127587940	RNF146	0.77	5.74	0.51	1.15e-7	Breast cancer;
THYM	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.74	-6.92	-0.58	5.17e-10	Personality dimensions;
THYM	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg09462578	chr12:12878428	APOLD1	-0.91	-5.39	-0.48	5.01e-7	Systemic lupus erythematosus;
THYM	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-5.22	-0.47	1.03e-6	Joint mobility (Beighton score);
THYM	cis	rs7247513	1.000	rs12459123	chr19:12689741	T/C	cg01871581	chr19:12707946	ZNF490	-0.86	-8.88	-0.67	4.06e-14	Bipolar disorder;
THYM	cis	rs4654899	0.785	rs10916911	chr1:21290061	C/T	cg01072550	chr1:21505969	NA	-0.77	-7.5	-0.61	3.31e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg08999081	chr20:33150536	PIGU	0.81	7.94	0.63	4.05e-12	Coronary artery disease;
THYM	cis	rs854765	0.547	rs8069811	chr17:17922280	G/A	cg04398451	chr17:18023971	MYO15A	-0.95	-9.84	-0.71	3.63e-16	Total body bone mineral density;
THYM	cis	rs11096990	0.855	rs11730771	chr4:39222407	C/T	cg24403649	chr4:39172243	NA	-0.65	-5.59	-0.5	2.13e-7	Cognitive function;
THYM	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg00898013	chr13:113819073	PROZ	-0.82	-8.1	-0.64	1.81e-12	Platelet distribution width;
THYM	cis	rs8078723	0.701	rs2305482	chr17:38140927	A/C	cg17467752	chr17:38218738	THRA	-0.81	-6.74	-0.57	1.2e-9	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg04455712	chr21:45112962	RRP1B	-0.61	-5.99	-0.52	3.65e-8	Mean corpuscular volume;
THYM	cis	rs6684428	0.610	rs12120132	chr1:56322054	G/A	cg11651538	chr1:56320950	NA	-0.63	-4.97	-0.45	2.91e-6	Airflow obstruction;
THYM	cis	rs700651	0.789	rs5007118	chr2:198909738	G/C	cg00792783	chr2:198669748	PLCL1	0.74	4.83	0.44	5.28e-6	Intracranial aneurysm;
THYM	cis	rs752010	0.619	rs10789406	chr1:42105182	G/T	cg06885757	chr1:42089581	HIVEP3	-0.6	-8.03	-0.64	2.56e-12	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-10.71	-0.74	5.17e-18	Primary sclerosing cholangitis;
THYM	cis	rs3771570	1.000	rs3771570	chr2:242382864	C/T	cg21155796	chr2:242212141	HDLBP	1.25	6.07	0.53	2.57e-8	Prostate cancer;
THYM	cis	rs7098100	0.530	rs10828266	chr10:22098701	A/G	cg04231319	chr10:21824447	MLLT10	0.33	4.71	0.44	8.43e-6	Breast cancer;
THYM	cis	rs7809950	0.678	rs62483640	chr7:106900214	T/G	cg23024343	chr7:107201750	COG5	-1.0	-8.43	-0.65	3.79e-13	Coronary artery disease;
THYM	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg12698349	chr2:225449008	CUL3	0.73	5.48	0.49	3.54e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs6424115	0.692	rs573361	chr1:24053674	A/T	cg15997130	chr1:24165203	NA	0.66	5.4	0.48	4.82e-7	Immature fraction of reticulocytes;
THYM	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg14004847	chr7:1930337	MAD1L1	-0.64	-5.12	-0.46	1.62e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg18876405	chr7:65276391	NA	0.63	5.53	0.49	2.83e-7	Aortic root size;
THYM	cis	rs6032067	0.759	rs6104052	chr20:43808783	T/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.29	-0.48	7.93e-7	Blood protein levels;
THYM	cis	rs8133932	0.701	rs7276114	chr21:47301187	C/T	cg20357416	chr21:47294739	PCBP3	0.89	5.87	0.52	6.3e-8	Schizophrenia;
THYM	cis	rs4642101	0.824	rs9852222	chr3:12848491	G/T	cg05775895	chr3:12838266	CAND2	0.94	8.62	0.66	1.49e-13	QRS complex (12-leadsum);
THYM	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg05283184	chr6:79620031	NA	-0.91	-8.67	-0.66	1.17e-13	Intelligence (multi-trait analysis);
THYM	cis	rs11603020	0.950	rs11229067	chr11:57374946	A/C	cg19752551	chr11:57585705	CTNND1	0.6	4.84	0.44	5.07e-6	Blood protein levels;
THYM	cis	rs60871478	0.735	rs73038177	chr7:842103	G/T	cg10248100	chr7:872053	UNC84A	0.74	4.85	0.45	4.86e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg10523679	chr1:76189770	ACADM	0.92	10.35	0.73	2.94e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6700896	0.966	rs11208689	chr1:66083197	G/A	cg04111102	chr1:66153794	NA	0.53	4.64	0.43	1.12e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg06238570	chr21:40685208	BRWD1	-0.96	-9.18	-0.69	9.29e-15	Cognitive function;
THYM	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg14416269	chr4:6271139	WFS1	0.52	5.24	0.47	9.81e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs977987	0.778	rs7206541	chr16:75436713	A/T	cg03315344	chr16:75512273	CHST6	0.77	6.31	0.54	8.75e-9	Dupuytren's disease;
THYM	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg07690219	chr3:49449608	TCTA;RHOA	-0.67	-4.49	-0.42	1.98e-5	Menarche (age at onset);
THYM	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg23711669	chr6:146136114	FBXO30	0.88	8.52	0.66	2.41e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11650494	0.908	rs117853079	chr17:47421593	G/C	cg08112188	chr17:47440006	ZNF652	1.25	5.41	0.49	4.62e-7	Prostate cancer;
THYM	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg20503657	chr10:835505	NA	1.17	8.29	0.65	7.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7705502	0.962	rs72812861	chr5:173387509	T/C	cg18693985	chr5:173351052	CPEB4	-0.76	-5.66	-0.5	1.58e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg22681709	chr2:178499509	PDE11A	-0.59	-5.62	-0.5	1.91e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg02725872	chr8:58115012	NA	-1.14	-7.59	-0.61	2.17e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs28595532	0.920	rs55668908	chr4:119769799	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs921968	0.565	rs6436069	chr2:219597185	T/C	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.66	-4.48	-0.42	2.09e-5	Gut microbiome composition (summer);
THYM	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg27129171	chr3:47204927	SETD2	0.77	7.65	0.62	1.67e-11	Colorectal cancer;
THYM	cis	rs9807841	0.670	rs10405617	chr19:10752968	C/T	cg17848348	chr19:10766748	ILF3	0.87	7.74	0.62	1.06e-11	Inflammatory skin disease;
THYM	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg03709012	chr19:19516395	GATAD2A	-0.74	-5.8	-0.51	8.48e-8	Tonsillectomy;
THYM	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg22244940	chr12:132335942	MMP17	0.54	4.95	0.45	3.19e-6	Migraine;
THYM	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg09359103	chr1:154839909	KCNN3	-0.76	-10.06	-0.72	1.22e-16	Prostate cancer;
THYM	cis	rs2932538	0.922	rs2932535	chr1:113201412	G/C	cg22162597	chr1:113214053	CAPZA1	-0.65	-5.32	-0.48	6.9e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs7010267	0.935	rs11573824	chr8:119959925	A/T	cg17171407	chr8:119960777	TNFRSF11B	0.6	4.87	0.45	4.36e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs9486719	1.000	rs2092096	chr6:96870919	A/G	cg18709589	chr6:96969512	KIAA0776	0.73	4.83	0.44	5.12e-6	Migraine;Coronary artery disease;
THYM	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg02070205	chr10:30722105	MAP3K8	-0.64	-5.14	-0.47	1.46e-6	Inflammatory bowel disease;
THYM	cis	rs11030122	0.702	rs66503725	chr11:3980998	G/A	cg18678763	chr11:4115507	RRM1	-0.44	-5.73	-0.51	1.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg08484992	chr16:88977278	CBFA2T3	0.39	4.94	0.45	3.35e-6	Social autistic-like traits;
THYM	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg06634786	chr22:41940651	POLR3H	-0.66	-4.8	-0.44	5.78e-6	Vitiligo;
THYM	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg15212455	chr7:39170539	POU6F2	0.65	6.01	0.52	3.38e-8	IgG glycosylation;
THYM	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg21926883	chr2:100939477	LONRF2	0.67	6.21	0.54	1.37e-8	Intelligence (multi-trait analysis);
THYM	trans	rs8002861	0.905	rs80209017	chr13:44473182	T/C	cg17145862	chr1:211918768	LPGAT1	1.04	12.02	0.78	8.8e-21	Leprosy;
THYM	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg00757033	chr12:89920650	WDR51B	0.76	11.34	0.76	2.39e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs478304	0.651	rs10896038	chr11:65505528	G/C	cg27068330	chr11:65405492	SIPA1	-0.96	-9.31	-0.69	4.93e-15	Acne (severe);
THYM	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg02478829	chr6:26598070	ABT1	-0.33	-4.49	-0.42	1.97e-5	Intelligence (multi-trait analysis);
THYM	cis	rs11731175	1.000	rs62342333	chr4:189858804	T/C	cg00431894	chr4:189871012	NA	-0.82	-6.24	-0.54	1.2e-8	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs901683	1.000	rs34897497	chr10:46024677	A/G	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs7901056	0.837	rs4749125	chr10:26727636	G/C	cg23318538	chr10:26883079	C10orf50	-0.39	-4.96	-0.45	3.05e-6	Lymphocyte counts;
THYM	cis	rs447921	0.861	rs56248611	chr17:74448255	G/A	cg17201438	chr17:74438067	UBE2O	0.77	5.46	0.49	3.74e-7	Mitochondrial DNA levels;
THYM	cis	rs2702888	0.525	rs2738141	chr8:6760785	A/G	cg26795848	chr8:6756730	NA	0.65	5.29	0.48	7.71e-7	Blood pressure;
THYM	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg15744005	chr10:104629667	AS3MT	0.91	9.78	0.71	4.8e-16	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03264133	chr6:25882463	NA	-1.07	-9.77	-0.71	5.01e-16	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg15704280	chr7:45808275	SEPT13	-0.84	-8.4	-0.65	4.28e-13	Height;
THYM	cis	rs12496230	0.855	rs1036971	chr3:66850677	T/A	cg04995300	chr3:66848608	NA	1.08	6.49	0.55	3.94e-9	Type 2 diabetes;
THYM	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.71	-4.59	-0.43	1.36e-5	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs240764	0.782	rs239231	chr6:101105022	G/A	cg21058520	chr6:100914733	NA	-0.57	-5.07	-0.46	1.96e-6	Neuroticism;
THYM	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg15704280	chr7:45808275	SEPT13	-1.0	-8.09	-0.64	1.93e-12	Height;
THYM	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.3	8.44	0.65	3.47e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs526231	0.575	rs26822	chr5:102518795	A/G	cg23492399	chr5:102201601	PAM	-0.7	-5.68	-0.5	1.45e-7	Primary biliary cholangitis;
THYM	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg08439880	chr3:133502540	NA	0.67	5.35	0.48	6.08e-7	Alcohol consumption (transferrin glycosylation);
THYM	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg13010199	chr12:38710504	ALG10B	-0.62	-4.62	-0.43	1.2e-5	Morning vs. evening chronotype;
THYM	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg23815491	chr16:72088622	HP	0.66	5.05	0.46	2.17e-6	Fibrinogen levels;
THYM	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg07930552	chr6:133119739	C6orf192	0.89	4.83	0.44	5.22e-6	Type 2 diabetes nephropathy;
THYM	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg24642844	chr7:1081250	C7orf50	-0.87	-6.5	-0.55	3.69e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2295359	1.000	rs2295359	chr1:67635950	G/A	cg11235152	chr1:67600687	NA	0.58	4.72	0.44	8.03e-6	Psoriasis;
THYM	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	5.64	0.5	1.76e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs3204270	0.684	rs57405099	chr17:79637065	T/C	cg18367735	chr17:79674897	NA	0.8	4.9	0.45	3.92e-6	Dental caries;
THYM	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	4.99	0.46	2.7e-6	Hip circumference adjusted for BMI;
THYM	cis	rs6840360	0.571	rs62327274	chr4:152548012	C/T	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.59	-0.43	1.37e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs4474465	1.000	rs11602360	chr11:78179336	A/G	cg02023728	chr11:77925099	USP35	-0.53	-4.52	-0.42	1.78e-5	Alzheimer's disease (survival time);
THYM	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg07362569	chr17:61921086	SMARCD2	0.69	6.06	0.53	2.67e-8	Prudent dietary pattern;
THYM	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg00277334	chr10:82204260	NA	-0.83	-10.18	-0.72	6.99e-17	Post bronchodilator FEV1;
THYM	cis	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg12826209	chr6:26865740	GUSBL1	0.9	4.96	0.45	3.09e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg15691649	chr6:25882328	NA	-0.66	-4.87	-0.45	4.48e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6087771	0.650	rs6060395	chr20:30219823	G/C	cg21427119	chr20:30132790	HM13	-0.64	-4.84	-0.45	4.92e-6	Subcortical brain region volumes;Putamen volume;
THYM	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg10802521	chr3:52805072	NEK4	-0.68	-5.76	-0.51	1.02e-7	Bipolar disorder;
THYM	cis	rs7586879	0.789	rs13428763	chr2:25132855	T/G	cg01884057	chr2:25150051	NA	0.52	4.64	0.43	1.12e-5	Body mass index;
THYM	cis	rs2456568	0.548	rs7117597	chr11:93655091	A/G	cg26875233	chr11:93583750	C11orf90	-0.52	-5.88	-0.52	6.02e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs600806	0.888	rs10858084	chr1:109882250	T/A	cg02175308	chr1:109941060	SORT1	-0.57	-4.96	-0.45	3.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg03806693	chr22:41940476	POLR3H	-0.84	-6.41	-0.55	5.51e-9	Neuroticism;
THYM	cis	rs9399401	0.633	rs6570511	chr6:142757368	G/A	cg04461802	chr6:142623433	GPR126	0.77	7.72	0.62	1.15e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs611744	0.934	rs604698	chr8:109238721	G/A	cg21045802	chr8:109455806	TTC35	0.59	5.25	0.47	9.08e-7	Dupuytren's disease;
THYM	cis	rs4780401	0.609	rs7205994	chr16:11815964	C/T	cg01061890	chr16:11836724	TXNDC11	-0.66	-5.44	-0.49	4.22e-7	Rheumatoid arthritis;
THYM	cis	rs995000	0.868	rs1168114	chr1:63156043	C/T	cg06896770	chr1:63153194	DOCK7	0.77	5.39	0.48	5.16e-7	Triglyceride levels;
THYM	cis	rs12216545	0.765	rs7792574	chr7:150224206	T/C	cg08960815	chr7:150264767	GIMAP4	-0.89	-8.27	-0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4792901	0.918	rs1613373	chr17:41680926	A/G	cg21940313	chr17:41620911	ETV4	0.43	4.52	0.42	1.76e-5	Dupuytren's disease;
THYM	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg06808227	chr14:105710500	BRF1	-1.05	-9.15	-0.68	1.07e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg14074117	chr16:1909714	C16orf73	-0.7	-4.45	-0.42	2.3e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg21475434	chr5:93447410	FAM172A	0.97	6.1	0.53	2.3e-8	Diabetic retinopathy;
THYM	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg06026331	chr20:60912101	LAMA5	-0.61	-4.8	-0.44	5.96e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs1499972	0.878	rs817512	chr3:117734787	T/C	cg07612923	chr3:117604196	NA	-1.5	-5.16	-0.47	1.38e-6	Schizophrenia;
THYM	cis	rs2731664	0.792	rs335452	chr5:176879671	C/T	cg14098951	chr5:176875120	PRR7	0.57	5.23	0.47	1.02e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg19901468	chr14:105411992	AHNAK2	-0.81	-6.59	-0.56	2.48e-9	Rheumatoid arthritis;
THYM	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg08645402	chr16:4508243	NA	0.76	6.87	0.58	6.72e-10	Schizophrenia;
THYM	cis	rs7107770	1.000	rs12787088	chr11:125094583	G/A	cg07747661	chr11:125106135	PKNOX2	-0.86	-5.3	-0.48	7.57e-7	Photic sneeze reflex;
THYM	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg07159469	chr16:89355005	ANKRD11	-0.82	-4.46	-0.42	2.23e-5	Skin colour saturation;
THYM	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4285028	0.898	rs4305455	chr3:121619774	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.83	-5.75	-0.51	1.07e-7	Multiple sclerosis;
THYM	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg01236616	chr12:121019343	POP5	-1.24	-9.25	-0.69	6.66e-15	Type 1 diabetes nephropathy;
THYM	cis	rs2637266	1.000	rs10824431	chr10:78356622	C/A	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs6032067	0.852	rs17424751	chr20:43814622	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs55871839	0.643	rs7004274	chr8:59810378	T/A	cg07426533	chr8:59803705	TOX	-0.7	-7.17	-0.59	1.65e-10	Pneumonia;
THYM	cis	rs9902453	1.000	rs9891871	chr17:28370191	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs4589258	0.788	rs11019172	chr11:90492074	A/T	cg26138821	chr11:89956704	CHORDC1	-0.56	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1448094	0.511	rs58742237	chr12:86166444	C/T	cg02569458	chr12:86230093	RASSF9	0.68	5.69	0.5	1.38e-7	Major depressive disorder;
THYM	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg02825527	chr7:2087843	MAD1L1	-0.82	-5.18	-0.47	1.24e-6	Neuroticism;
THYM	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg25036284	chr2:26402008	FAM59B	-0.74	-4.87	-0.45	4.39e-6	Gut microbiome composition (summer);
THYM	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg14895029	chr7:2775587	GNA12	-0.69	-4.94	-0.45	3.3e-6	Height;
THYM	cis	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg10792982	chr14:105748885	BRF1	0.72	7.38	0.6	5.93e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs17767294	0.708	rs72851139	chr6:28042698	G/T	cg08851530	chr6:28072375	NA	1.15	4.46	0.42	2.28e-5	Parkinson's disease;
THYM	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.67	9.16	0.68	1.04e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg07936489	chr17:37558343	FBXL20	0.81	5.29	0.48	7.76e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs17433780	0.504	rs4142706	chr1:89475230	A/C	cg10631373	chr1:89457642	RBMXL1;CCBL2	0.31	4.62	0.43	1.22e-5	Carotid intima media thickness;
THYM	cis	rs478304	1.000	rs478304	chr11:65494260	G/T	cg27068330	chr11:65405492	SIPA1	0.87	8.29	0.65	7.42e-13	Acne (severe);
THYM	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg01483505	chr11:975446	AP2A2	0.58	4.75	0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs11169225	0.756	rs3759124	chr12:50343166	G/A	cg23855989	chr12:50355821	AQP5	0.6	5.14	0.47	1.45e-6	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs17539620	0.534	rs7768635	chr6:154827861	C/T	cg17771515	chr6:154831774	CNKSR3	0.86	5.22	0.47	1.06e-6	Lipoprotein (a) levels;
THYM	cis	rs7909074	0.865	rs10900123	chr10:45376574	C/T	cg04218760	chr10:45406644	TMEM72	-0.56	-5.1	-0.46	1.73e-6	Mean corpuscular volume;
THYM	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg13289132	chr10:30722225	MAP3K8	-0.61	-5.04	-0.46	2.21e-6	Inflammatory bowel disease;
THYM	cis	rs3803170	0.536	rs7953810	chr12:112029291	T/C	cg10833066	chr12:111807467	FAM109A	-0.43	-4.59	-0.43	1.35e-5	Mean corpuscular hemoglobin;
THYM	cis	rs12681288	0.550	rs12549204	chr8:959085	G/T	cg08648136	chr8:956695	NA	0.58	5.0	0.46	2.57e-6	Schizophrenia;
THYM	cis	rs9916302	0.706	rs8078599	chr17:37518660	C/T	cg07936489	chr17:37558343	FBXL20	0.84	5.35	0.48	6.06e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6591182	0.504	rs7116712	chr11:65372518	A/G	cg17480646	chr11:65405466	SIPA1	-0.83	-7.23	-0.6	1.2e-10	Non-alcoholic fatty liver disease histology (lobular);
THYM	cis	rs921968	0.541	rs12617603	chr2:219369288	A/G	cg02176678	chr2:219576539	TTLL4	-0.73	-7.24	-0.6	1.18e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11214589	0.935	rs2186800	chr11:113242860	G/A	cg14159747	chr11:113255604	NA	0.35	7.23	0.6	1.23e-10	Neuroticism;
THYM	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.59	-5.11	-0.46	1.68e-6	IgG glycosylation;
THYM	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg08999081	chr20:33150536	PIGU	0.75	6.53	0.56	3.16e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs17102423	0.755	rs7161394	chr14:65563309	G/T	cg11161011	chr14:65562177	MAX	-0.83	-6.62	-0.56	2.13e-9	Obesity-related traits;
THYM	cis	rs10911232	0.507	rs10911212	chr1:183024469	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs12291225	0.679	rs11023170	chr11:14294909	A/G	cg05501817	chr11:14380813	RRAS2	-0.75	-5.72	-0.51	1.24e-7	Sense of smell;
THYM	cis	rs6700896	0.931	rs1938498	chr1:66098653	T/C	cg04111102	chr1:66153794	NA	0.55	5.23	0.47	9.89e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs965469	0.843	rs6051842	chr20:3397434	T/C	cg25506879	chr20:3388711	C20orf194	-0.84	-5.13	-0.47	1.51e-6	IFN-related cytopenia;
THYM	cis	rs1011018	0.628	rs4074827	chr7:139415455	G/A	cg06079564	chr7:139468310	HIPK2	-0.75	-4.84	-0.44	5.09e-6	Systolic blood pressure;
THYM	cis	rs7772486	0.719	rs2206141	chr6:146086192	A/G	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.43e-7	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17712092	chr4:129076599	LARP1B	0.85	6.97	0.58	4.1e-10	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1728785	1.000	rs1170433	chr16:68606081	A/G	cg02972257	chr16:68554789	NA	-0.75	-4.68	-0.43	9.39e-6	Ulcerative colitis;
THYM	cis	rs6424115	0.557	rs35904775	chr1:24180623	T/C	cg15997130	chr1:24165203	NA	-0.71	-5.97	-0.52	4.08e-8	Immature fraction of reticulocytes;
THYM	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg06238570	chr21:40685208	BRWD1	-0.97	-9.35	-0.69	4.03e-15	Cognitive function;
THYM	cis	rs13126513	0.708	rs4368610	chr4:100453746	G/T	cg05468953	chr4:100565104	NA	0.6	5.48	0.49	3.49e-7	Metabolite levels (MHPG);
THYM	cis	rs2282300	0.739	rs7952339	chr11:30327344	C/T	cg25418670	chr11:30344373	C11orf46	0.79	6.99	0.58	3.74e-10	Morning vs. evening chronotype;
THYM	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12667521	chr19:29218732	NA	0.89	8.17	0.64	1.34e-12	Methadone dose in opioid dependence;
THYM	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg25767906	chr1:53392781	SCP2	-0.57	-5.68	-0.5	1.5e-7	Monocyte count;
THYM	cis	rs7512552	0.839	rs832622	chr1:150392830	A/G	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg06238570	chr21:40685208	BRWD1	0.89	6.42	0.55	5.45e-9	Cognitive function;
THYM	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg11789530	chr4:8429930	ACOX3	0.74	5.99	0.52	3.74e-8	Response to antineoplastic agents;
THYM	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg05368731	chr17:41323189	NBR1	-1.2	-10.93	-0.75	1.72e-18	Menopause (age at onset);
THYM	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg11266682	chr4:10021025	SLC2A9	0.6	7.49	0.61	3.52e-11	Bone mineral density;
THYM	cis	rs950394	0.767	rs1401739	chr2:104987135	A/G	cg20302975	chr2:105468274	NA	-0.6	-4.47	-0.42	2.19e-5	Schizophrenia;
THYM	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg22189786	chr22:42395067	WBP2NL	0.67	5.35	0.48	6.07e-7	Birth weight;
THYM	trans	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs8067545	0.562	rs2526481	chr17:20127018	T/C	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs7119	0.717	rs12910594	chr15:77817103	G/A	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs6541297	1.000	rs4846839	chr1:230284924	A/G	cg20703242	chr1:230279135	GALNT2	0.96	6.3	0.54	9.23e-9	Coronary artery disease;
THYM	cis	rs9633835	0.642	rs11824092	chr11:13346294	A/G	cg13286116	chr11:13302098	ARNTL	-0.63	-6.44	-0.55	4.95e-9	Body mass index;
THYM	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg00684032	chr4:1343700	KIAA1530	0.54	4.67	0.43	9.81e-6	Obesity-related traits;
THYM	trans	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Bladder cancer;
THYM	cis	rs939658	0.805	rs8024813	chr15:79427260	A/G	cg17916960	chr15:79447300	NA	-0.73	-8.42	-0.65	3.9e-13	Refractive error;
THYM	cis	rs5758511	0.689	rs45441993	chr22:42471738	C/A	cg00645731	chr22:42541494	CYP2D7P1	0.62	4.46	0.42	2.21e-5	Birth weight;
THYM	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg24209194	chr3:40518798	ZNF619	0.57	4.58	0.43	1.4e-5	Renal cell carcinoma;
THYM	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	4.53	0.42	1.71e-5	Height;
THYM	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg21773646	chr17:80085082	CCDC57	0.31	4.49	0.42	2.02e-5	Life satisfaction;
THYM	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg16049864	chr8:95962084	TP53INP1	-0.86	-8.13	-0.64	1.62e-12	Type 2 diabetes;
THYM	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg07537917	chr2:241836409	C2orf54	-0.21	-4.89	-0.45	4.08e-6	Urinary metabolites;
THYM	cis	rs35883536	0.609	rs1855631	chr1:101040010	C/T	cg06223162	chr1:101003688	GPR88	-0.81	-6.91	-0.58	5.53e-10	Monocyte count;
THYM	cis	rs2625529	0.652	rs2929508	chr15:72246964	A/T	cg16672083	chr15:72433130	SENP8	0.52	4.63	0.43	1.14e-5	Red blood cell count;
THYM	cis	rs870825	0.616	rs6552805	chr4:185637894	C/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs8067545	0.611	rs2703776	chr17:20137709	C/A	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs11225247	0.772	rs12275349	chr11:102237720	C/T	cg11690896	chr11:102217788	BIRC2	1.12	5.18	0.47	1.23e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs9905704	0.918	rs11657676	chr17:56842043	A/G	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.89e-6	Testicular germ cell tumor;
THYM	cis	rs1448094	0.533	rs10863078	chr12:86152672	C/T	cg02569458	chr12:86230093	RASSF9	-0.65	-5.33	-0.48	6.59e-7	Major depressive disorder;
THYM	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.62	-4.82	-0.44	5.43e-6	Blood metabolite levels;
THYM	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg11905131	chr22:24372483	LOC391322	-0.9	-10.61	-0.74	8.23e-18	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6987853	0.966	rs2974349	chr8:42404040	A/G	cg09913449	chr8:42400586	C8orf40	-0.85	-6.34	-0.55	7.69e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg02734326	chr4:10020555	SLC2A9	0.76	6.89	0.58	6.16e-10	Bone mineral density;
THYM	cis	rs728616	0.867	rs61860041	chr10:81944331	G/A	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	trans	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg10856724	chr12:34555212	NA	-0.9	-7.99	-0.63	3.2e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7107174	0.901	rs1055248	chr11:77925573	T/C	cg02023728	chr11:77925099	USP35	0.69	6.55	0.56	2.9e-9	Testicular germ cell tumor;
THYM	cis	rs9733	0.525	rs11584184	chr1:150695689	A/T	cg09034736	chr1:150693464	HORMAD1	0.53	4.85	0.45	4.83e-6	Tonsillectomy;
THYM	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	8.23	0.65	9.9e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg13609457	chr4:120235615	NA	0.61	5.43	0.49	4.23e-7	Corneal astigmatism;
THYM	cis	rs6840360	1.000	rs7669977	chr4:152677527	T/C	cg22705602	chr4:152727874	NA	-0.59	-6.35	-0.55	7.46e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg18402987	chr7:1209562	NA	1.23	7.55	0.61	2.62e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs758324	0.687	rs156056	chr5:131473650	T/C	cg16205897	chr5:131564050	P4HA2	0.58	4.91	0.45	3.77e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs9826463	0.527	rs56088529	chr3:142146369	A/G	cg20824294	chr3:142316082	PLS1	0.76	5.3	0.48	7.53e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs6087990	0.814	rs2424895	chr20:31335978	C/T	cg13636640	chr20:31349939	DNMT3B	-0.86	-8.88	-0.67	4.01e-14	Ulcerative colitis;
THYM	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	6.09	0.53	2.42e-8	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg00999904	chr2:3704751	ALLC	-0.73	-4.99	-0.46	2.75e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg09307838	chr4:120376055	NA	0.71	5.07	0.46	1.98e-6	Corneal astigmatism;
THYM	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg18230493	chr5:56204884	C5orf35	-0.64	-4.86	-0.45	4.56e-6	Initial pursuit acceleration;
THYM	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.0	9.39	0.69	3.32e-15	Colorectal cancer;
THYM	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg11871910	chr12:69753446	YEATS4	1.05	9.46	0.7	2.37e-15	Blood protein levels;
THYM	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs11096990	0.551	rs11724855	chr4:39164999	G/A	cg24403649	chr4:39172243	NA	0.57	4.81	0.44	5.65e-6	Cognitive function;
THYM	cis	rs1371867	0.555	rs2861348	chr8:101285074	A/G	cg06636551	chr8:101224915	SPAG1	-0.63	-6.29	-0.54	9.77e-9	Atrioventricular conduction;
THYM	cis	rs87938	0.830	rs35135108	chr3:41166291	T/C	cg02247160	chr3:41243829	CTNNB1	-0.34	-4.59	-0.43	1.37e-5	Bone mineral density (hip);
THYM	cis	rs12310956	0.532	rs6488187	chr12:33975029	C/T	cg06521331	chr12:34319734	NA	-0.92	-8.57	-0.66	1.89e-13	Morning vs. evening chronotype;
THYM	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	10.73	0.74	4.66e-18	Chronic sinus infection;
THYM	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg16049864	chr8:95962084	TP53INP1	-0.76	-6.73	-0.57	1.29e-9	Type 2 diabetes;
THYM	cis	rs72720396	1.000	rs72720396	chr1:91191582	A/G	cg13456504	chr1:91191583	NA	1.03	6.98	0.58	3.91e-10	Morning vs. evening chronotype;Chronotype;
THYM	cis	rs7255436	0.965	rs7254882	chr19:8453822	A/G	cg10174797	chr19:8464628	RAB11B	0.43	5.19	0.47	1.21e-6	HDL cholesterol;
THYM	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.69	-5.16	-0.47	1.36e-6	Tonsillectomy;
THYM	cis	rs665401	0.653	rs339366	chr6:117174591	C/T	cg20376953	chr6:117187980	NA	0.61	4.89	0.45	4.05e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs11696501	0.688	rs6073788	chr20:44213773	C/T	cg11783356	chr20:44313418	WFDC10B	-0.67	-4.53	-0.42	1.73e-5	Brain structure;
THYM	cis	rs5758265	1	rs5758265	chr22:41617897	G/A	cg03806693	chr22:41940476	POLR3H	-0.8	-6.17	-0.53	1.68e-8	Depressive symptoms (multi-trait analysis);
THYM	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg17757837	chr7:157058334	UBE3C	-0.95	-8.74	-0.67	8.02e-14	Body mass index;
THYM	cis	rs4077515	0.874	rs4498662	chr9:139290251	C/G	cg14115884	chr9:139300582	SDCCAG3	0.76	8.19	0.64	1.21e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs782590	0.556	rs782579	chr2:55917604	A/G	cg18811423	chr2:55921094	PNPT1	0.66	5.38	0.48	5.36e-7	Metabolic syndrome;
THYM	cis	rs172166	0.610	rs156737	chr6:27895213	A/G	cg09682330	chr6:28411287	ZSCAN23	-0.53	-4.86	-0.45	4.64e-6	Cardiac Troponin-T levels;
THYM	cis	rs6032067	0.598	rs2741500	chr20:43944958	G/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.62	-5.74	-0.51	1.15e-7	Blood protein levels;
THYM	cis	rs67981189	0.789	rs2810073	chr14:71383848	A/G	cg15910301	chr14:71632612	NA	-0.5	-4.58	-0.43	1.41e-5	Schizophrenia;
THYM	cis	rs1065852	0.526	rs9623489	chr22:42397026	A/G	cg22189786	chr22:42395067	WBP2NL	0.54	5.55	0.49	2.6e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs17030434	1.000	rs732680	chr4:154725211	G/A	cg14289246	chr4:154710475	SFRP2	-0.75	-5.1	-0.46	1.72e-6	Electrocardiographic conduction measures;
THYM	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg08045932	chr20:61659980	NA	0.94	10.68	0.74	5.76e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.8	4.46	0.42	2.26e-5	Initial pursuit acceleration;
THYM	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg13852791	chr20:30311386	BCL2L1	0.68	4.93	0.45	3.47e-6	Mean corpuscular hemoglobin;
THYM	cis	rs9583531	0.527	rs9515274	chr13:111390429	A/G	cg24331049	chr13:111365604	ING1	0.69	5.43	0.49	4.31e-7	Coronary artery disease;
THYM	cis	rs40363	0.645	rs40447	chr16:3514841	G/A	cg21433313	chr16:3507492	NAT15	0.87	9.96	0.71	2.03e-16	Tuberculosis;
THYM	cis	rs870825	0.616	rs10428373	chr4:185639002	A/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg18252515	chr7:66147081	NA	-0.59	-4.49	-0.42	2.03e-5	Aortic root size;
THYM	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.74	-6.13	-0.53	1.95e-8	Blood metabolite levels;
THYM	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.62	-5.38	-0.48	5.24e-7	Rheumatoid arthritis;
THYM	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs59112743	0.510	rs2619548	chr6:15633785	G/T	cg10111214	chr6:14815676	NA	0.74	4.84	0.44	5.08e-6	Multiple keratinocyte cancers;
THYM	cis	rs6502050	0.723	rs66871014	chr17:80181874	G/A	cg10505658	chr17:80084571	CCDC57	-0.71	-7.41	-0.61	5.04e-11	Life satisfaction;
THYM	cis	rs7584330	0.554	rs7587496	chr2:238387632	A/G	cg14458575	chr2:238380390	NA	0.93	4.78	0.44	6.27e-6	Prostate cancer;
THYM	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs941408	0.963	rs1640268	chr19:2791469	T/C	cg06609049	chr19:2785107	THOP1	0.78	6.48	0.55	3.97e-9	Total cholesterol levels;
THYM	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg23260525	chr10:116636907	FAM160B1	0.49	5.02	0.46	2.38e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs981844	0.712	rs1350189	chr4:154744951	A/T	cg09973105	chr4:154681532	RNF175	0.49	4.46	0.42	2.26e-5	Response to statins (LDL cholesterol change);
THYM	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg04772025	chr11:68637568	NA	0.63	6.85	0.58	7.17e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg02187348	chr16:89574699	SPG7	-0.73	-6.14	-0.53	1.87e-8	Multiple myeloma (IgH translocation);
THYM	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg21475434	chr5:93447410	FAM172A	0.83	5.31	0.48	7.13e-7	Diabetic retinopathy;
THYM	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg10792982	chr14:105748885	BRF1	0.76	7.95	0.63	3.92e-12	Mean platelet volume;Platelet distribution width;
THYM	cis	rs61990749	0.597	rs7147516	chr14:78153980	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-1.17	-8.04	-0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs2637266	1.000	rs7081214	chr10:78361134	G/A	cg18941641	chr10:78392320	NA	0.75	6.56	0.56	2.81e-9	Pulmonary function;
THYM	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs11250464	1.000	rs11250464	chr10:1406364	A/G	cg08668359	chr10:1443807	ADARB2	0.57	5.0	0.46	2.59e-6	Radiation response;
THYM	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg23758822	chr17:41437982	NA	1.15	11.04	0.75	1.01e-18	Menopause (age at onset);
THYM	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.43	-6.6	-0.56	2.34e-9	Obesity-related traits;
THYM	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg12893697	chr11:970389	AP2A2	-0.32	-5.41	-0.49	4.73e-7	Alzheimer's disease (late onset);
THYM	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg26721908	chr21:47610096	LSS	0.89	7.35	0.6	6.71e-11	Testicular germ cell tumor;
THYM	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2717559	0.522	rs2585158	chr8:143875832	C/T	cg17252645	chr8:143867129	LY6D	0.82	10.09	0.72	1.08e-16	Urinary tract infection frequency;
THYM	cis	rs1691799	0.836	rs1184552	chr12:66756215	A/G	cg16791601	chr12:66731901	HELB	-0.73	-6.86	-0.58	6.96e-10	White blood cell count (basophil);
THYM	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs4845875	0.626	rs11121827	chr1:11832100	T/A	cg25341925	chr1:11908058	NPPA	0.43	4.64	0.43	1.1e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs6701037	0.566	rs1883102	chr1:175136793	T/A	cg17845761	chr1:175162550	KIAA0040	0.38	4.86	0.45	4.62e-6	Alcohol dependence;
THYM	cis	rs2898681	0.511	rs881743	chr4:53727450	A/G	cg00338735	chr4:53728038	RASL11B	0.5	4.89	0.45	4.03e-6	Optic nerve measurement (cup area);
THYM	cis	rs6032067	0.777	rs34085254	chr20:43786170	T/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.73	-7.87	-0.63	5.56e-12	Blood protein levels;
THYM	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg16049864	chr8:95962084	TP53INP1	-0.7	-6.2	-0.54	1.48e-8	Type 2 diabetes;
THYM	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg11764359	chr7:65958608	NA	-0.82	-6.91	-0.58	5.4e-10	Aortic root size;
THYM	cis	rs28595532	0.920	rs116612909	chr4:119749823	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs7043114	0.525	rs4744136	chr9:95275024	A/G	cg14631576	chr9:95140430	CENPP	0.76	7.24	0.6	1.18e-10	Height;
THYM	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg09549813	chr16:4587862	C16orf5	-0.5	-5.05	-0.46	2.16e-6	Schizophrenia;
THYM	cis	rs6032067	0.852	rs6032064	chr20:43854827	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.72	-7.65	-0.62	1.6e-11	Blood protein levels;
THYM	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg17264618	chr3:40429014	ENTPD3	-0.53	-5.15	-0.47	1.38e-6	Renal cell carcinoma;
THYM	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg27446573	chr6:127587934	RNF146	1.01	9.68	0.7	8.06e-16	Breast cancer;
THYM	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg05457628	chr5:178986728	RUFY1	-0.61	-6.09	-0.53	2.34e-8	Lung cancer;
THYM	cis	rs7119	0.651	rs12905044	chr15:77846215	G/A	cg10437265	chr15:77819839	NA	0.68	6.14	0.53	1.94e-8	Type 2 diabetes;
THYM	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg14416269	chr4:6271139	WFS1	0.48	4.83	0.44	5.18e-6	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs870825	0.616	rs28673855	chr4:185627416	T/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs6815814	0.950	rs5743789	chr4:38833173	A/T	cg06935464	chr4:38784597	TLR10	0.72	4.97	0.45	2.94e-6	Breast cancer;
THYM	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg10047753	chr17:41438598	NA	1.0	8.45	0.65	3.4e-13	Menopause (age at onset);
THYM	cis	rs448720	0.875	rs338338	chr15:68201422	A/G	cg24579218	chr15:68104479	NA	-0.53	-4.73	-0.44	7.66e-6	Cognitive performance;
THYM	cis	rs1018836	0.923	rs6988733	chr8:91535686	C/T	cg16814680	chr8:91681699	NA	-0.86	-7.89	-0.63	5.12e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg18252515	chr7:66147081	NA	1.43	8.54	0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg10523679	chr1:76189770	ACADM	-0.57	-4.83	-0.44	5.17e-6	Daytime sleep phenotypes;
THYM	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg13395646	chr4:1353034	KIAA1530	-0.61	-5.23	-0.47	1.02e-6	Obesity-related traits;
THYM	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg26818010	chr10:134567672	INPP5A	-0.93	-7.48	-0.61	3.71e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11771526	0.686	rs117514532	chr7:32316615	A/G	cg27532318	chr7:32358331	NA	0.83	4.66	0.43	1.04e-5	Body mass index;
THYM	cis	rs7771547	0.573	rs546353	chr6:36398597	C/A	cg07856975	chr6:36356162	ETV7	0.52	4.72	0.44	8.26e-6	Platelet distribution width;
THYM	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg20891283	chr12:69753455	YEATS4	-0.73	-6.09	-0.53	2.39e-8	Blood protein levels;
THYM	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-4.48	-0.42	2.05e-5	Aortic root size;
THYM	trans	rs8002861	0.765	rs12868462	chr13:44453480	C/T	cg17145862	chr1:211918768	LPGAT1	-0.97	-9.58	-0.7	1.28e-15	Leprosy;
THYM	cis	rs936229	1.000	rs936229	chr15:75132319	A/G	cg14664628	chr15:75095509	CSK	-1.03	-8.07	-0.64	2.12e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs7192380	0.965	rs7187634	chr16:69663371	T/C	cg09409435	chr16:70099608	PDXDC2	0.62	4.74	0.44	7.5e-6	Sjögren's syndrome;
THYM	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg26039829	chr8:22132926	PIWIL2	0.69	6.16	0.53	1.78e-8	Hypertriglyceridemia;
THYM	cis	rs12134245	0.719	rs61798831	chr1:91996588	C/T	cg21854759	chr1:92012499	NA	-0.7	-5.67	-0.5	1.5e-7	Breast cancer;
THYM	cis	rs8067545	0.578	rs9901336	chr17:20064190	G/A	cg13482628	chr17:19912719	NA	0.54	4.49	0.42	2e-5	Schizophrenia;
THYM	cis	rs6504663	1.000	rs6504661	chr17:48580126	A/T	cg22571038	chr17:48585470	MYCBPAP	-0.66	-5.17	-0.47	1.32e-6	Visceral fat;
THYM	cis	rs782590	0.837	rs2627769	chr2:55927288	G/C	cg18811423	chr2:55921094	PNPT1	0.79	7.57	0.61	2.43e-11	Metabolic syndrome;
THYM	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06873352	chr17:61820015	STRADA	0.79	9.84	0.71	3.66e-16	Prudent dietary pattern;
THYM	cis	rs72829446	0.530	rs9646411	chr17:7398909	A/G	cg02795151	chr17:7402630	POLR2A	-0.55	-5.04	-0.46	2.26e-6	Androgen levels;
THYM	cis	rs3126085	0.935	rs7533529	chr1:152176871	T/C	cg10321714	chr1:152280068	FLG	0.69	5.08	0.46	1.88e-6	Atopic dermatitis;
THYM	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg17063962	chr7:91808500	NA	-1.16	-13.12	-0.8	4.77e-23	Breast cancer;
THYM	cis	rs7213347	0.707	rs4790323	chr17:2181658	A/G	cg16513277	chr17:2031491	SMG6	-0.61	-4.55	-0.42	1.6e-5	Total body bone mineral density;
THYM	cis	rs9527	0.662	rs743575	chr10:104594906	T/G	cg04362960	chr10:104952993	NT5C2	0.64	4.98	0.45	2.85e-6	Arsenic metabolism;
THYM	trans	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7968440	0.966	rs1521516	chr12:51055708	C/T	cg20014596	chr12:50898483	DIP2B	0.54	4.46	0.42	2.29e-5	Fibrinogen;
THYM	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.65	5.71	0.51	1.3e-7	Platelet count;
THYM	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg15247329	chr7:2764246	NA	-0.7	-5.75	-0.51	1.1e-7	Height;
THYM	cis	rs6964587	0.626	rs35849169	chr7:91507313	A/G	cg22709100	chr7:91322751	NA	0.62	4.49	0.42	2.02e-5	Breast cancer;
THYM	cis	rs28595532	0.920	rs55758547	chr4:119769475	T/C	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	trans	rs8002861	0.905	rs6561149	chr13:44456782	T/G	cg17145862	chr1:211918768	LPGAT1	-0.97	-9.58	-0.7	1.28e-15	Leprosy;
THYM	cis	rs2072499	0.898	rs2736609	chr1:156202640	C/T	cg06970220	chr1:156163860	SLC25A44	0.73	6.03	0.53	3.15e-8	Testicular germ cell tumor;
THYM	trans	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg10856724	chr12:34555212	NA	-0.94	-8.13	-0.64	1.61e-12	Bladder cancer;
THYM	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg02640540	chr1:67518911	SLC35D1	-0.64	-4.68	-0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg18681998	chr4:17616180	MED28	0.95	9.51	0.7	1.88e-15	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2361701	0.636	rs1982244	chr17:78068948	C/T	cg09238746	chr17:78121135	EIF4A3	-0.78	-5.02	-0.46	2.45e-6	IgG glycosylation;
THYM	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg26149184	chr10:133730230	NA	0.77	4.65	0.43	1.07e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs4285028	0.898	rs12491991	chr3:121706021	A/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.74	5.08	0.46	1.87e-6	Multiple sclerosis;
THYM	cis	rs533581	0.866	rs4995274	chr16:88970040	T/C	cg08484992	chr16:88977278	CBFA2T3	0.38	4.73	0.44	7.84e-6	Social autistic-like traits;
THYM	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs2075230	0.542	rs2955616	chr17:7544084	A/G	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	-0.31	-4.51	-0.42	1.82e-5	Hormone measurements;
THYM	cis	rs11948739	0.610	rs994957	chr5:130291595	A/G	cg08523029	chr5:130500466	HINT1	-0.83	-6.03	-0.53	3.16e-8	Pediatric bone mineral content (hip);
THYM	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs2072499	0.966	rs2853643	chr1:156184831	G/A	cg24450063	chr1:156163899	SLC25A44	1.13	13.4	0.81	1.28e-23	Testicular germ cell tumor;
THYM	cis	rs10504073	0.584	rs55795863	chr8:49898055	A/G	cg00325661	chr8:49890786	NA	1.03	10.48	0.73	1.6e-17	Blood metabolite ratios;
THYM	cis	rs7940866	0.738	rs10791114	chr11:130889850	G/A	cg12179176	chr11:130786555	SNX19	0.68	5.53	0.49	2.81e-7	Schizophrenia;
THYM	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg09455208	chr3:40491958	NA	0.44	4.51	0.42	1.86e-5	Renal cell carcinoma;
THYM	cis	rs1299926	1.000	rs1298679	chr16:8870908	G/A	cg08365638	chr16:9212442	C16orf72	-0.96	-4.52	-0.42	1.79e-5	Anger;
THYM	cis	rs1345301	1.000	rs1345301	chr2:102875587	A/G	cg03938978	chr2:103052716	IL18RAP	-0.62	-6.09	-0.53	2.36e-8	Waist circumference;
THYM	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg15052019	chr19:19431593	KIAA0892;SF4	-0.63	-4.78	-0.44	6.46e-6	Tonsillectomy;
THYM	cis	rs4642101	0.793	rs13086170	chr3:12832604	G/C	cg05775895	chr3:12838266	CAND2	0.78	6.83	0.57	8.11e-10	QRS complex (12-leadsum);
THYM	cis	rs7119	0.604	rs2271398	chr15:77907784	G/A	cg10437265	chr15:77819839	NA	-0.5	-4.99	-0.46	2.78e-6	Type 2 diabetes;
THYM	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg19904058	chr10:135279010	LOC619207	-0.54	-5.06	-0.46	2.08e-6	Systemic lupus erythematosus;
THYM	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg20848291	chr7:100343083	ZAN	-0.61	-4.46	-0.42	2.26e-5	Other erythrocyte phenotypes;
THYM	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs67311347	0.577	rs11129870	chr3:40260406	G/A	cg13683864	chr3:40499215	RPL14	-0.69	-6.02	-0.53	3.23e-8	Renal cell carcinoma;
THYM	cis	rs4363385	0.597	rs6679201	chr1:152976840	C/A	cg13444842	chr1:152974279	SPRR3	-0.59	-4.68	-0.43	9.41e-6	Inflammatory skin disease;
THYM	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs17030434	0.728	rs2124641	chr4:154645810	T/C	cg14289246	chr4:154710475	SFRP2	0.75	5.13	0.47	1.53e-6	Electrocardiographic conduction measures;
THYM	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg22875332	chr1:76189707	ACADM	0.65	5.29	0.48	7.79e-7	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg18811423	chr2:55921094	PNPT1	0.73	6.99	0.58	3.79e-10	Metabolic syndrome;
THYM	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.48	4.51	0.42	1.89e-5	Birth weight;
THYM	cis	rs9364687	0.603	rs1047935	chr6:163997175	G/T	cg01639524	chr6:163818125	NA	0.5	4.89	0.45	4.07e-6	Body mass index;
THYM	cis	rs240764	0.658	rs705584	chr6:101261553	C/T	cg21058520	chr6:100914733	NA	-0.6	-5.29	-0.48	7.79e-7	Neuroticism;
THYM	cis	rs8063160	0.688	rs35415928	chr16:89724268	C/T	cg07984980	chr16:89898383	SPIRE2	1.3	5.19	0.47	1.2e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg07636037	chr3:49044803	WDR6	0.83	5.28	0.48	8.19e-7	Menarche (age at onset);
THYM	cis	rs10992471	0.756	rs7027595	chr9:95131553	C/T	cg14631576	chr9:95140430	CENPP	-0.95	-10.73	-0.74	4.66e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs250585	0.703	rs7204605	chr16:23553580	T/G	cg00143387	chr16:23521605	GGA2	-0.72	-4.58	-0.42	1.43e-5	Egg allergy;
THYM	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg08132940	chr7:1081526	C7orf50	-1.17	-6.67	-0.56	1.7e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs763014	0.898	rs4984897	chr16:632180	G/C	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg24672777	chr11:48374446	OR4C45	-0.87	-5.56	-0.5	2.48e-7	Axial length;
THYM	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg20283391	chr11:68216788	NA	-0.69	-5.14	-0.47	1.49e-6	Total body bone mineral density;
THYM	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg23574427	chr4:122746245	BBS7;CCNA2	-0.57	-5.18	-0.47	1.23e-6	Type 2 diabetes;
THYM	cis	rs55637147	0.671	rs4939141	chr11:57130892	G/A	cg15971518	chr11:57159174	PRG2	-0.65	-5.32	-0.48	6.78e-7	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs40363	0.645	rs1690447	chr16:3519211	T/C	cg21433313	chr16:3507492	NAT15	0.86	9.14	0.68	1.13e-14	Tuberculosis;
THYM	cis	rs12289510	0.682	rs948270	chr11:124954282	A/G	cg03868193	chr11:124958746	SLC37A2	-0.76	-6.45	-0.55	4.6e-9	Platelet-derived growth factor BB levels;
THYM	cis	rs6570726	0.791	rs6912079	chr6:145894949	G/A	cg23711669	chr6:146136114	FBXO30	0.98	10.77	0.74	3.75e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9660180	0.934	rs12729990	chr1:1812035	T/A	cg02915803	chr1:1606292	LOC728661;CDK11B	0.6	5.07	0.46	1.96e-6	Body mass index;
THYM	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg23803603	chr1:2058230	PRKCZ	-0.6	-5.22	-0.47	1.06e-6	Height;
THYM	cis	rs9443645	0.509	rs12176511	chr6:79565721	G/A	cg09184832	chr6:79620586	NA	0.61	5.16	0.47	1.34e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7809950	1.000	rs2520265	chr7:107181231	A/G	cg23024343	chr7:107201750	COG5	-0.94	-8.59	-0.66	1.7e-13	Coronary artery disease;
THYM	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.16	7.96	0.63	3.69e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4664308	0.967	rs62175559	chr2:160955833	G/A	cg03641300	chr2:160917029	PLA2R1	-0.75	-6.87	-0.58	6.63e-10	Idiopathic membranous nephropathy;
THYM	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Gout;
THYM	cis	rs7408868	0.908	rs45591935	chr19:15277006	T/C	cg14696996	chr19:15285081	NOTCH3	0.99	5.67	0.5	1.52e-7	Pulse pressure;
THYM	cis	rs10857712	0.904	rs7918164	chr10:135223323	G/A	cg17796960	chr10:135278976	LOC619207	-0.55	-4.65	-0.43	1.08e-5	Systemic lupus erythematosus;
THYM	cis	rs6918586	0.658	rs198837	chr6:26113398	A/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.79	7.08	0.59	2.53e-10	Schizophrenia;
THYM	cis	rs8133932	0.668	rs3788226	chr21:47300115	A/G	cg20357416	chr21:47294739	PCBP3	0.88	5.72	0.51	1.22e-7	Schizophrenia;
THYM	cis	rs728616	0.867	rs61860042	chr10:81946238	G/A	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs28595532	1.000	rs114039398	chr4:119631627	T/C	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs9560113	1.000	rs9555806	chr13:112179954	G/A	cg10483660	chr13:112241077	NA	0.55	4.96	0.45	3.1e-6	Menarche (age at onset);
THYM	cis	rs9527	0.615	rs10883804	chr10:104706520	G/A	cg15744005	chr10:104629667	AS3MT	-0.62	-4.73	-0.44	7.67e-6	Arsenic metabolism;
THYM	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg20203395	chr5:56204925	C5orf35	-0.67	-4.58	-0.42	1.44e-5	Initial pursuit acceleration;
THYM	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg26384229	chr12:38710491	ALG10B	0.95	7.06	0.59	2.68e-10	Bladder cancer;
THYM	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg11189052	chr15:85197271	WDR73	-0.62	-4.63	-0.43	1.16e-5	P wave terminal force;
THYM	trans	rs59827721	0.607	rs76183538	chr9:13852304	A/G	cg12515942	chr19:49552529	CGB8	0.66	6.99	0.58	3.72e-10	Inflammatory skin disease;
THYM	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg24399712	chr22:39784796	NA	-0.95	-10.92	-0.75	1.82e-18	Intelligence (multi-trait analysis);
THYM	cis	rs1007190	0.570	rs2906781	chr17:42793967	T/G	cg15406952	chr17:42872593	NA	0.77	4.85	0.45	4.81e-6	DNA methylation (variation);
THYM	cis	rs11574514	1.000	rs112526325	chr16:67761917	T/C	cg04582263	chr16:67973788	LCAT	1.08	5.08	0.46	1.85e-6	Crohn's disease;
THYM	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg22535103	chr8:58192502	C8orf71	-0.91	-5.93	-0.52	4.88e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg00495681	chr13:53174319	NA	0.73	7.39	0.6	5.76e-11	Lewy body disease;
THYM	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg06656553	chr16:89960601	TCF25	-0.95	-4.58	-0.43	1.41e-5	Skin colour saturation;
THYM	cis	rs4750440	0.614	rs898718	chr10:14027235	C/T	cg27542038	chr10:14027202	FRMD4A	-0.58	-4.98	-0.46	2.84e-6	Adiponectin levels;
THYM	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg03060546	chr3:49711283	APEH	0.74	6.04	0.53	2.97e-8	Resting heart rate;
THYM	cis	rs4788570	0.584	rs11862723	chr16:71704222	T/C	cg06353428	chr16:71660113	MARVELD3	1.28	8.72	0.67	8.76e-14	Intelligence (multi-trait analysis);
THYM	cis	rs7428297	1.000	rs9818587	chr3:127078094	G/A	cg21487550	chr3:127056955	NA	0.77	4.59	0.43	1.36e-5	Clozapine-induced agranulocytosis;
THYM	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg17366294	chr4:99064904	C4orf37	0.57	6.8	0.57	9.34e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.58	6.09	0.53	2.4e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	4.54	0.42	1.66e-5	Hip circumference adjusted for BMI;
THYM	cis	rs7666738	0.888	rs13110683	chr4:98983368	G/C	cg07917127	chr4:99064746	C4orf37	0.59	4.5	0.42	1.93e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2806561	1.000	rs2776822	chr1:23492782	A/G	cg08872493	chr1:23521417	HTR1D	-0.37	-4.54	-0.42	1.68e-5	Height;
THYM	cis	rs2732480	0.517	rs2634676	chr12:48738236	A/G	cg21466736	chr12:48725269	NA	-0.6	-5.36	-0.48	5.86e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs13315871	0.929	rs11717700	chr3:58250876	T/A	cg00563845	chr3:58318305	PXK	0.6	4.95	0.45	3.21e-6	Cholesterol, total;
THYM	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg00757033	chr12:89920650	WDR51B	0.77	11.72	0.77	3.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg26597838	chr10:835615	NA	1.23	8.88	0.67	4.1e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs13315871	0.929	rs13094898	chr3:58290143	G/A	cg00563845	chr3:58318305	PXK	0.59	5.03	0.46	2.29e-6	Cholesterol, total;
THYM	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4363385	0.567	rs7551791	chr1:153024267	A/T	cg13444842	chr1:152974279	SPRR3	-0.63	-4.96	-0.45	3.05e-6	Inflammatory skin disease;
THYM	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg15448220	chr1:150897856	SETDB1	0.9	7.66	0.62	1.56e-11	Melanoma;
THYM	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg02725872	chr8:58115012	NA	-1.11	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg04731861	chr2:219085781	ARPC2	-0.53	-5.03	-0.46	2.29e-6	Colorectal cancer;
THYM	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg08901578	chr4:187885870	NA	0.6	5.47	0.49	3.58e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05901451	chr6:126070800	HEY2	-0.97	-9.68	-0.7	7.99e-16	Brugada syndrome;
THYM	cis	rs901683	1.000	rs36054203	chr10:46037861	A/G	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg23221052	chr5:179740743	GFPT2	-0.95	-7.33	-0.6	7.68e-11	Height;
THYM	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg02869364	chr7:1081709	C7orf50	-0.61	-4.96	-0.45	3.03e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs13064411	0.696	rs6799610	chr3:113248748	A/C	cg18753928	chr3:113234510	CCDC52	0.96	9.65	0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs4731207	0.564	rs7776821	chr7:124657504	C/T	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg03806693	chr22:41940476	POLR3H	0.98	8.1	0.64	1.84e-12	Vitiligo;
THYM	cis	rs6456156	0.586	rs2285148	chr6:167490999	G/T	cg15592062	chr6:167189543	RPS6KA2	-0.45	-4.46	-0.42	2.26e-5	Primary biliary cholangitis;
THYM	cis	rs2333194	0.875	rs28716532	chr14:73769255	T/C	cg09844916	chr14:74004424	HEATR4;ACOT1	0.56	4.46	0.42	2.2e-5	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs4732038	0.510	rs12673750	chr7:134276201	T/C	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs1061377	1.000	rs34771104	chr4:39129052	G/T	cg24403649	chr4:39172243	NA	0.56	4.52	0.42	1.8e-5	Uric acid levels;
THYM	cis	rs6542838	0.611	rs13006398	chr2:99522323	T/A	cg08885076	chr2:99613938	TSGA10	-0.5	-4.66	-0.43	1.03e-5	Fear of minor pain;
THYM	cis	rs11096990	0.634	rs6852967	chr4:39283146	G/T	cg24403649	chr4:39172243	NA	-0.67	-5.84	-0.51	7.33e-8	Cognitive function;
THYM	cis	rs61931739	1.000	rs12311881	chr12:34036100	A/G	cg10856724	chr12:34555212	NA	0.63	5.33	0.48	6.57e-7	Morning vs. evening chronotype;
THYM	cis	rs35883536	1.000	rs12410168	chr1:101115321	G/A	cg06223162	chr1:101003688	GPR88	0.67	5.1	0.46	1.77e-6	Monocyte count;
THYM	cis	rs7131987	0.683	rs12366505	chr12:29474110	C/T	cg09582351	chr12:29534625	ERGIC2	-0.59	-5.13	-0.47	1.53e-6	QT interval;
THYM	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.14	0.47	1.49e-6	Height;
THYM	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg24060327	chr5:131705240	SLC22A5	0.8	6.52	0.56	3.35e-9	Blood metabolite levels;
THYM	cis	rs1467026	0.589	rs9876483	chr3:12803792	G/T	cg05775895	chr3:12838266	CAND2	0.87	7.32	0.6	7.83e-11	P wave duration;
THYM	cis	rs9419702	0.568	rs7920966	chr10:133555185	G/T	cg23460707	chr10:133558971	NA	0.45	4.7	0.43	8.86e-6	Survival in rectal cancer;
THYM	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg10803722	chr21:46713166	LOC642852	-0.41	-5.33	-0.48	6.47e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg04267008	chr7:1944627	MAD1L1	0.63	5.59	0.5	2.17e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg08773314	chr2:239334832	ASB1	0.64	8.45	0.66	3.33e-13	Multiple system atrophy;
THYM	cis	rs10208940	0.614	rs11894485	chr2:68824140	A/C	cg09157127	chr2:69201416	GKN1	0.89	4.71	0.43	8.61e-6	Urate levels in lean individuals;
THYM	trans	rs75518195	0.590	rs11131484	chr4:64727794	T/C	cg14706739	chr8:21916355	EPB49	0.76	7.35	0.6	6.93e-11	Triptolide cytotoxicity;
THYM	cis	rs10100465	0.924	rs1160120	chr8:118641568	A/G	cg09430518	chr8:118662568	NA	-0.32	-5.17	-0.47	1.29e-6	Leprosy;
THYM	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.42	-0.49	4.57e-7	Bipolar disorder;
THYM	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg03983476	chr2:10830698	NOL10	0.6	5.71	0.51	1.28e-7	Prostate cancer;
THYM	cis	rs2903698	0.565	rs13152113	chr4:76391079	A/C	cg03209871	chr4:76438412	RCHY1;THAP6	0.42	4.87	0.45	4.51e-6	Prion diseases;
THYM	cis	rs36051895	0.632	rs12349918	chr9:5125250	A/G	cg02405213	chr9:5042618	JAK2	-1.04	-11.53	-0.76	9.18e-20	Pediatric autoimmune diseases;
THYM	cis	rs2637266	1.000	rs7098790	chr10:78361077	T/A	cg18941641	chr10:78392320	NA	0.72	6.33	0.54	8.03e-9	Pulmonary function;
THYM	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg18305652	chr10:134549665	INPP5A	-0.74	-5.87	-0.52	6.24e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs4988958	0.527	rs3771155	chr2:103037826	A/G	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma (childhood onset);
THYM	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg10802521	chr3:52805072	NEK4	-0.73	-6.38	-0.55	6.43e-9	Bipolar disorder;
THYM	cis	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg08133631	chr1:26527909	CATSPER4	-0.61	-5.08	-0.46	1.92e-6	Obesity-related traits;
THYM	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.55	-0.73	1.12e-17	Primary sclerosing cholangitis;
THYM	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg25801113	chr15:45476975	SHF	-0.39	-4.48	-0.42	2.12e-5	Uric acid levels;
THYM	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs514406	0.800	rs4926930	chr1:53217335	A/G	cg25767906	chr1:53392781	SCP2	0.51	5.04	0.46	2.22e-6	Monocyte count;
THYM	cis	rs6754311	0.517	rs1469996	chr2:136542560	A/G	cg23851026	chr2:136556271	LCT	0.65	5.81	0.51	8.21e-8	Mosquito bite size;
THYM	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	4.62	0.43	1.22e-5	Rheumatoid arthritis;
THYM	cis	rs11756438	0.572	rs2638544	chr6:119001978	G/A	cg21191810	chr6:118973309	C6orf204	0.56	5.51	0.49	3.1e-7	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg09936400	chr10:82049201	MAT1A	0.43	4.57	0.42	1.45e-5	Post bronchodilator FEV1;
THYM	cis	rs7828089	0.519	rs2443500	chr8:22352342	C/T	cg12081754	chr8:22256438	SLC39A14	0.64	5.47	0.49	3.58e-7	Verbal declarative memory;
THYM	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg26131816	chr17:42072204	PYY	0.52	4.49	0.42	2.02e-5	Menopause (age at onset);
THYM	cis	rs4866334	1.000	rs74805322	chr5:18487623	C/A	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs6570726	0.791	rs385729	chr6:145855465	T/C	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4383453	0.539	rs56712020	chr3:123099368	G/A	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs6570726	0.791	rs10872577	chr6:145900560	G/T	cg23711669	chr6:146136114	FBXO30	0.98	10.25	0.72	4.91e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg05295671	chr13:79234353	RNF219	-0.69	-4.68	-0.43	9.36e-6	Large artery stroke;
THYM	cis	rs425277	0.628	rs10797427	chr1:2060732	C/T	cg24578937	chr1:2090814	PRKCZ	-0.6	-6.37	-0.55	6.86e-9	Height;
THYM	cis	rs986417	1.000	rs1951115	chr14:60922006	G/C	cg27398547	chr14:60952738	C14orf39	-1.15	-5.91	-0.52	5.37e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs6448317	0.539	rs11931422	chr4:24936925	T/C	cg21108841	chr4:24914750	CCDC149	-0.78	-6.53	-0.56	3.28e-9	Heschl's gyrus morphology;
THYM	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg14004847	chr7:1930337	MAD1L1	0.69	5.66	0.5	1.59e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7772486	0.902	rs1331643	chr6:146398873	T/A	cg23711669	chr6:146136114	FBXO30	0.88	8.72	0.67	9.02e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs747334	0.791	rs2901176	chr10:92743250	G/A	cg07620928	chr10:92689909	NA	0.61	5.41	0.49	4.75e-7	Fibroblast growth factor basic levels;
THYM	cis	rs11574514	1.000	rs76649027	chr16:67905994	G/A	cg09738193	chr16:67926317	PSKH1	-0.91	-4.66	-0.43	1.01e-5	Crohn's disease;
THYM	cis	rs4242434	0.757	rs4872531	chr8:22529695	A/G	cg03733263	chr8:22462867	KIAA1967	-1.14	-10.93	-0.75	1.77e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs28595532	0.841	rs114976553	chr4:119496056	A/G	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.21e-7	Cannabis dependence symptom count;
THYM	cis	rs939658	0.626	rs11636901	chr15:79446292	T/C	cg17916960	chr15:79447300	NA	-0.63	-6.8	-0.57	9.01e-10	Refractive error;
THYM	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06634786	chr22:41940651	POLR3H	0.82	6.28	0.54	1.01e-8	Vitiligo;
THYM	cis	rs1957429	0.808	rs6573580	chr14:65331766	C/G	cg23373153	chr14:65346875	NA	0.95	5.17	0.47	1.28e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg21775007	chr8:11205619	TDH	0.64	4.93	0.45	3.43e-6	Retinal vascular caliber;
THYM	cis	rs9522267	0.559	rs9522300	chr13:112236668	C/G	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs2777491	0.915	rs28578057	chr15:41621921	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.14	-12.89	-0.8	1.38e-22	Ulcerative colitis;
THYM	cis	rs478304	0.593	rs4645933	chr11:65485120	C/T	cg17480646	chr11:65405466	SIPA1	-0.95	-7.78	-0.62	8.92e-12	Acne (severe);
THYM	cis	rs3741151	1.000	rs112840535	chr11:73066771	G/A	cg12959048	chr11:73096162	RELT	-0.5	-4.78	-0.44	6.38e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg17063962	chr7:91808500	NA	1.16	13.11	0.8	4.9e-23	Breast cancer;
THYM	cis	rs782590	0.967	rs11125581	chr2:55796527	C/G	cg03859395	chr2:55845619	SMEK2	0.65	5.95	0.52	4.52e-8	Metabolic syndrome;
THYM	cis	rs4851254	0.660	rs58683655	chr2:100686519	G/C	cg22139774	chr2:100720529	AFF3	-0.41	-4.69	-0.43	9.07e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg18230493	chr5:56204884	C5orf35	-0.89	-6.62	-0.56	2.09e-9	Initial pursuit acceleration;
THYM	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg27588902	chr6:42928151	GNMT	-0.53	-5.01	-0.46	2.56e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg00129232	chr17:37814104	STARD3	0.69	4.45	0.42	2.32e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs9393777	0.841	rs34332556	chr6:27357414	C/G	cg23161317	chr6:28129485	ZNF389	1.11	4.64	0.43	1.1e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7267979	1.000	rs6050617	chr20:25421648	C/T	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg11166453	chr1:247681781	NA	0.69	5.38	0.48	5.45e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg16405210	chr4:1374714	KIAA1530	0.87	7.71	0.62	1.25e-11	Obesity-related traits;
THYM	cis	rs28595532	0.920	rs114544767	chr4:119728364	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs10751667	0.857	rs6597961	chr11:976677	T/C	cg01483505	chr11:975446	AP2A2	0.65	5.12	0.46	1.6e-6	Alzheimer's disease (late onset);
THYM	cis	rs7166081	0.672	rs12441715	chr15:67860587	G/A	cg24579218	chr15:68104479	NA	-0.7	-6.45	-0.55	4.62e-9	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
THYM	cis	rs1808579	0.904	rs891387	chr18:21103909	A/G	cg14672496	chr18:21087552	C18orf8	0.5	4.48	0.42	2.05e-5	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
THYM	cis	rs1729951	0.546	rs361246	chr3:136695667	G/A	cg21827317	chr3:136751795	NA	0.75	6.64	0.56	1.92e-9	Neuroticism;
THYM	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.13	-8.52	-0.66	2.33e-13	Schizophrenia;
THYM	cis	rs12190007	0.508	rs6605538	chr6:169731432	G/A	cg16388071	chr6:169726476	NA	0.69	5.99	0.52	3.71e-8	Obesity-related traits;
THYM	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	4.55	0.42	1.57e-5	Bipolar disorder;
THYM	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.64	4.59	0.43	1.35e-5	Aortic root size;
THYM	cis	rs11997175	0.784	rs36083407	chr8:33812930	G/T	ch.8.33884649F	chr8:33765107	NA	0.74	5.87	0.52	6.33e-8	Body mass index;
THYM	cis	rs9790314	0.875	rs336580	chr3:161082982	A/T	cg03342759	chr3:160939853	NMD3	-0.73	-6.32	-0.54	8.42e-9	Morning vs. evening chronotype;
THYM	cis	rs35883536	0.566	rs4908086	chr1:101088124	C/T	cg09408571	chr1:101003634	GPR88	0.43	5.15	0.47	1.4e-6	Monocyte count;
THYM	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.5	-4.79	-0.44	6.1e-6	Crohn's disease;
THYM	cis	rs34638657	0.872	rs7202258	chr16:82195013	T/C	cg09439754	chr16:82129088	HSD17B2	-0.59	-5.25	-0.47	9.2e-7	Lung adenocarcinoma;
THYM	cis	rs255428	0.522	rs673743	chr5:62867084	C/T	cg13713523	chr5:63802877	RGS7BP	0.55	4.68	0.43	9.44e-6	Major depressive disorder;
THYM	cis	rs11089937	0.616	rs7286793	chr22:22537341	A/G	cg06866756	chr22:22471216	NA	-0.46	-5.09	-0.46	1.79e-6	Periodontitis (PAL4Q3);
THYM	cis	rs1747683	0.966	rs10796059	chr10:13368987	T/C	cg25835351	chr10:13388524	SEPHS1	-0.35	-5.9	-0.52	5.49e-8	IgG glycosylation;
THYM	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg26566898	chr11:117069891	TAGLN	-0.4	-5.2	-0.47	1.13e-6	Blood protein levels;
THYM	trans	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs865483	0.860	rs12603185	chr17:35868304	T/C	cg06716730	chr17:35851459	DUSP14	0.42	6.89	0.58	5.94e-10	Monocyte count;
THYM	cis	rs1629083	0.875	rs1805	chr11:118076069	A/C	cg25155064	chr11:118100782	MPZL3	-0.51	-4.45	-0.42	2.35e-5	Lung cancer;
THYM	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11077998	0.967	rs7350963	chr17:80491067	G/A	cg11779900	chr17:80519722	FOXK2	-0.53	-4.52	-0.42	1.79e-5	Reticulocyte fraction of red cells;
THYM	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg11266682	chr4:10021025	SLC2A9	-0.52	-7.0	-0.58	3.57e-10	Bone mineral density;
THYM	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1348850	0.574	rs4893835	chr2:178442592	T/C	cg27490568	chr2:178487706	NA	0.53	4.62	0.43	1.2e-5	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs9814567	0.762	rs13071852	chr3:134223217	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.71	6.01	0.53	3.37e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2811415	0.627	rs13316354	chr3:127751772	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg00990874	chr7:1149470	C7orf50	-0.69	-5.17	-0.47	1.29e-6	Bronchopulmonary dysplasia;
THYM	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg08885076	chr2:99613938	TSGA10	0.52	5.02	0.46	2.4e-6	Chronic sinus infection;
THYM	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22857025	chr5:266934	NA	-1.5	-9.71	-0.71	6.9e-16	Breast cancer;
THYM	cis	rs2717559	0.541	rs34497317	chr8:143889053	T/A	cg17252645	chr8:143867129	LY6D	-0.62	-6.46	-0.55	4.47e-9	Urinary tract infection frequency;
THYM	cis	rs6570726	0.875	rs12524077	chr6:145866333	G/C	cg13319975	chr6:146136371	FBXO30	-0.66	-5.62	-0.5	1.89e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9467711	0.606	rs16891725	chr6:26479150	C/T	cg12826209	chr6:26865740	GUSBL1	0.82	4.72	0.44	8.13e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs198426	0.813	rs2017861	chr11:61481928	G/A	cg19838087	chr11:61442541	NA	0.56	5.59	0.5	2.19e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
THYM	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-8.12	-0.64	1.67e-12	Coronary artery disease;
THYM	cis	rs11645898	1.000	rs11645898	chr16:72229532	A/G	cg03805757	chr16:71968109	PKD1L3	-0.68	-5.19	-0.47	1.18e-6	Blood protein levels;
THYM	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg21028142	chr17:79581711	NPLOC4	0.61	6.22	0.54	1.32e-8	Eye color traits;
THYM	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg27129171	chr3:47204927	SETD2	0.71	5.94	0.52	4.69e-8	Birth weight;
THYM	cis	rs2408955	0.522	rs11168408	chr12:48498327	G/A	cg21466736	chr12:48725269	NA	0.49	4.85	0.45	4.81e-6	Glycated hemoglobin levels;
THYM	cis	rs478304	0.903	rs61895677	chr11:65549415	T/C	cg17480646	chr11:65405466	SIPA1	0.7	6.27	0.54	1.07e-8	Acne (severe);
THYM	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg00256281	chr22:41985642	PMM1	0.64	5.02	0.46	2.42e-6	Vitiligo;
THYM	cis	rs8016982	0.698	rs8011097	chr14:81702736	T/C	cg01989461	chr14:81687754	GTF2A1	0.82	7.69	0.62	1.38e-11	Schizophrenia;
THYM	cis	rs921968	0.565	rs2272191	chr2:219609776	G/A	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg06808227	chr14:105710500	BRF1	-1.05	-9.15	-0.68	1.07e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg14186256	chr22:23484241	RTDR1	0.96	9.57	0.7	1.38e-15	Bone mineral density;
THYM	cis	rs835154	0.845	rs835155	chr5:14875868	A/G	cg14843632	chr5:14870594	ANKH	-0.63	-5.72	-0.51	1.25e-7	Blood metabolite levels;
THYM	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg22166914	chr1:53195759	ZYG11B	-0.81	-8.7	-0.67	9.82e-14	Monocyte count;
THYM	cis	rs919433	0.617	rs700642	chr2:198600730	G/T	cg00792783	chr2:198669748	PLCL1	-0.81	-5.88	-0.52	6.14e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg06618935	chr21:46677482	NA	-0.98	-9.5	-0.7	1.95e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs34779708	0.897	rs7897827	chr10:35386237	C/T	cg03585969	chr10:35415529	CREM	0.67	4.76	0.44	6.91e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs208520	0.837	rs208498	chr6:66931560	G/A	cg07460842	chr6:66804631	NA	-0.78	-5.05	-0.46	2.16e-6	Exhaled nitric oxide output;
THYM	cis	rs919433	0.679	rs13394214	chr2:198527371	C/T	cg00792783	chr2:198669748	PLCL1	0.79	5.13	0.47	1.53e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs17102423	1.000	rs17102423	chr14:65604728	G/T	cg11161011	chr14:65562177	MAX	-0.64	-5.86	-0.52	6.58e-8	Obesity-related traits;
THYM	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg05368731	chr17:41323189	NBR1	1.25	11.46	0.76	1.31e-19	Menopause (age at onset);
THYM	cis	rs7731657	0.509	rs916956	chr5:130331705	C/G	cg08523029	chr5:130500466	HINT1	-0.81	-5.6	-0.5	2.04e-7	Fasting plasma glucose;
THYM	cis	rs2039659	0.640	rs9547328	chr13:86277265	T/A	cg25308322	chr13:86268291	NA	0.67	6.04	0.53	2.93e-8	Blood osmolality (transformed sodium);
THYM	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg13114125	chr14:105738426	BRF1	-0.75	-5.91	-0.52	5.39e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9902453	0.845	rs12452201	chr17:28214173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.64	0.43	1.11e-5	Coffee consumption (cups per day);
THYM	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs8049634	0.528	rs3785017	chr16:84093931	A/G	cg04832210	chr16:84151246	MBTPS1	-0.45	-4.47	-0.42	2.13e-5	Small cell lung carcinoma;
THYM	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg05393297	chr12:53359155	NA	-0.59	-6.63	-0.56	2.01e-9	Cancer (pleiotropy);
THYM	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg08109568	chr15:31115862	NA	0.54	5.23	0.47	1.02e-6	Huntington's disease progression;
THYM	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg27534772	chr1:16042836	PLEKHM2	0.53	6.07	0.53	2.6e-8	Systolic blood pressure;
THYM	cis	rs7578361	0.918	rs7369134	chr2:150373254	T/C	cg17961725	chr2:150454027	NA	0.76	5.69	0.5	1.39e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	4.47	0.42	2.13e-5	Alzheimer's disease;
THYM	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.75	-5.44	-0.49	4.22e-7	Birth weight;
THYM	cis	rs1385374	0.858	rs11059930	chr12:129297860	T/C	cg04043695	chr12:129287642	SLC15A4	-0.8	-4.83	-0.44	5.3e-6	Systemic lupus erythematosus;
THYM	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg08885076	chr2:99613938	TSGA10	-0.76	-7.33	-0.6	7.73e-11	Chronic sinus infection;
THYM	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg18876405	chr7:65276391	NA	0.71	6.58	0.56	2.57e-9	Aortic root size;
THYM	cis	rs72627123	0.867	rs12050413	chr14:74388372	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.1	6.61	0.56	2.24e-9	Morning vs. evening chronotype;
THYM	cis	rs9527	0.535	rs4917999	chr10:104963051	C/G	cg15744005	chr10:104629667	AS3MT	0.62	4.49	0.42	1.97e-5	Arsenic metabolism;
THYM	trans	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg07211511	chr3:129823064	LOC729375	-1.33	-9.19	-0.69	8.79e-15	Blood pressure (smoking interaction);
THYM	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	10.62	0.74	7.85e-18	Chronic sinus infection;
THYM	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.81	7.18	0.59	1.58e-10	Prudent dietary pattern;
THYM	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.89	7.64	0.62	1.71e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4901869	0.897	rs12878587	chr14:59339378	C/G	cg02291164	chr14:59296302	NA	0.8	8.12	0.64	1.64e-12	Panic disorder;
THYM	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg00944433	chr1:107599041	PRMT6	0.42	5.39	0.48	5.04e-7	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg24675056	chr1:15929824	NA	0.75	6.08	0.53	2.5e-8	Systolic blood pressure;
THYM	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.53	-4.86	-0.45	4.56e-6	Lymphocyte counts;
THYM	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs3126085	0.932	rs72696991	chr1:152250235	T/C	cg10321714	chr1:152280068	FLG	-0.76	-5.68	-0.5	1.47e-7	Atopic dermatitis;
THYM	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg18132916	chr6:79620363	NA	-0.6	-5.67	-0.5	1.53e-7	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg09455208	chr3:40491958	NA	-0.49	-4.86	-0.45	4.68e-6	Renal cell carcinoma;
THYM	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg09307838	chr4:120376055	NA	0.71	5.07	0.46	1.98e-6	Corneal astigmatism;
THYM	cis	rs12449964	0.524	rs7225934	chr17:17572544	T/C	cg04398451	chr17:18023971	MYO15A	0.59	4.89	0.45	4.13e-6	Coronary artery disease or ischemic stroke;
THYM	cis	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg10856724	chr12:34555212	NA	-1.07	-10.09	-0.72	1.09e-16	Morning vs. evening chronotype;
THYM	cis	rs4792901	0.918	rs34012717	chr17:41634581	A/T	cg21940313	chr17:41620911	ETV4	-0.48	-5.27	-0.48	8.38e-7	Dupuytren's disease;
THYM	cis	rs673253	0.556	rs517191	chr1:44116466	G/A	cg24466421	chr1:44070974	PTPRF	-0.61	-5.16	-0.47	1.37e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1113500	0.509	rs17020915	chr1:108647006	G/T	cg06207961	chr1:108661230	NA	0.62	4.52	0.42	1.81e-5	Growth-regulated protein alpha levels;
THYM	cis	rs10782582	0.522	rs12125933	chr1:76130920	C/T	cg10523679	chr1:76189770	ACADM	-0.57	-4.83	-0.44	5.17e-6	Daytime sleep phenotypes;
THYM	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg05373962	chr22:49881684	NA	-0.66	-6.02	-0.53	3.27e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg06623918	chr6:96969491	KIAA0776	1.08	9.78	0.71	4.98e-16	Headache;
THYM	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg07936489	chr17:37558343	FBXL20	0.82	5.69	0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs2710642	0.564	rs7558681	chr2:62840987	G/A	cg17519650	chr2:63277830	OTX1	0.64	4.71	0.44	8.46e-6	LDL cholesterol levels;LDL cholesterol;
THYM	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs9644630	0.696	rs13261824	chr8:19313912	C/G	cg06562184	chr8:19319451	CSGALNACT1	0.56	5.12	0.46	1.62e-6	Oropharynx cancer;
THYM	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg08999081	chr20:33150536	PIGU	-0.59	-5.28	-0.48	8.16e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs3771570	0.786	rs62186378	chr2:242211554	G/A	cg21155796	chr2:242212141	HDLBP	1.26	5.64	0.5	1.71e-7	Prostate cancer;
THYM	cis	rs7262634	1.000	rs73302076	chr20:45837411	A/G	cg18599129	chr20:45867857	ZMYND8	0.82	4.83	0.44	5.14e-6	Response to protease inhibitor treatment in hepatitis c (bilirubin toxicity);
THYM	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg17143192	chr8:8559678	CLDN23	-0.9	-6.78	-0.57	1e-9	Obesity-related traits;
THYM	cis	rs4455778	0.580	rs62454353	chr7:49087900	C/A	cg26309511	chr7:48887640	NA	0.68	5.94	0.52	4.63e-8	Lung cancer in never smokers;
THYM	cis	rs11039798	0.614	rs116427493	chr11:48776141	C/T	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs988913	1.000	rs9349740	chr6:54825708	A/C	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.74e-6	Menarche (age at onset);
THYM	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.19	-8.63	-0.66	1.37e-13	Gut microbiome composition (summer);
THYM	cis	rs1007190	0.570	rs7224712	chr17:42874218	G/T	cg15406952	chr17:42872593	NA	-0.84	-5.95	-0.52	4.45e-8	DNA methylation (variation);
THYM	cis	rs42648	0.837	rs42615	chr7:89950501	G/T	cg25739043	chr7:89950458	NA	-0.53	-4.53	-0.42	1.72e-5	Homocysteine levels;
THYM	cis	rs9534288	0.797	rs2104516	chr13:46602123	T/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.72	-0.44	8.2e-6	Blood protein levels;
THYM	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.86	0.74	2.46e-18	Chronic sinus infection;
THYM	cis	rs2403083	1.000	rs2403083	chr8:86108149	C/A	cg13721134	chr8:86350390	CA3	0.51	4.63	0.43	1.17e-5	Plasma amyloid beta peptide concentrations (ABx-40);
THYM	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs735539	1.000	rs6490606	chr13:21285096	C/G	cg02792322	chr13:21280448	IL17D	0.69	4.98	0.45	2.84e-6	Dental caries;
THYM	cis	rs2273669	0.667	rs12195378	chr6:109284255	A/G	cg17117243	chr6:109341365	SESN1	-0.86	-5.02	-0.46	2.41e-6	Prostate cancer;
THYM	cis	rs73086581	0.838	rs41398349	chr20:4024439	C/T	cg02187196	chr20:3869020	PANK2	-0.47	-5.16	-0.47	1.37e-6	Response to antidepressants in depression;
THYM	cis	rs7426056	0.530	rs2140148	chr2:204572140	A/C	cg13651908	chr2:204570033	CD28	-0.79	-6.13	-0.53	1.96e-8	Primary sclerosing cholangitis;
THYM	cis	rs700651	0.789	rs10497812	chr2:198911245	A/G	cg00792783	chr2:198669748	PLCL1	-0.74	-4.83	-0.44	5.28e-6	Intracranial aneurysm;
THYM	cis	rs8114671	0.562	rs7263157	chr20:33459127	G/A	cg08999081	chr20:33150536	PIGU	0.63	5.05	0.46	2.1e-6	Height;
THYM	cis	rs2836633	0.965	rs2836615	chr21:40048039	C/T	cg12884169	chr21:40033163	ERG	0.68	8.52	0.66	2.37e-13	Coronary artery disease;
THYM	cis	rs1062753	0.961	rs9620007	chr22:42405657	C/G	cg22189786	chr22:42395067	WBP2NL	0.54	5.55	0.49	2.6e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg02820040	chr2:241836501	C2orf54	-0.29	-6.15	-0.53	1.82e-8	Urinary metabolites;
THYM	cis	rs28408315	0.958	rs34851962	chr15:79203038	A/C	cg00540400	chr15:79124168	NA	0.61	4.74	0.44	7.43e-6	Lung cancer;Lung cancer in ever smokers;Lung adenocarcinoma;
THYM	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg23815491	chr16:72088622	HP	-0.79	-7.03	-0.58	3.13e-10	Prostate cancer;
THYM	cis	rs714027	0.605	rs1468176	chr22:30544516	G/A	cg27665648	chr22:30112403	NA	-0.52	-4.73	-0.44	7.79e-6	Lymphocyte counts;
THYM	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg03877680	chr5:178157825	ZNF354A	0.7	4.77	0.44	6.65e-6	Neutrophil percentage of white cells;
THYM	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs6456156	0.806	rs11967165	chr6:167529936	T/C	cg09487078	chr6:167525398	CCR6	-0.44	-4.92	-0.45	3.63e-6	Primary biliary cholangitis;
THYM	cis	rs4077515	0.967	rs4075760	chr9:139266697	A/G	cg14115884	chr9:139300582	SDCCAG3	0.7	6.74	0.57	1.23e-9	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs34638657	0.827	rs11641736	chr16:82206279	G/A	cg07307142	chr16:82071433	HSD17B2	-0.9	-6.48	-0.55	4.08e-9	Lung adenocarcinoma;
THYM	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg03806693	chr22:41940476	POLR3H	-0.95	-7.64	-0.62	1.68e-11	Vitiligo;
THYM	cis	rs1801251	0.685	rs1515961	chr2:233623763	C/A	cg08000102	chr2:233561755	GIGYF2	0.66	5.94	0.52	4.75e-8	Coronary artery disease;
THYM	cis	rs9486719	0.843	rs2472875	chr6:96844691	G/A	cg18709589	chr6:96969512	KIAA0776	0.75	4.49	0.42	2.02e-5	Migraine;Coronary artery disease;
THYM	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.74	-5.5	-0.49	3.24e-7	Cognitive test performance;
THYM	cis	rs8016982	0.674	rs1951614	chr14:81672106	A/G	cg01989461	chr14:81687754	GTF2A1	-0.86	-7.64	-0.62	1.67e-11	Schizophrenia;
THYM	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg27535305	chr1:53392650	SCP2	-0.4	-4.6	-0.43	1.3e-5	Monocyte count;
THYM	cis	rs4866334	1.000	rs78447918	chr5:18488634	T/A	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.85	8.94	0.68	3.08e-14	Blood protein levels;
THYM	cis	rs12580035	0.568	rs7315298	chr12:1912880	C/T	cg25356715	chr12:1904796	CACNA2D4	0.46	4.58	0.43	1.42e-5	Urate levels in lean individuals;
THYM	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg04842962	chr6:43655489	MRPS18A	1.39	14.99	0.84	8.89e-27	IgG glycosylation;
THYM	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06873352	chr17:61820015	STRADA	0.56	5.6	0.5	2.12e-7	Height;
THYM	cis	rs17102423	0.559	rs11627382	chr14:65480208	A/G	cg12032228	chr14:64854572	MTHFD1	-0.67	-4.5	-0.42	1.96e-5	Obesity-related traits;
THYM	cis	rs9393777	0.623	rs13211166	chr6:27265940	T/A	cg22548220	chr6:27277996	POM121L2	0.83	5.21	0.47	1.11e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg00757033	chr12:89920650	WDR51B	0.75	10.23	0.72	5.28e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg01570182	chr17:44337453	NA	-0.84	-9.31	-0.69	5.04e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs3820068	0.580	rs12082523	chr1:16005792	A/G	cg27534772	chr1:16042836	PLEKHM2	-0.54	-5.91	-0.52	5.23e-8	Systolic blood pressure;
THYM	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg02953382	chr22:24373134	LOC391322	0.73	6.62	0.56	2.16e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs7122937	0.648	rs12576156	chr11:2498818	C/T	cg27115973	chr11:2481206	KCNQ1	-0.5	-4.56	-0.42	1.52e-5	QT interval;
THYM	cis	rs7267979	1.000	rs2297497	chr20:25297909	C/T	cg08601574	chr20:25228251	PYGB	-0.57	-4.61	-0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg26314531	chr2:26401878	FAM59B	-0.76	-5.02	-0.46	2.37e-6	Gut microbiome composition (summer);
THYM	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.16	-0.75	5.56e-19	Primary sclerosing cholangitis;
THYM	cis	rs1950500	0.545	rs724165	chr14:24806229	G/A	cg22990158	chr14:24802150	ADCY4	-0.51	-5.42	-0.49	4.5e-7	Height;
THYM	cis	rs78062588	1.000	rs61300392	chr1:154575685	A/T	cg13098855	chr1:153588927	S100A14	0.58	4.67	0.43	1e-5	Lung cancer;
THYM	cis	rs6918586	0.616	rs1056314	chr6:26114653	G/A	cg03264133	chr6:25882463	NA	-0.64	-4.94	-0.45	3.34e-6	Schizophrenia;
THYM	cis	rs2219968	1.000	rs59541962	chr8:78964111	G/C	cg00738934	chr8:78996279	NA	0.91	9.75	0.71	5.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1843834	0.721	rs4674939	chr2:225613552	G/A	cg10193763	chr2:225306901	NA	-0.45	-4.82	-0.44	5.35e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs6500602	0.527	rs13338333	chr16:4443250	T/C	cg08645402	chr16:4508243	NA	0.7	5.41	0.49	4.67e-7	Schizophrenia;
THYM	cis	rs72627123	1.000	rs2302138	chr14:74363305	C/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.72	4.45	0.42	2.3e-5	Morning vs. evening chronotype;
THYM	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs6539288	0.901	rs2041894	chr12:107350167	A/G	cg26297688	chr12:107349093	C12orf23	-0.47	-4.96	-0.45	3.1e-6	Total body bone mineral density;
THYM	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg24209194	chr3:40518798	ZNF619	0.61	4.79	0.44	6.14e-6	Renal cell carcinoma;
THYM	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg26116260	chr4:7069785	GRPEL1	1.12	11.02	0.75	1.14e-18	Monocyte percentage of white cells;
THYM	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg11871910	chr12:69753446	YEATS4	1.06	9.77	0.71	5.01e-16	Blood protein levels;
THYM	trans	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg11223184	chr2:198033295	ANKRD44	-1.05	-7.79	-0.62	8.16e-12	Depressive symptoms;
THYM	cis	rs765787	0.505	rs12593605	chr15:45497448	T/A	cg24006582	chr15:45444508	DUOX1	0.8	6.48	0.55	3.97e-9	Uric acid levels;
THYM	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1978968	1.000	rs1076542	chr22:18446452	A/G	cg01550578	chr22:18484421	MICAL3	-0.69	-5.3	-0.48	7.41e-7	Presence of antiphospholipid antibodies;
THYM	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg07747251	chr5:1868357	NA	0.68	5.86	0.52	6.67e-8	Cardiovascular disease risk factors;
THYM	cis	rs17598306	0.873	rs2189774	chr7:96605287	A/G	cg23184042	chr7:96615519	DLX6AS	0.61	4.76	0.44	6.82e-6	Radiation response;
THYM	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg18538332	chr22:24372958	LOC391322	-1.05	-13.01	-0.8	8.12e-23	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs10095849	0.576	rs11785708	chr8:39491101	A/G	cg22755526	chr8:38854673	TM2D2;ADAM9	0.65	4.69	0.43	9.19e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg07424592	chr7:64974309	NA	1.04	4.87	0.45	4.36e-6	Diabetic kidney disease;
THYM	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	8.22	0.64	1.04e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	1.25	10.33	0.73	3.19e-17	Platelet count;
THYM	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg14196790	chr5:131705035	SLC22A5	0.5	4.46	0.42	2.27e-5	Breast cancer;Mosquito bite size;
THYM	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg23758822	chr17:41437982	NA	1.16	10.92	0.75	1.82e-18	Menopause (age at onset);
THYM	cis	rs514406	0.861	rs12141260	chr1:53300127	C/T	cg24675658	chr1:53192096	ZYG11B	-0.59	-4.8	-0.44	5.97e-6	Monocyte count;
THYM	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg12419862	chr22:24373484	LOC391322	0.75	7.1	0.59	2.24e-10	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs2289328	0.823	rs35565646	chr15:40660515	G/A	cg13931752	chr15:40660718	DISP2	0.65	5.34	0.48	6.31e-7	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
THYM	cis	rs7359276	1	rs7359276	chr15:78892661	C/T	cg18825076	chr15:78729989	IREB2	-0.57	-4.55	-0.42	1.59e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg08021120	chr3:195498017	MUC4	-0.86	-4.65	-0.43	1.09e-5	Lung disease severity in cystic fibrosis;
THYM	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg06636001	chr8:8085503	FLJ10661	0.61	5.08	0.46	1.84e-6	Systolic blood pressure;
THYM	cis	rs7267979	1.000	rs4815407	chr20:25341478	G/C	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4766646	0.757	rs4766641	chr12:110301492	T/A	cg10794374	chr12:110278745	NA	-0.22	-5.24	-0.47	9.56e-7	Metabolite levels (MHPG);
THYM	cis	rs6838801	0.964	rs4859456	chr4:77562958	T/C	cg01477861	chr4:77609841	SHROOM3	-0.45	-4.52	-0.42	1.79e-5	Cleft lip with or without cleft palate;
THYM	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg18512352	chr11:47633146	NA	-0.53	-6.34	-0.55	7.84e-9	Subjective well-being;
THYM	cis	rs654950	0.776	rs2759254	chr1:42035683	G/C	cg06885757	chr1:42089581	HIVEP3	-0.58	-7.82	-0.63	7.37e-12	Airway imaging phenotypes;
THYM	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg08859206	chr1:53392774	SCP2	0.52	5.48	0.49	3.48e-7	Monocyte count;
THYM	cis	rs11039798	0.688	rs8188953	chr11:48749201	A/T	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs66887589	0.777	rs2017058	chr4:120257739	T/C	cg13609457	chr4:120235615	NA	0.49	4.96	0.45	3.09e-6	Diastolic blood pressure;
THYM	cis	rs1829883	0.835	rs2511961	chr5:98878673	A/G	cg08333243	chr5:99726346	NA	0.5	4.49	0.42	1.98e-5	Hemostatic factors and hematological phenotypes;
THYM	cis	rs763014	0.898	rs12917944	chr16:622565	A/G	cg07343612	chr16:622815	PIGQ	-1.08	-11.34	-0.76	2.36e-19	Height;
THYM	cis	rs6011674	0.808	rs56946612	chr20:61849265	T/G	cg10436333	chr20:61883856	NKAIN4;FLJ16779	-0.81	-4.78	-0.44	6.45e-6	Response to cytadine analogues (cytosine arabinoside);
THYM	cis	rs10857712	0.851	rs7913420	chr10:135213854	C/T	cg19904058	chr10:135279010	LOC619207	-0.56	-5.39	-0.48	5.19e-7	Systemic lupus erythematosus;
THYM	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg22089800	chr15:90895588	ZNF774	0.7	5.65	0.5	1.7e-7	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg26384229	chr12:38710491	ALG10B	-0.79	-7.74	-0.62	1.08e-11	Heart rate;
THYM	cis	rs9814567	1.000	rs9864439	chr3:134298671	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.43	-0.65	3.72e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs12200560	0.505	rs211178	chr6:97074094	T/A	cg06623918	chr6:96969491	KIAA0776	0.76	5.87	0.52	6.31e-8	Coronary heart disease;
THYM	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg11812906	chr14:75593930	NEK9	0.89	8.22	0.64	1.03e-12	Height;
THYM	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg18402987	chr7:1209562	NA	0.72	5.21	0.47	1.1e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs897984	0.520	rs4889534	chr16:30865440	T/C	cg03418659	chr16:31128414	MYST1	0.64	4.68	0.43	9.46e-6	Dementia with Lewy bodies;
THYM	cis	rs6430585	0.527	rs7592050	chr2:136459227	C/T	cg07169764	chr2:136633963	MCM6	-1.02	-9.09	-0.68	1.43e-14	Corneal structure;
THYM	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg11526020	chr17:80870163	TBCD	0.45	4.46	0.42	2.26e-5	Glycated hemoglobin levels;
THYM	cis	rs1692580	0.870	rs262680	chr1:2167149	C/T	cg13918804	chr1:2043761	PRKCZ	-0.52	-4.56	-0.42	1.54e-5	Coronary artery disease;
THYM	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg06634786	chr22:41940651	POLR3H	0.61	4.74	0.44	7.41e-6	Vitiligo;
THYM	cis	rs747334	0.846	rs4553280	chr10:92716591	T/C	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs710216	0.843	rs2297972	chr1:43418026	C/T	cg16738646	chr1:43409193	SLC2A1	0.56	5.0	0.46	2.66e-6	Red cell distribution width;
THYM	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg10053473	chr17:62856997	LRRC37A3	0.89	7.23	0.6	1.19e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg20242066	chr2:136595261	LCT	-0.58	-7.42	-0.61	4.87e-11	Mosquito bite size;
THYM	cis	rs7731657	0.537	rs13355897	chr5:130360622	G/A	cg08523029	chr5:130500466	HINT1	-0.85	-5.98	-0.52	3.88e-8	Fasting plasma glucose;
THYM	cis	rs7953249	0.618	rs7954039	chr12:121398654	A/C	cg14101638	chr12:121416612	HNF1A	-0.48	-5.11	-0.46	1.65e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg01710189	chr8:22454888	PDLIM2	-0.55	-5.72	-0.51	1.21e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg02869364	chr7:1081709	C7orf50	-0.44	-4.83	-0.44	5.2e-6	Longevity;Endometriosis;
THYM	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.79e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs4595586	0.525	rs4768531	chr12:39417754	T/A	cg26384229	chr12:38710491	ALG10B	0.79	5.67	0.5	1.53e-7	Morning vs. evening chronotype;
THYM	cis	rs7760949	0.889	rs9475807	chr6:13934597	T/C	cg27413430	chr6:13925136	RNF182	0.53	4.74	0.44	7.6e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg12863693	chr15:85201151	NMB	0.54	4.47	0.42	2.16e-5	Schizophrenia;
THYM	cis	rs10208649	0.831	rs72906704	chr2:54255225	G/A	cg04546899	chr2:54196757	PSME4	0.68	4.7	0.43	8.91e-6	Body mass index;
THYM	cis	rs17384381	0.834	rs12130380	chr1:85901309	T/C	cg16011679	chr1:85725395	C1orf52	0.75	4.5	0.42	1.89e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.42	-5.09	-0.46	1.78e-6	Longevity;Endometriosis;
THYM	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg18305652	chr10:134549665	INPP5A	0.85	7.73	0.62	1.1e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg26384229	chr12:38710491	ALG10B	0.92	7.55	0.61	2.63e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2235642	0.507	rs9934455	chr16:1579483	C/T	cg19030554	chr16:1822289	NME3;MRPS34;EME2	-0.51	-5.06	-0.46	2.04e-6	Coronary artery disease;
THYM	cis	rs790123	0.553	rs7612991	chr3:122351791	T/C	cg15604389	chr3:122379662	NA	0.56	5.18	0.47	1.26e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs9420	0.925	rs78587207	chr11:57654991	T/G	cg19752551	chr11:57585705	CTNND1	-0.72	-7.34	-0.6	7.26e-11	Schizophrenia;
THYM	cis	rs61931739	0.929	rs3912551	chr12:34076696	C/T	cg06521331	chr12:34319734	NA	0.57	4.68	0.43	9.63e-6	Morning vs. evening chronotype;
THYM	cis	rs2219968	1.000	rs2128017	chr8:78964682	T/G	cg00738934	chr8:78996279	NA	0.91	9.74	0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.71	5.41	0.49	4.78e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg04731861	chr2:219085781	ARPC2	0.53	4.84	0.44	5.09e-6	Colorectal cancer;
THYM	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg01097406	chr16:89675127	NA	0.63	5.68	0.5	1.45e-7	Vitiligo;
THYM	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg02725872	chr8:58115012	NA	-1.11	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs9902453	1.000	rs57411618	chr17:28273052	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	4.69	0.43	9.31e-6	Coffee consumption (cups per day);
THYM	cis	rs2777491	0.874	rs1655556	chr15:41777935	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.11	-12.62	-0.79	5.02e-22	Ulcerative colitis;
THYM	cis	rs2039659	0.679	rs1753771	chr13:86259418	G/A	cg25308322	chr13:86268291	NA	0.64	5.58	0.5	2.3e-7	Blood osmolality (transformed sodium);
THYM	cis	rs2319125	0.683	rs1401049	chr17:64049733	A/G	cg04446870	chr17:64440273	PRKCA	0.5	4.48	0.42	2.12e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs9479482	1.000	rs11155697	chr6:150357423	C/T	cg25797454	chr6:150327115	RAET1K	0.43	4.47	0.42	2.18e-5	Alopecia areata;
THYM	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg08132940	chr7:1081526	C7orf50	-1.04	-6.45	-0.55	4.55e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4638749	0.677	rs7599646	chr2:108852343	C/T	cg06795125	chr2:108905320	SULT1C2	0.34	4.5	0.42	1.9e-5	Blood pressure;
THYM	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg00012203	chr2:219082015	ARPC2	0.63	4.98	0.46	2.82e-6	Pyoderma gangrenosum in inflammatory bowel disease;
THYM	cis	rs4343996	0.870	rs7780027	chr7:3386228	T/C	cg21248987	chr7:3385318	SDK1	-0.46	-5.51	-0.49	3.11e-7	Motion sickness;
THYM	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg05660106	chr1:15850417	CASP9	0.75	5.96	0.52	4.29e-8	Systolic blood pressure;
THYM	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg03388043	chr17:80084554	CCDC57	0.69	5.98	0.52	3.85e-8	Life satisfaction;
THYM	cis	rs6840360	1.000	rs907237	chr4:152601146	T/G	cg22705602	chr4:152727874	NA	-0.59	-6.33	-0.54	8.23e-9	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.56	4.88	0.45	4.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg04362960	chr10:104952993	NT5C2	0.57	4.67	0.43	9.9e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg04455712	chr21:45112962	RRP1B	0.57	5.55	0.49	2.56e-7	Mean corpuscular volume;
THYM	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg26818010	chr10:134567672	INPP5A	-0.91	-7.38	-0.6	5.95e-11	Migraine;
THYM	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg03060546	chr3:49711283	APEH	-0.67	-5.08	-0.46	1.85e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs8067545	0.611	rs2703786	chr17:20156369	T/C	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs28595532	0.764	rs115011450	chr4:119778171	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.76	0.51	1.02e-7	Cannabis dependence symptom count;
THYM	cis	rs736408	0.581	rs3617	chr3:52833805	C/A	cg17372223	chr3:52568218	NT5DC2	0.34	5.33	0.48	6.48e-7	Bipolar disorder;
THYM	cis	rs17443541	0.507	rs971325	chr2:200450294	A/G	cg03741458	chr2:200468445	NA	-0.8	-5.86	-0.52	6.75e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg06026331	chr20:60912101	LAMA5	-0.75	-5.36	-0.48	5.85e-7	Colorectal cancer;
THYM	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg23281280	chr6:28129359	ZNF389	0.67	5.28	0.48	8.33e-7	Depression;
THYM	cis	rs4523957	0.690	rs4790884	chr17:2105299	G/C	cg16513277	chr17:2031491	SMG6	-0.79	-7.76	-0.62	9.62e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1538970	0.781	rs713358	chr1:45988267	C/G	cg05343316	chr1:45956843	TESK2	0.82	5.17	0.47	1.28e-6	Platelet count;
THYM	cis	rs7818345	0.967	rs4412390	chr8:19270143	A/T	cg11303988	chr8:19266685	CSGALNACT1	-0.43	-4.74	-0.44	7.52e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs11048434	0.723	rs2080117	chr12:9138341	C/T	cg26114124	chr12:9217669	LOC144571	0.47	4.66	0.43	1.01e-5	Sjögren's syndrome;
THYM	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Body mass index;
THYM	cis	rs977987	0.806	rs2865530	chr16:75414376	G/T	cg03315344	chr16:75512273	CHST6	0.69	6.02	0.53	3.28e-8	Dupuytren's disease;
THYM	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg09184832	chr6:79620586	NA	-0.57	-4.51	-0.42	1.82e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10899021	0.920	rs61901541	chr11:74317985	T/C	cg25880958	chr11:74394337	NA	-0.77	-4.66	-0.43	1.04e-5	Response to metformin (IC50);
THYM	cis	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.62	0.43	1.23e-5	Obesity-related traits;
THYM	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg04267008	chr7:1944627	MAD1L1	-0.7	-6.53	-0.56	3.25e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs6987853	0.666	rs2923403	chr8:42447748	G/T	cg09913449	chr8:42400586	C8orf40	1.0	10.07	0.72	1.18e-16	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg11266682	chr4:10021025	SLC2A9	0.57	7.84	0.63	6.51e-12	Bone mineral density;
THYM	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg01966878	chr4:90757139	SNCA	-0.63	-5.0	-0.46	2.6e-6	Neuroticism;
THYM	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22857025	chr5:266934	NA	-1.43	-9.54	-0.7	1.58e-15	Breast cancer;
THYM	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg22709100	chr7:91322751	NA	0.61	4.83	0.44	5.26e-6	Breast cancer;
THYM	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg04111992	chr7:158790115	NA	-0.55	-4.94	-0.45	3.41e-6	Facial morphology (factor 20);
THYM	cis	rs10992471	0.729	rs7042335	chr9:95122547	C/T	cg14631576	chr9:95140430	CENPP	-0.95	-10.73	-0.74	4.66e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg24020549	chr11:64937741	SPDYC	-0.46	-4.45	-0.42	2.36e-5	Eosinophil percentage of white cells;
THYM	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg22841779	chr14:105766346	BRF1	-0.48	-6.0	-0.52	3.55e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-5.16	-0.47	1.35e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg07636037	chr3:49044803	WDR6	0.79	6.33	0.54	8.1e-9	Subjective well-being (multi-trait analysis);Menarche (age at onset);
THYM	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg27170947	chr2:26402098	FAM59B	0.58	4.89	0.45	4.18e-6	Gut microbiome composition (summer);
THYM	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg03433033	chr1:76189801	ACADM	0.77	10.22	0.72	5.5e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs427394	0.582	rs274667	chr5:6710771	A/G	cg10857441	chr5:6722123	POLS	0.7	7.46	0.61	3.98e-11	Menopause (age at onset);
THYM	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg14690197	chr8:22456421	C8orf58	0.48	4.68	0.43	9.65e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs12519773	1.000	rs959922	chr5:92450649	C/T	cg18783429	chr5:92414398	NA	-0.48	-4.55	-0.42	1.59e-5	Migraine;
THYM	trans	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs4851266	0.898	rs12615145	chr2:100853116	C/T	cg08017756	chr2:100939284	LONRF2	-0.56	-4.45	-0.42	2.31e-5	Educational attainment;
THYM	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg10523679	chr1:76189770	ACADM	0.85	8.83	0.67	5.33e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg12310025	chr6:25882481	NA	-0.67	-4.64	-0.43	1.1e-5	Height;
THYM	cis	rs997295	0.618	rs3784698	chr15:68007582	G/C	cg26545918	chr15:68124484	LBXCOR1	-0.5	-4.6	-0.43	1.32e-5	Motion sickness;
THYM	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg01191920	chr7:158217561	PTPRN2	0.89	8.56	0.66	1.95e-13	Obesity-related traits;
THYM	cis	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg06521331	chr12:34319734	NA	-1.0	-8.75	-0.67	7.87e-14	Morning vs. evening chronotype;
THYM	cis	rs34638657	0.702	rs62044258	chr16:82199461	C/T	cg09439754	chr16:82129088	HSD17B2	-0.51	-5.1	-0.46	1.74e-6	Lung adenocarcinoma;
THYM	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg13010199	chr12:38710504	ALG10B	-0.6	-5.22	-0.47	1.06e-6	Heart rate;
THYM	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs11696501	0.694	rs6073823	chr20:44256910	G/C	cg11783356	chr20:44313418	WFDC10B	-0.66	-4.52	-0.42	1.77e-5	Brain structure;
THYM	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg10518543	chr12:38710700	ALG10B	0.58	4.6	0.43	1.3e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg17173187	chr15:85201210	NMB	0.56	5.51	0.49	3e-7	Schizophrenia;
THYM	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg15557168	chr22:42548783	NA	-0.59	-4.61	-0.43	1.25e-5	Schizophrenia;
THYM	cis	rs8017423	1.000	rs11622075	chr14:90669894	G/T	cg04239629	chr14:90701769	NA	-0.6	-4.47	-0.42	2.16e-5	Mortality in heart failure;
THYM	cis	rs1994135	0.549	rs2218650	chr12:33734783	A/G	cg10856724	chr12:34555212	NA	-0.7	-5.41	-0.49	4.79e-7	Resting heart rate;
THYM	cis	rs80319144	1.000	rs76136261	chr2:159274969	G/C	cg24986868	chr2:159312599	PKP4;CCDC148	0.57	4.64	0.43	1.13e-5	Restless legs syndrome;
THYM	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-1.2	-5.18	-0.47	1.22e-6	Schizophrenia;
THYM	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg27446573	chr6:127587934	RNF146	1.08	8.91	0.67	3.57e-14	Breast cancer;
THYM	cis	rs1018836	0.774	rs35159732	chr8:91633094	A/G	cg16814680	chr8:91681699	NA	-0.85	-6.94	-0.58	4.76e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7640424	0.929	rs326358	chr3:107822310	C/T	cg09227934	chr3:107805635	CD47	0.53	4.74	0.44	7.62e-6	Body mass index;
THYM	cis	rs2658782	0.654	rs2605623	chr11:93249359	A/G	cg15737290	chr11:93063684	CCDC67	0.98	7.25	0.6	1.1e-10	Pulmonary function decline;
THYM	cis	rs10899021	0.920	rs11236171	chr11:74317518	C/T	cg25880958	chr11:74394337	NA	-0.77	-4.66	-0.43	1.04e-5	Response to metformin (IC50);
THYM	cis	rs478304	0.627	rs11604568	chr11:65511336	G/A	cg27068330	chr11:65405492	SIPA1	-0.95	-8.8	-0.67	6.03e-14	Acne (severe);
THYM	cis	rs72772090	0.539	rs11743410	chr5:96124453	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg08847533	chr14:75593920	NEK9	-0.96	-10.31	-0.73	3.66e-17	Height;
THYM	cis	rs3780378	1.000	rs3780378	chr9:5112288	C/T	cg02405213	chr9:5042618	JAK2	-0.58	-5.13	-0.47	1.54e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg15445000	chr17:37608096	MED1	-0.41	-5.04	-0.46	2.26e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs7487075	0.797	rs10785630	chr12:46880380	G/A	cg11331445	chr12:47219877	SLC38A4	0.5	4.81	0.44	5.64e-6	Itch intensity from mosquito bite;
THYM	cis	rs2299587	0.622	rs12334522	chr8:17889773	G/C	cg18067069	chr8:17937731	ASAH1	-0.6	-4.5	-0.42	1.96e-5	Economic and political preferences;
THYM	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.78	0.44	6.29e-6	Obesity-related traits;
THYM	cis	rs9914988	1.000	rs9916866	chr17:27183155	C/G	cg20469991	chr17:27169893	C17orf63	0.78	5.04	0.46	2.22e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg26384229	chr12:38710491	ALG10B	0.95	7.55	0.61	2.7e-11	Bladder cancer;
THYM	cis	rs11969893	0.850	rs9498418	chr6:101331838	A/T	cg12253828	chr6:101329408	ASCC3	1.2	6.43	0.55	5.21e-9	Economic and political preferences (immigration/crime);
THYM	cis	rs4780401	0.703	rs3190321	chr16:11773662	C/G	cg01061890	chr16:11836724	TXNDC11	-0.61	-4.55	-0.42	1.61e-5	Rheumatoid arthritis;
THYM	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg08048268	chr3:133502702	NA	-0.66	-5.59	-0.5	2.13e-7	Iron status biomarkers;
THYM	trans	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg07211511	chr3:129823064	LOC729375	-1.22	-9.75	-0.71	5.63e-16	Blood pressure (smoking interaction);
THYM	cis	rs6448317	0.520	rs13116411	chr4:24928949	G/A	cg21108841	chr4:24914750	CCDC149	-0.8	-6.99	-0.58	3.71e-10	Heschl's gyrus morphology;
THYM	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg06238570	chr21:40685208	BRWD1	-0.72	-6.28	-0.54	9.9e-9	Menarche (age at onset);
THYM	cis	rs13418717	1.000	rs13394375	chr2:127677701	C/T	cg25501666	chr2:127640322	NA	1.58	6.21	0.54	1.4e-8	Heart failure;
THYM	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg23803603	chr1:2058230	PRKCZ	-0.66	-6.08	-0.53	2.53e-8	Height;
THYM	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.25	10.23	0.72	5.3e-17	Platelet count;
THYM	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg16405210	chr4:1374714	KIAA1530	-0.88	-8.03	-0.64	2.56e-12	Longevity;
THYM	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg07606381	chr6:8435919	SLC35B3	0.59	4.51	0.42	1.85e-5	Motion sickness;
THYM	cis	rs11690935	0.549	rs796839	chr2:172916214	A/C	cg13550731	chr2:172543902	DYNC1I2	0.68	5.56	0.5	2.45e-7	Schizophrenia;
THYM	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg13319975	chr6:146136371	FBXO30	0.67	5.46	0.49	3.72e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03264133	chr6:25882463	NA	-0.81	-6.19	-0.54	1.52e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg00495681	chr13:53174319	NA	1.07	11.25	0.76	3.62e-19	Lewy body disease;
THYM	cis	rs2290159	0.752	rs3773352	chr3:12651982	G/C	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs7695732	0.595	rs2178585	chr4:89891411	A/T	cg17769793	chr4:89976368	FAM13A	-0.5	-5.57	-0.5	2.36e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.24	-0.65	9.17e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg02640540	chr1:67518911	SLC35D1	-0.64	-4.68	-0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg11752832	chr7:134001865	SLC35B4	0.76	5.72	0.51	1.24e-7	Mean platelet volume;
THYM	cis	rs193541	0.509	rs10040512	chr5:122233622	C/T	cg19808643	chr5:122110361	SNX2	-0.65	-5.45	-0.49	4.03e-7	Glucose homeostasis traits;
THYM	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs12291225	0.546	rs11023199	chr11:14394258	A/G	cg05501817	chr11:14380813	RRAS2	-0.79	-6.42	-0.55	5.45e-9	Sense of smell;
THYM	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs13006833	0.668	rs2664253	chr2:191148558	G/A	cg21644426	chr2:191273491	MFSD6	0.66	4.64	0.43	1.1e-5	Urinary metabolites;
THYM	cis	rs919433	0.617	rs10931791	chr2:198573612	A/C	cg00792783	chr2:198669748	PLCL1	-0.77	-5.4	-0.48	4.91e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg20283391	chr11:68216788	NA	-0.71	-5.27	-0.48	8.44e-7	Total body bone mineral density;
THYM	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg18357526	chr6:26021779	HIST1H4A	0.8	6.76	0.57	1.11e-9	Intelligence (multi-trait analysis);
THYM	cis	rs59698941	0.943	rs67162224	chr5:132289372	T/C	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg02269571	chr22:50332266	NA	-0.71	-4.91	-0.45	3.78e-6	Schizophrenia;
THYM	cis	rs654950	0.807	rs61773660	chr1:41993298	C/T	cg06885757	chr1:42089581	HIVEP3	-0.49	-5.98	-0.52	3.83e-8	Airway imaging phenotypes;
THYM	cis	rs11645898	1.000	rs72791115	chr16:72207315	T/C	cg14768367	chr16:72042858	DHODH	-0.67	-4.86	-0.45	4.72e-6	Blood protein levels;
THYM	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg19875535	chr5:140030758	IK	-0.63	-5.69	-0.5	1.43e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4595586	0.505	rs12826314	chr12:39379435	A/C	cg13010199	chr12:38710504	ALG10B	0.61	4.57	0.42	1.49e-5	Morning vs. evening chronotype;
THYM	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg07936489	chr17:37558343	FBXL20	0.81	5.85	0.51	6.81e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs6866344	0.697	rs17184281	chr5:178127563	G/A	cg03877680	chr5:178157825	ZNF354A	0.78	5.25	0.47	9.37e-7	Neutrophil percentage of white cells;
THYM	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	8.57	0.66	1.88e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs478304	0.718	rs61744384	chr11:65387378	T/A	cg17480646	chr11:65405466	SIPA1	-0.73	-6.18	-0.54	1.62e-8	Acne (severe);
THYM	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg09307838	chr4:120376055	NA	0.8	5.77	0.51	9.78e-8	Corneal astigmatism;
THYM	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg00898013	chr13:113819073	PROZ	-0.88	-9.0	-0.68	2.24e-14	Platelet distribution width;
THYM	cis	rs6032067	0.929	rs6017511	chr20:43833132	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs273218	0.573	rs10513033	chr5:53333477	T/C	ch.5.1024479R	chr5:53302184	ARL15	-1.13	-10.0	-0.72	1.68e-16	Migraine;
THYM	cis	rs13315871	0.860	rs17059098	chr3:58255739	G/A	cg00563845	chr3:58318305	PXK	0.61	5.19	0.47	1.18e-6	Cholesterol, total;
THYM	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg20295408	chr7:1910781	MAD1L1	-0.61	-4.85	-0.45	4.9100000000000004e-06	Bipolar disorder and schizophrenia;
THYM	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.16	-8.93	-0.68	3.25e-14	Platelet count;
THYM	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg03651054	chr13:50194643	NA	-0.49	-4.72	-0.44	8.22e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs314370	0.855	rs17883557	chr7:100494949	G/T	cg10426581	chr7:100472382	SRRT	1.13	8.97	0.68	2.57e-14	Resting heart rate;
THYM	cis	rs6988636	1.000	rs11992152	chr8:124189455	T/A	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs2278491	0.502	rs10095889	chr8:117758844	C/T	cg23513447	chr8:117778558	UTP23	-0.75	-5.36	-0.48	5.9e-7	Body mass index;
THYM	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.68	9.03	0.68	1.97e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2239547	0.522	rs2581797	chr3:52972468	C/T	cg11645453	chr3:52864694	ITIH4	-0.28	-4.67	-0.43	1e-5	Schizophrenia;
THYM	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs75059851	0.756	rs11223659	chr11:133844708	G/A	cg14047540	chr11:133829660	NA	-1.09	-7.23	-0.6	1.22e-10	Schizophrenia;
THYM	cis	rs8063160	0.935	rs78800020	chr16:90067136	G/C	cg07984980	chr16:89898383	SPIRE2	1.26	5.08	0.46	1.9e-6	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg20203395	chr5:56204925	C5orf35	-0.71	-4.96	-0.45	3.05e-6	Initial pursuit acceleration;
THYM	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22496380	chr5:211416	CCDC127	-1.39	-8.14	-0.64	1.49e-12	Breast cancer;
THYM	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg26384229	chr12:38710491	ALG10B	-0.61	-4.6	-0.43	1.29e-5	Heart rate;
THYM	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	9.78	0.71	4.77e-16	Platelet count;
THYM	cis	rs6918586	1.000	rs6918586	chr6:26097384	T/C	cg03517284	chr6:25882590	NA	-0.62	-4.64	-0.43	1.11e-5	Schizophrenia;
THYM	cis	rs17253792	0.822	rs17832371	chr14:56162302	C/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs818427	0.684	rs41115	chr5:112175770	G/A	cg04614008	chr5:112630677	MCC	-0.64	-4.6	-0.43	1.31e-5	Total body bone mineral density;
THYM	cis	rs7264396	0.563	rs2425130	chr20:34335059	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.77	-4.81	-0.44	5.72e-6	Total cholesterol levels;
THYM	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03647317	chr4:187891568	NA	-0.83	-9.1	-0.68	1.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.64	-4.59	-0.43	1.35e-5	Aortic root size;
THYM	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg02038168	chr22:39784481	NA	-0.61	-4.79	-0.44	6.24e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9902453	0.845	rs3102556	chr17:28042542	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.85	0.45	4.84e-6	Coffee consumption (cups per day);
THYM	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.97	8.9	0.67	3.72e-14	Chronic sinus infection;
THYM	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg00129232	chr17:37814104	STARD3	0.7	4.93	0.45	3.42e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs12579753	0.871	rs4255611	chr12:82215969	C/A	cg21231944	chr12:82153410	PPFIA2	-0.7	-5.38	-0.48	5.24e-7	Resting heart rate;
THYM	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg06238570	chr21:40685208	BRWD1	0.91	6.67	0.56	1.66e-9	Cognitive function;
THYM	cis	rs6032067	0.714	rs6017527	chr20:43886291	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.58	-6.45	-0.55	4.75e-9	Blood protein levels;
THYM	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg24257776	chr3:47051546	LOC100129354	-0.39	-4.6	-0.43	1.3e-5	Colorectal cancer;
THYM	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	5.03	0.46	2.33e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg04756594	chr16:24857601	SLC5A11	0.79	5.69	0.5	1.4e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4076764	0.846	rs12035840	chr1:163419177	G/C	cg06092702	chr1:163392909	NA	-0.58	-4.92	-0.45	3.58e-6	Motion sickness;
THYM	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	5.67	0.5	1.53e-7	Platelet count;
THYM	cis	rs2229238	0.868	rs72999422	chr1:154514942	G/A	cg21262032	chr1:154437693	IL6R	-0.64	-5.79	-0.51	8.9e-8	Coronary heart disease;
THYM	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg13010199	chr12:38710504	ALG10B	-0.71	-5.59	-0.5	2.18e-7	Heart rate;
THYM	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs7937682	0.663	rs3867466	chr11:111668256	A/C	cg09085632	chr11:111637200	PPP2R1B	1.22	13.43	0.81	1.13e-23	Primary sclerosing cholangitis;
THYM	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg15242686	chr22:24348715	GSTTP1	0.56	5.07	0.46	1.97e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg23758822	chr17:41437982	NA	1.16	10.97	0.75	1.43e-18	Menopause (age at onset);
THYM	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg26769984	chr7:1090371	C7orf50	0.83	5.6	0.5	2.04e-7	Bronchopulmonary dysplasia;
THYM	cis	rs12458462	0.812	rs34583578	chr18:77491070	C/T	cg11879182	chr18:77439856	CTDP1	0.82	7.9	0.63	4.85e-12	Monocyte count;
THYM	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg13695892	chr22:41940480	POLR3H	-0.56	-4.49	-0.42	2e-5	Neuroticism;
THYM	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg07341220	chr16:1583899	IFT140;TMEM204	-0.66	-5.57	-0.5	2.39e-7	Coronary artery disease;
THYM	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03576123	chr11:487126	PTDSS2	-1.29	-6.68	-0.57	1.6e-9	Body mass index;
THYM	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg06636001	chr8:8085503	FLJ10661	0.7	6.09	0.53	2.34e-8	Mood instability;
THYM	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.94	7.73	0.62	1.13e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg10523679	chr1:76189770	ACADM	0.92	10.35	0.73	2.94e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.49	0.49	3.33e-7	Platelet count;
THYM	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg11764359	chr7:65958608	NA	0.64	5.0	0.46	2.62e-6	Aortic root size;
THYM	cis	rs2072510	0.593	rs2660892	chr12:96420978	T/C	cg18817487	chr12:96390143	HAL	0.45	5.47	0.49	3.61e-7	Metabolite levels (small molecules and protein measures);
THYM	cis	rs2742234	0.541	rs10793426	chr10:43745280	G/A	cg06632098	chr10:43605906	RET	0.75	5.01	0.46	2.5e-6	Hirschsprung disease;
THYM	cis	rs10463554	0.927	rs34802	chr5:102427005	T/C	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs7901056	0.901	rs2992335	chr10:26727934	C/G	cg23318538	chr10:26883079	C10orf50	-0.39	-4.96	-0.45	3.05e-6	Lymphocyte counts;
THYM	cis	rs921968	0.541	rs526897	chr2:219433597	C/T	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6815814	0.851	rs17582893	chr4:38886420	G/A	cg06935464	chr4:38784597	TLR10	0.71	4.92	0.45	3.61e-6	Breast cancer;
THYM	cis	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg23682913	chr1:2080710	PRKCZ	0.59	4.7	0.43	8.76e-6	Height;
THYM	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg24060327	chr5:131705240	SLC22A5	-0.76	-5.58	-0.5	2.26e-7	Blood metabolite levels;
THYM	cis	rs2797160	1.000	rs1578794	chr6:126015469	T/C	cg16306078	chr6:126000798	NA	0.54	5.53	0.49	2.75e-7	Endometrial cancer;
THYM	cis	rs12039431	0.706	rs59482985	chr1:37981908	G/A	cg17933807	chr1:38061675	GNL2	-0.77	-5.63	-0.5	1.83e-7	Epithelial ovarian cancer;
THYM	cis	rs2404602	0.735	rs12903874	chr15:76693318	A/T	cg23625390	chr15:77176239	SCAPER	-0.65	-4.7	-0.43	8.68e-6	Blood metabolite levels;
THYM	cis	rs17598306	0.873	rs17657291	chr7:96603943	T/A	cg23184042	chr7:96615519	DLX6AS	0.61	4.76	0.44	6.82e-6	Radiation response;
THYM	cis	rs1403694	0.695	rs67173199	chr3:186432858	G/A	cg12454167	chr3:186435060	KNG1	0.5	6.72	0.57	1.35e-9	Blood protein levels;
THYM	cis	rs6496667	0.779	rs8034045	chr15:90947899	T/C	cg22089800	chr15:90895588	ZNF774	0.71	4.58	0.43	1.39e-5	Rheumatoid arthritis;
THYM	cis	rs11030122	0.702	rs10767713	chr11:3950157	T/C	cg18678763	chr11:4115507	RRM1	-0.43	-5.53	-0.49	2.79e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs17598306	0.873	rs17657291	chr7:96603943	T/A	cg13449377	chr7:96631089	DLX6AS	0.76	4.78	0.44	6.38e-6	Radiation response;
THYM	cis	rs490234	0.902	rs10739663	chr9:128278739	A/G	cg14078157	chr9:128172775	NA	-0.62	-4.98	-0.45	2.85e-6	Mean arterial pressure;
THYM	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg22968622	chr17:43663579	NA	-1.1	-9.99	-0.72	1.7e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg19016782	chr12:123741754	C12orf65	-0.71	-4.66	-0.43	1.05e-5	Neutrophil percentage of white cells;
THYM	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg08968635	chr6:28129556	ZNF389	0.61	4.59	0.43	1.35e-5	Parkinson's disease;
THYM	cis	rs929596	0.793	rs2741045	chr2:234580140	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.87	-6.16	-0.53	1.71e-8	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs55665837	0.559	rs9667144	chr11:14421101	C/T	cg05501817	chr11:14380813	RRAS2	0.76	6.44	0.55	4.82e-9	Vitamin D levels;
THYM	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	5.77	0.51	1.01e-7	Rheumatoid arthritis;
THYM	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg19913688	chr11:428466	ANO9	-0.88	-4.58	-0.42	1.43e-5	Body mass index;
THYM	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.53	4.73	0.44	7.67e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.59	5.3	0.48	7.4e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1747683	0.585	rs72781387	chr10:13355643	G/A	cg25835351	chr10:13388524	SEPHS1	-0.28	-4.81	-0.44	5.58e-6	IgG glycosylation;
THYM	cis	rs6531656	0.663	rs337623	chr4:38673845	A/G	cg24279243	chr4:38676559	KLF3	0.81	7.1	0.59	2.25e-10	Lymphocyte counts;
THYM	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs7607369	0.596	rs10165754	chr2:219287370	A/G	cg02176678	chr2:219576539	TTLL4	-0.69	-5.93	-0.52	4.89e-8	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg24692254	chr21:30365293	RNF160	-0.8	-4.84	-0.44	5.02e-6	Cognitive test performance;
THYM	cis	rs7553864	1.000	rs4551571	chr1:87614244	C/G	cg17420885	chr1:87600446	LOC339524	-0.75	-6.27	-0.54	1.06e-8	Smoking behavior;
THYM	cis	rs72772090	0.539	rs67140788	chr5:96116286	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.76	-4.79	-0.44	6.12e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4631830	0.863	rs2249986	chr10:51521684	T/G	cg16070123	chr10:51489643	NA	-0.52	-4.81	-0.44	5.7e-6	Prostate-specific antigen levels;
THYM	cis	rs7666738	1.000	rs880473	chr4:98922596	C/T	cg03676636	chr4:99064102	C4orf37	0.5	7.59	0.61	2.14e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10435719	0.580	rs13260712	chr8:11782570	A/C	cg21775007	chr8:11205619	TDH	-0.59	-4.55	-0.42	1.56e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs17331151	0.505	rs79993196	chr3:52697566	T/C	cg17372223	chr3:52568218	NT5DC2	0.6	4.7	0.43	8.8e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs10463554	0.667	rs57714862	chr5:102382729	G/C	cg23492399	chr5:102201601	PAM	-0.68	-5.13	-0.47	1.56e-6	Parkinson's disease;
THYM	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	trans	rs9747201	1.000	rs4239020	chr17:80176641	C/T	cg07393940	chr7:158741817	NA	1.1	8.4	0.65	4.38e-13	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs11089937	0.554	rs5995628	chr22:22549168	C/A	cg06866756	chr22:22471216	NA	-0.48	-5.35	-0.48	6.01e-7	Periodontitis (PAL4Q3);
THYM	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg00814883	chr7:100076585	TSC22D4	-1.0	-6.73	-0.57	1.26e-9	Platelet count;
THYM	cis	rs7084921	0.552	rs2862991	chr10:101876736	C/G	cg11344164	chr10:101878520	NA	-0.58	-5.68	-0.5	1.47e-7	Bone mineral density;
THYM	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg05707623	chr12:122985044	ZCCHC8	0.74	4.96	0.45	3.13e-6	Body mass index;
THYM	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22509189	chr2:225307070	NA	-0.89	-7.54	-0.61	2.77e-11	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs2237457	0.543	rs2529387	chr7:50701753	C/T	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.48e-6	Schizophrenia (treatment resistant);
THYM	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg22907277	chr7:1156413	C7orf50	0.87	7.57	0.61	2.43e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg02187348	chr16:89574699	SPG7	0.73	6.1	0.53	2.28e-8	Multiple myeloma (IgH translocation);
THYM	cis	rs2294693	0.947	rs10155663	chr6:40994301	T/G	cg14418226	chr6:40996092	UNC5CL	0.7	6.4	0.55	5.96e-9	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs7599312	0.534	rs7607373	chr2:213409719	G/A	cg16329650	chr2:213403929	ERBB4	0.99	11.42	0.76	1.61e-19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9563576	0.778	rs9316964	chr13:58582895	G/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs4730276	0.674	rs8440	chr7:107561392	G/A	cg23293999	chr7:106826042	HBP1	-0.6	-4.91	-0.45	3.8e-6	Ulcerative colitis;
THYM	cis	rs7107770	1.000	rs4936998	chr11:125096254	C/T	cg07747661	chr11:125106135	PKNOX2	-0.86	-5.3	-0.48	7.57e-7	Photic sneeze reflex;
THYM	cis	rs2637266	0.905	rs34173296	chr10:78343389	C/T	cg18941641	chr10:78392320	NA	0.69	5.55	0.49	2.57e-7	Pulmonary function;
THYM	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg10053473	chr17:62856997	LRRC37A3	0.81	7.07	0.59	2.57e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg02640540	chr1:67518911	SLC35D1	0.59	4.64	0.43	1.09e-5	Lymphocyte percentage of white cells;
THYM	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg24642844	chr7:1081250	C7orf50	-1.14	-6.82	-0.57	8.22e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg06618935	chr21:46677482	NA	-0.97	-8.79	-0.67	6.49e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg07870213	chr5:140052090	DND1	-0.68	-7.44	-0.61	4.53e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs4455778	0.580	rs7796581	chr7:49124966	C/T	cg26309511	chr7:48887640	NA	0.67	5.88	0.52	6.18e-8	Lung cancer in never smokers;
THYM	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.67	-5.23	-0.47	1.01e-6	Tonsillectomy;
THYM	cis	rs9311676	0.656	rs62258127	chr3:58397102	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs13177918	0.626	rs67026795	chr5:149831660	T/C	cg14059543	chr5:149831962	NA	-0.98	-8.37	-0.65	4.9e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs886144	0.628	rs2157908	chr15:91716130	A/G	cg21594043	chr15:92491578	SLCO3A1	0.48	4.64	0.43	1.13e-5	Metabolite levels;
THYM	cis	rs6815814	0.950	rs73236633	chr4:38839319	T/C	cg14665413	chr4:38859728	TLR6	-0.44	-4.47	-0.42	2.15e-5	Breast cancer;
THYM	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg13010199	chr12:38710504	ALG10B	0.64	4.61	0.43	1.25e-5	Morning vs. evening chronotype;
THYM	cis	rs9534288	0.797	rs7338189	chr13:46571035	T/C	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg26354017	chr1:205819088	PM20D1	0.59	4.61	0.43	1.24e-5	Parkinson's disease;
THYM	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg12560992	chr17:57184187	TRIM37	-0.92	-8.68	-0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs1018836	0.700	rs10504894	chr8:91516436	G/A	cg16814680	chr8:91681699	NA	-0.78	-6.91	-0.58	5.56e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs57920188	0.513	rs4290031	chr1:4094701	A/G	cg20703997	chr1:4087676	NA	0.85	5.69	0.5	1.41e-7	Interleukin-17 levels;
THYM	cis	rs7224685	0.569	rs2123841	chr17:4022557	G/A	cg07607921	chr17:4047574	ZZEF1;CYB5D2	0.87	4.72	0.44	8.19e-6	Type 2 diabetes;
THYM	cis	rs9790314	0.875	rs7615592	chr3:160981548	A/C	cg04691961	chr3:161091175	C3orf57	-0.56	-4.53	-0.42	1.69e-5	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06850241	chr22:41845214	NA	-0.57	-5.29	-0.48	7.69e-7	Vitiligo;
THYM	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg21427119	chr20:30132790	HM13	-0.89	-6.3	-0.54	9.12e-9	Mean corpuscular hemoglobin;
THYM	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg02018176	chr4:1364513	KIAA1530	-0.58	-4.62	-0.43	1.19e-5	Obesity-related traits;
THYM	cis	rs6980334	0.906	rs10264658	chr7:137779000	T/C	cg22979093	chr7:137028410	PTN	0.61	4.91	0.45	3.77e-6	Blood metabolite ratios;
THYM	trans	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg25214090	chr10:38739885	LOC399744	0.91	7.93	0.63	4.24e-12	Corneal astigmatism;
THYM	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.92	0.71	2.42e-16	Prudent dietary pattern;
THYM	cis	rs8067545	0.611	rs1373146	chr17:20206675	G/A	cg20830565	chr17:20408647	MGC102966	0.48	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs977987	0.806	rs4888383	chr16:75386349	C/T	cg03315344	chr16:75512273	CHST6	0.72	5.9	0.52	5.66e-8	Dupuytren's disease;
THYM	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs9810089	0.802	rs73222302	chr3:136098085	A/G	cg12473912	chr3:136751656	NA	0.58	4.69	0.43	9.32e-6	Gestational age at birth (child effect);
THYM	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs561341	0.609	rs739800	chr17:30190083	T/A	cg12000587	chr17:30186630	C17orf79	0.5	7.14	0.59	1.84e-10	Hip circumference adjusted for BMI;
THYM	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg25358565	chr5:93447407	FAM172A	1.37	10.94	0.75	1.67e-18	Diabetic retinopathy;
THYM	cis	rs2882877	0.648	rs11682165	chr2:190401523	T/C	cg10752008	chr2:190445175	SLC40A1	0.72	6.14	0.53	1.9e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4767364	0.961	rs10850031	chr12:112771063	T/G	cg10833066	chr12:111807467	FAM109A	0.45	4.91	0.45	3.81e-6	Oral cavity and pharyngeal cancer;
THYM	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg02602264	chr7:1026310	CYP2W1	-0.45	-4.58	-0.43	1.42e-5	Longevity;Endometriosis;
THYM	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs877282	0.898	rs11253344	chr10:765162	C/T	cg10556349	chr10:835070	NA	-0.78	-5.06	-0.46	2.06e-6	Uric acid levels;
THYM	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	trans	rs9951602	0.512	rs12458828	chr18:76648522	C/T	cg02800362	chr5:177631904	HNRNPAB	-1.05	-8.3	-0.65	6.88e-13	Obesity-related traits;
THYM	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg04234412	chr22:24373322	LOC391322	-1.05	-13.31	-0.81	1.97e-23	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs8067545	0.586	rs8080649	chr17:20069677	G/C	cg13482628	chr17:19912719	NA	0.56	4.61	0.43	1.28e-5	Schizophrenia;
THYM	cis	rs4077515	0.967	rs11145874	chr9:139290011	G/A	cg14115884	chr9:139300582	SDCCAG3	0.74	7.5	0.61	3.36e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg08067268	chr2:26466485	HADHB;HADHA	-0.68	-4.87	-0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs7255045	0.700	rs11085818	chr19:12952271	G/A	cg26870725	chr19:12978805	MAST1	-0.62	-4.61	-0.43	1.27e-5	Mean corpuscular volume;
THYM	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	4.81	0.44	5.59e-6	Schizophrenia;
THYM	cis	rs10911251	0.508	rs944970	chr1:183112566	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.66	0.43	1.02e-5	Colorectal cancer;
THYM	cis	rs977987	0.806	rs8050769	chr16:75388434	C/T	cg03315344	chr16:75512273	CHST6	0.72	5.9	0.52	5.66e-8	Dupuytren's disease;
THYM	cis	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.64	0.43	1.12e-5	Obesity-related traits;
THYM	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.62	5.02	0.46	2.45e-6	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7851660	0.805	rs10759981	chr9:100635780	A/G	cg13688889	chr9:100608707	NA	-0.7	-4.86	-0.45	4.55e-6	Strep throat;
THYM	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg21773646	chr17:80085082	CCDC57	0.32	4.5	0.42	1.93e-5	Life satisfaction;
THYM	cis	rs611744	0.967	rs655722	chr8:109197541	A/T	cg21045802	chr8:109455806	TTC35	0.58	5.15	0.47	1.43e-6	Dupuytren's disease;
THYM	cis	rs3741151	1.000	rs111882289	chr11:73053714	T/C	cg12959048	chr11:73096162	RELT	-0.5	-4.78	-0.44	6.38e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg04455712	chr21:45112962	RRP1B	0.54	5.04	0.46	2.22e-6	Mean corpuscular volume;
THYM	cis	rs9858542	0.537	rs2304442	chr3:49322027	A/T	cg00383909	chr3:49044727	WDR6	-0.72	-4.81	-0.44	5.6e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs425277	0.565	rs61775448	chr1:2045376	A/G	cg04315214	chr1:2043799	PRKCZ	0.66	5.55	0.49	2.56e-7	Height;
THYM	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg06481639	chr22:41940642	POLR3H	-0.82	-5.68	-0.5	1.49e-7	Vitiligo;
THYM	cis	rs295140	1.000	rs3769476	chr2:201181428	T/C	cg04283868	chr2:201171347	SPATS2L	0.74	5.53	0.49	2.81e-7	QT interval;
THYM	cis	rs12935418	0.583	rs2549852	chr16:81026015	G/A	cg16651780	chr16:81037892	C16orf61	-0.84	-6.56	-0.56	2.82e-9	Mean corpuscular volume;
THYM	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg00129232	chr17:37814104	STARD3	-0.73	-4.98	-0.45	2.87e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs11811982	0.655	rs7547092	chr1:227413438	T/C	cg09853570	chr1:228403422	OBSCN	1.21	4.67	0.43	9.81e-6	Optic disc area;
THYM	cis	rs9361491	0.608	rs4706069	chr6:79471568	T/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.88e-5	Intelligence (multi-trait analysis);
THYM	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.29	-0.48	7.75e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg11812906	chr14:75593930	NEK9	-0.77	-6.77	-0.57	1.07e-9	Height;
THYM	cis	rs2820651	0.614	rs55691140	chr10:1491025	G/A	cg13720710	chr10:1452970	ADARB2	0.79	5.03	0.46	2.28e-6	Migraine with aura;
THYM	cis	rs4940575	0.679	rs1545812	chr18:60832041	G/A	cg20947866	chr18:61143580	SERPINB5	0.9	5.36	0.48	5.72e-7	Breast cancer;
THYM	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg21433313	chr16:3507492	NAT15	0.82	9.6	0.7	1.2e-15	Tuberculosis;
THYM	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg18252515	chr7:66147081	NA	-1.65	-9.03	-0.68	1.94e-14	Diabetic kidney disease;
THYM	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg03161606	chr19:29218774	NA	0.59	4.75	0.44	7.25e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs860818	1.000	rs6955934	chr7:23251499	G/T	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs4642101	0.662	rs9874893	chr3:12833079	C/G	cg05775895	chr3:12838266	CAND2	1.08	10.33	0.73	3.32e-17	QRS complex (12-leadsum);
THYM	cis	rs4836694	0.574	rs3824542	chr9:132936132	C/T	cg13414629	chr9:132935646	FREQ	0.75	5.17	0.47	1.27e-6	Alzheimer's disease (cognitive decline);
THYM	cis	rs7845219	0.539	rs713113	chr8:95877787	C/T	cg16049864	chr8:95962084	TP53INP1	0.63	5.64	0.5	1.78e-7	Type 2 diabetes;
THYM	cis	rs3781426	1.000	rs10444192	chr10:126714166	C/T	cg04494136	chr10:126703576	CTBP2	-0.39	-5.24	-0.47	9.58e-7	Height;
THYM	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.34	-0.65	5.7e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg03684893	chr10:554711	DIP2C	0.7	6.18	0.54	1.56e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.71	6.48	0.55	4.1e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7833986	0.501	rs9650314	chr8:56903610	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	6.4	0.55	5.76e-9	Height;
THYM	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg08968635	chr6:28129556	ZNF389	0.66	5.19	0.47	1.21e-6	Depression;
THYM	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg00012203	chr2:219082015	ARPC2	0.69	5.87	0.52	6.36e-8	Colorectal cancer;
THYM	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg22467129	chr15:76604101	ETFA	-0.56	-5.37	-0.48	5.47e-7	Blood metabolite levels;
THYM	cis	rs3806843	0.676	rs778591	chr5:140025484	G/A	cg19875535	chr5:140030758	IK	-0.58	-5.14	-0.47	1.49e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs62244186	0.659	rs9855433	chr3:44468065	C/A	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.46	-4.81	-0.44	5.72e-6	Depressive symptoms;
THYM	cis	rs4499344	0.730	rs369859	chr19:33104305	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.61	0.62	2.02e-11	Mean platelet volume;
THYM	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg06238570	chr21:40685208	BRWD1	-0.97	-9.35	-0.69	4.03e-15	Cognitive function;
THYM	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg27494647	chr7:150038898	RARRES2	0.44	5.51	0.49	3.09e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6768930	0.509	rs11926924	chr3:57799360	A/C	cg24033633	chr3:57945695	NA	-0.4	-5.7	-0.5	1.35e-7	Obesity-related traits;
THYM	cis	rs9826463	0.582	rs73238186	chr3:142141180	A/C	cg20824294	chr3:142316082	PLS1	0.76	5.3	0.48	7.53e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.77	7.38	0.6	6.04e-11	Lymphocyte counts;
THYM	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg14768367	chr16:72042858	DHODH	0.65	5.08	0.46	1.89e-6	Fibrinogen levels;
THYM	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg17063962	chr7:91808500	NA	1.11	12.32	0.78	2.06e-21	Breast cancer;
THYM	cis	rs4866334	1.000	rs76533277	chr5:18488162	G/A	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs4499344	0.633	rs259246	chr19:33146154	G/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.92	7.75	0.62	1.02e-11	Mean platelet volume;
THYM	cis	rs790123	0.692	rs790126	chr3:122387655	G/A	cg15604389	chr3:122379662	NA	0.58	4.8	0.44	5.91e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.38	-0.48	5.36e-7	Menopause (age at onset);
THYM	cis	rs7078219	1.000	rs7078219	chr10:101274365	A/G	cg17888390	chr10:101282816	NA	0.5	4.78	0.44	6.28e-6	Dental caries;
THYM	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg25358565	chr5:93447407	FAM172A	1.43	10.15	0.72	8.05e-17	Diabetic retinopathy;
THYM	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.67	5.5	0.49	3.15e-7	Blood metabolite levels;
THYM	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg18252515	chr7:66147081	NA	-0.63	-4.69	-0.43	8.99e-6	Aortic root size;
THYM	cis	rs9393777	0.513	rs34388707	chr6:27050396	A/G	cg12292205	chr6:26970375	C6orf41	-0.97	-4.68	-0.43	9.51e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg12165864	chr7:66369176	NA	-0.79	-6.01	-0.52	3.47e-8	Corneal structure;
THYM	cis	rs7188861	0.603	rs2113260	chr16:11455993	C/T	cg00044050	chr16:11439710	C16orf75	0.88	6.35	0.55	7.42e-9	HDL cholesterol;
THYM	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9486719	0.895	rs4486019	chr6:96883814	T/C	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3780378	0.682	rs7861755	chr9:5273180	C/T	cg02405213	chr9:5042618	JAK2	-0.6	-5.22	-0.47	1.04e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs9902453	0.967	rs8067576	chr17:28444254	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	4.6	0.43	1.33e-5	Coffee consumption (cups per day);
THYM	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg06074448	chr4:187884817	NA	1.02	13.69	0.81	3.27e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg24209194	chr3:40518798	ZNF619	0.62	4.94	0.45	3.3e-6	Renal cell carcinoma;
THYM	cis	rs7172677	1.000	rs1806794	chr15:75422940	A/G	cg09165964	chr15:75287851	SCAMP5	-0.59	-4.5	-0.42	1.95e-5	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs1178127	0.719	rs1178166	chr7:18790781	A/G	cg13420273	chr7:18810212	HDAC9	0.52	4.62	0.43	1.19e-5	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs9914988	0.619	rs34580233	chr17:27317935	A/T	cg26182037	chr17:27055700	NEK8	0.84	4.94	0.45	3.29e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs539096	0.500	rs803678	chr1:44350898	G/T	cg12908607	chr1:44402522	ARTN	-0.6	-5.36	-0.48	5.85e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg21138405	chr5:131827807	IRF1	0.87	9.49	0.7	2.01e-15	Asthma (sex interaction);
THYM	cis	rs9880211	0.563	rs67589653	chr3:135811574	T/C	cg21827317	chr3:136751795	NA	-0.71	-5.16	-0.47	1.33e-6	Body mass index;Height;
THYM	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.09	0.64	1.91e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg24675658	chr1:53192096	ZYG11B	-0.67	-5.26	-0.47	8.84e-7	Monocyte count;
THYM	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg07532245	chr17:28927093	LRRC37B2	0.71	4.48	0.42	2.04e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2970992	0.764	rs7558261	chr2:101324632	A/T	cg01042948	chr2:101319752	NA	0.61	6.03	0.53	3.07e-8	Educational attainment;
THYM	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg11494091	chr17:61959527	GH2	-0.69	-6.49	-0.55	3.83e-9	Height;
THYM	cis	rs6456156	0.805	rs6909252	chr6:167527097	C/T	cg09487078	chr6:167525398	CCR6	-0.44	-4.92	-0.45	3.63e-6	Primary biliary cholangitis;
THYM	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs9486719	0.843	rs3860229	chr6:97036559	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-4.84	-0.44	5.06e-6	Migraine;Coronary artery disease;
THYM	cis	rs4660456	0.572	rs7519348	chr1:41160204	C/T	cg11417323	chr1:41160271	NFYC	-0.41	-4.47	-0.42	2.18e-5	Platelet count;
THYM	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2133450	0.712	rs17697853	chr3:7366195	A/G	cg19930620	chr3:7340148	GRM7	0.48	4.58	0.43	1.4e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg11752832	chr7:134001865	SLC35B4	0.65	4.58	0.43	1.41e-5	Mean platelet volume;
THYM	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg00256281	chr22:41985642	PMM1	0.62	4.78	0.44	6.4e-6	Vitiligo;
THYM	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg17328964	chr8:145687451	CYHR1	-0.86	-8.86	-0.67	4.52e-14	Age at first birth;
THYM	cis	rs763014	0.500	rs11865749	chr16:717971	C/G	cg27436995	chr16:743998	FBXL16	-0.54	-4.57	-0.42	1.46e-5	Height;
THYM	cis	rs11760633	0.527	rs67845389	chr7:1824534	A/C	cg27050990	chr7:2629313	IQCE	0.65	4.82	0.44	5.54e-6	Coronary artery disease;
THYM	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6087990	0.835	rs4911106	chr20:31331330	A/G	cg13636640	chr20:31349939	DNMT3B	0.92	9.68	0.7	8.12e-16	Ulcerative colitis;
THYM	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg23815491	chr16:72088622	HP	0.81	6.46	0.55	4.54e-9	Fibrinogen levels;
THYM	cis	rs73787773	0.867	rs73787775	chr5:111472611	C/A	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.88	-4.76	-0.44	6.87e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7200543	0.890	rs4985155	chr16:15129459	A/G	cg01933576	chr16:15083564	PDXDC1	-0.96	-8.15	-0.64	1.45e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-6.63	-0.56	2.01e-9	Schizophrenia;
THYM	cis	rs28595532	0.920	rs114581578	chr4:119756404	C/T	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs9902453	0.765	rs34585141	chr17:28336432	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.22	-0.54	1.3e-8	Coffee consumption (cups per day);
THYM	cis	rs7119	0.717	rs11635567	chr15:77819515	A/G	cg27398640	chr15:77910606	LINGO1	-0.56	-5.61	-0.5	2.03e-7	Type 2 diabetes;
THYM	cis	rs3741151	0.686	rs11822984	chr11:73261467	A/C	cg12959048	chr11:73096162	RELT	-0.52	-4.62	-0.43	1.21e-5	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2730245	0.527	rs2730237	chr7:158706166	A/G	cg01219135	chr7:158766336	NA	0.56	4.49	0.42	2.01e-5	Height;
THYM	cis	rs4750440	0.585	rs35982189	chr10:14029875	T/C	cg27542038	chr10:14027202	FRMD4A	-0.56	-4.53	-0.42	1.68e-5	Adiponectin levels;
THYM	cis	rs7078219	0.543	rs7095491	chr10:101274058	A/G	cg04972745	chr10:101287846	NA	-0.52	-4.8	-0.44	5.8e-6	Dental caries;
THYM	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.16	-0.75	5.56e-19	Primary sclerosing cholangitis;
THYM	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg13147721	chr7:65941812	NA	-1.16	-7.64	-0.62	1.7e-11	Diabetic kidney disease;
THYM	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg26384229	chr12:38710491	ALG10B	0.7	6.22	0.54	1.31e-8	Morning vs. evening chronotype;
THYM	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg06618935	chr21:46677482	NA	-0.96	-7.89	-0.63	5.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg06219351	chr7:158114137	PTPRN2	0.69	7.04	0.59	2.93e-10	Calcium levels;
THYM	cis	rs7246657	0.943	rs7246993	chr19:37890154	C/T	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.26	4.48	0.42	2.06e-5	Obesity-related traits;
THYM	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs12579753	1.000	rs7963577	chr12:82174115	T/C	cg21231944	chr12:82153410	PPFIA2	-0.69	-5.26	-0.47	8.95e-7	Resting heart rate;
THYM	cis	rs4866334	1.000	rs77766662	chr5:18485586	A/C	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg01097406	chr16:89675127	NA	-0.55	-4.72	-0.44	8.28e-6	Vitiligo;
THYM	cis	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-4.46	-0.42	2.22e-5	Neuroticism;
THYM	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg00898013	chr13:113819073	PROZ	0.8	8.11	0.64	1.74e-12	Platelet distribution width;
THYM	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg11266682	chr4:10021025	SLC2A9	0.54	6.39	0.55	6e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7942486	0.895	rs11022722	chr11:13270538	C/T	cg13286116	chr11:13302098	ARNTL	-0.72	-8.02	-0.64	2.79e-12	Neuroticism;
THYM	cis	rs8013055	0.699	rs66798104	chr14:105987782	C/G	cg04429589	chr14:105992532	TMEM121	-0.5	-5.53	-0.49	2.83e-7	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg00495681	chr13:53174319	NA	0.63	5.75	0.51	1.07e-7	Lewy body disease;
THYM	cis	rs901683	1.000	rs9422654	chr10:46051401	G/A	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg07402062	chr16:89894098	SPIRE2	0.48	4.66	0.43	1.05e-5	Vitiligo;
THYM	cis	rs7523273	0.565	rs2488248	chr1:207899682	C/T	cg22525895	chr1:207977042	MIR29B2	-0.53	-5.08	-0.46	1.91e-6	Schizophrenia;
THYM	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg20387954	chr3:183756860	HTR3D	0.53	5.08	0.46	1.85e-6	Anterior chamber depth;
THYM	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg22764044	chr5:178986830	RUFY1	0.52	5.26	0.47	8.97e-7	Lung cancer;
THYM	cis	rs7980799	0.711	rs1482993	chr12:33594515	G/A	cg10856724	chr12:34555212	NA	0.62	4.53	0.42	1.7e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg01966878	chr4:90757139	SNCA	-0.65	-5.17	-0.47	1.27e-6	Neuroticism;
THYM	cis	rs2970992	0.692	rs7558366	chr2:101324705	T/C	cg01042948	chr2:101319752	NA	0.57	5.4	0.48	4.97e-7	Educational attainment;
THYM	cis	rs12348691	0.503	rs7048394	chr9:100605433	T/C	cg13688889	chr9:100608707	NA	-0.9	-6.12	-0.53	2.06e-8	Alopecia areata;
THYM	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg02487422	chr3:49467188	NICN1	-0.6	-4.53	-0.42	1.72e-5	Resting heart rate;
THYM	cis	rs17744026	0.526	rs1453633	chr11:123761571	C/G	cg00079598	chr11:123676903	OR6M1	-0.48	-4.45	-0.42	2.3e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg07636037	chr3:49044803	WDR6	0.93	9.44	0.7	2.54e-15	Parkinson's disease;
THYM	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg02493740	chr2:85810744	VAMP5	-0.64	-5.05	-0.46	2.12e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs12600053	0.658	rs4783076	chr16:84848220	T/C	cg09249803	chr16:84846936	NA	0.47	5.08	0.46	1.86e-6	Asthma (childhood onset);
THYM	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg22764044	chr5:178986830	RUFY1	0.6	5.99	0.52	3.7e-8	Lung cancer;
THYM	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg05932139	chr16:680872	WFIKKN1	-0.59	-4.84	-0.44	5.07e-6	Height;
THYM	cis	rs926938	0.520	rs4140445	chr1:115291978	T/C	cg12756093	chr1:115239321	AMPD1	-0.6	-4.89	-0.45	4.06e-6	Autism;
THYM	cis	rs4509693	0.765	rs10786604	chr10:102495302	C/G	cg24127310	chr10:102502104	NA	1.24	9.04	0.68	1.9e-14	Alzheimer's disease;
THYM	cis	rs2985684	0.846	rs4476096	chr14:50019391	A/C	cg02151108	chr14:50098012	C14orf104	-0.75	-6.31	-0.54	8.87e-9	Carotid intima media thickness;
THYM	cis	rs7319311	0.565	rs9588148	chr13:111021081	G/T	cg06243866	chr13:111019493	COL4A2	0.69	4.51	0.42	1.86e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs747334	0.846	rs11186390	chr10:92717117	C/T	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs662064	0.962	rs2781230	chr1:10563717	G/A	cg20482658	chr1:10539492	PEX14	0.5	6.01	0.52	3.45e-8	Asthma;
THYM	trans	rs877282	1.000	rs11253363	chr10:771891	A/G	cg22713356	chr15:30763199	NA	1.26	10.68	0.74	5.76e-18	Uric acid levels;
THYM	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg26818010	chr10:134567672	INPP5A	0.94	7.59	0.61	2.22e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4455778	0.501	rs10250970	chr7:49052491	T/C	cg26309511	chr7:48887640	NA	0.63	5.5	0.49	3.13e-7	Lung cancer in never smokers;
THYM	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs11771526	0.901	rs41519845	chr7:32315443	A/T	cg13207630	chr7:32358064	NA	0.84	5.28	0.48	8.15e-7	Body mass index;
THYM	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg16482183	chr6:26056742	HIST1H1C	0.98	6.08	0.53	2.5e-8	Iron status biomarkers;
THYM	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg06532163	chr17:45867833	NA	0.66	6.75	0.57	1.17e-9	IgG glycosylation;
THYM	cis	rs7342694	0.965	rs12918486	chr16:81906626	T/A	cg08344351	chr16:81507328	CMIP	-0.34	-4.5	-0.42	1.93e-5	Coronary artery disease;
THYM	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg03476357	chr21:30257390	N6AMT1	0.6	4.57	0.42	1.45e-5	Dental caries;
THYM	cis	rs736801	0.521	rs41525648	chr5:131827775	A/G	cg21138405	chr5:131827807	IRF1	-0.71	-7.78	-0.62	8.79e-12	Breast cancer;Mosquito bite size;
THYM	cis	rs684232	0.644	rs2657613	chr17:623902	T/C	cg15660573	chr17:549704	VPS53	-0.82	-7.34	-0.6	7.14e-11	Prostate cancer;
THYM	cis	rs59698941	0.943	rs67806898	chr5:132296771	A/G	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg17143192	chr8:8559678	CLDN23	0.61	4.8	0.44	5.93e-6	Mood instability;
THYM	cis	rs10411161	0.702	rs8110461	chr19:52383569	A/C	cg25361850	chr19:52391789	ZNF577	0.72	4.96	0.45	3.09e-6	Breast cancer;
THYM	cis	rs72827839	0.846	rs41280120	chr17:46114692	C/G	cg23391107	chr17:45924227	SP6	0.79	5.42	0.49	4.55e-7	Ease of getting up in the morning;
THYM	cis	rs7187994	0.636	rs36081182	chr16:84772534	G/A	cg26765084	chr16:85018922	ZDHHC7	-0.48	-4.5	-0.42	1.94e-5	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg24531977	chr5:56204891	C5orf35	-1.03	-8.64	-0.66	1.34e-13	Initial pursuit acceleration;
THYM	cis	rs485842	1.000	rs579807	chr11:96026073	G/T	cg23866687	chr11:96026956	MAML2	0.45	6.3	0.54	9.23e-9	Corneal astigmatism;
THYM	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg26384229	chr12:38710491	ALG10B	0.97	7.38	0.6	5.91e-11	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg17366294	chr4:99064904	C4orf37	0.57	6.82	0.57	8.42e-10	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg18335740	chr13:41363409	SLC25A15	0.77	8.15	0.64	1.49e-12	Lewy body disease;
THYM	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs2229238	0.911	rs73023331	chr1:154508210	G/A	cg21262032	chr1:154437693	IL6R	-0.63	-5.65	-0.5	1.68e-7	Coronary heart disease;
THYM	cis	rs870825	0.587	rs28454955	chr4:185632701	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs911119	1.000	rs6048956	chr20:23609301	C/T	cg16589663	chr20:23618590	CST3	0.77	4.71	0.44	8.31e-6	Chronic kidney disease;
THYM	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg11335335	chr11:637885	DRD4	-0.63	-5.11	-0.46	1.64e-6	Systemic lupus erythematosus;
THYM	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg10377582	chr12:51612794	POU6F1	-0.67	-4.8	-0.44	5.83e-6	Cisplatin-induced ototoxicity;
THYM	cis	rs7246967	0.673	rs7248107	chr19:22878529	G/T	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg23711669	chr6:146136114	FBXO30	-0.92	-9.14	-0.68	1.15e-14	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs877282	0.898	rs12358966	chr10:758703	A/G	cg22713356	chr15:30763199	NA	1.39	11.11	0.75	7.34e-19	Uric acid levels;
THYM	trans	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Bladder cancer;
THYM	cis	rs6032067	0.929	rs17424696	chr20:43810734	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.58	-0.56	2.55e-9	Blood protein levels;
THYM	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.61	-0.43	1.27e-5	Type 2 diabetes;
THYM	cis	rs929596	0.785	rs11695484	chr2:234654449	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.96	-7.96	-0.63	3.58e-12	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg16060761	chr17:80687452	NA	0.61	4.86	0.45	4.7e-6	Glycated hemoglobin levels;
THYM	cis	rs13256369	0.802	rs12153	chr8:8560909	G/C	cg17143192	chr8:8559678	CLDN23	0.93	6.98	0.58	3.88e-10	Obesity-related traits;
THYM	cis	rs36051895	0.632	rs7036536	chr9:5181610	T/C	cg02405213	chr9:5042618	JAK2	-1.01	-11.19	-0.75	4.95e-19	Pediatric autoimmune diseases;
THYM	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg15693483	chr7:1102177	C7orf50	0.53	6.19	0.54	1.52e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg04602696	chr16:88846723	FAM38A	-0.69	-5.28	-0.48	8.15e-7	Plateletcrit;
THYM	cis	rs2219968	0.525	rs7819368	chr8:78872458	A/G	cg00738934	chr8:78996279	NA	0.6	4.94	0.45	3.35e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg05973401	chr12:123451056	ABCB9	0.7	4.6	0.43	1.28e-5	Neutrophil percentage of white cells;
THYM	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs3820068	0.544	rs7551750	chr1:16035008	T/C	cg27534772	chr1:16042836	PLEKHM2	0.51	5.25	0.47	9.14e-7	Systolic blood pressure;
THYM	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg01017244	chr2:74357527	NA	1.03	8.95	0.68	2.9e-14	Gestational age at birth (maternal effect);
THYM	cis	rs7942486	0.862	rs1351521	chr11:13268494	C/T	cg13286116	chr11:13302098	ARNTL	-0.72	-7.98	-0.63	3.36e-12	Neuroticism;
THYM	cis	rs7487075	0.780	rs12320197	chr12:46738883	A/G	cg11146691	chr12:47219737	SLC38A4	0.45	4.46	0.42	2.22e-5	Itch intensity from mosquito bite;
THYM	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg10792982	chr14:105748885	BRF1	0.74	7.57	0.61	2.45e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs73086581	1.000	rs6052209	chr20:3961747	G/A	cg02187196	chr20:3869020	PANK2	0.5	5.62	0.5	1.92e-7	Response to antidepressants in depression;
THYM	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg06481639	chr22:41940642	POLR3H	-0.84	-5.93	-0.52	4.87e-8	Vitiligo;
THYM	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg10515332	chr4:99064459	C4orf37	0.57	4.49	0.42	1.98e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg01616529	chr11:638424	DRD4	-0.75	-5.53	-0.49	2.83e-7	Systemic lupus erythematosus;
THYM	cis	rs7172809	0.524	rs4886857	chr15:77576567	T/C	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs9364687	0.639	rs13199835	chr6:163965150	G/C	cg01639524	chr6:163818125	NA	0.49	4.85	0.45	4.9e-6	Body mass index;
THYM	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg27588902	chr6:42928151	GNMT	-0.48	-4.62	-0.43	1.19e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs4654899	0.897	rs7545133	chr1:21206143	T/G	cg01072550	chr1:21505969	NA	0.7	6.49	0.55	3.83e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs7719624	0.870	rs10042825	chr5:135396084	A/T	cg12897067	chr5:135418308	NA	0.57	4.73	0.44	7.71e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs1823778	0.609	rs12968104	chr18:67650781	G/C	cg12929678	chr18:67624393	CD226	1.3	4.63	0.43	1.14e-5	Mean platelet volume;
THYM	cis	rs425277	0.585	rs2222217	chr1:2063164	G/A	cg13918804	chr1:2043761	PRKCZ	0.89	8.94	0.68	2.99e-14	Height;
THYM	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg09462578	chr12:12878428	APOLD1	-0.91	-5.39	-0.48	5.01e-7	Systemic lupus erythematosus;
THYM	cis	rs684232	0.666	rs2254134	chr17:628664	A/G	cg15660573	chr17:549704	VPS53	-0.84	-7.41	-0.61	5.16e-11	Prostate cancer;
THYM	cis	rs4474465	0.831	rs7121299	chr11:78189133	G/T	cg19901956	chr11:77921274	USP35	-0.61	-4.57	-0.42	1.47e-5	Alzheimer's disease (survival time);
THYM	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg14675211	chr2:100938903	LONRF2	0.77	8.32	0.65	6.49e-13	Intelligence (multi-trait analysis);
THYM	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg08847533	chr14:75593920	NEK9	-1.01	-11.32	-0.76	2.63e-19	Height;
THYM	cis	rs11741688	0.547	rs2856353	chr5:178405941	T/C	cg06875832	chr5:178980927	RUFY1	-0.48	-5.23	-0.47	9.94e-7	Sleep duration;
THYM	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg16615211	chr3:44902933	MIR564;TMEM42	0.49	5.08	0.46	1.9e-6	Depressive symptoms;
THYM	cis	rs2069036	1.000	rs4307622	chr10:16102103	G/T	cg26633223	chr10:15133461	NA	0.71	5.04	0.46	2.19e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg00908189	chr16:619842	PIGQ	1.02	9.27	0.69	6.03e-15	Height;
THYM	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg13010199	chr12:38710504	ALG10B	0.74	5.91	0.52	5.32e-8	Heart rate;
THYM	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg13683864	chr3:40499215	RPL14	-1.03	-10.89	-0.75	2.13e-18	Renal cell carcinoma;
THYM	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg18904891	chr8:8559673	CLDN23	0.6	5.1	0.46	1.77e-6	Joint mobility (Beighton score);
THYM	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.72	0.51	1.23e-7	Lung cancer in ever smokers;
THYM	cis	rs13040088	0.872	rs2295481	chr20:61574727	C/T	cg23096297	chr20:61557774	DIDO1	1.09	7.51	0.61	3.19e-11	Menopause (age at onset);
THYM	cis	rs713587	0.563	rs7605335	chr2:25109317	G/A	cg01884057	chr2:25150051	NA	0.64	6.32	0.54	8.32e-9	Body mass index in non-asthmatics;
THYM	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg14074117	chr16:1909714	C16orf73	-0.77	-5.83	-0.51	7.59e-8	Ankle injury;
THYM	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03264133	chr6:25882463	NA	0.68	5.22	0.47	1.03e-6	Blood metabolite levels;
THYM	cis	rs67385638	1.000	rs11036474	chr11:5275178	T/C	cg12559170	chr11:5275217	HBG2	0.83	7.72	0.62	1.18e-11	Hemoglobin levels;
THYM	cis	rs12956009	0.583	rs35970525	chr18:44882625	C/T	cg19077165	chr18:44547161	KATNAL2	-0.49	-4.7	-0.43	8.81e-6	Educational attainment (years of education);
THYM	cis	rs2282300	0.739	rs1222208	chr11:30361377	A/C	cg22891988	chr11:30607959	MPPED2	-0.73	-4.69	-0.43	9.12e-6	Morning vs. evening chronotype;
THYM	cis	rs6430585	0.941	rs60963894	chr2:136539670	T/G	cg23851026	chr2:136556271	LCT	0.64	5.85	0.51	6.99e-8	Corneal structure;
THYM	cis	rs4654899	0.795	rs61309203	chr1:21118489	A/T	cg01072550	chr1:21505969	NA	-0.68	-5.84	-0.51	7.16e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs2737265	0.723	rs2178951	chr8:116659534	A/G	cg04656070	chr8:116661063	TRPS1	-0.56	-6.48	-0.55	4.03e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Immature fraction of reticulocytes;
THYM	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg02887458	chr19:19495540	GATAD2A	-0.47	-4.95	-0.45	3.26e-6	Bipolar disorder;
THYM	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.71	-5.73	-0.51	1.15e-7	Systemic lupus erythematosus;
THYM	trans	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg10856724	chr12:34555212	NA	-1.01	-9.32	-0.69	4.76e-15	Bladder cancer;
THYM	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.92	-6.03	-0.53	3.11e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7772486	0.719	rs7753770	chr6:146066161	G/A	cg23711669	chr6:146136114	FBXO30	-0.97	-10.49	-0.73	1.45e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs870825	0.929	rs870822	chr4:185588200	C/T	cg04058563	chr4:185651563	MLF1IP	0.89	6.07	0.53	2.63e-8	Blood protein levels;
THYM	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs4866334	1.000	rs74805322	chr5:18487623	C/A	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs10214930	0.957	rs2057998	chr7:27796521	A/G	cg04422003	chr7:28448295	CREB5	-0.62	-4.62	-0.43	1.19e-5	Hypospadias;
THYM	cis	rs2921036	0.505	rs35190619	chr8:8361823	A/C	cg06636001	chr8:8085503	FLJ10661	-0.67	-5.37	-0.48	5.67e-7	Neuroticism;
THYM	cis	rs919433	0.679	rs1902249	chr2:198521356	T/C	cg05783139	chr2:198650985	BOLL	0.66	4.98	0.46	2.78e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg08000102	chr2:233561755	GIGYF2	0.68	5.97	0.52	4.08e-8	Coronary artery disease;
THYM	cis	rs2777491	0.957	rs919961	chr15:41651721	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.08	-11.71	-0.77	3.97e-20	Ulcerative colitis;
THYM	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg20891283	chr12:69753455	YEATS4	0.74	6.02	0.53	3.22e-8	Blood protein levels;
THYM	cis	rs7100689	0.646	rs7081889	chr10:82165427	C/A	cg09936400	chr10:82049201	MAT1A	0.42	4.72	0.44	8.06e-6	Post bronchodilator FEV1;
THYM	cis	rs7429990	0.896	rs7427648	chr3:48158239	C/T	cg02219026	chr3:48282209	ZNF589	0.59	4.46	0.42	2.23e-5	Educational attainment (years of education);
THYM	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg04772025	chr11:68637568	NA	0.58	6.1	0.53	2.33e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs28595532	0.688	rs116173135	chr4:119721949	C/T	cg21605333	chr4:119757512	SEC24D	1.61	6.33	0.54	8.03e-9	Cannabis dependence symptom count;
THYM	cis	rs4919044	0.866	rs11187263	chr10:94816817	T/C	cg05127821	chr10:94822908	CYP26C1	-1.21	-6.26	-0.54	1.09e-8	Coronary artery disease;
THYM	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg06634786	chr22:41940651	POLR3H	0.72	5.22	0.47	1.04e-6	Vitiligo;
THYM	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg00376283	chr12:123451042	ABCB9	-0.78	-6.19	-0.54	1.55e-8	Platelet count;
THYM	cis	rs7777677	0.925	rs4726540	chr7:142366268	C/T	cg21785750	chr7:142428317	NA	0.67	5.89	0.52	5.74e-8	Alcoholic chronic pancreatitis;
THYM	cis	rs9500256	0.655	rs12210275	chr6:58331759	C/T	cg16251399	chr6:58287822	GUSBL2	0.6	4.72	0.44	8.23e-6	Eosinophilic esophagitis (pediatric);
THYM	cis	rs858239	0.636	rs28706766	chr7:23169834	T/A	cg05407003	chr7:23246146	NA	-0.57	-4.65	-0.43	1.06e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs8016982	0.855	rs10149681	chr14:81686319	G/A	cg01989461	chr14:81687754	GTF2A1	0.61	4.51	0.42	1.84e-5	Schizophrenia;
THYM	cis	rs28595532	0.920	rs17325129	chr4:119778284	T/C	cg14228332	chr4:119757509	SEC24D	1.59	5.76	0.51	1.02e-7	Cannabis dependence symptom count;
THYM	cis	rs2742234	0.590	rs2505553	chr10:43681251	G/T	cg06632098	chr10:43605906	RET	-0.77	-4.96	-0.45	3.09e-6	Hirschsprung disease;
THYM	cis	rs887829	0.641	rs10167119	chr2:234589312	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.81	-6.58	-0.56	2.52e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg08045932	chr20:61659980	NA	0.94	10.68	0.74	5.76e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg12193833	chr17:30244370	NA	-0.63	-4.47	-0.42	2.2e-5	Hip circumference adjusted for BMI;
THYM	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg00990874	chr7:1149470	C7orf50	-0.69	-5.2	-0.47	1.14e-6	Bronchopulmonary dysplasia;
THYM	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg04918696	chr8:1004106	NA	0.42	4.67	0.43	9.78e-6	Schizophrenia;
THYM	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg18252515	chr7:66147081	NA	-0.87	-6.66	-0.56	1.74e-9	Corneal structure;
THYM	cis	rs4746818	0.901	rs7914719	chr10:70903832	T/C	cg04149295	chr10:70884716	VPS26A	0.78	5.27	0.48	8.48e-7	Left atrial antero-posterior diameter;
THYM	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs2932538	0.846	rs7546203	chr1:113154529	C/A	cg22162597	chr1:113214053	CAPZA1	0.65	5.32	0.48	6.9e-7	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.3	-4.73	-0.44	7.88e-6	Obesity-related traits;
THYM	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg19318889	chr4:1322082	MAEA	-0.58	-5.01	-0.46	2.53e-6	Longevity;
THYM	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg26384229	chr12:38710491	ALG10B	0.98	7.72	0.62	1.16e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs4975709	0.686	rs2307118	chr5:1881916	A/C	cg12288994	chr5:1860383	NA	0.62	4.69	0.43	9.04e-6	Cardiovascular disease risk factors;
THYM	cis	rs7772486	0.712	rs1292335	chr6:145967877	G/T	cg23711669	chr6:146136114	FBXO30	0.74	6.91	0.58	5.52e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg12262378	chr17:6899522	ALOX12	0.66	8.64	0.66	1.3e-13	Tonsillectomy;
THYM	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg10802521	chr3:52805072	NEK4	-0.8	-7.53	-0.61	2.92e-11	Bipolar disorder;
THYM	cis	rs916888	0.647	rs199520	chr17:44853872	G/A	cg01570182	chr17:44337453	NA	-0.64	-7.11	-0.59	2.16e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs5015933	0.801	rs3104546	chr9:128137669	T/C	cg14078157	chr9:128172775	NA	-0.55	-4.47	-0.42	2.16e-5	Body mass index;
THYM	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg04842962	chr6:43655489	MRPS18A	1.36	14.96	0.84	1.02e-26	IgG glycosylation;
THYM	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19346786	chr7:2764209	NA	-0.77	-6.8	-0.57	9.06e-10	Height;
THYM	cis	rs1061377	1.000	rs4974931	chr4:39110516	T/G	cg24403649	chr4:39172243	NA	0.56	4.56	0.42	1.55e-5	Uric acid levels;
THYM	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg21475434	chr5:93447410	FAM172A	0.96	6.12	0.53	2.05e-8	Diabetic retinopathy;
THYM	cis	rs6815814	0.861	rs28690449	chr4:38789132	C/T	cg06935464	chr4:38784597	TLR10	0.73	5.34	0.48	6.27e-7	Breast cancer;
THYM	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg19875535	chr5:140030758	IK	-0.61	-5.27	-0.48	8.57e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg00071950	chr4:10020882	SLC2A9	0.87	10.34	0.73	3.16e-17	Bone mineral density;
THYM	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg06640241	chr16:89574553	SPG7	0.71	6.01	0.52	3.43e-8	Multiple myeloma (IgH translocation);
THYM	cis	rs2882877	0.648	rs13018571	chr2:190395126	A/T	cg10752008	chr2:190445175	SLC40A1	0.73	5.95	0.52	4.49e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2354432	0.505	rs4424556	chr1:146863973	G/C	cg25205988	chr1:146714368	CHD1L	1.0	4.71	0.43	8.61e-6	Mitochondrial DNA levels;
THYM	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg17366294	chr4:99064904	C4orf37	0.54	6.33	0.54	8.05e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs912057	0.526	rs1294400	chr6:6733421	A/G	cg13809441	chr6:6737631	NA	-0.53	-6.16	-0.53	1.73e-8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg22508957	chr16:3507546	NAT15	0.67	9.28	0.69	5.62e-15	Tuberculosis;
THYM	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg15704280	chr7:45808275	SEPT13	-1.04	-13.43	-0.81	1.13e-23	Height;
THYM	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg24733560	chr20:60626293	TAF4	0.62	6.5	0.55	3.69e-9	Body mass index;
THYM	cis	rs611744	0.870	rs371878	chr8:109130620	T/G	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.06e-6	Dupuytren's disease;
THYM	cis	rs425277	1.000	rs262657	chr1:2088577	G/A	cg13918804	chr1:2043761	PRKCZ	-0.61	-4.62	-0.43	1.19e-5	Height;
THYM	cis	rs12950390	0.548	rs62076098	chr17:45860584	C/T	cg24803719	chr17:45855879	NA	-0.42	-4.45	-0.42	2.36e-5	IgG glycosylation;
THYM	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg20887711	chr4:1340912	KIAA1530	-0.98	-9.51	-0.7	1.87e-15	Longevity;
THYM	cis	rs8063160	0.756	rs35749174	chr16:89716493	G/A	cg07984980	chr16:89898383	SPIRE2	1.49	6.02	0.53	3.3e-8	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs1163251	0.902	rs487081	chr1:120217389	G/A	cg19096424	chr1:120255104	PHGDH	0.67	5.25	0.47	9.26e-7	Blood metabolite levels;
THYM	cis	rs9733	0.565	rs11804276	chr1:150685761	T/A	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs2976388	0.609	rs2572908	chr8:143802636	A/G	cg13446199	chr8:143762866	PSCA	-0.41	-4.54	-0.42	1.67e-5	Urinary tract infection frequency;
THYM	cis	rs240764	0.658	rs7740783	chr6:101263516	C/T	cg21058520	chr6:100914733	NA	-0.54	-4.63	-0.43	1.18e-5	Neuroticism;
THYM	cis	rs7553864	1.000	rs975040	chr1:87613682	G/A	cg17420885	chr1:87600446	LOC339524	-0.8	-6.69	-0.57	1.51e-9	Smoking behavior;
THYM	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg14675211	chr2:100938903	LONRF2	0.75	7.99	0.63	3.1e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7084921	0.578	rs12783521	chr10:101871748	C/A	cg11344164	chr10:101878520	NA	-0.55	-4.69	-0.43	9.12e-6	Bone mineral density;
THYM	cis	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6084875	0.840	rs730999	chr20:4731377	A/G	cg19614321	chr20:4804581	RASSF2	0.44	4.48	0.42	2.09e-5	Systemic lupus erythematosus;
THYM	cis	rs13202913	0.837	rs9383901	chr6:151788059	T/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.88	-5.1	-0.46	1.71e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs8048589	0.615	rs34098770	chr16:12237812	G/A	cg01990910	chr16:12207648	SNX29	-0.5	-5.68	-0.5	1.46e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs7578361	0.959	rs4072901	chr2:150446960	G/A	cg17961725	chr2:150454027	NA	0.75	6.45	0.55	4.58e-9	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg09165964	chr15:75287851	SCAMP5	1.1	11.28	0.76	3.13e-19	Blood trace element (Zn levels);
THYM	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.81	-0.63	7.44e-12	Chronic sinus infection;
THYM	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg23803603	chr1:2058230	PRKCZ	0.63	5.37	0.48	5.58e-7	Height;
THYM	cis	rs8103278	1.000	rs8109951	chr19:46289503	C/T	cg14061069	chr19:46274453	DMPK	-0.57	-5.64	-0.5	1.77e-7	Coronary artery disease;
THYM	cis	rs686320	1.000	rs616599	chr11:65254025	T/G	cg23743554	chr11:65321226	LTBP3	0.76	4.55	0.42	1.61e-5	Hip circumference adjusted for BMI;
THYM	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg11494091	chr17:61959527	GH2	0.69	6.32	0.54	8.45e-9	Height;
THYM	cis	rs6956675	0.831	rs4718878	chr7:62656497	T/C	cg08930214	chr7:62859557	LOC100287834	0.61	4.78	0.44	6.47e-6	Obesity-related traits;
THYM	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg11764359	chr7:65958608	NA	-0.85	-7.43	-0.61	4.73e-11	Aortic root size;
THYM	cis	rs1160297	0.609	rs78310136	chr2:53093171	G/A	cg07782112	chr2:53107842	NA	0.77	6.24	0.54	1.19e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs3112255	0.905	rs4851361	chr2:101286249	A/G	cg01042948	chr2:101319752	NA	-0.67	-5.93	-0.52	4.86e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg03684893	chr10:554711	DIP2C	0.73	5.43	0.49	4.29e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg24846680	chr1:228362309	C1orf69	0.58	4.68	0.43	9.49e-6	Diastolic blood pressure;
THYM	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	5.14	0.47	1.47e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2288884	0.767	rs12460118	chr19:52535803	C/T	cg05974498	chr19:52599256	ZNF841	0.35	4.51	0.42	1.85e-5	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);
THYM	cis	rs7646881	0.812	rs61387735	chr3:158456161	G/A	cg19483011	chr3:158453295	NA	-0.72	-4.68	-0.43	9.34e-6	Tetralogy of Fallot;
THYM	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03264133	chr6:25882463	NA	-0.86	-6.96	-0.58	4.36e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6032067	0.714	rs35343177	chr20:43845986	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.45	-5.37	-0.48	5.59e-7	Blood protein levels;
THYM	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg16624210	chr5:671434	TPPP	0.6	6.03	0.53	3.09e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs13070279	0.655	rs55670724	chr3:71782338	G/A	cg19388776	chr3:71835112	PROK2	0.89	5.31	0.48	7.27e-7	Monocyte count;
THYM	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg23187316	chr7:1099788	C7orf50	0.59	4.48	0.42	2.12e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs36051895	0.622	rs12335546	chr9:5072182	C/T	cg02405213	chr9:5042618	JAK2	-1.02	-10.8	-0.74	3.25e-18	Pediatric autoimmune diseases;
THYM	cis	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.1	-0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7084402	0.934	rs1649051	chr10:60321997	A/G	cg09696939	chr10:60272079	BICC1	-0.5	-6.05	-0.53	2.81e-8	Refractive error;
THYM	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.74	6.88	0.58	6.35e-10	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs4845459	0.967	rs4845454	chr1:152592184	C/T	cg26135325	chr1:152595322	LCE3A	-0.45	-5.13	-0.47	1.54e-6	Psoriasis;
THYM	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg04842962	chr6:43655489	MRPS18A	0.88	7.39	0.6	5.6e-11	IgG glycosylation;
THYM	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg10523679	chr1:76189770	ACADM	0.9	9.47	0.7	2.2e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2574704	0.561	rs2574712	chr3:11667602	G/A	cg07643000	chr3:11666825	VGLL4	-0.54	-5.33	-0.48	6.61e-7	Body mass index;
THYM	cis	rs4853012	0.887	rs2280642	chr2:74358252	T/A	cg01017244	chr2:74357527	NA	1.11	9.75	0.71	5.67e-16	Gestational age at birth (maternal effect);
THYM	cis	rs6768930	0.509	rs2061573	chr3:57763642	G/A	cg24033633	chr3:57945695	NA	-0.38	-5.27	-0.48	8.55e-7	Obesity-related traits;
THYM	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg13918804	chr1:2043761	PRKCZ	0.87	8.39	0.65	4.56e-13	Height;
THYM	cis	rs7610301	1.000	rs35795952	chr3:46645694	C/T	cg22951056	chr3:46887651	NA	-0.79	-5.11	-0.46	1.65e-6	Blood protein levels;
THYM	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg24399712	chr22:39784796	NA	-0.92	-8.47	-0.66	3e-13	Post bronchodilator FEV1;
THYM	cis	rs1971762	1.000	rs916134	chr12:54069803	A/G	cg16917193	chr12:54089295	NA	0.57	4.45	0.42	2.33e-5	Height;
THYM	cis	rs1018836	0.892	rs4735224	chr8:91567046	C/A	cg16814680	chr8:91681699	NA	-0.78	-6.42	-0.55	5.41e-9	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07167872	chr1:205819463	PM20D1	0.93	8.83	0.67	5.34e-14	Menarche (age at onset);
THYM	cis	rs9938149	0.966	rs28378192	chr16:88329660	C/T	cg04379563	chr16:87392076	FBXO31	-0.56	-4.64	-0.43	1.13e-5	Corneal structure;Central corneal thickness;
THYM	cis	rs7843479	0.965	rs2291317	chr8:21827162	C/T	cg17168535	chr8:21777572	XPO7	0.7	5.24	0.47	9.75e-7	Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17598306	1.000	rs17598306	chr7:96581811	A/G	cg26766885	chr7:96220185	NA	-0.62	-5.13	-0.47	1.56e-6	Radiation response;
THYM	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg24154853	chr7:158122151	PTPRN2	0.55	4.88	0.45	4.32e-6	Calcium levels;
THYM	cis	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.01	-9.8	-0.71	4.35e-16	Primary sclerosing cholangitis;
THYM	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg03806693	chr22:41940476	POLR3H	-1.1	-8.83	-0.67	5.2e-14	Vitiligo;
THYM	cis	rs17174870	0.911	rs17175275	chr2:112712329	G/A	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs9549260	0.755	rs7989711	chr13:41215696	C/T	cg21288729	chr13:41239152	FOXO1	0.71	5.46	0.49	3.86e-7	Red blood cell count;
THYM	cis	rs6430585	0.591	rs309170	chr2:136672775	C/T	cg23851026	chr2:136556271	LCT	0.67	6.53	0.56	3.16e-9	Corneal structure;
THYM	cis	rs240764	0.817	rs239237	chr6:101094940	A/G	cg21058520	chr6:100914733	NA	-0.57	-5.06	-0.46	2.04e-6	Neuroticism;
THYM	cis	rs7020830	0.867	rs563132	chr9:37245476	A/T	cg14294708	chr9:37120828	ZCCHC7	1.23	15.11	0.84	5.19e-27	Schizophrenia;
THYM	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg15744005	chr10:104629667	AS3MT	-0.84	-8.32	-0.65	6.21e-13	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7942486	0.895	rs1351520	chr11:13268538	A/G	cg13286116	chr11:13302098	ARNTL	-0.72	-7.98	-0.63	3.36e-12	Neuroticism;
THYM	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.91	9.1	0.68	1.36e-14	Birth weight;
THYM	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg18876405	chr7:65276391	NA	0.63	5.53	0.49	2.83e-7	Aortic root size;
THYM	trans	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg19862616	chr7:65841803	NCRNA00174	1.06	11.85	0.77	2e-20	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.73	-5.74	-0.51	1.15e-7	Total cholesterol levels;
THYM	cis	rs6920965	0.527	rs584032	chr6:126165003	G/A	cg05901451	chr6:126070800	HEY2	0.58	4.94	0.45	3.4e-6	High light scatter reticulocyte count;
THYM	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg13852791	chr20:30311386	BCL2L1	-0.94	-7.29	-0.6	9.28e-11	Mean corpuscular hemoglobin;
THYM	cis	rs728616	0.867	rs56000427	chr10:81986946	A/G	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.87	-0.45	4.49e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg07930552	chr6:133119739	C6orf192	1.03	6.0	0.52	3.63e-8	Type 2 diabetes nephropathy;
THYM	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg06191203	chr2:152266755	RIF1	-0.75	-4.99	-0.46	2.74e-6	Lung cancer;
THYM	cis	rs7020830	0.898	rs13284651	chr9:37222681	G/T	cg14294708	chr9:37120828	ZCCHC7	-1.25	-15.34	-0.84	1.9e-27	Schizophrenia;
THYM	cis	rs6466832	0.568	rs2471182	chr7:122312809	C/G	cg22586324	chr7:123296098	LMOD2	-0.91	-5.09	-0.46	1.83e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg09184832	chr6:79620586	NA	-0.58	-4.6	-0.43	1.28e-5	Intelligence (multi-trait analysis);
THYM	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.7	0.71	7.32e-16	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg02953382	chr22:24373134	LOC391322	-0.68	-5.18	-0.47	1.25e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs10924970	0.967	rs12027832	chr1:235385934	A/G	cg26050004	chr1:235667680	B3GALNT2	0.6	4.64	0.43	1.12e-5	Asthma;
THYM	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg11764359	chr7:65958608	NA	0.69	4.78	0.44	6.35e-6	Aortic root size;
THYM	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg02478829	chr6:26598070	ABT1	-0.33	-4.45	-0.42	2.33e-5	Intelligence (multi-trait analysis);
THYM	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.63	4.62	0.43	1.18e-5	Body mass index (adult);
THYM	cis	rs7568458	0.870	rs2366639	chr2:85809955	A/G	cg17127132	chr2:85788382	GGCX	0.64	4.91	0.45	3.83e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs12188164	0.840	rs67665078	chr5:428754	G/A	cg00049323	chr5:472564	LOC25845	-0.41	-4.84	-0.44	4.96e-6	Cystic fibrosis severity;
THYM	cis	rs611744	0.967	rs635219	chr8:109229243	C/T	cg21045802	chr8:109455806	TTC35	0.6	5.31	0.48	7.15e-7	Dupuytren's disease;
THYM	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg17105886	chr17:28927953	LRRC37B2	1.24	7.45	0.61	4.35e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6459804	0.935	rs72505543	chr7:157508867	G/A	cg05731713	chr7:157510257	PTPRN2	0.52	5.0	0.46	2.64e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg03709012	chr19:19516395	GATAD2A	-0.77	-6.07	-0.53	2.56e-8	Tonsillectomy;
THYM	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg11266682	chr4:10021025	SLC2A9	0.72	10.49	0.73	1.5e-17	Bone mineral density;
THYM	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg20007245	chr22:24372913	LOC391322	0.7	6.22	0.54	1.33e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg26769984	chr7:1090371	C7orf50	0.81	5.39	0.48	5.19e-7	Bronchopulmonary dysplasia;
THYM	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs12509991	0.582	rs4834092	chr4:127049367	T/C	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg22764044	chr5:178986830	RUFY1	0.52	5.26	0.47	8.97e-7	Lung cancer;
THYM	cis	rs2229238	0.774	rs4509570	chr1:154436384	G/C	cg21262032	chr1:154437693	IL6R	0.68	6.72	0.57	1.32e-9	Coronary heart disease;
THYM	cis	rs2273669	0.667	rs12206834	chr6:109303967	T/G	cg17117243	chr6:109341365	SESN1	-0.84	-4.94	-0.45	3.41e-6	Prostate cancer;
THYM	cis	rs2811415	0.597	rs9857492	chr3:127763522	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs2282300	0.702	rs2211018	chr11:30330079	C/T	cg25418670	chr11:30344373	C11orf46	0.82	6.98	0.58	3.93e-10	Morning vs. evening chronotype;
THYM	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs289828	0.519	rs289905	chr2:152086012	T/C	cg05960677	chr2:152117363	RBM43	-0.71	-7.57	-0.61	2.46e-11	Blood protein levels;
THYM	cis	rs7078219	0.714	rs888208	chr10:101295863	A/G	cg00674004	chr10:101280750	NA	0.52	4.67	0.43	9.7e-6	Dental caries;
THYM	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg23711669	chr6:146136114	FBXO30	-0.77	-7.15	-0.59	1.78e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1348850	0.526	rs10930797	chr2:178437553	C/G	cg27490568	chr2:178487706	NA	0.59	4.79	0.44	6.03e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs259282	0.602	rs194589	chr19:33144621	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.9	6.28	0.54	9.92e-9	Schizophrenia;
THYM	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg04248312	chr19:17393744	ANKLE1	-1.0	-13.06	-0.8	6.35e-23	Systemic lupus erythematosus;
THYM	cis	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg19847130	chr8:10466454	RP1L1	0.55	4.97	0.45	2.95e-6	Neuroticism;
THYM	cis	rs17443541	0.507	rs6726848	chr2:200451027	G/A	cg01795955	chr2:200468626	NA	-0.73	-4.86	-0.45	4.61e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7849270	1.000	rs7021449	chr9:131899312	T/C	cg14069949	chr9:131965419	NA	0.5	4.52	0.42	1.8e-5	Blood metabolite ratios;
THYM	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs62070183	0.882	rs17781136	chr17:31185042	C/T	cg23177095	chr17:30873196	MYO1D	0.6	4.58	0.43	1.39e-5	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs7769051	0.522	rs9493449	chr6:133126179	T/A	cg07930552	chr6:133119739	C6orf192	1.14	4.51	0.42	1.82e-5	Type 2 diabetes nephropathy;
THYM	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg03388043	chr17:80084554	CCDC57	-0.71	-5.85	-0.51	6.98e-8	Life satisfaction;
THYM	cis	rs7172809	0.897	rs17394448	chr15:77825149	C/A	cg22256960	chr15:77711686	NA	-0.68	-4.84	-0.44	5.06e-6	Glucose homeostasis traits;
THYM	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg06636001	chr8:8085503	FLJ10661	-0.73	-6.42	-0.55	5.24e-9	Neuroticism;
THYM	cis	rs4665809	0.590	rs11126339	chr2:26253223	T/C	cg22920501	chr2:26401640	FAM59B	-0.58	-5.04	-0.46	2.21e-6	Gut microbiome composition (summer);
THYM	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg11663144	chr21:46675770	NA	-0.71	-9.72	-0.71	6.46e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.55	-0.56	2.92e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg03709012	chr19:19516395	GATAD2A	0.79	6.38	0.55	6.42e-9	Tonsillectomy;
THYM	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg00083206	chr6:110721305	DDO	-0.56	-6.18	-0.54	1.59e-8	Platelet distribution width;
THYM	cis	rs17854409	1.000	rs6011427	chr20:61496680	C/T	cg06598544	chr20:61472147	COL9A3	-1.07	-7.3	-0.6	8.6e-11	Obesity-related traits;
THYM	cis	rs9733	0.628	rs72700895	chr1:150626029	C/T	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs7084402	0.967	rs1658477	chr10:60289607	A/G	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs929596	0.556	rs35984508	chr2:234587852	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.73	-5.77	-0.51	9.75e-8	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg07061783	chr6:25882402	NA	0.57	4.48	0.42	2.07e-5	Schizophrenia;
THYM	cis	rs4660261	0.562	rs3011223	chr1:44318286	T/C	cg12599982	chr1:44399894	ARTN	0.56	4.66	0.43	1.02e-5	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg24675056	chr1:15929824	NA	-0.81	-6.38	-0.55	6.39e-9	Systolic blood pressure;
THYM	cis	rs800586	0.500	rs2721963	chr8:116661174	A/C	cg04656070	chr8:116661063	TRPS1	-0.56	-6.45	-0.55	4.62e-9	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9733	0.596	rs11803569	chr1:150664077	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11644478	chr21:40555479	PSMG1	-0.8	-6.93	-0.58	4.93e-10	Cognitive function;
THYM	cis	rs1163251	0.902	rs514491	chr1:120216743	C/T	cg19096424	chr1:120255104	PHGDH	0.67	5.25	0.47	9.26e-7	Blood metabolite levels;
THYM	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.65	5.78	0.51	9.42e-8	Personality dimensions;
THYM	cis	rs4074961	0.527	rs6704190	chr1:38010751	C/T	cg17933807	chr1:38061675	GNL2	1.1	14.5	0.83	8e-26	Axial length;
THYM	trans	rs28595532	0.660	rs11933762	chr4:119307126	A/G	cg26518628	chr1:97050305	NA	-1.1	-8.54	-0.66	2.15e-13	Cannabis dependence symptom count;
THYM	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08704250	chr15:31115839	NA	-0.54	-6.18	-0.54	1.59e-8	Huntington's disease progression;
THYM	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg16405210	chr4:1374714	KIAA1530	-1.03	-9.59	-0.7	1.24e-15	Longevity;
THYM	cis	rs6500395	1.000	rs3743779	chr16:48574040	T/G	cg04672837	chr16:48644449	N4BP1	0.49	4.79	0.44	6.02e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7771547	0.642	rs9470309	chr6:36509751	A/G	cg07856975	chr6:36356162	ETV7	0.52	5.01	0.46	2.54e-6	Platelet distribution width;
THYM	cis	rs11723261	0.527	rs11731581	chr4:87932	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.83	7.61	0.62	2.02e-11	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg03060546	chr3:49711283	APEH	-0.67	-5.08	-0.46	1.85e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs8013055	0.846	rs11624007	chr14:105992183	A/C	cg23356831	chr14:105996513	TMEM121	0.61	6.39	0.55	6.06e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg11673840	chr17:47092156	IGF2BP1	-0.54	-7.3	-0.6	8.56e-11	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg02753203	chr1:228287806	NA	0.72	6.15	0.53	1.8e-8	Diastolic blood pressure;
THYM	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.64	0.43	1.1e-5	Bipolar disorder;
THYM	cis	rs9649465	1.000	rs13230294	chr7:123380821	T/C	cg15443791	chr7:124364398	NA	0.6	4.97	0.45	3.01e-6	Migraine;
THYM	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg13609457	chr4:120235615	NA	0.6	5.34	0.48	6.23e-7	Corneal astigmatism;
THYM	cis	rs7953249	0.807	rs2393775	chr12:121424574	G/A	cg02403541	chr12:121454288	C12orf43	-0.58	-4.72	-0.44	8.07e-6	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg20151795	chr6:28129481	ZNF389	0.75	4.59	0.43	1.36e-5	Parkinson's disease;
THYM	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.69	5.66	0.5	1.62e-7	Intelligence (multi-trait analysis);
THYM	trans	rs877282	0.945	rs11253390	chr10:788678	A/G	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs7772486	0.790	rs2253654	chr6:146199445	T/C	cg23711669	chr6:146136114	FBXO30	0.96	10.07	0.72	1.15e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg06634786	chr22:41940651	POLR3H	0.66	5.64	0.5	1.75e-7	Vitiligo;
THYM	cis	rs6032067	0.526	rs2743347	chr20:43920493	T/C	cg16667508	chr20:43936853	MATN4;RBPJL	-0.54	-5.46	-0.49	3.79e-7	Blood protein levels;
THYM	cis	rs7793919	0.652	rs6973046	chr7:4765018	A/G	cg09789173	chr7:4769017	FOXK1	0.8	7.62	0.62	1.84e-11	Mosquito bite size;
THYM	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs6964587	0.692	rs4727268	chr7:91840724	T/C	cg17063962	chr7:91808500	NA	1.0	8.63	0.66	1.4e-13	Breast cancer;
THYM	cis	rs28595532	1.000	rs17323012	chr4:119605671	A/G	cg11846333	chr4:119757529	SEC24D	1.36	4.52	0.42	1.79e-5	Cannabis dependence symptom count;
THYM	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg04607235	chr12:12878440	APOLD1	-0.93	-5.53	-0.49	2.79e-7	Systemic lupus erythematosus;
THYM	cis	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.57	-5.64	-0.5	1.77e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12379764	chr21:47803548	PCNT	0.7	4.94	0.45	3.31e-6	Testicular germ cell tumor;
THYM	cis	rs425277	1.000	rs1401138	chr1:2063149	C/T	cg00981070	chr1:2046702	PRKCZ	0.47	5.28	0.48	8.31e-7	Height;
THYM	cis	rs988913	0.813	rs1566723	chr6:54777833	G/A	cg19716238	chr6:54711378	FAM83B	0.54	5.58	0.5	2.22e-7	Menarche (age at onset);
THYM	cis	rs6840360	0.593	rs28602726	chr4:152499788	T/C	cg22705602	chr4:152727874	NA	-0.77	-8.64	-0.66	1.36e-13	Intelligence (multi-trait analysis);
THYM	cis	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg21138405	chr5:131827807	IRF1	0.51	4.96	0.45	3.1e-6	Asthma;
THYM	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg13395646	chr4:1353034	KIAA1530	-0.71	-6.45	-0.55	4.71e-9	Obesity-related traits;
THYM	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg26446133	chr18:72167187	CNDP2	-1.0	-9.97	-0.72	1.88e-16	Refractive error;
THYM	cis	rs7447927	0.950	rs13153461	chr5:138852369	G/A	cg01742263	chr5:138714339	SLC23A1	0.62	5.02	0.46	2.42e-6	Esophageal squamous cell carcinoma;
THYM	trans	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs6840360	0.615	rs6831810	chr4:152461995	A/G	cg17479576	chr4:152424074	FAM160A1	-0.85	-6.4	-0.55	5.9e-9	Intelligence (multi-trait analysis);
THYM	cis	rs2933343	0.700	rs789238	chr3:128636715	A/G	cg11901034	chr3:128598214	ACAD9	-0.68	-5.57	-0.5	2.4e-7	IgG glycosylation;
THYM	trans	rs561341	0.882	rs504887	chr17:30322881	T/A	cg20587970	chr11:113659929	NA	-1.24	-8.72	-0.67	8.92e-14	Hip circumference adjusted for BMI;
THYM	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg18758796	chr5:131593413	PDLIM4	0.51	4.82	0.44	5.5e-6	Breast cancer;
THYM	cis	rs1670533	1.000	rs652063	chr4:1084137	T/C	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg08067268	chr2:26466485	HADHB;HADHA	-0.68	-4.87	-0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.78	-7.17	-0.59	1.61e-10	Personality dimensions;
THYM	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs7193541	1.000	rs7193541	chr16:74664743	C/T	cg01733217	chr16:74700730	RFWD3	-0.74	-7.53	-0.61	2.94e-11	Multiple myeloma;
THYM	cis	rs9563576	0.778	rs8001420	chr13:58674679	T/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.6	4.5	0.42	1.9e-5	Body mass index;
THYM	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6541297	0.775	rs4846910	chr1:230291441	C/A	cg20703242	chr1:230279135	GALNT2	1.05	6.3	0.54	9.34e-9	Coronary artery disease;
THYM	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg08305652	chr11:111469057	NA	0.53	4.58	0.43	1.41e-5	Primary sclerosing cholangitis;
THYM	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg24375607	chr4:120327624	NA	0.53	4.47	0.42	2.2e-5	Educational attainment;
THYM	cis	rs1348850	0.526	rs2178017	chr2:178374788	G/T	cg27490568	chr2:178487706	NA	0.66	5.31	0.48	7.1e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs514406	0.698	rs576891	chr1:53364976	A/G	cg06600287	chr1:53387719	ECHDC2	-0.33	-5.21	-0.47	1.11e-6	Monocyte count;
THYM	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg03060546	chr3:49711283	APEH	0.74	6.04	0.53	2.97e-8	Resting heart rate;
THYM	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.75	-0.67	7.74e-14	Mean corpuscular volume;
THYM	cis	rs8031584	0.958	rs61997076	chr15:31216225	C/T	cg08109568	chr15:31115862	NA	-0.66	-5.97	-0.52	4.1e-8	Huntington's disease progression;
THYM	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg06634786	chr22:41940651	POLR3H	0.67	5.36	0.48	5.7e-7	Vitiligo;
THYM	cis	rs8017423	0.967	rs57793584	chr14:90714833	G/A	cg04239629	chr14:90701769	NA	-0.62	-4.55	-0.42	1.6e-5	Mortality in heart failure;
THYM	cis	rs7107770	0.941	rs12797405	chr11:125092491	G/A	cg04164023	chr11:125106101	PKNOX2	-0.81	-4.68	-0.43	9.65e-6	Photic sneeze reflex;
THYM	trans	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg10856724	chr12:34555212	NA	-1.02	-9.32	-0.69	4.7e-15	Bladder cancer;
THYM	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg14004847	chr7:1930337	MAD1L1	-0.67	-5.14	-0.47	1.45e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg18511798	chr11:2018149	H19;MIR675	-0.56	-5.49	-0.49	3.38e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs11771526	0.901	rs11773754	chr7:32304801	A/G	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.62	-5.54	-0.49	2.71e-7	Rheumatoid arthritis;
THYM	cis	rs12410462	0.681	rs113316536	chr1:227547033	T/G	cg23173402	chr1:227635558	NA	0.68	5.44	0.49	4.2e-7	Major depressive disorder;
THYM	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg13852791	chr20:30311386	BCL2L1	0.67	4.76	0.44	7.04e-6	Mean corpuscular hemoglobin;
THYM	cis	rs7216064	1.000	rs2052187	chr17:65834737	T/C	cg12091567	chr17:66097778	LOC651250	-0.71	-4.76	-0.44	6.86e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg25554036	chr4:6271136	WFS1	0.56	5.29	0.48	7.94e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs28595532	0.920	rs55869953	chr4:119751893	T/C	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg07460842	chr6:66804631	NA	-1.06	-7.89	-0.63	5.14e-12	Exhaled nitric oxide output;
THYM	cis	rs6138458	1.000	rs227624	chr20:24911562	T/C	cg26195577	chr20:24973756	C20orf3	1.11	10.52	0.73	1.29e-17	Blood protein levels;
THYM	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg01699819	chr7:1052092	C7orf50	-0.74	-6.58	-0.56	2.55e-9	Bronchopulmonary dysplasia;
THYM	cis	rs9733	0.536	rs6661415	chr1:150635869	G/A	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs981844	1.000	rs2405431	chr4:154656396	A/G	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs7107174	1.000	rs10793300	chr11:78019582	T/A	cg02023728	chr11:77925099	USP35	0.67	5.86	0.52	6.61e-8	Testicular germ cell tumor;
THYM	cis	rs662064	0.962	rs668805	chr1:10544547	A/G	cg20482658	chr1:10539492	PEX14	0.49	6.13	0.53	2e-8	Asthma;
THYM	cis	rs6456042	1.000	rs9459577	chr6:166534389	C/A	cg11088901	chr6:166572345	T	-0.51	-4.78	-0.44	6.47e-6	Asthma;
THYM	cis	rs6906287	0.573	rs12198461	chr6:118880640	T/G	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.12e-7	Electrocardiographic conduction measures;
THYM	cis	rs1158570	0.804	rs2185366	chr8:131342722	T/C	cg16277922	chr8:131349729	ASAP1	-0.58	-4.77	-0.44	6.58e-6	Platelet count;
THYM	cis	rs11785693	0.862	rs62491169	chr8:4986425	C/A	cg26367366	chr8:4980734	NA	1.18	6.09	0.53	2.39e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg18131467	chr2:239335373	ASB1	1.1	11.05	0.75	9.8e-19	Multiple system atrophy;
THYM	cis	rs9733	0.596	rs72702536	chr1:150662574	C/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs9399401	0.710	rs12190271	chr6:142681409	A/G	cg04461802	chr6:142623433	GPR126	-0.76	-7.19	-0.59	1.47e-10	Chronic obstructive pulmonary disease;
THYM	cis	rs2034650	0.506	rs1984793	chr15:40699373	G/T	cg12699599	chr15:40643142	PHGR1	-0.6	-5.49	-0.49	3.3e-7	Interstitial lung disease;
THYM	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg19875535	chr5:140030758	IK	0.63	5.59	0.5	2.16e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.82	0.44	5.4e-6	Bipolar disorder;
THYM	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg04681579	chr7:75027559	TRIM73;TRIM74	-0.78	-5.95	-0.52	4.43e-8	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9905704	0.874	rs28483505	chr17:56844109	G/C	cg12560992	chr17:57184187	TRIM37	0.68	4.73	0.44	7.89e-6	Testicular germ cell tumor;
THYM	cis	rs2806561	0.894	rs1738475	chr1:23536891	C/G	cg08872493	chr1:23521417	HTR1D	0.36	4.45	0.42	2.34e-5	Height;
THYM	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg15247329	chr7:2764246	NA	-0.71	-5.98	-0.52	3.94e-8	Height;
THYM	cis	rs7586879	0.575	rs6744205	chr2:25133148	T/C	cg15423357	chr2:25149977	NA	0.7	7.76	0.62	9.56e-12	Body mass index;
THYM	cis	rs4930776	0.966	rs4309236	chr12:5765936	T/C	cg02086166	chr12:5775618	ANO2	-0.58	-5.71	-0.51	1.3e-7	Plasma clusterin levels;
THYM	cis	rs8031584	1.000	rs12906054	chr15:31292023	A/C	cg08109568	chr15:31115862	NA	-0.59	-5.25	-0.47	9.17e-7	Huntington's disease progression;
THYM	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.75	-0.44	7.15e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg04772025	chr11:68637568	NA	0.68	7.21	0.59	1.33e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg26384229	chr12:38710491	ALG10B	0.71	5.51	0.49	3.05e-7	Morning vs. evening chronotype;
THYM	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg13319975	chr6:146136371	FBXO30	0.72	5.91	0.52	5.42e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12476592	0.516	rs6546002	chr2:63593829	A/C	cg17519650	chr2:63277830	OTX1	-0.67	-4.62	-0.43	1.2e-5	Childhood ear infection;
THYM	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg25358565	chr5:93447407	FAM172A	0.96	6.78	0.57	1.01e-9	Diabetic retinopathy;
THYM	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg06766960	chr11:133703094	NA	-0.61	-5.56	-0.5	2.42e-7	Childhood ear infection;
THYM	cis	rs911119	0.657	rs2145231	chr20:23625547	A/G	cg16589663	chr20:23618590	CST3	-0.83	-4.91	-0.45	3.72e-6	Chronic kidney disease;
THYM	cis	rs72627123	0.867	rs118139038	chr14:74415553	G/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.82	4.65	0.43	1.08e-5	Morning vs. evening chronotype;
THYM	cis	rs926938	0.584	rs1286558	chr1:115357587	C/T	cg12756093	chr1:115239321	AMPD1	0.58	4.69	0.43	9.31e-6	Autism;
THYM	cis	rs4662750	0.580	rs6715608	chr2:128353705	A/T	cg01966334	chr2:128378434	MYO7B	-0.6	-5.39	-0.48	5.07e-7	Renal cell carcinoma;
THYM	cis	rs2228479	0.850	rs79244293	chr16:89896220	T/C	cg06558623	chr16:89946397	TCF25	1.09	4.8	0.44	5.92e-6	Skin colour saturation;
THYM	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-6.49	-0.55	3.96e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7246657	0.943	rs8111782	chr19:37867904	A/G	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg18230493	chr5:56204884	C5orf35	-0.95	-6.68	-0.57	1.63e-9	Initial pursuit acceleration;
THYM	cis	rs6964587	0.626	rs6951795	chr7:91543764	T/C	cg22709100	chr7:91322751	NA	-0.62	-4.67	-0.43	9.72e-6	Breast cancer;
THYM	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg22467129	chr15:76604101	ETFA	-0.56	-5.37	-0.48	5.47e-7	Blood metabolite levels;
THYM	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg14416269	chr4:6271139	WFS1	-0.49	-4.97	-0.45	3.01e-6	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs7131987	0.650	rs12366527	chr12:29474256	C/G	cg09582351	chr12:29534625	ERGIC2	-0.59	-5.13	-0.47	1.53e-6	QT interval;
THYM	cis	rs860818	1.000	rs858242	chr7:23225342	T/A	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg00684032	chr4:1343700	KIAA1530	-0.66	-5.62	-0.5	1.9e-7	Obesity-related traits;
THYM	cis	rs1322639	0.574	rs9689193	chr6:169588074	A/G	cg04662567	chr6:169592167	NA	-0.64	-4.77	-0.44	6.65e-6	Pulse pressure;
THYM	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg21427119	chr20:30132790	HM13	-0.96	-7.02	-0.58	3.34e-10	Mean corpuscular hemoglobin;
THYM	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg00383909	chr3:49044727	WDR6	1.05	5.99	0.52	3.79e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs6840360	1.000	rs6535809	chr4:152592933	A/G	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.565	rs897732	chr1:53382816	A/C	cg22166914	chr1:53195759	ZYG11B	0.66	5.66	0.5	1.57e-7	Monocyte count;
THYM	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.61	5.3	0.48	7.56e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs981844	0.683	rs1037653	chr4:154749992	A/T	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg00631329	chr6:26305371	NA	-0.57	-6.87	-0.58	6.65e-10	Educational attainment;
THYM	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg22907277	chr7:1156413	C7orf50	0.87	9.1	0.68	1.41e-14	Longevity;Endometriosis;
THYM	cis	rs6570726	0.791	rs6570694	chr6:145911204	C/G	cg05347473	chr6:146136440	FBXO30	0.58	4.51	0.42	1.85e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg16680214	chr1:154839983	KCNN3	-0.39	-4.63	-0.43	1.15e-5	Prostate cancer;
THYM	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs1797081	1.000	rs780634	chr10:16864327	T/G	cg23933602	chr10:16859644	RSU1	0.91	9.98	0.72	1.86e-16	Platelet distribution width;
THYM	trans	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg25214090	chr10:38739885	LOC399744	0.84	7.24	0.6	1.16e-10	Corneal astigmatism;
THYM	cis	rs2836974	0.545	rs2776311	chr21:40716885	A/G	cg11890956	chr21:40555474	PSMG1	0.66	5.18	0.47	1.23e-6	Cognitive function;
THYM	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.78	-5.75	-0.51	1.07e-7	Prostate cancer;
THYM	cis	rs2463822	0.920	rs7924998	chr11:62073980	C/G	cg06239285	chr11:62104954	ASRGL1	-1.39	-7.05	-0.59	2.81e-10	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs6502050	0.835	rs34774430	chr17:80181919	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.06	-0.64	2.21e-12	Life satisfaction;
THYM	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg07570687	chr10:102243282	WNT8B	0.84	8.04	0.64	2.45e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9515201	0.859	rs9515199	chr13:111033704	C/T	cg05272587	chr13:111038400	COL4A2	0.75	6.51	0.56	3.57e-9	White matter hyperintensity burden;
THYM	cis	rs2282300	0.956	rs1717773	chr11:30383154	T/C	cg09906309	chr11:30344399	C11orf46	-0.72	-5.07	-0.46	1.97e-6	Morning vs. evening chronotype;
THYM	cis	rs3806843	0.868	rs2563291	chr5:140119599	T/A	cg19875535	chr5:140030758	IK	-0.6	-4.78	-0.44	6.41e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg00071950	chr4:10020882	SLC2A9	0.72	7.4	0.6	5.43e-11	Bone mineral density;
THYM	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg25566285	chr7:158114605	PTPRN2	-0.88	-10.98	-0.75	1.37e-18	Calcium levels;
THYM	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg18132916	chr6:79620363	NA	-0.6	-5.35	-0.48	6.07e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2301436	0.512	rs6925969	chr6:167501738	C/A	cg00271210	chr6:167070053	RPS6KA2	-0.54	-5.24	-0.47	9.81e-7	Crohn's disease;
THYM	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs761746	0.920	rs5998011	chr22:31889566	T/C	cg10537193	chr22:32026975	PISD	0.38	5.06	0.46	2e-6	Intelligence;
THYM	cis	rs55665837	1.000	rs11023224	chr11:14457739	G/A	cg19336497	chr11:14380999	RRAS2	-0.64	-7.04	-0.59	3e-10	Vitamin D levels;
THYM	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.7	5.75	0.51	1.08e-7	Blood metabolite levels;
THYM	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg06718696	chr17:78121285	EIF4A3	0.96	7.21	0.59	1.33e-10	Plateletcrit;Mean corpuscular hemoglobin concentration;
THYM	cis	rs9682041	0.877	rs12489967	chr3:170073339	A/C	cg21474897	chr3:170136489	CLDN11	-0.88	-4.65	-0.43	1.07e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs7432375	0.901	rs7618518	chr3:136370092	C/T	cg21827317	chr3:136751795	NA	-0.59	-5.04	-0.46	2.22e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4363385	0.626	rs12062847	chr1:153062994	A/G	cg06563695	chr1:153756334	NA	-0.62	-5.12	-0.46	1.61e-6	Inflammatory skin disease;
THYM	cis	rs988913	1.000	rs6922186	chr6:54811092	A/T	cg04690482	chr6:54711388	FAM83B	0.48	5.36	0.48	5.77e-7	Menarche (age at onset);
THYM	cis	rs6840360	0.615	rs4696267	chr4:152464500	A/G	cg17479576	chr4:152424074	FAM160A1	-0.83	-6.46	-0.55	4.43e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg01831904	chr17:28903510	LRRC37B2	-1.0	-5.11	-0.46	1.65e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs995000	0.895	rs1168124	chr1:63139730	C/T	cg06896770	chr1:63153194	DOCK7	-0.93	-7.32	-0.6	8.11e-11	Triglyceride levels;
THYM	cis	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg19693284	chr19:2783607	SGTA	0.68	5.39	0.48	5.02e-7	Total cholesterol levels;
THYM	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg11812906	chr14:75593930	NEK9	-0.89	-8.22	-0.64	1.03e-12	Height;
THYM	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg23803603	chr1:2058230	PRKCZ	-0.57	-4.84	-0.44	5.02e-6	Height;
THYM	cis	rs6430585	0.527	rs1446586	chr2:136407445	C/T	cg23851026	chr2:136556271	LCT	-0.62	-5.82	-0.51	8.02e-8	Corneal structure;
THYM	cis	rs4363385	0.818	rs557553	chr1:153010370	T/G	cg13444842	chr1:152974279	SPRR3	-0.59	-4.72	-0.44	8.04e-6	Inflammatory skin disease;
THYM	cis	rs365132	1.000	rs353490	chr5:176433063	C/T	cg17809377	chr5:176326619	HK3	-0.3	-4.45	-0.42	2.31e-5	Menarche and menopause (age at onset);Menopause (age at onset);
THYM	cis	rs17030434	0.834	rs1456399	chr4:154735242	C/T	cg14289246	chr4:154710475	SFRP2	-0.72	-5.21	-0.47	1.09e-6	Electrocardiographic conduction measures;
THYM	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg13695892	chr22:41940480	POLR3H	0.87	6.35	0.55	7.28e-9	Vitiligo;
THYM	cis	rs2777491	0.915	rs28526381	chr15:41621842	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.14	-12.89	-0.8	1.38e-22	Ulcerative colitis;
THYM	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg15501526	chr10:2543763	NA	0.79	7.77	0.62	9.05e-12	Age-related hearing impairment;
THYM	trans	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg25517755	chr10:38738941	LOC399744	-0.79	-7.77	-0.62	9.18e-12	Corneal astigmatism;
THYM	cis	rs7213347	0.780	rs170041	chr17:2170216	C/T	cg16513277	chr17:2031491	SMG6	0.61	4.5	0.42	1.93e-5	Total body bone mineral density;
THYM	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg14004847	chr7:1930337	MAD1L1	-0.6	-4.65	-0.43	1.07e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs245880	0.740	rs245897	chr7:29193940	C/T	cg17163760	chr7:29186267	CPVL	0.58	4.68	0.43	9.38e-6	Warfarin maintenance dose;
THYM	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.77	-6.99	-0.58	3.7e-10	Personality dimensions;
THYM	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg27532560	chr4:187881888	NA	-0.95	-11.68	-0.77	4.63e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs8133932	0.654	rs410902	chr21:47341794	G/A	cg20357416	chr21:47294739	PCBP3	0.8	4.88	0.45	4.26e-6	Schizophrenia;
THYM	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.92	-7.95	-0.63	3.81e-12	Menarche (age at onset);
THYM	cis	rs6988636	1.000	rs7002332	chr8:124185442	G/C	cg23067535	chr8:124195133	FAM83A	-1.1	-5.77	-0.51	9.8e-8	Urinary uromodulin levels;
THYM	cis	rs10411262	0.506	rs6509291	chr19:47186961	T/C	cg18040997	chr19:47551898	TMEM160	0.72	4.55	0.42	1.56e-5	Tonsillectomy;
THYM	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg09029085	chr17:47094198	IGF2BP1	0.48	6.85	0.58	7.27e-10	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs11048434	0.736	rs12812913	chr12:9110836	C/G	cg04155231	chr12:9217510	LOC144571	0.47	4.47	0.42	2.14e-5	Sjögren's syndrome;
THYM	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg18357526	chr6:26021779	HIST1H4A	0.77	6.57	0.56	2.74e-9	Intelligence (multi-trait analysis);
THYM	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg03690763	chr11:133734501	NA	-0.63	-5.22	-0.47	1.06e-6	Childhood ear infection;
THYM	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg11764359	chr7:65958608	NA	0.82	6.56	0.56	2.81e-9	Aortic root size;
THYM	cis	rs59112743	0.510	rs11757499	chr6:15599730	T/G	cg10111214	chr6:14815676	NA	0.74	4.84	0.44	5.08e-6	Multiple keratinocyte cancers;
THYM	cis	rs9796	0.624	rs9920619	chr15:41318845	A/G	cg21153102	chr15:41252147	NA	0.53	4.52	0.42	1.81e-5	Menopause (age at onset);
THYM	cis	rs12579753	0.871	rs10862363	chr12:82201254	T/A	cg21231944	chr12:82153410	PPFIA2	-0.66	-5.01	-0.46	2.51e-6	Resting heart rate;
THYM	cis	rs7119	0.717	rs12910512	chr15:77817253	C/A	cg27398640	chr15:77910606	LINGO1	-0.55	-5.61	-0.5	1.95e-7	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs35883536	0.514	rs4908062	chr1:101013211	T/C	cg06223162	chr1:101003688	GPR88	0.95	8.29	0.65	7.53e-13	Monocyte count;
THYM	cis	rs154659	0.887	rs154660	chr16:89667637	C/G	cg01710450	chr16:89662404	CPNE7	-0.69	-5.98	-0.52	3.98e-8	Tanning;
THYM	cis	rs7777677	0.925	rs2156964	chr7:142372587	C/T	cg21785750	chr7:142428317	NA	0.68	5.94	0.52	4.71e-8	Alcoholic chronic pancreatitis;
THYM	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg00898013	chr13:113819073	PROZ	-0.88	-9.0	-0.68	2.24e-14	Platelet distribution width;
THYM	cis	rs17102423	0.530	rs4902359	chr14:65542790	G/A	cg11161011	chr14:65562177	MAX	-0.69	-5.64	-0.5	1.76e-7	Obesity-related traits;
THYM	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg09549813	chr16:4587862	C16orf5	-0.53	-5.49	-0.49	3.37e-7	Schizophrenia;
THYM	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg15782153	chr7:917662	C7orf20	0.45	4.72	0.44	8.06e-6	Perceived unattractiveness to mosquitoes;
THYM	cis	rs6450176	1.000	rs6450175	chr5:53297824	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.81	-6.03	-0.53	3.17e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.63	4.7	0.43	8.9e-6	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs208520	0.837	rs208489	chr6:66927584	G/A	cg07460842	chr6:66804631	NA	-0.79	-4.96	-0.45	3.05e-6	Exhaled nitric oxide output;
THYM	cis	rs4975709	0.531	rs6884044	chr5:1871599	C/T	cg07747251	chr5:1868357	NA	0.66	5.92	0.52	5.09e-8	Cardiovascular disease risk factors;
THYM	cis	rs28595532	0.920	rs115240535	chr4:119745395	G/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg11327659	chr7:150037044	RARRES2	0.43	5.05	0.46	2.14e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7851660	0.844	rs4743139	chr9:100638420	A/G	cg13688889	chr9:100608707	NA	-0.75	-5.12	-0.47	1.59e-6	Strep throat;
THYM	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg21926883	chr2:100939477	LONRF2	-0.62	-5.46	-0.49	3.85e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.65	-5.68	-0.5	1.45e-7	Personality dimensions;
THYM	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg21433313	chr16:3507492	NAT15	0.84	9.65	0.7	9.27e-16	Tuberculosis;
THYM	cis	rs7665147	1	rs7665147	chr4:57767327	T/A	cg26694713	chr4:57773883	REST	0.75	4.83	0.44	5.13e-6	Platelet count;
THYM	cis	rs7216064	1.000	rs55939964	chr17:65869297	G/A	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg11812906	chr14:75593930	NEK9	-0.86	-8.02	-0.64	2.74e-12	Height;
THYM	cis	rs2976388	0.632	rs2585139	chr8:143808175	C/G	cg13446199	chr8:143762866	PSCA	-0.44	-4.91	-0.45	3.82e-6	Urinary tract infection frequency;
THYM	cis	rs7829975	0.501	rs4840353	chr8:8580570	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-4.55	-0.42	1.6e-5	Mood instability;
THYM	cis	rs9796	0.866	rs544744	chr15:41366290	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.58	-4.72	-0.44	8.26e-6	Menopause (age at onset);
THYM	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg00631329	chr6:26305371	NA	-0.6	-7.2	-0.59	1.38e-10	Educational attainment;
THYM	cis	rs425277	0.565	rs2480711	chr1:2111376	A/G	cg13918804	chr1:2043761	PRKCZ	-0.6	-5.23	-0.47	1.02e-6	Height;
THYM	cis	rs2710642	0.821	rs56373728	chr2:63095792	G/A	cg17519650	chr2:63277830	OTX1	0.68	4.87	0.45	4.44e-6	LDL cholesterol levels;LDL cholesterol;
THYM	cis	rs7666738	0.785	rs11097614	chr4:99092175	G/C	cg24818145	chr4:99064322	C4orf37	0.82	6.03	0.53	3.12e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg10856724	chr12:34555212	NA	-0.91	-8.12	-0.64	1.64e-12	Heart rate;
THYM	cis	rs11690935	0.959	rs6724337	chr2:172735329	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.8	-5.69	-0.5	1.43e-7	Schizophrenia;
THYM	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	5.33	0.48	6.64e-7	Electroencephalogram traits;
THYM	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17331151	0.505	rs71299610	chr3:52641703	T/G	cg17372223	chr3:52568218	NT5DC2	0.58	4.61	0.43	1.23e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg09517075	chr8:22133004	PIWIL2	0.64	5.69	0.5	1.42e-7	Hypertriglyceridemia;
THYM	cis	rs13064411	0.696	rs869343	chr3:113226705	C/T	cg18753928	chr3:113234510	CCDC52	-0.96	-9.65	-0.7	9.15e-16	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs3772130	1.000	rs35988617	chr3:121432902	A/G	cg01951420	chr3:121553821	IQCB1;EAF2	0.74	4.67	0.43	9.91e-6	Cognitive performance;
THYM	cis	rs921665	0.680	rs4854132	chr2:3199378	T/A	cg16434511	chr2:3151078	NA	-0.87	-5.46	-0.49	3.8e-7	World class endurance athleticism;
THYM	cis	rs4595586	0.505	rs12823590	chr12:39399750	A/T	cg26384229	chr12:38710491	ALG10B	0.67	5.16	0.47	1.33e-6	Morning vs. evening chronotype;
THYM	cis	rs10203711	1.000	rs907103	chr2:239564541	A/G	cg14580085	chr2:239553406	NA	0.68	6.07	0.53	2.58e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4803468	0.935	rs13346603	chr19:41945837	T/A	cg09537434	chr19:41945824	ATP5SL	1.05	9.66	0.7	8.82e-16	Height;
THYM	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg07532245	chr17:28927093	LRRC37B2	0.71	4.48	0.42	2.04e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2688608	0.588	rs10128205	chr10:75469648	C/G	cg19442545	chr10:75533431	FUT11	-0.58	-5.88	-0.52	6.06e-8	Inflammatory bowel disease;
THYM	cis	rs6450176	0.909	rs6884936	chr5:53293198	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-6.61	-0.56	2.22e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs2625529	0.824	rs12906711	chr15:72215065	A/G	cg16672083	chr15:72433130	SENP8	-0.56	-5.03	-0.46	2.35e-6	Red blood cell count;
THYM	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg02734326	chr4:10020555	SLC2A9	0.76	7.25	0.6	1.13e-10	Bone mineral density;
THYM	cis	rs11739663	0.553	rs60444023	chr5:586340	A/C	cg04476341	chr5:669733	TPPP	0.52	5.0	0.46	2.63e-6	Ulcerative colitis;
THYM	cis	rs7084402	0.967	rs11815274	chr10:60328891	A/G	cg07615347	chr10:60278583	BICC1	-0.54	-5.08	-0.46	1.91e-6	Refractive error;
THYM	cis	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg03159660	chr11:2078197	NA	0.62	4.6	0.43	1.3e-5	Calcium levels;
THYM	cis	rs6964587	0.839	rs6952459	chr7:91435820	T/A	cg22709100	chr7:91322751	NA	0.67	4.95	0.45	3.24e-6	Breast cancer;
THYM	cis	rs9311676	0.656	rs55668308	chr3:58388453	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg07460842	chr6:66804631	NA	-0.9	-6.58	-0.56	2.6e-9	Exhaled nitric oxide output;
THYM	cis	rs3741151	0.773	rs73546720	chr11:73252409	C/T	cg17517138	chr11:73019481	ARHGEF17	0.9	4.71	0.43	8.56e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs6430585	0.878	rs9677760	chr2:136538939	T/A	cg23851026	chr2:136556271	LCT	-0.65	-5.9	-0.52	5.51e-8	Corneal structure;
THYM	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg25566285	chr7:158114605	PTPRN2	0.77	6.92	0.58	5.36e-10	Response to amphetamines;
THYM	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg26384229	chr12:38710491	ALG10B	-1.06	-11.07	-0.75	8.9e-19	Heart rate;
THYM	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.81	5.91	0.52	5.36e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg00129232	chr17:37814104	STARD3	-0.87	-7.03	-0.59	3.07e-10	Asthma;
THYM	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12291225	0.839	rs4757244	chr11:14258655	A/G	cg19336497	chr11:14380999	RRAS2	0.56	5.44	0.49	4.07e-7	Sense of smell;
THYM	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg16586182	chr3:47516702	SCAP	-0.62	-5.45	-0.49	3.98e-7	Colorectal cancer;
THYM	cis	rs12142240	0.698	rs1135460	chr1:46815970	T/C	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs10887741	0.646	rs11202502	chr10:89437933	C/T	cg13926569	chr10:89418898	PAPSS2	0.61	6.79	0.57	9.67e-10	Exercise (leisure time);
THYM	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg18128536	chr17:47092178	IGF2BP1	-0.44	-4.89	-0.45	4.13e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs988913	0.957	rs7746965	chr6:54844432	G/T	cg19716238	chr6:54711378	FAM83B	0.5	4.91	0.45	3.76e-6	Menarche (age at onset);
THYM	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg00376283	chr12:123451042	ABCB9	0.74	5.11	0.46	1.67e-6	Neutrophil percentage of white cells;
THYM	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg09549813	chr16:4587862	C16orf5	0.58	6.19	0.54	1.49e-8	Schizophrenia;
THYM	cis	rs4730276	0.607	rs7794871	chr7:107522132	A/T	cg23293999	chr7:106826042	HBP1	-0.59	-4.71	-0.43	8.54e-6	Ulcerative colitis;
THYM	cis	rs28595532	0.764	rs56071514	chr4:119761833	T/C	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs514406	0.661	rs550561	chr1:53375134	C/T	cg25767906	chr1:53392781	SCP2	-0.64	-6.44	-0.55	4.84e-9	Monocyte count;
THYM	cis	rs2712184	0.756	rs2024487	chr2:217663271	C/T	cg05032264	chr2:217675019	NA	0.54	4.45	0.42	2.32e-5	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs728616	0.557	rs17107449	chr10:81715696	C/T	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2639990	1.000	rs632157	chr18:72911548	G/A	cg21330207	chr18:72916311	ZADH2	1.27	6.02	0.53	3.29e-8	Vascular endothelial growth factor levels;
THYM	cis	rs9325144	0.560	rs10506125	chr12:39120287	C/T	cg13010199	chr12:38710504	ALG10B	0.58	4.58	0.43	1.43e-5	Morning vs. evening chronotype;
THYM	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg16586182	chr3:47516702	SCAP	0.65	5.63	0.5	1.85e-7	Colorectal cancer;
THYM	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg11494091	chr17:61959527	GH2	1.08	16.92	0.87	2.03e-30	Prudent dietary pattern;
THYM	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg11752832	chr7:134001865	SLC35B4	0.68	4.63	0.43	1.14e-5	Mean platelet volume;
THYM	trans	rs10802346	0.545	rs2362252	chr1:246371574	A/C	cg22732515	chr19:44031385	ETHE1	1.04	9.22	0.69	7.6e-15	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg13683864	chr3:40499215	RPL14	-0.73	-6.56	-0.56	2.77e-9	Renal cell carcinoma;
THYM	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg05697832	chr7:4257050	SDK1	-0.71	-6.46	-0.55	4.42e-9	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
THYM	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg00071950	chr4:10020882	SLC2A9	0.85	9.64	0.7	9.78e-16	Bone mineral density;
THYM	cis	rs236352	0.538	rs8472	chr6:36896437	T/G	cg03410223	chr6:36853544	C6orf89	0.72	6.0	0.52	3.51e-8	Heart rate;
THYM	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg24846680	chr1:228362309	C1orf69	0.51	4.49	0.42	2.01e-5	Diastolic blood pressure;
THYM	cis	rs4713118	0.629	rs203889	chr6:28021775	T/G	cg23281280	chr6:28129359	ZNF389	0.61	4.74	0.44	7.58e-6	Parkinson's disease;
THYM	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg03188948	chr7:1209495	NA	1.04	6.09	0.53	2.41e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.12	-0.47	1.58e-6	Primary biliary cholangitis;
THYM	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg06713675	chr4:122721982	EXOSC9	-0.89	-10.08	-0.72	1.1e-16	Type 2 diabetes;
THYM	cis	rs9560113	1.000	rs9555810	chr13:112181437	C/G	cg14154082	chr13:112174009	NA	0.86	7.91	0.63	4.63e-12	Menarche (age at onset);
THYM	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg07570687	chr10:102243282	WNT8B	0.84	8.04	0.64	2.45e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg03709012	chr19:19516395	GATAD2A	-0.74	-5.8	-0.51	8.48e-8	Tonsillectomy;
THYM	cis	rs2404602	0.684	rs1011084	chr15:77007480	C/G	cg23625390	chr15:77176239	SCAPER	-0.83	-5.7	-0.5	1.36e-7	Blood metabolite levels;
THYM	cis	rs2219968	0.683	rs6992683	chr8:78907068	T/C	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9296092	0.517	rs9461877	chr6:33516667	C/T	cg13560919	chr6:33536144	NA	-0.93	-9.07	-0.68	1.58e-14	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	trans	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.37	0.65	5.06e-13	Corneal astigmatism;
THYM	cis	rs860818	1.000	rs1728327	chr7:23235483	A/G	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg24818145	chr4:99064322	C4orf37	0.73	5.76	0.51	1.02e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg17063962	chr7:91808500	NA	1.11	12.15	0.78	4.74e-21	Breast cancer;
THYM	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg16989719	chr2:238392110	NA	-0.6	-5.82	-0.51	8.08e-8	Prostate cancer;
THYM	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs4731207	0.724	rs10224946	chr7:124531338	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs8018808	1.000	rs11844594	chr14:77843814	T/C	cg20045696	chr14:77926864	AHSA1	-0.53	-4.74	-0.44	7.5e-6	Myeloid white cell count;
THYM	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg05855489	chr10:104503620	C10orf26	0.56	4.49	0.42	1.99e-5	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs8078723	1.000	rs4795412	chr17:38150604	C/T	cg17467752	chr17:38218738	THRA	0.87	7.22	0.59	1.3e-10	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs4767364	0.961	rs10850024	chr12:112718510	C/A	cg10833066	chr12:111807467	FAM109A	0.45	5.11	0.46	1.64e-6	Oral cavity and pharyngeal cancer;
THYM	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg08132940	chr7:1081526	C7orf50	-1.15	-6.55	-0.56	2.95e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg06850241	chr22:41845214	NA	0.54	4.53	0.42	1.74e-5	Cannabis dependence symptom count;
THYM	cis	rs800586	0.788	rs800574	chr8:116717451	A/C	cg04656070	chr8:116661063	TRPS1	0.48	4.57	0.42	1.47e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs854765	0.663	rs1108648	chr17:17750558	G/A	cg16928487	chr17:17741425	SREBF1	0.53	5.11	0.46	1.66e-6	Total body bone mineral density;
THYM	cis	rs10207060	1.000	rs10207060	chr2:240687289	A/C	cg20333904	chr2:240724165	NA	-0.57	-4.95	-0.45	3.15e-6	Obesity-related traits;
THYM	cis	rs9543976	0.858	rs9530447	chr13:76166802	G/A	cg01531495	chr13:76123901	UCHL3	0.75	5.05	0.46	2.1e-6	Diabetic retinopathy;
THYM	cis	rs6558530	0.965	rs7460287	chr8:1708274	G/C	cg09410841	chr8:1729607	CLN8	0.75	5.51	0.49	3.01e-7	Systolic blood pressure;
THYM	cis	rs7781557	1.000	rs4610658	chr7:102445895	T/C	cg06322601	chr7:102330635	NA	0.62	4.57	0.42	1.48e-5	Colorectal adenoma (advanced);
THYM	cis	rs4242434	0.857	rs11777808	chr8:22462755	A/C	cg03733263	chr8:22462867	KIAA1967	1.13	13.93	0.82	1.12e-24	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs4262150	0.883	rs72802882	chr5:152242673	C/T	cg06854687	chr5:151642065	NA	0.64	4.46	0.42	2.27e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg15448220	chr1:150897856	SETDB1	0.92	8.02	0.64	2.73e-12	Melanoma;
THYM	cis	rs912057	0.632	rs1294432	chr6:6745027	C/T	cg06612196	chr6:6737390	NA	0.71	11.9	0.77	1.57e-20	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg03929089	chr4:120376271	NA	-0.99	-12.81	-0.8	2.07e-22	Height;
THYM	cis	rs7513165	0.660	rs12040249	chr1:204158228	C/T	cg04791601	chr1:204159016	NA	0.37	4.6	0.43	1.31e-5	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
THYM	cis	rs10256972	0.527	rs2949170	chr7:1216438	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.48	-5.66	-0.5	1.58e-7	Longevity;Endometriosis;
THYM	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg00129232	chr17:37814104	STARD3	0.69	4.45	0.42	2.32e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs11771526	0.892	rs62457539	chr7:32364604	G/A	cg27532318	chr7:32358331	NA	0.95	5.63	0.5	1.85e-7	Body mass index;
THYM	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg27446573	chr6:127587934	RNF146	0.78	6.36	0.55	6.94e-9	Breast cancer;
THYM	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg02734326	chr4:10020555	SLC2A9	0.77	6.51	0.56	3.47e-9	Bone mineral density;
THYM	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg17911788	chr17:44343683	NA	0.56	5.57	0.5	2.37e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1557488	0.565	rs10750348	chr11:126695954	C/T	cg03950493	chr11:126582183	KIRREL3	-0.4	-4.55	-0.42	1.57e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs995000	0.965	rs3913007	chr1:62921586	T/C	cg06896770	chr1:63153194	DOCK7	1.0	8.17	0.64	1.31e-12	Triglyceride levels;
THYM	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg12011299	chr4:100065546	ADH4	0.81	7.8	0.62	7.91e-12	Alcohol dependence;
THYM	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg11266682	chr4:10021025	SLC2A9	0.66	9.75	0.71	5.71e-16	Bone mineral density;
THYM	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg01059385	chr22:42394853	WBP2NL	0.78	5.06	0.46	2.02e-6	Birth weight;
THYM	cis	rs28595532	0.920	rs56042726	chr4:119751777	T/A	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs6815814	0.851	rs9715769	chr4:38774489	A/C	cg02016764	chr4:38805732	TLR1	-0.53	-4.47	-0.42	2.12e-5	Breast cancer;
THYM	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg17775962	chr7:1200435	ZFAND2A	0.42	5.05	0.46	2.11e-6	Longevity;Endometriosis;
THYM	cis	rs28785552	0.800	rs1971063	chr19:53232854	G/C	cg22067481	chr19:53234126	ZNF611	-1.0	-10.98	-0.75	1.36e-18	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs17401966	0.894	rs11587309	chr1:10446596	G/T	cg19773385	chr1:10388646	KIF1B	-0.6	-4.69	-0.43	9.25e-6	Hepatocellular carcinoma;
THYM	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg11871910	chr12:69753446	YEATS4	1.06	9.8	0.71	4.32e-16	Blood protein levels;
THYM	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg20887711	chr4:1340912	KIAA1530	-0.55	-4.51	-0.42	1.85e-5	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3008870	1.000	rs2065000	chr1:67468124	G/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.97	-8.06	-0.64	2.24e-12	Lymphocyte percentage of white cells;
THYM	cis	rs9467711	0.651	rs13212534	chr6:25983010	G/A	cg16898833	chr6:26189333	HIST1H4D	1.33	4.61	0.43	1.28e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg04034577	chr2:241836375	C2orf54	-0.44	-7.84	-0.63	6.6e-12	Urinary metabolites;
THYM	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg04865290	chr3:52927548	TMEM110	-0.88	-4.55	-0.42	1.59e-5	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs1728785	1.000	rs1170443	chr16:68573295	G/C	cg02972257	chr16:68554789	NA	-0.75	-4.62	-0.43	1.22e-5	Ulcerative colitis;
THYM	cis	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg06521331	chr12:34319734	NA	-0.86	-6.28	-0.54	1.01e-8	Morning vs. evening chronotype;
THYM	cis	rs4499344	0.769	rs114289041	chr19:33083746	A/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.77	-5.4	-0.48	4.91e-7	Mean platelet volume;
THYM	cis	rs6840360	0.967	rs1511170	chr4:152701110	A/G	cg22705602	chr4:152727874	NA	-0.6	-6.54	-0.56	3.08e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1055129	0.681	rs2290771	chr17:73844748	A/G	cg12407791	chr17:73824354	UNC13D	-0.49	-5.31	-0.48	7.3e-7	White matter hyperintensity burden;
THYM	cis	rs9581943	0.967	rs9581929	chr13:28464203	C/T	cg16302790	chr13:28498334	PDX1	0.52	4.59	0.43	1.33e-5	Pancreatic cancer;
THYM	cis	rs11585357	0.947	rs72646789	chr1:17610030	C/T	cg08277548	chr1:17600880	PADI3	-0.93	-6.24	-0.54	1.23e-8	Hair shape;
THYM	cis	rs10489202	1.000	rs4656564	chr1:167928992	T/C	cg24449463	chr1:168025552	DCAF6	-0.85	-6.66	-0.56	1.81e-9	Schizophrenia;
THYM	cis	rs59698941	0.943	rs59634464	chr5:132178735	A/G	cg02081065	chr5:132209139	LEAP2	-0.96	-6.11	-0.53	2.22e-8	Apolipoprotein A-IV levels;
THYM	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg25208724	chr1:156163844	SLC25A44	1.17	13.26	0.81	2.43e-23	Testicular germ cell tumor;
THYM	cis	rs2721195	0.626	rs59464125	chr8:145857786	G/A	cg26752003	chr8:145688521	CYHR1	0.7	6.14	0.53	1.89e-8	Age at first birth;
THYM	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg17401067	chr22:41840292	TOB2	0.49	4.6	0.43	1.32e-5	Vitiligo;
THYM	cis	rs7523273	1.000	rs1142469	chr1:207965427	G/A	cg22525895	chr1:207977042	MIR29B2	-0.82	-7.7	-0.62	1.26e-11	Schizophrenia;
THYM	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg08807101	chr21:30365312	RNF160	0.94	7.64	0.62	1.69e-11	Dental caries;
THYM	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg02788857	chr8:22132959	PIWIL2	0.61	5.52	0.49	2.92e-7	Hypertriglyceridemia;
THYM	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg09469691	chr10:81107165	PPIF	0.72	5.92	0.52	5.13e-8	Height;
THYM	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg02725872	chr8:58115012	NA	1.1	8.57	0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs747782	0.639	rs61649224	chr11:48057640	G/A	cg24672777	chr11:48374446	OR4C45	-0.95	-5.2	-0.47	1.12e-6	Intraocular pressure;
THYM	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg03929089	chr4:120376271	NA	-1.0	-12.64	-0.79	4.61e-22	Height;
THYM	cis	rs6674176	0.628	rs12145999	chr1:44428632	C/T	cg15962314	chr1:44399869	ARTN	0.52	4.99	0.46	2.72e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs8017423	0.935	rs11159959	chr14:90733656	C/T	cg04374321	chr14:90722782	PSMC1	-0.64	-4.54	-0.42	1.65e-5	Mortality in heart failure;
THYM	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg12963246	chr6:28129442	ZNF389	0.79	6.64	0.56	1.93e-9	Parkinson's disease;
THYM	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg12193833	chr17:30244370	NA	-0.66	-4.78	-0.44	6.37e-6	Hip circumference adjusted for BMI;
THYM	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg07870213	chr5:140052090	DND1	0.73	8.28	0.65	7.61e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7904368	0.901	rs7923189	chr10:16850214	C/T	cg14835575	chr10:16859367	RSU1	0.6	4.93	0.45	3.47e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
THYM	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg13683864	chr3:40499215	RPL14	-1.01	-10.37	-0.73	2.73e-17	Renal cell carcinoma;
THYM	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.8	-6.83	-0.57	7.84e-10	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg03929089	chr4:120376271	NA	-0.99	-12.83	-0.8	1.9e-22	Height;
THYM	cis	rs4638749	0.677	rs6755078	chr2:108818270	T/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg11764359	chr7:65958608	NA	-0.67	-4.8	-0.44	5.81e-6	Aortic root size;
THYM	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.03	10.05	0.72	1.3e-16	Colorectal cancer;
THYM	cis	rs6496932	0.755	rs12905673	chr15:85889771	C/T	cg19183879	chr15:85880815	NA	-0.5	-4.49	-0.42	1.98e-5	Central corneal thickness;Corneal structure;
THYM	cis	rs6429082	0.714	rs704719	chr1:235667170	G/A	cg26050004	chr1:235667680	B3GALNT2	0.74	6.17	0.53	1.69e-8	Adiposity;
THYM	cis	rs931812	0.825	rs6993937	chr8:101898707	A/G	cg07585502	chr8:101912084	NA	-0.57	-4.52	-0.42	1.76e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg07606381	chr6:8435919	SLC35B3	0.62	4.62	0.43	1.21e-5	Motion sickness;
THYM	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg04234412	chr22:24373322	LOC391322	0.86	7.82	0.63	7.03e-12	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs6732160	0.967	rs6760964	chr2:73387386	C/G	cg24220031	chr2:73402428	NA	-0.68	-6.63	-0.56	2.07e-9	Intelligence (multi-trait analysis);
THYM	cis	rs3760982	0.585	rs11673490	chr19:44298885	C/A	cg11993925	chr19:44307056	LYPD5	0.64	5.02	0.46	2.4e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs684232	0.623	rs2543779	chr17:576362	C/A	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.38	-4.46	-0.42	2.25e-5	Prostate cancer;
THYM	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg15921436	chr17:44337874	NA	-0.91	-6.85	-0.58	7.19e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.03	9.77	0.71	5.25e-16	Colorectal cancer;
THYM	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs600806	0.815	rs10858088	chr1:109923586	C/T	cg23032129	chr1:109941072	SORT1	-0.59	-5.03	-0.46	2.31e-6	Intelligence (multi-trait analysis);
THYM	cis	rs870825	0.616	rs4444872	chr4:185628405	A/G	cg04058563	chr4:185651563	MLF1IP	1.02	8.16	0.64	1.36e-12	Blood protein levels;
THYM	cis	rs11997175	0.583	rs7464599	chr8:33817572	G/A	ch.8.33884649F	chr8:33765107	NA	0.79	5.73	0.51	1.16e-7	Body mass index;
THYM	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg10661904	chr17:79619235	PDE6G	-0.65	-6.26	-0.54	1.12e-8	Eye color traits;
THYM	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg17074396	chr22:49843754	NA	-0.4	-4.76	-0.44	6.95e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs8114671	0.562	rs6058137	chr20:33475074	G/A	cg08999081	chr20:33150536	PIGU	0.63	5.21	0.47	1.09e-6	Height;
THYM	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg22117172	chr7:91764530	CYP51A1	0.37	4.72	0.44	8.16e-6	Breast cancer;
THYM	cis	rs7635838	0.587	rs1992910	chr3:11311942	C/T	cg00170343	chr3:11313890	ATG7	0.66	4.92	0.45	3.63e-6	HDL cholesterol;
THYM	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03452623	chr4:187889614	NA	-1.16	-18.39	-0.88	4.68e-33	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg18402987	chr7:1209562	NA	1.1	6.73	0.57	1.27e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs921968	0.643	rs4674319	chr2:219510320	C/T	cg02176678	chr2:219576539	TTLL4	0.62	5.78	0.51	9.48e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg03517284	chr6:25882590	NA	-0.67	-4.47	-0.42	2.14e-5	Height;
THYM	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg06558623	chr16:89946397	TCF25	1.3	5.88	0.52	6.05e-8	Skin colour saturation;
THYM	cis	rs258322	0.606	rs164752	chr16:89722390	G/A	cg06017697	chr16:89976667	TCF25	-0.52	-4.5	-0.42	1.94e-5	Melanoma;Black vs. red hair color;
THYM	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg16586182	chr3:47516702	SCAP	-0.61	-5.27	-0.48	8.45e-7	Colorectal cancer;
THYM	cis	rs611744	0.647	rs647907	chr8:109251374	T/C	cg21045802	chr8:109455806	TTC35	0.66	5.99	0.52	3.78e-8	Dupuytren's disease;
THYM	cis	rs11989744	0.843	rs10481331	chr8:23559257	T/C	cg04349084	chr8:23602677	NA	0.49	5.3	0.48	7.6e-7	Waist-hip ratio;
THYM	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg23187316	chr7:1099788	C7orf50	0.59	4.52	0.42	1.76e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.43	-0.49	4.36e-7	Menopause (age at onset);
THYM	cis	rs2816062	0.813	rs6698315	chr1:18895806	A/G	cg18795169	chr1:18902165	NA	-0.99	-12.16	-0.78	4.55e-21	Urate levels in lean individuals;
THYM	cis	rs4262150	0.846	rs72802861	chr5:152230416	C/T	cg06854687	chr5:151642065	NA	0.66	4.63	0.43	1.17e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg25208724	chr1:156163844	SLC25A44	1.13	12.93	0.8	1.15e-22	Testicular germ cell tumor;
THYM	cis	rs6838801	0.521	rs12501918	chr4:77560294	T/C	cg01477861	chr4:77609841	SHROOM3	-0.47	-4.94	-0.45	3.35e-6	Cleft lip with or without cleft palate;
THYM	trans	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg10856724	chr12:34555212	NA	-1.01	-9.46	-0.7	2.39e-15	Bladder cancer;
THYM	cis	rs6032067	0.641	rs17423416	chr20:43758144	G/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.67	-5.92	-0.52	5.17e-8	Blood protein levels;
THYM	cis	rs56104184	0.578	rs7254608	chr19:49395774	G/T	cg21252483	chr19:49399788	TULP2	-0.64	-5.87	-0.52	6.41e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs861020	0.582	rs630065	chr1:209998662	C/T	cg05527609	chr1:210001259	C1orf107	0.84	6.74	0.57	1.22e-9	Orofacial clefts;
THYM	cis	rs55665837	1.000	rs3923294	chr11:14441402	T/G	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	trans	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg12310025	chr6:25882481	NA	0.66	5.35	0.48	6.12e-7	Schizophrenia;
THYM	cis	rs6570726	0.967	rs9403706	chr6:145795187	C/T	cg23711669	chr6:146136114	FBXO30	-0.76	-7.02	-0.58	3.36e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12122100	0.526	rs12122534	chr1:146504399	A/G	cg22671717	chr1:146548657	NA	0.51	5.03	0.46	2.28e-6	HIV-1 control;
THYM	cis	rs12496230	0.953	rs12494775	chr3:66874105	A/G	cg17646820	chr3:66848679	NA	-0.9	-5.47	-0.49	3.64e-7	Type 2 diabetes;
THYM	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg08885076	chr2:99613938	TSGA10	-0.66	-6.08	-0.53	2.47e-8	Chronic sinus infection;
THYM	cis	rs11969893	0.737	rs9386262	chr6:101427687	G/T	cg12253828	chr6:101329408	ASCC3	1.25	6.98	0.58	3.93e-10	Economic and political preferences (immigration/crime);
THYM	cis	rs3741151	1.000	rs57893472	chr11:73042826	C/T	cg12959048	chr11:73096162	RELT	-0.46	-4.81	-0.44	5.69e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	trans	rs4262150	0.883	rs72802890	chr5:152255145	G/T	cg08281791	chr5:76607845	PDE8B	0.92	6.91	0.58	5.62e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg08430604	chr3:44902960	MIR564;TMEM42	0.53	5.05	0.46	2.09e-6	Depressive symptoms;
THYM	cis	rs490234	0.902	rs10739662	chr9:128278687	T/C	cg14078157	chr9:128172775	NA	-0.62	-4.98	-0.45	2.85e-6	Mean arterial pressure;
THYM	cis	rs2115630	0.791	rs2008262	chr15:85305270	C/T	cg11189052	chr15:85197271	WDR73	-0.63	-4.97	-0.45	2.98e-6	P wave terminal force;
THYM	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	9.33	0.69	4.57e-15	Platelet count;
THYM	cis	rs3862030	0.839	rs12570859	chr10:104257226	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.68	-5.74	-0.51	1.15e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs6032067	0.929	rs2233898	chr20:43850525	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.41	-0.55	5.57e-9	Blood protein levels;
THYM	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg12935359	chr14:103987150	CKB	-0.41	-4.93	-0.45	3.49e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9733	0.566	rs112967224	chr1:150677263	G/A	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11890956	chr21:40555474	PSMG1	1.17	13.11	0.8	4.95e-23	Cognitive function;
THYM	cis	rs986417	1.000	rs6573313	chr14:60961299	A/G	cg27398547	chr14:60952738	C14orf39	1.22	6.38	0.55	6.44e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg06917634	chr15:78832804	PSMA4	0.96	8.76	0.67	7.4e-14	Sudden cardiac arrest;
THYM	cis	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg21775007	chr8:11205619	TDH	0.6	4.69	0.43	9.16e-6	Neuroticism;
THYM	trans	rs28595532	0.557	rs7696047	chr4:119303024	G/A	cg26518628	chr1:97050305	NA	-1.13	-8.18	-0.64	1.27e-12	Cannabis dependence symptom count;
THYM	cis	rs5985	0.659	rs3024326	chr6:6317942	A/G	cg16530177	chr6:6320324	F13A1	0.7	5.83	0.51	7.44e-8	End-stage coagulation;
THYM	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs7084921	0.547	rs12780035	chr10:101874844	C/T	cg11344164	chr10:101878520	NA	-0.55	-4.69	-0.43	9.12e-6	Bone mineral density;
THYM	cis	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.58	5.9	0.52	5.68e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2050392	0.931	rs2265187	chr10:30690844	C/T	cg02070205	chr10:30722105	MAP3K8	-0.5	-4.47	-0.42	2.18e-5	Inflammatory bowel disease;
THYM	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg27534772	chr1:16042836	PLEKHM2	-0.47	-5.15	-0.47	1.41e-6	Systolic blood pressure;
THYM	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg08901578	chr4:187885870	NA	-0.63	-5.79	-0.51	8.9e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28595532	0.920	rs114584210	chr4:119773363	G/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg06618935	chr21:46677482	NA	-0.97	-9.08	-0.68	1.51e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg01475377	chr6:109611718	NA	-0.56	-4.76	-0.44	7.04e-6	Reticulocyte fraction of red cells;
THYM	trans	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg07211511	chr3:129823064	LOC729375	-1.35	-9.54	-0.7	1.58e-15	Blood pressure (smoking interaction);
THYM	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.6	8.21	0.64	1.07e-12	Monocyte percentage of white cells;
THYM	cis	rs11030122	0.702	rs7950153	chr11:3951337	T/C	cg18678763	chr11:4115507	RRM1	-0.43	-5.53	-0.49	2.79e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg26721908	chr21:47610096	LSS	-0.87	-6.77	-0.57	1.08e-9	Testicular germ cell tumor;
THYM	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg22709100	chr7:91322751	NA	0.71	5.56	0.5	2.48e-7	Breast cancer;
THYM	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg09033563	chr22:24373618	LOC391322	0.6	5.6	0.5	2.05e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12476592	0.602	rs2592388	chr2:63896096	A/C	cg17519650	chr2:63277830	OTX1	-0.72	-4.68	-0.43	9.38e-6	Childhood ear infection;
THYM	cis	rs10911232	0.524	rs10911209	chr1:183013988	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs763014	0.865	rs2018789	chr16:632051	T/C	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs2562456	0.837	rs62110205	chr19:21760071	A/G	cg08562672	chr19:21860753	NA	-0.61	-4.72	-0.44	8.25e-6	Pain;
THYM	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg24069376	chr3:38537580	EXOG	0.69	6.79	0.57	9.87e-10	Electrocardiographic conduction measures;
THYM	cis	rs7178572	0.568	rs1565757	chr15:77657682	C/T	cg22256960	chr15:77711686	NA	-1.05	-8.4	-0.65	4.29e-13	Type 2 diabetes;
THYM	cis	rs931127	0.624	rs2306364	chr11:65412467	G/A	cg17480646	chr11:65405466	SIPA1	-0.76	-6.58	-0.56	2.56e-9	Systemic lupus erythematosus;
THYM	cis	rs860554	0.705	rs832144	chr1:201262477	G/A	cg01022117	chr1:201258280	PKP1	0.64	4.66	0.43	1.05e-5	Panic disorder;
THYM	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg24112000	chr20:60950667	NA	-0.8	-7.02	-0.58	3.26e-10	Colorectal cancer;
THYM	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs36051895	0.632	rs10974980	chr9:5140671	C/G	cg02405213	chr9:5042618	JAK2	-1.02	-10.39	-0.73	2.41e-17	Pediatric autoimmune diseases;
THYM	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg08859206	chr1:53392774	SCP2	-0.66	-7.55	-0.61	2.7e-11	Monocyte count;
THYM	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg21385522	chr1:16154831	NA	0.67	5.03	0.46	2.33e-6	Dilated cardiomyopathy;
THYM	cis	rs8112449	0.964	rs12977594	chr19:10520313	A/G	cg01466491	chr19:10523363	NA	-0.68	-6.58	-0.56	2.59e-9	Multiple sclerosis;Gastritis;
THYM	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg25918947	chr17:41365094	TMEM106A	-0.63	-5.18	-0.47	1.25e-6	Menopause (age at onset);
THYM	cis	rs2039659	0.719	rs1538051	chr13:86275893	A/C	cg25308322	chr13:86268291	NA	0.67	6.04	0.53	2.93e-8	Blood osmolality (transformed sodium);
THYM	cis	rs4343996	0.967	rs1525556	chr7:3351304	G/C	cg21248987	chr7:3385318	SDK1	-0.41	-4.95	-0.45	3.17e-6	Motion sickness;
THYM	cis	rs67460515	0.630	rs7638370	chr3:160921793	G/T	cg03342759	chr3:160939853	NMD3	-0.69	-5.23	-0.47	1.01e-6	Parkinson's disease;
THYM	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg11461670	chr8:22454935	PDLIM2	-0.36	-6.52	-0.56	3.3e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg13695892	chr22:41940480	POLR3H	-0.98	-7.49	-0.61	3.58e-11	Vitiligo;
THYM	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	8.11	0.64	1.8e-12	Lung cancer in ever smokers;
THYM	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg10053473	chr17:62856997	LRRC37A3	0.92	7.34	0.6	7.17e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs9462846	0.853	rs7741547	chr6:42873813	A/G	cg09436375	chr6:42928200	GNMT	-0.37	-4.51	-0.42	1.82e-5	Blood protein levels;
THYM	cis	rs289828	0.579	rs34538548	chr2:152147855	T/C	cg05960677	chr2:152117363	RBM43	0.75	7.25	0.6	1.1e-10	Blood protein levels;
THYM	cis	rs6543140	0.964	rs13390895	chr2:103075499	G/A	cg03938978	chr2:103052716	IL18RAP	0.58	5.84	0.51	7.16e-8	Blood protein levels;
THYM	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg03517284	chr6:25882590	NA	-0.8	-7.07	-0.59	2.61e-10	Intelligence (multi-trait analysis);
THYM	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg12000587	chr17:30186630	C17orf79	-0.47	-6.8	-0.57	9.04e-10	Hip circumference adjusted for BMI;
THYM	cis	rs7578361	1.000	rs6435551	chr2:150417183	T/A	cg17961725	chr2:150454027	NA	0.71	5.94	0.52	4.75e-8	Acute lymphoblastic leukemia (childhood);
THYM	trans	rs8002861	0.875	rs12869697	chr13:44439169	T/C	cg17145862	chr1:211918768	LPGAT1	-0.87	-7.86	-0.63	6.05e-12	Leprosy;
THYM	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs6710529	1	rs6710529	chr2:219645553	G/A	cg02176678	chr2:219576539	TTLL4	-0.46	-4.54	-0.42	1.62e-5	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg26043149	chr18:55253948	FECH	1.16	10.82	0.74	2.98e-18	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg18811423	chr2:55921094	PNPT1	0.69	6.41	0.55	5.6e-9	Metabolic syndrome;
THYM	cis	rs2637266	0.626	rs724113	chr10:78557309	C/T	cg18941641	chr10:78392320	NA	0.74	5.85	0.51	6.96e-8	Pulmonary function;
THYM	cis	rs6570726	0.791	rs425999	chr6:145819370	C/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.44	-0.49	4.16e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg13695892	chr22:41940480	POLR3H	0.86	6.35	0.55	7.2e-9	Vitiligo;
THYM	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.67	-6.26	-0.54	1.1e-8	Prudent dietary pattern;
THYM	cis	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg03159660	chr11:2078197	NA	0.61	4.63	0.43	1.17e-5	Calcium levels;
THYM	cis	rs288326	0.561	rs74953433	chr2:183872665	T/C	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.48	0.49	3.47e-7	Tonsillectomy;
THYM	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg12379764	chr21:47803548	PCNT	-0.67	-4.65	-0.43	1.09e-5	Testicular germ cell tumor;
THYM	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg18538332	chr22:24372958	LOC391322	1.09	14.7	0.83	3.24e-26	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs79387448	0.638	rs7600961	chr2:103035455	G/A	cg09003973	chr2:102972529	NA	1.08	6.39	0.55	6.26e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs4242434	0.787	rs1545837	chr8:22477807	T/C	cg21658235	chr8:22456391	C8orf58	0.58	5.16	0.47	1.32e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs889398	0.771	rs4985448	chr16:69899395	A/G	cg09409435	chr16:70099608	PDXDC2	0.66	5.25	0.47	9.17e-7	Body mass index;
THYM	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg19077165	chr18:44547161	KATNAL2	0.5	5.84	0.51	7.15e-8	Personality dimensions;
THYM	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg17554472	chr22:41940697	POLR3H	-0.71	-4.49	-0.42	2.01e-5	Vitiligo;
THYM	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg27286337	chr10:134555280	INPP5A	0.93	6.98	0.58	3.98e-10	Migraine;
THYM	cis	rs80319144	1.000	rs77920408	chr2:159227919	G/A	cg24986868	chr2:159312599	PKP4;CCDC148	0.58	4.66	0.43	1.05e-5	Restless legs syndrome;
THYM	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg13607699	chr17:42295918	UBTF	0.6	5.03	0.46	2.33e-6	Total body bone mineral density;
THYM	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg18681998	chr4:17616180	MED28	0.8	7.06	0.59	2.76e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13012494	chr21:47604986	C21orf56	-0.69	-4.8	-0.44	5.95e-6	Testicular germ cell tumor;
THYM	cis	rs11716531	0.537	rs7626646	chr3:27268316	G/T	cg02860705	chr3:27208620	NA	0.77	6.22	0.54	1.33e-8	Diastolic blood pressure;
THYM	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg17366294	chr4:99064904	C4orf37	0.57	6.81	0.57	8.63e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6988636	1.000	rs10096350	chr8:124184470	T/C	cg23067535	chr8:124195133	FAM83A	-1.1	-5.77	-0.51	9.8e-8	Urinary uromodulin levels;
THYM	cis	rs9309473	0.500	rs6757996	chr2:73772251	G/A	cg19565262	chr2:73869966	NAT8	-0.59	-4.93	-0.45	3.45e-6	Metabolite levels;
THYM	cis	rs2806561	0.734	rs7548692	chr1:23354877	T/A	cg12483005	chr1:23474871	LUZP1	0.54	5.47	0.49	3.57e-7	Height;
THYM	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg19761014	chr17:28927070	LRRC37B2	0.82	4.58	0.43	1.41e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7172809	0.561	rs74026923	chr15:77797927	C/T	cg22256960	chr15:77711686	NA	-0.61	-4.53	-0.42	1.7e-5	Glucose homeostasis traits;
THYM	cis	rs4455778	0.580	rs4524741	chr7:49105138	A/C	cg26309511	chr7:48887640	NA	0.68	5.94	0.52	4.63e-8	Lung cancer in never smokers;
THYM	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.67	-5.7	-0.5	1.37e-7	Coronary artery disease;
THYM	cis	rs8112449	0.893	rs12983665	chr19:10538373	A/G	cg01466491	chr19:10523363	NA	-0.67	-6.11	-0.53	2.17e-8	Multiple sclerosis;Gastritis;
THYM	cis	rs13256369	1.000	rs10103769	chr8:8573036	G/T	cg00074818	chr8:8560427	CLDN23	0.53	4.76	0.44	6.82e-6	Obesity-related traits;
THYM	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg13683864	chr3:40499215	RPL14	-0.91	-8.95	-0.68	2.94e-14	Renal cell carcinoma;
THYM	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg13695892	chr22:41940480	POLR3H	-0.77	-5.5	-0.49	3.17e-7	Vitiligo;
THYM	cis	rs2050392	0.762	rs306587	chr10:30722908	G/C	cg02070205	chr10:30722105	MAP3K8	-0.53	-4.54	-0.42	1.62e-5	Inflammatory bowel disease;
THYM	cis	rs6500395	1.000	rs1224	chr16:48572817	G/A	cg04672837	chr16:48644449	N4BP1	0.49	4.79	0.44	6.02e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs9902453	0.808	rs62068617	chr17:28144728	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.73	0.44	7.7e-6	Coffee consumption (cups per day);
THYM	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg17127132	chr2:85788382	GGCX	0.7	6.22	0.54	1.32e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs28829049	0.566	rs59681755	chr1:19528985	G/A	cg13387374	chr1:19411106	UBR4	0.64	4.68	0.43	9.41e-6	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs7267979	0.966	rs910996	chr20:25264196	A/G	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg03929089	chr4:120376271	NA	-0.99	-12.95	-0.8	1.04e-22	Height;
THYM	cis	rs72843506	0.656	rs10459970	chr17:19937341	G/A	cg12065943	chr17:19881925	AKAP10	-0.76	-4.58	-0.43	1.41e-5	Schizophrenia;
THYM	cis	rs7119038	0.818	rs56043232	chr11:118648373	C/T	cg19308663	chr11:118741387	NA	0.58	5.47	0.49	3.57e-7	Sjögren's syndrome;
THYM	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg11266682	chr4:10021025	SLC2A9	-0.6	-7.97	-0.63	3.55e-12	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs728616	0.717	rs61860016	chr10:81915889	G/C	cg27452691	chr10:81370291	SFTPA1	0.84	4.65	0.43	1.05e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg09455208	chr3:40491958	NA	0.52	5.47	0.49	3.62e-7	Renal cell carcinoma;
THYM	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06850241	chr22:41845214	NA	0.49	4.62	0.43	1.21e-5	Vitiligo;
THYM	cis	rs9790314	1.000	rs460508	chr3:161091089	C/G	cg04691961	chr3:161091175	C3orf57	0.6	5.01	0.46	2.5e-6	Morning vs. evening chronotype;
THYM	cis	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg09085632	chr11:111637200	PPP2R1B	1.16	11.93	0.77	1.35e-20	Primary sclerosing cholangitis;
THYM	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.37	-0.55	6.73e-9	Personality dimensions;
THYM	cis	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg09029085	chr17:47094198	IGF2BP1	0.47	6.53	0.56	3.17e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4845459	0.967	rs1581803	chr1:152592281	A/C	cg26135325	chr1:152595322	LCE3A	0.45	5.13	0.47	1.54e-6	Psoriasis;
THYM	trans	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg25214090	chr10:38739885	LOC399744	0.85	7.38	0.6	5.94e-11	Corneal astigmatism;
THYM	cis	rs6087990	0.899	rs4911110	chr20:31392366	C/T	cg13636640	chr20:31349939	DNMT3B	-0.91	-9.62	-0.7	1.07e-15	Ulcerative colitis;
THYM	cis	rs6496932	1.000	rs35796484	chr15:85825250	C/T	cg19183879	chr15:85880815	NA	0.54	4.56	0.42	1.53e-5	Central corneal thickness;Corneal structure;
THYM	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg26850624	chr5:429559	AHRR	-0.72	-5.31	-0.48	7.13e-7	Cystic fibrosis severity;
THYM	cis	rs2195525	0.572	rs3814758	chr11:119217818	A/G	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.46	5.21	0.47	1.09e-6	Urate levels;
THYM	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg10018233	chr7:150070692	REPIN1	0.45	7.76	0.62	9.63e-12	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg00024416	chr22:24240387	NA	-0.56	-5.56	-0.5	2.52e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	8.9	0.67	3.71e-14	Cognitive test performance;
THYM	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg15704280	chr7:45808275	SEPT13	-0.92	-8.38	-0.65	4.63e-13	Coronary artery disease;
THYM	cis	rs10493773	0.775	rs12738010	chr1:86102575	A/C	cg17807903	chr1:86174739	ZNHIT6	0.48	6.24	0.54	1.19e-8	Urate levels in overweight individuals;
THYM	cis	rs10992471	0.528	rs10761158	chr9:95205322	T/G	cg14631576	chr9:95140430	CENPP	-0.84	-8.02	-0.64	2.69e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.82	0.44	5.37e-6	Obesity-related traits;
THYM	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.64	4.88	0.45	4.24e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg02725872	chr8:58115012	NA	-0.69	-4.84	-0.44	5.03e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.39	5.76	0.51	1.05e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	trans	rs4650994	0.525	rs17361286	chr1:178521916	C/G	cg05059571	chr16:84539110	KIAA1609	-0.93	-10.98	-0.75	1.34e-18	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs3008870	0.709	rs62883160	chr1:67392889	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.79	6.63	0.56	1.99e-9	Lymphocyte percentage of white cells;
THYM	cis	rs10540	0.778	rs34046876	chr11:539058	C/T	cg21784768	chr11:537496	LRRC56	-1.21	-5.66	-0.5	1.61e-7	Body mass index;
THYM	cis	rs2281845	0.826	rs4915215	chr1:201077212	C/T	cg22815214	chr1:201083145	CACNA1S	-0.67	-6.19	-0.54	1.49e-8	Permanent tooth development;
THYM	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-4.79	-0.44	6.18e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03517284	chr6:25882590	NA	-0.97	-8.14	-0.64	1.49e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.596	rs7795218	chr7:124578380	C/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Body mass index;
THYM	cis	rs40363	0.868	rs37772	chr16:3512843	A/G	cg00484396	chr16:3507460	NAT15	0.69	8.08	0.64	2.08e-12	Tuberculosis;
THYM	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.94	-7.72	-0.62	1.16e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg11752832	chr7:134001865	SLC35B4	0.76	5.72	0.51	1.23e-7	Mean platelet volume;
THYM	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.73	7.27	0.6	1.02e-10	Lymphocyte counts;
THYM	cis	rs6500395	1.000	rs2354578	chr16:48593298	T/C	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7584330	0.518	rs78856668	chr2:238438055	A/C	cg14458575	chr2:238380390	NA	1.0	5.27	0.48	8.4e-7	Prostate cancer;
THYM	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg11752832	chr7:134001865	SLC35B4	0.7	5.01	0.46	2.5e-6	Mean platelet volume;
THYM	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg07507251	chr3:52567010	NT5DC2	0.41	4.89	0.45	4.17e-6	Bipolar disorder;
THYM	cis	rs899997	0.906	rs62010552	chr15:78987686	T/C	cg00639195	chr15:79103007	ADAMTS7	0.71	5.13	0.47	1.54e-6	Coronary artery disease or large artery stroke;
THYM	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg06481639	chr22:41940642	POLR3H	-0.67	-5.09	-0.46	1.79e-6	Vitiligo;
THYM	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg13395646	chr4:1353034	KIAA1530	-0.57	-5.59	-0.5	2.18e-7	Obesity-related traits;
THYM	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg06623918	chr6:96969491	KIAA0776	-1.11	-10.57	-0.74	9.82e-18	Headache;
THYM	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.34	-0.65	5.7e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs476633	0.691	rs28409265	chr15:41539404	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.66	-5.46	-0.49	3.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg12011299	chr4:100065546	ADH4	0.86	8.3	0.65	7.14e-13	Smoking initiation;
THYM	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg00999904	chr2:3704751	ALLC	-0.71	-4.85	-0.45	4.75e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg16586182	chr3:47516702	SCAP	0.63	5.6	0.5	2.12e-7	Colorectal cancer;
THYM	cis	rs2303759	0.676	rs10426452	chr19:49907690	G/A	cg22590775	chr19:49891494	CCDC155	0.56	4.8	0.44	5.93e-6	Multiple sclerosis;
THYM	cis	rs71403859	0.502	rs34766979	chr16:71475511	G/A	cg08717414	chr16:71523259	ZNF19	-1.45	-7.43	-0.61	4.75e-11	Post bronchodilator FEV1;
THYM	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.96	9.92	0.71	2.4e-16	Chronic sinus infection;
THYM	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg18402987	chr7:1209562	NA	0.73	5.27	0.48	8.58e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs5758659	0.594	rs739292	chr22:42368857	G/A	cg22189786	chr22:42395067	WBP2NL	-0.4	-4.48	-0.42	2.06e-5	Cognitive function;
THYM	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg27129171	chr3:47204927	SETD2	0.72	6.06	0.53	2.73e-8	Birth weight;
THYM	cis	rs4765905	1.000	rs10774035	chr12:2368674	C/T	cg09436713	chr12:2323135	CACNA1C	-0.36	-4.49	-0.42	2.04e-5	Schizophrenia;
THYM	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg00255919	chr5:131827918	IRF1	0.45	5.13	0.47	1.54e-6	Asthma (sex interaction);
THYM	cis	rs995000	0.868	rs6666816	chr1:63171199	C/T	cg06896770	chr1:63153194	DOCK7	-0.68	-4.86	-0.45	4.62e-6	Triglyceride levels;
THYM	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg22968622	chr17:43663579	NA	1.16	10.21	0.72	5.86e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7610301	0.954	rs4683250	chr3:46643208	C/T	cg22951056	chr3:46887651	NA	-0.77	-5.06	-0.46	2.06e-6	Blood protein levels;
THYM	cis	rs7567389	0.677	rs72845975	chr2:128086274	C/T	cg06038358	chr2:128176007	PROC	0.43	4.53	0.42	1.7e-5	Self-rated health;
THYM	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg11764359	chr7:65958608	NA	0.63	4.94	0.45	3.36e-6	Aortic root size;
THYM	cis	rs7084402	0.935	rs1658456	chr10:60304326	C/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.64	-0.5	1.72e-7	Refractive error;
THYM	cis	rs1003719	0.614	rs1053808	chr21:38525356	T/C	cg01329690	chr21:38580129	DSCR9	-0.34	-4.67	-0.43	9.8e-6	Eye color traits;
THYM	cis	rs66887589	0.837	rs6534135	chr4:120406302	A/G	cg13609457	chr4:120235615	NA	0.47	4.88	0.45	4.3e-6	Diastolic blood pressure;
THYM	cis	rs1448094	0.511	rs10746353	chr12:86150146	A/T	cg00310523	chr12:86230176	RASSF9	-0.57	-5.07	-0.46	1.98e-6	Major depressive disorder;
THYM	cis	rs8048589	0.604	rs11642033	chr16:12207990	A/G	cg02910054	chr16:12241554	SNX29	0.8	6.12	0.53	2.08e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs796364	0.806	rs11679676	chr2:201040981	C/T	cg17644776	chr2:200775616	C2orf69	-1.0	-4.48	-0.42	2.05e-5	Schizophrenia;
THYM	cis	rs425277	0.539	rs3128338	chr1:2046786	G/A	cg09260853	chr1:2094483	PRKCZ	-0.46	-4.71	-0.43	8.57e-6	Height;
THYM	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg03295274	chr13:50190584	NA	0.68	5.16	0.47	1.37e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
THYM	cis	rs2455799	0.552	rs2470516	chr3:15759050	T/G	cg16303742	chr3:15540471	COLQ	-0.55	-5.73	-0.51	1.19e-7	Mean platelet volume;
THYM	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs26232	0.583	rs26430	chr5:102365932	G/A	cg23492399	chr5:102201601	PAM	0.64	4.81	0.44	5.71e-6	Rheumatoid arthritis;
THYM	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	5.43	0.49	4.33e-7	Obesity-related traits;
THYM	cis	rs9549260	0.564	rs8000965	chr13:41279488	C/T	cg21288729	chr13:41239152	FOXO1	0.68	5.1	0.46	1.76e-6	Red blood cell count;
THYM	cis	rs55665837	0.961	rs12576926	chr11:14480292	C/T	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg06112835	chr11:68658793	MRPL21	-0.45	-6.44	-0.55	4.77e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11031096	0.711	rs11031156	chr11:4179021	C/T	cg22027985	chr11:4115532	RRM1	-0.5	-4.54	-0.42	1.63e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs2219968	0.525	rs4324910	chr8:78882513	A/G	cg00738934	chr8:78996279	NA	0.61	4.95	0.45	3.21e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6598955	0.671	rs11247908	chr1:26638222	G/A	cg08133631	chr1:26527909	CATSPER4	-0.58	-4.72	-0.44	8.08e-6	Obesity-related traits;
THYM	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg13609457	chr4:120235615	NA	0.51	4.8	0.44	5.83e-6	Corneal astigmatism;
THYM	cis	rs259964	1.000	rs259963	chr20:57824901	A/C	cg20910807	chr20:57875384	EDN3	-0.42	-4.54	-0.42	1.62e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs4662945	0.688	rs62174139	chr2:130202775	G/C	cg05903289	chr2:130345205	NA	-0.59	-5.69	-0.5	1.38e-7	Response to cytidine analogues (gemcitabine);
THYM	cis	rs1784581	0.775	rs7755404	chr6:162427731	T/C	cg17173639	chr6:162384350	PARK2	0.79	7.74	0.62	1.05e-11	Itch intensity from mosquito bite;
THYM	cis	rs59698941	0.943	rs41298946	chr5:132268390	A/G	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs9902453	0.933	rs9908901	chr17:28469713	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.83	0.44	5.26e-6	Coffee consumption (cups per day);
THYM	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg20744362	chr22:50050164	C22orf34	0.82	8.14	0.64	1.52e-12	Monocyte count;Monocyte percentage of white cells;
THYM	trans	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg17105206	chr16:67211972	KIAA0895L	-1.24	-7.06	-0.59	2.75e-10	Pulmonary function decline;
THYM	cis	rs1847202	0.787	rs13071878	chr3:72951084	G/A	cg27402429	chr3:72788294	NA	-0.71	-4.55	-0.42	1.56e-5	Motion sickness;
THYM	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg08999081	chr20:33150536	PIGU	-0.59	-4.66	-0.43	1.04e-5	Coronary artery disease;
THYM	cis	rs4845875	0.563	rs11121829	chr1:11834765	A/G	cg06193043	chr1:11908199	NPPA	0.58	4.83	0.44	5.33e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs9522267	0.535	rs4773393	chr13:112229755	A/G	cg10483660	chr13:112241077	NA	-0.58	-6.7	-0.57	1.49e-9	Hepatitis;
THYM	cis	rs12410462	0.502	rs78101727	chr1:227732069	C/T	cg04117972	chr1:227635322	NA	0.85	4.53	0.42	1.69e-5	Major depressive disorder;
THYM	cis	rs7681440	0.583	rs2619364	chr4:90759887	A/G	cg06632027	chr4:90757378	SNCA	-0.67	-5.33	-0.48	6.7e-7	Dementia with Lewy bodies;
THYM	cis	rs9649213	0.559	rs56997921	chr7:98009224	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.68	-5.75	-0.51	1.08e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg18477163	chr1:228402036	OBSCN	0.57	6.23	0.54	1.28e-8	Diastolic blood pressure;
THYM	cis	rs7668190	0.924	rs6554162	chr4:55093955	G/A	cg17187183	chr4:55093834	PDGFRA	0.61	4.61	0.43	1.27e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg15448220	chr1:150897856	SETDB1	0.88	7.49	0.61	3.44e-11	Melanoma;
THYM	cis	rs793571	0.650	rs12899638	chr15:58920275	G/A	cg05156742	chr15:59063176	FAM63B	0.68	5.5	0.49	3.16e-7	Schizophrenia;
THYM	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg02725872	chr8:58115012	NA	-0.81	-5.05	-0.46	2.12e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs3020264	0.566	rs2911968	chr8:6488505	C/T	cg14600420	chr8:7311130	SPAG11B	0.36	4.53	0.42	1.74e-5	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 24 weeks);
THYM	cis	rs10887741	0.546	rs7903516	chr10:89441102	T/C	cg13926569	chr10:89418898	PAPSS2	0.65	7.68	0.62	1.39e-11	Exercise (leisure time);
THYM	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg24531977	chr5:56204891	C5orf35	0.67	5.44	0.49	4.15e-7	Initial pursuit acceleration;
THYM	cis	rs6754311	0.773	rs680428	chr2:136630757	A/G	cg23851026	chr2:136556271	LCT	-0.5	-4.76	-0.44	6.97e-6	Mosquito bite size;
THYM	cis	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg12165864	chr7:66369176	NA	0.64	4.89	0.45	4.04e-6	Aortic root size;
THYM	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg08999081	chr20:33150536	PIGU	0.56	4.66	0.43	1.03e-5	Height;
THYM	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg15704280	chr7:45808275	SEPT13	-0.91	-8.03	-0.64	2.64e-12	Coronary artery disease;
THYM	cis	rs7404928	0.557	rs12927751	chr16:23938610	C/T	cg26685404	chr16:23957272	PRKCB	-0.58	-6.53	-0.56	3.16e-9	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs9915657	1.000	rs9910864	chr17:70123028	T/A	cg09344028	chr17:70110421	NA	0.46	4.5	0.42	1.94e-5	Thyroid hormone levels;
THYM	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.83	0.51	7.49e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.81	-7.97	-0.63	3.41e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12516959	chr21:47718080	NA	0.45	5.63	0.5	1.83e-7	Testicular germ cell tumor;
THYM	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg19748678	chr4:122722346	EXOSC9	0.73	5.15	0.47	1.42e-6	Type 2 diabetes;
THYM	trans	rs1973993	0.669	rs510552	chr1:96891671	A/G	cg10631902	chr5:14652156	NA	0.76	9.45	0.7	2.51e-15	Weight;
THYM	cis	rs11690935	0.550	rs4280427	chr2:172813218	G/A	cg13550731	chr2:172543902	DYNC1I2	0.64	4.95	0.45	3.23e-6	Schizophrenia;
THYM	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs13256369	1.000	rs10110591	chr8:8576608	G/T	cg00074818	chr8:8560427	CLDN23	-0.56	-5.27	-0.48	8.43e-7	Obesity-related traits;
THYM	cis	rs1448094	0.511	rs4278581	chr12:86151054	A/G	cg00310523	chr12:86230176	RASSF9	-0.56	-4.93	-0.45	3.47e-6	Major depressive disorder;
THYM	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg06634786	chr22:41940651	POLR3H	0.73	5.36	0.48	5.89e-7	Vitiligo;
THYM	cis	rs6546537	0.955	rs35947226	chr2:69845829	C/G	cg10773587	chr2:69614142	GFPT1	-0.58	-5.1	-0.46	1.76e-6	Serum thyroid-stimulating hormone levels;
THYM	cis	rs2742417	0.603	rs2673062	chr3:45763635	A/G	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs35934224	0.771	rs34820460	chr22:19869210	G/A	cg11182965	chr22:19864308	TXNRD2	-0.94	-7.08	-0.59	2.43e-10	Glaucoma (primary open-angle);
THYM	cis	rs10979	1.000	rs9403506	chr6:143887805	C/G	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs2219968	0.525	rs11987933	chr8:78871534	G/A	cg00738934	chr8:78996279	NA	0.6	4.94	0.45	3.35e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg15445000	chr17:37608096	MED1	0.41	5.04	0.46	2.26e-6	Urinary metabolites;
THYM	cis	rs600806	0.821	rs3879447	chr1:109891403	C/T	cg23616212	chr1:109941201	SORT1	-0.5	-4.72	-0.44	8.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1957429	0.901	rs1951490	chr14:65346957	G/T	cg23373153	chr14:65346875	NA	1.07	6.45	0.55	4.75e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg00576331	chr11:65640516	EFEMP2	0.68	4.58	0.43	1.42e-5	Crohn's disease;
THYM	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg08807101	chr21:30365312	RNF160	-0.8	-6.25	-0.54	1.15e-8	Dental caries;
THYM	cis	rs6785206	0.655	rs35627944	chr3:128534490	C/T	cg16766828	chr3:128327626	NA	0.5	4.67	0.43	1e-5	Lymphocyte percentage of white cells;
THYM	cis	rs34779708	0.931	rs2384287	chr10:35340559	A/G	cg03585969	chr10:35415529	CREM	0.64	4.5	0.42	1.93e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs1371867	0.810	rs2860518	chr8:101238120	G/T	cg06636551	chr8:101224915	SPAG1	0.61	5.79	0.51	9.01e-8	Atrioventricular conduction;
THYM	cis	rs62435770	0.790	rs62435792	chr6:169479271	G/A	cg07652237	chr6:170125491	PHF10	0.55	4.81	0.44	5.64e-6	Loneliness;
THYM	cis	rs2985684	0.948	rs12886130	chr14:50082753	T/C	cg02151108	chr14:50098012	C14orf104	-0.69	-5.74	-0.51	1.15e-7	Carotid intima media thickness;
THYM	cis	rs11771526	0.901	rs10244622	chr7:32302960	C/T	cg27511599	chr7:32358540	NA	0.6	4.49	0.42	2e-5	Body mass index;
THYM	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg00647820	chr17:40259828	DHX58	-0.62	-4.7	-0.43	8.68e-6	Fibrinogen levels;
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg12083535	chr12:100814114	SLC17A8	0.86	6.85	0.57	7.39e-10	Energy expenditure (24h);
THYM	cis	rs7584330	0.554	rs3751105	chr2:238428459	G/A	cg08992911	chr2:238395768	MLPH	0.82	5.08	0.46	1.9e-6	Prostate cancer;
THYM	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg00757033	chr12:89920650	WDR51B	0.75	10.23	0.72	5.28e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs4606347	0.789	rs75530919	chr1:66162617	G/T	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg26408565	chr15:76604113	ETFA	-0.55	-4.85	-0.45	4.73e-6	Blood metabolite levels;
THYM	cis	rs7536700	0.915	rs7533987	chr1:153660989	A/G	cg21279955	chr1:153747551	SLC27A3	-0.62	-4.56	-0.42	1.5e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg04267008	chr7:1944627	MAD1L1	0.62	5.51	0.49	3.01e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7224314	1.000	rs8070284	chr17:65387400	A/G	cg01507342	chr17:65387096	PITPNC1	-0.97	-10.88	-0.74	2.26e-18	Diisocyanate-induced asthma;
THYM	cis	rs192264	0.768	rs1069585	chr16:65981787	G/T	cg02795155	chr16:66785218	DYNC1LI2	0.58	4.58	0.43	1.4e-5	Subjective well-being;
THYM	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg00129232	chr17:37814104	STARD3	-0.95	-8.39	-0.65	4.42e-13	Asthma;
THYM	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.61	4.57	0.42	1.44e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg19875535	chr5:140030758	IK	0.61	5.25	0.47	9.4e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg19016782	chr12:123741754	C12orf65	-0.68	-4.49	-0.42	1.99e-5	Neutrophil percentage of white cells;
THYM	cis	rs208520	0.690	rs207094	chr6:66799009	G/A	cg07460842	chr6:66804631	NA	-1.06	-7.89	-0.63	5.14e-12	Exhaled nitric oxide output;
THYM	cis	rs7633857	0.532	rs9839984	chr3:160768912	C/T	cg03342759	chr3:160939853	NMD3	-0.63	-4.84	-0.44	5.04e-6	Educational attainment (years of education);
THYM	cis	rs8067545	0.750	rs11868084	chr17:19992717	A/G	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.61e-6	Schizophrenia;
THYM	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg11673840	chr17:47092156	IGF2BP1	-0.62	-8.26	-0.65	8.54e-13	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg12310025	chr6:25882481	NA	0.94	8.66	0.66	1.23e-13	Blood metabolite levels;
THYM	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11997175	0.509	rs67427312	chr8:33674377	A/G	ch.8.33884649F	chr8:33765107	NA	0.74	5.09	0.46	1.83e-6	Body mass index;
THYM	trans	rs4262150	0.883	rs12153328	chr5:152247221	T/C	cg08281791	chr5:76607845	PDE8B	0.93	6.87	0.58	6.5e-10	Bipolar disorder and schizophrenia;
THYM	trans	rs8002861	0.664	rs4942246	chr13:44404853	A/G	cg17145862	chr1:211918768	LPGAT1	0.85	7.65	0.62	1.63e-11	Leprosy;
THYM	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03647317	chr4:187891568	NA	-0.84	-9.05	-0.68	1.74e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg04944784	chr2:26401820	FAM59B	1.09	8.74	0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs7940866	0.845	rs2324314	chr11:130834589	A/C	cg12179176	chr11:130786555	SNX19	0.58	4.46	0.42	2.23e-5	Schizophrenia;
THYM	cis	rs7927771	0.725	rs11570094	chr11:47359706	A/C	cg18512352	chr11:47633146	NA	0.43	4.78	0.44	6.27e-6	Subjective well-being;
THYM	cis	rs448720	0.935	rs431214	chr15:68210593	T/C	cg23793686	chr15:68133972	NA	-0.5	-4.63	-0.43	1.17e-5	Cognitive performance;
THYM	cis	rs1160297	0.576	rs74181216	chr2:53093194	G/C	cg07782112	chr2:53107842	NA	0.77	6.24	0.54	1.19e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs526231	0.575	rs62362523	chr5:102313683	C/T	cg23492399	chr5:102201601	PAM	-0.61	-4.61	-0.43	1.27e-5	Primary biliary cholangitis;
THYM	cis	rs259964	1.000	rs259962	chr20:57824960	A/G	cg16205854	chr20:57875318	EDN3	-0.41	-4.57	-0.42	1.44e-5	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
THYM	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg18681998	chr4:17616180	MED28	-0.9	-8.5	-0.66	2.65e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7100689	0.646	rs10788586	chr10:82117435	A/G	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	6.9	0.58	5.65e-10	Obesity-related traits;
THYM	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg00757033	chr12:89920650	WDR51B	0.77	11.72	0.77	3.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg16342193	chr10:102329863	NA	-0.57	-5.93	-0.52	4.96e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs986417	1.000	rs1254265	chr14:60840478	T/C	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs977987	0.806	rs11640674	chr16:75394944	A/G	cg03315344	chr16:75512273	CHST6	0.72	6.11	0.53	2.19e-8	Dupuytren's disease;
THYM	cis	rs899997	1.000	rs12904489	chr15:79033925	T/A	cg00639195	chr15:79103007	ADAMTS7	-0.79	-5.55	-0.49	2.62e-7	Coronary artery disease or large artery stroke;
THYM	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	trans	rs11186	0.556	rs72906322	chr2:189957803	T/G	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg09455208	chr3:40491958	NA	0.46	4.66	0.43	1.02e-5	Renal cell carcinoma;
THYM	cis	rs11645898	0.810	rs72787046	chr16:72079342	A/G	cg14768367	chr16:72042858	DHODH	-0.8	-5.8	-0.51	8.85e-8	Blood protein levels;
THYM	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg14829155	chr15:31115871	NA	-0.55	-5.04	-0.46	2.26e-6	Huntington's disease progression;
THYM	cis	rs9811920	0.599	rs1688758	chr3:99539890	A/T	cg07805332	chr3:99536008	MIR548G;C3orf26	0.42	4.49	0.42	2.03e-5	Axial length;
THYM	cis	rs28595532	0.844	rs115573749	chr4:119756848	T/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs8048589	1.000	rs11648816	chr16:12184107	T/G	cg02910054	chr16:12241554	SNX29	0.71	5.87	0.52	6.48e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs7072216	0.763	rs942804	chr10:100168499	C/A	cg03852570	chr10:100175106	PYROXD2	0.38	4.89	0.45	4.04e-6	Metabolite levels;
THYM	cis	rs6138458	1.000	rs227658	chr20:24932028	A/G	cg06937882	chr20:24974362	C20orf3	-0.47	-4.45	-0.42	2.31e-5	Blood protein levels;
THYM	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg13852791	chr20:30311386	BCL2L1	0.74	5.35	0.48	6.15e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg23758822	chr17:41437982	NA	1.22	13.08	0.8	5.68e-23	Menopause (age at onset);
THYM	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg11301795	chr4:187892539	NA	-1.11	-18.94	-0.89	5.16e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.36	0.69	3.89e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6087990	0.735	rs2064350	chr20:31390533	T/C	cg13636640	chr20:31349939	DNMT3B	0.9	9.45	0.7	2.46e-15	Ulcerative colitis;
THYM	trans	rs4650994	0.544	rs6675811	chr1:178499068	T/A	cg05059571	chr16:84539110	KIAA1609	-0.84	-9.68	-0.7	7.86e-16	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg18477163	chr1:228402036	OBSCN	0.64	6.43	0.55	5.01e-9	Diastolic blood pressure;
THYM	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12039431	0.788	rs7535432	chr1:38051585	C/T	cg17933807	chr1:38061675	GNL2	-0.83	-6.17	-0.54	1.64e-8	Epithelial ovarian cancer;
THYM	cis	rs17321999	0.904	rs72787719	chr2:30474359	G/A	cg05247661	chr2:30472410	LBH	0.65	4.71	0.44	8.43e-6	Systemic lupus erythematosus;
THYM	cis	rs10511378	1.000	rs1520115	chr3:118182377	C/T	cg07612923	chr3:117604196	NA	0.68	4.56	0.42	1.53e-5	Obesity-related traits;
THYM	cis	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.59	-0.43	1.37e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg06917634	chr15:78832804	PSMA4	0.96	8.76	0.67	7.4e-14	Sudden cardiac arrest;
THYM	cis	rs5769765	0.671	rs138817	chr22:50163058	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.51	4.97	0.45	2.93e-6	Schizophrenia;
THYM	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg08885076	chr2:99613938	TSGA10	-0.66	-6.08	-0.53	2.47e-8	Chronic sinus infection;
THYM	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg26384229	chr12:38710491	ALG10B	0.95	7.64	0.62	1.67e-11	Bladder cancer;
THYM	cis	rs9527	0.590	rs2281877	chr10:104866062	C/T	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs644799	0.562	rs654345	chr11:95581865	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	5.88	0.52	6.1e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2213920	0.679	rs9409160	chr9:118227046	G/A	cg13918206	chr9:118159781	DEC1	0.8	4.54	0.42	1.67e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs4936891	0.520	rs4936874	chr11:123870227	C/T	cg22125253	chr11:123886957	OR10G4	0.57	4.96	0.45	3.05e-6	Male fertility;
THYM	cis	rs7104764	1.000	rs6598062	chr11:243712	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.16	10.92	0.75	1.77e-18	Menarche (age at onset);
THYM	cis	rs7572733	0.534	rs696817	chr2:198722225	A/G	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg06009448	chr7:1102226	C7orf50	0.45	5.14	0.47	1.49e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg13298116	chr11:62369859	EML3;MTA2	0.68	9.55	0.7	1.53e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2456568	0.548	rs6483280	chr11:93661592	T/C	cg26875233	chr11:93583750	C11orf90	-0.49	-5.53	-0.49	2.86e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2448490	0.642	rs573589	chr11:65483981	C/T	cg17480646	chr11:65405466	SIPA1	0.71	5.64	0.5	1.74e-7	Platelet count;
THYM	cis	rs55728055	0.661	rs7286496	chr22:31983760	G/A	cg10537193	chr22:32026975	PISD	-0.66	-4.61	-0.43	1.26e-5	Age-related hearing impairment;
THYM	cis	rs11083475	0.573	rs73040743	chr19:39269893	T/G	cg07403899	chr19:39283540	NA	-0.58	-4.59	-0.43	1.37e-5	Heart rate;
THYM	cis	rs6500395	0.775	rs8050844	chr16:48665696	A/G	cg04672837	chr16:48644449	N4BP1	0.47	4.62	0.43	1.18e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.1	7.58	0.61	2.26e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg10856724	chr12:34555212	NA	-1.07	-10.03	-0.72	1.46e-16	Morning vs. evening chronotype;
THYM	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg18252515	chr7:66147081	NA	-1.62	-8.8	-0.67	5.99e-14	Diabetic kidney disease;
THYM	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg12310025	chr6:25882481	NA	0.78	6.37	0.55	6.73e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg02380750	chr20:61661411	NA	0.63	6.24	0.54	1.23e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg06618935	chr21:46677482	NA	0.99	9.3	0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs10791323	0.604	rs2723615	chr11:133704567	C/T	cg14349672	chr11:133703707	NA	-0.52	-4.71	-0.44	8.28e-6	Childhood ear infection;
THYM	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg10319629	chr12:132285459	NA	0.53	4.91	0.45	3.84e-6	Migraine;
THYM	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.14	-0.64	1.54e-12	Mean corpuscular volume;
THYM	cis	rs6669072	0.565	rs10922930	chr1:91284800	T/A	cg08895590	chr1:91227319	NA	-0.39	-4.45	-0.42	2.32e-5	Cognitive function;
THYM	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.8	-5.41	-0.49	4.66e-7	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs960902	0.747	rs17020823	chr2:37717068	T/C	cg25341268	chr2:37734390	NA	0.55	4.59	0.43	1.36e-5	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs17407555	0.647	rs55811736	chr4:10014221	G/A	cg00071950	chr4:10020882	SLC2A9	-0.78	-6.15	-0.53	1.84e-8	Schizophrenia (age at onset);
THYM	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg07061783	chr6:25882402	NA	0.58	4.58	0.43	1.42e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9326248	0.581	rs10892063	chr11:116896155	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.67	5.33	0.48	6.64e-7	Blood protein levels;
THYM	cis	rs4788570	0.697	rs2173702	chr16:71812671	G/A	cg06353428	chr16:71660113	MARVELD3	1.41	8.74	0.67	8.32e-14	Intelligence (multi-trait analysis);
THYM	cis	rs9486719	1.000	rs4343922	chr6:96876903	C/T	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs2273669	0.588	rs114414265	chr6:109306489	C/A	cg17117243	chr6:109341365	SESN1	-0.84	-4.94	-0.45	3.41e-6	Prostate cancer;
THYM	cis	rs9362426	0.887	rs1209113	chr6:88079456	A/G	cg10393598	chr6:87862264	NA	-0.61	-4.85	-0.45	4.78e-6	Depressive episodes in bipolar disorder;
THYM	cis	rs61931739	0.612	rs1906136	chr12:33905293	C/T	cg06521331	chr12:34319734	NA	-0.56	-4.47	-0.42	2.16e-5	Morning vs. evening chronotype;
THYM	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg02725872	chr8:58115012	NA	-1.11	-8.56	-0.66	1.98e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs5769707	0.642	rs4824070	chr22:50031521	T/C	cg05373962	chr22:49881684	NA	-0.65	-6.07	-0.53	2.67e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs870825	0.616	rs6552802	chr4:185620751	C/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.47	-0.42	2.12e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg27068330	chr11:65405492	SIPA1	-0.79	-5.31	-0.48	7.12e-7	Breast cancer;
THYM	cis	rs59698941	0.891	rs59707248	chr5:132267535	C/T	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg12031863	chr16:4587854	C16orf5	0.44	4.71	0.44	8.33e-6	Schizophrenia;
THYM	cis	rs3768617	0.510	rs3768616	chr1:183103551	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.61	4.98	0.46	2.81e-6	Fuchs's corneal dystrophy;
THYM	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg18512352	chr11:47633146	NA	-0.49	-5.88	-0.52	6.07e-8	Subjective well-being;
THYM	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg12011299	chr4:100065546	ADH4	0.96	11.8	0.77	2.57e-20	Alcohol dependence;
THYM	cis	rs7267979	1.000	rs6083825	chr20:25366424	T/C	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4940575	0.627	rs1481032	chr18:60832655	C/A	cg20947866	chr18:61143580	SERPINB5	0.9	5.36	0.48	5.72e-7	Breast cancer;
THYM	cis	rs9431487	0.760	rs4846281	chr1:219013302	C/T	cg13962170	chr1:218691051	NA	-0.54	-4.8	-0.44	5.82e-6	Gut microbiome composition (summer);
THYM	cis	rs3126085	0.935	rs7550106	chr1:152197202	C/T	cg10321714	chr1:152280068	FLG	-0.67	-4.81	-0.44	5.71e-6	Atopic dermatitis;
THYM	cis	rs2067615	0.524	rs4964187	chr12:107080313	C/A	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	cis	rs7107174	1.000	rs1399196	chr11:78071876	A/G	cg19901956	chr11:77921274	USP35	-0.64	-5.3	-0.48	7.43e-7	Testicular germ cell tumor;
THYM	cis	rs34779708	0.733	rs11597184	chr10:35397396	G/A	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg27572855	chr1:25598939	RHD	0.64	5.09	0.46	1.82e-6	Erythrocyte sedimentation rate;
THYM	cis	rs960902	0.620	rs4384766	chr2:37733001	G/T	cg25341268	chr2:37734390	NA	-0.62	-5.19	-0.47	1.18e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs12142240	0.698	rs12385695	chr1:46819021	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11048434	0.661	rs34791180	chr12:9110919	T/C	cg13575925	chr12:9217583	LOC144571	0.53	4.94	0.45	3.31e-6	Sjögren's syndrome;
THYM	cis	rs854765	0.624	rs11652144	chr17:17733934	C/T	cg16928487	chr17:17741425	SREBF1	0.55	5.12	0.47	1.56e-6	Total body bone mineral density;
THYM	cis	rs7781557	0.646	rs12113759	chr7:102440914	C/T	cg06322601	chr7:102330635	NA	0.62	4.57	0.42	1.48e-5	Colorectal adenoma (advanced);
THYM	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg15247329	chr7:2764246	NA	-0.69	-5.64	-0.5	1.76e-7	Height;
THYM	cis	rs12257961	0.675	rs4750619	chr10:15347175	T/A	cg10616319	chr10:15468812	NA	-0.64	-5.27	-0.48	8.61e-7	Selective IgA deficiency;
THYM	cis	rs892961	1.000	rs2117924	chr17:75401310	C/T	cg11351908	chr17:75402473	SEPT9	0.57	5.65	0.5	1.7e-7	Airflow obstruction;
THYM	cis	rs7836436	1.000	rs56170125	chr8:121019617	C/T	cg05020510	chr8:120428057	NOV	0.93	4.85	0.45	4.73e-6	HIV-1 viral setpoint;
THYM	cis	rs10927875	0.619	rs12121764	chr1:16138059	A/T	cg21385522	chr1:16154831	NA	-0.74	-6.16	-0.53	1.7e-8	Dilated cardiomyopathy;
THYM	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.85	-7.56	-0.61	2.52e-11	Chronic sinus infection;
THYM	cis	rs6684428	0.706	rs10888942	chr1:56335432	C/G	cg11651538	chr1:56320950	NA	-0.66	-5.22	-0.47	1.04e-6	Airflow obstruction;
THYM	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.64	-5.1	-0.46	1.71e-6	Tonsillectomy;
THYM	cis	rs17739794	0.517	rs35856917	chr8:774395	C/G	cg07178994	chr8:816998	NA	-0.73	-6.39	-0.55	6.02e-9	Clozapine-induced cytotoxicity;
THYM	cis	rs7646881	1.000	rs73015655	chr3:158451882	A/C	cg19483011	chr3:158453295	NA	-0.69	-4.93	-0.45	3.45e-6	Tetralogy of Fallot;
THYM	cis	rs9420	0.528	rs11229080	chr11:57399511	T/C	cg19752551	chr11:57585705	CTNND1	-0.58	-5.17	-0.47	1.3e-6	Schizophrenia;
THYM	cis	rs4363385	0.693	rs581447	chr1:153033269	A/G	cg13444842	chr1:152974279	SPRR3	-0.62	-5.07	-0.46	1.96e-6	Inflammatory skin disease;
THYM	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg03433033	chr1:76189801	ACADM	-0.52	-5.49	-0.49	3.36e-7	Daytime sleep phenotypes;
THYM	cis	rs2319125	0.649	rs2083792	chr17:64052830	A/G	cg04446870	chr17:64440273	PRKCA	-0.5	-4.52	-0.42	1.76e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs7772486	0.875	rs10457792	chr6:146412415	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-5.18	-0.47	1.24e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6496667	0.779	rs8033897	chr15:90947842	T/G	cg22089800	chr15:90895588	ZNF774	0.74	4.78	0.44	6.28e-6	Rheumatoid arthritis;
THYM	cis	rs1993976	0.705	rs899672	chr15:98627683	A/C	cg22042896	chr15:99057957	FAM169B	-0.63	-4.65	-0.43	1.07e-5	Fat distribution (HIV);
THYM	cis	rs11711311	1.000	rs2603792	chr3:113509187	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.61	-5.47	-0.49	3.61e-7	IgG glycosylation;
THYM	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg01528321	chr10:82214614	TSPAN14	0.63	5.29	0.48	7.7300000000000005e-07	Post bronchodilator FEV1;
THYM	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg23758822	chr17:41437982	NA	1.17	11.06	0.75	9.04e-19	Menopause (age at onset);
THYM	cis	rs2290159	0.752	rs5746182	chr3:12672550	A/G	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs7851660	0.809	rs7034249	chr9:100653821	C/T	cg13688889	chr9:100608707	NA	-0.78	-5.67	-0.5	1.53e-7	Strep throat;
THYM	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	trans	rs8073060	0.614	rs225279	chr17:33974214	A/G	cg19694781	chr19:47549865	TMEM160	-1.0	-8.37	-0.65	5.05e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs17253792	0.545	rs35536987	chr14:56024021	A/G	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.09	-0.46	1.83e-6	Life satisfaction;
THYM	cis	rs4891159	0.790	rs683306	chr18:74112473	C/G	cg24786174	chr18:74118243	ZNF516	-0.87	-10.02	-0.72	1.48e-16	Longevity;
THYM	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg12408189	chr10:30722286	MAP3K8	0.57	5.09	0.46	1.82e-6	Inflammatory bowel disease;
THYM	cis	rs8048589	0.603	rs2457193	chr16:12178797	C/T	cg02910054	chr16:12241554	SNX29	0.58	4.52	0.42	1.81e-5	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg03929089	chr4:120376271	NA	-0.99	-12.83	-0.8	1.9e-22	Height;
THYM	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg05347473	chr6:146136440	FBXO30	-0.56	-4.45	-0.42	2.34e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg27129171	chr3:47204927	SETD2	0.8	7.67	0.62	1.5e-11	Colorectal cancer;
THYM	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg05043794	chr9:111880884	C9orf5	-0.43	-6.34	-0.55	7.61e-9	Menarche (age at onset);
THYM	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg03388043	chr17:80084554	CCDC57	0.69	5.98	0.52	3.85e-8	Life satisfaction;
THYM	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg02086790	chr16:375327	AXIN1	-0.44	-4.49	-0.42	2.01e-5	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.98	-4.88	-0.45	4.25e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg18681998	chr4:17616180	MED28	0.98	9.85	0.71	3.43e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg05335186	chr13:53173507	NA	-0.41	-4.83	-0.44	5.21e-6	Lewy body disease;
THYM	cis	rs7584330	0.626	rs2271809	chr2:238449107	A/G	cg14458575	chr2:238380390	NA	0.61	4.88	0.45	4.27e-6	Prostate cancer;
THYM	cis	rs7584330	0.554	rs7571100	chr2:238435305	G/T	cg08992911	chr2:238395768	MLPH	0.89	5.81	0.51	8.24e-8	Prostate cancer;
THYM	cis	rs116095464	1.000	rs3777237	chr5:307641	C/T	cg22857025	chr5:266934	NA	-1.59	-5.22	-0.47	1.06e-6	Breast cancer;
THYM	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7107174	0.892	rs4945265	chr11:78027458	G/A	cg02023728	chr11:77925099	USP35	0.65	5.83	0.51	7.52e-8	Testicular germ cell tumor;
THYM	cis	rs10214930	1.000	rs4481475	chr7:27771521	A/G	cg04422003	chr7:28448295	CREB5	0.62	4.62	0.43	1.19e-5	Hypospadias;
THYM	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg08847533	chr14:75593920	NEK9	0.58	4.7	0.43	8.65e-6	Caffeine consumption;
THYM	cis	rs1395	0.744	rs11126936	chr2:27483101	A/C	cg23587288	chr2:27483067	SLC30A3	0.7	6.23	0.54	1.26e-8	Blood metabolite levels;
THYM	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg14416269	chr4:6271139	WFS1	0.49	4.99	0.46	2.75e-6	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg05973401	chr12:123451056	ABCB9	0.68	4.58	0.43	1.39e-5	Neutrophil percentage of white cells;
THYM	cis	rs6430585	0.583	rs4988163	chr2:136628121	G/T	cg23851026	chr2:136556271	LCT	0.73	7.03	0.58	3.18e-10	Corneal structure;
THYM	cis	rs1003719	0.788	rs2835575	chr21:38455936	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.71	5.03	0.46	2.32e-6	Eye color traits;
THYM	cis	rs4690686	0.500	rs17062801	chr4:177262381	G/A	cg17059388	chr4:177262070	NA	0.48	6.73	0.57	1.29e-9	Essential tremor;
THYM	cis	rs921968	0.678	rs689116	chr2:219433888	C/A	cg02176678	chr2:219576539	TTLL4	0.64	6.08	0.53	2.49e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg10802521	chr3:52805072	NEK4	-0.59	-5.06	-0.46	2.02e-6	Electroencephalogram traits;
THYM	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg11812906	chr14:75593930	NEK9	-0.84	-7.72	-0.62	1.17e-11	Height;
THYM	cis	rs995000	0.899	rs1305520	chr1:62926057	A/T	cg06896770	chr1:63153194	DOCK7	-0.91	-7.58	-0.61	2.33e-11	Triglyceride levels;
THYM	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg18681998	chr4:17616180	MED28	1.02	9.73	0.71	6.13e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg24733560	chr20:60626293	TAF4	0.62	6.55	0.56	2.89e-9	Body mass index;
THYM	cis	rs887829	0.569	rs6711351	chr2:234634916	A/G	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.6	-4.97	-0.45	2.97e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs2730245	0.527	rs842693	chr7:158660491	C/T	cg11984989	chr7:158649758	WDR60	1.03	8.36	0.65	5.29e-13	Height;
THYM	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg00744431	chr10:134226547	PWWP2B	-0.59	-4.59	-0.43	1.34e-5	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs478304	0.593	rs6591188	chr11:65467953	T/C	cg27068330	chr11:65405492	SIPA1	-1.03	-10.31	-0.73	3.55e-17	Acne (severe);
THYM	cis	rs2732480	0.557	rs2634682	chr12:48732943	T/C	cg21466736	chr12:48725269	NA	-0.59	-5.43	-0.49	4.36e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg02503808	chr4:7069936	GRPEL1	0.93	7.72	0.62	1.19e-11	Monocyte percentage of white cells;
THYM	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg10057126	chr4:77819792	ANKRD56	0.72	6.26	0.54	1.11e-8	Emphysema distribution in smoking;
THYM	cis	rs4285028	0.948	rs12493408	chr3:121692119	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs9486719	1.000	rs11153018	chr6:96956137	G/A	cg18709589	chr6:96969512	KIAA0776	-0.73	-4.83	-0.44	5.28e-6	Migraine;Coronary artery disease;
THYM	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg09904177	chr6:26538194	HMGN4	0.53	4.5	0.42	1.94e-5	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg24250549	chr1:154909240	PMVK	0.79	6.82	0.57	8.33e-10	Prostate cancer;
THYM	cis	rs6674176	0.628	rs2301993	chr1:44426025	G/A	cg15962314	chr1:44399869	ARTN	0.53	5.32	0.48	6.88e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs245880	0.740	rs245887	chr7:29190408	G/A	cg17163760	chr7:29186267	CPVL	-0.59	-4.94	-0.45	3.3e-6	Warfarin maintenance dose;
THYM	cis	rs7582180	0.764	rs12999779	chr2:100924321	T/G	cg14675211	chr2:100938903	LONRF2	0.76	8.22	0.64	1.01e-12	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs12579753	1.000	rs11115017	chr12:82176914	C/A	cg07988820	chr12:82153109	PPFIA2	-0.78	-4.92	-0.45	3.61e-6	Resting heart rate;
THYM	cis	rs2997447	0.792	rs61775432	chr1:26416376	A/G	cg03844060	chr1:26490628	NA	0.66	4.5	0.42	1.92e-5	QRS complex (12-leadsum);
THYM	cis	rs7408868	1.000	rs6512018	chr19:15282138	T/C	cg14696996	chr19:15285081	NOTCH3	0.98	5.59	0.5	2.21e-7	Pulse pressure;
THYM	cis	rs6496667	0.954	rs7162211	chr15:90892585	G/C	cg22089800	chr15:90895588	ZNF774	0.74	5.0	0.46	2.65e-6	Rheumatoid arthritis;
THYM	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg18811423	chr2:55921094	PNPT1	0.69	6.41	0.55	5.6e-9	Metabolic syndrome;
THYM	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06481639	chr22:41940642	POLR3H	0.8	5.63	0.5	1.81e-7	Vitiligo;
THYM	cis	rs8048589	1.000	rs16958964	chr16:12186586	T/C	cg02910054	chr16:12241554	SNX29	0.69	5.44	0.49	4.19e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs3767633	0.764	rs4657095	chr1:161713853	A/G	cg27495845	chr1:161693088	FCRLB	0.78	4.67	0.43	9.96e-6	IgG glycosylation;
THYM	cis	rs477692	0.647	rs11016853	chr10:131443990	A/G	cg05714579	chr10:131428358	MGMT	-0.8	-6.91	-0.58	5.49e-10	Response to temozolomide;
THYM	cis	rs11651000	0.857	rs11658383	chr17:45842354	A/C	cg03474202	chr17:45855739	NA	-0.77	-6.74	-0.57	1.24e-9	IgG glycosylation;
THYM	cis	rs12367572	0.663	rs1118481	chr12:45354469	C/G	cg03114573	chr12:45410052	DBX2	-0.49	-4.71	-0.43	8.55e-6	Gut microbiome composition (summer);
THYM	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg00129232	chr17:37814104	STARD3	0.69	4.45	0.42	2.32e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.58	-0.5	2.26e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6988636	0.710	rs17315999	chr8:124153763	A/G	cg23067535	chr8:124195133	FAM83A	-0.99	-4.82	-0.44	5.52e-6	Urinary uromodulin levels;
THYM	cis	rs868036	1.000	rs4325504	chr15:68055570	A/G	cg24579218	chr15:68104479	NA	0.65	6.12	0.53	2.07e-8	Restless legs syndrome;
THYM	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.61	-5.37	-0.48	5.69e-7	Hip circumference adjusted for BMI;
THYM	trans	rs629535	0.665	rs2433331	chr8:70041943	T/C	cg21567404	chr3:27674614	NA	1.15	11.87	0.77	1.79e-20	Dupuytren's disease;
THYM	cis	rs12681287	0.640	rs10086340	chr8:87446789	G/T	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs3126085	1.000	rs2011331	chr1:152286002	T/C	cg10321714	chr1:152280068	FLG	-0.67	-5.14	-0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg21475434	chr5:93447410	FAM172A	-0.97	-6.09	-0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs4919694	1.000	rs12257941	chr10:104833161	C/T	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg05335186	chr13:53173507	NA	-0.58	-7.53	-0.61	2.9100000000000002e-11	Lewy body disease;
THYM	cis	rs67981189	0.647	rs36555	chr14:71364561	C/T	cg15910301	chr14:71632612	NA	-0.5	-4.47	-0.42	2.2e-5	Schizophrenia;
THYM	cis	rs11048434	0.518	rs7311267	chr12:9178678	C/T	cg26114124	chr12:9217669	LOC144571	-0.49	-4.46	-0.42	2.26e-5	Sjögren's syndrome;
THYM	cis	rs1904096	0.506	rs3113863	chr4:95147827	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.1	-0.46	1.7e-6	Type 2 diabetes;
THYM	cis	rs2050392	0.517	rs602097	chr10:30747546	C/T	cg25182066	chr10:30743637	MAP3K8	-0.57	-4.89	-0.45	4.16e-6	Inflammatory bowel disease;
THYM	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.03	6.9	0.58	5.76e-10	Smoking behavior;
THYM	cis	rs600806	0.815	rs10858094	chr1:109950858	T/C	cg16988986	chr1:109941118	SORT1	-0.43	-4.56	-0.42	1.5e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg06634786	chr22:41940651	POLR3H	0.7	4.93	0.45	3.53e-6	Vitiligo;
THYM	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	7.8	0.62	7.81e-12	Platelet count;
THYM	cis	rs4638749	0.588	rs13401731	chr2:108885340	C/T	cg06795125	chr2:108905320	SULT1C2	-0.35	-4.97	-0.45	2.91e-6	Blood pressure;
THYM	cis	rs6906287	0.625	rs7453914	chr6:118692981	A/T	cg21191810	chr6:118973309	C6orf204	0.6	5.77	0.51	1e-7	Electrocardiographic conduction measures;
THYM	cis	rs761746	0.960	rs4820980	chr22:31917415	A/G	cg01338084	chr22:32026380	PISD	-0.57	-4.84	-0.45	4.95e-6	Intelligence;
THYM	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Body mass index;
THYM	cis	rs66887589	0.934	rs2389873	chr4:120554714	A/G	cg13609457	chr4:120235615	NA	-0.48	-5.02	-0.46	2.39e-6	Diastolic blood pressure;
THYM	cis	rs2040771	0.740	rs9617783	chr22:19260575	C/A	cg02655711	chr22:19163373	SLC25A1	0.57	6.01	0.52	3.48e-8	Metabolite levels (small molecules and protein measures);
THYM	cis	rs4563143	0.514	rs73029076	chr19:29292032	G/T	cg04546413	chr19:29218101	NA	1.0	6.91	0.58	5.57e-10	Methadone dose in opioid dependence;
THYM	cis	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg21775007	chr8:11205619	TDH	-0.58	-4.49	-0.42	2.03e-5	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs2898681	0.561	rs2200225	chr4:53738411	A/G	cg21521518	chr4:53727714	RASL11B	0.54	5.25	0.47	9.1e-7	Optic nerve measurement (cup area);
THYM	cis	rs924712	0.677	rs10948879	chr6:54845489	T/G	cg04690482	chr6:54711388	FAM83B	-0.45	-5.27	-0.48	8.38e-7	Breast cancer;
THYM	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7193541	0.585	rs7978	chr16:74486189	T/C	cg01733217	chr16:74700730	RFWD3	-0.9	-9.86	-0.71	3.35e-16	Multiple myeloma;
THYM	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg02389323	chr16:88786976	FAM38A	0.93	5.74	0.51	1.15e-7	Plateletcrit;
THYM	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg17775962	chr7:1200435	ZFAND2A	0.51	5.74	0.51	1.11e-7	Longevity;Endometriosis;
THYM	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs9309711	0.698	rs9750503	chr2:3491772	A/G	cg10845886	chr2:3471009	TTC15	0.58	4.62	0.43	1.2e-5	Neurofibrillary tangles;
THYM	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.61	5.22	0.47	1.03e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg21784768	chr11:537496	LRRC56	-1.07	-5.36	-0.48	5.7e-7	Body mass index;
THYM	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg25072359	chr17:41440525	NA	0.77	5.74	0.51	1.15e-7	Menopause (age at onset);
THYM	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11644478	chr21:40555479	PSMG1	0.66	4.99	0.46	2.68e-6	Cognitive function;
THYM	cis	rs11031096	0.678	rs12292724	chr11:4176671	T/A	cg22027985	chr11:4115532	RRM1	-0.5	-4.54	-0.42	1.67e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs1642645	0.793	rs642579	chr1:42431397	C/T	cg10197057	chr1:42612518	NA	0.43	4.6	0.43	1.3e-5	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg24530246	chr3:53118167	NA	-0.85	-4.82	-0.44	5.52e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	5.78	0.51	9.49e-8	Height;
THYM	cis	rs9467711	0.651	rs115648484	chr6:25938767	T/A	cg16898833	chr6:26189333	HIST1H4D	1.35	4.67	0.43	9.89e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg21280719	chr6:42927975	GNMT	-0.53	-7.25	-0.6	1.12e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.32	0.54	8.42e-9	Platelet count;
THYM	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg20887711	chr4:1340912	KIAA1530	0.66	5.61	0.5	2.02e-7	Longevity;
THYM	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg19747945	chr6:42946146	PEX6	0.33	4.82	0.44	5.43e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg13683864	chr3:40499215	RPL14	-1.05	-11.54	-0.76	8.87e-20	Renal cell carcinoma;
THYM	cis	rs988913	1.000	rs1393776	chr6:54763018	A/C	cg04690482	chr6:54711388	FAM83B	-0.47	-5.21	-0.47	1.09e-6	Menarche (age at onset);
THYM	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg22920501	chr2:26401640	FAM59B	1.07	9.54	0.7	1.6e-15	Gut microbiome composition (summer);
THYM	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg04944784	chr2:26401820	FAM59B	1.09	8.74	0.67	8.1e-14	Gut microbiome composition (summer);
THYM	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg25427524	chr10:38739819	LOC399744	-0.65	-6.16	-0.53	1.75e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs10186029	0.509	rs7592621	chr2:213941177	C/T	cg08319019	chr2:214017104	IKZF2	-0.71	-5.38	-0.48	5.43e-7	Systemic sclerosis;
THYM	cis	rs919433	0.889	rs788004	chr2:198219032	C/T	cg00792783	chr2:198669748	PLCL1	0.76	5.45	0.49	3.89e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg14829155	chr15:31115871	NA	0.52	4.88	0.45	4.27e-6	Huntington's disease progression;
THYM	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg10515332	chr4:99064459	C4orf37	0.63	4.59	0.43	1.34e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg21784768	chr11:537496	LRRC56	-1.15	-5.74	-0.51	1.13e-7	Body mass index;
THYM	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg15744005	chr10:104629667	AS3MT	-0.78	-7.33	-0.6	7.48e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7172809	0.643	rs80347838	chr15:77841783	A/G	cg22256960	chr15:77711686	NA	-0.74	-5.36	-0.48	5.73e-7	Glucose homeostasis traits;
THYM	cis	rs6728642	0.572	rs13403225	chr2:97600827	A/G	cg26665480	chr2:98280029	ACTR1B	-0.74	-5.01	-0.46	2.56e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg25427524	chr10:38739819	LOC399744	-0.66	-6.13	-0.53	1.99e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs28647808	0.881	rs57394597	chr9:136261030	G/A	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs910187	0.678	rs7352690	chr20:45815352	C/G	cg27589058	chr20:45804311	EYA2	-0.62	-5.44	-0.49	4.1e-7	Migraine;
THYM	cis	rs4638749	0.677	rs7570544	chr2:108848137	C/T	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.64	-0.43	1.13e-5	Blood pressure;
THYM	cis	rs2120243	0.572	rs6441129	chr3:157125828	A/G	cg24825693	chr3:157122686	VEPH1	0.48	4.67	0.43	9.97e-6	Hepatocellular carcinoma in hepatitis B infection;
THYM	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg26924012	chr15:45694286	SPATA5L1	-1.01	-8.95	-0.68	2.83e-14	Homoarginine levels;
THYM	cis	rs686320	1.000	rs1194758	chr11:65238085	A/T	cg23743554	chr11:65321226	LTBP3	-0.74	-4.59	-0.43	1.34e-5	Hip circumference adjusted for BMI;
THYM	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg02640540	chr1:67518911	SLC35D1	0.58	4.67	0.43	9.97e-6	Lymphocyte percentage of white cells;
THYM	cis	rs2456568	0.900	rs1518571	chr11:93667420	C/A	cg26875233	chr11:93583750	C11orf90	-0.5	-4.88	-0.45	4.2e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs6570726	0.755	rs2092296	chr6:145893684	A/C	cg13319975	chr6:146136371	FBXO30	-0.63	-4.99	-0.46	2.75e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7216064	0.953	rs4790905	chr17:65863350	C/A	cg12091567	chr17:66097778	LOC651250	-0.71	-4.76	-0.44	6.86e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs17604090	0.793	rs17136535	chr7:29689158	C/T	cg19413766	chr7:29689036	LOC646762	-0.91	-5.02	-0.46	2.37e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs6918586	1.000	rs198806	chr6:26133616	A/G	cg15691649	chr6:25882328	NA	0.59	4.48	0.42	2.09e-5	Schizophrenia;
THYM	cis	rs1122608	0.543	rs56405759	chr19:11066205	C/T	cg17326582	chr19:11976514	ZNF439	0.64	4.6	0.43	1.3e-5	Coronary artery disease or ischemic stroke;Coronary artery disease;Coronary artery disease or large artery stroke;Coronary heart disease;Myocardial infarction (early onset);
THYM	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	4.78	0.44	6.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7336332	0.511	rs7998978	chr13:27999457	T/C	cg22138327	chr13:27999177	GTF3A	0.88	7.25	0.6	1.08e-10	Weight;
THYM	cis	rs9733	0.596	rs11586422	chr1:150679358	C/T	cg04414720	chr1:150670196	GOLPH3L	0.64	4.84	0.44	5e-6	Tonsillectomy;
THYM	cis	rs1829883	0.835	rs2682139	chr5:98909924	G/A	cg08333243	chr5:99726346	NA	0.52	4.55	0.42	1.62e-5	Hemostatic factors and hematological phenotypes;
THYM	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.89	0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg05896524	chr21:47604654	C21orf56	0.81	5.41	0.48	4.79e-7	Testicular germ cell tumor;
THYM	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-1.0	-10.05	-0.72	1.26e-16	Intelligence (multi-trait analysis);
THYM	cis	rs1878931	0.858	rs3760083	chr16:3450052	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.91	-8.48	-0.66	2.89e-13	Body mass index (adult);
THYM	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg11366901	chr6:160182831	ACAT2	1.21	9.98	0.72	1.8e-16	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg25358565	chr5:93447407	FAM172A	-1.0	-7.31	-0.6	8.27e-11	Diabetic retinopathy;
THYM	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg06238570	chr21:40685208	BRWD1	-0.69	-6.08	-0.53	2.47e-8	Menarche (age at onset);
THYM	cis	rs17030434	0.654	rs10021447	chr4:154646459	A/C	cg14289246	chr4:154710475	SFRP2	-0.68	-4.77	-0.44	6.56e-6	Electrocardiographic conduction measures;
THYM	cis	rs72772090	0.539	rs72773917	chr5:96111302	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-4.67	-0.43	9.81e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg18758796	chr5:131593413	PDLIM4	0.49	4.51	0.42	1.87e-5	Breast cancer;Mosquito bite size;
THYM	cis	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg24672777	chr11:48374446	OR4C45	0.73	4.6	0.43	1.28e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg26597838	chr10:835615	NA	1.52	11.37	0.76	2.08e-19	Eosinophil percentage of granulocytes;
THYM	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg11812906	chr14:75593930	NEK9	-0.87	-8.3	-0.65	7.13e-13	Height;
THYM	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.77	-0.44	6.61e-6	Eye color traits;
THYM	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg17830980	chr10:43048298	ZNF37B	-1.01	-9.91	-0.71	2.57e-16	Extrinsic epigenetic age acceleration;
THYM	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg20891283	chr12:69753455	YEATS4	0.77	6.38	0.55	6.28e-9	Response to diuretic therapy;
THYM	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg17644776	chr2:200775616	C2orf69	-0.77	-4.5	-0.42	1.95e-5	Schizophrenia;
THYM	cis	rs3126085	0.935	rs3120659	chr1:152293202	A/G	cg10321714	chr1:152280068	FLG	-0.67	-5.14	-0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.58	-7.69	-0.62	1.35e-11	Longevity;Endometriosis;
THYM	cis	rs17253792	0.749	rs79713967	chr14:56124186	T/C	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs9807989	0.811	rs7608638	chr2:102970289	A/G	cg03938978	chr2:103052716	IL18RAP	0.63	6.46	0.55	4.36e-9	Asthma;
THYM	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg14584255	chr6:163149320	PACRG;PARK2	0.76	6.74	0.57	1.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg04362960	chr10:104952993	NT5C2	0.6	5.11	0.46	1.66e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6032067	0.714	rs3761194	chr20:43885935	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.57	-5.5	-0.49	3.17e-7	Blood protein levels;
THYM	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg24579218	chr15:68104479	NA	-0.77	-7.19	-0.59	1.47e-10	Restless legs syndrome;
THYM	cis	rs28595532	0.920	rs56117870	chr4:119766583	T/C	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg07636037	chr3:49044803	WDR6	0.99	10.4	0.73	2.28e-17	Parkinson's disease;
THYM	cis	rs55728055	0.661	rs16989760	chr22:31951808	A/G	cg01338084	chr22:32026380	PISD	1.47	5.89	0.52	5.9e-8	Age-related hearing impairment;
THYM	cis	rs2976388	0.609	rs2572904	chr8:143792193	A/C	cg06565975	chr8:143823917	SLURP1	0.47	5.22	0.47	1.06e-6	Urinary tract infection frequency;
THYM	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.95	7.91	0.63	4.76e-12	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg02725872	chr8:58115012	NA	-0.73	-4.7	-0.43	8.91e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2976388	0.590	rs7828042	chr8:143819383	A/G	cg06565975	chr8:143823917	SLURP1	-0.61	-7.51	-0.61	3.22e-11	Urinary tract infection frequency;
THYM	cis	rs2742234	0.541	rs1254959	chr10:43700979	C/G	cg06632098	chr10:43605906	RET	0.79	5.1	0.46	1.73e-6	Hirschsprung disease;
THYM	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg02527881	chr3:46936655	PTH1R	-0.69	-7.14	-0.59	1.9e-10	Colorectal cancer;
THYM	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg08885076	chr2:99613938	TSGA10	-0.58	-5.74	-0.51	1.11e-7	Chronic sinus infection;
THYM	cis	rs9534288	0.830	rs1548325	chr13:46635101	A/G	cg15192986	chr13:46630673	CPB2	-0.66	-4.74	-0.44	7.64e-6	Blood protein levels;
THYM	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg14456004	chr13:21872349	NA	1.24	11.51	0.76	1.03e-19	White matter hyperintensity burden;
THYM	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg24675056	chr1:15929824	NA	0.73	5.89	0.52	5.95e-8	Systolic blood pressure;
THYM	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg19346786	chr7:2764209	NA	-0.71	-5.97	-0.52	4.13e-8	Height;
THYM	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg16049864	chr8:95962084	TP53INP1	-0.86	-8.13	-0.64	1.62e-12	Type 2 diabetes;
THYM	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg08885076	chr2:99613938	TSGA10	0.66	5.97	0.52	4.17e-8	Chronic sinus infection;
THYM	cis	rs7818345	0.595	rs58551730	chr8:19316627	T/A	cg06562184	chr8:19319451	CSGALNACT1	0.6	4.97	0.45	2.91e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs7107174	0.901	rs7110387	chr11:78117875	A/G	cg19901956	chr11:77921274	USP35	-0.66	-5.24	-0.47	9.63e-7	Testicular germ cell tumor;
THYM	cis	rs4866334	1.000	rs77016925	chr5:18487933	T/C	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg06453172	chr10:134556979	INPP5A	-0.67	-4.84	-0.44	5.1e-6	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs8032315	0.965	rs12906125	chr15:91427612	G/A	cg04510874	chr15:91427884	FES	0.66	4.93	0.45	3.5e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs17209837	0.607	rs45553044	chr7:87085613	A/G	cg04996195	chr7:87105398	ABCB4	0.63	4.79	0.44	6.03e-6	Gallbladder cancer;
THYM	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.43	-0.49	4.24e-7	Mean corpuscular volume;
THYM	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	6.88	0.58	6.25e-10	Lung cancer in ever smokers;
THYM	cis	rs9807989	0.507	rs6706002	chr2:103006104	A/G	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs4731207	0.565	rs4355714	chr7:124627521	T/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg06634786	chr22:41940651	POLR3H	-0.73	-5.36	-0.48	5.89e-7	Vitiligo;
THYM	cis	rs4788570	0.697	rs2334877	chr16:71833332	C/T	cg06353428	chr16:71660113	MARVELD3	1.41	8.74	0.67	8.32e-14	Intelligence (multi-trait analysis);
THYM	cis	rs4589258	0.933	rs1632631	chr11:90430822	A/G	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9527	0.615	rs4919682	chr10:104584330	C/T	cg15744005	chr10:104629667	AS3MT	-0.76	-5.98	-0.52	3.98e-8	Arsenic metabolism;
THYM	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg11663144	chr21:46675770	NA	-0.68	-9.11	-0.68	1.3e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs514406	0.668	rs1672911	chr1:53340320	T/C	cg16325326	chr1:53192061	ZYG11B	0.79	6.37	0.55	6.58e-9	Monocyte count;
THYM	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs977987	0.836	rs17685540	chr16:75323840	T/C	cg03315344	chr16:75512273	CHST6	0.83	6.93	0.58	5e-10	Dupuytren's disease;
THYM	cis	rs10779751	0.666	rs77270747	chr1:11214584	A/C	cg08854313	chr1:11322531	MTOR	-0.74	-6.26	-0.54	1.13e-8	Body mass index;
THYM	cis	rs6500395	1.000	rs1120276	chr16:48598517	C/G	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg00814883	chr7:100076585	TSC22D4	-0.99	-6.67	-0.56	1.67e-9	Platelet count;
THYM	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08704250	chr15:31115839	NA	-0.51	-6.06	-0.53	2.68e-8	Huntington's disease progression;
THYM	cis	rs9660180	0.967	rs12044597	chr1:1708801	A/G	cg17747265	chr1:1875780	NA	-0.8	-9.28	-0.69	5.65e-15	Body mass index;
THYM	cis	rs9816226	0.587	rs9863591	chr3:185841624	C/G	cg00760338	chr3:185826511	ETV5	-0.78	-6.42	-0.55	5.44e-9	Obesity;Body mass index;
THYM	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs1524976	0.943	rs62255325	chr3:65509446	T/A	cg16238336	chr3:65465873	MAGI1	-0.95	-4.81	-0.44	5.6e-6	PR interval;
THYM	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9733	0.596	rs6661872	chr1:150628357	C/G	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs13102973	0.720	rs7687641	chr4:135885739	C/T	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	cis	rs854765	0.583	rs4413022	chr17:17858280	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	6.46	0.55	4.39e-9	Total body bone mineral density;
THYM	cis	rs17407555	0.789	rs12648610	chr4:10114812	G/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-5.1	-0.46	1.71e-6	Schizophrenia (age at onset);
THYM	cis	rs7119	0.700	rs57471224	chr15:77888169	A/G	cg27398640	chr15:77910606	LINGO1	0.65	7.96	0.63	3.74e-12	Type 2 diabetes;
THYM	cis	rs13102973	0.965	rs4280794	chr4:135857174	T/C	cg14419869	chr4:135874104	NA	0.89	8.71	0.67	9.27e-14	Subjective well-being;
THYM	cis	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg03609598	chr5:56110824	MAP3K1	-0.84	-5.62	-0.5	1.87e-7	Initial pursuit acceleration;
THYM	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs7772486	0.686	rs857879	chr6:145974043	C/A	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg15704280	chr7:45808275	SEPT13	-0.99	-11.39	-0.76	1.85e-19	Coronary artery disease;
THYM	cis	rs2455799	0.613	rs11706879	chr3:15957130	A/C	cg16303742	chr3:15540471	COLQ	-0.54	-5.37	-0.48	5.67e-7	Mean platelet volume;
THYM	cis	rs9867325	1.000	rs9840500	chr3:136621338	A/G	cg21827317	chr3:136751795	NA	-0.76	-5.12	-0.47	1.57e-6	Body mass index;
THYM	cis	rs988913	1.000	rs9382404	chr6:54835218	C/G	cg18532076	chr6:54711417	FAM83B	0.5	4.91	0.45	3.78e-6	Menarche (age at onset);
THYM	cis	rs4845875	0.600	rs6696752	chr1:11835935	T/C	cg14194983	chr1:11908298	NPPA	0.54	4.97	0.45	2.93e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg15536230	chr21:44985092	HSF2BP	0.39	4.61	0.43	1.26e-5	Mean corpuscular volume;
THYM	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg07936489	chr17:37558343	FBXL20	-0.87	-5.78	-0.51	9.42e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs17407555	0.657	rs56346932	chr4:10377032	C/T	cg11266682	chr4:10021025	SLC2A9	-0.53	-4.95	-0.45	3.15e-6	Schizophrenia (age at onset);
THYM	cis	rs6840360	0.593	rs2089811	chr4:152685171	C/T	cg22705602	chr4:152727874	NA	0.82	11.14	0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.75	5.66	0.5	1.63e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4523957	0.651	rs1994883	chr17:2083881	T/A	cg16513277	chr17:2031491	SMG6	-0.95	-8.69	-0.67	1.05e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg18357526	chr6:26021779	HIST1H4A	0.71	6.12	0.53	2.04e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7258015	0.909	rs3176769	chr19:10447034	A/G	cg01466491	chr19:10523363	NA	0.65	5.14	0.47	1.47e-6	Systemic lupus erythematosus or rheumatoid arthritis;
THYM	cis	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg00495681	chr13:53174319	NA	-0.73	-6.66	-0.56	1.79e-9	Lewy body disease;
THYM	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.27	-0.65	8.17e-13	Personality dimensions;
THYM	cis	rs4794106	0.792	rs847682	chr17:48208274	C/T	cg13127421	chr17:48202128	SAMD14	-0.61	-4.83	-0.44	5.16e-6	Temporomandibular joint disorder;
THYM	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg13699009	chr12:122356056	WDR66	0.47	4.61	0.43	1.27e-5	Mean corpuscular volume;
THYM	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.88	7.48	0.61	3.68e-11	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg04176532	chr22:50317003	CRELD2	-0.41	-4.53	-0.42	1.7e-5	Schizophrenia;
THYM	cis	rs7216064	0.655	rs8078543	chr17:66037251	G/T	cg12091567	chr17:66097778	LOC651250	0.98	8.02	0.64	2.7e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs1286150	0.636	rs11851354	chr14:91498300	A/T	cg02136132	chr14:90527891	KCNK13	-0.66	-4.52	-0.42	1.8e-5	Total body bone mineral density;
THYM	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg16928487	chr17:17741425	SREBF1	0.56	5.44	0.49	4.09e-7	Total body bone mineral density;
THYM	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs36051895	0.632	rs12337904	chr9:5144606	C/G	cg02405213	chr9:5042618	JAK2	-1.02	-10.51	-0.73	1.37e-17	Pediatric autoimmune diseases;
THYM	cis	rs7512552	0.803	rs9436127	chr1:150490565	G/A	cg15654264	chr1:150340011	RPRD2	0.45	5.16	0.47	1.36e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7084402	0.967	rs1658451	chr10:60311527	A/T	cg09696939	chr10:60272079	BICC1	-0.47	-5.47	-0.49	3.63e-7	Refractive error;
THYM	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg19901468	chr14:105411992	AHNAK2	-0.79	-6.59	-0.56	2.43e-9	Rheumatoid arthritis;
THYM	cis	rs17253792	0.822	rs77250916	chr14:56042208	A/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs9790314	1.000	rs336591	chr3:161078080	A/G	cg04691961	chr3:161091175	C3orf57	-0.6	-5.27	-0.48	8.6e-7	Morning vs. evening chronotype;
THYM	cis	rs56309584	0.673	rs12451139	chr17:8119626	G/T	cg11257113	chr17:8062204	NA	-0.61	-4.45	-0.42	2.33e-5	Initial pursuit acceleration;
THYM	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg03354898	chr7:1950403	MAD1L1	-0.5	-4.62	-0.43	1.22e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs807669	0.903	rs2800974	chr22:19168087	C/T	cg02655711	chr22:19163373	SLC25A1	0.98	11.86	0.77	1.93e-20	Metabolite levels;
THYM	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg01236616	chr12:121019343	POP5	1.31	10.38	0.73	2.57e-17	Type 1 diabetes nephropathy;
THYM	cis	rs16866061	0.926	rs17479770	chr2:225335814	A/G	cg12698349	chr2:225449008	CUL3	1.08	8.66	0.66	1.18e-13	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg12658694	chr1:38397304	INPP5B	0.62	4.78	0.44	6.38e-6	Coronary artery disease;
THYM	cis	rs7828089	1.000	rs7823832	chr8:22264426	A/G	cg13512537	chr8:22265999	SLC39A14	-0.61	-5.13	-0.47	1.55e-6	Verbal declarative memory;
THYM	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.78	7.14	0.59	1.85e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg03676636	chr4:99064102	C4orf37	0.38	5.41	0.49	4.62e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs526231	0.543	rs246916	chr5:102557515	T/C	cg23492399	chr5:102201601	PAM	-0.71	-5.21	-0.47	1.09e-6	Primary biliary cholangitis;
THYM	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg04455712	chr21:45112962	RRP1B	0.51	4.52	0.42	1.75e-5	Mean corpuscular volume;
THYM	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg11812906	chr14:75593930	NEK9	0.87	8.3	0.65	7.13e-13	Height;
THYM	cis	rs3008870	1.000	rs2815371	chr1:67504313	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.93	7.76	0.62	9.52e-12	Lymphocyte percentage of white cells;
THYM	cis	rs35934224	0.769	rs76204326	chr22:19842302	G/C	cg11182965	chr22:19864308	TXNRD2	-0.83	-5.08	-0.46	1.88e-6	Glaucoma (primary open-angle);
THYM	cis	rs1018836	0.828	rs2105968	chr8:91591825	A/G	cg16814680	chr8:91681699	NA	-0.88	-7.61	-0.62	1.96e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs72781680	0.664	rs2712076	chr2:23993366	T/C	cg08917208	chr2:24149416	ATAD2B	0.85	4.5	0.42	1.96e-5	Lymphocyte counts;
THYM	cis	rs7843479	0.870	rs1809498	chr8:21836384	C/G	cg17168535	chr8:21777572	XPO7	-0.7	-5.37	-0.48	5.55e-7	Mean corpuscular volume;
THYM	cis	rs7584330	0.518	rs74003106	chr2:238447004	A/G	cg08992911	chr2:238395768	MLPH	0.9	5.47	0.49	3.65e-7	Prostate cancer;
THYM	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg06784218	chr1:46089804	CCDC17	-0.34	-5.03	-0.46	2.28e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg15445000	chr17:37608096	MED1	-0.4	-4.69	-0.43	9.05e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs6840360	0.571	rs1473305	chr4:152511721	T/G	cg22705602	chr4:152727874	NA	-0.78	-8.16	-0.64	1.38e-12	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.65	-5.63	-0.5	1.84e-7	Chronic sinus infection;
THYM	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg21385522	chr1:16154831	NA	0.83	6.03	0.53	3.18e-8	Dilated cardiomyopathy;
THYM	cis	rs11771526	0.710	rs7804577	chr7:32373104	A/G	cg13207630	chr7:32358064	NA	0.84	5.1	0.46	1.71e-6	Body mass index;
THYM	cis	rs735396	0.694	rs2264750	chr12:121450165	C/T	cg02403541	chr12:121454288	C12orf43	0.78	6.69	0.57	1.54e-9	N-glycan levels;
THYM	cis	rs6992820	0.933	rs35193637	chr8:56741274	A/C	cg06880721	chr8:56792545	LYN	-0.69	-5.75	-0.51	1.07e-7	Mean platelet volume;
THYM	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg14584255	chr6:163149320	PACRG;PARK2	0.69	6.24	0.54	1.2e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg15704280	chr7:45808275	SEPT13	-0.95	-9.62	-0.7	1.1e-15	Coronary artery disease;
THYM	cis	rs7104764	1.000	rs2272563	chr11:236871	T/C	cg18336825	chr11:236787	PSMD13;SIRT3	1.14	10.48	0.73	1.58e-17	Menarche (age at onset);
THYM	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg22841779	chr14:105766346	BRF1	-0.47	-5.81	-0.51	8.18e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg03647317	chr4:187891568	NA	-0.85	-9.12	-0.68	1.26e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg05335186	chr13:53173507	NA	-0.48	-6.7	-0.57	1.45e-9	Lewy body disease;
THYM	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg27034606	chr17:28928453	LRRC37B2	-0.77	-5.12	-0.47	1.59e-6	Body mass index;
THYM	cis	rs8048589	0.948	rs11648468	chr16:12181510	A/G	cg01990910	chr16:12207648	SNX29	0.45	5.25	0.47	9.32e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg03709012	chr19:19516395	GATAD2A	0.82	6.79	0.57	9.81e-10	Tonsillectomy;
THYM	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg16230307	chr14:35515116	FAM177A1	0.9	5.84	0.51	7.37e-8	Psoriasis;
THYM	cis	rs6500602	0.592	rs8051780	chr16:4434374	G/A	cg08645402	chr16:4508243	NA	0.7	5.76	0.51	1.01e-7	Schizophrenia;
THYM	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg11812906	chr14:75593930	NEK9	-0.78	-7.02	-0.58	3.28e-10	Height;
THYM	cis	rs17209837	0.607	rs1473154	chr7:87082042	A/G	cg04996195	chr7:87105398	ABCB4	0.63	4.79	0.44	6.03e-6	Gallbladder cancer;
THYM	cis	rs7567389	0.719	rs6430936	chr2:128007686	A/C	cg09760422	chr2:128146352	NA	-0.53	-5.65	-0.5	1.7e-7	Self-rated health;
THYM	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg19912559	chr1:40204330	PPIE	-0.64	-4.92	-0.45	3.61e-6	Blood protein levels;
THYM	cis	rs782590	0.967	rs11125579	chr2:55739804	T/C	cg18811423	chr2:55921094	PNPT1	0.71	6.85	0.57	7.45e-10	Metabolic syndrome;
THYM	cis	rs9807989	0.811	rs11688568	chr2:102969949	C/T	cg03938978	chr2:103052716	IL18RAP	0.63	6.46	0.55	4.36e-9	Asthma;
THYM	cis	rs12681287	0.640	rs13269259	chr8:87470453	G/A	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs6032067	0.777	rs34233258	chr20:43788265	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.73	-0.57	1.29e-9	Blood protein levels;
THYM	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg04398451	chr17:18023971	MYO15A	0.9	9.71	0.71	6.98e-16	Total body bone mineral density;
THYM	cis	rs7119038	0.629	rs73001429	chr11:118603165	T/G	cg19308663	chr11:118741387	NA	0.47	4.55	0.42	1.58e-5	Sjögren's syndrome;
THYM	cis	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg23422044	chr7:1970798	MAD1L1	-0.95	-6.58	-0.56	2.51e-9	Bipolar disorder;
THYM	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.83	-0.63	6.91e-12	Chronic sinus infection;
THYM	cis	rs10896135	0.526	rs624561	chr11:66414915	C/T	cg24851651	chr11:66362959	CCS	-0.85	-6.93	-0.58	4.97e-10	Bipolar disorder;
THYM	cis	rs67460515	0.563	rs6772723	chr3:160895074	C/G	cg12349858	chr3:160822545	B3GALNT1	0.61	4.76	0.44	7.04e-6	Parkinson's disease;
THYM	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg12560992	chr17:57184187	TRIM37	0.93	8.88	0.67	4.06e-14	Intelligence (multi-trait analysis);
THYM	cis	rs289828	0.507	rs17798290	chr2:152126473	T/G	cg05960677	chr2:152117363	RBM43	0.75	7.89	0.63	5.12e-12	Blood protein levels;
THYM	cis	rs2213920	0.679	rs4979536	chr9:118213738	C/T	cg13918206	chr9:118159781	DEC1	0.81	4.66	0.43	1.05e-5	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
THYM	cis	rs951188	0.602	rs114628672	chr2:150430402	T/C	cg17961725	chr2:150454027	NA	-1.03	-5.39	-0.48	5.11e-7	Daytime sleep phenotypes;
THYM	cis	rs425277	1.000	rs262676	chr1:2078482	T/A	cg00981070	chr1:2046702	PRKCZ	0.47	5.21	0.47	1.1e-6	Height;
THYM	cis	rs728616	0.867	rs12414521	chr10:81949534	G/C	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg26384229	chr12:38710491	ALG10B	0.99	7.38	0.6	5.84e-11	Bladder cancer;
THYM	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs7681440	0.606	rs2737000	chr4:90754022	G/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs2637266	0.667	rs2395406	chr10:78380519	G/A	cg18941641	chr10:78392320	NA	0.6	4.79	0.44	6.09e-6	Pulmonary function;
THYM	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg15744005	chr10:104629667	AS3MT	-0.83	-7.76	-0.62	9.57e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs11190604	1.000	rs7099913	chr10:102314777	T/C	cg07570687	chr10:102243282	WNT8B	0.77	6.81	0.57	8.82e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs5771242	0.845	rs2295225	chr22:50618797	C/G	cg11077631	chr22:50617003	PANX2	-0.55	-4.88	-0.45	4.21e-6	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
THYM	trans	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg25214090	chr10:38739885	LOC399744	0.92	7.7	0.62	1.26e-11	Corneal astigmatism;
THYM	cis	rs12410462	0.681	rs76191945	chr1:227673919	A/G	cg04117972	chr1:227635322	NA	0.83	4.72	0.44	8.27e-6	Major depressive disorder;
THYM	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg12935359	chr14:103987150	CKB	0.6	6.21	0.54	1.41e-8	Body mass index;
THYM	cis	rs636291	0.517	rs672606	chr1:10526144	G/A	cg20482658	chr1:10539492	PEX14	-0.34	-4.97	-0.45	2.98e-6	Prostate cancer;
THYM	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg06713675	chr4:122721982	EXOSC9	-0.86	-9.81	-0.71	4.29e-16	Type 2 diabetes;
THYM	cis	rs7586879	0.681	rs6723803	chr2:25120713	G/C	cg15423357	chr2:25149977	NA	0.68	7.53	0.61	2.9e-11	Body mass index;
THYM	cis	rs10214930	1.000	rs7800116	chr7:27822184	T/C	cg04422003	chr7:28448295	CREB5	-0.62	-4.62	-0.43	1.19e-5	Hypospadias;
THYM	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9549367	0.713	rs3024747	chr13:113821787	C/G	cg18105134	chr13:113819100	PROZ	-1.09	-8.84	-0.67	5.06e-14	Platelet distribution width;
THYM	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg14584255	chr6:163149320	PACRG;PARK2	0.76	6.74	0.57	1.22e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs738322	0.753	rs5756968	chr22:38595240	C/T	cg25457927	chr22:38595422	NA	0.51	5.31	0.48	7.17e-7	Cutaneous nevi;
THYM	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg05973401	chr12:123451056	ABCB9	0.68	4.55	0.42	1.58e-5	Neutrophil percentage of white cells;
THYM	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg12963246	chr6:28129442	ZNF389	0.72	6.12	0.53	2.05e-8	Depression;
THYM	cis	rs1883415	0.750	rs2076317	chr6:24490147	A/G	cg00346970	chr6:24499591	ALDH5A1	0.36	4.51	0.42	1.86e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs2456568	0.564	rs7119708	chr11:93626641	T/C	cg09189538	chr11:93579666	C11orf90	0.56	5.25	0.47	9.44e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs76878669	0.561	rs4630308	chr11:66162587	G/A	cg18002602	chr11:66138449	SLC29A2	0.47	4.84	0.44	5.1e-6	Educational attainment (years of education);
THYM	cis	rs2806561	0.765	rs605367	chr1:23518524	T/C	cg12483005	chr1:23474871	LUZP1	0.59	6.29	0.54	9.59e-9	Height;
THYM	cis	rs8078723	0.510	rs11655264	chr17:38138995	G/C	cg25038082	chr17:37896074	GRB7	-0.58	-4.86	-0.45	4.58e-6	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
THYM	cis	rs7119	0.745	rs11632602	chr15:77809764	C/G	cg27398640	chr15:77910606	LINGO1	-0.55	-5.61	-0.5	1.95e-7	Type 2 diabetes;
THYM	cis	rs13064411	0.627	rs9825827	chr3:113182231	T/C	cg18753928	chr3:113234510	CCDC52	-0.9	-8.68	-0.66	1.1e-13	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs13082711	0.911	rs13077400	chr3:27473066	A/G	cg02860705	chr3:27208620	NA	0.69	4.99	0.46	2.75e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg12311346	chr5:56204834	C5orf35	-0.82	-6.04	-0.53	3.01e-8	Initial pursuit acceleration;
THYM	cis	rs17174870	1.000	rs7575552	chr2:112673634	G/A	cg17354880	chr2:112658759	MERTK	-0.58	-4.48	-0.42	2.11e-5	Multiple sclerosis;
THYM	cis	rs7688540	0.511	rs61794969	chr4:188031	T/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.91	5.56	0.5	2.45e-7	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs4072705	0.586	rs7869042	chr9:127246751	C/T	cg01786973	chr9:127249749	NR5A1	-0.4	-5.24	-0.47	9.69e-7	Menarche (age at onset);
THYM	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg25554036	chr4:6271136	WFS1	0.56	5.29	0.48	7.94e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs859767	0.704	rs9287437	chr2:135357502	C/T	cg12500956	chr2:135428796	TMEM163	-0.47	-4.82	-0.44	5.54e-6	Neuroticism;
THYM	cis	rs2806561	0.704	rs674386	chr1:23521835	G/A	cg19743168	chr1:23544995	NA	0.62	6.31	0.54	8.74e-9	Height;
THYM	cis	rs7592578	0.882	rs2192010	chr2:191462133	C/T	cg10560079	chr2:191398806	TMEM194B	-0.93	-7.28	-0.6	9.81e-11	Diastolic blood pressure;
THYM	cis	rs4731207	0.671	rs6466949	chr7:124444900	T/C	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.96	0.45	3.04e-6	Obesity-related traits;
THYM	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg24678163	chr13:52769951	THSD1P	0.47	4.45	0.42	2.36e-5	Lewy body disease;
THYM	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.33	0.48	6.55e-7	Height;
THYM	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg01191920	chr7:158217561	PTPRN2	0.9	8.78	0.67	6.83e-14	Obesity-related traits;
THYM	cis	rs782590	0.967	rs1975487	chr2:55809054	A/G	cg03859395	chr2:55845619	SMEK2	0.6	5.46	0.49	3.8e-7	Metabolic syndrome;
THYM	cis	rs7236492	0.935	rs77865749	chr18:77216756	G/A	cg15644404	chr18:77186268	NFATC1	-1.06	-4.94	-0.45	3.41e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs2562456	0.917	rs2650805	chr19:21687939	T/G	cg21751540	chr19:21541537	ZNF738	0.7	4.89	0.45	4.11e-6	Pain;
THYM	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.45	5.53	0.49	2.87e-7	Monocyte percentage of white cells;
THYM	cis	rs300703	0.935	rs7568664	chr2:280939	A/G	cg21211680	chr2:198530	NA	1.33	5.61	0.5	1.97e-7	Blood protein levels;
THYM	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg14196790	chr5:131705035	SLC22A5	0.54	4.74	0.44	7.41e-6	Blood metabolite levels;
THYM	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg06558623	chr16:89946397	TCF25	1.34	5.64	0.5	1.76e-7	Skin colour saturation;
THYM	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg23260525	chr10:116636907	FAM160B1	0.53	5.33	0.48	6.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs3087591	0.960	rs9303642	chr17:29578360	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.64	-5.62	-0.5	1.87e-7	Hip circumference;
THYM	cis	rs1050631	0.592	rs1785933	chr18:33719191	T/C	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.58	4.56	0.42	1.54e-5	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg13395646	chr4:1353034	KIAA1530	-0.58	-5.47	-0.49	3.64e-7	Obesity-related traits;
THYM	cis	rs9905704	0.624	rs8080071	chr17:57093825	C/T	cg12560992	chr17:57184187	TRIM37	-0.68	-5.31	-0.48	7.04e-7	Testicular germ cell tumor;
THYM	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg24375607	chr4:120327624	NA	0.58	4.8	0.44	5.82e-6	Corneal astigmatism;
THYM	cis	rs7599762	0.882	rs12992087	chr2:238324700	C/T	cg25591469	chr2:238322789	COL6A3	0.49	5.67	0.5	1.52e-7	Intraocular pressure;
THYM	cis	rs985746	0.614	rs9994331	chr4:36791691	G/A	cg04301614	chr4:37585993	C4orf19	0.55	4.53	0.42	1.74e-5	Bone mineral density (Ward's triangle area);
THYM	cis	rs4363385	0.818	rs2711	chr1:153005156	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg26384229	chr12:38710491	ALG10B	1.0	7.56	0.61	2.54e-11	Bladder cancer;
THYM	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg24006582	chr15:45444508	DUOX1	-0.82	-7.12	-0.59	2.02e-10	Uric acid levels;
THYM	cis	rs2039659	0.719	rs1538056	chr13:86249446	A/G	cg25308322	chr13:86268291	NA	-0.69	-5.98	-0.52	3.97e-8	Blood osmolality (transformed sodium);
THYM	cis	rs10782582	0.593	rs77733234	chr1:76101655	A/T	cg03433033	chr1:76189801	ACADM	-0.52	-5.4	-0.48	4.97e-7	Daytime sleep phenotypes;
THYM	cis	rs2976388	0.669	rs2976391	chr8:143762724	C/A	cg13446199	chr8:143762866	PSCA	-0.41	-4.49	-0.42	1.97e-5	Urinary tract infection frequency;
THYM	cis	rs7100689	0.646	rs9804233	chr10:82134667	T/C	cg01528321	chr10:82214614	TSPAN14	0.79	6.01	0.52	3.47e-8	Post bronchodilator FEV1;
THYM	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg26597838	chr10:835615	NA	0.99	5.41	0.49	4.77e-7	Eosinophil percentage of granulocytes;
THYM	cis	rs4919687	0.550	rs17784294	chr10:104479385	G/T	cg15744005	chr10:104629667	AS3MT	-0.59	-4.66	-0.43	1.02e-5	Colorectal cancer;
THYM	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.81	-0.63	7.44e-12	Chronic sinus infection;
THYM	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs888194	0.587	rs6606711	chr12:109849297	A/G	cg10504392	chr12:110044639	NA	0.57	4.92	0.45	3.57e-6	Neuroticism;
THYM	cis	rs977987	0.737	rs8046697	chr16:75442144	T/C	cg03315344	chr16:75512273	CHST6	0.78	6.28	0.54	1.03e-8	Dupuytren's disease;
THYM	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg26384229	chr12:38710491	ALG10B	1.06	10.26	0.73	4.56e-17	Heart rate;
THYM	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg19318889	chr4:1322082	MAEA	0.49	4.48	0.42	2.07e-5	Longevity;
THYM	cis	rs12134245	0.776	rs61548854	chr1:92001536	C/T	cg25838465	chr1:92012736	NA	-0.9	-8.55	-0.66	2.09e-13	Breast cancer;
THYM	cis	rs42648	0.935	rs42629	chr7:89963324	G/T	cg25739043	chr7:89950458	NA	-0.55	-4.64	-0.43	1.12e-5	Homocysteine levels;
THYM	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.03	10.32	0.73	3.4e-17	Cognitive ability;
THYM	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg11812906	chr14:75593930	NEK9	-0.81	-7.31	-0.6	8.48e-11	Height;
THYM	cis	rs870825	1.000	rs870823	chr4:185588195	G/A	cg04058563	chr4:185651563	MLF1IP	1.0	6.98	0.58	3.96e-10	Blood protein levels;
THYM	cis	rs2034088	0.833	rs11247554	chr17:407465	C/A	cg06217071	chr17:408420	NA	0.88	8.82	0.67	5.58e-14	Hip circumference adjusted for BMI;
THYM	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg12011299	chr4:100065546	ADH4	0.69	6.2	0.54	1.46e-8	Alcohol dependence;
THYM	cis	rs4523957	0.583	rs2760739	chr17:2024217	C/T	cg16513277	chr17:2031491	SMG6	-0.96	-8.72	-0.67	9.17e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	7.45	0.61	4.17e-11	Platelet count;
THYM	cis	rs6499129	1.000	rs6499129	chr16:67458251	A/C	cg03615565	chr16:67572595	FAM65A	0.44	4.49	0.42	2.01e-5	Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs3126085	0.935	rs11204941	chr1:152203343	A/G	cg10321714	chr1:152280068	FLG	0.68	5.07	0.46	1.98e-6	Atopic dermatitis;
THYM	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg24399712	chr22:39784796	NA	-0.86	-7.78	-0.62	8.67e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs514406	0.929	rs1242224	chr1:53314887	G/A	cg16325326	chr1:53192061	ZYG11B	0.82	7.77	0.62	9e-12	Monocyte count;
THYM	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg26441486	chr22:50317300	CRELD2	0.44	7.08	0.59	2.46e-10	Schizophrenia;
THYM	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg05738196	chr6:26577821	NA	0.95	9.38	0.69	3.53e-15	Intelligence (multi-trait analysis);
THYM	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg24399712	chr22:39784796	NA	-0.76	-7.01	-0.58	3.47e-10	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg14983838	chr19:29218262	NA	0.99	8.0	0.63	2.97e-12	Methadone dose in opioid dependence;
THYM	cis	rs9393692	0.620	rs9357005	chr6:26336838	C/A	cg13736514	chr6:26305472	NA	-0.48	-5.0	-0.46	2.61e-6	Educational attainment;
THYM	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg07424592	chr7:64974309	NA	-0.96	-4.87	-0.45	4.36e-6	Diabetic kidney disease;
THYM	cis	rs7113850	0.541	rs76874215	chr11:24235158	G/A	ch.11.24196551F	chr11:24239977	NA	0.87	4.66	0.43	1.04e-5	Bone fracture in osteoporosis;
THYM	cis	rs7705042	0.727	rs1062158	chr5:141523000	C/T	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.98	-10.67	-0.74	6.18e-18	Menarche (age at onset);
THYM	cis	rs854765	0.654	rs11078400	chr17:17757728	A/G	cg16928487	chr17:17741425	SREBF1	0.51	5.14	0.47	1.48e-6	Total body bone mineral density;
THYM	cis	rs16944158	0.636	rs35622390	chr16:49639829	C/T	cg05126388	chr16:49670144	ZNF423	0.73	4.85	0.45	4.89e-6	IgG glycosylation;
THYM	cis	rs11574514	1.000	rs78575122	chr16:67869541	G/A	cg09738193	chr16:67926317	PSKH1	-0.9	-4.61	-0.43	1.28e-5	Crohn's disease;
THYM	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg19747945	chr6:42946146	PEX6	-0.34	-4.95	-0.45	3.18e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6032067	0.516	rs2743334	chr20:43919745	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.53	-5.02	-0.46	2.4e-6	Blood protein levels;
THYM	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg10523679	chr1:76189770	ACADM	-0.84	-6.96	-0.58	4.4e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7127900	0.583	rs71455921	chr11:2233635	A/C	cg25635251	chr11:2234043	NA	0.67	5.0	0.46	2.6e-6	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
THYM	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg06028605	chr16:24865363	SLC5A11	0.63	4.93	0.45	3.53e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs17193922	0.876	rs55813797	chr16:53551310	A/G	cg09728985	chr16:53543985	NA	-0.56	-4.64	-0.43	1.12e-5	Hip circumference adjusted for BMI;
THYM	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg20503657	chr10:835505	NA	1.14	7.96	0.63	3.64e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs912057	0.695	rs1294419	chr6:6742549	C/G	cg13809441	chr6:6737631	NA	0.43	4.86	0.45	4.62e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs7044106	0.791	rs4836831	chr9:123496570	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	7.53	0.61	2.89e-11	Hip circumference adjusted for BMI;
THYM	cis	rs6674176	0.561	rs12127226	chr1:44395309	C/T	cg13246856	chr1:44399776	ARTN	0.5	4.8	0.44	5.97e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs6429082	0.967	rs704709	chr1:235620964	C/T	cg26050004	chr1:235667680	B3GALNT2	0.6	5.42	0.49	4.5e-7	Adiposity;
THYM	cis	rs2033562	1.000	rs1347321	chr8:103548538	A/G	cg20611272	chr8:103548145	NA	0.42	5.11	0.46	1.65e-6	IgA nephropathy;
THYM	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg04750100	chr2:136595281	LCT	0.56	6.3	0.54	9.1e-9	Mosquito bite size;
THYM	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg17264618	chr3:40429014	ENTPD3	0.47	4.46	0.42	2.26e-5	Renal cell carcinoma;
THYM	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	5.0	0.46	2.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg06713675	chr4:122721982	EXOSC9	-0.88	-9.96	-0.71	1.96e-16	Type 2 diabetes;
THYM	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg11663144	chr21:46675770	NA	-0.72	-9.86	-0.71	3.32e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg12165864	chr7:66369176	NA	-0.65	-5.08	-0.46	1.89e-6	Aortic root size;
THYM	cis	rs7772486	0.875	rs11155452	chr6:146424631	C/T	cg13319975	chr6:146136371	FBXO30	-0.61	-4.96	-0.45	3.05e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg08999081	chr20:33150536	PIGU	-0.77	-6.95	-0.58	4.57e-10	Glomerular filtration rate (creatinine);
THYM	trans	rs877282	0.945	rs71491311	chr10:791747	G/A	cg22713356	chr15:30763199	NA	1.4	11.91	0.77	1.51e-20	Uric acid levels;
THYM	cis	rs1499972	0.941	rs62263114	chr3:117617722	T/A	cg07612923	chr3:117604196	NA	1.19	5.0	0.46	2.66e-6	Schizophrenia;
THYM	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs2133450	0.508	rs17047072	chr3:7349526	A/G	cg19930620	chr3:7340148	GRM7	-0.52	-5.62	-0.5	1.86e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg14784868	chr12:69753453	YEATS4	1.12	10.87	0.74	2.32e-18	Blood protein levels;
THYM	cis	rs240110	0.515	rs12530388	chr6:101329173	A/C	cg21058520	chr6:100914733	NA	-0.6	-5.09	-0.46	1.77e-6	Neuroticism;
THYM	cis	rs7084402	0.902	rs4245599	chr10:60365755	A/G	cg07615347	chr10:60278583	BICC1	0.55	5.06	0.46	2.03e-6	Refractive error;
THYM	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg14186256	chr22:23484241	RTDR1	0.95	9.24	0.69	7.12e-15	Bone mineral density;
THYM	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.71	-6.48	-0.55	4.1e-9	Personality dimensions;
THYM	cis	rs34526934	0.565	rs34729309	chr2:177034121	G/T	cg14324370	chr2:177042789	NA	-0.7	-5.97	-0.52	4.16e-8	Obstructive sleep apnea trait (apnea hypopnea index);
THYM	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg09021430	chr5:549028	NA	0.83	9.24	0.69	7.05e-15	Obesity-related traits;
THYM	cis	rs17604090	0.938	rs10241566	chr7:29690179	T/C	cg19413766	chr7:29689036	LOC646762	-0.91	-4.99	-0.46	2.69e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs17321999	1.000	rs906867	chr2:30478628	A/G	cg05247661	chr2:30472410	LBH	0.66	4.67	0.43	9.71e-6	Systemic lupus erythematosus;
THYM	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.62	4.84	0.44	5.02e-6	Menarche (age at onset);
THYM	cis	rs1065852	0.526	rs2413663	chr22:42402399	T/A	cg22189786	chr22:42395067	WBP2NL	0.54	5.55	0.49	2.6e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg02187348	chr16:89574699	SPG7	0.81	7.01	0.58	3.47e-10	Multiple myeloma (IgH translocation);
THYM	cis	rs6500395	0.926	rs11076571	chr16:48598064	A/G	cg04672837	chr16:48644449	N4BP1	0.48	4.58	0.43	1.39e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Bladder cancer;
THYM	cis	rs877282	0.898	rs11253339	chr10:759640	C/T	cg10556349	chr10:835070	NA	-0.78	-5.06	-0.46	2.06e-6	Uric acid levels;
THYM	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg00684032	chr4:1343700	KIAA1530	0.53	4.47	0.42	2.17e-5	Longevity;
THYM	cis	rs4819852	0.958	rs2240716	chr22:19969696	C/T	cg07821417	chr22:19972146	ARVCF	0.46	5.53	0.49	2.85e-7	Pulse pressure;
THYM	cis	rs7000551	0.725	rs2443496	chr8:22365788	G/A	cg12081754	chr8:22256438	SLC39A14	0.69	6.42	0.55	5.38e-9	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs6121246	0.609	rs6088997	chr20:30289824	A/G	cg13852791	chr20:30311386	BCL2L1	-0.89	-8.39	-0.65	4.4e-13	Mean corpuscular hemoglobin;
THYM	cis	rs9311676	0.656	rs11918201	chr3:58387777	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg11905131	chr22:24372483	LOC391322	-0.95	-10.55	-0.73	1.13e-17	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs11886999	0.680	rs62152972	chr2:96842653	C/T	cg10278162	chr2:97193688	NA	-0.71	-4.48	-0.42	2.11e-5	Cardiac Troponin-T levels;
THYM	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg22683308	chr4:1340831	KIAA1530	-0.64	-4.76	-0.44	6.8e-6	Longevity;
THYM	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Lung disease severity in cystic fibrosis;
THYM	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.53	5.0	0.46	2.58e-6	Lymphocyte counts;
THYM	cis	rs1691799	0.899	rs1168325	chr12:66728234	C/G	cg16791601	chr12:66731901	HELB	-0.76	-7.33	-0.6	7.6e-11	White blood cell count (basophil);
THYM	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6918586	0.616	rs1056314	chr6:26114653	G/A	cg07061783	chr6:25882402	NA	-0.58	-4.58	-0.43	1.42e-5	Schizophrenia;
THYM	cis	rs337100	0.521	rs12374528	chr5:122541973	G/A	cg04547002	chr5:122551801	NA	0.62	4.75	0.44	7.27e-6	Pulse pressure;
THYM	cis	rs12216545	0.765	rs6949018	chr7:150255583	G/A	cg08960815	chr7:150264767	GIMAP4	-0.87	-7.96	-0.63	3.61e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg10117171	chr1:25599238	RHD	0.71	5.47	0.49	3.67e-7	Erythrocyte sedimentation rate;
THYM	cis	rs5769765	0.542	rs5770720	chr22:50253101	A/G	cg08270630	chr22:50330655	NA	0.72	4.68	0.43	9.6e-6	Schizophrenia;
THYM	cis	rs9326248	0.530	rs511676	chr11:116824884	T/G	cg01368799	chr11:117014884	PAFAH1B2	0.86	4.7	0.43	8.89e-6	Blood protein levels;
THYM	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg06582575	chr6:163149167	PACRG;PARK2	1.16	6.92	0.58	5.14e-10	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22496380	chr5:211416	CCDC127	-1.31	-8.26	-0.65	8.38e-13	Breast cancer;
THYM	cis	rs9677476	0.863	rs4637098	chr2:232075528	C/T	cg23338755	chr2:231921595	PSMD1	0.64	4.76	0.44	6.93e-6	Food antigen IgG levels;
THYM	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg19077165	chr18:44547161	KATNAL2	0.51	6.0	0.52	3.58e-8	Personality dimensions;
THYM	cis	rs4919694	1.000	rs11191445	chr10:104651055	C/T	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs1018836	0.608	rs10111060	chr8:91491152	T/C	cg16814680	chr8:91681699	NA	-0.76	-6.27	-0.54	1.06e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs2340727	0.524	rs4656342	chr1:161942491	C/G	cg06514368	chr1:161719587	DUSP12	0.65	4.84	0.44	5.09e-6	White blood cell count;Hematology traits;
THYM	cis	rs988913	1.000	rs9475099	chr6:54839070	A/C	cg19716238	chr6:54711378	FAM83B	0.5	4.91	0.45	3.76e-6	Menarche (age at onset);
THYM	cis	rs35934224	0.783	rs28360650	chr22:19857061	A/G	cg11182965	chr22:19864308	TXNRD2	-0.68	-5.74	-0.51	1.11e-7	Glaucoma (primary open-angle);
THYM	cis	rs28785552	1.000	rs28785552	chr19:53234161	G/A	cg22067481	chr19:53234126	ZNF611	-1.06	-12.09	-0.78	6.34e-21	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg04282206	chr17:62833786	PLEKHM1P	-0.83	-8.06	-0.64	2.23e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs514406	0.929	rs562178	chr1:53319562	T/C	cg06600287	chr1:53387719	ECHDC2	-0.29	-4.69	-0.43	9.17e-6	Monocyte count;
THYM	cis	rs6988636	0.901	rs16898076	chr8:124187721	T/C	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs2050392	0.517	rs602097	chr10:30747546	C/T	cg13289132	chr10:30722225	MAP3K8	-0.66	-5.22	-0.47	1.05e-6	Inflammatory bowel disease;
THYM	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg10518543	chr12:38710700	ALG10B	-0.56	-4.48	-0.42	2.07e-5	Morning vs. evening chronotype;
THYM	cis	rs2963155	0.518	rs853184	chr5:142640901	C/T	cg17617527	chr5:142782415	NR3C1	1.19	6.6	0.56	2.33e-9	Breast cancer;
THYM	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg00990874	chr7:1149470	C7orf50	-0.63	-4.94	-0.45	3.36e-6	Bronchopulmonary dysplasia;
THYM	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg22655196	chr4:3374909	RGS12	0.58	6.97	0.58	4.17e-10	Serum sulfate level;
THYM	cis	rs2625529	0.668	rs12914070	chr15:72334279	T/C	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg10523679	chr1:76189770	ACADM	0.92	10.35	0.73	2.94e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs35883536	0.605	rs2133118	chr1:101034337	C/T	cg09408571	chr1:101003634	GPR88	-0.53	-5.73	-0.51	1.2e-7	Monocyte count;
THYM	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg07959070	chr22:50026188	C22orf34	-0.26	-4.68	-0.43	9.38e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2710642	0.777	rs2539987	chr2:63142864	A/G	cg17519650	chr2:63277830	OTX1	0.71	5.01	0.46	2.56e-6	LDL cholesterol levels;LDL cholesterol;
THYM	cis	rs3820068	0.608	rs10927840	chr1:16045250	A/G	cg24675056	chr1:15929824	NA	0.74	5.64	0.5	1.76e-7	Systolic blood pressure;
THYM	cis	rs7172677	0.538	rs1806795	chr15:75422744	A/G	cg09165964	chr15:75287851	SCAMP5	-0.59	-4.5	-0.42	1.95e-5	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg18811423	chr2:55921094	PNPT1	0.72	6.56	0.56	2.79e-9	Metabolic syndrome;
THYM	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg17063962	chr7:91808500	NA	1.15	12.37	0.79	1.64e-21	Breast cancer;
THYM	cis	rs1629083	0.902	rs10892226	chr11:118096618	G/A	cg25155064	chr11:118100782	MPZL3	-0.57	-5.04	-0.46	2.21e-6	Lung cancer;
THYM	cis	rs11158609	0.878	rs7160883	chr14:24673975	C/T	cg16000077	chr14:24777803	LTB4R2;CIDEB	0.4	5.13	0.47	1.51e-6	Systolic blood pressure (cigarette smoking interaction);
THYM	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7769051	0.522	rs62424539	chr6:133173272	C/T	cg22852734	chr6:133119734	C6orf192	1.04	4.96	0.45	3.1e-6	Type 2 diabetes nephropathy;
THYM	cis	rs10507349	1.000	rs35328831	chr13:26780341	T/C	cg18236477	chr13:26043066	ATP8A2	-0.58	-4.59	-0.43	1.37e-5	Type 2 diabetes;
THYM	cis	rs4845875	0.600	rs4846040	chr1:11837048	C/G	cg24844545	chr1:11908347	NPPA	0.57	4.77	0.44	6.74e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs7078219	0.714	rs10883369	chr10:101291367	C/T	cg23904955	chr10:101282759	NA	-0.41	-4.54	-0.42	1.65e-5	Dental caries;
THYM	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs2075230	0.705	rs1641531	chr17:7546791	C/G	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.74	-0.44	7.55e-6	Hormone measurements;
THYM	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg06789500	chr7:2109450	MAD1L1	-0.66	-4.45	-0.42	2.36e-5	Bipolar disorder;
THYM	cis	rs56161922	1.000	rs55821028	chr1:207843000	G/A	cg09557387	chr1:207818395	CR1L	1.14	5.13	0.47	1.52e-6	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg17063962	chr7:91808500	NA	1.1	12.09	0.78	6.22e-21	Breast cancer;
THYM	cis	rs4731207	0.698	rs7811608	chr7:124447848	T/C	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.53	0.56	3.27e-9	Total body bone mineral density;
THYM	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-6.01	-0.52	3.46e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs72828912	0.561	rs9393519	chr6:24056489	T/G	cg26336265	chr6:25042955	NA	-0.67	-4.54	-0.42	1.62e-5	Squamous cell lung carcinoma;
THYM	cis	rs367615	0.661	rs9326775	chr5:108836925	A/T	cg17395555	chr5:108820864	NA	0.74	8.69	0.67	1.04e-13	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs72772090	0.539	rs10515247	chr5:96111726	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.82	-4.67	-0.43	9.81e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs11645898	0.630	rs72791135	chr16:72259718	G/C	cg04170065	chr16:72153204	PMFBP1	-0.63	-4.81	-0.44	5.59e-6	Blood protein levels;
THYM	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg11366901	chr6:160182831	ACAT2	1.07	9.53	0.7	1.68e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs3916	0.955	rs35599677	chr12:121141458	G/A	cg10600917	chr12:121163489	ACADS	0.59	4.97	0.45	3.02e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.95	7.53	0.61	2.9e-11	Lymphocyte percentage of white cells;
THYM	cis	rs67460515	0.563	rs1599388	chr3:160846866	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-4.7	-0.43	8.93e-6	Parkinson's disease;
THYM	cis	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.33e-5	Retinal vascular caliber;
THYM	cis	rs11214589	0.651	rs11214594	chr11:113259332	G/A	cg14159747	chr11:113255604	NA	0.36	7.66	0.62	1.58e-11	Neuroticism;
THYM	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg04362960	chr10:104952993	NT5C2	0.63	4.47	0.42	2.12e-5	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg12573674	chr2:1569213	NA	-1.36	-8.99	-0.68	2.36e-14	IgG glycosylation;
THYM	cis	rs4819852	1.000	rs1034566	chr22:19984277	C/T	cg07821417	chr22:19972146	ARVCF	0.47	5.49	0.49	3.41e-7	Pulse pressure;
THYM	cis	rs8067545	0.578	rs4925091	chr17:20066988	T/C	cg13482628	chr17:19912719	NA	0.56	4.8	0.44	6.01e-6	Schizophrenia;
THYM	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg18105134	chr13:113819100	PROZ	1.01	9.27	0.69	5.98e-15	Platelet distribution width;
THYM	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg20608306	chr11:116969690	SIK3	-0.5	-6.17	-0.54	1.64e-8	Blood protein levels;
THYM	cis	rs11645898	0.504	rs79489472	chr16:71870359	C/T	cg14768367	chr16:72042858	DHODH	-0.7	-4.78	-0.44	6.38e-6	Blood protein levels;
THYM	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg10515332	chr4:99064459	C4orf37	0.57	4.53	0.42	1.72e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs344364	0.602	rs2437744	chr16:1908451	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.49	5.78	0.51	9.33e-8	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs6032067	0.538	rs62206431	chr20:43737073	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.54	-4.75	-0.44	7.25e-6	Blood protein levels;
THYM	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg22431228	chr1:16359049	CLCNKA	-0.57	-5.35	-0.48	5.97e-7	Systolic blood pressure;
THYM	cis	rs7582180	0.627	rs4149517	chr2:101014247	C/A	cg21926883	chr2:100939477	LONRF2	-0.66	-6.31	-0.54	8.84e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg23711669	chr6:146136114	FBXO30	0.83	7.77	0.62	9.16e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	7.0	0.58	3.57e-10	Bone mineral density;
THYM	cis	rs10752881	0.967	rs6695746	chr1:182991355	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Colorectal cancer;
THYM	cis	rs12478296	0.892	rs11897561	chr2:243014976	C/A	cg06360820	chr2:242988706	NA	-0.96	-6.27	-0.54	1.06e-8	Obesity-related traits;
THYM	cis	rs2976388	0.609	rs2164308	chr8:143785659	A/G	cg06565975	chr8:143823917	SLURP1	-0.47	-5.22	-0.47	1.06e-6	Urinary tract infection frequency;
THYM	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg22117172	chr7:91764530	CYP51A1	0.39	4.79	0.44	6.17e-6	Breast cancer;
THYM	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg06238570	chr21:40685208	BRWD1	0.83	5.82	0.51	8.02e-8	Cognitive function;
THYM	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg08999081	chr20:33150536	PIGU	-0.73	-6.56	-0.56	2.86e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg24375607	chr4:120327624	NA	0.64	4.47	0.42	2.18e-5	Corneal astigmatism;
THYM	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg02493740	chr2:85810744	VAMP5	-0.6	-4.57	-0.42	1.48e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs12579753	0.917	rs7954438	chr12:82184419	T/C	cg21231944	chr12:82153410	PPFIA2	-0.68	-5.12	-0.46	1.6e-6	Resting heart rate;
THYM	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg26597838	chr10:835615	NA	1.09	6.27	0.54	1.06e-8	Eosinophil percentage of granulocytes;
THYM	cis	rs28595532	0.920	rs116205107	chr4:119730910	G/A	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg21475434	chr5:93447410	FAM172A	-0.94	-5.31	-0.48	7.24e-7	Diabetic retinopathy;
THYM	trans	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg18709589	chr6:96969512	KIAA0776	0.63	4.48	0.42	2.08e-5	Migraine;Coronary artery disease;
THYM	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg05340658	chr4:99064831	C4orf37	0.54	4.55	0.42	1.58e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28595532	0.841	rs115852209	chr4:119753465	A/G	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg06558623	chr16:89946397	TCF25	1.44	6.25	0.54	1.14e-8	Skin colour saturation;
THYM	cis	rs7772486	0.875	rs2777483	chr6:146329235	A/G	cg05347473	chr6:146136440	FBXO30	0.57	4.52	0.42	1.77e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11886999	0.953	rs6725867	chr2:96874590	T/C	cg18419276	chr2:96971862	SNRNP200	-0.47	-5.28	-0.48	8.28e-7	Cardiac Troponin-T levels;
THYM	cis	rs11671005	0.735	rs11668420	chr19:58937836	G/A	cg18639983	chr19:58920768	ZNF584	0.6	5.01	0.46	2.48e-6	Mean platelet volume;
THYM	trans	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg20587970	chr11:113659929	NA	-1.27	-9.15	-0.68	1.08e-14	Hip circumference adjusted for BMI;
THYM	cis	rs8016982	0.674	rs11159494	chr14:81667611	G/C	cg21807262	chr14:81713016	NA	-0.57	-5.28	-0.48	8.05e-7	Schizophrenia;
THYM	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03264133	chr6:25882463	NA	-0.87	-7.64	-0.62	1.69e-11	Intelligence (multi-trait analysis);
THYM	cis	rs11112613	0.713	rs12321309	chr12:105943263	T/G	cg03607813	chr12:105948248	NA	1.06	9.06	0.68	1.69e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs4810479	0.513	rs3746506	chr20:44586036	G/A	cg23252815	chr20:44420276	WFDC3;DNTTIP1	0.49	5.21	0.47	1.11e-6	Metabolite levels;
THYM	cis	rs4642101	0.765	rs3732675	chr3:12858028	T/C	cg05775895	chr3:12838266	CAND2	0.84	7.1	0.59	2.24e-10	QRS complex (12-leadsum);
THYM	cis	rs7833986	0.501	rs2953922	chr8:56977485	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.4	0.6	5.43e-11	Height;
THYM	cis	rs67460515	0.563	rs11717272	chr3:160810355	A/G	cg12349858	chr3:160822545	B3GALNT1	0.61	5.03	0.46	2.36e-6	Parkinson's disease;
THYM	cis	rs2731664	0.792	rs337374	chr5:176890416	A/G	cg14098951	chr5:176875120	PRR7	-0.57	-5.17	-0.47	1.31e-6	Intelligence (multi-trait analysis);
THYM	trans	rs8002861	1.000	rs8002861	chr13:44474517	G/A	cg17145862	chr1:211918768	LPGAT1	1.04	12.02	0.78	8.8e-21	Leprosy;
THYM	cis	rs9522267	0.535	rs9522284	chr13:112229343	C/T	cg15979348	chr13:112237479	NA	-0.48	-4.46	-0.42	2.21e-5	Hepatitis;
THYM	cis	rs1003719	0.788	rs2835576	chr21:38457393	C/T	cg01329690	chr21:38580129	DSCR9	0.39	5.25	0.47	9.23e-7	Eye color traits;
THYM	cis	rs11031096	0.782	rs7130580	chr11:4169301	G/A	cg18678763	chr11:4115507	RRM1	-0.43	-5.46	-0.49	3.73e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7704138	0.639	rs4440309	chr5:55016916	A/C	cg18456523	chr5:54516805	NA	-0.58	-4.59	-0.43	1.34e-5	Height;
THYM	cis	rs920590	0.758	rs35896770	chr8:19665616	G/C	cg01411142	chr8:19674711	INTS10	0.66	5.04	0.46	2.24e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1021993	0.672	rs2247066	chr1:209473694	A/T	cg24997231	chr1:209527535	NA	0.5	4.55	0.42	1.57e-5	Gut microbiome composition (winter);
THYM	cis	rs8103278	0.740	rs2341097	chr19:46268902	C/T	cg14061069	chr19:46274453	DMPK	-0.57	-5.28	-0.48	8.1e-7	Coronary artery disease;
THYM	cis	rs10929159	0.928	rs2123513	chr2:236920638	T/C	cg14895183	chr2:236924282	AGAP1	0.54	4.67	0.43	9.81e-6	Parkinson's disease;
THYM	cis	rs2075230	0.542	rs2955616	chr17:7544084	A/G	cg27413385	chr17:7515425	FXR2	-0.36	-5.1	-0.46	1.74e-6	Hormone measurements;
THYM	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.01	-0.52	3.46e-8	Life satisfaction;
THYM	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg17264618	chr3:40429014	ENTPD3	0.54	5.09	0.46	1.78e-6	Renal cell carcinoma;
THYM	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg07460842	chr6:66804631	NA	1.11	8.22	0.64	1.06e-12	Exhaled nitric oxide output;
THYM	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg18811423	chr2:55921094	PNPT1	0.72	6.56	0.56	2.79e-9	Metabolic syndrome;
THYM	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg25237894	chr2:233734115	C2orf82	-0.35	-4.57	-0.42	1.47e-5	Coronary artery disease;
THYM	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03452623	chr4:187889614	NA	-1.17	-20.04	-0.9	6.92e-36	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06850241	chr22:41845214	NA	0.57	5.09	0.46	1.82e-6	Vitiligo;
THYM	cis	rs1728785	1.000	rs11647432	chr16:68565426	C/T	cg02972257	chr16:68554789	NA	-0.75	-4.57	-0.42	1.47e-5	Ulcerative colitis;
THYM	cis	rs988913	0.957	rs10485136	chr6:54756495	A/G	cg04690482	chr6:54711388	FAM83B	-0.45	-4.99	-0.46	2.68e-6	Menarche (age at onset);
THYM	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.33e-5	Alzheimer's disease;
THYM	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg16230307	chr14:35515116	FAM177A1	0.83	5.29	0.48	7.72e-7	Psoriasis;
THYM	cis	rs11039798	1.000	rs11530232	chr11:48622376	C/T	cg24672777	chr11:48374446	OR4C45	-1.08	-5.95	-0.52	4.42e-8	Axial length;
THYM	cis	rs7772486	0.623	rs9485021	chr6:146068797	A/G	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17209837	0.607	rs12539997	chr7:87131423	T/C	cg04996195	chr7:87105398	ABCB4	0.67	4.95	0.45	3.23e-6	Gallbladder cancer;
THYM	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs5769765	1.000	rs5770755	chr22:50280136	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.98	6.89	0.58	6.04e-10	Schizophrenia;
THYM	cis	rs1620921	0.967	rs783162	chr6:161182954	A/G	cg17993073	chr6:160527228	IGF2R	0.56	4.47	0.42	2.18e-5	Lipoprotein (a) - cholesterol levels;
THYM	cis	rs2340727	0.660	rs2340725	chr1:161943634	T/C	ch.1.159725313R	chr1:161458689	NA	-0.77	-5.21	-0.47	1.1e-6	White blood cell count;Hematology traits;
THYM	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg16680214	chr1:154839983	KCNN3	-0.39	-4.63	-0.43	1.15e-5	Prostate cancer;
THYM	cis	rs61931739	0.513	rs1608908	chr12:33895389	C/A	cg10856724	chr12:34555212	NA	-0.67	-5.94	-0.52	4.7e-8	Morning vs. evening chronotype;
THYM	cis	rs6541297	1.000	rs6665260	chr1:230279067	G/T	cg20703242	chr1:230279135	GALNT2	0.92	6.26	0.54	1.13e-8	Coronary artery disease;
THYM	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg00999904	chr2:3704751	ALLC	0.68	4.98	0.46	2.83e-6	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs6754311	0.509	rs13412397	chr2:136470714	G/A	cg20242066	chr2:136595261	LCT	-0.54	-5.9	-0.52	5.63e-8	Mosquito bite size;
THYM	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22496380	chr5:211416	CCDC127	-1.33	-7.99	-0.63	3.21e-12	Breast cancer;
THYM	cis	rs6121246	0.512	rs45443696	chr20:30311396	A/C	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs7772486	0.806	rs4243478	chr6:146284560	A/G	cg13319975	chr6:146136371	FBXO30	0.72	6.09	0.53	2.4e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.54	-5.26	-0.48	8.75e-7	Crohn's disease;
THYM	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg18252515	chr7:66147081	NA	0.64	4.69	0.43	9.21e-6	Aortic root size;
THYM	cis	rs4654899	0.802	rs57351360	chr1:21229538	T/A	cg01072550	chr1:21505969	NA	-0.7	-6.26	-0.54	1.12e-8	Superior frontal gyrus grey matter volume;
THYM	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg04455712	chr21:45112962	RRP1B	-0.55	-5.04	-0.46	2.2e-6	Mean corpuscular volume;
THYM	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg26384229	chr12:38710491	ALG10B	1.04	10.31	0.73	3.53e-17	Heart rate;
THYM	cis	rs4499344	0.633	rs259271	chr19:33157100	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.92	7.83	0.63	6.82e-12	Mean platelet volume;
THYM	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg17264618	chr3:40429014	ENTPD3	0.53	4.93	0.45	3.52e-6	Renal cell carcinoma;
THYM	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg13695892	chr22:41940480	POLR3H	0.85	6.98	0.58	3.94e-10	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg23730037	chr7:158596552	ESYT2	-0.5	-5.02	-0.46	2.37e-6	Height;
THYM	cis	rs514406	0.929	rs1672909	chr1:53340824	A/G	cg25767906	chr1:53392781	SCP2	-0.53	-5.26	-0.47	9.05e-7	Monocyte count;
THYM	cis	rs7631605	0.875	rs4678932	chr3:37096303	T/G	cg21328643	chr3:37258149	NA	-0.47	-4.45	-0.42	2.32e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs7267979	0.789	rs6050472	chr20:25219852	A/G	cg08601574	chr20:25228251	PYGB	0.71	5.76	0.51	1.05e-7	Liver enzyme levels (alkaline phosphatase);
THYM	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-13.7	-0.81	3.17e-24	Height;
THYM	cis	rs9905704	0.918	rs12947196	chr17:56902444	G/A	cg12560992	chr17:57184187	TRIM37	0.68	4.72	0.44	8.17e-6	Testicular germ cell tumor;
THYM	cis	rs7677751	0.806	rs7673027	chr4:55096180	T/A	cg17187183	chr4:55093834	PDGFRA	0.74	5.5	0.49	3.14e-7	Corneal astigmatism;
THYM	cis	rs10752881	1.000	rs6424880	chr1:182986679	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.79	0.44	6.13e-6	Colorectal cancer;
THYM	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg05335186	chr13:53173507	NA	-0.48	-6.7	-0.57	1.45e-9	Lewy body disease;
THYM	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg05368731	chr17:41323189	NBR1	1.06	6.9	0.58	5.68e-10	Menopause (age at onset);
THYM	cis	rs854765	0.583	rs9908832	chr17:17871068	C/T	cg16928487	chr17:17741425	SREBF1	-0.55	-5.38	-0.48	5.28e-7	Total body bone mineral density;
THYM	cis	rs514406	0.928	rs1672917	chr1:53291550	A/G	cg25767906	chr1:53392781	SCP2	-0.5	-4.75	-0.44	7.09e-6	Monocyte count;
THYM	cis	rs10911232	0.507	rs10911199	chr1:182998036	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs6531656	0.796	rs6531653	chr4:38618383	T/C	cg24279243	chr4:38676559	KLF3	0.85	6.35	0.55	7.45e-9	Lymphocyte counts;
THYM	cis	rs13108904	0.521	rs11247998	chr4:1363602	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.3	0.48	7.5e-7	Obesity-related traits;
THYM	cis	rs9915657	0.870	rs4140902	chr17:70133750	A/G	cg06234051	chr17:70120541	SOX9	-0.7	-6.4	-0.55	5.81e-9	Thyroid hormone levels;
THYM	cis	rs62070183	0.938	rs75782470	chr17:31073641	T/A	cg02981443	chr17:31254875	TMEM98	-0.54	-4.81	-0.44	5.61e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs240764	0.658	rs11155666	chr6:101234841	G/C	cg21058520	chr6:100914733	NA	0.6	5.29	0.48	7.79e-7	Neuroticism;
THYM	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg24308560	chr3:49941425	MST1R	-0.76	-6.48	-0.55	4.1e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg06784218	chr1:46089804	CCDC17	0.3	4.82	0.44	5.43e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7428297	0.943	rs13078084	chr3:127074386	A/G	cg25436886	chr3:127056972	NA	-0.72	-4.91	-0.45	3.81e-6	Clozapine-induced agranulocytosis;
THYM	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3112255	0.647	rs10175405	chr2:101319712	G/T	cg01042948	chr2:101319752	NA	-0.75	-6.75	-0.57	1.19e-9	Intelligence (multi-trait analysis);
THYM	cis	rs8044868	0.541	rs7202268	chr16:72086746	A/G	cg16558253	chr16:72132732	DHX38	-0.54	-4.58	-0.43	1.39e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs7740797	0.818	rs9371352	chr6:155133680	C/G	cg02865717	chr6:155053990	RBM16	0.46	4.64	0.43	1.11e-5	Colorectal or endometrial cancer;
THYM	cis	rs8063160	0.756	rs35026726	chr16:89791279	C/T	cg07984980	chr16:89898383	SPIRE2	1.6	6.42	0.55	5.28e-9	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
THYM	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg01416388	chr22:39784598	NA	-0.86	-8.31	-0.65	6.67e-13	Intelligence (multi-trait analysis);
THYM	cis	rs12579753	1.000	rs7963577	chr12:82174115	T/C	cg07988820	chr12:82153109	PPFIA2	-0.78	-4.97	-0.45	2.92e-6	Resting heart rate;
THYM	cis	rs4474465	0.790	rs4544031	chr11:78265403	G/C	cg19901956	chr11:77921274	USP35	0.61	4.64	0.43	1.12e-5	Alzheimer's disease (survival time);
THYM	cis	rs10208940	0.614	rs7560955	chr2:68770276	A/G	cg09157127	chr2:69201416	GKN1	0.75	4.47	0.42	2.2e-5	Urate levels in lean individuals;
THYM	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg05660106	chr1:15850417	CASP9	0.73	6.14	0.53	1.88e-8	Systolic blood pressure;
THYM	cis	rs7631605	0.905	rs2058476	chr3:37104896	G/T	cg21328643	chr3:37258149	NA	-0.47	-4.45	-0.42	2.32e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg10505658	chr17:80084571	CCDC57	-0.72	-7.71	-0.62	1.22e-11	Life satisfaction;
THYM	cis	rs8068544	0.606	rs77681389	chr17:40154419	T/C	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.47	-7.45	-0.61	4.22e-11	Reticulocyte fraction of red cells;Reticulocyte count;
THYM	cis	rs12257961	0.675	rs10752364	chr10:15352246	T/A	cg10616319	chr10:15468812	NA	-0.62	-4.94	-0.45	3.39e-6	Selective IgA deficiency;
THYM	cis	rs6032067	0.929	rs13043296	chr20:43805688	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg07061783	chr6:25882402	NA	-1.0	-9.37	-0.69	3.76e-15	Uric acid levels;
THYM	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12579753	0.917	rs4842410	chr12:82219225	A/T	cg21231944	chr12:82153410	PPFIA2	-0.7	-5.37	-0.48	5.68e-7	Resting heart rate;
THYM	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg13319975	chr6:146136371	FBXO30	-0.65	-5.16	-0.47	1.36e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg26384229	chr12:38710491	ALG10B	1.03	9.92	0.71	2.51e-16	Heart rate;
THYM	cis	rs2219968	0.525	rs6994543	chr8:78874084	C/T	cg00738934	chr8:78996279	NA	0.61	4.93	0.45	3.5e-6	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg26043149	chr18:55253948	FECH	1.11	10.16	0.72	7.43e-17	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg22431228	chr1:16359049	CLCNKA	0.43	4.66	0.43	1.03e-5	Systolic blood pressure;
THYM	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg11845111	chr2:191398756	TMEM194B	-0.92	-8.15	-0.64	1.43e-12	Pulse pressure;
THYM	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg03060546	chr3:49711283	APEH	-0.7	-5.83	-0.51	7.58e-8	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs6570726	0.935	rs447247	chr6:145812678	G/T	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg24450063	chr1:156163899	SLC25A44	1.16	14.83	0.84	1.8e-26	Testicular germ cell tumor;
THYM	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg09455208	chr3:40491958	NA	0.46	4.9	0.45	3.89e-6	Renal cell carcinoma;
THYM	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs241257	0.583	rs241260	chr1:4616066	C/G	cg00505606	chr1:3620638	TP73	-0.49	-4.78	-0.44	6.43e-6	Anxiety disorder;
THYM	cis	rs1372520	0.684	rs184810	chr4:90697979	T/C	cg01966878	chr4:90757139	SNCA	0.59	4.52	0.42	1.75e-5	Neuroticism;
THYM	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.91	6.2	0.54	1.43e-8	Smoking behavior;
THYM	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03576123	chr11:487126	PTDSS2	-1.48	-7.4	-0.6	5.54e-11	Body mass index;
THYM	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg18252515	chr7:66147081	NA	1.48	8.83	0.67	5.15e-14	Diabetic kidney disease;
THYM	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg16342193	chr10:102329863	NA	-0.59	-6.2	-0.54	1.48e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2862064	1.000	rs9313405	chr5:156447750	T/C	cg12943317	chr5:156479607	HAVCR1	-0.75	-4.65	-0.43	1.07e-5	Platelet count;
THYM	cis	rs4474465	0.850	rs11237537	chr11:78248397	C/T	cg19901956	chr11:77921274	USP35	-0.63	-4.63	-0.43	1.15e-5	Alzheimer's disease (survival time);
THYM	cis	rs208520	1.000	rs208535	chr6:66962286	G/A	cg07460842	chr6:66804631	NA	-0.85	-5.48	-0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs4866334	1.000	rs79038611	chr5:18503785	C/T	cg24599790	chr5:18972260	NA	-1.15	-4.67	-0.43	9.77e-6	IgG glycosylation;
THYM	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg05368731	chr17:41323189	NBR1	1.28	11.2	0.75	4.68e-19	Menopause (age at onset);
THYM	cis	rs12496230	1.000	rs13079612	chr3:66840534	T/C	cg23477460	chr3:66848765	NA	1.17	7.57	0.61	2.46e-11	Type 2 diabetes;
THYM	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg22509189	chr2:225307070	NA	-0.66	-5.36	-0.48	5.94e-7	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg08660285	chr1:67390436	MIER1;WDR78	0.93	7.76	0.62	9.52e-12	Lymphocyte percentage of white cells;
THYM	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg12963246	chr6:28129442	ZNF389	0.87	7.7	0.62	1.29e-11	Depression;
THYM	cis	rs72627123	0.749	rs72627137	chr14:74400177	C/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.11	6.6	0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs11997175	0.646	rs4612298	chr8:33713451	G/A	ch.8.33884649F	chr8:33765107	NA	0.63	4.76	0.44	6.85e-6	Body mass index;
THYM	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.59	4.6	0.43	1.32e-5	Calcium levels;
THYM	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11671005	0.737	rs11673101	chr19:58995053	G/C	cg02808233	chr19:58920810	ZNF584	0.57	4.51	0.42	1.89e-5	Mean platelet volume;
THYM	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg00129232	chr17:37814104	STARD3	-0.77	-5.27	-0.48	8.58e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg22852734	chr6:133119734	C6orf192	1.6	7.5	0.61	3.35e-11	Type 2 diabetes nephropathy;
THYM	cis	rs600806	0.778	rs11101960	chr1:110008778	C/T	cg02175308	chr1:109941060	SORT1	-0.55	-4.59	-0.43	1.33e-5	Intelligence (multi-trait analysis);
THYM	cis	rs56309584	0.715	rs78286057	chr17:8152039	C/A	cg08322244	chr17:8066669	VAMP2	-0.61	-5.35	-0.48	6.06e-7	Initial pursuit acceleration;
THYM	cis	rs7843479	0.601	rs1058486	chr8:21862551	A/G	cg17168535	chr8:21777572	XPO7	0.8	7.26	0.6	1.07e-10	Mean corpuscular volume;
THYM	cis	rs2797685	0.853	rs707462	chr1:7849880	A/G	cg06712362	chr1:7811235	CAMTA1	0.77	5.73	0.51	1.2e-7	Crohn's disease;
THYM	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg22907277	chr7:1156413	C7orf50	0.7	4.65	0.43	1.09e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs4363385	0.818	rs3795381	chr1:153004848	T/C	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs1160297	0.576	rs1376569	chr2:53087260	C/T	cg07782112	chr2:53107842	NA	0.77	6.31	0.54	8.76e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11779988	0.528	rs376771	chr8:17864985	G/A	cg01800426	chr8:17659068	MTUS1	-0.77	-5.37	-0.48	5.5e-7	Breast cancer;
THYM	cis	rs4988958	0.565	rs1035125	chr2:103033839	C/A	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma (childhood onset);
THYM	cis	rs611744	0.837	rs438191	chr8:109124222	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.06e-6	Dupuytren's disease;
THYM	cis	rs17433780	0.504	rs4142706	chr1:89475230	A/C	cg09516651	chr1:89888402	LOC400759	0.81	6.51	0.56	3.47e-9	Carotid intima media thickness;
THYM	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs35883536	0.647	rs10875316	chr1:101044150	G/A	cg06223162	chr1:101003688	GPR88	-0.79	-6.73	-0.57	1.26e-9	Monocyte count;
THYM	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg17173187	chr15:85201210	NMB	0.56	5.61	0.5	2.02e-7	Schizophrenia;
THYM	cis	rs9733	0.596	rs6690725	chr1:150632322	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs9807989	0.839	rs4988955	chr2:102967928	A/G	cg03938978	chr2:103052716	IL18RAP	0.64	6.7	0.57	1.48e-9	Asthma;
THYM	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg11317459	chr13:21872234	NA	1.23	9.84	0.71	3.7e-16	White matter hyperintensity burden;
THYM	cis	rs6674176	0.660	rs6680421	chr1:44408969	A/C	cg15962314	chr1:44399869	ARTN	-0.52	-4.56	-0.42	1.55e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs1395	0.767	rs1821986	chr2:27405835	A/G	cg23587288	chr2:27483067	SLC30A3	0.58	5.12	0.46	1.62e-6	Blood metabolite levels;
THYM	cis	rs1278352	0.767	rs1278364	chr10:127775962	A/G	cg08295661	chr10:127769903	ADAM12	-0.54	-5.43	-0.49	4.35e-7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg02825527	chr7:2087843	MAD1L1	-0.7	-4.47	-0.42	2.17e-5	Bipolar disorder;
THYM	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg24874828	chr4:187887005	NA	-0.72	-7.44	-0.61	4.48e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12410462	0.502	rs77615958	chr1:227806083	T/C	cg23173402	chr1:227635558	NA	0.86	6.28	0.54	1.02e-8	Major depressive disorder;
THYM	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.39	0.69	3.28e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11779988	0.629	rs11780813	chr8:17856014	T/C	cg01800426	chr8:17659068	MTUS1	-0.7	-5.09	-0.46	1.78e-6	Breast cancer;
THYM	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg09877947	chr5:131593287	PDLIM4	-0.52	-4.45	-0.42	2.36e-5	Breast cancer;
THYM	cis	rs1691799	0.899	rs1168293	chr12:66733904	G/A	cg16791601	chr12:66731901	HELB	-0.76	-7.23	-0.6	1.21e-10	White blood cell count (basophil);
THYM	cis	rs986417	0.748	rs4899011	chr14:60986698	A/G	cg27398547	chr14:60952738	C14orf39	1.13	6.18	0.54	1.57e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg16579431	chr16:433439	TMEM8A;LOC100134368	0.63	5.3	0.48	7.54e-7	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg17264618	chr3:40429014	ENTPD3	0.54	5.19	0.47	1.17e-6	Renal cell carcinoma;
THYM	cis	rs8074700	0.511	rs731748	chr17:46720178	G/A	cg06602723	chr17:46693336	HOXB8	0.49	4.66	0.43	1.04e-5	Body mass index in non-asthmatics;
THYM	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg06636551	chr8:101224915	SPAG1	-0.67	-6.52	-0.56	3.36e-9	Atrioventricular conduction;
THYM	cis	rs7616559	0.849	rs6441108	chr3:156771943	C/T	cg15697575	chr3:156784781	NA	0.4	5.2	0.47	1.15e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg05738196	chr6:26577821	NA	0.76	6.45	0.55	4.59e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.87	0.45	4.53e-6	Bipolar disorder;
THYM	cis	rs9810089	0.527	rs3957816	chr3:135955852	C/T	cg21827317	chr3:136751795	NA	0.64	5.99	0.52	3.69e-8	Gestational age at birth (child effect);
THYM	cis	rs4927850	1.000	rs4927704	chr3:195738228	C/T	cg12923728	chr3:195709715	SDHAP1	-0.79	-6.31	-0.54	8.86e-9	Pancreatic cancer;
THYM	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg09060608	chr5:178986726	RUFY1	0.51	5.05	0.46	2.12e-6	Lung cancer;
THYM	cis	rs12216545	0.737	rs4725910	chr7:150237268	A/G	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs55692411	0.537	rs7648652	chr3:50135412	A/C	cg14019146	chr3:50243930	SLC38A3	-0.61	-4.75	-0.44	7.08e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11039798	0.858	rs11039730	chr11:48440495	A/G	cg24672777	chr11:48374446	OR4C45	-1.05	-5.73	-0.51	1.18e-7	Axial length;
THYM	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg12560992	chr17:57184187	TRIM37	0.88	7.82	0.63	7.3e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9790314	1.000	rs336579	chr3:161086610	G/A	cg04691961	chr3:161091175	C3orf57	-0.6	-5.26	-0.47	8.85e-7	Morning vs. evening chronotype;
THYM	cis	rs12681287	0.640	rs7846090	chr8:87467724	A/T	cg27223183	chr8:87520930	FAM82B	-0.68	-5.16	-0.47	1.32e-6	Caudate activity during reward;
THYM	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg09877947	chr5:131593287	PDLIM4	0.59	4.79	0.44	6.11e-6	Blood metabolite levels;
THYM	cis	rs4986811	1.000	rs5030157	chr11:32450825	C/T	cg04096767	chr11:32449450	WT1	0.63	4.82	0.44	5.54e-6	Rubella-specific interleukin-6 secretion;
THYM	cis	rs73198271	0.740	rs10110711	chr8:8650456	C/T	cg06636001	chr8:8085503	FLJ10661	-0.7	-4.77	-0.44	6.56e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg24675056	chr1:15929824	NA	0.73	5.79	0.51	9.09e-8	Systolic blood pressure;
THYM	cis	rs9560113	0.960	rs61967677	chr13:112174044	A/G	cg14154082	chr13:112174009	NA	0.86	8.0	0.63	2.95e-12	Menarche (age at onset);
THYM	cis	rs9790314	0.628	rs1599381	chr3:160867680	G/A	cg03342759	chr3:160939853	NMD3	-0.61	-4.59	-0.43	1.35e-5	Morning vs. evening chronotype;
THYM	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.18	8.91	0.67	3.51e-14	Cognitive test performance;
THYM	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg10803722	chr21:46713166	LOC642852	-0.41	-5.33	-0.48	6.47e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4523957	0.590	rs9899427	chr17:2063550	A/T	cg16513277	chr17:2031491	SMG6	-0.93	-8.54	-0.66	2.22e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	trans	rs4650994	0.525	rs4076563	chr1:178516901	C/T	cg05059571	chr16:84539110	KIAA1609	-0.92	-10.85	-0.74	2.56e-18	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg18357526	chr6:26021779	HIST1H4A	0.78	6.67	0.57	1.65e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg08999081	chr20:33150536	PIGU	0.78	7.16	0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs1007190	0.764	rs8070598	chr17:42876865	T/C	cg15406952	chr17:42872593	NA	-0.84	-5.95	-0.52	4.45e-8	DNA methylation (variation);
THYM	cis	rs2777491	0.915	rs28583065	chr15:41608470	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.14	-12.89	-0.8	1.38e-22	Ulcerative colitis;
THYM	cis	rs72627123	0.867	rs113768127	chr14:74467839	T/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs476633	0.691	rs28568756	chr15:41539371	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.66	-5.59	-0.5	2.16e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg11764359	chr7:65958608	NA	-0.75	-6.05	-0.53	2.82e-8	Aortic root size;
THYM	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg09704166	chr2:114031854	PAX8;LOC440839	-0.71	-5.98	-0.52	3.95e-8	Lymphocyte counts;
THYM	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg20007245	chr22:24372913	LOC391322	-0.77	-7.87	-0.63	5.63e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7119	0.717	rs8032405	chr15:77825344	A/G	cg27398640	chr15:77910606	LINGO1	-0.56	-5.64	-0.5	1.76e-7	Type 2 diabetes;
THYM	cis	rs901683	1.000	rs71496609	chr10:46021031	C/A	cg18240400	chr10:46168597	ANUBL1	0.8	5.19	0.47	1.19e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg17264618	chr3:40429014	ENTPD3	0.46	4.51	0.42	1.82e-5	Renal cell carcinoma;
THYM	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg08994789	chr17:28903642	LRRC37B2	-1.05	-5.39	-0.48	5.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6722750	0.846	rs13394665	chr2:64391431	A/C	cg22352474	chr2:64371530	PELI1	-0.76	-6.84	-0.57	7.72e-10	Neuroticism;
THYM	cis	rs7107174	1.000	rs1385601	chr11:77936064	A/C	cg02023728	chr11:77925099	USP35	0.69	6.66	0.56	1.75e-9	Testicular germ cell tumor;
THYM	trans	rs8002861	0.905	rs11617551	chr13:44443977	T/C	cg17145862	chr1:211918768	LPGAT1	-0.87	-7.85	-0.63	6.13e-12	Leprosy;
THYM	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7580658	0.817	rs6761447	chr2:128074573	A/T	cg10021288	chr2:128175891	PROC	-0.74	-6.39	-0.55	6.13e-9	Protein C levels;
THYM	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg00484396	chr16:3507460	NAT15	0.49	4.72	0.44	8.23e-6	Body mass index (adult);
THYM	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg16928487	chr17:17741425	SREBF1	-0.59	-5.75	-0.51	1.1e-7	Total body bone mineral density;
THYM	cis	rs57590327	0.503	rs12638997	chr3:81844912	A/G	cg07356753	chr3:81810745	GBE1	-0.84	-6.19	-0.54	1.51e-8	Extraversion;
THYM	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg10360139	chr7:1886902	MAD1L1	-0.85	-7.68	-0.62	1.4e-11	Bipolar disorder and schizophrenia;
THYM	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg00852783	chr1:26633632	UBXN11	-0.79	-6.13	-0.53	1.99e-8	Obesity-related traits;
THYM	cis	rs7264396	0.887	rs6060431	chr20:34059337	A/G	cg26038318	chr20:34205095	SPAG4	0.53	4.47	0.42	2.15e-5	Total cholesterol levels;
THYM	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.5	4.74	0.44	7.62e-6	Lymphocyte counts;
THYM	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	9.39	0.69	3.37e-15	Chronic sinus infection;
THYM	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg19747945	chr6:42946146	PEX6	-0.34	-4.95	-0.45	3.18e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs8133932	0.736	rs11089025	chr21:47281579	C/A	cg20357416	chr21:47294739	PCBP3	-0.9	-6.21	-0.54	1.37e-8	Schizophrenia;
THYM	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.71	5.81	0.51	8.35e-8	Menarche (age at onset);
THYM	cis	rs7677751	0.767	rs6554158	chr4:55066077	G/A	cg17187183	chr4:55093834	PDGFRA	0.67	5.15	0.47	1.43e-6	Corneal astigmatism;
THYM	cis	rs7772486	0.806	rs2247317	chr6:146217570	C/T	cg23711669	chr6:146136114	FBXO30	0.85	8.24	0.65	9.39e-13	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg15536230	chr21:44985092	HSF2BP	0.41	4.5	0.42	1.91e-5	Mean corpuscular volume;
THYM	cis	rs4780401	0.642	rs7194145	chr16:11764615	T/G	cg01061890	chr16:11836724	TXNDC11	-0.6	-4.64	-0.43	1.11e-5	Rheumatoid arthritis;
THYM	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg03929089	chr4:120376271	NA	-1.01	-13.68	-0.81	3.47e-24	Height;
THYM	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg11301795	chr4:187892539	NA	-0.9	-10.41	-0.73	2.24e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg15693483	chr7:1102177	C7orf50	0.44	4.64	0.43	1.1e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10540	0.686	rs12421266	chr11:537120	C/T	cg21784768	chr11:537496	LRRC56	-1.21	-5.55	-0.5	2.53e-7	Body mass index;
THYM	cis	rs2072499	0.833	rs2842870	chr1:156200671	T/C	cg25208724	chr1:156163844	SLC25A44	1.01	10.88	0.74	2.2e-18	Testicular germ cell tumor;
THYM	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg09455208	chr3:40491958	NA	-0.45	-4.55	-0.42	1.59e-5	Renal cell carcinoma;
THYM	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg21100191	chr22:23484243	RTDR1	0.75	6.66	0.56	1.78e-9	Bone mineral density;
THYM	cis	rs4731207	0.596	rs12113770	chr7:124589740	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg19875535	chr5:140030758	IK	-0.63	-5.69	-0.5	1.43e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs919433	1.000	rs6761919	chr2:198163328	A/G	cg00792783	chr2:198669748	PLCL1	-0.67	-4.86	-0.45	4.68e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg09904177	chr6:26538194	HMGN4	0.64	5.41	0.49	4.78e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg26116260	chr4:7069785	GRPEL1	-0.98	-7.56	-0.61	2.53e-11	Monocyte percentage of white cells;
THYM	cis	rs4638749	0.501	rs1003018	chr2:108760922	G/T	cg25838818	chr2:108905173	SULT1C2	-0.52	-4.89	-0.45	4.13e-6	Blood pressure;
THYM	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	7.49	0.61	3.58e-11	Smoking behavior;
THYM	cis	rs9399401	0.921	rs4637667	chr6:142794021	C/A	cg04461802	chr6:142623433	GPR126	0.48	4.8	0.44	5.85e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs2404602	0.735	rs1607015	chr15:76702429	C/T	cg23482746	chr15:76478102	C15orf27	0.47	4.61	0.43	1.25e-5	Blood metabolite levels;
THYM	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg15445000	chr17:37608096	MED1	0.44	5.19	0.47	1.21e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs425277	1.000	rs425277	chr1:2069172	C/T	cg00981070	chr1:2046702	PRKCZ	0.48	5.31	0.48	7.23e-7	Height;
THYM	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg03806693	chr22:41940476	POLR3H	1.1	8.83	0.67	5.2e-14	Vitiligo;
THYM	cis	rs4638749	0.654	rs6761157	chr2:108816885	A/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs12579753	0.956	rs11115038	chr12:82214660	T/G	cg21231944	chr12:82153410	PPFIA2	-0.65	-4.87	-0.45	4.42e-6	Resting heart rate;
THYM	cis	rs11031096	0.754	rs10742242	chr11:4156851	T/C	cg18678763	chr11:4115507	RRM1	-0.43	-5.81	-0.51	8.3e-8	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs763014	0.865	rs62030874	chr16:632233	T/C	cg07343612	chr16:622815	PIGQ	-1.09	-11.34	-0.76	2.4e-19	Height;
THYM	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs11225247	0.772	rs10219215	chr11:102238237	C/T	cg06323957	chr11:102217781	BIRC2	1.02	4.74	0.44	7.52e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs12410462	0.581	rs112572966	chr1:227553905	C/T	cg23173402	chr1:227635558	NA	0.62	4.94	0.45	3.3e-6	Major depressive disorder;
THYM	cis	rs10256972	0.694	rs7784701	chr7:1003041	A/G	cg08883853	chr7:1026168	CYP2W1	-0.47	-4.91	-0.45	3.83e-6	Longevity;Endometriosis;
THYM	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg07362569	chr17:61921086	SMARCD2	0.63	5.47	0.49	3.67e-7	Prudent dietary pattern;
THYM	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg27129171	chr3:47204927	SETD2	0.73	6.89	0.58	6.09e-10	Colorectal cancer;
THYM	cis	rs7568458	0.591	rs55971080	chr2:85812746	T/C	cg17127132	chr2:85788382	GGCX	0.61	4.86	0.45	4.61e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs17331151	0.573	rs4687556	chr3:52890475	T/C	cg07884673	chr3:53033167	SFMBT1	-0.71	-4.71	-0.44	8.31e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs10170846	1.000	rs10170846	chr2:223517705	C/G	cg25565276	chr2:223520875	FARSB	-0.7	-5.57	-0.5	2.35e-7	Schizophrenia (inflammation and infection response interaction);
THYM	cis	rs7152530	0.571	rs7146746	chr14:98640387	C/T	cg05180522	chr14:98101740	NA	-0.6	-4.81	-0.44	5.61e-6	Staphylococcus aureus infection;
THYM	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg15704280	chr7:45808275	SEPT13	-0.95	-7.2	-0.59	1.44e-10	Coronary artery disease;
THYM	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg23574427	chr4:122746245	BBS7;CCNA2	-0.56	-5.15	-0.47	1.39e-6	Type 2 diabetes;
THYM	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg13395646	chr4:1353034	KIAA1530	-0.53	-4.77	-0.44	6.67e-6	Longevity;
THYM	cis	rs7589342	0.929	rs6719896	chr2:106428404	C/G	cg14210321	chr2:106509881	NCK2	0.72	5.12	0.46	1.62e-6	Addiction;
THYM	cis	rs34638657	0.872	rs6420437	chr16:82187181	T/C	cg09894383	chr16:82067445	HSD17B2	-0.52	-5.23	-0.47	1.01e-6	Lung adenocarcinoma;
THYM	cis	rs6840360	0.726	rs6816292	chr4:152730543	C/T	cg22705602	chr4:152727874	NA	0.65	7.76	0.62	9.45e-12	Intelligence (multi-trait analysis);
THYM	cis	rs516946	0.898	rs9694034	chr8:41523358	A/G	cg19441908	chr8:41529140	ANK1	0.62	4.9	0.45	3.87e-6	Type 2 diabetes;
THYM	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs8077889	0.672	rs2074143	chr17:41856622	A/G	cg26893861	chr17:41843967	DUSP3	1.13	12.5	0.79	8.69e-22	Triglycerides;
THYM	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg08885076	chr2:99613938	TSGA10	-0.68	-6.37	-0.55	6.85e-9	Chronic sinus infection;
THYM	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg15448220	chr1:150897856	SETDB1	0.88	7.27	0.6	1.02e-10	Melanoma;
THYM	cis	rs6450176	0.625	rs3822499	chr5:53289459	C/G	ch.5.1024479R	chr5:53302184	ARL15	-1.01	-8.07	-0.64	2.17e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg03806693	chr22:41940476	POLR3H	-0.79	-6.83	-0.57	8.12e-10	Neuroticism;
THYM	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg12386194	chr3:101231763	SENP7	0.71	5.39	0.48	5.17e-7	Colorectal cancer;
THYM	cis	rs6032067	0.759	rs6104052	chr20:43808783	T/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-6.1	-0.53	2.33e-8	Blood protein levels;
THYM	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg24147428	chr11:65409760	SIPA1	-0.74	-5.56	-0.5	2.42e-7	Blood pressure (age interaction);
THYM	cis	rs425535	0.941	rs420389	chr4:74858488	G/C	cg07868155	chr4:74864709	CXCL5	0.61	5.11	0.46	1.68e-6	Blood protein levels;
THYM	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.68	5.59	0.5	2.19e-7	Blood metabolite levels;
THYM	cis	rs981844	0.857	rs41320045	chr4:154720615	A/T	cg09973105	chr4:154681532	RNF175	0.7	5.94	0.52	4.67e-8	Response to statins (LDL cholesterol change);
THYM	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg07075026	chr17:47091521	IGF2BP1	-0.55	-6.44	-0.55	4.84e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg00495681	chr13:53174319	NA	0.73	6.78	0.57	1.01e-9	Lewy body disease;
THYM	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-4.55	-0.42	1.58e-5	Alzheimer's disease;
THYM	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg19318889	chr4:1322082	MAEA	0.5	4.51	0.42	1.83e-5	Longevity;
THYM	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.24	5.03	0.46	2.27e-6	Obesity-related traits;
THYM	cis	rs13102973	0.720	rs13122251	chr4:135887466	C/T	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.75	0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2066819	1.000	rs17118403	chr12:56630067	C/T	cg26714650	chr12:56694279	CS	-1.27	-6.32	-0.54	8.6e-9	Psoriasis vulgaris;
THYM	cis	rs2552220	0.818	rs11781143	chr8:6013029	G/A	cg06481462	chr8:7005678	NA	0.5	5.21	0.47	1.1e-6	Interleukin-8 levels;
THYM	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg09035930	chr12:129282057	SLC15A4	0.88	11.96	0.78	1.2e-20	Systemic lupus erythematosus;
THYM	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs13102973	0.674	rs11730572	chr4:135885397	C/T	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	cis	rs2637266	0.783	rs860167	chr10:78532936	A/G	cg18941641	chr10:78392320	NA	0.66	5.35	0.48	6.08e-7	Pulmonary function;
THYM	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg23583168	chr7:148888333	NA	-1.04	-13.97	-0.82	9.11e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs9787249	0.957	rs3738673	chr1:40204823	C/T	cg19912559	chr1:40204330	PPIE	0.63	4.67	0.43	9.98e-6	Blood protein levels;
THYM	cis	rs17102423	0.594	rs942628	chr14:65539463	C/G	cg11161011	chr14:65562177	MAX	-0.7	-5.68	-0.5	1.46e-7	Obesity-related traits;
THYM	cis	rs11039798	1.000	rs11039978	chr11:48760237	A/G	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs13256369	1.000	rs12550762	chr8:8576535	T/A	cg17143192	chr8:8559678	CLDN23	0.88	6.56	0.56	2.83e-9	Obesity-related traits;
THYM	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs854765	0.693	rs4924822	chr17:17748013	A/G	cg16928487	chr17:17741425	SREBF1	0.54	5.19	0.47	1.21e-6	Total body bone mineral density;
THYM	cis	rs3820068	0.655	rs59605679	chr1:15863796	T/G	cg05660106	chr1:15850417	CASP9	1.14	9.89	0.71	2.91e-16	Systolic blood pressure;
THYM	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg02953382	chr22:24373134	LOC391322	0.84	7.3	0.6	8.86e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs4690686	0.964	rs7687829	chr4:177254898	A/G	cg17059388	chr4:177262070	NA	0.37	4.86	0.45	4.7e-6	Essential tremor;
THYM	cis	rs10489202	1.000	rs7523437	chr1:168029365	A/G	cg24449463	chr1:168025552	DCAF6	-0.8	-6.3	-0.54	9.45e-9	Schizophrenia;
THYM	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg05738196	chr6:26577821	NA	0.6	4.91	0.45	3.71e-6	Schizophrenia;
THYM	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg13609457	chr4:120235615	NA	0.52	4.81	0.44	5.68e-6	Corneal astigmatism;
THYM	trans	rs10462794	0.789	rs7719895	chr5:4490338	C/T	cg03353000	chr22:41252913	ST13;XPNPEP3	1.17	7.02	0.58	3.26e-10	DNA methylation (variation);
THYM	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg00129232	chr17:37814104	STARD3	-0.87	-7.23	-0.6	1.23e-10	Asthma;
THYM	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg26031613	chr14:104095156	KLC1	0.75	5.11	0.46	1.63e-6	Body mass index;
THYM	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg06221963	chr1:154839813	KCNN3	-0.9	-11.69	-0.77	4.42e-20	Prostate cancer;
THYM	cis	rs6754311	0.773	rs680428	chr2:136630757	A/G	cg07169764	chr2:136633963	MCM6	-0.71	-6.05	-0.53	2.81e-8	Mosquito bite size;
THYM	cis	rs6570726	0.599	rs4398765	chr6:145935006	C/A	cg05347473	chr6:146136440	FBXO30	0.81	7.24	0.6	1.13e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg03806693	chr22:41940476	POLR3H	-1.02	-7.83	-0.63	6.94e-12	Vitiligo;
THYM	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg12350822	chr6:88032061	C6orf162;GJB7	-0.46	-5.69	-0.5	1.42e-7	Monocyte percentage of white cells;
THYM	cis	rs12478296	1.000	rs55717005	chr2:243041071	T/A	cg06360820	chr2:242988706	NA	-0.91	-5.52	-0.49	2.97e-7	Obesity-related traits;
THYM	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg02734326	chr4:10020555	SLC2A9	-0.56	-4.63	-0.43	1.17e-5	Bone mineral density;
THYM	cis	rs7917772	0.582	rs10786680	chr10:104317192	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs870825	0.616	rs7678900	chr4:185635249	A/G	cg04058563	chr4:185651563	MLF1IP	1.06	9.59	0.7	1.27e-15	Blood protein levels;
THYM	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.1	8.76	0.67	7.42e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg22875332	chr1:76189707	ACADM	0.89	12.06	0.78	7.38e-21	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs7187994	0.848	rs34139611	chr16:84772473	C/T	cg07647771	chr16:84786436	USP10	-0.57	-4.73	-0.44	7.65e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg22166914	chr1:53195759	ZYG11B	0.92	10.92	0.75	1.79e-18	Monocyte count;
THYM	cis	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg21775007	chr8:11205619	TDH	-0.73	-5.68	-0.5	1.49e-7	Retinal vascular caliber;
THYM	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg13447684	chr7:1895903	MAD1L1	0.71	6.93	0.58	5.05e-10	Bipolar disorder and schizophrenia;
THYM	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg22709100	chr7:91322751	NA	-0.61	-4.85	-0.45	4.9e-6	Breast cancer;
THYM	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs6980507	0.524	rs4568607	chr8:42364354	T/C	cg09913449	chr8:42400586	C8orf40	-0.78	-6.71	-0.57	1.41e-9	Glycated hemoglobin levels;
THYM	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg22664400	chr11:66445111	RBM4B	0.66	4.47	0.42	2.14e-5	Crohn's disease;
THYM	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg08847533	chr14:75593920	NEK9	-1.01	-11.32	-0.76	2.63e-19	Height;
THYM	cis	rs6570726	0.935	rs428659	chr6:145827039	T/C	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	8.39	0.65	4.55e-13	Lung cancer in ever smokers;
THYM	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-4.85	-0.45	4.85e-6	Total body bone mineral density;
THYM	cis	rs7567389	0.740	rs1604817	chr2:127999921	C/T	cg06038358	chr2:128176007	PROC	-0.49	-5.47	-0.49	3.63e-7	Self-rated health;
THYM	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22496380	chr5:211416	CCDC127	-1.33	-7.99	-0.63	3.21e-12	Breast cancer;
THYM	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-4.49	-0.42	1.99e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs1829883	0.835	rs2511902	chr5:98774365	A/T	cg08333243	chr5:99726346	NA	-0.56	-4.72	-0.44	8.14e-6	Hemostatic factors and hematological phenotypes;
THYM	cis	rs2637266	0.905	rs2579772	chr10:78406555	A/G	cg18941641	chr10:78392320	NA	0.77	6.59	0.56	2.41e-9	Pulmonary function;
THYM	cis	rs28595532	0.920	rs56117870	chr4:119766583	T/C	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs4919687	0.550	rs7904252	chr10:104456725	A/C	cg05855489	chr10:104503620	C10orf26	-0.66	-5.22	-0.47	1.03e-6	Colorectal cancer;
THYM	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4866334	1.000	rs116309900	chr5:18430285	G/T	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs2806561	0.765	rs682766	chr1:23516397	C/G	cg19743168	chr1:23544995	NA	0.55	5.64	0.5	1.77e-7	Height;
THYM	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	7.32	0.6	7.96e-11	Platelet count;
THYM	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06634786	chr22:41940651	POLR3H	0.79	6.02	0.53	3.27e-8	Vitiligo;
THYM	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg06636001	chr8:8085503	FLJ10661	-0.73	-6.25	-0.54	1.15e-8	Joint mobility (Beighton score);
THYM	cis	rs6450176	0.625	rs56193151	chr5:53287790	C/T	ch.5.1024479R	chr5:53302184	ARL15	-1.01	-8.07	-0.64	2.17e-12	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.75	0.67	7.59e-14	Cognitive test performance;
THYM	trans	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.66	-0.62	1.53e-11	Exhaled nitric oxide output;
THYM	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.25	6.12	0.53	2.12e-8	Obesity-related traits;
THYM	cis	rs1122608	0.540	rs4804553	chr19:11081405	T/C	cg17326582	chr19:11976514	ZNF439	0.6	4.62	0.43	1.19e-5	Coronary artery disease or ischemic stroke;Coronary artery disease;Coronary artery disease or large artery stroke;Coronary heart disease;Myocardial infarction (early onset);
THYM	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg02869364	chr7:1081709	C7orf50	-0.61	-4.91	-0.45	3.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs60695258	0.550	rs340648	chr4:87940940	A/G	cg10685359	chr4:87814065	C4orf36	0.45	5.81	0.51	8.24e-8	Hematocrit;
THYM	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.68	-5.28	-0.48	8.12e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg07936489	chr17:37558343	FBXL20	0.87	6.13	0.53	1.97e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs72827839	1.000	rs72827832	chr17:46407108	C/A	cg23391107	chr17:45924227	SP6	0.76	4.58	0.43	1.39e-5	Ease of getting up in the morning;
THYM	cis	rs2806561	0.664	rs55764475	chr1:23318983	C/T	cg12483005	chr1:23474871	LUZP1	0.53	5.41	0.49	4.7e-7	Height;
THYM	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg08885076	chr2:99613938	TSGA10	0.69	6.47	0.55	4.31e-9	Chronic sinus infection;
THYM	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg00530320	chr1:46809349	NSUN4	0.79	5.09	0.46	1.81e-6	Menopause (age at onset);
THYM	cis	rs11148252	0.716	rs1887360	chr13:52779166	A/G	cg00495681	chr13:53174319	NA	0.79	6.68	0.57	1.6e-9	Lewy body disease;
THYM	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.03	11.08	0.75	8.24e-19	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.657	rs10434028	chr4:120294464	T/G	cg25214090	chr10:38739885	LOC399744	0.86	7.35	0.6	6.87e-11	Corneal astigmatism;
THYM	cis	rs10540	1.000	rs61876342	chr11:496193	T/G	cg03576123	chr11:487126	PTDSS2	-1.22	-6.0	-0.52	3.56e-8	Body mass index;
THYM	cis	rs8013055	0.796	rs4074937	chr14:106000977	A/G	cg23356831	chr14:105996513	TMEM121	0.57	6.04	0.53	2.92e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs6541297	0.775	rs4846910	chr1:230291441	C/A	cg05784532	chr1:230284198	GALNT2	0.93	5.74	0.51	1.14e-7	Coronary artery disease;
THYM	cis	rs72627123	0.867	rs57731447	chr14:74487521	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.43	0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs912057	0.632	rs1294429	chr6:6744652	G/A	cg13809441	chr6:6737631	NA	0.44	5.32	0.48	6.97e-7	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg10452248	chr16:89456354	ANKRD11	-0.66	-4.77	-0.44	6.61e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs2070488	0.931	rs7630012	chr3:38552250	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-6.55	-0.56	2.97e-9	Electrocardiographic conduction measures;
THYM	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11644478	chr21:40555479	PSMG1	-0.56	-4.69	-0.43	9.07e-6	Menarche (age at onset);
THYM	cis	rs56104184	0.779	rs2131093	chr19:49350693	A/T	cg15549821	chr19:49342101	PLEKHA4	-1.1	-6.58	-0.56	2.6e-9	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2237457	0.897	rs886822	chr7:50718022	G/A	cg08586669	chr7:50727761	GRB10	0.31	4.69	0.43	9.01e-6	Schizophrenia (treatment resistant);
THYM	cis	rs6032067	0.925	rs35751129	chr20:43847658	C/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.48	-5.31	-0.48	7.29e-7	Blood protein levels;
THYM	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg03060546	chr3:49711283	APEH	0.77	6.37	0.55	6.65e-9	Resting heart rate;
THYM	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg21110456	chr7:2059412	MAD1L1	-0.43	-4.51	-0.42	1.86e-5	Neuroticism;
THYM	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg08132940	chr7:1081526	C7orf50	-1.16	-6.65	-0.56	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4664308	0.594	rs4665141	chr2:160890795	A/T	cg03641300	chr2:160917029	PLA2R1	-0.67	-5.84	-0.51	7.12e-8	Idiopathic membranous nephropathy;
THYM	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg12419862	chr22:24373484	LOC391322	-0.65	-4.66	-0.43	1.02e-5	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg13683864	chr3:40499215	RPL14	-0.91	-8.72	-0.67	8.93e-14	Renal cell carcinoma;
THYM	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg12560992	chr17:57184187	TRIM37	0.93	8.88	0.67	4.06e-14	Intelligence (multi-trait analysis);
THYM	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs988913	0.957	rs72645372	chr6:54788822	C/T	cg04690482	chr6:54711388	FAM83B	0.51	5.38	0.48	5.24e-7	Menarche (age at onset);
THYM	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg24375607	chr4:120327624	NA	0.65	4.55	0.42	1.61e-5	Corneal astigmatism;
THYM	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs714027	1.000	rs6006356	chr22:30503171	G/A	cg11564601	chr22:30592435	NA	-0.3	-5.45	-0.49	3.98e-7	Lymphocyte counts;
THYM	cis	rs17152411	0.947	rs55674450	chr10:126592153	G/T	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	1.01e-5	Height;
THYM	cis	rs3091242	0.900	rs35345536	chr1:25766488	A/G	cg10117171	chr1:25599238	RHD	-0.71	-5.47	-0.49	3.67e-7	Erythrocyte sedimentation rate;
THYM	cis	rs61931739	0.635	rs1352208	chr12:33932543	T/C	cg06521331	chr12:34319734	NA	-0.57	-4.76	-0.44	7e-6	Morning vs. evening chronotype;
THYM	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg19913688	chr11:428466	ANO9	-0.88	-4.6	-0.43	1.3e-5	Body mass index;
THYM	trans	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg10856724	chr12:34555212	NA	-0.94	-8.13	-0.64	1.61e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg11764359	chr7:65958608	NA	0.81	6.42	0.55	5.31e-9	Aortic root size;
THYM	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg26384229	chr12:38710491	ALG10B	0.95	7.55	0.61	2.7e-11	Bladder cancer;
THYM	cis	rs2933343	0.700	rs789233	chr3:128603150	G/T	cg11901034	chr3:128598214	ACAD9	-0.7	-5.68	-0.5	1.47e-7	IgG glycosylation;
THYM	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg17264618	chr3:40429014	ENTPD3	0.55	5.45	0.49	3.88e-7	Renal cell carcinoma;
THYM	cis	rs35883536	0.588	rs10465764	chr1:101105030	A/G	cg09408571	chr1:101003634	GPR88	0.43	5.16	0.47	1.34e-6	Monocyte count;
THYM	cis	rs7582180	0.676	rs10048665	chr2:100933085	A/G	cg14675211	chr2:100938903	LONRF2	0.77	8.23	0.65	9.81e-13	Intelligence (multi-trait analysis);
THYM	cis	rs901683	1.000	rs36070535	chr10:46022238	T/C	cg18240400	chr10:46168597	ANUBL1	0.8	5.19	0.47	1.19e-6	Red blood cell traits;Mean corpuscular volume;
THYM	trans	rs208520	0.661	rs207099	chr6:66796373	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.05	-7.66	-0.62	1.53e-11	Exhaled nitric oxide output;
THYM	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg03806693	chr22:41940476	POLR3H	1.03	8.19	0.64	1.18e-12	Vitiligo;
THYM	cis	rs2294693	0.786	rs12055704	chr6:40988504	C/T	cg14418226	chr6:40996092	UNC5CL	0.73	5.8	0.51	8.75e-8	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs858239	0.602	rs6953996	chr7:23175946	A/G	cg09755872	chr7:23245557	NA	-0.49	-4.68	-0.43	9.41e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7772486	0.701	rs7772717	chr6:145954854	T/C	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4786125	0.542	rs2345826	chr16:6916235	G/T	cg03623568	chr16:6915990	A2BP1	-1.02	-10.25	-0.72	4.76e-17	Heart rate variability traits (SDNN);
THYM	cis	rs11792861	0.591	rs7044275	chr9:111717138	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.83	7.14	0.59	1.83e-10	Menarche (age at onset);
THYM	cis	rs9866391	0.607	rs6808936	chr3:141109321	A/G	cg13411656	chr3:141121016	ZBTB38	-0.32	-4.73	-0.44	7.89e-6	Myopia;
THYM	cis	rs2290159	0.800	rs11709504	chr3:12674199	T/C	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs4851254	0.626	rs13001783	chr2:100689652	A/T	cg22139774	chr2:100720529	AFF3	-0.41	-4.69	-0.43	9.07e-6	Intelligence (multi-trait analysis);
THYM	cis	rs78456975	0.689	rs13391992	chr2:1542153	G/A	cg12573674	chr2:1569213	NA	-1.37	-6.46	-0.55	4.38e-9	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs72717009	0.825	rs7529225	chr1:161479352	G/A	cg15358701	chr1:161410459	NA	-0.92	-4.89	-0.45	4.1e-6	Rheumatoid arthritis;
THYM	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg07424592	chr7:64974309	NA	0.99	5.15	0.47	1.42e-6	Diabetic kidney disease;
THYM	cis	rs4866334	0.867	rs4866336	chr5:18484105	T/A	cg18608440	chr5:17519013	NA	-1.07	-4.95	-0.45	3.24e-6	IgG glycosylation;
THYM	cis	rs9611565	1.000	rs9611565	chr22:41767486	T/C	cg06634786	chr22:41940651	POLR3H	-0.59	-4.69	-0.43	9.23e-6	Vitiligo;
THYM	cis	rs17548007	1.000	rs34510257	chr12:103395292	C/T	cg27569040	chr12:103351855	ASCL1	-1.06	-4.52	-0.42	1.8e-5	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
THYM	cis	rs7927771	0.524	rs10838746	chr11:47706291	A/G	cg18512352	chr11:47633146	NA	0.4	4.47	0.42	2.14e-5	Subjective well-being;
THYM	cis	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg23422044	chr7:1970798	MAD1L1	-0.62	-4.46	-0.42	2.21e-5	Bipolar disorder;
THYM	cis	rs12410462	1.000	rs1587158	chr1:227658753	G/A	cg23173402	chr1:227635558	NA	-0.56	-5.26	-0.47	8.96e-7	Major depressive disorder;
THYM	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg18681998	chr4:17616180	MED28	0.85	7.68	0.62	1.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg02675527	chr2:114030824	PAX8;LOC440839	0.7	6.1	0.53	2.31e-8	Lymphocyte counts;
THYM	cis	rs870825	0.929	rs55746424	chr4:185589603	C/T	cg04058563	chr4:185651563	MLF1IP	1.01	7.14	0.59	1.9e-10	Blood protein levels;
THYM	cis	rs950776	0.648	rs57945453	chr15:78862845	C/T	cg06917634	chr15:78832804	PSMA4	0.88	7.36	0.6	6.64e-11	Sudden cardiac arrest;
THYM	trans	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg08807101	chr21:30365312	RNF160	-0.68	-4.46	-0.42	2.28e-5	Dental caries;
THYM	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg02887458	chr19:19495540	GATAD2A	-0.44	-5.19	-0.47	1.17e-6	Bipolar disorder;
THYM	cis	rs822354	1.000	rs266737	chr3:186477509	T/C	cg23249140	chr3:186560453	ADIPOQ	-0.48	-4.66	-0.43	1.02e-5	Adiponectin levels;
THYM	cis	rs500891	0.525	rs7774996	chr6:84073387	A/G	cg08257003	chr6:84140564	ME1	0.58	4.66	0.43	1.01e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg03060546	chr3:49711283	APEH	0.74	6.04	0.53	2.97e-8	Resting heart rate;
THYM	cis	rs6032067	0.527	rs6104012	chr20:43734571	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.5	-4.46	-0.42	2.29e-5	Blood protein levels;
THYM	cis	rs6840360	0.642	rs2709816	chr4:152380269	T/C	cg17479576	chr4:152424074	FAM160A1	-0.68	-5.17	-0.47	1.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2836633	0.895	rs2836597	chr21:40024424	A/G	cg05519781	chr21:40033154	ERG	0.69	6.65	0.56	1.82e-9	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs4292341	chr4:98959724	C/T	cg10515332	chr4:99064459	C4orf37	0.63	5.04	0.46	2.23e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg21970626	chr13:21893289	NA	-0.63	-5.77	-0.51	1.01e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs28595532	0.920	rs6818519	chr4:119787820	G/T	cg21605333	chr4:119757512	SEC24D	1.47	5.66	0.5	1.57e-7	Cannabis dependence symptom count;
THYM	cis	rs8103278	1.000	rs11671524	chr19:46327166	G/A	cg14061069	chr19:46274453	DMPK	-0.55	-5.27	-0.48	8.5e-7	Coronary artery disease;
THYM	cis	rs1978968	1.000	rs1076540	chr22:18439958	C/T	cg01550578	chr22:18484421	MICAL3	0.68	5.16	0.47	1.33e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs854765	0.583	rs4925129	chr17:17807186	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	6.16	0.53	1.72e-8	Total body bone mineral density;
THYM	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg05043794	chr9:111880884	C9orf5	-0.36	-4.99	-0.46	2.71e-6	Menarche (age at onset);
THYM	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.59	4.47	0.42	2.12e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs10782582	0.593	rs17647178	chr1:76210524	A/G	cg03433033	chr1:76189801	ACADM	-0.5	-5.08	-0.46	1.88e-6	Daytime sleep phenotypes;
THYM	cis	rs7078219	0.965	rs11190126	chr10:101271789	A/C	cg23904955	chr10:101282759	NA	-0.43	-5.03	-0.46	2.29e-6	Dental caries;
THYM	cis	rs4849845	0.889	rs7557096	chr2:121032043	A/T	cg03575764	chr2:121493832	NA	-0.64	-4.79	-0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.34	-0.65	5.7e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg11247378	chr22:39784982	NA	-0.98	-10.74	-0.74	4.42e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs59698941	0.943	rs67422135	chr5:132222728	T/A	cg02081065	chr5:132209139	LEAP2	-0.85	-5.74	-0.51	1.14e-7	Apolipoprotein A-IV levels;
THYM	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg08048268	chr3:133502702	NA	-0.67	-5.37	-0.48	5.6e-7	Iron status biomarkers;
THYM	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg26597838	chr10:835615	NA	1.23	8.88	0.67	4.1e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs7043114	0.525	rs6479417	chr9:95064562	G/C	cg14631576	chr9:95140430	CENPP	-0.85	-9.03	-0.68	1.99e-14	Height;
THYM	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg10802521	chr3:52805072	NEK4	-0.73	-6.43	-0.55	5.15e-9	Bipolar disorder;
THYM	cis	rs13006833	0.668	rs2664252	chr2:191148347	G/A	cg21644426	chr2:191273491	MFSD6	0.67	4.61	0.43	1.24e-5	Urinary metabolites;
THYM	cis	rs3892630	0.824	rs7247264	chr19:33239846	T/G	cg02283691	chr19:33182526	NUDT19	-0.41	-4.85	-0.45	4.83e-6	Red blood cell traits;
THYM	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg12963246	chr6:28129442	ZNF389	0.81	6.75	0.57	1.19e-9	Parkinson's disease;
THYM	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg11301795	chr4:187892539	NA	1.11	17.65	0.88	9.45e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg27286337	chr10:134555280	INPP5A	-1.06	-11.08	-0.75	8.22e-19	Migraine;
THYM	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14240646	chr10:27532245	ACBD5	-0.74	-4.57	-0.42	1.45e-5	Breast cancer;
THYM	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg19748678	chr4:122722346	EXOSC9	0.71	4.93	0.45	3.44e-6	Type 2 diabetes;
THYM	cis	rs807029	0.758	rs807027	chr10:102764607	T/A	cg04662943	chr10:102668895	NA	0.67	4.49	0.42	1.97e-5	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs2984613	1	rs2984613	chr1:156197380	C/T	cg25208724	chr1:156163844	SLC25A44	0.96	9.58	0.7	1.32e-15	Intracerebral hemorrhage;White matter hyperintensity burden;
THYM	cis	rs7731657	0.537	rs3981333	chr5:130375045	A/T	cg08523029	chr5:130500466	HINT1	-0.81	-5.67	-0.5	1.56e-7	Fasting plasma glucose;
THYM	cis	rs7043114	0.525	rs10992374	chr9:95336327	A/C	cg14631576	chr9:95140430	CENPP	-0.76	-7.28	-0.6	9.4e-11	Height;
THYM	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg14675211	chr2:100938903	LONRF2	0.76	8.42	0.65	3.99e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7191439	0.728	rs8056374	chr16:88790147	G/T	cg27087555	chr16:88793112	FAM38A	-1.55	-10.93	-0.75	1.76e-18	Plateletcrit;
THYM	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg21028142	chr17:79581711	NPLOC4	0.62	6.4	0.55	5.97e-9	Eye color traits;
THYM	cis	rs193541	0.509	rs12109789	chr5:122146619	C/G	cg19808643	chr5:122110361	SNX2	-0.57	-4.94	-0.45	3.32e-6	Glucose homeostasis traits;
THYM	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg22681709	chr2:178499509	PDE11A	-0.6	-5.19	-0.47	1.19e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs4664308	0.658	rs12987602	chr2:160960788	G/T	cg03641300	chr2:160917029	PLA2R1	-0.57	-5.12	-0.47	1.58e-6	Idiopathic membranous nephropathy;
THYM	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg13852791	chr20:30311386	BCL2L1	0.66	4.71	0.43	8.6e-6	Mean corpuscular hemoglobin;
THYM	cis	rs17443541	0.507	rs4675705	chr2:200456952	T/C	cg01795955	chr2:200468626	NA	-0.72	-5.0	-0.46	2.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1863824	0.625	rs11202023	chr10:88165453	C/T	cg06895675	chr10:88137553	NA	0.56	5.09	0.46	1.79e-6	Schizophrenia;
THYM	cis	rs9826463	0.582	rs73238138	chr3:142041137	T/C	cg20824294	chr3:142316082	PLS1	0.76	5.28	0.48	8.31e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs2898681	1.000	rs2003198	chr4:53748583	C/T	cg03786743	chr4:53727781	RASL11B	0.44	4.78	0.44	6.49e-6	Optic nerve measurement (cup area);
THYM	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg05855489	chr10:104503620	C10orf26	0.58	4.69	0.43	9.11e-6	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7189233	0.955	rs8058684	chr16:53515118	G/A	cg02965178	chr16:53538660	AKTIP	-0.58	-4.61	-0.43	1.26e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4474465	0.790	rs4945292	chr11:78254424	T/A	cg19901956	chr11:77921274	USP35	0.58	4.54	0.42	1.68e-5	Alzheimer's disease (survival time);
THYM	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg21475434	chr5:93447410	FAM172A	0.93	5.76	0.51	1.02e-7	Diabetic retinopathy;
THYM	cis	rs1580019	0.961	rs1868777	chr7:32494076	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.64	4.58	0.43	1.41e-5	Cognitive ability;
THYM	cis	rs7772486	0.686	rs2328708	chr6:146095739	G/A	cg23711669	chr6:146136114	FBXO30	-0.83	-7.92	-0.63	4.52e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs9633835	0.524	rs4757135	chr11:13280403	A/G	cg13286116	chr11:13302098	ARNTL	-0.72	-8.02	-0.64	2.71e-12	Body mass index;
THYM	cis	rs782590	0.934	rs17369191	chr2:55757885	T/C	cg03859395	chr2:55845619	SMEK2	0.66	6.08	0.53	2.51e-8	Metabolic syndrome;
THYM	cis	rs17030434	0.784	rs6835640	chr4:154650494	C/T	cg14289246	chr4:154710475	SFRP2	-0.73	-5.19	-0.47	1.2e-6	Electrocardiographic conduction measures;
THYM	cis	rs131777	0.575	rs963980	chr22:51022117	C/A	cg00083937	chr22:51039805	MAPK8IP2	0.59	5.16	0.47	1.36e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg02788857	chr8:22132959	PIWIL2	0.58	5.35	0.48	6.11e-7	Hypertriglyceridemia;
THYM	cis	rs7173743	0.750	rs12903355	chr15:79129145	A/T	cg00540400	chr15:79124168	NA	0.57	5.87	0.52	6.47e-8	Coronary artery disease;
THYM	cis	rs34638657	0.656	rs2911429	chr16:82203443	T/C	cg09439754	chr16:82129088	HSD17B2	-0.54	-4.76	-0.44	6.81e-6	Lung adenocarcinoma;
THYM	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg02503808	chr4:7069936	GRPEL1	0.94	8.14	0.64	1.53e-12	Monocyte percentage of white cells;
THYM	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs34638657	0.732	rs61111557	chr16:82201102	A/C	cg09439754	chr16:82129088	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg11905131	chr22:24372483	LOC391322	0.7	5.32	0.48	6.98e-7	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.87	0.71	3.15e-16	Prudent dietary pattern;
THYM	cis	rs2035647	0.537	rs3857868	chr7:137797764	T/A	cg06915773	chr7:137028165	PTN	0.6	4.9	0.45	3.92e-6	Blood metabolite levels;
THYM	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg10164272	chr16:89456328	ANKRD11	0.62	4.6	0.43	1.33e-5	Multiple myeloma (IgH translocation);
THYM	cis	rs425277	0.917	rs78395918	chr1:2045876	G/A	cg09260853	chr1:2094483	PRKCZ	0.53	4.88	0.45	4.22e-6	Height;
THYM	cis	rs7508	0.535	rs4124899	chr8:17785258	A/C	cg18067069	chr8:17937731	ASAH1	-0.66	-5.02	-0.46	2.43e-6	Atrial fibrillation;
THYM	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg26384229	chr12:38710491	ALG10B	0.9	6.97	0.58	4.22e-10	Morning vs. evening chronotype;
THYM	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg05043794	chr9:111880884	C9orf5	-0.41	-6.15	-0.53	1.8e-8	Menarche (age at onset);
THYM	cis	rs7546094	1.000	rs7554916	chr1:113123734	A/C	cg22162597	chr1:113214053	CAPZA1	0.45	4.63	0.43	1.15e-5	Platelet distribution width;
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg21736038	chr18:47013328	MIR1539;C18orf32	-0.92	-6.84	-0.57	7.65e-10	Energy expenditure (24h);
THYM	cis	rs9560113	0.960	rs4773378	chr13:112174154	G/A	cg10483660	chr13:112241077	NA	0.53	4.76	0.44	6.81e-6	Menarche (age at onset);
THYM	cis	rs877282	0.583	rs11253424	chr10:813426	C/T	cg10556349	chr10:835070	NA	-0.74	-4.88	-0.45	4.2e-6	Uric acid levels;
THYM	cis	rs919433	0.617	rs700638	chr2:198588950	A/C	cg05783139	chr2:198650985	BOLL	0.65	5.18	0.47	1.25e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg26384229	chr12:38710491	ALG10B	0.99	7.63	0.62	1.81e-11	Bladder cancer;
THYM	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.69	4.97	0.45	3.01e-6	Height;
THYM	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg13010199	chr12:38710504	ALG10B	-0.61	-4.6	-0.43	1.29e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg26384229	chr12:38710491	ALG10B	0.97	7.44	0.61	4.48e-11	Bladder cancer;
THYM	cis	rs1371867	0.846	rs1660316	chr8:101333049	T/C	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9807989	0.507	rs1833174	chr2:103034843	T/A	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg27129171	chr3:47204927	SETD2	0.73	6.06	0.53	2.69e-8	Birth weight;
THYM	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg27494647	chr7:150038898	RARRES2	0.47	5.41	0.49	4.77e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg13390004	chr1:15929781	NA	0.63	4.79	0.44	6.2e-6	Systolic blood pressure;
THYM	cis	rs17407555	0.821	rs4473652	chr4:10141617	G/C	cg00071950	chr4:10020882	SLC2A9	-0.77	-5.73	-0.51	1.16e-7	Schizophrenia (age at onset);
THYM	cis	rs3780378	0.967	rs7857730	chr9:5084049	G/T	cg02405213	chr9:5042618	JAK2	-0.64	-5.73	-0.51	1.2e-7	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg14004847	chr7:1930337	MAD1L1	-0.68	-5.47	-0.49	3.63e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg15604051	chr3:44754201	ZNF502	-0.58	-5.29	-0.48	7.98e-7	Depressive symptoms;
THYM	cis	rs3136739	0.764	rs6980538	chr8:42064609	C/A	cg16230352	chr8:42123158	NA	0.74	5.04	0.46	2.17e-6	Plasma plasminogen activator levels;
THYM	cis	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg16068833	chr1:26644515	UBXN11;CD52	0.26	4.5	0.42	1.9e-5	Obesity-related traits;
THYM	cis	rs713587	0.875	rs6746013	chr2:25143649	C/G	cg15423357	chr2:25149977	NA	0.7	7.69	0.62	1.38e-11	Body mass index in non-asthmatics;
THYM	cis	rs7487075	0.780	rs12307969	chr12:46759057	G/C	cg17501823	chr12:47219793	SLC38A4	0.5	4.68	0.43	9.49e-6	Itch intensity from mosquito bite;
THYM	cis	rs28647808	0.786	rs4962137	chr9:136256826	G/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.74	5.24	0.47	9.78e-7	Iron status biomarkers;
THYM	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg06238570	chr21:40685208	BRWD1	-0.72	-6.28	-0.54	9.9e-9	Menarche (age at onset);
THYM	cis	rs1018836	0.923	rs6986001	chr8:91650205	T/C	cg16814680	chr8:91681699	NA	-0.99	-9.51	-0.7	1.82e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	trans	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Bladder cancer;
THYM	cis	rs9837602	0.935	rs9875640	chr3:99729091	C/T	cg00175735	chr3:99903386	TMEM30C	-0.78	-4.71	-0.44	8.37e-6	Breast cancer;
THYM	cis	rs289828	0.538	rs59247111	chr2:152154339	C/T	cg05960677	chr2:152117363	RBM43	0.71	6.64	0.56	1.94e-9	Blood protein levels;
THYM	cis	rs9534288	0.699	rs9567621	chr13:46665814	A/G	cg15192986	chr13:46630673	CPB2	-0.66	-4.69	-0.43	9.06e-6	Blood protein levels;
THYM	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.83	0.74	2.77e-18	Diabetic retinopathy;
THYM	cis	rs9527	0.615	rs11191485	chr10:104729816	G/C	cg15744005	chr10:104629667	AS3MT	-0.61	-4.55	-0.42	1.61e-5	Arsenic metabolism;
THYM	cis	rs13418717	0.793	rs10180994	chr2:127660075	C/G	cg25501666	chr2:127640322	NA	1.39	6.15	0.53	1.8e-8	Heart failure;
THYM	cis	rs9443189	0.813	rs2748948	chr6:76437994	T/A	cg01950844	chr6:76311363	SENP6	-0.78	-4.52	-0.42	1.81e-5	Prostate cancer;
THYM	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg27129171	chr3:47204927	SETD2	0.74	7.2	0.59	1.42e-10	Colorectal cancer;
THYM	cis	rs11948739	0.610	rs1363695	chr5:130378027	C/T	cg08523029	chr5:130500466	HINT1	-0.85	-6.0	-0.52	3.63e-8	Pediatric bone mineral content (hip);
THYM	cis	rs7584330	0.554	rs6705908	chr2:238433965	A/G	cg10135854	chr2:238990085	SCLY	0.6	4.45	0.42	2.33e-5	Prostate cancer;
THYM	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg17366294	chr4:99064904	C4orf37	0.54	6.4	0.55	5.74e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9527	0.615	rs10883810	chr10:104727224	A/C	cg04362960	chr10:104952993	NT5C2	0.63	4.76	0.44	6.9e-6	Arsenic metabolism;
THYM	cis	rs17511627	0.808	rs1830861	chr13:26744583	C/T	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06634786	chr22:41940651	POLR3H	-0.73	-5.36	-0.48	5.89e-7	Vitiligo;
THYM	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg08660285	chr1:67390436	MIER1;WDR78	-0.97	-7.68	-0.62	1.43e-11	Lymphocyte percentage of white cells;
THYM	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg19077165	chr18:44547161	KATNAL2	-0.62	-7.95	-0.63	3.8e-12	Personality dimensions;
THYM	cis	rs6988636	1.000	rs62521841	chr8:124194625	G/A	cg22384356	chr8:124195192	FAM83A	-0.8	-4.73	-0.44	7.73e-6	Urinary uromodulin levels;
THYM	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg02640540	chr1:67518911	SLC35D1	-0.64	-4.68	-0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs478304	0.651	rs10896037	chr11:65503424	A/G	cg27068330	chr11:65405492	SIPA1	-0.95	-8.8	-0.67	6.03e-14	Acne (severe);
THYM	cis	rs11690935	0.959	rs3770452	chr2:172668682	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.83	-6.15	-0.53	1.8e-8	Schizophrenia;
THYM	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg17294928	chr15:75287854	SCAMP5	0.65	4.97	0.45	2.99e-6	Breast cancer;
THYM	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg23187316	chr7:1099788	C7orf50	0.58	4.45	0.42	2.32e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg27129171	chr3:47204927	SETD2	-0.71	-6.75	-0.57	1.16e-9	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs10009206	chr4:99056900	A/C	cg17366294	chr4:99064904	C4orf37	-0.6	-7.12	-0.59	2.01e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs3862030	0.694	rs2025712	chr10:104230064	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.71	-5.96	-0.52	4.3e-8	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs7084402	0.967	rs1649059	chr10:60312599	T/C	cg07615347	chr10:60278583	BICC1	0.58	5.28	0.48	8.13e-7	Refractive error;
THYM	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg00071950	chr4:10020882	SLC2A9	0.86	10.33	0.73	3.3e-17	Bone mineral density;
THYM	cis	rs854765	0.583	rs8070128	chr17:17804725	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-6.47	-0.55	4.29e-9	Total body bone mineral density;
THYM	cis	rs1978968	1.000	rs1076544	chr22:18446565	G/A	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.59	5.3	0.48	7.4e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06850241	chr22:41845214	NA	0.59	5.41	0.49	4.76e-7	Vitiligo;
THYM	cis	rs662064	0.544	rs12402967	chr1:10617924	T/C	cg20482658	chr1:10539492	PEX14	0.47	5.36	0.48	5.94e-7	Asthma;
THYM	cis	rs4845875	0.603	rs10864539	chr1:11833910	A/G	cg25341925	chr1:11908058	NPPA	0.43	4.7	0.43	8.87e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs3096299	0.967	rs3102383	chr16:89411295	G/A	cg02187348	chr16:89574699	SPG7	0.68	5.06	0.46	2.07e-6	Multiple myeloma (IgH translocation);
THYM	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg01059385	chr22:42394853	WBP2NL	0.78	5.06	0.46	2.02e-6	Birth weight;
THYM	cis	rs965469	0.895	rs12626130	chr20:3393192	G/T	cg25506879	chr20:3388711	C20orf194	-0.87	-5.25	-0.47	9.31e-7	IFN-related cytopenia;
THYM	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg13770153	chr20:60521292	NA	1.21	10.53	0.73	1.23e-17	Obesity-related traits;
THYM	cis	rs853679	0.599	rs202906	chr6:28011652	C/T	cg12963246	chr6:28129442	ZNF389	-0.84	-4.88	-0.45	4.24e-6	Depression;
THYM	cis	rs9906944	0.713	rs9899580	chr17:47106878	T/G	cg09029085	chr17:47094198	IGF2BP1	0.47	6.53	0.56	3.17e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs9403317	0.632	rs9385968	chr6:141920697	C/T	cg15052665	chr6:141804349	NA	0.76	5.75	0.51	1.08e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs55665837	0.559	rs9667144	chr11:14421101	C/T	cg19336497	chr11:14380999	RRAS2	0.81	10.81	0.74	3.05e-18	Vitamin D levels;
THYM	cis	rs10095849	0.680	rs13258794	chr8:39454425	T/A	cg22755526	chr8:38854673	TM2D2;ADAM9	0.66	4.48	0.42	2.04e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg14004847	chr7:1930337	MAD1L1	-0.67	-5.44	-0.49	4.22e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs12681288	0.550	rs4410933	chr8:959581	A/G	cg08648136	chr8:956695	NA	0.59	5.14	0.47	1.45e-6	Schizophrenia;
THYM	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs944002	1.000	rs61418148	chr14:103567020	T/C	cg16996574	chr14:103691482	NA	0.49	4.5	0.42	1.93e-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;
THYM	cis	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg07460842	chr6:66804631	NA	-0.91	-6.25	-0.54	1.14e-8	Exhaled nitric oxide output;
THYM	cis	rs6570726	0.935	rs371744	chr6:145841024	C/T	cg23711669	chr6:146136114	FBXO30	0.9	8.87	0.67	4.4e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs28374715	0.609	rs8043237	chr15:41514298	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.01	-8.29	-0.65	7.22e-13	Ulcerative colitis;
THYM	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	4.76	0.44	6.92e-6	Bipolar disorder;
THYM	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs7705042	0.865	rs4391200	chr5:141509537	A/G	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg12000587	chr17:30186630	C17orf79	-0.39	-4.74	-0.44	7.64e-6	Hip circumference adjusted for BMI;
THYM	cis	rs11008222	0.934	rs10826861	chr10:31040980	A/G	cg00941203	chr10:31016591	NA	-0.36	-4.97	-0.45	2.92e-6	Congenital left-sided heart lesions (maternal effect);
THYM	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg20587970	chr11:113659929	NA	-1.34	-8.87	-0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs9560113	0.597	rs947170	chr13:112241062	G/A	cg15979348	chr13:112237479	NA	-0.55	-5.18	-0.47	1.25e-6	Menarche (age at onset);
THYM	cis	rs28595532	0.920	rs28837152	chr4:119782868	G/A	cg21605333	chr4:119757512	SEC24D	1.56	6.29	0.54	9.68e-9	Cannabis dependence symptom count;
THYM	cis	rs7107174	1.000	rs1385600	chr11:77936166	C/T	cg02023728	chr11:77925099	USP35	-0.69	-6.65	-0.56	1.83e-9	Testicular germ cell tumor;
THYM	cis	rs73086581	0.687	rs73082600	chr20:3844365	G/A	cg02187196	chr20:3869020	PANK2	0.43	4.87	0.45	4.4e-6	Response to antidepressants in depression;
THYM	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg17366294	chr4:99064904	C4orf37	0.57	6.68	0.57	1.63e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg10661904	chr17:79619235	PDE6G	-0.57	-5.3	-0.48	7.61e-7	Eye color traits;
THYM	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.58	-4.98	-0.46	2.78e-6	Platelet count;
THYM	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg03517284	chr6:25882590	NA	0.71	5.64	0.5	1.75e-7	Schizophrenia;
THYM	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg03929089	chr4:120376271	NA	-0.82	-8.51	-0.66	2.45e-13	Height;
THYM	cis	rs752010	0.806	rs943375	chr1:42092152	A/G	cg22486000	chr1:42919398	ZMYND12	-0.43	-4.83	-0.44	5.16e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg06092702	chr1:163392909	NA	-0.62	-5.65	-0.5	1.69e-7	Motion sickness;
THYM	cis	rs7635838	0.718	rs2594991	chr3:11362704	G/A	cg00170343	chr3:11313890	ATG7	0.57	4.52	0.42	1.8e-5	HDL cholesterol;
THYM	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.81	5.63	0.5	1.81e-7	Huntington's disease progression;
THYM	cis	rs919433	0.750	rs788010	chr2:198230949	T/C	cg00792783	chr2:198669748	PLCL1	0.78	5.6	0.5	2.12e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg19875535	chr5:140030758	IK	0.58	4.65	0.43	1.08e-5	Depressive symptoms (multi-trait analysis);
THYM	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg12386194	chr3:101231763	SENP7	0.69	5.2	0.47	1.16e-6	Colorectal cancer;
THYM	cis	rs877282	0.898	rs34490091	chr10:765800	A/C	cg10556349	chr10:835070	NA	-0.8	-5.08	-0.46	1.91e-6	Uric acid levels;
THYM	cis	rs7107174	1.000	rs2511177	chr11:77922960	C/T	cg02023728	chr11:77925099	USP35	0.68	6.51	0.56	3.47e-9	Testicular germ cell tumor;
THYM	cis	rs870825	0.616	rs7660939	chr4:185640792	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs9486719	0.895	rs3798294	chr6:97049587	G/A	cg18709589	chr6:96969512	KIAA0776	-0.67	-4.64	-0.43	1.1e-5	Migraine;Coronary artery disease;
THYM	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg19875535	chr5:140030758	IK	0.6	4.75	0.44	7.26e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs12122100	0.545	rs1984615	chr1:146506206	G/A	cg02487331	chr1:146550467	NA	-0.6	-4.86	-0.45	4.65e-6	HIV-1 control;
THYM	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg09354556	chr3:47051341	NA	0.44	4.57	0.42	1.46e-5	Colorectal cancer;
THYM	cis	rs921968	0.541	rs7601872	chr2:219319885	C/G	cg02176678	chr2:219576539	TTLL4	-0.7	-7.19	-0.59	1.47e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2237457	0.965	rs12530592	chr7:50701814	C/T	cg08586669	chr7:50727761	GRB10	0.33	4.9	0.45	3.95e-6	Schizophrenia (treatment resistant);
THYM	cis	rs9527	0.662	rs4919686	chr10:104592249	A/C	cg08772003	chr10:104629869	AS3MT	-0.57	-4.51	-0.42	1.84e-5	Arsenic metabolism;
THYM	cis	rs7809950	0.731	rs4730238	chr7:107054787	G/A	cg23024343	chr7:107201750	COG5	-0.98	-7.9	-0.63	4.95e-12	Coronary artery disease;
THYM	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg17143192	chr8:8559678	CLDN23	-0.59	-4.67	-0.43	9.91e-6	Joint mobility (Beighton score);
THYM	cis	rs9443189	0.570	rs9343316	chr6:76411800	G/A	cg01950844	chr6:76311363	SENP6	1.05	6.66	0.56	1.73e-9	Prostate cancer;
THYM	cis	rs28595532	0.920	rs114210107	chr4:119734491	G/A	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs807029	0.533	rs2295716	chr10:102744214	T/C	cg14905631	chr10:102746534	C10orf2;MRPL43	0.36	4.93	0.45	3.49e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs17253792	0.822	rs76201070	chr14:56063604	A/C	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.31	0.6	8.34e-11	Obesity-related traits;
THYM	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg04647918	chr11:67383862	NA	0.66	5.31	0.48	7.07e-7	Mean corpuscular volume;
THYM	cis	rs4601821	1.000	rs4601821	chr11:113250346	A/G	cg14159747	chr11:113255604	NA	0.26	5.05	0.46	2.12e-6	Alcoholic chronic pancreatitis;
THYM	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg20486651	chr6:167070296	RPS6KA2	0.51	4.86	0.45	4.56e-6	Crohn's disease;
THYM	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg04518342	chr5:131593106	PDLIM4	0.48	5.37	0.48	5.55e-7	Breast cancer;
THYM	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg06238570	chr21:40685208	BRWD1	-0.75	-6.39	-0.55	6.18e-9	Menarche (age at onset);
THYM	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg11663144	chr21:46675770	NA	-0.71	-8.45	-0.65	3.4e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs73206853	0.843	rs12320025	chr12:110742991	A/G	cg24703420	chr12:111373904	NA	0.74	4.58	0.43	1.38e-5	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
THYM	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg04520793	chr17:42248056	ASB16	-0.33	-4.56	-0.42	1.54e-5	Total body bone mineral density;
THYM	cis	rs763014	0.898	rs8060921	chr16:635988	C/A	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs7429990	0.932	rs11130155	chr3:48140428	A/C	cg02219026	chr3:48282209	ZNF589	0.59	4.46	0.42	2.23e-5	Educational attainment (years of education);
THYM	cis	rs6032067	0.929	rs17424868	chr20:43818519	T/G	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg01710189	chr8:22454888	PDLIM2	-0.55	-5.88	-0.52	6.08e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg14784868	chr12:69753453	YEATS4	1.13	12.35	0.79	1.8e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.24	-4.55	-0.42	1.58e-5	Obesity-related traits;
THYM	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.2	-9.51	-0.7	1.8e-15	Platelet count;
THYM	cis	rs4474465	1.000	rs6592780	chr11:78199888	C/G	cg19901956	chr11:77921274	USP35	-0.65	-4.8	-0.44	5.97e-6	Alzheimer's disease (survival time);
THYM	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg07424592	chr7:64974309	NA	1.07	5.56	0.5	2.48e-7	Diabetic kidney disease;
THYM	cis	rs4907240	0.961	rs4907241	chr2:97241928	C/T	cg18419276	chr2:96971862	SNRNP200	0.38	4.47	0.42	2.13e-5	Event-related brain oscillations;
THYM	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg18357526	chr6:26021779	HIST1H4A	0.75	5.89	0.52	5.77e-8	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	4.46	0.42	2.21e-5	Diabetic retinopathy;
THYM	cis	rs36051895	0.664	rs7847141	chr9:5097171	A/T	cg02405213	chr9:5042618	JAK2	-0.99	-11.08	-0.75	8.21e-19	Pediatric autoimmune diseases;
THYM	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg24642844	chr7:1081250	C7orf50	-1.28	-8.22	-0.64	1.06e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11890956	chr21:40555474	PSMG1	1.15	12.55	0.79	6.97e-22	Cognitive function;
THYM	cis	rs11645898	0.765	rs112439757	chr16:72168337	C/T	cg03805757	chr16:71968109	PKD1L3	-0.79	-6.55	-0.56	2.99e-9	Blood protein levels;
THYM	cis	rs2403083	0.697	rs2403085	chr8:86113160	T/C	cg13721134	chr8:86350390	CA3	0.49	4.74	0.44	7.55e-6	Plasma amyloid beta peptide concentrations (ABx-40);
THYM	cis	rs8067545	1.000	rs3909258	chr17:19945819	C/G	cg13482628	chr17:19912719	NA	0.59	5.13	0.47	1.54e-6	Schizophrenia;
THYM	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg01324343	chr3:183735012	ABCC5	0.89	12.71	0.79	3.32e-22	Anterior chamber depth;
THYM	cis	rs7084402	0.902	rs10763557	chr10:60341515	C/T	cg07615347	chr10:60278583	BICC1	0.54	5.06	0.46	2.04e-6	Refractive error;
THYM	cis	rs7267979	0.873	rs6083853	chr20:25404541	T/C	cg08601574	chr20:25228251	PYGB	-0.58	-4.71	-0.43	8.54e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg18876405	chr7:65276391	NA	-0.56	-4.52	-0.42	1.77e-5	Aortic root size;
THYM	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06481639	chr22:41940642	POLR3H	0.8	5.63	0.5	1.81e-7	Vitiligo;
THYM	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg03806693	chr22:41940476	POLR3H	-1.07	-9.83	-0.71	3.85e-16	Vitiligo;
THYM	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg13695892	chr22:41940480	POLR3H	0.88	7.43	0.61	4.72e-11	Vitiligo;
THYM	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg22907277	chr7:1156413	C7orf50	0.7	4.61	0.43	1.27e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.72	4.74	0.44	7.54e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs420259	0.516	rs120961	chr16:23590302	C/T	cg00143387	chr16:23521605	GGA2	0.76	5.6	0.5	2.1e-7	Bipolar disorder;
THYM	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	0.59	7.96	0.63	3.74e-12	Monocyte percentage of white cells;
THYM	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.09	-5.32	-0.48	6.76e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9646944	0.501	rs10186052	chr2:103079608	G/A	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Blood protein levels;
THYM	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg24060327	chr5:131705240	SLC22A5	-0.83	-6.92	-0.58	5.2e-10	Breast cancer;
THYM	cis	rs28595532	0.920	rs116046128	chr4:119741990	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7084402	0.935	rs1658456	chr10:60304326	C/T	cg07615347	chr10:60278583	BICC1	0.57	5.36	0.48	5.86e-7	Refractive error;
THYM	cis	rs400736	0.930	rs225119	chr1:8044361	T/C	cg22678073	chr1:8087421	ERRFI1	0.47	4.97	0.45	2.96e-6	Response to antidepressants and depression;
THYM	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg08999081	chr20:33150536	PIGU	0.78	7.16	0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs995000	0.931	rs4329540	chr1:63027024	C/T	cg06896770	chr1:63153194	DOCK7	-0.92	-7.57	-0.61	2.41e-11	Triglyceride levels;
THYM	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg11764359	chr7:65958608	NA	-0.8	-6.15	-0.53	1.8e-8	Aortic root size;
THYM	cis	rs8180040	0.739	rs66539935	chr3:47025327	C/T	cg02527881	chr3:46936655	PTH1R	0.64	6.6	0.56	2.28e-9	Colorectal cancer;
THYM	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06850241	chr22:41845214	NA	-0.6	-5.28	-0.48	7.99e-7	Vitiligo;
THYM	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg24692254	chr21:30365293	RNF160	-0.94	-8.16	-0.64	1.38e-12	Dental caries;
THYM	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg08847533	chr14:75593920	NEK9	-0.96	-10.3	-0.73	3.86e-17	Height;
THYM	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg26967526	chr14:35346199	BAZ1A	-0.74	-4.84	-0.44	5.09e-6	Psoriasis;
THYM	cis	rs1011018	0.868	rs1011017	chr7:139463565	A/G	cg06079564	chr7:139468310	HIPK2	-0.77	-5.98	-0.52	3.9e-8	Systolic blood pressure;
THYM	cis	rs2050392	0.517	rs593400	chr10:30762088	A/G	cg02070205	chr10:30722105	MAP3K8	0.56	4.7	0.43	8.66e-6	Inflammatory bowel disease;
THYM	cis	rs28595532	0.920	rs114611353	chr4:119736607	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs227425	0.544	rs227422	chr14:70457653	A/C	cg12046056	chr14:71067695	MED6	0.56	4.58	0.43	1.43e-5	Bone mineral density;
THYM	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg09035930	chr12:129282057	SLC15A4	0.84	10.46	0.73	1.69e-17	Systemic lupus erythematosus;
THYM	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg03433033	chr1:76189801	ACADM	0.73	7.09	0.59	2.41e-10	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg07636037	chr3:49044803	WDR6	0.95	10.01	0.72	1.61e-16	Parkinson's disease;
THYM	cis	rs11039798	0.920	rs11040013	chr11:48782862	G/A	cg24672777	chr11:48374446	OR4C45	-1.12	-6.56	-0.56	2.85e-9	Axial length;
THYM	cis	rs2073300	1.000	rs2207989	chr20:23446014	T/G	cg12062639	chr20:23401060	NAPB	1.32	6.15	0.53	1.81e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs1065852	0.526	rs8138080	chr22:42396371	A/G	cg08431931	chr22:42394659	WBP2NL	-0.74	-6.01	-0.52	3.49e-8	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs1878931	0.520	rs2015640	chr16:3465018	G/C	cg22508957	chr16:3507546	NAT15	0.56	6.32	0.54	8.55e-9	Body mass index (adult);
THYM	cis	rs950880	0.710	rs873022	chr2:102955683	G/T	cg03938978	chr2:103052716	IL18RAP	-0.53	-4.64	-0.43	1.1e-5	Serum protein levels (sST2);
THYM	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg24642439	chr20:33292090	TP53INP2	0.62	4.91	0.45	3.85e-6	Coronary artery disease;
THYM	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg20503657	chr10:835505	NA	0.91	4.99	0.46	2.75e-6	Eosinophil percentage of granulocytes;
THYM	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs3796352	1.000	rs3806692	chr3:53080987	C/G	cg07884673	chr3:53033167	SFMBT1	1.15	6.62	0.56	2.13e-9	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs6430585	0.528	rs79826902	chr2:136670419	G/A	cg07169764	chr2:136633963	MCM6	1.18	10.98	0.75	1.39e-18	Corneal structure;
THYM	cis	rs7216064	0.773	rs74541577	chr17:65853651	C/T	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg06970220	chr1:156163860	SLC25A44	0.74	5.67	0.5	1.53e-7	Testicular germ cell tumor;
THYM	cis	rs6754311	0.678	rs309181	chr2:136614813	C/G	cg20242066	chr2:136595261	LCT	-0.6	-7.1	-0.59	2.23e-10	Mosquito bite size;
THYM	cis	rs6570726	0.791	rs446362	chr6:145878716	G/T	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6087990	1.000	rs2424900	chr20:31344342	G/C	cg13636640	chr20:31349939	DNMT3B	0.93	9.85	0.71	3.45e-16	Ulcerative colitis;
THYM	cis	rs6980334	0.798	rs10280394	chr7:137767201	C/A	cg18769353	chr7:137028617	PTN	0.65	5.05	0.46	2.13e-6	Blood metabolite ratios;
THYM	cis	rs13326165	0.585	rs11718729	chr3:52313454	C/A	cg08438690	chr3:52279403	PPM1M	-0.74	-4.64	-0.43	1.12e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs9677476	0.818	rs7598728	chr2:232086055	C/T	cg07929768	chr2:232055508	NA	0.61	6.16	0.53	1.76e-8	Food antigen IgG levels;
THYM	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg03676636	chr4:99064102	C4orf37	0.42	6.05	0.53	2.84e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs42648	0.792	rs4236517	chr7:89963465	A/T	cg25739043	chr7:89950458	NA	-0.51	-4.45	-0.42	2.31e-5	Homocysteine levels;
THYM	cis	rs11648785	0.777	rs12932473	chr16:90100389	C/T	cg04240660	chr16:89714849	CHMP1A	-0.52	-4.45	-0.42	2.36e-5	Tanning;
THYM	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg08885076	chr2:99613938	TSGA10	0.65	5.96	0.52	4.31e-8	Chronic sinus infection;
THYM	cis	rs7567389	0.719	rs6744237	chr2:128004045	C/G	cg09760422	chr2:128146352	NA	-0.53	-5.65	-0.5	1.7e-7	Self-rated health;
THYM	cis	rs11997175	0.603	rs6468199	chr8:33738770	A/C	ch.8.33884649F	chr8:33765107	NA	0.68	5.12	0.46	1.62e-6	Body mass index;
THYM	cis	rs28595532	0.920	rs116739193	chr4:119771024	G/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs2273669	0.504	rs1547325	chr6:109461506	A/C	cg17117243	chr6:109341365	SESN1	-0.85	-4.99	-0.46	2.77e-6	Prostate cancer;
THYM	cis	rs7211079	0.719	rs2289535	chr17:78111449	A/C	cg09238746	chr17:78121135	EIF4A3	-0.77	-5.2	-0.47	1.16e-6	Myocardial infarction;
THYM	cis	rs67478160	0.643	rs12434686	chr14:104316033	C/T	cg08213375	chr14:104286397	PPP1R13B	-0.56	-6.73	-0.57	1.26e-9	Schizophrenia;
THYM	cis	rs10799590	1.000	rs1436172	chr1:224843392	C/G	cg01808320	chr1:224927238	CNIH3	-0.53	-4.73	-0.44	7.81e-6	Opioid dependence;
THYM	cis	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg19847130	chr8:10466454	RP1L1	-0.46	-4.46	-0.42	2.21e-5	Myopia (pathological);
THYM	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg03877680	chr5:178157825	ZNF354A	0.74	5.13	0.47	1.53e-6	Neutrophil percentage of white cells;
THYM	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg22841779	chr14:105766346	BRF1	-0.47	-5.82	-0.51	7.97e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg17366294	chr4:99064904	C4orf37	0.48	5.42	0.49	4.47e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11603020	1.000	rs11603020	chr11:57374332	C/T	cg19752551	chr11:57585705	CTNND1	0.6	5.02	0.46	2.42e-6	Blood protein levels;
THYM	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs514406	0.825	rs12089511	chr1:53436427	A/T	cg24675658	chr1:53192096	ZYG11B	0.61	4.9	0.45	3.86e-6	Monocyte count;
THYM	cis	rs3768617	0.510	rs1886499	chr1:183095024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg11764359	chr7:65958608	NA	-0.82	-6.91	-0.58	5.4e-10	Aortic root size;
THYM	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.76	0.57	1.09e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2797685	1.000	rs697691	chr1:7885354	A/G	cg06712362	chr1:7811235	CAMTA1	0.68	4.96	0.45	3.09e-6	Crohn's disease;
THYM	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs7772486	0.790	rs1832362	chr6:146179955	C/T	cg13319975	chr6:146136371	FBXO30	-0.71	-5.81	-0.51	8.44e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2836633	0.859	rs8132069	chr21:40032611	T/C	cg12884169	chr21:40033163	ERG	0.7	8.36	0.65	5.29e-13	Coronary artery disease;
THYM	cis	rs16912285	0.688	rs7128680	chr11:24338796	C/T	ch.11.24196551F	chr11:24239977	NA	0.9	6.21	0.54	1.42e-8	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs6570726	1.000	rs386678	chr6:145869010	A/G	cg13319975	chr6:146136371	FBXO30	-0.65	-5.4	-0.48	4.97e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6960043	0.818	rs10258074	chr7:15064216	A/T	cg19272540	chr7:15055459	NA	-0.42	-4.71	-0.44	8.42e-6	Type 2 diabetes;
THYM	cis	rs7592578	0.766	rs12472081	chr2:191398545	G/A	cg10560079	chr2:191398806	TMEM194B	-0.91	-6.57	-0.56	2.63e-9	Diastolic blood pressure;
THYM	cis	rs8017423	0.967	rs61996919	chr14:90701803	A/C	cg04239629	chr14:90701769	NA	-0.62	-4.53	-0.42	1.73e-5	Mortality in heart failure;
THYM	cis	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg10856724	chr12:34555212	NA	-1.05	-10.54	-0.73	1.17e-17	Morning vs. evening chronotype;
THYM	cis	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg19847130	chr8:10466454	RP1L1	0.56	5.33	0.48	6.74e-7	Neuroticism;
THYM	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg06550200	chr5:1325588	CLPTM1L	0.78	6.4	0.55	5.8e-9	Lung cancer;
THYM	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg03859395	chr2:55845619	SMEK2	0.61	5.47	0.49	3.72e-7	Metabolic syndrome;
THYM	cis	rs2154427	1.000	rs2154427	chr21:34168573	G/A	cg21871883	chr21:34145043	C21orf49;C21orf66	0.96	4.63	0.43	1.18e-5	Bilirubin levels;
THYM	cis	rs1729951	0.575	rs361242	chr3:136698330	C/G	cg12473912	chr3:136751656	NA	0.63	5.12	0.47	1.57e-6	Neuroticism;
THYM	cis	rs995000	0.931	rs636497	chr1:62920029	A/G	cg06896770	chr1:63153194	DOCK7	0.9	7.29	0.6	9.07e-11	Triglyceride levels;
THYM	cis	rs752010	0.808	rs7529858	chr1:42086606	G/C	cg06885757	chr1:42089581	HIVEP3	0.6	7.65	0.62	1.61e-11	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs10779751	0.770	rs2015818	chr1:11170743	G/A	cg08854313	chr1:11322531	MTOR	0.89	7.88	0.63	5.4e-12	Body mass index;
THYM	cis	rs9677476	0.821	rs6731682	chr2:232106245	G/C	cg23338755	chr2:231921595	PSMD1	0.68	5.17	0.47	1.31e-6	Food antigen IgG levels;
THYM	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg22709100	chr7:91322751	NA	0.69	5.52	0.49	2.92e-7	Breast cancer;
THYM	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg17366294	chr4:99064904	C4orf37	-0.58	-6.98	-0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg24812749	chr6:127587940	RNF146	0.91	6.49	0.55	3.81e-9	Breast cancer;
THYM	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg03929089	chr4:120376271	NA	-0.95	-10.65	-0.74	6.93e-18	Height;
THYM	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11141652	chr22:24348549	GSTTP1	0.62	6.35	0.55	7.29e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7772486	0.597	rs2246132	chr6:146182515	C/G	cg05347473	chr6:146136440	FBXO30	0.81	7.21	0.59	1.34e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7584330	0.740	rs12471291	chr2:238441751	T/G	cg14458575	chr2:238380390	NA	0.73	6.13	0.53	2.02e-8	Prostate cancer;
THYM	cis	rs2282300	0.956	rs1222212	chr11:30374643	C/T	cg06241208	chr11:30344200	C11orf46	-0.8	-5.64	-0.5	1.73e-7	Morning vs. evening chronotype;
THYM	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg05552183	chr6:42928497	GNMT	0.58	4.71	0.43	8.5e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs28595532	0.841	rs115725150	chr4:119768647	T/A	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs28595532	0.920	rs115118317	chr4:119736613	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg26441486	chr22:50317300	CRELD2	-0.42	-6.44	-0.55	4.82e-9	Schizophrenia;
THYM	cis	rs763014	0.898	rs4984896	chr16:625493	C/T	cg07343612	chr16:622815	PIGQ	-1.05	-10.74	-0.74	4.28e-18	Height;
THYM	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg23982607	chr1:1823379	GNB1	-0.94	-10.04	-0.72	1.37e-16	Body mass index;
THYM	cis	rs7172677	0.960	rs11072526	chr15:75432517	T/C	cg09165964	chr15:75287851	SCAMP5	-0.63	-4.76	-0.44	6.86e-6	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs4713118	0.662	rs13218430	chr6:28029837	T/C	cg08968635	chr6:28129556	ZNF389	0.59	4.57	0.42	1.46e-5	Parkinson's disease;
THYM	cis	rs11264213	0.901	rs2791961	chr1:36371419	C/G	cg27506609	chr1:36549197	TEKT2	-0.83	-4.59	-0.43	1.38e-5	Schizophrenia;
THYM	trans	rs4596713	0.508	rs4745650	chr9:71777892	G/A	cg16512924	chr15:28394682	HERC2	0.83	6.92	0.58	5.28e-10	Headache;
THYM	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg04362960	chr10:104952993	NT5C2	0.59	4.96	0.45	3.02e-6	Reticulocyte count;
THYM	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg10047753	chr17:41438598	NA	1.12	10.51	0.73	1.36e-17	Menopause (age at onset);
THYM	cis	rs7772486	0.846	rs2892453	chr6:146377717	C/A	cg13319975	chr6:146136371	FBXO30	-0.72	-6.02	-0.53	3.33e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs782590	0.902	rs3762513	chr2:55762957	C/T	cg18811423	chr2:55921094	PNPT1	0.74	7.05	0.59	2.83e-10	Metabolic syndrome;
THYM	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg19761014	chr17:28927070	LRRC37B2	0.8	4.73	0.44	7.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs40363	0.951	rs72778117	chr16:3531827	T/C	cg21433313	chr16:3507492	NAT15	0.78	6.7	0.57	1.43e-9	Tuberculosis;
THYM	cis	rs11634944	0.506	rs765438	chr15:25236128	A/G	cg14481604	chr15:25334117	SNORD116-22	-0.66	-5.17	-0.47	1.3e-6	Interleukin-8 levels;
THYM	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.31	8.7	0.67	9.92e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs7950696	1	rs7950696	chr11:47481533	T/C	cg18512352	chr11:47633146	NA	0.45	4.94	0.45	3.39e-6	Platelet count;
THYM	cis	rs11696501	0.694	rs6073825	chr20:44258217	T/C	cg11783356	chr20:44313418	WFDC10B	-0.66	-4.52	-0.42	1.77e-5	Brain structure;
THYM	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg11965913	chr1:205819406	PM20D1	1.1	13.25	0.81	2.57e-23	Menarche (age at onset);
THYM	cis	rs28595532	0.920	rs116739193	chr4:119771024	G/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs4769475	0.810	rs4769473	chr13:26731419	A/T	cg13319468	chr13:27597730	NA	-0.6	-4.62	-0.43	1.2e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7191439	0.584	rs7193436	chr16:88748736	T/C	cg27087555	chr16:88793112	FAM38A	-1.35	-6.15	-0.53	1.78e-8	Plateletcrit;
THYM	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg13531842	chr10:38383804	ZNF37A	-0.54	-4.58	-0.42	1.44e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03264133	chr6:25882463	NA	-0.7	-5.49	-0.49	3.3e-7	Blood metabolite levels;
THYM	cis	rs470093	0.866	rs138064	chr22:44225873	C/A	cg09142166	chr22:44276013	PNPLA5	-0.6	-5.77	-0.51	9.87e-8	Staphylococcus aureus infection;
THYM	cis	rs6987853	0.563	rs2974312	chr8:42455846	C/T	cg09913449	chr8:42400586	C8orf40	0.64	5.64	0.5	1.73e-7	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4589258	0.737	rs10501731	chr11:90405329	A/G	cg26138821	chr11:89956704	CHORDC1	0.57	4.76	0.44	7.05e-6	Intelligence (multi-trait analysis);
THYM	cis	rs34375054	0.525	rs7133614	chr12:125605957	C/T	cg25124228	chr12:125621409	AACS	-0.8	-6.86	-0.58	6.94e-10	Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs240764	0.669	rs846800	chr6:101270498	C/G	cg21058520	chr6:100914733	NA	-0.6	-5.29	-0.48	7.79e-7	Neuroticism;
THYM	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7980799	0.716	rs10161311	chr12:33623204	G/A	cg06521331	chr12:34319734	NA	0.69	4.85	0.45	4.81e-6	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg18681998	chr4:17616180	MED28	-0.9	-7.56	-0.61	2.49e-11	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs7223966	0.881	rs3020608	chr17:61979993	C/A	cg18032289	chr17:61959525	GH2	-0.49	-4.7	-0.43	8.8e-6	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs28595532	0.920	rs114649974	chr4:119735341	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs951188	0.639	rs78958759	chr2:150414814	C/T	cg17961725	chr2:150454027	NA	-0.96	-5.16	-0.47	1.36e-6	Daytime sleep phenotypes;
THYM	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg18876405	chr7:65276391	NA	-0.61	-5.2	-0.47	1.13e-6	Aortic root size;
THYM	cis	rs9906944	0.707	rs3816272	chr17:47120467	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.43	-4.71	-0.44	8.43e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs9359856	0.510	rs3736984	chr6:90408589	C/T	cg13799429	chr6:90582589	CASP8AP2	0.84	8.26	0.65	8.31e-13	Bipolar disorder;
THYM	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg01097406	chr16:89675127	NA	0.6	5.08	0.46	1.88e-6	Vitiligo;
THYM	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg08645402	chr16:4508243	NA	0.76	6.87	0.58	6.72e-10	Schizophrenia;
THYM	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg07511668	chr11:68622177	NA	0.43	4.56	0.42	1.52e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg14517863	chr17:44321492	NA	0.46	5.11	0.46	1.69e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg18200150	chr17:30822561	MYO1D	-0.69	-6.06	-0.53	2.76e-8	Schizophrenia;
THYM	cis	rs36051895	0.623	rs7870536	chr9:5245493	C/T	cg02405213	chr9:5042618	JAK2	-0.93	-10.05	-0.72	1.31e-16	Pediatric autoimmune diseases;
THYM	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg23422044	chr7:1970798	MAD1L1	-0.95	-6.58	-0.56	2.51e-9	Bipolar disorder;
THYM	cis	rs7731657	0.529	rs115941363	chr5:130379400	T/G	cg08523029	chr5:130500466	HINT1	-0.78	-4.86	-0.45	4.68e-6	Fasting plasma glucose;
THYM	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg17173187	chr15:85201210	NMB	0.56	5.66	0.5	1.6e-7	Schizophrenia;
THYM	cis	rs4919669	0.546	rs4919652	chr10:104274157	A/C	cg00122347	chr10:104236741	TMEM180	0.61	4.83	0.44	5.12e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
THYM	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg08067268	chr2:26466485	HADHB;HADHA	0.66	4.7	0.43	8.88e-6	Gut microbiome composition (summer);
THYM	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg06789500	chr7:2109450	MAD1L1	-0.65	-4.46	-0.42	2.24e-5	Bipolar disorder;
THYM	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg06850241	chr22:41845214	NA	0.53	4.56	0.42	1.54e-5	Vitiligo;
THYM	cis	rs9649213	0.574	rs7791321	chr7:97944125	G/C	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.6e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg02725872	chr8:58115012	NA	-1.15	-7.43	-0.61	4.64e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs6902771	0.869	rs9322332	chr6:152166801	C/A	cg20253551	chr6:152129400	ESR1	-0.54	-4.47	-0.42	2.18e-5	Alcohol dependence;
THYM	cis	rs1062746	0.711	rs2303763	chr16:87376605	C/T	cg27365499	chr16:87376795	FBXO31	-0.6	-6.86	-0.58	6.92e-10	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg03909863	chr11:638404	DRD4	-0.68	-4.83	-0.44	5.13e-6	Systemic lupus erythematosus;
THYM	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg02782426	chr3:40428986	ENTPD3	0.56	5.02	0.46	2.41e-6	Renal cell carcinoma;
THYM	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	5.93	0.52	4.8e-8	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.91	0.58	5.57e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2273669	0.667	rs12215614	chr6:109313629	T/C	cg17117243	chr6:109341365	SESN1	-0.91	-5.54	-0.49	2.74e-7	Prostate cancer;
THYM	cis	rs2219968	0.743	rs34849429	chr8:78909689	G/T	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs73086581	1.000	rs73086595	chr20:3983448	A/G	cg02187196	chr20:3869020	PANK2	0.5	5.52	0.49	2.94e-7	Response to antidepressants in depression;
THYM	cis	rs3091242	1.000	rs646867	chr1:25709258	A/C	cg10117171	chr1:25599238	RHD	-0.65	-4.87	-0.45	4.47e-6	Erythrocyte sedimentation rate;
THYM	cis	rs6987853	0.931	rs3099936	chr8:42384331	C/T	cg09913449	chr8:42400586	C8orf40	-0.88	-8.02	-0.64	2.8e-12	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7599312	0.553	rs6710653	chr2:213404893	A/G	cg20637307	chr2:213403960	ERBB4	1.04	11.16	0.75	5.66e-19	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7426056	0.530	rs10515943	chr2:204582679	T/C	cg07930752	chr2:204569955	CD28	-0.73	-5.28	-0.48	8.21e-7	Primary sclerosing cholangitis;
THYM	cis	rs675209	0.813	rs1285875	chr6:7115927	C/G	cg24899545	chr6:7112846	RREB1	-0.49	-4.78	-0.44	6.5e-6	Urate levels;
THYM	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg15704280	chr7:45808275	SEPT13	-1.07	-15.26	-0.84	2.74e-27	Height;
THYM	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg16342193	chr10:102329863	NA	-0.62	-6.55	-0.56	2.88e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs728616	0.867	rs28365998	chr10:81965436	C/A	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg20891283	chr12:69753455	YEATS4	0.79	6.26	0.54	1.11e-8	Response to diuretic therapy;
THYM	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs786425	0.530	rs10734904	chr12:124204158	T/G	cg15249119	chr12:124971054	NCOR2	0.51	4.68	0.43	9.53e-6	Pubertal anthropometrics;
THYM	cis	rs2708977	0.966	rs749027	chr2:97203137	A/C	cg01950434	chr2:97203154	ARID5A	-0.58	-5.2	-0.47	1.17e-6	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg03396347	chr1:1875803	NA	-0.67	-6.62	-0.56	2.1e-9	Body mass index;
THYM	cis	rs12600053	0.554	rs4783077	chr16:84848221	A/G	cg09249803	chr16:84846936	NA	0.46	4.98	0.45	2.88e-6	Asthma (childhood onset);
THYM	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg05738196	chr6:26577821	NA	0.84	8.48	0.66	2.87e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg19847130	chr8:10466454	RP1L1	0.62	5.9	0.52	5.55e-8	Neuroticism;
THYM	cis	rs4589258	0.788	rs6483070	chr11:90469192	C/T	cg26138821	chr11:89956704	CHORDC1	-0.59	-4.81	-0.44	5.58e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9515201	0.740	rs9555695	chr13:111033125	C/T	cg05272587	chr13:111038400	COL4A2	-0.57	-4.88	-0.45	4.33e-6	White matter hyperintensity burden;
THYM	cis	rs7224737	1.000	rs1122326	chr17:40274873	A/C	cg02228675	chr17:40259724	DHX58	-0.65	-5.29	-0.48	7.96e-7	Fibrinogen levels;
THYM	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg25918947	chr17:41365094	TMEM106A	-0.64	-5.41	-0.49	4.65e-7	Menopause (age at onset);
THYM	cis	rs4642101	0.590	rs6799544	chr3:12812979	T/C	cg05775895	chr3:12838266	CAND2	0.72	5.68	0.5	1.44e-7	QRS complex (12-leadsum);
THYM	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	4.98	0.45	2.84e-6	Prudent dietary pattern;
THYM	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg08645402	chr16:4508243	NA	0.76	6.87	0.58	6.72e-10	Schizophrenia;
THYM	cis	rs9611519	1.000	rs5751069	chr22:41627775	C/G	cg03806693	chr22:41940476	POLR3H	-0.73	-5.77	-0.51	9.91e-8	Neuroticism;
THYM	cis	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg13443165	chr9:33130375	B4GALT1	-0.72	-5.23	-0.47	9.87e-7	IgG glycosylation;
THYM	cis	rs3126085	0.935	rs10888483	chr1:152252789	T/A	cg10321714	chr1:152280068	FLG	-0.76	-5.68	-0.5	1.47e-7	Atopic dermatitis;
THYM	cis	rs9914988	0.943	rs4795459	chr17:27113726	G/C	cg20469991	chr17:27169893	C17orf63	-0.78	-4.64	-0.43	1.11e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg25566285	chr7:158114605	PTPRN2	0.77	6.92	0.58	5.36e-10	Response to amphetamines;
THYM	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.55	6.02	0.53	3.22e-8	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7010267	0.870	rs7014574	chr8:119977077	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.6	4.87	0.45	4.36e-6	Total body bone mineral density (age 45-60);
THYM	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg22875332	chr1:76189707	ACADM	0.89	12.06	0.78	7.38e-21	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs72829446	0.530	rs7210231	chr17:7357864	C/A	cg02795151	chr17:7402630	POLR2A	0.51	5.48	0.49	3.49e-7	Androgen levels;
THYM	cis	rs250677	0.559	rs17109198	chr5:148369712	C/T	cg18129178	chr5:148520854	ABLIM3	-0.72	-5.38	-0.48	5.29e-7	Breast cancer;
THYM	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg03188948	chr7:1209495	NA	0.92	5.2	0.47	1.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6980334	0.679	rs1872929	chr7:137801413	G/T	cg22979093	chr7:137028410	PTN	-0.62	-4.76	-0.44	7.03e-6	Blood metabolite ratios;
THYM	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg18758796	chr5:131593413	PDLIM4	-0.5	-4.72	-0.44	8.15e-6	Breast cancer;
THYM	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.67	4.96	0.45	3.09e-6	Tonsillectomy;
THYM	cis	rs1823778	0.609	rs12955117	chr18:67628430	T/C	cg12929678	chr18:67624393	CD226	1.38	4.91	0.45	3.83e-6	Mean platelet volume;
THYM	cis	rs2219968	0.676	rs55878309	chr8:78839853	A/G	cg00738934	chr8:78996279	NA	-0.7	-6.22	-0.54	1.35e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4363385	0.818	rs1334848	chr1:153004721	A/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06481639	chr22:41940642	POLR3H	0.81	5.59	0.5	2.2e-7	Vitiligo;
THYM	cis	rs12257961	0.549	rs11259612	chr10:15382469	C/T	cg10616319	chr10:15468812	NA	-0.59	-4.98	-0.45	2.88e-6	Selective IgA deficiency;
THYM	cis	rs1061377	1.000	rs2163272	chr4:39114410	C/T	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs4820539	0.611	rs28451783	chr22:23488569	G/T	cg14186256	chr22:23484241	RTDR1	0.74	5.45	0.49	3.91e-7	Bone mineral density;
THYM	cis	rs7086627	0.506	rs10749575	chr10:82136921	C/T	cg00277334	chr10:82204260	NA	-0.49	-4.94	-0.45	3.35e-6	Post bronchodilator FEV1;
THYM	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg05313129	chr8:58192883	C8orf71	-0.8	-4.72	-0.44	8.06e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs595982	0.559	rs117227130	chr19:49367959	A/G	cg21252483	chr19:49399788	TULP2	-0.87	-6.06	-0.53	2.77e-8	Red cell distribution width;
THYM	cis	rs7131987	0.650	rs4331146	chr12:29440083	G/T	cg09582351	chr12:29534625	ERGIC2	-0.52	-4.64	-0.43	1.1e-5	QT interval;
THYM	cis	rs9790314	0.967	rs339101	chr3:161064193	A/T	cg04691961	chr3:161091175	C3orf57	-0.7	-6.21	-0.54	1.4e-8	Morning vs. evening chronotype;
THYM	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-5.35	-0.48	6.16e-7	Obesity-related traits;
THYM	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg14584255	chr6:163149320	PACRG;PARK2	0.6	5.5	0.49	3.26e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg16586182	chr3:47516702	SCAP	-0.67	-5.62	-0.5	1.9e-7	Colorectal cancer;
THYM	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg20744362	chr22:50050164	C22orf34	0.87	8.57	0.66	1.87e-13	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs56104184	0.775	rs56149557	chr19:49401384	C/A	cg19746536	chr19:49375674	PPP1R15A	0.81	4.59	0.43	1.34e-5	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg14159672	chr1:205819179	PM20D1	-0.71	-5.56	-0.5	2.5e-7	Menarche (age at onset);
THYM	cis	rs859767	0.741	rs6759065	chr2:135389197	A/G	cg12500956	chr2:135428796	TMEM163	-0.51	-5.09	-0.46	1.79e-6	Neuroticism;
THYM	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg26818010	chr10:134567672	INPP5A	0.65	5.4	0.48	5.01e-7	Migraine;
THYM	cis	rs55637147	0.553	rs10896611	chr11:57136291	C/G	cg15971518	chr11:57159174	PRG2	-0.62	-5.12	-0.46	1.62e-6	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs10752881	0.967	rs12404594	chr1:182988027	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.61	4.84	0.44	4.98e-6	Colorectal cancer;
THYM	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.67	-6.17	-0.53	1.69e-8	Chronic sinus infection;
THYM	cis	rs2237457	0.931	rs7792811	chr7:50707558	A/T	cg08586669	chr7:50727761	GRB10	0.31	4.77	0.44	6.66e-6	Schizophrenia (treatment resistant);
THYM	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2745959	0.611	rs2466574	chr1:208053853	A/G	cg11195082	chr1:207670065	CR1	-0.55	-4.61	-0.43	1.26e-5	Resting heart rate;
THYM	cis	rs6842789	0.510	rs56145570	chr4:124906132	C/T	cg01723706	chr4:124814442	LOC285419	0.75	4.7	0.43	8.94e-6	Neuroticism;
THYM	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg13695892	chr22:41940480	POLR3H	0.85	6.16	0.53	1.72e-8	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7940866	0.804	rs10894287	chr11:130808483	C/T	cg05962950	chr11:130786565	SNX19	0.75	6.18	0.54	1.6e-8	Schizophrenia;
THYM	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg03388043	chr17:80084554	CCDC57	0.69	5.64	0.5	1.75e-7	Life satisfaction;
THYM	cis	rs761746	0.920	rs5753662	chr22:31901432	G/A	cg10537193	chr22:32026975	PISD	0.4	5.17	0.47	1.3e-6	Intelligence;
THYM	cis	rs4803468	1.000	rs2241710	chr19:41912092	G/C	cg09537434	chr19:41945824	ATP5SL	-1.09	-10.13	-0.72	8.87e-17	Height;
THYM	cis	rs7683537	0.554	rs55830081	chr4:185666477	A/C	cg27112742	chr4:185696749	ACSL1	-0.9	-4.74	-0.44	7.64e-6	Systemic lupus erythematosus;
THYM	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg06784218	chr1:46089804	CCDC17	0.3	4.82	0.44	5.43e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg04990556	chr1:26633338	UBXN11	-0.87	-8.25	-0.65	8.82e-13	Obesity-related traits;
THYM	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg22974920	chr21:40686053	BRWD1	-0.63	-4.97	-0.45	2.98e-6	Cognitive function;
THYM	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-4.75	-0.44	7.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg20242066	chr2:136595261	LCT	-0.6	-7.1	-0.59	2.23e-10	Mosquito bite size;
THYM	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg18755752	chr8:142205143	DENND3	-0.81	-7.93	-0.63	4.28e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2456568	0.867	rs1395384	chr11:93663250	C/T	cg17595323	chr11:93583763	C11orf90	0.56	5.46	0.49	3.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs887829	0.588	rs6715325	chr2:234635241	A/G	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.57	-4.58	-0.43	1.42e-5	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs61931739	0.817	rs7297799	chr12:34260142	T/C	cg06521331	chr12:34319734	NA	-0.65	-5.23	-0.47	1.02e-6	Morning vs. evening chronotype;
THYM	cis	rs35883536	0.609	rs2647327	chr1:101041766	C/T	cg06223162	chr1:101003688	GPR88	0.79	6.84	0.57	7.78e-10	Monocyte count;
THYM	cis	rs10887741	1.000	rs12412482	chr10:89443799	C/T	cg13926569	chr10:89418898	PAPSS2	0.56	5.53	0.49	2.78e-7	Exercise (leisure time);
THYM	trans	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg19862616	chr7:65841803	NCRNA00174	-1.1	-13.67	-0.81	3.71e-24	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg26384229	chr12:38710491	ALG10B	-0.72	-5.64	-0.5	1.75e-7	Morning vs. evening chronotype;
THYM	cis	rs931127	0.554	rs3372	chr11:65485218	C/T	cg27068330	chr11:65405492	SIPA1	0.66	4.47	0.42	2.17e-5	Systemic lupus erythematosus;
THYM	cis	rs7100689	0.598	rs35353819	chr10:82135737	A/G	cg01528321	chr10:82214614	TSPAN14	0.77	5.81	0.51	8.17e-8	Post bronchodilator FEV1;
THYM	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22857025	chr5:266934	NA	-1.41	-9.3	-0.69	5.07e-15	Breast cancer;
THYM	cis	rs12282928	0.851	rs4980421	chr11:48301482	G/A	cg22827986	chr11:48284249	OR4X1	-0.53	-5.5	-0.49	3.18e-7	Migraine - clinic-based;
THYM	cis	rs11122272	0.701	rs11122273	chr1:231476789	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-4.54	-0.42	1.67e-5	Hemoglobin concentration;
THYM	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg24250549	chr1:154909240	PMVK	0.66	5.04	0.46	2.24e-6	Prostate cancer;
THYM	cis	rs920590	0.510	rs4922101	chr8:19648895	A/G	cg01411142	chr8:19674711	INTS10	0.77	5.81	0.51	8.31e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg10523679	chr1:76189770	ACADM	-0.87	-7.54	-0.61	2.79e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg04248312	chr19:17393744	ANKLE1	-0.98	-13.17	-0.8	3.8e-23	Systemic lupus erythematosus;
THYM	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg16524936	chr4:1340807	KIAA1530	-0.67	-5.29	-0.48	7.88e-7	Longevity;
THYM	cis	rs55728055	0.661	rs73162106	chr22:32034875	A/G	cg01338084	chr22:32026380	PISD	1.24	6.43	0.55	5.18e-9	Age-related hearing impairment;
THYM	cis	rs11948739	0.610	rs2214289	chr5:130257959	T/A	cg08523029	chr5:130500466	HINT1	0.82	5.84	0.51	7.23e-8	Pediatric bone mineral content (hip);
THYM	cis	rs10929159	0.928	rs4442947	chr2:236931642	G/C	cg14895183	chr2:236924282	AGAP1	0.54	4.54	0.42	1.64e-5	Parkinson's disease;
THYM	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg13114125	chr14:105738426	BRF1	-0.77	-6.19	-0.54	1.53e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg16306078	chr6:126000798	NA	-0.56	-5.61	-0.5	1.99e-7	Endometrial cancer;
THYM	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg27446573	chr6:127587934	RNF146	0.99	9.36	0.69	3.89e-15	Breast cancer;
THYM	cis	rs3768617	0.510	rs3818417	chr1:183079376	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs2637266	0.783	rs720249	chr10:78476143	T/C	cg18941641	chr10:78392320	NA	0.71	5.69	0.5	1.42e-7	Pulmonary function;
THYM	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg23482746	chr15:76478102	C15orf27	-0.41	-4.63	-0.43	1.18e-5	Blood metabolite levels;
THYM	cis	rs1784581	0.855	rs1790002	chr6:162384397	G/T	cg17173639	chr6:162384350	PARK2	-0.96	-9.61	-0.7	1.15e-15	Itch intensity from mosquito bite;
THYM	cis	rs3087591	0.960	rs4263003	chr17:29438508	G/T	cg24425628	chr17:29625626	OMG;NF1	0.65	5.41	0.49	4.76e-7	Hip circumference;
THYM	cis	rs4343996	0.692	rs10258501	chr7:3460355	A/C	cg21248987	chr7:3385318	SDK1	0.38	4.63	0.43	1.17e-5	Motion sickness;
THYM	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg26384229	chr12:38710491	ALG10B	0.95	7.06	0.59	2.68e-10	Bladder cancer;
THYM	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg24399712	chr22:39784796	NA	-0.87	-7.95	-0.63	3.81e-12	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg00801512	chr17:28996047	NA	-0.84	-5.46	-0.49	3.83e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7119	0.717	rs12901338	chr15:77804900	T/A	cg27398640	chr15:77910606	LINGO1	-0.52	-5.21	-0.47	1.12e-6	Type 2 diabetes;
THYM	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg00419117	chr1:228361641	C1orf69	0.48	4.49	0.42	2.01e-5	Diastolic blood pressure;
THYM	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg05457628	chr5:178986728	RUFY1	0.64	6.49	0.55	3.94e-9	Lung cancer;
THYM	cis	rs6430585	0.584	rs4954276	chr2:136402117	A/G	cg23851026	chr2:136556271	LCT	0.63	6.04	0.53	3.04e-8	Corneal structure;
THYM	cis	rs7084402	1.000	rs6481401	chr10:60268880	A/C	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg00383909	chr3:49044727	WDR6	1.27	7.71	0.62	1.22e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg25767906	chr1:53392781	SCP2	-0.53	-5.2	-0.47	1.13e-6	Monocyte count;
THYM	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg20242066	chr2:136595261	LCT	0.57	7.34	0.6	7.35e-11	Mosquito bite size;
THYM	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.09	0.64	1.91e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs61931739	0.613	rs1525898	chr12:33904445	G/T	cg06521331	chr12:34319734	NA	-0.56	-4.47	-0.42	2.16e-5	Morning vs. evening chronotype;
THYM	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg27129171	chr3:47204927	SETD2	0.8	7.93	0.63	4.18e-12	Colorectal cancer;
THYM	cis	rs717423	0.961	rs4740740	chr9:3846792	C/T	cg14199540	chr9:3305273	RFX3	-0.6	-4.45	-0.42	2.3e-5	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg24060327	chr5:131705240	SLC22A5	0.75	5.63	0.5	1.79e-7	Blood metabolite levels;
THYM	cis	rs4919044	0.674	rs11187260	chr10:94809187	A/G	cg05127821	chr10:94822908	CYP26C1	-1.23	-6.66	-0.56	1.76e-9	Coronary artery disease;
THYM	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg09455208	chr3:40491958	NA	0.49	5.1	0.46	1.75e-6	Renal cell carcinoma;
THYM	cis	rs1669338	0.507	rs4685609	chr3:3202279	T/C	cg16797762	chr3:3221439	CRBN	-1.01	-5.66	-0.5	1.57e-7	White matter integrity;
THYM	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg02527881	chr3:46936655	PTH1R	-0.83	-8.26	-0.65	8.31e-13	Birth weight;
THYM	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07157834	chr1:205819609	PM20D1	0.62	5.63	0.5	1.81e-7	Menarche (age at onset);
THYM	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11890956	chr21:40555474	PSMG1	-0.9	-9.49	-0.7	2.02e-15	Cognitive function;
THYM	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.56	-4.6	-0.43	1.3e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg09904177	chr6:26538194	HMGN4	0.64	5.41	0.49	4.78e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1003719	0.688	rs2835662	chr21:38568967	T/A	cg01329690	chr21:38580129	DSCR9	-0.36	-5.0	-0.46	2.67e-6	Eye color traits;
THYM	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg19761014	chr17:28927070	LRRC37B2	0.78	4.99	0.46	2.76e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg24642844	chr7:1081250	C7orf50	-1.29	-8.31	-0.65	6.62e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9902453	1.000	rs28664971	chr17:28437410	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.85	6.74	0.57	1.24e-9	Coffee consumption (cups per day);
THYM	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg20486651	chr6:167070296	RPS6KA2	0.5	4.79	0.44	6.18e-6	Crohn's disease;
THYM	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg03709012	chr19:19516395	GATAD2A	0.77	6.26	0.54	1.13e-8	Tonsillectomy;
THYM	cis	rs6032067	0.929	rs6017512	chr20:43835038	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.76	-0.51	1.01e-7	Blood protein levels;
THYM	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg08017756	chr2:100939284	LONRF2	-0.76	-7.53	-0.61	2.93e-11	Intelligence (multi-trait analysis);
THYM	cis	rs2835345	0.563	rs12482140	chr21:37824033	A/C	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.72	-4.75	-0.44	7.2e-6	Body mass index;
THYM	cis	rs10782582	0.593	rs12131493	chr1:76139172	G/A	cg22875332	chr1:76189707	ACADM	-0.54	-5.07	-0.46	1.97e-6	Daytime sleep phenotypes;
THYM	trans	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg26043149	chr18:55253948	FECH	1.16	10.82	0.74	2.98e-18	Gout;Urate levels;Serum uric acid levels;
THYM	trans	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg10856724	chr12:34555212	NA	-0.9	-8.08	-0.64	2.05e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1697139	0.563	rs6859520	chr5:66529020	C/T	cg11553311	chr5:66541588	NA	0.69	7.1	0.59	2.24e-10	Breast cancer;
THYM	cis	rs12681288	0.550	rs58295701	chr8:962136	T/C	cg08648136	chr8:956695	NA	0.56	4.92	0.45	3.57e-6	Schizophrenia;
THYM	cis	rs9359856	0.623	rs1179903	chr6:90321736	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.76	-7.52	-0.61	3.01e-11	Bipolar disorder;
THYM	cis	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.87	-7.37	-0.6	6.37e-11	Primary sclerosing cholangitis;
THYM	cis	rs2625529	0.824	rs11072339	chr15:72247190	C/T	cg16672083	chr15:72433130	SENP8	-0.56	-5.03	-0.46	2.35e-6	Red blood cell count;
THYM	cis	rs8048589	1.000	rs8059989	chr16:12185746	C/T	cg02910054	chr16:12241554	SNX29	0.65	5.41	0.49	4.72e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg09060608	chr5:178986726	RUFY1	0.5	5.39	0.48	5.13e-7	Lung cancer;
THYM	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.85e-6	Life satisfaction;
THYM	cis	rs8016982	0.698	rs8021385	chr14:81704682	G/A	cg01989461	chr14:81687754	GTF2A1	0.82	7.69	0.62	1.32e-11	Schizophrenia;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg14021550	chr2:469727	NA	-0.87	-6.89	-0.58	6.14e-10	Depressive symptoms;
THYM	cis	rs4866334	1.000	rs80007833	chr5:18489203	G/T	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.54	-5.1	-0.46	1.74e-6	Lymphocyte counts;
THYM	cis	rs2122469	0.546	rs73668039	chr8:20636625	T/A	cg17092985	chr8:20119213	NA	-1.0	-4.51	-0.42	1.87e-5	Serum tamsulosin hydrochloride concentration;
THYM	cis	rs4919044	0.674	rs9419766	chr10:94800788	G/A	cg05127821	chr10:94822908	CYP26C1	-1.23	-6.66	-0.56	1.76e-9	Coronary artery disease;
THYM	cis	rs1348850	0.526	rs7582179	chr2:178370631	A/G	cg27490568	chr2:178487706	NA	0.68	5.53	0.49	2.77e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6032067	0.929	rs11699850	chr20:43809049	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.79	5.73	0.51	1.16e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs13256369	0.951	rs12679360	chr8:8566269	G/T	cg00074818	chr8:8560427	CLDN23	-0.52	-5.36	-0.48	5.78e-7	Obesity-related traits;
THYM	cis	rs4148883	0.504	rs4147544	chr4:100134514	G/T	cg12011299	chr4:100065546	ADH4	-0.57	-5.17	-0.47	1.3e-6	Alcohol dependence;
THYM	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg04025307	chr7:1156635	C7orf50	0.71	4.64	0.43	1.1e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg13695892	chr22:41940480	POLR3H	0.9	7.31	0.6	8.34e-11	Vitiligo;
THYM	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg06418219	chr1:154948305	SHC1;CKS1B	0.78	6.0	0.52	3.55e-8	Prostate cancer;
THYM	cis	rs6539288	0.834	rs1545097	chr12:107313696	C/G	cg26297688	chr12:107349093	C12orf23	-0.47	-4.89	-0.45	4.15e-6	Total body bone mineral density;
THYM	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg27535305	chr1:53392650	SCP2	-0.4	-4.65	-0.43	1.06e-5	Monocyte count;
THYM	cis	rs13185784	0.703	rs1127580	chr5:179661528	C/T	cg02891314	chr5:179741120	GFPT2	0.67	4.69	0.43	9.26e-6	TRAIL levels;
THYM	cis	rs28595532	0.920	rs115860303	chr4:119734526	T/C	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs924607	0.583	rs12516251	chr5:608939	C/T	cg01125608	chr5:646071	CEP72	-0.59	-4.69	-0.43	9.03e-6	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg26039829	chr8:22132926	PIWIL2	0.7	6.46	0.55	4.46e-9	Hypertriglyceridemia;
THYM	cis	rs2282300	0.739	rs34044331	chr11:30264486	T/C	cg09906309	chr11:30344399	C11orf46	-0.72	-5.34	-0.48	6.24e-7	Morning vs. evening chronotype;
THYM	cis	rs34638657	0.518	rs4889467	chr16:82169385	C/T	cg09439754	chr16:82129088	HSD17B2	-0.53	-4.8	-0.44	5.8e-6	Lung adenocarcinoma;
THYM	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg10254923	chr16:769848	FAM173A	-0.54	-6.64	-0.56	1.91e-9	Height;
THYM	cis	rs926938	0.783	rs10858053	chr1:115297374	A/G	cg12756093	chr1:115239321	AMPD1	-0.71	-5.48	-0.49	3.52e-7	Autism;
THYM	cis	rs2276498	0.751	rs732344	chr20:52660863	A/G	cg23682609	chr20:52687365	BCAS1	0.56	4.55	0.42	1.6e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs7192750	0.586	rs2288029	chr16:71917058	G/A	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg12179176	chr11:130786555	SNX19	0.69	5.56	0.5	2.51e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg24375607	chr4:120327624	NA	0.58	4.8	0.44	5.82e-6	Corneal astigmatism;
THYM	cis	rs4523957	0.928	rs216176	chr17:2168509	G/C	cg16513277	chr17:2031491	SMG6	0.79	7.45	0.61	4.21e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg13010199	chr12:38710504	ALG10B	-0.64	-4.64	-0.43	1.13e-5	Bladder cancer;
THYM	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg03929089	chr4:120376271	NA	-0.94	-10.4	-0.73	2.34e-17	Coronary artery disease;
THYM	cis	rs6032067	0.929	rs6032049	chr20:43825556	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg07414643	chr4:187882934	NA	0.57	4.97	0.45	3.01e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs59112743	0.510	rs16876671	chr6:15604595	A/G	cg10111214	chr6:14815676	NA	0.76	4.95	0.45	3.2e-6	Multiple keratinocyte cancers;
THYM	cis	rs13326165	0.585	rs11710014	chr3:52359972	C/T	cg08438690	chr3:52279403	PPM1M	-0.78	-4.62	-0.43	1.19e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg10411590	chr13:21900810	NA	0.41	4.91	0.45	3.71e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs828999	0.688	rs1020172	chr1:108695802	T/C	cg24323958	chr1:108741884	SLC25A24	0.52	5.1	0.46	1.74e-6	Monocyte percentage of white cells;
THYM	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.7	6.53	0.56	3.28e-9	Total body bone mineral density;
THYM	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg19508488	chr2:152266495	RIF1	0.79	6.49	0.55	3.8e-9	Lung cancer;
THYM	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg06221963	chr1:154839813	KCNN3	-0.54	-5.24	-0.47	9.5e-7	Prostate cancer;
THYM	cis	rs11112613	0.713	rs11112591	chr12:105951620	C/T	cg03607813	chr12:105948248	NA	0.99	8.24	0.65	9.41e-13	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs7312774	0.618	rs10861680	chr12:107323730	T/C	cg16260113	chr12:107380972	MTERFD3	1.34	6.39	0.55	6.14e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg18230493	chr5:56204884	C5orf35	-0.89	-6.53	-0.56	3.25e-9	Initial pursuit acceleration;
THYM	cis	rs9435341	0.965	rs56111229	chr1:107566689	T/A	cg00944433	chr1:107599041	PRMT6	-0.42	-5.0	-0.46	2.58e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs4901869	0.931	rs12891570	chr14:59334338	T/A	cg02291164	chr14:59296302	NA	0.79	7.75	0.62	1e-11	Panic disorder;
THYM	cis	rs611744	0.967	rs595266	chr8:109193784	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs9649213	0.593	rs6969234	chr7:97987986	T/C	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6087990	0.748	rs4911255	chr20:31357580	A/T	cg13636640	chr20:31349939	DNMT3B	0.93	9.86	0.71	3.33e-16	Ulcerative colitis;
THYM	cis	rs6543140	0.929	rs11465700	chr2:103057668	G/A	cg03938978	chr2:103052716	IL18RAP	0.61	6.06	0.53	2.71e-8	Blood protein levels;
THYM	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg07936489	chr17:37558343	FBXL20	0.85	5.64	0.5	1.75e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6450176	1.000	rs3776706	chr5:53304933	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.13	-0.53	2.01e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs7084402	1.000	rs34774248	chr10:60269691	A/G	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs728616	0.717	rs12415523	chr10:81691976	T/C	cg05935833	chr10:81318306	SFTPA2	-0.77	-4.66	-0.43	1.04e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs1978968	0.956	rs7290762	chr22:18449130	C/G	cg01550578	chr22:18484421	MICAL3	0.69	5.21	0.47	1.1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs6570726	0.791	rs441290	chr6:145883183	A/G	cg13319975	chr6:146136371	FBXO30	-0.67	-5.47	-0.49	3.58e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs425277	1.000	rs381664	chr1:2088104	A/G	cg21394778	chr1:3037102	PRDM16	0.46	4.47	0.42	2.12e-5	Height;
THYM	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg05662444	chr5:154026397	NA	0.55	4.83	0.44	5.29e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03264133	chr6:25882463	NA	0.74	5.71	0.51	1.3e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.73	4.93	0.45	3.43e-6	Height;
THYM	cis	rs2806561	0.765	rs641032	chr1:23513980	C/T	cg12483005	chr1:23474871	LUZP1	-0.59	-6.38	-0.55	6.37e-9	Height;
THYM	cis	rs6570726	0.791	rs9403730	chr6:145907233	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-4.99	-0.46	2.75e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs6121246	0.559	rs6060919	chr20:30331922	A/T	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs10924970	0.967	rs4659654	chr1:235383188	A/G	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs2692947	0.673	rs2692894	chr2:96784934	T/G	cg23100626	chr2:96804247	ASTL	-0.39	-4.76	-0.44	6.93e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg13319975	chr6:146136371	FBXO30	0.67	5.5	0.49	3.15e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7098100	0.706	rs6650129	chr10:22280429	A/G	cg10900703	chr10:21824407	MLLT10	0.42	4.69	0.43	9.23e-6	Breast cancer;
THYM	cis	rs539096	0.830	rs11580074	chr1:44024484	A/G	cg00143623	chr1:44495758	SLC6A9	0.63	4.83	0.44	5.31e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2742234	0.541	rs12416428	chr10:43708998	G/A	cg06632098	chr10:43605906	RET	0.82	5.24	0.47	9.49e-7	Hirschsprung disease;
THYM	cis	rs78761021	0.720	rs56086072	chr17:9798412	C/T	cg26853458	chr17:9805074	RCVRN	0.53	4.46	0.42	2.24e-5	Type 2 diabetes;
THYM	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.73	0.44	7.75e-6	Lung cancer in ever smokers;
THYM	cis	rs548181	0.545	rs4486648	chr11:125610589	T/A	cg03464685	chr11:125439445	EI24	-1.29	-7.85	-0.63	6.28e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg25237894	chr2:233734115	C2orf82	0.34	4.53	0.42	1.74e-5	Coronary artery disease;
THYM	cis	rs10463554	0.927	rs257306	chr5:102417474	T/C	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Parkinson's disease;
THYM	cis	rs8133932	0.608	rs403192	chr21:47360641	C/T	cg20357416	chr21:47294739	PCBP3	0.84	5.17	0.47	1.29e-6	Schizophrenia;
THYM	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg12826209	chr6:26865740	GUSBL1	-0.7	-4.98	-0.45	2.85e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7191439	0.728	rs8056374	chr16:88790147	G/T	cg02389323	chr16:88786976	FAM38A	1.1	6.94	0.58	4.72e-10	Plateletcrit;
THYM	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg22189786	chr22:42395067	WBP2NL	0.48	4.48	0.42	2.11e-5	Birth weight;
THYM	cis	rs13102973	0.720	rs67429820	chr4:135888003	G/A	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.41e-13	Subjective well-being;
THYM	cis	rs7567389	0.505	rs56273408	chr2:128095588	T/C	cg06038358	chr2:128176007	PROC	0.45	4.81	0.44	5.58e-6	Self-rated health;
THYM	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg01616529	chr11:638424	DRD4	-0.78	-6.62	-0.56	2.16e-9	Systemic lupus erythematosus;
THYM	cis	rs11648796	0.879	rs12448432	chr16:778820	G/A	cg10254923	chr16:769848	FAM173A	0.5	5.66	0.5	1.63e-7	Height;
THYM	cis	rs6500395	1.000	rs1386040	chr16:48631207	A/G	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg24803719	chr17:45855879	NA	-0.6	-6.3	-0.54	9.35e-9	IgG glycosylation;
THYM	cis	rs7100689	0.646	rs1538823	chr10:82088040	C/A	cg01528321	chr10:82214614	TSPAN14	0.84	6.43	0.55	5.15e-9	Post bronchodilator FEV1;
THYM	cis	rs2237898	0.585	rs35550565	chr11:2880204	G/A	cg12614029	chr11:2160564	INS-IGF2;IGF2AS;IGF2	-1.2	-4.45	-0.42	2.33e-5	Mosquito bite size;
THYM	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06634786	chr22:41940651	POLR3H	-0.77	-5.78	-0.51	9.34e-8	Vitiligo;
THYM	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg00990874	chr7:1149470	C7orf50	-0.61	-4.74	-0.44	7.41e-6	Bronchopulmonary dysplasia;
THYM	cis	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4788570	0.625	rs2247603	chr16:71609364	G/A	cg06353428	chr16:71660113	MARVELD3	-1.44	-8.01	-0.64	2.84e-12	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	0.882	rs10256720	chr7:1210825	C/G	cg15693483	chr7:1102177	C7orf50	0.44	4.7	0.43	8.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg04025307	chr7:1156635	C7orf50	0.72	4.46	0.42	2.27e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2288912	0.838	rs2239375	chr19:45459851	T/C	cg09555818	chr19:45449301	APOC2	0.67	7.38	0.6	5.91e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
THYM	cis	rs4749080	0.573	rs4747546	chr10:26483523	C/T	cg15678844	chr10:26500780	MYO3A	-0.67	-4.6	-0.43	1.28e-5	Obesity-related traits;
THYM	cis	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg10856724	chr12:34555212	NA	1.05	10.54	0.73	1.17e-17	Morning vs. evening chronotype;
THYM	cis	rs4589258	0.737	rs2508412	chr11:90434873	T/G	cg26138821	chr11:89956704	CHORDC1	0.56	4.68	0.43	9.36e-6	Intelligence (multi-trait analysis);
THYM	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.68	-4.86	-0.45	4.61e-6	Colorectal cancer;
THYM	cis	rs1345301	1.000	rs10200410	chr2:102870871	G/A	cg03938978	chr2:103052716	IL18RAP	-0.6	-6.0	-0.52	3.55e-8	Waist circumference;
THYM	cis	rs6732160	0.588	rs13390460	chr2:73371476	G/A	cg24220031	chr2:73402428	NA	-0.73	-5.96	-0.52	4.26e-8	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06873352	chr17:61820015	STRADA	0.79	9.87	0.71	3.15e-16	Prudent dietary pattern;
THYM	cis	rs6430585	0.702	rs746857	chr2:136554890	G/A	cg23851026	chr2:136556271	LCT	-0.78	-7.53	-0.61	2.86e-11	Corneal structure;
THYM	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg18681998	chr4:17616180	MED28	0.81	7.08	0.59	2.43e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs992157	1.000	rs3731859	chr2:219124222	G/A	cg00012203	chr2:219082015	ARPC2	0.85	7.65	0.62	1.64e-11	Colorectal cancer;
THYM	cis	rs868036	1.000	rs1026731	chr15:68095018	G/A	cg24579218	chr15:68104479	NA	-0.65	-6.51	-0.56	3.59e-9	Restless legs syndrome;
THYM	cis	rs3015497	0.594	rs35637875	chr14:51132533	T/G	cg04730355	chr14:51134070	SAV1	-0.56	-4.92	-0.45	3.63e-6	Mean platelet volume;
THYM	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg27446573	chr6:127587934	RNF146	1.04	9.98	0.72	1.81e-16	Breast cancer;
THYM	cis	rs8033133	0.602	rs1549477	chr15:25332118	C/T	cg05951178	chr15:25328739	SNORD116-17;SNORD116-19	-0.69	-5.26	-0.47	9.01e-7	Blood osmolality (transformed sodium);
THYM	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg04944784	chr2:26401820	FAM59B	1.04	6.36	0.55	6.89e-9	Gut microbiome composition (summer);
THYM	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg13390004	chr1:15929781	NA	0.63	4.83	0.44	5.25e-6	Systolic blood pressure;
THYM	cis	rs877282	0.842	rs35872126	chr10:764545	G/A	cg10556349	chr10:835070	NA	-0.78	-5.06	-0.46	2.06e-6	Uric acid levels;
THYM	cis	rs78761021	0.755	rs17681812	chr17:9794540	C/T	cg26853458	chr17:9805074	RCVRN	0.53	4.49	0.42	2.01e-5	Type 2 diabetes;
THYM	cis	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg19693284	chr19:2783607	SGTA	0.66	5.22	0.47	1.05e-6	Total cholesterol levels;
THYM	cis	rs4845459	0.967	rs6701307	chr1:152590444	G/A	cg26135325	chr1:152595322	LCE3A	-0.45	-5.21	-0.47	1.09e-6	Psoriasis;
THYM	cis	rs478304	0.934	rs509206	chr11:65493807	C/T	cg17480646	chr11:65405466	SIPA1	0.7	5.96	0.52	4.35e-8	Acne (severe);
THYM	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg22117172	chr7:91764530	CYP51A1	0.38	4.85	0.45	4.86e-6	Breast cancer;
THYM	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-8.47	-0.66	3.07e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.95	6.19	0.54	1.54e-8	Smoking behavior;
THYM	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg04944784	chr2:26401820	FAM59B	-1.14	-8.12	-0.64	1.68e-12	Gut microbiome composition (summer);
THYM	cis	rs61990749	0.597	rs2364584	chr14:78152286	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-1.04	-6.71	-0.57	1.39e-9	Fibroblast growth factor basic levels;
THYM	cis	rs4713118	0.662	rs9468275	chr6:28026136	G/T	cg23161317	chr6:28129485	ZNF389	0.94	7.03	0.58	3.18e-10	Parkinson's disease;
THYM	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg24910161	chr17:38119198	GSDMA	0.48	4.8	0.44	5.85e-6	Self-reported allergy;
THYM	cis	rs863345	0.584	rs10908676	chr1:158506163	C/G	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs6840360	0.615	rs4696268	chr4:152464723	G/A	cg17479576	chr4:152424074	FAM160A1	-0.83	-6.46	-0.55	4.43e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg04287289	chr16:89883240	FANCA	-0.56	-4.86	-0.45	4.63e-6	Vitiligo;
THYM	cis	rs9814567	1.000	rs6782563	chr3:134295959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.08	0.64	2.04e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs454510	0.816	rs838987	chr1:120176127	A/G	cg16322792	chr1:120165303	ZNF697	0.63	5.01	0.46	2.47e-6	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
THYM	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.27	10.84	0.74	2.66e-18	Platelet count;
THYM	cis	rs2219968	0.683	rs34474702	chr8:78908286	C/T	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	trans	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg18187862	chr3:45730750	SACM1L	0.88	7.14	0.59	1.88e-10	Primary sclerosing cholangitis;
THYM	cis	rs7567389	0.853	rs7585314	chr2:127962493	T/C	cg09760422	chr2:128146352	NA	-0.49	-5.82	-0.51	7.81e-8	Self-rated health;
THYM	cis	rs6547741	0.967	rs4665999	chr2:27834444	T/C	cg27432699	chr2:27873401	GPN1	0.68	5.97	0.52	4.14e-8	Oral cavity cancer;
THYM	cis	rs73198271	0.740	rs28402110	chr8:8647249	C/A	cg06636001	chr8:8085503	FLJ10661	-0.76	-5.06	-0.46	2.01e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.71	4.7	0.43	8.91e-6	Lung cancer in ever smokers;
THYM	cis	rs9826463	0.582	rs116196326	chr3:142059684	A/T	cg20824294	chr3:142316082	PLS1	0.76	5.28	0.48	8.31e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg20486651	chr6:167070296	RPS6KA2	-0.49	-4.7	-0.43	8.94e-6	Crohn's disease;
THYM	cis	rs72781680	0.800	rs6718635	chr2:24066183	A/C	cg08917208	chr2:24149416	ATAD2B	1.11	4.97	0.45	2.9e-6	Lymphocyte counts;
THYM	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg08132940	chr7:1081526	C7orf50	-1.18	-6.8	-0.57	9.35e-10	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg10117171	chr1:25599238	RHD	-0.75	-5.56	-0.5	2.44e-7	Erythrocyte sedimentation rate;
THYM	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg14582100	chr15:45693742	SPATA5L1	0.63	5.25	0.47	9.45e-7	Homoarginine levels;
THYM	cis	rs9733	0.596	rs17658705	chr1:150678071	A/C	cg10589385	chr1:150898437	SETDB1	-0.64	-5.35	-0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg05333889	chr7:157238977	NA	-0.47	-4.65	-0.43	1.09e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs72627123	0.867	rs8020310	chr14:74494437	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.86	4.91	0.45	3.77e-6	Morning vs. evening chronotype;
THYM	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg13010199	chr12:38710504	ALG10B	0.71	5.49	0.49	3.34e-7	Heart rate;
THYM	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg27446573	chr6:127587934	RNF146	0.74	6.53	0.56	3.27e-9	Breast cancer;
THYM	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg08885076	chr2:99613938	TSGA10	-0.66	-6.08	-0.53	2.47e-8	Chronic sinus infection;
THYM	cis	rs1178127	0.719	rs894978	chr7:18789515	T/C	cg13420273	chr7:18810212	HDAC9	0.52	4.62	0.43	1.19e-5	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs7917772	0.512	rs11594073	chr10:104308193	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.69	-5.9	-0.52	5.54e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6840360	0.806	rs11932383	chr4:152716136	T/C	cg22705602	chr4:152727874	NA	0.55	5.84	0.51	7.37e-8	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-6.31	-0.54	8.68e-9	Total body bone mineral density;
THYM	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.37	5.27	0.48	8.36e-7	Obesity-related traits;
THYM	cis	rs4849845	0.925	rs934726	chr2:121012911	A/G	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg14798641	chr3:49314920	USP4;C3orf62	-0.69	-4.69	-0.43	9.23e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs9326248	0.530	rs7123517	chr11:117027755	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.95	5.34	0.48	6.34e-7	Blood protein levels;
THYM	cis	rs6009824	1.000	rs6009824	chr22:50086373	C/T	cg18178197	chr22:50098317	NA	0.85	6.73	0.57	1.3e-9	Natriuretic peptide levels;
THYM	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg26850624	chr5:429559	AHRR	-0.7	-5.6	-0.5	2.07e-7	Cystic fibrosis severity;
THYM	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg19875535	chr5:140030758	IK	-0.61	-5.27	-0.48	8.57e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs2299587	0.689	rs2299588	chr8:17801725	A/G	cg01800426	chr8:17659068	MTUS1	-0.57	-4.52	-0.42	1.79e-5	Economic and political preferences;
THYM	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15541040	chr2:3486749	NA	-0.55	-4.5	-0.42	1.95e-5	Neurofibrillary tangles;
THYM	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg14983838	chr19:29218262	NA	1.09	8.97	0.68	2.58e-14	Methadone dose in opioid dependence;
THYM	cis	rs889398	0.771	rs11075732	chr16:69766038	A/G	cg09409435	chr16:70099608	PDXDC2	-0.6	-4.55	-0.42	1.57e-5	Body mass index;
THYM	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg08736216	chr1:53307985	ZYG11A	-0.56	-5.1	-0.46	1.76e-6	Monocyte count;
THYM	cis	rs4845875	0.626	rs12734761	chr1:11834182	G/A	cg25341925	chr1:11908058	NPPA	0.43	4.66	0.43	1.03e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg03806693	chr22:41940476	POLR3H	-1.06	-8.74	-0.67	8.12e-14	Vitiligo;
THYM	cis	rs1335645	0.655	rs61804623	chr1:111650834	T/G	cg00321911	chr1:111669324	DRAM2	-1.14	-6.19	-0.54	1.49e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2075230	0.642	rs1641524	chr17:7549645	T/G	cg27413385	chr17:7515425	FXR2	-0.36	-5.31	-0.48	7.3e-7	Hormone measurements;
THYM	cis	rs73198271	0.653	rs3827811	chr8:8659038	C/T	cg06636001	chr8:8085503	FLJ10661	-0.64	-4.7	-0.43	8.87e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg06115741	chr20:33292138	TP53INP2	0.72	4.87	0.45	4.48e-6	Coronary artery disease;
THYM	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg02187348	chr16:89574699	SPG7	0.71	5.55	0.49	2.61e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg14345882	chr6:26364793	BTN3A2	0.58	5.49	0.49	3.39e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg26384229	chr12:38710491	ALG10B	-0.71	-5.48	-0.49	3.52e-7	Morning vs. evening chronotype;
THYM	cis	rs10927875	0.541	rs1739842	chr1:16342848	T/G	cg22431228	chr1:16359049	CLCNKA	-0.49	-4.61	-0.43	1.27e-5	Dilated cardiomyopathy;
THYM	cis	rs2069036	1.000	rs10795344	chr10:16113883	G/A	cg26633223	chr10:15133461	NA	0.7	5.2	0.47	1.15e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg10523679	chr1:76189770	ACADM	0.88	7.58	0.61	2.28e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs3847687	1.000	rs78233646	chr12:131520170	G/T	cg13586425	chr12:131519906	GPR133	-0.32	-5.18	-0.47	1.24e-6	Longevity;
THYM	cis	rs28595532	0.841	rs114123875	chr4:119733408	A/G	cg11846333	chr4:119757529	SEC24D	1.47	5.57	0.5	2.41e-7	Cannabis dependence symptom count;
THYM	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs6988636	1.000	rs13261100	chr8:124190312	G/A	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg18252515	chr7:66147081	NA	-0.68	-5.24	-0.47	9.83e-7	Aortic root size;
THYM	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs11696845	0.666	rs13042905	chr20:43379454	T/C	cg25301532	chr20:43378953	KCNK15	0.65	5.3	0.48	7.55e-7	Obesity-related traits;
THYM	cis	rs4792901	0.802	rs9915326	chr17:41588602	A/G	cg21940313	chr17:41620911	ETV4	-0.53	-5.03	-0.46	2.28e-6	Dupuytren's disease;
THYM	cis	rs478304	0.654	rs10896032	chr11:65459419	C/A	cg17480646	chr11:65405466	SIPA1	-0.97	-8.99	-0.68	2.44e-14	Acne (severe);
THYM	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg18252515	chr7:66147081	NA	-1.45	-8.59	-0.66	1.72e-13	Diabetic kidney disease;
THYM	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg13393036	chr8:95962371	TP53INP1	-0.46	-4.63	-0.43	1.18e-5	Type 2 diabetes;
THYM	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg06766960	chr11:133703094	NA	-0.61	-5.81	-0.51	8.3e-8	Childhood ear infection;
THYM	cis	rs3126085	1.000	rs2011331	chr1:152286002	T/C	cg26020982	chr1:152196106	HRNR	-0.35	-4.95	-0.45	3.26e-6	Atopic dermatitis;
THYM	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg04731861	chr2:219085781	ARPC2	-0.49	-4.69	-0.43	9.3e-6	Colorectal cancer;
THYM	cis	rs868036	0.672	rs7175517	chr15:68077630	A/G	cg24579218	chr15:68104479	NA	-0.82	-9.12	-0.68	1.26e-14	Restless legs syndrome;
THYM	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs7264396	0.616	rs6142476	chr20:34581216	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.63	-4.7	-0.43	8.77e-6	Total cholesterol levels;
THYM	cis	rs6435161	1.000	rs1039968	chr2:203557151	T/C	cg18429434	chr2:203499731	FAM117B	-0.77	-5.16	-0.47	1.35e-6	Total cholesterol levels;
THYM	cis	rs4951011	1.000	rs4951011	chr1:203766331	A/G	cg24343524	chr1:203763352	ZC3H11A	-0.6	-4.66	-0.43	1.01e-5	Breast cancer;
THYM	cis	rs835154	0.845	rs835156	chr5:14875813	C/A	cg14843632	chr5:14870594	ANKH	0.7	6.46	0.55	4.48e-9	Blood metabolite levels;
THYM	cis	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg13443165	chr9:33130375	B4GALT1	-0.87	-7.99	-0.63	3.23e-12	IgG glycosylation;
THYM	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	8.22	0.64	1.03e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Bladder cancer;
THYM	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg10803722	chr21:46713166	LOC642852	-0.41	-5.11	-0.46	1.69e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs58804349	0.581	rs2744081	chr10:43352400	C/A	cg08461752	chr10:43522343	NA	-0.98	-5.13	-0.47	1.52e-6	Pediatric bone mineral content (radius);
THYM	trans	rs8002861	0.905	rs9525869	chr13:44467210	A/G	cg17145862	chr1:211918768	LPGAT1	1.03	11.49	0.76	1.13e-19	Leprosy;
THYM	cis	rs669446	0.561	rs585652	chr1:44099910	T/C	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg14983838	chr19:29218262	NA	1.09	9.77	0.71	5e-16	Methadone dose in opioid dependence;
THYM	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	4.5	0.42	1.92e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg07936489	chr17:37558343	FBXL20	0.82	5.69	0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs17125944	0.615	rs8019585	chr14:53374843	G/A	cg00686598	chr14:53173677	PSMC6	1.02	4.61	0.43	1.27e-5	Alzheimer's disease (late onset);
THYM	cis	rs6570726	0.935	rs422540	chr6:145837815	G/T	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3087591	0.919	rs9913470	chr17:29566575	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.63	-5.33	-0.48	6.51e-7	Hip circumference;
THYM	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg06238570	chr21:40685208	BRWD1	-0.68	-5.74	-0.51	1.15e-7	Menarche (age at onset);
THYM	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg07167872	chr1:205819463	PM20D1	-0.74	-6.43	-0.55	5.11e-9	Menarche (age at onset);
THYM	cis	rs6840360	0.550	rs6853955	chr4:152510806	G/A	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05901451	chr6:126070800	HEY2	-0.93	-9.08	-0.68	1.49e-14	Brugada syndrome;
THYM	cis	rs1448094	0.556	rs17345522	chr12:86169929	T/C	cg00310523	chr12:86230176	RASSF9	0.56	4.94	0.45	3.29e-6	Major depressive disorder;
THYM	cis	rs1472147	0.955	rs3736614	chr7:128509048	T/G	cg00260937	chr7:128520193	KCP	0.53	4.89	0.45	4.04e-6	Calcium levels;
THYM	cis	rs7769051	1.000	rs9399041	chr6:133096233	T/G	cg22852734	chr6:133119734	C6orf192	1.29	8.22	0.64	1.04e-12	Type 2 diabetes nephropathy;
THYM	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs10979	0.964	rs9321922	chr6:143895231	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs9457247	0.638	rs239933	chr6:167413230	A/G	cg23791538	chr6:167370224	RNASET2	-0.57	-4.53	-0.42	1.73e-5	Crohn's disease;
THYM	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg03388043	chr17:80084554	CCDC57	-0.73	-6.06	-0.53	2.74e-8	Life satisfaction;
THYM	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg19761014	chr17:28927070	LRRC37B2	-0.82	-4.81	-0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg16414030	chr3:133502952	NA	-0.84	-8.51	-0.66	2.57e-13	Iron status biomarkers;
THYM	cis	rs747334	0.840	rs28849130	chr10:92711599	C/T	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs7833986	1.000	rs34404111	chr8:57099190	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.5	4.78	0.44	6.48e-6	Height;
THYM	cis	rs10883723	0.810	rs12162	chr10:104240498	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.72	4.48	0.42	2.11e-5	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2505998	0.833	rs2565203	chr10:43603735	A/G	cg06632098	chr10:43605906	RET	-1.15	-10.72	-0.74	4.81e-18	Hirschsprung disease;
THYM	cis	rs11779988	0.545	rs409217	chr8:17816597	C/G	cg01800426	chr8:17659068	MTUS1	-0.72	-4.91	-0.45	3.8e-6	Breast cancer;
THYM	cis	rs7772486	0.701	rs11155438	chr6:145950112	C/G	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg08132940	chr7:1081526	C7orf50	-1.15	-6.58	-0.56	2.59e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2504916	0.712	rs2504958	chr6:160750545	C/T	cg19643109	chr6:160697625	NA	-0.63	-4.8	-0.44	5.8e-6	Response to hepatitis C treatment;
THYM	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg12564285	chr5:131593104	PDLIM4	-0.42	-4.54	-0.42	1.67e-5	Blood metabolite levels;
THYM	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg11845111	chr2:191398756	TMEM194B	-0.95	-7.05	-0.59	2.89e-10	Diastolic blood pressure;
THYM	cis	rs9810089	0.843	rs838202	chr3:136035217	G/A	cg12473912	chr3:136751656	NA	0.6	4.87	0.45	4.42e-6	Gestational age at birth (child effect);
THYM	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg20242066	chr2:136595261	LCT	-0.6	-7.41	-0.61	5.17e-11	Mosquito bite size;
THYM	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg17063962	chr7:91808500	NA	1.13	12.83	0.8	1.9e-22	Breast cancer;
THYM	cis	rs10911232	0.507	rs6668980	chr1:183018857	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs2554380	0.891	rs2554383	chr15:84356316	A/G	cg14598478	chr15:84363061	ADAMTSL3	-0.65	-5.09	-0.46	1.83e-6	Height;
THYM	cis	rs1943345	0.642	rs642669	chr11:82892454	A/T	cg07047830	chr11:82868014	PCF11	0.69	5.75	0.51	1.07e-7	Obesity-related traits;
THYM	cis	rs17776563	0.887	rs11631086	chr15:89137185	G/A	cg01779732	chr15:90015521	RHCG	0.46	4.53	0.42	1.71e-5	Thyroid hormone levels;
THYM	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.24	-5.03	-0.46	2.35e-6	Obesity-related traits;
THYM	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg14582100	chr15:45693742	SPATA5L1	0.65	5.32	0.48	6.89e-7	Metabolite levels (small molecules and protein measures);
THYM	cis	rs28595532	0.920	rs115084148	chr4:119739290	A/G	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg19077165	chr18:44547161	KATNAL2	0.51	5.93	0.52	4.94e-8	Personality dimensions;
THYM	trans	rs4596713	0.508	rs13289984	chr9:71775047	A/C	cg16512924	chr15:28394682	HERC2	0.83	6.92	0.58	5.28e-10	Headache;
THYM	cis	rs1847202	1.000	rs11918615	chr3:72942407	T/C	cg25664220	chr3:72788482	NA	-0.61	-4.77	-0.44	6.65e-6	Motion sickness;
THYM	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.92e-8	Systolic blood pressure;
THYM	cis	rs2274459	0.908	rs12204620	chr6:33741063	C/T	cg06253072	chr6:33679850	C6orf125	0.51	4.49	0.42	1.99e-5	Obesity (extreme);
THYM	cis	rs960902	0.818	rs58694726	chr2:37718696	G/A	cg25341268	chr2:37734390	NA	0.53	4.47	0.42	2.15e-5	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs4363385	0.818	rs423692	chr1:153005681	T/G	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs4149423	1.000	rs4149423	chr2:108916044	A/G	cg06795125	chr2:108905320	SULT1C2	-0.6	-6.06	-0.53	2.7e-8	Lobe size;
THYM	cis	rs6665290	0.669	rs3768421	chr1:227177193	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.07	-11.62	-0.77	5.93e-20	Myeloid white cell count;
THYM	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08564027	chr20:61660810	NA	0.91	9.69	0.7	7.71e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs853679	0.599	rs149990	chr6:27998258	G/A	cg12963246	chr6:28129442	ZNF389	0.93	5.06	0.46	2.05e-6	Depression;
THYM	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg17830980	chr10:43048298	ZNF37B	-1.09	-10.96	-0.75	1.49e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs11771526	0.901	rs62457471	chr7:32306737	A/C	cg27532318	chr7:32358331	NA	0.73	4.71	0.44	8.4e-6	Body mass index;
THYM	cis	rs2276498	1.000	rs6127049	chr20:52616373	C/T	cg23682609	chr20:52687365	BCAS1	0.59	4.53	0.42	1.73e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs12478296	0.581	rs56142391	chr2:242992248	C/T	cg06360820	chr2:242988706	NA	-1.06	-7.65	-0.62	1.66e-11	Obesity-related traits;
THYM	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.26	0.48	8.81e-7	Melanoma;
THYM	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs77372450	0.591	rs62390773	chr5:157044673	C/T	cg00312553	chr5:157098553	C5orf52	-0.65	-4.63	-0.43	1.16e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs11030122	0.702	rs10835312	chr11:3950253	G/A	cg22027985	chr11:4115532	RRM1	-0.48	-4.59	-0.43	1.36e-5	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2953805	1	rs2953805	chr8:8914757	T/C	cg06636001	chr8:8085503	FLJ10661	0.79	6.7	0.57	1.48e-9	Neuroticism;Morning vs. evening chronotype;
THYM	cis	rs17539620	0.534	rs6557363	chr6:154827813	A/G	cg20019720	chr6:154832845	CNKSR3	0.59	7.2	0.59	1.41e-10	Lipoprotein (a) levels;
THYM	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg15736062	chr7:158136485	PTPRN2	0.57	4.73	0.44	7.65e-6	Response to amphetamines;
THYM	cis	rs3087591	0.919	rs11080141	chr17:29400158	G/A	cg24425628	chr17:29625626	OMG;NF1	0.64	5.51	0.49	3.01e-7	Hip circumference;
THYM	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg26384229	chr12:38710491	ALG10B	0.73	5.59	0.5	2.2e-7	Morning vs. evening chronotype;
THYM	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg13147721	chr7:65941812	NA	0.76	4.93	0.45	3.42e-6	Gout;
THYM	cis	rs514406	0.929	rs557715	chr1:53321593	C/G	cg25767906	chr1:53392781	SCP2	-0.53	-5.2	-0.47	1.13e-6	Monocyte count;
THYM	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg23018236	chr17:30244563	NA	-0.6	-4.45	-0.42	2.3e-5	Hip circumference adjusted for BMI;
THYM	cis	rs8017423	0.967	rs11621045	chr14:90714003	C/T	cg04239629	chr14:90701769	NA	-0.62	-4.52	-0.42	1.81e-5	Mortality in heart failure;
THYM	cis	rs3741151	0.892	rs3741152	chr11:73008914	G/A	cg12959048	chr11:73096162	RELT	-0.43	-4.72	-0.44	8.13e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs10751667	0.961	rs7396670	chr11:929269	A/G	cg01483505	chr11:975446	AP2A2	0.66	5.12	0.46	1.6e-6	Alzheimer's disease (late onset);
THYM	cis	rs907683	0.584	rs12621188	chr2:220287892	C/G	cg15015639	chr2:220282977	DES	0.38	5.0	0.46	2.63e-6	Resting heart rate;
THYM	cis	rs2282300	0.739	rs34044331	chr11:30264486	T/C	cg06241208	chr11:30344200	C11orf46	-0.77	-5.59	-0.5	2.15e-7	Morning vs. evening chronotype;
THYM	cis	rs11096990	0.750	rs2465242	chr4:39155416	A/T	cg24403649	chr4:39172243	NA	-0.6	-5.09	-0.46	1.77e-6	Cognitive function;
THYM	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg08431931	chr22:42394659	WBP2NL	0.71	4.96	0.45	3.07e-6	Birth weight;
THYM	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg26924012	chr15:45694286	SPATA5L1	-1.13	-11.03	-0.75	1.04e-18	Homoarginine levels;
THYM	cis	rs11608355	0.810	rs2217972	chr12:109857612	C/T	cg11367159	chr12:110044531	NA	0.6	5.17	0.47	1.31e-6	Neuroticism;
THYM	trans	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg10856724	chr12:34555212	NA	-0.98	-8.46	-0.66	3.16e-13	Bladder cancer;
THYM	cis	rs3892630	0.878	rs114224536	chr19:33211232	A/G	cg22980127	chr19:33182716	NUDT19	1.15	9.47	0.7	2.23e-15	Red blood cell traits;
THYM	cis	rs6450176	0.564	rs374050	chr5:53331646	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.93	-8.27	-0.65	8.09e-13	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs3781426	0.662	rs3781412	chr10:126715154	A/G	cg04494136	chr10:126703576	CTBP2	-0.41	-6.34	-0.55	7.67e-9	Height;
THYM	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9733	0.527	rs11204694	chr1:150653391	G/A	cg15448220	chr1:150897856	SETDB1	0.88	7.27	0.6	1.02e-10	Tonsillectomy;
THYM	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg10589385	chr1:150898437	SETDB1	0.62	5.08	0.46	1.9e-6	Melanoma;
THYM	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg10295955	chr4:187884368	NA	-1.17	-16.0	-0.85	1.07e-28	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.929	rs555741	chr1:53318851	T/G	cg08859206	chr1:53392774	SCP2	-0.66	-7.55	-0.61	2.7e-11	Monocyte count;
THYM	cis	rs600806	0.850	rs3931560	chr1:109966718	A/C	cg16988986	chr1:109941118	SORT1	-0.44	-4.67	-0.43	9.83e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9443189	0.570	rs775075	chr6:76380035	A/C	cg01950844	chr6:76311363	SENP6	-1.05	-6.66	-0.56	1.73e-9	Prostate cancer;
THYM	cis	rs7582180	0.614	rs4850931	chr2:101005145	C/T	cg14675211	chr2:100938903	LONRF2	0.66	6.46	0.55	4.5e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.53	-5.21	-0.47	1.1e-6	Crohn's disease;
THYM	cis	rs2688608	0.530	rs71507081	chr10:75493136	G/A	cg15838173	chr10:75533400	FUT11	-0.5	-5.09	-0.46	1.82e-6	Inflammatory bowel disease;
THYM	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg06558623	chr16:89946397	TCF25	0.88	4.75	0.44	7.33e-6	Skin colour saturation;
THYM	cis	rs600806	0.850	rs10858091	chr1:109935578	T/C	cg16988986	chr1:109941118	SORT1	-0.43	-4.56	-0.42	1.5e-5	Intelligence (multi-trait analysis);
THYM	cis	rs892961	0.932	rs2170863	chr17:75415037	C/T	cg11351908	chr17:75402473	SEPT9	0.56	5.5	0.49	3.23e-7	Airflow obstruction;
THYM	cis	rs4851254	0.618	rs13001130	chr2:100668699	G/A	cg22139774	chr2:100720529	AFF3	-0.39	-4.49	-0.42	1.99e-5	Intelligence (multi-trait analysis);
THYM	cis	rs490234	0.676	rs1129	chr9:128199873	A/G	cg14078157	chr9:128172775	NA	0.79	6.58	0.56	2.56e-9	Mean arterial pressure;
THYM	cis	rs752010	0.530	rs10789401	chr1:42081111	A/G	cg06885757	chr1:42089581	HIVEP3	0.78	11.69	0.77	4.25e-20	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs6424115	0.830	rs2229584	chr1:24200969	T/C	cg15997130	chr1:24165203	NA	0.76	6.39	0.55	6.14e-9	Immature fraction of reticulocytes;
THYM	cis	rs2439831	0.614	rs2467733	chr15:43693328	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	6.89	0.58	5.93e-10	Lung cancer in ever smokers;
THYM	cis	rs828999	0.688	rs1157390	chr1:108699096	C/T	cg24323958	chr1:108741884	SLC25A24	0.55	5.4	0.48	4.98e-7	Monocyte percentage of white cells;
THYM	cis	rs9902453	0.868	rs11080118	chr17:28475379	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.8	-6.23	-0.54	1.24e-8	Coffee consumption (cups per day);
THYM	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg12893697	chr11:970389	AP2A2	-0.31	-5.21	-0.47	1.08e-6	Alzheimer's disease (late onset);
THYM	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg20007245	chr22:24372913	LOC391322	-0.73	-6.57	-0.56	2.74e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg10518543	chr12:38710700	ALG10B	-0.57	-4.54	-0.42	1.67e-5	Morning vs. evening chronotype;
THYM	cis	rs2976388	1.000	rs1045605	chr8:143764101	C/G	cg13446199	chr8:143762866	PSCA	0.51	6.42	0.55	5.46e-9	Urinary tract infection frequency;
THYM	cis	rs7582403	0.778	rs6727415	chr2:148893407	A/G	cg23727674	chr2:148602993	ACVR2A	-0.62	-5.11	-0.46	1.69e-6	Neuroticism;
THYM	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.8	0.51	8.76e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	trans	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs9790314	0.846	rs7652267	chr3:160998497	A/G	cg03342759	chr3:160939853	NMD3	-0.95	-9.47	-0.7	2.2e-15	Morning vs. evening chronotype;
THYM	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.42	4.56	0.42	1.53e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs55728055	0.661	rs73160611	chr22:31803487	A/G	cg10537193	chr22:32026975	PISD	-0.91	-5.25	-0.47	9.24e-7	Age-related hearing impairment;
THYM	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg19913688	chr11:428466	ANO9	-0.88	-4.58	-0.42	1.43e-5	Body mass index;
THYM	cis	rs892961	0.932	rs7216155	chr17:75405155	C/G	cg11351908	chr17:75402473	SEPT9	0.59	5.74	0.51	1.11e-7	Airflow obstruction;
THYM	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.67	0.5	1.52e-7	Height;
THYM	cis	rs10203711	1.000	rs4663328	chr2:239574103	A/G	cg14580085	chr2:239553406	NA	-0.68	-6.18	-0.54	1.6e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg26384229	chr12:38710491	ALG10B	-0.67	-4.88	-0.45	4.31e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg11327659	chr7:150037044	RARRES2	0.44	5.14	0.47	1.45e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6496667	1.000	rs6496668	chr15:90893704	A/T	cg22089800	chr15:90895588	ZNF774	0.85	5.07	0.46	1.95e-6	Rheumatoid arthritis;
THYM	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-4.48	-0.42	2.05e-5	Aortic root size;
THYM	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg19774624	chr17:42201019	HDAC5	-0.76	-7.12	-0.59	2.05e-10	Total body bone mineral density;
THYM	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg02527881	chr3:46936655	PTH1R	-0.69	-7.14	-0.59	1.9e-10	Colorectal cancer;
THYM	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg18252515	chr7:66147081	NA	-0.63	-4.57	-0.42	1.49e-5	Aortic root size;
THYM	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg21138405	chr5:131827807	IRF1	0.7	7.53	0.61	2.88e-11	Breast cancer;Mosquito bite size;
THYM	cis	rs6840360	0.615	rs7695412	chr4:152488075	A/G	cg22705602	chr4:152727874	NA	-0.71	-7.94	-0.63	4.03e-12	Intelligence (multi-trait analysis);
THYM	cis	rs2487048	0.773	rs2472493	chr9:107695848	G/A	cg14019050	chr9:107690770	ABCA1	-0.63	-6.56	-0.56	2.86e-9	Intraocular pressure;
THYM	cis	rs7558911	0.801	rs10188598	chr2:202077613	A/G	cg12105450	chr2:202048100	CASP10	0.53	4.72	0.44	8.07e-6	Chronic lymphocytic leukemia;
THYM	cis	rs4851266	0.833	rs11685491	chr2:100858122	A/G	cg14675211	chr2:100938903	LONRF2	0.67	5.59	0.5	2.15e-7	Educational attainment;
THYM	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg03321784	chr17:37729644	NA	0.57	4.47	0.42	2.18e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs877282	0.898	rs35743076	chr10:758991	C/T	cg10556349	chr10:835070	NA	-0.8	-5.43	-0.49	4.34e-7	Uric acid levels;
THYM	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg00071950	chr4:10020882	SLC2A9	0.87	10.34	0.73	3.16e-17	Bone mineral density;
THYM	cis	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg07235805	chr18:78004237	PARD6G	0.42	4.64	0.43	1.14e-5	Opioid sensitivity;
THYM	cis	rs289828	0.868	rs3771886	chr2:152138522	T/C	cg05960677	chr2:152117363	RBM43	0.61	6.05	0.53	2.89e-8	Blood protein levels;
THYM	cis	rs1448094	0.511	rs56291271	chr12:86162287	G/A	cg00310523	chr12:86230176	RASSF9	0.61	5.31	0.48	7.29e-7	Major depressive disorder;
THYM	cis	rs11098499	0.532	rs4833624	chr4:120585497	C/T	cg13609457	chr4:120235615	NA	0.63	5.4	0.48	4.88e-7	Corneal astigmatism;
THYM	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs977987	0.843	rs8056080	chr16:75410798	C/A	cg03315344	chr16:75512273	CHST6	0.73	6.27	0.54	1.07e-8	Dupuytren's disease;
THYM	trans	rs8002861	0.967	rs7321596	chr13:44472255	G/A	cg17145862	chr1:211918768	LPGAT1	1.04	12.02	0.78	8.8e-21	Leprosy;
THYM	cis	rs1113500	1.000	rs1113500	chr1:108595442	G/T	cg06207961	chr1:108661230	NA	-0.7	-5.62	-0.5	1.94e-7	Growth-regulated protein alpha levels;
THYM	cis	rs909002	1.000	rs909002	chr1:32139635	C/T	cg13919466	chr1:32135498	COL16A1	-0.52	-5.28	-0.48	8.19e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2274459	1.000	rs12190954	chr6:33746618	A/G	cg06253072	chr6:33679850	C6orf125	0.52	4.65	0.43	1.07e-5	Obesity (extreme);
THYM	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg24154853	chr7:158122151	PTPRN2	0.56	4.91	0.45	3.76e-6	Calcium levels;
THYM	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg19774624	chr17:42201019	HDAC5	0.69	5.89	0.52	5.78e-8	Total body bone mineral density;
THYM	cis	rs17006441	0.866	rs62252236	chr3:69893064	A/G	cg18496212	chr3:69797108	MITF	0.68	6.85	0.57	7.35e-10	Hemoglobin concentration;
THYM	cis	rs2898681	0.581	rs10003908	chr4:53681089	T/C	cg21521518	chr4:53727714	RASL11B	0.47	5.33	0.48	6.52e-7	Optic nerve measurement (cup area);
THYM	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg14345882	chr6:26364793	BTN3A2	-0.62	-5.74	-0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs72627123	0.867	rs8015927	chr14:74465756	A/T	cg11191049	chr14:74485465	ENTPD5;C14orf45	-1.12	-6.43	-0.55	5.21e-9	Morning vs. evening chronotype;
THYM	cis	rs13315871	0.929	rs77487951	chr3:58290892	G/A	cg12435725	chr3:58293450	RPP14	-0.53	-5.57	-0.5	2.32e-7	Cholesterol, total;
THYM	cis	rs4589258	0.788	rs1573549	chr11:90464515	A/G	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.93	-0.45	3.53e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7772486	0.743	rs9403742	chr6:146060193	A/C	cg23711669	chr6:146136114	FBXO30	0.85	8.18	0.64	1.27e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6921919	0.583	rs7764722	chr6:28354533	C/T	cg18815343	chr6:28367644	ZSCAN12	-0.57	-4.5	-0.42	1.89e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1483890	0.723	rs6419767	chr3:69412505	G/A	cg22125112	chr3:69402811	FRMD4B	0.55	6.93	0.58	4.98e-10	Resting heart rate;
THYM	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg19774624	chr17:42201019	HDAC5	0.71	6.24	0.54	1.23e-8	Total body bone mineral density;
THYM	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg19774624	chr17:42201019	HDAC5	-0.77	-6.89	-0.58	5.99e-10	Total body bone mineral density;
THYM	cis	rs3768617	0.528	rs4652778	chr1:183097420	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.91	0.45	3.8e-6	Fuchs's corneal dystrophy;
THYM	cis	rs4888262	0.545	rs7342732	chr16:74698716	A/C	cg01733217	chr16:74700730	RFWD3	0.88	9.59	0.7	1.24e-15	Testicular germ cell tumor;
THYM	cis	rs7192750	0.517	rs152827	chr16:72126753	C/G	cg06353428	chr16:71660113	MARVELD3	1.17	4.58	0.43	1.42e-5	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs990171	0.913	rs2272128	chr2:103039929	G/A	cg13897122	chr2:103039542	IL18RAP	-0.39	-4.64	-0.43	1.12e-5	Lymphocyte counts;
THYM	trans	rs9951602	0.512	rs12607938	chr18:76651887	A/C	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg17264618	chr3:40429014	ENTPD3	0.51	5.09	0.46	1.82e-6	Renal cell carcinoma;
THYM	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg06238570	chr21:40685208	BRWD1	0.89	6.46	0.55	4.38e-9	Cognitive function;
THYM	cis	rs2276314	0.553	rs12964535	chr18:33611691	A/C	cg19628046	chr18:33552617	C18orf21	-0.65	-4.98	-0.46	2.8e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	4.46	0.42	2.23e-5	Rheumatoid arthritis;
THYM	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg03388025	chr16:89894329	SPIRE2	0.54	4.54	0.42	1.67e-5	Vitiligo;
THYM	cis	rs8016982	0.611	rs8008870	chr14:81709374	C/T	cg01989461	chr14:81687754	GTF2A1	0.87	7.71	0.62	1.24e-11	Schizophrenia;
THYM	cis	rs7617773	0.780	rs11720026	chr3:48377921	T/C	cg02219026	chr3:48282209	ZNF589	-0.67	-4.61	-0.43	1.25e-5	Coronary artery disease;
THYM	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg05932139	chr16:680872	WFIKKN1	-0.64	-5.31	-0.48	7.24e-7	Height;
THYM	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11890956	chr21:40555474	PSMG1	1.17	12.99	0.8	8.73e-23	Cognitive function;
THYM	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg17063962	chr7:91808500	NA	1.18	12.81	0.8	2.05e-22	Breast cancer;
THYM	cis	rs7772486	0.754	rs697055	chr6:146003790	C/G	cg13319975	chr6:146136371	FBXO30	-0.65	-5.27	-0.48	8.54e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6674176	0.569	rs34830883	chr1:44405339	T/C	cg15962314	chr1:44399869	ARTN	0.52	4.61	0.43	1.27e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs89107	0.549	rs17427116	chr6:118986198	G/A	cg21191810	chr6:118973309	C6orf204	0.57	5.95	0.52	4.46e-8	Cardiac structure and function;
THYM	cis	rs7131987	0.650	rs11050208	chr12:29510369	T/G	cg09582351	chr12:29534625	ERGIC2	-0.56	-4.55	-0.42	1.59e-5	QT interval;
THYM	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg18032289	chr17:61959525	GH2	-0.47	-4.47	-0.42	2.17e-5	Hip circumference adjusted for BMI;Body mass index;
THYM	cis	rs6430585	0.528	rs7573555	chr2:136694905	C/T	cg23851026	chr2:136556271	LCT	-0.76	-7.47	-0.61	3.81e-11	Corneal structure;
THYM	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-10.57	-0.74	9.94e-18	Primary sclerosing cholangitis;
THYM	cis	rs1629083	0.967	rs56315433	chr11:118114576	C/A	cg25155064	chr11:118100782	MPZL3	-0.57	-5.03	-0.46	2.34e-6	Lung cancer;
THYM	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg25282410	chr6:160211355	TCP1;MRPL18	1.17	11.49	0.76	1.16e-19	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.61e-20	Menopause (age at onset);
THYM	cis	rs4523957	0.855	rs12601834	chr17:2112431	C/T	cg16513277	chr17:2031491	SMG6	-0.79	-7.76	-0.62	9.62e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs515863	0.765	rs12876365	chr13:113911651	C/T	cg17329202	chr13:113807930	NA	0.57	4.69	0.43	8.97e-6	Blood protein levels;
THYM	cis	rs13064411	0.735	rs722392	chr3:113228294	A/G	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg05340658	chr4:99064831	C4orf37	0.54	4.51	0.42	1.83e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.08	-0.53	2.5e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs1620921	0.524	rs4440440	chr6:161183424	A/C	cg01280913	chr6:161186852	NA	-0.51	-4.65	-0.43	1.06e-5	Lipoprotein (a) - cholesterol levels;
THYM	cis	rs9938149	0.736	rs6540223	chr16:88321436	A/G	cg09789939	chr16:88532245	ZFPM1	0.56	4.52	0.42	1.81e-5	Corneal structure;Central corneal thickness;
THYM	cis	rs42648	0.869	rs6948139	chr7:89937781	T/A	cg25739043	chr7:89950458	NA	-0.53	-4.53	-0.42	1.72e-5	Homocysteine levels;
THYM	cis	rs6882076	0.883	rs1553318	chr5:156479323	G/C	cg12943317	chr5:156479607	HAVCR1	-0.78	-6.29	-0.54	9.58e-9	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
THYM	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg03388025	chr16:89894329	SPIRE2	0.53	4.62	0.43	1.21e-5	Vitiligo;
THYM	cis	rs7681423	1.000	rs2066864	chr4:155525695	G/A	cg20735720	chr4:155535218	FGG	-0.71	-5.57	-0.5	2.39e-7	Fibrinogen;
THYM	cis	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg10856724	chr12:34555212	NA	-1.08	-10.36	-0.73	2.78e-17	Morning vs. evening chronotype;
THYM	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg11764359	chr7:65958608	NA	-0.73	-5.55	-0.49	2.63e-7	Aortic root size;
THYM	cis	rs3781426	0.521	rs7923776	chr10:126690383	C/T	cg04494136	chr10:126703576	CTBP2	0.35	4.69	0.43	9.02e-6	Height;
THYM	cis	rs9906944	0.707	rs8068981	chr17:47122525	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.54	-5.48	-0.49	3.55e-7	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg13147721	chr7:65941812	NA	-0.59	-4.56	-0.42	1.51e-5	Diabetic kidney disease;
THYM	cis	rs4731207	0.596	rs1842615	chr7:124582871	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs9790314	1.000	rs6441373	chr3:161026717	T/G	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg06634786	chr22:41940651	POLR3H	0.71	5.04	0.46	2.19e-6	Vitiligo;
THYM	cis	rs59698941	0.882	rs12514947	chr5:132311567	G/T	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg05368731	chr17:41323189	NBR1	1.26	11.79	0.77	2.61e-20	Menopause (age at onset);
THYM	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg06636001	chr8:8085503	FLJ10661	0.62	5.23	0.47	1.01e-6	Systolic blood pressure;
THYM	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7122937	1.000	rs16928297	chr11:2486120	G/T	cg27115973	chr11:2481206	KCNQ1	-0.6	-6.62	-0.56	2.12e-9	QT interval;
THYM	cis	rs7264396	0.623	rs78949029	chr20:34384964	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.75	-4.56	-0.42	1.51e-5	Total cholesterol levels;
THYM	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg18252515	chr7:66147081	NA	0.63	4.7	0.43	8.9e-6	Aortic root size;
THYM	cis	rs8114671	0.562	rs6119536	chr20:33450041	A/G	cg08999081	chr20:33150536	PIGU	-0.62	-5.24	-0.47	9.56e-7	Height;
THYM	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs17286411	0.750	rs12444594	chr16:71941912	A/T	cg03805757	chr16:71968109	PKD1L3	0.56	4.59	0.43	1.35e-5	Blood protein levels;
THYM	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg21724239	chr8:58056113	NA	0.98	6.89	0.58	6.11e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg05313129	chr8:58192883	C8orf71	-0.84	-4.82	-0.44	5.33e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg14983838	chr19:29218262	NA	1.08	9.53	0.7	1.66e-15	Methadone dose in opioid dependence;
THYM	cis	rs988913	1.000	rs9396007	chr6:54807622	T/A	cg04690482	chr6:54711388	FAM83B	0.5	5.32	0.48	6.99e-7	Menarche (age at onset);
THYM	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg07570687	chr10:102243282	WNT8B	0.77	7.04	0.59	3.04e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12367572	0.620	rs2643151	chr12:45410808	A/G	cg03114573	chr12:45410052	DBX2	-0.61	-5.93	-0.52	4.96e-8	Gut microbiome composition (summer);
THYM	cis	rs7084402	0.934	rs1579394	chr10:60294625	T/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.65e-7	Refractive error;
THYM	cis	rs3781426	0.793	rs4962722	chr10:126702698	A/T	cg04494136	chr10:126703576	CTBP2	-0.46	-6.86	-0.58	6.96e-10	Height;
THYM	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg14004847	chr7:1930337	MAD1L1	-0.68	-5.47	-0.49	3.71e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs929354	1.000	rs1182378	chr7:157048322	T/C	cg05182265	chr7:156933206	UBE3C	0.63	7.88	0.63	5.39e-12	Body mass index;
THYM	cis	rs5758511	0.514	rs5751222	chr22:42517922	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.66	6.84	0.57	7.82e-10	Birth weight;
THYM	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg27446573	chr6:127587934	RNF146	0.74	6.53	0.56	3.27e-9	Breast cancer;
THYM	cis	rs539096	0.500	rs2367804	chr1:44314266	C/T	cg15962314	chr1:44399869	ARTN	0.53	5.48	0.49	3.49e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg06808227	chr14:105710500	BRF1	-0.99	-8.33	-0.65	6.16e-13	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg10661904	chr17:79619235	PDE6G	0.53	4.74	0.44	7.56e-6	Eye color traits;
THYM	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg20486651	chr6:167070296	RPS6KA2	-0.46	-4.51	-0.42	1.82e-5	Crohn's disease;
THYM	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg07061783	chr6:25882402	NA	-0.89	-8.59	-0.66	1.73e-13	Intelligence (multi-trait analysis);
THYM	cis	rs1797885	0.564	rs2596820	chr3:12601941	G/A	cg05467012	chr3:12595696	NA	0.56	4.68	0.43	9.48e-6	Immature fraction of reticulocytes;
THYM	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs7078219	0.576	rs989979	chr10:101322423	C/G	cg04972745	chr10:101287846	NA	-0.53	-4.71	-0.44	8.33e-6	Dental caries;
THYM	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg18105134	chr13:113819100	PROZ	-1.15	-10.31	-0.73	3.57e-17	Platelet distribution width;
THYM	cis	rs3092073	0.617	rs3746513	chr20:44594228	G/A	cg23252815	chr20:44420276	WFDC3;DNTTIP1	-0.5	-5.2	-0.47	1.12e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2072510	0.683	rs2246973	chr12:96427875	A/C	cg18817487	chr12:96390143	HAL	0.34	4.56	0.42	1.5e-5	Metabolite levels (small molecules and protein measures);
THYM	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg17372223	chr3:52568218	NT5DC2	0.37	5.68	0.5	1.48e-7	Electroencephalogram traits;
THYM	cis	rs67311347	0.544	rs1454492	chr3:40352884	C/T	cg13683864	chr3:40499215	RPL14	-0.71	-6.34	-0.55	7.82e-9	Renal cell carcinoma;
THYM	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	8.87	0.67	4.33e-14	Chronic sinus infection;
THYM	cis	rs295137	0.836	rs1217429	chr2:201094151	G/T	cg22973789	chr2:200321011	SATB2	0.59	4.47	0.42	2.14e-5	Asthma (bronchodilator response);
THYM	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	0.67	5.5	0.49	3.15e-7	Blood metabolite levels;
THYM	cis	rs6754459	0.603	rs11894441	chr2:3701972	A/G	cg10645314	chr2:3704589	ALLC	0.75	5.99	0.52	3.65e-8	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg06637938	chr14:75390232	RPS6KL1	0.64	6.47	0.55	4.35e-9	Caffeine consumption;
THYM	cis	rs16854884	0.657	rs10513235	chr3:143698664	T/C	cg05063096	chr3:143689810	C3orf58	0.69	4.53	0.42	1.69e-5	Economic and political preferences (feminism/equality);
THYM	cis	rs899997	0.773	rs62010525	chr15:78968310	C/G	cg04896959	chr15:78267971	NA	-0.8	-5.61	-0.5	1.97e-7	Coronary artery disease or large artery stroke;
THYM	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg09263875	chr16:632152	PIGQ	0.7	5.71	0.51	1.27e-7	Height;
THYM	cis	rs12142240	0.698	rs10158236	chr1:46820896	G/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs988913	0.706	rs9475130	chr6:54925466	C/T	cg04690482	chr6:54711388	FAM83B	0.46	4.71	0.44	8.41e-6	Menarche (age at onset);
THYM	cis	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	-0.56	-5.69	-0.5	1.39e-7	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6570726	0.935	rs425731	chr6:145834151	A/G	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03517284	chr6:25882590	NA	-0.97	-8.54	-0.66	2.15e-13	Intelligence (multi-trait analysis);
THYM	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg06112835	chr11:68658793	MRPL21	0.43	6.17	0.53	1.69e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs7584330	0.554	rs76408976	chr2:238384784	C/T	cg08992911	chr2:238395768	MLPH	1.19	7.0	0.58	3.61e-10	Prostate cancer;
THYM	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg10523679	chr1:76189770	ACADM	0.92	9.81	0.71	4.17e-16	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4732038	0.510	rs55798822	chr7:134272131	T/C	cg06906464	chr7:134288099	NA	-0.51	-5.0	-0.46	2.59e-6	Longevity;
THYM	cis	rs10992471	0.651	rs10124058	chr9:95522882	G/A	cg14631576	chr9:95140430	CENPP	-0.95	-8.6	-0.66	1.58e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.54	5.83	0.51	7.56e-8	Schizophrenia;
THYM	cis	rs4820539	0.933	rs2267004	chr22:23459863	G/A	cg21100191	chr22:23484243	RTDR1	0.74	6.35	0.55	7.43e-9	Bone mineral density;
THYM	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22455342	chr2:225449267	CUL3	-0.97	-9.01	-0.68	2.14e-14	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg26384229	chr12:38710491	ALG10B	-0.95	-8.26	-0.65	8.67e-13	Morning vs. evening chronotype;
THYM	cis	rs240764	0.817	rs6938440	chr6:101152009	T/C	cg21058520	chr6:100914733	NA	0.6	5.37	0.48	5.6e-7	Neuroticism;
THYM	cis	rs6424115	0.679	rs2294495	chr1:24075876	C/T	cg15997130	chr1:24165203	NA	-0.73	-5.43	-0.49	4.33e-7	Immature fraction of reticulocytes;
THYM	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg09238746	chr17:78121135	EIF4A3	-1.11	-9.48	-0.7	2.13e-15	Yeast infection;
THYM	cis	rs854765	0.551	rs56886154	chr17:17831473	C/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	6.34	0.55	7.83e-9	Total body bone mineral density;
THYM	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg18761221	chr20:60518478	NA	-0.65	-5.18	-0.47	1.22e-6	Obesity-related traits;
THYM	cis	rs1018836	0.923	rs13277387	chr8:91633713	C/G	cg16814680	chr8:91681699	NA	-0.84	-6.98	-0.58	4.03e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg02640540	chr1:67518911	SLC35D1	0.64	4.68	0.43	9.37e-6	Lymphocyte percentage of white cells;
THYM	cis	rs9807989	0.765	rs13424006	chr2:102967236	T/C	cg03938978	chr2:103052716	IL18RAP	0.63	6.56	0.56	2.81e-9	Asthma;
THYM	cis	rs2273669	0.667	rs7759014	chr6:109351125	A/G	cg17117243	chr6:109341365	SESN1	-0.89	-5.24	-0.47	9.49e-7	Prostate cancer;
THYM	cis	rs1018836	0.923	rs9643298	chr8:91552502	G/A	cg16814680	chr8:91681699	NA	-0.79	-7.05	-0.59	2.89e-10	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.27	9.78	0.71	4.84e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs314370	1.000	rs314370	chr7:100453208	T/C	cg10426581	chr7:100472382	SRRT	1.13	9.05	0.68	1.81e-14	Resting heart rate;
THYM	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg04731861	chr2:219085781	ARPC2	-0.56	-5.39	-0.48	5.21e-7	Colorectal cancer;
THYM	cis	rs2303759	0.918	rs8107548	chr19:49870643	T/C	cg22133161	chr19:49891603	CCDC155	0.83	5.56	0.5	2.45e-7	Multiple sclerosis;
THYM	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.95	-8.08	-0.64	2.08e-12	Menarche (age at onset);
THYM	cis	rs2189812	0.588	rs274620	chr7:86272783	G/C	cg15331781	chr7:86274443	GRM3	0.4	4.51	0.42	1.82e-5	IgG glycosylation;
THYM	cis	rs4845875	0.557	rs4846054	chr1:11869230	C/T	cg25341925	chr1:11908058	NPPA	0.48	5.05	0.46	2.11e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs9297145	0.585	rs17147666	chr7:98781457	A/C	cg05967295	chr7:98741636	SMURF1	-0.68	-5.31	-0.48	7.22e-7	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg00744431	chr10:134226547	PWWP2B	-0.63	-4.96	-0.45	3.13e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs13256369	0.802	rs12680019	chr8:8561698	A/G	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	trans	rs877282	1.000	rs12773872	chr10:771939	T/C	cg22713356	chr15:30763199	NA	1.38	11.57	0.76	7.71e-20	Uric acid levels;
THYM	cis	rs9876781	1.000	rs3214041	chr3:48454468	C/T	cg06066452	chr3:48470258	PLXNB1	0.26	4.81	0.44	5.69e-6	Longevity;
THYM	cis	rs870825	0.929	rs72689278	chr4:185593718	C/T	cg04058563	chr4:185651563	MLF1IP	1.05	7.92	0.63	4.51e-12	Blood protein levels;
THYM	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg09877947	chr5:131593287	PDLIM4	0.65	5.59	0.5	2.15e-7	Blood metabolite levels;
THYM	cis	rs4849845	0.925	rs4100690	chr2:121027361	T/G	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs778371	0.874	rs938575	chr2:233768788	G/A	cg08000102	chr2:233561755	GIGYF2	-0.72	-5.67	-0.5	1.56e-7	Schizophrenia;
THYM	cis	rs3087591	0.922	rs2905879	chr17:29545431	T/A	cg24425628	chr17:29625626	OMG;NF1	0.65	5.62	0.5	1.92e-7	Hip circumference;
THYM	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.16	-7.35	-0.6	6.78e-11	Gut microbiome composition (summer);
THYM	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg06238570	chr21:40685208	BRWD1	0.9	6.67	0.56	1.72e-9	Cognitive function;
THYM	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs853679	0.550	rs1233699	chr6:28169158	A/T	cg08968635	chr6:28129556	ZNF389	0.68	5.58	0.5	2.25e-7	Depression;
THYM	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg14008862	chr17:28927542	LRRC37B2	0.86	4.51	0.42	1.83e-5	Body mass index;
THYM	cis	rs2229238	0.868	rs12408461	chr1:154512710	T/C	cg21262032	chr1:154437693	IL6R	-0.64	-5.79	-0.51	8.9e-8	Coronary heart disease;
THYM	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs4788570	0.615	rs11075894	chr16:71690030	C/T	cg06353428	chr16:71660113	MARVELD3	1.29	8.73	0.67	8.5e-14	Intelligence (multi-trait analysis);
THYM	cis	rs11711311	0.824	rs9833810	chr3:113363762	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.56	-4.69	-0.43	9.15e-6	IgG glycosylation;
THYM	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg27286337	chr10:134555280	INPP5A	-1.09	-11.63	-0.77	5.73e-20	Migraine;
THYM	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs9790314	0.967	rs6762645	chr3:160948349	T/G	cg04691961	chr3:161091175	C3orf57	-0.6	-5.01	-0.46	2.53e-6	Morning vs. evening chronotype;
THYM	cis	rs4481887	0.861	rs10888345	chr1:248447533	A/G	cg00666640	chr1:248458726	OR2T12	0.54	4.57	0.42	1.48e-5	Common traits (Other);
THYM	cis	rs11997175	0.819	rs6415400	chr8:33783714	C/T	ch.8.33884649F	chr8:33765107	NA	0.78	6.42	0.55	5.3e-9	Body mass index;
THYM	cis	rs3862030	0.720	rs11593526	chr10:104228017	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.66	-5.41	-0.49	4.72e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg06521331	chr12:34319734	NA	-0.83	-6.39	-0.55	6.15e-9	Morning vs. evening chronotype;
THYM	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.9	0.45	3.98e-6	Prudent dietary pattern;
THYM	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg00383909	chr3:49044727	WDR6	-0.95	-5.68	-0.5	1.47e-7	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs7828089	0.602	rs7005505	chr8:22276393	T/C	cg13512537	chr8:22265999	SLC39A14	-0.66	-4.99	-0.46	2.74e-6	Verbal declarative memory;
THYM	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6430585	0.528	rs660002	chr2:136723504	C/T	cg23851026	chr2:136556271	LCT	0.69	7.27	0.6	1.02e-10	Corneal structure;
THYM	cis	rs13256369	1.000	rs12547721	chr8:8570671	C/T	cg18904891	chr8:8559673	CLDN23	0.7	5.21	0.47	1.1e-6	Obesity-related traits;
THYM	cis	rs6964587	0.692	rs10227225	chr7:91571074	A/G	cg22709100	chr7:91322751	NA	-0.63	-4.67	-0.43	1e-5	Breast cancer;
THYM	cis	rs7084402	0.902	rs1649017	chr10:60288531	T/C	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.73	-4.5	-0.42	1.93e-5	Alzheimer's disease;
THYM	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	6.28	0.54	9.92e-9	Coronary artery disease;
THYM	cis	rs2712184	0.875	rs7586692	chr2:217674703	G/T	cg05032264	chr2:217675019	NA	-0.54	-4.68	-0.43	9.4e-6	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
THYM	cis	rs9876781	0.967	rs9864815	chr3:48434063	G/A	cg06066452	chr3:48470258	PLXNB1	0.26	4.88	0.45	4.26e-6	Longevity;
THYM	cis	rs9611565	0.525	rs9611549	chr22:41705909	C/G	cg03806693	chr22:41940476	POLR3H	-0.84	-7.2	-0.59	1.37e-10	Vitiligo;
THYM	cis	rs2447097	1.000	rs2447097	chr17:2278064	A/C	cg27406664	chr17:2294951	MNT	0.57	5.37	0.48	5.54e-7	Autism spectrum disorder;
THYM	cis	rs921665	0.748	rs1869421	chr2:3202068	G/T	cg16434511	chr2:3151078	NA	-0.84	-5.41	-0.49	4.61e-7	World class endurance athleticism;
THYM	cis	rs2066819	1.000	rs58852079	chr12:56706922	A/C	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs11574514	1.000	rs76944074	chr16:67951827	G/A	cg09738193	chr16:67926317	PSKH1	-0.92	-4.52	-0.42	1.77e-5	Crohn's disease;
THYM	cis	rs4911259	0.552	rs6058925	chr20:31465374	G/A	cg13636640	chr20:31349939	DNMT3B	-0.63	-6.16	-0.53	1.74e-8	Inflammatory bowel disease;
THYM	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg03806693	chr22:41940476	POLR3H	-0.99	-7.63	-0.62	1.82e-11	Vitiligo;
THYM	cis	rs36051895	0.658	rs10974910	chr9:5010091	G/A	cg02405213	chr9:5042618	JAK2	-1.06	-11.63	-0.77	5.86e-20	Pediatric autoimmune diseases;
THYM	cis	rs3820068	0.608	rs7516683	chr1:16020502	A/G	cg24675056	chr1:15929824	NA	-0.8	-6.32	-0.54	8.57e-9	Systolic blood pressure;
THYM	cis	rs7084402	0.935	rs10740732	chr10:60352888	G/A	cg09696939	chr10:60272079	BICC1	-0.48	-5.89	-0.52	5.85e-8	Refractive error;
THYM	cis	rs10992471	0.603	rs7850528	chr9:95208992	A/G	cg14631576	chr9:95140430	CENPP	-1.0	-9.75	-0.71	5.55e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs9462846	0.841	rs13206802	chr6:42871148	G/A	cg09436375	chr6:42928200	GNMT	-0.37	-4.51	-0.42	1.83e-5	Blood protein levels;
THYM	cis	rs4730268	0.821	rs7790720	chr7:107441502	A/G	cg18560240	chr7:107437656	SLC26A3	-0.94	-5.34	-0.48	6.34e-7	IgG glycosylation;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg13607311	chr6:144262258	PLAGL1	-0.89	-6.84	-0.57	7.58e-10	Depressive symptoms;
THYM	cis	rs6575793	0.935	rs7493101	chr14:101046043	G/A	cg13521842	chr14:101036202	BEGAIN	-0.5	-4.52	-0.42	1.78e-5	Menarche (age at onset);
THYM	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg18681998	chr4:17616180	MED28	0.92	8.87	0.67	4.37e-14	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.62	0.43	1.2e-5	Obesity-related traits;
THYM	cis	rs1499972	0.941	rs55689237	chr3:117554899	C/G	cg07612923	chr3:117604196	NA	1.39	5.67	0.5	1.56e-7	Schizophrenia;
THYM	cis	rs9902453	0.904	rs9900112	chr17:28282910	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.82	6.22	0.54	1.3e-8	Coffee consumption (cups per day);
THYM	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg16576083	chr14:105354267	KIAA0284	0.55	5.05	0.46	2.15e-6	IgG glycosylation;
THYM	cis	rs12216545	0.765	rs10254007	chr7:150253381	C/T	cg00323915	chr7:150264987	GIMAP4	-0.49	-4.47	-0.42	2.16e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7809950	0.678	rs75617662	chr7:107030439	G/A	cg23024343	chr7:107201750	COG5	-0.97	-7.95	-0.63	3.81e-12	Coronary artery disease;
THYM	cis	rs4731207	0.662	rs4283967	chr7:124540535	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs35934224	0.769	rs78190485	chr22:19858175	A/C	cg11182965	chr22:19864308	TXNRD2	-0.79	-4.93	-0.45	3.51e-6	Glaucoma (primary open-angle);
THYM	cis	rs3796352	1.000	rs7622420	chr3:53111069	A/G	cg07884673	chr3:53033167	SFMBT1	0.97	4.91	0.45	3.74e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg01579765	chr21:45077557	HSF2BP	-0.52	-8.49	-0.66	2.78e-13	Mean corpuscular volume;
THYM	cis	rs7084402	1.000	rs7910442	chr10:60270260	T/G	cg09696939	chr10:60272079	BICC1	0.47	5.48	0.49	3.52e-7	Refractive error;
THYM	cis	rs1957429	0.901	rs8009996	chr14:65351582	A/G	cg23373153	chr14:65346875	NA	1.07	6.45	0.55	4.75e-9	Pediatric areal bone mineral density (radius);
THYM	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg02493740	chr2:85810744	VAMP5	-0.64	-4.97	-0.45	2.97e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs2075230	0.705	rs1641521	chr17:7550143	T/C	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	-0.3	-4.46	-0.42	2.28e-5	Hormone measurements;
THYM	cis	rs10095849	0.680	rs13276944	chr8:39457035	G/A	cg22755526	chr8:38854673	TM2D2;ADAM9	-0.63	-4.65	-0.43	1.08e-5	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.73	6.7	0.57	1.44e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs12579753	1.000	rs7306395	chr12:82175867	A/G	cg07988820	chr12:82153109	PPFIA2	-0.78	-4.97	-0.45	2.92e-6	Resting heart rate;
THYM	cis	rs1729951	0.575	rs835642	chr3:136703365	A/T	cg21827317	chr3:136751795	NA	0.75	6.71	0.57	1.41e-9	Neuroticism;
THYM	cis	rs17006441	1.000	rs35408095	chr3:69842773	A/G	cg18496212	chr3:69797108	MITF	0.67	6.78	0.57	9.94e-10	Hemoglobin concentration;
THYM	cis	rs13177918	0.626	rs13175436	chr5:149830537	A/T	cg14059543	chr5:149831962	NA	-0.96	-7.76	-0.62	9.58e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs9435341	0.965	rs12401598	chr1:107580533	C/A	cg00944433	chr1:107599041	PRMT6	-0.41	-5.03	-0.46	2.27e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg10803722	chr21:46713166	LOC642852	-0.5	-6.28	-0.54	1.02e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22857025	chr5:266934	NA	-1.59	-10.2	-0.72	6.04e-17	Breast cancer;
THYM	cis	rs2637266	0.783	rs864676	chr10:78509385	A/G	cg18941641	chr10:78392320	NA	0.71	5.69	0.5	1.38e-7	Pulmonary function;
THYM	cis	rs2067615	0.524	rs10861646	chr12:107071182	C/T	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.16	-5.63	-0.5	1.85e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9790314	1.000	rs3849524	chr3:161015589	C/T	cg03342759	chr3:160939853	NMD3	-0.76	-6.6	-0.56	2.38e-9	Morning vs. evening chronotype;
THYM	cis	rs10781543	0.967	rs7851507	chr9:139328722	G/T	cg14115884	chr9:139300582	SDCCAG3	0.71	6.34	0.55	7.58e-9	Monocyte percentage of white cells;
THYM	cis	rs2658782	0.526	rs3020062	chr11:93061159	T/C	cg15737290	chr11:93063684	CCDC67	1.16	11.14	0.75	6.15e-19	Pulmonary function decline;
THYM	cis	rs7618501	0.699	rs3733135	chr3:49939587	G/A	cg24308560	chr3:49941425	MST1R	-0.77	-6.63	-0.56	2.03e-9	Intelligence (multi-trait analysis);
THYM	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg20503657	chr10:835505	NA	1.14	8.17	0.64	1.34e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs7584099	0.516	rs1234396	chr2:148785781	T/C	cg23727674	chr2:148602993	ACVR2A	0.54	4.75	0.44	7.34e-6	Response to statin therapy;
THYM	cis	rs6732160	0.588	rs13403748	chr2:73371475	T/C	cg24220031	chr2:73402428	NA	-0.73	-5.96	-0.52	4.26e-8	Intelligence (multi-trait analysis);
THYM	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg06271696	chr7:157225062	NA	-0.61	-4.58	-0.43	1.42e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs7246967	0.673	rs62120313	chr19:22877183	G/C	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs9649213	0.593	rs6947340	chr7:97912241	A/G	cg07830472	chr7:97983916	BAIAP2L1	0.47	4.95	0.45	3.16e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3126085	0.935	rs11204939	chr1:152200942	G/C	cg10321714	chr1:152280068	FLG	0.68	5.07	0.46	1.98e-6	Atopic dermatitis;
THYM	cis	rs7192750	0.586	rs8054175	chr16:71990424	G/A	cg06353428	chr16:71660113	MARVELD3	0.71	5.31	0.48	7.32e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg17911788	chr17:44343683	NA	0.71	6.76	0.57	1.09e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7772486	0.597	rs7746618	chr6:146281367	T/C	cg23711669	chr6:146136114	FBXO30	-0.85	-8.02	-0.64	2.76e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg08704250	chr15:31115839	NA	-0.49	-5.47	-0.49	3.64e-7	Huntington's disease progression;
THYM	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg05340658	chr4:99064831	C4orf37	0.54	4.55	0.42	1.61e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.83	-6.1	-0.53	2.25e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg10856724	chr12:34555212	NA	-0.76	-6.99	-0.58	3.85e-10	Morning vs. evening chronotype;
THYM	cis	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg01364799	chr7:75623366	TMEM120A	0.66	4.78	0.44	6.45e-6	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg02176678	chr2:219576539	TTLL4	0.7	7.0	0.58	3.61e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11186	0.504	rs7420035	chr2:189968260	T/C	cg11041835	chr2:189156425	GULP1	0.8	4.58	0.43	1.41e-5	Parkinson's disease;
THYM	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg03709012	chr19:19516395	GATAD2A	-0.81	-6.72	-0.57	1.35e-9	Tonsillectomy;
THYM	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg01448562	chr3:133502909	NA	0.82	6.84	0.57	7.51e-10	Iron status biomarkers;
THYM	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	cis	rs3096299	0.685	rs2911244	chr16:89521860	A/G	cg06640241	chr16:89574553	SPG7	0.89	8.23	0.64	1e-12	Multiple myeloma (IgH translocation);
THYM	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg05234568	chr11:5960015	NA	-0.63	-5.58	-0.5	2.3e-7	DNA methylation (variation);
THYM	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg26384229	chr12:38710491	ALG10B	-0.82	-8.17	-0.64	1.32e-12	Heart rate;
THYM	cis	rs526231	0.543	rs257302	chr5:102416130	G/T	cg23492399	chr5:102201601	PAM	-0.67	-4.96	-0.45	3.05e-6	Primary biliary cholangitis;
THYM	cis	rs55728055	0.661	rs62237796	chr22:31976578	T/G	cg10537193	chr22:32026975	PISD	-0.87	-5.53	-0.49	2.78e-7	Age-related hearing impairment;
THYM	cis	rs7681440	0.583	rs1551980	chr4:90774724	G/A	cg06632027	chr4:90757378	SNCA	-0.66	-5.29	-0.48	7.91e-7	Dementia with Lewy bodies;
THYM	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg11266682	chr4:10021025	SLC2A9	0.67	9.44	0.7	2.59e-15	Bone mineral density;
THYM	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs888194	0.677	rs10850139	chr12:109875934	A/C	cg10504392	chr12:110044639	NA	0.6	5.49	0.49	3.28e-7	Neuroticism;
THYM	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.15	-11.35	-0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs6570726	0.818	rs437147	chr6:145875423	A/T	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3784262	0.528	rs8027188	chr15:58334799	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.66	-5.05	-0.46	2.13e-6	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
THYM	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg02725872	chr8:58115012	NA	-1.09	-6.87	-0.58	6.64e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg24675056	chr1:15929824	NA	0.73	5.89	0.52	5.95e-8	Systolic blood pressure;
THYM	cis	rs40363	0.680	rs4010628	chr16:3529779	G/A	cg05754148	chr16:3507555	NAT15	0.9	7.24	0.6	1.17e-10	Tuberculosis;
THYM	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg00071950	chr4:10020882	SLC2A9	0.77	7.71	0.62	1.24e-11	Bone mineral density;
THYM	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06481639	chr22:41940642	POLR3H	0.87	6.0	0.52	3.51e-8	Vitiligo;
THYM	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	9.39	0.69	3.37e-15	Chronic sinus infection;
THYM	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.77	6.94	0.58	4.86e-10	Prudent dietary pattern;
THYM	cis	rs11690935	0.550	rs55653103	chr2:172861816	T/C	cg13550731	chr2:172543902	DYNC1I2	0.63	4.84	0.44	4.98e-6	Schizophrenia;
THYM	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg26384229	chr12:38710491	ALG10B	0.98	7.63	0.62	1.82e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6956675	0.830	rs4585626	chr7:62671592	C/G	cg27518014	chr7:62859535	LOC100287834	-0.69	-5.33	-0.48	6.47e-7	Obesity-related traits;
THYM	cis	rs7772486	0.727	rs11155442	chr6:146140725	T/C	cg13319975	chr6:146136371	FBXO30	-0.64	-5.33	-0.48	6.48e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg27494647	chr7:150038898	RARRES2	0.39	4.55	0.42	1.61e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2303759	0.626	rs12982246	chr19:49801169	A/G	cg22133161	chr19:49891603	CCDC155	0.75	4.97	0.45	2.94e-6	Multiple sclerosis;
THYM	cis	rs13315871	0.929	rs1045115	chr3:58305199	C/T	cg12435725	chr3:58293450	RPP14	-0.53	-5.51	-0.49	3.09e-7	Cholesterol, total;
THYM	cis	rs7592578	0.882	rs58568707	chr2:191468987	G/A	cg11845111	chr2:191398756	TMEM194B	-1.0	-7.65	-0.62	1.66e-11	Diastolic blood pressure;
THYM	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg03609598	chr5:56110824	MAP3K1	-0.86	-5.8	-0.51	8.78e-8	Initial pursuit acceleration;
THYM	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.64	-0.5	1.73e-7	Menopause (age at onset);
THYM	cis	rs11792861	0.566	rs6477687	chr9:111837791	A/T	cg05043794	chr9:111880884	C9orf5	0.3	4.47	0.42	2.18e-5	Menarche (age at onset);
THYM	cis	rs4792901	0.685	rs9898065	chr17:41562473	T/G	cg21940313	chr17:41620911	ETV4	-0.55	-5.42	-0.49	4.55e-7	Dupuytren's disease;
THYM	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg24675658	chr1:53192096	ZYG11B	0.57	4.69	0.43	9.26e-6	Monocyte count;
THYM	cis	rs2901656	0.875	rs7516301	chr1:172372260	T/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.48	4.99	0.46	2.76e-6	Red cell distribution width;Platelet distribution width;
THYM	cis	rs4974559	0.594	rs11946384	chr4:1313566	T/C	cg02980000	chr4:1222292	CTBP1	0.78	5.19	0.47	1.17e-6	Systolic blood pressure;
THYM	cis	rs7631605	0.905	rs931721	chr3:37211972	T/C	cg21328643	chr3:37258149	NA	-0.51	-4.96	-0.45	3.08e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-5.9	-0.52	5.6e-8	Total cholesterol levels;
THYM	cis	rs7104764	1.000	rs76552490	chr11:212015	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	-1.12	-9.8	-0.71	4.34e-16	Menarche (age at onset);
THYM	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg20007245	chr22:24372913	LOC391322	-0.71	-6.25	-0.54	1.15e-8	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs72781680	1.000	rs56205282	chr2:24221317	C/T	cg08917208	chr2:24149416	ATAD2B	1.11	4.95	0.45	3.17e-6	Lymphocyte counts;
THYM	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	5.22	0.47	1.03e-6	Hip circumference adjusted for BMI;
THYM	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg06481639	chr22:41940642	POLR3H	-0.78	-6.06	-0.53	2.77e-8	Vitiligo;
THYM	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg10589385	chr1:150898437	SETDB1	0.59	4.68	0.43	9.37e-6	Melanoma;
THYM	cis	rs7224737	0.956	rs8081900	chr17:40289875	G/A	cg02228675	chr17:40259724	DHX58	-0.62	-5.13	-0.47	1.55e-6	Fibrinogen levels;
THYM	cis	rs1971762	0.583	rs1864448	chr12:54087856	T/G	cg16917193	chr12:54089295	NA	0.96	9.59	0.7	1.24e-15	Height;
THYM	cis	rs2302777	0.507	rs9889716	chr17:38108298	A/G	cg24910161	chr17:38119198	GSDMA	-0.58	-6.31	-0.54	8.93e-9	Multiple myeloma (hyperdiploidy);
THYM	cis	rs10769945	0.606	rs217236	chr11:1981259	T/C	cg18511798	chr11:2018149	H19;MIR675	0.51	4.69	0.43	9.21e-6	DNA methylation (variation);
THYM	trans	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg19862616	chr7:65841803	NCRNA00174	1.08	13.0	0.8	8.28e-23	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs11009175	0.725	rs4934646	chr10:33296609	C/T	cg00146027	chr10:33299147	NA	-0.76	-5.23	-0.47	1e-6	Depression (quantitative trait);
THYM	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg25427524	chr10:38739819	LOC399744	-0.64	-6.03	-0.53	3.1e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2233152	0.656	rs2287691	chr19:41286163	C/G	cg26767443	chr19:41316244	NA	0.7	4.45	0.42	2.37e-5	Kawasaki disease;
THYM	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.87	0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs12681287	0.640	rs13280468	chr8:87338452	C/T	cg27223183	chr8:87520930	FAM82B	-0.7	-5.3	-0.48	7.65e-7	Caudate activity during reward;
THYM	cis	rs9674544	0.556	rs1390154	chr17:47071483	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.45	-6.28	-0.54	1.01e-8	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
THYM	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg14159672	chr1:205819179	PM20D1	0.59	4.63	0.43	1.15e-5	Parkinson's disease;
THYM	cis	rs10931896	0.531	rs295117	chr2:201146828	C/T	cg17644776	chr2:200775616	C2orf69	0.66	5.31	0.48	7.26e-7	Systolic blood pressure;
THYM	cis	rs2997447	0.761	rs61776616	chr1:26455812	C/T	cg03844060	chr1:26490628	NA	0.69	4.84	0.44	5.01e-6	QRS complex (12-leadsum);
THYM	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg22105103	chr4:187893119	NA	0.88	9.57	0.7	1.35e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg16680214	chr1:154839983	KCNN3	-0.48	-5.39	-0.48	5.19e-7	Prostate cancer;
THYM	cis	rs6674176	0.597	rs4660262	chr1:44382524	G/A	cg15962314	chr1:44399869	ARTN	0.54	5.15	0.47	1.42e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs1003719	0.680	rs2835620	chr21:38505581	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-4.75	-0.44	7.3e-6	Eye color traits;
THYM	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg16031515	chr1:205743344	RAB7L1	-0.7	-7.15	-0.59	1.78e-10	Menarche (age at onset);
THYM	cis	rs539096	0.872	rs631248	chr1:44071221	C/T	cg00143623	chr1:44495758	SLC6A9	0.64	5.03	0.46	2.35e-6	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.73	4.66	0.43	1.05e-5	Diabetic retinopathy;
THYM	cis	rs2797160	1.000	rs1739375	chr6:126012013	T/C	cg16306078	chr6:126000798	NA	0.54	5.47	0.49	3.72e-7	Endometrial cancer;
THYM	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg06623918	chr6:96969491	KIAA0776	-1.03	-10.65	-0.74	6.92e-18	Headache;
THYM	cis	rs919433	0.647	rs2045242	chr2:198507649	G/A	cg00792783	chr2:198669748	PLCL1	0.81	5.31	0.48	7.04e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21659725	chr3:3221576	CRBN	0.9	9.83	0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg25767906	chr1:53392781	SCP2	-0.45	-4.45	-0.42	2.34e-5	Monocyte count;
THYM	trans	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Bladder cancer;
THYM	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg09323728	chr8:95962352	TP53INP1	-0.48	-4.93	-0.45	3.54e-6	Type 2 diabetes;
THYM	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg08901578	chr4:187885870	NA	-0.65	-6.08	-0.53	2.53e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg00012203	chr2:219082015	ARPC2	0.65	5.63	0.5	1.86e-7	Colorectal cancer;
THYM	cis	rs10905065	0.829	rs2246399	chr10:5799286	T/A	cg11519256	chr10:5708881	ASB13	-0.49	-4.68	-0.43	9.35e-6	Menopause (age at onset);
THYM	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	4.63	0.43	1.15e-5	Schizophrenia;
THYM	cis	rs8013055	0.796	rs28662250	chr14:105996341	C/G	cg23356831	chr14:105996513	TMEM121	0.61	6.28	0.54	1.01e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg12011299	chr4:100065546	ADH4	0.85	8.12	0.64	1.67e-12	Alcohol dependence;
THYM	cis	rs4430311	0.965	rs3008660	chr1:244024703	T/G	cg25706552	chr1:244017396	NA	-0.59	-5.34	-0.48	6.41e-7	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs11685299	1	rs11685299	chr2:225391296	C/A	cg22455342	chr2:225449267	CUL3	0.68	4.9	0.45	3.87e-6	Schizophrenia;
THYM	cis	rs2502731	0.561	rs3003606	chr9:130982416	C/T	cg09976142	chr9:130955436	CIZ1	0.52	5.01	0.46	2.48e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs600806	0.888	rs461200	chr1:109855404	G/A	cg02175308	chr1:109941060	SORT1	-0.54	-4.72	-0.44	8.03e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9807989	0.507	rs6543133	chr2:103040177	A/T	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs323167	0.723	rs321969	chr7:78313673	G/A	cg20996682	chr7:79084048	MAGI2	-0.59	-4.5	-0.42	1.9e-5	Schizophrenia;
THYM	cis	rs11096990	0.821	rs76235093	chr4:39282777	G/A	cg24403649	chr4:39172243	NA	-0.69	-5.2	-0.47	1.13e-6	Cognitive function;
THYM	cis	rs2050392	1.000	rs2265185	chr10:30691777	A/C	cg02070205	chr10:30722105	MAP3K8	-0.52	-4.67	-0.43	1e-5	Inflammatory bowel disease;
THYM	cis	rs1113500	0.933	rs12132785	chr1:108633083	A/T	cg06207961	chr1:108661230	NA	0.64	5.09	0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg26513180	chr16:89883248	FANCA	-0.67	-6.38	-0.55	6.39e-9	Vitiligo;
THYM	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg23332699	chr15:44069569	ELL3	0.73	4.71	0.43	8.55e-6	Lung cancer in ever smokers;
THYM	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10887741	0.690	rs12781358	chr10:89444367	C/T	cg13926569	chr10:89418898	PAPSS2	0.6	6.44	0.55	4.88e-9	Exercise (leisure time);
THYM	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.78	4.99	0.46	2.76e-6	Smoking behavior;
THYM	cis	rs1669338	0.588	rs7629889	chr3:3187643	C/T	cg16797762	chr3:3221439	CRBN	-0.91	-5.11	-0.46	1.68e-6	White matter integrity;
THYM	trans	rs75518195	0.543	rs4560443	chr4:64716361	C/T	cg14706739	chr8:21916355	EPB49	0.76	7.25	0.6	1.09e-10	Triptolide cytotoxicity;
THYM	cis	rs7172809	0.599	rs74026912	chr15:77730856	G/A	cg22256960	chr15:77711686	NA	-0.62	-4.57	-0.42	1.45e-5	Glucose homeostasis traits;
THYM	cis	rs10208649	0.908	rs11889527	chr2:54226315	A/G	cg04546899	chr2:54196757	PSME4	0.67	4.66	0.43	1.05e-5	Body mass index;
THYM	cis	rs7172809	0.897	rs1317320	chr15:77830090	G/A	cg10437265	chr15:77819839	NA	-0.55	-4.86	-0.45	4.68e-6	Glucose homeostasis traits;
THYM	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg03929089	chr4:120376271	NA	-0.99	-13.22	-0.8	2.95e-23	Height;
THYM	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.1	12.7	0.79	3.51e-22	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg00256281	chr22:41985642	PMM1	0.54	4.5	0.42	1.94e-5	Vitiligo;
THYM	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19346786	chr7:2764209	NA	0.79	7.2	0.59	1.37e-10	Height;
THYM	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.1	7.58	0.61	2.26e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs28595532	0.841	rs114735834	chr4:119772722	G/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	trans	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg19862616	chr7:65841803	NCRNA00174	1.09	12.64	0.79	4.47e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6430585	0.527	rs961360	chr2:136393658	A/G	cg23851026	chr2:136556271	LCT	0.64	5.84	0.51	7.37e-8	Corneal structure;
THYM	cis	rs12579753	0.956	rs7309624	chr12:82204266	C/A	cg21231944	chr12:82153410	PPFIA2	-0.65	-4.87	-0.45	4.42e-6	Resting heart rate;
THYM	cis	rs4343996	0.714	rs10268837	chr7:3467366	T/C	cg21248987	chr7:3385318	SDK1	0.39	4.69	0.43	9e-6	Motion sickness;
THYM	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg12698349	chr2:225449008	CUL3	-0.73	-5.47	-0.49	3.64e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs7219021	0.743	rs575556	chr17:46857487	A/C	cg09029085	chr17:47094198	IGF2BP1	-0.34	-4.46	-0.42	2.27e-5	Schizophrenia or bipolar disorder;
THYM	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.45	-0.55	4.59e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7312774	0.618	rs4964500	chr12:107320788	T/C	cg16260113	chr12:107380972	MTERFD3	1.34	6.39	0.55	6.14e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.53	0.49	2.84e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9399401	0.633	rs1329705	chr6:142753338	G/A	cg04461802	chr6:142623433	GPR126	0.76	7.38	0.6	5.91e-11	Chronic obstructive pulmonary disease;
THYM	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg18681998	chr4:17616180	MED28	0.97	9.74	0.71	5.95e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	trans	rs8073060	0.544	rs225283	chr17:33934912	A/G	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg12564285	chr5:131593104	PDLIM4	0.5	5.63	0.5	1.84e-7	Breast cancer;
THYM	cis	rs250585	0.736	rs250551	chr16:23440611	C/G	cg00143387	chr16:23521605	GGA2	0.74	5.27	0.48	8.6e-7	Egg allergy;
THYM	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg10515332	chr4:99064459	C4orf37	0.58	4.54	0.42	1.67e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11112613	0.713	rs2374502	chr12:105938939	T/C	cg03607813	chr12:105948248	NA	1.06	8.98	0.68	2.52e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
THYM	cis	rs4731207	0.698	rs12666427	chr7:124479352	A/G	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs12960472	0.539	rs7239027	chr18:52310887	A/G	cg26630735	chr18:52626848	CCDC68	-0.71	-4.56	-0.42	1.55e-5	Positive affect;
THYM	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg18240062	chr17:79603768	NPLOC4	0.73	6.55	0.56	2.9e-9	Eye color traits;
THYM	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg06112835	chr11:68658793	MRPL21	0.43	6.08	0.53	2.48e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs514406	0.798	rs576650	chr1:53327207	C/T	cg08736216	chr1:53307985	ZYG11A	-0.62	-5.47	-0.49	3.63e-7	Monocyte count;
THYM	cis	rs6499255	0.951	rs3169315	chr16:69720964	G/A	cg00738113	chr16:70207722	CLEC18C	-0.45	-4.57	-0.42	1.49e-5	IgE levels;
THYM	cis	rs7084402	0.967	rs1626606	chr10:60328088	C/T	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg24675658	chr1:53192096	ZYG11B	0.55	4.66	0.43	1.04e-5	Monocyte count;
THYM	cis	rs425277	1.000	rs74877653	chr1:2065949	C/T	cg23682913	chr1:2080710	PRKCZ	0.6	4.83	0.44	5.19e-6	Height;
THYM	trans	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg10856724	chr12:34555212	NA	-0.8	-6.99	-0.58	3.71e-10	Bladder cancer;
THYM	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg18876405	chr7:65276391	NA	0.72	6.83	0.57	7.86e-10	Calcium levels;
THYM	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg09307838	chr4:120376055	NA	0.7	4.95	0.45	3.15e-6	Corneal astigmatism;
THYM	cis	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg13443165	chr9:33130375	B4GALT1	-0.86	-7.96	-0.63	3.71e-12	IgG glycosylation;
THYM	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg26924012	chr15:45694286	SPATA5L1	0.66	4.86	0.45	4.69e-6	Response to fenofibrate (adiponectin levels);
THYM	cis	rs4936891	0.577	rs1453650	chr11:123921929	A/G	cg22125253	chr11:123886957	OR10G4	-0.54	-4.56	-0.42	1.53e-5	Male fertility;
THYM	cis	rs7610301	1.000	rs6787465	chr3:46645609	C/T	cg10242476	chr3:46619364	LRRC2;TDGF1	0.45	4.48	0.42	2.07e-5	Blood protein levels;
THYM	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.85	9.15	0.68	1.07e-14	Menarche (age at onset);
THYM	trans	rs10802346	0.545	rs10802345	chr1:246372834	C/T	cg22732515	chr19:44031385	ETHE1	1.06	9.24	0.69	7.1e-15	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs34638657	0.872	rs2967326	chr16:82188246	A/G	cg19807685	chr16:82068980	HSD17B2	-0.66	-5.08	-0.46	1.85e-6	Lung adenocarcinoma;
THYM	cis	rs10779751	0.770	rs1417131	chr1:11191922	T/C	cg08854313	chr1:11322531	MTOR	-0.72	-5.45	-0.49	3.89e-7	Body mass index;
THYM	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg02725872	chr8:58115012	NA	-0.97	-7.19	-0.59	1.48e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg18811423	chr2:55921094	PNPT1	0.69	6.42	0.55	5.24e-9	Metabolic syndrome;
THYM	trans	rs4866334	1.000	rs80012640	chr5:18455247	C/T	cg08675002	chr5:90437527	GPR98	-1.55	-7.42	-0.61	4.85e-11	IgG glycosylation;
THYM	cis	rs3008870	0.959	rs2985810	chr1:67376162	T/C	cg02640540	chr1:67518911	SLC35D1	0.64	4.6	0.43	1.33e-5	Lymphocyte percentage of white cells;
THYM	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7084402	0.967	rs1658459	chr10:60299246	C/A	cg07615347	chr10:60278583	BICC1	0.55	5.04	0.46	2.21e-6	Refractive error;
THYM	cis	rs611744	0.870	rs381742	chr8:109142079	G/T	cg21045802	chr8:109455806	TTC35	0.58	4.94	0.45	3.3e-6	Dupuytren's disease;
THYM	cis	rs7226229	1.000	rs2291036	chr17:20922702	G/C	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs1021993	0.868	rs906351	chr1:209527925	C/T	cg24997231	chr1:209527535	NA	-0.54	-4.5	-0.42	1.92e-5	Gut microbiome composition (winter);
THYM	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg05896524	chr21:47604654	C21orf56	-0.6	-4.51	-0.42	1.86e-5	Testicular germ cell tumor;
THYM	cis	rs1371867	0.846	rs2439460	chr8:101312665	C/T	cg00191853	chr8:101177733	SPAG1	-0.51	-5.03	-0.46	2.29e-6	Atrioventricular conduction;
THYM	cis	rs4638749	0.677	rs12329189	chr2:108812855	T/C	cg06795125	chr2:108905320	SULT1C2	-0.38	-4.9	-0.45	4.01e-6	Blood pressure;
THYM	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.2	-0.47	1.13e-6	Hemoglobin concentration;
THYM	cis	rs7333764	0.744	rs3737042	chr13:34185191	A/C	cg16285566	chr13:33682212	STARD13	-1.18	-4.51	-0.42	1.85e-5	CTACK levels;
THYM	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg06784218	chr1:46089804	CCDC17	0.3	4.52	0.42	1.76e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg11214544	chr1:2391121	NA	-0.65	-6.03	-0.53	3.13e-8	Non-obstructive azoospermia;
THYM	trans	rs877282	0.853	rs7069720	chr10:754487	A/G	cg22713356	chr15:30763199	NA	1.27	9.37	0.69	3.62e-15	Uric acid levels;
THYM	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.82	-5.46	-0.49	3.79e-7	Yeast infection;
THYM	cis	rs2970992	0.817	rs10176262	chr2:101335019	A/G	cg01042948	chr2:101319752	NA	-0.59	-5.84	-0.51	7.15e-8	Educational attainment;
THYM	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg25358565	chr5:93447407	FAM172A	1.31	11.12	0.75	6.98e-19	Diabetic retinopathy;
THYM	cis	rs34638657	0.872	rs7202258	chr16:82195013	T/C	cg07307142	chr16:82071433	HSD17B2	-1.01	-8.24	-0.65	9.59e-13	Lung adenocarcinoma;
THYM	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg02574844	chr11:5959923	NA	-0.54	-4.75	-0.44	7.09e-6	DNA methylation (variation);
THYM	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg06387496	chr7:2775674	GNA12	-0.43	-4.47	-0.42	2.2e-5	Height;
THYM	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg23989207	chr17:80870107	TBCD	0.59	4.84	0.44	4.99e-6	Glycated hemoglobin levels;
THYM	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg02869364	chr7:1081709	C7orf50	-0.61	-4.91	-0.45	3.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2811415	0.597	rs9873723	chr3:127729071	G/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg08807101	chr21:30365312	RNF160	0.94	7.65	0.62	1.66e-11	Dental caries;
THYM	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg14675211	chr2:100938903	LONRF2	0.76	7.95	0.63	3.85e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7772486	0.875	rs9322045	chr6:146384950	C/G	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7224737	1.000	rs11079034	chr17:40288890	G/A	cg20291162	chr17:40259547	DHX58	-0.7	-6.56	-0.56	2.78e-9	Fibrinogen levels;
THYM	cis	rs56309584	0.673	rs11651993	chr17:8115774	A/G	cg11257113	chr17:8062204	NA	-0.63	-4.69	-0.43	9.25e-6	Initial pursuit acceleration;
THYM	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg12564285	chr5:131593104	PDLIM4	0.44	4.57	0.42	1.46e-5	Blood metabolite levels;
THYM	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg15704280	chr7:45808275	SEPT13	-1.02	-8.31	-0.65	6.7e-13	Coronary artery disease;
THYM	cis	rs1062746	0.771	rs9308348	chr16:87371941	G/A	cg27119004	chr16:87376851	FBXO31	0.52	5.22	0.47	1.04e-6	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs11948739	0.573	rs6595970	chr5:130304557	C/A	cg08523029	chr5:130500466	HINT1	-0.79	-5.59	-0.5	2.2e-7	Pediatric bone mineral content (hip);
THYM	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg08975724	chr8:8085496	FLJ10661	0.67	4.87	0.45	4.51e-6	Neuroticism;
THYM	cis	rs7616559	0.512	rs1482866	chr3:156716741	A/C	cg15697575	chr3:156784781	NA	0.35	5.27	0.48	8.46e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs9653442	0.675	rs12995420	chr2:100652578	T/C	cg22139774	chr2:100720529	AFF3	-0.33	-4.89	-0.45	4.02e-6	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg12573674	chr2:1569213	NA	-1.39	-9.03	-0.68	1.95e-14	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs1843834	0.898	rs4674936	chr2:225553731	C/T	cg22455342	chr2:225449267	CUL3	0.6	4.62	0.43	1.23e-5	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs6430585	0.528	rs721765	chr2:136748779	C/A	cg04750100	chr2:136595281	LCT	0.56	4.94	0.45	3.41e-6	Corneal structure;
THYM	cis	rs34912216	0.542	rs13236488	chr7:4128872	A/G	cg03141780	chr7:4150753	SDK1	0.68	4.82	0.44	5.43e-6	Motion sickness;
THYM	cis	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg24308560	chr3:49941425	MST1R	-0.61	-4.92	-0.45	3.63e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7731657	0.537	rs10478958	chr5:130333536	C/A	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs9902453	0.904	rs8071742	chr17:28361669	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg14517863	chr17:44321492	NA	-0.44	-5.0	-0.46	2.59e-6	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg20295408	chr7:1910781	MAD1L1	-0.6	-4.78	-0.44	6.27e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs61931739	0.517	rs10844738	chr12:34059503	T/A	cg06521331	chr12:34319734	NA	-0.95	-9.13	-0.68	1.19e-14	Morning vs. evening chronotype;
THYM	cis	rs7980799	0.649	rs7972688	chr12:33653477	T/C	cg06521331	chr12:34319734	NA	0.66	4.62	0.43	1.22e-5	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg03433033	chr1:76189801	ACADM	-0.51	-5.31	-0.48	7.2e-7	Daytime sleep phenotypes;
THYM	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg17264618	chr3:40429014	ENTPD3	0.52	4.87	0.45	4.42e-6	Renal cell carcinoma;
THYM	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg10018233	chr7:150070692	REPIN1	0.38	5.42	0.49	4.46e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs8170	0.603	rs7249329	chr19:17423373	G/T	cg04749549	chr19:17459798	NA	-0.42	-5.16	-0.47	1.36e-6	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
THYM	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg17264618	chr3:40429014	ENTPD3	0.49	4.69	0.43	9.06e-6	Renal cell carcinoma;
THYM	cis	rs6539288	0.933	rs2053205	chr12:107306267	A/G	cg26297688	chr12:107349093	C12orf23	-0.47	-4.89	-0.45	4.15e-6	Total body bone mineral density;
THYM	cis	rs986417	0.818	rs6573319	chr14:61091913	C/G	cg27398547	chr14:60952738	C14orf39	1.08	5.23	0.47	1.01e-6	Gut microbiota (bacterial taxa);
THYM	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg22920501	chr2:26401640	FAM59B	-0.8	-7.19	-0.59	1.44e-10	Gut microbiome composition (summer);
THYM	cis	rs12701220	0.762	rs10247470	chr7:1092512	C/G	cg01699819	chr7:1052092	C7orf50	-0.67	-5.78	-0.51	9.62e-8	Bronchopulmonary dysplasia;
THYM	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg24675658	chr1:53192096	ZYG11B	-0.74	-6.51	-0.56	3.55e-9	Monocyte count;
THYM	cis	rs7940866	0.738	rs10791114	chr11:130889850	G/A	cg23692386	chr11:131799662	NTM	0.44	4.75	0.44	7.2e-6	Schizophrenia;
THYM	cis	rs2562456	0.874	rs2562408	chr19:21709881	C/G	cg21751540	chr19:21541537	ZNF738	0.66	4.6	0.43	1.3e-5	Pain;
THYM	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg02527881	chr3:46936655	PTH1R	0.56	5.26	0.47	9.05e-7	Colorectal cancer;
THYM	cis	rs6754311	0.773	rs4988226	chr2:136610598	A/G	cg07169764	chr2:136633963	MCM6	-0.72	-6.25	-0.54	1.18e-8	Mosquito bite size;
THYM	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg16586182	chr3:47516702	SCAP	-0.6	-5.16	-0.47	1.34e-6	Colorectal cancer;
THYM	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03647317	chr4:187891568	NA	-0.83	-9.53	-0.7	1.69e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10924970	0.967	rs7553200	chr1:235467940	C/T	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs10751667	1.000	rs7396366	chr11:986185	C/A	cg01483505	chr11:975446	AP2A2	0.63	4.98	0.45	2.88e-6	Alzheimer's disease (late onset);
THYM	cis	rs861020	1.000	rs622832	chr1:209974232	A/C	cg05527609	chr1:210001259	C1orf107	0.94	7.36	0.6	6.5500000000000006e-11	Orofacial clefts;
THYM	cis	rs5769765	1.000	rs2319458	chr22:50236306	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	4.75	0.44	7.17e-6	Schizophrenia;
THYM	cis	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg06521331	chr12:34319734	NA	-1.02	-10.14	-0.72	8.47e-17	Morning vs. evening chronotype;
THYM	cis	rs854765	0.583	rs8070722	chr17:17813562	C/T	cg04398451	chr17:18023971	MYO15A	-0.76	-6.96	-0.58	4.39e-10	Total body bone mineral density;
THYM	cis	rs11989744	1.000	rs34389484	chr8:23572963	T/G	cg04349084	chr8:23602677	NA	0.5	5.21	0.47	1.09e-6	Waist-hip ratio;
THYM	cis	rs1018836	0.851	rs6986359	chr8:91643162	A/G	cg16814680	chr8:91681699	NA	-0.99	-9.24	-0.69	7.07e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg00686598	chr14:53173677	PSMC6	1.39	7.01	0.58	3.52e-10	Alzheimer's disease (late onset);
THYM	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11644478	chr21:40555479	PSMG1	-0.82	-7.39	-0.6	5.7e-11	Cognitive function;
THYM	cis	rs4780401	0.728	rs6498239	chr16:11780774	T/C	cg01061890	chr16:11836724	TXNDC11	-0.62	-4.56	-0.42	1.5e-5	Rheumatoid arthritis;
THYM	cis	rs35264875	0.846	rs72930625	chr11:68867120	T/A	cg01993067	chr11:68851601	TPCN2	0.98	4.96	0.45	3.11e-6	Blond vs. brown hair color;
THYM	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.0	9.81	0.71	4.11e-16	Colorectal cancer;
THYM	cis	rs425277	0.917	rs78609670	chr1:2045886	G/T	cg13918804	chr1:2043761	PRKCZ	-0.65	-4.73	-0.44	7.73e-6	Height;
THYM	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg22974920	chr21:40686053	BRWD1	0.58	4.46	0.42	2.29e-5	Cognitive function;
THYM	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.5	-4.96	-0.45	3.07e-6	Crohn's disease;
THYM	cis	rs400736	0.930	rs442862	chr1:8079494	T/C	cg22678073	chr1:8087421	ERRFI1	0.45	4.79	0.44	6.13e-6	Response to antidepressants and depression;
THYM	cis	rs7246967	0.673	rs73022713	chr19:22876222	G/C	cg05241461	chr19:22816980	ZNF492	0.58	4.52	0.42	1.77e-5	Bronchopulmonary dysplasia;
THYM	cis	rs5753037	0.838	rs131293	chr22:30171031	T/G	cg27665648	chr22:30112403	NA	0.51	4.53	0.42	1.68e-5	Type 1 diabetes;
THYM	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg09307838	chr4:120376055	NA	0.64	4.65	0.43	1.05e-5	Corneal astigmatism;
THYM	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg12615879	chr12:58013172	SLC26A10	-0.64	-5.79	-0.51	9.07e-8	Multiple sclerosis;
THYM	cis	rs35883536	0.588	rs955337	chr1:101108834	A/T	cg06223162	chr1:101003688	GPR88	0.62	5.52	0.49	2.96e-7	Monocyte count;
THYM	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg18252515	chr7:66147081	NA	-1.43	-8.54	-0.66	2.19e-13	Diabetic kidney disease;
THYM	cis	rs7104764	0.957	rs519592	chr11:236811	G/A	cg18336825	chr11:236787	PSMD13;SIRT3	1.26	11.69	0.77	4.31e-20	Menarche (age at onset);
THYM	cis	rs4919687	0.550	rs12784517	chr10:104464970	T/C	cg18761893	chr10:103892519	PPRC1	0.61	4.69	0.43	9.13e-6	Colorectal cancer;
THYM	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg15536230	chr21:44985092	HSF2BP	-0.4	-4.83	-0.44	5.29e-6	Mean corpuscular volume;
THYM	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg01579765	chr21:45077557	HSF2BP	-0.5	-7.67	-0.62	1.51e-11	Mean corpuscular volume;
THYM	cis	rs6763280	1	rs6763280	chr3:46521298	G/A	cg02332537	chr3:46540019	RTP3	0.45	4.54	0.42	1.65e-5	Tonsillectomy;
THYM	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg21984481	chr17:79567631	NPLOC4	0.61	6.88	0.58	6.43e-10	Eye color traits;
THYM	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06850241	chr22:41845214	NA	-0.6	-5.32	-0.48	6.75e-7	Vitiligo;
THYM	cis	rs4072705	0.646	rs10120967	chr9:127244134	C/T	cg13476313	chr9:127244764	NR5A1	0.36	5.27	0.48	8.48e-7	Menarche (age at onset);
THYM	cis	rs240764	0.658	rs2132168	chr6:101178491	G/A	cg21058520	chr6:100914733	NA	0.56	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs4285028	0.948	rs12488851	chr3:121687192	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs548181	0.609	rs511822	chr11:125534115	C/T	cg03464685	chr11:125439445	EI24	1.41	8.24	0.65	9.25e-13	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8050907	0.744	rs7192051	chr16:4542117	A/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.24	5.07	0.46	1.98e-6	Obesity-related traits;
THYM	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.59	4.82	0.44	5.4e-6	Bipolar disorder;
THYM	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg19508488	chr2:152266495	RIF1	-0.79	-6.2	-0.54	1.45e-8	Lung cancer;
THYM	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs62435770	1.000	rs17184923	chr6:169506163	T/G	cg07652237	chr6:170125491	PHF10	0.55	4.91	0.45	3.84e-6	Loneliness;
THYM	cis	rs6032067	0.777	rs13039211	chr20:43784396	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs6083	0.512	rs17269397	chr15:58857378	A/G	cg05156742	chr15:59063176	FAM63B	-0.55	-4.88	-0.45	4.34e-6	Schizophrenia;
THYM	cis	rs17818399	1.000	rs17818399	chr2:46826026	A/C	cg09399716	chr2:46890238	NA	-0.54	-4.83	-0.44	5.16e-6	Height;
THYM	trans	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg25214090	chr10:38739885	LOC399744	0.93	7.92	0.63	4.43e-12	Corneal astigmatism;
THYM	cis	rs2639990	1.000	rs1702831	chr18:72897368	C/A	cg02750262	chr18:72916776	ZADH2	1.29	6.44	0.55	4.98e-9	Vascular endothelial growth factor levels;
THYM	cis	rs1448094	0.512	rs4362214	chr12:86245145	C/T	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs7107174	0.681	rs10899499	chr11:78124797	A/G	cg19901956	chr11:77921274	USP35	0.64	5.17	0.47	1.31e-6	Testicular germ cell tumor;
THYM	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg12935359	chr14:103987150	CKB	-0.62	-6.48	-0.55	3.97e-9	Body mass index;
THYM	cis	rs7192750	0.562	rs9302632	chr16:71943511	A/G	cg06353428	chr16:71660113	MARVELD3	0.71	5.01	0.46	2.47e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg14018140	chr10:458528	DIP2C	0.49	5.28	0.48	8.27e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg07606381	chr6:8435919	SLC35B3	0.66	4.93	0.45	3.51e-6	Motion sickness;
THYM	cis	rs6866344	0.570	rs59259518	chr5:178142628	C/T	cg03877680	chr5:178157825	ZNF354A	0.77	5.21	0.47	1.08e-6	Neutrophil percentage of white cells;
THYM	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg17644776	chr2:200775616	C2orf69	0.77	5.4	0.48	5.01e-7	Schizophrenia;
THYM	cis	rs28595532	0.925	rs116785973	chr4:119611350	G/A	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs35883536	0.647	rs2783693	chr1:101045040	C/T	cg06223162	chr1:101003688	GPR88	0.82	6.93	0.58	5.03e-10	Monocyte count;
THYM	cis	rs870825	0.655	rs12502771	chr4:185635834	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg00129232	chr17:37814104	STARD3	0.74	4.99	0.46	2.76e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs11696501	0.688	rs4810461	chr20:44278445	G/A	cg11783356	chr20:44313418	WFDC10B	-0.69	-4.74	-0.44	7.51e-6	Brain structure;
THYM	cis	rs67460515	0.563	rs9876142	chr3:160780968	A/G	cg12349858	chr3:160822545	B3GALNT1	-0.65	-5.25	-0.47	9.3e-7	Parkinson's disease;
THYM	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg14196790	chr5:131705035	SLC22A5	0.56	4.94	0.45	3.36e-6	Blood metabolite levels;
THYM	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.62	-0.5	1.9e-7	Menopause (age at onset);
THYM	cis	rs12908161	0.853	rs11633788	chr15:85305142	T/A	cg17173187	chr15:85201210	NMB	0.5	4.79	0.44	6.07e-6	Schizophrenia;
THYM	cis	rs988913	0.957	rs2064432	chr6:54782652	A/G	cg04690482	chr6:54711388	FAM83B	0.51	5.38	0.48	5.24e-7	Menarche (age at onset);
THYM	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg02725872	chr8:58115012	NA	-1.12	-7.66	-0.62	1.56e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs7809950	1.000	rs10274041	chr7:107261556	C/T	cg23024343	chr7:107201750	COG5	0.9	7.78	0.62	8.57e-12	Coronary artery disease;
THYM	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg26441486	chr22:50317300	CRELD2	0.43	7.26	0.6	1.06e-10	Schizophrenia;
THYM	cis	rs2299587	0.585	rs2073569	chr8:17782158	T/G	cg01800426	chr8:17659068	MTUS1	-0.69	-5.26	-0.48	8.75e-7	Economic and political preferences;
THYM	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg11812906	chr14:75593930	NEK9	-0.82	-7.38	-0.6	5.94e-11	Height;
THYM	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs9915657	0.870	rs1042667	chr17:70120551	A/C	cg09344028	chr17:70110421	NA	0.48	4.69	0.43	9.27e-6	Thyroid hormone levels;
THYM	cis	rs4474465	0.920	rs7941889	chr11:78154401	T/G	cg19901956	chr11:77921274	USP35	-0.62	-4.55	-0.42	1.61e-5	Alzheimer's disease (survival time);
THYM	cis	rs425277	0.561	rs11584491	chr1:2042543	A/G	cg24578937	chr1:2090814	PRKCZ	-0.56	-6.08	-0.53	2.47e-8	Height;
THYM	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg13609457	chr4:120235615	NA	-0.54	-5.01	-0.46	2.54e-6	Corneal astigmatism;
THYM	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg02551604	chr5:131831745	NA	0.87	6.92	0.58	5.23e-10	Asthma (sex interaction);
THYM	cis	rs6087990	0.735	rs1003522	chr20:31368560	T/C	cg13636640	chr20:31349939	DNMT3B	0.9	9.19	0.69	8.89e-15	Ulcerative colitis;
THYM	cis	rs7584330	0.737	rs6431539	chr2:238360708	G/T	cg16989719	chr2:238392110	NA	-0.6	-5.72	-0.51	1.22e-7	Prostate cancer;
THYM	cis	rs612683	0.824	rs17454919	chr1:100830370	A/G	cg06223162	chr1:101003688	GPR88	0.69	5.64	0.5	1.77e-7	Breast cancer;
THYM	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg21361702	chr7:150065534	REPIN1	-0.68	-4.98	-0.46	2.8e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg27129171	chr3:47204927	SETD2	0.74	7.2	0.59	1.42e-10	Colorectal cancer;
THYM	cis	rs10887741	0.646	rs11202501	chr10:89437208	C/T	cg13926569	chr10:89418898	PAPSS2	0.63	7.28	0.6	9.67e-11	Exercise (leisure time);
THYM	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg22105103	chr4:187893119	NA	0.89	9.4	0.69	3.23e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg02825527	chr7:2087843	MAD1L1	-0.69	-4.62	-0.43	1.19e-5	Bipolar disorder;
THYM	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg04750100	chr2:136595281	LCT	-0.58	-6.94	-0.58	4.82e-10	Mosquito bite size;
THYM	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Gout;
THYM	cis	rs11249608	0.548	rs6601007	chr5:178455796	G/C	cg01312482	chr5:178451176	ZNF879	-0.76	-6.3	-0.54	9.29e-9	Pubertal anthropometrics;
THYM	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg02734326	chr4:10020555	SLC2A9	-0.74	-5.96	-0.52	4.26e-8	Bone mineral density;
THYM	cis	rs4363385	0.667	rs2066004	chr1:152922896	A/G	cg07796016	chr1:152779584	LCE1C	-0.59	-4.54	-0.42	1.65e-5	Inflammatory skin disease;
THYM	cis	rs11577318	0.853	rs11803933	chr1:26629465	G/C	cg19677267	chr1:26645161	CD52;UBXN11	-0.46	-5.87	-0.52	6.35e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs6032067	0.929	rs17424668	chr20:43809647	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	0.5	5.65	0.5	1.7e-7	Blood protein levels;
THYM	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg20744362	chr22:50050164	C22orf34	0.82	8.07	0.64	2.17e-12	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2806561	0.704	rs856510	chr1:23524407	A/C	cg19743168	chr1:23544995	NA	0.62	6.31	0.54	8.74e-9	Height;
THYM	cis	rs6964587	0.839	rs12536702	chr7:91471576	G/C	cg17063962	chr7:91808500	NA	1.11	11.81	0.77	2.4e-20	Breast cancer;
THYM	cis	rs6901250	0.851	rs2175622	chr6:117149667	T/A	cg12892004	chr6:117198278	RFX6	0.71	6.96	0.58	4.39e-10	C-reactive protein levels;
THYM	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg17830980	chr10:43048298	ZNF37B	1.1	10.96	0.75	1.49e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg21658235	chr8:22456391	C8orf58	0.5	5.06	0.46	2.04e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17006441	0.932	rs34610895	chr3:69868324	G/A	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg00495681	chr13:53174319	NA	0.73	6.66	0.56	1.79e-9	Lewy body disease;
THYM	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.79	-7.25	-0.6	1.13e-10	Personality dimensions;
THYM	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg23281280	chr6:28129359	ZNF389	0.65	5.07	0.46	1.99e-6	Depression;
THYM	cis	rs7592578	0.581	rs59109438	chr2:191287683	A/G	cg21644426	chr2:191273491	MFSD6	-0.72	-4.91	-0.45	3.74e-6	Diastolic blood pressure;
THYM	cis	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg12981288	chr8:11183844	MTMR9	-0.46	-4.45	-0.42	2.33e-5	Retinal vascular caliber;
THYM	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg06532163	chr17:45867833	NA	0.65	6.55	0.56	2.91e-9	IgG glycosylation;
THYM	cis	rs6032067	1.000	rs6032069	chr20:43867388	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	0.7	7.3	0.6	8.92e-11	Blood protein levels;
THYM	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08704250	chr15:31115839	NA	-0.51	-6.33	-0.54	8.07e-9	Huntington's disease progression;
THYM	cis	rs7618915	1.000	rs3844291	chr3:52341215	A/C	cg10802521	chr3:52805072	NEK4	-0.63	-4.6	-0.43	1.32e-5	Bipolar disorder;
THYM	cis	rs749052	0.634	rs73995024	chr2:232799845	C/T	cg22331108	chr2:232478452	NA	-0.96	-4.47	-0.42	2.14e-5	Height;
THYM	cis	rs9443189	0.526	rs9359124	chr6:76200514	G/A	cg01950844	chr6:76311363	SENP6	1.11	5.29	0.48	7.84e-7	Prostate cancer;
THYM	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7267979	0.966	rs416745	chr20:25438868	T/C	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg17775962	chr7:1200435	ZFAND2A	-0.44	-5.26	-0.47	8.99e-7	Longevity;Endometriosis;
THYM	cis	rs3857067	0.806	rs4693001	chr4:95115097	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg21640587	chr11:117668038	DSCAML1	1.05	9.25	0.69	6.53e-15	Myopia;
THYM	cis	rs7523273	0.925	rs10863593	chr1:208018074	C/T	cg22525895	chr1:207977042	MIR29B2	0.87	6.38	0.55	6.41e-9	Schizophrenia;
THYM	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg07061783	chr6:25882402	NA	-0.9	-8.66	-0.66	1.18e-13	Intelligence (multi-trait analysis);
THYM	cis	rs733592	0.723	rs10875766	chr12:48593580	G/C	cg21466736	chr12:48725269	NA	-0.49	-5.33	-0.48	6.62e-7	Plateletcrit;
THYM	cis	rs8014204	0.901	rs6574200	chr14:75364451	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.59	-5.9	-0.52	5.57e-8	Caffeine consumption;
THYM	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg10248100	chr7:872053	UNC84A	0.74	4.99	0.46	2.75e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs865483	0.828	rs1016680	chr17:35874385	G/T	cg06716730	chr17:35851459	DUSP14	-0.42	-7.01	-0.58	3.46e-10	Monocyte count;
THYM	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg26384229	chr12:38710491	ALG10B	0.74	5.73	0.51	1.2e-7	Morning vs. evening chronotype;
THYM	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg08999081	chr20:33150536	PIGU	0.78	7.16	0.59	1.72e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs3862030	0.810	rs5870	chr10:104239100	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.68	-5.7	-0.5	1.36e-7	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs34172651	0.917	rs12599173	chr16:24823619	T/C	cg06028605	chr16:24865363	SLC5A11	0.53	5.08	0.46	1.87e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4563143	0.647	rs34218744	chr19:29256821	A/T	cg12667521	chr19:29218732	NA	0.96	8.39	0.65	4.58e-13	Methadone dose in opioid dependence;
THYM	cis	rs13256369	1.000	rs873064	chr8:8572380	G/A	cg17143192	chr8:8559678	CLDN23	0.91	6.72	0.57	1.33e-9	Obesity-related traits;
THYM	cis	rs8031584	1.000	rs12906054	chr15:31292023	A/C	cg14829155	chr15:31115871	NA	-0.55	-4.65	-0.43	1.08e-5	Huntington's disease progression;
THYM	cis	rs1448094	0.512	rs7137596	chr12:86239884	C/G	cg02569458	chr12:86230093	RASSF9	0.58	5.01	0.46	2.47e-6	Major depressive disorder;
THYM	cis	rs7107174	1.000	rs948662	chr11:77979829	A/G	cg19901956	chr11:77921274	USP35	-0.69	-5.32	-0.48	6.91e-7	Testicular germ cell tumor;
THYM	cis	rs4604732	0.527	rs7546805	chr1:247627259	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.69	4.61	0.43	1.28e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs10484885	0.824	rs72919976	chr6:90526686	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.87	-7.73	-0.62	1.13e-11	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs4642101	0.640	rs9877049	chr3:12821231	A/G	cg05775895	chr3:12838266	CAND2	1.06	10.78	0.74	3.67e-18	QRS complex (12-leadsum);
THYM	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg08508325	chr11:3079039	CARS	-0.53	-6.53	-0.56	3.22e-9	Longevity;
THYM	cis	rs10752881	0.935	rs12082051	chr1:183051614	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Colorectal cancer;
THYM	cis	rs3112255	0.967	rs1606552	chr2:101304053	T/G	cg01042948	chr2:101319752	NA	0.72	6.28	0.54	1.02e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03647317	chr4:187891568	NA	-0.82	-8.8	-0.67	5.94e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg13866156	chr1:1669148	SLC35E2	0.71	7.79	0.62	8.26e-12	Body mass index;
THYM	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg10117171	chr1:25599238	RHD	0.63	4.46	0.42	2.25e-5	Erythrocyte sedimentation rate;
THYM	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg06074448	chr4:187884817	NA	-0.99	-12.35	-0.79	1.79e-21	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg10792982	chr14:105748885	BRF1	0.7	7.06	0.59	2.66e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs910187	0.605	rs2281367	chr20:45808960	T/C	cg27589058	chr20:45804311	EYA2	-0.68	-6.03	-0.53	3.09e-8	Migraine;
THYM	cis	rs1445130	1.000	rs1445130	chr2:18834651	A/G	cg26077359	chr2:19280274	NA	0.78	4.53	0.42	1.71e-5	Bulimia nervosa;
THYM	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg16586182	chr3:47516702	SCAP	-0.63	-5.52	-0.49	2.96e-7	Colorectal cancer;
THYM	cis	rs919433	0.679	rs7600862	chr2:198534514	C/T	cg00792783	chr2:198669748	PLCL1	0.82	5.44	0.49	4.16e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.42	-5.05	-0.46	2.17e-6	Longevity;Endometriosis;
THYM	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg25566285	chr7:158114605	PTPRN2	0.89	10.22	0.72	5.47e-17	Calcium levels;
THYM	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg11366901	chr6:160182831	ACAT2	0.97	8.07	0.64	2.14e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7187994	0.848	rs62050862	chr16:84781949	G/A	cg07647771	chr16:84786436	USP10	-0.55	-5.06	-0.46	2.03e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg23803603	chr1:2058230	PRKCZ	-0.57	-5.03	-0.46	2.33e-6	Height;
THYM	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg27494647	chr7:150038898	RARRES2	0.49	6.03	0.53	3.09e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg22535103	chr8:58192502	C8orf71	-0.88	-5.76	-0.51	1.05e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg04398451	chr17:18023971	MYO15A	-0.99	-11.31	-0.76	2.67e-19	Total body bone mineral density;
THYM	cis	rs1278352	0.799	rs1278362	chr10:127775615	A/T	cg08295661	chr10:127769903	ADAM12	-0.44	-4.86	-0.45	4.66e-6	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
THYM	cis	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg02317251	chr4:10116515	WDR1	-0.56	-4.95	-0.45	3.23e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs4606347	0.932	rs2375803	chr1:66152889	A/G	cg04111102	chr1:66153794	NA	0.57	4.53	0.42	1.73e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg07167872	chr1:205819463	PM20D1	-0.6	-4.49	-0.42	1.98e-5	Parkinson's disease;
THYM	cis	rs7917772	0.628	rs4604806	chr10:104373904	G/A	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10851411	0.862	rs2255995	chr15:42816868	A/C	cg04308337	chr15:42867303	STARD9	-0.62	-4.57	-0.42	1.48e-5	Glucose homeostasis traits;
THYM	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg01831904	chr17:28903510	LRRC37B2	-1.05	-5.12	-0.46	1.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2219968	0.676	rs2879369	chr8:78839710	C/T	cg00738934	chr8:78996279	NA	-0.7	-6.22	-0.54	1.35e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4589258	0.788	rs1894135	chr11:90498227	A/G	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.96	-0.45	3.02e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4478037	0.749	rs72856153	chr3:33111182	T/G	cg19404215	chr3:33155277	CRTAP	0.99	6.8	0.57	9.1e-10	Major depressive disorder;
THYM	cis	rs3126085	0.935	rs4845426	chr1:152195359	A/G	cg26020982	chr1:152196106	HRNR	0.37	5.06	0.46	2.05e-6	Atopic dermatitis;
THYM	cis	rs13185784	0.703	rs6894217	chr5:179667806	G/A	cg23248424	chr5:179741104	GFPT2	0.69	4.59	0.43	1.37e-5	TRAIL levels;
THYM	cis	rs2806561	0.823	rs658508	chr1:23480362	T/C	cg19743168	chr1:23544995	NA	0.57	5.5	0.49	3.14e-7	Height;
THYM	cis	rs28595532	0.920	rs113034745	chr4:119750044	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12541335	0.615	rs4872464	chr8:22153381	G/A	cg02463440	chr8:22132932	PIWIL2	0.58	4.89	0.45	4.02e-6	Hypertriglyceridemia;
THYM	cis	rs7580658	0.676	rs4150407	chr2:128049631	C/T	cg09152259	chr2:128156114	NA	0.34	4.61	0.43	1.26e-5	Protein C levels;
THYM	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg09436375	chr6:42928200	GNMT	-0.4	-5.14	-0.47	1.47e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1335645	0.570	rs7514887	chr1:111667158	T/C	cg00321911	chr1:111669324	DRAM2	-1.27	-7.04	-0.59	2.96e-10	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg23758822	chr17:41437982	NA	1.16	11.05	0.75	9.86e-19	Menopause (age at onset);
THYM	cis	rs793108	0.742	rs867991	chr10:31389265	G/T	cg07137701	chr10:31611868	ZEB1	0.55	4.82	0.44	5.52e-6	Multiple sclerosis;Rheumatoid arthritis;
THYM	cis	rs931127	0.532	rs4930304	chr11:65463447	T/G	cg17480646	chr11:65405466	SIPA1	0.62	4.72	0.44	8.2e-6	Systemic lupus erythematosus;
THYM	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg24503407	chr1:205819492	PM20D1	-0.95	-9.42	-0.69	2.91e-15	Menarche (age at onset);
THYM	cis	rs113835537	0.529	rs74869459	chr11:66296569	T/C	cg24851651	chr11:66362959	CCS	0.71	4.76	0.44	7.03e-6	Airway imaging phenotypes;
THYM	cis	rs863345	0.604	rs10908660	chr1:158466189	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.81	-0.44	5.75e-6	Pneumococcal bacteremia;
THYM	cis	rs4474465	0.850	rs7112872	chr11:78227396	C/A	cg19901956	chr11:77921274	USP35	0.65	4.92	0.45	3.7e-6	Alzheimer's disease (survival time);
THYM	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg23583168	chr7:148888333	NA	0.99	13.45	0.81	1.01e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs6500395	1.000	rs9930199	chr16:48571263	A/G	cg04672837	chr16:48644449	N4BP1	0.49	4.79	0.44	6.02e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7567389	0.719	rs4150402	chr2:128050134	C/T	cg09760422	chr2:128146352	NA	0.4	4.52	0.42	1.8e-5	Self-rated health;
THYM	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg05283184	chr6:79620031	NA	-0.94	-9.21	-0.69	7.9e-15	Intelligence (multi-trait analysis);
THYM	cis	rs4478037	0.749	rs6550204	chr3:33107645	C/T	cg19404215	chr3:33155277	CRTAP	-1.05	-7.02	-0.58	3.33e-10	Major depressive disorder;
THYM	cis	rs6089584	0.587	rs13041784	chr20:60561671	T/C	cg06108461	chr20:60628389	TAF4	-0.79	-6.28	-0.54	9.91e-9	Body mass index;
THYM	cis	rs736408	0.812	rs2239699	chr3:52827915	C/T	cg10802521	chr3:52805072	NEK4	-0.69	-5.91	-0.52	5.33e-8	Bipolar disorder;
THYM	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg24874828	chr4:187887005	NA	-0.72	-7.44	-0.61	4.48e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6596100	0.538	rs55976357	chr5:132194565	C/A	cg02081065	chr5:132209139	LEAP2	-0.95	-6.14	-0.53	1.87e-8	Breast cancer;
THYM	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg26441486	chr22:50317300	CRELD2	0.45	7.72	0.62	1.18e-11	Schizophrenia;
THYM	cis	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg10856724	chr12:34555212	NA	-0.81	-7.21	-0.59	1.33e-10	Morning vs. evening chronotype;
THYM	cis	rs4731207	0.698	rs10272583	chr7:124509451	T/C	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg00256281	chr22:41985642	PMM1	0.64	5.16	0.47	1.34e-6	Vitiligo;
THYM	cis	rs4604732	0.642	rs7549312	chr1:247640078	C/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	4.8	0.44	5.87e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs9653442	0.835	rs1561230	chr2:100746642	C/T	cg22139774	chr2:100720529	AFF3	0.4	6.33	0.54	7.94e-9	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs7106204	1.000	rs7925633	chr11:24214815	A/G	ch.11.24196551F	chr11:24239977	NA	0.91	5.63	0.5	1.85e-7	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg14972814	chr11:95582409	MTMR2	-0.71	-6.61	-0.56	2.19e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs778371	0.676	rs7560115	chr2:233709465	T/G	cg08000102	chr2:233561755	GIGYF2	-0.81	-7.2	-0.59	1.41e-10	Schizophrenia;
THYM	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg17063962	chr7:91808500	NA	1.16	13.14	0.8	4.39e-23	Breast cancer;
THYM	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03264133	chr6:25882463	NA	-0.64	-4.81	-0.44	5.74e-6	Height;
THYM	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.77	-6.02	-0.53	3.23e-8	Blood metabolite levels;
THYM	cis	rs9522267	0.535	rs2039916	chr13:112238863	A/C	cg10483660	chr13:112241077	NA	-0.59	-6.84	-0.57	7.61e-10	Hepatitis;
THYM	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg19761014	chr17:28927070	LRRC37B2	0.8	4.73	0.44	7.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg22166914	chr1:53195759	ZYG11B	0.91	10.68	0.74	5.96e-18	Monocyte count;
THYM	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	5.34	0.48	6.41e-7	Obesity-related traits;
THYM	cis	rs611744	0.647	rs1609472	chr8:109269232	T/G	cg21045802	chr8:109455806	TTC35	0.62	5.38	0.48	5.32e-7	Dupuytren's disease;
THYM	cis	rs7119	0.717	rs12916822	chr15:77818548	G/T	cg27398640	chr15:77910606	LINGO1	-0.56	-5.66	-0.5	1.6e-7	Type 2 diabetes;
THYM	cis	rs2732480	0.538	rs2732462	chr12:48696384	A/G	cg21466736	chr12:48725269	NA	-0.56	-5.13	-0.47	1.51e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg12573674	chr2:1569213	NA	-1.16	-8.07	-0.64	2.18e-12	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.82	-0.63	7.28e-12	Chronic sinus infection;
THYM	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg08470875	chr2:26401718	FAM59B	-0.72	-4.46	-0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg02018176	chr4:1364513	KIAA1530	0.76	7.54	0.61	2.83e-11	Longevity;
THYM	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	4.69	0.43	9e-6	Menarche (age at onset);
THYM	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg05182265	chr7:156933206	UBE3C	-0.69	-9.32	-0.69	4.59e-15	Body mass index;
THYM	cis	rs9467711	0.585	rs3884025	chr6:25930088	G/A	cg16898833	chr6:26189333	HIST1H4D	1.33	4.61	0.43	1.28e-5	Autism spectrum disorder or schizophrenia;
THYM	trans	rs10118776	0.826	rs13302358	chr9:6202170	C/G	cg02532923	chr16:89110004	NA	1.01	7.85	0.63	6.11e-12	Small cell lung carcinoma;
THYM	cis	rs67460515	0.892	rs10513564	chr3:161059762	A/G	cg03342759	chr3:160939853	NMD3	-0.91	-7.85	-0.63	6.27e-12	Parkinson's disease;
THYM	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.74	-5.98	-0.52	3.89e-8	Menarche (age at onset);
THYM	cis	rs807669	0.807	rs698422	chr22:19205826	A/T	cg02655711	chr22:19163373	SLC25A1	0.64	7.22	0.59	1.3e-10	Metabolite levels;
THYM	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg19346786	chr7:2764209	NA	-0.59	-5.08	-0.46	1.88e-6	Height;
THYM	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg02038168	chr22:39784481	NA	-0.67	-5.52	-0.49	2.9e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.77	-5.02	-0.46	2.45e-6	Mean platelet volume;
THYM	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg22875332	chr1:76189707	ACADM	-0.54	-5.07	-0.46	1.96e-6	Daytime sleep phenotypes;
THYM	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.8	6.66	0.56	1.77e-9	Age at first birth;
THYM	cis	rs3791406	0.929	rs3828202	chr2:240030122	A/G	cg20627572	chr2:239991813	HDAC4	-0.46	-4.49	-0.42	2.04e-5	Skin aging (microtopography measurement);
THYM	cis	rs4148689	1.000	rs34855237	chr7:117199457	A/G	cg17204129	chr7:117119601	CFTR	-0.57	-4.47	-0.42	2.2e-5	Gout;
THYM	cis	rs12500482	0.935	rs12644638	chr4:2413461	C/T	cg07775547	chr4:1625484	NA	-0.53	-4.58	-0.43	1.42e-5	Cognitive function;
THYM	cis	rs8044995	0.563	rs3785116	chr16:68372730	G/A	cg09835421	chr16:68378352	PRMT7	-0.72	-4.53	-0.42	1.7e-5	Schizophrenia;
THYM	cis	rs9443189	0.570	rs485906	chr6:76300550	A/C	cg01950844	chr6:76311363	SENP6	1.1	6.88	0.58	6.48e-10	Prostate cancer;
THYM	cis	rs4986172	0.539	rs3744760	chr17:43195981	C/T	cg00677574	chr17:43221327	ACBD4	-0.57	-4.85	-0.45	4.85e-6	Height;
THYM	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.66	8.49	0.66	2.71e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4481887	0.893	rs9651175	chr1:248446888	G/T	cg00666640	chr1:248458726	OR2T12	0.54	4.57	0.42	1.48e-5	Common traits (Other);
THYM	cis	rs55794721	0.509	rs2982358	chr1:25745204	G/T	cg00786635	chr1:25594202	NA	0.91	7.17	0.59	1.64e-10	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs6933660	0.512	rs13202634	chr6:151800630	C/T	cg03596678	chr6:151814994	C6orf97	-0.73	-4.68	-0.43	9.56e-6	Menarche (age at onset);
THYM	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg24399712	chr22:39784796	NA	-0.93	-11.03	-0.75	1.08e-18	Intelligence (multi-trait analysis);
THYM	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg06728252	chr6:26598149	ABT1	-0.43	-5.11	-0.46	1.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.96	6.27	0.54	1.05e-8	Platelet count;
THYM	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.97	-5.31	-0.48	7.06e-7	Initial pursuit acceleration;
THYM	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs7408868	0.908	rs2074619	chr19:15276919	G/A	cg14696996	chr19:15285081	NOTCH3	0.98	5.61	0.5	2.02e-7	Pulse pressure;
THYM	cis	rs62070183	0.808	rs76373015	chr17:31142041	C/A	cg23177095	chr17:30873196	MYO1D	0.61	4.82	0.44	5.36e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs6754311	0.593	rs10202489	chr2:136494186	G/A	cg20242066	chr2:136595261	LCT	-0.6	-7.07	-0.59	2.64e-10	Mosquito bite size;
THYM	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg18876405	chr7:65276391	NA	0.61	5.2	0.47	1.13e-6	Aortic root size;
THYM	cis	rs921968	0.541	rs933995	chr2:219650718	G/A	cg02176678	chr2:219576539	TTLL4	-0.47	-4.56	-0.42	1.55e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg19610905	chr11:61596333	FADS2	-0.61	-5.16	-0.47	1.36e-6	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
THYM	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs490234	0.871	rs13288032	chr9:128255582	T/A	cg14078157	chr9:128172775	NA	-0.67	-5.47	-0.49	3.68e-7	Mean arterial pressure;
THYM	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg08431931	chr22:42394659	WBP2NL	0.71	4.96	0.45	3.07e-6	Birth weight;
THYM	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg19774624	chr17:42201019	HDAC5	0.77	6.89	0.58	5.99e-10	Total body bone mineral density;
THYM	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg01699819	chr7:1052092	C7orf50	-0.7	-5.94	-0.52	4.62e-8	Bronchopulmonary dysplasia;
THYM	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg12011299	chr4:100065546	ADH4	0.75	7.3	0.6	8.58e-11	Alcohol dependence;
THYM	cis	rs7941600	0.786	rs12273748	chr11:9360367	A/G	cg21110646	chr11:9336536	TMEM41B	0.99	5.58	0.5	2.23e-7	Coronary artery disease;
THYM	cis	rs4072705	0.614	rs35929043	chr9:127234356	T/C	cg01786973	chr9:127249749	NR5A1	0.4	4.95	0.45	3.2e-6	Menarche (age at onset);
THYM	cis	rs288326	0.561	rs78745965	chr2:183848475	T/C	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs28595532	1.000	rs11931194	chr4:119631160	C/T	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.15e-7	Cannabis dependence symptom count;
THYM	cis	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg05335186	chr13:53173507	NA	-0.58	-7.41	-0.61	5.04e-11	Lewy body disease;
THYM	cis	rs61931739	0.534	rs1608912	chr12:34008574	C/T	cg06521331	chr12:34319734	NA	-0.91	-8.09	-0.64	1.91e-12	Morning vs. evening chronotype;
THYM	cis	rs3768617	0.510	rs10752896	chr1:183068516	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.56	4.51	0.42	1.82e-5	Fuchs's corneal dystrophy;
THYM	cis	rs3820068	0.580	rs61169376	chr1:16003832	A/G	cg24675056	chr1:15929824	NA	0.74	5.88	0.52	5.96e-8	Systolic blood pressure;
THYM	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg19077165	chr18:44547161	KATNAL2	-0.61	-7.69	-0.62	1.33e-11	Personality dimensions;
THYM	cis	rs9311676	0.632	rs62258094	chr3:58371770	T/G	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg03690763	chr11:133734501	NA	-0.61	-4.75	-0.44	7.32e-6	Childhood ear infection;
THYM	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs7769051	0.708	rs9483514	chr6:133228716	G/A	cg22852734	chr6:133119734	C6orf192	1.1	6.8	0.57	9.04e-10	Type 2 diabetes nephropathy;
THYM	cis	rs500891	0.525	rs6937193	chr6:84095331	C/T	cg08257003	chr6:84140564	ME1	0.56	4.57	0.42	1.48e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs4076764	0.914	rs7536270	chr1:163377379	T/C	cg06092702	chr1:163392909	NA	-0.61	-5.3	-0.48	7.43e-7	Motion sickness;
THYM	cis	rs6430585	0.528	rs12476127	chr2:136763242	A/G	cg04750100	chr2:136595281	LCT	0.53	5.07	0.46	1.95e-6	Corneal structure;
THYM	cis	rs425277	0.606	rs12082939	chr1:2078922	C/T	cg23682913	chr1:2080710	PRKCZ	0.57	5.07	0.46	2e-6	Height;
THYM	cis	rs9677476	0.863	rs10187005	chr2:232077948	C/T	cg23338755	chr2:231921595	PSMD1	0.68	4.98	0.46	2.81e-6	Food antigen IgG levels;
THYM	cis	rs12956009	0.518	rs11663852	chr18:44887542	G/A	cg19077165	chr18:44547161	KATNAL2	-0.51	-4.93	-0.45	3.51e-6	Educational attainment (years of education);
THYM	cis	rs13064411	0.542	rs13082603	chr3:113223362	T/C	cg18753928	chr3:113234510	CCDC52	-0.84	-7.87	-0.63	5.58e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg20295408	chr7:1910781	MAD1L1	-0.63	-4.73	-0.44	7.7e-6	Schizophrenia;
THYM	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs7575217	0.697	rs34429055	chr2:101703696	G/C	cg23907051	chr2:101730305	TBC1D8	0.4	5.3	0.48	7.57e-7	Sum neutrophil eosinophil counts;Myeloid white cell count;Granulocyte count;
THYM	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03647317	chr4:187891568	NA	-0.84	-9.05	-0.68	1.74e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9311676	0.632	rs4130877	chr3:58374893	T/C	cg26110898	chr3:58419937	PDHB	0.44	4.51	0.42	1.83e-5	Systemic lupus erythematosus;
THYM	cis	rs6754311	0.731	rs309134	chr2:136755684	A/G	cg07169764	chr2:136633963	MCM6	-0.68	-5.97	-0.52	4.08e-8	Mosquito bite size;
THYM	cis	rs3820068	0.608	rs10927831	chr1:16028373	T/G	cg27534772	chr1:16042836	PLEKHM2	0.51	5.25	0.47	9.14e-7	Systolic blood pressure;
THYM	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg12165864	chr7:66369176	NA	-0.81	-6.03	-0.53	3.07e-8	Corneal structure;
THYM	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.64	4.91	0.45	3.81e-6	Multiple sclerosis;
THYM	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg22508957	chr16:3507546	NAT15	-0.41	-4.53	-0.42	1.71e-5	Body mass index (adult);
THYM	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg09263875	chr16:632152	PIGQ	0.67	5.33	0.48	6.6e-7	Height;
THYM	cis	rs13102973	0.640	rs10434071	chr4:135842080	C/G	cg14419869	chr4:135874104	NA	0.72	5.86	0.51	6.78e-8	Subjective well-being;
THYM	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg25358565	chr5:93447407	FAM172A	1.34	10.59	0.74	9.3e-18	Diabetic retinopathy;
THYM	cis	rs2463822	0.925	rs12292586	chr11:62156312	C/T	cg06239285	chr11:62104954	ASRGL1	-1.41	-7.07	-0.59	2.63e-10	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs3096299	0.967	rs2911253	chr16:89488587	T/G	cg06640241	chr16:89574553	SPG7	0.71	5.43	0.49	4.25e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg26384229	chr12:38710491	ALG10B	1.03	10.33	0.73	3.29e-17	Heart rate;
THYM	trans	rs629535	0.735	rs525610	chr8:70074535	A/G	cg21567404	chr3:27674614	NA	1.08	10.14	0.72	8.19e-17	Dupuytren's disease;
THYM	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg00256281	chr22:41985642	PMM1	0.64	5.05	0.46	2.17e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg08975724	chr8:8085496	FLJ10661	0.73	5.86	0.52	6.66e-8	Mood instability;
THYM	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14893161	chr1:205819251	PM20D1	0.94	10.13	0.72	8.71e-17	Menarche (age at onset);
THYM	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs1971762	0.563	rs4759284	chr12:54079491	G/A	cg16917193	chr12:54089295	NA	0.9	9.22	0.69	7.82e-15	Height;
THYM	cis	rs4280164	0.551	rs12436194	chr14:24804859	C/T	cg18846074	chr14:24801073	ADCY4	-0.61	-4.79	-0.44	6.18e-6	Parent of origin effect on language impairment (paternal);
THYM	cis	rs7818345	0.967	rs17479099	chr8:19277144	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.42	4.65	0.43	1.07e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg02070205	chr10:30722105	MAP3K8	-0.71	-6.19	-0.54	1.53e-8	Inflammatory bowel disease;
THYM	cis	rs6570726	0.791	rs952406	chr6:145925616	C/A	cg13319975	chr6:146136371	FBXO30	-0.63	-4.91	-0.45	3.81e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4973397	0.921	rs12622248	chr2:232289127	G/A	cg24172324	chr2:232258363	NA	-0.49	-4.5	-0.42	1.93e-5	Anti-saccade response;
THYM	cis	rs1994135	0.565	rs11052767	chr12:33731194	A/G	cg10856724	chr12:34555212	NA	-0.64	-5.11	-0.46	1.68e-6	Resting heart rate;
THYM	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.64	4.72	0.44	8.04e-6	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs10489202	1.000	rs2420	chr1:167886502	A/T	cg24449463	chr1:168025552	DCAF6	-0.83	-6.51	-0.56	3.58e-9	Schizophrenia;
THYM	cis	rs2219968	1.000	rs34130020	chr8:78962583	T/C	cg00738934	chr8:78996279	NA	0.91	9.75	0.71	5.6e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4604732	0.631	rs4411161	chr1:247632374	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.73	4.92	0.45	3.68e-6	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs41005	1.000	rs42357	chr2:8110896	C/T	cg03155496	chr2:8117019	LOC339788	0.92	8.82	0.67	5.48e-14	Response to anti-TNF therapy in rheumatoid arthritis;
THYM	cis	rs7027203	1.000	rs7864114	chr9:96551954	A/G	cg14598338	chr9:96623480	NA	0.44	4.71	0.43	8.55e-6	DNA methylation (variation);
THYM	cis	rs57590327	0.555	rs13062054	chr3:81833906	A/G	cg07356753	chr3:81810745	GBE1	-0.86	-6.59	-0.56	2.41e-9	Extraversion;
THYM	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg00814883	chr7:100076585	TSC22D4	-0.96	-6.41	-0.55	5.64e-9	Platelet count;
THYM	cis	rs6840360	0.593	rs10016160	chr4:152693998	A/G	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11890956	chr21:40555474	PSMG1	-0.66	-6.44	-0.55	4.92e-9	Menarche (age at onset);
THYM	cis	rs11031096	0.678	rs1442727	chr11:4188188	G/T	cg22027985	chr11:4115532	RRM1	0.53	4.91	0.45	3.77e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9733	0.621	rs932054	chr1:150539867	C/G	cg18016565	chr1:150552671	MCL1	-0.55	-4.45	-0.42	2.32e-5	Tonsillectomy;
THYM	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg08085267	chr17:45401833	C17orf57	0.68	4.92	0.45	3.56e-6	Very long-chain saturated fatty acid levels (fatty acid 20:0);
THYM	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg11789530	chr4:8429930	ACOX3	-0.7	-5.43	-0.49	4.36e-7	Response to antineoplastic agents;
THYM	cis	rs7781977	0.960	rs4917017	chr7:50335232	A/G	cg01139861	chr7:50343298	IKZF1	-0.7	-6.8	-0.57	9.04e-10	IgG glycosylation;
THYM	cis	rs79387448	0.638	rs116055209	chr2:103032189	C/T	cg09003973	chr2:102972529	NA	1.02	5.74	0.51	1.13e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs3771317	1.000	rs3771317	chr2:191543962	A/G	cg17118478	chr2:191543902	NAB1	-0.61	-4.45	-0.42	2.3e-5	Primary biliary cholangitis;
THYM	cis	rs600806	0.813	rs4970759	chr1:109982213	C/A	cg02175308	chr1:109941060	SORT1	-0.56	-4.88	-0.45	4.33e-6	Intelligence (multi-trait analysis);
THYM	cis	rs1843834	0.755	rs10192196	chr2:225577135	C/T	cg10193763	chr2:225306901	NA	-0.46	-5.08	-0.46	1.89e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs9902453	0.967	rs60176674	chr17:28479854	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	4.6	0.43	1.33e-5	Coffee consumption (cups per day);
THYM	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg11752832	chr7:134001865	SLC35B4	0.73	5.5	0.49	3.21e-7	Mean platelet volume;
THYM	trans	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg25214090	chr10:38739885	LOC399744	0.9	7.3	0.6	8.58e-11	Corneal astigmatism;
THYM	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs2820651	0.614	rs75834807	chr10:1485054	T/C	cg27404824	chr10:1454848	ADARB2	0.87	4.74	0.44	7.61e-6	Migraine with aura;
THYM	cis	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg06521331	chr12:34319734	NA	-1.03	-10.3	-0.73	3.74e-17	Morning vs. evening chronotype;
THYM	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg24838063	chr12:130822603	PIWIL1	0.91	7.18	0.59	1.54e-10	Menopause (age at onset);
THYM	cis	rs939658	0.805	rs11638004	chr15:79425765	A/C	cg17916960	chr15:79447300	NA	-0.71	-8.32	-0.65	6.29e-13	Refractive error;
THYM	cis	rs7131987	0.903	rs7970390	chr12:29398655	A/G	cg09582351	chr12:29534625	ERGIC2	-0.46	-4.47	-0.42	2.19e-5	QT interval;
THYM	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg10253484	chr15:75165896	SCAMP2	-0.63	-4.61	-0.43	1.23e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs887829	0.569	rs3755319	chr2:234667582	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.65	-5.06	-0.46	2.06e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg21226059	chr5:178986404	RUFY1	0.51	5.4	0.48	4.99e-7	Lung cancer;
THYM	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg13447684	chr7:1895903	MAD1L1	0.61	5.33	0.48	6.51e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs6906287	0.647	rs10457330	chr6:118731468	A/T	cg21191810	chr6:118973309	C6orf204	0.56	5.57	0.5	2.37e-7	Electrocardiographic conduction measures;
THYM	cis	rs4242434	0.819	rs1059592	chr8:22477778	G/A	cg03733263	chr8:22462867	KIAA1967	1.0	11.62	0.77	6.09e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs4074961	0.544	rs11264067	chr1:37991458	C/T	cg17933807	chr1:38061675	GNL2	1.02	10.49	0.73	1.47e-17	Axial length;
THYM	cis	rs62244186	0.659	rs9819766	chr3:44520980	G/C	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.47	-5.0	-0.46	2.6e-6	Depressive symptoms;
THYM	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg13447684	chr7:1895903	MAD1L1	0.58	4.87	0.45	4.47e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg23352942	chr3:46931381	PTH1R	-0.59	-5.23	-0.47	1.01e-6	Birth weight;
THYM	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg08772003	chr10:104629869	AS3MT	-0.56	-4.91	-0.45	3.8e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs858239	0.669	rs10950940	chr7:23196816	C/T	cg05407003	chr7:23246146	NA	0.58	4.83	0.44	5.14e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9311676	0.656	rs62258134	chr3:58398447	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs2963155	0.518	rs72801080	chr5:142751990	T/C	cg17617527	chr5:142782415	NR3C1	1.15	4.94	0.45	3.32e-6	Breast cancer;
THYM	cis	rs10504229	0.512	rs77289815	chr8:57995242	A/G	cg02725872	chr8:58115012	NA	-0.93	-4.65	-0.43	1.07e-5	Developmental language disorder (linguistic errors);
THYM	cis	rs9810089	0.802	rs10935182	chr3:136137422	G/A	cg21827317	chr3:136751795	NA	0.57	5.01	0.46	2.55e-6	Gestational age at birth (child effect);
THYM	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg10518543	chr12:38710700	ALG10B	-0.57	-4.61	-0.43	1.24e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg19346786	chr7:2764209	NA	-0.59	-5.16	-0.47	1.35e-6	Height;
THYM	cis	rs7680126	0.596	rs4637402	chr4:10045430	C/T	cg26689780	chr4:10079554	WDR1	-0.41	-4.54	-0.42	1.68e-5	Urate levels in lean individuals;Urate levels in overweight individuals;Urate levels in obese individuals;
THYM	cis	rs56235204	1	rs56235204	chr2:234114532	CT/C	cg23667432	chr2:233244439	ALPP	0.43	4.63	0.43	1.14e-5	Eosinophil counts;Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs6466832	0.568	rs73220296	chr7:122358460	A/G	cg22586324	chr7:123296098	LMOD2	-0.89	-4.89	-0.45	4.04e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4242434	0.889	rs11785755	chr8:22453223	C/A	cg01710189	chr8:22454888	PDLIM2	-0.56	-5.24	-0.47	9.57e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2552220	0.967	rs13268850	chr8:6003468	T/C	cg23638070	chr8:6569043	AGPAT5	-0.57	-4.54	-0.42	1.65e-5	Interleukin-8 levels;
THYM	cis	rs3750965	0.959	rs3376	chr11:68856680	G/A	cg01403660	chr11:68851641	TPCN2	0.72	5.75	0.51	1.07e-7	Hair color;
THYM	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg23205692	chr1:25664452	TMEM50A	-0.83	-6.37	-0.55	6.66e-9	Erythrocyte sedimentation rate;
THYM	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg06636001	chr8:8085503	FLJ10661	0.72	6.8	0.57	9.31e-10	Mood instability;
THYM	cis	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.76	0.44	7.03e-6	Obesity-related traits;
THYM	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg23161317	chr6:28129485	ZNF389	0.85	6.33	0.54	8.19e-9	Depression;
THYM	cis	rs500891	0.525	rs2324416	chr6:84074210	A/G	cg08257003	chr6:84140564	ME1	0.57	4.53	0.42	1.69e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg15744005	chr10:104629667	AS3MT	-0.78	-7.33	-0.6	7.48e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs61931739	0.817	rs188588	chr12:34215277	G/A	cg10856724	chr12:34555212	NA	-0.62	-5.55	-0.49	2.58e-7	Morning vs. evening chronotype;
THYM	cis	rs9443645	0.527	rs9343861	chr6:79744868	C/A	cg05283184	chr6:79620031	NA	-0.6	-4.67	-0.43	9.91e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7149242	0.697	rs12882815	chr14:101183142	C/G	cg18089426	chr14:101175970	NA	-0.58	-5.77	-0.51	9.74e-8	Platelet count;
THYM	cis	rs3768617	0.510	rs2027076	chr1:183073407	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.79	0.44	6.21e-6	Fuchs's corneal dystrophy;
THYM	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1729951	0.575	rs835642	chr3:136703365	A/T	cg12473912	chr3:136751656	NA	0.62	5.03	0.46	2.34e-6	Neuroticism;
THYM	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11625487	1.000	rs11625487	chr14:77961609	G/C	cg20045696	chr14:77926864	AHSA1	0.64	4.56	0.42	1.5e-5	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
THYM	cis	rs11771526	0.901	rs1530823	chr7:32311420	G/T	cg27511599	chr7:32358540	NA	-0.61	-4.59	-0.43	1.37e-5	Body mass index;
THYM	cis	rs8031584	1.000	rs8031584	chr15:31287343	A/T	cg08109568	chr15:31115862	NA	-0.61	-5.84	-0.51	7.29e-8	Huntington's disease progression;
THYM	cis	rs7428	0.527	rs1053560	chr2:85546192	C/T	cg24342717	chr2:85555507	TGOLN2	-0.74	-6.34	-0.55	7.78e-9	Ear protrusion;
THYM	trans	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg25214090	chr10:38739885	LOC399744	0.91	7.93	0.63	4.24e-12	Corneal astigmatism;
THYM	cis	rs9810089	0.903	rs10935185	chr3:136290529	C/G	cg21827317	chr3:136751795	NA	0.57	4.87	0.45	4.42e-6	Gestational age at birth (child effect);
THYM	cis	rs11723261	0.621	rs6599306	chr4:143439	C/G	cg12746427	chr4:53362	ZNF718;ZNF595	-0.87	-5.35	-0.48	6.15e-7	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs7247513	0.701	rs8107642	chr19:12766370	C/T	cg01871581	chr19:12707946	ZNF490	-0.76	-8.0	-0.63	2.98e-12	Bipolar disorder;
THYM	cis	rs7131987	0.834	rs12228468	chr12:29453610	A/C	cg09582351	chr12:29534625	ERGIC2	0.52	4.95	0.45	3.25e-6	QT interval;
THYM	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg18402987	chr7:1209562	NA	0.82	5.13	0.47	1.51e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.61	0.5	1.97e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg22974920	chr21:40686053	BRWD1	-0.64	-5.1	-0.46	1.74e-6	Cognitive function;
THYM	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg26314531	chr2:26401878	FAM59B	0.74	4.81	0.44	5.7e-6	Gut microbiome composition (summer);
THYM	cis	rs7078219	0.743	rs11190128	chr10:101275149	A/C	cg23904955	chr10:101282759	NA	-0.41	-4.89	-0.45	4.15e-6	Dental caries;
THYM	cis	rs4891159	0.548	rs12454625	chr18:74128751	A/G	cg24786174	chr18:74118243	ZNF516	0.97	14.43	0.83	1.15e-25	Longevity;
THYM	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg01616529	chr11:638424	DRD4	-0.78	-6.62	-0.56	2.16e-9	Systemic lupus erythematosus;
THYM	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs10751667	0.961	rs7395928	chr11:952605	T/G	cg01483505	chr11:975446	AP2A2	0.64	5.17	0.47	1.31e-6	Alzheimer's disease (late onset);
THYM	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg26967526	chr14:35346199	BAZ1A	-0.72	-5.33	-0.48	6.65e-7	Psoriasis;
THYM	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg19761014	chr17:28927070	LRRC37B2	0.85	4.9	0.45	3.96e-6	Body mass index;
THYM	cis	rs6686842	0.965	rs4660184	chr1:41524538	T/C	cg03387723	chr1:41708464	SCMH1	0.42	4.98	0.45	2.86e-6	Height;
THYM	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.69e-11	Aortic root size;
THYM	cis	rs12367572	1.000	rs10880704	chr12:45318430	C/T	cg03114573	chr12:45410052	DBX2	-0.53	-5.0	-0.46	2.61e-6	Gut microbiome composition (summer);
THYM	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs977987	0.806	rs8050059	chr16:75388731	C/T	cg03315344	chr16:75512273	CHST6	0.7	5.66	0.5	1.63e-7	Dupuytren's disease;
THYM	cis	rs4243830	0.826	rs3908553	chr1:6621921	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	1.1	4.96	0.45	3.1e-6	Body mass index;
THYM	cis	rs2227564	0.620	rs4746143	chr10:75477298	A/G	cg23231163	chr10:75533350	FUT11	-0.37	-4.72	-0.44	8.23e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg00129232	chr17:37814104	STARD3	0.71	4.8	0.44	5.94e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs9810089	0.527	rs895894	chr3:135955443	C/T	cg21827317	chr3:136751795	NA	0.66	6.07	0.53	2.61e-8	Gestational age at birth (child effect);
THYM	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg06112835	chr11:68658793	MRPL21	0.45	6.44	0.55	4.77e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg13918804	chr1:2043761	PRKCZ	-0.62	-4.68	-0.43	9.69e-6	Height;
THYM	cis	rs6121246	0.567	rs7361893	chr20:30200751	C/T	cg21427119	chr20:30132790	HM13	-0.86	-5.96	-0.52	4.2e-8	Mean corpuscular hemoglobin;
THYM	cis	rs7322722	0.716	rs424391	chr13:77614437	A/G	cg04565255	chr13:77565759	CLN5	0.43	4.49	0.42	2.04e-5	Preeclampsia;
THYM	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg03709012	chr19:19516395	GATAD2A	0.81	6.63	0.56	2.02e-9	Tonsillectomy;
THYM	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg03806693	chr22:41940476	POLR3H	1.07	8.61	0.66	1.55e-13	Vitiligo;
THYM	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg06636551	chr8:101224915	SPAG1	0.67	6.58	0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs501916	0.727	rs12439630	chr15:48035191	C/T	cg20869673	chr15:48010124	SEMA6D	0.68	5.15	0.47	1.38e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg00898013	chr13:113819073	PROZ	1.02	10.0	0.72	1.62e-16	Platelet distribution width;
THYM	cis	rs4689388	0.890	rs3821941	chr4:6286954	A/G	cg25554036	chr4:6271136	WFS1	0.5	4.5	0.42	1.96e-5	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs7404928	0.915	rs7203367	chr16:23902344	A/G	cg26685404	chr16:23957272	PRKCB	0.48	4.83	0.44	5.27e-6	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg14019146	chr3:50243930	SLC38A3	-0.56	-4.68	-0.43	9.51e-6	Body mass index;
THYM	cis	rs3741151	0.686	rs73546735	chr11:73256797	C/T	cg17517138	chr11:73019481	ARHGEF17	0.9	4.71	0.43	8.56e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg08132940	chr7:1081526	C7orf50	-1.16	-6.65	-0.56	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2731664	0.792	rs335435	chr5:176867943	A/G	cg14098951	chr5:176875120	PRR7	0.57	4.91	0.45	3.84e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9906944	0.707	rs4794019	chr17:47107290	G/T	cg11673840	chr17:47092156	IGF2BP1	-0.54	-5.48	-0.49	3.55e-7	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs11668609	0.505	rs60605343	chr19:24151288	T/C	cg15526094	chr19:24182596	NA	-0.63	-4.47	-0.42	2.13e-5	Response to taxane treatment (docetaxel);
THYM	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg25736982	chr6:160182554	ACAT2	0.64	4.49	0.42	2.02e-5	Iron status biomarkers;
THYM	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg02953382	chr22:24373134	LOC391322	-0.88	-9.51	-0.7	1.81e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs868036	0.718	rs28399056	chr15:68116010	C/A	cg24579218	chr15:68104479	NA	-0.8	-8.27	-0.65	8.25e-13	Restless legs syndrome;
THYM	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg04944784	chr2:26401820	FAM59B	-0.71	-5.48	-0.49	3.46e-7	Gut microbiome composition (summer);
THYM	cis	rs9810089	0.711	rs711972	chr3:136110018	C/T	cg21827317	chr3:136751795	NA	0.54	4.55	0.42	1.59e-5	Gestational age at birth (child effect);
THYM	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg03684893	chr10:554711	DIP2C	-0.7	-6.2	-0.54	1.48e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg09029085	chr17:47094198	IGF2BP1	0.48	6.85	0.58	7.27e-10	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7927771	0.524	rs2869024	chr11:47674101	G/A	cg18512352	chr11:47633146	NA	-0.41	-4.57	-0.42	1.49e-5	Subjective well-being;
THYM	cis	rs193541	0.527	rs10478570	chr5:122295857	A/G	cg19808643	chr5:122110361	SNX2	-0.61	-4.97	-0.45	2.95e-6	Glucose homeostasis traits;
THYM	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg12011299	chr4:100065546	ADH4	0.94	9.78	0.71	4.9e-16	Alcohol dependence;
THYM	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.27	-0.48	8.61e-7	Hemoglobin concentration;
THYM	cis	rs1160297	0.576	rs13030509	chr2:53110287	T/A	cg07782112	chr2:53107842	NA	0.74	5.94	0.52	4.7e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs2350702	0.660	rs1914776	chr2:49951309	G/A	cg22592722	chr2:49566210	NA	-0.56	-4.55	-0.42	1.6e-5	Morning vs. evening chronotype;
THYM	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.92	-10.65	-0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs9677476	0.863	rs3731775	chr2:232063578	G/A	cg07929768	chr2:232055508	NA	0.64	6.4	0.55	5.83e-9	Food antigen IgG levels;
THYM	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg26384229	chr12:38710491	ALG10B	0.95	7.98	0.63	3.38e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs28595532	0.920	rs115334469	chr4:119596194	G/C	cg21605333	chr4:119757512	SEC24D	1.42	4.79	0.44	6.16e-6	Cannabis dependence symptom count;
THYM	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg18252515	chr7:66147081	NA	1.49	9.3	0.69	5.16e-15	Gout;
THYM	cis	rs35264875	1.000	rs72919432	chr11:68829954	C/T	cg01993067	chr11:68851601	TPCN2	1.0	4.68	0.43	9.62e-6	Blond vs. brown hair color;
THYM	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	4.78	0.44	6.28e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6032067	0.777	rs62208382	chr20:43785549	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs6840360	0.642	rs2709838	chr4:152371364	G/A	cg17479576	chr4:152424074	FAM160A1	-0.68	-5.17	-0.47	1.28e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11690935	0.549	rs62183819	chr2:172904520	G/T	cg13550731	chr2:172543902	DYNC1I2	0.69	5.51	0.49	3.09e-7	Schizophrenia;
THYM	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	1.01	6.97	0.58	4.15e-10	Smoking behavior;
THYM	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg02753203	chr1:228287806	NA	0.94	9.7	0.71	7.21e-16	Diastolic blood pressure;
THYM	cis	rs7107174	1.000	rs2512537	chr11:77971947	T/C	cg19901956	chr11:77921274	USP35	-0.76	-5.83	-0.51	7.53e-8	Testicular germ cell tumor;
THYM	cis	rs72627123	0.867	rs113768127	chr14:74467839	T/C	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg20476274	chr7:133979776	SLC35B4	0.71	4.6	0.43	1.32e-5	Mean platelet volume;
THYM	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg24375607	chr4:120327624	NA	0.53	4.47	0.42	2.2e-5	Corneal astigmatism;
THYM	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg16325326	chr1:53192061	ZYG11B	0.96	10.87	0.74	2.35e-18	Monocyte count;
THYM	cis	rs920590	0.721	rs61180388	chr8:19670214	G/C	cg01411142	chr8:19674711	INTS10	0.64	5.02	0.46	2.4e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs59698941	0.943	rs10491277	chr5:132236361	G/C	cg02081065	chr5:132209139	LEAP2	-0.86	-5.85	-0.51	7.09e-8	Apolipoprotein A-IV levels;
THYM	cis	rs8133932	0.654	rs2776402	chr21:47360761	T/C	cg20357416	chr21:47294739	PCBP3	0.82	5.1	0.46	1.76e-6	Schizophrenia;
THYM	cis	rs992157	1.000	rs11554825	chr2:219125809	C/T	cg04731861	chr2:219085781	ARPC2	-0.5	-4.5	-0.42	1.93e-5	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4866334	1.000	rs79036917	chr5:18441030	A/C	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg00684032	chr4:1343700	KIAA1530	-0.68	-5.74	-0.51	1.15e-7	Obesity-related traits;
THYM	cis	rs9399401	0.626	rs4304190	chr6:142778912	A/G	cg03128060	chr6:142623767	GPR126	0.7	9.01	0.68	2.19e-14	Chronic obstructive pulmonary disease;
THYM	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg24209194	chr3:40518798	ZNF619	-0.68	-5.8	-0.51	8.73e-8	Renal cell carcinoma;
THYM	cis	rs2625529	0.824	rs4777475	chr15:72218206	C/T	cg16672083	chr15:72433130	SENP8	-0.55	-4.89	-0.45	4.1e-6	Red blood cell count;
THYM	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06850241	chr22:41845214	NA	0.53	4.85	0.45	4.76e-6	Vitiligo;
THYM	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg18850127	chr7:39170497	POU6F2	-0.54	-5.03	-0.46	2.3e-6	IgG glycosylation;
THYM	cis	rs420259	0.516	rs2239951	chr16:23504993	C/T	cg00143387	chr16:23521605	GGA2	-0.77	-5.51	-0.49	3.12e-7	Bipolar disorder;
THYM	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg11062466	chr8:58055876	NA	0.94	7.28	0.6	9.75e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs2859741	1.000	rs543121	chr1:37497098	T/C	cg09363841	chr1:37513479	NA	-0.69	-6.4	-0.55	5.96e-9	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
THYM	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg11789530	chr4:8429930	ACOX3	0.74	6.0	0.52	3.55e-8	Response to antineoplastic agents;
THYM	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg26384229	chr12:38710491	ALG10B	0.99	7.63	0.62	1.81e-11	Morning vs. evening chronotype;
THYM	cis	rs9902453	1.000	rs9897206	chr17:28406108	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-4.62	-0.43	1.2e-5	Coffee consumption (cups per day);
THYM	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.76	7.01	0.58	3.39e-10	Prudent dietary pattern;
THYM	cis	rs2070488	1.000	rs36006749	chr3:38443312	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	6.65	0.56	1.88e-9	Electrocardiographic conduction measures;
THYM	cis	rs6032067	0.777	rs17423897	chr20:43780307	T/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.93	-0.58	5.03e-10	Blood protein levels;
THYM	cis	rs988913	1.000	rs6929930	chr6:54812710	G/A	cg04690482	chr6:54711388	FAM83B	0.48	5.36	0.48	5.77e-7	Menarche (age at onset);
THYM	cis	rs7584330	0.504	rs11883500	chr2:238434434	C/T	cg08992911	chr2:238395768	MLPH	0.89	5.81	0.51	8.24e-8	Prostate cancer;
THYM	cis	rs714027	0.605	rs5763775	chr22:30503007	G/T	cg27665648	chr22:30112403	NA	-0.52	-4.73	-0.44	7.79e-6	Lymphocyte counts;
THYM	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg13010199	chr12:38710504	ALG10B	0.76	6.08	0.53	2.5e-8	Heart rate;
THYM	cis	rs863345	0.604	rs6666609	chr1:158498124	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.75e-6	Aortic root size;
THYM	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg18221576	chr1:22213934	HSPG2	-0.53	-4.58	-0.43	1.38e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs457717	0.798	rs3797412	chr5:75927954	A/G	cg08241785	chr5:75919281	F2RL2;IQGAP2	-0.32	-4.68	-0.43	9.5e-6	Hearing impairment;
THYM	cis	rs57221529	0.709	rs72707024	chr5:667915	G/A	cg16624210	chr5:671434	TPPP	0.85	6.19	0.54	1.5e-8	Lung disease severity in cystic fibrosis;
THYM	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg18825531	chr11:62321136	NA	-0.46	-5.32	-0.48	6.94e-7	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg14458575	chr2:238380390	NA	1.12	8.86	0.67	4.5e-14	Prostate cancer;
THYM	cis	rs516946	1.000	rs28602970	chr8:41524505	A/G	cg19441908	chr8:41529140	ANK1	0.62	4.9	0.45	3.87e-6	Type 2 diabetes;
THYM	cis	rs4604732	0.642	rs4472786	chr1:247636518	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.58	4.56	0.42	1.51e-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
THYM	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg06238570	chr21:40685208	BRWD1	0.92	6.91	0.58	5.61e-10	Cognitive function;
THYM	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs7578361	0.959	rs10207875	chr2:150394925	G/T	cg17961725	chr2:150454027	NA	0.69	5.49	0.49	3.32e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs11096990	0.634	rs4975001	chr4:39266464	T/C	cg24403649	chr4:39172243	NA	-0.66	-5.67	-0.5	1.55e-7	Cognitive function;
THYM	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs7731657	0.537	rs4705995	chr5:130350688	G/A	cg08523029	chr5:130500466	HINT1	-0.81	-5.6	-0.5	2.04e-7	Fasting plasma glucose;
THYM	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg11812906	chr14:75593930	NEK9	0.89	8.2	0.64	1.11e-12	Height;
THYM	cis	rs7772486	0.790	rs2249147	chr6:146184999	T/C	cg23711669	chr6:146136114	FBXO30	0.93	9.17	0.69	1e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7336332	0.598	rs1885988	chr13:28010262	C/T	cg22138327	chr13:27999177	GTF3A	-0.62	-4.74	-0.44	7.56e-6	Weight;
THYM	cis	rs909002	1.000	rs2292993	chr1:32140733	C/T	cg13919466	chr1:32135498	COL16A1	-0.53	-5.32	-0.48	6.81e-7	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg25214090	chr10:38739885	LOC399744	0.83	7.11	0.59	2.14e-10	Corneal astigmatism;
THYM	cis	rs6570726	0.764	rs9322028	chr6:145895797	G/T	cg05347473	chr6:146136440	FBXO30	0.58	4.52	0.42	1.8e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2290159	0.800	rs56363132	chr3:12680403	T/C	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs2256039	0.920	rs2256453	chr9:86796403	A/G	cg14555996	chr9:86785905	NA	-0.3	-4.77	-0.44	6.75e-6	Multiple system atrophy;
THYM	cis	rs240764	0.507	rs11155661	chr6:101229025	A/G	cg21058520	chr6:100914733	NA	-0.57	-4.51	-0.42	1.86e-5	Neuroticism;
THYM	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg09904177	chr6:26538194	HMGN4	0.64	5.41	0.49	4.78e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg10523679	chr1:76189770	ACADM	0.86	8.29	0.65	7.19e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	trans	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	5.7	0.5	1.37e-7	Schizophrenia;
THYM	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg06481639	chr22:41940642	POLR3H	-0.81	-5.63	-0.5	1.79e-7	Vitiligo;
THYM	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg12311346	chr5:56204834	C5orf35	-0.83	-6.09	-0.53	2.41e-8	Initial pursuit acceleration;
THYM	cis	rs1061377	0.501	rs62308278	chr4:39162658	G/T	cg24403649	chr4:39172243	NA	0.57	4.81	0.44	5.65e-6	Uric acid levels;
THYM	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.23	4.66	0.43	1.04e-5	Obesity-related traits;
THYM	cis	rs1003719	0.788	rs2835584	chr21:38460338	A/T	cg01329690	chr21:38580129	DSCR9	0.37	5.12	0.46	1.6e-6	Eye color traits;
THYM	cis	rs17030434	0.627	rs17371643	chr4:154769372	C/T	cg14289246	chr4:154710475	SFRP2	-0.71	-5.25	-0.47	9.1e-7	Electrocardiographic conduction measures;
THYM	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg03433033	chr1:76189801	ACADM	0.77	10.21	0.72	6.01e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2073300	1.000	rs6114139	chr20:23458390	T/G	cg12062639	chr20:23401060	NAPB	0.96	4.84	0.45	4.95e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs11671005	0.695	rs12972898	chr19:58956888	A/G	cg18639983	chr19:58920768	ZNF584	0.59	4.63	0.43	1.17e-5	Mean platelet volume;
THYM	cis	rs919433	0.617	rs4850807	chr2:198575975	G/A	cg05783139	chr2:198650985	BOLL	-0.63	-5.0	-0.46	2.58e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg18252515	chr7:66147081	NA	-0.66	-5.2	-0.47	1.16e-6	Aortic root size;
THYM	cis	rs12188164	0.686	rs11741946	chr5:421403	G/A	cg26850624	chr5:429559	AHRR	-0.69	-5.04	-0.46	2.22e-6	Cystic fibrosis severity;
THYM	cis	rs72827839	0.644	rs72833479	chr17:45960449	G/A	cg23391107	chr17:45924227	SP6	0.79	5.64	0.5	1.73e-7	Ease of getting up in the morning;
THYM	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg08017756	chr2:100939284	LONRF2	-0.73	-7.71	-0.62	1.25e-11	Intelligence (multi-trait analysis);
THYM	cis	rs3816788	0.792	rs729180	chr8:21817245	C/T	cg17168535	chr8:21777572	XPO7	0.89	8.14	0.64	1.54e-12	Lung cancer in ever smokers;
THYM	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.43	0.7	2.73e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2991971	1.000	rs667626	chr1:46020551	T/C	cg15605315	chr1:45957053	TESK2	0.65	5.13	0.47	1.52e-6	High light scatter reticulocyte count;
THYM	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg06558623	chr16:89946397	TCF25	1.33	5.62	0.5	1.94e-7	Skin colour saturation;
THYM	cis	rs921968	0.643	rs2556386	chr2:219534530	C/T	cg01872077	chr2:219646372	CYP27A1	-0.58	-4.49	-0.42	2e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9359856	0.510	rs6937789	chr6:90468775	C/G	cg13799429	chr6:90582589	CASP8AP2	0.84	7.98	0.63	3.27e-12	Bipolar disorder;
THYM	cis	rs11645898	0.687	rs1424241	chr16:72078907	G/A	cg14768367	chr16:72042858	DHODH	-0.6	-4.53	-0.42	1.74e-5	Blood protein levels;
THYM	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg11812906	chr14:75593930	NEK9	0.82	7.47	0.61	3.9e-11	Height;
THYM	cis	rs4631830	0.863	rs4935162	chr10:51525699	C/G	cg16070123	chr10:51489643	NA	-0.5	-4.53	-0.42	1.71e-5	Prostate-specific antigen levels;
THYM	cis	rs12476592	0.602	rs262526	chr2:63899478	C/T	cg17519650	chr2:63277830	OTX1	-0.72	-4.68	-0.43	9.38e-6	Childhood ear infection;
THYM	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg17264618	chr3:40429014	ENTPD3	0.5	4.81	0.44	5.73e-6	Renal cell carcinoma;
THYM	cis	rs5758511	0.514	rs5758580	chr22:42493875	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.66	6.84	0.57	7.82e-10	Birth weight;
THYM	cis	rs11645898	0.810	rs72787060	chr16:72105371	T/C	cg03805757	chr16:71968109	PKD1L3	-0.72	-5.21	-0.47	1.11e-6	Blood protein levels;
THYM	cis	rs9790314	0.967	rs463928	chr3:161087734	A/T	cg04691961	chr3:161091175	C3orf57	-0.69	-6.08	-0.53	2.48e-8	Morning vs. evening chronotype;
THYM	cis	rs9902453	0.817	rs880749	chr17:28059970	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-4.86	-0.45	4.68e-6	Coffee consumption (cups per day);
THYM	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs11577318	0.796	rs4625269	chr1:26626967	C/A	cg19677267	chr1:26645161	CD52;UBXN11	-0.46	-5.87	-0.52	6.35e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs13138355	1	rs13138355	chr4:83545976	C/T	cg10249074	chr4:83542146	C4orf11	-0.67	-5.27	-0.48	8.62e-7	Monocyte count;White blood cell count;Myeloid white cell count;
THYM	cis	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg06521331	chr12:34319734	NA	-0.8	-6.37	-0.55	6.85e-9	Morning vs. evening chronotype;
THYM	cis	rs1775715	0.870	rs10827001	chr10:32229734	C/T	cg04359828	chr10:32216031	ARHGAP12	0.41	5.07	0.46	1.95e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs67460515	0.892	rs7647374	chr3:160975576	T/A	cg03342759	chr3:160939853	NMD3	-0.93	-7.98	-0.63	3.34e-12	Parkinson's disease;
THYM	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.41	-4.97	-0.45	2.98e-6	Longevity;Endometriosis;
THYM	cis	rs2034650	0.563	rs12914315	chr15:40713878	C/T	cg12699599	chr15:40643142	PHGR1	0.55	5.18	0.47	1.22e-6	Interstitial lung disease;
THYM	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11905131	chr22:24372483	LOC391322	-0.88	-9.26	-0.69	6.29e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg19645103	chr12:69753606	YEATS4	-0.56	-4.52	-0.42	1.8e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg06728252	chr6:26598149	ABT1	-0.43	-5.11	-0.46	1.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs8031584	0.958	rs61997076	chr15:31216225	C/T	cg14829155	chr15:31115871	NA	-0.58	-4.88	-0.45	4.24e-6	Huntington's disease progression;
THYM	cis	rs12142240	0.698	rs79490411	chr1:46813568	G/A	cg00530320	chr1:46809349	NSUN4	0.83	5.34	0.48	6.39e-7	Menopause (age at onset);
THYM	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg24642844	chr7:1081250	C7orf50	-1.28	-8.22	-0.64	1.06e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg24399712	chr22:39784796	NA	0.93	10.5	0.73	1.42e-17	Intelligence (multi-trait analysis);
THYM	cis	rs684232	0.602	rs394747	chr17:562495	C/G	cg15660573	chr17:549704	VPS53	0.99	11.0	0.75	1.22e-18	Prostate cancer;
THYM	trans	rs8073060	0.586	rs225265	chr17:33961972	C/T	cg19694781	chr19:47549865	TMEM160	-0.95	-7.8	-0.62	7.8e-12	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg03188948	chr7:1209495	NA	0.9	5.0	0.46	2.66e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7426056	0.671	rs17533727	chr2:204602929	C/G	cg07930752	chr2:204569955	CD28	-0.66	-4.56	-0.42	1.55e-5	Primary sclerosing cholangitis;
THYM	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg23035555	chr19:3500370	DOHH	-0.81	-4.63	-0.43	1.17e-5	Total cholesterol levels;
THYM	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg26384229	chr12:38710491	ALG10B	1.05	10.43	0.73	1.96e-17	Heart rate;
THYM	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.13	-8.4	-0.65	4.32e-13	Platelet count;
THYM	cis	rs79149102	0.579	rs76518150	chr15:75292721	C/G	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	cis	rs2734839	0.537	rs11214603	chr11:113279922	G/A	cg14159747	chr11:113255604	NA	0.35	7.81	0.63	7.61e-12	Information processing speed;
THYM	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg06481639	chr22:41940642	POLR3H	-0.6	-4.47	-0.42	2.16e-5	Neuroticism;
THYM	cis	rs67311347	0.544	rs12635762	chr3:40332759	C/T	cg13683864	chr3:40499215	RPL14	0.75	6.92	0.58	5.26e-10	Renal cell carcinoma;
THYM	cis	rs61931739	0.533	rs7970871	chr12:33917301	G/A	cg10856724	chr12:34555212	NA	-0.63	-5.9	-0.52	5.54e-8	Morning vs. evening chronotype;
THYM	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg12000587	chr17:30186630	C17orf79	0.39	4.48	0.42	2.1e-5	Hip circumference adjusted for BMI;
THYM	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg27170947	chr2:26402098	FAM59B	0.79	6.27	0.54	1.05e-8	Gut microbiome composition (summer);
THYM	cis	rs28647808	1.000	rs28729896	chr9:136277796	C/T	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg18811423	chr2:55921094	PNPT1	0.77	7.34	0.6	7.35e-11	Metabolic syndrome;
THYM	cis	rs3820068	0.705	rs72645808	chr1:15870118	G/C	cg05660106	chr1:15850417	CASP9	1.13	9.21	0.69	7.98e-15	Systolic blood pressure;
THYM	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7246967	0.673	rs4933027	chr19:22903972	A/C	cg05241461	chr19:22816980	ZNF492	-0.61	-4.75	-0.44	7.2e-6	Bronchopulmonary dysplasia;
THYM	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	4.95	0.45	3.24e-6	Menarche (age at onset);
THYM	cis	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg13147721	chr7:65941812	NA	-0.89	-5.31	-0.48	7.23e-7	Gout;
THYM	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg03806693	chr22:41940476	POLR3H	1.1	8.94	0.68	3.12e-14	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs2277425	0.755	rs2277424	chr13:111522420	A/G	cg04513422	chr13:111522314	C13orf29	-0.61	-4.91	-0.45	3.73e-6	Sitting height ratio;
THYM	cis	rs6543140	0.964	rs13393175	chr2:103078849	T/G	cg03938978	chr2:103052716	IL18RAP	0.55	5.32	0.48	6.95e-7	Blood protein levels;
THYM	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.48	-4.67	-0.43	9.83e-6	Crohn's disease;
THYM	cis	rs2658782	0.704	rs2658766	chr11:93232229	G/A	cg15737290	chr11:93063684	CCDC67	0.97	7.01	0.58	3.45e-10	Pulmonary function decline;
THYM	cis	rs7226229	0.950	rs4985824	chr17:20951493	T/C	cg21263980	chr17:20946333	USP22	0.67	4.92	0.45	3.6e-6	Blood trace element (Se levels);
THYM	cis	rs916888	0.647	rs199519	chr17:44853924	G/A	cg01570182	chr17:44337453	NA	-0.64	-7.11	-0.59	2.16e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs12935418	0.673	rs2549886	chr16:81061232	T/C	cg16651780	chr16:81037892	C16orf61	-0.76	-5.48	-0.49	3.45e-7	Mean corpuscular volume;
THYM	cis	rs887829	0.641	rs10197460	chr2:234589190	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.81	-6.58	-0.56	2.52e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs8063761	0.689	rs4785763	chr16:90066936	G/T	cg09104284	chr16:90050102	AFG3L1	0.57	4.53	0.42	1.69e-5	Squamous cell carcinoma;
THYM	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg12031863	chr16:4587854	C16orf5	-0.46	-4.99	-0.46	2.75e-6	Schizophrenia;
THYM	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg26721908	chr21:47610096	LSS	0.89	7.35	0.6	6.71e-11	Testicular germ cell tumor;
THYM	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg08994789	chr17:28903642	LRRC37B2	1.08	5.41	0.49	4.69e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6840360	0.681	rs4519779	chr4:152301185	G/A	cg17479576	chr4:152424074	FAM160A1	-0.74	-5.49	-0.49	3.4e-7	Intelligence (multi-trait analysis);
THYM	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg22508957	chr16:3507546	NAT15	-0.67	-9.37	-0.69	3.59e-15	Tuberculosis;
THYM	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg10018233	chr7:150070692	REPIN1	0.38	5.41	0.48	4.8e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.65e-6	Aortic root size;
THYM	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg19346786	chr7:2764209	NA	-0.58	-4.99	-0.46	2.76e-6	Height;
THYM	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.04	7.1	0.59	2.26e-10	Platelet count;
THYM	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg12310025	chr6:25882481	NA	-0.9	-7.96	-0.63	3.65e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg22105103	chr4:187893119	NA	0.89	9.3	0.69	5.11e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs983545	1.000	rs1156336	chr3:16967221	A/T	cg24159436	chr3:16974681	PLCL2	0.35	4.88	0.45	4.34e-6	Blood protein levels;
THYM	cis	rs4919694	1.000	rs17881215	chr10:104629236	G/C	cg04362960	chr10:104952993	NT5C2	0.93	5.9	0.52	5.57e-8	Arsenic metabolism;
THYM	cis	rs9560113	0.509	rs4771759	chr13:112209217	A/G	cg10483660	chr13:112241077	NA	-0.61	-6.89	-0.58	6.14e-10	Menarche (age at onset);
THYM	cis	rs3204270	0.759	rs8065104	chr17:79672605	G/A	cg13117272	chr17:79681052	SLC25A10	-0.76	-4.76	-0.44	6.85e-6	Dental caries;
THYM	cis	rs752010	0.811	rs10749836	chr1:42086860	G/C	cg22486000	chr1:42919398	ZMYND12	-0.47	-5.41	-0.49	4.69e-7	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs6665290	0.935	rs1929864	chr1:227195500	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs6430585	0.584	rs4954276	chr2:136402117	A/G	cg04750100	chr2:136595281	LCT	0.57	6.0	0.52	3.62e-8	Corneal structure;
THYM	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.01	-0.52	3.48e-8	Psoriasis;
THYM	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg24812749	chr6:127587940	RNF146	0.74	5.46	0.49	3.73e-7	Breast cancer;
THYM	cis	rs7119038	0.774	rs11217037	chr11:118677086	G/A	cg19308663	chr11:118741387	NA	0.57	5.87	0.52	6.34e-8	Sjögren's syndrome;
THYM	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg02018176	chr4:1364513	KIAA1530	0.5	4.57	0.42	1.44e-5	Obesity-related traits;
THYM	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs9403317	0.609	rs9321834	chr6:142031004	A/C	cg15052665	chr6:141804349	NA	-0.63	-4.91	-0.45	3.81e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7172809	0.573	rs17470529	chr15:77673359	A/G	cg22256960	chr15:77711686	NA	-0.65	-4.82	-0.44	5.47e-6	Glucose homeostasis traits;
THYM	cis	rs12509991	0.582	rs7670854	chr4:127035477	T/A	cg04459504	chr4:126237325	FAT4	-0.62	-4.46	-0.42	2.26e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg01304814	chr3:48885189	PRKAR2A	0.96	4.86	0.45	4.55e-6	Cognitive function;
THYM	cis	rs12956009	0.583	rs11663609	chr18:44862757	C/T	cg19077165	chr18:44547161	KATNAL2	-0.49	-4.56	-0.42	1.5e-5	Educational attainment (years of education);
THYM	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg27446573	chr6:127587934	RNF146	1.05	7.83	0.63	6.8e-12	Breast cancer;
THYM	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg06191203	chr2:152266755	RIF1	-0.73	-5.06	-0.46	2.07e-6	Lung cancer;
THYM	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg06028808	chr11:68637592	NA	0.62	6.32	0.54	8.26e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs79247733	0.786	rs2286442	chr22:30772686	C/T	cg03868770	chr22:30783737	RNF215	-0.7	-4.62	-0.43	1.19e-5	Tonsillectomy;
THYM	cis	rs8017423	0.935	rs2149653	chr14:90669333	G/A	cg04239629	chr14:90701769	NA	-0.59	-4.45	-0.42	2.32e-5	Mortality in heart failure;
THYM	cis	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg02825527	chr7:2087843	MAD1L1	-0.7	-4.55	-0.42	1.58e-5	Bipolar disorder;
THYM	cis	rs4363657	0.666	rs16923647	chr12:21451395	A/G	cg14622193	chr12:21587445	NA	-0.87	-5.18	-0.47	1.23e-6	Bilirubin levels;Blood metabolite levels;
THYM	cis	rs5769765	0.862	rs138897	chr22:50231067	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.5	4.84	0.44	5.02e-6	Schizophrenia;
THYM	cis	rs2219968	0.828	rs62508223	chr8:78941534	G/C	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg10802521	chr3:52805072	NEK4	-0.64	-4.8	-0.44	5.94e-6	Bipolar disorder;
THYM	cis	rs514406	0.893	rs4584343	chr1:53434539	A/C	cg08736216	chr1:53307985	ZYG11A	0.61	5.57	0.5	2.41e-7	Monocyte count;
THYM	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.77	6.07	0.53	2.64e-8	Systemic lupus erythematosus;
THYM	cis	rs1788820	0.957	rs1652375	chr18:21109269	T/C	cg14672496	chr18:21087552	C18orf8	0.76	6.02	0.53	3.21e-8	Body mass index;
THYM	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg08859206	chr1:53392774	SCP2	-0.47	-4.72	-0.44	8.01e-6	Monocyte count;
THYM	cis	rs72653721	0.838	rs949557	chr6:11025983	C/T	cg24724428	chr6:11044888	ELOVL2	0.55	4.53	0.42	1.71e-5	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
THYM	cis	rs9644630	0.930	rs4921655	chr8:19366608	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.82	-8.65	-0.66	1.29e-13	Oropharynx cancer;
THYM	cis	rs8041943	0.643	rs11854766	chr15:79924403	A/G	cg20511832	chr15:78934280	CHRNB4	0.42	4.82	0.44	5.4e-6	Bone mineral density (spine) and age at menarche;
THYM	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg02640540	chr1:67518911	SLC35D1	0.67	5.11	0.46	1.64e-6	Lymphocyte percentage of white cells;
THYM	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg02527881	chr3:46936655	PTH1R	-0.64	-6.0	-0.52	3.59e-8	Colorectal cancer;
THYM	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg19761014	chr17:28927070	LRRC37B2	0.89	4.93	0.45	3.5e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13256369	1.000	rs1109619	chr8:8571616	G/T	cg18904891	chr8:8559673	CLDN23	0.7	5.21	0.47	1.1e-6	Obesity-related traits;
THYM	cis	rs8048589	1.000	rs11648816	chr16:12184107	T/G	cg01990910	chr16:12207648	SNX29	-0.44	-5.0	-0.46	2.58e-6	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	trans	rs637571	0.522	rs528736	chr11:65705108	A/G	cg17712092	chr4:129076599	LARP1B	0.94	8.13	0.64	1.62e-12	Eosinophil percentage of white cells;
THYM	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19346786	chr7:2764209	NA	-0.8	-7.18	-0.59	1.53e-10	Height;
THYM	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg04520793	chr17:42248056	ASB16	0.35	4.98	0.45	2.85e-6	Total body bone mineral density;
THYM	cis	rs77204473	0.549	rs12280210	chr11:116940449	T/C	cg20608306	chr11:116969690	SIK3	-0.68	-5.02	-0.46	2.36e-6	Eosinophil counts;Sum eosinophil basophil counts;
THYM	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg23791538	chr6:167370224	RNASET2	0.74	5.92	0.52	5.06e-8	Crohn's disease;
THYM	cis	rs6570726	0.577	rs441982	chr6:145842848	A/G	cg23711669	chr6:146136114	FBXO30	0.8	7.12	0.59	2.02e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs763014	0.898	rs2384978	chr16:625384	T/C	cg10281704	chr16:966864	LMF1	-0.26	-4.6	-0.43	1.32e-5	Height;
THYM	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg00677455	chr12:58241039	CTDSP2	0.72	4.87	0.45	4.51e-6	Multiple sclerosis;
THYM	cis	rs7072216	0.763	rs7911036	chr10:100167015	A/T	cg03852570	chr10:100175106	PYROXD2	0.38	4.89	0.45	4.04e-6	Metabolite levels;
THYM	cis	rs988913	1.000	rs9382407	chr6:54836638	T/C	cg18532076	chr6:54711417	FAM83B	0.5	4.91	0.45	3.78e-6	Menarche (age at onset);
THYM	cis	rs9880211	1.000	rs9883189	chr3:136289466	T/C	cg21827317	chr3:136751795	NA	-0.67	-4.5	-0.42	1.92e-5	Body mass index;Height;
THYM	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06850241	chr22:41845214	NA	0.59	5.16	0.47	1.37e-6	Vitiligo;
THYM	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg15556689	chr8:8085844	FLJ10661	0.61	4.71	0.44	8.4e-6	Mood instability;
THYM	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg04317338	chr11:64019027	PLCB3	0.86	5.93	0.52	4.88e-8	Mean platelet volume;
THYM	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg11965913	chr1:205819406	PM20D1	0.7	6.98	0.58	3.93e-10	Menarche (age at onset);
THYM	cis	rs6840360	0.967	rs6535812	chr4:152599374	C/A	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs11264213	0.591	rs4653157	chr1:36543278	C/T	cg27506609	chr1:36549197	TEKT2	-0.98	-5.23	-0.47	1.01e-6	Schizophrenia;
THYM	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg06064525	chr11:970664	AP2A2	-0.36	-7.05	-0.59	2.82e-10	Alzheimer's disease (late onset);
THYM	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	7.8	0.62	7.81e-12	Platelet count;
THYM	cis	rs76878669	0.561	rs6591217	chr11:66174653	G/A	cg08995609	chr11:66104115	RIN1	0.39	4.5	0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs4866334	1.000	rs76355495	chr5:18487262	G/A	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs7084402	0.934	rs1649089	chr10:60289695	T/C	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg07424592	chr7:64974309	NA	1.03	5.38	0.48	5.32e-7	Diabetic kidney disease;
THYM	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg09990169	chr2:241835740	C2orf54	-0.37	-6.08	-0.53	2.52e-8	Urinary metabolites;
THYM	cis	rs13064411	0.518	rs7623919	chr3:113219160	A/G	cg18753928	chr3:113234510	CCDC52	-0.78	-7.16	-0.59	1.68e-10	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs2046867	0.818	rs1502754	chr3:72895345	G/T	cg25664220	chr3:72788482	NA	-0.75	-5.79	-0.51	9.09e-8	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs1580019	0.885	rs4580942	chr7:32496435	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.59	0.56	2.42e-9	Cognitive ability;
THYM	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg00071950	chr4:10020882	SLC2A9	0.88	8.84	0.67	4.96e-14	Bone mineral density;
THYM	cis	rs9733	0.519	rs10788792	chr1:150638572	T/G	cg04414720	chr1:150670196	GOLPH3L	0.62	4.58	0.43	1.41e-5	Tonsillectomy;
THYM	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg22875332	chr1:76189707	ACADM	0.88	11.22	0.75	4.31e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs3772130	0.775	rs6769102	chr3:121560722	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.75	4.64	0.43	1.1e-5	Cognitive performance;
THYM	cis	rs9649213	0.593	rs6465667	chr7:97957885	G/A	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.6e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg10661904	chr17:79619235	PDE6G	-0.66	-6.41	-0.55	5.55e-9	Eye color traits;
THYM	cis	rs7523273	0.565	rs1359147	chr1:207886150	C/T	cg22525895	chr1:207977042	MIR29B2	0.53	5.03	0.46	2.34e-6	Schizophrenia;
THYM	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg27394845	chr17:28928406	LRRC37B2	0.98	4.8	0.44	5.8e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	trans	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg19862616	chr7:65841803	NCRNA00174	1.09	12.64	0.79	4.47e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6840360	0.571	rs11932059	chr4:152524496	G/A	cg22705602	chr4:152727874	NA	-0.78	-8.16	-0.64	1.38e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7084402	0.935	rs1896246	chr10:60276068	A/G	cg09696939	chr10:60272079	BICC1	0.47	5.55	0.49	2.62e-7	Refractive error;
THYM	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg03433033	chr1:76189801	ACADM	-0.65	-6.0	-0.52	3.54e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6684428	1.000	rs6693526	chr1:56349764	G/A	cg11651538	chr1:56320950	NA	-0.59	-4.48	-0.42	2.05e-5	Airflow obstruction;
THYM	cis	rs12579753	0.871	rs1922540	chr12:82197496	A/G	cg07988820	chr12:82153109	PPFIA2	-0.72	-4.47	-0.42	2.15e-5	Resting heart rate;
THYM	cis	rs611744	0.967	rs610452	chr8:109188263	T/C	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs2898681	0.519	rs76606067	chr4:53728221	G/T	cg00338735	chr4:53728038	RASL11B	0.62	4.59	0.43	1.35e-5	Optic nerve measurement (cup area);
THYM	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-5.27	-0.48	8.61e-7	Hemoglobin concentration;
THYM	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.67	6.16	0.53	1.73e-8	Personality dimensions;
THYM	cis	rs13177918	0.677	rs2070841	chr5:149824471	A/G	cg14059543	chr5:149831962	NA	-1.01	-7.71	-0.62	1.21e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg09165964	chr15:75287851	SCAMP5	-1.09	-10.42	-0.73	2.09e-17	Blood trace element (Zn levels);
THYM	cis	rs6598955	0.671	rs11247909	chr1:26640135	G/A	cg08133631	chr1:26527909	CATSPER4	-0.63	-5.22	-0.47	1.05e-6	Obesity-related traits;
THYM	cis	rs9790314	0.747	rs9848239	chr3:160823488	A/C	cg04691961	chr3:161091175	C3orf57	-0.59	-4.47	-0.42	2.17e-5	Morning vs. evening chronotype;
THYM	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg09436375	chr6:42928200	GNMT	-0.45	-5.92	-0.52	5.15e-8	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1372520	0.577	rs1811443	chr4:90747883	G/C	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg27535305	chr1:53392650	SCP2	-0.57	-6.37	-0.55	6.87e-9	Monocyte count;
THYM	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg14004847	chr7:1930337	MAD1L1	-0.65	-5.24	-0.47	9.68e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7264396	0.887	rs11698935	chr20:34075015	C/T	cg26038318	chr20:34205095	SPAG4	0.53	4.45	0.42	2.33e-5	Total cholesterol levels;
THYM	cis	rs931812	0.825	rs35515344	chr8:101896769	C/G	cg07239293	chr8:101170671	SPAG1	0.68	4.63	0.43	1.17e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.52	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs77372450	0.551	rs62390780	chr5:157056474	G/C	cg00312553	chr5:157098553	C5orf52	-0.65	-4.63	-0.43	1.16e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.64	-4.57	-0.42	1.49e-5	Gut microbiome composition (summer);
THYM	cis	rs886126	0.684	rs10744769	chr12:111650780	G/T	cg10833066	chr12:111807467	FAM109A	0.39	4.47	0.42	2.16e-5	Coronary heart disease;
THYM	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.59	0.5	2.13e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2249694	0.960	rs4335490	chr10:135402350	T/C	cg20169779	chr10:135381914	SYCE1	-0.53	-4.45	-0.42	2.34e-5	Obesity-related traits;
THYM	cis	rs4919044	0.866	rs55853605	chr10:94825097	G/A	cg05127821	chr10:94822908	CYP26C1	-1.24	-6.68	-0.57	1.64e-9	Coronary artery disease;
THYM	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg10802521	chr3:52805072	NEK4	-0.79	-7.42	-0.61	5e-11	Bipolar disorder;
THYM	cis	rs2732480	0.500	rs1387257	chr12:48636666	C/A	cg21466736	chr12:48725269	NA	-0.53	-4.91	-0.45	3.78e-6	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs1401999	0.510	rs2293001	chr3:183700211	C/T	cg01324343	chr3:183735012	ABCC5	0.59	6.18	0.54	1.63e-8	Anterior chamber depth;
THYM	cis	rs7580658	0.857	rs11890187	chr2:128083738	T/C	cg10021288	chr2:128175891	PROC	-0.72	-6.36	-0.55	7.09e-9	Protein C levels;
THYM	cis	rs11997175	0.603	rs67661085	chr8:33731976	A/G	ch.8.33884649F	chr8:33765107	NA	0.74	5.11	0.46	1.68e-6	Body mass index;
THYM	cis	rs3126085	1.000	rs3126095	chr1:152309683	G/A	cg10321714	chr1:152280068	FLG	-0.72	-5.44	-0.49	4.14e-7	Atopic dermatitis;
THYM	cis	rs9420	0.961	rs80304923	chr11:57522823	C/G	cg19752551	chr11:57585705	CTNND1	-0.73	-8.02	-0.64	2.79e-12	Schizophrenia;
THYM	cis	rs3845702	0.673	rs12468986	chr2:180862320	T/G	cg01881094	chr2:180872142	CWC22	0.92	5.53	0.49	2.76e-7	Schizophrenia;
THYM	cis	rs2282300	0.739	rs1222210	chr11:30362125	A/G	cg06241208	chr11:30344200	C11orf46	0.86	6.21	0.54	1.4e-8	Morning vs. evening chronotype;
THYM	cis	rs2898681	0.874	rs4864688	chr4:53742636	A/G	cg21521518	chr4:53727714	RASL11B	0.44	4.84	0.45	4.92e-6	Optic nerve measurement (cup area);
THYM	cis	rs2985684	0.894	rs4900932	chr14:50022928	A/G	cg02151108	chr14:50098012	C14orf104	-0.75	-6.29	-0.54	9.64e-9	Carotid intima media thickness;
THYM	cis	rs7610301	1.000	rs6799581	chr3:46644909	T/G	cg10242476	chr3:46619364	LRRC2;TDGF1	0.45	4.48	0.42	2.07e-5	Blood protein levels;
THYM	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg00071950	chr4:10020882	SLC2A9	-0.69	-6.11	-0.53	2.16e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs3741151	1.000	rs75004180	chr11:73024739	A/G	cg12959048	chr11:73096162	RELT	-0.5	-4.78	-0.44	6.38e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg05283184	chr6:79620031	NA	-0.91	-8.88	-0.67	4.11e-14	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg11764359	chr7:65958608	NA	-0.64	-5.0	-0.46	2.58e-6	Aortic root size;
THYM	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06850241	chr22:41845214	NA	-0.57	-5.15	-0.47	1.38e-6	Vitiligo;
THYM	cis	rs7584330	0.697	rs60278044	chr2:238357118	A/G	cg16989719	chr2:238392110	NA	-0.61	-5.61	-0.5	2.02e-7	Prostate cancer;
THYM	cis	rs9309473	0.519	rs12991161	chr2:73871371	G/A	cg19565262	chr2:73869966	NAT8	0.53	4.51	0.42	1.88e-5	Metabolite levels;
THYM	cis	rs2404602	0.735	rs56246286	chr15:76690731	C/T	cg23482746	chr15:76478102	C15orf27	0.45	4.57	0.42	1.44e-5	Blood metabolite levels;
THYM	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg24250549	chr1:154909240	PMVK	0.69	4.98	0.46	2.8e-6	Prostate cancer;
THYM	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg08188268	chr10:116634841	FAM160B1	-0.26	-4.48	-0.42	2.05e-5	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg00376283	chr12:123451042	ABCB9	-0.63	-4.5	-0.42	1.91e-5	Height;Educational attainment;Head circumference (infant);
THYM	cis	rs6809651	0.524	rs12638263	chr3:185795855	A/C	cg00760338	chr3:185826511	ETV5	-0.85	-5.71	-0.51	1.26e-7	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
THYM	cis	rs73198271	0.765	rs534103	chr8:8634069	A/G	cg15556689	chr8:8085844	FLJ10661	-0.67	-4.71	-0.44	8.29e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs13326165	0.543	rs10461028	chr3:52343742	A/G	cg08438690	chr3:52279403	PPM1M	-0.74	-4.65	-0.43	1.07e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs11039798	0.541	rs11040166	chr11:48965449	T/C	cg24672777	chr11:48374446	OR4C45	-1.1	-6.15	-0.53	1.81e-8	Axial length;
THYM	cis	rs36051895	0.659	rs10974935	chr9:5050307	C/T	cg02405213	chr9:5042618	JAK2	-1.04	-10.76	-0.74	3.89e-18	Pediatric autoimmune diseases;
THYM	cis	rs9972944	0.756	rs7222190	chr17:63764953	T/C	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs477692	0.569	rs10764886	chr10:131310680	C/T	cg05714579	chr10:131428358	MGMT	0.59	4.81	0.44	5.57e-6	Response to temozolomide;
THYM	cis	rs9296092	0.560	rs7765393	chr6:33525598	A/T	cg13560919	chr6:33536144	NA	-0.96	-9.48	-0.7	2.1e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg03929089	chr4:120376271	NA	-1.0	-12.64	-0.79	4.61e-22	Height;
THYM	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg17178900	chr1:205818956	PM20D1	0.99	10.73	0.74	4.65e-18	Menarche (age at onset);
THYM	cis	rs11563648	0.553	rs1361940	chr7:127005073	C/G	cg23081781	chr7:127225937	GCC1	-0.34	-4.57	-0.42	1.45e-5	Resting heart rate;
THYM	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg03188948	chr7:1209495	NA	0.91	5.04	0.46	2.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg16680214	chr1:154839983	KCNN3	-0.57	-6.82	-0.57	8.35e-10	Prostate cancer;
THYM	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18252515	chr7:66147081	NA	-0.66	-4.96	-0.45	3.11e-6	Aortic root size;
THYM	cis	rs899997	0.862	rs11072787	chr15:78972977	T/C	cg04896959	chr15:78267971	NA	-0.84	-6.49	-0.55	3.96e-9	Coronary artery disease or large artery stroke;
THYM	cis	rs7814319	0.674	rs7836698	chr8:97242849	C/T	cg20787634	chr8:97240163	UQCRB	-0.73	-7.16	-0.59	1.72e-10	Lung function (FVC);
THYM	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.69	9.12	0.68	1.23e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs4866334	1.000	rs78447918	chr5:18488634	T/A	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg01483505	chr11:975446	AP2A2	0.58	4.75	0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg00744431	chr10:134226547	PWWP2B	-0.58	-4.73	-0.44	7.66e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs7772486	0.790	rs10223507	chr6:146285204	C/A	cg05347473	chr6:146136440	FBXO30	-0.58	-4.48	-0.42	2.05e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7809950	1.000	rs7786801	chr7:107085889	C/T	cg23024343	chr7:107201750	COG5	-0.9	-8.07	-0.64	2.19e-12	Coronary artery disease;
THYM	cis	rs4731207	0.596	rs34555990	chr7:124587844	T/C	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs13256369	0.851	rs12541477	chr8:8563895	G/A	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs10895275	0.700	rs7933592	chr11:102042934	T/A	cg24447756	chr11:102105824	NA	0.49	4.62	0.43	1.19e-5	Migraine;
THYM	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg01475377	chr6:109611718	NA	-0.56	-4.72	-0.44	8.05e-6	Reticulocyte fraction of red cells;
THYM	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg22467129	chr15:76604101	ETFA	-0.56	-5.37	-0.48	5.47e-7	Blood metabolite levels;
THYM	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg06108461	chr20:60628389	TAF4	-1.07	-9.19	-0.69	9.08e-15	Body mass index;
THYM	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.86	-7.81	-0.63	7.44e-12	Chronic sinus infection;
THYM	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg11327659	chr7:150037044	RARRES2	0.4	4.63	0.43	1.15e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10887741	1.000	rs12761361	chr10:89427203	G/C	cg13926569	chr10:89418898	PAPSS2	0.57	5.89	0.52	5.78e-8	Exercise (leisure time);
THYM	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs7177699	0.557	rs7403728	chr15:79112016	T/G	cg15571903	chr15:79123663	NA	-0.58	-6.53	-0.56	3.25e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.73	5.54	0.49	2.68e-7	Eosinophil percentage of white cells;
THYM	cis	rs76798021	0.748	rs17237537	chr3:53662336	C/G	cg21503701	chr3:53781065	CACNA1D	-0.65	-4.75	-0.44	7.28e-6	Lung function (FEV1/FVC);
THYM	cis	rs7953508	0.659	rs1316739	chr12:93968256	G/A	cg18151635	chr12:93972918	NA	-0.79	-5.66	-0.5	1.6e-7	Pubertal anthropometrics;
THYM	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg12826209	chr6:26865740	GUSBL1	1.04	6.68	0.57	1.63e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6835098	1.000	rs2332654	chr4:174088399	C/T	cg08422745	chr4:174089978	GALNT7	-1.02	-8.74	-0.67	8.01e-14	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs6906287	0.647	rs10456917	chr6:118779419	A/C	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs2235573	0.653	rs6519095	chr22:38431917	G/A	cg19171272	chr22:38449367	NA	-0.51	-5.38	-0.48	5.38e-7	Glioblastoma;Glioma;
THYM	cis	rs2067615	0.524	rs10861645	chr12:107071130	C/T	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg02353165	chr6:42928485	GNMT	0.87	8.06	0.64	2.21e-12	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs8028313	0.609	rs28735117	chr15:67933892	C/T	cg24579218	chr15:68104479	NA	-0.73	-6.65	-0.56	1.83e-9	Obesity;
THYM	cis	rs4970988	0.501	rs11204713	chr1:150694623	T/A	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Urate levels;
THYM	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.89	-6.55	-0.56	2.88e-9	Electrocardiographic conduction measures;
THYM	cis	rs6987853	0.761	rs2974356	chr8:42434633	C/T	cg09913449	chr8:42400586	C8orf40	1.07	12.64	0.79	4.53e-22	Mean corpuscular hemoglobin concentration;
THYM	cis	rs854765	0.693	rs11657074	chr17:17770355	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-6.7	-0.57	1.48e-9	Total body bone mineral density;
THYM	cis	rs61990749	0.597	rs1549119	chr14:78219812	A/T	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.02	0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs9633835	1.000	rs9633835	chr11:13345593	C/T	cg13286116	chr11:13302098	ARNTL	0.57	5.88	0.52	5.98e-8	Body mass index;
THYM	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.84	7.23	0.6	1.24e-10	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs747334	0.543	rs7096430	chr10:92764460	C/T	cg07620928	chr10:92689909	NA	-0.58	-4.89	-0.45	4.05e-6	Fibroblast growth factor basic levels;
THYM	cis	rs6980334	0.798	rs10280394	chr7:137767201	C/A	cg22979093	chr7:137028410	PTN	0.62	4.9	0.45	3.91e-6	Blood metabolite ratios;
THYM	cis	rs665401	0.932	rs12201912	chr6:117229806	G/A	cg20376953	chr6:117187980	NA	0.63	5.08	0.46	1.87e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs4294134	0.832	rs11768962	chr7:135254692	C/T	cg08396481	chr7:135194601	CNOT4	0.82	4.62	0.43	1.19e-5	Paget's disease;
THYM	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg10018233	chr7:150070692	REPIN1	0.4	5.66	0.5	1.63e-7	Blood protein levels;Circulating chemerin levels;
THYM	trans	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.13	12.91	0.8	1.26e-22	Exhaled nitric oxide output;
THYM	cis	rs60695258	0.550	rs2007132	chr4:87972585	G/T	cg10685359	chr4:87814065	C4orf36	-0.46	-5.76	-0.51	1.04e-7	Hematocrit;
THYM	cis	rs835154	0.817	rs835157	chr5:14874533	T/C	cg14843632	chr5:14870594	ANKH	0.7	6.43	0.55	5.07e-9	Blood metabolite levels;
THYM	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg18402987	chr7:1209562	NA	1.05	6.33	0.54	7.99e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg03115019	chr17:80708279	FN3K	0.67	4.7	0.43	8.85e-6	Glycated hemoglobin levels;
THYM	cis	rs3768617	0.510	rs35968946	chr1:183114871	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.64	0.43	1.11e-5	Fuchs's corneal dystrophy;
THYM	cis	rs4654899	0.758	rs10218584	chr1:21474480	C/G	cg01072550	chr1:21505969	NA	0.8	7.91	0.63	4.63e-12	Superior frontal gyrus grey matter volume;
THYM	cis	rs4638749	0.677	rs10203004	chr2:108826535	G/T	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-13.33	-0.81	1.74e-23	Coronary artery disease;
THYM	cis	rs600806	0.778	rs10745357	chr1:110001876	G/C	cg02175308	chr1:109941060	SORT1	-0.55	-4.59	-0.43	1.33e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6840360	0.533	rs13121190	chr4:152729072	T/G	cg22705602	chr4:152727874	NA	0.78	10.5	0.73	1.43e-17	Intelligence (multi-trait analysis);
THYM	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg12560992	chr17:57184187	TRIM37	0.93	8.77	0.67	7.1e-14	Intelligence (multi-trait analysis);
THYM	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg08000102	chr2:233561755	GIGYF2	-0.68	-5.96	-0.52	4.34e-8	Coronary artery disease;
THYM	cis	rs7582180	0.700	rs11685401	chr2:100976685	A/G	cg14675211	chr2:100938903	LONRF2	0.6	5.68	0.5	1.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs6430585	0.583	rs12373779	chr2:136586840	A/C	cg04750100	chr2:136595281	LCT	0.52	4.96	0.45	3.05e-6	Corneal structure;
THYM	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg11366901	chr6:160182831	ACAT2	1.06	8.92	0.68	3.29e-14	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9359856	0.956	rs6934804	chr6:90316020	A/G	cg13799429	chr6:90582589	CASP8AP2	0.47	4.62	0.43	1.21e-5	Bipolar disorder;
THYM	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.82	6.2	0.54	1.46e-8	Multiple sclerosis;
THYM	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg03517284	chr6:25882590	NA	-0.83	-5.95	-0.52	4.42e-8	Intelligence (multi-trait analysis);
THYM	cis	rs901683	1.000	rs78766622	chr10:46087519	A/G	cg18240400	chr10:46168597	ANUBL1	0.73	4.73	0.44	7.89e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs9560113	0.508	rs2774425	chr13:112235077	A/G	cg15979348	chr13:112237479	NA	-0.56	-5.35	-0.48	6.06e-7	Menarche (age at onset);
THYM	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg02018176	chr4:1364513	KIAA1530	-0.53	-4.46	-0.42	2.23e-5	Obesity-related traits;
THYM	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg12165864	chr7:66369176	NA	-0.63	-4.95	-0.45	3.27e-6	Aortic root size;
THYM	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg06636551	chr8:101224915	SPAG1	0.64	5.91	0.52	5.28e-8	Atrioventricular conduction;
THYM	cis	rs240764	0.853	rs12206182	chr6:101033379	A/C	cg21058520	chr6:100914733	NA	0.56	4.82	0.44	5.38e-6	Neuroticism;
THYM	cis	rs4919694	1.000	rs74749600	chr10:104732996	T/C	cg15744005	chr10:104629667	AS3MT	-0.84	-4.62	-0.43	1.21e-5	Arsenic metabolism;
THYM	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg03877680	chr5:178157825	ZNF354A	0.74	5.12	0.47	1.57e-6	Neutrophil percentage of white cells;
THYM	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg05373962	chr22:49881684	NA	-0.66	-6.49	-0.55	3.92e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs3804749	0.934	rs13314114	chr3:122836000	T/C	cg26084141	chr3:122786895	PDIA5	0.46	4.67	0.43	9.95e-6	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs7809950	1.000	rs10273733	chr7:107258121	A/G	cg23024343	chr7:107201750	COG5	0.92	6.55	0.56	2.96e-9	Coronary artery disease;
THYM	trans	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg25517755	chr10:38738941	LOC399744	-0.76	-6.99	-0.58	3.79e-10	Corneal astigmatism;
THYM	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06481639	chr22:41940642	POLR3H	-0.81	-5.55	-0.49	2.58e-7	Vitiligo;
THYM	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg23260525	chr10:116636907	FAM160B1	0.5	5.12	0.47	1.58e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs9486719	0.947	rs2472908	chr6:96875998	A/T	cg18709589	chr6:96969512	KIAA0776	0.75	4.96	0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.75	4.53	0.42	1.72e-5	Diabetic retinopathy;
THYM	cis	rs2408955	0.522	rs4760679	chr12:48461635	G/T	cg21466736	chr12:48725269	NA	0.51	5.11	0.46	1.69e-6	Glycated hemoglobin levels;
THYM	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg05299048	chr3:52828583	ITIH3	0.59	4.49	0.42	1.98e-5	Bipolar disorder;
THYM	cis	rs7072216	0.763	rs10732782	chr10:100166506	C/A	cg03852570	chr10:100175106	PYROXD2	0.38	4.89	0.45	4.04e-6	Metabolite levels;
THYM	cis	rs17445774	0.857	rs6435043	chr2:200900974	C/G	cg17644776	chr2:200775616	C2orf69	0.68	5.36	0.48	5.87e-7	LDL cholesterol to HDL cholesterol ratio;
THYM	cis	rs2070433	0.539	rs2839312	chr21:47958225	T/C	cg12379764	chr21:47803548	PCNT	0.6	4.5	0.42	1.94e-5	Lymphocyte counts;
THYM	cis	rs4974559	0.790	rs11933855	chr4:1315183	C/T	cg16185996	chr4:1008614	FGFRL1	-0.42	-4.59	-0.43	1.36e-5	Systolic blood pressure;
THYM	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Body mass index;
THYM	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg04043695	chr12:129287642	SLC15A4	0.6	4.66	0.43	1.03e-5	Systemic lupus erythematosus;
THYM	cis	rs3741489	1.000	rs4758889	chr12:133475533	C/T	cg03157182	chr12:132655797	NA	-0.65	-4.73	-0.44	7.78e-6	Cognitive function;
THYM	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg10547057	chr6:26987810	LOC100270746;C6orf41	0.43	4.64	0.43	1.12e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9972944	0.902	rs9972947	chr17:63771088	G/A	cg07283582	chr17:63770753	CCDC46	0.65	5.25	0.47	9.39e-7	Total body bone mineral density;
THYM	cis	rs3960554	0.673	rs57358338	chr7:75732923	T/C	cg16489192	chr7:75678113	MDH2;STYXL1	-0.57	-4.7	-0.43	8.73e-6	Eotaxin levels;
THYM	cis	rs9768139	0.654	rs61474285	chr7:158121276	C/T	cg06219351	chr7:158114137	PTPRN2	-0.73	-7.05	-0.59	2.85e-10	Calcium levels;
THYM	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg17063962	chr7:91808500	NA	1.08	11.35	0.76	2.25e-19	Breast cancer;
THYM	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg24803719	chr17:45855879	NA	-0.6	-6.26	-0.54	1.08e-8	IgG glycosylation;
THYM	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs11190604	0.767	rs7085426	chr10:102163640	T/C	cg07570687	chr10:102243282	WNT8B	0.82	7.71	0.62	1.25e-11	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg11752832	chr7:134001865	SLC35B4	0.73	5.19	0.47	1.19e-6	Mean platelet volume;
THYM	cis	rs6459804	1.000	rs73163880	chr7:157508755	C/T	cg05731713	chr7:157510257	PTPRN2	0.51	4.81	0.44	5.76e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg03159660	chr11:2078197	NA	0.65	5.19	0.47	1.18e-6	Longevity;
THYM	trans	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg07393940	chr7:158741817	NA	1.14	9.25	0.69	6.69e-15	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	6.97	0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs4509693	0.943	rs4917907	chr10:102498140	A/G	cg24127310	chr10:102502104	NA	1.3	10.12	0.72	9.09e-17	Alzheimer's disease;
THYM	cis	rs13126513	0.645	rs13147975	chr4:100515246	C/T	cg05468953	chr4:100565104	NA	0.65	6.03	0.53	3.15e-8	Metabolite levels (MHPG);
THYM	cis	rs4909189	0.957	rs71547528	chr7:158135431	T/C	cg06219351	chr7:158114137	PTPRN2	-0.8	-7.17	-0.59	1.64e-10	Response to amphetamines;
THYM	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.24	-10.02	-0.72	1.53e-16	Platelet count;
THYM	cis	rs28595532	0.920	rs10004184	chr4:119486801	G/T	cg21605333	chr4:119757512	SEC24D	1.45	5.28	0.48	8.21e-7	Cannabis dependence symptom count;
THYM	cis	rs7107174	1.000	rs2512546	chr11:77957276	T/C	cg02023728	chr11:77925099	USP35	0.74	6.66	0.56	1.8e-9	Testicular germ cell tumor;
THYM	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg14018140	chr10:458528	DIP2C	-0.58	-6.25	-0.54	1.14e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs9807989	0.839	rs10206753	chr2:102968362	T/C	cg03938978	chr2:103052716	IL18RAP	0.63	6.56	0.56	2.81e-9	Asthma;
THYM	cis	rs6840360	0.642	rs11932398	chr4:152397554	T/G	cg17479576	chr4:152424074	FAM160A1	-0.69	-5.35	-0.48	6.16e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8060598	0.745	rs11642646	chr16:50741186	C/A	cg05261686	chr16:50743296	NOD2	0.39	4.87	0.45	4.48e-6	Leprosy;
THYM	cis	rs6906287	0.537	rs13192336	chr6:118875162	A/T	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.12e-7	Electrocardiographic conduction measures;
THYM	cis	rs61931739	0.635	rs10772123	chr12:33975557	C/T	cg06521331	chr12:34319734	NA	-0.62	-5.17	-0.47	1.31e-6	Morning vs. evening chronotype;
THYM	cis	rs2219968	0.683	rs35705872	chr8:78908974	G/A	cg00738934	chr8:78996279	NA	0.65	5.32	0.48	6.77e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2034088	0.965	rs4968070	chr17:446162	A/G	cg06217071	chr17:408420	NA	0.8	7.68	0.62	1.45e-11	Hip circumference adjusted for BMI;
THYM	cis	rs8067545	0.611	rs2107565	chr17:20088492	C/T	cg13482628	chr17:19912719	NA	-0.55	-4.53	-0.42	1.68e-5	Schizophrenia;
THYM	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg06600287	chr1:53387719	ECHDC2	0.35	5.32	0.48	7.02e-7	Monocyte count;
THYM	cis	rs5417	0.662	rs12601936	chr17:7172609	A/G	cg03186999	chr17:7165420	CLDN7	-0.51	-5.34	-0.48	6.43e-7	Diastolic blood pressure;
THYM	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.59	-4.69	-0.43	9.09e-6	Chronic sinus infection;
THYM	cis	rs13064411	0.542	rs9874747	chr3:113221258	G/A	cg18753928	chr3:113234510	CCDC52	-0.83	-7.84	-0.63	6.65e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg03676636	chr4:99064102	C4orf37	0.4	5.86	0.52	6.71e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2862064	0.745	rs2902133	chr5:156445687	G/A	cg12943317	chr5:156479607	HAVCR1	-0.83	-5.12	-0.46	1.61e-6	Platelet count;
THYM	cis	rs1971762	0.563	rs10747678	chr12:54077687	A/C	cg16917193	chr12:54089295	NA	-0.9	-9.22	-0.69	7.82e-15	Height;
THYM	trans	rs629535	0.551	rs62513429	chr8:70149995	A/C	cg21567404	chr3:27674614	NA	-0.88	-7.0	-0.58	3.66e-10	Dupuytren's disease;
THYM	cis	rs2976388	1.000	rs10216533	chr8:143763690	G/A	cg06565975	chr8:143823917	SLURP1	-0.45	-5.23	-0.47	9.95e-7	Urinary tract infection frequency;
THYM	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg07343612	chr16:622815	PIGQ	-1.08	-11.34	-0.76	2.36e-19	Height;
THYM	cis	rs2777491	0.574	rs11635906	chr15:41779260	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.19	-13.79	-0.82	2.06e-24	Ulcerative colitis;
THYM	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg11335335	chr11:637885	DRD4	-0.63	-5.11	-0.46	1.64e-6	Systemic lupus erythematosus;
THYM	cis	rs6032067	0.777	rs34085254	chr20:43786170	T/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.5	-0.55	3.78e-9	Blood protein levels;
THYM	cis	rs3862030	0.720	rs12569526	chr10:104237007	A/G	cg00122347	chr10:104236741	TMEM180	0.47	7.02	0.58	3.22e-10	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06850241	chr22:41845214	NA	0.59	5.36	0.48	5.81e-7	Vitiligo;
THYM	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg19761014	chr17:28927070	LRRC37B2	0.83	5.05	0.46	2.13e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg25817165	chr18:72167213	CNDP2	-0.92	-8.15	-0.64	1.48e-12	Refractive error;
THYM	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg24209194	chr3:40518798	ZNF619	0.58	4.78	0.44	6.32e-6	Renal cell carcinoma;
THYM	cis	rs747782	0.639	rs17198985	chr11:48183565	T/C	cg24672777	chr11:48374446	OR4C45	-1.1	-6.51	-0.56	3.57e-9	Intraocular pressure;
THYM	cis	rs981844	0.712	rs4696507	chr4:154753702	G/A	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs394563	0.775	rs448420	chr6:149785802	T/C	cg26849637	chr6:150530249	PPP1R14C	-0.43	-4.76	-0.44	6.79e-6	Dupuytren's disease;
THYM	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.73	0.57	1.29e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg11327659	chr7:150037044	RARRES2	0.43	5.14	0.47	1.49e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs1878931	0.513	rs35160989	chr16:3405506	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.96	8.89	0.67	3.85e-14	Body mass index (adult);
THYM	cis	rs2016266	0.787	rs4520636	chr12:53752133	G/T	cg26875137	chr12:53738046	NA	0.79	5.81	0.51	8.31e-8	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs425535	0.757	rs164616	chr4:74798566	A/G	cg07868155	chr4:74864709	CXCL5	0.67	4.77	0.44	6.66e-6	Blood protein levels;
THYM	cis	rs4638749	0.677	rs13389470	chr2:108806301	C/G	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg21775007	chr8:11205619	TDH	0.74	6.5	0.55	3.68e-9	Retinal vascular caliber;
THYM	cis	rs62435770	1.000	rs62435801	chr6:169499164	A/G	cg07652237	chr6:170125491	PHF10	0.58	5.28	0.48	8.32e-7	Loneliness;
THYM	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg08885076	chr2:99613938	TSGA10	-0.63	-6.05	-0.53	2.86e-8	Chronic sinus infection;
THYM	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Schizophrenia;
THYM	cis	rs2806561	0.765	rs2806565	chr1:23507068	A/G	cg19743168	chr1:23544995	NA	0.55	5.6	0.5	2.09e-7	Height;
THYM	cis	rs61931739	1.000	rs11052989	chr12:34057614	G/A	cg06521331	chr12:34319734	NA	0.6	4.61	0.43	1.25e-5	Morning vs. evening chronotype;
THYM	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg03388043	chr17:80084554	CCDC57	-0.66	-5.66	-0.5	1.61e-7	Life satisfaction;
THYM	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg02527881	chr3:46936655	PTH1R	-0.69	-7.14	-0.59	1.9e-10	Colorectal cancer;
THYM	cis	rs943437	0.557	rs7775711	chr6:112161786	G/A	cg20596647	chr6:112163498	FYN	0.42	4.46	0.42	2.22e-5	Parkinson's disease;
THYM	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg00191853	chr8:101177733	SPAG1	-0.56	-5.59	-0.5	2.15e-7	Atrioventricular conduction;
THYM	cis	rs11048434	0.761	rs2110191	chr12:9136263	G/A	cg13575925	chr12:9217583	LOC144571	0.55	5.48	0.49	3.45e-7	Sjögren's syndrome;
THYM	cis	rs728616	0.614	rs10887234	chr10:81715422	C/A	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg27490568	chr2:178487706	NA	0.6	5.64	0.5	1.75e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs6732160	0.845	rs6718690	chr2:73387162	C/T	cg24220031	chr2:73402428	NA	0.79	8.39	0.65	4.59e-13	Intelligence (multi-trait analysis);
THYM	cis	rs9788721	0.902	rs951266	chr15:78878541	C/T	cg04882995	chr15:78912658	CHRNA3	0.53	4.52	0.42	1.8e-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg17333051	chr19:2783644	SGTA	0.69	6.1	0.53	2.32e-8	Total cholesterol levels;
THYM	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs4343996	1.000	rs12700789	chr7:3358276	T/C	cg21248987	chr7:3385318	SDK1	-0.41	-4.94	-0.45	3.39e-6	Motion sickness;
THYM	cis	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg07460842	chr6:66804631	NA	-1.06	-7.93	-0.63	4.23e-12	Exhaled nitric oxide output;
THYM	cis	rs7772486	0.846	rs2492856	chr6:146323928	A/G	cg13319975	chr6:146136371	FBXO30	-0.72	-6.1	-0.53	2.24e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10924970	0.967	rs10925074	chr1:235365869	A/T	cg26050004	chr1:235667680	B3GALNT2	0.58	4.5	0.42	1.91e-5	Asthma;
THYM	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg07138768	chr7:917805	C7orf20	0.25	4.68	0.43	9.36e-6	Perceived unattractiveness to mosquitoes;
THYM	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg11752832	chr7:134001865	SLC35B4	0.74	5.65	0.5	1.69e-7	Mean platelet volume;
THYM	cis	rs868036	1.000	rs1026736	chr15:68101813	T/C	cg24579218	chr15:68104479	NA	-0.65	-6.51	-0.56	3.59e-9	Restless legs syndrome;
THYM	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-5.77	-0.51	9.69e-8	Gut microbiome composition (summer);
THYM	cis	rs4509693	0.782	rs12268880	chr10:102495285	G/C	cg15234845	chr10:102496500	NA	0.66	4.64	0.43	1.11e-5	Alzheimer's disease;
THYM	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg05802129	chr4:122689817	NA	-0.59	-4.65	-0.43	1.08e-5	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg03676636	chr4:99064102	C4orf37	0.38	5.41	0.49	4.62e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs66887589	0.934	rs4834792	chr4:120555696	T/A	cg13609457	chr4:120235615	NA	-0.48	-5.02	-0.46	2.39e-6	Diastolic blood pressure;
THYM	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg21644426	chr2:191273491	MFSD6	0.76	6.12	0.53	2.08e-8	Pulse pressure;
THYM	cis	rs6500395	1.000	rs1115758	chr16:48599609	T/C	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg13390004	chr1:15929781	NA	0.63	4.79	0.44	6.2e-6	Systolic blood pressure;
THYM	cis	rs295140	0.546	rs842830	chr2:201131124	C/T	cg23649088	chr2:200775458	C2orf69	-0.61	-5.15	-0.47	1.39e-6	QT interval;
THYM	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg11327659	chr7:150037044	RARRES2	0.39	4.51	0.42	1.83e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs79149102	0.579	rs7172989	chr15:75295905	C/T	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	cis	rs1005224	0.926	rs12892551	chr14:76159902	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.73	-6.16	-0.53	1.75e-8	Large artery stroke;
THYM	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg17830980	chr10:43048298	ZNF37B	-1.1	-10.99	-0.75	1.26e-18	Extrinsic epigenetic age acceleration;
THYM	cis	rs11252926	0.562	rs11252792	chr10:544369	G/A	cg14018140	chr10:458528	DIP2C	0.5	5.54	0.49	2.66e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs6499255	0.951	rs76407217	chr16:69690355	A/T	cg00738113	chr16:70207722	CLEC18C	-0.44	-4.57	-0.42	1.45e-5	IgE levels;
THYM	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg09549813	chr16:4587862	C16orf5	-0.57	-5.39	-0.48	5.03e-7	Schizophrenia;
THYM	cis	rs55883249	1.000	rs17453752	chr2:9766171	C/T	cg23886495	chr2:9695866	ADAM17	-0.75	-4.63	-0.43	1.17e-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs2046867	0.908	rs62251640	chr3:72801605	T/C	cg25664220	chr3:72788482	NA	-0.86	-6.54	-0.56	3.05e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.24	-8.95	-0.68	2.9e-14	Platelet count;
THYM	cis	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg15741354	chr8:8146129	NA	-0.27	-4.59	-0.43	1.34e-5	Joint mobility (Beighton score);
THYM	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg00012203	chr2:219082015	ARPC2	-0.65	-5.32	-0.48	6.78e-7	Colorectal cancer;
THYM	cis	rs11792861	0.589	rs75742991	chr9:111929624	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	5.27	0.48	8.45e-7	Menarche (age at onset);
THYM	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs6570726	0.791	rs400329	chr6:145879442	A/T	cg13319975	chr6:146136371	FBXO30	-0.63	-5.17	-0.47	1.27e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4654899	0.865	rs960564	chr1:21416435	G/T	cg01072550	chr1:21505969	NA	-0.76	-6.83	-0.57	7.84e-10	Superior frontal gyrus grey matter volume;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg03526503	chr1:28198483	C1orf38	-0.88	-6.88	-0.58	6.2e-10	Depressive symptoms;
THYM	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg00852783	chr1:26633632	UBXN11	0.86	8.95	0.68	2.92e-14	Obesity-related traits;
THYM	cis	rs539096	0.560	rs56201009	chr1:44098746	A/G	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Intelligence (multi-trait analysis);
THYM	cis	rs892961	0.867	rs1079354	chr17:75415713	C/T	cg05865280	chr17:75406074	SEPT9	0.5	8.39	0.65	4.57e-13	Airflow obstruction;
THYM	cis	rs477692	0.647	rs524804	chr10:131430686	G/A	cg05714579	chr10:131428358	MGMT	-0.82	-7.13	-0.59	1.98e-10	Response to temozolomide;
THYM	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg05552183	chr6:42928497	GNMT	0.58	4.61	0.43	1.23e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs7695732	0.595	rs34749134	chr4:89879488	C/T	cg17769793	chr4:89976368	FAM13A	0.49	5.28	0.48	8.06e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs425277	0.916	rs414777	chr1:2101687	G/A	cg23803603	chr1:2058230	PRKCZ	0.59	4.56	0.42	1.54e-5	Height;
THYM	cis	rs67072384	0.901	rs7936972	chr11:72479692	T/C	cg01380194	chr11:72452482	ARAP1	-0.98	-5.15	-0.47	1.4e-6	Alloimmunization response to red blood cell transfusion in sickle cell anemia;
THYM	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg15448220	chr1:150897856	SETDB1	0.9	7.51	0.61	3.27e-11	Melanoma;
THYM	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.65	0.5	1.64e-7	Tonsillectomy;
THYM	cis	rs7940866	0.774	rs12420126	chr11:130834811	C/T	cg12179176	chr11:130786555	SNX19	0.62	4.73	0.44	7.83e-6	Schizophrenia;
THYM	cis	rs66573146	0.539	rs56659624	chr4:7069377	G/C	cg02503808	chr4:7069936	GRPEL1	-0.96	-4.61	-0.43	1.25e-5	Granulocyte percentage of myeloid white cells;
THYM	cis	rs11190604	1.000	rs74210981	chr10:102287520	C/T	cg07570687	chr10:102243282	WNT8B	0.76	6.89	0.58	6.03e-10	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg11764359	chr7:65958608	NA	0.7	4.79	0.44	6.21e-6	Aortic root size;
THYM	cis	rs9658691	0.607	rs9658791	chr10:90777338	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.89	-5.79	-0.51	9.02e-8	Mosquito bite size;
THYM	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	6.73	0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg02527881	chr3:46936655	PTH1R	-0.61	-5.7	-0.51	1.33e-7	Colorectal cancer;
THYM	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg16423285	chr20:60520624	NA	-1.15	-9.25	-0.69	6.54e-15	Obesity-related traits;
THYM	cis	rs2898681	0.614	rs10016904	chr4:53694296	C/A	cg00338735	chr4:53728038	RASL11B	0.62	5.88	0.52	6.07e-8	Optic nerve measurement (cup area);
THYM	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06481639	chr22:41940642	POLR3H	0.87	5.95	0.52	4.49e-8	Vitiligo;
THYM	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg10515332	chr4:99064459	C4orf37	-0.66	-5.3	-0.48	7.63e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs57920188	0.584	rs57277002	chr1:4092054	T/G	cg20703997	chr1:4087676	NA	0.76	5.64	0.5	1.74e-7	Interleukin-17 levels;
THYM	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg03609598	chr5:56110824	MAP3K1	-0.83	-5.57	-0.5	2.35e-7	Initial pursuit acceleration;
THYM	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	4.96	0.45	3.09e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	1.0	9.38	0.69	3.51e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs28735056	0.591	rs2277724	chr18:77694294	C/A	cg20368463	chr18:77673604	PQLC1	-0.67	-5.04	-0.46	2.19e-6	Schizophrenia;
THYM	cis	rs2730245	0.583	rs2788473	chr7:158649280	T/C	cg11984989	chr7:158649758	WDR60	1.11	15.12	0.84	5.06e-27	Height;
THYM	cis	rs10237317	0.517	rs55772938	chr7:70025113	A/G	cg15520052	chr7:69808286	AUTS2	0.61	4.64	0.43	1.1e-5	Bipolar disorder;
THYM	cis	rs6500395	0.775	rs1968902	chr16:48663974	A/G	cg04672837	chr16:48644449	N4BP1	0.47	4.62	0.43	1.18e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2692947	0.655	rs2315668	chr2:96429562	T/C	cg23100626	chr2:96804247	ASTL	0.41	5.03	0.46	2.27e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs955333	0.540	rs62434185	chr6:154889016	T/G	cg20019720	chr6:154832845	CNKSR3	0.52	5.41	0.49	4.65e-7	Diabetic kidney disease;
THYM	cis	rs7631605	0.905	rs9829683	chr3:37217622	C/A	cg21328643	chr3:37258149	NA	-0.48	-4.51	-0.42	1.82e-5	Cerebrospinal P-tau181p levels;
THYM	cis	rs10751667	0.961	rs10794358	chr11:985547	C/T	ch.11.42038R	chr11:967971	AP2A2	0.61	4.88	0.45	4.31e-6	Alzheimer's disease (late onset);
THYM	cis	rs3091242	0.933	rs28633797	chr1:25741629	C/A	cg10117171	chr1:25599238	RHD	-0.67	-4.81	-0.44	5.71e-6	Erythrocyte sedimentation rate;
THYM	cis	rs7178572	0.568	rs4886866	chr15:77696166	A/T	cg22256960	chr15:77711686	NA	-1.06	-8.5	-0.66	2.6e-13	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9875589	0.509	rs11718142	chr3:14018793	G/T	cg03204825	chr3:13978759	TPRXL	-0.54	-4.67	-0.43	1.01e-5	Ovarian reserve;
THYM	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17127169	1.000	rs61786113	chr1:65421983	G/A	cg12075498	chr1:65428216	JAK1	-0.42	-5.17	-0.47	1.32e-6	Sitting height ratio;
THYM	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg03929089	chr4:120376271	NA	-1.03	-12.37	-0.79	1.63e-21	Height;
THYM	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg08901578	chr4:187885870	NA	-0.68	-6.63	-0.56	2.07e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2282930	0.512	rs2282927	chr7:50720271	A/C	cg08586669	chr7:50727761	GRB10	0.31	4.74	0.44	7.39e-6	Bone mineral density;
THYM	cis	rs12681287	0.547	rs10956873	chr8:87547028	T/C	cg27223183	chr8:87520930	FAM82B	0.71	5.56	0.5	2.44e-7	Caudate activity during reward;
THYM	cis	rs10484885	0.818	rs117562849	chr6:90249804	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.82	-6.8	-0.57	9.25e-10	QRS interval (sulfonylurea treatment interaction);
THYM	cis	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg13443165	chr9:33130375	B4GALT1	-0.84	-7.5	-0.61	3.34e-11	IgG glycosylation;
THYM	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg09517075	chr8:22133004	PIWIL2	0.63	5.74	0.51	1.14e-7	Hypertriglyceridemia;
THYM	cis	rs4343996	0.558	rs1915984	chr7:3409328	T/C	cg21248987	chr7:3385318	SDK1	0.4	5.04	0.46	2.21e-6	Motion sickness;
THYM	cis	rs11190604	0.943	rs3750632	chr10:102279295	G/C	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.61	-4.85	-0.45	4.85e-6	Total body bone mineral density;
THYM	cis	rs526231	0.543	rs34377	chr5:102400556	C/T	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.49e-6	Primary biliary cholangitis;
THYM	cis	rs10140922	0.966	rs10083387	chr14:35823669	G/A	cg07166546	chr14:35805898	NA	-0.27	-6.45	-0.55	4.68e-9	Hip circumference adjusted for BMI;
THYM	trans	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg10856724	chr12:34555212	NA	-1.02	-9.49	-0.7	2e-15	Bladder cancer;
THYM	cis	rs2742540	0.503	rs2653556	chr11:8906636	C/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.59	-4.99	-0.46	2.77e-6	Hematocrit;
THYM	cis	rs7572263	0.833	rs6710217	chr2:209050352	C/T	cg23998903	chr2:209048830	C2orf80	-0.4	-5.28	-0.48	8e-7	Glioma;Non-glioblastoma glioma;
THYM	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg08885076	chr2:99613938	TSGA10	0.7	6.51	0.56	3.59e-9	Chronic sinus infection;
THYM	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg19016782	chr12:123741754	C12orf65	-0.69	-4.5	-0.42	1.94e-5	Neutrophil percentage of white cells;
THYM	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg21231944	chr12:82153410	PPFIA2	-0.64	-4.76	-0.44	7.01e-6	Resting heart rate;
THYM	cis	rs7226229	1.000	rs3943299	chr17:20920611	A/C	cg21263980	chr17:20946333	USP22	0.67	5.02	0.46	2.38e-6	Blood trace element (Se levels);
THYM	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg24250549	chr1:154909240	PMVK	0.8	6.24	0.54	1.22e-8	Prostate cancer;
THYM	cis	rs34112283	0.592	rs4430884	chr2:144225629	A/C	cg17056048	chr2:144271431	ARHGAP15	0.66	6.56	0.56	2.84e-9	Neuroticism;
THYM	cis	rs7590720	0.731	rs1864253	chr2:216878008	C/G	cg12620499	chr2:216877984	MREG	1.03	8.62	0.66	1.49e-13	Alcohol dependence;
THYM	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg17264618	chr3:40429014	ENTPD3	-0.52	-4.94	-0.45	3.41e-6	Renal cell carcinoma;
THYM	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg20295408	chr7:1910781	MAD1L1	-0.57	-4.51	-0.42	1.84e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg17178900	chr1:205818956	PM20D1	0.65	4.99	0.46	2.71e-6	Menarche (age at onset);
THYM	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg23260525	chr10:116636907	FAM160B1	0.52	5.19	0.47	1.19e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.9	7.59	0.61	2.15e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg13852791	chr20:30311386	BCL2L1	0.67	4.76	0.44	7.04e-6	Mean corpuscular hemoglobin;
THYM	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg12310025	chr6:25882481	NA	-0.9	-8.78	-0.67	6.72e-14	Intelligence (multi-trait analysis);
THYM	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg10505658	chr17:80084571	CCDC57	-0.69	-7.95	-0.63	3.85e-12	Life satisfaction;
THYM	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.59	-4.5	-0.42	1.89e-5	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9479482	1.000	rs9478380	chr6:150354665	A/G	cg25797454	chr6:150327115	RAET1K	-0.43	-4.58	-0.42	1.43e-5	Alopecia areata;
THYM	cis	rs3741151	0.773	rs73544716	chr11:73170061	C/T	cg17517138	chr11:73019481	ARHGEF17	0.94	5.48	0.49	3.55e-7	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.71	-4.76	-0.44	6.82e-6	Gut microbiome composition (summer);
THYM	cis	rs611744	0.934	rs1452021	chr8:109207886	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.21	0.47	1.07e-6	Dupuytren's disease;
THYM	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg20283391	chr11:68216788	NA	-0.69	-5.14	-0.47	1.49e-6	Total body bone mineral density;
THYM	cis	rs1003719	0.715	rs2835639	chr21:38537016	G/C	cg01329690	chr21:38580129	DSCR9	-0.36	-5.07	-0.46	1.99e-6	Eye color traits;
THYM	cis	rs10504073	0.669	rs818560	chr8:50035417	C/T	cg00325661	chr8:49890786	NA	0.78	7.03	0.59	3.11e-10	Blood metabolite ratios;
THYM	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.74	4.48	0.42	2.08e-5	Diabetic retinopathy;
THYM	cis	rs56309584	0.560	rs7223859	chr17:8080853	C/T	cg08322244	chr17:8066669	VAMP2	0.51	4.73	0.44	7.66e-6	Initial pursuit acceleration;
THYM	cis	rs10929159	0.894	rs1349729	chr2:236928217	A/G	cg14895183	chr2:236924282	AGAP1	0.55	4.75	0.44	7.14e-6	Parkinson's disease;
THYM	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.81	6.04	0.53	3e-8	Cognitive test performance;
THYM	cis	rs240764	0.687	rs239248	chr6:101088315	T/A	cg21058520	chr6:100914733	NA	-0.57	-5.06	-0.46	2.04e-6	Neuroticism;
THYM	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7824557	0.707	rs2572419	chr8:11137820	C/T	cg21775007	chr8:11205619	TDH	-0.59	-4.82	-0.44	5.37e-6	Retinal vascular caliber;
THYM	cis	rs7107174	1.000	rs2373009	chr11:77945815	T/A	cg19901956	chr11:77921274	USP35	-0.83	-6.25	-0.54	1.14e-8	Testicular germ cell tumor;
THYM	cis	rs7917772	0.582	rs10883738	chr10:104321721	T/C	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs8044868	0.586	rs7188962	chr16:72098962	A/G	cg16558253	chr16:72132732	DHX38	-0.55	-4.56	-0.42	1.55e-5	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
THYM	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg06623918	chr6:96969491	KIAA0776	-1.09	-10.37	-0.73	2.65e-17	Headache;
THYM	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg13695892	chr22:41940480	POLR3H	-0.9	-7.07	-0.59	2.64e-10	Vitiligo;
THYM	cis	rs6473252	1.000	rs4739763	chr8:81818348	G/C	cg08595989	chr8:81827712	NA	-0.41	-4.52	-0.42	1.76e-5	Breast cancer;
THYM	cis	rs1950626	0.662	rs72700538	chr14:101441911	C/G	cg11887864	chr14:101510502	MIR1185-2	0.54	4.52	0.42	1.75e-5	Pelvic organ prolapse (moderate/severe);
THYM	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg11266682	chr4:10021025	SLC2A9	-0.68	-9.74	-0.71	5.95e-16	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs728616	0.867	rs34870056	chr10:81948055	G/A	cg18148530	chr10:81370782	SFTPA1	0.71	4.54	0.42	1.66e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs289828	0.538	rs289906	chr2:152086381	C/T	cg05960677	chr2:152117363	RBM43	-0.71	-7.57	-0.61	2.46e-11	Blood protein levels;
THYM	cis	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg09085632	chr11:111637200	PPP2R1B	1.19	12.63	0.79	4.9e-22	Primary sclerosing cholangitis;
THYM	cis	rs4969178	0.620	rs7219625	chr17:76390080	C/T	cg05887092	chr17:76393375	PGS1	0.4	4.52	0.42	1.78e-5	HDL cholesterol levels;
THYM	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.67	6.26	0.54	1.13e-8	Hip circumference adjusted for BMI;
THYM	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg15921436	chr17:44337874	NA	-0.8	-6.51	-0.56	3.51e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs66569888	0.507	rs11124097	chr2:106878601	A/G	cg16099169	chr2:106886729	NA	-0.68	-7.5	-0.61	3.43e-11	Facial morphology (factor 23);
THYM	cis	rs55728055	1.000	rs8142355	chr22:32081681	C/T	cg01338084	chr22:32026380	PISD	1.55	6.04	0.53	3.03e-8	Age-related hearing impairment;
THYM	cis	rs4285028	0.747	rs9808981	chr3:121429561	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.84	-7.2	-0.59	1.37e-10	Multiple sclerosis;
THYM	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg18252515	chr7:66147081	NA	-1.37	-8.05	-0.64	2.39e-12	Diabetic kidney disease;
THYM	cis	rs4638749	0.654	rs6761157	chr2:108816885	A/C	cg06795125	chr2:108905320	SULT1C2	-0.37	-4.86	-0.45	4.67e-6	Blood pressure;
THYM	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg01579765	chr21:45077557	HSF2BP	0.49	7.92	0.63	4.37e-12	Mean corpuscular volume;
THYM	cis	rs924712	0.645	rs2816811	chr6:54757791	C/G	cg04690482	chr6:54711388	FAM83B	0.44	5.06	0.46	2.01e-6	Breast cancer;
THYM	cis	rs8030379	0.875	rs28801104	chr15:84552843	C/T	cg15564896	chr15:84287328	SH3GL3	0.57	4.77	0.44	6.57e-6	Waist circumference adjusted for body mass index;Waist circumference;
THYM	cis	rs6876348	0.516	rs257904	chr5:128316255	C/T	cg02841155	chr5:128301328	SLC27A6	-0.5	-4.89	-0.45	4.18e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg18357526	chr6:26021779	HIST1H4A	0.79	6.25	0.54	1.14e-8	Intelligence (multi-trait analysis);
THYM	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg05234568	chr11:5960015	NA	-0.55	-4.46	-0.42	2.26e-5	DNA methylation (variation);
THYM	cis	rs4919687	0.550	rs10437480	chr10:104453024	C/G	cg04362960	chr10:104952993	NT5C2	0.61	4.9	0.45	4.01e-6	Colorectal cancer;
THYM	cis	rs262150	0.579	rs73167299	chr7:158784367	C/T	cg23058037	chr7:158824108	VIPR2	0.53	5.02	0.46	2.43e-6	Facial morphology (factor 20);
THYM	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg27532560	chr4:187881888	NA	-0.96	-11.4	-0.76	1.72e-19	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg21775007	chr8:11205619	TDH	-0.71	-5.49	-0.49	3.28e-7	Retinal vascular caliber;
THYM	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg01236616	chr12:121019343	POP5	1.31	10.47	0.73	1.61e-17	Type 1 diabetes nephropathy;
THYM	cis	rs10924970	0.967	rs12739707	chr1:235466564	C/G	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs6570726	0.846	rs973856	chr6:145781916	C/T	cg13319975	chr6:146136371	FBXO30	0.69	5.57	0.5	2.34e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3947	0.950	rs1293331	chr8:11698436	C/T	cg26752888	chr8:11627280	NEIL2	-0.71	-4.73	-0.44	7.89e-6	Blood protein levels;
THYM	cis	rs28595532	0.920	rs115688334	chr4:119770805	C/T	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs7216064	1.000	rs2128792	chr17:65857177	C/T	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg11965913	chr1:205819406	PM20D1	0.93	10.13	0.72	8.64e-17	Menarche (age at onset);
THYM	cis	rs995000	0.965	rs10789113	chr1:63015199	A/T	cg06896770	chr1:63153194	DOCK7	1.0	8.27	0.65	7.91e-13	Triglyceride levels;
THYM	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg15247329	chr7:2764246	NA	-0.69	-5.69	-0.5	1.4e-7	Height;
THYM	cis	rs9326248	0.581	rs6589590	chr11:116936081	A/C	cg20608306	chr11:116969690	SIK3	0.64	7.97	0.63	3.42e-12	Blood protein levels;
THYM	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.68	5.54	0.49	2.68e-7	Blood metabolite levels;
THYM	cis	rs11966931	1.000	rs67958225	chr6:108132458	G/A	cg25323841	chr6:108444506	NA	0.67	4.6	0.43	1.29e-5	Neutrophil percentage of white cells;
THYM	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg14004847	chr7:1930337	MAD1L1	0.64	5.46	0.49	3.72e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg10856724	chr12:34555212	NA	-1.03	-10.43	-0.73	2.02e-17	Morning vs. evening chronotype;
THYM	cis	rs10790268	1	rs10790268	chr11:118729391	A/G	cg19308663	chr11:118741387	NA	-0.57	-5.5	-0.49	3.2e-7	Rheumatoid arthritis;
THYM	cis	rs9733	0.526	rs11204698	chr1:150659545	G/A	cg10589385	chr1:150898437	SETDB1	0.66	5.58	0.5	2.27e-7	Tonsillectomy;
THYM	cis	rs9399401	0.849	rs962554	chr6:142734204	T/C	cg04461802	chr6:142623433	GPR126	0.49	4.97	0.45	3e-6	Chronic obstructive pulmonary disease;
THYM	cis	rs28595532	0.920	rs17259173	chr4:119777232	T/C	cg11846333	chr4:119757529	SEC24D	1.45	5.08	0.46	1.92e-6	Cannabis dependence symptom count;
THYM	cis	rs2637266	0.667	rs2395405	chr10:78380518	C/T	cg18941641	chr10:78392320	NA	0.6	4.79	0.44	6.09e-6	Pulmonary function;
THYM	trans	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg04842962	chr6:43655489	MRPS18A	1.38	14.25	0.83	2.57e-25	IgG glycosylation;
THYM	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg23791538	chr6:167370224	RNASET2	-0.78	-6.28	-0.54	1.02e-8	Crohn's disease;
THYM	cis	rs61931739	0.513	rs10844698	chr12:33890158	C/T	cg06521331	chr12:34319734	NA	-0.57	-4.61	-0.43	1.26e-5	Morning vs. evening chronotype;
THYM	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg03474202	chr17:45855739	NA	-0.77	-6.77	-0.57	1.08e-9	IgG glycosylation;
THYM	cis	rs2219968	0.525	rs4443653	chr8:78874466	T/C	cg00738934	chr8:78996279	NA	0.61	4.93	0.45	3.5e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg15212455	chr7:39170539	POU6F2	-0.57	-5.29	-0.48	7.72e-7	IgG glycosylation;
THYM	cis	rs912057	1.000	rs912057	chr6:6736931	C/T	cg13809441	chr6:6737631	NA	-0.44	-4.91	-0.45	3.84e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs250677	0.522	rs6580589	chr5:148360335	C/G	cg18129178	chr5:148520854	ABLIM3	0.72	5.4	0.48	4.94e-7	Breast cancer;
THYM	cis	rs67311347	0.544	rs9864664	chr3:40336226	T/C	cg24209194	chr3:40518798	ZNF619	0.55	4.6	0.43	1.29e-5	Renal cell carcinoma;
THYM	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg13647721	chr17:30228624	UTP6	0.76	4.98	0.46	2.83e-6	Height;
THYM	cis	rs75920871	0.528	rs7935913	chr11:116944348	A/G	cg20608306	chr11:116969690	SIK3	0.54	6.01	0.52	3.45e-8	Subjective well-being;
THYM	cis	rs2050392	0.517	rs160018	chr10:30772703	T/C	cg18806716	chr10:30721971	MAP3K8	-0.51	-4.67	-0.43	9.79e-6	Inflammatory bowel disease;
THYM	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg02503808	chr4:7069936	GRPEL1	0.99	8.48	0.66	2.89e-13	Monocyte percentage of white cells;
THYM	cis	rs2455799	0.573	rs2455830	chr3:15749213	C/T	cg16303742	chr3:15540471	COLQ	-0.58	-6.24	-0.54	1.2e-8	Mean platelet volume;
THYM	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg07636037	chr3:49044803	WDR6	1.0	10.78	0.74	3.59e-18	Parkinson's disease;
THYM	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg07424592	chr7:64974309	NA	1.06	5.48	0.49	3.47e-7	Diabetic kidney disease;
THYM	cis	rs1915146	0.901	rs6597884	chr10:126851174	T/C	cg05090351	chr10:126851162	NA	0.75	8.86	0.67	4.61e-14	Menarche (age at onset);
THYM	cis	rs1021993	0.672	rs2660633	chr1:209486652	A/G	cg24997231	chr1:209527535	NA	0.5	4.5	0.42	1.9e-5	Gut microbiome composition (winter);
THYM	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg24675056	chr1:15929824	NA	0.72	5.71	0.51	1.26e-7	Systolic blood pressure;
THYM	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg12560992	chr17:57184187	TRIM37	0.94	8.84	0.67	5.01e-14	Intelligence (multi-trait analysis);
THYM	cis	rs501916	0.634	rs8037600	chr15:48060331	A/G	cg20869673	chr15:48010124	SEMA6D	0.64	4.63	0.43	1.14e-5	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg07936489	chr17:37558343	FBXL20	-0.64	-4.64	-0.43	1.13e-5	Asthma;
THYM	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg25072359	chr17:41440525	NA	0.65	4.55	0.42	1.57e-5	Menopause (age at onset);
THYM	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.09	0.64	1.97e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.86	-8.85	-0.67	4.76e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg07777115	chr5:623756	CEP72	-0.8	-4.78	-0.44	6.48e-6	Obesity-related traits;
THYM	cis	rs7681440	0.583	rs2737024	chr4:90721560	A/G	cg06632027	chr4:90757378	SNCA	-0.66	-5.19	-0.47	1.18e-6	Dementia with Lewy bodies;
THYM	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg10515332	chr4:99064459	C4orf37	0.59	4.65	0.43	1.08e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg02953382	chr22:24373134	LOC391322	-0.76	-7.72	-0.62	1.19e-11	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs13202913	0.837	rs6906667	chr6:151772569	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.84	-4.72	-0.44	7.97e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs6604026	0.656	rs11164844	chr1:93416650	C/A	cg08249608	chr1:94090449	BCAR3	0.6	4.47	0.42	2.13e-5	Multiple sclerosis;
THYM	cis	rs514406	0.928	rs1672917	chr1:53291550	A/G	cg16325326	chr1:53192061	ZYG11B	0.85	8.17	0.64	1.34e-12	Monocyte count;
THYM	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg18825119	chr6:163149453	PACRG;PARK2	0.59	5.3	0.48	7.4e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.92	0.58	5.2400000000000005e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs2730245	0.545	rs2788472	chr7:158649304	T/C	cg11984989	chr7:158649758	WDR60	1.11	15.12	0.84	5.06e-27	Height;
THYM	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.85	8.94	0.68	3.08e-14	Blood protein levels;
THYM	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg04025307	chr7:1156635	C7orf50	0.82	8.33	0.65	5.94e-13	Longevity;Endometriosis;
THYM	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg27534772	chr1:16042836	PLEKHM2	0.53	5.9	0.52	5.65e-8	Systolic blood pressure;
THYM	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Bipolar disorder;
THYM	cis	rs4731207	0.596	rs11767737	chr7:124637905	A/G	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg06558623	chr16:89946397	TCF25	1.5	6.51	0.56	3.59e-9	Skin colour saturation;
THYM	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs17598306	0.935	rs17598132	chr7:96579339	C/T	cg26766885	chr7:96220185	NA	0.62	5.13	0.47	1.56e-6	Radiation response;
THYM	cis	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg21775007	chr8:11205619	TDH	0.69	5.95	0.52	4.38e-8	Retinal vascular caliber;
THYM	cis	rs11771526	0.901	rs2191000	chr7:32275098	C/A	cg27511599	chr7:32358540	NA	0.61	4.5	0.42	1.9e-5	Body mass index;
THYM	cis	rs9796	0.689	rs7180494	chr15:41451841	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.59	-4.58	-0.43	1.42e-5	Menopause (age at onset);
THYM	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg14584255	chr6:163149320	PACRG;PARK2	0.54	4.81	0.44	5.66e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs8048589	0.898	rs8063329	chr16:12186047	G/A	cg02910054	chr16:12241554	SNX29	0.69	5.64	0.5	1.77e-7	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs28785552	0.931	rs10406850	chr19:53240807	A/C	cg10871876	chr19:53194124	ZNF83	0.8	6.75	0.57	1.19e-9	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs684232	0.666	rs425961	chr17:573714	G/A	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.38	-4.47	-0.42	2.18e-5	Prostate cancer;
THYM	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.01	12.82	0.8	1.97e-22	Chronic sinus infection;
THYM	trans	rs12810016	0.803	rs12822640	chr12:83320116	C/G	cg04578774	chr11:44332664	ALX4	1.22	6.87	0.58	6.7e-10	Coronary artery aneurysm in Kawasaki disease;
THYM	cis	rs10875746	0.517	rs12721420	chr12:48358794	C/T	cg20731937	chr12:48336164	NA	0.68	5.32	0.48	6.86e-7	Longevity (90 years and older);
THYM	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg21427119	chr20:30132790	HM13	-1.0	-7.05	-0.59	2.92e-10	Mean corpuscular hemoglobin;
THYM	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg07570687	chr10:102243282	WNT8B	0.74	6.47	0.55	4.35e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs986417	1.000	rs1254291	chr14:60863570	A/T	cg27398547	chr14:60952738	C14orf39	-1.25	-6.45	-0.55	4.64e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs662064	0.926	rs589400	chr1:10561282	A/G	cg20482658	chr1:10539492	PEX14	0.48	5.85	0.51	7.01e-8	Asthma;
THYM	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg12564285	chr5:131593104	PDLIM4	0.44	4.8	0.44	5.93e-6	Blood metabolite levels;
THYM	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs72829446	0.530	rs8075009	chr17:7374508	A/T	cg02795151	chr17:7402630	POLR2A	0.54	5.58	0.5	2.23e-7	Androgen levels;
THYM	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg22166914	chr1:53195759	ZYG11B	-0.77	-8.25	-0.65	8.81e-13	Monocyte count;
THYM	cis	rs245880	0.740	rs245892	chr7:29191273	T/C	cg17163760	chr7:29186267	CPVL	-0.61	-4.93	-0.45	3.54e-6	Warfarin maintenance dose;
THYM	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg06108461	chr20:60628389	TAF4	-1.06	-9.16	-0.68	1.02e-14	Body mass index;
THYM	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.8	-5.59	-0.5	2.21e-7	Huntington's disease progression;
THYM	cis	rs55871839	0.684	rs9298002	chr8:59815118	T/C	cg07426533	chr8:59803705	TOX	-0.69	-7.22	-0.6	1.27e-10	Pneumonia;
THYM	cis	rs7926906	0.713	rs10741373	chr11:90520993	G/A	cg26138821	chr11:89956704	CHORDC1	-0.53	-4.72	-0.44	8.14e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg21138405	chr5:131827807	IRF1	-0.84	-9.29	-0.69	5.56e-15	Asthma (sex interaction);
THYM	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg10057126	chr4:77819792	ANKRD56	0.71	6.06	0.53	2.78e-8	Emphysema distribution in smoking;
THYM	cis	rs3780378	0.934	rs10815146	chr9:5015901	T/A	cg02405213	chr9:5042618	JAK2	-0.71	-6.32	-0.54	8.52e-9	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg02038168	chr22:39784481	NA	-0.61	-4.87	-0.45	4.39e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs2235642	0.601	rs2235647	chr16:1601331	C/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.54	-5.93	-0.52	4.97e-8	Coronary artery disease;
THYM	cis	rs7136702	1	rs7136702	chr12:50880216	A/G	cg20014596	chr12:50898483	DIP2B	0.46	4.55	0.42	1.6e-5	Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg04362960	chr10:104952993	NT5C2	0.6	5.11	0.46	1.66e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg21926883	chr2:100939477	LONRF2	-0.67	-6.3	-0.54	9.28e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg23791538	chr6:167370224	RNASET2	-0.78	-6.28	-0.54	1.02e-8	Crohn's disease;
THYM	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg20486651	chr6:167070296	RPS6KA2	0.5	4.73	0.44	7.7e-6	Crohn's disease;
THYM	cis	rs28595532	0.920	rs116401323	chr4:119721727	C/T	cg11846333	chr4:119757529	SEC24D	1.48	5.58	0.5	2.24e-7	Cannabis dependence symptom count;
THYM	cis	rs4243830	0.677	rs6693922	chr1:6584804	A/T	cg22792644	chr1:6614718	TAS1R1;NOL9	1.14	7.82	0.63	7.13e-12	Body mass index;
THYM	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg08975724	chr8:8085496	FLJ10661	0.7	5.49	0.49	3.28e-7	Mood instability;
THYM	cis	rs3741151	0.773	rs73548688	chr11:73279544	C/T	cg17517138	chr11:73019481	ARHGEF17	0.9	4.68	0.43	9.36e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs8112211	0.637	rs2270094	chr19:38840139	T/C	cg09474229	chr19:39360330	RINL	-0.71	-5.48	-0.49	3.52e-7	Blood protein levels;
THYM	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg05234568	chr11:5960015	NA	-0.63	-5.61	-0.5	2.02e-7	DNA methylation (variation);
THYM	cis	rs986417	0.901	rs10151423	chr14:60996667	A/G	cg27398547	chr14:60952738	C14orf39	1.18	6.51	0.56	3.56e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg09338302	chr7:1325757	NA	0.48	4.5	0.42	1.96e-5	Bipolar disorder;
THYM	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg14779329	chr11:130786720	SNX19	0.55	5.83	0.51	7.58e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05901451	chr6:126070800	HEY2	-0.68	-5.84	-0.51	7.41e-8	Brugada syndrome;
THYM	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.06	-10.49	-0.73	1.52e-17	Primary sclerosing cholangitis;
THYM	cis	rs6840360	0.582	rs2709812	chr4:152335749	C/T	cg17479576	chr4:152424074	FAM160A1	0.65	4.76	0.44	7.03e-6	Intelligence (multi-trait analysis);
THYM	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg13683864	chr3:40499215	RPL14	1.05	11.64	0.77	5.54e-20	Renal cell carcinoma;
THYM	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	7.65	0.62	1.65e-11	Smoking behavior;
THYM	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg12219531	chr12:120966889	COQ5	0.8	6.55	0.56	2.9e-9	High light scatter reticulocyte count;
THYM	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.26	-5.22	-0.47	1.07e-6	Obesity-related traits;
THYM	cis	rs6918586	1.000	rs198811	chr6:26128446	A/G	cg03264133	chr6:25882463	NA	-0.63	-4.79	-0.44	6.16e-6	Schizophrenia;
THYM	cis	rs7172809	0.573	rs60863150	chr15:77515940	C/A	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg02203224	chr12:123464087	ARL6IP4;OGFOD2	-0.53	-4.56	-0.42	1.52e-5	Platelet count;
THYM	cis	rs791888	1.000	rs791888	chr10:89412575	G/T	cg10377144	chr10:89419177	PAPSS2	-0.4	-6.5	-0.55	3.68e-9	Magnesium levels;
THYM	cis	rs7542375	0.683	rs11584914	chr1:221102989	A/G	cg16008148	chr1:221062819	NA	0.49	5.14	0.47	1.47e-6	Obesity-related traits;
THYM	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg05962950	chr11:130786565	SNX19	0.82	7.4	0.6	5.47e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs752010	0.695	rs11210508	chr1:42106935	A/G	cg06885757	chr1:42089581	HIVEP3	0.49	5.95	0.52	4.46e-8	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.67	4.56	0.42	1.5e-5	Lung cancer in ever smokers;
THYM	cis	rs9790314	0.586	rs11710916	chr3:161130070	A/G	cg03342759	chr3:160939853	NMD3	-0.84	-7.31	-0.6	8.38e-11	Morning vs. evening chronotype;
THYM	cis	rs3110496	0.650	rs563976	chr17:27905673	A/G	cg04498198	chr17:27899966	TP53I13	-0.56	-6.11	-0.53	2.15e-8	Height;
THYM	cis	rs28595532	0.764	rs115877991	chr4:119728298	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg24818145	chr4:99064322	C4orf37	0.68	5.34	0.48	6.39e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs79149102	0.579	rs12591175	chr15:75356073	C/T	cg17294928	chr15:75287854	SCAMP5	-0.94	-5.03	-0.46	2.27e-6	Lung cancer;
THYM	cis	rs11048434	0.723	rs2080116	chr12:9138183	A/G	cg13575925	chr12:9217583	LOC144571	0.55	5.45	0.49	3.89e-7	Sjögren's syndrome;
THYM	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs1401999	0.628	rs7639048	chr3:183746044	A/G	cg20387954	chr3:183756860	HTR3D	0.56	4.76	0.44	6.98e-6	Anterior chamber depth;
THYM	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg09263875	chr16:632152	PIGQ	0.7	5.71	0.51	1.27e-7	Height;
THYM	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg26384229	chr12:38710491	ALG10B	-0.74	-5.8	-0.51	8.85e-8	Bladder cancer;
THYM	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg03806693	chr22:41940476	POLR3H	1.01	8.3	0.65	7.1e-13	Vitiligo;
THYM	cis	rs2625529	0.668	rs35206011	chr15:72539494	T/C	cg16672083	chr15:72433130	SENP8	-0.53	-4.75	-0.44	7.14e-6	Red blood cell count;
THYM	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg11645453	chr3:52864694	ITIH4	0.33	5.25	0.47	9.28e-7	Schizophrenia;
THYM	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12472274	0.941	rs12616232	chr2:239080093	C/T	cg17459225	chr2:239074497	NA	0.76	5.39	0.48	5.14e-7	Phospholipid levels (plasma);
THYM	cis	rs800586	0.522	rs10086741	chr8:116671367	G/T	cg04656070	chr8:116661063	TRPS1	0.56	6.67	0.56	1.7e-9	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs12478296	0.591	rs4973646	chr2:243001373	C/T	cg06360820	chr2:242988706	NA	0.73	4.73	0.44	7.94e-6	Obesity-related traits;
THYM	cis	rs3796352	1.000	rs17052727	chr3:53070914	T/C	cg07884673	chr3:53033167	SFMBT1	1.02	5.3	0.48	7.55e-7	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg13447684	chr7:1895903	MAD1L1	0.56	4.73	0.44	7.88e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7224737	0.673	rs11079035	chr17:40289012	C/T	cg20291162	chr17:40259547	DHX58	-0.67	-5.33	-0.48	6.65e-7	Fibrinogen levels;
THYM	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg09307838	chr4:120376055	NA	-0.67	-4.76	-0.44	6.83e-6	Corneal astigmatism;
THYM	cis	rs7084402	0.967	rs1658480	chr10:60289374	C/G	cg07615347	chr10:60278583	BICC1	0.55	4.97	0.45	2.97e-6	Refractive error;
THYM	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg08470875	chr2:26401718	FAM59B	0.74	4.59	0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs425277	0.628	rs262668	chr1:2082602	A/G	cg24578937	chr1:2090814	PRKCZ	0.59	5.88	0.52	6.22e-8	Height;
THYM	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg05182265	chr7:156933206	UBE3C	-0.7	-9.61	-0.7	1.14e-15	Body mass index;
THYM	cis	rs4242434	0.927	rs13271626	chr8:22467760	C/G	cg21658235	chr8:22456391	C8orf58	0.52	5.15	0.47	1.42e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7553864	1.000	rs975039	chr1:87613676	C/T	cg17420885	chr1:87600446	LOC339524	-0.8	-6.69	-0.57	1.51e-9	Smoking behavior;
THYM	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg27125505	chr17:43679177	LOC644172	0.77	6.97	0.58	4.25e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.78	-7.17	-0.59	1.61e-10	Personality dimensions;
THYM	cis	rs112427907	1	rs112427907	chr3:47995270	G/A	cg04507495	chr3:47563649	NA	1.1	4.49	0.42	2.03e-5	Stem cell growth factor beta levels;
THYM	cis	rs11726022	0.927	rs13101597	chr4:188161030	A/C	cg09690449	chr4:187998952	NA	-0.49	-5.09	-0.46	1.79e-6	Systolic blood pressure (cigarette smoking interaction);
THYM	cis	rs7326068	0.576	rs9552273	chr13:21333750	A/C	cg02792322	chr13:21280448	IL17D	-0.65	-4.51	-0.42	1.86e-5	Schizophrenia, bipolar disorder and depression (combined);
THYM	cis	rs128738	0.500	rs12055301	chr5:131572219	G/A	cg22598563	chr5:131563921	P4HA2	0.53	4.51	0.42	1.84e-5	Giant cell arteritis;
THYM	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg00908189	chr16:619842	PIGQ	1.03	9.33	0.69	4.4e-15	Height;
THYM	cis	rs6988636	1.000	rs7002021	chr8:124185250	G/A	cg26140120	chr8:124219575	FAM83A	0.87	4.81	0.44	5.77e-6	Urinary uromodulin levels;
THYM	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg26597838	chr10:835615	NA	1.52	11.37	0.76	2.05e-19	Eosinophil percentage of granulocytes;
THYM	cis	rs72781680	0.898	rs72780191	chr2:24007122	T/C	cg08917208	chr2:24149416	ATAD2B	1.11	4.97	0.45	2.9e-6	Lymphocyte counts;
THYM	cis	rs7772486	0.738	rs2246334	chr6:146183635	G/A	cg13319975	chr6:146136371	FBXO30	-0.63	-5.18	-0.47	1.24e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.83	4.65	0.43	1.07e-5	Alzheimer's disease;
THYM	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs12282928	0.513	rs7948537	chr11:48342072	T/A	cg22827986	chr11:48284249	OR4X1	0.53	5.62	0.5	1.86e-7	Migraine - clinic-based;
THYM	cis	rs9393777	0.920	rs35120058	chr6:27358166	A/G	cg23161317	chr6:28129485	ZNF389	1.11	4.64	0.43	1.1e-5	Intelligence (multi-trait analysis);
THYM	cis	rs76878669	0.561	rs4930179	chr11:66157432	C/T	cg14263139	chr11:66104018	RIN1	-0.36	-4.46	-0.42	2.29e-5	Educational attainment (years of education);
THYM	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg00024416	chr22:24240387	NA	0.77	8.78	0.67	6.52e-14	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.78	-0.44	6.31e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg02018176	chr4:1364513	KIAA1530	0.77	7.2	0.59	1.38e-10	Longevity;
THYM	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg01579765	chr21:45077557	HSF2BP	0.53	8.63	0.66	1.37e-13	Mean corpuscular volume;
THYM	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg13609457	chr4:120235615	NA	0.6	5.34	0.48	6.23e-7	Corneal astigmatism;
THYM	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.79	6.94	0.58	4.8e-10	Tonsillectomy;
THYM	cis	rs72829446	0.530	rs2302761	chr17:7358520	C/T	cg02795151	chr17:7402630	POLR2A	0.54	5.5	0.49	3.15e-7	Androgen levels;
THYM	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg08999081	chr20:33150536	PIGU	0.79	7.48	0.61	3.72e-11	Glomerular filtration rate (creatinine);
THYM	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg27398817	chr8:82754497	SNX16	0.71	6.05	0.53	2.89e-8	Diastolic blood pressure;
THYM	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg12564285	chr5:131593104	PDLIM4	-0.43	-4.66	-0.43	1.04e-5	Breast cancer;
THYM	cis	rs6815814	0.904	rs7664239	chr4:38786304	T/C	cg06935464	chr4:38784597	TLR10	0.72	5.23	0.47	9.87e-7	Breast cancer;
THYM	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg14784868	chr12:69753453	YEATS4	1.12	10.87	0.74	2.32e-18	Blood protein levels;
THYM	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg00990874	chr7:1149470	C7orf50	-0.64	-4.78	-0.44	6.35e-6	Bronchopulmonary dysplasia;
THYM	cis	rs514406	0.929	rs12410420	chr1:53323754	T/C	cg22166914	chr1:53195759	ZYG11B	0.8	8.04	0.64	2.5e-12	Monocyte count;
THYM	cis	rs1003719	0.788	rs4817844	chr21:38447064	A/T	cg01329690	chr21:38580129	DSCR9	-0.37	-5.08	-0.46	1.85e-6	Eye color traits;
THYM	cis	rs73198271	0.740	rs28521727	chr8:8647217	T/C	cg15556689	chr8:8085844	FLJ10661	-0.73	-4.58	-0.43	1.39e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs986417	1.000	rs10149915	chr14:60943110	G/A	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs11585357	0.843	rs12095095	chr1:17625832	C/G	cg08277548	chr1:17600880	PADI3	-0.86	-5.23	-0.47	9.93e-7	Hair shape;
THYM	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg27446573	chr6:127587934	RNF146	1.08	9.0	0.68	2.23e-14	Breast cancer;
THYM	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg18681998	chr4:17616180	MED28	0.99	10.18	0.72	6.74e-17	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs17125944	0.686	rs7143400	chr14:53324891	A/C	cg00686598	chr14:53173677	PSMC6	-1.12	-5.04	-0.46	2.19e-6	Alzheimer's disease (late onset);
THYM	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.68	-6.71	-0.57	1.39e-9	Chronic sinus infection;
THYM	cis	rs6558530	0.932	rs7842425	chr8:1706041	G/T	cg09410841	chr8:1729607	CLN8	0.68	5.14	0.47	1.5e-6	Systolic blood pressure;
THYM	cis	rs7107174	1.000	rs10899454	chr11:77997513	T/C	cg02023728	chr11:77925099	USP35	0.67	5.88	0.52	6.07e-8	Testicular germ cell tumor;
THYM	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.63	-4.48	-0.42	2.05e-5	Gut microbiome composition (summer);
THYM	cis	rs11247915	0.561	rs11583258	chr1:26624270	C/T	cg00852783	chr1:26633632	UBXN11	0.77	6.08	0.53	2.48e-8	Obesity-related traits;
THYM	cis	rs7084402	0.967	rs11006170	chr10:60276369	T/C	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs887829	0.570	rs4553819	chr2:234594083	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-6.64	-0.56	1.98e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg27490568	chr2:178487706	NA	0.57	4.94	0.45	3.33e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg21775007	chr8:11205619	TDH	0.61	4.96	0.45	3.11e-6	Retinal vascular caliber;
THYM	cis	rs9311676	0.656	rs11915480	chr3:58377159	A/G	cg26110898	chr3:58419937	PDHB	0.44	4.56	0.42	1.53e-5	Systemic lupus erythematosus;
THYM	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg08994789	chr17:28903642	LRRC37B2	-1.06	-5.25	-0.47	9.31e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	8.08	0.64	2.01e-12	Smoking behavior;
THYM	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.9	7.28	0.6	9.61e-11	Lymphocyte percentage of white cells;
THYM	cis	rs12681287	0.752	rs10956786	chr8:87301237	T/C	cg27223183	chr8:87520930	FAM82B	-0.64	-4.91	-0.45	3.79e-6	Caudate activity during reward;
THYM	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs6684428	0.610	rs12123610	chr1:56312992	A/T	cg11651538	chr1:56320950	NA	0.7	4.7	0.43	8.73e-6	Airflow obstruction;
THYM	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg04944784	chr2:26401820	FAM59B	-0.71	-5.48	-0.49	3.46e-7	Gut microbiome composition (summer);
THYM	cis	rs1499972	0.941	rs62266129	chr3:117590704	G/C	cg07612923	chr3:117604196	NA	1.3	5.42	0.49	4.55e-7	Schizophrenia;
THYM	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24531977	chr5:56204891	C5orf35	1.02	8.59	0.66	1.73e-13	Initial pursuit acceleration;
THYM	cis	rs2075230	0.705	rs1641531	chr17:7546791	C/G	cg10509001	chr17:7553872	ATP1B2	-0.56	-4.52	-0.42	1.79e-5	Hormone measurements;
THYM	cis	rs7100689	0.784	rs4934153	chr10:82191255	T/C	cg01528321	chr10:82214614	TSPAN14	1.13	8.8	0.67	6.09e-14	Post bronchodilator FEV1;
THYM	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs4919087	0.851	rs3781373	chr10:99080585	C/T	cg19453742	chr10:98862320	SLIT1	-0.61	-5.08	-0.46	1.86e-6	Monocyte count;
THYM	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg03433033	chr1:76189801	ACADM	0.76	8.16	0.64	1.4e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg14972814	chr11:95582409	MTMR2	-0.58	-5.31	-0.48	7.17e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg21984481	chr17:79567631	NPLOC4	-0.61	-6.88	-0.58	6.43e-10	Eye color traits;
THYM	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.66	5.7	0.5	1.37e-7	Total body bone mineral density;
THYM	cis	rs8017423	0.935	rs8012303	chr14:90715829	G/A	cg04239629	chr14:90701769	NA	-0.62	-4.52	-0.42	1.81e-5	Mortality in heart failure;
THYM	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.5	-5.08	-0.46	1.88e-6	Primary biliary cholangitis;
THYM	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.07	7.63	0.62	1.83e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2404602	0.646	rs3764245	chr15:77223176	G/C	cg23625390	chr15:77176239	SCAPER	0.77	5.33	0.48	6.47e-7	Blood metabolite levels;
THYM	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.14	-0.64	1.51e-12	Personality dimensions;
THYM	cis	rs2120019	0.567	rs12385940	chr15:75168162	C/T	cg09165964	chr15:75287851	SCAMP5	-0.69	-4.89	-0.45	4.13e-6	Blood trace element (Zn levels);
THYM	cis	rs1403694	1.000	rs2304451	chr3:186437661	G/C	cg12454167	chr3:186435060	KNG1	0.44	5.82	0.51	7.8e-8	Blood protein levels;
THYM	cis	rs28647808	1.000	rs7032021	chr9:136276601	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.18	-4.93	-0.45	3.43e-6	Blood protein levels;
THYM	cis	rs55883249	1.000	rs75139639	chr2:9763905	A/T	cg23886495	chr2:9695866	ADAM17	0.8	5.03	0.46	2.29e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs17253792	0.545	rs35466279	chr14:56017022	C/T	cg01858014	chr14:56050164	KTN1	-1.09	-4.58	-0.43	1.39e-5	Putamen volume;
THYM	cis	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.59	-8.1	-0.64	1.86e-12	Monocyte percentage of white cells;
THYM	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg24006582	chr15:45444508	DUOX1	-0.83	-7.16	-0.59	1.7e-10	Uric acid levels;
THYM	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg10792982	chr14:105748885	BRF1	0.72	7.48	0.61	3.62e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2637266	1.000	rs2130799	chr10:78322922	C/T	cg18941641	chr10:78392320	NA	0.8	6.9	0.58	5.69e-10	Pulmonary function;
THYM	cis	rs4455778	0.539	rs7780870	chr7:49014630	A/G	cg26309511	chr7:48887640	NA	-0.5	-4.62	-0.43	1.2e-5	Lung cancer in never smokers;
THYM	cis	rs2455799	0.613	rs2470547	chr3:15737610	T/C	cg16303742	chr3:15540471	COLQ	-0.57	-6.16	-0.53	1.77e-8	Mean platelet volume;
THYM	cis	rs3126085	0.935	rs3126072	chr1:152279729	C/T	cg10321714	chr1:152280068	FLG	-0.67	-5.14	-0.47	1.5e-6	Atopic dermatitis;
THYM	cis	rs6570726	0.846	rs372904	chr6:145887425	T/C	cg05347473	chr6:146136440	FBXO30	0.57	4.48	0.42	2.04e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg18825119	chr6:163149453	PACRG;PARK2	-0.52	-4.75	-0.44	7.28e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1728785	1.000	rs1728792	chr16:68596534	G/C	cg02972257	chr16:68554789	NA	-0.76	-4.69	-0.43	9.2e-6	Ulcerative colitis;
THYM	cis	rs7107174	0.681	rs4340079	chr11:78007920	C/T	cg19901956	chr11:77921274	USP35	-0.66	-5.05	-0.46	2.13e-6	Testicular germ cell tumor;
THYM	cis	rs10489202	1.000	rs7538581	chr1:167979347	A/G	cg24449463	chr1:168025552	DCAF6	-0.83	-6.51	-0.56	3.58e-9	Schizophrenia;
THYM	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-13.44	-0.81	1.08e-23	Height;
THYM	cis	rs11696501	0.694	rs6124722	chr20:44263264	G/A	cg11783356	chr20:44313418	WFDC10B	-0.67	-4.63	-0.43	1.17e-5	Brain structure;
THYM	cis	rs7084402	0.967	rs1649036	chr10:60331878	C/A	cg09696939	chr10:60272079	BICC1	-0.46	-5.53	-0.49	2.75e-7	Refractive error;
THYM	cis	rs7809950	0.817	rs2222845	chr7:107281829	C/T	cg23024343	chr7:107201750	COG5	0.89	7.34	0.6	7.26e-11	Coronary artery disease;
THYM	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg08257088	chr16:3726052	TRAP1	-0.66	-4.94	-0.45	3.32e-6	Tuberculosis;
THYM	cis	rs988913	0.957	rs1910350	chr6:54852462	C/A	cg18532076	chr6:54711417	FAM83B	0.54	5.19	0.47	1.21e-6	Menarche (age at onset);
THYM	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg05347473	chr6:146136440	FBXO30	-0.81	-7.24	-0.6	1.13e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.64	-0.43	1.14e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg13395646	chr4:1353034	KIAA1530	-0.46	-4.47	-0.42	2.19e-5	Obesity-related traits;
THYM	cis	rs2692947	0.655	rs4605406	chr2:96583735	A/C	cg22654517	chr2:96458247	NA	0.72	5.31	0.48	7.29e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg20295408	chr7:1910781	MAD1L1	-0.63	-4.73	-0.44	7.72e-6	Schizophrenia;
THYM	cis	rs6674176	0.628	rs2240447	chr1:44415415	C/T	cg12908607	chr1:44402522	ARTN	-0.54	-4.64	-0.43	1.1e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs9788682	0.747	rs2656071	chr15:78745343	A/T	cg18825076	chr15:78729989	IREB2	-0.69	-5.51	-0.49	3.05e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs2115536	0.606	rs8024713	chr15:80206958	C/G	cg00225070	chr15:80189496	MTHFS	0.64	5.49	0.49	3.39e-7	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs4731207	0.596	rs11767649	chr7:124637517	C/T	cg05285228	chr7:124571219	POT1	0.68	5.08	0.46	1.88e-6	Cutaneous malignant melanoma;
THYM	cis	rs250677	0.652	rs1422582	chr5:148436925	T/C	cg18129178	chr5:148520854	ABLIM3	-0.76	-4.74	-0.44	7.64e-6	Breast cancer;
THYM	cis	rs4930103	0.904	rs4929984	chr11:2024683	A/C	cg18511798	chr11:2018149	H19;MIR675	0.59	5.87	0.52	6.44e-8	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg16506815	chr2:162101123	NA	0.72	5.84	0.51	7.38e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
THYM	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg14895029	chr7:2775587	GNA12	-0.68	-5.03	-0.46	2.27e-6	Height;
THYM	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs6918586	0.658	rs198809	chr6:26128766	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.65	-0.62	1.6e-11	Schizophrenia;
THYM	cis	rs761746	0.960	rs7289075	chr22:32013745	T/C	cg10537193	chr22:32026975	PISD	-0.34	-4.86	-0.45	4.72e-6	Intelligence;
THYM	cis	rs1011018	0.955	rs7810028	chr7:139461616	C/G	cg06079564	chr7:139468310	HIPK2	-0.73	-5.73	-0.51	1.2e-7	Systolic blood pressure;
THYM	cis	rs7917772	0.582	rs7075269	chr10:104365724	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	6.73	0.57	1.3e-9	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg05294307	chr14:35346193	BAZ1A	-0.85	-5.67	-0.5	1.52e-7	Psoriasis;
THYM	cis	rs10158481	0.727	rs9438891	chr1:25477602	A/G	cg09264742	chr1:25757510	TMEM57	-0.69	-5.1	-0.46	1.77e-6	Urate levels in obese individuals;
THYM	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg06521331	chr12:34319734	NA	-0.98	-8.71	-0.67	9.23e-14	Morning vs. evening chronotype;
THYM	cis	rs1448094	0.511	rs17345299	chr12:86166005	C/G	cg00310523	chr12:86230176	RASSF9	0.61	5.31	0.48	7.29e-7	Major depressive disorder;
THYM	cis	rs240764	0.853	rs2062634	chr6:101002618	G/C	cg21058520	chr6:100914733	NA	0.57	5.07	0.46	1.95e-6	Neuroticism;
THYM	cis	rs34638657	0.732	rs12597010	chr16:82199971	G/A	cg07307142	chr16:82071433	HSD17B2	-0.89	-8.11	-0.64	1.73e-12	Lung adenocarcinoma;
THYM	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.26	5.32	0.48	7.02e-7	Obesity-related traits;
THYM	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs58530613	1.000	rs80346939	chr4:124734350	T/C	cg11268546	chr4:124983615	NA	0.7	4.45	0.42	2.36e-5	Platelet count;
THYM	cis	rs295140	1.000	rs1431766	chr2:201191034	A/G	cg04283868	chr2:201171347	SPATS2L	0.74	5.53	0.49	2.81e-7	QT interval;
THYM	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg20387954	chr3:183756860	HTR3D	0.59	4.85	0.45	4.87e-6	Anterior chamber depth;
THYM	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg22664400	chr11:66445111	RBM4B	0.66	4.47	0.42	2.14e-5	Crohn's disease;
THYM	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.07	-0.46	1.97e-6	Bipolar disorder;
THYM	cis	rs80319144	1.000	rs78216340	chr2:159193005	C/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.61	4.69	0.43	8.96e-6	Restless legs syndrome;
THYM	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg07061783	chr6:25882402	NA	-0.86	-7.26	-0.6	1.04e-10	Intelligence (multi-trait analysis);
THYM	cis	rs12200560	0.505	rs211162	chr6:97067344	G/A	cg06623918	chr6:96969491	KIAA0776	0.74	5.68	0.5	1.45e-7	Coronary heart disease;
THYM	cis	rs11948739	0.610	rs4705882	chr5:130343041	A/G	cg08523029	chr5:130500466	HINT1	0.73	4.94	0.45	3.38e-6	Pediatric bone mineral content (hip);
THYM	cis	rs2637266	0.935	rs7921790	chr10:78368253	T/C	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.78	-4.79	-0.44	6.23e-6	Diabetic retinopathy;
THYM	cis	rs6429082	0.783	rs291365	chr1:235688043	A/G	cg26050004	chr1:235667680	B3GALNT2	0.78	6.83	0.57	8.01e-10	Adiposity;
THYM	cis	rs7312774	0.618	rs28716736	chr12:107364410	A/G	cg16260113	chr12:107380972	MTERFD3	1.36	6.74	0.57	1.2e-9	Severe influenza A (H1N1) infection;
THYM	cis	rs11648796	0.765	rs3829492	chr16:781633	G/A	cg10254923	chr16:769848	FAM173A	0.52	5.48	0.49	3.44e-7	Height;
THYM	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg10661904	chr17:79619235	PDE6G	-0.58	-5.3	-0.48	7.36e-7	Eye color traits;
THYM	cis	rs6867032	0.958	rs9312970	chr5:2002415	C/A	cg26168224	chr5:2018326	NA	-1.13	-11.47	-0.76	1.24e-19	Gut microbiome composition (winter);
THYM	cis	rs10463554	0.927	rs34811	chr5:102431821	A/G	cg23492399	chr5:102201601	PAM	-0.67	-5.18	-0.47	1.26e-6	Parkinson's disease;
THYM	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg27532560	chr4:187881888	NA	-0.96	-12.7	-0.79	3.41e-22	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6956675	0.793	rs6946559	chr7:62660568	A/T	cg08930214	chr7:62859557	LOC100287834	0.61	4.81	0.44	5.69e-6	Obesity-related traits;
THYM	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg00080972	chr5:178986291	RUFY1	0.57	7.35	0.6	6.84e-11	Lung cancer;
THYM	cis	rs11608355	0.597	rs2304548	chr12:109795166	T/G	cg10504392	chr12:110044639	NA	0.54	4.91	0.45	3.73e-6	Neuroticism;
THYM	cis	rs40363	0.723	rs2736	chr16:3536872	G/A	cg05754148	chr16:3507555	NAT15	-0.87	-6.93	-0.58	4.92e-10	Tuberculosis;
THYM	cis	rs6450176	1.000	rs9687611	chr5:53300288	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.82	-6.14	-0.53	1.94e-8	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs4481887	1.000	rs4360553	chr1:248467092	A/G	cg00666640	chr1:248458726	OR2T12	0.56	4.58	0.43	1.4e-5	Common traits (Other);
THYM	cis	rs7258015	1.000	rs7250300	chr19:10448660	C/A	cg01466491	chr19:10523363	NA	0.65	5.14	0.47	1.47e-6	Systemic lupus erythematosus or rheumatoid arthritis;
THYM	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg14584255	chr6:163149320	PACRG;PARK2	0.71	6.25	0.54	1.16e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4343996	0.870	rs4722708	chr7:3382563	A/T	cg21248987	chr7:3385318	SDK1	-0.4	-4.85	-0.45	4.87e-6	Motion sickness;
THYM	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg06550200	chr5:1325588	CLPTM1L	-0.72	-6.12	-0.53	2.09e-8	Lung cancer;
THYM	cis	rs12928939	0.517	rs9940234	chr16:71964805	C/T	cg03805757	chr16:71968109	PKD1L3	-0.99	-9.88	-0.71	2.99e-16	Post bronchodilator FEV1;
THYM	cis	rs9560113	0.509	rs28608633	chr13:112206880	G/A	cg10483660	chr13:112241077	NA	0.65	7.12	0.59	2.08e-10	Menarche (age at onset);
THYM	cis	rs2070488	1.000	rs7433707	chr3:38443180	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	6.65	0.56	1.88e-9	Electrocardiographic conduction measures;
THYM	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.84	-5.3	-0.48	7.34e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1003719	0.715	rs4261789	chr21:38503762	T/G	cg01329690	chr21:38580129	DSCR9	-0.42	-5.84	-0.51	7.24e-8	Eye color traits;
THYM	cis	rs6473252	0.966	rs55690008	chr8:81812513	T/C	cg08595989	chr8:81827712	NA	-0.41	-4.54	-0.42	1.65e-5	Breast cancer;
THYM	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg02887458	chr19:19495540	GATAD2A	-0.5	-5.78	-0.51	9.57e-8	Bipolar disorder;
THYM	cis	rs72627509	0.904	rs3796529	chr4:57797414	C/T	cg26694713	chr4:57773883	REST	0.76	4.85	0.45	4.78e-6	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg04156016	chr5:1868137	NA	0.51	4.8	0.44	5.87e-6	Cardiovascular disease risk factors;
THYM	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7943358	0.758	rs11023685	chr11:15709984	A/G	cg11966998	chr11:15692519	NA	-0.48	-5.04	-0.46	2.24e-6	Gut microbiome composition (summer);
THYM	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2991971	0.810	rs2036021	chr1:45901370	G/A	cg15605315	chr1:45957053	TESK2	0.62	4.92	0.45	3.57e-6	High light scatter reticulocyte count;
THYM	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg24531977	chr5:56204891	C5orf35	0.9	6.28	0.54	1.01e-8	Initial pursuit acceleration;
THYM	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg13397359	chr6:42928475	GNMT	0.64	5.59	0.5	2.14e-7	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs57994353	0.897	rs66477686	chr9:139372224	T/C	cg14115884	chr9:139300582	SDCCAG3	0.68	4.7	0.43	8.9e-6	Eosinophil counts;Cutaneous squamous cell carcinoma;
THYM	cis	rs8073060	0.821	rs11080355	chr17:33872694	T/A	cg24895173	chr17:33825374	SLFN12L	0.58	4.61	0.43	1.25e-5	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs10911251	0.528	rs4652779	chr1:183104552	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	5.06	0.46	2.02e-6	Colorectal cancer;
THYM	cis	rs7172809	0.548	rs75329354	chr15:77668065	C/T	cg22256960	chr15:77711686	NA	-0.65	-4.82	-0.44	5.47e-6	Glucose homeostasis traits;
THYM	cis	rs240764	0.658	rs60658003	chr6:101201191	C/A	cg21058520	chr6:100914733	NA	0.56	4.97	0.45	2.95e-6	Neuroticism;
THYM	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg07460842	chr6:66804631	NA	-1.06	-7.89	-0.63	5.14e-12	Exhaled nitric oxide output;
THYM	cis	rs9644630	0.696	rs13261824	chr8:19313912	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.67	7.57	0.61	2.42e-11	Oropharynx cancer;
THYM	cis	rs10819861	0.645	rs7045648	chr9:98855039	G/T	cg14508093	chr9:98862825	NA	-0.24	-4.6	-0.43	1.28e-5	Electrocardiographic traits;
THYM	cis	rs9902453	0.791	rs57719820	chr17:28335088	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs7224737	1.000	rs9889640	chr17:40293497	C/T	cg20291162	chr17:40259547	DHX58	-0.69	-6.44	-0.55	4.96e-9	Fibrinogen levels;
THYM	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg12310025	chr6:25882481	NA	-0.69	-5.41	-0.49	4.62e-7	Blood metabolite levels;
THYM	cis	rs3773445	0.740	rs1730221	chr3:25618408	C/G	cg02315353	chr3:25825455	NGLY1	0.54	4.67	0.43	9.98e-6	Airway responsiveness in chronic obstructive pulmonary disease;
THYM	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.59	0.66	1.68e-13	Colorectal cancer;
THYM	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg26384229	chr12:38710491	ALG10B	-0.74	-5.8	-0.51	8.85e-8	Bladder cancer;
THYM	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg11752832	chr7:134001865	SLC35B4	-0.6	-4.59	-0.43	1.34e-5	Mean platelet volume;
THYM	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.87	-0.45	4.45e-6	Eye color traits;
THYM	cis	rs7107770	1.000	rs6590139	chr11:125093850	G/A	cg07747661	chr11:125106135	PKNOX2	-0.88	-5.34	-0.48	6.29e-7	Photic sneeze reflex;
THYM	cis	rs28595532	0.841	rs112953035	chr4:119752450	T/C	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2731664	0.792	rs335434	chr5:176867276	A/G	cg14098951	chr5:176875120	PRR7	0.56	5.06	0.46	2.06e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg08999081	chr20:33150536	PIGU	0.76	6.73	0.57	1.27e-9	Glomerular filtration rate (creatinine);
THYM	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg21028142	chr17:79581711	NPLOC4	0.51	5.01	0.46	2.47e-6	Eye color traits;
THYM	trans	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg18335740	chr13:41363409	SLC25A15	0.7	7.52	0.61	3.02e-11	Lewy body disease;
THYM	cis	rs6448317	0.911	rs10939013	chr4:24903015	G/A	cg22968281	chr4:24586266	DHX15	-0.7	-5.2	-0.47	1.15e-6	Heschl's gyrus morphology;
THYM	cis	rs6547741	1.000	rs7604798	chr2:27824940	T/C	cg27432699	chr2:27873401	GPN1	0.68	5.97	0.52	4.14e-8	Oral cavity cancer;
THYM	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg01324343	chr3:183735012	ABCC5	0.9	13.35	0.81	1.59e-23	Anterior chamber depth;
THYM	cis	rs12216545	0.765	rs10235836	chr7:150231373	C/T	cg08960815	chr7:150264767	GIMAP4	0.89	8.27	0.65	8.02e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs427394	0.802	rs274721	chr5:6719164	C/T	cg10857441	chr5:6722123	POLS	-0.72	-8.87	-0.67	4.28e-14	Menopause (age at onset);
THYM	cis	rs7107174	1.000	rs10899477	chr11:78052104	A/T	cg02023728	chr11:77925099	USP35	0.61	5.83	0.51	7.47e-8	Testicular germ cell tumor;
THYM	cis	rs10832963	0.847	rs4237722	chr11:18639363	T/C	cg09201001	chr11:18656081	SPTY2D1	0.98	8.72	0.67	9.12e-14	Breast cancer;
THYM	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg14675211	chr2:100938903	LONRF2	0.77	8.3	0.65	6.91e-13	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg24375607	chr4:120327624	NA	0.62	5.56	0.5	2.45e-7	Corneal astigmatism;
THYM	cis	rs7605378	1.000	rs769957	chr2:200695524	A/C	cg17644776	chr2:200775616	C2orf69	0.64	4.92	0.45	3.6e-6	Osteoporosis;
THYM	cis	rs7267979	0.773	rs6132821	chr20:25226192	A/G	cg08601574	chr20:25228251	PYGB	0.7	5.75	0.51	1.1e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg22709100	chr7:91322751	NA	0.62	4.9	0.45	3.98e-6	Breast cancer;
THYM	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg17143192	chr8:8559678	CLDN23	0.7	5.26	0.48	8.83e-7	Mood instability;
THYM	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg11266682	chr4:10021025	SLC2A9	-0.54	-6.73	-0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6450176	0.909	rs12659966	chr5:53292892	C/G	ch.5.1024479R	chr5:53302184	ARL15	0.84	6.38	0.55	6.53e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs76662990	0.610	rs13359095	chr5:73932648	A/T	cg13275603	chr5:73927487	ENC1	-0.79	-4.6	-0.43	1.32e-5	Residual cognition;
THYM	cis	rs7246657	0.943	rs4801759	chr19:37954985	G/A	cg22634378	chr19:37742834	NA	0.66	5.5	0.49	3.24e-7	Coronary artery calcification;
THYM	cis	rs7100689	0.697	rs4934084	chr10:82116960	T/C	cg01528321	chr10:82214614	TSPAN14	0.97	7.39	0.6	5.79e-11	Post bronchodilator FEV1;
THYM	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg05738196	chr6:26577821	NA	-0.63	-5.12	-0.46	1.63e-6	Intelligence (multi-trait analysis);
THYM	cis	rs80319144	0.521	rs3796106	chr2:159312777	A/T	cg24986868	chr2:159312599	PKP4;CCDC148	0.52	4.99	0.46	2.77e-6	Restless legs syndrome;
THYM	cis	rs6748734	0.581	rs4675847	chr2:241865156	A/G	cg15164180	chr2:241846931	NA	-0.41	-4.93	-0.45	3.45e-6	Urinary metabolites;
THYM	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg00278517	chr6:167070616	RPS6KA2	-0.34	-4.64	-0.43	1.13e-5	Crohn's disease;
THYM	cis	rs2249625	0.526	rs17781511	chr6:72845455	C/T	cg27608224	chr6:72922399	RIMS1	-0.58	-4.9	-0.45	3.94e-6	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
THYM	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs10203711	0.966	rs10184252	chr2:239598164	A/G	cg14580085	chr2:239553406	NA	0.63	5.73	0.51	1.18e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9515201	0.886	rs55940034	chr13:111043309	A/G	cg06243866	chr13:111019493	COL4A2	-0.74	-6.01	-0.52	3.42e-8	White matter hyperintensity burden;
THYM	cis	rs11696501	0.688	rs6094197	chr20:44316492	C/T	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.26	5.5	0.49	3.15e-7	Obesity-related traits;
THYM	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg23758822	chr17:41437982	NA	1.27	14.18	0.82	3.54e-25	Menopause (age at onset);
THYM	cis	rs7586879	1.000	rs12713419	chr2:25121853	G/A	cg15423357	chr2:25149977	NA	0.53	4.99	0.46	2.77e-6	Body mass index;
THYM	cis	rs2294693	0.531	rs1883595	chr6:40935728	A/G	cg14418226	chr6:40996092	UNC5CL	-0.66	-5.05	-0.46	2.1e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs9911578	0.839	rs7214098	chr17:57204632	C/T	cg05425664	chr17:57184151	TRIM37	-0.59	-4.72	-0.44	8.26e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg09085632	chr11:111637200	PPP2R1B	1.16	11.93	0.77	1.35e-20	Primary sclerosing cholangitis;
THYM	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.14	-0.64	1.54e-12	Mean corpuscular volume;
THYM	cis	rs4454254	1.000	rs4440615	chr8:141057641	G/A	cg20071744	chr8:141057329	TRAPPC9	-0.5	-4.49	-0.42	1.99e-5	Pulse pressure;
THYM	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg18876405	chr7:65276391	NA	-0.63	-5.56	-0.5	2.48e-7	Aortic root size;
THYM	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg14196790	chr5:131705035	SLC22A5	-0.55	-5.04	-0.46	2.21e-6	Blood metabolite levels;
THYM	cis	rs6684428	0.706	rs10493187	chr1:56320969	C/T	cg11651538	chr1:56320950	NA	-0.63	-4.97	-0.45	2.91e-6	Airflow obstruction;
THYM	cis	rs2237457	0.508	rs2529428	chr7:50704950	C/A	cg08586669	chr7:50727761	GRB10	-0.29	-4.78	-0.44	6.48e-6	Schizophrenia (treatment resistant);
THYM	cis	rs4660261	0.526	rs2485997	chr1:44345841	G/C	cg12599982	chr1:44399894	ARTN	0.56	4.55	0.42	1.59e-5	Intelligence (multi-trait analysis);
THYM	cis	rs17253792	0.822	rs75560658	chr14:56079896	C/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs2658782	0.950	rs2446061	chr11:93149277	C/T	cg15737290	chr11:93063684	CCDC67	1.05	7.97	0.63	3.42e-12	Pulmonary function decline;
THYM	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg06028808	chr11:68637592	NA	0.65	6.8	0.57	9.29e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs12941150	0.571	rs17779649	chr17:70372779	G/T	cg12139369	chr17:71284979	CDC42EP4	-0.9	-5.12	-0.47	1.57e-6	Pulmonary function decline;
THYM	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg08109568	chr15:31115862	NA	0.8	7.31	0.6	8.51e-11	Huntington's disease progression;
THYM	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.505	rs447581	chr1:53177098	T/C	cg16325326	chr1:53192061	ZYG11B	0.94	10.53	0.73	1.21e-17	Monocyte count;
THYM	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg25358565	chr5:93447407	FAM172A	1.24	10.0	0.72	1.67e-16	Diabetic retinopathy;
THYM	cis	rs2456568	0.802	rs10831136	chr11:93636860	T/C	cg26875233	chr11:93583750	C11orf90	-0.53	-5.53	-0.49	2.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg00376283	chr12:123451042	ABCB9	0.8	6.41	0.55	5.49e-9	Platelet count;
THYM	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg06112835	chr11:68658793	MRPL21	0.45	6.39	0.55	6.21e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2637266	0.655	rs7902535	chr10:78460889	C/T	cg18941641	chr10:78392320	NA	0.75	5.91	0.52	5.4e-8	Pulmonary function;
THYM	cis	rs3008870	0.755	rs3736905	chr1:67392614	A/G	cg11518657	chr1:67396239	MIER1	0.64	4.56	0.42	1.53e-5	Lymphocyte percentage of white cells;
THYM	cis	rs2742234	0.590	rs2565201	chr10:43618484	T/C	cg06632098	chr10:43605906	RET	-0.78	-4.97	-0.45	2.99e-6	Hirschsprung disease;
THYM	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-1.14	-8.25	-0.65	8.96e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7072216	0.770	rs1061115	chr10:100177049	G/A	cg26618903	chr10:100175079	PYROXD2	-0.45	-4.51	-0.42	1.84e-5	Metabolite levels;
THYM	cis	rs7226229	0.898	rs12150138	chr17:20961526	T/C	cg21263980	chr17:20946333	USP22	0.65	4.55	0.42	1.61e-5	Blood trace element (Se levels);
THYM	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg03433033	chr1:76189801	ACADM	0.51	5.31	0.48	7.2e-7	Daytime sleep phenotypes;
THYM	cis	rs2811415	0.597	rs12695505	chr3:127791636	G/A	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs4930776	0.932	rs451118	chr12:5760643	A/G	cg02086166	chr12:5775618	ANO2	0.61	6.07	0.53	2.57e-8	Plasma clusterin levels;
THYM	cis	rs6430585	0.536	rs3213892	chr2:136552517	G/A	cg07169764	chr2:136633963	MCM6	1.19	13.81	0.82	1.9e-24	Corneal structure;
THYM	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.36	0.55	7.09e-9	Body mass index;
THYM	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg04043695	chr12:129287642	SLC15A4	0.59	4.6	0.43	1.33e-5	Systemic lupus erythematosus;
THYM	cis	rs2816062	0.786	rs2745320	chr1:18893592	G/A	cg18795169	chr1:18902165	NA	-0.99	-12.14	-0.78	5.02e-21	Urate levels in lean individuals;
THYM	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.52	0.73	1.31e-17	Prudent dietary pattern;
THYM	cis	rs2133450	0.526	rs62234956	chr3:7344222	A/G	cg19930620	chr3:7340148	GRM7	-0.5	-5.46	-0.49	3.72e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs28595532	0.920	rs116799007	chr4:119763562	A/G	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.88	5.64	0.5	1.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9913156	0.793	rs11568061	chr17:4546445	G/A	cg19197139	chr17:4613644	ARRB2	0.81	4.84	0.44	5.01e-6	Lymphocyte counts;
THYM	cis	rs6032067	0.929	rs62208428	chr20:43827578	A/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.5	-5.65	-0.5	1.7e-7	Blood protein levels;
THYM	cis	rs11771526	1.000	rs62457533	chr7:32355334	G/A	cg13207630	chr7:32358064	NA	1.08	6.32	0.54	8.55e-9	Body mass index;
THYM	cis	rs12611088	0.600	rs2682553	chr19:44004566	A/G	cg18042043	chr19:44147545	NA	-0.4	-4.57	-0.42	1.45e-5	Plasma amyloid beta peptide concentrations (ABx-42);
THYM	cis	rs2898681	0.581	rs11938140	chr4:53678057	T/A	cg21521518	chr4:53727714	RASL11B	0.47	5.33	0.48	6.52e-7	Optic nerve measurement (cup area);
THYM	cis	rs236907	0.679	rs12750330	chr1:171803556	G/A	cg20598894	chr1:171756153	METTL13	-0.68	-4.57	-0.42	1.45e-5	Mean platelet volume;
THYM	cis	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg09307838	chr4:120376055	NA	0.66	4.77	0.44	6.56e-6	Corneal astigmatism;
THYM	cis	rs9486719	1.000	rs2472884	chr6:96863965	C/T	cg18709589	chr6:96969512	KIAA0776	0.69	4.51	0.42	1.83e-5	Migraine;Coronary artery disease;
THYM	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.62	-4.82	-0.44	5.43e-6	Blood metabolite levels;
THYM	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.52e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.72	-4.53	-0.42	1.72e-5	Huntington's disease progression;
THYM	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg10047753	chr17:41438598	NA	-0.92	-7.87	-0.63	5.74e-12	Menopause (age at onset);
THYM	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06634786	chr22:41940651	POLR3H	-0.64	-4.92	-0.45	3.59e-6	Vitiligo;
THYM	cis	rs61931739	0.635	rs7138254	chr12:33914422	G/T	cg06521331	chr12:34319734	NA	-0.57	-4.76	-0.44	7e-6	Morning vs. evening chronotype;
THYM	cis	rs9660180	0.935	rs9786942	chr1:1759213	A/G	cg16926213	chr1:1841314	NA	0.55	5.8	0.51	8.83e-8	Body mass index;
THYM	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.24	-4.92	-0.45	3.64e-6	Obesity-related traits;
THYM	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	4.98	0.45	2.86e-6	Height;
THYM	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg17173187	chr15:85201210	NMB	-0.42	-4.55	-0.42	1.56e-5	P wave terminal force;
THYM	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg26769984	chr7:1090371	C7orf50	0.8	5.44	0.49	4.17e-7	Bronchopulmonary dysplasia;
THYM	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg04876069	chr12:132293656	NA	-0.65	-6.75	-0.57	1.17e-9	Migraine;
THYM	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg05660106	chr1:15850417	CASP9	0.76	6.27	0.54	1.06e-8	Systolic blood pressure;
THYM	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg11494091	chr17:61959527	GH2	0.67	6.22	0.54	1.32e-8	Height;
THYM	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg06873352	chr17:61820015	STRADA	0.52	4.99	0.46	2.71e-6	Height;
THYM	cis	rs236907	0.859	rs2181216	chr1:171744655	A/G	cg20598894	chr1:171756153	METTL13	-0.68	-5.0	-0.46	2.61e-6	Mean platelet volume;
THYM	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg16342193	chr10:102329863	NA	-0.52	-5.37	-0.48	5.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7084402	0.934	rs1658428	chr10:60330917	T/C	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs35883536	0.647	rs10493929	chr1:101043928	A/C	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	5.72	0.51	1.23e-7	Platelet count;
THYM	cis	rs4824093	0.610	rs56810176	chr22:50303149	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-1.07	-5.18	-0.47	1.22e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs6089829	0.888	rs6011559	chr20:61675620	C/T	cg03213289	chr20:61660250	NA	-1.02	-10.85	-0.74	2.54e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg02187348	chr16:89574699	SPG7	0.79	6.49	0.55	3.83e-9	Multiple myeloma (IgH translocation);
THYM	cis	rs1799864	1	rs1799864	chr3:46399208	G/A	cg07616471	chr3:46413711	CCR5	0.57	4.48	0.42	2.12e-5	Monocyte count;
THYM	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg07936489	chr17:37558343	FBXL20	-0.83	-5.56	-0.5	2.46e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs3942852	0.868	rs6485808	chr11:48109151	A/G	cg25800328	chr11:47736132	AGBL2	-0.49	-4.61	-0.43	1.24e-5	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs7179456	0.567	rs72745027	chr15:59094329	A/G	cg05156742	chr15:59063176	FAM63B	-0.56	-4.73	-0.44	7.88e-6	Asperger disorder;
THYM	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg04267008	chr7:1944627	MAD1L1	-0.7	-6.53	-0.56	3.25e-9	Bipolar disorder and schizophrenia;
THYM	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg24209194	chr3:40518798	ZNF619	0.66	5.39	0.48	5.19e-7	Renal cell carcinoma;
THYM	trans	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg06636001	chr8:8085503	FLJ10661	-0.73	-7.02	-0.58	3.36e-10	Triglycerides;
THYM	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7224314	1.000	rs62084077	chr17:65386837	G/A	cg01507342	chr17:65387096	PITPNC1	-0.91	-10.03	-0.72	1.41e-16	Diisocyanate-induced asthma;
THYM	cis	rs2046867	0.661	rs7637050	chr3:72910790	A/C	cg25664220	chr3:72788482	NA	-0.74	-6.6	-0.56	2.32e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.75	8.38	0.65	4.74e-13	Eosinophil percentage of white cells;
THYM	cis	rs75920871	0.528	rs682048	chr11:116828320	T/G	cg20608306	chr11:116969690	SIK3	-0.52	-5.51	-0.49	3.02e-7	Subjective well-being;
THYM	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg05896524	chr21:47604654	C21orf56	-0.69	-4.87	-0.45	4.4e-6	Testicular germ cell tumor;
THYM	cis	rs4474465	0.790	rs7481910	chr11:78264202	G/C	cg02023728	chr11:77925099	USP35	-0.54	-4.45	-0.42	2.35e-5	Alzheimer's disease (survival time);
THYM	cis	rs3924048	0.559	rs4580	chr1:12628188	T/C	cg00291366	chr1:12616550	NA	0.37	5.5	0.49	3.17e-7	Optic cup area;
THYM	cis	rs6665290	0.582	rs72764213	chr1:227207391	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.13	-15.51	-0.85	8.94e-28	Myeloid white cell count;
THYM	cis	rs1371867	0.846	rs2439458	chr8:101297984	T/C	cg06636551	chr8:101224915	SPAG1	-0.63	-6.29	-0.54	9.77e-9	Atrioventricular conduction;
THYM	cis	rs9787249	0.957	rs12239844	chr1:40217258	T/C	cg24920358	chr1:40204285	PPIE	0.6	5.52	0.49	2.96e-7	Blood protein levels;
THYM	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg22535103	chr8:58192502	C8orf71	-0.86	-4.82	-0.44	5.4e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg21138405	chr5:131827807	IRF1	-0.82	-8.6	-0.66	1.59e-13	Asthma (sex interaction);
THYM	cis	rs11085466	1.000	rs2292986	chr19:21776332	A/C	cg23004160	chr19:21646329	NA	0.62	4.53	0.42	1.74e-5	Colorectal or endometrial cancer;
THYM	cis	rs17102423	0.788	rs35176994	chr14:65596004	T/C	cg11161011	chr14:65562177	MAX	-0.85	-7.27	-0.6	1e-10	Obesity-related traits;
THYM	cis	rs10504073	0.647	rs62507246	chr8:50013449	G/A	cg00325661	chr8:49890786	NA	0.92	8.49	0.66	2.72e-13	Blood metabolite ratios;
THYM	cis	rs2456568	0.775	rs1607404	chr11:93660449	C/G	cg26875233	chr11:93583750	C11orf90	-0.52	-5.13	-0.47	1.53e-6	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg24692254	chr21:30365293	RNF160	1.06	9.92	0.71	2.4e-16	Dental caries;
THYM	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.46	0.49	3.85e-7	Platelet count;
THYM	cis	rs885814	1.000	rs12143671	chr1:21875097	C/T	cg14781605	chr1:21864896	ALPL	-0.68	-5.11	-0.46	1.65e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg14416269	chr4:6271139	WFS1	0.53	5.53	0.49	2.84e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs524023	0.958	rs12802649	chr11:64359627	C/T	cg19131476	chr11:64387923	NRXN2	-0.35	-4.84	-0.44	4.98e-6	Urate levels in obese individuals;
THYM	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg12564285	chr5:131593104	PDLIM4	0.44	4.78	0.44	6.47e-6	Breast cancer;
THYM	cis	rs28595532	0.920	rs55985953	chr4:119764971	T/A	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs2440129	0.611	rs10852889	chr17:6900845	C/T	cg05215272	chr17:6899095	ALOX12	0.63	8.72	0.67	8.83e-14	Tonsillectomy;
THYM	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg10360139	chr7:1886902	MAD1L1	-0.6	-5.11	-0.46	1.63e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg18806716	chr10:30721971	MAP3K8	-0.49	-4.63	-0.43	1.16e-5	Inflammatory bowel disease;
THYM	cis	rs1904096	0.506	rs8336	chr4:95211610	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.56	-4.86	-0.45	4.56e-6	Type 2 diabetes;
THYM	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg04362960	chr10:104952993	NT5C2	0.6	5.11	0.46	1.63e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4930103	0.782	rs10840167	chr11:2022023	G/T	cg06197492	chr11:2016605	H19	0.63	5.48	0.49	3.56e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg13395646	chr4:1353034	KIAA1530	-0.53	-4.76	-0.44	7.03e-6	Obesity-related traits;
THYM	cis	rs6956675	0.874	rs10266439	chr7:62647022	G/T	cg08930214	chr7:62859557	LOC100287834	0.6	4.83	0.44	5.33e-6	Obesity-related traits;
THYM	cis	rs992157	1.000	rs3731859	chr2:219124222	G/A	cg04731861	chr2:219085781	ARPC2	-0.5	-4.5	-0.42	1.93e-5	Colorectal cancer;
THYM	cis	rs12142240	0.698	rs17361887	chr1:46834775	A/G	cg14993813	chr1:46806288	NSUN4	-0.7	-4.65	-0.43	1.09e-5	Menopause (age at onset);
THYM	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg13147721	chr7:65941812	NA	-0.76	-4.91	-0.45	3.8e-6	Diabetic kidney disease;
THYM	cis	rs3733631	0.557	rs77018419	chr4:104685785	C/T	cg24090629	chr4:104641072	TACR3	-1.01	-5.6	-0.5	2.05e-7	Menarche (age at onset);
THYM	cis	rs2084637	1.000	rs9633953	chr11:122419642	C/T	cg16865908	chr11:121970496	LOC399959;MIR125B1	0.32	4.45	0.42	2.29e-5	Stroke;
THYM	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg01324343	chr3:183735012	ABCC5	0.85	11.53	0.76	9.24e-20	Anterior chamber depth;
THYM	cis	rs1270639	0.778	rs2906928	chr7:157444976	T/G	cg13357408	chr7:157437802	PTPRN2	0.46	4.92	0.45	3.65e-6	Colorectal cancer;
THYM	cis	rs611744	0.647	rs579162	chr8:109254842	A/G	cg21045802	chr8:109455806	TTC35	0.66	5.99	0.52	3.78e-8	Dupuytren's disease;
THYM	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg16797656	chr11:68205561	LRP5	-0.43	-4.62	-0.43	1.23e-5	Total body bone mineral density;
THYM	cis	rs736801	0.504	rs2070721	chr5:131825842	T/G	cg02551604	chr5:131831745	NA	-0.6	-4.7	-0.43	8.79e-6	Breast cancer;Mosquito bite size;
THYM	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg03351412	chr1:154909251	PMVK	0.67	4.65	0.43	1.07e-5	Prostate cancer;
THYM	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg00631329	chr6:26305371	NA	-0.63	-7.46	-0.61	3.99e-11	Educational attainment;
THYM	cis	rs6531656	0.633	rs337642	chr4:38613090	G/A	cg24279243	chr4:38676559	KLF3	0.81	6.99	0.58	3.82e-10	Lymphocyte counts;
THYM	cis	rs6952809	0.532	rs10272548	chr7:2439467	G/A	cg13581527	chr7:1708566	NA	-0.77	-5.3	-0.48	7.55e-7	Multiple sclerosis;
THYM	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg24503407	chr1:205819492	PM20D1	0.72	6.6	0.56	2.33e-9	Menarche (age at onset);
THYM	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg06521331	chr12:34319734	NA	-0.85	-6.33	-0.54	8.11e-9	Morning vs. evening chronotype;
THYM	cis	rs10089	1.000	rs72794396	chr5:127501386	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.94	5.66	0.5	1.6e-7	Ileal carcinoids;
THYM	cis	rs7688540	0.656	rs79657896	chr4:299261	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.78	5.16	0.47	1.33e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs3892630	0.588	rs12610342	chr19:33250690	C/T	cg22980127	chr19:33182716	NUDT19	1.13	10.27	0.73	4.38e-17	Red blood cell traits;
THYM	cis	rs7614311	0.636	rs56165216	chr3:63916620	C/T	cg22134162	chr3:63841271	THOC7	-0.56	-6.45	-0.55	4.61e-9	Lung function (FVC);Lung function (FEV1);
THYM	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs4474465	1.000	rs7927722	chr11:78210893	T/C	cg19901956	chr11:77921274	USP35	0.7	5.16	0.47	1.35e-6	Alzheimer's disease (survival time);
THYM	cis	rs12530845	0.725	rs74873522	chr7:135339632	A/C	cg19897172	chr7:135347071	PL-5283	-0.6	-5.45	-0.49	4.02e-7	Red blood cell traits;
THYM	cis	rs4332037	0.538	rs6951956	chr7:1934131	C/T	cg17551891	chr7:1960795	MAD1L1	-0.57	-4.67	-0.43	9.89e-6	Bipolar disorder;
THYM	cis	rs919433	0.680	rs6710530	chr2:198277551	G/A	cg05783139	chr2:198650985	BOLL	0.63	4.93	0.45	3.48e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs1957429	0.808	rs11628910	chr14:65332392	A/G	cg23373153	chr14:65346875	NA	0.95	5.17	0.47	1.28e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg09359103	chr1:154839909	KCNN3	-0.77	-9.65	-0.7	9.23e-16	Prostate cancer;
THYM	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs2882877	0.648	rs11677494	chr2:190401729	C/G	cg10752008	chr2:190445175	SLC40A1	0.72	6.14	0.53	1.9e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs665401	1.000	rs2750418	chr6:117259175	A/G	cg20376953	chr6:117187980	NA	-0.55	-4.49	-0.42	1.99e-5	Neutrophil percentage of granulocytes;
THYM	cis	rs2562456	0.516	rs56072098	chr19:21651960	G/T	cg21751540	chr19:21541537	ZNF738	0.73	5.2	0.47	1.16e-6	Pain;
THYM	cis	rs892961	0.932	rs7224116	chr17:75413177	A/G	cg05865280	chr17:75406074	SEPT9	0.48	8.14	0.64	1.51e-12	Airflow obstruction;
THYM	cis	rs7107174	0.901	rs7110387	chr11:78117875	A/G	cg02023728	chr11:77925099	USP35	0.6	5.47	0.49	3.63e-7	Testicular germ cell tumor;
THYM	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg26384229	chr12:38710491	ALG10B	0.99	7.94	0.63	3.99e-12	Drug-induced liver injury (flucloxacillin);
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg10233744	chr13:74557243	KLF12	-0.97	-7.32	-0.6	7.76e-11	Depressive symptoms;
THYM	cis	rs55665837	1.000	rs12276938	chr11:14463488	C/G	cg19336497	chr11:14380999	RRAS2	-0.64	-7.04	-0.59	3e-10	Vitamin D levels;
THYM	cis	rs7772486	0.790	rs9376970	chr6:146241472	A/C	cg23711669	chr6:146136114	FBXO30	-0.97	-10.08	-0.72	1.09e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1967309	0.625	rs730242	chr16:4070433	C/T	cg05465032	chr16:4658987	FAM100A	-0.47	-4.46	-0.42	2.22e-5	Response to Dalcetrapib treatment in acute coronary syndrome;
THYM	cis	rs7119	0.623	rs11637932	chr15:77847353	T/G	cg10437265	chr15:77819839	NA	0.68	6.14	0.53	1.94e-8	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2281845	0.791	rs1325313	chr1:201076167	C/T	cg22815214	chr1:201083145	CACNA1S	0.65	6.06	0.53	2.71e-8	Permanent tooth development;
THYM	cis	rs448720	0.840	rs405390	chr15:68169242	A/G	cg24579218	chr15:68104479	NA	0.66	5.85	0.51	6.99e-8	Cognitive performance;
THYM	cis	rs2933343	0.700	rs789239	chr3:128633808	T/C	cg11901034	chr3:128598214	ACAD9	-0.68	-5.57	-0.5	2.4e-7	IgG glycosylation;
THYM	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg03433033	chr1:76189801	ACADM	0.79	11.21	0.75	4.52e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg03060546	chr3:49711283	APEH	-0.77	-6.11	-0.53	2.21e-8	Resting heart rate;
THYM	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg19901468	chr14:105411992	AHNAK2	0.82	6.75	0.57	1.18e-9	Rheumatoid arthritis;
THYM	cis	rs4595586	0.525	rs2892450	chr12:39363678	G/A	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg14829155	chr15:31115871	NA	0.52	4.88	0.45	4.27e-6	Huntington's disease progression;
THYM	cis	rs6032067	0.929	rs62205504	chr20:43867894	C/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.71	-7.45	-0.61	4.33e-11	Blood protein levels;
THYM	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg13010199	chr12:38710504	ALG10B	0.73	5.82	0.51	7.99e-8	Heart rate;
THYM	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg16049864	chr8:95962084	TP53INP1	0.7	5.53	0.49	2.81e-7	Type 2 diabetes;
THYM	cis	rs4953076	0.573	rs67537903	chr2:44422111	G/A	cg04920474	chr2:44395004	PPM1B	0.66	5.49	0.49	3.38e-7	Height;
THYM	cis	rs2806561	0.704	rs6680974	chr1:23376233	A/G	cg12483005	chr1:23474871	LUZP1	0.54	5.49	0.49	3.4e-7	Height;
THYM	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg25072359	chr17:41440525	NA	-0.66	-4.63	-0.43	1.17e-5	Menopause (age at onset);
THYM	trans	rs58106596	0.800	rs11675826	chr2:232565507	T/C	cg01370599	chr3:116745421	NA	0.94	7.06	0.59	2.75e-10	White blood cell count;Lymphocyte counts;
THYM	cis	rs1113500	0.933	rs10881498	chr1:108634984	C/A	cg06207961	chr1:108661230	NA	0.64	5.09	0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.64	-0.5	1.73e-7	Menopause (age at onset);
THYM	cis	rs12478296	0.892	rs11893879	chr2:243010411	G/A	cg18898632	chr2:242989856	NA	-0.66	-4.45	-0.42	2.35e-5	Obesity-related traits;
THYM	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg11812906	chr14:75593930	NEK9	-0.87	-8.2	-0.64	1.16e-12	Height;
THYM	cis	rs17127169	1.000	rs61786114	chr1:65422990	T/C	cg12075498	chr1:65428216	JAK1	-0.42	-5.17	-0.47	1.32e-6	Sitting height ratio;
THYM	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg14675211	chr2:100938903	LONRF2	0.77	8.5	0.66	2.68e-13	Intelligence (multi-trait analysis);
THYM	cis	rs17030434	0.911	rs115948674	chr4:154742052	G/T	cg14289246	chr4:154710475	SFRP2	-0.81	-5.51	-0.49	3.08e-7	Electrocardiographic conduction measures;
THYM	cis	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg27168131	chr21:44088823	PDE9A	0.48	4.58	0.43	1.43e-5	Mean corpuscular volume;
THYM	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg03476357	chr21:30257390	N6AMT1	0.59	4.6	0.43	1.31e-5	Dental caries;
THYM	cis	rs36093924	0.646	rs5996094	chr22:42347060	A/G	cg10296410	chr22:42095368	MEI1	0.44	4.49	0.42	1.99e-5	Intelligence;
THYM	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs988913	0.706	rs7453866	chr6:54753626	A/C	cg18532076	chr6:54711417	FAM83B	0.46	4.69	0.43	8.99e-6	Menarche (age at onset);
THYM	cis	rs372883	0.597	rs2018956	chr21:30736622	C/A	cg08807101	chr21:30365312	RNF160	0.6	4.45	0.42	2.32e-5	Pancreatic cancer;
THYM	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg02869364	chr7:1081709	C7orf50	-0.61	-4.91	-0.45	3.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2075230	0.705	rs2955612	chr17:7549356	G/A	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.28	-4.62	-0.43	1.21e-5	Hormone measurements;
THYM	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg04455712	chr21:45112962	RRP1B	0.54	5.04	0.46	2.22e-6	Mean corpuscular volume;
THYM	trans	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.8	-8.98	-0.68	2.45e-14	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs2811415	0.597	rs998392	chr3:127768329	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs740474	0.831	rs2302103	chr5:140955777	C/T	cg24137543	chr5:140893634	NA	0.52	6.27	0.54	1.05e-8	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs28795989	0.896	rs28370977	chr4:7894414	T/G	cg12728606	chr4:7903970	AFAP1	0.43	4.52	0.42	1.76e-5	Intraocular pressure;
THYM	cis	rs6665290	0.935	rs1929862	chr1:227199718	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.13	-15.82	-0.85	2.26e-28	Myeloid white cell count;
THYM	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg06558623	chr16:89946397	TCF25	1.15	6.38	0.55	6.37e-9	Skin colour saturation;
THYM	cis	rs2898681	0.874	rs4864691	chr4:53755972	C/T	cg03786743	chr4:53727781	RASL11B	0.41	4.56	0.42	1.51e-5	Optic nerve measurement (cup area);
THYM	cis	rs758324	0.732	rs154729	chr5:131449049	C/T	cg16205897	chr5:131564050	P4HA2	0.59	4.86	0.45	4.64e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2487048	0.761	rs1800976	chr9:107690709	C/G	cg14019050	chr9:107690770	ABCA1	-0.71	-10.79	-0.74	3.4e-18	Intraocular pressure;
THYM	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg07570687	chr10:102243282	WNT8B	0.84	8.04	0.64	2.45e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs611744	0.967	rs637626	chr8:109235785	G/T	cg21045802	chr8:109455806	TTC35	0.59	5.25	0.47	9.08e-7	Dupuytren's disease;
THYM	cis	rs6542838	0.588	rs4851174	chr2:99530113	A/C	cg08885076	chr2:99613938	TSGA10	-0.53	-5.23	-0.47	9.93e-7	Fear of minor pain;
THYM	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg12179176	chr11:130786555	SNX19	0.78	6.73	0.57	1.27e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7582180	0.790	rs4851288	chr2:100920451	T/C	cg08017756	chr2:100939284	LONRF2	-0.76	-7.81	-0.63	7.52e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg03676636	chr4:99064102	C4orf37	0.39	5.7	0.5	1.37e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg02175503	chr12:58329896	NA	-0.74	-6.33	-0.54	7.98e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7631605	0.935	rs6786857	chr3:37205015	C/T	cg21328643	chr3:37258149	NA	-0.49	-4.69	-0.43	9.05e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs4430311	0.723	rs10157763	chr1:243995041	T/C	cg25706552	chr1:244017396	NA	-0.6	-5.09	-0.46	1.84e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs669446	0.533	rs7543520	chr1:44243866	T/C	cg12599982	chr1:44399894	ARTN	0.52	4.76	0.44	6.93e-6	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3087591	0.960	rs2953009	chr17:29498387	A/C	cg24425628	chr17:29625626	OMG;NF1	0.65	5.69	0.5	1.38e-7	Hip circumference;
THYM	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg03676636	chr4:99064102	C4orf37	0.45	6.98	0.58	4.06e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs80319144	0.521	rs77502408	chr2:159316964	A/G	cg24986868	chr2:159312599	PKP4;CCDC148	0.52	4.96	0.45	3.1e-6	Restless legs syndrome;
THYM	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs977102	0.556	rs67857762	chr3:67355810	C/T	cg06096184	chr3:66549732	LRIG1	0.66	4.6	0.43	1.32e-5	Response to amphetamines;
THYM	cis	rs3733631	1.000	rs7667662	chr4:104590704	A/G	cg24090629	chr4:104641072	TACR3	-0.87	-5.51	-0.49	3.08e-7	Menarche (age at onset);
THYM	cis	rs950394	0.767	rs17029770	chr2:104987030	G/A	cg20302975	chr2:105468274	NA	-0.6	-4.47	-0.42	2.19e-5	Schizophrenia;
THYM	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg14895029	chr7:2775587	GNA12	-0.67	-4.87	-0.45	4.38e-6	Height;
THYM	cis	rs995000	0.899	rs7518497	chr1:63177696	G/T	cg06896770	chr1:63153194	DOCK7	-0.84	-5.58	-0.5	2.31e-7	Triglyceride levels;
THYM	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs9563576	0.778	rs9563569	chr13:58571207	G/A	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs7757969	1.000	rs7757969	chr6:112132032	T/C	cg08601457	chr6:112115117	FYN	0.42	4.79	0.44	6.23e-6	Schizophrenia;
THYM	cis	rs11252926	0.527	rs11252754	chr10:538637	G/A	cg03684893	chr10:554711	DIP2C	-0.61	-4.87	-0.45	4.37e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs9583531	0.689	rs6492308	chr13:111377829	T/C	cg24331049	chr13:111365604	ING1	0.63	5.29	0.48	7.68e-7	Coronary artery disease;
THYM	cis	rs2073300	0.609	rs6132609	chr20:23400412	A/C	cg12062639	chr20:23401060	NAPB	1.1	5.73	0.51	1.16e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	trans	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs4731207	0.596	rs6466990	chr7:124691512	C/T	cg05285228	chr7:124571219	POT1	-0.65	-5.0	-0.46	2.64e-6	Cutaneous malignant melanoma;
THYM	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg00277334	chr10:82204260	NA	-0.53	-5.41	-0.49	4.75e-7	Post bronchodilator FEV1;
THYM	cis	rs595982	0.559	rs73061643	chr19:49368151	A/G	cg19746536	chr19:49375674	PPP1R15A	0.81	4.47	0.42	2.12e-5	Red cell distribution width;
THYM	cis	rs9560113	0.922	rs4773377	chr13:112174152	G/C	cg14154082	chr13:112174009	NA	0.86	8.0	0.63	2.95e-12	Menarche (age at onset);
THYM	cis	rs17598306	0.873	rs73402679	chr7:96591973	A/G	cg13449377	chr7:96631089	DLX6AS	0.76	4.78	0.44	6.38e-6	Radiation response;
THYM	cis	rs7246657	0.524	rs28542490	chr19:37456584	C/A	cg22634378	chr19:37742834	NA	0.66	4.82	0.44	5.33e-6	Coronary artery calcification;
THYM	cis	rs2235573	0.625	rs139905	chr22:38409596	C/T	cg19171272	chr22:38449367	NA	0.52	5.33	0.48	6.61e-7	Glioblastoma;Glioma;
THYM	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg06092702	chr1:163392909	NA	-0.62	-5.68	-0.5	1.48e-7	Motion sickness;
THYM	cis	rs901683	1.000	rs17157887	chr10:46020348	G/C	cg18240400	chr10:46168597	ANUBL1	0.8	5.19	0.47	1.19e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg17063962	chr7:91808500	NA	-1.12	-12.18	-0.78	4.12e-21	Breast cancer;
THYM	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg06728252	chr6:26598149	ABT1	-0.44	-5.24	-0.47	9.47e-7	Intelligence (multi-trait analysis);
THYM	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.71	5.41	0.49	4.78e-7	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg07511668	chr11:68622177	NA	-0.44	-4.63	-0.43	1.16e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs10501293	0.746	rs10768908	chr11:43020214	C/T	cg03447554	chr11:43094025	NA	0.61	4.51	0.42	1.83e-5	Cognitive performance;
THYM	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg16797656	chr11:68205561	LRP5	0.47	5.18	0.47	1.22e-6	Total body bone mineral density;
THYM	cis	rs13424612	0.839	rs4854063	chr2:240914090	T/C	cg01812947	chr2:240904978	NDUFA10	0.55	4.52	0.42	1.77e-5	Odorant perception (isobutyraldehyde);
THYM	cis	rs9611519	0.857	rs4820434	chr22:41637119	G/T	cg13695892	chr22:41940480	POLR3H	-0.62	-4.67	-0.43	9.89e-6	Neuroticism;
THYM	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg01579765	chr21:45077557	HSF2BP	-0.53	-8.68	-0.67	1.07e-13	Mean corpuscular volume;
THYM	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg15556689	chr8:8085844	FLJ10661	0.74	6.01	0.53	3.37e-8	Red cell distribution width;
THYM	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg03806693	chr22:41940476	POLR3H	-0.99	-7.63	-0.62	1.82e-11	Vitiligo;
THYM	cis	rs2290159	0.800	rs28462331	chr3:12660466	G/C	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs11690935	0.843	rs9784123	chr2:172785005	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.7	-4.89	-0.45	4.1e-6	Schizophrenia;
THYM	cis	rs7119	0.635	rs59745219	chr15:77884130	A/G	cg27398640	chr15:77910606	LINGO1	0.73	9.15	0.68	1.1e-14	Type 2 diabetes;
THYM	cis	rs9926296	0.681	rs12923946	chr16:89821080	C/T	cg26513180	chr16:89883248	FANCA	0.53	4.82	0.44	5.49e-6	Vitiligo;
THYM	cis	rs1018836	0.851	rs7014073	chr8:91618548	T/C	cg16814680	chr8:91681699	NA	-0.99	-9.24	-0.69	7.07e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg13695892	chr22:41940480	POLR3H	0.94	7.71	0.62	1.24e-11	Vitiligo;
THYM	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11644478	chr21:40555479	PSMG1	1.09	9.31	0.69	5.05e-15	Cognitive function;
THYM	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06634786	chr22:41940651	POLR3H	0.84	6.24	0.54	1.21e-8	Vitiligo;
THYM	cis	rs11605275	1.000	rs78249104	chr11:20027680	G/T	cg14835545	chr11:20032148	NAV2	-1.38	-6.49	-0.55	3.79e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6547741	0.844	rs7382	chr2:27873415	G/A	cg27432699	chr2:27873401	GPN1	-0.87	-7.73	-0.62	1.14e-11	Oral cavity cancer;
THYM	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg12963246	chr6:28129442	ZNF389	0.51	4.56	0.42	1.52e-5	Parkinson's disease;
THYM	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg11941060	chr3:133502564	NA	-0.73	-6.42	-0.55	5.36e-9	Iron status biomarkers;
THYM	cis	rs7082209	0.587	rs2505738	chr10:44817210	A/C	cg08683644	chr10:44853092	NA	0.62	4.77	0.44	6.65e-6	Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous);
THYM	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg17366294	chr4:99064904	C4orf37	0.53	5.81	0.51	8.43e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.72	5.55	0.49	2.56e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg04267008	chr7:1944627	MAD1L1	-0.66	-5.51	-0.49	3.06e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs6840360	0.571	rs12647566	chr4:152482525	C/T	cg22705602	chr4:152727874	NA	-0.77	-8.64	-0.66	1.36e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg18512352	chr11:47633146	NA	0.5	5.89	0.52	5.85e-8	Subjective well-being;
THYM	cis	rs9467160	0.511	rs796984	chr6:24440600	T/A	cg20631270	chr6:24437470	GPLD1	0.57	4.84	0.45	4.94e-6	Liver enzyme levels;
THYM	cis	rs55692411	0.537	rs35375092	chr3:50065274	G/A	cg14019146	chr3:50243930	SLC38A3	-0.6	-4.62	-0.43	1.23e-5	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg11764359	chr7:65958608	NA	0.85	7.06	0.59	2.77e-10	Aortic root size;
THYM	cis	rs1448094	0.511	rs10863083	chr12:86226739	C/A	cg02569458	chr12:86230093	RASSF9	0.57	4.83	0.44	5.31e-6	Major depressive disorder;
THYM	cis	rs1129187	0.748	rs6458312	chr6:42904274	G/T	cg19747945	chr6:42946146	PEX6	-0.32	-4.62	-0.43	1.19e-5	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs6435161	0.919	rs2162495	chr2:203578008	A/G	cg18429434	chr2:203499731	FAM117B	-0.79	-5.3	-0.48	7.37e-7	Total cholesterol levels;
THYM	cis	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg07460842	chr6:66804631	NA	-0.84	-5.65	-0.5	1.68e-7	Exhaled nitric oxide output;
THYM	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg12386194	chr3:101231763	SENP7	0.75	5.4	0.48	4.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg05340658	chr4:99064831	C4orf37	0.54	4.52	0.42	1.77e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9790314	0.586	rs34727114	chr3:161138929	A/C	cg03342759	chr3:160939853	NMD3	-0.87	-7.46	-0.61	4.13e-11	Morning vs. evening chronotype;
THYM	cis	rs4974559	0.790	rs10012582	chr4:1324481	G/A	cg02980000	chr4:1222292	CTBP1	0.82	5.04	0.46	2.24e-6	Systolic blood pressure;
THYM	cis	rs757110	0.770	rs1557765	chr11:17403639	T/C	cg15432903	chr11:17409602	KCNJ11	0.58	6.59	0.56	2.41e-9	Type 2 diabetes;
THYM	cis	rs12643440	0.538	rs981886	chr4:17136883	T/C	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg02734326	chr4:10020555	SLC2A9	0.78	6.67	0.56	1.68e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg09263875	chr16:632152	PIGQ	0.67	5.33	0.48	6.59e-7	Height;
THYM	cis	rs617791	0.678	rs551659	chr11:65749645	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.79	5.77	0.51	9.88e-8	Breast cancer;
THYM	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg04025307	chr7:1156635	C7orf50	0.87	8.91	0.67	3.5e-14	Longevity;Endometriosis;
THYM	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg17105886	chr17:28927953	LRRC37B2	1.26	7.32	0.6	8.11e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-4.57	-0.42	1.49e-5	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11148252	0.711	rs61957304	chr13:52798423	G/A	cg00495681	chr13:53174319	NA	0.73	7.36	0.6	6.45e-11	Lewy body disease;
THYM	cis	rs728616	0.558	rs55803802	chr10:81752664	A/G	cg27452691	chr10:81370291	SFTPA1	0.64	4.47	0.42	2.12e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.8	-5.86	-0.52	6.69e-8	Blood metabolite levels;
THYM	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg13695892	chr22:41940480	POLR3H	-0.67	-5.5	-0.49	3.22e-7	Vitiligo;
THYM	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg23730037	chr7:158596552	ESYT2	-0.49	-5.0	-0.46	2.66e-6	Height;
THYM	trans	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg10856724	chr12:34555212	NA	-0.99	-8.42	-0.65	3.84e-13	Bladder cancer;
THYM	cis	rs17001868	0.568	rs9607702	chr22:40739177	A/G	cg07138101	chr22:40742427	ADSL	0.94	5.71	0.51	1.3e-7	Mammographic density (dense area);
THYM	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.19	9.39	0.69	3.28e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg13010199	chr12:38710504	ALG10B	0.76	6.19	0.54	1.52e-8	Heart rate;
THYM	cis	rs2073300	0.609	rs6132617	chr20:23420151	G/C	cg12062639	chr20:23401060	NAPB	1.03	5.59	0.5	2.2e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs6722750	0.905	rs10170666	chr2:64379672	G/A	cg22352474	chr2:64371530	PELI1	0.8	6.7	0.57	1.49e-9	Neuroticism;
THYM	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg05313129	chr8:58192883	C8orf71	-0.83	-4.74	-0.44	7.5e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7267979	1.000	rs2259926	chr20:25281733	T/C	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs11605275	1.000	rs78687006	chr11:20032176	G/A	cg14835545	chr11:20032148	NAV2	-1.38	-7.35	-0.6	7e-11	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs919433	0.679	rs6737060	chr2:198524885	G/C	cg00792783	chr2:198669748	PLCL1	0.82	5.44	0.49	4.16e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs960902	0.738	rs7561053	chr2:37743181	G/A	cg25341268	chr2:37734390	NA	-0.68	-5.62	-0.5	1.87e-7	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg02734326	chr4:10020555	SLC2A9	0.78	6.67	0.56	1.68e-9	Bone mineral density;
THYM	cis	rs9527	0.590	rs12775302	chr10:104911356	A/G	cg04362960	chr10:104952993	NT5C2	0.65	5.06	0.46	2e-6	Arsenic metabolism;
THYM	cis	rs6546324	0.625	rs2861700	chr2:67855441	A/G	cg18237512	chr2:67827392	NA	0.79	4.75	0.44	7.23e-6	Endometriosis;
THYM	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg03929089	chr4:120376271	NA	0.99	10.92	0.75	1.81e-18	Height;
THYM	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg18252515	chr7:66147081	NA	0.66	4.87	0.45	4.38e-6	Aortic root size;
THYM	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg06582575	chr6:163149167	PACRG;PARK2	1.11	7.46	0.61	3.98e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2797160	0.875	rs12527010	chr6:125991507	A/G	cg16306078	chr6:126000798	NA	0.5	5.07	0.46	1.95e-6	Endometrial cancer;
THYM	cis	rs8106542	0.906	rs4548995	chr19:10740871	G/C	cg17848348	chr19:10766748	ILF3	-0.8	-6.62	-0.56	2.13e-9	Platelet distribution width;
THYM	cis	rs1003719	0.788	rs2835578	chr21:38457671	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.71	5.03	0.46	2.32e-6	Eye color traits;
THYM	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg17178900	chr1:205818956	PM20D1	-0.67	-5.2	-0.47	1.14e-6	Menarche (age at onset);
THYM	cis	rs1007190	0.881	rs12941574	chr17:43030679	C/T	cg15406952	chr17:42872593	NA	-0.78	-4.57	-0.42	1.49e-5	DNA methylation (variation);
THYM	cis	rs172166	0.610	rs276369	chr6:27919243	A/T	cg13525197	chr6:28411240	ZSCAN23	-0.64	-5.05	-0.46	2.13e-6	Cardiac Troponin-T levels;
THYM	cis	rs72949976	0.584	rs12471471	chr2:214023052	C/T	cg08319019	chr2:214017104	IKZF2	-0.82	-7.3	-0.6	8.83e-11	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs2290159	0.752	rs73130368	chr3:12667374	C/T	cg23032965	chr3:12705835	RAF1	0.87	5.63	0.5	1.85e-7	Cholesterol, total;
THYM	cis	rs854765	0.856	rs2955382	chr17:17947710	C/T	cg16928487	chr17:17741425	SREBF1	0.51	4.76	0.44	7.04e-6	Total body bone mineral density;
THYM	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4758317	1.000	rs4758317	chr11:8250811	G/T	cg20775162	chr11:8248503	LMO1	-0.41	-4.76	-0.44	7.03e-6	Alcohol consumption;
THYM	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Body mass index;
THYM	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg02398342	chr17:80708632	TBCD;FN3K	0.73	5.54	0.49	2.73e-7	Glycated hemoglobin levels;
THYM	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg16405210	chr4:1374714	KIAA1530	0.86	7.58	0.61	2.34e-11	Obesity-related traits;
THYM	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg06112835	chr11:68658793	MRPL21	0.43	6.08	0.53	2.48e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7626444	0.625	rs2686593	chr3:196477401	G/A	cg12930392	chr3:196481615	PAK2	0.4	4.92	0.45	3.58e-6	Monocyte count;
THYM	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg26384229	chr12:38710491	ALG10B	0.71	5.52	0.49	2.92e-7	Morning vs. evening chronotype;
THYM	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg24147428	chr11:65409760	SIPA1	-0.74	-5.56	-0.5	2.42e-7	Blood pressure (age interaction);
THYM	cis	rs2797160	1.000	rs1739380	chr6:126012858	T/C	cg16306078	chr6:126000798	NA	0.55	5.64	0.5	1.72e-7	Endometrial cancer;
THYM	cis	rs3126085	0.867	rs12027899	chr1:152253954	C/A	cg10321714	chr1:152280068	FLG	0.64	4.81	0.44	5.57e-6	Atopic dermatitis;
THYM	cis	rs921968	0.643	rs4674320	chr2:219510768	A/G	cg01872077	chr2:219646372	CYP27A1	0.58	4.49	0.42	2e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs885814	1.000	rs6658127	chr1:21875390	C/T	cg14781605	chr1:21864896	ALPL	-0.68	-5.19	-0.47	1.17e-6	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg15557168	chr22:42548783	NA	0.59	4.61	0.43	1.25e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs6570726	0.599	rs426371	chr6:145886469	A/G	cg13319975	chr6:146136371	FBXO30	0.66	5.33	0.48	6.53e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2039659	0.719	rs1753795	chr13:86253500	G/C	cg25308322	chr13:86268291	NA	0.66	5.5	0.49	3.13e-7	Blood osmolality (transformed sodium);
THYM	cis	rs790123	1.000	rs790115	chr3:122381117	C/T	cg15604389	chr3:122379662	NA	0.63	5.85	0.51	6.88e-8	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg27129171	chr3:47204927	SETD2	-0.72	-5.96	-0.52	4.3e-8	Birth weight;
THYM	cis	rs11771526	0.792	rs17161104	chr7:32298582	C/T	cg13207630	chr7:32358064	NA	0.72	4.69	0.43	9.2e-6	Body mass index;
THYM	cis	rs3793683	0.858	rs1571145	chr10:134583672	C/G	cg27286337	chr10:134555280	INPP5A	-0.98	-9.23	-0.69	7.29e-15	Migraine;
THYM	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg13319975	chr6:146136371	FBXO30	-0.68	-5.58	-0.5	2.24e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs763014	0.833	rs3743904	chr16:632767	A/G	cg07343612	chr16:622815	PIGQ	-1.1	-11.68	-0.77	4.59e-20	Height;
THYM	cis	rs7851660	0.809	rs3824495	chr9:100663700	A/C	cg13688889	chr9:100608707	NA	0.83	5.87	0.52	6.45e-8	Strep throat;
THYM	cis	rs800586	0.956	rs2736202	chr8:116792426	C/T	cg04656070	chr8:116661063	TRPS1	0.49	4.7	0.43	8.9e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs4731207	0.596	rs7799771	chr7:124649937	C/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs10929159	0.928	rs7596780	chr2:236924303	C/T	cg14895183	chr2:236924282	AGAP1	0.52	4.49	0.42	2.03e-5	Parkinson's disease;
THYM	cis	rs1797081	0.934	rs1797077	chr10:16853252	C/T	cg23933602	chr10:16859644	RSU1	0.93	10.67	0.74	6.12e-18	Platelet distribution width;
THYM	cis	rs7769051	0.522	rs6911773	chr6:133128848	T/C	cg22852734	chr6:133119734	C6orf192	1.5	6.21	0.54	1.4e-8	Type 2 diabetes nephropathy;
THYM	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs17604090	0.877	rs68169519	chr7:29685158	A/G	cg19413766	chr7:29689036	LOC646762	-0.93	-5.09	-0.46	1.77e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs868036	0.522	rs3784711	chr15:68072527	C/T	cg24579218	chr15:68104479	NA	0.64	6.53	0.56	3.18e-9	Restless legs syndrome;
THYM	cis	rs12368653	0.616	rs1027315	chr12:58034192	T/C	cg12615879	chr12:58013172	SLC26A10	0.57	5.82	0.51	8.03e-8	Multiple sclerosis;
THYM	cis	rs1129187	0.782	rs9462860	chr6:42947013	G/C	cg21280719	chr6:42927975	GNMT	-0.52	-6.89	-0.58	5.95e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg03609598	chr5:56110824	MAP3K1	-0.76	-4.63	-0.43	1.17e-5	Initial pursuit acceleration;
THYM	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs35825582	0.544	rs7574623	chr2:144187417	A/G	cg17056048	chr2:144271431	ARHGAP15	0.62	6.81	0.57	8.62e-10	Intelligence (multi-trait analysis);
THYM	cis	rs4478037	0.558	rs59139633	chr3:33080190	G/T	cg19404215	chr3:33155277	CRTAP	1.12	6.04	0.53	2.99e-8	Major depressive disorder;
THYM	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg24578937	chr1:2090814	PRKCZ	-0.55	-5.69	-0.5	1.37e-7	Height;
THYM	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg10047753	chr17:41438598	NA	0.98	8.23	0.65	9.67e-13	Menopause (age at onset);
THYM	cis	rs8016982	0.674	rs6574631	chr14:81675772	C/T	cg21807262	chr14:81713016	NA	-0.57	-5.28	-0.48	8.05e-7	Schizophrenia;
THYM	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg25566285	chr7:158114605	PTPRN2	-0.92	-12.6	-0.79	5.58e-22	Calcium levels;
THYM	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg00484396	chr16:3507460	NAT15	0.68	6.6	0.56	2.35e-9	Tuberculosis;
THYM	cis	rs4722166	0.630	rs13311199	chr7:22789793	A/C	cg05472934	chr7:22766657	IL6	0.9	6.98	0.58	3.9e-10	Lung cancer;
THYM	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26314531	chr2:26401878	FAM59B	0.76	4.99	0.46	2.75e-6	Gut microbiome composition (summer);
THYM	cis	rs11645898	0.935	rs8047881	chr16:72193906	A/G	cg03805757	chr16:71968109	PKD1L3	-0.6	-4.48	-0.42	2.06e-5	Blood protein levels;
THYM	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Body mass index;
THYM	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg09537434	chr19:41945824	ATP5SL	-1.15	-11.43	-0.76	1.51e-19	Height;
THYM	cis	rs28595532	0.841	rs114155681	chr4:119736427	A/G	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs12541335	0.615	rs4872464	chr8:22153381	G/A	cg09517075	chr8:22133004	PIWIL2	0.64	5.71	0.51	1.31e-7	Hypertriglyceridemia;
THYM	cis	rs4891159	0.790	rs11872411	chr18:74132051	C/T	cg24786174	chr18:74118243	ZNF516	-0.9	-10.77	-0.74	3.72e-18	Longevity;
THYM	cis	rs17443541	0.507	rs4675708	chr2:200457388	C/A	cg03741458	chr2:200468445	NA	-0.75	-5.77	-0.51	9.74e-8	Intelligence (multi-trait analysis);
THYM	cis	rs887829	0.570	rs13002774	chr2:234593706	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.79	-6.64	-0.56	1.94e-9	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	trans	rs3213961	0.683	rs72785990	chr2:33806405	T/A	cg19997179	chr2:620310	NA	0.56	7.08	0.59	2.47e-10	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
THYM	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11890956	chr21:40555474	PSMG1	-0.63	-5.77	-0.51	9.89e-8	Menarche (age at onset);
THYM	cis	rs7119	0.717	rs12915548	chr15:77818042	A/G	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs907683	0.570	rs2666104	chr2:220281010	C/T	cg15015639	chr2:220282977	DES	-0.4	-5.58	-0.5	2.26e-7	Resting heart rate;
THYM	cis	rs6598955	0.543	rs3795687	chr1:26560745	G/A	cg04990556	chr1:26633338	UBXN11	0.9	5.85	0.51	6.93e-8	Obesity-related traits;
THYM	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg26354017	chr1:205819088	PM20D1	0.54	4.53	0.42	1.74e-5	Parkinson's disease;
THYM	cis	rs9611519	1.000	rs5758264	chr22:41616284	T/G	cg03806693	chr22:41940476	POLR3H	-0.74	-5.66	-0.5	1.58e-7	Neuroticism;
THYM	cis	rs4919687	0.679	rs12762176	chr10:104499232	A/T	cg04362960	chr10:104952993	NT5C2	0.64	5.15	0.47	1.42e-6	Colorectal cancer;
THYM	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg13447684	chr7:1895903	MAD1L1	0.55	4.66	0.43	1.01e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs12973672	0.812	rs10419959	chr19:35764705	G/A	cg17925829	chr19:36399328	TYROBP	0.55	4.56	0.42	1.5e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg00684032	chr4:1343700	KIAA1530	0.58	4.84	0.44	5.11e-6	Obesity-related traits;
THYM	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg10792982	chr14:105748885	BRF1	0.75	7.8	0.62	7.96e-12	Mean platelet volume;Platelet distribution width;
THYM	cis	rs3857067	0.806	rs34396894	chr4:95097600	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.48	-0.42	2.07e-5	QT interval;
THYM	cis	rs36051895	0.695	rs59384377	chr9:5005034	A/T	cg02405213	chr9:5042618	JAK2	-1.03	-10.68	-0.74	5.96e-18	Pediatric autoimmune diseases;
THYM	cis	rs55702914	0.809	rs2914982	chr2:198202793	G/C	cg00792783	chr2:198669748	PLCL1	-0.63	-4.76	-0.44	6.97e-6	Major depression and alcohol dependence;
THYM	cis	rs9790314	0.875	rs459515	chr3:161092351	T/C	cg04691961	chr3:161091175	C3orf57	-0.65	-5.72	-0.51	1.24e-7	Morning vs. evening chronotype;
THYM	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg02038168	chr22:39784481	NA	-0.69	-5.59	-0.5	2.15e-7	Intelligence (multi-trait analysis);
THYM	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg06481639	chr22:41940642	POLR3H	0.84	5.85	0.51	6.94e-8	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg18352616	chr4:3374830	RGS12	0.69	7.51	0.61	3.15e-11	Serum sulfate level;
THYM	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg04944784	chr2:26401820	FAM59B	-0.79	-6.18	-0.54	1.61e-8	Gut microbiome composition (summer);
THYM	cis	rs12983728	0.831	rs34503352	chr19:58651296	G/A	cg07378217	chr19:58662286	ZNF329	-0.91	-5.85	-0.51	6.87e-8	Cholesterol, total;
THYM	cis	rs2455799	0.634	rs1584326	chr3:15903951	G/A	cg16303742	chr3:15540471	COLQ	-0.57	-5.76	-0.51	1.04e-7	Mean platelet volume;
THYM	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg24733560	chr20:60626293	TAF4	0.6	6.44	0.55	4.8e-9	Body mass index;
THYM	cis	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg10856724	chr12:34555212	NA	-0.78	-6.99	-0.58	3.83e-10	Morning vs. evening chronotype;
THYM	cis	rs7843479	0.965	rs11785657	chr8:21859485	G/A	cg17168535	chr8:21777572	XPO7	0.64	4.74	0.44	7.36e-6	Mean corpuscular volume;
THYM	cis	rs600550	0.528	rs7102260	chr11:59846035	A/T	cg02771260	chr11:59836817	MS4A3	-0.75	-5.51	-0.49	3.06e-7	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs2072510	0.750	rs2247570	chr12:96422377	T/C	cg18817487	chr12:96390143	HAL	0.43	5.22	0.47	1.07e-6	Metabolite levels (small molecules and protein measures);
THYM	cis	rs7809950	1.000	rs2712214	chr7:107188031	G/A	cg23024343	chr7:107201750	COG5	-0.94	-8.59	-0.66	1.7e-13	Coronary artery disease;
THYM	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs11252926	0.545	rs11252693	chr10:532139	A/G	cg03684893	chr10:554711	DIP2C	-0.64	-5.36	-0.48	5.89e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg18681998	chr4:17616180	MED28	0.79	6.77	0.57	1.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs6430585	0.528	rs309120	chr2:136708787	G/C	cg04750100	chr2:136595281	LCT	0.54	5.46	0.49	3.78e-7	Corneal structure;
THYM	cis	rs34638657	0.673	rs67661146	chr16:82199669	G/A	cg09439754	chr16:82129088	HSD17B2	-0.52	-5.22	-0.47	1.04e-6	Lung adenocarcinoma;
THYM	cis	rs4866334	1.000	rs80012640	chr5:18455247	C/T	cg04591469	chr5:17810299	NA	-1.12	-4.54	-0.42	1.65e-5	IgG glycosylation;
THYM	cis	rs919433	0.617	rs34632716	chr2:198542619	C/T	cg00792783	chr2:198669748	PLCL1	-0.77	-5.4	-0.48	4.91e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9649213	0.593	rs1468341	chr7:97987696	G/A	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7100689	0.826	rs7098414	chr10:82214586	A/C	cg01528321	chr10:82214614	TSPAN14	1.35	10.41	0.73	2.17e-17	Post bronchodilator FEV1;
THYM	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg09904177	chr6:26538194	HMGN4	0.64	5.41	0.49	4.78e-7	Intelligence (multi-trait analysis);
THYM	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.49	4.56	0.42	1.53e-5	Birth weight;
THYM	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg15693483	chr7:1102177	C7orf50	0.55	6.34	0.55	7.58e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3087591	0.960	rs2952995	chr17:29541061	T/C	cg24425628	chr17:29625626	OMG;NF1	0.65	5.62	0.5	1.92e-7	Hip circumference;
THYM	cis	rs806215	1.000	rs806215	chr7:127237312	T/C	cg08586737	chr7:127225949	GCC1	-0.39	-5.04	-0.46	2.19e-6	Type 2 diabetes;
THYM	cis	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg16489192	chr7:75678113	MDH2;STYXL1	0.59	6.1	0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4285028	0.699	rs7637495	chr3:121573850	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.81	-5.78	-0.51	9.34e-8	Multiple sclerosis;
THYM	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg16031515	chr1:205743344	RAB7L1	0.53	5.16	0.47	1.33e-6	Monocyte percentage of white cells;
THYM	cis	rs714027	1.000	rs5763821	chr22:30549071	A/C	cg11564601	chr22:30592435	NA	-0.27	-4.88	-0.45	4.35e-6	Lymphocyte counts;
THYM	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg19729930	chr2:74357872	NA	1.27	12.95	0.8	1.06e-22	Gestational age at birth (maternal effect);
THYM	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg16558253	chr16:72132732	DHX38	-0.54	-4.56	-0.42	1.54e-5	Fibrinogen levels;
THYM	cis	rs28595532	0.764	rs116788606	chr4:119748849	G/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg07362569	chr17:61921086	SMARCD2	0.7	6.23	0.54	1.25e-8	Prudent dietary pattern;
THYM	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg24846343	chr22:24311635	DDTL	0.44	5.53	0.49	2.77e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs877282	1.000	rs11253370	chr10:773712	G/A	cg10556349	chr10:835070	NA	-0.69	-4.81	-0.44	5.75e-6	Uric acid levels;
THYM	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg12981288	chr8:11183844	MTMR9	0.54	5.51	0.49	3.11e-7	Retinal vascular caliber;
THYM	cis	rs4523957	0.757	rs216199	chr17:2200871	C/T	cg16513277	chr17:2031491	SMG6	0.77	7.14	0.59	1.86e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs740474	0.554	rs251041	chr5:141027888	C/G	cg24137543	chr5:140893634	NA	0.48	5.96	0.52	4.22e-8	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs988913	0.678	rs9370387	chr6:55005362	C/T	cg18532076	chr6:54711417	FAM83B	0.48	4.45	0.42	2.33e-5	Menarche (age at onset);
THYM	cis	rs2692947	0.696	rs1724121	chr2:96808549	T/C	cg23100626	chr2:96804247	ASTL	0.36	4.97	0.45	3.01e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg23583168	chr7:148888333	NA	0.99	13.09	0.8	5.56e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs4242434	0.927	rs746011	chr8:22457804	C/T	cg21658235	chr8:22456391	C8orf58	0.59	5.4	0.48	5e-7	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs728616	0.867	rs61860417	chr10:81734727	C/T	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg26818010	chr10:134567672	INPP5A	-0.93	-7.48	-0.61	3.71e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs9583531	0.657	rs9521915	chr13:111384528	C/T	cg24331049	chr13:111365604	ING1	0.64	4.97	0.45	2.93e-6	Coronary artery disease;
THYM	cis	rs8014204	0.541	rs35591392	chr14:75157713	G/T	cg06637938	chr14:75390232	RPS6KL1	0.57	5.27	0.48	8.61e-7	Caffeine consumption;
THYM	cis	rs9790314	1.000	rs336567	chr3:161073046	A/G	cg04691961	chr3:161091175	C3orf57	-0.6	-5.23	-0.47	1.02e-6	Morning vs. evening chronotype;
THYM	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg11845111	chr2:191398756	TMEM194B	0.96	8.41	0.65	4.19e-13	Pulse pressure;
THYM	cis	rs28374715	0.681	rs28687846	chr15:41599902	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.24	-14.56	-0.83	6.14e-26	Ulcerative colitis;
THYM	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg24874828	chr4:187887005	NA	-0.72	-7.44	-0.61	4.48e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg03983476	chr2:10830698	NOL10	0.6	5.71	0.51	1.28e-7	Prostate cancer;
THYM	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg00814883	chr7:100076585	TSC22D4	-0.98	-6.62	-0.56	2.15e-9	Platelet count;
THYM	cis	rs950880	0.710	rs11681718	chr2:103051144	A/G	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.64	-0.43	1.1e-5	Serum protein levels (sST2);
THYM	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	0.626	rs2269810	chr7:91508837	T/C	cg22709100	chr7:91322751	NA	-0.62	-4.56	-0.42	1.51e-5	Breast cancer;
THYM	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.26	0.47	8.97e-7	Lung cancer in ever smokers;
THYM	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg02725872	chr8:58115012	NA	-0.91	-6.92	-0.58	5.22e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg23161317	chr6:28129485	ZNF389	0.69	5.6	0.5	2.06e-7	Cardiac Troponin-T levels;
THYM	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg02389323	chr16:88786976	FAM38A	0.97	6.21	0.54	1.42e-8	Plateletcrit;
THYM	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.78	5.08	0.46	1.9e-6	Diabetic retinopathy;
THYM	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg27129171	chr3:47204927	SETD2	-0.81	-7.75	-0.62	1.01e-11	Colorectal cancer;
THYM	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg23758822	chr17:41437982	NA	1.16	10.95	0.75	1.58e-18	Menopause (age at onset);
THYM	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg06064525	chr11:970664	AP2A2	-0.35	-6.67	-0.56	1.69e-9	Alzheimer's disease (late onset);
THYM	cis	rs11671005	0.735	rs34873624	chr19:58943402	G/A	cg18639983	chr19:58920768	ZNF584	0.59	4.82	0.44	5.48e-6	Mean platelet volume;
THYM	cis	rs630041	0.847	rs475753	chr1:20402677	G/T	cg15555335	chr1:20208763	OTUD3	0.81	4.58	0.43	1.39e-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
THYM	cis	rs6430585	0.640	rs3816155	chr2:136552526	A/C	cg04750100	chr2:136595281	LCT	-0.51	-4.79	-0.44	6.11e-6	Corneal structure;
THYM	cis	rs2730245	0.527	rs2036582	chr7:158701708	A/T	cg11984989	chr7:158649758	WDR60	0.9	7.48	0.61	3.69e-11	Height;
THYM	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg27572855	chr1:25598939	RHD	0.65	4.93	0.45	3.43e-6	Erythrocyte sedimentation rate;
THYM	cis	rs8064299	0.967	rs878906	chr17:72769334	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.65	5.68	0.5	1.45e-7	Monocyte count;
THYM	cis	rs11605275	0.901	rs11602997	chr11:20022527	C/A	cg14835545	chr11:20032148	NAV2	-1.37	-6.31	-0.54	8.69e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06634786	chr22:41940651	POLR3H	0.73	5.33	0.48	6.69e-7	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg02734326	chr4:10020555	SLC2A9	-0.6	-4.85	-0.45	4.9100000000000004e-06	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs8048589	1.000	rs11642386	chr16:12184064	C/A	cg01990910	chr16:12207648	SNX29	-0.45	-5.09	-0.46	1.78e-6	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.69	5.54	0.49	2.69e-7	Menarche (age at onset);
THYM	cis	rs870825	0.929	rs72689266	chr4:185591053	T/C	cg04058563	chr4:185651563	MLF1IP	0.96	6.73	0.57	1.26e-9	Blood protein levels;
THYM	cis	rs2637266	1.000	rs2894337	chr10:78344871	C/T	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg12408189	chr10:30722286	MAP3K8	-0.54	-4.81	-0.44	5.73e-6	Inflammatory bowel disease;
THYM	cis	rs990171	1.000	rs1807782	chr2:103033147	C/T	cg13897122	chr2:103039542	IL18RAP	-0.39	-4.64	-0.43	1.12e-5	Lymphocyte counts;
THYM	cis	rs1865721	0.728	rs8087297	chr18:73136221	T/A	cg26385618	chr18:73139727	C18orf62	-0.68	-5.0	-0.46	2.63e-6	Intelligence;
THYM	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.33	9.84	0.71	3.56e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4660306	0.961	rs4660871	chr1:45995232	C/A	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.57	-4.47	-0.42	2.12e-5	Homocysteine levels;
THYM	cis	rs273218	1.000	rs156442	chr5:53373029	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.93	8.01	0.63	2.85e-12	Migraine;
THYM	cis	rs6732160	0.934	rs2421390	chr2:73379103	T/C	cg24220031	chr2:73402428	NA	-0.65	-6.38	-0.55	6.44e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9790314	0.875	rs462514	chr3:161092809	C/T	cg04691961	chr3:161091175	C3orf57	-0.65	-5.72	-0.51	1.25e-7	Morning vs. evening chronotype;
THYM	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg22105103	chr4:187893119	NA	0.91	9.9	0.71	2.68e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6918586	0.594	rs198842	chr6:26111448	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.59	-0.61	2.21e-11	Schizophrenia;
THYM	cis	rs7818345	0.967	rs4546679	chr8:19283335	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.41	4.53	0.42	1.73e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.96	9.55	0.7	1.49e-15	Chronic sinus infection;
THYM	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg00376283	chr12:123451042	ABCB9	0.7	4.72	0.44	8.27e-6	Neutrophil percentage of white cells;
THYM	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg00484396	chr16:3507460	NAT15	-0.62	-6.72	-0.57	1.33e-9	Tuberculosis;
THYM	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg09455208	chr3:40491958	NA	0.51	5.24	0.47	9.48e-7	Renal cell carcinoma;
THYM	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg08885076	chr2:99613938	TSGA10	-0.46	-4.62	-0.43	1.18e-5	Fear of minor pain;
THYM	cis	rs300703	0.719	rs423314	chr2:195372	A/G	cg21211680	chr2:198530	NA	1.3	8.23	0.65	9.98e-13	Blood protein levels;
THYM	cis	rs259282	0.524	rs1559180	chr19:33127443	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.72	6.45	0.55	4.73e-9	Schizophrenia;
THYM	trans	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg01121180	chr19:51302454	C19orf48;SNORD88B	0.79	7.03	0.58	3.18e-10	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7781977	1.000	rs7781977	chr7:50346134	C/T	cg01139861	chr7:50343298	IKZF1	0.73	7.18	0.59	1.52e-10	IgG glycosylation;
THYM	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg17372223	chr3:52568218	NT5DC2	0.42	6.85	0.57	7.42e-10	Electroencephalogram traits;
THYM	cis	rs17209837	0.607	rs2888611	chr7:87103670	C/G	cg04996195	chr7:87105398	ABCB4	-0.62	-4.78	-0.44	6.49e-6	Gallbladder cancer;
THYM	cis	rs7772486	0.875	rs2474356	chr6:146296798	G/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.63	-0.5	1.81e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg03388043	chr17:80084554	CCDC57	0.72	6.04	0.53	3.05e-8	Life satisfaction;
THYM	cis	rs1018836	0.608	rs11997663	chr8:91474484	A/C	cg16814680	chr8:91681699	NA	-0.73	-5.88	-0.52	6.19e-8	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs12780046	0.611	rs10883275	chr10:100881693	G/T	cg20566587	chr10:101492029	COX15;CUTC	0.72	4.53	0.42	1.72e-5	Non-glioblastoma glioma;
THYM	cis	rs6876348	0.516	rs258000	chr5:128318616	G/A	cg02841155	chr5:128301328	SLC27A6	-0.5	-4.89	-0.45	4.18e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06873352	chr17:61820015	STRADA	0.57	5.68	0.5	1.46e-7	Height;
THYM	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22455342	chr2:225449267	CUL3	0.97	9.01	0.68	2.12e-14	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs13256369	0.708	rs11249886	chr8:8562021	T/A	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg07424592	chr7:64974309	NA	1.09	5.01	0.46	2.55e-6	Diabetic kidney disease;
THYM	cis	rs36051895	0.659	rs62541538	chr9:5038164	G/A	cg02405213	chr9:5042618	JAK2	-1.01	-10.31	-0.73	3.55e-17	Pediatric autoimmune diseases;
THYM	cis	rs6840360	0.554	rs4643789	chr4:152726691	C/T	cg22705602	chr4:152727874	NA	-0.81	-11.14	-0.75	6.15e-19	Intelligence (multi-trait analysis);
THYM	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg19077165	chr18:44547161	KATNAL2	-0.64	-8.14	-0.64	1.51e-12	Personality dimensions;
THYM	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg09165964	chr15:75287851	SCAMP5	-1.08	-10.79	-0.74	3.35e-18	Blood trace element (Zn levels);
THYM	cis	rs4866334	1.000	rs79246642	chr5:18442878	C/T	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs3791556	0.504	rs1001285	chr2:240107814	A/G	cg03281426	chr2:240109471	HDAC4	0.56	6.58	0.56	2.6e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs79149102	0.579	rs78434425	chr15:75304754	C/T	cg09165964	chr15:75287851	SCAMP5	-1.06	-5.16	-0.47	1.35e-6	Lung cancer;
THYM	cis	rs425277	0.583	rs3107151	chr1:2051513	T/G	cg10334053	chr1:2078117	PRKCZ	-0.46	-4.79	-0.44	6.05e-6	Height;
THYM	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg01097406	chr16:89675127	NA	0.54	4.78	0.44	6.34e-6	Vitiligo;
THYM	cis	rs35883536	0.647	rs34195036	chr1:101040429	C/A	cg06223162	chr1:101003688	GPR88	-0.87	-7.61	-0.62	1.96e-11	Monocyte count;
THYM	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.84	-8.47	-0.66	3.07e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs28493229	0.708	rs111410535	chr19:41158441	C/T	cg21869046	chr19:41225005	ITPKC	0.49	4.46	0.42	2.28e-5	Kawasaki disease;
THYM	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.76	4.66	0.43	1.04e-5	Diabetic retinopathy;
THYM	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg00786635	chr1:25594202	NA	-0.92	-7.28	-0.6	9.7e-11	Erythrocyte sedimentation rate;
THYM	cis	rs4713118	0.662	rs9468278	chr6:28028482	C/T	cg08968635	chr6:28129556	ZNF389	0.59	4.57	0.42	1.46e-5	Parkinson's disease;
THYM	cis	rs2976388	0.967	rs2978981	chr8:143759137	C/T	cg13446199	chr8:143762866	PSCA	0.5	5.96	0.52	4.36e-8	Urinary tract infection frequency;
THYM	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg02734326	chr4:10020555	SLC2A9	0.78	6.62	0.56	2.11e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6570726	0.791	rs6902404	chr6:145905254	G/A	cg13319975	chr6:146136371	FBXO30	-0.66	-5.23	-0.47	1.01e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7246657	0.943	rs2303131	chr19:37936025	G/A	cg23950597	chr19:37808831	NA	-0.74	-4.77	-0.44	6.59e-6	Coronary artery calcification;
THYM	cis	rs12318506	0.793	rs71460129	chr12:75699427	C/T	cg04728562	chr12:75699417	CAPS2	-1.39	-5.88	-0.52	6.12e-8	Coronary artery calcification;
THYM	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.64	4.53	0.42	1.71e-5	Height;
THYM	cis	rs4285028	0.948	rs12497349	chr3:121708517	T/C	cg01951420	chr3:121553821	IQCB1;EAF2	-0.74	-5.08	-0.46	1.87e-6	Multiple sclerosis;
THYM	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg07930192	chr7:1003750	NA	0.56	4.74	0.44	7.54e-6	Longevity;Endometriosis;
THYM	cis	rs6558530	0.836	rs7461600	chr8:1714642	G/T	cg09410841	chr8:1729607	CLN8	0.79	5.92	0.52	5.01e-8	Systolic blood pressure;
THYM	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg06112835	chr11:68658793	MRPL21	0.43	6.3	0.54	9.11e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs2901656	0.629	rs10752946	chr1:172376632	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.5	5.16	0.47	1.38e-6	Red cell distribution width;Platelet distribution width;
THYM	cis	rs6866344	0.526	rs34981407	chr5:178152195	A/C	cg03877680	chr5:178157825	ZNF354A	0.81	5.74	0.51	1.12e-7	Neutrophil percentage of white cells;
THYM	cis	rs7561149	0.715	rs66733621	chr2:179664050	A/G	cg12089249	chr2:179345200	MIR548N;PLEKHA3	0.77	5.02	0.46	2.43e-6	QT interval;
THYM	cis	rs1003719	0.715	rs2835653	chr21:38558636	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	trans	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg07393940	chr7:158741817	NA	-1.11	-7.47	-0.61	3.79e-11	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg15556689	chr8:8085844	FLJ10661	0.71	6.15	0.53	1.82e-8	Systolic blood pressure;
THYM	cis	rs6084875	0.840	rs2422934	chr20:4720146	G/A	cg19614321	chr20:4804581	RASSF2	0.45	4.53	0.42	1.7e-5	Systemic lupus erythematosus;
THYM	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg21226059	chr5:178986404	RUFY1	0.6	6.8	0.57	9.25e-10	Lung cancer;
THYM	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg09263875	chr16:632152	PIGQ	0.73	6.29	0.54	9.69e-9	Height;
THYM	cis	rs2319125	0.683	rs8182353	chr17:64048710	A/G	cg04446870	chr17:64440273	PRKCA	0.5	4.49	0.42	2e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs79149102	0.579	rs8040961	chr15:75291864	G/A	cg17294928	chr15:75287854	SCAMP5	-1.06	-5.68	-0.5	1.49e-7	Lung cancer;
THYM	cis	rs4747241	0.626	rs9415061	chr10:74081183	G/T	cg07828833	chr10:74069493	NA	-0.58	-4.83	-0.44	5.24e-6	Heschl's gyrus morphology;
THYM	cis	rs7772486	0.875	rs9373485	chr6:146401429	A/T	cg23711669	chr6:146136114	FBXO30	0.96	10.33	0.73	3.19e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs986417	0.818	rs4278669	chr14:60982075	T/C	cg27398547	chr14:60952738	C14orf39	1.27	6.35	0.55	7.34e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs2658782	1.000	rs2608216	chr11:93149172	G/A	cg16424440	chr11:93231842	C11orf75	-0.74	-4.69	-0.43	9.19e-6	Pulmonary function decline;
THYM	cis	rs7772486	0.686	rs9497395	chr6:146013592	A/G	cg23711669	chr6:146136114	FBXO30	-0.84	-7.61	-0.62	1.95e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg09703963	chr11:616879	IRF7;MUPCDH	-0.76	-6.38	-0.55	6.46e-9	Systemic lupus erythematosus;
THYM	cis	rs9430161	0.579	rs6694011	chr1:11036935	G/A	cg02454025	chr1:11042201	C1orf127	0.85	9.91	0.71	2.54e-16	Ewing sarcoma;
THYM	cis	rs6992820	0.902	rs6999008	chr8:56768236	G/A	cg06880721	chr8:56792545	LYN	-0.62	-5.41	-0.49	4.77e-7	Mean platelet volume;
THYM	cis	rs11252926	0.797	rs61837235	chr10:489363	G/A	cg03684893	chr10:554711	DIP2C	0.69	5.28	0.48	8.33e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg25554036	chr4:6271136	WFS1	0.59	5.47	0.49	3.68e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs921968	0.541	rs490483	chr2:219429052	A/T	cg02176678	chr2:219576539	TTLL4	0.73	7.22	0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg03806693	chr22:41940476	POLR3H	-1.23	-10.06	-0.72	1.2e-16	Vitiligo;
THYM	cis	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg05084668	chr3:125655381	ALG1L	-0.8	-4.62	-0.43	1.21e-5	Blood pressure (smoking interaction);
THYM	cis	rs394563	0.690	rs237009	chr6:149759552	C/T	cg03678062	chr6:149772716	ZC3H12D	-0.58	-4.85	-0.45	4.85e-6	Dupuytren's disease;
THYM	cis	rs4606347	0.789	rs61780879	chr1:66166208	C/T	cg04111102	chr1:66153794	NA	0.63	5.0	0.46	2.62e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs73787773	0.668	rs73227490	chr5:111473340	T/C	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.9	-4.87	-0.45	4.48e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs354225	0.544	rs12713267	chr2:54805607	T/C	cg23486701	chr2:54789491	SPTBN1	0.34	4.49	0.42	2e-5	Schizophrenia;
THYM	cis	rs1079204	1.000	rs10192690	chr2:219190713	A/G	cg05728596	chr2:219128475	GPBAR1	1.12	4.85	0.45	4.9e-6	Smooth-surface caries;
THYM	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg24678163	chr13:52769951	THSD1P	0.48	4.62	0.43	1.2e-5	Lewy body disease;
THYM	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg11266682	chr4:10021025	SLC2A9	-0.71	-9.43	-0.7	2.75e-15	Bone mineral density;
THYM	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg23281280	chr6:28129359	ZNF389	0.67	5.28	0.48	8.33e-7	Depression;
THYM	cis	rs12824058	0.844	rs10744458	chr12:130805820	C/T	cg24838063	chr12:130822603	PIWIL1	-0.75	-5.61	-0.5	1.99e-7	Menopause (age at onset);
THYM	cis	rs12579753	0.869	rs17692407	chr12:82171369	G/C	cg21231944	chr12:82153410	PPFIA2	-0.69	-5.26	-0.47	8.95e-7	Resting heart rate;
THYM	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg08772003	chr10:104629869	AS3MT	0.63	5.71	0.51	1.27e-7	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.41	-6.4	-0.55	5.78e-9	Obesity-related traits;
THYM	cis	rs17598306	0.873	rs2016644	chr7:96596049	C/T	cg23184042	chr7:96615519	DLX6AS	0.61	4.76	0.44	6.82e-6	Radiation response;
THYM	cis	rs6430585	0.591	rs309170	chr2:136672775	C/T	cg04750100	chr2:136595281	LCT	0.55	5.49	0.49	3.39e-7	Corneal structure;
THYM	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-5.93	-0.52	4.8e-8	Gut microbiome composition (summer);
THYM	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06481639	chr22:41940642	POLR3H	0.65	4.77	0.44	6.53e-6	Vitiligo;
THYM	cis	rs7107174	1.000	rs7117238	chr11:78040259	G/A	cg19901956	chr11:77921274	USP35	-0.65	-5.38	-0.48	5.41e-7	Testicular germ cell tumor;
THYM	cis	rs4746818	1.000	rs6480385	chr10:70904785	A/T	cg11621586	chr10:70884670	VPS26A	1.28	11.12	0.75	6.73e-19	Left atrial antero-posterior diameter;
THYM	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs6570726	0.764	rs9403731	chr6:145907937	G/A	cg05347473	chr6:146136440	FBXO30	0.57	4.46	0.42	2.26e-5	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs8002861	0.870	rs9525855	chr13:44431660	A/G	cg17145862	chr1:211918768	LPGAT1	0.87	9.02	0.68	2.02e-14	Leprosy;
THYM	cis	rs4455778	0.519	rs34062689	chr7:49035022	G/T	cg26309511	chr7:48887640	NA	0.61	5.51	0.49	3.11e-7	Lung cancer in never smokers;
THYM	cis	rs7633857	0.532	rs9858335	chr3:160760146	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-4.84	-0.44	5.04e-6	Educational attainment (years of education);
THYM	cis	rs3733631	0.512	rs74324844	chr4:104636603	A/G	cg24090629	chr4:104641072	TACR3	-0.82	-4.48	-0.42	2.07e-5	Menarche (age at onset);
THYM	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22496380	chr5:211416	CCDC127	-1.27	-7.93	-0.63	4.13e-12	Breast cancer;
THYM	cis	rs6570726	1.000	rs6570699	chr6:145920732	G/A	cg23711669	chr6:146136114	FBXO30	0.77	7.17	0.59	1.63e-10	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg21775007	chr8:11205619	TDH	-0.73	-5.66	-0.5	1.63e-7	Retinal vascular caliber;
THYM	cis	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg21775007	chr8:11205619	TDH	0.68	5.59	0.5	2.13e-7	Retinal vascular caliber;
THYM	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg13010199	chr12:38710504	ALG10B	-0.64	-5.56	-0.5	2.52e-7	Heart rate;
THYM	cis	rs113835537	0.529	rs57724777	chr11:66236431	G/A	cg10315249	chr11:66235081	PELI3	0.43	4.63	0.43	1.17e-5	Airway imaging phenotypes;
THYM	trans	rs9951602	0.512	rs8097996	chr18:76648035	A/G	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg07460842	chr6:66804631	NA	1.11	8.12	0.64	1.7e-12	Exhaled nitric oxide output;
THYM	cis	rs3812049	0.826	rs2409110	chr5:127433047	A/T	cg05443326	chr5:126853169	PRRC1	-0.65	-4.49	-0.42	2.02e-5	Lymphocyte counts;Red cell distribution width;
THYM	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10411161	0.702	rs7250138	chr19:52385232	G/C	cg25361850	chr19:52391789	ZNF577	0.71	4.99	0.46	2.69e-6	Breast cancer;
THYM	cis	rs61931739	0.817	rs592857	chr12:34197673	T/G	cg06521331	chr12:34319734	NA	-0.64	-5.37	-0.48	5.62e-7	Morning vs. evening chronotype;
THYM	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06481639	chr22:41940642	POLR3H	-0.75	-5.11	-0.46	1.66e-6	Vitiligo;
THYM	cis	rs13102973	0.899	rs13119071	chr4:135909862	G/T	cg14419869	chr4:135874104	NA	0.82	6.86	0.58	7.03e-10	Subjective well-being;
THYM	cis	rs910187	0.605	rs6066223	chr20:45803998	A/G	cg27589058	chr20:45804311	EYA2	0.7	6.42	0.55	5.42e-9	Migraine;
THYM	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg16558253	chr16:72132732	DHX38	-0.56	-4.87	-0.45	4.39e-6	Fibrinogen levels;
THYM	cis	rs1971762	0.563	rs4759285	chr12:54079513	G/T	cg16917193	chr12:54089295	NA	0.93	9.97	0.72	1.93e-16	Height;
THYM	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg00814883	chr7:100076585	TSC22D4	0.95	6.39	0.55	6.08e-9	Platelet count;
THYM	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg06238570	chr21:40685208	BRWD1	-0.97	-9.38	-0.69	3.44e-15	Cognitive function;
THYM	cis	rs7119038	0.818	rs11217042	chr11:118682528	G/A	cg19308663	chr11:118741387	NA	0.44	4.63	0.43	1.15e-5	Sjögren's syndrome;
THYM	cis	rs12765878	0.967	rs7920217	chr10:105668172	C/T	cg11005552	chr10:105648138	OBFC1	0.87	11.39	0.76	1.84e-19	Coronary artery disease;
THYM	cis	rs9649213	0.574	rs13238610	chr7:97909277	T/C	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2073300	0.609	rs6137913	chr20:23357725	C/T	cg12062639	chr20:23401060	NAPB	1.14	6.41	0.55	5.71e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs9807841	0.823	rs6511710	chr19:10827601	A/G	cg17848348	chr19:10766748	ILF3	-0.7	-5.8	-0.51	8.52e-8	Inflammatory skin disease;
THYM	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg22117172	chr7:91764530	CYP51A1	0.37	4.84	0.44	5.01e-6	Breast cancer;
THYM	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg00383909	chr3:49044727	WDR6	1.03	5.9	0.52	5.64e-8	Cognitive function;
THYM	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg22920501	chr2:26401640	FAM59B	-1.05	-9.42	-0.7	2.84e-15	Gut microbiome composition (summer);
THYM	cis	rs4606347	0.932	rs11807723	chr1:66145336	G/A	cg04111102	chr1:66153794	NA	0.57	4.53	0.42	1.73e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.91	0.45	3.8e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg04944784	chr2:26401820	FAM59B	1.08	8.57	0.66	1.87e-13	Gut microbiome composition (summer);
THYM	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg10661904	chr17:79619235	PDE6G	-0.54	-4.79	-0.44	6.25e-6	Eye color traits;
THYM	cis	rs11031096	0.727	rs7932702	chr11:4124372	C/T	cg08557956	chr11:4115526	RRM1	-0.5	-4.9	-0.45	3.94e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs11711311	1.000	rs3773682	chr3:113520576	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.62	-5.5	-0.49	3.26e-7	IgG glycosylation;
THYM	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg18876405	chr7:65276391	NA	0.58	4.99	0.46	2.75e-6	Aortic root size;
THYM	cis	rs4638749	0.501	rs1000173	chr2:108762878	A/G	cg25838818	chr2:108905173	SULT1C2	-0.47	-4.53	-0.42	1.72e-5	Blood pressure;
THYM	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1904096	0.506	rs13434570	chr4:95168019	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.58	-5.2	-0.47	1.14e-6	Type 2 diabetes;
THYM	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11890956	chr21:40555474	PSMG1	1.18	12.69	0.79	3.62e-22	Cognitive function;
THYM	cis	rs4509693	0.782	rs7897782	chr10:102495856	C/A	cg15234845	chr10:102496500	NA	0.64	4.53	0.42	1.71e-5	Alzheimer's disease;
THYM	cis	rs9522267	0.502	rs9515450	chr13:112234262	T/C	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	4.01e-10	Hepatitis;
THYM	cis	rs669446	0.527	rs72883034	chr1:44112379	T/C	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs9787249	0.915	rs58589165	chr1:40213670	A/T	cg19912559	chr1:40204330	PPIE	0.64	4.92	0.45	3.61e-6	Blood protein levels;
THYM	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg10047753	chr17:41438598	NA	0.95	7.42	0.61	5.03e-11	Menopause (age at onset);
THYM	cis	rs4237845	0.537	rs59401446	chr12:58259564	G/A	cg00677455	chr12:58241039	CTDSP2	0.8	6.91	0.58	5.45e-10	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg06618935	chr21:46677482	NA	-1.0	-9.29	-0.69	5.41e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg12560992	chr17:57184187	TRIM37	0.94	8.84	0.67	5.01e-14	Intelligence (multi-trait analysis);
THYM	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21659725	chr3:3221576	CRBN	-0.88	-9.81	-0.71	4.18e-16	Intelligence (multi-trait analysis);
THYM	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg18681998	chr4:17616180	MED28	-0.84	-7.13	-0.59	1.95e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg06600287	chr1:53387719	ECHDC2	-0.29	-4.69	-0.43	9.17e-6	Monocyte count;
THYM	trans	rs9929218	0.953	rs34909703	chr16:68740097	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.91	-7.97	-0.63	3.48e-12	Colorectal cancer;
THYM	cis	rs6992820	0.900	rs34751862	chr8:56703319	C/G	cg06880721	chr8:56792545	LYN	-0.71	-5.94	-0.52	4.57e-8	Mean platelet volume;
THYM	cis	rs12410462	1.000	rs12407171	chr1:227642282	G/A	cg04117972	chr1:227635322	NA	0.69	4.61	0.43	1.26e-5	Major depressive disorder;
THYM	cis	rs554111	0.571	rs4537519	chr1:21461370	T/C	cg01072550	chr1:21505969	NA	0.59	5.11	0.46	1.68e-6	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs4363385	0.510	rs6587724	chr1:153034501	T/A	cg13444842	chr1:152974279	SPRR3	-0.61	-4.8	-0.44	5.87e-6	Inflammatory skin disease;
THYM	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg04750100	chr2:136595281	LCT	-0.54	-6.51	-0.56	3.59e-9	Mosquito bite size;
THYM	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.99	6.38	0.55	6.45e-9	Smoking behavior;
THYM	cis	rs7760949	0.852	rs9475801	chr6:13933115	G/A	cg11053062	chr6:13924544	RNF182	-0.47	-4.54	-0.42	1.62e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs12135062	0.687	rs6685614	chr1:3108517	C/T	cg21609526	chr1:3105151	PRDM16	0.66	5.21	0.47	1.11e-6	Migraine;
THYM	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06873352	chr17:61820015	STRADA	0.57	5.68	0.5	1.46e-7	Height;
THYM	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2439831	0.681	rs1837959	chr15:43698679	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.79	6.89	0.58	5.93e-10	Lung cancer in ever smokers;
THYM	cis	rs6450176	0.909	rs7732139	chr5:53292017	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-6.61	-0.56	2.22e-9	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg19747945	chr6:42946146	PEX6	-0.34	-4.73	-0.44	7.71e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	4.55	0.42	1.6e-5	Renal function-related traits (BUN);
THYM	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg21138405	chr5:131827807	IRF1	0.86	9.3	0.69	5.23e-15	Asthma (sex interaction);
THYM	cis	rs4849845	0.925	rs4849842	chr2:121012666	T/A	cg03575764	chr2:121493832	NA	-0.63	-4.72	-0.44	8.26e-6	Mean platelet volume;
THYM	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg14458575	chr2:238380390	NA	1.0	7.94	0.63	3.96e-12	Prostate cancer;
THYM	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg00631329	chr6:26305371	NA	-0.6	-7.24	-0.6	1.15e-10	Educational attainment;
THYM	cis	rs6700896	0.931	rs4655585	chr1:66155627	T/C	cg04111102	chr1:66153794	NA	0.56	5.35	0.48	5.96e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7678296	0.649	rs77896458	chr4:37237843	A/G	cg06805348	chr4:37245195	KIAA1239	1.03	5.13	0.47	1.54e-6	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs4940575	0.679	rs11875184	chr18:60829553	A/G	cg20947866	chr18:61143580	SERPINB5	0.94	5.56	0.5	2.44e-7	Breast cancer;
THYM	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg00129232	chr17:37814104	STARD3	-0.9	-7.1	-0.59	2.26e-10	Asthma;
THYM	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg06636001	chr8:8085503	FLJ10661	0.64	5.46	0.49	3.76e-7	Mood instability;
THYM	cis	rs1978968	1.000	rs5992917	chr22:18443699	G/T	cg01550578	chr22:18484421	MICAL3	0.69	5.23	0.47	1e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs2195525	0.572	rs7928348	chr11:119218712	C/G	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.43	4.83	0.44	5.19e-6	Urate levels;
THYM	cis	rs3126085	1.000	rs3126098	chr1:152311923	T/C	cg26020982	chr1:152196106	HRNR	-0.37	-4.89	-0.45	4.13e-6	Atopic dermatitis;
THYM	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg17294928	chr15:75287854	SCAMP5	0.65	4.97	0.45	2.99e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	trans	rs877282	0.945	rs71489301	chr10:770191	A/G	cg22713356	chr15:30763199	NA	1.28	10.44	0.73	1.93e-17	Uric acid levels;
THYM	cis	rs72792324	1.000	rs4151697	chr5:140743661	C/T	cg00808170	chr5:140807787	PCDHGA4;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB8P;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGB2;PCDHGA7;PCDHGB5	0.72	4.67	0.43	9.72e-6	Mean platelet volume;
THYM	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs3126085	0.935	rs3126088	chr1:152305785	A/G	cg26020982	chr1:152196106	HRNR	-0.36	-4.95	-0.45	3.19e-6	Atopic dermatitis;
THYM	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg18252515	chr7:66147081	NA	-0.65	-4.87	-0.45	4.43e-6	Aortic root size;
THYM	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg03709012	chr19:19516395	GATAD2A	-0.71	-5.13	-0.47	1.51e-6	Tonsillectomy;
THYM	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg06636001	chr8:8085503	FLJ10661	0.64	5.81	0.51	8.26e-8	Joint mobility (Beighton score);
THYM	cis	rs10638925	1	rs10638925	chr3:194119749	C/CCATAAA	cg00834899	chr3:194121120	GP5	-0.54	-5.35	-0.48	6.18e-7	Platelet distribution width;
THYM	trans	rs8002861	0.967	rs9533691	chr13:44482208	A/G	cg17145862	chr1:211918768	LPGAT1	0.99	11.5	0.76	1.07e-19	Leprosy;
THYM	cis	rs113835537	0.559	rs74933537	chr11:66274958	A/C	cg10315249	chr11:66235081	PELI3	0.44	4.81	0.44	5.71e-6	Airway imaging phenotypes;
THYM	cis	rs73086581	1.000	rs17287486	chr20:3946267	T/C	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs524281	0.692	rs2452681	chr11:65814842	G/A	cg00563793	chr11:65837595	PACS1	-0.63	-4.72	-0.44	8.23e-6	Electroencephalogram traits;
THYM	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg04267008	chr7:1944627	MAD1L1	-0.57	-4.65	-0.43	1.09e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg15242686	chr22:24348715	GSTTP1	-0.63	-5.14	-0.47	1.46e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg05368731	chr17:41323189	NBR1	1.25	11.15	0.75	6.02e-19	Menopause (age at onset);
THYM	cis	rs34779708	0.966	rs4934538	chr10:35472150	T/C	cg03585969	chr10:35415529	CREM	0.67	4.56	0.42	1.55e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6828523	0.698	rs80082041	chr4:175855409	A/G	cg14561282	chr4:175839468	ADAM29	0.62	4.53	0.42	1.7e-5	Breast cancer;
THYM	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.9	-6.08	-0.53	2.49e-8	Schizophrenia;
THYM	cis	rs62435770	1.000	rs17789278	chr6:169542663	A/G	cg07652237	chr6:170125491	PHF10	-0.53	-4.73	-0.44	7.85e-6	Loneliness;
THYM	cis	rs12519773	0.526	rs4469186	chr5:92520266	T/C	cg18783429	chr5:92414398	NA	0.5	4.91	0.45	3.72e-6	Migraine;
THYM	cis	rs1113500	0.614	rs1343192	chr1:108613888	C/T	cg06207961	chr1:108661230	NA	0.7	5.18	0.47	1.22e-6	Growth-regulated protein alpha levels;
THYM	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg18876405	chr7:65276391	NA	0.63	5.53	0.49	2.83e-7	Aortic root size;
THYM	cis	rs9790314	0.695	rs7630763	chr3:160864865	T/C	cg03342759	chr3:160939853	NMD3	-0.61	-4.61	-0.43	1.25e-5	Morning vs. evening chronotype;
THYM	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg14675211	chr2:100938903	LONRF2	0.71	6.91	0.58	5.47e-10	Intelligence (multi-trait analysis);
THYM	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs61931739	0.517	rs2636073	chr12:34063049	C/T	cg06521331	chr12:34319734	NA	-0.95	-9.13	-0.68	1.19e-14	Morning vs. evening chronotype;
THYM	cis	rs12413816	0.963	rs12359348	chr10:13765950	C/T	cg16485048	chr10:13749193	FRMD4A	-0.58	-6.35	-0.55	7.36e-9	Red cell distribution width;
THYM	trans	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg25214090	chr10:38739885	LOC399744	0.97	8.33	0.65	5.98e-13	Corneal astigmatism;
THYM	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg27535305	chr1:53392650	SCP2	-0.59	-6.67	-0.56	1.7e-9	Monocyte count;
THYM	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg06634786	chr22:41940651	POLR3H	0.72	5.11	0.46	1.65e-6	Vitiligo;
THYM	cis	rs6076065	0.692	rs6083111	chr20:23374667	A/G	cg11657817	chr20:23433608	CST11	0.31	4.57	0.42	1.48e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs11645898	0.935	rs72787078	chr16:72158493	C/T	cg14768367	chr16:72042858	DHODH	-0.76	-5.49	-0.49	3.35e-7	Blood protein levels;
THYM	cis	rs28595532	0.920	rs56303276	chr4:119723514	C/T	cg14228332	chr4:119757509	SEC24D	1.58	5.72	0.51	1.22e-7	Cannabis dependence symptom count;
THYM	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.69	4.58	0.43	1.41e-5	Lung cancer in ever smokers;
THYM	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg08645402	chr16:4508243	NA	0.64	4.71	0.44	8.31e-6	Schizophrenia;
THYM	cis	rs6500395	0.962	rs9941336	chr16:48652769	G/A	cg04672837	chr16:48644449	N4BP1	0.48	4.59	0.43	1.35e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg20295408	chr7:1910781	MAD1L1	-0.69	-5.03	-0.46	2.27e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs870825	0.616	rs9715644	chr4:185632965	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs11085466	1.000	rs73552468	chr19:21772097	G/A	cg23026602	chr19:21646605	NA	-0.66	-4.84	-0.45	4.94e-6	Colorectal or endometrial cancer;
THYM	cis	rs4803468	1.000	rs1043413	chr19:41939297	C/G	cg09537434	chr19:41945824	ATP5SL	1.09	10.16	0.72	7.58e-17	Height;
THYM	cis	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg06521331	chr12:34319734	NA	-0.96	-8.88	-0.67	4.06e-14	Morning vs. evening chronotype;
THYM	cis	rs17854409	1.000	rs6010770	chr20:61494225	G/T	cg05147244	chr20:61493195	TCFL5	1.03	6.5	0.55	3.76e-9	Obesity-related traits;
THYM	cis	rs12310956	0.532	rs11494810	chr12:33952881	C/A	cg10856724	chr12:34555212	NA	-0.75	-6.8	-0.57	9.1e-10	Morning vs. evening chronotype;
THYM	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg06558623	chr16:89946397	TCF25	1.23	5.46	0.49	3.81e-7	Skin colour saturation;
THYM	cis	rs4975709	0.686	rs2307118	chr5:1881916	A/C	cg19770292	chr5:1868693	NA	0.51	4.68	0.43	9.52e-6	Cardiovascular disease risk factors;
THYM	cis	rs400736	1.000	rs400736	chr1:8078309	T/C	cg22678073	chr1:8087421	ERRFI1	0.46	4.84	0.44	5e-6	Response to antidepressants and depression;
THYM	cis	rs4713118	0.868	rs9468220	chr6:27732976	A/G	cg08968635	chr6:28129556	ZNF389	-0.67	-5.0	-0.46	2.66e-6	Parkinson's disease;
THYM	cis	rs113601626	1	rs113601626	chr2:24239189	T/TCCTGGC	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte percentage of white cells;
THYM	cis	rs791888	1.000	rs791882	chr10:89408258	C/T	cg10377144	chr10:89419177	PAPSS2	-0.4	-6.5	-0.55	3.68e-9	Magnesium levels;
THYM	cis	rs71403859	0.614	rs12149533	chr16:71801946	C/T	cg08717414	chr16:71523259	ZNF19	-0.92	-5.16	-0.47	1.32e-6	Post bronchodilator FEV1;
THYM	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg06850241	chr22:41845214	NA	0.54	4.77	0.44	6.68e-6	Vitiligo;
THYM	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.94	7.18	0.59	1.57e-10	Electrocardiographic conduction measures;
THYM	cis	rs1729951	0.575	rs1682357	chr3:136692009	G/A	cg21827317	chr3:136751795	NA	0.75	6.64	0.56	1.92e-9	Neuroticism;
THYM	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs8028313	0.731	rs11857017	chr15:67972908	A/G	cg24579218	chr15:68104479	NA	-0.72	-6.74	-0.57	1.19e-9	Obesity;
THYM	cis	rs9522267	0.535	rs914037	chr13:112235308	A/G	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg25554036	chr4:6271136	WFS1	-0.56	-5.29	-0.48	7.94e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs2997447	0.802	rs61775415	chr1:26391849	A/C	cg03844060	chr1:26490628	NA	0.68	4.67	0.43	1e-5	QRS complex (12-leadsum);
THYM	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg06238570	chr21:40685208	BRWD1	0.96	8.93	0.68	3.27e-14	Cognitive function;
THYM	cis	rs3845702	0.736	rs6433816	chr2:180809317	G/C	cg01881094	chr2:180872142	CWC22	-0.89	-5.34	-0.48	6.22e-7	Schizophrenia;
THYM	cis	rs758324	0.732	rs156044	chr5:131492527	T/C	cg16205897	chr5:131564050	P4HA2	0.52	4.6	0.43	1.29e-5	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs9905704	1.000	rs9905704	chr17:56632543	G/T	cg12560992	chr17:57184187	TRIM37	-0.68	-4.73	-0.44	7.7e-6	Testicular germ cell tumor;
THYM	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg24818145	chr4:99064322	C4orf37	0.67	5.23	0.47	1.01e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11577318	0.626	rs11806568	chr1:26686837	C/A	cg16664472	chr1:26644822	UBXN11;CD52	0.34	4.95	0.45	3.19e-6	Granulocyte percentage of myeloid white cells;
THYM	cis	rs3826795	0.569	rs34128150	chr19:46795109	C/A	cg15229275	chr19:46800054	HIF3A	0.93	5.64	0.5	1.77e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
THYM	cis	rs6563943	0.857	rs8053046	chr16:83636775	C/G	cg01935413	chr16:83636749	CDH13	0.5	4.92	0.45	3.7e-6	Height;
THYM	cis	rs11771526	0.901	rs17161123	chr7:32305426	G/A	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs6087990	0.735	rs2065576	chr20:31389009	C/T	cg13636640	chr20:31349939	DNMT3B	0.92	9.89	0.71	2.9e-16	Ulcerative colitis;
THYM	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg14972814	chr11:95582409	MTMR2	-0.7	-6.28	-0.54	9.97e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg07362569	chr17:61921086	SMARCD2	-0.74	-6.62	-0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03264133	chr6:25882463	NA	-0.89	-7.64	-0.62	1.75e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg10802521	chr3:52805072	NEK4	-0.72	-6.12	-0.53	2.09e-8	Bipolar disorder;
THYM	cis	rs2898681	0.614	rs28758563	chr4:53677777	C/T	cg00791764	chr4:53727839	RASL11B	0.41	4.66	0.43	1.01e-5	Optic nerve measurement (cup area);
THYM	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg18477163	chr1:228402036	OBSCN	-0.43	-4.69	-0.43	9.18e-6	Diastolic blood pressure;
THYM	cis	rs11118844	0.744	rs10863656	chr1:221952703	T/A	cg04222084	chr1:221915650	DUSP10	-0.95	-4.72	-0.44	8.22e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);White matter lesion progression;
THYM	cis	rs72627123	0.867	rs17094448	chr14:74440119	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	4.87	0.45	4.38e-6	Morning vs. evening chronotype;
THYM	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg16989719	chr2:238392110	NA	-0.62	-5.4	-0.48	4.82e-7	Prostate cancer;
THYM	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg00022866	chr11:64108440	CCDC88B	-0.51	-4.48	-0.42	2.07e-5	Platelet count;
THYM	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg23188684	chr11:67383651	NA	-0.62	-4.78	-0.44	6.31e-6	Mean corpuscular volume;
THYM	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg06917634	chr15:78832804	PSMA4	-0.82	-7.24	-0.6	1.17e-10	Sudden cardiac arrest;
THYM	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg06219351	chr7:158114137	PTPRN2	0.69	6.88	0.58	6.33e-10	Calcium levels;
THYM	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg09469691	chr10:81107165	PPIF	0.72	5.92	0.52	5.13e-8	Height;
THYM	cis	rs1775715	0.677	rs2799034	chr10:32175896	A/G	cg04359828	chr10:32216031	ARHGAP12	0.41	5.09	0.46	1.78e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg03213289	chr20:61660250	NA	0.91	9.48	0.7	2.14e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.68	0.5	1.45e-7	Height;
THYM	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.64	-4.56	-0.42	1.55e-5	Colorectal cancer;
THYM	cis	rs12282928	0.959	rs4980427	chr11:48296486	T/C	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg06112835	chr11:68658793	MRPL21	0.44	6.53	0.56	3.28e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs10887741	0.865	rs2145819	chr10:89418979	A/C	cg13926569	chr10:89418898	PAPSS2	-0.66	-7.0	-0.58	3.57e-10	Exercise (leisure time);
THYM	cis	rs59698941	0.943	rs12516596	chr5:132273608	C/G	cg02081065	chr5:132209139	LEAP2	-0.85	-5.66	-0.5	1.57e-7	Apolipoprotein A-IV levels;
THYM	trans	rs8002861	0.641	rs6561148	chr13:44426269	C/T	cg17145862	chr1:211918768	LPGAT1	0.86	7.46	0.61	4.13e-11	Leprosy;
THYM	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11890956	chr21:40555474	PSMG1	-0.66	-6.38	-0.55	6.51e-9	Menarche (age at onset);
THYM	cis	rs2302612	0.528	rs1117797	chr2:102821182	T/C	cg13315345	chr2:102803985	IL1RL2	0.68	4.58	0.43	1.4e-5	Serum protein levels (sST2);
THYM	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs72781680	0.716	rs2712071	chr2:23990419	A/G	cg08917208	chr2:24149416	ATAD2B	0.9	4.8	0.44	5.97e-6	Lymphocyte counts;
THYM	cis	rs4631830	0.863	rs4486572	chr10:51531805	A/G	cg10326726	chr10:51549505	MSMB	-0.6	-5.96	-0.52	4.35e-8	Prostate-specific antigen levels;
THYM	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	5.58	0.5	2.29e-7	Rheumatoid arthritis;
THYM	cis	rs7512552	0.839	rs11581351	chr1:150440200	G/C	cg15654264	chr1:150340011	RPRD2	0.44	5.12	0.47	1.58e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg10661904	chr17:79619235	PDE6G	-0.65	-6.34	-0.54	7.88e-9	Eye color traits;
THYM	cis	rs6674176	0.935	rs4314918	chr1:44377503	G/A	cg26023051	chr1:45103896	RNF220	0.78	5.05	0.46	2.11e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs12594515	1.000	rs6493172	chr15:45987213	T/G	cg01629716	chr15:45996671	NA	0.51	5.21	0.47	1.07e-6	Waist circumference;Weight;
THYM	cis	rs929354	1.000	rs1182378	chr7:157048322	T/C	cg17757837	chr7:157058334	UBE3C	-0.79	-6.82	-0.57	8.2e-10	Body mass index;
THYM	cis	rs2282300	0.739	rs1222215	chr11:30347596	C/T	cg06241208	chr11:30344200	C11orf46	-0.78	-5.65	-0.5	1.64e-7	Morning vs. evening chronotype;
THYM	cis	rs490234	0.841	rs1250736	chr9:128438005	A/G	cg14078157	chr9:128172775	NA	0.6	4.97	0.45	2.96e-6	Mean arterial pressure;
THYM	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	9.39	0.69	3.37e-15	Chronic sinus infection;
THYM	cis	rs1160297	0.609	rs12618983	chr2:53091691	C/T	cg07782112	chr2:53107842	NA	-0.77	-6.28	-0.54	1.02e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs6840360	1.000	rs10007015	chr4:152603528	C/G	cg22705602	chr4:152727874	NA	-0.63	-6.81	-0.57	8.8e-10	Intelligence (multi-trait analysis);
THYM	cis	rs34779708	0.966	rs12762493	chr10:35471873	G/A	cg03585969	chr10:35415529	CREM	0.67	5.01	0.46	2.51e-6	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9549260	0.755	rs17061503	chr13:41246758	A/G	cg21288729	chr13:41239152	FOXO1	-0.69	-5.54	-0.49	2.66e-7	Red blood cell count;
THYM	cis	rs7678296	0.649	rs73128366	chr4:37241908	T/C	cg06805348	chr4:37245195	KIAA1239	1.03	5.19	0.47	1.19e-6	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02475777	chr4:1388615	CRIPAK	-0.65	-4.78	-0.44	6.34e-6	Longevity;
THYM	trans	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Bladder cancer;
THYM	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg02269571	chr22:50332266	NA	-0.71	-4.91	-0.45	3.78e-6	Schizophrenia;
THYM	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg12386194	chr3:101231763	SENP7	0.69	5.16	0.47	1.34e-6	Colorectal cancer;
THYM	cis	rs9527	0.615	rs7899622	chr10:104727333	C/T	cg04362960	chr10:104952993	NT5C2	0.63	4.73	0.44	7.84e-6	Arsenic metabolism;
THYM	cis	rs9790314	1.000	rs336590	chr3:161079583	G/A	cg04691961	chr3:161091175	C3orf57	-0.6	-5.23	-0.47	1.02e-6	Morning vs. evening chronotype;
THYM	cis	rs35883536	0.647	rs12046413	chr1:101047430	T/C	cg09408571	chr1:101003634	GPR88	-0.47	-5.13	-0.47	1.56e-6	Monocyte count;
THYM	cis	rs7000551	0.621	rs13255244	chr8:22288342	T/C	cg12081754	chr8:22256438	SLC39A14	1.03	8.87	0.67	4.31e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs4731207	0.596	rs1525614	chr7:124658600	C/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg26384229	chr12:38710491	ALG10B	1.04	9.17	0.69	9.7e-15	Heart rate;
THYM	cis	rs7772486	0.875	rs2777479	chr6:146309178	C/A	cg23711669	chr6:146136114	FBXO30	0.9	8.92	0.68	3.32e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs72717009	0.825	rs6671753	chr1:161478708	G/A	cg15358701	chr1:161410459	NA	-0.95	-5.04	-0.46	2.24e-6	Rheumatoid arthritis;
THYM	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	4.93	0.45	3.54e-6	Bipolar disorder;
THYM	cis	rs10752881	1.000	rs10752885	chr1:182982878	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.64	5.06	0.46	2.03e-6	Colorectal cancer;
THYM	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.28	6.25	0.54	1.13e-8	Obesity-related traits;
THYM	cis	rs240764	0.658	rs1039030	chr6:101198707	G/A	cg21058520	chr6:100914733	NA	0.56	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs7666738	1.000	rs7666738	chr4:98968077	C/T	cg07917127	chr4:99064746	C4orf37	0.59	4.5	0.42	1.93e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3760982	0.585	rs67704568	chr19:44294019	T/C	cg11993925	chr19:44307056	LYPD5	0.64	5.0	0.46	2.58e-6	Breast cancer (estrogen-receptor negative);Breast cancer;
THYM	cis	rs6546324	0.625	rs6546325	chr2:67861901	C/A	cg18237512	chr2:67827392	NA	-0.78	-4.68	-0.43	9.42e-6	Endometriosis;
THYM	cis	rs8180040	0.739	rs66539935	chr3:47025327	C/T	cg09354556	chr3:47051341	NA	-0.43	-4.53	-0.42	1.7e-5	Colorectal cancer;
THYM	cis	rs12530845	0.623	rs73721669	chr7:135347107	C/G	cg23117316	chr7:135346802	PL-5283	-0.83	-6.31	-0.54	8.67e-9	Red blood cell traits;
THYM	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg26513180	chr16:89883248	FANCA	0.74	7.34	0.6	7.27e-11	Vitiligo;
THYM	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg06600287	chr1:53387719	ECHDC2	-0.31	-5.09	-0.46	1.78e-6	Monocyte count;
THYM	cis	rs4731207	0.596	rs1585967	chr7:124613344	T/C	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs6686842	1.000	rs17571940	chr1:41566191	C/T	cg03387723	chr1:41708464	SCMH1	0.44	5.22	0.47	1.06e-6	Height;
THYM	cis	rs13256369	0.802	rs1060106	chr8:8561452	A/G	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg27446573	chr6:127587934	RNF146	0.77	6.35	0.55	7.46e-9	Breast cancer;
THYM	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg18758796	chr5:131593413	PDLIM4	-0.51	-4.81	-0.44	5.55e-6	Breast cancer;
THYM	cis	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg21775007	chr8:11205619	TDH	0.74	6.67	0.57	1.65e-9	Retinal vascular caliber;
THYM	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg11494091	chr17:61959527	GH2	-0.95	-13.69	-0.81	3.27e-24	Prudent dietary pattern;
THYM	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg08645402	chr16:4508243	NA	0.76	6.87	0.58	6.72e-10	Schizophrenia;
THYM	cis	rs7107174	0.892	rs2512534	chr11:77970039	T/A	cg02023728	chr11:77925099	USP35	0.69	6.19	0.54	1.55e-8	Testicular germ cell tumor;
THYM	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs2898681	0.618	rs7677726	chr4:53739262	A/G	cg03786743	chr4:53727781	RASL11B	-0.57	-5.25	-0.47	9.41e-7	Optic nerve measurement (cup area);
THYM	cis	rs289828	0.524	rs13020962	chr2:152123543	G/A	cg05960677	chr2:152117363	RBM43	0.76	8.12	0.64	1.65e-12	Blood protein levels;
THYM	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg06558623	chr16:89946397	TCF25	1.51	8.29	0.65	7.35e-13	Skin colour saturation;
THYM	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg25072359	chr17:41440525	NA	0.72	4.89	0.45	4.03e-6	Menopause (age at onset);
THYM	cis	rs924712	0.584	rs10948867	chr6:54737821	T/A	cg04690482	chr6:54711388	FAM83B	-0.45	-4.93	-0.45	3.47e-6	Breast cancer;
THYM	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg07234876	chr8:600039	NA	0.89	4.6	0.43	1.29e-5	IgG glycosylation;
THYM	cis	rs870825	0.616	rs6552810	chr4:185644143	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg07606381	chr6:8435919	SLC35B3	0.66	4.93	0.45	3.51e-6	Motion sickness;
THYM	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg14137381	chr5:502291	SLC9A3	-0.65	-4.52	-0.42	1.77e-5	Cystic fibrosis severity;
THYM	cis	rs1129187	0.818	rs9462858	chr6:42946490	C/A	cg19747945	chr6:42946146	PEX6	-0.35	-5.04	-0.46	2.2e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs76662990	0.561	rs73113473	chr5:73942728	G/A	cg13275603	chr5:73927487	ENC1	-0.77	-4.63	-0.43	1.17e-5	Residual cognition;
THYM	cis	rs6429082	0.818	rs167092	chr1:235642359	A/G	cg26050004	chr1:235667680	B3GALNT2	0.75	6.57	0.56	2.74e-9	Adiposity;
THYM	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg23356831	chr14:105996513	TMEM121	0.58	6.17	0.54	1.64e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs2836974	0.566	rs2249666	chr21:40719241	C/T	cg11890956	chr21:40555474	PSMG1	0.67	5.3	0.48	7.41e-7	Cognitive function;
THYM	cis	rs1847202	0.717	rs13063437	chr3:72952388	A/G	cg25664220	chr3:72788482	NA	-0.65	-4.83	-0.44	5.21e-6	Motion sickness;
THYM	cis	rs2456568	0.802	rs10765640	chr11:93636462	C/T	cg26875233	chr11:93583750	C11orf90	-0.53	-5.53	-0.49	2.75e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg09184832	chr6:79620586	NA	-0.57	-4.45	-0.42	2.3e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6500395	1.000	rs7206647	chr16:48709220	G/C	cg04672837	chr16:48644449	N4BP1	-0.52	-5.09	-0.46	1.77e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2448490	0.629	rs7395672	chr11:65488982	G/A	cg27068330	chr11:65405492	SIPA1	0.76	6.21	0.54	1.39e-8	Platelet count;
THYM	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg16928487	chr17:17741425	SREBF1	-0.56	-5.55	-0.49	2.61e-7	Total body bone mineral density;
THYM	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg13695892	chr22:41940480	POLR3H	1.07	7.58	0.61	2.32e-11	Vitiligo;
THYM	cis	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg06521331	chr12:34319734	NA	-0.99	-9.11	-0.68	1.32e-14	Morning vs. evening chronotype;
THYM	cis	rs490234	0.812	rs2900229	chr9:128466312	A/G	cg14078157	chr9:128172775	NA	-0.66	-5.08	-0.46	1.86e-6	Mean arterial pressure;
THYM	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg05425664	chr17:57184151	TRIM37	-0.54	-4.49	-0.42	1.98e-5	Intelligence (multi-trait analysis);
THYM	cis	rs79349575	0.749	rs318093	chr17:46989354	A/G	cg26022315	chr17:47021804	SNF8	0.49	4.58	0.43	1.4e-5	Type 2 diabetes;
THYM	cis	rs1933112	1.000	rs1933109	chr1:168523624	C/G	cg17186328	chr1:168545835	XCL1	-0.55	-4.59	-0.43	1.37e-5	Blood protein levels;
THYM	trans	rs1974653	0.672	rs28610569	chr22:20071351	A/G	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg20295408	chr7:1910781	MAD1L1	-0.65	-4.85	-0.45	4.9e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs7590720	1.000	rs4674058	chr2:216909368	A/G	cg12620499	chr2:216877984	MREG	0.81	5.52	0.49	2.88e-7	Alcohol dependence;
THYM	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs6570726	0.791	rs365869	chr6:145884751	C/T	cg13319975	chr6:146136371	FBXO30	-0.64	-5.22	-0.47	1.06e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14893161	chr1:205819251	PM20D1	0.82	8.14	0.64	1.56e-12	Monocyte percentage of white cells;
THYM	cis	rs2562152	0.613	rs216599	chr16:109671	A/G	cg02949481	chr16:131562	MPG	0.75	4.7	0.43	8.82e-6	Glioblastoma;
THYM	cis	rs11039798	0.698	rs76315297	chr11:48240475	T/C	cg24672777	chr11:48374446	OR4C45	-1.14	-6.78	-0.57	1e-9	Axial length;
THYM	cis	rs28595532	0.920	rs116516492	chr4:119734247	C/G	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs9658691	0.607	rs9658750	chr10:90766596	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.88	-5.87	-0.52	6.48e-8	Mosquito bite size;
THYM	cis	rs7524258	0.868	rs1304712	chr1:7270538	C/T	cg07173049	chr1:7289937	CAMTA1	0.6	4.78	0.44	6.27e-6	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs9443645	0.589	rs6938951	chr6:79477620	A/C	cg05283184	chr6:79620031	NA	-0.61	-4.89	-0.45	4.09e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs2219968	0.781	rs11783145	chr8:78958614	C/G	cg00738934	chr8:78996279	NA	0.86	7.7	0.62	1.3e-11	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg16586182	chr3:47516702	SCAP	-0.63	-5.25	-0.47	9.07e-7	Colorectal cancer;
THYM	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg22920501	chr2:26401640	FAM59B	-0.71	-6.33	-0.54	7.92e-9	Gut microbiome composition (summer);
THYM	cis	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg13443165	chr9:33130375	B4GALT1	-0.86	-7.83	-0.63	6.91e-12	IgG glycosylation;
THYM	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg14893161	chr1:205819251	PM20D1	-0.63	-5.04	-0.46	2.24e-6	Menarche (age at onset);
THYM	cis	rs3126085	0.935	rs2152862	chr1:152259742	T/C	cg10321714	chr1:152280068	FLG	-0.64	-4.81	-0.44	5.57e-6	Atopic dermatitis;
THYM	cis	rs17102423	0.531	rs2763888	chr14:65571493	T/C	cg11161011	chr14:65562177	MAX	-0.7	-5.67	-0.5	1.52e-7	Obesity-related traits;
THYM	cis	rs4930103	0.935	rs11042170	chr11:2021625	C/T	cg06197492	chr11:2016605	H19	0.63	5.48	0.49	3.56e-7	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs7177699	0.581	rs7181432	chr15:79123779	C/T	cg00540400	chr15:79124168	NA	0.65	7.03	0.58	3.16e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs62103177	0.564	rs59188178	chr18:77723435	T/C	cg02751453	chr18:77725136	HSBP1L1	-0.61	-4.96	-0.45	3.05e-6	Opioid sensitivity;
THYM	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg09455208	chr3:40491958	NA	-0.45	-4.68	-0.43	9.54e-6	Renal cell carcinoma;
THYM	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg12379764	chr21:47803548	PCNT	-0.83	-5.37	-0.48	5.52e-7	Testicular germ cell tumor;
THYM	cis	rs10489525	0.550	rs6659415	chr1:115632211	C/T	cg01522456	chr1:115632236	TSPAN2	0.87	5.76	0.51	1.05e-7	Autism;
THYM	cis	rs9938149	0.736	rs7501109	chr16:88320862	C/G	cg09385650	chr16:88018033	BANP	0.26	4.74	0.44	7.63e-6	Corneal structure;Central corneal thickness;
THYM	cis	rs12410462	0.681	rs79461024	chr1:227568783	G/T	cg04117972	chr1:227635322	NA	0.8	4.82	0.44	5.36e-6	Major depressive disorder;
THYM	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg10802521	chr3:52805072	NEK4	-0.71	-5.96	-0.52	4.22e-8	Bipolar disorder;
THYM	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg01831904	chr17:28903510	LRRC37B2	-1.13	-5.5	-0.49	3.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg24733560	chr20:60626293	TAF4	0.62	6.64	0.56	1.96e-9	Body mass index;
THYM	cis	rs7103648	0.669	rs11039332	chr11:47695840	G/A	cg20307385	chr11:47447363	PSMC3	0.83	6.6	0.56	2.29e-9	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs7258015	1.000	rs7258015	chr19:10449358	T/C	cg01466491	chr19:10523363	NA	0.69	5.43	0.49	4.24e-7	Systemic lupus erythematosus or rheumatoid arthritis;
THYM	cis	rs10411161	0.702	rs11879336	chr19:52389627	C/T	cg25361850	chr19:52391789	ZNF577	0.84	5.4	0.48	4.89e-7	Breast cancer;
THYM	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.11	-10.66	-0.74	6.57e-18	Primary sclerosing cholangitis;
THYM	cis	rs3925075	0.966	rs11645917	chr16:31359826	C/T	cg02846316	chr16:31340340	ITGAM	0.59	6.12	0.53	2.13e-8	IgA nephropathy;
THYM	cis	rs854765	0.693	rs4924823	chr17:17764502	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-6.77	-0.57	1.08e-9	Total body bone mineral density;
THYM	cis	rs8014204	0.533	rs12434646	chr14:75178693	C/T	cg06637938	chr14:75390232	RPS6KL1	0.57	5.06	0.46	2.02e-6	Caffeine consumption;
THYM	cis	rs3008870	1.000	rs1925408	chr1:67365034	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	7.46	0.61	4e-11	Lymphocyte percentage of white cells;
THYM	cis	rs7487075	0.780	rs12307969	chr12:46759057	G/C	cg11146691	chr12:47219737	SLC38A4	0.47	4.61	0.43	1.24e-5	Itch intensity from mosquito bite;
THYM	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg22709100	chr7:91322751	NA	-0.6	-4.8	-0.44	5.84e-6	Breast cancer;
THYM	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.62e-15	Intelligence (multi-trait analysis);
THYM	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg18252515	chr7:66147081	NA	-0.71	-5.67	-0.5	1.56e-7	Aortic root size;
THYM	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg24531977	chr5:56204891	C5orf35	-1.0	-8.23	-0.65	9.77e-13	Initial pursuit acceleration;
THYM	cis	rs7107770	1.000	rs34140247	chr11:125092360	G/A	cg04164023	chr11:125106101	PKNOX2	-0.81	-4.62	-0.43	1.2e-5	Photic sneeze reflex;
THYM	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4731207	0.698	rs10263573	chr7:124469267	A/T	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs3892630	0.878	rs66788054	chr19:33190146	G/T	cg22980127	chr19:33182716	NUDT19	1.16	9.57	0.7	1.35e-15	Red blood cell traits;
THYM	cis	rs6842789	0.545	rs12642448	chr4:124921046	T/C	cg01723706	chr4:124814442	LOC285419	0.8	4.76	0.44	6.95e-6	Neuroticism;
THYM	cis	rs1971762	0.522	rs10747680	chr12:54077776	T/G	cg16917193	chr12:54089295	NA	0.9	9.22	0.69	7.82e-15	Height;
THYM	cis	rs554111	0.656	rs12021529	chr1:21306161	C/T	cg01072550	chr1:21505969	NA	-0.6	-5.34	-0.48	6.45e-7	Facial morphology (factor 17, height of vermillion upper lip);
THYM	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg16414030	chr3:133502952	NA	-0.83	-8.16	-0.64	1.38e-12	Iron status biomarkers;
THYM	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.68	5.01	0.46	2.48e-6	Tonsillectomy;
THYM	cis	rs7567851	0.623	rs1982130	chr2:178945786	C/T	cg17320194	chr2:178042734	NA	-0.8	-4.45	-0.42	2.36e-5	Height;
THYM	cis	rs56104184	0.830	rs28556985	chr19:49351149	C/T	cg19024700	chr19:49340765	PLEKHA4;HSD17B14	0.71	4.95	0.45	3.25e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs9682041	1.000	rs57508070	chr3:170074374	C/A	cg21474897	chr3:170136489	CLDN11	-0.98	-4.62	-0.43	1.2e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs73198271	0.960	rs73198288	chr8:8613940	G/A	cg06636001	chr8:8085503	FLJ10661	-0.71	-4.48	-0.42	2.04e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs11030122	0.702	rs1349583	chr11:3972236	G/A	cg18678763	chr11:4115507	RRM1	-0.44	-5.73	-0.51	1.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs752010	0.967	rs6681441	chr1:42098321	G/A	cg22486000	chr1:42919398	ZMYND12	-0.43	-4.86	-0.45	4.67e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs4849845	0.889	rs2289172	chr2:121046116	C/G	cg03575764	chr2:121493832	NA	0.64	4.79	0.44	6.06e-6	Mean platelet volume;
THYM	cis	rs4731207	0.596	rs7799523	chr7:124592033	C/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs9790314	1.000	rs336570	chr3:161072054	A/G	cg03342759	chr3:160939853	NMD3	0.75	6.64	0.56	1.95e-9	Morning vs. evening chronotype;
THYM	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg25282410	chr6:160211355	TCP1;MRPL18	1.04	8.6	0.66	1.64e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.07	9.37	0.69	3.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg08807101	chr21:30365312	RNF160	-0.92	-7.74	-0.62	1.05e-11	Dental caries;
THYM	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	7.46	0.61	4.05e-11	Lung cancer in ever smokers;
THYM	cis	rs28647808	0.881	rs28494844	chr9:136266188	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs6430585	0.583	rs59213715	chr2:136646582	A/C	cg20242066	chr2:136595261	LCT	0.56	5.16	0.47	1.38e-6	Corneal structure;
THYM	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.18	9.42	0.7	2.82e-15	Cognitive test performance;
THYM	cis	rs12935418	0.552	rs2602448	chr16:81022672	G/A	cg16651780	chr16:81037892	C16orf61	-0.82	-6.37	-0.55	6.81e-9	Mean corpuscular volume;
THYM	cis	rs7666738	0.785	rs11097614	chr4:99092175	G/C	cg10515332	chr4:99064459	C4orf37	0.66	4.85	0.45	4.73e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg14779329	chr11:130786720	SNX19	-0.52	-5.71	-0.51	1.26e-7	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg12386194	chr3:101231763	SENP7	0.66	5.0	0.46	2.59e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.73	-4.82	-0.44	5.35e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs904251	0.828	rs1757178	chr6:37486310	C/T	cg01843034	chr6:37503916	NA	0.65	5.04	0.46	2.25e-6	Cognitive performance;
THYM	cis	rs3008870	0.755	rs1121824	chr1:67475616	C/A	cg08660285	chr1:67390436	MIER1;WDR78	0.79	6.84	0.57	7.8e-10	Lymphocyte percentage of white cells;
THYM	cis	rs600806	0.850	rs4970751	chr1:109896600	A/C	cg23032129	chr1:109941072	SORT1	-0.57	-4.83	-0.44	5.22e-6	Intelligence (multi-trait analysis);
THYM	cis	rs678069	0.681	rs1521350	chr12:53157860	A/G	cg15260268	chr12:53613892	RARG	-1.33	-4.47	-0.42	2.17e-5	Electrodermal activity;
THYM	cis	rs9790314	0.871	rs339114	chr3:161109220	C/T	cg03342759	chr3:160939853	NMD3	0.82	7.54	0.61	2.76e-11	Morning vs. evening chronotype;
THYM	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.78	7.55	0.61	2.65e-11	Menarche (age at onset);
THYM	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg13114125	chr14:105738426	BRF1	-0.74	-5.78	-0.51	9.57e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs476633	0.708	rs9888708	chr15:41446030	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.69	-5.4	-0.48	4.82e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs6980334	0.680	rs10244249	chr7:137790650	A/C	cg06915773	chr7:137028165	PTN	0.58	4.74	0.44	7.59e-6	Blood metabolite ratios;
THYM	cis	rs7927771	0.524	rs7936948	chr11:47704200	T/G	cg20307385	chr11:47447363	PSMC3	0.6	4.51	0.42	1.87e-5	Subjective well-being;
THYM	cis	rs4478037	0.558	rs72854778	chr3:33071945	G/T	cg19404215	chr3:33155277	CRTAP	1.13	5.98	0.52	3.85e-8	Major depressive disorder;
THYM	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg19761014	chr17:28927070	LRRC37B2	0.85	4.9	0.45	3.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6032067	0.777	rs34916007	chr20:43782952	T/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.75	-8.27	-0.65	8.18e-13	Blood protein levels;
THYM	cis	rs9311676	0.656	rs11721168	chr3:58408679	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.56	-5.25	-0.47	9.33e-7	Lymphocyte counts;
THYM	cis	rs911263	0.961	rs17105278	chr14:68728479	T/C	cg18825221	chr14:68749962	RAD51L1	-0.59	-6.28	-0.54	1.01e-8	Primary biliary cholangitis;
THYM	cis	rs4654899	0.758	rs12402486	chr1:21447935	A/G	cg01072550	chr1:21505969	NA	0.79	7.73	0.62	1.11e-11	Superior frontal gyrus grey matter volume;
THYM	cis	rs7666738	0.606	rs3846446	chr4:99099768	C/A	cg24818145	chr4:99064322	C4orf37	0.64	5.0	0.46	2.65e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs654384	0.778	rs2342506	chr7:4176234	G/A	cg04612959	chr7:4183976	SDK1	0.56	4.97	0.45	2.93e-6	Positive affect;
THYM	cis	rs7226229	1.000	rs2054463	chr17:20919705	G/C	cg21263980	chr17:20946333	USP22	0.68	4.97	0.45	2.98e-6	Blood trace element (Se levels);
THYM	cis	rs2133450	0.712	rs1546235	chr3:7366864	T/A	cg19930620	chr3:7340148	GRM7	-0.48	-4.49	-0.42	1.98e-5	Early response to risperidone in schizophrenia;
THYM	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.7	-5.63	-0.5	1.84e-7	Tonsillectomy;
THYM	cis	rs9905704	0.846	rs28363318	chr17:56798207	T/C	cg12560992	chr17:57184187	TRIM37	0.64	4.46	0.42	2.28e-5	Testicular germ cell tumor;
THYM	cis	rs13315871	0.929	rs76226186	chr3:58318499	C/T	cg12435725	chr3:58293450	RPP14	-0.53	-5.51	-0.49	3.09e-7	Cholesterol, total;
THYM	cis	rs6700896	0.966	rs3790439	chr1:66085574	T/A	cg04111102	chr1:66153794	NA	0.53	4.64	0.43	1.12e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs6992848	0.759	rs4736021	chr8:141173692	G/A	cg22504031	chr8:141147661	TRAPPC9	0.64	4.95	0.45	3.19e-6	Response to amphetamines;
THYM	cis	rs9527	0.545	rs10218853	chr10:104796787	A/C	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg12893697	chr11:970389	AP2A2	-0.32	-5.35	-0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	trans	rs10802346	0.545	rs10924545	chr1:246364592	C/T	cg22732515	chr19:44031385	ETHE1	-1.0	-8.82	-0.67	5.62e-14	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs4746818	1.000	rs10823301	chr10:70885875	G/A	cg04149295	chr10:70884716	VPS26A	0.79	5.38	0.48	5.4e-7	Left atrial antero-posterior diameter;
THYM	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg09354556	chr3:47051341	NA	0.45	4.63	0.43	1.14e-5	Colorectal cancer;
THYM	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg02725872	chr8:58115012	NA	-1.09	-8.15	-0.64	1.43e-12	Developmental language disorder (linguistic errors);
THYM	cis	rs728616	0.867	rs61859766	chr10:81683040	G/A	cg05935833	chr10:81318306	SFTPA2	-0.78	-4.84	-0.45	4.92e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4372836	0.729	rs4611608	chr2:29064536	A/G	cg09522027	chr2:28974177	PPP1CB	0.66	5.08	0.46	1.89e-6	Body mass index;
THYM	cis	rs6700896	0.966	rs12067936	chr1:66088701	C/A	cg04111102	chr1:66153794	NA	0.53	4.64	0.43	1.12e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7584330	0.554	rs77194105	chr2:238436463	T/C	cg14458575	chr2:238380390	NA	1.03	5.54	0.49	2.71e-7	Prostate cancer;
THYM	cis	rs13126513	0.708	rs4699383	chr4:100467011	G/T	cg05468953	chr4:100565104	NA	-0.66	-6.14	-0.53	1.95e-8	Metabolite levels (MHPG);
THYM	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg12560992	chr17:57184187	TRIM37	-0.84	-7.36	-0.6	6.45e-11	Intelligence (multi-trait analysis);
THYM	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg06873352	chr17:61820015	STRADA	0.76	9.5	0.7	1.96e-15	Prudent dietary pattern;
THYM	cis	rs4601821	0.522	rs754672	chr11:113249136	C/T	cg14159747	chr11:113255604	NA	0.37	8.34	0.65	5.71e-13	Alcoholic chronic pancreatitis;
THYM	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs12817549	0.754	rs10859577	chr12:94175049	G/A	cg19571390	chr12:94157676	CRADD	0.55	4.61	0.43	1.26e-5	Hip circumference adjusted for BMI;
THYM	cis	rs6032067	0.852	rs17333103	chr20:43803613	C/T	cg20256260	chr20:43936981	MATN4;RBPJL	-0.73	-6.93	-0.58	5.03e-10	Blood protein levels;
THYM	cis	rs17125944	0.615	rs11629431	chr14:53320528	C/G	cg00686598	chr14:53173677	PSMC6	-1.07	-5.06	-0.46	2.07e-6	Alzheimer's disease (late onset);
THYM	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg11266682	chr4:10021025	SLC2A9	0.73	11.88	0.77	1.74e-20	Bone mineral density;
THYM	cis	rs7084402	0.967	rs1582827	chr10:60297102	T/C	cg09696939	chr10:60272079	BICC1	-0.47	-5.54	-0.49	2.65e-7	Refractive error;
THYM	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg25358565	chr5:93447407	FAM172A	1.36	10.75	0.74	4.11e-18	Diabetic retinopathy;
THYM	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg12826209	chr6:26865740	GUSBL1	0.84	6.07	0.53	2.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7084402	0.934	rs1658441	chr10:60323021	G/C	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg03806693	chr22:41940476	POLR3H	1.04	7.93	0.63	4.21e-12	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs2274459	0.841	rs2281918	chr6:33663055	G/A	cg06253072	chr6:33679850	C6orf125	0.49	4.9	0.45	3.87e-6	Obesity (extreme);
THYM	cis	rs240764	0.658	rs11155618	chr6:101181811	C/T	cg21058520	chr6:100914733	NA	0.56	4.91	0.45	3.8e-6	Neuroticism;
THYM	cis	rs4343996	0.727	rs10951159	chr7:3370465	G/T	cg21248987	chr7:3385318	SDK1	-0.38	-4.59	-0.43	1.35e-5	Motion sickness;
THYM	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg24308560	chr3:49941425	MST1R	0.79	6.93	0.58	5.04e-10	Intelligence (multi-trait analysis);
THYM	cis	rs11711311	1.000	rs2305546	chr3:113503354	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.61	-5.45	-0.49	4.02e-7	IgG glycosylation;
THYM	cis	rs8067545	0.611	rs2703795	chr17:20077141	C/A	cg20830565	chr17:20408647	MGC102966	0.48	4.45	0.42	2.3e-5	Schizophrenia;
THYM	cis	rs7582180	0.663	rs6542930	chr2:100944383	T/A	cg14675211	chr2:100938903	LONRF2	0.7	7.34	0.6	7.33e-11	Intelligence (multi-trait analysis);
THYM	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg04398451	chr17:18023971	MYO15A	0.92	8.33	0.65	6.12e-13	Total body bone mineral density;
THYM	cis	rs11776767	0.865	rs2409650	chr8:10690638	G/C	cg13457217	chr8:10683266	MIR1322;PINX1	-0.67	-5.02	-0.46	2.39e-6	Triglycerides;
THYM	cis	rs6748734	0.625	rs9288743	chr2:241821569	C/G	cg09990169	chr2:241835740	C2orf54	-0.31	-5.15	-0.47	1.43e-6	Urinary metabolites;
THYM	cis	rs3772130	0.923	rs3805127	chr3:121556751	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.78	4.92	0.45	3.65e-6	Cognitive performance;
THYM	cis	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg06521331	chr12:34319734	NA	-0.99	-8.73	-0.67	8.61e-14	Morning vs. evening chronotype;
THYM	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs7100689	0.646	rs2994390	chr10:82074395	C/A	cg01528321	chr10:82214614	TSPAN14	0.74	5.84	0.51	7.28e-8	Post bronchodilator FEV1;
THYM	cis	rs1784581	0.588	rs9355971	chr6:162421242	A/G	cg17173639	chr6:162384350	PARK2	0.81	7.48	0.61	3.75e-11	Itch intensity from mosquito bite;
THYM	cis	rs57920188	0.584	rs10915657	chr1:4092904	T/C	cg20703997	chr1:4087676	NA	0.74	5.2	0.47	1.13e-6	Interleukin-17 levels;
THYM	cis	rs6964587	0.621	rs39744	chr7:92043016	A/G	cg17063962	chr7:91808500	NA	0.83	7.03	0.58	3.16e-10	Breast cancer;
THYM	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.54	5.99	0.52	3.79e-8	Schizophrenia;
THYM	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg25036284	chr2:26402008	FAM59B	-0.74	-4.87	-0.45	4.39e-6	Gut microbiome composition (summer);
THYM	cis	rs10231759	0.530	rs741065	chr7:150500576	A/G	cg10409299	chr7:150498843	TMEM176B;TMEM176A	0.53	4.48	0.42	2.1e-5	Height;
THYM	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg12179176	chr11:130786555	SNX19	0.8	7.16	0.59	1.69e-10	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg18811423	chr2:55921094	PNPT1	0.73	6.99	0.58	3.79e-10	Metabolic syndrome;
THYM	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg10523679	chr1:76189770	ACADM	-0.86	-7.5	-0.61	3.3e-11	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9902453	0.765	rs8071576	chr17:28188554	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.81	6.22	0.54	1.35e-8	Coffee consumption (cups per day);
THYM	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs986417	0.901	rs1955690	chr14:61000492	A/G	cg27398547	chr14:60952738	C14orf39	-1.17	-6.74	-0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg15997130	chr1:24165203	NA	-0.77	-7.11	-0.59	2.15e-10	Immature fraction of reticulocytes;
THYM	cis	rs1957429	0.808	rs7144718	chr14:65333831	G/A	cg23373153	chr14:65346875	NA	0.91	4.92	0.45	3.69e-6	Pediatric areal bone mineral density (radius);
THYM	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg09549813	chr16:4587862	C16orf5	-0.6	-5.86	-0.52	6.52e-8	Schizophrenia;
THYM	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg06074448	chr4:187884817	NA	-1.01	-13.61	-0.81	4.75e-24	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7119	0.717	rs12898281	chr15:77786903	C/T	cg10437265	chr15:77819839	NA	-0.56	-4.99	-0.46	2.78e-6	Type 2 diabetes;
THYM	cis	rs2108225	1.000	rs989960	chr7:107445727	C/T	cg18560240	chr7:107437656	SLC26A3	-0.76	-5.52	-0.49	2.9e-7	Ulcerative colitis;
THYM	cis	rs6840360	0.615	rs66852535	chr4:152472227	C/A	cg22705602	chr4:152727874	NA	-0.71	-7.94	-0.63	4.03e-12	Intelligence (multi-trait analysis);
THYM	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg24006582	chr15:45444508	DUOX1	-0.83	-7.16	-0.59	1.7e-10	Uric acid levels;
THYM	cis	rs7177699	0.557	rs12442476	chr15:79117856	G/A	cg15571903	chr15:79123663	NA	0.58	6.75	0.57	1.15e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg19761014	chr17:28927070	LRRC37B2	0.85	4.9	0.45	3.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs362272	0.545	rs2749782	chr4:3339761	A/G	cg22655196	chr4:3374909	RGS12	0.6	7.28	0.6	9.44e-11	Serum sulfate level;
THYM	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg06238570	chr21:40685208	BRWD1	-0.71	-6.0	-0.52	3.63e-8	Menarche (age at onset);
THYM	cis	rs9364687	0.664	rs9364691	chr6:163947424	G/A	cg01639524	chr6:163818125	NA	0.49	4.86	0.45	4.7e-6	Body mass index;
THYM	cis	rs4282339	0.794	rs2974430	chr5:168267676	A/G	cg18364770	chr5:168310523	SLIT3	0.38	5.08	0.46	1.85e-6	Height;
THYM	cis	rs2070488	0.965	rs9877282	chr3:38541452	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.92	-6.89	-0.58	5.96e-10	Electrocardiographic conduction measures;
THYM	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg18538332	chr22:24372958	LOC391322	-1.05	-13.05	-0.8	6.64e-23	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3857067	0.806	rs2865343	chr4:95103005	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.47	-0.42	2.13e-5	QT interval;
THYM	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg00071950	chr4:10020882	SLC2A9	0.86	10.33	0.73	3.3e-17	Bone mineral density;
THYM	cis	rs11779988	0.543	rs379066	chr8:17881835	T/C	cg01800426	chr8:17659068	MTUS1	-0.65	-4.74	-0.44	7.44e-6	Breast cancer;
THYM	cis	rs995000	0.868	rs1168002	chr1:62934308	A/G	cg06896770	chr1:63153194	DOCK7	-0.9	-7.14	-0.59	1.85e-10	Triglyceride levels;
THYM	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg05294307	chr14:35346193	BAZ1A	-0.85	-5.94	-0.52	4.75e-8	Psoriasis;
THYM	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg06009448	chr7:1102226	C7orf50	0.5	5.21	0.47	1.11e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.26	-9.1	-0.68	1.4e-14	Gut microbiome composition (summer);
THYM	cis	rs55728055	1.000	rs55728055	chr22:32093268	G/C	cg10537193	chr22:32026975	PISD	-0.89	-5.26	-0.47	8.91e-7	Age-related hearing impairment;
THYM	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg27170947	chr2:26402098	FAM59B	0.78	6.09	0.53	2.36e-8	Gut microbiome composition (summer);
THYM	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg27087555	chr16:88793112	FAM38A	-1.27	-7.88	-0.63	5.51e-12	Plateletcrit;
THYM	cis	rs1568889	0.838	rs3812738	chr11:28129982	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg03929089	chr4:120376271	NA	-0.94	-10.74	-0.74	4.27e-18	Coronary artery disease;
THYM	cis	rs7000551	0.778	rs2469760	chr8:22365945	A/G	cg12081754	chr8:22256438	SLC39A14	0.66	6.17	0.53	1.7e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7224737	1.000	rs9889618	chr17:40293467	C/T	cg20291162	chr17:40259547	DHX58	-0.69	-6.44	-0.55	4.96e-9	Fibrinogen levels;
THYM	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg11752832	chr7:134001865	SLC35B4	0.73	5.51	0.49	3.08e-7	Mean platelet volume;
THYM	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg06784218	chr1:46089804	CCDC17	-0.3	-4.64	-0.43	1.1e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7264396	0.887	rs2236161	chr20:34101631	C/A	cg26038318	chr20:34205095	SPAG4	0.53	4.45	0.42	2.33e-5	Total cholesterol levels;
THYM	cis	rs7567389	0.710	rs72848615	chr2:128133598	T/A	cg09760422	chr2:128146352	NA	0.4	4.51	0.42	1.83e-5	Self-rated health;
THYM	cis	rs7177699	0.557	rs8026598	chr15:79112938	A/G	cg15571903	chr15:79123663	NA	0.57	6.57	0.56	2.71e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg02725872	chr8:58115012	NA	-1.11	-8.56	-0.66	1.98e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	11.87	0.77	1.82e-20	Chronic sinus infection;
THYM	cis	rs13108904	0.521	rs11247998	chr4:1363602	T/C	cg20887711	chr4:1340912	KIAA1530	0.61	4.77	0.44	6.7e-6	Obesity-related traits;
THYM	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2294693	0.945	rs68031000	chr6:41008841	G/T	cg21128951	chr6:40996213	UNC5CL	0.61	4.58	0.43	1.38e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs36051895	0.623	rs2146041	chr9:5262911	A/G	cg02405213	chr9:5042618	JAK2	-0.89	-8.57	-0.66	1.91e-13	Pediatric autoimmune diseases;
THYM	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg25427524	chr10:38739819	LOC399744	0.57	4.95	0.45	3.27e-6	Extrinsic epigenetic age acceleration;
THYM	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg09307838	chr4:120376055	NA	0.69	5.17	0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg00071950	chr4:10020882	SLC2A9	0.69	6.78	0.57	1.03e-9	Bone mineral density;
THYM	cis	rs7649443	0.959	rs6779689	chr3:197014173	T/C	cg20744464	chr3:196756875	MFI2	0.62	4.56	0.42	1.53e-5	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.92	8.1	0.64	1.84e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2456568	0.503	rs11020603	chr11:93667439	A/G	cg26875233	chr11:93583750	C11orf90	0.52	5.74	0.51	1.11e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs250677	0.522	rs919731	chr5:148352150	T/C	cg18129178	chr5:148520854	ABLIM3	0.69	5.06	0.46	2.05e-6	Breast cancer;
THYM	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg05347473	chr6:146136440	FBXO30	0.55	4.49	0.42	2.02e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg14779329	chr11:130786720	SNX19	0.47	4.94	0.45	3.41e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11030122	0.702	rs11030276	chr11:3946134	A/G	cg18678763	chr11:4115507	RRM1	-0.44	-5.73	-0.51	1.19e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg17554472	chr22:41940697	POLR3H	0.67	4.79	0.44	6.11e-6	Vitiligo;
THYM	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg16405210	chr4:1374714	KIAA1530	-1.11	-10.78	-0.74	3.66e-18	Longevity;
THYM	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg18512352	chr11:47633146	NA	-0.54	-7.07	-0.59	2.54e-10	Subjective well-being;
THYM	cis	rs78579285	0.510	rs78759106	chr16:88788535	T/C	cg04002220	chr16:89598305	SPG7	0.65	4.76	0.44	6.79e-6	Joint mobility (Beighton score);
THYM	cis	rs7937840	0.581	rs4963462	chr11:61886672	A/T	cg05871569	chr11:61891931	INCENP	-0.64	-4.9	-0.45	3.92e-6	Breast cancer;
THYM	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg24675658	chr1:53192096	ZYG11B	0.55	4.66	0.43	1.04e-5	Monocyte count;
THYM	trans	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.11e-8	Systolic blood pressure;
THYM	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg03433033	chr1:76189801	ACADM	0.79	11.21	0.75	4.52e-19	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06873352	chr17:61820015	STRADA	-0.54	-5.42	-0.49	4.56e-7	Height;
THYM	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11644478	chr21:40555479	PSMG1	1.11	10.07	0.72	1.16e-16	Cognitive function;
THYM	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg17366294	chr4:99064904	C4orf37	0.57	6.82	0.57	8.42e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4660306	1.000	rs1044717	chr1:45976587	A/G	cg03123370	chr1:45965343	CCDC163P;MMACHC	-0.67	-5.43	-0.49	4.37e-7	Homocysteine levels;
THYM	trans	rs4866334	1.000	rs76355495	chr5:18487262	G/A	cg08675002	chr5:90437527	GPR98	-1.55	-7.45	-0.61	4.32e-11	IgG glycosylation;
THYM	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg22655196	chr4:3374909	RGS12	0.65	7.71	0.62	1.25e-11	Serum sulfate level;
THYM	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg09904177	chr6:26538194	HMGN4	0.62	4.96	0.45	3.06e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06850241	chr22:41845214	NA	-0.59	-5.26	-0.47	8.86e-7	Vitiligo;
THYM	cis	rs9902453	1.000	rs8065059	chr17:28417376	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-4.97	-0.45	2.96e-6	Coffee consumption (cups per day);
THYM	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.61	7.75	0.62	1.01e-11	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg01097406	chr16:89675127	NA	0.53	4.76	0.44	6.95e-6	Hemoglobin concentration;
THYM	trans	rs8073060	0.544	rs225246	chr17:33944773	T/C	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs986417	0.901	rs9743622	chr14:61037163	A/T	cg27398547	chr14:60952738	C14orf39	1.21	6.17	0.53	1.69e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg11663144	chr21:46675770	NA	-0.71	-8.52	-0.66	2.34e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7152530	0.545	rs7160439	chr14:98637365	A/C	cg05180522	chr14:98101740	NA	-0.59	-4.7	-0.43	8.79e-6	Staphylococcus aureus infection;
THYM	cis	rs36051895	0.632	rs11788963	chr9:5120157	C/A	cg02405213	chr9:5042618	JAK2	-1.04	-11.53	-0.76	9.18e-20	Pediatric autoimmune diseases;
THYM	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg18876405	chr7:65276391	NA	0.63	5.53	0.49	2.83e-7	Aortic root size;
THYM	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.23	4.86	0.45	4.72e-6	Obesity-related traits;
THYM	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg11327659	chr7:150037044	RARRES2	0.42	4.97	0.45	2.94e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg04731861	chr2:219085781	ARPC2	-0.56	-5.31	-0.48	7.06e-7	Colorectal cancer;
THYM	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg20295408	chr7:1910781	MAD1L1	-0.61	-4.85	-0.45	4.9100000000000004e-06	Bipolar disorder and schizophrenia;
THYM	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.75	-5.5	-0.49	3.17e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs16912285	0.579	rs73438263	chr11:24265205	C/T	ch.11.24196551F	chr11:24239977	NA	0.93	4.93	0.45	3.48e-6	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg24692254	chr21:30365293	RNF160	0.66	4.81	0.44	5.71e-6	Selective IgA deficiency;
THYM	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg23260525	chr10:116636907	FAM160B1	0.53	5.45	0.49	3.95e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs58722170	0.627	rs12046650	chr1:38082123	C/T	cg17933807	chr1:38061675	GNL2	-0.9	-6.91	-0.58	5.62e-10	High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;
THYM	cis	rs1065852	0.526	rs9611711	chr22:42410695	G/A	cg09667013	chr22:42394590	WBP2NL	0.54	4.8	0.44	5.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs1403694	0.695	rs1851664	chr3:186436503	T/A	cg12454167	chr3:186435060	KNG1	0.53	7.54	0.61	2.83e-11	Blood protein levels;
THYM	cis	rs4749080	0.607	rs4749098	chr10:26483710	G/T	cg15678844	chr10:26500780	MYO3A	-0.67	-4.6	-0.43	1.28e-5	Obesity-related traits;
THYM	cis	rs9527	0.615	rs10883781	chr10:104581130	A/G	cg08772003	chr10:104629869	AS3MT	-0.63	-5.28	-0.48	8.1e-7	Arsenic metabolism;
THYM	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs2658782	1.000	rs2658781	chr11:93166368	C/T	cg16424440	chr11:93231842	C11orf75	0.73	4.59	0.43	1.34e-5	Pulmonary function decline;
THYM	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg02734326	chr4:10020555	SLC2A9	0.73	6.39	0.55	6.19e-9	Bone mineral density;
THYM	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg09549813	chr16:4587862	C16orf5	-0.48	-5.27	-0.48	8.56e-7	Schizophrenia;
THYM	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg27446573	chr6:127587934	RNF146	0.74	6.53	0.56	3.27e-9	Breast cancer;
THYM	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg24642439	chr20:33292090	TP53INP2	0.68	5.14	0.47	1.45e-6	Coronary artery disease;
THYM	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.77	5.6	0.5	2.09e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs791888	0.760	rs10788561	chr10:89423245	A/G	cg17916473	chr10:89419373	PAPSS2	0.44	4.68	0.43	9.68e-6	Magnesium levels;
THYM	cis	rs9913156	0.748	rs72835619	chr17:4557285	G/A	cg19197139	chr17:4613644	ARRB2	0.83	5.0	0.46	2.63e-6	Lymphocyte counts;
THYM	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg07169764	chr2:136633963	MCM6	-0.71	-6.27	-0.54	1.05e-8	Mosquito bite size;
THYM	cis	rs12519773	0.846	rs1496332	chr5:92439320	A/G	cg18783429	chr5:92414398	NA	0.48	4.55	0.42	1.59e-5	Migraine;
THYM	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg13695892	chr22:41940480	POLR3H	-1.02	-7.48	-0.61	3.69e-11	Vitiligo;
THYM	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg09021430	chr5:549028	NA	0.61	5.8	0.51	8.66e-8	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs9311676	0.594	rs55954186	chr3:58436476	G/A	cg26110898	chr3:58419937	PDHB	0.44	4.63	0.43	1.17e-5	Systemic lupus erythematosus;
THYM	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg01341218	chr17:43662625	NA	-1.07	-9.27	-0.69	5.9e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7586879	0.616	rs6545809	chr2:25126715	C/T	cg01884057	chr2:25150051	NA	0.73	7.9	0.63	4.81e-12	Body mass index;
THYM	cis	rs8180040	0.768	rs11915074	chr3:47309757	A/T	cg16586182	chr3:47516702	SCAP	0.69	6.0	0.52	3.63e-8	Colorectal cancer;
THYM	cis	rs11025559	0.716	rs1596376	chr11:20454229	T/C	cg19653624	chr11:20408972	PRMT3	-0.75	-5.24	-0.47	9.65e-7	Pursuit maintenance gain;
THYM	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg00256281	chr22:41985642	PMM1	0.64	5.02	0.46	2.42e-6	Vitiligo;
THYM	cis	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	-0.59	-6.1	-0.53	2.23e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-5.35	-0.48	5.98e-7	Lymphocyte counts;
THYM	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs7940866	0.809	rs2324317	chr11:130877142	T/C	cg05962950	chr11:130786565	SNX19	0.58	4.51	0.42	1.83e-5	Schizophrenia;
THYM	cis	rs2816062	0.721	rs2816047	chr1:18893728	A/C	cg18795169	chr1:18902165	NA	-0.98	-11.9	-0.77	1.55e-20	Urate levels in lean individuals;
THYM	cis	rs859767	0.887	rs859766	chr2:135342254	C/T	cg12500956	chr2:135428796	TMEM163	0.54	5.34	0.48	6.36e-7	Neuroticism;
THYM	cis	rs1005224	0.889	rs12717566	chr14:76147507	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.71	-5.83	-0.51	7.54e-8	Large artery stroke;
THYM	cis	rs883115	0.810	rs1932991	chr1:224783293	T/C	cg01808320	chr1:224927238	CNIH3	-0.52	-4.5	-0.42	1.9e-5	Cancer;
THYM	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg11125805	chr5:150678162	SLC36A3	0.58	7.9	0.63	4.92e-12	Skin aging (microtopography measurement);
THYM	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg19016782	chr12:123741754	C12orf65	-0.71	-4.66	-0.43	1.05e-5	Neutrophil percentage of white cells;
THYM	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4455778	0.538	rs4326333	chr7:49125565	A/T	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs7586673	0.930	rs6432667	chr2:161905001	T/C	cg22496339	chr2:162101262	NA	0.58	4.5	0.42	1.92e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg12350822	chr6:88032061	C6orf162;GJB7	0.58	8.04	0.64	2.52e-12	Monocyte percentage of white cells;
THYM	cis	rs11031096	0.655	rs56172516	chr11:4182004	G/T	cg08557956	chr11:4115526	RRM1	-0.52	-4.68	-0.43	9.36e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg06808227	chr14:105710500	BRF1	-1.03	-9.0	-0.68	2.32e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs13315871	1.000	rs11708590	chr3:58336635	A/G	cg12435725	chr3:58293450	RPP14	0.46	4.88	0.45	4.24e-6	Cholesterol, total;
THYM	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg19761014	chr17:28927070	LRRC37B2	0.89	5.28	0.48	8.14e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs427394	0.659	rs274725	chr5:6717408	C/G	cg10857441	chr5:6722123	POLS	-0.69	-7.44	-0.61	4.5e-11	Menopause (age at onset);
THYM	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg21138405	chr5:131827807	IRF1	0.83	9.49	0.7	2.08e-15	Asthma (sex interaction);
THYM	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg15247329	chr7:2764246	NA	-0.69	-5.68	-0.5	1.46e-7	Height;
THYM	cis	rs9554348	0.541	rs61966876	chr13:96937979	C/T	cg25169784	chr13:96706045	UGGT2	0.85	4.67	0.43	1e-5	Schizophrenia;
THYM	trans	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs11078597	0.731	rs12946666	chr17:1651304	C/G	cg18436246	chr17:1640651	WDR81	0.64	4.63	0.43	1.14e-5	Serum albumin level;
THYM	cis	rs1863824	0.625	rs7091192	chr10:88167456	A/G	cg06895675	chr10:88137553	NA	0.58	4.96	0.45	3.06e-6	Schizophrenia;
THYM	cis	rs9420	0.809	rs11600169	chr11:57464945	T/A	cg07694400	chr11:57308986	SMTNL1	-0.42	-4.5	-0.42	1.92e-5	Schizophrenia;
THYM	cis	rs1401999	0.807	rs9869029	chr3:183735286	C/G	cg01324343	chr3:183735012	ABCC5	0.86	12.94	0.8	1.09e-22	Anterior chamber depth;
THYM	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg06108461	chr20:60628389	TAF4	-0.81	-6.74	-0.57	1.22e-9	Body mass index;
THYM	cis	rs28595532	0.920	rs116108618	chr4:119763585	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg00908189	chr16:619842	PIGQ	1.05	9.25	0.69	6.62e-15	Height;
THYM	cis	rs12142240	0.698	rs6703669	chr1:46862555	C/T	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	trans	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg07211511	chr3:129823064	LOC729375	-1.32	-9.5	-0.7	1.89e-15	Blood pressure (smoking interaction);
THYM	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	7.66	0.62	1.54e-11	Platelet count;
THYM	cis	rs9479482	1.000	rs5006620	chr6:150336665	C/T	cg25797454	chr6:150327115	RAET1K	0.45	4.79	0.44	6.19e-6	Alopecia areata;
THYM	cis	rs12410462	1.000	rs12410243	chr1:227669474	A/G	cg23173402	chr1:227635558	NA	0.67	5.94	0.52	4.59e-8	Major depressive disorder;
THYM	cis	rs9467711	0.651	rs66790453	chr6:26107088	C/T	cg01386294	chr6:25732093	NA	0.9	4.88	0.45	4.34e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7572733	0.534	rs700662	chr2:198668751	T/C	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg13289132	chr10:30722225	MAP3K8	-0.66	-5.44	-0.49	4.06e-7	Inflammatory bowel disease;
THYM	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg18252515	chr7:66147081	NA	1.41	8.25	0.65	8.89e-13	Diabetic kidney disease;
THYM	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg15744692	chr15:45671195	LOC145663;GATM	0.45	4.48	0.42	2.08e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs2241584	0.967	rs9313736	chr5:175948316	A/G	cg02270010	chr5:175958651	RNF44	0.3	4.59	0.43	1.36e-5	Menopause (age at onset);
THYM	cis	rs854765	0.624	rs1889018	chr17:17734740	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.65	-5.45	-0.49	3.94e-7	Total body bone mineral density;
THYM	cis	rs6964587	0.626	rs2269810	chr7:91508837	T/C	cg17063962	chr7:91808500	NA	-0.99	-8.38	-0.65	4.64e-13	Breast cancer;
THYM	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22496380	chr5:211416	CCDC127	-1.32	-7.26	-0.6	1.04e-10	Breast cancer;
THYM	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg00645579	chr11:617140	IRF7;MUPCDH	-0.47	-6.04	-0.53	3.05e-8	Systemic lupus erythematosus;
THYM	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg11245990	chr11:68621969	NA	0.56	7.23	0.6	1.2e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11723261	0.582	rs11733927	chr4:166828	A/G	cg12746427	chr4:53362	ZNF718;ZNF595	0.82	5.69	0.5	1.38e-7	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg18200150	chr17:30822561	MYO1D	0.82	7.09	0.59	2.35e-10	Schizophrenia;
THYM	cis	rs7917772	0.582	rs7899004	chr10:104341435	C/T	cg00122347	chr10:104236741	TMEM180	0.38	5.05	0.46	2.15e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg07460842	chr6:66804631	NA	0.97	6.01	0.52	3.49e-8	Exhaled nitric oxide levels;
THYM	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg13531842	chr10:38383804	ZNF37A	-0.54	-4.53	-0.42	1.73e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	7.49	0.61	3.58e-11	Smoking behavior;
THYM	cis	rs1915146	0.546	rs9422857	chr10:126861278	C/G	cg23000734	chr10:126850823	CTBP2	0.74	8.34	0.65	5.64e-13	Menarche (age at onset);
THYM	cis	rs240764	0.612	rs2157342	chr6:100920655	A/T	cg21058520	chr6:100914733	NA	-0.57	-4.95	-0.45	3.19e-6	Neuroticism;
THYM	cis	rs6570726	0.791	rs6914203	chr6:145899975	C/A	cg23711669	chr6:146136114	FBXO30	0.94	9.44	0.7	2.59e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4930103	0.564	rs1618613	chr11:1969888	G/A	cg18511798	chr11:2018149	H19;MIR675	0.51	5.08	0.46	1.9e-6	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12579753	0.879	rs10778828	chr12:82117216	C/A	cg07988820	chr12:82153109	PPFIA2	-0.8	-5.29	-0.48	7.83e-7	Resting heart rate;
THYM	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg13607699	chr17:42295918	UBTF	0.63	5.26	0.47	9.04e-7	Total body bone mineral density;
THYM	cis	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg07460842	chr6:66804631	NA	-0.82	-4.95	-0.45	3.26e-6	Exhaled nitric oxide output;
THYM	cis	rs12791968	1.000	rs1552301	chr11:45002551	A/G	cg11846598	chr11:44996168	LOC221122	-0.9	-7.55	-0.61	2.63e-11	Inhibitory control;
THYM	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg18252515	chr7:66147081	NA	-0.66	-4.91	-0.45	3.8e-6	Aortic root size;
THYM	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg17063962	chr7:91808500	NA	1.13	12.06	0.78	7.27e-21	Breast cancer;
THYM	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.9	-5.84	-0.51	7.37e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg12419862	chr22:24373484	LOC391322	-0.73	-6.63	-0.56	2.03e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	7.76	0.62	9.78e-12	Cognitive test performance;
THYM	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg20587970	chr11:113659929	NA	-1.37	-8.96	-0.68	2.79e-14	Hip circumference adjusted for BMI;
THYM	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg05368731	chr17:41323189	NBR1	1.25	11.4	0.76	1.72e-19	Menopause (age at onset);
THYM	cis	rs10191773	0.589	rs11691239	chr2:112950600	A/C	cg07905836	chr2:113190072	RGPD8;RGPD5	-0.78	-4.54	-0.42	1.67e-5	Yeast infection;
THYM	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg10515332	chr4:99064459	C4orf37	0.63	5.08	0.46	1.85e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.11	9.31	0.69	4.88e-15	Colorectal cancer;
THYM	cis	rs4455778	0.600	rs4461853	chr7:49090901	T/C	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs12956009	0.583	rs12960952	chr18:44857476	C/T	cg19077165	chr18:44547161	KATNAL2	-0.49	-4.57	-0.42	1.49e-5	Educational attainment (years of education);
THYM	cis	rs11722228	0.549	rs2241488	chr4:10101131	T/C	cg02317251	chr4:10116515	WDR1	-0.56	-4.95	-0.45	3.23e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg06521331	chr12:34319734	NA	-0.74	-5.73	-0.51	1.19e-7	Morning vs. evening chronotype;
THYM	cis	rs1395	0.710	rs11674947	chr2:27471996	A/G	cg23587288	chr2:27483067	SLC30A3	-0.65	-5.82	-0.51	7.88e-8	Blood metabolite levels;
THYM	cis	rs2251381	0.722	rs2776252	chr21:30531705	G/A	cg24692254	chr21:30365293	RNF160	0.66	4.76	0.44	7.01e-6	Selective IgA deficiency;
THYM	trans	rs3960554	0.740	rs10216079	chr7:75690988	A/C	cg19862616	chr7:65841803	NCRNA00174	0.93	6.95	0.58	4.6e-10	Eotaxin levels;
THYM	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg00631329	chr6:26305371	NA	0.61	7.35	0.6	6.77e-11	Educational attainment;
THYM	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg00173435	chr12:106696525	TCP11L2	-0.66	-4.47	-0.42	2.16e-5	Tourette syndrome;
THYM	cis	rs9653442	0.609	rs2576678	chr2:100704810	T/C	cg22139774	chr2:100720529	AFF3	-0.35	-5.44	-0.49	4.2e-7	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg02038168	chr22:39784481	NA	-0.64	-4.91	-0.45	3.75e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs2235649	0.833	rs9933168	chr16:1848361	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs1568889	0.838	rs11030206	chr11:28099747	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.83	6.88	0.58	6.44e-10	Bipolar disorder;
THYM	cis	rs11122895	1.000	rs11691123	chr2:112463110	A/C	cg23262488	chr2:112468472	NA	0.62	8.52	0.66	2.39e-13	Allergic sensitization;
THYM	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg07936489	chr17:37558343	FBXL20	0.82	5.69	0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs10911232	0.524	rs4487994	chr1:182982173	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Hypertriglyceridemia;
THYM	cis	rs995000	0.509	rs912540	chr1:63135127	A/G	cg06896770	chr1:63153194	DOCK7	-0.96	-4.86	-0.45	4.57e-6	Triglyceride levels;
THYM	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg02269571	chr22:50332266	NA	-0.64	-4.83	-0.44	5.14e-6	Schizophrenia;
THYM	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg05043794	chr9:111880884	C9orf5	-0.43	-6.21	-0.54	1.39e-8	Menarche (age at onset);
THYM	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg06600287	chr1:53387719	ECHDC2	-0.38	-5.73	-0.51	1.17e-7	Monocyte count;
THYM	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg11366901	chr6:160182831	ACAT2	1.07	9.51	0.7	1.88e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs13082711	0.648	rs13085782	chr3:27404390	C/G	cg02860705	chr3:27208620	NA	1.05	7.4	0.6	5.51e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs1448094	0.512	rs61930862	chr12:86246567	A/G	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg02820040	chr2:241836501	C2orf54	-0.3	-5.52	-0.49	2.99e-7	Urinary metabolites;
THYM	cis	rs2235649	0.833	rs9929264	chr16:1851934	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs6539288	0.933	rs1822736	chr12:107309259	A/G	cg26297688	chr12:107349093	C12orf23	0.48	5.02	0.46	2.44e-6	Total body bone mineral density;
THYM	cis	rs17739167	0.550	rs6493014	chr15:42225008	A/G	cg20935245	chr15:42234343	EHD4	-0.38	-4.52	-0.42	1.76e-5	Monocyte count;
THYM	cis	rs7809950	0.817	rs58052742	chr7:107210003	A/G	cg23024343	chr7:107201750	COG5	1.03	8.94	0.68	3.03e-14	Coronary artery disease;
THYM	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg08807101	chr21:30365312	RNF160	0.94	7.6	0.62	2.04e-11	Dental caries;
THYM	cis	rs988913	1.000	rs9382402	chr6:54809493	C/T	cg19716238	chr6:54711378	FAM83B	0.49	5.07	0.46	1.99e-6	Menarche (age at onset);
THYM	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg04546413	chr19:29218101	NA	0.71	5.15	0.47	1.39e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg00814883	chr7:100076585	TSC22D4	-0.98	-6.58	-0.56	2.53e-9	Platelet count;
THYM	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg12179176	chr11:130786555	SNX19	0.89	8.25	0.65	8.93e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs73198271	0.740	rs10105920	chr8:8648737	A/G	cg06636001	chr8:8085503	FLJ10661	0.8	5.64	0.5	1.77e-7	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs3126085	0.935	rs3126091	chr1:152307338	T/C	cg26020982	chr1:152196106	HRNR	-0.39	-5.28	-0.48	8.24e-7	Atopic dermatitis;
THYM	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg10803722	chr21:46713166	LOC642852	-0.41	-5.11	-0.46	1.69e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4919694	1.000	rs76255497	chr10:104651955	T/C	cg04362960	chr10:104952993	NT5C2	1.06	6.74	0.57	1.22e-9	Arsenic metabolism;
THYM	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg03433033	chr1:76189801	ACADM	0.77	10.21	0.72	6.01e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9915657	0.870	rs12950966	chr17:70119245	C/G	cg06234051	chr17:70120541	SOX9	-0.75	-7.34	-0.6	7.09e-11	Thyroid hormone levels;
THYM	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg10523679	chr1:76189770	ACADM	0.89	8.55	0.66	2.05e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg05738196	chr6:26577821	NA	0.83	8.34	0.65	5.8e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4919044	0.808	rs9419763	chr10:94788965	G/A	cg05127821	chr10:94822908	CYP26C1	-1.32	-7.18	-0.59	1.51e-10	Coronary artery disease;
THYM	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg05775895	chr3:12838266	CAND2	1.03	10.19	0.72	6.35e-17	QRS complex (12-leadsum);
THYM	cis	rs55665837	1.000	rs10832257	chr11:14443316	A/G	cg19336497	chr11:14380999	RRAS2	-0.64	-7.05	-0.59	2.86e-10	Vitamin D levels;
THYM	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg24060327	chr5:131705240	SLC22A5	-0.73	-5.47	-0.49	3.61e-7	Blood metabolite levels;
THYM	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg15997130	chr1:24165203	NA	0.77	7.05	0.59	2.84e-10	Immature fraction of reticulocytes;
THYM	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg22025206	chr5:502436	SLC9A3	-0.54	-4.62	-0.43	1.22e-5	Cystic fibrosis severity;
THYM	cis	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg21775007	chr8:11205619	TDH	-0.73	-5.68	-0.5	1.49e-7	Retinal vascular caliber;
THYM	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs7719624	0.967	rs34098140	chr5:135362550	T/C	cg15329133	chr5:135467951	SMAD5;SMAD5OS	0.55	4.71	0.44	8.41e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs2268241	0.877	rs17887186	chr21:34779202	G/A	cg14850771	chr21:34775459	IFNGR2	1.04	6.96	0.58	4.26e-10	Obesity-related traits;
THYM	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg27490568	chr2:178487706	NA	-0.67	-5.56	-0.5	2.42e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs289828	0.538	rs6705180	chr2:152157792	A/G	cg05960677	chr2:152117363	RBM43	0.69	6.56	0.56	2.86e-9	Blood protein levels;
THYM	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg04362960	chr10:104952993	NT5C2	0.58	4.68	0.43	9.68e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs960902	0.592	rs10199137	chr2:37735381	C/T	cg25341268	chr2:37734390	NA	-0.7	-6.43	-0.55	5.06e-9	Response to TNF-alpha inhibitors in rheumatoid arthritis;
THYM	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg12288994	chr5:1860383	NA	0.88	7.23	0.6	1.24e-10	Cardiovascular disease risk factors;
THYM	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.76	-4.73	-0.44	7.87e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2249694	1.000	rs2249695	chr10:135352168	T/C	cg20169779	chr10:135381914	SYCE1	0.57	4.53	0.42	1.71e-5	Obesity-related traits;
THYM	cis	rs6032067	1.000	rs2233896	chr20:43850400	C/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.41	-0.55	5.57e-9	Blood protein levels;
THYM	cis	rs2276314	0.857	rs72883058	chr18:33612917	G/A	cg19628046	chr18:33552617	C18orf21	0.74	5.43	0.49	4.29e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg08564027	chr20:61660810	NA	0.92	9.77	0.71	5.02e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2066819	1.000	rs2643626	chr12:56726518	C/T	cg26714650	chr12:56694279	CS	1.34	7.72	0.62	1.17e-11	Psoriasis vulgaris;
THYM	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg24579218	chr15:68104479	NA	-0.83	-7.87	-0.63	5.69e-12	Restless legs syndrome;
THYM	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg19418458	chr7:158789849	NA	0.62	5.32	0.48	6.9e-7	Facial morphology (factor 20);
THYM	cis	rs4766646	0.619	rs4766639	chr12:110298925	A/G	cg10794374	chr12:110278745	NA	-0.22	-4.93	-0.45	3.43e-6	Metabolite levels (MHPG);
THYM	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.69	6.06	0.53	2.7e-8	Total body bone mineral density;
THYM	trans	rs7224737	0.750	rs731151	chr17:40279903	G/A	cg01049205	chr10:85997177	LRIT1	-1.08	-7.48	-0.61	3.67e-11	Fibrinogen levels;
THYM	cis	rs7078219	0.714	rs11190136	chr10:101287681	A/G	cg17888390	chr10:101282816	NA	-0.53	-5.14	-0.47	1.46e-6	Dental caries;
THYM	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg18512352	chr11:47633146	NA	-0.49	-5.98	-0.52	3.97e-8	Subjective well-being;
THYM	cis	rs13263959	0.523	rs10086771	chr8:142658923	G/T	cg24384331	chr8:142183860	DENND3	0.48	4.71	0.43	8.59e-6	Hair color;
THYM	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.84	-6.12	-0.53	2.12e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs7568458	0.905	rs6547620	chr2:85755928	C/T	cg17127132	chr2:85788382	GGCX	0.65	5.25	0.47	9.44e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs883565	0.792	rs784491	chr3:39174462	T/C	cg15678707	chr3:39149194	GORASP1;TTC21A	-0.67	-4.49	-0.42	1.97e-5	Handedness;
THYM	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg15838173	chr10:75533400	FUT11	0.54	5.46	0.49	3.8e-7	Inflammatory bowel disease;
THYM	trans	rs11722228	0.522	rs12503195	chr4:10082772	T/C	cg26043149	chr18:55253948	FECH	0.99	8.99	0.68	2.39e-14	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs2898681	0.519	rs7670068	chr4:53733984	T/G	cg21521518	chr4:53727714	RASL11B	0.49	4.51	0.42	1.82e-5	Optic nerve measurement (cup area);
THYM	cis	rs6138458	1.000	rs2387361	chr20:24899905	C/T	cg06937882	chr20:24974362	C20orf3	0.47	4.54	0.42	1.66e-5	Blood protein levels;
THYM	cis	rs2299587	0.560	rs12718385	chr8:17781257	T/C	cg01800426	chr8:17659068	MTUS1	-0.68	-5.17	-0.47	1.31e-6	Economic and political preferences;
THYM	cis	rs2085601	0.518	rs1060693	chr4:89944687	A/C	cg17769793	chr4:89976368	FAM13A	-0.53	-5.83	-0.51	7.75e-8	Hair greying;
THYM	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs6570726	0.935	rs419850	chr6:145827281	A/G	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4499344	0.664	rs4286210	chr19:33101221	T/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.61	0.62	2.02e-11	Mean platelet volume;
THYM	trans	rs4650994	0.507	rs56229230	chr1:178526563	G/A	cg05059571	chr16:84539110	KIAA1609	-0.93	-10.99	-0.75	1.27e-18	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg13010199	chr12:38710504	ALG10B	0.69	4.69	0.43	9.15e-6	Morning vs. evening chronotype;
THYM	cis	rs36051895	0.659	rs12339666	chr9:5063296	A/C	cg02405213	chr9:5042618	JAK2	1.02	10.03	0.72	1.43e-16	Pediatric autoimmune diseases;
THYM	cis	rs870825	0.616	rs2090589	chr4:185647731	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg14074117	chr16:1909714	C16orf73	-0.7	-4.45	-0.42	2.3e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg00495681	chr13:53174319	NA	0.84	8.67	0.66	1.17e-13	Lewy body disease;
THYM	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg02380750	chr20:61661411	NA	-0.64	-6.3	-0.54	9.29e-9	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg05802129	chr4:122689817	NA	-0.59	-4.65	-0.43	1.08e-5	Type 2 diabetes;
THYM	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.74	-0.44	7.41e-6	Eye color traits;
THYM	trans	rs75518195	0.543	rs17687721	chr4:64670507	C/T	cg14706739	chr8:21916355	EPB49	0.75	7.37	0.6	6.34e-11	Triptolide cytotoxicity;
THYM	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg02018176	chr4:1364513	KIAA1530	0.53	4.55	0.42	1.6e-5	Obesity-related traits;
THYM	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.74	5.42	0.49	4.51e-7	Height;
THYM	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg26513180	chr16:89883248	FANCA	0.74	7.34	0.6	7.27e-11	Vitiligo;
THYM	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.61	0.74	8.34e-18	Prudent dietary pattern;
THYM	cis	rs4243830	0.850	rs12563717	chr1:6599557	T/G	cg22792644	chr1:6614718	TAS1R1;NOL9	1.13	6.56	0.56	2.85e-9	Body mass index;
THYM	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg24257776	chr3:47051546	LOC100129354	0.41	4.8	0.44	5.81e-6	Colorectal cancer;
THYM	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg13852791	chr20:30311386	BCL2L1	0.75	5.6	0.5	2.1e-7	Mean corpuscular hemoglobin;
THYM	cis	rs9677476	0.689	rs55748426	chr2:232054897	G/C	cg23338755	chr2:231921595	PSMD1	0.73	5.43	0.49	4.37e-7	Food antigen IgG levels;
THYM	cis	rs6430585	0.528	rs309159	chr2:136684940	C/T	cg23851026	chr2:136556271	LCT	0.69	6.64	0.56	1.96e-9	Corneal structure;
THYM	cis	rs2502731	0.539	rs3003614	chr9:130994736	G/A	cg09976142	chr9:130955436	CIZ1	0.54	5.14	0.47	1.47e-6	Attention deficit hyperactivity disorder;
THYM	cis	rs12310956	0.532	rs6488187	chr12:33975029	C/T	cg10856724	chr12:34555212	NA	-0.75	-6.8	-0.57	9.1e-10	Morning vs. evening chronotype;
THYM	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg06238570	chr21:40685208	BRWD1	-0.69	-5.87	-0.52	6.38e-8	Menarche (age at onset);
THYM	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg17366294	chr4:99064904	C4orf37	0.56	6.72	0.57	1.31e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg22875332	chr1:76189707	ACADM	-0.74	-6.43	-0.55	5.04e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg23978390	chr7:1156363	C7orf50	0.68	5.28	0.48	8.11e-7	Longevity;Endometriosis;
THYM	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg15838173	chr10:75533400	FUT11	-0.62	-6.33	-0.54	8.17e-9	Inflammatory bowel disease;
THYM	cis	rs11690935	0.959	rs7562356	chr2:172626611	C/G	cg13550731	chr2:172543902	DYNC1I2	-0.82	-5.88	-0.52	6.17e-8	Schizophrenia;
THYM	cis	rs3772130	0.560	rs7649585	chr3:121562300	G/C	cg01951420	chr3:121553821	IQCB1;EAF2	0.86	7.17	0.59	1.63e-10	Cognitive performance;
THYM	cis	rs11654964	0.502	rs10491113	chr17:33004133	A/G	cg22228613	chr17:33904285	PEX12	-0.72	-4.61	-0.43	1.27e-5	Lobular breast cancer (menopausal hormone therapy interaction);
THYM	cis	rs7104764	1.000	rs9795476	chr11:235894	T/G	cg18336825	chr11:236787	PSMD13;SIRT3	1.11	9.81	0.71	4.22e-16	Menarche (age at onset);
THYM	cis	rs11771526	0.901	rs10264625	chr7:32304205	T/C	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs425277	0.561	rs925906	chr1:2044054	A/C	cg13918804	chr1:2043761	PRKCZ	0.91	9.16	0.68	1.06e-14	Height;
THYM	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs10799590	0.928	rs7521396	chr1:224828559	C/T	cg01808320	chr1:224927238	CNIH3	-0.54	-4.79	-0.44	6.21e-6	Opioid dependence;
THYM	cis	rs3087591	1.000	rs2107360	chr17:29697901	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.61	-5.18	-0.47	1.26e-6	Hip circumference;
THYM	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg25427524	chr10:38739819	LOC399744	-0.73	-6.77	-0.57	1.04e-9	Extrinsic epigenetic age acceleration;
THYM	cis	rs6960043	0.738	rs7798360	chr7:15055972	A/G	cg19272540	chr7:15055459	NA	0.5	5.47	0.49	3.7e-7	Type 2 diabetes;
THYM	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg06558623	chr16:89946397	TCF25	1.36	6.6	0.56	2.33e-9	Skin colour saturation;
THYM	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg11845111	chr2:191398756	TMEM194B	0.97	9.11	0.68	1.34e-14	Pulse pressure;
THYM	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg12288994	chr5:1860383	NA	0.86	7.08	0.59	2.44e-10	Cardiovascular disease risk factors;
THYM	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Body mass index;
THYM	cis	rs6479874	0.681	rs9415727	chr10:52886136	G/T	cg24609819	chr10:52840377	PRKG1	0.68	4.95	0.45	3.22e-6	Migraine;
THYM	cis	rs4660261	0.561	rs11210934	chr1:44369435	G/A	cg12908607	chr1:44402522	ARTN	-0.6	-5.43	-0.49	4.29e-7	Intelligence (multi-trait analysis);
THYM	cis	rs13256369	0.802	rs34762800	chr8:8559294	G/A	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	trans	rs8002861	0.935	rs1819595	chr13:44429716	T/A	cg17145862	chr1:211918768	LPGAT1	0.92	9.41	0.69	3.06e-15	Leprosy;
THYM	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.81	-5.52	-0.49	2.91e-7	Body mass index;
THYM	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg03929089	chr4:120376271	NA	-1.01	-13.68	-0.81	3.47e-24	Height;
THYM	cis	rs12137294	0.866	rs1077883	chr1:205210415	G/T	cg17889831	chr1:205181581	DSTYK	-0.41	-5.05	-0.46	2.13e-6	Red cell distribution width;
THYM	cis	rs6424115	0.830	rs2502994	chr1:24199363	T/C	cg15997130	chr1:24165203	NA	0.74	6.34	0.55	7.54e-9	Immature fraction of reticulocytes;
THYM	cis	rs2281845	0.895	rs1325309	chr1:201079458	T/A	cg22815214	chr1:201083145	CACNA1S	0.77	7.57	0.61	2.34e-11	Permanent tooth development;
THYM	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg26384229	chr12:38710491	ALG10B	-0.71	-5.53	-0.49	2.79e-7	Morning vs. evening chronotype;
THYM	cis	rs854765	0.583	rs4341796	chr17:17839024	C/A	cg16928487	chr17:17741425	SREBF1	-0.54	-5.21	-0.47	1.08e-6	Total body bone mineral density;
THYM	cis	rs9500256	0.967	rs4928431	chr6:58306258	A/G	cg17976157	chr6:58263193	GUSBL2	0.61	4.72	0.44	8.04e-6	Eosinophilic esophagitis (pediatric);
THYM	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg07414643	chr4:187882934	NA	-0.58	-5.11	-0.46	1.63e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9902453	0.845	rs7218113	chr17:28372130	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.82	-6.22	-0.54	1.3e-8	Coffee consumption (cups per day);
THYM	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg07936489	chr17:37558343	FBXL20	-0.76	-5.33	-0.48	6.57e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs4589258	0.788	rs10741370	chr11:90500110	A/G	cg26138821	chr11:89956704	CHORDC1	-0.58	-4.66	-0.43	1.03e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.08	-0.53	2.5e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg12386194	chr3:101231763	SENP7	0.7	5.29	0.48	7.69e-7	Colorectal cancer;
THYM	cis	rs10832963	1.000	rs11024739	chr11:18645843	A/C	cg09201001	chr11:18656081	SPTY2D1	-1.05	-9.35	-0.69	4.11e-15	Breast cancer;
THYM	cis	rs752010	0.695	rs10789407	chr1:42106538	G/T	cg06885757	chr1:42089581	HIVEP3	0.48	5.84	0.51	7.38e-8	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs9733	0.596	rs6685702	chr1:150656307	A/G	cg15448220	chr1:150897856	SETDB1	0.87	7.15	0.59	1.75e-10	Tonsillectomy;
THYM	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg09307838	chr4:120376055	NA	0.76	5.32	0.48	7.01e-7	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs900145	0.773	rs7107287	chr11:13312969	G/T	cg13286116	chr11:13302098	ARNTL	0.59	4.56	0.42	1.54e-5	Menarche (age at onset);
THYM	cis	rs7584330	0.740	rs13425580	chr2:238447168	T/C	cg16989719	chr2:238392110	NA	-0.51	-5.1	-0.46	1.72e-6	Prostate cancer;
THYM	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg06634786	chr22:41940651	POLR3H	0.64	4.97	0.45	2.91e-6	Vitiligo;
THYM	cis	rs2933343	0.700	rs2624910	chr3:128650275	G/C	cg11901034	chr3:128598214	ACAD9	-0.68	-5.57	-0.5	2.4e-7	IgG glycosylation;
THYM	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg20295408	chr7:1910781	MAD1L1	-0.63	-4.54	-0.42	1.67e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg15604051	chr3:44754201	ZNF502	-0.59	-5.18	-0.47	1.25e-6	Depressive symptoms;
THYM	cis	rs977987	0.843	rs62062564	chr16:75442622	G/A	cg03315344	chr16:75512273	CHST6	0.77	6.4	0.55	5.85e-9	Dupuytren's disease;
THYM	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.74	-6.92	-0.58	5.17e-10	Personality dimensions;
THYM	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs17433780	0.928	rs10922533	chr1:89456659	C/G	cg09516651	chr1:89888402	LOC400759	0.86	6.56	0.56	2.81e-9	Carotid intima media thickness;
THYM	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg04267008	chr7:1944627	MAD1L1	-0.57	-5.02	-0.46	2.45e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.687	rs6830176	chr4:99093955	G/C	cg17366294	chr4:99064904	C4orf37	0.48	5.43	0.49	4.3e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs289828	0.500	rs10209942	chr2:152158265	A/G	cg05960677	chr2:152117363	RBM43	0.66	6.17	0.53	1.67e-8	Blood protein levels;
THYM	cis	rs1747683	0.585	rs3781087	chr10:13381160	C/T	cg25835351	chr10:13388524	SEPHS1	0.28	4.89	0.45	4.14e-6	IgG glycosylation;
THYM	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg13395646	chr4:1353034	KIAA1530	0.61	5.56	0.5	2.42e-7	Obesity-related traits;
THYM	cis	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05901451	chr6:126070800	HEY2	-0.7	-6.0	-0.52	3.58e-8	Brugada syndrome;
THYM	cis	rs9787249	0.915	rs6664570	chr1:40206298	G/A	cg19912559	chr1:40204330	PPIE	0.64	4.89	0.45	4.06e-6	Blood protein levels;
THYM	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg15164180	chr2:241846931	NA	-0.4	-5.2	-0.47	1.16e-6	Urinary metabolites;
THYM	cis	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs10256972	0.577	rs2949179	chr7:1209885	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.69	-5.03	-0.46	2.32e-6	Longevity;Endometriosis;
THYM	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg03609598	chr5:56110824	MAP3K1	-0.89	-6.07	-0.53	2.63e-8	Initial pursuit acceleration;
THYM	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.93	-8.04	-0.64	2.47e-12	Menarche (age at onset);
THYM	cis	rs9790314	0.586	rs1839491	chr3:161126429	C/A	cg03342759	chr3:160939853	NMD3	-0.84	-7.31	-0.6	8.38e-11	Morning vs. evening chronotype;
THYM	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg27535305	chr1:53392650	SCP2	0.38	4.55	0.42	1.6e-5	Monocyte count;
THYM	cis	rs72827839	0.740	rs10514938	chr17:46322604	A/T	cg23391107	chr17:45924227	SP6	0.85	5.05	0.46	2.17e-6	Ease of getting up in the morning;
THYM	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg06238570	chr21:40685208	BRWD1	0.92	6.85	0.57	7.35e-10	Cognitive function;
THYM	cis	rs9443645	0.527	rs10943600	chr6:79611505	G/A	cg05283184	chr6:79620031	NA	-0.6	-4.68	-0.43	9.33e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7968440	1.000	rs2700479	chr12:51020471	A/G	cg20014596	chr12:50898483	DIP2B	0.56	4.55	0.42	1.57e-5	Fibrinogen;
THYM	cis	rs7224296	0.709	rs199518	chr17:44854580	A/C	cg17911788	chr17:44343683	NA	0.51	4.87	0.45	4.53e-6	Intelligence (multi-trait analysis);
THYM	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg13736514	chr6:26305472	NA	-0.62	-7.54	-0.61	2.81e-11	Educational attainment;
THYM	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs1267303	0.563	rs2486163	chr1:47004680	T/C	cg25110126	chr1:46999211	NA	0.66	4.98	0.46	2.83e-6	Monobrow;
THYM	cis	rs9807989	0.507	rs4851577	chr2:103028921	T/C	cg03938978	chr2:103052716	IL18RAP	0.74	9.76	0.71	5.45e-16	Asthma;
THYM	cis	rs6570726	0.791	rs1935612	chr6:145906090	T/A	cg13319975	chr6:146136371	FBXO30	-0.65	-5.13	-0.47	1.51e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg03115019	chr17:80708279	FN3K	0.64	4.46	0.42	2.24e-5	Glycated hemoglobin levels;
THYM	cis	rs761746	0.881	rs12484606	chr22:31937476	C/T	cg10537193	chr22:32026975	PISD	0.38	5.06	0.46	2.02e-6	Intelligence;
THYM	cis	rs1395	0.710	rs72817533	chr2:27482612	A/G	cg23587288	chr2:27483067	SLC30A3	-0.64	-5.72	-0.51	1.26e-7	Blood metabolite levels;
THYM	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg27129171	chr3:47204927	SETD2	0.79	7.89	0.63	5.02e-12	Colorectal cancer;
THYM	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.7	-5.09	-0.46	1.84e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg13609457	chr4:120235615	NA	0.56	5.36	0.48	5.76e-7	Corneal astigmatism;
THYM	cis	rs4285028	0.580	rs2293611	chr3:121643163	G/C	cg20356878	chr3:121714668	ILDR1	-0.57	-5.2	-0.47	1.15e-6	Multiple sclerosis;
THYM	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg00271210	chr6:167070053	RPS6KA2	-0.48	-4.9	-0.45	3.92e-6	Primary biliary cholangitis;
THYM	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg26384229	chr12:38710491	ALG10B	0.95	7.64	0.62	1.67e-11	Bladder cancer;
THYM	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg17757837	chr7:157058334	UBE3C	0.63	5.03	0.46	2.29e-6	Body mass index;
THYM	cis	rs17300741	0.509	rs11231816	chr11:64312403	A/G	cg08822897	chr11:64258103	NA	0.76	5.67	0.5	1.54e-7	Uric acid levels;
THYM	cis	rs6669072	0.610	rs1766164	chr1:91315863	T/A	cg08895590	chr1:91227319	NA	0.47	5.17	0.47	1.32e-6	Cognitive function;
THYM	cis	rs35883536	1.000	rs4908087	chr1:101088594	C/T	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.4	0.73	2.35e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg19418458	chr7:158789849	NA	-0.62	-5.57	-0.5	2.35e-7	Facial morphology (factor 20);
THYM	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg23332699	chr15:44069569	ELL3	0.79	4.81	0.44	5.75e-6	Lung cancer in ever smokers;
THYM	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs9527	0.590	rs10883830	chr10:104851285	G/A	cg04362960	chr10:104952993	NT5C2	0.61	4.61	0.43	1.23e-5	Arsenic metabolism;
THYM	cis	rs2404602	0.684	rs12437981	chr15:76842401	A/G	cg23625390	chr15:77176239	SCAPER	-0.87	-6.27	-0.54	1.04e-8	Blood metabolite levels;
THYM	cis	rs4638749	0.677	rs12712014	chr2:108812044	A/G	cg06795125	chr2:108905320	SULT1C2	0.37	4.83	0.44	5.26e-6	Blood pressure;
THYM	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg10803722	chr21:46713166	LOC642852	-0.42	-5.4	-0.48	5e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg18876405	chr7:65276391	NA	-0.55	-4.73	-0.44	7.84e-6	Aortic root size;
THYM	cis	rs9866391	0.607	rs724016	chr3:141105570	C/T	cg13411656	chr3:141121016	ZBTB38	0.36	5.5	0.49	3.2e-7	Myopia;
THYM	cis	rs9470366	0.527	rs10807170	chr6:36629444	C/T	cg08179530	chr6:36648295	CDKN1A	-0.62	-4.57	-0.42	1.46e-5	QRS duration;
THYM	cis	rs2354432	0.556	rs6593777	chr1:146884013	C/G	cg25205988	chr1:146714368	CHD1L	0.99	4.64	0.43	1.13e-5	Mitochondrial DNA levels;
THYM	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg02269571	chr22:50332266	NA	-0.81	-5.68	-0.5	1.44e-7	Schizophrenia;
THYM	cis	rs7078219	0.965	rs11190141	chr10:101292390	C/T	cg07044859	chr10:101282883	NA	-0.5	-5.44	-0.49	4.12e-7	Dental caries;
THYM	cis	rs793571	0.544	rs11638244	chr15:58907151	A/T	cg05156742	chr15:59063176	FAM63B	0.56	4.59	0.43	1.36e-5	Schizophrenia;
THYM	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03647317	chr4:187891568	NA	-0.84	-9.01	-0.68	2.13e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg07917127	chr4:99064746	C4orf37	0.59	4.5	0.42	1.93e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6032067	0.641	rs74174932	chr20:43756133	G/A	cg27176129	chr20:43937155	MATN4;RBPJL	-0.49	-5.39	-0.48	5.13e-7	Blood protein levels;
THYM	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.07	6.76	0.57	1.11e-9	Cognitive test performance;
THYM	cis	rs2806561	1.000	rs1757044	chr1:23515631	T/C	cg19743168	chr1:23544995	NA	0.62	6.62	0.56	2.1e-9	Height;
THYM	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.8	-7.5	-0.61	3.37e-11	Intelligence (multi-trait analysis);
THYM	cis	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg21775007	chr8:11205619	TDH	0.65	5.29	0.48	7.91e-7	Retinal vascular caliber;
THYM	cis	rs1403694	0.515	rs1624569	chr3:186450069	A/G	cg12454167	chr3:186435060	KNG1	0.44	5.89	0.52	5.76e-8	Blood protein levels;
THYM	cis	rs600550	0.528	rs10897006	chr11:59851874	C/G	cg02771260	chr11:59836817	MS4A3	-0.7	-5.05	-0.46	2.09e-6	Lipoprotein-associated phospholipase A2 activity and mass;
THYM	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs34638657	0.833	rs7200628	chr16:82200747	C/T	cg09894383	chr16:82067445	HSD17B2	-0.47	-5.24	-0.47	9.72e-7	Lung adenocarcinoma;
THYM	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg23205692	chr1:25664452	TMEM50A	0.89	6.94	0.58	4.81e-10	Erythrocyte sedimentation rate;
THYM	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg15212455	chr7:39170539	POU6F2	0.68	5.7	0.5	1.37e-7	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg03676636	chr4:99064102	C4orf37	0.36	4.98	0.46	2.79e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg15691649	chr6:25882328	NA	-0.65	-5.01	-0.46	2.48e-6	Blood metabolite levels;
THYM	cis	rs6956675	0.915	rs4285375	chr7:62650353	C/T	cg08930214	chr7:62859557	LOC100287834	0.6	4.69	0.43	9.2e-6	Obesity-related traits;
THYM	cis	rs67460515	0.892	rs13073147	chr3:161045237	T/C	cg03342759	chr3:160939853	NMD3	-0.94	-8.14	-0.64	1.55e-12	Parkinson's disease;
THYM	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs57590327	0.555	rs6795133	chr3:81756267	A/G	cg07356753	chr3:81810745	GBE1	-0.88	-6.79	-0.57	9.52e-10	Extraversion;
THYM	cis	rs3540	0.553	rs8042861	chr15:90977333	G/T	cg00487526	chr15:90818384	NA	-0.64	-5.0	-0.46	2.64e-6	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
THYM	cis	rs7553864	0.667	rs7512650	chr1:87609076	T/C	cg17420885	chr1:87600446	LOC339524	-0.85	-7.65	-0.62	1.63e-11	Smoking behavior;
THYM	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg27572855	chr1:25598939	RHD	0.65	4.93	0.45	3.43e-6	Erythrocyte sedimentation rate;
THYM	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg26031613	chr14:104095156	KLC1	0.79	5.22	0.47	1.06e-6	Body mass index;
THYM	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg22508957	chr16:3507546	NAT15	0.47	4.84	0.44	4.98e-6	Body mass index (adult);
THYM	cis	rs10832963	1.000	rs10832956	chr11:18645668	A/G	cg20219074	chr11:18656078	SPTY2D1	0.79	6.42	0.55	5.25e-9	Breast cancer;
THYM	cis	rs9796	0.621	rs557864	chr15:41471358	T/C	cg18705301	chr15:41695430	NDUFAF1	0.56	4.61	0.43	1.24e-5	Menopause (age at onset);
THYM	cis	rs6840360	1.000	rs6535814	chr4:152609694	A/G	cg22705602	chr4:152727874	NA	-0.56	-6.1	-0.53	2.31e-8	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg25918947	chr17:41365094	TMEM106A	-0.56	-4.52	-0.42	1.77e-5	Menopause (age at onset);
THYM	cis	rs6860806	0.661	rs2136187	chr5:131577894	T/C	cg24060327	chr5:131705240	SLC22A5	-0.69	-5.27	-0.48	8.64e-7	Breast cancer;
THYM	cis	rs9515201	0.787	rs9521734	chr13:111037289	A/T	cg05272587	chr13:111038400	COL4A2	-0.6	-4.86	-0.45	4.6e-6	White matter hyperintensity burden;
THYM	cis	rs28595532	0.920	rs115681185	chr4:119757700	G/A	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.69	6.26	0.54	1.11e-8	Blood protein levels;
THYM	cis	rs941408	0.515	rs56000942	chr19:2774104	G/C	cg17333051	chr19:2783644	SGTA	0.64	5.36	0.48	5.93e-7	Total cholesterol levels;
THYM	cis	rs11671005	0.735	rs3826683	chr19:58918733	T/C	cg18639983	chr19:58920768	ZNF584	0.59	5.0	0.46	2.63e-6	Mean platelet volume;
THYM	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg10047753	chr17:41438598	NA	1.07	9.29	0.69	5.32e-15	Menopause (age at onset);
THYM	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg01097406	chr16:89675127	NA	-0.55	-4.51	-0.42	1.83e-5	Vitiligo;
THYM	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg23758822	chr17:41437982	NA	1.17	11.09	0.75	7.75e-19	Menopause (age at onset);
THYM	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg21984481	chr17:79567631	NPLOC4	0.46	4.86	0.45	4.62e-6	Eye color traits;
THYM	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg08999081	chr20:33150536	PIGU	0.56	4.79	0.44	6.1e-6	Coronary artery disease;
THYM	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs10744422	1.000	rs2135014	chr12:123333065	C/T	cg25930673	chr12:123319894	HIP1R	-0.86	-4.84	-0.44	5.09e-6	Schizophrenia;
THYM	cis	rs56036086	0.938	rs6712	chr22:50637922	C/G	cg16473166	chr22:50639996	SELO	0.76	4.71	0.44	8.3e-6	Platelet count;Plateletcrit;
THYM	cis	rs17401966	0.931	rs12409754	chr1:10457540	T/C	cg19773385	chr1:10388646	KIF1B	-0.61	-4.75	-0.44	7.06e-6	Hepatocellular carcinoma;
THYM	cis	rs11039798	0.764	rs11040208	chr11:49012509	A/G	cg24672777	chr11:48374446	OR4C45	-1.08	-5.95	-0.52	4.42e-8	Axial length;
THYM	cis	rs7681440	0.538	rs1442149	chr4:90749132	A/T	cg06632027	chr4:90757378	SNCA	-0.67	-5.31	-0.48	7.27e-7	Dementia with Lewy bodies;
THYM	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg13695892	chr22:41940480	POLR3H	-0.91	-7.25	-0.6	1.09e-10	Vitiligo;
THYM	cis	rs236907	0.859	rs2223602	chr1:171781735	C/T	cg20598894	chr1:171756153	METTL13	-0.73	-5.09	-0.46	1.81e-6	Mean platelet volume;
THYM	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs950880	0.710	rs56166614	chr2:103056096	A/G	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.71	-0.44	8.33e-6	Serum protein levels (sST2);
THYM	cis	rs2811415	0.597	rs13083602	chr3:127758532	A/G	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs289828	0.538	rs10184314	chr2:152154032	C/G	cg05960677	chr2:152117363	RBM43	0.71	6.6	0.56	2.29e-9	Blood protein levels;
THYM	cis	rs2237457	0.543	rs2237444	chr7:50700153	C/T	cg08586669	chr7:50727761	GRB10	-0.29	-4.62	-0.43	1.19e-5	Schizophrenia (treatment resistant);
THYM	cis	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg16068833	chr1:26644515	UBXN11;CD52	0.27	4.64	0.43	1.12e-5	Obesity-related traits;
THYM	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.51	-5.24	-0.47	9.82e-7	Depressive symptoms;
THYM	cis	rs6956675	0.881	rs1829737	chr7:62576000	G/A	cg08930214	chr7:62859557	LOC100287834	0.61	4.51	0.42	1.85e-5	Obesity-related traits;
THYM	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg09307838	chr4:120376055	NA	-0.69	-5.17	-0.47	1.3e-6	Corneal astigmatism;
THYM	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg00129232	chr17:37814104	STARD3	0.69	4.51	0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg05182265	chr7:156933206	UBE3C	0.7	9.62	0.7	1.06e-15	Body mass index;
THYM	cis	rs453301	0.564	rs28649568	chr8:8959671	T/G	cg15556689	chr8:8085844	FLJ10661	-0.62	-4.74	-0.44	7.4e-6	Joint mobility (Beighton score);
THYM	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03517284	chr6:25882590	NA	-0.79	-6.07	-0.53	2.66e-8	Blood metabolite levels;
THYM	cis	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg20307385	chr11:47447363	PSMC3	0.81	6.51	0.56	3.46e-9	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs2133450	0.526	rs56129834	chr3:7345582	A/T	cg19930620	chr3:7340148	GRM7	-0.5	-5.46	-0.49	3.72e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs514406	0.893	rs6661115	chr1:53426148	G/A	cg08736216	chr1:53307985	ZYG11A	0.59	5.23	0.47	1.01e-6	Monocyte count;
THYM	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg24733560	chr20:60626293	TAF4	0.57	5.89	0.52	5.92e-8	Body mass index;
THYM	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg01324343	chr3:183735012	ABCC5	0.89	13.33	0.81	1.82e-23	Anterior chamber depth;
THYM	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg06558623	chr16:89946397	TCF25	1.36	6.6	0.56	2.33e-9	Skin colour saturation;
THYM	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg23187316	chr7:1099788	C7orf50	0.48	5.58	0.5	2.26e-7	Longevity;Endometriosis;
THYM	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg08773314	chr2:239334832	ASB1	0.64	9.92	0.71	2.51e-16	Multiple system atrophy;
THYM	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6084875	0.932	rs11697483	chr20:4725494	T/A	cg19614321	chr20:4804581	RASSF2	-0.46	-4.61	-0.43	1.28e-5	Systemic lupus erythematosus;
THYM	cis	rs7681440	0.606	rs356184	chr4:90703233	A/G	cg06632027	chr4:90757378	SNCA	0.64	5.02	0.46	2.42e-6	Dementia with Lewy bodies;
THYM	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg24642844	chr7:1081250	C7orf50	-1.29	-8.3	-0.65	7.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6500395	0.802	rs13330784	chr16:48661530	A/C	cg04672837	chr16:48644449	N4BP1	0.47	4.62	0.43	1.18e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg07460842	chr6:66804631	NA	1.11	8.12	0.64	1.7e-12	Exhaled nitric oxide output;
THYM	cis	rs2073300	1.000	rs6137957	chr20:23437384	G/A	cg12062639	chr20:23401060	NAPB	1.33	6.1	0.53	2.32e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs2933343	0.661	rs2630259	chr3:128606322	C/T	cg11901034	chr3:128598214	ACAD9	-0.71	-5.55	-0.49	2.56e-7	IgG glycosylation;
THYM	cis	rs112916054	1	rs112916054	chr17:31124262	C/T	cg02981443	chr17:31254875	TMEM98	-0.52	-4.6	-0.43	1.29e-5	Immature fraction of reticulocytes;
THYM	cis	rs700651	0.821	rs700663	chr2:198670478	T/A	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Intracranial aneurysm;
THYM	cis	rs865483	0.860	rs853228	chr17:35799889	G/T	cg06716730	chr17:35851459	DUSP14	0.43	7.3	0.6	8.71e-11	Monocyte count;
THYM	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg19774624	chr17:42201019	HDAC5	0.68	5.97	0.52	4.05e-8	Total body bone mineral density;
THYM	cis	rs9486719	1.000	rs2064947	chr6:97052754	C/T	cg18709589	chr6:96969512	KIAA0776	-0.64	-4.55	-0.42	1.57e-5	Migraine;Coronary artery disease;
THYM	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-5.77	-0.51	9.89e-8	Total cholesterol levels;
THYM	cis	rs870825	0.616	rs7681824	chr4:185617525	A/G	cg04058563	chr4:185651563	MLF1IP	1.07	9.69	0.71	7.45e-16	Blood protein levels;
THYM	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg17366294	chr4:99064904	C4orf37	0.48	5.41	0.49	4.69e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs6988636	1.000	rs28694222	chr8:124195017	C/T	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs990171	1.000	rs2041756	chr2:103049910	C/T	cg13897122	chr2:103039542	IL18RAP	0.42	5.17	0.47	1.27e-6	Lymphocyte counts;
THYM	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg12935359	chr14:103987150	CKB	-0.64	-6.43	-0.55	5.14e-9	Body mass index;
THYM	cis	rs9902453	0.679	rs2054847	chr17:28532013	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	4.79	0.44	6.11e-6	Coffee consumption (cups per day);
THYM	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.25	0.6	1.12e-10	Obesity-related traits;
THYM	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg19875535	chr5:140030758	IK	-0.62	-5.46	-0.49	3.83e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs12530845	0.673	rs4269479	chr7:135332379	C/T	cg19897172	chr7:135347071	PL-5283	-0.59	-5.31	-0.48	7.23e-7	Red blood cell traits;
THYM	trans	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg25517755	chr10:38738941	LOC399744	-0.77	-7.07	-0.59	2.64e-10	Corneal astigmatism;
THYM	cis	rs9790314	0.779	rs1599374	chr3:160891727	G/A	cg04691961	chr3:161091175	C3orf57	-0.59	-4.79	-0.44	6.04e-6	Morning vs. evening chronotype;
THYM	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg00074818	chr8:8560427	CLDN23	0.51	5.01	0.46	2.47e-6	Obesity-related traits;
THYM	cis	rs13082711	0.558	rs1844983	chr3:27370203	C/T	cg02860705	chr3:27208620	NA	-0.65	-5.0	-0.46	2.6e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs951188	0.688	rs78414629	chr2:150408048	T/C	cg17961725	chr2:150454027	NA	-0.85	-4.59	-0.43	1.35e-5	Daytime sleep phenotypes;
THYM	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg14993813	chr1:46806288	NSUN4	-0.7	-4.78	-0.44	6.44e-6	Menopause (age at onset);
THYM	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg11166453	chr1:247681781	NA	0.65	5.18	0.47	1.25e-6	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg10150615	chr22:24372951	LOC391322	-1.02	-12.28	-0.78	2.57e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs2050392	0.517	rs302423	chr10:30772513	A/G	cg18806716	chr10:30721971	MAP3K8	-0.52	-4.69	-0.43	9.18e-6	Inflammatory bowel disease;
THYM	cis	rs990171	1.000	rs7559479	chr2:103068787	C/T	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.13	-0.47	1.5e-6	Lymphocyte counts;
THYM	trans	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg25517755	chr10:38738941	LOC399744	0.79	7.77	0.62	9.18e-12	Corneal astigmatism;
THYM	cis	rs9549260	0.755	rs9532571	chr13:41218670	C/T	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs526231	0.543	rs171558	chr5:102577894	G/C	cg23492399	chr5:102201601	PAM	-0.68	-4.96	-0.45	3.08e-6	Primary biliary cholangitis;
THYM	cis	rs75920871	0.528	rs10082609	chr11:116949074	C/T	cg20608306	chr11:116969690	SIK3	-0.52	-5.78	-0.51	9.38e-8	Subjective well-being;
THYM	cis	rs4664308	1.000	rs1511218	chr2:160906390	T/C	cg03641300	chr2:160917029	PLA2R1	-0.75	-6.95	-0.58	4.48e-10	Idiopathic membranous nephropathy;
THYM	cis	rs240764	0.853	rs12660725	chr6:100978570	C/T	cg21058520	chr6:100914733	NA	0.57	5.03	0.46	2.35e-6	Neuroticism;
THYM	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9649465	0.935	rs7780086	chr7:123378471	C/A	cg15443791	chr7:124364398	NA	0.59	4.9	0.45	3.96e-6	Migraine;
THYM	cis	rs6732160	0.838	rs13411380	chr2:73382846	G/C	cg24220031	chr2:73402428	NA	-0.79	-8.39	-0.65	4.59e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03264133	chr6:25882463	NA	-0.99	-9.01	-0.68	2.12e-14	Blood metabolite levels;
THYM	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Body mass index;
THYM	cis	rs73198271	0.751	rs617813	chr8:8635888	A/G	cg06636001	chr8:8085503	FLJ10661	-0.8	-6.17	-0.53	1.68e-8	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs2710642	0.564	rs60144282	chr2:62843163	G/T	cg17519650	chr2:63277830	OTX1	0.62	4.61	0.43	1.25e-5	LDL cholesterol levels;LDL cholesterol;
THYM	cis	rs10269006	0.727	rs9641149	chr7:94370407	G/A	cg00347863	chr7:94220697	SGCE	0.53	4.56	0.42	1.51e-5	Breast cancer;
THYM	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs1991601	0.501	rs12612947	chr2:175288009	A/T	cg13365284	chr2:174830453	SP3	-0.8	-4.59	-0.43	1.36e-5	QRS complex (12-leadsum);
THYM	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22590775	chr19:49891494	CCDC155	0.78	6.32	0.54	8.4e-9	Multiple sclerosis;
THYM	cis	rs3204270	0.639	rs62077183	chr17:79658940	C/A	cg13117272	chr17:79681052	SLC25A10	-0.79	-5.0	-0.46	2.63e-6	Dental caries;
THYM	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06634786	chr22:41940651	POLR3H	-0.76	-5.54	-0.49	2.73e-7	Vitiligo;
THYM	cis	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg06521331	chr12:34319734	NA	-0.86	-6.39	-0.55	6.18e-9	Morning vs. evening chronotype;
THYM	cis	rs9604529	0.532	rs41291213	chr13:114774991	C/T	cg13259177	chr13:114761607	RASA3	-0.79	-5.08	-0.46	1.91e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7267979	0.966	rs2261720	chr20:25260641	T/G	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4589258	0.898	rs2511314	chr11:90434807	T/C	cg26138821	chr11:89956704	CHORDC1	0.7	5.86	0.52	6.6e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg18811423	chr2:55921094	PNPT1	0.67	6.2	0.54	1.45e-8	Metabolic syndrome;
THYM	cis	rs10779751	0.690	rs910661	chr1:11130116	C/A	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs17604090	0.887	rs7795109	chr7:29666244	G/A	cg19413766	chr7:29689036	LOC646762	-0.77	-4.71	-0.43	8.51e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg13443165	chr9:33130375	B4GALT1	0.85	7.83	0.63	6.8e-12	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7731657	0.537	rs4705850	chr5:130220358	A/G	cg08523029	chr5:130500466	HINT1	-0.74	-5.12	-0.47	1.59e-6	Fasting plasma glucose;
THYM	cis	rs7584330	0.626	rs2271809	chr2:238449107	A/G	cg16989719	chr2:238392110	NA	-0.46	-4.52	-0.42	1.79e-5	Prostate cancer;
THYM	cis	rs13185784	0.667	rs4454029	chr5:179645325	C/T	cg13944838	chr5:179740914	GFPT2	0.71	4.81	0.44	5.62e-6	TRAIL levels;
THYM	cis	rs7177699	0.557	rs9920493	chr15:79113846	A/C	cg00540400	chr15:79124168	NA	0.64	6.93	0.58	4.98e-10	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7447927	0.950	rs13181561	chr5:138850905	A/G	cg11459648	chr5:138714337	SLC23A1	-0.59	-4.91	-0.45	3.8e-6	Esophageal squamous cell carcinoma;
THYM	cis	rs11671005	0.693	rs11668757	chr19:58928299	A/T	cg18639983	chr19:58920768	ZNF584	0.61	5.02	0.46	2.37e-6	Mean platelet volume;
THYM	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg09877947	chr5:131593287	PDLIM4	-0.6	-4.94	-0.45	3.41e-6	Blood metabolite levels;
THYM	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg01324343	chr3:183735012	ABCC5	0.88	12.75	0.79	2.73e-22	Anterior chamber depth;
THYM	cis	rs11098499	0.575	rs9996586	chr4:120326942	A/G	cg13609457	chr4:120235615	NA	0.47	4.88	0.45	4.28e-6	Corneal astigmatism;
THYM	cis	rs10751667	0.600	rs6597948	chr11:1005308	C/T	cg20248691	chr11:532330	HRAS	-0.45	-4.54	-0.42	1.64e-5	Alzheimer's disease (late onset);
THYM	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg22875332	chr1:76189707	ACADM	0.9	10.43	0.73	1.98e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.14	-13.46	-0.81	9.59e-24	Chronic sinus infection;
THYM	cis	rs3804749	0.966	rs3792378	chr3:122845077	G/A	cg26084141	chr3:122786895	PDIA5	0.46	4.64	0.43	1.1e-5	Plateletcrit;Mean platelet volume;Platelet count;Platelet distribution width;
THYM	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg10661904	chr17:79619235	PDE6G	-0.53	-4.66	-0.43	1.03e-5	Eye color traits;
THYM	cis	rs4343996	0.967	rs34608458	chr7:3357881	G/A	cg21248987	chr7:3385318	SDK1	-0.4	-4.79	-0.44	6.16e-6	Motion sickness;
THYM	cis	rs4808199	1.000	rs60003758	chr19:19557353	A/G	cg03709012	chr19:19516395	GATAD2A	1.19	7.25	0.6	1.12e-10	Nonalcoholic fatty liver disease;
THYM	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	-0.7	-5.41	-0.49	4.65e-7	Tonsillectomy;
THYM	cis	rs2692947	0.683	rs2315416	chr2:96558477	C/T	cg22654517	chr2:96458247	NA	0.59	4.45	0.42	2.32e-5	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg07936489	chr17:37558343	FBXL20	0.82	5.69	0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs35110281	0.567	rs4819219	chr21:44984864	T/C	cg27168131	chr21:44088823	PDE9A	-0.45	-4.49	-0.42	2.01e-5	Mean corpuscular volume;
THYM	cis	rs9393777	0.545	rs56303243	chr6:26485727	G/A	cg12826209	chr6:26865740	GUSBL1	1.02	6.4	0.55	5.95e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg06850241	chr22:41845214	NA	-0.53	-4.56	-0.42	1.54e-5	Vitiligo;
THYM	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	10.29	0.73	3.99e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs34311866	0.808	rs11248059	chr4:960331	C/G	cg11017086	chr4:979022	SLC26A1	0.73	4.6	0.43	1.33e-5	Parkinson's disease;
THYM	cis	rs7727544	0.606	rs10058074	chr5:131686146	G/A	cg24060327	chr5:131705240	SLC22A5	-0.63	-4.66	-0.43	1.04e-5	Blood metabolite levels;
THYM	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.6	-11.28	-0.76	3.1400000000000002e-19	Hemostatic factors and hematological phenotypes;
THYM	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg08564027	chr20:61660810	NA	0.73	6.03	0.53	3.11e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg01751800	chr4:77820391	ANKRD56	0.55	4.59	0.43	1.36e-5	Emphysema distribution in smoking;
THYM	cis	rs2458413	0.933	rs2669450	chr8:105371752	C/T	cg04554929	chr8:105342491	NA	0.37	5.13	0.47	1.51e-6	Paget's disease;
THYM	cis	rs6732160	0.588	rs11126392	chr2:73374454	A/G	cg24220031	chr2:73402428	NA	-0.71	-5.79	-0.51	8.94e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg17294928	chr15:75287854	SCAMP5	0.69	4.84	0.44	5.06e-6	Breast cancer;
THYM	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg16006841	chr5:176797999	RGS14	-0.52	-5.94	-0.52	4.74e-8	Urate levels in lean individuals;
THYM	cis	rs7833986	0.534	rs10504198	chr8:57006254	G/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	6.82	0.57	8.29e-10	Height;
THYM	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg04455712	chr21:45112962	RRP1B	0.52	4.93	0.45	3.42e-6	Mean corpuscular volume;
THYM	cis	rs10158481	0.759	rs2206349	chr1:25487179	G/A	cg09264742	chr1:25757510	TMEM57	-0.63	-4.5	-0.42	1.89e-5	Urate levels in obese individuals;
THYM	cis	rs28595532	0.920	rs116023344	chr4:119760263	A/G	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg17178900	chr1:205818956	PM20D1	1.0	10.93	0.75	1.74e-18	Menarche (age at onset);
THYM	cis	rs4499344	0.504	rs259248	chr19:33148041	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.75	5.5	0.49	3.23e-7	Mean platelet volume;
THYM	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.63	-5.43	-0.49	4.34e-7	Rheumatoid arthritis;
THYM	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.1	-7.35	-0.6	6.83e-11	Platelet count;
THYM	cis	rs6842789	0.510	rs13130396	chr4:124878436	A/C	cg01723706	chr4:124814442	LOC285419	-0.74	-4.65	-0.43	1.07e-5	Neuroticism;
THYM	cis	rs4523957	0.552	rs2760742	chr17:2019037	A/G	cg16513277	chr17:2031491	SMG6	-0.96	-8.72	-0.67	9.17e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs17818399	0.620	rs1598517	chr2:46857401	C/T	cg09399716	chr2:46890238	NA	-0.44	-4.45	-0.42	2.32e-5	Height;
THYM	cis	rs7843479	0.582	rs7818254	chr8:21798316	C/T	cg17168535	chr8:21777572	XPO7	0.93	8.54	0.66	2.2e-13	Mean corpuscular volume;
THYM	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	5.11	0.46	1.68e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg21862992	chr11:68658383	NA	0.24	4.53	0.42	1.73e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.81	-4.97	-0.45	2.91e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg22974920	chr21:40686053	BRWD1	0.74	5.02	0.46	2.45e-6	Cognitive function;
THYM	cis	rs4917300	0.549	rs902819	chr8:143098548	C/T	cg26003909	chr8:143102224	NA	-0.32	-4.61	-0.43	1.26e-5	Amyotrophic lateral sclerosis;
THYM	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7772486	0.875	rs2814869	chr6:146315509	G/A	cg13319975	chr6:146136371	FBXO30	-0.64	-5.34	-0.48	6.3e-7	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg20290983	chr6:43655470	MRPS18A	1.39	14.66	0.83	3.93e-26	IgG glycosylation;
THYM	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg03213289	chr20:61660250	NA	0.91	9.46	0.7	2.34e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9682041	0.825	rs6785326	chr3:170095145	T/C	cg11886554	chr3:170076028	SKIL	1.23	4.71	0.44	8.47e-6	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs6435161	1.000	rs6748088	chr2:203556526	A/G	cg18429434	chr2:203499731	FAM117B	-0.77	-5.16	-0.47	1.35e-6	Total cholesterol levels;
THYM	cis	rs7757969	1.000	rs9387038	chr6:112125335	T/C	cg08601457	chr6:112115117	FYN	0.42	4.79	0.44	6.23e-6	Schizophrenia;
THYM	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	1.18	8.91	0.67	3.51e-14	Cognitive test performance;
THYM	cis	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg01364799	chr7:75623366	TMEM120A	-0.62	-4.46	-0.42	2.22e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs35934224	0.891	rs5993850	chr22:19869703	C/T	cg11182965	chr22:19864308	TXNRD2	-0.93	-6.94	-0.58	4.79e-10	Glaucoma (primary open-angle);
THYM	cis	rs2797160	1.000	rs2211419	chr6:125995533	C/T	cg16306078	chr6:126000798	NA	0.52	5.34	0.48	6.31e-7	Endometrial cancer;
THYM	trans	rs8002861	0.967	rs9525871	chr13:44477712	A/T	cg17145862	chr1:211918768	LPGAT1	0.99	11.5	0.76	1.06e-19	Leprosy;
THYM	cis	rs863345	0.564	rs10908667	chr1:158500121	G/A	cg12129480	chr1:158549410	OR10X1	-0.51	-4.88	-0.45	4.22e-6	Pneumococcal bacteremia;
THYM	cis	rs7772486	0.590	rs1890170	chr6:146071839	G/C	cg23711669	chr6:146136114	FBXO30	-0.84	-7.83	-0.63	6.82e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2455799	0.613	rs7633542	chr3:15816326	C/T	cg16303742	chr3:15540471	COLQ	-0.54	-5.78	-0.51	9.67e-8	Mean platelet volume;
THYM	cis	rs2552220	1.000	rs2552220	chr8:5999311	G/A	cg23638070	chr8:6569043	AGPAT5	-0.58	-4.74	-0.44	7.49e-6	Interleukin-8 levels;
THYM	cis	rs7264396	0.790	rs6121026	chr20:34266883	A/T	cg26038318	chr20:34205095	SPAG4	0.64	5.22	0.47	1.04e-6	Total cholesterol levels;
THYM	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg05043794	chr9:111880884	C9orf5	-0.4	-5.64	-0.5	1.71e-7	Menarche (age at onset);
THYM	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg18538332	chr22:24372958	LOC391322	1.05	13.67	0.81	3.63e-24	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10231759	0.583	rs17173612	chr7:150503360	T/G	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.64	4.8	0.44	5.92e-6	Height;
THYM	cis	rs56116382	0.605	rs12715435	chr3:49338992	G/A	cg00383909	chr3:49044727	WDR6	0.76	5.0	0.46	2.62e-6	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
THYM	cis	rs500891	0.525	rs1170339	chr6:84031251	T/C	cg21688264	chr6:84418724	SNAP91	0.74	4.51	0.42	1.87e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg25072359	chr17:41440525	NA	0.65	4.58	0.43	1.39e-5	Menopause (age at onset);
THYM	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg02725872	chr8:58115012	NA	-0.73	-5.38	-0.48	5.3e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg22875332	chr1:76189707	ACADM	0.69	5.48	0.49	3.44e-7	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2235649	0.753	rs4316755	chr16:1849916	T/G	cg03034668	chr16:1723424	CRAMP1L	-0.63	-5.42	-0.49	4.41e-7	Blood metabolite levels;
THYM	cis	rs933688	1.000	rs1363839	chr5:90671274	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.07	8.14	0.64	1.5e-12	Smoking behavior;
THYM	cis	rs3820068	0.608	rs7519899	chr1:16045579	A/G	cg05660106	chr1:15850417	CASP9	0.72	5.67	0.5	1.54e-7	Systolic blood pressure;
THYM	cis	rs7000551	0.671	rs34668161	chr8:22288815	A/G	cg12081754	chr8:22256438	SLC39A14	1.03	8.87	0.67	4.31e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg05973401	chr12:123451056	ABCB9	0.65	4.74	0.44	7.42e-6	Platelet count;
THYM	cis	rs6430585	0.646	rs1057031	chr2:136633962	G/A	cg20242066	chr2:136595261	LCT	0.47	4.61	0.43	1.24e-5	Corneal structure;
THYM	cis	rs17253792	0.822	rs10133962	chr14:56066088	G/A	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs7216064	1.000	rs35243555	chr17:65876477	G/C	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-5.16	-0.47	1.34e-6	Mood instability;
THYM	cis	rs7572733	0.515	rs13382697	chr2:198920560	A/C	cg00792783	chr2:198669748	PLCL1	0.73	4.79	0.44	6.22e-6	Dermatomyositis;
THYM	cis	rs7264396	0.832	rs224361	chr20:34061578	T/C	cg26038318	chr20:34205095	SPAG4	0.56	4.61	0.43	1.25e-5	Total cholesterol levels;
THYM	cis	rs4631830	0.863	rs10826127	chr10:51530757	G/A	cg16070123	chr10:51489643	NA	-0.53	-4.79	-0.44	6.07e-6	Prostate-specific antigen levels;
THYM	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg02753203	chr1:228287806	NA	0.76	6.55	0.56	2.91e-9	Diastolic blood pressure;
THYM	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg02734326	chr4:10020555	SLC2A9	-0.6	-4.7	-0.43	8.84e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs12121840	0.790	rs16847085	chr1:165534241	A/G	cg19407955	chr1:165599744	MGST3	-0.67	-4.68	-0.43	9.67e-6	Interleukin-1-receptor antagonist levels;
THYM	cis	rs2133450	0.526	rs12489441	chr3:7346788	C/G	cg19930620	chr3:7340148	GRM7	-0.52	-5.62	-0.5	1.86e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg12963246	chr6:28129442	ZNF389	0.57	5.06	0.46	2.09e-6	Cardiac Troponin-T levels;
THYM	cis	rs757110	0.933	rs4148646	chr11:17415190	C/G	cg15432903	chr11:17409602	KCNJ11	0.67	7.71	0.62	1.21e-11	Type 2 diabetes;
THYM	cis	rs2692947	0.770	rs12471925	chr2:96555522	C/A	cg22654517	chr2:96458247	NA	0.73	5.28	0.48	8.13e-7	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg27532560	chr4:187881888	NA	-0.96	-11.64	-0.77	5.39e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2811415	0.597	rs9848345	chr3:127779220	C/T	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs11690935	0.531	rs4280428	chr2:172813219	G/A	cg13550731	chr2:172543902	DYNC1I2	0.64	4.95	0.45	3.23e-6	Schizophrenia;
THYM	cis	rs1670533	0.746	rs688008	chr4:1082829	T/C	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	trans	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg06636001	chr8:8085503	FLJ10661	-0.78	-6.92	-0.58	5.26e-10	Monocyte count;
THYM	cis	rs6430585	0.528	rs10496738	chr2:136751488	C/T	cg23851026	chr2:136556271	LCT	0.78	6.95	0.58	4.47e-10	Corneal structure;
THYM	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg01579765	chr21:45077557	HSF2BP	-0.47	-7.52	-0.61	3.11e-11	Mean corpuscular volume;
THYM	cis	rs11608355	0.810	rs12424599	chr12:109866615	A/G	cg10504392	chr12:110044639	NA	0.65	5.37	0.48	5.56e-7	Neuroticism;
THYM	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg23815491	chr16:72088622	HP	0.81	6.46	0.55	4.54e-9	Fibrinogen levels;
THYM	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg02487422	chr3:49467188	NICN1	0.67	5.12	0.46	1.62e-6	Resting heart rate;
THYM	cis	rs6541297	1.000	rs4846836	chr1:230281316	G/A	cg20703242	chr1:230279135	GALNT2	0.92	5.97	0.52	4.17e-8	Coronary artery disease;
THYM	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg11965913	chr1:205819406	PM20D1	-0.74	-7.39	-0.6	5.55e-11	Monocyte percentage of white cells;
THYM	cis	rs7731657	0.537	rs2040779	chr5:130301539	T/G	cg08523029	chr5:130500466	HINT1	-0.79	-5.46	-0.49	3.76e-7	Fasting plasma glucose;
THYM	cis	rs1421811	0.606	rs981001	chr5:32721545	G/A	cg16267343	chr5:32710456	NPR3	0.9	7.4	0.6	5.3e-11	Blood pressure;
THYM	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg27129171	chr3:47204927	SETD2	-0.69	-6.65	-0.56	1.82e-9	Colorectal cancer;
THYM	cis	rs4805272	0.539	rs11883172	chr19:29318536	C/T	cg04546413	chr19:29218101	NA	0.84	5.17	0.47	1.3e-6	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	1.12	12.21	0.78	3.57e-21	Subjective well-being;
THYM	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg16680214	chr1:154839983	KCNN3	-0.45	-5.17	-0.47	1.3e-6	Prostate cancer;
THYM	cis	rs2997447	0.761	rs74384164	chr1:26430379	C/T	cg03844060	chr1:26490628	NA	0.7	4.81	0.44	5.61e-6	QRS complex (12-leadsum);
THYM	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg06636001	chr8:8085503	FLJ10661	-0.61	-5.02	-0.46	2.43e-6	Joint mobility (Beighton score);
THYM	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs2692947	0.770	rs72823920	chr2:96430876	G/A	cg23100626	chr2:96804247	ASTL	0.4	5.02	0.46	2.44e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs7172809	0.573	rs74027548	chr15:77512516	T/C	cg22256960	chr15:77711686	NA	-0.65	-4.84	-0.44	5.12e-6	Glucose homeostasis traits;
THYM	cis	rs9549260	0.755	rs2721071	chr13:41144507	G/A	cg21288729	chr13:41239152	FOXO1	0.71	5.53	0.49	2.84e-7	Red blood cell count;
THYM	cis	rs7267979	1.000	rs2257982	chr20:25269630	A/G	cg08601574	chr20:25228251	PYGB	0.57	4.61	0.43	1.25e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs28595532	1.000	rs56000725	chr4:119637675	G/A	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	12.92	0.8	1.2e-22	Height;
THYM	cis	rs7584330	0.554	rs74001399	chr2:238445440	G/A	cg08992911	chr2:238395768	MLPH	0.71	4.69	0.43	9.14e-6	Prostate cancer;
THYM	cis	rs4919687	0.550	rs7907503	chr10:104440050	C/T	cg04362960	chr10:104952993	NT5C2	0.6	4.88	0.45	4.22e-6	Colorectal cancer;
THYM	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg08975724	chr8:8085496	FLJ10661	-0.62	-5.12	-0.47	1.56e-6	Mood instability;
THYM	cis	rs28595532	0.920	rs115850161	chr4:119732447	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs1559088	0.744	rs12972060	chr19:33537096	C/T	cg03563238	chr19:33554763	RHPN2	0.52	4.51	0.42	1.84e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs17818399	0.926	rs35682608	chr2:46836542	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.63	4.59	0.43	1.37e-5	Height;
THYM	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg11327659	chr7:150037044	RARRES2	0.42	5.0	0.46	2.62e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs61990749	0.571	rs11628049	chr14:78308451	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.85	-5.16	-0.47	1.36e-6	Fibroblast growth factor basic levels;
THYM	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.11	-0.53	2.22e-8	Life satisfaction;
THYM	cis	rs9430161	0.579	rs6694011	chr1:11036935	G/A	cg27631724	chr1:11040367	C1orf127	0.68	6.42	0.55	5.25e-9	Ewing sarcoma;
THYM	cis	rs6694672	1.000	rs7554757	chr1:196973054	A/T	cg13682187	chr1:196946512	CFHR5	0.85	4.79	0.44	6.16e-6	Asthma;
THYM	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg03388043	chr17:80084554	CCDC57	0.69	5.98	0.52	3.85e-8	Life satisfaction;
THYM	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7818345	0.904	rs11780388	chr8:19271554	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.43	4.74	0.44	7.52e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs2637266	1.000	rs7897015	chr10:78366566	G/C	cg18941641	chr10:78392320	NA	0.84	7.37	0.6	6.11e-11	Pulmonary function;
THYM	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.36	-5.16	-0.47	1.35e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg24675056	chr1:15929824	NA	0.73	5.89	0.52	5.95e-8	Systolic blood pressure;
THYM	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08704250	chr15:31115839	NA	0.55	6.3	0.54	9.12e-9	Huntington's disease progression;
THYM	cis	rs3087591	1.000	rs2057769	chr17:29691368	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.61	-5.18	-0.47	1.26e-6	Hip circumference;
THYM	cis	rs524023	0.914	rs2666559	chr11:64439227	G/T	cg19131476	chr11:64387923	NRXN2	-0.41	-5.64	-0.5	1.72e-7	Urate levels in obese individuals;
THYM	cis	rs72828912	0.731	rs9393522	chr6:24066174	A/G	cg26336265	chr6:25042955	NA	-0.86	-5.43	-0.49	4.31e-7	Squamous cell lung carcinoma;
THYM	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs485842	1.000	rs539598	chr11:96026074	C/T	cg23866687	chr11:96026956	MAML2	0.45	6.35	0.55	7.49e-9	Corneal astigmatism;
THYM	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg18105134	chr13:113819100	PROZ	0.96	8.77	0.67	6.94e-14	Platelet distribution width;
THYM	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg08645402	chr16:4508243	NA	0.71	6.16	0.53	1.74e-8	Schizophrenia;
THYM	cis	rs6500395	0.890	rs11861666	chr16:48679914	G/T	cg04672837	chr16:48644449	N4BP1	0.48	4.65	0.43	1.06e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7572733	0.515	rs13408411	chr2:198825462	G/A	cg00792783	chr2:198669748	PLCL1	0.82	5.75	0.51	1.08e-7	Dermatomyositis;
THYM	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg12311346	chr5:56204834	C5orf35	-0.79	-5.64	-0.5	1.71e-7	Initial pursuit acceleration;
THYM	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg02725872	chr8:58115012	NA	-0.9	-5.24	-0.47	9.85e-7	Developmental language disorder (linguistic errors);
THYM	trans	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.11	8.17	0.64	1.3e-12	Exhaled nitric oxide output;
THYM	cis	rs11577318	0.579	rs35456934	chr1:26686864	G/A	cg16664472	chr1:26644822	UBXN11;CD52	0.34	4.95	0.45	3.19e-6	Granulocyte percentage of myeloid white cells;
THYM	cis	rs8130944	0.866	rs1878070	chr21:44123705	A/G	cg05030553	chr21:44061403	NA	-0.53	-4.65	-0.43	1.05e-5	Perceived unattractiveness to mosquitoes;
THYM	cis	rs9527	0.590	rs1475642	chr10:104546183	C/T	cg05855489	chr10:104503620	C10orf26	-0.7	-5.48	-0.49	3.5e-7	Arsenic metabolism;
THYM	cis	rs79387448	0.745	rs17027428	chr2:103163175	G/A	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs6047844	0.750	rs6113483	chr20:22036524	G/C	cg16502866	chr20:23015624	SSTR4	-0.58	-4.45	-0.42	2.3e-5	Male-pattern baldness;
THYM	cis	rs4866334	1.000	rs80033831	chr5:18481972	A/G	cg02002538	chr5:17811409	NA	-1.13	-4.53	-0.42	1.74e-5	IgG glycosylation;
THYM	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg20503657	chr10:835505	NA	1.14	7.86	0.63	5.98e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs1524976	1.000	rs62255280	chr3:65483527	T/C	cg16238336	chr3:65465873	MAGI1	-1.07	-6.29	-0.54	9.82e-9	PR interval;
THYM	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg17264618	chr3:40429014	ENTPD3	-0.52	-4.95	-0.45	3.22e-6	Renal cell carcinoma;
THYM	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06850241	chr22:41845214	NA	0.6	5.26	0.47	8.97e-7	Vitiligo;
THYM	trans	rs877282	1.000	rs11253367	chr10:773389	G/A	cg22713356	chr15:30763199	NA	1.34	10.99	0.75	1.32e-18	Uric acid levels;
THYM	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg23758822	chr17:41437982	NA	1.24	13.15	0.8	4.08e-23	Menopause (age at onset);
THYM	cis	rs71403859	0.502	rs8051974	chr16:71488771	C/T	cg08717414	chr16:71523259	ZNF19	-1.04	-5.37	-0.48	5.65e-7	Post bronchodilator FEV1;
THYM	cis	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg13443165	chr9:33130375	B4GALT1	-0.87	-7.97	-0.63	3.46e-12	IgG glycosylation;
THYM	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg11266682	chr4:10021025	SLC2A9	0.74	12.06	0.78	7.11e-21	Bone mineral density;
THYM	cis	rs7941600	0.708	rs4627080	chr11:9336349	G/T	cg19415743	chr11:9336845	TMEM41B	-1.14	-6.0	-0.52	3.6e-8	Coronary artery disease;
THYM	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.55	0.49	2.56e-7	Tonsillectomy;
THYM	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg23711669	chr6:146136114	FBXO30	0.83	7.77	0.62	9.16e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg24846343	chr22:24311635	DDTL	-0.43	-5.18	-0.47	1.23e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3917265	0.616	rs1922291	chr2:102828817	A/G	cg13315345	chr2:102803985	IL1RL2	0.66	7.86	0.63	6.07e-12	Atopic dermatitis;
THYM	cis	rs40363	0.723	rs757269	chr16:3538003	A/G	cg22508957	chr16:3507546	NAT15	-0.7	-7.05	-0.59	2.91e-10	Tuberculosis;
THYM	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Body mass index;
THYM	cis	rs4788570	0.615	rs6499531	chr16:71731485	T/C	cg06353428	chr16:71660113	MARVELD3	1.39	9.26	0.69	6.21e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7589342	0.929	rs7562054	chr2:106433513	G/C	cg14210321	chr2:106509881	NCK2	-0.72	-5.12	-0.46	1.62e-6	Addiction;
THYM	cis	rs2070677	0.736	rs60697302	chr10:135333894	G/A	cg20169779	chr10:135381914	SYCE1	-0.8	-4.72	-0.44	7.96e-6	Gout;
THYM	cis	rs61931739	0.857	rs999715	chr12:34143253	G/C	cg06521331	chr12:34319734	NA	-0.63	-5.1	-0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs240764	0.583	rs11155638	chr6:101203801	T/A	cg21058520	chr6:100914733	NA	0.6	5.28	0.48	8.25e-7	Neuroticism;
THYM	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg25036284	chr2:26402008	FAM59B	0.8	5.36	0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs346785	0.692	rs3803737	chr17:74289500	G/A	cg09812376	chr17:74270190	QRICH2	-0.48	-4.88	-0.45	4.35e-6	White matter hyperintensities in ischemic stroke;
THYM	cis	rs7688540	0.771	rs4129956	chr4:302008	A/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.73	4.93	0.45	3.46e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs9361491	0.608	rs9352628	chr6:79457447	T/G	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs13256369	0.708	rs9644772	chr8:8557685	G/A	cg18904891	chr8:8559673	CLDN23	0.74	5.66	0.5	1.6e-7	Obesity-related traits;
THYM	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg23887609	chr12:130822674	PIWIL1	0.61	4.59	0.43	1.37e-5	Menopause (age at onset);
THYM	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg04034577	chr2:241836375	C2orf54	-0.43	-7.58	-0.61	2.31e-11	Urinary metabolites;
THYM	cis	rs1003719	0.725	rs2187101	chr21:38452379	T/C	cg01329690	chr21:38580129	DSCR9	0.38	5.05	0.46	2.15e-6	Eye color traits;
THYM	cis	rs758324	0.732	rs152051	chr5:131539025	T/C	cg16205897	chr5:131564050	P4HA2	0.58	4.8	0.44	5.93e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs7599312	0.532	rs16848751	chr2:213389346	A/G	cg16329650	chr2:213403929	ERBB4	0.57	4.47	0.42	2.17e-5	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7267979	1.000	rs6115191	chr20:25440478	C/T	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	6.13	0.53	1.95e-8	Total body bone mineral density;
THYM	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg13609457	chr4:120235615	NA	0.66	5.61	0.5	2.03e-7	Corneal astigmatism;
THYM	cis	rs10949662	1.000	rs28716556	chr7:157535368	T/C	cg11757124	chr7:157526947	PTPRN2	-1.0	-9.0	-0.68	2.25e-14	Intelligence (multi-trait analysis);
THYM	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg26384229	chr12:38710491	ALG10B	0.97	7.82	0.63	7.33e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs11997175	0.531	rs113627999	chr8:33737335	G/T	ch.8.33884649F	chr8:33765107	NA	0.71	4.95	0.45	3.17e-6	Body mass index;
THYM	cis	rs7731657	0.510	rs2522030	chr5:130244071	C/T	cg08523029	chr5:130500466	HINT1	0.78	5.58	0.5	2.26e-7	Fasting plasma glucose;
THYM	cis	rs308403	0.509	rs309379	chr4:123671456	C/G	cg10495464	chr4:123653540	BBS12;LOC729338	0.98	8.86	0.67	4.47e-14	Blood protein levels;
THYM	cis	rs3916	0.794	rs10431384	chr12:121127347	C/T	cg21892295	chr12:121157589	UNC119B	0.47	5.2	0.47	1.12e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs7975161	0.630	rs6539131	chr12:104644697	A/G	cg25273343	chr12:104657179	TXNRD1	-0.78	-4.55	-0.42	1.58e-5	Toenail selenium levels;
THYM	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg06112835	chr11:68658793	MRPL21	0.43	6.1	0.53	2.3e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg13010199	chr12:38710504	ALG10B	-0.61	-5.39	-0.48	5.22e-7	Heart rate;
THYM	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg17366294	chr4:99064904	C4orf37	0.57	6.82	0.57	8.42e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11651000	0.947	rs59216876	chr17:45832965	G/A	cg03474202	chr17:45855739	NA	-0.72	-4.87	-0.45	4.42e-6	IgG glycosylation;
THYM	cis	rs877282	0.583	rs11253425	chr10:815173	G/A	cg10556349	chr10:835070	NA	-0.84	-5.48	-0.49	3.43e-7	Uric acid levels;
THYM	cis	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg13609457	chr4:120235615	NA	0.53	4.83	0.44	5.22e-6	Corneal astigmatism;
THYM	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.79	6.56	0.56	2.74e-9	Tonsillectomy;
THYM	cis	rs12216545	0.765	rs2373816	chr7:150271129	G/A	cg08960815	chr7:150264767	GIMAP4	-0.84	-7.74	-0.62	1.04e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4731207	0.596	rs1481328	chr7:124631026	C/T	cg05285228	chr7:124571219	POT1	0.7	5.28	0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg06713675	chr4:122721982	EXOSC9	0.51	4.75	0.44	7.13e-6	Type 2 diabetes;
THYM	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-4.87	-0.45	4.47e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs865483	0.861	rs1063215	chr17:35874936	A/G	cg06716730	chr17:35851459	DUSP14	0.43	7.13	0.59	1.92e-10	Monocyte count;
THYM	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg11984989	chr7:158649758	WDR60	1.17	15.44	0.85	1.22e-27	Height;
THYM	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs9563576	0.778	rs9563568	chr13:58568588	T/C	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs9549260	0.709	rs9549240	chr13:41186644	T/G	cg21288729	chr13:41239152	FOXO1	0.72	5.72	0.51	1.23e-7	Red blood cell count;
THYM	cis	rs2458413	0.563	rs2458419	chr8:105337141	G/C	cg23108931	chr8:105342351	NA	-0.32	-5.97	-0.52	4.11e-8	Paget's disease;
THYM	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs6539288	0.901	rs1444580	chr12:107314558	G/A	cg26297688	chr12:107349093	C12orf23	-0.47	-4.88	-0.45	4.27e-6	Total body bone mineral density;
THYM	cis	rs12586317	0.557	rs8004288	chr14:35679288	A/G	cg07166546	chr14:35805898	NA	-0.21	-5.0	-0.46	2.57e-6	Psoriasis;
THYM	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg08048268	chr3:133502702	NA	0.66	5.59	0.5	2.13e-7	Iron status biomarkers;
THYM	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.55	-5.02	-0.46	2.36e-6	Lymphocyte counts;
THYM	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg07022442	chr13:21864356	NA	0.72	4.78	0.44	6.38e-6	White matter hyperintensity burden;
THYM	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg13695892	chr22:41940480	POLR3H	0.89	7.27	0.6	1.02e-10	Vitiligo;
THYM	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg00277334	chr10:82204260	NA	-0.83	-10.18	-0.72	6.99e-17	Post bronchodilator FEV1;
THYM	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg16486109	chr11:613632	IRF7	0.47	5.59	0.5	2.19e-7	Systemic lupus erythematosus;
THYM	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg24209194	chr3:40518798	ZNF619	0.74	6.23	0.54	1.28e-8	Renal cell carcinoma;
THYM	cis	rs9807989	0.507	rs6710528	chr2:103016142	A/G	cg03938978	chr2:103052716	IL18RAP	-0.75	-9.77	-0.71	5.14e-16	Asthma;
THYM	cis	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-4.66	-0.43	1.03e-5	Monocyte percentage of white cells;
THYM	cis	rs6951245	0.882	rs10252404	chr7:1209607	C/A	cg23708337	chr7:1209742	NA	0.84	4.45	0.42	2.35e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7584330	0.652	rs7607231	chr2:238372896	T/C	cg16989719	chr2:238392110	NA	-0.61	-5.92	-0.52	5.04e-8	Prostate cancer;
THYM	cis	rs514406	0.893	rs1242326	chr1:53399104	C/A	cg16325326	chr1:53192061	ZYG11B	0.81	7.53	0.61	2.93e-11	Monocyte count;
THYM	cis	rs929596	0.561	rs11891311	chr2:234639310	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.88	7.16	0.59	1.72e-10	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs4563143	0.675	rs55849754	chr19:29279665	G/A	cg03161606	chr19:29218774	NA	0.87	7.3	0.6	8.75e-11	Methadone dose in opioid dependence;
THYM	cis	rs7104764	0.507	rs6598056	chr11:252283	A/G	cg18336825	chr11:236787	PSMD13;SIRT3	-0.91	-5.92	-0.52	5.14e-8	Menarche (age at onset);
THYM	cis	rs2806561	0.734	rs7548692	chr1:23354877	T/A	cg19743168	chr1:23544995	NA	0.5	4.88	0.45	4.32e-6	Height;
THYM	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg18252515	chr7:66147081	NA	-1.39	-8.32	-0.65	6.35e-13	Diabetic kidney disease;
THYM	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22307029	chr19:49891270	CCDC155	0.78	6.8	0.57	9.16e-10	Multiple sclerosis;
THYM	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg01528321	chr10:82214614	TSPAN14	0.63	5.31	0.48	7.07e-7	Post bronchodilator FEV1;
THYM	cis	rs6700896	0.966	rs7516341	chr1:66088143	T/C	cg04111102	chr1:66153794	NA	0.53	4.64	0.43	1.12e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs9420	0.784	rs12798206	chr11:57668479	T/G	cg19752551	chr11:57585705	CTNND1	-0.72	-7.2	-0.59	1.42e-10	Schizophrenia;
THYM	cis	rs7572733	0.534	rs1464211	chr2:198798630	G/A	cg00792783	chr2:198669748	PLCL1	0.82	5.75	0.51	1.08e-7	Dermatomyositis;
THYM	cis	rs4918072	0.874	rs3850670	chr10:105659369	C/T	cg11005552	chr10:105648138	OBFC1	0.75	6.25	0.54	1.15e-8	Coronary artery disease;
THYM	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg09222892	chr1:25734099	RHCE	0.59	4.64	0.43	1.11e-5	Erythrocyte sedimentation rate;
THYM	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg03452623	chr4:187889614	NA	-1.19	-19.33	-0.89	1.1e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1728785	0.688	rs7203363	chr16:68587692	T/A	cg02972257	chr16:68554789	NA	-0.76	-4.63	-0.43	1.14e-5	Ulcerative colitis;
THYM	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs58873874	0.737	rs111759027	chr5:156916636	A/C	cg08916508	chr5:156566250	MED7	-1.31	-4.98	-0.45	2.84e-6	Bipolar disorder (body mass index interaction);
THYM	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-6.68	-0.57	1.62e-9	Platelet count;
THYM	cis	rs416603	0.901	rs149597	chr16:11343942	C/G	cg00044050	chr16:11439710	C16orf75	-0.77	-5.92	-0.52	4.99e-8	Type 1 diabetes;
THYM	cis	rs5769765	0.542	rs5769751	chr22:50242733	T/G	cg02269571	chr22:50332266	NA	1.35	7.2	0.59	1.41e-10	Schizophrenia;
THYM	cis	rs6430585	0.528	rs6711493	chr2:136692553	A/G	cg07169764	chr2:136633963	MCM6	1.02	10.81	0.74	3.14e-18	Corneal structure;
THYM	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.58	-4.58	-0.43	1.41e-5	Bipolar disorder;
THYM	cis	rs7677751	0.806	rs4864847	chr4:55071953	G/A	cg17187183	chr4:55093834	PDGFRA	0.67	5.15	0.47	1.43e-6	Corneal astigmatism;
THYM	cis	rs3857067	0.836	rs12501138	chr4:95098444	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.49	-4.45	-0.42	2.32e-5	QT interval;
THYM	cis	rs6840360	0.571	rs4696273	chr4:152528477	G/A	cg17479576	chr4:152424074	FAM160A1	-0.84	-5.97	-0.52	4.15e-8	Intelligence (multi-trait analysis);
THYM	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg18132916	chr6:79620363	NA	-0.59	-5.29	-0.48	7.95e-7	Intelligence (multi-trait analysis);
THYM	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg14893161	chr1:205819251	PM20D1	0.59	4.56	0.42	1.55e-5	Menarche (age at onset);
THYM	cis	rs4638749	0.677	rs9631035	chr2:108818916	C/T	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.85e-7	Blood pressure;
THYM	cis	rs13082711	0.911	rs34878935	chr3:27466123	A/C	cg02860705	chr3:27208620	NA	0.72	5.14	0.47	1.46e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs7851660	0.809	rs7034648	chr9:100654093	C/A	cg13688889	chr9:100608707	NA	-0.78	-5.67	-0.5	1.53e-7	Strep throat;
THYM	cis	rs3136739	0.717	rs60117685	chr8:42091477	A/G	cg16230352	chr8:42123158	NA	0.75	4.66	0.43	1.03e-5	Plasma plasminogen activator levels;
THYM	cis	rs11711311	1.000	rs9811353	chr3:113483979	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.58	-5.13	-0.47	1.55e-6	IgG glycosylation;
THYM	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg01324343	chr3:183735012	ABCC5	0.65	8.85	0.67	4.75e-14	Anterior chamber depth;
THYM	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg03806693	chr22:41940476	POLR3H	-1.11	-8.99	-0.68	2.33e-14	Vitiligo;
THYM	cis	rs2404602	0.647	rs11072610	chr15:76930805	C/A	cg23625390	chr15:77176239	SCAPER	-0.95	-6.6	-0.56	2.3e-9	Blood metabolite levels;
THYM	cis	rs4343996	0.558	rs10235815	chr7:3413867	T/G	cg21248987	chr7:3385318	SDK1	0.4	4.91	0.45	3.72e-6	Motion sickness;
THYM	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg10523679	chr1:76189770	ACADM	0.9	9.47	0.7	2.2e-15	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs4631830	0.568	rs12781411	chr10:51491589	C/T	cg16070123	chr10:51489643	NA	0.57	5.35	0.48	6e-7	Prostate-specific antigen levels;
THYM	cis	rs56104184	0.775	rs3760785	chr19:49403178	G/T	cg17863274	chr19:49399704	TULP2	-0.88	-5.81	-0.51	8.31e-8	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.55	5.16	0.47	1.36e-6	Schizophrenia;
THYM	cis	rs6754311	0.550	rs12994270	chr2:136518103	T/A	cg04750100	chr2:136595281	LCT	-0.55	-6.28	-0.54	1.01e-8	Mosquito bite size;
THYM	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg11764359	chr7:65958608	NA	0.87	7.45	0.61	4.16e-11	Aortic root size;
THYM	cis	rs11690935	0.959	rs4668412	chr2:172619770	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.84	-6.16	-0.53	1.77e-8	Schizophrenia;
THYM	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg03354898	chr7:1950403	MAD1L1	-0.49	-4.75	-0.44	7.15e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6568490	0.556	rs2354095	chr6:108090237	A/G	cg03500965	chr6:108145777	SCML4	-0.4	-4.75	-0.44	7.2e-6	Lymphocyte counts;
THYM	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	7.98	0.63	3.34e-12	Platelet count;
THYM	cis	rs10752881	1.000	rs12035773	chr1:182985716	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.79	0.44	6.13e-6	Colorectal cancer;
THYM	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg24250549	chr1:154909240	PMVK	-0.66	-5.07	-0.46	1.92e-6	Prostate cancer;
THYM	cis	rs79149102	0.579	rs28394281	chr15:75326754	C/G	cg17294928	chr15:75287854	SCAMP5	-1.03	-5.57	-0.5	2.32e-7	Lung cancer;
THYM	cis	rs4927850	0.829	rs6768483	chr3:195745963	C/G	cg12923728	chr3:195709715	SDHAP1	-0.83	-6.31	-0.54	8.97e-9	Pancreatic cancer;
THYM	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg06238570	chr21:40685208	BRWD1	-0.97	-9.35	-0.69	4.03e-15	Cognitive function;
THYM	cis	rs2066819	1.000	rs1802236	chr12:56679751	A/G	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg01350728	chr13:21893604	NA	-0.57	-4.45	-0.42	2.31e-5	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs539096	0.872	rs631248	chr1:44071221	C/T	cg08936794	chr1:43833873	ELOVL1	0.64	4.57	0.42	1.47e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg02869364	chr7:1081709	C7orf50	-0.61	-4.92	-0.45	3.63e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2276314	0.857	rs6507158	chr18:33636066	A/C	cg19628046	chr18:33552617	C18orf21	0.74	5.43	0.49	4.29e-7	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs2279817	0.818	rs34304724	chr1:17994850	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.79	-4.63	-0.43	1.14e-5	Neuroticism;
THYM	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.77	6.97	0.58	4.11e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs4919694	1.000	rs17727044	chr10:104821256	A/T	cg15744005	chr10:104629667	AS3MT	-0.85	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs4606347	0.872	rs61781319	chr1:66105888	G/A	cg04111102	chr1:66153794	NA	0.59	4.54	0.42	1.67e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg09904177	chr6:26538194	HMGN4	0.53	4.5	0.42	1.95e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg12826209	chr6:26865740	GUSBL1	0.85	4.67	0.43	9.98e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.84	8.49	0.66	2.72e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7255045	0.742	rs10420014	chr19:12960947	G/T	cg26870725	chr19:12978805	MAST1	-0.69	-5.31	-0.48	7.23e-7	Mean corpuscular volume;
THYM	cis	rs72717009	0.825	rs7529425	chr1:161479599	G/A	cg23840854	chr1:161414152	NA	-1.01	-5.36	-0.48	5.81e-7	Rheumatoid arthritis;
THYM	cis	rs11760633	0.526	rs7805390	chr7:1826023	T/G	cg27050990	chr7:2629313	IQCE	0.64	4.6	0.43	1.31e-5	Coronary artery disease;
THYM	cis	rs514406	0.689	rs7548389	chr1:53404211	C/T	cg25767906	chr1:53392781	SCP2	-0.61	-5.97	-0.52	4.16e-8	Monocyte count;
THYM	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	4.55	0.42	1.6e-5	Renal function-related traits (BUN);
THYM	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.95	0.71	2.08e-16	Colorectal cancer;
THYM	cis	rs7584330	0.518	rs74003104	chr2:238446823	C/T	cg14458575	chr2:238380390	NA	0.82	4.53	0.42	1.74e-5	Prostate cancer;
THYM	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg20999797	chr1:1681921	NA	0.47	4.97	0.45	2.99e-6	Body mass index;
THYM	cis	rs6669384	0.774	rs61821315	chr1:208027696	C/T	cg00085493	chr1:208040203	NA	0.59	4.48	0.42	2.1e-5	Immune response to measles vaccine (measles-specific neutralising antibody titre);
THYM	cis	rs8050907	1.000	rs8061699	chr16:4632723	G/C	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.26	5.08	0.46	1.85e-6	Obesity-related traits;
THYM	cis	rs7124681	0.505	rs7126378	chr11:47585348	G/T	cg18512352	chr11:47633146	NA	0.44	4.72	0.44	8.23e-6	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
THYM	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg00744431	chr10:134226547	PWWP2B	-0.61	-4.69	-0.43	8.98e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs669446	0.562	rs11210907	chr1:44191759	C/T	cg15962314	chr1:44399869	ARTN	0.43	4.58	0.43	1.42e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg17054759	chr22:49844102	NA	-0.51	-4.88	-0.45	4.3e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11644478	chr21:40555479	PSMG1	1.02	8.54	0.66	2.14e-13	Cognitive function;
THYM	cis	rs2747539	1.000	rs68074572	chr20:32421026	G/T	cg06304546	chr20:32448765	NA	-0.81	-5.08	-0.46	1.9e-6	Dysphagia;
THYM	cis	rs1045902	0.516	rs7851	chr2:73478461	A/T	cg24220031	chr2:73402428	NA	-0.58	-5.15	-0.47	1.39e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4654899	0.828	rs6668591	chr1:21066557	A/G	cg01072550	chr1:21505969	NA	-0.61	-5.27	-0.48	8.41e-7	Superior frontal gyrus grey matter volume;
THYM	cis	rs733592	0.965	rs1978161	chr12:48467721	A/G	cg21466736	chr12:48725269	NA	0.48	5.29	0.48	7.82e-7	Plateletcrit;
THYM	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Gout;
THYM	cis	rs863345	0.625	rs10908663	chr1:158492121	C/T	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg26314531	chr2:26401878	FAM59B	-0.77	-5.36	-0.48	5.93e-7	Gut microbiome composition (summer);
THYM	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg05855489	chr10:104503620	C10orf26	-0.8	-7.2	-0.59	1.38e-10	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7523273	0.927	rs2796275	chr1:207950490	C/T	cg22525895	chr1:207977042	MIR29B2	0.81	7.7	0.62	1.3e-11	Schizophrenia;
THYM	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.92	-4.73	-0.44	7.76e-6	Alzheimer's disease;
THYM	cis	rs11039798	0.841	rs10839174	chr11:48931185	G/A	cg24672777	chr11:48374446	OR4C45	-1.13	-6.83	-0.57	7.89e-10	Axial length;
THYM	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg25358565	chr5:93447407	FAM172A	-0.96	-6.78	-0.57	1.01e-9	Diabetic retinopathy;
THYM	cis	rs2806561	0.754	rs648322	chr1:23294839	C/T	cg19743168	chr1:23544995	NA	0.56	5.31	0.48	7.17e-7	Height;
THYM	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-5.28	-0.48	8.25e-7	Chronic sinus infection;
THYM	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs2039659	0.719	rs1538050	chr13:86276094	C/T	cg25308322	chr13:86268291	NA	-0.62	-5.31	-0.48	7.18e-7	Blood osmolality (transformed sodium);
THYM	cis	rs669446	0.591	rs607062	chr1:44133016	A/G	cg12599982	chr1:44399894	ARTN	0.52	4.45	0.42	2.35e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3820068	0.603	rs6429753	chr1:15900537	A/G	cg05660106	chr1:15850417	CASP9	0.94	7.6	0.61	2.08e-11	Systolic blood pressure;
THYM	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg15557168	chr22:42548783	NA	0.58	4.68	0.43	9.66e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs9311676	0.656	rs11917529	chr3:58382158	C/T	cg26110898	chr3:58419937	PDHB	0.44	4.72	0.44	8.21e-6	Systemic lupus erythematosus;
THYM	cis	rs3741151	0.773	rs73544783	chr11:73221256	C/G	cg17517138	chr11:73019481	ARHGEF17	0.89	4.73	0.44	7.86e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs7119	0.717	rs11632729	chr15:77722006	G/A	cg10437265	chr15:77819839	NA	0.56	4.99	0.46	2.78e-6	Type 2 diabetes;
THYM	cis	rs6457821	1.000	rs73746446	chr6:35479115	A/G	cg05593667	chr6:35490744	NA	-0.89	-4.6	-0.43	1.28e-5	Height;
THYM	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg08885076	chr2:99613938	TSGA10	0.57	5.45	0.49	3.95e-7	Chronic sinus infection;
THYM	cis	rs13315871	0.615	rs6794695	chr3:58423498	A/C	cg12435725	chr3:58293450	RPP14	-0.35	-4.48	-0.42	2.06e-5	Cholesterol, total;
THYM	cis	rs12681288	0.523	rs11137122	chr8:954702	A/G	cg08648136	chr8:956695	NA	0.54	4.62	0.43	1.19e-5	Schizophrenia;
THYM	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.3	-0.48	7.34e-7	Monocyte percentage of white cells;
THYM	cis	rs1021993	0.597	rs2356722	chr1:209524734	A/G	cg06155620	chr1:209527581	NA	-0.52	-4.55	-0.42	1.58e-5	Gut microbiome composition (winter);
THYM	cis	rs72627123	0.867	rs73301493	chr14:74472197	C/A	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs12681287	0.547	rs11992656	chr8:87534869	T/A	cg27223183	chr8:87520930	FAM82B	0.71	5.56	0.5	2.44e-7	Caudate activity during reward;
THYM	cis	rs2798269	0.604	rs2798277	chr13:22155781	C/G	cg18095732	chr13:22033692	ZDHHC20	-0.61	-4.55	-0.42	1.6e-5	PR segment;
THYM	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.37	-0.48	5.53e-7	Monocyte percentage of white cells;
THYM	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg22508957	chr16:3507546	NAT15	0.51	5.37	0.48	5.62e-7	Body mass index (adult);
THYM	cis	rs7107174	1.000	rs2511155	chr11:77969223	G/A	cg02023728	chr11:77925099	USP35	0.68	6.03	0.53	3.06e-8	Testicular germ cell tumor;
THYM	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg07936489	chr17:37558343	FBXL20	-0.82	-5.61	-0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	7.48	0.61	3.77e-11	Platelet count;
THYM	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg15536230	chr21:44985092	HSF2BP	-0.38	-4.48	-0.42	2.11e-5	Mean corpuscular volume;
THYM	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg02725872	chr8:58115012	NA	-1.15	-7.6	-0.61	2.13e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs17854409	0.881	rs12625401	chr20:61472939	A/T	cg05147244	chr20:61493195	TCFL5	0.89	5.2	0.47	1.15e-6	Obesity-related traits;
THYM	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg03188948	chr7:1209495	NA	0.68	4.73	0.44	7.72e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg15693483	chr7:1102177	C7orf50	0.46	4.8	0.44	5.89e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2806561	0.929	rs628096	chr1:23537676	C/G	cg12483005	chr1:23474871	LUZP1	0.52	5.23	0.47	1.01e-6	Height;
THYM	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.68	-5.57	-0.5	2.4e-7	Blood metabolite levels;
THYM	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.68	9.03	0.68	1.97e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs17001868	0.527	rs73167009	chr22:40734249	T/C	cg07138101	chr22:40742427	ADSL	0.82	4.85	0.45	4.8e-6	Mammographic density (dense area);
THYM	cis	rs11809207	1.000	rs11247867	chr1:26517891	C/T	cg03844060	chr1:26490628	NA	0.7	5.01	0.46	2.51e-6	Height;
THYM	cis	rs26232	0.526	rs61654927	chr5:102382725	C/A	cg23492399	chr5:102201601	PAM	-0.68	-5.05	-0.46	2.15e-6	Rheumatoid arthritis;
THYM	cis	rs7941600	0.786	rs12273748	chr11:9360367	A/G	cg19415743	chr11:9336845	TMEM41B	0.9	4.63	0.43	1.15e-5	Coronary artery disease;
THYM	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg05738196	chr6:26577821	NA	0.69	5.64	0.5	1.72e-7	Intelligence (multi-trait analysis);
THYM	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg17333051	chr19:2783644	SGTA	0.73	6.31	0.54	8.81e-9	Total cholesterol levels;
THYM	cis	rs34912216	0.619	rs13233532	chr7:4131518	C/T	cg03141780	chr7:4150753	SDK1	0.68	5.17	0.47	1.29e-6	Motion sickness;
THYM	cis	rs10716631	1	rs10716631	chr2:219138170	T/G	cg04731861	chr2:219085781	ARPC2	-0.54	-4.88	-0.45	4.35e-6	High light scatter reticulocyte percentage of red cells;Plateletcrit;
THYM	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg26721908	chr21:47610096	LSS	-0.87	-6.27	-0.54	1.05e-8	Testicular germ cell tumor;
THYM	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	trans	rs28595532	0.557	rs4359977	chr4:119314055	T/C	cg26518628	chr1:97050305	NA	-1.22	-8.63	-0.66	1.39e-13	Cannabis dependence symptom count;
THYM	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg18105134	chr13:113819100	PROZ	-1.15	-10.31	-0.73	3.57e-17	Platelet distribution width;
THYM	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg16414030	chr3:133502952	NA	0.84	8.28	0.65	7.65e-13	Iron status biomarkers;
THYM	cis	rs2730245	0.527	rs712199	chr7:158662250	A/G	cg11984989	chr7:158649758	WDR60	1.01	8.07	0.64	2.13e-12	Height;
THYM	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg18252515	chr7:66147081	NA	-0.63	-4.74	-0.44	7.61e-6	Aortic root size;
THYM	cis	rs1451375	1.000	rs921450	chr7:50623260	A/G	cg18232548	chr7:50535776	DDC	-0.74	-5.73	-0.51	1.18e-7	Malaria;
THYM	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg26384229	chr12:38710491	ALG10B	-0.72	-5.64	-0.5	1.75e-7	Morning vs. evening chronotype;
THYM	cis	rs7078219	0.543	rs7095491	chr10:101274058	A/G	cg17888390	chr10:101282816	NA	-0.46	-4.67	-0.43	9.79e-6	Dental caries;
THYM	cis	rs6570726	0.902	rs9390326	chr6:145791222	A/G	cg13319975	chr6:146136371	FBXO30	0.68	5.75	0.51	1.07e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	10.73	0.74	4.66e-18	Chronic sinus infection;
THYM	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg26354017	chr1:205819088	PM20D1	0.98	10.67	0.74	6.25e-18	Menarche (age at onset);
THYM	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg10760299	chr15:45669010	GATM	0.87	6.61	0.56	2.21e-9	Homoarginine levels;
THYM	cis	rs6980334	0.679	rs3816829	chr7:137792420	A/G	cg18769353	chr7:137028617	PTN	0.64	5.06	0.46	2.01e-6	Blood metabolite ratios;
THYM	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg13609457	chr4:120235615	NA	0.54	5.0	0.46	2.63e-6	Corneal astigmatism;
THYM	cis	rs4919044	0.599	rs11187206	chr10:94659515	C/G	cg05127821	chr10:94822908	CYP26C1	-1.06	-6.33	-0.54	8.17e-9	Coronary artery disease;
THYM	cis	rs59107033	0.559	rs62262396	chr3:123105491	A/G	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Lymphocyte counts;
THYM	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.89	5.72	0.51	1.25e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	14.47	0.83	9.53e-26	Chronic sinus infection;
THYM	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg22709100	chr7:91322751	NA	0.61	4.86	0.45	4.66e-6	Breast cancer;
THYM	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.82	-5.23	-0.47	1e-6	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs72627123	0.531	rs3742806	chr14:74532523	A/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.29	7.08	0.59	2.46e-10	Morning vs. evening chronotype;
THYM	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg22535103	chr8:58192502	C8orf71	-0.88	-5.74	-0.51	1.11e-7	Developmental language disorder (linguistic errors);
THYM	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg10802521	chr3:52805072	NEK4	-0.74	-6.34	-0.55	7.65e-9	Bipolar disorder;
THYM	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg23428387	chr22:49814324	NA	-0.6	-6.24	-0.54	1.22e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg19196401	chr6:110721138	DDO	-0.59	-6.3	-0.54	9.2e-9	Platelet distribution width;
THYM	cis	rs13315871	1.000	rs9850717	chr3:58351875	C/T	cg12435725	chr3:58293450	RPP14	-0.5	-4.8	-0.44	5.93e-6	Cholesterol, total;
THYM	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg10523679	chr1:76189770	ACADM	-0.55	-4.67	-0.43	9.97e-6	Daytime sleep phenotypes;
THYM	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg23018236	chr17:30244563	NA	-0.6	-4.45	-0.42	2.3e-5	Hip circumference adjusted for BMI;
THYM	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg24818145	chr4:99064322	C4orf37	0.87	7.23	0.6	1.19e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4730276	0.674	rs6944829	chr7:107525732	C/A	cg23293999	chr7:106826042	HBP1	-0.56	-4.47	-0.42	2.16e-5	Ulcerative colitis;
THYM	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	10.29	0.73	3.95e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7940866	0.874	rs10791113	chr11:130873165	A/G	cg12179176	chr11:130786555	SNX19	0.59	4.55	0.42	1.58e-5	Schizophrenia;
THYM	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg24818145	chr4:99064322	C4orf37	0.64	4.77	0.44	6.62e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg02696790	chr15:75250997	RPP25	0.49	4.71	0.44	8.48e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg05660106	chr1:15850417	CASP9	0.75	6.12	0.53	2.11e-8	Systolic blood pressure;
THYM	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg19761014	chr17:28927070	LRRC37B2	0.85	5.14	0.47	1.48e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9467773	0.526	rs9688946	chr6:26367445	C/A	cg14345882	chr6:26364793	BTN3A2	0.35	4.66	0.43	1.01e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7589342	0.929	rs6725519	chr2:106445209	A/G	cg14210321	chr2:106509881	NCK2	0.72	5.15	0.47	1.4e-6	Addiction;
THYM	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg05738196	chr6:26577821	NA	0.86	8.72	0.67	9.13e-14	Intelligence (multi-trait analysis);
THYM	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg23131131	chr22:24373011	LOC391322	-0.81	-8.24	-0.65	9.31e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs8133932	0.654	rs420386	chr21:47364816	G/A	cg20357416	chr21:47294739	PCBP3	0.74	4.59	0.43	1.36e-5	Schizophrenia;
THYM	cis	rs8050907	0.744	rs78538387	chr16:4523167	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	1.24	4.58	0.43	1.38e-5	Obesity-related traits;
THYM	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg12386194	chr3:101231763	SENP7	-0.95	-7.6	-0.61	2.09e-11	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs17443541	0.507	rs768637	chr2:200474888	A/C	cg03741458	chr2:200468445	NA	-0.76	-5.6	-0.5	2.09e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11048434	0.736	rs2041624	chr12:9111855	C/G	cg04155231	chr12:9217510	LOC144571	0.48	4.49	0.42	2.03e-5	Sjögren's syndrome;
THYM	cis	rs611744	0.967	rs584716	chr8:109178634	A/T	cg21045802	chr8:109455806	TTC35	0.59	5.22	0.47	1.03e-6	Dupuytren's disease;
THYM	cis	rs7586879	0.616	rs876186	chr2:25125585	C/T	cg01884057	chr2:25150051	NA	0.73	7.9	0.63	4.81e-12	Body mass index;
THYM	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg22974920	chr21:40686053	BRWD1	-0.61	-4.75	-0.44	7.29e-6	Cognitive function;
THYM	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.56	-4.86	-0.45	4.6e-6	Prudent dietary pattern;
THYM	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.69	5.15	0.47	1.41e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	7.84	0.63	6.39e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs2562456	0.617	rs34203148	chr19:21773545	T/A	cg21751540	chr19:21541537	ZNF738	-0.7	-4.74	-0.44	7.48e-6	Pain;
THYM	cis	rs7191439	0.583	rs9935872	chr16:88788477	A/G	cg04602696	chr16:88846723	FAM38A	-0.62	-4.72	-0.44	8.13e-6	Plateletcrit;
THYM	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg24060327	chr5:131705240	SLC22A5	0.8	6.52	0.56	3.35e-9	Breast cancer;
THYM	cis	rs7592578	0.771	rs1128723	chr2:191366707	A/G	cg10560079	chr2:191398806	TMEM194B	-0.96	-7.9	-0.63	4.88e-12	Diastolic blood pressure;
THYM	cis	rs2637266	0.935	rs4353214	chr10:78393149	C/T	cg18941641	chr10:78392320	NA	-0.81	-6.99	-0.58	3.83e-10	Pulmonary function;
THYM	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg18876405	chr7:65276391	NA	0.57	4.81	0.44	5.65e-6	Aortic root size;
THYM	cis	rs9660180	0.837	rs915292	chr1:1792157	A/C	cg17747265	chr1:1875780	NA	-0.79	-9.12	-0.68	1.24e-14	Body mass index;
THYM	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.27	4.47	0.42	2.16e-5	Obesity-related traits;
THYM	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg05425664	chr17:57184151	TRIM37	-0.65	-5.21	-0.47	1.1e-6	Intelligence (multi-trait analysis);
THYM	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg07212818	chr11:638076	DRD4	-0.73	-5.06	-0.46	2.08e-6	Systemic lupus erythematosus;
THYM	cis	rs6952809	1.000	rs2023968	chr7:2451461	A/G	cg25507518	chr7:2405875	EIF3B	-0.54	-4.8	-0.44	6e-6	Multiple sclerosis;
THYM	cis	rs514406	0.861	rs35517489	chr1:53304062	G/C	cg08736216	chr1:53307985	ZYG11A	-0.6	-5.56	-0.5	2.46e-7	Monocyte count;
THYM	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg12311346	chr5:56204834	C5orf35	-0.79	-5.64	-0.5	1.71e-7	Initial pursuit acceleration;
THYM	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg27532560	chr4:187881888	NA	-0.95	-12.07	-0.78	7e-21	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.521	rs11247998	chr4:1363602	T/C	cg00684032	chr4:1343700	KIAA1530	0.79	7.14	0.59	1.84e-10	Obesity-related traits;
THYM	cis	rs3126085	0.935	rs3126043	chr1:152256030	C/G	cg26020982	chr1:152196106	HRNR	0.35	4.95	0.45	3.26e-6	Atopic dermatitis;
THYM	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs6840360	0.615	rs72728179	chr4:152477877	A/G	cg22705602	chr4:152727874	NA	-0.71	-7.43	-0.61	4.71e-11	Intelligence (multi-trait analysis);
THYM	cis	rs12530845	0.767	rs7784162	chr7:135305886	G/T	cg23117316	chr7:135346802	PL-5283	-0.59	-5.25	-0.47	9.41e-7	Red blood cell traits;
THYM	cis	rs990171	0.955	rs1573895	chr2:102982876	T/C	cg13897122	chr2:103039542	IL18RAP	-0.4	-4.76	-0.44	6.87e-6	Lymphocyte counts;
THYM	cis	rs7731657	0.588	rs6595977	chr5:130334642	T/G	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg01579765	chr21:45077557	HSF2BP	-0.49	-8.06	-0.64	2.29e-12	Mean corpuscular volume;
THYM	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg24006582	chr15:45444508	DUOX1	-0.83	-7.16	-0.59	1.7e-10	Uric acid levels;
THYM	cis	rs950027	0.787	rs1547487	chr15:45723983	A/G	cg26924012	chr15:45694286	SPATA5L1	0.56	4.56	0.42	1.5e-5	Response to fenofibrate (adiponectin levels);
THYM	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg17063962	chr7:91808500	NA	-1.13	-12.56	-0.79	6.81e-22	Breast cancer;
THYM	cis	rs2486012	1.000	rs3011227	chr1:44325409	G/A	cg06513818	chr1:43907433	KIAA0467	0.75	4.48	0.42	2.07e-5	Intelligence (multi-trait analysis);
THYM	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.43	4.55	0.42	1.59e-5	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg17054759	chr22:49844102	NA	-0.5	-4.67	-0.43	9.96e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg05962950	chr11:130786565	SNX19	0.98	10.43	0.73	2.04e-17	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2463822	1.000	rs2463820	chr11:62112290	A/T	cg06239285	chr11:62104954	ASRGL1	1.41	7.07	0.59	2.63e-10	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg05147244	chr20:61493195	TCFL5	1.02	6.22	0.54	1.34e-8	Obesity-related traits;
THYM	cis	rs270601	0.683	rs81598	chr5:131587960	C/G	cg04518342	chr5:131593106	PDLIM4	0.52	5.47	0.49	3.6e-7	Acylcarnitine levels;
THYM	cis	rs921968	0.565	rs4674328	chr2:219593203	T/C	cg02176678	chr2:219576539	TTLL4	-0.47	-4.56	-0.42	1.55e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg16586182	chr3:47516702	SCAP	0.68	5.66	0.5	1.58e-7	Colorectal cancer;
THYM	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg04944784	chr2:26401820	FAM59B	-0.65	-5.01	-0.46	2.54e-6	Gut microbiome composition (summer);
THYM	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg02753203	chr1:228287806	NA	-0.6	-5.14	-0.47	1.46e-6	Diastolic blood pressure;
THYM	cis	rs2552220	1.000	rs13273035	chr8:6008564	G/A	cg06481462	chr8:7005678	NA	0.51	5.21	0.47	1.08e-6	Interleukin-8 levels;
THYM	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg05025164	chr4:1340916	KIAA1530	0.91	7.11	0.59	2.11e-10	Longevity;
THYM	cis	rs4747241	0.626	rs10762511	chr10:74067312	T/C	cg07828833	chr10:74069493	NA	0.59	5.08	0.46	1.9e-6	Heschl's gyrus morphology;
THYM	cis	rs4842666	0.831	rs12230074	chr12:90090867	A/G	cg00757033	chr12:89920650	WDR51B	0.5	4.84	0.44	5.07e-6	Blood pressure;
THYM	cis	rs8013055	0.846	rs7160747	chr14:105983740	A/G	cg11597832	chr14:105993747	TMEM121	-0.53	-4.54	-0.42	1.62e-5	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1568889	1.000	rs16917735	chr11:28119980	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.74	-4.86	-0.45	4.66e-6	Bipolar disorder;
THYM	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.17	9.31	0.69	4.83e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs10751667	1.000	rs7395691	chr11:985006	T/C	cg01483505	chr11:975446	AP2A2	0.64	4.95	0.45	3.26e-6	Alzheimer's disease (late onset);
THYM	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg11663144	chr21:46675770	NA	-0.7	-9.8	-0.71	4.38e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2412459	0.635	rs7174767	chr15:40269800	T/C	cg16127683	chr15:40268777	EIF2AK4	0.59	5.23	0.47	1.01e-6	Response to haloperidol in psychosis;
THYM	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg07936489	chr17:37558343	FBXL20	-0.71	-5.25	-0.47	9.23e-7	Asthma;
THYM	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg13114125	chr14:105738426	BRF1	-0.72	-5.62	-0.5	1.91e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs7646881	0.812	rs79303235	chr3:158444793	C/T	cg19483011	chr3:158453295	NA	-0.73	-4.54	-0.42	1.65e-5	Tetralogy of Fallot;
THYM	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg14074117	chr16:1909714	C16orf73	-0.7	-4.45	-0.42	2.3e-5	Glomerular filtration rate in chronic kidney disease;
THYM	cis	rs7085104	0.727	rs12773892	chr10:104631177	G/T	cg04362960	chr10:104952993	NT5C2	0.94	6.29	0.54	9.71e-9	Immature fraction of reticulocytes;Schizophrenia;
THYM	cis	rs7248779	0.512	rs7250002	chr19:2413188	A/G	cg22729335	chr19:2427816	TIMM13	1.23	12.99	0.8	8.68e-23	Cortisol levels (saliva);
THYM	cis	rs7588746	0.868	rs12104649	chr2:201128832	C/T	cg23649088	chr2:200775458	C2orf69	-0.77	-5.22	-0.47	1.03e-6	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	4.48	0.42	2.12e-5	Rheumatoid arthritis;
THYM	cis	rs7584330	0.737	rs7584314	chr2:238361089	C/T	cg04447362	chr2:237654635	NA	0.48	4.49	0.42	2.03e-5	Prostate cancer;
THYM	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28595532	0.920	rs115841156	chr4:119740073	C/T	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs995000	0.965	rs10889353	chr1:63118196	A/C	cg06896770	chr1:63153194	DOCK7	1.0	8.13	0.64	1.61e-12	Triglyceride levels;
THYM	cis	rs10937405	0.642	rs2378502	chr3:189303711	G/T	cg13894444	chr3:189821064	LEPREL1	-0.62	-4.54	-0.42	1.64e-5	Lung adenocarcinoma;
THYM	cis	rs4474465	0.790	rs7106931	chr11:78229612	A/G	cg19901956	chr11:77921274	USP35	0.7	5.2	0.47	1.16e-6	Alzheimer's disease (survival time);
THYM	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg06115741	chr20:33292138	TP53INP2	0.7	4.65	0.43	1.06e-5	Coronary artery disease;
THYM	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg24503407	chr1:205819492	PM20D1	0.95	9.37	0.69	3.65e-15	Menarche (age at onset);
THYM	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg03690763	chr11:133734501	NA	-0.63	-5.22	-0.47	1.06e-6	Childhood ear infection;
THYM	cis	rs10089	1.000	rs10060390	chr5:127452947	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg21427119	chr20:30132790	HM13	-0.82	-5.6	-0.5	2.05e-7	Mean corpuscular hemoglobin;
THYM	cis	rs6570726	0.935	rs446242	chr6:145843866	A/G	cg13319975	chr6:146136371	FBXO30	-0.7	-6.05	-0.53	2.9e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg11266682	chr4:10021025	SLC2A9	0.73	12.79	0.8	2.29e-22	Bone mineral density;
THYM	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg22907277	chr7:1156413	C7orf50	0.78	6.56	0.56	2.87e-9	Longevity;Endometriosis;
THYM	cis	rs8180040	0.800	rs11130126	chr3:47306894	A/G	cg02527881	chr3:46936655	PTH1R	0.59	5.48	0.49	3.44e-7	Colorectal cancer;
THYM	cis	rs4654899	0.680	rs4654874	chr1:21156667	C/T	cg01072550	chr1:21505969	NA	-0.7	-6.81	-0.57	8.91e-10	Superior frontal gyrus grey matter volume;
THYM	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg04731861	chr2:219085781	ARPC2	0.54	5.05	0.46	2.11e-6	Colorectal cancer;
THYM	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4919044	0.866	rs4919592	chr10:94823413	G/A	cg05127821	chr10:94822908	CYP26C1	-1.24	-6.68	-0.57	1.64e-9	Coronary artery disease;
THYM	cis	rs1021993	1.000	rs2660640	chr1:209510190	A/C	cg06155620	chr1:209527581	NA	0.57	4.69	0.43	9.27e-6	Gut microbiome composition (winter);
THYM	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg10802521	chr3:52805072	NEK4	-0.71	-6.18	-0.54	1.57e-8	Bipolar disorder;
THYM	trans	rs75518195	0.500	rs17687745	chr4:64670736	C/T	cg14706739	chr8:21916355	EPB49	0.75	7.37	0.6	6.34e-11	Triptolide cytotoxicity;
THYM	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.65	5.07	0.46	1.92e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs11771526	0.792	rs11770580	chr7:32305009	T/C	cg27532318	chr7:32358331	NA	0.72	4.78	0.44	6.45e-6	Body mass index;
THYM	cis	rs62236223	1	rs62236223	chr22:31863554	T/C	cg10537193	chr22:32026975	PISD	-0.91	-5.27	-0.48	8.59e-7	Age-related hearing impairment;
THYM	cis	rs478304	0.651	rs11600918	chr11:65511965	A/G	cg27068330	chr11:65405492	SIPA1	-0.96	-9.31	-0.69	4.93e-15	Acne (severe);
THYM	cis	rs7719624	0.870	rs6894815	chr5:135395864	C/G	cg15329133	chr5:135467951	SMAD5;SMAD5OS	-0.55	-4.92	-0.45	3.64e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs2882877	0.735	rs11884632	chr2:190424842	G/C	cg10752008	chr2:190445175	SLC40A1	0.59	4.85	0.45	4.9e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg10295955	chr4:187884368	NA	-1.19	-17.25	-0.87	5.06e-31	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg01616529	chr11:638424	DRD4	-0.78	-6.62	-0.56	2.16e-9	Systemic lupus erythematosus;
THYM	cis	rs7649443	0.917	rs6782876	chr3:197021146	A/G	cg20744464	chr3:196756875	MFI2	0.62	4.56	0.42	1.53e-5	Nonsyndromic cleft lip with cleft palate;
THYM	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg17345569	chr6:42928274	GNMT	-0.52	-4.97	-0.45	3e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.82	4.54	0.42	1.67e-5	Alzheimer's disease;
THYM	cis	rs2219968	0.525	rs6987518	chr8:78885059	G/T	cg00738934	chr8:78996279	NA	0.61	4.95	0.45	3.21e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.71	5.61	0.5	1.96e-7	Tonsillectomy;
THYM	cis	rs1461503	0.932	rs7107575	chr11:122845406	C/T	cg27398637	chr11:122830231	C11orf63	0.69	6.48	0.55	4.11e-9	Menarche (age at onset);
THYM	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs28595532	0.920	rs115841156	chr4:119740073	C/T	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs10540	0.509	rs36002993	chr11:540005	C/T	cg21784768	chr11:537496	LRRC56	-1.26	-5.74	-0.51	1.15e-7	Body mass index;
THYM	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg00271210	chr6:167070053	RPS6KA2	-0.54	-5.42	-0.49	4.43e-7	Crohn's disease;
THYM	cis	rs11767557	1.000	rs56402156	chr7:143103481	G/A	cg05908241	chr7:143109367	NA	-0.63	-6.23	-0.54	1.27e-8	Alzheimer's disease (late onset);
THYM	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg03709012	chr19:19516395	GATAD2A	0.75	5.87	0.52	6.44e-8	Tonsillectomy;
THYM	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg16414030	chr3:133502952	NA	-0.95	-9.71	-0.71	6.99e-16	Iron status biomarkers;
THYM	cis	rs6531656	0.898	rs337616	chr4:38679329	A/T	cg24279243	chr4:38676559	KLF3	0.87	6.11	0.53	2.2e-8	Lymphocyte counts;
THYM	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg02891314	chr5:179741120	GFPT2	-0.97	-7.45	-0.61	4.29e-11	Height;
THYM	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg18305652	chr10:134549665	INPP5A	0.75	5.9	0.52	5.46e-8	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs7940866	0.774	rs7480903	chr11:130832276	A/G	cg12179176	chr11:130786555	SNX19	0.68	5.12	0.47	1.58e-6	Schizophrenia;
THYM	cis	rs6918586	0.658	rs198822	chr6:26123539	G/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.83	-7.65	-0.62	1.6e-11	Schizophrenia;
THYM	cis	rs7688540	0.771	rs61795007	chr4:255264	G/A	cg12746427	chr4:53362	ZNF718;ZNF595	0.67	4.9	0.45	3.93e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs6598955	0.671	rs11247910	chr1:26645666	G/A	cg08133631	chr1:26527909	CATSPER4	-0.63	-5.22	-0.47	1.05e-6	Obesity-related traits;
THYM	cis	rs477692	0.569	rs1771448	chr10:131296201	A/G	cg05714579	chr10:131428358	MGMT	-0.6	-4.94	-0.45	3.38e-6	Response to temozolomide;
THYM	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg03983476	chr2:10830698	NOL10	-0.6	-5.72	-0.51	1.25e-7	Prostate cancer;
THYM	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg18132916	chr6:79620363	NA	-0.59	-5.3	-0.48	7.63e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2625529	0.824	rs10518979	chr15:72268986	A/G	cg16672083	chr15:72433130	SENP8	-0.56	-5.05	-0.46	2.1e-6	Red blood cell count;
THYM	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg02018176	chr4:1364513	KIAA1530	0.5	4.57	0.42	1.44e-5	Obesity-related traits;
THYM	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs9534288	0.830	rs1126364	chr13:46633394	C/G	cg15192986	chr13:46630673	CPB2	-0.66	-4.66	-0.43	1.03e-5	Blood protein levels;
THYM	cis	rs236352	0.538	rs9470426	chr6:36846988	T/C	cg03410223	chr6:36853544	C6orf89	0.71	5.65	0.5	1.69e-7	Heart rate;
THYM	cis	rs886716	0.692	rs34066752	chr7:26567436	C/A	cg26364809	chr7:27145159	NA	-0.4	-4.85	-0.45	4.72e-6	Smoking behavior;
THYM	cis	rs8192282	0.739	rs10908846	chr1:154501364	C/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.59	-5.36	-0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs6591182	0.967	rs11227229	chr11:65354150	C/T	cg17480646	chr11:65405466	SIPA1	-0.59	-4.72	-0.44	8.17e-6	Non-alcoholic fatty liver disease histology (lobular);
THYM	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg24375607	chr4:120327624	NA	0.67	5.37	0.48	5.57e-7	Corneal astigmatism;
THYM	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.74	5.89	0.52	5.86e-8	Systemic lupus erythematosus and Systemic sclerosis;
THYM	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg26031613	chr14:104095156	KLC1	0.76	5.24	0.47	9.77e-7	Body mass index;
THYM	cis	rs977987	0.898	rs12918974	chr16:75493943	T/A	cg03315344	chr16:75512273	CHST6	0.72	5.41	0.49	4.78e-7	Dupuytren's disease;
THYM	cis	rs7173743	0.756	rs7169511	chr15:79128665	T/C	cg00540400	chr15:79124168	NA	0.6	6.52	0.56	3.43e-9	Coronary artery disease;
THYM	cis	rs4986172	0.726	rs12946454	chr17:43208121	A/T	cg24180402	chr17:43221464	ACBD4	0.59	4.79	0.44	6.15e-6	Height;
THYM	cis	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.7	0.43	8.83e-6	Obesity-related traits;
THYM	cis	rs2304069	0.614	rs216140	chr5:149443298	C/T	cg12661370	chr5:149340060	SLC26A2	0.72	5.58	0.5	2.24e-7	HIV-1 control;
THYM	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs9399401	0.667	rs6922607	chr6:142703483	A/G	cg03128060	chr6:142623767	GPR126	0.7	9.56	0.7	1.46e-15	Chronic obstructive pulmonary disease;
THYM	cis	rs7772486	0.790	rs7742333	chr6:146159029	A/G	cg13319975	chr6:146136371	FBXO30	0.63	5.27	0.48	8.52e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg10518543	chr12:38710700	ALG10B	-0.59	-4.76	-0.44	6.84e-6	Heart rate;
THYM	trans	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg10856724	chr12:34555212	NA	-0.87	-7.96	-0.63	3.59e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg12826209	chr6:26865740	GUSBL1	0.79	5.62	0.5	1.92e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7192750	0.562	rs9934803	chr16:71981630	T/G	cg06353428	chr16:71660113	MARVELD3	0.77	5.72	0.51	1.21e-7	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.41	-4.67	-0.43	1e-5	Monocyte percentage of white cells;
THYM	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg19761014	chr17:28927070	LRRC37B2	0.85	5.23	0.47	1.01e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4713118	0.581	rs200504	chr6:27785820	T/C	cg12963246	chr6:28129442	ZNF389	0.67	4.68	0.43	9.36e-6	Parkinson's disease;
THYM	cis	rs67385638	1.000	rs2855036	chr11:5272682	C/T	cg12559170	chr11:5275217	HBG2	0.88	9.08	0.68	1.53e-14	Hemoglobin levels;
THYM	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg22535103	chr8:58192502	C8orf71	-0.98	-6.32	-0.54	8.42e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs818427	0.684	rs2545164	chr5:112153665	C/T	cg04614008	chr5:112630677	MCC	-0.65	-4.69	-0.43	9.24e-6	Total body bone mineral density;
THYM	cis	rs790123	0.842	rs796889	chr3:122398461	T/C	cg17380795	chr3:122379686	NA	0.53	4.9	0.45	3.97e-6	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs4660261	0.526	rs2485997	chr1:44345841	G/C	cg15962314	chr1:44399869	ARTN	0.55	5.5	0.49	3.21e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4713118	0.629	rs203888	chr6:28021589	C/T	cg23281280	chr6:28129359	ZNF389	0.64	4.95	0.45	3.25e-6	Parkinson's disease;
THYM	cis	rs6960043	0.818	rs13220985	chr7:15062694	A/G	cg19272540	chr7:15055459	NA	0.44	4.86	0.45	4.56e-6	Type 2 diabetes;
THYM	cis	rs11645898	0.687	rs72787058	chr16:72105084	C/T	cg14768367	chr16:72042858	DHODH	-0.64	-4.71	-0.44	8.39e-6	Blood protein levels;
THYM	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.89	-8.7	-0.67	9.84e-14	Lung cancer;
THYM	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg12219531	chr12:120966889	COQ5	0.82	6.79	0.57	9.88e-10	High light scatter reticulocyte count;
THYM	cis	rs4730268	0.950	rs2051953	chr7:107440936	G/C	cg18560240	chr7:107437656	SLC26A3	-0.91	-5.09	-0.46	1.79e-6	IgG glycosylation;
THYM	cis	rs9355610	0.609	rs7772112	chr6:167408896	G/A	cg15592062	chr6:167189543	RPS6KA2	0.53	4.51	0.42	1.84e-5	Graves' disease;
THYM	cis	rs7834588	0.544	rs979843	chr8:63807649	T/G	cg20602954	chr8:63776762	NKAIN3	-0.63	-5.28	-0.48	8.14e-7	Response to Vitamin E supplementation;
THYM	cis	rs860818	1.000	rs858237	chr7:23239223	A/T	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs6138458	1.000	rs6114980	chr20:24974288	A/G	cg06937882	chr20:24974362	C20orf3	-0.46	-4.64	-0.43	1.11e-5	Blood protein levels;
THYM	cis	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg06521331	chr12:34319734	NA	-0.73	-5.66	-0.5	1.59e-7	Morning vs. evening chronotype;
THYM	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg00071950	chr4:10020882	SLC2A9	0.86	9.38	0.69	3.55e-15	Bone mineral density;
THYM	cis	rs9677476	0.779	rs60596955	chr2:232138241	C/T	cg07929768	chr2:232055508	NA	0.57	5.04	0.46	2.25e-6	Food antigen IgG levels;
THYM	trans	rs877282	0.842	rs12357963	chr10:757562	C/T	cg22713356	chr15:30763199	NA	1.35	9.87	0.71	3.11e-16	Uric acid levels;
THYM	cis	rs9826463	0.527	rs73238170	chr3:142100311	T/A	cg20824294	chr3:142316082	PLS1	0.77	5.31	0.48	7.08e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs4595586	0.545	rs7967295	chr12:39376866	G/A	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs6570726	0.620	rs12201226	chr6:145913419	A/T	cg13319975	chr6:146136371	FBXO30	-0.66	-5.33	-0.48	6.53e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4499344	0.730	rs2903755	chr19:33098870	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.61	0.62	1.96e-11	Mean platelet volume;
THYM	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg04455712	chr21:45112962	RRP1B	-0.51	-4.71	-0.44	8.41e-6	Mean corpuscular volume;
THYM	cis	rs739401	0.582	rs7932369	chr11:2958468	A/G	cg08508325	chr11:3079039	CARS	0.5	6.05	0.53	2.92e-8	Longevity;
THYM	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.83	8.39	0.65	4.55e-13	Chronic sinus infection;
THYM	cis	rs933688	0.938	rs10942634	chr5:90658392	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	8.19	0.64	1.19e-12	Smoking behavior;
THYM	cis	rs875971	1.000	rs1167411	chr7:65539264	C/G	cg11764359	chr7:65958608	NA	-0.82	-6.65	-0.56	1.85e-9	Aortic root size;
THYM	cis	rs6840360	0.571	rs11944139	chr4:152505291	T/C	cg17479576	chr4:152424074	FAM160A1	-0.85	-6.0	-0.52	3.58e-8	Intelligence (multi-trait analysis);
THYM	cis	rs56104184	0.887	rs67286688	chr19:49343329	T/C	cg26267310	chr19:49340593	PLEKHA4;HSD17B14	0.88	5.54	0.49	2.75e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg24812749	chr6:127587940	RNF146	0.94	7.62	0.62	1.91e-11	Breast cancer;
THYM	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg08132940	chr7:1081526	C7orf50	-1.16	-6.65	-0.56	1.86e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs11711311	1.000	rs1073040	chr3:113522123	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.62	-5.46	-0.49	3.77e-7	IgG glycosylation;
THYM	cis	rs58804349	0.685	rs11239855	chr10:43483879	A/G	cg08461752	chr10:43522343	NA	0.82	5.29	0.48	7.98e-7	Pediatric bone mineral content (radius);
THYM	cis	rs17253792	0.822	rs111467375	chr14:56046159	T/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs7578361	0.918	rs7569287	chr2:150379629	A/G	cg17961725	chr2:150454027	NA	-0.77	-5.72	-0.51	1.25e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs995000	0.931	rs998403	chr1:62928549	G/A	cg06896770	chr1:63153194	DOCK7	1.0	8.27	0.65	7.91e-13	Triglyceride levels;
THYM	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg12011299	chr4:100065546	ADH4	-0.85	-8.12	-0.64	1.67e-12	Alcohol dependence;
THYM	cis	rs11910985	0.546	rs9978916	chr21:48080492	A/C	cg23283320	chr21:48055893	PRMT2	1.27	7.94	0.63	3.95e-12	Cerebrospinal fluid t-tau:AB1-42 ratio;
THYM	cis	rs1829883	0.866	rs1523391	chr5:98794214	A/C	cg08333243	chr5:99726346	NA	-0.55	-4.98	-0.45	2.84e-6	Hemostatic factors and hematological phenotypes;
THYM	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg16586182	chr3:47516702	SCAP	0.68	5.83	0.51	7.45e-8	Colorectal cancer;
THYM	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg03388025	chr16:89894329	SPIRE2	0.54	4.62	0.43	1.2e-5	Vitiligo;
THYM	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg13114125	chr14:105738426	BRF1	-0.72	-5.61	-0.5	2.01e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs1003719	0.715	rs2835647	chr21:38546773	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.63	-4.52	-0.42	1.76e-5	Eye color traits;
THYM	cis	rs11886999	0.638	rs73958180	chr2:96844103	A/T	cg10278162	chr2:97193688	NA	-0.71	-4.48	-0.42	2.11e-5	Cardiac Troponin-T levels;
THYM	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg13607699	chr17:42295918	UBTF	0.9	9.27	0.69	5.91e-15	Total body bone mineral density;
THYM	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg11843238	chr5:131593191	PDLIM4	-0.46	-4.57	-0.42	1.47e-5	Acylcarnitine levels;
THYM	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg18252515	chr7:66147081	NA	-1.31	-7.48	-0.61	3.77e-11	Diabetic kidney disease;
THYM	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg12386194	chr3:101231763	SENP7	0.97	7.83	0.63	6.87e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2219968	0.923	rs2101106	chr8:78948481	A/C	cg00738934	chr8:78996279	NA	0.86	9.45	0.7	2.44e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg08999081	chr20:33150536	PIGU	-0.56	-4.83	-0.44	5.18e-6	Height;
THYM	cis	rs4343996	0.537	rs7791343	chr7:3416780	A/C	cg21248987	chr7:3385318	SDK1	0.4	4.91	0.45	3.72e-6	Motion sickness;
THYM	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg27490568	chr2:178487706	NA	0.54	4.68	0.43	9.42e-6	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	cis	rs7322722	0.838	rs591576	chr13:77590936	A/G	cg04565255	chr13:77565759	CLN5	0.51	5.28	0.48	8.25e-7	Preeclampsia;
THYM	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg08847533	chr14:75593920	NEK9	1.02	11.25	0.76	3.61e-19	Height;
THYM	cis	rs2075230	0.705	rs1641522	chr17:7549851	C/T	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.28	-4.62	-0.43	1.21e-5	Hormone measurements;
THYM	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg00078996	chr12:132293329	NA	-0.69	-8.01	-0.63	2.91e-12	Migraine;
THYM	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.56	-5.2	-0.47	1.12e-6	Lymphocyte counts;
THYM	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg25427524	chr10:38739819	LOC399744	-0.77	-7.15	-0.59	1.79e-10	Extrinsic epigenetic age acceleration;
THYM	cis	rs7258465	0.965	rs10408290	chr19:18542701	C/T	cg01380346	chr19:18557039	ELL	-0.49	-5.01	-0.46	2.53e-6	Breast cancer;
THYM	cis	rs28595532	0.841	rs116521340	chr4:119757415	C/A	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs12368653	0.666	rs799265	chr12:58112189	A/G	cg12615879	chr12:58013172	SLC26A10	0.52	5.14	0.47	1.48e-6	Multiple sclerosis;
THYM	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg17366294	chr4:99064904	C4orf37	0.54	6.33	0.54	8.05e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg24450063	chr1:156163899	SLC25A44	1.16	14.93	0.84	1.16e-26	Testicular germ cell tumor;
THYM	cis	rs4363385	0.818	rs419721	chr1:153006902	C/T	cg13444842	chr1:152974279	SPRR3	-0.57	-4.56	-0.42	1.5e-5	Inflammatory skin disease;
THYM	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs910187	0.678	rs6124967	chr20:45813624	T/C	cg27589058	chr20:45804311	EYA2	-0.59	-5.07	-0.46	1.95e-6	Migraine;
THYM	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg08125733	chr17:73851984	WBP2	1.19	8.97	0.68	2.65e-14	Psoriasis;
THYM	cis	rs3796352	1.000	rs13072457	chr3:53102389	G/A	cg07884673	chr3:53033167	SFMBT1	1.15	5.67	0.5	1.51e-7	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs67981189	0.865	rs2189806	chr14:71388398	T/A	cg15910301	chr14:71632612	NA	-0.5	-4.61	-0.43	1.24e-5	Schizophrenia;
THYM	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg20587970	chr11:113659929	NA	-1.36	-9.02	-0.68	2.09e-14	Hip circumference adjusted for BMI;
THYM	cis	rs28595532	0.920	rs114653217	chr4:119769216	G/A	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs2340727	0.524	rs6693833	chr1:161943058	A/G	ch.1.159725313R	chr1:161458689	NA	0.79	5.52	0.49	2.98e-7	White blood cell count;Hematology traits;
THYM	cis	rs1003719	0.788	rs3787782	chr21:38462909	T/C	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs899997	0.862	rs12912524	chr15:78952756	G/A	cg04896959	chr15:78267971	NA	0.76	5.47	0.49	3.61e-7	Coronary artery disease or large artery stroke;
THYM	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs864643	0.773	rs11915323	chr3:39593103	C/T	cg20142358	chr3:39093977	WDR48	-0.64	-4.57	-0.42	1.49e-5	Attention deficit hyperactivity disorder;
THYM	cis	rs7084402	0.902	rs10763557	chr10:60341515	C/T	cg27040468	chr10:60456715	BICC1	-0.54	-4.49	-0.42	1.98e-5	Refractive error;
THYM	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg16342193	chr10:102329863	NA	-0.56	-5.83	-0.51	7.7e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs9649213	0.593	rs11760930	chr7:97915789	G/A	cg07830472	chr7:97983916	BAIAP2L1	-0.45	-4.62	-0.43	1.21e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg19318889	chr4:1322082	MAEA	-0.52	-4.53	-0.42	1.7e-5	Obesity-related traits;
THYM	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22496380	chr5:211416	CCDC127	-1.39	-8.13	-0.64	1.62e-12	Breast cancer;
THYM	cis	rs2836633	0.895	rs991816	chr21:40042150	C/A	cg05519781	chr21:40033154	ERG	0.77	7.28	0.6	9.64e-11	Coronary artery disease;
THYM	cis	rs1160297	0.601	rs1864534	chr2:53109005	G/T	cg07782112	chr2:53107842	NA	0.76	6.11	0.53	2.16e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs13315871	0.929	rs7628038	chr3:58313813	T/C	cg12435725	chr3:58293450	RPP14	-0.53	-5.82	-0.51	7.92e-8	Cholesterol, total;
THYM	cis	rs12282928	0.959	rs873043	chr11:48278965	T/A	cg22827986	chr11:48284249	OR4X1	-0.52	-5.4	-0.48	4.95e-7	Migraine - clinic-based;
THYM	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7762018	0.769	rs4716385	chr6:170127608	G/T	cg19338460	chr6:170058176	WDR27	-0.7	-4.7	-0.43	8.9e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs61931739	1.000	rs12424741	chr12:34022771	C/T	cg06521331	chr12:34319734	NA	0.58	4.57	0.42	1.49e-5	Morning vs. evening chronotype;
THYM	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg05025164	chr4:1340916	KIAA1530	-0.88	-6.77	-0.57	1.04e-9	Longevity;
THYM	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg26850624	chr5:429559	AHRR	-0.71	-5.5	-0.49	3.24e-7	Cystic fibrosis severity;
THYM	cis	rs1520896	0.841	rs1553074	chr11:20262655	G/A	cg21745110	chr11:19798742	NAV2	-0.72	-4.7	-0.43	8.66e-6	Response to platinum-based chemotherapy (cisplatin);
THYM	cis	rs7940866	0.834	rs2324315	chr11:130839772	C/G	cg23692386	chr11:131799662	NTM	0.5	5.3	0.48	7.66e-7	Schizophrenia;
THYM	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg02018176	chr4:1364513	KIAA1530	0.6	4.69	0.43	9.22e-6	Obesity-related traits;
THYM	cis	rs317689	0.690	rs595348	chr12:69638610	T/C	cg20891283	chr12:69753455	YEATS4	0.62	4.55	0.42	1.59e-5	Response to diuretic therapy;
THYM	cis	rs10911251	0.508	rs2245784	chr1:183107665	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.66	0.43	1.03e-5	Colorectal cancer;
THYM	cis	rs425277	0.583	rs925905	chr1:2044037	T/C	cg23682913	chr1:2080710	PRKCZ	-0.59	-5.34	-0.48	6.27e-7	Height;
THYM	cis	rs240764	0.507	rs9404022	chr6:101199726	T/C	cg21058520	chr6:100914733	NA	-0.57	-4.51	-0.42	1.86e-5	Neuroticism;
THYM	cis	rs11622475	0.677	rs7145372	chr14:104359121	A/G	cg12183467	chr14:104352244	NA	0.63	5.45	0.49	4.03e-7	Bipolar disorder;
THYM	cis	rs870825	0.616	rs6818447	chr4:185650154	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs757081	0.667	rs615424	chr11:17210481	G/A	cg07093617	chr11:18158918	MRGPRX3	-0.49	-4.61	-0.43	1.23e-5	Systolic blood pressure;
THYM	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg12826209	chr6:26865740	GUSBL1	0.84	6.07	0.53	2.61e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7000551	0.751	rs2449348	chr8:22359572	C/T	cg12081754	chr8:22256438	SLC39A14	0.67	6.18	0.54	1.6e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg27034606	chr17:28928453	LRRC37B2	0.7	4.52	0.42	1.76e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs61931739	0.635	rs10772122	chr12:33964674	A/C	cg10856724	chr12:34555212	NA	-0.64	-6.04	-0.53	3.04e-8	Morning vs. evening chronotype;
THYM	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg14895029	chr7:2775587	GNA12	-0.68	-5.03	-0.46	2.27e-6	Height;
THYM	cis	rs2195525	0.572	rs10892351	chr11:119218530	T/G	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.44	4.83	0.44	5.2e-6	Urate levels;
THYM	cis	rs4919687	0.550	rs12761195	chr10:104465374	T/C	cg04362960	chr10:104952993	NT5C2	0.61	4.89	0.45	4.08e-6	Colorectal cancer;
THYM	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg06609049	chr19:2785107	THOP1	1.2	12.95	0.8	1.07e-22	Total cholesterol levels;
THYM	cis	rs7586879	0.616	rs13410999	chr2:25097939	T/C	cg27107076	chr2:25050844	ADCY3	-0.29	-4.62	-0.43	1.2e-5	Body mass index;
THYM	cis	rs990171	0.913	rs4851587	chr2:103073474	C/T	cg13897122	chr2:103039542	IL18RAP	-0.42	-5.13	-0.47	1.5e-6	Lymphocyte counts;
THYM	cis	rs2456568	0.525	rs6483269	chr11:93620428	C/T	cg17595323	chr11:93583763	C11orf90	0.51	5.3	0.48	7.37e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg08439880	chr3:133502540	NA	-0.59	-4.59	-0.43	1.37e-5	Iron status biomarkers;
THYM	cis	rs7107174	1.000	rs2511185	chr11:77982496	C/A	cg19901956	chr11:77921274	USP35	-0.64	-4.97	-0.45	2.97e-6	Testicular germ cell tumor;
THYM	cis	rs11792861	0.619	rs2289481	chr9:111712924	G/C	cg05043794	chr9:111880884	C9orf5	-0.35	-4.95	-0.45	3.16e-6	Menarche (age at onset);
THYM	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg07636037	chr3:49044803	WDR6	0.87	7.65	0.62	1.6e-11	Menarche (age at onset);
THYM	cis	rs3126085	0.935	rs12144058	chr1:152170216	C/T	cg10321714	chr1:152280068	FLG	0.65	4.72	0.44	8.02e-6	Atopic dermatitis;
THYM	cis	rs2334880	0.678	rs12922830	chr16:71447270	C/T	cg06353428	chr16:71660113	MARVELD3	-1.04	-5.79	-0.51	9.06e-8	Malaria;
THYM	cis	rs2073300	1.000	rs78000067	chr20:23439507	A/G	cg12062639	chr20:23401060	NAPB	1.33	6.1	0.53	2.32e-8	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs4731207	0.596	rs7790975	chr7:124577944	A/T	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg18357526	chr6:26021779	HIST1H4A	0.79	6.62	0.56	2.14e-9	Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.606	rs262669	chr1:2082489	A/G	cg09260853	chr1:2094483	PRKCZ	-0.47	-4.67	-0.43	9.79e-6	Height;
THYM	cis	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg26384229	chr12:38710491	ALG10B	-0.74	-5.7	-0.5	1.34e-7	Bladder cancer;
THYM	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03264133	chr6:25882463	NA	-0.84	-6.71	-0.57	1.39e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6867032	1.000	rs2129472	chr5:2016247	G/A	cg26168224	chr5:2018326	NA	1.29	15.56	0.85	7.19e-28	Gut microbiome composition (winter);
THYM	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg17211192	chr8:82754475	SNX16	-0.8	-7.24	-0.6	1.18e-10	Diastolic blood pressure;
THYM	cis	rs7394190	0.748	rs4114992	chr10:75566829	A/G	cg07699608	chr10:75541558	CHCHD1	0.91	4.93	0.45	3.49e-6	Incident atrial fibrillation;
THYM	cis	rs1912528	0.783	rs6536588	chr4:140862671	C/T	cg11128457	chr4:140864437	MAML3	0.48	5.3	0.48	7.46e-7	Educational attainment (years of education);
THYM	cis	rs921968	0.643	rs552882	chr2:219401726	G/A	cg02176678	chr2:219576539	TTLL4	0.68	6.66	0.56	1.76e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7705042	0.865	rs2338822	chr5:141503059	T/C	cg07392085	chr5:141489673	NDFIP1	0.54	4.57	0.42	1.47e-5	Asthma;
THYM	cis	rs6456156	0.774	rs968333	chr6:167526198	A/T	cg09487078	chr6:167525398	CCR6	0.41	4.67	0.43	9.86e-6	Primary biliary cholangitis;
THYM	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.83	-8.34	-0.65	5.7e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs270601	0.661	rs10036208	chr5:131571323	T/C	cg18758796	chr5:131593413	PDLIM4	0.53	4.8	0.44	5.98e-6	Acylcarnitine levels;
THYM	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg12698349	chr2:225449008	CUL3	-0.76	-5.13	-0.47	1.53e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs4849845	0.886	rs934722	chr2:121010443	A/T	cg03575764	chr2:121493832	NA	-0.64	-4.78	-0.44	6.47e-6	Mean platelet volume;
THYM	cis	rs4909189	0.957	rs11766348	chr7:158135857	G/A	cg25566285	chr7:158114605	PTPRN2	0.78	7.07	0.59	2.55e-10	Response to amphetamines;
THYM	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg17294928	chr15:75287854	SCAMP5	0.9	7.53	0.61	2.92e-11	Blood trace element (Zn levels);
THYM	cis	rs6960043	0.689	rs12538003	chr7:15058692	G/A	cg19272540	chr7:15055459	NA	0.5	5.33	0.48	6.68e-7	Type 2 diabetes;
THYM	cis	rs3768617	0.528	rs2027082	chr1:183084608	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs2354432	0.556	rs59180647	chr1:146772062	C/T	cg25205988	chr1:146714368	CHD1L	-1.0	-5.33	-0.48	6.54e-7	Mitochondrial DNA levels;
THYM	cis	rs2085601	0.542	rs1708682	chr4:89965285	C/T	cg17769793	chr4:89976368	FAM13A	-0.59	-6.86	-0.58	6.96e-10	Hair greying;
THYM	cis	rs7465272	1.000	rs35900184	chr8:143693411	C/T	cg10104451	chr8:143696006	ARC	-0.8	-5.56	-0.5	2.49e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs4372836	0.729	rs10865508	chr2:29053704	G/C	cg09522027	chr2:28974177	PPP1CB	0.61	4.55	0.42	1.58e-5	Body mass index;
THYM	cis	rs17253792	0.908	rs74354306	chr14:56065778	T/G	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg17173187	chr15:85201210	NMB	0.56	5.67	0.5	1.5e-7	Schizophrenia;
THYM	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-5.69	-0.5	1.4e-7	Gut microbiome composition (summer);
THYM	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg17372223	chr3:52568218	NT5DC2	0.32	4.77	0.44	6.54e-6	Intelligence (multi-trait analysis);
THYM	trans	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs1756650	0.602	rs10151708	chr14:87929724	C/T	cg10325478	chr14:88793021	KCNK10	-0.64	-4.81	-0.44	5.59e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
THYM	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg00383909	chr3:49044727	WDR6	1.06	6.06	0.53	2.79e-8	Cognitive function;
THYM	cis	rs2034088	0.897	rs11652657	chr17:439124	A/G	cg06217071	chr17:408420	NA	0.86	10.44	0.73	1.9e-17	Hip circumference adjusted for BMI;
THYM	cis	rs28595532	0.920	rs115850161	chr4:119732447	T/C	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs78472555	0.789	rs2603229	chr15:100263499	T/C	cg18869061	chr15:100272053	LYSMD4	0.78	4.71	0.44	8.45e-6	Post bronchodilator FEV1/FVC ratio in COPD;
THYM	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg20486651	chr6:167070296	RPS6KA2	-0.48	-4.76	-0.44	6.84e-6	Crohn's disease;
THYM	cis	rs7267979	1.000	rs2500436	chr20:25406366	G/C	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs7772486	0.754	rs702304	chr6:145990797	A/G	cg23711669	chr6:146136114	FBXO30	-0.99	-10.65	-0.74	6.87e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg11214544	chr1:2391121	NA	-0.65	-6.07	-0.53	2.59e-8	Non-obstructive azoospermia;
THYM	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.89	0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg19875535	chr5:140030758	IK	-0.67	-5.76	-0.51	1.05e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg23131131	chr22:24373011	LOC391322	-0.89	-9.98	-0.72	1.8e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs13064411	0.696	rs7619913	chr3:113017503	A/G	cg18753928	chr3:113234510	CCDC52	-0.84	-7.3	-0.6	8.73e-11	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs6570726	0.791	rs12208019	chr6:145935572	T/C	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg08736216	chr1:53307985	ZYG11A	0.66	5.34	0.48	6.35e-7	Monocyte count;
THYM	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs4363385	0.510	rs11205182	chr1:153045748	C/T	cg13444842	chr1:152974279	SPRR3	-0.6	-4.74	-0.44	7.54e-6	Inflammatory skin disease;
THYM	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg00106254	chr7:1943704	MAD1L1	-0.49	-4.49	-0.42	2.01e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg12923728	chr3:195709715	SDHAP1	-0.78	-6.36	-0.55	6.99e-9	Pancreatic cancer;
THYM	cis	rs28595532	1.000	rs17258106	chr4:119675406	C/T	cg11846333	chr4:119757529	SEC24D	-1.48	-4.8	-0.44	6.01e-6	Cannabis dependence symptom count;
THYM	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	cis	rs1021993	0.597	rs2055698	chr1:209548546	G/A	cg06155620	chr1:209527581	NA	-0.52	-4.64	-0.43	1.12e-5	Gut microbiome composition (winter);
THYM	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg15316289	chr22:50310904	ALG12;CRELD2	0.56	5.51	0.49	3.1e-7	Schizophrenia;
THYM	cis	rs300703	0.678	rs423643	chr2:199648	A/C	cg21211680	chr2:198530	NA	1.07	6.38	0.55	6.33e-9	Blood protein levels;
THYM	cis	rs12579753	1.000	rs12811607	chr12:82233619	T/G	cg21231944	chr12:82153410	PPFIA2	-0.65	-4.83	-0.44	5.17e-6	Resting heart rate;
THYM	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg06532163	chr17:45867833	NA	0.64	6.45	0.55	4.65e-9	IgG glycosylation;
THYM	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg11266682	chr4:10021025	SLC2A9	0.75	12.66	0.79	4.08e-22	Bone mineral density;
THYM	cis	rs1286150	0.627	rs75486330	chr14:91496150	T/C	cg02136132	chr14:90527891	KCNK13	-0.66	-4.52	-0.42	1.8e-5	Total body bone mineral density;
THYM	cis	rs7777677	0.925	rs9655661	chr7:142370125	A/G	cg21785750	chr7:142428317	NA	0.67	5.88	0.52	6.1e-8	Alcoholic chronic pancreatitis;
THYM	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg02825527	chr7:2087843	MAD1L1	-0.71	-4.57	-0.42	1.46e-5	Bipolar disorder;
THYM	cis	rs9560113	0.960	rs950891	chr13:112173992	G/A	cg14154082	chr13:112174009	NA	-0.82	-7.93	-0.63	4.21e-12	Menarche (age at onset);
THYM	trans	rs9929218	0.551	rs1886697	chr16:68716179	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.16	15.95	0.85	1.29e-28	Colorectal cancer;
THYM	cis	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg13443165	chr9:33130375	B4GALT1	0.74	5.44	0.49	4.08e-7	IgG glycosylation;
THYM	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg10047753	chr17:41438598	NA	-0.97	-7.99	-0.63	3.21e-12	Menopause (age at onset);
THYM	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg10057126	chr4:77819792	ANKRD56	0.71	6.01	0.53	3.36e-8	Emphysema distribution in smoking;
THYM	cis	rs9486719	1.000	rs4839837	chr6:96908706	G/A	cg06623918	chr6:96969491	KIAA0776	0.79	4.58	0.43	1.4e-5	Migraine;Coronary artery disease;
THYM	cis	rs513349	0.964	rs210139	chr6:33543409	A/C	cg07679836	chr6:33548423	BAK1	0.34	4.65	0.43	1.08e-5	Platelet count;
THYM	cis	rs6032067	0.929	rs6017510	chr20:43831785	A/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.74	-8.23	-0.64	1e-12	Blood protein levels;
THYM	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg05368731	chr17:41323189	NBR1	1.25	11.63	0.77	5.89e-20	Menopause (age at onset);
THYM	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg17063962	chr7:91808500	NA	1.16	13.12	0.8	4.77e-23	Breast cancer;
THYM	cis	rs3849570	0.695	rs6809528	chr3:81872048	A/C	cg07356753	chr3:81810745	GBE1	-0.71	-4.95	-0.45	3.18e-6	Waist circumference;Body mass index;
THYM	cis	rs208520	0.690	rs851459	chr6:66813989	A/G	cg07460842	chr6:66804631	NA	-1.06	-7.89	-0.63	5.14e-12	Exhaled nitric oxide output;
THYM	cis	rs4769475	1.000	rs7319418	chr13:26728225	C/T	cg13319468	chr13:27597730	NA	-0.6	-4.65	-0.43	1.06e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg06521331	chr12:34319734	NA	-1.0	-8.82	-0.67	5.43e-14	Morning vs. evening chronotype;
THYM	cis	rs7119	0.651	rs12904208	chr15:77845911	C/T	cg10437265	chr15:77819839	NA	0.68	6.14	0.53	1.94e-8	Type 2 diabetes;
THYM	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.78	7.01	0.58	3.37e-10	Prudent dietary pattern;
THYM	cis	rs921968	0.565	rs6436081	chr2:219637884	A/G	cg02176678	chr2:219576539	TTLL4	-0.46	-4.54	-0.42	1.62e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs11031096	0.683	rs55898672	chr11:4189284	G/C	cg08557956	chr11:4115526	RRM1	-0.59	-5.44	-0.49	4.19e-7	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg17063962	chr7:91808500	NA	1.15	12.12	0.78	5.47e-21	Breast cancer;
THYM	cis	rs425277	0.917	rs78395918	chr1:2045876	G/A	cg00981070	chr1:2046702	PRKCZ	0.46	4.85	0.45	4.9e-6	Height;
THYM	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg01236616	chr12:121019343	POP5	1.21	9.45	0.7	2.43e-15	Type 1 diabetes nephropathy;
THYM	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg25566285	chr7:158114605	PTPRN2	0.92	11.63	0.77	5.69e-20	Calcium levels;
THYM	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg27034606	chr17:28928453	LRRC37B2	0.83	5.47	0.49	3.6e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg24818145	chr4:99064322	C4orf37	-0.74	-5.88	-0.52	6.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7772486	0.686	rs9403739	chr6:146015357	A/G	cg13319975	chr6:146136371	FBXO30	0.68	5.27	0.48	8.44e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6570726	0.935	rs391820	chr6:145821284	C/T	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.36e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6500395	1.000	rs6500395	chr16:48621402	T/C	cg04672837	chr16:48644449	N4BP1	0.51	4.98	0.45	2.85e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs2286885	1.000	rs10819169	chr9:129249625	C/T	cg14294646	chr9:129243551	FAM125B	-0.57	-5.05	-0.46	2.13e-6	Intraocular pressure;
THYM	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg05738196	chr6:26577821	NA	0.58	4.7	0.43	8.91e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg03709012	chr19:19516395	GATAD2A	0.73	5.59	0.5	2.16e-7	Tonsillectomy;
THYM	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.17	-8.75	-0.67	7.68e-14	Platelet count;
THYM	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg10360139	chr7:1886902	MAD1L1	-0.6	-5.26	-0.47	8.86e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg04772025	chr11:68637568	NA	0.66	6.99	0.58	3.79e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.58	-10.94	-0.75	1.64e-18	Hemostatic factors and hematological phenotypes;
THYM	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg00495681	chr13:53174319	NA	0.73	6.85	0.57	7.36e-10	Lewy body disease;
THYM	cis	rs7809950	0.953	rs28687365	chr7:107106712	A/C	cg23024343	chr7:107201750	COG5	-0.91	-8.18	-0.64	1.25e-12	Coronary artery disease;
THYM	cis	rs3816788	0.792	rs13257744	chr8:21872853	T/C	cg17168535	chr8:21777572	XPO7	0.83	7.22	0.6	1.26e-10	Lung cancer in ever smokers;
THYM	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg11266682	chr4:10021025	SLC2A9	0.54	6.73	0.57	1.27e-9	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.76	-6.74	-0.57	1.22e-9	Personality dimensions;
THYM	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg05660106	chr1:15850417	CASP9	0.76	6.27	0.54	1.06e-8	Systolic blood pressure;
THYM	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg24549020	chr5:56110836	MAP3K1	-0.7	-4.61	-0.43	1.28e-5	Initial pursuit acceleration;
THYM	cis	rs17174870	0.725	rs10195405	chr2:112756591	A/T	cg17354880	chr2:112658759	MERTK	-0.55	-4.6	-0.43	1.3e-5	Multiple sclerosis;
THYM	cis	rs757081	0.667	rs12577525	chr11:17260116	G/A	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.6	-0.43	1.29e-5	Systolic blood pressure;
THYM	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.16e-6	Diabetic retinopathy;
THYM	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg16680214	chr1:154839983	KCNN3	-0.55	-6.94	-0.58	4.8e-10	Prostate cancer;
THYM	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg08048268	chr3:133502702	NA	-0.66	-5.71	-0.51	1.27e-7	Iron status biomarkers;
THYM	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg10803722	chr21:46713166	LOC642852	-0.39	-5.07	-0.46	1.97e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg12963246	chr6:28129442	ZNF389	0.56	5.05	0.46	2.12e-6	Cardiac Troponin-T levels;
THYM	cis	rs1691799	0.867	rs2172881	chr12:66766039	C/G	cg16791601	chr12:66731901	HELB	-0.77	-7.38	-0.6	6.07e-11	White blood cell count (basophil);
THYM	cis	rs10911251	0.508	rs729672	chr1:183109236	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.66	0.43	1.02e-5	Colorectal cancer;
THYM	cis	rs7106204	0.590	rs7114724	chr11:24239976	A/G	ch.11.24196551F	chr11:24239977	NA	1.0	7.19	0.59	1.5e-10	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.83	5.49	0.49	3.4e-7	Platelet count;
THYM	cis	rs73198271	0.740	rs10098636	chr8:8647324	C/T	cg06636001	chr8:8085503	FLJ10661	-0.76	-5.06	-0.46	2.01e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs7973719	0.769	rs61917956	chr12:7348659	T/C	cg07052231	chr12:7363540	PEX5	0.61	5.25	0.47	9.43e-7	IgG glycosylation;
THYM	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
THYM	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg06618935	chr21:46677482	NA	-0.96	-9.3	-0.69	5.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg27394845	chr17:28928406	LRRC37B2	0.91	4.58	0.42	1.44e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6918586	0.615	rs198824	chr6:26122783	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.85	-7.77	-0.62	9.2e-12	Schizophrenia;
THYM	cis	rs11997175	0.550	rs6468206	chr8:33780878	A/C	ch.8.33884649F	chr8:33765107	NA	0.71	5.31	0.48	7.16e-7	Body mass index;
THYM	cis	rs6443245	0.591	rs2648383	chr3:9621647	T/G	cg20517764	chr3:9027454	SRGAP3	-0.59	-4.57	-0.42	1.44e-5	Daytime sleep phenotypes;
THYM	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg06028808	chr11:68637592	NA	0.66	7.04	0.59	2.94e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs12586317	0.553	rs78124218	chr14:35570606	G/A	cg16230307	chr14:35515116	FAM177A1	0.9	5.84	0.51	7.37e-8	Psoriasis;
THYM	cis	rs514406	0.698	rs1775540	chr1:53407893	C/A	cg06600287	chr1:53387719	ECHDC2	-0.34	-5.37	-0.48	5.55e-7	Monocyte count;
THYM	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg18681998	chr4:17616180	MED28	0.99	10.08	0.72	1.09e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs72627123	0.867	rs73303107	chr14:74477284	A/G	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs4891159	0.548	rs948646	chr18:74118168	G/A	cg24786174	chr18:74118243	ZNF516	0.96	14.26	0.83	2.4e-25	Longevity;
THYM	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg11166453	chr1:247681781	NA	-0.67	-5.27	-0.48	8.55e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg14018140	chr10:458528	DIP2C	-0.56	-6.08	-0.53	2.48e-8	Psychosis in Alzheimer's disease;
THYM	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg14456004	chr13:21872349	NA	-1.25	-10.05	-0.72	1.28e-16	White matter hyperintensity burden;
THYM	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11644478	chr21:40555479	PSMG1	1.07	9.23	0.69	7.24e-15	Cognitive function;
THYM	cis	rs7914558	0.902	rs3736922	chr10:104850632	A/G	cg15744005	chr10:104629667	AS3MT	0.75	7.05	0.59	2.83e-10	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs75920871	0.545	rs7939934	chr11:116861268	A/T	cg20608306	chr11:116969690	SIK3	-0.5	-5.39	-0.48	5.05e-7	Subjective well-being;
THYM	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg18240062	chr17:79603768	NPLOC4	0.74	6.52	0.56	3.45e-9	Eye color traits;
THYM	cis	rs4907240	0.921	rs2278563	chr2:97212693	C/T	cg01950434	chr2:97203154	ARID5A	-0.56	-4.71	-0.43	8.52e-6	Event-related brain oscillations;
THYM	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg08847533	chr14:75593920	NEK9	1.02	11.28	0.76	3.21e-19	Height;
THYM	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg20283391	chr11:68216788	NA	-0.58	-4.6	-0.43	1.32e-5	Total body bone mineral density;
THYM	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg13752114	chr3:195489708	MUC4	0.69	4.49	0.42	1.99e-5	Lung disease severity in cystic fibrosis;
THYM	cis	rs7584330	0.697	rs1979762	chr2:238436502	T/C	cg14458575	chr2:238380390	NA	0.62	4.89	0.45	4.15e-6	Prostate cancer;
THYM	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg04287289	chr16:89883240	FANCA	0.66	6.1	0.53	2.33e-8	Vitiligo;
THYM	cis	rs863345	0.527	rs7514555	chr1:158445138	G/T	cg12129480	chr1:158549410	OR10X1	-0.47	-4.62	-0.43	1.23e-5	Pneumococcal bacteremia;
THYM	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg11461670	chr8:22454935	PDLIM2	0.36	6.52	0.56	3.36e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg14159672	chr1:205819179	PM20D1	0.92	9.11	0.68	1.32e-14	Menarche (age at onset);
THYM	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg18200150	chr17:30822561	MYO1D	0.86	7.53	0.61	2.88e-11	Schizophrenia;
THYM	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg19761014	chr17:28927070	LRRC37B2	0.85	4.93	0.45	3.46e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7568458	0.905	rs6739015	chr2:85755357	A/G	cg17127132	chr2:85788382	GGCX	0.65	5.25	0.47	9.44e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	trans	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg19862616	chr7:65841803	NCRNA00174	1.1	12.73	0.79	2.97e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs1395	1.000	rs1659695	chr2:27406944	T/A	cg23587288	chr2:27483067	SLC30A3	0.57	4.98	0.46	2.79e-6	Blood metabolite levels;
THYM	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	4.47	0.42	2.12e-5	Aortic root size;
THYM	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg23131131	chr22:24373011	LOC391322	-0.88	-9.76	-0.71	5.47e-16	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs500891	0.525	rs1170483	chr6:84038253	G/C	cg08257003	chr6:84140564	ME1	0.56	4.47	0.42	2.19e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs2663905	0.706	rs2683260	chr15:81385552	A/C	cg25029264	chr15:81426347	C15orf26	-0.71	-4.67	-0.43	1e-5	QT interval (drug interaction);
THYM	cis	rs17253792	0.749	rs45458197	chr14:56145018	A/T	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg22709100	chr7:91322751	NA	-0.62	-4.96	-0.45	3.05e-6	Breast cancer;
THYM	cis	rs1823778	0.609	rs1960819	chr18:67702586	A/G	cg13164537	chr18:67624071	CD226	1.11	4.94	0.45	3.28e-6	Mean platelet volume;
THYM	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg10760299	chr15:45669010	GATM	0.85	6.57	0.56	2.69e-9	Homoarginine levels;
THYM	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg23422044	chr7:1970798	MAD1L1	-0.94	-6.44	-0.55	4.84e-9	Bipolar disorder;
THYM	cis	rs6840360	0.638	rs6816002	chr4:152589439	C/T	cg22705602	chr4:152727874	NA	-0.82	-11.0	-0.75	1.2e-18	Intelligence (multi-trait analysis);
THYM	cis	rs7404928	0.557	rs1858870	chr16:23923433	A/T	cg26685404	chr16:23957272	PRKCB	-0.62	-7.22	-0.6	1.28e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	5.01	0.46	2.48e-6	Lung cancer in ever smokers;
THYM	cis	rs7267979	0.966	rs6107031	chr20:25350677	C/T	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs35660623	0.867	rs6983180	chr8:10660117	C/G	cg12395012	chr8:11607386	GATA4	-0.96	-5.25	-0.47	9.42e-7	3-hydroxypropylmercapturic acid levels in smokers;
THYM	cis	rs2219968	0.525	rs987472	chr8:78881334	C/T	cg00738934	chr8:78996279	NA	0.61	4.95	0.45	3.21e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs12121840	0.790	rs79586623	chr1:165532012	T/C	cg19407955	chr1:165599744	MGST3	-0.65	-4.63	-0.43	1.16e-5	Interleukin-1-receptor antagonist levels;
THYM	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.78	-6.97	-0.58	4.21e-10	Prudent dietary pattern;
THYM	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01570182	chr17:44337453	NA	0.91	9.94	0.71	2.22e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs78761021	0.755	rs62064480	chr17:9794251	G/A	cg26853458	chr17:9805074	RCVRN	0.53	4.49	0.42	2.01e-5	Type 2 diabetes;
THYM	cis	rs600806	0.850	rs115935180	chr1:109976775	C/G	cg23616212	chr1:109941201	SORT1	-0.48	-4.47	-0.42	2.17e-5	Intelligence (multi-trait analysis);
THYM	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg07343612	chr16:622815	PIGQ	-1.08	-10.53	-0.73	1.25e-17	Height;
THYM	cis	rs4687717	0.689	rs4687716	chr3:53277094	G/A	cg16894138	chr3:53270350	TKT	0.84	6.9	0.58	5.67e-10	Blood metabolite levels;Blood metabolite ratios;
THYM	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs10927875	0.691	rs1048302	chr1:16340879	T/G	cg22431228	chr1:16359049	CLCNKA	-0.52	-4.99	-0.46	2.71e-6	Dilated cardiomyopathy;
THYM	cis	rs9814567	0.752	rs4456908	chr3:134340353	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.78	-7.57	-0.61	2.38e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs1403694	0.515	rs1648697	chr3:186449194	A/G	cg12454167	chr3:186435060	KNG1	0.44	5.89	0.52	5.76e-8	Blood protein levels;
THYM	cis	rs7192750	0.586	rs4788447	chr16:71874860	C/T	cg06353428	chr16:71660113	MARVELD3	0.73	5.17	0.47	1.3e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs288326	0.561	rs79775314	chr2:183752749	C/A	cg09997497	chr2:183902928	NCKAP1	1.11	5.07	0.46	1.94e-6	Blood protein levels;
THYM	cis	rs11690935	0.959	rs6759575	chr2:172689068	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.81	-5.84	-0.51	7.21e-8	Schizophrenia;
THYM	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs3772130	0.962	rs9826473	chr3:121556219	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	0.75	4.66	0.43	1.03e-5	Cognitive performance;
THYM	cis	rs4979906	1.000	rs12264636	chr10:79448539	C/G	cg07817648	chr10:79422355	NA	0.74	5.37	0.48	5.49e-7	Mortality in heart failure;
THYM	cis	rs11603020	0.950	rs28362951	chr11:57372526	A/G	cg19752551	chr11:57585705	CTNND1	-0.59	-4.95	-0.45	3.25e-6	Blood protein levels;
THYM	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg16524936	chr4:1340807	KIAA1530	-0.59	-4.53	-0.42	1.74e-5	Longevity;
THYM	cis	rs611744	0.538	rs2298605	chr8:109272006	T/C	cg21045802	chr8:109455806	TTC35	0.71	6.6	0.56	2.32e-9	Dupuytren's disease;
THYM	cis	rs4242434	0.889	rs11783129	chr8:22453426	G/A	cg11461670	chr8:22454935	PDLIM2	-0.38	-6.56	-0.56	2.84e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs870825	0.548	rs12513029	chr4:185665118	G/A	cg27112742	chr4:185696749	ACSL1	-0.79	-4.65	-0.43	1.08e-5	Blood protein levels;
THYM	cis	rs7188861	0.681	rs6498184	chr16:11435990	A/G	cg00044050	chr16:11439710	C16orf75	-0.95	-4.77	-0.44	6.56e-6	HDL cholesterol;
THYM	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg24060327	chr5:131705240	SLC22A5	0.76	5.58	0.5	2.26e-7	Blood metabolite levels;
THYM	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg15316289	chr22:50310904	ALG12;CRELD2	-0.5	-4.89	-0.45	4.12e-6	Schizophrenia;
THYM	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg06238570	chr21:40685208	BRWD1	-0.96	-9.24	-0.69	7.07e-15	Cognitive function;
THYM	cis	rs11048434	0.736	rs2041624	chr12:9111855	C/G	cg13575925	chr12:9217583	LOC144571	0.53	4.99	0.46	2.77e-6	Sjögren's syndrome;
THYM	cis	rs295140	1.000	rs12618057	chr2:201171355	T/C	cg04283868	chr2:201171347	SPATS2L	0.75	5.77	0.51	1e-7	QT interval;
THYM	cis	rs6531656	0.663	rs337604	chr4:38648703	C/T	cg24279243	chr4:38676559	KLF3	-0.79	-6.43	-0.55	5.02e-9	Lymphocyte counts;
THYM	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg10150615	chr22:24372951	LOC391322	0.91	7.75	0.62	1.01e-11	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg07570687	chr10:102243282	WNT8B	0.75	6.63	0.56	2.07e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7772486	0.719	rs702317	chr6:146005010	C/T	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.54e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg27494647	chr7:150038898	RARRES2	-0.4	-4.59	-0.43	1.35e-5	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs10504073	0.647	rs62507247	chr8:50013554	T/G	cg00325661	chr8:49890786	NA	0.9	8.16	0.64	1.38e-12	Blood metabolite ratios;
THYM	cis	rs2901656	0.934	rs2285170	chr1:172425529	C/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.53	5.53	0.49	2.84e-7	Red cell distribution width;Platelet distribution width;
THYM	cis	rs2072732	0.904	rs2981857	chr1:2971521	T/C	cg08733933	chr1:2954429	NA	-0.55	-4.54	-0.42	1.64e-5	Plateletcrit;
THYM	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg03806693	chr22:41940476	POLR3H	-1.07	-10.12	-0.72	9.31e-17	Vitiligo;
THYM	cis	rs7394190	0.748	rs4746151	chr10:75578720	G/T	cg07699608	chr10:75541558	CHCHD1	0.96	5.1	0.46	1.77e-6	Incident atrial fibrillation;
THYM	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg15316289	chr22:50310904	ALG12;CRELD2	-0.51	-5.06	-0.46	2.07e-6	Schizophrenia;
THYM	cis	rs2046867	0.644	rs56947804	chr3:72788435	T/C	cg25664220	chr3:72788482	NA	-0.89	-6.97	-0.58	4.22e-10	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs4242434	0.927	rs746011	chr8:22457804	C/T	cg03733263	chr8:22462867	KIAA1967	1.2	11.86	0.77	1.94e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs861020	1.000	rs642961	chr1:209989270	A/G	cg05527609	chr1:210001259	C1orf107	0.96	7.47	0.61	3.83e-11	Orofacial clefts;
THYM	cis	rs35883536	1.000	rs2065784	chr1:101096056	A/G	cg09408571	chr1:101003634	GPR88	-0.45	-4.64	-0.43	1.1e-5	Monocyte count;
THYM	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg12011299	chr4:100065546	ADH4	-0.57	-5.14	-0.47	1.48e-6	Alcohol dependence;
THYM	cis	rs539096	0.607	rs3001723	chr1:44037685	G/A	cg00143623	chr1:44495758	SLC6A9	-0.56	-4.77	-0.44	6.7e-6	Intelligence (multi-trait analysis);
THYM	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs72949976	0.511	rs11903721	chr2:214016752	G/C	cg08319019	chr2:214017104	IKZF2	-0.86	-7.64	-0.62	1.68e-11	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs514406	0.861	rs7417821	chr1:53295117	A/G	cg16325326	chr1:53192061	ZYG11B	0.76	7.23	0.6	1.24e-10	Monocyte count;
THYM	cis	rs9302635	0.513	rs8050238	chr16:72154187	C/T	cg23815491	chr16:72088622	HP	0.65	4.75	0.44	7.15e-6	Blood protein levels;
THYM	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg07636037	chr3:49044803	WDR6	0.92	7.94	0.63	4.07e-12	Menarche (age at onset);
THYM	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg14675211	chr2:100938903	LONRF2	0.75	7.95	0.63	3.92e-12	Intelligence (multi-trait analysis);
THYM	cis	rs10203711	1.000	rs2334022	chr2:239565612	T/C	cg14580085	chr2:239553406	NA	0.68	6.18	0.54	1.62e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9807841	0.592	rs2043304	chr19:10772112	T/C	cg17848348	chr19:10766748	ILF3	-0.8	-6.51	-0.56	3.52e-9	Inflammatory skin disease;
THYM	cis	rs611744	0.934	rs609102	chr8:109227406	A/G	cg21045802	chr8:109455806	TTC35	0.59	5.15	0.47	1.38e-6	Dupuytren's disease;
THYM	cis	rs669446	0.561	rs517849	chr1:44081873	A/C	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs208515	0.560	rs207084	chr6:66776966	T/C	cg07460842	chr6:66804631	NA	-1.22	-14.82	-0.84	1.93e-26	Exhaled nitric oxide levels;
THYM	cis	rs17407555	0.779	rs73218769	chr4:10157280	A/G	cg11266682	chr4:10021025	SLC2A9	-0.58	-5.52	-0.49	2.92e-7	Schizophrenia (age at onset);
THYM	cis	rs28595532	0.841	rs56388366	chr4:119769242	A/G	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg10018233	chr7:150070692	REPIN1	0.44	5.93	0.52	4.94e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg06558623	chr16:89946397	TCF25	0.88	4.75	0.44	7.33e-6	Skin colour saturation;
THYM	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	trans	rs10462794	0.789	rs7719895	chr5:4490338	C/T	cg17105206	chr16:67211972	KIAA0895L	1.15	7.12	0.59	2.01e-10	DNA methylation (variation);
THYM	cis	rs240764	0.579	rs6937520	chr6:101173735	C/T	cg21058520	chr6:100914733	NA	0.61	5.13	0.47	1.55e-6	Neuroticism;
THYM	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs11690935	0.851	rs9808259	chr2:172648974	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.81	-5.87	-0.52	6.34e-8	Schizophrenia;
THYM	cis	rs28785552	0.554	rs11084182	chr19:53213411	A/G	cg10871876	chr19:53194124	ZNF83	0.72	5.59	0.5	2.21e-7	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.72	5.56	0.5	2.5e-7	Tonsillectomy;
THYM	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg12963246	chr6:28129442	ZNF389	-0.81	-6.75	-0.57	1.19e-9	Parkinson's disease;
THYM	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs11771526	0.901	rs62457503	chr7:32330980	A/C	cg27532318	chr7:32358331	NA	0.74	4.72	0.44	7.97e-6	Body mass index;
THYM	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg06238570	chr21:40685208	BRWD1	-0.69	-6.08	-0.53	2.47e-8	Menarche (age at onset);
THYM	cis	rs4242434	0.819	rs6999893	chr8:22465427	T/C	cg03733263	chr8:22462867	KIAA1967	0.94	10.44	0.73	1.92e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs7011507	0.594	rs72639030	chr8:49351414	A/G	cg08774009	chr8:49309094	NA	-0.6	-4.71	-0.44	8.47e-6	Inflammatory bowel disease;Ulcerative colitis;
THYM	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs11186	0.556	rs72908321	chr2:189973051	C/A	cg11041835	chr2:189156425	GULP1	0.8	4.52	0.42	1.79e-5	Parkinson's disease;
THYM	cis	rs28374715	0.662	rs691906	chr15:41474636	T/A	cg18705301	chr15:41695430	NDUFAF1	1.04	8.82	0.67	5.6e-14	Ulcerative colitis;
THYM	cis	rs73086581	0.687	rs16989002	chr20:3850703	G/C	cg02187196	chr20:3869020	PANK2	0.44	5.03	0.46	2.36e-6	Response to antidepressants in depression;
THYM	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	9.14	0.68	1.15e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	trans	rs877282	0.733	rs11253342	chr10:765072	A/G	cg22713356	chr15:30763199	NA	1.36	10.13	0.72	8.77e-17	Uric acid levels;
THYM	cis	rs986417	0.636	rs8020587	chr14:60952612	A/G	cg27398547	chr14:60952738	C14orf39	1.17	6.74	0.57	1.21e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18252515	chr7:66147081	NA	-0.66	-4.96	-0.45	3.11e-6	Aortic root size;
THYM	cis	rs4363385	0.693	rs6656812	chr1:152930254	C/T	cg07796016	chr1:152779584	LCE1C	0.59	4.66	0.43	1.04e-5	Inflammatory skin disease;
THYM	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg17691542	chr6:26056736	HIST1H1C	0.98	6.78	0.57	1.01e-9	Iron status biomarkers;
THYM	cis	rs7584330	0.554	rs80151891	chr2:238398826	G/T	cg08992911	chr2:238395768	MLPH	1.09	6.35	0.55	7.39e-9	Prostate cancer;
THYM	cis	rs1073160	1.000	rs1073160	chr12:9058562	A/G	cg04155231	chr12:9217510	LOC144571	-0.47	-4.45	-0.42	2.35e-5	Small cell lung carcinoma;
THYM	cis	rs10805346	0.558	rs12506562	chr4:10106954	G/T	cg26409237	chr4:10041000	SLC2A9	0.46	4.73	0.44	7.91e-6	Urate levels in overweight individuals;Urate levels in obese individuals;
THYM	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg07414643	chr4:187882934	NA	0.57	5.07	0.46	1.98e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs600806	0.850	rs3768494	chr1:109935427	A/G	cg23616212	chr1:109941201	SORT1	-0.49	-4.66	-0.43	1.01e-5	Intelligence (multi-trait analysis);
THYM	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg04282206	chr17:62833786	PLEKHM1P	-0.83	-8.06	-0.64	2.23e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7119	0.679	rs12902698	chr15:77809010	A/C	cg10437265	chr15:77819839	NA	0.77	7.7	0.62	1.29e-11	Type 2 diabetes;
THYM	cis	rs9549260	0.816	rs7328594	chr13:41253764	T/C	cg21288729	chr13:41239152	FOXO1	0.72	5.74	0.51	1.15e-7	Red blood cell count;
THYM	cis	rs7426056	0.671	rs3181106	chr2:204591153	G/T	cg07930752	chr2:204569955	CD28	0.68	4.93	0.45	3.52e-6	Primary sclerosing cholangitis;
THYM	cis	rs3773445	0.837	rs1730231	chr3:25620717	T/A	cg02315353	chr3:25825455	NGLY1	0.62	5.63	0.5	1.82e-7	Airway responsiveness in chronic obstructive pulmonary disease;
THYM	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg00147172	chr22:46423604	NA	-0.28	-4.92	-0.45	3.57e-6	Dupuytren's disease;
THYM	cis	rs919433	0.619	rs699318	chr2:198281743	T/C	cg00792783	chr2:198669748	PLCL1	0.82	5.67	0.5	1.54e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs6011002	0.872	rs73920935	chr20:62297400	T/C	cg08432509	chr20:62317768	RTEL1	0.69	4.49	0.42	2.01e-5	Dental caries;
THYM	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg08901578	chr4:187885870	NA	-0.67	-6.43	-0.55	5.07e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1065852	0.503	rs9620006	chr22:42399547	T/A	cg22189786	chr22:42395067	WBP2NL	0.54	5.55	0.49	2.6e-7	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	trans	rs17716202	1.000	rs17716202	chr5:55904898	A/G	cg01557754	chr17:7342661	FGF11	0.98	7.0	0.58	3.61e-10	Psychosis in Alzheimer's disease;
THYM	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.7	-5.39	-0.48	5.09e-7	Total cholesterol levels;
THYM	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg17264618	chr3:40429014	ENTPD3	0.46	4.45	0.42	2.29e-5	Renal cell carcinoma;
THYM	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg15693483	chr7:1102177	C7orf50	0.54	6.26	0.54	1.1e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9361491	0.578	rs1180827	chr6:79434628	G/C	cg04547799	chr6:79944526	HMGN3	-0.66	-4.88	-0.45	4.34e-6	Intelligence (multi-trait analysis);
THYM	trans	rs9929218	0.817	rs3114404	chr16:68722096	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.94	-7.24	-0.6	1.14e-10	Colorectal cancer;
THYM	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs6674176	0.932	rs12410334	chr1:44442521	A/C	cg15962314	chr1:44399869	ARTN	0.49	4.49	0.42	2.03e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	trans	rs916888	0.647	rs199517	chr17:44854587	A/G	cg01341218	chr17:43662625	NA	-0.82	-6.99	-0.58	3.87e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs7917772	0.582	rs10786689	chr10:104356359	T/C	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs6665290	0.935	rs1929863	chr1:227195728	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.14	-16.31	-0.86	2.76e-29	Myeloid white cell count;
THYM	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03264133	chr6:25882463	NA	-0.87	-7.97	-0.63	3.42e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06481639	chr22:41940642	POLR3H	-0.8	-5.39	-0.48	5.08e-7	Vitiligo;
THYM	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.15e-7	Intelligence (multi-trait analysis);
THYM	cis	rs4979906	1.000	rs4979786	chr10:79444965	T/C	cg07817648	chr10:79422355	NA	-0.76	-5.64	-0.5	1.77e-7	Mortality in heart failure;
THYM	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg08847533	chr14:75593920	NEK9	-0.97	-10.38	-0.73	2.59e-17	Height;
THYM	cis	rs2658782	0.951	rs2608215	chr11:93148817	G/A	cg15737290	chr11:93063684	CCDC67	1.01	7.95	0.63	3.81e-12	Pulmonary function decline;
THYM	cis	rs728616	0.541	rs61860401	chr10:81723522	C/T	cg27452691	chr10:81370291	SFTPA1	0.59	4.6	0.43	1.33e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg27170947	chr2:26402098	FAM59B	-0.57	-4.87	-0.45	4.37e-6	Gut microbiome composition (summer);
THYM	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg16586182	chr3:47516702	SCAP	-0.59	-5.08	-0.46	1.88e-6	Colorectal cancer;
THYM	cis	rs55728055	0.661	rs16989379	chr22:32058269	G/A	cg01338084	chr22:32026380	PISD	1.47	5.89	0.52	5.9e-8	Age-related hearing impairment;
THYM	cis	rs9826463	0.702	rs55994893	chr3:142304694	G/C	cg20824294	chr3:142316082	PLS1	0.64	4.62	0.43	1.2e-5	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs8017423	0.791	rs7146250	chr14:90711703	A/G	cg04239629	chr14:90701769	NA	-0.64	-4.69	-0.43	9.24e-6	Mortality in heart failure;
THYM	cis	rs6665290	0.904	rs1045285	chr1:227179054	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.13	-15.82	-0.85	2.26e-28	Myeloid white cell count;
THYM	cis	rs40363	0.729	rs6501176	chr16:3522197	A/G	cg05754148	chr16:3507555	NAT15	-0.81	-8.17	-0.64	1.29e-12	Tuberculosis;
THYM	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.67	5.26	0.47	8.97e-7	Lung cancer in ever smokers;
THYM	cis	rs9362426	1.000	rs406900	chr6:88085447	T/C	cg10393598	chr6:87862264	NA	-0.61	-4.83	-0.44	5.13e-6	Depressive episodes in bipolar disorder;
THYM	cis	rs4803468	0.935	rs12602	chr19:41889748	T/C	cg09537434	chr19:41945824	ATP5SL	-1.06	-9.37	-0.69	3.75e-15	Height;
THYM	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg10295955	chr4:187884368	NA	-1.16	-16.24	-0.86	3.64e-29	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2745959	0.509	rs2745948	chr1:208051059	C/T	cg11195082	chr1:207670065	CR1	-0.52	-4.48	-0.42	2.05e-5	Resting heart rate;
THYM	cis	rs9677476	1.000	rs6704770	chr2:232109816	T/G	cg07929768	chr2:232055508	NA	0.52	5.42	0.49	4.48e-7	Food antigen IgG levels;
THYM	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg14972814	chr11:95582409	MTMR2	-0.7	-6.18	-0.54	1.56e-8	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6728642	0.803	rs11891458	chr2:97632450	G/T	cg26665480	chr2:98280029	ACTR1B	-0.8	-4.5	-0.42	1.95e-5	Bipolar disorder lithium response (continuous) or schizophrenia;
THYM	cis	rs6429082	0.627	rs2016437	chr1:235539355	T/G	cg26050004	chr1:235667680	B3GALNT2	-0.63	-4.69	-0.43	9.16e-6	Adiposity;
THYM	trans	rs6588480	0.667	rs559991	chr1:53982525	G/A	cg04105923	chr6:106451610	NA	-0.76	-7.18	-0.59	1.55e-10	Response to statin therapy;
THYM	cis	rs7106204	0.748	rs6484028	chr11:24222438	A/G	ch.11.24196551F	chr11:24239977	NA	1.04	7.55	0.61	2.59e-11	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs854765	0.583	rs12603148	chr17:17865257	C/T	cg04398451	chr17:18023971	MYO15A	-0.8	-7.37	-0.6	6.29e-11	Total body bone mineral density;
THYM	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs28647808	0.881	rs4962047	chr9:136262916	T/C	cg14268506	chr9:136215580	SNORD36B;MED22;SNORD24;RPL7A	-1.13	-5.15	-0.47	1.4e-6	Blood protein levels;
THYM	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11890956	chr21:40555474	PSMG1	-0.92	-10.1	-0.72	1.01e-16	Cognitive function;
THYM	cis	rs7772486	0.875	rs854148	chr6:146310979	G/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.66	-0.5	1.62e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11890956	chr21:40555474	PSMG1	-0.9	-9.61	-0.7	1.12e-15	Cognitive function;
THYM	cis	rs4523957	0.583	rs6503302	chr17:2052704	C/T	cg16513277	chr17:2031491	SMG6	-1.02	-9.49	-0.7	2.03e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs9534288	0.699	rs4280137	chr13:46664008	G/A	cg15192986	chr13:46630673	CPB2	-0.65	-4.6	-0.43	1.28e-5	Blood protein levels;
THYM	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg18252515	chr7:66147081	NA	0.63	4.54	0.42	1.65e-5	Aortic root size;
THYM	cis	rs2235642	0.592	rs743963	chr16:1657350	A/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-5.24	-0.47	9.75e-7	Coronary artery disease;
THYM	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg16680214	chr1:154839983	KCNN3	-0.58	-7.26	-0.6	1.04e-10	Prostate cancer;
THYM	cis	rs4845459	0.967	rs6677595	chr1:152590187	C/T	cg27206522	chr1:152595629	LCE3A	-0.51	-4.54	-0.42	1.66e-5	Psoriasis;
THYM	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg06636001	chr8:8085503	FLJ10661	0.68	5.62	0.5	1.93e-7	Neuroticism;
THYM	cis	rs7119	0.651	rs12917044	chr15:77850146	A/G	cg27398640	chr15:77910606	LINGO1	0.59	5.98	0.52	3.96e-8	Type 2 diabetes;
THYM	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg12311346	chr5:56204834	C5orf35	-0.82	-6.01	-0.52	3.47e-8	Initial pursuit acceleration;
THYM	cis	rs425277	1.000	rs262667	chr1:2082722	T/C	cg00981070	chr1:2046702	PRKCZ	0.47	5.21	0.47	1.1e-6	Height;
THYM	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg09904177	chr6:26538194	HMGN4	0.64	5.4	0.48	4.93e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06634786	chr22:41940651	POLR3H	0.63	4.92	0.45	3.62e-6	Vitiligo;
THYM	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg02725872	chr8:58115012	NA	-0.73	-4.67	-0.43	9.96e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	1.17	9.38	0.69	3.52e-15	Cognitive test performance;
THYM	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg07343612	chr16:622815	PIGQ	-1.08	-10.52	-0.73	1.27e-17	Height;
THYM	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg05738196	chr6:26577821	NA	0.6	4.91	0.45	3.71e-6	Schizophrenia;
THYM	cis	rs1018836	0.828	rs4735236	chr8:91583909	A/G	cg16814680	chr8:91681699	NA	-0.9	-7.85	-0.63	6.16e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg11301795	chr4:187892539	NA	-1.09	-16.54	-0.86	1.01e-29	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs56775891	0.527	rs71367544	chr18:77574374	C/T	cg25357022	chr18:77495084	CTDP1	-0.72	-4.84	-0.44	5e-6	Schizophrenia;
THYM	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.43	0.7	2.73e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	5.68	0.5	1.46e-7	Height;
THYM	cis	rs4595586	0.505	rs11611321	chr12:39390803	C/T	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs365132	1.000	rs601923	chr5:176417386	C/G	cg17809377	chr5:176326619	HK3	-0.3	-4.55	-0.42	1.59e-5	Menarche and menopause (age at onset);Menopause (age at onset);
THYM	cis	rs6840360	0.571	rs4696274	chr4:152528478	C/A	cg22705602	chr4:152727874	NA	-0.81	-8.74	-0.67	8.26e-14	Intelligence (multi-trait analysis);
THYM	cis	rs1005224	0.782	rs34882722	chr14:76153896	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.71	-5.77	-0.51	1e-7	Large artery stroke;
THYM	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.76	-5.02	-0.46	2.38e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg22709100	chr7:91322751	NA	-0.6	-4.8	-0.44	5.84e-6	Breast cancer;
THYM	cis	rs11690935	0.959	rs6758704	chr2:172655097	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.82	-6.02	-0.53	3.29e-8	Schizophrenia;
THYM	cis	rs4455778	0.580	rs10261034	chr7:49092554	C/A	cg26309511	chr7:48887640	NA	0.68	5.94	0.52	4.63e-8	Lung cancer in never smokers;
THYM	cis	rs1061377	1.000	rs3796509	chr4:39110186	G/T	cg24403649	chr4:39172243	NA	0.56	4.56	0.42	1.55e-5	Uric acid levels;
THYM	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg11752832	chr7:134001865	SLC35B4	0.76	5.72	0.51	1.24e-7	Mean platelet volume;
THYM	cis	rs9790314	0.747	rs1610158	chr3:160815050	A/G	cg04691961	chr3:161091175	C3orf57	0.64	5.05	0.46	2.17e-6	Morning vs. evening chronotype;
THYM	cis	rs7828089	0.935	rs896375	chr8:22262098	A/G	cg12081754	chr8:22256438	SLC39A14	0.62	5.46	0.49	3.87e-7	Verbal declarative memory;
THYM	cis	rs16866061	1.000	rs17480230	chr2:225399864	G/A	cg12698349	chr2:225449008	CUL3	1.14	10.37	0.73	2.69e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg14349672	chr11:133703707	NA	0.57	5.35	0.48	6e-7	Childhood ear infection;
THYM	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg02527881	chr3:46936655	PTH1R	-0.8	-7.91	-0.63	4.77e-12	Birth weight;
THYM	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.72	0.51	1.23e-7	Lung cancer in ever smokers;
THYM	cis	rs561341	0.843	rs879945	chr17:30242796	G/A	cg12193833	chr17:30244370	NA	-0.63	-4.58	-0.43	1.41e-5	Hip circumference adjusted for BMI;
THYM	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg24209194	chr3:40518798	ZNF619	0.56	4.48	0.42	2.11e-5	Renal cell carcinoma;
THYM	cis	rs7777677	0.925	rs6960743	chr7:142369601	T/C	cg21785750	chr7:142428317	NA	0.67	5.88	0.52	6.1e-8	Alcoholic chronic pancreatitis;
THYM	cis	rs9287719	0.781	rs6714413	chr2:10758859	C/T	cg02196655	chr2:10830764	NOL10	-0.45	-4.77	-0.44	6.77e-6	Prostate cancer;
THYM	cis	rs2730245	0.527	rs62475645	chr7:158656825	G/A	cg24397884	chr7:158709396	WDR60	0.55	5.31	0.48	7.11e-7	Height;
THYM	cis	rs76935404	0.811	rs12151139	chr19:41433543	A/G	cg19493303	chr19:41414353	NA	-0.56	-5.11	-0.46	1.69e-6	nicotine metabolite ratio in current smokers;
THYM	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg21427119	chr20:30132790	HM13	-0.97	-7.07	-0.59	2.63e-10	Mean corpuscular hemoglobin;
THYM	cis	rs4731207	0.671	rs4731221	chr7:124481403	T/A	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs7940866	0.903	rs1433980	chr11:130870956	A/G	cg23692386	chr11:131799662	NTM	0.47	5.27	0.48	8.34e-7	Schizophrenia;
THYM	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg24675658	chr1:53192096	ZYG11B	0.73	6.39	0.55	6.03e-9	Monocyte count;
THYM	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.42	4.98	0.45	2.88e-6	Schizophrenia;
THYM	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	5.78	0.51	9.59e-8	Height;
THYM	cis	rs2404602	0.647	rs118129828	chr15:77015200	T/C	cg23625390	chr15:77176239	SCAPER	-0.83	-5.98	-0.52	3.96e-8	Blood metabolite levels;
THYM	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg04944784	chr2:26401820	FAM59B	-1.05	-7.66	-0.62	1.54e-11	Gut microbiome composition (summer);
THYM	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg23187316	chr7:1099788	C7orf50	0.59	4.49	0.42	2.01e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-13.87	-0.82	1.48e-24	Height;
THYM	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg11189052	chr15:85197271	WDR73	-0.68	-5.36	-0.48	5.73e-7	P wave terminal force;
THYM	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg06028605	chr16:24865363	SLC5A11	0.55	5.15	0.47	1.41e-6	Intelligence (multi-trait analysis);
THYM	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg14779329	chr11:130786720	SNX19	0.49	5.07	0.46	1.98e-6	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs3796619	0.924	rs4690209	chr4:1077575	G/A	cg27284194	chr4:1044797	NA	0.53	4.95	0.45	3.22e-6	Recombination rate (males);
THYM	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg03060546	chr3:49711283	APEH	0.71	5.0	0.46	2.62e-6	Resting heart rate;
THYM	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.63	11.24	0.76	3.76e-19	Hemostatic factors and hematological phenotypes;
THYM	cis	rs6429082	0.689	rs4659923	chr1:235709519	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.63	-4.79	-0.44	6.16e-6	Adiposity;
THYM	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg11502198	chr6:26597334	ABT1	0.63	5.59	0.5	2.14e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	5.75	0.51	1.1e-7	Height;
THYM	cis	rs7849270	1.000	rs3739847	chr9:131911574	A/G	cg14069949	chr9:131965419	NA	-0.5	-4.52	-0.42	1.8e-5	Blood metabolite ratios;
THYM	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.0	7.21	0.59	1.33e-10	Smoking behavior;
THYM	trans	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg10856724	chr12:34555212	NA	-0.9	-8.12	-0.64	1.66e-12	Bladder cancer;
THYM	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg25358565	chr5:93447407	FAM172A	1.34	10.59	0.74	9.3e-18	Diabetic retinopathy;
THYM	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg01324343	chr3:183735012	ABCC5	0.85	11.39	0.76	1.84e-19	Anterior chamber depth;
THYM	cis	rs9581857	0.579	rs75872792	chr13:27996064	G/T	cg22138327	chr13:27999177	GTF3A	1.04	6.13	0.53	1.97e-8	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs2139634	0.965	rs12496623	chr3:46541541	A/C	cg02332537	chr3:46540019	RTP3	0.47	4.98	0.45	2.88e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7178572	0.568	rs11072653	chr15:77693934	C/T	cg22256960	chr15:77711686	NA	-1.05	-8.4	-0.65	4.29e-13	Type 2 diabetes;
THYM	cis	rs4731207	0.967	rs2267708	chr7:124392512	C/T	cg05285228	chr7:124571219	POT1	0.62	4.8	0.44	5.94e-6	Cutaneous malignant melanoma;
THYM	cis	rs995000	0.931	rs624660	chr1:62920388	C/A	cg06896770	chr1:63153194	DOCK7	0.91	7.48	0.61	3.73e-11	Triglyceride levels;
THYM	cis	rs807029	0.533	rs3740485	chr10:102750621	C/T	cg14905631	chr10:102746534	C10orf2;MRPL43	0.36	5.05	0.46	2.14e-6	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs76878669	0.561	rs10896111	chr11:66115690	T/C	cg18002602	chr11:66138449	SLC29A2	-0.49	-4.77	-0.44	6.59e-6	Educational attainment (years of education);
THYM	cis	rs2898681	1.000	rs2898681	chr4:53757000	C/T	cg03786743	chr4:53727781	RASL11B	0.44	4.9	0.45	3.9e-6	Optic nerve measurement (cup area);
THYM	cis	rs12476592	0.543	rs12713494	chr2:63698162	G/T	cg17519650	chr2:63277830	OTX1	-0.7	-4.68	-0.43	9.57e-6	Childhood ear infection;
THYM	cis	rs7809950	0.678	rs12672451	chr7:106853817	C/G	cg23024343	chr7:107201750	COG5	-1.0	-8.43	-0.65	3.79e-13	Coronary artery disease;
THYM	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg17366294	chr4:99064904	C4orf37	0.53	6.16	0.53	1.74e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg04025307	chr7:1156635	C7orf50	0.82	8.6	0.66	1.65e-13	Longevity;Endometriosis;
THYM	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg18681998	chr4:17616180	MED28	0.92	8.85	0.67	4.73e-14	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs2319125	0.649	rs1373077	chr17:64050754	A/G	cg04446870	chr17:64440273	PRKCA	0.5	4.48	0.42	2.12e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs11209185	0.602	rs1926300	chr1:68439174	G/A	cg22082780	chr1:68452167	NA	0.49	5.74	0.51	1.14e-7	Itch intensity from mosquito bite adjusted by bite size;
THYM	cis	rs7772486	0.790	rs2265472	chr6:146220758	G/C	cg13319975	chr6:146136371	FBXO30	-0.73	-6.11	-0.53	2.19e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs673253	0.556	rs2274465	chr1:44121557	C/G	cg09903430	chr1:44172605	ST3GAL3	0.5	4.57	0.42	1.49e-5	Intelligence (multi-trait analysis);
THYM	cis	rs10992471	0.603	rs4744141	chr9:95352140	T/C	cg14631576	chr9:95140430	CENPP	-0.96	-8.92	-0.68	3.33e-14	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs288326	0.561	rs75848966	chr2:183878093	A/C	cg09997497	chr2:183902928	NCKAP1	1.24	5.44	0.49	4.08e-7	Blood protein levels;
THYM	cis	rs2505998	0.833	rs2505533	chr10:43594453	A/G	cg06632098	chr10:43605906	RET	-1.1	-10.64	-0.74	7.21e-18	Hirschsprung disease;
THYM	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.81	-6.29	-0.54	9.55e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg22431228	chr1:16359049	CLCNKA	0.5	4.46	0.42	2.28e-5	Dilated cardiomyopathy;
THYM	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg24209194	chr3:40518798	ZNF619	0.56	4.56	0.42	1.52e-5	Renal cell carcinoma;
THYM	cis	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg16306078	chr6:126000798	NA	-0.47	-4.64	-0.43	1.12e-5	Endometrial cancer;
THYM	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg03476357	chr21:30257390	N6AMT1	0.6	4.57	0.42	1.44e-5	Dental caries;
THYM	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9902453	0.791	rs7219163	chr17:28210703	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	5.39	0.48	5.11e-7	Coffee consumption (cups per day);
THYM	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg01579765	chr21:45077557	HSF2BP	-0.54	-8.75	-0.67	7.69e-14	Mean corpuscular volume;
THYM	cis	rs17253792	0.822	rs76557162	chr14:56064701	A/G	cg01858014	chr14:56050164	KTN1	-1.23	-5.16	-0.47	1.36e-6	Putamen volume;
THYM	cis	rs2898681	0.581	rs936690	chr4:53691035	A/G	cg00791764	chr4:53727839	RASL11B	0.43	5.44	0.49	4.18e-7	Optic nerve measurement (cup area);
THYM	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg01831904	chr17:28903510	LRRC37B2	0.91	4.95	0.45	3.24e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg01483505	chr11:975446	AP2A2	0.58	4.75	0.44	7.18e-6	Alzheimer's disease (late onset);
THYM	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg03188948	chr7:1209495	NA	0.68	4.87	0.45	4.48e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg03929089	chr4:120376271	NA	-1.04	-11.96	-0.78	1.2e-20	Height;
THYM	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.2e-16	Bone mineral density;
THYM	cis	rs684232	0.644	rs1227030	chr17:619882	C/T	cg15660573	chr17:549704	VPS53	-0.83	-7.35	-0.6	6.96e-11	Prostate cancer;
THYM	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs3820068	0.705	rs72643701	chr1:15866219	G/A	cg05660106	chr1:15850417	CASP9	1.14	9.89	0.71	2.91e-16	Systolic blood pressure;
THYM	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg06028808	chr11:68637592	NA	0.67	7.26	0.6	1.07e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7584330	0.504	rs11890255	chr2:238434605	A/G	cg08992911	chr2:238395768	MLPH	0.86	5.46	0.49	3.76e-7	Prostate cancer;
THYM	cis	rs7131987	0.903	rs10843371	chr12:29414232	G/A	cg09582351	chr12:29534625	ERGIC2	-0.48	-4.59	-0.43	1.36e-5	QT interval;
THYM	cis	rs911555	0.570	rs942862	chr14:104022124	G/C	cg12935359	chr14:103987150	CKB	-0.56	-6.71	-0.57	1.4e-9	Intelligence (multi-trait analysis);
THYM	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg18681998	chr4:17616180	MED28	0.91	8.58	0.66	1.75e-13	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg00898013	chr13:113819073	PROZ	-0.88	-9.0	-0.68	2.24e-14	Platelet distribution width;
THYM	cis	rs995000	0.931	rs1168086	chr1:63112389	A/G	cg06896770	chr1:63153194	DOCK7	-0.9	-7.29	-0.6	8.97e-11	Triglyceride levels;
THYM	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.77	4.68	0.43	9.49e-6	Diabetic retinopathy;
THYM	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg17054759	chr22:49844102	NA	-0.52	-4.74	-0.44	7.53e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	8.7	0.67	9.84e-14	Chronic sinus infection;
THYM	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg15693483	chr7:1102177	C7orf50	0.4	5.8	0.51	8.8e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs4650994	0.544	rs4075631	chr1:178506594	C/A	cg05059571	chr16:84539110	KIAA1609	-0.86	-9.99	-0.72	1.74e-16	HDL cholesterol levels;HDL cholesterol;
THYM	cis	rs17253792	0.822	rs78429067	chr14:56092551	G/A	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg17518825	chr2:46523461	EPAS1	-0.42	-4.61	-0.43	1.25e-5	HDL cholesterol;
THYM	cis	rs7618501	0.699	rs2681780	chr3:49897830	C/T	cg24308560	chr3:49941425	MST1R	-0.72	-6.06	-0.53	2.76e-8	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg18252515	chr7:66147081	NA	0.63	4.54	0.42	1.65e-5	Aortic root size;
THYM	cis	rs72949976	1.000	rs62186568	chr2:214033955	G/A	cg08319019	chr2:214017104	IKZF2	-0.6	-4.46	-0.42	2.24e-5	Lung cancer;Squamous cell lung carcinoma;
THYM	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg17333051	chr19:2783644	SGTA	0.71	6.16	0.53	1.77e-8	Total cholesterol levels;
THYM	cis	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg07460842	chr6:66804631	NA	-1.23	-15.63	-0.85	5.34e-28	Exhaled nitric oxide output;
THYM	cis	rs6598955	0.671	rs17163866	chr1:26648088	A/G	cg08133631	chr1:26527909	CATSPER4	-0.62	-4.93	-0.45	3.42e-6	Obesity-related traits;
THYM	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs4780401	0.678	rs7189287	chr16:11764608	A/G	cg01061890	chr16:11836724	TXNDC11	-0.6	-4.64	-0.43	1.11e-5	Rheumatoid arthritis;
THYM	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg00484396	chr16:3507460	NAT15	0.68	8.83	0.67	5.13e-14	Tuberculosis;
THYM	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23221052	chr5:179740743	GFPT2	-0.85	-6.79	-0.57	9.66e-10	Height;
THYM	cis	rs7957197	0.624	rs55805582	chr12:121486388	G/T	cg13567169	chr12:121410855	C12orf27	0.47	4.53	0.42	1.72e-5	Type 2 diabetes;
THYM	cis	rs11031096	0.711	rs10767881	chr11:4205122	C/G	cg08557956	chr11:4115526	RRM1	-0.55	-4.97	-0.45	2.9e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.18	9.38	0.69	3.42e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7940866	0.838	rs1991898	chr11:130801786	C/G	cg05962950	chr11:130786565	SNX19	-0.81	-6.65	-0.56	1.85e-9	Schizophrenia;
THYM	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg16031515	chr1:205743344	RAB7L1	0.53	4.58	0.43	1.43e-5	Menarche (age at onset);
THYM	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg14972814	chr11:95582409	MTMR2	-0.66	-5.1	-0.46	1.72e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10823500	0.777	rs10762348	chr10:71952322	C/A	cg02100629	chr10:71892760	AIFM2	-0.37	-4.48	-0.42	2.1e-5	Blood protein levels;
THYM	cis	rs13631	0.697	rs1018330	chr9:139980385	A/C	cg03717367	chr9:139980219	LOC100289341;MAN1B1	0.67	6.01	0.52	3.41e-8	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9905759	0.603	rs4130509	chr17:7930778	C/T	cg14438174	chr17:7137923	DVL2	-0.54	-4.52	-0.42	1.8e-5	Childhood ear infection;
THYM	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.37	-0.48	5.48e-7	Menopause (age at onset);
THYM	cis	rs11792861	0.591	rs7044275	chr9:111717138	T/C	cg05043794	chr9:111880884	C9orf5	-0.35	-4.83	-0.44	5.31e-6	Menarche (age at onset);
THYM	cis	rs12368653	0.666	rs799267	chr12:58113158	C/T	cg12615879	chr12:58013172	SLC26A10	0.52	5.14	0.47	1.48e-6	Multiple sclerosis;
THYM	cis	rs11696845	0.666	rs6073533	chr20:43361082	G/T	cg25301532	chr20:43378953	KCNK15	-0.55	-4.68	-0.43	9.64e-6	Obesity-related traits;
THYM	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg04918696	chr8:1004106	NA	-0.41	-4.63	-0.43	1.15e-5	Schizophrenia;
THYM	cis	rs7513165	1.000	rs7513165	chr1:204147186	C/T	cg04791601	chr1:204159016	NA	-0.37	-4.77	-0.44	6.76e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
THYM	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg23428387	chr22:49814324	NA	-0.58	-6.04	-0.53	2.99e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7173743	0.756	rs12903613	chr15:79129076	G/T	cg15571903	chr15:79123663	NA	0.55	6.25	0.54	1.14e-8	Coronary artery disease;
THYM	cis	rs2139634	0.896	rs885486	chr3:46511226	T/C	cg02332537	chr3:46540019	RTP3	0.44	4.49	0.42	2.02e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9420	0.961	rs682503	chr11:57640994	C/G	cg19752551	chr11:57585705	CTNND1	0.74	7.54	0.61	2.75e-11	Schizophrenia;
THYM	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg24642844	chr7:1081250	C7orf50	-1.13	-4.76	-0.44	6.82e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1018836	0.818	rs715057	chr8:91624340	T/C	cg16814680	chr8:91681699	NA	-0.98	-9.08	-0.68	1.5e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg25251562	chr2:3704773	ALLC	-0.83	-5.59	-0.5	2.16e-7	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs7572263	0.959	rs7583625	chr2:209048739	A/G	cg23998903	chr2:209048830	C2orf80	-0.43	-5.66	-0.5	1.6e-7	Glioma;Non-glioblastoma glioma;
THYM	cis	rs786425	0.530	rs7308398	chr12:124226800	T/A	cg15249119	chr12:124971054	NCOR2	0.55	5.09	0.46	1.79e-6	Pubertal anthropometrics;
THYM	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg04398451	chr17:18023971	MYO15A	-0.92	-9.33	-0.69	4.39e-15	Total body bone mineral density;
THYM	cis	rs883115	0.791	rs10799589	chr1:224819278	C/T	cg21444086	chr1:224821584	CNIH3	0.5	4.64	0.43	1.11e-5	Cancer;
THYM	cis	rs7772486	0.748	rs2748484	chr6:146333653	C/T	cg13319975	chr6:146136371	FBXO30	-0.72	-6.09	-0.53	2.36e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs870825	0.616	rs4519834	chr4:185633865	A/G	cg04058563	chr4:185651563	MLF1IP	-1.11	-9.62	-0.7	1.08e-15	Blood protein levels;
THYM	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg04043695	chr12:129287642	SLC15A4	0.63	5.05	0.46	2.16e-6	Systemic lupus erythematosus;
THYM	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg25358565	chr5:93447407	FAM172A	1.36	10.86	0.74	2.47e-18	Diabetic retinopathy;
THYM	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.77	-7.17	-0.59	1.64e-10	Personality dimensions;
THYM	cis	rs977987	0.843	rs10431974	chr16:75435461	A/G	cg03315344	chr16:75512273	CHST6	0.77	6.31	0.54	8.75e-9	Dupuytren's disease;
THYM	cis	rs6032067	0.641	rs35227660	chr20:43756697	C/G	cg16667508	chr20:43936853	MATN4;RBPJL	-0.7	-7.59	-0.61	2.14e-11	Blood protein levels;
THYM	cis	rs11190604	0.767	rs11190531	chr10:102187310	T/A	cg07570687	chr10:102243282	WNT8B	0.81	7.79	0.62	8.34e-12	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs3849570	1.000	rs3860595	chr3:81811784	A/G	cg07356753	chr3:81810745	GBE1	-0.74	-5.31	-0.48	7.06e-7	Waist circumference;Body mass index;
THYM	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg07578070	chr6:150326732	RAET1K	0.54	4.51	0.42	1.88e-5	Alopecia areata;
THYM	cis	rs13185784	0.625	rs4270655	chr5:179645244	A/G	cg23248424	chr5:179741104	GFPT2	-0.7	-4.57	-0.42	1.48e-5	TRAIL levels;
THYM	cis	rs1461503	0.966	rs10892938	chr11:122841921	A/C	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs2195525	0.539	rs1893265	chr11:119218930	C/T	cg16996281	chr11:119217884	MFRP;C1QTNF5	0.45	4.99	0.46	2.7e-6	Urate levels;
THYM	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06873352	chr17:61820015	STRADA	0.56	5.59	0.5	2.18e-7	Height;
THYM	cis	rs13326165	0.585	rs11715382	chr3:52269616	C/T	cg08438690	chr3:52279403	PPM1M	-0.82	-4.58	-0.43	1.43e-5	HDL cholesterol;HDL cholesterol levels;
THYM	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg12386194	chr3:101231763	SENP7	0.69	5.14	0.47	1.48e-6	Colorectal cancer;
THYM	cis	rs67311347	0.544	rs2278927	chr3:40350447	G/A	cg13683864	chr3:40499215	RPL14	-0.78	-7.15	-0.59	1.74e-10	Renal cell carcinoma;
THYM	cis	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.96	0.45	3.04e-6	Obesity-related traits;
THYM	cis	rs2625529	0.590	rs3803471	chr15:72500786	A/G	cg16672083	chr15:72433130	SENP8	-0.52	-4.65	-0.43	1.06e-5	Red blood cell count;
THYM	cis	rs9858542	0.537	rs9863142	chr3:49366741	C/G	cg00383909	chr3:49044727	WDR6	0.67	4.49	0.42	2.04e-5	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg03859395	chr2:55845619	SMEK2	0.7	6.23	0.54	1.28e-8	Metabolic syndrome;
THYM	cis	rs8016982	0.674	rs759939	chr14:81663453	G/C	cg21807262	chr14:81713016	NA	-0.57	-5.28	-0.48	8.05e-7	Schizophrenia;
THYM	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-6.36	-0.55	6.94e-9	Chronic sinus infection;
THYM	cis	rs198389	0.589	rs198399	chr1:11883629	T/A	cg24844545	chr1:11908347	NPPA	-0.48	-4.54	-0.42	1.67e-5	B-type natriuretic peptide levels;NT-proBNP levels in acute coronary syndrome;
THYM	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg03351412	chr1:154909251	PMVK	0.7	5.38	0.48	5.4e-7	Prostate cancer;
THYM	cis	rs9486719	1.000	rs12208124	chr6:97027942	C/T	cg18709589	chr6:96969512	KIAA0776	-0.68	-4.68	-0.43	9.36e-6	Migraine;Coronary artery disease;
THYM	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg21773646	chr17:80085082	CCDC57	-0.36	-5.09	-0.46	1.83e-6	Life satisfaction;
THYM	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg10802521	chr3:52805072	NEK4	-0.73	-6.35	-0.55	7.48e-9	Bipolar disorder;
THYM	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg24692254	chr21:30365293	RNF160	-0.98	-9.15	-0.68	1.08e-14	Dental caries;
THYM	cis	rs1371867	0.875	rs1660311	chr8:101330579	C/T	cg06636551	chr8:101224915	SPAG1	-0.67	-6.58	-0.56	2.52e-9	Atrioventricular conduction;
THYM	cis	rs13102973	0.897	rs10434068	chr4:135840331	A/G	cg14419869	chr4:135874104	NA	0.9	8.46	0.66	3.24e-13	Subjective well-being;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg02403951	chr16:24580196	RBBP6	-0.99	-7.55	-0.61	2.66e-11	Depressive symptoms;
THYM	cis	rs860554	0.705	rs1779301	chr1:201263330	C/G	cg01022117	chr1:201258280	PKP1	0.64	4.66	0.43	1.05e-5	Panic disorder;
THYM	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg06784218	chr1:46089804	CCDC17	-0.32	-4.82	-0.44	5.41e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg24308560	chr3:49941425	MST1R	0.63	4.78	0.44	6.37e-6	Body mass index;
THYM	cis	rs6429082	0.738	rs2131921	chr1:235705157	C/T	cg26050004	chr1:235667680	B3GALNT2	0.61	4.47	0.42	2.16e-5	Adiposity;
THYM	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg14159672	chr1:205819179	PM20D1	-0.72	-5.65	-0.5	1.66e-7	Menarche (age at onset);
THYM	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11890956	chr21:40555474	PSMG1	1.07	10.25	0.72	4.79e-17	Cognitive function;
THYM	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg04772025	chr11:68637568	NA	0.61	6.32	0.54	8.56e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs112998813	0.571	rs7328349	chr13:114930401	G/A	cg26703057	chr13:114071457	NA	0.76	4.48	0.42	2.06e-5	Nodular sclerosis Hodgkin lymphoma;
THYM	cis	rs1499972	0.941	rs62263123	chr3:117632263	G/A	cg07612923	chr3:117604196	NA	1.19	5.0	0.46	2.66e-6	Schizophrenia;
THYM	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg06917634	chr15:78832804	PSMA4	0.96	8.76	0.67	7.4e-14	Sudden cardiac arrest;
THYM	cis	rs6570726	0.791	rs4335004	chr6:145904764	G/A	cg23711669	chr6:146136114	FBXO30	0.98	10.77	0.74	3.75e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11822910	0.815	rs11229028	chr11:57193918	G/A	cg00522883	chr11:57194120	SLC43A3	0.65	4.9	0.45	3.92e-6	Platelet distribution width;
THYM	cis	rs62191099	0.601	rs7603207	chr2:239847836	A/C	cg19714454	chr2:240091133	HDAC4	0.56	4.92	0.45	3.66e-6	Alcohol dependence;
THYM	cis	rs7568458	0.777	rs12473819	chr2:85773061	A/G	cg17127132	chr2:85788382	GGCX	0.64	5.36	0.48	5.88e-7	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06634786	chr22:41940651	POLR3H	0.8	6.18	0.54	1.56e-8	Vitiligo;
THYM	cis	rs7582180	0.590	rs11123828	chr2:100960918	T/G	cg08017756	chr2:100939284	LONRF2	-0.76	-7.81	-0.63	7.51e-12	Intelligence (multi-trait analysis);
THYM	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg04673462	chr1:38461896	NA	0.44	5.25	0.47	9.3e-7	Coronary artery disease;
THYM	cis	rs57590327	0.503	rs17019299	chr3:81851643	A/G	cg07356753	chr3:81810745	GBE1	-0.84	-6.21	-0.54	1.4e-8	Extraversion;
THYM	cis	rs4481887	1.000	rs4589143	chr1:248470446	A/G	cg13385794	chr1:248469461	NA	0.65	4.66	0.43	1.04e-5	Common traits (Other);
THYM	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg25036284	chr2:26402008	FAM59B	0.78	5.19	0.47	1.18e-6	Gut microbiome composition (summer);
THYM	trans	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg10856724	chr12:34555212	NA	-0.88	-7.53	-0.61	2.92e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg03060546	chr3:49711283	APEH	-0.67	-5.08	-0.46	1.85e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg00149659	chr3:10157352	C3orf10	0.75	4.49	0.42	2.01e-5	Alzheimer's disease;
THYM	cis	rs78579285	0.507	rs1061247	chr16:88781791	A/C	cg04002220	chr16:89598305	SPG7	0.58	4.54	0.42	1.65e-5	Joint mobility (Beighton score);
THYM	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg13609457	chr4:120235615	NA	0.53	4.84	0.45	4.93e-6	Corneal astigmatism;
THYM	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg06238570	chr21:40685208	BRWD1	0.92	6.85	0.57	7.35e-10	Cognitive function;
THYM	cis	rs11969893	0.850	rs9390713	chr6:101424262	G/A	cg12253828	chr6:101329408	ASCC3	1.23	6.93	0.58	5.09e-10	Economic and political preferences (immigration/crime);
THYM	cis	rs4595586	0.525	rs7313120	chr12:39388027	A/G	cg26384229	chr12:38710491	ALG10B	0.69	5.19	0.47	1.18e-6	Morning vs. evening chronotype;
THYM	cis	rs7404928	0.557	rs195996	chr16:23954510	A/G	cg26685404	chr16:23957272	PRKCB	-0.63	-7.24	-0.6	1.16e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.67	4.61	0.43	1.26e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg11266682	chr4:10021025	SLC2A9	-0.51	-6.07	-0.53	2.57e-8	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg10505658	chr17:80084571	CCDC57	0.7	8.07	0.64	2.18e-12	Life satisfaction;
THYM	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg16586182	chr3:47516702	SCAP	0.69	5.74	0.51	1.13e-7	Colorectal cancer;
THYM	cis	rs56036086	0.702	rs73187236	chr22:50617726	C/T	cg16473166	chr22:50639996	SELO	0.89	4.55	0.42	1.59e-5	Platelet count;Plateletcrit;
THYM	cis	rs4430311	0.723	rs6672195	chr1:243959543	T/C	cg25706552	chr1:244017396	NA	-0.6	-5.23	-0.47	1.01e-6	Post-traumatic stress disorder (asjusted for relatedness);
THYM	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg27129171	chr3:47204927	SETD2	0.71	6.66	0.56	1.81e-9	Colorectal cancer;
THYM	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg04476341	chr5:669733	TPPP	-0.45	-4.51	-0.42	1.83e-5	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs55871839	0.684	rs6988143	chr8:59810572	C/T	cg07426533	chr8:59803705	TOX	-0.67	-6.88	-0.58	6.33e-10	Pneumonia;
THYM	cis	rs981844	0.714	rs6853529	chr4:154706267	C/T	cg09973105	chr4:154681532	RNF175	-0.48	-4.45	-0.42	2.34e-5	Response to statins (LDL cholesterol change);
THYM	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg26531700	chr6:26746687	NA	0.54	4.45	0.42	2.32e-5	Intelligence (multi-trait analysis);
THYM	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg02070205	chr10:30722105	MAP3K8	-0.64	-5.14	-0.47	1.46e-6	Inflammatory bowel disease;
THYM	cis	rs34658409	1	rs34658409	chr8:42433985	TC/T	cg09913449	chr8:42400586	C8orf40	1.03	11.38	0.76	1.96e-19	Mean corpuscular hemoglobin concentration;
THYM	cis	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg18904891	chr8:8559673	CLDN23	0.6	4.74	0.44	7.59e-6	Neuroticism;
THYM	cis	rs10949662	1.000	rs10949662	chr7:157534105	A/G	cg11757124	chr7:157526947	PTPRN2	0.99	9.23	0.69	7.23e-15	Intelligence (multi-trait analysis);
THYM	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs6163	0.588	rs10786706	chr10:104500659	C/T	cg15744005	chr10:104629667	AS3MT	-0.79	-7.65	-0.62	1.66e-11	Waist circumference;Hip circumference;
THYM	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg03806693	chr22:41940476	POLR3H	0.86	6.65	0.56	1.87e-9	Neuroticism;
THYM	cis	rs11690935	0.851	rs10930502	chr2:172890588	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.75	-5.62	-0.5	1.9e-7	Schizophrenia;
THYM	cis	rs2554380	1.000	rs2554380	chr15:84315884	C/T	cg14598478	chr15:84363061	ADAMTSL3	-0.6	-4.65	-0.43	1.05e-5	Height;
THYM	cis	rs4824093	0.610	rs58671506	chr22:50288983	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-1.04	-4.76	-0.44	6.85e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs12701220	0.503	rs12531999	chr7:1181601	T/A	cg01699819	chr7:1052092	C7orf50	-0.69	-5.84	-0.51	7.15e-8	Bronchopulmonary dysplasia;
THYM	cis	rs5769707	0.967	rs2187891	chr22:49994094	C/T	cg17074396	chr22:49843754	NA	-0.39	-4.59	-0.43	1.34e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9831754	0.906	rs1588650	chr3:78410750	T/G	cg06138941	chr3:78371609	NA	-0.64	-4.59	-0.43	1.36e-5	Calcium levels;
THYM	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06634786	chr22:41940651	POLR3H	0.63	4.92	0.45	3.62e-6	Vitiligo;
THYM	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08704250	chr15:31115839	NA	-0.52	-6.16	-0.53	1.75e-8	Huntington's disease progression;
THYM	cis	rs4077515	0.901	rs3812573	chr9:139276680	C/T	cg14115884	chr9:139300582	SDCCAG3	0.73	6.9	0.58	5.79e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs4803468	0.967	rs4803462	chr19:41908936	T/A	cg09537434	chr19:41945824	ATP5SL	-1.09	-10.17	-0.72	7.25e-17	Height;
THYM	cis	rs236907	0.859	rs12753043	chr1:171761821	G/A	cg20598894	chr1:171756153	METTL13	-0.74	-5.59	-0.5	2.16e-7	Mean platelet volume;
THYM	cis	rs9361491	0.608	rs9343794	chr6:79444925	G/A	cg04547799	chr6:79944526	HMGN3	-0.64	-4.54	-0.42	1.64e-5	Intelligence (multi-trait analysis);
THYM	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg13447684	chr7:1895903	MAD1L1	0.5	4.47	0.42	2.15e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg13390004	chr1:15929781	NA	-0.62	-4.75	-0.44	7.29e-6	Systolic blood pressure;
THYM	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg19507638	chr5:93509721	C5orf36	-0.67	-4.49	-0.42	2.04e-5	Diabetic retinopathy;
THYM	cis	rs9549260	0.755	rs7333037	chr13:41215256	A/T	cg21288729	chr13:41239152	FOXO1	0.71	5.46	0.49	3.86e-7	Red blood cell count;
THYM	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg23332699	chr15:44069569	ELL3	0.75	4.64	0.43	1.13e-5	Lung cancer in ever smokers;
THYM	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs490234	0.702	rs12553882	chr9:128195044	G/A	cg14078157	chr9:128172775	NA	-0.79	-6.47	-0.55	4.3e-9	Mean arterial pressure;
THYM	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.84	5.75	0.51	1.06e-7	Platelet count;
THYM	cis	rs7100689	0.646	rs10736347	chr10:82134465	G/A	cg01528321	chr10:82214614	TSPAN14	0.79	6.01	0.52	3.47e-8	Post bronchodilator FEV1;
THYM	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.54	-7.29	-0.6	9.08e-11	Monocyte percentage of white cells;
THYM	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.53	-5.15	-0.47	1.42e-6	Lymphocyte counts;
THYM	cis	rs12289510	0.539	rs7938473	chr11:124949992	A/G	cg03868193	chr11:124958746	SLC37A2	-0.59	-4.66	-0.43	1.02e-5	Platelet-derived growth factor BB levels;
THYM	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-10.65	-0.74	6.72e-18	Coronary artery disease;
THYM	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg12963246	chr6:28129442	ZNF389	0.72	6.12	0.53	2.05e-8	Parkinson's disease;
THYM	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg17143192	chr8:8559678	CLDN23	0.61	4.55	0.42	1.57e-5	Mood instability;
THYM	cis	rs17253792	0.822	rs77676035	chr14:56096229	G/A	cg01858014	chr14:56050164	KTN1	-1.11	-4.78	-0.44	6.45e-6	Putamen volume;
THYM	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg18758796	chr5:131593413	PDLIM4	0.5	4.46	0.42	2.22e-5	Breast cancer;Mosquito bite size;
THYM	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg19748678	chr4:122722346	EXOSC9	0.73	5.15	0.47	1.42e-6	Type 2 diabetes;
THYM	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg08807101	chr21:30365312	RNF160	-0.67	-4.87	-0.45	4.5e-6	Dental caries;
THYM	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03576123	chr11:487126	PTDSS2	-1.29	-6.68	-0.57	1.6e-9	Body mass index;
THYM	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg25237894	chr2:233734115	C2orf82	-0.34	-4.52	-0.42	1.79e-5	Coronary artery disease;
THYM	cis	rs4072705	0.967	rs10760369	chr9:127397400	A/G	cg13476313	chr9:127244764	NR5A1	0.32	4.75	0.44	7.27e-6	Menarche (age at onset);
THYM	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg05373962	chr22:49881684	NA	-0.66	-6.59	-0.56	2.41e-9	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs10781543	0.845	rs35763810	chr9:139323799	A/G	cg14115884	chr9:139300582	SDCCAG3	0.68	6.05	0.53	2.82e-8	Monocyte percentage of white cells;
THYM	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.62	5.74	0.51	1.12e-7	Personality dimensions;
THYM	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg18758796	chr5:131593413	PDLIM4	0.52	4.96	0.45	3.14e-6	Blood metabolite levels;
THYM	cis	rs9443645	0.509	rs9352668	chr6:79572678	A/G	cg18132916	chr6:79620363	NA	-0.53	-4.82	-0.44	5.35e-6	Intelligence (multi-trait analysis);
THYM	cis	rs654128	0.920	rs339364	chr6:117171919	T/C	cg12892004	chr6:117198278	RFX6	-0.83	-4.9	-0.45	3.99e-6	Telomere length;
THYM	cis	rs4866334	1.000	rs76355495	chr5:18487262	G/A	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.79e-7	IgG glycosylation;
THYM	cis	rs10779751	0.734	rs2791649	chr1:11132561	A/G	cg08854313	chr1:11322531	MTOR	0.86	7.01	0.58	3.51e-10	Body mass index;
THYM	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	4.5	0.42	1.92e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg18512352	chr11:47633146	NA	-0.52	-6.29	-0.54	9.61e-9	Subjective well-being;
THYM	cis	rs2688608	0.901	rs2459446	chr10:75601596	C/T	cg15838173	chr10:75533400	FUT11	0.46	4.93	0.45	3.45e-6	Inflammatory bowel disease;
THYM	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg03806693	chr22:41940476	POLR3H	1.03	9.17	0.69	9.96e-15	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg23758822	chr17:41437982	NA	1.22	11.98	0.78	1.07e-20	Menopause (age at onset);
THYM	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06634786	chr22:41940651	POLR3H	-0.69	-5.31	-0.48	7.18e-7	Vitiligo;
THYM	cis	rs9972944	0.902	rs9972956	chr17:63771092	T/C	cg07283582	chr17:63770753	CCDC46	0.65	5.25	0.47	9.39e-7	Total body bone mineral density;
THYM	cis	rs2806561	0.729	rs35919647	chr1:23326072	C/T	cg19743168	chr1:23544995	NA	-0.57	-5.21	-0.47	1.11e-6	Height;
THYM	cis	rs9534288	0.797	rs4294711	chr13:46575557	C/T	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs9359856	0.564	rs72913976	chr6:90390233	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.9	-8.12	-0.64	1.7e-12	Bipolar disorder;
THYM	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg10018233	chr7:150070692	REPIN1	0.38	5.41	0.48	4.8e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.14	-0.64	1.54e-12	Mean corpuscular volume;
THYM	cis	rs79149102	0.579	rs12593542	chr15:75282147	C/G	cg17294928	chr15:75287854	SCAMP5	-1.07	-5.89	-0.52	5.71e-8	Lung cancer;
THYM	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg01579765	chr21:45077557	HSF2BP	-0.46	-7.25	-0.6	1.12e-10	Mean corpuscular volume;
THYM	cis	rs7823896	0.929	rs73311383	chr8:110145123	C/A	cg18044723	chr8:109261011	EIF3E	-0.89	-4.68	-0.43	9.42e-6	Myopia (pathological);
THYM	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg15744005	chr10:104629667	AS3MT	-0.83	-7.65	-0.62	1.61e-11	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7084402	0.967	rs1649091	chr10:60289440	T/A	cg07615347	chr10:60278583	BICC1	0.56	5.22	0.47	1.07e-6	Refractive error;
THYM	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg06219351	chr7:158114137	PTPRN2	-0.77	-7.95	-0.63	3.79e-12	Calcium levels;
THYM	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg09085632	chr11:111637200	PPP2R1B	0.95	8.44	0.65	3.45e-13	Primary sclerosing cholangitis;
THYM	cis	rs10503871	0.545	rs6468436	chr8:30469293	T/A	cg12158488	chr8:31336998	NA	-0.41	-4.53	-0.42	1.75e-5	Metabolite levels  (X-11787);
THYM	cis	rs6674176	0.628	rs4660758	chr1:44424879	A/C	cg15962314	chr1:44399869	ARTN	0.55	5.6	0.5	2.09e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg06112835	chr11:68658793	MRPL21	0.42	6.19	0.54	1.54e-8	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7582180	0.602	rs7585582	chr2:100998030	G/C	cg08017756	chr2:100939284	LONRF2	-0.72	-7.39	-0.6	5.75e-11	Intelligence (multi-trait analysis);
THYM	cis	rs763014	0.931	rs1981483	chr16:630665	G/A	cg00908189	chr16:619842	PIGQ	1.03	9.46	0.7	2.34e-15	Height;
THYM	cis	rs2219968	0.828	rs13265358	chr8:78930198	T/C	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs4845875	0.600	rs6699881	chr1:11836628	T/C	cg24844545	chr1:11908347	NPPA	0.57	4.77	0.44	6.74e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs4722166	0.630	rs13311155	chr7:22789789	A/C	cg13104385	chr7:22767384	IL6	0.54	4.57	0.42	1.46e-5	Lung cancer;
THYM	cis	rs7084402	0.764	rs2393455	chr10:60374898	C/A	cg09696939	chr10:60272079	BICC1	-0.45	-5.37	-0.48	5.6e-7	Refractive error;
THYM	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg01570182	chr17:44337453	NA	0.62	6.5	0.55	3.74e-9	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs865483	0.929	rs8064314	chr17:35858392	A/G	cg06716730	chr17:35851459	DUSP14	0.41	6.59	0.56	2.48e-9	Monocyte count;
THYM	cis	rs11214589	0.665	rs11214587	chr11:113232422	T/G	cg14159747	chr11:113255604	NA	0.32	6.06	0.53	2.76e-8	Neuroticism;
THYM	cis	rs2455799	0.593	rs13085352	chr3:15914845	T/C	cg16303742	chr3:15540471	COLQ	-0.57	-5.76	-0.51	1.04e-7	Mean platelet volume;
THYM	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg09165964	chr15:75287851	SCAMP5	-0.97	-8.7	-0.67	1e-13	Blood trace element (Zn levels);
THYM	cis	rs84178	0.683	rs548566	chr11:2782648	A/G	cg15168906	chr11:2162783	IGF2AS;INS-IGF2;IGF2	-0.68	-4.46	-0.42	2.28e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs2562456	0.876	rs2681370	chr19:21736838	T/C	cg21751540	chr19:21541537	ZNF738	-0.69	-4.75	-0.44	7.1e-6	Pain;
THYM	cis	rs16866061	1.000	rs11688397	chr2:225393173	C/T	cg22455342	chr2:225449267	CUL3	0.67	4.84	0.44	4.98e-6	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs2282032	0.527	rs2282033	chr14:90769635	G/T	cg14092571	chr14:90743983	NA	-0.63	-6.26	-0.54	1.11e-8	Longevity;
THYM	cis	rs9876781	0.967	rs7618883	chr3:48498456	A/T	cg06066452	chr3:48470258	PLXNB1	0.27	4.71	0.44	8.4e-6	Longevity;
THYM	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg05738196	chr6:26577821	NA	0.95	9.51	0.7	1.86e-15	Intelligence (multi-trait analysis);
THYM	cis	rs7940866	0.845	rs1991899	chr11:130801649	C/T	cg12179176	chr11:130786555	SNX19	-0.6	-4.79	-0.44	6.02e-6	Schizophrenia;
THYM	cis	rs7404928	0.557	rs195986	chr16:23951546	C/G	cg26685404	chr16:23957272	PRKCB	-0.62	-7.25	-0.6	1.13e-10	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs9543976	0.623	rs8192764	chr13:76179215	G/C	cg01531495	chr13:76123901	UCHL3	0.66	4.8	0.44	5.85e-6	Diabetic retinopathy;
THYM	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.0	0.63	3.07e-12	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg18402987	chr7:1209562	NA	1.02	6.05	0.53	2.92e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg27532560	chr4:187881888	NA	-0.95	-11.68	-0.77	4.63e-20	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.08	7.49	0.61	3.58e-11	Smoking behavior;
THYM	cis	rs919433	0.680	rs699319	chr2:198281776	C/A	cg05783139	chr2:198650985	BOLL	0.63	4.93	0.45	3.48e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.62	4.91	0.45	3.8e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7772486	0.790	rs11760	chr6:146205973	G/T	cg23711669	chr6:146136114	FBXO30	0.91	9.21	0.69	8.1e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg12564285	chr5:131593104	PDLIM4	0.44	4.72	0.44	7.99e-6	Breast cancer;
THYM	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg07570687	chr10:102243282	WNT8B	0.75	6.59	0.56	2.4e-9	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg22590775	chr19:49891494	CCDC155	-0.6	-4.51	-0.42	1.84e-5	Multiple sclerosis;
THYM	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg20607798	chr8:58055168	NA	0.84	4.75	0.44	7.27e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs728616	0.867	rs4520539	chr10:81740529	C/G	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	trans	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg25214090	chr10:38739885	LOC399744	0.86	7.29	0.6	9.28e-11	Corneal astigmatism;
THYM	cis	rs1050631	0.592	rs1785932	chr18:33719434	C/T	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.32	0.48	6.94e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs7605378	0.964	rs2689763	chr2:200689555	G/A	cg17644776	chr2:200775616	C2orf69	0.64	4.97	0.45	2.96e-6	Osteoporosis;
THYM	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg10515332	chr4:99064459	C4orf37	0.59	4.7	0.43	8.7e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs40363	1.000	rs37767	chr16:3514962	C/T	cg21433313	chr16:3507492	NAT15	0.81	6.9	0.58	5.87e-10	Tuberculosis;
THYM	cis	rs9644630	0.658	rs4427190	chr8:19321385	C/T	cg06562184	chr8:19319451	CSGALNACT1	-0.65	-6.0	-0.52	3.5e-8	Oropharynx cancer;
THYM	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg26924012	chr15:45694286	SPATA5L1	0.9	7.63	0.62	1.77e-11	Homoarginine levels;
THYM	cis	rs13315871	1.000	rs4075403	chr3:58411445	G/C	cg12435725	chr3:58293450	RPP14	-0.46	-4.93	-0.45	3.54e-6	Cholesterol, total;
THYM	cis	rs7119	0.717	rs12904212	chr15:77815833	C/A	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs8133932	0.608	rs413246	chr21:47346066	G/A	cg20357416	chr21:47294739	PCBP3	0.8	4.88	0.45	4.26e-6	Schizophrenia;
THYM	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg11764359	chr7:65958608	NA	0.66	4.59	0.43	1.38e-5	Aortic root size;
THYM	cis	rs1975974	1.000	rs67946006	chr17:21723940	T/C	cg18423549	chr17:21743878	NA	-0.57	-4.46	-0.42	2.28e-5	Psoriasis;
THYM	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg03188948	chr7:1209495	NA	0.91	5.04	0.46	2.24e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2069036	0.909	rs10795346	chr10:16118222	G/C	cg26633223	chr10:15133461	NA	0.72	5.39	0.48	5.12e-7	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg16524936	chr4:1340807	KIAA1530	-0.63	-4.85	-0.45	4.79e-6	Longevity;
THYM	cis	rs4805272	0.626	rs12610050	chr19:29331324	A/T	cg14983838	chr19:29218262	NA	0.76	5.75	0.51	1.08e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.22	4.8	0.44	6.01e-6	Obesity-related traits;
THYM	cis	rs55883249	1.000	rs62119422	chr2:9726599	A/G	cg23886495	chr2:9695866	ADAM17	0.82	5.32	0.48	6.79e-7	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs7267979	1.000	rs6107045	chr20:25441936	G/A	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg18252515	chr7:66147081	NA	0.69	5.46	0.49	3.79e-7	Aortic root size;
THYM	cis	rs2069036	0.855	rs12415711	chr10:16078544	A/G	cg26633223	chr10:15133461	NA	0.68	4.96	0.45	3.08e-6	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.85	-7.92	-0.63	4.43e-12	Lung cancer;
THYM	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg08645402	chr16:4508243	NA	0.75	6.94	0.58	4.69e-10	Schizophrenia;
THYM	cis	rs860554	0.640	rs2268150	chr1:201257838	G/A	cg01022117	chr1:201258280	PKP1	-0.65	-6.27	-0.54	1.06e-8	Panic disorder;
THYM	cis	rs1620921	0.967	rs783173	chr6:161172942	C/G	cg17993073	chr6:160527228	IGF2R	0.58	4.51	0.42	1.83e-5	Lipoprotein (a) - cholesterol levels;
THYM	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg05872129	chr22:39784769	NA	-1.04	-10.98	-0.75	1.35e-18	Intelligence (multi-trait analysis);
THYM	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg04865290	chr3:52927548	TMEM110	-0.96	-4.97	-0.45	2.97e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg01299579	chr2:10830716	NOL10	0.49	4.65	0.43	1.06e-5	Prostate cancer;
THYM	cis	rs11096990	0.892	rs11931354	chr4:39231476	A/G	cg24403649	chr4:39172243	NA	-0.66	-5.65	-0.5	1.68e-7	Cognitive function;
THYM	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg04025307	chr7:1156635	C7orf50	0.71	5.98	0.52	3.83e-8	Longevity;Endometriosis;
THYM	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg01416388	chr22:39784598	NA	-0.79	-6.23	-0.54	1.25e-8	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs13256369	0.865	rs13282523	chr8:8577293	C/G	cg17143192	chr8:8559678	CLDN23	0.77	5.89	0.52	5.72e-8	Obesity-related traits;
THYM	cis	rs7191439	0.858	rs2340973	chr16:88773396	G/A	cg27087555	chr16:88793112	FAM38A	-1.19	-6.66	-0.56	1.77e-9	Plateletcrit;
THYM	cis	rs9796	0.870	rs28479904	chr15:41268305	G/T	cg21153102	chr15:41252147	NA	0.73	6.67	0.56	1.69e-9	Menopause (age at onset);
THYM	cis	rs941408	0.890	rs1640269	chr19:2793194	A/C	cg17333051	chr19:2783644	SGTA	0.54	4.84	0.45	4.95e-6	Total cholesterol levels;
THYM	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg13395646	chr4:1353034	KIAA1530	0.59	5.31	0.48	7.33e-7	Obesity-related traits;
THYM	cis	rs425277	0.606	rs2257684	chr1:2077872	A/G	cg13918804	chr1:2043761	PRKCZ	-0.82	-7.43	-0.61	4.76e-11	Height;
THYM	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg06873352	chr17:61820015	STRADA	-0.51	-5.0	-0.46	2.59e-6	Height;
THYM	cis	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg13446199	chr8:143762866	PSCA	-0.41	-4.54	-0.42	1.67e-5	Urinary tract infection frequency;
THYM	cis	rs7246657	0.943	rs7257672	chr19:37823859	G/C	cg22634378	chr19:37742834	NA	0.65	5.34	0.48	6.2e-7	Coronary artery calcification;
THYM	cis	rs7872515	0.536	rs4302907	chr9:94774086	T/C	cg13922115	chr9:95397568	IPPK	0.88	4.46	0.42	2.25e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs500891	0.525	rs9766300	chr6:84083733	T/A	cg08257003	chr6:84140564	ME1	0.58	4.66	0.43	1.01e-5	Platelet-derived growth factor BB levels;
THYM	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	6.73	0.57	1.29e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg11764359	chr7:65958608	NA	-0.74	-6.15	-0.53	1.85e-8	Aortic root size;
THYM	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg22920501	chr2:26401640	FAM59B	1.05	9.27	0.69	6.16e-15	Gut microbiome composition (summer);
THYM	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.92	6.89	0.58	5.96e-10	Electrocardiographic conduction measures;
THYM	cis	rs11252926	0.800	rs2209625	chr10:747115	A/C	cg03684893	chr10:554711	DIP2C	0.67	5.23	0.47	9.99e-7	Psychosis in Alzheimer's disease;
THYM	cis	rs6728302	1.000	rs4973032	chr2:232990462	G/T	cg15348839	chr2:232224846	NA	1.12	4.49	0.42	1.98e-5	Height;
THYM	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	trans	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg25517755	chr10:38738941	LOC399744	-0.77	-7.17	-0.59	1.66e-10	Corneal astigmatism;
THYM	cis	rs8067545	1.000	rs34291370	chr17:19942335	G/A	cg13482628	chr17:19912719	NA	0.58	4.97	0.45	2.92e-6	Schizophrenia;
THYM	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg23428387	chr22:49814324	NA	-0.5	-4.84	-0.44	4.99e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg13695892	chr22:41940480	POLR3H	0.84	6.25	0.54	1.16e-8	Vitiligo;
THYM	cis	rs2456568	0.802	rs1574515	chr11:93629643	T/C	cg17595323	chr11:93583763	C11orf90	-0.58	-6.09	-0.53	2.38e-8	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg18305652	chr10:134549665	INPP5A	0.79	6.5	0.55	3.69e-9	Migraine;
THYM	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.67	5.5	0.49	3.21e-7	Blood metabolite levels;
THYM	cis	rs7216064	1.000	rs8067892	chr17:65837983	A/G	cg12091567	chr17:66097778	LOC651250	-0.71	-4.76	-0.44	6.86e-6	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg16414030	chr3:133502952	NA	-0.84	-8.47	-0.66	3.08e-13	Iron status biomarkers;
THYM	cis	rs17407555	0.738	rs56402960	chr4:10086473	T/A	cg11266682	chr4:10021025	SLC2A9	-0.56	-5.39	-0.48	5.08e-7	Schizophrenia (age at onset);
THYM	cis	rs941408	1.000	rs759068	chr19:2792566	G/A	cg19693284	chr19:2783607	SGTA	0.72	5.44	0.49	4.08e-7	Total cholesterol levels;
THYM	cis	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg06521331	chr12:34319734	NA	-1.04	-10.35	-0.73	2.92e-17	Morning vs. evening chronotype;
THYM	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg23791538	chr6:167370224	RNASET2	-0.78	-6.28	-0.54	1.02e-8	Crohn's disease;
THYM	cis	rs4535497	0.525	rs4975639	chr5:1108250	A/G	cg13592947	chr5:1111049	SLC12A7	0.55	6.03	0.53	3.13e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg25811766	chr13:21894605	NA	0.74	5.17	0.47	1.28e-6	White matter hyperintensity burden;
THYM	trans	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg10856724	chr12:34555212	NA	-0.96	-8.66	-0.66	1.22e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2282300	0.702	rs4379811	chr11:30294760	C/T	cg25418670	chr11:30344373	C11orf46	0.82	6.97	0.58	4.25e-10	Morning vs. evening chronotype;
THYM	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg18128536	chr17:47092178	IGF2BP1	-0.43	-4.73	-0.44	7.88e-6	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs7267979	0.966	rs7270835	chr20:25435067	C/T	cg08601574	chr20:25228251	PYGB	0.58	4.66	0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg05738196	chr6:26577821	NA	0.83	8.34	0.65	5.8e-13	Intelligence (multi-trait analysis);
THYM	cis	rs2125062	0.715	rs4917724	chr10:97982642	G/C	cg07577957	chr10:98803188	SLIT1	0.59	4.54	0.42	1.64e-5	Colorectal adenoma (advanced);
THYM	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg04282206	chr17:62833786	PLEKHM1P	0.84	7.74	0.62	1.06e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg09354556	chr3:47051341	NA	0.46	4.66	0.43	1.04e-5	Colorectal cancer;
THYM	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg06618935	chr21:46677482	NA	-0.98	-9.5	-0.7	1.95e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg18230493	chr5:56204884	C5orf35	-0.91	-6.8	-0.57	9.08e-10	Initial pursuit acceleration;
THYM	cis	rs7705502	1.000	rs7705502	chr5:173320815	G/A	cg18693985	chr5:173351052	CPEB4	-0.78	-5.64	-0.5	1.71e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs11690935	0.550	rs62183801	chr2:172867475	G/A	cg13550731	chr2:172543902	DYNC1I2	0.56	4.46	0.42	2.28e-5	Schizophrenia;
THYM	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg06634786	chr22:41940651	POLR3H	-0.73	-5.57	-0.5	2.37e-7	Vitiligo;
THYM	cis	rs11785693	0.862	rs10503292	chr8:4992275	A/G	cg26367366	chr8:4980734	NA	1.17	6.02	0.53	3.22e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg06850241	chr22:41845214	NA	0.54	4.85	0.45	4.79e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg26384229	chr12:38710491	ALG10B	0.93	7.75	0.62	1.02e-11	Bladder cancer;
THYM	cis	rs72827839	1.000	rs17624626	chr17:46535805	G/A	cg23391107	chr17:45924227	SP6	0.77	4.61	0.43	1.24e-5	Ease of getting up in the morning;
THYM	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg12963246	chr6:28129442	ZNF389	0.76	6.3	0.54	9.06e-9	Depression;
THYM	cis	rs9565309	0.579	rs8002862	chr13:77584428	T/C	cg13866767	chr13:78470850	EDNRB	1.06	4.81	0.44	5.76e-6	Morning vs. evening chronotype;
THYM	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg09263875	chr16:632152	PIGQ	0.73	6.29	0.54	9.69e-9	Height;
THYM	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg20469991	chr17:27169893	C17orf63	-0.76	-4.78	-0.44	6.27e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs3771570	0.901	rs55811034	chr2:242406245	C/T	cg21155796	chr2:242212141	HDLBP	1.14	5.7	0.5	1.33e-7	Prostate cancer;
THYM	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg24154853	chr7:158122151	PTPRN2	0.54	4.75	0.44	7.13e-6	Calcium levels;
THYM	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.65	4.7	0.43	8.91e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg17173187	chr15:85201210	NMB	0.56	5.51	0.49	3.07e-7	Schizophrenia;
THYM	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg00908189	chr16:619842	PIGQ	1.03	9.46	0.7	2.34e-15	Height;
THYM	cis	rs3791406	0.963	rs3791408	chr2:240030591	C/T	cg27074582	chr2:240114406	HDAC4	-0.44	-4.48	-0.42	2.05e-5	Skin aging (microtopography measurement);
THYM	cis	rs13256369	0.802	rs11249884	chr8:8561552	C/T	cg18904891	chr8:8559673	CLDN23	-0.74	-5.84	-0.51	7.31e-8	Obesity-related traits;
THYM	trans	rs1920324	0.622	rs6437492	chr3:103888802	C/T	cg01901466	chr14:93388880	CHGA	0.64	6.86	0.58	7.09e-10	Colorectal cancer;
THYM	cis	rs7584330	0.554	rs13405619	chr2:238445661	C/T	cg08992911	chr2:238395768	MLPH	0.71	4.69	0.43	9.14e-6	Prostate cancer;
THYM	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22496380	chr5:211416	CCDC127	-1.31	-8.26	-0.65	8.38e-13	Breast cancer;
THYM	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg01191920	chr7:158217561	PTPRN2	-1.03	-11.72	-0.77	3.79e-20	Obesity-related traits;
THYM	cis	rs698813	0.674	rs6725676	chr2:44497828	T/A	cg04920474	chr2:44395004	PPM1B	0.58	4.68	0.43	9.6e-6	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
THYM	cis	rs1395	1.000	rs1275537	chr2:27441302	C/G	cg23587288	chr2:27483067	SLC30A3	-0.63	-5.86	-0.52	6.54e-8	Blood metabolite levels;
THYM	cis	rs2273669	0.667	rs11752532	chr6:109335969	C/G	cg17117243	chr6:109341365	SESN1	-0.9	-5.3	-0.48	7.34e-7	Prostate cancer;
THYM	cis	rs8030485	0.571	rs7165489	chr15:79427450	C/T	cg17916960	chr15:79447300	NA	-0.6	-6.0	-0.52	3.6e-8	Left ventricle wall thickness;
THYM	cis	rs236907	0.859	rs6656852	chr1:171752373	A/G	cg20598894	chr1:171756153	METTL13	-0.74	-5.59	-0.5	2.16e-7	Mean platelet volume;
THYM	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg05283184	chr6:79620031	NA	-0.88	-8.41	-0.65	4.12e-13	Intelligence (multi-trait analysis);
THYM	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg02725872	chr8:58115012	NA	-1.14	-7.59	-0.61	2.17e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg02734326	chr4:10020555	SLC2A9	-0.61	-4.98	-0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs2294693	0.947	rs9381025	chr6:40986623	C/T	cg14418226	chr6:40996092	UNC5CL	0.67	5.96	0.52	4.34e-8	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs6573333	1.000	rs10133880	chr14:61410039	G/T	cg15534086	chr14:61120234	NA	-1.3	-4.54	-0.42	1.64e-5	Immune reponse to smallpox (secreted IFN-alpha);
THYM	cis	rs7578361	1.000	rs12232959	chr2:150432377	C/G	cg17961725	chr2:150454027	NA	0.71	6.03	0.53	3.1e-8	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg25918947	chr17:41365094	TMEM106A	-0.65	-5.41	-0.49	4.7e-7	Menopause (age at onset);
THYM	cis	rs4746818	0.818	rs10823302	chr10:70895418	G/T	cg11621586	chr10:70884670	VPS26A	1.31	11.97	0.78	1.11e-20	Left atrial antero-posterior diameter;
THYM	cis	rs939574	1.000	rs908196	chr2:220088248	A/G	cg00496455	chr2:220118770	TUBA4A;TUBA4B	-1.24	-5.76	-0.51	1.05e-7	Platelet distribution width;
THYM	cis	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg10856724	chr12:34555212	NA	-0.85	-7.53	-0.61	2.95e-11	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12216545	0.711	rs6960291	chr7:150250577	G/T	cg08960815	chr7:150264767	GIMAP4	-0.86	-7.8	-0.62	7.83e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs2688608	0.587	rs2894040	chr10:75478159	A/C	cg19442545	chr10:75533431	FUT11	-0.51	-5.22	-0.47	1.03e-6	Inflammatory bowel disease;
THYM	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg10661904	chr17:79619235	PDE6G	0.66	6.41	0.55	5.55e-9	Eye color traits;
THYM	cis	rs17604090	0.877	rs28516764	chr7:29685245	T/G	cg19413766	chr7:29689036	LOC646762	-0.93	-5.09	-0.46	1.77e-6	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs986417	0.901	rs1955697	chr14:61028435	T/C	cg27398547	chr14:60952738	C14orf39	1.18	5.73	0.51	1.18e-7	Gut microbiota (bacterial taxa);
THYM	cis	rs651907	0.617	rs797776	chr3:101610243	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.63	5.3	0.48	7.63e-7	Colorectal cancer;
THYM	cis	rs2901656	0.627	rs7528296	chr1:172381383	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.45	4.68	0.43	9.69e-6	Red cell distribution width;Platelet distribution width;
THYM	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.96	6.24	0.54	1.22e-8	Smoking behavior;
THYM	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs1642645	0.872	rs4660210	chr1:42476676	C/T	cg10197057	chr1:42612518	NA	0.45	4.97	0.45	2.93e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs13256369	0.802	rs11995449	chr8:8559898	G/A	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg04455712	chr21:45112962	RRP1B	0.49	4.48	0.42	2.07e-5	Mean corpuscular volume;
THYM	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg20891283	chr12:69753455	YEATS4	1.09	12.1	0.78	5.96e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg06634786	chr22:41940651	POLR3H	0.73	5.33	0.48	6.69e-7	Vitiligo;
THYM	cis	rs9527	0.590	rs7901197	chr10:104840433	C/T	cg04362960	chr10:104952993	NT5C2	0.61	4.65	0.43	1.08e-5	Arsenic metabolism;
THYM	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06634786	chr22:41940651	POLR3H	-0.76	-5.54	-0.49	2.73e-7	Vitiligo;
THYM	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg08000102	chr2:233561755	GIGYF2	0.69	6.09	0.53	2.35e-8	Coronary artery disease;
THYM	cis	rs4813003	0.551	rs13045771	chr20:44780406	C/T	cg11783356	chr20:44313418	WFDC10B	1.11	4.76	0.44	7.05e-6	Kawasaki disease;
THYM	cis	rs6867032	0.958	rs4505990	chr5:2015811	A/G	cg26168224	chr5:2018326	NA	1.29	15.56	0.85	7.19e-28	Gut microbiome composition (winter);
THYM	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg00071950	chr4:10020882	SLC2A9	-0.53	-4.63	-0.43	1.14e-5	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg10760299	chr15:45669010	GATM	-0.83	-6.35	-0.55	7.28e-9	Homoarginine levels;
THYM	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	4.47	0.42	2.17e-5	Rheumatoid arthritis;
THYM	cis	rs240764	0.782	rs12216199	chr6:101152723	C/A	cg21058520	chr6:100914733	NA	0.58	5.22	0.47	1.04e-6	Neuroticism;
THYM	cis	rs6076065	0.723	rs6132607	chr20:23390373	C/G	cg11657817	chr20:23433608	CST11	-0.31	-4.51	-0.42	1.88e-5	Facial morphology (factor 15, philtrum width);
THYM	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg02734326	chr4:10020555	SLC2A9	0.8	7.56	0.61	2.47e-11	Bone mineral density;
THYM	cis	rs3960554	0.808	rs79864016	chr7:75655838	A/G	cg16489192	chr7:75678113	MDH2;STYXL1	-0.54	-4.59	-0.43	1.34e-5	Eotaxin levels;
THYM	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg22875332	chr1:76189707	ACADM	0.87	10.83	0.74	2.76e-18	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.94	-6.29	-0.54	9.6e-9	Schizophrenia;
THYM	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06634786	chr22:41940651	POLR3H	-0.75	-5.41	-0.49	4.71e-7	Vitiligo;
THYM	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg03188948	chr7:1209495	NA	0.9	5.02	0.46	2.38e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03647317	chr4:187891568	NA	0.83	9.53	0.7	1.69e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10911232	0.507	rs10797817	chr1:182999136	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs28785552	0.800	rs10853855	chr19:53232293	A/G	cg22067481	chr19:53234126	ZNF611	-1.0	-10.98	-0.75	1.36e-18	Response to paliperidone in schizophrenia (PANSS score);
THYM	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.98	-9.83	-0.71	3.91e-16	Primary sclerosing cholangitis;
THYM	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg18252515	chr7:66147081	NA	-1.43	-8.6	-0.66	1.65e-13	Diabetic kidney disease;
THYM	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg02725872	chr8:58115012	NA	-1.1	-8.57	-0.66	1.84e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs2898681	0.581	rs936690	chr4:53691035	A/G	cg00338735	chr4:53728038	RASL11B	0.61	5.69	0.5	1.4e-7	Optic nerve measurement (cup area);
THYM	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg04990556	chr1:26633338	UBXN11	-0.89	-8.52	-0.66	2.34e-13	Obesity-related traits;
THYM	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg06634786	chr22:41940651	POLR3H	0.7	4.89	0.45	4.14e-6	Vitiligo;
THYM	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg18252515	chr7:66147081	NA	-0.63	-4.69	-0.43	8.99e-6	Aortic root size;
THYM	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg26924012	chr15:45694286	SPATA5L1	1.15	11.35	0.76	2.22e-19	Homoarginine levels;
THYM	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg23730037	chr7:158596552	ESYT2	-0.54	-5.53	-0.49	2.78e-7	Height;
THYM	cis	rs6831352	0.918	rs2213035	chr4:100064233	G/A	cg12011299	chr4:100065546	ADH4	-0.82	-7.61	-0.62	1.96e-11	Alcohol dependence;
THYM	cis	rs9534288	0.797	rs2182482	chr13:46582654	T/A	cg15192986	chr13:46630673	CPB2	-0.62	-4.65	-0.43	1.07e-5	Blood protein levels;
THYM	cis	rs11771526	1.000	rs11771526	chr7:32342618	A/G	cg27511599	chr7:32358540	NA	0.74	5.06	0.46	2.07e-6	Body mass index;
THYM	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03517284	chr6:25882590	NA	0.88	6.66	0.56	1.77e-9	Blood metabolite levels;
THYM	cis	rs11048434	0.761	rs2110192	chr12:9136351	A/T	cg13575925	chr12:9217583	LOC144571	0.55	5.48	0.49	3.45e-7	Sjögren's syndrome;
THYM	cis	rs10782582	0.593	rs114421765	chr1:76141802	C/T	cg03433033	chr1:76189801	ACADM	-0.52	-5.42	-0.49	4.44e-7	Daytime sleep phenotypes;
THYM	cis	rs1018836	0.545	rs4236827	chr8:91688943	A/T	cg16814680	chr8:91681699	NA	-0.93	-9.61	-0.7	1.12e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7568458	0.846	rs6705971	chr2:85761417	G/T	cg17127132	chr2:85788382	GGCX	-0.68	-6.1	-0.53	2.28e-8	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg00071950	chr4:10020882	SLC2A9	-0.56	-4.95	-0.45	3.24e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08704250	chr15:31115839	NA	-0.53	-6.18	-0.54	1.61e-8	Huntington's disease progression;
THYM	cis	rs11690935	0.959	rs12185567	chr2:172560729	A/C	cg13550731	chr2:172543902	DYNC1I2	0.88	6.5	0.55	3.76e-9	Schizophrenia;
THYM	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg12011299	chr4:100065546	ADH4	0.85	8.2	0.64	1.12e-12	Smoking initiation;
THYM	cis	rs6032067	0.866	rs2233901	chr20:43851094	A/G	cg27176129	chr20:43937155	MATN4;RBPJL	0.5	5.5	0.49	3.14e-7	Blood protein levels;
THYM	cis	rs3087591	0.959	rs9893872	chr17:29571195	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.68	-5.95	-0.52	4.46e-8	Hip circumference;
THYM	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	5.47	0.49	3.59e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4805272	0.512	rs11879141	chr19:29320335	G/A	cg04546413	chr19:29218101	NA	0.85	5.48	0.49	3.44e-7	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
THYM	cis	rs35264875	1.000	rs72928636	chr11:68848386	C/T	cg23845249	chr11:68861649	NA	0.55	6.53	0.56	3.22e-9	Blond vs. brown hair color;
THYM	cis	rs7582403	0.844	rs10439198	chr2:148863083	C/T	cg23727674	chr2:148602993	ACVR2A	-0.57	-4.72	-0.44	8.09e-6	Neuroticism;
THYM	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg21784768	chr11:537496	LRRC56	-1.07	-5.36	-0.48	5.7e-7	Body mass index;
THYM	cis	rs9677476	1.000	rs12621280	chr2:232132984	C/G	cg07929768	chr2:232055508	NA	0.59	5.74	0.51	1.12e-7	Food antigen IgG levels;
THYM	cis	rs7100689	0.646	rs1047952	chr10:82126808	C/G	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg08885076	chr2:99613938	TSGA10	0.66	5.97	0.52	4.17e-8	Chronic sinus infection;
THYM	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.88	0.63	5.43e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.92	5.02	0.46	2.41e-6	Initial pursuit acceleration;
THYM	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.72	-6.86	-0.58	6.85e-10	Chronic sinus infection;
THYM	cis	rs6570726	0.902	rs406979	chr6:145838983	G/T	cg23711669	chr6:146136114	FBXO30	0.9	8.87	0.67	4.4e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs79149102	0.579	rs58068887	chr15:75286140	G/A	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	cis	rs7582180	0.663	rs2309794	chr2:100954270	G/A	cg14675211	chr2:100938903	LONRF2	0.7	7.33	0.6	7.43e-11	Intelligence (multi-trait analysis);
THYM	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg00129232	chr17:37814104	STARD3	0.76	5.25	0.47	9.3e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg15536230	chr21:44985092	HSF2BP	-0.44	-5.47	-0.49	3.59e-7	Mean corpuscular volume;
THYM	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs526231	0.547	rs34780	chr5:102453557	G/A	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.49e-6	Primary biliary cholangitis;
THYM	cis	rs4866334	1.000	rs74851546	chr5:18487135	C/T	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg17264618	chr3:40429014	ENTPD3	0.52	5.05	0.46	2.09e-6	Renal cell carcinoma;
THYM	cis	rs892961	0.932	rs9646396	chr17:75416755	G/A	cg11351908	chr17:75402473	SEPT9	0.58	5.23	0.47	1e-6	Airflow obstruction;
THYM	cis	rs262150	0.579	rs4909110	chr7:158787332	C/T	cg12257156	chr7:158823799	VIPR2	0.67	5.87	0.52	6.35e-8	Facial morphology (factor 20);
THYM	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.64	-0.5	1.73e-7	Menopause (age at onset);
THYM	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg26384229	chr12:38710491	ALG10B	-0.9	-7.35	-0.6	6.77e-11	Morning vs. evening chronotype;
THYM	cis	rs1065852	0.526	rs2097562	chr22:42389500	T/C	cg09667013	chr22:42394590	WBP2NL	0.54	4.8	0.44	5.85e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs860554	0.705	rs832165	chr1:201255517	G/C	cg01022117	chr1:201258280	PKP1	0.67	4.89	0.45	4.1e-6	Panic disorder;
THYM	cis	rs12579753	0.956	rs7309624	chr12:82204266	C/A	cg07988820	chr12:82153109	PPFIA2	-0.72	-4.47	-0.42	2.15e-5	Resting heart rate;
THYM	cis	rs4690686	0.500	rs4690431	chr4:177264251	G/A	cg17059388	chr4:177262070	NA	0.48	6.73	0.57	1.29e-9	Essential tremor;
THYM	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.95	6.38	0.55	6.56e-9	Platelet count;
THYM	cis	rs6700896	0.931	rs1805096	chr1:66102257	C/T	cg04111102	chr1:66153794	NA	0.55	5.23	0.47	9.89e-7	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg16329650	chr2:213403929	ERBB4	1.04	12.35	0.79	1.8e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs3091242	0.967	rs1053438	chr1:25687901	T/C	cg27572855	chr1:25598939	RHD	-0.67	-5.03	-0.46	2.36e-6	Erythrocyte sedimentation rate;
THYM	cis	rs478304	0.654	rs11227260	chr11:65461158	G/T	cg27068330	chr11:65405492	SIPA1	-1.09	-11.72	-0.77	3.7e-20	Acne (severe);
THYM	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg06238570	chr21:40685208	BRWD1	0.93	6.95	0.58	4.63e-10	Cognitive function;
THYM	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg07777115	chr5:623756	CEP72	-0.79	-4.7	-0.43	8.8e-6	Obesity-related traits;
THYM	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg26850624	chr5:429559	AHRR	0.53	4.5	0.42	1.93e-5	Cystic fibrosis severity;
THYM	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg11965913	chr1:205819406	PM20D1	0.89	9.35	0.69	3.97e-15	Menarche (age at onset);
THYM	cis	rs926938	0.783	rs2144428	chr1:115269211	G/A	cg12756093	chr1:115239321	AMPD1	-0.74	-5.8	-0.51	8.82e-8	Autism;
THYM	cis	rs3204270	0.684	rs62080212	chr17:79642500	G/A	cg18367735	chr17:79674897	NA	0.8	4.9	0.45	3.92e-6	Dental caries;
THYM	cis	rs4631830	0.832	rs2611513	chr10:51515457	A/G	cg16070123	chr10:51489643	NA	0.5	4.56	0.42	1.55e-5	Prostate-specific antigen levels;
THYM	cis	rs6570726	0.846	rs6570698	chr6:145918635	C/G	cg13319975	chr6:146136371	FBXO30	-0.66	-5.22	-0.47	1.06e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4930103	0.935	rs2071095	chr11:2020627	C/A	cg21926276	chr11:2035255	NA	0.27	4.53	0.42	1.7e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs28595532	0.920	rs114390336	chr4:119771452	C/T	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.68	4.93	0.45	3.41e-6	Height;
THYM	cis	rs7107770	1.000	rs34692341	chr11:125107547	T/C	cg07747661	chr11:125106135	PKNOX2	-0.92	-5.28	-0.48	8.31e-7	Photic sneeze reflex;
THYM	cis	rs4455778	0.580	rs59806378	chr7:49129934	T/A	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg07690219	chr3:49449608	TCTA;RHOA	-0.69	-4.62	-0.43	1.21e-5	Menarche (age at onset);
THYM	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg11366901	chr6:160182831	ACAT2	-1.01	-9.01	-0.68	2.12e-14	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs9479482	0.967	rs763574	chr6:150349415	G/C	cg25797454	chr6:150327115	RAET1K	0.43	4.47	0.42	2.18e-5	Alopecia areata;
THYM	cis	rs9372253	0.509	rs2057149	chr6:110717493	C/T	cg19196401	chr6:110721138	DDO	-0.52	-4.53	-0.42	1.7e-5	Platelet distribution width;
THYM	cis	rs8073060	0.963	rs11080354	chr17:33872407	A/G	cg07895132	chr17:33825172	SLFN12L	-0.59	-5.25	-0.47	9.3e-7	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg10589385	chr1:150898437	SETDB1	0.64	5.29	0.48	7.86e-7	Melanoma;
THYM	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg05182265	chr7:156933206	UBE3C	-0.69	-9.32	-0.69	4.58e-15	Body mass index;
THYM	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg01483505	chr11:975446	AP2A2	0.58	4.73	0.44	7.73e-6	Alzheimer's disease (late onset);
THYM	cis	rs6570726	0.935	rs421690	chr6:145834594	A/C	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6876348	0.544	rs257897	chr5:128314092	G/A	cg25555059	chr5:128301488	SLC27A6	-0.45	-4.73	-0.44	7.81e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs789852	1.000	rs711980	chr3:194324558	G/C	cg18000598	chr3:194342907	TMEM44	-1.19	-6.79	-0.57	9.81e-10	QT interval;
THYM	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg06418219	chr1:154948305	SHC1;CKS1B	-0.76	-6.18	-0.54	1.57e-8	Prostate cancer;
THYM	cis	rs7582180	0.700	rs11685401	chr2:100976685	A/G	cg08017756	chr2:100939284	LONRF2	-0.72	-7.42	-0.61	4.95e-11	Intelligence (multi-trait analysis);
THYM	cis	rs13315871	1.000	rs35792042	chr3:58409668	C/T	cg00563845	chr3:58318305	PXK	0.53	4.67	0.43	9.78e-6	Cholesterol, total;
THYM	cis	rs6964587	0.610	rs7788951	chr7:91468765	A/T	cg22709100	chr7:91322751	NA	0.64	4.71	0.44	8.32e-6	Breast cancer;
THYM	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg06784218	chr1:46089804	CCDC17	-0.29	-4.46	-0.42	2.21e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs6456042	0.893	rs1056053	chr6:166571443	C/T	cg11088901	chr6:166572345	T	-0.54	-5.22	-0.47	1.03e-6	Asthma;
THYM	cis	rs6840360	0.571	rs28454076	chr4:152520083	G/T	cg22705602	chr4:152727874	NA	-0.78	-8.73	-0.67	8.56e-14	Intelligence (multi-trait analysis);
THYM	cis	rs4747241	0.556	rs4495815	chr10:74068978	G/T	cg07828833	chr10:74069493	NA	0.59	4.95	0.45	3.25e-6	Heschl's gyrus morphology;
THYM	cis	rs3760047	0.668	rs2858922	chr16:207218	G/A	cg25425005	chr16:202905	HBZ	-0.79	-5.81	-0.51	8.4e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7119	0.623	rs12905318	chr15:77845873	T/C	cg27398640	chr15:77910606	LINGO1	-0.61	-6.05	-0.53	2.92e-8	Type 2 diabetes;
THYM	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg12310025	chr6:25882481	NA	-0.69	-5.58	-0.5	2.3e-7	Blood metabolite levels;
THYM	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.58	4.99	0.46	2.72e-6	Hip circumference adjusted for BMI;
THYM	trans	rs3960554	0.808	rs57721466	chr7:75710049	C/T	cg19862616	chr7:65841803	NCRNA00174	0.93	6.95	0.58	4.6e-10	Eotaxin levels;
THYM	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-4.79	-0.44	6.22e-6	Diabetic retinopathy;
THYM	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.96	8.0	0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg03517284	chr6:25882590	NA	-0.69	-4.65	-0.43	1.06e-5	Height;
THYM	cis	rs7818345	0.935	rs12542575	chr8:19286558	A/T	cg11303988	chr8:19266685	CSGALNACT1	0.43	4.89	0.45	4.06e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.04e-11	Morning vs. evening chronotype;
THYM	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg13010199	chr12:38710504	ALG10B	-0.73	-5.82	-0.51	7.99e-8	Heart rate;
THYM	cis	rs9372253	0.818	rs2207360	chr6:110706337	G/C	cg00083206	chr6:110721305	DDO	-0.5	-5.48	-0.49	3.55e-7	Platelet distribution width;
THYM	trans	rs2340727	0.673	rs28505989	chr1:161941382	C/G	cg21574204	chr6:28048958	ZNF165	-1.27	-7.17	-0.59	1.6e-10	White blood cell count;Hematology traits;
THYM	cis	rs10979	1.000	rs12215667	chr6:143893213	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs2282032	0.527	rs60971518	chr14:90765745	A/G	cg14092571	chr14:90743983	NA	0.64	6.32	0.54	8.28e-9	Longevity;
THYM	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg08968635	chr6:28129556	ZNF389	0.68	5.52	0.49	2.96e-7	Depression;
THYM	cis	rs7523273	0.606	rs2796262	chr1:207915180	G/A	cg22525895	chr1:207977042	MIR29B2	0.95	10.42	0.73	2.1e-17	Schizophrenia;
THYM	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.24	8.87	0.67	4.33e-14	Cognitive test performance;
THYM	cis	rs3772130	0.527	rs2141614	chr3:121590173	G/A	cg20356878	chr3:121714668	ILDR1	0.71	6.34	0.55	7.58e-9	Cognitive performance;
THYM	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg12379764	chr21:47803548	PCNT	-0.7	-4.61	-0.43	1.24e-5	Testicular germ cell tumor;
THYM	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg10057126	chr4:77819792	ANKRD56	0.7	5.93	0.52	4.87e-8	Emphysema distribution in smoking;
THYM	cis	rs2976388	0.566	rs13250661	chr8:143804134	C/T	cg06565975	chr8:143823917	SLURP1	-0.7	-8.31	-0.65	6.72e-13	Urinary tract infection frequency;
THYM	cis	rs7617773	0.743	rs13081633	chr3:48357281	A/G	cg02219026	chr3:48282209	ZNF589	-0.64	-4.54	-0.42	1.62e-5	Coronary artery disease;
THYM	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg02734326	chr4:10020555	SLC2A9	0.71	6.16	0.53	1.72e-8	Bone mineral density;
THYM	cis	rs944002	1.000	rs61462345	chr14:103564935	C/G	cg16996574	chr14:103691482	NA	0.51	4.71	0.44	8.42e-6	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);Mean platelet volume;
THYM	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg10792982	chr14:105748885	BRF1	0.7	7.08	0.59	2.5e-10	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9527	0.590	rs1541213	chr10:104885330	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.64	-4.46	-0.42	2.27e-5	Arsenic metabolism;
THYM	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg01341218	chr17:43662625	NA	-1.07	-9.27	-0.69	5.9e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs4455778	0.538	rs7796590	chr7:49124983	C/T	cg26309511	chr7:48887640	NA	0.67	5.88	0.52	6.18e-8	Lung cancer in never smokers;
THYM	trans	rs1974653	0.672	rs8139374	chr22:20093522	C/T	cg08822737	chr17:71088851	SLC39A11	-1.01	-7.03	-0.58	3.18e-10	Schizophrenia;
THYM	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg24250549	chr1:154909240	PMVK	0.8	6.36	0.55	7.09e-9	Prostate cancer;
THYM	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg22907277	chr7:1156413	C7orf50	0.81	4.94	0.45	3.35e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-5.65	-0.5	1.71e-7	Gut microbiome composition (summer);
THYM	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.71	5.81	0.51	8.35e-8	Menarche (age at onset);
THYM	cis	rs7584330	0.740	rs11891348	chr2:238440449	T/G	cg16989719	chr2:238392110	NA	-0.63	-5.38	-0.48	5.4e-7	Prostate cancer;
THYM	trans	rs17216035	0.509	rs6796224	chr3:6476042	G/A	cg17567317	chr22:38349719	POLR2F;C22orf23	0.81	6.95	0.58	4.54e-10	Visceral adipose tissue adjusted for BMI;
THYM	cis	rs41357746	0.525	rs57030473	chr15:67776678	A/G	cg24579218	chr15:68104479	NA	0.56	4.78	0.44	6.4e-6	Total body bone mineral density;
THYM	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg08772003	chr10:104629869	AS3MT	-0.64	-5.68	-0.5	1.46e-7	Arsenic metabolism;
THYM	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg12560992	chr17:57184187	TRIM37	0.7	5.55	0.49	2.59e-7	Testicular germ cell tumor;
THYM	cis	rs2282300	0.739	rs34224414	chr11:30251041	T/G	cg09906309	chr11:30344399	C11orf46	-0.72	-5.34	-0.48	6.24e-7	Morning vs. evening chronotype;
THYM	cis	rs514406	0.798	rs504816	chr1:53307957	T/G	cg25767906	chr1:53392781	SCP2	-0.56	-5.2	-0.47	1.13e-6	Monocyte count;
THYM	cis	rs4523957	0.928	rs216223	chr17:2155948	C/T	cg16513277	chr17:2031491	SMG6	0.79	7.41	0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg05340658	chr4:99064831	C4orf37	0.55	4.64	0.43	1.11e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9649213	0.614	rs59120980	chr7:98017730	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.68	-5.75	-0.51	1.08e-7	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.09	-7.74	-0.62	1.06e-11	Platelet count;
THYM	cis	rs2050392	0.858	rs2250569	chr10:30698914	G/C	cg02070205	chr10:30722105	MAP3K8	-0.5	-4.49	-0.42	2.01e-5	Inflammatory bowel disease;
THYM	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.57	4.65	0.43	1.06e-5	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs11148252	0.766	rs74697307	chr13:52897573	C/T	cg05335186	chr13:53173507	NA	0.48	5.99	0.52	3.78e-8	Lewy body disease;
THYM	cis	rs611744	0.967	rs2600614	chr8:109198079	T/A	cg21045802	chr8:109455806	TTC35	0.59	5.32	0.48	7e-7	Dupuytren's disease;
THYM	cis	rs10463554	0.963	rs257294	chr5:102467267	A/G	cg23492399	chr5:102201601	PAM	-0.69	-5.07	-0.46	1.92e-6	Parkinson's disease;
THYM	cis	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg06521331	chr12:34319734	NA	-0.97	-8.5	-0.66	2.63e-13	Morning vs. evening chronotype;
THYM	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg03959625	chr15:84868606	LOC388152	0.47	4.53	0.42	1.7e-5	Schizophrenia;
THYM	cis	rs459571	0.715	rs401826	chr9:136890591	C/T	cg13789015	chr9:136890014	NCRNA00094	0.87	7.1	0.59	2.2e-10	Platelet distribution width;
THYM	cis	rs921968	0.565	rs6757772	chr2:219618497	T/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs4930103	0.564	rs1618613	chr11:1969888	G/A	cg06197492	chr11:2016605	H19	-0.53	-4.65	-0.43	1.08e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg04234412	chr22:24373322	LOC391322	0.92	9.31	0.69	4.89e-15	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6570726	0.967	rs7772286	chr6:145930423	A/T	cg23711669	chr6:146136114	FBXO30	-0.84	-8.04	-0.64	2.54e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg01304814	chr3:48885189	PRKAR2A	0.9	4.71	0.44	8.28e-6	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
THYM	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg01475377	chr6:109611718	NA	-0.54	-4.5	-0.42	1.93e-5	Reticulocyte fraction of red cells;
THYM	cis	rs912057	0.582	rs1294412	chr6:6739854	A/G	cg06612196	chr6:6737390	NA	0.77	14.62	0.83	4.77e-26	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg20203395	chr5:56204925	C5orf35	-0.67	-4.58	-0.42	1.44e-5	Initial pursuit acceleration;
THYM	cis	rs28595532	0.841	rs116521340	chr4:119757415	C/A	cg21605333	chr4:119757512	SEC24D	1.67	6.19	0.54	1.52e-8	Cannabis dependence symptom count;
THYM	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg19875535	chr5:140030758	IK	0.64	5.47	0.49	3.67e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	5.48	0.49	3.49e-7	Obesity-related traits;
THYM	cis	rs7772486	0.790	rs3924498	chr6:146233338	A/T	cg23711669	chr6:146136114	FBXO30	-0.96	-10.01	-0.72	1.54e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs7584330	0.554	rs13395743	chr2:238437554	C/T	cg08992911	chr2:238395768	MLPH	0.89	5.81	0.51	8.24e-8	Prostate cancer;
THYM	cis	rs9733	0.596	rs1415148	chr1:150705755	G/A	cg10589385	chr1:150898437	SETDB1	0.62	5.26	0.47	8.86e-7	Tonsillectomy;
THYM	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2637266	0.935	rs2579719	chr10:78400026	A/G	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs13202913	0.518	rs13205543	chr6:151813779	C/T	cg03596678	chr6:151814994	C6orf97	-0.76	-4.91	-0.45	3.72e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs981844	0.890	rs56184506	chr4:154685889	G/T	cg09973105	chr4:154681532	RNF175	-0.66	-5.44	-0.49	4.11e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg08999081	chr20:33150536	PIGU	-0.62	-5.27	-0.48	8.42e-7	Coronary artery disease;
THYM	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg13531842	chr10:38383804	ZNF37A	-0.56	-4.63	-0.43	1.17e-5	Extrinsic epigenetic age acceleration;
THYM	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg12564285	chr5:131593104	PDLIM4	0.53	5.95	0.52	4.38e-8	Breast cancer;
THYM	cis	rs7027203	0.797	rs3996254	chr9:96591239	A/G	cg14598338	chr9:96623480	NA	-0.49	-5.22	-0.47	1.07e-6	DNA methylation (variation);
THYM	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg24818145	chr4:99064322	C4orf37	0.75	5.9	0.52	5.53e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4343996	0.727	rs4499989	chr7:3371291	T/G	cg21248987	chr7:3385318	SDK1	-0.39	-4.69	-0.43	8.96e-6	Motion sickness;
THYM	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg03929089	chr4:120376271	NA	-1.01	-12.07	-0.78	6.9299999999999992e-21	Height;
THYM	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg19052272	chr2:3704530	ALLC	0.59	4.62	0.43	1.19e-5	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
THYM	cis	rs6598955	0.671	rs17163866	chr1:26648088	A/G	cg16068833	chr1:26644515	UBXN11;CD52	0.28	4.64	0.43	1.12e-5	Obesity-related traits;
THYM	cis	rs2041840	0.521	rs2251879	chr2:37485215	A/T	cg25727520	chr2:37576821	QPCT	-0.39	-4.59	-0.43	1.38e-5	Chronic lymphocytic leukemia;
THYM	cis	rs6500395	0.775	rs11640119	chr16:48662840	C/T	cg04672837	chr16:48644449	N4BP1	0.47	4.62	0.43	1.18e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg07404485	chr7:94953653	PON1	-0.95	-9.28	-0.69	5.7e-15	Paraoxonase activity;
THYM	cis	rs7968440	1.000	rs2700485	chr12:51103992	C/T	cg20014596	chr12:50898483	DIP2B	0.54	4.46	0.42	2.29e-5	Fibrinogen;
THYM	cis	rs9302065	0.565	rs2992905	chr13:95958190	C/T	cg24476569	chr13:95954382	ABCC4	-0.78	-7.91	-0.63	4.59e-12	Blood metabolite levels;
THYM	cis	rs2066819	1.000	rs74496027	chr12:56726340	C/T	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs7772486	0.875	rs9403765	chr6:146368041	C/T	cg13319975	chr6:146136371	FBXO30	0.71	5.86	0.52	6.71e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg18252515	chr7:66147081	NA	-1.38	-8.0	-0.63	2.98e-12	Diabetic kidney disease;
THYM	cis	rs1448094	0.512	rs6539929	chr12:86244932	T/C	cg02569458	chr12:86230093	RASSF9	0.58	4.98	0.46	2.82e-6	Major depressive disorder;
THYM	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg26384229	chr12:38710491	ALG10B	1.07	10.65	0.74	6.83e-18	Heart rate;
THYM	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg03676636	chr4:99064102	C4orf37	0.43	6.32	0.54	8.55e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg07532245	chr17:28927093	LRRC37B2	0.71	4.48	0.42	2.04e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg06481639	chr22:41940642	POLR3H	-0.61	-4.48	-0.42	2.09e-5	Neuroticism;
THYM	cis	rs240764	0.817	rs239249	chr6:101087081	G/A	cg21058520	chr6:100914733	NA	-0.57	-5.0	-0.46	2.59e-6	Neuroticism;
THYM	cis	rs7772486	0.727	rs2235481	chr6:146056848	T/C	cg05347473	chr6:146136440	FBXO30	-0.82	-7.43	-0.61	4.73e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs790123	0.581	rs2877628	chr3:122352678	A/G	cg15604389	chr3:122379662	NA	0.58	5.42	0.49	4.51e-7	Response to angiotensin II receptor blocker therapy;
THYM	cis	rs7172809	0.897	rs74026930	chr15:77825253	G/A	cg10437265	chr15:77819839	NA	-0.53	-4.57	-0.42	1.48e-5	Glucose homeostasis traits;
THYM	cis	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg06521331	chr12:34319734	NA	-0.99	-9.12	-0.68	1.23e-14	Morning vs. evening chronotype;
THYM	cis	rs7524258	0.868	rs4243825	chr1:7308264	T/C	cg07173049	chr1:7289937	CAMTA1	0.81	6.33	0.54	8.04e-9	Tourette's syndrome or obsessive-compulsive disorder;
THYM	cis	rs11722228	0.522	rs2241468	chr4:10113905	G/A	cg02317251	chr4:10116515	WDR1	-0.56	-4.95	-0.45	3.23e-6	Gout;Urate levels;Serum uric acid levels;
THYM	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.0	10.08	0.72	1.13e-16	Cognitive ability;
THYM	cis	rs13006833	0.694	rs291448	chr2:191177216	T/C	cg27211696	chr2:191398769	TMEM194B	0.56	4.47	0.42	2.19e-5	Urinary metabolites;
THYM	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg27129171	chr3:47204927	SETD2	0.71	6.88	0.58	6.3e-10	Colorectal cancer;
THYM	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06481639	chr22:41940642	POLR3H	0.72	5.15	0.47	1.42e-6	Vitiligo;
THYM	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg26384229	chr12:38710491	ALG10B	0.7	5.46	0.49	3.75e-7	Morning vs. evening chronotype;
THYM	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03264133	chr6:25882463	NA	-0.88	-7.56	-0.61	2.53e-11	Intelligence (multi-trait analysis);
THYM	cis	rs4386084	1.000	rs34702709	chr15:50221230	A/C	cg21557108	chr15:50410962	ATP8B4	0.45	4.49	0.42	1.97e-5	Basophil percentage of white cells;Basophil percentage of granulocytes;
THYM	cis	rs951188	0.744	rs72992992	chr2:150347583	G/A	cg17961725	chr2:150454027	NA	-0.94	-4.8	-0.44	5.89e-6	Daytime sleep phenotypes;
THYM	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg17105886	chr17:28927953	LRRC37B2	1.31	7.85	0.63	6.35e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9549260	0.591	rs9577115	chr13:41276553	T/C	cg21288729	chr13:41239152	FOXO1	0.66	4.94	0.45	3.29e-6	Red blood cell count;
THYM	cis	rs6570726	0.935	rs429306	chr6:145827016	T/C	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs10496034	0.541	rs13398208	chr2:54941710	C/G	cg25815024	chr2:219696567	PRKAG3	1.11	7.02	0.58	3.34e-10	Refractive astigmatism;
THYM	cis	rs7512552	0.839	rs12046446	chr1:150460855	T/G	cg15654264	chr1:150340011	RPRD2	0.45	5.19	0.47	1.18e-6	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4474465	0.790	rs4945290	chr11:78252249	C/T	cg19901956	chr11:77921274	USP35	0.61	4.6	0.43	1.3e-5	Alzheimer's disease (survival time);
THYM	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg19077165	chr18:44547161	KATNAL2	-0.62	-8.11	-0.64	1.8e-12	Personality dimensions;
THYM	cis	rs2180341	0.842	rs6569476	chr6:127553539	G/A	cg27446573	chr6:127587934	RNF146	1.08	8.91	0.67	3.57e-14	Breast cancer;
THYM	cis	rs7615952	0.736	rs9866347	chr3:125669925	C/T	cg05084668	chr3:125655381	ALG1L	-1.0	-5.44	-0.49	4.18e-7	Blood pressure (smoking interaction);
THYM	cis	rs7107174	1.000	rs7939646	chr11:78111613	C/T	cg02023728	chr11:77925099	USP35	-0.63	-6.11	-0.53	2.23e-8	Testicular germ cell tumor;
THYM	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs1050631	0.592	rs1631346	chr18:33709664	T/G	cg23776217	chr18:34409391	KIAA1328;C18orf10	0.59	4.56	0.42	1.52e-5	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs4690686	0.500	rs2168032	chr4:177272957	A/G	cg17059388	chr4:177262070	NA	0.48	6.7	0.57	1.45e-9	Essential tremor;
THYM	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19346786	chr7:2764209	NA	0.6	5.04	0.46	2.2e-6	Height;
THYM	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg00684032	chr4:1343700	KIAA1530	0.6	5.38	0.48	5.29e-7	Obesity-related traits;
THYM	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg10518543	chr12:38710700	ALG10B	-0.59	-4.7	-0.43	8.88e-6	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg26384229	chr12:38710491	ALG10B	0.94	7.9	0.63	4.92e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs2066819	1.000	rs118130855	chr12:56677979	T/A	cg26714650	chr12:56694279	CS	-1.35	-7.01	-0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs1448094	0.534	rs974818	chr12:86144307	T/C	cg02569458	chr12:86230093	RASSF9	-0.66	-5.64	-0.5	1.77e-7	Major depressive disorder;
THYM	cis	rs73086581	1.000	rs73086505	chr20:3921571	A/G	cg02187196	chr20:3869020	PANK2	0.51	5.72	0.51	1.26e-7	Response to antidepressants in depression;
THYM	cis	rs9972944	0.729	rs2024275	chr17:63768913	C/T	cg07283582	chr17:63770753	CCDC46	-0.67	-5.19	-0.47	1.19e-6	Total body bone mineral density;
THYM	cis	rs752010	0.806	rs4457567	chr1:42091407	C/T	cg22486000	chr1:42919398	ZMYND12	-0.43	-4.83	-0.44	5.16e-6	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.33	10.0	0.72	1.62e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7616559	0.925	rs4680326	chr3:156715450	G/A	cg15697575	chr3:156784781	NA	0.4	5.05	0.46	2.12e-6	Carotid artery intima media thickness (sex interaction);
THYM	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg06636001	chr8:8085503	FLJ10661	0.77	7.01	0.58	3.47e-10	Triglycerides;
THYM	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg07636037	chr3:49044803	WDR6	0.99	10.4	0.73	2.28e-17	Parkinson's disease;
THYM	cis	rs3806843	0.676	rs753280	chr5:140024042	C/T	cg19875535	chr5:140030758	IK	0.59	5.27	0.48	8.44e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg18252515	chr7:66147081	NA	-0.72	-5.6	-0.5	2.03e-7	Aortic root size;
THYM	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg22920501	chr2:26401640	FAM59B	-1.06	-9.71	-0.71	7e-16	Gut microbiome composition (summer);
THYM	cis	rs7107174	1.000	rs4945267	chr11:78037933	G/A	cg19901956	chr11:77921274	USP35	-0.67	-5.55	-0.49	2.56e-7	Testicular germ cell tumor;
THYM	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg22920501	chr2:26401640	FAM59B	-0.77	-6.95	-0.58	4.55e-10	Gut microbiome composition (summer);
THYM	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg24846680	chr1:228362309	C1orf69	0.53	4.71	0.43	8.6e-6	Diastolic blood pressure;
THYM	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg07414643	chr4:187882934	NA	0.67	5.95	0.52	4.52e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs10037758	0.528	rs258002	chr5:128319288	A/G	cg25555059	chr5:128301488	SLC27A6	-0.45	-4.74	-0.44	7.63e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg24531977	chr5:56204891	C5orf35	-0.64	-4.87	-0.45	4.46e-6	Coronary artery disease;
THYM	cis	rs55871839	0.708	rs7000535	chr8:59804351	T/C	cg07426533	chr8:59803705	TOX	-0.61	-5.86	-0.52	6.67e-8	Pneumonia;
THYM	cis	rs6988636	1.000	rs28694222	chr8:124195017	C/T	cg23067535	chr8:124195133	FAM83A	-1.07	-5.8	-0.51	8.66e-8	Urinary uromodulin levels;
THYM	cis	rs2811415	0.597	rs13070488	chr3:127784118	T/C	cg05377949	chr3:127951287	EEFSEC	0.38	4.74	0.44	7.36e-6	Lung function (FEV1/FVC);
THYM	cis	rs7192750	0.538	rs28594331	chr16:71863482	C/T	cg06353428	chr16:71660113	MARVELD3	0.72	5.1	0.46	1.74e-6	LDL cholesterol levels;Total cholesterol levels;
THYM	cis	rs7264396	0.528	rs7273880	chr20:34551507	A/G	cg26038318	chr20:34205095	SPAG4	0.59	4.81	0.44	5.6e-6	Total cholesterol levels;
THYM	cis	rs7580658	0.637	rs1566822	chr2:127987391	A/G	cg18942985	chr2:128523110	WDR33	-0.48	-4.52	-0.42	1.78e-5	Protein C levels;
THYM	cis	rs7072216	0.763	rs942804	chr10:100168499	C/A	cg26618903	chr10:100175079	PYROXD2	-0.48	-4.6	-0.43	1.33e-5	Metabolite levels;
THYM	cis	rs675209	0.553	rs10458206	chr6:7084214	C/T	cg24899545	chr6:7112846	RREB1	-0.52	-4.95	-0.45	3.24e-6	Urate levels;
THYM	cis	rs16828019	0.640	rs35201793	chr1:41521922	G/A	cg16989117	chr1:40781907	COL9A2	0.96	4.71	0.44	8.49e-6	Intelligence (multi-trait analysis);
THYM	cis	rs798766	1.000	rs3099555	chr4:1725651	T/C	cg00006948	chr4:1768889	NA	-0.94	-4.93	-0.45	3.43e-6	Bladder cancer;Urinary bladder cancer;
THYM	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.57	-4.59	-0.43	1.37e-5	Bipolar disorder;
THYM	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg01579765	chr21:45077557	HSF2BP	-0.5	-8.31	-0.65	6.78e-13	Mean corpuscular volume;
THYM	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg11189052	chr15:85197271	WDR73	-0.68	-5.36	-0.48	5.73e-7	P wave terminal force;
THYM	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.51	0.66	2.47e-13	Colorectal cancer;
THYM	cis	rs1950626	0.716	rs34572720	chr14:101447150	G/A	cg11887864	chr14:101510502	MIR1185-2	0.54	4.52	0.42	1.75e-5	Pelvic organ prolapse (moderate/severe);
THYM	cis	rs6496667	1.000	rs6496667	chr15:90893668	C/A	cg22089800	chr15:90895588	ZNF774	0.74	5.0	0.46	2.65e-6	Rheumatoid arthritis;
THYM	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg16989719	chr2:238392110	NA	-0.65	-5.93	-0.52	4.98e-8	Prostate cancer;
THYM	cis	rs637571	0.780	rs653914	chr11:65676516	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.58	5.92	0.52	4.99e-8	Eosinophil percentage of white cells;
THYM	cis	rs7829975	0.511	rs2980512	chr8:8140901	T/C	cg06636001	chr8:8085503	FLJ10661	0.79	7.75	0.62	9.97e-12	Mood instability;
THYM	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg07599136	chr5:415885	AHRR	0.93	5.17	0.47	1.29e-6	Fat distribution (HIV);
THYM	cis	rs3796352	1.000	rs11707780	chr3:53084326	A/G	cg07884673	chr3:53033167	SFMBT1	-1.02	-6.2	-0.54	1.45e-8	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs9880211	0.613	rs13081671	chr3:135876549	C/T	cg21827317	chr3:136751795	NA	-0.68	-4.93	-0.45	3.52e-6	Body mass index;Height;
THYM	cis	rs56104184	0.725	rs1466896	chr19:49385253	C/G	cg17863274	chr19:49399704	TULP2	-0.92	-5.49	-0.49	3.32e-7	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2456568	0.867	rs4753111	chr11:93658410	A/G	cg17595323	chr11:93583763	C11orf90	-0.58	-5.75	-0.51	1.06e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs58799304	0.531	rs12035615	chr1:156055344	C/T	cg15685922	chr1:156045208	MEX3A	-0.45	-4.6	-0.43	1.29e-5	Ischemic stroke;
THYM	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg11764359	chr7:65958608	NA	-0.83	-6.59	-0.56	2.44e-9	Aortic root size;
THYM	cis	rs7107174	0.711	rs66583694	chr11:78037773	C/T	cg19901956	chr11:77921274	USP35	-0.65	-5.38	-0.48	5.38e-7	Testicular germ cell tumor;
THYM	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.93	6.05	0.53	2.87e-8	Platelet count;
THYM	cis	rs514406	0.505	rs12726160	chr1:53175099	A/G	cg16325326	chr1:53192061	ZYG11B	0.98	11.15	0.75	5.97e-19	Monocyte count;
THYM	cis	rs56104184	0.779	rs17272666	chr19:49356294	T/C	cg21252483	chr19:49399788	TULP2	-0.71	-4.89	-0.45	4.09e-6	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs2124499	0.967	rs10934646	chr3:123084541	A/G	cg04890266	chr3:123102914	ADCY5	0.63	5.01	0.46	2.51e-6	Body mass index;
THYM	cis	rs9915657	0.773	rs9894696	chr17:70099487	C/T	cg06234051	chr17:70120541	SOX9	-0.64	-6.08	-0.53	2.49e-8	Thyroid hormone levels;
THYM	cis	rs55728055	0.661	rs62237765	chr22:31956981	A/G	cg10537193	chr22:32026975	PISD	-0.68	-4.64	-0.43	1.11e-5	Age-related hearing impairment;
THYM	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg05313129	chr8:58192883	C8orf71	-0.88	-5.11	-0.46	1.69e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg00271210	chr6:167070053	RPS6KA2	-0.72	-7.96	-0.63	3.73e-12	Crohn's disease;
THYM	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg15704280	chr7:45808275	SEPT13	1.01	7.86	0.63	5.81e-12	Coronary artery disease;
THYM	cis	rs909002	1.000	rs1474182	chr1:32136398	C/T	cg13919466	chr1:32135498	COL16A1	-0.54	-5.52	-0.49	2.91e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9790314	1.000	rs7647327	chr3:161016421	T/C	cg04691961	chr3:161091175	C3orf57	-0.6	-5.09	-0.46	1.8e-6	Morning vs. evening chronotype;
THYM	trans	rs9951602	0.512	rs7232551	chr18:76650702	G/A	cg02800362	chr5:177631904	HNRNPAB	1.13	8.94	0.68	3.09e-14	Obesity-related traits;
THYM	cis	rs6860806	0.695	rs6867282	chr5:131583120	G/C	cg04518342	chr5:131593106	PDLIM4	0.48	5.39	0.48	5.21e-7	Breast cancer;
THYM	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg17830980	chr10:43048298	ZNF37B	-1.04	-10.47	-0.73	1.67e-17	Extrinsic epigenetic age acceleration;
THYM	cis	rs9733	0.596	rs72702556	chr1:150680115	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg11301795	chr4:187892539	NA	-1.11	-18.07	-0.88	1.66e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2276314	0.857	rs8097597	chr18:33619448	A/G	cg05985134	chr18:33552581	C18orf21	0.66	4.84	0.44	5.02e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs420259	0.516	rs2097662	chr16:23523345	C/A	cg00143387	chr16:23521605	GGA2	-0.75	-5.37	-0.48	5.57e-7	Bipolar disorder;
THYM	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.92	7.95	0.63	3.8e-12	Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg18252515	chr7:66147081	NA	-0.66	-4.58	-0.43	1.42e-5	Aortic root size;
THYM	cis	rs9733	0.596	rs34600506	chr1:150687808	C/G	cg10589385	chr1:150898437	SETDB1	0.64	5.35	0.48	5.99e-7	Tonsillectomy;
THYM	cis	rs7772486	0.727	rs4896843	chr6:146063451	T/C	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.54e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	4.97	0.45	2.98e-6	Total body bone mineral density;
THYM	cis	rs40363	0.645	rs250627	chr16:3527050	G/A	cg05754148	chr16:3507555	NAT15	0.72	7.22	0.6	1.3e-10	Tuberculosis;
THYM	cis	rs775227	0.574	rs79709668	chr3:113161265	G/A	cg18753928	chr3:113234510	CCDC52	-0.8	-5.57	-0.5	2.33e-7	Dental caries;
THYM	cis	rs2885056	0.800	rs8105074	chr19:10708692	A/G	cg04833646	chr19:10679720	CDKN2D	1.17	7.93	0.63	4.16e-12	Red cell distribution width;
THYM	cis	rs297325	0.812	rs10766342	chr11:16760796	G/A	cg20214553	chr11:17278779	NA	0.4	4.48	0.42	2.09e-5	Obesity and osteoporosis;
THYM	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg26441486	chr22:50317300	CRELD2	0.44	7.57	0.61	2.37e-11	Schizophrenia;
THYM	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.53	4.92	0.45	3.64e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg21475434	chr5:93447410	FAM172A	0.92	5.7	0.5	1.35e-7	Diabetic retinopathy;
THYM	cis	rs3750965	0.881	rs61057353	chr11:68817050	C/G	cg01403660	chr11:68851641	TPCN2	0.63	4.59	0.43	1.33e-5	Hair color;
THYM	cis	rs2730245	0.527	rs2527187	chr7:158716912	T/C	cg01219135	chr7:158766336	NA	-0.58	-4.73	-0.44	7.7e-6	Height;
THYM	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg02825527	chr7:2087843	MAD1L1	-0.8	-5.07	-0.46	1.94e-6	Neuroticism;
THYM	cis	rs2070488	0.965	rs2366119	chr3:38484453	C/T	cg24069376	chr3:38537580	EXOG	0.68	6.73	0.57	1.26e-9	Electrocardiographic conduction measures;
THYM	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg06808227	chr14:105710500	BRF1	-1.05	-9.15	-0.68	1.07e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg25767906	chr1:53392781	SCP2	0.52	5.18	0.47	1.22e-6	Monocyte count;
THYM	cis	rs10463554	0.926	rs26429	chr5:102366053	C/T	cg23492399	chr5:102201601	PAM	0.64	4.81	0.44	5.71e-6	Parkinson's disease;
THYM	cis	rs7173743	0.756	rs8032842	chr15:79125849	G/A	cg00540400	chr15:79124168	NA	0.62	6.61	0.56	2.2e-9	Coronary artery disease;
THYM	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg16624210	chr5:671434	TPPP	0.76	5.61	0.5	2.03e-7	Obesity-related traits;
THYM	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg01528321	chr10:82214614	TSPAN14	0.66	5.16	0.47	1.35e-6	Post bronchodilator FEV1;
THYM	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.78	-5.8	-0.51	8.48e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6430585	0.583	rs2839740	chr2:136648883	G/T	cg23851026	chr2:136556271	LCT	0.81	7.31	0.6	8.35e-11	Corneal structure;
THYM	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg14349672	chr11:133703707	NA	-0.54	-4.77	-0.44	6.63e-6	Childhood ear infection;
THYM	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg11764359	chr7:65958608	NA	0.83	6.64	0.56	1.93e-9	Aortic root size;
THYM	cis	rs6558530	0.777	rs3812477	chr8:1734452	C/G	cg09410841	chr8:1729607	CLN8	0.79	5.65	0.5	1.65e-7	Systolic blood pressure;
THYM	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg13699009	chr12:122356056	WDR66	0.46	4.54	0.42	1.63e-5	Mean corpuscular volume;
THYM	cis	rs4851266	0.898	rs12053126	chr2:100864646	A/T	cg14675211	chr2:100938903	LONRF2	0.67	5.58	0.5	2.28e-7	Educational attainment;
THYM	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg08994789	chr17:28903642	LRRC37B2	-1.08	-5.35	-0.48	5.98e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6988636	0.892	rs58116120	chr8:124191776	T/G	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs1331623	0.955	rs2900160	chr9:122196840	A/T	cg25935911	chr9:122132261	DBC1	-0.52	-4.72	-0.44	8.05e-6	Height;
THYM	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg15704280	chr7:45808275	SEPT13	0.99	8.27	0.65	8.17e-13	Coronary artery disease;
THYM	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19346786	chr7:2764209	NA	-0.7	-5.86	-0.52	6.63e-8	Height;
THYM	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg06611532	chr13:114900021	NA	0.64	7.17	0.59	1.6e-10	Schizophrenia;
THYM	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg13852791	chr20:30311386	BCL2L1	0.83	6.43	0.55	5.21e-9	Mean corpuscular hemoglobin;
THYM	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg10589385	chr1:150898437	SETDB1	0.64	5.4	0.48	4.9e-7	Melanoma;
THYM	cis	rs57920188	0.584	rs10915657	chr1:4092904	T/C	cg08764037	chr1:3634867	TP73	-0.46	-4.68	-0.43	9.45e-6	Interleukin-17 levels;
THYM	cis	rs1678542	1.000	rs1284464	chr12:57964617	G/A	cg12615879	chr12:58013172	SLC26A10	-0.51	-4.57	-0.42	1.46e-5	Rheumatoid arthritis;
THYM	cis	rs72781680	0.898	rs79023848	chr2:24038174	C/A	cg08917208	chr2:24149416	ATAD2B	1.11	4.97	0.45	2.9e-6	Lymphocyte counts;
THYM	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg09359103	chr1:154839909	KCNN3	-0.73	-9.27	-0.69	5.9e-15	Prostate cancer;
THYM	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg24675658	chr1:53192096	ZYG11B	-0.82	-7.54	-0.61	2.75e-11	Monocyte count;
THYM	cis	rs7246657	0.765	rs7247259	chr19:37851090	T/C	cg22634378	chr19:37742834	NA	0.65	5.34	0.48	6.2e-7	Coronary artery calcification;
THYM	cis	rs2658782	0.826	rs1975820	chr11:93081815	G/A	cg15737290	chr11:93063684	CCDC67	0.99	8.21	0.64	1.09e-12	Pulmonary function decline;
THYM	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg22968622	chr17:43663579	NA	1.03	8.05	0.64	2.32e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg24531977	chr5:56204891	C5orf35	0.72	5.77	0.51	9.7e-8	Initial pursuit acceleration;
THYM	cis	rs7226229	0.904	rs2364331	chr17:20922917	T/A	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs1371867	0.846	rs1660312	chr8:101330634	C/G	cg00191853	chr8:101177733	SPAG1	-0.57	-5.63	-0.5	1.81e-7	Atrioventricular conduction;
THYM	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg12573674	chr2:1569213	NA	-1.22	-7.61	-0.62	2.02e-11	IgG glycosylation;
THYM	cis	rs4970966	1.000	rs4970966	chr1:150584103	A/C	cg21937128	chr1:150971889	FAM63A	0.32	4.66	0.43	1.02e-5	Granulocyte percentage of myeloid white cells;Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10752881	1.000	rs10752881	chr1:182973491	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.6	4.77	0.44	6.55e-6	Colorectal cancer;
THYM	cis	rs4819852	0.958	rs758374	chr22:19971552	T/C	cg07821417	chr22:19972146	ARVCF	0.46	5.53	0.49	2.85e-7	Pulse pressure;
THYM	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg24250549	chr1:154909240	PMVK	0.67	5.08	0.46	1.84e-6	Prostate cancer;
THYM	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg10760299	chr15:45669010	GATM	0.87	6.83	0.57	7.98e-10	Homoarginine levels;
THYM	cis	rs2319125	0.683	rs8078381	chr17:64044668	C/T	cg04446870	chr17:64440273	PRKCA	0.5	4.48	0.42	2.12e-5	&beta2-Glycoprotein I (β2-GPI) plasma levels;
THYM	cis	rs28595532	0.764	rs55913633	chr4:119747444	C/A	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs11966931	0.947	rs11968258	chr6:108133059	G/A	cg25323841	chr6:108444506	NA	0.67	4.6	0.43	1.29e-5	Neutrophil percentage of white cells;
THYM	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg06766960	chr11:133703094	NA	-0.6	-5.5	-0.49	3.19e-7	Childhood ear infection;
THYM	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg05335186	chr13:53173507	NA	-0.5	-6.44	-0.55	4.81e-9	Lewy body disease;
THYM	cis	rs6686842	1.000	rs12125555	chr1:41707111	A/G	cg03387723	chr1:41708464	SCMH1	-0.43	-5.03	-0.46	2.34e-6	Height;
THYM	cis	rs7818345	0.569	rs4317590	chr8:19357642	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.47	4.58	0.43	1.42e-5	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6429082	0.667	rs10802800	chr1:235706283	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.67	-4.75	-0.44	7.13e-6	Adiposity;
THYM	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs79149102	0.579	rs6495135	chr15:75295030	T/C	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	cis	rs4919669	0.668	rs4146428	chr10:104401721	G/A	cg24934431	chr10:104597864	CYP17A1	0.57	4.87	0.45	4.38e-6	Systolic blood pressure (long-term average);Mean arterial pressure (long-term average);
THYM	cis	rs425277	0.606	rs3128339	chr1:2046938	G/T	cg09260853	chr1:2094483	PRKCZ	-0.46	-4.71	-0.43	8.57e-6	Height;
THYM	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.88	5.64	0.5	1.78e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1372520	0.684	rs2619341	chr4:90741773	A/G	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs868036	0.958	rs11635424	chr15:68037578	C/T	cg24579218	chr15:68104479	NA	-0.64	-6.08	-0.53	2.53e-8	Restless legs syndrome;
THYM	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.73	-7.27	-0.6	1.01e-10	Lymphocyte counts;
THYM	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08109568	chr15:31115862	NA	-0.62	-5.94	-0.52	4.67e-8	Huntington's disease progression;
THYM	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg07424592	chr7:64974309	NA	1.06	5.48	0.49	3.47e-7	Diabetic kidney disease;
THYM	cis	rs6570726	0.811	rs375873	chr6:145812371	G/T	cg23711669	chr6:146136114	FBXO30	0.77	7.34	0.6	7.09e-11	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17005891	0.877	rs7669538	chr4:83563158	A/G	cg10249074	chr4:83542146	C4orf11	-0.66	-5.27	-0.48	8.48e-7	Sum eosinophil basophil counts;Eosinophil counts;
THYM	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg24818145	chr4:99064322	C4orf37	0.82	6.46	0.55	4.38e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3771570	1.000	rs62193221	chr2:242354632	T/C	cg21155796	chr2:242212141	HDLBP	1.17	5.7	0.5	1.36e-7	Prostate cancer;
THYM	cis	rs7172809	0.653	rs16968897	chr15:77825298	A/G	cg22256960	chr15:77711686	NA	-0.66	-4.85	-0.45	4.86e-6	Glucose homeostasis traits;
THYM	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.82	5.49	0.49	3.33e-7	Platelet count;
THYM	cis	rs988913	0.957	rs4141552	chr6:54759929	A/G	cg04690482	chr6:54711388	FAM83B	0.45	4.84	0.44	5.08e-6	Menarche (age at onset);
THYM	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg14675211	chr2:100938903	LONRF2	0.77	8.11	0.64	1.75e-12	Intelligence (multi-trait analysis);
THYM	cis	rs6546324	0.580	rs6724133	chr2:67858671	A/G	cg18237512	chr2:67827392	NA	-0.79	-4.75	-0.44	7.23e-6	Endometriosis;
THYM	cis	rs7084402	0.967	rs1658481	chr10:60289339	A/G	cg07615347	chr10:60278583	BICC1	0.56	5.06	0.46	2.03e-6	Refractive error;
THYM	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-14.81	-0.84	2.05e-26	Height;
THYM	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg10505658	chr17:80084571	CCDC57	-0.74	-8.21	-0.64	1.06e-12	Life satisfaction;
THYM	cis	rs3003334	1	rs3003334	chr1:24199869	G/A	cg15997130	chr1:24165203	NA	0.74	6.34	0.55	7.54e-9	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;
THYM	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06850241	chr22:41845214	NA	-0.54	-4.74	-0.44	7.44e-6	Vitiligo;
THYM	cis	rs72781680	0.898	rs12620558	chr2:23936022	G/A	cg08917208	chr2:24149416	ATAD2B	1.1	4.81	0.44	5.71e-6	Lymphocyte counts;
THYM	cis	rs79387448	0.745	rs72995652	chr2:103171651	C/A	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg01299579	chr2:10830716	NOL10	-0.49	-4.65	-0.43	1.06e-5	Prostate cancer;
THYM	cis	rs7772486	0.790	rs3923579	chr6:146230232	C/G	cg13319975	chr6:146136371	FBXO30	0.7	5.77	0.51	1.01e-7	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs12760731	0.720	rs12741848	chr1:178334941	A/G	cg06907405	chr16:48400475	SIAH1	-1.2	-7.43	-0.61	4.77e-11	Obesity-related traits;
THYM	cis	rs4866334	1.000	rs77766662	chr5:18485586	A/C	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4499344	0.730	rs421607	chr19:33104951	A/G	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.89	7.61	0.62	2.02e-11	Mean platelet volume;
THYM	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg18758796	chr5:131593413	PDLIM4	-0.5	-4.72	-0.44	8.15e-6	Breast cancer;
THYM	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg17054759	chr22:49844102	NA	-0.52	-5.01	-0.46	2.51e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22857025	chr5:266934	NA	-1.37	-8.88	-0.67	4.08e-14	Breast cancer;
THYM	cis	rs9443189	0.865	rs2748940	chr6:76434027	C/T	cg01950844	chr6:76311363	SENP6	-0.79	-4.47	-0.42	2.13e-5	Prostate cancer;
THYM	cis	rs995000	0.931	rs10789114	chr1:63034222	T/C	cg06896770	chr1:63153194	DOCK7	1.0	8.17	0.64	1.31e-12	Triglyceride levels;
THYM	cis	rs8111500	0.793	rs10412111	chr19:49155256	G/A	cg07051648	chr19:49177693	NTN5;SEC1	0.6	4.51	0.42	1.87e-5	Elevated serum carcinoembryonic antigen levels;
THYM	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.76	-4.97	-0.45	3e-6	Mean platelet volume;
THYM	cis	rs11771526	0.892	rs62457541	chr7:32372566	G/A	cg27511599	chr7:32358540	NA	0.75	5.02	0.46	2.42e-6	Body mass index;
THYM	cis	rs1163251	0.837	rs592762	chr1:120247355	A/G	cg19096424	chr1:120255104	PHGDH	0.71	5.24	0.47	9.57e-7	Blood metabolite levels;
THYM	cis	rs4988958	0.565	rs6732138	chr2:103009662	G/A	cg03938978	chr2:103052716	IL18RAP	0.73	9.51	0.7	1.82e-15	Asthma (childhood onset);
THYM	cis	rs9394152	0.810	rs9380364	chr6:33471721	T/C	cg13560919	chr6:33536144	NA	0.73	6.26	0.54	1.09e-8	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs2455799	0.573	rs924753	chr3:15706124	C/T	cg16303742	chr3:15540471	COLQ	-0.54	-5.81	-0.51	8.22e-8	Mean platelet volume;
THYM	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	10.36	0.73	2.81e-17	Chronic sinus infection;
THYM	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg18758796	chr5:131593413	PDLIM4	0.5	4.72	0.44	8.15e-6	Acylcarnitine levels;
THYM	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg06917634	chr15:78832804	PSMA4	-0.83	-6.84	-0.57	7.67e-10	Sudden cardiac arrest;
THYM	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg24596788	chr1:163392923	NA	-0.77	-7.43	-0.61	4.68e-11	Motion sickness;
THYM	cis	rs78366141	0.649	rs7674009	chr4:89683324	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	-1.14	-4.83	-0.44	5.23e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg17757837	chr7:157058334	UBE3C	0.65	5.25	0.47	9.38e-7	Body mass index;
THYM	cis	rs7178572	0.568	rs4886515	chr15:77686886	G/A	cg22256960	chr15:77711686	NA	-1.05	-8.4	-0.65	4.29e-13	Type 2 diabetes;
THYM	cis	rs6860806	0.632	rs4330455	chr5:131586349	T/C	cg09877947	chr5:131593287	PDLIM4	0.61	5.31	0.48	7.27e-7	Breast cancer;
THYM	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg12560992	chr17:57184187	TRIM37	0.92	8.68	0.67	1.1e-13	Intelligence (multi-trait analysis);
THYM	cis	rs12042938	0.507	rs1655301	chr1:231731730	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-5.81	-0.51	8.3e-8	Neuranatomic and neurocognitive phenotypes;
THYM	cis	rs2882667	0.690	rs288007	chr5:138230628	C/T	cg09476006	chr5:138032270	NA	0.56	4.45	0.42	2.32e-5	Age-related hearing impairment (SNP x SNP interaction);
THYM	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg05738196	chr6:26577821	NA	0.93	9.24	0.69	6.9e-15	Intelligence (multi-trait analysis);
THYM	cis	rs6430585	0.528	rs614193	chr2:136653925	A/T	cg23851026	chr2:136556271	LCT	0.71	6.97	0.58	4.16e-10	Corneal structure;
THYM	cis	rs12310956	0.532	rs1352210	chr12:33983187	A/G	cg10856724	chr12:34555212	NA	-0.71	-6.55	-0.56	2.92e-9	Morning vs. evening chronotype;
THYM	cis	rs7584330	0.737	rs1497127	chr2:238369282	A/G	cg14458575	chr2:238380390	NA	0.94	7.81	0.63	7.65e-12	Prostate cancer;
THYM	cis	rs4919694	1.000	rs12241091	chr10:104808997	G/A	cg04362960	chr10:104952993	NT5C2	1.14	6.92	0.58	5.36e-10	Arsenic metabolism;
THYM	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg26531700	chr6:26746687	NA	0.56	4.76	0.44	6.91e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7781977	0.960	rs28625973	chr7:50334208	A/G	cg01139861	chr7:50343298	IKZF1	0.65	6.09	0.53	2.34e-8	IgG glycosylation;
THYM	cis	rs853679	0.599	rs149943	chr6:28002388	G/A	cg23161317	chr6:28129485	ZNF389	0.98	4.56	0.42	1.53e-5	Depression;
THYM	cis	rs7909074	0.966	rs879074	chr10:45400053	G/A	cg04218760	chr10:45406644	TMEM72	-0.64	-5.63	-0.5	1.79e-7	Mean corpuscular volume;
THYM	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg05234568	chr11:5960015	NA	-0.55	-4.46	-0.42	2.26e-5	DNA methylation (variation);
THYM	cis	rs3768617	0.510	rs10797852	chr1:183101302	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.92	0.45	3.65e-6	Fuchs's corneal dystrophy;
THYM	cis	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg09307838	chr4:120376055	NA	0.78	5.89	0.52	5.7e-8	Corneal astigmatism;
THYM	cis	rs7100689	0.542	rs7096715	chr10:82195949	T/C	cg00277334	chr10:82204260	NA	-0.54	-5.52	-0.49	2.88e-7	Post bronchodilator FEV1;
THYM	cis	rs6860806	0.661	rs3763112	chr5:131586480	A/G	cg18301423	chr5:131593218	PDLIM4	0.48	4.5	0.42	1.96e-5	Breast cancer;
THYM	cis	rs9649213	0.593	rs3823740	chr7:97957104	T/G	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.6e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg05973401	chr12:123451056	ABCB9	0.68	4.55	0.42	1.58e-5	Neutrophil percentage of white cells;
THYM	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg12011299	chr4:100065546	ADH4	0.69	5.93	0.52	4.87e-8	Alcohol dependence;
THYM	trans	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs929596	0.785	rs6714634	chr2:234664765	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.99	8.42	0.65	3.96e-13	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs4951011	0.706	rs883197	chr1:203758393	A/C	cg24343524	chr1:203763352	ZC3H11A	0.69	6.07	0.53	2.67e-8	Breast cancer;
THYM	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.69	5.39	0.48	5.08e-7	Tonsillectomy;
THYM	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg26597838	chr10:835615	NA	1.26	9.13	0.68	1.17e-14	Eosinophil percentage of granulocytes;
THYM	cis	rs79149102	0.579	rs8040961	chr15:75291864	G/A	cg09165964	chr15:75287851	SCAMP5	-1.15	-6.55	-0.56	2.9e-9	Lung cancer;
THYM	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg13695892	chr22:41940480	POLR3H	-0.99	-7.48	-0.61	3.75e-11	Vitiligo;
THYM	cis	rs2219968	0.525	rs28491269	chr8:78884180	T/G	cg00738934	chr8:78996279	NA	0.61	4.95	0.45	3.21e-6	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg10856724	chr12:34555212	NA	-0.82	-7.26	-0.6	1.03e-10	Morning vs. evening chronotype;
THYM	cis	rs354225	0.544	rs10183867	chr2:54812722	C/G	cg23486701	chr2:54789491	SPTBN1	0.36	4.83	0.44	5.14e-6	Schizophrenia;
THYM	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg06582575	chr6:163149167	PACRG;PARK2	1.02	6.67	0.56	1.66e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs2404602	0.552	rs4886823	chr15:76965402	A/G	cg23625390	chr15:77176239	SCAPER	-0.75	-4.87	-0.45	4.53e-6	Blood metabolite levels;
THYM	cis	rs2742417	0.603	rs2742448	chr3:45764246	C/T	cg04837898	chr3:45731254	SACM1L	0.73	5.21	0.47	1.08e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg21433313	chr16:3507492	NAT15	-0.56	-4.9	-0.45	3.9e-6	Body mass index (adult);
THYM	cis	rs7106204	0.920	rs7946615	chr11:24221036	T/C	ch.11.24196551F	chr11:24239977	NA	0.96	6.08	0.53	2.49e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs6988636	1.000	rs16898097	chr8:124195034	G/C	cg22384356	chr8:124195192	FAM83A	-0.82	-5.02	-0.46	2.43e-6	Urinary uromodulin levels;
THYM	cis	rs4389656	0.767	rs369769	chr5:6720712	T/C	cg10857441	chr5:6722123	POLS	-0.44	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs524023	0.958	rs3825016	chr11:64359286	C/T	cg19131476	chr11:64387923	NRXN2	-0.35	-4.84	-0.44	4.98e-6	Urate levels in obese individuals;
THYM	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg20887711	chr4:1340912	KIAA1530	0.66	5.61	0.5	2.02e-7	Longevity;
THYM	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg05283184	chr6:79620031	NA	-0.94	-9.22	-0.69	7.51e-15	Intelligence (multi-trait analysis);
THYM	cis	rs3126085	0.515	rs4322234	chr1:152353768	A/G	cg10321714	chr1:152280068	FLG	-0.63	-4.55	-0.42	1.61e-5	Atopic dermatitis;
THYM	cis	rs34638657	0.827	rs6564996	chr16:82207542	T/C	cg09894383	chr16:82067445	HSD17B2	-0.5	-4.92	-0.45	3.63e-6	Lung adenocarcinoma;
THYM	cis	rs939658	1.000	rs8033963	chr15:79455350	C/T	cg17916960	chr15:79447300	NA	0.75	8.81	0.67	5.71e-14	Refractive error;
THYM	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg14675211	chr2:100938903	LONRF2	0.75	7.97	0.63	3.51e-12	Intelligence (multi-trait analysis);
THYM	cis	rs6570726	0.791	rs13202312	chr6:145913093	T/G	cg23711669	chr6:146136114	FBXO30	0.98	10.65	0.74	6.74e-18	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs750460	0.844	rs28588430	chr15:74223430	C/G	cg23484268	chr15:74220776	LOXL1	0.42	4.61	0.43	1.24e-5	Height;
THYM	cis	rs9467160	0.871	rs7762593	chr6:24449417	G/A	cg20631270	chr6:24437470	GPLD1	0.75	5.9	0.52	5.48e-8	Liver enzyme levels;
THYM	cis	rs4363385	0.818	rs2070964	chr1:153004213	C/T	cg13444842	chr1:152974279	SPRR3	-0.6	-4.88	-0.45	4.26e-6	Inflammatory skin disease;
THYM	trans	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg25214090	chr10:38739885	LOC399744	0.85	7.16	0.59	1.7e-10	Corneal astigmatism;
THYM	cis	rs7558911	0.711	rs12693930	chr2:202044232	G/A	cg12105450	chr2:202048100	CASP10	0.5	4.5	0.42	1.95e-5	Chronic lymphocytic leukemia;
THYM	cis	rs11608355	0.960	rs3742021	chr12:109883117	T/C	cg11367159	chr12:110044531	NA	0.65	6.28	0.54	9.91e-9	Neuroticism;
THYM	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.34	0.48	6.29e-7	Height;
THYM	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg24060327	chr5:131705240	SLC22A5	0.83	6.82	0.57	8.5e-10	Breast cancer;
THYM	cis	rs10946292	0.706	rs3012447	chr6:170432049	G/A	cg15033140	chr6:170411909	NA	0.61	4.45	0.42	2.32e-5	Obesity-related traits;
THYM	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg07537917	chr2:241836409	C2orf54	-0.26	-5.83	-0.51	7.57e-8	Urinary metabolites;
THYM	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11644478	chr21:40555479	PSMG1	1.03	8.47	0.66	3.02e-13	Cognitive function;
THYM	cis	rs1371867	0.875	rs1660344	chr8:101324659	A/G	cg00191853	chr8:101177733	SPAG1	-0.57	-5.6	-0.5	2.06e-7	Atrioventricular conduction;
THYM	cis	rs858239	0.730	rs858290	chr7:23248036	A/G	cg18081818	chr7:23246105	NA	-0.6	-5.43	-0.49	4.39e-7	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7860634	1.000	rs7860634	chr9:139089679	C/T	cg04455058	chr9:139085579	NA	0.65	6.09	0.53	2.34e-8	Thyroid hormone levels;
THYM	cis	rs9653442	0.609	rs2576678	chr2:100704810	T/C	cg07810366	chr2:100720526	AFF3	-0.41	-6.11	-0.53	2.21e-8	Type 1 diabetes;Rheumatoid arthritis;Intelligence (multi-trait analysis);
THYM	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg09165964	chr15:75287851	SCAMP5	-1.08	-10.79	-0.74	3.35e-18	Blood trace element (Zn levels);
THYM	cis	rs425277	0.585	rs3128294	chr1:2065343	G/C	cg09260853	chr1:2094483	PRKCZ	-0.5	-4.95	-0.45	3.22e-6	Height;
THYM	cis	rs863345	0.604	rs2054991	chr1:158506083	A/G	cg12129480	chr1:158549410	OR10X1	0.5	4.84	0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs4285028	0.948	rs35415993	chr3:121669236	C/A	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg13695892	chr22:41940480	POLR3H	-1.06	-8.47	-0.66	3.07e-13	Vitiligo;
THYM	cis	rs324014	0.874	rs324013	chr12:57510661	C/T	cg21147422	chr12:56664361	COQ10A	0.51	4.6	0.43	1.33e-5	Itch intensity from mosquito bite adjusted by bite size;Itch intensity from mosquito bite;
THYM	cis	rs7578361	0.918	rs4667426	chr2:150393466	C/A	cg17961725	chr2:150454027	NA	0.69	5.35	0.48	6.07e-7	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs11574514	1.000	rs75760574	chr16:67644173	G/A	cg09738193	chr16:67926317	PSKH1	-0.92	-4.49	-0.42	2e-5	Crohn's disease;
THYM	cis	rs586688	1.000	rs525492	chr1:201638858	G/A	cg07139329	chr1:201708558	NAV1	0.5	4.82	0.44	5.37e-6	Obesity-related traits;
THYM	cis	rs10782582	0.593	rs4646960	chr1:76211103	C/A	cg22875332	chr1:76189707	ACADM	-0.52	-4.82	-0.44	5.5e-6	Daytime sleep phenotypes;
THYM	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.66	-5.79	-0.51	8.93e-8	Chronic sinus infection;
THYM	cis	rs2455799	0.573	rs2470523	chr3:15768091	G/C	cg16303742	chr3:15540471	COLQ	-0.56	-5.98	-0.52	3.83e-8	Mean platelet volume;
THYM	trans	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg10856724	chr12:34555212	NA	-0.86	-7.61	-0.62	2.01e-11	Bladder cancer;
THYM	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg14972814	chr11:95582409	MTMR2	-0.71	-6.48	-0.55	4.09e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs9595908	0.897	rs12429688	chr13:33146212	G/T	cg12383807	chr13:33924137	NA	-0.53	-4.55	-0.42	1.59e-5	Body mass index;
THYM	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg10802521	chr3:52805072	NEK4	-0.79	-7.58	-0.61	2.3e-11	Intelligence (multi-trait analysis);
THYM	cis	rs17407555	0.657	rs73224462	chr4:10386992	C/A	cg11266682	chr4:10021025	SLC2A9	-0.52	-5.11	-0.46	1.68e-6	Schizophrenia (age at onset);
THYM	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.62	5.32	0.48	6.81e-7	Height;
THYM	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.73	-0.44	7.65e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg06521331	chr12:34319734	NA	-0.84	-6.43	-0.55	5e-9	Morning vs. evening chronotype;
THYM	cis	rs9807841	0.858	rs34626880	chr19:10840428	T/C	cg17848348	chr19:10766748	ILF3	-0.62	-5.01	-0.46	2.51e-6	Inflammatory skin disease;
THYM	cis	rs79387448	0.655	rs75579337	chr2:102917302	C/A	cg09003973	chr2:102972529	NA	1.25	6.26	0.54	1.12e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs73198271	0.740	rs10105920	chr8:8648737	A/G	cg15556689	chr8:8085844	FLJ10661	0.75	4.92	0.45	3.57e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs1448094	0.512	rs7134732	chr12:86241908	T/C	cg00310523	chr12:86230176	RASSF9	0.53	4.75	0.44	7.21e-6	Major depressive disorder;
THYM	cis	rs3812565	0.506	rs4259518	chr9:139322503	T/C	cg14115884	chr9:139300582	SDCCAG3	0.65	5.43	0.49	4.26e-7	Granulocyte percentage of myeloid white cells;
THYM	cis	rs12310956	0.532	rs11052935	chr12:33970946	C/T	cg10856724	chr12:34555212	NA	-0.75	-6.8	-0.57	9.1e-10	Morning vs. evening chronotype;
THYM	cis	rs9399401	0.601	rs9321870	chr6:142800758	A/T	cg04461802	chr6:142623433	GPR126	0.52	5.24	0.47	9.47e-7	Chronic obstructive pulmonary disease;
THYM	cis	rs6430585	0.702	rs73958637	chr2:136546927	C/T	cg23851026	chr2:136556271	LCT	0.74	7.29	0.6	9.19e-11	Corneal structure;
THYM	cis	rs1691799	0.867	rs1168330	chr12:66763167	C/T	cg16791601	chr12:66731901	HELB	0.64	5.6	0.5	2.09e-7	White blood cell count (basophil);
THYM	cis	rs6754311	0.593	rs10202489	chr2:136494186	G/A	cg07169764	chr2:136633963	MCM6	-0.65	-5.41	-0.49	4.61e-7	Mosquito bite size;
THYM	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg24375607	chr4:120327624	NA	0.64	5.36	0.48	5.86e-7	Corneal astigmatism;
THYM	cis	rs2299587	0.560	rs3913555	chr8:17781810	A/C	cg01800426	chr8:17659068	MTUS1	-0.69	-5.26	-0.48	8.75e-7	Economic and political preferences;
THYM	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg14784868	chr12:69753453	YEATS4	-1.13	-12.26	-0.78	2.8e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7000551	0.688	rs2948145	chr8:22367792	T/C	cg12081754	chr8:22256438	SLC39A14	0.64	6.07	0.53	2.59e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7084402	0.967	rs12259990	chr10:60297574	A/G	cg07615347	chr10:60278583	BICC1	-0.56	-5.21	-0.47	1.09e-6	Refractive error;
THYM	cis	rs4730276	0.674	rs66999558	chr7:107544531	G/A	cg23293999	chr7:106826042	HBP1	-0.6	-4.89	-0.45	4.08e-6	Ulcerative colitis;
THYM	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs61774743	0.681	rs10749805	chr1:41850182	C/T	cg08462924	chr1:41848221	NA	0.82	10.13	0.72	8.65e-17	Intelligence (multi-trait analysis);
THYM	cis	rs9549260	0.564	rs4943808	chr13:41293950	C/T	cg21288729	chr13:41239152	FOXO1	0.68	5.14	0.47	1.49e-6	Red blood cell count;
THYM	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.52	4.66	0.43	1.03e-5	Lymphocyte counts;
THYM	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.96	8.85	0.67	4.81e-14	Chronic sinus infection;
THYM	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg21226059	chr5:178986404	RUFY1	0.51	5.4	0.48	4.99e-7	Lung cancer;
THYM	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg24531977	chr5:56204891	C5orf35	-1.02	-8.53	-0.66	2.28e-13	Initial pursuit acceleration;
THYM	cis	rs12122100	0.696	rs12733095	chr1:146545741	C/T	cg03526459	chr1:146549940	NA	-0.66	-4.49	-0.42	1.97e-5	HIV-1 control;
THYM	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	4.88	0.45	4.25e-6	Prudent dietary pattern;
THYM	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Diabetic kidney disease;
THYM	cis	rs9790314	0.521	rs2122527	chr3:161091636	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-6.64	-0.56	1.93e-9	Morning vs. evening chronotype;
THYM	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg21100191	chr22:23484243	RTDR1	0.75	6.66	0.56	1.78e-9	Bone mineral density;
THYM	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs9362426	1.000	rs9450662	chr6:88088593	A/C	cg10393598	chr6:87862264	NA	-0.59	-4.7	-0.43	8.85e-6	Depressive episodes in bipolar disorder;
THYM	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg14345882	chr6:26364793	BTN3A2	0.62	5.74	0.51	1.14e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6570726	0.905	rs406799	chr6:145821837	G/C	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg06634786	chr22:41940651	POLR3H	0.72	5.18	0.47	1.25e-6	Vitiligo;
THYM	cis	rs17443541	0.507	rs6742907	chr2:200455180	C/A	cg03741458	chr2:200468445	NA	-0.78	-5.63	-0.5	1.84e-7	Intelligence (multi-trait analysis);
THYM	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg13390004	chr1:15929781	NA	0.63	4.8	0.44	5.87e-6	Systolic blood pressure;
THYM	cis	rs796364	0.589	rs6743217	chr2:201134914	G/A	cg17644776	chr2:200775616	C2orf69	-0.74	-4.47	-0.42	2.18e-5	Schizophrenia;
THYM	cis	rs35883536	0.528	rs10783138	chr1:101031061	C/T	cg09408571	chr1:101003634	GPR88	0.56	5.96	0.52	4.27e-8	Monocyte count;
THYM	cis	rs9479482	1.000	rs11155696	chr6:150357283	G/A	cg25797454	chr6:150327115	RAET1K	0.43	4.47	0.42	2.18e-5	Alopecia areata;
THYM	cis	rs1950500	0.545	rs1950501	chr14:24806800	C/G	cg22990158	chr14:24802150	ADCY4	-0.46	-5.03	-0.46	2.28e-6	Height;
THYM	trans	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg10856724	chr12:34555212	NA	-0.88	-7.81	-0.63	7.52e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs7404928	0.535	rs12926067	chr16:23927248	T/A	cg26685404	chr16:23957272	PRKCB	-0.58	-6.53	-0.56	3.16e-9	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg18402987	chr7:1209562	NA	0.64	5.02	0.46	2.4e-6	Longevity;Endometriosis;
THYM	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg27034606	chr17:28928453	LRRC37B2	0.84	5.56	0.5	2.48e-7	Body mass index;
THYM	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg04043695	chr12:129287642	SLC15A4	0.6	4.83	0.44	5.27e-6	Systemic lupus erythematosus;
THYM	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg08999081	chr20:33150536	PIGU	-0.55	-4.85	-0.45	4.82e-6	Height;
THYM	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg10755058	chr3:40428713	ENTPD3	-0.52	-4.45	-0.42	2.29e-5	Renal cell carcinoma;
THYM	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.56	-5.12	-0.46	1.62e-6	Lymphocyte counts;
THYM	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg13010199	chr12:38710504	ALG10B	0.73	5.82	0.51	7.99e-8	Heart rate;
THYM	cis	rs6424115	0.546	rs35993651	chr1:24180613	C/G	cg15997130	chr1:24165203	NA	-0.71	-5.97	-0.52	4.08e-8	Immature fraction of reticulocytes;
THYM	cis	rs7336332	0.598	rs12018313	chr13:28012266	C/A	cg22138327	chr13:27999177	GTF3A	0.62	4.62	0.43	1.21e-5	Weight;
THYM	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg11663144	chr21:46675770	NA	-0.71	-9.92	-0.71	2.44e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3741798	1.000	rs61922026	chr12:12486428	C/G	cg08615371	chr12:12503544	MANSC1	0.88	4.89	0.45	4.17e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg23058037	chr7:158824108	VIPR2	0.52	4.86	0.45	4.71e-6	Facial morphology (factor 20);
THYM	cis	rs1021993	0.553	rs5008730	chr1:209470007	G/A	cg24997231	chr1:209527535	NA	0.5	4.55	0.42	1.57e-5	Gut microbiome composition (winter);
THYM	trans	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg10856724	chr12:34555212	NA	-1.06	-7.79	-0.62	8.32e-12	Bladder cancer;
THYM	cis	rs4788570	0.584	rs4788548	chr16:71655361	A/G	cg06353428	chr16:71660113	MARVELD3	1.27	9.09	0.68	1.46e-14	Intelligence (multi-trait analysis);
THYM	cis	rs8071789	1.000	rs8071789	chr17:38006333	C/T	cg24910161	chr17:38119198	GSDMA	0.45	4.5	0.42	1.91e-5	Selective IgA deficiency;
THYM	trans	rs4596713	0.538	rs7865373	chr9:71765105	T/C	cg16512924	chr15:28394682	HERC2	0.83	6.91	0.58	5.43e-10	Headache;
THYM	cis	rs12410462	0.681	rs115959512	chr1:227599578	T/C	cg23173402	chr1:227635558	NA	0.83	6.46	0.55	4.49e-9	Major depressive disorder;
THYM	cis	rs7705502	0.780	rs56285306	chr5:173299900	T/C	cg18693985	chr5:173351052	CPEB4	-0.79	-5.72	-0.51	1.24e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs950394	1.000	rs12465971	chr2:104990379	A/T	cg20302975	chr2:105468274	NA	-0.78	-4.58	-0.43	1.4e-5	Schizophrenia;
THYM	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg18681998	chr4:17616180	MED28	0.82	6.96	0.58	4.31e-10	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs11225247	0.881	rs75561520	chr11:102263309	A/G	cg06323957	chr11:102217781	BIRC2	1.06	4.86	0.45	4.56e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg04234412	chr22:24373322	LOC391322	-1.02	-13.09	-0.8	5.56e-23	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs4589258	0.933	rs11019133	chr11:90405440	A/G	cg26834418	chr11:89957033	CHORDC1	0.5	4.48	0.42	2.06e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9522267	0.535	rs11069900	chr13:112233285	G/A	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs2625529	0.730	rs8182011	chr15:72389948	C/T	cg16672083	chr15:72433130	SENP8	0.5	4.48	0.42	2.11e-5	Red blood cell count;
THYM	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg00757033	chr12:89920650	WDR51B	0.75	10.23	0.72	5.28e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	1.13	9.49	0.7	2.05e-15	Cognitive test performance;
THYM	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg18876405	chr7:65276391	NA	0.7	5.95	0.52	4.42e-8	Aortic root size;
THYM	cis	rs12681287	0.752	rs9283958	chr8:87253048	T/C	cg27223183	chr8:87520930	FAM82B	-0.66	-5.0	-0.46	2.66e-6	Caudate activity during reward;
THYM	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg26354017	chr1:205819088	PM20D1	0.72	6.17	0.54	1.64e-8	Menarche (age at onset);
THYM	cis	rs7918232	0.891	rs10443987	chr10:27375377	A/T	cg14442939	chr10:27389572	ANKRD26	0.79	4.47	0.42	2.13e-5	Breast cancer;
THYM	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg13852791	chr20:30311386	BCL2L1	0.88	7.22	0.6	1.26e-10	Mean corpuscular hemoglobin;
THYM	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.65	0.74	6.85e-18	Prudent dietary pattern;
THYM	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06634786	chr22:41940651	POLR3H	-0.78	-5.76	-0.51	1.02e-7	Vitiligo;
THYM	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg23583168	chr7:148888333	NA	-1.05	-13.53	-0.81	7.04e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg06618935	chr21:46677482	NA	-0.99	-9.3	-0.69	5.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6815814	0.950	rs5743789	chr4:38833173	A/T	cg14665413	chr4:38859728	TLR6	-0.41	-4.87	-0.45	4.51e-6	Breast cancer;
THYM	cis	rs2456568	0.867	rs7935801	chr11:93658000	G/A	cg17595323	chr11:93583763	C11orf90	-0.58	-5.75	-0.51	1.06e-7	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg12219531	chr12:120966889	COQ5	0.79	6.38	0.55	6.43e-9	High light scatter reticulocyte count;
THYM	cis	rs11089937	0.637	rs988200	chr22:22509108	C/G	cg21401457	chr22:22472743	NA	0.58	4.6	0.43	1.28e-5	Periodontitis (PAL4Q3);
THYM	cis	rs425535	0.817	rs193263	chr4:74850823	T/A	cg07868155	chr4:74864709	CXCL5	0.66	5.57	0.5	2.41e-7	Blood protein levels;
THYM	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg14779329	chr11:130786720	SNX19	0.54	5.87	0.52	6.3e-8	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg03676636	chr4:99064102	C4orf37	-0.41	-5.8	-0.51	8.66e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2073300	1.000	rs6137983	chr20:23469465	C/A	cg12062639	chr20:23401060	NAPB	1.29	5.64	0.5	1.73e-7	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs9677476	0.738	rs72985811	chr2:232137146	A/C	cg07929768	chr2:232055508	NA	0.59	5.34	0.48	6.27e-7	Food antigen IgG levels;
THYM	cis	rs6032067	0.714	rs35343177	chr20:43845986	A/G	cg20256260	chr20:43936981	MATN4;RBPJL	-0.61	-5.89	-0.52	5.91e-8	Blood protein levels;
THYM	cis	rs75920871	0.528	rs1531707	chr11:116944712	G/A	cg20608306	chr11:116969690	SIK3	-0.53	-5.88	-0.52	5.96e-8	Subjective well-being;
THYM	cis	rs2295359	0.892	rs11209004	chr1:67613932	G/A	cg11235152	chr1:67600687	NA	0.7	5.96	0.52	4.24e-8	Psoriasis;
THYM	cis	rs61931739	0.817	rs10772144	chr12:34242463	A/C	cg06521331	chr12:34319734	NA	-0.64	-5.37	-0.48	5.62e-7	Morning vs. evening chronotype;
THYM	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.5	-0.66	2.65e-13	Monocyte count;
THYM	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg23161317	chr6:28129485	ZNF389	1.02	7.95	0.63	3.81e-12	Depression;
THYM	cis	rs6480314	1.000	rs3814184	chr10:69966251	G/A	cg27159792	chr10:69524182	NA	0.75	4.73	0.44	7.77e-6	Optic nerve measurement (disc area);
THYM	cis	rs3796619	1.000	rs4045481	chr4:1090625	C/T	cg27284194	chr4:1044797	NA	0.52	4.83	0.44	5.32e-6	Recombination rate (males);
THYM	cis	rs2303759	1.000	rs2303759	chr19:49869051	T/G	cg22590775	chr19:49891494	CCDC155	0.82	6.7	0.57	1.49e-9	Multiple sclerosis;
THYM	cis	rs4148689	1.000	rs4148688	chr7:117135025	C/G	cg17204129	chr7:117119601	CFTR	-0.64	-5.08	-0.46	1.85e-6	Gout;
THYM	cis	rs5760092	0.755	rs5760096	chr22:24247310	A/G	cg12419862	chr22:24373484	LOC391322	-0.64	-4.81	-0.44	5.56e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.63	5.41	0.49	4.79e-7	Height;
THYM	cis	rs8013055	0.796	rs35592422	chr14:105996593	G/C	cg23356831	chr14:105996513	TMEM121	0.61	6.39	0.55	6.06e-9	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
THYM	cis	rs988913	0.634	rs9464182	chr6:54921938	A/G	cg04690482	chr6:54711388	FAM83B	0.46	4.71	0.44	8.41e-6	Menarche (age at onset);
THYM	cis	rs7580658	0.929	rs2276583	chr2:128014684	G/A	cg10021288	chr2:128175891	PROC	-0.78	-6.82	-0.57	8.26e-10	Protein C levels;
THYM	cis	rs7851660	0.874	rs10818175	chr9:100633386	T/C	cg13688889	chr9:100608707	NA	-0.79	-5.92	-0.52	5.07e-8	Strep throat;
THYM	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg11366901	chr6:160182831	ACAT2	1.07	9.53	0.7	1.68e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs2067615	0.524	rs1882543	chr12:107067160	A/G	cg15890332	chr12:107067104	RFX4	-0.46	-5.34	-0.48	6.31e-7	Heart rate;
THYM	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg19761014	chr17:28927070	LRRC37B2	0.82	4.81	0.44	5.61e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2455799	0.533	rs2470513	chr3:15750056	G/A	cg16303742	chr3:15540471	COLQ	-0.56	-5.98	-0.52	3.83e-8	Mean platelet volume;
THYM	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg14972814	chr11:95582409	MTMR2	-0.63	-4.86	-0.45	4.64e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs147649347	1	rs147649347	chr2:24210076	GATAA/G	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
THYM	cis	rs7828089	1.000	rs7837521	chr8:22264151	G/T	cg13512537	chr8:22265999	SLC39A14	-0.63	-5.24	-0.47	9.82e-7	Verbal declarative memory;
THYM	cis	rs921968	0.565	rs1541777	chr2:219587291	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs3771570	0.901	rs73006381	chr2:242406654	G/C	cg21155796	chr2:242212141	HDLBP	1.14	5.7	0.5	1.33e-7	Prostate cancer;
THYM	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg21433313	chr16:3507492	NAT15	-0.87	-10.19	-0.72	6.57e-17	Tuberculosis;
THYM	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg21280719	chr6:42927975	GNMT	-0.51	-6.74	-0.57	1.24e-9	Alzheimer's disease in APOE e4+ carriers;
THYM	trans	rs9929218	0.551	rs7201437	chr16:68727130	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.06	12.89	0.8	1.44e-22	Colorectal cancer;
THYM	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg25072359	chr17:41440525	NA	0.65	4.57	0.42	1.47e-5	Menopause (age at onset);
THYM	cis	rs131777	0.577	rs5770928	chr22:51029091	G/C	cg25309564	chr22:51001381	C22orf41	0.59	4.55	0.42	1.57e-5	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg17173187	chr15:85201210	NMB	0.58	5.83	0.51	7.57e-8	Schizophrenia;
THYM	cis	rs288326	0.561	rs75473200	chr2:183762165	C/T	cg09997497	chr2:183902928	NCKAP1	1.22	5.35	0.48	6e-7	Blood protein levels;
THYM	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg02038168	chr22:39784481	NA	-0.69	-5.59	-0.5	2.15e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7731657	0.537	rs3962196	chr5:130372512	A/T	cg08523029	chr5:130500466	HINT1	-0.85	-5.98	-0.52	3.88e-8	Fasting plasma glucose;
THYM	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg01097406	chr16:89675127	NA	0.85	7.68	0.62	1.44e-11	Vitiligo;
THYM	cis	rs3847687	1.000	rs11061291	chr12:131518875	C/T	cg13586425	chr12:131519906	GPR133	-0.31	-4.83	-0.44	5.27e-6	Longevity;
THYM	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg18477163	chr1:228402036	OBSCN	0.57	6.33	0.54	8.11e-9	Diastolic blood pressure;
THYM	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg05335186	chr13:53173507	NA	-0.41	-5.15	-0.47	1.38e-6	Lewy body disease;
THYM	cis	rs2294693	0.947	rs4714417	chr6:40987782	A/G	cg14418226	chr6:40996092	UNC5CL	0.72	6.48	0.55	4.14e-9	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg26721908	chr21:47610096	LSS	-1.02	-7.79	-0.62	8.31e-12	Testicular germ cell tumor;
THYM	cis	rs11648796	0.717	rs10682	chr16:767430	C/G	cg01252526	chr16:711033	WDR90	-0.73	-6.85	-0.57	7.33e-10	Height;
THYM	cis	rs900145	0.773	rs11022753	chr11:13310854	A/G	cg13286116	chr11:13302098	ARNTL	0.58	4.48	0.42	2.11e-5	Menarche (age at onset);
THYM	cis	rs4455778	0.580	rs7455537	chr7:49076576	G/A	cg26309511	chr7:48887640	NA	0.69	5.99	0.52	3.78e-8	Lung cancer in never smokers;
THYM	cis	rs4242434	0.819	rs6999893	chr8:22465427	T/C	cg11461670	chr8:22454935	PDLIM2	-0.32	-6.32	-0.54	8.53e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2108622	0.727	rs3093193	chr19:15991914	C/G	cg13772218	chr19:15982569	NA	0.5	4.48	0.42	2.06e-5	Circulating phylloquinone levels;Vitamin E levels;Acenocoumarol maintenance dosage;Response to Vitamin E supplementation;Metabolite levels;Warfarin maintenance dose;
THYM	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg04865290	chr3:52927548	TMEM110	-0.96	-5.01	-0.46	2.52e-6	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg15052019	chr19:19431593	KIAA0892;SF4	0.69	5.35	0.48	5.98e-7	Tonsillectomy;
THYM	trans	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg17063962	chr7:91808500	NA	1.08	11.35	0.76	2.25e-19	Breast cancer;
THYM	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg06917634	chr15:78832804	PSMA4	-0.82	-7.3	-0.6	8.93e-11	Sudden cardiac arrest;
THYM	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg06108461	chr20:60628389	TAF4	-1.02	-8.05	-0.64	2.31e-12	Body mass index;
THYM	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg11764359	chr7:65958608	NA	-0.63	-4.75	-0.44	7.13e-6	Cotinine glucuronidation;
THYM	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg19677267	chr1:26645161	CD52;UBXN11	-0.44	-5.78	-0.51	9.33e-8	Granulocyte percentage of myeloid white cells;
THYM	cis	rs9915657	0.870	rs4140903	chr17:70133771	C/T	cg06234051	chr17:70120541	SOX9	-0.71	-6.55	-0.56	3e-9	Thyroid hormone levels;
THYM	cis	rs1472147	0.518	rs1565629	chr7:128445370	G/A	cg00734629	chr7:128471146	FLNC	0.76	4.49	0.42	1.98e-5	Calcium levels;
THYM	cis	rs2281845	0.965	rs3738263	chr1:201083506	A/G	cg22815214	chr1:201083145	CACNA1S	0.8	7.61	0.62	1.95e-11	Permanent tooth development;
THYM	cis	rs4474465	1.000	rs11237520	chr11:78201201	G/C	cg19901956	chr11:77921274	USP35	-0.65	-4.8	-0.44	5.97e-6	Alzheimer's disease (survival time);
THYM	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-1.05	-9.43	-0.7	2.73e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg08742575	chr21:47604166	C21orf56	0.75	5.66	0.5	1.58e-7	Testicular germ cell tumor;
THYM	cis	rs7973719	0.833	rs7962563	chr12:7353514	G/A	cg07052231	chr12:7363540	PEX5	0.59	5.02	0.46	2.44e-6	IgG glycosylation;
THYM	cis	rs12478296	1.000	rs55767645	chr2:242999350	G/A	cg06360820	chr2:242988706	NA	-1.18	-6.98	-0.58	3.9e-10	Obesity-related traits;
THYM	cis	rs2131877	0.830	rs62285217	chr3:194871405	G/A	cg21937377	chr3:194868750	C3orf21	0.39	4.53	0.42	1.69e-5	Non-small cell lung cancer;
THYM	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg18252515	chr7:66147081	NA	0.67	5.18	0.47	1.24e-6	Aortic root size;
THYM	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg10295955	chr4:187884368	NA	-1.2	-16.44	-0.86	1.58e-29	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg18402987	chr7:1209562	NA	0.7	4.99	0.46	2.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	trans	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs2279817	0.863	rs11203441	chr1:18026725	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.74	4.64	0.43	1.13e-5	Neuroticism;
THYM	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg02887458	chr19:19495540	GATAD2A	-0.49	-5.38	-0.48	5.37e-7	Bipolar disorder;
THYM	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg22535103	chr8:58192502	C8orf71	-0.88	-5.02	-0.46	2.42e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg12311346	chr5:56204834	C5orf35	0.61	4.61	0.43	1.23e-5	Initial pursuit acceleration;
THYM	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	8.51	0.66	2.52e-13	Cognitive test performance;
THYM	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg03517284	chr6:25882590	NA	0.71	5.59	0.5	2.14e-7	Schizophrenia;
THYM	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg13877915	chr19:58951672	ZNF132	0.57	4.72	0.44	8.22e-6	Uric acid clearance;
THYM	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9399401	0.667	rs12213892	chr6:142702234	A/G	cg03128060	chr6:142623767	GPR126	0.7	9.47	0.7	2.29e-15	Chronic obstructive pulmonary disease;
THYM	cis	rs3087591	0.960	rs34941185	chr17:29425587	G/A	cg24425628	chr17:29625626	OMG;NF1	0.64	5.52	0.49	2.89e-7	Hip circumference;
THYM	cis	rs7113850	0.541	rs77054343	chr11:24215636	A/G	ch.11.24196551F	chr11:24239977	NA	0.99	4.94	0.45	3.35e-6	Bone fracture in osteoporosis;
THYM	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg00277334	chr10:82204260	NA	-0.83	-9.82	-0.71	4.06e-16	Post bronchodilator FEV1;
THYM	cis	rs2109514	0.561	rs4273775	chr7:116094656	T/C	cg12739419	chr7:116140593	CAV2	-0.45	-4.49	-0.42	2.03e-5	Prevalent atrial fibrillation;
THYM	cis	rs713587	0.776	rs3731623	chr2:25163783	T/C	cg15423357	chr2:25149977	NA	0.61	6.54	0.56	3.06e-9	Body mass index in non-asthmatics;
THYM	cis	rs78366141	0.536	rs80239864	chr4:89698183	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	1.36	5.48	0.49	3.43e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs192264	0.680	rs1103969	chr16:65972818	T/G	cg02795155	chr16:66785218	DYNC1LI2	0.6	4.83	0.44	5.25e-6	Subjective well-being;
THYM	cis	rs919433	0.889	rs787995	chr2:198216853	T/G	cg00792783	chr2:198669748	PLCL1	0.76	5.45	0.49	3.89e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg10803722	chr21:46713166	LOC642852	-0.5	-6.17	-0.54	1.63e-8	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg12011299	chr4:100065546	ADH4	0.68	6.08	0.53	2.47e-8	Alcohol dependence;
THYM	cis	rs17125944	0.686	rs77625717	chr14:53336544	T/C	cg00686598	chr14:53173677	PSMC6	1.12	5.02	0.46	2.38e-6	Alzheimer's disease (late onset);
THYM	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	1.1	12.7	0.79	3.51e-22	Intelligence (multi-trait analysis);
THYM	trans	rs75518195	0.500	rs2347820	chr4:64716783	G/A	cg14706739	chr8:21916355	EPB49	0.76	7.25	0.6	1.09e-10	Triptolide cytotoxicity;
THYM	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg07648498	chr16:89883185	FANCA	0.61	4.78	0.44	6.45e-6	Vitiligo;
THYM	cis	rs11018874	0.532	rs11018867	chr11:89862345	C/T	cg05041596	chr11:89867385	NAALAD2	0.74	4.56	0.42	1.55e-5	White blood cell types;
THYM	cis	rs28595532	0.920	rs56124677	chr4:119772213	C/T	cg21605333	chr4:119757512	SEC24D	1.66	6.14	0.53	1.94e-8	Cannabis dependence symptom count;
THYM	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg10523679	chr1:76189770	ACADM	-0.92	-8.05	-0.64	2.32e-12	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg13395646	chr4:1353034	KIAA1530	-0.56	-4.69	-0.43	8.99e-6	Longevity;
THYM	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg12011299	chr4:100065546	ADH4	0.87	8.44	0.65	3.61e-13	Alcohol dependence;
THYM	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg26818010	chr10:134567672	INPP5A	-0.89	-7.1	-0.59	2.25e-10	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
THYM	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg18681998	chr4:17616180	MED28	0.79	6.77	0.57	1.06e-9	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg17911788	chr17:44343683	NA	0.59	5.92	0.52	5.02e-8	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg02782426	chr3:40428986	ENTPD3	0.53	4.67	0.43	9.83e-6	Renal cell carcinoma;
THYM	cis	rs7688540	0.771	rs12505835	chr4:297525	G/C	cg12746427	chr4:53362	ZNF718;ZNF595	0.69	4.74	0.44	7.38e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg24308560	chr3:49941425	MST1R	-0.63	-4.74	-0.44	7.57e-6	Body mass index;
THYM	cis	rs12586317	0.531	rs57856432	chr14:35719708	G/T	cg07166546	chr14:35805898	NA	-0.21	-5.07	-0.46	1.99e-6	Psoriasis;
THYM	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.59	5.3	0.48	7.4e-7	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs1021993	0.672	rs2660641	chr1:209509884	G/A	cg24997231	chr1:209527535	NA	0.51	4.66	0.43	1.03e-5	Gut microbiome composition (winter);
THYM	cis	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg00495681	chr13:53174319	NA	0.63	5.75	0.51	1.07e-7	Lewy body disease;
THYM	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg24846343	chr22:24311635	DDTL	0.44	5.33	0.48	6.63e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg03929089	chr4:120376271	NA	-0.94	-10.6	-0.74	8.79e-18	Coronary artery disease;
THYM	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg05025164	chr4:1340916	KIAA1530	0.88	6.83	0.57	8.17e-10	Longevity;
THYM	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg15445000	chr17:37608096	MED1	0.44	5.08	0.46	1.85e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13732083	chr21:47605072	C21orf56	-0.71	-4.99	-0.46	2.78e-6	Testicular germ cell tumor;
THYM	cis	rs988913	1.000	rs1503142	chr6:54818948	C/T	cg19716238	chr6:54711378	FAM83B	0.49	5.12	0.47	1.58e-6	Menarche (age at onset);
THYM	cis	rs1883415	0.759	rs2744586	chr6:24507676	A/C	cg00346970	chr6:24499591	ALDH5A1	0.47	5.66	0.5	1.61e-7	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs17539620	0.534	rs6557363	chr6:154827813	A/G	cg17771515	chr6:154831774	CNKSR3	0.85	5.11	0.46	1.65e-6	Lipoprotein (a) levels;
THYM	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg19077165	chr18:44547161	KATNAL2	0.5	5.84	0.51	7.15e-8	Personality dimensions;
THYM	trans	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg10856724	chr12:34555212	NA	-0.94	-8.39	-0.65	4.44e-13	Bladder cancer;
THYM	cis	rs11603020	0.950	rs11229063	chr11:57369730	G/A	cg19752551	chr11:57585705	CTNND1	-0.57	-4.8	-0.44	5.82e-6	Blood protein levels;
THYM	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-1.0	-8.66	-0.66	1.23e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11644478	chr21:40555479	PSMG1	-1.11	-9.87	-0.71	3.08e-16	Cognitive function;
THYM	cis	rs12478296	1.000	rs67535150	chr2:243046099	A/G	cg06360820	chr2:242988706	NA	-0.94	-5.72	-0.51	1.25e-7	Obesity-related traits;
THYM	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg17063962	chr7:91808500	NA	-1.1	-12.47	-0.79	1.01e-21	Breast cancer;
THYM	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg24675056	chr1:15929824	NA	0.73	5.89	0.52	5.95e-8	Systolic blood pressure;
THYM	cis	rs9906944	0.545	rs2088140	chr17:47094599	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.63	-6.38	-0.55	6.5e-9	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg25319279	chr11:5960081	NA	-0.66	-5.64	-0.5	1.73e-7	DNA methylation (variation);
THYM	cis	rs17818399	0.712	rs13008088	chr2:46781580	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.64	4.67	0.43	1.01e-5	Height;
THYM	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg09307838	chr4:120376055	NA	0.66	4.77	0.44	6.56e-6	Corneal astigmatism;
THYM	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg22920501	chr2:26401640	FAM59B	-0.74	-6.28	-0.54	9.97e-9	Gut microbiome composition (summer);
THYM	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg13609457	chr4:120235615	NA	0.54	5.02	0.46	2.4e-6	Corneal astigmatism;
THYM	cis	rs854765	0.718	rs6502629	chr17:17869642	A/G	cg16928487	chr17:17741425	SREBF1	-0.59	-5.44	-0.49	4.14e-7	Total body bone mineral density;
THYM	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg09904177	chr6:26538194	HMGN4	0.63	5.14	0.47	1.46e-6	Intelligence (multi-trait analysis);
THYM	cis	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg06521331	chr12:34319734	NA	-0.73	-5.66	-0.5	1.59e-7	Morning vs. evening chronotype;
THYM	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.76	0.44	7.04e-6	Bipolar disorder;
THYM	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7107174	0.892	rs1567891	chr11:78101985	A/G	cg02023728	chr11:77925099	USP35	0.63	6.01	0.53	3.35e-8	Testicular germ cell tumor;
THYM	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg24642439	chr20:33292090	TP53INP2	0.59	4.48	0.42	2.04e-5	Coronary artery disease;
THYM	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs13177918	0.626	rs13170300	chr5:149829311	G/A	cg14059543	chr5:149831962	NA	-0.94	-8.1	-0.64	1.86e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs62070183	0.938	rs9911168	chr17:31036154	C/T	cg23177095	chr17:30873196	MYO1D	0.65	5.15	0.47	1.43e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg11494091	chr17:61959527	GH2	0.7	6.39	0.55	6.1e-9	Height;
THYM	cis	rs9814567	0.762	rs13067564	chr3:134209956	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.71	6.01	0.53	3.37e-8	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg18758796	chr5:131593413	PDLIM4	0.51	4.83	0.44	5.32e-6	Breast cancer;
THYM	cis	rs11779988	0.545	rs208759	chr8:17807929	G/C	cg01800426	chr8:17659068	MTUS1	-0.75	-5.18	-0.47	1.25e-6	Breast cancer;
THYM	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg10760299	chr15:45669010	GATM	0.84	6.39	0.55	6.21e-9	Homoarginine levels;
THYM	cis	rs7084402	0.967	rs1658442	chr10:60318897	G/A	cg07615347	chr10:60278583	BICC1	0.56	5.15	0.47	1.4e-6	Refractive error;
THYM	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg09033563	chr22:24373618	LOC391322	-0.61	-5.62	-0.5	1.94e-7	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs28595532	0.920	rs114162429	chr4:119741078	T/C	cg21605333	chr4:119757512	SEC24D	1.62	6.39	0.55	6.15e-9	Cannabis dependence symptom count;
THYM	cis	rs860818	1.000	rs858282	chr7:23250035	T/C	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg15247329	chr7:2764246	NA	-0.71	-5.88	-0.52	6.01e-8	Height;
THYM	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg26116260	chr4:7069785	GRPEL1	0.58	4.75	0.44	7.16e-6	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
THYM	cis	rs6669072	0.510	rs1663707	chr1:91279749	G/A	cg08895590	chr1:91227319	NA	-0.41	-4.82	-0.44	5.41e-6	Cognitive function;
THYM	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.64	4.59	0.43	1.36e-5	Lung cancer in ever smokers;
THYM	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg07606381	chr6:8435919	SLC35B3	0.62	4.66	0.43	1.04e-5	Motion sickness;
THYM	cis	rs7833986	0.501	rs2719227	chr8:57043794	A/G	cg23139584	chr8:56987506	RPS20;SNORD54	-0.57	-6.61	-0.56	2.27e-9	Height;
THYM	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg17105886	chr17:28927953	LRRC37B2	1.18	6.06	0.53	2.79e-8	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs10479542	0.784	rs7702303	chr5:178986436	G/A	cg14820908	chr5:178986412	RUFY1	0.64	7.07	0.59	2.57e-10	Lung cancer;
THYM	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg00277334	chr10:82204260	NA	-0.84	-10.07	-0.72	1.16e-16	Post bronchodilator FEV1;
THYM	cis	rs6980334	1.000	rs6980334	chr7:137788492	A/G	cg18769353	chr7:137028617	PTN	-0.63	-5.06	-0.46	2.01e-6	Blood metabolite ratios;
THYM	cis	rs13256369	0.802	rs1060107	chr8:8561399	G/T	cg18904891	chr8:8559673	CLDN23	0.66	4.9	0.45	3.93e-6	Obesity-related traits;
THYM	cis	rs4866334	1.000	rs79038611	chr5:18503785	C/T	cg04591469	chr5:17810299	NA	-1.14	-4.6	-0.43	1.28e-5	IgG glycosylation;
THYM	cis	rs10504073	0.545	rs4406405	chr8:49957261	G/C	cg00325661	chr8:49890786	NA	1.07	10.28	0.73	4.26e-17	Blood metabolite ratios;
THYM	cis	rs2731664	0.792	rs385981	chr5:176886539	C/T	cg14098951	chr5:176875120	PRR7	0.57	5.17	0.47	1.31e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg06917634	chr15:78832804	PSMA4	-0.68	-4.74	-0.44	7.57e-6	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs919433	0.680	rs1961558	chr2:198487278	C/T	cg00792783	chr2:198669748	PLCL1	0.82	5.77	0.51	9.79e-8	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg22920501	chr2:26401640	FAM59B	-0.83	-7.3	-0.6	8.69e-11	Gut microbiome composition (summer);
THYM	cis	rs986417	1.000	rs10142455	chr14:60980963	G/A	cg27398547	chr14:60952738	C14orf39	1.25	6.45	0.55	4.74e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg18512352	chr11:47633146	NA	-0.53	-6.56	-0.56	2.75e-9	Subjective well-being;
THYM	cis	rs4363385	0.588	rs6661059	chr1:153027257	A/T	cg13444842	chr1:152974279	SPRR3	-0.62	-4.96	-0.45	3.14e-6	Inflammatory skin disease;
THYM	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg12310025	chr6:25882481	NA	-0.92	-8.34	-0.65	5.62e-13	Blood metabolite levels;
THYM	cis	rs2732480	0.577	rs1489109	chr12:48738780	C/A	cg21466736	chr12:48725269	NA	-0.6	-5.35	-0.48	6.07e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.97	8.79	0.67	6.29e-14	Chronic sinus infection;
THYM	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.96	8.59	0.66	1.68e-13	Colorectal cancer;
THYM	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg14784868	chr12:69753453	YEATS4	1.13	12.31	0.78	2.2e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs4803468	1.000	rs284655	chr19:41928765	C/T	cg09537434	chr19:41945824	ATP5SL	-1.06	-9.61	-0.7	1.1e-15	Height;
THYM	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg18230493	chr5:56204884	C5orf35	-0.86	-6.17	-0.54	1.63e-8	Initial pursuit acceleration;
THYM	cis	rs2742234	0.504	rs10899780	chr10:43725796	T/C	cg06632098	chr10:43605906	RET	0.8	5.26	0.47	8.98e-7	Hirschsprung disease;
THYM	cis	rs72627123	0.867	rs58894370	chr14:74485382	C/T	cg12022184	chr14:74485813	ENTPD5;C14orf45	0.88	5.03	0.46	2.28e-6	Morning vs. evening chronotype;
THYM	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg10505658	chr17:80084571	CCDC57	0.73	8.14	0.64	1.56e-12	Life satisfaction;
THYM	cis	rs6427356	0.513	rs10908533	chr1:157147574	A/C	cg27547283	chr1:156698502	C1orf66;ISG20L2	-0.58	-4.49	-0.42	2.02e-5	Attention deficit hyperactivity disorder and conduct disorder;
THYM	cis	rs73198271	0.740	rs10105690	chr8:8649232	G/T	cg15556689	chr8:8085844	FLJ10661	-0.75	-4.92	-0.45	3.57e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.72	0.51	1.23e-7	Lung cancer in ever smokers;
THYM	cis	rs11645898	0.935	rs11640722	chr16:72172300	C/T	cg14768367	chr16:72042858	DHODH	-0.77	-5.59	-0.5	2.21e-7	Blood protein levels;
THYM	cis	rs6815814	0.898	rs1106956	chr4:38889811	A/G	cg14665413	chr4:38859728	TLR6	-0.39	-4.49	-0.42	1.98e-5	Breast cancer;
THYM	cis	rs8067545	0.750	rs28603224	chr17:19985052	G/A	cg13482628	chr17:19912719	NA	0.59	5.0	0.46	2.64e-6	Schizophrenia;
THYM	cis	rs4642101	0.662	rs1969154	chr3:12829156	A/G	cg11882607	chr3:12858926	CAND2	-0.4	-4.52	-0.42	1.76e-5	QRS complex (12-leadsum);
THYM	cis	rs526231	0.667	rs187580	chr5:102627355	T/G	cg23492399	chr5:102201601	PAM	-0.69	-4.65	-0.43	1.09e-5	Primary biliary cholangitis;
THYM	cis	rs11574514	1.000	rs74645730	chr16:67749378	G/T	cg09738193	chr16:67926317	PSKH1	-0.92	-4.53	-0.42	1.69e-5	Crohn's disease;
THYM	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg18904891	chr8:8559673	CLDN23	-0.6	-4.89	-0.45	4.08e-6	Mood instability;
THYM	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg23851026	chr2:136556271	LCT	-0.56	-5.9	-0.52	5.57e-8	Mosquito bite size;
THYM	cis	rs1050631	0.564	rs684890	chr18:33744677	T/C	cg25426722	chr18:33708991	SLC39A6;ELP2	0.64	5.0	0.46	2.61e-6	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg06221963	chr1:154839813	KCNN3	-0.85	-10.07	-0.72	1.16e-16	Prostate cancer;
THYM	cis	rs3772130	1.000	rs33988592	chr3:121415610	G/A	cg01951420	chr3:121553821	IQCB1;EAF2	0.74	4.67	0.43	9.91e-6	Cognitive performance;
THYM	cis	rs2403083	0.697	rs2403086	chr8:86113204	C/G	cg13721134	chr8:86350390	CA3	0.49	4.74	0.44	7.55e-6	Plasma amyloid beta peptide concentrations (ABx-40);
THYM	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	5.92	0.52	5.15e-8	Total body bone mineral density;
THYM	cis	rs4343996	0.676	rs4358698	chr7:3378616	A/T	cg21248987	chr7:3385318	SDK1	-0.37	-4.47	-0.42	2.16e-5	Motion sickness;
THYM	cis	rs425277	0.606	rs2257182	chr1:2082566	C/T	cg13918804	chr1:2043761	PRKCZ	0.68	6.08	0.53	2.45e-8	Height;
THYM	cis	rs11096990	0.656	rs2123027	chr4:39291113	C/T	cg24403649	chr4:39172243	NA	-0.64	-5.48	-0.49	3.43e-7	Cognitive function;
THYM	trans	rs11098499	0.657	rs10434028	chr4:120294464	T/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.92	-0.58	5.35e-10	Corneal astigmatism;
THYM	cis	rs3733631	1.000	rs3733631	chr4:104641103	G/C	cg24090629	chr4:104641072	TACR3	-0.86	-5.51	-0.49	3.1e-7	Menarche (age at onset);
THYM	cis	rs7964899	1.000	rs10845979	chr12:14492516	A/G	cg24274211	chr12:13658913	NA	0.48	4.68	0.43	9.52e-6	Educational attainment (years of education);
THYM	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg24655701	chr11:122023504	LOC399959;MIR100	0.86	7.03	0.58	3.07e-10	Energy expenditure (24h);
THYM	cis	rs2276498	0.751	rs11905945	chr20:52658593	C/T	cg23682609	chr20:52687365	BCAS1	-0.6	-4.79	-0.44	6.11e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs75139539	0.661	rs72883868	chr1:43959126	T/C	cg06872673	chr1:43127922	PPIH	1.28	4.72	0.44	7.99e-6	Plateletcrit;
THYM	cis	rs12791968	0.765	rs12790121	chr11:45001089	G/A	cg11846598	chr11:44996168	LOC221122	-0.82	-6.07	-0.53	2.59e-8	Inhibitory control;
THYM	cis	rs3741151	1.000	rs75109191	chr11:73023532	T/C	cg12959048	chr11:73096162	RELT	-0.5	-4.78	-0.44	6.38e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs2882877	0.648	rs66883355	chr2:190397021	G/A	cg10752008	chr2:190445175	SLC40A1	0.72	6.14	0.53	1.9e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg14349672	chr11:133703707	NA	-0.54	-4.77	-0.44	6.63e-6	Childhood ear infection;
THYM	cis	rs651907	0.512	rs771324	chr3:101610365	T/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	6.15	0.53	1.84e-8	Colorectal cancer;
THYM	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg20203395	chr5:56204925	C5orf35	0.67	4.57	0.42	1.45e-5	Initial pursuit acceleration;
THYM	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg24250549	chr1:154909240	PMVK	0.78	6.77	0.57	1.05e-9	Prostate cancer;
THYM	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7781557	1.000	rs11496066	chr7:102486254	T/C	cg06322601	chr7:102330635	NA	0.67	5.05	0.46	2.1e-6	Colorectal adenoma (advanced);
THYM	cis	rs10208940	0.614	rs13002040	chr2:68833658	A/G	cg09157127	chr2:69201416	GKN1	0.89	4.71	0.43	8.61e-6	Urate levels in lean individuals;
THYM	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg14004847	chr7:1930337	MAD1L1	-0.68	-5.36	-0.48	5.74e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7572733	0.534	rs700674	chr2:198693703	C/T	cg00792783	chr2:198669748	PLCL1	0.84	5.89	0.52	5.8e-8	Dermatomyositis;
THYM	cis	rs7523273	0.606	rs2724398	chr1:207993699	A/G	cg22525895	chr1:207977042	MIR29B2	-0.94	-9.82	-0.71	3.93e-16	Schizophrenia;
THYM	cis	rs921968	0.565	rs35358516	chr2:219625723	A/C	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs5769765	0.671	rs138841	chr22:50181960	C/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.49	4.68	0.43	9.46e-6	Schizophrenia;
THYM	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs2439831	0.867	rs2242068	chr15:43699304	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.73	4.91	0.45	3.73e-6	Lung cancer in ever smokers;
THYM	cis	rs9549260	0.564	rs9646110	chr13:41308301	A/T	cg21288729	chr13:41239152	FOXO1	-0.65	-4.82	-0.44	5.47e-6	Red blood cell count;
THYM	cis	rs2806561	1.000	rs2806561	chr1:23504795	C/T	cg08872493	chr1:23521417	HTR1D	-0.39	-5.06	-0.46	2.05e-6	Height;
THYM	cis	rs901683	0.702	rs113019116	chr10:46093939	A/G	cg18240400	chr10:46168597	ANUBL1	0.64	4.8	0.44	5.9e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs77236434	0.826	rs73562574	chr8:13180329	C/G	cg06835018	chr8:12272982	NA	-0.74	-4.46	-0.42	2.25e-5	Familial hepatitis B virus-related hepatocellular carcinoma;
THYM	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg16414030	chr3:133502952	NA	-0.84	-8.28	-0.65	7.65e-13	Iron status biomarkers;
THYM	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg03388043	chr17:80084554	CCDC57	0.69	5.87	0.52	6.34e-8	Life satisfaction;
THYM	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs56161922	0.908	rs55952744	chr1:207860158	C/G	cg09557387	chr1:207818395	CR1L	1.27	5.76	0.51	1.02e-7	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
THYM	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg06656553	chr16:89960601	TCF25	-0.95	-4.58	-0.43	1.41e-5	Skin colour saturation;
THYM	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs4482178	0.850	rs79255836	chr13:86265862	C/T	cg25308322	chr13:86268291	NA	0.68	4.75	0.44	7.32e-6	Amyotrophic lateral sclerosis (sporadic);
THYM	cis	rs2742417	0.609	rs11709306	chr3:45773732	G/A	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs9826463	0.582	rs11708870	chr3:142070013	A/G	cg20824294	chr3:142316082	PLS1	0.76	5.28	0.48	8.31e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg17063962	chr7:91808500	NA	-1.1	-12.47	-0.79	1.01e-21	Breast cancer;
THYM	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.96	-8.0	-0.63	2.98e-12	Lymphocyte percentage of white cells;
THYM	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg22920501	chr2:26401640	FAM59B	-0.75	-6.42	-0.55	5.4e-9	Gut microbiome composition (summer);
THYM	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg14584255	chr6:163149320	PACRG;PARK2	0.66	5.22	0.47	1.07e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg01579765	chr21:45077557	HSF2BP	0.5	8.14	0.64	1.54e-12	Mean corpuscular volume;
THYM	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg23428387	chr22:49814324	NA	-0.53	-4.89	-0.45	4.02e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg27170947	chr2:26402098	FAM59B	-0.77	-5.97	-0.52	4.12e-8	Gut microbiome composition (summer);
THYM	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg27284194	chr4:1044797	NA	-0.64	-4.89	-0.45	4.08e-6	Recombination rate (females);
THYM	cis	rs17739794	0.764	rs2336409	chr8:809079	A/C	cg01971667	chr8:817044	NA	-0.8	-6.96	-0.58	4.3e-10	Clozapine-induced cytotoxicity;
THYM	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg21100191	chr22:23484243	RTDR1	0.75	6.65	0.56	1.84e-9	Bone mineral density;
THYM	cis	rs28595532	0.844	rs116721336	chr4:119536538	A/G	cg11846333	chr4:119757529	SEC24D	1.36	4.83	0.44	5.23e-6	Cannabis dependence symptom count;
THYM	cis	rs7044106	0.791	rs2900177	chr9:123497645	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.76	6.47	0.55	4.16e-9	Hip circumference adjusted for BMI;
THYM	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg16624210	chr5:671434	TPPP	0.76	5.63	0.5	1.86e-7	Obesity-related traits;
THYM	cis	rs858239	0.636	rs28706766	chr7:23169834	T/A	cg18081818	chr7:23246105	NA	-0.53	-4.72	-0.44	7.96e-6	Cerebrospinal fluid biomarker levels;
THYM	cis	rs7727544	0.606	rs72795121	chr5:131638324	T/A	cg14196790	chr5:131705035	SLC22A5	0.52	4.93	0.45	3.43e-6	Blood metabolite levels;
THYM	cis	rs2455799	0.613	rs13080145	chr3:15880060	C/G	cg16303742	chr3:15540471	COLQ	-0.53	-5.59	-0.5	2.12e-7	Mean platelet volume;
THYM	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.77	6.56	0.56	2.79e-9	Tonsillectomy;
THYM	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg14416269	chr4:6271139	WFS1	-0.56	-5.68	-0.5	1.48e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs11628318	0.515	rs10144272	chr14:103086289	T/G	cg27124170	chr14:102829869	TECPR2;CINP	-0.65	-4.47	-0.42	2.15e-5	Platelet count;
THYM	cis	rs2688608	0.592	rs7909802	chr10:75484186	G/C	cg23231163	chr10:75533350	FUT11	-0.41	-5.9	-0.52	5.54e-8	Inflammatory bowel disease;
THYM	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg16405210	chr4:1374714	KIAA1530	-0.67	-5.43	-0.49	4.37e-7	Longevity;
THYM	cis	rs6840360	0.593	rs1429559	chr4:152681952	A/G	cg22705602	chr4:152727874	NA	-0.82	-11.14	-0.75	6.26e-19	Intelligence (multi-trait analysis);
THYM	cis	rs11690935	0.632	rs62184165	chr2:172558328	A/G	cg13550731	chr2:172543902	DYNC1I2	0.68	5.43	0.49	4.3e-7	Schizophrenia;
THYM	cis	rs4595586	0.545	rs7486598	chr12:39371159	C/T	cg26384229	chr12:38710491	ALG10B	0.72	5.42	0.49	4.52e-7	Morning vs. evening chronotype;
THYM	cis	rs8114671	0.562	rs1801310	chr20:33517014	A/G	cg08999081	chr20:33150536	PIGU	0.63	5.21	0.47	1.09e-6	Height;
THYM	cis	rs7927771	0.524	rs7129797	chr11:47667167	G/C	cg20307385	chr11:47447363	PSMC3	0.61	4.66	0.43	1.03e-5	Subjective well-being;
THYM	cis	rs11690935	0.632	rs34242651	chr2:172553999	G/A	cg13550731	chr2:172543902	DYNC1I2	0.67	5.33	0.48	6.5e-7	Schizophrenia;
THYM	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg11812906	chr14:75593930	NEK9	-0.87	-7.93	-0.63	4.14e-12	Height;
THYM	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg16989719	chr2:238392110	NA	-0.6	-5.82	-0.51	8.08e-8	Prostate cancer;
THYM	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg18806716	chr10:30721971	MAP3K8	-0.52	-4.72	-0.44	8.07e-6	Inflammatory bowel disease;
THYM	cis	rs6495367	1.000	rs1007366	chr15:79379541	G/A	cg17916960	chr15:79447300	NA	0.59	6.47	0.55	4.32e-9	Spherical equivalent (joint analysis main effects and education interaction);
THYM	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg27394845	chr17:28928406	LRRC37B2	0.97	4.85	0.45	4.9100000000000004e-06	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg12011299	chr4:100065546	ADH4	-0.87	-8.39	-0.65	4.49e-13	Alcohol dependence;
THYM	cis	rs11809207	0.501	rs3762460	chr1:26495550	A/G	cg00147160	chr1:26503991	CNKSR1	0.5	6.41	0.55	5.66e-9	Height;
THYM	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg23281280	chr6:28129359	ZNF389	0.61	4.94	0.45	3.3e-6	Depression;
THYM	cis	rs476633	0.573	rs2099652	chr15:41528745	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.88	-6.99	-0.58	3.82e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs9388451	0.536	rs34725880	chr6:126155237	A/G	cg05901451	chr6:126070800	HEY2	-0.6	-4.48	-0.42	2.1e-5	Brugada syndrome;
THYM	cis	rs483180	0.859	rs478093	chr1:120255126	C/T	cg19096424	chr1:120255104	PHGDH	-0.87	-7.33	-0.6	7.66e-11	Macular telangiectasia type 2;
THYM	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.89	8.09	0.64	1.91e-12	Monocyte percentage of white cells;
THYM	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22496380	chr5:211416	CCDC127	-1.44	-9.2	-0.69	8.29e-15	Breast cancer;
THYM	cis	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg21775007	chr8:11205619	TDH	-0.73	-5.68	-0.5	1.49e-7	Retinal vascular caliber;
THYM	cis	rs654950	1.000	rs621680	chr1:41984584	C/T	cg06885757	chr1:42089581	HIVEP3	-0.52	-6.87	-0.58	6.69e-10	Airway imaging phenotypes;
THYM	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg10518543	chr12:38710700	ALG10B	-0.57	-4.54	-0.42	1.67e-5	Morning vs. evening chronotype;
THYM	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg04267008	chr7:1944627	MAD1L1	-0.63	-5.77	-0.51	1.01e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs9992101	0.547	rs13146163	chr4:77412091	G/T	cg20311846	chr4:77356250	SHROOM3	-0.45	-4.72	-0.44	8.12e-6	Creatinine levels;
THYM	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg11905131	chr22:24372483	LOC391322	0.71	6.3	0.54	9.25e-9	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs17253792	0.822	rs75049893	chr14:56089158	A/G	cg01858014	chr14:56050164	KTN1	-1.19	-4.86	-0.45	4.66e-6	Putamen volume;
THYM	cis	rs4499344	1.000	rs4499344	chr19:33073431	G/A	cg27413643	chr19:33165484	ANKRD27;RGS9BP	-0.81	-6.2	-0.54	1.46e-8	Mean platelet volume;
THYM	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg14690197	chr8:22456421	C8orf58	0.52	4.89	0.45	4.07e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs12410462	0.579	rs116701416	chr1:227641947	G/A	cg23173402	chr1:227635558	NA	1.03	6.45	0.55	4.64e-9	Major depressive disorder;
THYM	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg08885076	chr2:99613938	TSGA10	0.62	5.67	0.5	1.5e-7	Chronic sinus infection;
THYM	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg15744005	chr10:104629667	AS3MT	-0.82	-7.79	-0.62	8.37e-12	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg22841779	chr14:105766346	BRF1	-0.47	-5.88	-0.52	6.12e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs8067235	1.000	rs8067235	chr17:79024637	A/G	cg12472449	chr17:79022879	BAIAP2	-0.66	-6.13	-0.53	1.97e-8	Memory performance;
THYM	cis	rs1045902	0.532	rs2288631	chr2:73455747	C/T	cg24220031	chr2:73402428	NA	-0.59	-4.92	-0.45	3.57e-6	Intelligence (multi-trait analysis);
THYM	cis	rs7224737	1.000	rs731152	chr17:40279680	G/A	cg02228675	chr17:40259724	DHX58	-0.66	-5.49	-0.49	3.28e-7	Fibrinogen levels;
THYM	cis	rs7267979	1.000	rs2387881	chr20:25378172	A/G	cg08601574	chr20:25228251	PYGB	-0.59	-4.81	-0.44	5.66e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4389656	0.740	rs274706	chr5:6726629	T/C	cg10857441	chr5:6722123	POLS	-0.44	-4.59	-0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg08994789	chr17:28903642	LRRC37B2	-1.0	-4.97	-0.45	3.01e-6	Body mass index;
THYM	cis	rs12620999	0.878	rs7593514	chr2:237980691	A/G	cg15976283	chr2:238042351	NA	-0.58	-4.58	-0.43	1.42e-5	Systemic lupus erythematosus;
THYM	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg06112835	chr11:68658793	MRPL21	0.43	6.3	0.54	9.11e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg03676636	chr4:99064102	C4orf37	0.45	6.84	0.57	7.76e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg15693483	chr7:1102177	C7orf50	0.52	6.02	0.53	3.29e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg24818145	chr4:99064322	C4orf37	0.75	6.04	0.53	2.94e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11645898	0.935	rs72787077	chr16:72156674	C/T	cg03805757	chr16:71968109	PKD1L3	-0.73	-5.29	-0.48	7.84e-7	Blood protein levels;
THYM	cis	rs11674184	0.743	rs12470971	chr2:11725241	A/G	cg07314298	chr2:11723111	GREB1	0.62	5.96	0.52	4.33e-8	Endometriosis;
THYM	cis	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg26384229	chr12:38710491	ALG10B	-0.71	-5.66	-0.5	1.58e-7	Morning vs. evening chronotype;
THYM	cis	rs12519773	0.967	rs1496331	chr5:92445784	G/T	cg18783429	chr5:92414398	NA	0.48	4.55	0.42	1.59e-5	Migraine;
THYM	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.79	-0.82	2.08e-24	Height;
THYM	cis	rs9807989	0.507	rs10208196	chr2:102996345	G/A	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg01699819	chr7:1052092	C7orf50	-0.57	-4.82	-0.44	5.34e-6	Bronchopulmonary dysplasia;
THYM	cis	rs3126085	0.935	rs11588174	chr1:152175970	C/T	cg26020982	chr1:152196106	HRNR	-0.34	-4.52	-0.42	1.76e-5	Atopic dermatitis;
THYM	cis	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg06565975	chr8:143823917	SLURP1	0.44	4.93	0.45	3.51e-6	Urinary tract infection frequency;
THYM	cis	rs7917772	0.582	rs12411442	chr10:104349531	A/G	cg00122347	chr10:104236741	TMEM180	-0.41	-5.81	-0.51	8.15e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs1538970	0.816	rs61788356	chr1:46006675	C/T	cg05343316	chr1:45956843	TESK2	0.83	5.28	0.48	8.03e-7	Platelet count;
THYM	cis	rs6032067	1.000	rs13041304	chr20:43811697	G/A	cg20256260	chr20:43936981	MATN4;RBPJL	-0.71	-6.68	-0.57	1.6e-9	Blood protein levels;
THYM	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.53	-4.51	-0.42	1.87e-5	Menarche (age at onset);
THYM	cis	rs865483	0.764	rs113593735	chr17:35755546	A/G	cg06716730	chr17:35851459	DUSP14	-0.43	-7.52	-0.61	3.11e-11	Monocyte count;
THYM	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs922692	1.000	rs72743199	chr15:78975855	A/T	cg15571903	chr15:79123663	NA	-0.58	-5.21	-0.47	1.1e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6669072	0.565	rs11578876	chr1:91281546	G/A	cg08895590	chr1:91227319	NA	-0.39	-4.45	-0.42	2.32e-5	Cognitive function;
THYM	cis	rs10411161	0.640	rs7252303	chr19:52389357	G/A	cg25361850	chr19:52391789	ZNF577	0.74	5.18	0.47	1.22e-6	Breast cancer;
THYM	cis	rs9921222	0.500	rs11648673	chr16:377794	G/A	cg07492924	chr16:433825	LOC100134368	0.52	5.51	0.49	3.04e-7	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs2240255	0.710	rs4999690	chr16:74778006	A/G	cg04447128	chr16:74771998	FA2H	0.57	5.21	0.47	1.11e-6	White matter lesion progression (adjusted for white matter lesion burden at baseline);
THYM	cis	rs1729951	0.514	rs75977	chr3:136700549	C/A	cg12473912	chr3:136751656	NA	0.63	5.12	0.46	1.61e-6	Neuroticism;
THYM	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg12386194	chr3:101231763	SENP7	0.71	5.39	0.48	5.17e-7	Colorectal cancer;
THYM	cis	rs4343996	0.521	rs10277545	chr7:3424362	C/T	cg21248987	chr7:3385318	SDK1	0.39	4.99	0.46	2.68e-6	Motion sickness;
THYM	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg24675658	chr1:53192096	ZYG11B	0.56	4.62	0.43	1.21e-5	Monocyte count;
THYM	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg15242686	chr22:24348715	GSTTP1	0.54	4.97	0.45	2.92e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7620363	1.000	rs7620363	chr3:34013205	C/T	cg25105657	chr3:33925802	NA	0.39	4.47	0.42	2.16e-5	Non-substance related behavioral disinhibition;
THYM	cis	rs7786877	0.723	rs7812123	chr7:100211556	C/A	cg04499151	chr7:100231278	TFR2	0.62	4.49	0.42	1.98e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17598306	0.873	rs2894085	chr7:96584407	G/C	cg26766885	chr7:96220185	NA	0.62	5.13	0.47	1.56e-6	Radiation response;
THYM	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg26384229	chr12:38710491	ALG10B	0.73	5.4	0.48	5.01e-7	Morning vs. evening chronotype;
THYM	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg22105103	chr4:187893119	NA	0.95	10.29	0.73	3.97e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg18252515	chr7:66147081	NA	-1.49	-9.3	-0.69	5.16e-15	Gout;
THYM	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg18876405	chr7:65276391	NA	-0.65	-5.53	-0.49	2.85e-7	Aortic root size;
THYM	cis	rs34638657	0.833	rs7200628	chr16:82200747	C/T	cg07307142	chr16:82071433	HSD17B2	-0.93	-8.28	-0.65	7.8e-13	Lung adenocarcinoma;
THYM	cis	rs7177699	0.567	rs67745769	chr15:79124832	G/A	cg00540400	chr15:79124168	NA	-0.64	-6.65	-0.56	1.89e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs7267979	0.833	rs4619688	chr20:25244101	C/G	cg08601574	chr20:25228251	PYGB	0.59	4.68	0.43	9.42e-6	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg13695892	chr22:41940480	POLR3H	0.89	7.04	0.59	3e-10	Vitiligo;
THYM	cis	rs7809950	0.871	rs11771278	chr7:107285925	C/T	cg23024343	chr7:107201750	COG5	0.66	5.62	0.5	1.94e-7	Coronary artery disease;
THYM	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg21475434	chr5:93447410	FAM172A	0.97	6.09	0.53	2.35e-8	Diabetic retinopathy;
THYM	trans	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg19862616	chr7:65841803	NCRNA00174	1.1	12.73	0.79	2.97e-22	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg06582575	chr6:163149167	PACRG;PARK2	1.06	7.53	0.61	2.92e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs586688	0.696	rs1256457	chr1:201659739	T/C	cg14168733	chr1:201708718	NAV1	-0.6	-5.55	-0.49	2.61e-7	Obesity-related traits;
THYM	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg02527881	chr3:46936655	PTH1R	0.53	5.06	0.46	2.01e-6	Colorectal cancer;
THYM	cis	rs4911259	0.593	rs6058924	chr20:31464467	G/A	cg13636640	chr20:31349939	DNMT3B	-0.63	-6.18	-0.54	1.61e-8	Inflammatory bowel disease;
THYM	cis	rs5769707	0.632	rs135876	chr22:50013573	A/G	cg17054759	chr22:49844102	NA	-0.53	-4.65	-0.43	1.09e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg06219351	chr7:158114137	PTPRN2	-0.74	-7.14	-0.59	1.86e-10	Calcium levels;
THYM	cis	rs7169223	0.653	rs1976007	chr15:79085023	T/C	cg21242079	chr15:79101063	ADAMTS7	0.52	4.85	0.45	4.74e-6	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs10791323	0.576	rs4937840	chr11:133734322	C/G	cg06766960	chr11:133703094	NA	-0.56	-5.39	-0.48	5.22e-7	Childhood ear infection;
THYM	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg20283391	chr11:68216788	NA	-0.65	-4.65	-0.43	1.07e-5	Total body bone mineral density (age 0-15);
THYM	cis	rs11696501	0.637	rs6130865	chr20:44211845	C/T	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.49	-0.42	2.03e-5	Brain structure;
THYM	trans	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.21	14.72	0.83	3.07e-26	Exhaled nitric oxide output;
THYM	cis	rs7106204	0.764	rs57490470	chr11:24234370	A/G	ch.11.24196551F	chr11:24239977	NA	0.87	4.66	0.43	1.04e-5	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs921968	0.565	rs4674329	chr2:219595507	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg25319279	chr11:5960081	NA	-0.62	-5.38	-0.48	5.42e-7	DNA methylation (variation);
THYM	cis	rs9533799	0.505	rs111293505	chr13:44821973	C/T	cg10230591	chr13:44818496	NA	-0.68	-4.49	-0.42	2.02e-5	Amyotrophic lateral sclerosis;
THYM	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	5.35	0.48	6.05e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs56309584	0.560	rs72479723	chr17:8076741	A/G	cg08322244	chr17:8066669	VAMP2	-0.55	-5.21	-0.47	1.09e-6	Initial pursuit acceleration;
THYM	cis	rs6598955	0.671	rs59143843	chr1:26641595	G/T	cg20415053	chr1:26527928	CATSPER4	-0.58	-4.71	-0.43	8.58e-6	Obesity-related traits;
THYM	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg04772025	chr11:68637568	NA	0.61	6.5	0.56	3.65e-9	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.55	5.07	0.46	1.97e-6	Rheumatoid arthritis;
THYM	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg02527881	chr3:46936655	PTH1R	0.54	5.21	0.47	1.1e-6	Colorectal cancer;
THYM	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg08067268	chr2:26466485	HADHB;HADHA	0.68	4.89	0.45	4.08e-6	Gut microbiome composition (summer);
THYM	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	5.5	0.49	3.19e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs4918072	0.754	rs4918065	chr10:105617578	T/C	cg11005552	chr10:105648138	OBFC1	0.65	4.92	0.45	3.58e-6	Coronary artery disease;
THYM	cis	rs2235649	0.843	rs9932890	chr16:1847868	G/T	cg03034668	chr16:1723424	CRAMP1L	0.57	4.91	0.45	3.81e-6	Blood metabolite levels;
THYM	cis	rs7428	0.545	rs9248	chr2:85537312	G/A	cg24342717	chr2:85555507	TGOLN2	-0.74	-6.45	-0.55	4.56e-9	Ear protrusion;
THYM	cis	rs35883536	1.000	rs17403905	chr1:101107358	T/C	cg06223162	chr1:101003688	GPR88	0.63	4.77	0.44	6.71e-6	Monocyte count;
THYM	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg13852791	chr20:30311386	BCL2L1	0.74	5.35	0.48	6.15e-7	Mean corpuscular hemoglobin;
THYM	cis	rs7172809	0.552	rs59204923	chr15:77819262	G/A	cg22256960	chr15:77711686	NA	-0.67	-4.83	-0.44	5.2e-6	Glucose homeostasis traits;
THYM	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg27535305	chr1:53392650	SCP2	-0.4	-4.58	-0.43	1.41e-5	Monocyte count;
THYM	cis	rs7572733	0.576	rs6734781	chr2:198759973	G/A	cg05783139	chr2:198650985	BOLL	0.62	4.84	0.44	5.09e-6	Dermatomyositis;
THYM	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg06238570	chr21:40685208	BRWD1	-0.68	-5.74	-0.51	1.15e-7	Menarche (age at onset);
THYM	cis	rs131805	1.000	rs131805	chr22:50964153	T/C	cg25309564	chr22:51001381	C22orf41	0.71	4.81	0.44	5.76e-6	Granulocyte percentage of myeloid white cells;
THYM	cis	rs2562456	1.000	rs2359155	chr19:21671869	C/A	cg21751540	chr19:21541537	ZNF738	0.64	4.51	0.42	1.84e-5	Pain;
THYM	cis	rs2115630	0.641	rs11073613	chr15:85185893	G/A	cg11189052	chr15:85197271	WDR73	-0.64	-5.12	-0.47	1.58e-6	P wave terminal force;
THYM	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.83	-7.04	-0.59	2.94e-10	Systemic lupus erythematosus;
THYM	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg12386194	chr3:101231763	SENP7	0.69	5.13	0.47	1.52e-6	Colorectal cancer;
THYM	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg23851026	chr2:136556271	LCT	0.5	4.69	0.43	9.14e-6	Mosquito bite size;
THYM	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg26384229	chr12:38710491	ALG10B	1.05	10.44	0.73	1.86e-17	Heart rate;
THYM	cis	rs8067545	0.611	rs7219615	chr17:20132558	T/A	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs11809207	0.523	rs2802343	chr1:26498570	T/C	cg26412358	chr1:26503933	CNKSR1	0.36	5.01	0.46	2.48e-6	Height;
THYM	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg05457628	chr5:178986728	RUFY1	0.64	6.53	0.56	3.29e-9	Lung cancer;
THYM	cis	rs7695732	0.595	rs9307055	chr4:89900252	T/C	cg17769793	chr4:89976368	FAM13A	-0.49	-5.39	-0.48	5.23e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs6539288	0.803	rs4479083	chr12:107321245	G/C	cg26297688	chr12:107349093	C12orf23	-0.52	-6.11	-0.53	2.16e-8	Total body bone mineral density;
THYM	cis	rs9912789	0.744	rs9893755	chr17:79187432	C/T	cg14413466	chr17:79170920	AZI1	0.62	4.91	0.45	3.81e-6	Frontotemporal dementia;
THYM	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg08017756	chr2:100939284	LONRF2	-0.75	-7.56	-0.61	2.54e-11	Intelligence (multi-trait analysis);
THYM	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg12935359	chr14:103987150	CKB	-0.63	-6.45	-0.55	4.63e-9	Body mass index;
THYM	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg15693483	chr7:1102177	C7orf50	0.51	5.81	0.51	8.44e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1062746	0.834	rs9308347	chr16:87371752	C/T	cg27365499	chr16:87376795	FBXO31	0.58	6.02	0.53	3.23e-8	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg12935359	chr14:103987150	CKB	0.53	5.96	0.52	4.33e-8	Intelligence (multi-trait analysis);
THYM	cis	rs7192380	0.965	rs3848278	chr16:69640867	T/C	cg09409435	chr16:70099608	PDXDC2	0.62	4.73	0.44	7.92e-6	Sjögren's syndrome;
THYM	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg06238570	chr21:40685208	BRWD1	0.89	6.46	0.55	4.38e-9	Cognitive function;
THYM	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg23131131	chr22:24373011	LOC391322	-0.86	-8.56	-0.66	1.94e-13	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg21775007	chr8:11205619	TDH	0.68	5.59	0.5	2.13e-7	Retinal vascular caliber;
THYM	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg06582575	chr6:163149167	PACRG;PARK2	1.11	7.46	0.61	3.98e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	4.6	0.43	1.29e-5	Rheumatoid arthritis;
THYM	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg24690094	chr11:67383802	NA	0.69	4.56	0.42	1.55e-5	Mean corpuscular volume;
THYM	cis	rs4343996	0.869	rs6974577	chr7:3511350	G/T	cg21248987	chr7:3385318	SDK1	0.4	4.68	0.43	9.52e-6	Motion sickness;
THYM	cis	rs11696501	0.688	rs6073833	chr20:44279894	T/G	cg11783356	chr20:44313418	WFDC10B	-0.68	-4.74	-0.44	7.46e-6	Brain structure;
THYM	cis	rs919433	0.680	rs8539	chr2:198362018	A/G	cg00792783	chr2:198669748	PLCL1	0.8	5.54	0.49	2.64e-7	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg00898013	chr13:113819073	PROZ	-0.88	-9.0	-0.68	2.24e-14	Platelet distribution width;
THYM	cis	rs870825	0.860	rs72689295	chr4:185600930	T/C	cg04058563	chr4:185651563	MLF1IP	1.05	7.96	0.63	3.6e-12	Blood protein levels;
THYM	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg12560992	chr17:57184187	TRIM37	-0.92	-8.69	-0.67	1.04e-13	Intelligence (multi-trait analysis);
THYM	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg04455712	chr21:45112962	RRP1B	0.56	5.35	0.48	6.18e-7	Mean corpuscular volume;
THYM	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.68	-4.54	-0.42	1.68e-5	Body mass index (adult);
THYM	cis	rs2294693	0.945	rs9369260	chr6:41010368	C/G	cg14418226	chr6:40996092	UNC5CL	-0.72	-5.89	-0.52	5.85e-8	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs7695732	0.595	rs6532091	chr4:89877367	C/T	cg17769793	chr4:89976368	FAM13A	0.49	5.28	0.48	8.06e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg17855130	chr1:164819399	PBX1	-1.01	-7.12	-0.59	2.02e-10	Subcortical brain region volumes;
THYM	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg18131467	chr2:239335373	ASB1	1.08	10.3	0.73	3.84e-17	Multiple system atrophy;
THYM	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.76	-5.77	-0.51	9.89e-8	Total cholesterol levels;
THYM	cis	rs7814319	0.838	rs10955067	chr8:97230982	C/T	cg20787634	chr8:97240163	UQCRB	-0.7	-8.16	-0.64	1.39e-12	Lung function (FVC);
THYM	cis	rs6980334	0.817	rs3805361	chr7:137794519	C/T	cg11874123	chr7:137028198	PTN	0.67	5.17	0.47	1.29e-6	Blood metabolite ratios;
THYM	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg00376283	chr12:123451042	ABCB9	0.73	5.03	0.46	2.29e-6	Neutrophil percentage of white cells;
THYM	cis	rs673253	0.593	rs3791134	chr1:44049156	G/A	cg24466421	chr1:44070974	PTPRF	-0.6	-5.3	-0.48	7.53e-7	Intelligence (multi-trait analysis);
THYM	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg07636037	chr3:49044803	WDR6	0.98	10.05	0.72	1.28e-16	Parkinson's disease;
THYM	cis	rs2334880	0.678	rs12444714	chr16:71452606	C/T	cg06353428	chr16:71660113	MARVELD3	-0.98	-5.24	-0.47	9.84e-7	Malaria;
THYM	cis	rs59698941	0.943	rs10491278	chr5:132220436	A/C	cg02081065	chr5:132209139	LEAP2	-0.85	-5.74	-0.51	1.14e-7	Apolipoprotein A-IV levels;
THYM	trans	rs4749080	0.541	rs10828957	chr10:26445051	G/T	cg00192819	chr18:76486611	NA	1.0	7.09	0.59	2.41e-10	Obesity-related traits;
THYM	cis	rs8192282	0.739	rs12118074	chr1:154477585	G/A	cg16683920	chr1:154474344	TDRD10;SHE	-0.6	-5.48	-0.49	3.55e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs7772486	0.875	rs2777476	chr6:146345024	A/G	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11048434	0.736	rs1805722	chr12:9145056	T/C	cg04155231	chr12:9217510	LOC144571	0.5	4.95	0.45	3.27e-6	Sjögren's syndrome;
THYM	cis	rs12935418	0.616	rs2549854	chr16:81026639	C/T	cg16651780	chr16:81037892	C16orf61	0.81	6.15	0.53	1.81e-8	Mean corpuscular volume;
THYM	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg11189052	chr15:85197271	WDR73	-0.66	-5.15	-0.47	1.41e-6	P wave terminal force;
THYM	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg11882607	chr3:12858926	CAND2	-0.4	-4.48	-0.42	2.09e-5	QRS complex (12-leadsum);
THYM	cis	rs2439831	0.850	rs28509275	chr15:44098105	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.77	5.56	0.5	2.48e-7	Lung cancer in ever smokers;
THYM	cis	rs929596	0.606	rs10178992	chr2:234657877	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.92	-7.83	-0.63	7.02e-12	Total bilirubin levels in HIV-1 infection;
THYM	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg26384229	chr12:38710491	ALG10B	-0.89	-9.06	-0.68	1.67e-14	Heart rate;
THYM	cis	rs12950390	0.548	rs7215477	chr17:45858117	A/C	cg24803719	chr17:45855879	NA	-0.42	-4.45	-0.42	2.36e-5	IgG glycosylation;
THYM	cis	rs1061377	1.000	rs7685082	chr4:39118092	G/A	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg05335186	chr13:53173507	NA	-0.47	-5.51	-0.49	3.05e-7	Lewy body disease;
THYM	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg22907277	chr7:1156413	C7orf50	0.6	5.07	0.46	1.94e-6	Longevity;Endometriosis;
THYM	cis	rs9302635	0.513	rs35460163	chr16:72177060	C/T	cg23815491	chr16:72088622	HP	0.79	6.29	0.54	9.85e-9	Blood protein levels;
THYM	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs3008870	0.727	rs11208971	chr1:67383901	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.76	6.44	0.55	4.77e-9	Lymphocyte percentage of white cells;
THYM	cis	rs425277	0.606	rs262664	chr1:2083537	G/C	cg10334053	chr1:2078117	PRKCZ	0.48	4.73	0.44	7.65e-6	Height;
THYM	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg27034606	chr17:28928453	LRRC37B2	-0.81	-5.39	-0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7940866	0.903	rs1347283	chr11:130868583	T/G	cg23692386	chr11:131799662	NTM	0.46	4.99	0.46	2.76e-6	Schizophrenia;
THYM	cis	rs7607369	0.714	rs2272190	chr2:219609995	G/C	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Red blood cell count;Amyotrophic lateral sclerosis;
THYM	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.72	0.51	1.23e-7	Lung cancer in ever smokers;
THYM	cis	rs6946131	1.000	rs10269692	chr7:54787067	G/A	cg16668896	chr7:54900801	NA	0.38	4.59	0.43	1.35e-5	Systemic lupus erythematosus;
THYM	cis	rs6061231	0.701	rs6061505	chr20:60960211	G/A	cg24112000	chr20:60950667	NA	-0.78	-7.1	-0.59	2.3e-10	Colorectal cancer;
THYM	cis	rs80319144	1.000	rs113558390	chr2:159207713	A/G	cg24986868	chr2:159312599	PKP4;CCDC148	0.59	4.75	0.44	7.21e-6	Restless legs syndrome;
THYM	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg13695892	chr22:41940480	POLR3H	0.99	7.46	0.61	4.15e-11	Vitiligo;
THYM	cis	rs863345	0.604	rs10797018	chr1:158490112	G/A	cg12129480	chr1:158549410	OR10X1	-0.5	-4.84	-0.44	5.06e-6	Pneumococcal bacteremia;
THYM	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03452623	chr4:187889614	NA	-1.17	-20.04	-0.9	6.92e-36	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg01871581	chr19:12707946	ZNF490	-0.77	-7.76	-0.62	9.65e-12	Bipolar disorder;
THYM	cis	rs240764	0.853	rs12206945	chr6:101018032	C/T	cg21058520	chr6:100914733	NA	-0.59	-5.16	-0.47	1.37e-6	Neuroticism;
THYM	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg24163568	chr5:669837	TPPP	0.6	5.57	0.5	2.32e-7	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
THYM	cis	rs901683	1.000	rs12779976	chr10:46042932	C/T	cg18240400	chr10:46168597	ANUBL1	-0.72	-4.93	-0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs17174870	0.955	rs1400325	chr2:112680934	C/T	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg06609049	chr19:2785107	THOP1	0.67	5.83	0.51	7.46e-8	Total cholesterol levels;
THYM	trans	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg10856724	chr12:34555212	NA	-0.96	-8.66	-0.66	1.22e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1823778	0.609	rs3934438	chr18:67604812	A/G	cg13164537	chr18:67624071	CD226	1.16	4.76	0.44	6.79e-6	Mean platelet volume;
THYM	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg00530320	chr1:46809349	NSUN4	0.7	4.86	0.45	4.71e-6	Menopause (age at onset);
THYM	cis	rs865483	0.895	rs1112173	chr17:35760056	C/T	cg06716730	chr17:35851459	DUSP14	-0.44	-7.64	-0.62	1.73e-11	Monocyte count;
THYM	cis	rs7043114	0.525	rs710162	chr9:95059790	A/T	cg14631576	chr9:95140430	CENPP	0.85	9.03	0.68	1.99e-14	Height;
THYM	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg24642844	chr7:1081250	C7orf50	-1.16	-6.69	-0.57	1.51e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	-0.66	-4.75	-0.44	7.09e-6	Tonsillectomy;
THYM	cis	rs1568889	1.000	rs1568889	chr11:28009463	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	4.9	0.45	3.95e-6	Bipolar disorder;
THYM	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg07424592	chr7:64974309	NA	1.03	5.36	0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07167872	chr1:205819463	PM20D1	1.05	10.93	0.75	1.71e-18	Menarche (age at onset);
THYM	cis	rs9902453	0.765	rs2628191	chr17:28051140	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.83	-6.53	-0.56	3.17e-9	Coffee consumption (cups per day);
THYM	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-4.61	-0.43	1.25e-5	Drug-induced liver injury (flucloxacillin);
THYM	trans	rs11109072	1.000	rs7971692	chr12:97902406	T/C	cg17633015	chr7:2020501	MAD1L1	0.9	6.88	0.58	6.35e-10	Obesity (early onset extreme);
THYM	cis	rs611744	0.506	rs13280454	chr8:109263240	A/G	cg21045802	chr8:109455806	TTC35	0.65	5.73	0.51	1.18e-7	Dupuytren's disease;
THYM	cis	rs2276314	0.857	rs62101379	chr18:33584902	G/A	cg19628046	chr18:33552617	C18orf21	0.74	5.22	0.47	1.05e-6	Endometriosis;Drug-induced torsades de pointes;
THYM	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg26441486	chr22:50317300	CRELD2	-0.42	-6.65	-0.56	1.83e-9	Schizophrenia;
THYM	cis	rs9635726	0.638	rs2952155	chr17:37861718	T/C	cg00129232	chr17:37814104	STARD3	-0.69	-4.82	-0.44	5.43e-6	Primary biliary cholangitis;
THYM	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg14895029	chr7:2775587	GNA12	-0.68	-4.95	-0.45	3.24e-6	Height;
THYM	cis	rs9914988	0.887	rs12451790	chr17:27112000	C/G	cg20469991	chr17:27169893	C17orf63	-0.77	-4.59	-0.43	1.33e-5	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs28595532	0.920	rs17323034	chr4:119606518	G/A	cg11846333	chr4:119757529	SEC24D	1.38	4.94	0.45	3.4e-6	Cannabis dependence symptom count;
THYM	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.06	12.1	0.78	6.07e-21	Height;
THYM	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg16414030	chr3:133502952	NA	-0.85	-8.29	-0.65	7.41e-13	Iron status biomarkers;
THYM	cis	rs2012796	0.743	rs8020575	chr14:81859521	G/A	cg02996355	chr14:81879375	NA	0.85	6.63	0.56	2.06e-9	Night sleep phenotypes;
THYM	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg03388043	chr17:80084554	CCDC57	0.68	5.74	0.51	1.13e-7	Life satisfaction;
THYM	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg06064525	chr11:970664	AP2A2	0.35	6.59	0.56	2.4e-9	Alzheimer's disease (late onset);
THYM	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg10518543	chr12:38710700	ALG10B	-0.57	-4.57	-0.42	1.47e-5	Morning vs. evening chronotype;
THYM	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg10661904	chr17:79619235	PDE6G	0.66	6.41	0.55	5.55e-9	Eye color traits;
THYM	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg17509989	chr5:176798049	RGS14	-0.64	-5.96	-0.52	4.25e-8	Hemoglobin concentration;Hematocrit;
THYM	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg14972814	chr11:95582409	MTMR2	-0.71	-6.59	-0.56	2.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg06108461	chr20:60628389	TAF4	-1.06	-9.16	-0.68	1.02e-14	Body mass index;
THYM	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg03909863	chr11:638404	DRD4	-0.76	-5.83	-0.51	7.48e-8	Systemic lupus erythematosus;
THYM	cis	rs919433	0.679	rs55656916	chr2:198519628	T/C	cg05783139	chr2:198650985	BOLL	0.67	5.05	0.46	2.12e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs11039798	1.000	rs7924372	chr11:48556319	T/A	cg24672777	chr11:48374446	OR4C45	-1.08	-5.95	-0.52	4.42e-8	Axial length;
THYM	cis	rs7772486	0.790	rs2265918	chr6:146219164	A/G	cg13319975	chr6:146136371	FBXO30	-0.74	-6.33	-0.54	7.91e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6988636	0.818	rs62521808	chr8:124169568	C/T	cg23067535	chr8:124195133	FAM83A	-1.03	-4.98	-0.46	2.82e-6	Urinary uromodulin levels;
THYM	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg10047753	chr17:41438598	NA	1.14	10.48	0.73	1.57e-17	Menopause (age at onset);
THYM	cis	rs4951018	0.526	rs4245718	chr1:205652472	G/A	cg17178900	chr1:205818956	PM20D1	-0.59	-4.54	-0.42	1.64e-5	Prostate-specific antigen levels;
THYM	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg05347473	chr6:146136440	FBXO30	0.57	4.52	0.42	1.78e-5	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg10047753	chr17:41438598	NA	1.14	10.51	0.73	1.38e-17	Menopause (age at onset);
THYM	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.83	0.57	8.15e-10	Body mass index;
THYM	cis	rs7119	0.717	rs11631274	chr15:77816431	A/T	cg10437265	chr15:77819839	NA	0.77	7.65	0.62	1.67e-11	Type 2 diabetes;
THYM	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.6	-5.26	-0.47	9.02e-7	Height;
THYM	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg26566898	chr11:117069891	TAGLN	-0.4	-5.14	-0.47	1.45e-6	Blood protein levels;
THYM	cis	rs835154	0.845	rs835156	chr5:14875813	C/A	cg11792786	chr5:14870083	ANKH	-0.45	-4.8	-0.44	5.96e-6	Blood metabolite levels;
THYM	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg18904891	chr8:8559673	CLDN23	-0.57	-4.93	-0.45	3.53e-6	Myopia (pathological);
THYM	cis	rs7107174	0.688	rs11237489	chr11:78130325	G/A	cg02023728	chr11:77925099	USP35	0.54	4.53	0.42	1.69e-5	Testicular germ cell tumor;
THYM	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg11301795	chr4:187892539	NA	-1.11	-17.65	-0.88	9.45e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs868036	1.000	rs1871307	chr15:68100623	C/T	cg24579218	chr15:68104479	NA	-0.65	-6.51	-0.56	3.59e-9	Restless legs syndrome;
THYM	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg03188948	chr7:1209495	NA	0.92	5.2	0.47	1.15e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7200543	1.000	rs1121	chr16:15131076	G/A	cg01933576	chr16:15083564	PDXDC1	-0.99	-8.04	-0.64	2.48e-12	Glycerophospholipid levels;Metabolic traits;Body mass index;Triglyceride levels;
THYM	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg23352942	chr3:46931381	PTH1R	-0.82	-8.93	-0.68	3.13e-14	Birth weight;
THYM	cis	rs7616559	0.820	rs1482856	chr3:156754441	G/A	cg15697575	chr3:156784781	NA	0.41	5.3	0.48	7.61e-7	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg11764359	chr7:65958608	NA	-0.62	-4.73	-0.44	7.94e-6	Aortic root size;
THYM	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg10589385	chr1:150898437	SETDB1	0.65	5.45	0.49	4.01e-7	Melanoma;
THYM	cis	rs2637266	0.935	rs2637265	chr10:78326104	A/G	cg18941641	chr10:78392320	NA	0.69	5.5	0.49	3.16e-7	Pulmonary function;
THYM	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg10523679	chr1:76189770	ACADM	0.89	6.69	0.57	1.56e-9	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs9633835	0.802	rs55769038	chr11:13331808	G/A	cg13286116	chr11:13302098	ARNTL	-0.67	-7.02	-0.58	3.33e-10	Body mass index;
THYM	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg23750338	chr8:142222470	SLC45A4	-0.52	-4.87	-0.45	4.48e-6	Immature fraction of reticulocytes;
THYM	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg18876405	chr7:65276391	NA	0.59	4.91	0.45	3.8e-6	Aortic root size;
THYM	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg13393036	chr8:95962371	TP53INP1	-0.45	-4.61	-0.43	1.27e-5	Type 2 diabetes;
THYM	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06481639	chr22:41940642	POLR3H	0.66	4.79	0.44	6.09e-6	Vitiligo;
THYM	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg14675211	chr2:100938903	LONRF2	0.77	8.39	0.65	4.51e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	7.27	0.6	9.96e-11	Platelet count;
THYM	cis	rs9486719	0.522	rs4839683	chr6:96851933	A/G	cg18709589	chr6:96969512	KIAA0776	0.71	4.86	0.45	4.54e-6	Migraine;Coronary artery disease;
THYM	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.8	6.76	0.57	1.09e-9	Lymphocyte percentage of white cells;
THYM	cis	rs875971	0.793	rs460678	chr7:65527200	C/G	cg18876405	chr7:65276391	NA	0.67	5.76	0.51	1.04e-7	Aortic root size;
THYM	cis	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg07460842	chr6:66804631	NA	1.08	8.22	0.64	1.03e-12	Exhaled nitric oxide output;
THYM	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14893161	chr1:205819251	PM20D1	0.94	10.23	0.72	5.42e-17	Menarche (age at onset);
THYM	cis	rs6430585	0.583	rs59213715	chr2:136646582	A/C	cg23851026	chr2:136556271	LCT	0.81	7.31	0.6	8.35e-11	Corneal structure;
THYM	cis	rs7568458	0.905	rs10172544	chr2:85788270	C/A	cg17127132	chr2:85788382	GGCX	0.59	4.46	0.42	2.28e-5	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs9302635	0.550	rs35959677	chr16:72200801	G/T	cg23815491	chr16:72088622	HP	0.83	6.27	0.54	1.06e-8	Blood protein levels;
THYM	cis	rs4631830	0.900	rs7075009	chr10:51544143	T/G	cg16070123	chr10:51489643	NA	-0.52	-4.7	-0.43	8.94e-6	Prostate-specific antigen levels;
THYM	cis	rs4523957	0.651	rs9908373	chr17:2086534	G/A	cg16513277	chr17:2031491	SMG6	-0.98	-8.68	-0.67	1.08e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg24250549	chr1:154909240	PMVK	0.79	6.82	0.57	8.33e-10	Prostate cancer;
THYM	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg25072359	chr17:41440525	NA	0.68	4.62	0.43	1.21e-5	Menopause (age at onset);
THYM	cis	rs72781680	0.821	rs17045981	chr2:24109316	A/G	cg10599693	chr2:24300242	SF3B14	0.83	4.56	0.42	1.5e-5	Lymphocyte counts;
THYM	cis	rs9970807	0.892	rs4634932	chr1:56996191	C/T	cg11959316	chr1:57001742	PPAP2B	-0.55	-5.18	-0.47	1.24e-6	Myocardial infarction;Coronary artery disease;
THYM	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg03388043	chr17:80084554	CCDC57	-0.72	-6.05	-0.53	2.84e-8	Life satisfaction;
THYM	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.27	5.74	0.51	1.13e-7	Obesity-related traits;
THYM	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg06028808	chr11:68637592	NA	0.71	7.61	0.62	1.99e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg10856724	chr12:34555212	NA	-0.89	-8.1	-0.64	1.89e-12	Morning vs. evening chronotype;
THYM	cis	rs2274459	0.841	rs3818532	chr6:33679807	C/T	cg06253072	chr6:33679850	C6orf125	-0.51	-5.21	-0.47	1.08e-6	Obesity (extreme);
THYM	cis	rs7267979	0.899	rs442834	chr20:25458096	A/G	cg03522245	chr20:25566470	NINL	0.57	4.48	0.42	2.1e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs858239	0.670	rs6967526	chr7:23159241	C/A	cg05407003	chr7:23246146	NA	-0.55	-4.54	-0.42	1.66e-5	Cerebrospinal fluid biomarker levels;
THYM	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg24692254	chr21:30365293	RNF160	0.89	7.8	0.62	7.91e-12	Dental caries;
THYM	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg25918947	chr17:41365094	TMEM106A	-0.66	-5.64	-0.5	1.73e-7	Menopause (age at onset);
THYM	cis	rs883115	0.791	rs10799589	chr1:224819278	C/T	cg01808320	chr1:224927238	CNIH3	0.58	4.76	0.44	6.87e-6	Cancer;
THYM	cis	rs10924970	0.967	rs6677573	chr1:235377979	T/G	cg26050004	chr1:235667680	B3GALNT2	0.6	4.59	0.43	1.35e-5	Asthma;
THYM	cis	rs11696501	0.688	rs2281211	chr20:44312858	C/T	cg11783356	chr20:44313418	WFDC10B	-0.71	-4.79	-0.44	6.07e-6	Brain structure;
THYM	cis	rs62435770	1.000	rs62435804	chr6:169500848	A/T	cg07652237	chr6:170125491	PHF10	0.55	4.91	0.45	3.84e-6	Loneliness;
THYM	cis	rs3126085	0.935	rs12063165	chr1:152176357	C/T	cg10321714	chr1:152280068	FLG	0.65	4.72	0.44	8.02e-6	Atopic dermatitis;
THYM	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg03605463	chr16:89740564	NA	0.9	6.82	0.57	8.49e-10	Vitiligo;
THYM	cis	rs6519955	0.892	rs8137273	chr22:46440007	T/G	cg05468064	chr22:46423449	NA	0.42	5.36	0.48	5.93e-7	Dupuytren's disease;
THYM	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs6448317	0.954	rs13139649	chr4:24922007	C/A	cg22968281	chr4:24586266	DHX15	0.66	4.53	0.42	1.69e-5	Heschl's gyrus morphology;
THYM	cis	rs13315871	0.929	rs77178267	chr3:58320657	T/G	cg12435725	chr3:58293450	RPP14	-0.47	-4.95	-0.45	3.22e-6	Cholesterol, total;
THYM	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg11266682	chr4:10021025	SLC2A9	0.73	11.88	0.77	1.74e-20	Bone mineral density;
THYM	cis	rs3916	0.911	rs2239758	chr12:121162637	A/G	cg10600917	chr12:121163489	ACADS	0.59	5.13	0.47	1.55e-6	Urinary metabolites (H-NMR features);
THYM	cis	rs7834588	0.544	rs1947483	chr8:63811000	T/C	cg12194929	chr8:63776755	NKAIN3	-0.53	-4.47	-0.42	2.2e-5	Response to Vitamin E supplementation;
THYM	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg12165864	chr7:66369176	NA	0.66	5.09	0.46	1.83e-6	Aortic root size;
THYM	cis	rs2279817	0.955	rs2270977	chr1:18023509	T/C	cg21791023	chr1:18019539	ARHGEF10L	0.82	5.24	0.47	9.52e-7	Neuroticism;
THYM	cis	rs7586879	0.639	rs7580081	chr2:25097072	G/C	cg01884057	chr2:25150051	NA	0.7	7.27	0.6	1.01e-10	Body mass index;
THYM	cis	rs6840360	0.615	rs1962910	chr4:152479392	T/A	cg22705602	chr4:152727874	NA	-0.71	-7.94	-0.63	4.03e-12	Intelligence (multi-trait analysis);
THYM	cis	rs7107174	0.636	rs11237451	chr11:78025459	G/A	cg02023728	chr11:77925099	USP35	-0.56	-5.06	-0.46	2.04e-6	Testicular germ cell tumor;
THYM	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg07131210	chr7:1025825	CYP2W1	-0.83	-4.53	-0.42	1.7e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9876781	1.000	rs12487542	chr3:48426076	C/G	cg06066452	chr3:48470258	PLXNB1	0.26	4.88	0.45	4.26e-6	Longevity;
THYM	cis	rs2984613	1	rs2984613	chr1:156197380	C/T	cg24450063	chr1:156163899	SLC25A44	0.99	10.79	0.74	3.41e-18	Intracerebral hemorrhage;White matter hyperintensity burden;
THYM	cis	rs9611565	0.525	rs1883827	chr22:41703579	A/G	cg13695892	chr22:41940480	POLR3H	-0.63	-5.05	-0.46	2.16e-6	Vitiligo;
THYM	cis	rs11077998	0.933	rs3736204	chr17:80530279	C/T	cg10255544	chr17:80519551	FOXK2	0.51	4.51	0.42	1.84e-5	Reticulocyte fraction of red cells;
THYM	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08045932	chr20:61659980	NA	-0.87	-9.63	-0.7	1.04e-15	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg22681709	chr2:178499509	PDE11A	-0.58	-5.45	-0.49	3.91e-7	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
THYM	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg15704280	chr7:45808275	SEPT13	-1.08	-13.87	-0.82	1.48e-24	Height;
THYM	cis	rs13064411	0.696	rs3732803	chr3:113211957	T/C	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs7772486	0.686	rs2072911	chr6:146056801	G/A	cg23711669	chr6:146136114	FBXO30	-0.85	-8.17	-0.64	1.34e-12	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4788570	0.510	rs9931074	chr16:71667680	C/T	cg06353428	chr16:71660113	MARVELD3	1.27	8.51	0.66	2.53e-13	Intelligence (multi-trait analysis);
THYM	cis	rs77688320	0.517	rs2287054	chr2:202319038	G/A	cg06686451	chr2:201350984	NA	-0.59	-4.46	-0.42	2.28e-5	Breast cancer;
THYM	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg13695892	chr22:41940480	POLR3H	-0.91	-7.56	-0.61	2.53e-11	Vitiligo;
THYM	cis	rs1079204	1.000	rs6708662	chr2:219188669	T/C	cg05728596	chr2:219128475	GPBAR1	1.14	4.92	0.45	3.6e-6	Smooth-surface caries;
THYM	cis	rs2456568	0.771	rs2102333	chr11:93634749	G/A	cg17347335	chr11:93583973	C11orf90	-0.48	-4.58	-0.43	1.39e-5	Response to serotonin reuptake inhibitors in major depressive disorder;
THYM	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg06453172	chr10:134556979	INPP5A	-0.66	-4.78	-0.44	6.35e-6	Migraine;
THYM	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg17074396	chr22:49843754	NA	-0.38	-4.51	-0.42	1.86e-5	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs921968	0.643	rs13431399	chr2:219469498	G/C	cg02176678	chr2:219576539	TTLL4	-0.72	-7.15	-0.59	1.75e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs490234	0.812	rs13300639	chr9:128407298	A/G	cg14078157	chr9:128172775	NA	-0.67	-5.13	-0.47	1.54e-6	Mean arterial pressure;
THYM	cis	rs459571	0.629	rs441233	chr9:136876021	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.79	-6.23	-0.54	1.25e-8	Platelet distribution width;
THYM	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg23574427	chr4:122746245	BBS7;CCNA2	-0.54	-4.88	-0.45	4.3e-6	Type 2 diabetes;
THYM	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg08999081	chr20:33150536	PIGU	0.78	7.15	0.59	1.78e-10	Glomerular filtration rate (creatinine);
THYM	cis	rs2235642	0.893	rs8051295	chr16:1588087	A/G	cg07341220	chr16:1583899	IFT140;TMEM204	-0.66	-5.42	-0.49	4.56e-7	Coronary artery disease;
THYM	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg19913688	chr11:428466	ANO9	-0.97	-4.61	-0.43	1.23e-5	Body mass index;
THYM	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs4845875	0.564	rs2151655	chr1:11845518	G/C	cg24844545	chr1:11908347	NPPA	0.57	4.78	0.44	6.39e-6	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg02487422	chr3:49467188	NICN1	0.63	4.82	0.44	5.48e-6	Resting heart rate;
THYM	cis	rs7177026	0.500	rs7181683	chr15:79927736	G/A	cg20511832	chr15:78934280	CHRNB4	0.44	5.03	0.46	2.27e-6	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
THYM	cis	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg07460842	chr6:66804631	NA	0.92	5.5	0.49	3.15e-7	Exhaled nitric oxide levels;
THYM	cis	rs9928842	0.824	rs889515	chr16:75251299	T/C	cg09066997	chr16:75300724	BCAR1	0.78	5.0	0.46	2.65e-6	Alcoholic chronic pancreatitis;
THYM	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg03859395	chr2:55845619	SMEK2	0.6	5.46	0.49	3.72e-7	Metabolic syndrome;
THYM	cis	rs1994135	0.692	rs7958788	chr12:33692179	T/C	cg10856724	chr12:34555212	NA	-0.63	-4.95	-0.45	3.23e-6	Resting heart rate;
THYM	cis	rs1775715	0.870	rs1615256	chr10:32254101	T/C	cg04359828	chr10:32216031	ARHGAP12	0.41	5.21	0.47	1.11e-6	Bipolar disorder with mood-incongruent psychosis;
THYM	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg18252515	chr7:66147081	NA	1.6	8.71	0.67	9.29e-14	Diabetic kidney disease;
THYM	cis	rs10208940	0.614	rs7569777	chr2:68830881	G/A	cg09157127	chr2:69201416	GKN1	0.9	4.76	0.44	6.94e-6	Urate levels in lean individuals;
THYM	cis	rs11608355	0.618	rs60819157	chr12:109795766	G/A	cg11367159	chr12:110044531	NA	0.54	5.01	0.46	2.56e-6	Neuroticism;
THYM	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg07936489	chr17:37558343	FBXL20	-0.82	-5.69	-0.5	1.43e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg10856724	chr12:34555212	NA	-0.79	-7.37	-0.6	6.29e-11	Morning vs. evening chronotype;
THYM	cis	rs11214589	0.905	rs12805699	chr11:113241810	T/A	cg14159747	chr11:113255604	NA	0.36	7.77	0.62	9.29e-12	Neuroticism;
THYM	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11890956	chr21:40555474	PSMG1	1.1	10.87	0.74	2.33e-18	Cognitive function;
THYM	cis	rs868036	0.609	rs2045960	chr15:68092079	G/A	cg24579218	chr15:68104479	NA	-0.84	-8.38	-0.65	4.65e-13	Restless legs syndrome;
THYM	cis	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg19677267	chr1:26645161	CD52;UBXN11	0.53	4.96	0.45	3.04e-6	Obesity-related traits;
THYM	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	4.6	0.43	1.31e-5	Mood instability;
THYM	cis	rs1559088	0.947	rs7256182	chr19:33558591	G/A	cg03563238	chr19:33554763	RHPN2	-0.51	-4.53	-0.42	1.69e-5	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs4523957	0.855	rs216212	chr17:2134214	T/C	cg16513277	chr17:2031491	SMG6	0.83	8.22	0.64	1.04e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7769051	0.803	rs56148066	chr6:133230115	G/A	cg07930552	chr6:133119739	C6orf192	0.91	5.11	0.46	1.66e-6	Type 2 diabetes nephropathy;
THYM	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg08997352	chr12:9597637	DDX12	-0.62	-5.01	-0.46	2.53e-6	IgG glycosylation;
THYM	cis	rs6960043	0.905	rs10264723	chr7:15054370	T/C	cg19272540	chr7:15055459	NA	0.53	5.98	0.52	3.98e-8	Type 2 diabetes;
THYM	cis	rs7904368	0.754	rs66491181	chr10:16849430	T/C	cg14835575	chr10:16859367	RSU1	0.71	5.22	0.47	1.06e-6	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
THYM	cis	rs9814567	0.896	rs10935123	chr3:134345327	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.82	-8.47	-0.66	3e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs7412746	0.611	rs111842513	chr1:150712926	G/A	cg15448220	chr1:150897856	SETDB1	0.86	7.21	0.59	1.33e-10	Melanoma;
THYM	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg08859206	chr1:53392774	SCP2	0.46	4.81	0.44	5.75e-6	Monocyte count;
THYM	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg09667013	chr22:42394590	WBP2NL	0.52	4.48	0.42	2.1e-5	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11644478	chr21:40555479	PSMG1	-0.95	-7.1	-0.59	2.31e-10	Cognitive function;
THYM	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg24910161	chr17:38119198	GSDMA	0.47	4.93	0.45	3.55e-6	Self-reported allergy;
THYM	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.41	-6.17	-0.54	1.63e-8	Obesity-related traits;
THYM	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.57	4.81	0.44	5.69e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.42	4.63	0.43	1.17e-5	Hemoglobin concentration;
THYM	cis	rs7246657	0.653	rs4805208	chr19:37674259	G/A	cg22634378	chr19:37742834	NA	0.65	4.66	0.43	1.01e-5	Coronary artery calcification;
THYM	cis	rs6906287	0.647	rs11153763	chr6:118938738	G/A	cg21191810	chr6:118973309	C6orf204	0.57	5.73	0.51	1.17e-7	Electrocardiographic conduction measures;
THYM	cis	rs807669	0.903	rs807668	chr22:19162686	A/G	cg02655711	chr22:19163373	SLC25A1	0.98	11.86	0.77	1.93e-20	Metabolite levels;
THYM	cis	rs1697139	0.583	rs13186050	chr5:66528139	C/T	cg11553311	chr5:66541588	NA	0.68	6.85	0.58	7.2e-10	Breast cancer;
THYM	cis	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg00495681	chr13:53174319	NA	-0.72	-5.99	-0.52	3.65e-8	Lewy body disease;
THYM	cis	rs761746	0.804	rs5749304	chr22:31967775	A/G	cg01338084	chr22:32026380	PISD	-0.54	-4.66	-0.43	1.03e-5	Intelligence;
THYM	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg15592062	chr6:167189543	RPS6KA2	-0.59	-6.16	-0.53	1.73e-8	Crohn's disease;
THYM	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg02478829	chr6:26598070	ABT1	-0.4	-5.09	-0.46	1.79e-6	Intelligence (multi-trait analysis);
THYM	cis	rs6906287	0.631	rs2798321	chr6:118991602	G/T	cg01113488	chr6:119027122	NA	0.56	4.56	0.42	1.55e-5	Electrocardiographic conduction measures;
THYM	cis	rs7772486	0.840	rs11155451	chr6:146422524	A/G	cg23711669	chr6:146136114	FBXO30	0.97	10.62	0.74	7.88e-18	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs13256369	0.756	rs13282580	chr8:8562903	C/T	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs13256369	0.901	rs13251887	chr8:8568678	G/A	cg18904891	chr8:8559673	CLDN23	0.67	4.97	0.45	3e-6	Obesity-related traits;
THYM	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg26967526	chr14:35346199	BAZ1A	-0.75	-4.92	-0.45	3.59e-6	Psoriasis;
THYM	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg23187316	chr7:1099788	C7orf50	0.59	4.52	0.42	1.76e-5	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg03609598	chr5:56110824	MAP3K1	-0.7	-4.57	-0.42	1.49e-5	Initial pursuit acceleration;
THYM	cis	rs4930103	0.935	rs11042167	chr11:2020901	G/A	cg21926276	chr11:2035255	NA	0.27	4.52	0.42	1.8e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs1267303	0.642	rs116078607	chr1:46999238	G/A	cg25110126	chr1:46999211	NA	0.77	6.12	0.53	2.1e-8	Monobrow;
THYM	cis	rs9660180	0.935	rs2180311	chr1:1748734	T/C	cg17747265	chr1:1875780	NA	-0.8	-9.28	-0.69	5.65e-15	Body mass index;
THYM	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg09904177	chr6:26538194	HMGN4	0.53	4.47	0.42	2.16e-5	Intelligence (multi-trait analysis);
THYM	trans	rs8073060	0.572	rs1634683	chr17:33941560	G/C	cg19694781	chr19:47549865	TMEM160	-0.99	-8.63	-0.66	1.4e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg08807101	chr21:30365312	RNF160	-0.8	-6.25	-0.54	1.15e-8	Dental caries;
THYM	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg03690763	chr11:133734501	NA	-0.63	-5.15	-0.47	1.43e-6	Childhood ear infection;
THYM	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg06784218	chr1:46089804	CCDC17	0.29	4.61	0.43	1.25e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.76	-4.97	-0.45	3e-6	Mean platelet volume;
THYM	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg06238570	chr21:40685208	BRWD1	0.9	6.54	0.56	3.06e-9	Cognitive function;
THYM	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs988913	1.000	rs7765236	chr6:54835567	G/A	cg19716238	chr6:54711378	FAM83B	0.48	4.99	0.46	2.75e-6	Menarche (age at onset);
THYM	cis	rs4786125	0.920	rs7194057	chr16:6895960	T/C	cg03623568	chr16:6915990	A2BP1	-0.79	-6.31	-0.54	8.96e-9	Heart rate variability traits (SDNN);
THYM	cis	rs7178572	0.568	rs4243045	chr15:77455914	A/C	cg22256960	chr15:77711686	NA	-1.01	-7.9	-0.63	4.83e-12	Type 2 diabetes;
THYM	cis	rs921968	0.643	rs596076	chr2:219451015	T/G	cg02176678	chr2:219576539	TTLL4	0.63	6.07	0.53	2.56e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg07212818	chr11:638076	DRD4	-0.79	-6.69	-0.57	1.57e-9	Systemic lupus erythematosus;
THYM	cis	rs6840360	0.642	rs7682837	chr4:152427686	C/T	cg17479576	chr4:152424074	FAM160A1	-0.73	-5.68	-0.5	1.45e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7584330	0.737	rs61212490	chr2:238365230	T/C	cg14458575	chr2:238380390	NA	0.91	7.65	0.62	1.61e-11	Prostate cancer;
THYM	cis	rs10540	0.778	rs34046876	chr11:539058	C/T	cg03576123	chr11:487126	PTDSS2	-1.2	-5.39	-0.48	5.04e-7	Body mass index;
THYM	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.04	-7.05	-0.59	2.85e-10	Platelet count;
THYM	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg03709012	chr19:19516395	GATAD2A	0.79	6.53	0.56	3.21e-9	Tonsillectomy;
THYM	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.61	5.17	0.47	1.31e-6	Height;
THYM	cis	rs13088645	0.729	rs7620040	chr3:134163082	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-5.19	-0.47	1.17e-6	Coronary artery disease;
THYM	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.72	-5.5	-0.49	3.19e-7	Eosinophil percentage of white cells;
THYM	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	5.53	0.49	2.84e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs9677476	1.000	rs7584535	chr2:232106857	C/T	cg07929768	chr2:232055508	NA	0.52	5.4	0.48	4.92e-7	Food antigen IgG levels;
THYM	cis	rs6754311	0.593	rs7355359	chr2:136462441	C/T	cg20242066	chr2:136595261	LCT	-0.55	-6.03	-0.53	3.1e-8	Mosquito bite size;
THYM	cis	rs6430585	0.528	rs12474975	chr2:136702118	A/T	cg20242066	chr2:136595261	LCT	0.56	5.2	0.47	1.14e-6	Corneal structure;
THYM	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg23205692	chr1:25664452	TMEM50A	-0.83	-6.37	-0.55	6.66e-9	Erythrocyte sedimentation rate;
THYM	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg06713675	chr4:122721982	EXOSC9	-0.59	-5.69	-0.5	1.41e-7	Type 2 diabetes;
THYM	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg10523679	chr1:76189770	ACADM	-0.89	-8.55	-0.66	2.05e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg22508957	chr16:3507546	NAT15	0.49	5.2	0.47	1.13e-6	Body mass index (adult);
THYM	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg03433033	chr1:76189801	ACADM	-0.78	-8.35	-0.65	5.48e-13	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03517284	chr6:25882590	NA	-0.78	-6.24	-0.54	1.22e-8	Blood metabolite levels;
THYM	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg13114125	chr14:105738426	BRF1	-0.68	-5.22	-0.47	1.06e-6	Mean platelet volume;Platelet distribution width;
THYM	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg00645579	chr11:617140	IRF7;MUPCDH	-0.52	-6.46	-0.55	4.44e-9	Systemic lupus erythematosus;
THYM	cis	rs4731207	0.565	rs7780392	chr7:124575655	C/T	cg05285228	chr7:124571219	POT1	-0.69	-5.25	-0.47	9.35e-7	Cutaneous malignant melanoma;
THYM	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg12893697	chr11:970389	AP2A2	-0.32	-5.35	-0.48	6.01e-7	Alzheimer's disease (late onset);
THYM	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg19077165	chr18:44547161	KATNAL2	-0.66	-8.03	-0.64	2.57e-12	Personality dimensions;
THYM	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs2018683	0.739	rs10233884	chr7:28972307	A/G	cg27487796	chr7:28973253	NA	-0.26	-4.65	-0.43	1.08e-5	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
THYM	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg15704280	chr7:45808275	SEPT13	-1.08	-13.67	-0.81	3.63e-24	Height;
THYM	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg04944784	chr2:26401820	FAM59B	-0.79	-6.18	-0.54	1.61e-8	Gut microbiome composition (summer);
THYM	cis	rs11039798	0.502	rs961863	chr11:48417021	T/C	cg24672777	chr11:48374446	OR4C45	0.96	6.27	0.54	1.05e-8	Axial length;
THYM	cis	rs11809207	1.000	rs4659412	chr1:26518470	C/T	cg03844060	chr1:26490628	NA	0.7	5.01	0.46	2.51e-6	Height;
THYM	cis	rs4268898	0.662	rs17789375	chr2:24502554	G/T	cg06627628	chr2:24431161	ITSN2	-0.73	-5.15	-0.47	1.42e-6	Asthma;
THYM	cis	rs6596100	0.500	rs35534543	chr5:132160057	C/T	cg02081065	chr5:132209139	LEAP2	-0.91	-5.94	-0.52	4.76e-8	Breast cancer;
THYM	cis	rs763014	0.865	rs62030874	chr16:632233	T/C	cg09263875	chr16:632152	PIGQ	0.69	5.75	0.51	1.1e-7	Height;
THYM	cis	rs61931739	0.929	rs7955240	chr12:34066388	G/A	cg06521331	chr12:34319734	NA	0.57	4.68	0.43	9.63e-6	Morning vs. evening chronotype;
THYM	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg03806693	chr22:41940476	POLR3H	-1.19	-10.1	-0.72	1.03e-16	Vitiligo;
THYM	trans	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg10856724	chr12:34555212	NA	-0.99	-8.42	-0.65	3.84e-13	Bladder cancer;
THYM	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg11764359	chr7:65958608	NA	0.88	7.55	0.61	2.69e-11	Aortic root size;
THYM	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.82	8.1	0.64	1.87e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs4631830	0.720	rs2611471	chr10:51503559	G/C	cg16070123	chr10:51489643	NA	-0.53	-4.91	-0.45	3.71e-6	Prostate-specific antigen levels;
THYM	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg26384229	chr12:38710491	ALG10B	0.95	7.64	0.62	1.67e-11	Bladder cancer;
THYM	cis	rs80319144	0.857	rs79267963	chr2:159285874	T/G	cg24986868	chr2:159312599	PKP4;CCDC148	0.6	4.73	0.44	7.69e-6	Restless legs syndrome;
THYM	cis	rs89107	0.549	rs4945623	chr6:118980556	G/C	cg01113488	chr6:119027122	NA	0.57	4.9	0.45	3.96e-6	Cardiac structure and function;
THYM	cis	rs2290159	0.747	rs6777175	chr3:12646255	A/T	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs911263	0.887	rs8015139	chr14:68739301	G/T	cg18825221	chr14:68749962	RAD51L1	-0.62	-6.94	-0.58	4.73e-10	Primary biliary cholangitis;
THYM	cis	rs13256369	0.590	rs10113115	chr8:8559588	A/G	cg00074818	chr8:8560427	CLDN23	0.49	4.71	0.44	8.37e-6	Obesity-related traits;
THYM	trans	rs9296092	0.517	rs7743445	chr6:33470600	G/T	cg00929798	chr10:135150139	CALY	0.69	6.91	0.58	5.61e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs7799006	0.606	rs34417375	chr7:2315105	C/T	cg08027265	chr7:2291960	NA	-0.42	-5.15	-0.47	1.38e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs3733631	0.947	rs2189220	chr4:104598099	T/A	cg24090629	chr4:104641072	TACR3	-0.87	-5.51	-0.49	3.08e-7	Menarche (age at onset);
THYM	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06850241	chr22:41845214	NA	-0.59	-5.34	-0.48	6.24e-7	Vitiligo;
THYM	cis	rs6032067	0.704	rs35009666	chr20:43786020	C/T	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs2066819	1.000	rs2306694	chr12:56680636	C/T	cg26714650	chr12:56694279	CS	1.35	7.01	0.58	3.41e-10	Psoriasis vulgaris;
THYM	cis	rs6570726	0.791	rs6570693	chr6:145910841	C/T	cg13319975	chr6:146136371	FBXO30	-0.63	-4.98	-0.45	2.87e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg24838063	chr12:130822603	PIWIL1	0.96	7.85	0.63	6.3e-12	Menopause (age at onset);
THYM	cis	rs425277	0.585	rs3107156	chr1:2060630	T/C	cg17426766	chr1:2046864	PRKCZ	-0.4	-4.63	-0.43	1.15e-5	Height;
THYM	cis	rs112998813	0.571	rs9590395	chr13:114927224	C/G	cg02694521	chr13:114055881	NA	0.58	4.48	0.42	2.12e-5	Nodular sclerosis Hodgkin lymphoma;
THYM	cis	rs7323507	0.659	rs1333985	chr13:110581878	A/G	cg07669776	chr13:110975691	COL4A2	-0.51	-4.66	-0.43	1.02e-5	Lung function (FVC);
THYM	cis	rs1878931	0.597	rs37814	chr16:3455247	C/T	cg21433313	chr16:3507492	NAT15	0.6	4.99	0.46	2.68e-6	Body mass index (adult);
THYM	trans	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg10856724	chr12:34555212	NA	-0.88	-8.1	-0.64	1.84e-12	Bladder cancer;
THYM	cis	rs7618501	0.669	rs2230590	chr3:49936102	T/C	cg24308560	chr3:49941425	MST1R	-0.77	-6.63	-0.56	2.03e-9	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg06634786	chr22:41940651	POLR3H	0.66	5.13	0.47	1.54e-6	Vitiligo;
THYM	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg16342193	chr10:102329863	NA	-0.59	-6.2	-0.54	1.48e-8	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs2732480	0.577	rs2732466	chr12:48732459	A/G	cg21466736	chr12:48725269	NA	-0.6	-5.36	-0.48	5.86e-7	Hemoglobin concentration;Red blood cell count;Hematocrit;
THYM	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg03929089	chr4:120376271	NA	-0.8	-8.07	-0.64	2.1e-12	Height;
THYM	cis	rs9467711	0.591	rs16891315	chr6:26111756	T/C	cg01386294	chr6:25732093	NA	0.9	4.88	0.45	4.34e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7107174	0.901	rs7941639	chr11:78116959	A/G	cg02023728	chr11:77925099	USP35	-0.58	-5.4	-0.48	4.85e-7	Testicular germ cell tumor;
THYM	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg08439880	chr3:133502540	NA	-0.79	-6.68	-0.57	1.6e-9	Iron status biomarkers;
THYM	cis	rs3847687	1.000	rs11061290	chr12:131518747	C/T	cg25772418	chr12:131519998	GPR133	-0.45	-6.47	-0.55	4.18e-9	Longevity;
THYM	cis	rs1568889	0.838	rs4614434	chr11:28302234	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs9677476	0.863	rs7601741	chr2:232062351	C/T	cg23338755	chr2:231921595	PSMD1	0.71	5.35	0.48	6.14e-7	Food antigen IgG levels;
THYM	cis	rs4631830	0.720	rs2125770	chr10:51514824	T/C	cg10326726	chr10:51549505	MSMB	-0.48	-4.77	-0.44	6.52e-6	Prostate-specific antigen levels;
THYM	cis	rs7818345	0.613	rs13261732	chr8:19330215	T/C	cg01280390	chr8:19363452	CSGALNACT1	0.6	5.19	0.47	1.17e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg20887711	chr4:1340912	KIAA1530	0.96	8.88	0.67	4.18e-14	Longevity;
THYM	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg25319279	chr11:5960081	NA	-0.62	-5.34	-0.48	6.32e-7	DNA methylation (variation);
THYM	cis	rs7772486	0.790	rs9399571	chr6:146282061	A/G	cg13319975	chr6:146136371	FBXO30	0.72	6.09	0.53	2.44e-8	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs682457	0.573	rs9971436	chr11:87947490	G/A	cg24704476	chr1:956799	AGRN	0.83	6.89	0.58	6.06e-10	Post-traumatic stress disorder;
THYM	cis	rs2885056	0.830	rs2018810	chr19:10669172	A/G	cg04833646	chr19:10679720	CDKN2D	1.12	10.26	0.73	4.53e-17	Red cell distribution width;
THYM	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs9296092	0.538	rs80012910	chr6:33519542	G/A	cg13560919	chr6:33536144	NA	-0.94	-9.31	-0.69	4.9e-15	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs2658782	0.789	rs2658773	chr11:93126914	A/G	cg15737290	chr11:93063684	CCDC67	0.9	7.12	0.59	2.06e-10	Pulmonary function decline;
THYM	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg19747945	chr6:42946146	PEX6	-0.33	-4.82	-0.44	5.43e-6	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg27394845	chr17:28928406	LRRC37B2	0.98	4.9	0.45	3.99e-6	Body mass index;
THYM	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg10523679	chr1:76189770	ACADM	0.84	6.01	0.53	3.36e-8	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg21110456	chr7:2059412	MAD1L1	-0.43	-4.51	-0.42	1.89e-5	Neuroticism;
THYM	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg17830980	chr10:43048298	ZNF37B	-1.01	-10.1	-0.72	1.02e-16	Extrinsic epigenetic age acceleration;
THYM	cis	rs6987853	0.761	rs2974321	chr8:42424727	A/G	cg09913449	chr8:42400586	C8orf40	1.08	11.86	0.77	1.8899999999999998e-20	Mean corpuscular hemoglobin concentration;
THYM	cis	rs986417	0.892	rs11628559	chr14:61038153	G/C	cg27398547	chr14:60952738	C14orf39	1.21	6.17	0.53	1.69e-8	Gut microbiota (bacterial taxa);
THYM	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg16342193	chr10:102329863	NA	-0.5	-5.13	-0.47	1.54e-6	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg02353165	chr6:42928485	GNMT	0.82	7.21	0.59	1.33e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg04772025	chr11:68637568	NA	0.66	6.9	0.58	5.88e-10	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs1829883	1.000	rs1523381	chr5:98773754	T/C	cg08333243	chr5:99726346	NA	-0.57	-5.59	-0.5	2.13e-7	Hemostatic factors and hematological phenotypes;
THYM	cis	rs425535	0.941	rs2564594	chr4:74858300	A/T	cg07868155	chr4:74864709	CXCL5	-0.61	-5.11	-0.46	1.68e-6	Blood protein levels;
THYM	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg08508325	chr11:3079039	CARS	-0.53	-6.46	-0.55	4.51e-9	Longevity;
THYM	cis	rs735539	0.521	rs574139	chr13:21425816	T/G	cg02792322	chr13:21280448	IL17D	-0.66	-4.78	-0.44	6.37e-6	Dental caries;
THYM	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs7219021	0.774	rs9909916	chr17:46961493	C/T	cg09029085	chr17:47094198	IGF2BP1	0.36	4.55	0.42	1.61e-5	Schizophrenia or bipolar disorder;
THYM	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	4.5	0.42	1.91e-5	Bipolar disorder;
THYM	cis	rs7953508	0.506	rs1316740	chr12:93968288	C/A	cg18151635	chr12:93972918	NA	-0.87	-6.12	-0.53	2.07e-8	Pubertal anthropometrics;
THYM	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg08742575	chr21:47604166	C21orf56	0.68	5.41	0.49	4.7e-7	Testicular germ cell tumor;
THYM	cis	rs1113500	0.702	rs11185262	chr1:108639742	C/T	cg06207961	chr1:108661230	NA	0.64	5.09	0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs4319547	0.737	rs10846921	chr12:122943376	G/T	cg05707623	chr12:122985044	ZCCHC8	0.68	4.82	0.44	5.47e-6	Body mass index;
THYM	cis	rs6598955	0.671	rs11247914	chr1:26648838	G/T	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.53	0.42	1.69e-5	Obesity-related traits;
THYM	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg08885076	chr2:99613938	TSGA10	-0.69	-6.07	-0.53	2.66e-8	Chronic sinus infection;
THYM	cis	rs7586879	0.639	rs6749170	chr2:25110962	A/G	cg15423357	chr2:25149977	NA	0.68	7.41	0.61	5.24e-11	Body mass index;
THYM	cis	rs41311933	1.000	rs16910253	chr9:123748830	G/C	cg13567360	chr9:123745713	C5	-0.96	-5.55	-0.49	2.57e-7	Coronary artery disease;
THYM	cis	rs2455799	0.574	rs2455800	chr3:15701589	T/G	cg16303742	chr3:15540471	COLQ	-0.56	-5.62	-0.5	1.92e-7	Mean platelet volume;
THYM	cis	rs863345	0.604	rs2054992	chr1:158506015	G/A	cg12129480	chr1:158549410	OR10X1	-0.49	-4.83	-0.44	5.3e-6	Pneumococcal bacteremia;
THYM	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9359856	1.000	rs2026650	chr6:90311633	C/G	cg13799429	chr6:90582589	CASP8AP2	0.47	4.56	0.42	1.51e-5	Bipolar disorder;
THYM	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.88	-6.35	-0.55	7.49e-9	Electrocardiographic conduction measures;
THYM	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg25036284	chr2:26402008	FAM59B	-0.76	-5.32	-0.48	6.89e-7	Gut microbiome composition (summer);
THYM	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg10047753	chr17:41438598	NA	1.15	10.55	0.73	1.12e-17	Menopause (age at onset);
THYM	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg22683308	chr4:1340831	KIAA1530	-0.6	-4.83	-0.44	5.3e-6	Longevity;
THYM	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg12564285	chr5:131593104	PDLIM4	0.43	4.67	0.43	9.75e-6	Breast cancer;
THYM	trans	rs9747201	0.609	rs9303022	chr17:80170651	C/G	cg07393940	chr7:158741817	NA	1.09	8.13	0.64	1.6e-12	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs1550582	1.000	rs4909827	chr8:135517576	C/T	cg17885191	chr8:135476712	NA	0.75	4.8	0.44	5.81e-6	Educational attainment;
THYM	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg03806693	chr22:41940476	POLR3H	-1.22	-11.17	-0.75	5.43e-19	Vitiligo;
THYM	cis	rs9905704	0.918	rs72828707	chr17:56883236	A/G	cg12560992	chr17:57184187	TRIM37	0.68	4.72	0.44	8.17e-6	Testicular germ cell tumor;
THYM	cis	rs7100689	0.577	rs10749551	chr10:82054001	A/C	cg01528321	chr10:82214614	TSPAN14	0.95	7.0	0.58	3.68e-10	Post bronchodilator FEV1;
THYM	cis	rs13315871	0.929	rs71311849	chr3:58230809	G/A	cg12435725	chr3:58293450	RPP14	-0.52	-5.62	-0.5	1.91e-7	Cholesterol, total;
THYM	cis	rs4355801	0.571	rs2326045	chr8:119877113	T/A	cg17171407	chr8:119960777	TNFRSF11B	-0.61	-4.91	-0.45	3.83e-6	Bone mineral density;
THYM	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg05660106	chr1:15850417	CASP9	-0.76	-5.95	-0.52	4.53e-8	Systolic blood pressure;
THYM	cis	rs7572263	0.724	rs7579275	chr2:209053080	A/C	cg23998903	chr2:209048830	C2orf80	-0.46	-4.78	-0.44	6.38e-6	Glioma;Non-glioblastoma glioma;
THYM	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg07777115	chr5:623756	CEP72	-0.8	-4.84	-0.44	4.96e-6	Obesity-related traits;
THYM	cis	rs7078219	0.543	rs7096296	chr10:101277816	A/G	cg23904955	chr10:101282759	NA	0.41	5.36	0.48	5.93e-7	Dental caries;
THYM	cis	rs7193541	0.826	rs56143602	chr16:74694692	T/C	cg01733217	chr16:74700730	RFWD3	0.8	7.73	0.62	1.1e-11	Multiple myeloma;
THYM	cis	rs981844	0.712	rs878911	chr4:154755615	A/G	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs2302729	0.789	rs876503	chr12:2797179	A/G	cg19945202	chr12:2788847	CACNA1C	-0.87	-4.67	-0.43	9.74e-6	Sleep quality;
THYM	cis	rs9810089	0.814	rs10804640	chr3:136165695	G/A	cg21827317	chr3:136751795	NA	0.59	5.05	0.46	2.11e-6	Gestational age at birth (child effect);
THYM	cis	rs1005224	0.895	rs11624114	chr14:76131800	A/G	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.7	-5.55	-0.49	2.62e-7	Large artery stroke;
THYM	cis	rs9658691	0.607	rs9658757	chr10:90769455	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.88	-5.87	-0.52	6.48e-8	Mosquito bite size;
THYM	cis	rs7084402	0.967	rs2917949	chr10:60329166	G/A	cg07615347	chr10:60278583	BICC1	0.54	5.08	0.46	1.91e-6	Refractive error;
THYM	cis	rs147120681	1	rs147120681	chr1:101239293	CT/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.59	-4.54	-0.42	1.67e-5	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
THYM	cis	rs4907240	0.921	rs2278563	chr2:97212693	C/T	cg18419276	chr2:96971862	SNRNP200	-0.38	-4.5	-0.42	1.94e-5	Event-related brain oscillations;
THYM	trans	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg25517755	chr10:38738941	LOC399744	-0.76	-6.94	-0.58	4.78e-10	Corneal astigmatism;
THYM	cis	rs758324	0.732	rs152198	chr5:131438810	C/T	cg16205897	chr5:131564050	P4HA2	0.57	4.86	0.45	4.58e-6	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg14784868	chr12:69753453	YEATS4	1.13	12.23	0.78	3.21e-21	Cerebrospinal fluid biomarker levels;
THYM	cis	rs4363385	0.747	rs946099	chr1:152971618	A/G	cg13444842	chr1:152974279	SPRR3	-0.57	-4.53	-0.42	1.71e-5	Inflammatory skin disease;
THYM	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg13147721	chr7:65941812	NA	-0.94	-5.74	-0.51	1.13e-7	Diabetic kidney disease;
THYM	cis	rs9296092	0.517	rs6911036	chr6:33471652	C/G	cg13560919	chr6:33536144	NA	-0.84	-6.92	-0.58	5.15e-10	Age at smoking initiation in chronic obstructive pulmonary disease;
THYM	cis	rs7106204	0.925	rs3924745	chr11:24223001	G/A	ch.11.24196551F	chr11:24239977	NA	1.05	7.76	0.62	9.67e-12	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs490234	0.702	rs13284572	chr9:128258270	T/C	cg14078157	chr9:128172775	NA	-0.76	-6.42	-0.55	5.35e-9	Mean arterial pressure;
THYM	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.93	-7.08	-0.59	2.52e-10	Multiple sclerosis;
THYM	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg10047753	chr17:41438598	NA	1.19	11.33	0.76	2.52e-19	Menopause (age at onset);
THYM	cis	rs8048589	0.604	rs62038898	chr16:12223637	A/G	cg01990910	chr16:12207648	SNX29	-0.54	-6.08	-0.53	2.51e-8	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
THYM	cis	rs295140	0.605	rs159320	chr2:201187775	A/G	cg17644776	chr2:200775616	C2orf69	0.58	4.5	0.42	1.91e-5	QT interval;
THYM	cis	rs4589258	0.788	rs1894137	chr11:90497983	A/C	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.94	-0.45	3.36e-6	Intelligence (multi-trait analysis);
THYM	cis	rs425277	0.538	rs169037	chr1:2095582	G/T	cg17426766	chr1:2046864	PRKCZ	0.45	5.47	0.49	3.71e-7	Height;
THYM	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg08736216	chr1:53307985	ZYG11A	0.56	5.24	0.47	9.73e-7	Monocyte count;
THYM	cis	rs1971762	0.527	rs4759211	chr12:53930945	T/C	cg16917193	chr12:54089295	NA	0.7	6.18	0.54	1.6e-8	Height;
THYM	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg05182265	chr7:156933206	UBE3C	-0.7	-9.62	-0.7	1.06e-15	Body mass index;
THYM	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06634786	chr22:41940651	POLR3H	0.84	6.24	0.54	1.21e-8	Vitiligo;
THYM	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.59	0.5	2.17e-7	Obesity-related traits;
THYM	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg22709100	chr7:91322751	NA	0.71	5.55	0.49	2.59e-7	Breast cancer;
THYM	cis	rs1003719	0.788	rs9977602	chr21:38450650	G/T	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs9381040	0.692	rs4714430	chr6:41157054	T/G	cg03526776	chr6:41159608	TREML2	0.47	4.66	0.43	1.05e-5	Alzheimer's disease (late onset);
THYM	cis	rs7942486	0.895	rs35681858	chr11:13270008	C/T	cg13286116	chr11:13302098	ARNTL	-0.72	-8.02	-0.64	2.79e-12	Neuroticism;
THYM	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg18252515	chr7:66147081	NA	-0.66	-5.2	-0.47	1.16e-6	Aortic root size;
THYM	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7772486	0.875	rs854146	chr6:146341033	A/G	cg13319975	chr6:146136371	FBXO30	-0.68	-5.66	-0.5	1.62e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs514406	0.760	rs475969	chr1:53292607	T/A	cg25767906	chr1:53392781	SCP2	-0.53	-4.95	-0.45	3.18e-6	Monocyte count;
THYM	cis	rs7818345	0.637	rs13280711	chr8:19353600	T/A	cg01280390	chr8:19363452	CSGALNACT1	0.6	5.08	0.46	1.84e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs7582180	0.700	rs4640404	chr2:100980523	C/T	cg21926883	chr2:100939477	LONRF2	0.66	6.14	0.53	1.89e-8	Intelligence (multi-trait analysis);
THYM	cis	rs17818399	0.547	rs4952831	chr2:46761181	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.66	-4.7	-0.43	8.94e-6	Height;
THYM	cis	rs12476592	0.543	rs262532	chr2:63906020	G/A	cg17519650	chr2:63277830	OTX1	-0.69	-4.69	-0.43	9.3e-6	Childhood ear infection;
THYM	cis	rs6138458	1.000	rs227621	chr20:24910528	A/C	cg06937882	chr20:24974362	C20orf3	-0.47	-4.54	-0.42	1.66e-5	Blood protein levels;
THYM	cis	rs3820068	0.608	rs12091750	chr1:16042766	T/C	cg27534772	chr1:16042836	PLEKHM2	0.51	5.25	0.47	9.14e-7	Systolic blood pressure;
THYM	cis	rs2710642	0.849	rs4671450	chr2:62981869	C/A	cg17519650	chr2:63277830	OTX1	-0.68	-4.57	-0.42	1.44e-5	LDL cholesterol levels;LDL cholesterol;
THYM	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg15445000	chr17:37608096	MED1	-0.42	-5.08	-0.46	1.91e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs2219968	0.961	rs2200014	chr8:78956394	A/T	cg00738934	chr8:78996279	NA	-0.91	-9.74	-0.71	6.05e-16	Prostate cancer (SNP x SNP interaction);
THYM	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-7.21	-0.59	1.35e-10	Coronary artery disease;
THYM	cis	rs478304	0.934	rs610037	chr11:65546857	A/C	cg17480646	chr11:65405466	SIPA1	0.7	6.27	0.54	1.07e-8	Acne (severe);
THYM	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg06108461	chr20:60628389	TAF4	-0.83	-7.0	-0.58	3.59e-10	Body mass index;
THYM	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg01341218	chr17:43662625	NA	-0.87	-7.53	-0.61	2.93e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs11690935	0.877	rs13024846	chr2:172835803	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.82	-5.99	-0.52	3.77e-8	Schizophrenia;
THYM	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.63	4.96	0.45	3.07e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg09455208	chr3:40491958	NA	0.43	4.59	0.43	1.34e-5	Renal cell carcinoma;
THYM	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg21773646	chr17:80085082	CCDC57	0.36	5.08	0.46	1.88e-6	Life satisfaction;
THYM	cis	rs919433	0.647	rs2045242	chr2:198507649	G/A	cg05783139	chr2:198650985	BOLL	0.66	4.96	0.45	3.04e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs870825	0.616	rs7660064	chr4:185617529	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	9.65	0.7	9.06e-16	Blood protein levels;
THYM	cis	rs4454254	1.000	rs4440615	chr8:141057641	G/A	cg06693505	chr8:141057453	TRAPPC9	-0.47	-4.47	-0.42	2.16e-5	Pulse pressure;
THYM	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg01416388	chr22:39784598	NA	-0.85	-7.67	-0.62	1.48e-11	Intelligence (multi-trait analysis);
THYM	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06850241	chr22:41845214	NA	-0.52	-4.57	-0.42	1.48e-5	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg18252515	chr7:66147081	NA	-1.44	-8.51	-0.66	2.48e-13	Diabetic kidney disease;
THYM	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.6	-5.86	-0.52	6.65e-8	Longevity;Endometriosis;
THYM	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7172809	0.573	rs77952682	chr15:77409894	G/A	cg22256960	chr15:77711686	NA	-0.71	-5.06	-0.46	2.06e-6	Glucose homeostasis traits;
THYM	cis	rs7246657	0.943	rs10405407	chr19:37839164	C/T	cg22634378	chr19:37742834	NA	0.65	5.34	0.48	6.2e-7	Coronary artery calcification;
THYM	cis	rs2742234	0.666	rs715106	chr10:43616751	C/A	cg06632098	chr10:43605906	RET	-0.8	-5.05	-0.46	2.1e-6	Hirschsprung disease;
THYM	cis	rs2276498	0.751	rs2276487	chr20:52656815	T/G	cg23682609	chr20:52687365	BCAS1	0.54	4.49	0.42	2.04e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs9527	0.590	rs1475642	chr10:104546183	C/T	cg08772003	chr10:104629869	AS3MT	0.63	5.36	0.48	5.87e-7	Arsenic metabolism;
THYM	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg11502198	chr6:26597334	ABT1	0.64	5.6	0.5	2.03e-7	Intelligence (multi-trait analysis);
THYM	trans	rs2189609	0.521	rs2526066	chr16:74037837	A/C	cg06175578	chr8:42249154	VDAC3	0.91	6.84	0.57	7.61e-10	Energy expenditure (24h);
THYM	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg01341218	chr17:43662625	NA	1.13	9.52	0.7	1.72e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.94	-4.59	-0.43	1.34e-5	Alzheimer's disease;
THYM	cis	rs7412746	0.611	rs2864873	chr1:150814174	A/G	cg10589385	chr1:150898437	SETDB1	0.62	5.17	0.47	1.27e-6	Melanoma;
THYM	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg13683864	chr3:40499215	RPL14	-1.03	-11.36	-0.76	2.14e-19	Renal cell carcinoma;
THYM	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg18252515	chr7:66147081	NA	-0.69	-5.4	-0.48	4.81e-7	Aortic root size;
THYM	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg02493740	chr2:85810744	VAMP5	-0.64	-4.96	-0.45	3.07e-6	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
THYM	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg19748678	chr4:122722346	EXOSC9	0.73	5.15	0.47	1.42e-6	Type 2 diabetes;
THYM	cis	rs3126085	0.935	rs1390488	chr1:152199500	T/C	cg26020982	chr1:152196106	HRNR	0.34	4.52	0.42	1.76e-5	Atopic dermatitis;
THYM	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg23583168	chr7:148888333	NA	-1.08	-15.63	-0.85	5.22e-28	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg06713675	chr4:122721982	EXOSC9	-0.51	-4.7	-0.43	8.75e-6	Type 2 diabetes;
THYM	cis	rs3768617	0.510	rs10797842	chr1:183081867	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.77	0.44	6.72e-6	Fuchs's corneal dystrophy;
THYM	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	1.19	8.92	0.68	3.36e-14	Cognitive test performance;
THYM	cis	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg13443165	chr9:33130375	B4GALT1	-0.87	-7.99	-0.63	3.23e-12	IgG glycosylation;
THYM	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg24375607	chr4:120327624	NA	0.65	5.2	0.47	1.16e-6	Corneal astigmatism;
THYM	cis	rs9733	0.596	rs6681990	chr1:150695929	A/G	cg09034736	chr1:150693464	HORMAD1	0.53	4.85	0.45	4.83e-6	Tonsillectomy;
THYM	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.17	8.67	0.66	1.13e-13	Cognitive test performance;
THYM	cis	rs3820068	0.705	rs4646109	chr1:15817319	T/C	cg05660106	chr1:15850417	CASP9	1.15	10.57	0.74	9.96e-18	Systolic blood pressure;
THYM	cis	rs7084402	0.967	rs1649058	chr10:60317087	G/A	cg09696939	chr10:60272079	BICC1	-0.47	-5.55	-0.49	2.62e-7	Refractive error;
THYM	cis	rs7772486	0.846	rs9403767	chr6:146402386	G/T	cg13319975	chr6:146136371	FBXO30	-0.6	-4.79	-0.44	6.15e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2235649	0.588	rs11863172	chr16:1909083	C/G	cg03034668	chr16:1723424	CRAMP1L	-0.62	-4.5	-0.42	1.95e-5	Blood metabolite levels;
THYM	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg23260525	chr10:116636907	FAM160B1	0.53	5.33	0.48	6.63e-7	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs988913	0.706	rs1155749	chr6:54730383	T/C	cg04690482	chr6:54711388	FAM83B	0.44	4.56	0.42	1.5e-5	Menarche (age at onset);
THYM	cis	rs41271473	0.526	rs12136157	chr1:228703236	T/C	cg10167378	chr1:228756711	NA	0.76	4.67	0.43	1e-5	Chronic lymphocytic leukemia;
THYM	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg06713675	chr4:122721982	EXOSC9	-0.51	-4.75	-0.44	7.13e-6	Type 2 diabetes;
THYM	cis	rs3806843	0.868	rs2262573	chr5:140123627	T/A	cg19875535	chr5:140030758	IK	-0.6	-4.75	-0.44	7.26e-6	Depressive symptoms (multi-trait analysis);
THYM	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg27394845	chr17:28928406	LRRC37B2	0.99	4.85	0.45	4.74e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7226229	0.950	rs2364327	chr17:20939424	G/C	cg21263980	chr17:20946333	USP22	0.66	4.82	0.44	5.48e-6	Blood trace element (Se levels);
THYM	cis	rs7616559	0.584	rs11719102	chr3:156786544	C/T	cg15697575	chr3:156784781	NA	0.44	6.5	0.55	3.73e-9	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs17270561	0.887	rs9358870	chr6:25719210	T/C	cg16482183	chr6:26056742	HIST1H1C	0.69	4.78	0.44	6.29e-6	Iron status biomarkers;
THYM	cis	rs4662945	1.000	rs896794	chr2:130216609	T/C	cg05903289	chr2:130345205	NA	-0.53	-5.2	-0.47	1.16e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	4.72	0.44	8.24e-6	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg11494091	chr17:61959527	GH2	1.08	16.55	0.86	9.73e-30	Prudent dietary pattern;
THYM	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg07362569	chr17:61921086	SMARCD2	0.73	6.46	0.55	4.48e-9	Prudent dietary pattern;
THYM	cis	rs10927875	0.691	rs1048261	chr1:16340951	A/T	cg22431228	chr1:16359049	CLCNKA	-0.52	-4.99	-0.46	2.71e-6	Dilated cardiomyopathy;
THYM	cis	rs6906287	0.647	rs10457338	chr6:118784018	T/C	cg21191810	chr6:118973309	C6orf204	0.57	5.74	0.51	1.15e-7	Electrocardiographic conduction measures;
THYM	cis	rs6500395	1.000	rs7188741	chr16:48607966	T/C	cg04672837	chr16:48644449	N4BP1	0.54	5.5	0.49	3.25e-7	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs1003719	0.788	rs2835592	chr21:38464387	G/A	cg01329690	chr21:38580129	DSCR9	0.37	5.08	0.46	1.85e-6	Eye color traits;
THYM	cis	rs7107174	1.000	rs4944195	chr11:78003499	T/C	cg19901956	chr11:77921274	USP35	-0.69	-5.3	-0.48	7.42e-7	Testicular germ cell tumor;
THYM	cis	rs2742234	0.590	rs2293020	chr10:43692887	A/G	cg06632098	chr10:43605906	RET	0.75	4.88	0.45	4.29e-6	Hirschsprung disease;
THYM	cis	rs994014	0.691	rs58877260	chr4:82271025	C/T	cg17825130	chr4:82283507	NA	0.51	4.54	0.42	1.66e-5	Height;
THYM	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg12893697	chr11:970389	AP2A2	-0.31	-5.21	-0.47	1.1e-6	Alzheimer's disease (late onset);
THYM	cis	rs4786125	0.769	rs4129042	chr16:6901398	G/T	cg03623568	chr16:6915990	A2BP1	0.76	6.18	0.54	1.56e-8	Heart rate variability traits (SDNN);
THYM	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg10018233	chr7:150070692	REPIN1	0.38	5.41	0.48	4.8e-7	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	5.89	0.52	5.84e-8	Rheumatoid arthritis;
THYM	cis	rs7027203	0.828	rs4744287	chr9:96585567	A/G	cg13679303	chr9:96623674	NA	0.51	5.15	0.47	1.38e-6	DNA methylation (variation);
THYM	cis	rs2562456	0.833	rs2968076	chr19:21637101	C/T	cg21751540	chr19:21541537	ZNF738	0.78	5.09	0.46	1.77e-6	Pain;
THYM	cis	rs8017423	1.000	rs2183189	chr14:90670057	A/G	cg04239629	chr14:90701769	NA	-0.59	-4.45	-0.42	2.32e-5	Mortality in heart failure;
THYM	cis	rs2637266	1.000	rs7073355	chr10:78354419	G/A	cg18941641	chr10:78392320	NA	0.8	6.99	0.58	3.86e-10	Pulmonary function;
THYM	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg26721908	chr21:47610096	LSS	-0.75	-5.43	-0.49	4.35e-7	Testicular germ cell tumor;
THYM	cis	rs6570726	0.846	rs6570700	chr6:145931552	A/G	cg13319975	chr6:146136371	FBXO30	-0.65	-5.26	-0.47	9.03e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs17345786	0.520	rs12638134	chr3:101334609	G/T	cg12386194	chr3:101231763	SENP7	0.59	5.06	0.46	2.04e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9527	0.615	rs2152915	chr10:104691732	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.7	-5.01	-0.46	2.51e-6	Arsenic metabolism;
THYM	trans	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17712092	chr4:129076599	LARP1B	0.91	7.63	0.62	1.8e-11	Breast cancer;
THYM	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg16342193	chr10:102329863	NA	-0.52	-5.46	-0.49	3.85e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg24818145	chr4:99064322	C4orf37	0.78	6.19	0.54	1.54e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg10862848	chr6:42927986	GNMT	-0.52	-6.91	-0.58	5.41e-10	Alzheimer's disease in APOE e4+ carriers;
THYM	cis	rs9595908	0.931	rs9595595	chr13:33047815	T/G	cg12383807	chr13:33924137	NA	-0.52	-4.48	-0.42	2.09e-5	Body mass index;
THYM	cis	rs669446	0.561	rs530201	chr1:44102257	T/C	cg00143623	chr1:44495758	SLC6A9	0.59	4.51	0.42	1.84e-5	Amyotrophic lateral sclerosis (age of onset);
THYM	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg07169764	chr2:136633963	MCM6	0.7	5.89	0.52	5.94e-8	Mosquito bite size;
THYM	cis	rs1986734	0.576	rs2068063	chr4:77417203	C/T	cg20311846	chr4:77356250	SHROOM3	0.43	4.66	0.43	1.01e-5	Eosinophilic esophagitis (pediatric);Metabolite levels (small molecules and protein measures);
THYM	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg16586182	chr3:47516702	SCAP	0.68	5.69	0.5	1.4e-7	Colorectal cancer;
THYM	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg08645402	chr16:4508243	NA	0.76	6.87	0.58	6.72e-10	Schizophrenia;
THYM	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg24531977	chr5:56204891	C5orf35	-0.66	-5.11	-0.46	1.64e-6	Coronary artery disease;
THYM	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06481639	chr22:41940642	POLR3H	-0.67	-4.62	-0.43	1.21e-5	Vitiligo;
THYM	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg24531977	chr5:56204891	C5orf35	-1.0	-8.34	-0.65	5.78e-13	Initial pursuit acceleration;
THYM	cis	rs12586317	0.531	rs72666607	chr14:35770806	G/C	cg07166546	chr14:35805898	NA	-0.22	-5.27	-0.48	8.43e-7	Psoriasis;
THYM	cis	rs9309473	0.539	rs7574268	chr2:73904872	C/T	cg19565262	chr2:73869966	NAT8	0.53	4.5	0.42	1.96e-5	Metabolite levels;
THYM	cis	rs2440129	0.611	rs2292352	chr17:6902887	A/G	cg05215272	chr17:6899095	ALOX12	0.65	9.44	0.7	2.56e-15	Tonsillectomy;
THYM	cis	rs12643440	0.502	rs56163730	chr4:17143120	A/G	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs79149102	0.579	rs74025863	chr15:75284161	T/C	cg17294928	chr15:75287854	SCAMP5	-1.07	-5.72	-0.51	1.25e-7	Lung cancer;
THYM	cis	rs6032067	0.641	rs6017495	chr20:43756955	G/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.7	-7.59	-0.61	2.14e-11	Blood protein levels;
THYM	cis	rs9788682	0.747	rs2656074	chr15:78741384	T/C	cg18825076	chr15:78729989	IREB2	-0.7	-5.36	-0.48	5.71e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs12200560	0.505	rs11153095	chr6:97078592	T/C	cg06623918	chr6:96969491	KIAA0776	-0.74	-5.48	-0.49	3.51e-7	Coronary heart disease;
THYM	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg17796960	chr10:135278976	LOC619207	-0.59	-4.95	-0.45	3.24e-6	Systemic lupus erythematosus;
THYM	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg10117171	chr1:25599238	RHD	-0.67	-4.91	-0.45	3.83e-6	Erythrocyte sedimentation rate;
THYM	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg07570687	chr10:102243282	WNT8B	0.84	8.36	0.65	5.31e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs3849570	0.961	rs11710970	chr3:81693489	T/C	cg07356753	chr3:81810745	GBE1	-0.85	-6.46	-0.55	4.54e-9	Waist circumference;Body mass index;
THYM	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg27423445	chr12:12879764	APOLD1	0.53	4.45	0.42	2.3e-5	Systemic lupus erythematosus;
THYM	cis	rs7731657	0.537	rs4705996	chr5:130355586	C/G	cg08523029	chr5:130500466	HINT1	0.85	6.19	0.54	1.53e-8	Fasting plasma glucose;
THYM	cis	rs7428297	0.943	rs1806568	chr3:127070925	C/T	cg21487550	chr3:127056955	NA	0.73	4.58	0.42	1.43e-5	Clozapine-induced agranulocytosis;
THYM	cis	rs28476539	0.610	rs13135867	chr4:83573377	A/T	cg10249074	chr4:83542146	C4orf11	-0.65	-5.13	-0.47	1.51e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs3126085	0.935	rs1858479	chr1:152294823	A/T	cg10321714	chr1:152280068	FLG	-0.68	-4.95	-0.45	3.18e-6	Atopic dermatitis;
THYM	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg17757837	chr7:157058334	UBE3C	0.65	5.26	0.48	8.75e-7	Body mass index;
THYM	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	5.34	0.48	6.37e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9563576	0.778	rs9634698	chr13:58616824	G/T	cg26284685	chr13:57714554	PRR20E;PRR20D;PRR20C;PRR20B;PRR20A	0.64	4.76	0.44	6.89e-6	Body mass index;
THYM	cis	rs17401966	1.000	rs35837142	chr1:10322358	C/G	cg20482658	chr1:10539492	PEX14	0.39	4.66	0.43	1.04e-5	Hepatocellular carcinoma;
THYM	cis	rs7119038	0.818	rs3889239	chr11:118619960	C/T	cg19308663	chr11:118741387	NA	0.57	5.33	0.48	6.51e-7	Sjögren's syndrome;
THYM	cis	rs9677476	0.821	rs6708809	chr2:232112730	A/C	cg07929768	chr2:232055508	NA	0.62	6.08	0.53	2.54e-8	Food antigen IgG levels;
THYM	cis	rs9875589	0.509	rs4685061	chr3:14043823	G/A	cg03204825	chr3:13978759	TPRXL	-0.54	-4.67	-0.43	1.01e-5	Ovarian reserve;
THYM	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.81	6.36	0.55	6.89e-9	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.98	11.87	0.77	1.82e-20	Chronic sinus infection;
THYM	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg11812906	chr14:75593930	NEK9	-0.86	-8.02	-0.64	2.74e-12	Height;
THYM	cis	rs7631605	0.905	rs11920928	chr3:37210874	T/C	cg21328643	chr3:37258149	NA	-0.51	-4.96	-0.45	3.08e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg19847130	chr8:10466454	RP1L1	0.5	4.75	0.44	7.15e-6	Neuroticism;
THYM	cis	rs752010	0.574	rs2148636	chr1:42119844	C/T	cg06885757	chr1:42089581	HIVEP3	-0.49	-5.32	-0.48	6.99e-7	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg07424592	chr7:64974309	NA	-1.04	-5.27	-0.48	8.52e-7	Diabetic kidney disease;
THYM	cis	rs4523957	0.890	rs9895551	chr17:2115922	C/G	cg16513277	chr17:2031491	SMG6	0.79	7.76	0.62	9.54e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg06636001	chr8:8085503	FLJ10661	0.73	6.4	0.55	5.8e-9	Mood instability;
THYM	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg18876405	chr7:65276391	NA	0.63	5.56	0.5	2.48e-7	Aortic root size;
THYM	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg19507638	chr5:93509721	C5orf36	-0.68	-4.55	-0.42	1.56e-5	Diabetic retinopathy;
THYM	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs72315235	1	rs72315235	chr5:77785721	CAGAA/C	cg02375208	chr5:77804381	LHFPL2	0.61	5.45	0.49	3.92e-7	Plateletcrit;Platelet count;Platelet distribution width;
THYM	cis	rs13102973	0.682	rs6535054	chr4:135886055	A/C	cg14419869	chr4:135874104	NA	0.89	8.29	0.65	7.23e-13	Subjective well-being;
THYM	cis	rs11676855	0.893	rs6721399	chr2:235936607	A/G	cg14917874	chr2:235941519	SH3BP4	0.63	5.62	0.5	1.91e-7	Dialysis-related mortality;
THYM	cis	rs6510489	1.000	rs8106676	chr19:35994126	G/A	cg15078284	chr19:36004994	DMKN	0.42	4.62	0.43	1.22e-5	Bipolar disorder;
THYM	cis	rs13102973	0.965	rs6535050	chr4:135874115	A/C	cg14419869	chr4:135874104	NA	-0.82	-7.94	-0.63	4.06e-12	Subjective well-being;
THYM	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg10295955	chr4:187884368	NA	-1.19	-18.09	-0.88	1.54e-32	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs36051895	0.626	rs9695934	chr9:5153108	C/G	cg02405213	chr9:5042618	JAK2	-1.04	-11.68	-0.77	4.5e-20	Pediatric autoimmune diseases;
THYM	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg04362960	chr10:104952993	NT5C2	0.6	5.11	0.46	1.66e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7000551	0.751	rs2461490	chr8:22370115	G/C	cg12081754	chr8:22256438	SLC39A14	0.66	5.9	0.52	5.48e-8	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs9534288	0.830	rs940	chr13:46627480	C/G	cg15192986	chr13:46630673	CPB2	-0.66	-4.74	-0.44	7.64e-6	Blood protein levels;
THYM	cis	rs7582180	0.663	rs6542944	chr2:100988038	T/C	cg14675211	chr2:100938903	LONRF2	0.59	5.65	0.5	1.67e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9902453	0.845	rs2321331	chr17:28025528	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	4.85	0.45	4.84e-6	Coffee consumption (cups per day);
THYM	cis	rs12681287	1.000	rs7833786	chr8:87271374	C/T	cg27223183	chr8:87520930	FAM82B	0.58	4.51	0.42	1.87e-5	Caudate activity during reward;
THYM	cis	rs6084875	0.840	rs2025118	chr20:4723691	C/T	cg19614321	chr20:4804581	RASSF2	0.44	4.47	0.42	2.19e-5	Systemic lupus erythematosus;
THYM	cis	rs11650494	0.803	rs117801358	chr17:47447950	C/A	cg08112188	chr17:47440006	ZNF652	1.24	5.37	0.48	5.59e-7	Prostate cancer;
THYM	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-5.24	-0.47	9.55e-7	Chronic sinus infection;
THYM	cis	rs4499344	0.730	rs410616	chr19:33106109	T/C	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.84	6.93	0.58	5.11e-10	Mean platelet volume;
THYM	cis	rs2455799	0.613	rs2246960	chr3:15717693	G/A	cg16303742	chr3:15540471	COLQ	-0.55	-5.63	-0.5	1.81e-7	Mean platelet volume;
THYM	cis	rs425277	0.583	rs1467217	chr1:2045165	G/A	cg23803603	chr1:2058230	PRKCZ	-0.59	-5.39	-0.48	5.2e-7	Height;
THYM	cis	rs11252926	0.897	rs7092330	chr10:583771	G/C	cg14018140	chr10:458528	DIP2C	0.49	4.82	0.44	5.4e-6	Psychosis in Alzheimer's disease;
THYM	cis	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg16489192	chr7:75678113	MDH2;STYXL1	0.58	6.09	0.53	2.4e-8	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg10589385	chr1:150898437	SETDB1	0.65	5.33	0.48	6.6e-7	Melanoma;
THYM	cis	rs7830933	0.780	rs9644033	chr8:23610639	A/T	cg04349084	chr8:23602677	NA	0.6	6.62	0.56	2.1e-9	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI in non-smokers;
THYM	cis	rs9972944	0.676	rs9303489	chr17:63784817	T/C	cg07283582	chr17:63770753	CCDC46	0.74	6.0	0.52	3.59e-8	Total body bone mineral density;
THYM	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg09359103	chr1:154839909	KCNN3	-0.73	-9.27	-0.69	5.9e-15	Prostate cancer;
THYM	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg13114125	chr14:105738426	BRF1	-0.7	-5.53	-0.49	2.81e-7	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg07424592	chr7:64974309	NA	1.06	5.48	0.49	3.47e-7	Diabetic kidney disease;
THYM	cis	rs10791323	0.576	rs4937840	chr11:133734322	C/G	cg03690763	chr11:133734501	NA	-0.58	-4.96	-0.45	3.1e-6	Childhood ear infection;
THYM	cis	rs11190604	0.806	rs76835764	chr10:102193612	C/T	cg07570687	chr10:102243282	WNT8B	0.85	8.46	0.66	3.16e-13	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs863345	0.604	rs11264983	chr1:158462218	A/C	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs28595532	1.000	rs28595532	chr4:119716950	A/C	cg14228332	chr4:119757509	SEC24D	1.39	5.0	0.46	2.62e-6	Cannabis dependence symptom count;
THYM	cis	rs28595532	0.920	rs55869953	chr4:119751893	T/C	cg11846333	chr4:119757529	SEC24D	1.46	5.14	0.47	1.44e-6	Cannabis dependence symptom count;
THYM	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg25703541	chr22:24373054	LOC391322	-0.95	-12.42	-0.79	1.28e-21	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs7927771	0.524	rs10838774	chr11:47856114	A/G	cg20307385	chr11:47447363	PSMC3	0.62	4.76	0.44	7.03e-6	Subjective well-being;
THYM	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg08999081	chr20:33150536	PIGU	0.81	7.02	0.58	3.28e-10	Coronary artery disease;
THYM	cis	rs4595586	0.545	rs12814188	chr12:39380853	C/T	cg13010199	chr12:38710504	ALG10B	0.6	4.48	0.42	2.06e-5	Morning vs. evening chronotype;
THYM	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg11301795	chr4:187892539	NA	1.05	12.72	0.79	3.12e-22	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg14008862	chr17:28927542	LRRC37B2	0.86	4.61	0.43	1.24e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg06808227	chr14:105710500	BRF1	-1.02	-8.84	-0.67	4.97e-14	Mean platelet volume;Platelet distribution width;
THYM	cis	rs995000	0.868	rs4409689	chr1:63177365	A/G	cg06896770	chr1:63153194	DOCK7	0.68	4.86	0.45	4.62e-6	Triglyceride levels;
THYM	cis	rs524281	0.692	rs10791845	chr11:65834340	C/G	cg00563793	chr11:65837595	PACS1	-0.73	-5.14	-0.47	1.48e-6	Electroencephalogram traits;
THYM	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg00129232	chr17:37814104	STARD3	-0.7	-4.74	-0.44	7.43e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg11764359	chr7:65958608	NA	0.62	4.73	0.44	7.94e-6	Aortic root size;
THYM	cis	rs2408955	0.521	rs10875749	chr12:48531917	T/A	cg21466736	chr12:48725269	NA	0.47	4.62	0.43	1.21e-5	Glycated hemoglobin levels;
THYM	cis	rs966423	0.550	rs13002451	chr2:218301341	A/G	cg15335768	chr2:218268053	DIRC3	-0.37	-5.33	-0.48	6.65e-7	Thyroid cancer;
THYM	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.13	13.59	0.81	5.3e-24	Chronic sinus infection;
THYM	cis	rs236907	0.859	rs61807979	chr1:171764281	G/A	cg20598894	chr1:171756153	METTL13	-0.74	-5.59	-0.5	2.16e-7	Mean platelet volume;
THYM	cis	rs7584330	0.554	rs75918156	chr2:238426287	G/A	cg14458575	chr2:238380390	NA	0.79	4.65	0.43	1.06e-5	Prostate cancer;
THYM	trans	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg10856724	chr12:34555212	NA	-0.89	-8.35	-0.65	5.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg15501526	chr10:2543763	NA	0.75	7.12	0.59	2.02e-10	Age-related hearing impairment;
THYM	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.76	5.64	0.5	1.76e-7	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg04362960	chr10:104952993	NT5C2	0.58	4.69	0.43	9.04e-6	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-7.93	-0.63	4.23e-12	Chronic sinus infection;
THYM	cis	rs2046867	0.862	rs62251653	chr3:72811827	C/T	cg25664220	chr3:72788482	NA	-0.87	-6.53	-0.56	3.22e-9	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
THYM	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs1483890	0.723	rs1483888	chr3:69413329	G/T	cg22125112	chr3:69402811	FRMD4B	0.56	6.96	0.58	4.28e-10	Resting heart rate;
THYM	cis	rs854765	0.583	rs7207395	chr17:17819335	C/T	cg04398451	chr17:18023971	MYO15A	-0.83	-7.74	-0.62	1.04e-11	Total body bone mineral density;
THYM	cis	rs7772486	0.875	rs10872582	chr6:146373061	G/A	cg23711669	chr6:146136114	FBXO30	0.9	8.82	0.67	5.37e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7762018	0.607	rs3800544	chr6:170058374	C/T	cg19338460	chr6:170058176	WDR27	-0.96	-5.67	-0.5	1.51e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg23791538	chr6:167370224	RNASET2	-0.72	-5.66	-0.5	1.58e-7	Crohn's disease;
THYM	cis	rs4919044	0.808	rs4917898	chr10:94808637	T/A	cg05127821	chr10:94822908	CYP26C1	-1.23	-6.66	-0.56	1.76e-9	Coronary artery disease;
THYM	cis	rs7084402	0.935	rs4141671	chr10:60338753	T/C	cg09696939	chr10:60272079	BICC1	0.48	5.62	0.5	1.92e-7	Refractive error;
THYM	cis	rs9896850	0.513	rs10445407	chr17:79261809	A/C	cg14413466	chr17:79170920	AZI1	0.66	5.69	0.5	1.41e-7	Frontotemporal dementia;
THYM	cis	rs4460079	0.531	rs4582212	chr4:114839860	A/G	cg02060584	chr4:113970739	ANK2	0.56	4.58	0.43	1.39e-5	Blood pressure measurement (high sodium and potassium intervention);
THYM	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.92	-6.03	-0.53	3.11e-8	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
THYM	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg04546413	chr19:29218101	NA	1.09	9.4	0.69	3.15e-15	Methadone dose in opioid dependence;
THYM	cis	rs7084402	0.935	rs893370	chr10:60360834	A/T	cg07615347	chr10:60278583	BICC1	0.55	5.12	0.47	1.59e-6	Refractive error;
THYM	cis	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg07460842	chr6:66804631	NA	0.85	5.48	0.49	3.48e-7	Exhaled nitric oxide output;
THYM	cis	rs6938	0.640	rs2415249	chr15:75242040	G/A	cg02696790	chr15:75250997	RPP25	0.5	4.57	0.42	1.46e-5	Breast cancer;
THYM	cis	rs2359714	0.646	rs9428240	chr1:118831676	A/G	cg15553612	chr1:119520934	TBX15	-0.63	-4.62	-0.43	1.19e-5	Breast size;
THYM	cis	rs240764	0.717	rs180963	chr6:101127213	T/C	cg21058520	chr6:100914733	NA	-0.54	-4.53	-0.42	1.74e-5	Neuroticism;
THYM	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4731207	0.596	rs10264766	chr7:124572916	T/A	cg05285228	chr7:124571219	POT1	-0.65	-4.84	-0.44	4.97e-6	Cutaneous malignant melanoma;
THYM	cis	rs4919694	1.000	rs12258551	chr10:104767892	C/G	cg15744005	chr10:104629667	AS3MT	-0.84	-4.64	-0.43	1.1e-5	Arsenic metabolism;
THYM	cis	rs6754311	0.731	rs309164	chr2:136691825	T/C	cg04750100	chr2:136595281	LCT	0.53	5.96	0.52	4.24e-8	Mosquito bite size;
THYM	cis	rs10979	1.000	rs9484768	chr6:143887928	C/T	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg10047753	chr17:41438598	NA	1.16	10.56	0.73	1.08e-17	Menopause (age at onset);
THYM	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.98	9.52	0.7	1.78e-15	Cognitive ability;
THYM	cis	rs7084921	0.579	rs11596253	chr10:101849411	C/A	cg11344164	chr10:101878520	NA	-0.55	-4.76	-0.44	6.9e-6	Bone mineral density;
THYM	cis	rs7584330	0.554	rs11892169	chr2:238432809	G/A	cg08992911	chr2:238395768	MLPH	0.9	5.85	0.51	6.96e-8	Prostate cancer;
THYM	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg24733560	chr20:60626293	TAF4	0.51	4.58	0.43	1.41e-5	Body mass index;
THYM	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg11266682	chr4:10021025	SLC2A9	0.73	11.88	0.77	1.74e-20	Bone mineral density;
THYM	cis	rs877282	0.898	rs12357995	chr10:765739	T/C	cg10556349	chr10:835070	NA	-0.79	-5.05	-0.46	2.14e-6	Uric acid levels;
THYM	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs1062753	0.527	rs2187959	chr22:42347844	T/G	cg11601000	chr22:42348013	LOC339674	-0.45	-4.84	-0.44	5.09e-6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
THYM	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg11965913	chr1:205819406	PM20D1	0.55	5.08	0.46	1.85e-6	Menarche (age at onset);
THYM	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg00898013	chr13:113819073	PROZ	-1.02	-10.0	-0.72	1.62e-16	Platelet distribution width;
THYM	cis	rs7666738	0.927	rs11736876	chr4:98987206	A/G	cg17366294	chr4:99064904	C4orf37	0.53	5.9	0.52	5.67e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg25427524	chr10:38739819	LOC399744	-0.69	-6.25	-0.54	1.19e-8	Extrinsic epigenetic age acceleration;
THYM	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg08430604	chr3:44902960	MIR564;TMEM42	0.53	5.05	0.46	2.09e-6	Depressive symptoms;
THYM	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg21475434	chr5:93447410	FAM172A	-1.01	-6.51	-0.56	3.47e-9	Diabetic retinopathy;
THYM	cis	rs12291225	0.679	rs7934671	chr11:14305101	C/T	cg05501817	chr11:14380813	RRAS2	-0.75	-5.76	-0.51	1.02e-7	Sense of smell;
THYM	cis	rs1160297	0.609	rs1828336	chr2:53096937	G/T	cg07782112	chr2:53107842	NA	0.79	6.37	0.55	6.61e-9	Hemostatic factors and hematological phenotypes;
THYM	cis	rs17818399	0.547	rs62134736	chr2:46766446	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.65	4.52	0.42	1.81e-5	Height;
THYM	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg24675056	chr1:15929824	NA	0.73	5.86	0.52	6.71e-8	Systolic blood pressure;
THYM	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg14784868	chr12:69753453	YEATS4	1.12	10.87	0.74	2.32e-18	Blood protein levels;
THYM	cis	rs782590	0.537	rs12619903	chr2:55884106	T/A	cg18811423	chr2:55921094	PNPT1	-0.58	-5.07	-0.46	1.96e-6	Metabolic syndrome;
THYM	cis	rs6473252	0.966	rs4739761	chr8:81811441	G/A	cg08595989	chr8:81827712	NA	-0.41	-4.54	-0.42	1.65e-5	Breast cancer;
THYM	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg03060546	chr3:49711283	APEH	-0.67	-5.08	-0.46	1.85e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg05025164	chr4:1340916	KIAA1530	0.9	6.86	0.58	6.98e-10	Longevity;
THYM	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg23202291	chr11:1979235	NA	0.55	4.52	0.42	1.82e-5	DNA methylation (parent-of-origin);DNA methylation (variation);
THYM	cis	rs11690935	0.589	rs6729945	chr2:172864695	C/G	cg13550731	chr2:172543902	DYNC1I2	0.58	4.57	0.42	1.48e-5	Schizophrenia;
THYM	cis	rs6596100	0.538	rs56097052	chr5:132194430	A/G	cg02081065	chr5:132209139	LEAP2	-0.8	-5.3	-0.48	7.51e-7	Breast cancer;
THYM	cis	rs4731207	0.698	rs16871295	chr7:124461288	C/G	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs9467160	0.734	rs9467170	chr6:24452754	G/A	cg20631270	chr6:24437470	GPLD1	0.72	5.69	0.5	1.41e-7	Liver enzyme levels;
THYM	cis	rs17174870	0.955	rs77781750	chr2:112767824	A/G	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs13082711	0.911	rs11718991	chr3:27452944	A/G	cg02860705	chr3:27208620	NA	0.69	4.91	0.45	3.77e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs988913	0.957	rs7746965	chr6:54844432	G/T	cg04690482	chr6:54711388	FAM83B	0.49	5.28	0.48	8.01e-7	Menarche (age at onset);
THYM	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg19875535	chr5:140030758	IK	-0.64	-5.55	-0.49	2.57e-7	Depressive symptoms (multi-trait analysis);
THYM	cis	rs478304	0.654	rs12289836	chr11:65436888	C/T	cg27068330	chr11:65405492	SIPA1	1.05	10.98	0.75	1.33e-18	Acne (severe);
THYM	cis	rs4242434	0.889	rs4592028	chr8:22449484	T/C	cg11461670	chr8:22454935	PDLIM2	-0.39	-6.55	-0.56	2.92e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs1023500	1.000	rs10154646	chr22:42331409	G/C	cg19448990	chr22:41842841	TOB2	-0.76	-4.81	-0.44	5.66e-6	Schizophrenia;
THYM	cis	rs16917546	0.935	rs10822050	chr10:64438771	T/C	cg03961010	chr10:64397487	ZNF365	-0.69	-5.62	-0.5	1.92e-7	Basal cell carcinoma;
THYM	cis	rs6840360	0.593	rs4696286	chr4:152606547	G/A	cg22705602	chr4:152727874	NA	-0.82	-11.4	-0.76	1.76e-19	Intelligence (multi-trait analysis);
THYM	cis	rs10489202	0.657	rs201540	chr1:167992883	G/A	cg24449463	chr1:168025552	DCAF6	-0.92	-9.44	-0.7	2.67e-15	Schizophrenia;
THYM	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Intelligence (multi-trait analysis);
THYM	cis	rs988913	1.000	rs6941291	chr6:54837376	A/G	cg04690482	chr6:54711388	FAM83B	0.48	5.32	0.48	7.02e-7	Menarche (age at onset);
THYM	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg02696790	chr15:75250997	RPP25	-0.51	-5.47	-0.49	3.63e-7	Systemic lupus erythematosus;
THYM	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg26031613	chr14:104095156	KLC1	-0.68	-4.45	-0.42	2.34e-5	Bone mineral density;
THYM	cis	rs238914	0.599	rs2519193	chr11:114000247	C/G	cg18231614	chr11:113558886	TMPRSS5	-0.59	-4.67	-0.43	9.85e-6	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Myeloid white cell count;Neutrophil count;Granulocyte count;
THYM	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg06784218	chr1:46089804	CCDC17	-0.3	-4.64	-0.43	1.1e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs59698941	0.943	rs12515752	chr5:132312960	C/G	cg02081065	chr5:132209139	LEAP2	-0.73	-4.79	-0.44	6.17e-6	Apolipoprotein A-IV levels;
THYM	cis	rs7809950	1.000	rs7809950	chr7:107237807	T/C	cg23024343	chr7:107201750	COG5	0.93	7.64	0.62	1.75e-11	Coronary artery disease;
THYM	cis	rs6960043	0.875	rs17168594	chr7:15048776	T/C	cg19272540	chr7:15055459	NA	-0.55	-6.74	-0.57	1.21e-9	Type 2 diabetes;
THYM	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	1.02	9.95	0.71	2.08e-16	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg02380750	chr20:61661411	NA	0.61	6.07	0.53	2.6e-8	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg27129171	chr3:47204927	SETD2	0.78	7.73	0.62	1.09e-11	Colorectal cancer;
THYM	cis	rs9527	0.615	rs10883804	chr10:104706520	G/A	cg04362960	chr10:104952993	NT5C2	0.61	4.69	0.43	9.05e-6	Arsenic metabolism;
THYM	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg02887458	chr19:19495540	GATAD2A	-0.48	-5.42	-0.49	4.57e-7	Bipolar disorder;
THYM	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg18132916	chr6:79620363	NA	-0.59	-5.5	-0.49	3.19e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg06634786	chr22:41940651	POLR3H	0.7	4.92	0.45	3.59e-6	Vitiligo;
THYM	cis	rs6763768	0.606	rs13062474	chr3:53331547	C/T	cg16894138	chr3:53270350	TKT	0.69	5.19	0.47	1.21e-6	Bacterial meningitis;
THYM	cis	rs2180341	0.532	rs6933893	chr6:127707250	A/G	cg24812749	chr6:127587940	RNF146	0.77	5.75	0.51	1.07e-7	Breast cancer;
THYM	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg14784868	chr12:69753453	YEATS4	1.12	10.85	0.74	2.55e-18	Blood protein levels;
THYM	cis	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg10856724	chr12:34555212	NA	-0.82	-7.07	-0.59	2.6e-10	Morning vs. evening chronotype;
THYM	cis	rs6860806	0.631	rs7736284	chr5:131588151	T/C	cg12564285	chr5:131593104	PDLIM4	0.52	5.69	0.5	1.37e-7	Breast cancer;
THYM	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9902453	0.838	rs7217638	chr17:28336772	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-4.73	-0.44	7.74e-6	Coffee consumption (cups per day);
THYM	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg15052019	chr19:19431593	KIAA0892;SF4	0.66	5.26	0.47	8.89e-7	Tonsillectomy;
THYM	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg10792982	chr14:105748885	BRF1	0.72	7.38	0.6	5.93e-11	Mean platelet volume;Platelet distribution width;
THYM	cis	rs3892630	0.817	rs35408716	chr19:33187961	A/C	cg02283691	chr19:33182526	NUDT19	-0.4	-4.75	-0.44	7.23e-6	Red blood cell traits;
THYM	cis	rs2857078	0.772	rs2079008	chr17:42322132	C/A	cg13607699	chr17:42295918	UBTF	-0.83	-7.32	-0.6	7.87e-11	Red cell distribution width;Reticulocyte count;
THYM	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg00801512	chr17:28996047	NA	0.71	4.76	0.44	7.05e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4478037	0.732	rs12490111	chr3:33103007	G/A	cg19404215	chr3:33155277	CRTAP	1.05	6.56	0.56	2.8e-9	Major depressive disorder;
THYM	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs28595532	0.920	rs115076001	chr4:119764346	T/G	cg14228332	chr4:119757509	SEC24D	1.59	5.77	0.51	9.83e-8	Cannabis dependence symptom count;
THYM	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	6.13	0.53	1.95e-8	Total body bone mineral density;
THYM	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg02725872	chr8:58115012	NA	-1.11	-8.69	-0.67	1.04e-13	Developmental language disorder (linguistic errors);
THYM	cis	rs2227564	0.620	rs4746148	chr10:75534488	C/T	cg00564723	chr10:75632066	CAMK2G	-0.54	-4.77	-0.44	6.67e-6	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs539096	0.501	rs713191	chr1:44314553	A/G	cg13246856	chr1:44399776	ARTN	0.48	4.95	0.45	3.27e-6	Intelligence (multi-trait analysis);
THYM	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	6.72	0.57	1.31e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs728616	0.867	rs75447386	chr10:81739647	G/A	cg27452691	chr10:81370291	SFTPA1	0.84	4.64	0.43	1.13e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg17264618	chr3:40429014	ENTPD3	0.54	5.14	0.47	1.47e-6	Renal cell carcinoma;
THYM	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3126085	0.877	rs7535536	chr1:152193544	A/G	cg10321714	chr1:152280068	FLG	0.69	5.04	0.46	2.22e-6	Atopic dermatitis;
THYM	cis	rs611744	0.870	rs596703	chr8:109160146	A/G	cg21045802	chr8:109455806	TTC35	-0.67	-6.47	-0.55	4.27e-9	Dupuytren's disease;
THYM	cis	rs6701037	0.625	rs34270511	chr1:175128543	C/T	cg00958927	chr1:175162553	KIAA0040	-0.33	-4.48	-0.42	2.06e-5	Alcohol dependence;
THYM	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg00071950	chr4:10020882	SLC2A9	-0.54	-4.6	-0.43	1.31e-5	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs8020441	0.541	rs8012745	chr14:51160753	G/A	cg04730355	chr14:51134070	SAV1	0.93	5.59	0.5	2.2e-7	Cognitive performance;
THYM	cis	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg10856724	chr12:34555212	NA	0.85	7.65	0.62	1.61e-11	Morning vs. evening chronotype;
THYM	cis	rs10463554	0.892	rs32842	chr5:102478002	A/G	cg23492399	chr5:102201601	PAM	-0.69	-5.07	-0.46	1.92e-6	Parkinson's disease;
THYM	cis	rs1892700	0.853	rs2834237	chr21:34943200	A/C	cg24865779	chr21:34775042	IFNGR2	0.47	4.57	0.42	1.48e-5	Educational attainment;
THYM	cis	rs2806561	0.964	rs1757041	chr1:23506063	G/A	cg19743168	chr1:23544995	NA	0.62	6.63	0.56	2.06e-9	Height;
THYM	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg15921436	chr17:44337874	NA	0.95	6.92	0.58	5.33e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg11141652	chr22:24348549	GSTTP1	0.67	6.55	0.56	2.91e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs13185784	0.626	rs62406981	chr5:179639886	G/A	cg06495631	chr5:178692806	ADAMTS2	0.52	5.13	0.47	1.55e-6	TRAIL levels;
THYM	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg17178900	chr1:205818956	PM20D1	0.78	7.62	0.62	1.86e-11	Menarche (age at onset);
THYM	cis	rs8180040	0.726	rs2305638	chr3:47046842	G/C	cg16586182	chr3:47516702	SCAP	-0.59	-4.58	-0.43	1.39e-5	Colorectal cancer;
THYM	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg08017756	chr2:100939284	LONRF2	-0.73	-7.58	-0.61	2.26e-11	Intelligence (multi-trait analysis);
THYM	cis	rs6732160	0.588	rs10192654	chr2:73370882	A/T	cg24220031	chr2:73402428	NA	0.75	6.04	0.53	2.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.68	-5.62	-0.5	1.91e-7	Blood metabolite levels;
THYM	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg06917634	chr15:78832804	PSMA4	-0.82	-7.24	-0.6	1.17e-10	Sudden cardiac arrest;
THYM	cis	rs6700896	0.931	rs4655743	chr1:66087301	G/C	cg04111102	chr1:66153794	NA	0.53	4.64	0.43	1.12e-5	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg10856724	chr12:34555212	NA	-0.9	-9.01	-0.68	2.13e-14	Morning vs. evening chronotype;
THYM	cis	rs6500395	1.000	rs11640463	chr16:48644434	A/T	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs62045849	0.546	rs71395385	chr16:89196279	A/G	cg06035645	chr16:89190857	ACSF3	0.92	4.82	0.44	5.51e-6	Red blood cell count;
THYM	cis	rs886774	0.507	rs6956931	chr7:107521188	C/T	cg23293999	chr7:106826042	HBP1	-0.58	-4.47	-0.42	2.18e-5	Ulcerative colitis;
THYM	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.52	0.42	1.75e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9329289	0.510	rs2029604	chr10:2554700	T/C	cg15501526	chr10:2543763	NA	0.5	4.58	0.43	1.39e-5	Age-related hearing impairment;
THYM	cis	rs7247513	0.866	rs7247171	chr19:12706000	T/C	cg01871581	chr19:12707946	ZNF490	-0.87	-9.36	-0.69	3.84e-15	Bipolar disorder;
THYM	cis	rs12291225	0.585	rs11023194	chr11:14369769	T/C	cg05501817	chr11:14380813	RRAS2	-0.8	-6.63	-0.56	2.05e-9	Sense of smell;
THYM	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg18681998	chr4:17616180	MED28	0.97	9.8	0.71	4.41e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg10803722	chr21:46713166	LOC642852	-0.42	-5.58	-0.5	2.24e-7	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs2688608	0.592	rs11000758	chr10:75493610	A/T	cg19442545	chr10:75533431	FUT11	-0.51	-5.22	-0.47	1.03e-6	Inflammatory bowel disease;
THYM	cis	rs8133932	0.637	rs7283688	chr21:47301354	T/A	cg08707771	chr21:46690014	POFUT2	-0.76	-4.62	-0.43	1.22e-5	Schizophrenia;
THYM	cis	rs7487075	0.780	rs12307969	chr12:46759057	G/C	cg21428710	chr12:47219797	SLC38A4	0.5	4.72	0.44	8.19e-6	Itch intensity from mosquito bite;
THYM	cis	rs4072705	1.000	rs4838206	chr9:127511924	T/G	cg13476313	chr9:127244764	NR5A1	0.31	4.79	0.44	6.18e-6	Menarche (age at onset);
THYM	cis	rs11186	0.591	rs61410138	chr2:189964395	T/C	cg11041835	chr2:189156425	GULP1	0.81	4.77	0.44	6.73e-6	Parkinson's disease;
THYM	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg20587970	chr11:113659929	NA	1.34	8.87	0.67	4.2e-14	Hip circumference adjusted for BMI;
THYM	cis	rs9992101	0.547	rs10032549	chr4:77398015	A/G	cg20311846	chr4:77356250	SHROOM3	-0.43	-4.56	-0.42	1.53e-5	Creatinine levels;
THYM	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	4.67	0.43	1e-5	Schizophrenia;
THYM	cis	rs926938	0.584	rs360606	chr1:115391769	C/T	cg12756093	chr1:115239321	AMPD1	0.59	4.76	0.44	7.03e-6	Autism;
THYM	cis	rs2290159	0.948	rs9852128	chr3:12635623	A/G	cg23032965	chr3:12705835	RAF1	0.7	4.81	0.44	5.59e-6	Cholesterol, total;
THYM	cis	rs854765	0.654	rs9911281	chr17:17762457	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-6.77	-0.57	1.08e-9	Total body bone mineral density;
THYM	cis	rs11650494	0.908	rs75092916	chr17:47412578	T/C	cg08112188	chr17:47440006	ZNF652	1.25	5.41	0.49	4.62e-7	Prostate cancer;
THYM	cis	rs988913	0.706	rs6908568	chr6:54881564	C/G	cg04690482	chr6:54711388	FAM83B	0.44	4.58	0.43	1.39e-5	Menarche (age at onset);
THYM	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg06138931	chr13:21896616	NA	0.61	5.06	0.46	2.02e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg06138931	chr13:21896616	NA	0.6	5.11	0.46	1.65e-6	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg07936489	chr17:37558343	FBXL20	-0.67	-4.9	-0.45	3.86e-6	Asthma;
THYM	cis	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg10856724	chr12:34555212	NA	-0.91	-9.35	-0.69	4.1e-15	Morning vs. evening chronotype;
THYM	cis	rs425277	0.585	rs3107143	chr1:2045372	G/C	cg04315214	chr1:2043799	PRKCZ	0.66	5.55	0.49	2.56e-7	Height;
THYM	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg25036284	chr2:26402008	FAM59B	0.8	5.36	0.48	5.72e-7	Gut microbiome composition (summer);
THYM	cis	rs4642101	0.561	rs9831765	chr3:12805934	A/T	cg11882607	chr3:12858926	CAND2	-0.45	-5.09	-0.46	1.84e-6	QRS complex (12-leadsum);
THYM	cis	rs13256369	0.755	rs12550057	chr8:8562268	G/A	cg18904891	chr8:8559673	CLDN23	0.73	5.59	0.5	2.19e-7	Obesity-related traits;
THYM	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg24069376	chr3:38537580	EXOG	-0.65	-6.39	-0.55	6.13e-9	Electrocardiographic conduction measures;
THYM	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg06582575	chr6:163149167	PACRG;PARK2	1.21	8.09	0.64	1.96e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs17152411	0.843	rs7896051	chr10:126583119	T/C	cg07906193	chr10:126599966	NA	0.69	4.67	0.43	9.83e-6	Height;
THYM	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg03188948	chr7:1209495	NA	0.85	4.73	0.44	7.92e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2835345	0.563	rs73204246	chr21:37824700	G/C	cg20643029	chr21:37915044	CLDN14	0.63	5.39	0.48	5.05e-7	Pulmonary function;
THYM	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg16624210	chr5:671434	TPPP	0.69	5.06	0.46	2.02e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg06873352	chr17:61820015	STRADA	0.6	5.92	0.52	5.13e-8	Height;
THYM	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg23791538	chr6:167370224	RNASET2	-0.74	-5.92	-0.52	5.06e-8	Crohn's disease;
THYM	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg05340658	chr4:99064831	C4orf37	0.58	4.72	0.44	8.07e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg04842962	chr6:43655489	MRPS18A	1.01	8.61	0.66	1.54e-13	IgG glycosylation;
THYM	cis	rs12135062	0.687	rs6685614	chr1:3108517	C/T	cg00254258	chr1:3105189	PRDM16	0.63	5.1	0.46	1.72e-6	Migraine;
THYM	cis	rs2688608	0.620	rs11000767	chr10:75516626	G/T	cg23231163	chr10:75533350	FUT11	-0.48	-6.93	-0.58	5.09e-10	Inflammatory bowel disease;
THYM	cis	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg06558623	chr16:89946397	TCF25	1.18	5.5	0.49	3.19e-7	Skin colour saturation;
THYM	cis	rs13315871	0.929	rs13080508	chr3:58300116	G/A	cg12435725	chr3:58293450	RPP14	-0.5	-5.35	-0.48	6.13e-7	Cholesterol, total;
THYM	cis	rs7589342	0.801	rs2889605	chr2:106525073	T/C	cg14210321	chr2:106509881	NCK2	-0.79	-5.99	-0.52	3.75e-8	Addiction;
THYM	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg13393036	chr8:95962371	TP53INP1	-0.43	-4.5	-0.42	1.89e-5	Type 2 diabetes;
THYM	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	4.88	0.45	4.27e-6	Prudent dietary pattern;
THYM	cis	rs2334880	0.678	rs12922597	chr16:71452393	T/C	cg06353428	chr16:71660113	MARVELD3	-0.84	-4.61	-0.43	1.26e-5	Malaria;
THYM	cis	rs6121246	0.609	rs6089054	chr20:30323141	A/G	cg13852791	chr20:30311386	BCL2L1	0.87	8.17	0.64	1.31e-12	Mean corpuscular hemoglobin;
THYM	cis	rs17854409	0.764	rs8116995	chr20:61475824	A/G	cg05147244	chr20:61493195	TCFL5	0.97	5.66	0.5	1.61e-7	Obesity-related traits;
THYM	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.7	-4.94	-0.45	3.4e-6	Body mass index;
THYM	cis	rs79387448	0.745	rs6742433	chr2:103175360	C/T	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs425277	0.583	rs10910046	chr1:2041155	C/T	cg24578937	chr1:2090814	PRKCZ	-0.58	-6.17	-0.53	1.68e-8	Height;
THYM	cis	rs10752881	0.905	rs12132262	chr1:182989949	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Colorectal cancer;
THYM	cis	rs4654899	0.865	rs3856173	chr1:21114833	C/T	cg01072550	chr1:21505969	NA	-0.61	-5.27	-0.48	8.41e-7	Superior frontal gyrus grey matter volume;
THYM	trans	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg06636001	chr8:8085503	FLJ10661	0.78	6.98	0.58	3.96e-10	C-reactive protein levels or triglyceride levels (pleiotropy);
THYM	cis	rs9826463	0.582	rs73238152	chr3:142071081	C/T	cg20824294	chr3:142316082	PLS1	0.76	5.28	0.48	8.31e-7	QRS duration in Tripanosoma cruzi seropositivity;
THYM	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs11174202	0.814	rs12830041	chr12:62230910	C/G	cg11441379	chr12:63026424	NA	-0.58	-4.46	-0.42	2.24e-5	Anorexia nervosa;
THYM	cis	rs7178572	0.568	rs1823100	chr15:77402744	C/T	cg22256960	chr15:77711686	NA	-0.93	-7.23	-0.6	1.24e-10	Type 2 diabetes;
THYM	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg18477163	chr1:228402036	OBSCN	0.61	6.64	0.56	1.92e-9	Diastolic blood pressure;
THYM	cis	rs3892630	0.878	rs11878394	chr19:33205844	G/C	cg02283691	chr19:33182526	NUDT19	-0.4	-4.71	-0.44	8.35e-6	Red blood cell traits;
THYM	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg20486651	chr6:167070296	RPS6KA2	-0.5	-4.79	-0.44	6.18e-6	Crohn's disease;
THYM	cis	rs10186029	0.509	rs13425936	chr2:213940346	C/T	cg08319019	chr2:214017104	IKZF2	-0.67	-5.16	-0.47	1.34e-6	Systemic sclerosis;
THYM	cis	rs883565	0.771	rs1053516	chr3:39137883	G/A	cg15678707	chr3:39149194	GORASP1;TTC21A	0.77	5.52	0.49	2.95e-7	Handedness;
THYM	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg02725872	chr8:58115012	NA	-0.87	-6.16	-0.53	1.73e-8	Developmental language disorder (linguistic errors);
THYM	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg26384229	chr12:38710491	ALG10B	-0.71	-5.62	-0.5	1.9e-7	Morning vs. evening chronotype;
THYM	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs7089973	0.836	rs1046492	chr10:116624067	C/T	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.14	-0.47	1.5e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs11711311	1.000	rs921741	chr3:113444051	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.59	-5.19	-0.47	1.2e-6	IgG glycosylation;
THYM	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg03929089	chr4:120376271	NA	0.96	10.32	0.73	3.41e-17	Height;
THYM	trans	rs7794364	0.681	rs10242758	chr7:117522956	G/T	cg21837391	chr1:1159412	SDF4	0.92	7.57	0.61	2.39e-11	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs9534288	0.797	rs1326401	chr13:46571602	A/G	cg15192986	chr13:46630673	CPB2	0.63	4.64	0.43	1.12e-5	Blood protein levels;
THYM	cis	rs2116941	1.000	rs8104426	chr19:10338676	G/T	cg01850179	chr19:10340795	S1PR2	0.66	9.05	0.68	1.77e-14	Pulse pressure;
THYM	cis	rs514406	0.698	rs1672913	chr1:53408326	A/T	cg16325326	chr1:53192061	ZYG11B	0.69	5.67	0.5	1.56e-7	Monocyte count;
THYM	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg01699819	chr7:1052092	C7orf50	-0.76	-6.11	-0.53	2.17e-8	Bronchopulmonary dysplasia;
THYM	cis	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg01056808	chr11:92085533	FAT3	-0.75	-5.17	-0.47	1.32e-6	Subcortical brain region volumes;
THYM	cis	rs9828933	0.938	rs9809432	chr3:64002953	G/A	cg16258503	chr3:63850278	ATXN7;THOC7	-0.73	-4.46	-0.42	2.27e-5	Type 2 diabetes;
THYM	cis	rs7705502	0.779	rs6864880	chr5:173298226	C/T	cg18693985	chr5:173351052	CPEB4	-0.79	-5.72	-0.51	1.24e-7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
THYM	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg14972814	chr11:95582409	MTMR2	-0.62	-5.43	-0.49	4.39e-7	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	5.46	0.49	3.85e-7	Lung cancer in ever smokers;
THYM	cis	rs17006441	0.932	rs13078066	chr3:69844818	A/T	cg18496212	chr3:69797108	MITF	0.7	7.17	0.59	1.64e-10	Hemoglobin concentration;
THYM	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg23187316	chr7:1099788	C7orf50	0.61	4.68	0.43	9.5e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3126085	0.935	rs1496050	chr1:152163549	T/C	cg26020982	chr1:152196106	HRNR	0.34	4.52	0.42	1.76e-5	Atopic dermatitis;
THYM	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03647317	chr4:187891568	NA	-0.83	-9.1	-0.68	1.38e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg11266682	chr4:10021025	SLC2A9	0.73	12.79	0.8	2.29e-22	Bone mineral density;
THYM	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg22875332	chr1:76189707	ACADM	-0.54	-5.15	-0.47	1.39e-6	Daytime sleep phenotypes;
THYM	cis	rs1048238	0.548	rs848217	chr1:16272250	A/G	cg21385522	chr1:16154831	NA	-0.86	-7.53	-0.61	2.95e-11	Systolic blood pressure;
THYM	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg11502198	chr6:26597334	ABT1	0.64	5.68	0.5	1.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs59698941	0.943	rs67551921	chr5:132289033	G/A	cg27099455	chr5:132201840	GDF9;UQCRQ	0.61	4.51	0.42	1.82e-5	Apolipoprotein A-IV levels;
THYM	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg08508325	chr11:3079039	CARS	-0.56	-7.28	-0.6	9.41e-11	Longevity;
THYM	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg04025307	chr7:1156635	C7orf50	0.78	6.67	0.56	1.66e-9	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7107174	1.000	rs10793309	chr11:78093799	G/A	cg19901956	chr11:77921274	USP35	-0.65	-5.34	-0.48	6.41e-7	Testicular germ cell tumor;
THYM	cis	rs2303759	0.709	rs8102658	chr19:49828855	C/T	cg22133161	chr19:49891603	CCDC155	0.75	4.97	0.45	2.94e-6	Multiple sclerosis;
THYM	trans	rs8073060	0.586	rs2428464	chr17:34021994	C/G	cg19694781	chr19:47549865	TMEM160	-1.01	-8.58	-0.66	1.8e-13	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
THYM	cis	rs7695732	0.595	rs1458557	chr4:89887545	C/T	cg17769793	chr4:89976368	FAM13A	-0.49	-5.39	-0.48	5.23e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs2133450	0.526	rs73020271	chr3:7346412	C/T	cg19930620	chr3:7340148	GRM7	-0.52	-5.62	-0.5	1.86e-7	Early response to risperidone in schizophrenia;
THYM	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg06634786	chr22:41940651	POLR3H	0.71	5.04	0.46	2.19e-6	Cannabis dependence symptom count;
THYM	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg10053473	chr17:62856997	LRRC37A3	0.81	7.07	0.59	2.57e-10	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
THYM	cis	rs10847980	0.590	rs75794148	chr12:123287329	C/G	cg25930673	chr12:123319894	HIP1R	1.06	4.89	0.45	4.15e-6	Adiponectin levels;
THYM	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg19507638	chr5:93509721	C5orf36	-0.72	-4.65	-0.43	1.06e-5	Diabetic retinopathy;
THYM	cis	rs981844	0.712	rs1037649	chr4:154737796	G/A	cg09973105	chr4:154681532	RNF175	0.52	4.98	0.46	2.84e-6	Response to statins (LDL cholesterol change);
THYM	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg24289452	chr6:170231220	NA	-0.62	-5.29	-0.48	7.97e-7	Thiazide-induced adverse metabolic effects in hypertensive patients;
THYM	cis	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg06521331	chr12:34319734	NA	-0.96	-9.28	-0.69	5.69e-15	Morning vs. evening chronotype;
THYM	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg24308560	chr3:49941425	MST1R	0.8	6.87	0.58	6.61e-10	Intelligence (multi-trait analysis);
THYM	cis	rs6674176	0.932	rs12410334	chr1:44442521	A/C	cg26023051	chr1:45103896	RNF220	0.68	4.53	0.42	1.7e-5	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	trans	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg19862616	chr7:65841803	NCRNA00174	0.95	9.75	0.71	5.75e-16	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg10057126	chr4:77819792	ANKRD56	0.58	4.76	0.44	6.98e-6	Emphysema distribution in smoking;
THYM	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg10661904	chr17:79619235	PDE6G	-0.59	-5.65	-0.5	1.69e-7	Eye color traits;
THYM	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7731657	0.537	rs13182786	chr5:130246400	T/C	cg08523029	chr5:130500466	HINT1	0.82	5.88	0.52	6.03e-8	Fasting plasma glucose;
THYM	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg12350822	chr6:88032061	C6orf162;GJB7	-0.41	-5.2	-0.47	1.15e-6	Monocyte percentage of white cells;
THYM	cis	rs72827839	0.615	rs72827864	chr17:46492878	C/T	cg23391107	chr17:45924227	SP6	0.86	5.55	0.5	2.54e-7	Ease of getting up in the morning;
THYM	cis	rs7264396	0.676	rs6060723	chr20:34549947	G/C	cg26038318	chr20:34205095	SPAG4	0.59	4.81	0.44	5.6e-6	Total cholesterol levels;
THYM	cis	rs654950	0.934	rs638859	chr1:42001444	A/G	cg06885757	chr1:42089581	HIVEP3	0.54	6.93	0.58	5.05e-10	Airway imaging phenotypes;
THYM	cis	rs6956675	0.534	rs7780975	chr7:62652443	G/A	cg27056864	chr7:62859493	LOC100287834	0.56	5.06	0.46	2.05e-6	Obesity-related traits;
THYM	cis	rs9814567	1.000	rs9985356	chr3:134232920	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.77	7.67	0.62	1.5e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
THYM	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg27535305	chr1:53392650	SCP2	0.58	6.56	0.56	2.85e-9	Monocyte count;
THYM	cis	rs7818345	0.569	rs4317590	chr8:19357642	A/G	cg01280390	chr8:19363452	CSGALNACT1	0.61	5.04	0.46	2.18e-6	Language performance in older adults (adjusted for episodic memory);
THYM	cis	rs4455778	0.538	rs7786675	chr7:49123150	C/T	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-5.16	-0.47	1.34e-6	Hemoglobin concentration;
THYM	cis	rs6547741	1.000	rs11127071	chr2:27838058	C/A	cg27432699	chr2:27873401	GPN1	0.72	6.28	0.54	1.01e-8	Oral cavity cancer;
THYM	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg16778714	chr17:28903809	LRRC37B2	-0.76	-4.49	-0.42	2.03e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg17644776	chr2:200775616	C2orf69	-0.7	-4.97	-0.45	2.92e-6	Schizophrenia;
THYM	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg06634786	chr22:41940651	POLR3H	0.73	5.36	0.48	5.89e-7	Vitiligo;
THYM	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg00191853	chr8:101177733	SPAG1	-0.56	-5.57	-0.5	2.38e-7	Atrioventricular conduction;
THYM	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg03388043	chr17:80084554	CCDC57	-0.66	-5.48	-0.49	3.48e-7	Life satisfaction;
THYM	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs7915131	1.000	rs7086136	chr10:64410072	C/T	cg03961010	chr10:64397487	ZNF365	-0.71	-5.29	-0.48	7.89e-7	Schizophrenia;
THYM	cis	rs6539288	0.899	rs4964192	chr12:107308792	A/G	cg26297688	chr12:107349093	C12orf23	-0.47	-4.89	-0.45	4.15e-6	Total body bone mineral density;
THYM	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg26850624	chr5:429559	AHRR	-0.66	-5.24	-0.47	9.83e-7	Cystic fibrosis severity;
THYM	cis	rs7274811	0.901	rs55990870	chr20:32302908	C/T	cg08240466	chr20:32847653	ASIP	-0.56	-4.8	-0.44	6.01e-6	Height;
THYM	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08045932	chr20:61659980	NA	0.93	10.63	0.74	7.5e-18	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.93	9.71	0.71	6.8e-16	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.88	10.3	0.73	3.73e-17	Chronic sinus infection;
THYM	cis	rs4731207	0.698	rs4731218	chr7:124472015	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs11948739	0.573	rs4705993	chr5:130333733	C/T	cg08523029	chr5:130500466	HINT1	0.72	4.91	0.45	3.85e-6	Pediatric bone mineral content (hip);
THYM	trans	rs877282	1.000	rs12763443	chr10:771941	G/A	cg22713356	chr15:30763199	NA	1.38	11.57	0.76	7.71e-20	Uric acid levels;
THYM	cis	rs12472274	0.646	rs2305171	chr2:239097140	G/A	cg17459225	chr2:239074497	NA	0.74	5.08	0.46	1.91e-6	Phospholipid levels (plasma);
THYM	cis	rs8070740	0.898	rs8078914	chr17:5323924	T/C	cg25236894	chr17:5323110	RPAIN;NUP88	0.72	6.03	0.53	3.15e-8	Menopause (age at onset);
THYM	cis	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg06521331	chr12:34319734	NA	-1.03	-10.3	-0.73	3.74e-17	Morning vs. evening chronotype;
THYM	cis	rs854765	0.618	rs8066982	chr17:17851377	T/C	cg04398451	chr17:18023971	MYO15A	-0.78	-7.23	-0.6	1.22e-10	Total body bone mineral density;
THYM	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg06532163	chr17:45867833	NA	0.65	6.55	0.56	2.91e-9	IgG glycosylation;
THYM	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg21427119	chr20:30132790	HM13	-0.71	-4.79	-0.44	6.16e-6	Mean corpuscular hemoglobin;
THYM	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg18681998	chr4:17616180	MED28	0.99	10.09	0.72	1.05e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs5985	0.583	rs7758057	chr6:6307578	C/G	cg16530177	chr6:6320324	F13A1	-0.56	-4.98	-0.45	2.9e-6	End-stage coagulation;
THYM	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg07936489	chr17:37558343	FBXL20	-0.82	-5.61	-0.5	2.01e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs988913	0.957	rs6908170	chr6:54821152	C/T	cg18532076	chr6:54711417	FAM83B	0.54	5.01	0.46	2.5e-6	Menarche (age at onset);
THYM	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg14784868	chr12:69753453	YEATS4	0.81	6.31	0.54	8.9e-9	Response to diuretic therapy;
THYM	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg20295408	chr7:1910781	MAD1L1	-0.61	-4.85	-0.45	4.75e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4866334	1.000	rs116612534	chr5:18506467	C/A	cg18608440	chr5:17519013	NA	1.17	5.24	0.47	9.84e-7	IgG glycosylation;
THYM	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg11375102	chr16:1583810	IFT140;TMEM204	-0.6	-5.01	-0.46	2.5e-6	Coronary artery disease;
THYM	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.77	-5.11	-0.46	1.66e-6	Mean platelet volume;
THYM	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/C	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.88	-4.54	-0.42	1.65e-5	Vitiligo;
THYM	cis	rs2495707	0.624	rs2489008	chr10:102422934	C/T	cg00272971	chr10:102419564	NA	-0.53	-5.84	-0.51	7.37e-8	Body mass index;
THYM	cis	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg13609457	chr4:120235615	NA	0.5	4.78	0.44	6.36e-6	Diastolic blood pressure;
THYM	cis	rs924712	0.677	rs239790	chr6:54800874	C/T	cg04690482	chr6:54711388	FAM83B	-0.46	-5.4	-0.48	4.87e-7	Breast cancer;
THYM	cis	rs995000	0.899	rs1168045	chr1:62982891	C/T	cg06896770	chr1:63153194	DOCK7	-0.89	-7.45	-0.61	4.29e-11	Triglyceride levels;
THYM	cis	rs2282300	0.956	rs654710	chr11:30394303	A/G	cg25418670	chr11:30344373	C11orf46	0.67	5.11	0.46	1.65e-6	Morning vs. evening chronotype;
THYM	cis	rs12643440	0.538	rs66857912	chr4:17146347	T/C	cg22650099	chr4:17144496	NA	-0.64	-4.49	-0.42	2.01e-5	Metabolite levels (Pyroglutamine);
THYM	cis	rs4638749	0.953	rs12475415	chr2:108860477	G/A	cg06795125	chr2:108905320	SULT1C2	-0.42	-5.48	-0.49	3.42e-7	Blood pressure;
THYM	trans	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs526231	0.543	rs26525	chr5:102464923	G/C	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.49e-6	Primary biliary cholangitis;
THYM	cis	rs1150668	0.796	rs1005125	chr6:28367355	G/A	cg13525197	chr6:28411240	ZSCAN23	-0.67	-5.32	-0.48	6.9e-7	Pubertal anthropometrics;
THYM	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22857025	chr5:266934	NA	-1.56	-10.61	-0.74	8.25e-18	Breast cancer;
THYM	cis	rs612683	0.518	rs565590	chr1:100846956	T/C	cg06223162	chr1:101003688	GPR88	0.71	5.97	0.52	4.16e-8	Breast cancer;
THYM	cis	rs988913	0.874	rs12662124	chr6:54802336	A/G	cg18532076	chr6:54711417	FAM83B	0.52	4.79	0.44	6.22e-6	Menarche (age at onset);
THYM	cis	rs921968	0.643	rs524012	chr2:219433273	T/G	cg02176678	chr2:219576539	TTLL4	0.68	6.71	0.57	1.42e-9	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7507204	0.723	rs62125964	chr19:3414742	C/A	cg08380311	chr19:3435252	NFIC	0.92	7.44	0.61	4.44e-11	Height;
THYM	cis	rs7582180	0.663	rs2309794	chr2:100954270	G/A	cg21926883	chr2:100939477	LONRF2	-0.65	-6.15	-0.53	1.8e-8	Intelligence (multi-trait analysis);
THYM	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	5.08	0.46	1.89e-6	Bipolar disorder;
THYM	cis	rs10887741	0.690	rs4934357	chr10:89439533	G/A	cg13926569	chr10:89418898	PAPSS2	0.62	6.85	0.57	7.32e-10	Exercise (leisure time);
THYM	cis	rs11645898	0.687	rs11075919	chr16:72106906	T/C	cg14768367	chr16:72042858	DHODH	-0.59	-4.45	-0.42	2.31e-5	Blood protein levels;
THYM	cis	rs912057	0.695	rs1294419	chr6:6742549	C/G	cg06612196	chr6:6737390	NA	0.69	9.83	0.71	3.75e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs10887741	0.646	rs2077773	chr10:89435501	G/A	cg13926569	chr10:89418898	PAPSS2	0.63	7.28	0.6	9.67e-11	Exercise (leisure time);
THYM	cis	rs9302065	0.565	rs2992908	chr13:95960600	G/A	cg24476569	chr13:95954382	ABCC4	-0.79	-8.08	-0.64	2.05e-12	Blood metabolite levels;
THYM	cis	rs6430585	0.583	rs73957037	chr2:136588031	C/A	cg23851026	chr2:136556271	LCT	0.69	7.14	0.59	1.85e-10	Corneal structure;
THYM	cis	rs12983728	0.831	rs79222418	chr19:58664418	T/C	cg07378217	chr19:58662286	ZNF329	-0.91	-5.68	-0.5	1.46e-7	Cholesterol, total;
THYM	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03517284	chr6:25882590	NA	-1.19	-11.31	-0.76	2.72e-19	Intelligence (multi-trait analysis);
THYM	cis	rs490234	0.783	rs4838278	chr9:128403509	T/C	cg14078157	chr9:128172775	NA	-0.66	-5.15	-0.47	1.43e-6	Mean arterial pressure;
THYM	cis	rs11605275	1.000	rs73434181	chr11:20024254	G/C	cg14835545	chr11:20032148	NAV2	-1.38	-6.36	-0.55	6.98e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs9677476	0.648	rs7565313	chr2:232054514	A/G	cg07929768	chr2:232055508	NA	0.63	6.4	0.55	5.93e-9	Food antigen IgG levels;
THYM	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg17264618	chr3:40429014	ENTPD3	-0.49	-4.67	-0.43	1.01e-5	Renal cell carcinoma;
THYM	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg14349672	chr11:133703707	NA	-0.52	-4.59	-0.43	1.37e-5	Childhood ear infection;
THYM	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	8.22	0.64	1.02e-12	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7267979	0.706	rs6138542	chr20:25207773	C/A	cg03522245	chr20:25566470	NINL	0.62	4.47	0.42	2.15e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs12478296	1.000	rs7603984	chr2:243047294	A/G	cg06360820	chr2:242988706	NA	-1.07	-6.54	-0.56	3.06e-9	Obesity-related traits;
THYM	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg24399712	chr22:39784796	NA	-0.9	-10.36	-0.73	2.87e-17	Intelligence (multi-trait analysis);
THYM	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg03690763	chr11:133734501	NA	-0.62	-5.15	-0.47	1.43e-6	Childhood ear infection;
THYM	cis	rs2069036	0.903	rs4484996	chr10:16074553	A/G	cg26633223	chr10:15133461	NA	-0.63	-4.47	-0.42	2.17e-5	Urate levels (BMI interaction);Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
THYM	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg05457628	chr5:178986728	RUFY1	0.56	5.2	0.47	1.14e-6	Lung cancer;
THYM	cis	rs7546094	1.000	rs2999154	chr1:113222456	G/T	cg22162597	chr1:113214053	CAPZA1	-0.47	-4.7	-0.43	8.7e-6	Platelet distribution width;
THYM	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg02524346	chr8:600233	NA	-0.92	-4.69	-0.43	9e-6	IgG glycosylation;
THYM	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.68	-4.87	-0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs7107174	1.000	rs10899456	chr11:78000155	C/G	cg19901956	chr11:77921274	USP35	-0.68	-5.26	-0.48	8.74e-7	Testicular germ cell tumor;
THYM	cis	rs7829975	0.777	rs6989926	chr8:8547313	A/C	cg17143192	chr8:8559678	CLDN23	-0.63	-4.76	-0.44	6.82e-6	Mood instability;
THYM	cis	rs11048434	0.723	rs2080117	chr12:9138341	C/T	cg13575925	chr12:9217583	LOC144571	0.55	5.45	0.49	3.89e-7	Sjögren's syndrome;
THYM	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg01831904	chr17:28903510	LRRC37B2	-1.03	-5.09	-0.46	1.82e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg20685674	chr1:26233538	STMN1	-0.41	-4.53	-0.42	1.69e-5	Plateletcrit;Mean corpuscular volume;
THYM	cis	rs3017493	0.685	rs78711146	chr11:70671687	G/A	cg03578926	chr11:70508032	SHANK2	0.86	4.83	0.44	5.2e-6	Renal transplant outcome;
THYM	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg01191920	chr7:158217561	PTPRN2	0.9	8.77	0.67	6.91e-14	Obesity-related traits;
THYM	cis	rs901683	1.000	rs71496612	chr10:46032505	C/A	cg18240400	chr10:46168597	ANUBL1	0.72	4.93	0.45	3.43e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg20503657	chr10:835505	NA	1.17	8.29	0.65	7.24e-13	Eosinophil percentage of granulocytes;
THYM	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg16624210	chr5:671434	TPPP	0.67	4.84	0.44	5.03e-6	Lung disease severity in cystic fibrosis;
THYM	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg01577475	chr2:114033581	PAX8;LOC440839	-0.54	-5.07	-0.46	1.93e-6	Lymphocyte counts;
THYM	cis	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg06521331	chr12:34319734	NA	-0.97	-8.86	-0.67	4.58e-14	Morning vs. evening chronotype;
THYM	cis	rs6539288	0.739	rs4964511	chr12:107360246	T/C	cg26297688	chr12:107349093	C12orf23	-0.44	-4.62	-0.43	1.21e-5	Total body bone mineral density;
THYM	cis	rs921968	0.643	rs2278529	chr2:219502132	C/T	cg02176678	chr2:219576539	TTLL4	0.63	6.23	0.54	1.24e-8	Mean corpuscular hemoglobin concentration;
THYM	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg17105886	chr17:28927953	LRRC37B2	1.29	6.73	0.57	1.26e-9	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9303280	0.617	rs6503525	chr17:38095174	C/G	cg24910161	chr17:38119198	GSDMA	0.55	6.76	0.57	1.11e-9	Self-reported allergy;
THYM	cis	rs7072216	0.763	rs2274243	chr10:100175267	T/C	cg03852570	chr10:100175106	PYROXD2	0.38	5.0	0.46	2.64e-6	Metabolite levels;
THYM	cis	rs3112255	0.935	rs4851365	chr2:101291137	C/T	cg01042948	chr2:101319752	NA	-0.7	-5.96	-0.52	4.3e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.69	0.74	5.59e-18	Chronic sinus infection;
THYM	cis	rs898549	0.520	rs11238822	chr10:44535833	G/C	cg27599783	chr10:45480162	RASSF4	0.5	4.57	0.42	1.47e-5	Obesity-related traits;
THYM	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs6835098	0.692	rs6822683	chr4:174063974	G/A	cg08422745	chr4:174089978	GALNT7	-0.93	-7.61	-0.62	2.02e-11	Dementia and core Alzheimer's disease neuropathologic changes;
THYM	cis	rs28595532	0.920	rs115838006	chr4:119754356	T/C	cg14228332	chr4:119757509	SEC24D	1.58	5.78	0.51	9.49e-8	Cannabis dependence symptom count;
THYM	cis	rs1178127	0.765	rs1178129	chr7:18768334	T/G	cg13420273	chr7:18810212	HDAC9	0.61	4.86	0.45	4.59e-6	Facial morphology (factor 12, vertical position of sublabial sulcus relative to central midface);
THYM	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg08067268	chr2:26466485	HADHB;HADHA	0.81	4.65	0.43	1.07e-5	Gut microbiome composition (summer);
THYM	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg03060546	chr3:49711283	APEH	-0.73	-5.64	-0.5	1.74e-7	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.94	5.99	0.52	3.66e-8	Platelet count;
THYM	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg20744362	chr22:50050164	C22orf34	0.82	8.4	0.65	4.27e-13	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs9515201	0.884	rs11838776	chr13:111040681	G/A	cg06243866	chr13:111019493	COL4A2	-0.81	-7.0	-0.58	3.55e-10	White matter hyperintensity burden;
THYM	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg01579765	chr21:45077557	HSF2BP	-0.47	-7.43	-0.61	4.78e-11	Coronary artery disease;
THYM	cis	rs2806561	0.894	rs598438	chr1:23531563	C/T	cg08872493	chr1:23521417	HTR1D	0.36	4.45	0.42	2.34e-5	Height;
THYM	cis	rs4731207	0.672	rs62478914	chr7:124456654	G/A	cg05285228	chr7:124571219	POT1	0.66	5.23	0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg14416269	chr4:6271139	WFS1	0.56	5.68	0.5	1.48e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs11214589	0.806	rs4551806	chr11:113250540	T/A	cg14159747	chr11:113255604	NA	0.37	8.42	0.65	3.9e-13	Neuroticism;
THYM	cis	rs6429082	0.764	rs291377	chr1:235695186	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.78	-6.44	-0.55	4.93e-9	Adiposity;
THYM	cis	rs3791556	0.853	rs35245395	chr2:240107661	C/T	cg27074582	chr2:240114406	HDAC4	0.54	4.75	0.44	7.2e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs6796502	0.541	rs28440083	chr3:46881986	A/G	cg22309949	chr3:46792192	NA	-0.82	-4.57	-0.42	1.49e-5	Breast cancer;
THYM	cis	rs7432375	0.901	rs1729951	chr3:136500733	T/G	cg21827317	chr3:136751795	NA	-0.62	-5.19	-0.47	1.17e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg12310025	chr6:25882481	NA	-0.93	-8.4	-0.65	4.23e-13	Intelligence (multi-trait analysis);
THYM	cis	rs4642101	0.737	rs4447735	chr3:12825513	C/T	cg05775895	chr3:12838266	CAND2	0.82	7.35	0.6	6.83e-11	QRS complex (12-leadsum);
THYM	cis	rs4713118	0.869	rs6930992	chr6:27712120	A/C	cg08968635	chr6:28129556	ZNF389	0.68	5.23	0.47	9.97e-7	Parkinson's disease;
THYM	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg13695892	chr22:41940480	POLR3H	0.85	6.16	0.53	1.72e-8	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs990171	1.000	rs2270297	chr2:102992675	T/C	cg13897122	chr2:103039542	IL18RAP	-0.4	-4.71	-0.44	8.29e-6	Lymphocyte counts;
THYM	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg17143192	chr8:8559678	CLDN23	-0.68	-5.06	-0.46	2.03e-6	Mood instability;
THYM	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg22981736	chr15:31284413	MTMR10	-0.57	-4.78	-0.44	6.42e-6	Huntington's disease progression;
THYM	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg07414643	chr4:187882934	NA	0.67	5.92	0.52	5.16e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg24375607	chr4:120327624	NA	0.64	5.08	0.46	1.92e-6	Corneal astigmatism;
THYM	cis	rs12367572	0.965	rs7952764	chr12:45246211	C/A	cg03114573	chr12:45410052	DBX2	-0.57	-5.24	-0.47	9.46e-7	Gut microbiome composition (summer);
THYM	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg03806693	chr22:41940476	POLR3H	1.07	8.23	0.65	9.65e-13	Cannabis dependence symptom count;
THYM	cis	rs1209950	1.000	rs1209950	chr21:40173528	A/G	cg01359822	chr21:40176597	ETS2	-0.7	-5.64	-0.5	1.75e-7	Non-small cell lung cancer (survival);
THYM	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg10515332	chr4:99064459	C4orf37	0.6	4.82	0.44	5.45e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs2219968	0.828	rs4412362	chr8:78930579	C/T	cg00738934	chr8:78996279	NA	-0.82	-8.49	-0.66	2.78e-13	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg07492924	chr16:433825	LOC100134368	0.45	4.85	0.45	4.9100000000000004e-06	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs8041943	0.550	rs72730820	chr15:79890104	C/T	cg20511832	chr15:78934280	CHRNB4	0.47	4.56	0.42	1.5e-5	Bone mineral density (spine) and age at menarche;
THYM	cis	rs4074961	0.585	rs10752600	chr1:38067552	G/T	cg17933807	chr1:38061675	GNL2	1.11	15.99	0.85	1.07e-28	Axial length;
THYM	cis	rs7940866	0.834	rs10791108	chr11:130849354	T/A	cg12179176	chr11:130786555	SNX19	0.68	5.15	0.47	1.41e-6	Schizophrenia;
THYM	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg22105103	chr4:187893119	NA	0.95	10.29	0.73	3.97e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9462846	0.853	rs9462850	chr6:42872475	C/T	cg09436375	chr6:42928200	GNMT	-0.37	-4.51	-0.42	1.82e-5	Blood protein levels;
THYM	cis	rs72960926	0.744	rs55867620	chr6:75038763	G/A	cg03266952	chr6:74778945	NA	-0.86	-4.52	-0.42	1.78e-5	Metabolite levels (MHPG);
THYM	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg16325326	chr1:53192061	ZYG11B	0.82	7.77	0.62	9e-12	Monocyte count;
THYM	cis	rs4595586	0.545	rs12827197	chr12:39404362	C/T	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs6542838	0.703	rs7593332	chr2:99467991	A/G	cg08885076	chr2:99613938	TSGA10	-0.48	-4.67	-0.43	9.84e-6	Fear of minor pain;
THYM	cis	rs5760092	0.842	rs5751763	chr22:24247793	T/C	cg23131131	chr22:24373011	LOC391322	-0.75	-5.35	-0.48	6.01e-7	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs8070740	0.891	rs4790264	chr17:5336791	G/T	cg25236894	chr17:5323110	RPAIN;NUP88	0.71	5.22	0.47	1.04e-6	Menopause (age at onset);
THYM	cis	rs28595532	0.920	rs114670456	chr4:119771202	A/G	cg11846333	chr4:119757529	SEC24D	1.45	5.07	0.46	1.94e-6	Cannabis dependence symptom count;
THYM	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg23958373	chr8:599963	NA	1.01	4.74	0.44	7.6e-6	IgG glycosylation;
THYM	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg27535305	chr1:53392650	SCP2	0.4	4.68	0.43	9.51e-6	Monocyte count;
THYM	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg08742575	chr21:47604166	C21orf56	0.75	5.65	0.5	1.68e-7	Testicular germ cell tumor;
THYM	cis	rs28595532	0.920	rs115006522	chr4:119732499	A/G	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs13418717	0.793	rs57113328	chr2:127667120	G/A	cg25501666	chr2:127640322	NA	1.36	6.65	0.56	1.89e-9	Heart failure;
THYM	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg00256281	chr22:41985642	PMM1	0.63	4.85	0.45	4.87e-6	Vitiligo;
THYM	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg02527881	chr3:46936655	PTH1R	0.57	5.5	0.49	3.16e-7	Colorectal cancer;
THYM	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg02070205	chr10:30722105	MAP3K8	-0.6	-4.96	-0.45	3.08e-6	Inflammatory bowel disease;
THYM	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg02018176	chr4:1364513	KIAA1530	-0.53	-4.47	-0.42	2.18e-5	Obesity-related traits;
THYM	cis	rs4523957	0.690	rs11078855	chr17:2091308	A/G	cg16513277	chr17:2031491	SMG6	0.94	8.81	0.67	5.81e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6840360	0.642	rs56301462	chr4:152452128	T/G	cg17479576	chr4:152424074	FAM160A1	-0.66	-5.02	-0.46	2.44e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg11752832	chr7:134001865	SLC35B4	0.74	5.65	0.5	1.69e-7	Mean platelet volume;
THYM	cis	rs2235649	0.833	rs4335769	chr16:1849376	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.45	-4.86	-0.45	4.71e-6	Blood metabolite levels;
THYM	cis	rs10463554	1.000	rs3776862	chr5:102331721	G/A	cg23492399	chr5:102201601	PAM	-0.63	-4.94	-0.45	3.36e-6	Parkinson's disease;
THYM	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg17366294	chr4:99064904	C4orf37	0.48	5.43	0.49	4.3e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs877282	0.898	rs10904547	chr10:766283	C/T	cg10556349	chr10:835070	NA	-0.78	-5.04	-0.46	2.2e-6	Uric acid levels;
THYM	cis	rs61990749	0.597	rs2112136	chr14:78248952	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	1.14	7.59	0.61	2.19e-11	Fibroblast growth factor basic levels;
THYM	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03517284	chr6:25882590	NA	-0.79	-6.07	-0.53	2.66e-8	Blood metabolite levels;
THYM	cis	rs4866334	1.000	rs77552202	chr5:18489043	A/T	cg02002538	chr5:17811409	NA	-1.09	-4.53	-0.42	1.7e-5	IgG glycosylation;
THYM	cis	rs3741151	0.773	rs73542938	chr11:73103012	G/C	cg17517138	chr11:73019481	ARHGEF17	0.99	5.79	0.51	9.03e-8	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs8192282	0.739	rs6691727	chr1:154497005	C/T	cg16683920	chr1:154474344	TDRD10;SHE	0.59	5.36	0.48	5.82e-7	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
THYM	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	0.76	5.14	0.47	1.49e-6	Height;
THYM	cis	rs2235642	0.893	rs8051295	chr16:1588087	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.64	-5.56	-0.5	2.45e-7	Coronary artery disease;
THYM	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	10.57	0.74	1.01e-17	Prudent dietary pattern;
THYM	cis	rs6772849	0.830	rs4857917	chr3:128376178	C/T	cg23732725	chr3:128766093	NA	-0.5	-4.64	-0.43	1.1e-5	Monocyte percentage of white cells;Monocyte count;
THYM	cis	rs3020333	0.653	rs851983	chr6:152024415	A/G	cg22157087	chr6:152012887	ESR1	0.46	4.99	0.46	2.76e-6	Total body bone mineral density;
THYM	cis	rs34017685	0.609	rs7558220	chr2:71330331	C/T	cg25705148	chr2:72079498	NA	-1.0	-4.65	-0.43	1.06e-5	Stem cell growth factor beta levels;
THYM	cis	rs6570726	0.935	rs413916	chr6:145831400	T/C	cg23711669	chr6:146136114	FBXO30	0.9	9.18	0.69	9.22e-15	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9522267	0.535	rs9522286	chr13:112230909	A/G	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg26384229	chr12:38710491	ALG10B	1.03	9.52	0.7	1.76e-15	Heart rate;
THYM	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg24675056	chr1:15929824	NA	0.73	5.79	0.51	9.09e-8	Systolic blood pressure;
THYM	cis	rs61931739	0.635	rs7979207	chr12:33910566	C/T	cg10856724	chr12:34555212	NA	0.63	5.9	0.52	5.54e-8	Morning vs. evening chronotype;
THYM	cis	rs6860806	0.661	rs28472559	chr5:131581611	G/A	cg18758796	chr5:131593413	PDLIM4	0.61	6.05	0.53	2.92e-8	Breast cancer;
THYM	cis	rs12681287	0.517	rs34367154	chr8:87508749	A/T	cg27223183	chr8:87520930	FAM82B	-0.71	-5.46	-0.49	3.8e-7	Caudate activity during reward;
THYM	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg05890377	chr2:74357713	NA	1.09	10.23	0.72	5.23e-17	Gestational age at birth (maternal effect);
THYM	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg13390004	chr1:15929781	NA	0.63	4.77	0.44	6.76e-6	Systolic blood pressure;
THYM	cis	rs13102973	0.864	rs7442176	chr4:135899575	C/A	cg14419869	chr4:135874104	NA	-0.78	-6.5	-0.55	3.76e-9	Subjective well-being;
THYM	cis	rs7107174	0.901	rs2450138	chr11:77924870	C/T	cg19901956	chr11:77921274	USP35	-0.77	-6.01	-0.53	3.34e-8	Testicular germ cell tumor;
THYM	cis	rs7546094	1.000	rs6669096	chr1:113132361	T/C	cg22162597	chr1:113214053	CAPZA1	0.45	4.63	0.43	1.15e-5	Platelet distribution width;
THYM	cis	rs9549260	0.564	rs4245402	chr13:41287540	C/T	cg21288729	chr13:41239152	FOXO1	0.65	4.98	0.45	2.89e-6	Red blood cell count;
THYM	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-5.08	-0.46	1.91e-6	Gut microbiome composition (summer);
THYM	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg15997130	chr1:24165203	NA	-0.7	-5.25	-0.47	9.11e-7	Immature fraction of reticulocytes;
THYM	cis	rs10489525	1.000	rs10489525	chr1:115263685	A/G	cg12756093	chr1:115239321	AMPD1	0.68	5.05	0.46	2.17e-6	Autism;
THYM	cis	rs4788570	0.615	rs4788822	chr16:71681515	A/G	cg06353428	chr16:71660113	MARVELD3	1.26	8.32	0.65	6.23e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7107174	1.000	rs10899453	chr11:77997482	A/C	cg19901956	chr11:77921274	USP35	-0.73	-5.49	-0.49	3.3e-7	Testicular germ cell tumor;
THYM	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg11502198	chr6:26597334	ABT1	0.61	5.15	0.47	1.39e-6	Intelligence (multi-trait analysis);
THYM	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg20887711	chr4:1340912	KIAA1530	0.69	6.1	0.53	2.32e-8	Longevity;
THYM	cis	rs828999	0.688	rs6659201	chr1:108694118	T/C	cg24323958	chr1:108741884	SLC25A24	0.51	5.03	0.46	2.29e-6	Monocyte percentage of white cells;
THYM	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg18252515	chr7:66147081	NA	0.63	4.47	0.42	2.13e-5	Aortic root size;
THYM	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg18761221	chr20:60518478	NA	-0.68	-5.75	-0.51	1.09e-7	Obesity-related traits;
THYM	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg02869364	chr7:1081709	C7orf50	-0.63	-5.1	-0.46	1.77e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3008870	0.755	rs1925409	chr1:67365089	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.81	-6.81	-0.57	8.73e-10	Lymphocyte percentage of white cells;
THYM	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs6575793	1.000	rs8006543	chr14:101033420	C/T	cg13521842	chr14:101036202	BEGAIN	-0.53	-4.82	-0.44	5.33e-6	Menarche (age at onset);
THYM	cis	rs17739794	0.557	rs35400327	chr8:808789	A/G	cg07178994	chr8:816998	NA	0.47	4.57	0.42	1.46e-5	Clozapine-induced cytotoxicity;
THYM	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg10802521	chr3:52805072	NEK4	-0.79	-7.42	-0.61	5e-11	Bipolar disorder;
THYM	cis	rs72627123	0.867	rs73303122	chr14:74486797	A/G	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.12	6.52	0.56	3.44e-9	Morning vs. evening chronotype;
THYM	cis	rs7756236	0.521	rs9394368	chr6:36630525	C/G	cg08179530	chr6:36648295	CDKN1A	-0.61	-4.5	-0.42	1.9e-5	QRS duration;
THYM	cis	rs10992471	0.603	rs1121978	chr9:95140351	T/G	cg14631576	chr9:95140430	CENPP	-1.04	-11.32	-0.76	2.57e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg14780466	chr2:20870812	GDF7	0.69	6.34	0.54	7.87e-9	Abdominal aortic aneurysm;
THYM	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg04896959	chr15:78267971	NA	0.93	8.58	0.66	1.81e-13	Coronary artery disease or large artery stroke;
THYM	cis	rs9807841	0.592	rs2742313	chr19:10799750	T/C	cg17848348	chr19:10766748	ILF3	-0.74	-5.89	-0.52	5.7e-8	Inflammatory skin disease;
THYM	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg13147721	chr7:65941812	NA	-0.76	-4.93	-0.45	3.42e-6	Diabetic kidney disease;
THYM	cis	rs10737909	0.728	rs1780588	chr1:15554229	T/G	cg03960804	chr1:15570129	NA	0.44	4.49	0.42	1.97e-5	Migraine;
THYM	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg09904177	chr6:26538194	HMGN4	0.64	5.41	0.49	4.78e-7	Intelligence (multi-trait analysis);
THYM	cis	rs11997175	0.646	rs10954936	chr8:33686165	C/T	ch.8.33884649F	chr8:33765107	NA	0.66	5.03	0.46	2.33e-6	Body mass index;
THYM	cis	rs4731207	0.596	rs2170354	chr7:124665919	G/A	cg05285228	chr7:124571219	POT1	-0.6	-4.52	-0.42	1.76e-5	Cutaneous malignant melanoma;
THYM	cis	rs695646	1	rs695646	chr22:29709663	G/GC	cg10230314	chr22:30552801	HORMAD2	-0.66	-4.88	-0.45	4.26e-6	Mean platelet volume;
THYM	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	18.27	0.88	7.47e-33	Chronic sinus infection;
THYM	cis	rs9527	0.662	rs10786714	chr10:104598606	G/C	cg15744005	chr10:104629667	AS3MT	-0.69	-5.45	-0.49	3.99e-7	Arsenic metabolism;
THYM	cis	rs42648	0.869	rs42617	chr7:89952046	T/A	cg25739043	chr7:89950458	NA	-0.56	-4.68	-0.43	9.51e-6	Homocysteine levels;
THYM	cis	rs4363385	0.693	rs10788849	chr1:152902240	C/A	cg07796016	chr1:152779584	LCE1C	-0.56	-4.51	-0.42	1.87e-5	Inflammatory skin disease;
THYM	cis	rs10256972	0.758	rs7789093	chr7:1002981	T/C	cg02602264	chr7:1026310	CYP2W1	-0.54	-5.13	-0.47	1.52e-6	Longevity;Endometriosis;
THYM	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg22467129	chr15:76604101	ETFA	-0.56	-5.16	-0.47	1.37e-6	Blood metabolite levels;
THYM	cis	rs8114671	0.527	rs6060112	chr20:33489276	A/T	cg08999081	chr20:33150536	PIGU	0.63	5.21	0.47	1.09e-6	Height;
THYM	cis	rs7084402	0.935	rs893370	chr10:60360834	A/T	cg27040468	chr10:60456715	BICC1	-0.54	-4.5	-0.42	1.92e-5	Refractive error;
THYM	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg05313129	chr8:58192883	C8orf71	-0.86	-5.0	-0.46	2.62e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg15536230	chr21:44985092	HSF2BP	-0.38	-4.53	-0.42	1.69e-5	Mean corpuscular volume;
THYM	cis	rs11122272	0.668	rs1122131	chr1:231476501	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-4.46	-0.42	2.24e-5	Hemoglobin concentration;
THYM	cis	rs9933309	0.916	rs57953994	chr16:88846803	G/A	cg00153919	chr16:88859944	NA	-0.62	-5.51	-0.49	3.06e-7	Glycated hemoglobin levels;
THYM	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3781426	1.000	rs3781428	chr10:126702843	C/T	cg04494136	chr10:126703576	CTBP2	-0.4	-5.35	-0.48	6.06e-7	Height;
THYM	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.89	9.14	0.68	1.12e-14	Menarche (age at onset);
THYM	cis	rs9868809	0.881	rs2286652	chr3:48689192	G/A	cg00383909	chr3:49044727	WDR6	1.13	5.77	0.51	9.81e-8	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs11645898	0.935	rs4788615	chr16:72192372	G/A	cg14768367	chr16:72042858	DHODH	-0.74	-5.36	-0.48	5.94e-7	Blood protein levels;
THYM	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg03859395	chr2:55845619	SMEK2	-0.5	-4.59	-0.43	1.37e-5	Metabolic syndrome;
THYM	cis	rs9875589	0.509	rs1601868	chr3:14065450	T/C	cg03204825	chr3:13978759	TPRXL	-0.51	-4.46	-0.42	2.26e-5	Ovarian reserve;
THYM	cis	rs4282339	0.794	rs2974431	chr5:168267682	A/T	cg18364770	chr5:168310523	SLIT3	0.38	5.08	0.46	1.85e-6	Height;
THYM	cis	rs7178572	1.000	rs952472	chr15:77776562	A/C	cg22256960	chr15:77711686	NA	-0.94	-7.93	-0.63	4.23e-12	Type 2 diabetes;
THYM	cis	rs13279522	0.536	rs6472248	chr8:67013291	T/C	cg20171999	chr8:67343066	NA	-0.46	-4.6	-0.43	1.3e-5	Coronary heart disease event reduction (statin therapy interaction);
THYM	cis	rs74417235	0.684	rs13186731	chr5:154056002	C/T	cg05662444	chr5:154026397	NA	0.55	4.83	0.44	5.29e-6	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
THYM	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.04	-10.47	-0.73	1.61e-17	Primary sclerosing cholangitis;
THYM	cis	rs4731207	0.596	rs12537473	chr7:124586711	G/A	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg04731861	chr2:219085781	ARPC2	0.54	5.05	0.46	2.11e-6	Colorectal cancer;
THYM	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg01966878	chr4:90757139	SNCA	-0.63	-4.91	-0.45	3.72e-6	Neuroticism;
THYM	cis	rs10489202	1.000	rs10489202	chr1:167903079	A/C	cg24449463	chr1:168025552	DCAF6	0.78	6.11	0.53	2.19e-8	Schizophrenia;
THYM	trans	rs10922244	0.692	rs12042609	chr1:197477448	C/T	cg17042715	chr13:75814730	LOC647288	-1.04	-7.85	-0.63	6.18e-12	Depressive symptoms;
THYM	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs7216064	1.000	rs12451721	chr17:65939075	G/A	cg12091567	chr17:66097778	LOC651250	-0.69	-4.51	-0.42	1.86e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs6032067	0.925	rs35751129	chr20:43847658	C/A	cg16667508	chr20:43936853	MATN4;RBPJL	-0.68	-7.11	-0.59	2.19e-10	Blood protein levels;
THYM	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg26384229	chr12:38710491	ALG10B	-0.69	-5.34	-0.48	6.37e-7	Morning vs. evening chronotype;
THYM	cis	rs4889855	0.505	rs6565467	chr17:78610113	A/G	cg16591659	chr17:78472290	NA	-0.41	-5.19	-0.47	1.22e-6	Fractional excretion of uric acid;
THYM	cis	rs6815814	0.950	rs5743794	chr4:38832727	C/T	cg02016764	chr4:38805732	TLR1	-0.51	-5.08	-0.46	1.85e-6	Breast cancer;
THYM	cis	rs11850957	0.502	rs58424382	chr14:25444195	T/C	cg26846476	chr14:24838993	NFATC4	0.93	4.77	0.44	6.66e-6	Subcutaneous adipose tissue;
THYM	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg12826209	chr6:26865740	GUSBL1	0.87	4.6	0.43	1.28e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs67460515	0.892	rs2054710	chr3:161090616	C/T	cg03342759	chr3:160939853	NMD3	-0.88	-7.6	-0.61	2.07e-11	Parkinson's disease;
THYM	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg02596486	chr22:25115120	PIWIL3	-0.41	-4.51	-0.42	1.82e-5	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg23583168	chr7:148888333	NA	-1.06	-13.95	-0.82	1.01e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
THYM	cis	rs9914988	0.943	rs4794838	chr17:27131095	T/C	cg20469991	chr17:27169893	C17orf63	-0.77	-4.87	-0.45	4.4e-6	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
THYM	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg03806693	chr22:41940476	POLR3H	-1.03	-8.1	-0.64	1.87e-12	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg27446573	chr6:127587934	RNF146	0.76	6.64	0.56	1.9e-9	Breast cancer;
THYM	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg16405210	chr4:1374714	KIAA1530	-1.03	-9.38	-0.69	3.54e-15	Longevity;
THYM	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg04455712	chr21:45112962	RRP1B	0.49	4.48	0.42	2.07e-5	Mean corpuscular volume;
THYM	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg01831904	chr17:28903510	LRRC37B2	-1.02	-5.06	-0.46	2.05e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg01238044	chr22:24384105	GSTT1	0.6	4.9	0.45	4e-6	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs11677370	0.574	rs12329183	chr2:3866943	G/A	cg17052675	chr2:3827356	NA	-0.69	-6.46	-0.55	4.47e-9	Type 2 diabetes;
THYM	cis	rs9660180	0.967	rs61422524	chr1:1767565	C/A	cg13866156	chr1:1669148	SLC35E2	-0.69	-6.69	-0.57	1.55e-9	Body mass index;
THYM	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	15.57	0.85	6.94e-28	Chronic sinus infection;
THYM	cis	rs459571	0.920	rs455073	chr9:136909141	G/C	cg13789015	chr9:136890014	NCRNA00094	0.84	7.16	0.59	1.69e-10	Platelet distribution width;
THYM	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg03859395	chr2:55845619	SMEK2	0.6	5.52	0.49	2.95e-7	Metabolic syndrome;
THYM	cis	rs11997175	0.646	rs28785323	chr8:33736104	C/G	ch.8.33884649F	chr8:33765107	NA	0.68	5.1	0.46	1.76e-6	Body mass index;
THYM	cis	rs12519773	0.502	rs4613686	chr5:92498497	A/G	cg18783429	chr5:92414398	NA	0.48	4.55	0.42	1.57e-5	Migraine;
THYM	trans	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg07393940	chr7:158741817	NA	1.08	8.35	0.65	5.48e-13	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg11663144	chr21:46675770	NA	-0.72	-10.04	-0.72	1.33e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.64	5.63	0.5	1.82e-7	Height;
THYM	cis	rs425277	1.000	rs262654	chr1:2089526	G/A	cg00981070	chr1:2046702	PRKCZ	0.47	5.21	0.47	1.1e-6	Height;
THYM	cis	rs57920188	0.584	rs57277002	chr1:4092054	T/G	cg08764037	chr1:3634867	TP73	-0.44	-4.68	-0.43	9.63e-6	Interleukin-17 levels;
THYM	cis	rs4664308	0.618	rs66667042	chr2:160886703	A/C	cg03641300	chr2:160917029	PLA2R1	-0.63	-5.3	-0.48	7.6e-7	Idiopathic membranous nephropathy;
THYM	cis	rs4481887	1.000	rs11204626	chr1:248458974	T/A	cg13385794	chr1:248469461	NA	0.67	4.62	0.43	1.22e-5	Common traits (Other);
THYM	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg15536230	chr21:44985092	HSF2BP	0.44	5.45	0.49	4.05e-7	Mean corpuscular volume;
THYM	cis	rs11031096	0.754	rs3817657	chr11:4142592	T/C	cg18678763	chr11:4115507	RRM1	-0.38	-5.17	-0.47	1.27e-6	Mean corpuscular volume;Mean corpuscular hemoglobin;
THYM	cis	rs714027	0.565	rs2285667	chr22:30384104	T/A	cg27665648	chr22:30112403	NA	0.5	4.58	0.43	1.4e-5	Lymphocyte counts;
THYM	cis	rs1784581	0.761	rs7741581	chr6:162435250	C/T	cg17173639	chr6:162384350	PARK2	0.77	7.51	0.61	3.19e-11	Itch intensity from mosquito bite;
THYM	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg02038168	chr22:39784481	NA	-0.65	-4.78	-0.44	6.29e-6	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
THYM	cis	rs6674176	0.597	rs9326136	chr1:44390392	A/G	cg15962314	chr1:44399869	ARTN	-0.51	-4.75	-0.44	7.14e-6	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;
THYM	cis	rs10769945	0.538	rs739906	chr11:1980568	T/C	cg18511798	chr11:2018149	H19;MIR675	0.5	4.53	0.42	1.7e-5	DNA methylation (variation);
THYM	cis	rs9638182	0.673	rs13221253	chr7:72922233	A/G	cg22888238	chr7:73256761	WBSCR27	-1.04	-4.55	-0.42	1.59e-5	Triglycerides;
THYM	cis	rs1267303	0.642	rs1267301	chr1:46992853	C/G	cg16387850	chr1:46982889	NA	0.47	5.64	0.5	1.74e-7	Monobrow;
THYM	cis	rs6539288	0.933	rs1444581	chr12:107314251	A/G	cg26297688	chr12:107349093	C12orf23	-0.49	-5.22	-0.47	1.03e-6	Total body bone mineral density;
THYM	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.9	5.72	0.51	1.23e-7	Platelet count;
THYM	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg26384229	chr12:38710491	ALG10B	0.71	5.52	0.49	2.92e-7	Morning vs. evening chronotype;
THYM	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg11764359	chr7:65958608	NA	0.85	7.08	0.59	2.47e-10	Aortic root size;
THYM	cis	rs9649465	0.967	rs12531955	chr7:123377066	G/A	cg15443791	chr7:124364398	NA	0.59	4.9	0.45	3.96e-6	Migraine;
THYM	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg07648498	chr16:89883185	FANCA	0.61	4.49	0.42	2.02e-5	Vitiligo;
THYM	trans	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg19862616	chr7:65841803	NCRNA00174	1.06	11.85	0.77	2e-20	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg13607699	chr17:42295918	UBTF	0.6	5.03	0.46	2.33e-6	Total body bone mineral density;
THYM	cis	rs250677	0.522	rs1432801	chr5:148390979	T/C	cg18129178	chr5:148520854	ABLIM3	-0.71	-5.31	-0.48	7.05e-7	Breast cancer;
THYM	cis	rs4077515	0.870	rs11793497	chr9:139271850	A/G	cg14115884	chr9:139300582	SDCCAG3	0.73	6.9	0.58	5.79e-10	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg18758796	chr5:131593413	PDLIM4	0.5	4.79	0.44	6.25e-6	Breast cancer;
THYM	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg00080972	chr5:178986291	RUFY1	0.52	6.1	0.53	2.26e-8	Lung cancer;
THYM	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg06027949	chr8:82754900	SNX16	-0.64	-5.35	-0.48	6.18e-7	Diastolic blood pressure;
THYM	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg04267008	chr7:1944627	MAD1L1	-0.57	-5.01	-0.46	2.56e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs12681287	0.604	rs71502657	chr8:87478781	T/A	cg27223183	chr8:87520930	FAM82B	-0.68	-5.11	-0.46	1.65e-6	Caudate activity during reward;
THYM	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg26384229	chr12:38710491	ALG10B	0.94	7.47	0.61	3.88e-11	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22857025	chr5:266934	NA	-1.59	-10.2	-0.72	6.04e-17	Breast cancer;
THYM	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg03929089	chr4:120376271	NA	-1.03	-12.35	-0.78	1.83e-21	Height;
THYM	cis	rs8135828	0.710	rs462444	chr22:29974831	A/G	cg16189954	chr22:29138267	HSCB;CHEK2	-0.74	-4.5	-0.42	1.94e-5	Lipid traits;
THYM	cis	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg12826209	chr6:26865740	GUSBL1	0.98	4.51	0.42	1.82e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs73198271	0.960	rs11776546	chr8:8609181	T/G	cg06636001	chr8:8085503	FLJ10661	-0.73	-4.71	-0.43	8.61e-6	Bone ultrasound measurement (broadband ultrasound attenuation);
THYM	cis	rs1267303	0.642	rs3737740	chr1:47000596	G/A	cg25110126	chr1:46999211	NA	0.77	6.12	0.53	2.1e-8	Monobrow;
THYM	cis	rs11608355	1.000	rs7132057	chr12:109880279	A/C	cg10504392	chr12:110044639	NA	0.66	6.22	0.54	1.35e-8	Neuroticism;
THYM	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg15704280	chr7:45808275	SEPT13	1.02	8.31	0.65	6.7e-13	Height;
THYM	cis	rs7582180	0.614	rs1030901	chr2:101007314	G/A	cg14675211	chr2:100938903	LONRF2	0.64	6.17	0.53	1.69e-8	Intelligence (multi-trait analysis);
THYM	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg09307838	chr4:120376055	NA	0.66	4.81	0.44	5.67e-6	Corneal astigmatism;
THYM	cis	rs4474465	1.000	rs7950756	chr11:78157309	A/G	cg19901956	chr11:77921274	USP35	-0.61	-4.55	-0.42	1.56e-5	Alzheimer's disease (survival time);
THYM	cis	rs2303759	0.918	rs7251704	chr19:49890873	T/G	cg24324837	chr19:49891574	CCDC155	0.67	6.55	0.56	2.96e-9	Multiple sclerosis;
THYM	cis	rs1198430	1.000	rs1198439	chr1:23749593	A/T	cg27447006	chr1:23763279	ASAP3	0.83	4.45	0.42	2.29e-5	Total cholesterol levels;
THYM	cis	rs988913	0.678	rs10434833	chr6:54983383	T/C	cg18532076	chr6:54711417	FAM83B	0.49	4.51	0.42	1.83e-5	Menarche (age at onset);
THYM	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg02725872	chr8:58115012	NA	-1.12	-7.25	-0.6	1.11e-10	Developmental language disorder (linguistic errors);
THYM	cis	rs4731207	0.596	rs4507709	chr7:124651533	C/T	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg13010199	chr12:38710504	ALG10B	-0.6	-5.3	-0.48	7.56e-7	Heart rate;
THYM	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.41	6.33	0.54	7.93e-9	Obesity-related traits;
THYM	cis	rs61931739	0.534	rs1843733	chr12:34047626	T/C	cg10856724	chr12:34555212	NA	-0.75	-6.73	-0.57	1.25e-9	Morning vs. evening chronotype;
THYM	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg04750100	chr2:136595281	LCT	-0.54	-6.43	-0.55	5.16e-9	Mosquito bite size;
THYM	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg15247329	chr7:2764246	NA	-0.65	-5.48	-0.49	3.5e-7	Height;
THYM	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs72627123	0.867	rs80298117	chr14:74447383	G/C	cg11191049	chr14:74485465	ENTPD5;C14orf45	1.14	6.41	0.55	5.69e-9	Morning vs. evening chronotype;
THYM	cis	rs6840360	0.593	rs10033405	chr4:152474489	A/G	cg17479576	chr4:152424074	FAM160A1	-0.83	-6.46	-0.55	4.43e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg08017756	chr2:100939284	LONRF2	-0.74	-7.76	-0.62	9.59e-12	Intelligence (multi-trait analysis);
THYM	cis	rs1568889	0.938	rs6484358	chr11:28260364	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	4.86	0.45	4.55e-6	Bipolar disorder;
THYM	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg18252515	chr7:66147081	NA	-0.66	-5.0	-0.46	2.65e-6	Aortic root size;
THYM	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06873352	chr17:61820015	STRADA	0.79	9.97	0.72	1.89e-16	Prudent dietary pattern;
THYM	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg24818145	chr4:99064322	C4orf37	0.68	5.26	0.47	8.89e-7	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg02527881	chr3:46936655	PTH1R	-0.65	-6.44	-0.55	4.94e-9	Colorectal cancer;
THYM	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg24818145	chr4:99064322	C4orf37	0.75	6.12	0.53	2.07e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg16068833	chr1:26644515	UBXN11;CD52	0.26	4.5	0.42	1.9e-5	Obesity-related traits;
THYM	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg27534772	chr1:16042836	PLEKHM2	0.5	5.5	0.49	3.22e-7	Systolic blood pressure;
THYM	cis	rs7586879	0.929	rs6545807	chr2:25124358	C/T	cg01884057	chr2:25150051	NA	0.65	6.42	0.55	5.27e-9	Body mass index;
THYM	cis	rs4455778	0.561	rs6975663	chr7:49122743	G/C	cg26309511	chr7:48887640	NA	0.67	5.91	0.52	5.29e-8	Lung cancer in never smokers;
THYM	cis	rs10857712	0.521	rs10857714	chr10:135235370	C/A	cg00491522	chr10:135256596	NA	0.63	5.2	0.47	1.15e-6	Systemic lupus erythematosus;
THYM	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.53	6.59	0.56	2.39e-9	Schizophrenia;
THYM	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	14.47	0.83	9.53e-26	Chronic sinus infection;
THYM	cis	rs1568889	0.838	rs6484359	chr11:28262328	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg12698349	chr2:225449008	CUL3	-0.72	-5.36	-0.48	5.85e-7	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs6087990	0.966	rs1883730	chr20:31337487	T/A	cg13636640	chr20:31349939	DNMT3B	0.94	10.74	0.74	4.38e-18	Ulcerative colitis;
THYM	cis	rs9649465	1.000	rs12537287	chr7:123364747	G/A	cg15443791	chr7:124364398	NA	0.6	4.97	0.45	3.01e-6	Migraine;
THYM	cis	rs7580658	0.676	rs2174270	chr2:128006078	C/T	cg10021288	chr2:128175891	PROC	-0.62	-5.89	-0.52	5.93e-8	Protein C levels;
THYM	cis	rs912057	0.671	rs1294435	chr6:6745455	G/A	cg13809441	chr6:6737631	NA	0.42	5.05	0.46	2.11e-6	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
THYM	cis	rs13256369	0.708	rs11783670	chr8:8559394	G/A	cg00074818	chr8:8560427	CLDN23	0.59	5.49	0.49	3.4e-7	Obesity-related traits;
THYM	cis	rs7772486	0.777	rs1546966	chr6:146386018	G/T	cg23711669	chr6:146136114	FBXO30	0.72	6.73	0.57	1.28e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4919694	1.000	rs12257935	chr10:104803062	C/A	cg04362960	chr10:104952993	NT5C2	1.12	6.8	0.57	9.39e-10	Arsenic metabolism;
THYM	cis	rs11225247	0.772	rs11501344	chr11:102228252	A/G	cg06323957	chr11:102217781	BIRC2	1.02	4.74	0.44	7.52e-6	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs2290159	0.800	rs11128607	chr3:12673275	A/G	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg26384229	chr12:38710491	ALG10B	0.95	7.57	0.61	2.35e-11	Bladder cancer;
THYM	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg08885076	chr2:99613938	TSGA10	0.59	5.23	0.47	1.01e-6	Chronic sinus infection;
THYM	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg06623918	chr6:96969491	KIAA0776	-1.05	-10.59	-0.74	9.01e-18	Headache;
THYM	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.27	6.27	0.54	1.04e-8	Obesity-related traits;
THYM	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg06481639	chr22:41940642	POLR3H	0.7	5.12	0.47	1.57e-6	Vitiligo;
THYM	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg08859206	chr1:53392774	SCP2	-0.8	-9.2	-0.69	8.64e-15	Monocyte count;
THYM	cis	rs8067545	0.611	rs2526477	chr17:20131193	A/G	cg13482628	chr17:19912719	NA	-0.53	-4.47	-0.42	2.16e-5	Schizophrenia;
THYM	cis	rs6570726	0.935	rs392014	chr6:145843691	A/C	cg13319975	chr6:146136371	FBXO30	-0.68	-5.58	-0.5	2.23e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.74	5.72	0.51	1.23e-7	Lung cancer in ever smokers;
THYM	cis	rs7216064	1.000	rs11079706	chr17:65835470	G/T	cg12091567	chr17:66097778	LOC651250	-0.7	-4.52	-0.42	1.8e-5	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
THYM	cis	rs6089829	0.888	rs6011559	chr20:61675620	C/T	cg08045932	chr20:61659980	NA	-0.97	-10.33	-0.73	3.24e-17	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg14004847	chr7:1930337	MAD1L1	0.67	5.38	0.48	5.35e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg14675211	chr2:100938903	LONRF2	0.77	8.32	0.65	6.49e-13	Intelligence (multi-trait analysis);
THYM	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.71	4.54	0.42	1.65e-5	Diabetic retinopathy;
THYM	cis	rs2806561	0.514	rs10917360	chr1:23539010	C/T	cg19743168	chr1:23544995	NA	0.96	8.63	0.66	1.41e-13	Height;
THYM	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs9992101	0.680	rs4266316	chr4:77319743	C/T	cg20311846	chr4:77356250	SHROOM3	-0.54	-5.96	-0.52	4.32e-8	Creatinine levels;
THYM	cis	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.56	-0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.81	-7.07	-0.59	2.57e-10	Intelligence (multi-trait analysis);
THYM	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg11764359	chr7:65958608	NA	0.78	6.31	0.54	8.88e-9	Aortic root size;
THYM	cis	rs4866334	0.867	rs78373067	chr5:18463912	A/G	cg24599790	chr5:18972260	NA	-1.14	-4.69	-0.43	9.25e-6	IgG glycosylation;
THYM	cis	rs72712511	0.641	rs34236292	chr4:140786038	G/T	cg15010390	chr4:140216957	NDUFC1	0.63	4.54	0.42	1.66e-5	Intelligence (multi-trait analysis);
THYM	cis	rs4731207	0.751	rs4584095	chr7:124500210	C/T	cg05285228	chr7:124571219	POT1	-0.66	-5.23	-0.47	1.02e-6	Cutaneous malignant melanoma;
THYM	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg07636037	chr3:49044803	WDR6	0.87	7.94	0.63	4.12e-12	Parkinson's disease;
THYM	cis	rs236352	0.576	rs3778016	chr6:36842192	C/T	cg03410223	chr6:36853544	C6orf89	0.71	5.65	0.5	1.69e-7	Heart rate;
THYM	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	10.86	0.74	2.46e-18	Chronic sinus infection;
THYM	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg21609526	chr1:3105151	PRDM16	-0.66	-5.56	-0.5	2.52e-7	Migraine;
THYM	cis	rs6921919	0.583	rs740622	chr6:28398291	T/C	cg18815343	chr6:28367644	ZSCAN12	-0.59	-4.53	-0.42	1.74e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs61931739	0.890	rs1687020	chr12:34137924	G/C	cg10856724	chr12:34555212	NA	-0.64	-5.51	-0.49	3.09e-7	Morning vs. evening chronotype;
THYM	trans	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.13	12.41	0.79	1.36e-21	Exhaled nitric oxide output;
THYM	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg13010199	chr12:38710504	ALG10B	0.64	4.61	0.43	1.25e-5	Morning vs. evening chronotype;
THYM	cis	rs4889855	0.505	rs7501740	chr17:78610345	A/G	cg16591659	chr17:78472290	NA	-0.4	-5.09	-0.46	1.83e-6	Fractional excretion of uric acid;
THYM	cis	rs7772486	0.875	rs9322044	chr6:146369608	T/C	cg23711669	chr6:146136114	FBXO30	0.96	10.36	0.73	2.84e-17	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.38	-4.46	-0.42	2.21e-5	Monocyte percentage of white cells;
THYM	cis	rs860554	0.660	rs832167	chr1:201255782	T/C	cg01022117	chr1:201258280	PKP1	0.64	4.71	0.43	8.51e-6	Panic disorder;
THYM	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg17173187	chr15:85201210	NMB	0.56	5.51	0.49	3e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg04034577	chr2:241836375	C2orf54	-0.45	-8.0	-0.63	2.98e-12	Urinary metabolites;
THYM	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg12011299	chr4:100065546	ADH4	-0.86	-8.22	-0.64	1.06e-12	Alcohol dependence;
THYM	cis	rs4731207	0.596	rs6967887	chr7:124609490	G/A	cg05285228	chr7:124571219	POT1	-0.7	-5.28	-0.48	8.15e-7	Cutaneous malignant melanoma;
THYM	cis	rs3810291	1.000	rs8101149	chr19:47600441	A/G	cg12068280	chr19:46804528	HIF3A	0.4	4.49	0.42	2.03e-5	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);BMI in smokers;Hip circumference;Body mass index;Body mass index in physically active individuals;
THYM	cis	rs686320	1.000	rs1194758	chr11:65238085	A/T	cg20588859	chr11:65321429	LTBP3	-0.82	-4.79	-0.44	6.04e-6	Hip circumference adjusted for BMI;
THYM	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg25566285	chr7:158114605	PTPRN2	0.92	11.54	0.76	9.07e-20	Calcium levels;
THYM	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg26677194	chr12:130822605	PIWIL1	0.82	6.47	0.55	4.22e-9	Menopause (age at onset);
THYM	cis	rs9435341	1.000	rs9435341	chr1:107616641	T/C	cg09367891	chr1:107599246	PRMT6	-0.7	-5.11	-0.46	1.67e-6	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs1003719	0.788	rs2835579	chr21:38457965	T/C	cg01329690	chr21:38580129	DSCR9	0.39	5.25	0.47	9.23e-7	Eye color traits;
THYM	cis	rs6570726	0.935	rs414646	chr6:145831685	T/C	cg13319975	chr6:146136371	FBXO30	-0.7	-5.96	-0.52	4.18e-8	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg02389323	chr16:88786976	FAM38A	0.97	6.21	0.54	1.42e-8	Plateletcrit;
THYM	cis	rs763014	0.898	rs916416	chr16:632198	T/A	cg09263875	chr16:632152	PIGQ	0.71	5.98	0.52	3.92e-8	Height;
THYM	cis	rs4953076	0.573	rs7593987	chr2:44393532	C/T	cg04920474	chr2:44395004	PPM1B	-0.64	-5.25	-0.47	9.37e-7	Height;
THYM	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg27284194	chr4:1044797	NA	0.63	4.81	0.44	5.77e-6	Recombination rate (females);
THYM	cis	rs8141529	0.732	rs5997408	chr22:29207915	G/A	cg02153584	chr22:29168773	CCDC117	0.58	4.56	0.42	1.52e-5	Lymphocyte counts;
THYM	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg12310025	chr6:25882481	NA	-0.73	-5.72	-0.51	1.22e-7	Blood metabolite levels;
THYM	cis	rs61931739	0.613	rs1525898	chr12:33904445	G/T	cg10856724	chr12:34555212	NA	-0.62	-5.55	-0.49	2.56e-7	Morning vs. evening chronotype;
THYM	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.63	-5.91	-0.52	5.44e-8	Bone mineral density;
THYM	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg21926883	chr2:100939477	LONRF2	-0.58	-4.99	-0.46	2.76e-6	Intelligence (multi-trait analysis);
THYM	cis	rs9470366	0.637	rs4151702	chr6:36645988	G/C	cg24425727	chr6:36645648	CDKN1A	-0.64	-4.69	-0.43	9.01e-6	QRS duration;
THYM	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg02487422	chr3:49467188	NICN1	0.63	4.92	0.45	3.66e-6	Resting heart rate;
THYM	cis	rs4589258	0.788	rs7945337	chr11:90465013	A/G	cg26138821	chr11:89956704	CHORDC1	-0.6	-4.9	-0.45	3.9e-6	Intelligence (multi-trait analysis);
THYM	cis	rs11096990	0.855	rs2566177	chr4:39156178	G/C	cg24403649	chr4:39172243	NA	-0.64	-5.4	-0.48	4.98e-7	Cognitive function;
THYM	cis	rs828999	0.654	rs9325363	chr1:108713557	G/T	cg24323958	chr1:108741884	SLC25A24	-0.57	-5.66	-0.5	1.63e-7	Monocyte percentage of white cells;
THYM	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.61	4.5	0.42	1.92e-5	Ulcerative colitis;Inflammatory bowel disease;
THYM	cis	rs6951245	0.542	rs28460147	chr7:1217192	G/A	cg08132940	chr7:1081526	C7orf50	-1.17	-5.73	-0.51	1.18e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs6812193	0.518	rs2869881	chr4:77205745	T/C	cg20311846	chr4:77356250	SHROOM3	-0.51	-4.54	-0.42	1.62e-5	Parkinson's disease;
THYM	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03517284	chr6:25882590	NA	0.74	5.89	0.52	5.89e-8	Blood metabolite levels;
THYM	cis	rs8038465	0.594	rs55816897	chr15:73869767	G/T	cg15420318	chr15:73925796	NPTN	0.74	6.75	0.57	1.19e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg03188948	chr7:1209495	NA	0.7	4.87	0.45	4.46e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs3126085	0.560	rs3818831	chr1:152331240	G/A	cg10321714	chr1:152280068	FLG	-0.7	-5.16	-0.47	1.32e-6	Atopic dermatitis;
THYM	cis	rs10782582	0.593	rs6704444	chr1:76205108	T/C	cg22875332	chr1:76189707	ACADM	-0.53	-4.92	-0.45	3.65e-6	Daytime sleep phenotypes;
THYM	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg04944784	chr2:26401820	FAM59B	-0.62	-4.73	-0.44	7.71e-6	Gut microbiome composition (summer);
THYM	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg14004847	chr7:1930337	MAD1L1	-0.66	-4.88	-0.45	4.28e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg08999081	chr20:33150536	PIGU	0.57	5.02	0.46	2.37e-6	Height;
THYM	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg14972814	chr11:95582409	MTMR2	-0.72	-6.7	-0.57	1.44e-9	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
THYM	cis	rs6032067	0.673	rs13039345	chr20:43895932	G/C	cg20256260	chr20:43936981	MATN4;RBPJL	-0.63	-5.46	-0.49	3.78e-7	Blood protein levels;
THYM	cis	rs870825	0.929	rs56106324	chr4:185589901	C/A	cg04058563	chr4:185651563	MLF1IP	0.96	6.66	0.56	1.78e-9	Blood protein levels;
THYM	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg04972856	chr6:88032051	C6orf162;GJB7	-0.4	-4.7	-0.43	8.66e-6	Monocyte percentage of white cells;
THYM	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg23281280	chr6:28129359	ZNF389	0.67	5.28	0.48	8.33e-7	Depression;
THYM	cis	rs72828912	0.731	rs55691906	chr6:24068410	C/T	cg19882886	chr6:25043046	NA	-0.86	-4.47	-0.42	2.14e-5	Squamous cell lung carcinoma;
THYM	cis	rs13202913	0.837	rs6906678	chr6:151772395	A/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.87	-4.6	-0.43	1.32e-5	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg22535103	chr8:58192502	C8orf71	-1.04	-6.51	-0.56	3.56e-9	Developmental language disorder (linguistic errors);
THYM	cis	rs7760949	0.889	rs9475795	chr6:13931270	A/C	cg27413430	chr6:13925136	RNF182	0.54	4.78	0.44	6.3e-6	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg07424592	chr7:64974309	NA	-1.03	-5.36	-0.48	5.84e-7	Diabetic kidney disease;
THYM	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg07606381	chr6:8435919	SLC35B3	0.61	4.69	0.43	9.14e-6	Motion sickness;
THYM	cis	rs4072705	0.646	rs7037254	chr9:127245412	C/T	cg13476313	chr9:127244764	NR5A1	-0.36	-5.27	-0.48	8.48e-7	Menarche (age at onset);
THYM	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.27	4.47	0.42	2.16e-5	Obesity-related traits;
THYM	cis	rs6500395	1.000	rs11647048	chr16:48623227	T/G	cg04672837	chr16:48644449	N4BP1	0.48	4.64	0.43	1.13e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs11756438	0.572	rs2638550	chr6:118998481	C/G	cg21191810	chr6:118973309	C6orf204	0.56	5.65	0.5	1.7e-7	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs10089	1.000	rs4835941	chr5:127430905	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.03	6.77	0.57	1.06e-9	Ileal carcinoids;
THYM	trans	rs10962692	0.608	rs11792249	chr9:16864076	A/G	cg03221025	chr16:88955224	CBFA2T3	0.75	7.2	0.59	1.37e-10	Ovarian cancer in BRCA2 mutation carriers;Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;
THYM	cis	rs2294693	0.898	rs6458195	chr6:40972498	A/T	cg14769373	chr6:40998127	UNC5CL	0.58	4.62	0.43	1.22e-5	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.53	-4.99	-0.46	2.68e-6	Lymphocyte counts;
THYM	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg21361702	chr7:150065534	REPIN1	0.69	4.92	0.45	3.65e-6	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs6496667	0.865	rs10438436	chr15:90908781	A/G	cg22089800	chr15:90895588	ZNF774	-0.86	-5.21	-0.47	1.12e-6	Rheumatoid arthritis;
THYM	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg26446133	chr18:72167187	CNDP2	-1.02	-7.49	-0.61	3.5e-11	Refractive error;
THYM	cis	rs561341	0.843	rs879945	chr17:30242796	G/A	cg12000587	chr17:30186630	C17orf79	-0.4	-4.79	-0.44	6.21e-6	Hip circumference adjusted for BMI;
THYM	cis	rs10779751	0.734	rs1194820	chr1:11129259	A/C	cg08854313	chr1:11322531	MTOR	0.86	7.32	0.6	7.91e-11	Body mass index;
THYM	cis	rs7584330	0.737	rs6431539	chr2:238360708	G/T	cg14458575	chr2:238380390	NA	0.91	7.41	0.61	5.09e-11	Prostate cancer;
THYM	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg10589385	chr1:150898437	SETDB1	0.63	5.2	0.47	1.14e-6	Melanoma;
THYM	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg05294307	chr14:35346193	BAZ1A	-0.86	-6.04	-0.53	2.97e-8	Psoriasis;
THYM	cis	rs4788570	0.543	rs4788820	chr16:71660115	G/C	cg06353428	chr16:71660113	MARVELD3	1.39	9.47	0.7	2.29e-15	Intelligence (multi-trait analysis);
THYM	cis	rs236352	0.504	rs9349017	chr6:36811600	G/A	cg03410223	chr6:36853544	C6orf89	0.61	4.6	0.43	1.31e-5	Heart rate;
THYM	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg26769984	chr7:1090371	C7orf50	0.8	5.32	0.48	6.95e-7	Bronchopulmonary dysplasia;
THYM	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg15592062	chr6:167189543	RPS6KA2	0.59	6.16	0.53	1.73e-8	Crohn's disease;
THYM	cis	rs6531656	1.000	rs6531656	chr4:38684201	C/T	cg24279243	chr4:38676559	KLF3	0.87	6.11	0.53	2.2e-8	Lymphocyte counts;
THYM	cis	rs2016266	0.859	rs56225815	chr12:53740090	C/G	cg26875137	chr12:53738046	NA	-0.78	-5.78	-0.51	9.62e-8	Bone mineral density (spine);Bone mineral density;
THYM	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg15316289	chr22:50310904	ALG12;CRELD2	0.52	5.32	0.48	6.77e-7	Schizophrenia;
THYM	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg14004847	chr7:1930337	MAD1L1	-0.63	-4.93	-0.45	3.49e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs4466137	0.953	rs6869030	chr5:83007311	C/T	cg16102102	chr5:83017553	HAPLN1	-1.07	-10.56	-0.73	1.06e-17	Prostate cancer;
THYM	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg22841779	chr14:105766346	BRF1	-0.48	-6.0	-0.52	3.55e-8	Mean platelet volume;Platelet distribution width;
THYM	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06850241	chr22:41845214	NA	0.59	5.16	0.47	1.37e-6	Vitiligo;
THYM	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs78761021	0.755	rs79379978	chr17:9794488	G/A	cg26853458	chr17:9805074	RCVRN	0.53	4.49	0.42	2.01e-5	Type 2 diabetes;
THYM	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg12350822	chr6:88032061	C6orf162;GJB7	-0.42	-5.3	-0.48	7.34e-7	Monocyte percentage of white cells;
THYM	cis	rs67311347	0.524	rs7649168	chr3:40356158	T/C	cg13683864	chr3:40499215	RPL14	-0.71	-6.29	-0.54	9.68e-9	Renal cell carcinoma;
THYM	cis	rs61008539	0.586	rs6959154	chr7:856320	C/T	cg00475322	chr7:917719	C7orf20	0.46	5.62	0.5	1.87e-7	Perceived unattractiveness to mosquitoes;
THYM	cis	rs7513165	0.935	rs7538055	chr1:204161069	A/G	cg04791601	chr1:204159016	NA	0.4	5.05	0.46	2.12e-6	Psychosis proneness (hypomanic personality scale);Psychosis proneness (hypomanic personality scale and perceptual aberration scale);Psychosis proneness (hypomanic personality scale and revised social anhedonia scale);Psychosis proneness (hypomanic personality scale and revised physical anhedonia scale);
THYM	cis	rs6490294	0.583	rs4767364	chr12:112521448	G/A	cg10833066	chr12:111807467	FAM109A	0.47	5.23	0.47	1.02e-6	Mean platelet volume;
THYM	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg26384229	chr12:38710491	ALG10B	1.0	7.83	0.63	6.92e-12	Bladder cancer;
THYM	cis	rs7119	0.700	rs7497168	chr15:77886231	A/C	cg10437265	chr15:77819839	NA	-0.65	-6.32	-0.54	8.31e-9	Type 2 diabetes;
THYM	cis	rs10886503	0.920	rs7898879	chr10:121258249	G/A	cg13260278	chr10:121265587	RGS10	-0.66	-5.9	-0.52	5.57e-8	Obstetric antiphospholipid syndrome;
THYM	cis	rs7000551	0.663	rs7827093	chr8:22334610	A/G	cg12081754	chr8:22256438	SLC39A14	0.56	5.0	0.46	2.59e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs2067615	0.542	rs4433659	chr12:107082496	G/T	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	cis	rs303386	0.520	rs12143634	chr1:99598759	A/G	cg03593336	chr1:99471295	LPPR5	0.42	4.84	0.44	5.08e-6	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors);Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin);
THYM	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg25918947	chr17:41365094	TMEM106A	-0.67	-5.61	-0.5	2e-7	Menopause (age at onset);
THYM	cis	rs2730245	0.569	rs842692	chr7:158657228	T/C	cg24397884	chr7:158709396	WDR60	0.5	5.41	0.49	4.79e-7	Height;
THYM	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg02734326	chr4:10020555	SLC2A9	-0.63	-5.28	-0.48	8.26e-7	Cleft plate (environmental tobacco smoke interaction);
THYM	trans	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.93	-8.78	-0.67	6.81e-14	Brugada syndrome;
THYM	cis	rs3741151	0.773	rs17310361	chr11:73233724	T/C	cg17517138	chr11:73019481	ARHGEF17	0.9	4.73	0.44	7.74e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs950881	0.601	rs11465705	chr2:103058810	T/G	cg01241218	chr2:102972058	NA	0.76	4.94	0.45	3.41e-6	Allergy;
THYM	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg03605463	chr16:89740564	NA	-0.61	-4.51	-0.42	1.83e-5	Vitiligo;
THYM	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	1.13	9.14	0.68	1.12e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs1018836	0.851	rs10808620	chr8:91622940	T/C	cg16814680	chr8:91681699	NA	-0.99	-9.24	-0.69	7.07e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg27394845	chr17:28928406	LRRC37B2	0.91	4.58	0.42	1.44e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7941600	0.655	rs61875699	chr11:9360940	G/A	cg19415743	chr11:9336845	TMEM41B	0.91	4.59	0.43	1.36e-5	Coronary artery disease;
THYM	cis	rs8038465	0.662	rs7497012	chr15:73968719	G/A	cg15420318	chr15:73925796	NPTN	0.56	4.77	0.44	6.71e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg00071950	chr4:10020882	SLC2A9	0.74	7.27	0.6	9.88e-11	Bone mineral density;
THYM	cis	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg19847130	chr8:10466454	RP1L1	0.51	4.75	0.44	7.25e-6	Neuroticism;
THYM	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg05368731	chr17:41323189	NBR1	1.26	11.55	0.76	8.34e-20	Menopause (age at onset);
THYM	cis	rs665401	0.899	rs339328	chr6:117208509	G/T	cg20376953	chr6:117187980	NA	0.6	4.82	0.44	5.5e-6	Neutrophil percentage of granulocytes;
THYM	cis	rs4654899	0.802	rs10493004	chr1:21442736	T/C	cg01072550	chr1:21505969	NA	-0.76	-6.75	-0.57	1.15e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs61931739	0.857	rs1828514	chr12:34139600	A/G	cg06521331	chr12:34319734	NA	-0.6	-4.85	-0.45	4.77e-6	Morning vs. evening chronotype;
THYM	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg25072359	chr17:41440525	NA	0.65	4.49	0.42	1.99e-5	Menopause (age at onset);
THYM	cis	rs8050907	0.744	rs11861315	chr16:4518783	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	1.28	5.13	0.47	1.5e-6	Obesity-related traits;
THYM	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg10589385	chr1:150898437	SETDB1	0.66	5.48	0.49	3.44e-7	Melanoma;
THYM	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg02734326	chr4:10020555	SLC2A9	0.77	7.16	0.59	1.73e-10	Bone mineral density;
THYM	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg08847533	chr14:75593920	NEK9	-0.97	-10.19	-0.72	6.35e-17	Height;
THYM	cis	rs7695732	0.595	rs7697900	chr4:89908624	C/T	cg17769793	chr4:89976368	FAM13A	-0.49	-5.39	-0.48	5.23e-7	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg02269571	chr22:50332266	NA	-0.72	-5.42	-0.49	4.48e-7	Schizophrenia;
THYM	cis	rs4243830	0.737	rs925744	chr1:6615695	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-1.06	-7.07	-0.59	2.6e-10	Body mass index;
THYM	cis	rs7772486	0.875	rs2748501	chr6:146312258	G/A	cg13319975	chr6:146136371	FBXO30	-0.68	-5.66	-0.5	1.62e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg08048268	chr3:133502702	NA	-0.63	-5.18	-0.47	1.23e-6	Iron status biomarkers;
THYM	cis	rs4072705	0.646	rs915034	chr9:127244955	G/A	cg01786973	chr9:127249749	NR5A1	0.4	5.22	0.47	1.06e-6	Menarche (age at onset);
THYM	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg12011299	chr4:100065546	ADH4	-0.94	-9.81	-0.71	4.3e-16	Alcohol dependence;
THYM	cis	rs1691799	0.899	rs1168299	chr12:66736074	C/G	cg16791601	chr12:66731901	HELB	-0.75	-7.27	-0.6	1.03e-10	White blood cell count (basophil);
THYM	cis	rs7432375	0.901	rs4521165	chr3:136369710	T/C	cg21827317	chr3:136751795	NA	-0.59	-5.04	-0.46	2.22e-6	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
THYM	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.98	-4.81	-0.44	5.56e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2070677	0.935	rs12245492	chr10:135419727	A/G	cg20169779	chr10:135381914	SYCE1	-0.75	-5.76	-0.51	1.03e-7	Gout;
THYM	cis	rs7937890	0.810	rs10734224	chr11:14424124	G/T	cg19336497	chr11:14380999	RRAS2	-0.44	-4.63	-0.43	1.15e-5	Mitochondrial DNA levels;
THYM	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg17105886	chr17:28927953	LRRC37B2	1.3	6.83	0.57	8.15e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7944735	0.575	rs34972471	chr11:48050391	G/A	cg25800328	chr11:47736132	AGBL2	0.42	4.49	0.42	1.97e-5	Intraocular pressure;
THYM	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.11	-11.16	-0.75	5.56e-19	Primary sclerosing cholangitis;
THYM	cis	rs2073300	0.609	rs17830281	chr20:23350525	C/T	cg12062639	chr20:23401060	NAPB	1.2	6.43	0.55	5e-9	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs10276381	0.579	rs73072543	chr7:28146850	A/G	cg23204968	chr7:27183816	HOXA5	0.62	4.46	0.42	2.25e-5	Crohn's disease;
THYM	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg06784218	chr1:46089804	CCDC17	0.29	4.5	0.42	1.89e-5	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs2742417	0.603	rs2742395	chr3:45758595	A/G	cg04837898	chr3:45731254	SACM1L	-0.71	-4.99	-0.46	2.77e-6	Response to anti-depressant treatment in major depressive disorder;
THYM	cis	rs262150	0.579	rs4909110	chr7:158787332	C/T	cg23058037	chr7:158824108	VIPR2	0.5	4.64	0.43	1.12e-5	Facial morphology (factor 20);
THYM	cis	rs763014	0.931	rs62030903	chr16:638323	T/A	cg09263875	chr16:632152	PIGQ	0.73	5.95	0.52	4.44e-8	Height;
THYM	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg07424592	chr7:64974309	NA	0.92	4.7	0.43	8.89e-6	Diabetic kidney disease;
THYM	cis	rs7937	0.693	rs12973666	chr19:41289397	C/G	cg21869046	chr19:41225005	ITPKC	0.3	4.55	0.42	1.62e-5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Chronic obstructive pulmonary disease;Emphysema imaging phenotypes;
THYM	cis	rs8018808	0.935	rs11159262	chr14:77928735	A/G	cg20045696	chr14:77926864	AHSA1	0.5	4.54	0.42	1.63e-5	Myeloid white cell count;
THYM	cis	rs2554380	0.891	rs1426164	chr15:84301836	G/A	cg14598478	chr15:84363061	ADAMTSL3	-0.62	-4.87	-0.45	4.46e-6	Height;
THYM	cis	rs1113500	0.541	rs11185240	chr1:108582810	A/G	cg06207961	chr1:108661230	NA	0.7	4.87	0.45	4.51e-6	Growth-regulated protein alpha levels;
THYM	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg07362569	chr17:61921086	SMARCD2	0.73	6.56	0.56	2.84e-9	Prudent dietary pattern;
THYM	cis	rs6546324	0.625	rs6730286	chr2:67848054	C/T	cg18237512	chr2:67827392	NA	-0.8	-4.77	-0.44	6.69e-6	Endometriosis;
THYM	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg22907277	chr7:1156413	C7orf50	0.82	4.98	0.46	2.83e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2688608	0.592	rs3933085	chr10:75483331	C/T	cg15838173	chr10:75533400	FUT11	-0.54	-5.36	-0.48	5.84e-7	Inflammatory bowel disease;
THYM	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-5.62	-0.5	1.9e-7	Morning vs. evening chronotype;
THYM	cis	rs4523957	0.854	rs404392	chr17:2191000	G/A	cg16513277	chr17:2031491	SMG6	0.79	7.41	0.61	5.15e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg09307838	chr4:120376055	NA	0.65	4.79	0.44	6.07e-6	Corneal astigmatism;
THYM	cis	rs36051895	0.695	rs60221565	chr9:5029077	T/G	cg02405213	chr9:5042618	JAK2	-1.04	-10.94	-0.75	1.62e-18	Pediatric autoimmune diseases;
THYM	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.16	14.47	0.83	9.53e-26	Chronic sinus infection;
THYM	cis	rs6733011	0.519	rs12712037	chr2:99463025	G/T	cg08885076	chr2:99613938	TSGA10	-0.48	-4.5	-0.42	1.95e-5	Bipolar disorder;
THYM	cis	rs10911232	0.507	rs10797821	chr1:183012559	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.57	4.54	0.42	1.66e-5	Hypertriglyceridemia;
THYM	cis	rs12478296	0.591	rs7573042	chr2:242996589	A/G	cg06360820	chr2:242988706	NA	-0.68	-4.77	-0.44	6.73e-6	Obesity-related traits;
THYM	cis	rs9807989	0.507	rs10204757	chr2:102998974	A/C	cg03938978	chr2:103052716	IL18RAP	0.75	9.77	0.71	5.14e-16	Asthma;
THYM	cis	rs7894051	1.000	rs7897693	chr10:135200478	G/A	cg20534287	chr10:135191450	PAOX	-0.6	-4.77	-0.44	6.76e-6	Lifespan;
THYM	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg07404485	chr7:94953653	PON1	-0.88	-8.11	-0.64	1.75e-12	Paraoxonase activity;
THYM	cis	rs34599045	0.708	rs10888519	chr1:152901858	A/T	cg24332770	chr1:152658287	LCE2B	0.46	4.49	0.42	1.99e-5	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9894429	0.604	rs9912071	chr17:79609654	G/A	cg21028142	chr17:79581711	NPLOC4	0.55	5.12	0.47	1.58e-6	Eye color traits;
THYM	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg12179176	chr11:130786555	SNX19	0.78	6.73	0.57	1.27e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg03264133	chr6:25882463	NA	-0.65	-5.09	-0.46	1.81e-6	Schizophrenia;
THYM	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.72	4.65	0.43	1.07e-5	Lymphocyte percentage of white cells;
THYM	cis	rs1061377	1.000	rs36090629	chr4:39138815	A/G	cg24403649	chr4:39172243	NA	0.59	4.78	0.44	6.29e-6	Uric acid levels;
THYM	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg06808227	chr14:105710500	BRF1	-1.02	-8.64	-0.66	1.33e-13	Mean platelet volume;Platelet distribution width;
THYM	cis	rs2717559	0.542	rs2585156	chr8:143879795	G/A	cg17252645	chr8:143867129	LY6D	-0.8	-9.6	-0.7	1.15e-15	Urinary tract infection frequency;
THYM	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg24375607	chr4:120327624	NA	0.58	4.74	0.44	7.61e-6	Corneal astigmatism;
THYM	cis	rs3087591	1.000	rs6505234	chr17:29688299	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.61	-5.18	-0.47	1.26e-6	Hip circumference;
THYM	cis	rs10492096	0.947	rs11064231	chr12:6604415	T/G	cg13857086	chr12:6580257	VAMP1	0.87	5.27	0.48	8.47e-7	Hip geometry;
THYM	cis	rs11696501	0.843	rs6073774	chr20:44150077	C/A	cg11783356	chr20:44313418	WFDC10B	-0.69	-4.63	-0.43	1.15e-5	Brain structure;
THYM	cis	rs7246657	0.943	rs13345116	chr19:37847098	A/T	cg22634378	chr19:37742834	NA	0.65	5.34	0.48	6.2e-7	Coronary artery calcification;
THYM	cis	rs400736	0.930	rs226251	chr1:8024690	T/C	cg22678073	chr1:8087421	ERRFI1	0.47	4.97	0.45	2.98e-6	Response to antidepressants and depression;
THYM	cis	rs3781426	0.824	rs3781427	chr10:126703215	A/G	cg04494136	chr10:126703576	CTBP2	-0.47	-7.1	-0.59	2.2e-10	Height;
THYM	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg12165864	chr7:66369176	NA	0.64	4.97	0.45	2.97e-6	Aortic root size;
THYM	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg00898013	chr13:113819073	PROZ	-0.93	-9.52	-0.7	1.74e-15	Platelet distribution width;
THYM	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg00376283	chr12:123451042	ABCB9	0.78	6.43	0.55	5.1e-9	Platelet count;
THYM	cis	rs1978968	1.000	rs7286219	chr22:18445709	G/C	cg01550578	chr22:18484421	MICAL3	0.68	5.2	0.47	1.15e-6	Presence of antiphospholipid antibodies;
THYM	cis	rs4455778	0.724	rs993871	chr7:48993937	C/T	cg26309511	chr7:48887640	NA	0.55	5.06	0.46	2.02e-6	Lung cancer in never smokers;
THYM	cis	rs919433	0.679	rs13394214	chr2:198527371	C/T	cg05783139	chr2:198650985	BOLL	0.67	5.05	0.46	2.12e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs988913	1.000	rs9370343	chr6:54820676	G/A	cg18532076	chr6:54711417	FAM83B	0.51	5.03	0.46	2.34e-6	Menarche (age at onset);
THYM	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg07511668	chr11:68622177	NA	0.43	4.63	0.43	1.15e-5	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg10319629	chr12:132285459	NA	0.53	5.15	0.47	1.39e-6	Migraine;
THYM	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.84	-6.12	-0.53	2.12e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg18512352	chr11:47633146	NA	-0.53	-6.43	-0.55	5.09e-9	Subjective well-being;
THYM	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg27534772	chr1:16042836	PLEKHM2	0.54	5.93	0.52	4.92e-8	Systolic blood pressure;
THYM	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg03647317	chr4:187891568	NA	-0.84	-9.02	-0.68	2.08e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg01651570	chr14:104194141	ZFYVE21	0.52	4.45	0.42	2.33e-5	Schizophrenia;
THYM	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg26412358	chr1:26503933	CNKSR1	0.34	4.76	0.44	7.06e-6	Height;
THYM	cis	rs2267708	0.504	rs3903523	chr7:124668032	A/G	cg05285228	chr7:124571219	POT1	-0.6	-4.52	-0.42	1.81e-5	Chronic lymphocytic leukemia;
THYM	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg17264618	chr3:40429014	ENTPD3	-0.51	-5.04	-0.46	2.25e-6	Renal cell carcinoma;
THYM	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg01699819	chr7:1052092	C7orf50	-0.86	-7.74	-0.62	1.04e-11	Bronchopulmonary dysplasia;
THYM	cis	rs2290159	0.800	rs2290162	chr3:12647457	A/G	cg05467012	chr3:12595696	NA	0.7	4.46	0.42	2.22e-5	Cholesterol, total;
THYM	cis	rs13102973	0.600	rs7662887	chr4:135883864	G/A	cg14419869	chr4:135874104	NA	0.85	7.05	0.59	2.84e-10	Subjective well-being;
THYM	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg09307838	chr4:120376055	NA	0.7	5.24	0.47	9.74e-7	Corneal astigmatism;
THYM	cis	rs240764	0.579	rs9386233	chr6:101149540	C/T	cg21058520	chr6:100914733	NA	-0.6	-4.97	-0.45	2.92e-6	Neuroticism;
THYM	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg06028605	chr16:24865363	SLC5A11	0.58	5.69	0.5	1.42e-7	Intelligence (multi-trait analysis);
THYM	cis	rs8051149	0.688	rs12444533	chr16:87869711	C/T	cg08401758	chr16:87887443	SLC7A5	0.49	4.57	0.42	1.45e-5	Blood metabolite levels;
THYM	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs12681288	0.550	rs59004371	chr8:962393	T/C	cg08648136	chr8:956695	NA	0.56	4.92	0.45	3.57e-6	Schizophrenia;
THYM	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg03433033	chr1:76189801	ACADM	0.77	10.21	0.72	6.01e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg11494091	chr17:61959527	GH2	1.09	17.19	0.87	6.43e-31	Prudent dietary pattern;
THYM	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg05373962	chr22:49881684	NA	-0.61	-5.8	-0.51	8.49e-8	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs16937	0.662	rs10900472	chr1:205181526	A/G	cg17889831	chr1:205181581	DSTYK	-0.41	-5.07	-0.46	1.95e-6	Schizophrenia;
THYM	cis	rs7731657	0.537	rs72801738	chr5:130207637	A/G	cg08523029	chr5:130500466	HINT1	-0.77	-5.3	-0.48	7.42e-7	Fasting plasma glucose;
THYM	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.67	0.7	8.59e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	trans	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg10856724	chr12:34555212	NA	-0.87	-7.74	-0.62	1.07e-11	Bladder cancer;
THYM	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg21110456	chr7:2059412	MAD1L1	-0.46	-4.92	-0.45	3.61e-6	Neuroticism;
THYM	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg27068330	chr11:65405492	SIPA1	-0.81	-5.52	-0.49	2.95e-7	Breast cancer;
THYM	cis	rs7267979	1.000	rs4815421	chr20:25386509	G/A	cg08601574	chr20:25228251	PYGB	-0.58	-4.66	-0.43	1.01e-5	Liver enzyme levels (alkaline phosphatase);
THYM	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg01017244	chr2:74357527	NA	1.11	9.75	0.71	5.67e-16	Gestational age at birth (maternal effect);
THYM	cis	rs6867032	0.917	rs10474734	chr5:2004208	A/G	cg26168224	chr5:2018326	NA	1.16	11.32	0.76	2.53e-19	Gut microbiome composition (winter);
THYM	cis	rs9649213	0.593	rs3779194	chr7:98010277	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg26131816	chr17:42072204	PYY	0.54	4.66	0.43	1.05e-5	Menopause (age at onset);
THYM	cis	rs1299926	0.702	rs9924807	chr16:8865963	G/T	cg08365638	chr16:9212442	C16orf72	0.95	4.45	0.42	2.3e-5	Anger;
THYM	cis	rs4595586	0.545	rs7967931	chr12:39375162	A/C	cg26384229	chr12:38710491	ALG10B	0.7	5.29	0.48	7.95e-7	Morning vs. evening chronotype;
THYM	cis	rs13040088	1.000	rs2295000	chr20:61536938	A/G	cg23096297	chr20:61557774	DIDO1	-1.03	-7.11	-0.59	2.11e-10	Menopause (age at onset);
THYM	cis	rs4474465	1.000	rs908003	chr11:78190340	A/T	cg19901956	chr11:77921274	USP35	-0.69	-4.88	-0.45	4.24e-6	Alzheimer's disease (survival time);
THYM	cis	rs2235642	0.893	rs8051295	chr16:1588087	A/G	cg00463982	chr16:1583984	IFT140;TMEM204	-0.62	-5.26	-0.48	8.71e-7	Coronary artery disease;
THYM	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg22974920	chr21:40686053	BRWD1	-0.59	-4.64	-0.43	1.13e-5	Cognitive function;
THYM	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg11461670	chr8:22454935	PDLIM2	0.36	6.01	0.52	3.39e-8	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg15110403	chr19:17392923	ANKLE1	-0.58	-5.01	-0.46	2.46e-6	Systemic lupus erythematosus;
THYM	cis	rs4595586	0.525	rs7977228	chr12:39395060	A/G	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg18876405	chr7:65276391	NA	0.76	7.19	0.59	1.45e-10	Aortic root size;
THYM	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg14129053	chr2:1895732	MYT1L	1.13	4.49	0.42	1.99e-5	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs9660180	0.836	rs12038134	chr1:1703865	T/A	cg03396347	chr1:1875803	NA	-0.67	-6.72	-0.57	1.34e-9	Body mass index;
THYM	cis	rs2135507	0.515	rs6814526	chr4:83534647	C/T	cg10249074	chr4:83542146	C4orf11	-0.58	-4.63	-0.43	1.17e-5	Juvenile osteochondritis dissecans;
THYM	cis	rs612683	0.658	rs12407689	chr1:100999585	C/G	cg09408571	chr1:101003634	GPR88	0.56	6.59	0.56	2.46e-9	Breast cancer;
THYM	cis	rs4499344	0.730	rs259286	chr19:33164759	C/T	cg27413643	chr19:33165484	ANKRD27;RGS9BP	0.99	8.5	0.66	2.67e-13	Mean platelet volume;
THYM	cis	rs1580019	0.961	rs766657	chr7:32499510	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.75	6.62	0.56	2.16e-9	Cognitive ability;
THYM	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs6964587	0.541	rs6947170	chr7:91451471	A/G	cg17063962	chr7:91808500	NA	0.97	8.03	0.64	2.56e-12	Breast cancer;
THYM	cis	rs34421088	0.585	rs10101661	chr8:11593504	C/T	cg12395012	chr8:11607386	GATA4	0.58	4.64	0.43	1.11e-5	Neuroticism;
THYM	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg04842962	chr6:43655489	MRPS18A	1.4	15.48	0.85	1.01e-27	IgG glycosylation;
THYM	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg02221750	chr19:17393354	ANKLE1	-0.96	-8.86	-0.67	4.58e-14	Systemic lupus erythematosus;
THYM	cis	rs7106204	0.609	rs34376029	chr11:24291233	C/T	ch.11.24196551F	chr11:24239977	NA	0.96	5.9	0.52	5.51e-8	Response to Homoharringtonine (cytotoxicity);
THYM	cis	rs4638749	0.677	rs10190865	chr2:108843624	T/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs6840360	0.806	rs13149588	chr4:152717757	C/T	cg22705602	chr4:152727874	NA	0.54	5.83	0.51	7.43e-8	Intelligence (multi-trait analysis);
THYM	cis	rs78707713	0.592	rs3829182	chr10:71251384	A/G	cg08851181	chr10:71228077	TSPAN15	-0.79	-5.87	-0.52	6.26e-8	Venous thromboembolism;
THYM	cis	rs34779708	0.966	rs4934737	chr10:35512799	T/C	cg03585969	chr10:35415529	CREM	0.63	4.48	0.42	2.09e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs6063399	0.502	rs3091737	chr20:47993307	C/T	cg06950567	chr20:48807318	CEBPB	-0.64	-4.78	-0.44	6.38e-6	Obesity-related traits;
THYM	cis	rs12935418	0.616	rs874054	chr16:81006142	T/C	cg16651780	chr16:81037892	C16orf61	0.88	6.52	0.56	3.34e-9	Mean corpuscular volume;
THYM	cis	rs9959145	1.000	rs9946557	chr18:12563861	T/C	cg14160804	chr18:12703040	PSMG2;CEP76	-0.91	-4.52	-0.42	1.79e-5	Immune response to smallpox vaccine (IL-6);
THYM	trans	rs10118776	0.677	rs13296741	chr9:6187395	G/T	cg02532923	chr16:89110004	NA	1.01	7.85	0.63	6.11e-12	Small cell lung carcinoma;
THYM	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg24846680	chr1:228362309	C1orf69	-0.51	-4.6	-0.43	1.3e-5	Diastolic blood pressure;
THYM	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg24399712	chr22:39784796	NA	-0.84	-5.98	-0.52	3.88e-8	IgG glycosylation;
THYM	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg08807101	chr21:30365312	RNF160	-0.81	-6.14	-0.53	1.88e-8	Dental caries;
THYM	cis	rs58873874	0.737	rs11134767	chr5:156908653	C/T	cg08916508	chr5:156566250	MED7	-1.31	-4.98	-0.45	2.84e-6	Bipolar disorder (body mass index interaction);
THYM	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs2862064	0.929	rs2862062	chr5:156445677	C/T	cg12943317	chr5:156479607	HAVCR1	-0.85	-4.89	-0.45	4.08e-6	Platelet count;
THYM	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg13609457	chr4:120235615	NA	0.58	5.21	0.47	1.11e-6	Corneal astigmatism;
THYM	cis	rs4713118	0.662	rs464312	chr6:27967591	T/A	cg23281280	chr6:28129359	ZNF389	0.58	4.61	0.43	1.28e-5	Parkinson's disease;
THYM	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg03388043	chr17:80084554	CCDC57	-0.72	-6.04	-0.53	3.05e-8	Life satisfaction;
THYM	cis	rs3126085	0.935	rs11204934	chr1:152176848	C/A	cg10321714	chr1:152280068	FLG	-0.7	-5.07	-0.46	1.95e-6	Atopic dermatitis;
THYM	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg08645402	chr16:4508243	NA	-0.76	-6.87	-0.58	6.72e-10	Schizophrenia;
THYM	cis	rs758324	0.687	rs152047	chr5:131548938	G/A	cg16205897	chr5:131564050	P4HA2	0.56	4.56	0.42	1.51e-5	Alzheimer's disease in APOE e4- carriers;
THYM	cis	rs921968	0.565	rs6708192	chr2:219592227	A/G	cg02176678	chr2:219576539	TTLL4	-0.45	-4.55	-0.42	1.61e-5	Mean corpuscular hemoglobin concentration;
THYM	cis	rs6499255	0.951	rs12596823	chr16:69634757	A/C	cg00738113	chr16:70207722	CLEC18C	-0.46	-4.54	-0.42	1.66e-5	IgE levels;
THYM	cis	rs877282	0.947	rs7923867	chr10:768094	G/A	cg10556349	chr10:835070	NA	-0.81	-5.51	-0.49	3.06e-7	Uric acid levels;
THYM	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg05340658	chr4:99064831	C4orf37	0.54	4.54	0.42	1.64e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg16325326	chr1:53192061	ZYG11B	-0.84	-8.51	-0.66	2.53e-13	Monocyte count;
THYM	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg14004847	chr7:1930337	MAD1L1	-0.67	-5.24	-0.47	9.77e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs9796	0.621	rs691702	chr15:41474399	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.58	-4.79	-0.44	6.07e-6	Menopause (age at onset);
THYM	cis	rs7589342	0.839	rs1465641	chr2:106438936	C/T	cg14210321	chr2:106509881	NCK2	-0.69	-4.9	-0.45	4.01e-6	Addiction;
THYM	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19346786	chr7:2764209	NA	-0.71	-6.02	-0.53	3.29e-8	Height;
THYM	cis	rs6840360	0.533	rs13147021	chr4:152722688	A/C	cg22705602	chr4:152727874	NA	0.76	9.95	0.71	2.12e-16	Intelligence (multi-trait analysis);
THYM	cis	rs6918586	0.658	rs198843	chr6:26110314	A/T	cg07061783	chr6:25882402	NA	0.58	4.57	0.42	1.46e-5	Schizophrenia;
THYM	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs28374715	0.662	rs10851403	chr15:41466087	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.02	-8.4	-0.65	4.27e-13	Ulcerative colitis;
THYM	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg10248100	chr7:872053	UNC84A	0.74	4.99	0.46	2.75e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg24209194	chr3:40518798	ZNF619	0.61	4.79	0.44	6.14e-6	Renal cell carcinoma;
THYM	cis	rs7098100	0.851	rs10828250	chr10:21847178	C/G	cg04231319	chr10:21824447	MLLT10	-0.33	-4.71	-0.43	8.53e-6	Breast cancer;
THYM	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg08200252	chr7:75115859	POM121C	0.62	5.34	0.48	6.29e-7	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs7084402	0.905	rs1649031	chr10:60279742	G/A	cg07615347	chr10:60278583	BICC1	-0.56	-5.22	-0.47	1.07e-6	Refractive error;
THYM	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg07636037	chr3:49044803	WDR6	0.99	10.47	0.73	1.67e-17	Parkinson's disease;
THYM	cis	rs9796	0.840	rs1009913	chr15:41331050	C/T	cg18705301	chr15:41695430	NDUFAF1	0.58	4.8	0.44	5.81e-6	Menopause (age at onset);
THYM	cis	rs1448094	0.556	rs11614513	chr12:86167756	G/C	cg02569458	chr12:86230093	RASSF9	0.62	5.34	0.48	6.31e-7	Major depressive disorder;
THYM	cis	rs3820068	0.734	rs6674806	chr1:15902656	A/G	cg05660106	chr1:15850417	CASP9	1.15	9.45	0.7	2.49e-15	Systolic blood pressure;
THYM	trans	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg10856724	chr12:34555212	NA	-1.01	-9.23	-0.69	7.34e-15	Bladder cancer;
THYM	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg00684032	chr4:1343700	KIAA1530	0.7	5.74	0.51	1.11e-7	Obesity-related traits;
THYM	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg23978390	chr7:1156363	C7orf50	0.7	5.24	0.47	9.48e-7	Longevity;Endometriosis;
THYM	cis	rs854765	0.583	rs6502619	chr17:17779704	C/G	cg16928487	chr17:17741425	SREBF1	0.56	5.36	0.48	5.91e-7	Total body bone mineral density;
THYM	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg12310025	chr6:25882481	NA	0.68	5.56	0.5	2.47e-7	Schizophrenia;
THYM	cis	rs9682041	0.660	rs34158232	chr3:170115360	T/C	cg11886554	chr3:170076028	SKIL	1.04	4.62	0.43	1.18e-5	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
THYM	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg24818145	chr4:99064322	C4orf37	0.75	6.03	0.53	3.13e-8	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg25214090	chr10:38739885	LOC399744	-0.91	-7.75	-0.62	1.01e-11	Corneal astigmatism;
THYM	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.81	5.88	0.52	6.21e-8	Electrocardiographic conduction measures;
THYM	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	4.58	0.43	1.41e-5	Bipolar disorder;
THYM	cis	rs17174870	0.955	rs58065683	chr2:112756581	A/G	cg17354880	chr2:112658759	MERTK	-0.59	-4.66	-0.43	1.05e-5	Multiple sclerosis;
THYM	cis	rs8030485	0.728	rs4778886	chr15:79389019	T/C	cg17916960	chr15:79447300	NA	0.55	5.53	0.49	2.81e-7	Left ventricle wall thickness;
THYM	cis	rs714031	0.967	rs5757763	chr22:40065005	A/G	cg21377881	chr22:40064566	CACNA1I	-0.67	-5.78	-0.51	9.63e-8	Schizophrenia;
THYM	cis	rs78773383	0.505	rs13123782	chr4:39377405	A/C	cg16714752	chr4:39368184	RFC1	0.5	4.71	0.44	8.33e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs11785693	0.819	rs6994891	chr8:4989856	T/A	cg26367366	chr8:4980734	NA	1.21	5.9	0.52	5.46e-8	Neuroticism (multi-trait analysis);Neuroticism;
THYM	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg14019146	chr3:50243930	SLC38A3	-0.55	-4.53	-0.42	1.69e-5	Body mass index;
THYM	cis	rs7772486	0.790	rs2254288	chr6:146204470	G/A	cg13319975	chr6:146136371	FBXO30	-0.76	-6.48	-0.55	4.09e-9	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs7584330	0.554	rs74001386	chr2:238425333	T/A	cg14458575	chr2:238380390	NA	0.79	4.65	0.43	1.06e-5	Prostate cancer;
THYM	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg14004847	chr7:1930337	MAD1L1	-0.62	-4.73	-0.44	7.66e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs6430585	0.528	rs309120	chr2:136708787	G/C	cg20242066	chr2:136595261	LCT	0.53	5.59	0.5	2.18e-7	Corneal structure;
THYM	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs447921	0.813	rs4419085	chr17:74443683	C/T	cg17201438	chr17:74438067	UBE2O	-0.77	-5.46	-0.49	3.74e-7	Mitochondrial DNA levels;
THYM	cis	rs7236492	0.532	rs8090536	chr18:77195553	C/T	cg15644404	chr18:77186268	NFATC1	-0.73	-4.49	-0.42	2.02e-5	Inflammatory bowel disease;Crohn's disease;
THYM	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg10661904	chr17:79619235	PDE6G	0.57	5.3	0.48	7.61e-7	Eye color traits;
THYM	cis	rs3091242	0.967	rs665372	chr1:25719235	A/C	cg23205692	chr1:25664452	TMEM50A	0.85	6.69	0.57	1.54e-9	Erythrocyte sedimentation rate;
THYM	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.77	-5.05	-0.46	2.13e-6	Mean platelet volume;
THYM	cis	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg12826209	chr6:26865740	GUSBL1	0.9	4.96	0.45	3.09e-6	Autism spectrum disorder or schizophrenia;
THYM	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	4.63	0.43	1.17e-5	Hip circumference adjusted for BMI;
THYM	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg24818145	chr4:99064322	C4orf37	0.87	7.23	0.6	1.19e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg17063962	chr7:91808500	NA	1.12	12.68	0.79	3.85e-22	Breast cancer;
THYM	cis	rs2797160	0.651	rs1268092	chr6:126029043	A/G	cg05901451	chr6:126070800	HEY2	-0.59	-4.92	-0.45	3.66e-6	Endometrial cancer;
THYM	cis	rs7172809	0.897	rs16968895	chr15:77825121	A/G	cg10437265	chr15:77819839	NA	-0.53	-4.57	-0.42	1.48e-5	Glucose homeostasis traits;
THYM	cis	rs7617773	0.778	rs11715776	chr3:48377611	G/C	cg02219026	chr3:48282209	ZNF589	-0.67	-4.61	-0.43	1.25e-5	Coronary artery disease;
THYM	cis	rs6860806	0.695	rs11952099	chr5:131576772	A/G	cg24060327	chr5:131705240	SLC22A5	-0.69	-5.27	-0.48	8.64e-7	Breast cancer;
THYM	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg08999081	chr20:33150536	PIGU	0.71	6.16	0.53	1.73e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg19774624	chr17:42201019	HDAC5	0.85	8.23	0.65	9.73e-13	Total body bone mineral density;
THYM	cis	rs9394931	1.000	rs9394931	chr6:42873245	C/T	cg09436375	chr6:42928200	GNMT	0.4	4.98	0.46	2.79e-6	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid);
THYM	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg24549020	chr5:56110836	MAP3K1	0.7	4.51	0.42	1.83e-5	Initial pursuit acceleration;
THYM	cis	rs6121246	0.697	rs8118150	chr20:30436088	G/A	cg21427119	chr20:30132790	HM13	-0.71	-4.57	-0.42	1.49e-5	Mean corpuscular hemoglobin;
THYM	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03517284	chr6:25882590	NA	-1.02	-9.34	-0.69	4.3e-15	Intelligence (multi-trait analysis);
THYM	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg22467129	chr15:76604101	ETFA	-0.57	-5.3	-0.48	7.65e-7	Blood metabolite levels;
THYM	cis	rs12714314	0.957	rs2060195	chr2:1955801	A/G	cg05313794	chr2:1845466	MYT1L	-0.51	-4.55	-0.42	1.58e-5	Type 2 diabetes (age of onset);
THYM	cis	rs7772486	0.875	rs12194437	chr6:146411440	A/G	cg13319975	chr6:146136371	FBXO30	-0.61	-4.96	-0.45	3.05e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg02825527	chr7:2087843	MAD1L1	-0.7	-4.55	-0.42	1.58e-5	Bipolar disorder;
THYM	cis	rs9361491	0.608	rs9352632	chr6:79462226	G/C	cg04547799	chr6:79944526	HMGN3	-0.64	-4.51	-0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg16797656	chr11:68205561	LRP5	0.44	4.52	0.42	1.8e-5	Total body bone mineral density;
THYM	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs1061377	0.965	rs7677729	chr4:39121990	C/T	cg24403649	chr4:39172243	NA	0.56	4.55	0.42	1.59e-5	Uric acid levels;
THYM	cis	rs897984	0.553	rs2335013	chr16:30877346	T/G	cg03418659	chr16:31128414	MYST1	0.61	4.51	0.42	1.82e-5	Dementia with Lewy bodies;
THYM	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08704250	chr15:31115839	NA	0.69	7.77	0.62	9.15e-12	Huntington's disease progression;
THYM	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg27394845	chr17:28928406	LRRC37B2	0.91	4.58	0.42	1.44e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs6570726	0.846	rs4896824	chr6:145927048	C/T	cg13319975	chr6:146136371	FBXO30	-0.66	-5.22	-0.47	1.06e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs62070183	0.752	rs17781005	chr17:31132529	T/C	cg23177095	chr17:30873196	MYO1D	0.66	5.07	0.46	2e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs11771526	0.901	rs62456038	chr7:32288663	G/A	cg27532318	chr7:32358331	NA	0.77	5.06	0.46	2.03e-6	Body mass index;
THYM	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg25811766	chr13:21894605	NA	-0.77	-4.91	-0.45	3.82e-6	White matter hyperintensity burden;
THYM	cis	rs13082711	0.954	rs35523848	chr3:27552800	A/C	cg02860705	chr3:27208620	NA	0.76	5.0	0.46	2.57e-6	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
THYM	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg13736514	chr6:26305472	NA	-0.66	-6.8	-0.57	9.14e-10	Educational attainment;
THYM	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg21773646	chr17:80085082	CCDC57	-0.36	-5.08	-0.46	1.88e-6	Life satisfaction;
THYM	cis	rs9807841	0.592	rs10419865	chr19:10772685	C/G	cg17848348	chr19:10766748	ILF3	-0.76	-6.17	-0.53	1.68e-8	Inflammatory skin disease;
THYM	cis	rs4866334	1.000	rs75534671	chr5:18487744	G/A	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs7226229	0.904	rs62058988	chr17:20940651	T/A	cg21263980	chr17:20946333	USP22	0.64	4.72	0.44	8.12e-6	Blood trace element (Se levels);
THYM	cis	rs7100689	0.622	rs7897994	chr10:82133304	T/G	cg01528321	chr10:82214614	TSPAN14	0.79	6.04	0.53	3.01e-8	Post bronchodilator FEV1;
THYM	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg14583973	chr4:3374767	RGS12	0.61	5.94	0.52	4.63e-8	Serum sulfate level;
THYM	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg06728252	chr6:26598149	ABT1	-0.43	-5.11	-0.46	1.64e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2282300	0.956	rs2685286	chr11:30381588	G/A	cg25418670	chr11:30344373	C11orf46	-0.74	-5.84	-0.51	7.14e-8	Morning vs. evening chronotype;
THYM	cis	rs901683	0.850	rs73291122	chr10:46099403	G/C	cg18240400	chr10:46168597	ANUBL1	0.64	4.8	0.44	5.9e-6	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.95	8.7	0.67	9.84e-14	Chronic sinus infection;
THYM	cis	rs3820068	0.705	rs951225	chr1:15826292	G/A	cg05660106	chr1:15850417	CASP9	1.13	10.23	0.72	5.39e-17	Systolic blood pressure;
THYM	cis	rs9649213	0.593	rs6465678	chr7:98004057	T/C	cg09267113	chr7:98030324	BAIAP2L1	0.49	4.45	0.42	2.35e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs112998813	0.571	rs11147317	chr13:114939396	A/G	cg02694521	chr13:114055881	NA	0.55	4.6	0.43	1.31e-5	Nodular sclerosis Hodgkin lymphoma;
THYM	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03452623	chr4:187889614	NA	-1.19	-19.26	-0.89	1.45e-34	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg07636037	chr3:49044803	WDR6	0.95	9.55	0.7	1.53e-15	Parkinson's disease;
THYM	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg26031613	chr14:104095156	KLC1	0.73	4.99	0.46	2.74e-6	Body mass index;
THYM	cis	rs909002	0.800	rs1061770	chr1:32096265	A/G	cg13919466	chr1:32135498	COL16A1	-0.49	-4.95	-0.45	3.23e-6	Intelligence (multi-trait analysis);
THYM	cis	rs747334	0.540	rs7076190	chr10:92763765	G/T	cg07620928	chr10:92689909	NA	-0.59	-5.01	-0.46	2.54e-6	Fibroblast growth factor basic levels;
THYM	cis	rs55665837	1.000	rs11023227	chr11:14459087	T/C	cg19336497	chr11:14380999	RRAS2	-0.64	-7.04	-0.59	3e-10	Vitamin D levels;
THYM	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg27034606	chr17:28928453	LRRC37B2	0.84	5.58	0.5	2.28e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg06598544	chr20:61472147	COL9A3	1.12	7.39	0.6	5.69e-11	Obesity-related traits;
THYM	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg24812749	chr6:127587940	RNF146	0.99	8.06	0.64	2.3e-12	Breast cancer;
THYM	cis	rs7119038	0.731	rs28409215	chr11:118679304	G/A	cg19308663	chr11:118741387	NA	0.57	5.87	0.52	6.34e-8	Sjögren's syndrome;
THYM	cis	rs12200560	0.505	rs927271	chr6:97075910	T/G	cg06623918	chr6:96969491	KIAA0776	0.72	5.39	0.48	5.1e-7	Coronary heart disease;
THYM	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg06009448	chr7:1102226	C7orf50	0.53	5.59	0.5	2.15e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs12142240	0.698	rs45517837	chr1:46859225	A/G	cg00530320	chr1:46809349	NSUN4	0.77	5.47	0.49	3.69e-7	Menopause (age at onset);
THYM	cis	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg16898833	chr6:26189333	HIST1H4D	0.98	4.56	0.42	1.53e-5	Autism spectrum disorder or schizophrenia;
THYM	cis	rs4363385	0.693	rs4845497	chr1:152904162	T/C	cg07796016	chr1:152779584	LCE1C	-0.56	-4.51	-0.42	1.84e-5	Inflammatory skin disease;
THYM	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg21775007	chr8:11205619	TDH	0.65	5.19	0.47	1.17e-6	Retinal vascular caliber;
THYM	cis	rs9522267	0.535	rs9522290	chr13:112233130	A/G	cg10483660	chr13:112241077	NA	-0.6	-6.98	-0.58	3.9e-10	Hepatitis;
THYM	cis	rs6121246	0.512	rs6060941	chr20:30367383	C/T	cg13852791	chr20:30311386	BCL2L1	1.03	10.1	0.72	9.97e-17	Mean corpuscular hemoglobin;
THYM	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg09307838	chr4:120376055	NA	0.75	5.41	0.49	4.76e-7	Corneal astigmatism;
THYM	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg14416269	chr4:6271139	WFS1	0.56	5.74	0.51	1.13e-7	Type 2 diabetes and other traits;Type 2 diabetes;
THYM	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg16624210	chr5:671434	TPPP	0.82	6.32	0.54	8.3e-9	Obesity-related traits;
THYM	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.78	5.85	0.51	6.98e-8	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs425277	0.628	rs3107147	chr1:2048729	G/A	cg23682913	chr1:2080710	PRKCZ	-0.55	-5.05	-0.46	2.09e-6	Height;
THYM	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg26441486	chr22:50317300	CRELD2	-0.44	-4.45	-0.42	2.33e-5	Schizophrenia;
THYM	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg12179176	chr11:130786555	SNX19	0.87	8.19	0.64	1.2e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14893161	chr1:205819251	PM20D1	0.93	10.04	0.72	1.38e-16	Menarche (age at onset);
THYM	cis	rs2440129	0.611	rs1042356	chr17:6902743	G/A	cg12262378	chr17:6899522	ALOX12	0.66	8.89	0.67	3.81e-14	Tonsillectomy;
THYM	cis	rs854765	0.647	rs1008135	chr17:18027143	A/G	cg04398451	chr17:18023971	MYO15A	-0.97	-10.7	-0.74	5.21e-18	Total body bone mineral density;
THYM	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg21926883	chr2:100939477	LONRF2	-0.59	-5.18	-0.47	1.25e-6	Intelligence (multi-trait analysis);
THYM	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22857025	chr5:266934	NA	-1.59	-10.2	-0.72	6.04e-17	Breast cancer;
THYM	cis	rs4866334	1.000	rs77523779	chr5:18486747	C/A	cg04591469	chr5:17810299	NA	-1.12	-4.55	-0.42	1.56e-5	IgG glycosylation;
THYM	cis	rs4746818	0.793	rs2805914	chr10:70859291	A/G	cg11621586	chr10:70884670	VPS26A	0.87	5.14	0.47	1.49e-6	Left atrial antero-posterior diameter;
THYM	cis	rs4242434	0.672	rs10113779	chr8:22485934	G/C	cg21658235	chr8:22456391	C8orf58	0.5	4.84	0.44	5.1e-6	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg09307838	chr4:120376055	NA	0.77	5.63	0.5	1.86e-7	Corneal astigmatism;
THYM	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg22907277	chr7:1156413	C7orf50	0.83	5.1	0.46	1.71e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg18681998	chr4:17616180	MED28	-0.93	-7.87	-0.63	5.57e-12	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg14779329	chr11:130786720	SNX19	0.57	6.35	0.55	7.49e-9	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs425277	0.606	rs16824792	chr1:2039521	G/T	cg00981070	chr1:2046702	PRKCZ	-0.4	-4.91	-0.45	3.83e-6	Height;
THYM	cis	rs988913	0.958	rs9475078	chr6:54809589	T/A	cg04690482	chr6:54711388	FAM83B	0.47	5.25	0.47	9.12e-7	Menarche (age at onset);
THYM	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	7.5	0.61	3.41e-11	Platelet count;
THYM	cis	rs4722166	0.695	rs4722177	chr7:22798531	T/C	cg05472934	chr7:22766657	IL6	0.7	6.14	0.53	1.86e-8	Lung cancer;
THYM	cis	rs3087591	0.708	rs67065748	chr17:29605631	T/A	cg24425628	chr17:29625626	OMG;NF1	0.63	5.38	0.48	5.3e-7	Hip circumference;
THYM	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg27535305	chr1:53392650	SCP2	0.66	7.27	0.6	9.92e-11	Monocyte count;
THYM	cis	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg08133631	chr1:26527909	CATSPER4	-0.59	-4.94	-0.45	3.38e-6	Obesity-related traits;
THYM	cis	rs859767	0.741	rs35599954	chr2:135392481	T/C	cg12500956	chr2:135428796	TMEM163	-0.5	-5.13	-0.47	1.54e-6	Neuroticism;
THYM	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg16989719	chr2:238392110	NA	-0.6	-5.82	-0.51	8.08e-8	Prostate cancer;
THYM	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7258465	0.965	rs10409003	chr19:18543054	C/T	cg04166595	chr19:18636596	NA	0.62	4.7	0.43	8.77e-6	Breast cancer;
THYM	cis	rs981844	0.645	rs72731677	chr4:154671475	C/G	cg09973105	chr4:154681532	RNF175	-0.65	-5.41	-0.49	4.77e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg16099169	chr2:106886729	NA	0.86	7.47	0.61	3.91e-11	Facial morphology (factor 23);
THYM	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg06026331	chr20:60912101	LAMA5	0.73	5.66	0.5	1.59e-7	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg16624210	chr5:671434	TPPP	-0.76	-5.61	-0.5	2.03e-7	Obesity-related traits;
THYM	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg21028142	chr17:79581711	NPLOC4	0.64	6.74	0.57	1.23e-9	Eye color traits;
THYM	cis	rs7187994	0.806	rs12445172	chr16:84747016	C/G	cg07647771	chr16:84786436	USP10	-0.54	-4.96	-0.45	3.13e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg25566285	chr7:158114605	PTPRN2	-0.87	-10.96	-0.75	1.5e-18	Calcium levels;
THYM	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg03806693	chr22:41940476	POLR3H	-1.1	-8.73	-0.67	8.71e-14	Vitiligo;
THYM	cis	rs7404928	0.557	rs195999	chr16:23956965	G/T	cg26685404	chr16:23957272	PRKCB	-0.56	-6.49	-0.55	3.83e-9	Primary biliary cholangitis;Rheumatoid arthritis;
THYM	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg05738196	chr6:26577821	NA	0.88	8.08	0.64	2.07e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg21028142	chr17:79581711	NPLOC4	0.54	5.04	0.46	2.24e-6	Eye color traits;
THYM	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg10360139	chr7:1886902	MAD1L1	-0.6	-5.39	-0.48	5.09e-7	Bipolar disorder and schizophrenia;
THYM	cis	rs1609391	0.543	rs9881139	chr3:136634040	A/G	cg15507776	chr3:136538369	TMEM22	0.64	4.9	0.45	4.02e-6	Neuroticism;
THYM	cis	rs11886999	0.812	rs72825868	chr2:96897659	A/T	cg18419276	chr2:96971862	SNRNP200	-0.52	-4.98	-0.45	2.84e-6	Cardiac Troponin-T levels;
THYM	cis	rs7833986	0.501	rs2953897	chr8:56980569	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.61	7.4	0.6	5.43e-11	Height;
THYM	cis	rs7429990	0.965	rs13074973	chr3:48028144	T/A	cg02219026	chr3:48282209	ZNF589	0.6	4.5	0.42	1.89e-5	Educational attainment (years of education);
THYM	cis	rs5760092	0.755	rs3884794	chr22:24251766	C/A	cg04234412	chr22:24373322	LOC391322	-0.87	-6.49	-0.55	3.83e-9	Urinary 1,3-butadiene metabolite levels in smokers;
THYM	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg10047753	chr17:41438598	NA	1.18	11.26	0.76	3.4e-19	Menopause (age at onset);
THYM	cis	rs9527	0.615	rs11191485	chr10:104729816	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-4.68	-0.43	9.59e-6	Arsenic metabolism;
THYM	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.87	-7.42	-0.61	4.86e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs3771570	1.000	rs62193210	chr2:242323616	G/A	cg21155796	chr2:242212141	HDLBP	1.23	5.67	0.5	1.53e-7	Prostate cancer;
THYM	cis	rs860818	1.000	rs1637216	chr7:23236129	C/A	cg05407003	chr7:23246146	NA	-1.27	-4.72	-0.44	8.18e-6	Initial pursuit acceleration;
THYM	cis	rs400736	0.740	rs225129	chr1:8094164	T/A	cg22678073	chr1:8087421	ERRFI1	0.45	4.61	0.43	1.25e-5	Response to antidepressants and depression;
THYM	cis	rs9649213	0.593	rs736753	chr7:97931489	G/T	cg07830472	chr7:97983916	BAIAP2L1	-0.44	-4.55	-0.42	1.6e-5	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg17644776	chr2:200775616	C2orf69	0.8	4.82	0.44	5.52e-6	Schizophrenia;
THYM	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg05234568	chr11:5960015	NA	-0.63	-5.53	-0.49	2.76e-7	DNA methylation (variation);
THYM	cis	rs10979	0.931	rs9484770	chr6:143896758	A/G	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg10802521	chr3:52805072	NEK4	-0.72	-6.12	-0.53	2.09e-8	Bipolar disorder;
THYM	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.84	-6.79	-0.57	9.63e-10	Intelligence (multi-trait analysis);
THYM	cis	rs61990749	0.597	rs11623088	chr14:78137735	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-1.17	-8.02	-0.64	2.7e-12	Fibroblast growth factor basic levels;
THYM	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14159672	chr1:205819179	PM20D1	0.78	7.17	0.59	1.65e-10	Monocyte percentage of white cells;
THYM	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	6.12	0.53	2.12e-8	Schizophrenia;
THYM	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg06618935	chr21:46677482	NA	-0.97	-9.14	-0.68	1.12e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg06028808	chr11:68637592	NA	0.71	7.73	0.62	1.13e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg18252515	chr7:66147081	NA	-0.65	-4.83	-0.44	5.15e-6	Aortic root size;
THYM	cis	rs763014	0.931	rs7199839	chr16:636126	T/C	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg16624210	chr5:671434	TPPP	0.76	5.61	0.5	2.03e-7	Obesity-related traits;
THYM	cis	rs508618	0.666	rs480902	chr1:231531627	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.65	4.98	0.45	2.86e-6	Red blood cell count;
THYM	cis	rs950880	0.710	rs17027179	chr2:103057159	C/T	cg03938978	chr2:103052716	IL18RAP	-0.55	-4.71	-0.44	8.33e-6	Serum protein levels (sST2);
THYM	cis	rs6424115	0.644	rs2267960	chr1:24068544	T/C	cg15997130	chr1:24165203	NA	0.67	5.5	0.49	3.16e-7	Immature fraction of reticulocytes;
THYM	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg26441486	chr22:50317300	CRELD2	0.36	5.0	0.46	2.57e-6	Schizophrenia;
THYM	cis	rs7177699	0.557	rs8035093	chr15:79120670	T/C	cg15571903	chr15:79123663	NA	0.58	6.75	0.57	1.15e-9	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
THYM	cis	rs1878931	0.597	rs2680221	chr16:3462595	A/G	cg21433313	chr16:3507492	NAT15	0.61	5.03	0.46	2.31e-6	Body mass index (adult);
THYM	cis	rs7107174	0.748	rs2063730	chr11:78048524	A/C	cg02023728	chr11:77925099	USP35	0.59	5.5	0.49	3.14e-7	Testicular germ cell tumor;
THYM	cis	rs40363	1.000	rs1690443	chr16:3517787	C/G	cg05754148	chr16:3507555	NAT15	0.88	7.96	0.63	3.57e-12	Tuberculosis;
THYM	cis	rs977987	0.835	rs7200616	chr16:75366089	G/A	cg03315344	chr16:75512273	CHST6	0.8	6.6	0.56	2.37e-9	Dupuytren's disease;
THYM	cis	rs11651000	0.761	rs11657388	chr17:45820707	C/G	cg06532163	chr17:45867833	NA	0.58	5.76	0.51	1.03e-7	IgG glycosylation;
THYM	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg16230307	chr14:35515116	FAM177A1	0.82	5.28	0.48	8.12e-7	Psoriasis;
THYM	cis	rs13177918	0.677	rs13177970	chr5:149826010	A/G	cg14059543	chr5:149831962	NA	-1.01	-7.71	-0.62	1.21e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs12711979	0.740	rs6711964	chr2:3820916	A/T	cg17052675	chr2:3827356	NA	-0.48	-5.19	-0.47	1.19e-6	Itch intensity from mosquito bite adjusted by bite size;
THYM	trans	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg25214090	chr10:38739885	LOC399744	0.93	7.97	0.63	3.44e-12	Corneal astigmatism;
THYM	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs757081	0.667	rs60173525	chr11:17259967	A/G	cg15432903	chr11:17409602	KCNJ11	-0.48	-4.6	-0.43	1.29e-5	Systolic blood pressure;
THYM	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg03806693	chr22:41940476	POLR3H	1.07	9.32	0.69	4.75e-15	Vitiligo;
THYM	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg00339695	chr16:24857497	SLC5A11	-0.7	-6.02	-0.53	3.27e-8	Intelligence (multi-trait analysis);
THYM	cis	rs12935418	0.672	rs2602424	chr16:81043205	A/G	cg16651780	chr16:81037892	C16orf61	-0.83	-6.51	-0.56	3.48e-9	Mean corpuscular volume;
THYM	cis	rs76662990	0.610	rs10474420	chr5:73934274	A/G	cg13275603	chr5:73927487	ENC1	-0.78	-4.52	-0.42	1.81e-5	Residual cognition;
THYM	trans	rs1318862	0.578	rs3133370	chr11:92026446	A/G	cg17836842	chr2:28319151	BRE	-0.92	-7.33	-0.6	7.69e-11	Subcortical brain region volumes;
THYM	cis	rs910187	0.678	rs3818006	chr20:45816328	A/G	cg27589058	chr20:45804311	EYA2	-0.59	-5.04	-0.46	2.21e-6	Migraine;
THYM	cis	rs765787	0.530	rs2899378	chr15:45537584	C/T	cg24006582	chr15:45444508	DUOX1	0.81	6.55	0.56	2.99e-9	Uric acid levels;
THYM	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22857025	chr5:266934	NA	-1.53	-10.46	-0.73	1.73e-17	Breast cancer;
THYM	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg22467129	chr15:76604101	ETFA	-0.56	-5.27	-0.48	8.62e-7	Blood metabolite levels;
THYM	cis	rs12579753	0.869	rs12366921	chr12:82223024	G/A	cg07988820	chr12:82153109	PPFIA2	-0.73	-4.55	-0.42	1.59e-5	Resting heart rate;
THYM	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.91	10.41	0.73	2.22e-17	Prudent dietary pattern;
THYM	cis	rs11642862	0.901	rs76345698	chr16:30946165	G/A	cg01070095	chr16:30968205	SETD1A	0.73	4.79	0.44	6.24e-6	Tonsillectomy;
THYM	cis	rs17407555	0.518	rs16891234	chr4:9946163	A/G	cg11266682	chr4:10021025	SLC2A9	-0.66	-6.71	-0.57	1.39e-9	Schizophrenia (age at onset);
THYM	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg02753203	chr1:228287806	NA	-0.61	-5.28	-0.48	8.19e-7	Diastolic blood pressure;
THYM	cis	rs13126513	0.642	rs2718685	chr4:100436419	C/G	cg05468953	chr4:100565104	NA	-0.68	-5.75	-0.51	1.06e-7	Metabolite levels (MHPG);
THYM	cis	rs10504073	0.565	rs974780	chr8:49930976	G/A	cg00325661	chr8:49890786	NA	1.04	10.53	0.73	1.2e-17	Blood metabolite ratios;
THYM	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22857025	chr5:266934	NA	-1.57	-9.68	-0.7	8.05e-16	Breast cancer;
THYM	cis	rs289828	0.560	rs10165186	chr2:152158177	T/A	cg05960677	chr2:152117363	RBM43	0.69	6.56	0.56	2.86e-9	Blood protein levels;
THYM	cis	rs28595532	0.920	rs28538455	chr4:119486817	T/C	cg14228332	chr4:119757509	SEC24D	1.38	4.99	0.46	2.77e-6	Cannabis dependence symptom count;
THYM	cis	rs9329289	0.510	rs1155447	chr10:2553240	C/T	cg15501526	chr10:2543763	NA	0.5	4.62	0.43	1.19e-5	Age-related hearing impairment;
THYM	cis	rs9467711	0.606	rs9358938	chr6:26387546	C/T	cg12826209	chr6:26865740	GUSBL1	1.06	5.68	0.5	1.5e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs10992471	0.528	rs4744135	chr9:95251874	A/C	cg14631576	chr9:95140430	CENPP	0.84	8.02	0.64	2.69e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
THYM	cis	rs12765878	1.000	rs10883943	chr10:105651416	G/T	cg11005552	chr10:105648138	OBFC1	0.87	11.39	0.76	1.84e-19	Coronary artery disease;
THYM	cis	rs10411161	0.702	rs11879319	chr19:52389592	C/T	cg25361850	chr19:52391789	ZNF577	0.74	5.15	0.47	1.39e-6	Breast cancer;
THYM	cis	rs4930776	0.932	rs376708	chr12:5762980	A/G	cg02086166	chr12:5775618	ANO2	0.61	5.99	0.52	3.74e-8	Plasma clusterin levels;
THYM	cis	rs73086581	1.000	rs6107391	chr20:3983083	A/G	cg02187196	chr20:3869020	PANK2	0.49	5.45	0.49	4.01e-7	Response to antidepressants in depression;
THYM	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg03188948	chr7:1209495	NA	0.93	5.2	0.47	1.16e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs1160297	0.609	rs1828338	chr2:53096951	T/C	cg07782112	chr2:53107842	NA	0.78	6.19	0.54	1.55e-8	Hemostatic factors and hematological phenotypes;
THYM	cis	rs7833986	0.534	rs72653924	chr8:56906088	C/T	cg23139584	chr8:56987506	RPS20;SNORD54	0.56	6.4	0.55	5.76e-9	Height;
THYM	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs425535	0.817	rs1821623	chr4:74804846	C/G	cg07868155	chr4:74864709	CXCL5	0.62	4.46	0.42	2.23e-5	Blood protein levels;
THYM	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg18357526	chr6:26021779	HIST1H4A	0.75	6.47	0.55	4.17e-9	Intelligence (multi-trait analysis);
THYM	cis	rs7980799	0.682	rs1580396	chr12:33615841	C/A	cg06521331	chr12:34319734	NA	0.69	4.93	0.45	3.47e-6	Heart rate;Heart rate variability traits (RMSSD);
THYM	cis	rs6496667	0.557	rs2601201	chr15:90958000	C/T	cg22089800	chr15:90895588	ZNF774	0.63	4.6	0.43	1.33e-5	Rheumatoid arthritis;
THYM	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg12893428	chr3:195717962	SDHAP1	0.54	4.83	0.44	5.31e-6	Pancreatic cancer;
THYM	cis	rs7777677	0.925	rs73543808	chr7:142367857	T/C	cg21785750	chr7:142428317	NA	0.68	6.02	0.53	3.31e-8	Alcoholic chronic pancreatitis;
THYM	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg08000102	chr2:233561755	GIGYF2	0.7	6.28	0.54	9.92e-9	Coronary artery disease;
THYM	cis	rs9788682	0.747	rs2568485	chr15:78752114	C/T	cg18825076	chr15:78729989	IREB2	-0.69	-5.51	-0.49	3.05e-7	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
THYM	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg20503657	chr10:835505	NA	1.15	8.15	0.64	1.44e-12	Eosinophil percentage of granulocytes;
THYM	cis	rs6598955	0.671	rs12088858	chr1:26643708	C/A	cg19677267	chr1:26645161	CD52;UBXN11	0.51	4.7	0.43	8.83e-6	Obesity-related traits;
THYM	cis	rs17006441	0.932	rs11921388	chr3:69900383	A/G	cg18496212	chr3:69797108	MITF	0.68	6.85	0.57	7.35e-10	Hemoglobin concentration;
THYM	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg11502198	chr6:26597334	ABT1	0.64	5.68	0.5	1.48e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg01819863	chr10:32635814	EPC1	0.93	5.73	0.51	1.16e-7	Sexual dysfunction (female);
THYM	cis	rs883565	0.655	rs4645092	chr3:39051718	G/A	cg15678707	chr3:39149194	GORASP1;TTC21A	0.67	5.0	0.46	2.59e-6	Handedness;
THYM	cis	rs1365505	0.587	rs4238382	chr15:50484746	T/A	cg26188685	chr15:50540269	HDC	-0.55	-4.64	-0.43	1.13e-5	Blood metabolite ratios;
THYM	cis	rs1335645	1.000	rs1043096	chr1:111682307	C/G	cg00321911	chr1:111669324	DRAM2	1.16	6.4	0.55	5.95e-9	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs12681287	0.608	rs2953511	chr8:87340870	G/A	cg27223183	chr8:87520930	FAM82B	-0.7	-5.3	-0.48	7.65e-7	Caudate activity during reward;
THYM	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg24450063	chr1:156163899	SLC25A44	1.18	14.83	0.84	1.8e-26	Testicular germ cell tumor;
THYM	cis	rs1843834	0.755	rs10194591	chr2:225574276	T/A	cg22455342	chr2:225449267	CUL3	0.59	4.68	0.43	9.33e-6	IgE levels in asthmatics (D.p. specific);
THYM	cis	rs1568889	0.838	rs1483858	chr11:28189639	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.84	7.39	0.6	5.6e-11	Bipolar disorder;
THYM	trans	rs10233018	0.810	rs6466631	chr7:117551963	C/A	cg21837391	chr1:1159412	SDF4	0.87	6.94	0.58	4.78e-10	Depressive symptoms;Depression;
THYM	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg22920501	chr2:26401640	FAM59B	0.84	7.52	0.61	3.02e-11	Gut microbiome composition (summer);
THYM	cis	rs1448094	0.533	rs7307617	chr12:86151317	T/C	cg02569458	chr12:86230093	RASSF9	-0.64	-5.48	-0.49	3.46e-7	Major depressive disorder;
THYM	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg00071950	chr4:10020882	SLC2A9	0.87	9.94	0.71	2.22e-16	Bone mineral density;
THYM	cis	rs11948739	0.501	rs2419755	chr5:130252835	A/G	cg08523029	chr5:130500466	HINT1	0.82	5.88	0.52	6.03e-8	Pediatric bone mineral content (hip);
THYM	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg26513180	chr16:89883248	FANCA	0.72	7.12	0.59	2.05e-10	Vitiligo;
THYM	cis	rs12135062	0.755	rs1553287	chr1:3101277	G/A	cg21609526	chr1:3105151	PRDM16	-0.65	-5.26	-0.47	8.86e-7	Migraine;
THYM	cis	rs3741151	1.000	rs75114310	chr11:73042047	C/T	cg12959048	chr11:73096162	RELT	-0.5	-4.78	-0.44	6.38e-6	GIP levels in response to oral glucose tolerance test (120 minutes);
THYM	cis	rs62070183	0.938	rs1990825	chr17:31056292	G/A	cg02981443	chr17:31254875	TMEM98	-0.54	-4.81	-0.44	5.69e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs1003719	0.788	rs13050757	chr21:38465345	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg09307838	chr4:120376055	NA	0.71	5.05	0.46	2.13e-6	Corneal astigmatism;
THYM	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.68	4.76	0.44	7.06e-6	Lung cancer in ever smokers;
THYM	cis	rs7704138	0.639	rs4865980	chr5:55016195	A/G	cg18456523	chr5:54516805	NA	-0.58	-4.59	-0.43	1.34e-5	Height;
THYM	cis	rs9554348	0.541	rs60769907	chr13:96954029	T/C	cg25169784	chr13:96706045	UGGT2	0.85	4.66	0.43	1.03e-5	Schizophrenia;
THYM	cis	rs4969178	0.622	rs11657987	chr17:76387363	G/T	cg05887092	chr17:76393375	PGS1	0.42	4.88	0.45	4.32e-6	HDL cholesterol levels;
THYM	cis	rs17102423	0.530	rs4902357	chr14:65542067	C/G	cg11161011	chr14:65562177	MAX	-0.7	-5.74	-0.51	1.12e-7	Obesity-related traits;
THYM	cis	rs71636778	0.509	rs34976021	chr1:27298564	C/A	cg16022904	chr1:26870173	RPS6KA1	0.84	4.55	0.42	1.58e-5	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
THYM	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg13695892	chr22:41940480	POLR3H	0.86	6.33	0.54	8.08e-9	Vitiligo;
THYM	cis	rs6032067	0.673	rs6017532	chr20:43904095	C/T	cg16667508	chr20:43936853	MATN4;RBPJL	-0.64	-6.6	-0.56	2.35e-9	Blood protein levels;
THYM	cis	rs35264875	0.846	rs72930627	chr11:68867121	C/A	cg23845249	chr11:68861649	NA	0.62	7.41	0.61	5.1e-11	Blond vs. brown hair color;
THYM	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.48	-4.63	-0.43	1.15e-5	Longevity;Endometriosis;
THYM	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg07131210	chr7:1025825	CYP2W1	-0.85	-4.72	-0.44	8.19e-6	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs7192380	1.000	rs11640319	chr16:69633515	G/A	cg09409435	chr16:70099608	PDXDC2	0.62	4.73	0.44	7.92e-6	Sjögren's syndrome;
THYM	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg05025164	chr4:1340916	KIAA1530	0.9	6.86	0.58	6.98e-10	Longevity;
THYM	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.78	-5.42	-0.49	4.5e-7	Gut microbiome composition (summer);
THYM	cis	rs7584330	0.554	rs7570873	chr2:238435054	G/A	cg08992911	chr2:238395768	MLPH	0.89	5.81	0.51	8.24e-8	Prostate cancer;
THYM	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg15693483	chr7:1102177	C7orf50	0.53	6.19	0.54	1.52e-8	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg12000587	chr17:30186630	C17orf79	-0.46	-6.97	-0.58	4.08e-10	Hip circumference adjusted for BMI;
THYM	cis	rs1865721	0.771	rs724764	chr18:73139742	C/T	cg26385618	chr18:73139727	C18orf62	-0.65	-4.88	-0.45	4.33e-6	Intelligence;
THYM	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg06558623	chr16:89946397	TCF25	1.49	6.44	0.55	4.78e-9	Skin colour saturation;
THYM	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg22709100	chr7:91322751	NA	-0.6	-4.8	-0.44	5.84e-6	Breast cancer;
THYM	trans	rs10802346	0.545	rs6662672	chr1:246387611	A/C	cg13514129	chr1:39547527	MACF1	1.02	10.05	0.72	1.3e-16	Fractional exhaled nitric oxide (childhood);
THYM	cis	rs2625529	0.652	rs2957740	chr15:72307691	A/G	cg16672083	chr15:72433130	SENP8	0.49	4.53	0.42	1.73e-5	Red blood cell count;
THYM	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg10802521	chr3:52805072	NEK4	-0.71	-6.18	-0.54	1.57e-8	Bipolar disorder;
THYM	trans	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg25214090	chr10:38739885	LOC399744	0.96	8.24	0.65	9.27e-13	Corneal astigmatism;
THYM	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg11764359	chr7:65958608	NA	0.85	7.0	0.58	3.62e-10	Aortic root size;
THYM	cis	rs7103648	0.695	rs6485758	chr11:47530024	G/A	cg20307385	chr11:47447363	PSMC3	0.91	7.13	0.59	1.95e-10	Diastolic blood pressure;Systolic blood pressure;
THYM	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg15592062	chr6:167189543	RPS6KA2	0.59	6.16	0.53	1.73e-8	Crohn's disease;
THYM	cis	rs6964587	0.610	rs10953056	chr7:91466700	C/T	cg17063962	chr7:91808500	NA	0.99	8.37	0.65	4.96e-13	Breast cancer;
THYM	cis	rs16866061	0.926	rs1523919	chr2:225403615	G/A	cg22455342	chr2:225449267	CUL3	0.67	4.58	0.43	1.4e-5	Acute graft versus host disease in bone marrow transplantation (recipient effect);
THYM	cis	rs6918586	0.658	rs13161	chr6:26114702	C/T	cg07061783	chr6:25882402	NA	0.58	4.58	0.43	1.42e-5	Schizophrenia;
THYM	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06634786	chr22:41940651	POLR3H	-0.68	-5.11	-0.46	1.67e-6	Vitiligo;
THYM	cis	rs7187994	0.848	rs34923260	chr16:84773460	A/G	cg07647771	chr16:84786436	USP10	-0.57	-5.0	-0.46	2.57e-6	Reticulocyte count;Reticulocyte fraction of red cells;
THYM	cis	rs478304	0.903	rs546202	chr11:65510024	C/T	cg17480646	chr11:65405466	SIPA1	-0.7	-6.13	-0.53	2e-8	Acne (severe);
THYM	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06850241	chr22:41845214	NA	-0.59	-5.36	-0.48	5.85e-7	Vitiligo;
THYM	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg13135455	chr2:241860318	NA	-0.41	-4.88	-0.45	4.24e-6	Urinary metabolites;
THYM	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg20503657	chr10:835505	NA	1.42	9.74	0.71	5.94e-16	Eosinophil percentage of granulocytes;
THYM	cis	rs2445762	0.642	rs8041933	chr15:51617746	G/A	cg00184732	chr15:51633821	GLDN	0.59	4.48	0.42	2.05e-5	Hormone measurements;
THYM	cis	rs4242434	0.819	rs1871902	chr8:22470710	G/A	cg11461670	chr8:22454935	PDLIM2	-0.34	-6.44	-0.55	4.92e-9	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
THYM	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg11941060	chr3:133502564	NA	-0.73	-6.42	-0.55	5.36e-9	Iron status biomarkers;
THYM	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg06850241	chr22:41845214	NA	-0.54	-4.72	-0.44	8.19e-6	Vitiligo;
THYM	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg12573674	chr2:1569213	NA	-1.35	-8.81	-0.67	5.84e-14	IgG glycosylation;
THYM	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.0	10.07	0.72	1.18e-16	Cognitive ability;
THYM	cis	rs77372450	0.551	rs73814843	chr5:157063058	A/C	cg00312553	chr5:157098553	C5orf52	-0.65	-4.63	-0.43	1.16e-5	Bipolar disorder (body mass index interaction);
THYM	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg08772003	chr10:104629869	AS3MT	-0.65	-5.77	-0.51	9.98e-8	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg06634786	chr22:41940651	POLR3H	0.73	5.36	0.48	5.89e-7	Vitiligo;
THYM	cis	rs9554348	0.541	rs61966932	chr13:96986915	G/A	cg25169784	chr13:96706045	UGGT2	0.85	4.55	0.42	1.58e-5	Schizophrenia;
THYM	cis	rs2072499	0.966	rs2244144	chr1:156184598	G/A	cg24450063	chr1:156163899	SLC25A44	1.13	13.4	0.81	1.28e-23	Testicular germ cell tumor;
THYM	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg24250549	chr1:154909240	PMVK	0.67	5.11	0.46	1.63e-6	Prostate cancer;
THYM	cis	rs79387448	0.745	rs79107058	chr2:103164257	C/A	cg09003973	chr2:102972529	NA	0.75	4.63	0.43	1.14e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs1823778	0.609	rs11151555	chr18:67690603	G/T	cg13164537	chr18:67624071	CD226	1.11	4.47	0.42	2.14e-5	Mean platelet volume;
THYM	trans	rs10962692	0.608	rs62541877	chr9:16852453	G/A	cg03221025	chr16:88955224	CBFA2T3	0.75	7.4	0.6	5.52e-11	Ovarian cancer in BRCA2 mutation carriers;Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Serous invasive ovarian cancer;Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;
THYM	cis	rs4285028	0.848	rs77630152	chr3:121681194	C/T	cg01951420	chr3:121553821	IQCB1;EAF2	-0.72	-4.94	-0.45	3.38e-6	Multiple sclerosis;
THYM	cis	rs1050631	0.592	rs1785930	chr18:33723718	A/G	cg25426722	chr18:33708991	SLC39A6;ELP2	0.66	5.32	0.48	6.94e-7	Esophageal squamous cell cancer (length of survival);
THYM	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg08017756	chr2:100939284	LONRF2	-0.75	-7.76	-0.62	9.51e-12	Intelligence (multi-trait analysis);
THYM	cis	rs9302635	0.513	rs12444701	chr16:72155240	C/T	cg23815491	chr16:72088622	HP	0.7	5.32	0.48	6.83e-7	Blood protein levels;
THYM	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-13.33	-0.81	1.74e-23	Coronary artery disease;
THYM	cis	rs61990749	0.544	rs8003979	chr14:78211290	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	1.17	8.04	0.64	2.52e-12	Fibroblast growth factor basic levels;
THYM	cis	rs1629083	0.967	rs17121997	chr11:118131049	T/C	cg25155064	chr11:118100782	MPZL3	-0.57	-5.03	-0.46	2.28e-6	Lung cancer;
THYM	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg13695892	chr22:41940480	POLR3H	0.85	6.16	0.53	1.72e-8	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs36051895	0.622	rs10974952	chr9:5079828	A/T	cg02405213	chr9:5042618	JAK2	-1.01	-10.92	-0.75	1.8e-18	Pediatric autoimmune diseases;
THYM	cis	rs7771547	0.508	rs3798471	chr6:36499571	C/T	cg07856975	chr6:36356162	ETV7	0.56	5.49	0.49	3.3e-7	Platelet distribution width;
THYM	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	cg00122347	chr10:104236741	TMEM180	-0.38	-5.18	-0.47	1.24e-6	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg14820908	chr5:178986412	RUFY1	-0.64	-6.94	-0.58	4.84e-10	Lung cancer;
THYM	cis	rs7113850	0.541	rs75893426	chr11:24210429	T/C	ch.11.24196551F	chr11:24239977	NA	0.89	4.57	0.42	1.48e-5	Bone fracture in osteoporosis;
THYM	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg14456004	chr13:21872349	NA	1.26	11.44	0.76	1.44e-19	White matter hyperintensity burden;
THYM	cis	rs6980334	0.817	rs10228704	chr7:137795206	T/C	cg11874123	chr7:137028198	PTN	0.67	5.17	0.47	1.29e-6	Blood metabolite ratios;
THYM	cis	rs17604090	0.878	rs4000284	chr7:29726917	G/A	cg19413766	chr7:29689036	LOC646762	-0.95	-5.37	-0.48	5.65e-7	Facial emotion recognition;Facial emotion recognition (sad faces);
THYM	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg18252515	chr7:66147081	NA	-0.87	-6.66	-0.56	1.74e-9	Corneal structure;
THYM	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg13393036	chr8:95962371	TP53INP1	-0.48	-4.72	-0.44	7.96e-6	Type 2 diabetes;
THYM	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg07606381	chr6:8435919	SLC35B3	0.6	4.47	0.42	2.12e-5	Motion sickness;
THYM	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg14004847	chr7:1930337	MAD1L1	-0.65	-5.12	-0.47	1.57e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs901683	1.000	rs10508896	chr10:46030643	A/G	cg18240400	chr10:46168597	ANUBL1	0.65	4.56	0.42	1.52e-5	Red blood cell traits;Mean corpuscular volume;
THYM	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg01097406	chr16:89675127	NA	-0.62	-5.19	-0.47	1.17e-6	Vitiligo;
THYM	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg12560992	chr17:57184187	TRIM37	-0.91	-8.51	-0.66	2.54e-13	Intelligence (multi-trait analysis);
THYM	cis	rs7772486	0.875	rs932522	chr6:146374026	A/G	cg23711669	chr6:146136114	FBXO30	-0.91	-9.09	-0.68	1.43e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg09184832	chr6:79620586	NA	0.57	4.51	0.42	1.85e-5	Intelligence (multi-trait analysis);
THYM	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	1.16	9.09	0.68	1.44e-14	Cognitive test performance;
THYM	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg18252515	chr7:66147081	NA	-1.45	-8.59	-0.66	1.72e-13	Diabetic kidney disease;
THYM	cis	rs1747683	0.932	rs6602648	chr10:13383212	C/T	cg00142036	chr10:13388442	SEPHS1	-0.29	-5.17	-0.47	1.27e-6	IgG glycosylation;
THYM	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg09307838	chr4:120376055	NA	0.71	5.41	0.49	4.61e-7	Corneal astigmatism;
THYM	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg04876606	chr3:49977596	RBM6	-0.55	-4.52	-0.42	1.78e-5	Parkinson's disease;
THYM	cis	rs988913	1.000	rs9370342	chr6:54820670	C/A	cg19716238	chr6:54711378	FAM83B	0.48	4.95	0.45	3.15e-6	Menarche (age at onset);
THYM	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg05962950	chr11:130786565	SNX19	0.82	7.4	0.6	5.47e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg23131131	chr22:24373011	LOC391322	-0.83	-7.96	-0.63	3.63e-12	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg27284194	chr4:1044797	NA	0.62	4.73	0.44	7.81e-6	Recombination rate (females);
THYM	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg12011299	chr4:100065546	ADH4	0.81	8.21	0.64	1.1e-12	Alcohol dependence;
THYM	cis	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg01364799	chr7:75623366	TMEM120A	-0.63	-4.49	-0.42	1.99e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs6500395	1.000	rs9933976	chr16:48590145	A/G	cg04672837	chr16:48644449	N4BP1	0.49	4.79	0.44	6.02e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	6.49	0.55	3.94e-9	Obesity-related traits;
THYM	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg13390004	chr1:15929781	NA	0.64	4.85	0.45	4.88e-6	Systolic blood pressure;
THYM	cis	rs4803468	0.967	rs13344547	chr19:41945848	G/T	cg09537434	chr19:41945824	ATP5SL	1.1	10.47	0.73	1.63e-17	Height;
THYM	cis	rs9527	1.000	rs4919690	chr10:104616500	C/T	cg15744005	chr10:104629667	AS3MT	0.77	5.6	0.5	2.11e-7	Arsenic metabolism;
THYM	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg05283184	chr6:79620031	NA	-1.0	-9.68	-0.7	8.13e-16	Intelligence (multi-trait analysis);
THYM	cis	rs6430585	0.583	rs730005	chr2:136582694	T/C	cg07169764	chr2:136633963	MCM6	1.18	13.45	0.81	1.03e-23	Corneal structure;
THYM	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.73	-6.5	-0.55	3.67e-9	Chronic sinus infection;
THYM	cis	rs2730245	0.527	rs842702	chr7:158696814	C/T	cg01219135	chr7:158766336	NA	0.56	4.49	0.42	2.01e-5	Height;
THYM	cis	rs2637266	1.000	rs12262400	chr10:78386862	T/C	cg18941641	chr10:78392320	NA	0.81	6.99	0.58	3.83e-10	Pulmonary function;
THYM	cis	rs11696501	0.688	rs6032419	chr20:44297963	T/A	cg11783356	chr20:44313418	WFDC10B	-0.71	-4.91	-0.45	3.76e-6	Brain structure;
THYM	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg13010199	chr12:38710504	ALG10B	-0.62	-4.46	-0.42	2.21e-5	Bladder cancer;
THYM	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg19761014	chr17:28927070	LRRC37B2	0.85	4.9	0.45	3.92e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg06532163	chr17:45867833	NA	0.65	6.55	0.56	2.91e-9	IgG glycosylation;
THYM	cis	rs1799949	0.832	rs2070835	chr17:41174025	A/C	cg05368731	chr17:41323189	NBR1	1.27	11.41	0.76	1.71e-19	Menopause (age at onset);
THYM	cis	rs514406	0.798	rs4351588	chr1:53263826	A/T	cg08736216	chr1:53307985	ZYG11A	0.57	4.67	0.43	9.87e-6	Monocyte count;
THYM	cis	rs4819852	1.000	rs4819852	chr22:19988167	G/A	cg07821417	chr22:19972146	ARVCF	0.42	4.59	0.43	1.34e-5	Pulse pressure;
THYM	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	5.09	0.46	1.8e-6	Menarche (age at onset);
THYM	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg04476341	chr5:669733	TPPP	0.6	4.46	0.42	2.21e-5	Obesity-related traits;
THYM	cis	rs9549260	0.755	rs7985364	chr13:41179580	C/G	cg21288729	chr13:41239152	FOXO1	0.66	5.41	0.48	4.8e-7	Red blood cell count;
THYM	cis	rs2050392	0.517	rs602097	chr10:30747546	C/T	cg18806716	chr10:30721971	MAP3K8	-0.51	-4.66	-0.43	1.04e-5	Inflammatory bowel disease;
THYM	cis	rs12148329	0.545	rs12903231	chr15:81017344	T/C	cg01654770	chr15:80543586	NA	-0.89	-4.55	-0.42	1.6e-5	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs40363	0.620	rs1137454	chr16:3533577	C/G	cg00484396	chr16:3507460	NAT15	-0.73	-8.89	-0.67	3.86e-14	Tuberculosis;
THYM	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg18681998	chr4:17616180	MED28	0.99	10.08	0.72	1.09e-16	Parasitemia in Tripanosoma cruzi seropositivity;
THYM	cis	rs9326248	0.520	rs7127881	chr11:116880798	G/A	cg20608306	chr11:116969690	SIK3	0.58	6.98	0.58	4.04e-10	Blood protein levels;
THYM	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg10802521	chr3:52805072	NEK4	-0.75	-7.03	-0.58	3.15e-10	Bipolar disorder;
THYM	cis	rs1469039	0.872	rs888345	chr8:140646990	C/T	cg17290943	chr8:141107717	TRAPPC9	-0.57	-4.45	-0.42	2.29e-5	Menarche (age at onset);
THYM	cis	rs526231	0.543	rs42431	chr5:102400063	C/T	cg23492399	chr5:102201601	PAM	0.66	4.86	0.45	4.62e-6	Primary biliary cholangitis;
THYM	cis	rs595982	0.559	rs17206714	chr19:49362001	T/A	cg17863274	chr19:49399704	TULP2	-0.93	-5.69	-0.5	1.43e-7	Red cell distribution width;
THYM	cis	rs775227	0.574	rs60279293	chr3:113096087	T/G	cg18753928	chr3:113234510	CCDC52	-0.76	-5.35	-0.48	6.02e-7	Dental caries;
THYM	cis	rs12681287	0.752	rs4282548	chr8:87270792	A/T	cg27223183	chr8:87520930	FAM82B	-0.66	-5.0	-0.46	2.66e-6	Caudate activity during reward;
THYM	cis	rs67981189	0.896	rs7146591	chr14:71438228	C/T	cg15910301	chr14:71632612	NA	-0.51	-4.68	-0.43	9.44e-6	Schizophrenia;
THYM	cis	rs7598759	0.548	rs1823328	chr2:232355184	G/A	cg19187155	chr2:232395269	NMUR1	0.86	7.76	0.62	9.62e-12	Noise-induced hearing loss;
THYM	cis	rs1003719	0.762	rs4399800	chr21:38489478	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.68	4.86	0.45	4.64e-6	Eye color traits;
THYM	trans	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg10856724	chr12:34555212	NA	-0.9	-8.08	-0.64	2.05e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs1853207	1.000	rs17110192	chr10:96441927	C/G	cg18318006	chr10:97169147	SORBS1	0.93	4.55	0.42	1.58e-5	Blood metabolite levels;
THYM	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg16624210	chr5:671434	TPPP	0.76	5.61	0.5	2.03e-7	Obesity-related traits;
THYM	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg24069376	chr3:38537580	EXOG	0.61	5.93	0.52	4.88e-8	Electrocardiographic conduction measures;
THYM	cis	rs10208649	0.710	rs10190353	chr2:54242825	C/A	cg04546899	chr2:54196757	PSME4	0.68	4.73	0.44	7.94e-6	Body mass index;
THYM	cis	rs1728785	1.000	rs1728781	chr16:68567794	A/T	cg02972257	chr16:68554789	NA	-0.74	-4.54	-0.42	1.63e-5	Ulcerative colitis;
THYM	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg27034606	chr17:28928453	LRRC37B2	0.81	5.39	0.48	5.18e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg04944784	chr2:26401820	FAM59B	1.03	5.7	0.5	1.34e-7	Gut microbiome composition (summer);
THYM	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg04876069	chr12:132293656	NA	-0.69	-5.85	-0.51	6.95e-8	Migraine;
THYM	cis	rs7772486	0.875	rs10457796	chr6:146416087	T/G	cg13319975	chr6:146136371	FBXO30	-0.63	-5.18	-0.47	1.24e-6	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg15247329	chr7:2764246	NA	-0.67	-5.56	-0.5	2.44e-7	Height;
THYM	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	5.51	0.49	3.07e-7	Bipolar disorder;
THYM	cis	rs2072510	0.569	rs7306086	chr12:96390502	T/C	cg18817487	chr12:96390143	HAL	0.47	5.71	0.51	1.31e-7	Metabolite levels (small molecules and protein measures);
THYM	cis	rs1448094	0.511	rs4897823	chr12:86161484	C/T	cg00310523	chr12:86230176	RASSF9	0.58	5.01	0.46	2.49e-6	Major depressive disorder;
THYM	cis	rs2439831	0.681	rs2242067	chr15:43699303	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.69	4.64	0.43	1.11e-5	Lung cancer in ever smokers;
THYM	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg06873352	chr17:61820015	STRADA	0.75	8.77	0.67	7.17e-14	Prudent dietary pattern;
THYM	cis	rs7528419	1.000	rs7528419	chr1:109817192	A/G	cg00908766	chr1:109817496	CELSR2	-0.9	-7.17	-0.59	1.58e-10	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;Lipoprotein-associated phospholipase A2 activity and mass;Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease;Cholesterol, total;Coronary artery disease;
THYM	cis	rs8067545	1.000	rs8067545	chr17:19912710	T/C	cg13482628	chr17:19912719	NA	0.58	4.93	0.45	3.51e-6	Schizophrenia;
THYM	cis	rs12310956	0.510	rs10844693	chr12:33865197	A/G	cg10856724	chr12:34555212	NA	0.63	5.52	0.49	2.91e-7	Morning vs. evening chronotype;
THYM	cis	rs59197085	0.534	rs2307038	chr7:128449356	A/C	cg00734629	chr7:128471146	FLNC	0.76	4.51	0.42	1.89e-5	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
THYM	trans	rs7794364	0.658	rs7807677	chr7:117502574	C/T	cg21837391	chr1:1159412	SDF4	0.86	6.91	0.58	5.48e-10	Idiopathic osteonecrosis of the femoral head;
THYM	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg13609457	chr4:120235615	NA	0.59	5.25	0.47	9.25e-7	Corneal astigmatism;
THYM	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg26384229	chr12:38710491	ALG10B	0.73	5.59	0.5	2.2e-7	Morning vs. evening chronotype;
THYM	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg27494647	chr7:150038898	RARRES2	0.46	5.82	0.51	8.06e-8	Blood protein levels;Circulating chemerin levels;
THYM	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.73	-4.82	-0.44	5.35e-6	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs514406	0.505	rs269292	chr1:53187911	T/C	cg16325326	chr1:53192061	ZYG11B	0.98	10.84	0.74	2.68e-18	Monocyte count;
THYM	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg16680214	chr1:154839983	KCNN3	-0.51	-6.33	-0.54	8.22e-9	Prostate cancer;
THYM	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg20203395	chr5:56204925	C5orf35	-0.67	-4.58	-0.42	1.44e-5	Initial pursuit acceleration;
THYM	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06850241	chr22:41845214	NA	0.57	5.09	0.46	1.82e-6	Vitiligo;
THYM	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg22307297	chr20:60903441	LAMA5	0.54	4.76	0.44	6.8e-6	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
THYM	cis	rs10927875	0.632	rs2013745	chr1:16126676	G/A	cg21385522	chr1:16154831	NA	-1.36	-13.42	-0.81	1.19e-23	Dilated cardiomyopathy;
THYM	cis	rs7584330	0.518	rs11884238	chr2:238424671	T/G	cg08992911	chr2:238395768	MLPH	0.79	5.0	0.46	2.62e-6	Prostate cancer;
THYM	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg13695892	chr22:41940480	POLR3H	0.88	7.43	0.61	4.72e-11	Vitiligo;
THYM	cis	rs5417	0.662	rs8067500	chr17:7172631	A/G	cg14660024	chr17:7154518	C17orf81;DULLARD	-0.78	-6.27	-0.54	1.06e-8	Diastolic blood pressure;
THYM	cis	rs6427499	0.563	rs11265297	chr1:159890459	A/G	cg15641364	chr1:159892206	TAGLN2	-0.43	-4.83	-0.44	5.22e-6	Platelet distribution width;
THYM	cis	rs6960043	0.818	rs2358158	chr7:15054063	T/C	cg19272540	chr7:15055459	NA	0.54	5.9	0.52	5.67e-8	Type 2 diabetes;
THYM	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg02725872	chr8:58115012	NA	-0.73	-4.7	-0.43	8.91e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs12817549	0.754	rs4144499	chr12:94151844	C/T	cg19571390	chr12:94157676	CRADD	0.59	4.91	0.45	3.72e-6	Hip circumference adjusted for BMI;
THYM	cis	rs11023332	0.800	rs12271890	chr11:14934686	A/G	cg19336497	chr11:14380999	RRAS2	-0.51	-4.73	-0.44	7.95e-6	Adiponectin levels;Vitamin D levels;
THYM	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg02187348	chr16:89574699	SPG7	0.75	5.65	0.5	1.65e-7	Multiple myeloma (IgH translocation);
THYM	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg19748678	chr4:122722346	EXOSC9	0.73	5.15	0.47	1.42e-6	Type 2 diabetes;
THYM	cis	rs5771069	0.933	rs137845	chr22:50439430	A/G	cg27467552	chr22:50353597	PIM3	-0.45	-4.81	-0.44	5.73e-6	Ulcerative colitis;
THYM	cis	rs921968	0.541	rs3770213	chr2:219508372	A/T	cg02176678	chr2:219576539	TTLL4	-0.73	-7.22	-0.6	1.27e-10	Mean corpuscular hemoglobin concentration;
THYM	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-4.73	-0.44	7.65e-6	Alzheimer's disease;
THYM	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg17366294	chr4:99064904	C4orf37	0.52	6.07	0.53	2.64e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	10.73	0.74	4.66e-18	Chronic sinus infection;
THYM	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg02725872	chr8:58115012	NA	-1.11	-7.58	-0.61	2.31e-11	Developmental language disorder (linguistic errors);
THYM	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg18876405	chr7:65276391	NA	0.57	4.72	0.44	7.99e-6	Aortic root size;
THYM	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg05738196	chr6:26577821	NA	0.93	9.1	0.68	1.38e-14	Intelligence (multi-trait analysis);
THYM	cis	rs728616	0.867	rs61860421	chr10:81743399	C/T	cg18148530	chr10:81370782	SFTPA1	0.75	4.88	0.45	4.34e-6	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs854765	0.583	rs9635697	chr17:17870394	T/A	cg16928487	chr17:17741425	SREBF1	-0.55	-5.47	-0.49	3.62e-7	Total body bone mineral density;
THYM	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg27535305	chr1:53392650	SCP2	0.4	4.68	0.43	9.51e-6	Monocyte count;
THYM	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg01819863	chr10:32635814	EPC1	1.04	6.64	0.56	1.9e-9	Sexual dysfunction (female);
THYM	cis	rs4595586	0.505	rs11615603	chr12:39409450	C/G	cg26384229	chr12:38710491	ALG10B	0.66	5.1	0.46	1.75e-6	Morning vs. evening chronotype;
THYM	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.25	5.68	0.5	1.49e-7	Obesity-related traits;
THYM	trans	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg10856724	chr12:34555212	NA	-1.02	-9.56	-0.7	1.47e-15	Bladder cancer;
THYM	cis	rs1642645	0.872	rs661428	chr1:42451518	A/C	cg10197057	chr1:42612518	NA	0.44	4.72	0.44	8.15e-6	Left ventricular obstructive tract defect (maternal effect);
THYM	cis	rs4601821	0.965	rs10891543	chr11:113255895	A/G	cg14159747	chr11:113255604	NA	0.26	5.02	0.46	2.41e-6	Alcoholic chronic pancreatitis;
THYM	cis	rs7772486	0.686	rs857883	chr6:145969214	G/T	cg13319975	chr6:146136371	FBXO30	0.66	5.42	0.49	4.51e-7	Lobe attachment (rater-scored or self-reported);
THYM	trans	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg18335740	chr13:41363409	SLC25A15	0.75	7.93	0.63	4.13e-12	Lewy body disease;
THYM	cis	rs7917772	0.582	rs7087984	chr10:104380686	G/A	cg00122347	chr10:104236741	TMEM180	-0.41	-5.77	-0.51	9.92e-8	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
THYM	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg03476357	chr21:30257390	N6AMT1	-0.6	-4.55	-0.42	1.58e-5	Dental caries;
THYM	cis	rs7586879	0.575	rs6744205	chr2:25133148	T/C	cg01884057	chr2:25150051	NA	0.73	7.92	0.63	4.47e-12	Body mass index;
THYM	cis	rs889398	0.802	rs2937121	chr16:69870409	T/G	cg09409435	chr16:70099608	PDXDC2	-0.66	-5.34	-0.48	6.36e-7	Body mass index;
THYM	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.79	-6.63	-0.56	2.06e-9	Intelligence (multi-trait analysis);
THYM	cis	rs6596100	0.538	rs1393244	chr5:132186007	T/G	cg02081065	chr5:132209139	LEAP2	-0.8	-5.37	-0.48	5.51e-7	Breast cancer;
THYM	cis	rs4654899	0.567	rs9426735	chr1:21505472	A/T	cg01072550	chr1:21505969	NA	-0.72	-6.33	-0.54	7.98e-9	Superior frontal gyrus grey matter volume;
THYM	cis	rs7089973	0.872	rs60820172	chr10:116625891	C/T	cg08188268	chr10:116634841	FAM160B1	-0.31	-5.14	-0.47	1.5e-6	Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs2562456	0.833	rs552800	chr19:21484642	G/A	cg21751540	chr19:21541537	ZNF738	0.72	4.72	0.44	8.17e-6	Pain;
THYM	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg02734326	chr4:10020555	SLC2A9	0.78	6.67	0.56	1.68e-9	Bone mineral density;
THYM	cis	rs7084402	0.935	rs10763556	chr10:60341398	A/G	cg07615347	chr10:60278583	BICC1	-0.54	-5.06	-0.46	2.04e-6	Refractive error;
THYM	cis	rs1461503	0.934	rs930983	chr11:122834414	A/G	cg27398637	chr11:122830231	C11orf63	-0.63	-5.49	-0.49	3.34e-7	Menarche (age at onset);
THYM	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg10360139	chr7:1886902	MAD1L1	-0.57	-4.86	-0.45	4.62e-6	Bipolar disorder and schizophrenia;
THYM	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg10047753	chr17:41438598	NA	0.98	8.08	0.64	2.01e-12	Menopause (age at onset);
THYM	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg02734326	chr4:10020555	SLC2A9	-0.56	-4.63	-0.43	1.17e-5	Bone mineral density;
THYM	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg17173187	chr15:85201210	NMB	0.57	5.66	0.5	1.61e-7	Schizophrenia;
THYM	cis	rs1018836	0.608	rs12679836	chr8:91465287	A/G	cg16814680	chr8:91681699	NA	-0.71	-5.72	-0.51	1.22e-7	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg21926883	chr2:100939477	LONRF2	-0.63	-5.88	-0.52	5.99e-8	Intelligence (multi-trait analysis);
THYM	cis	rs4638749	0.627	rs4676185	chr2:108841908	G/C	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs665401	0.965	rs9489065	chr6:117234711	C/T	cg20376953	chr6:117187980	NA	-0.57	-4.58	-0.43	1.4e-5	Neutrophil percentage of granulocytes;
THYM	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg17105886	chr17:28927953	LRRC37B2	1.3	6.95	0.58	4.49e-10	Body mass index;
THYM	cis	rs6952808	1.000	rs12699404	chr7:1894022	A/T	cg14004847	chr7:1930337	MAD1L1	-0.64	-4.58	-0.42	1.43e-5	Bipolar disorder and schizophrenia;
THYM	cis	rs11122895	0.791	rs7559932	chr2:112467132	A/G	cg23262488	chr2:112468472	NA	0.47	5.33	0.48	6.64e-7	Allergic sensitization;
THYM	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg03806693	chr22:41940476	POLR3H	1.07	8.31	0.65	6.6e-13	Vitiligo;
THYM	cis	rs7833986	1.000	rs34230678	chr8:57083117	T/C	cg23139584	chr8:56987506	RPS20;SNORD54	0.52	5.03	0.46	2.31e-6	Height;
THYM	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg12935359	chr14:103987150	CKB	-0.63	-6.62	-0.56	2.09e-9	Body mass index;
THYM	cis	rs9733	0.596	rs11204704	chr1:150671630	T/C	cg09034736	chr1:150693464	HORMAD1	0.52	4.66	0.43	1.04e-5	Tonsillectomy;
THYM	cis	rs600806	0.850	rs3931560	chr1:109966718	A/C	cg02175308	chr1:109941060	SORT1	-0.61	-5.38	-0.48	5.35e-7	Intelligence (multi-trait analysis);
THYM	cis	rs7616559	0.962	rs1482863	chr3:156731644	T/A	cg15697575	chr3:156784781	NA	0.4	4.99	0.46	2.71e-6	Carotid artery intima media thickness (sex interaction);
THYM	cis	rs854765	0.693	rs8080061	chr17:17776389	C/T	cg16928487	chr17:17741425	SREBF1	0.52	5.23	0.47	1.01e-6	Total body bone mineral density;
THYM	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	1.12	8.13	0.64	1.64e-12	Cognitive test performance;
THYM	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg03806693	chr22:41940476	POLR3H	1.11	8.99	0.68	2.33e-14	Vitiligo;
THYM	cis	rs6500395	0.890	rs9936445	chr16:48617754	T/G	cg04672837	chr16:48644449	N4BP1	0.48	4.64	0.43	1.13e-5	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.26	6.46	0.55	4.49e-9	Obesity-related traits;
THYM	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg10505658	chr17:80084571	CCDC57	0.7	8.07	0.64	2.18e-12	Life satisfaction;
THYM	cis	rs4638749	0.677	rs12611470	chr2:108839349	C/T	cg25838818	chr2:108905173	SULT1C2	-0.55	-5.53	-0.49	2.86e-7	Blood pressure;
THYM	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.7	5.65	0.5	1.64e-7	Tonsillectomy;
THYM	cis	rs79387448	0.745	rs6749440	chr2:103101846	C/T	cg09003973	chr2:102972529	NA	0.76	4.67	0.43	1.01e-5	Gut microbiota (bacterial taxa);
THYM	cis	rs7772486	0.875	rs2328712	chr6:146344563	T/C	cg23711669	chr6:146136114	FBXO30	0.9	8.82	0.67	5.37e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs1062177	1.000	rs2915887	chr5:151205504	C/T	cg14319409	chr5:151304409	GLRA1	0.55	4.45	0.42	2.33e-5	Preschool internalizing problems;
THYM	cis	rs2075230	0.588	rs1642802	chr17:7544271	T/C	cg08090557	chr17:7464088	TNFSF13;TNFSF12-TNFSF13;SENP3	-0.31	-4.51	-0.42	1.82e-5	Hormone measurements;
THYM	cis	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg24375607	chr4:120327624	NA	0.64	4.51	0.42	1.85e-5	Corneal astigmatism;
THYM	cis	rs981844	0.816	rs56109239	chr4:154726500	A/G	cg09973105	chr4:154681532	RNF175	-0.66	-5.45	-0.49	3.98e-7	Response to statins (LDL cholesterol change);
THYM	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg03060546	chr3:49711283	APEH	-0.67	-5.08	-0.46	1.85e-6	Ulcerative colitis;Blood protein levels;Crohn's disease;
THYM	cis	rs7586879	0.593	rs10198356	chr2:25130592	A/G	cg27107076	chr2:25050844	ADCY3	-0.29	-4.73	-0.44	7.91e-6	Body mass index;
THYM	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg00271210	chr6:167070053	RPS6KA2	-0.69	-7.42	-0.61	4.85e-11	Crohn's disease;
THYM	cis	rs2976388	0.647	rs2164307	chr8:143788831	A/T	cg06565975	chr8:143823917	SLURP1	0.44	4.93	0.45	3.51e-6	Urinary tract infection frequency;
THYM	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg02887458	chr19:19495540	GATAD2A	-0.46	-5.1	-0.46	1.72e-6	Bipolar disorder;
THYM	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg00129232	chr17:37814104	STARD3	0.73	5.33	0.48	6.69e-7	Glomerular filtration rate (creatinine);
THYM	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg26031613	chr14:104095156	KLC1	0.78	5.2	0.47	1.14e-6	Bone mineral density;
THYM	cis	rs2502731	0.539	rs3003614	chr9:130994736	G/A	cg13642260	chr9:130955380	CIZ1	0.7	5.46	0.49	3.79e-7	Attention deficit hyperactivity disorder;
THYM	cis	rs3096299	0.746	rs9931120	chr16:89501357	A/G	cg02187348	chr16:89574699	SPG7	0.79	6.79	0.57	9.45e-10	Multiple myeloma (IgH translocation);
THYM	cis	rs750460	0.808	rs2165241	chr15:74222202	A/G	cg23484268	chr15:74220776	LOXL1	0.42	4.62	0.43	1.2e-5	Height;
THYM	cis	rs7586879	0.828	rs13012304	chr2:25122246	C/T	cg01884057	chr2:25150051	NA	0.52	4.58	0.43	1.39e-5	Body mass index;
THYM	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg12350822	chr6:88032061	C6orf162;GJB7	-0.44	-5.49	-0.49	3.28e-7	Monocyte percentage of white cells;
THYM	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg23231163	chr10:75533350	FUT11	-0.49	-7.03	-0.59	3.06e-10	Inflammatory bowel disease;
THYM	cis	rs4845875	0.557	rs6659541	chr1:11836442	G/A	cg25341925	chr1:11908058	NPPA	0.42	4.49	0.42	1.99e-5	Midregional pro atrial natriuretic peptide levels;
THYM	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.13	7.78	0.62	8.66e-12	Smoking behavior;
THYM	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg07936489	chr17:37558343	FBXL20	0.81	5.85	0.51	6.81e-8	Glomerular filtration rate (creatinine);
THYM	cis	rs1461503	0.868	rs7126785	chr11:122839564	C/A	cg27398637	chr11:122830231	C11orf63	-0.7	-6.65	-0.56	1.85e-9	Menarche (age at onset);
THYM	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg02696790	chr15:75250997	RPP25	-0.46	-4.72	-0.44	8.11e-6	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
THYM	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg03676636	chr4:99064102	C4orf37	0.42	6.05	0.53	2.83e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg26446133	chr18:72167187	CNDP2	-1.01	-7.46	-0.61	4.05e-11	Refractive error;
THYM	cis	rs62064224	0.546	rs62065495	chr17:30834617	T/C	cg18200150	chr17:30822561	MYO1D	0.65	5.59	0.5	2.2e-7	Schizophrenia;
THYM	cis	rs597539	0.503	rs7131462	chr11:68610143	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.61	-4.69	-0.43	9.11e-6	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
THYM	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg12219531	chr12:120966889	COQ5	0.84	6.97	0.58	4.08e-10	High light scatter reticulocyte count;
THYM	cis	rs4664308	0.810	rs59019419	chr2:161061287	G/A	cg03641300	chr2:160917029	PLA2R1	-0.75	-6.64	-0.56	1.96e-9	Idiopathic membranous nephropathy;
THYM	trans	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg10856724	chr12:34555212	NA	-0.96	-8.61	-0.66	1.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs4780401	0.609	rs8047190	chr16:11807097	T/C	cg01061890	chr16:11836724	TXNDC11	-0.66	-5.44	-0.49	4.13e-7	Rheumatoid arthritis;
THYM	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg23758822	chr17:41437982	NA	1.17	11.05	0.75	9.8e-19	Menopause (age at onset);
THYM	cis	rs9943465	0.688	rs2628154	chr10:132065841	A/G	cg02700606	chr10:131763134	EBF3	0.73	4.75	0.44	7.24e-6	Epstein-Barr virus copy number in lymphoblastoid cell lines;
THYM	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg05962950	chr11:130786565	SNX19	0.92	8.77	0.67	7.05e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg24812749	chr6:127587940	RNF146	0.97	7.88	0.63	5.36e-12	Breast cancer;
THYM	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg10523679	chr1:76189770	ACADM	0.9	8.78	0.67	6.7e-14	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg26513180	chr16:89883248	FANCA	0.72	7.12	0.59	2.05e-10	Vitiligo;
THYM	cis	rs12188164	0.686	rs11741946	chr5:421403	G/A	cg21159260	chr5:475889	SLC9A3	0.44	4.65	0.43	1.06e-5	Cystic fibrosis severity;
THYM	cis	rs1003719	0.667	rs6517404	chr21:38494918	C/T	cg01329690	chr21:38580129	DSCR9	0.35	4.71	0.44	8.46e-6	Eye color traits;
THYM	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11644478	chr21:40555479	PSMG1	-0.58	-4.76	-0.44	6.94e-6	Menarche (age at onset);
THYM	cis	rs4363385	0.818	rs1334849	chr1:153004652	A/G	cg13444842	chr1:152974279	SPRR3	0.59	4.79	0.44	6.17e-6	Inflammatory skin disease;
THYM	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg08067268	chr2:26466485	HADHB;HADHA	-0.68	-4.87	-0.45	4.43e-6	Gut microbiome composition (summer);
THYM	cis	rs877282	0.853	rs12777155	chr10:754731	G/C	cg10556349	chr10:835070	NA	-0.69	-4.49	-0.42	2.03e-5	Uric acid levels;
THYM	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg03676636	chr4:99064102	C4orf37	0.44	6.64	0.56	1.98e-9	Colonoscopy-negative controls vs population controls;
THYM	cis	rs6598955	0.671	rs11247904	chr1:26621804	G/A	cg16068833	chr1:26644515	UBXN11;CD52	0.26	4.5	0.42	1.9e-5	Obesity-related traits;
THYM	cis	rs3126085	0.935	rs10888470	chr1:152200472	T/C	cg10321714	chr1:152280068	FLG	0.65	4.72	0.44	8.02e-6	Atopic dermatitis;
THYM	cis	rs2294693	0.947	rs736795	chr6:40998141	G/A	cg21128951	chr6:40996213	UNC5CL	0.6	4.95	0.45	3.24e-6	Gastric cancer;Non-cardia gastric cancer;
THYM	cis	rs7729447	0.804	rs4867471	chr5:32693456	A/T	cg16267343	chr5:32710456	NPR3	0.79	7.16	0.59	1.69e-10	Blood pressure;
THYM	cis	rs477895	1.000	rs477895	chr11:64048912	C/T	cg06130144	chr11:64578348	MEN1	-0.85	-4.48	-0.42	2.1e-5	Mean platelet volume;
THYM	cis	rs863345	0.625	rs12075903	chr1:158458932	A/G	cg12129480	chr1:158549410	OR10X1	-0.49	-4.68	-0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs7512552	0.780	rs1260411	chr1:150382088	G/A	cg15654264	chr1:150340011	RPRD2	0.46	5.4	0.48	4.83e-7	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
THYM	cis	rs2075230	0.850	rs6503039	chr17:7470060	A/G	cg16696476	chr17:8191344	RANGRF;SLC25A35	0.29	4.54	0.42	1.66e-5	Hormone measurements;
THYM	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg10523679	chr1:76189770	ACADM	0.92	10.35	0.73	2.94e-17	Blood metabolite levels;Acylcarnitine levels;
THYM	cis	rs10208649	0.808	rs77805752	chr2:54264643	G/C	cg04546899	chr2:54196757	PSME4	0.68	4.73	0.44	7.94e-6	Body mass index;
THYM	cis	rs4731207	0.596	rs10252798	chr7:124637211	A/G	cg05285228	chr7:124571219	POT1	-0.72	-5.51	-0.49	3.02e-7	Cutaneous malignant melanoma;
THYM	cis	rs3771570	0.901	rs62190413	chr2:242417950	G/A	cg21155796	chr2:242212141	HDLBP	1.14	5.7	0.5	1.33e-7	Prostate cancer;
THYM	cis	rs11731175	0.961	rs3911065	chr4:189860731	A/T	cg00431894	chr4:189871012	NA	-0.83	-6.41	-0.55	5.52e-9	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg24250549	chr1:154909240	PMVK	0.8	6.36	0.55	7.09e-9	Prostate cancer;
THYM	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg06009448	chr7:1102226	C7orf50	0.53	5.59	0.5	2.17e-7	C-reactive protein levels or total cholesterol levels (pleiotropy);
THYM	cis	rs2932538	0.961	rs3013441	chr1:113192605	C/T	cg22162597	chr1:113214053	CAPZA1	-0.61	-5.08	-0.46	1.92e-6	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
THYM	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.5	-5.94	-0.52	4.62e-8	Longevity;Endometriosis;
THYM	cis	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg16306078	chr6:126000798	NA	0.53	5.22	0.47	1.03e-6	Endometrial cancer;
THYM	cis	rs919433	0.680	rs2564389	chr2:198260098	A/T	cg05783139	chr2:198650985	BOLL	0.64	5.04	0.46	2.23e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg25282410	chr6:160211355	TCP1;MRPL18	1.02	8.23	0.65	9.9e-13	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg05340658	chr4:99064831	C4orf37	0.55	4.74	0.44	7.44e-6	Colonoscopy-negative controls vs population controls;
THYM	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-14.05	-0.82	6.23e-25	Height;
THYM	cis	rs11252926	0.545	rs11252693	chr10:532139	A/G	cg14018140	chr10:458528	DIP2C	-0.47	-4.84	-0.45	4.92e-6	Psychosis in Alzheimer's disease;
THYM	trans	rs629535	0.547	rs72654095	chr8:70120770	A/G	cg21567404	chr3:27674614	NA	-0.9	-7.03	-0.58	3.17e-10	Dupuytren's disease;
THYM	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg06873352	chr17:61820015	STRADA	0.8	9.97	0.72	1.92e-16	Prudent dietary pattern;
THYM	cis	rs40363	0.723	rs8060367	chr16:3537919	C/A	cg01073479	chr16:3509474	NAT15	-0.68	-5.45	-0.49	4.02e-7	Tuberculosis;
THYM	cis	rs8020441	0.541	rs72681665	chr14:51167012	C/A	cg04730355	chr14:51134070	SAV1	0.81	4.47	0.42	2.14e-5	Cognitive performance;
THYM	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg17074396	chr22:49843754	NA	-0.4	-4.76	-0.44	6.95e-6	Monocyte count;Monocyte percentage of white cells;
THYM	cis	rs2070433	0.660	rs11701034	chr21:47793235	A/G	cg12379764	chr21:47803548	PCNT	0.84	5.0	0.46	2.64e-6	Lymphocyte counts;
THYM	trans	rs2540513	0.643	rs34573	chr12:96523704	G/T	cg08385097	chr2:60984209	PAPOLG	0.89	6.95	0.58	4.47e-10	Small intestine neuroendocrine tumor;
THYM	cis	rs6763768	0.606	rs13082092	chr3:53373204	T/G	cg22900224	chr3:52804907	NEK4	0.72	4.71	0.43	8.6e-6	Bacterial meningitis;
THYM	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg04398451	chr17:18023971	MYO15A	0.76	6.96	0.58	4.39e-10	Total body bone mineral density;
THYM	cis	rs4523957	0.928	rs216204	chr17:2196659	G/A	cg16513277	chr17:2031491	SMG6	0.79	7.37	0.6	6.32e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
THYM	cis	rs7428	0.527	rs7607284	chr2:85547376	C/G	cg24342717	chr2:85555507	TGOLN2	-0.79	-6.32	-0.54	8.53e-9	Ear protrusion;
THYM	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg13390004	chr1:15929781	NA	0.61	4.63	0.43	1.15e-5	Systolic blood pressure;
THYM	cis	rs1878931	0.697	rs10048148	chr16:3417450	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.95	9.1	0.68	1.41e-14	Body mass index (adult);
THYM	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg03388043	chr17:80084554	CCDC57	0.69	5.98	0.52	3.85e-8	Life satisfaction;
THYM	cis	rs26232	0.521	rs40508	chr5:102443938	A/T	cg23492399	chr5:102201601	PAM	-0.68	-5.01	-0.46	2.49e-6	Rheumatoid arthritis;
THYM	cis	rs514406	0.505	rs405208	chr1:53176674	C/T	cg27535305	chr1:53392650	SCP2	-0.39	-4.46	-0.42	2.26e-5	Monocyte count;
THYM	cis	rs113835537	0.529	rs60358007	chr11:66222353	G/A	cg10315249	chr11:66235081	PELI3	0.44	4.72	0.44	8.05e-6	Airway imaging phenotypes;
THYM	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.32	9.88	0.71	2.93e-16	Gut microbiome composition (summer);
THYM	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg25834613	chr7:1915315	MAD1L1	0.53	4.74	0.44	7.53e-6	Bipolar disorder;
THYM	cis	rs4851254	0.517	rs13020141	chr2:100653842	G/A	cg22139774	chr2:100720529	AFF3	-0.39	-4.46	-0.42	2.21e-5	Intelligence (multi-trait analysis);
THYM	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg23505145	chr19:12996616	KLF1	1.01	9.94	0.71	2.26e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs490234	0.718	rs2819622	chr9:128173724	T/C	cg14078157	chr9:128172775	NA	-0.85	-6.77	-0.57	1.05e-9	Mean arterial pressure;
THYM	cis	rs782590	0.608	rs10207590	chr2:55921782	G/C	cg18811423	chr2:55921094	PNPT1	-0.62	-5.83	-0.51	7.71e-8	Metabolic syndrome;
THYM	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg01831904	chr17:28903510	LRRC37B2	-1.13	-5.5	-0.49	3.13e-7	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7246967	0.673	rs8103430	chr19:22931498	A/G	cg05241461	chr19:22816980	ZNF492	0.59	4.61	0.43	1.26e-5	Bronchopulmonary dysplasia;
THYM	cis	rs9435341	0.965	rs1730862	chr1:107614003	G/A	cg00944433	chr1:107599041	PRMT6	0.42	5.39	0.48	5.04e-7	Facial morphology (factor 21, depth of nasal alae);
THYM	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg14664628	chr15:75095509	CSK	-0.67	-5.31	-0.48	7.18e-7	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.69	6.09	0.53	2.41e-8	Total body bone mineral density;
THYM	cis	rs6032067	0.777	rs80323300	chr20:43785287	T/C	cg27176129	chr20:43937155	MATN4;RBPJL	-0.51	-5.69	-0.5	1.4e-7	Blood protein levels;
THYM	cis	rs72781680	1.000	rs55982282	chr2:24188128	G/A	cg08917208	chr2:24149416	ATAD2B	1.08	4.91	0.45	3.8e-6	Lymphocyte counts;
THYM	cis	rs76662990	0.610	rs7700314	chr5:73943841	A/G	cg13275603	chr5:73927487	ENC1	-0.77	-4.63	-0.43	1.17e-5	Residual cognition;
THYM	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg14349672	chr11:133703707	NA	-0.52	-4.77	-0.44	6.62e-6	Childhood ear infection;
THYM	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg14784868	chr12:69753453	YEATS4	-0.82	-6.73	-0.57	1.25e-9	Blood protein levels;
THYM	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg02734326	chr4:10020555	SLC2A9	0.61	4.98	0.46	2.81e-6	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06634786	chr22:41940651	POLR3H	0.79	4.83	0.44	5.25e-6	Vitiligo;
THYM	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg26384229	chr12:38710491	ALG10B	-0.89	-9.06	-0.68	1.67e-14	Heart rate;
THYM	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg04972856	chr6:88032051	C6orf162;GJB7	0.37	4.85	0.45	4.74e-6	Monocyte percentage of white cells;
THYM	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg23758822	chr17:41437982	NA	1.16	11.04	0.75	1.02e-18	Menopause (age at onset);
THYM	cis	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg18252515	chr7:66147081	NA	0.67	4.94	0.45	3.31e-6	Aortic root size;
THYM	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg22709100	chr7:91322751	NA	0.6	4.8	0.44	5.84e-6	Breast cancer;
THYM	cis	rs62244186	0.659	rs6441844	chr3:44503579	C/T	cg09333631	chr3:44802604	KIF15;KIAA1143	-0.46	-4.93	-0.45	3.49e-6	Depressive symptoms;
THYM	cis	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg08133631	chr1:26527909	CATSPER4	-0.61	-5.08	-0.46	1.92e-6	Obesity-related traits;
THYM	cis	rs7772486	0.754	rs4360151	chr6:146255079	A/C	cg23711669	chr6:146136114	FBXO30	-0.9	-8.72	-0.67	9.04e-14	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg03474202	chr17:45855739	NA	-0.74	-6.44	-0.55	4.93e-9	IgG glycosylation;
THYM	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg05313129	chr8:58192883	C8orf71	-0.86	-5.05	-0.46	2.1e-6	Developmental language disorder (linguistic errors);
THYM	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg05340658	chr4:99064831	C4orf37	0.53	4.51	0.42	1.86e-5	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9543976	1.000	rs9565177	chr13:76195403	T/G	cg01531495	chr13:76123901	UCHL3	-0.71	-4.82	-0.44	5.48e-6	Diabetic retinopathy;
THYM	cis	rs2067615	0.524	rs4964483	chr12:107099057	T/C	cg15890332	chr12:107067104	RFX4	0.46	5.34	0.48	6.31e-7	Heart rate;
THYM	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	7.92	0.63	4.36e-12	Lung cancer in ever smokers;
THYM	cis	rs7772486	0.790	rs9403756	chr6:146257761	C/G	cg13319975	chr6:146136371	FBXO30	0.7	5.74	0.51	1.14e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg21984481	chr17:79567631	NPLOC4	-0.46	-4.86	-0.45	4.62e-6	Eye color traits;
THYM	cis	rs13064411	0.735	rs10511326	chr3:113216325	T/C	cg10517650	chr3:113235015	CCDC52	-0.61	-5.35	-0.48	6.01e-7	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs939658	0.805	rs35462901	chr15:79442201	C/T	cg17916960	chr15:79447300	NA	-0.73	-8.58	-0.66	1.81e-13	Refractive error;
THYM	cis	rs7772486	0.754	rs9399567	chr6:146147295	C/T	cg23711669	chr6:146136114	FBXO30	0.94	9.95	0.71	2.1e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs4383453	0.539	rs4678021	chr3:123102376	A/G	cg04890266	chr3:123102914	ADCY5	-0.83	-8.75	-0.67	7.74e-14	Gestational age at birth (maternal effect);
THYM	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg14196790	chr5:131705035	SLC22A5	0.55	5.04	0.46	2.21e-6	Blood metabolite levels;
THYM	trans	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.22	-14.33	-0.83	1.74e-25	Exhaled nitric oxide output;
THYM	cis	rs6901250	0.655	rs636252	chr6:117157774	A/G	cg12892004	chr6:117198278	RFX6	-0.56	-4.57	-0.42	1.49e-5	C-reactive protein levels;
THYM	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg15448220	chr1:150897856	SETDB1	0.9	7.66	0.62	1.56e-11	Melanoma;
THYM	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg00129232	chr17:37814104	STARD3	-0.75	-5.0	-0.46	2.67e-6	Glomerular filtration rate (creatinine);
THYM	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg16586182	chr3:47516702	SCAP	-0.64	-5.61	-0.5	2.03e-7	Colorectal cancer;
THYM	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12893428	chr3:195717962	SDHAP1	0.51	4.57	0.42	1.49e-5	Pancreatic cancer;
THYM	cis	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg10856724	chr12:34555212	NA	-0.92	-9.27	-0.69	6.02e-15	Morning vs. evening chronotype;
THYM	cis	rs6748734	0.625	rs9288743	chr2:241821569	C/G	cg15164180	chr2:241846931	NA	-0.33	-4.54	-0.42	1.66e-5	Urinary metabolites;
THYM	cis	rs1357245	0.597	rs12330703	chr3:27096518	C/G	cg03895047	chr3:27114861	NA	0.49	4.58	0.43	1.42e-5	Breast cancer;
THYM	cis	rs7560272	0.723	rs6729468	chr2:73765253	C/A	cg19565262	chr2:73869966	NAT8	-0.53	-4.57	-0.42	1.45e-5	Schizophrenia;
THYM	cis	rs7551222	0.681	rs4252686	chr1:204496895	A/G	cg20240347	chr1:204465584	NA	-0.51	-4.54	-0.42	1.64e-5	Schizophrenia;
THYM	cis	rs300703	0.604	rs373375	chr2:203350	C/A	cg21211680	chr2:198530	NA	1.26	8.21	0.64	1.09e-12	Blood protein levels;
THYM	cis	rs7327064	0.573	rs1410634	chr13:36739346	A/G	cg15718287	chr13:36702658	DCLK1	0.46	4.82	0.44	5.38e-6	Economic and political preferences;
THYM	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg22117172	chr7:91764530	CYP51A1	0.37	4.84	0.44	5.01e-6	Breast cancer;
THYM	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg10253484	chr15:75165896	SCAMP2	-0.67	-4.53	-0.42	1.73e-5	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
THYM	cis	rs56341938	0.866	rs62275517	chr3:168731047	G/C	cg09107232	chr3:169491072	MYNN	0.55	4.75	0.44	7.23e-6	Lung function (FEV1/FVC);
THYM	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.54	4.91	0.45	3.83e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs6720763	1.000	rs7569147	chr2:167989691	A/G	cg10633051	chr2:168042982	XIRP2	0.68	5.31	0.48	7.21e-7	Atopic dermatitis;
THYM	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg00717180	chr2:96193071	NA	-0.72	-7.45	-0.61	4.21e-11	HDL cholesterol;
THYM	cis	rs1018836	0.923	rs6989123	chr8:91551234	A/T	cg16814680	chr8:91681699	NA	-0.84	-7.59	-0.61	2.21e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
THYM	cis	rs3755605	1.000	rs3755605	chr3:169756119	C/T	cg18444028	chr3:169782040	GPR160	0.59	4.73	0.44	7.89e-6	Testicular germ cell tumor;
THYM	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg17105886	chr17:28927953	LRRC37B2	1.3	6.82	0.57	8.56e-10	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs7635838	0.617	rs2594971	chr3:11313910	G/A	cg00170343	chr3:11313890	ATG7	0.66	4.92	0.45	3.63e-6	HDL cholesterol;
THYM	cis	rs2797160	1.000	rs1630556	chr6:126013155	A/G	cg16306078	chr6:126000798	NA	0.55	5.64	0.5	1.72e-7	Endometrial cancer;
THYM	cis	rs887829	0.569	rs10179091	chr2:234657983	A/G	cg11272349	chr2:234637253	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A9;UGT1A7;UGT1A5;UGT1A3	-0.57	-4.76	-0.44	6.89e-6	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
THYM	cis	rs10256972	0.721	rs6975972	chr7:1070468	A/G	cg02869364	chr7:1081709	C7orf50	-0.43	-4.98	-0.46	2.82e-6	Longevity;Endometriosis;
THYM	cis	rs11723261	0.664	rs4627799	chr4:132389	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.74	5.35	0.48	5.98e-7	Immune response to smallpox vaccine (IL-6);
THYM	cis	rs2249625	0.526	rs17725666	chr6:72889711	G/A	cg27608224	chr6:72922399	RIMS1	-0.53	-4.48	-0.42	2.04e-5	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
THYM	cis	rs72712511	0.571	rs34257120	chr4:140764780	G/A	cg15010390	chr4:140216957	NDUFC1	0.62	4.67	0.43	9.92e-6	Intelligence (multi-trait analysis);
THYM	cis	rs2730245	0.527	rs2036582	chr7:158701708	A/T	cg24397884	chr7:158709396	WDR60	0.49	4.89	0.45	4.11e-6	Height;
THYM	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg26721908	chr21:47610096	LSS	0.85	6.78	0.57	1.03e-9	Testicular germ cell tumor;
THYM	cis	rs7009516	0.544	rs2291574	chr8:24249668	T/C	cg01759110	chr8:24241694	ADAMDEC1	-0.55	-4.67	-0.43	9.94e-6	Hair greying;
THYM	cis	rs10499694	0.933	rs11575356	chr7:50594821	T/C	cg18232548	chr7:50535776	DDC	-0.62	-5.1	-0.46	1.75e-6	Body mass index;
THYM	cis	rs9581857	0.579	rs9581836	chr13:27963824	T/G	cg22138327	chr13:27999177	GTF3A	0.99	5.52	0.49	2.99e-7	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg03676636	chr4:99064102	C4orf37	0.4	5.85	0.51	7.1e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs8067545	0.641	rs119672	chr17:19818601	A/G	cg20830565	chr17:20408647	MGC102966	-0.54	-5.02	-0.46	2.45e-6	Schizophrenia;
THYM	cis	rs57143961	1	rs57143961	chr19:16533225	C/CT	cg10248733	chr19:16607483	C19orf44;CALR3	-0.73	-5.06	-0.46	2.06e-6	Lymphocyte percentage of white cells;
THYM	cis	rs1011018	0.955	rs7456421	chr7:139415775	G/C	cg06079564	chr7:139468310	HIPK2	-0.73	-5.5	-0.49	3.19e-7	Systolic blood pressure;
THYM	cis	rs1403694	1.000	rs2651640	chr3:186438393	G/A	cg12454167	chr3:186435060	KNG1	0.45	6.0	0.52	3.58e-8	Blood protein levels;
THYM	cis	rs2219968	1.000	rs13276048	chr8:78975258	G/A	cg00738934	chr8:78996279	NA	0.92	10.06	0.72	1.2e-16	Prostate cancer (SNP x SNP interaction);
THYM	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg10589385	chr1:150898437	SETDB1	0.64	5.4	0.48	4.9e-7	Melanoma;
THYM	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg18876405	chr7:65276391	NA	-0.62	-5.25	-0.47	9.11e-7	Aortic root size;
THYM	cis	rs6860806	0.661	rs6871350	chr5:131580220	A/G	cg18758796	chr5:131593413	PDLIM4	0.61	6.05	0.53	2.91e-8	Breast cancer;
THYM	cis	rs17006441	0.932	rs35017084	chr3:69868629	C/T	cg18496212	chr3:69797108	MITF	0.67	6.7	0.57	1.44e-9	Hemoglobin concentration;
THYM	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg08508325	chr11:3079039	CARS	-0.55	-6.88	-0.58	6.38e-10	Longevity;
THYM	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg07606381	chr6:8435919	SLC35B3	0.68	5.11	0.46	1.7e-6	Motion sickness;
THYM	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg00757033	chr12:89920650	WDR51B	0.75	10.23	0.72	5.28e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
THYM	cis	rs7542375	0.683	rs11118625	chr1:221103388	A/G	cg16008148	chr1:221062819	NA	0.45	5.13	0.47	1.5e-6	Obesity-related traits;
THYM	cis	rs12200560	0.505	rs12192623	chr6:97081432	A/G	cg06623918	chr6:96969491	KIAA0776	-0.72	-5.25	-0.47	9.45e-7	Coronary heart disease;
THYM	cis	rs28595532	0.920	rs56283736	chr4:119747268	A/G	cg14228332	chr4:119757509	SEC24D	1.47	5.61	0.5	1.99e-7	Cannabis dependence symptom count;
THYM	cis	rs752010	0.905	rs10890150	chr1:42095603	A/C	cg06885757	chr1:42089581	HIVEP3	0.52	6.5	0.56	3.62e-9	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs6842047	1.000	rs1877320	chr4:187131279	G/A	cg09526685	chr4:187126073	CYP4V2	1.23	6.35	0.55	7.22e-9	Blood protein levels;
THYM	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg08772003	chr10:104629869	AS3MT	-0.63	-5.62	-0.5	1.87e-7	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs2235642	0.964	rs9939655	chr16:1577963	A/G	cg08296037	chr16:1584118	IFT140;TMEM204	-0.61	-5.01	-0.46	2.53e-6	Coronary artery disease;
THYM	cis	rs1267303	0.637	rs1745371	chr1:46985192	C/T	cg25110126	chr1:46999211	NA	0.62	4.81	0.44	5.57e-6	Monobrow;
THYM	cis	rs10979	1.000	rs9390113	chr6:143896205	G/A	cg25407410	chr6:143891975	LOC285740	-0.61	-5.14	-0.47	1.47e-6	Hypospadias;
THYM	cis	rs6138458	1.000	rs6114984	chr20:24976610	A/G	cg26195577	chr20:24973756	C20orf3	1.09	11.01	0.75	1.16e-18	Blood protein levels;
THYM	cis	rs17019602	0.585	rs2296877	chr1:108152630	G/T	cg02990361	chr1:107599529	PRMT6	0.78	4.65	0.43	1.09e-5	IgA nephropathy;
THYM	cis	rs2898681	1.000	rs2411281	chr4:53757057	G/A	cg03786743	chr4:53727781	RASL11B	0.44	4.9	0.45	3.9e-6	Optic nerve measurement (cup area);
THYM	cis	rs2708977	0.933	rs2464914	chr2:97179828	A/G	cg01950434	chr2:97203154	ARID5A	-0.52	-4.61	-0.43	1.26e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs7100689	0.784	rs4934139	chr10:82177023	C/A	cg01528321	chr10:82214614	TSPAN14	1.1	9.02	0.68	2.1e-14	Post bronchodilator FEV1;
THYM	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	trans	rs11186	0.591	rs61410138	chr2:189964395	T/C	cg14780845	chr17:41323115	NBR1	0.81	6.87	0.58	6.8e-10	Parkinson's disease;
THYM	cis	rs7578361	0.959	rs4667337	chr2:150450828	A/G	cg17961725	chr2:150454027	NA	-0.75	-6.45	-0.55	4.58e-9	Acute lymphoblastic leukemia (childhood);
THYM	cis	rs2692947	0.673	rs2917662	chr2:96794957	G/A	cg23100626	chr2:96804247	ASTL	0.39	4.77	0.44	6.56e-6	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
THYM	cis	rs12410462	0.579	rs116423559	chr1:227575014	A/G	cg23173402	chr1:227635558	NA	0.75	5.88	0.52	6.19e-8	Major depressive disorder;
THYM	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg00990874	chr7:1149470	C7orf50	-0.61	-4.82	-0.44	5.35e-6	Bronchopulmonary dysplasia;
THYM	cis	rs12476592	0.602	rs2604614	chr2:63894133	T/G	cg17519650	chr2:63277830	OTX1	-0.72	-4.68	-0.43	9.38e-6	Childhood ear infection;
THYM	cis	rs2282300	0.739	rs1717772	chr11:30340133	C/T	cg06241208	chr11:30344200	C11orf46	-0.79	-5.65	-0.5	1.64e-7	Morning vs. evening chronotype;
THYM	trans	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg10856724	chr12:34555212	NA	-0.89	-8.35	-0.65	5.53e-13	Drug-induced liver injury (flucloxacillin);
THYM	trans	rs11186	0.556	rs60396510	chr2:189952875	G/T	cg14780845	chr17:41323115	NBR1	0.82	6.95	0.58	4.56e-10	Parkinson's disease;
THYM	cis	rs12817211	0.524	rs1554845	chr12:50523504	C/T	cg06168149	chr12:50497778	GPD1	0.31	4.75	0.44	7.11e-6	Colorectal or endometrial cancer;
THYM	cis	rs2073300	1.000	rs6036422	chr20:23456962	A/T	cg12062639	chr20:23401060	NAPB	0.99	4.96	0.45	3.07e-6	Peripheral arterial disease (traffic-related air pollution interaction);
THYM	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.51	4.75	0.44	7.22e-6	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
THYM	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg00129232	chr17:37814104	STARD3	0.69	4.51	0.42	1.84e-5	Glomerular filtration rate (creatinine);
THYM	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg06713675	chr4:122721982	EXOSC9	-0.89	-10.51	-0.73	1.33e-17	Type 2 diabetes;
THYM	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg26384229	chr12:38710491	ALG10B	0.73	5.59	0.5	2.2e-7	Morning vs. evening chronotype;
THYM	cis	rs654950	0.841	rs2759247	chr1:41991756	G/C	cg06885757	chr1:42089581	HIVEP3	-0.47	-5.62	-0.5	1.92e-7	Airway imaging phenotypes;
THYM	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg18576210	chr6:26033786	HIST1H3B;HIST1H2AB	-0.89	-8.11	-0.64	1.74e-12	Intelligence (multi-trait analysis);
THYM	cis	rs10752881	1.000	rs4304541	chr1:182970238	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.58	4.67	0.43	9.78e-6	Colorectal cancer;
THYM	cis	rs7772486	0.790	rs7753696	chr6:146279098	G/T	cg23711669	chr6:146136114	FBXO30	-0.96	-10.08	-0.72	1.11e-16	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs6450176	0.638	rs16881969	chr5:53300748	A/G	ch.5.1024479R	chr5:53302184	ARL15	1.21	10.03	0.72	1.4e-16	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
THYM	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22496380	chr5:211416	CCDC127	-1.32	-7.26	-0.6	1.04e-10	Breast cancer;
THYM	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg12463550	chr7:65579703	CRCP	-0.57	-4.76	-0.44	7.01e-6	Aortic root size;
THYM	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg03806693	chr22:41940476	POLR3H	-1.04	-7.64	-0.62	1.75e-11	Crohn's disease;Inflammatory bowel disease;
THYM	cis	rs7809950	0.954	rs2520247	chr7:107143946	A/T	cg23024343	chr7:107201750	COG5	-0.91	-8.24	-0.65	9.37e-13	Coronary artery disease;
THYM	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg10547057	chr6:26987810	LOC100270746;C6orf41	-0.52	-5.71	-0.51	1.3e-7	Autism spectrum disorder or schizophrenia;
THYM	cis	rs34912216	0.542	rs12701400	chr7:4132004	A/T	cg26550874	chr7:4183528	SDK1	0.6	4.46	0.42	2.22e-5	Motion sickness;
THYM	cis	rs9796	0.558	rs11855102	chr15:41513257	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.57	-4.72	-0.44	8.25e-6	Menopause (age at onset);
THYM	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg19077165	chr18:44547161	KATNAL2	0.5	5.8	0.51	8.74e-8	Personality dimensions;
THYM	cis	rs600806	0.888	rs4603158	chr1:109879549	C/T	cg02175308	chr1:109941060	SORT1	-0.57	-4.96	-0.45	3.14e-6	Intelligence (multi-trait analysis);
THYM	trans	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg10856724	chr12:34555212	NA	-0.89	-7.94	-0.63	4.02e-12	Drug-induced liver injury (flucloxacillin);
THYM	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg16325326	chr1:53192061	ZYG11B	-0.77	-5.72	-0.51	1.21e-7	Monocyte count;
THYM	cis	rs2229238	0.911	rs111600849	chr1:154487489	G/A	cg21262032	chr1:154437693	IL6R	-0.6	-5.39	-0.48	5.21e-7	Coronary heart disease;
THYM	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.1	-10.9	-0.75	2.01e-18	Primary sclerosing cholangitis;
THYM	cis	rs16944613	0.541	rs7183319	chr15:91095032	A/T	cg26821196	chr15:91095069	CRTC3	0.8	4.61	0.43	1.24e-5	Colorectal cancer;
THYM	cis	rs2070488	1.000	rs7373816	chr3:38490443	C/A	cg24069376	chr3:38537580	EXOG	0.66	6.6	0.56	2.37e-9	Electrocardiographic conduction measures;
THYM	cis	rs289828	0.507	rs11683487	chr2:152142549	G/T	cg05960677	chr2:152117363	RBM43	0.76	7.7	0.62	1.26e-11	Blood protein levels;
THYM	cis	rs7772486	0.692	rs1577916	chr6:146069789	G/A	cg13319975	chr6:146136371	FBXO30	0.65	5.27	0.48	8.54e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs13040088	1.000	rs13040088	chr20:61549202	A/G	cg23096297	chr20:61557774	DIDO1	1.06	7.32	0.6	8.1e-11	Menopause (age at onset);
THYM	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg11366901	chr6:160182831	ACAT2	1.07	9.53	0.7	1.68e-15	Age-related macular degeneration (geographic atrophy);
THYM	cis	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg01364799	chr7:75623366	TMEM120A	0.63	4.56	0.42	1.51e-5	Coffee consumption;Coffee consumption (cups per day);
THYM	cis	rs9522267	0.604	rs1412177	chr13:112199278	A/C	cg10483660	chr13:112241077	NA	0.56	5.94	0.52	4.65e-8	Hepatitis;
THYM	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg06636001	chr8:8085503	FLJ10661	0.75	6.68	0.57	1.58e-9	Joint mobility (Beighton score);
THYM	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg21028142	chr17:79581711	NPLOC4	0.65	6.7	0.57	1.44e-9	Eye color traits;
THYM	cis	rs6541297	0.938	rs7551742	chr1:230290118	A/G	cg05784532	chr1:230284198	GALNT2	0.76	4.81	0.44	5.68e-6	Coronary artery disease;
THYM	cis	rs3791556	0.898	rs3791549	chr2:240109024	A/G	cg27074582	chr2:240114406	HDAC4	-0.54	-4.86	-0.45	4.7e-6	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
THYM	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg21775007	chr8:11205619	TDH	0.64	5.14	0.47	1.48e-6	Retinal vascular caliber;
THYM	cis	rs10089	1.000	rs6887847	chr5:127473807	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	1.02	7.11	0.59	2.11e-10	Ileal carcinoids;
THYM	cis	rs6840360	0.642	rs4235219	chr4:152346103	T/G	cg17479576	chr4:152424074	FAM160A1	-0.7	-5.3	-0.48	7.43e-7	Intelligence (multi-trait analysis);
THYM	cis	rs2708977	0.901	rs3731938	chr2:97166204	A/G	cg01950434	chr2:97203154	ARID5A	-0.51	-4.51	-0.42	1.88e-5	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs55702914	0.967	rs61328028	chr2:198223754	A/G	cg00792783	chr2:198669748	PLCL1	0.63	4.56	0.42	1.55e-5	Major depression and alcohol dependence;
THYM	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg18806716	chr10:30721971	MAP3K8	0.5	4.62	0.43	1.22e-5	Inflammatory bowel disease;
THYM	cis	rs977987	0.806	rs56343285	chr16:75409797	A/G	cg03315344	chr16:75512273	CHST6	0.72	6.09	0.53	2.34e-8	Dupuytren's disease;
THYM	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg17264618	chr3:40429014	ENTPD3	0.53	4.99	0.46	2.69e-6	Renal cell carcinoma;
THYM	cis	rs6987853	0.736	rs35295075	chr8:42428852	A/G	cg09913449	chr8:42400586	C8orf40	1.08	12.65	0.79	4.44e-22	Mean corpuscular hemoglobin concentration;
THYM	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg02275930	chr1:2372054	NA	-1.03	-9.08	-0.68	1.54e-14	Non-obstructive azoospermia;
THYM	cis	rs684232	0.563	rs12939528	chr17:524391	C/T	cg08489349	chr17:656181	ELP2P;GEMIN4	-0.39	-4.77	-0.44	6.73e-6	Prostate cancer;
THYM	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg08470875	chr2:26401718	FAM59B	0.74	4.59	0.43	1.35e-5	Gut microbiome composition (summer);
THYM	cis	rs863345	0.604	rs1873509	chr1:158461563	A/G	cg12129480	chr1:158549410	OR10X1	0.49	4.68	0.43	9.57e-6	Pneumococcal bacteremia;
THYM	cis	rs859767	0.887	rs842362	chr2:135341120	C/T	cg12500956	chr2:135428796	TMEM163	0.55	5.37	0.48	5.51e-7	Neuroticism;
THYM	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg22166914	chr1:53195759	ZYG11B	0.69	5.65	0.5	1.67e-7	Monocyte count;
THYM	cis	rs778371	0.871	rs2675954	chr2:233750627	C/G	cg08000102	chr2:233561755	GIGYF2	-0.84	-7.04	-0.59	2.98e-10	Schizophrenia;
THYM	cis	rs72627123	0.656	rs6574169	chr14:74637178	G/A	cg11191049	chr14:74485465	ENTPD5;C14orf45	-1.29	-7.08	-0.59	2.46e-10	Morning vs. evening chronotype;
THYM	cis	rs9470366	0.816	rs7774130	chr6:36623756	C/T	cg24425727	chr6:36645648	CDKN1A	-0.58	-4.73	-0.44	7.82e-6	QRS duration;
THYM	cis	rs11122895	0.509	rs6708131	chr2:112445659	C/T	cg23262488	chr2:112468472	NA	0.5	6.59	0.56	2.44e-9	Allergic sensitization;
THYM	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg03806693	chr22:41940476	POLR3H	1.07	8.31	0.65	6.6e-13	Vitiligo;
THYM	cis	rs2075230	0.705	rs1641540	chr17:7545187	C/T	cg16696476	chr17:8191344	RANGRF;SLC25A35	-0.29	-4.74	-0.44	7.55e-6	Hormone measurements;
THYM	cis	rs6570726	0.818	rs9399555	chr6:145877554	T/C	cg13319975	chr6:146136371	FBXO30	-0.66	-5.46	-0.49	3.79e-7	Lobe attachment (rater-scored or self-reported);
THYM	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg27446573	chr6:127587934	RNF146	0.7	6.13	0.53	1.99e-8	Breast cancer;
THYM	cis	rs7224737	1.000	rs739636	chr17:40281063	T/G	cg02450064	chr17:40260053	DHX58	-0.53	-4.58	-0.42	1.43e-5	Fibrinogen levels;
THYM	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26314531	chr2:26401878	FAM59B	-0.79	-5.37	-0.48	5.67e-7	Gut microbiome composition (summer);
THYM	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg09033563	chr22:24373618	LOC391322	-0.57	-5.09	-0.46	1.82e-6	Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs78456975	0.739	rs28913003	chr2:1519620	A/T	cg12573674	chr2:1569213	NA	-1.35	-6.39	-0.55	6.13e-9	Placebo response in major depressive disorder (% change in symptom score);
THYM	cis	rs1113500	0.897	rs10785832	chr1:108638899	G/A	cg06207961	chr1:108661230	NA	0.64	5.09	0.46	1.83e-6	Growth-regulated protein alpha levels;
THYM	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg27398817	chr8:82754497	SNX16	-0.82	-6.42	-0.55	5.39e-9	Diastolic blood pressure;
THYM	cis	rs7172809	0.599	rs10519158	chr15:77412457	G/C	cg22256960	chr15:77711686	NA	-0.64	-4.75	-0.44	7.32e-6	Glucose homeostasis traits;
THYM	cis	rs7412746	0.611	rs11803940	chr1:150685835	A/G	cg10589385	chr1:150898437	SETDB1	0.66	5.58	0.5	2.27e-7	Melanoma;
THYM	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg13114125	chr14:105738426	BRF1	-0.68	-5.22	-0.47	1.06e-6	Mean platelet volume;Platelet distribution width;
THYM	cis	rs752010	0.631	rs7515066	chr1:42076915	A/G	cg06885757	chr1:42089581	HIVEP3	-0.78	-12.01	-0.78	9.2e-21	Lupus nephritis in systemic lupus erythematosus;
THYM	cis	rs7809950	0.817	rs2237671	chr7:107131528	A/T	cg23024343	chr7:107201750	COG5	-1.03	-8.96	-0.68	2.81e-14	Coronary artery disease;
THYM	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.73	-5.11	-0.46	1.67e-6	Gut microbiome composition (summer);
THYM	cis	rs9581857	0.556	rs9581864	chr13:28041567	T/C	cg22138327	chr13:27999177	GTF3A	0.65	4.55	0.42	1.6e-5	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
THYM	cis	rs13256369	0.851	rs13254997	chr8:8563753	G/C	cg17143192	chr8:8559678	CLDN23	0.97	7.44	0.61	4.55e-11	Obesity-related traits;
THYM	cis	rs977987	0.806	rs11642572	chr16:75452782	C/T	cg03315344	chr16:75512273	CHST6	0.76	6.16	0.53	1.7e-8	Dupuytren's disease;
THYM	cis	rs10208940	0.614	rs35859515	chr2:68750492	T/C	cg09157127	chr2:69201416	GKN1	0.89	4.71	0.43	8.61e-6	Urate levels in lean individuals;
THYM	cis	rs654950	0.875	rs687766	chr1:41998849	C/G	cg06885757	chr1:42089581	HIVEP3	0.45	5.34	0.48	6.42e-7	Airway imaging phenotypes;
THYM	cis	rs4076764	0.535	rs4409627	chr1:163382050	A/G	cg06092702	chr1:163392909	NA	0.54	4.82	0.44	5.54e-6	Motion sickness;
THYM	cis	rs9876781	0.967	rs2885509	chr3:48418219	G/T	cg06066452	chr3:48470258	PLXNB1	-0.26	-4.93	-0.45	3.52e-6	Longevity;
THYM	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg00801512	chr17:28996047	NA	-0.75	-4.58	-0.43	1.43e-5	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg17264618	chr3:40429014	ENTPD3	0.47	4.54	0.42	1.62e-5	Renal cell carcinoma;
THYM	cis	rs4731207	0.596	rs6956910	chr7:124642364	A/C	cg05285228	chr7:124571219	POT1	-0.68	-5.08	-0.46	1.88e-6	Cutaneous malignant melanoma;
THYM	cis	rs7586879	0.639	rs6713978	chr2:25120851	T/C	cg15423357	chr2:25149977	NA	0.68	7.53	0.61	2.9e-11	Body mass index;
THYM	cis	rs7688540	0.771	rs11724176	chr4:224901	C/T	cg12746427	chr4:53362	ZNF718;ZNF595	0.72	4.88	0.45	4.35e-6	Facial morphology (factor 6, height of vermillion lower lip);
THYM	cis	rs919433	0.617	rs2037590	chr2:198584775	T/A	cg05783139	chr2:198650985	BOLL	-0.63	-5.0	-0.46	2.58e-6	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
THYM	cis	rs714027	0.566	rs4820827	chr22:30477589	T/C	cg27665648	chr22:30112403	NA	-0.52	-4.71	-0.44	8.35e-6	Lymphocyte counts;
THYM	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26314531	chr2:26401878	FAM59B	0.78	5.13	0.47	1.55e-6	Gut microbiome composition (summer);
THYM	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg17294928	chr15:75287854	SCAMP5	0.64	4.55	0.42	1.58e-5	Caffeine consumption;
THYM	cis	rs3796352	1.000	rs34244302	chr3:53102236	C/G	cg07884673	chr3:53033167	SFMBT1	1.15	5.67	0.5	1.51e-7	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs2742234	0.541	rs7098236	chr10:43740508	T/C	cg06632098	chr10:43605906	RET	0.74	4.97	0.45	2.95e-6	Hirschsprung disease;
THYM	cis	rs4730268	0.821	rs73419929	chr7:107438452	T/G	cg18560240	chr7:107437656	SLC26A3	-0.93	-5.18	-0.47	1.22e-6	IgG glycosylation;
THYM	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg08048268	chr3:133502702	NA	-0.68	-5.56	-0.5	2.46e-7	Iron status biomarkers;
THYM	cis	rs2404602	0.647	rs62026889	chr15:76917885	C/T	cg23625390	chr15:77176239	SCAPER	-0.9	-6.22	-0.54	1.3e-8	Blood metabolite levels;
THYM	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg01579765	chr21:45077557	HSF2BP	0.53	8.63	0.66	1.37e-13	Mean corpuscular volume;
THYM	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg10950924	chr17:47092072	IGF2BP1	-0.63	-7.38	-0.6	6.04e-11	Intelligence (multi-trait analysis);Body fat percentage;
THYM	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg08470875	chr2:26401718	FAM59B	0.72	4.46	0.42	2.22e-5	Gut microbiome composition (summer);
THYM	cis	rs526231	0.512	rs28022	chr5:102464367	T/C	cg23492399	chr5:102201601	PAM	-0.7	-5.23	-0.47	9.9e-7	Primary biliary cholangitis;
THYM	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg08773314	chr2:239334832	ASB1	0.64	9.62	0.7	1.05e-15	Multiple system atrophy;
THYM	cis	rs854765	0.583	rs11078405	chr17:17824978	G/T	cg16928487	chr17:17741425	SREBF1	-0.56	-5.44	-0.49	4.09e-7	Total body bone mineral density;
THYM	cis	rs17511627	0.708	rs7987427	chr13:26743219	G/C	cg13319468	chr13:27597730	NA	-0.68	-5.42	-0.49	4.51e-7	Alzheimer's disease;
THYM	cis	rs425277	0.958	rs262639	chr1:2107061	G/T	cg09260853	chr1:2094483	PRKCZ	0.52	4.87	0.45	4.42e-6	Height;
THYM	cis	rs854765	0.583	rs4244602	chr17:17841456	A/G	cg04398451	chr17:18023971	MYO15A	-0.8	-7.45	-0.61	4.24e-11	Total body bone mineral density;
THYM	cis	rs7572263	0.724	rs12986551	chr2:209052303	T/C	cg23998903	chr2:209048830	C2orf80	-0.46	-4.75	-0.44	7.2e-6	Glioma;Non-glioblastoma glioma;
THYM	cis	rs514406	0.929	rs11206035	chr1:53323571	T/C	cg24675658	chr1:53192096	ZYG11B	-0.61	-4.93	-0.45	3.52e-6	Monocyte count;
THYM	cis	rs6543140	0.964	rs4851593	chr2:103089227	C/T	cg03938978	chr2:103052716	IL18RAP	-0.6	-5.18	-0.47	1.22e-6	Blood protein levels;
THYM	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg04455712	chr21:45112962	RRP1B	-0.51	-4.71	-0.44	8.41e-6	Mean corpuscular volume;
THYM	cis	rs79387448	0.626	rs80277428	chr2:103080056	G/A	cg09003973	chr2:102972529	NA	1.3	6.53	0.56	3.15e-9	Gut microbiota (bacterial taxa);
THYM	cis	rs7302981	0.741	rs10783342	chr12:50628466	C/T	cg20014596	chr12:50898483	DIP2B	0.49	4.53	0.42	1.71e-5	Systolic blood pressure;
THYM	cis	rs1345301	0.609	rs56389410	chr2:102867663	C/T	cg03938978	chr2:103052716	IL18RAP	-0.51	-4.97	-0.45	2.93e-6	Waist circumference;
THYM	cis	rs763014	0.898	rs2384978	chr16:625384	T/C	cg00908189	chr16:619842	PIGQ	1.01	9.15	0.68	1.08e-14	Height;
THYM	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg27279351	chr12:120934652	DYNLL1	0.95	8.61	0.66	1.52e-13	High light scatter reticulocyte count;
THYM	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg10515332	chr4:99064459	C4orf37	0.61	4.94	0.45	3.28e-6	Colonoscopy-negative controls vs population controls;
THYM	cis	rs7020830	0.516	rs36047049	chr9:37375472	G/T	cg14294708	chr9:37120828	ZCCHC7	0.99	8.19	0.64	1.2e-12	Schizophrenia;
THYM	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg18132916	chr6:79620363	NA	-0.59	-5.29	-0.48	7.95e-7	Intelligence (multi-trait analysis);
THYM	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg21984481	chr17:79567631	NPLOC4	0.61	6.89	0.58	6.13e-10	Eye color traits;
THYM	cis	rs4266144	0.562	rs56357317	chr3:156835174	T/A	cg16248515	chr3:156840234	NA	-0.77	-7.05	-0.59	2.8e-10	Coronary artery disease;
THYM	cis	rs9486719	0.947	rs11757102	chr6:96885073	G/A	cg18709589	chr6:96969512	KIAA0776	-0.75	-4.96	-0.45	3.09e-6	Migraine;Coronary artery disease;
THYM	cis	rs1021993	0.672	rs2660634	chr1:209483013	C/A	cg24997231	chr1:209527535	NA	0.5	4.55	0.42	1.57e-5	Gut microbiome composition (winter);
THYM	cis	rs9584850	0.522	rs9517299	chr13:99095031	C/T	cg07423050	chr13:99094983	FARP1	0.4	4.62	0.43	1.21e-5	Neuroticism;
THYM	cis	rs3796352	1.000	rs11714876	chr3:53101640	C/G	cg07884673	chr3:53033167	SFMBT1	-1.13	-5.69	-0.5	1.4e-7	Immune reponse to smallpox (secreted IL-2);
THYM	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg11764359	chr7:65958608	NA	-0.63	-4.76	-0.44	6.87e-6	Aortic root size;
THYM	cis	rs4662945	0.724	rs4427966	chr2:130221148	G/A	cg05903289	chr2:130345205	NA	-0.53	-4.86	-0.45	4.54e-6	Response to cytidine analogues (gemcitabine);
THYM	cis	rs1497406	0.744	rs924203	chr1:16511539	G/T	cg03887218	chr1:16534349	ARHGEF19	0.47	4.48	0.42	2.05e-5	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
THYM	cis	rs3126085	0.825	rs11204938	chr1:152193990	A/G	cg10321714	chr1:152280068	FLG	0.69	5.04	0.46	2.22e-6	Atopic dermatitis;
THYM	cis	rs2769264	0.546	rs12047617	chr1:151392597	G/A	cg18801370	chr1:151430492	POGZ	0.65	4.7	0.43	8.63e-6	Blood trace element (Cu levels);
THYM	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg06784218	chr1:46089804	CCDC17	-0.32	-4.82	-0.44	5.41e-6	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
THYM	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg07606381	chr6:8435919	SLC35B3	-0.63	-4.64	-0.43	1.11e-5	Motion sickness;
THYM	cis	rs10911232	0.524	rs10737238	chr1:183025303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.59	4.72	0.44	7.98e-6	Hypertriglyceridemia;
THYM	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg11266682	chr4:10021025	SLC2A9	0.64	8.06	0.64	2.2e-12	Cleft plate (environmental tobacco smoke interaction);
THYM	cis	rs11756438	0.572	rs1857312	chr6:119001526	A/C	cg21191810	chr6:118973309	C6orf204	0.56	5.51	0.49	3.1e-7	QT interval;Bipolar disorder or attention deficit hyperactivity disorder;
THYM	cis	rs4642101	0.680	rs6442330	chr3:12820501	A/G	cg05775895	chr3:12838266	CAND2	0.84	7.37	0.6	6.32e-11	QRS complex (12-leadsum);
THYM	cis	rs11574514	1.000	rs78563448	chr16:67731204	A/G	cg09738193	chr16:67926317	PSKH1	-0.91	-4.66	-0.43	1.01e-5	Crohn's disease;
THYM	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg26384229	chr12:38710491	ALG10B	0.88	7.14	0.59	1.88e-10	Bladder cancer;
THYM	cis	rs7631605	0.935	rs963078	chr3:37220509	G/T	cg21328643	chr3:37258149	NA	-0.5	-4.85	-0.45	4.77e-6	Cerebrospinal P-tau181p levels;
THYM	cis	rs763014	0.898	rs8060585	chr16:635794	C/G	cg05932139	chr16:680872	WFIKKN1	-0.54	-4.5	-0.42	1.93e-5	Height;
THYM	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg08859206	chr1:53392774	SCP2	0.6	6.91	0.58	5.52e-10	Monocyte count;
THYM	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg14008862	chr17:28927542	LRRC37B2	0.94	5.08	0.46	1.88e-6	Mean corpuscular hemoglobin;Mean corpuscular volume;
THYM	cis	rs55728055	0.661	rs12160763	chr22:31794754	A/G	cg10537193	chr22:32026975	PISD	-0.91	-5.25	-0.47	9.24e-7	Age-related hearing impairment;
THYM	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	1.05	9.26	0.69	6.31e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
THYM	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg15604051	chr3:44754201	ZNF502	-0.57	-5.17	-0.47	1.28e-6	Depressive symptoms;
THYM	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg19761014	chr17:28927070	LRRC37B2	0.89	4.93	0.45	3.5e-6	Body mass index;
THYM	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg24818145	chr4:99064322	C4orf37	0.73	5.84	0.51	7.3e-8	Colonoscopy-negative controls vs population controls;
THYM	cis	rs12817211	0.502	rs7294618	chr12:50512975	G/A	cg06168149	chr12:50497778	GPD1	0.3	4.54	0.42	1.65e-5	Colorectal or endometrial cancer;
THYM	cis	rs6500395	0.962	rs3743780	chr16:48647480	A/G	cg04672837	chr16:48644449	N4BP1	0.5	4.93	0.45	3.53e-6	Response to tocilizumab in rheumatoid arthritis;
THYM	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg10377582	chr12:51612794	POU6F1	-0.6	-4.62	-0.43	1.2e-5	Cisplatin-induced ototoxicity;
THYM	cis	rs13064411	0.696	rs2129434	chr3:113138763	A/C	cg18753928	chr3:113234510	CCDC52	-0.91	-8.22	-0.64	1.04e-12	Response to simvastatin treatment (PCSK9 protein level change);
THYM	cis	rs11225247	1.000	rs7104841	chr11:102270051	T/C	cg06323957	chr11:102217781	BIRC2	1.0	4.65	0.43	1.05e-5	Vein graft stenosis in coronary artery bypass grafting;
THYM	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg24375607	chr4:120327624	NA	0.68	5.44	0.49	4.13e-7	Corneal astigmatism;
THYM	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.51	-4.94	-0.45	3.37e-6	Lymphocyte counts;
THYM	cis	rs28476539	0.640	rs7672297	chr4:83554880	G/T	cg10249074	chr4:83542146	C4orf11	-0.64	-5.06	-0.46	2.03e-6	Sum neutrophil eosinophil counts;Granulocyte count;
THYM	cis	rs11840576	0.588	rs332311	chr13:110319646	C/T	cg15975806	chr13:110319607	NA	-0.74	-5.93	-0.52	4.9e-8	Paclitaxel disposition in epithelial ovarian cancer;
THYM	cis	rs747334	0.846	rs7067705	chr10:92721657	T/G	cg07620928	chr10:92689909	NA	0.58	5.12	0.46	1.62e-6	Fibroblast growth factor basic levels;
THYM	cis	rs11096990	0.634	rs6531706	chr4:39296167	T/C	cg24403649	chr4:39172243	NA	-0.64	-5.49	-0.49	3.36e-7	Cognitive function;
THYM	cis	rs7833986	0.501	rs2976038	chr8:57028864	G/A	cg23139584	chr8:56987506	RPS20;SNORD54	0.58	6.88	0.58	6.47e-10	Height;
THYM	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg16342193	chr10:102329863	NA	-0.55	-5.67	-0.5	1.51e-7	Palmitoleic acid (16:1n-7) levels;
THYM	cis	rs3780378	0.875	rs4372063	chr9:5003338	C/T	cg02405213	chr9:5042618	JAK2	-0.63	-5.2	-0.47	1.12e-6	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
THYM	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg10505658	chr17:80084571	CCDC57	-0.73	-8.14	-0.64	1.56e-12	Life satisfaction;
THYM	cis	rs728616	0.614	rs12253608	chr10:81712483	T/C	cg27452691	chr10:81370291	SFTPA1	0.6	4.49	0.42	1.98e-5	Chronic obstructive pulmonary disease-related biomarkers;
THYM	cis	rs7584330	0.666	rs72620819	chr2:238354982	C/T	cg14458575	chr2:238380390	NA	1.12	7.87	0.63	5.7e-12	Prostate cancer;
THYM	cis	rs59698941	0.891	rs72799497	chr5:132291148	T/C	cg02081065	chr5:132209139	LEAP2	-0.84	-5.69	-0.5	1.39e-7	Apolipoprotein A-IV levels;
THYM	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg14349672	chr11:133703707	NA	-0.51	-4.69	-0.43	9.19e-6	Childhood ear infection;
THYM	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21659725	chr3:3221576	CRBN	-0.9	-9.83	-0.71	3.76e-16	Intelligence (multi-trait analysis);
THYM	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg13607699	chr17:42295918	UBTF	0.91	9.16	0.68	1.05e-14	Total body bone mineral density;
THYM	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg17366294	chr4:99064904	C4orf37	0.58	6.98	0.58	3.9e-10	Colonoscopy-negative controls vs population controls;
THYM	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg03983476	chr2:10830698	NOL10	-0.6	-5.71	-0.51	1.28e-7	Prostate cancer;
THYM	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg07362569	chr17:61921086	SMARCD2	0.74	6.62	0.56	2.14e-9	Prudent dietary pattern;
THYM	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg22907277	chr7:1156413	C7orf50	0.7	6.45	0.55	4.68e-9	Longevity;Endometriosis;
THYM	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg23161317	chr6:28129485	ZNF389	0.87	6.29	0.54	9.47e-9	Depression;
THYM	cis	rs988913	1.000	rs7753255	chr6:54832973	C/T	cg04690482	chr6:54711388	FAM83B	0.46	5.19	0.47	1.2e-6	Menarche (age at onset);
THYM	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg26441486	chr22:50317300	CRELD2	0.43	6.57	0.56	2.71e-9	Schizophrenia;